cancer_type	qtl_type	tag_SNP	LD	SNP_id	gene_id	gene_symbol	t-stat	p-value	FDR	beta	r	Traits	SNP_position	Gene_position
BRCA	cis	rs1577917	0.655	rs1059307	ENSG00000203875.9	SNHG5	42.76	1.57e-231	2.73e-225	0.9	0.8	Response to antipsychotic treatment;	chr6:85678170	chr6:85660950~85678736:-
BRCA	cis	rs1577917	0.655	rs9444352	ENSG00000203875.9	SNHG5	37.94	1.57e-198	5.45e-193	0.87	0.76	Response to antipsychotic treatment;	chr6:85547817	chr6:85660950~85678736:-
BRCA	cis	rs858239	0.6	rs7787110	ENSG00000230658.1	KLHL7-AS1	36.68	8.82e-190	1.77e-184	0.97	0.75	Cerebrospinal fluid biomarker levels;	chr7:23098855	chr7:23101228~23105703:-
BRCA	cis	rs62445005	1	rs62445005	ENSG00000211697.3	TRGV5	36.38	9.53e-188	1.4e-182	1.06	0.75	Shingles;	chr7:38346957	chr7:38343894~38350022:-
BRCA	cis	rs858239	0.6	rs10256524	ENSG00000230658.1	KLHL7-AS1	36.24	1.01e-186	1.39e-181	0.97	0.75	Cerebrospinal fluid biomarker levels;	chr7:23105328	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.6	rs28646184	ENSG00000230658.1	KLHL7-AS1	36.06	1.67e-185	2.01e-180	0.96	0.75	Cerebrospinal fluid biomarker levels;	chr7:23099976	chr7:23101228~23105703:-
BRCA	cis	rs2882667	0.69	rs12656942	ENSG00000253404.1	AC034243.1	-35.74	3.16e-183	3.11e-178	-0.99	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138840769	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.686	rs62381196	ENSG00000253404.1	AC034243.1	-35.74	3.16e-183	3.11e-178	-0.99	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138841000	chr5:138744434~138753309:-
BRCA	cis	rs858239	0.6	rs2072369	ENSG00000230658.1	KLHL7-AS1	35.73	3.75e-183	3.67e-178	0.96	0.74	Cerebrospinal fluid biomarker levels;	chr7:23106570	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.6	rs6961131	ENSG00000230658.1	KLHL7-AS1	35.72	3.88e-183	3.78e-178	0.96	0.74	Cerebrospinal fluid biomarker levels;	chr7:23095171	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.6	rs7790157	ENSG00000230658.1	KLHL7-AS1	35.72	4.34e-183	4.19e-178	0.96	0.74	Cerebrospinal fluid biomarker levels;	chr7:23087379	chr7:23101228~23105703:-
BRCA	cis	rs2882667	0.69	rs1828188	ENSG00000253404.1	AC034243.1	-35.67	8.82e-183	8.44e-178	-0.99	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138836307	chr5:138744434~138753309:-
BRCA	cis	rs858239	0.6	rs2014768	ENSG00000230658.1	KLHL7-AS1	35.67	9.25e-183	8.61e-178	0.96	0.74	Cerebrospinal fluid biomarker levels;	chr7:23082821	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.6	rs6978827	ENSG00000230658.1	KLHL7-AS1	35.67	9.25e-183	8.61e-178	0.96	0.74	Cerebrospinal fluid biomarker levels;	chr7:23085925	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.6	rs6960001	ENSG00000230658.1	KLHL7-AS1	35.67	9.25e-183	8.61e-178	0.96	0.74	Cerebrospinal fluid biomarker levels;	chr7:23091257	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.6	rs10237755	ENSG00000230658.1	KLHL7-AS1	35.67	9.25e-183	8.61e-178	0.96	0.74	Cerebrospinal fluid biomarker levels;	chr7:23091945	chr7:23101228~23105703:-
BRCA	cis	rs2882667	0.69	rs4835707	ENSG00000253404.1	AC034243.1	-35.66	1.03e-182	9.51e-178	-0.99	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138838831	chr5:138744434~138753309:-
BRCA	cis	rs858239	0.6	rs10256361	ENSG00000230658.1	KLHL7-AS1	35.64	1.59e-182	1.46e-177	0.96	0.74	Cerebrospinal fluid biomarker levels;	chr7:23084266	chr7:23101228~23105703:-
BRCA	cis	rs2882667	0.69	rs1039788	ENSG00000253404.1	AC034243.1	-35.62	2.01e-182	1.84e-177	-0.99	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138835812	chr5:138744434~138753309:-
BRCA	cis	rs858239	0.6	rs1115941	ENSG00000230658.1	KLHL7-AS1	35.62	2.18e-182	1.98e-177	0.96	0.74	Cerebrospinal fluid biomarker levels;	chr7:23097569	chr7:23101228~23105703:-
BRCA	cis	rs2882667	0.654	rs12517514	ENSG00000253404.1	AC034243.1	-35.55	6.51e-182	5.85e-177	-1	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138814430	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs1976568	ENSG00000253404.1	AC034243.1	-35.53	8.67e-182	7.73e-177	-0.98	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138844627	chr5:138744434~138753309:-
BRCA	cis	rs858239	0.6	rs10233039	ENSG00000230658.1	KLHL7-AS1	35.5	1.39e-181	1.23e-176	0.96	0.74	Cerebrospinal fluid biomarker levels;	chr7:23103494	chr7:23101228~23105703:-
BRCA	cis	rs2882667	0.69	rs6884198	ENSG00000253404.1	AC034243.1	-35.48	2.09e-181	1.83e-176	-0.99	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138828618	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs4835706	ENSG00000253404.1	AC034243.1	-35.48	2.09e-181	1.83e-176	-0.99	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138829037	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.722	rs4835649	ENSG00000253404.1	AC034243.1	-35.47	2.14e-181	1.86e-176	-1	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138810534	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs6860780	ENSG00000253404.1	AC034243.1	-35.47	2.16e-181	1.87e-176	-0.99	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138824367	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs9327826	ENSG00000253404.1	AC034243.1	-35.46	2.64e-181	2.27e-176	-0.98	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138846318	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs6880786	ENSG00000253404.1	AC034243.1	-35.45	3.37e-181	2.88e-176	-0.98	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138845874	chr5:138744434~138753309:-
BRCA	cis	rs858239	0.6	rs10235786	ENSG00000230658.1	KLHL7-AS1	35.44	3.81e-181	3.22e-176	0.95	0.74	Cerebrospinal fluid biomarker levels;	chr7:23100321	chr7:23101228~23105703:-
BRCA	cis	rs2882667	0.654	rs1972072	ENSG00000253404.1	AC034243.1	-35.41	6.32e-181	5.32e-176	-0.98	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138849604	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs1627698	ENSG00000253404.1	AC034243.1	-35.41	6.38e-181	5.34e-176	-1	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138741777	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs6873425	ENSG00000253404.1	AC034243.1	-35.38	1.03e-180	8.62e-176	-1	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138819556	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.654	rs160406	ENSG00000253404.1	AC034243.1	-35.36	1.41e-180	1.17e-175	-1	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138748032	chr5:138744434~138753309:-
BRCA	cis	rs858239	0.601	rs73272048	ENSG00000230658.1	KLHL7-AS1	35.29	3.93e-180	3.19e-175	0.96	0.74	Cerebrospinal fluid biomarker levels;	chr7:23113034	chr7:23101228~23105703:-
BRCA	cis	rs2882667	0.587	rs288015	ENSG00000253404.1	AC034243.1	-35.24	8.65e-180	6.89e-175	-0.99	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138859528	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs17207772	ENSG00000253404.1	AC034243.1	35.18	2.44e-179	1.93e-174	0.98	0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138906131	chr5:138744434~138753309:-
BRCA	cis	rs858239	0.601	rs1034963	ENSG00000230658.1	KLHL7-AS1	35.17	2.86e-179	2.23e-174	0.95	0.74	Cerebrospinal fluid biomarker levels;	chr7:23108854	chr7:23101228~23105703:-
BRCA	cis	rs2882667	0.69	rs7714455	ENSG00000253404.1	AC034243.1	-35.17	2.88e-179	2.24e-174	-1	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138818281	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs2662543	ENSG00000253404.1	AC034243.1	35.17	2.9e-179	2.25e-174	0.98	0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138898441	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs825754	ENSG00000253404.1	AC034243.1	-35.16	3.49e-179	2.7e-174	-0.99	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138796200	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.621	rs55901834	ENSG00000253404.1	AC034243.1	-35.15	3.66e-179	2.81e-174	-0.98	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138844094	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.722	rs825751	ENSG00000253404.1	AC034243.1	-35.14	4.98e-179	3.79e-174	-0.99	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138798180	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs825762	ENSG00000253404.1	AC034243.1	-35.13	5.36e-179	4.07e-174	-1	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138801981	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs10038162	ENSG00000253404.1	AC034243.1	-35.09	1.01e-178	7.6e-174	-0.99	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138901066	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs495638	ENSG00000253404.1	AC034243.1	-35.07	1.51e-178	1.13e-173	-0.99	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138865253	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs288042	ENSG00000253404.1	AC034243.1	35.07	1.51e-178	1.13e-173	0.99	0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138867345	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs288016	ENSG00000253404.1	AC034243.1	-35.07	1.54e-178	1.15e-173	-0.99	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138859299	chr5:138744434~138753309:-
BRCA	cis	rs858239	0.6	rs13438179	ENSG00000230658.1	KLHL7-AS1	35.04	2.43e-178	1.8e-173	0.95	0.74	Cerebrospinal fluid biomarker levels;	chr7:23104232	chr7:23101228~23105703:-
BRCA	cis	rs2882667	0.69	rs288025	ENSG00000253404.1	AC034243.1	35.03	2.92e-178	2.16e-173	0.99	0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138887944	chr5:138744434~138753309:-
BRCA	cis	rs858239	0.6	rs7785842	ENSG00000230658.1	KLHL7-AS1	34.96	7.89e-178	5.78e-173	0.95	0.73	Cerebrospinal fluid biomarker levels;	chr7:23102087	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.6	rs7456915	ENSG00000230658.1	KLHL7-AS1	34.96	7.9e-178	5.78e-173	0.95	0.73	Cerebrospinal fluid biomarker levels;	chr7:23103430	chr7:23101228~23105703:-
BRCA	cis	rs2882667	0.69	rs825748	ENSG00000253404.1	AC034243.1	-34.95	1.03e-177	7.5e-173	-1	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138800378	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs700625	ENSG00000253404.1	AC034243.1	-34.93	1.43e-177	1.01e-172	-0.99	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138763908	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.654	rs2940595	ENSG00000253404.1	AC034243.1	-34.93	1.43e-177	1.01e-172	-0.99	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138765348	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs851278	ENSG00000253404.1	AC034243.1	-34.93	1.43e-177	1.01e-172	-0.99	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138767577	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.589	rs825770	ENSG00000253404.1	AC034243.1	-34.93	1.43e-177	1.01e-172	-0.99	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138779530	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs825769	ENSG00000253404.1	AC034243.1	-34.93	1.43e-177	1.01e-172	-0.99	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138779666	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs700627	ENSG00000253404.1	AC034243.1	-34.93	1.43e-177	1.01e-172	-0.99	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138783711	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs825758	ENSG00000253404.1	AC034243.1	-34.93	1.43e-177	1.01e-172	-0.99	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138791288	chr5:138744434~138753309:-
BRCA	cis	rs1577917	0.655	rs6454472	ENSG00000203875.9	SNHG5	34.93	1.45e-177	1.02e-172	0.83	0.73	Response to antipsychotic treatment;	chr6:85514335	chr6:85660950~85678736:-
BRCA	cis	rs2882667	0.69	rs825761	ENSG00000253404.1	AC034243.1	-34.92	1.59e-177	1.11e-172	-1	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138802318	chr5:138744434~138753309:-
BRCA	cis	rs858239	0.57	rs10271613	ENSG00000230658.1	KLHL7-AS1	34.9	2.28e-177	1.59e-172	0.95	0.73	Cerebrospinal fluid biomarker levels;	chr7:23122967	chr7:23101228~23105703:-
BRCA	cis	rs2882667	0.69	rs288030	ENSG00000253404.1	AC034243.1	34.8	1.07e-176	7.29e-172	0.98	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138880594	chr5:138744434~138753309:-
BRCA	cis	rs858239	0.57	rs10242166	ENSG00000230658.1	KLHL7-AS1	34.8	1.1e-176	7.46e-172	0.95	0.73	Cerebrospinal fluid biomarker levels;	chr7:23123180	chr7:23101228~23105703:-
BRCA	cis	rs2882667	0.69	rs700616	ENSG00000253404.1	AC034243.1	-34.77	1.77e-176	1.18e-171	-0.99	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138752184	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.654	rs700617	ENSG00000253404.1	AC034243.1	-34.77	1.77e-176	1.18e-171	-0.99	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138752290	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs700618	ENSG00000253404.1	AC034243.1	-34.77	1.77e-176	1.18e-171	-0.99	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138752429	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs825746	ENSG00000253404.1	AC034243.1	-34.76	2.27e-176	1.51e-171	-1	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138800930	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.72	rs56044552	ENSG00000253404.1	AC034243.1	-34.73	3.58e-176	2.37e-171	-0.98	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138841265	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.591	rs56322405	ENSG00000253404.1	AC034243.1	-34.7	5.75e-176	3.79e-171	-0.98	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138837693	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.654	rs6863054	ENSG00000253404.1	AC034243.1	-34.67	8.33e-176	5.48e-171	-0.97	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138853166	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs1039789	ENSG00000253404.1	AC034243.1	-34.67	9.54e-176	6.26e-171	-0.97	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138835734	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs6887841	ENSG00000253404.1	AC034243.1	-34.66	1.09e-175	7.15e-171	-0.97	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138840221	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs6421921	ENSG00000253404.1	AC034243.1	-34.62	1.92e-175	1.25e-170	-0.98	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138831581	chr5:138744434~138753309:-
BRCA	cis	rs858239	0.601	rs15775	ENSG00000230658.1	KLHL7-AS1	34.59	3.26e-175	2.11e-170	0.94	0.73	Cerebrospinal fluid biomarker levels;	chr7:23125082	chr7:23101228~23105703:-
BRCA	cis	rs2882667	0.69	rs176382	ENSG00000253404.1	AC034243.1	34.57	4.8e-175	3.1e-170	0.98	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138891078	chr5:138744434~138753309:-
BRCA	cis	rs858239	0.6	rs2072368	ENSG00000230658.1	KLHL7-AS1	34.54	6.9e-175	4.44e-170	0.95	0.73	Cerebrospinal fluid biomarker levels;	chr7:23106493	chr7:23101228~23105703:-
BRCA	cis	rs2882667	0.69	rs4835705	ENSG00000253404.1	AC034243.1	-34.53	9e-175	5.77e-170	-0.98	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138827887	chr5:138744434~138753309:-
BRCA	cis	rs858239	0.6	rs1468592	ENSG00000230658.1	KLHL7-AS1	-34.43	4.4e-174	2.82e-169	-0.94	-0.73	Cerebrospinal fluid biomarker levels;	chr7:23101028	chr7:23101228~23105703:-
BRCA	cis	rs2882667	0.69	rs288004	ENSG00000253404.1	AC034243.1	34.43	4.61e-174	2.94e-169	0.97	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138895956	chr5:138744434~138753309:-
BRCA	cis	rs858239	0.6	rs9691762	ENSG00000230658.1	KLHL7-AS1	34.42	5.44e-174	3.46e-169	0.94	0.73	Cerebrospinal fluid biomarker levels;	chr7:23086303	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.601	rs10255228	ENSG00000230658.1	KLHL7-AS1	34.4	7.09e-174	4.5e-169	0.95	0.73	Cerebrospinal fluid biomarker levels;	chr7:23119244	chr7:23101228~23105703:-
BRCA	cis	rs2882667	0.62	rs3789151	ENSG00000253404.1	AC034243.1	-34.4	7.14e-174	4.51e-169	-0.98	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138809771	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.587	rs6596450	ENSG00000253404.1	AC034243.1	-34.39	8.13e-174	5.12e-169	-0.98	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138810831	chr5:138744434~138753309:-
BRCA	cis	rs858239	0.601	rs1981665	ENSG00000230658.1	KLHL7-AS1	34.39	8.4e-174	5.28e-169	0.94	0.73	Cerebrospinal fluid biomarker levels;	chr7:23128350	chr7:23101228~23105703:-
BRCA	cis	rs2882667	0.599	rs288008	ENSG00000253404.1	AC034243.1	34.39	8.44e-174	5.29e-169	0.97	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138893632	chr5:138744434~138753309:-
BRCA	cis	rs858239	0.601	rs929507	ENSG00000230658.1	KLHL7-AS1	34.38	9e-174	5.6e-169	0.94	0.73	Cerebrospinal fluid biomarker levels;	chr7:23127045	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.601	rs929508	ENSG00000230658.1	KLHL7-AS1	34.38	9e-174	5.6e-169	0.94	0.73	Cerebrospinal fluid biomarker levels;	chr7:23127090	chr7:23101228~23105703:-
BRCA	cis	rs2882667	0.654	rs884470	ENSG00000253404.1	AC034243.1	-34.33	2.31e-173	1.42e-168	-0.98	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138820236	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs288013	ENSG00000253404.1	AC034243.1	-34.27	5.26e-173	3.19e-168	-0.98	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138860128	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.654	rs288019	ENSG00000253404.1	AC034243.1	-34.27	5.5e-173	3.32e-168	-0.97	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138855704	chr5:138744434~138753309:-
BRCA	cis	rs858239	0.57	rs6968242	ENSG00000230658.1	KLHL7-AS1	34.26	6.15e-173	3.71e-168	0.94	0.73	Cerebrospinal fluid biomarker levels;	chr7:23127792	chr7:23101228~23105703:-
BRCA	cis	rs2882667	0.69	rs160405	ENSG00000253404.1	AC034243.1	34.25	8.31e-173	4.99e-168	0.98	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138748387	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs7710288	ENSG00000253404.1	AC034243.1	-34.24	8.7e-173	5.21e-168	-0.96	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138844049	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs13172507	ENSG00000253404.1	AC034243.1	34.2	1.71e-172	1.02e-167	0.97	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138907409	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs176381	ENSG00000253404.1	AC034243.1	-34.19	2.17e-172	1.29e-167	-0.98	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138861042	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs1828187	ENSG00000253404.1	AC034243.1	34.18	2.53e-172	1.49e-167	0.97	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138836531	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs288023	ENSG00000253404.1	AC034243.1	34.16	3.55e-172	2.08e-167	0.97	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888359	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs288011	ENSG00000253404.1	AC034243.1	-34.11	7.23e-172	4.15e-167	-0.97	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138864250	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs288010	ENSG00000253404.1	AC034243.1	-34.11	7.23e-172	4.15e-167	-0.97	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138864340	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs288041	ENSG00000253404.1	AC034243.1	34.11	7.23e-172	4.15e-167	0.97	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138868322	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs1725335	ENSG00000253404.1	AC034243.1	-34.04	2.31e-171	1.3e-166	-0.98	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138745541	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs6872423	ENSG00000253404.1	AC034243.1	34.03	2.67e-171	1.5e-166	0.98	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138911089	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs700624	ENSG00000253404.1	AC034243.1	-33.97	7.41e-171	4.05e-166	-0.97	-0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138763332	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.587	rs2174972	ENSG00000253404.1	AC034243.1	-33.97	7.41e-171	4.05e-166	-0.97	-0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138766229	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs2693963	ENSG00000253404.1	AC034243.1	-33.97	7.41e-171	4.05e-166	-0.97	-0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138770637	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs1567313	ENSG00000253404.1	AC034243.1	-33.97	7.41e-171	4.05e-166	-0.97	-0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138775013	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs288039	ENSG00000253404.1	AC034243.1	33.97	7.75e-171	4.22e-166	0.97	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138870511	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs288038	ENSG00000253404.1	AC034243.1	33.97	7.75e-171	4.22e-166	0.97	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138871844	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs13178601	ENSG00000253404.1	AC034243.1	33.93	1.36e-170	7.36e-166	0.99	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138931688	chr5:138744434~138753309:-
BRCA	cis	rs858239	0.601	rs6980224	ENSG00000230658.1	KLHL7-AS1	33.93	1.37e-170	7.38e-166	0.94	0.72	Cerebrospinal fluid biomarker levels;	chr7:23109518	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.6	rs7776649	ENSG00000230658.1	KLHL7-AS1	33.93	1.41e-170	7.6e-166	0.95	0.72	Cerebrospinal fluid biomarker levels;	chr7:23079698	chr7:23101228~23105703:-
BRCA	cis	rs2882667	0.69	rs288031	ENSG00000253404.1	AC034243.1	33.89	2.79e-170	1.5e-165	0.97	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138880377	chr5:138744434~138753309:-
BRCA	cis	rs858239	0.632	rs13438452	ENSG00000230658.1	KLHL7-AS1	33.83	6.68e-170	3.56e-165	0.94	0.72	Cerebrospinal fluid biomarker levels;	chr7:23134563	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.601	rs10278776	ENSG00000230658.1	KLHL7-AS1	33.71	4.84e-169	2.54e-164	0.94	0.72	Cerebrospinal fluid biomarker levels;	chr7:23130140	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.6	rs13438188	ENSG00000230658.1	KLHL7-AS1	-33.7	5.85e-169	3.06e-164	-0.93	-0.72	Cerebrospinal fluid biomarker levels;	chr7:23104578	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.601	rs4599714	ENSG00000230658.1	KLHL7-AS1	33.69	6.79e-169	3.54e-164	0.94	0.72	Cerebrospinal fluid biomarker levels;	chr7:23129182	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.601	rs3735228	ENSG00000230658.1	KLHL7-AS1	33.68	7.71e-169	4.01e-164	0.94	0.72	Cerebrospinal fluid biomarker levels;	chr7:23130808	chr7:23101228~23105703:-
BRCA	cis	rs2882667	0.69	rs311596	ENSG00000253404.1	AC034243.1	-33.63	1.78e-168	9.1e-164	-0.97	-0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138736393	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs13181762	ENSG00000253404.1	AC034243.1	33.62	2.19e-168	1.11e-163	0.97	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138914417	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs13177415	ENSG00000253404.1	AC034243.1	33.61	2.36e-168	1.2e-163	0.97	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138914251	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs160398	ENSG00000253404.1	AC034243.1	33.58	4.08e-168	2.05e-163	0.97	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138727750	chr5:138744434~138753309:-
BRCA	cis	rs858239	0.601	rs1558313	ENSG00000230658.1	KLHL7-AS1	33.54	7.16e-168	3.56e-163	0.94	0.72	Cerebrospinal fluid biomarker levels;	chr7:23116460	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.601	rs6962526	ENSG00000230658.1	KLHL7-AS1	33.54	7.16e-168	3.56e-163	0.94	0.72	Cerebrospinal fluid biomarker levels;	chr7:23118614	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.539	rs6971673	ENSG00000230658.1	KLHL7-AS1	33.54	7.16e-168	3.56e-163	0.94	0.72	Cerebrospinal fluid biomarker levels;	chr7:23119904	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.601	rs10278700	ENSG00000230658.1	KLHL7-AS1	33.54	7.16e-168	3.56e-163	0.94	0.72	Cerebrospinal fluid biomarker levels;	chr7:23120910	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.601	rs10263110	ENSG00000230658.1	KLHL7-AS1	33.54	7.16e-168	3.56e-163	0.94	0.72	Cerebrospinal fluid biomarker levels;	chr7:23120932	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.57	rs10235467	ENSG00000230658.1	KLHL7-AS1	33.53	8.89e-168	4.41e-163	0.93	0.72	Cerebrospinal fluid biomarker levels;	chr7:23109189	chr7:23101228~23105703:-
BRCA	cis	rs2882667	0.69	rs10515504	ENSG00000253404.1	AC034243.1	-33.51	1.26e-167	6.24e-163	-0.97	-0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138887305	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs10043478	ENSG00000253404.1	AC034243.1	33.46	2.81e-167	1.38e-162	0.96	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138853022	chr5:138744434~138753309:-
BRCA	cis	rs858239	0.601	rs11982002	ENSG00000230658.1	KLHL7-AS1	33.45	3.28e-167	1.6e-162	0.94	0.72	Cerebrospinal fluid biomarker levels;	chr7:23123651	chr7:23101228~23105703:-
BRCA	cis	rs2882667	0.654	rs1703211	ENSG00000253404.1	AC034243.1	-33.43	4.57e-167	2.23e-162	-0.97	-0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138740587	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs1651032	ENSG00000253404.1	AC034243.1	-33.4	6.65e-167	3.22e-162	-0.96	-0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138743151	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.658	rs311592	ENSG00000253404.1	AC034243.1	33.22	1.29e-165	6.12e-161	0.97	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138734506	chr5:138744434~138753309:-
BRCA	cis	rs858239	0.601	rs4140959	ENSG00000230658.1	KLHL7-AS1	33.2	1.89e-165	8.94e-161	0.94	0.72	Cerebrospinal fluid biomarker levels;	chr7:23131157	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.601	rs987257	ENSG00000230658.1	KLHL7-AS1	33.16	3.17e-165	1.48e-160	0.93	0.72	Cerebrospinal fluid biomarker levels;	chr7:23108221	chr7:23101228~23105703:-
BRCA	cis	rs2882667	0.69	rs1059110	ENSG00000253404.1	AC034243.1	33.1	9.17e-165	4.26e-160	0.97	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138930857	chr5:138744434~138753309:-
BRCA	cis	rs858239	0.6	rs6461691	ENSG00000230658.1	KLHL7-AS1	33.01	3.58e-164	1.65e-159	0.93	0.72	Cerebrospinal fluid biomarker levels;	chr7:23099726	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.6	rs10241208	ENSG00000230658.1	KLHL7-AS1	32.98	6.54e-164	3e-159	0.93	0.71	Cerebrospinal fluid biomarker levels;	chr7:23105295	chr7:23101228~23105703:-
BRCA	cis	rs2882667	0.69	rs311597	ENSG00000253404.1	AC034243.1	32.98	6.58e-164	3.02e-159	0.97	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138720212	chr5:138744434~138753309:-
BRCA	cis	rs858239	0.6	rs10266123	ENSG00000230658.1	KLHL7-AS1	32.94	1.18e-163	5.38e-159	0.94	0.71	Cerebrospinal fluid biomarker levels;	chr7:23096868	chr7:23101228~23105703:-
BRCA	cis	rs2882667	0.69	rs160402	ENSG00000253404.1	AC034243.1	32.93	1.32e-163	6.04e-159	0.97	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138723599	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs160401	ENSG00000253404.1	AC034243.1	-32.91	1.91e-163	8.69e-159	-0.96	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138725652	chr5:138744434~138753309:-
BRCA	cis	rs858239	0.632	rs7811903	ENSG00000230658.1	KLHL7-AS1	32.84	6.38e-163	2.89e-158	0.94	0.71	Cerebrospinal fluid biomarker levels;	chr7:23079437	chr7:23101228~23105703:-
BRCA	cis	rs2882667	0.69	rs825669	ENSG00000253404.1	AC034243.1	-32.84	6.49e-163	2.94e-158	-0.96	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138731258	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs10068280	ENSG00000253404.1	AC034243.1	32.79	1.26e-162	5.67e-158	0.97	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138931394	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.628	rs3749663	ENSG00000253404.1	AC034243.1	32.77	1.8e-162	8.08e-158	0.96	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138935498	chr5:138744434~138753309:-
BRCA	cis	rs858239	0.541	rs4624924	ENSG00000230658.1	KLHL7-AS1	32.74	2.82e-162	1.26e-157	0.93	0.71	Cerebrospinal fluid biomarker levels;	chr7:23129224	chr7:23101228~23105703:-
BRCA	cis	rs2882667	0.69	rs9327829	ENSG00000253404.1	AC034243.1	-32.72	4.09e-162	1.83e-157	-0.97	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138925982	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs3749664	ENSG00000253404.1	AC034243.1	32.69	6.29e-162	2.8e-157	0.96	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138935732	chr5:138744434~138753309:-
BRCA	cis	rs858239	0.601	rs6948469	ENSG00000230658.1	KLHL7-AS1	32.66	1.1e-161	4.85e-157	0.93	0.71	Cerebrospinal fluid biomarker levels;	chr7:23135147	chr7:23101228~23105703:-
BRCA	cis	rs2882667	0.69	rs2351463	ENSG00000253404.1	AC034243.1	32.54	7.71e-161	3.36e-156	0.96	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138923113	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.654	rs700626	ENSG00000253404.1	AC034243.1	-32.47	2.34e-160	1.01e-155	-0.97	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138782249	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs3804199	ENSG00000253404.1	AC034243.1	-32.46	2.69e-160	1.16e-155	-0.94	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138826440	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs311599	ENSG00000253404.1	AC034243.1	32.45	3.24e-160	1.39e-155	0.96	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138718994	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs288033	ENSG00000253404.1	AC034243.1	32.44	4.07e-160	1.74e-155	0.94	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138878405	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs7446631	ENSG00000253404.1	AC034243.1	32.43	4.67e-160	1.99e-155	0.94	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138891376	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs288014	ENSG00000253404.1	AC034243.1	-32.42	5.36e-160	2.27e-155	-0.94	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138860104	chr5:138744434~138753309:-
BRCA	cis	rs858239	0.6	rs4628176	ENSG00000230658.1	KLHL7-AS1	32.4	7.57e-160	3.19e-155	0.93	0.71	Cerebrospinal fluid biomarker levels;	chr7:23102947	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.6	rs10488077	ENSG00000230658.1	KLHL7-AS1	32.37	1.11e-159	4.67e-155	0.92	0.71	Cerebrospinal fluid biomarker levels;	chr7:23104563	chr7:23101228~23105703:-
BRCA	cis	rs2882667	0.587	rs1848506	ENSG00000253404.1	AC034243.1	-32.36	1.47e-159	6.15e-155	-0.93	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138846768	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs1848505	ENSG00000253404.1	AC034243.1	-32.36	1.47e-159	6.15e-155	-0.93	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138846841	chr5:138744434~138753309:-
BRCA	cis	rs858239	0.601	rs6461693	ENSG00000230658.1	KLHL7-AS1	-32.34	1.85e-159	7.73e-155	-0.92	-0.71	Cerebrospinal fluid biomarker levels;	chr7:23120514	chr7:23101228~23105703:-
BRCA	cis	rs2882667	0.69	rs4835708	ENSG00000253404.1	AC034243.1	-32.33	2.18e-159	9.1e-155	-0.93	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138844204	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs6877187	ENSG00000253404.1	AC034243.1	-32.29	4.01e-159	1.67e-154	-0.94	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138823655	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs891996	ENSG00000253404.1	AC034243.1	32.29	4.09e-159	1.7e-154	0.95	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138932127	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs700620	ENSG00000253404.1	AC034243.1	-32.27	6.16e-159	2.53e-154	-0.94	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138762247	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.659	rs700621	ENSG00000253404.1	AC034243.1	-32.27	6.16e-159	2.53e-154	-0.94	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138762741	chr5:138744434~138753309:-
BRCA	cis	rs858239	0.6	rs7341483	ENSG00000230658.1	KLHL7-AS1	-32.26	7.57e-159	3.09e-154	-0.92	-0.71	Cerebrospinal fluid biomarker levels;	chr7:23088038	chr7:23101228~23105703:-
BRCA	cis	rs2882667	0.69	rs2016720	ENSG00000253404.1	AC034243.1	32.24	9.27e-159	3.78e-154	0.95	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138928369	chr5:138744434~138753309:-
BRCA	cis	rs1577917	0.56	rs9450288	ENSG00000203875.9	SNHG5	32.23	1.17e-158	4.75e-154	0.8	0.71	Response to antipsychotic treatment;	chr6:85511868	chr6:85660950~85678736:-
BRCA	cis	rs2882667	0.598	rs10078179	ENSG00000253404.1	AC034243.1	32.22	1.33e-158	5.41e-154	0.94	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138920410	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.654	rs1095374	ENSG00000253404.1	AC034243.1	-32.22	1.37e-158	5.56e-154	-0.94	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138759517	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.659	rs12719515	ENSG00000253404.1	AC034243.1	32.19	2.04e-158	8.23e-154	0.93	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138905629	chr5:138744434~138753309:-
BRCA	cis	rs2739330	0.828	rs5751770	ENSG00000273295.1	AP000350.5	32.11	7.71e-158	3.09e-153	0.81	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23901432~23907068:-
BRCA	cis	rs2739330	0.828	rs5760108	ENSG00000273295.1	AP000350.5	32.06	1.91e-157	7.62e-153	0.81	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23901432~23907068:-
BRCA	cis	rs858239	0.6	rs2003555	ENSG00000230658.1	KLHL7-AS1	32.04	2.43e-157	9.59e-153	0.92	0.7	Cerebrospinal fluid biomarker levels;	chr7:23083296	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.6	rs7784929	ENSG00000230658.1	KLHL7-AS1	32.04	2.43e-157	9.59e-153	0.92	0.7	Cerebrospinal fluid biomarker levels;	chr7:23084658	chr7:23101228~23105703:-
BRCA	cis	rs2882667	0.69	rs288022	ENSG00000253404.1	AC034243.1	32.04	2.55e-157	1e-152	0.94	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888586	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.598	rs288020	ENSG00000253404.1	AC034243.1	32.04	2.55e-157	1e-152	0.94	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888609	chr5:138744434~138753309:-
BRCA	cis	rs858239	0.6	rs10256359	ENSG00000230658.1	KLHL7-AS1	32.02	3.44e-157	1.35e-152	0.93	0.7	Cerebrospinal fluid biomarker levels;	chr7:23084258	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.601	rs10239760	ENSG00000230658.1	KLHL7-AS1	31.99	5.61e-157	2.19e-152	0.93	0.7	Cerebrospinal fluid biomarker levels;	chr7:23110331	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.6	rs6961406	ENSG00000230658.1	KLHL7-AS1	31.99	5.76e-157	2.23e-152	0.92	0.7	Cerebrospinal fluid biomarker levels;	chr7:23095272	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.6	rs6461690	ENSG00000230658.1	KLHL7-AS1	31.99	5.76e-157	2.23e-152	0.92	0.7	Cerebrospinal fluid biomarker levels;	chr7:23095915	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.6	rs6967419	ENSG00000230658.1	KLHL7-AS1	31.99	5.76e-157	2.23e-152	0.92	0.7	Cerebrospinal fluid biomarker levels;	chr7:23096691	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.6	rs7799422	ENSG00000230658.1	KLHL7-AS1	31.98	6.33e-157	2.45e-152	0.92	0.7	Cerebrospinal fluid biomarker levels;	chr7:23088794	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.6	rs28483572	ENSG00000230658.1	KLHL7-AS1	31.97	7.72e-157	2.98e-152	0.92	0.7	Cerebrospinal fluid biomarker levels;	chr7:23092166	chr7:23101228~23105703:-
BRCA	cis	rs2739330	0.828	rs2877178	ENSG00000273295.1	AP000350.5	31.94	1.2e-156	4.61e-152	0.82	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23901432~23907068:-
BRCA	cis	rs2882667	0.69	rs9327827	ENSG00000253404.1	AC034243.1	31.86	4.27e-156	1.63e-151	0.92	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138846639	chr5:138744434~138753309:-
BRCA	cis	rs858239	0.601	rs12539331	ENSG00000230658.1	KLHL7-AS1	31.84	6.65e-156	2.54e-151	0.93	0.7	Cerebrospinal fluid biomarker levels;	chr7:23111711	chr7:23101228~23105703:-
BRCA	cis	rs2882667	0.722	rs2011462	ENSG00000253404.1	AC034243.1	-31.74	3.1e-155	1.17e-150	-0.92	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138827083	chr5:138744434~138753309:-
BRCA	cis	rs858239	0.601	rs7805206	ENSG00000230658.1	KLHL7-AS1	31.64	1.7e-154	6.34e-150	0.89	0.7	Cerebrospinal fluid biomarker levels;	chr7:23120591	chr7:23101228~23105703:-
BRCA	cis	rs2882667	0.658	rs172664	ENSG00000253404.1	AC034243.1	31.54	8.42e-154	3.11e-149	0.92	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138720617	chr5:138744434~138753309:-
BRCA	cis	rs858239	0.539	rs870476	ENSG00000230658.1	KLHL7-AS1	31.53	8.67e-154	3.2e-149	0.91	0.7	Cerebrospinal fluid biomarker levels;	chr7:23153652	chr7:23101228~23105703:-
BRCA	cis	rs2882667	0.69	rs288012	ENSG00000253404.1	AC034243.1	-31.52	1.16e-153	4.27e-149	-0.92	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138860584	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs1703212	ENSG00000253404.1	AC034243.1	-31.47	2.66e-153	9.73e-149	-0.93	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138742863	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.659	rs10056014	ENSG00000253404.1	AC034243.1	31.46	2.93e-153	1.07e-148	0.93	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138920329	chr5:138744434~138753309:-
BRCA	cis	rs858239	0.601	rs10224327	ENSG00000230658.1	KLHL7-AS1	31.4	8e-153	2.9e-148	0.91	0.7	Cerebrospinal fluid biomarker levels;	chr7:23122201	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.601	rs6971002	ENSG00000230658.1	KLHL7-AS1	31.39	9.46e-153	3.43e-148	0.91	0.7	Cerebrospinal fluid biomarker levels;	chr7:23132685	chr7:23101228~23105703:-
BRCA	cis	rs5850	0.557	rs10270788	ENSG00000230658.1	KLHL7-AS1	31.37	1.32e-152	4.76e-148	0.92	0.7	Blood protein levels;	chr7:23149381	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.539	rs28716381	ENSG00000230658.1	KLHL7-AS1	31.37	1.32e-152	4.76e-148	0.92	0.7	Cerebrospinal fluid biomarker levels;	chr7:23149396	chr7:23101228~23105703:-
BRCA	cis	rs2882667	0.69	rs160400	ENSG00000253404.1	AC034243.1	-31.35	1.57e-152	5.64e-148	-0.92	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138727330	chr5:138744434~138753309:-
BRCA	cis	rs858239	0.539	rs1358442	ENSG00000230658.1	KLHL7-AS1	31.35	1.75e-152	6.24e-148	0.92	0.7	Cerebrospinal fluid biomarker levels;	chr7:23150120	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.539	rs28624974	ENSG00000230658.1	KLHL7-AS1	31.35	1.79e-152	6.37e-148	0.92	0.7	Cerebrospinal fluid biomarker levels;	chr7:23149317	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.539	rs6945510	ENSG00000230658.1	KLHL7-AS1	31.34	2.13e-152	7.56e-148	0.92	0.7	Cerebrospinal fluid biomarker levels;	chr7:23152621	chr7:23101228~23105703:-
BRCA	cis	rs2882667	0.69	rs700623	ENSG00000253404.1	AC034243.1	-31.29	4.26e-152	1.5e-147	-0.92	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138762993	chr5:138744434~138753309:-
BRCA	cis	rs858239	0.601	rs764534	ENSG00000230658.1	KLHL7-AS1	31.29	4.43e-152	1.55e-147	0.91	0.7	Cerebrospinal fluid biomarker levels;	chr7:23114316	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.601	rs2068459	ENSG00000230658.1	KLHL7-AS1	31.29	4.43e-152	1.55e-147	0.91	0.7	Cerebrospinal fluid biomarker levels;	chr7:23114694	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.539	rs2141305	ENSG00000230658.1	KLHL7-AS1	31.29	4.83e-152	1.69e-147	0.92	0.7	Cerebrospinal fluid biomarker levels;	chr7:23152280	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.539	rs10280815	ENSG00000230658.1	KLHL7-AS1	31.26	7.1e-152	2.48e-147	0.92	0.7	Cerebrospinal fluid biomarker levels;	chr7:23148751	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.539	rs10225608	ENSG00000230658.1	KLHL7-AS1	31.26	7.1e-152	2.48e-147	0.92	0.7	Cerebrospinal fluid biomarker levels;	chr7:23149289	chr7:23101228~23105703:-
BRCA	cis	rs2882667	0.69	rs6890932	ENSG00000253404.1	AC034243.1	31.24	1.01e-151	3.52e-147	0.93	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138910639	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs700629	ENSG00000253404.1	AC034243.1	-31.23	1.13e-151	3.91e-147	-0.92	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138788305	chr5:138744434~138753309:-
BRCA	cis	rs858239	0.601	rs73272053	ENSG00000230658.1	KLHL7-AS1	31.21	1.61e-151	5.55e-147	0.91	0.7	Cerebrospinal fluid biomarker levels;	chr7:23115906	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.539	rs10279194	ENSG00000230658.1	KLHL7-AS1	31.2	1.93e-151	6.61e-147	0.91	0.69	Cerebrospinal fluid biomarker levels;	chr7:23151464	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.539	rs3950345	ENSG00000230658.1	KLHL7-AS1	31.2	1.93e-151	6.61e-147	0.91	0.69	Cerebrospinal fluid biomarker levels;	chr7:23151495	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.539	rs2178139	ENSG00000230658.1	KLHL7-AS1	31.2	1.93e-151	6.61e-147	0.91	0.69	Cerebrospinal fluid biomarker levels;	chr7:23152017	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.539	rs2141306	ENSG00000230658.1	KLHL7-AS1	31.2	1.93e-151	6.61e-147	0.91	0.69	Cerebrospinal fluid biomarker levels;	chr7:23152045	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.571	rs2390755	ENSG00000230658.1	KLHL7-AS1	31.19	2.35e-151	7.98e-147	0.92	0.69	Cerebrospinal fluid biomarker levels;	chr7:23151097	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.539	rs2178140	ENSG00000230658.1	KLHL7-AS1	31.18	2.67e-151	9.09e-147	0.91	0.69	Cerebrospinal fluid biomarker levels;	chr7:23152006	chr7:23101228~23105703:-
BRCA	cis	rs2882667	0.69	rs3763016	ENSG00000253404.1	AC034243.1	31.15	4.08e-151	1.38e-146	0.92	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138935043	chr5:138744434~138753309:-
BRCA	cis	rs858239	0.539	rs4365988	ENSG00000230658.1	KLHL7-AS1	31.15	4.34e-151	1.47e-146	0.92	0.69	Cerebrospinal fluid biomarker levels;	chr7:23151252	chr7:23101228~23105703:-
BRCA	cis	rs2882667	0.69	rs160403	ENSG00000253404.1	AC034243.1	31.11	7.6e-151	2.56e-146	0.91	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138722793	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.659	rs311595	ENSG00000253404.1	AC034243.1	31.1	9.08e-151	3.05e-146	0.92	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138736183	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs160399	ENSG00000253404.1	AC034243.1	31.07	1.53e-150	5.12e-146	0.91	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138727552	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs9327830	ENSG00000253404.1	AC034243.1	31.05	2.05e-150	6.85e-146	0.93	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138936560	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs311602	ENSG00000253404.1	AC034243.1	31.03	3.22e-150	1.07e-145	0.92	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138717370	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs930063	ENSG00000253404.1	AC034243.1	31.03	3.22e-150	1.07e-145	0.92	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138717929	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs930062	ENSG00000253404.1	AC034243.1	31.03	3.22e-150	1.07e-145	0.92	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138717934	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs274118	ENSG00000253404.1	AC034243.1	30.99	5.73e-150	1.89e-145	0.92	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138729198	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs274117	ENSG00000253404.1	AC034243.1	30.99	5.73e-150	1.89e-145	0.92	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138729359	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs906695	ENSG00000253404.1	AC034243.1	30.98	6.94e-150	2.29e-145	0.93	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138803588	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs274119	ENSG00000253404.1	AC034243.1	30.97	7.32e-150	2.41e-145	0.92	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138728530	chr5:138744434~138753309:-
BRCA	cis	rs858239	0.632	rs1985769	ENSG00000230658.1	KLHL7-AS1	30.97	7.83e-150	2.56e-145	0.91	0.69	Cerebrospinal fluid biomarker levels;	chr7:23082887	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.6	rs28499396	ENSG00000230658.1	KLHL7-AS1	30.97	7.83e-150	2.56e-145	0.91	0.69	Cerebrospinal fluid biomarker levels;	chr7:23084479	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.6	rs7789237	ENSG00000230658.1	KLHL7-AS1	30.97	7.83e-150	2.56e-145	0.91	0.69	Cerebrospinal fluid biomarker levels;	chr7:23085094	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.6	rs4409314	ENSG00000230658.1	KLHL7-AS1	30.94	1.19e-149	3.89e-145	0.9	0.69	Cerebrospinal fluid biomarker levels;	chr7:23088333	chr7:23101228~23105703:-
BRCA	cis	rs2882667	0.69	rs7709789	ENSG00000253404.1	AC034243.1	30.91	2.08e-149	6.78e-145	0.93	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138938762	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.628	rs311605	ENSG00000253404.1	AC034243.1	30.91	2.11e-149	6.86e-145	0.94	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138710150	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs1651358	ENSG00000253404.1	AC034243.1	-30.86	4.42e-149	1.43e-144	-0.93	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138745318	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.654	rs884469	ENSG00000253404.1	AC034243.1	-30.85	5.48e-149	1.77e-144	-0.91	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138820270	chr5:138744434~138753309:-
BRCA	cis	rs858239	0.539	rs6965833	ENSG00000230658.1	KLHL7-AS1	30.85	5.56e-149	1.79e-144	0.91	0.69	Cerebrospinal fluid biomarker levels;	chr7:23152747	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.539	rs6949363	ENSG00000230658.1	KLHL7-AS1	30.85	5.56e-149	1.79e-144	0.91	0.69	Cerebrospinal fluid biomarker levels;	chr7:23152775	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.509	rs6975524	ENSG00000230658.1	KLHL7-AS1	30.83	7.86e-149	2.51e-144	0.91	0.69	Cerebrospinal fluid biomarker levels;	chr7:23146833	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.539	rs6955726	ENSG00000230658.1	KLHL7-AS1	30.83	7.86e-149	2.51e-144	0.91	0.69	Cerebrospinal fluid biomarker levels;	chr7:23147072	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.539	rs6956828	ENSG00000230658.1	KLHL7-AS1	30.83	7.86e-149	2.51e-144	0.91	0.69	Cerebrospinal fluid biomarker levels;	chr7:23147728	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.539	rs4504540	ENSG00000230658.1	KLHL7-AS1	30.82	9.06e-149	2.89e-144	0.91	0.69	Cerebrospinal fluid biomarker levels;	chr7:23146579	chr7:23101228~23105703:-
BRCA	cis	rs2739330	0.828	rs5760107	ENSG00000273295.1	AP000350.5	30.82	9.19e-149	2.93e-144	0.81	0.69	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23901432~23907068:-
BRCA	cis	rs2739330	0.789	rs5760109	ENSG00000273295.1	AP000350.5	30.81	1.12e-148	3.57e-144	0.81	0.69	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23901432~23907068:-
BRCA	cis	rs858239	0.539	rs4294098	ENSG00000230658.1	KLHL7-AS1	30.8	1.22e-148	3.87e-144	0.91	0.69	Cerebrospinal fluid biomarker levels;	chr7:23146376	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.539	rs6976957	ENSG00000230658.1	KLHL7-AS1	30.76	2.23e-148	7.03e-144	0.91	0.69	Cerebrospinal fluid biomarker levels;	chr7:23147714	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.601	rs764533	ENSG00000230658.1	KLHL7-AS1	30.76	2.37e-148	7.47e-144	0.92	0.69	Cerebrospinal fluid biomarker levels;	chr7:23114256	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.539	rs57864591	ENSG00000230658.1	KLHL7-AS1	30.76	2.39e-148	7.51e-144	0.92	0.69	Cerebrospinal fluid biomarker levels;	chr7:23144805	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.539	rs6955969	ENSG00000230658.1	KLHL7-AS1	30.72	4.38e-148	1.37e-143	0.91	0.69	Cerebrospinal fluid biomarker levels;	chr7:23147080	chr7:23101228~23105703:-
BRCA	cis	rs2882667	0.69	rs6596456	ENSG00000253404.1	AC034243.1	-30.7	6.28e-148	1.96e-143	-0.91	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138831808	chr5:138744434~138753309:-
BRCA	cis	rs858239	0.539	rs7791200	ENSG00000230658.1	KLHL7-AS1	30.68	8.83e-148	2.75e-143	0.92	0.69	Cerebrospinal fluid biomarker levels;	chr7:23142502	chr7:23101228~23105703:-
BRCA	cis	rs2882667	0.69	rs13158360	ENSG00000253404.1	AC034243.1	30.68	9.15e-148	2.84e-143	0.91	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138922488	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.728	rs10037071	ENSG00000253404.1	AC034243.1	30.58	4.05e-147	1.25e-142	0.92	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138942158	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs423469	ENSG00000253404.1	AC034243.1	30.5	1.66e-146	5.09e-142	0.9	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138898427	chr5:138744434~138753309:-
BRCA	cis	rs858239	0.602	rs6953996	ENSG00000230658.1	KLHL7-AS1	30.46	3.07e-146	9.41e-142	0.9	0.69	Cerebrospinal fluid biomarker levels;	chr7:23136327	chr7:23101228~23105703:-
BRCA	cis	rs2882667	0.728	rs7722413	ENSG00000253404.1	AC034243.1	30.45	3.72e-146	1.14e-141	0.92	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138942562	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs825749	ENSG00000253404.1	AC034243.1	-30.44	4.3e-146	1.31e-141	-0.91	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138800232	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.654	rs6862845	ENSG00000253404.1	AC034243.1	30.26	7.49e-145	2.26e-140	0.92	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138937456	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.654	rs7709770	ENSG00000253404.1	AC034243.1	-30.21	1.55e-144	4.67e-140	-0.96	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138813650	chr5:138744434~138753309:-
BRCA	cis	rs858239	0.6	rs7776644	ENSG00000230658.1	KLHL7-AS1	30.2	2.08e-144	6.27e-140	0.91	0.68	Cerebrospinal fluid biomarker levels;	chr7:23079688	chr7:23101228~23105703:-
BRCA	cis	rs2882667	0.622	rs34645817	ENSG00000253404.1	AC034243.1	-30.12	7.08e-144	2.12e-139	-0.95	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138816944	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.619	rs6861556	ENSG00000253404.1	AC034243.1	-30.07	1.57e-143	4.69e-139	-0.94	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138852351	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs6596455	ENSG00000253404.1	AC034243.1	-30.05	2.2e-143	6.54e-139	-0.94	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138831416	chr5:138744434~138753309:-
BRCA	cis	rs2739330	0.796	rs2154594	ENSG00000273295.1	AP000350.5	-30.04	2.46e-143	7.33e-139	-0.8	-0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23901432~23907068:-
BRCA	cis	rs858239	0.571	rs6953020	ENSG00000230658.1	KLHL7-AS1	30.03	3.23e-143	9.59e-139	0.9	0.68	Cerebrospinal fluid biomarker levels;	chr7:23132513	chr7:23101228~23105703:-
BRCA	cis	rs2739330	0.828	rs4820572	ENSG00000273295.1	AP000350.5	30.01	4.24e-143	1.25e-138	0.81	0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23901432~23907068:-
BRCA	cis	rs2739330	0.796	rs5760106	ENSG00000273295.1	AP000350.5	-30.01	4.38e-143	1.29e-138	-0.81	-0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23901432~23907068:-
BRCA	cis	rs2882667	0.69	rs995177	ENSG00000253404.1	AC034243.1	-30	4.64e-143	1.37e-138	-0.94	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138833874	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.654	rs7710300	ENSG00000253404.1	AC034243.1	-30	4.64e-143	1.37e-138	-0.94	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138834793	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.654	rs825760	ENSG00000253404.1	AC034243.1	-29.99	5.54e-143	1.63e-138	-0.96	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138804285	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs9942422	ENSG00000253404.1	AC034243.1	29.99	6.07e-143	1.78e-138	0.92	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138936847	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs4835703	ENSG00000253404.1	AC034243.1	-29.96	9.84e-143	2.88e-138	-0.95	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138815048	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.654	rs4835704	ENSG00000253404.1	AC034243.1	-29.94	1.28e-142	3.74e-138	-0.95	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138815636	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs6596453	ENSG00000253404.1	AC034243.1	-29.94	1.28e-142	3.74e-138	-0.95	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138816202	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs7736925	ENSG00000253404.1	AC034243.1	-29.92	1.77e-142	5.14e-138	-0.95	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138818841	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.654	rs883333	ENSG00000253404.1	AC034243.1	-29.92	1.77e-142	5.14e-138	-0.95	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138819781	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.728	rs10068766	ENSG00000253404.1	AC034243.1	29.86	4.41e-142	1.27e-137	0.91	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138941095	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs12186373	ENSG00000253404.1	AC034243.1	29.84	5.98e-142	1.72e-137	0.94	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138912885	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs10044401	ENSG00000253404.1	AC034243.1	29.83	7.33e-142	2.1e-137	0.94	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138901868	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs10067361	ENSG00000253404.1	AC034243.1	29.83	7.33e-142	2.1e-137	0.94	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138905185	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs185956	ENSG00000253404.1	AC034243.1	29.83	7.85e-142	2.25e-137	0.94	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138894574	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.658	rs288003	ENSG00000253404.1	AC034243.1	29.79	1.42e-141	4.04e-137	0.94	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138896266	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs288002	ENSG00000253404.1	AC034243.1	29.79	1.42e-141	4.04e-137	0.94	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138896398	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs288009	ENSG00000253404.1	AC034243.1	29.79	1.54e-141	4.37e-137	0.94	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138892973	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs9327831	ENSG00000253404.1	AC034243.1	29.76	2.23e-141	6.33e-137	0.91	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138936597	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs160404	ENSG00000253404.1	AC034243.1	29.76	2.47e-141	6.99e-137	0.92	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138748580	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs13174008	ENSG00000253404.1	AC034243.1	29.71	5.46e-141	1.54e-136	0.9	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138922220	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs288007	ENSG00000253404.1	AC034243.1	29.68	7.88e-141	2.22e-136	0.94	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138894939	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs288018	ENSG00000253404.1	AC034243.1	-29.67	9.77e-141	2.74e-136	-0.94	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138856727	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs288017	ENSG00000253404.1	AC034243.1	-29.67	9.77e-141	2.74e-136	-0.94	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138857826	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.654	rs2351247	ENSG00000253404.1	AC034243.1	-29.65	1.45e-140	4.06e-136	-0.93	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138849456	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs10155636	ENSG00000253404.1	AC034243.1	29.62	2.32e-140	6.5e-136	0.94	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138926301	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.652	rs700622	ENSG00000253404.1	AC034243.1	-29.59	3.89e-140	1.07e-135	-0.94	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138762862	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs7722965	ENSG00000253404.1	AC034243.1	-29.59	3.89e-140	1.07e-135	-0.94	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138764766	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs1976562	ENSG00000253404.1	AC034243.1	-29.59	3.89e-140	1.07e-135	-0.94	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138774905	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.658	rs10076442	ENSG00000253404.1	AC034243.1	29.58	4.53e-140	1.25e-135	0.9	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138941090	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs825677	ENSG00000253404.1	AC034243.1	-29.56	5.73e-140	1.58e-135	-0.94	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138769081	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.628	rs10076629	ENSG00000253404.1	AC034243.1	29.51	1.42e-139	3.88e-135	0.94	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138920272	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.659	rs11750067	ENSG00000253404.1	AC034243.1	29.51	1.42e-139	3.88e-135	0.94	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138920589	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs9327828	ENSG00000253404.1	AC034243.1	29.47	2.32e-139	6.32e-135	0.94	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138925859	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs288028	ENSG00000253404.1	AC034243.1	29.47	2.34e-139	6.39e-135	0.92	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138886300	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs10054682	ENSG00000253404.1	AC034243.1	29.47	2.49e-139	6.78e-135	0.93	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138923754	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs11953339	ENSG00000253404.1	AC034243.1	29.47	2.49e-139	6.78e-135	0.93	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138923853	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs288024	ENSG00000253404.1	AC034243.1	29.45	3.52e-139	9.52e-135	0.93	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888103	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs167009	ENSG00000253404.1	AC034243.1	-29.45	3.69e-139	9.96e-135	-0.94	-0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138864768	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.659	rs288037	ENSG00000253404.1	AC034243.1	29.45	3.69e-139	9.96e-135	0.94	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138872752	chr5:138744434~138753309:-
BRCA	cis	rs858239	0.669	rs12539467	ENSG00000230658.1	KLHL7-AS1	29.44	4.38e-139	1.18e-134	0.9	0.67	Cerebrospinal fluid biomarker levels;	chr7:23076240	chr7:23101228~23105703:-
BRCA	cis	rs2882667	0.69	rs10071381	ENSG00000253404.1	AC034243.1	29.42	5.85e-139	1.57e-134	0.9	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138937159	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs288026	ENSG00000253404.1	AC034243.1	29.4	7.56e-139	2.03e-134	0.93	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138886905	chr5:138744434~138753309:-
BRCA	cis	rs858239	0.601	rs2141307	ENSG00000230658.1	KLHL7-AS1	29.39	9.4e-139	2.51e-134	0.87	0.67	Cerebrospinal fluid biomarker levels;	chr7:23151805	chr7:23101228~23105703:-
BRCA	cis	rs2882667	0.69	rs288036	ENSG00000253404.1	AC034243.1	29.37	1.26e-138	3.38e-134	0.93	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138875206	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs288040	ENSG00000253404.1	AC034243.1	29.34	2.14e-138	5.71e-134	0.93	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138869205	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs825759	ENSG00000253404.1	AC034243.1	-29.32	2.61e-138	6.93e-134	-0.93	-0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138790250	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs700619	ENSG00000253404.1	AC034243.1	-29.31	3.18e-138	8.42e-134	-0.93	-0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138753060	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs825672	ENSG00000253404.1	AC034243.1	-29.31	3.31e-138	8.76e-134	-0.93	-0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138759954	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs288035	ENSG00000253404.1	AC034243.1	29.26	7.68e-138	2.02e-133	0.93	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138876728	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs288032	ENSG00000253404.1	AC034243.1	29.26	7.68e-138	2.02e-133	0.93	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138879639	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs288021	ENSG00000253404.1	AC034243.1	29.17	3.02e-137	7.9e-133	0.93	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888594	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs17031	ENSG00000253404.1	AC034243.1	29.14	4.65e-137	1.22e-132	0.91	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138934853	chr5:138744434~138753309:-
BRCA	cis	rs858239	0.511	rs10256996	ENSG00000230658.1	KLHL7-AS1	-29.12	7.48e-137	1.95e-132	-0.84	-0.67	Cerebrospinal fluid biomarker levels;	chr7:23105676	chr7:23101228~23105703:-
BRCA	cis	rs507080	0.922	rs525485	ENSG00000255239.1	AP002954.6	29.11	8.3e-137	2.16e-132	0.82	0.67	Serum metabolite levels;	chr11:118685045	chr11:118688039~118690600:-
BRCA	cis	rs2882667	0.587	rs825674	ENSG00000253404.1	AC034243.1	-29.07	1.55e-136	3.95e-132	-0.95	-0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138767031	chr5:138744434~138753309:-
BRCA	cis	rs2486288	0.656	rs6493145	ENSG00000259520.4	CTD-2651B20.3	29.02	3.42e-136	8.65e-132	0.83	0.67	Glomerular filtration rate;	chr15:45281664	chr15:45251580~45279251:-
BRCA	cis	rs858239	0.699	rs858260	ENSG00000230658.1	KLHL7-AS1	29.01	3.94e-136	9.96e-132	0.88	0.67	Cerebrospinal fluid biomarker levels;	chr7:23173315	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.632	rs6952947	ENSG00000230658.1	KLHL7-AS1	-28.96	9.54e-136	2.35e-131	-0.88	-0.67	Cerebrospinal fluid biomarker levels;	chr7:23081423	chr7:23101228~23105703:-
BRCA	cis	rs2882667	0.69	rs10463975	ENSG00000253404.1	AC034243.1	28.96	9.7e-136	2.39e-131	0.94	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138927560	chr5:138744434~138753309:-
BRCA	cis	rs2486288	0.656	rs8024620	ENSG00000259520.4	CTD-2651B20.3	28.92	1.72e-135	4.2e-131	0.83	0.67	Glomerular filtration rate;	chr15:45282131	chr15:45251580~45279251:-
BRCA	cis	rs1577917	0.74	rs2475792	ENSG00000203875.9	SNHG5	28.9	2.31e-135	5.64e-131	0.75	0.67	Response to antipsychotic treatment;	chr6:85682384	chr6:85660950~85678736:-
BRCA	cis	rs2486288	0.656	rs12908818	ENSG00000259520.4	CTD-2651B20.3	28.9	2.46e-135	5.99e-131	0.83	0.67	Glomerular filtration rate;	chr15:45279470	chr15:45251580~45279251:-
BRCA	cis	rs2486288	0.656	rs62026703	ENSG00000259520.4	CTD-2651B20.3	28.88	3.55e-135	8.56e-131	0.83	0.67	Glomerular filtration rate;	chr15:45277731	chr15:45251580~45279251:-
BRCA	cis	rs2486288	0.656	rs7165039	ENSG00000259520.4	CTD-2651B20.3	28.88	3.55e-135	8.56e-131	0.83	0.67	Glomerular filtration rate;	chr15:45278215	chr15:45251580~45279251:-
BRCA	cis	rs2882667	0.728	rs10068786	ENSG00000253404.1	AC034243.1	28.87	3.84e-135	9.22e-131	0.93	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138941255	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs311601	ENSG00000253404.1	AC034243.1	28.86	4.64e-135	1.11e-130	0.94	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138717697	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs10078079	ENSG00000253404.1	AC034243.1	28.85	5.06e-135	1.21e-130	0.94	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138920450	chr5:138744434~138753309:-
BRCA	cis	rs2486288	0.656	rs7166580	ENSG00000259520.4	CTD-2651B20.3	28.85	5.58e-135	1.34e-130	0.83	0.67	Glomerular filtration rate;	chr15:45279011	chr15:45251580~45279251:-
BRCA	cis	rs2486288	0.656	rs6493143	ENSG00000259520.4	CTD-2651B20.3	28.79	1.41e-134	3.31e-130	0.83	0.67	Glomerular filtration rate;	chr15:45278583	chr15:45251580~45279251:-
BRCA	cis	rs2486288	0.586	rs12909883	ENSG00000259520.4	CTD-2651B20.3	28.78	1.63e-134	3.82e-130	0.83	0.67	Glomerular filtration rate;	chr15:45279856	chr15:45251580~45279251:-
BRCA	cis	rs2486288	0.656	rs7171312	ENSG00000259520.4	CTD-2651B20.3	28.78	1.72e-134	4.02e-130	0.83	0.67	Glomerular filtration rate;	chr15:45278027	chr15:45251580~45279251:-
BRCA	cis	rs858239	0.665	rs6964665	ENSG00000230658.1	KLHL7-AS1	28.75	2.51e-134	5.87e-130	0.87	0.67	Cerebrospinal fluid biomarker levels;	chr7:23171733	chr7:23101228~23105703:-
BRCA	cis	rs2486288	0.656	rs12910009	ENSG00000259520.4	CTD-2651B20.3	28.74	2.88e-134	6.71e-130	0.83	0.67	Glomerular filtration rate;	chr15:45280210	chr15:45251580~45279251:-
BRCA	cis	rs2486288	0.586	rs12909625	ENSG00000259520.4	CTD-2651B20.3	28.72	4.05e-134	9.39e-130	0.83	0.66	Glomerular filtration rate;	chr15:45279855	chr15:45251580~45279251:-
BRCA	cis	rs1577917	0.74	rs9344542	ENSG00000203875.9	SNHG5	28.71	5.15e-134	1.19e-129	0.75	0.66	Response to antipsychotic treatment;	chr6:85684187	chr6:85660950~85678736:-
BRCA	cis	rs858239	0.539	rs2103281	ENSG00000230658.1	KLHL7-AS1	28.71	5.45e-134	1.26e-129	0.87	0.66	Cerebrospinal fluid biomarker levels;	chr7:23154612	chr7:23101228~23105703:-
BRCA	cis	rs2882667	0.554	rs1368425	ENSG00000253404.1	AC034243.1	28.69	6.51e-134	1.5e-129	0.89	0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138944528	chr5:138744434~138753309:-
BRCA	cis	rs1577917	0.74	rs9353327	ENSG00000203875.9	SNHG5	-28.69	6.68e-134	1.54e-129	-0.76	-0.66	Response to antipsychotic treatment;	chr6:85684348	chr6:85660950~85678736:-
BRCA	cis	rs2882667	0.69	rs288029	ENSG00000253404.1	AC034243.1	28.68	8.34e-134	1.92e-129	0.92	0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138881616	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs10045605	ENSG00000253404.1	AC034243.1	28.62	2.01e-133	4.62e-129	0.94	0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138936458	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.654	rs10044432	ENSG00000253404.1	AC034243.1	28.61	2.54e-133	5.84e-129	0.94	0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138939207	chr5:138744434~138753309:-
BRCA	cis	rs2486288	0.656	rs2413771	ENSG00000259520.4	CTD-2651B20.3	28.52	9.81e-133	2.24e-128	0.82	0.66	Glomerular filtration rate;	chr15:45260942	chr15:45251580~45279251:-
BRCA	cis	rs2486288	0.656	rs6493144	ENSG00000259520.4	CTD-2651B20.3	-28.42	5.11e-132	1.16e-127	-0.82	-0.66	Glomerular filtration rate;	chr15:45281291	chr15:45251580~45279251:-
BRCA	cis	rs858239	0.539	rs10247268	ENSG00000230658.1	KLHL7-AS1	28.41	5.75e-132	1.31e-127	0.88	0.66	Cerebrospinal fluid biomarker levels;	chr7:23147560	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.539	rs6461694	ENSG00000230658.1	KLHL7-AS1	28.41	5.75e-132	1.31e-127	0.88	0.66	Cerebrospinal fluid biomarker levels;	chr7:23148160	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.539	rs6461695	ENSG00000230658.1	KLHL7-AS1	28.41	6.1e-132	1.38e-127	0.87	0.66	Cerebrospinal fluid biomarker levels;	chr7:23158165	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.539	rs4559148	ENSG00000230658.1	KLHL7-AS1	28.37	1.2e-131	2.71e-127	0.88	0.66	Cerebrospinal fluid biomarker levels;	chr7:23146348	chr7:23101228~23105703:-
BRCA	cis	rs2882667	0.628	rs13171173	ENSG00000253404.1	AC034243.1	-28.37	1.24e-131	2.8e-127	-0.91	-0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138706775	chr5:138744434~138753309:-
BRCA	cis	rs858239	0.508	rs7805071	ENSG00000230658.1	KLHL7-AS1	28.33	2.32e-131	5.21e-127	0.88	0.66	Cerebrospinal fluid biomarker levels;	chr7:23150593	chr7:23101228~23105703:-
BRCA	cis	rs507080	0.885	rs693037	ENSG00000255239.1	AP002954.6	28.31	3.27e-131	7.34e-127	0.8	0.66	Serum metabolite levels;	chr11:118682617	chr11:118688039~118690600:-
BRCA	cis	rs858239	0.539	rs4377861	ENSG00000230658.1	KLHL7-AS1	28.31	3.3e-131	7.39e-127	0.88	0.66	Cerebrospinal fluid biomarker levels;	chr7:23146350	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.508	rs7805085	ENSG00000230658.1	KLHL7-AS1	28.3	3.37e-131	7.54e-127	0.87	0.66	Cerebrospinal fluid biomarker levels;	chr7:23150624	chr7:23101228~23105703:-
BRCA	cis	rs507080	0.922	rs625513	ENSG00000255239.1	AP002954.6	28.3	3.4e-131	7.6e-127	0.8	0.66	Serum metabolite levels;	chr11:118685010	chr11:118688039~118690600:-
BRCA	cis	rs507080	0.922	rs546890	ENSG00000255239.1	AP002954.6	28.3	3.51e-131	7.75e-127	0.8	0.66	Serum metabolite levels;	chr11:118686489	chr11:118688039~118690600:-
BRCA	cis	rs507080	0.883	rs693306	ENSG00000255239.1	AP002954.6	28.3	3.51e-131	7.75e-127	0.8	0.66	Serum metabolite levels;	chr11:118687624	chr11:118688039~118690600:-
BRCA	cis	rs507080	0.922	rs561845	ENSG00000255239.1	AP002954.6	28.3	3.51e-131	7.75e-127	0.8	0.66	Serum metabolite levels;	chr11:118688118	chr11:118688039~118690600:-
BRCA	cis	rs507080	0.922	rs638805	ENSG00000255239.1	AP002954.6	28.3	3.51e-131	7.75e-127	0.8	0.66	Serum metabolite levels;	chr11:118688180	chr11:118688039~118690600:-
BRCA	cis	rs507080	0.845	rs510408	ENSG00000255239.1	AP002954.6	28.3	3.51e-131	7.75e-127	0.8	0.66	Serum metabolite levels;	chr11:118688192	chr11:118688039~118690600:-
BRCA	cis	rs507080	0.845	rs509641	ENSG00000255239.1	AP002954.6	28.3	3.51e-131	7.75e-127	0.8	0.66	Serum metabolite levels;	chr11:118688243	chr11:118688039~118690600:-
BRCA	cis	rs507080	0.883	rs563549	ENSG00000255239.1	AP002954.6	28.3	3.51e-131	7.75e-127	0.8	0.66	Serum metabolite levels;	chr11:118688244	chr11:118688039~118690600:-
BRCA	cis	rs507080	0.885	rs533144	ENSG00000255239.1	AP002954.6	28.27	5.94e-131	1.31e-126	0.79	0.66	Serum metabolite levels;	chr11:118688538	chr11:118688039~118690600:-
BRCA	cis	rs507080	0.922	rs558907	ENSG00000255239.1	AP002954.6	28.26	6.89e-131	1.52e-126	0.8	0.66	Serum metabolite levels;	chr11:118687746	chr11:118688039~118690600:-
BRCA	cis	rs507080	0.885	rs7926959	ENSG00000255239.1	AP002954.6	28.22	1.23e-130	2.7e-126	0.8	0.66	Serum metabolite levels;	chr11:118689157	chr11:118688039~118690600:-
BRCA	cis	rs507080	0.663	rs7926970	ENSG00000255239.1	AP002954.6	28.22	1.23e-130	2.7e-126	0.8	0.66	Serum metabolite levels;	chr11:118689172	chr11:118688039~118690600:-
BRCA	cis	rs858239	0.539	rs6975852	ENSG00000230658.1	KLHL7-AS1	28.22	1.3e-130	2.83e-126	0.88	0.66	Cerebrospinal fluid biomarker levels;	chr7:23147035	chr7:23101228~23105703:-
BRCA	cis	rs507080	0.922	rs514143	ENSG00000255239.1	AP002954.6	28.2	1.88e-130	4.1e-126	0.8	0.66	Serum metabolite levels;	chr11:118687740	chr11:118688039~118690600:-
BRCA	cis	rs507080	0.922	rs555356	ENSG00000255239.1	AP002954.6	28.16	3.41e-130	7.43e-126	0.8	0.66	Serum metabolite levels;	chr11:118687369	chr11:118688039~118690600:-
BRCA	cis	rs858239	0.508	rs2390754	ENSG00000230658.1	KLHL7-AS1	28.16	3.42e-130	7.43e-126	0.87	0.66	Cerebrospinal fluid biomarker levels;	chr7:23150875	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.539	rs2390757	ENSG00000230658.1	KLHL7-AS1	28.15	3.75e-130	8.14e-126	0.87	0.66	Cerebrospinal fluid biomarker levels;	chr7:23151873	chr7:23101228~23105703:-
BRCA	cis	rs1577917	0.839	rs6454492	ENSG00000203875.9	SNHG5	-28.13	5.53e-130	1.2e-125	-0.77	-0.66	Response to antipsychotic treatment;	chr6:85773496	chr6:85660950~85678736:-
BRCA	cis	rs2882667	0.69	rs825747	ENSG00000253404.1	AC034243.1	-28.05	2e-129	4.33e-125	-0.93	-0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138800896	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.69	rs11954103	ENSG00000253404.1	AC034243.1	27.94	1.19e-128	2.56e-124	0.94	0.65	Age-related hearing impairment (SNP x SNP interaction);	chr5:138933459	chr5:138744434~138753309:-
BRCA	cis	rs1577917	0.771	rs7762321	ENSG00000203875.9	SNHG5	27.72	3.65e-127	7.79e-123	0.74	0.65	Response to antipsychotic treatment;	chr6:85702428	chr6:85660950~85678736:-
BRCA	cis	rs2739330	0.76	rs1002286	ENSG00000273295.1	AP000350.5	-27.69	6.38e-127	1.36e-122	-0.77	-0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23901432~23907068:-
BRCA	cis	rs858239	0.539	rs10254544	ENSG00000230658.1	KLHL7-AS1	27.66	1.03e-126	2.19e-122	0.87	0.65	Cerebrospinal fluid biomarker levels;	chr7:23180616	chr7:23101228~23105703:-
BRCA	cis	rs1577917	0.682	rs1173417	ENSG00000203875.9	SNHG5	27.53	7.53e-126	1.57e-121	0.73	0.65	Response to antipsychotic treatment;	chr6:85694223	chr6:85660950~85678736:-
BRCA	cis	rs1577917	0.682	rs1173419	ENSG00000203875.9	SNHG5	-27.49	1.44e-125	3.01e-121	-0.73	-0.65	Response to antipsychotic treatment;	chr6:85692445	chr6:85660950~85678736:-
BRCA	cis	rs2882667	0.728	rs13181830	ENSG00000253404.1	AC034243.1	-27.47	2.02e-125	4.2e-121	-0.86	-0.65	Age-related hearing impairment (SNP x SNP interaction);	chr5:138944727	chr5:138744434~138753309:-
BRCA	cis	rs801193	1	rs2659909	ENSG00000226824.5	RP4-756H11.3	-27.28	4.5e-124	9.23e-120	-0.77	-0.65	Aortic root size;	chr7:66695292	chr7:66654538~66669855:+
BRCA	cis	rs801193	1	rs2420824	ENSG00000226824.5	RP4-756H11.3	27.25	7.18e-124	1.47e-119	0.77	0.65	Aortic root size;	chr7:66666129	chr7:66654538~66669855:+
BRCA	cis	rs1577917	0.74	rs7775864	ENSG00000203875.9	SNHG5	27.2	1.6e-123	3.26e-119	0.73	0.64	Response to antipsychotic treatment;	chr6:85538041	chr6:85660950~85678736:-
BRCA	cis	rs875971	0.66	rs2013222	ENSG00000226824.5	RP4-756H11.3	27.14	4.2e-123	8.3e-119	0.77	0.64	Aortic root size;	chr7:66570949	chr7:66654538~66669855:+
BRCA	cis	rs1577917	0.74	rs2842614	ENSG00000203875.9	SNHG5	-27.14	4.27e-123	8.44e-119	-0.73	-0.64	Response to antipsychotic treatment;	chr6:85596351	chr6:85660950~85678736:-
BRCA	cis	rs1577917	0.74	rs9353320	ENSG00000203875.9	SNHG5	27.13	4.82e-123	9.5e-119	0.73	0.64	Response to antipsychotic treatment;	chr6:85535130	chr6:85660950~85678736:-
BRCA	cis	rs1577917	0.74	rs9344533	ENSG00000203875.9	SNHG5	27.12	5.2e-123	1.03e-118	0.72	0.64	Response to antipsychotic treatment;	chr6:85526470	chr6:85660950~85678736:-
BRCA	cis	rs2739330	0.796	rs1006771	ENSG00000273295.1	AP000350.5	27.09	9.35e-123	1.82e-118	0.76	0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23901432~23907068:-
BRCA	cis	rs3814244	0.569	rs2051993	ENSG00000255733.4	IFNG-AS1	27.08	1.03e-122	1.99e-118	0.56	0.64	Itch intensity from mosquito bite adjusted by bite size;	chr12:68019898	chr12:67989445~68234686:+
BRCA	cis	rs1577917	0.74	rs2758843	ENSG00000203875.9	SNHG5	-27.02	2.73e-122	5.26e-118	-0.73	-0.64	Response to antipsychotic treatment;	chr6:85618713	chr6:85660950~85678736:-
BRCA	cis	rs9322193	0.923	rs9766004	ENSG00000231760.4	RP11-350J20.5	26.98	4.84e-122	9.22e-118	0.79	0.64	Lung cancer;	chr6:149754363	chr6:149796151~149826294:-
BRCA	cis	rs1577917	0.74	rs7771612	ENSG00000203875.9	SNHG5	26.89	1.99e-121	3.77e-117	0.72	0.64	Response to antipsychotic treatment;	chr6:85554656	chr6:85660950~85678736:-
BRCA	cis	rs858239	0.537	rs2286272	ENSG00000230658.1	KLHL7-AS1	26.84	5.02e-121	9.46e-117	0.85	0.64	Cerebrospinal fluid biomarker levels;	chr7:23184748	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.537	rs10279691	ENSG00000230658.1	KLHL7-AS1	26.82	7.06e-121	1.32e-116	0.85	0.64	Cerebrospinal fluid biomarker levels;	chr7:23188768	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.537	rs6955115	ENSG00000230658.1	KLHL7-AS1	26.79	1.02e-120	1.92e-116	0.85	0.64	Cerebrospinal fluid biomarker levels;	chr7:23187525	chr7:23101228~23105703:-
BRCA	cis	rs801193	1	rs2707856	ENSG00000226824.5	RP4-756H11.3	-26.67	6.96e-120	1.28e-115	-0.77	-0.64	Aortic root size;	chr7:66746023	chr7:66654538~66669855:+
BRCA	cis	rs1577917	0.883	rs1415749	ENSG00000203875.9	SNHG5	26.63	1.34e-119	2.46e-115	0.74	0.64	Response to antipsychotic treatment;	chr6:86069366	chr6:85660950~85678736:-
BRCA	cis	rs801193	0.904	rs4718403	ENSG00000226824.5	RP4-756H11.3	-26.57	3.33e-119	6.03e-115	-0.77	-0.64	Aortic root size;	chr7:66777742	chr7:66654538~66669855:+
BRCA	cis	rs1577917	0.655	rs9359658	ENSG00000203875.9	SNHG5	26.57	3.61e-119	6.53e-115	0.72	0.64	Response to antipsychotic treatment;	chr6:85596051	chr6:85660950~85678736:-
BRCA	cis	rs801193	1	rs4717319	ENSG00000226824.5	RP4-756H11.3	-26.56	4.16e-119	7.52e-115	-0.77	-0.64	Aortic root size;	chr7:66777606	chr7:66654538~66669855:+
BRCA	cis	rs858239	0.508	rs10242104	ENSG00000230658.1	KLHL7-AS1	26.47	1.76e-118	3.14e-114	0.85	0.63	Cerebrospinal fluid biomarker levels;	chr7:23180831	chr7:23101228~23105703:-
BRCA	cis	rs801193	1	rs3778909	ENSG00000226824.5	RP4-756H11.3	-26.45	2.15e-118	3.82e-114	-0.77	-0.63	Aortic root size;	chr7:66790659	chr7:66654538~66669855:+
BRCA	cis	rs2739330	0.734	rs2000467	ENSG00000273295.1	AP000350.5	-26.43	3.21e-118	5.67e-114	-0.76	-0.63	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23901432~23907068:-
BRCA	cis	rs1577917	0.629	rs7761762	ENSG00000203875.9	SNHG5	26.41	4.69e-118	8.26e-114	0.71	0.63	Response to antipsychotic treatment;	chr6:85496250	chr6:85660950~85678736:-
BRCA	cis	rs2486288	0.656	rs7167146	ENSG00000259520.4	CTD-2651B20.3	-26.39	6.11e-118	1.07e-113	-0.82	-0.63	Glomerular filtration rate;	chr15:45279188	chr15:45251580~45279251:-
BRCA	cis	rs3814244	0.528	rs17104682	ENSG00000255733.4	IFNG-AS1	-26.34	1.3e-117	2.27e-113	-0.54	-0.63	Itch intensity from mosquito bite adjusted by bite size;	chr12:68033256	chr12:67989445~68234686:+
BRCA	cis	rs801193	1	rs1553610	ENSG00000226824.5	RP4-756H11.3	-26.33	1.47e-117	2.54e-113	-0.76	-0.63	Aortic root size;	chr7:66732246	chr7:66654538~66669855:+
BRCA	cis	rs801193	1	rs2707845	ENSG00000226824.5	RP4-756H11.3	-26.33	1.47e-117	2.54e-113	-0.76	-0.63	Aortic root size;	chr7:66733811	chr7:66654538~66669855:+
BRCA	cis	rs801193	1	rs2707850	ENSG00000226824.5	RP4-756H11.3	-26.33	1.47e-117	2.54e-113	-0.76	-0.63	Aortic root size;	chr7:66738883	chr7:66654538~66669855:+
BRCA	cis	rs801193	0.967	rs1110414	ENSG00000226824.5	RP4-756H11.3	-26.33	1.47e-117	2.54e-113	-0.76	-0.63	Aortic root size;	chr7:66740595	chr7:66654538~66669855:+
BRCA	cis	rs801193	1	rs7783924	ENSG00000226824.5	RP4-756H11.3	-26.33	1.47e-117	2.54e-113	-0.76	-0.63	Aortic root size;	chr7:66744070	chr7:66654538~66669855:+
BRCA	cis	rs801193	1	rs7789184	ENSG00000226824.5	RP4-756H11.3	-26.33	1.47e-117	2.54e-113	-0.76	-0.63	Aortic root size;	chr7:66745208	chr7:66654538~66669855:+
BRCA	cis	rs801193	1	rs2707854	ENSG00000226824.5	RP4-756H11.3	-26.33	1.47e-117	2.54e-113	-0.76	-0.63	Aortic root size;	chr7:66747610	chr7:66654538~66669855:+
BRCA	cis	rs1577917	0.883	rs9450375	ENSG00000203875.9	SNHG5	26.3	2.31e-117	3.97e-113	0.74	0.63	Response to antipsychotic treatment;	chr6:86046911	chr6:85660950~85678736:-
BRCA	cis	rs801193	1	rs3800812	ENSG00000226824.5	RP4-756H11.3	-26.27	4.01e-117	6.89e-113	-0.76	-0.63	Aortic root size;	chr7:66758474	chr7:66654538~66669855:+
BRCA	cis	rs801193	1	rs4279493	ENSG00000226824.5	RP4-756H11.3	-26.27	4.01e-117	6.89e-113	-0.76	-0.63	Aortic root size;	chr7:66761633	chr7:66654538~66669855:+
BRCA	cis	rs801193	0.761	rs2659888	ENSG00000226824.5	RP4-756H11.3	-26.24	6.87e-117	1.17e-112	-0.76	-0.63	Aortic root size;	chr7:66765184	chr7:66654538~66669855:+
BRCA	cis	rs1577917	0.883	rs13212415	ENSG00000203875.9	SNHG5	-26.21	1.12e-116	1.9e-112	-0.74	-0.63	Response to antipsychotic treatment;	chr6:85898365	chr6:85660950~85678736:-
BRCA	cis	rs1577917	0.839	rs1447159	ENSG00000203875.9	SNHG5	-26.21	1.12e-116	1.9e-112	-0.74	-0.63	Response to antipsychotic treatment;	chr6:85899531	chr6:85660950~85678736:-
BRCA	cis	rs801193	1	rs62466793	ENSG00000226824.5	RP4-756H11.3	-26.19	1.42e-116	2.4e-112	-0.76	-0.63	Aortic root size;	chr7:66726530	chr7:66654538~66669855:+
BRCA	cis	rs801193	0.904	rs4718405	ENSG00000226824.5	RP4-756H11.3	-26.13	3.94e-116	6.52e-112	-0.74	-0.63	Aortic root size;	chr7:66789659	chr7:66654538~66669855:+
BRCA	cis	rs801193	1	rs6958520	ENSG00000226824.5	RP4-756H11.3	-26.11	4.66e-116	7.68e-112	-0.76	-0.63	Aortic root size;	chr7:66686466	chr7:66654538~66669855:+
BRCA	cis	rs801193	1	rs7788576	ENSG00000226824.5	RP4-756H11.3	26.06	1.03e-115	1.69e-111	0.76	0.63	Aortic root size;	chr7:66683315	chr7:66654538~66669855:+
BRCA	cis	rs3814244	0.528	rs2870960	ENSG00000255733.4	IFNG-AS1	26.06	1.04e-115	1.7e-111	0.55	0.63	Itch intensity from mosquito bite adjusted by bite size;	chr12:68032848	chr12:67989445~68234686:+
BRCA	cis	rs801193	1	rs6975195	ENSG00000226824.5	RP4-756H11.3	26.04	1.46e-115	2.38e-111	0.76	0.63	Aortic root size;	chr7:66659787	chr7:66654538~66669855:+
BRCA	cis	rs801193	1	rs2707836	ENSG00000226824.5	RP4-756H11.3	-26.03	1.73e-115	2.81e-111	-0.76	-0.63	Aortic root size;	chr7:66695448	chr7:66654538~66669855:+
BRCA	cis	rs801193	0.844	rs7779971	ENSG00000226824.5	RP4-756H11.3	-26.03	1.73e-115	2.81e-111	-0.76	-0.63	Aortic root size;	chr7:66696803	chr7:66654538~66669855:+
BRCA	cis	rs3814244	0.528	rs56393928	ENSG00000255733.4	IFNG-AS1	26.02	2.07e-115	3.36e-111	0.55	0.63	Itch intensity from mosquito bite adjusted by bite size;	chr12:68029927	chr12:67989445~68234686:+
BRCA	cis	rs801193	1	rs2659906	ENSG00000226824.5	RP4-756H11.3	-25.98	3.91e-115	6.27e-111	-0.75	-0.63	Aortic root size;	chr7:66700323	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.638	rs7793569	ENSG00000226824.5	RP4-756H11.3	25.97	4.81e-115	7.66e-111	0.76	0.63	Aortic root size;	chr7:66651646	chr7:66654538~66669855:+
BRCA	cis	rs801193	1	rs3857688	ENSG00000226824.5	RP4-756H11.3	25.97	4.81e-115	7.66e-111	0.76	0.63	Aortic root size;	chr7:66662819	chr7:66654538~66669855:+
BRCA	cis	rs801193	1	rs2286684	ENSG00000226824.5	RP4-756H11.3	25.97	4.81e-115	7.66e-111	0.76	0.63	Aortic root size;	chr7:66664843	chr7:66654538~66669855:+
BRCA	cis	rs801193	0.935	rs2286683	ENSG00000226824.5	RP4-756H11.3	25.97	4.81e-115	7.66e-111	0.76	0.63	Aortic root size;	chr7:66664856	chr7:66654538~66669855:+
BRCA	cis	rs801193	1	rs10274773	ENSG00000226824.5	RP4-756H11.3	25.97	4.81e-115	7.66e-111	0.76	0.63	Aortic root size;	chr7:66668591	chr7:66654538~66669855:+
BRCA	cis	rs3814244	0.528	rs12228471	ENSG00000255733.4	IFNG-AS1	25.96	5.42e-115	8.61e-111	0.54	0.63	Itch intensity from mosquito bite adjusted by bite size;	chr12:68027842	chr12:67989445~68234686:+
BRCA	cis	rs801193	0.935	rs2659916	ENSG00000226824.5	RP4-756H11.3	-25.96	5.65e-115	8.98e-111	-0.76	-0.63	Aortic root size;	chr7:66686365	chr7:66654538~66669855:+
BRCA	cis	rs801193	1	rs11773829	ENSG00000226824.5	RP4-756H11.3	25.95	6.07e-115	9.63e-111	0.76	0.63	Aortic root size;	chr7:66676087	chr7:66654538~66669855:+
BRCA	cis	rs1577917	0.804	rs2786854	ENSG00000203875.9	SNHG5	-25.94	7.46e-115	1.18e-110	-0.73	-0.63	Response to antipsychotic treatment;	chr6:85959022	chr6:85660950~85678736:-
BRCA	cis	rs801193	0.967	rs2707849	ENSG00000226824.5	RP4-756H11.3	-25.94	7.8e-115	1.23e-110	-0.75	-0.63	Aortic root size;	chr7:66687725	chr7:66654538~66669855:+
BRCA	cis	rs801193	1	rs2659912	ENSG00000226824.5	RP4-756H11.3	-25.94	7.81e-115	1.23e-110	-0.76	-0.63	Aortic root size;	chr7:66693012	chr7:66654538~66669855:+
BRCA	cis	rs801193	1	rs1553609	ENSG00000226824.5	RP4-756H11.3	-25.91	1.22e-114	1.91e-110	-0.76	-0.63	Aortic root size;	chr7:66732152	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.66	rs801192	ENSG00000226824.5	RP4-756H11.3	25.9	1.35e-114	2.1e-110	0.76	0.63	Aortic root size;	chr7:66566965	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.66	rs801190	ENSG00000226824.5	RP4-756H11.3	25.9	1.35e-114	2.1e-110	0.76	0.63	Aortic root size;	chr7:66568046	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.66	rs3857686	ENSG00000226824.5	RP4-756H11.3	25.9	1.35e-114	2.1e-110	0.76	0.63	Aortic root size;	chr7:66571204	chr7:66654538~66669855:+
BRCA	cis	rs916888	0.773	rs9896243	ENSG00000262539.1	RP11-259G18.3	25.88	1.99e-114	3.07e-110	1.03	0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:46259551~46260606:-
BRCA	cis	rs875971	0.66	rs7807930	ENSG00000226824.5	RP4-756H11.3	25.87	2.17e-114	3.35e-110	0.76	0.63	Aortic root size;	chr7:66622178	chr7:66654538~66669855:+
BRCA	cis	rs801193	1	rs10234018	ENSG00000226824.5	RP4-756H11.3	25.86	2.72e-114	4.19e-110	0.76	0.63	Aortic root size;	chr7:66681297	chr7:66654538~66669855:+
BRCA	cis	rs858239	0.537	rs6942981	ENSG00000230658.1	KLHL7-AS1	25.85	3.26e-114	5.02e-110	0.84	0.63	Cerebrospinal fluid biomarker levels;	chr7:23191929	chr7:23101228~23105703:-
BRCA	cis	rs875971	0.638	rs6460305	ENSG00000226824.5	RP4-756H11.3	25.84	3.86e-114	5.92e-110	0.76	0.62	Aortic root size;	chr7:66595421	chr7:66654538~66669855:+
BRCA	cis	rs801193	0.935	rs11772264	ENSG00000226824.5	RP4-756H11.3	-25.83	3.97e-114	6.08e-110	-0.75	-0.62	Aortic root size;	chr7:66711400	chr7:66654538~66669855:+
BRCA	cis	rs801193	0.967	rs2707853	ENSG00000226824.5	RP4-756H11.3	-25.82	4.93e-114	7.52e-110	-0.76	-0.62	Aortic root size;	chr7:66749023	chr7:66654538~66669855:+
BRCA	cis	rs3814244	0.569	rs11177008	ENSG00000255733.4	IFNG-AS1	25.81	5.56e-114	8.48e-110	0.54	0.62	Itch intensity from mosquito bite adjusted by bite size;	chr12:68021024	chr12:67989445~68234686:+
BRCA	cis	rs875971	0.66	rs28698552	ENSG00000226824.5	RP4-756H11.3	-25.81	5.98e-114	9.12e-110	-0.76	-0.62	Aortic root size;	chr7:66540031	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.619	rs12533585	ENSG00000226824.5	RP4-756H11.3	-25.8	6.42e-114	9.78e-110	-0.76	-0.62	Aortic root size;	chr7:66519618	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.638	rs6960778	ENSG00000226824.5	RP4-756H11.3	25.79	7.58e-114	1.15e-109	0.76	0.62	Aortic root size;	chr7:66606610	chr7:66654538~66669855:+
BRCA	cis	rs801193	1	rs62466794	ENSG00000226824.5	RP4-756H11.3	-25.77	1.13e-113	1.7e-109	-0.76	-0.62	Aortic root size;	chr7:66726592	chr7:66654538~66669855:+
BRCA	cis	rs858239	0.899	rs2268745	ENSG00000230658.1	KLHL7-AS1	25.76	1.17e-113	1.77e-109	0.84	0.62	Cerebrospinal fluid biomarker levels;	chr7:23277981	chr7:23101228~23105703:-
BRCA	cis	rs1577917	0.883	rs2660575	ENSG00000203875.9	SNHG5	-25.75	1.38e-113	2.09e-109	-0.73	-0.62	Response to antipsychotic treatment;	chr6:85975277	chr6:85660950~85678736:-
BRCA	cis	rs875971	0.66	rs10272357	ENSG00000226824.5	RP4-756H11.3	25.74	1.76e-113	2.65e-109	0.76	0.62	Aortic root size;	chr7:66598087	chr7:66654538~66669855:+
BRCA	cis	rs801193	0.935	rs3800820	ENSG00000226824.5	RP4-756H11.3	25.74	1.87e-113	2.8e-109	0.76	0.62	Aortic root size;	chr7:66682191	chr7:66654538~66669855:+
BRCA	cis	rs801193	0.935	rs2659899	ENSG00000226824.5	RP4-756H11.3	-25.71	2.91e-113	4.33e-109	-0.75	-0.62	Aortic root size;	chr7:66721734	chr7:66654538~66669855:+
BRCA	cis	rs801193	1	rs2659889	ENSG00000226824.5	RP4-756H11.3	-25.66	6.49e-113	9.56e-109	-0.76	-0.62	Aortic root size;	chr7:66752125	chr7:66654538~66669855:+
BRCA	cis	rs507080	0.769	rs7389	ENSG00000255239.1	AP002954.6	-25.64	8.26e-113	1.21e-108	-0.74	-0.62	Serum metabolite levels;	chr11:118657756	chr11:118688039~118690600:-
BRCA	cis	rs801193	0.967	rs2707841	ENSG00000226824.5	RP4-756H11.3	-25.61	1.3e-112	1.91e-108	-0.75	-0.62	Aortic root size;	chr7:66692033	chr7:66654538~66669855:+
BRCA	cis	rs801193	1	rs4717310	ENSG00000226824.5	RP4-756H11.3	-25.61	1.3e-112	1.91e-108	-0.75	-0.62	Aortic root size;	chr7:66696020	chr7:66654538~66669855:+
BRCA	cis	rs801193	1	rs7785213	ENSG00000226824.5	RP4-756H11.3	25.61	1.4e-112	2.05e-108	0.76	0.62	Aortic root size;	chr7:66673991	chr7:66654538~66669855:+
BRCA	cis	rs801193	1	rs2003301	ENSG00000226824.5	RP4-756H11.3	25.57	2.67e-112	3.9e-108	0.76	0.62	Aortic root size;	chr7:66682669	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.638	rs10249404	ENSG00000226824.5	RP4-756H11.3	25.55	3.34e-112	4.85e-108	0.76	0.62	Aortic root size;	chr7:66581737	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.638	rs3898855	ENSG00000226824.5	RP4-756H11.3	25.54	4.12e-112	5.95e-108	0.75	0.62	Aortic root size;	chr7:66571411	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.638	rs10278816	ENSG00000226824.5	RP4-756H11.3	25.54	4.12e-112	5.95e-108	0.75	0.62	Aortic root size;	chr7:66572000	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.66	rs10281080	ENSG00000226824.5	RP4-756H11.3	25.54	4.12e-112	5.95e-108	0.75	0.62	Aortic root size;	chr7:66577454	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.66	rs10950044	ENSG00000226824.5	RP4-756H11.3	25.54	4.12e-112	5.95e-108	0.75	0.62	Aortic root size;	chr7:66577989	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.66	rs7807944	ENSG00000226824.5	RP4-756H11.3	25.53	5.08e-112	7.32e-108	0.76	0.62	Aortic root size;	chr7:66622208	chr7:66654538~66669855:+
BRCA	cis	rs858239	0.899	rs7794684	ENSG00000230658.1	KLHL7-AS1	25.48	1.01e-111	1.45e-107	0.83	0.62	Cerebrospinal fluid biomarker levels;	chr7:23271186	chr7:23101228~23105703:-
BRCA	cis	rs875971	0.522	rs1968127	ENSG00000226824.5	RP4-756H11.3	25.47	1.14e-111	1.62e-107	0.75	0.62	Aortic root size;	chr7:66591816	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.66	rs79009421	ENSG00000226824.5	RP4-756H11.3	25.47	1.2e-111	1.71e-107	0.76	0.62	Aortic root size;	chr7:66603522	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.66	rs6460308	ENSG00000226824.5	RP4-756H11.3	25.46	1.49e-111	2.11e-107	0.76	0.62	Aortic root size;	chr7:66619753	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.66	rs801211	ENSG00000226824.5	RP4-756H11.3	25.45	1.64e-111	2.32e-107	0.75	0.62	Aortic root size;	chr7:66550702	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.638	rs801205	ENSG00000226824.5	RP4-756H11.3	25.45	1.64e-111	2.32e-107	0.75	0.62	Aortic root size;	chr7:66557157	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.617	rs810400	ENSG00000226824.5	RP4-756H11.3	25.45	1.64e-111	2.32e-107	0.75	0.62	Aortic root size;	chr7:66557902	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.66	rs62465434	ENSG00000226824.5	RP4-756H11.3	-25.45	1.73e-111	2.44e-107	-0.75	-0.62	Aortic root size;	chr7:66540165	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.66	rs13224319	ENSG00000226824.5	RP4-756H11.3	-25.45	1.73e-111	2.44e-107	-0.75	-0.62	Aortic root size;	chr7:66542376	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.66	rs801217	ENSG00000226824.5	RP4-756H11.3	25.45	1.73e-111	2.44e-107	0.75	0.62	Aortic root size;	chr7:66545590	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.638	rs801216	ENSG00000226824.5	RP4-756H11.3	25.45	1.73e-111	2.44e-107	0.75	0.62	Aortic root size;	chr7:66546680	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.66	rs12698534	ENSG00000226824.5	RP4-756H11.3	-25.44	1.95e-111	2.73e-107	-0.75	-0.62	Aortic root size;	chr7:66521858	chr7:66654538~66669855:+
BRCA	cis	rs507080	0.769	rs745663	ENSG00000255239.1	AP002954.6	25.43	2.36e-111	3.3e-107	0.74	0.62	Serum metabolite levels;	chr11:118658886	chr11:118688039~118690600:-
BRCA	cis	rs801193	1	rs7782320	ENSG00000226824.5	RP4-756H11.3	-25.42	2.7e-111	3.77e-107	-0.75	-0.62	Aortic root size;	chr7:66712111	chr7:66654538~66669855:+
BRCA	cis	rs1577917	0.883	rs6454505	ENSG00000203875.9	SNHG5	-25.39	4.44e-111	6.19e-107	-0.72	-0.62	Response to antipsychotic treatment;	chr6:85882644	chr6:85660950~85678736:-
BRCA	cis	rs858239	0.899	rs2268747	ENSG00000230658.1	KLHL7-AS1	25.38	5.04e-111	7.01e-107	0.83	0.62	Cerebrospinal fluid biomarker levels;	chr7:23273843	chr7:23101228~23105703:-
BRCA	cis	rs875971	0.638	rs35986979	ENSG00000226824.5	RP4-756H11.3	25.38	5.33e-111	7.41e-107	0.76	0.62	Aortic root size;	chr7:66624003	chr7:66654538~66669855:+
BRCA	cis	rs858239	0.568	rs6970694	ENSG00000230658.1	KLHL7-AS1	25.36	7.18e-111	9.95e-107	0.83	0.62	Cerebrospinal fluid biomarker levels;	chr7:23211209	chr7:23101228~23105703:-
BRCA	cis	rs875971	0.642	rs35526611	ENSG00000226824.5	RP4-756H11.3	25.29	2.2e-110	3.01e-106	0.75	0.62	Aortic root size;	chr7:66629021	chr7:66654538~66669855:+
BRCA	cis	rs6952407	1	rs6952407	ENSG00000226824.5	RP4-756H11.3	25.28	2.47e-110	3.37e-106	0.75	0.62	Cotinine glucuronidation;	chr7:66580525	chr7:66654538~66669855:+
BRCA	cis	rs2486288	0.656	rs11631021	ENSG00000259520.4	CTD-2651B20.3	25.16	1.59e-109	2.13e-105	0.78	0.61	Glomerular filtration rate;	chr15:45264631	chr15:45251580~45279251:-
BRCA	cis	rs801193	1	rs2055682	ENSG00000226824.5	RP4-756H11.3	-25.15	1.71e-109	2.29e-105	-0.75	-0.61	Aortic root size;	chr7:66795302	chr7:66654538~66669855:+
BRCA	cis	rs858239	0.67	rs6967526	ENSG00000230658.1	KLHL7-AS1	25.09	4.39e-109	5.86e-105	0.81	0.61	Cerebrospinal fluid biomarker levels;	chr7:23119622	chr7:23101228~23105703:-
BRCA	cis	rs875971	0.619	rs10278371	ENSG00000226824.5	RP4-756H11.3	25.08	5.69e-109	7.58e-105	0.75	0.61	Aortic root size;	chr7:66586553	chr7:66654538~66669855:+
BRCA	cis	rs858239	0.899	rs28635122	ENSG00000230658.1	KLHL7-AS1	25.04	9.81e-109	1.3e-104	0.83	0.61	Cerebrospinal fluid biomarker levels;	chr7:23270562	chr7:23101228~23105703:-
BRCA	cis	rs801193	1	rs17566701	ENSG00000226824.5	RP4-756H11.3	-25.04	1.01e-108	1.35e-104	-0.75	-0.61	Aortic root size;	chr7:66728196	chr7:66654538~66669855:+
BRCA	cis	rs858239	0.899	rs5850	ENSG00000230658.1	KLHL7-AS1	25.02	1.42e-108	1.88e-104	0.82	0.61	Cerebrospinal fluid biomarker levels;	chr7:23274928	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.867	rs10250602	ENSG00000230658.1	KLHL7-AS1	25	1.79e-108	2.37e-104	0.83	0.61	Cerebrospinal fluid biomarker levels;	chr7:23264082	chr7:23101228~23105703:-
BRCA	cis	rs801193	0.967	rs3800823	ENSG00000226824.5	RP4-756H11.3	24.94	4.74e-108	6.19e-104	0.75	0.61	Aortic root size;	chr7:66682123	chr7:66654538~66669855:+
BRCA	cis	rs2739330	0.761	rs5760176	ENSG00000273295.1	AP000350.5	-24.93	5.6e-108	7.3e-104	-0.73	-0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23901432~23907068:-
BRCA	cis	rs858239	0.601	rs6461702	ENSG00000230658.1	KLHL7-AS1	24.89	1.08e-107	1.4e-103	0.82	0.61	Cerebrospinal fluid biomarker levels;	chr7:23209654	chr7:23101228~23105703:-
BRCA	cis	rs2739330	0.731	rs5751792	ENSG00000273295.1	AP000350.5	24.87	1.55e-107	1.99e-103	0.73	0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23901432~23907068:-
BRCA	cis	rs875971	0.66	rs10215132	ENSG00000226824.5	RP4-756H11.3	24.86	1.7e-107	2.18e-103	0.75	0.61	Aortic root size;	chr7:66589419	chr7:66654538~66669855:+
BRCA	cis	rs801193	1	rs10252765	ENSG00000226824.5	RP4-756H11.3	-24.85	1.92e-107	2.46e-103	-0.74	-0.61	Aortic root size;	chr7:66763745	chr7:66654538~66669855:+
BRCA	cis	rs858239	0.601	rs28673077	ENSG00000230658.1	KLHL7-AS1	24.84	2.25e-107	2.87e-103	0.83	0.61	Cerebrospinal fluid biomarker levels;	chr7:23211235	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.536	rs6956974	ENSG00000230658.1	KLHL7-AS1	-24.76	8.04e-107	1.02e-102	-0.79	-0.61	Cerebrospinal fluid biomarker levels;	chr7:23212699	chr7:23101228~23105703:-
BRCA	cis	rs875971	0.66	rs1860468	ENSG00000226824.5	RP4-756H11.3	24.75	9.35e-107	1.18e-102	0.74	0.61	Aortic root size;	chr7:66642265	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.619	rs2302918	ENSG00000226824.5	RP4-756H11.3	-24.75	9.62e-107	1.22e-102	-0.75	-0.61	Aortic root size;	chr7:66535945	chr7:66654538~66669855:+
BRCA	cis	rs858239	0.699	rs955187	ENSG00000230658.1	KLHL7-AS1	-24.73	1.37e-106	1.72e-102	-0.8	-0.61	Cerebrospinal fluid biomarker levels;	chr7:23154986	chr7:23101228~23105703:-
BRCA	cis	rs875971	0.66	rs3764903	ENSG00000226824.5	RP4-756H11.3	24.72	1.58e-106	1.98e-102	0.74	0.61	Aortic root size;	chr7:66633495	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.66	rs1860470	ENSG00000226824.5	RP4-756H11.3	24.72	1.63e-106	2.04e-102	0.74	0.61	Aortic root size;	chr7:66638707	chr7:66654538~66669855:+
BRCA	cis	rs2882667	0.628	rs13173618	ENSG00000253404.1	AC034243.1	24.71	1.66e-106	2.09e-102	0.93	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:138804091	chr5:138744434~138753309:-
BRCA	cis	rs3814244	0.528	rs7306466	ENSG00000255733.4	IFNG-AS1	24.65	4.28e-106	5.31e-102	0.52	0.61	Itch intensity from mosquito bite adjusted by bite size;	chr12:68014942	chr12:67989445~68234686:+
BRCA	cis	rs1577917	0.518	rs2475787	ENSG00000203875.9	SNHG5	24.62	7.16e-106	8.83e-102	0.68	0.61	Response to antipsychotic treatment;	chr6:85705518	chr6:85660950~85678736:-
BRCA	cis	rs801193	0.967	rs2420827	ENSG00000226824.5	RP4-756H11.3	24.62	7.31e-106	9.01e-102	0.74	0.61	Aortic root size;	chr7:66682114	chr7:66654538~66669855:+
BRCA	cis	rs858239	0.899	rs10262243	ENSG00000230658.1	KLHL7-AS1	24.58	1.27e-105	1.56e-101	0.81	0.61	Cerebrospinal fluid biomarker levels;	chr7:23251368	chr7:23101228~23105703:-
BRCA	cis	rs2739330	0.828	rs5751770	ENSG00000225282.1	AP000350.6	24.48	6.63e-105	8.06e-101	0.73	0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23926900~23929574:+
BRCA	cis	rs858239	0.536	rs6961109	ENSG00000230658.1	KLHL7-AS1	24.46	8.56e-105	1.04e-100	0.79	0.6	Cerebrospinal fluid biomarker levels;	chr7:23212794	chr7:23101228~23105703:-
BRCA	cis	rs3814244	0.528	rs7952790	ENSG00000255733.4	IFNG-AS1	24.43	1.32e-104	1.6e-100	0.52	0.6	Itch intensity from mosquito bite adjusted by bite size;	chr12:68012672	chr12:67989445~68234686:+
BRCA	cis	rs801193	0.967	rs34356500	ENSG00000226824.5	RP4-756H11.3	-24.42	1.53e-104	1.85e-100	-0.72	-0.6	Aortic root size;	chr7:66771620	chr7:66654538~66669855:+
BRCA	cis	rs858239	0.899	rs1881203	ENSG00000230658.1	KLHL7-AS1	24.41	1.89e-104	2.28e-100	0.8	0.6	Cerebrospinal fluid biomarker levels;	chr7:23253189	chr7:23101228~23105703:-
BRCA	cis	rs7104764	1	rs6598060	ENSG00000277290.1	RP11-326C3.16	-24.36	4.04e-104	4.86e-100	-0.66	-0.6	Menarche (age at onset);	chr11:243987	chr11:243099~243483:-
BRCA	cis	rs3814244	0.528	rs12582272	ENSG00000255733.4	IFNG-AS1	24.34	5.63e-104	6.76e-100	0.52	0.6	Itch intensity from mosquito bite adjusted by bite size;	chr12:68006298	chr12:67989445~68234686:+
BRCA	cis	rs2739330	0.828	rs5760108	ENSG00000225282.1	AP000350.6	24.3	1.04e-103	1.23e-99	0.73	0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23926900~23929574:+
BRCA	cis	rs1577917	0.696	rs10806334	ENSG00000203875.9	SNHG5	-24.25	2.47e-103	2.92e-99	-0.7	-0.6	Response to antipsychotic treatment;	chr6:85729611	chr6:85660950~85678736:-
BRCA	cis	rs875971	0.628	rs6974355	ENSG00000226824.5	RP4-756H11.3	-24.23	3.4e-103	4.01e-99	-0.74	-0.6	Aortic root size;	chr7:66376994	chr7:66654538~66669855:+
BRCA	cis	rs7104764	1	rs1128322	ENSG00000277290.1	RP11-326C3.16	24.19	5.77e-103	6.79e-99	0.64	0.6	Menarche (age at onset);	chr11:244197	chr11:243099~243483:-
BRCA	cis	rs12439619	0.846	rs28697264	ENSG00000278603.1	RP13-608F4.5	24.17	8.01e-103	9.38e-99	0.99	0.6	Intelligence (multi-trait analysis);	chr15:82265559	chr15:82472203~82472426:+
BRCA	cis	rs12439619	0.774	rs2867649	ENSG00000278603.1	RP13-608F4.5	24.17	8.07e-103	9.45e-99	1	0.6	Intelligence (multi-trait analysis);	chr15:82262331	chr15:82472203~82472426:+
BRCA	cis	rs858239	0.899	rs28458177	ENSG00000230658.1	KLHL7-AS1	24.16	9.17e-103	1.07e-98	0.8	0.6	Cerebrospinal fluid biomarker levels;	chr7:23255253	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.899	rs10085838	ENSG00000230658.1	KLHL7-AS1	24.14	1.24e-102	1.45e-98	0.81	0.6	Cerebrospinal fluid biomarker levels;	chr7:23258796	chr7:23101228~23105703:-
BRCA	cis	rs7104764	1	rs10902113	ENSG00000277290.1	RP11-326C3.16	-24.13	1.51e-102	1.76e-98	-0.64	-0.6	Menarche (age at onset);	chr11:245523	chr11:243099~243483:-
BRCA	cis	rs7104764	1	rs7482591	ENSG00000277290.1	RP11-326C3.16	-24.13	1.51e-102	1.76e-98	-0.64	-0.6	Menarche (age at onset);	chr11:245861	chr11:243099~243483:-
BRCA	cis	rs7104764	1	rs10902114	ENSG00000277290.1	RP11-326C3.16	-24.13	1.6e-102	1.86e-98	-0.64	-0.6	Menarche (age at onset);	chr11:246234	chr11:243099~243483:-
BRCA	cis	rs875971	0.577	rs35072105	ENSG00000226824.5	RP4-756H11.3	24.12	1.84e-102	2.14e-98	0.73	0.6	Aortic root size;	chr7:66144830	chr7:66654538~66669855:+
BRCA	cis	rs7104764	1	rs6598061	ENSG00000277290.1	RP11-326C3.16	-24.11	2.08e-102	2.4e-98	-0.64	-0.6	Menarche (age at onset);	chr11:243853	chr11:243099~243483:-
BRCA	cis	rs7104764	1	rs10902112	ENSG00000277290.1	RP11-326C3.16	-24.11	2.08e-102	2.4e-98	-0.64	-0.6	Menarche (age at onset);	chr11:244106	chr11:243099~243483:-
BRCA	cis	rs7104764	0.917	rs7107362	ENSG00000277290.1	RP11-326C3.16	-24.11	2.08e-102	2.4e-98	-0.64	-0.6	Menarche (age at onset);	chr11:244108	chr11:243099~243483:-
BRCA	cis	rs7104764	1	rs7128044	ENSG00000277290.1	RP11-326C3.16	-24.11	2.08e-102	2.4e-98	-0.64	-0.6	Menarche (age at onset);	chr11:244115	chr11:243099~243483:-
BRCA	cis	rs7104764	0.957	rs7116130	ENSG00000277290.1	RP11-326C3.16	-24.11	2.08e-102	2.4e-98	-0.64	-0.6	Menarche (age at onset);	chr11:244129	chr11:243099~243483:-
BRCA	cis	rs7104764	1	rs7128029	ENSG00000277290.1	RP11-326C3.16	-24.11	2.08e-102	2.4e-98	-0.64	-0.6	Menarche (age at onset);	chr11:244141	chr11:243099~243483:-
BRCA	cis	rs7104764	1	rs1128320	ENSG00000277290.1	RP11-326C3.16	-24.11	2.08e-102	2.4e-98	-0.64	-0.6	Menarche (age at onset);	chr11:244167	chr11:243099~243483:-
BRCA	cis	rs7104764	0.957	rs1128321	ENSG00000277290.1	RP11-326C3.16	-24.11	2.08e-102	2.4e-98	-0.64	-0.6	Menarche (age at onset);	chr11:244171	chr11:243099~243483:-
BRCA	cis	rs875971	0.666	rs13242072	ENSG00000226824.5	RP4-756H11.3	24.1	2.46e-102	2.83e-98	0.73	0.6	Aortic root size;	chr7:66301001	chr7:66654538~66669855:+
BRCA	cis	rs7104764	1	rs6598063	ENSG00000277290.1	RP11-326C3.16	-24.08	3.1e-102	3.55e-98	-0.64	-0.6	Menarche (age at onset);	chr11:243672	chr11:243099~243483:-
BRCA	cis	rs7104764	1	rs6598062	ENSG00000277290.1	RP11-326C3.16	-24.08	3.1e-102	3.55e-98	-0.64	-0.6	Menarche (age at onset);	chr11:243712	chr11:243099~243483:-
BRCA	cis	rs7104764	0.957	rs6598064	ENSG00000277290.1	RP11-326C3.16	-24.05	5.46e-102	6.23e-98	-0.64	-0.6	Menarche (age at onset);	chr11:243557	chr11:243099~243483:-
BRCA	cis	rs3814244	0.528	rs10878723	ENSG00000255733.4	IFNG-AS1	24.05	5.55e-102	6.33e-98	0.51	0.6	Itch intensity from mosquito bite adjusted by bite size;	chr12:68005493	chr12:67989445~68234686:+
BRCA	cis	rs7104764	1	rs2272565	ENSG00000277290.1	RP11-326C3.16	-24.04	6.09e-102	6.94e-98	-0.64	-0.6	Menarche (age at onset);	chr11:244414	chr11:243099~243483:-
BRCA	cis	rs875971	0.706	rs1643374	ENSG00000226824.5	RP4-756H11.3	-23.98	1.6e-101	1.81e-97	-0.73	-0.6	Aortic root size;	chr7:66407695	chr7:66654538~66669855:+
BRCA	cis	rs2739330	0.828	rs2877178	ENSG00000225282.1	AP000350.6	23.97	1.85e-101	2.1e-97	0.73	0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23926900~23929574:+
BRCA	cis	rs3814244	0.528	rs11177002	ENSG00000255733.4	IFNG-AS1	23.96	2.02e-101	2.29e-97	0.51	0.6	Itch intensity from mosquito bite adjusted by bite size;	chr12:68003377	chr12:67989445~68234686:+
BRCA	cis	rs858239	0.738	rs7807879	ENSG00000230658.1	KLHL7-AS1	23.93	3.49e-101	3.91e-97	0.8	0.6	Cerebrospinal fluid biomarker levels;	chr7:23220969	chr7:23101228~23105703:-
BRCA	cis	rs801193	1	rs2659915	ENSG00000226824.5	RP4-756H11.3	-23.92	3.79e-101	4.25e-97	-0.72	-0.6	Aortic root size;	chr7:66688114	chr7:66654538~66669855:+
BRCA	cis	rs7104764	1	rs6598065	ENSG00000277290.1	RP11-326C3.16	-23.92	4.1e-101	4.6e-97	-0.64	-0.6	Menarche (age at onset);	chr11:243211	chr11:243099~243483:-
BRCA	cis	rs12439619	0.846	rs62012003	ENSG00000278603.1	RP13-608F4.5	23.9	5.48e-101	6.09e-97	0.99	0.6	Intelligence (multi-trait analysis);	chr15:82183236	chr15:82472203~82472426:+
BRCA	cis	rs875971	0.66	rs801193	ENSG00000226824.5	RP4-756H11.3	23.9	5.56e-101	6.18e-97	0.72	0.59	Aortic root size;	chr7:66565625	chr7:66654538~66669855:+
BRCA	cis	rs12439619	0.768	rs28694364	ENSG00000278603.1	RP13-608F4.5	23.87	8.86e-101	9.79e-97	0.99	0.59	Intelligence (multi-trait analysis);	chr15:82208119	chr15:82472203~82472426:+
BRCA	cis	rs2882667	0.69	rs11749163	ENSG00000253404.1	AC034243.1	23.84	1.33e-100	1.47e-96	0.79	0.59	Age-related hearing impairment (SNP x SNP interaction);	chr5:138926981	chr5:138744434~138753309:-
BRCA	cis	rs858239	0.67	rs3807452	ENSG00000230658.1	KLHL7-AS1	-23.84	1.42e-100	1.56e-96	-0.79	-0.59	Cerebrospinal fluid biomarker levels;	chr7:23122462	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.738	rs13225593	ENSG00000230658.1	KLHL7-AS1	23.77	4.12e-100	4.51e-96	0.79	0.59	Cerebrospinal fluid biomarker levels;	chr7:23220688	chr7:23101228~23105703:-
BRCA	cis	rs3814244	0.528	rs61923060	ENSG00000255733.4	IFNG-AS1	23.67	1.79e-99	1.94e-95	0.51	0.59	Itch intensity from mosquito bite adjusted by bite size;	chr12:67997341	chr12:67989445~68234686:+
BRCA	cis	rs12439619	0.846	rs62013464	ENSG00000278603.1	RP13-608F4.5	23.66	2.16e-99	2.33e-95	0.98	0.59	Intelligence (multi-trait analysis);	chr15:82288250	chr15:82472203~82472426:+
BRCA	cis	rs12439619	0.846	rs62012056	ENSG00000278603.1	RP13-608F4.5	23.66	2.27e-99	2.44e-95	0.99	0.59	Intelligence (multi-trait analysis);	chr15:82247278	chr15:82472203~82472426:+
BRCA	cis	rs12439619	0.81	rs28876157	ENSG00000278603.1	RP13-608F4.5	23.63	3.42e-99	3.67e-95	0.98	0.59	Intelligence (multi-trait analysis);	chr15:82216708	chr15:82472203~82472426:+
BRCA	cis	rs12439619	0.846	rs62011975	ENSG00000278603.1	RP13-608F4.5	23.6	5.51e-99	5.87e-95	0.99	0.59	Intelligence (multi-trait analysis);	chr15:82159213	chr15:82472203~82472426:+
BRCA	cis	rs875971	0.54	rs35510581	ENSG00000226824.5	RP4-756H11.3	23.59	6.01e-99	6.37e-95	0.72	0.59	Aortic root size;	chr7:66113790	chr7:66654538~66669855:+
BRCA	cis	rs858239	0.806	rs10268610	ENSG00000230658.1	KLHL7-AS1	23.58	7.07e-99	7.48e-95	0.79	0.59	Cerebrospinal fluid biomarker levels;	chr7:23235145	chr7:23101228~23105703:-
BRCA	cis	rs1577917	0.538	rs6454483	ENSG00000203875.9	SNHG5	23.58	7.09e-99	7.5e-95	0.66	0.59	Response to antipsychotic treatment;	chr6:85708565	chr6:85660950~85678736:-
BRCA	cis	rs12439619	0.846	rs62012059	ENSG00000278603.1	RP13-608F4.5	23.57	8.88e-99	9.27e-95	0.99	0.59	Intelligence (multi-trait analysis);	chr15:82251669	chr15:82472203~82472426:+
BRCA	cis	rs875971	0.558	rs4433015	ENSG00000226824.5	RP4-756H11.3	23.5	2.51e-98	2.58e-94	0.71	0.59	Aortic root size;	chr7:66174736	chr7:66654538~66669855:+
BRCA	cis	rs801193	1	rs13239306	ENSG00000226824.5	RP4-756H11.3	23.48	3.24e-98	3.32e-94	0.73	0.59	Aortic root size;	chr7:66671030	chr7:66654538~66669855:+
BRCA	cis	rs2739330	0.789	rs5760109	ENSG00000225282.1	AP000350.6	23.34	3.02e-97	3.04e-93	0.72	0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23926900~23929574:+
BRCA	cis	rs12439619	0.739	rs62012046	ENSG00000278603.1	RP13-608F4.5	23.33	3.46e-97	3.48e-93	0.98	0.59	Intelligence (multi-trait analysis);	chr15:82236824	chr15:82472203~82472426:+
BRCA	cis	rs12439619	0.774	rs62012047	ENSG00000278603.1	RP13-608F4.5	23.33	3.46e-97	3.48e-93	0.98	0.59	Intelligence (multi-trait analysis);	chr15:82236852	chr15:82472203~82472426:+
BRCA	cis	rs12439619	0.846	rs62012004	ENSG00000278603.1	RP13-608F4.5	23.31	4.39e-97	4.4e-93	0.98	0.59	Intelligence (multi-trait analysis);	chr15:82183924	chr15:82472203~82472426:+
BRCA	cis	rs3814244	0.528	rs7962511	ENSG00000255733.4	IFNG-AS1	23.31	4.92e-97	4.93e-93	0.5	0.59	Itch intensity from mosquito bite adjusted by bite size;	chr12:68002854	chr12:67989445~68234686:+
BRCA	cis	rs12439619	0.81	rs62012049	ENSG00000278603.1	RP13-608F4.5	23.29	5.9e-97	5.9e-93	0.97	0.59	Intelligence (multi-trait analysis);	chr15:82237722	chr15:82472203~82472426:+
BRCA	cis	rs2739330	0.76	rs5751761	ENSG00000273295.1	AP000350.5	-23.28	7.17e-97	7.17e-93	-0.69	-0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23901432~23907068:-
BRCA	cis	rs2739330	0.828	rs5760108	ENSG00000218537.1	MIF-AS1	23.28	7.52e-97	7.51e-93	0.75	0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23894426~23898930:-
BRCA	cis	rs12439619	0.846	rs62010071	ENSG00000278603.1	RP13-608F4.5	23.22	1.74e-96	1.72e-92	0.98	0.58	Intelligence (multi-trait analysis);	chr15:82289442	chr15:82472203~82472426:+
BRCA	cis	rs2739330	0.828	rs5751770	ENSG00000218537.1	MIF-AS1	23.21	2.2e-96	2.18e-92	0.75	0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23894426~23898930:-
BRCA	cis	rs2739330	0.828	rs5760107	ENSG00000225282.1	AP000350.6	23.2	2.37e-96	2.34e-92	0.72	0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23926900~23929574:+
BRCA	cis	rs12439619	0.846	rs28470877	ENSG00000278603.1	RP13-608F4.5	23.15	5.04e-96	4.92e-92	0.97	0.58	Intelligence (multi-trait analysis);	chr15:82245797	chr15:82472203~82472426:+
BRCA	cis	rs2739330	0.828	rs2877178	ENSG00000218537.1	MIF-AS1	23.14	6.32e-96	6.16e-92	0.75	0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23894426~23898930:-
BRCA	cis	rs1577917	0.518	rs6454482	ENSG00000203875.9	SNHG5	23.14	6.71e-96	6.52e-92	0.65	0.58	Response to antipsychotic treatment;	chr6:85708470	chr6:85660950~85678736:-
BRCA	cis	rs1577917	0.739	rs9450318	ENSG00000203875.9	SNHG5	23.07	1.99e-95	1.91e-91	0.66	0.58	Response to antipsychotic treatment;	chr6:85717459	chr6:85660950~85678736:-
BRCA	cis	rs950027	0.549	rs1719250	ENSG00000259520.4	CTD-2651B20.3	-22.99	6.55e-95	6.16e-91	-0.72	-0.58	Response to fenofibrate (adiponectin levels);	chr15:45317575	chr15:45251580~45279251:-
BRCA	cis	rs1577917	0.538	rs7755996	ENSG00000203875.9	SNHG5	22.98	7.35e-95	6.91e-91	0.65	0.58	Response to antipsychotic treatment;	chr6:85714002	chr6:85660950~85678736:-
BRCA	cis	rs858239	1	rs156407	ENSG00000230658.1	KLHL7-AS1	22.95	1.17e-94	1.1e-90	0.78	0.58	Cerebrospinal fluid biomarker levels;	chr7:23276020	chr7:23101228~23105703:-
BRCA	cis	rs62229266	0.654	rs62230787	ENSG00000231106.2	LINC01436	22.93	1.48e-94	1.38e-90	0.68	0.58	Mitral valve prolapse;	chr21:36004182	chr21:36005338~36007838:+
BRCA	cis	rs1799949	1	rs8070085	ENSG00000198496.9	NBR2	22.88	3.52e-94	3.25e-90	0.68	0.58	Menopause (age at onset);	chr17:43189967	chr17:43125610~43153671:+
BRCA	cis	rs2739330	0.76	rs1002286	ENSG00000225282.1	AP000350.6	-22.86	4.49e-94	4.12e-90	-0.72	-0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23926900~23929574:+
BRCA	cis	rs858239	0.932	rs1728320	ENSG00000230658.1	KLHL7-AS1	22.75	2.48e-93	2.25e-89	0.76	0.58	Cerebrospinal fluid biomarker levels;	chr7:23280170	chr7:23101228~23105703:-
BRCA	cis	rs2739330	0.796	rs2154594	ENSG00000225282.1	AP000350.6	-22.7	5.19e-93	4.69e-89	-0.71	-0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23926900~23929574:+
BRCA	cis	rs858239	0.72	rs10227559	ENSG00000230658.1	KLHL7-AS1	22.69	6.31e-93	5.66e-89	0.78	0.58	Cerebrospinal fluid biomarker levels;	chr7:23232525	chr7:23101228~23105703:-
BRCA	cis	rs916888	0.773	rs9896243	ENSG00000214401.4	KANSL1-AS1	22.69	6.33e-93	5.69e-89	0.93	0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:46193576~46196723:+
BRCA	cis	rs7104764	0.957	rs519592	ENSG00000277290.1	RP11-326C3.16	-22.67	8.49e-93	7.6e-89	-0.6	-0.57	Menarche (age at onset);	chr11:236811	chr11:243099~243483:-
BRCA	cis	rs3814244	0.832	rs11177006	ENSG00000255733.4	IFNG-AS1	22.66	9.55e-93	8.51e-89	0.49	0.57	Itch intensity from mosquito bite adjusted by bite size;	chr12:68019317	chr12:67989445~68234686:+
BRCA	cis	rs1577917	0.771	rs9362239	ENSG00000203875.9	SNHG5	22.64	1.28e-92	1.14e-88	0.66	0.57	Response to antipsychotic treatment;	chr6:85719545	chr6:85660950~85678736:-
BRCA	cis	rs875971	0.505	rs1167386	ENSG00000226824.5	RP4-756H11.3	22.61	2.06e-92	1.83e-88	0.7	0.57	Aortic root size;	chr7:66048109	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.505	rs1167385	ENSG00000226824.5	RP4-756H11.3	22.59	2.63e-92	2.33e-88	0.7	0.57	Aortic root size;	chr7:66048321	chr7:66654538~66669855:+
BRCA	cis	rs9399135	0.967	rs2150681	ENSG00000232876.1	CTA-212D2.2	22.58	3.35e-92	2.97e-88	0.71	0.57	Red blood cell count;	chr6:135054094	chr6:135055033~135060550:+
BRCA	cis	rs9399135	0.967	rs7750300	ENSG00000232876.1	CTA-212D2.2	-22.57	3.9e-92	3.45e-88	-0.7	-0.57	Red blood cell count;	chr6:135029812	chr6:135055033~135060550:+
BRCA	cis	rs801193	0.901	rs4273746	ENSG00000226824.5	RP4-756H11.3	22.57	4.05e-92	3.58e-88	0.71	0.57	Aortic root size;	chr7:66836124	chr7:66654538~66669855:+
BRCA	cis	rs2739330	0.796	rs5760106	ENSG00000225282.1	AP000350.6	-22.56	4.38e-92	3.87e-88	-0.71	-0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23926900~23929574:+
BRCA	cis	rs858239	0.699	rs1881200	ENSG00000230658.1	KLHL7-AS1	-22.56	4.41e-92	3.89e-88	-0.74	-0.57	Cerebrospinal fluid biomarker levels;	chr7:23162018	chr7:23101228~23105703:-
BRCA	cis	rs875971	0.505	rs1723275	ENSG00000226824.5	RP4-756H11.3	22.55	5.48e-92	4.83e-88	0.7	0.57	Aortic root size;	chr7:66039646	chr7:66654538~66669855:+
BRCA	cis	rs2739330	0.828	rs4820572	ENSG00000225282.1	AP000350.6	22.54	5.84e-92	5.14e-88	0.71	0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23926900~23929574:+
BRCA	cis	rs875971	0.505	rs2462573	ENSG00000226824.5	RP4-756H11.3	22.54	6.34e-92	5.57e-88	0.7	0.57	Aortic root size;	chr7:66042405	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.508	rs10258739	ENSG00000226824.5	RP4-756H11.3	22.5	1.15e-91	1.01e-87	0.69	0.57	Aortic root size;	chr7:66597948	chr7:66654538~66669855:+
BRCA	cis	rs858239	0.965	rs156429	ENSG00000230658.1	KLHL7-AS1	22.49	1.35e-91	1.18e-87	0.77	0.57	Cerebrospinal fluid biomarker levels;	chr7:23266401	chr7:23101228~23105703:-
BRCA	cis	rs9399135	0.933	rs41294852	ENSG00000232876.1	CTA-212D2.2	-22.46	1.98e-91	1.73e-87	-0.7	-0.57	Red blood cell count;	chr6:135055241	chr6:135055033~135060550:+
BRCA	cis	rs10256972	0.552	rs2960830	ENSG00000229043.2	AC091729.9	-22.46	2.04e-91	1.77e-87	-0.71	-0.57	Endometriosis;Longevity;	chr7:1161005	chr7:1160374~1165267:+
BRCA	cis	rs875971	1	rs3981131	ENSG00000226824.5	RP4-756H11.3	-22.45	2.28e-91	1.98e-87	-0.68	-0.57	Aortic root size;	chr7:66486690	chr7:66654538~66669855:+
BRCA	cis	rs9399135	0.967	rs12661423	ENSG00000232876.1	CTA-212D2.2	-22.44	2.55e-91	2.21e-87	-0.7	-0.57	Red blood cell count;	chr6:135028432	chr6:135055033~135060550:+
BRCA	cis	rs10256972	0.552	rs2960831	ENSG00000229043.2	AC091729.9	-22.43	3.04e-91	2.64e-87	-0.71	-0.57	Endometriosis;Longevity;	chr7:1161556	chr7:1160374~1165267:+
BRCA	cis	rs875971	0.522	rs1880556	ENSG00000226824.5	RP4-756H11.3	-22.42	3.42e-91	2.95e-87	-0.68	-0.57	Aortic root size;	chr7:65967557	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.522	rs781144	ENSG00000226824.5	RP4-756H11.3	-22.39	5.63e-91	4.82e-87	-0.68	-0.57	Aortic root size;	chr7:65975357	chr7:66654538~66669855:+
BRCA	cis	rs9399135	0.967	rs9389258	ENSG00000232876.1	CTA-212D2.2	-22.38	6.36e-91	5.44e-87	-0.7	-0.57	Red blood cell count;	chr6:135040002	chr6:135055033~135060550:+
BRCA	cis	rs875971	0.577	rs34888281	ENSG00000226824.5	RP4-756H11.3	22.38	6.6e-91	5.63e-87	0.7	0.57	Aortic root size;	chr7:66120784	chr7:66654538~66669855:+
BRCA	cis	rs801193	0.839	rs12534943	ENSG00000226824.5	RP4-756H11.3	22.37	7.33e-91	6.24e-87	0.69	0.57	Aortic root size;	chr7:66605533	chr7:66654538~66669855:+
BRCA	cis	rs9399135	0.933	rs28384512	ENSG00000232876.1	CTA-212D2.2	-22.37	7.58e-91	6.45e-87	-0.69	-0.57	Red blood cell count;	chr6:135055094	chr6:135055033~135060550:+
BRCA	cis	rs3814244	0.528	rs2906859	ENSG00000255733.4	IFNG-AS1	22.37	7.9e-91	6.72e-87	0.47	0.57	Itch intensity from mosquito bite adjusted by bite size;	chr12:68002355	chr12:67989445~68234686:+
BRCA	cis	rs3814244	0.528	rs2906854	ENSG00000255733.4	IFNG-AS1	-22.35	1e-90	8.49e-87	-0.48	-0.57	Itch intensity from mosquito bite adjusted by bite size;	chr12:67993566	chr12:67989445~68234686:+
BRCA	cis	rs875971	0.508	rs6947808	ENSG00000226824.5	RP4-756H11.3	22.34	1.18e-90	9.98e-87	0.69	0.57	Aortic root size;	chr7:66580095	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.508	rs10242423	ENSG00000226824.5	RP4-756H11.3	22.34	1.2e-90	1.01e-86	0.69	0.57	Aortic root size;	chr7:66594188	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.508	rs10253883	ENSG00000226824.5	RP4-756H11.3	22.34	1.2e-90	1.01e-86	0.69	0.57	Aortic root size;	chr7:66596151	chr7:66654538~66669855:+
BRCA	cis	rs9399135	0.967	rs7766189	ENSG00000232876.1	CTA-212D2.2	-22.34	1.24e-90	1.04e-86	-0.7	-0.57	Red blood cell count;	chr6:135032713	chr6:135055033~135060550:+
BRCA	cis	rs9399135	0.967	rs9402676	ENSG00000232876.1	CTA-212D2.2	-22.34	1.25e-90	1.05e-86	-0.7	-0.57	Red blood cell count;	chr6:135034369	chr6:135055033~135060550:+
BRCA	cis	rs9399135	0.967	rs2297338	ENSG00000232876.1	CTA-212D2.2	-22.34	1.29e-90	1.08e-86	-0.7	-0.57	Red blood cell count;	chr6:135054624	chr6:135055033~135060550:+
BRCA	cis	rs9399135	0.967	rs2183709	ENSG00000232876.1	CTA-212D2.2	-22.33	1.35e-90	1.13e-86	-0.7	-0.57	Red blood cell count;	chr6:135055953	chr6:135055033~135060550:+
BRCA	cis	rs9399135	0.967	rs4142299	ENSG00000232876.1	CTA-212D2.2	-22.33	1.35e-90	1.13e-86	-0.7	-0.57	Red blood cell count;	chr6:135056048	chr6:135055033~135060550:+
BRCA	cis	rs9399135	0.967	rs34546690	ENSG00000232876.1	CTA-212D2.2	-22.33	1.38e-90	1.16e-86	-0.69	-0.57	Red blood cell count;	chr6:135048571	chr6:135055033~135060550:+
BRCA	cis	rs3814244	0.868	rs11177007	ENSG00000255733.4	IFNG-AS1	22.33	1.38e-90	1.16e-86	0.48	0.57	Itch intensity from mosquito bite adjusted by bite size;	chr12:68020964	chr12:67989445~68234686:+
BRCA	cis	rs9399135	0.967	rs9373122	ENSG00000232876.1	CTA-212D2.2	-22.32	1.54e-90	1.29e-86	-0.69	-0.57	Red blood cell count;	chr6:135052396	chr6:135055033~135060550:+
BRCA	cis	rs9399135	0.967	rs4896125	ENSG00000232876.1	CTA-212D2.2	-22.31	1.82e-90	1.51e-86	-0.69	-0.57	Red blood cell count;	chr6:135021431	chr6:135055033~135060550:+
BRCA	cis	rs9399135	0.935	rs949547	ENSG00000232876.1	CTA-212D2.2	-22.31	1.82e-90	1.51e-86	-0.69	-0.57	Red blood cell count;	chr6:135022361	chr6:135055033~135060550:+
BRCA	cis	rs9399135	0.935	rs2150680	ENSG00000232876.1	CTA-212D2.2	-22.31	1.82e-90	1.51e-86	-0.69	-0.57	Red blood cell count;	chr6:135025993	chr6:135055033~135060550:+
BRCA	cis	rs9399135	0.967	rs11756988	ENSG00000232876.1	CTA-212D2.2	-22.31	1.82e-90	1.51e-86	-0.69	-0.57	Red blood cell count;	chr6:135026457	chr6:135055033~135060550:+
BRCA	cis	rs9399135	0.967	rs11754783	ENSG00000232876.1	CTA-212D2.2	-22.31	1.82e-90	1.51e-86	-0.69	-0.57	Red blood cell count;	chr6:135026523	chr6:135055033~135060550:+
BRCA	cis	rs9399135	0.844	rs13209789	ENSG00000232876.1	CTA-212D2.2	-22.31	1.93e-90	1.6e-86	-0.69	-0.57	Red blood cell count;	chr6:135046778	chr6:135055033~135060550:+
BRCA	cis	rs9399135	0.967	rs6915770	ENSG00000232876.1	CTA-212D2.2	-22.31	1.93e-90	1.6e-86	-0.69	-0.57	Red blood cell count;	chr6:135048076	chr6:135055033~135060550:+
BRCA	cis	rs9399135	0.935	rs9376086	ENSG00000232876.1	CTA-212D2.2	-22.31	1.93e-90	1.6e-86	-0.69	-0.57	Red blood cell count;	chr6:135050191	chr6:135055033~135060550:+
BRCA	cis	rs9399135	0.967	rs1041480	ENSG00000232876.1	CTA-212D2.2	-22.31	1.93e-90	1.6e-86	-0.69	-0.57	Red blood cell count;	chr6:135051938	chr6:135055033~135060550:+
BRCA	cis	rs875971	1	rs6956179	ENSG00000226824.5	RP4-756H11.3	22.3	2.17e-90	1.79e-86	0.68	0.57	Aortic root size;	chr7:66341672	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.508	rs10950045	ENSG00000226824.5	RP4-756H11.3	22.3	2.25e-90	1.85e-86	0.69	0.57	Aortic root size;	chr7:66601386	chr7:66654538~66669855:+
BRCA	cis	rs801193	0.839	rs6968619	ENSG00000226824.5	RP4-756H11.3	22.3	2.25e-90	1.85e-86	0.69	0.57	Aortic root size;	chr7:66603880	chr7:66654538~66669855:+
BRCA	cis	rs801193	0.805	rs12532355	ENSG00000226824.5	RP4-756H11.3	22.3	2.25e-90	1.85e-86	0.69	0.57	Aortic root size;	chr7:66605597	chr7:66654538~66669855:+
BRCA	cis	rs9399135	0.967	rs10872427	ENSG00000232876.1	CTA-212D2.2	-22.3	2.26e-90	1.85e-86	-0.7	-0.57	Red blood cell count;	chr6:135032314	chr6:135055033~135060550:+
BRCA	cis	rs9399135	0.967	rs1854865	ENSG00000232876.1	CTA-212D2.2	-22.29	2.54e-90	2.09e-86	-0.69	-0.57	Red blood cell count;	chr6:135039162	chr6:135055033~135060550:+
BRCA	cis	rs9399135	0.967	rs6919862	ENSG00000232876.1	CTA-212D2.2	-22.29	2.72e-90	2.23e-86	-0.7	-0.57	Red blood cell count;	chr6:135031305	chr6:135055033~135060550:+
BRCA	cis	rs9399135	0.935	rs11759999	ENSG00000232876.1	CTA-212D2.2	-22.28	2.89e-90	2.36e-86	-0.7	-0.57	Red blood cell count;	chr6:135049357	chr6:135055033~135060550:+
BRCA	cis	rs9399135	0.935	rs11760000	ENSG00000232876.1	CTA-212D2.2	-22.28	2.89e-90	2.36e-86	-0.7	-0.57	Red blood cell count;	chr6:135049358	chr6:135055033~135060550:+
BRCA	cis	rs9399135	0.967	rs2297340	ENSG00000232876.1	CTA-212D2.2	-22.28	3e-90	2.46e-86	-0.7	-0.57	Red blood cell count;	chr6:135054920	chr6:135055033~135060550:+
BRCA	cis	rs9399135	0.967	rs11755229	ENSG00000232876.1	CTA-212D2.2	-22.27	3.51e-90	2.86e-86	-0.69	-0.57	Red blood cell count;	chr6:135048775	chr6:135055033~135060550:+
BRCA	cis	rs9399135	0.967	rs9389261	ENSG00000232876.1	CTA-212D2.2	-22.27	3.51e-90	2.86e-86	-0.69	-0.57	Red blood cell count;	chr6:135050010	chr6:135055033~135060550:+
BRCA	cis	rs9399135	0.967	rs9376085	ENSG00000232876.1	CTA-212D2.2	-22.27	3.51e-90	2.86e-86	-0.69	-0.57	Red blood cell count;	chr6:135050086	chr6:135055033~135060550:+
BRCA	cis	rs9399135	0.967	rs6569990	ENSG00000232876.1	CTA-212D2.2	-22.27	3.52e-90	2.86e-86	-0.69	-0.57	Red blood cell count;	chr6:135044680	chr6:135055033~135060550:+
BRCA	cis	rs9399135	0.967	rs13191501	ENSG00000232876.1	CTA-212D2.2	-22.27	3.52e-90	2.86e-86	-0.69	-0.57	Red blood cell count;	chr6:135045742	chr6:135055033~135060550:+
BRCA	cis	rs9399135	0.967	rs6908512	ENSG00000232876.1	CTA-212D2.2	-22.27	3.52e-90	2.86e-86	-0.69	-0.57	Red blood cell count;	chr6:135046619	chr6:135055033~135060550:+
BRCA	cis	rs9399135	0.967	rs59329760	ENSG00000232876.1	CTA-212D2.2	-22.25	4.48e-90	3.63e-86	-0.69	-0.57	Red blood cell count;	chr6:135021299	chr6:135055033~135060550:+
BRCA	cis	rs10256972	0.552	rs2960837	ENSG00000229043.2	AC091729.9	-22.25	4.77e-90	3.86e-86	-0.71	-0.57	Endometriosis;Longevity;	chr7:1164321	chr7:1160374~1165267:+
BRCA	cis	rs10256972	0.552	rs6978842	ENSG00000229043.2	AC091729.9	-22.21	8.72e-90	6.96e-86	-0.69	-0.57	Endometriosis;Longevity;	chr7:1164963	chr7:1160374~1165267:+
BRCA	cis	rs858239	0.699	rs1881201	ENSG00000230658.1	KLHL7-AS1	-22.2	9.56e-90	7.62e-86	-0.73	-0.57	Cerebrospinal fluid biomarker levels;	chr7:23154394	chr7:23101228~23105703:-
BRCA	cis	rs9399135	0.935	rs987690	ENSG00000232876.1	CTA-212D2.2	-22.2	1.02e-89	8.14e-86	-0.69	-0.57	Red blood cell count;	chr6:135029241	chr6:135055033~135060550:+
BRCA	cis	rs801193	0.844	rs2244022	ENSG00000226824.5	RP4-756H11.3	-22.2	1.04e-89	8.31e-86	-0.68	-0.57	Aortic root size;	chr7:66737443	chr7:66654538~66669855:+
BRCA	cis	rs9399135	0.838	rs4896126	ENSG00000232876.1	CTA-212D2.2	-22.19	1.21e-89	9.56e-86	-0.69	-0.57	Red blood cell count;	chr6:135021648	chr6:135055033~135060550:+
BRCA	cis	rs9402673	0.517	rs978036	ENSG00000232876.1	CTA-212D2.2	-22.19	1.21e-89	9.56e-86	-0.69	-0.57	High light scatter reticulocyte count;Reticulocyte count;	chr6:135021765	chr6:135055033~135060550:+
BRCA	cis	rs9399135	0.967	rs1023179	ENSG00000232876.1	CTA-212D2.2	-22.19	1.21e-89	9.56e-86	-0.69	-0.57	Red blood cell count;	chr6:135022691	chr6:135055033~135060550:+
BRCA	cis	rs9399135	0.967	rs952674	ENSG00000232876.1	CTA-212D2.2	-22.19	1.21e-89	9.56e-86	-0.69	-0.57	Red blood cell count;	chr6:135028019	chr6:135055033~135060550:+
BRCA	cis	rs875971	0.543	rs801191	ENSG00000226824.5	RP4-756H11.3	22.17	1.51e-89	1.19e-85	0.69	0.57	Aortic root size;	chr7:66567968	chr7:66654538~66669855:+
BRCA	cis	rs9399135	0.967	rs1041481	ENSG00000232876.1	CTA-212D2.2	-22.16	1.92e-89	1.51e-85	-0.69	-0.57	Red blood cell count;	chr6:135013925	chr6:135055033~135060550:+
BRCA	cis	rs9399135	0.967	rs1014020	ENSG00000232876.1	CTA-212D2.2	-22.16	1.94e-89	1.53e-85	-0.69	-0.57	Red blood cell count;	chr6:135013288	chr6:135055033~135060550:+
BRCA	cis	rs9399135	0.967	rs2327580	ENSG00000232876.1	CTA-212D2.2	-22.13	3.07e-89	2.41e-85	-0.69	-0.57	Red blood cell count;	chr6:135043279	chr6:135055033~135060550:+
BRCA	cis	rs858239	1	rs166663	ENSG00000230658.1	KLHL7-AS1	22.12	3.31e-89	2.59e-85	0.75	0.57	Cerebrospinal fluid biomarker levels;	chr7:23277123	chr7:23101228~23105703:-
BRCA	cis	rs9399135	0.967	rs6929661	ENSG00000232876.1	CTA-212D2.2	-22.12	3.37e-89	2.64e-85	-0.69	-0.57	Red blood cell count;	chr6:135007654	chr6:135055033~135060550:+
BRCA	cis	rs9399135	0.967	rs2327578	ENSG00000232876.1	CTA-212D2.2	-22.12	3.37e-89	2.64e-85	-0.69	-0.57	Red blood cell count;	chr6:135008831	chr6:135055033~135060550:+
BRCA	cis	rs9399135	0.967	rs6902438	ENSG00000232876.1	CTA-212D2.2	-22.11	3.94e-89	3.07e-85	-0.69	-0.57	Red blood cell count;	chr6:135015449	chr6:135055033~135060550:+
BRCA	cis	rs9399135	0.935	rs6908681	ENSG00000232876.1	CTA-212D2.2	-22.11	3.94e-89	3.07e-85	-0.69	-0.57	Red blood cell count;	chr6:135016595	chr6:135055033~135060550:+
BRCA	cis	rs9399135	0.967	rs6925424	ENSG00000232876.1	CTA-212D2.2	-22.11	4.17e-89	3.23e-85	-0.69	-0.57	Red blood cell count;	chr6:134992810	chr6:135055033~135060550:+
BRCA	cis	rs9399135	0.967	rs17638970	ENSG00000232876.1	CTA-212D2.2	-22.11	4.17e-89	3.23e-85	-0.69	-0.57	Red blood cell count;	chr6:134998925	chr6:135055033~135060550:+
BRCA	cis	rs9399135	0.933	rs4559100	ENSG00000232876.1	CTA-212D2.2	-22.11	4.17e-89	3.23e-85	-0.69	-0.57	Red blood cell count;	chr6:135002947	chr6:135055033~135060550:+
BRCA	cis	rs9399135	0.967	rs12527707	ENSG00000232876.1	CTA-212D2.2	-22.11	4.17e-89	3.23e-85	-0.69	-0.57	Red blood cell count;	chr6:135003373	chr6:135055033~135060550:+
BRCA	cis	rs9399135	0.967	rs9389251	ENSG00000232876.1	CTA-212D2.2	-22.11	4.17e-89	3.23e-85	-0.69	-0.57	Red blood cell count;	chr6:135004579	chr6:135055033~135060550:+
BRCA	cis	rs9399135	0.967	rs7763836	ENSG00000232876.1	CTA-212D2.2	-22.1	4.37e-89	3.39e-85	-0.69	-0.56	Red blood cell count;	chr6:135041240	chr6:135055033~135060550:+
BRCA	cis	rs9399135	0.967	rs45544135	ENSG00000232876.1	CTA-212D2.2	-22.1	4.86e-89	3.75e-85	-0.69	-0.56	Red blood cell count;	chr6:135002913	chr6:135055033~135060550:+
BRCA	cis	rs801193	0.773	rs801207	ENSG00000226824.5	RP4-756H11.3	22.09	5.12e-89	3.95e-85	0.68	0.56	Aortic root size;	chr7:66555603	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.66	rs10263935	ENSG00000226824.5	RP4-756H11.3	-22.08	5.85e-89	4.5e-85	-0.68	-0.56	Aortic root size;	chr7:66631041	chr7:66654538~66669855:+
BRCA	cis	rs3814244	0.528	rs1468487	ENSG00000255733.4	IFNG-AS1	-22.06	8.65e-89	6.57e-85	-0.47	-0.56	Itch intensity from mosquito bite adjusted by bite size;	chr12:67996602	chr12:67989445~68234686:+
BRCA	cis	rs3814244	0.868	rs10878726	ENSG00000255733.4	IFNG-AS1	22.05	9.52e-89	7.22e-85	0.47	0.56	Itch intensity from mosquito bite adjusted by bite size;	chr12:68022865	chr12:67989445~68234686:+
BRCA	cis	rs9399135	0.967	rs6902954	ENSG00000232876.1	CTA-212D2.2	-22.05	1e-88	7.59e-85	-0.69	-0.56	Red blood cell count;	chr6:134992856	chr6:135055033~135060550:+
BRCA	cis	rs3814244	0.528	rs2860609	ENSG00000255733.4	IFNG-AS1	-22.05	1.02e-88	7.71e-85	-0.47	-0.56	Itch intensity from mosquito bite adjusted by bite size;	chr12:67997215	chr12:67989445~68234686:+
BRCA	cis	rs10256972	0.577	rs6962809	ENSG00000229043.2	AC091729.9	-22.04	1.08e-88	8.17e-85	-0.7	-0.56	Endometriosis;Longevity;	chr7:1169253	chr7:1160374~1165267:+
BRCA	cis	rs858239	0.636	rs7808488	ENSG00000230658.1	KLHL7-AS1	22.04	1.16e-88	8.74e-85	0.74	0.56	Cerebrospinal fluid biomarker levels;	chr7:23182251	chr7:23101228~23105703:-
BRCA	cis	rs2739330	0.731	rs5751792	ENSG00000250470.1	AP000351.3	22.03	1.25e-88	9.43e-85	0.7	0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23976904~23977585:-
BRCA	cis	rs62229266	0.682	rs11700546	ENSG00000231106.2	LINC01436	22.03	1.39e-88	1.05e-84	0.66	0.56	Mitral valve prolapse;	chr21:35998841	chr21:36005338~36007838:+
BRCA	cis	rs875971	0.929	rs778712	ENSG00000226824.5	RP4-756H11.3	-22.01	1.82e-88	1.37e-84	-0.68	-0.56	Aortic root size;	chr7:66384991	chr7:66654538~66669855:+
BRCA	cis	rs9402673	0.558	rs9688342	ENSG00000232876.1	CTA-212D2.2	-22.01	1.91e-88	1.44e-84	-0.69	-0.56	High light scatter reticulocyte count;Reticulocyte count;	chr6:135001888	chr6:135055033~135060550:+
BRCA	cis	rs9399135	0.967	rs9389254	ENSG00000232876.1	CTA-212D2.2	-22	2.05e-88	1.53e-84	-0.69	-0.56	Red blood cell count;	chr6:135009571	chr6:135055033~135060550:+
BRCA	cis	rs9399135	0.967	rs9389253	ENSG00000232876.1	CTA-212D2.2	-21.99	2.34e-88	1.75e-84	-0.69	-0.56	Red blood cell count;	chr6:135008617	chr6:135055033~135060550:+
BRCA	cis	rs9399135	0.967	rs7741626	ENSG00000232876.1	CTA-212D2.2	-21.99	2.45e-88	1.83e-84	-0.69	-0.56	Red blood cell count;	chr6:134993044	chr6:135055033~135060550:+
BRCA	cis	rs9389248	0.5	rs116273677	ENSG00000232876.1	CTA-212D2.2	-21.99	2.55e-88	1.9e-84	-0.69	-0.56	High light scatter reticulocyte percentage of red cells;	chr6:135017997	chr6:135055033~135060550:+
BRCA	cis	rs9399135	0.967	rs4895439	ENSG00000232876.1	CTA-212D2.2	-21.98	2.81e-88	2.09e-84	-0.69	-0.56	Red blood cell count;	chr6:134997716	chr6:135055033~135060550:+
BRCA	cis	rs9399135	0.935	rs11754504	ENSG00000232876.1	CTA-212D2.2	-21.98	2.81e-88	2.09e-84	-0.69	-0.56	Red blood cell count;	chr6:135000371	chr6:135055033~135060550:+
BRCA	cis	rs9399135	0.869	rs9402675	ENSG00000232876.1	CTA-212D2.2	-21.98	2.81e-88	2.09e-84	-0.69	-0.56	Red blood cell count;	chr6:135004656	chr6:135055033~135060550:+
BRCA	cis	rs2906856	0.848	rs3015001	ENSG00000255733.4	IFNG-AS1	-21.98	2.93e-88	2.18e-84	-0.47	-0.56	Mosquito bite size;	chr12:68003593	chr12:67989445~68234686:+
BRCA	cis	rs9399135	0.933	rs9389262	ENSG00000232876.1	CTA-212D2.2	-21.98	3e-88	2.23e-84	-0.69	-0.56	Red blood cell count;	chr6:135055271	chr6:135055033~135060550:+
BRCA	cis	rs9399135	0.967	rs3756799	ENSG00000232876.1	CTA-212D2.2	-21.96	3.91e-88	2.89e-84	-0.69	-0.56	Red blood cell count;	chr6:135019873	chr6:135055033~135060550:+
BRCA	cis	rs801193	0.844	rs732465	ENSG00000226824.5	RP4-756H11.3	-21.96	4.02e-88	2.97e-84	-0.68	-0.56	Aortic root size;	chr7:66533463	chr7:66654538~66669855:+
BRCA	cis	rs9399135	0.967	rs6910530	ENSG00000232876.1	CTA-212D2.2	-21.96	4.09e-88	3.02e-84	-0.7	-0.56	Red blood cell count;	chr6:135011632	chr6:135055033~135060550:+
BRCA	cis	rs2882667	0.964	rs2288824	ENSG00000253404.1	AC034243.1	21.92	6.47e-88	4.75e-84	0.74	0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:138962707	chr5:138744434~138753309:-
BRCA	cis	rs875971	0.929	rs10950041	ENSG00000226824.5	RP4-756H11.3	-21.91	7.51e-88	5.5e-84	-0.68	-0.56	Aortic root size;	chr7:66508888	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.964	rs778708	ENSG00000226824.5	RP4-756H11.3	-21.89	1.08e-87	7.87e-84	-0.68	-0.56	Aortic root size;	chr7:66391332	chr7:66654538~66669855:+
BRCA	cis	rs875971	1	rs12533997	ENSG00000226824.5	RP4-756H11.3	-21.89	1.17e-87	8.55e-84	-0.68	-0.56	Aortic root size;	chr7:66500390	chr7:66654538~66669855:+
BRCA	cis	rs9399135	0.967	rs4451151	ENSG00000232876.1	CTA-212D2.2	-21.87	1.37e-87	9.99e-84	-0.69	-0.56	Red blood cell count;	chr6:134989408	chr6:135055033~135060550:+
BRCA	cis	rs9399135	0.967	rs12527683	ENSG00000232876.1	CTA-212D2.2	-21.87	1.48e-87	1.08e-83	-0.69	-0.56	Red blood cell count;	chr6:135003396	chr6:135055033~135060550:+
BRCA	cis	rs9399135	1	rs1014021	ENSG00000232876.1	CTA-212D2.2	21.86	1.71e-87	1.24e-83	0.69	0.56	Red blood cell count;	chr6:135013462	chr6:135055033~135060550:+
BRCA	cis	rs10256972	0.577	rs4999286	ENSG00000229043.2	AC091729.9	-21.86	1.76e-87	1.28e-83	-0.71	-0.56	Endometriosis;Longevity;	chr7:1159870	chr7:1160374~1165267:+
BRCA	cis	rs875971	1	rs778710	ENSG00000226824.5	RP4-756H11.3	-21.86	1.83e-87	1.33e-83	-0.68	-0.56	Aortic root size;	chr7:66389847	chr7:66654538~66669855:+
BRCA	cis	rs875971	1	rs778696	ENSG00000226824.5	RP4-756H11.3	-21.85	2.09e-87	1.51e-83	-0.68	-0.56	Aortic root size;	chr7:66405826	chr7:66654538~66669855:+
BRCA	cis	rs875971	1	rs778694	ENSG00000226824.5	RP4-756H11.3	-21.85	2.09e-87	1.51e-83	-0.68	-0.56	Aortic root size;	chr7:66406571	chr7:66654538~66669855:+
BRCA	cis	rs875971	1	rs4718344	ENSG00000226824.5	RP4-756H11.3	-21.85	2.09e-87	1.51e-83	-0.68	-0.56	Aortic root size;	chr7:66409394	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.737	rs7803424	ENSG00000226824.5	RP4-756H11.3	-21.85	2.09e-87	1.51e-83	-0.68	-0.56	Aortic root size;	chr7:66415618	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.83	rs7799834	ENSG00000226824.5	RP4-756H11.3	-21.85	2.09e-87	1.51e-83	-0.68	-0.56	Aortic root size;	chr7:66415707	chr7:66654538~66669855:+
BRCA	cis	rs9399135	0.967	rs9376082	ENSG00000232876.1	CTA-212D2.2	-21.82	3.26e-87	2.35e-83	-0.67	-0.56	Red blood cell count;	chr6:135025251	chr6:135055033~135060550:+
BRCA	cis	rs875971	0.965	rs10267430	ENSG00000226824.5	RP4-756H11.3	21.82	3.31e-87	2.38e-83	0.68	0.56	Aortic root size;	chr7:66278036	chr7:66654538~66669855:+
BRCA	cis	rs875971	1	rs10215948	ENSG00000226824.5	RP4-756H11.3	21.81	3.42e-87	2.46e-83	0.68	0.56	Aortic root size;	chr7:66282799	chr7:66654538~66669855:+
BRCA	cis	rs2739330	0.761	rs5760176	ENSG00000250470.1	AP000351.3	-21.8	4.31e-87	3.08e-83	-0.69	-0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23976904~23977585:-
BRCA	cis	rs9399135	0.816	rs4134030	ENSG00000232876.1	CTA-212D2.2	-21.78	5.3e-87	3.79e-83	-0.67	-0.56	Red blood cell count;	chr6:135032956	chr6:135055033~135060550:+
BRCA	cis	rs9399135	0.967	rs6923827	ENSG00000232876.1	CTA-212D2.2	-21.77	6.26e-87	4.46e-83	-0.68	-0.56	Red blood cell count;	chr6:135014244	chr6:135055033~135060550:+
BRCA	cis	rs2739330	0.796	rs1006771	ENSG00000225282.1	AP000350.6	21.77	7.02e-87	5e-83	0.69	0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23926900~23929574:+
BRCA	cis	rs875971	0.964	rs55748098	ENSG00000226824.5	RP4-756H11.3	21.76	7.2e-87	5.12e-83	0.68	0.56	Aortic root size;	chr7:66298631	chr7:66654538~66669855:+
BRCA	cis	rs875971	1	rs10257427	ENSG00000226824.5	RP4-756H11.3	21.76	7.24e-87	5.15e-83	0.68	0.56	Aortic root size;	chr7:66278221	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.964	rs778723	ENSG00000226824.5	RP4-756H11.3	-21.76	7.68e-87	5.45e-83	-0.67	-0.56	Aortic root size;	chr7:66364510	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.895	rs4718349	ENSG00000226824.5	RP4-756H11.3	-21.76	8.15e-87	5.77e-83	-0.68	-0.56	Aortic root size;	chr7:66444024	chr7:66654538~66669855:+
BRCA	cis	rs875971	1	rs2042133	ENSG00000226824.5	RP4-756H11.3	-21.76	8.15e-87	5.77e-83	-0.68	-0.56	Aortic root size;	chr7:66466935	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.964	rs2161065	ENSG00000226824.5	RP4-756H11.3	-21.76	8.15e-87	5.77e-83	-0.68	-0.56	Aortic root size;	chr7:66467918	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs12698521	ENSG00000226824.5	RP4-756H11.3	-21.76	8.15e-87	5.77e-83	-0.68	-0.56	Aortic root size;	chr7:66474502	chr7:66654538~66669855:+
BRCA	cis	rs10256972	0.577	rs2949179	ENSG00000229043.2	AC091729.9	-21.75	9.33e-87	6.59e-83	-0.68	-0.56	Endometriosis;Longevity;	chr7:1170249	chr7:1160374~1165267:+
BRCA	cis	rs10256972	0.504	rs2949178	ENSG00000229043.2	AC091729.9	-21.75	9.33e-87	6.59e-83	-0.68	-0.56	Endometriosis;Longevity;	chr7:1170289	chr7:1160374~1165267:+
BRCA	cis	rs9399135	0.967	rs1590975	ENSG00000232876.1	CTA-212D2.2	-21.73	1.24e-86	8.72e-83	-0.67	-0.56	Red blood cell count;	chr6:135030950	chr6:135055033~135060550:+
BRCA	cis	rs875971	1	rs709595	ENSG00000226824.5	RP4-756H11.3	-21.73	1.28e-86	9.03e-83	-0.67	-0.56	Aortic root size;	chr7:66352346	chr7:66654538~66669855:+
BRCA	cis	rs875971	1	rs811880	ENSG00000226824.5	RP4-756H11.3	-21.73	1.28e-86	9.03e-83	-0.67	-0.56	Aortic root size;	chr7:66353659	chr7:66654538~66669855:+
BRCA	cis	rs9399135	1	rs6569988	ENSG00000232876.1	CTA-212D2.2	-21.72	1.38e-86	9.68e-83	-0.68	-0.56	Red blood cell count;	chr6:135031165	chr6:135055033~135060550:+
BRCA	cis	rs875971	1	rs6460296	ENSG00000226824.5	RP4-756H11.3	-21.72	1.38e-86	9.68e-83	-0.67	-0.56	Aortic root size;	chr7:66430152	chr7:66654538~66669855:+
BRCA	cis	rs858239	0.799	rs10279941	ENSG00000230658.1	KLHL7-AS1	21.72	1.47e-86	1.03e-82	0.74	0.56	Cerebrospinal fluid biomarker levels;	chr7:23330889	chr7:23101228~23105703:-
BRCA	cis	rs875971	0.895	rs3857684	ENSG00000226824.5	RP4-756H11.3	-21.71	1.73e-86	1.21e-82	-0.67	-0.56	Aortic root size;	chr7:66473171	chr7:66654538~66669855:+
BRCA	cis	rs9399135	0.967	rs4637662	ENSG00000232876.1	CTA-212D2.2	-21.7	1.88e-86	1.32e-82	-0.68	-0.56	Red blood cell count;	chr6:134977020	chr6:135055033~135060550:+
BRCA	cis	rs9399135	0.933	rs7755680	ENSG00000232876.1	CTA-212D2.2	-21.7	1.97e-86	1.38e-82	-0.68	-0.56	Red blood cell count;	chr6:134973121	chr6:135055033~135060550:+
BRCA	cis	rs875971	1	rs875971	ENSG00000226824.5	RP4-756H11.3	21.69	2.28e-86	1.59e-82	0.67	0.56	Aortic root size;	chr7:66152608	chr7:66654538~66669855:+
BRCA	cis	rs875971	1	rs55962648	ENSG00000226824.5	RP4-756H11.3	21.67	3.06e-86	2.13e-82	0.68	0.56	Aortic root size;	chr7:66160764	chr7:66654538~66669855:+
BRCA	cis	rs62229266	0.682	rs2835224	ENSG00000231106.2	LINC01436	21.66	3.19e-86	2.22e-82	0.65	0.56	Mitral valve prolapse;	chr21:35997732	chr21:36005338~36007838:+
BRCA	cis	rs9399135	0.967	rs4896119	ENSG00000232876.1	CTA-212D2.2	-21.66	3.21e-86	2.23e-82	-0.68	-0.56	Red blood cell count;	chr6:134972253	chr6:135055033~135060550:+
BRCA	cis	rs9399135	1	rs11754265	ENSG00000232876.1	CTA-212D2.2	-21.66	3.24e-86	2.25e-82	-0.68	-0.56	Red blood cell count;	chr6:135035078	chr6:135055033~135060550:+
BRCA	cis	rs858239	0.932	rs858272	ENSG00000230658.1	KLHL7-AS1	21.66	3.25e-86	2.25e-82	0.75	0.56	Cerebrospinal fluid biomarker levels;	chr7:23237166	chr7:23101228~23105703:-
BRCA	cis	rs9399135	0.967	rs4388304	ENSG00000232876.1	CTA-212D2.2	-21.65	4.09e-86	2.83e-82	-0.68	-0.56	Red blood cell count;	chr6:134988459	chr6:135055033~135060550:+
BRCA	cis	rs875971	0.965	rs9969301	ENSG00000226824.5	RP4-756H11.3	21.64	4.39e-86	3.03e-82	0.67	0.56	Aortic root size;	chr7:66316668	chr7:66654538~66669855:+
BRCA	cis	rs9399135	0.967	rs4895436	ENSG00000232876.1	CTA-212D2.2	-21.64	4.76e-86	3.28e-82	-0.68	-0.56	Red blood cell count;	chr6:134973863	chr6:135055033~135060550:+
BRCA	cis	rs9399135	0.967	rs4896122	ENSG00000232876.1	CTA-212D2.2	-21.64	4.76e-86	3.28e-82	-0.68	-0.56	Red blood cell count;	chr6:134973943	chr6:135055033~135060550:+
BRCA	cis	rs9399135	0.935	rs4273704	ENSG00000232876.1	CTA-212D2.2	-21.64	4.76e-86	3.28e-82	-0.68	-0.56	Red blood cell count;	chr6:134976382	chr6:135055033~135060550:+
BRCA	cis	rs875971	1	rs778706	ENSG00000226824.5	RP4-756H11.3	-21.63	5.36e-86	3.68e-82	-0.68	-0.56	Aortic root size;	chr7:66395437	chr7:66654538~66669855:+
BRCA	cis	rs9399135	0.967	rs9376075	ENSG00000232876.1	CTA-212D2.2	-21.63	5.57e-86	3.83e-82	-0.68	-0.56	Red blood cell count;	chr6:134975825	chr6:135055033~135060550:+
BRCA	cis	rs875971	1	rs2420168	ENSG00000226824.5	RP4-756H11.3	21.62	6.44e-86	4.42e-82	0.67	0.56	Aortic root size;	chr7:66165644	chr7:66654538~66669855:+
BRCA	cis	rs9399135	0.967	rs9389256	ENSG00000232876.1	CTA-212D2.2	-21.62	6.55e-86	4.49e-82	-0.67	-0.56	Red blood cell count;	chr6:135010116	chr6:135055033~135060550:+
BRCA	cis	rs9399135	0.904	rs4895438	ENSG00000232876.1	CTA-212D2.2	-21.6	8.18e-86	5.61e-82	-0.67	-0.56	Red blood cell count;	chr6:134996527	chr6:135055033~135060550:+
BRCA	cis	rs875971	0.929	rs6970860	ENSG00000226824.5	RP4-756H11.3	-21.6	8.77e-86	6e-82	-0.68	-0.56	Aortic root size;	chr7:66511647	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.522	rs4718286	ENSG00000226824.5	RP4-756H11.3	-21.6	8.93e-86	6.11e-82	-0.68	-0.56	Aortic root size;	chr7:65827777	chr7:66654538~66669855:+
BRCA	cis	rs17711722	0.585	rs6942660	ENSG00000226824.5	RP4-756H11.3	-21.6	8.93e-86	6.11e-82	-0.68	-0.56	Calcium levels;	chr7:65837419	chr7:66654538~66669855:+
BRCA	cis	rs9399135	0.967	rs7741515	ENSG00000232876.1	CTA-212D2.2	21.58	1.2e-85	8.17e-82	0.68	0.56	Red blood cell count;	chr6:135053230	chr6:135055033~135060550:+
BRCA	cis	rs875971	0.522	rs4718285	ENSG00000226824.5	RP4-756H11.3	-21.57	1.26e-85	8.55e-82	-0.67	-0.56	Aortic root size;	chr7:65827018	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.929	rs12535036	ENSG00000226824.5	RP4-756H11.3	-21.57	1.31e-85	8.91e-82	-0.67	-0.56	Aortic root size;	chr7:66499076	chr7:66654538~66669855:+
BRCA	cis	rs875971	1	rs6970030	ENSG00000226824.5	RP4-756H11.3	-21.57	1.31e-85	8.91e-82	-0.67	-0.56	Aortic root size;	chr7:66503692	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.928	rs6970357	ENSG00000226824.5	RP4-756H11.3	-21.57	1.31e-85	8.91e-82	-0.67	-0.56	Aortic root size;	chr7:66503891	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.895	rs778700	ENSG00000226824.5	RP4-756H11.3	-21.57	1.36e-85	9.24e-82	-0.67	-0.56	Aortic root size;	chr7:66401463	chr7:66654538~66669855:+
BRCA	cis	rs875971	1	rs778699	ENSG00000226824.5	RP4-756H11.3	-21.57	1.36e-85	9.24e-82	-0.67	-0.56	Aortic root size;	chr7:66403303	chr7:66654538~66669855:+
BRCA	cis	rs875971	1	rs11974219	ENSG00000226824.5	RP4-756H11.3	21.57	1.42e-85	9.63e-82	0.67	0.56	Aortic root size;	chr7:66182423	chr7:66654538~66669855:+
BRCA	cis	rs875971	1	rs1565531	ENSG00000226824.5	RP4-756H11.3	21.56	1.42e-85	9.64e-82	0.67	0.56	Aortic root size;	chr7:66198126	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.964	rs6978429	ENSG00000226824.5	RP4-756H11.3	-21.56	1.43e-85	9.67e-82	-0.67	-0.56	Aortic root size;	chr7:66494889	chr7:66654538~66669855:+
BRCA	cis	rs875971	1	rs4718357	ENSG00000226824.5	RP4-756H11.3	-21.56	1.43e-85	9.67e-82	-0.67	-0.56	Aortic root size;	chr7:66495891	chr7:66654538~66669855:+
BRCA	cis	rs17711722	0.701	rs4467826	ENSG00000226824.5	RP4-756H11.3	-21.56	1.43e-85	9.67e-82	-0.67	-0.56	Calcium levels;	chr7:65903721	chr7:66654538~66669855:+
BRCA	cis	rs875971	1	rs6958271	ENSG00000226824.5	RP4-756H11.3	-21.56	1.46e-85	9.88e-82	-0.68	-0.56	Aortic root size;	chr7:66514344	chr7:66654538~66669855:+
BRCA	cis	rs875971	1	rs6958277	ENSG00000226824.5	RP4-756H11.3	-21.56	1.46e-85	9.88e-82	-0.68	-0.56	Aortic root size;	chr7:66514362	chr7:66654538~66669855:+
BRCA	cis	rs875971	1	rs12532998	ENSG00000226824.5	RP4-756H11.3	-21.56	1.5e-85	1.01e-81	-0.67	-0.56	Aortic root size;	chr7:66502472	chr7:66654538~66669855:+
BRCA	cis	rs17711722	0.727	rs35850374	ENSG00000226824.5	RP4-756H11.3	-21.56	1.56e-85	1.06e-81	-0.68	-0.56	Calcium levels;	chr7:65892789	chr7:66654538~66669855:+
BRCA	cis	rs9399135	0.935	rs4445070	ENSG00000232876.1	CTA-212D2.2	-21.56	1.64e-85	1.11e-81	-0.68	-0.56	Red blood cell count;	chr6:134988074	chr6:135055033~135060550:+
BRCA	cis	rs9399135	0.967	rs4896121	ENSG00000232876.1	CTA-212D2.2	-21.55	1.73e-85	1.17e-81	-0.68	-0.56	Red blood cell count;	chr6:134972507	chr6:135055033~135060550:+
BRCA	cis	rs875971	0.964	rs6945019	ENSG00000226824.5	RP4-756H11.3	-21.54	1.92e-85	1.3e-81	-0.68	-0.56	Aortic root size;	chr7:66457471	chr7:66654538~66669855:+
BRCA	cis	rs875971	1	rs4718307	ENSG00000226824.5	RP4-756H11.3	21.54	2.08e-85	1.4e-81	0.67	0.56	Aortic root size;	chr7:66146001	chr7:66654538~66669855:+
BRCA	cis	rs875971	1	rs7801282	ENSG00000226824.5	RP4-756H11.3	21.54	2.08e-85	1.4e-81	0.67	0.56	Aortic root size;	chr7:66148700	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.929	rs778692	ENSG00000226824.5	RP4-756H11.3	-21.53	2.24e-85	1.51e-81	-0.67	-0.55	Aortic root size;	chr7:66407462	chr7:66654538~66669855:+
BRCA	cis	rs875971	1	rs4718343	ENSG00000226824.5	RP4-756H11.3	-21.53	2.24e-85	1.51e-81	-0.67	-0.55	Aortic root size;	chr7:66409301	chr7:66654538~66669855:+
BRCA	cis	rs875971	1	rs1968225	ENSG00000226824.5	RP4-756H11.3	-21.53	2.24e-85	1.51e-81	-0.67	-0.55	Aortic root size;	chr7:66409786	chr7:66654538~66669855:+
BRCA	cis	rs875971	1	rs6460295	ENSG00000226824.5	RP4-756H11.3	-21.53	2.24e-85	1.51e-81	-0.67	-0.55	Aortic root size;	chr7:66417741	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.964	rs6978721	ENSG00000226824.5	RP4-756H11.3	-21.53	2.24e-85	1.51e-81	-0.67	-0.55	Aortic root size;	chr7:66418217	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.929	rs34406470	ENSG00000226824.5	RP4-756H11.3	-21.5	3.58e-85	2.39e-81	-0.68	-0.55	Aortic root size;	chr7:66464969	chr7:66654538~66669855:+
BRCA	cis	rs875971	1	rs2420591	ENSG00000226824.5	RP4-756H11.3	-21.5	3.84e-85	2.57e-81	-0.67	-0.55	Aortic root size;	chr7:66447394	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.516	rs6945322	ENSG00000226824.5	RP4-756H11.3	-21.5	4.01e-85	2.68e-81	-0.67	-0.55	Aortic root size;	chr7:65871069	chr7:66654538~66669855:+
BRCA	cis	rs9399135	0.967	rs13218642	ENSG00000232876.1	CTA-212D2.2	-21.49	4.5e-85	3.01e-81	-0.68	-0.55	Red blood cell count;	chr6:134988802	chr6:135055033~135060550:+
BRCA	cis	rs875971	0.964	rs778721	ENSG00000226824.5	RP4-756H11.3	-21.48	4.83e-85	3.22e-81	-0.67	-0.55	Aortic root size;	chr7:66380410	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.964	rs1643388	ENSG00000226824.5	RP4-756H11.3	-21.48	4.95e-85	3.3e-81	-0.67	-0.55	Aortic root size;	chr7:66379575	chr7:66654538~66669855:+
BRCA	cis	rs875971	1	rs778722	ENSG00000226824.5	RP4-756H11.3	-21.48	4.95e-85	3.3e-81	-0.67	-0.55	Aortic root size;	chr7:66379841	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.522	rs709604	ENSG00000226824.5	RP4-756H11.3	21.48	5.34e-85	3.56e-81	0.68	0.55	Aortic root size;	chr7:66032447	chr7:66654538~66669855:+
BRCA	cis	rs875971	1	rs7789554	ENSG00000226824.5	RP4-756H11.3	-21.47	5.56e-85	3.7e-81	-0.67	-0.55	Aortic root size;	chr7:66481051	chr7:66654538~66669855:+
BRCA	cis	rs875971	1	rs4717300	ENSG00000226824.5	RP4-756H11.3	-21.47	5.56e-85	3.7e-81	-0.67	-0.55	Aortic root size;	chr7:66482393	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.895	rs1974769	ENSG00000226824.5	RP4-756H11.3	-21.47	5.56e-85	3.7e-81	-0.67	-0.55	Aortic root size;	chr7:66485627	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.895	rs6460300	ENSG00000226824.5	RP4-756H11.3	-21.47	5.56e-85	3.7e-81	-0.67	-0.55	Aortic root size;	chr7:66487937	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs7803416	ENSG00000226824.5	RP4-756H11.3	-21.47	5.56e-85	3.7e-81	-0.67	-0.55	Aortic root size;	chr7:66489212	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.964	rs2277911	ENSG00000226824.5	RP4-756H11.3	-21.47	5.56e-85	3.7e-81	-0.67	-0.55	Aortic root size;	chr7:66493638	chr7:66654538~66669855:+
BRCA	cis	rs875971	1	rs9986696	ENSG00000226824.5	RP4-756H11.3	21.47	5.61e-85	3.73e-81	0.68	0.55	Aortic root size;	chr7:66239589	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.895	rs12698520	ENSG00000226824.5	RP4-756H11.3	-21.47	6.21e-85	4.13e-81	-0.67	-0.55	Aortic root size;	chr7:66453720	chr7:66654538~66669855:+
BRCA	cis	rs875971	1	rs12698523	ENSG00000226824.5	RP4-756H11.3	-21.46	6.4e-85	4.25e-81	-0.67	-0.55	Aortic root size;	chr7:66503126	chr7:66654538~66669855:+
BRCA	cis	rs858239	1	rs199348	ENSG00000230658.1	KLHL7-AS1	21.46	6.62e-85	4.39e-81	0.73	0.55	Cerebrospinal fluid biomarker levels;	chr7:23253479	chr7:23101228~23105703:-
BRCA	cis	rs875971	1	rs3735148	ENSG00000226824.5	RP4-756H11.3	-21.46	6.72e-85	4.46e-81	-0.67	-0.55	Aortic root size;	chr7:66506022	chr7:66654538~66669855:+
BRCA	cis	rs858239	0.896	rs1637193	ENSG00000230658.1	KLHL7-AS1	21.46	6.74e-85	4.47e-81	0.74	0.55	Cerebrospinal fluid biomarker levels;	chr7:23220632	chr7:23101228~23105703:-
BRCA	cis	rs9399135	0.967	rs4376365	ENSG00000232876.1	CTA-212D2.2	-21.46	6.93e-85	4.6e-81	-0.68	-0.55	Red blood cell count;	chr6:134986602	chr6:135055033~135060550:+
BRCA	cis	rs875971	1	rs778726	ENSG00000226824.5	RP4-756H11.3	-21.45	8.11e-85	5.36e-81	-0.67	-0.55	Aortic root size;	chr7:66363744	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.767	rs1695815	ENSG00000226824.5	RP4-756H11.3	-21.45	8.11e-85	5.36e-81	-0.67	-0.55	Aortic root size;	chr7:66366357	chr7:66654538~66669855:+
BRCA	cis	rs875971	1	rs778685	ENSG00000226824.5	RP4-756H11.3	-21.45	8.11e-85	5.36e-81	-0.67	-0.55	Aortic root size;	chr7:66371189	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.929	rs778682	ENSG00000226824.5	RP4-756H11.3	-21.45	8.11e-85	5.36e-81	-0.67	-0.55	Aortic root size;	chr7:66372947	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.964	rs11765965	ENSG00000226824.5	RP4-756H11.3	-21.45	8.11e-85	5.36e-81	-0.67	-0.55	Aortic root size;	chr7:66377234	chr7:66654538~66669855:+
BRCA	cis	rs875971	1	rs6957199	ENSG00000226824.5	RP4-756H11.3	-21.45	8.31e-85	5.49e-81	-0.67	-0.55	Aortic root size;	chr7:66513532	chr7:66654538~66669855:+
BRCA	cis	rs11763147	1	rs11763147	ENSG00000226824.5	RP4-756H11.3	21.45	8.36e-85	5.53e-81	0.66	0.55	Corneal structure;	chr7:65861834	chr7:66654538~66669855:+
BRCA	cis	rs858239	1	rs858239	ENSG00000230658.1	KLHL7-AS1	21.45	8.37e-85	5.53e-81	0.74	0.55	Cerebrospinal fluid biomarker levels;	chr7:23246696	chr7:23101228~23105703:-
BRCA	cis	rs875971	0.895	rs10755833	ENSG00000226824.5	RP4-756H11.3	-21.44	9.08e-85	5.98e-81	-0.67	-0.55	Aortic root size;	chr7:66448930	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.895	rs1833495	ENSG00000226824.5	RP4-756H11.3	-21.44	9.08e-85	5.98e-81	-0.67	-0.55	Aortic root size;	chr7:66456608	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.964	rs6945032	ENSG00000226824.5	RP4-756H11.3	-21.44	9.08e-85	5.98e-81	-0.67	-0.55	Aortic root size;	chr7:66457499	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.929	rs12673810	ENSG00000226824.5	RP4-756H11.3	-21.44	9.08e-85	5.98e-81	-0.67	-0.55	Aortic root size;	chr7:66458866	chr7:66654538~66669855:+
BRCA	cis	rs875971	1	rs6961155	ENSG00000226824.5	RP4-756H11.3	-21.44	9.08e-85	5.98e-81	-0.67	-0.55	Aortic root size;	chr7:66468308	chr7:66654538~66669855:+
BRCA	cis	rs875971	1	rs7789768	ENSG00000226824.5	RP4-756H11.3	-21.44	9.08e-85	5.98e-81	-0.67	-0.55	Aortic root size;	chr7:66473993	chr7:66654538~66669855:+
BRCA	cis	rs875971	1	rs1363055	ENSG00000226824.5	RP4-756H11.3	-21.44	9.08e-85	5.98e-81	-0.67	-0.55	Aortic root size;	chr7:66478288	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.964	rs9691480	ENSG00000226824.5	RP4-756H11.3	-21.44	9.08e-85	5.98e-81	-0.67	-0.55	Aortic root size;	chr7:66479319	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs1981799	ENSG00000226824.5	RP4-756H11.3	-21.44	9.13e-85	6.01e-81	-0.67	-0.55	Aortic root size;	chr7:66490572	chr7:66654538~66669855:+
BRCA	cis	rs9399135	0.967	rs12526055	ENSG00000232876.1	CTA-212D2.2	-21.43	9.92e-85	6.52e-81	-0.68	-0.55	Red blood cell count;	chr6:135004780	chr6:135055033~135060550:+
BRCA	cis	rs875971	0.522	rs7784623	ENSG00000226824.5	RP4-756H11.3	-21.42	1.19e-84	7.79e-81	-0.67	-0.55	Aortic root size;	chr7:65930047	chr7:66654538~66669855:+
BRCA	cis	rs801193	0.66	rs10950049	ENSG00000226824.5	RP4-756H11.3	-21.42	1.24e-84	8.14e-81	-0.67	-0.55	Aortic root size;	chr7:66765873	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.964	rs12668936	ENSG00000226824.5	RP4-756H11.3	-21.42	1.28e-84	8.36e-81	-0.67	-0.55	Aortic root size;	chr7:66449417	chr7:66654538~66669855:+
BRCA	cis	rs17711722	0.64	rs13237956	ENSG00000226824.5	RP4-756H11.3	-21.42	1.28e-84	8.38e-81	-0.67	-0.55	Calcium levels;	chr7:65853042	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.522	rs1617484	ENSG00000226824.5	RP4-756H11.3	-21.42	1.29e-84	8.44e-81	-0.67	-0.55	Aortic root size;	chr7:65998108	chr7:66654538~66669855:+
BRCA	cis	rs9399135	0.967	rs13199205	ENSG00000232876.1	CTA-212D2.2	-21.41	1.33e-84	8.73e-81	-0.68	-0.55	Red blood cell count;	chr6:134965367	chr6:135055033~135060550:+
BRCA	cis	rs9399135	0.967	rs6909975	ENSG00000232876.1	CTA-212D2.2	-21.41	1.38e-84	9.03e-81	-0.67	-0.55	Red blood cell count;	chr6:134994432	chr6:135055033~135060550:+
BRCA	cis	rs9399135	0.967	rs7773126	ENSG00000232876.1	CTA-212D2.2	-21.41	1.38e-84	9.03e-81	-0.67	-0.55	Red blood cell count;	chr6:134997252	chr6:135055033~135060550:+
BRCA	cis	rs801193	0.66	rs1016265	ENSG00000226824.5	RP4-756H11.3	-21.41	1.4e-84	9.16e-81	-0.67	-0.55	Aortic root size;	chr7:66749580	chr7:66654538~66669855:+
BRCA	cis	rs801193	0.66	rs4610622	ENSG00000226824.5	RP4-756H11.3	-21.41	1.4e-84	9.16e-81	-0.67	-0.55	Aortic root size;	chr7:66759510	chr7:66654538~66669855:+
BRCA	cis	rs875971	1	rs7781698	ENSG00000226824.5	RP4-756H11.3	-21.41	1.45e-84	9.47e-81	-0.67	-0.55	Aortic root size;	chr7:66431325	chr7:66654538~66669855:+
BRCA	cis	rs875971	1	rs4717292	ENSG00000226824.5	RP4-756H11.3	-21.41	1.48e-84	9.69e-81	-0.67	-0.55	Aortic root size;	chr7:66430611	chr7:66654538~66669855:+
BRCA	cis	rs875971	1	rs35149210	ENSG00000226824.5	RP4-756H11.3	-21.41	1.48e-84	9.69e-81	-0.67	-0.55	Aortic root size;	chr7:66464938	chr7:66654538~66669855:+
BRCA	cis	rs875971	1	rs2077593	ENSG00000226824.5	RP4-756H11.3	-21.4	1.62e-84	1.05e-80	-0.67	-0.55	Aortic root size;	chr7:66427543	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.522	rs34973832	ENSG00000226824.5	RP4-756H11.3	-21.4	1.64e-84	1.07e-80	-0.67	-0.55	Aortic root size;	chr7:65931217	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.522	rs6960048	ENSG00000226824.5	RP4-756H11.3	-21.39	1.82e-84	1.19e-80	-0.67	-0.55	Aortic root size;	chr7:65943052	chr7:66654538~66669855:+
BRCA	cis	rs17711722	0.675	rs6947132	ENSG00000226824.5	RP4-756H11.3	21.38	2.32e-84	1.5e-80	0.67	0.55	Calcium levels;	chr7:65808508	chr7:66654538~66669855:+
BRCA	cis	rs875971	1	rs937495	ENSG00000226824.5	RP4-756H11.3	21.37	2.47e-84	1.6e-80	0.67	0.55	Aortic root size;	chr7:66314811	chr7:66654538~66669855:+
BRCA	cis	rs875971	1	rs2036264	ENSG00000226824.5	RP4-756H11.3	21.37	2.47e-84	1.6e-80	0.67	0.55	Aortic root size;	chr7:66334917	chr7:66654538~66669855:+
BRCA	cis	rs875971	1	rs7783613	ENSG00000226824.5	RP4-756H11.3	21.37	2.47e-84	1.6e-80	0.67	0.55	Aortic root size;	chr7:66340274	chr7:66654538~66669855:+
BRCA	cis	rs2882667	0.893	rs10054796	ENSG00000253404.1	AC034243.1	21.35	3.37e-84	2.18e-80	0.71	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:138958655	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.893	rs10069961	ENSG00000253404.1	AC034243.1	21.35	3.37e-84	2.18e-80	0.71	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:138958879	chr5:138744434~138753309:-
BRCA	cis	rs2739330	0.828	rs5760107	ENSG00000218537.1	MIF-AS1	21.34	4.13e-84	2.66e-80	0.72	0.55	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23894426~23898930:-
BRCA	cis	rs12439619	0.705	rs17354185	ENSG00000278603.1	RP13-608F4.5	-21.34	4.25e-84	2.74e-80	-0.96	-0.55	Intelligence (multi-trait analysis);	chr15:82133829	chr15:82472203~82472426:+
BRCA	cis	rs17711722	0.701	rs55773927	ENSG00000226824.5	RP4-756H11.3	-21.33	5.01e-84	3.23e-80	-0.67	-0.55	Calcium levels;	chr7:65872915	chr7:66654538~66669855:+
BRCA	cis	rs801193	0.66	rs1962050	ENSG00000226824.5	RP4-756H11.3	21.32	5.31e-84	3.41e-80	0.66	0.55	Aortic root size;	chr7:66775021	chr7:66654538~66669855:+
BRCA	cis	rs17711722	1	rs17711722	ENSG00000226824.5	RP4-756H11.3	21.32	5.74e-84	3.69e-80	0.67	0.55	Calcium levels;	chr7:65806210	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.838	rs2173570	ENSG00000226824.5	RP4-756H11.3	21.31	6.61e-84	4.25e-80	0.67	0.55	Aortic root size;	chr7:66297976	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.965	rs28682868	ENSG00000226824.5	RP4-756H11.3	21.3	7.29e-84	4.68e-80	0.67	0.55	Aortic root size;	chr7:66224822	chr7:66654538~66669855:+
BRCA	cis	rs858239	0.73	rs10255155	ENSG00000230658.1	KLHL7-AS1	-21.3	7.4e-84	4.75e-80	-0.72	-0.55	Cerebrospinal fluid biomarker levels;	chr7:23362528	chr7:23101228~23105703:-
BRCA	cis	rs858239	1	rs858240	ENSG00000230658.1	KLHL7-AS1	21.3	7.64e-84	4.9e-80	0.74	0.55	Cerebrospinal fluid biomarker levels;	chr7:23244618	chr7:23101228~23105703:-
BRCA	cis	rs875971	1	rs6460292	ENSG00000226824.5	RP4-756H11.3	21.29	8.34e-84	5.34e-80	0.67	0.55	Aortic root size;	chr7:66345088	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.965	rs7794930	ENSG00000226824.5	RP4-756H11.3	21.29	8.86e-84	5.68e-80	0.67	0.55	Aortic root size;	chr7:66313559	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.964	rs778735	ENSG00000226824.5	RP4-756H11.3	-21.28	9.82e-84	6.28e-80	-0.67	-0.55	Aortic root size;	chr7:66349822	chr7:66654538~66669855:+
BRCA	cis	rs875971	1	rs6963646	ENSG00000226824.5	RP4-756H11.3	21.27	1.15e-83	7.38e-80	0.67	0.55	Aortic root size;	chr7:66220780	chr7:66654538~66669855:+
BRCA	cis	rs2882667	0.893	rs7717375	ENSG00000253404.1	AC034243.1	21.26	1.25e-83	8e-80	0.71	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:138955716	chr5:138744434~138753309:-
BRCA	cis	rs9399135	1	rs4475342	ENSG00000232876.1	CTA-212D2.2	-21.26	1.41e-83	9.01e-80	-0.67	-0.55	Red blood cell count;	chr6:134962210	chr6:135055033~135060550:+
BRCA	cis	rs2739330	0.789	rs5760109	ENSG00000218537.1	MIF-AS1	21.25	1.5e-83	9.58e-80	0.71	0.55	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23894426~23898930:-
BRCA	cis	rs858239	0.831	rs7796541	ENSG00000230658.1	KLHL7-AS1	21.24	1.68e-83	1.07e-79	0.73	0.55	Cerebrospinal fluid biomarker levels;	chr7:23349454	chr7:23101228~23105703:-
BRCA	cis	rs12439619	0.693	rs17269819	ENSG00000278603.1	RP13-608F4.5	21.23	2.12e-83	1.34e-79	0.85	0.55	Intelligence (multi-trait analysis);	chr15:82174660	chr15:82472203~82472426:+
BRCA	cis	rs875971	0.964	rs60193905	ENSG00000226824.5	RP4-756H11.3	-21.21	2.95e-83	1.87e-79	-0.66	-0.55	Aortic root size;	chr7:66506273	chr7:66654538~66669855:+
BRCA	cis	rs9399135	0.967	rs9399129	ENSG00000232876.1	CTA-212D2.2	-21.2	3.23e-83	2.04e-79	-0.67	-0.55	Red blood cell count;	chr6:134964010	chr6:135055033~135060550:+
BRCA	cis	rs875971	0.54	rs4717275	ENSG00000226824.5	RP4-756H11.3	21.2	3.27e-83	2.07e-79	0.67	0.55	Aortic root size;	chr7:65800193	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.867	rs1002053	ENSG00000226824.5	RP4-756H11.3	21.2	3.45e-83	2.18e-79	0.67	0.55	Aortic root size;	chr7:66333558	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.505	rs6955582	ENSG00000226824.5	RP4-756H11.3	-21.19	3.69e-83	2.33e-79	-0.67	-0.55	Aortic root size;	chr7:65966699	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.83	rs4718358	ENSG00000226824.5	RP4-756H11.3	-21.18	4.09e-83	2.58e-79	-0.67	-0.55	Aortic root size;	chr7:66508681	chr7:66654538~66669855:+
BRCA	cis	rs875971	1	rs6979382	ENSG00000226824.5	RP4-756H11.3	-21.18	4.17e-83	2.63e-79	-0.67	-0.55	Aortic root size;	chr7:66421388	chr7:66654538~66669855:+
BRCA	cis	rs875971	1	rs6961990	ENSG00000226824.5	RP4-756H11.3	-21.18	4.17e-83	2.63e-79	-0.67	-0.55	Aortic root size;	chr7:66423583	chr7:66654538~66669855:+
BRCA	cis	rs801193	0.66	rs2659897	ENSG00000226824.5	RP4-756H11.3	21.18	4.57e-83	2.88e-79	0.67	0.55	Aortic root size;	chr7:66722728	chr7:66654538~66669855:+
BRCA	cis	rs1577917	0.771	rs6454486	ENSG00000203875.9	SNHG5	21.17	5.16e-83	3.25e-79	0.63	0.55	Response to antipsychotic treatment;	chr6:85723869	chr6:85660950~85678736:-
BRCA	cis	rs10256972	0.514	rs2140578	ENSG00000229043.2	AC091729.9	-21.16	5.62e-83	3.54e-79	-0.7	-0.55	Endometriosis;Longevity;	chr7:1174367	chr7:1160374~1165267:+
BRCA	cis	rs875971	1	rs6961717	ENSG00000226824.5	RP4-756H11.3	21.16	5.85e-83	3.68e-79	0.66	0.55	Aortic root size;	chr7:66122550	chr7:66654538~66669855:+
BRCA	cis	rs875971	1	rs6958484	ENSG00000226824.5	RP4-756H11.3	21.16	6.13e-83	3.85e-79	0.66	0.55	Aortic root size;	chr7:66134459	chr7:66654538~66669855:+
BRCA	cis	rs17711722	0.701	rs781145	ENSG00000226824.5	RP4-756H11.3	-21.16	6.32e-83	3.96e-79	-0.67	-0.55	Calcium levels;	chr7:65975383	chr7:66654538~66669855:+
BRCA	cis	rs1153858	0.621	rs1719237	ENSG00000259520.4	CTD-2651B20.3	-21.15	6.39e-83	4.01e-79	-0.76	-0.55	Homoarginine levels;	chr15:45287624	chr15:45251580~45279251:-
BRCA	cis	rs875971	1	rs2087647	ENSG00000226824.5	RP4-756H11.3	21.15	6.55e-83	4.11e-79	0.66	0.55	Aortic root size;	chr7:66128201	chr7:66654538~66669855:+
BRCA	cis	rs801193	0.636	rs2659895	ENSG00000226824.5	RP4-756H11.3	-21.14	8.14e-83	5.1e-79	-0.67	-0.55	Aortic root size;	chr7:66731484	chr7:66654538~66669855:+
BRCA	cis	rs9399135	0.967	rs9376077	ENSG00000232876.1	CTA-212D2.2	-21.13	9.14e-83	5.72e-79	-0.67	-0.55	Red blood cell count;	chr6:134978575	chr6:135055033~135060550:+
BRCA	cis	rs9399135	1	rs35123050	ENSG00000232876.1	CTA-212D2.2	-21.1	1.41e-82	8.78e-79	-0.67	-0.55	Red blood cell count;	chr6:134981602	chr6:135055033~135060550:+
BRCA	cis	rs801193	0.66	rs974239	ENSG00000226824.5	RP4-756H11.3	-21.1	1.49e-82	9.26e-79	-0.67	-0.55	Aortic root size;	chr7:66748504	chr7:66654538~66669855:+
BRCA	cis	rs875971	1	rs1981798	ENSG00000226824.5	RP4-756H11.3	-21.09	1.64e-82	1.02e-78	-0.67	-0.55	Aortic root size;	chr7:66489916	chr7:66654538~66669855:+
BRCA	cis	rs17711722	0.727	rs2658585	ENSG00000226824.5	RP4-756H11.3	-21.08	1.87e-82	1.16e-78	-0.67	-0.55	Calcium levels;	chr7:65996954	chr7:66654538~66669855:+
BRCA	cis	rs1153858	0.621	rs1706824	ENSG00000259520.4	CTD-2651B20.3	-21.08	1.94e-82	1.2e-78	-0.75	-0.55	Homoarginine levels;	chr15:45287750	chr15:45251580~45279251:-
BRCA	cis	rs858239	0.665	rs858306	ENSG00000230658.1	KLHL7-AS1	21.07	2.36e-82	1.46e-78	0.72	0.55	Cerebrospinal fluid biomarker levels;	chr7:23203135	chr7:23101228~23105703:-
BRCA	cis	rs875971	0.895	rs7788984	ENSG00000226824.5	RP4-756H11.3	-21.06	2.71e-82	1.68e-78	-0.67	-0.55	Aortic root size;	chr7:66450629	chr7:66654538~66669855:+
BRCA	cis	rs875971	1	rs1540651	ENSG00000226824.5	RP4-756H11.3	21.06	2.75e-82	1.7e-78	0.67	0.55	Aortic root size;	chr7:66185134	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.522	rs4502988	ENSG00000226824.5	RP4-756H11.3	-21.05	2.81e-82	1.74e-78	-0.67	-0.55	Aortic root size;	chr7:65832759	chr7:66654538~66669855:+
BRCA	cis	rs858239	0.698	rs4265084	ENSG00000230658.1	KLHL7-AS1	21.04	3.25e-82	2.01e-78	0.73	0.55	Cerebrospinal fluid biomarker levels;	chr7:23367621	chr7:23101228~23105703:-
BRCA	cis	rs17711722	0.701	rs781143	ENSG00000226824.5	RP4-756H11.3	-21.04	3.26e-82	2.02e-78	-0.66	-0.55	Calcium levels;	chr7:65974892	chr7:66654538~66669855:+
BRCA	cis	rs875971	1	rs11971949	ENSG00000226824.5	RP4-756H11.3	21.04	3.74e-82	2.31e-78	0.67	0.55	Aortic root size;	chr7:66161027	chr7:66654538~66669855:+
BRCA	cis	rs858239	0.698	rs858295	ENSG00000230658.1	KLHL7-AS1	21.02	4.95e-82	3.05e-78	0.72	0.55	Cerebrospinal fluid biomarker levels;	chr7:23205950	chr7:23101228~23105703:-
BRCA	cis	rs801193	0.66	rs2659914	ENSG00000226824.5	RP4-756H11.3	-21.01	5.3e-82	3.26e-78	-0.67	-0.55	Aortic root size;	chr7:66691927	chr7:66654538~66669855:+
BRCA	cis	rs801193	0.591	rs2707839	ENSG00000226824.5	RP4-756H11.3	-21.01	5.3e-82	3.26e-78	-0.67	-0.55	Aortic root size;	chr7:66728097	chr7:66654538~66669855:+
BRCA	cis	rs875971	1	rs11974264	ENSG00000226824.5	RP4-756H11.3	21.01	5.52e-82	3.4e-78	0.67	0.55	Aortic root size;	chr7:66182595	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.522	rs10807697	ENSG00000226824.5	RP4-756H11.3	-21.01	5.7e-82	3.5e-78	-0.66	-0.55	Aortic root size;	chr7:65951183	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.54	rs736270	ENSG00000226824.5	RP4-756H11.3	-20.98	8.09e-82	4.96e-78	-0.67	-0.55	Aortic root size;	chr7:65963835	chr7:66654538~66669855:+
BRCA	cis	rs17711722	0.74	rs7809991	ENSG00000226824.5	RP4-756H11.3	-20.98	8.35e-82	5.11e-78	-0.66	-0.54	Calcium levels;	chr7:65941231	chr7:66654538~66669855:+
BRCA	cis	rs12439619	0.693	rs8034801	ENSG00000278603.1	RP13-608F4.5	20.96	1.06e-81	6.49e-78	0.84	0.54	Intelligence (multi-trait analysis);	chr15:82183996	chr15:82472203~82472426:+
BRCA	cis	rs12439619	0.693	rs28689861	ENSG00000278603.1	RP13-608F4.5	20.95	1.34e-81	8.16e-78	0.84	0.54	Intelligence (multi-trait analysis);	chr15:82206369	chr15:82472203~82472426:+
BRCA	cis	rs875971	0.54	rs1723268	ENSG00000226824.5	RP4-756H11.3	-20.93	1.8e-81	1.09e-77	-0.66	-0.54	Aortic root size;	chr7:66008093	chr7:66654538~66669855:+
BRCA	cis	rs875971	1	rs6945843	ENSG00000226824.5	RP4-756H11.3	20.92	2.05e-81	1.24e-77	0.66	0.54	Aortic root size;	chr7:66269796	chr7:66654538~66669855:+
BRCA	cis	rs1153858	0.621	rs2413769	ENSG00000259520.4	CTD-2651B20.3	-20.91	2.33e-81	1.41e-77	-0.76	-0.54	Homoarginine levels;	chr15:45269670	chr15:45251580~45279251:-
BRCA	cis	rs875971	1	rs10244498	ENSG00000226824.5	RP4-756H11.3	-20.9	2.84e-81	1.72e-77	-0.67	-0.54	Aortic root size;	chr7:66651069	chr7:66654538~66669855:+
BRCA	cis	rs2019137	0.539	rs11123170	ENSG00000189223.12	PAX8-AS1	-20.89	3.01e-81	1.81e-77	-0.78	-0.54	Lymphocyte counts;	chr2:113221363	chr2:113211522~113276581:+
BRCA	cis	rs2019137	0.56	rs6707386	ENSG00000189223.12	PAX8-AS1	-20.89	3.09e-81	1.86e-77	-0.78	-0.54	Lymphocyte counts;	chr2:113223445	chr2:113211522~113276581:+
BRCA	cis	rs801193	0.613	rs2659900	ENSG00000226824.5	RP4-756H11.3	-20.89	3.23e-81	1.94e-77	-0.67	-0.54	Aortic root size;	chr7:66719456	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.965	rs6971509	ENSG00000226824.5	RP4-756H11.3	20.88	3.73e-81	2.24e-77	0.66	0.54	Aortic root size;	chr7:66249983	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.522	rs2008188	ENSG00000226824.5	RP4-756H11.3	-20.87	4.16e-81	2.5e-77	-0.66	-0.54	Aortic root size;	chr7:65964026	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.522	rs1917563	ENSG00000226824.5	RP4-756H11.3	20.87	4.37e-81	2.62e-77	0.66	0.54	Aortic root size;	chr7:65950660	chr7:66654538~66669855:+
BRCA	cis	rs801193	0.636	rs10233806	ENSG00000226824.5	RP4-756H11.3	20.86	5.01e-81	3e-77	0.67	0.54	Aortic root size;	chr7:66653261	chr7:66654538~66669855:+
BRCA	cis	rs801193	0.548	rs2659904	ENSG00000226824.5	RP4-756H11.3	-20.86	5.02e-81	3.01e-77	-0.67	-0.54	Aortic root size;	chr7:66713615	chr7:66654538~66669855:+
BRCA	cis	rs10256972	0.552	rs2949195	ENSG00000229043.2	AC091729.9	-20.86	5.36e-81	3.21e-77	-0.69	-0.54	Endometriosis;Longevity;	chr7:1163069	chr7:1160374~1165267:+
BRCA	cis	rs6452524	0.618	rs10462394	ENSG00000249664.1	CTD-2227C6.2	20.85	5.82e-81	3.48e-77	0.63	0.54	Hypertension (SNP x SNP interaction);	chr5:83058735	chr5:83012285~83013109:-
BRCA	cis	rs10256972	0.567	rs2949185	ENSG00000229043.2	AC091729.9	-20.84	6.78e-81	4.05e-77	-0.69	-0.54	Endometriosis;Longevity;	chr7:1169377	chr7:1160374~1165267:+
BRCA	cis	rs17711722	0.727	rs1880555	ENSG00000226824.5	RP4-756H11.3	-20.83	8.01e-81	4.77e-77	-0.66	-0.54	Calcium levels;	chr7:65967580	chr7:66654538~66669855:+
BRCA	cis	rs2019137	0.56	rs7578633	ENSG00000189223.12	PAX8-AS1	-20.82	8.56e-81	5.09e-77	-0.78	-0.54	Lymphocyte counts;	chr2:113221073	chr2:113211522~113276581:+
BRCA	cis	rs2739330	0.828	rs4820572	ENSG00000218537.1	MIF-AS1	20.82	9.07e-81	5.39e-77	0.71	0.54	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23894426~23898930:-
BRCA	cis	rs875971	0.522	rs2949690	ENSG00000226824.5	RP4-756H11.3	20.81	1.08e-80	6.39e-77	0.66	0.54	Aortic root size;	chr7:66018255	chr7:66654538~66669855:+
BRCA	cis	rs875971	1	rs7792762	ENSG00000226824.5	RP4-756H11.3	-20.81	1.12e-80	6.63e-77	-0.66	-0.54	Aortic root size;	chr7:66539151	chr7:66654538~66669855:+
BRCA	cis	rs1153858	0.621	rs12913645	ENSG00000259520.4	CTD-2651B20.3	20.8	1.25e-80	7.41e-77	0.76	0.54	Homoarginine levels;	chr15:45262868	chr15:45251580~45279251:-
BRCA	cis	rs2486288	0.656	rs1706767	ENSG00000259520.4	CTD-2651B20.3	20.8	1.26e-80	7.48e-77	0.68	0.54	Glomerular filtration rate;	chr15:45276901	chr15:45251580~45279251:-
BRCA	cis	rs875971	1	rs709597	ENSG00000226824.5	RP4-756H11.3	20.76	2.04e-80	1.21e-76	0.66	0.54	Aortic root size;	chr7:66360996	chr7:66654538~66669855:+
BRCA	cis	rs12439619	0.693	rs7165536	ENSG00000278603.1	RP13-608F4.5	20.76	2.07e-80	1.22e-76	0.86	0.54	Intelligence (multi-trait analysis);	chr15:82273743	chr15:82472203~82472426:+
BRCA	cis	rs12439619	0.693	rs4778989	ENSG00000278603.1	RP13-608F4.5	20.76	2.31e-80	1.37e-76	0.85	0.54	Intelligence (multi-trait analysis);	chr15:82276963	chr15:82472203~82472426:+
BRCA	cis	rs875971	0.898	rs6977501	ENSG00000226824.5	RP4-756H11.3	20.75	2.46e-80	1.45e-76	0.66	0.54	Aortic root size;	chr7:66228355	chr7:66654538~66669855:+
BRCA	cis	rs67383717	0.777	rs591486	ENSG00000175611.10	LINC00476	-20.75	2.46e-80	1.45e-76	-0.56	-0.54	Parkinson's disease (pesticide exposure interaction);	chr9:95887764	chr9:95759231~95875977:-
BRCA	cis	rs875971	0.54	rs781152	ENSG00000226824.5	RP4-756H11.3	-20.75	2.7e-80	1.59e-76	-0.67	-0.54	Aortic root size;	chr7:66014585	chr7:66654538~66669855:+
BRCA	cis	rs17711722	0.727	rs781151	ENSG00000226824.5	RP4-756H11.3	-20.75	2.7e-80	1.59e-76	-0.67	-0.54	Calcium levels;	chr7:66014891	chr7:66654538~66669855:+
BRCA	cis	rs2739330	0.587	rs4820571	ENSG00000273295.1	AP000350.5	20.74	2.75e-80	1.62e-76	0.63	0.54	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23901432~23907068:-
BRCA	cis	rs858239	0.932	rs199355	ENSG00000230658.1	KLHL7-AS1	20.74	2.82e-80	1.66e-76	0.71	0.54	Cerebrospinal fluid biomarker levels;	chr7:23256914	chr7:23101228~23105703:-
BRCA	cis	rs858239	0.932	rs1637190	ENSG00000230658.1	KLHL7-AS1	20.74	2.86e-80	1.68e-76	0.71	0.54	Cerebrospinal fluid biomarker levels;	chr7:23229446	chr7:23101228~23105703:-
BRCA	cis	rs9399135	0.967	rs9321481	ENSG00000232876.1	CTA-212D2.2	20.74	2.89e-80	1.7e-76	0.66	0.54	Red blood cell count;	chr6:135031510	chr6:135055033~135060550:+
BRCA	cis	rs17507216	1	rs17507216	ENSG00000278603.1	RP13-608F4.5	-20.74	3.03e-80	1.78e-76	-0.85	-0.54	Excessive daytime sleepiness;	chr15:82558175	chr15:82472203~82472426:+
BRCA	cis	rs10256972	0.552	rs7805591	ENSG00000229043.2	AC091729.9	-20.71	4.24e-80	2.48e-76	-0.69	-0.54	Endometriosis;Longevity;	chr7:1171109	chr7:1160374~1165267:+
BRCA	cis	rs6452524	0.618	rs6452501	ENSG00000249664.1	CTD-2227C6.2	20.69	6.22e-80	3.63e-76	0.63	0.54	Hypertension (SNP x SNP interaction);	chr5:83068681	chr5:83012285~83013109:-
BRCA	cis	rs6452524	0.56	rs6895174	ENSG00000249664.1	CTD-2227C6.2	20.67	8.51e-80	4.95e-76	0.63	0.54	Hypertension (SNP x SNP interaction);	chr5:83071606	chr5:83012285~83013109:-
BRCA	cis	rs2739330	0.796	rs5760106	ENSG00000218537.1	MIF-AS1	-20.64	1.18e-79	6.88e-76	-0.71	-0.54	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23894426~23898930:-
BRCA	cis	rs6452524	0.618	rs6452502	ENSG00000249664.1	CTD-2227C6.2	20.64	1.2e-79	6.95e-76	0.63	0.54	Hypertension (SNP x SNP interaction);	chr5:83074578	chr5:83012285~83013109:-
BRCA	cis	rs6452524	0.618	rs6452503	ENSG00000249664.1	CTD-2227C6.2	20.64	1.2e-79	6.95e-76	0.63	0.54	Hypertension (SNP x SNP interaction);	chr5:83074596	chr5:83012285~83013109:-
BRCA	cis	rs2739330	0.734	rs2000467	ENSG00000225282.1	AP000350.6	-20.63	1.41e-79	8.16e-76	-0.68	-0.54	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23926900~23929574:+
BRCA	cis	rs6452524	0.618	rs6452504	ENSG00000249664.1	CTD-2227C6.2	20.63	1.45e-79	8.38e-76	0.63	0.54	Hypertension (SNP x SNP interaction);	chr5:83074625	chr5:83012285~83013109:-
BRCA	cis	rs858239	1	rs156421	ENSG00000230658.1	KLHL7-AS1	20.62	1.62e-79	9.38e-76	0.71	0.54	Cerebrospinal fluid biomarker levels;	chr7:23272868	chr7:23101228~23105703:-
BRCA	cis	rs6452524	0.618	rs1993948	ENSG00000249664.1	CTD-2227C6.2	20.6	2.25e-79	1.3e-75	0.63	0.54	Hypertension (SNP x SNP interaction);	chr5:83076461	chr5:83012285~83013109:-
BRCA	cis	rs62229266	0.771	rs11701590	ENSG00000231106.2	LINC01436	20.6	2.38e-79	1.38e-75	0.61	0.54	Mitral valve prolapse;	chr21:36012432	chr21:36005338~36007838:+
BRCA	cis	rs2882667	0.964	rs12108892	ENSG00000253404.1	AC034243.1	20.59	2.66e-79	1.53e-75	0.69	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:138963941	chr5:138744434~138753309:-
BRCA	cis	rs6452524	0.618	rs6452506	ENSG00000249664.1	CTD-2227C6.2	20.59	2.7e-79	1.55e-75	0.63	0.54	Hypertension (SNP x SNP interaction);	chr5:83075844	chr5:83012285~83013109:-
BRCA	cis	rs6452524	0.618	rs1871203	ENSG00000249664.1	CTD-2227C6.2	20.58	2.97e-79	1.71e-75	0.63	0.54	Hypertension (SNP x SNP interaction);	chr5:83059567	chr5:83012285~83013109:-
BRCA	cis	rs6452524	0.589	rs6882386	ENSG00000249664.1	CTD-2227C6.2	20.54	5.29e-79	3.03e-75	0.63	0.54	Hypertension (SNP x SNP interaction);	chr5:83065555	chr5:83012285~83013109:-
BRCA	cis	rs6452524	0.618	rs6860752	ENSG00000249664.1	CTD-2227C6.2	20.54	5.29e-79	3.03e-75	0.63	0.54	Hypertension (SNP x SNP interaction);	chr5:83065587	chr5:83012285~83013109:-
BRCA	cis	rs6452524	0.618	rs6867727	ENSG00000249664.1	CTD-2227C6.2	20.54	5.55e-79	3.17e-75	0.62	0.54	Hypertension (SNP x SNP interaction);	chr5:83061333	chr5:83012285~83013109:-
BRCA	cis	rs6452524	0.618	rs7723639	ENSG00000249664.1	CTD-2227C6.2	20.54	5.55e-79	3.17e-75	0.62	0.54	Hypertension (SNP x SNP interaction);	chr5:83062610	chr5:83012285~83013109:-
BRCA	cis	rs6452524	0.618	rs2306336	ENSG00000249664.1	CTD-2227C6.2	20.54	5.55e-79	3.17e-75	0.62	0.54	Hypertension (SNP x SNP interaction);	chr5:83064964	chr5:83012285~83013109:-
BRCA	cis	rs6452524	0.618	rs3899556	ENSG00000249664.1	CTD-2227C6.2	20.54	5.68e-79	3.24e-75	0.62	0.54	Hypertension (SNP x SNP interaction);	chr5:83067862	chr5:83012285~83013109:-
BRCA	cis	rs1577917	0.958	rs12197463	ENSG00000203875.9	SNHG5	-20.53	6.28e-79	3.58e-75	-0.63	-0.54	Response to antipsychotic treatment;	chr6:85735524	chr6:85660950~85678736:-
BRCA	cis	rs6452524	0.618	rs10051445	ENSG00000249664.1	CTD-2227C6.2	20.52	7.41e-79	4.22e-75	0.63	0.54	Hypertension (SNP x SNP interaction);	chr5:83060280	chr5:83012285~83013109:-
BRCA	cis	rs858239	1	rs156425	ENSG00000230658.1	KLHL7-AS1	-20.52	7.65e-79	4.36e-75	-0.7	-0.54	Cerebrospinal fluid biomarker levels;	chr7:23269500	chr7:23101228~23105703:-
BRCA	cis	rs875971	0.522	rs1701760	ENSG00000226824.5	RP4-756H11.3	-20.51	8.11e-79	4.61e-75	-0.65	-0.54	Aortic root size;	chr7:66008701	chr7:66654538~66669855:+
BRCA	cis	rs875971	1	rs2420820	ENSG00000226824.5	RP4-756H11.3	20.51	8.18e-79	4.65e-75	0.66	0.54	Aortic root size;	chr7:66626920	chr7:66654538~66669855:+
BRCA	cis	rs2739330	0.761	rs5760176	ENSG00000225282.1	AP000350.6	-20.5	9.77e-79	5.56e-75	-0.67	-0.54	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23926900~23929574:+
BRCA	cis	rs875971	1	rs1544549	ENSG00000226824.5	RP4-756H11.3	20.5	1.01e-78	5.72e-75	0.66	0.54	Aortic root size;	chr7:66625676	chr7:66654538~66669855:+
BRCA	cis	rs62229266	0.771	rs62230790	ENSG00000231106.2	LINC01436	20.5	1.05e-78	5.97e-75	0.61	0.54	Mitral valve prolapse;	chr21:36016613	chr21:36005338~36007838:+
BRCA	cis	rs12439619	0.693	rs9944185	ENSG00000278603.1	RP13-608F4.5	20.49	1.08e-78	6.14e-75	0.81	0.54	Intelligence (multi-trait analysis);	chr15:82157927	chr15:82472203~82472426:+
BRCA	cis	rs1577917	0.958	rs66807489	ENSG00000203875.9	SNHG5	-20.44	2.42e-78	1.37e-74	-0.63	-0.53	Response to antipsychotic treatment;	chr6:85730984	chr6:85660950~85678736:-
BRCA	cis	rs997154	0.579	rs12889177	ENSG00000279656.1	RP11-298I3.6	-20.41	3.83e-78	2.16e-74	-0.74	-0.53	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:23022120	chr14:23023083~23024217:-
BRCA	cis	rs2739330	0.731	rs5751792	ENSG00000225282.1	AP000350.6	20.39	4.73e-78	2.66e-74	0.67	0.53	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23926900~23929574:+
BRCA	cis	rs875971	1	rs1167612	ENSG00000226824.5	RP4-756H11.3	20.38	5.78e-78	3.24e-74	0.66	0.53	Aortic root size;	chr7:66102989	chr7:66654538~66669855:+
BRCA	cis	rs6452524	0.618	rs255561	ENSG00000249664.1	CTD-2227C6.2	20.38	6.05e-78	3.39e-74	0.63	0.53	Hypertension (SNP x SNP interaction);	chr5:83054991	chr5:83012285~83013109:-
BRCA	cis	rs1431005	0.793	rs7695310	ENSG00000250620.1	RP11-91J3.3	20.37	7.1e-78	3.97e-74	0.67	0.53	Response to statin therapy;	chr4:187415987	chr4:187413564~187415697:+
BRCA	cis	rs875971	0.964	rs697969	ENSG00000226824.5	RP4-756H11.3	20.35	8.46e-78	4.73e-74	0.66	0.53	Aortic root size;	chr7:66093491	chr7:66654538~66669855:+
BRCA	cis	rs875971	1	rs1182882	ENSG00000226824.5	RP4-756H11.3	20.35	8.46e-78	4.73e-74	0.66	0.53	Aortic root size;	chr7:66097076	chr7:66654538~66669855:+
BRCA	cis	rs6452524	0.618	rs7722924	ENSG00000249664.1	CTD-2227C6.2	20.34	9.65e-78	5.39e-74	0.62	0.53	Hypertension (SNP x SNP interaction);	chr5:83060223	chr5:83012285~83013109:-
BRCA	cis	rs6452524	0.618	rs2075685	ENSG00000249664.1	CTD-2227C6.2	20.34	1.02e-77	5.7e-74	0.62	0.53	Hypertension (SNP x SNP interaction);	chr5:83076846	chr5:83012285~83013109:-
BRCA	cis	rs1577917	0.958	rs12195776	ENSG00000203875.9	SNHG5	-20.32	1.33e-77	7.41e-74	-0.63	-0.53	Response to antipsychotic treatment;	chr6:85778881	chr6:85660950~85678736:-
BRCA	cis	rs62229266	0.773	rs878606	ENSG00000231106.2	LINC01436	20.32	1.45e-77	8.07e-74	0.62	0.53	Mitral valve prolapse;	chr21:36034394	chr21:36005338~36007838:+
BRCA	cis	rs7309	0.935	rs1921309	ENSG00000227403.1	AC009299.3	-20.31	1.52e-77	8.47e-74	-0.69	-0.53	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161192464	chr2:161244739~161249050:+
BRCA	cis	rs1431005	0.893	rs7663709	ENSG00000250620.1	RP11-91J3.3	20.31	1.65e-77	9.16e-74	0.66	0.53	Response to statin therapy;	chr4:187414777	chr4:187413564~187415697:+
BRCA	cis	rs1577917	0.958	rs12213343	ENSG00000203875.9	SNHG5	-20.31	1.66e-77	9.22e-74	-0.63	-0.53	Response to antipsychotic treatment;	chr6:85733301	chr6:85660950~85678736:-
BRCA	cis	rs1577917	0.958	rs12215265	ENSG00000203875.9	SNHG5	-20.31	1.66e-77	9.22e-74	-0.63	-0.53	Response to antipsychotic treatment;	chr6:85734251	chr6:85660950~85678736:-
BRCA	cis	rs6452524	0.648	rs27364	ENSG00000249664.1	CTD-2227C6.2	20.3	1.96e-77	1.09e-73	0.62	0.53	Hypertension (SNP x SNP interaction);	chr5:83052137	chr5:83012285~83013109:-
BRCA	cis	rs858239	1	rs199357	ENSG00000230658.1	KLHL7-AS1	-20.27	2.89e-77	1.6e-73	-0.7	-0.53	Cerebrospinal fluid biomarker levels;	chr7:23248690	chr7:23101228~23105703:-
BRCA	cis	rs6452524	0.618	rs1478487	ENSG00000249664.1	CTD-2227C6.2	20.24	4.49e-77	2.48e-73	0.62	0.53	Hypertension (SNP x SNP interaction);	chr5:83080900	chr5:83012285~83013109:-
BRCA	cis	rs2019137	0.56	rs11123172	ENSG00000189223.12	PAX8-AS1	20.24	4.72e-77	2.6e-73	0.76	0.53	Lymphocyte counts;	chr2:113226726	chr2:113211522~113276581:+
BRCA	cis	rs10256972	0.567	rs2960835	ENSG00000229043.2	AC091729.9	-20.23	4.89e-77	2.7e-73	-0.68	-0.53	Endometriosis;Longevity;	chr7:1163327	chr7:1160374~1165267:+
BRCA	cis	rs62229266	0.804	rs2835231	ENSG00000231106.2	LINC01436	20.23	5.19e-77	2.86e-73	0.61	0.53	Mitral valve prolapse;	chr21:36018300	chr21:36005338~36007838:+
BRCA	cis	rs1431005	0.784	rs67451289	ENSG00000250620.1	RP11-91J3.3	20.23	5.26e-77	2.9e-73	0.66	0.53	Response to statin therapy;	chr4:187415295	chr4:187413564~187415697:+
BRCA	cis	rs9399135	0.967	rs6923765	ENSG00000232876.1	CTA-212D2.2	20.22	6.09e-77	3.35e-73	0.66	0.53	Red blood cell count;	chr6:135014038	chr6:135055033~135060550:+
BRCA	cis	rs7301826	0.651	rs1554807	ENSG00000256250.1	RP11-989F5.1	20.21	6.71e-77	3.68e-73	0.62	0.53	Plasma plasminogen activator levels;	chr12:130795872	chr12:130810606~130812438:+
BRCA	cis	rs2019137	0.539	rs4849177	ENSG00000189223.12	PAX8-AS1	-20.21	6.95e-77	3.81e-73	-0.75	-0.53	Lymphocyte counts;	chr2:113225007	chr2:113211522~113276581:+
BRCA	cis	rs858239	0.932	rs1728313	ENSG00000230658.1	KLHL7-AS1	20.2	7.71e-77	4.23e-73	0.69	0.53	Cerebrospinal fluid biomarker levels;	chr7:23231412	chr7:23101228~23105703:-
BRCA	cis	rs62229266	0.74	rs4817759	ENSG00000231106.2	LINC01436	20.18	1.02e-76	5.59e-73	0.6	0.53	Mitral valve prolapse;	chr21:36017261	chr21:36005338~36007838:+
BRCA	cis	rs2739330	0.796	rs1006771	ENSG00000218537.1	MIF-AS1	20.18	1.04e-76	5.67e-73	0.7	0.53	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23894426~23898930:-
BRCA	cis	rs2882667	0.964	rs67296915	ENSG00000253404.1	AC034243.1	20.18	1.07e-76	5.86e-73	0.67	0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:138965910	chr5:138744434~138753309:-
BRCA	cis	rs62229266	0.74	rs2835233	ENSG00000231106.2	LINC01436	20.18	1.08e-76	5.92e-73	0.6	0.53	Mitral valve prolapse;	chr21:36021284	chr21:36005338~36007838:+
BRCA	cis	rs6452524	0.618	rs4266384	ENSG00000249664.1	CTD-2227C6.2	20.18	1.12e-76	6.11e-73	0.63	0.53	Hypertension (SNP x SNP interaction);	chr5:83080872	chr5:83012285~83013109:-
BRCA	cis	rs858239	0.669	rs6461688	ENSG00000230658.1	KLHL7-AS1	20.17	1.17e-76	6.36e-73	0.7	0.53	Cerebrospinal fluid biomarker levels;	chr7:23076996	chr7:23101228~23105703:-
BRCA	cis	rs7309	0.935	rs6432674	ENSG00000227403.1	AC009299.3	-20.17	1.25e-76	6.82e-73	-0.69	-0.53	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161168811	chr2:161244739~161249050:+
BRCA	cis	rs1577917	0.687	rs1470531	ENSG00000203875.9	SNHG5	-20.16	1.33e-76	7.27e-73	-0.62	-0.53	Response to antipsychotic treatment;	chr6:85797651	chr6:85660950~85678736:-
BRCA	cis	rs7309	0.81	rs11684253	ENSG00000227403.1	AC009299.3	-20.15	1.62e-76	8.83e-73	-0.69	-0.53	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161178025	chr2:161244739~161249050:+
BRCA	cis	rs7309	0.935	rs11884495	ENSG00000227403.1	AC009299.3	-20.13	2.08e-76	1.13e-72	-0.69	-0.53	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161203458	chr2:161244739~161249050:+
BRCA	cis	rs1577917	0.958	rs13207173	ENSG00000203875.9	SNHG5	-20.13	2.26e-76	1.23e-72	-0.63	-0.53	Response to antipsychotic treatment;	chr6:85747804	chr6:85660950~85678736:-
BRCA	cis	rs62229266	0.771	rs2835232	ENSG00000231106.2	LINC01436	20.13	2.27e-76	1.23e-72	0.6	0.53	Mitral valve prolapse;	chr21:36021129	chr21:36005338~36007838:+
BRCA	cis	rs875971	0.522	rs9530	ENSG00000226824.5	RP4-756H11.3	-20.12	2.52e-76	1.37e-72	-0.65	-0.53	Aortic root size;	chr7:65960907	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.929	rs4122249	ENSG00000226824.5	RP4-756H11.3	-20.12	2.62e-76	1.42e-72	-0.65	-0.53	Aortic root size;	chr7:66455949	chr7:66654538~66669855:+
BRCA	cis	rs2019137	0.539	rs6755040	ENSG00000189223.12	PAX8-AS1	-20.12	2.7e-76	1.46e-72	-0.75	-0.53	Lymphocyte counts;	chr2:113223560	chr2:113211522~113276581:+
BRCA	cis	rs1577917	0.958	rs10944136	ENSG00000203875.9	SNHG5	-20.11	2.98e-76	1.61e-72	-0.63	-0.53	Response to antipsychotic treatment;	chr6:85738781	chr6:85660950~85678736:-
BRCA	cis	rs2019137	0.56	rs4849179	ENSG00000189223.12	PAX8-AS1	-20.09	3.88e-76	2.1e-72	-0.75	-0.53	Lymphocyte counts;	chr2:113227593	chr2:113211522~113276581:+
BRCA	cis	rs1431005	0.893	rs998344	ENSG00000250620.1	RP11-91J3.3	20.09	4.13e-76	2.23e-72	0.65	0.53	Response to statin therapy;	chr4:187413335	chr4:187413564~187415697:+
BRCA	cis	rs2739330	0.796	rs2154594	ENSG00000218537.1	MIF-AS1	-20.08	4.37e-76	2.36e-72	-0.69	-0.53	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23894426~23898930:-
BRCA	cis	rs7301826	0.651	rs12228957	ENSG00000256250.1	RP11-989F5.1	-20.07	4.87e-76	2.63e-72	-0.62	-0.53	Plasma plasminogen activator levels;	chr12:130811521	chr12:130810606~130812438:+
BRCA	cis	rs7301826	0.651	rs12228959	ENSG00000256250.1	RP11-989F5.1	-20.07	4.87e-76	2.63e-72	-0.62	-0.53	Plasma plasminogen activator levels;	chr12:130811523	chr12:130810606~130812438:+
BRCA	cis	rs7301826	0.61	rs4759791	ENSG00000256250.1	RP11-989F5.1	-20.07	4.95e-76	2.66e-72	-0.62	-0.53	Plasma plasminogen activator levels;	chr12:130811950	chr12:130810606~130812438:+
BRCA	cis	rs7301826	0.651	rs4759521	ENSG00000256250.1	RP11-989F5.1	-20.07	4.95e-76	2.66e-72	-0.62	-0.53	Plasma plasminogen activator levels;	chr12:130812768	chr12:130810606~130812438:+
BRCA	cis	rs7301826	0.651	rs10734981	ENSG00000256250.1	RP11-989F5.1	-20.07	4.95e-76	2.66e-72	-0.62	-0.53	Plasma plasminogen activator levels;	chr12:130813350	chr12:130810606~130812438:+
BRCA	cis	rs7301826	0.651	rs10744483	ENSG00000256250.1	RP11-989F5.1	-20.07	4.95e-76	2.66e-72	-0.62	-0.53	Plasma plasminogen activator levels;	chr12:130813661	chr12:130810606~130812438:+
BRCA	cis	rs7301826	0.651	rs10744484	ENSG00000256250.1	RP11-989F5.1	-20.07	4.95e-76	2.66e-72	-0.62	-0.53	Plasma plasminogen activator levels;	chr12:130813961	chr12:130810606~130812438:+
BRCA	cis	rs7301826	0.651	rs10773824	ENSG00000256250.1	RP11-989F5.1	-20.07	5.07e-76	2.73e-72	-0.62	-0.53	Plasma plasminogen activator levels;	chr12:130814306	chr12:130810606~130812438:+
BRCA	cis	rs2019137	0.56	rs10206269	ENSG00000189223.12	PAX8-AS1	-20.07	5.37e-76	2.89e-72	-0.76	-0.53	Lymphocyte counts;	chr2:113232816	chr2:113211522~113276581:+
BRCA	cis	rs858239	0.73	rs858289	ENSG00000230658.1	KLHL7-AS1	20.07	5.46e-76	2.94e-72	0.69	0.53	Cerebrospinal fluid biomarker levels;	chr7:23208539	chr7:23101228~23105703:-
BRCA	cis	rs1577917	0.916	rs12206726	ENSG00000203875.9	SNHG5	-20.06	5.74e-76	3.08e-72	-0.63	-0.53	Response to antipsychotic treatment;	chr6:85789998	chr6:85660950~85678736:-
BRCA	cis	rs1577917	0.958	rs12209259	ENSG00000203875.9	SNHG5	-20.06	5.74e-76	3.08e-72	-0.63	-0.53	Response to antipsychotic treatment;	chr6:85792630	chr6:85660950~85678736:-
BRCA	cis	rs7301826	0.627	rs10773823	ENSG00000256250.1	RP11-989F5.1	-20.06	5.74e-76	3.09e-72	-0.62	-0.53	Plasma plasminogen activator levels;	chr12:130809956	chr12:130810606~130812438:+
BRCA	cis	rs1577917	0.958	rs1545376	ENSG00000203875.9	SNHG5	20.06	5.93e-76	3.19e-72	0.62	0.53	Response to antipsychotic treatment;	chr6:85794864	chr6:85660950~85678736:-
BRCA	cis	rs1577917	0.958	rs7453105	ENSG00000203875.9	SNHG5	-20.06	6.01e-76	3.23e-72	-0.63	-0.53	Response to antipsychotic treatment;	chr6:85791043	chr6:85660950~85678736:-
BRCA	cis	rs7301826	0.651	rs4759517	ENSG00000256250.1	RP11-989F5.1	-20.05	6.63e-76	3.56e-72	-0.62	-0.53	Plasma plasminogen activator levels;	chr12:130799153	chr12:130810606~130812438:+
BRCA	cis	rs858239	0.73	rs858290	ENSG00000230658.1	KLHL7-AS1	20.04	8.63e-76	4.62e-72	0.69	0.53	Cerebrospinal fluid biomarker levels;	chr7:23208417	chr7:23101228~23105703:-
BRCA	cis	rs875971	1	rs2220626	ENSG00000226824.5	RP4-756H11.3	20.03	8.89e-76	4.76e-72	0.65	0.53	Aortic root size;	chr7:66081075	chr7:66654538~66669855:+
BRCA	cis	rs7301826	0.61	rs9668291	ENSG00000256250.1	RP11-989F5.1	-20.03	9.05e-76	4.84e-72	-0.62	-0.53	Plasma plasminogen activator levels;	chr12:130812363	chr12:130810606~130812438:+
BRCA	cis	rs7301826	0.651	rs10773825	ENSG00000256250.1	RP11-989F5.1	-20.03	9.16e-76	4.9e-72	-0.61	-0.53	Plasma plasminogen activator levels;	chr12:130814368	chr12:130810606~130812438:+
BRCA	cis	rs1431005	0.893	rs7676864	ENSG00000250620.1	RP11-91J3.3	20.03	9.71e-76	5.19e-72	0.65	0.53	Response to statin therapy;	chr4:187400331	chr4:187413564~187415697:+
BRCA	cis	rs7301826	0.651	rs7132657	ENSG00000256250.1	RP11-989F5.1	-20.02	1.15e-75	6.15e-72	-0.62	-0.53	Plasma plasminogen activator levels;	chr12:130800642	chr12:130810606~130812438:+
BRCA	cis	rs7301826	0.651	rs10848210	ENSG00000256250.1	RP11-989F5.1	-20.01	1.24e-75	6.63e-72	-0.62	-0.53	Plasma plasminogen activator levels;	chr12:130827475	chr12:130810606~130812438:+
BRCA	cis	rs7301826	0.627	rs4325342	ENSG00000256250.1	RP11-989F5.1	-20.01	1.24e-75	6.63e-72	-0.62	-0.53	Plasma plasminogen activator levels;	chr12:130827937	chr12:130810606~130812438:+
BRCA	cis	rs2739330	0.734	rs2000467	ENSG00000218537.1	MIF-AS1	-20	1.43e-75	7.61e-72	-0.7	-0.53	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23894426~23898930:-
BRCA	cis	rs7301826	0.651	rs1973834	ENSG00000256250.1	RP11-989F5.1	-20	1.44e-75	7.67e-72	-0.62	-0.53	Plasma plasminogen activator levels;	chr12:130795612	chr12:130810606~130812438:+
BRCA	cis	rs858239	0.669	rs6461687	ENSG00000230658.1	KLHL7-AS1	20	1.44e-75	7.68e-72	0.69	0.53	Cerebrospinal fluid biomarker levels;	chr7:23076961	chr7:23101228~23105703:-
BRCA	cis	rs7301826	0.651	rs4759794	ENSG00000256250.1	RP11-989F5.1	-20	1.44e-75	7.68e-72	-0.62	-0.53	Plasma plasminogen activator levels;	chr12:130812803	chr12:130810606~130812438:+
BRCA	cis	rs7301826	0.651	rs10744485	ENSG00000256250.1	RP11-989F5.1	-20	1.44e-75	7.68e-72	-0.62	-0.53	Plasma plasminogen activator levels;	chr12:130814005	chr12:130810606~130812438:+
BRCA	cis	rs2019137	0.56	rs7421852	ENSG00000189223.12	PAX8-AS1	-20	1.53e-75	8.12e-72	-0.76	-0.53	Lymphocyte counts;	chr2:113232684	chr2:113211522~113276581:+
BRCA	cis	rs7301826	0.651	rs10848209	ENSG00000256250.1	RP11-989F5.1	-19.99	1.65e-75	8.75e-72	-0.62	-0.53	Plasma plasminogen activator levels;	chr12:130826727	chr12:130810606~130812438:+
BRCA	cis	rs7301826	0.61	rs7957899	ENSG00000256250.1	RP11-989F5.1	-19.99	1.76e-75	9.34e-72	-0.62	-0.53	Plasma plasminogen activator levels;	chr12:130794531	chr12:130810606~130812438:+
BRCA	cis	rs3814244	0.515	rs2906862	ENSG00000255733.4	IFNG-AS1	-19.98	1.82e-75	9.63e-72	-0.43	-0.53	Itch intensity from mosquito bite adjusted by bite size;	chr12:68005371	chr12:67989445~68234686:+
BRCA	cis	rs1577917	0.917	rs4098044	ENSG00000203875.9	SNHG5	-19.98	1.94e-75	1.03e-71	-0.63	-0.53	Response to antipsychotic treatment;	chr6:85752348	chr6:85660950~85678736:-
BRCA	cis	rs1577917	0.958	rs12192033	ENSG00000203875.9	SNHG5	-19.97	2.19e-75	1.16e-71	-0.62	-0.53	Response to antipsychotic treatment;	chr6:85762841	chr6:85660950~85678736:-
BRCA	cis	rs7301826	0.651	rs7295705	ENSG00000256250.1	RP11-989F5.1	-19.97	2.21e-75	1.17e-71	-0.61	-0.53	Plasma plasminogen activator levels;	chr12:130817340	chr12:130810606~130812438:+
BRCA	cis	rs7301826	0.627	rs73162873	ENSG00000256250.1	RP11-989F5.1	-19.96	2.4e-75	1.27e-71	-0.62	-0.53	Plasma plasminogen activator levels;	chr12:130811468	chr12:130810606~130812438:+
BRCA	cis	rs7301826	0.61	rs4759789	ENSG00000256250.1	RP11-989F5.1	-19.95	2.99e-75	1.58e-71	-0.62	-0.53	Plasma plasminogen activator levels;	chr12:130811835	chr12:130810606~130812438:+
BRCA	cis	rs858239	0.633	rs858300	ENSG00000230658.1	KLHL7-AS1	19.95	3.05e-75	1.61e-71	0.69	0.53	Cerebrospinal fluid biomarker levels;	chr7:23205012	chr7:23101228~23105703:-
BRCA	cis	rs7301826	0.651	rs10734979	ENSG00000256250.1	RP11-989F5.1	-19.94	3.49e-75	1.84e-71	-0.61	-0.53	Plasma plasminogen activator levels;	chr12:130804409	chr12:130810606~130812438:+
BRCA	cis	rs1577917	0.958	rs12216074	ENSG00000203875.9	SNHG5	-19.93	3.74e-75	1.97e-71	-0.62	-0.53	Response to antipsychotic treatment;	chr6:85810284	chr6:85660950~85678736:-
BRCA	cis	rs2019137	0.56	rs10175462	ENSG00000189223.12	PAX8-AS1	-19.93	3.84e-75	2.02e-71	-0.75	-0.53	Lymphocyte counts;	chr2:113230915	chr2:113211522~113276581:+
BRCA	cis	rs17507216	0.958	rs72751643	ENSG00000278603.1	RP13-608F4.5	19.93	3.86e-75	2.03e-71	0.83	0.53	Excessive daytime sleepiness;	chr15:82559444	chr15:82472203~82472426:+
BRCA	cis	rs7301826	0.651	rs7971046	ENSG00000256250.1	RP11-989F5.1	-19.92	4.4e-75	2.31e-71	-0.61	-0.53	Plasma plasminogen activator levels;	chr12:130802262	chr12:130810606~130812438:+
BRCA	cis	rs1577917	0.958	rs34795473	ENSG00000203875.9	SNHG5	-19.92	4.43e-75	2.33e-71	-0.62	-0.53	Response to antipsychotic treatment;	chr6:85752081	chr6:85660950~85678736:-
BRCA	cis	rs1577917	0.958	rs6454487	ENSG00000203875.9	SNHG5	19.92	4.62e-75	2.42e-71	0.61	0.53	Response to antipsychotic treatment;	chr6:85737150	chr6:85660950~85678736:-
BRCA	cis	rs858239	0.932	rs858275	ENSG00000230658.1	KLHL7-AS1	19.91	4.95e-75	2.6e-71	0.68	0.53	Cerebrospinal fluid biomarker levels;	chr7:23254525	chr7:23101228~23105703:-
BRCA	cis	rs7301826	0.651	rs4759519	ENSG00000256250.1	RP11-989F5.1	-19.91	5.36e-75	2.81e-71	-0.61	-0.52	Plasma plasminogen activator levels;	chr12:130804963	chr12:130810606~130812438:+
BRCA	cis	rs1577917	0.917	rs1414201	ENSG00000203875.9	SNHG5	-19.91	5.45e-75	2.85e-71	-0.62	-0.52	Response to antipsychotic treatment;	chr6:85790598	chr6:85660950~85678736:-
BRCA	cis	rs10256972	0.539	rs2949174	ENSG00000229043.2	AC091729.9	-19.89	7.25e-75	3.79e-71	-0.68	-0.52	Endometriosis;Longevity;	chr7:1174287	chr7:1160374~1165267:+
BRCA	cis	rs875971	1	rs697970	ENSG00000226824.5	RP4-756H11.3	19.88	7.96e-75	4.16e-71	0.65	0.52	Aortic root size;	chr7:66095065	chr7:66654538~66669855:+
BRCA	cis	rs7301826	0.571	rs4759788	ENSG00000256250.1	RP11-989F5.1	-19.87	9.32e-75	4.86e-71	-0.62	-0.52	Plasma plasminogen activator levels;	chr12:130811769	chr12:130810606~130812438:+
BRCA	cis	rs3814244	0.515	rs2906856	ENSG00000255733.4	IFNG-AS1	-19.86	1.06e-74	5.51e-71	-0.43	-0.52	Itch intensity from mosquito bite adjusted by bite size;	chr12:67996421	chr12:67989445~68234686:+
BRCA	cis	rs2882667	0.964	rs12719517	ENSG00000253404.1	AC034243.1	19.86	1.07e-74	5.59e-71	0.71	0.52	Age-related hearing impairment (SNP x SNP interaction);	chr5:138969813	chr5:138744434~138753309:-
BRCA	cis	rs62229266	0.804	rs62230822	ENSG00000231106.2	LINC01436	19.86	1.13e-74	5.86e-71	0.6	0.52	Mitral valve prolapse;	chr21:36057647	chr21:36005338~36007838:+
BRCA	cis	rs1577917	0.958	rs12191340	ENSG00000203875.9	SNHG5	-19.86	1.14e-74	5.94e-71	-0.62	-0.52	Response to antipsychotic treatment;	chr6:85811682	chr6:85660950~85678736:-
BRCA	cis	rs62229266	0.804	rs56279140	ENSG00000231106.2	LINC01436	19.85	1.34e-74	6.98e-71	0.59	0.52	Mitral valve prolapse;	chr21:36052063	chr21:36005338~36007838:+
BRCA	cis	rs7301826	0.627	rs1077317	ENSG00000256250.1	RP11-989F5.1	-19.84	1.38e-74	7.18e-71	-0.61	-0.52	Plasma plasminogen activator levels;	chr12:130830432	chr12:130810606~130812438:+
BRCA	cis	rs62229266	0.804	rs2835259	ENSG00000231106.2	LINC01436	19.84	1.4e-74	7.27e-71	0.59	0.52	Mitral valve prolapse;	chr21:36053004	chr21:36005338~36007838:+
BRCA	cis	rs62229266	0.804	rs62230821	ENSG00000231106.2	LINC01436	19.84	1.4e-74	7.29e-71	0.59	0.52	Mitral valve prolapse;	chr21:36052818	chr21:36005338~36007838:+
BRCA	cis	rs62229266	0.804	rs62230788	ENSG00000231106.2	LINC01436	19.83	1.69e-74	8.75e-71	0.64	0.52	Mitral valve prolapse;	chr21:36008039	chr21:36005338~36007838:+
BRCA	cis	rs875971	1	rs6946143	ENSG00000226824.5	RP4-756H11.3	-19.82	1.95e-74	1.01e-70	-0.64	-0.52	Aortic root size;	chr7:66114735	chr7:66654538~66669855:+
BRCA	cis	rs801193	0.742	rs9969300	ENSG00000226824.5	RP4-756H11.3	19.81	2.21e-74	1.14e-70	0.63	0.52	Aortic root size;	chr7:66316659	chr7:66654538~66669855:+
BRCA	cis	rs7309	0.935	rs10930013	ENSG00000227403.1	AC009299.3	-19.81	2.26e-74	1.17e-70	-0.69	-0.52	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161213814	chr2:161244739~161249050:+
BRCA	cis	rs62229266	0.804	rs2255858	ENSG00000231106.2	LINC01436	19.79	2.79e-74	1.44e-70	0.58	0.52	Mitral valve prolapse;	chr21:36040454	chr21:36005338~36007838:+
BRCA	cis	rs2906856	0.921	rs1019076	ENSG00000255733.4	IFNG-AS1	-19.79	2.9e-74	1.5e-70	-0.43	-0.52	Mosquito bite size;	chr12:68004338	chr12:67989445~68234686:+
BRCA	cis	rs7301826	0.651	rs2037789	ENSG00000256250.1	RP11-989F5.1	19.79	3.21e-74	1.65e-70	0.61	0.52	Plasma plasminogen activator levels;	chr12:130803747	chr12:130810606~130812438:+
BRCA	cis	rs1577917	0.876	rs4618490	ENSG00000203875.9	SNHG5	-19.77	3.79e-74	1.94e-70	-0.62	-0.52	Response to antipsychotic treatment;	chr6:85808685	chr6:85660950~85678736:-
BRCA	cis	rs62229266	0.804	rs12483151	ENSG00000231106.2	LINC01436	19.75	5.62e-74	2.87e-70	0.58	0.52	Mitral valve prolapse;	chr21:36047280	chr21:36005338~36007838:+
BRCA	cis	rs62229266	0.804	rs11088331	ENSG00000231106.2	LINC01436	19.74	5.79e-74	2.96e-70	0.59	0.52	Mitral valve prolapse;	chr21:36049574	chr21:36005338~36007838:+
BRCA	cis	rs62229266	0.804	rs880221	ENSG00000231106.2	LINC01436	19.74	6.45e-74	3.29e-70	0.58	0.52	Mitral valve prolapse;	chr21:36048487	chr21:36005338~36007838:+
BRCA	cis	rs7301826	0.651	rs4759525	ENSG00000256250.1	RP11-989F5.1	-19.73	6.69e-74	3.42e-70	-0.61	-0.52	Plasma plasminogen activator levels;	chr12:130831736	chr12:130810606~130812438:+
BRCA	cis	rs1577917	0.958	rs1414199	ENSG00000203875.9	SNHG5	-19.73	6.8e-74	3.47e-70	-0.61	-0.52	Response to antipsychotic treatment;	chr6:85812652	chr6:85660950~85678736:-
BRCA	cis	rs7301826	0.651	rs7968675	ENSG00000256250.1	RP11-989F5.1	-19.72	8.8e-74	4.48e-70	-0.61	-0.52	Plasma plasminogen activator levels;	chr12:130818832	chr12:130810606~130812438:+
BRCA	cis	rs2882667	0.964	rs12055237	ENSG00000253404.1	AC034243.1	19.7	1.08e-73	5.49e-70	0.68	0.52	Age-related hearing impairment (SNP x SNP interaction);	chr5:138971617	chr5:138744434~138753309:-
BRCA	cis	rs62229266	0.804	rs2835263	ENSG00000231106.2	LINC01436	-19.69	1.28e-73	6.46e-70	-0.58	-0.52	Mitral valve prolapse;	chr21:36057947	chr21:36005338~36007838:+
BRCA	cis	rs7301826	0.651	rs10848206	ENSG00000256250.1	RP11-989F5.1	-19.65	2.22e-73	1.12e-69	-0.61	-0.52	Plasma plasminogen activator levels;	chr12:130796926	chr12:130810606~130812438:+
BRCA	cis	rs7301826	0.557	rs7953184	ENSG00000256250.1	RP11-989F5.1	19.62	3.29e-73	1.66e-69	0.61	0.52	Plasma plasminogen activator levels;	chr12:130800307	chr12:130810606~130812438:+
BRCA	cis	rs2739330	0.76	rs5751761	ENSG00000225282.1	AP000350.6	-19.59	5.13e-73	2.57e-69	-0.65	-0.52	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23926900~23929574:+
BRCA	cis	rs73086581	1	rs73086581	ENSG00000229539.1	RP11-119B16.2	19.59	5.2e-73	2.6e-69	0.89	0.52	Response to antidepressants in depression;	chr20:3996678	chr20:3888239~3888868:-
BRCA	cis	rs4423214	1	rs4944957	ENSG00000254682.1	RP11-660L16.2	-19.58	5.86e-73	2.94e-69	-0.66	-0.52	Vitamin D levels;	chr11:71456989	chr11:71448674~71452157:+
BRCA	cis	rs62229266	0.804	rs2835241	ENSG00000231106.2	LINC01436	-19.58	6.6e-73	3.3e-69	-0.59	-0.52	Mitral valve prolapse;	chr21:36039082	chr21:36005338~36007838:+
BRCA	cis	rs3931020	0.745	rs10874274	ENSG00000272864.1	RP11-17E13.2	-19.53	1.32e-72	6.56e-69	-0.61	-0.52	Resistin levels;	chr1:74786450	chr1:74698769~74699333:-
BRCA	cis	rs858239	0.932	rs1624451	ENSG00000230658.1	KLHL7-AS1	-19.48	2.42e-72	1.2e-68	-0.67	-0.52	Cerebrospinal fluid biomarker levels;	chr7:23222816	chr7:23101228~23105703:-
BRCA	cis	rs7195287	0.826	rs9925824	ENSG00000276791.1	CTD-2270P14.5	-19.48	2.73e-72	1.35e-68	-0.53	-0.52	Eosinophil counts;	chr16:2777972	chr16:2777319~2780568:+
BRCA	cis	rs2882667	0.931	rs11955952	ENSG00000253404.1	AC034243.1	19.46	3.38e-72	1.67e-68	0.64	0.52	Age-related hearing impairment (SNP x SNP interaction);	chr5:138993430	chr5:138744434~138753309:-
BRCA	cis	rs1577917	0.958	rs4707223	ENSG00000203875.9	SNHG5	-19.45	3.7e-72	1.82e-68	-0.62	-0.52	Response to antipsychotic treatment;	chr6:85800084	chr6:85660950~85678736:-
BRCA	cis	rs2739330	0.76	rs1002286	ENSG00000218537.1	MIF-AS1	-19.45	3.96e-72	1.95e-68	-0.68	-0.52	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23894426~23898930:-
BRCA	cis	rs67383717	0.643	rs10759883	ENSG00000175611.10	LINC00476	-19.45	3.96e-72	1.95e-68	-0.55	-0.52	Parkinson's disease (pesticide exposure interaction);	chr9:95790481	chr9:95759231~95875977:-
BRCA	cis	rs507080	0.501	rs626645	ENSG00000255239.1	AP002954.6	19.42	5.86e-72	2.88e-68	0.58	0.52	Serum metabolite levels;	chr11:118704471	chr11:118688039~118690600:-
BRCA	cis	rs2882667	0.931	rs10070021	ENSG00000253404.1	AC034243.1	19.41	6.79e-72	3.32e-68	0.65	0.52	Age-related hearing impairment (SNP x SNP interaction);	chr5:138989017	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.964	rs11739351	ENSG00000253404.1	AC034243.1	19.34	1.86e-71	9.03e-68	0.67	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:138976053	chr5:138744434~138753309:-
BRCA	cis	rs875971	0.862	rs6460290	ENSG00000226824.5	RP4-756H11.3	19.31	2.97e-71	1.43e-67	0.63	0.51	Aortic root size;	chr7:66344119	chr7:66654538~66669855:+
BRCA	cis	rs2882667	0.964	rs11958050	ENSG00000253404.1	AC034243.1	19.31	3.12e-71	1.5e-67	0.65	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:138966139	chr5:138744434~138753309:-
BRCA	cis	rs3931020	0.745	rs1969111	ENSG00000272864.1	RP11-17E13.2	19.28	4.47e-71	2.14e-67	0.62	0.51	Resistin levels;	chr1:74797801	chr1:74698769~74699333:-
BRCA	cis	rs73086581	1	rs6107386	ENSG00000229539.1	RP11-119B16.2	19.25	6.97e-71	3.33e-67	0.87	0.51	Response to antidepressants in depression;	chr20:3992109	chr20:3888239~3888868:-
BRCA	cis	rs875971	0.862	rs11773628	ENSG00000226824.5	RP4-756H11.3	19.23	9.13e-71	4.35e-67	0.63	0.51	Aortic root size;	chr7:66517644	chr7:66654538~66669855:+
BRCA	cis	rs73086581	1	rs73088416	ENSG00000229539.1	RP11-119B16.2	19.22	1.13e-70	5.36e-67	0.88	0.51	Response to antidepressants in depression;	chr20:4014629	chr20:3888239~3888868:-
BRCA	cis	rs17507216	1	rs17356118	ENSG00000278603.1	RP13-608F4.5	19.18	1.73e-70	8.18e-67	0.8	0.51	Excessive daytime sleepiness;	chr15:82569149	chr15:82472203~82472426:+
BRCA	cis	rs2882667	0.931	rs6596457	ENSG00000253404.1	AC034243.1	19.18	1.74e-70	8.21e-67	0.64	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:138987690	chr5:138744434~138753309:-
BRCA	cis	rs858239	0.896	rs1637192	ENSG00000230658.1	KLHL7-AS1	19.18	1.84e-70	8.67e-67	0.67	0.51	Cerebrospinal fluid biomarker levels;	chr7:23220895	chr7:23101228~23105703:-
BRCA	cis	rs875971	0.862	rs949930	ENSG00000226824.5	RP4-756H11.3	19.18	1.94e-70	9.15e-67	0.62	0.51	Aortic root size;	chr7:66301835	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs12537823	ENSG00000226824.5	RP4-756H11.3	-19.16	2.31e-70	1.09e-66	-0.63	-0.51	Aortic root size;	chr7:66255897	chr7:66654538~66669855:+
BRCA	cis	rs494459	0.964	rs576283	ENSG00000255239.1	AP002954.6	19.16	2.37e-70	1.11e-66	0.58	0.51	Height;	chr11:118703185	chr11:118688039~118690600:-
BRCA	cis	rs507080	0.524	rs524409	ENSG00000255239.1	AP002954.6	19.16	2.37e-70	1.11e-66	0.58	0.51	Serum metabolite levels;	chr11:118703602	chr11:118688039~118690600:-
BRCA	cis	rs875971	0.825	rs1000464	ENSG00000226824.5	RP4-756H11.3	19.16	2.4e-70	1.12e-66	0.63	0.51	Aortic root size;	chr7:66312922	chr7:66654538~66669855:+
BRCA	cis	rs494459	0.929	rs627391	ENSG00000255239.1	AP002954.6	19.16	2.47e-70	1.16e-66	0.58	0.51	Height;	chr11:118703207	chr11:118688039~118690600:-
BRCA	cis	rs875971	0.862	rs709596	ENSG00000226824.5	RP4-756H11.3	-19.15	2.7e-70	1.26e-66	-0.62	-0.51	Aortic root size;	chr7:66360926	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.658	rs432667	ENSG00000226824.5	RP4-756H11.3	-19.14	3.18e-70	1.48e-66	-0.63	-0.51	Aortic root size;	chr7:66049646	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs10276077	ENSG00000226824.5	RP4-756H11.3	19.12	4.32e-70	2.01e-66	0.63	0.51	Aortic root size;	chr7:66263424	chr7:66654538~66669855:+
BRCA	cis	rs858239	0.796	rs433395	ENSG00000230658.1	KLHL7-AS1	19.11	4.8e-70	2.24e-66	0.67	0.51	Cerebrospinal fluid biomarker levels;	chr7:23362336	chr7:23101228~23105703:-
BRCA	cis	rs875971	0.564	rs313804	ENSG00000226824.5	RP4-756H11.3	-19.11	5.28e-70	2.46e-66	-0.63	-0.51	Aortic root size;	chr7:66049635	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.662	rs448725	ENSG00000226824.5	RP4-756H11.3	-19.11	5.28e-70	2.46e-66	-0.63	-0.51	Aortic root size;	chr7:66049641	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.825	rs4587224	ENSG00000226824.5	RP4-756H11.3	19.1	5.54e-70	2.58e-66	0.62	0.51	Aortic root size;	chr7:66271195	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.792	rs6971752	ENSG00000226824.5	RP4-756H11.3	19.1	5.54e-70	2.58e-66	0.62	0.51	Aortic root size;	chr7:66272999	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs10950033	ENSG00000226824.5	RP4-756H11.3	19.1	5.54e-70	2.58e-66	0.62	0.51	Aortic root size;	chr7:66274686	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs11760844	ENSG00000226824.5	RP4-756H11.3	19.1	5.54e-70	2.58e-66	0.62	0.51	Aortic root size;	chr7:66274896	chr7:66654538~66669855:+
BRCA	cis	rs2882667	0.931	rs1433009	ENSG00000253404.1	AC034243.1	19.09	6.55e-70	3.03e-66	0.63	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:138998095	chr5:138744434~138753309:-
BRCA	cis	rs2019137	0.539	rs4849181	ENSG00000189223.12	PAX8-AS1	-19.09	6.79e-70	3.15e-66	-0.74	-0.51	Lymphocyte counts;	chr2:113234393	chr2:113211522~113276581:+
BRCA	cis	rs2882667	0.931	rs10074461	ENSG00000253404.1	AC034243.1	19.09	6.82e-70	3.16e-66	0.62	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:138984126	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.931	rs10068237	ENSG00000253404.1	AC034243.1	19.08	7.33e-70	3.39e-66	0.64	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:139002271	chr5:138744434~138753309:-
BRCA	cis	rs3814244	1	rs3814244	ENSG00000255733.4	IFNG-AS1	-19.07	9.02e-70	4.16e-66	-0.42	-0.51	Itch intensity from mosquito bite adjusted by bite size;	chr12:68019691	chr12:67989445~68234686:+
BRCA	cis	rs2882667	0.931	rs10075039	ENSG00000253404.1	AC034243.1	19.07	9.47e-70	4.36e-66	0.64	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:139002165	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.861	rs13176902	ENSG00000253404.1	AC034243.1	19.06	9.52e-70	4.39e-66	0.64	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:139057640	chr5:138744434~138753309:-
BRCA	cis	rs875971	0.862	rs4149461	ENSG00000226824.5	RP4-756H11.3	19.06	9.64e-70	4.44e-66	0.62	0.51	Aortic root size;	chr7:66279745	chr7:66654538~66669855:+
BRCA	cis	rs507080	0.501	rs494459	ENSG00000255239.1	AP002954.6	-19.04	1.27e-69	5.82e-66	-0.57	-0.51	Serum metabolite levels;	chr11:118703966	chr11:118688039~118690600:-
BRCA	cis	rs1577917	0.958	rs9647601	ENSG00000203875.9	SNHG5	-19.04	1.33e-69	6.11e-66	-0.6	-0.51	Response to antipsychotic treatment;	chr6:85740109	chr6:85660950~85678736:-
BRCA	cis	rs73086581	1	rs17214949	ENSG00000229539.1	RP11-119B16.2	19.04	1.39e-69	6.37e-66	0.86	0.51	Response to antidepressants in depression;	chr20:3960305	chr20:3888239~3888868:-
BRCA	cis	rs73086581	1	rs17215054	ENSG00000229539.1	RP11-119B16.2	19.04	1.39e-69	6.37e-66	0.86	0.51	Response to antidepressants in depression;	chr20:3964132	chr20:3888239~3888868:-
BRCA	cis	rs73086581	1	rs17287486	ENSG00000229539.1	RP11-119B16.2	19.04	1.39e-69	6.37e-66	0.86	0.51	Response to antidepressants in depression;	chr20:3965620	chr20:3888239~3888868:-
BRCA	cis	rs73086581	1	rs73086540	ENSG00000229539.1	RP11-119B16.2	19.04	1.39e-69	6.37e-66	0.86	0.51	Response to antidepressants in depression;	chr20:3970203	chr20:3888239~3888868:-
BRCA	cis	rs73086581	1	rs73086544	ENSG00000229539.1	RP11-119B16.2	19.04	1.39e-69	6.37e-66	0.86	0.51	Response to antidepressants in depression;	chr20:3970281	chr20:3888239~3888868:-
BRCA	cis	rs73086581	1	rs2326289	ENSG00000229539.1	RP11-119B16.2	19.04	1.39e-69	6.37e-66	0.86	0.51	Response to antidepressants in depression;	chr20:3971653	chr20:3888239~3888868:-
BRCA	cis	rs73086581	1	rs73086549	ENSG00000229539.1	RP11-119B16.2	19.04	1.39e-69	6.37e-66	0.86	0.51	Response to antidepressants in depression;	chr20:3974015	chr20:3888239~3888868:-
BRCA	cis	rs875971	0.862	rs11763189	ENSG00000226824.5	RP4-756H11.3	-19.02	1.68e-69	7.7e-66	-0.63	-0.51	Aortic root size;	chr7:66518542	chr7:66654538~66669855:+
BRCA	cis	rs73086581	1	rs113812453	ENSG00000229539.1	RP11-119B16.2	19.02	1.78e-69	8.14e-66	0.86	0.51	Response to antidepressants in depression;	chr20:3982546	chr20:3888239~3888868:-
BRCA	cis	rs73086581	0.947	rs17287577	ENSG00000229539.1	RP11-119B16.2	19.02	1.78e-69	8.14e-66	0.86	0.51	Response to antidepressants in depression;	chr20:3985607	chr20:3888239~3888868:-
BRCA	cis	rs7301826	0.651	rs4514465	ENSG00000256250.1	RP11-989F5.1	-19.02	1.82e-69	8.32e-66	-0.6	-0.51	Plasma plasminogen activator levels;	chr12:130829124	chr12:130810606~130812438:+
BRCA	cis	rs3931020	0.772	rs1475396	ENSG00000272864.1	RP11-17E13.2	-19.02	1.9e-69	8.67e-66	-0.61	-0.51	Resistin levels;	chr1:74776712	chr1:74698769~74699333:-
BRCA	cis	rs875971	0.8	rs427557	ENSG00000226824.5	RP4-756H11.3	-19.01	1.95e-69	8.89e-66	-0.62	-0.51	Aortic root size;	chr7:66054263	chr7:66654538~66669855:+
BRCA	cis	rs2882667	0.898	rs11950819	ENSG00000253404.1	AC034243.1	19.01	2.08e-69	9.49e-66	0.64	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:139061411	chr5:138744434~138753309:-
BRCA	cis	rs875971	0.83	rs587360	ENSG00000226824.5	RP4-756H11.3	-19.01	2.18e-69	9.92e-66	-0.62	-0.51	Aortic root size;	chr7:66057711	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs10282433	ENSG00000226824.5	RP4-756H11.3	19	2.38e-69	1.08e-65	0.62	0.51	Aortic root size;	chr7:66256452	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.928	rs2036263	ENSG00000226824.5	RP4-756H11.3	19	2.48e-69	1.12e-65	0.62	0.51	Aortic root size;	chr7:66335210	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs10240949	ENSG00000226824.5	RP4-756H11.3	19	2.48e-69	1.12e-65	0.62	0.51	Aortic root size;	chr7:66339430	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs7782704	ENSG00000226824.5	RP4-756H11.3	19	2.48e-69	1.12e-65	0.62	0.51	Aortic root size;	chr7:66340379	chr7:66654538~66669855:+
BRCA	cis	rs3814244	0.515	rs3015002	ENSG00000255733.4	IFNG-AS1	-19	2.49e-69	1.13e-65	-0.41	-0.51	Itch intensity from mosquito bite adjusted by bite size;	chr12:68010853	chr12:67989445~68234686:+
BRCA	cis	rs3931020	0.772	rs1409785	ENSG00000272864.1	RP11-17E13.2	-18.98	2.96e-69	1.34e-65	-0.61	-0.51	Resistin levels;	chr1:74782438	chr1:74698769~74699333:-
BRCA	cis	rs875971	0.862	rs10261398	ENSG00000226824.5	RP4-756H11.3	18.98	3.37e-69	1.53e-65	0.62	0.51	Aortic root size;	chr7:66285177	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs10224872	ENSG00000226824.5	RP4-756H11.3	18.98	3.37e-69	1.53e-65	0.62	0.51	Aortic root size;	chr7:66294786	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs6959268	ENSG00000226824.5	RP4-756H11.3	18.97	3.42e-69	1.55e-65	0.62	0.51	Aortic root size;	chr7:66347979	chr7:66654538~66669855:+
BRCA	cis	rs1577917	0.958	rs6454488	ENSG00000203875.9	SNHG5	-18.95	4.87e-69	2.2e-65	-0.6	-0.51	Response to antipsychotic treatment;	chr6:85741124	chr6:85660950~85678736:-
BRCA	cis	rs875971	0.83	rs427575	ENSG00000226824.5	RP4-756H11.3	-18.95	4.89e-69	2.21e-65	-0.62	-0.51	Aortic root size;	chr7:66054232	chr7:66654538~66669855:+
BRCA	cis	rs7301826	0.651	rs7956851	ENSG00000256250.1	RP11-989F5.1	-18.95	5.03e-69	2.27e-65	-0.59	-0.51	Plasma plasminogen activator levels;	chr12:130834554	chr12:130810606~130812438:+
BRCA	cis	rs7104764	0.778	rs7930823	ENSG00000277290.1	RP11-326C3.16	18.92	7.42e-69	3.33e-65	0.49	0.51	Menarche (age at onset);	chr11:206767	chr11:243099~243483:-
BRCA	cis	rs73086581	1	rs34640283	ENSG00000229539.1	RP11-119B16.2	18.92	7.76e-69	3.47e-65	0.85	0.51	Response to antidepressants in depression;	chr20:4008929	chr20:3888239~3888868:-
BRCA	cis	rs1577917	0.958	rs12190603	ENSG00000203875.9	SNHG5	-18.91	8.87e-69	3.96e-65	-0.6	-0.51	Response to antipsychotic treatment;	chr6:85766000	chr6:85660950~85678736:-
BRCA	cis	rs73086581	0.945	rs6052222	ENSG00000229539.1	RP11-119B16.2	18.9	9.91e-69	4.42e-65	0.85	0.51	Response to antidepressants in depression;	chr20:3992146	chr20:3888239~3888868:-
BRCA	cis	rs875971	0.862	rs4718319	ENSG00000226824.5	RP4-756H11.3	18.9	9.94e-69	4.43e-65	0.62	0.51	Aortic root size;	chr7:66187797	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.723	rs28391294	ENSG00000226824.5	RP4-756H11.3	18.9	9.94e-69	4.43e-65	0.62	0.51	Aortic root size;	chr7:66189328	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.83	rs6967708	ENSG00000226824.5	RP4-756H11.3	18.9	9.94e-69	4.43e-65	0.62	0.51	Aortic root size;	chr7:66192326	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.895	rs7782806	ENSG00000226824.5	RP4-756H11.3	18.9	9.94e-69	4.43e-65	0.62	0.51	Aortic root size;	chr7:66192910	chr7:66654538~66669855:+
BRCA	cis	rs73086581	1	rs73086597	ENSG00000229539.1	RP11-119B16.2	18.9	1.03e-68	4.6e-65	0.85	0.51	Response to antidepressants in depression;	chr20:4002924	chr20:3888239~3888868:-
BRCA	cis	rs1577917	0.837	rs806529	ENSG00000203875.9	SNHG5	-18.89	1.06e-68	4.71e-65	-0.6	-0.51	Response to antipsychotic treatment;	chr6:85757403	chr6:85660950~85678736:-
BRCA	cis	rs10256972	0.552	rs2949192	ENSG00000229043.2	AC091729.9	-18.89	1.14e-68	5.05e-65	-0.63	-0.51	Endometriosis;Longevity;	chr7:1164205	chr7:1160374~1165267:+
BRCA	cis	rs875971	0.862	rs2420174	ENSG00000226824.5	RP4-756H11.3	18.89	1.16e-68	5.15e-65	0.62	0.51	Aortic root size;	chr7:66180374	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs2420173	ENSG00000226824.5	RP4-756H11.3	18.89	1.16e-68	5.15e-65	0.62	0.51	Aortic root size;	chr7:66180412	chr7:66654538~66669855:+
BRCA	cis	rs858239	0.614	rs10229956	ENSG00000230658.1	KLHL7-AS1	-18.89	1.2e-68	5.33e-65	-0.64	-0.5	Cerebrospinal fluid biomarker levels;	chr7:23363317	chr7:23101228~23105703:-
BRCA	cis	rs507080	0.501	rs625735	ENSG00000255239.1	AP002954.6	18.89	1.21e-68	5.36e-65	0.57	0.5	Serum metabolite levels;	chr11:118704710	chr11:118688039~118690600:-
BRCA	cis	rs875971	0.862	rs1983372	ENSG00000226824.5	RP4-756H11.3	18.88	1.32e-68	5.83e-65	0.61	0.5	Aortic root size;	chr7:66146364	chr7:66654538~66669855:+
BRCA	cis	rs2882667	0.898	rs3925110	ENSG00000253404.1	AC034243.1	18.88	1.32e-68	5.86e-65	0.64	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139035676	chr5:138744434~138753309:-
BRCA	cis	rs801193	0.569	rs13226966	ENSG00000226824.5	RP4-756H11.3	-18.87	1.4e-68	6.21e-65	-0.62	-0.5	Aortic root size;	chr7:66768636	chr7:66654538~66669855:+
BRCA	cis	rs73086581	1	rs73086588	ENSG00000229539.1	RP11-119B16.2	18.87	1.6e-68	7.08e-65	0.85	0.5	Response to antidepressants in depression;	chr20:4001577	chr20:3888239~3888868:-
BRCA	cis	rs73086581	1	rs73086595	ENSG00000229539.1	RP11-119B16.2	18.87	1.6e-68	7.08e-65	0.85	0.5	Response to antidepressants in depression;	chr20:4002801	chr20:3888239~3888868:-
BRCA	cis	rs875971	0.862	rs778734	ENSG00000226824.5	RP4-756H11.3	-18.87	1.6e-68	7.1e-65	-0.62	-0.5	Aortic root size;	chr7:66349862	chr7:66654538~66669855:+
BRCA	cis	rs1577917	0.958	rs2324817	ENSG00000203875.9	SNHG5	-18.85	1.97e-68	8.7e-65	-0.6	-0.5	Response to antipsychotic treatment;	chr6:85752936	chr6:85660950~85678736:-
BRCA	cis	rs875971	0.862	rs778724	ENSG00000226824.5	RP4-756H11.3	-18.85	2.03e-68	8.95e-65	-0.62	-0.5	Aortic root size;	chr7:66364304	chr7:66654538~66669855:+
BRCA	cis	rs1577917	0.958	rs6921315	ENSG00000203875.9	SNHG5	-18.85	2.04e-68	9e-65	-0.6	-0.5	Response to antipsychotic treatment;	chr6:85761950	chr6:85660950~85678736:-
BRCA	cis	rs2882667	0.929	rs17207828	ENSG00000253404.1	AC034243.1	18.85	2.11e-68	9.28e-65	0.67	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:138964146	chr5:138744434~138753309:-
BRCA	cis	rs858239	0.665	rs858305	ENSG00000230658.1	KLHL7-AS1	-18.84	2.33e-68	1.03e-64	-0.67	-0.5	Cerebrospinal fluid biomarker levels;	chr7:23203211	chr7:23101228~23105703:-
BRCA	cis	rs2882667	0.931	rs10069528	ENSG00000253404.1	AC034243.1	18.82	2.97e-68	1.3e-64	0.64	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139018338	chr5:138744434~138753309:-
BRCA	cis	rs1431005	0.893	rs9684748	ENSG00000250620.1	RP11-91J3.3	18.82	3.06e-68	1.34e-64	0.63	0.5	Response to statin therapy;	chr4:187398070	chr4:187413564~187415697:+
BRCA	cis	rs1577917	0.876	rs11752223	ENSG00000203875.9	SNHG5	-18.79	4.33e-68	1.89e-64	-0.59	-0.5	Response to antipsychotic treatment;	chr6:85863676	chr6:85660950~85678736:-
BRCA	cis	rs1577917	0.958	rs12660846	ENSG00000203875.9	SNHG5	-18.79	4.33e-68	1.89e-64	-0.59	-0.5	Response to antipsychotic treatment;	chr6:85864091	chr6:85660950~85678736:-
BRCA	cis	rs1577917	0.917	rs2218594	ENSG00000203875.9	SNHG5	-18.79	4.55e-68	1.99e-64	-0.59	-0.5	Response to antipsychotic treatment;	chr6:85834048	chr6:85660950~85678736:-
BRCA	cis	rs1577917	0.958	rs2197648	ENSG00000203875.9	SNHG5	-18.79	4.55e-68	1.99e-64	-0.59	-0.5	Response to antipsychotic treatment;	chr6:85834169	chr6:85660950~85678736:-
BRCA	cis	rs1577917	0.816	rs9353349	ENSG00000203875.9	SNHG5	18.79	4.8e-68	2.09e-64	0.6	0.5	Response to antipsychotic treatment;	chr6:85998007	chr6:85660950~85678736:-
BRCA	cis	rs2882667	0.898	rs6882583	ENSG00000253404.1	AC034243.1	18.79	4.86e-68	2.12e-64	0.64	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139050107	chr5:138744434~138753309:-
BRCA	cis	rs1577917	1	rs16876529	ENSG00000203875.9	SNHG5	-18.79	4.93e-68	2.15e-64	-0.59	-0.5	Response to antipsychotic treatment;	chr6:85881484	chr6:85660950~85678736:-
BRCA	cis	rs875971	0.862	rs880166	ENSG00000226824.5	RP4-756H11.3	18.77	6.01e-68	2.61e-64	0.62	0.5	Aortic root size;	chr7:66205775	chr7:66654538~66669855:+
BRCA	cis	rs1577917	0.958	rs12213431	ENSG00000203875.9	SNHG5	-18.77	6.04e-68	2.63e-64	-0.59	-0.5	Response to antipsychotic treatment;	chr6:85791238	chr6:85660950~85678736:-
BRCA	cis	rs858239	0.676	rs3807459	ENSG00000230658.1	KLHL7-AS1	18.77	6.2e-68	2.7e-64	0.65	0.5	Cerebrospinal fluid biomarker levels;	chr7:23350132	chr7:23101228~23105703:-
BRCA	cis	rs875971	0.895	rs4145009	ENSG00000226824.5	RP4-756H11.3	18.77	6.47e-68	2.81e-64	0.62	0.5	Aortic root size;	chr7:66261628	chr7:66654538~66669855:+
BRCA	cis	rs2882667	0.898	rs13182437	ENSG00000253404.1	AC034243.1	18.76	6.65e-68	2.89e-64	0.64	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139051460	chr5:138744434~138753309:-
BRCA	cis	rs875971	0.798	rs57739047	ENSG00000226824.5	RP4-756H11.3	-18.76	6.74e-68	2.93e-64	-0.62	-0.5	Aortic root size;	chr7:66507579	chr7:66654538~66669855:+
BRCA	cis	rs73086581	1	rs73086535	ENSG00000229539.1	RP11-119B16.2	18.76	6.83e-68	2.97e-64	0.85	0.5	Response to antidepressants in depression;	chr20:3963503	chr20:3888239~3888868:-
BRCA	cis	rs73086581	0.947	rs55794220	ENSG00000229539.1	RP11-119B16.2	18.76	6.83e-68	2.97e-64	0.85	0.5	Response to antidepressants in depression;	chr20:3975755	chr20:3888239~3888868:-
BRCA	cis	rs875971	0.83	rs6950137	ENSG00000226824.5	RP4-756H11.3	-18.76	7.05e-68	3.06e-64	-0.62	-0.5	Aortic root size;	chr7:66511623	chr7:66654538~66669855:+
BRCA	cis	rs73086581	1	rs3746665	ENSG00000229539.1	RP11-119B16.2	-18.76	7.27e-68	3.15e-64	-0.81	-0.5	Response to antidepressants in depression;	chr20:3929759	chr20:3888239~3888868:-
BRCA	cis	rs7104764	0.917	rs3825075	ENSG00000277290.1	RP11-326C3.16	18.76	7.33e-68	3.18e-64	0.51	0.5	Menarche (age at onset);	chr11:217140	chr11:243099~243483:-
BRCA	cis	rs1577917	0.958	rs10455448	ENSG00000203875.9	SNHG5	-18.75	7.63e-68	3.31e-64	-0.59	-0.5	Response to antipsychotic treatment;	chr6:85823893	chr6:85660950~85678736:-
BRCA	cis	rs1577917	0.917	rs13196576	ENSG00000203875.9	SNHG5	-18.75	7.63e-68	3.31e-64	-0.59	-0.5	Response to antipsychotic treatment;	chr6:85824348	chr6:85660950~85678736:-
BRCA	cis	rs1577917	0.958	rs3857480	ENSG00000203875.9	SNHG5	-18.75	7.63e-68	3.31e-64	-0.59	-0.5	Response to antipsychotic treatment;	chr6:85825431	chr6:85660950~85678736:-
BRCA	cis	rs1577917	1	rs12204015	ENSG00000203875.9	SNHG5	-18.75	8.68e-68	3.76e-64	-0.6	-0.5	Response to antipsychotic treatment;	chr6:85888616	chr6:85660950~85678736:-
BRCA	cis	rs1577917	0.917	rs4707226	ENSG00000203875.9	SNHG5	-18.74	8.93e-68	3.87e-64	-0.59	-0.5	Response to antipsychotic treatment;	chr6:85818110	chr6:85660950~85678736:-
BRCA	cis	rs73086581	0.891	rs55871214	ENSG00000229539.1	RP11-119B16.2	18.74	9.01e-68	3.9e-64	0.85	0.5	Response to antidepressants in depression;	chr20:3985059	chr20:3888239~3888868:-
BRCA	cis	rs73086581	1	rs56069856	ENSG00000229539.1	RP11-119B16.2	18.74	9.01e-68	3.9e-64	0.85	0.5	Response to antidepressants in depression;	chr20:3985062	chr20:3888239~3888868:-
BRCA	cis	rs7195287	0.779	rs2335454	ENSG00000276791.1	CTD-2270P14.5	18.74	9.11e-68	3.94e-64	0.53	0.5	Eosinophil counts;	chr16:2778156	chr16:2777319~2780568:+
BRCA	cis	rs2882667	0.898	rs13163536	ENSG00000253404.1	AC034243.1	18.74	9.55e-68	4.13e-64	0.64	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139041530	chr5:138744434~138753309:-
BRCA	cis	rs875971	0.825	rs1129531	ENSG00000226824.5	RP4-756H11.3	18.74	9.84e-68	4.25e-64	0.62	0.5	Aortic root size;	chr7:66154117	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.798	rs6460304	ENSG00000226824.5	RP4-756H11.3	-18.72	1.19e-67	5.12e-64	-0.62	-0.5	Aortic root size;	chr7:66499741	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs6945775	ENSG00000226824.5	RP4-756H11.3	-18.72	1.19e-67	5.12e-64	-0.62	-0.5	Aortic root size;	chr7:66503987	chr7:66654538~66669855:+
BRCA	cis	rs801193	0.569	rs11772819	ENSG00000226824.5	RP4-756H11.3	-18.71	1.34e-67	5.79e-64	-0.62	-0.5	Aortic root size;	chr7:66752983	chr7:66654538~66669855:+
BRCA	cis	rs801193	0.569	rs7800620	ENSG00000226824.5	RP4-756H11.3	-18.71	1.34e-67	5.79e-64	-0.62	-0.5	Aortic root size;	chr7:66758701	chr7:66654538~66669855:+
BRCA	cis	rs2882667	0.861	rs10037106	ENSG00000253404.1	AC034243.1	18.71	1.44e-67	6.22e-64	0.63	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139029801	chr5:138744434~138753309:-
BRCA	cis	rs875971	0.862	rs908915	ENSG00000226824.5	RP4-756H11.3	18.7	1.53e-67	6.59e-64	0.61	0.5	Aortic root size;	chr7:66149664	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs4236208	ENSG00000226824.5	RP4-756H11.3	18.7	1.73e-67	7.44e-64	0.62	0.5	Aortic root size;	chr7:66284091	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.83	rs778715	ENSG00000226824.5	RP4-756H11.3	-18.7	1.74e-67	7.48e-64	-0.62	-0.5	Aortic root size;	chr7:66384222	chr7:66654538~66669855:+
BRCA	cis	rs2882667	0.931	rs12719518	ENSG00000253404.1	AC034243.1	18.69	1.83e-67	7.88e-64	0.62	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139005287	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.931	rs7706391	ENSG00000253404.1	AC034243.1	18.69	1.86e-67	7.98e-64	0.63	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139013475	chr5:138744434~138753309:-
BRCA	cis	rs2739330	0.76	rs1002286	ENSG00000250470.1	AP000351.3	-18.68	2.04e-67	8.76e-64	-0.62	-0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23976904~23977585:-
BRCA	cis	rs2882667	1	rs10064130	ENSG00000253404.1	AC034243.1	18.68	2.18e-67	9.33e-64	0.67	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:138973618	chr5:138744434~138753309:-
BRCA	cis	rs875971	0.862	rs10256544	ENSG00000226824.5	RP4-756H11.3	-18.68	2.2e-67	9.42e-64	-0.62	-0.5	Aortic root size;	chr7:66210141	chr7:66654538~66669855:+
BRCA	cis	rs2882667	0.898	rs10058347	ENSG00000253404.1	AC034243.1	18.68	2.22e-67	9.52e-64	0.63	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139025669	chr5:138744434~138753309:-
BRCA	cis	rs875971	0.862	rs7809814	ENSG00000226824.5	RP4-756H11.3	18.67	2.55e-67	1.09e-63	0.61	0.5	Aortic root size;	chr7:66150410	chr7:66654538~66669855:+
BRCA	cis	rs1577917	0.958	rs34994386	ENSG00000203875.9	SNHG5	-18.66	3.03e-67	1.29e-63	-0.59	-0.5	Response to antipsychotic treatment;	chr6:85814417	chr6:85660950~85678736:-
BRCA	cis	rs9399135	0.66	rs9376072	ENSG00000232876.1	CTA-212D2.2	-18.65	3.15e-67	1.35e-63	-0.61	-0.5	Red blood cell count;	chr6:134959381	chr6:135055033~135060550:+
BRCA	cis	rs1577917	0.958	rs36042496	ENSG00000203875.9	SNHG5	-18.65	3.54e-67	1.51e-63	-0.59	-0.5	Response to antipsychotic treatment;	chr6:85814496	chr6:85660950~85678736:-
BRCA	cis	rs1577917	0.917	rs1584273	ENSG00000203875.9	SNHG5	-18.65	3.54e-67	1.51e-63	-0.59	-0.5	Response to antipsychotic treatment;	chr6:85814859	chr6:85660950~85678736:-
BRCA	cis	rs1577917	0.958	rs12198971	ENSG00000203875.9	SNHG5	-18.65	3.54e-67	1.51e-63	-0.59	-0.5	Response to antipsychotic treatment;	chr6:85815727	chr6:85660950~85678736:-
BRCA	cis	rs1577917	0.958	rs34230196	ENSG00000203875.9	SNHG5	-18.65	3.54e-67	1.51e-63	-0.59	-0.5	Response to antipsychotic treatment;	chr6:85816304	chr6:85660950~85678736:-
BRCA	cis	rs1577917	0.876	rs12212808	ENSG00000203875.9	SNHG5	-18.65	3.54e-67	1.51e-63	-0.59	-0.5	Response to antipsychotic treatment;	chr6:85824254	chr6:85660950~85678736:-
BRCA	cis	rs1577917	0.917	rs13213603	ENSG00000203875.9	SNHG5	-18.65	3.54e-67	1.51e-63	-0.59	-0.5	Response to antipsychotic treatment;	chr6:85825040	chr6:85660950~85678736:-
BRCA	cis	rs1577917	0.958	rs2324839	ENSG00000203875.9	SNHG5	-18.65	3.54e-67	1.51e-63	-0.59	-0.5	Response to antipsychotic treatment;	chr6:85827224	chr6:85660950~85678736:-
BRCA	cis	rs1577917	0.958	rs3900313	ENSG00000203875.9	SNHG5	-18.65	3.54e-67	1.51e-63	-0.59	-0.5	Response to antipsychotic treatment;	chr6:85827436	chr6:85660950~85678736:-
BRCA	cis	rs875971	0.862	rs4368860	ENSG00000226824.5	RP4-756H11.3	18.64	3.61e-67	1.53e-63	0.61	0.5	Aortic root size;	chr7:66143495	chr7:66654538~66669855:+
BRCA	cis	rs801193	0.569	rs7782587	ENSG00000226824.5	RP4-756H11.3	-18.64	3.96e-67	1.68e-63	-0.61	-0.5	Aortic root size;	chr7:66701485	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs4718330	ENSG00000226824.5	RP4-756H11.3	18.63	4.11e-67	1.74e-63	0.62	0.5	Aortic root size;	chr7:66250256	chr7:66654538~66669855:+
BRCA	cis	rs801193	0.569	rs2659893	ENSG00000226824.5	RP4-756H11.3	-18.63	4.16e-67	1.77e-63	-0.62	-0.5	Aortic root size;	chr7:66735006	chr7:66654538~66669855:+
BRCA	cis	rs801193	0.569	rs2659892	ENSG00000226824.5	RP4-756H11.3	-18.63	4.16e-67	1.77e-63	-0.62	-0.5	Aortic root size;	chr7:66735318	chr7:66654538~66669855:+
BRCA	cis	rs801193	0.569	rs2707847	ENSG00000226824.5	RP4-756H11.3	-18.63	4.16e-67	1.77e-63	-0.62	-0.5	Aortic root size;	chr7:66737884	chr7:66654538~66669855:+
BRCA	cis	rs62229266	0.835	rs998384	ENSG00000231106.2	LINC01436	18.63	4.21e-67	1.78e-63	0.57	0.5	Mitral valve prolapse;	chr21:36073228	chr21:36005338~36007838:+
BRCA	cis	rs2882667	0.898	rs6882330	ENSG00000253404.1	AC034243.1	18.63	4.57e-67	1.93e-63	0.63	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139046493	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.898	rs6882526	ENSG00000253404.1	AC034243.1	18.63	4.57e-67	1.93e-63	0.63	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139046679	chr5:138744434~138753309:-
BRCA	cis	rs17507216	0.958	rs28648832	ENSG00000278603.1	RP13-608F4.5	18.62	4.94e-67	2.09e-63	0.79	0.5	Excessive daytime sleepiness;	chr15:82567642	chr15:82472203~82472426:+
BRCA	cis	rs2882667	0.931	rs7720150	ENSG00000253404.1	AC034243.1	18.62	4.95e-67	2.09e-63	0.62	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:138998380	chr5:138744434~138753309:-
BRCA	cis	rs801193	0.569	rs2659907	ENSG00000226824.5	RP4-756H11.3	-18.62	5.32e-67	2.24e-63	-0.62	-0.5	Aortic root size;	chr7:66699045	chr7:66654538~66669855:+
BRCA	cis	rs73086581	1	rs6052220	ENSG00000229539.1	RP11-119B16.2	18.62	5.34e-67	2.25e-63	0.82	0.5	Response to antidepressants in depression;	chr20:3989947	chr20:3888239~3888868:-
BRCA	cis	rs875971	0.862	rs778686	ENSG00000226824.5	RP4-756H11.3	-18.6	6.74e-67	2.84e-63	-0.62	-0.5	Aortic root size;	chr7:66370923	chr7:66654538~66669855:+
BRCA	cis	rs801193	0.569	rs2659908	ENSG00000226824.5	RP4-756H11.3	-18.59	7.47e-67	3.14e-63	-0.61	-0.5	Aortic root size;	chr7:66695835	chr7:66654538~66669855:+
BRCA	cis	rs73086581	1	rs6107391	ENSG00000229539.1	RP11-119B16.2	18.59	7.78e-67	3.27e-63	0.83	0.5	Response to antidepressants in depression;	chr20:4002436	chr20:3888239~3888868:-
BRCA	cis	rs875971	0.862	rs7786892	ENSG00000226824.5	RP4-756H11.3	18.59	7.87e-67	3.31e-63	0.61	0.5	Aortic root size;	chr7:66163889	chr7:66654538~66669855:+
BRCA	cis	rs801193	0.527	rs2707837	ENSG00000226824.5	RP4-756H11.3	-18.59	7.93e-67	3.33e-63	-0.61	-0.5	Aortic root size;	chr7:66716086	chr7:66654538~66669855:+
BRCA	cis	rs73086581	1	rs6107393	ENSG00000229539.1	RP11-119B16.2	18.58	8.95e-67	3.75e-63	0.84	0.5	Response to antidepressants in depression;	chr20:4007091	chr20:3888239~3888868:-
BRCA	cis	rs875971	0.862	rs778702	ENSG00000226824.5	RP4-756H11.3	-18.58	9.15e-67	3.83e-63	-0.62	-0.5	Aortic root size;	chr7:66399848	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs1643375	ENSG00000226824.5	RP4-756H11.3	-18.58	9.28e-67	3.88e-63	-0.62	-0.5	Aortic root size;	chr7:66407690	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs778680	ENSG00000226824.5	RP4-756H11.3	-18.58	9.42e-67	3.94e-63	-0.62	-0.5	Aortic root size;	chr7:66375427	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs11769079	ENSG00000226824.5	RP4-756H11.3	-18.58	9.42e-67	3.94e-63	-0.62	-0.5	Aortic root size;	chr7:66377141	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs1695820	ENSG00000226824.5	RP4-756H11.3	-18.58	9.42e-67	3.94e-63	-0.62	-0.5	Aortic root size;	chr7:66379576	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs6962717	ENSG00000226824.5	RP4-756H11.3	-18.57	9.51e-67	3.98e-63	-0.62	-0.5	Aortic root size;	chr7:66418748	chr7:66654538~66669855:+
BRCA	cis	rs801193	0.548	rs2659891	ENSG00000226824.5	RP4-756H11.3	-18.57	9.55e-67	3.99e-63	-0.62	-0.5	Aortic root size;	chr7:66736127	chr7:66654538~66669855:+
BRCA	cis	rs801193	0.548	rs7805152	ENSG00000226824.5	RP4-756H11.3	-18.57	9.55e-67	3.99e-63	-0.62	-0.5	Aortic root size;	chr7:66744266	chr7:66654538~66669855:+
BRCA	cis	rs9399135	0.684	rs1135205	ENSG00000232876.1	CTA-212D2.2	-18.57	9.79e-67	4.09e-63	-0.62	-0.5	Red blood cell count;	chr6:134960657	chr6:135055033~135060550:+
BRCA	cis	rs875971	0.83	rs809025	ENSG00000226824.5	RP4-756H11.3	-18.57	1.09e-66	4.54e-63	-0.62	-0.5	Aortic root size;	chr7:66384832	chr7:66654538~66669855:+
BRCA	cis	rs6597981	0.592	rs10902218	ENSG00000279672.1	CMB9-55F22.1	-18.56	1.17e-66	4.87e-63	-0.55	-0.5	Breast cancer;	chr11:743813	chr11:779617~780755:+
BRCA	cis	rs2882667	0.898	rs6862393	ENSG00000253404.1	AC034243.1	18.56	1.22e-66	5.08e-63	0.63	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139029009	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.898	rs10038121	ENSG00000253404.1	AC034243.1	18.55	1.27e-66	5.28e-63	0.63	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139053913	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.898	rs6890272	ENSG00000253404.1	AC034243.1	18.55	1.32e-66	5.48e-63	0.63	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139035427	chr5:138744434~138753309:-
BRCA	cis	rs875971	0.862	rs778684	ENSG00000226824.5	RP4-756H11.3	-18.55	1.32e-66	5.49e-63	-0.62	-0.5	Aortic root size;	chr7:66371416	chr7:66654538~66669855:+
BRCA	cis	rs801193	0.569	rs881285	ENSG00000226824.5	RP4-756H11.3	18.55	1.41e-66	5.82e-63	0.62	0.5	Aortic root size;	chr7:66654433	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.767	rs1643394	ENSG00000226824.5	RP4-756H11.3	-18.55	1.42e-66	5.88e-63	-0.62	-0.5	Aortic root size;	chr7:66371107	chr7:66654538~66669855:+
BRCA	cis	rs2882667	0.838	rs11958529	ENSG00000253404.1	AC034243.1	18.54	1.65e-66	6.82e-63	0.62	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139059379	chr5:138744434~138753309:-
BRCA	cis	rs801193	0.569	rs4717315	ENSG00000226824.5	RP4-756H11.3	-18.53	1.69e-66	7e-63	-0.61	-0.5	Aortic root size;	chr7:66713338	chr7:66654538~66669855:+
BRCA	cis	rs801193	0.569	rs2707824	ENSG00000226824.5	RP4-756H11.3	-18.53	1.73e-66	7.13e-63	-0.61	-0.5	Aortic root size;	chr7:66724256	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs6460302	ENSG00000226824.5	RP4-756H11.3	-18.53	1.75e-66	7.22e-63	-0.62	-0.5	Aortic root size;	chr7:66495270	chr7:66654538~66669855:+
BRCA	cis	rs1577917	0.958	rs4707236	ENSG00000203875.9	SNHG5	-18.53	1.86e-66	7.69e-63	-0.58	-0.5	Response to antipsychotic treatment;	chr6:85874249	chr6:85660950~85678736:-
BRCA	cis	rs1577917	0.916	rs7759727	ENSG00000203875.9	SNHG5	-18.52	1.96e-66	8.08e-63	-0.59	-0.5	Response to antipsychotic treatment;	chr6:85809160	chr6:85660950~85678736:-
BRCA	cis	rs1577917	0.958	rs12196230	ENSG00000203875.9	SNHG5	-18.52	2.01e-66	8.26e-63	-0.59	-0.5	Response to antipsychotic treatment;	chr6:85810242	chr6:85660950~85678736:-
BRCA	cis	rs875971	0.756	rs4718328	ENSG00000226824.5	RP4-756H11.3	18.52	2.17e-66	8.93e-63	0.61	0.5	Aortic root size;	chr7:66228350	chr7:66654538~66669855:+
BRCA	cis	rs1577917	1	rs2816815	ENSG00000203875.9	SNHG5	-18.51	2.4e-66	9.87e-63	-0.58	-0.5	Response to antipsychotic treatment;	chr6:85981938	chr6:85660950~85678736:-
BRCA	cis	rs2882667	0.898	rs6867343	ENSG00000253404.1	AC034243.1	18.51	2.47e-66	1.02e-62	0.63	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139038739	chr5:138744434~138753309:-
BRCA	cis	rs62229266	0.804	rs998383	ENSG00000231106.2	LINC01436	18.5	2.55e-66	1.05e-62	0.57	0.5	Mitral valve prolapse;	chr21:36073441	chr21:36005338~36007838:+
BRCA	cis	rs801193	0.569	rs13242290	ENSG00000226824.5	RP4-756H11.3	18.5	2.65e-66	1.09e-62	0.62	0.5	Aortic root size;	chr7:66656898	chr7:66654538~66669855:+
BRCA	cis	rs801193	0.569	rs3846973	ENSG00000226824.5	RP4-756H11.3	18.5	2.65e-66	1.09e-62	0.62	0.5	Aortic root size;	chr7:66655048	chr7:66654538~66669855:+
BRCA	cis	rs801193	0.569	rs6951302	ENSG00000226824.5	RP4-756H11.3	18.5	2.78e-66	1.14e-62	0.62	0.5	Aortic root size;	chr7:66667525	chr7:66654538~66669855:+
BRCA	cis	rs858239	0.676	rs274032	ENSG00000230658.1	KLHL7-AS1	18.5	2.85e-66	1.17e-62	0.66	0.5	Cerebrospinal fluid biomarker levels;	chr7:23334940	chr7:23101228~23105703:-
BRCA	cis	rs801193	0.591	rs4506088	ENSG00000226824.5	RP4-756H11.3	18.49	2.92e-66	1.19e-62	0.62	0.5	Aortic root size;	chr7:66670470	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.651	rs2420596	ENSG00000226824.5	RP4-756H11.3	-18.49	3.03e-66	1.24e-62	-0.62	-0.5	Aortic root size;	chr7:66450996	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.52	rs2420597	ENSG00000226824.5	RP4-756H11.3	-18.49	3.03e-66	1.24e-62	-0.62	-0.5	Aortic root size;	chr7:66450999	chr7:66654538~66669855:+
BRCA	cis	rs62229266	0.771	rs7280136	ENSG00000231106.2	LINC01436	-18.49	3.06e-66	1.25e-62	-0.56	-0.5	Mitral valve prolapse;	chr21:36060612	chr21:36005338~36007838:+
BRCA	cis	rs2882667	0.898	rs2882792	ENSG00000253404.1	AC034243.1	18.49	3.06e-66	1.25e-62	0.63	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139044791	chr5:138744434~138753309:-
BRCA	cis	rs875971	0.861	rs801215	ENSG00000226824.5	RP4-756H11.3	18.49	3.07e-66	1.26e-62	0.62	0.5	Aortic root size;	chr7:66546951	chr7:66654538~66669855:+
BRCA	cis	rs2882667	0.894	rs1433008	ENSG00000253404.1	AC034243.1	18.49	3.2e-66	1.3e-62	0.62	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:138997975	chr5:138744434~138753309:-
BRCA	cis	rs2882667	1	rs2882667	ENSG00000253404.1	AC034243.1	18.49	3.3e-66	1.34e-62	0.66	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:138978417	chr5:138744434~138753309:-
BRCA	cis	rs801193	0.569	rs2013908	ENSG00000226824.5	RP4-756H11.3	18.48	3.68e-66	1.5e-62	0.62	0.5	Aortic root size;	chr7:66656082	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs6460306	ENSG00000226824.5	RP4-756H11.3	18.47	4.01e-66	1.63e-62	0.62	0.5	Aortic root size;	chr7:66595806	chr7:66654538~66669855:+
BRCA	cis	rs2882667	0.858	rs4643949	ENSG00000253404.1	AC034243.1	18.47	4.07e-66	1.65e-62	0.63	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139036656	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.931	rs10044736	ENSG00000253404.1	AC034243.1	-18.47	4.35e-66	1.77e-62	-0.62	-0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:138985120	chr5:138744434~138753309:-
BRCA	cis	rs801193	0.569	rs11761542	ENSG00000226824.5	RP4-756H11.3	-18.47	4.4e-66	1.78e-62	-0.62	-0.5	Aortic root size;	chr7:66753209	chr7:66654538~66669855:+
BRCA	cis	rs1577917	1	rs9647603	ENSG00000203875.9	SNHG5	-18.46	4.84e-66	1.96e-62	-0.58	-0.5	Response to antipsychotic treatment;	chr6:85929623	chr6:85660950~85678736:-
BRCA	cis	rs2882667	0.931	rs10075951	ENSG00000253404.1	AC034243.1	18.45	5.14e-66	2.08e-62	0.62	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139020274	chr5:138744434~138753309:-
BRCA	cis	rs875971	0.862	rs10274883	ENSG00000226824.5	RP4-756H11.3	18.44	5.94e-66	2.4e-62	0.62	0.5	Aortic root size;	chr7:66651104	chr7:66654538~66669855:+
BRCA	cis	rs801193	0.591	rs721717	ENSG00000226824.5	RP4-756H11.3	18.44	6.23e-66	2.51e-62	0.62	0.5	Aortic root size;	chr7:66665305	chr7:66654538~66669855:+
BRCA	cis	rs1577917	0.958	rs2660576	ENSG00000203875.9	SNHG5	-18.44	6.46e-66	2.6e-62	-0.58	-0.5	Response to antipsychotic treatment;	chr6:85941885	chr6:85660950~85678736:-
BRCA	cis	rs875971	0.862	rs2024192	ENSG00000226824.5	RP4-756H11.3	18.43	7.33e-66	2.95e-62	0.62	0.5	Aortic root size;	chr7:66576460	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs1968126	ENSG00000226824.5	RP4-756H11.3	18.43	7.6e-66	3.06e-62	0.62	0.5	Aortic root size;	chr7:66592017	chr7:66654538~66669855:+
BRCA	cis	rs1577917	1	rs7747824	ENSG00000203875.9	SNHG5	-18.42	7.69e-66	3.09e-62	-0.58	-0.5	Response to antipsychotic treatment;	chr6:85937388	chr6:85660950~85678736:-
BRCA	cis	rs801193	0.548	rs2109297	ENSG00000226824.5	RP4-756H11.3	18.42	8.07e-66	3.24e-62	0.62	0.5	Aortic root size;	chr7:66657397	chr7:66654538~66669855:+
BRCA	cis	rs7847628	0.587	rs10760117	ENSG00000226752.6	PSMD5-AS1	-18.42	8.15e-66	3.28e-62	-0.61	-0.5	Birth weight;	chr9:120824459	chr9:120824828~120854385:+
BRCA	cis	rs1577917	1	rs2812972	ENSG00000203875.9	SNHG5	-18.42	8.38e-66	3.36e-62	-0.58	-0.5	Response to antipsychotic treatment;	chr6:85960162	chr6:85660950~85678736:-
BRCA	cis	rs875971	0.862	rs13232191	ENSG00000226824.5	RP4-756H11.3	-18.42	8.46e-66	3.39e-62	-0.62	-0.5	Aortic root size;	chr7:66521661	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs10950043	ENSG00000226824.5	RP4-756H11.3	-18.42	8.46e-66	3.39e-62	-0.62	-0.5	Aortic root size;	chr7:66523623	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs17747530	ENSG00000226824.5	RP4-756H11.3	-18.42	8.46e-66	3.39e-62	-0.62	-0.5	Aortic root size;	chr7:66529742	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs13536	ENSG00000226824.5	RP4-756H11.3	18.42	8.46e-66	3.39e-62	0.62	0.5	Aortic root size;	chr7:66554203	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs801209	ENSG00000226824.5	RP4-756H11.3	18.42	8.46e-66	3.39e-62	0.62	0.5	Aortic root size;	chr7:66554403	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs801206	ENSG00000226824.5	RP4-756H11.3	18.42	8.46e-66	3.39e-62	0.62	0.5	Aortic root size;	chr7:66556979	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs801204	ENSG00000226824.5	RP4-756H11.3	18.42	8.46e-66	3.39e-62	0.62	0.5	Aortic root size;	chr7:66557934	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs801203	ENSG00000226824.5	RP4-756H11.3	18.42	8.46e-66	3.39e-62	0.62	0.5	Aortic root size;	chr7:66558025	chr7:66654538~66669855:+
BRCA	cis	rs992157	1	rs992157	ENSG00000261338.2	RP11-378A13.1	-18.42	8.75e-66	3.5e-62	-0.51	-0.5	Colorectal cancer;	chr2:218290058	chr2:218255319~218257366:+
BRCA	cis	rs2882667	0.861	rs10043676	ENSG00000253404.1	AC034243.1	18.41	9.45e-66	3.77e-62	0.62	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139053872	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.861	rs10075541	ENSG00000253404.1	AC034243.1	18.41	9.45e-66	3.77e-62	0.62	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139054629	chr5:138744434~138753309:-
BRCA	cis	rs875971	0.83	rs6976714	ENSG00000226824.5	RP4-756H11.3	-18.41	9.5e-66	3.79e-62	-0.62	-0.5	Aortic root size;	chr7:66426474	chr7:66654538~66669855:+
BRCA	cis	rs7847628	0.587	rs4837796	ENSG00000226752.6	PSMD5-AS1	18.41	9.83e-66	3.92e-62	0.6	0.5	Birth weight;	chr9:120848010	chr9:120824828~120854385:+
BRCA	cis	rs875971	0.862	rs35378740	ENSG00000226824.5	RP4-756H11.3	-18.39	1.22e-65	4.85e-62	-0.61	-0.5	Aortic root size;	chr7:66522725	chr7:66654538~66669855:+
BRCA	cis	rs73086581	1	rs11906274	ENSG00000229539.1	RP11-119B16.2	18.38	1.36e-65	5.37e-62	0.83	0.49	Response to antidepressants in depression;	chr20:3964889	chr20:3888239~3888868:-
BRCA	cis	rs73086581	1	rs6052196	ENSG00000229539.1	RP11-119B16.2	18.38	1.36e-65	5.37e-62	0.83	0.49	Response to antidepressants in depression;	chr20:3965177	chr20:3888239~3888868:-
BRCA	cis	rs73086581	1	rs6116130	ENSG00000229539.1	RP11-119B16.2	18.38	1.36e-65	5.37e-62	0.83	0.49	Response to antidepressants in depression;	chr20:3966379	chr20:3888239~3888868:-
BRCA	cis	rs73086581	1	rs6052209	ENSG00000229539.1	RP11-119B16.2	18.38	1.37e-65	5.42e-62	0.83	0.49	Response to antidepressants in depression;	chr20:3981100	chr20:3888239~3888868:-
BRCA	cis	rs7847628	0.587	rs12684934	ENSG00000226752.6	PSMD5-AS1	-18.38	1.53e-65	6.04e-62	-0.61	-0.49	Birth weight;	chr9:120830881	chr9:120824828~120854385:+
BRCA	cis	rs2882667	0.898	rs11952020	ENSG00000253404.1	AC034243.1	18.37	1.65e-65	6.51e-62	0.62	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139059467	chr5:138744434~138753309:-
BRCA	cis	rs875971	0.862	rs801194	ENSG00000226824.5	RP4-756H11.3	18.37	1.66e-65	6.55e-62	0.61	0.49	Aortic root size;	chr7:66563508	chr7:66654538~66669855:+
BRCA	cis	rs2882667	0.894	rs10054478	ENSG00000253404.1	AC034243.1	18.37	1.7e-65	6.72e-62	0.62	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139018386	chr5:138744434~138753309:-
BRCA	cis	rs1577917	1	rs35385043	ENSG00000203875.9	SNHG5	-18.37	1.71e-65	6.75e-62	-0.58	-0.49	Response to antipsychotic treatment;	chr6:85938828	chr6:85660950~85678736:-
BRCA	cis	rs1577917	1	rs35760725	ENSG00000203875.9	SNHG5	-18.37	1.71e-65	6.75e-62	-0.58	-0.49	Response to antipsychotic treatment;	chr6:85939267	chr6:85660950~85678736:-
BRCA	cis	rs875971	0.755	rs76288834	ENSG00000226824.5	RP4-756H11.3	18.36	1.84e-65	7.25e-62	0.62	0.49	Aortic root size;	chr7:66604815	chr7:66654538~66669855:+
BRCA	cis	rs73086581	1	rs6052217	ENSG00000229539.1	RP11-119B16.2	18.36	1.87e-65	7.37e-62	0.83	0.49	Response to antidepressants in depression;	chr20:3989564	chr20:3888239~3888868:-
BRCA	cis	rs73086581	1	rs6052218	ENSG00000229539.1	RP11-119B16.2	18.36	1.87e-65	7.37e-62	0.83	0.49	Response to antidepressants in depression;	chr20:3989565	chr20:3888239~3888868:-
BRCA	cis	rs73086581	0.945	rs6052219	ENSG00000229539.1	RP11-119B16.2	18.36	1.87e-65	7.37e-62	0.83	0.49	Response to antidepressants in depression;	chr20:3989660	chr20:3888239~3888868:-
BRCA	cis	rs875971	0.767	rs61348003	ENSG00000226824.5	RP4-756H11.3	-18.36	1.92e-65	7.55e-62	-0.61	-0.49	Aortic root size;	chr7:66540947	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.825	rs801202	ENSG00000226824.5	RP4-756H11.3	18.36	1.92e-65	7.55e-62	0.61	0.49	Aortic root size;	chr7:66558942	chr7:66654538~66669855:+
BRCA	cis	rs2882667	0.931	rs10038799	ENSG00000253404.1	AC034243.1	18.36	2.02e-65	7.95e-62	0.62	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139026594	chr5:138744434~138753309:-
BRCA	cis	rs1577917	1	rs1911552	ENSG00000203875.9	SNHG5	-18.35	2.12e-65	8.33e-62	-0.58	-0.49	Response to antipsychotic treatment;	chr6:85928306	chr6:85660950~85678736:-
BRCA	cis	rs875971	0.862	rs13226170	ENSG00000226824.5	RP4-756H11.3	-18.35	2.33e-65	9.13e-62	-0.61	-0.49	Aortic root size;	chr7:66534311	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs2420611	ENSG00000226824.5	RP4-756H11.3	-18.35	2.33e-65	9.13e-62	-0.61	-0.49	Aortic root size;	chr7:66534333	chr7:66654538~66669855:+
BRCA	cis	rs801193	0.569	rs10950050	ENSG00000226824.5	RP4-756H11.3	-18.34	2.42e-65	9.48e-62	-0.61	-0.49	Aortic root size;	chr7:66774601	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.825	rs66981195	ENSG00000226824.5	RP4-756H11.3	18.34	2.5e-65	9.78e-62	0.62	0.49	Aortic root size;	chr7:66614048	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs3926380	ENSG00000226824.5	RP4-756H11.3	18.34	2.5e-65	9.78e-62	0.62	0.49	Aortic root size;	chr7:66615658	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.825	rs1860472	ENSG00000226824.5	RP4-756H11.3	18.34	2.5e-65	9.78e-62	0.62	0.49	Aortic root size;	chr7:66617736	chr7:66654538~66669855:+
BRCA	cis	rs3931020	0.72	rs1327090	ENSG00000272864.1	RP11-17E13.2	-18.33	2.77e-65	1.08e-61	-0.6	-0.49	Resistin levels;	chr1:74800795	chr1:74698769~74699333:-
BRCA	cis	rs875971	0.862	rs4718377	ENSG00000226824.5	RP4-756H11.3	18.33	3.05e-65	1.19e-61	0.61	0.49	Aortic root size;	chr7:66584691	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs10278014	ENSG00000226824.5	RP4-756H11.3	18.33	3.05e-65	1.19e-61	0.61	0.49	Aortic root size;	chr7:66586277	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs6971059	ENSG00000226824.5	RP4-756H11.3	18.32	3.41e-65	1.33e-61	0.62	0.49	Aortic root size;	chr7:66602045	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs778720	ENSG00000226824.5	RP4-756H11.3	18.32	3.48e-65	1.35e-61	0.61	0.49	Aortic root size;	chr7:66381288	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs801195	ENSG00000226824.5	RP4-756H11.3	18.31	3.61e-65	1.41e-61	0.61	0.49	Aortic root size;	chr7:66561128	chr7:66654538~66669855:+
BRCA	cis	rs1577917	1	rs6914463	ENSG00000203875.9	SNHG5	-18.31	3.61e-65	1.41e-61	-0.58	-0.49	Response to antipsychotic treatment;	chr6:85943697	chr6:85660950~85678736:-
BRCA	cis	rs2739330	0.587	rs4820571	ENSG00000225282.1	AP000350.6	18.31	3.86e-65	1.5e-61	0.6	0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23926900~23929574:+
BRCA	cis	rs875971	0.756	rs2901210	ENSG00000226824.5	RP4-756H11.3	18.31	3.97e-65	1.54e-61	0.61	0.49	Aortic root size;	chr7:66552518	chr7:66654538~66669855:+
BRCA	cis	rs2882667	0.931	rs13153618	ENSG00000253404.1	AC034243.1	18.3	4.43e-65	1.72e-61	0.61	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139017087	chr5:138744434~138753309:-
BRCA	cis	rs875971	0.825	rs7384021	ENSG00000226824.5	RP4-756H11.3	18.3	4.55e-65	1.77e-61	0.62	0.49	Aortic root size;	chr7:66612917	chr7:66654538~66669855:+
BRCA	cis	rs1577917	1	rs13199006	ENSG00000203875.9	SNHG5	-18.29	5.01e-65	1.94e-61	-0.58	-0.49	Response to antipsychotic treatment;	chr6:85898990	chr6:85660950~85678736:-
BRCA	cis	rs1577917	1	rs7766645	ENSG00000203875.9	SNHG5	-18.29	5.01e-65	1.94e-61	-0.58	-0.49	Response to antipsychotic treatment;	chr6:85912520	chr6:85660950~85678736:-
BRCA	cis	rs73086581	0.945	rs6037715	ENSG00000229539.1	RP11-119B16.2	18.28	6.12e-65	2.36e-61	0.81	0.49	Response to antidepressants in depression;	chr20:3991519	chr20:3888239~3888868:-
BRCA	cis	rs875971	0.893	rs62465470	ENSG00000226824.5	RP4-756H11.3	18.28	6.17e-65	2.38e-61	0.61	0.49	Aortic root size;	chr7:66136231	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.789	rs7808013	ENSG00000226824.5	RP4-756H11.3	18.27	6.22e-65	2.4e-61	0.61	0.49	Aortic root size;	chr7:66606209	chr7:66654538~66669855:+
BRCA	cis	rs1577917	1	rs4707239	ENSG00000203875.9	SNHG5	-18.27	6.38e-65	2.46e-61	-0.58	-0.49	Response to antipsychotic treatment;	chr6:85900999	chr6:85660950~85678736:-
BRCA	cis	rs17507216	1	rs17158413	ENSG00000278603.1	RP13-608F4.5	18.27	6.57e-65	2.53e-61	0.78	0.49	Excessive daytime sleepiness;	chr15:82566658	chr15:82472203~82472426:+
BRCA	cis	rs73086581	1	rs17215529	ENSG00000229539.1	RP11-119B16.2	18.27	6.73e-65	2.59e-61	0.81	0.49	Response to antidepressants in depression;	chr20:3994755	chr20:3888239~3888868:-
BRCA	cis	rs875971	0.825	rs10281499	ENSG00000226824.5	RP4-756H11.3	18.27	6.81e-65	2.62e-61	0.61	0.49	Aortic root size;	chr7:66583979	chr7:66654538~66669855:+
BRCA	cis	rs2882667	0.898	rs3828600	ENSG00000253404.1	AC034243.1	18.26	7.92e-65	3.04e-61	0.62	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139051170	chr5:138744434~138753309:-
BRCA	cis	rs875971	0.862	rs6955837	ENSG00000226824.5	RP4-756H11.3	18.26	8.07e-65	3.1e-61	0.61	0.49	Aortic root size;	chr7:66578155	chr7:66654538~66669855:+
BRCA	cis	rs2882667	0.898	rs11956089	ENSG00000253404.1	AC034243.1	-18.25	8.2e-65	3.15e-61	-0.62	-0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139058915	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.898	rs12719519	ENSG00000253404.1	AC034243.1	18.25	9.22e-65	3.54e-61	0.61	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139039998	chr5:138744434~138753309:-
BRCA	cis	rs1577917	1	rs6923148	ENSG00000203875.9	SNHG5	18.24	9.68e-65	3.71e-61	0.58	0.49	Response to antipsychotic treatment;	chr6:86058068	chr6:85660950~85678736:-
BRCA	cis	rs801193	0.569	rs6978178	ENSG00000226824.5	RP4-756H11.3	18.24	1.01e-64	3.88e-61	0.61	0.49	Aortic root size;	chr7:66658097	chr7:66654538~66669855:+
BRCA	cis	rs1577917	1	rs2166663	ENSG00000203875.9	SNHG5	-18.23	1.12e-64	4.3e-61	-0.58	-0.49	Response to antipsychotic treatment;	chr6:85884178	chr6:85660950~85678736:-
BRCA	cis	rs1577917	0.958	rs16876530	ENSG00000203875.9	SNHG5	-18.23	1.12e-64	4.3e-61	-0.58	-0.49	Response to antipsychotic treatment;	chr6:85885923	chr6:85660950~85678736:-
BRCA	cis	rs2882667	0.898	rs2351465	ENSG00000253404.1	AC034243.1	18.23	1.19e-64	4.54e-61	0.61	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139028162	chr5:138744434~138753309:-
BRCA	cis	rs7847628	0.551	rs10818476	ENSG00000226752.6	PSMD5-AS1	-18.23	1.22e-64	4.64e-61	-0.6	-0.49	Birth weight;	chr9:120809760	chr9:120824828~120854385:+
BRCA	cis	rs7847628	0.587	rs1060817	ENSG00000226752.6	PSMD5-AS1	-18.22	1.41e-64	5.39e-61	-0.6	-0.49	Birth weight;	chr9:120820914	chr9:120824828~120854385:+
BRCA	cis	rs1577917	0.958	rs11758508	ENSG00000203875.9	SNHG5	18.21	1.48e-64	5.62e-61	0.59	0.49	Response to antipsychotic treatment;	chr6:85797160	chr6:85660950~85678736:-
BRCA	cis	rs2882667	0.931	rs10077896	ENSG00000253404.1	AC034243.1	18.21	1.49e-64	5.68e-61	0.61	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139021067	chr5:138744434~138753309:-
BRCA	cis	rs1577917	1	rs2816821	ENSG00000203875.9	SNHG5	-18.21	1.58e-64	6.01e-61	-0.58	-0.49	Response to antipsychotic treatment;	chr6:85947366	chr6:85660950~85678736:-
BRCA	cis	rs2882667	0.898	rs2043272	ENSG00000253404.1	AC034243.1	18.21	1.63e-64	6.2e-61	0.61	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139054942	chr5:138744434~138753309:-
BRCA	cis	rs858239	0.712	rs200717	ENSG00000230658.1	KLHL7-AS1	18.2	1.64e-64	6.24e-61	0.64	0.49	Cerebrospinal fluid biomarker levels;	chr7:23352652	chr7:23101228~23105703:-
BRCA	cis	rs1577917	1	rs4706254	ENSG00000203875.9	SNHG5	-18.2	1.72e-64	6.54e-61	-0.58	-0.49	Response to antipsychotic treatment;	chr6:85893095	chr6:85660950~85678736:-
BRCA	cis	rs1577917	0.958	rs7739241	ENSG00000203875.9	SNHG5	-18.2	1.76e-64	6.69e-61	-0.58	-0.49	Response to antipsychotic treatment;	chr6:85866078	chr6:85660950~85678736:-
BRCA	cis	rs1577917	0.958	rs12202712	ENSG00000203875.9	SNHG5	-18.2	1.76e-64	6.69e-61	-0.58	-0.49	Response to antipsychotic treatment;	chr6:85868823	chr6:85660950~85678736:-
BRCA	cis	rs1577917	0.958	rs1337843	ENSG00000203875.9	SNHG5	-18.2	1.77e-64	6.72e-61	-0.58	-0.49	Response to antipsychotic treatment;	chr6:85965827	chr6:85660950~85678736:-
BRCA	cis	rs2882667	0.898	rs2116789	ENSG00000253404.1	AC034243.1	18.16	2.86e-64	1.08e-60	0.62	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139058573	chr5:138744434~138753309:-
BRCA	cis	rs875971	0.862	rs10263690	ENSG00000226824.5	RP4-756H11.3	18.16	2.9e-64	1.1e-60	0.61	0.49	Aortic root size;	chr7:66301466	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs10250544	ENSG00000226824.5	RP4-756H11.3	18.16	2.9e-64	1.1e-60	0.61	0.49	Aortic root size;	chr7:66301574	chr7:66654538~66669855:+
BRCA	cis	rs2739330	0.731	rs5751792	ENSG00000231271.1	AP000350.8	18.16	2.96e-64	1.12e-60	0.62	0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23949918~23954042:+
BRCA	cis	rs2882667	1	rs10064201	ENSG00000253404.1	AC034243.1	18.15	3.45e-64	1.3e-60	0.65	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:138973716	chr5:138744434~138753309:-
BRCA	cis	rs73086581	1	rs56324992	ENSG00000229539.1	RP11-119B16.2	18.14	3.98e-64	1.5e-60	0.79	0.49	Response to antidepressants in depression;	chr20:3997506	chr20:3888239~3888868:-
BRCA	cis	rs9322193	0.607	rs9322229	ENSG00000231760.4	RP11-350J20.5	18.14	4.12e-64	1.55e-60	0.66	0.49	Lung cancer;	chr6:149908949	chr6:149796151~149826294:-
BRCA	cis	rs2882667	0.898	rs4380651	ENSG00000253404.1	AC034243.1	18.11	5.92e-64	2.22e-60	0.63	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139055383	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.898	rs10045761	ENSG00000253404.1	AC034243.1	18.11	5.99e-64	2.24e-60	0.62	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139061600	chr5:138744434~138753309:-
BRCA	cis	rs1577917	0.837	rs10944157	ENSG00000203875.9	SNHG5	-18.11	6.39e-64	2.39e-60	-0.58	-0.49	Response to antipsychotic treatment;	chr6:85867481	chr6:85660950~85678736:-
BRCA	cis	rs9545047	0.935	rs1475797	ENSG00000227676.3	LINC01068	-18.11	6.48e-64	2.42e-60	-0.62	-0.49	Schizophrenia;	chr13:79519690	chr13:79566727~79571436:+
BRCA	cis	rs875971	0.798	rs12698522	ENSG00000226824.5	RP4-756H11.3	-18.09	7.95e-64	2.96e-60	-0.61	-0.49	Aortic root size;	chr7:66502354	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.83	rs28714531	ENSG00000226824.5	RP4-756H11.3	-18.09	7.95e-64	2.96e-60	-0.61	-0.49	Aortic root size;	chr7:66503250	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs12698526	ENSG00000226824.5	RP4-756H11.3	-18.09	7.95e-64	2.96e-60	-0.61	-0.49	Aortic root size;	chr7:66504118	chr7:66654538~66669855:+
BRCA	cis	rs9399135	0.66	rs4472368	ENSG00000232876.1	CTA-212D2.2	-18.08	8.62e-64	3.21e-60	-0.6	-0.49	Red blood cell count;	chr6:134953094	chr6:135055033~135060550:+
BRCA	cis	rs2455601	0.638	rs2742484	ENSG00000254860.4	TMEM9B-AS1	18.08	8.93e-64	3.32e-60	0.52	0.49	Schizophrenia;	chr11:8966536	chr11:8964675~8977527:+
BRCA	cis	rs875971	0.862	rs7783779	ENSG00000226824.5	RP4-756H11.3	18.07	9.99e-64	3.71e-60	0.61	0.49	Aortic root size;	chr7:66331639	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs1875057	ENSG00000226824.5	RP4-756H11.3	18.07	1.02e-63	3.79e-60	0.61	0.49	Aortic root size;	chr7:66266868	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs6960446	ENSG00000226824.5	RP4-756H11.3	18.07	1.02e-63	3.79e-60	0.61	0.49	Aortic root size;	chr7:66268272	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.789	rs10260426	ENSG00000226824.5	RP4-756H11.3	18.07	1.02e-63	3.79e-60	0.61	0.49	Aortic root size;	chr7:66271055	chr7:66654538~66669855:+
BRCA	cis	rs2882667	0.931	rs10075893	ENSG00000253404.1	AC034243.1	-18.07	1.04e-63	3.85e-60	-0.61	-0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139020182	chr5:138744434~138753309:-
BRCA	cis	rs1577917	1	rs6454513	ENSG00000203875.9	SNHG5	18.06	1.22e-63	4.49e-60	0.58	0.49	Response to antipsychotic treatment;	chr6:86010331	chr6:85660950~85678736:-
BRCA	cis	rs875971	0.862	rs3893216	ENSG00000226824.5	RP4-756H11.3	18.06	1.22e-63	4.52e-60	0.61	0.49	Aortic root size;	chr7:66325720	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs6958294	ENSG00000226824.5	RP4-756H11.3	18.06	1.22e-63	4.52e-60	0.61	0.49	Aortic root size;	chr7:66329809	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs2088655	ENSG00000226824.5	RP4-756H11.3	18.06	1.22e-63	4.52e-60	0.61	0.49	Aortic root size;	chr7:66330724	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.895	rs10447522	ENSG00000226824.5	RP4-756H11.3	18.06	1.22e-63	4.52e-60	0.61	0.49	Aortic root size;	chr7:66331087	chr7:66654538~66669855:+
BRCA	cis	rs1577917	0.958	rs11756510	ENSG00000203875.9	SNHG5	-18.06	1.26e-63	4.67e-60	-0.6	-0.49	Response to antipsychotic treatment;	chr6:85990076	chr6:85660950~85678736:-
BRCA	cis	rs2455601	0.638	rs2248245	ENSG00000254860.4	TMEM9B-AS1	18.05	1.38e-63	5.08e-60	0.52	0.49	Schizophrenia;	chr11:8966803	chr11:8964675~8977527:+
BRCA	cis	rs73086581	1	rs6037708	ENSG00000229539.1	RP11-119B16.2	18.05	1.41e-63	5.21e-60	0.81	0.49	Response to antidepressants in depression;	chr20:3980606	chr20:3888239~3888868:-
BRCA	cis	rs62229266	0.633	rs743420	ENSG00000231106.2	LINC01436	18.04	1.61e-63	5.94e-60	0.54	0.49	Mitral valve prolapse;	chr21:36015104	chr21:36005338~36007838:+
BRCA	cis	rs875971	0.862	rs7796162	ENSG00000226824.5	RP4-756H11.3	18.04	1.67e-63	6.13e-60	0.61	0.49	Aortic root size;	chr7:66280771	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs2088653	ENSG00000226824.5	RP4-756H11.3	18.04	1.71e-63	6.3e-60	0.61	0.49	Aortic root size;	chr7:66343621	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs6460293	ENSG00000226824.5	RP4-756H11.3	18.04	1.71e-63	6.3e-60	0.61	0.49	Aortic root size;	chr7:66345205	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs778736	ENSG00000226824.5	RP4-756H11.3	-18.03	1.74e-63	6.38e-60	-0.61	-0.49	Aortic root size;	chr7:66348861	chr7:66654538~66669855:+
BRCA	cis	rs992157	0.965	rs62182826	ENSG00000261338.2	RP11-378A13.1	18.03	1.94e-63	7.13e-60	0.51	0.49	Colorectal cancer;	chr2:218284000	chr2:218255319~218257366:+
BRCA	cis	rs2882667	0.861	rs11959727	ENSG00000253404.1	AC034243.1	18.02	1.98e-63	7.28e-60	0.62	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139061276	chr5:138744434~138753309:-
BRCA	cis	rs875971	0.862	rs2901152	ENSG00000226824.5	RP4-756H11.3	18.02	2.23e-63	8.19e-60	0.61	0.49	Aortic root size;	chr7:66300017	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.755	rs10228885	ENSG00000226824.5	RP4-756H11.3	18.01	2.28e-63	8.36e-60	0.61	0.49	Aortic root size;	chr7:66315542	chr7:66654538~66669855:+
BRCA	cis	rs7847628	0.587	rs3793638	ENSG00000226752.6	PSMD5-AS1	-18.01	2.32e-63	8.49e-60	-0.6	-0.49	Birth weight;	chr9:120820419	chr9:120824828~120854385:+
BRCA	cis	rs875971	0.825	rs6951503	ENSG00000226824.5	RP4-756H11.3	18.01	2.43e-63	8.89e-60	0.61	0.49	Aortic root size;	chr7:66253949	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.79	rs10257911	ENSG00000226824.5	RP4-756H11.3	17.99	3.05e-63	1.11e-59	0.61	0.49	Aortic root size;	chr7:66278783	chr7:66654538~66669855:+
BRCA	cis	rs2283792	0.812	rs240066	ENSG00000224086.5	LL22NC03-86G7.1	17.98	3.44e-63	1.26e-59	0.53	0.49	Multiple sclerosis;	chr22:21938623	chr22:21938293~21977632:+
BRCA	cis	rs7301826	0.585	rs6486600	ENSG00000256250.1	RP11-989F5.1	-17.98	3.49e-63	1.27e-59	-0.57	-0.49	Plasma plasminogen activator levels;	chr12:130808432	chr12:130810606~130812438:+
BRCA	cis	rs7301826	0.651	rs12820597	ENSG00000256250.1	RP11-989F5.1	17.97	4.37e-63	1.59e-59	0.59	0.49	Plasma plasminogen activator levels;	chr12:130795640	chr12:130810606~130812438:+
BRCA	cis	rs2882667	1	rs2060222	ENSG00000253404.1	AC034243.1	17.97	4.38e-63	1.59e-59	0.64	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:138972777	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.867	rs11749045	ENSG00000253404.1	AC034243.1	17.96	5.1e-63	1.85e-59	0.61	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139085271	chr5:138744434~138753309:-
BRCA	cis	rs992157	1	rs13429408	ENSG00000261338.2	RP11-378A13.1	17.94	5.93e-63	2.15e-59	0.51	0.49	Colorectal cancer;	chr2:218278137	chr2:218255319~218257366:+
BRCA	cis	rs801193	0.548	rs6975044	ENSG00000226824.5	RP4-756H11.3	-17.94	5.97e-63	2.16e-59	-0.6	-0.49	Aortic root size;	chr7:66762495	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.83	rs778711	ENSG00000226824.5	RP4-756H11.3	-17.94	5.99e-63	2.17e-59	-0.61	-0.49	Aortic root size;	chr7:66386670	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs1083554	ENSG00000226824.5	RP4-756H11.3	-17.94	5.99e-63	2.17e-59	-0.61	-0.49	Aortic root size;	chr7:66387354	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs778707	ENSG00000226824.5	RP4-756H11.3	-17.94	5.99e-63	2.17e-59	-0.61	-0.49	Aortic root size;	chr7:66392040	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs778705	ENSG00000226824.5	RP4-756H11.3	-17.94	5.99e-63	2.17e-59	-0.61	-0.49	Aortic root size;	chr7:66396128	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs778697	ENSG00000226824.5	RP4-756H11.3	-17.94	5.99e-63	2.17e-59	-0.61	-0.49	Aortic root size;	chr7:66405439	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.798	rs7789615	ENSG00000226824.5	RP4-756H11.3	-17.94	5.99e-63	2.17e-59	-0.61	-0.49	Aortic root size;	chr7:66413674	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs6978028	ENSG00000226824.5	RP4-756H11.3	-17.94	6.16e-63	2.23e-59	-0.61	-0.49	Aortic root size;	chr7:66421313	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.895	rs12531677	ENSG00000226824.5	RP4-756H11.3	17.93	6.84e-63	2.47e-59	0.6	0.49	Aortic root size;	chr7:66304099	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs7798630	ENSG00000226824.5	RP4-756H11.3	17.93	6.84e-63	2.47e-59	0.6	0.49	Aortic root size;	chr7:66306492	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs28470208	ENSG00000226824.5	RP4-756H11.3	17.93	6.98e-63	2.52e-59	0.6	0.49	Aortic root size;	chr7:66119713	chr7:66654538~66669855:+
BRCA	cis	rs67383717	0.672	rs589458	ENSG00000175611.10	LINC00476	17.93	7.02e-63	2.53e-59	0.52	0.49	Parkinson's disease (pesticide exposure interaction);	chr9:95878389	chr9:95759231~95875977:-
BRCA	cis	rs875971	0.862	rs2909688	ENSG00000226824.5	RP4-756H11.3	-17.92	8.17e-63	2.94e-59	-0.61	-0.49	Aortic root size;	chr7:66376625	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs11984115	ENSG00000226824.5	RP4-756H11.3	17.92	8.51e-63	3.06e-59	0.6	0.49	Aortic root size;	chr7:66308872	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs6947339	ENSG00000226824.5	RP4-756H11.3	-17.92	8.64e-63	3.11e-59	-0.61	-0.49	Aortic root size;	chr7:66423483	chr7:66654538~66669855:+
BRCA	cis	rs73086581	0.898	rs11906452	ENSG00000229539.1	RP11-119B16.2	17.91	9.93e-63	3.57e-59	0.79	0.49	Response to antidepressants in depression;	chr20:4000912	chr20:3888239~3888868:-
BRCA	cis	rs9545047	0.905	rs9318644	ENSG00000227676.3	LINC01068	-17.91	1.02e-62	3.66e-59	-0.62	-0.49	Schizophrenia;	chr13:79510042	chr13:79566727~79571436:+
BRCA	cis	rs7301826	0.651	rs34749116	ENSG00000256250.1	RP11-989F5.1	17.88	1.37e-62	4.91e-59	0.59	0.48	Plasma plasminogen activator levels;	chr12:130796207	chr12:130810606~130812438:+
BRCA	cis	rs875971	0.862	rs1167390	ENSG00000226824.5	RP4-756H11.3	17.85	2.1e-62	7.5e-59	0.6	0.48	Aortic root size;	chr7:66110906	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs35034167	ENSG00000226824.5	RP4-756H11.3	17.85	2.1e-62	7.5e-59	0.6	0.48	Aortic root size;	chr7:66115179	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs11765791	ENSG00000226824.5	RP4-756H11.3	-17.85	2.18e-62	7.8e-59	-0.6	-0.48	Aortic root size;	chr7:66471587	chr7:66654538~66669855:+
BRCA	cis	rs3814244	0.54	rs2159064	ENSG00000255733.4	IFNG-AS1	-17.84	2.37e-62	8.48e-59	-0.39	-0.48	Itch intensity from mosquito bite adjusted by bite size;	chr12:68017126	chr12:67989445~68234686:+
BRCA	cis	rs73086581	0.786	rs6037705	ENSG00000229539.1	RP11-119B16.2	17.84	2.53e-62	9.03e-59	0.79	0.48	Response to antidepressants in depression;	chr20:3972183	chr20:3888239~3888868:-
BRCA	cis	rs875971	0.767	rs12668005	ENSG00000226824.5	RP4-756H11.3	-17.83	2.68e-62	9.59e-59	-0.6	-0.48	Aortic root size;	chr7:66444034	chr7:66654538~66669855:+
BRCA	cis	rs1577917	0.917	rs35738006	ENSG00000203875.9	SNHG5	-17.83	2.71e-62	9.69e-59	-0.6	-0.48	Response to antipsychotic treatment;	chr6:85936591	chr6:85660950~85678736:-
BRCA	cis	rs9399135	0.66	rs4267967	ENSG00000232876.1	CTA-212D2.2	-17.83	2.72e-62	9.71e-59	-0.59	-0.48	Red blood cell count;	chr6:134951339	chr6:135055033~135060550:+
BRCA	cis	rs9545047	0.935	rs9530922	ENSG00000227676.3	LINC01068	-17.83	2.75e-62	9.8e-59	-0.62	-0.48	Schizophrenia;	chr13:79469002	chr13:79566727~79571436:+
BRCA	cis	rs6597981	0.604	rs7945912	ENSG00000279672.1	CMB9-55F22.1	17.82	3.21e-62	1.14e-58	0.54	0.48	Breast cancer;	chr11:750849	chr11:779617~780755:+
BRCA	cis	rs875971	0.895	rs6460278	ENSG00000226824.5	RP4-756H11.3	17.82	3.21e-62	1.15e-58	0.6	0.48	Aortic root size;	chr7:66197749	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs6460279	ENSG00000226824.5	RP4-756H11.3	17.82	3.21e-62	1.15e-58	0.6	0.48	Aortic root size;	chr7:66197774	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs28491091	ENSG00000226824.5	RP4-756H11.3	17.82	3.21e-62	1.15e-58	0.6	0.48	Aortic root size;	chr7:66204077	chr7:66654538~66669855:+
BRCA	cis	rs2739330	0.761	rs5760176	ENSG00000231271.1	AP000350.8	-17.82	3.38e-62	1.2e-58	-0.61	-0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23949918~23954042:+
BRCA	cis	rs1577917	1	rs34281561	ENSG00000203875.9	SNHG5	-17.81	3.88e-62	1.38e-58	-0.59	-0.48	Response to antipsychotic treatment;	chr6:85992154	chr6:85660950~85678736:-
BRCA	cis	rs1577917	1	rs35419329	ENSG00000203875.9	SNHG5	-17.81	3.88e-62	1.38e-58	-0.59	-0.48	Response to antipsychotic treatment;	chr6:85992573	chr6:85660950~85678736:-
BRCA	cis	rs1577917	1	rs12216328	ENSG00000203875.9	SNHG5	-17.81	3.88e-62	1.38e-58	-0.59	-0.48	Response to antipsychotic treatment;	chr6:85993700	chr6:85660950~85678736:-
BRCA	cis	rs9545047	0.935	rs8002042	ENSG00000227676.3	LINC01068	-17.8	4.17e-62	1.48e-58	-0.61	-0.48	Schizophrenia;	chr13:79486552	chr13:79566727~79571436:+
BRCA	cis	rs875971	0.862	rs1612452	ENSG00000226824.5	RP4-756H11.3	17.8	4.4e-62	1.56e-58	0.6	0.48	Aortic root size;	chr7:66108909	chr7:66654538~66669855:+
BRCA	cis	rs6964833	1	rs4717907	ENSG00000123965.13	PMS2P5	17.78	5.39e-62	1.91e-58	0.76	0.48	Menarche (age at onset);	chr7:74672169	chr7:74894116~74897835:+
BRCA	cis	rs1577917	1	rs1999852	ENSG00000203875.9	SNHG5	-17.78	5.72e-62	2.03e-58	-0.58	-0.48	Response to antipsychotic treatment;	chr6:85996020	chr6:85660950~85678736:-
BRCA	cis	rs1577917	1	rs12208493	ENSG00000203875.9	SNHG5	-17.77	6.56e-62	2.32e-58	-0.6	-0.48	Response to antipsychotic treatment;	chr6:85952549	chr6:85660950~85678736:-
BRCA	cis	rs1577917	1	rs12213149	ENSG00000203875.9	SNHG5	-17.77	6.56e-62	2.32e-58	-0.6	-0.48	Response to antipsychotic treatment;	chr6:85958926	chr6:85660950~85678736:-
BRCA	cis	rs2019137	0.56	rs7578633	ENSG00000274877.1	RP11-65I12.1	-17.77	6.68e-62	2.36e-58	-0.66	-0.48	Lymphocyte counts;	chr2:113221073	chr2:113237595~113240825:+
BRCA	cis	rs1431005	0.963	rs72725287	ENSG00000250620.1	RP11-91J3.3	17.76	7.86e-62	2.77e-58	0.6	0.48	Response to statin therapy;	chr4:187477151	chr4:187413564~187415697:+
BRCA	cis	rs7301826	0.651	rs2277336	ENSG00000256250.1	RP11-989F5.1	17.75	8.34e-62	2.94e-58	0.58	0.48	Plasma plasminogen activator levels;	chr12:130801574	chr12:130810606~130812438:+
BRCA	cis	rs875971	0.825	rs28480509	ENSG00000226824.5	RP4-756H11.3	17.75	8.82e-62	3.11e-58	0.6	0.48	Aortic root size;	chr7:66634237	chr7:66654538~66669855:+
BRCA	cis	rs9545047	0.935	rs4885633	ENSG00000227676.3	LINC01068	-17.75	9.14e-62	3.22e-58	-0.61	-0.48	Schizophrenia;	chr13:79469720	chr13:79566727~79571436:+
BRCA	cis	rs7208859	0.673	rs2269915	ENSG00000263531.1	RP13-753N3.1	17.74	9.36e-62	3.3e-58	0.95	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30906326	chr17:30863921~30864940:-
BRCA	cis	rs7208859	0.673	rs2269916	ENSG00000263531.1	RP13-753N3.1	17.74	9.36e-62	3.3e-58	0.95	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30906745	chr17:30863921~30864940:-
BRCA	cis	rs7208859	0.673	rs11649765	ENSG00000263531.1	RP13-753N3.1	17.74	9.36e-62	3.3e-58	0.95	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30906870	chr17:30863921~30864940:-
BRCA	cis	rs17507216	1	rs3850610	ENSG00000278603.1	RP13-608F4.5	-17.73	1.16e-61	4.08e-58	-0.7	-0.48	Excessive daytime sleepiness;	chr15:82552642	chr15:82472203~82472426:+
BRCA	cis	rs2019137	0.56	rs6707386	ENSG00000274877.1	RP11-65I12.1	-17.73	1.18e-61	4.14e-58	-0.65	-0.48	Lymphocyte counts;	chr2:113223445	chr2:113237595~113240825:+
BRCA	cis	rs3931020	0.508	rs28568334	ENSG00000272864.1	RP11-17E13.2	-17.73	1.19e-61	4.18e-58	-0.59	-0.48	Resistin levels;	chr1:74733615	chr1:74698769~74699333:-
BRCA	cis	rs1577917	1	rs791856	ENSG00000203875.9	SNHG5	17.72	1.23e-61	4.32e-58	0.57	0.48	Response to antipsychotic treatment;	chr6:85972123	chr6:85660950~85678736:-
BRCA	cis	rs9399135	0.66	rs4646868	ENSG00000232876.1	CTA-212D2.2	-17.72	1.25e-61	4.39e-58	-0.59	-0.48	Red blood cell count;	chr6:134950808	chr6:135055033~135060550:+
BRCA	cis	rs9399135	0.636	rs4646871	ENSG00000232876.1	CTA-212D2.2	17.72	1.28e-61	4.48e-58	0.59	0.48	Red blood cell count;	chr6:134944479	chr6:135055033~135060550:+
BRCA	cis	rs7208859	0.673	rs73263776	ENSG00000263531.1	RP13-753N3.1	17.72	1.37e-61	4.82e-58	0.94	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30884313	chr17:30863921~30864940:-
BRCA	cis	rs7208859	0.623	rs11650271	ENSG00000263531.1	RP13-753N3.1	17.72	1.37e-61	4.82e-58	0.94	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30886925	chr17:30863921~30864940:-
BRCA	cis	rs12439619	0.921	rs4778672	ENSG00000278603.1	RP13-608F4.5	-17.71	1.41e-61	4.96e-58	-0.71	-0.48	Intelligence (multi-trait analysis);	chr15:82245013	chr15:82472203~82472426:+
BRCA	cis	rs1577917	0.771	rs3812133	ENSG00000203875.9	SNHG5	-17.71	1.58e-61	5.52e-58	-0.64	-0.48	Response to antipsychotic treatment;	chr6:85644693	chr6:85660950~85678736:-
BRCA	cis	rs875971	0.862	rs1860469	ENSG00000226824.5	RP4-756H11.3	17.7	1.59e-61	5.59e-58	0.6	0.48	Aortic root size;	chr7:66641888	chr7:66654538~66669855:+
BRCA	cis	rs2019137	0.539	rs11123170	ENSG00000274877.1	RP11-65I12.1	-17.7	1.63e-61	5.72e-58	-0.65	-0.48	Lymphocyte counts;	chr2:113221363	chr2:113237595~113240825:+
BRCA	cis	rs875971	0.862	rs4718383	ENSG00000226824.5	RP4-756H11.3	17.69	1.87e-61	6.54e-58	0.6	0.48	Aortic root size;	chr7:66643422	chr7:66654538~66669855:+
BRCA	cis	rs7301826	0.651	rs7299281	ENSG00000256250.1	RP11-989F5.1	17.69	1.98e-61	6.93e-58	0.57	0.48	Plasma plasminogen activator levels;	chr12:130818587	chr12:130810606~130812438:+
BRCA	cis	rs3931020	0.508	rs11485298	ENSG00000272864.1	RP11-17E13.2	-17.68	2.28e-61	7.95e-58	-0.59	-0.48	Resistin levels;	chr1:74752068	chr1:74698769~74699333:-
BRCA	cis	rs3931020	0.508	rs4145871	ENSG00000272864.1	RP11-17E13.2	-17.68	2.28e-61	7.95e-58	-0.59	-0.48	Resistin levels;	chr1:74753020	chr1:74698769~74699333:-
BRCA	cis	rs3931020	0.508	rs2345436	ENSG00000272864.1	RP11-17E13.2	-17.68	2.28e-61	7.96e-58	-0.59	-0.48	Resistin levels;	chr1:74733056	chr1:74698769~74699333:-
BRCA	cis	rs2882667	0.861	rs11242445	ENSG00000253404.1	AC034243.1	17.67	2.49e-61	8.68e-58	0.6	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139081365	chr5:138744434~138753309:-
BRCA	cis	rs7301826	0.61	rs7961690	ENSG00000256250.1	RP11-989F5.1	17.67	2.66e-61	9.27e-58	0.57	0.48	Plasma plasminogen activator levels;	chr12:130812335	chr12:130810606~130812438:+
BRCA	cis	rs1577917	1	rs12192992	ENSG00000203875.9	SNHG5	-17.66	3.02e-61	1.05e-57	-0.59	-0.48	Response to antipsychotic treatment;	chr6:85900197	chr6:85660950~85678736:-
BRCA	cis	rs1577917	1	rs12200330	ENSG00000203875.9	SNHG5	-17.66	3.11e-61	1.08e-57	-0.6	-0.48	Response to antipsychotic treatment;	chr6:85946935	chr6:85660950~85678736:-
BRCA	cis	rs10256972	0.567	rs7782651	ENSG00000229043.2	AC091729.9	-17.65	3.54e-61	1.23e-57	-0.64	-0.48	Endometriosis;Longevity;	chr7:1120259	chr7:1160374~1165267:+
BRCA	cis	rs1577917	0.958	rs11756615	ENSG00000203875.9	SNHG5	-17.65	3.55e-61	1.23e-57	-0.6	-0.48	Response to antipsychotic treatment;	chr6:85970117	chr6:85660950~85678736:-
BRCA	cis	rs1577917	0.958	rs10944168	ENSG00000203875.9	SNHG5	-17.65	3.55e-61	1.23e-57	-0.6	-0.48	Response to antipsychotic treatment;	chr6:85970438	chr6:85660950~85678736:-
BRCA	cis	rs10256972	0.616	rs4585652	ENSG00000229043.2	AC091729.9	-17.64	3.65e-61	1.27e-57	-0.64	-0.48	Endometriosis;Longevity;	chr7:1105760	chr7:1160374~1165267:+
BRCA	cis	rs1577917	1	rs1857964	ENSG00000203875.9	SNHG5	-17.63	4.53e-61	1.56e-57	-0.59	-0.48	Response to antipsychotic treatment;	chr6:85926276	chr6:85660950~85678736:-
BRCA	cis	rs801193	0.569	rs35070132	ENSG00000226824.5	RP4-756H11.3	-17.62	4.81e-61	1.66e-57	-0.6	-0.48	Aortic root size;	chr7:66773096	chr7:66654538~66669855:+
BRCA	cis	rs992157	0.932	rs56109829	ENSG00000261338.2	RP11-378A13.1	17.62	4.87e-61	1.68e-57	0.5	0.48	Colorectal cancer;	chr2:218285017	chr2:218255319~218257366:+
BRCA	cis	rs7301826	0.627	rs4334059	ENSG00000256250.1	RP11-989F5.1	-17.61	5.57e-61	1.92e-57	-0.57	-0.48	Plasma plasminogen activator levels;	chr12:130829669	chr12:130810606~130812438:+
BRCA	cis	rs1577917	1	rs955197	ENSG00000203875.9	SNHG5	-17.61	5.57e-61	1.92e-57	-0.59	-0.48	Response to antipsychotic treatment;	chr6:86019957	chr6:85660950~85678736:-
BRCA	cis	rs875971	0.862	rs6964437	ENSG00000226824.5	RP4-756H11.3	17.6	6.28e-61	2.16e-57	0.6	0.48	Aortic root size;	chr7:66221457	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs6952182	ENSG00000226824.5	RP4-756H11.3	17.6	6.78e-61	2.33e-57	0.6	0.48	Aortic root size;	chr7:66218330	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs9791712	ENSG00000226824.5	RP4-756H11.3	17.6	7.02e-61	2.41e-57	0.6	0.48	Aortic root size;	chr7:66640176	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs9791713	ENSG00000226824.5	RP4-756H11.3	17.6	7.02e-61	2.41e-57	0.6	0.48	Aortic root size;	chr7:66640211	chr7:66654538~66669855:+
BRCA	cis	rs1577917	1	rs13194429	ENSG00000203875.9	SNHG5	-17.59	7.73e-61	2.65e-57	-0.59	-0.48	Response to antipsychotic treatment;	chr6:85936987	chr6:85660950~85678736:-
BRCA	cis	rs1577917	1	rs955196	ENSG00000203875.9	SNHG5	17.58	8.3e-61	2.84e-57	0.58	0.48	Response to antipsychotic treatment;	chr6:86020233	chr6:85660950~85678736:-
BRCA	cis	rs992157	1	rs2168704	ENSG00000261338.2	RP11-378A13.1	17.58	8.71e-61	2.98e-57	0.5	0.48	Colorectal cancer;	chr2:218277769	chr2:218255319~218257366:+
BRCA	cis	rs1577917	1	rs1337850	ENSG00000203875.9	SNHG5	-17.58	9.1e-61	3.11e-57	-0.59	-0.48	Response to antipsychotic treatment;	chr6:86019385	chr6:85660950~85678736:-
BRCA	cis	rs1577917	0.798	rs7772384	ENSG00000203875.9	SNHG5	-17.58	9.13e-61	3.12e-57	-0.58	-0.48	Response to antipsychotic treatment;	chr6:85929962	chr6:85660950~85678736:-
BRCA	cis	rs9601248	0.529	rs2783125	ENSG00000227676.3	LINC01068	17.57	9.89e-61	3.38e-57	0.6	0.48	Major depressive disorder;	chr13:79583755	chr13:79566727~79571436:+
BRCA	cis	rs875971	0.83	rs12673450	ENSG00000226824.5	RP4-756H11.3	-17.56	1.07e-60	3.66e-57	-0.6	-0.48	Aortic root size;	chr7:66544233	chr7:66654538~66669855:+
BRCA	cis	rs1431005	0.893	rs67136716	ENSG00000250620.1	RP11-91J3.3	17.56	1.08e-60	3.68e-57	0.62	0.48	Response to statin therapy;	chr4:187414928	chr4:187413564~187415697:+
BRCA	cis	rs1577917	0.958	rs11755642	ENSG00000203875.9	SNHG5	-17.56	1.14e-60	3.89e-57	-0.6	-0.48	Response to antipsychotic treatment;	chr6:85740348	chr6:85660950~85678736:-
BRCA	cis	rs875971	0.862	rs6460282	ENSG00000226824.5	RP4-756H11.3	17.56	1.16e-60	3.95e-57	0.6	0.48	Aortic root size;	chr7:66226259	chr7:66654538~66669855:+
BRCA	cis	rs1577917	1	rs10498958	ENSG00000203875.9	SNHG5	17.56	1.16e-60	3.97e-57	0.6	0.48	Response to antipsychotic treatment;	chr6:85939987	chr6:85660950~85678736:-
BRCA	cis	rs1431005	1	rs56063429	ENSG00000250620.1	RP11-91J3.3	17.56	1.19e-60	4.04e-57	0.6	0.48	Response to statin therapy;	chr4:187450476	chr4:187413564~187415697:+
BRCA	cis	rs1431005	0.927	rs12651176	ENSG00000250620.1	RP11-91J3.3	17.54	1.41e-60	4.78e-57	0.6	0.48	Response to statin therapy;	chr4:187439724	chr4:187413564~187415697:+
BRCA	cis	rs7301826	0.627	rs34103763	ENSG00000256250.1	RP11-989F5.1	17.54	1.52e-60	5.15e-57	0.57	0.48	Plasma plasminogen activator levels;	chr12:130805604	chr12:130810606~130812438:+
BRCA	cis	rs10256972	0.591	rs6968988	ENSG00000229043.2	AC091729.9	-17.54	1.59e-60	5.4e-57	-0.61	-0.48	Endometriosis;Longevity;	chr7:1129983	chr7:1160374~1165267:+
BRCA	cis	rs17507216	0.718	rs4779033	ENSG00000278603.1	RP13-608F4.5	-17.53	1.7e-60	5.76e-57	-0.82	-0.48	Excessive daytime sleepiness;	chr15:82576634	chr15:82472203~82472426:+
BRCA	cis	rs1577917	0.958	rs11755048	ENSG00000203875.9	SNHG5	-17.53	1.74e-60	5.91e-57	-0.61	-0.48	Response to antipsychotic treatment;	chr6:85804616	chr6:85660950~85678736:-
BRCA	cis	rs1577917	1	rs13217384	ENSG00000203875.9	SNHG5	-17.53	1.81e-60	6.13e-57	-0.58	-0.48	Response to antipsychotic treatment;	chr6:86010282	chr6:85660950~85678736:-
BRCA	cis	rs7208859	0.673	rs11657270	ENSG00000263531.1	RP13-753N3.1	17.52	1.96e-60	6.64e-57	0.93	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887369	chr17:30863921~30864940:-
BRCA	cis	rs7208859	0.673	rs9911989	ENSG00000263531.1	RP13-753N3.1	-17.51	2.17e-60	7.35e-57	-0.95	-0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30910684	chr17:30863921~30864940:-
BRCA	cis	rs3814244	0.966	rs10784666	ENSG00000255733.4	IFNG-AS1	-17.51	2.32e-60	7.82e-57	-0.39	-0.48	Itch intensity from mosquito bite adjusted by bite size;	chr12:68021923	chr12:67989445~68234686:+
BRCA	cis	rs3814244	0.966	rs10784667	ENSG00000255733.4	IFNG-AS1	-17.51	2.32e-60	7.82e-57	-0.39	-0.48	Itch intensity from mosquito bite adjusted by bite size;	chr12:68021996	chr12:67989445~68234686:+
BRCA	cis	rs7617773	0.817	rs11720622	ENSG00000229759.1	MRPS18AP1	17.51	2.37e-60	8e-57	0.54	0.48	Coronary artery disease;	chr3:48205189	chr3:48256350~48256938:-
BRCA	cis	rs7617773	0.817	rs6806112	ENSG00000229759.1	MRPS18AP1	17.5	2.51e-60	8.46e-57	0.55	0.48	Coronary artery disease;	chr3:48234587	chr3:48256350~48256938:-
BRCA	cis	rs7208859	0.673	rs61348930	ENSG00000263531.1	RP13-753N3.1	17.5	2.59e-60	8.71e-57	0.94	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30894745	chr17:30863921~30864940:-
BRCA	cis	rs7208859	0.614	rs28758251	ENSG00000263531.1	RP13-753N3.1	17.5	2.59e-60	8.71e-57	0.94	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30896294	chr17:30863921~30864940:-
BRCA	cis	rs7208859	0.673	rs9899943	ENSG00000263531.1	RP13-753N3.1	17.5	2.59e-60	8.71e-57	0.94	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30896907	chr17:30863921~30864940:-
BRCA	cis	rs7208859	0.673	rs11080138	ENSG00000263531.1	RP13-753N3.1	17.5	2.59e-60	8.71e-57	0.94	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30897524	chr17:30863921~30864940:-
BRCA	cis	rs7208859	0.673	rs73265612	ENSG00000263531.1	RP13-753N3.1	17.5	2.59e-60	8.71e-57	0.94	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30898965	chr17:30863921~30864940:-
BRCA	cis	rs7208859	0.673	rs11658435	ENSG00000263531.1	RP13-753N3.1	17.5	2.59e-60	8.71e-57	0.94	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30901543	chr17:30863921~30864940:-
BRCA	cis	rs7208859	0.673	rs73265624	ENSG00000263531.1	RP13-753N3.1	17.5	2.59e-60	8.71e-57	0.94	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30905048	chr17:30863921~30864940:-
BRCA	cis	rs7174755	0.743	rs4777035	ENSG00000260657.2	RP11-315D16.4	-17.5	2.6e-60	8.74e-57	-0.57	-0.48	Major depressive disorder;	chr15:68312831	chr15:68267792~68277994:-
BRCA	cis	rs9545047	0.901	rs7338530	ENSG00000227676.3	LINC01068	-17.49	3.06e-60	1.03e-56	-0.61	-0.48	Schizophrenia;	chr13:79477715	chr13:79566727~79571436:+
BRCA	cis	rs7301826	0.61	rs36051740	ENSG00000256250.1	RP11-989F5.1	17.49	3.09e-60	1.04e-56	0.56	0.48	Plasma plasminogen activator levels;	chr12:130808177	chr12:130810606~130812438:+
BRCA	cis	rs7301826	0.627	rs7978987	ENSG00000256250.1	RP11-989F5.1	17.48	3.33e-60	1.12e-56	0.58	0.48	Plasma plasminogen activator levels;	chr12:130796949	chr12:130810606~130812438:+
BRCA	cis	rs1431005	1	rs60320548	ENSG00000250620.1	RP11-91J3.3	17.48	3.62e-60	1.21e-56	0.6	0.48	Response to statin therapy;	chr4:187436265	chr4:187413564~187415697:+
BRCA	cis	rs9545047	0.935	rs7339303	ENSG00000227676.3	LINC01068	-17.47	3.64e-60	1.22e-56	-0.6	-0.48	Schizophrenia;	chr13:79516730	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.905	rs7321953	ENSG00000227676.3	LINC01068	-17.47	3.64e-60	1.22e-56	-0.6	-0.48	Schizophrenia;	chr13:79517404	chr13:79566727~79571436:+
BRCA	cis	rs3814244	0.897	rs4141135	ENSG00000255733.4	IFNG-AS1	17.46	4.47e-60	1.49e-56	0.38	0.48	Itch intensity from mosquito bite adjusted by bite size;	chr12:68025050	chr12:67989445~68234686:+
BRCA	cis	rs7208859	0.673	rs2433	ENSG00000263531.1	RP13-753N3.1	17.44	5.99e-60	1.99e-56	0.94	0.48	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30899210	chr17:30863921~30864940:-
BRCA	cis	rs6452524	0.711	rs1478486	ENSG00000249664.1	CTD-2227C6.2	17.44	6.22e-60	2.04e-56	0.56	0.48	Hypertension (SNP x SNP interaction);	chr5:83081185	chr5:83012285~83013109:-
BRCA	cis	rs1153858	1	rs1980288	ENSG00000259520.4	CTD-2651B20.3	-17.43	6.46e-60	2.12e-56	-0.64	-0.48	Homoarginine levels;	chr15:45328414	chr15:45251580~45279251:-
BRCA	cis	rs9545047	0.935	rs7988601	ENSG00000227676.3	LINC01068	-17.43	6.84e-60	2.24e-56	-0.6	-0.48	Schizophrenia;	chr13:79475648	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.935	rs6563110	ENSG00000227676.3	LINC01068	-17.43	6.84e-60	2.24e-56	-0.6	-0.48	Schizophrenia;	chr13:79477137	chr13:79566727~79571436:+
BRCA	cis	rs977987	0.735	rs166013	ENSG00000261783.1	RP11-252K23.2	17.43	6.89e-60	2.26e-56	0.63	0.48	Dupuytren's disease;	chr16:75400248	chr16:75379818~75381260:-
BRCA	cis	rs1577917	1	rs12201571	ENSG00000203875.9	SNHG5	-17.42	7.76e-60	2.53e-56	-0.58	-0.47	Response to antipsychotic treatment;	chr6:85900032	chr6:85660950~85678736:-
BRCA	cis	rs1577917	1	rs11759855	ENSG00000203875.9	SNHG5	-17.42	7.76e-60	2.53e-56	-0.58	-0.47	Response to antipsychotic treatment;	chr6:85901123	chr6:85660950~85678736:-
BRCA	cis	rs875971	0.862	rs1167408	ENSG00000226824.5	RP4-756H11.3	17.41	8.79e-60	2.86e-56	0.59	0.47	Aortic root size;	chr7:66091121	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.83	rs1167406	ENSG00000226824.5	RP4-756H11.3	17.41	8.79e-60	2.86e-56	0.59	0.47	Aortic root size;	chr7:66091949	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs1167399	ENSG00000226824.5	RP4-756H11.3	17.41	8.79e-60	2.86e-56	0.59	0.47	Aortic root size;	chr7:66096890	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs57866200	ENSG00000226824.5	RP4-756H11.3	17.41	8.79e-60	2.86e-56	0.59	0.47	Aortic root size;	chr7:66100405	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs709609	ENSG00000226824.5	RP4-756H11.3	17.41	9.21e-60	2.99e-56	0.6	0.47	Aortic root size;	chr7:66095574	chr7:66654538~66669855:+
BRCA	cis	rs6452524	0.534	rs10061690	ENSG00000249664.1	CTD-2227C6.2	17.4	9.38e-60	3.05e-56	0.57	0.47	Hypertension (SNP x SNP interaction);	chr5:83063226	chr5:83012285~83013109:-
BRCA	cis	rs1577917	0.917	rs35283633	ENSG00000203875.9	SNHG5	-17.4	9.64e-60	3.13e-56	-0.59	-0.47	Response to antipsychotic treatment;	chr6:85981069	chr6:85660950~85678736:-
BRCA	cis	rs1577917	1	rs34581302	ENSG00000203875.9	SNHG5	-17.4	9.74e-60	3.16e-56	-0.58	-0.47	Response to antipsychotic treatment;	chr6:85996230	chr6:85660950~85678736:-
BRCA	cis	rs1577917	1	rs12216203	ENSG00000203875.9	SNHG5	-17.4	1.03e-59	3.34e-56	-0.59	-0.47	Response to antipsychotic treatment;	chr6:85965583	chr6:85660950~85678736:-
BRCA	cis	rs1577917	1	rs12199516	ENSG00000203875.9	SNHG5	-17.39	1.14e-59	3.71e-56	-0.58	-0.47	Response to antipsychotic treatment;	chr6:86016503	chr6:85660950~85678736:-
BRCA	cis	rs7301826	0.56	rs12829294	ENSG00000256250.1	RP11-989F5.1	17.38	1.26e-59	4.07e-56	0.57	0.47	Plasma plasminogen activator levels;	chr12:130825427	chr12:130810606~130812438:+
BRCA	cis	rs9399137	0.507	rs4896129	ENSG00000232876.1	CTA-212D2.2	-17.38	1.28e-59	4.12e-56	-0.61	-0.47	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135028707	chr6:135055033~135060550:+
BRCA	cis	rs9389248	0.708	rs7750574	ENSG00000232876.1	CTA-212D2.2	-17.37	1.45e-59	4.67e-56	-0.61	-0.47	High light scatter reticulocyte percentage of red cells;	chr6:135029794	chr6:135055033~135060550:+
BRCA	cis	rs9399137	0.507	rs6923512	ENSG00000232876.1	CTA-212D2.2	17.37	1.45e-59	4.68e-56	0.61	0.47	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135014130	chr6:135055033~135060550:+
BRCA	cis	rs7301826	0.651	rs6486601	ENSG00000256250.1	RP11-989F5.1	17.36	1.67e-59	5.36e-56	0.56	0.47	Plasma plasminogen activator levels;	chr12:130816692	chr12:130810606~130812438:+
BRCA	cis	rs7301826	0.627	rs61937256	ENSG00000256250.1	RP11-989F5.1	17.35	2.04e-59	6.55e-56	0.56	0.47	Plasma plasminogen activator levels;	chr12:130818100	chr12:130810606~130812438:+
BRCA	cis	rs9399137	0.507	rs13209780	ENSG00000232876.1	CTA-212D2.2	-17.35	2.1e-59	6.74e-56	-0.61	-0.47	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135023657	chr6:135055033~135060550:+
BRCA	cis	rs992157	1	rs4674280	ENSG00000261338.2	RP11-378A13.1	-17.34	2.16e-59	6.93e-56	-0.49	-0.47	Colorectal cancer;	chr2:218276735	chr2:218255319~218257366:+
BRCA	cis	rs1577917	1	rs12199784	ENSG00000203875.9	SNHG5	-17.33	2.44e-59	7.81e-56	-0.57	-0.47	Response to antipsychotic treatment;	chr6:86017090	chr6:85660950~85678736:-
BRCA	cis	rs7617773	0.817	rs6796490	ENSG00000229759.1	MRPS18AP1	17.33	2.53e-59	8.11e-56	0.54	0.47	Coronary artery disease;	chr3:48195614	chr3:48256350~48256938:-
BRCA	cis	rs7847628	0.55	rs12343516	ENSG00000226752.6	PSMD5-AS1	-17.33	2.74e-59	8.74e-56	-0.59	-0.47	Birth weight;	chr9:120841191	chr9:120824828~120854385:+
BRCA	cis	rs7617773	0.817	rs11130162	ENSG00000229759.1	MRPS18AP1	17.32	2.85e-59	9.09e-56	0.54	0.47	Coronary artery disease;	chr3:48256121	chr3:48256350~48256938:-
BRCA	cis	rs6964833	1	rs36044436	ENSG00000123965.13	PMS2P5	17.31	3.36e-59	1.07e-55	0.79	0.47	Menarche (age at onset);	chr7:74675495	chr7:74894116~74897835:+
BRCA	cis	rs9399137	0.507	rs11154791	ENSG00000232876.1	CTA-212D2.2	-17.31	3.48e-59	1.11e-55	-0.61	-0.47	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135058010	chr6:135055033~135060550:+
BRCA	cis	rs2019137	0.56	rs11123172	ENSG00000274877.1	RP11-65I12.1	17.31	3.5e-59	1.11e-55	0.64	0.47	Lymphocyte counts;	chr2:113226726	chr2:113237595~113240825:+
BRCA	cis	rs9399137	0.507	rs7745289	ENSG00000232876.1	CTA-212D2.2	-17.3	3.71e-59	1.18e-55	-0.61	-0.47	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135059189	chr6:135055033~135060550:+
BRCA	cis	rs9399137	0.507	rs11759062	ENSG00000232876.1	CTA-212D2.2	-17.3	3.71e-59	1.18e-55	-0.61	-0.47	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135060110	chr6:135055033~135060550:+
BRCA	cis	rs9399137	0.507	rs11759077	ENSG00000232876.1	CTA-212D2.2	-17.3	3.71e-59	1.18e-55	-0.61	-0.47	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135060213	chr6:135055033~135060550:+
BRCA	cis	rs1577917	1	rs1962716	ENSG00000203875.9	SNHG5	-17.3	3.81e-59	1.21e-55	-0.58	-0.47	Response to antipsychotic treatment;	chr6:85938718	chr6:85660950~85678736:-
BRCA	cis	rs2019137	0.56	rs10206269	ENSG00000274877.1	RP11-65I12.1	-17.29	4.23e-59	1.34e-55	-0.65	-0.47	Lymphocyte counts;	chr2:113232816	chr2:113237595~113240825:+
BRCA	cis	rs17711722	0.653	rs2460421	ENSG00000226824.5	RP4-756H11.3	17.29	4.66e-59	1.47e-55	0.58	0.47	Calcium levels;	chr7:66026136	chr7:66654538~66669855:+
BRCA	cis	rs1577917	1	rs10455455	ENSG00000203875.9	SNHG5	-17.29	4.67e-59	1.48e-55	-0.6	-0.47	Response to antipsychotic treatment;	chr6:85960496	chr6:85660950~85678736:-
BRCA	cis	rs9399137	0.507	rs13197750	ENSG00000232876.1	CTA-212D2.2	-17.28	4.77e-59	1.5e-55	-0.61	-0.47	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134991242	chr6:135055033~135060550:+
BRCA	cis	rs9399137	0.507	rs7761964	ENSG00000232876.1	CTA-212D2.2	-17.28	4.77e-59	1.5e-55	-0.61	-0.47	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134993127	chr6:135055033~135060550:+
BRCA	cis	rs9399137	0.507	rs11753673	ENSG00000232876.1	CTA-212D2.2	-17.28	4.77e-59	1.5e-55	-0.61	-0.47	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134995338	chr6:135055033~135060550:+
BRCA	cis	rs9399137	0.507	rs12663447	ENSG00000232876.1	CTA-212D2.2	-17.28	4.77e-59	1.5e-55	-0.61	-0.47	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134995888	chr6:135055033~135060550:+
BRCA	cis	rs9399137	0.507	rs4895437	ENSG00000232876.1	CTA-212D2.2	-17.28	4.77e-59	1.5e-55	-0.61	-0.47	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134996216	chr6:135055033~135060550:+
BRCA	cis	rs1426063	0.614	rs77982391	ENSG00000260265.1	RP11-44F21.5	17.27	5.58e-59	1.76e-55	1.07	0.47	QT interval;	chr4:75125224	chr4:75081702~75084717:-
BRCA	cis	rs1431005	0.893	rs12501227	ENSG00000250620.1	RP11-91J3.3	17.26	6.44e-59	2.02e-55	0.61	0.47	Response to statin therapy;	chr4:187401223	chr4:187413564~187415697:+
BRCA	cis	rs3931020	0.548	rs969435	ENSG00000272864.1	RP11-17E13.2	17.26	6.74e-59	2.12e-55	0.59	0.47	Resistin levels;	chr1:74808182	chr1:74698769~74699333:-
BRCA	cis	rs9399137	0.507	rs6940878	ENSG00000232876.1	CTA-212D2.2	-17.26	6.77e-59	2.13e-55	-0.62	-0.47	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135045171	chr6:135055033~135060550:+
BRCA	cis	rs1577917	1	rs12205336	ENSG00000203875.9	SNHG5	-17.26	6.99e-59	2.2e-55	-0.59	-0.47	Response to antipsychotic treatment;	chr6:86012649	chr6:85660950~85678736:-
BRCA	cis	rs1577917	1	rs12209127	ENSG00000203875.9	SNHG5	-17.26	6.99e-59	2.2e-55	-0.59	-0.47	Response to antipsychotic treatment;	chr6:86014709	chr6:85660950~85678736:-
BRCA	cis	rs10256972	0.591	rs10229680	ENSG00000229043.2	AC091729.9	-17.26	7.07e-59	2.22e-55	-0.62	-0.47	Endometriosis;Longevity;	chr7:1118929	chr7:1160374~1165267:+
BRCA	cis	rs2019137	0.56	rs4849179	ENSG00000274877.1	RP11-65I12.1	-17.25	7.37e-59	2.31e-55	-0.63	-0.47	Lymphocyte counts;	chr2:113227593	chr2:113237595~113240825:+
BRCA	cis	rs2019137	0.539	rs4849177	ENSG00000274877.1	RP11-65I12.1	-17.25	7.6e-59	2.38e-55	-0.63	-0.47	Lymphocyte counts;	chr2:113225007	chr2:113237595~113240825:+
BRCA	cis	rs9399137	0.507	rs6569986	ENSG00000232876.1	CTA-212D2.2	-17.24	8.12e-59	2.54e-55	-0.61	-0.47	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134990503	chr6:135055033~135060550:+
BRCA	cis	rs1577917	1	rs13196930	ENSG00000203875.9	SNHG5	-17.24	8.19e-59	2.57e-55	-0.59	-0.47	Response to antipsychotic treatment;	chr6:85942527	chr6:85660950~85678736:-
BRCA	cis	rs1577917	0.917	rs35038582	ENSG00000203875.9	SNHG5	-17.24	8.29e-59	2.59e-55	-0.57	-0.47	Response to antipsychotic treatment;	chr6:86011587	chr6:85660950~85678736:-
BRCA	cis	rs1577917	1	rs7760207	ENSG00000203875.9	SNHG5	-17.24	8.29e-59	2.59e-55	-0.57	-0.47	Response to antipsychotic treatment;	chr6:86011982	chr6:85660950~85678736:-
BRCA	cis	rs7301826	0.58	rs61938969	ENSG00000256250.1	RP11-989F5.1	17.24	8.61e-59	2.69e-55	0.56	0.47	Plasma plasminogen activator levels;	chr12:130831525	chr12:130810606~130812438:+
BRCA	cis	rs2882667	1	rs10515505	ENSG00000253404.1	AC034243.1	17.24	8.92e-59	2.79e-55	0.61	0.47	Age-related hearing impairment (SNP x SNP interaction);	chr5:138977457	chr5:138744434~138753309:-
BRCA	cis	rs1577917	1	rs35797755	ENSG00000203875.9	SNHG5	-17.22	1.14e-58	3.57e-55	-0.57	-0.47	Response to antipsychotic treatment;	chr6:85996836	chr6:85660950~85678736:-
BRCA	cis	rs1426063	0.614	rs74949513	ENSG00000260265.1	RP11-44F21.5	17.21	1.36e-58	4.23e-55	1.06	0.47	QT interval;	chr4:75124631	chr4:75081702~75084717:-
BRCA	cis	rs1426063	0.541	rs116664844	ENSG00000260265.1	RP11-44F21.5	17.21	1.36e-58	4.23e-55	1.06	0.47	QT interval;	chr4:75125677	chr4:75081702~75084717:-
BRCA	cis	rs1426063	0.541	rs114162294	ENSG00000260265.1	RP11-44F21.5	17.21	1.36e-58	4.23e-55	1.06	0.47	QT interval;	chr4:75125682	chr4:75081702~75084717:-
BRCA	cis	rs7301826	0.603	rs7975825	ENSG00000256250.1	RP11-989F5.1	-17.2	1.47e-58	4.58e-55	-0.56	-0.47	Plasma plasminogen activator levels;	chr12:130803899	chr12:130810606~130812438:+
BRCA	cis	rs1577917	1	rs68171315	ENSG00000203875.9	SNHG5	-17.2	1.55e-58	4.81e-55	-0.59	-0.47	Response to antipsychotic treatment;	chr6:85997682	chr6:85660950~85678736:-
BRCA	cis	rs1577917	1	rs12212733	ENSG00000203875.9	SNHG5	-17.19	1.71e-58	5.3e-55	-0.58	-0.47	Response to antipsychotic treatment;	chr6:86016295	chr6:85660950~85678736:-
BRCA	cis	rs9399137	0.507	rs12663810	ENSG00000232876.1	CTA-212D2.2	-17.18	1.92e-58	5.95e-55	-0.62	-0.47	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134968644	chr6:135055033~135060550:+
BRCA	cis	rs1426063	0.614	rs76087197	ENSG00000260265.1	RP11-44F21.5	17.18	1.93e-58	5.99e-55	1.06	0.47	QT interval;	chr4:75134108	chr4:75081702~75084717:-
BRCA	cis	rs9399137	0.507	rs13064	ENSG00000232876.1	CTA-212D2.2	-17.18	2.07e-58	6.41e-55	-0.61	-0.47	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134966395	chr6:135055033~135060550:+
BRCA	cis	rs2019137	0.56	rs7421852	ENSG00000274877.1	RP11-65I12.1	-17.17	2.09e-58	6.48e-55	-0.64	-0.47	Lymphocyte counts;	chr2:113232684	chr2:113237595~113240825:+
BRCA	cis	rs9399137	0.507	rs13196486	ENSG00000232876.1	CTA-212D2.2	-17.17	2.11e-58	6.55e-55	-0.61	-0.47	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134962736	chr6:135055033~135060550:+
BRCA	cis	rs9399137	0.507	rs6918512	ENSG00000232876.1	CTA-212D2.2	-17.17	2.11e-58	6.55e-55	-0.61	-0.47	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134963701	chr6:135055033~135060550:+
BRCA	cis	rs9399137	0.507	rs35571217	ENSG00000232876.1	CTA-212D2.2	-17.17	2.11e-58	6.55e-55	-0.61	-0.47	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134969217	chr6:135055033~135060550:+
BRCA	cis	rs2019137	0.56	rs10175462	ENSG00000274877.1	RP11-65I12.1	-17.17	2.17e-58	6.72e-55	-0.63	-0.47	Lymphocyte counts;	chr2:113230915	chr2:113237595~113240825:+
BRCA	cis	rs1577917	1	rs12207305	ENSG00000203875.9	SNHG5	-17.17	2.3e-58	7.12e-55	-0.57	-0.47	Response to antipsychotic treatment;	chr6:86013784	chr6:85660950~85678736:-
BRCA	cis	rs1577917	0.958	rs12192546	ENSG00000203875.9	SNHG5	17.17	2.34e-58	7.26e-55	0.59	0.47	Response to antipsychotic treatment;	chr6:85766766	chr6:85660950~85678736:-
BRCA	cis	rs2019137	0.539	rs6755040	ENSG00000274877.1	RP11-65I12.1	-17.16	2.55e-58	7.91e-55	-0.63	-0.47	Lymphocyte counts;	chr2:113223560	chr2:113237595~113240825:+
BRCA	cis	rs1577917	0.958	rs28442244	ENSG00000203875.9	SNHG5	17.16	2.61e-58	8.08e-55	0.56	0.47	Response to antipsychotic treatment;	chr6:85991518	chr6:85660950~85678736:-
BRCA	cis	rs2739330	0.587	rs4820571	ENSG00000218537.1	MIF-AS1	17.15	2.84e-58	8.77e-55	0.61	0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23894426~23898930:-
BRCA	cis	rs1577917	0.652	rs75593931	ENSG00000203875.9	SNHG5	-17.15	3.08e-58	9.51e-55	-0.58	-0.47	Response to antipsychotic treatment;	chr6:86009821	chr6:85660950~85678736:-
BRCA	cis	rs1577917	0.959	rs12201739	ENSG00000203875.9	SNHG5	-17.15	3.08e-58	9.51e-55	-0.58	-0.47	Response to antipsychotic treatment;	chr6:86011021	chr6:85660950~85678736:-
BRCA	cis	rs9399137	0.507	rs56164974	ENSG00000232876.1	CTA-212D2.2	-17.14	3.23e-58	9.96e-55	-0.61	-0.47	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134967578	chr6:135055033~135060550:+
BRCA	cis	rs10716631	1	rs10716631	ENSG00000261338.2	RP11-378A13.1	17.14	3.27e-58	1.01e-54	0.5	0.47	Plateletcrit;High light scatter reticulocyte percentage of red cells;	chr2:218273447	chr2:218255319~218257366:+
BRCA	cis	rs1426063	0.614	rs79750906	ENSG00000260265.1	RP11-44F21.5	17.12	4.37e-58	1.35e-54	1.05	0.47	QT interval;	chr4:75139193	chr4:75081702~75084717:-
BRCA	cis	rs3931020	0.72	rs927904	ENSG00000272864.1	RP11-17E13.2	-17.12	4.52e-58	1.39e-54	-0.61	-0.47	Resistin levels;	chr1:74794644	chr1:74698769~74699333:-
BRCA	cis	rs1577917	0.958	rs13207354	ENSG00000203875.9	SNHG5	-17.11	4.81e-58	1.48e-54	-0.56	-0.47	Response to antipsychotic treatment;	chr6:85990545	chr6:85660950~85678736:-
BRCA	cis	rs1577917	1	rs12204365	ENSG00000203875.9	SNHG5	-17.11	4.81e-58	1.48e-54	-0.56	-0.47	Response to antipsychotic treatment;	chr6:85990814	chr6:85660950~85678736:-
BRCA	cis	rs1577917	1	rs12663651	ENSG00000203875.9	SNHG5	-17.11	4.81e-58	1.48e-54	-0.56	-0.47	Response to antipsychotic treatment;	chr6:85991937	chr6:85660950~85678736:-
BRCA	cis	rs1577917	0.958	rs11755864	ENSG00000203875.9	SNHG5	-17.11	4.97e-58	1.52e-54	-0.56	-0.47	Response to antipsychotic treatment;	chr6:85982073	chr6:85660950~85678736:-
BRCA	cis	rs9399137	0.507	rs12664898	ENSG00000232876.1	CTA-212D2.2	-17.1	5.67e-58	1.74e-54	-0.61	-0.47	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134967525	chr6:135055033~135060550:+
BRCA	cis	rs1577917	1	rs6936048	ENSG00000203875.9	SNHG5	-17.1	5.72e-58	1.75e-54	-0.56	-0.47	Response to antipsychotic treatment;	chr6:85992890	chr6:85660950~85678736:-
BRCA	cis	rs10256972	0.553	rs4236381	ENSG00000229043.2	AC091729.9	-17.09	6.56e-58	2.01e-54	-0.62	-0.47	Endometriosis;Longevity;	chr7:1126087	chr7:1160374~1165267:+
BRCA	cis	rs3814244	0.933	rs10878725	ENSG00000255733.4	IFNG-AS1	-17.09	6.79e-58	2.08e-54	-0.39	-0.47	Itch intensity from mosquito bite adjusted by bite size;	chr12:68020930	chr12:67989445~68234686:+
BRCA	cis	rs1577917	1	rs36096931	ENSG00000203875.9	SNHG5	-17.09	6.91e-58	2.11e-54	-0.56	-0.47	Response to antipsychotic treatment;	chr6:85983416	chr6:85660950~85678736:-
BRCA	cis	rs6964833	0.935	rs13238996	ENSG00000123965.13	PMS2P5	17.08	7.15e-58	2.18e-54	0.78	0.47	Menarche (age at onset);	chr7:74655318	chr7:74894116~74897835:+
BRCA	cis	rs992157	0.965	rs13419763	ENSG00000261338.2	RP11-378A13.1	17.08	7.78e-58	2.37e-54	0.5	0.47	Colorectal cancer;	chr2:218270227	chr2:218255319~218257366:+
BRCA	cis	rs8062405	1	rs1987472	ENSG00000259982.1	CDC37P1	17.08	7.85e-58	2.4e-54	0.58	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814456	chr16:28700294~28701540:-
BRCA	cis	rs8062405	0.895	rs56186137	ENSG00000259982.1	CDC37P1	17.08	7.85e-58	2.4e-54	0.58	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814632	chr16:28700294~28701540:-
BRCA	cis	rs1577917	1	rs2324843	ENSG00000203875.9	SNHG5	-17.07	8.7e-58	2.65e-54	-0.58	-0.47	Response to antipsychotic treatment;	chr6:85907783	chr6:85660950~85678736:-
BRCA	cis	rs875971	0.862	rs6460307	ENSG00000226824.5	RP4-756H11.3	-17.06	9.24e-58	2.81e-54	-0.58	-0.47	Aortic root size;	chr7:66595884	chr7:66654538~66669855:+
BRCA	cis	rs9399137	0.507	rs4896128	ENSG00000232876.1	CTA-212D2.2	17.06	1e-57	3.06e-54	0.6	0.47	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135028618	chr6:135055033~135060550:+
BRCA	cis	rs1577917	1	rs12190604	ENSG00000203875.9	SNHG5	-17.05	1.11e-57	3.38e-54	-0.58	-0.47	Response to antipsychotic treatment;	chr6:86006497	chr6:85660950~85678736:-
BRCA	cis	rs10256972	0.681	rs12702016	ENSG00000229043.2	AC091729.9	-17.04	1.2e-57	3.65e-54	-0.63	-0.47	Endometriosis;Longevity;	chr7:1089756	chr7:1160374~1165267:+
BRCA	cis	rs992157	0.965	rs13427681	ENSG00000261338.2	RP11-378A13.1	17.04	1.29e-57	3.91e-54	0.49	0.47	Colorectal cancer;	chr2:218302840	chr2:218255319~218257366:+
BRCA	cis	rs7617773	0.817	rs6787500	ENSG00000229759.1	MRPS18AP1	17.04	1.3e-57	3.94e-54	0.54	0.47	Coronary artery disease;	chr3:48257949	chr3:48256350~48256938:-
BRCA	cis	rs9399137	0.507	rs6904897	ENSG00000232876.1	CTA-212D2.2	-17.04	1.36e-57	4.11e-54	-0.59	-0.47	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135061842	chr6:135055033~135060550:+
BRCA	cis	rs12022452	0.591	rs12042242	ENSG00000238287.1	RP11-656D10.3	17.03	1.37e-57	4.15e-54	0.72	0.47	Age-related hearing impairment (SNP x SNP interaction);	chr1:40528201	chr1:40493157~40508661:-
BRCA	cis	rs9399137	0.507	rs4580893	ENSG00000232876.1	CTA-212D2.2	-17.02	1.66e-57	5.03e-54	-0.61	-0.47	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134976524	chr6:135055033~135060550:+
BRCA	cis	rs6964833	0.935	rs34630792	ENSG00000123965.13	PMS2P5	17.02	1.67e-57	5.06e-54	0.76	0.47	Menarche (age at onset);	chr7:74646869	chr7:74894116~74897835:+
BRCA	cis	rs8062405	0.824	rs62034326	ENSG00000259982.1	CDC37P1	17.02	1.71e-57	5.18e-54	0.57	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28527972	chr16:28700294~28701540:-
BRCA	cis	rs8062405	0.824	rs4788084	ENSG00000259982.1	CDC37P1	17.02	1.71e-57	5.18e-54	0.57	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28528527	chr16:28700294~28701540:-
BRCA	cis	rs9399137	0.507	rs4594969	ENSG00000232876.1	CTA-212D2.2	-17.01	1.82e-57	5.49e-54	-0.6	-0.47	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134964448	chr6:135055033~135060550:+
BRCA	cis	rs6452524	0.561	rs4331874	ENSG00000249664.1	CTD-2227C6.2	17.01	1.83e-57	5.53e-54	0.57	0.47	Hypertension (SNP x SNP interaction);	chr5:83068253	chr5:83012285~83013109:-
BRCA	cis	rs858239	0.862	rs1728292	ENSG00000230658.1	KLHL7-AS1	17.01	1.86e-57	5.61e-54	0.61	0.47	Cerebrospinal fluid biomarker levels;	chr7:23223855	chr7:23101228~23105703:-
BRCA	cis	rs10256972	0.591	rs6950319	ENSG00000229043.2	AC091729.9	-17.01	1.99e-57	6e-54	-0.61	-0.47	Endometriosis;Longevity;	chr7:1121688	chr7:1160374~1165267:+
BRCA	cis	rs9399137	0.507	rs28384513	ENSG00000232876.1	CTA-212D2.2	-17	2.09e-57	6.29e-54	-0.61	-0.47	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135055071	chr6:135055033~135060550:+
BRCA	cis	rs12439619	0.883	rs62012045	ENSG00000278603.1	RP13-608F4.5	17	2.22e-57	6.68e-54	0.7	0.47	Intelligence (multi-trait analysis);	chr15:82229366	chr15:82472203~82472426:+
BRCA	cis	rs9399137	0.507	rs11757723	ENSG00000232876.1	CTA-212D2.2	-16.99	2.37e-57	7.15e-54	-0.61	-0.47	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134970155	chr6:135055033~135060550:+
BRCA	cis	rs2455601	0.574	rs2568094	ENSG00000254860.4	TMEM9B-AS1	16.99	2.4e-57	7.21e-54	0.5	0.47	Schizophrenia;	chr11:8970671	chr11:8964675~8977527:+
BRCA	cis	rs7301826	0.651	rs4759517	ENSG00000256299.1	RP11-989F5.3	-16.99	2.46e-57	7.41e-54	-0.53	-0.47	Plasma plasminogen activator levels;	chr12:130799153	chr12:130810821~130812622:-
BRCA	cis	rs2882667	0.898	rs6863347	ENSG00000253404.1	AC034243.1	16.99	2.52e-57	7.57e-54	0.59	0.47	Age-related hearing impairment (SNP x SNP interaction);	chr5:139025446	chr5:138744434~138753309:-
BRCA	cis	rs8062405	0.964	rs11860513	ENSG00000259982.1	CDC37P1	16.99	2.56e-57	7.69e-54	0.58	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814099	chr16:28700294~28701540:-
BRCA	cis	rs9399135	0.66	rs4440481	ENSG00000232876.1	CTA-212D2.2	-16.99	2.57e-57	7.71e-54	-0.57	-0.47	Red blood cell count;	chr6:134955558	chr6:135055033~135060550:+
BRCA	cis	rs8062405	0.754	rs62034323	ENSG00000259982.1	CDC37P1	16.98	2.77e-57	8.31e-54	0.57	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28525152	chr16:28700294~28701540:-
BRCA	cis	rs8062405	0.824	rs62034324	ENSG00000259982.1	CDC37P1	16.98	2.77e-57	8.31e-54	0.57	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28525441	chr16:28700294~28701540:-
BRCA	cis	rs2455601	0.638	rs2742478	ENSG00000254860.4	TMEM9B-AS1	16.98	2.79e-57	8.36e-54	0.5	0.47	Schizophrenia;	chr11:8974552	chr11:8964675~8977527:+
BRCA	cis	rs11155671	0.53	rs7763849	ENSG00000268592.3	RAET1E-AS1	16.98	2.79e-57	8.37e-54	0.57	0.47	Testicular germ cell tumor;	chr6:149885244	chr6:149863494~149919507:+
BRCA	cis	rs875971	0.862	rs6944374	ENSG00000226824.5	RP4-756H11.3	16.98	2.94e-57	8.81e-54	0.59	0.47	Aortic root size;	chr7:66221942	chr7:66654538~66669855:+
BRCA	cis	rs1577917	1	rs12215037	ENSG00000203875.9	SNHG5	-16.97	3.06e-57	9.17e-54	-0.59	-0.47	Response to antipsychotic treatment;	chr6:86017913	chr6:85660950~85678736:-
BRCA	cis	rs1153858	1	rs12909158	ENSG00000259520.4	CTD-2651B20.3	-16.96	3.62e-57	1.08e-53	-0.63	-0.47	Homoarginine levels;	chr15:45328976	chr15:45251580~45279251:-
BRCA	cis	rs10256972	0.641	rs12702017	ENSG00000229043.2	AC091729.9	-16.96	3.62e-57	1.08e-53	-0.62	-0.47	Endometriosis;Longevity;	chr7:1089777	chr7:1160374~1165267:+
BRCA	cis	rs494459	0.838	rs555649	ENSG00000255239.1	AP002954.6	16.96	3.87e-57	1.16e-53	0.53	0.47	Height;	chr11:118781100	chr11:118688039~118690600:-
BRCA	cis	rs62229266	0.839	rs11088335	ENSG00000231106.2	LINC01436	16.96	3.89e-57	1.16e-53	0.53	0.47	Mitral valve prolapse;	chr21:36098037	chr21:36005338~36007838:+
BRCA	cis	rs8062405	0.964	rs78613234	ENSG00000259982.1	CDC37P1	16.96	3.94e-57	1.18e-53	0.58	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828104	chr16:28700294~28701540:-
BRCA	cis	rs8062405	1	rs62036624	ENSG00000259982.1	CDC37P1	16.96	3.94e-57	1.18e-53	0.58	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828609	chr16:28700294~28701540:-
BRCA	cis	rs1577917	1	rs34852683	ENSG00000203875.9	SNHG5	-16.96	3.94e-57	1.18e-53	-0.55	-0.47	Response to antipsychotic treatment;	chr6:85992612	chr6:85660950~85678736:-
BRCA	cis	rs7617773	0.817	rs17786132	ENSG00000229759.1	MRPS18AP1	16.95	3.99e-57	1.19e-53	0.6	0.46	Coronary artery disease;	chr3:48207930	chr3:48256350~48256938:-
BRCA	cis	rs7617773	0.817	rs35456569	ENSG00000229759.1	MRPS18AP1	16.95	3.99e-57	1.19e-53	0.6	0.46	Coronary artery disease;	chr3:48209409	chr3:48256350~48256938:-
BRCA	cis	rs7208859	0.623	rs9914242	ENSG00000263531.1	RP13-753N3.1	16.95	4.06e-57	1.21e-53	0.87	0.46	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30889227	chr17:30863921~30864940:-
BRCA	cis	rs8062405	0.792	rs12446550	ENSG00000259982.1	CDC37P1	16.95	4.28e-57	1.28e-53	0.57	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28532060	chr16:28700294~28701540:-
BRCA	cis	rs7301826	0.58	rs12821464	ENSG00000256250.1	RP11-989F5.1	16.94	4.75e-57	1.42e-53	0.56	0.46	Plasma plasminogen activator levels;	chr12:130838174	chr12:130810606~130812438:+
BRCA	cis	rs17507216	0.609	rs1431716	ENSG00000278603.1	RP13-608F4.5	16.93	5.2e-57	1.55e-53	0.82	0.46	Excessive daytime sleepiness;	chr15:82676180	chr15:82472203~82472426:+
BRCA	cis	rs12439619	0.921	rs56042848	ENSG00000278603.1	RP13-608F4.5	16.93	5.24e-57	1.56e-53	0.69	0.46	Intelligence (multi-trait analysis);	chr15:82235244	chr15:82472203~82472426:+
BRCA	cis	rs8062405	0.824	rs28698667	ENSG00000259982.1	CDC37P1	16.93	5.39e-57	1.6e-53	0.57	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28521750	chr16:28700294~28701540:-
BRCA	cis	rs1577917	0.958	rs7747897	ENSG00000203875.9	SNHG5	-16.93	5.72e-57	1.7e-53	-0.56	-0.46	Response to antipsychotic treatment;	chr6:85937631	chr6:85660950~85678736:-
BRCA	cis	rs8062405	1	rs12444171	ENSG00000259982.1	CDC37P1	16.92	6.63e-57	1.97e-53	0.58	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28833930	chr16:28700294~28701540:-
BRCA	cis	rs73086581	1	rs17287822	ENSG00000229539.1	RP11-119B16.2	16.91	6.79e-57	2.01e-53	0.74	0.46	Response to antidepressants in depression;	chr20:3997889	chr20:3888239~3888868:-
BRCA	cis	rs1577917	0.876	rs1582127	ENSG00000203875.9	SNHG5	-16.91	7.14e-57	2.12e-53	-0.55	-0.46	Response to antipsychotic treatment;	chr6:85987486	chr6:85660950~85678736:-
BRCA	cis	rs9389248	0.737	rs56358308	ENSG00000232876.1	CTA-212D2.2	-16.91	7.3e-57	2.16e-53	-0.6	-0.46	High light scatter reticulocyte percentage of red cells;	chr6:134985842	chr6:135055033~135060550:+
BRCA	cis	rs9399137	0.507	rs11754021	ENSG00000232876.1	CTA-212D2.2	-16.91	7.3e-57	2.16e-53	-0.6	-0.46	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134987237	chr6:135055033~135060550:+
BRCA	cis	rs62229266	0.625	rs2051395	ENSG00000231106.2	LINC01436	-16.91	7.38e-57	2.19e-53	-0.51	-0.46	Mitral valve prolapse;	chr21:36058967	chr21:36005338~36007838:+
BRCA	cis	rs8062405	1	rs55991577	ENSG00000259982.1	CDC37P1	16.91	7.42e-57	2.2e-53	0.58	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28831704	chr16:28700294~28701540:-
BRCA	cis	rs8062405	1	rs56358680	ENSG00000259982.1	CDC37P1	16.91	7.42e-57	2.2e-53	0.58	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28831797	chr16:28700294~28701540:-
BRCA	cis	rs7617773	0.817	rs11707606	ENSG00000229759.1	MRPS18AP1	16.91	7.44e-57	2.2e-53	0.6	0.46	Coronary artery disease;	chr3:48195597	chr3:48256350~48256938:-
BRCA	cis	rs8062405	1	rs8055138	ENSG00000259982.1	CDC37P1	16.9	7.76e-57	2.3e-53	0.58	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28880144	chr16:28700294~28701540:-
BRCA	cis	rs1577917	1	rs10455456	ENSG00000203875.9	SNHG5	-16.9	8.67e-57	2.56e-53	-0.56	-0.46	Response to antipsychotic treatment;	chr6:85960604	chr6:85660950~85678736:-
BRCA	cis	rs8062405	1	rs62036626	ENSG00000259982.1	CDC37P1	16.89	8.95e-57	2.64e-53	0.58	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28832963	chr16:28700294~28701540:-
BRCA	cis	rs8062405	1	rs62036657	ENSG00000259982.1	CDC37P1	16.89	8.95e-57	2.64e-53	0.58	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28833044	chr16:28700294~28701540:-
BRCA	cis	rs9601248	0.529	rs2783126	ENSG00000227676.3	LINC01068	16.89	9.85e-57	2.9e-53	0.58	0.46	Major depressive disorder;	chr13:79584566	chr13:79566727~79571436:+
BRCA	cis	rs9601248	0.529	rs9545142	ENSG00000227676.3	LINC01068	16.89	9.85e-57	2.9e-53	0.58	0.46	Major depressive disorder;	chr13:79588420	chr13:79566727~79571436:+
BRCA	cis	rs8062405	1	rs56404918	ENSG00000259982.1	CDC37P1	16.88	1e-56	2.96e-53	0.58	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835519	chr16:28700294~28701540:-
BRCA	cis	rs8062405	1	rs55719896	ENSG00000259982.1	CDC37P1	16.88	1e-56	2.96e-53	0.58	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835545	chr16:28700294~28701540:-
BRCA	cis	rs17507216	0.671	rs4779035	ENSG00000278603.1	RP13-608F4.5	16.88	1.09e-56	3.2e-53	0.8	0.46	Excessive daytime sleepiness;	chr15:82591686	chr15:82472203~82472426:+
BRCA	cis	rs8062405	1	rs55830740	ENSG00000259982.1	CDC37P1	16.88	1.14e-56	3.35e-53	0.58	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835828	chr16:28700294~28701540:-
BRCA	cis	rs8062405	1	rs62037371	ENSG00000259982.1	CDC37P1	16.87	1.16e-56	3.42e-53	0.58	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28878810	chr16:28700294~28701540:-
BRCA	cis	rs8062405	0.679	rs72793818	ENSG00000259982.1	CDC37P1	16.87	1.31e-56	3.83e-53	0.59	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28881816	chr16:28700294~28701540:-
BRCA	cis	rs73086581	0.838	rs56401022	ENSG00000229539.1	RP11-119B16.2	16.86	1.43e-56	4.18e-53	0.77	0.46	Response to antidepressants in depression;	chr20:4043634	chr20:3888239~3888868:-
BRCA	cis	rs8062405	1	rs4788101	ENSG00000259982.1	CDC37P1	16.86	1.45e-56	4.24e-53	0.58	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28856483	chr16:28700294~28701540:-
BRCA	cis	rs8062405	0.737	rs11861132	ENSG00000259982.1	CDC37P1	16.86	1.45e-56	4.24e-53	0.58	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28860539	chr16:28700294~28701540:-
BRCA	cis	rs8062405	1	rs11861174	ENSG00000259982.1	CDC37P1	16.86	1.45e-56	4.24e-53	0.58	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28860668	chr16:28700294~28701540:-
BRCA	cis	rs8062405	1	rs4788102	ENSG00000259982.1	CDC37P1	16.86	1.45e-56	4.24e-53	0.58	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28862077	chr16:28700294~28701540:-
BRCA	cis	rs8062405	1	rs62037367	ENSG00000259982.1	CDC37P1	16.86	1.45e-56	4.24e-53	0.58	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863226	chr16:28700294~28701540:-
BRCA	cis	rs8062405	1	rs7198606	ENSG00000259982.1	CDC37P1	16.86	1.45e-56	4.24e-53	0.58	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863801	chr16:28700294~28701540:-
BRCA	cis	rs8062405	0.929	rs11864750	ENSG00000259982.1	CDC37P1	16.86	1.45e-56	4.24e-53	0.58	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863883	chr16:28700294~28701540:-
BRCA	cis	rs8062405	0.964	rs7193733	ENSG00000259982.1	CDC37P1	16.86	1.45e-56	4.24e-53	0.58	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28864161	chr16:28700294~28701540:-
BRCA	cis	rs8062405	1	rs8055982	ENSG00000259982.1	CDC37P1	16.86	1.45e-56	4.24e-53	0.58	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28869881	chr16:28700294~28701540:-
BRCA	cis	rs8062405	1	rs7498665	ENSG00000259982.1	CDC37P1	16.86	1.45e-56	4.24e-53	0.58	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28871920	chr16:28700294~28701540:-
BRCA	cis	rs8062405	0.964	rs11864107	ENSG00000259982.1	CDC37P1	16.86	1.45e-56	4.24e-53	0.58	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28874610	chr16:28700294~28701540:-
BRCA	cis	rs9399137	0.507	rs13214669	ENSG00000232876.1	CTA-212D2.2	-16.84	1.81e-56	5.3e-53	-0.61	-0.46	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134978821	chr6:135055033~135060550:+
BRCA	cis	rs7617773	0.817	rs11130163	ENSG00000229759.1	MRPS18AP1	16.84	1.88e-56	5.48e-53	0.53	0.46	Coronary artery disease;	chr3:48271168	chr3:48256350~48256938:-
BRCA	cis	rs8062405	1	rs9972693	ENSG00000259982.1	CDC37P1	16.83	1.98e-56	5.78e-53	0.58	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28848481	chr16:28700294~28701540:-
BRCA	cis	rs8062405	0.964	rs9972768	ENSG00000259982.1	CDC37P1	16.83	1.98e-56	5.78e-53	0.58	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28850413	chr16:28700294~28701540:-
BRCA	cis	rs8062405	0.965	rs62037363	ENSG00000259982.1	CDC37P1	16.83	1.98e-56	5.78e-53	0.58	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28853721	chr16:28700294~28701540:-
BRCA	cis	rs8062405	1	rs7205323	ENSG00000259982.1	CDC37P1	16.83	1.98e-56	5.78e-53	0.58	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28854571	chr16:28700294~28701540:-
BRCA	cis	rs2283792	0.812	rs94194	ENSG00000224086.5	LL22NC03-86G7.1	-16.83	2.07e-56	6.03e-53	-0.49	-0.46	Multiple sclerosis;	chr22:21933937	chr22:21938293~21977632:+
BRCA	cis	rs9399135	0.622	rs3817776	ENSG00000232876.1	CTA-212D2.2	16.83	2.09e-56	6.1e-53	0.57	0.46	Red blood cell count;	chr6:134935618	chr6:135055033~135060550:+
BRCA	cis	rs1577917	1	rs10944169	ENSG00000203875.9	SNHG5	-16.83	2.16e-56	6.28e-53	-0.55	-0.46	Response to antipsychotic treatment;	chr6:85973318	chr6:85660950~85678736:-
BRCA	cis	rs62229266	0.659	rs2255734	ENSG00000231106.2	LINC01436	16.82	2.26e-56	6.57e-53	0.51	0.46	Mitral valve prolapse;	chr21:36039611	chr21:36005338~36007838:+
BRCA	cis	rs8062405	1	rs62037365	ENSG00000259982.1	CDC37P1	16.82	2.36e-56	6.86e-53	0.58	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28857641	chr16:28700294~28701540:-
BRCA	cis	rs1577917	1	rs12201735	ENSG00000203875.9	SNHG5	-16.82	2.39e-56	6.97e-53	-0.56	-0.46	Response to antipsychotic treatment;	chr6:85947221	chr6:85660950~85678736:-
BRCA	cis	rs7301826	0.627	rs73162873	ENSG00000256299.1	RP11-989F5.3	-16.81	2.62e-56	7.62e-53	-0.53	-0.46	Plasma plasminogen activator levels;	chr12:130811468	chr12:130810821~130812622:-
BRCA	cis	rs8062405	1	rs62037364	ENSG00000259982.1	CDC37P1	16.81	2.65e-56	7.69e-53	0.58	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28857374	chr16:28700294~28701540:-
BRCA	cis	rs8062405	0.965	rs56040780	ENSG00000259982.1	CDC37P1	16.81	2.69e-56	7.82e-53	0.58	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28850560	chr16:28700294~28701540:-
BRCA	cis	rs8062405	1	rs3088215	ENSG00000259982.1	CDC37P1	16.81	2.82e-56	8.18e-53	0.58	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28842675	chr16:28700294~28701540:-
BRCA	cis	rs8062405	1	rs28403629	ENSG00000259982.1	CDC37P1	16.81	2.82e-56	8.18e-53	0.58	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28843448	chr16:28700294~28701540:-
BRCA	cis	rs8062405	1	rs61737565	ENSG00000259982.1	CDC37P1	16.81	2.82e-56	8.18e-53	0.58	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28844201	chr16:28700294~28701540:-
BRCA	cis	rs8062405	1	rs4788099	ENSG00000259982.1	CDC37P1	16.81	2.82e-56	8.18e-53	0.58	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28844406	chr16:28700294~28701540:-
BRCA	cis	rs9399135	0.527	rs61738492	ENSG00000232876.1	CTA-212D2.2	-16.81	2.84e-56	8.23e-53	-0.6	-0.46	Red blood cell count;	chr6:134961633	chr6:135055033~135060550:+
BRCA	cis	rs62229266	0.659	rs2835242	ENSG00000231106.2	LINC01436	16.8	3.09e-56	8.96e-53	0.51	0.46	Mitral valve prolapse;	chr21:36041234	chr21:36005338~36007838:+
BRCA	cis	rs2739330	0.761	rs5760176	ENSG00000218537.1	MIF-AS1	-16.79	3.33e-56	9.63e-53	-0.61	-0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23894426~23898930:-
BRCA	cis	rs8062405	0.929	rs11150609	ENSG00000259982.1	CDC37P1	16.79	3.34e-56	9.67e-53	0.58	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28859275	chr16:28700294~28701540:-
BRCA	cis	rs9399137	0.507	rs10484496	ENSG00000232876.1	CTA-212D2.2	-16.79	3.36e-56	9.72e-53	-0.6	-0.46	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134978544	chr6:135055033~135060550:+
BRCA	cis	rs1577917	0.958	rs12199832	ENSG00000203875.9	SNHG5	-16.79	3.46e-56	1e-52	-0.56	-0.46	Response to antipsychotic treatment;	chr6:85943030	chr6:85660950~85678736:-
BRCA	cis	rs1577917	0.958	rs12207374	ENSG00000203875.9	SNHG5	-16.79	3.46e-56	1e-52	-0.56	-0.46	Response to antipsychotic treatment;	chr6:85946927	chr6:85660950~85678736:-
BRCA	cis	rs7301826	0.651	rs7132657	ENSG00000256299.1	RP11-989F5.3	-16.79	3.59e-56	1.04e-52	-0.53	-0.46	Plasma plasminogen activator levels;	chr12:130800642	chr12:130810821~130812622:-
BRCA	cis	rs62229266	0.659	rs2835245	ENSG00000231106.2	LINC01436	16.79	3.66e-56	1.06e-52	0.51	0.46	Mitral valve prolapse;	chr21:36044410	chr21:36005338~36007838:+
BRCA	cis	rs7301826	0.651	rs10734979	ENSG00000256299.1	RP11-989F5.3	-16.78	3.82e-56	1.1e-52	-0.53	-0.46	Plasma plasminogen activator levels;	chr12:130804409	chr12:130810821~130812622:-
BRCA	cis	rs7617773	0.817	rs936427	ENSG00000229759.1	MRPS18AP1	-16.78	3.85e-56	1.11e-52	-0.59	-0.46	Coronary artery disease;	chr3:48259584	chr3:48256350~48256938:-
BRCA	cis	rs7301826	0.61	rs4759791	ENSG00000256299.1	RP11-989F5.3	-16.78	3.92e-56	1.13e-52	-0.53	-0.46	Plasma plasminogen activator levels;	chr12:130811950	chr12:130810821~130812622:-
BRCA	cis	rs7301826	0.651	rs4759521	ENSG00000256299.1	RP11-989F5.3	-16.78	3.92e-56	1.13e-52	-0.53	-0.46	Plasma plasminogen activator levels;	chr12:130812768	chr12:130810821~130812622:-
BRCA	cis	rs7301826	0.651	rs10734981	ENSG00000256299.1	RP11-989F5.3	-16.78	3.92e-56	1.13e-52	-0.53	-0.46	Plasma plasminogen activator levels;	chr12:130813350	chr12:130810821~130812622:-
BRCA	cis	rs7301826	0.651	rs10744483	ENSG00000256299.1	RP11-989F5.3	-16.78	3.92e-56	1.13e-52	-0.53	-0.46	Plasma plasminogen activator levels;	chr12:130813661	chr12:130810821~130812622:-
BRCA	cis	rs7301826	0.651	rs10744484	ENSG00000256299.1	RP11-989F5.3	-16.78	3.92e-56	1.13e-52	-0.53	-0.46	Plasma plasminogen activator levels;	chr12:130813961	chr12:130810821~130812622:-
BRCA	cis	rs62229266	0.659	rs2835258	ENSG00000231106.2	LINC01436	16.78	3.92e-56	1.13e-52	0.51	0.46	Mitral valve prolapse;	chr21:36052067	chr21:36005338~36007838:+
BRCA	cis	rs7301826	0.651	rs1554807	ENSG00000256299.1	RP11-989F5.3	16.78	3.97e-56	1.15e-52	0.53	0.46	Plasma plasminogen activator levels;	chr12:130795872	chr12:130810821~130812622:-
BRCA	cis	rs1577917	0.876	rs12201992	ENSG00000203875.9	SNHG5	-16.78	4.14e-56	1.19e-52	-0.55	-0.46	Response to antipsychotic treatment;	chr6:85908501	chr6:85660950~85678736:-
BRCA	cis	rs1577917	1	rs12201880	ENSG00000203875.9	SNHG5	-16.78	4.14e-56	1.19e-52	-0.55	-0.46	Response to antipsychotic treatment;	chr6:85917289	chr6:85660950~85678736:-
BRCA	cis	rs1577917	1	rs7756203	ENSG00000203875.9	SNHG5	-16.78	4.14e-56	1.19e-52	-0.55	-0.46	Response to antipsychotic treatment;	chr6:85917989	chr6:85660950~85678736:-
BRCA	cis	rs1577917	1	rs10944161	ENSG00000203875.9	SNHG5	-16.78	4.14e-56	1.19e-52	-0.55	-0.46	Response to antipsychotic treatment;	chr6:85920658	chr6:85660950~85678736:-
BRCA	cis	rs1577917	1	rs1857965	ENSG00000203875.9	SNHG5	-16.78	4.14e-56	1.19e-52	-0.55	-0.46	Response to antipsychotic treatment;	chr6:85921058	chr6:85660950~85678736:-
BRCA	cis	rs1577917	1	rs7771342	ENSG00000203875.9	SNHG5	-16.78	4.14e-56	1.19e-52	-0.55	-0.46	Response to antipsychotic treatment;	chr6:85922218	chr6:85660950~85678736:-
BRCA	cis	rs1577917	1	rs12154056	ENSG00000203875.9	SNHG5	-16.78	4.14e-56	1.19e-52	-0.55	-0.46	Response to antipsychotic treatment;	chr6:85924376	chr6:85660950~85678736:-
BRCA	cis	rs7301826	0.627	rs10773823	ENSG00000256299.1	RP11-989F5.3	-16.77	4.33e-56	1.25e-52	-0.53	-0.46	Plasma plasminogen activator levels;	chr12:130809956	chr12:130810821~130812622:-
BRCA	cis	rs5760092	0.618	rs5996631	ENSG00000273295.1	AP000350.5	-16.77	4.4e-56	1.27e-52	-0.6	-0.46	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23901432~23907068:-
BRCA	cis	rs2882667	0.929	rs34846849	ENSG00000253404.1	AC034243.1	16.77	4.65e-56	1.34e-52	0.63	0.46	Age-related hearing impairment (SNP x SNP interaction);	chr5:139024889	chr5:138744434~138753309:-
BRCA	cis	rs8062405	1	rs4788095	ENSG00000259982.1	CDC37P1	16.77	4.77e-56	1.37e-52	0.57	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28820038	chr16:28700294~28701540:-
BRCA	cis	rs8062405	0.964	rs72793809	ENSG00000259982.1	CDC37P1	16.77	4.77e-56	1.37e-52	0.57	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821061	chr16:28700294~28701540:-
BRCA	cis	rs1153858	1	rs7171577	ENSG00000259520.4	CTD-2651B20.3	-16.77	4.81e-56	1.38e-52	-0.62	-0.46	Homoarginine levels;	chr15:45335781	chr15:45251580~45279251:-
BRCA	cis	rs62229266	0.609	rs12482541	ENSG00000231106.2	LINC01436	16.76	5.04e-56	1.44e-52	0.51	0.46	Mitral valve prolapse;	chr21:36047445	chr21:36005338~36007838:+
BRCA	cis	rs62229266	0.609	rs2835253	ENSG00000231106.2	LINC01436	16.76	5.04e-56	1.44e-52	0.51	0.46	Mitral valve prolapse;	chr21:36047447	chr21:36005338~36007838:+
BRCA	cis	rs8062405	1	rs62036617	ENSG00000259982.1	CDC37P1	16.76	5.2e-56	1.49e-52	0.57	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28816177	chr16:28700294~28701540:-
BRCA	cis	rs2739330	0.731	rs5751792	ENSG00000218537.1	MIF-AS1	16.76	5.28e-56	1.51e-52	0.61	0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23894426~23898930:-
BRCA	cis	rs2283792	0.812	rs5995269	ENSG00000224086.5	LL22NC03-86G7.1	-16.76	5.5e-56	1.57e-52	-0.49	-0.46	Multiple sclerosis;	chr22:21935025	chr22:21938293~21977632:+
BRCA	cis	rs6964833	1	rs4717906	ENSG00000123965.13	PMS2P5	16.75	6.08e-56	1.74e-52	0.75	0.46	Menarche (age at onset);	chr7:74671923	chr7:74894116~74897835:+
BRCA	cis	rs7617773	0.694	rs13099560	ENSG00000229759.1	MRPS18AP1	-16.75	6.19e-56	1.77e-52	-0.53	-0.46	Coronary artery disease;	chr3:48163278	chr3:48256350~48256938:-
BRCA	cis	rs1577917	1	rs6940458	ENSG00000203875.9	SNHG5	-16.75	6.22e-56	1.78e-52	-0.55	-0.46	Response to antipsychotic treatment;	chr6:85935274	chr6:85660950~85678736:-
BRCA	cis	rs7301826	0.651	rs10773825	ENSG00000256299.1	RP11-989F5.3	-16.75	6.4e-56	1.83e-52	-0.52	-0.46	Plasma plasminogen activator levels;	chr12:130814368	chr12:130810821~130812622:-
BRCA	cis	rs1577917	1	rs10455158	ENSG00000203875.9	SNHG5	-16.74	6.56e-56	1.87e-52	-0.56	-0.46	Response to antipsychotic treatment;	chr6:85963107	chr6:85660950~85678736:-
BRCA	cis	rs2882667	0.858	rs11957633	ENSG00000253404.1	AC034243.1	16.74	6.74e-56	1.93e-52	0.63	0.46	Age-related hearing impairment (SNP x SNP interaction);	chr5:139028705	chr5:138744434~138753309:-
BRCA	cis	rs17507216	0.681	rs28877110	ENSG00000278603.1	RP13-608F4.5	16.74	6.8e-56	1.94e-52	0.81	0.46	Excessive daytime sleepiness;	chr15:82672111	chr15:82472203~82472426:+
BRCA	cis	rs1153858	1	rs10519021	ENSG00000259520.4	CTD-2651B20.3	-16.74	7e-56	2e-52	-0.61	-0.46	Homoarginine levels;	chr15:45339597	chr15:45251580~45279251:-
BRCA	cis	rs62229266	0.633	rs34259635	ENSG00000231106.2	LINC01436	16.73	7.37e-56	2.1e-52	0.51	0.46	Mitral valve prolapse;	chr21:36031272	chr21:36005338~36007838:+
BRCA	cis	rs4718428	1	rs12534637	ENSG00000226824.5	RP4-756H11.3	-16.73	7.77e-56	2.22e-52	-0.58	-0.46	Corneal structure;	chr7:66862667	chr7:66654538~66669855:+
BRCA	cis	rs62229266	0.659	rs2835243	ENSG00000231106.2	LINC01436	16.73	8.12e-56	2.32e-52	0.51	0.46	Mitral valve prolapse;	chr21:36041648	chr21:36005338~36007838:+
BRCA	cis	rs62229266	0.659	rs62230814	ENSG00000231106.2	LINC01436	16.73	8.16e-56	2.33e-52	0.51	0.46	Mitral valve prolapse;	chr21:36031248	chr21:36005338~36007838:+
BRCA	cis	rs2882667	0.822	rs11738376	ENSG00000253404.1	AC034243.1	16.72	8.71e-56	2.48e-52	0.63	0.46	Age-related hearing impairment (SNP x SNP interaction);	chr5:139062483	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.858	rs11242444	ENSG00000253404.1	AC034243.1	16.72	8.83e-56	2.52e-52	0.63	0.46	Age-related hearing impairment (SNP x SNP interaction);	chr5:139070690	chr5:138744434~138753309:-
BRCA	cis	rs7301826	0.651	rs4759519	ENSG00000256299.1	RP11-989F5.3	-16.72	8.89e-56	2.53e-52	-0.52	-0.46	Plasma plasminogen activator levels;	chr12:130804963	chr12:130810821~130812622:-
BRCA	cis	rs7301826	0.651	rs12228957	ENSG00000256299.1	RP11-989F5.3	-16.72	9.26e-56	2.64e-52	-0.53	-0.46	Plasma plasminogen activator levels;	chr12:130811521	chr12:130810821~130812622:-
BRCA	cis	rs7301826	0.651	rs12228959	ENSG00000256299.1	RP11-989F5.3	-16.72	9.26e-56	2.64e-52	-0.53	-0.46	Plasma plasminogen activator levels;	chr12:130811523	chr12:130810821~130812622:-
BRCA	cis	rs1426063	0.614	rs17199779	ENSG00000260265.1	RP11-44F21.5	-16.72	9.28e-56	2.64e-52	-1	-0.46	QT interval;	chr4:75105647	chr4:75081702~75084717:-
BRCA	cis	rs7301826	0.651	rs10848210	ENSG00000256299.1	RP11-989F5.3	-16.71	9.98e-56	2.84e-52	-0.53	-0.46	Plasma plasminogen activator levels;	chr12:130827475	chr12:130810821~130812622:-
BRCA	cis	rs7301826	0.627	rs4325342	ENSG00000256299.1	RP11-989F5.3	-16.71	9.98e-56	2.84e-52	-0.53	-0.46	Plasma plasminogen activator levels;	chr12:130827937	chr12:130810821~130812622:-
BRCA	cis	rs62229266	0.625	rs62230813	ENSG00000231106.2	LINC01436	16.71	1.05e-55	2.99e-52	0.5	0.46	Mitral valve prolapse;	chr21:36031134	chr21:36005338~36007838:+
BRCA	cis	rs7301826	0.651	rs7295705	ENSG00000256299.1	RP11-989F5.3	-16.7	1.14e-55	3.23e-52	-0.52	-0.46	Plasma plasminogen activator levels;	chr12:130817340	chr12:130810821~130812622:-
BRCA	cis	rs10256972	0.63	rs13235747	ENSG00000229043.2	AC091729.9	-16.7	1.16e-55	3.29e-52	-0.61	-0.46	Endometriosis;Longevity;	chr7:1089487	chr7:1160374~1165267:+
BRCA	cis	rs8062405	1	rs4451951	ENSG00000259982.1	CDC37P1	16.7	1.17e-55	3.32e-52	0.57	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28824884	chr16:28700294~28701540:-
BRCA	cis	rs17507216	0.718	rs7161977	ENSG00000278603.1	RP13-608F4.5	16.7	1.18e-55	3.36e-52	0.81	0.46	Excessive daytime sleepiness;	chr15:82646782	chr15:82472203~82472426:+
BRCA	cis	rs10935480	0.904	rs13065271	ENSG00000239445.4	ST3GAL6-AS1	-16.7	1.23e-55	3.49e-52	-0.48	-0.46	Blood protein levels;	chr3:98715649	chr3:98714330~98732651:-
BRCA	cis	rs1577917	0.959	rs34258068	ENSG00000203875.9	SNHG5	-16.7	1.23e-55	3.5e-52	-0.56	-0.46	Response to antipsychotic treatment;	chr6:85969731	chr6:85660950~85678736:-
BRCA	cis	rs8062405	1	rs62036620	ENSG00000259982.1	CDC37P1	16.69	1.26e-55	3.58e-52	0.57	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821776	chr16:28700294~28701540:-
BRCA	cis	rs8062405	1	rs62036621	ENSG00000259982.1	CDC37P1	16.69	1.26e-55	3.58e-52	0.57	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821978	chr16:28700294~28701540:-
BRCA	cis	rs1426063	0.614	rs76931926	ENSG00000260265.1	RP11-44F21.5	16.69	1.27e-55	3.61e-52	1.01	0.46	QT interval;	chr4:75106902	chr4:75081702~75084717:-
BRCA	cis	rs9545047	0.901	rs314688	ENSG00000227676.3	LINC01068	16.68	1.43e-55	4.04e-52	0.58	0.46	Schizophrenia;	chr13:79449171	chr13:79566727~79571436:+
BRCA	cis	rs7617773	0.817	rs13068265	ENSG00000229759.1	MRPS18AP1	16.68	1.5e-55	4.22e-52	0.59	0.46	Coronary artery disease;	chr3:48260124	chr3:48256350~48256938:-
BRCA	cis	rs17507216	0.718	rs72751675	ENSG00000278603.1	RP13-608F4.5	16.68	1.5e-55	4.23e-52	0.81	0.46	Excessive daytime sleepiness;	chr15:82630452	chr15:82472203~82472426:+
BRCA	cis	rs2882667	0.858	rs11956159	ENSG00000253404.1	AC034243.1	16.67	1.69e-55	4.77e-52	0.63	0.46	Age-related hearing impairment (SNP x SNP interaction);	chr5:139072879	chr5:138744434~138753309:-
BRCA	cis	rs1426063	0.614	rs115279737	ENSG00000260265.1	RP11-44F21.5	16.67	1.69e-55	4.77e-52	1	0.46	QT interval;	chr4:75107557	chr4:75081702~75084717:-
BRCA	cis	rs62229266	0.659	rs7275820	ENSG00000231106.2	LINC01436	16.67	1.82e-55	5.14e-52	0.5	0.46	Mitral valve prolapse;	chr21:36037116	chr21:36005338~36007838:+
BRCA	cis	rs1153858	1	rs56850226	ENSG00000259520.4	CTD-2651B20.3	-16.65	2.24e-55	6.3e-52	-0.61	-0.46	Homoarginine levels;	chr15:45340920	chr15:45251580~45279251:-
BRCA	cis	rs9399137	0.507	rs6940258	ENSG00000232876.1	CTA-212D2.2	-16.65	2.34e-55	6.59e-52	-0.59	-0.46	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135044994	chr6:135055033~135060550:+
BRCA	cis	rs2739330	0.76	rs5751761	ENSG00000218537.1	MIF-AS1	-16.65	2.38e-55	6.68e-52	-0.6	-0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23894426~23898930:-
BRCA	cis	rs9399137	0.507	rs61738647	ENSG00000232876.1	CTA-212D2.2	-16.64	2.59e-55	7.29e-52	-0.6	-0.46	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134961597	chr6:135055033~135060550:+
BRCA	cis	rs7617773	0.746	rs4130995	ENSG00000229759.1	MRPS18AP1	16.63	2.82e-55	7.93e-52	0.53	0.46	Coronary artery disease;	chr3:48316765	chr3:48256350~48256938:-
BRCA	cis	rs7301826	0.651	rs7971046	ENSG00000256299.1	RP11-989F5.3	-16.63	2.86e-55	8.02e-52	-0.52	-0.46	Plasma plasminogen activator levels;	chr12:130802262	chr12:130810821~130812622:-
BRCA	cis	rs8062405	1	rs3888190	ENSG00000259982.1	CDC37P1	16.63	2.97e-55	8.33e-52	0.58	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28878165	chr16:28700294~28701540:-
BRCA	cis	rs2882667	0.858	rs10900856	ENSG00000253404.1	AC034243.1	-16.63	3.06e-55	8.57e-52	-0.63	-0.46	Age-related hearing impairment (SNP x SNP interaction);	chr5:139082057	chr5:138744434~138753309:-
BRCA	cis	rs8062405	1	rs2008514	ENSG00000259982.1	CDC37P1	-16.63	3.08e-55	8.64e-52	-0.56	-0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814284	chr16:28700294~28701540:-
BRCA	cis	rs1431005	1	rs12650667	ENSG00000250620.1	RP11-91J3.3	16.62	3.2e-55	8.97e-52	0.59	0.46	Response to statin therapy;	chr4:187424873	chr4:187413564~187415697:+
BRCA	cis	rs7301826	0.651	rs2037789	ENSG00000256299.1	RP11-989F5.3	16.62	3.3e-55	9.25e-52	0.52	0.46	Plasma plasminogen activator levels;	chr12:130803747	chr12:130810821~130812622:-
BRCA	cis	rs507080	0.922	rs555356	ENSG00000255422.1	AP002954.4	-16.62	3.38e-55	9.46e-52	-0.57	-0.46	Serum metabolite levels;	chr11:118687369	chr11:118704607~118750263:+
BRCA	cis	rs2283792	0.687	rs381849	ENSG00000224086.5	LL22NC03-86G7.1	-16.62	3.46e-55	9.68e-52	-0.48	-0.46	Multiple sclerosis;	chr22:21951341	chr22:21938293~21977632:+
BRCA	cis	rs62229266	0.652	rs7280551	ENSG00000231106.2	LINC01436	16.61	3.82e-55	1.07e-51	0.5	0.46	Mitral valve prolapse;	chr21:36037311	chr21:36005338~36007838:+
BRCA	cis	rs2487048	0.761	rs1800976	ENSG00000226334.1	RP11-217B7.2	-16.6	4.34e-55	1.21e-51	-0.58	-0.46	Intraocular pressure;	chr9:104928428	chr9:104927553~104928892:+
BRCA	cis	rs1577917	1	rs10944170	ENSG00000203875.9	SNHG5	-16.6	4.48e-55	1.25e-51	-0.55	-0.46	Response to antipsychotic treatment;	chr6:85975751	chr6:85660950~85678736:-
BRCA	cis	rs1577917	1	rs12213740	ENSG00000203875.9	SNHG5	-16.6	4.48e-55	1.25e-51	-0.55	-0.46	Response to antipsychotic treatment;	chr6:85947015	chr6:85660950~85678736:-
BRCA	cis	rs35160687	0.862	rs17737955	ENSG00000273080.1	RP11-301O19.1	16.59	4.74e-55	1.32e-51	0.56	0.46	Night sleep phenotypes;	chr2:86280891	chr2:86195590~86196049:+
BRCA	cis	rs6964833	1	rs34324835	ENSG00000123965.13	PMS2P5	16.59	4.8e-55	1.34e-51	0.76	0.46	Menarche (age at onset);	chr7:74717986	chr7:74894116~74897835:+
BRCA	cis	rs1577917	0.958	rs13213551	ENSG00000203875.9	SNHG5	-16.59	5.25e-55	1.46e-51	-0.54	-0.46	Response to antipsychotic treatment;	chr6:85898983	chr6:85660950~85678736:-
BRCA	cis	rs1577917	1	rs34622557	ENSG00000203875.9	SNHG5	-16.59	5.25e-55	1.46e-51	-0.54	-0.46	Response to antipsychotic treatment;	chr6:85921134	chr6:85660950~85678736:-
BRCA	cis	rs1577917	1	rs1911553	ENSG00000203875.9	SNHG5	-16.59	5.25e-55	1.46e-51	-0.54	-0.46	Response to antipsychotic treatment;	chr6:85921174	chr6:85660950~85678736:-
BRCA	cis	rs1577917	1	rs1995688	ENSG00000203875.9	SNHG5	-16.59	5.25e-55	1.46e-51	-0.54	-0.46	Response to antipsychotic treatment;	chr6:85922601	chr6:85660950~85678736:-
BRCA	cis	rs1426063	0.614	rs17000261	ENSG00000260265.1	RP11-44F21.5	16.57	6.08e-55	1.69e-51	0.95	0.46	QT interval;	chr4:75108766	chr4:75081702~75084717:-
BRCA	cis	rs9322193	0.566	rs5024811	ENSG00000231760.4	RP11-350J20.5	-16.57	6.11e-55	1.7e-51	-0.62	-0.46	Lung cancer;	chr6:149924898	chr6:149796151~149826294:-
BRCA	cis	rs8062405	0.824	rs62034319	ENSG00000259982.1	CDC37P1	16.57	6.25e-55	1.73e-51	0.56	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28520867	chr16:28700294~28701540:-
BRCA	cis	rs73086581	0.838	rs11906481	ENSG00000229539.1	RP11-119B16.2	16.57	6.34e-55	1.76e-51	0.76	0.46	Response to antidepressants in depression;	chr20:4048059	chr20:3888239~3888868:-
BRCA	cis	rs35160687	0.862	rs13024964	ENSG00000273080.1	RP11-301O19.1	16.57	6.39e-55	1.77e-51	0.56	0.46	Night sleep phenotypes;	chr2:86284745	chr2:86195590~86196049:+
BRCA	cis	rs7301826	0.651	rs10848206	ENSG00000256299.1	RP11-989F5.3	-16.57	6.5e-55	1.8e-51	-0.53	-0.46	Plasma plasminogen activator levels;	chr12:130796926	chr12:130810821~130812622:-
BRCA	cis	rs1577917	1	rs12664335	ENSG00000203875.9	SNHG5	16.57	6.62e-55	1.84e-51	0.55	0.46	Response to antipsychotic treatment;	chr6:85888056	chr6:85660950~85678736:-
BRCA	cis	rs6964833	0.786	rs35633336	ENSG00000123965.13	PMS2P5	16.57	6.72e-55	1.86e-51	0.74	0.46	Menarche (age at onset);	chr7:74643961	chr7:74894116~74897835:+
BRCA	cis	rs2283792	0.718	rs239918	ENSG00000224086.5	LL22NC03-86G7.1	-16.56	7.23e-55	2e-51	-0.48	-0.46	Multiple sclerosis;	chr22:21959457	chr22:21938293~21977632:+
BRCA	cis	rs7617773	0.817	rs13059037	ENSG00000229759.1	MRPS18AP1	16.56	7.31e-55	2.02e-51	0.59	0.46	Coronary artery disease;	chr3:48246389	chr3:48256350~48256938:-
BRCA	cis	rs1431005	1	rs55849435	ENSG00000250620.1	RP11-91J3.3	16.56	7.43e-55	2.06e-51	0.59	0.46	Response to statin therapy;	chr4:187455185	chr4:187413564~187415697:+
BRCA	cis	rs6964833	0.935	rs35735900	ENSG00000123965.13	PMS2P5	16.56	7.53e-55	2.08e-51	0.74	0.46	Menarche (age at onset);	chr7:74651887	chr7:74894116~74897835:+
BRCA	cis	rs6964833	0.872	rs4717903	ENSG00000123965.13	PMS2P5	16.56	7.62e-55	2.11e-51	0.74	0.46	Menarche (age at onset);	chr7:74653827	chr7:74894116~74897835:+
BRCA	cis	rs1426063	0.614	rs114761716	ENSG00000260265.1	RP11-44F21.5	16.55	8.31e-55	2.3e-51	1	0.46	QT interval;	chr4:75107209	chr4:75081702~75084717:-
BRCA	cis	rs7301826	0.627	rs1077317	ENSG00000256299.1	RP11-989F5.3	-16.54	9.31e-55	2.57e-51	-0.52	-0.46	Plasma plasminogen activator levels;	chr12:130830432	chr12:130810821~130812622:-
BRCA	cis	rs2019137	0.539	rs4849181	ENSG00000274877.1	RP11-65I12.1	-16.53	1.16e-54	3.19e-51	-0.62	-0.46	Lymphocyte counts;	chr2:113234393	chr2:113237595~113240825:+
BRCA	cis	rs35160687	0.862	rs13023154	ENSG00000273080.1	RP11-301O19.1	-16.52	1.18e-54	3.25e-51	-0.56	-0.46	Night sleep phenotypes;	chr2:86289861	chr2:86195590~86196049:+
BRCA	cis	rs7301826	0.61	rs7957899	ENSG00000256299.1	RP11-989F5.3	-16.52	1.22e-54	3.36e-51	-0.52	-0.46	Plasma plasminogen activator levels;	chr12:130794531	chr12:130810821~130812622:-
BRCA	cis	rs7301826	0.651	rs1973834	ENSG00000256299.1	RP11-989F5.3	-16.52	1.26e-54	3.47e-51	-0.52	-0.46	Plasma plasminogen activator levels;	chr12:130795612	chr12:130810821~130812622:-
BRCA	cis	rs1153858	1	rs56806728	ENSG00000259520.4	CTD-2651B20.3	-16.52	1.28e-54	3.53e-51	-0.6	-0.46	Homoarginine levels;	chr15:45345616	chr15:45251580~45279251:-
BRCA	cis	rs1431005	1	rs72723291	ENSG00000250620.1	RP11-91J3.3	16.52	1.31e-54	3.59e-51	0.59	0.46	Response to statin therapy;	chr4:187425714	chr4:187413564~187415697:+
BRCA	cis	rs9322193	0.566	rs3922947	ENSG00000231760.4	RP11-350J20.5	-16.52	1.33e-54	3.65e-51	-0.63	-0.46	Lung cancer;	chr6:149924856	chr6:149796151~149826294:-
BRCA	cis	rs35160687	0.862	rs12476706	ENSG00000273080.1	RP11-301O19.1	16.51	1.51e-54	4.15e-51	0.56	0.46	Night sleep phenotypes;	chr2:86301247	chr2:86195590~86196049:+
BRCA	cis	rs1577917	1	rs12663690	ENSG00000203875.9	SNHG5	16.51	1.52e-54	4.18e-51	0.55	0.46	Response to antipsychotic treatment;	chr6:85930444	chr6:85660950~85678736:-
BRCA	cis	rs10256972	0.591	rs11766651	ENSG00000229043.2	AC091729.9	-16.5	1.54e-54	4.24e-51	-0.6	-0.46	Endometriosis;Longevity;	chr7:1122010	chr7:1160374~1165267:+
BRCA	cis	rs7617773	0.851	rs7647817	ENSG00000229759.1	MRPS18AP1	16.5	1.56e-54	4.28e-51	0.59	0.46	Coronary artery disease;	chr3:48195017	chr3:48256350~48256938:-
BRCA	cis	rs7301826	0.651	rs7968675	ENSG00000256299.1	RP11-989F5.3	-16.5	1.62e-54	4.44e-51	-0.52	-0.46	Plasma plasminogen activator levels;	chr12:130818832	chr12:130810821~130812622:-
BRCA	cis	rs1153858	1	rs56669689	ENSG00000259520.4	CTD-2651B20.3	-16.5	1.68e-54	4.61e-51	-0.59	-0.46	Homoarginine levels;	chr15:45345531	chr15:45251580~45279251:-
BRCA	cis	rs2882667	0.822	rs13187096	ENSG00000253404.1	AC034243.1	16.49	1.82e-54	4.99e-51	0.63	0.45	Age-related hearing impairment (SNP x SNP interaction);	chr5:139068399	chr5:138744434~138753309:-
BRCA	cis	rs8062405	0.824	rs4788083	ENSG00000259982.1	CDC37P1	16.49	1.85e-54	5.06e-51	0.54	0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28534128	chr16:28700294~28701540:-
BRCA	cis	rs1153858	1	rs4775906	ENSG00000259520.4	CTD-2651B20.3	-16.49	1.86e-54	5.08e-51	-0.6	-0.45	Homoarginine levels;	chr15:45346096	chr15:45251580~45279251:-
BRCA	cis	rs7617773	0.817	rs11709691	ENSG00000229759.1	MRPS18AP1	16.49	1.87e-54	5.11e-51	0.59	0.45	Coronary artery disease;	chr3:48262179	chr3:48256350~48256938:-
BRCA	cis	rs9399137	0.507	rs4451150	ENSG00000232876.1	CTA-212D2.2	-16.49	1.9e-54	5.2e-51	-0.59	-0.45	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134957925	chr6:135055033~135060550:+
BRCA	cis	rs7617773	0.779	rs77957078	ENSG00000229759.1	MRPS18AP1	16.48	2.04e-54	5.58e-51	0.59	0.45	Coronary artery disease;	chr3:48289796	chr3:48256350~48256938:-
BRCA	cis	rs1153858	1	rs7179743	ENSG00000259520.4	CTD-2651B20.3	-16.48	2.13e-54	5.82e-51	-0.6	-0.45	Homoarginine levels;	chr15:45346133	chr15:45251580~45279251:-
BRCA	cis	rs7617773	0.817	rs35414021	ENSG00000229759.1	MRPS18AP1	16.48	2.15e-54	5.87e-51	0.59	0.45	Coronary artery disease;	chr3:48252034	chr3:48256350~48256938:-
BRCA	cis	rs507080	0.922	rs514143	ENSG00000255422.1	AP002954.4	-16.48	2.15e-54	5.87e-51	-0.57	-0.45	Serum metabolite levels;	chr11:118687740	chr11:118704607~118750263:+
BRCA	cis	rs4718428	1	rs4718428	ENSG00000226824.5	RP4-756H11.3	-16.48	2.19e-54	5.96e-51	-0.57	-0.45	Corneal structure;	chr7:66956459	chr7:66654538~66669855:+
BRCA	cis	rs7301826	0.651	rs4759525	ENSG00000256299.1	RP11-989F5.3	-16.48	2.19e-54	5.97e-51	-0.52	-0.45	Plasma plasminogen activator levels;	chr12:130831736	chr12:130810821~130812622:-
BRCA	cis	rs1577917	1	rs34106666	ENSG00000203875.9	SNHG5	-16.48	2.21e-54	6.02e-51	-0.55	-0.45	Response to antipsychotic treatment;	chr6:85966540	chr6:85660950~85678736:-
BRCA	cis	rs1577917	1	rs1337844	ENSG00000203875.9	SNHG5	-16.48	2.21e-54	6.02e-51	-0.55	-0.45	Response to antipsychotic treatment;	chr6:85967555	chr6:85660950~85678736:-
BRCA	cis	rs1577917	0.958	rs884842	ENSG00000203875.9	SNHG5	-16.48	2.21e-54	6.02e-51	-0.55	-0.45	Response to antipsychotic treatment;	chr6:85970679	chr6:85660950~85678736:-
BRCA	cis	rs1577917	1	rs12207610	ENSG00000203875.9	SNHG5	-16.48	2.25e-54	6.13e-51	-0.55	-0.45	Response to antipsychotic treatment;	chr6:85978298	chr6:85660950~85678736:-
BRCA	cis	rs1577917	0.958	rs12203457	ENSG00000203875.9	SNHG5	-16.48	2.25e-54	6.13e-51	-0.55	-0.45	Response to antipsychotic treatment;	chr6:85979559	chr6:85660950~85678736:-
BRCA	cis	rs10935480	0.935	rs4857414	ENSG00000239445.4	ST3GAL6-AS1	-16.47	2.28e-54	6.21e-51	-0.48	-0.45	Blood protein levels;	chr3:98713715	chr3:98714330~98732651:-
BRCA	cis	rs2882667	0.858	rs11957527	ENSG00000253404.1	AC034243.1	16.47	2.34e-54	6.35e-51	0.62	0.45	Age-related hearing impairment (SNP x SNP interaction);	chr5:139069206	chr5:138744434~138753309:-
BRCA	cis	rs7301826	0.61	rs4759789	ENSG00000256299.1	RP11-989F5.3	-16.47	2.4e-54	6.53e-51	-0.52	-0.45	Plasma plasminogen activator levels;	chr12:130811835	chr12:130810821~130812622:-
BRCA	cis	rs7301826	0.651	rs4759794	ENSG00000256299.1	RP11-989F5.3	-16.47	2.45e-54	6.67e-51	-0.52	-0.45	Plasma plasminogen activator levels;	chr12:130812803	chr12:130810821~130812622:-
BRCA	cis	rs7301826	0.651	rs10744485	ENSG00000256299.1	RP11-989F5.3	-16.47	2.45e-54	6.67e-51	-0.52	-0.45	Plasma plasminogen activator levels;	chr12:130814005	chr12:130810821~130812622:-
BRCA	cis	rs1153858	1	rs11852800	ENSG00000259520.4	CTD-2651B20.3	16.45	2.98e-54	8.07e-51	0.6	0.45	Homoarginine levels;	chr15:45346933	chr15:45251580~45279251:-
BRCA	cis	rs35160687	0.64	rs13015186	ENSG00000273080.1	RP11-301O19.1	16.45	3.26e-54	8.83e-51	0.56	0.45	Night sleep phenotypes;	chr2:86258455	chr2:86195590~86196049:+
BRCA	cis	rs1577917	1	rs1018184	ENSG00000203875.9	SNHG5	16.44	3.41e-54	9.22e-51	0.53	0.45	Response to antipsychotic treatment;	chr6:85938757	chr6:85660950~85678736:-
BRCA	cis	rs2283792	0.745	rs5756306	ENSG00000224086.5	LL22NC03-86G7.1	16.44	3.42e-54	9.26e-51	0.47	0.45	Multiple sclerosis;	chr22:21978846	chr22:21938293~21977632:+
BRCA	cis	rs7617773	0.817	rs13072018	ENSG00000229759.1	MRPS18AP1	16.44	3.62e-54	9.79e-51	0.59	0.45	Coronary artery disease;	chr3:48278842	chr3:48256350~48256938:-
BRCA	cis	rs507080	0.922	rs546890	ENSG00000255422.1	AP002954.4	-16.43	4.05e-54	1.09e-50	-0.56	-0.45	Serum metabolite levels;	chr11:118686489	chr11:118704607~118750263:+
BRCA	cis	rs507080	0.883	rs693306	ENSG00000255422.1	AP002954.4	-16.43	4.05e-54	1.09e-50	-0.56	-0.45	Serum metabolite levels;	chr11:118687624	chr11:118704607~118750263:+
BRCA	cis	rs507080	0.922	rs561845	ENSG00000255422.1	AP002954.4	-16.43	4.05e-54	1.09e-50	-0.56	-0.45	Serum metabolite levels;	chr11:118688118	chr11:118704607~118750263:+
BRCA	cis	rs507080	0.922	rs638805	ENSG00000255422.1	AP002954.4	-16.43	4.05e-54	1.09e-50	-0.56	-0.45	Serum metabolite levels;	chr11:118688180	chr11:118704607~118750263:+
BRCA	cis	rs507080	0.845	rs510408	ENSG00000255422.1	AP002954.4	-16.43	4.05e-54	1.09e-50	-0.56	-0.45	Serum metabolite levels;	chr11:118688192	chr11:118704607~118750263:+
BRCA	cis	rs507080	0.845	rs509641	ENSG00000255422.1	AP002954.4	-16.43	4.05e-54	1.09e-50	-0.56	-0.45	Serum metabolite levels;	chr11:118688243	chr11:118704607~118750263:+
BRCA	cis	rs507080	0.883	rs563549	ENSG00000255422.1	AP002954.4	-16.43	4.05e-54	1.09e-50	-0.56	-0.45	Serum metabolite levels;	chr11:118688244	chr11:118704607~118750263:+
BRCA	cis	rs62229266	0.693	rs2835264	ENSG00000231106.2	LINC01436	16.42	4.39e-54	1.18e-50	0.51	0.45	Mitral valve prolapse;	chr21:36063667	chr21:36005338~36007838:+
BRCA	cis	rs10935480	1	rs10935480	ENSG00000239445.4	ST3GAL6-AS1	-16.42	4.42e-54	1.19e-50	-0.48	-0.45	Blood protein levels;	chr3:98713142	chr3:98714330~98732651:-
BRCA	cis	rs7617773	0.71	rs36064160	ENSG00000229759.1	MRPS18AP1	16.42	4.47e-54	1.2e-50	0.59	0.45	Coronary artery disease;	chr3:48201611	chr3:48256350~48256938:-
BRCA	cis	rs950027	0.62	rs1346267	ENSG00000259520.4	CTD-2651B20.3	-16.42	4.48e-54	1.21e-50	-0.58	-0.45	Response to fenofibrate (adiponectin levels);	chr15:45398791	chr15:45251580~45279251:-
BRCA	cis	rs2882667	0.858	rs13176497	ENSG00000253404.1	AC034243.1	16.42	4.56e-54	1.23e-50	0.62	0.45	Age-related hearing impairment (SNP x SNP interaction);	chr5:139110385	chr5:138744434~138753309:-
BRCA	cis	rs7301826	0.61	rs9668291	ENSG00000256299.1	RP11-989F5.3	-16.41	5.3e-54	1.42e-50	-0.52	-0.45	Plasma plasminogen activator levels;	chr12:130812363	chr12:130810821~130812622:-
BRCA	cis	rs7617773	0.817	rs13094727	ENSG00000229759.1	MRPS18AP1	16.41	5.3e-54	1.42e-50	0.59	0.45	Coronary artery disease;	chr3:48281999	chr3:48256350~48256938:-
BRCA	cis	rs2487048	0.725	rs2246293	ENSG00000226334.1	RP11-217B7.2	16.41	5.34e-54	1.43e-50	0.57	0.45	Intraocular pressure;	chr9:104928557	chr9:104927553~104928892:+
BRCA	cis	rs1577917	1	rs884841	ENSG00000203875.9	SNHG5	-16.41	5.44e-54	1.46e-50	-0.55	-0.45	Response to antipsychotic treatment;	chr6:85970582	chr6:85660950~85678736:-
BRCA	cis	rs7301826	0.651	rs10773824	ENSG00000256299.1	RP11-989F5.3	-16.41	5.52e-54	1.48e-50	-0.52	-0.45	Plasma plasminogen activator levels;	chr12:130814306	chr12:130810821~130812622:-
BRCA	cis	rs507080	0.885	rs7926959	ENSG00000255422.1	AP002954.4	-16.4	6.06e-54	1.62e-50	-0.56	-0.45	Serum metabolite levels;	chr11:118689157	chr11:118704607~118750263:+
BRCA	cis	rs507080	0.663	rs7926970	ENSG00000255422.1	AP002954.4	-16.4	6.06e-54	1.62e-50	-0.56	-0.45	Serum metabolite levels;	chr11:118689172	chr11:118704607~118750263:+
BRCA	cis	rs1153858	1	rs16942000	ENSG00000259520.4	CTD-2651B20.3	-16.4	6.21e-54	1.66e-50	-0.6	-0.45	Homoarginine levels;	chr15:45340805	chr15:45251580~45279251:-
BRCA	cis	rs17507216	0.718	rs72751662	ENSG00000278603.1	RP13-608F4.5	16.39	6.53e-54	1.74e-50	0.8	0.45	Excessive daytime sleepiness;	chr15:82594705	chr15:82472203~82472426:+
BRCA	cis	rs2882667	0.858	rs11949916	ENSG00000253404.1	AC034243.1	16.39	6.66e-54	1.78e-50	0.62	0.45	Age-related hearing impairment (SNP x SNP interaction);	chr5:139060588	chr5:138744434~138753309:-
BRCA	cis	rs2739330	0.796	rs1006771	ENSG00000099984.9	GSTT2	-16.39	6.77e-54	1.81e-50	-0.55	-0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23980123~23983911:+
BRCA	cis	rs507080	0.885	rs533144	ENSG00000255422.1	AP002954.4	-16.38	7.72e-54	2.06e-50	-0.56	-0.45	Serum metabolite levels;	chr11:118688538	chr11:118704607~118750263:+
BRCA	cis	rs35160687	0.829	rs13017143	ENSG00000273080.1	RP11-301O19.1	-16.38	7.85e-54	2.09e-50	-0.55	-0.45	Night sleep phenotypes;	chr2:86239426	chr2:86195590~86196049:+
BRCA	cis	rs1153858	0.887	rs7171163	ENSG00000259520.4	CTD-2651B20.3	-16.38	8.02e-54	2.14e-50	-0.6	-0.45	Homoarginine levels;	chr15:45344197	chr15:45251580~45279251:-
BRCA	cis	rs1153858	1	rs12101539	ENSG00000259520.4	CTD-2651B20.3	-16.37	8.37e-54	2.23e-50	-0.6	-0.45	Homoarginine levels;	chr15:45358468	chr15:45251580~45279251:-
BRCA	cis	rs7617773	0.817	rs34728236	ENSG00000229759.1	MRPS18AP1	16.37	8.53e-54	2.27e-50	0.59	0.45	Coronary artery disease;	chr3:48217618	chr3:48256350~48256938:-
BRCA	cis	rs7617773	0.817	rs79310258	ENSG00000229759.1	MRPS18AP1	16.37	8.53e-54	2.27e-50	0.59	0.45	Coronary artery disease;	chr3:48218177	chr3:48256350~48256938:-
BRCA	cis	rs507080	0.922	rs558907	ENSG00000255422.1	AP002954.4	-16.37	8.64e-54	2.3e-50	-0.56	-0.45	Serum metabolite levels;	chr11:118687746	chr11:118704607~118750263:+
BRCA	cis	rs1577917	1	rs12201741	ENSG00000203875.9	SNHG5	-16.37	8.67e-54	2.31e-50	-0.54	-0.45	Response to antipsychotic treatment;	chr6:85892901	chr6:85660950~85678736:-
BRCA	cis	rs1153858	1	rs61365925	ENSG00000259520.4	CTD-2651B20.3	-16.37	9.18e-54	2.44e-50	-0.6	-0.45	Homoarginine levels;	chr15:45358113	chr15:45251580~45279251:-
BRCA	cis	rs1577917	1	rs12215903	ENSG00000203875.9	SNHG5	-16.36	1.04e-53	2.75e-50	-0.55	-0.45	Response to antipsychotic treatment;	chr6:85965310	chr6:85660950~85678736:-
BRCA	cis	rs1431005	1	rs72499925	ENSG00000250620.1	RP11-91J3.3	16.35	1.13e-53	2.99e-50	0.58	0.45	Response to statin therapy;	chr4:187432596	chr4:187413564~187415697:+
BRCA	cis	rs7188445	0.592	rs17767281	ENSG00000261390.4	RP11-345M22.2	-16.35	1.14e-53	3.02e-50	-0.55	-0.45	Urate levels;	chr16:79708544	chr16:79715232~79770563:-
BRCA	cis	rs4853012	0.838	rs72915068	ENSG00000217702.2	RP11-287D1.4	16.35	1.15e-53	3.05e-50	0.68	0.45	Gestational age at birth (maternal effect);	chr2:74129058	chr2:74130583~74135395:+
BRCA	cis	rs1153858	0.945	rs7182300	ENSG00000259520.4	CTD-2651B20.3	-16.35	1.2e-53	3.17e-50	-0.6	-0.45	Homoarginine levels;	chr15:45342730	chr15:45251580~45279251:-
BRCA	cis	rs1153858	1	rs67831559	ENSG00000259520.4	CTD-2651B20.3	-16.35	1.2e-53	3.17e-50	-0.6	-0.45	Homoarginine levels;	chr15:45357109	chr15:45251580~45279251:-
BRCA	cis	rs7617773	0.779	rs3731487	ENSG00000229759.1	MRPS18AP1	16.34	1.27e-53	3.35e-50	0.59	0.45	Coronary artery disease;	chr3:48188134	chr3:48256350~48256938:-
BRCA	cis	rs1153858	1	rs2066090	ENSG00000259520.4	CTD-2651B20.3	-16.34	1.27e-53	3.36e-50	-0.6	-0.45	Homoarginine levels;	chr15:45357820	chr15:45251580~45279251:-
BRCA	cis	rs62229266	0.563	rs6517325	ENSG00000231106.2	LINC01436	16.34	1.33e-53	3.51e-50	0.51	0.45	Mitral valve prolapse;	chr21:36062680	chr21:36005338~36007838:+
BRCA	cis	rs7617773	0.784	rs11715799	ENSG00000229759.1	MRPS18AP1	16.34	1.35e-53	3.55e-50	0.59	0.45	Coronary artery disease;	chr3:48213730	chr3:48256350~48256938:-
BRCA	cis	rs4718428	1	rs1830070	ENSG00000226824.5	RP4-756H11.3	-16.34	1.4e-53	3.68e-50	-0.57	-0.45	Corneal structure;	chr7:66884684	chr7:66654538~66669855:+
BRCA	cis	rs7617773	0.78	rs9846818	ENSG00000229759.1	MRPS18AP1	16.34	1.41e-53	3.71e-50	0.53	0.45	Coronary artery disease;	chr3:48334195	chr3:48256350~48256938:-
BRCA	cis	rs7301826	0.651	rs4514465	ENSG00000256299.1	RP11-989F5.3	-16.33	1.42e-53	3.74e-50	-0.52	-0.45	Plasma plasminogen activator levels;	chr12:130829124	chr12:130810821~130812622:-
BRCA	cis	rs507080	0.922	rs625513	ENSG00000255422.1	AP002954.4	-16.33	1.43e-53	3.76e-50	-0.56	-0.45	Serum metabolite levels;	chr11:118685010	chr11:118704607~118750263:+
BRCA	cis	rs7617773	0.78	rs3731489	ENSG00000229759.1	MRPS18AP1	16.33	1.46e-53	3.84e-50	0.58	0.45	Coronary artery disease;	chr3:48187416	chr3:48256350~48256938:-
BRCA	cis	rs2882667	0.858	rs11242447	ENSG00000253404.1	AC034243.1	16.33	1.48e-53	3.9e-50	0.62	0.45	Age-related hearing impairment (SNP x SNP interaction);	chr5:139090484	chr5:138744434~138753309:-
BRCA	cis	rs1153858	1	rs16952714	ENSG00000259520.4	CTD-2651B20.3	-16.33	1.51e-53	3.96e-50	-0.6	-0.45	Homoarginine levels;	chr15:45358160	chr15:45251580~45279251:-
BRCA	cis	rs1577917	0.916	rs12203358	ENSG00000203875.9	SNHG5	-16.32	1.67e-53	4.4e-50	-0.55	-0.45	Response to antipsychotic treatment;	chr6:85893506	chr6:85660950~85678736:-
BRCA	cis	rs2882667	0.858	rs35812969	ENSG00000253404.1	AC034243.1	16.31	1.85e-53	4.84e-50	0.62	0.45	Age-related hearing impairment (SNP x SNP interaction);	chr5:139041861	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.858	rs11242442	ENSG00000253404.1	AC034243.1	16.31	1.85e-53	4.84e-50	0.62	0.45	Age-related hearing impairment (SNP x SNP interaction);	chr5:139044800	chr5:138744434~138753309:-
BRCA	cis	rs1426063	0.614	rs76512224	ENSG00000260265.1	RP11-44F21.5	16.31	1.86e-53	4.88e-50	1.03	0.45	QT interval;	chr4:75144808	chr4:75081702~75084717:-
BRCA	cis	rs1153858	1	rs4775907	ENSG00000259520.4	CTD-2651B20.3	-16.31	1.88e-53	4.92e-50	-0.59	-0.45	Homoarginine levels;	chr15:45346449	chr15:45251580~45279251:-
BRCA	cis	rs2882667	0.858	rs6882112	ENSG00000253404.1	AC034243.1	-16.3	2.11e-53	5.52e-50	-0.59	-0.45	Age-related hearing impairment (SNP x SNP interaction);	chr5:139078046	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.858	rs17207870	ENSG00000253404.1	AC034243.1	16.3	2.24e-53	5.87e-50	0.62	0.45	Age-related hearing impairment (SNP x SNP interaction);	chr5:139052048	chr5:138744434~138753309:-
BRCA	cis	rs1153858	1	rs12439274	ENSG00000259520.4	CTD-2651B20.3	-16.3	2.28e-53	5.95e-50	-0.59	-0.45	Homoarginine levels;	chr15:45344469	chr15:45251580~45279251:-
BRCA	cis	rs1153858	1	rs4774577	ENSG00000259520.4	CTD-2651B20.3	-16.29	2.39e-53	6.24e-50	-0.6	-0.45	Homoarginine levels;	chr15:45352487	chr15:45251580~45279251:-
BRCA	cis	rs1153858	1	rs4774578	ENSG00000259520.4	CTD-2651B20.3	-16.29	2.39e-53	6.24e-50	-0.6	-0.45	Homoarginine levels;	chr15:45353853	chr15:45251580~45279251:-
BRCA	cis	rs61524473	1	rs61524473	ENSG00000259520.4	CTD-2651B20.3	-16.29	2.39e-53	6.24e-50	-0.6	-0.45	Metabolite levels (small molecules and protein measures);	chr15:45354085	chr15:45251580~45279251:-
BRCA	cis	rs1153858	1	rs10444821	ENSG00000259520.4	CTD-2651B20.3	-16.29	2.39e-53	6.24e-50	-0.6	-0.45	Homoarginine levels;	chr15:45355038	chr15:45251580~45279251:-
BRCA	cis	rs1153858	1	rs72623915	ENSG00000259520.4	CTD-2651B20.3	-16.29	2.39e-53	6.24e-50	-0.6	-0.45	Homoarginine levels;	chr15:45355235	chr15:45251580~45279251:-
BRCA	cis	rs1153858	1	rs66714503	ENSG00000259520.4	CTD-2651B20.3	-16.29	2.39e-53	6.24e-50	-0.6	-0.45	Homoarginine levels;	chr15:45355840	chr15:45251580~45279251:-
BRCA	cis	rs7617773	0.78	rs35411187	ENSG00000229759.1	MRPS18AP1	16.29	2.52e-53	6.57e-50	0.59	0.45	Coronary artery disease;	chr3:48318527	chr3:48256350~48256938:-
BRCA	cis	rs7617773	0.78	rs11714176	ENSG00000229759.1	MRPS18AP1	16.29	2.52e-53	6.57e-50	0.59	0.45	Coronary artery disease;	chr3:48319372	chr3:48256350~48256938:-
BRCA	cis	rs1431005	0.964	rs59345911	ENSG00000250620.1	RP11-91J3.3	16.29	2.64e-53	6.88e-50	0.58	0.45	Response to statin therapy;	chr4:187436078	chr4:187413564~187415697:+
BRCA	cis	rs8062405	0.698	rs7188071	ENSG00000259982.1	CDC37P1	-16.28	2.81e-53	7.3e-50	-0.58	-0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28906323	chr16:28700294~28701540:-
BRCA	cis	rs1153858	1	rs11070453	ENSG00000259520.4	CTD-2651B20.3	-16.28	2.86e-53	7.42e-50	-0.6	-0.45	Homoarginine levels;	chr15:45352956	chr15:45251580~45279251:-
BRCA	cis	rs1153858	1	rs12593230	ENSG00000259520.4	CTD-2651B20.3	-16.28	2.86e-53	7.42e-50	-0.6	-0.45	Homoarginine levels;	chr15:45354770	chr15:45251580~45279251:-
BRCA	cis	rs8062405	0.824	rs240702	ENSG00000259982.1	CDC37P1	16.28	3.04e-53	7.88e-50	0.55	0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28520032	chr16:28700294~28701540:-
BRCA	cis	rs17507216	0.718	rs72751657	ENSG00000278603.1	RP13-608F4.5	16.27	3.29e-53	8.53e-50	0.8	0.45	Excessive daytime sleepiness;	chr15:82581259	chr15:82472203~82472426:+
BRCA	cis	rs6452524	0.569	rs7720588	ENSG00000249664.1	CTD-2227C6.2	16.27	3.4e-53	8.82e-50	0.56	0.45	Hypertension (SNP x SNP interaction);	chr5:83081107	chr5:83012285~83013109:-
BRCA	cis	rs7617773	0.78	rs34630841	ENSG00000229759.1	MRPS18AP1	16.26	3.6e-53	9.33e-50	0.59	0.45	Coronary artery disease;	chr3:48301771	chr3:48256350~48256938:-
BRCA	cis	rs2739330	0.76	rs1002286	ENSG00000231271.1	AP000350.8	-16.26	3.66e-53	9.48e-50	-0.57	-0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23949918~23954042:+
BRCA	cis	rs992157	0.835	rs7559416	ENSG00000261338.2	RP11-378A13.1	-16.26	3.93e-53	1.02e-49	-0.47	-0.45	Colorectal cancer;	chr2:218285488	chr2:218255319~218257366:+
BRCA	cis	rs1426063	0.614	rs17199632	ENSG00000260265.1	RP11-44F21.5	16.26	3.98e-53	1.03e-49	0.99	0.45	QT interval;	chr4:75103663	chr4:75081702~75084717:-
BRCA	cis	rs1153858	1	rs7163720	ENSG00000259520.4	CTD-2651B20.3	-16.26	3.99e-53	1.03e-49	-0.59	-0.45	Homoarginine levels;	chr15:45347176	chr15:45251580~45279251:-
BRCA	cis	rs1426063	0.614	rs78784058	ENSG00000260265.1	RP11-44F21.5	16.25	4.32e-53	1.12e-49	0.96	0.45	QT interval;	chr4:75108738	chr4:75081702~75084717:-
BRCA	cis	rs7617773	0.817	rs3731497	ENSG00000229759.1	MRPS18AP1	16.25	4.51e-53	1.17e-49	0.58	0.45	Coronary artery disease;	chr3:48185063	chr3:48256350~48256938:-
BRCA	cis	rs2882667	0.858	rs7724108	ENSG00000253404.1	AC034243.1	-16.25	4.55e-53	1.17e-49	-0.61	-0.45	Age-related hearing impairment (SNP x SNP interaction);	chr5:139075233	chr5:138744434~138753309:-
BRCA	cis	rs7301826	0.651	rs10848209	ENSG00000256299.1	RP11-989F5.3	-16.24	4.88e-53	1.26e-49	-0.51	-0.45	Plasma plasminogen activator levels;	chr12:130826727	chr12:130810821~130812622:-
BRCA	cis	rs7617773	0.78	rs36075665	ENSG00000229759.1	MRPS18AP1	16.23	5.21e-53	1.34e-49	0.59	0.45	Coronary artery disease;	chr3:48301597	chr3:48256350~48256938:-
BRCA	cis	rs7617773	0.78	rs4511916	ENSG00000229759.1	MRPS18AP1	16.23	5.45e-53	1.4e-49	0.59	0.45	Coronary artery disease;	chr3:48308876	chr3:48256350~48256938:-
BRCA	cis	rs7617773	0.815	rs6793150	ENSG00000229759.1	MRPS18AP1	16.23	5.45e-53	1.4e-49	0.59	0.45	Coronary artery disease;	chr3:48310070	chr3:48256350~48256938:-
BRCA	cis	rs7617773	0.78	rs6793239	ENSG00000229759.1	MRPS18AP1	16.23	5.45e-53	1.4e-49	0.59	0.45	Coronary artery disease;	chr3:48310128	chr3:48256350~48256938:-
BRCA	cis	rs7617773	0.78	rs6782166	ENSG00000229759.1	MRPS18AP1	16.23	5.45e-53	1.4e-49	0.59	0.45	Coronary artery disease;	chr3:48310193	chr3:48256350~48256938:-
BRCA	cis	rs7617773	0.78	rs4130522	ENSG00000229759.1	MRPS18AP1	16.23	5.45e-53	1.4e-49	0.59	0.45	Coronary artery disease;	chr3:48310823	chr3:48256350~48256938:-
BRCA	cis	rs7617773	0.78	rs13081169	ENSG00000229759.1	MRPS18AP1	16.23	5.45e-53	1.4e-49	0.59	0.45	Coronary artery disease;	chr3:48315307	chr3:48256350~48256938:-
BRCA	cis	rs1426063	0.614	rs75345649	ENSG00000260265.1	RP11-44F21.5	16.23	5.53e-53	1.42e-49	1	0.45	QT interval;	chr4:75100963	chr4:75081702~75084717:-
BRCA	cis	rs1426063	0.614	rs77333523	ENSG00000260265.1	RP11-44F21.5	16.23	5.53e-53	1.42e-49	1	0.45	QT interval;	chr4:75101024	chr4:75081702~75084717:-
BRCA	cis	rs1153858	1	rs7167900	ENSG00000259520.4	CTD-2651B20.3	-16.23	5.74e-53	1.47e-49	-0.59	-0.45	Homoarginine levels;	chr15:45347273	chr15:45251580~45279251:-
BRCA	cis	rs7617773	0.815	rs7624450	ENSG00000229759.1	MRPS18AP1	16.23	5.77e-53	1.48e-49	0.59	0.45	Coronary artery disease;	chr3:48308885	chr3:48256350~48256938:-
BRCA	cis	rs1153858	1	rs12591058	ENSG00000259520.4	CTD-2651B20.3	-16.22	6.02e-53	1.55e-49	-0.59	-0.45	Homoarginine levels;	chr15:45347974	chr15:45251580~45279251:-
BRCA	cis	rs4853012	0.838	rs12619982	ENSG00000217702.2	RP11-287D1.4	16.22	6.03e-53	1.55e-49	0.69	0.45	Gestational age at birth (maternal effect);	chr2:74128895	chr2:74130583~74135395:+
BRCA	cis	rs1153858	0.725	rs74572151	ENSG00000259520.4	CTD-2651B20.3	-16.22	6.05e-53	1.55e-49	-0.6	-0.45	Homoarginine levels;	chr15:45355328	chr15:45251580~45279251:-
BRCA	cis	rs8062405	1	rs8062405	ENSG00000259982.1	CDC37P1	-16.22	6.18e-53	1.59e-49	-0.55	-0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28826585	chr16:28700294~28701540:-
BRCA	cis	rs2882667	0.858	rs11741150	ENSG00000253404.1	AC034243.1	16.22	6.41e-53	1.65e-49	0.61	0.45	Age-related hearing impairment (SNP x SNP interaction);	chr5:139095768	chr5:138744434~138753309:-
BRCA	cis	rs7617773	0.78	rs7632297	ENSG00000229759.1	MRPS18AP1	16.22	6.53e-53	1.68e-49	0.59	0.45	Coronary artery disease;	chr3:48306673	chr3:48256350~48256938:-
BRCA	cis	rs7617773	0.78	rs35297395	ENSG00000229759.1	MRPS18AP1	16.22	6.57e-53	1.68e-49	0.59	0.45	Coronary artery disease;	chr3:48301392	chr3:48256350~48256938:-
BRCA	cis	rs507080	0.885	rs693037	ENSG00000255422.1	AP002954.4	-16.22	6.58e-53	1.69e-49	-0.56	-0.45	Serum metabolite levels;	chr11:118682617	chr11:118704607~118750263:+
BRCA	cis	rs2882667	0.858	rs66839813	ENSG00000253404.1	AC034243.1	16.2	7.84e-53	2e-49	0.6	0.45	Age-related hearing impairment (SNP x SNP interaction);	chr5:139106633	chr5:138744434~138753309:-
BRCA	cis	rs6964833	1	rs17515241	ENSG00000123965.13	PMS2P5	-16.2	8.2e-53	2.09e-49	-0.73	-0.45	Menarche (age at onset);	chr7:74717695	chr7:74894116~74897835:+
BRCA	cis	rs7617773	0.78	rs13082859	ENSG00000229759.1	MRPS18AP1	16.2	8.25e-53	2.1e-49	0.59	0.45	Coronary artery disease;	chr3:48303185	chr3:48256350~48256938:-
BRCA	cis	rs7617773	0.78	rs35778847	ENSG00000229759.1	MRPS18AP1	16.2	8.25e-53	2.1e-49	0.59	0.45	Coronary artery disease;	chr3:48305495	chr3:48256350~48256938:-
BRCA	cis	rs7617773	0.78	rs34749846	ENSG00000229759.1	MRPS18AP1	16.2	8.25e-53	2.1e-49	0.59	0.45	Coronary artery disease;	chr3:48305678	chr3:48256350~48256938:-
BRCA	cis	rs7617773	0.78	rs79089926	ENSG00000229759.1	MRPS18AP1	16.2	8.25e-53	2.1e-49	0.59	0.45	Coronary artery disease;	chr3:48307074	chr3:48256350~48256938:-
BRCA	cis	rs7617773	0.78	rs36121690	ENSG00000229759.1	MRPS18AP1	16.2	8.36e-53	2.13e-49	0.59	0.45	Coronary artery disease;	chr3:48304021	chr3:48256350~48256938:-
BRCA	cis	rs7617773	0.746	rs6796343	ENSG00000229759.1	MRPS18AP1	16.2	8.46e-53	2.16e-49	0.58	0.45	Coronary artery disease;	chr3:48240531	chr3:48256350~48256938:-
BRCA	cis	rs7617773	0.78	rs35190747	ENSG00000229759.1	MRPS18AP1	16.2	8.63e-53	2.2e-49	0.59	0.45	Coronary artery disease;	chr3:48301800	chr3:48256350~48256938:-
BRCA	cis	rs7617773	0.78	rs4511915	ENSG00000229759.1	MRPS18AP1	16.2	8.63e-53	2.2e-49	0.59	0.45	Coronary artery disease;	chr3:48302368	chr3:48256350~48256938:-
BRCA	cis	rs7617773	0.78	rs13066758	ENSG00000229759.1	MRPS18AP1	16.2	8.63e-53	2.2e-49	0.59	0.45	Coronary artery disease;	chr3:48302387	chr3:48256350~48256938:-
BRCA	cis	rs7617773	0.78	rs4392440	ENSG00000229759.1	MRPS18AP1	16.2	8.63e-53	2.2e-49	0.59	0.45	Coronary artery disease;	chr3:48302430	chr3:48256350~48256938:-
BRCA	cis	rs7617773	0.743	rs7621785	ENSG00000229759.1	MRPS18AP1	16.2	8.67e-53	2.21e-49	0.59	0.45	Coronary artery disease;	chr3:48302218	chr3:48256350~48256938:-
BRCA	cis	rs2455601	0.638	rs11042148	ENSG00000254860.4	TMEM9B-AS1	16.19	9e-53	2.29e-49	0.5	0.45	Schizophrenia;	chr11:8987127	chr11:8964675~8977527:+
BRCA	cis	rs9399137	0.529	rs7739722	ENSG00000232876.1	CTA-212D2.2	-16.19	9.37e-53	2.38e-49	-0.56	-0.45	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134961087	chr6:135055033~135060550:+
BRCA	cis	rs2455601	0.638	rs3815991	ENSG00000254860.4	TMEM9B-AS1	-16.19	9.83e-53	2.5e-49	-0.52	-0.45	Schizophrenia;	chr11:8986122	chr11:8964675~8977527:+
BRCA	cis	rs7617773	0.78	rs7653152	ENSG00000229759.1	MRPS18AP1	16.17	1.24e-52	3.14e-49	0.6	0.45	Coronary artery disease;	chr3:48320607	chr3:48256350~48256938:-
BRCA	cis	rs1426063	0.614	rs17000262	ENSG00000260265.1	RP11-44F21.5	16.17	1.25e-52	3.18e-49	0.93	0.45	QT interval;	chr4:75108836	chr4:75081702~75084717:-
BRCA	cis	rs62229266	0.659	rs2026259	ENSG00000231106.2	LINC01436	16.17	1.27e-52	3.22e-49	0.49	0.45	Mitral valve prolapse;	chr21:36058329	chr21:36005338~36007838:+
BRCA	cis	rs1153858	1	rs7169587	ENSG00000259520.4	CTD-2651B20.3	-16.16	1.33e-52	3.36e-49	-0.59	-0.45	Homoarginine levels;	chr15:45348181	chr15:45251580~45279251:-
BRCA	cis	rs2882667	0.755	rs55650316	ENSG00000253404.1	AC034243.1	16.16	1.38e-52	3.48e-49	0.62	0.45	Age-related hearing impairment (SNP x SNP interaction);	chr5:139131603	chr5:138744434~138753309:-
BRCA	cis	rs7301826	0.571	rs4759788	ENSG00000256299.1	RP11-989F5.3	-16.15	1.5e-52	3.79e-49	-0.51	-0.45	Plasma plasminogen activator levels;	chr12:130811769	chr12:130810821~130812622:-
BRCA	cis	rs1426063	0.614	rs17000264	ENSG00000260265.1	RP11-44F21.5	16.15	1.55e-52	3.9e-49	0.95	0.45	QT interval;	chr4:75108962	chr4:75081702~75084717:-
BRCA	cis	rs2729354	0.909	rs2729374	ENSG00000265566.2	RN7SL605P	-16.14	1.68e-52	4.23e-49	-0.71	-0.45	Blood protein levels;	chr11:57559454	chr11:57528085~57528365:-
BRCA	cis	rs2882667	0.858	rs13170388	ENSG00000253404.1	AC034243.1	16.14	1.85e-52	4.66e-49	0.61	0.45	Age-related hearing impairment (SNP x SNP interaction);	chr5:139101176	chr5:138744434~138753309:-
BRCA	cis	rs1153858	0.943	rs28605551	ENSG00000259520.4	CTD-2651B20.3	-16.13	2.14e-52	5.37e-49	-0.59	-0.45	Homoarginine levels;	chr15:45349522	chr15:45251580~45279251:-
BRCA	cis	rs62229266	0.839	rs11702763	ENSG00000231106.2	LINC01436	16.12	2.19e-52	5.5e-49	0.53	0.45	Mitral valve prolapse;	chr21:36098406	chr21:36005338~36007838:+
BRCA	cis	rs7301826	0.557	rs7953184	ENSG00000256299.1	RP11-989F5.3	16.12	2.41e-52	6.02e-49	0.51	0.45	Plasma plasminogen activator levels;	chr12:130800307	chr12:130810821~130812622:-
BRCA	cis	rs2882667	0.858	rs13177503	ENSG00000253404.1	AC034243.1	16.11	2.67e-52	6.68e-49	0.61	0.45	Age-related hearing impairment (SNP x SNP interaction);	chr5:139097070	chr5:138744434~138753309:-
BRCA	cis	rs7617773	0.78	rs11718350	ENSG00000229759.1	MRPS18AP1	16.11	2.69e-52	6.73e-49	0.59	0.45	Coronary artery disease;	chr3:48319502	chr3:48256350~48256938:-
BRCA	cis	rs3814244	0.751	rs12832728	ENSG00000255733.4	IFNG-AS1	-16.1	2.84e-52	7.1e-49	-0.36	-0.45	Itch intensity from mosquito bite adjusted by bite size;	chr12:68026623	chr12:67989445~68234686:+
BRCA	cis	rs1431005	1	rs1431005	ENSG00000250620.1	RP11-91J3.3	-16.09	3.33e-52	8.29e-49	-0.56	-0.45	Response to statin therapy;	chr4:187424214	chr4:187413564~187415697:+
BRCA	cis	rs507080	0.922	rs525485	ENSG00000255422.1	AP002954.4	-16.09	3.43e-52	8.53e-49	-0.56	-0.45	Serum metabolite levels;	chr11:118685045	chr11:118704607~118750263:+
BRCA	cis	rs7617773	0.78	rs3197223	ENSG00000229759.1	MRPS18AP1	16.09	3.53e-52	8.77e-49	0.59	0.45	Coronary artery disease;	chr3:48294367	chr3:48256350~48256938:-
BRCA	cis	rs2882667	0.858	rs13174479	ENSG00000253404.1	AC034243.1	16.09	3.58e-52	8.91e-49	0.6	0.45	Age-related hearing impairment (SNP x SNP interaction);	chr5:139108481	chr5:138744434~138753309:-
BRCA	cis	rs8062405	0.72	rs9926245	ENSG00000259982.1	CDC37P1	16.09	3.6e-52	8.95e-49	0.54	0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28544385	chr16:28700294~28701540:-
BRCA	cis	rs7617773	0.817	rs3731555	ENSG00000229759.1	MRPS18AP1	16.08	3.64e-52	9.04e-49	0.58	0.45	Coronary artery disease;	chr3:48164612	chr3:48256350~48256938:-
BRCA	cis	rs7617773	0.78	rs13067450	ENSG00000229759.1	MRPS18AP1	16.07	4.18e-52	1.04e-48	0.58	0.45	Coronary artery disease;	chr3:48295716	chr3:48256350~48256938:-
BRCA	cis	rs7617773	0.78	rs4479622	ENSG00000229759.1	MRPS18AP1	16.07	4.18e-52	1.04e-48	0.58	0.45	Coronary artery disease;	chr3:48296683	chr3:48256350~48256938:-
BRCA	cis	rs7617773	0.78	rs34946886	ENSG00000229759.1	MRPS18AP1	16.07	4.18e-52	1.04e-48	0.58	0.45	Coronary artery disease;	chr3:48296997	chr3:48256350~48256938:-
BRCA	cis	rs7617773	0.78	rs34589064	ENSG00000229759.1	MRPS18AP1	16.07	4.18e-52	1.04e-48	0.58	0.45	Coronary artery disease;	chr3:48298059	chr3:48256350~48256938:-
BRCA	cis	rs7617773	0.78	rs2541	ENSG00000229759.1	MRPS18AP1	16.07	4.18e-52	1.04e-48	0.58	0.45	Coronary artery disease;	chr3:48298128	chr3:48256350~48256938:-
BRCA	cis	rs7617773	0.78	rs13085251	ENSG00000229759.1	MRPS18AP1	16.07	4.18e-52	1.04e-48	0.58	0.45	Coronary artery disease;	chr3:48298555	chr3:48256350~48256938:-
BRCA	cis	rs1153858	1	rs4775909	ENSG00000259520.4	CTD-2651B20.3	-16.07	4.29e-52	1.06e-48	-0.59	-0.45	Homoarginine levels;	chr15:45350844	chr15:45251580~45279251:-
BRCA	cis	rs7617773	0.674	rs13069029	ENSG00000229759.1	MRPS18AP1	16.07	4.5e-52	1.12e-48	0.59	0.45	Coronary artery disease;	chr3:48313534	chr3:48256350~48256938:-
BRCA	cis	rs8062405	0.789	rs2106480	ENSG00000259982.1	CDC37P1	16.06	4.78e-52	1.18e-48	0.54	0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28526650	chr16:28700294~28701540:-
BRCA	cis	rs8037818	1	rs4643284	ENSG00000276724.1	RP11-1000B6.7	-16.05	5.56e-52	1.37e-48	-0.6	-0.45	Obesity-related traits;	chr15:32639897	chr15:32583612~32584312:+
BRCA	cis	rs7617773	0.78	rs77044321	ENSG00000229759.1	MRPS18AP1	16.05	5.79e-52	1.43e-48	0.59	0.45	Coronary artery disease;	chr3:48307824	chr3:48256350~48256938:-
BRCA	cis	rs7617773	0.743	rs13081633	ENSG00000229759.1	MRPS18AP1	16.05	5.79e-52	1.43e-48	0.59	0.45	Coronary artery disease;	chr3:48315791	chr3:48256350~48256938:-
BRCA	cis	rs2729354	0.953	rs2649650	ENSG00000265566.2	RN7SL605P	-16.05	5.85e-52	1.44e-48	-0.7	-0.45	Blood protein levels;	chr11:57560094	chr11:57528085~57528365:-
BRCA	cis	rs12022452	0.506	rs11208363	ENSG00000238287.1	RP11-656D10.3	-16.04	6.32e-52	1.55e-48	-0.69	-0.45	Age-related hearing impairment (SNP x SNP interaction);	chr1:40544782	chr1:40493157~40508661:-
BRCA	cis	rs6964833	0.935	rs34762099	ENSG00000123965.13	PMS2P5	16.04	6.51e-52	1.6e-48	0.73	0.44	Menarche (age at onset);	chr7:74636378	chr7:74894116~74897835:+
BRCA	cis	rs8062405	1	rs80275162	ENSG00000259982.1	CDC37P1	16.04	6.83e-52	1.67e-48	0.57	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28852196	chr16:28700294~28701540:-
BRCA	cis	rs2487048	0.725	rs2422493	ENSG00000226334.1	RP11-217B7.2	-16.03	7.01e-52	1.72e-48	-0.57	-0.44	Intraocular pressure;	chr9:104928714	chr9:104927553~104928892:+
BRCA	cis	rs7617773	0.817	rs13100815	ENSG00000229759.1	MRPS18AP1	16.02	8.87e-52	2.17e-48	0.58	0.44	Coronary artery disease;	chr3:48245959	chr3:48256350~48256938:-
BRCA	cis	rs8062405	0.824	rs4788085	ENSG00000259982.1	CDC37P1	16	1.11e-51	2.71e-48	0.54	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28523682	chr16:28700294~28701540:-
BRCA	cis	rs8062405	0.824	rs28772958	ENSG00000259982.1	CDC37P1	16	1.11e-51	2.71e-48	0.54	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28523984	chr16:28700294~28701540:-
BRCA	cis	rs7617773	0.746	rs7619865	ENSG00000229759.1	MRPS18AP1	16	1.13e-51	2.76e-48	0.52	0.44	Coronary artery disease;	chr3:48329090	chr3:48256350~48256938:-
BRCA	cis	rs2487048	0.761	rs2980083	ENSG00000226334.1	RP11-217B7.2	-15.99	1.31e-51	3.19e-48	-0.57	-0.44	Intraocular pressure;	chr9:104929081	chr9:104927553~104928892:+
BRCA	cis	rs2882667	0.858	rs11948429	ENSG00000253404.1	AC034243.1	15.97	1.5e-51	3.65e-48	0.6	0.44	Age-related hearing impairment (SNP x SNP interaction);	chr5:139122895	chr5:138744434~138753309:-
BRCA	cis	rs2729354	1	rs2848630	ENSG00000265566.2	RN7SL605P	-15.97	1.52e-51	3.7e-48	-0.7	-0.44	Blood protein levels;	chr11:57589434	chr11:57528085~57528365:-
BRCA	cis	rs2739330	0.76	rs5751761	ENSG00000250470.1	AP000351.3	-15.97	1.58e-51	3.83e-48	-0.54	-0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23976904~23977585:-
BRCA	cis	rs6452524	0.534	rs10514246	ENSG00000249664.1	CTD-2227C6.2	15.97	1.6e-51	3.9e-48	0.55	0.44	Hypertension (SNP x SNP interaction);	chr5:83069979	chr5:83012285~83013109:-
BRCA	cis	rs2882667	0.858	rs2043271	ENSG00000253404.1	AC034243.1	15.97	1.65e-51	3.99e-48	0.6	0.44	Age-related hearing impairment (SNP x SNP interaction);	chr5:139123419	chr5:138744434~138753309:-
BRCA	cis	rs4853012	0.838	rs60705299	ENSG00000217702.2	RP11-287D1.4	15.97	1.65e-51	4e-48	0.64	0.44	Gestational age at birth (maternal effect);	chr2:74118243	chr2:74130583~74135395:+
BRCA	cis	rs1431005	0.892	rs72725288	ENSG00000250620.1	RP11-91J3.3	15.96	1.93e-51	4.69e-48	0.56	0.44	Response to statin therapy;	chr4:187477411	chr4:187413564~187415697:+
BRCA	cis	rs7617773	0.817	rs34225441	ENSG00000229759.1	MRPS18AP1	15.95	2.09e-51	5.06e-48	0.58	0.44	Coronary artery disease;	chr3:48267401	chr3:48256350~48256938:-
BRCA	cis	rs1153858	1	rs9783731	ENSG00000259520.4	CTD-2651B20.3	15.95	2.19e-51	5.31e-48	0.58	0.44	Homoarginine levels;	chr15:45350686	chr15:45251580~45279251:-
BRCA	cis	rs35160687	0.901	rs7571424	ENSG00000273080.1	RP11-301O19.1	15.94	2.29e-51	5.53e-48	0.5	0.44	Night sleep phenotypes;	chr2:86312037	chr2:86195590~86196049:+
BRCA	cis	rs1431005	0.892	rs72725289	ENSG00000250620.1	RP11-91J3.3	15.94	2.35e-51	5.68e-48	0.56	0.44	Response to statin therapy;	chr4:187477579	chr4:187413564~187415697:+
BRCA	cis	rs2729354	1	rs2729355	ENSG00000265566.2	RN7SL605P	-15.94	2.39e-51	5.77e-48	-0.7	-0.44	Blood protein levels;	chr11:57586510	chr11:57528085~57528365:-
BRCA	cis	rs17507216	0.588	rs28864981	ENSG00000278603.1	RP13-608F4.5	15.94	2.4e-51	5.78e-48	0.77	0.44	Excessive daytime sleepiness;	chr15:82695420	chr15:82472203~82472426:+
BRCA	cis	rs17507216	0.628	rs8032321	ENSG00000278603.1	RP13-608F4.5	15.94	2.4e-51	5.78e-48	0.77	0.44	Excessive daytime sleepiness;	chr15:82698956	chr15:82472203~82472426:+
BRCA	cis	rs17507216	0.628	rs8040488	ENSG00000278603.1	RP13-608F4.5	15.94	2.4e-51	5.78e-48	0.77	0.44	Excessive daytime sleepiness;	chr15:82699081	chr15:82472203~82472426:+
BRCA	cis	rs1577917	1	rs12190598	ENSG00000203875.9	SNHG5	-15.94	2.48e-51	5.98e-48	-0.54	-0.44	Response to antipsychotic treatment;	chr6:85976356	chr6:85660950~85678736:-
BRCA	cis	rs7617773	0.643	rs78159520	ENSG00000229759.1	MRPS18AP1	15.94	2.51e-51	6.04e-48	0.58	0.44	Coronary artery disease;	chr3:48307533	chr3:48256350~48256938:-
BRCA	cis	rs992157	0.835	rs2292555	ENSG00000261338.2	RP11-378A13.1	-15.93	2.77e-51	6.67e-48	-0.47	-0.44	Colorectal cancer;	chr2:218282159	chr2:218255319~218257366:+
BRCA	cis	rs7617773	0.78	rs13079728	ENSG00000229759.1	MRPS18AP1	15.92	2.99e-51	7.18e-48	0.58	0.44	Coronary artery disease;	chr3:48297870	chr3:48256350~48256938:-
BRCA	cis	rs9399137	0.507	rs4289677	ENSG00000232876.1	CTA-212D2.2	-15.91	3.46e-51	8.3e-48	-0.57	-0.44	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134954347	chr6:135055033~135060550:+
BRCA	cis	rs9399137	0.507	rs4520025	ENSG00000232876.1	CTA-212D2.2	-15.89	4.24e-51	1.01e-47	-0.55	-0.44	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134957481	chr6:135055033~135060550:+
BRCA	cis	rs801193	0.613	rs2016325	ENSG00000226824.5	RP4-756H11.3	15.89	4.37e-51	1.04e-47	0.54	0.44	Aortic root size;	chr7:66858513	chr7:66654538~66669855:+
BRCA	cis	rs17507216	0.718	rs28587782	ENSG00000278603.1	RP13-608F4.5	15.89	4.37e-51	1.05e-47	0.74	0.44	Excessive daytime sleepiness;	chr15:82576881	chr15:82472203~82472426:+
BRCA	cis	rs7617773	0.746	rs4371540	ENSG00000229759.1	MRPS18AP1	15.89	4.69e-51	1.12e-47	0.59	0.44	Coronary artery disease;	chr3:48312053	chr3:48256350~48256938:-
BRCA	cis	rs1577917	0.958	rs12208227	ENSG00000203875.9	SNHG5	-15.86	6.78e-51	1.61e-47	-0.54	-0.44	Response to antipsychotic treatment;	chr6:85961226	chr6:85660950~85678736:-
BRCA	cis	rs10256972	0.516	rs12702081	ENSG00000229043.2	AC091729.9	-15.86	6.87e-51	1.64e-47	-0.58	-0.44	Endometriosis;Longevity;	chr7:1101892	chr7:1160374~1165267:+
BRCA	cis	rs2729354	0.953	rs2649663	ENSG00000265566.2	RN7SL605P	-15.86	6.96e-51	1.66e-47	-0.69	-0.44	Blood protein levels;	chr11:57589832	chr11:57528085~57528365:-
BRCA	cis	rs992157	0.775	rs1877714	ENSG00000261338.2	RP11-378A13.1	-15.85	7.51e-51	1.79e-47	-0.47	-0.44	Colorectal cancer;	chr2:218270205	chr2:218255319~218257366:+
BRCA	cis	rs4853012	0.838	rs4452177	ENSG00000217702.2	RP11-287D1.4	15.85	7.93e-51	1.88e-47	0.64	0.44	Gestational age at birth (maternal effect);	chr2:74118079	chr2:74130583~74135395:+
BRCA	cis	rs992157	0.804	rs7559525	ENSG00000261338.2	RP11-378A13.1	-15.84	8.1e-51	1.92e-47	-0.47	-0.44	Colorectal cancer;	chr2:218285584	chr2:218255319~218257366:+
BRCA	cis	rs2882667	0.858	rs11959803	ENSG00000253404.1	AC034243.1	15.84	8.48e-51	2.01e-47	0.61	0.44	Age-related hearing impairment (SNP x SNP interaction);	chr5:139115626	chr5:138744434~138753309:-
BRCA	cis	rs9399137	0.561	rs11753985	ENSG00000232876.1	CTA-212D2.2	-15.84	8.64e-51	2.05e-47	-0.55	-0.44	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134959300	chr6:135055033~135060550:+
BRCA	cis	rs992157	0.835	rs13005100	ENSG00000261338.2	RP11-378A13.1	-15.84	8.83e-51	2.09e-47	-0.47	-0.44	Colorectal cancer;	chr2:218287044	chr2:218255319~218257366:+
BRCA	cis	rs992157	0.835	rs13031757	ENSG00000261338.2	RP11-378A13.1	-15.84	8.83e-51	2.09e-47	-0.47	-0.44	Colorectal cancer;	chr2:218287203	chr2:218255319~218257366:+
BRCA	cis	rs992157	0.866	rs2292554	ENSG00000261338.2	RP11-378A13.1	-15.84	8.88e-51	2.1e-47	-0.47	-0.44	Colorectal cancer;	chr2:218282145	chr2:218255319~218257366:+
BRCA	cis	rs6452524	0.935	rs7718284	ENSG00000249664.1	CTD-2227C6.2	-15.83	9.27e-51	2.2e-47	-0.52	-0.44	Hypertension (SNP x SNP interaction);	chr5:83082488	chr5:83012285~83013109:-
BRCA	cis	rs992157	0.775	rs7559428	ENSG00000261338.2	RP11-378A13.1	-15.83	9.86e-51	2.33e-47	-0.47	-0.44	Colorectal cancer;	chr2:218285515	chr2:218255319~218257366:+
BRCA	cis	rs11673344	0.562	rs256740	ENSG00000226686.6	LINC01535	-15.83	1.02e-50	2.42e-47	-0.59	-0.44	Obesity-related traits;	chr19:37365451	chr19:37251912~37265535:+
BRCA	cis	rs992157	0.835	rs11677953	ENSG00000261338.2	RP11-378A13.1	-15.82	1.11e-50	2.61e-47	-0.47	-0.44	Colorectal cancer;	chr2:218256940	chr2:218255319~218257366:+
BRCA	cis	rs11673344	0.58	rs320881	ENSG00000226686.6	LINC01535	15.82	1.17e-50	2.76e-47	0.59	0.44	Obesity-related traits;	chr19:37246948	chr19:37251912~37265535:+
BRCA	cis	rs4853012	0.941	rs60291089	ENSG00000217702.2	RP11-287D1.4	15.81	1.23e-50	2.89e-47	0.64	0.44	Gestational age at birth (maternal effect);	chr2:74117763	chr2:74130583~74135395:+
BRCA	cis	rs4853012	0.838	rs58759652	ENSG00000217702.2	RP11-287D1.4	15.81	1.23e-50	2.89e-47	0.64	0.44	Gestational age at birth (maternal effect);	chr2:74117775	chr2:74130583~74135395:+
BRCA	cis	rs2882667	0.858	rs11750382	ENSG00000253404.1	AC034243.1	-15.81	1.25e-50	2.95e-47	-0.6	-0.44	Age-related hearing impairment (SNP x SNP interaction);	chr5:139121305	chr5:138744434~138753309:-
BRCA	cis	rs7617773	0.78	rs11706277	ENSG00000229759.1	MRPS18AP1	15.8	1.37e-50	3.23e-47	0.59	0.44	Coronary artery disease;	chr3:48318943	chr3:48256350~48256938:-
BRCA	cis	rs992157	0.835	rs6729058	ENSG00000261338.2	RP11-378A13.1	-15.79	1.6e-50	3.77e-47	-0.47	-0.44	Colorectal cancer;	chr2:218283646	chr2:218255319~218257366:+
BRCA	cis	rs2882667	0.858	rs11242448	ENSG00000253404.1	AC034243.1	15.78	1.95e-50	4.58e-47	0.6	0.44	Age-related hearing impairment (SNP x SNP interaction);	chr5:139107465	chr5:138744434~138753309:-
BRCA	cis	rs992157	0.835	rs34353396	ENSG00000261338.2	RP11-378A13.1	-15.78	1.95e-50	4.59e-47	-0.47	-0.44	Colorectal cancer;	chr2:218289259	chr2:218255319~218257366:+
BRCA	cis	rs1153858	1	rs1554521	ENSG00000259520.4	CTD-2651B20.3	15.77	2.04e-50	4.78e-47	0.58	0.44	Homoarginine levels;	chr15:45371991	chr15:45251580~45279251:-
BRCA	cis	rs7617773	0.746	rs11713476	ENSG00000229759.1	MRPS18AP1	15.76	2.32e-50	5.45e-47	0.54	0.44	Coronary artery disease;	chr3:48333944	chr3:48256350~48256938:-
BRCA	cis	rs7617773	0.817	rs3729577	ENSG00000229759.1	MRPS18AP1	15.76	2.49e-50	5.84e-47	0.58	0.44	Coronary artery disease;	chr3:48187504	chr3:48256350~48256938:-
BRCA	cis	rs992157	0.835	rs12987219	ENSG00000261338.2	RP11-378A13.1	-15.75	2.55e-50	5.98e-47	-0.46	-0.44	Colorectal cancer;	chr2:218279426	chr2:218255319~218257366:+
BRCA	cis	rs2729354	0.953	rs1846567	ENSG00000265566.2	RN7SL605P	-15.75	2.67e-50	6.26e-47	-0.7	-0.44	Blood protein levels;	chr11:57590120	chr11:57528085~57528365:-
BRCA	cis	rs992157	0.835	rs10932769	ENSG00000261338.2	RP11-378A13.1	-15.75	2.76e-50	6.47e-47	-0.47	-0.44	Colorectal cancer;	chr2:218282522	chr2:218255319~218257366:+
BRCA	cis	rs10256972	0.568	rs1133043	ENSG00000229043.2	AC091729.9	-15.75	2.77e-50	6.48e-47	-0.57	-0.44	Endometriosis;Longevity;	chr7:1093669	chr7:1160374~1165267:+
BRCA	cis	rs2729354	0.953	rs2848625	ENSG00000265566.2	RN7SL605P	-15.74	2.88e-50	6.74e-47	-0.69	-0.44	Blood protein levels;	chr11:57563177	chr11:57528085~57528365:-
BRCA	cis	rs62229266	0.557	rs4817761	ENSG00000231106.2	LINC01436	15.74	2.93e-50	6.85e-47	0.52	0.44	Mitral valve prolapse;	chr21:36023258	chr21:36005338~36007838:+
BRCA	cis	rs11155671	0.53	rs7763849	ENSG00000216906.2	RP11-350J20.9	15.74	2.94e-50	6.88e-47	0.53	0.44	Testicular germ cell tumor;	chr6:149885244	chr6:149904243~149906418:+
BRCA	cis	rs7208859	0.573	rs11654035	ENSG00000263531.1	RP13-753N3.1	15.74	3.19e-50	7.46e-47	0.85	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809408	chr17:30863921~30864940:-
BRCA	cis	rs8062405	0.824	rs153106	ENSG00000259982.1	CDC37P1	15.73	3.34e-50	7.81e-47	0.53	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28515576	chr16:28700294~28701540:-
BRCA	cis	rs2882667	0.858	rs11951899	ENSG00000253404.1	AC034243.1	15.73	3.58e-50	8.36e-47	0.61	0.44	Age-related hearing impairment (SNP x SNP interaction);	chr5:139038621	chr5:138744434~138753309:-
BRCA	cis	rs4853012	0.838	rs6707729	ENSG00000217702.2	RP11-287D1.4	15.73	3.59e-50	8.38e-47	0.64	0.44	Gestational age at birth (maternal effect);	chr2:74117558	chr2:74130583~74135395:+
BRCA	cis	rs992157	0.835	rs4674282	ENSG00000261338.2	RP11-378A13.1	-15.73	3.67e-50	8.55e-47	-0.47	-0.44	Colorectal cancer;	chr2:218279507	chr2:218255319~218257366:+
BRCA	cis	rs2729354	1	rs2729354	ENSG00000265566.2	RN7SL605P	-15.72	3.84e-50	8.95e-47	-0.69	-0.44	Blood protein levels;	chr11:57588497	chr11:57528085~57528365:-
BRCA	cis	rs992157	0.717	rs11692780	ENSG00000261338.2	RP11-378A13.1	-15.72	3.86e-50	9e-47	-0.47	-0.44	Colorectal cancer;	chr2:218284440	chr2:218255319~218257366:+
BRCA	cis	rs2882667	0.754	rs11746434	ENSG00000253404.1	AC034243.1	15.71	4.33e-50	1.01e-46	0.6	0.44	Age-related hearing impairment (SNP x SNP interaction);	chr5:139099614	chr5:138744434~138753309:-
BRCA	cis	rs10256972	0.706	rs4285396	ENSG00000229043.2	AC091729.9	-15.71	4.46e-50	1.04e-46	-0.58	-0.44	Endometriosis;Longevity;	chr7:1084102	chr7:1160374~1165267:+
BRCA	cis	rs4853012	0.838	rs4563249	ENSG00000217702.2	RP11-287D1.4	15.7	5.05e-50	1.17e-46	0.63	0.44	Gestational age at birth (maternal effect);	chr2:74126889	chr2:74130583~74135395:+
BRCA	cis	rs992157	0.835	rs7585702	ENSG00000261338.2	RP11-378A13.1	-15.7	5.22e-50	1.21e-46	-0.46	-0.44	Colorectal cancer;	chr2:218281884	chr2:218255319~218257366:+
BRCA	cis	rs2729354	1	rs2511983	ENSG00000265566.2	RN7SL605P	-15.69	5.44e-50	1.26e-46	-0.68	-0.44	Blood protein levels;	chr11:57579401	chr11:57528085~57528365:-
BRCA	cis	rs2455601	0.573	rs2653573	ENSG00000254860.4	TMEM9B-AS1	15.69	5.91e-50	1.37e-46	0.45	0.44	Schizophrenia;	chr11:8968327	chr11:8964675~8977527:+
BRCA	cis	rs1976403	0.659	rs10799701	ENSG00000227001.3	NBPF2P	15.68	6.93e-50	1.6e-46	0.5	0.44	Liver enzyme levels (alkaline phosphatase);	chr1:21494497	chr1:21424625~21427967:-
BRCA	cis	rs11673344	0.563	rs256744	ENSG00000226686.6	LINC01535	-15.67	7.41e-50	1.72e-46	-0.58	-0.44	Obesity-related traits;	chr19:37364586	chr19:37251912~37265535:+
BRCA	cis	rs62229266	0.557	rs4817760	ENSG00000231106.2	LINC01436	15.67	7.49e-50	1.74e-46	0.52	0.44	Mitral valve prolapse;	chr21:36023003	chr21:36005338~36007838:+
BRCA	cis	rs8062405	0.823	rs7202948	ENSG00000259982.1	CDC37P1	15.67	7.62e-50	1.76e-46	0.53	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28546968	chr16:28700294~28701540:-
BRCA	cis	rs2882667	0.824	rs13189485	ENSG00000253404.1	AC034243.1	15.66	7.97e-50	1.84e-46	0.61	0.44	Age-related hearing impairment (SNP x SNP interaction);	chr5:139139712	chr5:138744434~138753309:-
BRCA	cis	rs992157	0.835	rs10932768	ENSG00000261338.2	RP11-378A13.1	-15.66	8.32e-50	1.93e-46	-0.47	-0.44	Colorectal cancer;	chr2:218281476	chr2:218255319~218257366:+
BRCA	cis	rs2581828	0.656	rs2581800	ENSG00000242142.1	SERBP1P3	15.66	8.33e-50	1.93e-46	0.48	0.44	Crohn's disease;	chr3:53075336	chr3:53064283~53065091:-
BRCA	cis	rs1153858	1	rs60476496	ENSG00000259520.4	CTD-2651B20.3	-15.65	1.03e-49	2.37e-46	-0.59	-0.44	Homoarginine levels;	chr15:45421603	chr15:45251580~45279251:-
BRCA	cis	rs992157	0.717	rs3817266	ENSG00000261338.2	RP11-378A13.1	-15.64	1.06e-49	2.45e-46	-0.46	-0.44	Colorectal cancer;	chr2:218277871	chr2:218255319~218257366:+
BRCA	cis	rs992157	0.835	rs2292551	ENSG00000261338.2	RP11-378A13.1	-15.64	1.06e-49	2.45e-46	-0.46	-0.44	Colorectal cancer;	chr2:218278506	chr2:218255319~218257366:+
BRCA	cis	rs9660180	0.62	rs3817856	ENSG00000268575.1	RP1-283E3.8	15.64	1.13e-49	2.61e-46	0.48	0.44	Body mass index;	chr1:1732392	chr1:1702736~1737688:-
BRCA	cis	rs11673344	0.642	rs11083420	ENSG00000226686.6	LINC01535	15.63	1.17e-49	2.71e-46	0.59	0.44	Obesity-related traits;	chr19:37317901	chr19:37251912~37265535:+
BRCA	cis	rs992157	0.731	rs1399132	ENSG00000261338.2	RP11-378A13.1	15.63	1.2e-49	2.77e-46	0.45	0.44	Colorectal cancer;	chr2:218295047	chr2:218255319~218257366:+
BRCA	cis	rs17507216	0.718	rs7165690	ENSG00000278603.1	RP13-608F4.5	15.62	1.4e-49	3.21e-46	0.74	0.44	Excessive daytime sleepiness;	chr15:82654804	chr15:82472203~82472426:+
BRCA	cis	rs17507216	0.628	rs4627310	ENSG00000278603.1	RP13-608F4.5	15.62	1.44e-49	3.31e-46	0.75	0.44	Excessive daytime sleepiness;	chr15:82708330	chr15:82472203~82472426:+
BRCA	cis	rs992157	0.835	rs2271543	ENSG00000261338.2	RP11-378A13.1	-15.62	1.48e-49	3.41e-46	-0.46	-0.44	Colorectal cancer;	chr2:218277768	chr2:218255319~218257366:+
BRCA	cis	rs6597981	0.675	rs4963120	ENSG00000279672.1	CMB9-55F22.1	-15.61	1.52e-49	3.48e-46	-0.49	-0.44	Breast cancer;	chr11:825777	chr11:779617~780755:+
BRCA	cis	rs992157	0.835	rs12987180	ENSG00000261338.2	RP11-378A13.1	-15.61	1.55e-49	3.56e-46	-0.46	-0.44	Colorectal cancer;	chr2:218279366	chr2:218255319~218257366:+
BRCA	cis	rs992157	0.835	rs4674283	ENSG00000261338.2	RP11-378A13.1	-15.61	1.55e-49	3.56e-46	-0.46	-0.44	Colorectal cancer;	chr2:218279531	chr2:218255319~218257366:+
BRCA	cis	rs2882667	0.756	rs11957953	ENSG00000253404.1	AC034243.1	15.6	1.82e-49	4.17e-46	0.61	0.44	Age-related hearing impairment (SNP x SNP interaction);	chr5:139143688	chr5:138744434~138753309:-
BRCA	cis	rs4853012	0.838	rs59570457	ENSG00000217702.2	RP11-287D1.4	15.59	2.06e-49	4.71e-46	0.64	0.43	Gestational age at birth (maternal effect);	chr2:74117155	chr2:74130583~74135395:+
BRCA	cis	rs992157	0.835	rs2045434	ENSG00000261338.2	RP11-378A13.1	-15.58	2.43e-49	5.53e-46	-0.46	-0.43	Colorectal cancer;	chr2:218279775	chr2:218255319~218257366:+
BRCA	cis	rs17507216	0.628	rs28371837	ENSG00000278603.1	RP13-608F4.5	15.57	2.79e-49	6.35e-46	0.75	0.43	Excessive daytime sleepiness;	chr15:82714435	chr15:82472203~82472426:+
BRCA	cis	rs4853012	0.793	rs6707619	ENSG00000217702.2	RP11-287D1.4	15.57	2.82e-49	6.41e-46	0.63	0.43	Gestational age at birth (maternal effect);	chr2:74117529	chr2:74130583~74135395:+
BRCA	cis	rs9660180	0.62	rs34298494	ENSG00000268575.1	RP1-283E3.8	15.56	2.84e-49	6.46e-46	0.49	0.43	Body mass index;	chr1:1731963	chr1:1702736~1737688:-
BRCA	cis	rs67311347	1	rs6801859	ENSG00000223797.4	ENTPD3-AS1	-15.56	2.86e-49	6.51e-46	-0.48	-0.43	Renal cell carcinoma;	chr3:40451727	chr3:40313802~40453329:-
BRCA	cis	rs4853012	0.838	rs72911122	ENSG00000217702.2	RP11-287D1.4	15.56	2.97e-49	6.74e-46	0.64	0.43	Gestational age at birth (maternal effect);	chr2:74116992	chr2:74130583~74135395:+
BRCA	cis	rs2455601	0.786	rs3763914	ENSG00000254860.4	TMEM9B-AS1	15.56	3.01e-49	6.83e-46	0.5	0.43	Schizophrenia;	chr11:8919156	chr11:8964675~8977527:+
BRCA	cis	rs8062405	0.965	rs8049439	ENSG00000259982.1	CDC37P1	15.56	3.1e-49	7.03e-46	0.52	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28826194	chr16:28700294~28701540:-
BRCA	cis	rs11673344	0.642	rs55926714	ENSG00000226686.6	LINC01535	15.56	3.1e-49	7.04e-46	0.58	0.43	Obesity-related traits;	chr19:37307974	chr19:37251912~37265535:+
BRCA	cis	rs6452524	0.532	rs27363	ENSG00000249664.1	CTD-2227C6.2	15.56	3.21e-49	7.29e-46	0.55	0.43	Hypertension (SNP x SNP interaction);	chr5:83040943	chr5:83012285~83013109:-
BRCA	cis	rs977987	0.806	rs1549306	ENSG00000261783.1	RP11-252K23.2	-15.55	3.36e-49	7.62e-46	-0.55	-0.43	Dupuytren's disease;	chr16:75381443	chr16:75379818~75381260:-
BRCA	cis	rs2882667	0.858	rs11744972	ENSG00000253404.1	AC034243.1	15.55	3.49e-49	7.9e-46	0.57	0.43	Age-related hearing impairment (SNP x SNP interaction);	chr5:139093100	chr5:138744434~138753309:-
BRCA	cis	rs7301826	1	rs7301826	ENSG00000256250.1	RP11-989F5.1	-15.54	3.73e-49	8.45e-46	-0.5	-0.43	Plasma plasminogen activator levels;	chr12:130806556	chr12:130810606~130812438:+
BRCA	cis	rs6452524	0.508	rs40214	ENSG00000249664.1	CTD-2227C6.2	-15.54	4.08e-49	9.22e-46	-0.52	-0.43	Hypertension (SNP x SNP interaction);	chr5:83000359	chr5:83012285~83013109:-
BRCA	cis	rs143626010	1	rs143626010	ENSG00000259982.1	CDC37P1	15.54	4.1e-49	9.26e-46	0.55	0.43	Mosquito bite size;	chr16:28528081	chr16:28700294~28701540:-
BRCA	cis	rs11123170	0.65	rs2289897	ENSG00000189223.12	PAX8-AS1	-15.53	4.36e-49	9.84e-46	-0.71	-0.43	Renal function-related traits (BUN);	chr2:113219877	chr2:113211522~113276581:+
BRCA	cis	rs1061377	1	rs10018049	ENSG00000249207.1	RP11-360F5.1	-15.53	4.44e-49	1e-45	-0.49	-0.43	Uric acid levels;	chr4:39115781	chr4:39112677~39126818:-
BRCA	cis	rs9399137	0.507	rs7748708	ENSG00000232876.1	CTA-212D2.2	-15.53	4.69e-49	1.06e-45	-0.54	-0.43	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134954004	chr6:135055033~135060550:+
BRCA	cis	rs1061377	1	rs35116118	ENSG00000249207.1	RP11-360F5.1	-15.52	4.78e-49	1.08e-45	-0.5	-0.43	Uric acid levels;	chr4:39127293	chr4:39112677~39126818:-
BRCA	cis	rs528808	1	rs528808	ENSG00000219755.1	RP1-199J3.5	15.52	4.81e-49	1.08e-45	0.67	0.43	Age-related hearing impairment;	chr6:99656413	chr6:99575712~99576456:+
BRCA	cis	rs35160687	0.901	rs6713456	ENSG00000273080.1	RP11-301O19.1	15.52	4.98e-49	1.12e-45	0.49	0.43	Night sleep phenotypes;	chr2:86280530	chr2:86195590~86196049:+
BRCA	cis	rs8062405	0.755	rs12447461	ENSG00000259982.1	CDC37P1	15.52	5.32e-49	1.2e-45	0.55	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28571620	chr16:28700294~28701540:-
BRCA	cis	rs8062405	0.755	rs111693583	ENSG00000259982.1	CDC37P1	15.52	5.32e-49	1.2e-45	0.55	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28572289	chr16:28700294~28701540:-
BRCA	cis	rs7617773	0.78	rs3731550	ENSG00000229759.1	MRPS18AP1	15.51	5.43e-49	1.22e-45	0.57	0.43	Coronary artery disease;	chr3:48165093	chr3:48256350~48256938:-
BRCA	cis	rs7617773	0.817	rs3731534	ENSG00000229759.1	MRPS18AP1	15.51	5.43e-49	1.22e-45	0.57	0.43	Coronary artery disease;	chr3:48170287	chr3:48256350~48256938:-
BRCA	cis	rs1976403	0.659	rs10799700	ENSG00000227001.3	NBPF2P	15.51	5.5e-49	1.24e-45	0.5	0.43	Liver enzyme levels (alkaline phosphatase);	chr1:21494475	chr1:21424625~21427967:-
BRCA	cis	rs1153858	0.943	rs8038342	ENSG00000259520.4	CTD-2651B20.3	-15.51	5.82e-49	1.31e-45	-0.57	-0.43	Homoarginine levels;	chr15:45359339	chr15:45251580~45279251:-
BRCA	cis	rs1153858	1	rs4774579	ENSG00000259520.4	CTD-2651B20.3	-15.51	5.82e-49	1.31e-45	-0.57	-0.43	Homoarginine levels;	chr15:45359605	chr15:45251580~45279251:-
BRCA	cis	rs992157	0.798	rs1017698	ENSG00000261338.2	RP11-378A13.1	-15.51	5.99e-49	1.35e-45	-0.45	-0.43	Colorectal cancer;	chr2:218305802	chr2:218255319~218257366:+
BRCA	cis	rs1061377	1	rs12499266	ENSG00000249207.1	RP11-360F5.1	15.51	6.05e-49	1.36e-45	0.49	0.43	Uric acid levels;	chr4:39118133	chr4:39112677~39126818:-
BRCA	cis	rs1061377	1	rs10030904	ENSG00000249207.1	RP11-360F5.1	-15.5	6.67e-49	1.5e-45	-0.49	-0.43	Uric acid levels;	chr4:39113603	chr4:39112677~39126818:-
BRCA	cis	rs8062405	0.691	rs11646653	ENSG00000259982.1	CDC37P1	-15.5	6.8e-49	1.52e-45	-0.54	-0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28910828	chr16:28700294~28701540:-
BRCA	cis	rs7208859	0.623	rs3794796	ENSG00000263531.1	RP13-753N3.1	15.5	6.82e-49	1.53e-45	0.84	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30803862	chr17:30863921~30864940:-
BRCA	cis	rs3931020	1	rs10874122	ENSG00000272864.1	RP11-17E13.2	-15.49	7.47e-49	1.67e-45	-0.55	-0.43	Resistin levels;	chr1:74770182	chr1:74698769~74699333:-
BRCA	cis	rs3931020	0.962	rs2185695	ENSG00000272864.1	RP11-17E13.2	-15.49	7.57e-49	1.69e-45	-0.56	-0.43	Resistin levels;	chr1:74792197	chr1:74698769~74699333:-
BRCA	cis	rs7301826	1	rs4759787	ENSG00000256250.1	RP11-989F5.1	-15.48	8.35e-49	1.87e-45	-0.49	-0.43	Plasma plasminogen activator levels;	chr12:130805635	chr12:130810606~130812438:+
BRCA	cis	rs7617773	0.709	rs4404473	ENSG00000229759.1	MRPS18AP1	15.48	8.56e-49	1.91e-45	0.59	0.43	Coronary artery disease;	chr3:48312136	chr3:48256350~48256938:-
BRCA	cis	rs7617773	0.817	rs3731513	ENSG00000229759.1	MRPS18AP1	15.47	8.89e-49	1.98e-45	0.57	0.43	Coronary artery disease;	chr3:48178047	chr3:48256350~48256938:-
BRCA	cis	rs1061377	1	rs2381284	ENSG00000249207.1	RP11-360F5.1	-15.47	8.9e-49	1.99e-45	-0.49	-0.43	Uric acid levels;	chr4:39117976	chr4:39112677~39126818:-
BRCA	cis	rs7301826	1	rs4759793	ENSG00000256250.1	RP11-989F5.1	-15.47	8.92e-49	1.99e-45	-0.49	-0.43	Plasma plasminogen activator levels;	chr12:130812693	chr12:130810606~130812438:+
BRCA	cis	rs1153858	1	rs7402650	ENSG00000259520.4	CTD-2651B20.3	-15.47	9.05e-49	2.02e-45	-0.59	-0.43	Homoarginine levels;	chr15:45409697	chr15:45251580~45279251:-
BRCA	cis	rs7301826	1	rs10773822	ENSG00000256250.1	RP11-989F5.1	-15.47	9.18e-49	2.05e-45	-0.49	-0.43	Plasma plasminogen activator levels;	chr12:130804562	chr12:130810606~130812438:+
BRCA	cis	rs8062405	0.824	rs7191618	ENSG00000259982.1	CDC37P1	15.47	9.46e-49	2.11e-45	0.52	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554346	chr16:28700294~28701540:-
BRCA	cis	rs1061377	1	rs10026775	ENSG00000249207.1	RP11-360F5.1	-15.47	9.71e-49	2.16e-45	-0.49	-0.43	Uric acid levels;	chr4:39115155	chr4:39112677~39126818:-
BRCA	cis	rs1061377	1	rs3733276	ENSG00000249207.1	RP11-360F5.1	-15.47	9.71e-49	2.16e-45	-0.49	-0.43	Uric acid levels;	chr4:39115291	chr4:39112677~39126818:-
BRCA	cis	rs1061377	1	rs3733277	ENSG00000249207.1	RP11-360F5.1	-15.47	9.71e-49	2.16e-45	-0.49	-0.43	Uric acid levels;	chr4:39115483	chr4:39112677~39126818:-
BRCA	cis	rs1061377	1	rs3733278	ENSG00000249207.1	RP11-360F5.1	-15.47	9.71e-49	2.16e-45	-0.49	-0.43	Uric acid levels;	chr4:39115615	chr4:39112677~39126818:-
BRCA	cis	rs1061377	1	rs3733279	ENSG00000249207.1	RP11-360F5.1	-15.47	9.71e-49	2.16e-45	-0.49	-0.43	Uric acid levels;	chr4:39115625	chr4:39112677~39126818:-
BRCA	cis	rs7301826	0.966	rs10734980	ENSG00000256250.1	RP11-989F5.1	-15.47	9.78e-49	2.18e-45	-0.49	-0.43	Plasma plasminogen activator levels;	chr12:130810081	chr12:130810606~130812438:+
BRCA	cis	rs1061377	0.965	rs7669376	ENSG00000249207.1	RP11-360F5.1	-15.46	1.03e-48	2.3e-45	-0.49	-0.43	Uric acid levels;	chr4:39116717	chr4:39112677~39126818:-
BRCA	cis	rs2455601	0.786	rs11042127	ENSG00000254860.4	TMEM9B-AS1	15.46	1.09e-48	2.43e-45	0.49	0.43	Schizophrenia;	chr11:8926039	chr11:8964675~8977527:+
BRCA	cis	rs7617773	0.78	rs7645425	ENSG00000229759.1	MRPS18AP1	15.46	1.12e-48	2.5e-45	0.57	0.43	Coronary artery disease;	chr3:48320879	chr3:48256350~48256938:-
BRCA	cis	rs7617773	0.743	rs11716371	ENSG00000229759.1	MRPS18AP1	15.46	1.12e-48	2.5e-45	0.57	0.43	Coronary artery disease;	chr3:48321260	chr3:48256350~48256938:-
BRCA	cis	rs7617773	0.78	rs6793223	ENSG00000229759.1	MRPS18AP1	15.46	1.12e-48	2.5e-45	0.57	0.43	Coronary artery disease;	chr3:48322611	chr3:48256350~48256938:-
BRCA	cis	rs7617773	0.78	rs11714944	ENSG00000229759.1	MRPS18AP1	15.46	1.12e-48	2.5e-45	0.57	0.43	Coronary artery disease;	chr3:48325481	chr3:48256350~48256938:-
BRCA	cis	rs7617773	0.78	rs7653336	ENSG00000229759.1	MRPS18AP1	15.46	1.12e-48	2.5e-45	0.57	0.43	Coronary artery disease;	chr3:48327974	chr3:48256350~48256938:-
BRCA	cis	rs1061377	1	rs13182	ENSG00000249207.1	RP11-360F5.1	-15.46	1.13e-48	2.5e-45	-0.49	-0.43	Uric acid levels;	chr4:39121293	chr4:39112677~39126818:-
BRCA	cis	rs8062405	0.755	rs7186573	ENSG00000259982.1	CDC37P1	15.45	1.18e-48	2.62e-45	0.54	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576068	chr16:28700294~28701540:-
BRCA	cis	rs8062405	0.755	rs62034325	ENSG00000259982.1	CDC37P1	15.45	1.19e-48	2.65e-45	0.55	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28527319	chr16:28700294~28701540:-
BRCA	cis	rs2581828	0.656	rs2336723	ENSG00000242142.1	SERBP1P3	15.44	1.3e-48	2.88e-45	0.48	0.43	Crohn's disease;	chr3:53072031	chr3:53064283~53065091:-
BRCA	cis	rs7617773	0.743	rs4632568	ENSG00000229759.1	MRPS18AP1	15.44	1.37e-48	3.05e-45	0.56	0.43	Coronary artery disease;	chr3:48326329	chr3:48256350~48256938:-
BRCA	cis	rs7617773	0.78	rs4541431	ENSG00000229759.1	MRPS18AP1	15.44	1.39e-48	3.09e-45	0.56	0.43	Coronary artery disease;	chr3:48323728	chr3:48256350~48256938:-
BRCA	cis	rs7617773	0.743	rs13071960	ENSG00000229759.1	MRPS18AP1	15.44	1.39e-48	3.09e-45	0.56	0.43	Coronary artery disease;	chr3:48326047	chr3:48256350~48256938:-
BRCA	cis	rs7617773	0.78	rs11130164	ENSG00000229759.1	MRPS18AP1	15.44	1.39e-48	3.09e-45	0.56	0.43	Coronary artery disease;	chr3:48327544	chr3:48256350~48256938:-
BRCA	cis	rs1061377	1	rs9998867	ENSG00000249207.1	RP11-360F5.1	-15.44	1.4e-48	3.09e-45	-0.49	-0.43	Uric acid levels;	chr4:39117542	chr4:39112677~39126818:-
BRCA	cis	rs1061377	0.803	rs6857761	ENSG00000249207.1	RP11-360F5.1	-15.44	1.46e-48	3.24e-45	-0.49	-0.43	Uric acid levels;	chr4:39118353	chr4:39112677~39126818:-
BRCA	cis	rs2455601	0.786	rs3751064	ENSG00000254860.4	TMEM9B-AS1	15.43	1.49e-48	3.29e-45	0.49	0.43	Schizophrenia;	chr11:8937356	chr11:8964675~8977527:+
BRCA	cis	rs7617773	0.747	rs34076262	ENSG00000229759.1	MRPS18AP1	15.43	1.56e-48	3.44e-45	0.56	0.43	Coronary artery disease;	chr3:48328926	chr3:48256350~48256938:-
BRCA	cis	rs1061377	0.932	rs35464499	ENSG00000249207.1	RP11-360F5.1	-15.43	1.58e-48	3.49e-45	-0.49	-0.43	Uric acid levels;	chr4:39127670	chr4:39112677~39126818:-
BRCA	cis	rs1061377	1	rs1036037	ENSG00000249207.1	RP11-360F5.1	-15.43	1.63e-48	3.6e-45	-0.49	-0.43	Uric acid levels;	chr4:39111272	chr4:39112677~39126818:-
BRCA	cis	rs1976403	0.633	rs1697422	ENSG00000227001.3	NBPF2P	15.42	1.79e-48	3.94e-45	0.5	0.43	Liver enzyme levels (alkaline phosphatase);	chr1:21495404	chr1:21424625~21427967:-
BRCA	cis	rs8062405	0.754	rs3859172	ENSG00000259982.1	CDC37P1	15.41	1.95e-48	4.31e-45	0.52	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554837	chr16:28700294~28701540:-
BRCA	cis	rs1153858	0.943	rs4774580	ENSG00000259520.4	CTD-2651B20.3	-15.41	2.05e-48	4.52e-45	-0.57	-0.43	Homoarginine levels;	chr15:45359888	chr15:45251580~45279251:-
BRCA	cis	rs1153858	1	rs8042786	ENSG00000259520.4	CTD-2651B20.3	-15.41	2.08e-48	4.58e-45	-0.58	-0.43	Homoarginine levels;	chr15:45411341	chr15:45251580~45279251:-
BRCA	cis	rs992157	0.796	rs55680399	ENSG00000261338.2	RP11-378A13.1	15.41	2.11e-48	4.65e-45	0.45	0.43	Colorectal cancer;	chr2:218295898	chr2:218255319~218257366:+
BRCA	cis	rs11673344	0.642	rs12462487	ENSG00000226686.6	LINC01535	15.4	2.19e-48	4.81e-45	0.57	0.43	Obesity-related traits;	chr19:37311211	chr19:37251912~37265535:+
BRCA	cis	rs3091242	0.9	rs669063	ENSG00000261349.1	RP3-465N24.5	-15.4	2.24e-48	4.92e-45	-0.48	-0.43	Erythrocyte sedimentation rate;	chr1:25394663	chr1:25266102~25267136:-
BRCA	cis	rs3931020	1	rs3931020	ENSG00000272864.1	RP11-17E13.2	-15.4	2.28e-48	5.01e-45	-0.54	-0.43	Resistin levels;	chr1:74769633	chr1:74698769~74699333:-
BRCA	cis	rs1061377	1	rs9997089	ENSG00000249207.1	RP11-360F5.1	-15.4	2.29e-48	5.04e-45	-0.49	-0.43	Uric acid levels;	chr4:39119263	chr4:39112677~39126818:-
BRCA	cis	rs1061377	1	rs28465556	ENSG00000249207.1	RP11-360F5.1	-15.4	2.29e-48	5.04e-45	-0.49	-0.43	Uric acid levels;	chr4:39119569	chr4:39112677~39126818:-
BRCA	cis	rs1061377	1	rs10027813	ENSG00000249207.1	RP11-360F5.1	-15.4	2.29e-48	5.04e-45	-0.49	-0.43	Uric acid levels;	chr4:39119818	chr4:39112677~39126818:-
BRCA	cis	rs1061377	1	rs9990755	ENSG00000249207.1	RP11-360F5.1	-15.4	2.29e-48	5.04e-45	-0.49	-0.43	Uric acid levels;	chr4:39119819	chr4:39112677~39126818:-
BRCA	cis	rs1061377	1	rs7676008	ENSG00000249207.1	RP11-360F5.1	-15.4	2.29e-48	5.04e-45	-0.49	-0.43	Uric acid levels;	chr4:39120154	chr4:39112677~39126818:-
BRCA	cis	rs1061377	1	rs7655122	ENSG00000249207.1	RP11-360F5.1	-15.4	2.29e-48	5.04e-45	-0.49	-0.43	Uric acid levels;	chr4:39120396	chr4:39112677~39126818:-
BRCA	cis	rs1153858	1	rs8032904	ENSG00000259520.4	CTD-2651B20.3	-15.39	2.61e-48	5.74e-45	-0.57	-0.43	Homoarginine levels;	chr15:45359111	chr15:45251580~45279251:-
BRCA	cis	rs1061377	1	rs2890659	ENSG00000249207.1	RP11-360F5.1	-15.39	2.63e-48	5.76e-45	-0.49	-0.43	Uric acid levels;	chr4:39125401	chr4:39112677~39126818:-
BRCA	cis	rs2882667	0.788	rs11959691	ENSG00000253404.1	AC034243.1	15.39	2.66e-48	5.83e-45	0.6	0.43	Age-related hearing impairment (SNP x SNP interaction);	chr5:139145399	chr5:138744434~138753309:-
BRCA	cis	rs17507216	0.718	rs17158403	ENSG00000278603.1	RP13-608F4.5	15.39	2.67e-48	5.86e-45	0.73	0.43	Excessive daytime sleepiness;	chr15:82572478	chr15:82472203~82472426:+
BRCA	cis	rs7301826	0.932	rs1007246	ENSG00000256250.1	RP11-989F5.1	-15.38	2.81e-48	6.16e-45	-0.49	-0.43	Plasma plasminogen activator levels;	chr12:130795585	chr12:130810606~130812438:+
BRCA	cis	rs992157	0.835	rs6707559	ENSG00000261338.2	RP11-378A13.1	15.38	3.1e-48	6.79e-45	0.45	0.43	Colorectal cancer;	chr2:218278050	chr2:218255319~218257366:+
BRCA	cis	rs17507216	0.628	rs28737193	ENSG00000278603.1	RP13-608F4.5	15.37	3.27e-48	7.15e-45	0.74	0.43	Excessive daytime sleepiness;	chr15:82701318	chr15:82472203~82472426:+
BRCA	cis	rs7301826	0.967	rs4759790	ENSG00000256250.1	RP11-989F5.1	-15.37	3.32e-48	7.27e-45	-0.49	-0.43	Plasma plasminogen activator levels;	chr12:130811845	chr12:130810606~130812438:+
BRCA	cis	rs7301826	1	rs1609985	ENSG00000256250.1	RP11-989F5.1	-15.37	3.47e-48	7.59e-45	-0.5	-0.43	Plasma plasminogen activator levels;	chr12:130835625	chr12:130810606~130812438:+
BRCA	cis	rs7617773	0.963	rs6766754	ENSG00000229759.1	MRPS18AP1	-15.37	3.5e-48	7.64e-45	-0.49	-0.43	Coronary artery disease;	chr3:48141099	chr3:48256350~48256938:-
BRCA	cis	rs7617773	0.832	rs6775114	ENSG00000229759.1	MRPS18AP1	-15.37	3.5e-48	7.64e-45	-0.49	-0.43	Coronary artery disease;	chr3:48141130	chr3:48256350~48256938:-
BRCA	cis	rs2882667	0.515	rs13161286	ENSG00000253404.1	AC034243.1	15.36	3.74e-48	8.15e-45	0.61	0.43	Age-related hearing impairment (SNP x SNP interaction);	chr5:139148416	chr5:138744434~138753309:-
BRCA	cis	rs8062405	1	rs7187776	ENSG00000259982.1	CDC37P1	15.36	3.8e-48	8.29e-45	0.51	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28846324	chr16:28700294~28701540:-
BRCA	cis	rs2455601	0.786	rs2568070	ENSG00000254860.4	TMEM9B-AS1	15.36	3.84e-48	8.37e-45	0.46	0.43	Schizophrenia;	chr11:8955346	chr11:8964675~8977527:+
BRCA	cis	rs2882667	0.824	rs11748097	ENSG00000253404.1	AC034243.1	15.36	3.85e-48	8.4e-45	0.59	0.43	Age-related hearing impairment (SNP x SNP interaction);	chr5:139144198	chr5:138744434~138753309:-
BRCA	cis	rs2882667	0.858	rs11959851	ENSG00000253404.1	AC034243.1	15.36	3.93e-48	8.58e-45	0.56	0.43	Age-related hearing impairment (SNP x SNP interaction);	chr5:139085716	chr5:138744434~138753309:-
BRCA	cis	rs6452524	0.905	rs7736289	ENSG00000249664.1	CTD-2227C6.2	15.36	3.99e-48	8.69e-45	0.5	0.43	Hypertension (SNP x SNP interaction);	chr5:83082401	chr5:83012285~83013109:-
BRCA	cis	rs1153858	1	rs7164602	ENSG00000259520.4	CTD-2651B20.3	-15.35	4.25e-48	9.25e-45	-0.57	-0.43	Homoarginine levels;	chr15:45379127	chr15:45251580~45279251:-
BRCA	cis	rs1153858	1	rs12441971	ENSG00000259520.4	CTD-2651B20.3	-15.35	4.25e-48	9.25e-45	-0.57	-0.43	Homoarginine levels;	chr15:45379759	chr15:45251580~45279251:-
BRCA	cis	rs1153858	1	rs1346268	ENSG00000259520.4	CTD-2651B20.3	-15.35	4.25e-48	9.25e-45	-0.57	-0.43	Homoarginine levels;	chr15:45380831	chr15:45251580~45279251:-
BRCA	cis	rs7208859	0.623	rs9895785	ENSG00000263531.1	RP13-753N3.1	-15.35	4.3e-48	9.35e-45	-0.8	-0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780690	chr17:30863921~30864940:-
BRCA	cis	rs1153858	0.943	rs12439575	ENSG00000259520.4	CTD-2651B20.3	-15.35	4.5e-48	9.78e-45	-0.57	-0.43	Homoarginine levels;	chr15:45392618	chr15:45251580~45279251:-
BRCA	cis	rs1153858	1	rs12440038	ENSG00000259520.4	CTD-2651B20.3	-15.35	4.56e-48	9.91e-45	-0.58	-0.43	Homoarginine levels;	chr15:45414541	chr15:45251580~45279251:-
BRCA	cis	rs1061377	1	rs9999327	ENSG00000249207.1	RP11-360F5.1	-15.34	4.6e-48	1e-44	-0.49	-0.43	Uric acid levels;	chr4:39110111	chr4:39112677~39126818:-
BRCA	cis	rs1061377	0.965	rs6833654	ENSG00000249207.1	RP11-360F5.1	-15.34	4.6e-48	1e-44	-0.49	-0.43	Uric acid levels;	chr4:39110701	chr4:39112677~39126818:-
BRCA	cis	rs1061377	1	rs9998481	ENSG00000249207.1	RP11-360F5.1	-15.34	4.69e-48	1.02e-44	-0.49	-0.43	Uric acid levels;	chr4:39117215	chr4:39112677~39126818:-
BRCA	cis	rs1153858	0.943	rs67045941	ENSG00000259520.4	CTD-2651B20.3	-15.34	4.71e-48	1.02e-44	-0.57	-0.43	Homoarginine levels;	chr15:45384813	chr15:45251580~45279251:-
BRCA	cis	rs1153858	1	rs67744121	ENSG00000259520.4	CTD-2651B20.3	-15.34	4.71e-48	1.02e-44	-0.57	-0.43	Homoarginine levels;	chr15:45385039	chr15:45251580~45279251:-
BRCA	cis	rs1061377	1	rs1036038	ENSG00000249207.1	RP11-360F5.1	-15.34	4.73e-48	1.03e-44	-0.49	-0.43	Uric acid levels;	chr4:39111383	chr4:39112677~39126818:-
BRCA	cis	rs1061377	1	rs1560396	ENSG00000249207.1	RP11-360F5.1	-15.34	4.73e-48	1.03e-44	-0.49	-0.43	Uric acid levels;	chr4:39112092	chr4:39112677~39126818:-
BRCA	cis	rs1061377	1	rs1560397	ENSG00000249207.1	RP11-360F5.1	-15.34	4.73e-48	1.03e-44	-0.49	-0.43	Uric acid levels;	chr4:39112265	chr4:39112677~39126818:-
BRCA	cis	rs1061377	1	rs2381285	ENSG00000249207.1	RP11-360F5.1	-15.34	4.73e-48	1.03e-44	-0.49	-0.43	Uric acid levels;	chr4:39112775	chr4:39112677~39126818:-
BRCA	cis	rs1061377	1	rs62310332	ENSG00000249207.1	RP11-360F5.1	-15.34	4.73e-48	1.03e-44	-0.49	-0.43	Uric acid levels;	chr4:39112939	chr4:39112677~39126818:-
BRCA	cis	rs1061377	0.965	rs3796510	ENSG00000249207.1	RP11-360F5.1	-15.34	4.73e-48	1.03e-44	-0.49	-0.43	Uric acid levels;	chr4:39113309	chr4:39112677~39126818:-
BRCA	cis	rs1061377	0.932	rs6855118	ENSG00000249207.1	RP11-360F5.1	-15.34	4.73e-48	1.03e-44	-0.49	-0.43	Uric acid levels;	chr4:39114322	chr4:39112677~39126818:-
BRCA	cis	rs1061377	1	rs6829234	ENSG00000249207.1	RP11-360F5.1	-15.34	4.73e-48	1.03e-44	-0.49	-0.43	Uric acid levels;	chr4:39114586	chr4:39112677~39126818:-
BRCA	cis	rs1061377	1	rs6812540	ENSG00000249207.1	RP11-360F5.1	-15.34	4.73e-48	1.03e-44	-0.49	-0.43	Uric acid levels;	chr4:39114803	chr4:39112677~39126818:-
BRCA	cis	rs6452524	0.935	rs6868416	ENSG00000249664.1	CTD-2227C6.2	15.34	4.9e-48	1.06e-44	0.51	0.43	Hypertension (SNP x SNP interaction);	chr5:83084320	chr5:83012285~83013109:-
BRCA	cis	rs1061377	1	rs1982009	ENSG00000249207.1	RP11-360F5.1	-15.34	5.01e-48	1.08e-44	-0.49	-0.43	Uric acid levels;	chr4:39123253	chr4:39112677~39126818:-
BRCA	cis	rs1061377	0.965	rs1138494	ENSG00000249207.1	RP11-360F5.1	-15.34	5.01e-48	1.08e-44	-0.49	-0.43	Uric acid levels;	chr4:39123315	chr4:39112677~39126818:-
BRCA	cis	rs6452524	0.935	rs1478485	ENSG00000249664.1	CTD-2227C6.2	15.34	5.01e-48	1.09e-44	0.51	0.43	Hypertension (SNP x SNP interaction);	chr5:83084708	chr5:83012285~83013109:-
BRCA	cis	rs2882667	0.824	rs12173085	ENSG00000253404.1	AC034243.1	15.34	5.01e-48	1.09e-44	0.59	0.43	Age-related hearing impairment (SNP x SNP interaction);	chr5:139144336	chr5:138744434~138753309:-
BRCA	cis	rs1061377	0.965	rs1046655	ENSG00000249207.1	RP11-360F5.1	-15.34	5.03e-48	1.09e-44	-0.49	-0.43	Uric acid levels;	chr4:39126127	chr4:39112677~39126818:-
BRCA	cis	rs1061377	1	rs7694760	ENSG00000249207.1	RP11-360F5.1	-15.34	5.03e-48	1.09e-44	-0.49	-0.43	Uric acid levels;	chr4:39126481	chr4:39112677~39126818:-
BRCA	cis	rs1061377	1	rs2163272	ENSG00000249207.1	RP11-360F5.1	-15.34	5.04e-48	1.09e-44	-0.49	-0.43	Uric acid levels;	chr4:39112790	chr4:39112677~39126818:-
BRCA	cis	rs1061377	0.965	rs11728058	ENSG00000249207.1	RP11-360F5.1	-15.33	5.29e-48	1.15e-44	-0.49	-0.43	Uric acid levels;	chr4:39128224	chr4:39112677~39126818:-
BRCA	cis	rs1061377	1	rs17508864	ENSG00000249207.1	RP11-360F5.1	-15.33	5.29e-48	1.15e-44	-0.49	-0.43	Uric acid levels;	chr4:39129025	chr4:39112677~39126818:-
BRCA	cis	rs1061377	1	rs2163273	ENSG00000249207.1	RP11-360F5.1	-15.33	5.36e-48	1.16e-44	-0.49	-0.43	Uric acid levels;	chr4:39112835	chr4:39112677~39126818:-
BRCA	cis	rs1061377	1	rs35437629	ENSG00000249207.1	RP11-360F5.1	-15.33	5.45e-48	1.18e-44	-0.49	-0.43	Uric acid levels;	chr4:39131712	chr4:39112677~39126818:-
BRCA	cis	rs1061377	1	rs34771104	ENSG00000249207.1	RP11-360F5.1	-15.33	5.49e-48	1.19e-44	-0.49	-0.43	Uric acid levels;	chr4:39127432	chr4:39112677~39126818:-
BRCA	cis	rs2019137	0.868	rs6755639	ENSG00000189223.12	PAX8-AS1	-15.33	5.5e-48	1.19e-44	-0.59	-0.43	Lymphocyte counts;	chr2:113224233	chr2:113211522~113276581:+
BRCA	cis	rs7617773	0.78	rs13084616	ENSG00000229759.1	MRPS18AP1	-15.33	5.65e-48	1.22e-44	-0.56	-0.43	Coronary artery disease;	chr3:48298209	chr3:48256350~48256938:-
BRCA	cis	rs1061377	1	rs7685082	ENSG00000249207.1	RP11-360F5.1	-15.33	5.7e-48	1.23e-44	-0.49	-0.43	Uric acid levels;	chr4:39116472	chr4:39112677~39126818:-
BRCA	cis	rs2455601	0.744	rs11042133	ENSG00000254860.4	TMEM9B-AS1	15.33	5.83e-48	1.26e-44	0.49	0.43	Schizophrenia;	chr11:8944964	chr11:8964675~8977527:+
BRCA	cis	rs1061377	1	rs4974997	ENSG00000249207.1	RP11-360F5.1	-15.32	6.01e-48	1.3e-44	-0.49	-0.43	Uric acid levels;	chr4:39109151	chr4:39112677~39126818:-
BRCA	cis	rs9399137	0.507	rs4896118	ENSG00000232876.1	CTA-212D2.2	15.32	6.19e-48	1.33e-44	0.54	0.43	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134954927	chr6:135055033~135060550:+
BRCA	cis	rs1061377	1	rs7657926	ENSG00000249207.1	RP11-360F5.1	-15.32	6.21e-48	1.34e-44	-0.49	-0.43	Uric acid levels;	chr4:39132443	chr4:39112677~39126818:-
BRCA	cis	rs1061377	1	rs11096982	ENSG00000249207.1	RP11-360F5.1	-15.32	6.21e-48	1.34e-44	-0.49	-0.43	Uric acid levels;	chr4:39133247	chr4:39112677~39126818:-
BRCA	cis	rs1061377	1	rs11727875	ENSG00000249207.1	RP11-360F5.1	-15.32	6.21e-48	1.34e-44	-0.49	-0.43	Uric acid levels;	chr4:39133699	chr4:39112677~39126818:-
BRCA	cis	rs8062405	0.755	rs17640009	ENSG00000259982.1	CDC37P1	15.31	6.95e-48	1.5e-44	0.54	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28584379	chr16:28700294~28701540:-
BRCA	cis	rs1061377	1	rs7685468	ENSG00000249207.1	RP11-360F5.1	-15.31	7.28e-48	1.57e-44	-0.49	-0.43	Uric acid levels;	chr4:39116649	chr4:39112677~39126818:-
BRCA	cis	rs9399137	0.507	rs7768278	ENSG00000232876.1	CTA-212D2.2	-15.31	7.39e-48	1.59e-44	-0.53	-0.43	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134953819	chr6:135055033~135060550:+
BRCA	cis	rs11673344	0.642	rs73025481	ENSG00000226686.6	LINC01535	15.3	7.56e-48	1.63e-44	0.57	0.43	Obesity-related traits;	chr19:37346437	chr19:37251912~37265535:+
BRCA	cis	rs1061377	0.965	rs3733275	ENSG00000249207.1	RP11-360F5.1	-15.3	7.62e-48	1.64e-44	-0.49	-0.43	Uric acid levels;	chr4:39121077	chr4:39112677~39126818:-
BRCA	cis	rs2455601	0.766	rs1109304	ENSG00000254860.4	TMEM9B-AS1	15.3	7.67e-48	1.65e-44	0.48	0.43	Schizophrenia;	chr11:8933908	chr11:8964675~8977527:+
BRCA	cis	rs1061377	0.965	rs7677729	ENSG00000249207.1	RP11-360F5.1	-15.3	7.69e-48	1.65e-44	-0.49	-0.43	Uric acid levels;	chr4:39120370	chr4:39112677~39126818:-
BRCA	cis	rs1061377	1	rs3796511	ENSG00000249207.1	RP11-360F5.1	-15.3	7.69e-48	1.65e-44	-0.49	-0.43	Uric acid levels;	chr4:39120586	chr4:39112677~39126818:-
BRCA	cis	rs1061377	1	rs3733274	ENSG00000249207.1	RP11-360F5.1	-15.3	7.69e-48	1.65e-44	-0.49	-0.43	Uric acid levels;	chr4:39120957	chr4:39112677~39126818:-
BRCA	cis	rs7301826	1	rs4759524	ENSG00000256250.1	RP11-989F5.1	-15.3	7.87e-48	1.69e-44	-0.49	-0.43	Plasma plasminogen activator levels;	chr12:130831065	chr12:130810606~130812438:+
BRCA	cis	rs992157	0.804	rs6758540	ENSG00000261338.2	RP11-378A13.1	-15.3	7.93e-48	1.7e-44	-0.46	-0.43	Colorectal cancer;	chr2:218273902	chr2:218255319~218257366:+
BRCA	cis	rs67383717	0.527	rs12004422	ENSG00000175611.10	LINC00476	15.3	8.14e-48	1.75e-44	0.46	0.43	Parkinson's disease (pesticide exposure interaction);	chr9:95873393	chr9:95759231~95875977:-
BRCA	cis	rs1061377	1	rs7664078	ENSG00000249207.1	RP11-360F5.1	-15.3	8.36e-48	1.79e-44	-0.49	-0.43	Uric acid levels;	chr4:39116583	chr4:39112677~39126818:-
BRCA	cis	rs1061377	1	rs4974998	ENSG00000249207.1	RP11-360F5.1	-15.3	8.52e-48	1.83e-44	-0.49	-0.43	Uric acid levels;	chr4:39109129	chr4:39112677~39126818:-
BRCA	cis	rs992157	0.835	rs2292550	ENSG00000261338.2	RP11-378A13.1	-15.29	8.62e-48	1.85e-44	-0.46	-0.43	Colorectal cancer;	chr2:218275565	chr2:218255319~218257366:+
BRCA	cis	rs1153858	0.945	rs16943246	ENSG00000259520.4	CTD-2651B20.3	-15.29	9.01e-48	1.93e-44	-0.58	-0.43	Homoarginine levels;	chr15:45428399	chr15:45251580~45279251:-
BRCA	cis	rs1153858	1	rs16942568	ENSG00000259520.4	CTD-2651B20.3	-15.29	9.16e-48	1.96e-44	-0.57	-0.43	Homoarginine levels;	chr15:45385192	chr15:45251580~45279251:-
BRCA	cis	rs6452524	0.901	rs10079680	ENSG00000249664.1	CTD-2227C6.2	15.29	9.21e-48	1.97e-44	0.5	0.43	Hypertension (SNP x SNP interaction);	chr5:83082746	chr5:83012285~83013109:-
BRCA	cis	rs11690935	1	rs2138348	ENSG00000228389.1	AC068039.4	-15.29	9.47e-48	2.03e-44	-0.55	-0.43	Schizophrenia;	chr2:171701662	chr2:171773482~171775844:+
BRCA	cis	rs2882667	0.66	rs6894907	ENSG00000253404.1	AC034243.1	15.28	9.7e-48	2.08e-44	0.52	0.43	Age-related hearing impairment (SNP x SNP interaction);	chr5:139106815	chr5:138744434~138753309:-
BRCA	cis	rs1153858	1	rs12594857	ENSG00000259520.4	CTD-2651B20.3	-15.28	1.01e-47	2.17e-44	-0.57	-0.43	Homoarginine levels;	chr15:45374980	chr15:45251580~45279251:-
BRCA	cis	rs1153858	1	rs4271549	ENSG00000259520.4	CTD-2651B20.3	-15.28	1.05e-47	2.25e-44	-0.56	-0.43	Homoarginine levels;	chr15:45360532	chr15:45251580~45279251:-
BRCA	cis	rs1153858	1	rs4627277	ENSG00000259520.4	CTD-2651B20.3	-15.28	1.05e-47	2.25e-44	-0.56	-0.43	Homoarginine levels;	chr15:45360570	chr15:45251580~45279251:-
BRCA	cis	rs1061377	0.722	rs34803689	ENSG00000249207.1	RP11-360F5.1	-15.28	1.07e-47	2.29e-44	-0.49	-0.43	Uric acid levels;	chr4:39116665	chr4:39112677~39126818:-
BRCA	cis	rs8062405	0.755	rs55792032	ENSG00000259982.1	CDC37P1	15.27	1.15e-47	2.46e-44	0.53	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28588090	chr16:28700294~28701540:-
BRCA	cis	rs1153858	1	rs4395020	ENSG00000259520.4	CTD-2651B20.3	-15.27	1.16e-47	2.47e-44	-0.57	-0.43	Homoarginine levels;	chr15:45360691	chr15:45251580~45279251:-
BRCA	cis	rs8062405	0.755	rs4788073	ENSG00000259982.1	CDC37P1	15.27	1.24e-47	2.64e-44	0.53	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28583228	chr16:28700294~28701540:-
BRCA	cis	rs1153858	0.943	rs11070454	ENSG00000259520.4	CTD-2651B20.3	-15.27	1.24e-47	2.64e-44	-0.57	-0.43	Homoarginine levels;	chr15:45388054	chr15:45251580~45279251:-
BRCA	cis	rs2487048	0.905	rs2437812	ENSG00000226334.1	RP11-217B7.2	-15.26	1.29e-47	2.76e-44	-0.58	-0.43	Intraocular pressure;	chr9:104930920	chr9:104927553~104928892:+
BRCA	cis	rs1577917	0.876	rs12190735	ENSG00000203875.9	SNHG5	-15.26	1.35e-47	2.88e-44	-0.51	-0.43	Response to antipsychotic treatment;	chr6:85976749	chr6:85660950~85678736:-
BRCA	cis	rs11673344	0.642	rs55755939	ENSG00000226686.6	LINC01535	15.26	1.4e-47	2.99e-44	0.58	0.43	Obesity-related traits;	chr19:37353723	chr19:37251912~37265535:+
BRCA	cis	rs7301826	1	rs1106369	ENSG00000256250.1	RP11-989F5.1	-15.25	1.42e-47	3.02e-44	-0.49	-0.43	Plasma plasminogen activator levels;	chr12:130815550	chr12:130810606~130812438:+
BRCA	cis	rs1061377	1	rs7673299	ENSG00000249207.1	RP11-360F5.1	-15.25	1.45e-47	3.09e-44	-0.49	-0.43	Uric acid levels;	chr4:39109138	chr4:39112677~39126818:-
BRCA	cis	rs2882667	0.66	rs3088052	ENSG00000253404.1	AC034243.1	15.25	1.46e-47	3.1e-44	0.54	0.43	Age-related hearing impairment (SNP x SNP interaction);	chr5:139121126	chr5:138744434~138753309:-
BRCA	cis	rs1153858	1	rs3759899	ENSG00000259520.4	CTD-2651B20.3	-15.25	1.49e-47	3.18e-44	-0.56	-0.43	Homoarginine levels;	chr15:45363705	chr15:45251580~45279251:-
BRCA	cis	rs1061377	1	rs9990742	ENSG00000249207.1	RP11-360F5.1	-15.25	1.5e-47	3.2e-44	-0.49	-0.43	Uric acid levels;	chr4:39119794	chr4:39112677~39126818:-
BRCA	cis	rs1153858	1	rs4625670	ENSG00000259520.4	CTD-2651B20.3	-15.24	1.64e-47	3.48e-44	-0.56	-0.43	Homoarginine levels;	chr15:45360728	chr15:45251580~45279251:-
BRCA	cis	rs1153858	1	rs1049503	ENSG00000259520.4	CTD-2651B20.3	-15.24	1.64e-47	3.48e-44	-0.56	-0.43	Homoarginine levels;	chr15:45361509	chr15:45251580~45279251:-
BRCA	cis	rs11673344	0.624	rs862234	ENSG00000226686.6	LINC01535	-15.24	1.68e-47	3.56e-44	-0.57	-0.43	Obesity-related traits;	chr19:37237100	chr19:37251912~37265535:+
BRCA	cis	rs1061377	1	rs1897136	ENSG00000249207.1	RP11-360F5.1	-15.24	1.71e-47	3.63e-44	-0.48	-0.43	Uric acid levels;	chr4:39131242	chr4:39112677~39126818:-
BRCA	cis	rs1061377	1	rs1897137	ENSG00000249207.1	RP11-360F5.1	-15.24	1.71e-47	3.63e-44	-0.48	-0.43	Uric acid levels;	chr4:39131387	chr4:39112677~39126818:-
BRCA	cis	rs1061377	1	rs7681116	ENSG00000249207.1	RP11-360F5.1	-15.24	1.71e-47	3.63e-44	-0.48	-0.43	Uric acid levels;	chr4:39133015	chr4:39112677~39126818:-
BRCA	cis	rs7301826	0.967	rs4759792	ENSG00000256250.1	RP11-989F5.1	-15.24	1.77e-47	3.75e-44	-0.49	-0.43	Plasma plasminogen activator levels;	chr12:130812086	chr12:130810606~130812438:+
BRCA	cis	rs11673344	0.555	rs502546	ENSG00000226686.6	LINC01535	-15.23	1.84e-47	3.89e-44	-0.58	-0.43	Obesity-related traits;	chr19:37361788	chr19:37251912~37265535:+
BRCA	cis	rs1153858	1	rs11858495	ENSG00000259520.4	CTD-2651B20.3	15.23	2.01e-47	4.26e-44	0.56	0.43	Homoarginine levels;	chr15:45345464	chr15:45251580~45279251:-
BRCA	cis	rs1061377	0.965	rs10018622	ENSG00000249207.1	RP11-360F5.1	-15.22	2.15e-47	4.56e-44	-0.48	-0.43	Uric acid levels;	chr4:39133944	chr4:39112677~39126818:-
BRCA	cis	rs2882667	0.858	rs6596460	ENSG00000253404.1	AC034243.1	15.22	2.31e-47	4.88e-44	0.57	0.43	Age-related hearing impairment (SNP x SNP interaction);	chr5:139078491	chr5:138744434~138753309:-
BRCA	cis	rs35160687	0.814	rs7563887	ENSG00000273080.1	RP11-301O19.1	15.21	2.35e-47	4.97e-44	0.48	0.43	Night sleep phenotypes;	chr2:86288998	chr2:86195590~86196049:+
BRCA	cis	rs6452524	0.935	rs1017794	ENSG00000249664.1	CTD-2227C6.2	15.21	2.38e-47	5.02e-44	0.5	0.43	Hypertension (SNP x SNP interaction);	chr5:83086236	chr5:83012285~83013109:-
BRCA	cis	rs7301826	1	rs4759523	ENSG00000256250.1	RP11-989F5.1	-15.21	2.39e-47	5.04e-44	-0.49	-0.43	Plasma plasminogen activator levels;	chr12:130830867	chr12:130810606~130812438:+
BRCA	cis	rs1061377	1	rs4974931	ENSG00000249207.1	RP11-360F5.1	-15.21	2.47e-47	5.21e-44	-0.49	-0.43	Uric acid levels;	chr4:39108896	chr4:39112677~39126818:-
BRCA	cis	rs1426063	0.614	rs17000260	ENSG00000260265.1	RP11-44F21.5	15.21	2.53e-47	5.33e-44	0.89	0.43	QT interval;	chr4:75108576	chr4:75081702~75084717:-
BRCA	cis	rs3931020	1	rs12410060	ENSG00000272864.1	RP11-17E13.2	-15.21	2.62e-47	5.52e-44	-0.54	-0.43	Resistin levels;	chr1:74780164	chr1:74698769~74699333:-
BRCA	cis	rs9389248	0.69	rs6569982	ENSG00000232876.1	CTA-212D2.2	-15.2	2.65e-47	5.6e-44	-0.53	-0.43	High light scatter reticulocyte percentage of red cells;	chr6:134935357	chr6:135055033~135060550:+
BRCA	cis	rs1972460	0.506	rs62012050	ENSG00000278603.1	RP13-608F4.5	15.2	2.78e-47	5.85e-44	0.61	0.43	Intelligence (multi-trait analysis);	chr15:82239933	chr15:82472203~82472426:+
BRCA	cis	rs6452524	0.935	rs11750799	ENSG00000249664.1	CTD-2227C6.2	15.2	2.81e-47	5.92e-44	0.5	0.43	Hypertension (SNP x SNP interaction);	chr5:83082983	chr5:83012285~83013109:-
BRCA	cis	rs2455601	0.744	rs2568085	ENSG00000254860.4	TMEM9B-AS1	-15.2	2.82e-47	5.94e-44	-0.44	-0.43	Schizophrenia;	chr11:8954201	chr11:8964675~8977527:+
BRCA	cis	rs1153858	1	rs12595087	ENSG00000259520.4	CTD-2651B20.3	-15.2	2.88e-47	6.07e-44	-0.56	-0.43	Homoarginine levels;	chr15:45363034	chr15:45251580~45279251:-
BRCA	cis	rs992157	0.798	rs4996257	ENSG00000261338.2	RP11-378A13.1	15.2	2.91e-47	6.12e-44	0.44	0.43	Colorectal cancer;	chr2:218298113	chr2:218255319~218257366:+
BRCA	cis	rs992157	0.7	rs10165153	ENSG00000261338.2	RP11-378A13.1	15.2	2.92e-47	6.15e-44	0.45	0.43	Colorectal cancer;	chr2:218294906	chr2:218255319~218257366:+
BRCA	cis	rs1153858	1	rs1890565	ENSG00000259520.4	CTD-2651B20.3	-15.2	2.95e-47	6.2e-44	-0.56	-0.43	Homoarginine levels;	chr15:45371101	chr15:45251580~45279251:-
BRCA	cis	rs1153858	1	rs4534782	ENSG00000259520.4	CTD-2651B20.3	-15.19	3.17e-47	6.67e-44	-0.56	-0.43	Homoarginine levels;	chr15:45360735	chr15:45251580~45279251:-
BRCA	cis	rs1153858	1	rs66528868	ENSG00000259520.4	CTD-2651B20.3	-15.18	3.47e-47	7.28e-44	-0.57	-0.43	Homoarginine levels;	chr15:45376349	chr15:45251580~45279251:-
BRCA	cis	rs1153858	1	rs7494956	ENSG00000259520.4	CTD-2651B20.3	-15.18	3.47e-47	7.28e-44	-0.57	-0.43	Homoarginine levels;	chr15:45376367	chr15:45251580~45279251:-
BRCA	cis	rs992157	0.798	rs10193383	ENSG00000261338.2	RP11-378A13.1	15.18	3.63e-47	7.62e-44	0.45	0.43	Colorectal cancer;	chr2:218292969	chr2:218255319~218257366:+
BRCA	cis	rs992157	0.798	rs10206064	ENSG00000261338.2	RP11-378A13.1	15.18	3.63e-47	7.62e-44	0.45	0.43	Colorectal cancer;	chr2:218293236	chr2:218255319~218257366:+
BRCA	cis	rs1061377	1	rs3796509	ENSG00000249207.1	RP11-360F5.1	-15.18	3.65e-47	7.66e-44	-0.49	-0.43	Uric acid levels;	chr4:39108566	chr4:39112677~39126818:-
BRCA	cis	rs35160687	0.814	rs6547673	ENSG00000273080.1	RP11-301O19.1	15.18	3.65e-47	7.66e-44	0.48	0.43	Night sleep phenotypes;	chr2:86301815	chr2:86195590~86196049:+
BRCA	cis	rs992157	0.798	rs2382817	ENSG00000261338.2	RP11-378A13.1	15.18	3.79e-47	7.93e-44	0.45	0.43	Colorectal cancer;	chr2:218286495	chr2:218255319~218257366:+
BRCA	cis	rs7617773	1	rs12496784	ENSG00000229759.1	MRPS18AP1	-15.17	4.05e-47	8.48e-44	-0.48	-0.43	Coronary artery disease;	chr3:48144777	chr3:48256350~48256938:-
BRCA	cis	rs7617773	0.743	rs11715876	ENSG00000229759.1	MRPS18AP1	15.16	4.38e-47	9.16e-44	0.56	0.43	Coronary artery disease;	chr3:48336432	chr3:48256350~48256938:-
BRCA	cis	rs7617773	0.817	rs11928691	ENSG00000229759.1	MRPS18AP1	15.16	4.42e-47	9.24e-44	0.51	0.43	Coronary artery disease;	chr3:48245275	chr3:48256350~48256938:-
BRCA	cis	rs1153858	1	rs12437887	ENSG00000259520.4	CTD-2651B20.3	-15.16	4.62e-47	9.65e-44	-0.57	-0.43	Homoarginine levels;	chr15:45376896	chr15:45251580~45279251:-
BRCA	cis	rs7617773	0.78	rs13066044	ENSG00000229759.1	MRPS18AP1	15.16	4.64e-47	9.71e-44	0.56	0.43	Coronary artery disease;	chr3:48335786	chr3:48256350~48256938:-
BRCA	cis	rs1153858	1	rs67461176	ENSG00000259520.4	CTD-2651B20.3	-15.15	5.28e-47	1.1e-43	-0.57	-0.42	Homoarginine levels;	chr15:45384621	chr15:45251580~45279251:-
BRCA	cis	rs1153858	1	rs66939267	ENSG00000259520.4	CTD-2651B20.3	-15.15	5.28e-47	1.1e-43	-0.57	-0.42	Homoarginine levels;	chr15:45384704	chr15:45251580~45279251:-
BRCA	cis	rs992157	0.732	rs10932771	ENSG00000261338.2	RP11-378A13.1	15.15	5.36e-47	1.12e-43	0.44	0.42	Colorectal cancer;	chr2:218305513	chr2:218255319~218257366:+
BRCA	cis	rs7617773	0.78	rs11720026	ENSG00000229759.1	MRPS18AP1	15.15	5.39e-47	1.12e-43	0.56	0.42	Coronary artery disease;	chr3:48336431	chr3:48256350~48256938:-
BRCA	cis	rs2581828	0.965	rs2581829	ENSG00000242142.1	SERBP1P3	-15.15	5.43e-47	1.13e-43	-0.47	-0.42	Crohn's disease;	chr3:53099510	chr3:53064283~53065091:-
BRCA	cis	rs7617773	0.778	rs11707997	ENSG00000229759.1	MRPS18AP1	15.15	5.57e-47	1.16e-43	0.56	0.42	Coronary artery disease;	chr3:48336385	chr3:48256350~48256938:-
BRCA	cis	rs7617773	0.707	rs13061269	ENSG00000229759.1	MRPS18AP1	15.14	5.7e-47	1.19e-43	0.56	0.42	Coronary artery disease;	chr3:48331853	chr3:48256350~48256938:-
BRCA	cis	rs7617773	0.78	rs11716848	ENSG00000229759.1	MRPS18AP1	15.14	5.7e-47	1.19e-43	0.56	0.42	Coronary artery disease;	chr3:48337010	chr3:48256350~48256938:-
BRCA	cis	rs2882667	0.824	rs1560656	ENSG00000253404.1	AC034243.1	-15.14	5.88e-47	1.22e-43	-0.57	-0.42	Age-related hearing impairment (SNP x SNP interaction);	chr5:139135100	chr5:138744434~138753309:-
BRCA	cis	rs7301826	0.934	rs10773826	ENSG00000256250.1	RP11-989F5.1	-15.14	5.9e-47	1.23e-43	-0.49	-0.42	Plasma plasminogen activator levels;	chr12:130836629	chr12:130810606~130812438:+
BRCA	cis	rs7208859	0.623	rs73269923	ENSG00000263531.1	RP13-753N3.1	15.13	6.5e-47	1.35e-43	0.84	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775553	chr17:30863921~30864940:-
BRCA	cis	rs6452524	0.935	rs10942321	ENSG00000249664.1	CTD-2227C6.2	15.13	6.59e-47	1.37e-43	0.5	0.42	Hypertension (SNP x SNP interaction);	chr5:83083200	chr5:83012285~83013109:-
BRCA	cis	rs1153858	1	rs12437840	ENSG00000259520.4	CTD-2651B20.3	-15.13	6.78e-47	1.41e-43	-0.57	-0.42	Homoarginine levels;	chr15:45376857	chr15:45251580~45279251:-
BRCA	cis	rs7617773	0.778	rs11715776	ENSG00000229759.1	MRPS18AP1	15.13	6.84e-47	1.42e-43	0.56	0.42	Coronary artery disease;	chr3:48336121	chr3:48256350~48256938:-
BRCA	cis	rs9322193	0.607	rs6557165	ENSG00000231760.4	RP11-350J20.5	-15.13	6.99e-47	1.45e-43	-0.56	-0.42	Lung cancer;	chr6:149906883	chr6:149796151~149826294:-
BRCA	cis	rs8037818	1	rs8037102	ENSG00000276724.1	RP11-1000B6.7	-15.13	7.01e-47	1.45e-43	-0.6	-0.42	Obesity-related traits;	chr15:32640449	chr15:32583612~32584312:+
BRCA	cis	rs1153858	1	rs2114501	ENSG00000259520.4	CTD-2651B20.3	-15.13	7.12e-47	1.48e-43	-0.56	-0.42	Homoarginine levels;	chr15:45378118	chr15:45251580~45279251:-
BRCA	cis	rs1153858	0.887	rs7164139	ENSG00000259520.4	CTD-2651B20.3	-15.12	7.44e-47	1.54e-43	-0.57	-0.42	Homoarginine levels;	chr15:45378653	chr15:45251580~45279251:-
BRCA	cis	rs2729354	1	rs2649662	ENSG00000265566.2	RN7SL605P	15.12	7.79e-47	1.61e-43	0.64	0.42	Blood protein levels;	chr11:57585089	chr11:57528085~57528365:-
BRCA	cis	rs7617773	0.78	rs71323395	ENSG00000229759.1	MRPS18AP1	15.12	7.81e-47	1.61e-43	0.56	0.42	Coronary artery disease;	chr3:48332587	chr3:48256350~48256938:-
BRCA	cis	rs7617773	0.743	rs71323397	ENSG00000229759.1	MRPS18AP1	15.12	7.81e-47	1.61e-43	0.56	0.42	Coronary artery disease;	chr3:48333384	chr3:48256350~48256938:-
BRCA	cis	rs7617773	0.676	rs13060020	ENSG00000229759.1	MRPS18AP1	15.12	7.98e-47	1.65e-43	0.56	0.42	Coronary artery disease;	chr3:48331156	chr3:48256350~48256938:-
BRCA	cis	rs1153858	1	rs9788780	ENSG00000259520.4	CTD-2651B20.3	-15.12	7.99e-47	1.65e-43	-0.57	-0.42	Homoarginine levels;	chr15:45393289	chr15:45251580~45279251:-
BRCA	cis	rs6452524	0.905	rs1478482	ENSG00000249664.1	CTD-2227C6.2	15.11	8.19e-47	1.69e-43	0.5	0.42	Hypertension (SNP x SNP interaction);	chr5:83111279	chr5:83012285~83013109:-
BRCA	cis	rs1153858	1	rs1365610	ENSG00000259520.4	CTD-2651B20.3	-15.11	8.3e-47	1.71e-43	-0.57	-0.42	Homoarginine levels;	chr15:45402412	chr15:45251580~45279251:-
BRCA	cis	rs7617773	0.817	rs6791930	ENSG00000229759.1	MRPS18AP1	15.11	8.38e-47	1.73e-43	0.53	0.42	Coronary artery disease;	chr3:48288410	chr3:48256350~48256938:-
BRCA	cis	rs7617773	0.817	rs6794644	ENSG00000229759.1	MRPS18AP1	15.11	8.38e-47	1.73e-43	0.53	0.42	Coronary artery disease;	chr3:48288547	chr3:48256350~48256938:-
BRCA	cis	rs7301826	1	rs2001483	ENSG00000256250.1	RP11-989F5.1	-15.11	9.12e-47	1.88e-43	-0.49	-0.42	Plasma plasminogen activator levels;	chr12:130834100	chr12:130810606~130812438:+
BRCA	cis	rs1976403	0.633	rs1780324	ENSG00000227001.3	NBPF2P	15.1	9.4e-47	1.94e-43	0.48	0.42	Liver enzyme levels (alkaline phosphatase);	chr1:21495264	chr1:21424625~21427967:-
BRCA	cis	rs7617773	0.78	rs13082158	ENSG00000229759.1	MRPS18AP1	15.1	9.57e-47	1.97e-43	0.56	0.42	Coronary artery disease;	chr3:48330980	chr3:48256350~48256938:-
BRCA	cis	rs7617773	0.78	rs11710257	ENSG00000229759.1	MRPS18AP1	15.1	9.57e-47	1.97e-43	0.56	0.42	Coronary artery disease;	chr3:48331724	chr3:48256350~48256938:-
BRCA	cis	rs977987	0.778	rs4888400	ENSG00000261783.1	RP11-252K23.2	-15.1	1e-46	2.07e-43	-0.54	-0.42	Dupuytren's disease;	chr16:75391698	chr16:75379818~75381260:-
BRCA	cis	rs1153858	1	rs4775937	ENSG00000259520.4	CTD-2651B20.3	-15.1	1.02e-46	2.1e-43	-0.57	-0.42	Homoarginine levels;	chr15:45386416	chr15:45251580~45279251:-
BRCA	cis	rs1153858	1	rs4775911	ENSG00000259520.4	CTD-2651B20.3	15.09	1.06e-46	2.19e-43	0.56	0.42	Homoarginine levels;	chr15:45357589	chr15:45251580~45279251:-
BRCA	cis	rs7104764	0.507	rs7111364	ENSG00000277290.1	RP11-326C3.16	-15.09	1.11e-46	2.28e-43	-0.52	-0.42	Menarche (age at onset);	chr11:258542	chr11:243099~243483:-
BRCA	cis	rs7208859	0.623	rs11658022	ENSG00000263531.1	RP13-753N3.1	15.09	1.12e-46	2.31e-43	0.85	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30758341	chr17:30863921~30864940:-
BRCA	cis	rs6452524	0.935	rs7736296	ENSG00000249664.1	CTD-2227C6.2	-15.08	1.25e-46	2.56e-43	-0.49	-0.42	Hypertension (SNP x SNP interaction);	chr5:83082421	chr5:83012285~83013109:-
BRCA	cis	rs977987	0.806	rs4146809	ENSG00000261783.1	RP11-252K23.2	15.08	1.3e-46	2.66e-43	0.53	0.42	Dupuytren's disease;	chr16:75381877	chr16:75379818~75381260:-
BRCA	cis	rs7617773	0.817	rs4131361	ENSG00000229759.1	MRPS18AP1	15.07	1.35e-46	2.76e-43	0.53	0.42	Coronary artery disease;	chr3:48287322	chr3:48256350~48256938:-
BRCA	cis	rs7104764	0.507	rs7121085	ENSG00000277290.1	RP11-326C3.16	-15.07	1.5e-46	3.07e-43	-0.52	-0.42	Menarche (age at onset);	chr11:258523	chr11:243099~243483:-
BRCA	cis	rs2929278	0.736	rs2412823	ENSG00000249839.1	AC011330.5	15.06	1.66e-46	3.38e-43	0.5	0.42	Schizophrenia;	chr15:43935072	chr15:43663654~43684339:-
BRCA	cis	rs200367988	1	rs200367988	ENSG00000271670.1	RP11-95I16.4	-15.05	1.78e-46	3.64e-43	-0.47	-0.42	Prostate-specific antigen levels (conditioned on lead SNPs);Prostate-specific antigen levels;	chr10:120915337	chr10:120879256~120880667:-
BRCA	cis	rs7617773	0.817	rs6800492	ENSG00000229759.1	MRPS18AP1	15.05	1.83e-46	3.74e-43	0.52	0.42	Coronary artery disease;	chr3:48282400	chr3:48256350~48256938:-
BRCA	cis	rs10256972	0.706	rs12701969	ENSG00000229043.2	AC091729.9	-15.05	1.91e-46	3.89e-43	-0.58	-0.42	Endometriosis;Longevity;	chr7:1082213	chr7:1160374~1165267:+
BRCA	cis	rs7617773	0.817	rs9818937	ENSG00000229759.1	MRPS18AP1	15.05	1.91e-46	3.9e-43	0.52	0.42	Coronary artery disease;	chr3:48283791	chr3:48256350~48256938:-
BRCA	cis	rs1061377	0.861	rs35739603	ENSG00000249207.1	RP11-360F5.1	-15.04	1.99e-46	4.05e-43	-0.49	-0.42	Uric acid levels;	chr4:39107938	chr4:39112677~39126818:-
BRCA	cis	rs977987	0.806	rs4993970	ENSG00000261783.1	RP11-252K23.2	-15.04	2e-46	4.08e-43	-0.53	-0.42	Dupuytren's disease;	chr16:75377721	chr16:75379818~75381260:-
BRCA	cis	rs977987	0.736	rs4888392	ENSG00000261783.1	RP11-252K23.2	-15.04	2e-46	4.08e-43	-0.53	-0.42	Dupuytren's disease;	chr16:75378364	chr16:75379818~75381260:-
BRCA	cis	rs6452524	0.836	rs10041617	ENSG00000249664.1	CTD-2227C6.2	15.04	2.18e-46	4.44e-43	0.49	0.42	Hypertension (SNP x SNP interaction);	chr5:83096535	chr5:83012285~83013109:-
BRCA	cis	rs977987	0.806	rs1109342	ENSG00000261783.1	RP11-252K23.2	15.03	2.39e-46	4.87e-43	0.55	0.42	Dupuytren's disease;	chr16:75411777	chr16:75379818~75381260:-
BRCA	cis	rs17507216	0.718	rs4779034	ENSG00000278603.1	RP13-608F4.5	15.03	2.48e-46	5.03e-43	0.68	0.42	Excessive daytime sleepiness;	chr15:82576799	chr15:82472203~82472426:+
BRCA	cis	rs9389248	0.69	rs1028314	ENSG00000232876.1	CTA-212D2.2	15.02	2.64e-46	5.36e-43	0.53	0.42	High light scatter reticulocyte percentage of red cells;	chr6:134934572	chr6:135055033~135060550:+
BRCA	cis	rs11155671	0.53	rs7763849	ENSG00000231760.4	RP11-350J20.5	15.01	2.83e-46	5.75e-43	0.52	0.42	Testicular germ cell tumor;	chr6:149885244	chr6:149796151~149826294:-
BRCA	cis	rs992157	0.798	rs7587220	ENSG00000261338.2	RP11-378A13.1	-15.01	2.88e-46	5.84e-43	-0.45	-0.42	Colorectal cancer;	chr2:218296141	chr2:218255319~218257366:+
BRCA	cis	rs992157	0.798	rs4674284	ENSG00000261338.2	RP11-378A13.1	-15.01	2.88e-46	5.84e-43	-0.45	-0.42	Colorectal cancer;	chr2:218296518	chr2:218255319~218257366:+
BRCA	cis	rs7301826	0.585	rs6486600	ENSG00000256299.1	RP11-989F5.3	-15.01	3.01e-46	6.11e-43	-0.48	-0.42	Plasma plasminogen activator levels;	chr12:130808432	chr12:130810821~130812622:-
BRCA	cis	rs2729354	0.903	rs2729371	ENSG00000265566.2	RN7SL605P	-15.01	3.01e-46	6.11e-43	-0.68	-0.42	Blood protein levels;	chr11:57553849	chr11:57528085~57528365:-
BRCA	cis	rs11690935	0.959	rs10184866	ENSG00000228389.1	AC068039.4	15.01	3.02e-46	6.13e-43	0.54	0.42	Schizophrenia;	chr2:171752446	chr2:171773482~171775844:+
BRCA	cis	rs2882667	0.638	rs6895690	ENSG00000253404.1	AC034243.1	15	3.25e-46	6.57e-43	0.53	0.42	Age-related hearing impairment (SNP x SNP interaction);	chr5:139130162	chr5:138744434~138753309:-
BRCA	cis	rs6452524	0.836	rs1478484	ENSG00000249664.1	CTD-2227C6.2	15	3.32e-46	6.71e-43	0.5	0.42	Hypertension (SNP x SNP interaction);	chr5:83085055	chr5:83012285~83013109:-
BRCA	cis	rs6452524	0.935	rs7714710	ENSG00000249664.1	CTD-2227C6.2	15	3.32e-46	6.71e-43	0.5	0.42	Hypertension (SNP x SNP interaction);	chr5:83085750	chr5:83012285~83013109:-
BRCA	cis	rs7617773	0.779	rs9833309	ENSG00000229759.1	MRPS18AP1	15	3.44e-46	6.94e-43	0.52	0.42	Coronary artery disease;	chr3:48285960	chr3:48256350~48256938:-
BRCA	cis	rs7617773	0.817	rs9853804	ENSG00000229759.1	MRPS18AP1	15	3.44e-46	6.94e-43	0.52	0.42	Coronary artery disease;	chr3:48286239	chr3:48256350~48256938:-
BRCA	cis	rs7617773	0.817	rs9834095	ENSG00000229759.1	MRPS18AP1	15	3.44e-46	6.94e-43	0.52	0.42	Coronary artery disease;	chr3:48286261	chr3:48256350~48256938:-
BRCA	cis	rs7617773	0.963	rs12494304	ENSG00000229759.1	MRPS18AP1	-14.99	3.65e-46	7.37e-43	-0.48	-0.42	Coronary artery disease;	chr3:48136539	chr3:48256350~48256938:-
BRCA	cis	rs1153858	1	rs11070456	ENSG00000259520.4	CTD-2651B20.3	-14.99	3.81e-46	7.68e-43	-0.57	-0.42	Homoarginine levels;	chr15:45394637	chr15:45251580~45279251:-
BRCA	cis	rs7188445	0.592	rs7199794	ENSG00000261390.4	RP11-345M22.2	14.98	4.17e-46	8.4e-43	0.51	0.42	Urate levels;	chr16:79708296	chr16:79715232~79770563:-
BRCA	cis	rs1153858	1	rs3809472	ENSG00000259520.4	CTD-2651B20.3	-14.98	4.19e-46	8.43e-43	-0.57	-0.42	Homoarginine levels;	chr15:45402120	chr15:45251580~45279251:-
BRCA	cis	rs1153858	1	rs1820518	ENSG00000259520.4	CTD-2651B20.3	-14.98	4.19e-46	8.43e-43	-0.57	-0.42	Homoarginine levels;	chr15:45402381	chr15:45251580~45279251:-
BRCA	cis	rs6452524	0.935	rs3901654	ENSG00000249664.1	CTD-2227C6.2	14.98	4.55e-46	9.15e-43	0.5	0.42	Hypertension (SNP x SNP interaction);	chr5:83110519	chr5:83012285~83013109:-
BRCA	cis	rs8037818	1	rs4544214	ENSG00000276724.1	RP11-1000B6.7	14.97	4.64e-46	9.3e-43	0.6	0.42	Obesity-related traits;	chr15:32639703	chr15:32583612~32584312:+
BRCA	cis	rs977987	0.778	rs11858992	ENSG00000261783.1	RP11-252K23.2	-14.97	4.75e-46	9.51e-43	-0.53	-0.42	Dupuytren's disease;	chr16:75377547	chr16:75379818~75381260:-
BRCA	cis	rs1153858	1	rs7181167	ENSG00000259520.4	CTD-2651B20.3	-14.97	4.89e-46	9.81e-43	-0.57	-0.42	Homoarginine levels;	chr15:45394038	chr15:45251580~45279251:-
BRCA	cis	rs11690935	0.959	rs4667694	ENSG00000228389.1	AC068039.4	14.97	4.97e-46	9.96e-43	0.54	0.42	Schizophrenia;	chr2:171748889	chr2:171773482~171775844:+
BRCA	cis	rs5760092	0.618	rs5996631	ENSG00000225282.1	AP000350.6	-14.97	5e-46	1e-42	-0.58	-0.42	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23926900~23929574:+
BRCA	cis	rs7617773	0.817	rs4131362	ENSG00000229759.1	MRPS18AP1	14.96	5.61e-46	1.12e-42	0.52	0.42	Coronary artery disease;	chr3:48287546	chr3:48256350~48256938:-
BRCA	cis	rs11690935	1	rs6433311	ENSG00000228389.1	AC068039.4	-14.95	6.26e-46	1.25e-42	-0.54	-0.42	Schizophrenia;	chr2:171692738	chr2:171773482~171775844:+
BRCA	cis	rs7617773	0.963	rs12493256	ENSG00000229759.1	MRPS18AP1	-14.95	6.4e-46	1.28e-42	-0.48	-0.42	Coronary artery disease;	chr3:48135257	chr3:48256350~48256938:-
BRCA	cis	rs7617773	0.744	rs2125482	ENSG00000229759.1	MRPS18AP1	14.94	7.08e-46	1.41e-42	0.52	0.42	Coronary artery disease;	chr3:48281643	chr3:48256350~48256938:-
BRCA	cis	rs8037818	1	rs11071856	ENSG00000276724.1	RP11-1000B6.7	-14.93	7.95e-46	1.58e-42	-0.63	-0.42	Obesity-related traits;	chr15:32633591	chr15:32583612~32584312:+
BRCA	cis	rs6452524	0.935	rs1478480	ENSG00000249664.1	CTD-2227C6.2	14.93	8.09e-46	1.61e-42	0.49	0.42	Hypertension (SNP x SNP interaction);	chr5:83112117	chr5:83012285~83013109:-
BRCA	cis	rs11690935	0.959	rs7562356	ENSG00000228389.1	AC068039.4	14.93	8.12e-46	1.61e-42	0.54	0.42	Schizophrenia;	chr2:171770101	chr2:171773482~171775844:+
BRCA	cis	rs6452524	0.508	rs256795	ENSG00000249664.1	CTD-2227C6.2	-14.92	8.9e-46	1.77e-42	-0.51	-0.42	Hypertension (SNP x SNP interaction);	chr5:83001543	chr5:83012285~83013109:-
BRCA	cis	rs7617773	0.78	rs35297486	ENSG00000229759.1	MRPS18AP1	14.92	9.62e-46	1.91e-42	0.56	0.42	Coronary artery disease;	chr3:48336657	chr3:48256350~48256938:-
BRCA	cis	rs11690935	0.959	rs12185567	ENSG00000228389.1	AC068039.4	-14.91	1.09e-45	2.15e-42	-0.53	-0.42	Schizophrenia;	chr2:171704219	chr2:171773482~171775844:+
BRCA	cis	rs858239	0.665	rs858306	ENSG00000226816.2	AC005082.12	14.9	1.18e-45	2.33e-42	0.48	0.42	Cerebrospinal fluid biomarker levels;	chr7:23203135	chr7:23206013~23208045:+
BRCA	cis	rs2729354	0.903	rs1846568	ENSG00000265566.2	RN7SL605P	-14.9	1.18e-45	2.34e-42	-0.65	-0.42	Blood protein levels;	chr11:57590241	chr11:57528085~57528365:-
BRCA	cis	rs11673344	0.642	rs12462708	ENSG00000226686.6	LINC01535	-14.9	1.22e-45	2.4e-42	-0.56	-0.42	Obesity-related traits;	chr19:37306676	chr19:37251912~37265535:+
BRCA	cis	rs7208859	0.573	rs55661352	ENSG00000263531.1	RP13-753N3.1	14.89	1.28e-45	2.53e-42	0.85	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30718610	chr17:30863921~30864940:-
BRCA	cis	rs1153858	1	rs11070457	ENSG00000259520.4	CTD-2651B20.3	-14.89	1.36e-45	2.69e-42	-0.56	-0.42	Homoarginine levels;	chr15:45394745	chr15:45251580~45279251:-
BRCA	cis	rs1061377	1	rs6829450	ENSG00000249207.1	RP11-360F5.1	-14.88	1.48e-45	2.91e-42	-0.48	-0.42	Uric acid levels;	chr4:39114721	chr4:39112677~39126818:-
BRCA	cis	rs11690935	0.921	rs6710698	ENSG00000228389.1	AC068039.4	14.88	1.51e-45	2.98e-42	0.53	0.42	Schizophrenia;	chr2:171739568	chr2:171773482~171775844:+
BRCA	cis	rs7301826	0.651	rs34749116	ENSG00000256299.1	RP11-989F5.3	14.88	1.53e-45	3.01e-42	0.5	0.42	Plasma plasminogen activator levels;	chr12:130796207	chr12:130810821~130812622:-
BRCA	cis	rs6452524	0.901	rs17284211	ENSG00000249664.1	CTD-2227C6.2	14.88	1.56e-45	3.08e-42	0.49	0.42	Hypertension (SNP x SNP interaction);	chr5:83098706	chr5:83012285~83013109:-
BRCA	cis	rs6452524	0.935	rs1382374	ENSG00000249664.1	CTD-2227C6.2	14.88	1.56e-45	3.08e-42	0.49	0.42	Hypertension (SNP x SNP interaction);	chr5:83101010	chr5:83012285~83013109:-
BRCA	cis	rs8062405	0.755	rs62034358	ENSG00000259982.1	CDC37P1	14.87	1.69e-45	3.32e-42	0.53	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576276	chr16:28700294~28701540:-
BRCA	cis	rs8062405	0.755	rs12445823	ENSG00000259982.1	CDC37P1	14.87	1.69e-45	3.32e-42	0.53	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576728	chr16:28700294~28701540:-
BRCA	cis	rs8062405	0.723	rs12445744	ENSG00000259982.1	CDC37P1	14.87	1.69e-45	3.32e-42	0.53	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28577074	chr16:28700294~28701540:-
BRCA	cis	rs8062405	0.755	rs4787455	ENSG00000259982.1	CDC37P1	14.87	1.69e-45	3.32e-42	0.53	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28578134	chr16:28700294~28701540:-
BRCA	cis	rs11690935	1	rs6757773	ENSG00000228389.1	AC068039.4	-14.86	1.86e-45	3.65e-42	-0.53	-0.42	Schizophrenia;	chr2:171693120	chr2:171773482~171775844:+
BRCA	cis	rs6452524	0.905	rs6896548	ENSG00000249664.1	CTD-2227C6.2	14.86	1.91e-45	3.75e-42	0.49	0.42	Hypertension (SNP x SNP interaction);	chr5:83089247	chr5:83012285~83013109:-
BRCA	cis	rs6452524	0.935	rs1580311	ENSG00000249664.1	CTD-2227C6.2	14.85	2.04e-45	4e-42	0.49	0.42	Hypertension (SNP x SNP interaction);	chr5:83091667	chr5:83012285~83013109:-
BRCA	cis	rs6452524	0.935	rs1382376	ENSG00000249664.1	CTD-2227C6.2	14.85	2.05e-45	4.01e-42	0.49	0.42	Hypertension (SNP x SNP interaction);	chr5:83095418	chr5:83012285~83013109:-
BRCA	cis	rs6452524	0.935	rs12109517	ENSG00000249664.1	CTD-2227C6.2	14.85	2.05e-45	4.01e-42	0.49	0.42	Hypertension (SNP x SNP interaction);	chr5:83095947	chr5:83012285~83013109:-
BRCA	cis	rs6452524	0.935	rs12109514	ENSG00000249664.1	CTD-2227C6.2	14.85	2.05e-45	4.01e-42	0.49	0.42	Hypertension (SNP x SNP interaction);	chr5:83095965	chr5:83012285~83013109:-
BRCA	cis	rs1061377	1	rs1061377	ENSG00000249207.1	RP11-360F5.1	-14.85	2.1e-45	4.1e-42	-0.48	-0.42	Uric acid levels;	chr4:39123130	chr4:39112677~39126818:-
BRCA	cis	rs7617773	0.817	rs9311421	ENSG00000229759.1	MRPS18AP1	14.85	2.19e-45	4.28e-42	0.5	0.42	Coronary artery disease;	chr3:48251588	chr3:48256350~48256938:-
BRCA	cis	rs1061377	1	rs13109200	ENSG00000249207.1	RP11-360F5.1	-14.85	2.26e-45	4.42e-42	-0.48	-0.42	Uric acid levels;	chr4:39124396	chr4:39112677~39126818:-
BRCA	cis	rs1061377	1	rs13144374	ENSG00000249207.1	RP11-360F5.1	-14.85	2.26e-45	4.42e-42	-0.48	-0.42	Uric acid levels;	chr4:39128859	chr4:39112677~39126818:-
BRCA	cis	rs6452524	0.905	rs6884981	ENSG00000249664.1	CTD-2227C6.2	14.84	2.29e-45	4.48e-42	0.49	0.42	Hypertension (SNP x SNP interaction);	chr5:83087339	chr5:83012285~83013109:-
BRCA	cis	rs11690935	1	rs312918	ENSG00000228389.1	AC068039.4	14.84	2.3e-45	4.5e-42	0.52	0.42	Schizophrenia;	chr2:171713077	chr2:171773482~171775844:+
BRCA	cis	rs3931020	0.657	rs10890142	ENSG00000272864.1	RP11-17E13.2	-14.84	2.34e-45	4.58e-42	-0.56	-0.42	Resistin levels;	chr1:74713445	chr1:74698769~74699333:-
BRCA	cis	rs1153858	1	rs2056493	ENSG00000259520.4	CTD-2651B20.3	-14.84	2.42e-45	4.73e-42	-0.57	-0.42	Homoarginine levels;	chr15:45356074	chr15:45251580~45279251:-
BRCA	cis	rs11690935	0.959	rs2292815	ENSG00000228389.1	AC068039.4	14.84	2.44e-45	4.77e-42	0.54	0.42	Schizophrenia;	chr2:171730141	chr2:171773482~171775844:+
BRCA	cis	rs4853012	0.941	rs4852329	ENSG00000217702.2	RP11-287D1.4	14.84	2.52e-45	4.92e-42	0.7	0.42	Gestational age at birth (maternal effect);	chr2:74127417	chr2:74130583~74135395:+
BRCA	cis	rs3931020	0.688	rs277375	ENSG00000272864.1	RP11-17E13.2	-14.83	2.63e-45	5.12e-42	-0.55	-0.42	Resistin levels;	chr1:74738459	chr1:74698769~74699333:-
BRCA	cis	rs977987	0.843	rs11860231	ENSG00000261783.1	RP11-252K23.2	-14.83	2.72e-45	5.3e-42	-0.54	-0.42	Dupuytren's disease;	chr16:75351261	chr16:75379818~75381260:-
BRCA	cis	rs6452524	0.935	rs6880566	ENSG00000249664.1	CTD-2227C6.2	14.83	2.84e-45	5.52e-42	0.49	0.42	Hypertension (SNP x SNP interaction);	chr5:83086909	chr5:83012285~83013109:-
BRCA	cis	rs1061377	1	rs7675782	ENSG00000249207.1	RP11-360F5.1	-14.83	2.91e-45	5.66e-42	-0.47	-0.42	Uric acid levels;	chr4:39120048	chr4:39112677~39126818:-
BRCA	cis	rs2882667	0.66	rs11951084	ENSG00000253404.1	AC034243.1	14.82	3.25e-45	6.32e-42	0.53	0.42	Age-related hearing impairment (SNP x SNP interaction);	chr5:139125858	chr5:138744434~138753309:-
BRCA	cis	rs4423214	0.765	rs2002064	ENSG00000254682.1	RP11-660L16.2	-14.82	3.28e-45	6.38e-42	-0.56	-0.42	Vitamin D levels;	chr11:71452374	chr11:71448674~71452157:+
BRCA	cis	rs11690935	0.959	rs1474074	ENSG00000228389.1	AC068039.4	14.81	3.43e-45	6.67e-42	0.53	0.42	Schizophrenia;	chr2:171803342	chr2:171773482~171775844:+
BRCA	cis	rs11690935	0.959	rs35391289	ENSG00000228389.1	AC068039.4	14.81	3.45e-45	6.7e-42	0.54	0.42	Schizophrenia;	chr2:171778473	chr2:171773482~171775844:+
BRCA	cis	rs7617773	0.963	rs9822496	ENSG00000229759.1	MRPS18AP1	14.81	3.45e-45	6.71e-42	0.47	0.42	Coronary artery disease;	chr3:48139843	chr3:48256350~48256938:-
BRCA	cis	rs7617773	0.925	rs7374376	ENSG00000229759.1	MRPS18AP1	-14.81	3.55e-45	6.9e-42	-0.47	-0.42	Coronary artery disease;	chr3:48131197	chr3:48256350~48256938:-
BRCA	cis	rs992157	0.798	rs12053514	ENSG00000261338.2	RP11-378A13.1	-14.81	3.68e-45	7.14e-42	-0.44	-0.42	Colorectal cancer;	chr2:218303242	chr2:218255319~218257366:+
BRCA	cis	rs1153858	1	rs10519022	ENSG00000259520.4	CTD-2651B20.3	14.8	3.75e-45	7.28e-42	0.54	0.42	Homoarginine levels;	chr15:45371486	chr15:45251580~45279251:-
BRCA	cis	rs11690935	0.959	rs12692973	ENSG00000228389.1	AC068039.4	-14.8	3.96e-45	7.67e-42	-0.53	-0.42	Schizophrenia;	chr2:171785547	chr2:171773482~171775844:+
BRCA	cis	rs6452524	0.935	rs1011979	ENSG00000249664.1	CTD-2227C6.2	14.8	4.19e-45	8.11e-42	0.49	0.42	Hypertension (SNP x SNP interaction);	chr5:83097431	chr5:83012285~83013109:-
BRCA	cis	rs977987	0.585	rs62059845	ENSG00000261783.1	RP11-252K23.2	-14.79	4.69e-45	9.08e-42	-0.53	-0.42	Dupuytren's disease;	chr16:75396815	chr16:75379818~75381260:-
BRCA	cis	rs977987	0.778	rs62059846	ENSG00000261783.1	RP11-252K23.2	-14.79	4.69e-45	9.08e-42	-0.53	-0.42	Dupuytren's disease;	chr16:75396911	chr16:75379818~75381260:-
BRCA	cis	rs1061377	1	rs28607301	ENSG00000249207.1	RP11-360F5.1	-14.79	4.78e-45	9.25e-42	-0.47	-0.42	Uric acid levels;	chr4:39136460	chr4:39112677~39126818:-
BRCA	cis	rs4728142	0.604	rs13242262	ENSG00000275106.1	RP11-309L24.10	-14.78	4.89e-45	9.45e-42	-0.53	-0.42	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128951310	chr7:128952527~128953316:-
BRCA	cis	rs17507216	0.671	rs28582623	ENSG00000278603.1	RP13-608F4.5	14.78	5.07e-45	9.79e-42	0.67	0.42	Excessive daytime sleepiness;	chr15:82577381	chr15:82472203~82472426:+
BRCA	cis	rs1155848	0.892	rs1023293	ENSG00000227354.5	RBM26-AS1	14.78	5.14e-45	9.94e-42	0.93	0.42	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79480285	chr13:79406309~79424328:+
BRCA	cis	rs4423214	0.84	rs1792315	ENSG00000254682.1	RP11-660L16.2	-14.78	5.17e-45	9.99e-42	-0.55	-0.42	Vitamin D levels;	chr11:71454501	chr11:71448674~71452157:+
BRCA	cis	rs1061377	1	rs1036036	ENSG00000249207.1	RP11-360F5.1	-14.78	5.31e-45	1.02e-41	-0.47	-0.42	Uric acid levels;	chr4:39111104	chr4:39112677~39126818:-
BRCA	cis	rs6452524	0.935	rs1580310	ENSG00000249664.1	CTD-2227C6.2	14.77	5.52e-45	1.06e-41	0.49	0.42	Hypertension (SNP x SNP interaction);	chr5:83091792	chr5:83012285~83013109:-
BRCA	cis	rs6452524	0.901	rs1600362	ENSG00000249664.1	CTD-2227C6.2	14.77	5.64e-45	1.09e-41	0.49	0.42	Hypertension (SNP x SNP interaction);	chr5:83091354	chr5:83012285~83013109:-
BRCA	cis	rs992157	0.798	rs10932772	ENSG00000261338.2	RP11-378A13.1	14.77	6.01e-45	1.16e-41	0.44	0.42	Colorectal cancer;	chr2:218312425	chr2:218255319~218257366:+
BRCA	cis	rs11690935	1	rs6721680	ENSG00000228389.1	AC068039.4	-14.77	6.06e-45	1.17e-41	-0.53	-0.42	Schizophrenia;	chr2:171687403	chr2:171773482~171775844:+
BRCA	cis	rs11690935	0.959	rs11904009	ENSG00000228389.1	AC068039.4	14.76	6.19e-45	1.19e-41	0.53	0.42	Schizophrenia;	chr2:171770833	chr2:171773482~171775844:+
BRCA	cis	rs1153858	0.943	rs7402632	ENSG00000259520.4	CTD-2651B20.3	-14.76	6.54e-45	1.26e-41	-0.57	-0.42	Homoarginine levels;	chr15:45409715	chr15:45251580~45279251:-
BRCA	cis	rs9918079	0.56	rs10008376	ENSG00000273133.1	RP11-799M12.2	14.76	6.64e-45	1.28e-41	0.51	0.42	Obesity-related traits;	chr4:15622332	chr4:15563698~15564253:-
BRCA	cis	rs6452524	0.901	rs1580309	ENSG00000249664.1	CTD-2227C6.2	14.76	6.68e-45	1.29e-41	0.49	0.42	Hypertension (SNP x SNP interaction);	chr5:83091948	chr5:83012285~83013109:-
BRCA	cis	rs10256972	0.706	rs12701970	ENSG00000229043.2	AC091729.9	-14.76	6.8e-45	1.31e-41	-0.55	-0.42	Endometriosis;Longevity;	chr7:1082322	chr7:1160374~1165267:+
BRCA	cis	rs858239	0.73	rs858289	ENSG00000226816.2	AC005082.12	14.76	6.85e-45	1.32e-41	0.48	0.42	Cerebrospinal fluid biomarker levels;	chr7:23208539	chr7:23206013~23208045:+
BRCA	cis	rs35160687	0.901	rs12620833	ENSG00000273080.1	RP11-301O19.1	14.76	6.92e-45	1.33e-41	0.49	0.42	Night sleep phenotypes;	chr2:86245747	chr2:86195590~86196049:+
BRCA	cis	rs11690935	1	rs34542126	ENSG00000228389.1	AC068039.4	-14.75	7.01e-45	1.35e-41	-0.53	-0.42	Schizophrenia;	chr2:171686195	chr2:171773482~171775844:+
BRCA	cis	rs3931020	0.657	rs7522428	ENSG00000272864.1	RP11-17E13.2	-14.75	7.24e-45	1.39e-41	-0.56	-0.42	Resistin levels;	chr1:74712676	chr1:74698769~74699333:-
BRCA	cis	rs858239	0.73	rs858290	ENSG00000226816.2	AC005082.12	14.75	7.46e-45	1.43e-41	0.48	0.42	Cerebrospinal fluid biomarker levels;	chr7:23208417	chr7:23206013~23208045:+
BRCA	cis	rs2581828	0.965	rs2564961	ENSG00000242142.1	SERBP1P3	14.75	7.65e-45	1.47e-41	0.47	0.42	Crohn's disease;	chr3:53102445	chr3:53064283~53065091:-
BRCA	cis	rs1061377	1	rs36090629	ENSG00000249207.1	RP11-360F5.1	-14.74	7.95e-45	1.53e-41	-0.47	-0.42	Uric acid levels;	chr4:39137195	chr4:39112677~39126818:-
BRCA	cis	rs1061377	0.87	rs73238544	ENSG00000249207.1	RP11-360F5.1	-14.74	7.95e-45	1.53e-41	-0.47	-0.42	Uric acid levels;	chr4:39137343	chr4:39112677~39126818:-
BRCA	cis	rs858239	0.698	rs858295	ENSG00000226816.2	AC005082.12	14.74	8.02e-45	1.54e-41	0.48	0.42	Cerebrospinal fluid biomarker levels;	chr7:23205950	chr7:23206013~23208045:+
BRCA	cis	rs35160687	0.901	rs12999029	ENSG00000273080.1	RP11-301O19.1	14.74	8.15e-45	1.56e-41	0.49	0.42	Night sleep phenotypes;	chr2:86275790	chr2:86195590~86196049:+
BRCA	cis	rs35160687	0.901	rs67903513	ENSG00000273080.1	RP11-301O19.1	14.74	8.36e-45	1.61e-41	0.49	0.42	Night sleep phenotypes;	chr2:86284976	chr2:86195590~86196049:+
BRCA	cis	rs2581828	0.965	rs35783750	ENSG00000242142.1	SERBP1P3	14.73	8.89e-45	1.71e-41	0.46	0.42	Crohn's disease;	chr3:53100847	chr3:53064283~53065091:-
BRCA	cis	rs2581828	0.965	rs34454739	ENSG00000242142.1	SERBP1P3	14.73	8.89e-45	1.71e-41	0.46	0.42	Crohn's disease;	chr3:53100955	chr3:53064283~53065091:-
BRCA	cis	rs7208859	0.673	rs3816780	ENSG00000263531.1	RP13-753N3.1	14.73	9.59e-45	1.84e-41	0.77	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30834340	chr17:30863921~30864940:-
BRCA	cis	rs3931020	0.688	rs277396	ENSG00000272864.1	RP11-17E13.2	14.72	1e-44	1.92e-41	0.56	0.42	Resistin levels;	chr1:74747964	chr1:74698769~74699333:-
BRCA	cis	rs977987	0.806	rs8050769	ENSG00000261783.1	RP11-252K23.2	-14.72	1e-44	1.92e-41	-0.53	-0.42	Dupuytren's disease;	chr16:75354536	chr16:75379818~75381260:-
BRCA	cis	rs977987	0.806	rs6564252	ENSG00000261783.1	RP11-252K23.2	-14.72	1.01e-44	1.94e-41	-0.53	-0.41	Dupuytren's disease;	chr16:75355042	chr16:75379818~75381260:-
BRCA	cis	rs11690935	1	rs11678984	ENSG00000228389.1	AC068039.4	-14.72	1.01e-44	1.94e-41	-0.53	-0.41	Schizophrenia;	chr2:171679338	chr2:171773482~171775844:+
BRCA	cis	rs977987	0.806	rs4887818	ENSG00000261783.1	RP11-252K23.2	-14.72	1.05e-44	2e-41	-0.54	-0.41	Dupuytren's disease;	chr16:75328097	chr16:75379818~75381260:-
BRCA	cis	rs7301826	0.651	rs7956851	ENSG00000256299.1	RP11-989F5.3	-14.72	1.06e-44	2.02e-41	-0.47	-0.41	Plasma plasminogen activator levels;	chr12:130834554	chr12:130810821~130812622:-
BRCA	cis	rs7301826	0.651	rs12820597	ENSG00000256299.1	RP11-989F5.3	14.72	1.08e-44	2.06e-41	0.49	0.41	Plasma plasminogen activator levels;	chr12:130795640	chr12:130810821~130812622:-
BRCA	cis	rs4728142	0.564	rs10954213	ENSG00000275106.1	RP11-309L24.10	-14.72	1.08e-44	2.07e-41	-0.53	-0.41	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128949373	chr7:128952527~128953316:-
BRCA	cis	rs6452524	0.868	rs10071617	ENSG00000249664.1	CTD-2227C6.2	14.71	1.14e-44	2.17e-41	0.48	0.41	Hypertension (SNP x SNP interaction);	chr5:83103207	chr5:83012285~83013109:-
BRCA	cis	rs7301826	0.651	rs2277336	ENSG00000256299.1	RP11-989F5.3	14.71	1.15e-44	2.2e-41	0.49	0.41	Plasma plasminogen activator levels;	chr12:130801574	chr12:130810821~130812622:-
BRCA	cis	rs10256972	0.681	rs6979076	ENSG00000229043.2	AC091729.9	14.71	1.16e-44	2.22e-41	0.55	0.41	Endometriosis;Longevity;	chr7:1076611	chr7:1160374~1165267:+
BRCA	cis	rs7301826	0.627	rs7978987	ENSG00000256299.1	RP11-989F5.3	14.71	1.18e-44	2.25e-41	0.49	0.41	Plasma plasminogen activator levels;	chr12:130796949	chr12:130810821~130812622:-
BRCA	cis	rs7617773	0.78	rs13090538	ENSG00000229759.1	MRPS18AP1	14.71	1.22e-44	2.32e-41	0.54	0.41	Coronary artery disease;	chr3:48329279	chr3:48256350~48256938:-
BRCA	cis	rs858239	0.633	rs858300	ENSG00000226816.2	AC005082.12	14.71	1.25e-44	2.37e-41	0.48	0.41	Cerebrospinal fluid biomarker levels;	chr7:23205012	chr7:23206013~23208045:+
BRCA	cis	rs3931020	0.688	rs1051122	ENSG00000272864.1	RP11-17E13.2	-14.71	1.27e-44	2.42e-41	-0.55	-0.41	Resistin levels;	chr1:74724768	chr1:74698769~74699333:-
BRCA	cis	rs3931020	0.688	rs968358	ENSG00000272864.1	RP11-17E13.2	-14.71	1.27e-44	2.42e-41	-0.55	-0.41	Resistin levels;	chr1:74728305	chr1:74698769~74699333:-
BRCA	cis	rs1426063	0.614	rs17266308	ENSG00000260265.1	RP11-44F21.5	-14.7	1.32e-44	2.51e-41	-0.88	-0.41	QT interval;	chr4:75137695	chr4:75081702~75084717:-
BRCA	cis	rs6452524	0.967	rs1564211	ENSG00000249664.1	CTD-2227C6.2	14.7	1.32e-44	2.51e-41	0.48	0.41	Hypertension (SNP x SNP interaction);	chr5:83117014	chr5:83012285~83013109:-
BRCA	cis	rs7301826	0.627	rs4334059	ENSG00000256299.1	RP11-989F5.3	-14.7	1.35e-44	2.56e-41	-0.48	-0.41	Plasma plasminogen activator levels;	chr12:130829669	chr12:130810821~130812622:-
BRCA	cis	rs977987	0.806	rs2865531	ENSG00000261783.1	RP11-252K23.2	-14.7	1.35e-44	2.58e-41	-0.53	-0.41	Dupuytren's disease;	chr16:75356418	chr16:75379818~75381260:-
BRCA	cis	rs11155671	0.53	rs7763849	ENSG00000223701.3	RAET1E-AS1	14.7	1.36e-44	2.59e-41	0.51	0.41	Testicular germ cell tumor;	chr6:149885244	chr6:149884431~149919508:+
BRCA	cis	rs6452524	0.935	rs1542539	ENSG00000249664.1	CTD-2227C6.2	14.7	1.42e-44	2.7e-41	0.48	0.41	Hypertension (SNP x SNP interaction);	chr5:83116033	chr5:83012285~83013109:-
BRCA	cis	rs6452524	0.935	rs1543847	ENSG00000249664.1	CTD-2227C6.2	14.7	1.42e-44	2.7e-41	0.48	0.41	Hypertension (SNP x SNP interaction);	chr5:83116044	chr5:83012285~83013109:-
BRCA	cis	rs977987	0.806	rs2903033	ENSG00000261783.1	RP11-252K23.2	-14.7	1.44e-44	2.74e-41	-0.53	-0.41	Dupuytren's disease;	chr16:75355708	chr16:75379818~75381260:-
BRCA	cis	rs11690935	0.921	rs10200608	ENSG00000228389.1	AC068039.4	14.69	1.47e-44	2.79e-41	0.53	0.41	Schizophrenia;	chr2:171741419	chr2:171773482~171775844:+
BRCA	cis	rs2906856	0.526	rs2906852	ENSG00000255733.4	IFNG-AS1	14.69	1.47e-44	2.79e-41	0.38	0.41	Mosquito bite size;	chr12:67985701	chr12:67989445~68234686:+
BRCA	cis	rs7301826	0.603	rs7975825	ENSG00000256299.1	RP11-989F5.3	-14.69	1.49e-44	2.82e-41	-0.48	-0.41	Plasma plasminogen activator levels;	chr12:130803899	chr12:130810821~130812622:-
BRCA	cis	rs3096299	0.685	rs12446145	ENSG00000274627.1	RP11-104N10.2	14.69	1.53e-44	2.91e-41	0.43	0.41	Multiple myeloma (IgH translocation);	chr16:89476287	chr16:89516797~89522217:+
BRCA	cis	rs7301826	1	rs4619189	ENSG00000256250.1	RP11-989F5.1	-14.69	1.54e-44	2.93e-41	-0.48	-0.41	Plasma plasminogen activator levels;	chr12:130829252	chr12:130810606~130812438:+
BRCA	cis	rs11690935	0.959	rs3770452	ENSG00000228389.1	AC068039.4	14.69	1.55e-44	2.95e-41	0.53	0.41	Schizophrenia;	chr2:171812172	chr2:171773482~171775844:+
BRCA	cis	rs977987	0.806	rs4887823	ENSG00000261783.1	RP11-252K23.2	-14.69	1.56e-44	2.97e-41	-0.53	-0.41	Dupuytren's disease;	chr16:75399176	chr16:75379818~75381260:-
BRCA	cis	rs6452524	0.935	rs7703318	ENSG00000249664.1	CTD-2227C6.2	14.69	1.6e-44	3.04e-41	0.48	0.41	Hypertension (SNP x SNP interaction);	chr5:83118234	chr5:83012285~83013109:-
BRCA	cis	rs4728142	0.625	rs4731533	ENSG00000275106.1	RP11-309L24.10	-14.69	1.62e-44	3.08e-41	-0.52	-0.41	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128962088	chr7:128952527~128953316:-
BRCA	cis	rs977987	0.771	rs4888387	ENSG00000261783.1	RP11-252K23.2	-14.68	1.65e-44	3.13e-41	-0.53	-0.41	Dupuytren's disease;	chr16:75355857	chr16:75379818~75381260:-
BRCA	cis	rs8040855	0.579	rs28521166	ENSG00000259295.5	CSPG4P12	-14.68	1.66e-44	3.15e-41	-0.5	-0.41	Bulimia nervosa;	chr15:85184801	chr15:85191438~85213905:+
BRCA	cis	rs9322193	0.923	rs9766004	ENSG00000268592.3	RAET1E-AS1	14.68	1.67e-44	3.16e-41	0.51	0.41	Lung cancer;	chr6:149754363	chr6:149863494~149919507:+
BRCA	cis	rs11690935	0.921	rs7594711	ENSG00000228389.1	AC068039.4	14.68	1.68e-44	3.19e-41	0.55	0.41	Schizophrenia;	chr2:172030734	chr2:171773482~171775844:+
BRCA	cis	rs2739330	0.734	rs2000467	ENSG00000099984.9	GSTT2	14.68	1.71e-44	3.25e-41	0.51	0.41	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23980123~23983911:+
BRCA	cis	rs11690935	0.959	rs7597387	ENSG00000228389.1	AC068039.4	14.68	1.76e-44	3.33e-41	0.53	0.41	Schizophrenia;	chr2:171720606	chr2:171773482~171775844:+
BRCA	cis	rs11690935	0.959	rs7355594	ENSG00000228389.1	AC068039.4	14.67	1.88e-44	3.56e-41	0.53	0.41	Schizophrenia;	chr2:171782938	chr2:171773482~171775844:+
BRCA	cis	rs11690935	1	rs3795999	ENSG00000228389.1	AC068039.4	-14.67	1.89e-44	3.57e-41	-0.53	-0.41	Schizophrenia;	chr2:171687973	chr2:171773482~171775844:+
BRCA	cis	rs2581828	0.965	rs4337632	ENSG00000242142.1	SERBP1P3	14.67	1.89e-44	3.58e-41	0.46	0.41	Crohn's disease;	chr3:53103295	chr3:53064283~53065091:-
BRCA	cis	rs992157	0.767	rs2382822	ENSG00000261338.2	RP11-378A13.1	-14.67	1.98e-44	3.74e-41	-0.44	-0.41	Colorectal cancer;	chr2:218308604	chr2:218255319~218257366:+
BRCA	cis	rs11690935	0.959	rs10803863	ENSG00000228389.1	AC068039.4	-14.67	1.98e-44	3.74e-41	-0.53	-0.41	Schizophrenia;	chr2:171678827	chr2:171773482~171775844:+
BRCA	cis	rs11690935	1	rs312925	ENSG00000228389.1	AC068039.4	14.67	1.99e-44	3.77e-41	0.52	0.41	Schizophrenia;	chr2:171707412	chr2:171773482~171775844:+
BRCA	cis	rs7397814	0.558	rs4764447	ENSG00000256673.1	RP11-599J14.2	14.67	2.08e-44	3.92e-41	0.48	0.41	IgG glycosylation;	chr12:9426513	chr12:9398355~9414851:-
BRCA	cis	rs3931020	0.688	rs525487	ENSG00000272864.1	RP11-17E13.2	14.66	2.18e-44	4.12e-41	0.57	0.41	Resistin levels;	chr1:74751736	chr1:74698769~74699333:-
BRCA	cis	rs977987	0.806	rs4888383	ENSG00000261783.1	RP11-252K23.2	-14.66	2.21e-44	4.18e-41	-0.53	-0.41	Dupuytren's disease;	chr16:75352451	chr16:75379818~75381260:-
BRCA	cis	rs1061377	1	rs9996285	ENSG00000249207.1	RP11-360F5.1	-14.66	2.33e-44	4.4e-41	-0.47	-0.41	Uric acid levels;	chr4:39130556	chr4:39112677~39126818:-
BRCA	cis	rs6452524	0.935	rs7718472	ENSG00000249664.1	CTD-2227C6.2	14.66	2.33e-44	4.41e-41	0.48	0.41	Hypertension (SNP x SNP interaction);	chr5:83082603	chr5:83012285~83013109:-
BRCA	cis	rs1061377	1	rs12646251	ENSG00000249207.1	RP11-360F5.1	-14.65	2.43e-44	4.59e-41	-0.48	-0.41	Uric acid levels;	chr4:39132751	chr4:39112677~39126818:-
BRCA	cis	rs8062405	0.755	rs4787457	ENSG00000259982.1	CDC37P1	14.65	2.63e-44	4.96e-41	0.53	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28544079	chr16:28700294~28701540:-
BRCA	cis	rs11690935	0.959	rs2674484	ENSG00000228389.1	AC068039.4	14.64	2.73e-44	5.14e-41	0.53	0.41	Schizophrenia;	chr2:171718102	chr2:171773482~171775844:+
BRCA	cis	rs11690935	0.879	rs908671	ENSG00000228389.1	AC068039.4	14.64	2.75e-44	5.19e-41	0.53	0.41	Schizophrenia;	chr2:171833755	chr2:171773482~171775844:+
BRCA	cis	rs10170846	1	rs10170846	ENSG00000261428.2	RP11-16P6.1	-14.64	2.76e-44	5.19e-41	-0.51	-0.41	Schizophrenia (inflammation and infection response interaction);	chr2:222652986	chr2:222566899~222569719:-
BRCA	cis	rs8062405	0.755	rs62034350	ENSG00000259982.1	CDC37P1	14.64	2.87e-44	5.4e-41	0.53	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28550935	chr16:28700294~28701540:-
BRCA	cis	rs6452524	0.935	rs10076059	ENSG00000249664.1	CTD-2227C6.2	14.64	2.98e-44	5.61e-41	0.48	0.41	Hypertension (SNP x SNP interaction);	chr5:83105698	chr5:83012285~83013109:-
BRCA	cis	rs6452524	0.935	rs7736783	ENSG00000249664.1	CTD-2227C6.2	14.64	2.98e-44	5.61e-41	0.48	0.41	Hypertension (SNP x SNP interaction);	chr5:83107050	chr5:83012285~83013109:-
BRCA	cis	rs6452524	0.935	rs11951257	ENSG00000249664.1	CTD-2227C6.2	14.64	2.98e-44	5.61e-41	0.48	0.41	Hypertension (SNP x SNP interaction);	chr5:83107492	chr5:83012285~83013109:-
BRCA	cis	rs11690935	0.694	rs312921	ENSG00000228389.1	AC068039.4	14.63	3.27e-44	6.15e-41	0.52	0.41	Schizophrenia;	chr2:171710715	chr2:171773482~171775844:+
BRCA	cis	rs8062405	0.755	rs7193402	ENSG00000259982.1	CDC37P1	14.63	3.33e-44	6.26e-41	0.52	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28574806	chr16:28700294~28701540:-
BRCA	cis	rs11690935	0.959	rs6722757	ENSG00000228389.1	AC068039.4	14.62	3.45e-44	6.48e-41	0.53	0.41	Schizophrenia;	chr2:171735453	chr2:171773482~171775844:+
BRCA	cis	rs11690935	0.959	rs10166005	ENSG00000228389.1	AC068039.4	14.62	3.49e-44	6.56e-41	0.53	0.41	Schizophrenia;	chr2:171750784	chr2:171773482~171775844:+
BRCA	cis	rs977987	0.806	rs4888404	ENSG00000261783.1	RP11-252K23.2	-14.62	3.5e-44	6.58e-41	-0.53	-0.41	Dupuytren's disease;	chr16:75394199	chr16:75379818~75381260:-
BRCA	cis	rs11690935	0.959	rs66835971	ENSG00000228389.1	AC068039.4	14.62	3.63e-44	6.81e-41	0.53	0.41	Schizophrenia;	chr2:171820949	chr2:171773482~171775844:+
BRCA	cis	rs6964833	1	rs17515241	ENSG00000277053.3	GTF2IP1	14.62	3.74e-44	7.03e-41	0.57	0.41	Menarche (age at onset);	chr7:74717695	chr7:75185385~75237696:-
BRCA	cis	rs11690935	0.959	rs973889	ENSG00000228389.1	AC068039.4	14.61	3.86e-44	7.25e-41	0.53	0.41	Schizophrenia;	chr2:171723444	chr2:171773482~171775844:+
BRCA	cis	rs12439619	1	rs35152457	ENSG00000278603.1	RP13-608F4.5	14.61	3.96e-44	7.44e-41	0.59	0.41	Intelligence (multi-trait analysis);	chr15:82254207	chr15:82472203~82472426:+
BRCA	cis	rs977987	0.806	rs2285225	ENSG00000261783.1	RP11-252K23.2	-14.61	4.11e-44	7.7e-41	-0.53	-0.41	Dupuytren's disease;	chr16:75395354	chr16:75379818~75381260:-
BRCA	cis	rs11690935	0.959	rs4668412	ENSG00000228389.1	AC068039.4	14.61	4.19e-44	7.86e-41	0.53	0.41	Schizophrenia;	chr2:171763260	chr2:171773482~171775844:+
BRCA	cis	rs2729354	0.779	rs2454663	ENSG00000265566.2	RN7SL605P	-14.61	4.33e-44	8.11e-41	-0.66	-0.41	Blood protein levels;	chr11:57590610	chr11:57528085~57528365:-
BRCA	cis	rs2455601	0.786	rs10279	ENSG00000254860.4	TMEM9B-AS1	14.6	4.42e-44	8.29e-41	0.45	0.41	Schizophrenia;	chr11:8947762	chr11:8964675~8977527:+
BRCA	cis	rs11690935	1	rs12053003	ENSG00000228389.1	AC068039.4	-14.6	4.47e-44	8.38e-41	-0.53	-0.41	Schizophrenia;	chr2:171680840	chr2:171773482~171775844:+
BRCA	cis	rs11690935	0.959	rs1113389	ENSG00000228389.1	AC068039.4	14.6	4.63e-44	8.67e-41	0.53	0.41	Schizophrenia;	chr2:171778855	chr2:171773482~171775844:+
BRCA	cis	rs8062405	0.755	rs4788074	ENSG00000259982.1	CDC37P1	-14.6	4.69e-44	8.78e-41	-0.52	-0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28582276	chr16:28700294~28701540:-
BRCA	cis	rs7301826	0.61	rs7961690	ENSG00000256299.1	RP11-989F5.3	14.6	4.74e-44	8.87e-41	0.48	0.41	Plasma plasminogen activator levels;	chr12:130812335	chr12:130810821~130812622:-
BRCA	cis	rs9545047	0.735	rs314690	ENSG00000227676.3	LINC01068	14.6	4.77e-44	8.92e-41	0.53	0.41	Schizophrenia;	chr13:79434822	chr13:79566727~79571436:+
BRCA	cis	rs11690935	0.959	rs6705200	ENSG00000228389.1	AC068039.4	14.6	4.85e-44	9.06e-41	0.52	0.41	Schizophrenia;	chr2:171781090	chr2:171773482~171775844:+
BRCA	cis	rs11690935	0.959	rs7572215	ENSG00000228389.1	AC068039.4	14.59	5.13e-44	9.58e-41	0.53	0.41	Schizophrenia;	chr2:171777718	chr2:171773482~171775844:+
BRCA	cis	rs6452524	0.935	rs10045744	ENSG00000249664.1	CTD-2227C6.2	14.59	5.17e-44	9.66e-41	0.48	0.41	Hypertension (SNP x SNP interaction);	chr5:83113688	chr5:83012285~83013109:-
BRCA	cis	rs8062405	0.722	rs3785354	ENSG00000259982.1	CDC37P1	14.59	5.23e-44	9.77e-41	0.53	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28539346	chr16:28700294~28701540:-
BRCA	cis	rs977987	0.806	rs11643410	ENSG00000261783.1	RP11-252K23.2	-14.59	5.3e-44	9.89e-41	-0.53	-0.41	Dupuytren's disease;	chr16:75394408	chr16:75379818~75381260:-
BRCA	cis	rs858239	0.636	rs7808488	ENSG00000226816.2	AC005082.12	14.59	5.43e-44	1.01e-40	0.47	0.41	Cerebrospinal fluid biomarker levels;	chr7:23182251	chr7:23206013~23208045:+
BRCA	cis	rs7301826	0.627	rs34103763	ENSG00000256299.1	RP11-989F5.3	14.59	5.46e-44	1.02e-40	0.48	0.41	Plasma plasminogen activator levels;	chr12:130805604	chr12:130810821~130812622:-
BRCA	cis	rs35160687	1	rs35160687	ENSG00000273080.1	RP11-301O19.1	14.58	5.57e-44	1.04e-40	0.49	0.41	Night sleep phenotypes;	chr2:86244991	chr2:86195590~86196049:+
BRCA	cis	rs8062405	0.755	rs56209193	ENSG00000259982.1	CDC37P1	14.58	5.57e-44	1.04e-40	0.52	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28574315	chr16:28700294~28701540:-
BRCA	cis	rs977987	0.806	rs766521	ENSG00000261783.1	RP11-252K23.2	14.58	5.65e-44	1.05e-40	0.52	0.41	Dupuytren's disease;	chr16:75390256	chr16:75379818~75381260:-
BRCA	cis	rs3096299	0.685	rs4238830	ENSG00000274627.1	RP11-104N10.2	14.58	5.67e-44	1.06e-40	0.43	0.41	Multiple myeloma (IgH translocation);	chr16:89473833	chr16:89516797~89522217:+
BRCA	cis	rs1061377	0.76	rs7678457	ENSG00000249207.1	RP11-360F5.1	-14.58	5.86e-44	1.09e-40	-0.47	-0.41	Uric acid levels;	chr4:39136041	chr4:39112677~39126818:-
BRCA	cis	rs3091242	0.933	rs4649084	ENSG00000261349.1	RP3-465N24.5	-14.58	6.06e-44	1.13e-40	-0.47	-0.41	Erythrocyte sedimentation rate;	chr1:25426126	chr1:25266102~25267136:-
BRCA	cis	rs11690935	0.959	rs12692974	ENSG00000228389.1	AC068039.4	14.58	6.13e-44	1.14e-40	0.52	0.41	Schizophrenia;	chr2:171806746	chr2:171773482~171775844:+
BRCA	cis	rs7301826	0.966	rs4759795	ENSG00000256250.1	RP11-989F5.1	-14.58	6.19e-44	1.15e-40	-0.48	-0.41	Plasma plasminogen activator levels;	chr12:130816355	chr12:130810606~130812438:+
BRCA	cis	rs507080	0.501	rs625735	ENSG00000255422.1	AP002954.4	-14.57	6.31e-44	1.17e-40	-0.47	-0.41	Serum metabolite levels;	chr11:118704710	chr11:118704607~118750263:+
BRCA	cis	rs977987	0.527	rs62059844	ENSG00000261783.1	RP11-252K23.2	-14.57	6.41e-44	1.19e-40	-0.53	-0.41	Dupuytren's disease;	chr16:75395839	chr16:75379818~75381260:-
BRCA	cis	rs5760092	0.618	rs5996631	ENSG00000218537.1	MIF-AS1	-14.57	6.5e-44	1.21e-40	-0.6	-0.41	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23894426~23898930:-
BRCA	cis	rs8062405	0.755	rs4788080	ENSG00000259982.1	CDC37P1	14.57	6.66e-44	1.24e-40	0.53	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28546760	chr16:28700294~28701540:-
BRCA	cis	rs8062405	0.755	rs4787456	ENSG00000259982.1	CDC37P1	14.57	6.66e-44	1.24e-40	0.53	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548252	chr16:28700294~28701540:-
BRCA	cis	rs8062405	0.755	rs4788078	ENSG00000259982.1	CDC37P1	14.57	6.66e-44	1.24e-40	0.53	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548660	chr16:28700294~28701540:-
BRCA	cis	rs11690935	0.798	rs13018768	ENSG00000228389.1	AC068039.4	14.57	6.66e-44	1.24e-40	0.53	0.41	Schizophrenia;	chr2:171742082	chr2:171773482~171775844:+
BRCA	cis	rs11690935	0.959	rs10194102	ENSG00000228389.1	AC068039.4	14.57	6.84e-44	1.27e-40	0.53	0.41	Schizophrenia;	chr2:171769633	chr2:171773482~171775844:+
BRCA	cis	rs4423214	0.84	rs1792224	ENSG00000254682.1	RP11-660L16.2	-14.57	6.92e-44	1.29e-40	-0.55	-0.41	Vitamin D levels;	chr11:71465095	chr11:71448674~71452157:+
BRCA	cis	rs4423214	0.84	rs1792226	ENSG00000254682.1	RP11-660L16.2	-14.57	6.92e-44	1.29e-40	-0.55	-0.41	Vitamin D levels;	chr11:71465528	chr11:71448674~71452157:+
BRCA	cis	rs4423214	0.84	rs1790344	ENSG00000254682.1	RP11-660L16.2	-14.57	6.92e-44	1.29e-40	-0.55	-0.41	Vitamin D levels;	chr11:71465851	chr11:71448674~71452157:+
BRCA	cis	rs4423214	0.84	rs1790343	ENSG00000254682.1	RP11-660L16.2	-14.57	6.92e-44	1.29e-40	-0.55	-0.41	Vitamin D levels;	chr11:71466161	chr11:71448674~71452157:+
BRCA	cis	rs4423214	0.84	rs1792227	ENSG00000254682.1	RP11-660L16.2	-14.57	6.92e-44	1.29e-40	-0.55	-0.41	Vitamin D levels;	chr11:71466366	chr11:71448674~71452157:+
BRCA	cis	rs4423214	0.84	rs1790341	ENSG00000254682.1	RP11-660L16.2	-14.57	6.92e-44	1.29e-40	-0.55	-0.41	Vitamin D levels;	chr11:71466532	chr11:71448674~71452157:+
BRCA	cis	rs4423214	0.84	rs1540127	ENSG00000254682.1	RP11-660L16.2	-14.57	6.92e-44	1.29e-40	-0.55	-0.41	Vitamin D levels;	chr11:71467992	chr11:71448674~71452157:+
BRCA	cis	rs11690935	0.959	rs13419987	ENSG00000228389.1	AC068039.4	14.56	7.07e-44	1.31e-40	0.53	0.41	Schizophrenia;	chr2:171767404	chr2:171773482~171775844:+
BRCA	cis	rs4728142	0.604	rs2272347	ENSG00000275106.1	RP11-309L24.10	14.56	7.2e-44	1.34e-40	0.51	0.41	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128979361	chr7:128952527~128953316:-
BRCA	cis	rs8040855	0.794	rs4843024	ENSG00000259295.5	CSPG4P12	-14.56	7.34e-44	1.36e-40	-0.58	-0.41	Bulimia nervosa;	chr15:85162669	chr15:85191438~85213905:+
BRCA	cis	rs977987	0.778	rs2113232	ENSG00000261783.1	RP11-252K23.2	-14.56	7.36e-44	1.37e-40	-0.52	-0.41	Dupuytren's disease;	chr16:75357287	chr16:75379818~75381260:-
BRCA	cis	rs7301826	1	rs10744482	ENSG00000256250.1	RP11-989F5.1	-14.56	7.62e-44	1.41e-40	-0.48	-0.41	Plasma plasminogen activator levels;	chr12:130813650	chr12:130810606~130812438:+
BRCA	cis	rs7617773	0.963	rs12495221	ENSG00000229759.1	MRPS18AP1	-14.56	7.74e-44	1.44e-40	-0.46	-0.41	Coronary artery disease;	chr3:48137688	chr3:48256350~48256938:-
BRCA	cis	rs11690935	0.959	rs3770451	ENSG00000228389.1	AC068039.4	14.55	7.99e-44	1.48e-40	0.52	0.41	Schizophrenia;	chr2:171812205	chr2:171773482~171775844:+
BRCA	cis	rs6452524	0.935	rs767771	ENSG00000249664.1	CTD-2227C6.2	14.55	8.17e-44	1.52e-40	0.48	0.41	Hypertension (SNP x SNP interaction);	chr5:83108117	chr5:83012285~83013109:-
BRCA	cis	rs977987	0.806	rs1895490	ENSG00000261783.1	RP11-252K23.2	-14.55	8.26e-44	1.53e-40	-0.52	-0.41	Dupuytren's disease;	chr16:75358908	chr16:75379818~75381260:-
BRCA	cis	rs2455601	0.744	rs7938995	ENSG00000254860.4	TMEM9B-AS1	14.55	8.65e-44	1.6e-40	0.45	0.41	Schizophrenia;	chr11:8954128	chr11:8964675~8977527:+
BRCA	cis	rs73086581	1	rs17215340	ENSG00000229539.1	RP11-119B16.2	-14.55	8.86e-44	1.64e-40	-0.67	-0.41	Response to antidepressants in depression;	chr20:3989526	chr20:3888239~3888868:-
BRCA	cis	rs11690935	0.959	rs10207085	ENSG00000228389.1	AC068039.4	14.54	9.01e-44	1.67e-40	0.52	0.41	Schizophrenia;	chr2:171729375	chr2:171773482~171775844:+
BRCA	cis	rs977987	0.806	rs11862095	ENSG00000261783.1	RP11-252K23.2	-14.54	9.56e-44	1.77e-40	-0.53	-0.41	Dupuytren's disease;	chr16:75351520	chr16:75379818~75381260:-
BRCA	cis	rs6452524	0.967	rs2974443	ENSG00000249664.1	CTD-2227C6.2	14.54	9.94e-44	1.84e-40	0.49	0.41	Hypertension (SNP x SNP interaction);	chr5:83184595	chr5:83012285~83013109:-
BRCA	cis	rs6452524	0.967	rs2974441	ENSG00000249664.1	CTD-2227C6.2	14.53	1.02e-43	1.88e-40	0.49	0.41	Hypertension (SNP x SNP interaction);	chr5:83193330	chr5:83012285~83013109:-
BRCA	cis	rs977987	0.806	rs11865004	ENSG00000261783.1	RP11-252K23.2	-14.53	1.06e-43	1.96e-40	-0.52	-0.41	Dupuytren's disease;	chr16:75361879	chr16:75379818~75381260:-
BRCA	cis	rs494459	0.964	rs576283	ENSG00000255422.1	AP002954.4	-14.53	1.07e-43	1.97e-40	-0.47	-0.41	Height;	chr11:118703185	chr11:118704607~118750263:+
BRCA	cis	rs507080	0.524	rs524409	ENSG00000255422.1	AP002954.4	-14.53	1.07e-43	1.97e-40	-0.47	-0.41	Serum metabolite levels;	chr11:118703602	chr11:118704607~118750263:+
BRCA	cis	rs977987	0.806	rs7185640	ENSG00000261783.1	RP11-252K23.2	-14.53	1.07e-43	1.98e-40	-0.52	-0.41	Dupuytren's disease;	chr16:75360501	chr16:75379818~75381260:-
BRCA	cis	rs977987	0.806	rs11640674	ENSG00000261783.1	RP11-252K23.2	-14.53	1.07e-43	1.98e-40	-0.52	-0.41	Dupuytren's disease;	chr16:75361046	chr16:75379818~75381260:-
BRCA	cis	rs992157	0.698	rs6746089	ENSG00000261338.2	RP11-378A13.1	14.53	1.11e-43	2.05e-40	0.43	0.41	Colorectal cancer;	chr2:218305654	chr2:218255319~218257366:+
BRCA	cis	rs507080	0.769	rs7389	ENSG00000255422.1	AP002954.4	14.53	1.14e-43	2.11e-40	0.5	0.41	Serum metabolite levels;	chr11:118657756	chr11:118704607~118750263:+
BRCA	cis	rs11690935	1	rs1554166	ENSG00000228389.1	AC068039.4	14.52	1.2e-43	2.22e-40	0.52	0.41	Schizophrenia;	chr2:171685099	chr2:171773482~171775844:+
BRCA	cis	rs9918079	0.56	rs7438356	ENSG00000273133.1	RP11-799M12.2	-14.52	1.23e-43	2.26e-40	-0.5	-0.41	Obesity-related traits;	chr4:15623147	chr4:15563698~15564253:-
BRCA	cis	rs7301826	0.61	rs36051740	ENSG00000256299.1	RP11-989F5.3	14.51	1.42e-43	2.61e-40	0.47	0.41	Plasma plasminogen activator levels;	chr12:130808177	chr12:130810821~130812622:-
BRCA	cis	rs977987	0.806	rs35263058	ENSG00000261783.1	RP11-252K23.2	-14.51	1.42e-43	2.62e-40	-0.52	-0.41	Dupuytren's disease;	chr16:75358039	chr16:75379818~75381260:-
BRCA	cis	rs507080	0.769	rs745663	ENSG00000255422.1	AP002954.4	-14.51	1.42e-43	2.62e-40	-0.5	-0.41	Serum metabolite levels;	chr11:118658886	chr11:118704607~118750263:+
BRCA	cis	rs7208859	0.623	rs11657662	ENSG00000263531.1	RP13-753N3.1	-14.51	1.43e-43	2.63e-40	-0.79	-0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30749329	chr17:30863921~30864940:-
BRCA	cis	rs494459	0.929	rs627391	ENSG00000255422.1	AP002954.4	-14.51	1.43e-43	2.64e-40	-0.47	-0.41	Height;	chr11:118703207	chr11:118704607~118750263:+
BRCA	cis	rs1153858	0.887	rs28569043	ENSG00000259520.4	CTD-2651B20.3	-14.51	1.44e-43	2.65e-40	-0.55	-0.41	Homoarginine levels;	chr15:45438728	chr15:45251580~45279251:-
BRCA	cis	rs11690935	0.959	rs6433314	ENSG00000228389.1	AC068039.4	14.5	1.47e-43	2.71e-40	0.52	0.41	Schizophrenia;	chr2:171804461	chr2:171773482~171775844:+
BRCA	cis	rs11690935	0.959	rs7604918	ENSG00000228389.1	AC068039.4	14.5	1.57e-43	2.88e-40	0.52	0.41	Schizophrenia;	chr2:171731584	chr2:171773482~171775844:+
BRCA	cis	rs11690935	0.959	rs10497374	ENSG00000228389.1	AC068039.4	14.5	1.6e-43	2.93e-40	0.52	0.41	Schizophrenia;	chr2:171784113	chr2:171773482~171775844:+
BRCA	cis	rs11690935	0.918	rs11757	ENSG00000228389.1	AC068039.4	14.5	1.63e-43	2.99e-40	0.53	0.41	Schizophrenia;	chr2:171784535	chr2:171773482~171775844:+
BRCA	cis	rs11690935	0.959	rs67204065	ENSG00000228389.1	AC068039.4	14.5	1.65e-43	3.02e-40	0.52	0.41	Schizophrenia;	chr2:171816114	chr2:171773482~171775844:+
BRCA	cis	rs7301826	0.56	rs12829294	ENSG00000256299.1	RP11-989F5.3	14.49	1.66e-43	3.06e-40	0.48	0.41	Plasma plasminogen activator levels;	chr12:130825427	chr12:130810821~130812622:-
BRCA	cis	rs11690935	0.921	rs4668414	ENSG00000228389.1	AC068039.4	14.48	1.87e-43	3.43e-40	0.53	0.41	Schizophrenia;	chr2:171847781	chr2:171773482~171775844:+
BRCA	cis	rs11690935	0.959	rs6759575	ENSG00000228389.1	AC068039.4	14.48	1.89e-43	3.46e-40	0.52	0.41	Schizophrenia;	chr2:171832558	chr2:171773482~171775844:+
BRCA	cis	rs3091242	0.933	rs12402120	ENSG00000261349.1	RP3-465N24.5	-14.48	1.93e-43	3.54e-40	-0.46	-0.41	Erythrocyte sedimentation rate;	chr1:25425141	chr1:25266102~25267136:-
BRCA	cis	rs11690935	0.959	rs6745143	ENSG00000228389.1	AC068039.4	14.48	1.95e-43	3.58e-40	0.52	0.41	Schizophrenia;	chr2:171793872	chr2:171773482~171775844:+
BRCA	cis	rs11690935	0.959	rs6758704	ENSG00000228389.1	AC068039.4	14.48	1.95e-43	3.58e-40	0.52	0.41	Schizophrenia;	chr2:171798587	chr2:171773482~171775844:+
BRCA	cis	rs3931020	0.688	rs277374	ENSG00000272864.1	RP11-17E13.2	14.48	1.96e-43	3.6e-40	0.56	0.41	Resistin levels;	chr1:74734802	chr1:74698769~74699333:-
BRCA	cis	rs11690935	0.959	rs10206062	ENSG00000228389.1	AC068039.4	14.48	1.97e-43	3.6e-40	0.52	0.41	Schizophrenia;	chr2:171720766	chr2:171773482~171775844:+
BRCA	cis	rs2581828	0.965	rs2581830	ENSG00000242142.1	SERBP1P3	14.48	2.04e-43	3.74e-40	0.46	0.41	Crohn's disease;	chr3:53100082	chr3:53064283~53065091:-
BRCA	cis	rs11690935	0.959	rs12692970	ENSG00000228389.1	AC068039.4	14.47	2.1e-43	3.85e-40	0.52	0.41	Schizophrenia;	chr2:171737687	chr2:171773482~171775844:+
BRCA	cis	rs1061377	1	rs56119980	ENSG00000249207.1	RP11-360F5.1	-14.47	2.12e-43	3.88e-40	-0.48	-0.41	Uric acid levels;	chr4:39139390	chr4:39112677~39126818:-
BRCA	cis	rs992157	0.767	rs2014615	ENSG00000261338.2	RP11-378A13.1	14.47	2.14e-43	3.93e-40	0.43	0.41	Colorectal cancer;	chr2:218306468	chr2:218255319~218257366:+
BRCA	cis	rs8062405	0.723	rs4788079	ENSG00000259982.1	CDC37P1	14.47	2.22e-43	4.07e-40	0.52	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548042	chr16:28700294~28701540:-
BRCA	cis	rs11690935	1	rs35549875	ENSG00000228389.1	AC068039.4	-14.47	2.25e-43	4.12e-40	-0.53	-0.41	Schizophrenia;	chr2:171675882	chr2:171773482~171775844:+
BRCA	cis	rs7301826	0.651	rs6486601	ENSG00000256299.1	RP11-989F5.3	14.45	2.72e-43	4.97e-40	0.48	0.41	Plasma plasminogen activator levels;	chr12:130816692	chr12:130810821~130812622:-
BRCA	cis	rs4423214	0.84	rs1629220	ENSG00000254682.1	RP11-660L16.2	-14.45	2.73e-43	4.98e-40	-0.55	-0.41	Vitamin D levels;	chr11:71463507	chr11:71448674~71452157:+
BRCA	cis	rs4728142	0.604	rs10229001	ENSG00000275106.1	RP11-309L24.10	-14.45	2.77e-43	5.04e-40	-0.52	-0.41	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128959343	chr7:128952527~128953316:-
BRCA	cis	rs11690935	0.921	rs908670	ENSG00000228389.1	AC068039.4	14.45	2.89e-43	5.27e-40	0.52	0.41	Schizophrenia;	chr2:171833670	chr2:171773482~171775844:+
BRCA	cis	rs5769707	0.609	rs135861	ENSG00000188511.11	C22orf34	14.44	3.09e-43	5.62e-40	0.44	0.41	Monocyte percentage of white cells;Monocyte count;	chr22:49604470	chr22:49414524~49657542:-
BRCA	cis	rs35160687	0.901	rs12472676	ENSG00000273080.1	RP11-301O19.1	14.44	3.22e-43	5.86e-40	0.48	0.41	Night sleep phenotypes;	chr2:86283692	chr2:86195590~86196049:+
BRCA	cis	rs35160687	0.901	rs10520415	ENSG00000273080.1	RP11-301O19.1	-14.43	3.49e-43	6.33e-40	-0.48	-0.41	Night sleep phenotypes;	chr2:86271615	chr2:86195590~86196049:+
BRCA	cis	rs35160687	0.901	rs6714362	ENSG00000273080.1	RP11-301O19.1	-14.43	3.55e-43	6.41e-40	-0.48	-0.41	Night sleep phenotypes;	chr2:86249465	chr2:86195590~86196049:+
BRCA	cis	rs4853012	0.838	rs4429500	ENSG00000217702.2	RP11-287D1.4	14.43	3.6e-43	6.5e-40	0.57	0.41	Gestational age at birth (maternal effect);	chr2:74118209	chr2:74130583~74135395:+
BRCA	cis	rs977987	0.806	rs8050059	ENSG00000261783.1	RP11-252K23.2	-14.43	3.68e-43	6.65e-40	-0.53	-0.41	Dupuytren's disease;	chr16:75354833	chr16:75379818~75381260:-
BRCA	cis	rs3931020	0.688	rs455032	ENSG00000272864.1	RP11-17E13.2	14.43	3.72e-43	6.71e-40	0.54	0.41	Resistin levels;	chr1:74730804	chr1:74698769~74699333:-
BRCA	cis	rs977987	0.806	rs4888386	ENSG00000261783.1	RP11-252K23.2	-14.43	3.76e-43	6.78e-40	-0.53	-0.41	Dupuytren's disease;	chr16:75355842	chr16:75379818~75381260:-
BRCA	cis	rs7301826	0.651	rs7299281	ENSG00000256299.1	RP11-989F5.3	14.42	3.97e-43	7.15e-40	0.47	0.41	Plasma plasminogen activator levels;	chr12:130818587	chr12:130810821~130812622:-
BRCA	cis	rs4423214	0.798	rs12224205	ENSG00000254682.1	RP11-660L16.2	-14.42	4.18e-43	7.53e-40	-0.55	-0.41	Vitamin D levels;	chr11:71469946	chr11:71448674~71452157:+
BRCA	cis	rs507080	0.501	rs626645	ENSG00000255422.1	AP002954.4	-14.42	4.2e-43	7.56e-40	-0.47	-0.41	Serum metabolite levels;	chr11:118704471	chr11:118704607~118750263:+
BRCA	cis	rs5769707	0.609	rs739247	ENSG00000188511.11	C22orf34	14.42	4.22e-43	7.59e-40	0.44	0.41	Monocyte percentage of white cells;Monocyte count;	chr22:49603009	chr22:49414524~49657542:-
BRCA	cis	rs35160687	0.901	rs12472390	ENSG00000273080.1	RP11-301O19.1	14.42	4.23e-43	7.62e-40	0.48	0.41	Night sleep phenotypes;	chr2:86247960	chr2:86195590~86196049:+
BRCA	cis	rs2019137	0.868	rs3748916	ENSG00000189223.12	PAX8-AS1	14.41	4.65e-43	8.36e-40	0.56	0.41	Lymphocyte counts;	chr2:113226456	chr2:113211522~113276581:+
BRCA	cis	rs11690935	0.959	rs6709156	ENSG00000228389.1	AC068039.4	14.41	4.67e-43	8.39e-40	0.52	0.41	Schizophrenia;	chr2:171735434	chr2:171773482~171775844:+
BRCA	cis	rs9918079	0.506	rs10214	ENSG00000273133.1	RP11-799M12.2	14.41	4.69e-43	8.43e-40	0.51	0.41	Obesity-related traits;	chr4:15604808	chr4:15563698~15564253:-
BRCA	cis	rs11690935	0.959	rs76324055	ENSG00000228389.1	AC068039.4	14.41	4.8e-43	8.61e-40	0.53	0.41	Schizophrenia;	chr2:171763640	chr2:171773482~171775844:+
BRCA	cis	rs11690935	0.959	rs77280952	ENSG00000228389.1	AC068039.4	14.41	4.8e-43	8.61e-40	0.53	0.41	Schizophrenia;	chr2:171763641	chr2:171773482~171775844:+
BRCA	cis	rs11690935	0.959	rs75922913	ENSG00000228389.1	AC068039.4	14.41	4.8e-43	8.61e-40	0.53	0.41	Schizophrenia;	chr2:171763642	chr2:171773482~171775844:+
BRCA	cis	rs8062405	0.723	rs113208333	ENSG00000259982.1	CDC37P1	14.4	4.96e-43	8.9e-40	0.52	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28594839	chr16:28700294~28701540:-
BRCA	cis	rs7301826	0.627	rs61937256	ENSG00000256299.1	RP11-989F5.3	14.4	4.99e-43	8.95e-40	0.48	0.41	Plasma plasminogen activator levels;	chr12:130818100	chr12:130810821~130812622:-
BRCA	cis	rs977987	0.835	rs8046109	ENSG00000261783.1	RP11-252K23.2	-14.4	5e-43	8.96e-40	-0.53	-0.41	Dupuytren's disease;	chr16:75326198	chr16:75379818~75381260:-
BRCA	cis	rs992157	0.798	rs7557709	ENSG00000261338.2	RP11-378A13.1	14.4	5.1e-43	9.13e-40	0.43	0.41	Colorectal cancer;	chr2:218302806	chr2:218255319~218257366:+
BRCA	cis	rs7617773	0.963	rs6800730	ENSG00000229759.1	MRPS18AP1	14.4	5.15e-43	9.23e-40	0.46	0.41	Coronary artery disease;	chr3:48132720	chr3:48256350~48256938:-
BRCA	cis	rs11690935	0.921	rs7355523	ENSG00000228389.1	AC068039.4	14.39	5.88e-43	1.05e-39	0.53	0.41	Schizophrenia;	chr2:171887911	chr2:171773482~171775844:+
BRCA	cis	rs2455601	0.882	rs11042106	ENSG00000254860.4	TMEM9B-AS1	-14.38	6.41e-43	1.15e-39	-0.47	-0.41	Schizophrenia;	chr11:8874536	chr11:8964675~8977527:+
BRCA	cis	rs11690935	0.959	rs7608403	ENSG00000228389.1	AC068039.4	14.38	6.52e-43	1.16e-39	0.52	0.41	Schizophrenia;	chr2:171790255	chr2:171773482~171775844:+
BRCA	cis	rs8062405	0.691	rs743590	ENSG00000259982.1	CDC37P1	14.38	7.01e-43	1.25e-39	0.52	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28596909	chr16:28700294~28701540:-
BRCA	cis	rs2019137	1	rs2019137	ENSG00000189223.12	PAX8-AS1	14.37	7.05e-43	1.26e-39	0.56	0.41	Lymphocyte counts;	chr2:113216055	chr2:113211522~113276581:+
BRCA	cis	rs35160687	0.865	rs10189492	ENSG00000273080.1	RP11-301O19.1	14.37	7.18e-43	1.28e-39	0.48	0.41	Night sleep phenotypes;	chr2:86251779	chr2:86195590~86196049:+
BRCA	cis	rs2283792	0.633	rs240068	ENSG00000224086.5	LL22NC03-86G7.1	-14.37	7.43e-43	1.32e-39	-0.43	-0.41	Multiple sclerosis;	chr22:21936031	chr22:21938293~21977632:+
BRCA	cis	rs977987	0.806	rs17696696	ENSG00000261783.1	RP11-252K23.2	14.37	7.44e-43	1.33e-39	0.51	0.41	Dupuytren's disease;	chr16:75359454	chr16:75379818~75381260:-
BRCA	cis	rs17507216	0.591	rs7163848	ENSG00000278603.1	RP13-608F4.5	14.37	7.76e-43	1.38e-39	0.7	0.41	Excessive daytime sleepiness;	chr15:82729563	chr15:82472203~82472426:+
BRCA	cis	rs4718428	0.96	rs6460317	ENSG00000226824.5	RP4-756H11.3	-14.37	7.77e-43	1.38e-39	-0.51	-0.41	Corneal structure;	chr7:66925268	chr7:66654538~66669855:+
BRCA	cis	rs55794721	0.509	rs11249248	ENSG00000261349.1	RP3-465N24.5	-14.36	8.23e-43	1.46e-39	-0.46	-0.41	Mean corpuscular volume;Plateletcrit;	chr1:25426560	chr1:25266102~25267136:-
BRCA	cis	rs1153858	0.945	rs1974981	ENSG00000259520.4	CTD-2651B20.3	14.36	8.32e-43	1.48e-39	0.54	0.41	Homoarginine levels;	chr15:45436925	chr15:45251580~45279251:-
BRCA	cis	rs11690935	0.959	rs11897196	ENSG00000228389.1	AC068039.4	14.36	8.41e-43	1.49e-39	0.52	0.41	Schizophrenia;	chr2:171729085	chr2:171773482~171775844:+
BRCA	cis	rs12439619	1	rs12439619	ENSG00000278603.1	RP13-608F4.5	14.36	8.43e-43	1.5e-39	0.58	0.41	Intelligence (multi-trait analysis);	chr15:82254605	chr15:82472203~82472426:+
BRCA	cis	rs507080	0.501	rs494459	ENSG00000255422.1	AP002954.4	14.35	9.02e-43	1.6e-39	0.47	0.41	Serum metabolite levels;	chr11:118703966	chr11:118704607~118750263:+
BRCA	cis	rs17711722	0.565	rs73372653	ENSG00000164669.11	INTS4P1	-14.35	9.06e-43	1.61e-39	-0.52	-0.41	Calcium levels;	chr7:65977808	chr7:65141225~65234216:+
BRCA	cis	rs8062405	0.69	rs7187604	ENSG00000259982.1	CDC37P1	14.35	9.44e-43	1.67e-39	0.52	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554632	chr16:28700294~28701540:-
BRCA	cis	rs6452524	0.935	rs9293330	ENSG00000249664.1	CTD-2227C6.2	14.35	9.47e-43	1.68e-39	0.48	0.41	Hypertension (SNP x SNP interaction);	chr5:83102299	chr5:83012285~83013109:-
BRCA	cis	rs858239	0.699	rs1881200	ENSG00000226816.2	AC005082.12	-14.35	9.66e-43	1.71e-39	-0.46	-0.41	Cerebrospinal fluid biomarker levels;	chr7:23162018	chr7:23206013~23208045:+
BRCA	cis	rs977987	0.788	rs7184525	ENSG00000261783.1	RP11-252K23.2	-14.35	1e-42	1.77e-39	-0.52	-0.41	Dupuytren's disease;	chr16:75403288	chr16:75379818~75381260:-
BRCA	cis	rs4853012	0.838	rs61521879	ENSG00000217702.2	RP11-287D1.4	14.35	1e-42	1.78e-39	0.57	0.41	Gestational age at birth (maternal effect);	chr2:74119081	chr2:74130583~74135395:+
BRCA	cis	rs3931020	0.657	rs277369	ENSG00000272864.1	RP11-17E13.2	14.34	1.06e-42	1.88e-39	0.55	0.41	Resistin levels;	chr1:74768977	chr1:74698769~74699333:-
BRCA	cis	rs7104764	0.507	rs6598054	ENSG00000277290.1	RP11-326C3.16	14.34	1.07e-42	1.89e-39	0.48	0.41	Menarche (age at onset);	chr11:254010	chr11:243099~243483:-
BRCA	cis	rs4423214	0.84	rs1619577	ENSG00000254682.1	RP11-660L16.2	-14.34	1.07e-42	1.89e-39	-0.55	-0.41	Vitamin D levels;	chr11:71470439	chr11:71448674~71452157:+
BRCA	cis	rs35160687	0.901	rs13017338	ENSG00000273080.1	RP11-301O19.1	14.34	1.09e-42	1.93e-39	0.48	0.41	Night sleep phenotypes;	chr2:86274430	chr2:86195590~86196049:+
BRCA	cis	rs10262624	0.504	rs4722255	ENSG00000234286.1	AC006026.13	-14.34	1.12e-42	1.98e-39	-0.47	-0.41	Schizophrenia;	chr7:23706453	chr7:23680195~23680786:-
BRCA	cis	rs2019137	0.967	rs895412	ENSG00000189223.12	PAX8-AS1	14.33	1.16e-42	2.04e-39	0.55	0.41	Lymphocyte counts;	chr2:113216387	chr2:113211522~113276581:+
BRCA	cis	rs8062405	0.755	rs4788076	ENSG00000259982.1	CDC37P1	14.33	1.21e-42	2.13e-39	0.52	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28558684	chr16:28700294~28701540:-
BRCA	cis	rs9326248	0.53	rs6589576	ENSG00000254851.1	RP11-109L13.1	14.33	1.24e-42	2.18e-39	0.7	0.41	Blood protein levels;	chr11:116865072	chr11:117135528~117138582:+
BRCA	cis	rs7617773	0.817	rs745116	ENSG00000229759.1	MRPS18AP1	14.32	1.36e-42	2.39e-39	0.5	0.41	Coronary artery disease;	chr3:48231046	chr3:48256350~48256938:-
BRCA	cis	rs4718428	0.924	rs6971897	ENSG00000226824.5	RP4-756H11.3	-14.32	1.41e-42	2.49e-39	-0.5	-0.41	Corneal structure;	chr7:66947787	chr7:66654538~66669855:+
BRCA	cis	rs11690935	0.959	rs10204501	ENSG00000228389.1	AC068039.4	14.31	1.45e-42	2.55e-39	0.52	0.41	Schizophrenia;	chr2:171732355	chr2:171773482~171775844:+
BRCA	cis	rs11690935	0.959	rs10204502	ENSG00000228389.1	AC068039.4	14.31	1.45e-42	2.55e-39	0.52	0.41	Schizophrenia;	chr2:171732356	chr2:171773482~171775844:+
BRCA	cis	rs11690935	0.959	rs10204622	ENSG00000228389.1	AC068039.4	14.31	1.45e-42	2.55e-39	0.52	0.41	Schizophrenia;	chr2:171732472	chr2:171773482~171775844:+
BRCA	cis	rs3096299	0.582	rs12935119	ENSG00000274627.1	RP11-104N10.2	14.31	1.45e-42	2.55e-39	0.41	0.41	Multiple myeloma (IgH translocation);	chr16:89476466	chr16:89516797~89522217:+
BRCA	cis	rs2739330	0.828	rs4820572	ENSG00000250470.1	AP000351.3	14.31	1.46e-42	2.57e-39	0.5	0.41	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23976904~23977585:-
BRCA	cis	rs4423214	0.84	rs1792235	ENSG00000254682.1	RP11-660L16.2	-14.31	1.5e-42	2.63e-39	-0.54	-0.41	Vitamin D levels;	chr11:71470427	chr11:71448674~71452157:+
BRCA	cis	rs2882667	0.683	rs13188935	ENSG00000253404.1	AC034243.1	14.31	1.51e-42	2.65e-39	0.5	0.41	Age-related hearing impairment (SNP x SNP interaction);	chr5:139116536	chr5:138744434~138753309:-
BRCA	cis	rs7301826	0.58	rs61938969	ENSG00000256299.1	RP11-989F5.3	14.31	1.54e-42	2.7e-39	0.47	0.41	Plasma plasminogen activator levels;	chr12:130831525	chr12:130810821~130812622:-
BRCA	cis	rs4814920	0.818	rs4813376	ENSG00000275142.1	RP5-999L4.2	14.31	1.55e-42	2.71e-39	0.61	0.41	Bipolar disorder (body mass index interaction);	chr20:19870811	chr20:19871891~19872284:+
BRCA	cis	rs4853012	0.838	rs6715351	ENSG00000217702.2	RP11-287D1.4	14.31	1.55e-42	2.72e-39	0.57	0.41	Gestational age at birth (maternal effect);	chr2:74118992	chr2:74130583~74135395:+
BRCA	cis	rs1431005	0.858	rs11132461	ENSG00000250620.1	RP11-91J3.3	-14.31	1.55e-42	2.73e-39	-0.51	-0.41	Response to statin therapy;	chr4:187509161	chr4:187413564~187415697:+
BRCA	cis	rs2739330	0.796	rs5760106	ENSG00000099984.9	GSTT2	14.3	1.64e-42	2.88e-39	0.5	0.41	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23980123~23983911:+
BRCA	cis	rs73086581	0.617	rs2300213	ENSG00000229539.1	RP11-119B16.2	-14.3	1.73e-42	3.02e-39	-0.56	-0.41	Response to antidepressants in depression;	chr20:4006076	chr20:3888239~3888868:-
BRCA	cis	rs977987	0.806	rs11862582	ENSG00000261783.1	RP11-252K23.2	-14.3	1.78e-42	3.11e-39	-0.52	-0.4	Dupuytren's disease;	chr16:75397397	chr16:75379818~75381260:-
BRCA	cis	rs2658782	1	rs2658779	ENSG00000279684.1	RP11-755E23.2	14.29	1.9e-42	3.33e-39	0.61	0.4	Pulmonary function decline;	chr11:93429971	chr11:93286629~93288903:-
BRCA	cis	rs9918079	0.56	rs10008975	ENSG00000273133.1	RP11-799M12.2	-14.29	1.95e-42	3.4e-39	-0.5	-0.4	Obesity-related traits;	chr4:15622948	chr4:15563698~15564253:-
BRCA	cis	rs11690935	0.802	rs34636594	ENSG00000228389.1	AC068039.4	14.29	2.02e-42	3.52e-39	0.54	0.4	Schizophrenia;	chr2:172046366	chr2:171773482~171775844:+
BRCA	cis	rs3931020	0.688	rs405445	ENSG00000272864.1	RP11-17E13.2	14.29	2.04e-42	3.57e-39	0.55	0.4	Resistin levels;	chr1:74755466	chr1:74698769~74699333:-
BRCA	cis	rs35160687	0.901	rs35762338	ENSG00000273080.1	RP11-301O19.1	14.28	2.1e-42	3.66e-39	0.47	0.4	Night sleep phenotypes;	chr2:86286430	chr2:86195590~86196049:+
BRCA	cis	rs4728142	0.525	rs4731534	ENSG00000275106.1	RP11-309L24.10	-14.28	2.1e-42	3.67e-39	-0.51	-0.4	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128965540	chr7:128952527~128953316:-
BRCA	cis	rs3096299	0.685	rs4785675	ENSG00000274627.1	RP11-104N10.2	14.28	2.22e-42	3.86e-39	0.42	0.4	Multiple myeloma (IgH translocation);	chr16:89473566	chr16:89516797~89522217:+
BRCA	cis	rs11690935	0.959	rs7586207	ENSG00000228389.1	AC068039.4	14.28	2.23e-42	3.89e-39	0.51	0.4	Schizophrenia;	chr2:171814584	chr2:171773482~171775844:+
BRCA	cis	rs11690935	0.959	rs6724337	ENSG00000228389.1	AC068039.4	14.28	2.29e-42	3.99e-39	0.52	0.4	Schizophrenia;	chr2:171878819	chr2:171773482~171775844:+
BRCA	cis	rs11690935	0.921	rs3770445	ENSG00000228389.1	AC068039.4	14.28	2.31e-42	4.02e-39	0.52	0.4	Schizophrenia;	chr2:171852409	chr2:171773482~171775844:+
BRCA	cis	rs7301826	1	rs10848205	ENSG00000256250.1	RP11-989F5.1	-14.26	2.64e-42	4.58e-39	-0.47	-0.4	Plasma plasminogen activator levels;	chr12:130796169	chr12:130810606~130812438:+
BRCA	cis	rs858239	0.699	rs1881201	ENSG00000226816.2	AC005082.12	-14.26	2.77e-42	4.81e-39	-0.46	-0.4	Cerebrospinal fluid biomarker levels;	chr7:23154394	chr7:23206013~23208045:+
BRCA	cis	rs10262624	0.504	rs59865844	ENSG00000234286.1	AC006026.13	14.26	2.95e-42	5.11e-39	0.47	0.4	Schizophrenia;	chr7:23693421	chr7:23680195~23680786:-
BRCA	cis	rs9918079	0.56	rs7685083	ENSG00000273133.1	RP11-799M12.2	14.25	2.98e-42	5.17e-39	0.5	0.4	Obesity-related traits;	chr4:15609148	chr4:15563698~15564253:-
BRCA	cis	rs2188561	0.697	rs739518	ENSG00000241764.3	AC002467.7	14.24	3.36e-42	5.82e-39	0.55	0.4	Alcohol consumption;	chr7:107743682	chr7:107742817~107744581:-
BRCA	cis	rs4728142	0.584	rs6965542	ENSG00000275106.1	RP11-309L24.10	-14.24	3.56e-42	6.15e-39	-0.51	-0.4	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129015864	chr7:128952527~128953316:-
BRCA	cis	rs3931020	0.657	rs277368	ENSG00000272864.1	RP11-17E13.2	14.24	3.73e-42	6.45e-39	0.55	0.4	Resistin levels;	chr1:74764922	chr1:74698769~74699333:-
BRCA	cis	rs35160687	0.901	rs12714180	ENSG00000273080.1	RP11-301O19.1	14.23	4.01e-42	6.92e-39	0.47	0.4	Night sleep phenotypes;	chr2:86298200	chr2:86195590~86196049:+
BRCA	cis	rs9389248	0.69	rs728030	ENSG00000232876.1	CTA-212D2.2	14.23	4.24e-42	7.32e-39	0.5	0.4	High light scatter reticulocyte percentage of red cells;	chr6:134925156	chr6:135055033~135060550:+
BRCA	cis	rs9918079	0.56	rs4557256	ENSG00000273133.1	RP11-799M12.2	-14.22	4.42e-42	7.61e-39	-0.5	-0.4	Obesity-related traits;	chr4:15625024	chr4:15563698~15564253:-
BRCA	cis	rs35160687	0.901	rs35281683	ENSG00000273080.1	RP11-301O19.1	14.21	4.93e-42	8.48e-39	0.47	0.4	Night sleep phenotypes;	chr2:86299249	chr2:86195590~86196049:+
BRCA	cis	rs977987	0.778	rs4888413	ENSG00000261783.1	RP11-252K23.2	-14.21	4.97e-42	8.55e-39	-0.52	-0.4	Dupuytren's disease;	chr16:75409325	chr16:75379818~75381260:-
BRCA	cis	rs977987	0.778	rs8057849	ENSG00000261783.1	RP11-252K23.2	-14.21	4.97e-42	8.55e-39	-0.52	-0.4	Dupuytren's disease;	chr16:75409918	chr16:75379818~75381260:-
BRCA	cis	rs35160687	0.871	rs11127028	ENSG00000273080.1	RP11-301O19.1	14.21	5.24e-42	9e-39	0.47	0.4	Night sleep phenotypes;	chr2:86310386	chr2:86195590~86196049:+
BRCA	cis	rs9918079	0.542	rs12499412	ENSG00000273133.1	RP11-799M12.2	14.21	5.24e-42	9.01e-39	0.5	0.4	Obesity-related traits;	chr4:15600629	chr4:15563698~15564253:-
BRCA	cis	rs6452524	0.935	rs6896953	ENSG00000249664.1	CTD-2227C6.2	-14.21	5.37e-42	9.22e-39	-0.47	-0.4	Hypertension (SNP x SNP interaction);	chr5:83089284	chr5:83012285~83013109:-
BRCA	cis	rs9918079	0.542	rs6414765	ENSG00000273133.1	RP11-799M12.2	-14.21	5.38e-42	9.24e-39	-0.5	-0.4	Obesity-related traits;	chr4:15624870	chr4:15563698~15564253:-
BRCA	cis	rs977987	0.778	rs4888412	ENSG00000261783.1	RP11-252K23.2	-14.2	5.49e-42	9.43e-39	-0.52	-0.4	Dupuytren's disease;	chr16:75409298	chr16:75379818~75381260:-
BRCA	cis	rs35160687	0.901	rs10200186	ENSG00000273080.1	RP11-301O19.1	14.2	5.68e-42	9.75e-39	0.47	0.4	Night sleep phenotypes;	chr2:86300300	chr2:86195590~86196049:+
BRCA	cis	rs35160687	0.842	rs10200526	ENSG00000273080.1	RP11-301O19.1	14.2	5.68e-42	9.75e-39	0.47	0.4	Night sleep phenotypes;	chr2:86300476	chr2:86195590~86196049:+
BRCA	cis	rs8040855	0.599	rs4643289	ENSG00000259295.5	CSPG4P12	-14.2	5.75e-42	9.87e-39	-0.48	-0.4	Bulimia nervosa;	chr15:85183483	chr15:85191438~85213905:+
BRCA	cis	rs9918079	0.58	rs13120905	ENSG00000273133.1	RP11-799M12.2	14.2	5.81e-42	9.97e-39	0.5	0.4	Obesity-related traits;	chr4:15610665	chr4:15563698~15564253:-
BRCA	cis	rs35160687	0.901	rs34048420	ENSG00000273080.1	RP11-301O19.1	14.2	5.85e-42	1e-38	0.47	0.4	Night sleep phenotypes;	chr2:86302625	chr2:86195590~86196049:+
BRCA	cis	rs35160687	0.901	rs34069316	ENSG00000273080.1	RP11-301O19.1	14.2	5.85e-42	1e-38	0.47	0.4	Night sleep phenotypes;	chr2:86302669	chr2:86195590~86196049:+
BRCA	cis	rs35160687	0.901	rs11127026	ENSG00000273080.1	RP11-301O19.1	14.2	5.85e-42	1e-38	0.47	0.4	Night sleep phenotypes;	chr2:86304625	chr2:86195590~86196049:+
BRCA	cis	rs35160687	0.901	rs12478575	ENSG00000273080.1	RP11-301O19.1	14.2	5.85e-42	1e-38	0.47	0.4	Night sleep phenotypes;	chr2:86308191	chr2:86195590~86196049:+
BRCA	cis	rs2019137	0.901	rs4849176	ENSG00000189223.12	PAX8-AS1	14.2	5.85e-42	1e-38	0.56	0.4	Lymphocyte counts;	chr2:113220359	chr2:113211522~113276581:+
BRCA	cis	rs977987	0.806	rs4888411	ENSG00000261783.1	RP11-252K23.2	-14.2	5.86e-42	1.01e-38	-0.52	-0.4	Dupuytren's disease;	chr16:75409285	chr16:75379818~75381260:-
BRCA	cis	rs3931020	0.688	rs452242	ENSG00000272864.1	RP11-17E13.2	14.2	6.04e-42	1.04e-38	0.55	0.4	Resistin levels;	chr1:74759941	chr1:74698769~74699333:-
BRCA	cis	rs9545047	0.716	rs9565500	ENSG00000227676.3	LINC01068	-14.19	6.16e-42	1.05e-38	-0.49	-0.4	Schizophrenia;	chr13:79433416	chr13:79566727~79571436:+
BRCA	cis	rs4728142	0.564	rs11767711	ENSG00000275106.1	RP11-309L24.10	-14.19	6.42e-42	1.1e-38	-0.51	-0.4	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129011778	chr7:128952527~128953316:-
BRCA	cis	rs6452524	0.967	rs2662243	ENSG00000249664.1	CTD-2227C6.2	14.19	6.82e-42	1.17e-38	0.48	0.4	Hypertension (SNP x SNP interaction);	chr5:83192630	chr5:83012285~83013109:-
BRCA	cis	rs8062405	0.755	rs2077031	ENSG00000259982.1	CDC37P1	14.18	7.17e-42	1.23e-38	0.52	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28591847	chr16:28700294~28701540:-
BRCA	cis	rs2739330	0.789	rs5760109	ENSG00000250470.1	AP000351.3	14.18	7.36e-42	1.26e-38	0.49	0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23976904~23977585:-
BRCA	cis	rs35160687	0.901	rs13020869	ENSG00000273080.1	RP11-301O19.1	14.18	7.38e-42	1.26e-38	0.47	0.4	Night sleep phenotypes;	chr2:86296237	chr2:86195590~86196049:+
BRCA	cis	rs3091242	0.933	rs926438	ENSG00000261349.1	RP3-465N24.5	-14.18	7.49e-42	1.28e-38	-0.45	-0.4	Erythrocyte sedimentation rate;	chr1:25427147	chr1:25266102~25267136:-
BRCA	cis	rs35160687	0.901	rs12714179	ENSG00000273080.1	RP11-301O19.1	14.17	7.79e-42	1.33e-38	0.47	0.4	Night sleep phenotypes;	chr2:86287835	chr2:86195590~86196049:+
BRCA	cis	rs977987	0.806	rs4887824	ENSG00000261783.1	RP11-252K23.2	-14.17	8.3e-42	1.41e-38	-0.52	-0.4	Dupuytren's disease;	chr16:75407715	chr16:75379818~75381260:-
BRCA	cis	rs2188561	0.697	rs4730258	ENSG00000241764.3	AC002467.7	14.15	1.03e-41	1.75e-38	0.54	0.4	Alcohol consumption;	chr7:107755787	chr7:107742817~107744581:-
BRCA	cis	rs2658782	1	rs2608216	ENSG00000279684.1	RP11-755E23.2	-14.14	1.13e-41	1.91e-38	-0.61	-0.4	Pulmonary function decline;	chr11:93416006	chr11:93286629~93288903:-
BRCA	cis	rs2658782	0.95	rs2446061	ENSG00000279684.1	RP11-755E23.2	-14.14	1.13e-41	1.91e-38	-0.61	-0.4	Pulmonary function decline;	chr11:93416111	chr11:93286629~93288903:-
BRCA	cis	rs2882667	0.638	rs2351905	ENSG00000253404.1	AC034243.1	14.14	1.17e-41	1.98e-38	0.51	0.4	Age-related hearing impairment (SNP x SNP interaction);	chr5:139135641	chr5:138744434~138753309:-
BRCA	cis	rs977987	0.806	rs72787160	ENSG00000261783.1	RP11-252K23.2	-14.14	1.2e-41	2.03e-38	-0.51	-0.4	Dupuytren's disease;	chr16:75411264	chr16:75379818~75381260:-
BRCA	cis	rs4728142	0.604	rs12155080	ENSG00000275106.1	RP11-309L24.10	-14.14	1.22e-41	2.07e-38	-0.5	-0.4	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129018685	chr7:128952527~128953316:-
BRCA	cis	rs11690935	0.851	rs9808259	ENSG00000228389.1	AC068039.4	14.13	1.32e-41	2.23e-38	0.51	0.4	Schizophrenia;	chr2:171792464	chr2:171773482~171775844:+
BRCA	cis	rs9918079	0.56	rs13147590	ENSG00000273133.1	RP11-799M12.2	14.13	1.32e-41	2.23e-38	0.5	0.4	Obesity-related traits;	chr4:15619565	chr4:15563698~15564253:-
BRCA	cis	rs9322193	0.607	rs4870078	ENSG00000231760.4	RP11-350J20.5	-14.13	1.36e-41	2.3e-38	-0.55	-0.4	Lung cancer;	chr6:149880676	chr6:149796151~149826294:-
BRCA	cis	rs2111504	0.583	rs1015839	ENSG00000267213.4	AC007773.2	14.13	1.4e-41	2.36e-38	0.5	0.4	Bipolar disorder;	chr19:32390365	chr19:32390050~32405560:-
BRCA	cis	rs4728142	0.604	rs7783384	ENSG00000275106.1	RP11-309L24.10	-14.12	1.42e-41	2.4e-38	-0.5	-0.4	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129041243	chr7:128952527~128953316:-
BRCA	cis	rs2739330	0.587	rs4820571	ENSG00000250470.1	AP000351.3	14.12	1.44e-41	2.44e-38	0.48	0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23976904~23977585:-
BRCA	cis	rs11690935	0.918	rs12692978	ENSG00000228389.1	AC068039.4	14.12	1.49e-41	2.52e-38	0.53	0.4	Schizophrenia;	chr2:171869471	chr2:171773482~171775844:+
BRCA	cis	rs2108622	0.727	rs55954696	ENSG00000267453.5	AC004791.2	-14.12	1.52e-41	2.56e-38	-0.48	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15870995	chr19:15851993~15864904:-
BRCA	cis	rs3931020	0.657	rs277376	ENSG00000272864.1	RP11-17E13.2	14.12	1.56e-41	2.64e-38	0.55	0.4	Resistin levels;	chr1:74776562	chr1:74698769~74699333:-
BRCA	cis	rs7301826	0.58	rs12821464	ENSG00000256299.1	RP11-989F5.3	14.12	1.57e-41	2.66e-38	0.47	0.4	Plasma plasminogen activator levels;	chr12:130838174	chr12:130810821~130812622:-
BRCA	cis	rs2739330	0.828	rs5760107	ENSG00000250470.1	AP000351.3	14.12	1.58e-41	2.66e-38	0.49	0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23976904~23977585:-
BRCA	cis	rs4728142	0.584	rs7796963	ENSG00000275106.1	RP11-309L24.10	-14.11	1.62e-41	2.73e-38	-0.5	-0.4	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128988947	chr7:128952527~128953316:-
BRCA	cis	rs3091242	1	rs9689	ENSG00000261349.1	RP3-465N24.5	-14.11	1.74e-41	2.93e-38	-0.44	-0.4	Erythrocyte sedimentation rate;	chr1:25361785	chr1:25266102~25267136:-
BRCA	cis	rs6452524	0.935	rs2731846	ENSG00000249664.1	CTD-2227C6.2	14.11	1.76e-41	2.97e-38	0.47	0.4	Hypertension (SNP x SNP interaction);	chr5:83193781	chr5:83012285~83013109:-
BRCA	cis	rs4728142	0.604	rs10239340	ENSG00000275106.1	RP11-309L24.10	-14.11	1.78e-41	2.99e-38	-0.5	-0.4	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129028456	chr7:128952527~128953316:-
BRCA	cis	rs4728142	0.604	rs6467222	ENSG00000275106.1	RP11-309L24.10	-14.11	1.78e-41	2.99e-38	-0.5	-0.4	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129034365	chr7:128952527~128953316:-
BRCA	cis	rs2108622	0.727	rs62106156	ENSG00000267453.5	AC004791.2	-14.1	1.97e-41	3.32e-38	-0.48	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15869614	chr19:15851993~15864904:-
BRCA	cis	rs2283792	0.622	rs239917	ENSG00000224086.5	LL22NC03-86G7.1	-14.09	2.18e-41	3.66e-38	-0.42	-0.4	Multiple sclerosis;	chr22:21960091	chr22:21938293~21977632:+
BRCA	cis	rs3096299	0.658	rs4785679	ENSG00000274627.1	RP11-104N10.2	14.09	2.2e-41	3.7e-38	0.41	0.4	Multiple myeloma (IgH translocation);	chr16:89499705	chr16:89516797~89522217:+
BRCA	cis	rs11690935	0.959	rs10167419	ENSG00000228389.1	AC068039.4	14.08	2.28e-41	3.83e-38	0.51	0.4	Schizophrenia;	chr2:171793316	chr2:171773482~171775844:+
BRCA	cis	rs7044106	0.791	rs4617229	ENSG00000226752.6	PSMD5-AS1	-14.08	2.35e-41	3.94e-38	-0.49	-0.4	Hip circumference adjusted for BMI;	chr9:120718418	chr9:120824828~120854385:+
BRCA	cis	rs2188561	0.697	rs3735607	ENSG00000241764.3	AC002467.7	14.08	2.51e-41	4.21e-38	0.55	0.4	Alcohol consumption;	chr7:107743833	chr7:107742817~107744581:-
BRCA	cis	rs2658782	1	rs2658782	ENSG00000279684.1	RP11-755E23.2	-14.08	2.52e-41	4.23e-38	-0.61	-0.4	Pulmonary function decline;	chr11:93433565	chr11:93286629~93288903:-
BRCA	cis	rs2283792	0.935	rs2283794	ENSG00000224086.5	LL22NC03-86G7.1	-14.07	2.64e-41	4.41e-38	-0.42	-0.4	Multiple sclerosis;	chr22:21858180	chr22:21938293~21977632:+
BRCA	cis	rs35160687	0.901	rs17738096	ENSG00000273080.1	RP11-301O19.1	14.07	2.65e-41	4.43e-38	0.47	0.4	Night sleep phenotypes;	chr2:86286770	chr2:86195590~86196049:+
BRCA	cis	rs9918079	0.56	rs12651550	ENSG00000273133.1	RP11-799M12.2	-14.07	2.66e-41	4.45e-38	-0.49	-0.4	Obesity-related traits;	chr4:15639395	chr4:15563698~15564253:-
BRCA	cis	rs4423214	0.84	rs1123007	ENSG00000254682.1	RP11-660L16.2	-14.07	2.66e-41	4.45e-38	-0.55	-0.4	Vitamin D levels;	chr11:71474311	chr11:71448674~71452157:+
BRCA	cis	rs4423214	0.84	rs1792234	ENSG00000254682.1	RP11-660L16.2	-14.07	2.7e-41	4.51e-38	-0.54	-0.4	Vitamin D levels;	chr11:71470972	chr11:71448674~71452157:+
BRCA	cis	rs4853012	0.941	rs2421752	ENSG00000217702.2	RP11-287D1.4	14.07	2.71e-41	4.53e-38	0.63	0.4	Gestational age at birth (maternal effect);	chr2:74114488	chr2:74130583~74135395:+
BRCA	cis	rs3091242	0.934	rs686631	ENSG00000261349.1	RP3-465N24.5	-14.07	2.73e-41	4.55e-38	-0.45	-0.4	Erythrocyte sedimentation rate;	chr1:25393108	chr1:25266102~25267136:-
BRCA	cis	rs6964833	1	rs34324835	ENSG00000277053.3	GTF2IP1	-14.07	2.81e-41	4.7e-38	-0.57	-0.4	Menarche (age at onset);	chr7:74717986	chr7:75185385~75237696:-
BRCA	cis	rs2455601	0.882	rs11042105	ENSG00000254860.4	TMEM9B-AS1	14.06	3.01e-41	5.02e-38	0.47	0.4	Schizophrenia;	chr11:8872963	chr11:8964675~8977527:+
BRCA	cis	rs11690935	0.885	rs6727017	ENSG00000228389.1	AC068039.4	14.06	3.03e-41	5.05e-38	0.51	0.4	Schizophrenia;	chr2:171910337	chr2:171773482~171775844:+
BRCA	cis	rs9918079	0.56	rs6414767	ENSG00000273133.1	RP11-799M12.2	-14.06	3.13e-41	5.22e-38	-0.5	-0.4	Obesity-related traits;	chr4:15654098	chr4:15563698~15564253:-
BRCA	cis	rs977987	0.778	rs1109341	ENSG00000261783.1	RP11-252K23.2	-14.06	3.14e-41	5.24e-38	-0.51	-0.4	Dupuytren's disease;	chr16:75411707	chr16:75379818~75381260:-
BRCA	cis	rs11603023	0.967	rs494560	ENSG00000255239.1	AP002954.6	-14.06	3.15e-41	5.26e-38	-0.45	-0.4	Cholesterol, total;	chr11:118650844	chr11:118688039~118690600:-
BRCA	cis	rs9918079	0.506	rs7696127	ENSG00000273133.1	RP11-799M12.2	-14.05	3.32e-41	5.53e-38	-0.49	-0.4	Obesity-related traits;	chr4:15641330	chr4:15563698~15564253:-
BRCA	cis	rs2283792	1	rs1892846	ENSG00000224086.5	LL22NC03-86G7.1	-14.05	3.4e-41	5.66e-38	-0.42	-0.4	Multiple sclerosis;	chr22:21832190	chr22:21938293~21977632:+
BRCA	cis	rs2283792	1	rs1892848	ENSG00000224086.5	LL22NC03-86G7.1	-14.05	3.4e-41	5.66e-38	-0.42	-0.4	Multiple sclerosis;	chr22:21832273	chr22:21938293~21977632:+
BRCA	cis	rs2283792	0.967	rs5999823	ENSG00000224086.5	LL22NC03-86G7.1	-14.04	3.76e-41	6.24e-38	-0.42	-0.4	Multiple sclerosis;	chr22:21856587	chr22:21938293~21977632:+
BRCA	cis	rs4728142	0.604	rs7807018	ENSG00000275106.1	RP11-309L24.10	-14.04	3.98e-41	6.61e-38	-0.5	-0.4	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129000134	chr7:128952527~128953316:-
BRCA	cis	rs7208859	0.573	rs56031503	ENSG00000263531.1	RP13-753N3.1	14.03	4.12e-41	6.83e-38	0.73	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748647	chr17:30863921~30864940:-
BRCA	cis	rs3096299	0.685	rs12935112	ENSG00000274627.1	RP11-104N10.2	-14.03	4.14e-41	6.88e-38	-0.4	-0.4	Multiple myeloma (IgH translocation);	chr16:89476450	chr16:89516797~89522217:+
BRCA	cis	rs1789	0.786	rs6449161	ENSG00000273133.1	RP11-799M12.2	-14.03	4.2e-41	6.97e-38	-0.51	-0.4	Blood protein levels;	chr4:15691331	chr4:15563698~15564253:-
BRCA	cis	rs2739330	0.828	rs5760108	ENSG00000099984.9	GSTT2	-14.03	4.25e-41	7.05e-38	-0.47	-0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23980123~23983911:+
BRCA	cis	rs35160687	0.871	rs2278105	ENSG00000273080.1	RP11-301O19.1	14.03	4.29e-41	7.12e-38	0.47	0.4	Night sleep phenotypes;	chr2:86239393	chr2:86195590~86196049:+
BRCA	cis	rs9918079	0.56	rs7662032	ENSG00000273133.1	RP11-799M12.2	-14.03	4.37e-41	7.24e-38	-0.49	-0.4	Obesity-related traits;	chr4:15633791	chr4:15563698~15564253:-
BRCA	cis	rs1789	0.839	rs9997068	ENSG00000273133.1	RP11-799M12.2	-14.03	4.49e-41	7.43e-38	-0.5	-0.4	Blood protein levels;	chr4:15649367	chr4:15563698~15564253:-
BRCA	cis	rs6452524	0.935	rs10474081	ENSG00000249664.1	CTD-2227C6.2	14.03	4.57e-41	7.57e-38	0.49	0.4	Hypertension (SNP x SNP interaction);	chr5:83095064	chr5:83012285~83013109:-
BRCA	cis	rs11690935	0.959	rs6754817	ENSG00000228389.1	AC068039.4	14.02	4.77e-41	7.89e-38	0.52	0.4	Schizophrenia;	chr2:171806884	chr2:171773482~171775844:+
BRCA	cis	rs1167827	1	rs1167827	ENSG00000127957.15	PMS2P3	-14.01	5.25e-41	8.68e-38	-0.4	-0.4	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75533848	chr7:75502930~75528148:-
BRCA	cis	rs16828019	0.929	rs111309254	ENSG00000235358.1	RP11-399E6.1	14.01	5.27e-41	8.71e-38	0.75	0.4	Intelligence (multi-trait analysis);	chr1:41270328	chr1:41242373~41284861:+
BRCA	cis	rs16828019	0.929	rs4131949	ENSG00000235358.1	RP11-399E6.1	14.01	5.27e-41	8.71e-38	0.75	0.4	Intelligence (multi-trait analysis);	chr1:41272965	chr1:41242373~41284861:+
BRCA	cis	rs16828019	0.929	rs35813191	ENSG00000235358.1	RP11-399E6.1	14.01	5.27e-41	8.71e-38	0.75	0.4	Intelligence (multi-trait analysis);	chr1:41277128	chr1:41242373~41284861:+
BRCA	cis	rs4722166	0.541	rs1800795	ENSG00000179428.2	AC073072.5	-14.01	5.6e-41	9.25e-38	-0.44	-0.4	Lung cancer;	chr7:22727026	chr7:22725395~22727620:-
BRCA	cis	rs6452524	0.905	rs10040244	ENSG00000249664.1	CTD-2227C6.2	14.01	5.69e-41	9.39e-38	0.49	0.4	Hypertension (SNP x SNP interaction);	chr5:83089242	chr5:83012285~83013109:-
BRCA	cis	rs35160687	0.901	rs12622200	ENSG00000273080.1	RP11-301O19.1	-14	5.9e-41	9.73e-38	-0.47	-0.4	Night sleep phenotypes;	chr2:86271472	chr2:86195590~86196049:+
BRCA	cis	rs3091242	0.933	rs11802413	ENSG00000261349.1	RP3-465N24.5	14	6.17e-41	1.02e-37	0.44	0.4	Erythrocyte sedimentation rate;	chr1:25434429	chr1:25266102~25267136:-
BRCA	cis	rs2111504	0.559	rs12460112	ENSG00000267213.4	AC007773.2	14	6.32e-41	1.04e-37	0.5	0.4	Bipolar disorder;	chr19:32363928	chr19:32390050~32405560:-
BRCA	cis	rs2455601	0.882	rs10840139	ENSG00000254860.4	TMEM9B-AS1	14	6.38e-41	1.05e-37	0.47	0.4	Schizophrenia;	chr11:8873291	chr11:8964675~8977527:+
BRCA	cis	rs7617773	0.779	rs11718329	ENSG00000229759.1	MRPS18AP1	14	6.38e-41	1.05e-37	0.48	0.4	Coronary artery disease;	chr3:48268338	chr3:48256350~48256938:-
BRCA	cis	rs35160687	0.901	rs12478653	ENSG00000273080.1	RP11-301O19.1	-14	6.5e-41	1.07e-37	-0.46	-0.4	Night sleep phenotypes;	chr2:86308271	chr2:86195590~86196049:+
BRCA	cis	rs16828019	0.852	rs11209531	ENSG00000235358.1	RP11-399E6.1	14	6.51e-41	1.07e-37	0.76	0.4	Intelligence (multi-trait analysis);	chr1:41105349	chr1:41242373~41284861:+
BRCA	cis	rs7208859	0.623	rs7503335	ENSG00000263531.1	RP13-753N3.1	13.99	6.61e-41	1.09e-37	0.73	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30746944	chr17:30863921~30864940:-
BRCA	cis	rs10170846	0.924	rs3768973	ENSG00000261428.2	RP11-16P6.1	13.99	6.75e-41	1.11e-37	0.5	0.4	Schizophrenia (inflammation and infection response interaction);	chr2:222571683	chr2:222566899~222569719:-
BRCA	cis	rs3091242	0.867	rs602052	ENSG00000261349.1	RP3-465N24.5	-13.99	7.11e-41	1.17e-37	-0.45	-0.4	Erythrocyte sedimentation rate;	chr1:25395715	chr1:25266102~25267136:-
BRCA	cis	rs16828019	0.852	rs71648536	ENSG00000235358.1	RP11-399E6.1	13.99	7.18e-41	1.18e-37	0.76	0.4	Intelligence (multi-trait analysis);	chr1:41166336	chr1:41242373~41284861:+
BRCA	cis	rs16828019	0.852	rs12759050	ENSG00000235358.1	RP11-399E6.1	13.98	7.45e-41	1.22e-37	0.76	0.4	Intelligence (multi-trait analysis);	chr1:41198532	chr1:41242373~41284861:+
BRCA	cis	rs16828019	0.789	rs34216154	ENSG00000235358.1	RP11-399E6.1	13.98	7.45e-41	1.22e-37	0.76	0.4	Intelligence (multi-trait analysis);	chr1:41205235	chr1:41242373~41284861:+
BRCA	cis	rs2108622	0.727	rs62106155	ENSG00000267453.5	AC004791.2	-13.98	7.63e-41	1.25e-37	-0.48	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15869550	chr19:15851993~15864904:-
BRCA	cis	rs4423214	0.84	rs4435028	ENSG00000254682.1	RP11-660L16.2	-13.98	7.77e-41	1.28e-37	-0.54	-0.4	Vitamin D levels;	chr11:71472644	chr11:71448674~71452157:+
BRCA	cis	rs4423214	0.802	rs4616066	ENSG00000254682.1	RP11-660L16.2	-13.98	7.77e-41	1.28e-37	-0.54	-0.4	Vitamin D levels;	chr11:71472800	chr11:71448674~71452157:+
BRCA	cis	rs4423214	0.802	rs4402322	ENSG00000254682.1	RP11-660L16.2	-13.98	7.77e-41	1.28e-37	-0.54	-0.4	Vitamin D levels;	chr11:71472969	chr11:71448674~71452157:+
BRCA	cis	rs4423214	0.802	rs2276358	ENSG00000254682.1	RP11-660L16.2	-13.98	7.77e-41	1.28e-37	-0.54	-0.4	Vitamin D levels;	chr11:71473452	chr11:71448674~71452157:+
BRCA	cis	rs4423214	0.84	rs3794057	ENSG00000254682.1	RP11-660L16.2	-13.98	7.77e-41	1.28e-37	-0.54	-0.4	Vitamin D levels;	chr11:71475698	chr11:71448674~71452157:+
BRCA	cis	rs4423214	0.84	rs2017686	ENSG00000254682.1	RP11-660L16.2	-13.98	7.77e-41	1.28e-37	-0.54	-0.4	Vitamin D levels;	chr11:71476015	chr11:71448674~71452157:+
BRCA	cis	rs9918079	0.56	rs4698402	ENSG00000273133.1	RP11-799M12.2	-13.98	8.04e-41	1.32e-37	-0.49	-0.4	Obesity-related traits;	chr4:15628180	chr4:15563698~15564253:-
BRCA	cis	rs2111504	0.583	rs2868082	ENSG00000267213.4	AC007773.2	13.98	8.13e-41	1.33e-37	0.5	0.4	Bipolar disorder;	chr19:32368475	chr19:32390050~32405560:-
BRCA	cis	rs2658782	0.547	rs3133454	ENSG00000279684.1	RP11-755E23.2	-13.97	8.39e-41	1.38e-37	-0.54	-0.4	Pulmonary function decline;	chr11:93325853	chr11:93286629~93288903:-
BRCA	cis	rs16828019	0.929	rs12029321	ENSG00000235358.1	RP11-399E6.1	13.97	8.69e-41	1.42e-37	0.76	0.4	Intelligence (multi-trait analysis);	chr1:41216858	chr1:41242373~41284861:+
BRCA	cis	rs16828019	0.929	rs11209734	ENSG00000235358.1	RP11-399E6.1	13.97	8.69e-41	1.42e-37	0.76	0.4	Intelligence (multi-trait analysis);	chr1:41232402	chr1:41242373~41284861:+
BRCA	cis	rs16828019	0.929	rs12037037	ENSG00000235358.1	RP11-399E6.1	13.97	8.69e-41	1.42e-37	0.76	0.4	Intelligence (multi-trait analysis);	chr1:41232584	chr1:41242373~41284861:+
BRCA	cis	rs11168854	0.656	rs7969963	ENSG00000258017.1	RP11-386G11.10	-13.97	8.78e-41	1.44e-37	-0.54	-0.4	Body mass index;	chr12:49118222	chr12:49127782~49147869:+
BRCA	cis	rs2111504	0.583	rs1008425	ENSG00000267213.4	AC007773.2	13.97	8.82e-41	1.44e-37	0.5	0.4	Bipolar disorder;	chr19:32361239	chr19:32390050~32405560:-
BRCA	cis	rs4423214	0.84	rs1792231	ENSG00000254682.1	RP11-660L16.2	-13.97	9.09e-41	1.49e-37	-0.54	-0.4	Vitamin D levels;	chr11:71471635	chr11:71448674~71452157:+
BRCA	cis	rs4853012	0.887	rs77148265	ENSG00000217702.2	RP11-287D1.4	13.97	9.31e-41	1.52e-37	0.63	0.4	Gestational age at birth (maternal effect);	chr2:74112392	chr2:74130583~74135395:+
BRCA	cis	rs8040855	0.599	rs6496791	ENSG00000259295.5	CSPG4P12	-13.96	9.55e-41	1.56e-37	-0.48	-0.4	Bulimia nervosa;	chr15:85182428	chr15:85191438~85213905:+
BRCA	cis	rs8062405	0.755	rs4149398	ENSG00000259982.1	CDC37P1	13.96	9.96e-41	1.63e-37	0.51	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28597617	chr16:28700294~28701540:-
BRCA	cis	rs2108622	0.727	rs62106157	ENSG00000267453.5	AC004791.2	-13.95	1.06e-40	1.73e-37	-0.47	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15869638	chr19:15851993~15864904:-
BRCA	cis	rs2108622	0.727	rs62106158	ENSG00000267453.5	AC004791.2	-13.95	1.06e-40	1.73e-37	-0.47	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15869682	chr19:15851993~15864904:-
BRCA	cis	rs8062405	0.723	rs62031562	ENSG00000259982.1	CDC37P1	13.95	1.07e-40	1.75e-37	0.51	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28598008	chr16:28700294~28701540:-
BRCA	cis	rs16828019	0.852	rs34286980	ENSG00000235358.1	RP11-399E6.1	13.95	1.08e-40	1.76e-37	0.76	0.4	Intelligence (multi-trait analysis);	chr1:41142717	chr1:41242373~41284861:+
BRCA	cis	rs16828019	0.852	rs12742803	ENSG00000235358.1	RP11-399E6.1	13.95	1.08e-40	1.76e-37	0.76	0.4	Intelligence (multi-trait analysis);	chr1:41182459	chr1:41242373~41284861:+
BRCA	cis	rs16828019	0.852	rs12408956	ENSG00000235358.1	RP11-399E6.1	13.95	1.08e-40	1.76e-37	0.76	0.4	Intelligence (multi-trait analysis);	chr1:41186280	chr1:41242373~41284861:+
BRCA	cis	rs16828019	0.852	rs35992757	ENSG00000235358.1	RP11-399E6.1	13.95	1.08e-40	1.76e-37	0.76	0.4	Intelligence (multi-trait analysis);	chr1:41187190	chr1:41242373~41284861:+
BRCA	cis	rs8062405	0.723	rs35175818	ENSG00000259982.1	CDC37P1	13.95	1.09e-40	1.78e-37	0.51	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28597425	chr16:28700294~28701540:-
BRCA	cis	rs7208859	0.524	rs73988172	ENSG00000263531.1	RP13-753N3.1	13.95	1.11e-40	1.81e-37	0.72	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759314	chr17:30863921~30864940:-
BRCA	cis	rs4728142	0.604	rs4731541	ENSG00000275106.1	RP11-309L24.10	-13.95	1.11e-40	1.82e-37	-0.5	-0.4	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129038182	chr7:128952527~128953316:-
BRCA	cis	rs2019137	0.936	rs12620738	ENSG00000189223.12	PAX8-AS1	13.95	1.17e-40	1.91e-37	0.54	0.4	Lymphocyte counts;	chr2:113206162	chr2:113211522~113276581:+
BRCA	cis	rs2739330	0.828	rs2877178	ENSG00000099984.9	GSTT2	-13.95	1.18e-40	1.92e-37	-0.48	-0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23980123~23983911:+
BRCA	cis	rs16828019	0.852	rs3766324	ENSG00000235358.1	RP11-399E6.1	13.95	1.18e-40	1.93e-37	0.76	0.4	Intelligence (multi-trait analysis);	chr1:41122981	chr1:41242373~41284861:+
BRCA	cis	rs11690935	0.851	rs7581072	ENSG00000228389.1	AC068039.4	13.94	1.21e-40	1.98e-37	0.5	0.4	Schizophrenia;	chr2:171994938	chr2:171773482~171775844:+
BRCA	cis	rs2019137	0.936	rs3811059	ENSG00000189223.12	PAX8-AS1	13.94	1.22e-40	1.99e-37	0.54	0.4	Lymphocyte counts;	chr2:113204494	chr2:113211522~113276581:+
BRCA	cis	rs8040855	0.579	rs6496797	ENSG00000259295.5	CSPG4P12	-13.94	1.23e-40	2.01e-37	-0.47	-0.4	Bulimia nervosa;	chr15:85183624	chr15:85191438~85213905:+
BRCA	cis	rs2283792	1	rs6518986	ENSG00000224086.5	LL22NC03-86G7.1	-13.94	1.24e-40	2.02e-37	-0.41	-0.4	Multiple sclerosis;	chr22:21831058	chr22:21938293~21977632:+
BRCA	cis	rs2283792	1	rs5999750	ENSG00000224086.5	LL22NC03-86G7.1	-13.94	1.24e-40	2.02e-37	-0.41	-0.4	Multiple sclerosis;	chr22:21833720	chr22:21938293~21977632:+
BRCA	cis	rs4423214	0.84	rs1790339	ENSG00000254682.1	RP11-660L16.2	-13.94	1.24e-40	2.03e-37	-0.54	-0.4	Vitamin D levels;	chr11:71471715	chr11:71448674~71452157:+
BRCA	cis	rs3096299	0.658	rs3934737	ENSG00000274627.1	RP11-104N10.2	13.94	1.26e-40	2.05e-37	0.41	0.4	Multiple myeloma (IgH translocation);	chr16:89493801	chr16:89516797~89522217:+
BRCA	cis	rs7617773	0.817	rs9837228	ENSG00000229759.1	MRPS18AP1	-13.94	1.27e-40	2.07e-37	-0.48	-0.4	Coronary artery disease;	chr3:48282976	chr3:48256350~48256938:-
BRCA	cis	rs16828019	0.852	rs12759023	ENSG00000235358.1	RP11-399E6.1	13.94	1.31e-40	2.14e-37	0.76	0.4	Intelligence (multi-trait analysis);	chr1:41138306	chr1:41242373~41284861:+
BRCA	cis	rs2739330	0.796	rs5760106	ENSG00000250470.1	AP000351.3	-13.93	1.44e-40	2.34e-37	-0.49	-0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23976904~23977585:-
BRCA	cis	rs2188561	0.697	rs12539555	ENSG00000241764.3	AC002467.7	13.93	1.47e-40	2.39e-37	0.55	0.4	Alcohol consumption;	chr7:107764028	chr7:107742817~107744581:-
BRCA	cis	rs2188561	0.697	rs6956243	ENSG00000241764.3	AC002467.7	13.92	1.53e-40	2.49e-37	0.55	0.4	Alcohol consumption;	chr7:107748466	chr7:107742817~107744581:-
BRCA	cis	rs2108622	0.727	rs7256877	ENSG00000267453.5	AC004791.2	-13.92	1.61e-40	2.61e-37	-0.47	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15869873	chr19:15851993~15864904:-
BRCA	cis	rs8062405	0.723	rs762633	ENSG00000259982.1	CDC37P1	13.92	1.62e-40	2.64e-37	0.51	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28597020	chr16:28700294~28701540:-
BRCA	cis	rs7240205	0.853	rs4555225	ENSG00000275805.1	RP11-349H17.2	-13.92	1.63e-40	2.65e-37	-0.43	-0.4	Breast cancer;	chr18:26561892	chr18:26565723~26575626:-
BRCA	cis	rs1789	0.903	rs4470622	ENSG00000273133.1	RP11-799M12.2	-13.92	1.68e-40	2.72e-37	-0.5	-0.4	Blood protein levels;	chr4:15672552	chr4:15563698~15564253:-
BRCA	cis	rs2111504	0.559	rs7250813	ENSG00000267213.4	AC007773.2	13.91	1.85e-40	3.01e-37	0.5	0.4	Bipolar disorder;	chr19:32358815	chr19:32390050~32405560:-
BRCA	cis	rs7104764	0.507	rs6598056	ENSG00000277290.1	RP11-326C3.16	13.9	1.92e-40	3.11e-37	0.45	0.4	Menarche (age at onset);	chr11:252283	chr11:243099~243483:-
BRCA	cis	rs2108622	0.727	rs9305069	ENSG00000267453.5	AC004791.2	-13.9	1.98e-40	3.2e-37	-0.47	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15872576	chr19:15851993~15864904:-
BRCA	cis	rs2108622	0.683	rs56228205	ENSG00000267453.5	AC004791.2	-13.9	2.01e-40	3.26e-37	-0.47	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871163	chr19:15851993~15864904:-
BRCA	cis	rs2108622	0.727	rs12609900	ENSG00000267453.5	AC004791.2	-13.9	2.04e-40	3.31e-37	-0.47	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871604	chr19:15851993~15864904:-
BRCA	cis	rs2108622	0.727	rs62107763	ENSG00000267453.5	AC004791.2	-13.9	2.04e-40	3.31e-37	-0.47	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871788	chr19:15851993~15864904:-
BRCA	cis	rs2108622	0.727	rs62107764	ENSG00000267453.5	AC004791.2	-13.9	2.04e-40	3.31e-37	-0.47	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871848	chr19:15851993~15864904:-
BRCA	cis	rs2108622	0.727	rs8101038	ENSG00000267453.5	AC004791.2	-13.9	2.04e-40	3.31e-37	-0.47	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15872054	chr19:15851993~15864904:-
BRCA	cis	rs3931020	0.671	rs1327088	ENSG00000272864.1	RP11-17E13.2	-13.9	2.05e-40	3.31e-37	-0.47	-0.4	Resistin levels;	chr1:74789807	chr1:74698769~74699333:-
BRCA	cis	rs16828019	0.929	rs8179465	ENSG00000235358.1	RP11-399E6.1	13.89	2.18e-40	3.52e-37	0.75	0.4	Intelligence (multi-trait analysis);	chr1:41236075	chr1:41242373~41284861:+
BRCA	cis	rs16828019	0.852	rs16827876	ENSG00000235358.1	RP11-399E6.1	13.89	2.18e-40	3.52e-37	0.76	0.4	Intelligence (multi-trait analysis);	chr1:41073864	chr1:41242373~41284861:+
BRCA	cis	rs16828019	0.852	rs34979067	ENSG00000235358.1	RP11-399E6.1	13.89	2.18e-40	3.52e-37	0.76	0.4	Intelligence (multi-trait analysis);	chr1:41077412	chr1:41242373~41284861:+
BRCA	cis	rs16828019	0.852	rs35190461	ENSG00000235358.1	RP11-399E6.1	13.89	2.18e-40	3.52e-37	0.76	0.4	Intelligence (multi-trait analysis);	chr1:41077463	chr1:41242373~41284861:+
BRCA	cis	rs16828019	0.852	rs12022978	ENSG00000235358.1	RP11-399E6.1	13.89	2.18e-40	3.52e-37	0.76	0.4	Intelligence (multi-trait analysis);	chr1:41088416	chr1:41242373~41284861:+
BRCA	cis	rs2108622	0.727	rs62107770	ENSG00000267453.5	AC004791.2	-13.89	2.22e-40	3.59e-37	-0.48	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15874615	chr19:15851993~15864904:-
BRCA	cis	rs7240205	0.853	rs10853666	ENSG00000275805.1	RP11-349H17.2	13.89	2.28e-40	3.69e-37	0.43	0.4	Breast cancer;	chr18:26564147	chr18:26565723~26575626:-
BRCA	cis	rs7617773	0.78	rs34523942	ENSG00000229759.1	MRPS18AP1	13.89	2.29e-40	3.69e-37	0.5	0.4	Coronary artery disease;	chr3:48301179	chr3:48256350~48256938:-
BRCA	cis	rs2108622	0.701	rs3093209	ENSG00000267453.5	AC004791.2	-13.89	2.38e-40	3.84e-37	-0.48	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15877610	chr19:15851993~15864904:-
BRCA	cis	rs2108622	0.559	rs7252638	ENSG00000267453.5	AC004791.2	-13.89	2.39e-40	3.85e-37	-0.47	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15870215	chr19:15851993~15864904:-
BRCA	cis	rs2108622	0.727	rs7253684	ENSG00000267453.5	AC004791.2	-13.89	2.39e-40	3.85e-37	-0.47	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15870316	chr19:15851993~15864904:-
BRCA	cis	rs16828019	0.852	rs12044539	ENSG00000235358.1	RP11-399E6.1	13.89	2.4e-40	3.86e-37	0.75	0.4	Intelligence (multi-trait analysis);	chr1:41196060	chr1:41242373~41284861:+
BRCA	cis	rs7617773	0.817	rs9847953	ENSG00000229759.1	MRPS18AP1	13.88	2.44e-40	3.93e-37	0.48	0.4	Coronary artery disease;	chr3:48241205	chr3:48256350~48256938:-
BRCA	cis	rs2108622	0.727	rs7253873	ENSG00000267453.5	AC004791.2	-13.88	2.47e-40	3.97e-37	-0.47	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15870090	chr19:15851993~15864904:-
BRCA	cis	rs4728142	0.604	rs10954215	ENSG00000275106.1	RP11-309L24.10	-13.88	2.69e-40	4.32e-37	-0.5	-0.39	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129005459	chr7:128952527~128953316:-
BRCA	cis	rs2108622	0.727	rs3093216	ENSG00000267453.5	AC004791.2	-13.87	2.8e-40	4.5e-37	-0.48	-0.39	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15876927	chr19:15851993~15864904:-
BRCA	cis	rs2108622	0.727	rs76984410	ENSG00000267453.5	AC004791.2	-13.87	2.88e-40	4.63e-37	-0.47	-0.39	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871890	chr19:15851993~15864904:-
BRCA	cis	rs2108622	0.727	rs77780918	ENSG00000267453.5	AC004791.2	-13.87	2.88e-40	4.63e-37	-0.47	-0.39	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871897	chr19:15851993~15864904:-
BRCA	cis	rs2487048	0.773	rs2472493	ENSG00000226334.1	RP11-217B7.2	-13.87	2.89e-40	4.64e-37	-0.52	-0.39	Intraocular pressure;	chr9:104933567	chr9:104927553~104928892:+
BRCA	cis	rs9918079	0.524	rs4235379	ENSG00000273133.1	RP11-799M12.2	-13.87	2.9e-40	4.65e-37	-0.5	-0.39	Obesity-related traits;	chr4:15657655	chr4:15563698~15564253:-
BRCA	cis	rs2188561	0.638	rs3735609	ENSG00000241764.3	AC002467.7	13.86	3.06e-40	4.91e-37	0.55	0.39	Alcohol consumption;	chr7:107743299	chr7:107742817~107744581:-
BRCA	cis	rs4728142	0.604	rs6969930	ENSG00000275106.1	RP11-309L24.10	-13.86	3.16e-40	5.07e-37	-0.5	-0.39	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128990259	chr7:128952527~128953316:-
BRCA	cis	rs4728142	0.604	rs4731536	ENSG00000275106.1	RP11-309L24.10	-13.86	3.16e-40	5.07e-37	-0.5	-0.39	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129000239	chr7:128952527~128953316:-
BRCA	cis	rs2188561	0.697	rs34986332	ENSG00000241764.3	AC002467.7	13.86	3.16e-40	5.07e-37	0.54	0.39	Alcohol consumption;	chr7:107739010	chr7:107742817~107744581:-
BRCA	cis	rs9918079	0.56	rs4698409	ENSG00000273133.1	RP11-799M12.2	-13.86	3.21e-40	5.14e-37	-0.49	-0.39	Obesity-related traits;	chr4:15658143	chr4:15563698~15564253:-
BRCA	cis	rs10262624	0.528	rs5029444	ENSG00000234286.1	AC006026.13	13.86	3.36e-40	5.38e-37	0.46	0.39	Schizophrenia;	chr7:23698176	chr7:23680195~23680786:-
BRCA	cis	rs1185460	0.967	rs1177563	ENSG00000271751.1	RP11-110I1.14	-13.86	3.42e-40	5.47e-37	-0.49	-0.39	Coronary artery disease;	chr11:119078373	chr11:119065263~119065677:-
BRCA	cis	rs2739330	0.828	rs4820572	ENSG00000099984.9	GSTT2	-13.85	3.52e-40	5.64e-37	-0.48	-0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23980123~23983911:+
BRCA	cis	rs7240205	0.853	rs34288695	ENSG00000275805.1	RP11-349H17.2	13.85	3.54e-40	5.66e-37	0.42	0.39	Breast cancer;	chr18:26563122	chr18:26565723~26575626:-
BRCA	cis	rs7617773	0.78	rs71323396	ENSG00000229759.1	MRPS18AP1	13.85	3.72e-40	5.95e-37	0.51	0.39	Coronary artery disease;	chr3:48333244	chr3:48256350~48256938:-
BRCA	cis	rs1789	0.903	rs6850422	ENSG00000273133.1	RP11-799M12.2	-13.85	3.77e-40	6.03e-37	-0.5	-0.39	Blood protein levels;	chr4:15680814	chr4:15563698~15564253:-
BRCA	cis	rs16828019	0.852	rs12729586	ENSG00000235358.1	RP11-399E6.1	13.85	3.78e-40	6.04e-37	0.75	0.39	Intelligence (multi-trait analysis);	chr1:41056705	chr1:41242373~41284861:+
BRCA	cis	rs16828019	0.704	rs34486565	ENSG00000235358.1	RP11-399E6.1	13.85	3.78e-40	6.04e-37	0.75	0.39	Intelligence (multi-trait analysis);	chr1:41056838	chr1:41242373~41284861:+
BRCA	cis	rs2108622	0.711	rs113059233	ENSG00000267453.5	AC004791.2	-13.85	3.8e-40	6.07e-37	-0.47	-0.39	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15866558	chr19:15851993~15864904:-
BRCA	cis	rs2188561	0.638	rs28690459	ENSG00000241764.3	AC002467.7	13.85	3.8e-40	6.08e-37	0.54	0.39	Alcohol consumption;	chr7:107740258	chr7:107742817~107744581:-
BRCA	cis	rs3096299	0.719	rs2965817	ENSG00000274627.1	RP11-104N10.2	13.85	3.81e-40	6.09e-37	0.41	0.39	Multiple myeloma (IgH translocation);	chr16:89446826	chr16:89516797~89522217:+
BRCA	cis	rs2658782	1	rs2658778	ENSG00000279684.1	RP11-755E23.2	-13.85	3.83e-40	6.11e-37	-0.59	-0.39	Pulmonary function decline;	chr11:93415782	chr11:93286629~93288903:-
BRCA	cis	rs16828019	0.852	rs12048187	ENSG00000235358.1	RP11-399E6.1	13.85	3.83e-40	6.12e-37	0.76	0.39	Intelligence (multi-trait analysis);	chr1:41150511	chr1:41242373~41284861:+
BRCA	cis	rs16828019	0.852	rs71648540	ENSG00000235358.1	RP11-399E6.1	13.84	3.96e-40	6.32e-37	0.75	0.39	Intelligence (multi-trait analysis);	chr1:41256623	chr1:41242373~41284861:+
BRCA	cis	rs9918079	0.542	rs1789	ENSG00000273133.1	RP11-799M12.2	-13.84	4e-40	6.39e-37	-0.49	-0.39	Obesity-related traits;	chr4:15662912	chr4:15563698~15564253:-
BRCA	cis	rs2487048	0.773	rs2472494	ENSG00000226334.1	RP11-217B7.2	-13.84	4.19e-40	6.69e-37	-0.52	-0.39	Intraocular pressure;	chr9:104933258	chr9:104927553~104928892:+
BRCA	cis	rs3091242	0.933	rs10903129	ENSG00000261349.1	RP3-465N24.5	-13.84	4.2e-40	6.7e-37	-0.44	-0.39	Erythrocyte sedimentation rate;	chr1:25442446	chr1:25266102~25267136:-
BRCA	cis	rs16828019	0.852	rs12742379	ENSG00000235358.1	RP11-399E6.1	13.84	4.21e-40	6.71e-37	0.75	0.39	Intelligence (multi-trait analysis);	chr1:41060709	chr1:41242373~41284861:+
BRCA	cis	rs7617773	0.784	rs9850672	ENSG00000229759.1	MRPS18AP1	13.84	4.24e-40	6.75e-37	0.48	0.39	Coronary artery disease;	chr3:48259682	chr3:48256350~48256938:-
BRCA	cis	rs7240205	0.853	rs58806199	ENSG00000275805.1	RP11-349H17.2	-13.84	4.33e-40	6.89e-37	-0.43	-0.39	Breast cancer;	chr18:26562683	chr18:26565723~26575626:-
BRCA	cis	rs2658782	0.547	rs3020052	ENSG00000279684.1	RP11-755E23.2	-13.83	4.45e-40	7.09e-37	-0.53	-0.39	Pulmonary function decline;	chr11:93322018	chr11:93286629~93288903:-
BRCA	cis	rs992157	0.735	rs13430006	ENSG00000261338.2	RP11-378A13.1	-13.83	4.47e-40	7.11e-37	-0.41	-0.39	Colorectal cancer;	chr2:218248366	chr2:218255319~218257366:+
BRCA	cis	rs6964833	1	rs36044436	ENSG00000277053.3	GTF2IP1	-13.83	4.55e-40	7.24e-37	-0.56	-0.39	Menarche (age at onset);	chr7:74675495	chr7:75185385~75237696:-
BRCA	cis	rs2739330	0.796	rs2154594	ENSG00000250470.1	AP000351.3	-13.83	4.86e-40	7.73e-37	-0.48	-0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23976904~23977585:-
BRCA	cis	rs10262624	0.528	rs722294	ENSG00000234286.1	AC006026.13	13.82	5.04e-40	8.02e-37	0.45	0.39	Schizophrenia;	chr7:23706966	chr7:23680195~23680786:-
BRCA	cis	rs7044106	0.791	rs10985008	ENSG00000226752.6	PSMD5-AS1	-13.82	5.24e-40	8.33e-37	-0.48	-0.39	Hip circumference adjusted for BMI;	chr9:120730682	chr9:120824828~120854385:+
BRCA	cis	rs12594515	1	rs8039622	ENSG00000273972.1	CTD-2306A12.1	-13.82	5.28e-40	8.39e-37	-0.46	-0.39	Weight;Waist circumference;	chr15:45694233	chr15:45702640~45703183:+
BRCA	cis	rs4722166	0.63	rs7808457	ENSG00000179428.2	AC073072.5	13.82	5.31e-40	8.43e-37	0.44	0.39	Lung cancer;	chr7:22758646	chr7:22725395~22727620:-
BRCA	cis	rs16828019	0.929	rs2363805	ENSG00000235358.1	RP11-399E6.1	13.81	5.52e-40	8.76e-37	0.75	0.39	Intelligence (multi-trait analysis);	chr1:41253762	chr1:41242373~41284861:+
BRCA	cis	rs2283792	0.967	rs11704205	ENSG00000224086.5	LL22NC03-86G7.1	-13.81	5.53e-40	8.79e-37	-0.41	-0.39	Multiple sclerosis;	chr22:21790964	chr22:21938293~21977632:+
BRCA	cis	rs11690935	0.885	rs6725388	ENSG00000228389.1	AC068039.4	13.81	5.56e-40	8.82e-37	0.5	0.39	Schizophrenia;	chr2:171873505	chr2:171773482~171775844:+
BRCA	cis	rs2283792	0.967	rs743409	ENSG00000224086.5	LL22NC03-86G7.1	-13.81	5.82e-40	9.22e-37	-0.42	-0.39	Multiple sclerosis;	chr22:21774926	chr22:21938293~21977632:+
BRCA	cis	rs16828019	0.929	rs10524	ENSG00000235358.1	RP11-399E6.1	13.81	5.96e-40	9.44e-37	0.74	0.39	Intelligence (multi-trait analysis);	chr1:41260801	chr1:41242373~41284861:+
BRCA	cis	rs11603023	0.874	rs613243	ENSG00000255239.1	AP002954.6	13.81	5.97e-40	9.47e-37	0.44	0.39	Cholesterol, total;	chr11:118643304	chr11:118688039~118690600:-
BRCA	cis	rs2188561	0.697	rs10808154	ENSG00000241764.3	AC002467.7	13.81	5.98e-40	9.47e-37	0.55	0.39	Alcohol consumption;	chr7:107745951	chr7:107742817~107744581:-
BRCA	cis	rs17711722	0.522	rs6957759	ENSG00000164669.11	INTS4P1	-13.81	5.98e-40	9.47e-37	-0.5	-0.39	Calcium levels;	chr7:65806798	chr7:65141225~65234216:+
BRCA	cis	rs17711722	0.522	rs4642526	ENSG00000164669.11	INTS4P1	-13.81	6.01e-40	9.52e-37	-0.5	-0.39	Calcium levels;	chr7:65751755	chr7:65141225~65234216:+
BRCA	cis	rs11603023	0.772	rs540800	ENSG00000255239.1	AP002954.6	13.81	6.05e-40	9.58e-37	0.45	0.39	Cholesterol, total;	chr11:118694942	chr11:118688039~118690600:-
BRCA	cis	rs16828019	0.852	rs3904243	ENSG00000235358.1	RP11-399E6.1	13.81	6.1e-40	9.66e-37	0.76	0.39	Intelligence (multi-trait analysis);	chr1:41109180	chr1:41242373~41284861:+
BRCA	cis	rs12594515	1	rs11070467	ENSG00000273972.1	CTD-2306A12.1	13.81	6.13e-40	9.72e-37	0.46	0.39	Weight;Waist circumference;	chr15:45692803	chr15:45702640~45703183:+
BRCA	cis	rs2108622	0.727	rs7254940	ENSG00000267453.5	AC004791.2	-13.81	6.15e-40	9.74e-37	-0.47	-0.39	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15873698	chr19:15851993~15864904:-
BRCA	cis	rs2117029	0.555	rs9788139	ENSG00000258017.1	RP11-386G11.10	-13.81	6.17e-40	9.76e-37	-0.53	-0.39	Intelligence (multi-trait analysis);	chr12:49126886	chr12:49127782~49147869:+
BRCA	cis	rs2117029	0.619	rs2241727	ENSG00000258017.1	RP11-386G11.10	-13.8	6.31e-40	9.99e-37	-0.53	-0.39	Intelligence (multi-trait analysis);	chr12:49131225	chr12:49127782~49147869:+
BRCA	cis	rs2108622	0.683	rs111388185	ENSG00000267453.5	AC004791.2	-13.8	6.86e-40	1.08e-36	-0.47	-0.39	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15866604	chr19:15851993~15864904:-
BRCA	cis	rs2108622	0.683	rs112571591	ENSG00000267453.5	AC004791.2	-13.8	6.86e-40	1.08e-36	-0.47	-0.39	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15866635	chr19:15851993~15864904:-
BRCA	cis	rs2108622	0.647	rs111427692	ENSG00000267453.5	AC004791.2	-13.8	6.86e-40	1.08e-36	-0.47	-0.39	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15866669	chr19:15851993~15864904:-
BRCA	cis	rs17608059	0.524	rs9897978	ENSG00000141028.6	CDRT15P1	13.79	7.06e-40	1.12e-36	0.51	0.39	Temperament;	chr17:13996939	chr17:14024514~14025488:+
BRCA	cis	rs11603023	0.625	rs633683	ENSG00000255239.1	AP002954.6	13.79	7.12e-40	1.12e-36	0.45	0.39	Cholesterol, total;	chr11:118634025	chr11:118688039~118690600:-
BRCA	cis	rs2108622	0.711	rs113343664	ENSG00000267453.5	AC004791.2	-13.79	7.54e-40	1.19e-36	-0.47	-0.39	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15868183	chr19:15851993~15864904:-
BRCA	cis	rs2455601	1	rs72632952	ENSG00000254860.4	TMEM9B-AS1	13.79	7.65e-40	1.21e-36	0.47	0.39	Schizophrenia;	chr11:8896429	chr11:8964675~8977527:+
BRCA	cis	rs16828019	0.929	rs1032728	ENSG00000235358.1	RP11-399E6.1	13.79	7.71e-40	1.22e-36	0.75	0.39	Intelligence (multi-trait analysis);	chr1:41213894	chr1:41242373~41284861:+
BRCA	cis	rs16828019	0.929	rs35286837	ENSG00000235358.1	RP11-399E6.1	13.79	7.71e-40	1.22e-36	0.75	0.39	Intelligence (multi-trait analysis);	chr1:41217326	chr1:41242373~41284861:+
BRCA	cis	rs9918079	0.56	rs4698406	ENSG00000273133.1	RP11-799M12.2	-13.79	7.72e-40	1.22e-36	-0.5	-0.39	Obesity-related traits;	chr4:15638994	chr4:15563698~15564253:-
BRCA	cis	rs2108622	0.727	rs8104311	ENSG00000267453.5	AC004791.2	-13.79	7.73e-40	1.22e-36	-0.47	-0.39	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871950	chr19:15851993~15864904:-
BRCA	cis	rs4423214	0.84	rs1792229	ENSG00000254682.1	RP11-660L16.2	-13.79	7.76e-40	1.22e-36	-0.53	-0.39	Vitamin D levels;	chr11:71468349	chr11:71448674~71452157:+
BRCA	cis	rs2188561	0.708	rs9718496	ENSG00000241764.3	AC002467.7	13.79	7.77e-40	1.22e-36	0.54	0.39	Alcohol consumption;	chr7:107730187	chr7:107742817~107744581:-
BRCA	cis	rs17711722	0.565	rs4275112	ENSG00000164669.11	INTS4P1	13.78	8e-40	1.26e-36	0.5	0.39	Calcium levels;	chr7:65733651	chr7:65141225~65234216:+
BRCA	cis	rs6452524	1	rs7738033	ENSG00000249664.1	CTD-2227C6.2	13.78	8e-40	1.26e-36	0.46	0.39	Hypertension (SNP x SNP interaction);	chr5:83135470	chr5:83012285~83013109:-
BRCA	cis	rs6452524	1	rs6860239	ENSG00000249664.1	CTD-2227C6.2	13.78	8e-40	1.26e-36	0.46	0.39	Hypertension (SNP x SNP interaction);	chr5:83136022	chr5:83012285~83013109:-
BRCA	cis	rs12594515	1	rs8039974	ENSG00000273972.1	CTD-2306A12.1	-13.78	8.02e-40	1.26e-36	-0.46	-0.39	Weight;Waist circumference;	chr15:45694467	chr15:45702640~45703183:+
BRCA	cis	rs67311347	1	rs2276870	ENSG00000223797.4	ENTPD3-AS1	-13.78	8.1e-40	1.28e-36	-0.44	-0.39	Renal cell carcinoma;	chr3:40457691	chr3:40313802~40453329:-
BRCA	cis	rs2108622	0.727	rs12609468	ENSG00000267453.5	AC004791.2	-13.78	8.29e-40	1.31e-36	-0.47	-0.39	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15867004	chr19:15851993~15864904:-
BRCA	cis	rs2188561	0.697	rs13242107	ENSG00000241764.3	AC002467.7	13.78	8.29e-40	1.31e-36	0.54	0.39	Alcohol consumption;	chr7:107734800	chr7:107742817~107744581:-
BRCA	cis	rs2188561	0.697	rs12705421	ENSG00000241764.3	AC002467.7	13.78	8.37e-40	1.32e-36	0.55	0.39	Alcohol consumption;	chr7:107760984	chr7:107742817~107744581:-
BRCA	cis	rs11690935	1	rs312924	ENSG00000228389.1	AC068039.4	-13.78	8.46e-40	1.33e-36	-0.49	-0.39	Schizophrenia;	chr2:171707511	chr2:171773482~171775844:+
BRCA	cis	rs977987	0.806	rs4888405	ENSG00000261783.1	RP11-252K23.2	-13.78	8.49e-40	1.34e-36	-0.5	-0.39	Dupuytren's disease;	chr16:75394298	chr16:75379818~75381260:-
BRCA	cis	rs11690935	0.885	rs10202823	ENSG00000228389.1	AC068039.4	13.78	8.57e-40	1.35e-36	0.5	0.39	Schizophrenia;	chr2:171923622	chr2:171773482~171775844:+
BRCA	cis	rs16828019	0.777	rs16911	ENSG00000235358.1	RP11-399E6.1	13.77	8.84e-40	1.39e-36	0.75	0.39	Intelligence (multi-trait analysis);	chr1:41032349	chr1:41242373~41284861:+
BRCA	cis	rs11690935	0.885	rs6750058	ENSG00000228389.1	AC068039.4	13.77	8.89e-40	1.4e-36	0.5	0.39	Schizophrenia;	chr2:171930399	chr2:171773482~171775844:+
BRCA	cis	rs4853012	0.941	rs78128123	ENSG00000217702.2	RP11-287D1.4	13.77	9.1e-40	1.43e-36	0.65	0.39	Gestational age at birth (maternal effect);	chr2:74120398	chr2:74130583~74135395:+
BRCA	cis	rs200895692	1	rs200895692	ENSG00000227533.4	SLC2A1-AS1	13.77	9.15e-40	1.44e-36	0.69	0.39	Monocyte count;	chr1:42956299	chr1:42959049~42983358:+
BRCA	cis	rs2108622	0.727	rs8102532	ENSG00000267453.5	AC004791.2	-13.77	9.27e-40	1.46e-36	-0.47	-0.39	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15869250	chr19:15851993~15864904:-
BRCA	cis	rs2487048	0.804	rs2472496	ENSG00000226334.1	RP11-217B7.2	-13.77	9.34e-40	1.47e-36	-0.51	-0.39	Intraocular pressure;	chr9:104933072	chr9:104927553~104928892:+
BRCA	cis	rs6700559	1	rs6700559	ENSG00000260088.1	RP11-92G12.3	13.76	1.08e-39	1.7e-36	0.48	0.39	Coronary artery disease;	chr1:200676945	chr1:200669507~200694250:+
BRCA	cis	rs2108622	0.649	rs113055956	ENSG00000267453.5	AC004791.2	-13.76	1.11e-39	1.74e-36	-0.47	-0.39	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15866502	chr19:15851993~15864904:-
BRCA	cis	rs11690935	0.851	rs10174055	ENSG00000228389.1	AC068039.4	13.75	1.16e-39	1.82e-36	0.5	0.39	Schizophrenia;	chr2:171993303	chr2:171773482~171775844:+
BRCA	cis	rs16828019	0.852	rs12729448	ENSG00000235358.1	RP11-399E6.1	13.75	1.18e-39	1.84e-36	0.75	0.39	Intelligence (multi-trait analysis);	chr1:41044162	chr1:41242373~41284861:+
BRCA	cis	rs16828019	0.852	rs2268678	ENSG00000235358.1	RP11-399E6.1	13.75	1.18e-39	1.84e-36	0.75	0.39	Intelligence (multi-trait analysis);	chr1:41045381	chr1:41242373~41284861:+
BRCA	cis	rs16828019	0.852	rs10489520	ENSG00000235358.1	RP11-399E6.1	13.75	1.18e-39	1.84e-36	0.75	0.39	Intelligence (multi-trait analysis);	chr1:41046083	chr1:41242373~41284861:+
BRCA	cis	rs16828019	0.852	rs12406620	ENSG00000235358.1	RP11-399E6.1	13.75	1.18e-39	1.84e-36	0.75	0.39	Intelligence (multi-trait analysis);	chr1:41046992	chr1:41242373~41284861:+
BRCA	cis	rs2188561	0.697	rs66560125	ENSG00000241764.3	AC002467.7	13.74	1.28e-39	2e-36	0.54	0.39	Alcohol consumption;	chr7:107729589	chr7:107742817~107744581:-
BRCA	cis	rs2739330	0.789	rs5760109	ENSG00000099984.9	GSTT2	-13.74	1.35e-39	2.11e-36	-0.47	-0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23980123~23983911:+
BRCA	cis	rs1577917	0.545	rs9294338	ENSG00000203875.9	SNHG5	13.73	1.43e-39	2.24e-36	0.45	0.39	Response to antipsychotic treatment;	chr6:85764650	chr6:85660950~85678736:-
BRCA	cis	rs2117029	0.521	rs2114845	ENSG00000258017.1	RP11-386G11.10	-13.72	1.58e-39	2.46e-36	-0.53	-0.39	Intelligence (multi-trait analysis);	chr12:49164750	chr12:49127782~49147869:+
BRCA	cis	rs9918079	0.542	rs7688984	ENSG00000273133.1	RP11-799M12.2	-13.72	1.65e-39	2.57e-36	-0.5	-0.39	Obesity-related traits;	chr4:15655630	chr4:15563698~15564253:-
BRCA	cis	rs2283792	0.967	rs5999550	ENSG00000224086.5	LL22NC03-86G7.1	-13.72	1.7e-39	2.66e-36	-0.4	-0.39	Multiple sclerosis;	chr22:21796997	chr22:21938293~21977632:+
BRCA	cis	rs7240205	0.853	rs10432165	ENSG00000275805.1	RP11-349H17.2	-13.72	1.73e-39	2.7e-36	-0.43	-0.39	Breast cancer;	chr18:26555361	chr18:26565723~26575626:-
BRCA	cis	rs16828019	0.852	rs2300649	ENSG00000235358.1	RP11-399E6.1	13.72	1.74e-39	2.71e-36	0.76	0.39	Intelligence (multi-trait analysis);	chr1:41103531	chr1:41242373~41284861:+
BRCA	cis	rs9918079	0.643	rs35414597	ENSG00000273133.1	RP11-799M12.2	13.72	1.76e-39	2.75e-36	0.51	0.39	Obesity-related traits;	chr4:15564113	chr4:15563698~15564253:-
BRCA	cis	rs12594515	1	rs12911309	ENSG00000273972.1	CTD-2306A12.1	-13.71	1.78e-39	2.77e-36	-0.46	-0.39	Weight;Waist circumference;	chr15:45693521	chr15:45702640~45703183:+
BRCA	cis	rs2117029	0.521	rs12227610	ENSG00000258017.1	RP11-386G11.10	-13.71	1.82e-39	2.84e-36	-0.53	-0.39	Intelligence (multi-trait analysis);	chr12:49146153	chr12:49127782~49147869:+
BRCA	cis	rs7301826	0.934	rs10848212	ENSG00000256250.1	RP11-989F5.1	13.71	1.88e-39	2.93e-36	0.46	0.39	Plasma plasminogen activator levels;	chr12:130837455	chr12:130810606~130812438:+
BRCA	cis	rs12594515	1	rs12595137	ENSG00000273972.1	CTD-2306A12.1	-13.71	1.9e-39	2.95e-36	-0.46	-0.39	Weight;Waist circumference;	chr15:45693907	chr15:45702640~45703183:+
BRCA	cis	rs12594515	0.967	rs12595138	ENSG00000273972.1	CTD-2306A12.1	-13.71	1.9e-39	2.95e-36	-0.46	-0.39	Weight;Waist circumference;	chr15:45693910	chr15:45702640~45703183:+
BRCA	cis	rs12594515	0.967	rs11070465	ENSG00000273972.1	CTD-2306A12.1	-13.71	1.94e-39	3.02e-36	-0.45	-0.39	Weight;Waist circumference;	chr15:45692701	chr15:45702640~45703183:+
BRCA	cis	rs16828019	0.777	rs2300658	ENSG00000235358.1	RP11-399E6.1	13.71	1.95e-39	3.03e-36	0.75	0.39	Intelligence (multi-trait analysis);	chr1:41039350	chr1:41242373~41284861:+
BRCA	cis	rs2117029	0.586	rs11168874	ENSG00000258017.1	RP11-386G11.10	-13.71	1.98e-39	3.08e-36	-0.53	-0.39	Intelligence (multi-trait analysis);	chr12:49133753	chr12:49127782~49147869:+
BRCA	cis	rs7617773	0.817	rs3937	ENSG00000229759.1	MRPS18AP1	13.7	2e-39	3.11e-36	0.48	0.39	Coronary artery disease;	chr3:48270912	chr3:48256350~48256938:-
BRCA	cis	rs2188561	0.615	rs13226711	ENSG00000241764.3	AC002467.7	13.7	2e-39	3.11e-36	0.55	0.39	Alcohol consumption;	chr7:107754897	chr7:107742817~107744581:-
BRCA	cis	rs16828019	0.852	rs11209545	ENSG00000235358.1	RP11-399E6.1	13.7	2.02e-39	3.15e-36	0.75	0.39	Intelligence (multi-trait analysis);	chr1:41110685	chr1:41242373~41284861:+
BRCA	cis	rs16828019	0.852	rs11209576	ENSG00000235358.1	RP11-399E6.1	13.7	2.02e-39	3.15e-36	0.75	0.39	Intelligence (multi-trait analysis);	chr1:41120357	chr1:41242373~41284861:+
BRCA	cis	rs2188561	0.666	rs13231387	ENSG00000241764.3	AC002467.7	13.7	2.04e-39	3.17e-36	0.54	0.39	Alcohol consumption;	chr7:107749534	chr7:107742817~107744581:-
BRCA	cis	rs2739330	0.828	rs5751770	ENSG00000099984.9	GSTT2	-13.7	2.07e-39	3.21e-36	-0.46	-0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23980123~23983911:+
BRCA	cis	rs2108622	0.701	rs118144071	ENSG00000267453.5	AC004791.2	-13.7	2.07e-39	3.22e-36	-0.47	-0.39	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15868384	chr19:15851993~15864904:-
BRCA	cis	rs6452524	0.967	rs1031901	ENSG00000249664.1	CTD-2227C6.2	13.7	2.07e-39	3.22e-36	0.46	0.39	Hypertension (SNP x SNP interaction);	chr5:83147904	chr5:83012285~83013109:-
BRCA	cis	rs2117029	0.555	rs9788140	ENSG00000258017.1	RP11-386G11.10	-13.7	2.13e-39	3.31e-36	-0.53	-0.39	Intelligence (multi-trait analysis);	chr12:49126738	chr12:49127782~49147869:+
BRCA	cis	rs2404602	0.598	rs11634019	ENSG00000259422.1	RP11-593F23.1	-13.69	2.37e-39	3.68e-36	-0.54	-0.39	Blood metabolite levels;	chr15:76342339	chr15:76174891~76181486:-
BRCA	cis	rs2188561	0.697	rs13224313	ENSG00000241764.3	AC002467.7	13.69	2.41e-39	3.73e-36	0.53	0.39	Alcohol consumption;	chr7:107741907	chr7:107742817~107744581:-
BRCA	cis	rs2111504	0.583	rs2111503	ENSG00000267213.4	AC007773.2	13.69	2.43e-39	3.77e-36	0.49	0.39	Bipolar disorder;	chr19:32383819	chr19:32390050~32405560:-
BRCA	cis	rs2739330	0.828	rs5760107	ENSG00000099984.9	GSTT2	-13.69	2.46e-39	3.82e-36	-0.47	-0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23980123~23983911:+
BRCA	cis	rs2117029	0.521	rs7953169	ENSG00000258017.1	RP11-386G11.10	-13.69	2.5e-39	3.88e-36	-0.53	-0.39	Intelligence (multi-trait analysis);	chr12:49184389	chr12:49127782~49147869:+
BRCA	cis	rs7617773	0.817	rs6801801	ENSG00000229759.1	MRPS18AP1	13.68	2.6e-39	4.03e-36	0.48	0.39	Coronary artery disease;	chr3:48284943	chr3:48256350~48256938:-
BRCA	cis	rs1577917	0.545	rs1335443	ENSG00000203875.9	SNHG5	-13.68	2.67e-39	4.13e-36	-0.44	-0.39	Response to antipsychotic treatment;	chr6:85769019	chr6:85660950~85678736:-
BRCA	cis	rs2019137	0.936	rs902696	ENSG00000189223.12	PAX8-AS1	-13.68	2.71e-39	4.2e-36	-0.53	-0.39	Lymphocyte counts;	chr2:113197302	chr2:113211522~113276581:+
BRCA	cis	rs9918079	0.56	rs6449153	ENSG00000273133.1	RP11-799M12.2	-13.67	2.87e-39	4.44e-36	-0.5	-0.39	Obesity-related traits;	chr4:15629593	chr4:15563698~15564253:-
BRCA	cis	rs2658782	0.547	rs3020065	ENSG00000279684.1	RP11-755E23.2	-13.67	2.92e-39	4.52e-36	-0.53	-0.39	Pulmonary function decline;	chr11:93326733	chr11:93286629~93288903:-
BRCA	cis	rs9918079	0.6	rs12500587	ENSG00000273133.1	RP11-799M12.2	13.67	2.93e-39	4.53e-36	0.51	0.39	Obesity-related traits;	chr4:15579131	chr4:15563698~15564253:-
BRCA	cis	rs2108622	0.683	rs6512067	ENSG00000267453.5	AC004791.2	-13.67	3.06e-39	4.72e-36	-0.46	-0.39	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15872141	chr19:15851993~15864904:-
BRCA	cis	rs12594515	1	rs11070464	ENSG00000273972.1	CTD-2306A12.1	-13.67	3.13e-39	4.83e-36	-0.45	-0.39	Weight;Waist circumference;	chr15:45692578	chr15:45702640~45703183:+
BRCA	cis	rs11168854	0.656	rs7969967	ENSG00000258017.1	RP11-386G11.10	13.67	3.13e-39	4.84e-36	0.53	0.39	Body mass index;	chr12:49118234	chr12:49127782~49147869:+
BRCA	cis	rs7684446	1	rs7684446	ENSG00000273133.1	RP11-799M12.2	13.67	3.17e-39	4.89e-36	0.47	0.39	Red blood cell count;	chr4:15591241	chr4:15563698~15564253:-
BRCA	cis	rs2283792	1	rs2266967	ENSG00000224086.5	LL22NC03-86G7.1	-13.66	3.21e-39	4.95e-36	-0.4	-0.39	Multiple sclerosis;	chr22:21802500	chr22:21938293~21977632:+
BRCA	cis	rs9918079	0.6	rs61021642	ENSG00000273133.1	RP11-799M12.2	13.66	3.3e-39	5.09e-36	0.51	0.39	Obesity-related traits;	chr4:15575702	chr4:15563698~15564253:-
BRCA	cis	rs9918079	0.56	rs4270584	ENSG00000273133.1	RP11-799M12.2	13.66	3.34e-39	5.15e-36	0.49	0.39	Obesity-related traits;	chr4:15599176	chr4:15563698~15564253:-
BRCA	cis	rs7182621	0.846	rs12915935	ENSG00000259363.4	CTD-2054N24.2	-13.65	3.79e-39	5.83e-36	-0.46	-0.39	Colonoscopy-negative controls vs population controls;	chr15:99871875	chr15:99807023~99877148:+
BRCA	cis	rs7240205	0.816	rs2019480	ENSG00000275805.1	RP11-349H17.2	13.65	3.94e-39	6.06e-36	0.42	0.39	Breast cancer;	chr18:26545720	chr18:26565723~26575626:-
BRCA	cis	rs12594515	1	rs8038058	ENSG00000273972.1	CTD-2306A12.1	-13.64	4.12e-39	6.32e-36	-0.45	-0.39	Weight;Waist circumference;	chr15:45698074	chr15:45702640~45703183:+
BRCA	cis	rs11673344	0.734	rs320887	ENSG00000226686.6	LINC01535	-13.64	4.13e-39	6.34e-36	-0.54	-0.39	Obesity-related traits;	chr19:37202536	chr19:37251912~37265535:+
BRCA	cis	rs12594515	1	rs12906442	ENSG00000273972.1	CTD-2306A12.1	-13.64	4.2e-39	6.45e-36	-0.45	-0.39	Weight;Waist circumference;	chr15:45693056	chr15:45702640~45703183:+
BRCA	cis	rs1800795	0.652	rs7802307	ENSG00000179428.2	AC073072.5	-13.64	4.24e-39	6.51e-36	-0.43	-0.39	Cerebrospinal fluid clusterin levels in APOEe4- carriers;	chr7:22726814	chr7:22725395~22727620:-
BRCA	cis	rs8040855	0.599	rs2342123	ENSG00000259295.5	CSPG4P12	13.64	4.25e-39	6.52e-36	0.46	0.39	Bulimia nervosa;	chr15:85181918	chr15:85191438~85213905:+
BRCA	cis	rs977987	0.872	rs1559339	ENSG00000261783.1	RP11-252K23.2	-13.64	4.28e-39	6.56e-36	-0.5	-0.39	Dupuytren's disease;	chr16:75284748	chr16:75379818~75381260:-
BRCA	cis	rs8040855	0.599	rs1964724	ENSG00000259295.5	CSPG4P12	-13.64	4.31e-39	6.61e-36	-0.46	-0.39	Bulimia nervosa;	chr15:85183269	chr15:85191438~85213905:+
BRCA	cis	rs2108622	0.727	rs12610967	ENSG00000267453.5	AC004791.2	-13.64	4.49e-39	6.88e-36	-0.47	-0.39	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15867119	chr19:15851993~15864904:-
BRCA	cis	rs2108622	0.711	rs12609820	ENSG00000267453.5	AC004791.2	-13.64	4.49e-39	6.88e-36	-0.47	-0.39	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15867247	chr19:15851993~15864904:-
BRCA	cis	rs2108622	0.668	rs62106153	ENSG00000267453.5	AC004791.2	-13.64	4.49e-39	6.88e-36	-0.47	-0.39	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15867697	chr19:15851993~15864904:-
BRCA	cis	rs2108622	0.727	rs12611242	ENSG00000267453.5	AC004791.2	-13.64	4.49e-39	6.88e-36	-0.47	-0.39	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15867754	chr19:15851993~15864904:-
BRCA	cis	rs2108622	0.727	rs12611308	ENSG00000267453.5	AC004791.2	-13.64	4.49e-39	6.88e-36	-0.47	-0.39	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15867776	chr19:15851993~15864904:-
BRCA	cis	rs2108622	0.727	rs12610189	ENSG00000267453.5	AC004791.2	-13.64	4.49e-39	6.88e-36	-0.47	-0.39	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15867831	chr19:15851993~15864904:-
BRCA	cis	rs16828019	0.852	rs71648534	ENSG00000235358.1	RP11-399E6.1	13.63	4.58e-39	7.01e-36	0.75	0.39	Intelligence (multi-trait analysis);	chr1:41148075	chr1:41242373~41284861:+
BRCA	cis	rs16828019	0.852	rs71648535	ENSG00000235358.1	RP11-399E6.1	13.63	4.58e-39	7.01e-36	0.75	0.39	Intelligence (multi-trait analysis);	chr1:41148078	chr1:41242373~41284861:+
BRCA	cis	rs3096299	0.685	rs4785571	ENSG00000274627.1	RP11-104N10.2	13.63	4.63e-39	7.09e-36	0.41	0.39	Multiple myeloma (IgH translocation);	chr16:89498761	chr16:89516797~89522217:+
BRCA	cis	rs2019137	0.868	rs6755639	ENSG00000274877.1	RP11-65I12.1	-13.63	4.71e-39	7.21e-36	-0.51	-0.39	Lymphocyte counts;	chr2:113224233	chr2:113237595~113240825:+
BRCA	cis	rs7617773	0.743	rs6804986	ENSG00000229759.1	MRPS18AP1	13.63	4.87e-39	7.45e-36	0.49	0.39	Coronary artery disease;	chr3:48322105	chr3:48256350~48256938:-
BRCA	cis	rs2019137	0.936	rs3828188	ENSG00000189223.12	PAX8-AS1	13.62	5.08e-39	7.77e-36	0.53	0.39	Lymphocyte counts;	chr2:113196670	chr2:113211522~113276581:+
BRCA	cis	rs3096299	0.658	rs34590044	ENSG00000274627.1	RP11-104N10.2	13.62	5.15e-39	7.89e-36	0.4	0.39	Multiple myeloma (IgH translocation);	chr16:89476749	chr16:89516797~89522217:+
BRCA	cis	rs16828019	0.852	rs3820090	ENSG00000235358.1	RP11-399E6.1	13.62	5.22e-39	7.98e-36	0.75	0.39	Intelligence (multi-trait analysis);	chr1:41107980	chr1:41242373~41284861:+
BRCA	cis	rs2111504	0.583	rs10853921	ENSG00000267213.4	AC007773.2	-13.62	5.56e-39	8.5e-36	-0.5	-0.39	Bipolar disorder;	chr19:32370899	chr19:32390050~32405560:-
BRCA	cis	rs12594515	0.967	rs11070466	ENSG00000273972.1	CTD-2306A12.1	-13.62	5.65e-39	8.65e-36	-0.45	-0.39	Weight;Waist circumference;	chr15:45692757	chr15:45702640~45703183:+
BRCA	cis	rs17711722	0.565	rs4717276	ENSG00000164669.11	INTS4P1	-13.61	5.8e-39	8.86e-36	-0.49	-0.39	Calcium levels;	chr7:65829754	chr7:65141225~65234216:+
BRCA	cis	rs7617773	0.817	rs11710861	ENSG00000229759.1	MRPS18AP1	13.61	5.81e-39	8.87e-36	0.47	0.39	Coronary artery disease;	chr3:48256070	chr3:48256350~48256938:-
BRCA	cis	rs2019137	0.936	rs3828189	ENSG00000189223.12	PAX8-AS1	13.61	5.93e-39	9.06e-36	0.53	0.39	Lymphocyte counts;	chr2:113196919	chr2:113211522~113276581:+
BRCA	cis	rs2283792	1	rs5999521	ENSG00000224086.5	LL22NC03-86G7.1	-13.61	5.98e-39	9.14e-36	-0.4	-0.39	Multiple sclerosis;	chr22:21792110	chr22:21938293~21977632:+
BRCA	cis	rs2117029	0.521	rs10875925	ENSG00000258017.1	RP11-386G11.10	-13.61	5.99e-39	9.14e-36	-0.53	-0.39	Intelligence (multi-trait analysis);	chr12:49142575	chr12:49127782~49147869:+
BRCA	cis	rs2117029	0.586	rs11168882	ENSG00000258017.1	RP11-386G11.10	-13.61	5.99e-39	9.14e-36	-0.53	-0.39	Intelligence (multi-trait analysis);	chr12:49143560	chr12:49127782~49147869:+
BRCA	cis	rs11690935	0.851	rs7573003	ENSG00000228389.1	AC068039.4	13.61	6.12e-39	9.35e-36	0.5	0.39	Schizophrenia;	chr2:171884905	chr2:171773482~171775844:+
BRCA	cis	rs8040855	0.599	rs6496800	ENSG00000259295.5	CSPG4P12	-13.6	6.64e-39	1.01e-35	-0.46	-0.39	Bulimia nervosa;	chr15:85185055	chr15:85191438~85213905:+
BRCA	cis	rs3096299	0.563	rs4600467	ENSG00000274627.1	RP11-104N10.2	13.6	6.85e-39	1.04e-35	0.41	0.39	Multiple myeloma (IgH translocation);	chr16:89496108	chr16:89516797~89522217:+
BRCA	cis	rs2019137	0.936	rs4849169	ENSG00000189223.12	PAX8-AS1	13.6	6.98e-39	1.06e-35	0.53	0.39	Lymphocyte counts;	chr2:113196080	chr2:113211522~113276581:+
BRCA	cis	rs2019137	0.836	rs4848318	ENSG00000189223.12	PAX8-AS1	13.6	6.98e-39	1.06e-35	0.53	0.39	Lymphocyte counts;	chr2:113196375	chr2:113211522~113276581:+
BRCA	cis	rs2019137	0.936	rs2241978	ENSG00000189223.12	PAX8-AS1	13.6	6.98e-39	1.06e-35	0.53	0.39	Lymphocyte counts;	chr2:113196429	chr2:113211522~113276581:+
BRCA	cis	rs1789	0.653	rs13142069	ENSG00000273133.1	RP11-799M12.2	13.59	7.4e-39	1.13e-35	0.46	0.39	Blood protein levels;	chr4:15592069	chr4:15563698~15564253:-
BRCA	cis	rs8040855	0.599	rs6496792	ENSG00000259295.5	CSPG4P12	-13.58	8.27e-39	1.26e-35	-0.47	-0.39	Bulimia nervosa;	chr15:85182514	chr15:85191438~85213905:+
BRCA	cis	rs8040855	0.599	rs6496793	ENSG00000259295.5	CSPG4P12	-13.58	8.27e-39	1.26e-35	-0.47	-0.39	Bulimia nervosa;	chr15:85182515	chr15:85191438~85213905:+
BRCA	cis	rs8040855	0.599	rs6496795	ENSG00000259295.5	CSPG4P12	-13.58	8.27e-39	1.26e-35	-0.47	-0.39	Bulimia nervosa;	chr15:85182622	chr15:85191438~85213905:+
BRCA	cis	rs11690935	0.885	rs6752812	ENSG00000228389.1	AC068039.4	13.58	8.39e-39	1.28e-35	0.49	0.39	Schizophrenia;	chr2:171986588	chr2:171773482~171775844:+
BRCA	cis	rs2283792	0.871	rs8136867	ENSG00000224086.5	LL22NC03-86G7.1	-13.58	8.53e-39	1.3e-35	-0.41	-0.39	Multiple sclerosis;	chr22:21850504	chr22:21938293~21977632:+
BRCA	cis	rs12594515	1	rs6493167	ENSG00000273972.1	CTD-2306A12.1	-13.58	8.86e-39	1.35e-35	-0.45	-0.39	Weight;Waist circumference;	chr15:45694611	chr15:45702640~45703183:+
BRCA	cis	rs12594515	1	rs6493168	ENSG00000273972.1	CTD-2306A12.1	-13.58	8.86e-39	1.35e-35	-0.45	-0.39	Weight;Waist circumference;	chr15:45694613	chr15:45702640~45703183:+
BRCA	cis	rs9545047	0.716	rs418150	ENSG00000227676.3	LINC01068	-13.58	8.9e-39	1.35e-35	-0.46	-0.39	Schizophrenia;	chr13:79432675	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.716	rs643778	ENSG00000227676.3	LINC01068	-13.57	9.11e-39	1.38e-35	-0.47	-0.39	Schizophrenia;	chr13:79423937	chr13:79566727~79571436:+
BRCA	cis	rs3096299	0.685	rs3803681	ENSG00000274627.1	RP11-104N10.2	13.57	9.14e-39	1.39e-35	0.4	0.39	Multiple myeloma (IgH translocation);	chr16:89478348	chr16:89516797~89522217:+
BRCA	cis	rs7617773	0.817	rs9819094	ENSG00000229759.1	MRPS18AP1	13.57	9.3e-39	1.41e-35	0.47	0.39	Coronary artery disease;	chr3:48278068	chr3:48256350~48256938:-
BRCA	cis	rs2108622	0.727	rs2158511	ENSG00000267453.5	AC004791.2	-13.57	9.48e-39	1.44e-35	-0.47	-0.39	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15875837	chr19:15851993~15864904:-
BRCA	cis	rs3096299	0.658	rs4291902	ENSG00000274627.1	RP11-104N10.2	13.57	9.52e-39	1.45e-35	0.41	0.39	Multiple myeloma (IgH translocation);	chr16:89493907	chr16:89516797~89522217:+
BRCA	cis	rs7044106	0.791	rs10985009	ENSG00000226752.6	PSMD5-AS1	13.57	9.97e-39	1.51e-35	0.47	0.39	Hip circumference adjusted for BMI;	chr9:120730761	chr9:120824828~120854385:+
BRCA	cis	rs11690935	0.843	rs9784123	ENSG00000228389.1	AC068039.4	13.57	1e-38	1.52e-35	0.5	0.39	Schizophrenia;	chr2:171928495	chr2:171773482~171775844:+
BRCA	cis	rs11690935	0.843	rs9784070	ENSG00000228389.1	AC068039.4	13.56	1.03e-38	1.56e-35	0.5	0.39	Schizophrenia;	chr2:171928497	chr2:171773482~171775844:+
BRCA	cis	rs7044106	0.5	rs56725168	ENSG00000226752.6	PSMD5-AS1	-13.56	1.09e-38	1.66e-35	-0.48	-0.39	Hip circumference adjusted for BMI;	chr9:120730298	chr9:120824828~120854385:+
BRCA	cis	rs10935480	0.771	rs7634817	ENSG00000239445.4	ST3GAL6-AS1	13.55	1.14e-38	1.73e-35	0.42	0.39	Blood protein levels;	chr3:98743681	chr3:98714330~98732651:-
BRCA	cis	rs7743045	0.504	rs10499090	ENSG00000253194.1	RP11-351A11.1	13.55	1.16e-38	1.76e-35	0.48	0.39	Mean platelet volume;	chr6:119000386	chr6:118934785~119031541:+
BRCA	cis	rs3091242	0.934	rs666686	ENSG00000261349.1	RP3-465N24.5	-13.55	1.18e-38	1.79e-35	-0.43	-0.39	Erythrocyte sedimentation rate;	chr1:25393020	chr1:25266102~25267136:-
BRCA	cis	rs2117029	0.555	rs10783304	ENSG00000258017.1	RP11-386G11.10	-13.55	1.22e-38	1.85e-35	-0.53	-0.39	Intelligence (multi-trait analysis);	chr12:49106615	chr12:49127782~49147869:+
BRCA	cis	rs12594515	1	rs7173144	ENSG00000273972.1	CTD-2306A12.1	-13.54	1.3e-38	1.96e-35	-0.45	-0.39	Weight;Waist circumference;	chr15:45698998	chr15:45702640~45703183:+
BRCA	cis	rs2019137	0.936	rs2305133	ENSG00000189223.12	PAX8-AS1	13.54	1.32e-38	2e-35	0.53	0.39	Lymphocyte counts;	chr2:113199244	chr2:113211522~113276581:+
BRCA	cis	rs2019137	0.936	rs12612729	ENSG00000189223.12	PAX8-AS1	13.54	1.32e-38	2e-35	0.53	0.39	Lymphocyte counts;	chr2:113199471	chr2:113211522~113276581:+
BRCA	cis	rs2019137	0.936	rs731834	ENSG00000189223.12	PAX8-AS1	13.54	1.32e-38	2e-35	0.53	0.39	Lymphocyte counts;	chr2:113199621	chr2:113211522~113276581:+
BRCA	cis	rs2019137	0.905	rs2276561	ENSG00000189223.12	PAX8-AS1	13.54	1.33e-38	2.01e-35	0.53	0.39	Lymphocyte counts;	chr2:113198794	chr2:113211522~113276581:+
BRCA	cis	rs3096299	0.685	rs8050512	ENSG00000274627.1	RP11-104N10.2	13.54	1.39e-38	2.11e-35	0.39	0.39	Multiple myeloma (IgH translocation);	chr16:89485912	chr16:89516797~89522217:+
BRCA	cis	rs7208859	0.623	rs9898084	ENSG00000263531.1	RP13-753N3.1	13.54	1.43e-38	2.16e-35	0.71	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30755316	chr17:30863921~30864940:-
BRCA	cis	rs2117029	0.555	rs7978448	ENSG00000258017.1	RP11-386G11.10	-13.53	1.46e-38	2.2e-35	-0.54	-0.39	Intelligence (multi-trait analysis);	chr12:49113157	chr12:49127782~49147869:+
BRCA	cis	rs2283792	1	rs2283792	ENSG00000224086.5	LL22NC03-86G7.1	-13.53	1.48e-38	2.23e-35	-0.4	-0.39	Multiple sclerosis;	chr22:21776836	chr22:21938293~21977632:+
BRCA	cis	rs3096299	0.632	rs4399533	ENSG00000274627.1	RP11-104N10.2	13.53	1.59e-38	2.39e-35	0.4	0.39	Multiple myeloma (IgH translocation);	chr16:89472974	chr16:89516797~89522217:+
BRCA	cis	rs1577917	1	rs11758849	ENSG00000203875.9	SNHG5	-13.53	1.61e-38	2.42e-35	-0.49	-0.39	Response to antipsychotic treatment;	chr6:85998544	chr6:85660950~85678736:-
BRCA	cis	rs8040855	0.599	rs4577058	ENSG00000259295.5	CSPG4P12	-13.52	1.69e-38	2.55e-35	-0.46	-0.39	Bulimia nervosa;	chr15:85183227	chr15:85191438~85213905:+
BRCA	cis	rs3096299	0.754	rs2965816	ENSG00000274627.1	RP11-104N10.2	-13.52	1.7e-38	2.55e-35	-0.4	-0.39	Multiple myeloma (IgH translocation);	chr16:89447775	chr16:89516797~89522217:+
BRCA	cis	rs2117029	0.554	rs12579015	ENSG00000258017.1	RP11-386G11.10	-13.52	1.77e-38	2.67e-35	-0.52	-0.39	Intelligence (multi-trait analysis);	chr12:49162648	chr12:49127782~49147869:+
BRCA	cis	rs11168854	0.62	rs11168888	ENSG00000258017.1	RP11-386G11.10	-13.52	1.8e-38	2.71e-35	-0.54	-0.39	Body mass index;	chr12:49149614	chr12:49127782~49147869:+
BRCA	cis	rs4718428	0.705	rs11028	ENSG00000226824.5	RP4-756H11.3	-13.51	1.92e-38	2.88e-35	-0.51	-0.39	Corneal structure;	chr7:66811230	chr7:66654538~66669855:+
BRCA	cis	rs8040855	0.579	rs4843029	ENSG00000259295.5	CSPG4P12	-13.51	1.93e-38	2.9e-35	-0.46	-0.39	Bulimia nervosa;	chr15:85182164	chr15:85191438~85213905:+
BRCA	cis	rs2658782	0.951	rs2608214	ENSG00000279684.1	RP11-755E23.2	-13.51	1.94e-38	2.91e-35	-0.55	-0.39	Pulmonary function decline;	chr11:93415499	chr11:93286629~93288903:-
BRCA	cis	rs67311347	1	rs2276871	ENSG00000223797.4	ENTPD3-AS1	13.51	1.95e-38	2.93e-35	0.43	0.39	Renal cell carcinoma;	chr3:40457782	chr3:40313802~40453329:-
BRCA	cis	rs35160687	0.787	rs10186289	ENSG00000273080.1	RP11-301O19.1	13.51	1.96e-38	2.94e-35	0.43	0.39	Night sleep phenotypes;	chr2:86285865	chr2:86195590~86196049:+
BRCA	cis	rs1789	0.786	rs6414768	ENSG00000273133.1	RP11-799M12.2	-13.51	1.98e-38	2.97e-35	-0.49	-0.39	Blood protein levels;	chr4:15693740	chr4:15563698~15564253:-
BRCA	cis	rs1789	0.903	rs4453929	ENSG00000273133.1	RP11-799M12.2	-13.51	2.01e-38	3.02e-35	-0.48	-0.39	Blood protein levels;	chr4:15670550	chr4:15563698~15564253:-
BRCA	cis	rs1577917	0.545	rs7755958	ENSG00000203875.9	SNHG5	13.51	2.02e-38	3.03e-35	0.44	0.39	Response to antipsychotic treatment;	chr6:85778793	chr6:85660950~85678736:-
BRCA	cis	rs2019137	0.967	rs902695	ENSG00000189223.12	PAX8-AS1	13.5	2.05e-38	3.07e-35	0.53	0.39	Lymphocyte counts;	chr2:113197497	chr2:113211522~113276581:+
BRCA	cis	rs2117029	0.523	rs12227296	ENSG00000258017.1	RP11-386G11.10	-13.5	2.06e-38	3.09e-35	-0.52	-0.39	Intelligence (multi-trait analysis);	chr12:49136712	chr12:49127782~49147869:+
BRCA	cis	rs7617773	0.851	rs6775179	ENSG00000229759.1	MRPS18AP1	13.5	2.11e-38	3.16e-35	0.47	0.39	Coronary artery disease;	chr3:48271928	chr3:48256350~48256938:-
BRCA	cis	rs2108622	0.727	rs3093193	ENSG00000267453.5	AC004791.2	-13.5	2.24e-38	3.35e-35	-0.47	-0.39	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15881104	chr19:15851993~15864904:-
BRCA	cis	rs2117029	0.521	rs11168885	ENSG00000258017.1	RP11-386G11.10	-13.5	2.24e-38	3.36e-35	-0.52	-0.39	Intelligence (multi-trait analysis);	chr12:49146204	chr12:49127782~49147869:+
BRCA	cis	rs12594515	1	rs7172161	ENSG00000273972.1	CTD-2306A12.1	-13.5	2.25e-38	3.37e-35	-0.45	-0.39	Weight;Waist circumference;	chr15:45698582	chr15:45702640~45703183:+
BRCA	cis	rs1789	0.903	rs4616746	ENSG00000273133.1	RP11-799M12.2	-13.49	2.28e-38	3.42e-35	-0.48	-0.39	Blood protein levels;	chr4:15671475	chr4:15563698~15564253:-
BRCA	cis	rs1789	0.868	rs4631041	ENSG00000273133.1	RP11-799M12.2	-13.49	2.28e-38	3.42e-35	-0.48	-0.39	Blood protein levels;	chr4:15671772	chr4:15563698~15564253:-
BRCA	cis	rs11168854	0.719	rs11168902	ENSG00000258017.1	RP11-386G11.10	-13.49	2.29e-38	3.42e-35	-0.54	-0.39	Body mass index;	chr12:49174483	chr12:49127782~49147869:+
BRCA	cis	rs2117029	0.553	rs11168903	ENSG00000258017.1	RP11-386G11.10	-13.49	2.29e-38	3.42e-35	-0.54	-0.39	Intelligence (multi-trait analysis);	chr12:49174883	chr12:49127782~49147869:+
BRCA	cis	rs2108622	0.727	rs3093207	ENSG00000267453.5	AC004791.2	-13.49	2.36e-38	3.53e-35	-0.46	-0.39	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15877848	chr19:15851993~15864904:-
BRCA	cis	rs2739330	0.796	rs2154594	ENSG00000099984.9	GSTT2	13.49	2.4e-38	3.6e-35	0.47	0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23980123~23983911:+
BRCA	cis	rs11123170	0.543	rs35222158	ENSG00000189223.12	PAX8-AS1	-13.49	2.47e-38	3.69e-35	-0.66	-0.39	Renal function-related traits (BUN);	chr2:113229052	chr2:113211522~113276581:+
BRCA	cis	rs16828019	0.852	rs34386859	ENSG00000235358.1	RP11-399E6.1	13.49	2.53e-38	3.78e-35	0.74	0.39	Intelligence (multi-trait analysis);	chr1:41098352	chr1:41242373~41284861:+
BRCA	cis	rs2117029	0.521	rs6580702	ENSG00000258017.1	RP11-386G11.10	-13.49	2.55e-38	3.81e-35	-0.52	-0.39	Intelligence (multi-trait analysis);	chr12:49169483	chr12:49127782~49147869:+
BRCA	cis	rs2111504	0.583	rs8104714	ENSG00000267213.4	AC007773.2	13.48	2.58e-38	3.85e-35	0.48	0.39	Bipolar disorder;	chr19:32381203	chr19:32390050~32405560:-
BRCA	cis	rs34779708	0.931	rs4934704	ENSG00000230534.5	RP11-297A16.2	13.48	2.61e-38	3.91e-35	0.48	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35043236	chr10:35098006~35127020:-
BRCA	cis	rs11123170	0.65	rs2289897	ENSG00000274877.1	RP11-65I12.1	-13.48	2.7e-38	4.03e-35	-0.59	-0.39	Renal function-related traits (BUN);	chr2:113219877	chr2:113237595~113240825:+
BRCA	cis	rs8100891	0.537	rs10409835	ENSG00000267213.4	AC007773.2	-13.48	2.73e-38	4.07e-35	-0.55	-0.39	Neuroticism;	chr19:32397754	chr19:32390050~32405560:-
BRCA	cis	rs2283792	0.622	rs2266979	ENSG00000224086.5	LL22NC03-86G7.1	-13.48	2.73e-38	4.07e-35	-0.41	-0.39	Multiple sclerosis;	chr22:21977447	chr22:21938293~21977632:+
BRCA	cis	rs2117029	0.554	rs35884657	ENSG00000258017.1	RP11-386G11.10	-13.48	2.84e-38	4.23e-35	-0.54	-0.39	Intelligence (multi-trait analysis);	chr12:49137317	chr12:49127782~49147869:+
BRCA	cis	rs11123170	0.543	rs4849180	ENSG00000189223.12	PAX8-AS1	-13.48	2.85e-38	4.25e-35	-0.66	-0.39	Renal function-related traits (BUN);	chr2:113227609	chr2:113211522~113276581:+
BRCA	cis	rs992157	0.687	rs35271699	ENSG00000261338.2	RP11-378A13.1	13.47	2.97e-38	4.43e-35	0.4	0.39	Colorectal cancer;	chr2:218252759	chr2:218255319~218257366:+
BRCA	cis	rs2117029	0.521	rs58336603	ENSG00000258017.1	RP11-386G11.10	-13.47	2.98e-38	4.44e-35	-0.52	-0.39	Intelligence (multi-trait analysis);	chr12:49163105	chr12:49127782~49147869:+
BRCA	cis	rs2117029	0.553	rs1991427	ENSG00000258017.1	RP11-386G11.10	-13.47	2.98e-38	4.44e-35	-0.52	-0.39	Intelligence (multi-trait analysis);	chr12:49164175	chr12:49127782~49147869:+
BRCA	cis	rs6964833	1	rs4717906	ENSG00000277053.3	GTF2IP1	-13.46	3.25e-38	4.84e-35	-0.53	-0.38	Menarche (age at onset);	chr7:74671923	chr7:75185385~75237696:-
BRCA	cis	rs7617773	0.78	rs6442111	ENSG00000229759.1	MRPS18AP1	13.46	3.27e-38	4.88e-35	0.47	0.38	Coronary artery disease;	chr3:48270570	chr3:48256350~48256938:-
BRCA	cis	rs9532669	0.926	rs2039119	ENSG00000176268.5	CYCSP34	-13.46	3.32e-38	4.94e-35	-0.4	-0.38	Cervical cancer;	chr13:40872432	chr13:40863599~40863902:-
BRCA	cis	rs12594515	1	rs8031128	ENSG00000273972.1	CTD-2306A12.1	-13.46	3.34e-38	4.97e-35	-0.45	-0.38	Weight;Waist circumference;	chr15:45696330	chr15:45702640~45703183:+
BRCA	cis	rs12594515	0.967	rs71405295	ENSG00000273972.1	CTD-2306A12.1	-13.46	3.34e-38	4.97e-35	-0.45	-0.38	Weight;Waist circumference;	chr15:45696723	chr15:45702640~45703183:+
BRCA	cis	rs2283792	0.622	rs381523	ENSG00000224086.5	LL22NC03-86G7.1	-13.46	3.42e-38	5.08e-35	-0.4	-0.38	Multiple sclerosis;	chr22:21951257	chr22:21938293~21977632:+
BRCA	cis	rs12594515	1	rs8026221	ENSG00000273972.1	CTD-2306A12.1	-13.46	3.43e-38	5.1e-35	-0.45	-0.38	Weight;Waist circumference;	chr15:45695712	chr15:45702640~45703183:+
BRCA	cis	rs3096299	0.685	rs3803682	ENSG00000274627.1	RP11-104N10.2	13.46	3.44e-38	5.12e-35	0.4	0.38	Multiple myeloma (IgH translocation);	chr16:89478228	chr16:89516797~89522217:+
BRCA	cis	rs12594515	1	rs8027000	ENSG00000273972.1	CTD-2306A12.1	-13.46	3.53e-38	5.25e-35	-0.45	-0.38	Weight;Waist circumference;	chr15:45695597	chr15:45702640~45703183:+
BRCA	cis	rs2658782	0.756	rs3019205	ENSG00000279684.1	RP11-755E23.2	-13.46	3.58e-38	5.33e-35	-0.55	-0.38	Pulmonary function decline;	chr11:93376387	chr11:93286629~93288903:-
BRCA	cis	rs7240205	0.818	rs12964926	ENSG00000275805.1	RP11-349H17.2	13.45	3.65e-38	5.43e-35	0.41	0.38	Breast cancer;	chr18:26567363	chr18:26565723~26575626:-
BRCA	cis	rs3096299	0.719	rs2911262	ENSG00000274627.1	RP11-104N10.2	13.45	3.81e-38	5.66e-35	0.39	0.38	Multiple myeloma (IgH translocation);	chr16:89448633	chr16:89516797~89522217:+
BRCA	cis	rs12594515	0.904	rs8032875	ENSG00000273972.1	CTD-2306A12.1	-13.45	3.82e-38	5.67e-35	-0.45	-0.38	Weight;Waist circumference;	chr15:45705812	chr15:45702640~45703183:+
BRCA	cis	rs12594515	0.874	rs8032878	ENSG00000273972.1	CTD-2306A12.1	-13.45	3.82e-38	5.67e-35	-0.45	-0.38	Weight;Waist circumference;	chr15:45705817	chr15:45702640~45703183:+
BRCA	cis	rs6452524	0.967	rs2731844	ENSG00000249664.1	CTD-2227C6.2	13.44	4.08e-38	6.06e-35	0.46	0.38	Hypertension (SNP x SNP interaction);	chr5:83192627	chr5:83012285~83013109:-
BRCA	cis	rs6452524	0.901	rs2940540	ENSG00000249664.1	CTD-2227C6.2	13.44	4.08e-38	6.06e-35	0.46	0.38	Hypertension (SNP x SNP interaction);	chr5:83193004	chr5:83012285~83013109:-
BRCA	cis	rs17711722	0.522	rs62469933	ENSG00000164669.11	INTS4P1	-13.44	4.12e-38	6.12e-35	-0.48	-0.38	Calcium levels;	chr7:65800652	chr7:65141225~65234216:+
BRCA	cis	rs11123170	0.64	rs2863240	ENSG00000189223.12	PAX8-AS1	13.44	4.19e-38	6.22e-35	0.59	0.38	Renal function-related traits (BUN);	chr2:113212539	chr2:113211522~113276581:+
BRCA	cis	rs2283792	0.812	rs240064	ENSG00000224086.5	LL22NC03-86G7.1	13.44	4.22e-38	6.26e-35	0.4	0.38	Multiple sclerosis;	chr22:21927265	chr22:21938293~21977632:+
BRCA	cis	rs12594515	0.967	rs11856523	ENSG00000273972.1	CTD-2306A12.1	-13.44	4.23e-38	6.27e-35	-0.45	-0.38	Weight;Waist circumference;	chr15:45697297	chr15:45702640~45703183:+
BRCA	cis	rs7240205	0.818	rs4264473	ENSG00000275805.1	RP11-349H17.2	13.44	4.26e-38	6.32e-35	0.41	0.38	Breast cancer;	chr18:26565915	chr18:26565723~26575626:-
BRCA	cis	rs12594515	1	rs7162201	ENSG00000273972.1	CTD-2306A12.1	-13.44	4.47e-38	6.63e-35	-0.45	-0.38	Weight;Waist circumference;	chr15:45700460	chr15:45702640~45703183:+
BRCA	cis	rs12594515	0.967	rs67854274	ENSG00000273972.1	CTD-2306A12.1	-13.43	4.59e-38	6.8e-35	-0.45	-0.38	Weight;Waist circumference;	chr15:45698320	chr15:45702640~45703183:+
BRCA	cis	rs12594515	1	rs6493176	ENSG00000273972.1	CTD-2306A12.1	-13.43	4.63e-38	6.86e-35	-0.45	-0.38	Weight;Waist circumference;	chr15:45697828	chr15:45702640~45703183:+
BRCA	cis	rs12594515	0.967	rs8039088	ENSG00000273972.1	CTD-2306A12.1	-13.43	4.63e-38	6.86e-35	-0.45	-0.38	Weight;Waist circumference;	chr15:45697980	chr15:45702640~45703183:+
BRCA	cis	rs12594515	1	rs8038320	ENSG00000273972.1	CTD-2306A12.1	-13.43	4.63e-38	6.86e-35	-0.45	-0.38	Weight;Waist circumference;	chr15:45698069	chr15:45702640~45703183:+
BRCA	cis	rs12594515	1	rs58368732	ENSG00000273972.1	CTD-2306A12.1	-13.43	4.82e-38	7.13e-35	-0.45	-0.38	Weight;Waist circumference;	chr15:45698333	chr15:45702640~45703183:+
BRCA	cis	rs12594515	1	rs6493175	ENSG00000273972.1	CTD-2306A12.1	-13.43	4.86e-38	7.19e-35	-0.45	-0.38	Weight;Waist circumference;	chr15:45697700	chr15:45702640~45703183:+
BRCA	cis	rs992157	0.735	rs13388024	ENSG00000261338.2	RP11-378A13.1	13.42	5.14e-38	7.6e-35	0.39	0.38	Colorectal cancer;	chr2:218233050	chr2:218255319~218257366:+
BRCA	cis	rs6964833	1	rs4717907	ENSG00000277053.3	GTF2IP1	-13.42	5.39e-38	7.97e-35	-0.51	-0.38	Menarche (age at onset);	chr7:74672169	chr7:75185385~75237696:-
BRCA	cis	rs7617773	0.817	rs936426	ENSG00000229759.1	MRPS18AP1	13.42	5.54e-38	8.18e-35	0.46	0.38	Coronary artery disease;	chr3:48173763	chr3:48256350~48256938:-
BRCA	cis	rs7240205	0.853	rs2000649	ENSG00000275805.1	RP11-349H17.2	13.42	5.72e-38	8.45e-35	0.41	0.38	Breast cancer;	chr18:26552897	chr18:26565723~26575626:-
BRCA	cis	rs2117029	0.521	rs11168910	ENSG00000258017.1	RP11-386G11.10	-13.41	5.89e-38	8.69e-35	-0.53	-0.38	Intelligence (multi-trait analysis);	chr12:49192707	chr12:49127782~49147869:+
BRCA	cis	rs7240205	0.853	rs1941160	ENSG00000275805.1	RP11-349H17.2	13.41	5.92e-38	8.73e-35	0.41	0.38	Breast cancer;	chr18:26553529	chr18:26565723~26575626:-
BRCA	cis	rs858239	0.699	rs955187	ENSG00000226816.2	AC005082.12	-13.41	6.09e-38	8.98e-35	-0.45	-0.38	Cerebrospinal fluid biomarker levels;	chr7:23154986	chr7:23206013~23208045:+
BRCA	cis	rs12429206	0.52	rs1870839	ENSG00000233672.5	RNASEH2B-AS1	-13.41	6.14e-38	9.05e-35	-0.6	-0.38	Prostate-specific antigen levels (conditioned on lead SNPs);	chr13:50899732	chr13:50862172~50910764:-
BRCA	cis	rs2117029	0.555	rs2047101	ENSG00000258017.1	RP11-386G11.10	-13.41	6.2e-38	9.14e-35	-0.53	-0.38	Intelligence (multi-trait analysis);	chr12:49103860	chr12:49127782~49147869:+
BRCA	cis	rs12594515	1	rs6493169	ENSG00000273972.1	CTD-2306A12.1	13.41	6.2e-38	9.14e-35	0.45	0.38	Weight;Waist circumference;	chr15:45694796	chr15:45702640~45703183:+
BRCA	cis	rs6964833	0.935	rs13238996	ENSG00000277053.3	GTF2IP1	-13.41	6.32e-38	9.31e-35	-0.54	-0.38	Menarche (age at onset);	chr7:74655318	chr7:75185385~75237696:-
BRCA	cis	rs8040855	0.599	rs8037195	ENSG00000259295.5	CSPG4P12	-13.4	6.48e-38	9.54e-35	-0.46	-0.38	Bulimia nervosa;	chr15:85181455	chr15:85191438~85213905:+
BRCA	cis	rs6964833	0.872	rs4717903	ENSG00000277053.3	GTF2IP1	-13.4	6.48e-38	9.54e-35	-0.53	-0.38	Menarche (age at onset);	chr7:74653827	chr7:75185385~75237696:-
BRCA	cis	rs73086581	0.645	rs2103659	ENSG00000229539.1	RP11-119B16.2	-13.4	6.66e-38	9.82e-35	-0.51	-0.38	Response to antidepressants in depression;	chr20:4001925	chr20:3888239~3888868:-
BRCA	cis	rs6964833	0.935	rs35735900	ENSG00000277053.3	GTF2IP1	-13.4	6.68e-38	9.83e-35	-0.53	-0.38	Menarche (age at onset);	chr7:74651887	chr7:75185385~75237696:-
BRCA	cis	rs2412819	0.545	rs17795279	ENSG00000249839.1	AC011330.5	13.4	6.69e-38	9.85e-35	0.57	0.38	Lung cancer;	chr15:43637180	chr15:43663654~43684339:-
BRCA	cis	rs12594515	0.967	rs11857628	ENSG00000273972.1	CTD-2306A12.1	-13.4	6.85e-38	1.01e-34	-0.45	-0.38	Weight;Waist circumference;	chr15:45706008	chr15:45702640~45703183:+
BRCA	cis	rs2283792	1	rs5749986	ENSG00000224086.5	LL22NC03-86G7.1	13.4	6.92e-38	1.02e-34	0.4	0.38	Multiple sclerosis;	chr22:21803372	chr22:21938293~21977632:+
BRCA	cis	rs12594515	1	rs6493172	ENSG00000273972.1	CTD-2306A12.1	-13.4	6.97e-38	1.03e-34	-0.45	-0.38	Weight;Waist circumference;	chr15:45695015	chr15:45702640~45703183:+
BRCA	cis	rs6452524	0.868	rs1564379	ENSG00000249664.1	CTD-2227C6.2	13.4	7.04e-38	1.04e-34	0.45	0.38	Hypertension (SNP x SNP interaction);	chr5:83082143	chr5:83012285~83013109:-
BRCA	cis	rs7240205	0.853	rs6508448	ENSG00000275805.1	RP11-349H17.2	13.4	7.13e-38	1.05e-34	0.41	0.38	Breast cancer;	chr18:26556863	chr18:26565723~26575626:-
BRCA	cis	rs12594515	1	rs8025258	ENSG00000273972.1	CTD-2306A12.1	-13.39	7.55e-38	1.11e-34	-0.45	-0.38	Weight;Waist circumference;	chr15:45695356	chr15:45702640~45703183:+
BRCA	cis	rs17711722	0.523	rs313812	ENSG00000164669.11	INTS4P1	13.39	7.59e-38	1.11e-34	0.48	0.38	Calcium levels;	chr7:66040056	chr7:65141225~65234216:+
BRCA	cis	rs17507216	0.667	rs13379724	ENSG00000278603.1	RP13-608F4.5	13.39	7.72e-38	1.13e-34	0.59	0.38	Excessive daytime sleepiness;	chr15:82619892	chr15:82472203~82472426:+
BRCA	cis	rs6452524	0.967	rs965674	ENSG00000249664.1	CTD-2227C6.2	13.39	7.76e-38	1.14e-34	0.46	0.38	Hypertension (SNP x SNP interaction);	chr5:83186765	chr5:83012285~83013109:-
BRCA	cis	rs6452524	0.967	rs2662242	ENSG00000249664.1	CTD-2227C6.2	13.39	7.76e-38	1.14e-34	0.46	0.38	Hypertension (SNP x SNP interaction);	chr5:83189066	chr5:83012285~83013109:-
BRCA	cis	rs2108622	0.785	rs3093199	ENSG00000267453.5	AC004791.2	-13.39	7.87e-38	1.16e-34	-0.46	-0.38	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15879061	chr19:15851993~15864904:-
BRCA	cis	rs12594515	1	rs6493170	ENSG00000273972.1	CTD-2306A12.1	-13.38	8.11e-38	1.19e-34	-0.45	-0.38	Weight;Waist circumference;	chr15:45694821	chr15:45702640~45703183:+
BRCA	cis	rs17711722	0.523	rs365896	ENSG00000164669.11	INTS4P1	13.38	8.23e-38	1.21e-34	0.48	0.38	Calcium levels;	chr7:66045710	chr7:65141225~65234216:+
BRCA	cis	rs2117029	0.555	rs3741621	ENSG00000258017.1	RP11-386G11.10	-13.38	8.66e-38	1.27e-34	-0.53	-0.38	Intelligence (multi-trait analysis);	chr12:49100242	chr12:49127782~49147869:+
BRCA	cis	rs6964833	0.786	rs35633336	ENSG00000277053.3	GTF2IP1	-13.38	8.72e-38	1.28e-34	-0.53	-0.38	Menarche (age at onset);	chr7:74643961	chr7:75185385~75237696:-
BRCA	cis	rs7115242	1	rs7115242	ENSG00000254851.1	RP11-109L13.1	13.38	8.77e-38	1.29e-34	0.72	0.38	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117037567	chr11:117135528~117138582:+
BRCA	cis	rs12594515	0.506	rs74199860	ENSG00000273972.1	CTD-2306A12.1	-13.38	8.96e-38	1.31e-34	-0.45	-0.38	Weight;Waist circumference;	chr15:45696992	chr15:45702640~45703183:+
BRCA	cis	rs6452524	0.967	rs11949474	ENSG00000249664.1	CTD-2227C6.2	13.37	9.09e-38	1.33e-34	0.46	0.38	Hypertension (SNP x SNP interaction);	chr5:83179759	chr5:83012285~83013109:-
BRCA	cis	rs7044106	0.791	rs7043969	ENSG00000226752.6	PSMD5-AS1	-13.37	9.45e-38	1.38e-34	-0.47	-0.38	Hip circumference adjusted for BMI;	chr9:120731711	chr9:120824828~120854385:+
BRCA	cis	rs367615	0.552	rs2963024	ENSG00000249476.1	CTD-2587M2.1	-13.37	9.6e-38	1.4e-34	-0.43	-0.38	Colorectal cancer (SNP x SNP interaction);	chr5:109395072	chr5:109237120~109326369:-
BRCA	cis	rs34779708	0.931	rs7079498	ENSG00000230534.5	RP11-297A16.2	13.37	9.9e-38	1.45e-34	0.49	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35086416	chr10:35098006~35127020:-
BRCA	cis	rs9481169	0.85	rs13210247	ENSG00000255389.1	C6orf3	-13.37	1e-37	1.46e-34	-0.64	-0.38	Inflammatory skin disease;	chr6:111601517	chr6:111599875~111602295:+
BRCA	cis	rs6700559	0.683	rs4915450	ENSG00000260088.1	RP11-92G12.3	-13.37	1.01e-37	1.48e-34	-0.47	-0.38	Coronary artery disease;	chr1:200672461	chr1:200669507~200694250:+
BRCA	cis	rs7301826	1	rs7301826	ENSG00000256299.1	RP11-989F5.3	-13.36	1.04e-37	1.53e-34	-0.43	-0.38	Plasma plasminogen activator levels;	chr12:130806556	chr12:130810821~130812622:-
BRCA	cis	rs5760092	0.572	rs738806	ENSG00000273295.1	AP000350.5	13.36	1.1e-37	1.6e-34	0.49	0.38	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23891985	chr22:23901432~23907068:-
BRCA	cis	rs7617773	0.815	rs9825637	ENSG00000229759.1	MRPS18AP1	13.36	1.12e-37	1.63e-34	0.49	0.38	Coronary artery disease;	chr3:48330792	chr3:48256350~48256938:-
BRCA	cis	rs2117029	0.521	rs12229524	ENSG00000258017.1	RP11-386G11.10	-13.36	1.13e-37	1.65e-34	-0.52	-0.38	Intelligence (multi-trait analysis);	chr12:49191570	chr12:49127782~49147869:+
BRCA	cis	rs12594515	1	rs8032361	ENSG00000273972.1	CTD-2306A12.1	-13.36	1.13e-37	1.65e-34	-0.45	-0.38	Weight;Waist circumference;	chr15:45696355	chr15:45702640~45703183:+
BRCA	cis	rs12594515	1	rs8029209	ENSG00000273972.1	CTD-2306A12.1	-13.35	1.16e-37	1.69e-34	-0.45	-0.38	Weight;Waist circumference;	chr15:45701291	chr15:45702640~45703183:+
BRCA	cis	rs4380275	0.782	rs4854276	ENSG00000272342.1	RP13-539J13.1	13.35	1.21e-37	1.76e-34	0.45	0.38	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:764357	chr2:739588~740164:-
BRCA	cis	rs11603023	0.967	rs7936556	ENSG00000255239.1	AP002954.6	-13.35	1.25e-37	1.82e-34	-0.44	-0.38	Cholesterol, total;	chr11:118630582	chr11:118688039~118690600:-
BRCA	cis	rs7626444	0.625	rs9826214	ENSG00000272359.1	U4	-13.35	1.25e-37	1.82e-34	-0.45	-0.38	Monocyte count;	chr3:196751342	chr3:196747192~196747324:-
BRCA	cis	rs6452524	1	rs9293332	ENSG00000249664.1	CTD-2227C6.2	13.35	1.26e-37	1.83e-34	0.45	0.38	Hypertension (SNP x SNP interaction);	chr5:83141546	chr5:83012285~83013109:-
BRCA	cis	rs11690935	0.885	rs7602037	ENSG00000228389.1	AC068039.4	13.34	1.31e-37	1.91e-34	0.48	0.38	Schizophrenia;	chr2:171961268	chr2:171773482~171775844:+
BRCA	cis	rs1789	0.872	rs4333182	ENSG00000273133.1	RP11-799M12.2	-13.34	1.33e-37	1.94e-34	-0.49	-0.38	Blood protein levels;	chr4:15683089	chr4:15563698~15564253:-
BRCA	cis	rs6700559	0.967	rs4072552	ENSG00000260088.1	RP11-92G12.3	-13.33	1.46e-37	2.13e-34	-0.47	-0.38	Coronary artery disease;	chr1:200680003	chr1:200669507~200694250:+
BRCA	cis	rs6964833	0.935	rs34630792	ENSG00000277053.3	GTF2IP1	-13.33	1.47e-37	2.14e-34	-0.53	-0.38	Menarche (age at onset);	chr7:74646869	chr7:75185385~75237696:-
BRCA	cis	rs4423214	0.879	rs1790345	ENSG00000254682.1	RP11-660L16.2	-13.33	1.53e-37	2.22e-34	-0.51	-0.38	Vitamin D levels;	chr11:71434895	chr11:71448674~71452157:+
BRCA	cis	rs6700559	1	rs10494821	ENSG00000260088.1	RP11-92G12.3	-13.33	1.61e-37	2.33e-34	-0.47	-0.38	Coronary artery disease;	chr1:200673357	chr1:200669507~200694250:+
BRCA	cis	rs6700559	1	rs6667172	ENSG00000260088.1	RP11-92G12.3	-13.33	1.61e-37	2.33e-34	-0.47	-0.38	Coronary artery disease;	chr1:200674710	chr1:200669507~200694250:+
BRCA	cis	rs6700559	1	rs6427838	ENSG00000260088.1	RP11-92G12.3	-13.33	1.61e-37	2.33e-34	-0.47	-0.38	Coronary artery disease;	chr1:200676519	chr1:200669507~200694250:+
BRCA	cis	rs6700559	1	rs12061346	ENSG00000260088.1	RP11-92G12.3	-13.33	1.61e-37	2.33e-34	-0.47	-0.38	Coronary artery disease;	chr1:200677648	chr1:200669507~200694250:+
BRCA	cis	rs6700559	1	rs7533971	ENSG00000260088.1	RP11-92G12.3	-13.33	1.61e-37	2.33e-34	-0.47	-0.38	Coronary artery disease;	chr1:200678243	chr1:200669507~200694250:+
BRCA	cis	rs6700559	1	rs10919998	ENSG00000260088.1	RP11-92G12.3	-13.33	1.61e-37	2.33e-34	-0.47	-0.38	Coronary artery disease;	chr1:200679182	chr1:200669507~200694250:+
BRCA	cis	rs73086581	0.592	rs6037702	ENSG00000229539.1	RP11-119B16.2	-13.32	1.66e-37	2.41e-34	-0.52	-0.38	Response to antidepressants in depression;	chr20:3955745	chr20:3888239~3888868:-
BRCA	cis	rs3096299	0.632	rs8051537	ENSG00000274627.1	RP11-104N10.2	13.32	1.74e-37	2.52e-34	0.39	0.38	Multiple myeloma (IgH translocation);	chr16:89477976	chr16:89516797~89522217:+
BRCA	cis	rs9322193	0.607	rs9322229	ENSG00000216906.2	RP11-350J20.9	13.31	1.86e-37	2.7e-34	0.5	0.38	Lung cancer;	chr6:149908949	chr6:149904243~149906418:+
BRCA	cis	rs16828019	0.789	rs36084778	ENSG00000235358.1	RP11-399E6.1	13.31	1.9e-37	2.75e-34	0.74	0.38	Intelligence (multi-trait analysis);	chr1:41013866	chr1:41242373~41284861:+
BRCA	cis	rs16828019	0.777	rs11209363	ENSG00000235358.1	RP11-399E6.1	13.31	1.9e-37	2.75e-34	0.74	0.38	Intelligence (multi-trait analysis);	chr1:41019405	chr1:41242373~41284861:+
BRCA	cis	rs367615	0.506	rs2963013	ENSG00000249476.1	CTD-2587M2.1	-13.31	1.95e-37	2.82e-34	-0.44	-0.38	Colorectal cancer (SNP x SNP interaction);	chr5:109440110	chr5:109237120~109326369:-
BRCA	cis	rs992157	0.661	rs17653757	ENSG00000261338.2	RP11-378A13.1	13.31	2e-37	2.9e-34	0.39	0.38	Colorectal cancer;	chr2:218244641	chr2:218255319~218257366:+
BRCA	cis	rs17711722	0.523	rs313812	ENSG00000226824.5	RP4-756H11.3	13.3	2.18e-37	3.15e-34	0.48	0.38	Calcium levels;	chr7:66040056	chr7:66654538~66669855:+
BRCA	cis	rs12594515	1	rs8043291	ENSG00000273972.1	CTD-2306A12.1	-13.3	2.23e-37	3.23e-34	-0.45	-0.38	Weight;Waist circumference;	chr15:45704049	chr15:45702640~45703183:+
BRCA	cis	rs12594515	1	rs56412446	ENSG00000273972.1	CTD-2306A12.1	-13.3	2.23e-37	3.23e-34	-0.45	-0.38	Weight;Waist circumference;	chr15:45704226	chr15:45702640~45703183:+
BRCA	cis	rs12594515	1	rs57299255	ENSG00000273972.1	CTD-2306A12.1	-13.3	2.23e-37	3.23e-34	-0.45	-0.38	Weight;Waist circumference;	chr15:45704334	chr15:45702640~45703183:+
BRCA	cis	rs8059260	0.668	rs78573173	ENSG00000274038.1	RP11-66H6.4	-13.29	2.39e-37	3.45e-34	-0.6	-0.38	Alcohol consumption over the past year;	chr16:11017642	chr16:11056556~11057034:+
BRCA	cis	rs6452524	0.967	rs4290995	ENSG00000249664.1	CTD-2227C6.2	13.29	2.39e-37	3.46e-34	0.45	0.38	Hypertension (SNP x SNP interaction);	chr5:83182177	chr5:83012285~83013109:-
BRCA	cis	rs8100891	0.537	rs10417152	ENSG00000267213.4	AC007773.2	-13.29	2.4e-37	3.46e-34	-0.56	-0.38	Neuroticism;	chr19:32397994	chr19:32390050~32405560:-
BRCA	cis	rs4423214	0.84	rs1790328	ENSG00000254682.1	RP11-660L16.2	-13.29	2.52e-37	3.64e-34	-0.51	-0.38	Vitamin D levels;	chr11:71436992	chr11:71448674~71452157:+
BRCA	cis	rs12594515	1	rs12592190	ENSG00000273972.1	CTD-2306A12.1	-13.28	2.58e-37	3.72e-34	-0.45	-0.38	Weight;Waist circumference;	chr15:45701830	chr15:45702640~45703183:+
BRCA	cis	rs12594515	1	rs11854554	ENSG00000273972.1	CTD-2306A12.1	-13.28	2.58e-37	3.72e-34	-0.45	-0.38	Weight;Waist circumference;	chr15:45702348	chr15:45702640~45703183:+
BRCA	cis	rs12594515	1	rs35182335	ENSG00000273972.1	CTD-2306A12.1	-13.28	2.58e-37	3.72e-34	-0.45	-0.38	Weight;Waist circumference;	chr15:45702986	chr15:45702640~45703183:+
BRCA	cis	rs12594515	1	rs11855509	ENSG00000273972.1	CTD-2306A12.1	-13.28	2.58e-37	3.72e-34	-0.45	-0.38	Weight;Waist circumference;	chr15:45703276	chr15:45702640~45703183:+
BRCA	cis	rs12594515	1	rs11855562	ENSG00000273972.1	CTD-2306A12.1	-13.28	2.58e-37	3.72e-34	-0.45	-0.38	Weight;Waist circumference;	chr15:45703461	chr15:45702640~45703183:+
BRCA	cis	rs7626444	0.625	rs7648479	ENSG00000272359.1	U4	-13.28	2.79e-37	4.03e-34	-0.45	-0.38	Monocyte count;	chr3:196750342	chr3:196747192~196747324:-
BRCA	cis	rs2283792	0.73	rs2083565	ENSG00000224086.5	LL22NC03-86G7.1	-13.28	2.81e-37	4.05e-34	-0.4	-0.38	Multiple sclerosis;	chr22:21929985	chr22:21938293~21977632:+
BRCA	cis	rs2729354	0.768	rs1001956	ENSG00000265566.2	RN7SL605P	-13.27	2.96e-37	4.26e-34	-0.58	-0.38	Blood protein levels;	chr11:57499476	chr11:57528085~57528365:-
BRCA	cis	rs11123170	0.543	rs2863242	ENSG00000189223.12	PAX8-AS1	-13.27	3.1e-37	4.46e-34	-0.65	-0.38	Renal function-related traits (BUN);	chr2:113231659	chr2:113211522~113276581:+
BRCA	cis	rs2283792	0.73	rs2027790	ENSG00000224086.5	LL22NC03-86G7.1	-13.26	3.22e-37	4.64e-34	-0.4	-0.38	Multiple sclerosis;	chr22:21933592	chr22:21938293~21977632:+
BRCA	cis	rs12594515	1	rs56220882	ENSG00000273972.1	CTD-2306A12.1	-13.26	3.33e-37	4.79e-34	-0.45	-0.38	Weight;Waist circumference;	chr15:45704877	chr15:45702640~45703183:+
BRCA	cis	rs2739330	0.828	rs5751770	ENSG00000250470.1	AP000351.3	13.26	3.34e-37	4.81e-34	0.45	0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23976904~23977585:-
BRCA	cis	rs2283792	0.935	rs8141851	ENSG00000224086.5	LL22NC03-86G7.1	-13.26	3.38e-37	4.87e-34	-0.4	-0.38	Multiple sclerosis;	chr22:21812161	chr22:21938293~21977632:+
BRCA	cis	rs6700559	1	rs7527499	ENSG00000260088.1	RP11-92G12.3	-13.26	3.57e-37	5.13e-34	-0.46	-0.38	Coronary artery disease;	chr1:200676217	chr1:200669507~200694250:+
BRCA	cis	rs12594515	0.967	rs11854477	ENSG00000273972.1	CTD-2306A12.1	-13.25	3.63e-37	5.21e-34	-0.44	-0.38	Weight;Waist circumference;	chr15:45706147	chr15:45702640~45703183:+
BRCA	cis	rs8059260	0.542	rs6498148	ENSG00000274038.1	RP11-66H6.4	-13.25	3.63e-37	5.21e-34	-0.6	-0.38	Alcohol consumption over the past year;	chr16:11018374	chr16:11056556~11057034:+
BRCA	cis	rs8040855	0.557	rs9744503	ENSG00000259295.5	CSPG4P12	-13.25	3.71e-37	5.33e-34	-0.46	-0.38	Bulimia nervosa;	chr15:85180986	chr15:85191438~85213905:+
BRCA	cis	rs7301826	1	rs4759793	ENSG00000256299.1	RP11-989F5.3	-13.25	3.73e-37	5.35e-34	-0.43	-0.38	Plasma plasminogen activator levels;	chr12:130812693	chr12:130810821~130812622:-
BRCA	cis	rs2658782	0.724	rs1869914	ENSG00000279684.1	RP11-755E23.2	-13.25	3.73e-37	5.35e-34	-0.54	-0.38	Pulmonary function decline;	chr11:93379326	chr11:93286629~93288903:-
BRCA	cis	rs73086581	0.592	rs2300217	ENSG00000229539.1	RP11-119B16.2	13.25	3.78e-37	5.42e-34	0.51	0.38	Response to antidepressants in depression;	chr20:3957928	chr20:3888239~3888868:-
BRCA	cis	rs7301826	1	rs10773822	ENSG00000256299.1	RP11-989F5.3	-13.25	3.86e-37	5.54e-34	-0.43	-0.38	Plasma plasminogen activator levels;	chr12:130804562	chr12:130810821~130812622:-
BRCA	cis	rs7301826	1	rs4759787	ENSG00000256299.1	RP11-989F5.3	-13.25	3.91e-37	5.6e-34	-0.42	-0.38	Plasma plasminogen activator levels;	chr12:130805635	chr12:130810821~130812622:-
BRCA	cis	rs7301826	0.966	rs10734980	ENSG00000256299.1	RP11-989F5.3	-13.25	3.96e-37	5.67e-34	-0.42	-0.38	Plasma plasminogen activator levels;	chr12:130810081	chr12:130810821~130812622:-
BRCA	cis	rs7301826	1	rs1106369	ENSG00000256299.1	RP11-989F5.3	-13.25	3.99e-37	5.72e-34	-0.43	-0.38	Plasma plasminogen activator levels;	chr12:130815550	chr12:130810821~130812622:-
BRCA	cis	rs858239	0.665	rs858305	ENSG00000226816.2	AC005082.12	-13.24	4.02e-37	5.76e-34	-0.44	-0.38	Cerebrospinal fluid biomarker levels;	chr7:23203211	chr7:23206013~23208045:+
BRCA	cis	rs6452524	1	rs1382368	ENSG00000249664.1	CTD-2227C6.2	13.24	4.02e-37	5.76e-34	0.44	0.38	Hypertension (SNP x SNP interaction);	chr5:83155256	chr5:83012285~83013109:-
BRCA	cis	rs6452524	1	rs1382366	ENSG00000249664.1	CTD-2227C6.2	13.24	4.02e-37	5.76e-34	0.44	0.38	Hypertension (SNP x SNP interaction);	chr5:83156352	chr5:83012285~83013109:-
BRCA	cis	rs4814920	0.818	rs4813377	ENSG00000275142.1	RP5-999L4.2	-13.24	4.08e-37	5.85e-34	-0.55	-0.38	Bipolar disorder (body mass index interaction);	chr20:19870822	chr20:19871891~19872284:+
BRCA	cis	rs35160687	0.722	rs6728029	ENSG00000273080.1	RP11-301O19.1	-13.24	4.14e-37	5.93e-34	-0.42	-0.38	Night sleep phenotypes;	chr2:86328258	chr2:86195590~86196049:+
BRCA	cis	rs4853012	0.941	rs7571083	ENSG00000217702.2	RP11-287D1.4	13.24	4.22e-37	6.04e-34	0.58	0.38	Gestational age at birth (maternal effect);	chr2:74115133	chr2:74130583~74135395:+
BRCA	cis	rs34779708	0.931	rs12268745	ENSG00000230534.5	RP11-297A16.2	13.24	4.25e-37	6.08e-34	0.48	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35017061	chr10:35098006~35127020:-
BRCA	cis	rs2117029	0.521	rs1039225	ENSG00000258017.1	RP11-386G11.10	-13.24	4.3e-37	6.15e-34	-0.52	-0.38	Intelligence (multi-trait analysis);	chr12:49188909	chr12:49127782~49147869:+
BRCA	cis	rs2111504	0.945	rs1861780	ENSG00000267213.4	AC007773.2	-13.24	4.35e-37	6.22e-34	-0.56	-0.38	Bipolar disorder;	chr19:32372138	chr19:32390050~32405560:-
BRCA	cis	rs4718428	0.705	rs3800817	ENSG00000226824.5	RP4-756H11.3	-13.24	4.47e-37	6.39e-34	-0.5	-0.38	Corneal structure;	chr7:66798563	chr7:66654538~66669855:+
BRCA	cis	rs3096299	0.719	rs2965945	ENSG00000274627.1	RP11-104N10.2	13.23	4.61e-37	6.59e-34	0.39	0.38	Multiple myeloma (IgH translocation);	chr16:89447609	chr16:89516797~89522217:+
BRCA	cis	rs6452524	1	rs6864479	ENSG00000249664.1	CTD-2227C6.2	13.23	4.62e-37	6.61e-34	0.44	0.38	Hypertension (SNP x SNP interaction);	chr5:83166421	chr5:83012285~83013109:-
BRCA	cis	rs11723261	0.621	rs6599306	ENSG00000275426.1	CH17-262A2.1	-13.23	4.65e-37	6.65e-34	-0.6	-0.38	Immune response to smallpox vaccine (IL-6);	chr4:149655	chr4:149738~150317:+
BRCA	cis	rs7240205	0.853	rs10454719	ENSG00000275805.1	RP11-349H17.2	-13.23	4.7e-37	6.71e-34	-0.41	-0.38	Breast cancer;	chr18:26559666	chr18:26565723~26575626:-
BRCA	cis	rs2015599	0.623	rs3782505	ENSG00000257176.2	RP11-996F15.2	13.23	4.72e-37	6.75e-34	0.46	0.38	Platelet count;Mean platelet volume;	chr12:29292236	chr12:29280418~29317848:-
BRCA	cis	rs6700559	1	rs4311922	ENSG00000260088.1	RP11-92G12.3	-13.23	4.77e-37	6.81e-34	-0.46	-0.38	Coronary artery disease;	chr1:200674257	chr1:200669507~200694250:+
BRCA	cis	rs6700559	0.967	rs4447009	ENSG00000260088.1	RP11-92G12.3	-13.23	4.77e-37	6.81e-34	-0.46	-0.38	Coronary artery disease;	chr1:200674278	chr1:200669507~200694250:+
BRCA	cis	rs6700559	1	rs4265457	ENSG00000260088.1	RP11-92G12.3	-13.23	4.77e-37	6.81e-34	-0.46	-0.38	Coronary artery disease;	chr1:200674326	chr1:200669507~200694250:+
BRCA	cis	rs12594515	0.935	rs8042519	ENSG00000273972.1	CTD-2306A12.1	-13.23	4.84e-37	6.91e-34	-0.45	-0.38	Weight;Waist circumference;	chr15:45704143	chr15:45702640~45703183:+
BRCA	cis	rs8059260	0.668	rs75811377	ENSG00000274038.1	RP11-66H6.4	-13.23	4.86e-37	6.93e-34	-0.6	-0.38	Alcohol consumption over the past year;	chr16:11023451	chr16:11056556~11057034:+
BRCA	cis	rs4423214	0.879	rs1790330	ENSG00000254682.1	RP11-660L16.2	-13.22	5.15e-37	7.34e-34	-0.51	-0.38	Vitamin D levels;	chr11:71436779	chr11:71448674~71452157:+
BRCA	cis	rs11123170	0.64	rs931472	ENSG00000189223.12	PAX8-AS1	13.22	5.41e-37	7.71e-34	0.58	0.38	Renal function-related traits (BUN);	chr2:113212371	chr2:113211522~113276581:+
BRCA	cis	rs35160687	0.814	rs1863063	ENSG00000273080.1	RP11-301O19.1	13.22	5.58e-37	7.94e-34	0.42	0.38	Night sleep phenotypes;	chr2:86291126	chr2:86195590~86196049:+
BRCA	cis	rs7208859	0.673	rs9889755	ENSG00000263531.1	RP13-753N3.1	-13.21	5.66e-37	8.06e-34	-0.66	-0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30907487	chr17:30863921~30864940:-
BRCA	cis	rs2015599	0.623	rs1072724	ENSG00000257176.2	RP11-996F15.2	13.21	5.86e-37	8.35e-34	0.46	0.38	Platelet count;Mean platelet volume;	chr12:29289205	chr12:29280418~29317848:-
BRCA	cis	rs6452524	0.967	rs4616871	ENSG00000249664.1	CTD-2227C6.2	13.21	5.95e-37	8.46e-34	0.45	0.38	Hypertension (SNP x SNP interaction);	chr5:83175271	chr5:83012285~83013109:-
BRCA	cis	rs6700559	0.967	rs6688581	ENSG00000260088.1	RP11-92G12.3	-13.21	6.22e-37	8.84e-34	-0.46	-0.38	Coronary artery disease;	chr1:200670028	chr1:200669507~200694250:+
BRCA	cis	rs6700559	1	rs3806358	ENSG00000260088.1	RP11-92G12.3	-13.21	6.22e-37	8.84e-34	-0.46	-0.38	Coronary artery disease;	chr1:200670555	chr1:200669507~200694250:+
BRCA	cis	rs6452524	1	rs6452528	ENSG00000249664.1	CTD-2227C6.2	13.21	6.32e-37	8.98e-34	0.44	0.38	Hypertension (SNP x SNP interaction);	chr5:83162560	chr5:83012285~83013109:-
BRCA	cis	rs12594515	1	rs12594515	ENSG00000273972.1	CTD-2306A12.1	13.2	6.41e-37	9.11e-34	0.44	0.38	Weight;Waist circumference;	chr15:45692873	chr15:45702640~45703183:+
BRCA	cis	rs11123170	0.543	rs12472361	ENSG00000189223.12	PAX8-AS1	-13.2	6.44e-37	9.16e-34	-0.65	-0.38	Renal function-related traits (BUN);	chr2:113223068	chr2:113211522~113276581:+
BRCA	cis	rs4423214	0.879	rs1792264	ENSG00000254682.1	RP11-660L16.2	-13.2	6.45e-37	9.17e-34	-0.51	-0.38	Vitamin D levels;	chr11:71439201	chr11:71448674~71452157:+
BRCA	cis	rs2015599	0.623	rs7358667	ENSG00000257176.2	RP11-996F15.2	13.2	6.49e-37	9.22e-34	0.45	0.38	Platelet count;Mean platelet volume;	chr12:29290236	chr12:29280418~29317848:-
BRCA	cis	rs7240205	0.853	rs4404156	ENSG00000275805.1	RP11-349H17.2	13.2	6.49e-37	9.22e-34	0.4	0.38	Breast cancer;	chr18:26563490	chr18:26565723~26575626:-
BRCA	cis	rs3096299	0.692	rs4785565	ENSG00000274627.1	RP11-104N10.2	13.2	6.52e-37	9.26e-34	0.39	0.38	Multiple myeloma (IgH translocation);	chr16:89449351	chr16:89516797~89522217:+
BRCA	cis	rs12594515	1	rs8033148	ENSG00000273972.1	CTD-2306A12.1	-13.2	6.61e-37	9.38e-34	-0.44	-0.38	Weight;Waist circumference;	chr15:45705731	chr15:45702640~45703183:+
BRCA	cis	rs67311347	1	rs7628796	ENSG00000223797.4	ENTPD3-AS1	-13.2	6.67e-37	9.46e-34	-0.43	-0.38	Renal cell carcinoma;	chr3:40465841	chr3:40313802~40453329:-
BRCA	cis	rs2188561	0.697	rs6947099	ENSG00000241764.3	AC002467.7	13.2	6.85e-37	9.72e-34	0.54	0.38	Alcohol consumption;	chr7:107720471	chr7:107742817~107744581:-
BRCA	cis	rs7849270	1	rs7036236	ENSG00000268707.1	RP11-247A12.7	-13.2	6.88e-37	9.76e-34	-0.47	-0.38	Blood metabolite ratios;	chr9:129137020	chr9:129170434~129170940:+
BRCA	cis	rs4722166	0.63	rs12537614	ENSG00000179428.2	AC073072.5	-13.2	7.02e-37	9.96e-34	-0.42	-0.38	Lung cancer;	chr7:22749932	chr7:22725395~22727620:-
BRCA	cis	rs6452524	1	rs10043018	ENSG00000249664.1	CTD-2227C6.2	13.19	7.1e-37	1.01e-33	0.44	0.38	Hypertension (SNP x SNP interaction);	chr5:83138498	chr5:83012285~83013109:-
BRCA	cis	rs6452524	0.935	rs10037501	ENSG00000249664.1	CTD-2227C6.2	13.19	7.1e-37	1.01e-33	0.44	0.38	Hypertension (SNP x SNP interaction);	chr5:83138722	chr5:83012285~83013109:-
BRCA	cis	rs6452524	0.904	rs6452525	ENSG00000249664.1	CTD-2227C6.2	13.19	7.1e-37	1.01e-33	0.44	0.38	Hypertension (SNP x SNP interaction);	chr5:83138752	chr5:83012285~83013109:-
BRCA	cis	rs6452524	1	rs7716931	ENSG00000249664.1	CTD-2227C6.2	13.19	7.1e-37	1.01e-33	0.44	0.38	Hypertension (SNP x SNP interaction);	chr5:83138856	chr5:83012285~83013109:-
BRCA	cis	rs6452524	1	rs7721416	ENSG00000249664.1	CTD-2227C6.2	13.19	7.1e-37	1.01e-33	0.44	0.38	Hypertension (SNP x SNP interaction);	chr5:83139174	chr5:83012285~83013109:-
BRCA	cis	rs12594515	1	rs8032835	ENSG00000273972.1	CTD-2306A12.1	-13.19	7.12e-37	1.01e-33	-0.44	-0.38	Weight;Waist circumference;	chr15:45705699	chr15:45702640~45703183:+
BRCA	cis	rs6452524	1	rs6882220	ENSG00000249664.1	CTD-2227C6.2	13.19	7.34e-37	1.04e-33	0.44	0.38	Hypertension (SNP x SNP interaction);	chr5:83139715	chr5:83012285~83013109:-
BRCA	cis	rs6452524	1	rs13358361	ENSG00000249664.1	CTD-2227C6.2	13.19	7.89e-37	1.12e-33	0.44	0.38	Hypertension (SNP x SNP interaction);	chr5:83160237	chr5:83012285~83013109:-
BRCA	cis	rs16828019	0.852	rs12045171	ENSG00000235358.1	RP11-399E6.1	13.18	7.97e-37	1.13e-33	0.68	0.38	Intelligence (multi-trait analysis);	chr1:41063133	chr1:41242373~41284861:+
BRCA	cis	rs8040855	0.825	rs3964197	ENSG00000259295.5	CSPG4P12	13.18	8.04e-37	1.14e-33	0.5	0.38	Bulimia nervosa;	chr15:85178681	chr15:85191438~85213905:+
BRCA	cis	rs34779708	0.931	rs7923172	ENSG00000230534.5	RP11-297A16.2	13.18	8.19e-37	1.16e-33	0.48	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35020439	chr10:35098006~35127020:-
BRCA	cis	rs7044106	0.762	rs1158554	ENSG00000226752.6	PSMD5-AS1	-13.18	8.28e-37	1.17e-33	-0.46	-0.38	Hip circumference adjusted for BMI;	chr9:120638620	chr9:120824828~120854385:+
BRCA	cis	rs17507216	0.667	rs72753916	ENSG00000278603.1	RP13-608F4.5	13.18	8.36e-37	1.18e-33	0.6	0.38	Excessive daytime sleepiness;	chr15:82684001	chr15:82472203~82472426:+
BRCA	cis	rs9308062	1	rs9308062	ENSG00000273449.1	RP11-218F10.3	-13.18	8.68e-37	1.23e-33	-0.39	-0.38	Small cell lung carcinoma;	chr4:163517048	chr4:163529771~163530697:+
BRCA	cis	rs17711722	0.523	rs365896	ENSG00000226824.5	RP4-756H11.3	13.18	8.7e-37	1.23e-33	0.47	0.38	Calcium levels;	chr7:66045710	chr7:66654538~66669855:+
BRCA	cis	rs2283792	1	rs3810610	ENSG00000224086.5	LL22NC03-86G7.1	-13.17	8.92e-37	1.26e-33	-0.39	-0.38	Multiple sclerosis;	chr22:21761209	chr22:21938293~21977632:+
BRCA	cis	rs12594515	1	rs12185095	ENSG00000273972.1	CTD-2306A12.1	-13.17	8.98e-37	1.27e-33	-0.45	-0.38	Weight;Waist circumference;	chr15:45702437	chr15:45702640~45703183:+
BRCA	cis	rs2739330	0.828	rs2877178	ENSG00000250470.1	AP000351.3	13.17	9.19e-37	1.3e-33	0.46	0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23976904~23977585:-
BRCA	cis	rs6452524	1	rs6452526	ENSG00000249664.1	CTD-2227C6.2	13.17	9.31e-37	1.31e-33	0.44	0.38	Hypertension (SNP x SNP interaction);	chr5:83140992	chr5:83012285~83013109:-
BRCA	cis	rs6452524	1	rs6452527	ENSG00000249664.1	CTD-2227C6.2	13.17	9.31e-37	1.31e-33	0.44	0.38	Hypertension (SNP x SNP interaction);	chr5:83141021	chr5:83012285~83013109:-
BRCA	cis	rs6452524	1	rs10055844	ENSG00000249664.1	CTD-2227C6.2	13.17	9.31e-37	1.31e-33	0.44	0.38	Hypertension (SNP x SNP interaction);	chr5:83141276	chr5:83012285~83013109:-
BRCA	cis	rs6452524	1	rs10077862	ENSG00000249664.1	CTD-2227C6.2	13.17	9.31e-37	1.31e-33	0.44	0.38	Hypertension (SNP x SNP interaction);	chr5:83141322	chr5:83012285~83013109:-
BRCA	cis	rs34779708	0.931	rs3740083	ENSG00000230534.5	RP11-297A16.2	13.16	1.01e-36	1.43e-33	0.48	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35031455	chr10:35098006~35127020:-
BRCA	cis	rs6452524	1	rs62374374	ENSG00000249664.1	CTD-2227C6.2	13.16	1.04e-36	1.46e-33	0.44	0.38	Hypertension (SNP x SNP interaction);	chr5:83144838	chr5:83012285~83013109:-
BRCA	cis	rs6452524	1	rs1382372	ENSG00000249664.1	CTD-2227C6.2	13.16	1.04e-36	1.46e-33	0.44	0.38	Hypertension (SNP x SNP interaction);	chr5:83145237	chr5:83012285~83013109:-
BRCA	cis	rs6452524	1	rs1382371	ENSG00000249664.1	CTD-2227C6.2	13.16	1.04e-36	1.46e-33	0.44	0.38	Hypertension (SNP x SNP interaction);	chr5:83145300	chr5:83012285~83013109:-
BRCA	cis	rs6452524	1	rs1382369	ENSG00000249664.1	CTD-2227C6.2	13.16	1.04e-36	1.46e-33	0.44	0.38	Hypertension (SNP x SNP interaction);	chr5:83145610	chr5:83012285~83013109:-
BRCA	cis	rs6452524	1	rs2386240	ENSG00000249664.1	CTD-2227C6.2	13.16	1.04e-36	1.46e-33	0.44	0.38	Hypertension (SNP x SNP interaction);	chr5:83147192	chr5:83012285~83013109:-
BRCA	cis	rs6452524	1	rs9986131	ENSG00000249664.1	CTD-2227C6.2	13.16	1.04e-36	1.46e-33	0.44	0.38	Hypertension (SNP x SNP interaction);	chr5:83149037	chr5:83012285~83013109:-
BRCA	cis	rs8100891	0.537	rs3746016	ENSG00000267213.4	AC007773.2	-13.16	1.08e-36	1.51e-33	-0.58	-0.38	Neuroticism;	chr19:32386353	chr19:32390050~32405560:-
BRCA	cis	rs4423214	0.879	rs1630498	ENSG00000254682.1	RP11-660L16.2	-13.16	1.11e-36	1.56e-33	-0.5	-0.38	Vitamin D levels;	chr11:71439739	chr11:71448674~71452157:+
BRCA	cis	rs34779708	0.931	rs12261654	ENSG00000230534.5	RP11-297A16.2	13.15	1.12e-36	1.58e-33	0.47	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35033096	chr10:35098006~35127020:-
BRCA	cis	rs2658782	0.547	rs3020054	ENSG00000279684.1	RP11-755E23.2	-13.15	1.15e-36	1.62e-33	-0.5	-0.38	Pulmonary function decline;	chr11:93322390	chr11:93286629~93288903:-
BRCA	cis	rs9309711	0.643	rs10188449	ENSG00000225234.1	TRAPPC12-AS1	-13.15	1.18e-36	1.66e-33	-0.39	-0.38	Neurofibrillary tangles;	chr2:3476595	chr2:3481242~3482409:-
BRCA	cis	rs7849270	1	rs2297112	ENSG00000268707.1	RP11-247A12.7	-13.15	1.19e-36	1.68e-33	-0.46	-0.38	Blood metabolite ratios;	chr9:129137901	chr9:129170434~129170940:+
BRCA	cis	rs6452524	1	rs62374373	ENSG00000249664.1	CTD-2227C6.2	13.15	1.21e-36	1.7e-33	0.44	0.38	Hypertension (SNP x SNP interaction);	chr5:83137389	chr5:83012285~83013109:-
BRCA	cis	rs7849270	0.921	rs6478864	ENSG00000268707.1	RP11-247A12.7	-13.14	1.27e-36	1.78e-33	-0.47	-0.38	Blood metabolite ratios;	chr9:129118351	chr9:129170434~129170940:+
BRCA	cis	rs7849270	0.851	rs7861663	ENSG00000268707.1	RP11-247A12.7	-13.14	1.27e-36	1.78e-33	-0.47	-0.38	Blood metabolite ratios;	chr9:129118667	chr9:129170434~129170940:+
BRCA	cis	rs6700559	0.903	rs6661240	ENSG00000260088.1	RP11-92G12.3	-13.14	1.27e-36	1.79e-33	-0.46	-0.38	Coronary artery disease;	chr1:200669719	chr1:200669507~200694250:+
BRCA	cis	rs6452524	1	rs7710900	ENSG00000249664.1	CTD-2227C6.2	13.14	1.29e-36	1.81e-33	0.44	0.38	Hypertension (SNP x SNP interaction);	chr5:83137201	chr5:83012285~83013109:-
BRCA	cis	rs7586673	0.893	rs889925	ENSG00000227403.1	AC009299.3	-13.14	1.38e-36	1.94e-33	-0.51	-0.38	Intelligence (multi-trait analysis);	chr2:161115086	chr2:161244739~161249050:+
BRCA	cis	rs7586673	0.93	rs2884364	ENSG00000227403.1	AC009299.3	-13.14	1.38e-36	1.94e-33	-0.51	-0.38	Intelligence (multi-trait analysis);	chr2:161121136	chr2:161244739~161249050:+
BRCA	cis	rs2283792	1	rs13943	ENSG00000224086.5	LL22NC03-86G7.1	-13.13	1.42e-36	1.99e-33	-0.39	-0.38	Multiple sclerosis;	chr22:21761913	chr22:21938293~21977632:+
BRCA	cis	rs6700559	0.804	rs11588318	ENSG00000260088.1	RP11-92G12.3	-13.13	1.46e-36	2.05e-33	-0.46	-0.38	Coronary artery disease;	chr1:200669534	chr1:200669507~200694250:+
BRCA	cis	rs765787	0.53	rs4774542	ENSG00000259520.4	CTD-2651B20.3	-13.13	1.48e-36	2.07e-33	-0.46	-0.38	Uric acid levels;	chr15:45233828	chr15:45251580~45279251:-
BRCA	cis	rs55794721	0.509	rs873308	ENSG00000261349.1	RP3-465N24.5	13.12	1.6e-36	2.25e-33	0.42	0.38	Mean corpuscular volume;Plateletcrit;	chr1:25432164	chr1:25266102~25267136:-
BRCA	cis	rs2658782	0.789	rs3019206	ENSG00000279684.1	RP11-755E23.2	-13.12	1.7e-36	2.38e-33	-0.53	-0.38	Pulmonary function decline;	chr11:93377907	chr11:93286629~93288903:-
BRCA	cis	rs9309711	0.666	rs6723101	ENSG00000225234.1	TRAPPC12-AS1	-13.11	1.78e-36	2.49e-33	-0.39	-0.38	Neurofibrillary tangles;	chr2:3480672	chr2:3481242~3482409:-
BRCA	cis	rs4718428	0.705	rs4717331	ENSG00000226824.5	RP4-756H11.3	-13.11	1.8e-36	2.52e-33	-0.5	-0.38	Corneal structure;	chr7:66913899	chr7:66654538~66669855:+
BRCA	cis	rs16828019	0.704	rs4996176	ENSG00000235358.1	RP11-399E6.1	13.11	1.81e-36	2.54e-33	0.74	0.38	Intelligence (multi-trait analysis);	chr1:41022496	chr1:41242373~41284861:+
BRCA	cis	rs16828019	0.777	rs35496942	ENSG00000235358.1	RP11-399E6.1	13.11	1.81e-36	2.54e-33	0.74	0.38	Intelligence (multi-trait analysis);	chr1:41023232	chr1:41242373~41284861:+
BRCA	cis	rs7849270	0.959	rs7039031	ENSG00000268707.1	RP11-247A12.7	-13.11	1.81e-36	2.54e-33	-0.46	-0.38	Blood metabolite ratios;	chr9:129137116	chr9:129170434~129170940:+
BRCA	cis	rs9309711	0.666	rs6767	ENSG00000225234.1	TRAPPC12-AS1	-13.11	1.87e-36	2.61e-33	-0.39	-0.38	Neurofibrillary tangles;	chr2:3479434	chr2:3481242~3482409:-
BRCA	cis	rs9309711	0.623	rs7569694	ENSG00000225234.1	TRAPPC12-AS1	-13.11	1.87e-36	2.61e-33	-0.39	-0.38	Neurofibrillary tangles;	chr2:3479619	chr2:3481242~3482409:-
BRCA	cis	rs6452524	1	rs2126988	ENSG00000249664.1	CTD-2227C6.2	13.1	1.99e-36	2.78e-33	0.44	0.38	Hypertension (SNP x SNP interaction);	chr5:83146496	chr5:83012285~83013109:-
BRCA	cis	rs6452524	1	rs17284288	ENSG00000249664.1	CTD-2227C6.2	13.1	1.99e-36	2.78e-33	0.44	0.38	Hypertension (SNP x SNP interaction);	chr5:83148997	chr5:83012285~83013109:-
BRCA	cis	rs12134133	1	rs28371614	ENSG00000274245.1	RP11-357P18.2	13.1	2e-36	2.79e-33	0.52	0.38	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207331929	chr1:207372559~207373252:+
BRCA	cis	rs992157	0.735	rs13392177	ENSG00000261338.2	RP11-378A13.1	-13.1	2.06e-36	2.88e-33	-0.39	-0.38	Colorectal cancer;	chr2:218248233	chr2:218255319~218257366:+
BRCA	cis	rs7208859	0.623	rs609063	ENSG00000263531.1	RP13-753N3.1	13.1	2.06e-36	2.88e-33	0.75	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30624495	chr17:30863921~30864940:-
BRCA	cis	rs11123170	0.543	rs4849178	ENSG00000189223.12	PAX8-AS1	-13.1	2.11e-36	2.94e-33	-0.64	-0.38	Renal function-related traits (BUN);	chr2:113225031	chr2:113211522~113276581:+
BRCA	cis	rs6452524	1	rs10037872	ENSG00000249664.1	CTD-2227C6.2	13.1	2.14e-36	2.98e-33	0.44	0.38	Hypertension (SNP x SNP interaction);	chr5:83144101	chr5:83012285~83013109:-
BRCA	cis	rs17711722	0.522	rs62469933	ENSG00000226824.5	RP4-756H11.3	-13.1	2.17e-36	3.02e-33	-0.47	-0.38	Calcium levels;	chr7:65800652	chr7:66654538~66669855:+
BRCA	cis	rs5769707	0.609	rs2007024	ENSG00000188511.11	C22orf34	13.1	2.2e-36	3.06e-33	0.39	0.38	Monocyte percentage of white cells;Monocyte count;	chr22:49595167	chr22:49414524~49657542:-
BRCA	cis	rs4423214	0.879	rs1792283	ENSG00000254682.1	RP11-660L16.2	-13.1	2.2e-36	3.07e-33	-0.51	-0.38	Vitamin D levels;	chr11:71424090	chr11:71448674~71452157:+
BRCA	cis	rs2283792	0.967	rs3810609	ENSG00000224086.5	LL22NC03-86G7.1	-13.09	2.31e-36	3.22e-33	-0.39	-0.38	Multiple sclerosis;	chr22:21758513	chr22:21938293~21977632:+
BRCA	cis	rs7044106	0.791	rs2416799	ENSG00000226752.6	PSMD5-AS1	-13.09	2.32e-36	3.23e-33	-0.45	-0.38	Hip circumference adjusted for BMI;	chr9:120718588	chr9:120824828~120854385:+
BRCA	cis	rs4423214	0.879	rs1790324	ENSG00000254682.1	RP11-660L16.2	-13.09	2.42e-36	3.37e-33	-0.49	-0.38	Vitamin D levels;	chr11:71439474	chr11:71448674~71452157:+
BRCA	cis	rs8100891	0.506	rs4804992	ENSG00000267213.4	AC007773.2	-13.09	2.46e-36	3.43e-33	-0.56	-0.38	Neuroticism;	chr19:32367885	chr19:32390050~32405560:-
BRCA	cis	rs8062405	0.558	rs231976	ENSG00000259982.1	CDC37P1	13.08	2.51e-36	3.5e-33	0.43	0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28534266	chr16:28700294~28701540:-
BRCA	cis	rs6452524	1	rs10474093	ENSG00000249664.1	CTD-2227C6.2	13.08	2.6e-36	3.62e-33	0.44	0.38	Hypertension (SNP x SNP interaction);	chr5:83141612	chr5:83012285~83013109:-
BRCA	cis	rs6452524	0.935	rs10473868	ENSG00000249664.1	CTD-2227C6.2	13.08	2.6e-36	3.62e-33	0.44	0.38	Hypertension (SNP x SNP interaction);	chr5:83141628	chr5:83012285~83013109:-
BRCA	cis	rs992157	0.71	rs10169718	ENSG00000261338.2	RP11-378A13.1	-13.08	2.64e-36	3.66e-33	-0.39	-0.38	Colorectal cancer;	chr2:218238857	chr2:218255319~218257366:+
BRCA	cis	rs11123170	0.569	rs1049137	ENSG00000189223.12	PAX8-AS1	-13.08	2.69e-36	3.74e-33	-0.65	-0.38	Renal function-related traits (BUN);	chr2:113217533	chr2:113211522~113276581:+
BRCA	cis	rs8062405	0.755	rs17707300	ENSG00000259982.1	CDC37P1	13.08	2.71e-36	3.76e-33	0.47	0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28582026	chr16:28700294~28701540:-
BRCA	cis	rs8100891	0.537	rs58591218	ENSG00000267213.4	AC007773.2	-13.08	2.73e-36	3.8e-33	-0.57	-0.38	Neuroticism;	chr19:32399876	chr19:32390050~32405560:-
BRCA	cis	rs9309711	0.666	rs6723126	ENSG00000225234.1	TRAPPC12-AS1	-13.07	2.84e-36	3.94e-33	-0.39	-0.38	Neurofibrillary tangles;	chr2:3480729	chr2:3481242~3482409:-
BRCA	cis	rs4423214	0.879	rs1792282	ENSG00000254682.1	RP11-660L16.2	-13.07	2.88e-36	4e-33	-0.51	-0.38	Vitamin D levels;	chr11:71424120	chr11:71448674~71452157:+
BRCA	cis	rs9309711	0.666	rs11127429	ENSG00000225234.1	TRAPPC12-AS1	-13.07	2.88e-36	4e-33	-0.4	-0.38	Neurofibrillary tangles;	chr2:3481453	chr2:3481242~3482409:-
BRCA	cis	rs9309711	0.666	rs11127430	ENSG00000225234.1	TRAPPC12-AS1	-13.07	2.88e-36	4e-33	-0.4	-0.38	Neurofibrillary tangles;	chr2:3481471	chr2:3481242~3482409:-
BRCA	cis	rs16828019	0.777	rs35044078	ENSG00000235358.1	RP11-399E6.1	13.07	2.9e-36	4.03e-33	0.74	0.38	Intelligence (multi-trait analysis);	chr1:41008728	chr1:41242373~41284861:+
BRCA	cis	rs6452524	1	rs6452524	ENSG00000249664.1	CTD-2227C6.2	-13.07	2.91e-36	4.03e-33	-0.44	-0.38	Hypertension (SNP x SNP interaction);	chr5:83137962	chr5:83012285~83013109:-
BRCA	cis	rs1150668	0.796	rs728122	ENSG00000216901.1	AL022393.7	13.07	2.99e-36	4.15e-33	0.45	0.38	Pubertal anthropometrics;	chr6:28431347	chr6:28176188~28176674:+
BRCA	cis	rs34779708	0.897	rs4934527	ENSG00000230534.5	RP11-297A16.2	13.07	3.07e-36	4.25e-33	0.47	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:34992190	chr10:35098006~35127020:-
BRCA	cis	rs2015599	0.549	rs7134796	ENSG00000257176.2	RP11-996F15.2	13.06	3.1e-36	4.3e-33	0.45	0.38	Platelet count;Mean platelet volume;	chr12:29294361	chr12:29280418~29317848:-
BRCA	cis	rs1426063	0.614	rs74670563	ENSG00000260265.1	RP11-44F21.5	13.05	3.54e-36	4.9e-33	0.93	0.37	QT interval;	chr4:75094656	chr4:75081702~75084717:-
BRCA	cis	rs1426063	0.614	rs115338890	ENSG00000260265.1	RP11-44F21.5	13.05	3.54e-36	4.9e-33	0.93	0.37	QT interval;	chr4:75094719	chr4:75081702~75084717:-
BRCA	cis	rs1426063	0.541	rs116304289	ENSG00000260265.1	RP11-44F21.5	13.05	3.54e-36	4.9e-33	0.93	0.37	QT interval;	chr4:75095072	chr4:75081702~75084717:-
BRCA	cis	rs34779708	0.658	rs4934715	ENSG00000230534.5	RP11-297A16.2	13.05	3.63e-36	5.02e-33	0.48	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35076064	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.931	rs2244100	ENSG00000230534.5	RP11-297A16.2	-13.05	3.68e-36	5.08e-33	-0.46	-0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35034708	chr10:35098006~35127020:-
BRCA	cis	rs7626444	0.543	rs843528	ENSG00000272359.1	U4	-13.05	3.71e-36	5.13e-33	-0.44	-0.37	Monocyte count;	chr3:196753464	chr3:196747192~196747324:-
BRCA	cis	rs2015599	0.584	rs7299283	ENSG00000257176.2	RP11-996F15.2	13.05	3.72e-36	5.15e-33	0.45	0.37	Platelet count;Mean platelet volume;	chr12:29277442	chr12:29280418~29317848:-
BRCA	cis	rs7626444	0.584	rs844542	ENSG00000272359.1	U4	-13.05	3.77e-36	5.21e-33	-0.44	-0.37	Monocyte count;	chr3:196752432	chr3:196747192~196747324:-
BRCA	cis	rs7044106	0.791	rs7036196	ENSG00000226752.6	PSMD5-AS1	-13.04	3.97e-36	5.49e-33	-0.45	-0.37	Hip circumference adjusted for BMI;	chr9:120717179	chr9:120824828~120854385:+
BRCA	cis	rs9309711	0.689	rs4535075	ENSG00000225234.1	TRAPPC12-AS1	-13.04	4.04e-36	5.58e-33	-0.39	-0.37	Neurofibrillary tangles;	chr2:3477945	chr2:3481242~3482409:-
BRCA	cis	rs6991838	0.584	rs6993876	ENSG00000272010.1	CTD-3025N20.3	13.04	4.12e-36	5.69e-33	0.4	0.37	Intelligence (multi-trait analysis);	chr8:65601240	chr8:65591850~65592472:-
BRCA	cis	rs6452524	1	rs1031902	ENSG00000249664.1	CTD-2227C6.2	13.04	4.13e-36	5.7e-33	0.43	0.37	Hypertension (SNP x SNP interaction);	chr5:83152308	chr5:83012285~83013109:-
BRCA	cis	rs34779708	0.931	rs12773169	ENSG00000230534.5	RP11-297A16.2	13.04	4.15e-36	5.73e-33	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35077534	chr10:35098006~35127020:-
BRCA	cis	rs7240205	0.816	rs7233016	ENSG00000275805.1	RP11-349H17.2	-13.04	4.23e-36	5.83e-33	-0.39	-0.37	Breast cancer;	chr18:26541387	chr18:26565723~26575626:-
BRCA	cis	rs6452524	1	rs6868817	ENSG00000249664.1	CTD-2227C6.2	13.04	4.31e-36	5.95e-33	0.44	0.37	Hypertension (SNP x SNP interaction);	chr5:83142287	chr5:83012285~83013109:-
BRCA	cis	rs6452524	0.967	rs10042018	ENSG00000249664.1	CTD-2227C6.2	13.04	4.31e-36	5.95e-33	0.44	0.37	Hypertension (SNP x SNP interaction);	chr5:83142490	chr5:83012285~83013109:-
BRCA	cis	rs6452524	0.967	rs10036418	ENSG00000249664.1	CTD-2227C6.2	13.04	4.31e-36	5.95e-33	0.44	0.37	Hypertension (SNP x SNP interaction);	chr5:83142493	chr5:83012285~83013109:-
BRCA	cis	rs6452524	1	rs10055948	ENSG00000249664.1	CTD-2227C6.2	13.04	4.31e-36	5.95e-33	0.44	0.37	Hypertension (SNP x SNP interaction);	chr5:83143437	chr5:83012285~83013109:-
BRCA	cis	rs8040855	0.756	rs2342118	ENSG00000259295.5	CSPG4P12	-13.03	4.41e-36	6.09e-33	-0.52	-0.37	Bulimia nervosa;	chr15:85149785	chr15:85191438~85213905:+
BRCA	cis	rs34779708	0.931	rs7084196	ENSG00000230534.5	RP11-297A16.2	13.03	4.48e-36	6.18e-33	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35078233	chr10:35098006~35127020:-
BRCA	cis	rs4380275	0.809	rs6753699	ENSG00000272342.1	RP13-539J13.1	13.03	4.54e-36	6.26e-33	0.44	0.37	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:766081	chr2:739588~740164:-
BRCA	cis	rs7301826	0.967	rs4759792	ENSG00000256299.1	RP11-989F5.3	-13.03	4.6e-36	6.34e-33	-0.42	-0.37	Plasma plasminogen activator levels;	chr12:130812086	chr12:130810821~130812622:-
BRCA	cis	rs2015599	0.623	rs1006410	ENSG00000257176.2	RP11-996F15.2	13.03	4.66e-36	6.43e-33	0.45	0.37	Platelet count;Mean platelet volume;	chr12:29282682	chr12:29280418~29317848:-
BRCA	cis	rs12134133	1	rs4844590	ENSG00000274245.1	RP11-357P18.2	13.03	4.72e-36	6.5e-33	0.51	0.37	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207322784	chr1:207372559~207373252:+
BRCA	cis	rs7626444	0.625	rs7638090	ENSG00000272359.1	U4	-13.02	4.86e-36	6.69e-33	-0.44	-0.37	Monocyte count;	chr3:196749965	chr3:196747192~196747324:-
BRCA	cis	rs7626444	0.625	rs2669637	ENSG00000272359.1	U4	-13.02	4.86e-36	6.69e-33	-0.44	-0.37	Monocyte count;	chr3:196750498	chr3:196747192~196747324:-
BRCA	cis	rs7626444	0.625	rs1718410	ENSG00000272359.1	U4	-13.02	4.86e-36	6.69e-33	-0.44	-0.37	Monocyte count;	chr3:196750789	chr3:196747192~196747324:-
BRCA	cis	rs8062405	0.721	rs151181	ENSG00000259982.1	CDC37P1	13.02	4.86e-36	6.69e-33	0.47	0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28479196	chr16:28700294~28701540:-
BRCA	cis	rs2283792	0.73	rs2329884	ENSG00000224086.5	LL22NC03-86G7.1	-13.02	5.03e-36	6.92e-33	-0.39	-0.37	Multiple sclerosis;	chr22:21927890	chr22:21938293~21977632:+
BRCA	cis	rs4718428	0.672	rs13241598	ENSG00000226824.5	RP4-756H11.3	-13.02	5.09e-36	6.99e-33	-0.5	-0.37	Corneal structure;	chr7:66835665	chr7:66654538~66669855:+
BRCA	cis	rs11118620	0.622	rs11118618	ENSG00000272823.1	RP11-295M18.6	13.02	5.16e-36	7.09e-33	0.47	0.37	Heart failure;	chr1:220838204	chr1:220828676~220829211:-
BRCA	cis	rs6991838	0.584	rs7459944	ENSG00000272010.1	CTD-3025N20.3	-13.02	5.24e-36	7.2e-33	-0.4	-0.37	Intelligence (multi-trait analysis);	chr8:65566040	chr8:65591850~65592472:-
BRCA	cis	rs7626444	0.625	rs2686590	ENSG00000272359.1	U4	-13.02	5.26e-36	7.22e-33	-0.45	-0.37	Monocyte count;	chr3:196765568	chr3:196747192~196747324:-
BRCA	cis	rs7044106	0.791	rs747819	ENSG00000226752.6	PSMD5-AS1	-13.02	5.35e-36	7.35e-33	-0.46	-0.37	Hip circumference adjusted for BMI;	chr9:120726163	chr9:120824828~120854385:+
BRCA	cis	rs7044106	0.762	rs1324473	ENSG00000226752.6	PSMD5-AS1	13.02	5.35e-36	7.35e-33	0.46	0.37	Hip circumference adjusted for BMI;	chr9:120642332	chr9:120824828~120854385:+
BRCA	cis	rs7044106	0.791	rs10984998	ENSG00000226752.6	PSMD5-AS1	-13.02	5.42e-36	7.45e-33	-0.45	-0.37	Hip circumference adjusted for BMI;	chr9:120719238	chr9:120824828~120854385:+
BRCA	cis	rs8059260	0.736	rs80207136	ENSG00000274038.1	RP11-66H6.4	-13.01	5.77e-36	7.92e-33	-0.59	-0.37	Alcohol consumption over the past year;	chr16:11015480	chr16:11056556~11057034:+
BRCA	cis	rs11123170	0.64	rs1015754	ENSG00000189223.12	PAX8-AS1	13.01	5.86e-36	8.03e-33	0.57	0.37	Renal function-related traits (BUN);	chr2:113210413	chr2:113211522~113276581:+
BRCA	cis	rs1150668	0.796	rs2247002	ENSG00000216901.1	AL022393.7	13.01	5.86e-36	8.03e-33	0.45	0.37	Pubertal anthropometrics;	chr6:28430174	chr6:28176188~28176674:+
BRCA	cis	rs16828019	0.704	rs12031277	ENSG00000235358.1	RP11-399E6.1	13.01	5.88e-36	8.07e-33	0.73	0.37	Intelligence (multi-trait analysis);	chr1:41026129	chr1:41242373~41284861:+
BRCA	cis	rs7626444	0.627	rs5021326	ENSG00000272359.1	U4	-13.01	5.97e-36	8.19e-33	-0.44	-0.37	Monocyte count;	chr3:196750757	chr3:196747192~196747324:-
BRCA	cis	rs7301826	0.967	rs4759790	ENSG00000256299.1	RP11-989F5.3	-13	6.09e-36	8.35e-33	-0.42	-0.37	Plasma plasminogen activator levels;	chr12:130811845	chr12:130810821~130812622:-
BRCA	cis	rs7626444	0.625	rs2669638	ENSG00000272359.1	U4	-13	6.22e-36	8.52e-33	-0.44	-0.37	Monocyte count;	chr3:196750527	chr3:196747192~196747324:-
BRCA	cis	rs7626444	0.625	rs2686593	ENSG00000272359.1	U4	-13	6.22e-36	8.52e-33	-0.44	-0.37	Monocyte count;	chr3:196750530	chr3:196747192~196747324:-
BRCA	cis	rs17826219	0.568	rs11658027	ENSG00000263531.1	RP13-753N3.1	-13	6.25e-36	8.56e-33	-0.69	-0.37	Body mass index;	chr17:30767864	chr17:30863921~30864940:-
BRCA	cis	rs9309711	0.623	rs4641971	ENSG00000225234.1	TRAPPC12-AS1	13	6.48e-36	8.87e-33	0.39	0.37	Neurofibrillary tangles;	chr2:3478086	chr2:3481242~3482409:-
BRCA	cis	rs7044106	0.791	rs735110	ENSG00000226752.6	PSMD5-AS1	-13	6.67e-36	9.13e-33	-0.46	-0.37	Hip circumference adjusted for BMI;	chr9:120726662	chr9:120824828~120854385:+
BRCA	cis	rs2015599	0.623	rs7313552	ENSG00000257176.2	RP11-996F15.2	12.99	6.9e-36	9.44e-33	0.45	0.37	Platelet count;Mean platelet volume;	chr12:29277302	chr12:29280418~29317848:-
BRCA	cis	rs34779708	0.966	rs17591857	ENSG00000230534.5	RP11-297A16.2	-12.99	7.25e-36	9.91e-33	-0.47	-0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35210115	chr10:35098006~35127020:-
BRCA	cis	rs4718428	0.672	rs36038499	ENSG00000226824.5	RP4-756H11.3	-12.99	7.39e-36	1.01e-32	-0.5	-0.37	Corneal structure;	chr7:66824628	chr7:66654538~66669855:+
BRCA	cis	rs7301826	0.932	rs1007246	ENSG00000256299.1	RP11-989F5.3	-12.99	7.56e-36	1.03e-32	-0.42	-0.37	Plasma plasminogen activator levels;	chr12:130795585	chr12:130810821~130812622:-
BRCA	cis	rs7849270	1	rs7020708	ENSG00000268707.1	RP11-247A12.7	-12.98	7.82e-36	1.07e-32	-0.47	-0.37	Blood metabolite ratios;	chr9:129122852	chr9:129170434~129170940:+
BRCA	cis	rs34779708	0.931	rs7099593	ENSG00000230534.5	RP11-297A16.2	12.98	7.98e-36	1.09e-32	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35077950	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.931	rs13376801	ENSG00000230534.5	RP11-297A16.2	12.98	7.98e-36	1.09e-32	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35081515	chr10:35098006~35127020:-
BRCA	cis	rs1555322	0.53	rs6060341	ENSG00000126005.14	MMP24-AS1	12.98	8.07e-36	1.1e-32	0.5	0.37	Attention deficit hyperactivity disorder;	chr20:35275830	chr20:35216462~35278131:-
BRCA	cis	rs34779708	0.931	rs7897457	ENSG00000230534.5	RP11-297A16.2	12.98	8.27e-36	1.13e-32	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35097112	chr10:35098006~35127020:-
BRCA	cis	rs6991838	0.557	rs67046768	ENSG00000272010.1	CTD-3025N20.3	-12.98	8.29e-36	1.13e-32	-0.39	-0.37	Intelligence (multi-trait analysis);	chr8:65577486	chr8:65591850~65592472:-
BRCA	cis	rs7301826	1	rs4759524	ENSG00000256299.1	RP11-989F5.3	-12.98	8.47e-36	1.16e-32	-0.42	-0.37	Plasma plasminogen activator levels;	chr12:130831065	chr12:130810821~130812622:-
BRCA	cis	rs2729354	0.768	rs2848640	ENSG00000265566.2	RN7SL605P	-12.98	8.48e-36	1.16e-32	-0.56	-0.37	Blood protein levels;	chr11:57495207	chr11:57528085~57528365:-
BRCA	cis	rs9309711	0.643	rs4264589	ENSG00000225234.1	TRAPPC12-AS1	-12.97	8.56e-36	1.17e-32	-0.39	-0.37	Neurofibrillary tangles;	chr2:3477327	chr2:3481242~3482409:-
BRCA	cis	rs7044106	0.791	rs3904196	ENSG00000226752.6	PSMD5-AS1	-12.97	8.62e-36	1.17e-32	-0.45	-0.37	Hip circumference adjusted for BMI;	chr9:120718091	chr9:120824828~120854385:+
BRCA	cis	rs2739330	0.828	rs5760108	ENSG00000250470.1	AP000351.3	12.97	8.72e-36	1.19e-32	0.45	0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23976904~23977585:-
BRCA	cis	rs8100891	0.537	rs10405382	ENSG00000267213.4	AC007773.2	-12.97	8.73e-36	1.19e-32	-0.55	-0.37	Neuroticism;	chr19:32405810	chr19:32390050~32405560:-
BRCA	cis	rs7626444	0.625	rs843539	ENSG00000272359.1	U4	-12.97	8.77e-36	1.19e-32	-0.44	-0.37	Monocyte count;	chr3:196747985	chr3:196747192~196747324:-
BRCA	cis	rs7626444	0.625	rs2686596	ENSG00000272359.1	U4	-12.97	8.77e-36	1.19e-32	-0.44	-0.37	Monocyte count;	chr3:196748248	chr3:196747192~196747324:-
BRCA	cis	rs7626444	0.625	rs2686595	ENSG00000272359.1	U4	-12.97	8.77e-36	1.19e-32	-0.44	-0.37	Monocyte count;	chr3:196748271	chr3:196747192~196747324:-
BRCA	cis	rs7626444	0.625	rs843529	ENSG00000272359.1	U4	12.97	8.9e-36	1.21e-32	0.45	0.37	Monocyte count;	chr3:196753724	chr3:196747192~196747324:-
BRCA	cis	rs7626444	0.625	rs2931210	ENSG00000272359.1	U4	-12.97	8.98e-36	1.22e-32	-0.45	-0.37	Monocyte count;	chr3:196749805	chr3:196747192~196747324:-
BRCA	cis	rs4718428	0.705	rs62465692	ENSG00000226824.5	RP4-756H11.3	-12.97	9.19e-36	1.25e-32	-0.5	-0.37	Corneal structure;	chr7:66830758	chr7:66654538~66669855:+
BRCA	cis	rs7626444	0.626	rs5021325	ENSG00000272359.1	U4	-12.97	9.21e-36	1.25e-32	-0.45	-0.37	Monocyte count;	chr3:196750758	chr3:196747192~196747324:-
BRCA	cis	rs7044106	0.791	rs7036766	ENSG00000226752.6	PSMD5-AS1	-12.97	9.33e-36	1.27e-32	-0.45	-0.37	Hip circumference adjusted for BMI;	chr9:120717343	chr9:120824828~120854385:+
BRCA	cis	rs7586673	0.93	rs7591506	ENSG00000227403.1	AC009299.3	-12.96	9.7e-36	1.32e-32	-0.5	-0.37	Intelligence (multi-trait analysis);	chr2:161104414	chr2:161244739~161249050:+
BRCA	cis	rs2108622	0.727	rs7251296	ENSG00000267453.5	AC004791.2	-12.96	9.84e-36	1.34e-32	-0.43	-0.37	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15872926	chr19:15851993~15864904:-
BRCA	cis	rs6452524	1	rs11740478	ENSG00000249664.1	CTD-2227C6.2	12.96	9.85e-36	1.34e-32	0.43	0.37	Hypertension (SNP x SNP interaction);	chr5:83150567	chr5:83012285~83013109:-
BRCA	cis	rs7849270	0.959	rs7032712	ENSG00000268707.1	RP11-247A12.7	-12.96	1e-35	1.36e-32	-0.47	-0.37	Blood metabolite ratios;	chr9:129130808	chr9:129170434~129170940:+
BRCA	cis	rs2283792	1	rs5999515	ENSG00000224086.5	LL22NC03-86G7.1	12.96	1.02e-35	1.39e-32	0.39	0.37	Multiple sclerosis;	chr22:21790812	chr22:21938293~21977632:+
BRCA	cis	rs6452524	0.934	rs2940543	ENSG00000249664.1	CTD-2227C6.2	12.96	1.02e-35	1.39e-32	0.44	0.37	Hypertension (SNP x SNP interaction);	chr5:83187297	chr5:83012285~83013109:-
BRCA	cis	rs6452524	0.967	rs2974450	ENSG00000249664.1	CTD-2227C6.2	12.96	1.02e-35	1.39e-32	0.44	0.37	Hypertension (SNP x SNP interaction);	chr5:83187323	chr5:83012285~83013109:-
BRCA	cis	rs6452524	0.967	rs2974449	ENSG00000249664.1	CTD-2227C6.2	12.96	1.02e-35	1.39e-32	0.44	0.37	Hypertension (SNP x SNP interaction);	chr5:83187465	chr5:83012285~83013109:-
BRCA	cis	rs6452524	0.967	rs2662241	ENSG00000249664.1	CTD-2227C6.2	12.96	1.02e-35	1.39e-32	0.44	0.37	Hypertension (SNP x SNP interaction);	chr5:83188774	chr5:83012285~83013109:-
BRCA	cis	rs6452524	0.935	rs2940544	ENSG00000249664.1	CTD-2227C6.2	12.96	1.02e-35	1.39e-32	0.44	0.37	Hypertension (SNP x SNP interaction);	chr5:83189785	chr5:83012285~83013109:-
BRCA	cis	rs6452524	0.967	rs2731865	ENSG00000249664.1	CTD-2227C6.2	12.96	1.02e-35	1.39e-32	0.44	0.37	Hypertension (SNP x SNP interaction);	chr5:83190570	chr5:83012285~83013109:-
BRCA	cis	rs1426063	0.614	rs77625282	ENSG00000260265.1	RP11-44F21.5	12.95	1.08e-35	1.46e-32	0.9	0.37	QT interval;	chr4:75089646	chr4:75081702~75084717:-
BRCA	cis	rs1426063	0.614	rs75112697	ENSG00000260265.1	RP11-44F21.5	12.95	1.08e-35	1.46e-32	0.9	0.37	QT interval;	chr4:75089725	chr4:75081702~75084717:-
BRCA	cis	rs4718428	0.705	rs13227468	ENSG00000226824.5	RP4-756H11.3	-12.95	1.08e-35	1.47e-32	-0.51	-0.37	Corneal structure;	chr7:66968576	chr7:66654538~66669855:+
BRCA	cis	rs8100891	0.537	rs10415145	ENSG00000267213.4	AC007773.2	12.95	1.1e-35	1.49e-32	0.55	0.37	Neuroticism;	chr19:32350147	chr19:32390050~32405560:-
BRCA	cis	rs8100891	0.537	rs73034216	ENSG00000267213.4	AC007773.2	-12.95	1.12e-35	1.52e-32	-0.56	-0.37	Neuroticism;	chr19:32392510	chr19:32390050~32405560:-
BRCA	cis	rs34779708	0.931	rs13376871	ENSG00000230534.5	RP11-297A16.2	12.95	1.16e-35	1.57e-32	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35080128	chr10:35098006~35127020:-
BRCA	cis	rs7849270	0.959	rs713218	ENSG00000268707.1	RP11-247A12.7	-12.95	1.19e-35	1.62e-32	-0.46	-0.37	Blood metabolite ratios;	chr9:129138491	chr9:129170434~129170940:+
BRCA	cis	rs6782228	0.675	rs6806687	ENSG00000242551.2	POU5F1P6	12.94	1.21e-35	1.64e-32	0.46	0.37	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128672946	chr3:128674735~128677005:-
BRCA	cis	rs765787	0.53	rs1706764	ENSG00000259520.4	CTD-2651B20.3	12.94	1.23e-35	1.67e-32	0.45	0.37	Uric acid levels;	chr15:45232058	chr15:45251580~45279251:-
BRCA	cis	rs4718428	0.662	rs34577323	ENSG00000226824.5	RP4-756H11.3	-12.94	1.24e-35	1.67e-32	-0.5	-0.37	Corneal structure;	chr7:66845054	chr7:66654538~66669855:+
BRCA	cis	rs1426063	0.614	rs6534447	ENSG00000260265.1	RP11-44F21.5	-12.94	1.26e-35	1.7e-32	-0.87	-0.37	QT interval;	chr4:75080682	chr4:75081702~75084717:-
BRCA	cis	rs2015599	0.563	rs11050168	ENSG00000257176.2	RP11-996F15.2	12.94	1.26e-35	1.71e-32	0.45	0.37	Platelet count;Mean platelet volume;	chr12:29273760	chr12:29280418~29317848:-
BRCA	cis	rs7626444	0.625	rs843541	ENSG00000272359.1	U4	-12.94	1.27e-35	1.72e-32	-0.44	-0.37	Monocyte count;	chr3:196748879	chr3:196747192~196747324:-
BRCA	cis	rs2015599	0.623	rs2288128	ENSG00000257176.2	RP11-996F15.2	12.94	1.29e-35	1.74e-32	0.44	0.37	Platelet count;Mean platelet volume;	chr12:29316054	chr12:29280418~29317848:-
BRCA	cis	rs2015599	0.584	rs2288129	ENSG00000257176.2	RP11-996F15.2	12.94	1.29e-35	1.74e-32	0.44	0.37	Platelet count;Mean platelet volume;	chr12:29316355	chr12:29280418~29317848:-
BRCA	cis	rs7182621	0.774	rs12101368	ENSG00000259363.4	CTD-2054N24.2	-12.94	1.31e-35	1.76e-32	-0.44	-0.37	Colonoscopy-negative controls vs population controls;	chr15:99872475	chr15:99807023~99877148:+
BRCA	cis	rs34779708	0.931	rs4007289	ENSG00000230534.5	RP11-297A16.2	12.94	1.31e-35	1.77e-32	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:34980862	chr10:35098006~35127020:-
BRCA	cis	rs7849270	1	rs10819466	ENSG00000268707.1	RP11-247A12.7	-12.94	1.32e-35	1.78e-32	-0.47	-0.37	Blood metabolite ratios;	chr9:129119213	chr9:129170434~129170940:+
BRCA	cis	rs4718428	0.705	rs4718424	ENSG00000226824.5	RP4-756H11.3	-12.93	1.35e-35	1.82e-32	-0.5	-0.37	Corneal structure;	chr7:66911108	chr7:66654538~66669855:+
BRCA	cis	rs9322193	0.923	rs9766004	ENSG00000216906.2	RP11-350J20.9	12.93	1.39e-35	1.87e-32	0.45	0.37	Lung cancer;	chr6:149754363	chr6:149904243~149906418:+
BRCA	cis	rs8100891	0.537	rs4805754	ENSG00000267213.4	AC007773.2	-12.93	1.41e-35	1.91e-32	-0.55	-0.37	Neuroticism;	chr19:32346260	chr19:32390050~32405560:-
BRCA	cis	rs765787	0.53	rs2668737	ENSG00000259520.4	CTD-2651B20.3	12.93	1.42e-35	1.92e-32	0.45	0.37	Uric acid levels;	chr15:45230601	chr15:45251580~45279251:-
BRCA	cis	rs8059260	0.668	rs79389789	ENSG00000274038.1	RP11-66H6.4	-12.93	1.43e-35	1.93e-32	-0.58	-0.37	Alcohol consumption over the past year;	chr16:11015168	chr16:11056556~11057034:+
BRCA	cis	rs34779708	0.931	rs2490663	ENSG00000230534.5	RP11-297A16.2	-12.93	1.44e-35	1.94e-32	-0.45	-0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35040807	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.966	rs12260130	ENSG00000230534.5	RP11-297A16.2	12.93	1.46e-35	1.96e-32	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35178743	chr10:35098006~35127020:-
BRCA	cis	rs2739330	0.76	rs5751761	ENSG00000231271.1	AP000350.8	-12.93	1.48e-35	1.99e-32	-0.47	-0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23949918~23954042:+
BRCA	cis	rs7849270	1	rs3739843	ENSG00000268707.1	RP11-247A12.7	-12.93	1.49e-35	2.01e-32	-0.47	-0.37	Blood metabolite ratios;	chr9:129120682	chr9:129170434~129170940:+
BRCA	cis	rs6991838	0.584	rs6994213	ENSG00000272010.1	CTD-3025N20.3	-12.92	1.56e-35	2.1e-32	-0.39	-0.37	Intelligence (multi-trait analysis);	chr8:65601497	chr8:65591850~65592472:-
BRCA	cis	rs2188561	0.697	rs2072064	ENSG00000241764.3	AC002467.7	12.92	1.59e-35	2.13e-32	0.52	0.37	Alcohol consumption;	chr7:107694068	chr7:107742817~107744581:-
BRCA	cis	rs6991838	0.53	rs6472217	ENSG00000272010.1	CTD-3025N20.3	12.92	1.63e-35	2.19e-32	0.39	0.37	Intelligence (multi-trait analysis);	chr8:65635496	chr8:65591850~65592472:-
BRCA	cis	rs6991838	0.584	rs6472218	ENSG00000272010.1	CTD-3025N20.3	12.92	1.63e-35	2.19e-32	0.39	0.37	Intelligence (multi-trait analysis);	chr8:65635502	chr8:65591850~65592472:-
BRCA	cis	rs10256972	0.732	rs12701856	ENSG00000229043.2	AC091729.9	-12.91	1.68e-35	2.25e-32	-0.48	-0.37	Endometriosis;Longevity;	chr7:1068071	chr7:1160374~1165267:+
BRCA	cis	rs1426063	0.614	rs7684790	ENSG00000260265.1	RP11-44F21.5	12.91	1.68e-35	2.26e-32	0.91	0.37	QT interval;	chr4:75090873	chr4:75081702~75084717:-
BRCA	cis	rs1426063	0.614	rs78046076	ENSG00000260265.1	RP11-44F21.5	12.91	1.68e-35	2.26e-32	0.91	0.37	QT interval;	chr4:75091818	chr4:75081702~75084717:-
BRCA	cis	rs4718428	0.705	rs12698547	ENSG00000226824.5	RP4-756H11.3	-12.91	1.74e-35	2.33e-32	-0.5	-0.37	Corneal structure;	chr7:66813271	chr7:66654538~66669855:+
BRCA	cis	rs7626444	0.625	rs1798634	ENSG00000272359.1	U4	-12.91	1.74e-35	2.33e-32	-0.44	-0.37	Monocyte count;	chr3:196747416	chr3:196747192~196747324:-
BRCA	cis	rs7626444	0.625	rs1798635	ENSG00000272359.1	U4	-12.91	1.74e-35	2.33e-32	-0.44	-0.37	Monocyte count;	chr3:196747418	chr3:196747192~196747324:-
BRCA	cis	rs858239	0.932	rs1624451	ENSG00000226816.2	AC005082.12	-12.91	1.8e-35	2.41e-32	-0.43	-0.37	Cerebrospinal fluid biomarker levels;	chr7:23222816	chr7:23206013~23208045:+
BRCA	cis	rs2658782	0.789	rs3020057	ENSG00000279684.1	RP11-755E23.2	-12.91	1.86e-35	2.49e-32	-0.52	-0.37	Pulmonary function decline;	chr11:93385349	chr11:93286629~93288903:-
BRCA	cis	rs6991838	0.584	rs4737221	ENSG00000272010.1	CTD-3025N20.3	-12.9	1.95e-35	2.61e-32	-0.4	-0.37	Intelligence (multi-trait analysis);	chr8:65569075	chr8:65591850~65592472:-
BRCA	cis	rs34779708	0.966	rs7077242	ENSG00000230534.5	RP11-297A16.2	-12.9	1.98e-35	2.65e-32	-0.47	-0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35193037	chr10:35098006~35127020:-
BRCA	cis	rs10170846	0.8	rs10194743	ENSG00000261428.2	RP11-16P6.1	12.9	2.02e-35	2.7e-32	0.45	0.37	Schizophrenia (inflammation and infection response interaction);	chr2:222653432	chr2:222566899~222569719:-
BRCA	cis	rs7626444	0.625	rs1104375	ENSG00000272359.1	U4	-12.9	2.02e-35	2.7e-32	-0.44	-0.37	Monocyte count;	chr3:196749172	chr3:196747192~196747324:-
BRCA	cis	rs2188561	0.697	rs2237679	ENSG00000241764.3	AC002467.7	12.89	2.14e-35	2.87e-32	0.52	0.37	Alcohol consumption;	chr7:107693581	chr7:107742817~107744581:-
BRCA	cis	rs7044106	0.791	rs10818473	ENSG00000226752.6	PSMD5-AS1	-12.89	2.19e-35	2.94e-32	-0.45	-0.37	Hip circumference adjusted for BMI;	chr9:120721877	chr9:120824828~120854385:+
BRCA	cis	rs1577917	0.545	rs1832070	ENSG00000203875.9	SNHG5	12.89	2.2e-35	2.95e-32	0.42	0.37	Response to antipsychotic treatment;	chr6:85773454	chr6:85660950~85678736:-
BRCA	cis	rs2108622	0.527	rs67617968	ENSG00000267453.5	AC004791.2	-12.89	2.26e-35	3.02e-32	-0.42	-0.37	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15866755	chr19:15851993~15864904:-
BRCA	cis	rs1426063	0.541	rs58959724	ENSG00000260265.1	RP11-44F21.5	12.89	2.3e-35	3.07e-32	0.89	0.37	QT interval;	chr4:75073543	chr4:75081702~75084717:-
BRCA	cis	rs73086581	0.568	rs6084541	ENSG00000229539.1	RP11-119B16.2	-12.89	2.32e-35	3.1e-32	-0.49	-0.37	Response to antidepressants in depression;	chr20:3982084	chr20:3888239~3888868:-
BRCA	cis	rs10256972	0.732	rs1574108	ENSG00000229043.2	AC091729.9	-12.88	2.35e-35	3.14e-32	-0.48	-0.37	Endometriosis;Longevity;	chr7:1066169	chr7:1160374~1165267:+
BRCA	cis	rs1426063	0.614	rs76204704	ENSG00000260265.1	RP11-44F21.5	12.88	2.4e-35	3.2e-32	0.92	0.37	QT interval;	chr4:75097804	chr4:75081702~75084717:-
BRCA	cis	rs1426063	0.614	rs80030693	ENSG00000260265.1	RP11-44F21.5	12.88	2.4e-35	3.2e-32	0.92	0.37	QT interval;	chr4:75099929	chr4:75081702~75084717:-
BRCA	cis	rs11123170	0.543	rs2166421	ENSG00000189223.12	PAX8-AS1	-12.88	2.4e-35	3.2e-32	-0.65	-0.37	Renal function-related traits (BUN);	chr2:113232665	chr2:113211522~113276581:+
BRCA	cis	rs34779708	0.931	rs2505631	ENSG00000230534.5	RP11-297A16.2	-12.88	2.4e-35	3.2e-32	-0.45	-0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35079457	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.897	rs7897827	ENSG00000230534.5	RP11-297A16.2	12.88	2.44e-35	3.26e-32	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35097309	chr10:35098006~35127020:-
BRCA	cis	rs7044106	0.791	rs4837793	ENSG00000226752.6	PSMD5-AS1	-12.88	2.47e-35	3.29e-32	-0.45	-0.37	Hip circumference adjusted for BMI;	chr9:120721343	chr9:120824828~120854385:+
BRCA	cis	rs4380275	0.782	rs60367761	ENSG00000272342.1	RP13-539J13.1	12.88	2.49e-35	3.32e-32	0.44	0.37	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:766414	chr2:739588~740164:-
BRCA	cis	rs6452524	1	rs4591730	ENSG00000249664.1	CTD-2227C6.2	12.88	2.57e-35	3.42e-32	0.43	0.37	Hypertension (SNP x SNP interaction);	chr5:83151983	chr5:83012285~83013109:-
BRCA	cis	rs34779708	0.966	rs4934540	ENSG00000230534.5	RP11-297A16.2	12.88	2.59e-35	3.45e-32	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35185771	chr10:35098006~35127020:-
BRCA	cis	rs6452524	0.967	rs2731861	ENSG00000249664.1	CTD-2227C6.2	12.88	2.6e-35	3.46e-32	0.44	0.37	Hypertension (SNP x SNP interaction);	chr5:83189445	chr5:83012285~83013109:-
BRCA	cis	rs34779708	0.966	rs4934539	ENSG00000230534.5	RP11-297A16.2	12.88	2.6e-35	3.47e-32	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35183271	chr10:35098006~35127020:-
BRCA	cis	rs7626444	0.625	rs1798637	ENSG00000272359.1	U4	-12.87	2.65e-35	3.54e-32	-0.44	-0.37	Monocyte count;	chr3:196749768	chr3:196747192~196747324:-
BRCA	cis	rs4380275	0.782	rs11691064	ENSG00000272342.1	RP13-539J13.1	12.87	2.68e-35	3.57e-32	0.43	0.37	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:755718	chr2:739588~740164:-
BRCA	cis	rs34779708	0.897	rs4934716	ENSG00000230534.5	RP11-297A16.2	12.87	2.71e-35	3.62e-32	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35080371	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.966	rs1478463	ENSG00000230534.5	RP11-297A16.2	12.87	2.76e-35	3.67e-32	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35184107	chr10:35098006~35127020:-
BRCA	cis	rs6991838	0.557	rs67685675	ENSG00000272010.1	CTD-3025N20.3	-12.87	2.77e-35	3.69e-32	-0.39	-0.37	Intelligence (multi-trait analysis);	chr8:65574371	chr8:65591850~65592472:-
BRCA	cis	rs6991838	0.584	rs66486920	ENSG00000272010.1	CTD-3025N20.3	-12.87	2.77e-35	3.69e-32	-0.39	-0.37	Intelligence (multi-trait analysis);	chr8:65574458	chr8:65591850~65592472:-
BRCA	cis	rs6991838	0.584	rs60023200	ENSG00000272010.1	CTD-3025N20.3	-12.87	2.77e-35	3.69e-32	-0.39	-0.37	Intelligence (multi-trait analysis);	chr8:65574547	chr8:65591850~65592472:-
BRCA	cis	rs6991838	0.584	rs61083799	ENSG00000272010.1	CTD-3025N20.3	-12.87	2.77e-35	3.69e-32	-0.39	-0.37	Intelligence (multi-trait analysis);	chr8:65574868	chr8:65591850~65592472:-
BRCA	cis	rs7829975	0.593	rs2921077	ENSG00000253893.2	FAM85B	-12.87	2.85e-35	3.8e-32	-0.46	-0.37	Mood instability;	chr8:8446992	chr8:8167819~8226614:-
BRCA	cis	rs9545047	0.716	rs7333904	ENSG00000227676.3	LINC01068	12.86	2.95e-35	3.92e-32	0.44	0.37	Schizophrenia;	chr13:79281413	chr13:79566727~79571436:+
BRCA	cis	rs4718428	0.705	rs4717328	ENSG00000226824.5	RP4-756H11.3	-12.86	2.96e-35	3.94e-32	-0.5	-0.37	Corneal structure;	chr7:66887678	chr7:66654538~66669855:+
BRCA	cis	rs6964833	0.935	rs34762099	ENSG00000277053.3	GTF2IP1	-12.86	2.99e-35	3.98e-32	-0.52	-0.37	Menarche (age at onset);	chr7:74636378	chr7:75185385~75237696:-
BRCA	cis	rs7301826	1	rs4759523	ENSG00000256299.1	RP11-989F5.3	-12.86	3.04e-35	4.05e-32	-0.42	-0.37	Plasma plasminogen activator levels;	chr12:130830867	chr12:130810821~130812622:-
BRCA	cis	rs8100891	0.537	rs113427979	ENSG00000267213.4	AC007773.2	-12.86	3.08e-35	4.09e-32	-0.56	-0.37	Neuroticism;	chr19:32364502	chr19:32390050~32405560:-
BRCA	cis	rs8100891	0.537	rs4805758	ENSG00000267213.4	AC007773.2	-12.86	3.08e-35	4.09e-32	-0.56	-0.37	Neuroticism;	chr19:32375518	chr19:32390050~32405560:-
BRCA	cis	rs7626444	0.625	rs1798636	ENSG00000272359.1	U4	-12.86	3.15e-35	4.19e-32	-0.44	-0.37	Monocyte count;	chr3:196749733	chr3:196747192~196747324:-
BRCA	cis	rs1150668	0.83	rs2859365	ENSG00000216901.1	AL022393.7	-12.86	3.15e-35	4.19e-32	-0.45	-0.37	Pubertal anthropometrics;	chr6:28423688	chr6:28176188~28176674:+
BRCA	cis	rs9309711	0.643	rs4535074	ENSG00000225234.1	TRAPPC12-AS1	-12.86	3.24e-35	4.29e-32	-0.38	-0.37	Neurofibrillary tangles;	chr2:3477866	chr2:3481242~3482409:-
BRCA	cis	rs6452524	0.967	rs2940542	ENSG00000249664.1	CTD-2227C6.2	12.85	3.28e-35	4.35e-32	0.44	0.37	Hypertension (SNP x SNP interaction);	chr5:83185734	chr5:83012285~83013109:-
BRCA	cis	rs8040855	0.627	rs12905036	ENSG00000259295.5	CSPG4P12	12.85	3.28e-35	4.36e-32	0.54	0.37	Bulimia nervosa;	chr15:85094557	chr15:85191438~85213905:+
BRCA	cis	rs34779708	0.931	rs34954932	ENSG00000230534.5	RP11-297A16.2	12.85	3.34e-35	4.43e-32	0.46	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35121879	chr10:35098006~35127020:-
BRCA	cis	rs4718428	0.705	rs4718422	ENSG00000226824.5	RP4-756H11.3	-12.85	3.36e-35	4.46e-32	-0.5	-0.37	Corneal structure;	chr7:66894282	chr7:66654538~66669855:+
BRCA	cis	rs6991838	0.584	rs34226237	ENSG00000272010.1	CTD-3025N20.3	-12.85	3.43e-35	4.55e-32	-0.39	-0.37	Intelligence (multi-trait analysis);	chr8:65600930	chr8:65591850~65592472:-
BRCA	cis	rs34779708	0.966	rs1057108	ENSG00000230534.5	RP11-297A16.2	12.85	3.48e-35	4.61e-32	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35196021	chr10:35098006~35127020:-
BRCA	cis	rs8100891	0.537	rs10424665	ENSG00000267213.4	AC007773.2	-12.85	3.5e-35	4.63e-32	-0.53	-0.37	Neuroticism;	chr19:32404725	chr19:32390050~32405560:-
BRCA	cis	rs858239	0.932	rs1637190	ENSG00000226816.2	AC005082.12	12.85	3.55e-35	4.7e-32	0.43	0.37	Cerebrospinal fluid biomarker levels;	chr7:23229446	chr7:23206013~23208045:+
BRCA	cis	rs4718428	0.705	rs13231140	ENSG00000226824.5	RP4-756H11.3	-12.85	3.56e-35	4.72e-32	-0.5	-0.37	Corneal structure;	chr7:66896631	chr7:66654538~66669855:+
BRCA	cis	rs6452524	1	rs7732092	ENSG00000249664.1	CTD-2227C6.2	12.85	3.6e-35	4.76e-32	0.43	0.37	Hypertension (SNP x SNP interaction);	chr5:83141110	chr5:83012285~83013109:-
BRCA	cis	rs34779708	0.966	rs10827493	ENSG00000230534.5	RP11-297A16.2	12.85	3.62e-35	4.79e-32	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35166048	chr10:35098006~35127020:-
BRCA	cis	rs6991838	0.584	rs4449837	ENSG00000272010.1	CTD-3025N20.3	-12.84	3.73e-35	4.94e-32	-0.39	-0.37	Intelligence (multi-trait analysis);	chr8:65575917	chr8:65591850~65592472:-
BRCA	cis	rs6991838	0.584	rs57042777	ENSG00000272010.1	CTD-3025N20.3	-12.84	3.73e-35	4.94e-32	-0.39	-0.37	Intelligence (multi-trait analysis);	chr8:65576855	chr8:65591850~65592472:-
BRCA	cis	rs6452524	1	rs6882179	ENSG00000249664.1	CTD-2227C6.2	12.84	3.79e-35	5.01e-32	0.43	0.37	Hypertension (SNP x SNP interaction);	chr5:83139582	chr5:83012285~83013109:-
BRCA	cis	rs765787	0.53	rs4331289	ENSG00000259520.4	CTD-2651B20.3	12.84	3.81e-35	5.04e-32	0.45	0.37	Uric acid levels;	chr15:45223140	chr15:45251580~45279251:-
BRCA	cis	rs8040855	0.627	rs35668291	ENSG00000259295.5	CSPG4P12	12.84	3.83e-35	5.06e-32	0.54	0.37	Bulimia nervosa;	chr15:85109582	chr15:85191438~85213905:+
BRCA	cis	rs6452524	1	rs6863300	ENSG00000249664.1	CTD-2227C6.2	12.84	3.85e-35	5.09e-32	0.44	0.37	Hypertension (SNP x SNP interaction);	chr5:83139629	chr5:83012285~83013109:-
BRCA	cis	rs6452524	1	rs4590162	ENSG00000249664.1	CTD-2227C6.2	12.84	3.97e-35	5.24e-32	0.43	0.37	Hypertension (SNP x SNP interaction);	chr5:83145621	chr5:83012285~83013109:-
BRCA	cis	rs1061377	0.748	rs11096977	ENSG00000249207.1	RP11-360F5.1	-12.84	3.97e-35	5.25e-32	-0.42	-0.37	Uric acid levels;	chr4:39106186	chr4:39112677~39126818:-
BRCA	cis	rs6452524	1	rs6452531	ENSG00000249664.1	CTD-2227C6.2	12.83	4.29e-35	5.66e-32	0.43	0.37	Hypertension (SNP x SNP interaction);	chr5:83170355	chr5:83012285~83013109:-
BRCA	cis	rs1061377	0.71	rs12503506	ENSG00000249207.1	RP11-360F5.1	-12.83	4.3e-35	5.67e-32	-0.42	-0.37	Uric acid levels;	chr4:39082553	chr4:39112677~39126818:-
BRCA	cis	rs34779708	0.966	rs12775799	ENSG00000230534.5	RP11-297A16.2	12.83	4.32e-35	5.7e-32	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35199336	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.966	rs11010122	ENSG00000230534.5	RP11-297A16.2	12.83	4.32e-35	5.7e-32	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35204590	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.9	rs73262807	ENSG00000230534.5	RP11-297A16.2	12.83	4.32e-35	5.7e-32	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35207458	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.966	rs4934736	ENSG00000230534.5	RP11-297A16.2	12.83	4.32e-35	5.7e-32	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35207940	chr10:35098006~35127020:-
BRCA	cis	rs6991838	0.584	rs3765205	ENSG00000272010.1	CTD-3025N20.3	-12.83	4.41e-35	5.81e-32	-0.39	-0.37	Intelligence (multi-trait analysis);	chr8:65605251	chr8:65591850~65592472:-
BRCA	cis	rs765787	0.53	rs4238376	ENSG00000259520.4	CTD-2651B20.3	12.83	4.44e-35	5.85e-32	0.45	0.37	Uric acid levels;	chr15:45249689	chr15:45251580~45279251:-
BRCA	cis	rs765787	0.53	rs4238377	ENSG00000259520.4	CTD-2651B20.3	12.83	4.44e-35	5.85e-32	0.45	0.37	Uric acid levels;	chr15:45249783	chr15:45251580~45279251:-
BRCA	cis	rs765787	0.53	rs4775844	ENSG00000259520.4	CTD-2651B20.3	12.83	4.44e-35	5.85e-32	0.45	0.37	Uric acid levels;	chr15:45249850	chr15:45251580~45279251:-
BRCA	cis	rs7626444	0.647	rs844546	ENSG00000272359.1	U4	-12.83	4.46e-35	5.88e-32	-0.44	-0.37	Monocyte count;	chr3:196748403	chr3:196747192~196747324:-
BRCA	cis	rs7626444	0.625	rs843540	ENSG00000272359.1	U4	-12.83	4.46e-35	5.88e-32	-0.44	-0.37	Monocyte count;	chr3:196748442	chr3:196747192~196747324:-
BRCA	cis	rs765787	0.53	rs3759893	ENSG00000259520.4	CTD-2651B20.3	12.83	4.48e-35	5.91e-32	0.45	0.37	Uric acid levels;	chr15:45250752	chr15:45251580~45279251:-
BRCA	cis	rs34779708	0.966	rs7070427	ENSG00000230534.5	RP11-297A16.2	12.83	4.56e-35	6e-32	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35196761	chr10:35098006~35127020:-
BRCA	cis	rs7044106	0.791	rs12554440	ENSG00000226752.6	PSMD5-AS1	-12.82	4.59e-35	6.05e-32	-0.46	-0.37	Hip circumference adjusted for BMI;	chr9:120723055	chr9:120824828~120854385:+
BRCA	cis	rs7849270	1	rs10988214	ENSG00000268707.1	RP11-247A12.7	-12.82	4.61e-35	6.07e-32	-0.46	-0.37	Blood metabolite ratios;	chr9:129121473	chr9:129170434~129170940:+
BRCA	cis	rs7849270	1	rs932833	ENSG00000268707.1	RP11-247A12.7	-12.82	4.61e-35	6.07e-32	-0.46	-0.37	Blood metabolite ratios;	chr9:129121762	chr9:129170434~129170940:+
BRCA	cis	rs6452524	0.967	rs4541638	ENSG00000249664.1	CTD-2227C6.2	12.82	4.63e-35	6.09e-32	0.44	0.37	Hypertension (SNP x SNP interaction);	chr5:83181325	chr5:83012285~83013109:-
BRCA	cis	rs765787	0.53	rs2554454	ENSG00000259520.4	CTD-2651B20.3	12.82	4.73e-35	6.22e-32	0.45	0.37	Uric acid levels;	chr15:45229338	chr15:45251580~45279251:-
BRCA	cis	rs9595066	0.715	rs9567366	ENSG00000227258.4	SMIM2-AS1	-12.82	4.76e-35	6.26e-32	-0.6	-0.37	Schizophrenia;	chr13:44108837	chr13:44110451~44240517:+
BRCA	cis	rs55665837	1	rs7121171	ENSG00000251991.1	RNU7-49P	12.82	4.77e-35	6.28e-32	0.4	0.37	Vitamin D levels;	chr11:14424874	chr11:14478892~14478953:+
BRCA	cis	rs7182621	0.639	rs35049216	ENSG00000259363.4	CTD-2054N24.2	-12.82	4.85e-35	6.38e-32	-0.5	-0.37	Colonoscopy-negative controls vs population controls;	chr15:99872562	chr15:99807023~99877148:+
BRCA	cis	rs9494142	0.592	rs1547247	ENSG00000232876.1	CTA-212D2.2	-12.81	5.12e-35	6.72e-32	-0.53	-0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;Lymphocyte counts;	chr6:135069698	chr6:135055033~135060550:+
BRCA	cis	rs6991838	0.584	rs4737748	ENSG00000272010.1	CTD-3025N20.3	12.81	5.21e-35	6.84e-32	0.39	0.37	Intelligence (multi-trait analysis);	chr8:65613630	chr8:65591850~65592472:-
BRCA	cis	rs6991838	0.53	rs35038843	ENSG00000272010.1	CTD-3025N20.3	-12.81	5.21e-35	6.84e-32	-0.39	-0.37	Intelligence (multi-trait analysis);	chr8:65610263	chr8:65591850~65592472:-
BRCA	cis	rs6991838	0.584	rs7841652	ENSG00000272010.1	CTD-3025N20.3	-12.81	5.22e-35	6.85e-32	-0.39	-0.37	Intelligence (multi-trait analysis);	chr8:65606392	chr8:65591850~65592472:-
BRCA	cis	rs6782228	0.675	rs9813845	ENSG00000242551.2	POU5F1P6	-12.81	5.24e-35	6.87e-32	-0.47	-0.37	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128680780	chr3:128674735~128677005:-
BRCA	cis	rs1426063	0.614	rs76325897	ENSG00000260265.1	RP11-44F21.5	12.81	5.34e-35	7e-32	0.89	0.37	QT interval;	chr4:75084747	chr4:75081702~75084717:-
BRCA	cis	rs1426063	0.614	rs76093954	ENSG00000260265.1	RP11-44F21.5	12.81	5.34e-35	7e-32	0.89	0.37	QT interval;	chr4:75087994	chr4:75081702~75084717:-
BRCA	cis	rs1426063	0.614	rs114977200	ENSG00000260265.1	RP11-44F21.5	12.81	5.34e-35	7e-32	0.89	0.37	QT interval;	chr4:75088736	chr4:75081702~75084717:-
BRCA	cis	rs12134133	1	rs28371583	ENSG00000274245.1	RP11-357P18.2	12.81	5.36e-35	7.03e-32	0.5	0.37	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207321334	chr1:207372559~207373252:+
BRCA	cis	rs34779708	0.966	rs10827487	ENSG00000230534.5	RP11-297A16.2	12.81	5.54e-35	7.26e-32	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35117950	chr10:35098006~35127020:-
BRCA	cis	rs1577917	0.545	rs9344548	ENSG00000203875.9	SNHG5	12.81	5.55e-35	7.28e-32	0.42	0.37	Response to antipsychotic treatment;	chr6:85777619	chr6:85660950~85678736:-
BRCA	cis	rs7044106	0.791	rs4836829	ENSG00000226752.6	PSMD5-AS1	-12.8	5.72e-35	7.49e-32	-0.45	-0.37	Hip circumference adjusted for BMI;	chr9:120720469	chr9:120824828~120854385:+
BRCA	cis	rs2658782	0.901	rs11604909	ENSG00000279684.1	RP11-755E23.2	-12.8	5.76e-35	7.54e-32	-0.56	-0.37	Pulmonary function decline;	chr11:93485189	chr11:93286629~93288903:-
BRCA	cis	rs7849270	1	rs7849160	ENSG00000268707.1	RP11-247A12.7	-12.8	5.82e-35	7.61e-32	-0.46	-0.37	Blood metabolite ratios;	chr9:129112273	chr9:129170434~129170940:+
BRCA	cis	rs1061377	0.748	rs6810770	ENSG00000249207.1	RP11-360F5.1	-12.8	5.83e-35	7.63e-32	-0.42	-0.37	Uric acid levels;	chr4:39106545	chr4:39112677~39126818:-
BRCA	cis	rs6452524	0.967	rs2974444	ENSG00000249664.1	CTD-2227C6.2	12.8	5.96e-35	7.8e-32	0.44	0.37	Hypertension (SNP x SNP interaction);	chr5:83185174	chr5:83012285~83013109:-
BRCA	cis	rs7188445	0.787	rs7189954	ENSG00000261390.4	RP11-345M22.2	12.8	6.01e-35	7.86e-32	0.46	0.37	Urate levels;	chr16:79701150	chr16:79715232~79770563:-
BRCA	cis	rs34779708	0.966	rs4934732	ENSG00000230534.5	RP11-297A16.2	12.8	6.03e-35	7.89e-32	0.46	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35142756	chr10:35098006~35127020:-
BRCA	cis	rs765787	0.53	rs2433229	ENSG00000259520.4	CTD-2651B20.3	12.8	6.05e-35	7.91e-32	0.45	0.37	Uric acid levels;	chr15:45223037	chr15:45251580~45279251:-
BRCA	cis	rs34779708	0.966	rs17500582	ENSG00000230534.5	RP11-297A16.2	12.8	6.08e-35	7.95e-32	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35209860	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.931	rs12776390	ENSG00000230534.5	RP11-297A16.2	12.8	6.21e-35	8.12e-32	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35102607	chr10:35098006~35127020:-
BRCA	cis	rs6991838	0.55	rs12335006	ENSG00000272010.1	CTD-3025N20.3	12.8	6.22e-35	8.13e-32	0.39	0.37	Intelligence (multi-trait analysis);	chr8:65619394	chr8:65591850~65592472:-
BRCA	cis	rs6991838	0.612	rs12335276	ENSG00000272010.1	CTD-3025N20.3	12.8	6.22e-35	8.13e-32	0.39	0.37	Intelligence (multi-trait analysis);	chr8:65619668	chr8:65591850~65592472:-
BRCA	cis	rs8062405	0.721	rs151303	ENSG00000259982.1	CDC37P1	12.8	6.31e-35	8.24e-32	0.48	0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28481189	chr16:28700294~28701540:-
BRCA	cis	rs34779708	0.897	rs9665538	ENSG00000230534.5	RP11-297A16.2	12.8	6.35e-35	8.29e-32	0.46	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35172110	chr10:35098006~35127020:-
BRCA	cis	rs2283792	0.622	rs5756323	ENSG00000224086.5	LL22NC03-86G7.1	12.79	6.42e-35	8.38e-32	0.38	0.37	Multiple sclerosis;	chr22:21980398	chr22:21938293~21977632:+
BRCA	cis	rs34779708	0.931	rs13377158	ENSG00000230534.5	RP11-297A16.2	-12.79	6.48e-35	8.47e-32	-0.46	-0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35081537	chr10:35098006~35127020:-
BRCA	cis	rs6991838	0.584	rs7463649	ENSG00000272010.1	CTD-3025N20.3	-12.79	6.55e-35	8.55e-32	-0.39	-0.37	Intelligence (multi-trait analysis);	chr8:65573760	chr8:65591850~65592472:-
BRCA	cis	rs6991838	0.584	rs7463740	ENSG00000272010.1	CTD-3025N20.3	-12.79	6.55e-35	8.55e-32	-0.39	-0.37	Intelligence (multi-trait analysis);	chr8:65573950	chr8:65591850~65592472:-
BRCA	cis	rs6991838	0.584	rs66467166	ENSG00000272010.1	CTD-3025N20.3	-12.79	6.55e-35	8.55e-32	-0.39	-0.37	Intelligence (multi-trait analysis);	chr8:65574165	chr8:65591850~65592472:-
BRCA	cis	rs8177376	1	rs534804	ENSG00000254905.1	RP11-712L6.7	12.79	6.67e-35	8.7e-32	0.54	0.37	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126205873	chr11:126292922~126294254:-
BRCA	cis	rs34779708	0.966	rs878264	ENSG00000230534.5	RP11-297A16.2	12.79	6.68e-35	8.72e-32	0.46	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35151653	chr10:35098006~35127020:-
BRCA	cis	rs6991838	0.612	rs7832407	ENSG00000272010.1	CTD-3025N20.3	12.79	6.75e-35	8.79e-32	0.39	0.37	Intelligence (multi-trait analysis);	chr8:65621071	chr8:65591850~65592472:-
BRCA	cis	rs6991838	0.551	rs7007505	ENSG00000272010.1	CTD-3025N20.3	12.79	6.75e-35	8.79e-32	0.39	0.37	Intelligence (multi-trait analysis);	chr8:65621719	chr8:65591850~65592472:-
BRCA	cis	rs6991838	0.584	rs7012856	ENSG00000272010.1	CTD-3025N20.3	12.79	6.75e-35	8.79e-32	0.39	0.37	Intelligence (multi-trait analysis);	chr8:65622740	chr8:65591850~65592472:-
BRCA	cis	rs6991838	0.55	rs7817112	ENSG00000272010.1	CTD-3025N20.3	12.79	6.75e-35	8.79e-32	0.39	0.37	Intelligence (multi-trait analysis);	chr8:65624885	chr8:65591850~65592472:-
BRCA	cis	rs6991838	0.584	rs2048650	ENSG00000272010.1	CTD-3025N20.3	12.79	6.75e-35	8.79e-32	0.39	0.37	Intelligence (multi-trait analysis);	chr8:65625664	chr8:65591850~65592472:-
BRCA	cis	rs6991838	0.584	rs4737749	ENSG00000272010.1	CTD-3025N20.3	12.79	6.75e-35	8.79e-32	0.39	0.37	Intelligence (multi-trait analysis);	chr8:65627672	chr8:65591850~65592472:-
BRCA	cis	rs6991838	0.584	rs10092109	ENSG00000272010.1	CTD-3025N20.3	12.79	6.75e-35	8.79e-32	0.39	0.37	Intelligence (multi-trait analysis);	chr8:65627683	chr8:65591850~65592472:-
BRCA	cis	rs6991838	0.584	rs6997959	ENSG00000272010.1	CTD-3025N20.3	12.79	6.75e-35	8.79e-32	0.39	0.37	Intelligence (multi-trait analysis);	chr8:65628247	chr8:65591850~65592472:-
BRCA	cis	rs6991838	0.584	rs7814841	ENSG00000272010.1	CTD-3025N20.3	12.79	6.75e-35	8.79e-32	0.39	0.37	Intelligence (multi-trait analysis);	chr8:65629328	chr8:65591850~65592472:-
BRCA	cis	rs6991838	0.584	rs11985628	ENSG00000272010.1	CTD-3025N20.3	12.79	6.75e-35	8.79e-32	0.39	0.37	Intelligence (multi-trait analysis);	chr8:65630504	chr8:65591850~65592472:-
BRCA	cis	rs6991838	0.557	rs13266834	ENSG00000272010.1	CTD-3025N20.3	12.79	6.75e-35	8.79e-32	0.39	0.37	Intelligence (multi-trait analysis);	chr8:65631303	chr8:65591850~65592472:-
BRCA	cis	rs6991838	0.584	rs13268343	ENSG00000272010.1	CTD-3025N20.3	12.79	6.75e-35	8.79e-32	0.39	0.37	Intelligence (multi-trait analysis);	chr8:65631742	chr8:65591850~65592472:-
BRCA	cis	rs6991838	0.584	rs1533285	ENSG00000272010.1	CTD-3025N20.3	12.79	6.75e-35	8.79e-32	0.39	0.37	Intelligence (multi-trait analysis);	chr8:65637129	chr8:65591850~65592472:-
BRCA	cis	rs6991838	0.584	rs10957361	ENSG00000272010.1	CTD-3025N20.3	12.79	6.77e-35	8.81e-32	0.39	0.37	Intelligence (multi-trait analysis);	chr8:65619626	chr8:65591850~65592472:-
BRCA	cis	rs17711722	0.522	rs6957759	ENSG00000226824.5	RP4-756H11.3	-12.79	6.82e-35	8.88e-32	-0.46	-0.37	Calcium levels;	chr7:65806798	chr7:66654538~66669855:+
BRCA	cis	rs8040855	0.627	rs17541051	ENSG00000259295.5	CSPG4P12	12.79	6.89e-35	8.96e-32	0.54	0.37	Bulimia nervosa;	chr15:85106122	chr15:85191438~85213905:+
BRCA	cis	rs6991838	0.584	rs4388482	ENSG00000272010.1	CTD-3025N20.3	-12.79	6.92e-35	9e-32	-0.39	-0.37	Intelligence (multi-trait analysis);	chr8:65583968	chr8:65591850~65592472:-
BRCA	cis	rs6991838	0.584	rs4637885	ENSG00000272010.1	CTD-3025N20.3	-12.79	6.92e-35	9e-32	-0.39	-0.37	Intelligence (multi-trait analysis);	chr8:65584849	chr8:65591850~65592472:-
BRCA	cis	rs2283792	0.73	rs894095	ENSG00000224086.5	LL22NC03-86G7.1	-12.79	6.96e-35	9.05e-32	-0.39	-0.37	Multiple sclerosis;	chr22:21928404	chr22:21938293~21977632:+
BRCA	cis	rs10256972	0.721	rs2030959	ENSG00000229043.2	AC091729.9	-12.78	7.16e-35	9.31e-32	-0.48	-0.37	Endometriosis;Longevity;	chr7:1036270	chr7:1160374~1165267:+
BRCA	cis	rs2658782	0.694	rs3019221	ENSG00000279684.1	RP11-755E23.2	-12.78	7.32e-35	9.52e-32	-0.52	-0.37	Pulmonary function decline;	chr11:93346534	chr11:93286629~93288903:-
BRCA	cis	rs34779708	0.931	rs11010125	ENSG00000230534.5	RP11-297A16.2	12.78	7.36e-35	9.56e-32	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35214025	chr10:35098006~35127020:-
BRCA	cis	rs6991838	0.584	rs7835313	ENSG00000272010.1	CTD-3025N20.3	12.78	7.38e-35	9.59e-32	0.39	0.37	Intelligence (multi-trait analysis);	chr8:65633891	chr8:65591850~65592472:-
BRCA	cis	rs8062405	0.754	rs151179	ENSG00000259982.1	CDC37P1	12.78	7.57e-35	9.83e-32	0.47	0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28475735	chr16:28700294~28701540:-
BRCA	cis	rs765787	0.53	rs2433228	ENSG00000259520.4	CTD-2651B20.3	12.78	7.76e-35	1.01e-31	0.45	0.37	Uric acid levels;	chr15:45223173	chr15:45251580~45279251:-
BRCA	cis	rs765787	0.53	rs11854690	ENSG00000259520.4	CTD-2651B20.3	12.78	7.76e-35	1.01e-31	0.45	0.37	Uric acid levels;	chr15:45223818	chr15:45251580~45279251:-
BRCA	cis	rs765787	0.53	rs28733848	ENSG00000259520.4	CTD-2651B20.3	12.78	7.76e-35	1.01e-31	0.45	0.37	Uric acid levels;	chr15:45223849	chr15:45251580~45279251:-
BRCA	cis	rs765787	0.53	rs11854689	ENSG00000259520.4	CTD-2651B20.3	12.78	7.76e-35	1.01e-31	0.45	0.37	Uric acid levels;	chr15:45223854	chr15:45251580~45279251:-
BRCA	cis	rs765787	0.53	rs1706830	ENSG00000259520.4	CTD-2651B20.3	12.78	7.76e-35	1.01e-31	0.45	0.37	Uric acid levels;	chr15:45224031	chr15:45251580~45279251:-
BRCA	cis	rs765787	0.53	rs1706831	ENSG00000259520.4	CTD-2651B20.3	12.78	7.76e-35	1.01e-31	0.45	0.37	Uric acid levels;	chr15:45224032	chr15:45251580~45279251:-
BRCA	cis	rs765787	0.53	rs2433227	ENSG00000259520.4	CTD-2651B20.3	12.78	7.76e-35	1.01e-31	0.45	0.37	Uric acid levels;	chr15:45224921	chr15:45251580~45279251:-
BRCA	cis	rs765787	0.53	rs2413786	ENSG00000259520.4	CTD-2651B20.3	12.78	7.76e-35	1.01e-31	0.45	0.37	Uric acid levels;	chr15:45233196	chr15:45251580~45279251:-
BRCA	cis	rs8040855	0.627	rs12913859	ENSG00000259295.5	CSPG4P12	12.78	7.81e-35	1.01e-31	0.54	0.37	Bulimia nervosa;	chr15:85095187	chr15:85191438~85213905:+
BRCA	cis	rs34779708	0.966	rs17499247	ENSG00000230534.5	RP11-297A16.2	12.78	7.84e-35	1.02e-31	0.46	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35137827	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.966	rs10827491	ENSG00000230534.5	RP11-297A16.2	12.78	7.84e-35	1.02e-31	0.46	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35138467	chr10:35098006~35127020:-
BRCA	cis	rs6452524	1	rs7716962	ENSG00000249664.1	CTD-2227C6.2	12.78	7.92e-35	1.03e-31	0.43	0.37	Hypertension (SNP x SNP interaction);	chr5:83138913	chr5:83012285~83013109:-
BRCA	cis	rs34779708	0.966	rs12782948	ENSG00000230534.5	RP11-297A16.2	12.77	8.34e-35	1.08e-31	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35161679	chr10:35098006~35127020:-
BRCA	cis	rs6452524	0.967	rs28360104	ENSG00000249664.1	CTD-2227C6.2	12.77	8.88e-35	1.15e-31	0.44	0.37	Hypertension (SNP x SNP interaction);	chr5:83181525	chr5:83012285~83013109:-
BRCA	cis	rs34779708	0.931	rs7099036	ENSG00000230534.5	RP11-297A16.2	12.77	8.89e-35	1.15e-31	0.46	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35060646	chr10:35098006~35127020:-
BRCA	cis	rs765787	0.53	rs2668751	ENSG00000259520.4	CTD-2651B20.3	12.76	9.24e-35	1.2e-31	0.45	0.37	Uric acid levels;	chr15:45225095	chr15:45251580~45279251:-
BRCA	cis	rs765787	0.53	rs1648286	ENSG00000259520.4	CTD-2651B20.3	12.76	9.24e-35	1.2e-31	0.45	0.37	Uric acid levels;	chr15:45225188	chr15:45251580~45279251:-
BRCA	cis	rs4423214	0.879	rs736894	ENSG00000254682.1	RP11-660L16.2	12.76	9.32e-35	1.21e-31	0.5	0.37	Vitamin D levels;	chr11:71441212	chr11:71448674~71452157:+
BRCA	cis	rs765787	0.53	rs1648285	ENSG00000259520.4	CTD-2651B20.3	12.76	9.8e-35	1.27e-31	0.44	0.37	Uric acid levels;	chr15:45225307	chr15:45251580~45279251:-
BRCA	cis	rs1061377	0.748	rs6812316	ENSG00000249207.1	RP11-360F5.1	-12.76	9.8e-35	1.27e-31	-0.42	-0.37	Uric acid levels;	chr4:39106617	chr4:39112677~39126818:-
BRCA	cis	rs858239	0.896	rs1637192	ENSG00000226816.2	AC005082.12	12.75	1.02e-34	1.31e-31	0.43	0.37	Cerebrospinal fluid biomarker levels;	chr7:23220895	chr7:23206013~23208045:+
BRCA	cis	rs7849270	1	rs10819471	ENSG00000268707.1	RP11-247A12.7	-12.75	1.02e-34	1.32e-31	-0.46	-0.37	Blood metabolite ratios;	chr9:129134046	chr9:129170434~129170940:+
BRCA	cis	rs10256972	0.786	rs3735686	ENSG00000229043.2	AC091729.9	-12.75	1.06e-34	1.37e-31	-0.46	-0.37	Endometriosis;Longevity;	chr7:1022891	chr7:1160374~1165267:+
BRCA	cis	rs34779708	0.931	rs11010077	ENSG00000230534.5	RP11-297A16.2	-12.75	1.08e-34	1.39e-31	-0.44	-0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35039160	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.966	rs12257770	ENSG00000230534.5	RP11-297A16.2	12.75	1.09e-34	1.4e-31	0.45	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35228306	chr10:35098006~35127020:-
BRCA	cis	rs4718428	0.672	rs12530806	ENSG00000226824.5	RP4-756H11.3	-12.75	1.09e-34	1.41e-31	-0.49	-0.37	Corneal structure;	chr7:66925737	chr7:66654538~66669855:+
BRCA	cis	rs34779708	0.931	rs11010083	ENSG00000230534.5	RP11-297A16.2	12.74	1.12e-34	1.45e-31	0.46	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35062603	chr10:35098006~35127020:-
BRCA	cis	rs8040855	0.659	rs8037886	ENSG00000259295.5	CSPG4P12	-12.74	1.13e-34	1.45e-31	-0.54	-0.37	Bulimia nervosa;	chr15:85143533	chr15:85191438~85213905:+
BRCA	cis	rs765787	0.53	rs28815867	ENSG00000259520.4	CTD-2651B20.3	12.74	1.13e-34	1.45e-31	0.45	0.37	Uric acid levels;	chr15:45234607	chr15:45251580~45279251:-
BRCA	cis	rs765787	0.53	rs4775819	ENSG00000259520.4	CTD-2651B20.3	12.74	1.13e-34	1.46e-31	0.44	0.37	Uric acid levels;	chr15:45233768	chr15:45251580~45279251:-
BRCA	cis	rs9487094	0.67	rs12199154	ENSG00000260273.1	RP11-425D10.10	-12.74	1.14e-34	1.47e-31	-0.42	-0.37	Height;	chr6:109501793	chr6:109382795~109383666:+
BRCA	cis	rs7849270	1	rs7849270	ENSG00000268707.1	RP11-247A12.7	-12.74	1.14e-34	1.47e-31	-0.46	-0.37	Blood metabolite ratios;	chr9:129112362	chr9:129170434~129170940:+
BRCA	cis	rs34779708	0.931	rs11010130	ENSG00000230534.5	RP11-297A16.2	12.74	1.14e-34	1.47e-31	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35224379	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.897	rs11010131	ENSG00000230534.5	RP11-297A16.2	12.74	1.14e-34	1.47e-31	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35224388	chr10:35098006~35127020:-
BRCA	cis	rs4718428	0.705	rs12536410	ENSG00000226824.5	RP4-756H11.3	-12.74	1.15e-34	1.48e-31	-0.5	-0.37	Corneal structure;	chr7:66789303	chr7:66654538~66669855:+
BRCA	cis	rs12594515	0.694	rs2068295	ENSG00000273972.1	CTD-2306A12.1	-12.74	1.16e-34	1.5e-31	-0.43	-0.37	Weight;Waist circumference;	chr15:45693348	chr15:45702640~45703183:+
BRCA	cis	rs7849270	0.959	rs4836641	ENSG00000268707.1	RP11-247A12.7	12.74	1.16e-34	1.5e-31	0.49	0.37	Blood metabolite ratios;	chr9:129149953	chr9:129170434~129170940:+
BRCA	cis	rs62229266	0.626	rs2835268	ENSG00000231106.2	LINC01436	12.74	1.17e-34	1.5e-31	0.41	0.37	Mitral valve prolapse;	chr21:36076838	chr21:36005338~36007838:+
BRCA	cis	rs2019137	0.901	rs4849176	ENSG00000274877.1	RP11-65I12.1	12.74	1.18e-34	1.52e-31	0.48	0.37	Lymphocyte counts;	chr2:113220359	chr2:113237595~113240825:+
BRCA	cis	rs2015599	0.623	rs7964831	ENSG00000257176.2	RP11-996F15.2	-12.74	1.18e-34	1.52e-31	-0.44	-0.37	Platelet count;Mean platelet volume;	chr12:29286655	chr12:29280418~29317848:-
BRCA	cis	rs12594515	0.694	rs2068294	ENSG00000273972.1	CTD-2306A12.1	-12.74	1.2e-34	1.54e-31	-0.43	-0.37	Weight;Waist circumference;	chr15:45693350	chr15:45702640~45703183:+
BRCA	cis	rs34779708	0.966	rs17591781	ENSG00000230534.5	RP11-297A16.2	12.74	1.2e-34	1.55e-31	0.46	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35209610	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.966	rs2045917	ENSG00000230534.5	RP11-297A16.2	12.74	1.23e-34	1.57e-31	0.46	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35129598	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.931	rs4934711	ENSG00000230534.5	RP11-297A16.2	12.74	1.23e-34	1.57e-31	0.46	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35071382	chr10:35098006~35127020:-
BRCA	cis	rs1426063	0.614	rs7671634	ENSG00000260265.1	RP11-44F21.5	12.74	1.24e-34	1.59e-31	0.9	0.37	QT interval;	chr4:75090883	chr4:75081702~75084717:-
BRCA	cis	rs2117029	0.561	rs7957983	ENSG00000258017.1	RP11-386G11.10	-12.74	1.24e-34	1.6e-31	-0.5	-0.37	Intelligence (multi-trait analysis);	chr12:49115204	chr12:49127782~49147869:+
BRCA	cis	rs2117029	0.587	rs7958572	ENSG00000258017.1	RP11-386G11.10	-12.74	1.24e-34	1.6e-31	-0.5	-0.37	Intelligence (multi-trait analysis);	chr12:49115658	chr12:49127782~49147869:+
BRCA	cis	rs6991838	0.584	rs3812412	ENSG00000272010.1	CTD-3025N20.3	12.73	1.24e-34	1.6e-31	0.39	0.37	Intelligence (multi-trait analysis);	chr8:65634857	chr8:65591850~65592472:-
BRCA	cis	rs11123170	0.529	rs1015755	ENSG00000189223.12	PAX8-AS1	-12.73	1.24e-34	1.6e-31	-0.64	-0.37	Renal function-related traits (BUN);	chr2:113210730	chr2:113211522~113276581:+
BRCA	cis	rs6991838	0.556	rs7846527	ENSG00000272010.1	CTD-3025N20.3	-12.73	1.26e-34	1.62e-31	-0.39	-0.37	Intelligence (multi-trait analysis);	chr8:65586522	chr8:65591850~65592472:-
BRCA	cis	rs6991838	0.584	rs4320587	ENSG00000272010.1	CTD-3025N20.3	-12.73	1.26e-34	1.62e-31	-0.39	-0.37	Intelligence (multi-trait analysis);	chr8:65586991	chr8:65591850~65592472:-
BRCA	cis	rs6991838	0.584	rs35941313	ENSG00000272010.1	CTD-3025N20.3	-12.73	1.26e-34	1.62e-31	-0.39	-0.37	Intelligence (multi-trait analysis);	chr8:65587498	chr8:65591850~65592472:-
BRCA	cis	rs55665837	1	rs11023216	ENSG00000251991.1	RNU7-49P	12.73	1.27e-34	1.64e-31	0.4	0.37	Vitamin D levels;	chr11:14415607	chr11:14478892~14478953:+
BRCA	cis	rs1891275	0.551	rs1891271	ENSG00000228701.1	TNKS2-AS1	-12.73	1.31e-34	1.69e-31	-0.48	-0.37	Intelligence (multi-trait analysis);	chr10:91666566	chr10:91782839~91798291:-
BRCA	cis	rs7301826	1	rs1609985	ENSG00000256299.1	RP11-989F5.3	-12.73	1.36e-34	1.75e-31	-0.42	-0.37	Plasma plasminogen activator levels;	chr12:130835625	chr12:130810821~130812622:-
BRCA	cis	rs7626444	0.585	rs860050	ENSG00000272359.1	U4	-12.73	1.38e-34	1.76e-31	-0.43	-0.37	Monocyte count;	chr3:196747576	chr3:196747192~196747324:-
BRCA	cis	rs6991838	0.584	rs1053088	ENSG00000272010.1	CTD-3025N20.3	12.73	1.39e-34	1.78e-31	0.4	0.37	Intelligence (multi-trait analysis);	chr8:65603548	chr8:65591850~65592472:-
BRCA	cis	rs34779708	0.931	rs72789609	ENSG00000230534.5	RP11-297A16.2	12.72	1.4e-34	1.79e-31	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35017278	chr10:35098006~35127020:-
BRCA	cis	rs55665837	1	rs10832254	ENSG00000251991.1	RNU7-49P	12.72	1.42e-34	1.81e-31	0.4	0.37	Vitamin D levels;	chr11:14413152	chr11:14478892~14478953:+
BRCA	cis	rs55665837	1	rs11023214	ENSG00000251991.1	RNU7-49P	12.72	1.42e-34	1.81e-31	0.4	0.37	Vitamin D levels;	chr11:14414713	chr11:14478892~14478953:+
BRCA	cis	rs6991838	0.557	rs4737222	ENSG00000272010.1	CTD-3025N20.3	-12.72	1.47e-34	1.89e-31	-0.39	-0.37	Intelligence (multi-trait analysis);	chr8:65587878	chr8:65591850~65592472:-
BRCA	cis	rs34779708	0.931	rs11010101	ENSG00000230534.5	RP11-297A16.2	12.72	1.51e-34	1.93e-31	0.46	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35122117	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.966	rs11010102	ENSG00000230534.5	RP11-297A16.2	12.72	1.51e-34	1.93e-31	0.46	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35122138	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.931	rs7908573	ENSG00000230534.5	RP11-297A16.2	12.72	1.51e-34	1.93e-31	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35020585	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.931	rs17583009	ENSG00000230534.5	RP11-297A16.2	12.72	1.51e-34	1.93e-31	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35031987	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.898	rs11595898	ENSG00000230534.5	RP11-297A16.2	12.72	1.51e-34	1.93e-31	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35037335	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.931	rs35886556	ENSG00000230534.5	RP11-297A16.2	12.72	1.51e-34	1.93e-31	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35046057	chr10:35098006~35127020:-
BRCA	cis	rs1577917	0.545	rs9450325	ENSG00000203875.9	SNHG5	12.72	1.54e-34	1.97e-31	0.42	0.37	Response to antipsychotic treatment;	chr6:85766096	chr6:85660950~85678736:-
BRCA	cis	rs8100891	0.537	rs4805755	ENSG00000267213.4	AC007773.2	12.71	1.56e-34	1.99e-31	0.54	0.37	Neuroticism;	chr19:32363564	chr19:32390050~32405560:-
BRCA	cis	rs8018967	1	rs8018967	ENSG00000258408.1	NT5CP2	-12.71	1.56e-34	1.99e-31	-0.39	-0.37	Blood metabolite ratios;	chr14:73510230	chr14:73539221~73539781:-
BRCA	cis	rs34779708	0.966	rs34776628	ENSG00000230534.5	RP11-297A16.2	12.71	1.58e-34	2.02e-31	0.46	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35137396	chr10:35098006~35127020:-
BRCA	cis	rs7626444	0.605	rs7642801	ENSG00000272359.1	U4	-12.71	1.63e-34	2.08e-31	-0.44	-0.37	Monocyte count;	chr3:196763435	chr3:196747192~196747324:-
BRCA	cis	rs6452524	1	rs6887846	ENSG00000249664.1	CTD-2227C6.2	-12.71	1.67e-34	2.12e-31	-0.43	-0.37	Hypertension (SNP x SNP interaction);	chr5:83140542	chr5:83012285~83013109:-
BRCA	cis	rs765787	0.53	rs4775822	ENSG00000259520.4	CTD-2651B20.3	12.71	1.68e-34	2.14e-31	0.44	0.37	Uric acid levels;	chr15:45234929	chr15:45251580~45279251:-
BRCA	cis	rs765787	0.53	rs11854294	ENSG00000259520.4	CTD-2651B20.3	12.71	1.68e-34	2.14e-31	0.44	0.37	Uric acid levels;	chr15:45235798	chr15:45251580~45279251:-
BRCA	cis	rs7626444	0.584	rs7633044	ENSG00000272359.1	U4	-12.7	1.73e-34	2.21e-31	-0.44	-0.37	Monocyte count;	chr3:196763772	chr3:196747192~196747324:-
BRCA	cis	rs4718428	0.607	rs66954441	ENSG00000226824.5	RP4-756H11.3	-12.7	1.77e-34	2.26e-31	-0.49	-0.37	Corneal structure;	chr7:66904222	chr7:66654538~66669855:+
BRCA	cis	rs1891275	0.576	rs1891272	ENSG00000228701.1	TNKS2-AS1	-12.7	1.85e-34	2.35e-31	-0.48	-0.37	Intelligence (multi-trait analysis);	chr10:91666306	chr10:91782839~91798291:-
BRCA	cis	rs2412819	0.571	rs7174260	ENSG00000249839.1	AC011330.5	-12.7	1.87e-34	2.38e-31	-0.56	-0.37	Lung cancer;	chr15:43751988	chr15:43663654~43684339:-
BRCA	cis	rs10129255	0.5	rs10143242	ENSG00000223648.3	IGHV3-64	12.7	1.88e-34	2.39e-31	0.29	0.37	Kawasaki disease;	chr14:106681814	chr14:106643132~106658258:-
BRCA	cis	rs8040855	0.627	rs11637512	ENSG00000259295.5	CSPG4P12	12.7	1.89e-34	2.41e-31	0.54	0.37	Bulimia nervosa;	chr15:85105528	chr15:85191438~85213905:+
BRCA	cis	rs765787	0.53	rs12917187	ENSG00000259520.4	CTD-2651B20.3	12.69	2e-34	2.54e-31	0.44	0.37	Uric acid levels;	chr15:45246099	chr15:45251580~45279251:-
BRCA	cis	rs765787	0.53	rs11639403	ENSG00000259520.4	CTD-2651B20.3	12.69	2e-34	2.54e-31	0.44	0.37	Uric acid levels;	chr15:45246152	chr15:45251580~45279251:-
BRCA	cis	rs765787	0.53	rs2413782	ENSG00000259520.4	CTD-2651B20.3	12.69	2e-34	2.54e-31	0.44	0.37	Uric acid levels;	chr15:45246292	chr15:45251580~45279251:-
BRCA	cis	rs765787	0.53	rs2413780	ENSG00000259520.4	CTD-2651B20.3	12.69	2e-34	2.54e-31	0.44	0.37	Uric acid levels;	chr15:45246668	chr15:45251580~45279251:-
BRCA	cis	rs765787	0.53	rs11636018	ENSG00000259520.4	CTD-2651B20.3	12.69	2e-34	2.54e-31	0.44	0.37	Uric acid levels;	chr15:45246939	chr15:45251580~45279251:-
BRCA	cis	rs765787	0.556	rs2413778	ENSG00000259520.4	CTD-2651B20.3	12.69	2e-34	2.54e-31	0.44	0.37	Uric acid levels;	chr15:45247199	chr15:45251580~45279251:-
BRCA	cis	rs765787	0.53	rs28756676	ENSG00000259520.4	CTD-2651B20.3	12.69	2e-34	2.54e-31	0.44	0.37	Uric acid levels;	chr15:45248162	chr15:45251580~45279251:-
BRCA	cis	rs34779708	0.966	rs12765038	ENSG00000230534.5	RP11-297A16.2	12.69	2.01e-34	2.55e-31	0.46	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35127585	chr10:35098006~35127020:-
BRCA	cis	rs765787	0.53	rs55771002	ENSG00000259520.4	CTD-2651B20.3	12.69	2.06e-34	2.61e-31	0.44	0.37	Uric acid levels;	chr15:45249368	chr15:45251580~45279251:-
BRCA	cis	rs765787	0.53	rs55920042	ENSG00000259520.4	CTD-2651B20.3	12.69	2.06e-34	2.61e-31	0.44	0.37	Uric acid levels;	chr15:45249379	chr15:45251580~45279251:-
BRCA	cis	rs34779708	0.966	rs4934737	ENSG00000230534.5	RP11-297A16.2	12.69	2.12e-34	2.69e-31	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35223871	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.931	rs4934700	ENSG00000230534.5	RP11-297A16.2	12.69	2.15e-34	2.72e-31	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35021914	chr10:35098006~35127020:-
BRCA	cis	rs2739330	0.828	rs4820572	ENSG00000231271.1	AP000350.8	12.68	2.17e-34	2.75e-31	0.46	0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23949918~23954042:+
BRCA	cis	rs7626444	0.625	rs843535	ENSG00000272359.1	U4	-12.68	2.2e-34	2.78e-31	-0.44	-0.37	Monocyte count;	chr3:196746193	chr3:196747192~196747324:-
BRCA	cis	rs2283792	0.967	rs5755099	ENSG00000224086.5	LL22NC03-86G7.1	-12.68	2.2e-34	2.78e-31	-0.39	-0.37	Multiple sclerosis;	chr22:21770751	chr22:21938293~21977632:+
BRCA	cis	rs3096299	0.685	rs4329923	ENSG00000274627.1	RP11-104N10.2	12.68	2.29e-34	2.9e-31	0.39	0.37	Multiple myeloma (IgH translocation);	chr16:89493770	chr16:89516797~89522217:+
BRCA	cis	rs2117029	0.587	rs1865157	ENSG00000258017.1	RP11-386G11.10	-12.68	2.32e-34	2.94e-31	-0.49	-0.37	Intelligence (multi-trait analysis);	chr12:49129003	chr12:49127782~49147869:+
BRCA	cis	rs34779708	0.931	rs67976880	ENSG00000230534.5	RP11-297A16.2	12.68	2.33e-34	2.95e-31	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35083333	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.931	rs72789687	ENSG00000230534.5	RP11-297A16.2	12.68	2.33e-34	2.95e-31	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35083561	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.931	rs35997236	ENSG00000230534.5	RP11-297A16.2	12.68	2.33e-34	2.95e-31	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35087762	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.931	rs4934719	ENSG00000230534.5	RP11-297A16.2	12.68	2.33e-34	2.95e-31	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35087841	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.931	rs4934720	ENSG00000230534.5	RP11-297A16.2	12.68	2.33e-34	2.95e-31	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35087872	chr10:35098006~35127020:-
BRCA	cis	rs67311347	1	rs7641495	ENSG00000223797.4	ENTPD3-AS1	-12.68	2.34e-34	2.96e-31	-0.41	-0.37	Renal cell carcinoma;	chr3:40453199	chr3:40313802~40453329:-
BRCA	cis	rs765787	0.53	rs28396110	ENSG00000259520.4	CTD-2651B20.3	12.68	2.35e-34	2.97e-31	0.44	0.37	Uric acid levels;	chr15:45244711	chr15:45251580~45279251:-
BRCA	cis	rs765787	0.53	rs4775834	ENSG00000259520.4	CTD-2651B20.3	12.68	2.35e-34	2.97e-31	0.44	0.37	Uric acid levels;	chr15:45245313	chr15:45251580~45279251:-
BRCA	cis	rs765787	0.53	rs4775835	ENSG00000259520.4	CTD-2651B20.3	12.68	2.35e-34	2.97e-31	0.44	0.37	Uric acid levels;	chr15:45245355	chr15:45251580~45279251:-
BRCA	cis	rs765787	0.53	rs4775836	ENSG00000259520.4	CTD-2651B20.3	12.68	2.35e-34	2.97e-31	0.44	0.37	Uric acid levels;	chr15:45245466	chr15:45251580~45279251:-
BRCA	cis	rs765787	0.53	rs4775837	ENSG00000259520.4	CTD-2651B20.3	12.68	2.35e-34	2.97e-31	0.44	0.37	Uric acid levels;	chr15:45245486	chr15:45251580~45279251:-
BRCA	cis	rs4718428	0.705	rs28648401	ENSG00000226824.5	RP4-756H11.3	-12.68	2.4e-34	3.04e-31	-0.49	-0.37	Corneal structure;	chr7:66902145	chr7:66654538~66669855:+
BRCA	cis	rs2134046	0.555	rs11854483	ENSG00000278603.1	RP13-608F4.5	12.68	2.4e-34	3.04e-31	0.48	0.37	Cognitive ability;	chr15:82267217	chr15:82472203~82472426:+
BRCA	cis	rs34779708	0.931	rs4934721	ENSG00000230534.5	RP11-297A16.2	12.67	2.43e-34	3.07e-31	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35088787	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.931	rs2148482	ENSG00000230534.5	RP11-297A16.2	12.67	2.43e-34	3.07e-31	0.46	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35059982	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.931	rs11593858	ENSG00000230534.5	RP11-297A16.2	12.67	2.47e-34	3.12e-31	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35092445	chr10:35098006~35127020:-
BRCA	cis	rs6452524	0.967	rs2974445	ENSG00000249664.1	CTD-2227C6.2	-12.67	2.54e-34	3.21e-31	-0.44	-0.37	Hypertension (SNP x SNP interaction);	chr5:83185561	chr5:83012285~83013109:-
BRCA	cis	rs4718428	0.705	rs10267335	ENSG00000226824.5	RP4-756H11.3	-12.67	2.56e-34	3.23e-31	-0.49	-0.37	Corneal structure;	chr7:66938233	chr7:66654538~66669855:+
BRCA	cis	rs17711722	0.528	rs73138179	ENSG00000164669.11	INTS4P1	-12.67	2.6e-34	3.28e-31	-0.48	-0.37	Calcium levels;	chr7:65829495	chr7:65141225~65234216:+
BRCA	cis	rs10129255	0.5	rs9324092	ENSG00000223648.3	IGHV3-64	-12.67	2.63e-34	3.31e-31	-0.29	-0.37	Kawasaki disease;	chr14:106683806	chr14:106643132~106658258:-
BRCA	cis	rs34779708	0.897	rs34481177	ENSG00000230534.5	RP11-297A16.2	12.67	2.64e-34	3.33e-31	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35091985	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.931	rs4934723	ENSG00000230534.5	RP11-297A16.2	12.67	2.64e-34	3.33e-31	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35092835	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.931	rs72789690	ENSG00000230534.5	RP11-297A16.2	12.67	2.64e-34	3.33e-31	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35093889	chr10:35098006~35127020:-
BRCA	cis	rs7182621	0.639	rs12906068	ENSG00000259363.4	CTD-2054N24.2	-12.66	2.73e-34	3.44e-31	-0.49	-0.37	Colonoscopy-negative controls vs population controls;	chr15:99873422	chr15:99807023~99877148:+
BRCA	cis	rs3823536	0.583	rs1874327	ENSG00000275106.1	RP11-309L24.10	-12.66	2.75e-34	3.46e-31	-0.48	-0.37	Sjögren's syndrome;	chr7:128945322	chr7:128952527~128953316:-
BRCA	cis	rs34779708	0.966	rs10827492	ENSG00000230534.5	RP11-297A16.2	-12.66	2.78e-34	3.5e-31	-0.46	-0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35140897	chr10:35098006~35127020:-
BRCA	cis	rs3823536	0.505	rs3925323	ENSG00000275106.1	RP11-309L24.10	-12.66	2.82e-34	3.55e-31	-0.48	-0.37	Sjögren's syndrome;	chr7:128952187	chr7:128952527~128953316:-
BRCA	cis	rs3823536	0.583	rs10954214	ENSG00000275106.1	RP11-309L24.10	-12.66	2.86e-34	3.6e-31	-0.48	-0.37	Sjögren's syndrome;	chr7:128949579	chr7:128952527~128953316:-
BRCA	cis	rs8059260	0.604	rs16957984	ENSG00000274038.1	RP11-66H6.4	-12.66	2.89e-34	3.63e-31	-0.58	-0.37	Alcohol consumption over the past year;	chr16:11051105	chr16:11056556~11057034:+
BRCA	cis	rs34779708	0.931	rs66887762	ENSG00000230534.5	RP11-297A16.2	12.66	2.95e-34	3.71e-31	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35041649	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.931	rs4934524	ENSG00000230534.5	RP11-297A16.2	12.66	2.98e-34	3.75e-31	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:34981993	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.931	rs4934693	ENSG00000230534.5	RP11-297A16.2	12.66	2.98e-34	3.75e-31	0.47	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:34982916	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.931	rs59418206	ENSG00000230534.5	RP11-297A16.2	12.66	3e-34	3.78e-31	0.47	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35042696	chr10:35098006~35127020:-
BRCA	cis	rs8040855	0.756	rs12909477	ENSG00000259295.5	CSPG4P12	-12.66	3e-34	3.78e-31	-0.54	-0.36	Bulimia nervosa;	chr15:85146644	chr15:85191438~85213905:+
BRCA	cis	rs67311347	1	rs1454497	ENSG00000223797.4	ENTPD3-AS1	-12.65	3.06e-34	3.84e-31	-0.41	-0.36	Renal cell carcinoma;	chr3:40454835	chr3:40313802~40453329:-
BRCA	cis	rs8040855	0.627	rs4980357	ENSG00000259295.5	CSPG4P12	12.65	3.15e-34	3.95e-31	0.53	0.36	Bulimia nervosa;	chr15:85064878	chr15:85191438~85213905:+
BRCA	cis	rs8040855	0.627	rs4980356	ENSG00000259295.5	CSPG4P12	12.65	3.15e-34	3.95e-31	0.53	0.36	Bulimia nervosa;	chr15:85064901	chr15:85191438~85213905:+
BRCA	cis	rs765787	0.53	rs2899381	ENSG00000259520.4	CTD-2651B20.3	12.65	3.2e-34	4.01e-31	0.44	0.36	Uric acid levels;	chr15:45237432	chr15:45251580~45279251:-
BRCA	cis	rs34779708	0.931	rs2384283	ENSG00000230534.5	RP11-297A16.2	12.65	3.2e-34	4.02e-31	0.47	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35037861	chr10:35098006~35127020:-
BRCA	cis	rs7626444	0.625	rs843531	ENSG00000272359.1	U4	-12.64	3.44e-34	4.31e-31	-0.43	-0.36	Monocyte count;	chr3:196754900	chr3:196747192~196747324:-
BRCA	cis	rs1501911	0.53	rs161941	ENSG00000248489.1	CTD-2007H13.3	-12.64	3.48e-34	4.37e-31	-0.41	-0.36	Lung function (FEV1/FVC);	chr5:98863500	chr5:98929171~98995013:+
BRCA	cis	rs765787	0.53	rs2413784	ENSG00000259520.4	CTD-2651B20.3	12.64	3.56e-34	4.46e-31	0.44	0.36	Uric acid levels;	chr15:45238318	chr15:45251580~45279251:-
BRCA	cis	rs1555322	0.505	rs591590	ENSG00000126005.14	MMP24-AS1	12.63	3.76e-34	4.71e-31	0.49	0.36	Attention deficit hyperactivity disorder;	chr20:35278225	chr20:35216462~35278131:-
BRCA	cis	rs765787	0.53	rs11636440	ENSG00000259520.4	CTD-2651B20.3	12.63	3.82e-34	4.78e-31	0.44	0.36	Uric acid levels;	chr15:45243784	chr15:45251580~45279251:-
BRCA	cis	rs10256972	0.758	rs7799391	ENSG00000229043.2	AC091729.9	-12.63	3.87e-34	4.85e-31	-0.47	-0.36	Endometriosis;Longevity;	chr7:1042930	chr7:1160374~1165267:+
BRCA	cis	rs2019137	0.868	rs3748916	ENSG00000274877.1	RP11-65I12.1	12.63	3.88e-34	4.86e-31	0.47	0.36	Lymphocyte counts;	chr2:113226456	chr2:113237595~113240825:+
BRCA	cis	rs8059260	0.604	rs78753859	ENSG00000274038.1	RP11-66H6.4	-12.63	3.88e-34	4.86e-31	-0.57	-0.36	Alcohol consumption over the past year;	chr16:11052774	chr16:11056556~11057034:+
BRCA	cis	rs3823536	0.583	rs7800687	ENSG00000275106.1	RP11-309L24.10	-12.63	4.02e-34	5.03e-31	-0.48	-0.36	Sjögren's syndrome;	chr7:128953665	chr7:128952527~128953316:-
BRCA	cis	rs765787	0.53	rs28414644	ENSG00000259520.4	CTD-2651B20.3	12.63	4.04e-34	5.05e-31	0.44	0.36	Uric acid levels;	chr15:45244523	chr15:45251580~45279251:-
BRCA	cis	rs34779708	0.897	rs4934529	ENSG00000230534.5	RP11-297A16.2	12.63	4.07e-34	5.09e-31	0.47	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35013448	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.897	rs12830	ENSG00000230534.5	RP11-297A16.2	12.63	4.07e-34	5.09e-31	0.47	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35013777	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.931	rs7920095	ENSG00000230534.5	RP11-297A16.2	12.63	4.07e-34	5.09e-31	0.47	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35014406	chr10:35098006~35127020:-
BRCA	cis	rs35160687	0.842	rs1863051	ENSG00000273080.1	RP11-301O19.1	12.63	4.13e-34	5.16e-31	0.41	0.36	Night sleep phenotypes;	chr2:86332025	chr2:86195590~86196049:+
BRCA	cis	rs34779708	0.966	rs11010129	ENSG00000230534.5	RP11-297A16.2	12.63	4.18e-34	5.23e-31	0.47	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35221894	chr10:35098006~35127020:-
BRCA	cis	rs7626444	0.647	rs843537	ENSG00000272359.1	U4	-12.62	4.25e-34	5.32e-31	-0.44	-0.36	Monocyte count;	chr3:196746532	chr3:196747192~196747324:-
BRCA	cis	rs3823536	0.583	rs2280714	ENSG00000275106.1	RP11-309L24.10	-12.62	4.35e-34	5.43e-31	-0.48	-0.36	Sjögren's syndrome;	chr7:128954671	chr7:128952527~128953316:-
BRCA	cis	rs2019137	1	rs2019137	ENSG00000274877.1	RP11-65I12.1	12.62	4.42e-34	5.53e-31	0.47	0.36	Lymphocyte counts;	chr2:113216055	chr2:113237595~113240825:+
BRCA	cis	rs8059260	0.604	rs76969865	ENSG00000274038.1	RP11-66H6.4	-12.62	4.52e-34	5.64e-31	-0.57	-0.36	Alcohol consumption over the past year;	chr16:11050092	chr16:11056556~11057034:+
BRCA	cis	rs7626444	0.565	rs7613010	ENSG00000272359.1	U4	-12.61	4.76e-34	5.93e-31	-0.44	-0.36	Monocyte count;	chr3:196763350	chr3:196747192~196747324:-
BRCA	cis	rs55665837	1	rs10832268	ENSG00000251991.1	RNU7-49P	12.61	4.78e-34	5.96e-31	0.4	0.36	Vitamin D levels;	chr11:14443522	chr11:14478892~14478953:+
BRCA	cis	rs55665837	1	rs10832269	ENSG00000251991.1	RNU7-49P	12.61	4.78e-34	5.96e-31	0.4	0.36	Vitamin D levels;	chr11:14443523	chr11:14478892~14478953:+
BRCA	cis	rs55665837	1	rs10832271	ENSG00000251991.1	RNU7-49P	12.61	4.78e-34	5.96e-31	0.4	0.36	Vitamin D levels;	chr11:14445373	chr11:14478892~14478953:+
BRCA	cis	rs992157	0.71	rs13026485	ENSG00000261338.2	RP11-378A13.1	-12.61	4.96e-34	6.18e-31	-0.37	-0.36	Colorectal cancer;	chr2:218193261	chr2:218255319~218257366:+
BRCA	cis	rs765787	0.53	rs1706832	ENSG00000259520.4	CTD-2651B20.3	12.61	4.98e-34	6.21e-31	0.44	0.36	Uric acid levels;	chr15:45224975	chr15:45251580~45279251:-
BRCA	cis	rs4380275	0.782	rs4854369	ENSG00000272342.1	RP13-539J13.1	12.61	5.05e-34	6.29e-31	0.44	0.36	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:752530	chr2:739588~740164:-
BRCA	cis	rs1891275	0.551	rs7900863	ENSG00000228701.1	TNKS2-AS1	-12.61	5.09e-34	6.35e-31	-0.47	-0.36	Intelligence (multi-trait analysis);	chr10:91665737	chr10:91782839~91798291:-
BRCA	cis	rs1891275	0.551	rs4933692	ENSG00000228701.1	TNKS2-AS1	-12.61	5.17e-34	6.44e-31	-0.47	-0.36	Intelligence (multi-trait analysis);	chr10:91664876	chr10:91782839~91798291:-
BRCA	cis	rs1426063	0.614	rs115690958	ENSG00000260265.1	RP11-44F21.5	12.61	5.19e-34	6.46e-31	0.88	0.36	QT interval;	chr4:75078364	chr4:75081702~75084717:-
BRCA	cis	rs8100891	0.537	rs11880569	ENSG00000267213.4	AC007773.2	-12.61	5.22e-34	6.51e-31	-0.55	-0.36	Neuroticism;	chr19:32478348	chr19:32390050~32405560:-
BRCA	cis	rs55665837	1	rs12295723	ENSG00000251991.1	RNU7-49P	12.59	5.89e-34	7.32e-31	0.4	0.36	Vitamin D levels;	chr11:14428655	chr11:14478892~14478953:+
BRCA	cis	rs55665837	1	rs12295888	ENSG00000251991.1	RNU7-49P	12.59	5.89e-34	7.32e-31	0.4	0.36	Vitamin D levels;	chr11:14428985	chr11:14478892~14478953:+
BRCA	cis	rs765787	0.53	rs2413785	ENSG00000259520.4	CTD-2651B20.3	12.59	5.93e-34	7.37e-31	0.44	0.36	Uric acid levels;	chr15:45238183	chr15:45251580~45279251:-
BRCA	cis	rs1891275	0.551	rs2421629	ENSG00000228701.1	TNKS2-AS1	-12.59	6.01e-34	7.47e-31	-0.47	-0.36	Intelligence (multi-trait analysis);	chr10:91664018	chr10:91782839~91798291:-
BRCA	cis	rs7626444	0.563	rs2686598	ENSG00000272359.1	U4	-12.59	6.01e-34	7.47e-31	-0.43	-0.36	Monocyte count;	chr3:196760848	chr3:196747192~196747324:-
BRCA	cis	rs7626444	0.625	rs9877495	ENSG00000272359.1	U4	-12.59	6.04e-34	7.5e-31	-0.43	-0.36	Monocyte count;	chr3:196756409	chr3:196747192~196747324:-
BRCA	cis	rs7626444	0.625	rs2686599	ENSG00000272359.1	U4	-12.59	6.04e-34	7.5e-31	-0.43	-0.36	Monocyte count;	chr3:196756923	chr3:196747192~196747324:-
BRCA	cis	rs7626444	0.625	rs1403101	ENSG00000272359.1	U4	-12.59	6.04e-34	7.5e-31	-0.43	-0.36	Monocyte count;	chr3:196758203	chr3:196747192~196747324:-
BRCA	cis	rs7626444	0.628	rs1684464	ENSG00000272359.1	U4	-12.59	6.04e-34	7.5e-31	-0.43	-0.36	Monocyte count;	chr3:196758643	chr3:196747192~196747324:-
BRCA	cis	rs7626444	0.625	rs1486358	ENSG00000272359.1	U4	-12.59	6.04e-34	7.5e-31	-0.43	-0.36	Monocyte count;	chr3:196758719	chr3:196747192~196747324:-
BRCA	cis	rs4380275	0.782	rs4468850	ENSG00000272342.1	RP13-539J13.1	12.59	6.07e-34	7.54e-31	0.44	0.36	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:749467	chr2:739588~740164:-
BRCA	cis	rs7849270	0.959	rs3118628	ENSG00000268707.1	RP11-247A12.7	12.59	6.09e-34	7.56e-31	0.5	0.36	Blood metabolite ratios;	chr9:129123000	chr9:129170434~129170940:+
BRCA	cis	rs7849270	1	rs6478867	ENSG00000268707.1	RP11-247A12.7	12.59	6.27e-34	7.78e-31	0.45	0.36	Blood metabolite ratios;	chr9:129141644	chr9:129170434~129170940:+
BRCA	cis	rs73086581	0.524	rs2253977	ENSG00000229539.1	RP11-119B16.2	-12.59	6.28e-34	7.8e-31	-0.47	-0.36	Response to antidepressants in depression;	chr20:3958493	chr20:3888239~3888868:-
BRCA	cis	rs17711722	0.522	rs4642526	ENSG00000226824.5	RP4-756H11.3	-12.59	6.34e-34	7.87e-31	-0.45	-0.36	Calcium levels;	chr7:65751755	chr7:66654538~66669855:+
BRCA	cis	rs2019137	0.967	rs895412	ENSG00000274877.1	RP11-65I12.1	12.58	6.57e-34	8.14e-31	0.47	0.36	Lymphocyte counts;	chr2:113216387	chr2:113237595~113240825:+
BRCA	cis	rs34779708	0.966	rs17591163	ENSG00000230534.5	RP11-297A16.2	12.58	6.57e-34	8.14e-31	0.48	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35176351	chr10:35098006~35127020:-
BRCA	cis	rs55665837	1	rs10047429	ENSG00000251991.1	RNU7-49P	12.58	6.71e-34	8.31e-31	0.4	0.36	Vitamin D levels;	chr11:14417486	chr11:14478892~14478953:+
BRCA	cis	rs55665837	1	rs10047457	ENSG00000251991.1	RNU7-49P	12.58	6.71e-34	8.31e-31	0.4	0.36	Vitamin D levels;	chr11:14417913	chr11:14478892~14478953:+
BRCA	cis	rs1061377	0.748	rs12649085	ENSG00000249207.1	RP11-360F5.1	-12.58	6.98e-34	8.65e-31	-0.42	-0.36	Uric acid levels;	chr4:39106459	chr4:39112677~39126818:-
BRCA	cis	rs765787	0.53	rs1706835	ENSG00000259520.4	CTD-2651B20.3	12.58	7.21e-34	8.93e-31	0.44	0.36	Uric acid levels;	chr15:45225686	chr15:45251580~45279251:-
BRCA	cis	rs765787	0.53	rs1631533	ENSG00000259520.4	CTD-2651B20.3	12.58	7.21e-34	8.93e-31	0.44	0.36	Uric acid levels;	chr15:45226430	chr15:45251580~45279251:-
BRCA	cis	rs34779708	0.966	rs1213392	ENSG00000230534.5	RP11-297A16.2	12.58	7.23e-34	8.95e-31	0.44	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35141357	chr10:35098006~35127020:-
BRCA	cis	rs1891275	0.588	rs6583782	ENSG00000228701.1	TNKS2-AS1	-12.57	7.31e-34	9.05e-31	-0.47	-0.36	Intelligence (multi-trait analysis);	chr10:91666022	chr10:91782839~91798291:-
BRCA	cis	rs2739330	0.789	rs5760109	ENSG00000231271.1	AP000350.8	12.57	7.37e-34	9.13e-31	0.45	0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23949918~23954042:+
BRCA	cis	rs765787	0.53	rs7165889	ENSG00000259520.4	CTD-2651B20.3	12.57	7.55e-34	9.34e-31	0.44	0.36	Uric acid levels;	chr15:45239442	chr15:45251580~45279251:-
BRCA	cis	rs765787	0.53	rs11070451	ENSG00000259520.4	CTD-2651B20.3	12.57	7.55e-34	9.34e-31	0.44	0.36	Uric acid levels;	chr15:45241343	chr15:45251580~45279251:-
BRCA	cis	rs765787	0.53	rs28897155	ENSG00000259520.4	CTD-2651B20.3	12.57	7.55e-34	9.34e-31	0.44	0.36	Uric acid levels;	chr15:45241776	chr15:45251580~45279251:-
BRCA	cis	rs3823536	0.583	rs10236569	ENSG00000275106.1	RP11-309L24.10	-12.57	7.56e-34	9.35e-31	-0.47	-0.36	Sjögren's syndrome;	chr7:128957533	chr7:128952527~128953316:-
BRCA	cis	rs11690935	0.788	rs10201053	ENSG00000228389.1	AC068039.4	12.56	8.12e-34	1e-30	0.46	0.36	Schizophrenia;	chr2:172024653	chr2:171773482~171775844:+
BRCA	cis	rs8040855	0.86	rs7172266	ENSG00000259295.5	CSPG4P12	-12.56	8.22e-34	1.02e-30	-0.47	-0.36	Bulimia nervosa;	chr15:85172982	chr15:85191438~85213905:+
BRCA	cis	rs34779708	0.931	rs7079205	ENSG00000230534.5	RP11-297A16.2	12.56	8.24e-34	1.02e-30	0.46	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35035691	chr10:35098006~35127020:-
BRCA	cis	rs765787	0.53	rs4775831	ENSG00000259520.4	CTD-2651B20.3	12.56	8.53e-34	1.05e-30	0.44	0.36	Uric acid levels;	chr15:45242524	chr15:45251580~45279251:-
BRCA	cis	rs765787	0.53	rs4775832	ENSG00000259520.4	CTD-2651B20.3	12.56	8.53e-34	1.05e-30	0.44	0.36	Uric acid levels;	chr15:45242630	chr15:45251580~45279251:-
BRCA	cis	rs34779708	0.931	rs11597483	ENSG00000230534.5	RP11-297A16.2	12.56	8.65e-34	1.07e-30	0.47	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:34996189	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.931	rs35317849	ENSG00000230534.5	RP11-297A16.2	12.56	8.65e-34	1.07e-30	0.47	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:34996793	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.931	rs34304999	ENSG00000230534.5	RP11-297A16.2	12.56	8.73e-34	1.08e-30	0.47	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35076777	chr10:35098006~35127020:-
BRCA	cis	rs7849270	0.959	rs9408986	ENSG00000268707.1	RP11-247A12.7	12.56	8.78e-34	1.08e-30	0.5	0.36	Blood metabolite ratios;	chr9:129126156	chr9:129170434~129170940:+
BRCA	cis	rs858239	0.669	rs6461688	ENSG00000226816.2	AC005082.12	12.56	8.8e-34	1.09e-30	0.42	0.36	Cerebrospinal fluid biomarker levels;	chr7:23076996	chr7:23206013~23208045:+
BRCA	cis	rs8040855	0.627	rs12904238	ENSG00000259295.5	CSPG4P12	12.55	9.06e-34	1.12e-30	0.52	0.36	Bulimia nervosa;	chr15:85096610	chr15:85191438~85213905:+
BRCA	cis	rs2564921	0.73	rs2564922	ENSG00000242142.1	SERBP1P3	12.55	9.11e-34	1.12e-30	0.42	0.36	Height;	chr3:53091453	chr3:53064283~53065091:-
BRCA	cis	rs8100891	0.537	rs73034207	ENSG00000267213.4	AC007773.2	-12.55	9.14e-34	1.13e-30	-0.56	-0.36	Neuroticism;	chr19:32384863	chr19:32390050~32405560:-
BRCA	cis	rs6452524	1	rs10042854	ENSG00000249664.1	CTD-2227C6.2	-12.55	9.37e-34	1.15e-30	-0.42	-0.36	Hypertension (SNP x SNP interaction);	chr5:83143876	chr5:83012285~83013109:-
BRCA	cis	rs34779708	0.931	rs4351760	ENSG00000230534.5	RP11-297A16.2	12.55	9.45e-34	1.16e-30	0.47	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:34991326	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.898	rs4934695	ENSG00000230534.5	RP11-297A16.2	12.55	9.45e-34	1.16e-30	0.47	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:34991677	chr10:35098006~35127020:-
BRCA	cis	rs765787	0.53	rs1706837	ENSG00000259520.4	CTD-2651B20.3	12.55	9.52e-34	1.17e-30	0.44	0.36	Uric acid levels;	chr15:45226838	chr15:45251580~45279251:-
BRCA	cis	rs8040855	0.627	rs4843019	ENSG00000259295.5	CSPG4P12	-12.55	9.83e-34	1.21e-30	-0.53	-0.36	Bulimia nervosa;	chr15:85101228	chr15:85191438~85213905:+
BRCA	cis	rs4718428	0.705	rs68168107	ENSG00000226824.5	RP4-756H11.3	-12.55	9.93e-34	1.22e-30	-0.49	-0.36	Corneal structure;	chr7:66790251	chr7:66654538~66669855:+
BRCA	cis	rs2283792	1	rs9607287	ENSG00000224086.5	LL22NC03-86G7.1	-12.55	1e-33	1.23e-30	-0.38	-0.36	Multiple sclerosis;	chr22:21809136	chr22:21938293~21977632:+
BRCA	cis	rs2283792	0.967	rs5749998	ENSG00000224086.5	LL22NC03-86G7.1	-12.54	1.02e-33	1.25e-30	-0.38	-0.36	Multiple sclerosis;	chr22:21808085	chr22:21938293~21977632:+
BRCA	cis	rs34779708	0.931	rs11597392	ENSG00000230534.5	RP11-297A16.2	12.54	1.03e-33	1.27e-30	0.47	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:34999647	chr10:35098006~35127020:-
BRCA	cis	rs8062405	0.54	rs151226	ENSG00000259982.1	CDC37P1	12.54	1.06e-33	1.3e-30	0.42	0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28538502	chr16:28700294~28701540:-
BRCA	cis	rs801193	0.591	rs9986881	ENSG00000226824.5	RP4-756H11.3	-12.54	1.07e-33	1.32e-30	-0.45	-0.36	Aortic root size;	chr7:66708053	chr7:66654538~66669855:+
BRCA	cis	rs11168854	0.651	rs12227770	ENSG00000258017.1	RP11-386G11.10	-12.54	1.1e-33	1.35e-30	-0.49	-0.36	Body mass index;	chr12:49183065	chr12:49127782~49147869:+
BRCA	cis	rs67311347	1	rs962847	ENSG00000223797.4	ENTPD3-AS1	-12.54	1.11e-33	1.36e-30	-0.4	-0.36	Renal cell carcinoma;	chr3:40453665	chr3:40313802~40453329:-
BRCA	cis	rs9322193	0.607	rs9322229	ENSG00000268592.3	RAET1E-AS1	12.54	1.12e-33	1.37e-30	0.48	0.36	Lung cancer;	chr6:149908949	chr6:149863494~149919507:+
BRCA	cis	rs34779708	0.897	rs9787566	ENSG00000230534.5	RP11-297A16.2	12.53	1.17e-33	1.43e-30	0.47	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:34990527	chr10:35098006~35127020:-
BRCA	cis	rs1891275	0.54	rs10732773	ENSG00000228701.1	TNKS2-AS1	-12.53	1.17e-33	1.44e-30	-0.47	-0.36	Intelligence (multi-trait analysis);	chr10:91656468	chr10:91782839~91798291:-
BRCA	cis	rs7626444	0.625	rs1357287	ENSG00000272359.1	U4	-12.53	1.22e-33	1.49e-30	-0.43	-0.36	Monocyte count;	chr3:196758096	chr3:196747192~196747324:-
BRCA	cis	rs10885997	0.626	rs2301179	ENSG00000266200.5	PNLIPRP2	-12.53	1.23e-33	1.5e-30	-0.42	-0.36	Phospholipid levels (plasma);	chr10:116645109	chr10:116620953~116645143:+
BRCA	cis	rs765787	0.53	rs4442750	ENSG00000259520.4	CTD-2651B20.3	12.53	1.23e-33	1.51e-30	0.44	0.36	Uric acid levels;	chr15:45243130	chr15:45251580~45279251:-
BRCA	cis	rs765787	0.53	rs4444275	ENSG00000259520.4	CTD-2651B20.3	12.53	1.23e-33	1.51e-30	0.44	0.36	Uric acid levels;	chr15:45243149	chr15:45251580~45279251:-
BRCA	cis	rs765787	0.53	rs4270107	ENSG00000259520.4	CTD-2651B20.3	12.53	1.23e-33	1.51e-30	0.44	0.36	Uric acid levels;	chr15:45243152	chr15:45251580~45279251:-
BRCA	cis	rs765787	0.53	rs4544188	ENSG00000259520.4	CTD-2651B20.3	12.53	1.23e-33	1.51e-30	0.44	0.36	Uric acid levels;	chr15:45243195	chr15:45251580~45279251:-
BRCA	cis	rs1155848	0.571	rs6563125	ENSG00000227354.5	RBM26-AS1	12.52	1.28e-33	1.57e-30	0.71	0.36	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79630618	chr13:79406309~79424328:+
BRCA	cis	rs7208859	0.573	rs216443	ENSG00000263531.1	RP13-753N3.1	12.52	1.3e-33	1.6e-30	0.73	0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30604853	chr17:30863921~30864940:-
BRCA	cis	rs765787	0.53	rs7167389	ENSG00000259520.4	CTD-2651B20.3	12.52	1.33e-33	1.63e-30	0.44	0.36	Uric acid levels;	chr15:45243485	chr15:45251580~45279251:-
BRCA	cis	rs765787	0.53	rs2413776	ENSG00000259520.4	CTD-2651B20.3	12.51	1.43e-33	1.75e-30	0.44	0.36	Uric acid levels;	chr15:45251972	chr15:45251580~45279251:-
BRCA	cis	rs10256972	0.721	rs4720249	ENSG00000229043.2	AC091729.9	-12.51	1.45e-33	1.77e-30	-0.47	-0.36	Endometriosis;Longevity;	chr7:1032927	chr7:1160374~1165267:+
BRCA	cis	rs7044106	0.664	rs7861679	ENSG00000226752.6	PSMD5-AS1	12.51	1.48e-33	1.81e-30	0.44	0.36	Hip circumference adjusted for BMI;	chr9:120613311	chr9:120824828~120854385:+
BRCA	cis	rs34779708	0.931	rs11592404	ENSG00000230534.5	RP11-297A16.2	12.51	1.5e-33	1.83e-30	0.47	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:34984548	chr10:35098006~35127020:-
BRCA	cis	rs1426063	0.614	rs78681370	ENSG00000260265.1	RP11-44F21.5	12.51	1.52e-33	1.86e-30	0.88	0.36	QT interval;	chr4:75081556	chr4:75081702~75084717:-
BRCA	cis	rs1426063	0.614	rs17000212	ENSG00000260265.1	RP11-44F21.5	12.51	1.52e-33	1.86e-30	0.88	0.36	QT interval;	chr4:75081611	chr4:75081702~75084717:-
BRCA	cis	rs1426063	0.614	rs77018380	ENSG00000260265.1	RP11-44F21.5	12.51	1.52e-33	1.86e-30	0.88	0.36	QT interval;	chr4:75081621	chr4:75081702~75084717:-
BRCA	cis	rs34779708	0.931	rs79749947	ENSG00000230534.5	RP11-297A16.2	12.51	1.55e-33	1.89e-30	0.47	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:34988153	chr10:35098006~35127020:-
BRCA	cis	rs11673344	0.566	rs1968251	ENSG00000226686.6	LINC01535	-12.51	1.55e-33	1.9e-30	-0.47	-0.36	Obesity-related traits;	chr19:37457005	chr19:37251912~37265535:+
BRCA	cis	rs8040855	0.627	rs3816105	ENSG00000259295.5	CSPG4P12	12.5	1.6e-33	1.96e-30	0.53	0.36	Bulimia nervosa;	chr15:85097680	chr15:85191438~85213905:+
BRCA	cis	rs8040855	0.627	rs2304418	ENSG00000259295.5	CSPG4P12	12.5	1.6e-33	1.96e-30	0.53	0.36	Bulimia nervosa;	chr15:85097752	chr15:85191438~85213905:+
BRCA	cis	rs7945705	0.714	rs2653570	ENSG00000254860.4	TMEM9B-AS1	12.5	1.6e-33	1.96e-30	0.32	0.36	Hemoglobin concentration;	chr11:8966276	chr11:8964675~8977527:+
BRCA	cis	rs1891275	0.551	rs7908678	ENSG00000228701.1	TNKS2-AS1	12.5	1.64e-33	2e-30	0.46	0.36	Intelligence (multi-trait analysis);	chr10:91659253	chr10:91782839~91798291:-
BRCA	cis	rs34779708	0.966	rs12761675	ENSG00000230534.5	RP11-297A16.2	-12.5	1.67e-33	2.03e-30	-0.46	-0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35149409	chr10:35098006~35127020:-
BRCA	cis	rs2117029	0.619	rs10747562	ENSG00000258017.1	RP11-386G11.10	-12.5	1.7e-33	2.07e-30	-0.49	-0.36	Intelligence (multi-trait analysis);	chr12:49111401	chr12:49127782~49147869:+
BRCA	cis	rs2117029	0.619	rs11168862	ENSG00000258017.1	RP11-386G11.10	-12.5	1.7e-33	2.07e-30	-0.49	-0.36	Intelligence (multi-trait analysis);	chr12:49112175	chr12:49127782~49147869:+
BRCA	cis	rs7849270	0.959	rs2900271	ENSG00000268707.1	RP11-247A12.7	12.5	1.72e-33	2.09e-30	0.48	0.36	Blood metabolite ratios;	chr9:129132655	chr9:129170434~129170940:+
BRCA	cis	rs1061377	0.748	rs6816202	ENSG00000249207.1	RP11-360F5.1	-12.5	1.74e-33	2.11e-30	-0.42	-0.36	Uric acid levels;	chr4:39106868	chr4:39112677~39126818:-
BRCA	cis	rs1061377	0.748	rs6842561	ENSG00000249207.1	RP11-360F5.1	-12.5	1.74e-33	2.11e-30	-0.42	-0.36	Uric acid levels;	chr4:39106873	chr4:39112677~39126818:-
BRCA	cis	rs34779708	0.966	rs2505639	ENSG00000230534.5	RP11-297A16.2	-12.5	1.74e-33	2.12e-30	-0.44	-0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35185493	chr10:35098006~35127020:-
BRCA	cis	rs10129255	0.5	rs4774008	ENSG00000223648.3	IGHV3-64	12.49	1.75e-33	2.13e-30	0.29	0.36	Kawasaki disease;	chr14:106681273	chr14:106643132~106658258:-
BRCA	cis	rs8040855	0.69	rs8041189	ENSG00000259295.5	CSPG4P12	-12.49	1.78e-33	2.17e-30	-0.54	-0.36	Bulimia nervosa;	chr15:85143096	chr15:85191438~85213905:+
BRCA	cis	rs11673344	0.734	rs1234250	ENSG00000226686.6	LINC01535	-12.49	1.79e-33	2.17e-30	-0.49	-0.36	Obesity-related traits;	chr19:37199518	chr19:37251912~37265535:+
BRCA	cis	rs8040855	0.627	rs1532776	ENSG00000259295.5	CSPG4P12	12.49	1.87e-33	2.27e-30	0.53	0.36	Bulimia nervosa;	chr15:85081383	chr15:85191438~85213905:+
BRCA	cis	rs2739330	0.828	rs5760107	ENSG00000231271.1	AP000350.8	12.49	1.87e-33	2.27e-30	0.45	0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23949918~23954042:+
BRCA	cis	rs6452524	0.967	rs2974448	ENSG00000249664.1	CTD-2227C6.2	12.49	1.9e-33	2.3e-30	0.44	0.36	Hypertension (SNP x SNP interaction);	chr5:83190937	chr5:83012285~83013109:-
BRCA	cis	rs34779708	0.931	rs10508815	ENSG00000230534.5	RP11-297A16.2	12.49	1.9e-33	2.31e-30	0.45	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35043693	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.931	rs4934697	ENSG00000230534.5	RP11-297A16.2	12.49	1.91e-33	2.31e-30	0.47	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:34998264	chr10:35098006~35127020:-
BRCA	cis	rs4380275	0.782	rs4335978	ENSG00000272342.1	RP13-539J13.1	12.48	1.97e-33	2.39e-30	0.44	0.36	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:750078	chr2:739588~740164:-
BRCA	cis	rs10256972	0.758	rs9801444	ENSG00000229043.2	AC091729.9	12.48	1.98e-33	2.4e-30	0.47	0.36	Endometriosis;Longevity;	chr7:1040808	chr7:1160374~1165267:+
BRCA	cis	rs34779708	0.868	rs2384352	ENSG00000230534.5	RP11-297A16.2	12.48	1.98e-33	2.4e-30	0.46	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35203904	chr10:35098006~35127020:-
BRCA	cis	rs55794721	0.509	rs11249248	ENSG00000224183.1	SDHDP6	-12.48	2.05e-33	2.48e-30	-0.44	-0.36	Mean corpuscular volume;Plateletcrit;	chr1:25426560	chr1:25294164~25294643:-
BRCA	cis	rs34779708	0.931	rs2001893	ENSG00000230534.5	RP11-297A16.2	12.48	2.05e-33	2.49e-30	0.45	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35011695	chr10:35098006~35127020:-
BRCA	cis	rs7849270	1	rs2254230	ENSG00000268707.1	RP11-247A12.7	12.48	2.05e-33	2.49e-30	0.47	0.36	Blood metabolite ratios;	chr9:129142898	chr9:129170434~129170940:+
BRCA	cis	rs34779708	0.931	rs68039650	ENSG00000230534.5	RP11-297A16.2	12.48	2.06e-33	2.5e-30	0.47	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35096571	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.931	rs35136660	ENSG00000230534.5	RP11-297A16.2	12.48	2.06e-33	2.5e-30	0.47	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35097045	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.897	rs12764820	ENSG00000230534.5	RP11-297A16.2	12.48	2.06e-33	2.5e-30	0.47	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35097393	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.931	rs67261877	ENSG00000230534.5	RP11-297A16.2	12.48	2.06e-33	2.5e-30	0.47	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35097412	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.931	rs12768019	ENSG00000230534.5	RP11-297A16.2	12.48	2.06e-33	2.5e-30	0.47	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35100915	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.966	rs12769484	ENSG00000230534.5	RP11-297A16.2	12.48	2.1e-33	2.55e-30	0.47	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35176818	chr10:35098006~35127020:-
BRCA	cis	rs8100891	0.537	rs4805762	ENSG00000267213.4	AC007773.2	-12.48	2.11e-33	2.56e-30	-0.53	-0.36	Neuroticism;	chr19:32473048	chr19:32390050~32405560:-
BRCA	cis	rs11690935	0.851	rs10930502	ENSG00000228389.1	AC068039.4	12.48	2.17e-33	2.63e-30	0.45	0.36	Schizophrenia;	chr2:172025679	chr2:171773482~171775844:+
BRCA	cis	rs34779708	0.966	rs35079558	ENSG00000230534.5	RP11-297A16.2	12.47	2.29e-33	2.77e-30	0.47	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35190958	chr10:35098006~35127020:-
BRCA	cis	rs1891275	0.551	rs4933687	ENSG00000228701.1	TNKS2-AS1	-12.47	2.38e-33	2.88e-30	-0.46	-0.36	Intelligence (multi-trait analysis);	chr10:91650642	chr10:91782839~91798291:-
BRCA	cis	rs858239	0.67	rs3807452	ENSG00000226816.2	AC005082.12	-12.47	2.4e-33	2.9e-30	-0.42	-0.36	Cerebrospinal fluid biomarker levels;	chr7:23122462	chr7:23206013~23208045:+
BRCA	cis	rs8040855	0.658	rs11634877	ENSG00000259295.5	CSPG4P12	12.46	2.45e-33	2.96e-30	0.52	0.36	Bulimia nervosa;	chr15:85068246	chr15:85191438~85213905:+
BRCA	cis	rs8040855	0.627	rs11632175	ENSG00000259295.5	CSPG4P12	12.46	2.45e-33	2.96e-30	0.52	0.36	Bulimia nervosa;	chr15:85068449	chr15:85191438~85213905:+
BRCA	cis	rs6991838	0.55	rs4737750	ENSG00000272010.1	CTD-3025N20.3	12.46	2.46e-33	2.97e-30	0.38	0.36	Intelligence (multi-trait analysis);	chr8:65638724	chr8:65591850~65592472:-
BRCA	cis	rs55665837	1	rs12288873	ENSG00000251991.1	RNU7-49P	12.46	2.49e-33	3e-30	0.39	0.36	Vitamin D levels;	chr11:14428919	chr11:14478892~14478953:+
BRCA	cis	rs2404602	0.647	rs36114653	ENSG00000259422.1	RP11-593F23.1	-12.46	2.5e-33	3.02e-30	-0.48	-0.36	Blood metabolite levels;	chr15:76733052	chr15:76174891~76181486:-
BRCA	cis	rs1891275	0.551	rs7908547	ENSG00000228701.1	TNKS2-AS1	-12.46	2.51e-33	3.04e-30	-0.47	-0.36	Intelligence (multi-trait analysis);	chr10:91659230	chr10:91782839~91798291:-
BRCA	cis	rs7626444	0.625	rs843530	ENSG00000272359.1	U4	-12.46	2.52e-33	3.04e-30	-0.42	-0.36	Monocyte count;	chr3:196754153	chr3:196747192~196747324:-
BRCA	cis	rs2564921	0.73	rs60579898	ENSG00000242142.1	SERBP1P3	-12.46	2.52e-33	3.04e-30	-0.42	-0.36	Height;	chr3:53069965	chr3:53064283~53065091:-
BRCA	cis	rs765787	0.53	rs16941017	ENSG00000259520.4	CTD-2651B20.3	12.46	2.53e-33	3.05e-30	0.44	0.36	Uric acid levels;	chr15:45251083	chr15:45251580~45279251:-
BRCA	cis	rs6452524	0.78	rs2386237	ENSG00000249664.1	CTD-2227C6.2	12.46	2.56e-33	3.09e-30	0.45	0.36	Hypertension (SNP x SNP interaction);	chr5:83101852	chr5:83012285~83013109:-
BRCA	cis	rs977987	0.872	rs10781976	ENSG00000261783.1	RP11-252K23.2	-12.46	2.62e-33	3.16e-30	-0.46	-0.36	Dupuytren's disease;	chr16:75280940	chr16:75379818~75381260:-
BRCA	cis	rs765787	0.53	rs11636367	ENSG00000259520.4	CTD-2651B20.3	12.46	2.66e-33	3.2e-30	0.44	0.36	Uric acid levels;	chr15:45243664	chr15:45251580~45279251:-
BRCA	cis	rs4380275	0.782	rs60367761	ENSG00000223751.1	AC116609.2	12.45	2.8e-33	3.38e-30	0.44	0.36	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:766414	chr2:742488~747767:+
BRCA	cis	rs1891275	0.506	rs4933214	ENSG00000228701.1	TNKS2-AS1	-12.45	2.82e-33	3.39e-30	-0.47	-0.36	Intelligence (multi-trait analysis);	chr10:91658004	chr10:91782839~91798291:-
BRCA	cis	rs34779708	0.966	rs34630580	ENSG00000230534.5	RP11-297A16.2	12.45	2.83e-33	3.41e-30	0.47	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35160300	chr10:35098006~35127020:-
BRCA	cis	rs8100891	0.537	rs28562777	ENSG00000267213.4	AC007773.2	-12.45	2.85e-33	3.43e-30	-0.53	-0.36	Neuroticism;	chr19:32409913	chr19:32390050~32405560:-
BRCA	cis	rs34779708	0.931	rs17591135	ENSG00000230534.5	RP11-297A16.2	12.45	2.87e-33	3.45e-30	0.47	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35176262	chr10:35098006~35127020:-
BRCA	cis	rs17711722	0.565	rs4275112	ENSG00000226824.5	RP4-756H11.3	12.45	2.92e-33	3.51e-30	0.45	0.36	Calcium levels;	chr7:65733651	chr7:66654538~66669855:+
BRCA	cis	rs7301826	0.934	rs10773826	ENSG00000256299.1	RP11-989F5.3	-12.45	2.95e-33	3.55e-30	-0.41	-0.36	Plasma plasminogen activator levels;	chr12:130836629	chr12:130810821~130812622:-
BRCA	cis	rs34779708	0.931	rs7923217	ENSG00000230534.5	RP11-297A16.2	12.45	2.95e-33	3.55e-30	0.44	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35020661	chr10:35098006~35127020:-
BRCA	cis	rs17711722	0.565	rs4717276	ENSG00000226824.5	RP4-756H11.3	-12.45	2.96e-33	3.56e-30	-0.45	-0.36	Calcium levels;	chr7:65829754	chr7:66654538~66669855:+
BRCA	cis	rs34779708	0.931	rs55724039	ENSG00000230534.5	RP11-297A16.2	12.44	3.05e-33	3.66e-30	0.47	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35176469	chr10:35098006~35127020:-
BRCA	cis	rs1150668	0.796	rs9468372	ENSG00000216901.1	AL022393.7	12.44	3.05e-33	3.67e-30	0.44	0.36	Pubertal anthropometrics;	chr6:28411584	chr6:28176188~28176674:+
BRCA	cis	rs6991838	0.584	rs34494846	ENSG00000272010.1	CTD-3025N20.3	-12.44	3.06e-33	3.67e-30	-0.39	-0.36	Intelligence (multi-trait analysis);	chr8:65602397	chr8:65591850~65592472:-
BRCA	cis	rs1891275	0.551	rs2421624	ENSG00000228701.1	TNKS2-AS1	-12.44	3.08e-33	3.7e-30	-0.47	-0.36	Intelligence (multi-trait analysis);	chr10:91656659	chr10:91782839~91798291:-
BRCA	cis	rs1891275	0.551	rs2421625	ENSG00000228701.1	TNKS2-AS1	-12.44	3.08e-33	3.7e-30	-0.47	-0.36	Intelligence (multi-trait analysis);	chr10:91656744	chr10:91782839~91798291:-
BRCA	cis	rs1891275	0.576	rs7900117	ENSG00000228701.1	TNKS2-AS1	-12.44	3.08e-33	3.7e-30	-0.47	-0.36	Intelligence (multi-trait analysis);	chr10:91657530	chr10:91782839~91798291:-
BRCA	cis	rs1891275	0.551	rs4933213	ENSG00000228701.1	TNKS2-AS1	-12.44	3.08e-33	3.7e-30	-0.47	-0.36	Intelligence (multi-trait analysis);	chr10:91657947	chr10:91782839~91798291:-
BRCA	cis	rs1891275	0.515	rs7358148	ENSG00000228701.1	TNKS2-AS1	-12.44	3.08e-33	3.7e-30	-0.47	-0.36	Intelligence (multi-trait analysis);	chr10:91658775	chr10:91782839~91798291:-
BRCA	cis	rs1891275	0.515	rs7908980	ENSG00000228701.1	TNKS2-AS1	-12.44	3.08e-33	3.7e-30	-0.47	-0.36	Intelligence (multi-trait analysis);	chr10:91659545	chr10:91782839~91798291:-
BRCA	cis	rs1891275	0.551	rs4933690	ENSG00000228701.1	TNKS2-AS1	-12.44	3.08e-33	3.7e-30	-0.47	-0.36	Intelligence (multi-trait analysis);	chr10:91659810	chr10:91782839~91798291:-
BRCA	cis	rs1891275	0.576	rs4933216	ENSG00000228701.1	TNKS2-AS1	-12.44	3.08e-33	3.7e-30	-0.47	-0.36	Intelligence (multi-trait analysis);	chr10:91659825	chr10:91782839~91798291:-
BRCA	cis	rs1891275	0.551	rs4933691	ENSG00000228701.1	TNKS2-AS1	-12.44	3.08e-33	3.7e-30	-0.47	-0.36	Intelligence (multi-trait analysis);	chr10:91660200	chr10:91782839~91798291:-
BRCA	cis	rs1891275	0.551	rs2421626	ENSG00000228701.1	TNKS2-AS1	-12.44	3.08e-33	3.7e-30	-0.47	-0.36	Intelligence (multi-trait analysis);	chr10:91661177	chr10:91782839~91798291:-
BRCA	cis	rs1891275	0.551	rs2421627	ENSG00000228701.1	TNKS2-AS1	-12.44	3.08e-33	3.7e-30	-0.47	-0.36	Intelligence (multi-trait analysis);	chr10:91662226	chr10:91782839~91798291:-
BRCA	cis	rs1891275	0.551	rs2421628	ENSG00000228701.1	TNKS2-AS1	-12.44	3.08e-33	3.7e-30	-0.47	-0.36	Intelligence (multi-trait analysis);	chr10:91662412	chr10:91782839~91798291:-
BRCA	cis	rs1891275	0.515	rs10881945	ENSG00000228701.1	TNKS2-AS1	-12.44	3.08e-33	3.7e-30	-0.47	-0.36	Intelligence (multi-trait analysis);	chr10:91663826	chr10:91782839~91798291:-
BRCA	cis	rs34779708	0.931	rs9663401	ENSG00000230534.5	RP11-297A16.2	12.44	3.08e-33	3.7e-30	0.47	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:34989921	chr10:35098006~35127020:-
BRCA	cis	rs17711722	0.565	rs73372653	ENSG00000226824.5	RP4-756H11.3	-12.44	3.09e-33	3.71e-30	-0.46	-0.36	Calcium levels;	chr7:65977808	chr7:66654538~66669855:+
BRCA	cis	rs34779708	0.833	rs12777517	ENSG00000230534.5	RP11-297A16.2	12.44	3.1e-33	3.71e-30	0.47	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35184999	chr10:35098006~35127020:-
BRCA	cis	rs1891275	0.551	rs10881941	ENSG00000228701.1	TNKS2-AS1	-12.44	3.3e-33	3.96e-30	-0.47	-0.36	Intelligence (multi-trait analysis);	chr10:91655154	chr10:91782839~91798291:-
BRCA	cis	rs1891275	0.576	rs10881942	ENSG00000228701.1	TNKS2-AS1	-12.44	3.3e-33	3.96e-30	-0.47	-0.36	Intelligence (multi-trait analysis);	chr10:91655263	chr10:91782839~91798291:-
BRCA	cis	rs1891275	0.516	rs10881943	ENSG00000228701.1	TNKS2-AS1	-12.44	3.3e-33	3.96e-30	-0.47	-0.36	Intelligence (multi-trait analysis);	chr10:91655373	chr10:91782839~91798291:-
BRCA	cis	rs992157	0.643	rs10191283	ENSG00000261338.2	RP11-378A13.1	12.44	3.3e-33	3.96e-30	0.38	0.36	Colorectal cancer;	chr2:218192032	chr2:218255319~218257366:+
BRCA	cis	rs11673344	0.566	rs2385181	ENSG00000226686.6	LINC01535	-12.43	3.37e-33	4.03e-30	-0.46	-0.36	Obesity-related traits;	chr19:37395428	chr19:37251912~37265535:+
BRCA	cis	rs875971	1	rs10215948	ENSG00000222364.1	RNU6-96P	12.43	3.4e-33	4.07e-30	0.41	0.36	Aortic root size;	chr7:66282799	chr7:66395191~66395286:+
BRCA	cis	rs8040855	0.627	rs11631548	ENSG00000259295.5	CSPG4P12	12.43	3.42e-33	4.09e-30	0.53	0.36	Bulimia nervosa;	chr15:85076017	chr15:85191438~85213905:+
BRCA	cis	rs1891275	0.551	rs4933681	ENSG00000228701.1	TNKS2-AS1	-12.43	3.45e-33	4.12e-30	-0.47	-0.36	Intelligence (multi-trait analysis);	chr10:91643365	chr10:91782839~91798291:-
BRCA	cis	rs1891275	0.551	rs7071844	ENSG00000228701.1	TNKS2-AS1	-12.43	3.45e-33	4.12e-30	-0.47	-0.36	Intelligence (multi-trait analysis);	chr10:91644092	chr10:91782839~91798291:-
BRCA	cis	rs9545047	0.716	rs9318638	ENSG00000227676.3	LINC01068	-12.43	3.47e-33	4.14e-30	-0.42	-0.36	Schizophrenia;	chr13:79412018	chr13:79566727~79571436:+
BRCA	cis	rs765787	0.53	rs3759895	ENSG00000259520.4	CTD-2651B20.3	12.43	3.48e-33	4.17e-30	0.44	0.36	Uric acid levels;	chr15:45251672	chr15:45251580~45279251:-
BRCA	cis	rs11673344	0.566	rs7254009	ENSG00000226686.6	LINC01535	-12.43	3.59e-33	4.3e-30	-0.46	-0.36	Obesity-related traits;	chr19:37427707	chr19:37251912~37265535:+
BRCA	cis	rs7829975	0.688	rs6995407	ENSG00000253893.2	FAM85B	-12.43	3.6e-33	4.3e-30	-0.44	-0.36	Mood instability;	chr8:8527137	chr8:8167819~8226614:-
BRCA	cis	rs2117029	0.587	rs57853986	ENSG00000258017.1	RP11-386G11.10	-12.43	3.6e-33	4.3e-30	-0.49	-0.36	Intelligence (multi-trait analysis);	chr12:49124612	chr12:49127782~49147869:+
BRCA	cis	rs7829975	0.624	rs7823056	ENSG00000253893.2	FAM85B	-12.43	3.63e-33	4.34e-30	-0.44	-0.36	Mood instability;	chr8:8525195	chr8:8167819~8226614:-
BRCA	cis	rs10875746	0.807	rs12313300	ENSG00000240399.1	RP1-228P16.1	-12.43	3.68e-33	4.39e-30	-0.49	-0.36	Longevity (90 years and older);	chr12:48076934	chr12:48054813~48055591:-
BRCA	cis	rs9487094	0.689	rs9480949	ENSG00000260273.1	RP11-425D10.10	12.43	3.69e-33	4.41e-30	0.42	0.36	Height;	chr6:109407238	chr6:109382795~109383666:+
BRCA	cis	rs10875746	0.855	rs12310999	ENSG00000240399.1	RP1-228P16.1	-12.42	3.75e-33	4.48e-30	-0.49	-0.36	Longevity (90 years and older);	chr12:48053875	chr12:48054813~48055591:-
BRCA	cis	rs10875746	0.903	rs61918774	ENSG00000240399.1	RP1-228P16.1	-12.42	3.75e-33	4.48e-30	-0.49	-0.36	Longevity (90 years and older);	chr12:48054351	chr12:48054813~48055591:-
BRCA	cis	rs12134133	1	rs2490261	ENSG00000274245.1	RP11-357P18.2	12.42	3.77e-33	4.5e-30	0.49	0.36	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207304124	chr1:207372559~207373252:+
BRCA	cis	rs10875746	0.807	rs12297004	ENSG00000240399.1	RP1-228P16.1	-12.42	3.83e-33	4.57e-30	-0.49	-0.36	Longevity (90 years and older);	chr12:48060037	chr12:48054813~48055591:-
BRCA	cis	rs2564921	0.704	rs57916015	ENSG00000242142.1	SERBP1P3	-12.42	3.91e-33	4.67e-30	-0.44	-0.36	Height;	chr3:52971094	chr3:53064283~53065091:-
BRCA	cis	rs875971	0.965	rs9969301	ENSG00000222364.1	RNU6-96P	12.42	3.96e-33	4.72e-30	0.41	0.36	Aortic root size;	chr7:66316668	chr7:66395191~66395286:+
BRCA	cis	rs4423214	0.879	rs1790353	ENSG00000254682.1	RP11-660L16.2	-12.42	3.96e-33	4.72e-30	-0.49	-0.36	Vitamin D levels;	chr11:71425684	chr11:71448674~71452157:+
BRCA	cis	rs34779708	0.931	rs35848945	ENSG00000230534.5	RP11-297A16.2	12.42	3.97e-33	4.73e-30	0.46	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:34998633	chr10:35098006~35127020:-
BRCA	cis	rs8040855	0.627	rs17540307	ENSG00000259295.5	CSPG4P12	12.42	4.02e-33	4.79e-30	0.53	0.36	Bulimia nervosa;	chr15:85090614	chr15:85191438~85213905:+
BRCA	cis	rs3091242	1	rs9689	ENSG00000224183.1	SDHDP6	-12.42	4.07e-33	4.85e-30	-0.42	-0.36	Erythrocyte sedimentation rate;	chr1:25361785	chr1:25294164~25294643:-
BRCA	cis	rs10256972	0.758	rs11979275	ENSG00000229043.2	AC091729.9	-12.42	4.1e-33	4.89e-30	-0.47	-0.36	Endometriosis;Longevity;	chr7:1029699	chr7:1160374~1165267:+
BRCA	cis	rs10256972	0.758	rs11980081	ENSG00000229043.2	AC091729.9	-12.42	4.1e-33	4.89e-30	-0.47	-0.36	Endometriosis;Longevity;	chr7:1029736	chr7:1160374~1165267:+
BRCA	cis	rs1891275	0.527	rs35812291	ENSG00000228701.1	TNKS2-AS1	-12.42	4.14e-33	4.92e-30	-0.47	-0.36	Intelligence (multi-trait analysis);	chr10:91642584	chr10:91782839~91798291:-
BRCA	cis	rs11673344	0.544	rs6508721	ENSG00000226686.6	LINC01535	-12.42	4.17e-33	4.96e-30	-0.46	-0.36	Obesity-related traits;	chr19:37419119	chr19:37251912~37265535:+
BRCA	cis	rs3091242	0.933	rs4649084	ENSG00000224183.1	SDHDP6	-12.41	4.2e-33	5e-30	-0.44	-0.36	Erythrocyte sedimentation rate;	chr1:25426126	chr1:25294164~25294643:-
BRCA	cis	rs7945705	0.719	rs2012680	ENSG00000254860.4	TMEM9B-AS1	12.41	4.46e-33	5.3e-30	0.32	0.36	Hemoglobin concentration;	chr11:8974512	chr11:8964675~8977527:+
BRCA	cis	rs34779708	0.966	rs4934735	ENSG00000230534.5	RP11-297A16.2	-12.41	4.49e-33	5.34e-30	-0.45	-0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35207802	chr10:35098006~35127020:-
BRCA	cis	rs2564921	0.679	rs12635933	ENSG00000242142.1	SERBP1P3	-12.41	4.51e-33	5.35e-30	-0.44	-0.36	Height;	chr3:53015087	chr3:53064283~53065091:-
BRCA	cis	rs2283792	1	rs3788332	ENSG00000224086.5	LL22NC03-86G7.1	-12.41	4.57e-33	5.43e-30	-0.37	-0.36	Multiple sclerosis;	chr22:21817278	chr22:21938293~21977632:+
BRCA	cis	rs2134046	0.587	rs11854289	ENSG00000278603.1	RP13-608F4.5	-12.4	4.69e-33	5.57e-30	-0.46	-0.36	Cognitive ability;	chr15:82266461	chr15:82472203~82472426:+
BRCA	cis	rs2108622	1	rs62107762	ENSG00000267453.5	AC004791.2	-12.4	4.75e-33	5.64e-30	-0.46	-0.36	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871728	chr19:15851993~15864904:-
BRCA	cis	rs11673344	0.566	rs2385180	ENSG00000226686.6	LINC01535	-12.4	4.81e-33	5.71e-30	-0.46	-0.36	Obesity-related traits;	chr19:37431454	chr19:37251912~37265535:+
BRCA	cis	rs10875746	0.903	rs58952582	ENSG00000240399.1	RP1-228P16.1	-12.4	4.91e-33	5.83e-30	-0.49	-0.36	Longevity (90 years and older);	chr12:48064665	chr12:48054813~48055591:-
BRCA	cis	rs10256972	0.758	rs4723649	ENSG00000229043.2	AC091729.9	-12.4	4.94e-33	5.86e-30	-0.47	-0.36	Endometriosis;Longevity;	chr7:1032269	chr7:1160374~1165267:+
BRCA	cis	rs34779708	0.931	rs4934724	ENSG00000230534.5	RP11-297A16.2	12.4	4.98e-33	5.91e-30	0.46	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35104741	chr10:35098006~35127020:-
BRCA	cis	rs10875746	0.855	rs12296244	ENSG00000240399.1	RP1-228P16.1	-12.4	5e-33	5.93e-30	-0.49	-0.36	Longevity (90 years and older);	chr12:48047696	chr12:48054813~48055591:-
BRCA	cis	rs7301826	1	rs2001483	ENSG00000256299.1	RP11-989F5.3	-12.4	5.04e-33	5.97e-30	-0.4	-0.36	Plasma plasminogen activator levels;	chr12:130834100	chr12:130810821~130812622:-
BRCA	cis	rs34779708	0.931	rs34087268	ENSG00000230534.5	RP11-297A16.2	12.4	5.06e-33	6e-30	0.47	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35057796	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.931	rs58159560	ENSG00000230534.5	RP11-297A16.2	12.4	5.06e-33	6e-30	0.47	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35062321	chr10:35098006~35127020:-
BRCA	cis	rs2564921	0.73	rs1811351	ENSG00000242142.1	SERBP1P3	-12.4	5.08e-33	6.02e-30	-0.44	-0.36	Height;	chr3:53064759	chr3:53064283~53065091:-
BRCA	cis	rs1891275	0.576	rs2000178	ENSG00000228701.1	TNKS2-AS1	-12.4	5.13e-33	6.08e-30	-0.47	-0.36	Intelligence (multi-trait analysis);	chr10:91653287	chr10:91782839~91798291:-
BRCA	cis	rs1891275	0.551	rs2027486	ENSG00000228701.1	TNKS2-AS1	-12.4	5.13e-33	6.08e-30	-0.47	-0.36	Intelligence (multi-trait analysis);	chr10:91654229	chr10:91782839~91798291:-
BRCA	cis	rs1891275	0.551	rs2421623	ENSG00000228701.1	TNKS2-AS1	-12.39	5.25e-33	6.22e-30	-0.47	-0.36	Intelligence (multi-trait analysis);	chr10:91654700	chr10:91782839~91798291:-
BRCA	cis	rs858239	0.932	rs1728313	ENSG00000226816.2	AC005082.12	12.39	5.28e-33	6.26e-30	0.41	0.36	Cerebrospinal fluid biomarker levels;	chr7:23231412	chr7:23206013~23208045:+
BRCA	cis	rs875971	0.965	rs10267430	ENSG00000222364.1	RNU6-96P	12.39	5.41e-33	6.4e-30	0.41	0.36	Aortic root size;	chr7:66278036	chr7:66395191~66395286:+
BRCA	cis	rs10129255	0.509	rs756583	ENSG00000223648.3	IGHV3-64	12.39	5.42e-33	6.42e-30	0.28	0.36	Kawasaki disease;	chr14:106680002	chr14:106643132~106658258:-
BRCA	cis	rs1891275	0.551	rs2421621	ENSG00000228701.1	TNKS2-AS1	-12.39	5.43e-33	6.43e-30	-0.47	-0.36	Intelligence (multi-trait analysis);	chr10:91640344	chr10:91782839~91798291:-
BRCA	cis	rs10875746	0.903	rs10875735	ENSG00000240399.1	RP1-228P16.1	-12.39	5.45e-33	6.45e-30	-0.49	-0.36	Longevity (90 years and older);	chr12:48070023	chr12:48054813~48055591:-
BRCA	cis	rs10875746	0.855	rs17122620	ENSG00000240399.1	RP1-228P16.1	-12.39	5.45e-33	6.45e-30	-0.49	-0.36	Longevity (90 years and older);	chr12:48070692	chr12:48054813~48055591:-
BRCA	cis	rs10875746	0.859	rs4760680	ENSG00000240399.1	RP1-228P16.1	-12.39	5.45e-33	6.45e-30	-0.49	-0.36	Longevity (90 years and older);	chr12:48072914	chr12:48054813~48055591:-
BRCA	cis	rs10875746	0.903	rs11168386	ENSG00000240399.1	RP1-228P16.1	-12.39	5.45e-33	6.45e-30	-0.49	-0.36	Longevity (90 years and older);	chr12:48074194	chr12:48054813~48055591:-
BRCA	cis	rs10875746	0.903	rs12315625	ENSG00000240399.1	RP1-228P16.1	-12.39	5.45e-33	6.45e-30	-0.49	-0.36	Longevity (90 years and older);	chr12:48078670	chr12:48054813~48055591:-
BRCA	cis	rs10875746	0.903	rs10875738	ENSG00000240399.1	RP1-228P16.1	-12.39	5.45e-33	6.45e-30	-0.49	-0.36	Longevity (90 years and older);	chr12:48079956	chr12:48054813~48055591:-
BRCA	cis	rs10875746	0.903	rs12301339	ENSG00000240399.1	RP1-228P16.1	-12.39	5.45e-33	6.45e-30	-0.49	-0.36	Longevity (90 years and older);	chr12:48081450	chr12:48054813~48055591:-
BRCA	cis	rs8040855	0.627	rs62019482	ENSG00000259295.5	CSPG4P12	12.39	5.49e-33	6.49e-30	0.52	0.36	Bulimia nervosa;	chr15:85071796	chr15:85191438~85213905:+
BRCA	cis	rs12134133	1	rs28371597	ENSG00000274245.1	RP11-357P18.2	12.39	5.58e-33	6.6e-30	0.51	0.36	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207323551	chr1:207372559~207373252:+
BRCA	cis	rs997154	0.655	rs4981454	ENSG00000279656.1	RP11-298I3.6	12.39	5.6e-33	6.63e-30	0.52	0.36	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:22952977	chr14:23023083~23024217:-
BRCA	cis	rs55665837	1	rs12804549	ENSG00000251991.1	RNU7-49P	12.39	5.69e-33	6.73e-30	0.39	0.36	Vitamin D levels;	chr11:14416212	chr11:14478892~14478953:+
BRCA	cis	rs34779708	0.966	rs2045918	ENSG00000230534.5	RP11-297A16.2	12.39	5.7e-33	6.74e-30	0.46	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35129589	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.966	rs4294520	ENSG00000230534.5	RP11-297A16.2	12.39	5.7e-33	6.74e-30	0.46	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35133578	chr10:35098006~35127020:-
BRCA	cis	rs875971	1	rs10257427	ENSG00000222364.1	RNU6-96P	12.39	5.75e-33	6.79e-30	0.41	0.36	Aortic root size;	chr7:66278221	chr7:66395191~66395286:+
BRCA	cis	rs997154	0.655	rs7147394	ENSG00000279656.1	RP11-298I3.6	12.39	5.76e-33	6.8e-30	0.51	0.36	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:22941845	chr14:23023083~23024217:-
BRCA	cis	rs34779708	0.931	rs2384275	ENSG00000230534.5	RP11-297A16.2	12.39	5.77e-33	6.81e-30	0.44	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35008214	chr10:35098006~35127020:-
BRCA	cis	rs1891275	0.601	rs7358034	ENSG00000228701.1	TNKS2-AS1	-12.39	5.77e-33	6.82e-30	-0.47	-0.36	Intelligence (multi-trait analysis);	chr10:91659007	chr10:91782839~91798291:-
BRCA	cis	rs9487094	0.67	rs2024850	ENSG00000260273.1	RP11-425D10.10	-12.38	5.84e-33	6.89e-30	-0.42	-0.36	Height;	chr6:109497253	chr6:109382795~109383666:+
BRCA	cis	rs3823536	0.583	rs3778750	ENSG00000275106.1	RP11-309L24.10	-12.38	5.87e-33	6.92e-30	-0.47	-0.36	Sjögren's syndrome;	chr7:128977035	chr7:128952527~128953316:-
BRCA	cis	rs1891275	0.551	rs4933684	ENSG00000228701.1	TNKS2-AS1	-12.38	5.88e-33	6.94e-30	-0.47	-0.36	Intelligence (multi-trait analysis);	chr10:91647805	chr10:91782839~91798291:-
BRCA	cis	rs34779708	0.931	rs35126129	ENSG00000230534.5	RP11-297A16.2	12.38	5.93e-33	7e-30	0.47	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35163213	chr10:35098006~35127020:-
BRCA	cis	rs11673344	0.566	rs10419281	ENSG00000226686.6	LINC01535	-12.38	6.15e-33	7.25e-30	-0.46	-0.36	Obesity-related traits;	chr19:37459351	chr19:37251912~37265535:+
BRCA	cis	rs1891275	0.551	rs7088831	ENSG00000228701.1	TNKS2-AS1	-12.38	6.16e-33	7.26e-30	-0.47	-0.36	Intelligence (multi-trait analysis);	chr10:91652695	chr10:91782839~91798291:-
BRCA	cis	rs8100891	0.537	rs1057395	ENSG00000267213.4	AC007773.2	-12.38	6.18e-33	7.29e-30	-0.53	-0.36	Neuroticism;	chr19:32483832	chr19:32390050~32405560:-
BRCA	cis	rs8100891	0.537	rs1057397	ENSG00000267213.4	AC007773.2	-12.38	6.18e-33	7.29e-30	-0.53	-0.36	Neuroticism;	chr19:32484007	chr19:32390050~32405560:-
BRCA	cis	rs10256972	0.758	rs2280724	ENSG00000229043.2	AC091729.9	-12.38	6.28e-33	7.4e-30	-0.46	-0.36	Endometriosis;Longevity;	chr7:1025084	chr7:1160374~1165267:+
BRCA	cis	rs875971	0.964	rs55748098	ENSG00000222364.1	RNU6-96P	12.38	6.3e-33	7.43e-30	0.41	0.36	Aortic root size;	chr7:66298631	chr7:66395191~66395286:+
BRCA	cis	rs7182621	0.546	rs12906587	ENSG00000259363.4	CTD-2054N24.2	12.38	6.35e-33	7.48e-30	0.47	0.36	Colonoscopy-negative controls vs population controls;	chr15:99837114	chr15:99807023~99877148:+
BRCA	cis	rs34779708	0.931	rs10437420	ENSG00000230534.5	RP11-297A16.2	-12.38	6.36e-33	7.5e-30	-0.44	-0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35046116	chr10:35098006~35127020:-
BRCA	cis	rs10875746	0.903	rs12304476	ENSG00000240399.1	RP1-228P16.1	-12.38	6.4e-33	7.53e-30	-0.49	-0.36	Longevity (90 years and older);	chr12:48088370	chr12:48054813~48055591:-
BRCA	cis	rs10875746	0.903	rs3782911	ENSG00000240399.1	RP1-228P16.1	-12.38	6.4e-33	7.53e-30	-0.49	-0.36	Longevity (90 years and older);	chr12:48089709	chr12:48054813~48055591:-
BRCA	cis	rs10875746	0.859	rs3782910	ENSG00000240399.1	RP1-228P16.1	-12.38	6.4e-33	7.53e-30	-0.49	-0.36	Longevity (90 years and older);	chr12:48089724	chr12:48054813~48055591:-
BRCA	cis	rs10875746	0.903	rs989144	ENSG00000240399.1	RP1-228P16.1	-12.38	6.4e-33	7.53e-30	-0.49	-0.36	Longevity (90 years and older);	chr12:48090190	chr12:48054813~48055591:-
BRCA	cis	rs10875746	0.903	rs61918806	ENSG00000240399.1	RP1-228P16.1	-12.38	6.4e-33	7.53e-30	-0.49	-0.36	Longevity (90 years and older);	chr12:48090650	chr12:48054813~48055591:-
BRCA	cis	rs10875746	0.903	rs11168403	ENSG00000240399.1	RP1-228P16.1	-12.38	6.4e-33	7.53e-30	-0.49	-0.36	Longevity (90 years and older);	chr12:48091175	chr12:48054813~48055591:-
BRCA	cis	rs7617773	0.817	rs9830016	ENSG00000229759.1	MRPS18AP1	12.38	6.4e-33	7.54e-30	0.43	0.36	Coronary artery disease;	chr3:48241004	chr3:48256350~48256938:-
BRCA	cis	rs11673344	0.566	rs256735	ENSG00000226686.6	LINC01535	-12.37	6.48e-33	7.63e-30	-0.46	-0.36	Obesity-related traits;	chr19:37375141	chr19:37251912~37265535:+
BRCA	cis	rs858239	0.669	rs6461687	ENSG00000226816.2	AC005082.12	12.37	6.55e-33	7.71e-30	0.41	0.36	Cerebrospinal fluid biomarker levels;	chr7:23076961	chr7:23206013~23208045:+
BRCA	cis	rs3823536	0.583	rs7789423	ENSG00000275106.1	RP11-309L24.10	-12.37	6.62e-33	7.79e-30	-0.47	-0.36	Sjögren's syndrome;	chr7:128981150	chr7:128952527~128953316:-
BRCA	cis	rs3823536	0.583	rs6948928	ENSG00000275106.1	RP11-309L24.10	-12.37	6.62e-33	7.79e-30	-0.47	-0.36	Sjögren's syndrome;	chr7:128983043	chr7:128952527~128953316:-
BRCA	cis	rs1789	0.706	rs8180240	ENSG00000273133.1	RP11-799M12.2	-12.37	6.91e-33	8.12e-30	-0.48	-0.36	Blood protein levels;	chr4:15699952	chr4:15563698~15564253:-
BRCA	cis	rs3823536	0.604	rs13221560	ENSG00000275106.1	RP11-309L24.10	-12.37	7.19e-33	8.44e-30	-0.46	-0.36	Sjögren's syndrome;	chr7:129023121	chr7:128952527~128953316:-
BRCA	cis	rs1891275	0.551	rs7087959	ENSG00000228701.1	TNKS2-AS1	-12.36	7.25e-33	8.52e-30	-0.47	-0.36	Intelligence (multi-trait analysis);	chr10:91656160	chr10:91782839~91798291:-
BRCA	cis	rs8100891	0.537	rs28729153	ENSG00000267213.4	AC007773.2	-12.36	7.34e-33	8.61e-30	-0.54	-0.36	Neuroticism;	chr19:32416672	chr19:32390050~32405560:-
BRCA	cis	rs34779708	0.966	rs34296409	ENSG00000230534.5	RP11-297A16.2	12.36	7.42e-33	8.71e-30	0.46	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35115685	chr10:35098006~35127020:-
BRCA	cis	rs2882667	0.652	rs6596463	ENSG00000253404.1	AC034243.1	12.36	7.45e-33	8.74e-30	0.45	0.36	Age-related hearing impairment (SNP x SNP interaction);	chr5:139109237	chr5:138744434~138753309:-
BRCA	cis	rs17711722	0.51	rs11767457	ENSG00000164669.11	INTS4P1	-12.36	7.5e-33	8.8e-30	-0.46	-0.36	Calcium levels;	chr7:65825628	chr7:65141225~65234216:+
BRCA	cis	rs6991838	0.584	rs35790435	ENSG00000272010.1	CTD-3025N20.3	-12.36	7.5e-33	8.8e-30	-0.38	-0.36	Intelligence (multi-trait analysis);	chr8:65590288	chr8:65591850~65592472:-
BRCA	cis	rs34779708	0.966	rs7913615	ENSG00000230534.5	RP11-297A16.2	12.36	7.58e-33	8.89e-30	0.46	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35134029	chr10:35098006~35127020:-
BRCA	cis	rs55665837	1	rs12792120	ENSG00000251991.1	RNU7-49P	12.36	7.61e-33	8.93e-30	0.39	0.36	Vitamin D levels;	chr11:14447897	chr11:14478892~14478953:+
BRCA	cis	rs875971	0.862	rs6460290	ENSG00000222364.1	RNU6-96P	12.36	7.66e-33	8.98e-30	0.41	0.36	Aortic root size;	chr7:66344119	chr7:66395191~66395286:+
BRCA	cis	rs10875746	0.903	rs12306451	ENSG00000240399.1	RP1-228P16.1	-12.36	7.76e-33	9.09e-30	-0.48	-0.36	Longevity (90 years and older);	chr12:48089458	chr12:48054813~48055591:-
BRCA	cis	rs3091242	0.933	rs11802413	ENSG00000224183.1	SDHDP6	12.36	7.76e-33	9.1e-30	0.43	0.36	Erythrocyte sedimentation rate;	chr1:25434429	chr1:25294164~25294643:-
BRCA	cis	rs10875746	0.855	rs2269936	ENSG00000240399.1	RP1-228P16.1	-12.36	7.84e-33	9.18e-30	-0.49	-0.36	Longevity (90 years and older);	chr12:48031452	chr12:48054813~48055591:-
BRCA	cis	rs875971	1	rs1565531	ENSG00000222364.1	RNU6-96P	12.36	7.87e-33	9.22e-30	0.41	0.36	Aortic root size;	chr7:66198126	chr7:66395191~66395286:+
BRCA	cis	rs8100891	0.537	rs7253039	ENSG00000267213.4	AC007773.2	-12.36	7.88e-33	9.23e-30	-0.53	-0.36	Neuroticism;	chr19:32482171	chr19:32390050~32405560:-
BRCA	cis	rs10256972	0.721	rs6975972	ENSG00000229043.2	AC091729.9	-12.36	7.89e-33	9.24e-30	-0.46	-0.36	Endometriosis;Longevity;	chr7:1030832	chr7:1160374~1165267:+
BRCA	cis	rs34779708	0.966	rs4934725	ENSG00000230534.5	RP11-297A16.2	12.36	7.91e-33	9.27e-30	0.46	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35109308	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.966	rs12774834	ENSG00000230534.5	RP11-297A16.2	12.36	7.91e-33	9.27e-30	0.46	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35111142	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.966	rs12775759	ENSG00000230534.5	RP11-297A16.2	12.36	7.91e-33	9.27e-30	0.46	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35111255	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.966	rs35777088	ENSG00000230534.5	RP11-297A16.2	12.36	7.91e-33	9.27e-30	0.46	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35120120	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.966	rs11592567	ENSG00000230534.5	RP11-297A16.2	12.36	7.91e-33	9.27e-30	0.46	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35120441	chr10:35098006~35127020:-
BRCA	cis	rs8100891	0.537	rs2012353	ENSG00000267213.4	AC007773.2	-12.36	7.99e-33	9.35e-30	-0.54	-0.36	Neuroticism;	chr19:32408387	chr19:32390050~32405560:-
BRCA	cis	rs34779708	0.966	rs12773647	ENSG00000230534.5	RP11-297A16.2	12.35	8.05e-33	9.42e-30	0.46	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35151399	chr10:35098006~35127020:-
BRCA	cis	rs10875746	0.903	rs886588	ENSG00000240399.1	RP1-228P16.1	-12.35	8.05e-33	9.42e-30	-0.48	-0.36	Longevity (90 years and older);	chr12:48083639	chr12:48054813~48055591:-
BRCA	cis	rs3823536	0.544	rs12532542	ENSG00000275106.1	RP11-309L24.10	-12.35	8.14e-33	9.53e-30	-0.46	-0.36	Sjögren's syndrome;	chr7:129027358	chr7:128952527~128953316:-
BRCA	cis	rs3823536	0.583	rs4731540	ENSG00000275106.1	RP11-309L24.10	-12.35	8.14e-33	9.53e-30	-0.46	-0.36	Sjögren's syndrome;	chr7:129028196	chr7:128952527~128953316:-
BRCA	cis	rs2564921	0.704	rs62253649	ENSG00000242142.1	SERBP1P3	-12.35	8.17e-33	9.56e-30	-0.43	-0.36	Height;	chr3:52967831	chr3:53064283~53065091:-
BRCA	cis	rs34779708	0.931	rs34876468	ENSG00000230534.5	RP11-297A16.2	12.35	8.32e-33	9.74e-30	0.46	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35135522	chr10:35098006~35127020:-
BRCA	cis	rs2404602	0.647	rs11852395	ENSG00000259422.1	RP11-593F23.1	-12.35	8.4e-33	9.83e-30	-0.48	-0.36	Blood metabolite levels;	chr15:76795444	chr15:76174891~76181486:-
BRCA	cis	rs875971	1	rs778710	ENSG00000222364.1	RNU6-96P	-12.35	8.44e-33	9.87e-30	-0.41	-0.36	Aortic root size;	chr7:66389847	chr7:66395191~66395286:+
BRCA	cis	rs10129255	0.536	rs3944157	ENSG00000211972.2	IGHV3-66	12.35	8.44e-33	9.88e-30	0.25	0.36	Kawasaki disease;	chr14:106682286	chr14:106675017~106675544:-
BRCA	cis	rs7945705	0.747	rs2568020	ENSG00000254860.4	TMEM9B-AS1	12.35	8.54e-33	9.98e-30	0.32	0.36	Hemoglobin concentration;	chr11:8973168	chr11:8964675~8977527:+
BRCA	cis	rs4423214	0.625	rs78685409	ENSG00000254682.1	RP11-660L16.2	-12.35	8.59e-33	1e-29	-0.49	-0.36	Vitamin D levels;	chr11:71426337	chr11:71448674~71452157:+
BRCA	cis	rs4380275	0.809	rs6753699	ENSG00000223751.1	AC116609.2	12.35	8.65e-33	1.01e-29	0.44	0.36	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:766081	chr2:742488~747767:+
BRCA	cis	rs7945705	0.747	rs2742480	ENSG00000254860.4	TMEM9B-AS1	12.35	8.78e-33	1.03e-29	0.32	0.36	Hemoglobin concentration;	chr11:8971583	chr11:8964675~8977527:+
BRCA	cis	rs11098499	0.954	rs13145352	ENSG00000245958.5	RP11-33B1.1	12.35	8.85e-33	1.03e-29	0.35	0.36	Corneal astigmatism;	chr4:119488808	chr4:119454791~119552025:+
BRCA	cis	rs7301826	1	rs10744482	ENSG00000256299.1	RP11-989F5.3	-12.35	8.92e-33	1.04e-29	-0.41	-0.36	Plasma plasminogen activator levels;	chr12:130813650	chr12:130810821~130812622:-
BRCA	cis	rs4423214	0.592	rs11233977	ENSG00000254682.1	RP11-660L16.2	-12.35	8.93e-33	1.04e-29	-0.54	-0.36	Vitamin D levels;	chr11:71510559	chr11:71448674~71452157:+
BRCA	cis	rs10875746	0.903	rs11168401	ENSG00000240399.1	RP1-228P16.1	-12.34	9e-33	1.05e-29	-0.48	-0.36	Longevity (90 years and older);	chr12:48087736	chr12:48054813~48055591:-
BRCA	cis	rs34779708	0.897	rs16935880	ENSG00000230534.5	RP11-297A16.2	12.34	9.06e-33	1.06e-29	0.46	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35126540	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.966	rs4934730	ENSG00000230534.5	RP11-297A16.2	12.34	9.06e-33	1.06e-29	0.46	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35126627	chr10:35098006~35127020:-
BRCA	cis	rs992157	0.71	rs12612347	ENSG00000261338.2	RP11-378A13.1	-12.34	9.25e-33	1.08e-29	-0.37	-0.36	Colorectal cancer;	chr2:218192615	chr2:218255319~218257366:+
BRCA	cis	rs875971	0.929	rs778712	ENSG00000222364.1	RNU6-96P	-12.34	9.26e-33	1.08e-29	-0.41	-0.36	Aortic root size;	chr7:66384991	chr7:66395191~66395286:+
BRCA	cis	rs10129255	0.556	rs9324093	ENSG00000211972.2	IGHV3-66	12.34	9.37e-33	1.09e-29	0.25	0.36	Kawasaki disease;	chr14:106683893	chr14:106675017~106675544:-
BRCA	cis	rs6991838	0.584	rs7812446	ENSG00000272010.1	CTD-3025N20.3	-12.34	9.47e-33	1.1e-29	-0.38	-0.36	Intelligence (multi-trait analysis);	chr8:65593753	chr8:65591850~65592472:-
BRCA	cis	rs6991838	0.557	rs7812390	ENSG00000272010.1	CTD-3025N20.3	-12.34	9.47e-33	1.1e-29	-0.38	-0.36	Intelligence (multi-trait analysis);	chr8:65593982	chr8:65591850~65592472:-
BRCA	cis	rs34779708	0.931	rs1926556	ENSG00000230534.5	RP11-297A16.2	12.34	9.51e-33	1.11e-29	0.46	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35055979	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.931	rs1926554	ENSG00000230534.5	RP11-297A16.2	12.34	9.51e-33	1.11e-29	0.46	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35056041	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.931	rs4934710	ENSG00000230534.5	RP11-297A16.2	12.34	9.51e-33	1.11e-29	0.46	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35061488	chr10:35098006~35127020:-
BRCA	cis	rs8059260	0.736	rs7200623	ENSG00000274038.1	RP11-66H6.4	-12.34	9.61e-33	1.12e-29	-0.56	-0.36	Alcohol consumption over the past year;	chr16:11001188	chr16:11056556~11057034:+
BRCA	cis	rs6991838	0.584	rs16932245	ENSG00000272010.1	CTD-3025N20.3	-12.34	9.65e-33	1.12e-29	-0.38	-0.36	Intelligence (multi-trait analysis);	chr8:65597810	chr8:65591850~65592472:-
BRCA	cis	rs6991838	0.557	rs57419568	ENSG00000272010.1	CTD-3025N20.3	-12.34	9.65e-33	1.12e-29	-0.38	-0.36	Intelligence (multi-trait analysis);	chr8:65598633	chr8:65591850~65592472:-
BRCA	cis	rs34779708	0.966	rs34605125	ENSG00000230534.5	RP11-297A16.2	12.34	9.76e-33	1.14e-29	0.46	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35122318	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.966	rs11599606	ENSG00000230534.5	RP11-297A16.2	12.34	9.82e-33	1.14e-29	0.46	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35117698	chr10:35098006~35127020:-
BRCA	cis	rs6991838	0.584	rs1053087	ENSG00000272010.1	CTD-3025N20.3	-12.34	9.86e-33	1.15e-29	-0.38	-0.36	Intelligence (multi-trait analysis);	chr8:65603630	chr8:65591850~65592472:-
BRCA	cis	rs2404602	0.647	rs11072610	ENSG00000259422.1	RP11-593F23.1	-12.33	9.98e-33	1.16e-29	-0.47	-0.36	Blood metabolite levels;	chr15:76638464	chr15:76174891~76181486:-
BRCA	cis	rs2564921	0.73	rs930122	ENSG00000242142.1	SERBP1P3	12.33	1.02e-32	1.19e-29	0.42	0.36	Height;	chr3:53085313	chr3:53064283~53065091:-
BRCA	cis	rs6991838	0.584	rs16932250	ENSG00000272010.1	CTD-3025N20.3	-12.33	1.03e-32	1.2e-29	-0.38	-0.36	Intelligence (multi-trait analysis);	chr8:65598779	chr8:65591850~65592472:-
BRCA	cis	rs34779708	1	rs12769189	ENSG00000230534.5	RP11-297A16.2	12.33	1.05e-32	1.22e-29	0.46	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35110740	chr10:35098006~35127020:-
BRCA	cis	rs8040855	0.627	rs12909130	ENSG00000259295.5	CSPG4P12	12.33	1.06e-32	1.23e-29	0.52	0.36	Bulimia nervosa;	chr15:85047270	chr15:85191438~85213905:+
BRCA	cis	rs2564921	0.73	rs56386026	ENSG00000242142.1	SERBP1P3	-12.33	1.07e-32	1.24e-29	-0.44	-0.36	Height;	chr3:53080524	chr3:53064283~53065091:-
BRCA	cis	rs34779708	0.931	rs34375045	ENSG00000230534.5	RP11-297A16.2	12.33	1.07e-32	1.24e-29	0.46	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35073428	chr10:35098006~35127020:-
BRCA	cis	rs8100891	0.537	rs10410770	ENSG00000267213.4	AC007773.2	-12.33	1.07e-32	1.24e-29	-0.55	-0.36	Neuroticism;	chr19:32411498	chr19:32390050~32405560:-
BRCA	cis	rs67311347	1	rs11914297	ENSG00000223797.4	ENTPD3-AS1	12.33	1.07e-32	1.24e-29	0.41	0.36	Renal cell carcinoma;	chr3:40368579	chr3:40313802~40453329:-
BRCA	cis	rs6991838	0.584	rs1053085	ENSG00000272010.1	CTD-3025N20.3	-12.33	1.07e-32	1.24e-29	-0.38	-0.36	Intelligence (multi-trait analysis);	chr8:65603753	chr8:65591850~65592472:-
BRCA	cis	rs10256972	0.616	rs7806746	ENSG00000229043.2	AC091729.9	-12.33	1.07e-32	1.24e-29	-0.44	-0.36	Endometriosis;Longevity;	chr7:1035937	chr7:1160374~1165267:+
BRCA	cis	rs875971	0.929	rs778692	ENSG00000222364.1	RNU6-96P	-12.33	1.1e-32	1.28e-29	-0.41	-0.36	Aortic root size;	chr7:66407462	chr7:66395191~66395286:+
BRCA	cis	rs875971	1	rs4718343	ENSG00000222364.1	RNU6-96P	-12.33	1.1e-32	1.28e-29	-0.41	-0.36	Aortic root size;	chr7:66409301	chr7:66395191~66395286:+
BRCA	cis	rs875971	1	rs1968225	ENSG00000222364.1	RNU6-96P	-12.33	1.1e-32	1.28e-29	-0.41	-0.36	Aortic root size;	chr7:66409786	chr7:66395191~66395286:+
BRCA	cis	rs875971	1	rs6460295	ENSG00000222364.1	RNU6-96P	-12.33	1.1e-32	1.28e-29	-0.41	-0.36	Aortic root size;	chr7:66417741	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.964	rs6978721	ENSG00000222364.1	RNU6-96P	-12.33	1.1e-32	1.28e-29	-0.41	-0.36	Aortic root size;	chr7:66418217	chr7:66395191~66395286:+
BRCA	cis	rs6538678	0.824	rs7299632	ENSG00000258343.1	RP11-536G4.2	-12.32	1.11e-32	1.29e-29	-0.58	-0.36	Lupus nephritis in systemic lupus erythematosus;	chr12:95838376	chr12:95795345~95858839:-
BRCA	cis	rs1426063	0.614	rs75846524	ENSG00000260265.1	RP11-44F21.5	12.32	1.12e-32	1.3e-29	0.88	0.36	QT interval;	chr4:75083172	chr4:75081702~75084717:-
BRCA	cis	rs34779708	0.966	rs998658	ENSG00000230534.5	RP11-297A16.2	12.32	1.14e-32	1.32e-29	0.44	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35119726	chr10:35098006~35127020:-
BRCA	cis	rs10875746	0.903	rs10875740	ENSG00000240399.1	RP1-228P16.1	-12.32	1.15e-32	1.33e-29	-0.48	-0.36	Longevity (90 years and older);	chr12:48095334	chr12:48054813~48055591:-
BRCA	cis	rs875971	0.862	rs949930	ENSG00000222364.1	RNU6-96P	12.32	1.16e-32	1.35e-29	0.41	0.36	Aortic root size;	chr7:66301835	chr7:66395191~66395286:+
BRCA	cis	rs10875746	0.855	rs10875730	ENSG00000240399.1	RP1-228P16.1	-12.32	1.16e-32	1.35e-29	-0.48	-0.36	Longevity (90 years and older);	chr12:48034092	chr12:48054813~48055591:-
BRCA	cis	rs8062405	1	rs62036616	ENSG00000259982.1	CDC37P1	12.32	1.18e-32	1.37e-29	0.47	0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814986	chr16:28700294~28701540:-
BRCA	cis	rs2564921	0.666	rs62253656	ENSG00000242142.1	SERBP1P3	-12.32	1.2e-32	1.39e-29	-0.43	-0.36	Height;	chr3:52989412	chr3:53064283~53065091:-
BRCA	cis	rs6452524	0.868	rs2386235	ENSG00000249664.1	CTD-2227C6.2	12.32	1.21e-32	1.4e-29	0.45	0.36	Hypertension (SNP x SNP interaction);	chr5:83101452	chr5:83012285~83013109:-
BRCA	cis	rs10875746	0.81	rs10875732	ENSG00000240399.1	RP1-228P16.1	-12.32	1.21e-32	1.41e-29	-0.49	-0.36	Longevity (90 years and older);	chr12:48048322	chr12:48054813~48055591:-
BRCA	cis	rs2404602	0.647	rs12898416	ENSG00000259422.1	RP11-593F23.1	-12.32	1.22e-32	1.41e-29	-0.48	-0.36	Blood metabolite levels;	chr15:76749951	chr15:76174891~76181486:-
BRCA	cis	rs6991838	0.584	rs73236948	ENSG00000272010.1	CTD-3025N20.3	-12.32	1.23e-32	1.43e-29	-0.38	-0.36	Intelligence (multi-trait analysis);	chr8:65609176	chr8:65591850~65592472:-
BRCA	cis	rs7301826	0.966	rs4759795	ENSG00000256299.1	RP11-989F5.3	-12.32	1.24e-32	1.43e-29	-0.41	-0.36	Plasma plasminogen activator levels;	chr12:130816355	chr12:130810821~130812622:-
BRCA	cis	rs858239	1	rs166663	ENSG00000226816.2	AC005082.12	12.31	1.24e-32	1.43e-29	0.42	0.36	Cerebrospinal fluid biomarker levels;	chr7:23277123	chr7:23206013~23208045:+
BRCA	cis	rs34779708	0.931	rs4934535	ENSG00000230534.5	RP11-297A16.2	12.31	1.24e-32	1.44e-29	0.46	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35143793	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.966	rs4934734	ENSG00000230534.5	RP11-297A16.2	12.31	1.24e-32	1.44e-29	0.46	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35145445	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.966	rs12769575	ENSG00000230534.5	RP11-297A16.2	12.31	1.24e-32	1.44e-29	0.46	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35146999	chr10:35098006~35127020:-
BRCA	cis	rs2739330	0.587	rs4820571	ENSG00000231271.1	AP000350.8	12.31	1.25e-32	1.45e-29	0.44	0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23949918~23954042:+
BRCA	cis	rs7849270	0.959	rs3124509	ENSG00000268707.1	RP11-247A12.7	12.31	1.25e-32	1.45e-29	0.45	0.36	Blood metabolite ratios;	chr9:129134720	chr9:129170434~129170940:+
BRCA	cis	rs6991838	0.584	rs4737747	ENSG00000272010.1	CTD-3025N20.3	-12.31	1.26e-32	1.46e-29	-0.38	-0.36	Intelligence (multi-trait analysis);	chr8:65607024	chr8:65591850~65592472:-
BRCA	cis	rs875971	0.862	rs709596	ENSG00000222364.1	RNU6-96P	-12.31	1.26e-32	1.46e-29	-0.41	-0.36	Aortic root size;	chr7:66360926	chr7:66395191~66395286:+
BRCA	cis	rs8100891	0.537	rs28672356	ENSG00000267213.4	AC007773.2	-12.31	1.26e-32	1.46e-29	-0.53	-0.36	Neuroticism;	chr19:32416937	chr19:32390050~32405560:-
BRCA	cis	rs7849270	1	rs3124511	ENSG00000268707.1	RP11-247A12.7	12.31	1.27e-32	1.47e-29	0.46	0.36	Blood metabolite ratios;	chr9:129139179	chr9:129170434~129170940:+
BRCA	cis	rs10129255	0.536	rs3944157	ENSG00000223648.3	IGHV3-64	12.31	1.29e-32	1.49e-29	0.28	0.36	Kawasaki disease;	chr14:106682286	chr14:106643132~106658258:-
BRCA	cis	rs853679	0.517	rs9393895	ENSG00000220721.1	OR1F12	12.31	1.29e-32	1.5e-29	0.48	0.36	Depression;	chr6:28159843	chr6:28073316~28074233:+
BRCA	cis	rs6452524	0.868	rs10057303	ENSG00000249664.1	CTD-2227C6.2	12.31	1.3e-32	1.5e-29	0.45	0.36	Hypertension (SNP x SNP interaction);	chr5:83098564	chr5:83012285~83013109:-
BRCA	cis	rs858239	0.932	rs858275	ENSG00000226816.2	AC005082.12	12.31	1.3e-32	1.51e-29	0.41	0.36	Cerebrospinal fluid biomarker levels;	chr7:23254525	chr7:23206013~23208045:+
BRCA	cis	rs2117029	0.586	rs2114846	ENSG00000258017.1	RP11-386G11.10	-12.31	1.3e-32	1.51e-29	-0.48	-0.36	Intelligence (multi-trait analysis);	chr12:49154493	chr12:49127782~49147869:+
BRCA	cis	rs2564921	0.615	rs56129941	ENSG00000242142.1	SERBP1P3	-12.31	1.31e-32	1.51e-29	-0.44	-0.36	Height;	chr3:53007328	chr3:53064283~53065091:-
BRCA	cis	rs2015599	0.54	rs12301475	ENSG00000257176.2	RP11-996F15.2	12.31	1.31e-32	1.52e-29	0.43	0.36	Platelet count;Mean platelet volume;	chr12:29253144	chr12:29280418~29317848:-
BRCA	cis	rs34779708	0.966	rs11010095	ENSG00000230534.5	RP11-297A16.2	12.31	1.34e-32	1.55e-29	0.44	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35107020	chr10:35098006~35127020:-
BRCA	cis	rs875971	1	rs778696	ENSG00000222364.1	RNU6-96P	-12.31	1.37e-32	1.58e-29	-0.41	-0.36	Aortic root size;	chr7:66405826	chr7:66395191~66395286:+
BRCA	cis	rs875971	1	rs778694	ENSG00000222364.1	RNU6-96P	-12.31	1.37e-32	1.58e-29	-0.41	-0.36	Aortic root size;	chr7:66406571	chr7:66395191~66395286:+
BRCA	cis	rs875971	1	rs4718344	ENSG00000222364.1	RNU6-96P	-12.31	1.37e-32	1.58e-29	-0.41	-0.36	Aortic root size;	chr7:66409394	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.737	rs7803424	ENSG00000222364.1	RNU6-96P	-12.31	1.37e-32	1.58e-29	-0.41	-0.36	Aortic root size;	chr7:66415618	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.83	rs7799834	ENSG00000222364.1	RNU6-96P	-12.31	1.37e-32	1.58e-29	-0.41	-0.36	Aortic root size;	chr7:66415707	chr7:66395191~66395286:+
BRCA	cis	rs2404602	0.647	rs11072618	ENSG00000259422.1	RP11-593F23.1	-12.3	1.38e-32	1.6e-29	-0.48	-0.36	Blood metabolite levels;	chr15:76727001	chr15:76174891~76181486:-
BRCA	cis	rs875971	0.964	rs778708	ENSG00000222364.1	RNU6-96P	-12.3	1.4e-32	1.62e-29	-0.41	-0.36	Aortic root size;	chr7:66391332	chr7:66395191~66395286:+
BRCA	cis	rs34779708	0.966	rs4934536	ENSG00000230534.5	RP11-297A16.2	12.3	1.4e-32	1.62e-29	0.46	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35152241	chr10:35098006~35127020:-
BRCA	cis	rs8040855	0.597	rs12902942	ENSG00000259295.5	CSPG4P12	12.3	1.41e-32	1.62e-29	0.52	0.36	Bulimia nervosa;	chr15:85041573	chr15:85191438~85213905:+
BRCA	cis	rs7849270	1	rs3124512	ENSG00000268707.1	RP11-247A12.7	12.3	1.41e-32	1.62e-29	0.45	0.36	Blood metabolite ratios;	chr9:129141602	chr9:129170434~129170940:+
BRCA	cis	rs34779708	0.966	rs12775548	ENSG00000230534.5	RP11-297A16.2	12.3	1.41e-32	1.63e-29	0.46	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35190576	chr10:35098006~35127020:-
BRCA	cis	rs875971	0.862	rs10282433	ENSG00000222364.1	RNU6-96P	12.3	1.42e-32	1.64e-29	0.41	0.36	Aortic root size;	chr7:66256452	chr7:66395191~66395286:+
BRCA	cis	rs11673344	0.566	rs185368	ENSG00000226686.6	LINC01535	-12.3	1.42e-32	1.64e-29	-0.46	-0.36	Obesity-related traits;	chr19:37381827	chr19:37251912~37265535:+
BRCA	cis	rs11673344	0.566	rs185369	ENSG00000226686.6	LINC01535	-12.3	1.42e-32	1.64e-29	-0.46	-0.36	Obesity-related traits;	chr19:37376137	chr19:37251912~37265535:+
BRCA	cis	rs6538678	0.857	rs4762626	ENSG00000258343.1	RP11-536G4.2	-12.3	1.43e-32	1.65e-29	-0.57	-0.36	Lupus nephritis in systemic lupus erythematosus;	chr12:95811383	chr12:95795345~95858839:-
BRCA	cis	rs11690935	0.851	rs10201430	ENSG00000228389.1	AC068039.4	12.3	1.44e-32	1.66e-29	0.44	0.36	Schizophrenia;	chr2:171956715	chr2:171773482~171775844:+
BRCA	cis	rs4380275	0.782	rs11691064	ENSG00000223751.1	AC116609.2	12.3	1.44e-32	1.66e-29	0.44	0.36	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:755718	chr2:742488~747767:+
BRCA	cis	rs2404602	0.647	rs1443115	ENSG00000259422.1	RP11-593F23.1	-12.3	1.44e-32	1.66e-29	-0.48	-0.36	Blood metabolite levels;	chr15:76749488	chr15:76174891~76181486:-
BRCA	cis	rs10875746	0.951	rs2228500	ENSG00000240399.1	RP1-228P16.1	12.3	1.46e-32	1.69e-29	0.48	0.36	Longevity (90 years and older);	chr12:48132929	chr12:48054813~48055591:-
BRCA	cis	rs875971	1	rs9986696	ENSG00000222364.1	RNU6-96P	12.3	1.46e-32	1.69e-29	0.41	0.36	Aortic root size;	chr7:66239589	chr7:66395191~66395286:+
BRCA	cis	rs853679	0.517	rs9357065	ENSG00000220721.1	OR1F12	12.3	1.5e-32	1.73e-29	0.48	0.36	Depression;	chr6:28161802	chr6:28073316~28074233:+
BRCA	cis	rs1891275	0.551	rs2000177	ENSG00000228701.1	TNKS2-AS1	-12.3	1.5e-32	1.73e-29	-0.47	-0.36	Intelligence (multi-trait analysis);	chr10:91653237	chr10:91782839~91798291:-
BRCA	cis	rs858239	1	rs156421	ENSG00000226816.2	AC005082.12	12.3	1.5e-32	1.73e-29	0.41	0.36	Cerebrospinal fluid biomarker levels;	chr7:23272868	chr7:23206013~23208045:+
BRCA	cis	rs2188561	0.697	rs7787927	ENSG00000241764.3	AC002467.7	12.3	1.51e-32	1.74e-29	0.47	0.36	Alcohol consumption;	chr7:107763915	chr7:107742817~107744581:-
BRCA	cis	rs8040855	0.627	rs11630697	ENSG00000259295.5	CSPG4P12	12.3	1.51e-32	1.74e-29	0.52	0.36	Bulimia nervosa;	chr15:85063214	chr15:85191438~85213905:+
BRCA	cis	rs2564921	0.704	rs56155510	ENSG00000242142.1	SERBP1P3	-12.3	1.52e-32	1.75e-29	-0.44	-0.36	Height;	chr3:53009621	chr3:53064283~53065091:-
BRCA	cis	rs2337406	0.925	rs76288499	ENSG00000274576.2	IGHV2-70	-12.3	1.54e-32	1.77e-29	-0.41	-0.36	Alzheimer's disease (late onset);	chr14:106686309	chr14:106770577~106771020:-
BRCA	cis	rs8062405	0.964	rs7187333	ENSG00000259982.1	CDC37P1	12.3	1.54e-32	1.77e-29	0.47	0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28854595	chr16:28700294~28701540:-
BRCA	cis	rs8062405	0.755	rs62031607	ENSG00000259982.1	CDC37P1	12.29	1.55e-32	1.78e-29	0.47	0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620209	chr16:28700294~28701540:-
BRCA	cis	rs7849270	1	rs7037163	ENSG00000268707.1	RP11-247A12.7	-12.29	1.56e-32	1.8e-29	-0.46	-0.36	Blood metabolite ratios;	chr9:129132061	chr9:129170434~129170940:+
BRCA	cis	rs2117029	0.619	rs2753	ENSG00000258017.1	RP11-386G11.10	-12.29	1.56e-32	1.8e-29	-0.48	-0.36	Intelligence (multi-trait analysis);	chr12:49127889	chr12:49127782~49147869:+
BRCA	cis	rs2117029	0.586	rs10783308	ENSG00000258017.1	RP11-386G11.10	-12.29	1.57e-32	1.81e-29	-0.48	-0.36	Intelligence (multi-trait analysis);	chr12:49137675	chr12:49127782~49147869:+
BRCA	cis	rs875971	1	rs778726	ENSG00000222364.1	RNU6-96P	-12.29	1.57e-32	1.81e-29	-0.41	-0.36	Aortic root size;	chr7:66363744	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.767	rs1695815	ENSG00000222364.1	RNU6-96P	-12.29	1.57e-32	1.81e-29	-0.41	-0.36	Aortic root size;	chr7:66366357	chr7:66395191~66395286:+
BRCA	cis	rs875971	1	rs778685	ENSG00000222364.1	RNU6-96P	-12.29	1.57e-32	1.81e-29	-0.41	-0.36	Aortic root size;	chr7:66371189	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.929	rs778682	ENSG00000222364.1	RNU6-96P	-12.29	1.57e-32	1.81e-29	-0.41	-0.36	Aortic root size;	chr7:66372947	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.964	rs11765965	ENSG00000222364.1	RNU6-96P	-12.29	1.57e-32	1.81e-29	-0.41	-0.36	Aortic root size;	chr7:66377234	chr7:66395191~66395286:+
BRCA	cis	rs3823536	0.583	rs921403	ENSG00000275106.1	RP11-309L24.10	-12.29	1.58e-32	1.82e-29	-0.46	-0.36	Sjögren's syndrome;	chr7:129036670	chr7:128952527~128953316:-
BRCA	cis	rs4774565	0.762	rs11634585	ENSG00000244879.4	GABPB1-AS1	12.29	1.6e-32	1.84e-29	0.37	0.36	Breast cancer;	chr15:50364252	chr15:50354959~50372202:+
BRCA	cis	rs4423214	0.879	rs1792277	ENSG00000254682.1	RP11-660L16.2	-12.29	1.6e-32	1.84e-29	-0.48	-0.36	Vitamin D levels;	chr11:71427872	chr11:71448674~71452157:+
BRCA	cis	rs853679	0.517	rs9393896	ENSG00000220721.1	OR1F12	12.29	1.61e-32	1.85e-29	0.48	0.36	Depression;	chr6:28159925	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.517	rs9393897	ENSG00000220721.1	OR1F12	12.29	1.61e-32	1.85e-29	0.48	0.36	Depression;	chr6:28159932	chr6:28073316~28074233:+
BRCA	cis	rs34779708	0.966	rs35814343	ENSG00000230534.5	RP11-297A16.2	12.29	1.63e-32	1.88e-29	0.46	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35138786	chr10:35098006~35127020:-
BRCA	cis	rs10256972	0.713	rs10435026	ENSG00000229043.2	AC091729.9	-12.29	1.66e-32	1.9e-29	-0.47	-0.36	Endometriosis;Longevity;	chr7:1026312	chr7:1160374~1165267:+
BRCA	cis	rs34779708	0.966	rs12762493	ENSG00000230534.5	RP11-297A16.2	12.29	1.67e-32	1.91e-29	0.44	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35182945	chr10:35098006~35127020:-
BRCA	cis	rs11690935	0.851	rs6433319	ENSG00000228389.1	AC068039.4	12.28	1.77e-32	2.03e-29	0.44	0.36	Schizophrenia;	chr2:171974442	chr2:171773482~171775844:+
BRCA	cis	rs858239	1	rs156425	ENSG00000226816.2	AC005082.12	-12.28	1.77e-32	2.03e-29	-0.41	-0.36	Cerebrospinal fluid biomarker levels;	chr7:23269500	chr7:23206013~23208045:+
BRCA	cis	rs6991838	0.557	rs7012578	ENSG00000272010.1	CTD-3025N20.3	-12.28	1.78e-32	2.04e-29	-0.38	-0.36	Intelligence (multi-trait analysis);	chr8:65592592	chr8:65591850~65592472:-
BRCA	cis	rs34779708	0.966	rs4934537	ENSG00000230534.5	RP11-297A16.2	12.28	1.78e-32	2.05e-29	0.46	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35152584	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.966	rs12784482	ENSG00000230534.5	RP11-297A16.2	12.28	1.78e-32	2.05e-29	0.46	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35157937	chr10:35098006~35127020:-
BRCA	cis	rs853679	0.517	rs9468298	ENSG00000220721.1	OR1F12	12.28	1.84e-32	2.11e-29	0.48	0.36	Depression;	chr6:28154567	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.517	rs9295759	ENSG00000220721.1	OR1F12	12.28	1.84e-32	2.11e-29	0.48	0.36	Depression;	chr6:28156691	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.517	rs9348796	ENSG00000220721.1	OR1F12	12.28	1.84e-32	2.11e-29	0.48	0.36	Depression;	chr6:28158424	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.517	rs11552219	ENSG00000220721.1	OR1F12	12.28	1.84e-32	2.11e-29	0.48	0.36	Depression;	chr6:28159056	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.517	rs9357066	ENSG00000220721.1	OR1F12	12.28	1.84e-32	2.11e-29	0.48	0.36	Depression;	chr6:28162053	chr6:28073316~28074233:+
BRCA	cis	rs875971	0.895	rs778700	ENSG00000222364.1	RNU6-96P	-12.28	1.84e-32	2.11e-29	-0.41	-0.36	Aortic root size;	chr7:66401463	chr7:66395191~66395286:+
BRCA	cis	rs875971	1	rs778699	ENSG00000222364.1	RNU6-96P	-12.28	1.84e-32	2.11e-29	-0.41	-0.36	Aortic root size;	chr7:66403303	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.862	rs778724	ENSG00000222364.1	RNU6-96P	-12.28	1.85e-32	2.12e-29	-0.42	-0.36	Aortic root size;	chr7:66364304	chr7:66395191~66395286:+
BRCA	cis	rs3823536	0.583	rs1072767	ENSG00000275106.1	RP11-309L24.10	-12.28	1.87e-32	2.14e-29	-0.46	-0.36	Sjögren's syndrome;	chr7:129033151	chr7:128952527~128953316:-
BRCA	cis	rs875971	0.825	rs4587224	ENSG00000222364.1	RNU6-96P	12.28	1.89e-32	2.16e-29	0.41	0.36	Aortic root size;	chr7:66271195	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.792	rs6971752	ENSG00000222364.1	RNU6-96P	12.28	1.89e-32	2.16e-29	0.41	0.36	Aortic root size;	chr7:66272999	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.862	rs10950033	ENSG00000222364.1	RNU6-96P	12.28	1.89e-32	2.16e-29	0.41	0.36	Aortic root size;	chr7:66274686	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.862	rs11760844	ENSG00000222364.1	RNU6-96P	12.28	1.89e-32	2.16e-29	0.41	0.36	Aortic root size;	chr7:66274896	chr7:66395191~66395286:+
BRCA	cis	rs11690935	0.851	rs6731562	ENSG00000228389.1	AC068039.4	12.28	1.9e-32	2.18e-29	0.44	0.36	Schizophrenia;	chr2:171941742	chr2:171773482~171775844:+
BRCA	cis	rs1150668	0.83	rs2531831	ENSG00000216901.1	AL022393.7	12.27	1.91e-32	2.18e-29	0.43	0.36	Pubertal anthropometrics;	chr6:28420988	chr6:28176188~28176674:+
BRCA	cis	rs10875746	0.855	rs10875731	ENSG00000240399.1	RP1-228P16.1	-12.27	1.91e-32	2.19e-29	-0.48	-0.36	Longevity (90 years and older);	chr12:48038960	chr12:48054813~48055591:-
BRCA	cis	rs875971	1	rs709595	ENSG00000222364.1	RNU6-96P	-12.27	1.91e-32	2.19e-29	-0.41	-0.36	Aortic root size;	chr7:66352346	chr7:66395191~66395286:+
BRCA	cis	rs875971	1	rs811880	ENSG00000222364.1	RNU6-96P	-12.27	1.91e-32	2.19e-29	-0.41	-0.36	Aortic root size;	chr7:66353659	chr7:66395191~66395286:+
BRCA	cis	rs7849270	1	rs932835	ENSG00000268707.1	RP11-247A12.7	-12.27	1.92e-32	2.19e-29	-0.45	-0.36	Blood metabolite ratios;	chr9:129124792	chr9:129170434~129170940:+
BRCA	cis	rs2117029	0.556	rs1057725	ENSG00000258017.1	RP11-386G11.10	-12.27	1.94e-32	2.21e-29	-0.48	-0.36	Intelligence (multi-trait analysis);	chr12:49128795	chr12:49127782~49147869:+
BRCA	cis	rs67311347	1	rs9849992	ENSG00000223797.4	ENTPD3-AS1	12.27	1.94e-32	2.22e-29	0.4	0.36	Renal cell carcinoma;	chr3:40360649	chr3:40313802~40453329:-
BRCA	cis	rs3823536	0.583	rs11760442	ENSG00000275106.1	RP11-309L24.10	-12.27	1.94e-32	2.22e-29	-0.46	-0.36	Sjögren's syndrome;	chr7:129016066	chr7:128952527~128953316:-
BRCA	cis	rs3823536	0.583	rs3847099	ENSG00000275106.1	RP11-309L24.10	-12.27	1.94e-32	2.22e-29	-0.46	-0.36	Sjögren's syndrome;	chr7:129016777	chr7:128952527~128953316:-
BRCA	cis	rs3823536	0.604	rs3857852	ENSG00000275106.1	RP11-309L24.10	-12.27	1.94e-32	2.22e-29	-0.46	-0.36	Sjögren's syndrome;	chr7:129017223	chr7:128952527~128953316:-
BRCA	cis	rs875971	0.964	rs778723	ENSG00000222364.1	RNU6-96P	-12.27	1.95e-32	2.23e-29	-0.41	-0.36	Aortic root size;	chr7:66364510	chr7:66395191~66395286:+
BRCA	cis	rs34779708	0.966	rs1545757	ENSG00000230534.5	RP11-297A16.2	12.27	1.95e-32	2.23e-29	0.46	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35156660	chr10:35098006~35127020:-
BRCA	cis	rs875971	1	rs2420168	ENSG00000222364.1	RNU6-96P	12.27	1.96e-32	2.24e-29	0.41	0.36	Aortic root size;	chr7:66165644	chr7:66395191~66395286:+
BRCA	cis	rs2108622	1	rs55744319	ENSG00000267453.5	AC004791.2	-12.27	1.96e-32	2.24e-29	-0.46	-0.36	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871011	chr19:15851993~15864904:-
BRCA	cis	rs8100891	0.537	rs737093	ENSG00000267213.4	AC007773.2	-12.27	1.96e-32	2.24e-29	-0.53	-0.36	Neuroticism;	chr19:32486500	chr19:32390050~32405560:-
BRCA	cis	rs875971	0.965	rs28682868	ENSG00000222364.1	RNU6-96P	12.27	2e-32	2.28e-29	0.41	0.36	Aortic root size;	chr7:66224822	chr7:66395191~66395286:+
BRCA	cis	rs67180937	0.645	rs1909197	ENSG00000272750.1	RP11-378J18.8	-12.27	2.09e-32	2.39e-29	-0.49	-0.36	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222645879	chr1:222658867~222661512:-
BRCA	cis	rs7849270	1	rs3739847	ENSG00000268707.1	RP11-247A12.7	12.27	2.1e-32	2.4e-29	0.44	0.36	Blood metabolite ratios;	chr9:129149295	chr9:129170434~129170940:+
BRCA	cis	rs2283792	0.73	rs738858	ENSG00000224086.5	LL22NC03-86G7.1	-12.27	2.1e-32	2.4e-29	-0.37	-0.36	Multiple sclerosis;	chr22:21926544	chr22:21938293~21977632:+
BRCA	cis	rs875971	0.862	rs10276077	ENSG00000222364.1	RNU6-96P	12.26	2.13e-32	2.44e-29	0.41	0.36	Aortic root size;	chr7:66263424	chr7:66395191~66395286:+
BRCA	cis	rs3091242	0.933	rs926438	ENSG00000224183.1	SDHDP6	-12.26	2.14e-32	2.44e-29	-0.43	-0.36	Erythrocyte sedimentation rate;	chr1:25427147	chr1:25294164~25294643:-
BRCA	cis	rs875971	0.862	rs6959268	ENSG00000222364.1	RNU6-96P	12.26	2.19e-32	2.5e-29	0.41	0.36	Aortic root size;	chr7:66347979	chr7:66395191~66395286:+
BRCA	cis	rs875971	1	rs2077593	ENSG00000222364.1	RNU6-96P	-12.26	2.23e-32	2.54e-29	-0.41	-0.36	Aortic root size;	chr7:66427543	chr7:66395191~66395286:+
BRCA	cis	rs12134133	1	rs2802235	ENSG00000274245.1	RP11-357P18.2	12.26	2.24e-32	2.55e-29	0.49	0.36	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207298454	chr1:207372559~207373252:+
BRCA	cis	rs853679	0.517	rs9368556	ENSG00000220721.1	OR1F12	12.26	2.25e-32	2.56e-29	0.48	0.36	Depression;	chr6:28163375	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.517	rs9368557	ENSG00000220721.1	OR1F12	12.26	2.25e-32	2.56e-29	0.48	0.36	Depression;	chr6:28163759	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.517	rs9380059	ENSG00000220721.1	OR1F12	12.26	2.25e-32	2.56e-29	0.48	0.36	Depression;	chr6:28164580	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.517	rs9380060	ENSG00000220721.1	OR1F12	12.26	2.25e-32	2.56e-29	0.48	0.36	Depression;	chr6:28164825	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.517	rs35227624	ENSG00000220721.1	OR1F12	12.26	2.25e-32	2.56e-29	0.48	0.36	Depression;	chr6:28164948	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.517	rs9380061	ENSG00000220721.1	OR1F12	12.26	2.25e-32	2.56e-29	0.48	0.36	Depression;	chr6:28165025	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.517	rs9368558	ENSG00000220721.1	OR1F12	12.26	2.25e-32	2.56e-29	0.48	0.36	Depression;	chr6:28165528	chr6:28073316~28074233:+
BRCA	cis	rs34779708	0.966	rs2045915	ENSG00000230534.5	RP11-297A16.2	12.26	2.32e-32	2.64e-29	0.44	0.35	Inflammatory bowel disease;Crohn's disease;	chr10:35129688	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.966	rs35146199	ENSG00000230534.5	RP11-297A16.2	12.26	2.34e-32	2.67e-29	0.46	0.35	Inflammatory bowel disease;Crohn's disease;	chr10:35172011	chr10:35098006~35127020:-
BRCA	cis	rs67311347	1	rs11715214	ENSG00000223797.4	ENTPD3-AS1	12.25	2.44e-32	2.77e-29	0.4	0.35	Renal cell carcinoma;	chr3:40361513	chr3:40313802~40453329:-
BRCA	cis	rs853679	0.517	rs12332979	ENSG00000220721.1	OR1F12	12.25	2.49e-32	2.84e-29	0.47	0.35	Depression;	chr6:28173770	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.517	rs67878650	ENSG00000220721.1	OR1F12	12.25	2.49e-32	2.84e-29	0.47	0.35	Depression;	chr6:28174809	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.569	rs9348798	ENSG00000220721.1	OR1F12	12.25	2.49e-32	2.84e-29	0.47	0.35	Depression;	chr6:28175233	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.517	rs9380065	ENSG00000220721.1	OR1F12	12.25	2.49e-32	2.84e-29	0.47	0.35	Depression;	chr6:28176973	chr6:28073316~28074233:+
BRCA	cis	rs2117029	0.653	rs1476137	ENSG00000258017.1	RP11-386G11.10	-12.25	2.5e-32	2.84e-29	-0.48	-0.35	Intelligence (multi-trait analysis);	chr12:49129930	chr12:49127782~49147869:+
BRCA	cis	rs2404602	0.672	rs35374222	ENSG00000259422.1	RP11-593F23.1	-12.25	2.51e-32	2.85e-29	-0.47	-0.35	Blood metabolite levels;	chr15:76779053	chr15:76174891~76181486:-
BRCA	cis	rs875971	0.964	rs778721	ENSG00000222364.1	RNU6-96P	-12.25	2.52e-32	2.87e-29	-0.41	-0.35	Aortic root size;	chr7:66380410	chr7:66395191~66395286:+
BRCA	cis	rs875971	1	rs11974219	ENSG00000222364.1	RNU6-96P	12.25	2.53e-32	2.88e-29	0.41	0.35	Aortic root size;	chr7:66182423	chr7:66395191~66395286:+
BRCA	cis	rs2919917	0.628	rs2717544	ENSG00000254352.1	RP11-578O24.2	-12.25	2.53e-32	2.88e-29	-0.49	-0.35	Lymphocyte counts;	chr8:78724307	chr8:78723796~78724136:-
BRCA	cis	rs2019137	0.936	rs12620738	ENSG00000274877.1	RP11-65I12.1	12.25	2.57e-32	2.92e-29	0.46	0.35	Lymphocyte counts;	chr2:113206162	chr2:113237595~113240825:+
BRCA	cis	rs2108622	0.958	rs56340170	ENSG00000267453.5	AC004791.2	-12.25	2.58e-32	2.93e-29	-0.46	-0.35	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871067	chr19:15851993~15864904:-
BRCA	cis	rs2404602	0.647	rs12904149	ENSG00000259422.1	RP11-593F23.1	-12.25	2.59e-32	2.94e-29	-0.47	-0.35	Blood metabolite levels;	chr15:76751311	chr15:76174891~76181486:-
BRCA	cis	rs6991838	0.53	rs6472217	ENSG00000200714.1	Y_RNA	12.25	2.6e-32	2.95e-29	0.41	0.35	Intelligence (multi-trait analysis);	chr8:65635496	chr8:65592731~65592820:+
BRCA	cis	rs6991838	0.584	rs6472218	ENSG00000200714.1	Y_RNA	12.25	2.6e-32	2.95e-29	0.41	0.35	Intelligence (multi-trait analysis);	chr8:65635502	chr8:65592731~65592820:+
BRCA	cis	rs875971	0.964	rs1643388	ENSG00000222364.1	RNU6-96P	-12.25	2.63e-32	2.99e-29	-0.41	-0.35	Aortic root size;	chr7:66379575	chr7:66395191~66395286:+
BRCA	cis	rs875971	1	rs778722	ENSG00000222364.1	RNU6-96P	-12.25	2.63e-32	2.99e-29	-0.41	-0.35	Aortic root size;	chr7:66379841	chr7:66395191~66395286:+
BRCA	cis	rs8100891	0.537	rs2302772	ENSG00000267213.4	AC007773.2	-12.24	2.64e-32	3e-29	-0.53	-0.35	Neuroticism;	chr19:32411144	chr19:32390050~32405560:-
BRCA	cis	rs2404602	0.647	rs12439141	ENSG00000259422.1	RP11-593F23.1	-12.24	2.65e-32	3.01e-29	-0.48	-0.35	Blood metabolite levels;	chr15:76803082	chr15:76174891~76181486:-
BRCA	cis	rs853679	0.517	rs4713146	ENSG00000220721.1	OR1F12	12.24	2.65e-32	3.01e-29	0.48	0.35	Depression;	chr6:28143758	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.517	rs9393894	ENSG00000220721.1	OR1F12	12.24	2.65e-32	3.01e-29	0.48	0.35	Depression;	chr6:28144784	chr6:28073316~28074233:+
BRCA	cis	rs2019137	0.936	rs3811059	ENSG00000274877.1	RP11-65I12.1	12.24	2.68e-32	3.04e-29	0.46	0.35	Lymphocyte counts;	chr2:113204494	chr2:113237595~113240825:+
BRCA	cis	rs2739330	0.587	rs4820571	ENSG00000099984.9	GSTT2	-12.24	2.7e-32	3.06e-29	-0.43	-0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23980123~23983911:+
BRCA	cis	rs853679	0.513	rs9468296	ENSG00000220721.1	OR1F12	12.24	2.71e-32	3.08e-29	0.48	0.35	Depression;	chr6:28145952	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.517	rs9295761	ENSG00000220721.1	OR1F12	12.24	2.72e-32	3.09e-29	0.47	0.35	Depression;	chr6:28180209	chr6:28073316~28074233:+
BRCA	cis	rs10875746	0.855	rs11168369	ENSG00000240399.1	RP1-228P16.1	-12.24	2.72e-32	3.09e-29	-0.48	-0.35	Longevity (90 years and older);	chr12:48037385	chr12:48054813~48055591:-
BRCA	cis	rs8177376	1	rs17656	ENSG00000254905.1	RP11-712L6.7	12.24	2.74e-32	3.11e-29	0.51	0.35	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126263287	chr11:126292922~126294254:-
BRCA	cis	rs11676348	0.818	rs1126579	ENSG00000261338.2	RP11-378A13.1	-12.24	2.78e-32	3.15e-29	-0.38	-0.35	Ulcerative colitis;	chr2:218136011	chr2:218255319~218257366:+
BRCA	cis	rs875971	1	rs937495	ENSG00000222364.1	RNU6-96P	12.24	2.85e-32	3.23e-29	0.41	0.35	Aortic root size;	chr7:66314811	chr7:66395191~66395286:+
BRCA	cis	rs875971	1	rs2036264	ENSG00000222364.1	RNU6-96P	12.24	2.85e-32	3.23e-29	0.41	0.35	Aortic root size;	chr7:66334917	chr7:66395191~66395286:+
BRCA	cis	rs875971	1	rs7783613	ENSG00000222364.1	RNU6-96P	12.24	2.85e-32	3.23e-29	0.41	0.35	Aortic root size;	chr7:66340274	chr7:66395191~66395286:+
BRCA	cis	rs34779708	0.931	rs4934731	ENSG00000230534.5	RP11-297A16.2	12.24	2.85e-32	3.24e-29	0.44	0.35	Inflammatory bowel disease;Crohn's disease;	chr10:35142708	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.966	rs57081218	ENSG00000230534.5	RP11-297A16.2	12.24	2.86e-32	3.24e-29	0.44	0.35	Inflammatory bowel disease;Crohn's disease;	chr10:35145680	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.897	rs35784065	ENSG00000230534.5	RP11-297A16.2	12.24	2.87e-32	3.25e-29	0.46	0.35	Inflammatory bowel disease;Crohn's disease;	chr10:35064646	chr10:35098006~35127020:-
BRCA	cis	rs4718428	0.705	rs2901311	ENSG00000226824.5	RP4-756H11.3	-12.24	2.87e-32	3.25e-29	-0.49	-0.35	Corneal structure;	chr7:66950082	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.838	rs2173570	ENSG00000222364.1	RNU6-96P	12.24	2.87e-32	3.26e-29	0.41	0.35	Aortic root size;	chr7:66297976	chr7:66395191~66395286:+
BRCA	cis	rs6538678	0.746	rs4762630	ENSG00000258343.1	RP11-536G4.2	-12.24	2.9e-32	3.29e-29	-0.58	-0.35	Lupus nephritis in systemic lupus erythematosus;	chr12:95850631	chr12:95795345~95858839:-
BRCA	cis	rs10129255	0.536	rs10139058	ENSG00000223648.3	IGHV3-64	12.24	2.9e-32	3.29e-29	0.28	0.35	Kawasaki disease;	chr14:106685899	chr14:106643132~106658258:-
BRCA	cis	rs8062405	0.964	rs62036614	ENSG00000259982.1	CDC37P1	12.24	2.9e-32	3.29e-29	0.47	0.35	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28813364	chr16:28700294~28701540:-
BRCA	cis	rs7586673	1	rs16845584	ENSG00000227403.1	AC009299.3	12.24	2.91e-32	3.3e-29	0.48	0.35	Intelligence (multi-trait analysis);	chr2:161067319	chr2:161244739~161249050:+
BRCA	cis	rs875971	0.964	rs778735	ENSG00000222364.1	RNU6-96P	-12.24	2.91e-32	3.3e-29	-0.41	-0.35	Aortic root size;	chr7:66349822	chr7:66395191~66395286:+
BRCA	cis	rs34779708	0.966	rs17499811	ENSG00000230534.5	RP11-297A16.2	12.24	2.92e-32	3.3e-29	0.46	0.35	Inflammatory bowel disease;Crohn's disease;	chr10:35167287	chr10:35098006~35127020:-
BRCA	cis	rs875971	1	rs55962648	ENSG00000222364.1	RNU6-96P	12.23	2.95e-32	3.35e-29	0.41	0.35	Aortic root size;	chr7:66160764	chr7:66395191~66395286:+
BRCA	cis	rs3823536	0.583	rs6973975	ENSG00000275106.1	RP11-309L24.10	-12.23	3e-32	3.4e-29	-0.46	-0.35	Sjögren's syndrome;	chr7:129035495	chr7:128952527~128953316:-
BRCA	cis	rs875971	0.928	rs2036263	ENSG00000222364.1	RNU6-96P	12.23	3.03e-32	3.44e-29	0.41	0.35	Aortic root size;	chr7:66335210	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.862	rs10240949	ENSG00000222364.1	RNU6-96P	12.23	3.03e-32	3.44e-29	0.41	0.35	Aortic root size;	chr7:66339430	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.862	rs7782704	ENSG00000222364.1	RNU6-96P	12.23	3.03e-32	3.44e-29	0.41	0.35	Aortic root size;	chr7:66340379	chr7:66395191~66395286:+
BRCA	cis	rs67311347	1	rs17078511	ENSG00000223797.4	ENTPD3-AS1	12.23	3.15e-32	3.56e-29	0.4	0.35	Renal cell carcinoma;	chr3:40354763	chr3:40313802~40453329:-
BRCA	cis	rs34779708	0.966	rs4934538	ENSG00000230534.5	RP11-297A16.2	12.23	3.16e-32	3.57e-29	0.46	0.35	Inflammatory bowel disease;Crohn's disease;	chr10:35183222	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.931	rs11010067	ENSG00000230534.5	RP11-297A16.2	-12.23	3.22e-32	3.64e-29	-0.44	-0.35	Inflammatory bowel disease;Crohn's disease;	chr10:35006503	chr10:35098006~35127020:-
BRCA	cis	rs875971	1	rs778706	ENSG00000222364.1	RNU6-96P	-12.23	3.22e-32	3.64e-29	-0.41	-0.35	Aortic root size;	chr7:66395437	chr7:66395191~66395286:+
BRCA	cis	rs7301826	1	rs10848205	ENSG00000256299.1	RP11-989F5.3	-12.23	3.26e-32	3.69e-29	-0.4	-0.35	Plasma plasminogen activator levels;	chr12:130796169	chr12:130810821~130812622:-
BRCA	cis	rs875971	0.862	rs4149461	ENSG00000222364.1	RNU6-96P	12.22	3.27e-32	3.7e-29	0.41	0.35	Aortic root size;	chr7:66279745	chr7:66395191~66395286:+
BRCA	cis	rs9487094	0.67	rs2024849	ENSG00000260273.1	RP11-425D10.10	12.22	3.29e-32	3.71e-29	0.41	0.35	Height;	chr6:109497088	chr6:109382795~109383666:+
BRCA	cis	rs853679	0.517	rs9380056	ENSG00000220721.1	OR1F12	12.22	3.33e-32	3.76e-29	0.47	0.35	Depression;	chr6:28136698	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.517	rs9380057	ENSG00000220721.1	OR1F12	12.22	3.33e-32	3.76e-29	0.47	0.35	Depression;	chr6:28136856	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.517	rs6941992	ENSG00000220721.1	OR1F12	12.22	3.33e-32	3.76e-29	0.47	0.35	Depression;	chr6:28138363	chr6:28073316~28074233:+
BRCA	cis	rs4713118	0.516	rs4713142	ENSG00000220721.1	OR1F12	12.22	3.33e-32	3.76e-29	0.47	0.35	Parkinson's disease;	chr6:28138569	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.517	rs4713143	ENSG00000220721.1	OR1F12	12.22	3.33e-32	3.76e-29	0.47	0.35	Depression;	chr6:28138981	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.517	rs4713144	ENSG00000220721.1	OR1F12	12.22	3.33e-32	3.76e-29	0.47	0.35	Depression;	chr6:28139012	chr6:28073316~28074233:+
BRCA	cis	rs34779708	0.931	rs2384289	ENSG00000230534.5	RP11-297A16.2	12.22	3.38e-32	3.81e-29	0.44	0.35	Inflammatory bowel disease;Crohn's disease;	chr10:35054597	chr10:35098006~35127020:-
BRCA	cis	rs875971	1	rs6958484	ENSG00000222364.1	RNU6-96P	12.22	3.41e-32	3.85e-29	0.41	0.35	Aortic root size;	chr7:66134459	chr7:66395191~66395286:+
BRCA	cis	rs875971	1	rs6963646	ENSG00000222364.1	RNU6-96P	12.22	3.42e-32	3.86e-29	0.41	0.35	Aortic root size;	chr7:66220780	chr7:66395191~66395286:+
BRCA	cis	rs1061377	0.674	rs34506243	ENSG00000249207.1	RP11-360F5.1	-12.22	3.48e-32	3.93e-29	-0.4	-0.35	Uric acid levels;	chr4:39082702	chr4:39112677~39126818:-
BRCA	cis	rs6991838	0.584	rs6994213	ENSG00000200714.1	Y_RNA	-12.22	3.5e-32	3.95e-29	-0.41	-0.35	Intelligence (multi-trait analysis);	chr8:65601497	chr8:65592731~65592820:+
BRCA	cis	rs875971	0.862	rs4236208	ENSG00000222364.1	RNU6-96P	12.22	3.55e-32	4.01e-29	0.41	0.35	Aortic root size;	chr7:66284091	chr7:66395191~66395286:+
BRCA	cis	rs4423214	0.592	rs10898186	ENSG00000254682.1	RP11-660L16.2	-12.22	3.57e-32	4.03e-29	-0.53	-0.35	Vitamin D levels;	chr11:71477754	chr11:71448674~71452157:+
BRCA	cis	rs875971	1	rs2087647	ENSG00000222364.1	RNU6-96P	12.22	3.59e-32	4.05e-29	0.41	0.35	Aortic root size;	chr7:66128201	chr7:66395191~66395286:+
BRCA	cis	rs875971	1	rs6961717	ENSG00000222364.1	RNU6-96P	12.22	3.63e-32	4.09e-29	0.41	0.35	Aortic root size;	chr7:66122550	chr7:66395191~66395286:+
BRCA	cis	rs2564921	0.73	rs2253675	ENSG00000242142.1	SERBP1P3	-12.21	3.65e-32	4.11e-29	-0.41	-0.35	Height;	chr3:53085518	chr3:53064283~53065091:-
BRCA	cis	rs858239	0.67	rs6967526	ENSG00000226816.2	AC005082.12	12.21	3.66e-32	4.12e-29	0.41	0.35	Cerebrospinal fluid biomarker levels;	chr7:23119622	chr7:23206013~23208045:+
BRCA	cis	rs8100891	0.537	rs7258196	ENSG00000267213.4	AC007773.2	-12.21	3.67e-32	4.14e-29	-0.53	-0.35	Neuroticism;	chr19:32453659	chr19:32390050~32405560:-
BRCA	cis	rs4380275	0.782	rs4468850	ENSG00000223751.1	AC116609.2	12.21	3.71e-32	4.19e-29	0.45	0.35	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:749467	chr2:742488~747767:+
BRCA	cis	rs8062405	0.558	rs151228	ENSG00000259982.1	CDC37P1	12.21	3.73e-32	4.2e-29	0.41	0.35	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28551705	chr16:28700294~28701540:-
BRCA	cis	rs7849270	1	rs10819469	ENSG00000268707.1	RP11-247A12.7	-12.21	3.75e-32	4.22e-29	-0.44	-0.35	Blood metabolite ratios;	chr9:129119788	chr9:129170434~129170940:+
BRCA	cis	rs6991838	0.584	rs7835313	ENSG00000200714.1	Y_RNA	12.21	3.77e-32	4.25e-29	0.41	0.35	Intelligence (multi-trait analysis);	chr8:65633891	chr8:65592731~65592820:+
BRCA	cis	rs875971	0.862	rs11773628	ENSG00000222364.1	RNU6-96P	12.21	3.78e-32	4.26e-29	0.41	0.35	Aortic root size;	chr7:66517644	chr7:66395191~66395286:+
BRCA	cis	rs4380275	0.782	rs4854369	ENSG00000223751.1	AC116609.2	12.21	3.8e-32	4.29e-29	0.45	0.35	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:752530	chr2:742488~747767:+
BRCA	cis	rs853679	0.517	rs4711164	ENSG00000220721.1	OR1F12	12.2	4.12e-32	4.63e-29	0.47	0.35	Depression;	chr6:28147378	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.517	rs4711165	ENSG00000220721.1	OR1F12	12.2	4.12e-32	4.63e-29	0.47	0.35	Depression;	chr6:28147406	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.517	rs4713148	ENSG00000220721.1	OR1F12	12.2	4.12e-32	4.63e-29	0.47	0.35	Depression;	chr6:28148143	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.517	rs9348794	ENSG00000220721.1	OR1F12	12.2	4.12e-32	4.63e-29	0.47	0.35	Depression;	chr6:28149979	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.517	rs9295758	ENSG00000220721.1	OR1F12	12.2	4.12e-32	4.63e-29	0.47	0.35	Depression;	chr6:28152885	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.517	rs17774663	ENSG00000220721.1	OR1F12	12.2	4.12e-32	4.63e-29	0.47	0.35	Depression;	chr6:28153120	chr6:28073316~28074233:+
BRCA	cis	rs2117029	0.619	rs9325145	ENSG00000258017.1	RP11-386G11.10	-12.2	4.15e-32	4.67e-29	-0.48	-0.35	Intelligence (multi-trait analysis);	chr12:49132101	chr12:49127782~49147869:+
BRCA	cis	rs10875746	0.903	rs2158516	ENSG00000240399.1	RP1-228P16.1	-12.2	4.21e-32	4.73e-29	-0.48	-0.35	Longevity (90 years and older);	chr12:48097051	chr12:48054813~48055591:-
BRCA	cis	rs11676348	0.846	rs4674260	ENSG00000261338.2	RP11-378A13.1	-12.2	4.22e-32	4.75e-29	-0.38	-0.35	Ulcerative colitis;	chr2:218137653	chr2:218255319~218257366:+
BRCA	cis	rs34779708	0.931	rs10466072	ENSG00000230534.5	RP11-297A16.2	12.2	4.22e-32	4.75e-29	0.44	0.35	Inflammatory bowel disease;Crohn's disease;	chr10:35113828	chr10:35098006~35127020:-
BRCA	cis	rs11676348	0.811	rs13027120	ENSG00000261338.2	RP11-378A13.1	12.2	4.23e-32	4.76e-29	0.37	0.35	Ulcerative colitis;	chr2:218156191	chr2:218255319~218257366:+
BRCA	cis	rs11673344	0.615	rs2921561	ENSG00000226686.6	LINC01535	12.2	4.28e-32	4.82e-29	0.45	0.35	Obesity-related traits;	chr19:37348969	chr19:37251912~37265535:+
BRCA	cis	rs875971	0.862	rs778734	ENSG00000222364.1	RNU6-96P	-12.2	4.33e-32	4.86e-29	-0.41	-0.35	Aortic root size;	chr7:66349862	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.862	rs778686	ENSG00000222364.1	RNU6-96P	-12.2	4.33e-32	4.86e-29	-0.41	-0.35	Aortic root size;	chr7:66370923	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.862	rs10261398	ENSG00000222364.1	RNU6-96P	12.2	4.34e-32	4.87e-29	0.41	0.35	Aortic root size;	chr7:66285177	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.862	rs10224872	ENSG00000222364.1	RNU6-96P	12.2	4.34e-32	4.87e-29	0.41	0.35	Aortic root size;	chr7:66294786	chr7:66395191~66395286:+
BRCA	cis	rs8100891	0.537	rs2302773	ENSG00000267213.4	AC007773.2	-12.2	4.4e-32	4.94e-29	-0.54	-0.35	Neuroticism;	chr19:32436405	chr19:32390050~32405560:-
BRCA	cis	rs8100891	0.537	rs738093	ENSG00000267213.4	AC007773.2	-12.2	4.4e-32	4.94e-29	-0.54	-0.35	Neuroticism;	chr19:32439601	chr19:32390050~32405560:-
BRCA	cis	rs7849270	1	rs10988223	ENSG00000268707.1	RP11-247A12.7	-12.19	4.52e-32	5.08e-29	-0.44	-0.35	Blood metabolite ratios;	chr9:129140742	chr9:129170434~129170940:+
BRCA	cis	rs34779708	0.931	rs4934533	ENSG00000230534.5	RP11-297A16.2	12.19	4.53e-32	5.08e-29	0.44	0.35	Inflammatory bowel disease;Crohn's disease;	chr10:35070691	chr10:35098006~35127020:-
BRCA	cis	rs6991838	0.584	rs7823840	ENSG00000272010.1	CTD-3025N20.3	-12.19	4.53e-32	5.09e-29	-0.38	-0.35	Intelligence (multi-trait analysis);	chr8:65606766	chr8:65591850~65592472:-
BRCA	cis	rs2739330	0.796	rs2154594	ENSG00000231271.1	AP000350.8	-12.19	4.56e-32	5.12e-29	-0.44	-0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23949918~23954042:+
BRCA	cis	rs4713118	0.587	rs9393899	ENSG00000220721.1	OR1F12	12.19	4.61e-32	5.17e-29	0.47	0.35	Parkinson's disease;	chr6:28165750	chr6:28073316~28074233:+
BRCA	cis	rs10875746	0.903	rs725454	ENSG00000240399.1	RP1-228P16.1	-12.19	4.66e-32	5.23e-29	-0.47	-0.35	Longevity (90 years and older);	chr12:48108317	chr12:48054813~48055591:-
BRCA	cis	rs10256972	0.621	rs10951594	ENSG00000229043.2	AC091729.9	-12.19	4.68e-32	5.25e-29	-0.44	-0.35	Endometriosis;Longevity;	chr7:1048971	chr7:1160374~1165267:+
BRCA	cis	rs2015599	0.514	rs10843376	ENSG00000257176.2	RP11-996F15.2	12.19	4.72e-32	5.29e-29	0.42	0.35	Platelet count;Mean platelet volume;	chr12:29283651	chr12:29280418~29317848:-
BRCA	cis	rs11168854	0.719	rs11168890	ENSG00000258017.1	RP11-386G11.10	-12.19	4.72e-32	5.3e-29	-0.48	-0.35	Body mass index;	chr12:49150130	chr12:49127782~49147869:+
BRCA	cis	rs875971	1	rs4718307	ENSG00000222364.1	RNU6-96P	12.19	4.77e-32	5.35e-29	0.4	0.35	Aortic root size;	chr7:66146001	chr7:66395191~66395286:+
BRCA	cis	rs875971	1	rs7801282	ENSG00000222364.1	RNU6-96P	12.19	4.77e-32	5.35e-29	0.4	0.35	Aortic root size;	chr7:66148700	chr7:66395191~66395286:+
BRCA	cis	rs3823536	0.583	rs10279821	ENSG00000275106.1	RP11-309L24.10	-12.19	4.8e-32	5.38e-29	-0.46	-0.35	Sjögren's syndrome;	chr7:129043493	chr7:128952527~128953316:-
BRCA	cis	rs2404602	0.647	rs12440511	ENSG00000259422.1	RP11-593F23.1	-12.19	4.82e-32	5.4e-29	-0.47	-0.35	Blood metabolite levels;	chr15:76700794	chr15:76174891~76181486:-
BRCA	cis	rs2108622	0.958	rs79400241	ENSG00000267453.5	AC004791.2	-12.19	4.83e-32	5.42e-29	-0.46	-0.35	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15873592	chr19:15851993~15864904:-
BRCA	cis	rs875971	0.862	rs10256544	ENSG00000222364.1	RNU6-96P	-12.19	4.88e-32	5.47e-29	-0.41	-0.35	Aortic root size;	chr7:66210141	chr7:66395191~66395286:+
BRCA	cis	rs10129255	0.556	rs9324093	ENSG00000223648.3	IGHV3-64	12.19	5.02e-32	5.62e-29	0.27	0.35	Kawasaki disease;	chr14:106683893	chr14:106643132~106658258:-
BRCA	cis	rs7182621	0.639	rs34701806	ENSG00000259363.4	CTD-2054N24.2	-12.18	5.05e-32	5.66e-29	-0.47	-0.35	Colonoscopy-negative controls vs population controls;	chr15:99872953	chr15:99807023~99877148:+
BRCA	cis	rs875971	0.651	rs313829	ENSG00000226824.5	RP4-756H11.3	12.18	5.07e-32	5.68e-29	0.47	0.35	Aortic root size;	chr7:66087510	chr7:66654538~66669855:+
BRCA	cis	rs150992	0.711	rs161735	ENSG00000248489.1	CTD-2007H13.3	12.18	5.37e-32	6.01e-29	0.41	0.35	Body mass index;	chr5:98862026	chr5:98929171~98995013:+
BRCA	cis	rs10875746	0.903	rs12313404	ENSG00000240399.1	RP1-228P16.1	-12.18	5.37e-32	6.01e-29	-0.48	-0.35	Longevity (90 years and older);	chr12:48098265	chr12:48054813~48055591:-
BRCA	cis	rs4774565	0.762	rs34565064	ENSG00000244879.4	GABPB1-AS1	-12.18	5.45e-32	6.1e-29	-0.37	-0.35	Breast cancer;	chr15:50371706	chr15:50354959~50372202:+
BRCA	cis	rs853679	0.517	rs4713145	ENSG00000220721.1	OR1F12	12.18	5.49e-32	6.14e-29	0.47	0.35	Depression;	chr6:28139049	chr6:28073316~28074233:+
BRCA	cis	rs3091242	0.867	rs602052	ENSG00000224183.1	SDHDP6	-12.18	5.52e-32	6.17e-29	-0.43	-0.35	Erythrocyte sedimentation rate;	chr1:25395715	chr1:25294164~25294643:-
BRCA	cis	rs2564921	0.73	rs73082047	ENSG00000242142.1	SERBP1P3	-12.18	5.59e-32	6.24e-29	-0.44	-0.35	Height;	chr3:53070344	chr3:53064283~53065091:-
BRCA	cis	rs4380275	0.782	rs4854276	ENSG00000223751.1	AC116609.2	12.17	5.61e-32	6.27e-29	0.43	0.35	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:764357	chr2:742488~747767:+
BRCA	cis	rs4423214	0.879	rs10898144	ENSG00000254682.1	RP11-660L16.2	-12.17	5.61e-32	6.27e-29	-0.47	-0.35	Vitamin D levels;	chr11:71440494	chr11:71448674~71452157:+
BRCA	cis	rs977987	0.872	rs4888422	ENSG00000261783.1	RP11-252K23.2	-12.17	5.63e-32	6.29e-29	-0.45	-0.35	Dupuytren's disease;	chr16:75436678	chr16:75379818~75381260:-
BRCA	cis	rs6991838	0.53	rs35038843	ENSG00000200714.1	Y_RNA	-12.17	5.69e-32	6.35e-29	-0.41	-0.35	Intelligence (multi-trait analysis);	chr8:65610263	chr8:65592731~65592820:+
BRCA	cis	rs6991838	0.584	rs4737748	ENSG00000200714.1	Y_RNA	12.17	5.69e-32	6.35e-29	0.41	0.35	Intelligence (multi-trait analysis);	chr8:65613630	chr8:65592731~65592820:+
BRCA	cis	rs9487094	0.67	rs11754455	ENSG00000260273.1	RP11-425D10.10	12.17	5.86e-32	6.55e-29	0.41	0.35	Height;	chr6:109496680	chr6:109382795~109383666:+
BRCA	cis	rs6991838	0.584	rs7841652	ENSG00000200714.1	Y_RNA	-12.17	5.89e-32	6.57e-29	-0.41	-0.35	Intelligence (multi-trait analysis);	chr8:65606392	chr8:65592731~65592820:+
BRCA	cis	rs6991838	0.584	rs3765205	ENSG00000200714.1	Y_RNA	-12.17	5.9e-32	6.58e-29	-0.41	-0.35	Intelligence (multi-trait analysis);	chr8:65605251	chr8:65592731~65592820:+
BRCA	cis	rs7044106	0.791	rs4836830	ENSG00000226752.6	PSMD5-AS1	-12.17	5.99e-32	6.68e-29	-0.43	-0.35	Hip circumference adjusted for BMI;	chr9:120721390	chr9:120824828~120854385:+
BRCA	cis	rs853679	0.517	rs1947862	ENSG00000220721.1	OR1F12	12.17	6.03e-32	6.72e-29	0.47	0.35	Depression;	chr6:28137418	chr6:28073316~28074233:+
BRCA	cis	rs8040855	0.627	rs11632658	ENSG00000259295.5	CSPG4P12	-12.17	6.06e-32	6.76e-29	-0.51	-0.35	Bulimia nervosa;	chr15:85062982	chr15:85191438~85213905:+
BRCA	cis	rs2117029	0.521	rs1056875	ENSG00000258017.1	RP11-386G11.10	-12.17	6.07e-32	6.77e-29	-0.48	-0.35	Intelligence (multi-trait analysis);	chr12:49186397	chr12:49127782~49147869:+
BRCA	cis	rs6991838	0.55	rs12335006	ENSG00000200714.1	Y_RNA	12.17	6.11e-32	6.81e-29	0.41	0.35	Intelligence (multi-trait analysis);	chr8:65619394	chr8:65592731~65592820:+
BRCA	cis	rs6991838	0.612	rs12335276	ENSG00000200714.1	Y_RNA	12.17	6.11e-32	6.81e-29	0.41	0.35	Intelligence (multi-trait analysis);	chr8:65619668	chr8:65592731~65592820:+
BRCA	cis	rs992157	0.71	rs6752254	ENSG00000261338.2	RP11-378A13.1	12.17	6.13e-32	6.83e-29	0.36	0.35	Colorectal cancer;	chr2:218194020	chr2:218255319~218257366:+
BRCA	cis	rs8100891	0.537	rs1030094	ENSG00000267213.4	AC007773.2	-12.17	6.17e-32	6.87e-29	-0.5	-0.35	Neuroticism;	chr19:32419525	chr19:32390050~32405560:-
BRCA	cis	rs10129255	0.536	rs17113249	ENSG00000223648.3	IGHV3-64	12.17	6.19e-32	6.89e-29	0.28	0.35	Kawasaki disease;	chr14:106678273	chr14:106643132~106658258:-
BRCA	cis	rs34779708	0.966	rs113170867	ENSG00000230534.5	RP11-297A16.2	12.17	6.21e-32	6.92e-29	0.46	0.35	Inflammatory bowel disease;Crohn's disease;	chr10:35161219	chr10:35098006~35127020:-
BRCA	cis	rs8040855	0.657	rs6496733	ENSG00000259295.5	CSPG4P12	-12.17	6.21e-32	6.92e-29	-0.5	-0.35	Bulimia nervosa;	chr15:85129945	chr15:85191438~85213905:+
BRCA	cis	rs4380275	0.782	rs4335978	ENSG00000223751.1	AC116609.2	12.16	6.25e-32	6.96e-29	0.45	0.35	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:750078	chr2:742488~747767:+
BRCA	cis	rs3823536	0.583	rs10156169	ENSG00000275106.1	RP11-309L24.10	-12.16	6.28e-32	6.99e-29	-0.46	-0.35	Sjögren's syndrome;	chr7:129044517	chr7:128952527~128953316:-
BRCA	cis	rs2404602	0.647	rs11629727	ENSG00000259422.1	RP11-593F23.1	-12.16	6.28e-32	7e-29	-0.47	-0.35	Blood metabolite levels;	chr15:76716697	chr15:76174891~76181486:-
BRCA	cis	rs34779708	0.931	rs6481935	ENSG00000230534.5	RP11-297A16.2	12.16	6.39e-32	7.12e-29	0.44	0.35	Inflammatory bowel disease;Crohn's disease;	chr10:35054031	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.931	rs12242882	ENSG00000230534.5	RP11-297A16.2	12.16	6.39e-32	7.12e-29	0.44	0.35	Inflammatory bowel disease;Crohn's disease;	chr10:35058932	chr10:35098006~35127020:-
BRCA	cis	rs8100891	0.537	rs11883143	ENSG00000267213.4	AC007773.2	-12.16	6.4e-32	7.12e-29	-0.5	-0.35	Neuroticism;	chr19:32478350	chr19:32390050~32405560:-
BRCA	cis	rs853679	0.517	rs4713150	ENSG00000220721.1	OR1F12	12.16	6.47e-32	7.19e-29	0.47	0.35	Depression;	chr6:28168434	chr6:28073316~28074233:+
BRCA	cis	rs4713118	0.527	rs4713151	ENSG00000220721.1	OR1F12	12.16	6.47e-32	7.19e-29	0.47	0.35	Parkinson's disease;	chr6:28168578	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.517	rs9393901	ENSG00000220721.1	OR1F12	12.16	6.47e-32	7.19e-29	0.47	0.35	Depression;	chr6:28169019	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.517	rs3173443	ENSG00000220721.1	OR1F12	12.16	6.47e-32	7.19e-29	0.47	0.35	Depression;	chr6:28169249	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.517	rs4713152	ENSG00000220721.1	OR1F12	12.16	6.47e-32	7.19e-29	0.47	0.35	Depression;	chr6:28169676	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.517	rs9348797	ENSG00000220721.1	OR1F12	12.16	6.47e-32	7.19e-29	0.47	0.35	Depression;	chr6:28169755	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.517	rs9380062	ENSG00000220721.1	OR1F12	12.16	6.47e-32	7.19e-29	0.47	0.35	Depression;	chr6:28169791	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.542	rs9380063	ENSG00000220721.1	OR1F12	12.16	6.47e-32	7.19e-29	0.47	0.35	Depression;	chr6:28170075	chr6:28073316~28074233:+
BRCA	cis	rs2117029	0.586	rs11168884	ENSG00000258017.1	RP11-386G11.10	-12.16	6.51e-32	7.24e-29	-0.48	-0.35	Intelligence (multi-trait analysis);	chr12:49146109	chr12:49127782~49147869:+
BRCA	cis	rs34779708	0.931	rs17582416	ENSG00000230534.5	RP11-297A16.2	12.16	6.51e-32	7.24e-29	0.44	0.35	Inflammatory bowel disease;Crohn's disease;	chr10:34998722	chr10:35098006~35127020:-
BRCA	cis	rs6991838	0.584	rs10957361	ENSG00000200714.1	Y_RNA	12.16	6.52e-32	7.25e-29	0.41	0.35	Intelligence (multi-trait analysis);	chr8:65619626	chr8:65592731~65592820:+
BRCA	cis	rs853679	0.517	rs9468297	ENSG00000220721.1	OR1F12	12.16	6.54e-32	7.27e-29	0.47	0.35	Depression;	chr6:28151096	chr6:28073316~28074233:+
BRCA	cis	rs9487094	0.778	rs61318425	ENSG00000260273.1	RP11-425D10.10	12.16	6.63e-32	7.37e-29	0.46	0.35	Height;	chr6:109427303	chr6:109382795~109383666:+
BRCA	cis	rs34779708	0.931	rs12767414	ENSG00000230534.5	RP11-297A16.2	12.16	6.63e-32	7.37e-29	0.43	0.35	Inflammatory bowel disease;Crohn's disease;	chr10:35101265	chr10:35098006~35127020:-
BRCA	cis	rs6991838	0.612	rs7832407	ENSG00000200714.1	Y_RNA	12.16	6.63e-32	7.37e-29	0.41	0.35	Intelligence (multi-trait analysis);	chr8:65621071	chr8:65592731~65592820:+
BRCA	cis	rs6991838	0.551	rs7007505	ENSG00000200714.1	Y_RNA	12.16	6.63e-32	7.37e-29	0.41	0.35	Intelligence (multi-trait analysis);	chr8:65621719	chr8:65592731~65592820:+
BRCA	cis	rs6991838	0.584	rs7012856	ENSG00000200714.1	Y_RNA	12.16	6.63e-32	7.37e-29	0.41	0.35	Intelligence (multi-trait analysis);	chr8:65622740	chr8:65592731~65592820:+
BRCA	cis	rs6991838	0.55	rs7817112	ENSG00000200714.1	Y_RNA	12.16	6.63e-32	7.37e-29	0.41	0.35	Intelligence (multi-trait analysis);	chr8:65624885	chr8:65592731~65592820:+
BRCA	cis	rs6991838	0.584	rs2048650	ENSG00000200714.1	Y_RNA	12.16	6.63e-32	7.37e-29	0.41	0.35	Intelligence (multi-trait analysis);	chr8:65625664	chr8:65592731~65592820:+
BRCA	cis	rs6991838	0.584	rs4737749	ENSG00000200714.1	Y_RNA	12.16	6.63e-32	7.37e-29	0.41	0.35	Intelligence (multi-trait analysis);	chr8:65627672	chr8:65592731~65592820:+
BRCA	cis	rs6991838	0.584	rs10092109	ENSG00000200714.1	Y_RNA	12.16	6.63e-32	7.37e-29	0.41	0.35	Intelligence (multi-trait analysis);	chr8:65627683	chr8:65592731~65592820:+
BRCA	cis	rs6991838	0.584	rs6997959	ENSG00000200714.1	Y_RNA	12.16	6.63e-32	7.37e-29	0.41	0.35	Intelligence (multi-trait analysis);	chr8:65628247	chr8:65592731~65592820:+
BRCA	cis	rs6991838	0.584	rs7814841	ENSG00000200714.1	Y_RNA	12.16	6.63e-32	7.37e-29	0.41	0.35	Intelligence (multi-trait analysis);	chr8:65629328	chr8:65592731~65592820:+
BRCA	cis	rs6991838	0.584	rs11985628	ENSG00000200714.1	Y_RNA	12.16	6.63e-32	7.37e-29	0.41	0.35	Intelligence (multi-trait analysis);	chr8:65630504	chr8:65592731~65592820:+
BRCA	cis	rs6991838	0.557	rs13266834	ENSG00000200714.1	Y_RNA	12.16	6.63e-32	7.37e-29	0.41	0.35	Intelligence (multi-trait analysis);	chr8:65631303	chr8:65592731~65592820:+
BRCA	cis	rs6991838	0.584	rs13268343	ENSG00000200714.1	Y_RNA	12.16	6.63e-32	7.37e-29	0.41	0.35	Intelligence (multi-trait analysis);	chr8:65631742	chr8:65592731~65592820:+
BRCA	cis	rs6991838	0.584	rs1533285	ENSG00000200714.1	Y_RNA	12.16	6.63e-32	7.37e-29	0.41	0.35	Intelligence (multi-trait analysis);	chr8:65637129	chr8:65592731~65592820:+
BRCA	cis	rs875971	0.862	rs778684	ENSG00000222364.1	RNU6-96P	-12.16	6.84e-32	7.59e-29	-0.41	-0.35	Aortic root size;	chr7:66371416	chr7:66395191~66395286:+
BRCA	cis	rs7849270	1	rs3124513	ENSG00000268707.1	RP11-247A12.7	12.15	6.95e-32	7.71e-29	0.44	0.35	Blood metabolite ratios;	chr9:129142314	chr9:129170434~129170940:+
BRCA	cis	rs7849270	1	rs3124514	ENSG00000268707.1	RP11-247A12.7	12.15	6.95e-32	7.71e-29	0.44	0.35	Blood metabolite ratios;	chr9:129142329	chr9:129170434~129170940:+
BRCA	cis	rs2117029	0.553	rs731350	ENSG00000258017.1	RP11-386G11.10	-12.15	7.01e-32	7.77e-29	-0.48	-0.35	Intelligence (multi-trait analysis);	chr12:49130804	chr12:49127782~49147869:+
BRCA	cis	rs34779708	0.966	rs10508816	ENSG00000230534.5	RP11-297A16.2	12.15	7.02e-32	7.79e-29	0.44	0.35	Inflammatory bowel disease;Crohn's disease;	chr10:35171048	chr10:35098006~35127020:-
BRCA	cis	rs4423214	0.798	rs1894100	ENSG00000254682.1	RP11-660L16.2	-12.15	7.09e-32	7.86e-29	-0.48	-0.35	Vitamin D levels;	chr11:71419297	chr11:71448674~71452157:+
BRCA	cis	rs9487094	0.813	rs12528712	ENSG00000260273.1	RP11-425D10.10	12.15	7.18e-32	7.96e-29	0.45	0.35	Height;	chr6:109339681	chr6:109382795~109383666:+
BRCA	cis	rs7849270	1	rs3118632	ENSG00000268707.1	RP11-247A12.7	12.15	7.18e-32	7.96e-29	0.44	0.35	Blood metabolite ratios;	chr9:129139005	chr9:129170434~129170940:+
BRCA	cis	rs34779708	0.931	rs12248333	ENSG00000230534.5	RP11-297A16.2	12.15	7.2e-32	7.98e-29	0.44	0.35	Inflammatory bowel disease;Crohn's disease;	chr10:35074049	chr10:35098006~35127020:-
BRCA	cis	rs10129255	0.5	rs2105991	ENSG00000223648.3	IGHV3-64	12.15	7.37e-32	8.17e-29	0.28	0.35	Kawasaki disease;	chr14:106682022	chr14:106643132~106658258:-
BRCA	cis	rs875971	0.83	rs778715	ENSG00000222364.1	RNU6-96P	-12.15	7.4e-32	8.2e-29	-0.42	-0.35	Aortic root size;	chr7:66384222	chr7:66395191~66395286:+
BRCA	cis	rs8062405	1	rs12446589	ENSG00000259982.1	CDC37P1	12.15	7.54e-32	8.35e-29	0.47	0.35	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28859641	chr16:28700294~28701540:-
BRCA	cis	rs875971	1	rs875971	ENSG00000222364.1	RNU6-96P	12.15	7.63e-32	8.45e-29	0.4	0.35	Aortic root size;	chr7:66152608	chr7:66395191~66395286:+
BRCA	cis	rs34779708	0.931	rs11596502	ENSG00000230534.5	RP11-297A16.2	12.15	7.65e-32	8.47e-29	0.46	0.35	Inflammatory bowel disease;Crohn's disease;	chr10:35098259	chr10:35098006~35127020:-
BRCA	cis	rs2404602	0.684	rs1011084	ENSG00000259422.1	RP11-593F23.1	-12.14	7.84e-32	8.67e-29	-0.47	-0.35	Blood metabolite levels;	chr15:76715139	chr15:76174891~76181486:-
BRCA	cis	rs7945705	0.747	rs1980429	ENSG00000254860.4	TMEM9B-AS1	12.14	7.89e-32	8.73e-29	0.32	0.35	Hemoglobin concentration;	chr11:8988927	chr11:8964675~8977527:+
BRCA	cis	rs875971	0.862	rs12537823	ENSG00000222364.1	RNU6-96P	-12.14	7.89e-32	8.73e-29	-0.41	-0.35	Aortic root size;	chr7:66255897	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.767	rs1643394	ENSG00000222364.1	RNU6-96P	-12.14	7.94e-32	8.78e-29	-0.41	-0.35	Aortic root size;	chr7:66371107	chr7:66395191~66395286:+
BRCA	cis	rs10129255	0.536	rs6576201	ENSG00000223648.3	IGHV3-64	-12.14	7.95e-32	8.79e-29	-0.27	-0.35	Kawasaki disease;	chr14:106683696	chr14:106643132~106658258:-
BRCA	cis	rs7945705	0.747	rs10840158	ENSG00000254860.4	TMEM9B-AS1	12.14	7.95e-32	8.79e-29	0.32	0.35	Hemoglobin concentration;	chr11:8999350	chr11:8964675~8977527:+
BRCA	cis	rs2117029	0.586	rs7954521	ENSG00000258017.1	RP11-386G11.10	-12.14	8.06e-32	8.91e-29	-0.48	-0.35	Intelligence (multi-trait analysis);	chr12:49151857	chr12:49127782~49147869:+
BRCA	cis	rs2117029	0.553	rs2162644	ENSG00000258017.1	RP11-386G11.10	-12.14	8.06e-32	8.91e-29	-0.48	-0.35	Intelligence (multi-trait analysis);	chr12:49154407	chr12:49127782~49147869:+
BRCA	cis	rs853679	0.517	rs35193936	ENSG00000220721.1	OR1F12	12.14	8.12e-32	8.97e-29	0.46	0.35	Depression;	chr6:28108492	chr6:28073316~28074233:+
BRCA	cis	rs6991838	0.584	rs34226237	ENSG00000200714.1	Y_RNA	-12.14	8.13e-32	8.99e-29	-0.41	-0.35	Intelligence (multi-trait analysis);	chr8:65600930	chr8:65592731~65592820:+
BRCA	cis	rs34779708	0.966	rs2126984	ENSG00000230534.5	RP11-297A16.2	12.14	8.27e-32	9.14e-29	0.43	0.35	Inflammatory bowel disease;Crohn's disease;	chr10:35121363	chr10:35098006~35127020:-
BRCA	cis	rs2019137	0.936	rs902696	ENSG00000274877.1	RP11-65I12.1	-12.14	8.51e-32	9.39e-29	-0.45	-0.35	Lymphocyte counts;	chr2:113197302	chr2:113237595~113240825:+
BRCA	cis	rs10875746	0.859	rs11558768	ENSG00000240399.1	RP1-228P16.1	-12.14	8.52e-32	9.4e-29	-0.46	-0.35	Longevity (90 years and older);	chr12:48184006	chr12:48054813~48055591:-
BRCA	cis	rs34779708	0.966	rs6481941	ENSG00000230534.5	RP11-297A16.2	12.14	8.58e-32	9.47e-29	0.44	0.35	Inflammatory bowel disease;Crohn's disease;	chr10:35151213	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.931	rs12240347	ENSG00000230534.5	RP11-297A16.2	12.13	8.88e-32	9.79e-29	0.44	0.35	Inflammatory bowel disease;Crohn's disease;	chr10:35070547	chr10:35098006~35127020:-
BRCA	cis	rs875971	0.862	rs1981799	ENSG00000222364.1	RNU6-96P	-12.13	9.07e-32	9.99e-29	-0.41	-0.35	Aortic root size;	chr7:66490572	chr7:66395191~66395286:+
BRCA	cis	rs10129255	0.536	rs8004835	ENSG00000211972.2	IGHV3-66	12.13	9.11e-32	1e-28	0.24	0.35	Kawasaki disease;	chr14:106686361	chr14:106675017~106675544:-
BRCA	cis	rs11673344	0.566	rs11666708	ENSG00000226686.6	LINC01535	-12.13	9.18e-32	1.01e-28	-0.45	-0.35	Obesity-related traits;	chr19:37396208	chr19:37251912~37265535:+
BRCA	cis	rs34779708	0.931	rs11010082	ENSG00000230534.5	RP11-297A16.2	12.13	9.19e-32	1.01e-28	0.44	0.35	Inflammatory bowel disease;Crohn's disease;	chr10:35062227	chr10:35098006~35127020:-
BRCA	cis	rs3823536	0.583	rs3807302	ENSG00000275106.1	RP11-309L24.10	-12.13	9.27e-32	1.02e-28	-0.46	-0.35	Sjögren's syndrome;	chr7:129004803	chr7:128952527~128953316:-
BRCA	cis	rs2564921	0.704	rs56058643	ENSG00000242142.1	SERBP1P3	-12.13	9.29e-32	1.02e-28	-0.43	-0.35	Height;	chr3:53093751	chr3:53064283~53065091:-
BRCA	cis	rs2188561	0.697	rs3735606	ENSG00000241764.3	AC002467.7	12.13	9.31e-32	1.03e-28	0.46	0.35	Alcohol consumption;	chr7:107743864	chr7:107742817~107744581:-
BRCA	cis	rs2337406	0.925	rs2011167	ENSG00000274576.2	IGHV2-70	-12.13	9.37e-32	1.03e-28	-0.41	-0.35	Alzheimer's disease (late onset);	chr14:106680831	chr14:106770577~106771020:-
BRCA	cis	rs67311347	1	rs13073003	ENSG00000223797.4	ENTPD3-AS1	-12.13	9.41e-32	1.04e-28	-0.39	-0.35	Renal cell carcinoma;	chr3:40462835	chr3:40313802~40453329:-
BRCA	cis	rs67311347	1	rs6801185	ENSG00000223797.4	ENTPD3-AS1	-12.13	9.41e-32	1.04e-28	-0.39	-0.35	Renal cell carcinoma;	chr3:40463569	chr3:40313802~40453329:-
BRCA	cis	rs9487094	0.626	rs12215077	ENSG00000260273.1	RP11-425D10.10	-12.13	9.43e-32	1.04e-28	-0.42	-0.35	Height;	chr6:109731677	chr6:109382795~109383666:+
BRCA	cis	rs875971	0.825	rs1000464	ENSG00000222364.1	RNU6-96P	12.13	9.44e-32	1.04e-28	0.41	0.35	Aortic root size;	chr7:66312922	chr7:66395191~66395286:+
BRCA	cis	rs6991838	0.584	rs3812412	ENSG00000200714.1	Y_RNA	12.12	9.62e-32	1.06e-28	0.41	0.35	Intelligence (multi-trait analysis);	chr8:65634857	chr8:65592731~65592820:+
BRCA	cis	rs875971	0.929	rs34406470	ENSG00000222364.1	RNU6-96P	-12.12	9.72e-32	1.07e-28	-0.41	-0.35	Aortic root size;	chr7:66464969	chr7:66395191~66395286:+
BRCA	cis	rs10875746	0.855	rs73102067	ENSG00000240399.1	RP1-228P16.1	-12.12	9.72e-32	1.07e-28	-0.48	-0.35	Longevity (90 years and older);	chr12:48100643	chr12:48054813~48055591:-
BRCA	cis	rs875971	0.862	rs6460302	ENSG00000222364.1	RNU6-96P	-12.12	9.86e-32	1.08e-28	-0.41	-0.35	Aortic root size;	chr7:66495270	chr7:66395191~66395286:+
BRCA	cis	rs2919917	0.628	rs4739135	ENSG00000254352.1	RP11-578O24.2	12.12	9.9e-32	1.09e-28	0.48	0.35	Lymphocyte counts;	chr8:78656057	chr8:78723796~78724136:-
BRCA	cis	rs853679	0.517	rs9380058	ENSG00000220721.1	OR1F12	12.12	1.01e-31	1.11e-28	0.47	0.35	Depression;	chr6:28159666	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.517	rs9393898	ENSG00000220721.1	OR1F12	12.12	1.01e-31	1.11e-28	0.47	0.35	Depression;	chr6:28162598	chr6:28073316~28074233:+
BRCA	cis	rs10256972	0.621	rs2280725	ENSG00000229043.2	AC091729.9	-12.12	1.01e-31	1.11e-28	-0.44	-0.35	Endometriosis;Longevity;	chr7:1047790	chr7:1160374~1165267:+
BRCA	cis	rs875971	0.965	rs7794930	ENSG00000222364.1	RNU6-96P	12.12	1.02e-31	1.12e-28	0.4	0.35	Aortic root size;	chr7:66313559	chr7:66395191~66395286:+
BRCA	cis	rs7829975	0.711	rs4841051	ENSG00000253893.2	FAM85B	12.12	1.02e-31	1.13e-28	0.42	0.35	Mood instability;	chr8:8828136	chr8:8167819~8226614:-
BRCA	cis	rs853679	0.517	rs36078605	ENSG00000220721.1	OR1F12	12.12	1.03e-31	1.13e-28	0.46	0.35	Depression;	chr6:28110254	chr6:28073316~28074233:+
BRCA	cis	rs875971	1	rs4717292	ENSG00000222364.1	RNU6-96P	-12.12	1.03e-31	1.14e-28	-0.4	-0.35	Aortic root size;	chr7:66430611	chr7:66395191~66395286:+
BRCA	cis	rs875971	1	rs35149210	ENSG00000222364.1	RNU6-96P	-12.12	1.03e-31	1.14e-28	-0.4	-0.35	Aortic root size;	chr7:66464938	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.862	rs4718319	ENSG00000222364.1	RNU6-96P	12.12	1.03e-31	1.14e-28	0.41	0.35	Aortic root size;	chr7:66187797	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.723	rs28391294	ENSG00000222364.1	RNU6-96P	12.12	1.03e-31	1.14e-28	0.41	0.35	Aortic root size;	chr7:66189328	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.83	rs6967708	ENSG00000222364.1	RNU6-96P	12.12	1.03e-31	1.14e-28	0.41	0.35	Aortic root size;	chr7:66192326	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.895	rs7782806	ENSG00000222364.1	RNU6-96P	12.12	1.03e-31	1.14e-28	0.41	0.35	Aortic root size;	chr7:66192910	chr7:66395191~66395286:+
BRCA	cis	rs10875746	0.951	rs8804	ENSG00000240399.1	RP1-228P16.1	-12.12	1.05e-31	1.15e-28	-0.47	-0.35	Longevity (90 years and older);	chr12:48147974	chr12:48054813~48055591:-
BRCA	cis	rs8062405	0.755	rs62031607	ENSG00000278665.1	RP11-666O2.4	12.12	1.05e-31	1.16e-28	0.39	0.35	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620209	chr16:28599241~28601881:-
BRCA	cis	rs11673344	0.566	rs8109103	ENSG00000226686.6	LINC01535	12.12	1.06e-31	1.16e-28	0.45	0.35	Obesity-related traits;	chr19:37503209	chr19:37251912~37265535:+
BRCA	cis	rs67311347	1	rs9865348	ENSG00000223797.4	ENTPD3-AS1	12.12	1.06e-31	1.16e-28	0.4	0.35	Renal cell carcinoma;	chr3:40356167	chr3:40313802~40453329:-
BRCA	cis	rs875971	1	rs6946143	ENSG00000222364.1	RNU6-96P	-12.11	1.07e-31	1.17e-28	-0.4	-0.35	Aortic root size;	chr7:66114735	chr7:66395191~66395286:+
BRCA	cis	rs8062405	1	rs62036622	ENSG00000259982.1	CDC37P1	12.11	1.08e-31	1.19e-28	0.46	0.35	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28825882	chr16:28700294~28701540:-
BRCA	cis	rs11676348	0.755	rs13410318	ENSG00000261338.2	RP11-378A13.1	12.11	1.09e-31	1.19e-28	0.38	0.35	Ulcerative colitis;	chr2:218158187	chr2:218255319~218257366:+
BRCA	cis	rs7182621	0.639	rs35248328	ENSG00000259363.4	CTD-2054N24.2	-12.11	1.09e-31	1.2e-28	-0.46	-0.35	Colonoscopy-negative controls vs population controls;	chr15:99873399	chr15:99807023~99877148:+
BRCA	cis	rs11123170	0.529	rs35606997	ENSG00000189223.12	PAX8-AS1	-12.11	1.1e-31	1.2e-28	-0.58	-0.35	Renal function-related traits (BUN);	chr2:113215773	chr2:113211522~113276581:+
BRCA	cis	rs875971	0.862	rs11763189	ENSG00000222364.1	RNU6-96P	-12.11	1.1e-31	1.21e-28	-0.41	-0.35	Aortic root size;	chr7:66518542	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.862	rs880166	ENSG00000222364.1	RNU6-96P	12.11	1.11e-31	1.21e-28	0.41	0.35	Aortic root size;	chr7:66205775	chr7:66395191~66395286:+
BRCA	cis	rs2117029	0.554	rs12306494	ENSG00000258017.1	RP11-386G11.10	-12.11	1.11e-31	1.21e-28	-0.47	-0.35	Intelligence (multi-trait analysis);	chr12:49136998	chr12:49127782~49147869:+
BRCA	cis	rs875971	0.83	rs6976714	ENSG00000222364.1	RNU6-96P	-12.11	1.11e-31	1.22e-28	-0.41	-0.35	Aortic root size;	chr7:66426474	chr7:66395191~66395286:+
BRCA	cis	rs2919917	0.628	rs2717540	ENSG00000254352.1	RP11-578O24.2	12.11	1.14e-31	1.25e-28	0.5	0.35	Lymphocyte counts;	chr8:78710128	chr8:78723796~78724136:-
BRCA	cis	rs67311347	1	rs9860162	ENSG00000223797.4	ENTPD3-AS1	12.11	1.15e-31	1.26e-28	0.4	0.35	Renal cell carcinoma;	chr3:40362384	chr3:40313802~40453329:-
BRCA	cis	rs10875746	0.859	rs12305511	ENSG00000240399.1	RP1-228P16.1	12.11	1.16e-31	1.27e-28	0.46	0.35	Longevity (90 years and older);	chr12:48188933	chr12:48054813~48055591:-
BRCA	cis	rs2117029	0.586	rs1874908	ENSG00000258017.1	RP11-386G11.10	-12.11	1.16e-31	1.28e-28	-0.47	-0.35	Intelligence (multi-trait analysis);	chr12:49190247	chr12:49127782~49147869:+
BRCA	cis	rs7849270	1	rs7023900	ENSG00000268707.1	RP11-247A12.7	-12.11	1.17e-31	1.29e-28	-0.44	-0.35	Blood metabolite ratios;	chr9:129128873	chr9:129170434~129170940:+
BRCA	cis	rs2739330	0.796	rs1006771	ENSG00000250470.1	AP000351.3	12.11	1.18e-31	1.29e-28	0.43	0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23976904~23977585:-
BRCA	cis	rs853679	0.517	rs4713141	ENSG00000220721.1	OR1F12	12.11	1.18e-31	1.29e-28	0.47	0.35	Depression;	chr6:28133900	chr6:28073316~28074233:+
BRCA	cis	rs7899628	1	rs7899628	ENSG00000226864.1	ATE1-AS1	-12.1	1.19e-31	1.3e-28	-0.48	-0.35	Breast cancer;	chr10:121904429	chr10:121928312~121951965:+
BRCA	cis	rs875971	0.83	rs809025	ENSG00000222364.1	RNU6-96P	-12.1	1.2e-31	1.31e-28	-0.41	-0.35	Aortic root size;	chr7:66384832	chr7:66395191~66395286:+
BRCA	cis	rs35160687	0.842	rs11685863	ENSG00000273080.1	RP11-301O19.1	-12.1	1.2e-31	1.32e-28	-0.4	-0.35	Night sleep phenotypes;	chr2:86327361	chr2:86195590~86196049:+
BRCA	cis	rs875971	0.862	rs1643375	ENSG00000222364.1	RNU6-96P	-12.1	1.2e-31	1.32e-28	-0.41	-0.35	Aortic root size;	chr7:66407690	chr7:66395191~66395286:+
BRCA	cis	rs853679	0.517	rs9393890	ENSG00000220721.1	OR1F12	12.1	1.21e-31	1.33e-28	0.46	0.35	Depression;	chr6:28096077	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.517	rs9366715	ENSG00000220721.1	OR1F12	12.1	1.21e-31	1.33e-28	0.46	0.35	Depression;	chr6:28096855	chr6:28073316~28074233:+
BRCA	cis	rs2117029	0.554	rs2334930	ENSG00000258017.1	RP11-386G11.10	-12.1	1.21e-31	1.33e-28	-0.47	-0.35	Intelligence (multi-trait analysis);	chr12:49175528	chr12:49127782~49147869:+
BRCA	cis	rs2117029	0.586	rs7957998	ENSG00000258017.1	RP11-386G11.10	-12.1	1.21e-31	1.33e-28	-0.47	-0.35	Intelligence (multi-trait analysis);	chr12:49180240	chr12:49127782~49147869:+
BRCA	cis	rs11673344	0.526	rs2306201	ENSG00000226686.6	LINC01535	12.1	1.23e-31	1.34e-28	0.48	0.35	Obesity-related traits;	chr19:37586573	chr19:37251912~37265535:+
BRCA	cis	rs11673344	0.526	rs2291001	ENSG00000226686.6	LINC01535	12.1	1.23e-31	1.34e-28	0.48	0.35	Obesity-related traits;	chr19:37594431	chr19:37251912~37265535:+
BRCA	cis	rs2658782	0.724	rs2605627	ENSG00000279684.1	RP11-755E23.2	-12.1	1.23e-31	1.34e-28	-0.52	-0.35	Pulmonary function decline;	chr11:93526349	chr11:93286629~93288903:-
BRCA	cis	rs875971	1	rs6460296	ENSG00000222364.1	RNU6-96P	-12.1	1.26e-31	1.38e-28	-0.4	-0.35	Aortic root size;	chr7:66430152	chr7:66395191~66395286:+
BRCA	cis	rs10129255	0.509	rs756583	ENSG00000211972.2	IGHV3-66	12.1	1.29e-31	1.41e-28	0.24	0.35	Kawasaki disease;	chr14:106680002	chr14:106675017~106675544:-
BRCA	cis	rs875971	0.862	rs778680	ENSG00000222364.1	RNU6-96P	-12.1	1.29e-31	1.41e-28	-0.41	-0.35	Aortic root size;	chr7:66375427	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.862	rs11769079	ENSG00000222364.1	RNU6-96P	-12.1	1.29e-31	1.41e-28	-0.41	-0.35	Aortic root size;	chr7:66377141	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.862	rs1695820	ENSG00000222364.1	RNU6-96P	-12.1	1.29e-31	1.41e-28	-0.41	-0.35	Aortic root size;	chr7:66379576	chr7:66395191~66395286:+
BRCA	cis	rs150992	0.609	rs4703049	ENSG00000248489.1	CTD-2007H13.3	12.1	1.31e-31	1.43e-28	0.39	0.35	Body mass index;	chr5:99004679	chr5:98929171~98995013:+
BRCA	cis	rs875971	0.862	rs778702	ENSG00000222364.1	RNU6-96P	-12.09	1.34e-31	1.46e-28	-0.41	-0.35	Aortic root size;	chr7:66399848	chr7:66395191~66395286:+
BRCA	cis	rs853679	0.517	rs1947863	ENSG00000220721.1	OR1F12	12.09	1.34e-31	1.46e-28	0.47	0.35	Depression;	chr6:28131566	chr6:28073316~28074233:+
BRCA	cis	rs10129255	0.536	rs10139058	ENSG00000211972.2	IGHV3-66	12.09	1.36e-31	1.48e-28	0.24	0.35	Kawasaki disease;	chr14:106685899	chr14:106675017~106675544:-
BRCA	cis	rs150992	0.711	rs2617507	ENSG00000248489.1	CTD-2007H13.3	12.09	1.37e-31	1.49e-28	0.41	0.35	Body mass index;	chr5:98912548	chr5:98929171~98995013:+
BRCA	cis	rs3091242	0.934	rs686631	ENSG00000224183.1	SDHDP6	-12.09	1.37e-31	1.49e-28	-0.43	-0.35	Erythrocyte sedimentation rate;	chr1:25393108	chr1:25294164~25294643:-
BRCA	cis	rs7044106	0.762	rs7044226	ENSG00000226752.6	PSMD5-AS1	-12.09	1.37e-31	1.5e-28	-0.43	-0.35	Hip circumference adjusted for BMI;	chr9:120704050	chr9:120824828~120854385:+
BRCA	cis	rs8062405	1	rs62037369	ENSG00000259982.1	CDC37P1	12.09	1.38e-31	1.5e-28	0.47	0.35	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28872520	chr16:28700294~28701540:-
BRCA	cis	rs8062405	0.965	rs7359397	ENSG00000259982.1	CDC37P1	12.09	1.38e-31	1.5e-28	0.47	0.35	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28874338	chr16:28700294~28701540:-
BRCA	cis	rs853679	0.517	rs3757185	ENSG00000220721.1	OR1F12	12.09	1.39e-31	1.51e-28	0.47	0.35	Depression;	chr6:28139998	chr6:28073316~28074233:+
BRCA	cis	rs7301826	1	rs4619189	ENSG00000256299.1	RP11-989F5.3	-12.09	1.39e-31	1.51e-28	-0.4	-0.35	Plasma plasminogen activator levels;	chr12:130829252	chr12:130810821~130812622:-
BRCA	cis	rs6991838	0.584	rs14213	ENSG00000272010.1	CTD-3025N20.3	12.09	1.39e-31	1.51e-28	0.37	0.35	Intelligence (multi-trait analysis);	chr8:65602719	chr8:65591850~65592472:-
BRCA	cis	rs2117029	0.586	rs10783307	ENSG00000258017.1	RP11-386G11.10	-12.09	1.39e-31	1.52e-28	-0.47	-0.35	Intelligence (multi-trait analysis);	chr12:49135822	chr12:49127782~49147869:+
BRCA	cis	rs875971	1	rs2420591	ENSG00000222364.1	RNU6-96P	-12.09	1.4e-31	1.52e-28	-0.4	-0.35	Aortic root size;	chr7:66447394	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.862	rs6962717	ENSG00000222364.1	RNU6-96P	-12.09	1.4e-31	1.53e-28	-0.41	-0.35	Aortic root size;	chr7:66418748	chr7:66395191~66395286:+
BRCA	cis	rs4423214	0.879	rs1792281	ENSG00000254682.1	RP11-660L16.2	-12.09	1.41e-31	1.53e-28	-0.48	-0.35	Vitamin D levels;	chr11:71424450	chr11:71448674~71452157:+
BRCA	cis	rs2564921	0.704	rs12053904	ENSG00000242142.1	SERBP1P3	-12.09	1.41e-31	1.54e-28	-0.42	-0.35	Height;	chr3:52991821	chr3:53064283~53065091:-
BRCA	cis	rs2564921	0.679	rs2115779	ENSG00000242142.1	SERBP1P3	-12.09	1.41e-31	1.54e-28	-0.42	-0.35	Height;	chr3:52992698	chr3:53064283~53065091:-
BRCA	cis	rs2404602	0.684	rs12591622	ENSG00000259422.1	RP11-593F23.1	-12.09	1.42e-31	1.54e-28	-0.47	-0.35	Blood metabolite levels;	chr15:76638314	chr15:76174891~76181486:-
BRCA	cis	rs2015599	0.623	rs10843385	ENSG00000257176.2	RP11-996F15.2	-12.09	1.45e-31	1.57e-28	-0.43	-0.35	Platelet count;Mean platelet volume;	chr12:29323100	chr12:29280418~29317848:-
BRCA	cis	rs673078	0.607	rs7967900	ENSG00000275759.1	RP11-131L12.3	12.08	1.47e-31	1.6e-28	0.54	0.35	Glucose homeostasis traits;	chr12:118381902	chr12:118428281~118428870:+
BRCA	cis	rs875971	1	rs1540651	ENSG00000222364.1	RNU6-96P	12.08	1.49e-31	1.62e-28	0.41	0.35	Aortic root size;	chr7:66185134	chr7:66395191~66395286:+
BRCA	cis	rs875971	1	rs7789554	ENSG00000222364.1	RNU6-96P	-12.08	1.51e-31	1.64e-28	-0.4	-0.35	Aortic root size;	chr7:66481051	chr7:66395191~66395286:+
BRCA	cis	rs875971	1	rs4717300	ENSG00000222364.1	RNU6-96P	-12.08	1.51e-31	1.64e-28	-0.4	-0.35	Aortic root size;	chr7:66482393	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.895	rs1974769	ENSG00000222364.1	RNU6-96P	-12.08	1.51e-31	1.64e-28	-0.4	-0.35	Aortic root size;	chr7:66485627	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.895	rs6460300	ENSG00000222364.1	RNU6-96P	-12.08	1.51e-31	1.64e-28	-0.4	-0.35	Aortic root size;	chr7:66487937	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.862	rs7803416	ENSG00000222364.1	RNU6-96P	-12.08	1.51e-31	1.64e-28	-0.4	-0.35	Aortic root size;	chr7:66489212	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.964	rs2277911	ENSG00000222364.1	RNU6-96P	-12.08	1.51e-31	1.64e-28	-0.4	-0.35	Aortic root size;	chr7:66493638	chr7:66395191~66395286:+
BRCA	cis	rs6142102	0.602	rs2268086	ENSG00000276073.1	RP5-1125A11.7	12.08	1.54e-31	1.68e-28	0.4	0.35	Skin pigmentation;	chr20:34060932	chr20:33985617~33988989:-
BRCA	cis	rs8040855	0.597	rs994989	ENSG00000259295.5	CSPG4P12	12.08	1.55e-31	1.68e-28	0.52	0.35	Bulimia nervosa;	chr15:85117485	chr15:85191438~85213905:+
BRCA	cis	rs9487094	0.922	rs10872034	ENSG00000260273.1	RP11-425D10.10	12.08	1.57e-31	1.71e-28	0.43	0.35	Height;	chr6:109486036	chr6:109382795~109383666:+
BRCA	cis	rs875971	1	rs6979382	ENSG00000222364.1	RNU6-96P	-12.08	1.62e-31	1.76e-28	-0.41	-0.35	Aortic root size;	chr7:66421388	chr7:66395191~66395286:+
BRCA	cis	rs875971	1	rs6961990	ENSG00000222364.1	RNU6-96P	-12.08	1.62e-31	1.76e-28	-0.41	-0.35	Aortic root size;	chr7:66423583	chr7:66395191~66395286:+
BRCA	cis	rs853679	0.542	rs6934769	ENSG00000220721.1	OR1F12	12.08	1.62e-31	1.76e-28	0.46	0.35	Depression;	chr6:28123153	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.517	rs17711801	ENSG00000220721.1	OR1F12	12.08	1.62e-31	1.76e-28	0.46	0.35	Depression;	chr6:28124529	chr6:28073316~28074233:+
BRCA	cis	rs4713118	0.527	rs9461433	ENSG00000220721.1	OR1F12	12.08	1.62e-31	1.76e-28	0.46	0.35	Parkinson's disease;	chr6:28127394	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.517	rs9468292	ENSG00000220721.1	OR1F12	12.08	1.62e-31	1.76e-28	0.46	0.35	Depression;	chr6:28127577	chr6:28073316~28074233:+
BRCA	cis	rs7849270	1	rs7036114	ENSG00000268707.1	RP11-247A12.7	-12.08	1.63e-31	1.77e-28	-0.44	-0.35	Blood metabolite ratios;	chr9:129131127	chr9:129170434~129170940:+
BRCA	cis	rs35160687	0.814	rs4392258	ENSG00000273080.1	RP11-301O19.1	-12.07	1.65e-31	1.79e-28	-0.4	-0.35	Night sleep phenotypes;	chr2:86325454	chr2:86195590~86196049:+
BRCA	cis	rs875971	0.862	rs1983372	ENSG00000222364.1	RNU6-96P	12.07	1.7e-31	1.85e-28	0.4	0.35	Aortic root size;	chr7:66146364	chr7:66395191~66395286:+
BRCA	cis	rs7829975	0.84	rs572366	ENSG00000253893.2	FAM85B	-12.07	1.71e-31	1.85e-28	-0.43	-0.35	Mood instability;	chr8:8721284	chr8:8167819~8226614:-
BRCA	cis	rs853679	0.517	rs1904840	ENSG00000220721.1	OR1F12	12.07	1.71e-31	1.86e-28	0.47	0.35	Depression;	chr6:28140454	chr6:28073316~28074233:+
BRCA	cis	rs875971	0.895	rs10755833	ENSG00000222364.1	RNU6-96P	-12.07	1.72e-31	1.87e-28	-0.4	-0.35	Aortic root size;	chr7:66448930	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.895	rs1833495	ENSG00000222364.1	RNU6-96P	-12.07	1.72e-31	1.87e-28	-0.4	-0.35	Aortic root size;	chr7:66456608	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.964	rs6945032	ENSG00000222364.1	RNU6-96P	-12.07	1.72e-31	1.87e-28	-0.4	-0.35	Aortic root size;	chr7:66457499	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.929	rs12673810	ENSG00000222364.1	RNU6-96P	-12.07	1.72e-31	1.87e-28	-0.4	-0.35	Aortic root size;	chr7:66458866	chr7:66395191~66395286:+
BRCA	cis	rs875971	1	rs6961155	ENSG00000222364.1	RNU6-96P	-12.07	1.72e-31	1.87e-28	-0.4	-0.35	Aortic root size;	chr7:66468308	chr7:66395191~66395286:+
BRCA	cis	rs875971	1	rs7789768	ENSG00000222364.1	RNU6-96P	-12.07	1.72e-31	1.87e-28	-0.4	-0.35	Aortic root size;	chr7:66473993	chr7:66395191~66395286:+
BRCA	cis	rs875971	1	rs1363055	ENSG00000222364.1	RNU6-96P	-12.07	1.72e-31	1.87e-28	-0.4	-0.35	Aortic root size;	chr7:66478288	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.964	rs9691480	ENSG00000222364.1	RNU6-96P	-12.07	1.72e-31	1.87e-28	-0.4	-0.35	Aortic root size;	chr7:66479319	chr7:66395191~66395286:+
BRCA	cis	rs10129255	0.536	rs8004835	ENSG00000223648.3	IGHV3-64	12.07	1.74e-31	1.89e-28	0.27	0.35	Kawasaki disease;	chr14:106686361	chr14:106643132~106658258:-
BRCA	cis	rs875971	1	rs6460292	ENSG00000222364.1	RNU6-96P	12.07	1.76e-31	1.91e-28	0.4	0.35	Aortic root size;	chr7:66345088	chr7:66395191~66395286:+
BRCA	cis	rs10875746	0.903	rs11168420	ENSG00000240399.1	RP1-228P16.1	-12.07	1.76e-31	1.91e-28	-0.47	-0.35	Longevity (90 years and older);	chr12:48122113	chr12:48054813~48055591:-
BRCA	cis	rs2015599	0.601	rs17715086	ENSG00000257176.2	RP11-996F15.2	-12.07	1.78e-31	1.93e-28	-0.43	-0.35	Platelet count;Mean platelet volume;	chr12:29329073	chr12:29280418~29317848:-
BRCA	cis	rs853679	0.598	rs9380054	ENSG00000220721.1	OR1F12	12.06	1.82e-31	1.97e-28	0.46	0.35	Depression;	chr6:28099759	chr6:28073316~28074233:+
BRCA	cis	rs4713118	0.547	rs2116981	ENSG00000220721.1	OR1F12	12.06	1.82e-31	1.97e-28	0.46	0.35	Parkinson's disease;	chr6:28100173	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.517	rs9368552	ENSG00000220721.1	OR1F12	12.06	1.82e-31	1.97e-28	0.46	0.35	Depression;	chr6:28100648	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.542	rs34131763	ENSG00000220721.1	OR1F12	12.06	1.82e-31	1.97e-28	0.46	0.35	Depression;	chr6:28107222	chr6:28073316~28074233:+
BRCA	cis	rs11317778	1	rs11317778	ENSG00000248489.1	CTD-2007H13.3	12.06	1.82e-31	1.97e-28	0.41	0.35	Eosinophil percentage of white cells;Eosinophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr5:98905525	chr5:98929171~98995013:+
BRCA	cis	rs8062405	1	rs12325113	ENSG00000259982.1	CDC37P1	12.06	1.83e-31	1.98e-28	0.46	0.35	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28837347	chr16:28700294~28701540:-
BRCA	cis	rs56163509	1	rs56163509	ENSG00000259982.1	CDC37P1	12.06	1.83e-31	1.98e-28	0.46	0.35	Tonsillectomy;Mean corpuscular volume;	chr16:28853150	chr16:28700294~28701540:-
BRCA	cis	rs3091242	0.933	rs12402120	ENSG00000224183.1	SDHDP6	-12.06	1.85e-31	2e-28	-0.42	-0.35	Erythrocyte sedimentation rate;	chr1:25425141	chr1:25294164~25294643:-
BRCA	cis	rs875971	1	rs12532998	ENSG00000222364.1	RNU6-96P	-12.06	1.86e-31	2.02e-28	-0.4	-0.35	Aortic root size;	chr7:66502472	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.929	rs12535036	ENSG00000222364.1	RNU6-96P	-12.06	1.88e-31	2.04e-28	-0.4	-0.35	Aortic root size;	chr7:66499076	chr7:66395191~66395286:+
BRCA	cis	rs875971	1	rs6970030	ENSG00000222364.1	RNU6-96P	-12.06	1.88e-31	2.04e-28	-0.4	-0.35	Aortic root size;	chr7:66503692	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.928	rs6970357	ENSG00000222364.1	RNU6-96P	-12.06	1.88e-31	2.04e-28	-0.4	-0.35	Aortic root size;	chr7:66503891	chr7:66395191~66395286:+
BRCA	cis	rs11673344	0.583	rs7247090	ENSG00000226686.6	LINC01535	12.06	1.89e-31	2.04e-28	0.45	0.35	Obesity-related traits;	chr19:37522509	chr19:37251912~37265535:+
BRCA	cis	rs875971	0.964	rs6978429	ENSG00000222364.1	RNU6-96P	-12.06	1.9e-31	2.05e-28	-0.4	-0.35	Aortic root size;	chr7:66494889	chr7:66395191~66395286:+
BRCA	cis	rs875971	1	rs4718357	ENSG00000222364.1	RNU6-96P	-12.06	1.9e-31	2.05e-28	-0.4	-0.35	Aortic root size;	chr7:66495891	chr7:66395191~66395286:+
BRCA	cis	rs1061377	0.748	rs13117988	ENSG00000249207.1	RP11-360F5.1	-12.06	1.9e-31	2.05e-28	-0.4	-0.35	Uric acid levels;	chr4:39092219	chr4:39112677~39126818:-
BRCA	cis	rs875971	0.898	rs6977501	ENSG00000222364.1	RNU6-96P	12.06	1.95e-31	2.1e-28	0.41	0.35	Aortic root size;	chr7:66228355	chr7:66395191~66395286:+
BRCA	cis	rs4774565	0.762	rs8041193	ENSG00000244879.4	GABPB1-AS1	-12.06	1.95e-31	2.11e-28	-0.37	-0.35	Breast cancer;	chr15:50369960	chr15:50354959~50372202:+
BRCA	cis	rs2739330	0.796	rs5760106	ENSG00000231271.1	AP000350.8	-12.06	1.96e-31	2.12e-28	-0.44	-0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23949918~23954042:+
BRCA	cis	rs10875746	0.903	rs4760681	ENSG00000240399.1	RP1-228P16.1	-12.06	1.96e-31	2.12e-28	-0.47	-0.35	Longevity (90 years and older);	chr12:48111447	chr12:48054813~48055591:-
BRCA	cis	rs853679	0.517	rs3757187	ENSG00000220721.1	OR1F12	12.06	2.01e-31	2.17e-28	0.47	0.35	Depression;	chr6:28139876	chr6:28073316~28074233:+
BRCA	cis	rs1061377	0.748	rs35904472	ENSG00000249207.1	RP11-360F5.1	-12.05	2.02e-31	2.19e-28	-0.4	-0.35	Uric acid levels;	chr4:39094901	chr4:39112677~39126818:-
BRCA	cis	rs1061377	0.748	rs10856841	ENSG00000249207.1	RP11-360F5.1	-12.05	2.02e-31	2.19e-28	-0.4	-0.35	Uric acid levels;	chr4:39095240	chr4:39112677~39126818:-
BRCA	cis	rs2117029	0.555	rs7958241	ENSG00000258017.1	RP11-386G11.10	12.05	2.03e-31	2.19e-28	0.47	0.35	Intelligence (multi-trait analysis);	chr12:49115479	chr12:49127782~49147869:+
BRCA	cis	rs10129255	0.536	rs6576201	ENSG00000211972.2	IGHV3-66	-12.05	2.05e-31	2.21e-28	-0.24	-0.35	Kawasaki disease;	chr14:106683696	chr14:106675017~106675544:-
BRCA	cis	rs9322193	0.566	rs5024811	ENSG00000216906.2	RP11-350J20.9	-12.05	2.06e-31	2.23e-28	-0.47	-0.35	Lung cancer;	chr6:149924898	chr6:149904243~149906418:+
BRCA	cis	rs875971	0.895	rs4718349	ENSG00000222364.1	RNU6-96P	-12.05	2.08e-31	2.24e-28	-0.4	-0.35	Aortic root size;	chr7:66444024	chr7:66395191~66395286:+
BRCA	cis	rs875971	1	rs2042133	ENSG00000222364.1	RNU6-96P	-12.05	2.08e-31	2.24e-28	-0.4	-0.35	Aortic root size;	chr7:66466935	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.964	rs2161065	ENSG00000222364.1	RNU6-96P	-12.05	2.08e-31	2.24e-28	-0.4	-0.35	Aortic root size;	chr7:66467918	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.862	rs12698521	ENSG00000222364.1	RNU6-96P	-12.05	2.08e-31	2.24e-28	-0.4	-0.35	Aortic root size;	chr7:66474502	chr7:66395191~66395286:+
BRCA	cis	rs10875746	0.951	rs4760690	ENSG00000240399.1	RP1-228P16.1	-12.05	2.13e-31	2.3e-28	-0.47	-0.35	Longevity (90 years and older);	chr12:48169870	chr12:48054813~48055591:-
BRCA	cis	rs2919917	0.628	rs6981103	ENSG00000254352.1	RP11-578O24.2	12.05	2.14e-31	2.3e-28	0.48	0.35	Lymphocyte counts;	chr8:78691702	chr8:78723796~78724136:-
BRCA	cis	rs34779708	0.931	rs12771399	ENSG00000230534.5	RP11-297A16.2	12.05	2.15e-31	2.32e-28	0.46	0.35	Inflammatory bowel disease;Crohn's disease;	chr10:35163449	chr10:35098006~35127020:-
BRCA	cis	rs853679	0.517	rs9393891	ENSG00000220721.1	OR1F12	12.05	2.21e-31	2.38e-28	0.46	0.35	Depression;	chr6:28111382	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.517	rs9468286	ENSG00000220721.1	OR1F12	12.05	2.21e-31	2.38e-28	0.46	0.35	Depression;	chr6:28111650	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.517	rs9380055	ENSG00000220721.1	OR1F12	12.05	2.21e-31	2.38e-28	0.46	0.35	Depression;	chr6:28113851	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.517	rs9368553	ENSG00000220721.1	OR1F12	12.05	2.21e-31	2.38e-28	0.46	0.35	Depression;	chr6:28114487	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.517	rs9368554	ENSG00000220721.1	OR1F12	12.05	2.21e-31	2.38e-28	0.46	0.35	Depression;	chr6:28114933	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.517	rs4713137	ENSG00000220721.1	OR1F12	12.05	2.21e-31	2.38e-28	0.46	0.35	Depression;	chr6:28115743	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.517	rs9348793	ENSG00000220721.1	OR1F12	12.05	2.21e-31	2.38e-28	0.46	0.35	Depression;	chr6:28116411	chr6:28073316~28074233:+
BRCA	cis	rs4713118	0.586	rs6905516	ENSG00000220721.1	OR1F12	12.05	2.21e-31	2.38e-28	0.46	0.35	Parkinson's disease;	chr6:28118700	chr6:28073316~28074233:+
BRCA	cis	rs4713118	0.586	rs6905522	ENSG00000220721.1	OR1F12	12.05	2.21e-31	2.38e-28	0.46	0.35	Parkinson's disease;	chr6:28118701	chr6:28073316~28074233:+
BRCA	cis	rs4713118	0.586	rs9468290	ENSG00000220721.1	OR1F12	12.05	2.21e-31	2.38e-28	0.46	0.35	Parkinson's disease;	chr6:28119896	chr6:28073316~28074233:+
BRCA	cis	rs2019137	0.936	rs3828188	ENSG00000274877.1	RP11-65I12.1	12.04	2.27e-31	2.44e-28	0.45	0.35	Lymphocyte counts;	chr2:113196670	chr2:113237595~113240825:+
BRCA	cis	rs875971	1	rs12533997	ENSG00000222364.1	RNU6-96P	-12.04	2.27e-31	2.44e-28	-0.4	-0.35	Aortic root size;	chr7:66500390	chr7:66395191~66395286:+
BRCA	cis	rs765787	0.53	rs11636410	ENSG00000259520.4	CTD-2651B20.3	-12.04	2.27e-31	2.44e-28	-0.43	-0.35	Uric acid levels;	chr15:45243715	chr15:45251580~45279251:-
BRCA	cis	rs10515750	0.643	rs10063413	ENSG00000251405.2	CTB-109A12.1	-12.04	2.28e-31	2.45e-28	-0.68	-0.35	Lung function (FEV1/FVC);	chr5:157384435	chr5:157362615~157460078:-
BRCA	cis	rs7849270	1	rs7021449	ENSG00000268707.1	RP11-247A12.7	-12.04	2.37e-31	2.54e-28	-0.43	-0.35	Blood metabolite ratios;	chr9:129137033	chr9:129170434~129170940:+
BRCA	cis	rs875971	0.862	rs2420174	ENSG00000222364.1	RNU6-96P	12.04	2.38e-31	2.56e-28	0.41	0.35	Aortic root size;	chr7:66180374	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.862	rs2420173	ENSG00000222364.1	RNU6-96P	12.04	2.38e-31	2.56e-28	0.41	0.35	Aortic root size;	chr7:66180412	chr7:66395191~66395286:+
BRCA	cis	rs875971	1	rs12698523	ENSG00000222364.1	RNU6-96P	-12.04	2.42e-31	2.6e-28	-0.4	-0.35	Aortic root size;	chr7:66503126	chr7:66395191~66395286:+
BRCA	cis	rs673078	0.607	rs17512763	ENSG00000275759.1	RP11-131L12.3	-12.04	2.42e-31	2.6e-28	-0.54	-0.35	Glucose homeostasis traits;	chr12:118400974	chr12:118428281~118428870:+
BRCA	cis	rs853679	0.517	rs868987	ENSG00000220721.1	OR1F12	-12.04	2.43e-31	2.61e-28	-0.47	-0.35	Depression;	chr6:28142370	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.517	rs9368555	ENSG00000220721.1	OR1F12	12.04	2.46e-31	2.64e-28	0.47	0.35	Depression;	chr6:28141189	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.517	rs9393893	ENSG00000220721.1	OR1F12	12.04	2.46e-31	2.64e-28	0.47	0.35	Depression;	chr6:28141484	chr6:28073316~28074233:+
BRCA	cis	rs2919917	0.554	rs2086755	ENSG00000254352.1	RP11-578O24.2	12.04	2.47e-31	2.65e-28	0.49	0.35	Lymphocyte counts;	chr8:78701809	chr8:78723796~78724136:-
BRCA	cis	rs4713118	0.516	rs7739216	ENSG00000220721.1	OR1F12	12.04	2.47e-31	2.65e-28	0.46	0.35	Parkinson's disease;	chr6:28112168	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.517	rs35512245	ENSG00000220721.1	OR1F12	12.04	2.47e-31	2.65e-28	0.46	0.35	Depression;	chr6:28112175	chr6:28073316~28074233:+
BRCA	cis	rs1501911	0.509	rs330422	ENSG00000248489.1	CTD-2007H13.3	12.03	2.59e-31	2.78e-28	0.4	0.35	Lung function (FEV1/FVC);	chr5:98859184	chr5:98929171~98995013:+
BRCA	cis	rs2404602	0.647	rs11855296	ENSG00000259422.1	RP11-593F23.1	-12.03	2.6e-31	2.78e-28	-0.48	-0.35	Blood metabolite levels;	chr15:76800621	chr15:76174891~76181486:-
BRCA	cis	rs6991838	0.584	rs4275254	ENSG00000272010.1	CTD-3025N20.3	-12.03	2.61e-31	2.8e-28	-0.37	-0.35	Intelligence (multi-trait analysis);	chr8:65589129	chr8:65591850~65592472:-
BRCA	cis	rs67311347	1	rs4973993	ENSG00000223797.4	ENTPD3-AS1	12.03	2.63e-31	2.82e-28	0.42	0.35	Renal cell carcinoma;	chr3:40411469	chr3:40313802~40453329:-
BRCA	cis	rs67311347	1	rs4973994	ENSG00000223797.4	ENTPD3-AS1	12.03	2.63e-31	2.82e-28	0.42	0.35	Renal cell carcinoma;	chr3:40411533	chr3:40313802~40453329:-
BRCA	cis	rs875971	0.756	rs4718328	ENSG00000222364.1	RNU6-96P	12.03	2.63e-31	2.82e-28	0.41	0.35	Aortic root size;	chr7:66228350	chr7:66395191~66395286:+
BRCA	cis	rs4722166	0.695	rs56061963	ENSG00000179428.2	AC073072.5	-12.03	2.64e-31	2.83e-28	-0.37	-0.35	Lung cancer;	chr7:22760778	chr7:22725395~22727620:-
BRCA	cis	rs35160687	0.736	rs6746198	ENSG00000273080.1	RP11-301O19.1	-12.03	2.64e-31	2.83e-28	-0.4	-0.35	Night sleep phenotypes;	chr2:86314990	chr2:86195590~86196049:+
BRCA	cis	rs2404602	0.647	rs11072628	ENSG00000259422.1	RP11-593F23.1	-12.03	2.67e-31	2.86e-28	-0.47	-0.35	Blood metabolite levels;	chr15:76815420	chr15:76174891~76181486:-
BRCA	cis	rs875971	0.867	rs1002053	ENSG00000222364.1	RNU6-96P	12.03	2.69e-31	2.88e-28	0.4	0.35	Aortic root size;	chr7:66333558	chr7:66395191~66395286:+
BRCA	cis	rs875971	1	rs11974264	ENSG00000222364.1	RNU6-96P	12.03	2.7e-31	2.89e-28	0.4	0.35	Aortic root size;	chr7:66182595	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.964	rs6945019	ENSG00000222364.1	RNU6-96P	-12.03	2.75e-31	2.94e-28	-0.4	-0.35	Aortic root size;	chr7:66457471	chr7:66395191~66395286:+
BRCA	cis	rs2404602	0.647	rs35710279	ENSG00000259422.1	RP11-593F23.1	-12.03	2.75e-31	2.95e-28	-0.47	-0.35	Blood metabolite levels;	chr15:76789893	chr15:76174891~76181486:-
BRCA	cis	rs7849270	1	rs713219	ENSG00000268707.1	RP11-247A12.7	-12.03	2.77e-31	2.96e-28	-0.43	-0.35	Blood metabolite ratios;	chr9:129138641	chr9:129170434~129170940:+
BRCA	cis	rs875971	0.83	rs6950137	ENSG00000222364.1	RNU6-96P	-12.02	2.81e-31	3.01e-28	-0.41	-0.35	Aortic root size;	chr7:66511623	chr7:66395191~66395286:+
BRCA	cis	rs11123170	0.529	rs1015753	ENSG00000189223.12	PAX8-AS1	-12.02	2.81e-31	3.01e-28	-0.59	-0.35	Renal function-related traits (BUN);	chr2:113211226	chr2:113211522~113276581:+
BRCA	cis	rs150992	0.585	rs331931	ENSG00000248489.1	CTD-2007H13.3	12.02	2.84e-31	3.04e-28	0.41	0.35	Body mass index;	chr5:98834012	chr5:98929171~98995013:+
BRCA	cis	rs875971	0.798	rs57739047	ENSG00000222364.1	RNU6-96P	-12.02	2.88e-31	3.08e-28	-0.41	-0.35	Aortic root size;	chr7:66507579	chr7:66395191~66395286:+
BRCA	cis	rs34779708	0.733	rs11597184	ENSG00000230534.5	RP11-297A16.2	12.02	2.98e-31	3.19e-28	0.45	0.35	Inflammatory bowel disease;Crohn's disease;	chr10:35108468	chr10:35098006~35127020:-
BRCA	cis	rs2019137	0.936	rs3828189	ENSG00000274877.1	RP11-65I12.1	12.02	2.99e-31	3.19e-28	0.45	0.35	Lymphocyte counts;	chr2:113196919	chr2:113237595~113240825:+
BRCA	cis	rs875971	0.965	rs6971509	ENSG00000222364.1	RNU6-96P	12.02	3.02e-31	3.23e-28	0.4	0.35	Aortic root size;	chr7:66249983	chr7:66395191~66395286:+
BRCA	cis	rs7182621	0.639	rs12906050	ENSG00000259363.4	CTD-2054N24.2	-12.02	3.03e-31	3.23e-28	-0.46	-0.35	Colonoscopy-negative controls vs population controls;	chr15:99873384	chr15:99807023~99877148:+
BRCA	cis	rs10875746	0.903	rs11168418	ENSG00000240399.1	RP1-228P16.1	-12.02	3.04e-31	3.25e-28	-0.46	-0.35	Longevity (90 years and older);	chr12:48121971	chr12:48054813~48055591:-
BRCA	cis	rs10875746	0.855	rs73102065	ENSG00000240399.1	RP1-228P16.1	-12.02	3.07e-31	3.28e-28	-0.47	-0.35	Longevity (90 years and older);	chr12:48098824	chr12:48054813~48055591:-
BRCA	cis	rs2019137	0.936	rs4849169	ENSG00000274877.1	RP11-65I12.1	12.02	3.08e-31	3.29e-28	0.45	0.35	Lymphocyte counts;	chr2:113196080	chr2:113237595~113240825:+
BRCA	cis	rs2019137	0.836	rs4848318	ENSG00000274877.1	RP11-65I12.1	12.02	3.08e-31	3.29e-28	0.45	0.35	Lymphocyte counts;	chr2:113196375	chr2:113237595~113240825:+
BRCA	cis	rs2019137	0.936	rs2241978	ENSG00000274877.1	RP11-65I12.1	12.02	3.08e-31	3.29e-28	0.45	0.35	Lymphocyte counts;	chr2:113196429	chr2:113237595~113240825:+
BRCA	cis	rs7849270	1	rs34055941	ENSG00000268707.1	RP11-247A12.7	-12.01	3.11e-31	3.32e-28	-0.44	-0.35	Blood metabolite ratios;	chr9:129132797	chr9:129170434~129170940:+
BRCA	cis	rs2882667	0.522	rs7731574	ENSG00000253404.1	AC034243.1	-12.01	3.12e-31	3.33e-28	-0.44	-0.35	Age-related hearing impairment (SNP x SNP interaction);	chr5:139118503	chr5:138744434~138753309:-
BRCA	cis	rs875971	0.964	rs12668936	ENSG00000222364.1	RNU6-96P	-12.01	3.15e-31	3.36e-28	-0.4	-0.35	Aortic root size;	chr7:66449417	chr7:66395191~66395286:+
BRCA	cis	rs10129255	0.53	rs11624912	ENSG00000223648.3	IGHV3-64	12.01	3.15e-31	3.36e-28	0.28	0.35	Kawasaki disease;	chr14:106673891	chr14:106643132~106658258:-
BRCA	cis	rs7182621	0.639	rs1561047	ENSG00000259363.4	CTD-2054N24.2	-12.01	3.18e-31	3.39e-28	-0.47	-0.35	Colonoscopy-negative controls vs population controls;	chr15:99874606	chr15:99807023~99877148:+
BRCA	cis	rs150992	0.609	rs78721487	ENSG00000248489.1	CTD-2007H13.3	12.01	3.21e-31	3.42e-28	0.39	0.35	Body mass index;	chr5:98992926	chr5:98929171~98995013:+
BRCA	cis	rs11676348	0.846	rs7607437	ENSG00000261338.2	RP11-378A13.1	-12.01	3.23e-31	3.44e-28	-0.38	-0.35	Ulcerative colitis;	chr2:218143669	chr2:218255319~218257366:+
BRCA	cis	rs2404602	0.684	rs10851888	ENSG00000259422.1	RP11-593F23.1	-12.01	3.27e-31	3.48e-28	-0.47	-0.35	Blood metabolite levels;	chr15:76610165	chr15:76174891~76181486:-
BRCA	cis	rs150992	0.547	rs325217	ENSG00000248489.1	CTD-2007H13.3	12.01	3.27e-31	3.49e-28	0.4	0.35	Body mass index;	chr5:98844109	chr5:98929171~98995013:+
BRCA	cis	rs2117029	0.553	rs11168909	ENSG00000258017.1	RP11-386G11.10	-12.01	3.29e-31	3.5e-28	-0.47	-0.35	Intelligence (multi-trait analysis);	chr12:49183092	chr12:49127782~49147869:+
BRCA	cis	rs853679	0.517	rs2281588	ENSG00000220721.1	OR1F12	12.01	3.3e-31	3.51e-28	0.46	0.35	Depression;	chr6:28104824	chr6:28073316~28074233:+
BRCA	cis	rs2919917	0.628	rs894222	ENSG00000254352.1	RP11-578O24.2	-12.01	3.31e-31	3.53e-28	-0.49	-0.35	Lymphocyte counts;	chr8:78737034	chr8:78723796~78724136:-
BRCA	cis	rs875971	0.895	rs12698520	ENSG00000222364.1	RNU6-96P	-12.01	3.31e-31	3.53e-28	-0.4	-0.35	Aortic root size;	chr7:66453720	chr7:66395191~66395286:+
BRCA	cis	rs10129255	0.556	rs8010005	ENSG00000223648.3	IGHV3-64	12	3.49e-31	3.71e-28	0.27	0.35	Kawasaki disease;	chr14:106777987	chr14:106643132~106658258:-
BRCA	cis	rs10129255	0.556	rs6576224	ENSG00000223648.3	IGHV3-64	12	3.49e-31	3.71e-28	0.27	0.35	Kawasaki disease;	chr14:106777997	chr14:106643132~106658258:-
BRCA	cis	rs10129255	0.518	rs8010020	ENSG00000223648.3	IGHV3-64	12	3.49e-31	3.71e-28	0.27	0.35	Kawasaki disease;	chr14:106778016	chr14:106643132~106658258:-
BRCA	cis	rs875971	1	rs6945843	ENSG00000222364.1	RNU6-96P	12	3.5e-31	3.73e-28	0.4	0.35	Aortic root size;	chr7:66269796	chr7:66395191~66395286:+
BRCA	cis	rs8072100	0.84	rs2136751	ENSG00000228782.6	CTD-2026D20.3	12	3.53e-31	3.75e-28	0.38	0.35	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47378727	chr17:47450568~47492492:-
BRCA	cis	rs853679	0.542	rs9393892	ENSG00000220721.1	OR1F12	12	3.62e-31	3.84e-28	0.46	0.35	Depression;	chr6:28113616	chr6:28073316~28074233:+
BRCA	cis	rs875971	0.862	rs4718330	ENSG00000222364.1	RNU6-96P	12	3.63e-31	3.86e-28	0.41	0.35	Aortic root size;	chr7:66250256	chr7:66395191~66395286:+
BRCA	cis	rs875971	1	rs6956179	ENSG00000222364.1	RNU6-96P	12	3.67e-31	3.9e-28	0.4	0.35	Aortic root size;	chr7:66341672	chr7:66395191~66395286:+
BRCA	cis	rs2404602	0.647	rs11072631	ENSG00000259422.1	RP11-593F23.1	-12	3.72e-31	3.94e-28	-0.47	-0.35	Blood metabolite levels;	chr15:76840568	chr15:76174891~76181486:-
BRCA	cis	rs17711722	0.503	rs453835	ENSG00000164669.11	INTS4P1	12	3.74e-31	3.97e-28	0.45	0.35	Calcium levels;	chr7:66046172	chr7:65141225~65234216:+
BRCA	cis	rs9545047	0.604	rs314695	ENSG00000227676.3	LINC01068	-12	3.76e-31	3.99e-28	-0.41	-0.35	Schizophrenia;	chr13:79432206	chr13:79566727~79571436:+
BRCA	cis	rs11123170	0.529	rs112692022	ENSG00000189223.12	PAX8-AS1	-12	3.79e-31	4.03e-28	-0.58	-0.35	Renal function-related traits (BUN);	chr2:113212605	chr2:113211522~113276581:+
BRCA	cis	rs10875746	0.903	rs17122666	ENSG00000240399.1	RP1-228P16.1	-12	3.8e-31	4.03e-28	-0.47	-0.35	Longevity (90 years and older);	chr12:48108791	chr12:48054813~48055591:-
BRCA	cis	rs10129255	0.5	rs1024350	ENSG00000223648.3	IGHV3-64	11.99	3.83e-31	4.06e-28	0.27	0.35	Kawasaki disease;	chr14:106685105	chr14:106643132~106658258:-
BRCA	cis	rs10875746	0.903	rs11168427	ENSG00000240399.1	RP1-228P16.1	-11.99	3.89e-31	4.13e-28	-0.47	-0.35	Longevity (90 years and older);	chr12:48145196	chr12:48054813~48055591:-
BRCA	cis	rs10875746	0.951	rs61918826	ENSG00000240399.1	RP1-228P16.1	-11.99	3.89e-31	4.13e-28	-0.47	-0.35	Longevity (90 years and older);	chr12:48150195	chr12:48054813~48055591:-
BRCA	cis	rs10875746	0.904	rs10875750	ENSG00000240399.1	RP1-228P16.1	-11.99	3.89e-31	4.13e-28	-0.47	-0.35	Longevity (90 years and older);	chr12:48151847	chr12:48054813~48055591:-
BRCA	cis	rs2117029	0.554	rs2334931	ENSG00000258017.1	RP11-386G11.10	-11.99	3.93e-31	4.17e-28	-0.47	-0.35	Intelligence (multi-trait analysis);	chr12:49174130	chr12:49127782~49147869:+
BRCA	cis	rs2117029	0.586	rs10875929	ENSG00000258017.1	RP11-386G11.10	-11.99	3.93e-31	4.17e-28	-0.47	-0.35	Intelligence (multi-trait analysis);	chr12:49174605	chr12:49127782~49147869:+
BRCA	cis	rs2117029	0.586	rs11168904	ENSG00000258017.1	RP11-386G11.10	-11.99	3.93e-31	4.17e-28	-0.47	-0.35	Intelligence (multi-trait analysis);	chr12:49177234	chr12:49127782~49147869:+
BRCA	cis	rs2117029	0.586	rs10875931	ENSG00000258017.1	RP11-386G11.10	-11.99	3.93e-31	4.17e-28	-0.47	-0.35	Intelligence (multi-trait analysis);	chr12:49179513	chr12:49127782~49147869:+
BRCA	cis	rs2117029	0.554	rs7954530	ENSG00000258017.1	RP11-386G11.10	-11.99	3.93e-31	4.17e-28	-0.47	-0.35	Intelligence (multi-trait analysis);	chr12:49179742	chr12:49127782~49147869:+
BRCA	cis	rs2404602	0.647	rs4312276	ENSG00000259422.1	RP11-593F23.1	-11.99	3.95e-31	4.19e-28	-0.46	-0.35	Blood metabolite levels;	chr15:76872020	chr15:76174891~76181486:-
BRCA	cis	rs8072100	0.84	rs1912482	ENSG00000228782.6	CTD-2026D20.3	11.99	3.99e-31	4.22e-28	0.38	0.35	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47377517	chr17:47450568~47492492:-
BRCA	cis	rs875971	1	rs11971949	ENSG00000222364.1	RNU6-96P	11.99	4.08e-31	4.32e-28	0.4	0.35	Aortic root size;	chr7:66161027	chr7:66395191~66395286:+
BRCA	cis	rs7849270	1	rs2541161	ENSG00000268707.1	RP11-247A12.7	11.99	4.1e-31	4.34e-28	0.44	0.35	Blood metabolite ratios;	chr9:129122523	chr9:129170434~129170940:+
BRCA	cis	rs9532669	0.89	rs4941999	ENSG00000176268.5	CYCSP34	11.99	4.11e-31	4.35e-28	0.39	0.35	Cervical cancer;	chr13:40859926	chr13:40863599~40863902:-
BRCA	cis	rs2404602	0.647	rs55778276	ENSG00000259422.1	RP11-593F23.1	-11.99	4.24e-31	4.49e-28	-0.47	-0.35	Blood metabolite levels;	chr15:76844249	chr15:76174891~76181486:-
BRCA	cis	rs2337406	1	rs17095456	ENSG00000274576.2	IGHV2-70	-11.98	4.31e-31	4.56e-28	-0.39	-0.35	Alzheimer's disease (late onset);	chr14:106676559	chr14:106770577~106771020:-
BRCA	cis	rs7182621	0.639	rs1561048	ENSG00000259363.4	CTD-2054N24.2	-11.98	4.38e-31	4.63e-28	-0.45	-0.35	Colonoscopy-negative controls vs population controls;	chr15:99875369	chr15:99807023~99877148:+
BRCA	cis	rs4380275	0.782	rs11127506	ENSG00000272342.1	RP13-539J13.1	-11.98	4.41e-31	4.66e-28	-0.42	-0.35	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:751300	chr2:739588~740164:-
BRCA	cis	rs6782228	0.628	rs7641584	ENSG00000242551.2	POU5F1P6	-11.98	4.43e-31	4.68e-28	-0.44	-0.35	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128673787	chr3:128674735~128677005:-
BRCA	cis	rs9487094	0.744	rs13192476	ENSG00000260273.1	RP11-425D10.10	11.98	4.46e-31	4.72e-28	0.45	0.35	Height;	chr6:109403951	chr6:109382795~109383666:+
BRCA	cis	rs2117029	0.586	rs6580701	ENSG00000258017.1	RP11-386G11.10	-11.98	4.61e-31	4.86e-28	-0.47	-0.35	Intelligence (multi-trait analysis);	chr12:49163482	chr12:49127782~49147869:+
BRCA	cis	rs2019137	0.936	rs2305133	ENSG00000274877.1	RP11-65I12.1	11.98	4.71e-31	4.97e-28	0.45	0.35	Lymphocyte counts;	chr2:113199244	chr2:113237595~113240825:+
BRCA	cis	rs2019137	0.936	rs12612729	ENSG00000274877.1	RP11-65I12.1	11.98	4.71e-31	4.97e-28	0.45	0.35	Lymphocyte counts;	chr2:113199471	chr2:113237595~113240825:+
BRCA	cis	rs2019137	0.936	rs731834	ENSG00000274877.1	RP11-65I12.1	11.98	4.71e-31	4.97e-28	0.45	0.35	Lymphocyte counts;	chr2:113199621	chr2:113237595~113240825:+
BRCA	cis	rs2019137	0.905	rs2276561	ENSG00000274877.1	RP11-65I12.1	11.97	4.78e-31	5.04e-28	0.45	0.35	Lymphocyte counts;	chr2:113198794	chr2:113237595~113240825:+
BRCA	cis	rs2404602	0.647	rs34103231	ENSG00000259422.1	RP11-593F23.1	-11.97	4.81e-31	5.07e-28	-0.47	-0.35	Blood metabolite levels;	chr15:76620349	chr15:76174891~76181486:-
BRCA	cis	rs11673344	0.566	rs1545755	ENSG00000226686.6	LINC01535	11.97	4.81e-31	5.08e-28	0.45	0.35	Obesity-related traits;	chr19:37490607	chr19:37251912~37265535:+
BRCA	cis	rs875971	1	rs7781698	ENSG00000222364.1	RNU6-96P	-11.97	4.82e-31	5.09e-28	-0.4	-0.35	Aortic root size;	chr7:66431325	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.651	rs2420596	ENSG00000222364.1	RNU6-96P	-11.97	5.04e-31	5.31e-28	-0.41	-0.35	Aortic root size;	chr7:66450996	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.52	rs2420597	ENSG00000222364.1	RNU6-96P	-11.97	5.04e-31	5.31e-28	-0.41	-0.35	Aortic root size;	chr7:66450999	chr7:66395191~66395286:+
BRCA	cis	rs992157	0.71	rs10167446	ENSG00000261338.2	RP11-378A13.1	11.97	5.1e-31	5.38e-28	0.36	0.35	Colorectal cancer;	chr2:218192143	chr2:218255319~218257366:+
BRCA	cis	rs950027	0.787	rs1153845	ENSG00000259520.4	CTD-2651B20.3	11.97	5.14e-31	5.42e-28	0.43	0.35	Response to fenofibrate (adiponectin levels);	chr15:45432531	chr15:45251580~45279251:-
BRCA	cis	rs11118620	0.622	rs11118618	ENSG00000238078.1	LINC01352	11.97	5.15e-31	5.42e-28	0.44	0.35	Heart failure;	chr1:220838204	chr1:220829255~220832429:+
BRCA	cis	rs10256972	0.524	rs6945202	ENSG00000229043.2	AC091729.9	-11.97	5.15e-31	5.43e-28	-0.44	-0.35	Endometriosis;Longevity;	chr7:1076922	chr7:1160374~1165267:+
BRCA	cis	rs853679	0.517	rs56364346	ENSG00000220721.1	OR1F12	11.97	5.2e-31	5.47e-28	0.46	0.35	Depression;	chr6:28082984	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.517	rs9357061	ENSG00000220721.1	OR1F12	11.97	5.2e-31	5.47e-28	0.46	0.35	Depression;	chr6:28083994	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.517	rs9368550	ENSG00000220721.1	OR1F12	11.97	5.2e-31	5.47e-28	0.46	0.35	Depression;	chr6:28084025	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.542	rs2295594	ENSG00000220721.1	OR1F12	11.97	5.2e-31	5.47e-28	0.46	0.35	Depression;	chr6:28085319	chr6:28073316~28074233:+
BRCA	cis	rs2564921	0.693	rs2581798	ENSG00000242142.1	SERBP1P3	11.97	5.23e-31	5.51e-28	0.41	0.35	Height;	chr3:53073584	chr3:53064283~53065091:-
BRCA	cis	rs853679	0.517	rs9380052	ENSG00000220721.1	OR1F12	11.96	5.25e-31	5.52e-28	0.46	0.35	Depression;	chr6:28096845	chr6:28073316~28074233:+
BRCA	cis	rs2404602	0.622	rs9635380	ENSG00000259422.1	RP11-593F23.1	-11.96	5.27e-31	5.54e-28	-0.47	-0.35	Blood metabolite levels;	chr15:76811138	chr15:76174891~76181486:-
BRCA	cis	rs875971	1	rs3735148	ENSG00000222364.1	RNU6-96P	-11.96	5.41e-31	5.69e-28	-0.4	-0.35	Aortic root size;	chr7:66506022	chr7:66395191~66395286:+
BRCA	cis	rs8062405	1	rs72793811	ENSG00000259982.1	CDC37P1	11.96	5.45e-31	5.73e-28	0.46	0.35	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828071	chr16:28700294~28701540:-
BRCA	cis	rs2404602	0.647	rs11072625	ENSG00000259422.1	RP11-593F23.1	11.96	5.46e-31	5.75e-28	0.46	0.35	Blood metabolite levels;	chr15:76792643	chr15:76174891~76181486:-
BRCA	cis	rs6991838	0.55	rs4737750	ENSG00000200714.1	Y_RNA	11.96	5.53e-31	5.82e-28	0.4	0.35	Intelligence (multi-trait analysis);	chr8:65638724	chr8:65592731~65592820:+
BRCA	cis	rs1155848	0.571	rs6563127	ENSG00000227354.5	RBM26-AS1	11.96	5.54e-31	5.83e-28	0.66	0.35	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79642012	chr13:79406309~79424328:+
BRCA	cis	rs8100891	0.537	rs2111504	ENSG00000267213.4	AC007773.2	-11.96	5.55e-31	5.83e-28	-0.5	-0.35	Neuroticism;	chr19:32426549	chr19:32390050~32405560:-
BRCA	cis	rs2404602	0.647	rs2404604	ENSG00000259422.1	RP11-593F23.1	-11.96	5.59e-31	5.88e-28	-0.46	-0.35	Blood metabolite levels;	chr15:76698764	chr15:76174891~76181486:-
BRCA	cis	rs11676348	0.846	rs6723449	ENSG00000261338.2	RP11-378A13.1	11.95	5.86e-31	6.16e-28	0.37	0.35	Ulcerative colitis;	chr2:218132857	chr2:218255319~218257366:+
BRCA	cis	rs8062405	0.54	rs480400	ENSG00000259982.1	CDC37P1	11.95	5.97e-31	6.26e-28	0.4	0.35	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28563294	chr16:28700294~28701540:-
BRCA	cis	rs853679	0.517	rs56310871	ENSG00000220721.1	OR1F12	11.95	6.09e-31	6.39e-28	0.46	0.35	Depression;	chr6:28076704	chr6:28073316~28074233:+
BRCA	cis	rs34779708	0.931	rs4934702	ENSG00000230534.5	RP11-297A16.2	11.95	6.34e-31	6.65e-28	0.44	0.35	Inflammatory bowel disease;Crohn's disease;	chr10:35034146	chr10:35098006~35127020:-
BRCA	cis	rs10129255	0.5	rs6576225	ENSG00000223648.3	IGHV3-64	11.95	6.35e-31	6.66e-28	0.27	0.35	Kawasaki disease;	chr14:106778120	chr14:106643132~106658258:-
BRCA	cis	rs10129255	0.5	rs6576226	ENSG00000223648.3	IGHV3-64	11.95	6.35e-31	6.66e-28	0.27	0.35	Kawasaki disease;	chr14:106778135	chr14:106643132~106658258:-
BRCA	cis	rs8062405	1	rs72793812	ENSG00000259982.1	CDC37P1	11.95	6.39e-31	6.7e-28	0.46	0.35	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28829060	chr16:28700294~28701540:-
BRCA	cis	rs10129255	0.5	rs2105989	ENSG00000223648.3	IGHV3-64	11.95	6.48e-31	6.79e-28	0.28	0.35	Kawasaki disease;	chr14:106682199	chr14:106643132~106658258:-
BRCA	cis	rs875971	0.895	rs3857684	ENSG00000222364.1	RNU6-96P	-11.94	6.49e-31	6.8e-28	-0.4	-0.35	Aortic root size;	chr7:66473171	chr7:66395191~66395286:+
BRCA	cis	rs10875746	0.951	rs10875756	ENSG00000240399.1	RP1-228P16.1	-11.94	6.61e-31	6.92e-28	-0.47	-0.35	Longevity (90 years and older);	chr12:48168521	chr12:48054813~48055591:-
BRCA	cis	rs6538678	0.784	rs7297403	ENSG00000258343.1	RP11-536G4.2	-11.94	6.66e-31	6.97e-28	-0.56	-0.35	Lupus nephritis in systemic lupus erythematosus;	chr12:95846683	chr12:95795345~95858839:-
BRCA	cis	rs6452524	0.868	rs17205699	ENSG00000249664.1	CTD-2227C6.2	11.94	6.8e-31	7.12e-28	0.44	0.35	Hypertension (SNP x SNP interaction);	chr5:83098479	chr5:83012285~83013109:-
BRCA	cis	rs9487094	0.813	rs12528566	ENSG00000260273.1	RP11-425D10.10	11.94	6.84e-31	7.16e-28	0.45	0.35	Height;	chr6:109416945	chr6:109382795~109383666:+
BRCA	cis	rs2739330	0.828	rs2877178	ENSG00000231271.1	AP000350.8	11.94	6.94e-31	7.26e-28	0.43	0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23949918~23954042:+
BRCA	cis	rs2739330	0.828	rs5751770	ENSG00000231271.1	AP000350.8	11.94	6.94e-31	7.26e-28	0.43	0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23949918~23954042:+
BRCA	cis	rs2919917	0.628	rs10109359	ENSG00000254352.1	RP11-578O24.2	11.94	6.95e-31	7.27e-28	0.48	0.35	Lymphocyte counts;	chr8:78694369	chr8:78723796~78724136:-
BRCA	cis	rs6452524	0.836	rs62372713	ENSG00000249664.1	CTD-2227C6.2	11.94	6.98e-31	7.3e-28	0.44	0.35	Hypertension (SNP x SNP interaction);	chr5:83090635	chr5:83012285~83013109:-
BRCA	cis	rs11676348	0.818	rs7426289	ENSG00000261338.2	RP11-378A13.1	-11.94	7.05e-31	7.37e-28	-0.37	-0.35	Ulcerative colitis;	chr2:218101592	chr2:218255319~218257366:+
BRCA	cis	rs853679	0.517	rs2273564	ENSG00000220721.1	OR1F12	11.94	7.07e-31	7.38e-28	0.46	0.35	Depression;	chr6:28089816	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.517	rs1853097	ENSG00000220721.1	OR1F12	11.94	7.07e-31	7.38e-28	0.46	0.35	Depression;	chr6:28090857	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.517	rs9393888	ENSG00000220721.1	OR1F12	11.94	7.07e-31	7.38e-28	0.46	0.35	Depression;	chr6:28091439	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.517	rs3734573	ENSG00000220721.1	OR1F12	11.94	7.07e-31	7.38e-28	0.46	0.35	Depression;	chr6:28091659	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.517	rs3823180	ENSG00000220721.1	OR1F12	11.94	7.07e-31	7.38e-28	0.46	0.35	Depression;	chr6:28093966	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.517	rs9368551	ENSG00000220721.1	OR1F12	11.94	7.07e-31	7.38e-28	0.46	0.35	Depression;	chr6:28094014	chr6:28073316~28074233:+
BRCA	cis	rs7586673	1	rs7586673	ENSG00000227403.1	AC009299.3	-11.94	7.13e-31	7.45e-28	-0.47	-0.35	Intelligence (multi-trait analysis);	chr2:161067009	chr2:161244739~161249050:+
BRCA	cis	rs875971	0.862	rs7786892	ENSG00000222364.1	RNU6-96P	11.94	7.18e-31	7.5e-28	0.4	0.35	Aortic root size;	chr7:66163889	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.929	rs6970860	ENSG00000222364.1	RNU6-96P	-11.93	7.21e-31	7.53e-28	-0.4	-0.35	Aortic root size;	chr7:66511647	chr7:66395191~66395286:+
BRCA	cis	rs4722166	0.645	rs1404006	ENSG00000179428.2	AC073072.5	-11.93	7.21e-31	7.54e-28	-0.37	-0.35	Lung cancer;	chr7:22755458	chr7:22725395~22727620:-
BRCA	cis	rs2019137	0.967	rs902695	ENSG00000274877.1	RP11-65I12.1	11.93	7.26e-31	7.58e-28	0.45	0.35	Lymphocyte counts;	chr2:113197497	chr2:113237595~113240825:+
BRCA	cis	rs10875746	0.951	rs10875748	ENSG00000240399.1	RP1-228P16.1	-11.93	7.28e-31	7.6e-28	-0.46	-0.35	Longevity (90 years and older);	chr12:48132577	chr12:48054813~48055591:-
BRCA	cis	rs875971	0.825	rs1129531	ENSG00000222364.1	RNU6-96P	11.93	7.3e-31	7.63e-28	0.41	0.35	Aortic root size;	chr7:66154117	chr7:66395191~66395286:+
BRCA	cis	rs35160687	0.842	rs1863052	ENSG00000273080.1	RP11-301O19.1	11.93	7.36e-31	7.69e-28	0.39	0.35	Night sleep phenotypes;	chr2:86332235	chr2:86195590~86196049:+
BRCA	cis	rs875971	0.798	rs6460304	ENSG00000222364.1	RNU6-96P	-11.93	7.57e-31	7.9e-28	-0.41	-0.35	Aortic root size;	chr7:66499741	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.862	rs6945775	ENSG00000222364.1	RNU6-96P	-11.93	7.57e-31	7.9e-28	-0.41	-0.35	Aortic root size;	chr7:66503987	chr7:66395191~66395286:+
BRCA	cis	rs875971	1	rs3981131	ENSG00000222364.1	RNU6-96P	-11.93	7.58e-31	7.91e-28	-0.39	-0.35	Aortic root size;	chr7:66486690	chr7:66395191~66395286:+
BRCA	cis	rs2919917	0.628	rs1036751	ENSG00000254352.1	RP11-578O24.2	-11.93	7.6e-31	7.94e-28	-0.49	-0.35	Lymphocyte counts;	chr8:78729671	chr8:78723796~78724136:-
BRCA	cis	rs4423214	0.592	rs10898191	ENSG00000254682.1	RP11-660L16.2	-11.93	7.63e-31	7.97e-28	-0.52	-0.35	Vitamin D levels;	chr11:71483555	chr11:71448674~71452157:+
BRCA	cis	rs10129255	0.518	rs2006284	ENSG00000223648.3	IGHV3-64	11.93	7.63e-31	7.97e-28	0.27	0.35	Kawasaki disease;	chr14:106676185	chr14:106643132~106658258:-
BRCA	cis	rs10875746	0.903	rs11168414	ENSG00000240399.1	RP1-228P16.1	-11.93	7.78e-31	8.11e-28	-0.47	-0.35	Longevity (90 years and older);	chr12:48118548	chr12:48054813~48055591:-
BRCA	cis	rs2117029	0.586	rs10875928	ENSG00000258017.1	RP11-386G11.10	-11.93	7.79e-31	8.12e-28	-0.47	-0.35	Intelligence (multi-trait analysis);	chr12:49162520	chr12:49127782~49147869:+
BRCA	cis	rs35160687	0.842	rs7593440	ENSG00000273080.1	RP11-301O19.1	-11.93	7.89e-31	8.22e-28	-0.39	-0.35	Night sleep phenotypes;	chr2:86323534	chr2:86195590~86196049:+
BRCA	cis	rs9545047	0.604	rs2876740	ENSG00000227676.3	LINC01068	-11.93	8e-31	8.34e-28	-0.4	-0.35	Schizophrenia;	chr13:79409829	chr13:79566727~79571436:+
BRCA	cis	rs10875746	0.951	rs10875747	ENSG00000240399.1	RP1-228P16.1	-11.92	8.15e-31	8.49e-28	-0.46	-0.35	Longevity (90 years and older);	chr12:48132078	chr12:48054813~48055591:-
BRCA	cis	rs875971	1	rs709597	ENSG00000222364.1	RNU6-96P	11.92	8.19e-31	8.53e-28	0.4	0.35	Aortic root size;	chr7:66360996	chr7:66395191~66395286:+
BRCA	cis	rs10256972	0.684	rs2363279	ENSG00000229043.2	AC091729.9	-11.92	8.22e-31	8.56e-28	-0.44	-0.35	Endometriosis;Longevity;	chr7:1056507	chr7:1160374~1165267:+
BRCA	cis	rs2404602	0.611	rs2404734	ENSG00000259422.1	RP11-593F23.1	-11.92	8.47e-31	8.82e-28	-0.46	-0.35	Blood metabolite levels;	chr15:76643824	chr15:76174891~76181486:-
BRCA	cis	rs10129255	0.5	rs7161740	ENSG00000223648.3	IGHV3-64	11.92	8.5e-31	8.85e-28	0.27	0.35	Kawasaki disease;	chr14:106776119	chr14:106643132~106658258:-
BRCA	cis	rs2980439	0.818	rs2948294	ENSG00000253893.2	FAM85B	-11.92	8.56e-31	8.91e-28	-0.45	-0.35	Neuroticism;	chr8:8237439	chr8:8167819~8226614:-
BRCA	cis	rs875971	0.929	rs10950041	ENSG00000222364.1	RNU6-96P	-11.92	8.58e-31	8.93e-28	-0.4	-0.35	Aortic root size;	chr7:66508888	chr7:66395191~66395286:+
BRCA	cis	rs853679	0.517	rs9357063	ENSG00000220721.1	OR1F12	11.92	8.66e-31	9.02e-28	0.46	0.35	Depression;	chr6:28092227	chr6:28073316~28074233:+
BRCA	cis	rs2404602	0.647	rs10851892	ENSG00000259422.1	RP11-593F23.1	-11.92	8.72e-31	9.07e-28	-0.47	-0.35	Blood metabolite levels;	chr15:76884150	chr15:76174891~76181486:-
BRCA	cis	rs2882667	0.505	rs6596465	ENSG00000253404.1	AC034243.1	-11.92	8.74e-31	9.09e-28	-0.44	-0.35	Age-related hearing impairment (SNP x SNP interaction);	chr5:139147337	chr5:138744434~138753309:-
BRCA	cis	rs34779708	0.931	rs11010132	ENSG00000230534.5	RP11-297A16.2	11.92	8.84e-31	9.2e-28	0.43	0.35	Inflammatory bowel disease;Crohn's disease;	chr10:35228337	chr10:35098006~35127020:-
BRCA	cis	rs853679	0.517	rs1904841	ENSG00000220721.1	OR1F12	11.91	9.02e-31	9.37e-28	0.46	0.35	Depression;	chr6:28140307	chr6:28073316~28074233:+
BRCA	cis	rs1555322	0.53	rs2297789	ENSG00000126005.14	MMP24-AS1	-11.91	9.31e-31	9.68e-28	-0.46	-0.35	Attention deficit hyperactivity disorder;	chr20:35279445	chr20:35216462~35278131:-
BRCA	cis	rs2739330	0.828	rs5760108	ENSG00000231271.1	AP000350.8	11.91	9.36e-31	9.72e-28	0.43	0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23949918~23954042:+
BRCA	cis	rs2729354	0.729	rs2848634	ENSG00000265566.2	RN7SL605P	-11.91	9.57e-31	9.94e-28	-0.5	-0.35	Blood protein levels;	chr11:57484855	chr11:57528085~57528365:-
BRCA	cis	rs9487094	0.813	rs13195517	ENSG00000260273.1	RP11-425D10.10	11.91	9.6e-31	9.97e-28	0.45	0.35	Height;	chr6:109415050	chr6:109382795~109383666:+
BRCA	cis	rs853679	0.517	rs7755442	ENSG00000220721.1	OR1F12	11.91	9.66e-31	1e-27	0.45	0.35	Depression;	chr6:28071237	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.517	rs55747925	ENSG00000220721.1	OR1F12	11.91	9.66e-31	1e-27	0.45	0.35	Depression;	chr6:28076559	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.517	rs34716816	ENSG00000220721.1	OR1F12	11.91	9.66e-31	1e-27	0.45	0.35	Depression;	chr6:28078391	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.517	rs9380049	ENSG00000220721.1	OR1F12	11.91	9.66e-31	1e-27	0.45	0.35	Depression;	chr6:28080757	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.517	rs9380050	ENSG00000220721.1	OR1F12	11.91	9.66e-31	1e-27	0.45	0.35	Depression;	chr6:28080760	chr6:28073316~28074233:+
BRCA	cis	rs34779708	0.966	rs1148245	ENSG00000230534.5	RP11-297A16.2	11.91	9.9e-31	1.03e-27	0.43	0.35	Inflammatory bowel disease;Crohn's disease;	chr10:35222966	chr10:35098006~35127020:-
BRCA	cis	rs150992	0.632	rs34491	ENSG00000248489.1	CTD-2007H13.3	11.9	1.02e-30	1.06e-27	0.39	0.35	Body mass index;	chr5:98974118	chr5:98929171~98995013:+
BRCA	cis	rs10875746	0.859	rs12305647	ENSG00000240399.1	RP1-228P16.1	-11.9	1.04e-30	1.08e-27	-0.45	-0.35	Longevity (90 years and older);	chr12:48189178	chr12:48054813~48055591:-
BRCA	cis	rs35160687	0.842	rs10200619	ENSG00000273080.1	RP11-301O19.1	-11.9	1.05e-30	1.09e-27	-0.39	-0.35	Night sleep phenotypes;	chr2:86321725	chr2:86195590~86196049:+
BRCA	cis	rs7743045	0.625	rs9387624	ENSG00000253194.1	RP11-351A11.1	11.9	1.06e-30	1.1e-27	0.44	0.35	Mean platelet volume;	chr6:119010723	chr6:118934785~119031541:+
BRCA	cis	rs11673344	0.502	rs17304703	ENSG00000226686.6	LINC01535	11.9	1.07e-30	1.11e-27	0.47	0.35	Obesity-related traits;	chr19:37582646	chr19:37251912~37265535:+
BRCA	cis	rs7849270	1	rs2541164	ENSG00000268707.1	RP11-247A12.7	-11.9	1.07e-30	1.11e-27	-0.45	-0.35	Blood metabolite ratios;	chr9:129114629	chr9:129170434~129170940:+
BRCA	cis	rs875971	0.862	rs7809814	ENSG00000222364.1	RNU6-96P	11.9	1.1e-30	1.13e-27	0.4	0.35	Aortic root size;	chr7:66150410	chr7:66395191~66395286:+
BRCA	cis	rs4853012	0.775	rs12465641	ENSG00000217702.2	RP11-287D1.4	-11.89	1.1e-30	1.14e-27	-0.52	-0.35	Gestational age at birth (maternal effect);	chr2:74110588	chr2:74130583~74135395:+
BRCA	cis	rs1789	0.706	rs7696938	ENSG00000273133.1	RP11-799M12.2	11.89	1.13e-30	1.17e-27	0.46	0.35	Blood protein levels;	chr4:15701954	chr4:15563698~15564253:-
BRCA	cis	rs10875746	0.951	rs58865997	ENSG00000240399.1	RP1-228P16.1	-11.89	1.13e-30	1.17e-27	-0.47	-0.35	Longevity (90 years and older);	chr12:48173090	chr12:48054813~48055591:-
BRCA	cis	rs2404602	0.647	rs12914196	ENSG00000259422.1	RP11-593F23.1	-11.89	1.17e-30	1.21e-27	-0.46	-0.35	Blood metabolite levels;	chr15:76649020	chr15:76174891~76181486:-
BRCA	cis	rs6452524	0.868	rs62372714	ENSG00000249664.1	CTD-2227C6.2	11.89	1.2e-30	1.24e-27	0.44	0.35	Hypertension (SNP x SNP interaction);	chr5:83095449	chr5:83012285~83013109:-
BRCA	cis	rs11676348	0.776	rs11690316	ENSG00000261338.2	RP11-378A13.1	-11.89	1.2e-30	1.24e-27	-0.37	-0.35	Ulcerative colitis;	chr2:218152739	chr2:218255319~218257366:+
BRCA	cis	rs67311347	1	rs11129876	ENSG00000223797.4	ENTPD3-AS1	-11.89	1.2e-30	1.24e-27	-0.39	-0.35	Renal cell carcinoma;	chr3:40360145	chr3:40313802~40453329:-
BRCA	cis	rs4380275	0.782	rs11127506	ENSG00000223751.1	AC116609.2	-11.89	1.21e-30	1.25e-27	-0.44	-0.35	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:751300	chr2:742488~747767:+
BRCA	cis	rs853679	0.517	rs12174753	ENSG00000220721.1	OR1F12	11.88	1.22e-30	1.26e-27	0.45	0.35	Depression;	chr6:28074687	chr6:28073316~28074233:+
BRCA	cis	rs150992	0.609	rs161935	ENSG00000248489.1	CTD-2007H13.3	11.88	1.23e-30	1.27e-27	0.39	0.35	Body mass index;	chr5:98982733	chr5:98929171~98995013:+
BRCA	cis	rs150992	0.632	rs161936	ENSG00000248489.1	CTD-2007H13.3	11.88	1.23e-30	1.27e-27	0.39	0.35	Body mass index;	chr5:98982953	chr5:98929171~98995013:+
BRCA	cis	rs853679	0.517	rs9283884	ENSG00000220721.1	OR1F12	-11.88	1.23e-30	1.28e-27	-0.45	-0.35	Depression;	chr6:28167882	chr6:28073316~28074233:+
BRCA	cis	rs875971	0.862	rs4368860	ENSG00000222364.1	RNU6-96P	11.88	1.26e-30	1.3e-27	0.4	0.35	Aortic root size;	chr7:66143495	chr7:66395191~66395286:+
BRCA	cis	rs875971	1	rs1981798	ENSG00000222364.1	RNU6-96P	-11.88	1.26e-30	1.3e-27	-0.4	-0.35	Aortic root size;	chr7:66489916	chr7:66395191~66395286:+
BRCA	cis	rs6991838	0.584	rs10089708	ENSG00000272010.1	CTD-3025N20.3	11.88	1.26e-30	1.3e-27	0.37	0.35	Intelligence (multi-trait analysis);	chr8:65642927	chr8:65591850~65592472:-
BRCA	cis	rs6991838	0.584	rs6991731	ENSG00000272010.1	CTD-3025N20.3	11.88	1.26e-30	1.3e-27	0.37	0.35	Intelligence (multi-trait analysis);	chr8:65643232	chr8:65591850~65592472:-
BRCA	cis	rs9487094	0.961	rs9487100	ENSG00000260273.1	RP11-425D10.10	11.88	1.26e-30	1.31e-27	0.42	0.35	Height;	chr6:109429207	chr6:109382795~109383666:+
BRCA	cis	rs12134133	1	rs61822697	ENSG00000274245.1	RP11-357P18.2	11.88	1.27e-30	1.31e-27	0.49	0.35	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207311819	chr1:207372559~207373252:+
BRCA	cis	rs853679	0.517	rs9393885	ENSG00000220721.1	OR1F12	11.88	1.28e-30	1.32e-27	0.45	0.35	Depression;	chr6:28082231	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.517	rs9393886	ENSG00000220721.1	OR1F12	11.88	1.28e-30	1.32e-27	0.45	0.35	Depression;	chr6:28082261	chr6:28073316~28074233:+
BRCA	cis	rs4713118	0.515	rs9368549	ENSG00000220721.1	OR1F12	11.88	1.28e-30	1.32e-27	0.45	0.35	Parkinson's disease;	chr6:28082269	chr6:28073316~28074233:+
BRCA	cis	rs11123170	0.503	rs28679654	ENSG00000189223.12	PAX8-AS1	-11.88	1.29e-30	1.33e-27	-0.58	-0.35	Renal function-related traits (BUN);	chr2:113210040	chr2:113211522~113276581:+
BRCA	cis	rs992157	0.585	rs62182795	ENSG00000261338.2	RP11-378A13.1	-11.88	1.33e-30	1.37e-27	-0.35	-0.35	Colorectal cancer;	chr2:218235479	chr2:218255319~218257366:+
BRCA	cis	rs34779708	0.75	rs35032841	ENSG00000230534.5	RP11-297A16.2	11.88	1.34e-30	1.38e-27	0.43	0.35	Inflammatory bowel disease;Crohn's disease;	chr10:35023759	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.742	rs35912711	ENSG00000230534.5	RP11-297A16.2	11.88	1.34e-30	1.38e-27	0.43	0.35	Inflammatory bowel disease;Crohn's disease;	chr10:35024068	chr10:35098006~35127020:-
BRCA	cis	rs853679	0.517	rs6922063	ENSG00000220721.1	OR1F12	11.88	1.35e-30	1.39e-27	0.45	0.35	Depression;	chr6:28126588	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.517	rs2275508	ENSG00000220721.1	OR1F12	11.88	1.35e-30	1.39e-27	0.45	0.35	Depression;	chr6:28126953	chr6:28073316~28074233:+
BRCA	cis	rs11673344	0.526	rs17244769	ENSG00000226686.6	LINC01535	11.87	1.36e-30	1.4e-27	0.47	0.35	Obesity-related traits;	chr19:37562031	chr19:37251912~37265535:+
BRCA	cis	rs6991838	0.584	rs6993876	ENSG00000200714.1	Y_RNA	11.87	1.37e-30	1.41e-27	0.4	0.35	Intelligence (multi-trait analysis);	chr8:65601240	chr8:65592731~65592820:+
BRCA	cis	rs10875746	0.951	rs4760689	ENSG00000240399.1	RP1-228P16.1	-11.87	1.39e-30	1.43e-27	-0.47	-0.35	Longevity (90 years and older);	chr12:48169861	chr12:48054813~48055591:-
BRCA	cis	rs11676348	0.846	rs7594532	ENSG00000261338.2	RP11-378A13.1	-11.87	1.39e-30	1.43e-27	-0.37	-0.35	Ulcerative colitis;	chr2:218143277	chr2:218255319~218257366:+
BRCA	cis	rs3091242	0.933	rs10903129	ENSG00000224183.1	SDHDP6	-11.87	1.41e-30	1.45e-27	-0.41	-0.35	Erythrocyte sedimentation rate;	chr1:25442446	chr1:25294164~25294643:-
BRCA	cis	rs4722166	0.597	rs1554606	ENSG00000179428.2	AC073072.5	-11.87	1.42e-30	1.46e-27	-0.36	-0.35	Lung cancer;	chr7:22729088	chr7:22725395~22727620:-
BRCA	cis	rs875971	1	rs6957199	ENSG00000222364.1	RNU6-96P	-11.87	1.42e-30	1.47e-27	-0.4	-0.35	Aortic root size;	chr7:66513532	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.893	rs62465470	ENSG00000222364.1	RNU6-96P	11.87	1.43e-30	1.47e-27	0.4	0.35	Aortic root size;	chr7:66136231	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.895	rs7788984	ENSG00000222364.1	RNU6-96P	-11.87	1.44e-30	1.48e-27	-0.4	-0.35	Aortic root size;	chr7:66450629	chr7:66395191~66395286:+
BRCA	cis	rs2658782	0.724	rs2658770	ENSG00000279684.1	RP11-755E23.2	-11.87	1.46e-30	1.5e-27	-0.51	-0.35	Pulmonary function decline;	chr11:93528720	chr11:93286629~93288903:-
BRCA	cis	rs4718428	0.672	rs4718412	ENSG00000226824.5	RP4-756H11.3	11.87	1.47e-30	1.51e-27	0.47	0.35	Corneal structure;	chr7:66821880	chr7:66654538~66669855:+
BRCA	cis	rs992157	0.56	rs4674275	ENSG00000261338.2	RP11-378A13.1	-11.87	1.47e-30	1.51e-27	-0.35	-0.35	Colorectal cancer;	chr2:218233015	chr2:218255319~218257366:+
BRCA	cis	rs853679	0.517	rs4713135	ENSG00000220721.1	OR1F12	11.87	1.47e-30	1.51e-27	0.45	0.35	Depression;	chr6:28071808	chr6:28073316~28074233:+
BRCA	cis	rs8072100	0.84	rs11079774	ENSG00000228782.6	CTD-2026D20.3	11.87	1.49e-30	1.53e-27	0.37	0.35	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47402340	chr17:47450568~47492492:-
BRCA	cis	rs875971	0.895	rs4145009	ENSG00000222364.1	RNU6-96P	11.87	1.49e-30	1.53e-27	0.41	0.35	Aortic root size;	chr7:66261628	chr7:66395191~66395286:+
BRCA	cis	rs673078	0.607	rs7309484	ENSG00000275759.1	RP11-131L12.3	-11.87	1.49e-30	1.53e-27	-0.54	-0.35	Glucose homeostasis traits;	chr12:118400833	chr12:118428281~118428870:+
BRCA	cis	rs4722166	0.597	rs2069845	ENSG00000179428.2	AC073072.5	-11.86	1.55e-30	1.59e-27	-0.36	-0.34	Lung cancer;	chr7:22730530	chr7:22725395~22727620:-
BRCA	cis	rs2283792	1	rs6928	ENSG00000224086.5	LL22NC03-86G7.1	-11.86	1.61e-30	1.65e-27	-0.36	-0.34	Multiple sclerosis;	chr22:21760715	chr22:21938293~21977632:+
BRCA	cis	rs10129255	0.518	rs7143784	ENSG00000223648.3	IGHV3-64	11.86	1.61e-30	1.65e-27	0.27	0.34	Kawasaki disease;	chr14:106687277	chr14:106643132~106658258:-
BRCA	cis	rs62103177	0.564	rs7228971	ENSG00000261126.6	RP11-795F19.1	-11.86	1.65e-30	1.69e-27	-0.46	-0.34	Opioid sensitivity;	chr18:79978025	chr18:80046900~80095482:+
BRCA	cis	rs875971	0.862	rs908915	ENSG00000222364.1	RNU6-96P	11.86	1.66e-30	1.7e-27	0.4	0.34	Aortic root size;	chr7:66149664	chr7:66395191~66395286:+
BRCA	cis	rs6991838	0.584	rs7836349	ENSG00000272010.1	CTD-3025N20.3	-11.85	1.68e-30	1.72e-27	-0.37	-0.34	Intelligence (multi-trait analysis);	chr8:65591328	chr8:65591850~65592472:-
BRCA	cis	rs2404602	0.684	rs57682236	ENSG00000259422.1	RP11-593F23.1	-11.85	1.72e-30	1.76e-27	-0.46	-0.34	Blood metabolite levels;	chr15:76576137	chr15:76174891~76181486:-
BRCA	cis	rs2919917	0.628	rs12680932	ENSG00000254352.1	RP11-578O24.2	-11.85	1.72e-30	1.76e-27	-0.5	-0.34	Lymphocyte counts;	chr8:78685516	chr8:78723796~78724136:-
BRCA	cis	rs2882667	0.505	rs7721110	ENSG00000253404.1	AC034243.1	11.85	1.74e-30	1.78e-27	0.44	0.34	Age-related hearing impairment (SNP x SNP interaction);	chr5:139146817	chr5:138744434~138753309:-
BRCA	cis	rs8072100	0.84	rs12453233	ENSG00000228782.6	CTD-2026D20.3	11.85	1.75e-30	1.79e-27	0.37	0.34	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47377204	chr17:47450568~47492492:-
BRCA	cis	rs10875746	0.951	rs2286021	ENSG00000240399.1	RP1-228P16.1	-11.85	1.81e-30	1.85e-27	-0.47	-0.34	Longevity (90 years and older);	chr12:48134437	chr12:48054813~48055591:-
BRCA	cis	rs2404602	0.647	rs11637096	ENSG00000259422.1	RP11-593F23.1	-11.85	1.83e-30	1.87e-27	-0.45	-0.34	Blood metabolite levels;	chr15:76638761	chr15:76174891~76181486:-
BRCA	cis	rs858239	0.932	rs858272	ENSG00000226816.2	AC005082.12	11.85	1.84e-30	1.88e-27	0.41	0.34	Cerebrospinal fluid biomarker levels;	chr7:23237166	chr7:23206013~23208045:+
BRCA	cis	rs2243480	1	rs1618893	ENSG00000226824.5	RP4-756H11.3	-11.85	1.84e-30	1.89e-27	-0.63	-0.34	Diabetic kidney disease;	chr7:66631132	chr7:66654538~66669855:+
BRCA	cis	rs10129255	0.5	rs6576230	ENSG00000223648.3	IGHV3-64	11.85	1.86e-30	1.9e-27	0.27	0.34	Kawasaki disease;	chr14:106778539	chr14:106643132~106658258:-
BRCA	cis	rs992157	0.56	rs12992937	ENSG00000261338.2	RP11-378A13.1	-11.84	1.86e-30	1.9e-27	-0.35	-0.34	Colorectal cancer;	chr2:218222349	chr2:218255319~218257366:+
BRCA	cis	rs992157	0.56	rs4674274	ENSG00000261338.2	RP11-378A13.1	-11.84	1.86e-30	1.9e-27	-0.35	-0.34	Colorectal cancer;	chr2:218224408	chr2:218255319~218257366:+
BRCA	cis	rs2442825	0.693	rs2255558	ENSG00000206573.7	THUMPD3-AS1	11.84	1.93e-30	1.97e-27	0.31	0.34	Cerebrospinal fluid clusterin levels;	chr3:9375148	chr3:9349689~9398579:-
BRCA	cis	rs2442825	0.72	rs2648561	ENSG00000206573.7	THUMPD3-AS1	11.84	1.93e-30	1.97e-27	0.31	0.34	Cerebrospinal fluid clusterin levels;	chr3:9376399	chr3:9349689~9398579:-
BRCA	cis	rs2980436	1	rs2980436	ENSG00000253893.2	FAM85B	11.84	1.98e-30	2.02e-27	0.45	0.34	Schizophrenia;	chr8:8234503	chr8:8167819~8226614:-
BRCA	cis	rs150992	0.609	rs447044	ENSG00000248489.1	CTD-2007H13.3	11.84	2.04e-30	2.08e-27	0.39	0.34	Body mass index;	chr5:98995572	chr5:98929171~98995013:+
BRCA	cis	rs875971	1	rs6958271	ENSG00000222364.1	RNU6-96P	-11.84	2.06e-30	2.1e-27	-0.4	-0.34	Aortic root size;	chr7:66514344	chr7:66395191~66395286:+
BRCA	cis	rs875971	1	rs6958277	ENSG00000222364.1	RNU6-96P	-11.84	2.06e-30	2.1e-27	-0.4	-0.34	Aortic root size;	chr7:66514362	chr7:66395191~66395286:+
BRCA	cis	rs8072100	0.84	rs9895746	ENSG00000228782.6	CTD-2026D20.3	11.83	2.11e-30	2.15e-27	0.37	0.34	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47401733	chr17:47450568~47492492:-
BRCA	cis	rs2015599	0.56	rs3948497	ENSG00000257176.2	RP11-996F15.2	-11.83	2.12e-30	2.16e-27	-0.43	-0.34	Platelet count;Mean platelet volume;	chr12:29247552	chr12:29280418~29317848:-
BRCA	cis	rs7826238	0.539	rs2945891	ENSG00000253893.2	FAM85B	-11.83	2.15e-30	2.19e-27	-0.44	-0.34	Systolic blood pressure;	chr8:8297953	chr8:8167819~8226614:-
BRCA	cis	rs10875746	0.951	rs7485355	ENSG00000240399.1	RP1-228P16.1	-11.83	2.15e-30	2.19e-27	-0.47	-0.34	Longevity (90 years and older);	chr12:48154559	chr12:48054813~48055591:-
BRCA	cis	rs10129255	0.518	rs10150460	ENSG00000223648.3	IGHV3-64	-11.83	2.15e-30	2.19e-27	-0.27	-0.34	Kawasaki disease;	chr14:106677179	chr14:106643132~106658258:-
BRCA	cis	rs2283792	0.567	rs2027789	ENSG00000224086.5	LL22NC03-86G7.1	-11.83	2.17e-30	2.21e-27	-0.38	-0.34	Multiple sclerosis;	chr22:21933490	chr22:21938293~21977632:+
BRCA	cis	rs2404602	0.647	rs12440965	ENSG00000259422.1	RP11-593F23.1	-11.83	2.17e-30	2.21e-27	-0.46	-0.34	Blood metabolite levels;	chr15:76666250	chr15:76174891~76181486:-
BRCA	cis	rs6904897	0.563	rs4896117	ENSG00000232876.1	CTA-212D2.2	11.83	2.24e-30	2.28e-27	0.43	0.34	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr6:134908262	chr6:135055033~135060550:+
BRCA	cis	rs8062405	1	rs12443881	ENSG00000259982.1	CDC37P1	11.82	2.31e-30	2.35e-27	0.45	0.34	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28830456	chr16:28700294~28701540:-
BRCA	cis	rs11673344	0.526	rs8111790	ENSG00000226686.6	LINC01535	11.82	2.34e-30	2.38e-27	0.47	0.34	Obesity-related traits;	chr19:37565861	chr19:37251912~37265535:+
BRCA	cis	rs858239	0.896	rs1637193	ENSG00000226816.2	AC005082.12	11.82	2.34e-30	2.38e-27	0.41	0.34	Cerebrospinal fluid biomarker levels;	chr7:23220632	chr7:23206013~23208045:+
BRCA	cis	rs10129255	0.518	rs8009612	ENSG00000223648.3	IGHV3-64	11.82	2.35e-30	2.38e-27	0.27	0.34	Kawasaki disease;	chr14:106777510	chr14:106643132~106658258:-
BRCA	cis	rs3091242	0.9	rs669063	ENSG00000224183.1	SDHDP6	-11.82	2.36e-30	2.4e-27	-0.41	-0.34	Erythrocyte sedimentation rate;	chr1:25394663	chr1:25294164~25294643:-
BRCA	cis	rs10875746	0.951	rs11168433	ENSG00000240399.1	RP1-228P16.1	-11.82	2.39e-30	2.43e-27	-0.47	-0.34	Longevity (90 years and older);	chr12:48164281	chr12:48054813~48055591:-
BRCA	cis	rs10129255	0.5	rs988134	ENSG00000223648.3	IGHV3-64	11.82	2.43e-30	2.47e-27	0.27	0.34	Kawasaki disease;	chr14:106776698	chr14:106643132~106658258:-
BRCA	cis	rs10129255	0.5	rs988133	ENSG00000223648.3	IGHV3-64	11.82	2.43e-30	2.47e-27	0.27	0.34	Kawasaki disease;	chr14:106776724	chr14:106643132~106658258:-
BRCA	cis	rs11690935	0.788	rs6715929	ENSG00000228389.1	AC068039.4	11.82	2.45e-30	2.49e-27	0.42	0.34	Schizophrenia;	chr2:172012600	chr2:171773482~171775844:+
BRCA	cis	rs150992	0.632	rs34489	ENSG00000248489.1	CTD-2007H13.3	-11.82	2.46e-30	2.5e-27	-0.39	-0.34	Body mass index;	chr5:98977180	chr5:98929171~98995013:+
BRCA	cis	rs2564921	0.704	rs35671032	ENSG00000242142.1	SERBP1P3	-11.82	2.48e-30	2.52e-27	-0.41	-0.34	Height;	chr3:52972039	chr3:53064283~53065091:-
BRCA	cis	rs11673344	0.566	rs256733	ENSG00000226686.6	LINC01535	11.82	2.54e-30	2.58e-27	0.44	0.34	Obesity-related traits;	chr19:37384729	chr19:37251912~37265535:+
BRCA	cis	rs10129255	0.536	rs6576223	ENSG00000223648.3	IGHV3-64	11.81	2.55e-30	2.59e-27	0.27	0.34	Kawasaki disease;	chr14:106776448	chr14:106643132~106658258:-
BRCA	cis	rs8040855	0.547	rs17611171	ENSG00000259295.5	CSPG4P12	11.81	2.58e-30	2.62e-27	0.51	0.34	Bulimia nervosa;	chr15:85029468	chr15:85191438~85213905:+
BRCA	cis	rs10129255	0.556	rs6576222	ENSG00000223648.3	IGHV3-64	11.81	2.58e-30	2.62e-27	0.27	0.34	Kawasaki disease;	chr14:106776442	chr14:106643132~106658258:-
BRCA	cis	rs10129255	0.518	rs11847766	ENSG00000223648.3	IGHV3-64	11.81	2.65e-30	2.69e-27	0.27	0.34	Kawasaki disease;	chr14:106779186	chr14:106643132~106658258:-
BRCA	cis	rs2188561	0.697	rs7782475	ENSG00000241764.3	AC002467.7	-11.81	2.66e-30	2.7e-27	-0.45	-0.34	Alcohol consumption;	chr7:107745806	chr7:107742817~107744581:-
BRCA	cis	rs11669181	1	rs11669181	ENSG00000267147.2	CTC-548K16.1	11.81	2.68e-30	2.72e-27	0.38	0.34	Conotruncal heart defects (maternal effects);	chr19:14334326	chr19:14333743~14343916:+
BRCA	cis	rs8040855	0.627	rs12900012	ENSG00000259295.5	CSPG4P12	11.81	2.68e-30	2.72e-27	0.5	0.34	Bulimia nervosa;	chr15:85046955	chr15:85191438~85213905:+
BRCA	cis	rs7829975	0.593	rs2979241	ENSG00000253893.2	FAM85B	-11.81	2.68e-30	2.72e-27	-0.44	-0.34	Mood instability;	chr8:8445843	chr8:8167819~8226614:-
BRCA	cis	rs673078	0.607	rs17441172	ENSG00000275759.1	RP11-131L12.3	11.81	2.69e-30	2.73e-27	0.52	0.34	Glucose homeostasis traits;	chr12:118430456	chr12:118428281~118428870:+
BRCA	cis	rs150992	0.711	rs326489	ENSG00000248489.1	CTD-2007H13.3	11.8	2.86e-30	2.9e-27	0.4	0.34	Body mass index;	chr5:98841105	chr5:98929171~98995013:+
BRCA	cis	rs150992	0.632	rs1472622	ENSG00000248489.1	CTD-2007H13.3	-11.8	2.86e-30	2.9e-27	-0.39	-0.34	Body mass index;	chr5:99000749	chr5:98929171~98995013:+
BRCA	cis	rs2382817	0.58	rs6756265	ENSG00000261338.2	RP11-378A13.1	-11.8	2.86e-30	2.9e-27	-0.35	-0.34	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr2:218230831	chr2:218255319~218257366:+
BRCA	cis	rs6142102	0.602	rs4911145	ENSG00000276073.1	RP5-1125A11.7	11.8	3.03e-30	3.07e-27	0.39	0.34	Skin pigmentation;	chr20:34027417	chr20:33985617~33988989:-
BRCA	cis	rs853679	0.517	rs9380047	ENSG00000220721.1	OR1F12	11.8	3.05e-30	3.09e-27	0.45	0.34	Depression;	chr6:28070115	chr6:28073316~28074233:+
BRCA	cis	rs8040855	0.965	rs1961276	ENSG00000259295.5	CSPG4P12	11.8	3.06e-30	3.09e-27	0.43	0.34	Bulimia nervosa;	chr15:85170986	chr15:85191438~85213905:+
BRCA	cis	rs1823874	0.581	rs11855419	ENSG00000182397.13	DNM1P46	11.8	3.07e-30	3.1e-27	0.38	0.34	IgG glycosylation;	chr15:99787275	chr15:99790156~99806927:-
BRCA	cis	rs11673344	0.526	rs55909413	ENSG00000226686.6	LINC01535	11.79	3.15e-30	3.19e-27	0.47	0.34	Obesity-related traits;	chr19:37578663	chr19:37251912~37265535:+
BRCA	cis	rs11673344	0.526	rs73033122	ENSG00000226686.6	LINC01535	11.79	3.15e-30	3.19e-27	0.47	0.34	Obesity-related traits;	chr19:37586006	chr19:37251912~37265535:+
BRCA	cis	rs8040855	0.627	rs4842863	ENSG00000259295.5	CSPG4P12	11.79	3.26e-30	3.3e-27	0.5	0.34	Bulimia nervosa;	chr15:85098974	chr15:85191438~85213905:+
BRCA	cis	rs150992	0.609	rs363929	ENSG00000248489.1	CTD-2007H13.3	11.79	3.27e-30	3.3e-27	0.39	0.34	Body mass index;	chr5:98985933	chr5:98929171~98995013:+
BRCA	cis	rs4423214	0.592	rs11234027	ENSG00000254682.1	RP11-660L16.2	-11.79	3.28e-30	3.31e-27	-0.51	-0.34	Vitamin D levels;	chr11:71523061	chr11:71448674~71452157:+
BRCA	cis	rs853679	0.517	rs6932109	ENSG00000220721.1	OR1F12	-11.79	3.29e-30	3.32e-27	-0.45	-0.34	Depression;	chr6:28110525	chr6:28073316~28074233:+
BRCA	cis	rs2404602	0.735	rs12906143	ENSG00000259422.1	RP11-593F23.1	-11.79	3.29e-30	3.32e-27	-0.46	-0.34	Blood metabolite levels;	chr15:76417182	chr15:76174891~76181486:-
BRCA	cis	rs853679	0.55	rs6901017	ENSG00000220721.1	OR1F12	11.79	3.31e-30	3.34e-27	0.44	0.34	Depression;	chr6:28184805	chr6:28073316~28074233:+
BRCA	cis	rs2404602	0.647	rs11072612	ENSG00000259422.1	RP11-593F23.1	-11.79	3.36e-30	3.4e-27	-0.45	-0.34	Blood metabolite levels;	chr15:76668643	chr15:76174891~76181486:-
BRCA	cis	rs992157	0.56	rs10932763	ENSG00000261338.2	RP11-378A13.1	-11.79	3.42e-30	3.46e-27	-0.35	-0.34	Colorectal cancer;	chr2:218221140	chr2:218255319~218257366:+
BRCA	cis	rs6782228	0.606	rs7613073	ENSG00000242551.2	POU5F1P6	-11.79	3.46e-30	3.49e-27	-0.44	-0.34	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128669660	chr3:128674735~128677005:-
BRCA	cis	rs2404602	0.647	rs2404600	ENSG00000259422.1	RP11-593F23.1	-11.79	3.47e-30	3.5e-27	-0.46	-0.34	Blood metabolite levels;	chr15:76881216	chr15:76174891~76181486:-
BRCA	cis	rs9309711	0.666	rs4321399	ENSG00000225234.1	TRAPPC12-AS1	-11.78	3.51e-30	3.54e-27	-0.36	-0.34	Neurofibrillary tangles;	chr2:3477888	chr2:3481242~3482409:-
BRCA	cis	rs34779708	1	rs34779708	ENSG00000230534.5	RP11-297A16.2	11.78	3.52e-30	3.56e-27	0.43	0.34	Inflammatory bowel disease;Crohn's disease;	chr10:35177257	chr10:35098006~35127020:-
BRCA	cis	rs11089937	0.929	rs5750624	ENSG00000211639.2	IGLV4-60	11.78	3.56e-30	3.59e-27	0.31	0.34	Periodontitis (PAL4Q3);	chr22:22165354	chr22:22162199~22162681:+
BRCA	cis	rs150992	0.711	rs331918	ENSG00000248489.1	CTD-2007H13.3	11.78	3.58e-30	3.61e-27	0.4	0.34	Body mass index;	chr5:98823040	chr5:98929171~98995013:+
BRCA	cis	rs1185460	1	rs1185460	ENSG00000271751.1	RP11-110I1.14	11.78	3.63e-30	3.66e-27	0.44	0.34	Coronary artery disease;	chr11:119072723	chr11:119065263~119065677:-
BRCA	cis	rs7714584	1	rs11741861	ENSG00000197083.10	ZNF300P1	-11.78	3.72e-30	3.75e-27	-0.57	-0.34	Crohn's disease;	chr5:150898347	chr5:150930645~150946289:-
BRCA	cis	rs9545047	0.604	rs2765078	ENSG00000227676.3	LINC01068	11.78	3.76e-30	3.79e-27	0.4	0.34	Schizophrenia;	chr13:79420604	chr13:79566727~79571436:+
BRCA	cis	rs12922040	0.701	rs12149912	ENSG00000263335.1	AF001548.5	-11.78	3.79e-30	3.81e-27	-0.4	-0.34	Serum uric acid levels in response to allopurinol in gout;	chr16:15774798	chr16:15726674~15732993:+
BRCA	cis	rs150992	0.678	rs161950	ENSG00000248489.1	CTD-2007H13.3	-11.78	3.8e-30	3.83e-27	-0.39	-0.34	Body mass index;	chr5:98924533	chr5:98929171~98995013:+
BRCA	cis	rs858239	1	rs156407	ENSG00000226816.2	AC005082.12	11.78	3.82e-30	3.85e-27	0.41	0.34	Cerebrospinal fluid biomarker levels;	chr7:23276020	chr7:23206013~23208045:+
BRCA	cis	rs8072100	0.84	rs12452796	ENSG00000228782.6	CTD-2026D20.3	-11.78	3.85e-30	3.87e-27	-0.37	-0.34	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47402367	chr17:47450568~47492492:-
BRCA	cis	rs34779708	0.931	rs35388511	ENSG00000230534.5	RP11-297A16.2	11.77	3.91e-30	3.93e-27	0.43	0.34	Inflammatory bowel disease;Crohn's disease;	chr10:35007688	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.931	rs34815241	ENSG00000230534.5	RP11-297A16.2	11.77	3.91e-30	3.93e-27	0.43	0.34	Inflammatory bowel disease;Crohn's disease;	chr10:35007748	chr10:35098006~35127020:-
BRCA	cis	rs8062405	0.69	rs6498089	ENSG00000278665.1	RP11-666O2.4	-11.77	3.92e-30	3.94e-27	-0.36	-0.34	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28617979	chr16:28599241~28601881:-
BRCA	cis	rs6991838	0.557	rs67046768	ENSG00000200714.1	Y_RNA	-11.77	3.94e-30	3.97e-27	-0.4	-0.34	Intelligence (multi-trait analysis);	chr8:65577486	chr8:65592731~65592820:+
BRCA	cis	rs62103177	0.525	rs4799116	ENSG00000261126.6	RP11-795F19.1	-11.77	3.95e-30	3.98e-27	-0.41	-0.34	Opioid sensitivity;	chr18:79976735	chr18:80046900~80095482:+
BRCA	cis	rs11676348	0.755	rs1008562	ENSG00000261338.2	RP11-378A13.1	11.77	3.99e-30	4.01e-27	0.37	0.34	Ulcerative colitis;	chr2:218162249	chr2:218255319~218257366:+
BRCA	cis	rs11673344	0.526	rs17244713	ENSG00000226686.6	LINC01535	11.77	4e-30	4.02e-27	0.47	0.34	Obesity-related traits;	chr19:37559938	chr19:37251912~37265535:+
BRCA	cis	rs992157	0.56	rs12987130	ENSG00000261338.2	RP11-378A13.1	-11.77	4.05e-30	4.07e-27	-0.35	-0.34	Colorectal cancer;	chr2:218240267	chr2:218255319~218257366:+
BRCA	cis	rs11673344	0.518	rs73033134	ENSG00000226686.6	LINC01535	11.77	4.05e-30	4.07e-27	0.47	0.34	Obesity-related traits;	chr19:37596046	chr19:37251912~37265535:+
BRCA	cis	rs2404602	0.647	rs12913024	ENSG00000259422.1	RP11-593F23.1	-11.77	4.05e-30	4.07e-27	-0.46	-0.34	Blood metabolite levels;	chr15:76852875	chr15:76174891~76181486:-
BRCA	cis	rs7714584	1	rs12656600	ENSG00000197083.10	ZNF300P1	11.77	4.06e-30	4.09e-27	0.52	0.34	Crohn's disease;	chr5:150932310	chr5:150930645~150946289:-
BRCA	cis	rs8072100	0.807	rs2175290	ENSG00000228782.6	CTD-2026D20.3	11.77	4.14e-30	4.16e-27	0.37	0.34	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47402551	chr17:47450568~47492492:-
BRCA	cis	rs10129255	0.5	rs8022547	ENSG00000223648.3	IGHV3-64	11.77	4.19e-30	4.22e-27	0.26	0.34	Kawasaki disease;	chr14:106781985	chr14:106643132~106658258:-
BRCA	cis	rs150992	0.632	rs162341	ENSG00000248489.1	CTD-2007H13.3	11.77	4.21e-30	4.24e-27	0.39	0.34	Body mass index;	chr5:98967230	chr5:98929171~98995013:+
BRCA	cis	rs10129255	0.5	rs8014529	ENSG00000223648.3	IGHV3-64	11.77	4.29e-30	4.31e-27	0.27	0.34	Kawasaki disease;	chr14:106784065	chr14:106643132~106658258:-
BRCA	cis	rs10935480	0.634	rs1585488	ENSG00000239445.4	ST3GAL6-AS1	-11.76	4.48e-30	4.5e-27	-0.36	-0.34	Blood protein levels;	chr3:98640819	chr3:98714330~98732651:-
BRCA	cis	rs8062405	0.895	rs62036658	ENSG00000259982.1	CDC37P1	11.76	4.5e-30	4.52e-27	0.45	0.34	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28839050	chr16:28700294~28701540:-
BRCA	cis	rs9545047	0.604	rs2477397	ENSG00000227676.3	LINC01068	-11.76	4.75e-30	4.76e-27	-0.41	-0.34	Schizophrenia;	chr13:79428211	chr13:79566727~79571436:+
BRCA	cis	rs992157	0.56	rs7605980	ENSG00000261338.2	RP11-378A13.1	11.76	4.76e-30	4.77e-27	0.36	0.34	Colorectal cancer;	chr2:218236146	chr2:218255319~218257366:+
BRCA	cis	rs11676348	0.791	rs6726126	ENSG00000261338.2	RP11-378A13.1	-11.75	4.83e-30	4.84e-27	-0.37	-0.34	Ulcerative colitis;	chr2:218087510	chr2:218255319~218257366:+
BRCA	cis	rs7044106	0.791	rs10984997	ENSG00000226752.6	PSMD5-AS1	-11.75	4.9e-30	4.91e-27	-0.41	-0.34	Hip circumference adjusted for BMI;	chr9:120718928	chr9:120824828~120854385:+
BRCA	cis	rs8040855	0.575	rs12912860	ENSG00000259295.5	CSPG4P12	11.75	5e-30	5.01e-27	0.51	0.34	Bulimia nervosa;	chr15:85030267	chr15:85191438~85213905:+
BRCA	cis	rs853679	0.55	rs1225598	ENSG00000220721.1	OR1F12	11.75	5.02e-30	5.03e-27	0.43	0.34	Depression;	chr6:28193021	chr6:28073316~28074233:+
BRCA	cis	rs2404602	0.735	rs1607017	ENSG00000259422.1	RP11-593F23.1	-11.75	5.05e-30	5.06e-27	-0.45	-0.34	Blood metabolite levels;	chr15:76434124	chr15:76174891~76181486:-
BRCA	cis	rs10129255	0.5	rs12101190	ENSG00000223648.3	IGHV3-64	11.75	5.09e-30	5.1e-27	0.26	0.34	Kawasaki disease;	chr14:106784149	chr14:106643132~106658258:-
BRCA	cis	rs10129255	0.518	rs8004895	ENSG00000223648.3	IGHV3-64	11.75	5.09e-30	5.1e-27	0.26	0.34	Kawasaki disease;	chr14:106785139	chr14:106643132~106658258:-
BRCA	cis	rs992157	0.56	rs1514132	ENSG00000261338.2	RP11-378A13.1	-11.75	5.23e-30	5.24e-27	-0.35	-0.34	Colorectal cancer;	chr2:218219359	chr2:218255319~218257366:+
BRCA	cis	rs4722166	0.508	rs1474347	ENSG00000179428.2	AC073072.5	11.74	5.32e-30	5.32e-27	0.36	0.34	Lung cancer;	chr7:22728505	chr7:22725395~22727620:-
BRCA	cis	rs321358	0.945	rs12420595	ENSG00000271584.1	RP11-89C3.4	11.74	5.32e-30	5.32e-27	0.6	0.34	Body mass index;	chr11:111115871	chr11:111091932~111097357:-
BRCA	cis	rs6991838	0.584	rs2175810	ENSG00000272010.1	CTD-3025N20.3	-11.74	5.33e-30	5.33e-27	-0.36	-0.34	Intelligence (multi-trait analysis);	chr8:65643583	chr8:65591850~65592472:-
BRCA	cis	rs11673344	0.526	rs55865869	ENSG00000226686.6	LINC01535	11.74	5.34e-30	5.34e-27	0.47	0.34	Obesity-related traits;	chr19:37578683	chr19:37251912~37265535:+
BRCA	cis	rs6142102	0.602	rs932388	ENSG00000276073.1	RP5-1125A11.7	-11.74	5.36e-30	5.36e-27	-0.39	-0.34	Skin pigmentation;	chr20:34069572	chr20:33985617~33988989:-
BRCA	cis	rs2283792	1	rs2006893	ENSG00000224086.5	LL22NC03-86G7.1	-11.74	5.36e-30	5.36e-27	-0.36	-0.34	Multiple sclerosis;	chr22:21774389	chr22:21938293~21977632:+
BRCA	cis	rs8040855	0.627	rs11634975	ENSG00000259295.5	CSPG4P12	11.74	5.37e-30	5.37e-27	0.49	0.34	Bulimia nervosa;	chr15:85063247	chr15:85191438~85213905:+
BRCA	cis	rs10129255	0.5	rs34326748	ENSG00000223648.3	IGHV3-64	11.74	5.4e-30	5.4e-27	0.26	0.34	Kawasaki disease;	chr14:106782523	chr14:106643132~106658258:-
BRCA	cis	rs10129255	0.5	rs10143385	ENSG00000223648.3	IGHV3-64	11.74	5.4e-30	5.4e-27	0.26	0.34	Kawasaki disease;	chr14:106782559	chr14:106643132~106658258:-
BRCA	cis	rs9545047	0.511	rs1624537	ENSG00000227676.3	LINC01068	11.74	5.4e-30	5.4e-27	0.4	0.34	Schizophrenia;	chr13:79411686	chr13:79566727~79571436:+
BRCA	cis	rs10256972	0.621	rs2363285	ENSG00000229043.2	AC091729.9	-11.74	5.51e-30	5.5e-27	-0.41	-0.34	Endometriosis;Longevity;	chr7:1052008	chr7:1160374~1165267:+
BRCA	cis	rs2404602	0.735	rs1607015	ENSG00000259422.1	RP11-593F23.1	-11.74	5.52e-30	5.51e-27	-0.46	-0.34	Blood metabolite levels;	chr15:76410088	chr15:76174891~76181486:-
BRCA	cis	rs9487094	0.961	rs9480948	ENSG00000260273.1	RP11-425D10.10	11.74	5.61e-30	5.6e-27	0.42	0.34	Height;	chr6:109407148	chr6:109382795~109383666:+
BRCA	cis	rs673078	0.562	rs4767672	ENSG00000275759.1	RP11-131L12.3	-11.74	5.64e-30	5.62e-27	-0.53	-0.34	Glucose homeostasis traits;	chr12:118397048	chr12:118428281~118428870:+
BRCA	cis	rs673078	0.607	rs73205594	ENSG00000275759.1	RP11-131L12.3	-11.74	5.64e-30	5.62e-27	-0.53	-0.34	Glucose homeostasis traits;	chr12:118397168	chr12:118428281~118428870:+
BRCA	cis	rs7849270	1	rs4713	ENSG00000268707.1	RP11-247A12.7	11.74	5.65e-30	5.64e-27	0.41	0.34	Blood metabolite ratios;	chr9:129148526	chr9:129170434~129170940:+
BRCA	cis	rs1062177	1	rs12653926	ENSG00000213433.5	RPLP1P6	-11.74	5.7e-30	5.69e-27	-0.45	-0.34	Preschool internalizing problems;	chr5:151870687	chr5:151765859~151766378:-
BRCA	cis	rs2882667	0.627	rs1549203	ENSG00000253404.1	AC034243.1	-11.74	5.75e-30	5.73e-27	-0.43	-0.34	Age-related hearing impairment (SNP x SNP interaction);	chr5:139132655	chr5:138744434~138753309:-
BRCA	cis	rs875971	0.964	rs60193905	ENSG00000222364.1	RNU6-96P	-11.74	5.77e-30	5.76e-27	-0.39	-0.34	Aortic root size;	chr7:66506273	chr7:66395191~66395286:+
BRCA	cis	rs2015599	0.623	rs12581107	ENSG00000257176.2	RP11-996F15.2	-11.74	5.8e-30	5.79e-27	-0.43	-0.34	Platelet count;Mean platelet volume;	chr12:29352358	chr12:29280418~29317848:-
BRCA	cis	rs6991838	0.584	rs7459944	ENSG00000200714.1	Y_RNA	-11.74	5.84e-30	5.83e-27	-0.4	-0.34	Intelligence (multi-trait analysis);	chr8:65566040	chr8:65592731~65592820:+
BRCA	cis	rs9322193	0.566	rs3922947	ENSG00000216906.2	RP11-350J20.9	-11.73	5.94e-30	5.92e-27	-0.46	-0.34	Lung cancer;	chr6:149924856	chr6:149904243~149906418:+
BRCA	cis	rs2404602	0.735	rs11632222	ENSG00000259422.1	RP11-593F23.1	-11.73	5.99e-30	5.97e-27	-0.46	-0.34	Blood metabolite levels;	chr15:76420586	chr15:76174891~76181486:-
BRCA	cis	rs11673344	0.526	rs17303902	ENSG00000226686.6	LINC01535	11.73	6.01e-30	5.99e-27	0.47	0.34	Obesity-related traits;	chr19:37551912	chr19:37251912~37265535:+
BRCA	cis	rs11673344	0.526	rs55754546	ENSG00000226686.6	LINC01535	11.73	6.01e-30	5.99e-27	0.47	0.34	Obesity-related traits;	chr19:37552860	chr19:37251912~37265535:+
BRCA	cis	rs10875746	0.859	rs4760622	ENSG00000240399.1	RP1-228P16.1	-11.73	6.03e-30	6.01e-27	-0.44	-0.34	Longevity (90 years and older);	chr12:48198177	chr12:48054813~48055591:-
BRCA	cis	rs8040855	0.627	rs72757059	ENSG00000259295.5	CSPG4P12	11.73	6.06e-30	6.04e-27	0.49	0.34	Bulimia nervosa;	chr15:85059918	chr15:85191438~85213905:+
BRCA	cis	rs10129255	0.719	rs7156660	ENSG00000211970.3	IGHV4-61	-11.73	6.29e-30	6.26e-27	-0.24	-0.34	Kawasaki disease;	chr14:106673171	chr14:106639119~106639657:-
BRCA	cis	rs673078	0.607	rs7968011	ENSG00000275759.1	RP11-131L12.3	-11.73	6.42e-30	6.39e-27	-0.54	-0.34	Glucose homeostasis traits;	chr12:118382001	chr12:118428281~118428870:+
BRCA	cis	rs9487094	0.961	rs752262	ENSG00000260273.1	RP11-425D10.10	11.73	6.43e-30	6.39e-27	0.42	0.34	Height;	chr6:109449796	chr6:109382795~109383666:+
BRCA	cis	rs6452524	0.868	rs1011981	ENSG00000249664.1	CTD-2227C6.2	11.72	6.54e-30	6.5e-27	0.41	0.34	Hypertension (SNP x SNP interaction);	chr5:83097869	chr5:83012285~83013109:-
BRCA	cis	rs6452524	0.868	rs17284218	ENSG00000249664.1	CTD-2227C6.2	11.72	6.54e-30	6.5e-27	0.41	0.34	Hypertension (SNP x SNP interaction);	chr5:83099530	chr5:83012285~83013109:-
BRCA	cis	rs4423214	0.559	rs10898228	ENSG00000254682.1	RP11-660L16.2	-11.72	6.56e-30	6.52e-27	-0.51	-0.34	Vitamin D levels;	chr11:71517312	chr11:71448674~71452157:+
BRCA	cis	rs10129255	0.5	rs59939897	ENSG00000223648.3	IGHV3-64	11.72	6.6e-30	6.56e-27	0.26	0.34	Kawasaki disease;	chr14:106783414	chr14:106643132~106658258:-
BRCA	cis	rs10875746	0.859	rs4760695	ENSG00000240399.1	RP1-228P16.1	-11.72	6.6e-30	6.56e-27	-0.45	-0.34	Longevity (90 years and older);	chr12:48198065	chr12:48054813~48055591:-
BRCA	cis	rs6782228	0.675	rs9841987	ENSG00000242551.2	POU5F1P6	-11.72	6.61e-30	6.57e-27	-0.44	-0.34	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128666299	chr3:128674735~128677005:-
BRCA	cis	rs321358	0.945	rs10502129	ENSG00000271584.1	RP11-89C3.4	11.72	6.79e-30	6.74e-27	0.6	0.34	Body mass index;	chr11:111107405	chr11:111091932~111097357:-
BRCA	cis	rs4727443	0.932	rs7803714	ENSG00000214313.7	AZGP1P1	-11.72	6.92e-30	6.87e-27	-0.35	-0.34	Interstitial lung disease;	chr7:99987527	chr7:99980762~99987535:+
BRCA	cis	rs6142102	0.602	rs4911402	ENSG00000276073.1	RP5-1125A11.7	-11.72	6.95e-30	6.9e-27	-0.4	-0.34	Skin pigmentation;	chr20:34079839	chr20:33985617~33988989:-
BRCA	cis	rs2015599	0.645	rs12578931	ENSG00000257176.2	RP11-996F15.2	-11.72	7.06e-30	7e-27	-0.43	-0.34	Platelet count;Mean platelet volume;	chr12:29358608	chr12:29280418~29317848:-
BRCA	cis	rs2015599	0.623	rs4931174	ENSG00000257176.2	RP11-996F15.2	-11.72	7.06e-30	7e-27	-0.43	-0.34	Platelet count;Mean platelet volume;	chr12:29360545	chr12:29280418~29317848:-
BRCA	cis	rs321358	0.945	rs17537360	ENSG00000271584.1	RP11-89C3.4	11.72	7.16e-30	7.11e-27	0.6	0.34	Body mass index;	chr11:111116921	chr11:111091932~111097357:-
BRCA	cis	rs6991838	0.584	rs10089708	ENSG00000200714.1	Y_RNA	11.72	7.22e-30	7.16e-27	0.4	0.34	Intelligence (multi-trait analysis);	chr8:65642927	chr8:65592731~65592820:+
BRCA	cis	rs6991838	0.584	rs6991731	ENSG00000200714.1	Y_RNA	11.72	7.22e-30	7.16e-27	0.4	0.34	Intelligence (multi-trait analysis);	chr8:65643232	chr8:65592731~65592820:+
BRCA	cis	rs6991838	0.557	rs67685675	ENSG00000200714.1	Y_RNA	-11.71	7.33e-30	7.26e-27	-0.4	-0.34	Intelligence (multi-trait analysis);	chr8:65574371	chr8:65592731~65592820:+
BRCA	cis	rs6991838	0.584	rs66486920	ENSG00000200714.1	Y_RNA	-11.71	7.33e-30	7.26e-27	-0.4	-0.34	Intelligence (multi-trait analysis);	chr8:65574458	chr8:65592731~65592820:+
BRCA	cis	rs6991838	0.584	rs60023200	ENSG00000200714.1	Y_RNA	-11.71	7.33e-30	7.26e-27	-0.4	-0.34	Intelligence (multi-trait analysis);	chr8:65574547	chr8:65592731~65592820:+
BRCA	cis	rs6991838	0.584	rs61083799	ENSG00000200714.1	Y_RNA	-11.71	7.33e-30	7.26e-27	-0.4	-0.34	Intelligence (multi-trait analysis);	chr8:65574868	chr8:65592731~65592820:+
BRCA	cis	rs1075265	0.633	rs7591431	ENSG00000233266.1	HMGB1P31	11.71	7.55e-30	7.47e-27	0.42	0.34	Chronotype;Morning vs. evening chronotype;	chr2:53995028	chr2:54051334~54051760:+
BRCA	cis	rs9545047	0.604	rs9318640	ENSG00000227676.3	LINC01068	-11.71	7.55e-30	7.47e-27	-0.4	-0.34	Schizophrenia;	chr13:79426527	chr13:79566727~79571436:+
BRCA	cis	rs2404602	0.647	rs12898810	ENSG00000259422.1	RP11-593F23.1	-11.71	7.55e-30	7.47e-27	-0.46	-0.34	Blood metabolite levels;	chr15:76612397	chr15:76174891~76181486:-
BRCA	cis	rs67180937	0.645	rs2270707	ENSG00000272750.1	RP11-378J18.8	11.71	7.59e-30	7.51e-27	0.45	0.34	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222664252	chr1:222658867~222661512:-
BRCA	cis	rs10129255	0.5	rs8006888	ENSG00000223648.3	IGHV3-64	11.71	7.6e-30	7.52e-27	0.26	0.34	Kawasaki disease;	chr14:106782219	chr14:106643132~106658258:-
BRCA	cis	rs6782228	0.651	rs9852825	ENSG00000242551.2	POU5F1P6	-11.71	7.71e-30	7.63e-27	-0.44	-0.34	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128668514	chr3:128674735~128677005:-
BRCA	cis	rs6782228	0.651	rs9289332	ENSG00000242551.2	POU5F1P6	-11.71	7.71e-30	7.63e-27	-0.44	-0.34	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128669041	chr3:128674735~128677005:-
BRCA	cis	rs2564921	0.73	rs2564939	ENSG00000242142.1	SERBP1P3	11.71	7.8e-30	7.71e-27	0.42	0.34	Height;	chr3:53072864	chr3:53064283~53065091:-
BRCA	cis	rs2729354	0.729	rs2581923	ENSG00000265566.2	RN7SL605P	-11.71	7.87e-30	7.78e-27	-0.5	-0.34	Blood protein levels;	chr11:57482518	chr11:57528085~57528365:-
BRCA	cis	rs9322193	0.607	rs6557165	ENSG00000216906.2	RP11-350J20.9	-11.71	8e-30	7.91e-27	-0.44	-0.34	Lung cancer;	chr6:149906883	chr6:149904243~149906418:+
BRCA	cis	rs11673344	0.526	rs17305193	ENSG00000226686.6	LINC01535	11.71	8.03e-30	7.93e-27	0.47	0.34	Obesity-related traits;	chr19:37598764	chr19:37251912~37265535:+
BRCA	cis	rs992157	0.56	rs7578940	ENSG00000261338.2	RP11-378A13.1	-11.7	8.16e-30	8.06e-27	-0.35	-0.34	Colorectal cancer;	chr2:218218595	chr2:218255319~218257366:+
BRCA	cis	rs9545047	0.604	rs2265382	ENSG00000227676.3	LINC01068	-11.7	8.24e-30	8.14e-27	-0.4	-0.34	Schizophrenia;	chr13:79426196	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs2477395	ENSG00000227676.3	LINC01068	-11.7	8.31e-30	8.2e-27	-0.4	-0.34	Schizophrenia;	chr13:79427679	chr13:79566727~79571436:+
BRCA	cis	rs875971	0.83	rs4718358	ENSG00000222364.1	RNU6-96P	-11.7	8.32e-30	8.21e-27	-0.39	-0.34	Aortic root size;	chr7:66508681	chr7:66395191~66395286:+
BRCA	cis	rs6991838	0.584	rs34494846	ENSG00000200714.1	Y_RNA	-11.7	8.36e-30	8.25e-27	-0.4	-0.34	Intelligence (multi-trait analysis);	chr8:65602397	chr8:65592731~65592820:+
BRCA	cis	rs2412819	0.559	rs8040336	ENSG00000249839.1	AC011330.5	-11.7	8.45e-30	8.34e-27	-0.39	-0.34	Lung cancer;	chr15:43761419	chr15:43663654~43684339:-
BRCA	cis	rs9545047	0.625	rs9545109	ENSG00000227676.3	LINC01068	11.7	8.46e-30	8.34e-27	0.4	0.34	Schizophrenia;	chr13:79413480	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.518	rs7328494	ENSG00000227676.3	LINC01068	11.7	8.46e-30	8.34e-27	0.4	0.34	Schizophrenia;	chr13:79414673	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs2147568	ENSG00000227676.3	LINC01068	11.7	8.46e-30	8.34e-27	0.4	0.34	Schizophrenia;	chr13:79417091	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs9530917	ENSG00000227676.3	LINC01068	11.7	8.46e-30	8.34e-27	0.4	0.34	Schizophrenia;	chr13:79417719	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs7990321	ENSG00000227676.3	LINC01068	11.7	8.46e-30	8.34e-27	0.4	0.34	Schizophrenia;	chr13:79418066	chr13:79566727~79571436:+
BRCA	cis	rs10129255	0.518	rs10136903	ENSG00000223648.3	IGHV3-64	11.7	8.51e-30	8.39e-27	0.27	0.34	Kawasaki disease;	chr14:106778866	chr14:106643132~106658258:-
BRCA	cis	rs875971	0.862	rs28470208	ENSG00000222364.1	RNU6-96P	11.7	8.51e-30	8.39e-27	0.4	0.34	Aortic root size;	chr7:66119713	chr7:66395191~66395286:+
BRCA	cis	rs11676348	0.755	rs6436026	ENSG00000261338.2	RP11-378A13.1	-11.7	8.54e-30	8.42e-27	-0.36	-0.34	Ulcerative colitis;	chr2:218087015	chr2:218255319~218257366:+
BRCA	cis	rs9487094	0.922	rs10782162	ENSG00000260273.1	RP11-425D10.10	-11.7	8.79e-30	8.66e-27	-0.42	-0.34	Height;	chr6:109485060	chr6:109382795~109383666:+
BRCA	cis	rs10129255	0.536	rs10142951	ENSG00000223648.3	IGHV3-64	11.7	8.81e-30	8.68e-27	0.26	0.34	Kawasaki disease;	chr14:106782337	chr14:106643132~106658258:-
BRCA	cis	rs150992	0.632	rs326493	ENSG00000248489.1	CTD-2007H13.3	11.69	8.97e-30	8.83e-27	0.38	0.34	Body mass index;	chr5:98966251	chr5:98929171~98995013:+
BRCA	cis	rs2980439	0.846	rs2980437	ENSG00000253893.2	FAM85B	11.69	9.05e-30	8.92e-27	0.44	0.34	Neuroticism;	chr8:8237241	chr8:8167819~8226614:-
BRCA	cis	rs150992	0.593	rs34497	ENSG00000248489.1	CTD-2007H13.3	11.69	9.14e-30	8.97e-27	0.38	0.34	Body mass index;	chr5:98962885	chr5:98929171~98995013:+
BRCA	cis	rs321358	0.945	rs10502130	ENSG00000271584.1	RP11-89C3.4	11.69	9.14e-30	8.97e-27	0.6	0.34	Body mass index;	chr11:111107437	chr11:111091932~111097357:-
BRCA	cis	rs321358	0.945	rs73017109	ENSG00000271584.1	RP11-89C3.4	11.69	9.14e-30	8.97e-27	0.6	0.34	Body mass index;	chr11:111108484	chr11:111091932~111097357:-
BRCA	cis	rs321358	0.887	rs1470537	ENSG00000271584.1	RP11-89C3.4	11.69	9.14e-30	8.97e-27	0.6	0.34	Body mass index;	chr11:111109328	chr11:111091932~111097357:-
BRCA	cis	rs321358	0.945	rs12421769	ENSG00000271584.1	RP11-89C3.4	11.69	9.14e-30	8.97e-27	0.6	0.34	Body mass index;	chr11:111109500	chr11:111091932~111097357:-
BRCA	cis	rs321358	0.945	rs73017114	ENSG00000271584.1	RP11-89C3.4	11.69	9.14e-30	8.97e-27	0.6	0.34	Body mass index;	chr11:111111582	chr11:111091932~111097357:-
BRCA	cis	rs321358	0.945	rs17458493	ENSG00000271584.1	RP11-89C3.4	11.69	9.14e-30	8.97e-27	0.6	0.34	Body mass index;	chr11:111112156	chr11:111091932~111097357:-
BRCA	cis	rs321358	0.945	rs17458541	ENSG00000271584.1	RP11-89C3.4	11.69	9.14e-30	8.97e-27	0.6	0.34	Body mass index;	chr11:111113182	chr11:111091932~111097357:-
BRCA	cis	rs321358	0.836	rs17458597	ENSG00000271584.1	RP11-89C3.4	11.69	9.14e-30	8.97e-27	0.6	0.34	Body mass index;	chr11:111113599	chr11:111091932~111097357:-
BRCA	cis	rs321358	0.945	rs73017176	ENSG00000271584.1	RP11-89C3.4	11.69	9.14e-30	8.97e-27	0.6	0.34	Body mass index;	chr11:111113879	chr11:111091932~111097357:-
BRCA	cis	rs321358	0.887	rs80221187	ENSG00000271584.1	RP11-89C3.4	11.69	9.14e-30	8.97e-27	0.6	0.34	Body mass index;	chr11:111113977	chr11:111091932~111097357:-
BRCA	cis	rs321358	0.945	rs73017177	ENSG00000271584.1	RP11-89C3.4	11.69	9.14e-30	8.97e-27	0.6	0.34	Body mass index;	chr11:111114034	chr11:111091932~111097357:-
BRCA	cis	rs321358	0.895	rs73017179	ENSG00000271584.1	RP11-89C3.4	11.69	9.14e-30	8.97e-27	0.6	0.34	Body mass index;	chr11:111114037	chr11:111091932~111097357:-
BRCA	cis	rs321358	0.945	rs1356411	ENSG00000271584.1	RP11-89C3.4	11.69	9.14e-30	8.97e-27	0.6	0.34	Body mass index;	chr11:111115371	chr11:111091932~111097357:-
BRCA	cis	rs8059260	0.736	rs78121798	ENSG00000274038.1	RP11-66H6.4	-11.69	9.18e-30	9.02e-27	-0.54	-0.34	Alcohol consumption over the past year;	chr16:10984224	chr16:11056556~11057034:+
BRCA	cis	rs6991838	0.584	rs4449837	ENSG00000200714.1	Y_RNA	-11.69	9.22e-30	9.05e-27	-0.39	-0.34	Intelligence (multi-trait analysis);	chr8:65575917	chr8:65592731~65592820:+
BRCA	cis	rs6991838	0.584	rs57042777	ENSG00000200714.1	Y_RNA	-11.69	9.22e-30	9.05e-27	-0.39	-0.34	Intelligence (multi-trait analysis);	chr8:65576855	chr8:65592731~65592820:+
BRCA	cis	rs8100891	0.537	rs16967057	ENSG00000267213.4	AC007773.2	11.69	9.26e-30	9.09e-27	0.5	0.34	Neuroticism;	chr19:32423172	chr19:32390050~32405560:-
BRCA	cis	rs150992	0.593	rs34496	ENSG00000248489.1	CTD-2007H13.3	11.69	9.29e-30	9.12e-27	0.38	0.34	Body mass index;	chr5:98963812	chr5:98929171~98995013:+
BRCA	cis	rs12134133	1	rs2564973	ENSG00000274245.1	RP11-357P18.2	11.69	9.36e-30	9.19e-27	0.46	0.34	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207306759	chr1:207372559~207373252:+
BRCA	cis	rs10875746	0.855	rs10875729	ENSG00000240399.1	RP1-228P16.1	-11.69	9.41e-30	9.23e-27	-0.45	-0.34	Longevity (90 years and older);	chr12:48032943	chr12:48054813~48055591:-
BRCA	cis	rs8062405	0.789	rs28676837	ENSG00000278665.1	RP11-666O2.4	-11.69	9.7e-30	9.52e-27	-0.36	-0.34	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28615742	chr16:28599241~28601881:-
BRCA	cis	rs673078	0.607	rs61943447	ENSG00000275759.1	RP11-131L12.3	-11.69	9.77e-30	9.58e-27	-0.53	-0.34	Glucose homeostasis traits;	chr12:118430598	chr12:118428281~118428870:+
BRCA	cis	rs11723261	0.582	rs11732336	ENSG00000275426.1	CH17-262A2.1	11.69	9.85e-30	9.66e-27	0.48	0.34	Immune response to smallpox vaccine (IL-6);	chr4:146728	chr4:149738~150317:+
BRCA	cis	rs4722166	0.695	rs4722177	ENSG00000179428.2	AC073072.5	-11.69	9.91e-30	9.72e-27	-0.36	-0.34	Lung cancer;	chr7:22758912	chr7:22725395~22727620:-
BRCA	cis	rs2929278	0.736	rs2412823	ENSG00000205771.5	CATSPER2P1	11.68	1.01e-29	9.9e-27	0.42	0.34	Schizophrenia;	chr15:43935072	chr15:43726918~43747094:-
BRCA	cis	rs9545047	0.519	rs8001281	ENSG00000227676.3	LINC01068	11.68	1.02e-29	9.95e-27	0.4	0.34	Schizophrenia;	chr13:79410707	chr13:79566727~79571436:+
BRCA	cis	rs10129255	0.518	rs8009594	ENSG00000223648.3	IGHV3-64	11.68	1.02e-29	9.99e-27	0.26	0.34	Kawasaki disease;	chr14:106777494	chr14:106643132~106658258:-
BRCA	cis	rs12134133	1	rs2782846	ENSG00000274245.1	RP11-357P18.2	11.68	1.02e-29	1e-26	0.46	0.34	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207300495	chr1:207372559~207373252:+
BRCA	cis	rs6991838	0.584	rs4737221	ENSG00000200714.1	Y_RNA	-11.68	1.07e-29	1.05e-26	-0.4	-0.34	Intelligence (multi-trait analysis);	chr8:65569075	chr8:65592731~65592820:+
BRCA	cis	rs321358	0.945	rs73015196	ENSG00000271584.1	RP11-89C3.4	11.68	1.07e-29	1.05e-26	0.6	0.34	Body mass index;	chr11:111104608	chr11:111091932~111097357:-
BRCA	cis	rs673078	0.607	rs61943400	ENSG00000275759.1	RP11-131L12.3	-11.68	1.09e-29	1.07e-26	-0.53	-0.34	Glucose homeostasis traits;	chr12:118398236	chr12:118428281~118428870:+
BRCA	cis	rs673078	0.607	rs61943401	ENSG00000275759.1	RP11-131L12.3	-11.68	1.09e-29	1.07e-26	-0.53	-0.34	Glucose homeostasis traits;	chr12:118398527	chr12:118428281~118428870:+
BRCA	cis	rs673078	0.607	rs61943402	ENSG00000275759.1	RP11-131L12.3	-11.68	1.09e-29	1.07e-26	-0.53	-0.34	Glucose homeostasis traits;	chr12:118398808	chr12:118428281~118428870:+
BRCA	cis	rs853679	0.517	rs9393887	ENSG00000220721.1	OR1F12	11.67	1.11e-29	1.08e-26	0.45	0.34	Depression;	chr6:28091242	chr6:28073316~28074233:+
BRCA	cis	rs1062177	0.906	rs2964573	ENSG00000213433.5	RPLP1P6	-11.67	1.12e-29	1.09e-26	-0.44	-0.34	Preschool internalizing problems;	chr5:151780561	chr5:151765859~151766378:-
BRCA	cis	rs6782228	0.675	rs56141228	ENSG00000242551.2	POU5F1P6	-11.67	1.12e-29	1.09e-26	-0.44	-0.34	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128667199	chr3:128674735~128677005:-
BRCA	cis	rs9545047	0.604	rs9318641	ENSG00000227676.3	LINC01068	-11.67	1.14e-29	1.11e-26	-0.4	-0.34	Schizophrenia;	chr13:79426545	chr13:79566727~79571436:+
BRCA	cis	rs301901	0.683	rs34485458	ENSG00000250155.1	CTD-2353F22.1	-11.67	1.15e-29	1.12e-26	-0.39	-0.34	Height;	chr5:36861889	chr5:36666214~36725195:-
BRCA	cis	rs10129255	0.5	rs6576231	ENSG00000223648.3	IGHV3-64	11.67	1.15e-29	1.13e-26	0.26	0.34	Kawasaki disease;	chr14:106783693	chr14:106643132~106658258:-
BRCA	cis	rs6991838	0.584	rs7842085	ENSG00000272010.1	CTD-3025N20.3	11.67	1.17e-29	1.14e-26	0.37	0.34	Intelligence (multi-trait analysis);	chr8:65636787	chr8:65591850~65592472:-
BRCA	cis	rs2404602	0.647	rs920712	ENSG00000259422.1	RP11-593F23.1	-11.67	1.19e-29	1.17e-26	-0.44	-0.34	Blood metabolite levels;	chr15:76741593	chr15:76174891~76181486:-
BRCA	cis	rs9545047	0.604	rs1748761	ENSG00000227676.3	LINC01068	11.67	1.2e-29	1.18e-26	0.4	0.34	Schizophrenia;	chr13:79407491	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs2763809	ENSG00000227676.3	LINC01068	11.67	1.2e-29	1.18e-26	0.4	0.34	Schizophrenia;	chr13:79407544	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs1748762	ENSG00000227676.3	LINC01068	11.67	1.2e-29	1.18e-26	0.4	0.34	Schizophrenia;	chr13:79407914	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs1748763	ENSG00000227676.3	LINC01068	11.67	1.2e-29	1.18e-26	0.4	0.34	Schizophrenia;	chr13:79407965	chr13:79566727~79571436:+
BRCA	cis	rs11123170	0.64	rs2863240	ENSG00000274877.1	RP11-65I12.1	11.66	1.24e-29	1.21e-26	0.49	0.34	Renal function-related traits (BUN);	chr2:113212539	chr2:113237595~113240825:+
BRCA	cis	rs853679	0.55	rs1233707	ENSG00000220721.1	OR1F12	11.66	1.24e-29	1.21e-26	0.43	0.34	Depression;	chr6:28205175	chr6:28073316~28074233:+
BRCA	cis	rs6991838	0.584	rs35790435	ENSG00000200714.1	Y_RNA	-11.66	1.25e-29	1.22e-26	-0.4	-0.34	Intelligence (multi-trait analysis);	chr8:65590288	chr8:65592731~65592820:+
BRCA	cis	rs9545047	0.604	rs7331867	ENSG00000227676.3	LINC01068	-11.66	1.26e-29	1.23e-26	-0.4	-0.34	Schizophrenia;	chr13:79418791	chr13:79566727~79571436:+
BRCA	cis	rs34779708	0.897	rs7900480	ENSG00000230534.5	RP11-297A16.2	-11.66	1.3e-29	1.27e-26	-0.42	-0.34	Inflammatory bowel disease;Crohn's disease;	chr10:35049771	chr10:35098006~35127020:-
BRCA	cis	rs9595066	0.627	rs4942287	ENSG00000227258.4	SMIM2-AS1	-11.66	1.3e-29	1.27e-26	-0.55	-0.34	Schizophrenia;	chr13:44160560	chr13:44110451~44240517:+
BRCA	cis	rs6991838	0.584	rs1053088	ENSG00000200714.1	Y_RNA	11.66	1.32e-29	1.28e-26	0.4	0.34	Intelligence (multi-trait analysis);	chr8:65603548	chr8:65592731~65592820:+
BRCA	cis	rs11673344	0.526	rs8101610	ENSG00000226686.6	LINC01535	-11.66	1.32e-29	1.29e-26	-0.46	-0.34	Obesity-related traits;	chr19:37566604	chr19:37251912~37265535:+
BRCA	cis	rs321358	0.945	rs7931995	ENSG00000271584.1	RP11-89C3.4	11.66	1.32e-29	1.29e-26	0.59	0.34	Body mass index;	chr11:111117691	chr11:111091932~111097357:-
BRCA	cis	rs6904897	0.538	rs4639353	ENSG00000232876.1	CTA-212D2.2	11.66	1.33e-29	1.3e-26	0.43	0.34	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr6:134903190	chr6:135055033~135060550:+
BRCA	cis	rs150992	0.609	rs393697	ENSG00000248489.1	CTD-2007H13.3	11.66	1.34e-29	1.3e-26	0.38	0.34	Body mass index;	chr5:98991357	chr5:98929171~98995013:+
BRCA	cis	rs8040855	0.965	rs11073990	ENSG00000259295.5	CSPG4P12	11.66	1.34e-29	1.31e-26	0.41	0.34	Bulimia nervosa;	chr15:85168070	chr15:85191438~85213905:+
BRCA	cis	rs1062177	1	rs892006	ENSG00000213433.5	RPLP1P6	-11.66	1.35e-29	1.31e-26	-0.43	-0.34	Preschool internalizing problems;	chr5:151801329	chr5:151765859~151766378:-
BRCA	cis	rs1062177	1	rs12515762	ENSG00000213433.5	RPLP1P6	-11.65	1.36e-29	1.32e-26	-0.44	-0.34	Preschool internalizing problems;	chr5:151830361	chr5:151765859~151766378:-
BRCA	cis	rs2404602	0.622	rs11637296	ENSG00000259422.1	RP11-593F23.1	-11.65	1.36e-29	1.33e-26	-0.46	-0.34	Blood metabolite levels;	chr15:76915544	chr15:76174891~76181486:-
BRCA	cis	rs853679	0.55	rs1150689	ENSG00000220721.1	OR1F12	11.65	1.41e-29	1.37e-26	0.43	0.34	Depression;	chr6:28197321	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.55	rs1225599	ENSG00000220721.1	OR1F12	11.65	1.41e-29	1.37e-26	0.43	0.34	Depression;	chr6:28197412	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.574	rs1233705	ENSG00000220721.1	OR1F12	11.65	1.41e-29	1.37e-26	0.43	0.34	Depression;	chr6:28198669	chr6:28073316~28074233:+
BRCA	cis	rs8040855	0.965	rs4843027	ENSG00000259295.5	CSPG4P12	-11.65	1.41e-29	1.37e-26	-0.42	-0.34	Bulimia nervosa;	chr15:85171892	chr15:85191438~85213905:+
BRCA	cis	rs7743045	0.573	rs6929403	ENSG00000253194.1	RP11-351A11.1	11.65	1.41e-29	1.37e-26	0.43	0.34	Mean platelet volume;	chr6:119025747	chr6:118934785~119031541:+
BRCA	cis	rs673078	0.607	rs7137055	ENSG00000275759.1	RP11-131L12.3	-11.65	1.44e-29	1.4e-26	-0.53	-0.34	Glucose homeostasis traits;	chr12:118395030	chr12:118428281~118428870:+
BRCA	cis	rs673078	0.607	rs7137184	ENSG00000275759.1	RP11-131L12.3	-11.65	1.44e-29	1.4e-26	-0.53	-0.34	Glucose homeostasis traits;	chr12:118395163	chr12:118428281~118428870:+
BRCA	cis	rs6991838	0.584	rs73236948	ENSG00000200714.1	Y_RNA	-11.65	1.45e-29	1.41e-26	-0.4	-0.34	Intelligence (multi-trait analysis);	chr8:65609176	chr8:65592731~65592820:+
BRCA	cis	rs2919917	0.628	rs13267679	ENSG00000254352.1	RP11-578O24.2	-11.65	1.45e-29	1.41e-26	-0.5	-0.34	Lymphocyte counts;	chr8:78711603	chr8:78723796~78724136:-
BRCA	cis	rs34779708	0.966	rs11010135	ENSG00000230534.5	RP11-297A16.2	11.65	1.47e-29	1.43e-26	0.45	0.34	Inflammatory bowel disease;Crohn's disease;	chr10:35229135	chr10:35098006~35127020:-
BRCA	cis	rs9487094	0.961	rs12528822	ENSG00000260273.1	RP11-425D10.10	11.65	1.47e-29	1.43e-26	0.41	0.34	Height;	chr6:109340338	chr6:109382795~109383666:+
BRCA	cis	rs321358	0.945	rs17537367	ENSG00000271584.1	RP11-89C3.4	11.65	1.47e-29	1.43e-26	0.59	0.34	Body mass index;	chr11:111117008	chr11:111091932~111097357:-
BRCA	cis	rs853679	0.517	rs9393884	ENSG00000220721.1	OR1F12	11.65	1.48e-29	1.44e-26	0.44	0.34	Depression;	chr6:28079011	chr6:28073316~28074233:+
BRCA	cis	rs6142102	0.602	rs2268079	ENSG00000276073.1	RP5-1125A11.7	-11.64	1.51e-29	1.46e-26	-0.39	-0.34	Skin pigmentation;	chr20:34008944	chr20:33985617~33988989:-
BRCA	cis	rs7044106	0.791	rs2416797	ENSG00000226752.6	PSMD5-AS1	-11.64	1.51e-29	1.47e-26	-0.41	-0.34	Hip circumference adjusted for BMI;	chr9:120718322	chr9:120824828~120854385:+
BRCA	cis	rs7044106	0.791	rs2416798	ENSG00000226752.6	PSMD5-AS1	-11.64	1.51e-29	1.47e-26	-0.41	-0.34	Hip circumference adjusted for BMI;	chr9:120718325	chr9:120824828~120854385:+
BRCA	cis	rs8059260	0.668	rs8055893	ENSG00000274038.1	RP11-66H6.4	-11.64	1.52e-29	1.48e-26	-0.53	-0.34	Alcohol consumption over the past year;	chr16:10977938	chr16:11056556~11057034:+
BRCA	cis	rs6452524	0.87	rs2174976	ENSG00000249664.1	CTD-2227C6.2	11.64	1.53e-29	1.49e-26	0.42	0.34	Hypertension (SNP x SNP interaction);	chr5:83197136	chr5:83012285~83013109:-
BRCA	cis	rs6991838	0.584	rs4737747	ENSG00000200714.1	Y_RNA	-11.64	1.54e-29	1.5e-26	-0.4	-0.34	Intelligence (multi-trait analysis);	chr8:65607024	chr8:65592731~65592820:+
BRCA	cis	rs1062177	1	rs62394155	ENSG00000213433.5	RPLP1P6	-11.64	1.54e-29	1.5e-26	-0.45	-0.34	Preschool internalizing problems;	chr5:151868508	chr5:151765859~151766378:-
BRCA	cis	rs853679	0.55	rs1233699	ENSG00000220721.1	OR1F12	11.64	1.55e-29	1.51e-26	0.43	0.34	Depression;	chr6:28201380	chr6:28073316~28074233:+
BRCA	cis	rs2404602	0.735	rs11857015	ENSG00000259422.1	RP11-593F23.1	-11.64	1.57e-29	1.52e-26	-0.45	-0.34	Blood metabolite levels;	chr15:76357049	chr15:76174891~76181486:-
BRCA	cis	rs6991838	0.584	rs1053085	ENSG00000200714.1	Y_RNA	-11.64	1.57e-29	1.53e-26	-0.4	-0.34	Intelligence (multi-trait analysis);	chr8:65603753	chr8:65592731~65592820:+
BRCA	cis	rs7044106	0.762	rs7849566	ENSG00000226752.6	PSMD5-AS1	-11.64	1.57e-29	1.53e-26	-0.41	-0.34	Hip circumference adjusted for BMI;	chr9:120698491	chr9:120824828~120854385:+
BRCA	cis	rs853679	0.517	rs16893666	ENSG00000220721.1	OR1F12	-11.64	1.58e-29	1.53e-26	-0.44	-0.34	Depression;	chr6:28086929	chr6:28073316~28074233:+
BRCA	cis	rs10129255	0.518	rs12590732	ENSG00000223648.3	IGHV3-64	-11.64	1.58e-29	1.54e-26	-0.26	-0.34	Kawasaki disease;	chr14:106779612	chr14:106643132~106658258:-
BRCA	cis	rs6142102	0.602	rs4911395	ENSG00000276073.1	RP5-1125A11.7	-11.64	1.63e-29	1.58e-26	-0.39	-0.34	Skin pigmentation;	chr20:33992095	chr20:33985617~33988989:-
BRCA	cis	rs853679	0.55	rs1237875	ENSG00000220721.1	OR1F12	-11.63	1.67e-29	1.62e-26	-0.43	-0.34	Depression;	chr6:28205232	chr6:28073316~28074233:+
BRCA	cis	rs6991838	0.584	rs4388482	ENSG00000200714.1	Y_RNA	-11.63	1.71e-29	1.65e-26	-0.39	-0.34	Intelligence (multi-trait analysis);	chr8:65583968	chr8:65592731~65592820:+
BRCA	cis	rs6991838	0.584	rs4637885	ENSG00000200714.1	Y_RNA	-11.63	1.71e-29	1.65e-26	-0.39	-0.34	Intelligence (multi-trait analysis);	chr8:65584849	chr8:65592731~65592820:+
BRCA	cis	rs6991838	0.584	rs7463649	ENSG00000200714.1	Y_RNA	-11.63	1.74e-29	1.68e-26	-0.39	-0.34	Intelligence (multi-trait analysis);	chr8:65573760	chr8:65592731~65592820:+
BRCA	cis	rs6991838	0.584	rs7463740	ENSG00000200714.1	Y_RNA	-11.63	1.74e-29	1.68e-26	-0.39	-0.34	Intelligence (multi-trait analysis);	chr8:65573950	chr8:65592731~65592820:+
BRCA	cis	rs6991838	0.584	rs66467166	ENSG00000200714.1	Y_RNA	-11.63	1.74e-29	1.68e-26	-0.39	-0.34	Intelligence (multi-trait analysis);	chr8:65574165	chr8:65592731~65592820:+
BRCA	cis	rs8040855	0.576	rs62022528	ENSG00000259295.5	CSPG4P12	11.63	1.75e-29	1.7e-26	0.5	0.34	Bulimia nervosa;	chr15:84992030	chr15:85191438~85213905:+
BRCA	cis	rs875971	0.862	rs1167390	ENSG00000222364.1	RNU6-96P	11.63	1.77e-29	1.71e-26	0.4	0.34	Aortic root size;	chr7:66110906	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.862	rs35034167	ENSG00000222364.1	RNU6-96P	11.63	1.77e-29	1.71e-26	0.4	0.34	Aortic root size;	chr7:66115179	chr7:66395191~66395286:+
BRCA	cis	rs7849270	0.879	rs10760587	ENSG00000268707.1	RP11-247A12.7	11.63	1.78e-29	1.72e-26	0.42	0.34	Blood metabolite ratios;	chr9:129083737	chr9:129170434~129170940:+
BRCA	cis	rs321358	0.945	rs17458885	ENSG00000271584.1	RP11-89C3.4	11.63	1.78e-29	1.72e-26	0.59	0.34	Body mass index;	chr11:111117222	chr11:111091932~111097357:-
BRCA	cis	rs34779708	0.931	rs2384287	ENSG00000230534.5	RP11-297A16.2	11.63	1.78e-29	1.72e-26	0.43	0.34	Inflammatory bowel disease;Crohn's disease;	chr10:35051631	chr10:35098006~35127020:-
BRCA	cis	rs34375054	0.738	rs10846834	ENSG00000279233.1	RP11-158L12.4	11.63	1.81e-29	1.75e-26	0.38	0.34	Post bronchodilator FEV1/FVC ratio;	chr12:125141024	chr12:125138245~125141711:+
BRCA	cis	rs8072100	0.84	rs4968319	ENSG00000228782.6	CTD-2026D20.3	11.63	1.81e-29	1.76e-26	0.36	0.34	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47387601	chr17:47450568~47492492:-
BRCA	cis	rs858239	0.965	rs156429	ENSG00000226816.2	AC005082.12	11.62	1.87e-29	1.81e-26	0.4	0.34	Cerebrospinal fluid biomarker levels;	chr7:23266401	chr7:23206013~23208045:+
BRCA	cis	rs67311347	1	rs73080138	ENSG00000223797.4	ENTPD3-AS1	11.62	1.88e-29	1.82e-26	0.38	0.34	Renal cell carcinoma;	chr3:40474926	chr3:40313802~40453329:-
BRCA	cis	rs9322193	0.566	rs5024811	ENSG00000268592.3	RAET1E-AS1	-11.62	1.95e-29	1.89e-26	-0.46	-0.34	Lung cancer;	chr6:149924898	chr6:149863494~149919507:+
BRCA	cis	rs11676348	0.818	rs6436033	ENSG00000261338.2	RP11-378A13.1	-11.62	1.96e-29	1.9e-26	-0.36	-0.34	Ulcerative colitis;	chr2:218119040	chr2:218255319~218257366:+
BRCA	cis	rs150992	0.57	rs398436	ENSG00000248489.1	CTD-2007H13.3	11.62	1.98e-29	1.92e-26	0.38	0.34	Body mass index;	chr5:98991352	chr5:98929171~98995013:+
BRCA	cis	rs7580658	0.864	rs3088374	ENSG00000236682.1	AC068282.3	-11.62	2.04e-29	1.98e-26	-0.44	-0.34	Protein C levels;	chr2:127304472	chr2:127389130~127400580:+
BRCA	cis	rs1062177	0.951	rs2915876	ENSG00000213433.5	RPLP1P6	-11.61	2.06e-29	1.99e-26	-0.44	-0.34	Preschool internalizing problems;	chr5:151771184	chr5:151765859~151766378:-
BRCA	cis	rs8059260	0.736	rs16957883	ENSG00000274038.1	RP11-66H6.4	-11.61	2.08e-29	2.01e-26	-0.53	-0.34	Alcohol consumption over the past year;	chr16:10994788	chr16:11056556~11057034:+
BRCA	cis	rs12134133	1	rs6658718	ENSG00000274245.1	RP11-357P18.2	11.61	2.08e-29	2.01e-26	0.44	0.34	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207285561	chr1:207372559~207373252:+
BRCA	cis	rs6142102	0.602	rs4911399	ENSG00000276073.1	RP5-1125A11.7	-11.61	2.08e-29	2.01e-26	-0.39	-0.34	Skin pigmentation;	chr20:34035612	chr20:33985617~33988989:-
BRCA	cis	rs6142102	0.602	rs4911396	ENSG00000276073.1	RP5-1125A11.7	-11.61	2.08e-29	2.01e-26	-0.39	-0.34	Skin pigmentation;	chr20:33992139	chr20:33985617~33988989:-
BRCA	cis	rs7829975	0.806	rs2428	ENSG00000253893.2	FAM85B	-11.61	2.09e-29	2.02e-26	-0.41	-0.34	Mood instability;	chr8:8783635	chr8:8167819~8226614:-
BRCA	cis	rs9545047	0.604	rs2265381	ENSG00000227676.3	LINC01068	-11.61	2.12e-29	2.04e-26	-0.4	-0.34	Schizophrenia;	chr13:79425903	chr13:79566727~79571436:+
BRCA	cis	rs6142102	0.581	rs4911148	ENSG00000276073.1	RP5-1125A11.7	-11.61	2.12e-29	2.05e-26	-0.39	-0.34	Skin pigmentation;	chr20:34080438	chr20:33985617~33988989:-
BRCA	cis	rs6142102	0.602	rs1054534	ENSG00000276073.1	RP5-1125A11.7	-11.61	2.13e-29	2.06e-26	-0.39	-0.34	Skin pigmentation;	chr20:34017521	chr20:33985617~33988989:-
BRCA	cis	rs875971	0.862	rs778720	ENSG00000222364.1	RNU6-96P	11.61	2.2e-29	2.12e-26	0.4	0.34	Aortic root size;	chr7:66381288	chr7:66395191~66395286:+
BRCA	cis	rs4727443	0.899	rs886453	ENSG00000214313.7	AZGP1P1	-11.61	2.22e-29	2.14e-26	-0.34	-0.34	Interstitial lung disease;	chr7:99990602	chr7:99980762~99987535:+
BRCA	cis	rs2404602	0.622	rs1567671	ENSG00000259422.1	RP11-593F23.1	-11.61	2.23e-29	2.15e-26	-0.46	-0.34	Blood metabolite levels;	chr15:76916859	chr15:76174891~76181486:-
BRCA	cis	rs9487094	0.885	rs2208209	ENSG00000260273.1	RP11-425D10.10	11.61	2.25e-29	2.17e-26	0.42	0.34	Height;	chr6:109581800	chr6:109382795~109383666:+
BRCA	cis	rs321358	0.945	rs73015199	ENSG00000271584.1	RP11-89C3.4	11.6	2.29e-29	2.21e-26	0.59	0.34	Body mass index;	chr11:111104952	chr11:111091932~111097357:-
BRCA	cis	rs858239	1	rs858239	ENSG00000226816.2	AC005082.12	11.6	2.3e-29	2.21e-26	0.4	0.34	Cerebrospinal fluid biomarker levels;	chr7:23246696	chr7:23206013~23208045:+
BRCA	cis	rs6991838	0.557	rs4737222	ENSG00000200714.1	Y_RNA	-11.6	2.3e-29	2.22e-26	-0.39	-0.34	Intelligence (multi-trait analysis);	chr8:65587878	chr8:65592731~65592820:+
BRCA	cis	rs992157	0.661	rs10171839	ENSG00000261338.2	RP11-378A13.1	11.6	2.31e-29	2.23e-26	0.35	0.34	Colorectal cancer;	chr2:218186591	chr2:218255319~218257366:+
BRCA	cis	rs6991838	0.612	rs7842162	ENSG00000272010.1	CTD-3025N20.3	11.6	2.36e-29	2.28e-26	0.36	0.34	Intelligence (multi-trait analysis);	chr8:65644057	chr8:65591850~65592472:-
BRCA	cis	rs6991838	0.584	rs1053087	ENSG00000200714.1	Y_RNA	-11.6	2.38e-29	2.29e-26	-0.4	-0.34	Intelligence (multi-trait analysis);	chr8:65603630	chr8:65592731~65592820:+
BRCA	cis	rs12134133	1	rs2782840	ENSG00000274245.1	RP11-357P18.2	11.6	2.39e-29	2.3e-26	0.46	0.34	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207310838	chr1:207372559~207373252:+
BRCA	cis	rs150992	0.655	rs327807	ENSG00000248489.1	CTD-2007H13.3	-11.6	2.47e-29	2.38e-26	-0.38	-0.34	Body mass index;	chr5:98942448	chr5:98929171~98995013:+
BRCA	cis	rs1062177	1	rs2915877	ENSG00000213433.5	RPLP1P6	-11.59	2.53e-29	2.44e-26	-0.44	-0.34	Preschool internalizing problems;	chr5:151771040	chr5:151765859~151766378:-
BRCA	cis	rs1062177	1	rs2964576	ENSG00000213433.5	RPLP1P6	-11.59	2.53e-29	2.44e-26	-0.44	-0.34	Preschool internalizing problems;	chr5:151771041	chr5:151765859~151766378:-
BRCA	cis	rs673078	0.607	rs17512644	ENSG00000275759.1	RP11-131L12.3	-11.59	2.55e-29	2.46e-26	-0.53	-0.34	Glucose homeostasis traits;	chr12:118359963	chr12:118428281~118428870:+
BRCA	cis	rs673078	0.607	rs17512652	ENSG00000275759.1	RP11-131L12.3	-11.59	2.55e-29	2.46e-26	-0.53	-0.34	Glucose homeostasis traits;	chr12:118361278	chr12:118428281~118428870:+
BRCA	cis	rs875971	0.862	rs1612452	ENSG00000222364.1	RNU6-96P	11.59	2.6e-29	2.5e-26	0.4	0.34	Aortic root size;	chr7:66108909	chr7:66395191~66395286:+
BRCA	cis	rs9487094	0.961	rs11153180	ENSG00000260273.1	RP11-425D10.10	11.59	2.61e-29	2.51e-26	0.41	0.34	Height;	chr6:109423238	chr6:109382795~109383666:+
BRCA	cis	rs1062177	1	rs973529	ENSG00000213433.5	RPLP1P6	-11.59	2.65e-29	2.55e-26	-0.43	-0.34	Preschool internalizing problems;	chr5:151808597	chr5:151765859~151766378:-
BRCA	cis	rs3779195	0.929	rs10953259	ENSG00000272950.1	RP11-307C18.1	-11.59	2.65e-29	2.55e-26	-0.53	-0.34	Sex hormone-binding globulin levels;	chr7:98383795	chr7:98322853~98323430:+
BRCA	cis	rs7586673	0.964	rs34444368	ENSG00000227403.1	AC009299.3	-11.59	2.71e-29	2.6e-26	-0.47	-0.34	Intelligence (multi-trait analysis);	chr2:161097706	chr2:161244739~161249050:+
BRCA	cis	rs9545047	0.567	rs2296287	ENSG00000227676.3	LINC01068	11.59	2.72e-29	2.61e-26	0.39	0.34	Schizophrenia;	chr13:79407045	chr13:79566727~79571436:+
BRCA	cis	rs4722166	0.695	rs35779989	ENSG00000179428.2	AC073072.5	-11.59	2.74e-29	2.64e-26	-0.36	-0.34	Lung cancer;	chr7:22760695	chr7:22725395~22727620:-
BRCA	cis	rs6991838	0.556	rs7846527	ENSG00000200714.1	Y_RNA	-11.59	2.76e-29	2.65e-26	-0.39	-0.34	Intelligence (multi-trait analysis);	chr8:65586522	chr8:65592731~65592820:+
BRCA	cis	rs6991838	0.584	rs4320587	ENSG00000200714.1	Y_RNA	-11.59	2.76e-29	2.65e-26	-0.39	-0.34	Intelligence (multi-trait analysis);	chr8:65586991	chr8:65592731~65592820:+
BRCA	cis	rs6991838	0.584	rs35941313	ENSG00000200714.1	Y_RNA	-11.59	2.76e-29	2.65e-26	-0.39	-0.34	Intelligence (multi-trait analysis);	chr8:65587498	chr8:65592731~65592820:+
BRCA	cis	rs2455601	1	rs12223690	ENSG00000254860.4	TMEM9B-AS1	11.58	2.84e-29	2.72e-26	0.42	0.34	Schizophrenia;	chr11:8880277	chr11:8964675~8977527:+
BRCA	cis	rs11676348	0.818	rs6436031	ENSG00000261338.2	RP11-378A13.1	-11.58	2.87e-29	2.76e-26	-0.36	-0.34	Ulcerative colitis;	chr2:218114536	chr2:218255319~218257366:+
BRCA	cis	rs150992	0.592	rs2455423	ENSG00000248489.1	CTD-2007H13.3	11.58	2.9e-29	2.78e-26	0.38	0.34	Body mass index;	chr5:98990844	chr5:98929171~98995013:+
BRCA	cis	rs150992	0.609	rs559574	ENSG00000248489.1	CTD-2007H13.3	11.58	2.9e-29	2.78e-26	0.38	0.34	Body mass index;	chr5:98991122	chr5:98929171~98995013:+
BRCA	cis	rs150992	0.609	rs443726	ENSG00000248489.1	CTD-2007H13.3	11.58	2.9e-29	2.78e-26	0.38	0.34	Body mass index;	chr5:98991163	chr5:98929171~98995013:+
BRCA	cis	rs150992	0.592	rs407562	ENSG00000248489.1	CTD-2007H13.3	11.58	2.9e-29	2.78e-26	0.38	0.34	Body mass index;	chr5:98991512	chr5:98929171~98995013:+
BRCA	cis	rs2455601	1	rs12418190	ENSG00000254860.4	TMEM9B-AS1	11.58	2.93e-29	2.81e-26	0.42	0.34	Schizophrenia;	chr11:8878271	chr11:8964675~8977527:+
BRCA	cis	rs9545047	0.604	rs912639	ENSG00000227676.3	LINC01068	-11.58	2.93e-29	2.81e-26	-0.39	-0.34	Schizophrenia;	chr13:79409788	chr13:79566727~79571436:+
BRCA	cis	rs321358	1	rs429803	ENSG00000271584.1	RP11-89C3.4	11.58	3e-29	2.88e-26	0.58	0.34	Body mass index;	chr11:111132263	chr11:111091932~111097357:-
BRCA	cis	rs6142102	0.602	rs11696338	ENSG00000276073.1	RP5-1125A11.7	-11.58	3.02e-29	2.9e-26	-0.39	-0.34	Skin pigmentation;	chr20:34099805	chr20:33985617~33988989:-
BRCA	cis	rs150992	0.609	rs116183885	ENSG00000248489.1	CTD-2007H13.3	11.58	3.07e-29	2.94e-26	0.38	0.34	Body mass index;	chr5:98990735	chr5:98929171~98995013:+
BRCA	cis	rs150992	0.534	rs115121903	ENSG00000248489.1	CTD-2007H13.3	11.58	3.07e-29	2.94e-26	0.38	0.34	Body mass index;	chr5:98990736	chr5:98929171~98995013:+
BRCA	cis	rs2404602	0.647	rs7181506	ENSG00000259422.1	RP11-593F23.1	11.58	3.09e-29	2.96e-26	0.44	0.34	Blood metabolite levels;	chr15:76643336	chr15:76174891~76181486:-
BRCA	cis	rs673078	0.607	rs61943443	ENSG00000275759.1	RP11-131L12.3	-11.57	3.17e-29	3.03e-26	-0.53	-0.34	Glucose homeostasis traits;	chr12:118416602	chr12:118428281~118428870:+
BRCA	cis	rs2015599	0.623	rs1072724	ENSG00000275476.1	RP11-996F15.4	11.57	3.17e-29	3.03e-26	0.39	0.34	Platelet count;Mean platelet volume;	chr12:29289205	chr12:29277397~29277882:-
BRCA	cis	rs8062405	0.754	rs28410083	ENSG00000278665.1	RP11-666O2.4	-11.57	3.22e-29	3.08e-26	-0.36	-0.34	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620039	chr16:28599241~28601881:-
BRCA	cis	rs8062405	0.789	rs1968751	ENSG00000278665.1	RP11-666O2.4	-11.57	3.22e-29	3.08e-26	-0.36	-0.34	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620438	chr16:28599241~28601881:-
BRCA	cis	rs11123170	0.542	rs28522253	ENSG00000189223.12	PAX8-AS1	-11.57	3.28e-29	3.14e-26	-0.58	-0.34	Renal function-related traits (BUN);	chr2:113209810	chr2:113211522~113276581:+
BRCA	cis	rs992157	0.56	rs6738394	ENSG00000261338.2	RP11-378A13.1	-11.57	3.33e-29	3.18e-26	-0.35	-0.34	Colorectal cancer;	chr2:218245902	chr2:218255319~218257366:+
BRCA	cis	rs9545047	0.604	rs7987193	ENSG00000227676.3	LINC01068	-11.57	3.38e-29	3.23e-26	-0.39	-0.34	Schizophrenia;	chr13:79408449	chr13:79566727~79571436:+
BRCA	cis	rs6904897	0.563	rs6569976	ENSG00000232876.1	CTA-212D2.2	-11.57	3.43e-29	3.28e-26	-0.43	-0.34	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr6:134903615	chr6:135055033~135060550:+
BRCA	cis	rs1062177	1	rs62377945	ENSG00000213433.5	RPLP1P6	-11.56	3.45e-29	3.3e-26	-0.43	-0.34	Preschool internalizing problems;	chr5:151828443	chr5:151765859~151766378:-
BRCA	cis	rs150992	0.632	rs395668	ENSG00000248489.1	CTD-2007H13.3	11.56	3.47e-29	3.32e-26	0.38	0.34	Body mass index;	chr5:98991611	chr5:98929171~98995013:+
BRCA	cis	rs150992	0.609	rs449204	ENSG00000248489.1	CTD-2007H13.3	11.56	3.47e-29	3.32e-26	0.38	0.34	Body mass index;	chr5:98991775	chr5:98929171~98995013:+
BRCA	cis	rs150992	0.609	rs378089	ENSG00000248489.1	CTD-2007H13.3	11.56	3.47e-29	3.32e-26	0.38	0.34	Body mass index;	chr5:98991818	chr5:98929171~98995013:+
BRCA	cis	rs150992	0.587	rs422127	ENSG00000248489.1	CTD-2007H13.3	11.56	3.47e-29	3.32e-26	0.38	0.34	Body mass index;	chr5:98991984	chr5:98929171~98995013:+
BRCA	cis	rs150992	0.609	rs113423144	ENSG00000248489.1	CTD-2007H13.3	11.56	3.47e-29	3.32e-26	0.38	0.34	Body mass index;	chr5:98992055	chr5:98929171~98995013:+
BRCA	cis	rs150992	0.609	rs380156	ENSG00000248489.1	CTD-2007H13.3	11.56	3.47e-29	3.32e-26	0.38	0.34	Body mass index;	chr5:98992386	chr5:98929171~98995013:+
BRCA	cis	rs321358	1	rs419633	ENSG00000271584.1	RP11-89C3.4	11.56	3.5e-29	3.34e-26	0.58	0.34	Body mass index;	chr11:111132187	chr11:111091932~111097357:-
BRCA	cis	rs7188445	1	rs7188445	ENSG00000261390.4	RP11-345M22.2	-11.56	3.5e-29	3.34e-26	-0.45	-0.34	Urate levels;	chr16:79701090	chr16:79715232~79770563:-
BRCA	cis	rs853679	0.55	rs1233704	ENSG00000220721.1	OR1F12	-11.56	3.51e-29	3.36e-26	-0.42	-0.34	Depression;	chr6:28199145	chr6:28073316~28074233:+
BRCA	cis	rs2880765	0.566	rs17553790	ENSG00000259295.5	CSPG4P12	-11.56	3.53e-29	3.38e-26	-0.44	-0.34	Coronary artery disease;	chr15:85470434	chr15:85191438~85213905:+
BRCA	cis	rs2404602	0.735	rs4886798	ENSG00000259422.1	RP11-593F23.1	11.56	3.74e-29	3.58e-26	0.45	0.34	Blood metabolite levels;	chr15:76380885	chr15:76174891~76181486:-
BRCA	cis	rs6750795	0.502	rs11685196	ENSG00000181798.2	LINC00471	-11.56	3.75e-29	3.58e-26	-0.4	-0.34	Height;	chr2:231516587	chr2:231508426~231514339:-
BRCA	cis	rs1062177	1	rs2964571	ENSG00000213433.5	RPLP1P6	-11.55	3.83e-29	3.66e-26	-0.43	-0.34	Preschool internalizing problems;	chr5:151791695	chr5:151765859~151766378:-
BRCA	cis	rs1062177	1	rs2915869	ENSG00000213433.5	RPLP1P6	-11.55	3.83e-29	3.66e-26	-0.43	-0.34	Preschool internalizing problems;	chr5:151791948	chr5:151765859~151766378:-
BRCA	cis	rs6142102	0.602	rs6142069	ENSG00000276073.1	RP5-1125A11.7	-11.55	3.9e-29	3.72e-26	-0.39	-0.34	Skin pigmentation;	chr20:33972736	chr20:33985617~33988989:-
BRCA	cis	rs9487094	0.567	rs13198879	ENSG00000260273.1	RP11-425D10.10	11.55	4.01e-29	3.83e-26	0.44	0.34	Height;	chr6:109769861	chr6:109382795~109383666:+
BRCA	cis	rs10875746	0.904	rs11168422	ENSG00000240399.1	RP1-228P16.1	-11.55	4.01e-29	3.83e-26	-0.45	-0.34	Longevity (90 years and older);	chr12:48125722	chr12:48054813~48055591:-
BRCA	cis	rs34779708	0.931	rs4934709	ENSG00000230534.5	RP11-297A16.2	-11.55	4.02e-29	3.84e-26	-0.42	-0.34	Inflammatory bowel disease;Crohn's disease;	chr10:35050396	chr10:35098006~35127020:-
BRCA	cis	rs9545047	0.604	rs9530891	ENSG00000227676.3	LINC01068	11.55	4.14e-29	3.95e-26	0.39	0.34	Schizophrenia;	chr13:79284750	chr13:79566727~79571436:+
BRCA	cis	rs858239	1	rs199357	ENSG00000226816.2	AC005082.12	-11.55	4.18e-29	3.99e-26	-0.39	-0.34	Cerebrospinal fluid biomarker levels;	chr7:23248690	chr7:23206013~23208045:+
BRCA	cis	rs992157	0.56	rs6436047	ENSG00000261338.2	RP11-378A13.1	11.55	4.19e-29	3.99e-26	0.34	0.34	Colorectal cancer;	chr2:218244190	chr2:218255319~218257366:+
BRCA	cis	rs6782228	0.509	rs2811495	ENSG00000242551.2	POU5F1P6	-11.55	4.2e-29	4.01e-26	-0.42	-0.34	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128641114	chr3:128674735~128677005:-
BRCA	cis	rs6782228	0.565	rs2811496	ENSG00000242551.2	POU5F1P6	-11.55	4.2e-29	4.01e-26	-0.42	-0.34	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128641115	chr3:128674735~128677005:-
BRCA	cis	rs10759883	0.612	rs816675	ENSG00000175611.10	LINC00476	-11.55	4.21e-29	4.01e-26	-0.4	-0.34	Nicotine dependence;	chr9:95806799	chr9:95759231~95875977:-
BRCA	cis	rs10759883	0.627	rs816674	ENSG00000175611.10	LINC00476	-11.55	4.21e-29	4.01e-26	-0.4	-0.34	Nicotine dependence;	chr9:95807835	chr9:95759231~95875977:-
BRCA	cis	rs6991838	0.584	rs16932250	ENSG00000200714.1	Y_RNA	-11.54	4.29e-29	4.08e-26	-0.4	-0.34	Intelligence (multi-trait analysis);	chr8:65598779	chr8:65592731~65592820:+
BRCA	cis	rs10875746	0.729	rs11168355	ENSG00000240399.1	RP1-228P16.1	11.54	4.35e-29	4.14e-26	0.44	0.34	Longevity (90 years and older);	chr12:48017195	chr12:48054813~48055591:-
BRCA	cis	rs875971	0.861	rs801215	ENSG00000222364.1	RNU6-96P	11.54	4.35e-29	4.14e-26	0.4	0.34	Aortic root size;	chr7:66546951	chr7:66395191~66395286:+
BRCA	cis	rs10759883	0.587	rs6478977	ENSG00000175611.10	LINC00476	-11.54	4.4e-29	4.19e-26	-0.39	-0.34	Nicotine dependence;	chr9:95797994	chr9:95759231~95875977:-
BRCA	cis	rs12922040	0.651	rs35288467	ENSG00000263335.1	AF001548.5	-11.54	4.41e-29	4.2e-26	-0.4	-0.34	Serum uric acid levels in response to allopurinol in gout;	chr16:15773097	chr16:15726674~15732993:+
BRCA	cis	rs1062177	0.95	rs892005	ENSG00000213433.5	RPLP1P6	-11.54	4.49e-29	4.28e-26	-0.43	-0.34	Preschool internalizing problems;	chr5:151801060	chr5:151765859~151766378:-
BRCA	cis	rs9487094	0.961	rs12206928	ENSG00000260273.1	RP11-425D10.10	11.54	4.5e-29	4.28e-26	0.41	0.34	Height;	chr6:109357908	chr6:109382795~109383666:+
BRCA	cis	rs2404602	0.684	rs157759	ENSG00000259422.1	RP11-593F23.1	11.54	4.51e-29	4.29e-26	0.43	0.34	Blood metabolite levels;	chr15:76554649	chr15:76174891~76181486:-
BRCA	cis	rs6991838	0.584	rs16932245	ENSG00000200714.1	Y_RNA	-11.54	4.59e-29	4.37e-26	-0.4	-0.34	Intelligence (multi-trait analysis);	chr8:65597810	chr8:65592731~65592820:+
BRCA	cis	rs6991838	0.557	rs57419568	ENSG00000200714.1	Y_RNA	-11.54	4.59e-29	4.37e-26	-0.4	-0.34	Intelligence (multi-trait analysis);	chr8:65598633	chr8:65592731~65592820:+
BRCA	cis	rs6142102	0.602	rs2300209	ENSG00000276073.1	RP5-1125A11.7	-11.54	4.64e-29	4.41e-26	-0.39	-0.34	Skin pigmentation;	chr20:34055294	chr20:33985617~33988989:-
BRCA	cis	rs9487094	0.848	rs1322816	ENSG00000260273.1	RP11-425D10.10	11.53	4.7e-29	4.47e-26	0.41	0.34	Height;	chr6:109382524	chr6:109382795~109383666:+
BRCA	cis	rs2283792	0.905	rs5755694	ENSG00000224086.5	LL22NC03-86G7.1	-11.53	4.77e-29	4.54e-26	-0.35	-0.34	Multiple sclerosis;	chr22:21846241	chr22:21938293~21977632:+
BRCA	cis	rs1062177	1	rs6890099	ENSG00000213433.5	RPLP1P6	-11.53	4.8e-29	4.56e-26	-0.43	-0.34	Preschool internalizing problems;	chr5:151772401	chr5:151765859~151766378:-
BRCA	cis	rs10759883	0.651	rs7852346	ENSG00000175611.10	LINC00476	-11.53	4.88e-29	4.64e-26	-0.39	-0.34	Nicotine dependence;	chr9:95786167	chr9:95759231~95875977:-
BRCA	cis	rs150992	0.609	rs2927648	ENSG00000248489.1	CTD-2007H13.3	11.53	4.88e-29	4.64e-26	0.38	0.34	Body mass index;	chr5:98990273	chr5:98929171~98995013:+
BRCA	cis	rs2015599	0.623	rs7358667	ENSG00000275476.1	RP11-996F15.4	11.53	4.97e-29	4.72e-26	0.39	0.34	Platelet count;Mean platelet volume;	chr12:29290236	chr12:29277397~29277882:-
BRCA	cis	rs2153535	0.58	rs2225766	ENSG00000230939.1	RP11-314C16.1	-11.53	5.08e-29	4.82e-26	-0.4	-0.34	Motion sickness;	chr6:8481600	chr6:8784178~8785445:+
BRCA	cis	rs3779195	0.627	rs6950023	ENSG00000272950.1	RP11-307C18.1	11.53	5.12e-29	4.87e-26	0.55	0.34	Sex hormone-binding globulin levels;	chr7:98286323	chr7:98322853~98323430:+
BRCA	cis	rs3779195	0.627	rs6967728	ENSG00000272950.1	RP11-307C18.1	11.53	5.12e-29	4.87e-26	0.55	0.34	Sex hormone-binding globulin levels;	chr7:98286325	chr7:98322853~98323430:+
BRCA	cis	rs875971	0.756	rs2901210	ENSG00000222364.1	RNU6-96P	11.53	5.14e-29	4.88e-26	0.4	0.34	Aortic root size;	chr7:66552518	chr7:66395191~66395286:+
BRCA	cis	rs11676348	0.783	rs13035513	ENSG00000261338.2	RP11-378A13.1	-11.52	5.25e-29	4.98e-26	-0.36	-0.34	Ulcerative colitis;	chr2:218095957	chr2:218255319~218257366:+
BRCA	cis	rs7044106	0.537	rs10818474	ENSG00000226752.6	PSMD5-AS1	-11.52	5.28e-29	5.01e-26	-0.42	-0.34	Hip circumference adjusted for BMI;	chr9:120727686	chr9:120824828~120854385:+
BRCA	cis	rs9487094	0.885	rs13212766	ENSG00000260273.1	RP11-425D10.10	11.52	5.3e-29	5.03e-26	0.41	0.34	Height;	chr6:109384228	chr6:109382795~109383666:+
BRCA	cis	rs9487094	0.961	rs3757234	ENSG00000260273.1	RP11-425D10.10	11.52	5.3e-29	5.03e-26	0.41	0.34	Height;	chr6:109385087	chr6:109382795~109383666:+
BRCA	cis	rs673078	0.607	rs17440893	ENSG00000275759.1	RP11-131L12.3	-11.52	5.31e-29	5.03e-26	-0.52	-0.34	Glucose homeostasis traits;	chr12:118362532	chr12:118428281~118428870:+
BRCA	cis	rs55665837	1	rs11023215	ENSG00000251991.1	RNU7-49P	11.52	5.36e-29	5.08e-26	0.37	0.34	Vitamin D levels;	chr11:14415424	chr11:14478892~14478953:+
BRCA	cis	rs7829975	0.564	rs2976855	ENSG00000253893.2	FAM85B	-11.52	5.36e-29	5.08e-26	-0.43	-0.34	Mood instability;	chr8:8444284	chr8:8167819~8226614:-
BRCA	cis	rs1062177	1	rs12518722	ENSG00000213433.5	RPLP1P6	-11.52	5.4e-29	5.12e-26	-0.44	-0.34	Preschool internalizing problems;	chr5:151851899	chr5:151765859~151766378:-
BRCA	cis	rs10759883	0.603	rs10985156	ENSG00000175611.10	LINC00476	11.52	5.4e-29	5.12e-26	0.39	0.34	Nicotine dependence;	chr9:95831462	chr9:95759231~95875977:-
BRCA	cis	rs7301826	0.934	rs10848212	ENSG00000256299.1	RP11-989F5.3	11.52	5.48e-29	5.19e-26	0.38	0.34	Plasma plasminogen activator levels;	chr12:130837455	chr12:130810821~130812622:-
BRCA	cis	rs8059260	0.668	rs16957894	ENSG00000274038.1	RP11-66H6.4	-11.52	5.55e-29	5.26e-26	-0.52	-0.34	Alcohol consumption over the past year;	chr16:10996501	chr16:11056556~11057034:+
BRCA	cis	rs853679	0.517	rs1340004	ENSG00000220721.1	OR1F12	11.52	5.58e-29	5.29e-26	0.45	0.34	Depression;	chr6:28135913	chr6:28073316~28074233:+
BRCA	cis	rs9545047	0.604	rs9601227	ENSG00000227676.3	LINC01068	-11.52	5.63e-29	5.34e-26	-0.4	-0.34	Schizophrenia;	chr13:79420805	chr13:79566727~79571436:+
BRCA	cis	rs801193	0.569	rs10950050	ENSG00000222364.1	RNU6-96P	-11.52	5.64e-29	5.35e-26	-0.39	-0.34	Aortic root size;	chr7:66774601	chr7:66395191~66395286:+
BRCA	cis	rs2658782	0.724	rs2605629	ENSG00000279684.1	RP11-755E23.2	11.52	5.73e-29	5.43e-26	0.5	0.34	Pulmonary function decline;	chr11:93530871	chr11:93286629~93288903:-
BRCA	cis	rs7829975	0.564	rs2921060	ENSG00000253893.2	FAM85B	11.51	5.83e-29	5.52e-26	0.43	0.34	Mood instability;	chr8:8460307	chr8:8167819~8226614:-
BRCA	cis	rs10129255	1	rs11627342	ENSG00000211970.3	IGHV4-61	-11.51	5.86e-29	5.54e-26	-0.25	-0.34	Kawasaki disease;	chr14:106675823	chr14:106639119~106639657:-
BRCA	cis	rs8040855	0.627	rs12909971	ENSG00000259295.5	CSPG4P12	11.51	5.88e-29	5.57e-26	0.47	0.34	Bulimia nervosa;	chr15:85045767	chr15:85191438~85213905:+
BRCA	cis	rs2015599	0.623	rs3782505	ENSG00000275476.1	RP11-996F15.4	11.51	5.91e-29	5.6e-26	0.39	0.34	Platelet count;Mean platelet volume;	chr12:29292236	chr12:29277397~29277882:-
BRCA	cis	rs673078	0.607	rs7299040	ENSG00000275759.1	RP11-131L12.3	-11.51	6.05e-29	5.73e-26	-0.53	-0.34	Glucose homeostasis traits;	chr12:118380660	chr12:118428281~118428870:+
BRCA	cis	rs11123170	0.543	rs4849180	ENSG00000274877.1	RP11-65I12.1	-11.51	6.06e-29	5.73e-26	-0.55	-0.34	Renal function-related traits (BUN);	chr2:113227609	chr2:113237595~113240825:+
BRCA	cis	rs9487094	0.744	rs13212535	ENSG00000260273.1	RP11-425D10.10	11.51	6.12e-29	5.79e-26	0.45	0.34	Height;	chr6:109713188	chr6:109382795~109383666:+
BRCA	cis	rs801193	0.66	rs2659897	ENSG00000222364.1	RNU6-96P	11.51	6.23e-29	5.89e-26	0.39	0.34	Aortic root size;	chr7:66722728	chr7:66395191~66395286:+
BRCA	cis	rs9322193	0.923	rs9766004	ENSG00000223701.3	RAET1E-AS1	11.51	6.25e-29	5.91e-26	0.41	0.34	Lung cancer;	chr6:149754363	chr6:149884431~149919508:+
BRCA	cis	rs875971	0.862	rs2024192	ENSG00000222364.1	RNU6-96P	11.51	6.31e-29	5.96e-26	0.4	0.34	Aortic root size;	chr7:66576460	chr7:66395191~66395286:+
BRCA	cis	rs1062177	1	rs41494545	ENSG00000213433.5	RPLP1P6	11.51	6.32e-29	5.98e-26	0.44	0.34	Preschool internalizing problems;	chr5:151855533	chr5:151765859~151766378:-
BRCA	cis	rs150992	0.593	rs326491	ENSG00000248489.1	CTD-2007H13.3	11.51	6.32e-29	5.98e-26	0.38	0.34	Body mass index;	chr5:98972225	chr5:98929171~98995013:+
BRCA	cis	rs801193	0.66	rs2659914	ENSG00000222364.1	RNU6-96P	-11.5	6.39e-29	6.04e-26	-0.39	-0.34	Aortic root size;	chr7:66691927	chr7:66395191~66395286:+
BRCA	cis	rs801193	0.591	rs2707839	ENSG00000222364.1	RNU6-96P	-11.5	6.39e-29	6.04e-26	-0.39	-0.34	Aortic root size;	chr7:66728097	chr7:66395191~66395286:+
BRCA	cis	rs2404602	0.735	rs4886805	ENSG00000259422.1	RP11-593F23.1	11.5	6.56e-29	6.19e-26	0.44	0.34	Blood metabolite levels;	chr15:76447043	chr15:76174891~76181486:-
BRCA	cis	rs10935480	0.551	rs34070949	ENSG00000239445.4	ST3GAL6-AS1	-11.5	6.59e-29	6.23e-26	-0.36	-0.34	Blood protein levels;	chr3:98635347	chr3:98714330~98732651:-
BRCA	cis	rs6991838	0.584	rs7812446	ENSG00000200714.1	Y_RNA	-11.5	6.68e-29	6.31e-26	-0.39	-0.34	Intelligence (multi-trait analysis);	chr8:65593753	chr8:65592731~65592820:+
BRCA	cis	rs6991838	0.557	rs7812390	ENSG00000200714.1	Y_RNA	-11.5	6.68e-29	6.31e-26	-0.39	-0.34	Intelligence (multi-trait analysis);	chr8:65593982	chr8:65592731~65592820:+
BRCA	cis	rs1062177	1	rs2347596	ENSG00000213433.5	RPLP1P6	-11.5	6.77e-29	6.4e-26	-0.43	-0.34	Preschool internalizing problems;	chr5:151799638	chr5:151765859~151766378:-
BRCA	cis	rs150992	0.609	rs7711061	ENSG00000248489.1	CTD-2007H13.3	-11.5	6.82e-29	6.44e-26	-0.38	-0.34	Body mass index;	chr5:99003535	chr5:98929171~98995013:+
BRCA	cis	rs2455601	1	rs7104661	ENSG00000254860.4	TMEM9B-AS1	11.5	6.85e-29	6.46e-26	0.42	0.34	Schizophrenia;	chr11:8880954	chr11:8964675~8977527:+
BRCA	cis	rs67311347	1	rs9874499	ENSG00000223797.4	ENTPD3-AS1	11.5	6.91e-29	6.53e-26	0.38	0.34	Renal cell carcinoma;	chr3:40400417	chr3:40313802~40453329:-
BRCA	cis	rs2015599	0.549	rs7134796	ENSG00000275476.1	RP11-996F15.4	11.5	6.94e-29	6.55e-26	0.39	0.34	Platelet count;Mean platelet volume;	chr12:29294361	chr12:29277397~29277882:-
BRCA	cis	rs875971	1	rs1167612	ENSG00000222364.1	RNU6-96P	11.49	7.08e-29	6.68e-26	0.39	0.34	Aortic root size;	chr7:66102989	chr7:66395191~66395286:+
BRCA	cis	rs4722166	0.695	rs7808122	ENSG00000179428.2	AC073072.5	-11.49	7.27e-29	6.85e-26	-0.35	-0.34	Lung cancer;	chr7:22758461	chr7:22725395~22727620:-
BRCA	cis	rs11676348	0.818	rs7423433	ENSG00000261338.2	RP11-378A13.1	-11.49	7.35e-29	6.93e-26	-0.36	-0.34	Ulcerative colitis;	chr2:218120361	chr2:218255319~218257366:+
BRCA	cis	rs9487094	0.885	rs1590306	ENSG00000260273.1	RP11-425D10.10	11.49	7.38e-29	6.96e-26	0.41	0.34	Height;	chr6:109359747	chr6:109382795~109383666:+
BRCA	cis	rs875971	0.862	rs35378740	ENSG00000222364.1	RNU6-96P	-11.49	7.43e-29	7e-26	-0.39	-0.34	Aortic root size;	chr7:66522725	chr7:66395191~66395286:+
BRCA	cis	rs12134133	1	rs2782842	ENSG00000274245.1	RP11-357P18.2	11.49	7.49e-29	7.06e-26	0.45	0.34	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207310231	chr1:207372559~207373252:+
BRCA	cis	rs875971	0.862	rs13232191	ENSG00000222364.1	RNU6-96P	-11.49	7.5e-29	7.06e-26	-0.39	-0.34	Aortic root size;	chr7:66521661	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.862	rs10950043	ENSG00000222364.1	RNU6-96P	-11.49	7.5e-29	7.06e-26	-0.39	-0.34	Aortic root size;	chr7:66523623	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.862	rs17747530	ENSG00000222364.1	RNU6-96P	-11.49	7.5e-29	7.06e-26	-0.39	-0.34	Aortic root size;	chr7:66529742	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.862	rs13536	ENSG00000222364.1	RNU6-96P	11.49	7.5e-29	7.06e-26	0.39	0.34	Aortic root size;	chr7:66554203	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.862	rs801209	ENSG00000222364.1	RNU6-96P	11.49	7.5e-29	7.06e-26	0.39	0.34	Aortic root size;	chr7:66554403	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.862	rs801206	ENSG00000222364.1	RNU6-96P	11.49	7.5e-29	7.06e-26	0.39	0.34	Aortic root size;	chr7:66556979	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.862	rs801204	ENSG00000222364.1	RNU6-96P	11.49	7.5e-29	7.06e-26	0.39	0.34	Aortic root size;	chr7:66557934	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.862	rs801203	ENSG00000222364.1	RNU6-96P	11.49	7.5e-29	7.06e-26	0.39	0.34	Aortic root size;	chr7:66558025	chr7:66395191~66395286:+
BRCA	cis	rs8072100	0.84	rs9912311	ENSG00000228782.6	CTD-2026D20.3	11.49	7.5e-29	7.07e-26	0.36	0.34	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47469766	chr17:47450568~47492492:-
BRCA	cis	rs2404602	0.647	rs11631394	ENSG00000259422.1	RP11-593F23.1	-11.49	7.57e-29	7.13e-26	-0.43	-0.34	Blood metabolite levels;	chr15:76680868	chr15:76174891~76181486:-
BRCA	cis	rs9487094	0.961	rs9480957	ENSG00000260273.1	RP11-425D10.10	11.49	7.57e-29	7.13e-26	0.41	0.34	Height;	chr6:109430398	chr6:109382795~109383666:+
BRCA	cis	rs9545047	0.604	rs1853830	ENSG00000227676.3	LINC01068	-11.49	7.59e-29	7.15e-26	-0.39	-0.34	Schizophrenia;	chr13:79406877	chr13:79566727~79571436:+
BRCA	cis	rs1062177	1	rs17741826	ENSG00000213433.5	RPLP1P6	11.49	7.71e-29	7.26e-26	0.44	0.34	Preschool internalizing problems;	chr5:151769701	chr5:151765859~151766378:-
BRCA	cis	rs11676348	0.811	rs4674255	ENSG00000261338.2	RP11-378A13.1	-11.49	7.72e-29	7.26e-26	-0.36	-0.34	Ulcerative colitis;	chr2:218122602	chr2:218255319~218257366:+
BRCA	cis	rs673078	0.607	rs73207504	ENSG00000275759.1	RP11-131L12.3	-11.49	7.74e-29	7.28e-26	-0.53	-0.34	Glucose homeostasis traits;	chr12:118427914	chr12:118428281~118428870:+
BRCA	cis	rs1062177	1	rs2964578	ENSG00000213433.5	RPLP1P6	-11.49	7.8e-29	7.34e-26	-0.44	-0.34	Preschool internalizing problems;	chr5:151767637	chr5:151765859~151766378:-
BRCA	cis	rs11676348	0.818	rs7425447	ENSG00000261338.2	RP11-378A13.1	-11.49	7.81e-29	7.35e-26	-0.36	-0.34	Ulcerative colitis;	chr2:218115460	chr2:218255319~218257366:+
BRCA	cis	rs150992	0.79	rs325220	ENSG00000248489.1	CTD-2007H13.3	11.48	8.13e-29	7.65e-26	0.38	0.34	Body mass index;	chr5:98968860	chr5:98929171~98995013:+
BRCA	cis	rs150992	0.72	rs469018	ENSG00000248489.1	CTD-2007H13.3	11.48	8.21e-29	7.72e-26	0.37	0.34	Body mass index;	chr5:98953530	chr5:98929171~98995013:+
BRCA	cis	rs150992	0.714	rs76798907	ENSG00000248489.1	CTD-2007H13.3	11.48	8.29e-29	7.79e-26	0.38	0.34	Body mass index;	chr5:98990780	chr5:98929171~98995013:+
BRCA	cis	rs875971	0.862	rs10263690	ENSG00000222364.1	RNU6-96P	11.48	8.32e-29	7.82e-26	0.39	0.34	Aortic root size;	chr7:66301466	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.862	rs10250544	ENSG00000222364.1	RNU6-96P	11.48	8.32e-29	7.82e-26	0.39	0.34	Aortic root size;	chr7:66301574	chr7:66395191~66395286:+
BRCA	cis	rs5769707	0.521	rs739244	ENSG00000188511.11	C22orf34	11.48	8.32e-29	7.82e-26	0.35	0.34	Monocyte percentage of white cells;Monocyte count;	chr22:49666510	chr22:49414524~49657542:-
BRCA	cis	rs11676348	0.714	rs4674254	ENSG00000261338.2	RP11-378A13.1	-11.48	8.42e-29	7.91e-26	-0.36	-0.34	Ulcerative colitis;	chr2:218121354	chr2:218255319~218257366:+
BRCA	cis	rs11676348	0.818	rs4674256	ENSG00000261338.2	RP11-378A13.1	-11.48	8.42e-29	7.91e-26	-0.36	-0.34	Ulcerative colitis;	chr2:218123170	chr2:218255319~218257366:+
BRCA	cis	rs494459	0.838	rs555649	ENSG00000255422.1	AP002954.4	-11.48	8.45e-29	7.95e-26	-0.39	-0.34	Height;	chr11:118781100	chr11:118704607~118750263:+
BRCA	cis	rs321358	0.943	rs402820	ENSG00000271584.1	RP11-89C3.4	11.48	8.47e-29	7.96e-26	0.58	0.34	Body mass index;	chr11:111132480	chr11:111091932~111097357:-
BRCA	cis	rs1062177	1	rs1062177	ENSG00000213433.5	RPLP1P6	-11.48	8.52e-29	8e-26	-0.43	-0.34	Preschool internalizing problems;	chr5:151805140	chr5:151765859~151766378:-
BRCA	cis	rs11676348	0.846	rs3890158	ENSG00000261338.2	RP11-378A13.1	-11.48	8.64e-29	8.12e-26	-0.36	-0.33	Ulcerative colitis;	chr2:218125569	chr2:218255319~218257366:+
BRCA	cis	rs4727443	1	rs6974373	ENSG00000214313.7	AZGP1P1	-11.48	8.66e-29	8.14e-26	-0.34	-0.33	Interstitial lung disease;	chr7:99993270	chr7:99980762~99987535:+
BRCA	cis	rs875971	0.862	rs13226170	ENSG00000222364.1	RNU6-96P	-11.47	8.76e-29	8.23e-26	-0.39	-0.33	Aortic root size;	chr7:66534311	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.862	rs2420611	ENSG00000222364.1	RNU6-96P	-11.47	8.76e-29	8.23e-26	-0.39	-0.33	Aortic root size;	chr7:66534333	chr7:66395191~66395286:+
BRCA	cis	rs2404602	0.647	rs3812909	ENSG00000259422.1	RP11-593F23.1	-11.47	8.77e-29	8.24e-26	-0.43	-0.33	Blood metabolite levels;	chr15:76883859	chr15:76174891~76181486:-
BRCA	cis	rs875971	0.964	rs697969	ENSG00000222364.1	RNU6-96P	11.47	8.8e-29	8.27e-26	0.39	0.33	Aortic root size;	chr7:66093491	chr7:66395191~66395286:+
BRCA	cis	rs875971	1	rs1182882	ENSG00000222364.1	RNU6-96P	11.47	8.8e-29	8.27e-26	0.39	0.33	Aortic root size;	chr7:66097076	chr7:66395191~66395286:+
BRCA	cis	rs9545047	0.604	rs7332367	ENSG00000227676.3	LINC01068	-11.47	8.8e-29	8.27e-26	-0.39	-0.33	Schizophrenia;	chr13:79339816	chr13:79566727~79571436:+
BRCA	cis	rs9487094	0.961	rs1923725	ENSG00000260273.1	RP11-425D10.10	11.47	8.81e-29	8.27e-26	0.41	0.33	Height;	chr6:109387685	chr6:109382795~109383666:+
BRCA	cis	rs9487094	0.961	rs12524639	ENSG00000260273.1	RP11-425D10.10	11.47	8.81e-29	8.27e-26	0.41	0.33	Height;	chr6:109388256	chr6:109382795~109383666:+
BRCA	cis	rs2404602	0.647	rs11072607	ENSG00000259422.1	RP11-593F23.1	-11.47	8.82e-29	8.29e-26	-0.44	-0.33	Blood metabolite levels;	chr15:76616188	chr15:76174891~76181486:-
BRCA	cis	rs12134133	1	rs2661357	ENSG00000274245.1	RP11-357P18.2	11.47	8.86e-29	8.32e-26	0.45	0.33	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207310593	chr1:207372559~207373252:+
BRCA	cis	rs1062177	1	rs2915880	ENSG00000213433.5	RPLP1P6	-11.47	8.96e-29	8.41e-26	-0.43	-0.33	Preschool internalizing problems;	chr5:151767773	chr5:151765859~151766378:-
BRCA	cis	rs4423214	0.879	rs1792284	ENSG00000254682.1	RP11-660L16.2	11.47	9.04e-29	8.48e-26	0.46	0.33	Vitamin D levels;	chr11:71423920	chr11:71448674~71452157:+
BRCA	cis	rs6991838	0.557	rs7012578	ENSG00000200714.1	Y_RNA	-11.47	9.1e-29	8.54e-26	-0.39	-0.33	Intelligence (multi-trait analysis);	chr8:65592592	chr8:65592731~65592820:+
BRCA	cis	rs875971	0.755	rs76288834	ENSG00000222364.1	RNU6-96P	11.47	9.22e-29	8.65e-26	0.4	0.33	Aortic root size;	chr7:66604815	chr7:66395191~66395286:+
BRCA	cis	rs801193	0.66	rs10950049	ENSG00000222364.1	RNU6-96P	-11.47	9.29e-29	8.71e-26	-0.39	-0.33	Aortic root size;	chr7:66765873	chr7:66395191~66395286:+
BRCA	cis	rs150992	0.609	rs2937709	ENSG00000248489.1	CTD-2007H13.3	11.47	9.36e-29	8.78e-26	0.38	0.33	Body mass index;	chr5:98993120	chr5:98929171~98995013:+
BRCA	cis	rs150992	0.632	rs1104262	ENSG00000248489.1	CTD-2007H13.3	11.47	9.36e-29	8.78e-26	0.38	0.33	Body mass index;	chr5:98993145	chr5:98929171~98995013:+
BRCA	cis	rs67311347	1	rs9822909	ENSG00000223797.4	ENTPD3-AS1	11.47	9.36e-29	8.78e-26	0.41	0.33	Renal cell carcinoma;	chr3:40415593	chr3:40313802~40453329:-
BRCA	cis	rs801193	0.66	rs1016265	ENSG00000222364.1	RNU6-96P	-11.47	9.42e-29	8.83e-26	-0.39	-0.33	Aortic root size;	chr7:66749580	chr7:66395191~66395286:+
BRCA	cis	rs801193	0.66	rs4610622	ENSG00000222364.1	RNU6-96P	-11.47	9.42e-29	8.83e-26	-0.39	-0.33	Aortic root size;	chr7:66759510	chr7:66395191~66395286:+
BRCA	cis	rs875971	1	rs10244498	ENSG00000222364.1	RNU6-96P	-11.47	9.57e-29	8.97e-26	-0.39	-0.33	Aortic root size;	chr7:66651069	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.862	rs11984115	ENSG00000222364.1	RNU6-96P	11.46	9.78e-29	9.17e-26	0.4	0.33	Aortic root size;	chr7:66308872	chr7:66395191~66395286:+
BRCA	cis	rs11123170	0.543	rs35222158	ENSG00000274877.1	RP11-65I12.1	-11.46	1.04e-28	9.73e-26	-0.55	-0.33	Renal function-related traits (BUN);	chr2:113229052	chr2:113237595~113240825:+
BRCA	cis	rs2739330	0.796	rs1006771	ENSG00000231271.1	AP000350.8	11.46	1.05e-28	9.81e-26	0.42	0.33	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23949918~23954042:+
BRCA	cis	rs9318086	0.712	rs9318099	ENSG00000205861.10	C1QTNF9B-AS1	11.46	1.06e-28	9.88e-26	0.42	0.33	Myopia (pathological);	chr13:23868323	chr13:23888889~23897263:+
BRCA	cis	rs11676348	0.783	rs4674252	ENSG00000261338.2	RP11-378A13.1	-11.46	1.06e-28	9.95e-26	-0.36	-0.33	Ulcerative colitis;	chr2:218119755	chr2:218255319~218257366:+
BRCA	cis	rs801193	0.548	rs2659904	ENSG00000222364.1	RNU6-96P	-11.45	1.08e-28	1.01e-25	-0.39	-0.33	Aortic root size;	chr7:66713615	chr7:66395191~66395286:+
BRCA	cis	rs2455601	1	rs56336128	ENSG00000254860.4	TMEM9B-AS1	11.45	1.09e-28	1.02e-25	0.42	0.33	Schizophrenia;	chr11:8886752	chr11:8964675~8977527:+
BRCA	cis	rs2117029	0.555	rs2279596	ENSG00000258017.1	RP11-386G11.10	-11.45	1.1e-28	1.03e-25	-0.45	-0.33	Intelligence (multi-trait analysis);	chr12:49104968	chr12:49127782~49147869:+
BRCA	cis	rs6142102	0.58	rs6142101	ENSG00000276073.1	RP5-1125A11.7	-11.45	1.11e-28	1.03e-25	-0.39	-0.33	Skin pigmentation;	chr20:34110039	chr20:33985617~33988989:-
BRCA	cis	rs9545047	0.604	rs9565497	ENSG00000227676.3	LINC01068	-11.45	1.12e-28	1.05e-25	-0.39	-0.33	Schizophrenia;	chr13:79406330	chr13:79566727~79571436:+
BRCA	cis	rs150992	0.609	rs366000	ENSG00000248489.1	CTD-2007H13.3	-11.45	1.12e-28	1.05e-25	-0.37	-0.33	Body mass index;	chr5:98991705	chr5:98929171~98995013:+
BRCA	cis	rs9487094	0.922	rs11153181	ENSG00000260273.1	RP11-425D10.10	11.45	1.13e-28	1.06e-25	0.41	0.33	Height;	chr6:109428824	chr6:109382795~109383666:+
BRCA	cis	rs4727443	1	rs4727443	ENSG00000214313.7	AZGP1P1	-11.45	1.14e-28	1.06e-25	-0.34	-0.33	Interstitial lung disease;	chr7:99995723	chr7:99980762~99987535:+
BRCA	cis	rs875971	0.895	rs12531677	ENSG00000222364.1	RNU6-96P	11.45	1.15e-28	1.07e-25	0.39	0.33	Aortic root size;	chr7:66304099	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.862	rs7798630	ENSG00000222364.1	RNU6-96P	11.45	1.15e-28	1.07e-25	0.39	0.33	Aortic root size;	chr7:66306492	chr7:66395191~66395286:+
BRCA	cis	rs11673344	0.801	rs76806623	ENSG00000226686.6	LINC01535	11.45	1.18e-28	1.1e-25	0.47	0.33	Obesity-related traits;	chr19:37132525	chr19:37251912~37265535:+
BRCA	cis	rs1062177	1	rs2915882	ENSG00000213433.5	RPLP1P6	-11.44	1.18e-28	1.11e-25	-0.43	-0.33	Preschool internalizing problems;	chr5:151765875	chr5:151765859~151766378:-
BRCA	cis	rs10759883	0.627	rs816683	ENSG00000175611.10	LINC00476	-11.44	1.2e-28	1.12e-25	-0.39	-0.33	Nicotine dependence;	chr9:95822819	chr9:95759231~95875977:-
BRCA	cis	rs875971	0.862	rs2088653	ENSG00000222364.1	RNU6-96P	11.44	1.21e-28	1.13e-25	0.39	0.33	Aortic root size;	chr7:66343621	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.862	rs6460293	ENSG00000222364.1	RNU6-96P	11.44	1.21e-28	1.13e-25	0.39	0.33	Aortic root size;	chr7:66345205	chr7:66395191~66395286:+
BRCA	cis	rs10256972	0.684	rs4724039	ENSG00000229043.2	AC091729.9	-11.44	1.21e-28	1.13e-25	-0.42	-0.33	Endometriosis;Longevity;	chr7:1071997	chr7:1160374~1165267:+
BRCA	cis	rs1062177	1	rs2915878	ENSG00000213433.5	RPLP1P6	-11.44	1.22e-28	1.14e-25	-0.43	-0.33	Preschool internalizing problems;	chr5:151770101	chr5:151765859~151766378:-
BRCA	cis	rs9487094	0.922	rs12208933	ENSG00000260273.1	RP11-425D10.10	11.44	1.22e-28	1.14e-25	0.42	0.33	Height;	chr6:109582583	chr6:109382795~109383666:+
BRCA	cis	rs2658782	0.724	rs2605626	ENSG00000279684.1	RP11-755E23.2	-11.44	1.23e-28	1.15e-25	-0.49	-0.33	Pulmonary function decline;	chr11:93520737	chr11:93286629~93288903:-
BRCA	cis	rs6142102	0.58	rs761233	ENSG00000276073.1	RP5-1125A11.7	-11.44	1.25e-28	1.16e-25	-0.38	-0.33	Skin pigmentation;	chr20:33981080	chr20:33985617~33988989:-
BRCA	cis	rs10759883	0.651	rs816670	ENSG00000175611.10	LINC00476	-11.44	1.25e-28	1.16e-25	-0.39	-0.33	Nicotine dependence;	chr9:95813152	chr9:95759231~95875977:-
BRCA	cis	rs3779195	0.929	rs2906184	ENSG00000272950.1	RP11-307C18.1	-11.44	1.26e-28	1.17e-25	-0.53	-0.33	Sex hormone-binding globulin levels;	chr7:98310675	chr7:98322853~98323430:+
BRCA	cis	rs801193	0.66	rs974239	ENSG00000222364.1	RNU6-96P	-11.44	1.28e-28	1.2e-25	-0.39	-0.33	Aortic root size;	chr7:66748504	chr7:66395191~66395286:+
BRCA	cis	rs8040855	0.576	rs62022527	ENSG00000259295.5	CSPG4P12	11.44	1.29e-28	1.2e-25	0.49	0.33	Bulimia nervosa;	chr15:84988022	chr15:85191438~85213905:+
BRCA	cis	rs11673344	0.832	rs11540540	ENSG00000226686.6	LINC01535	11.44	1.29e-28	1.21e-25	0.47	0.33	Obesity-related traits;	chr19:37129629	chr19:37251912~37265535:+
BRCA	cis	rs2442825	0.693	rs2728928	ENSG00000206573.7	THUMPD3-AS1	-11.44	1.3e-28	1.21e-25	-0.29	-0.33	Cerebrospinal fluid clusterin levels;	chr3:9388275	chr3:9349689~9398579:-
BRCA	cis	rs875971	0.755	rs10228885	ENSG00000222364.1	RNU6-96P	11.44	1.31e-28	1.22e-25	0.39	0.33	Aortic root size;	chr7:66315542	chr7:66395191~66395286:+
BRCA	cis	rs801193	0.636	rs2659895	ENSG00000222364.1	RNU6-96P	-11.43	1.32e-28	1.23e-25	-0.39	-0.33	Aortic root size;	chr7:66731484	chr7:66395191~66395286:+
BRCA	cis	rs9545047	0.604	rs1028770	ENSG00000227676.3	LINC01068	-11.43	1.33e-28	1.24e-25	-0.38	-0.33	Schizophrenia;	chr13:79297346	chr13:79566727~79571436:+
BRCA	cis	rs10875746	0.859	rs11168371	ENSG00000240399.1	RP1-228P16.1	-11.43	1.35e-28	1.26e-25	-0.45	-0.33	Longevity (90 years and older);	chr12:48043903	chr12:48054813~48055591:-
BRCA	cis	rs10759883	0.627	rs10760189	ENSG00000175611.10	LINC00476	11.43	1.35e-28	1.26e-25	0.39	0.33	Nicotine dependence;	chr9:95838543	chr9:95759231~95875977:-
BRCA	cis	rs6991838	0.584	rs2175810	ENSG00000200714.1	Y_RNA	-11.43	1.36e-28	1.27e-25	-0.38	-0.33	Intelligence (multi-trait analysis);	chr8:65643583	chr8:65592731~65592820:+
BRCA	cis	rs7743045	0.625	rs9387628	ENSG00000253194.1	RP11-351A11.1	-11.43	1.36e-28	1.27e-25	-0.42	-0.33	Mean platelet volume;	chr6:119031853	chr6:118934785~119031541:+
BRCA	cis	rs9487094	0.744	rs11964533	ENSG00000260273.1	RP11-425D10.10	11.43	1.37e-28	1.28e-25	0.44	0.33	Height;	chr6:109737797	chr6:109382795~109383666:+
BRCA	cis	rs2243480	1	rs2420171	ENSG00000226824.5	RP4-756H11.3	11.43	1.39e-28	1.29e-25	0.65	0.33	Diabetic kidney disease;	chr7:66172773	chr7:66654538~66669855:+
BRCA	cis	rs2404602	0.684	rs8029283	ENSG00000259422.1	RP11-593F23.1	-11.43	1.39e-28	1.29e-25	-0.43	-0.33	Blood metabolite levels;	chr15:76544799	chr15:76174891~76181486:-
BRCA	cis	rs11123170	0.64	rs931472	ENSG00000274877.1	RP11-65I12.1	11.43	1.41e-28	1.31e-25	0.48	0.33	Renal function-related traits (BUN);	chr2:113212371	chr2:113237595~113240825:+
BRCA	cis	rs7598759	0.548	rs1584462	ENSG00000181798.2	LINC00471	-11.43	1.43e-28	1.33e-25	-0.4	-0.33	Noise-induced hearing loss;	chr2:231505087	chr2:231508426~231514339:-
BRCA	cis	rs7684253	0.565	rs7680140	ENSG00000269949.1	RP11-738E22.3	-11.43	1.43e-28	1.33e-25	-0.38	-0.33	Migraine;	chr4:56957291	chr4:56960927~56961373:-
BRCA	cis	rs150992	0.711	rs1069182	ENSG00000248489.1	CTD-2007H13.3	-11.43	1.44e-28	1.34e-25	-0.39	-0.33	Body mass index;	chr5:98806512	chr5:98929171~98995013:+
BRCA	cis	rs150992	0.673	rs992773	ENSG00000248489.1	CTD-2007H13.3	-11.43	1.44e-28	1.34e-25	-0.39	-0.33	Body mass index;	chr5:98808169	chr5:98929171~98995013:+
BRCA	cis	rs11676348	0.846	rs4674257	ENSG00000261338.2	RP11-378A13.1	-11.43	1.44e-28	1.34e-25	-0.35	-0.33	Ulcerative colitis;	chr2:218124051	chr2:218255319~218257366:+
BRCA	cis	rs801193	0.569	rs7782587	ENSG00000222364.1	RNU6-96P	-11.43	1.45e-28	1.35e-25	-0.39	-0.33	Aortic root size;	chr7:66701485	chr7:66395191~66395286:+
BRCA	cis	rs5760092	0.618	rs5996631	ENSG00000231271.1	AP000350.8	-11.43	1.45e-28	1.35e-25	-0.47	-0.33	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23949918~23954042:+
BRCA	cis	rs10129255	0.701	rs2005643	ENSG00000211970.3	IGHV4-61	-11.42	1.46e-28	1.36e-25	-0.23	-0.33	Kawasaki disease;	chr14:106676288	chr14:106639119~106639657:-
BRCA	cis	rs10759883	0.627	rs689697	ENSG00000175611.10	LINC00476	11.42	1.46e-28	1.36e-25	0.39	0.33	Nicotine dependence;	chr9:95876560	chr9:95759231~95875977:-
BRCA	cis	rs10515750	0.643	rs10054755	ENSG00000251405.2	CTB-109A12.1	11.42	1.46e-28	1.36e-25	0.65	0.33	Lung function (FEV1/FVC);	chr5:157384037	chr5:157362615~157460078:-
BRCA	cis	rs10515750	0.643	rs10063539	ENSG00000251405.2	CTB-109A12.1	11.42	1.46e-28	1.36e-25	0.65	0.33	Lung function (FEV1/FVC);	chr5:157384666	chr5:157362615~157460078:-
BRCA	cis	rs9487094	0.961	rs11153177	ENSG00000260273.1	RP11-425D10.10	11.42	1.46e-28	1.36e-25	0.41	0.33	Height;	chr6:109416225	chr6:109382795~109383666:+
BRCA	cis	rs10759883	0.627	rs816673	ENSG00000175611.10	LINC00476	-11.42	1.49e-28	1.38e-25	-0.39	-0.33	Nicotine dependence;	chr9:95811134	chr9:95759231~95875977:-
BRCA	cis	rs7714584	1	rs4579248	ENSG00000197083.10	ZNF300P1	11.42	1.52e-28	1.41e-25	0.55	0.33	Crohn's disease;	chr5:150888589	chr5:150930645~150946289:-
BRCA	cis	rs4423214	0.592	rs10898193	ENSG00000254682.1	RP11-660L16.2	11.42	1.53e-28	1.42e-25	0.49	0.33	Vitamin D levels;	chr11:71486037	chr11:71448674~71452157:+
BRCA	cis	rs7829975	0.593	rs2921061	ENSG00000253893.2	FAM85B	-11.42	1.54e-28	1.43e-25	-0.43	-0.33	Mood instability;	chr8:8460105	chr8:8167819~8226614:-
BRCA	cis	rs6991838	0.584	rs14213	ENSG00000200714.1	Y_RNA	11.42	1.54e-28	1.43e-25	0.39	0.33	Intelligence (multi-trait analysis);	chr8:65602719	chr8:65592731~65592820:+
BRCA	cis	rs2729354	0.817	rs2250673	ENSG00000265566.2	RN7SL605P	-11.42	1.54e-28	1.43e-25	-0.49	-0.33	Blood protein levels;	chr11:57500697	chr11:57528085~57528365:-
BRCA	cis	rs11673344	0.77	rs7257135	ENSG00000226686.6	LINC01535	11.42	1.55e-28	1.44e-25	0.47	0.33	Obesity-related traits;	chr19:37088726	chr19:37251912~37265535:+
BRCA	cis	rs2243480	1	rs958550	ENSG00000226824.5	RP4-756H11.3	11.42	1.56e-28	1.45e-25	0.62	0.33	Diabetic kidney disease;	chr7:66170692	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs778736	ENSG00000222364.1	RNU6-96P	-11.42	1.57e-28	1.46e-25	-0.39	-0.33	Aortic root size;	chr7:66348861	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.862	rs2901152	ENSG00000222364.1	RNU6-96P	11.42	1.58e-28	1.47e-25	0.39	0.33	Aortic root size;	chr7:66300017	chr7:66395191~66395286:+
BRCA	cis	rs150992	0.609	rs2927654	ENSG00000248489.1	CTD-2007H13.3	11.42	1.59e-28	1.48e-25	0.37	0.33	Body mass index;	chr5:98993195	chr5:98929171~98995013:+
BRCA	cis	rs7598759	0.527	rs12987949	ENSG00000181798.2	LINC00471	-11.42	1.59e-28	1.48e-25	-0.41	-0.33	Noise-induced hearing loss;	chr2:231502800	chr2:231508426~231514339:-
BRCA	cis	rs7847628	0.765	rs7026635	ENSG00000226752.6	PSMD5-AS1	11.42	1.59e-28	1.48e-25	0.46	0.33	Birth weight;	chr9:120787749	chr9:120824828~120854385:+
BRCA	cis	rs11690935	0.686	rs10165126	ENSG00000228389.1	AC068039.4	11.41	1.62e-28	1.51e-25	0.42	0.33	Schizophrenia;	chr2:171963793	chr2:171773482~171775844:+
BRCA	cis	rs1062177	1	rs72802204	ENSG00000213433.5	RPLP1P6	-11.41	1.63e-28	1.51e-25	-0.43	-0.33	Preschool internalizing problems;	chr5:151803622	chr5:151765859~151766378:-
BRCA	cis	rs62103177	0.525	rs4799117	ENSG00000261126.6	RP11-795F19.1	-11.41	1.64e-28	1.52e-25	-0.41	-0.33	Opioid sensitivity;	chr18:79996604	chr18:80046900~80095482:+
BRCA	cis	rs62103177	0.525	rs4283293	ENSG00000261126.6	RP11-795F19.1	-11.41	1.64e-28	1.52e-25	-0.41	-0.33	Opioid sensitivity;	chr18:79999582	chr18:80046900~80095482:+
BRCA	cis	rs2455601	1	rs11042108	ENSG00000254860.4	TMEM9B-AS1	11.41	1.67e-28	1.55e-25	0.42	0.33	Schizophrenia;	chr11:8884474	chr11:8964675~8977527:+
BRCA	cis	rs875971	0.862	rs7783779	ENSG00000222364.1	RNU6-96P	11.41	1.68e-28	1.56e-25	0.39	0.33	Aortic root size;	chr7:66331639	chr7:66395191~66395286:+
BRCA	cis	rs7044106	0.791	rs10984994	ENSG00000226752.6	PSMD5-AS1	11.41	1.68e-28	1.56e-25	0.4	0.33	Hip circumference adjusted for BMI;	chr9:120716491	chr9:120824828~120854385:+
BRCA	cis	rs858239	1	rs858240	ENSG00000226816.2	AC005082.12	11.41	1.69e-28	1.57e-25	0.39	0.33	Cerebrospinal fluid biomarker levels;	chr7:23244618	chr7:23206013~23208045:+
BRCA	cis	rs7044106	0.762	rs10818471	ENSG00000226752.6	PSMD5-AS1	-11.41	1.71e-28	1.59e-25	-0.41	-0.33	Hip circumference adjusted for BMI;	chr9:120631767	chr9:120824828~120854385:+
BRCA	cis	rs150992	0.609	rs78254063	ENSG00000248489.1	CTD-2007H13.3	11.41	1.72e-28	1.59e-25	0.37	0.33	Body mass index;	chr5:98990803	chr5:98929171~98995013:+
BRCA	cis	rs67311347	0.955	rs4974068	ENSG00000223797.4	ENTPD3-AS1	11.41	1.74e-28	1.61e-25	0.38	0.33	Renal cell carcinoma;	chr3:40335438	chr3:40313802~40453329:-
BRCA	cis	rs4722166	0.695	rs7787893	ENSG00000179428.2	AC073072.5	-11.41	1.75e-28	1.62e-25	-0.35	-0.33	Lung cancer;	chr7:22734818	chr7:22725395~22727620:-
BRCA	cis	rs9545047	0.604	rs2763810	ENSG00000227676.3	LINC01068	11.41	1.75e-28	1.62e-25	0.39	0.33	Schizophrenia;	chr13:79405544	chr13:79566727~79571436:+
BRCA	cis	rs1062177	0.826	rs2053063	ENSG00000213433.5	RPLP1P6	-11.41	1.75e-28	1.62e-25	-0.42	-0.33	Preschool internalizing problems;	chr5:151787203	chr5:151765859~151766378:-
BRCA	cis	rs7201929	1	rs12920514	ENSG00000259982.1	CDC37P1	-11.41	1.76e-28	1.64e-25	-0.46	-0.33	QT interval;	chr16:28824579	chr16:28700294~28701540:-
BRCA	cis	rs8062405	0.69	rs762634	ENSG00000259982.1	CDC37P1	11.4	1.81e-28	1.67e-25	0.44	0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28592014	chr16:28700294~28701540:-
BRCA	cis	rs801193	0.569	rs13226966	ENSG00000222364.1	RNU6-96P	-11.4	1.81e-28	1.68e-25	-0.39	-0.33	Aortic root size;	chr7:66768636	chr7:66395191~66395286:+
BRCA	cis	rs7598759	0.527	rs7571691	ENSG00000181798.2	LINC00471	-11.4	1.83e-28	1.69e-25	-0.4	-0.33	Noise-induced hearing loss;	chr2:231504690	chr2:231508426~231514339:-
BRCA	cis	rs853679	0.55	rs1233701	ENSG00000220721.1	OR1F12	-11.4	1.83e-28	1.69e-25	-0.42	-0.33	Depression;	chr6:28200948	chr6:28073316~28074233:+
BRCA	cis	rs7580658	0.724	rs7568261	ENSG00000236682.1	AC068282.3	-11.4	1.85e-28	1.71e-25	-0.43	-0.33	Protein C levels;	chr2:127359748	chr2:127389130~127400580:+
BRCA	cis	rs9545047	0.604	rs9545104	ENSG00000227676.3	LINC01068	11.4	1.85e-28	1.71e-25	0.39	0.33	Schizophrenia;	chr13:79404000	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs9545106	ENSG00000227676.3	LINC01068	11.4	1.85e-28	1.71e-25	0.39	0.33	Schizophrenia;	chr13:79404130	chr13:79566727~79571436:+
BRCA	cis	rs150992	0.632	rs34490	ENSG00000248489.1	CTD-2007H13.3	11.4	1.87e-28	1.73e-25	0.37	0.33	Body mass index;	chr5:98974967	chr5:98929171~98995013:+
BRCA	cis	rs7945705	0.747	rs2653605	ENSG00000254860.4	TMEM9B-AS1	11.4	1.87e-28	1.73e-25	0.3	0.33	Hemoglobin concentration;	chr11:8971762	chr11:8964675~8977527:+
BRCA	cis	rs853679	0.55	rs9295762	ENSG00000220721.1	OR1F12	-11.4	1.88e-28	1.74e-25	-0.42	-0.33	Depression;	chr6:28187640	chr6:28073316~28074233:+
BRCA	cis	rs875971	1	rs7792762	ENSG00000222364.1	RNU6-96P	-11.4	1.92e-28	1.77e-25	-0.39	-0.33	Aortic root size;	chr7:66539151	chr7:66395191~66395286:+
BRCA	cis	rs2117029	0.555	rs10747561	ENSG00000258017.1	RP11-386G11.10	-11.4	1.92e-28	1.78e-25	-0.44	-0.33	Intelligence (multi-trait analysis);	chr12:49106726	chr12:49127782~49147869:+
BRCA	cis	rs1062177	1	rs2964585	ENSG00000213433.5	RPLP1P6	-11.4	1.97e-28	1.82e-25	-0.43	-0.33	Preschool internalizing problems;	chr5:151762334	chr5:151765859~151766378:-
BRCA	cis	rs10759883	0.627	rs10125109	ENSG00000175611.10	LINC00476	-11.39	1.98e-28	1.83e-25	-0.4	-0.33	Nicotine dependence;	chr9:95799228	chr9:95759231~95875977:-
BRCA	cis	rs9487094	0.961	rs7773095	ENSG00000260273.1	RP11-425D10.10	-11.39	2e-28	1.85e-25	-0.41	-0.33	Height;	chr6:109405874	chr6:109382795~109383666:+
BRCA	cis	rs2404602	0.647	rs11072616	ENSG00000259422.1	RP11-593F23.1	-11.39	2.01e-28	1.86e-25	-0.43	-0.33	Blood metabolite levels;	chr15:76692928	chr15:76174891~76181486:-
BRCA	cis	rs875971	0.862	rs801194	ENSG00000222364.1	RNU6-96P	11.39	2.02e-28	1.87e-25	0.39	0.33	Aortic root size;	chr7:66563508	chr7:66395191~66395286:+
BRCA	cis	rs801193	0.527	rs2707837	ENSG00000222364.1	RNU6-96P	-11.39	2.06e-28	1.9e-25	-0.39	-0.33	Aortic root size;	chr7:66716086	chr7:66395191~66395286:+
BRCA	cis	rs2581828	0.632	rs891369	ENSG00000242142.1	SERBP1P3	-11.39	2.07e-28	1.91e-25	-0.42	-0.33	Crohn's disease;	chr3:53102535	chr3:53064283~53065091:-
BRCA	cis	rs11123170	0.543	rs2863242	ENSG00000274877.1	RP11-65I12.1	-11.39	2.07e-28	1.92e-25	-0.54	-0.33	Renal function-related traits (BUN);	chr2:113231659	chr2:113237595~113240825:+
BRCA	cis	rs9322193	0.607	rs6557165	ENSG00000268592.3	RAET1E-AS1	-11.39	2.08e-28	1.92e-25	-0.43	-0.33	Lung cancer;	chr6:149906883	chr6:149863494~149919507:+
BRCA	cis	rs2153535	0.58	rs7748455	ENSG00000230939.1	RP11-314C16.1	-11.39	2.11e-28	1.95e-25	-0.4	-0.33	Motion sickness;	chr6:8453392	chr6:8784178~8785445:+
BRCA	cis	rs2658782	0.724	rs2248020	ENSG00000279684.1	RP11-755E23.2	-11.39	2.11e-28	1.95e-25	-0.46	-0.33	Pulmonary function decline;	chr11:93526799	chr11:93286629~93288903:-
BRCA	cis	rs7044106	0.762	rs7357638	ENSG00000226752.6	PSMD5-AS1	-11.39	2.12e-28	1.96e-25	-0.41	-0.33	Hip circumference adjusted for BMI;	chr9:120626926	chr9:120824828~120854385:+
BRCA	cis	rs150992	0.861	rs467728	ENSG00000248489.1	CTD-2007H13.3	11.39	2.13e-28	1.97e-25	0.37	0.33	Body mass index;	chr5:98953863	chr5:98929171~98995013:+
BRCA	cis	rs9487094	0.744	rs13211604	ENSG00000260273.1	RP11-425D10.10	11.39	2.14e-28	1.98e-25	0.45	0.33	Height;	chr6:109712525	chr6:109382795~109383666:+
BRCA	cis	rs6991838	0.584	rs7823840	ENSG00000200714.1	Y_RNA	-11.39	2.16e-28	1.99e-25	-0.39	-0.33	Intelligence (multi-trait analysis);	chr8:65606766	chr8:65592731~65592820:+
BRCA	cis	rs875971	0.862	rs1875057	ENSG00000222364.1	RNU6-96P	11.39	2.17e-28	2e-25	0.39	0.33	Aortic root size;	chr7:66266868	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.862	rs6960446	ENSG00000222364.1	RNU6-96P	11.39	2.17e-28	2e-25	0.39	0.33	Aortic root size;	chr7:66268272	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.789	rs10260426	ENSG00000222364.1	RNU6-96P	11.39	2.17e-28	2e-25	0.39	0.33	Aortic root size;	chr7:66271055	chr7:66395191~66395286:+
BRCA	cis	rs1062177	1	rs2016409	ENSG00000213433.5	RPLP1P6	11.39	2.17e-28	2.01e-25	0.44	0.33	Preschool internalizing problems;	chr5:151746763	chr5:151765859~151766378:-
BRCA	cis	rs6539288	0.677	rs1348565	ENSG00000260329.1	RP11-412D9.4	-11.39	2.18e-28	2.01e-25	-0.38	-0.33	Total body bone mineral density;	chr12:106935326	chr12:106954029~106955497:-
BRCA	cis	rs7945705	0.747	rs1123936	ENSG00000254860.4	TMEM9B-AS1	11.38	2.19e-28	2.02e-25	0.3	0.33	Hemoglobin concentration;	chr11:8981759	chr11:8964675~8977527:+
BRCA	cis	rs6142102	0.602	rs10485503	ENSG00000276073.1	RP5-1125A11.7	-11.38	2.2e-28	2.03e-25	-0.38	-0.33	Skin pigmentation;	chr20:33970036	chr20:33985617~33988989:-
BRCA	cis	rs801193	0.569	rs11761542	ENSG00000222364.1	RNU6-96P	-11.38	2.21e-28	2.04e-25	-0.39	-0.33	Aortic root size;	chr7:66753209	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.862	rs3893216	ENSG00000222364.1	RNU6-96P	11.38	2.22e-28	2.05e-25	0.39	0.33	Aortic root size;	chr7:66325720	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.862	rs6958294	ENSG00000222364.1	RNU6-96P	11.38	2.22e-28	2.05e-25	0.39	0.33	Aortic root size;	chr7:66329809	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.862	rs2088655	ENSG00000222364.1	RNU6-96P	11.38	2.22e-28	2.05e-25	0.39	0.33	Aortic root size;	chr7:66330724	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.895	rs10447522	ENSG00000222364.1	RNU6-96P	11.38	2.22e-28	2.05e-25	0.39	0.33	Aortic root size;	chr7:66331087	chr7:66395191~66395286:+
BRCA	cis	rs10875746	0.68	rs4760610	ENSG00000240399.1	RP1-228P16.1	-11.38	2.23e-28	2.06e-25	-0.44	-0.33	Longevity (90 years and older);	chr12:48024442	chr12:48054813~48055591:-
BRCA	cis	rs801193	0.569	rs2659908	ENSG00000222364.1	RNU6-96P	-11.38	2.24e-28	2.07e-25	-0.39	-0.33	Aortic root size;	chr7:66695835	chr7:66395191~66395286:+
BRCA	cis	rs801193	0.569	rs2707824	ENSG00000222364.1	RNU6-96P	-11.38	2.24e-28	2.07e-25	-0.39	-0.33	Aortic root size;	chr7:66724256	chr7:66395191~66395286:+
BRCA	cis	rs6539288	0.677	rs10778515	ENSG00000260329.1	RP11-412D9.4	-11.38	2.26e-28	2.08e-25	-0.38	-0.33	Total body bone mineral density;	chr12:106938703	chr12:106954029~106955497:-
BRCA	cis	rs3779195	0.697	rs13232861	ENSG00000272950.1	RP11-307C18.1	11.38	2.26e-28	2.09e-25	0.52	0.33	Sex hormone-binding globulin levels;	chr7:98299769	chr7:98322853~98323430:+
BRCA	cis	rs150992	0.609	rs113868271	ENSG00000248489.1	CTD-2007H13.3	11.38	2.31e-28	2.13e-25	0.37	0.33	Body mass index;	chr5:98992741	chr5:98929171~98995013:+
BRCA	cis	rs150992	0.631	rs112393710	ENSG00000248489.1	CTD-2007H13.3	11.38	2.31e-28	2.13e-25	0.37	0.33	Body mass index;	chr5:98992761	chr5:98929171~98995013:+
BRCA	cis	rs150992	0.631	rs111871078	ENSG00000248489.1	CTD-2007H13.3	11.38	2.31e-28	2.13e-25	0.37	0.33	Body mass index;	chr5:98992766	chr5:98929171~98995013:+
BRCA	cis	rs4727443	0.966	rs66748925	ENSG00000214313.7	AZGP1P1	-11.38	2.33e-28	2.15e-25	-0.34	-0.33	Interstitial lung disease;	chr7:99992220	chr7:99980762~99987535:+
BRCA	cis	rs11105298	0.891	rs10858890	ENSG00000258302.2	RP11-981P6.1	11.38	2.38e-28	2.19e-25	0.38	0.33	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89513389	chr12:89561129~89594878:+
BRCA	cis	rs875971	0.862	rs4718377	ENSG00000222364.1	RNU6-96P	11.38	2.39e-28	2.2e-25	0.39	0.33	Aortic root size;	chr7:66584691	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.862	rs10278014	ENSG00000222364.1	RNU6-96P	11.38	2.39e-28	2.2e-25	0.39	0.33	Aortic root size;	chr7:66586277	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.767	rs61348003	ENSG00000222364.1	RNU6-96P	-11.38	2.41e-28	2.22e-25	-0.39	-0.33	Aortic root size;	chr7:66540947	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.825	rs801202	ENSG00000222364.1	RNU6-96P	11.38	2.41e-28	2.22e-25	0.39	0.33	Aortic root size;	chr7:66558942	chr7:66395191~66395286:+
BRCA	cis	rs11723261	0.582	rs4634177	ENSG00000275426.1	CH17-262A2.1	11.37	2.44e-28	2.25e-25	0.47	0.33	Immune response to smallpox vaccine (IL-6);	chr4:143055	chr4:149738~150317:+
BRCA	cis	rs2404602	0.647	rs11632765	ENSG00000259422.1	RP11-593F23.1	11.37	2.45e-28	2.26e-25	0.42	0.33	Blood metabolite levels;	chr15:76681920	chr15:76174891~76181486:-
BRCA	cis	rs2243480	1	rs2707844	ENSG00000226824.5	RP4-756H11.3	-11.37	2.48e-28	2.28e-25	-0.65	-0.33	Diabetic kidney disease;	chr7:66594522	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs1796220	ENSG00000226824.5	RP4-756H11.3	-11.37	2.48e-28	2.28e-25	-0.65	-0.33	Diabetic kidney disease;	chr7:66597113	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs2707831	ENSG00000226824.5	RP4-756H11.3	-11.37	2.48e-28	2.28e-25	-0.65	-0.33	Diabetic kidney disease;	chr7:66597524	chr7:66654538~66669855:+
BRCA	cis	rs150992	0.821	rs326480	ENSG00000248489.1	CTD-2007H13.3	11.37	2.49e-28	2.29e-25	0.37	0.33	Body mass index;	chr5:98949263	chr5:98929171~98995013:+
BRCA	cis	rs150992	0.609	rs77892628	ENSG00000248489.1	CTD-2007H13.3	11.37	2.52e-28	2.32e-25	0.37	0.33	Body mass index;	chr5:98990624	chr5:98929171~98995013:+
BRCA	cis	rs150992	0.609	rs77231989	ENSG00000248489.1	CTD-2007H13.3	11.37	2.52e-28	2.32e-25	0.37	0.33	Body mass index;	chr5:98990650	chr5:98929171~98995013:+
BRCA	cis	rs150992	0.631	rs79191251	ENSG00000248489.1	CTD-2007H13.3	11.37	2.52e-28	2.32e-25	0.37	0.33	Body mass index;	chr5:98990680	chr5:98929171~98995013:+
BRCA	cis	rs4713118	0.587	rs61471148	ENSG00000220721.1	OR1F12	11.37	2.57e-28	2.37e-25	0.44	0.33	Parkinson's disease;	chr6:28069254	chr6:28073316~28074233:+
BRCA	cis	rs875971	0.862	rs1968126	ENSG00000222364.1	RNU6-96P	11.37	2.59e-28	2.38e-25	0.39	0.33	Aortic root size;	chr7:66592017	chr7:66395191~66395286:+
BRCA	cis	rs1891275	0.515	rs11186666	ENSG00000228701.1	TNKS2-AS1	-11.37	2.6e-28	2.39e-25	-0.39	-0.33	Intelligence (multi-trait analysis);	chr10:91718162	chr10:91782839~91798291:-
BRCA	cis	rs11096990	0.593	rs4580660	ENSG00000249207.1	RP11-360F5.1	-11.37	2.62e-28	2.41e-25	-0.39	-0.33	Cognitive function;	chr4:39152216	chr4:39112677~39126818:-
BRCA	cis	rs2153535	0.541	rs945304	ENSG00000230939.1	RP11-314C16.1	-11.37	2.63e-28	2.42e-25	-0.4	-0.33	Motion sickness;	chr6:8442659	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs1889715	ENSG00000230939.1	RP11-314C16.1	-11.37	2.63e-28	2.42e-25	-0.4	-0.33	Motion sickness;	chr6:8443242	chr6:8784178~8785445:+
BRCA	cis	rs6782228	0.675	rs4443194	ENSG00000242551.2	POU5F1P6	-11.37	2.64e-28	2.43e-25	-0.43	-0.33	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128664603	chr3:128674735~128677005:-
BRCA	cis	rs6782228	0.675	rs4857918	ENSG00000242551.2	POU5F1P6	-11.37	2.64e-28	2.43e-25	-0.43	-0.33	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128665117	chr3:128674735~128677005:-
BRCA	cis	rs34779708	0.771	rs12098283	ENSG00000230534.5	RP11-297A16.2	11.37	2.65e-28	2.43e-25	0.42	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35189187	chr10:35098006~35127020:-
BRCA	cis	rs10759883	0.627	rs816684	ENSG00000175611.10	LINC00476	-11.36	2.68e-28	2.46e-25	-0.39	-0.33	Nicotine dependence;	chr9:95822707	chr9:95759231~95875977:-
BRCA	cis	rs2404602	0.647	rs4886837	ENSG00000259422.1	RP11-593F23.1	-11.36	2.68e-28	2.46e-25	-0.43	-0.33	Blood metabolite levels;	chr15:76864076	chr15:76174891~76181486:-
BRCA	cis	rs150992	0.79	rs161731	ENSG00000248489.1	CTD-2007H13.3	11.36	2.69e-28	2.47e-25	0.38	0.33	Body mass index;	chr5:98984339	chr5:98929171~98995013:+
BRCA	cis	rs2243480	1	rs10807702	ENSG00000226824.5	RP4-756H11.3	-11.36	2.7e-28	2.48e-25	-0.64	-0.33	Diabetic kidney disease;	chr7:66302856	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs6947339	ENSG00000222364.1	RNU6-96P	-11.36	2.72e-28	2.5e-25	-0.39	-0.33	Aortic root size;	chr7:66423483	chr7:66395191~66395286:+
BRCA	cis	rs10759883	0.549	rs816680	ENSG00000175611.10	LINC00476	-11.36	2.75e-28	2.53e-25	-0.39	-0.33	Nicotine dependence;	chr9:95804111	chr9:95759231~95875977:-
BRCA	cis	rs2404602	0.647	rs11633869	ENSG00000259422.1	RP11-593F23.1	11.36	2.79e-28	2.56e-25	0.43	0.33	Blood metabolite levels;	chr15:76840981	chr15:76174891~76181486:-
BRCA	cis	rs1891275	0.515	rs4244930	ENSG00000228701.1	TNKS2-AS1	-11.36	2.82e-28	2.59e-25	-0.39	-0.33	Intelligence (multi-trait analysis);	chr10:91707092	chr10:91782839~91798291:-
BRCA	cis	rs673078	0.607	rs4767671	ENSG00000275759.1	RP11-131L12.3	-11.36	2.84e-28	2.61e-25	-0.54	-0.33	Glucose homeostasis traits;	chr12:118396038	chr12:118428281~118428870:+
BRCA	cis	rs7240205	0.724	rs6508447	ENSG00000275805.1	RP11-349H17.2	11.36	2.85e-28	2.62e-25	0.34	0.33	Breast cancer;	chr18:26552657	chr18:26565723~26575626:-
BRCA	cis	rs2153535	0.58	rs2327053	ENSG00000230939.1	RP11-314C16.1	-11.36	2.87e-28	2.63e-25	-0.4	-0.33	Motion sickness;	chr6:8442894	chr6:8784178~8785445:+
BRCA	cis	rs9309711	0.621	rs7586472	ENSG00000225234.1	TRAPPC12-AS1	-11.36	2.87e-28	2.64e-25	-0.36	-0.33	Neurofibrillary tangles;	chr2:3469899	chr2:3481242~3482409:-
BRCA	cis	rs11673344	0.9	rs11671112	ENSG00000226686.6	LINC01535	11.36	2.89e-28	2.65e-25	0.47	0.33	Obesity-related traits;	chr19:37169384	chr19:37251912~37265535:+
BRCA	cis	rs801193	0.613	rs2659900	ENSG00000222364.1	RNU6-96P	-11.36	2.91e-28	2.67e-25	-0.39	-0.33	Aortic root size;	chr7:66719456	chr7:66395191~66395286:+
BRCA	cis	rs8072100	0.777	rs9914653	ENSG00000228782.6	CTD-2026D20.3	11.36	2.93e-28	2.69e-25	0.36	0.33	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47460029	chr17:47450568~47492492:-
BRCA	cis	rs150992	0.587	rs4703340	ENSG00000248489.1	CTD-2007H13.3	-11.36	2.94e-28	2.7e-25	-0.37	-0.33	Body mass index;	chr5:99009083	chr5:98929171~98995013:+
BRCA	cis	rs875971	0.825	rs6951503	ENSG00000222364.1	RNU6-96P	11.36	2.96e-28	2.72e-25	0.39	0.33	Aortic root size;	chr7:66253949	chr7:66395191~66395286:+
BRCA	cis	rs8062405	0.754	rs151179	ENSG00000278665.1	RP11-666O2.4	11.35	2.99e-28	2.75e-25	0.36	0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28475735	chr16:28599241~28601881:-
BRCA	cis	rs673078	0.607	rs61943399	ENSG00000275759.1	RP11-131L12.3	-11.35	3.03e-28	2.78e-25	-0.52	-0.33	Glucose homeostasis traits;	chr12:118393628	chr12:118428281~118428870:+
BRCA	cis	rs10759883	0.58	rs2026031	ENSG00000175611.10	LINC00476	11.35	3.03e-28	2.78e-25	0.39	0.33	Nicotine dependence;	chr9:95859068	chr9:95759231~95875977:-
BRCA	cis	rs62034325	0.697	rs710410	ENSG00000259982.1	CDC37P1	11.35	3.07e-28	2.81e-25	0.44	0.33	Body mass index;	chr16:28592021	chr16:28700294~28701540:-
BRCA	cis	rs6504950	0.705	rs17745123	ENSG00000275710.1	RP11-257O5.4	11.35	3.12e-28	2.85e-25	0.41	0.33	Breast cancer;	chr17:54910871	chr17:54964474~54964679:+
BRCA	cis	rs10759883	0.627	rs12349742	ENSG00000175611.10	LINC00476	11.35	3.13e-28	2.87e-25	0.39	0.33	Nicotine dependence;	chr9:95857698	chr9:95759231~95875977:-
BRCA	cis	rs801193	0.569	rs2659907	ENSG00000222364.1	RNU6-96P	-11.35	3.15e-28	2.89e-25	-0.39	-0.33	Aortic root size;	chr7:66699045	chr7:66395191~66395286:+
BRCA	cis	rs11123170	0.569	rs1049137	ENSG00000274877.1	RP11-65I12.1	-11.35	3.17e-28	2.9e-25	-0.54	-0.33	Renal function-related traits (BUN);	chr2:113217533	chr2:113237595~113240825:+
BRCA	cis	rs11123170	0.543	rs12472361	ENSG00000274877.1	RP11-65I12.1	-11.35	3.22e-28	2.94e-25	-0.54	-0.33	Renal function-related traits (BUN);	chr2:113223068	chr2:113237595~113240825:+
BRCA	cis	rs2404602	0.647	rs4886840	ENSG00000259422.1	RP11-593F23.1	-11.35	3.23e-28	2.96e-25	-0.42	-0.33	Blood metabolite levels;	chr15:76886661	chr15:76174891~76181486:-
BRCA	cis	rs10759883	0.603	rs13299166	ENSG00000175611.10	LINC00476	11.35	3.23e-28	2.96e-25	0.39	0.33	Nicotine dependence;	chr9:95833249	chr9:95759231~95875977:-
BRCA	cis	rs801193	0.66	rs1962050	ENSG00000222364.1	RNU6-96P	11.35	3.25e-28	2.97e-25	0.38	0.33	Aortic root size;	chr7:66775021	chr7:66395191~66395286:+
BRCA	cis	rs8059260	0.604	rs741177	ENSG00000274038.1	RP11-66H6.4	-11.34	3.33e-28	3.05e-25	-0.49	-0.33	Alcohol consumption over the past year;	chr16:11051791	chr16:11056556~11057034:+
BRCA	cis	rs321358	1	rs321361	ENSG00000271584.1	RP11-89C3.4	11.34	3.34e-28	3.05e-25	0.55	0.33	Body mass index;	chr11:111125495	chr11:111091932~111097357:-
BRCA	cis	rs321358	1	rs321362	ENSG00000271584.1	RP11-89C3.4	11.34	3.34e-28	3.05e-25	0.55	0.33	Body mass index;	chr11:111125754	chr11:111091932~111097357:-
BRCA	cis	rs321358	1	rs321363	ENSG00000271584.1	RP11-89C3.4	11.34	3.34e-28	3.05e-25	0.55	0.33	Body mass index;	chr11:111125929	chr11:111091932~111097357:-
BRCA	cis	rs150992	0.587	rs10040066	ENSG00000248489.1	CTD-2007H13.3	-11.34	3.34e-28	3.05e-25	-0.37	-0.33	Body mass index;	chr5:99001333	chr5:98929171~98995013:+
BRCA	cis	rs150992	0.609	rs4565239	ENSG00000248489.1	CTD-2007H13.3	-11.34	3.34e-28	3.05e-25	-0.37	-0.33	Body mass index;	chr5:99002144	chr5:98929171~98995013:+
BRCA	cis	rs875971	0.79	rs10257911	ENSG00000222364.1	RNU6-96P	11.34	3.38e-28	3.09e-25	0.39	0.33	Aortic root size;	chr7:66278783	chr7:66395191~66395286:+
BRCA	cis	rs7945705	0.692	rs2742470	ENSG00000254860.4	TMEM9B-AS1	11.34	3.41e-28	3.12e-25	0.3	0.33	Hemoglobin concentration;	chr11:8982455	chr11:8964675~8977527:+
BRCA	cis	rs4718428	0.705	rs13220977	ENSG00000226824.5	RP4-756H11.3	11.34	3.43e-28	3.14e-25	0.44	0.33	Corneal structure;	chr7:66872661	chr7:66654538~66669855:+
BRCA	cis	rs2404602	0.647	rs12903331	ENSG00000259422.1	RP11-593F23.1	-11.34	3.44e-28	3.15e-25	-0.42	-0.33	Blood metabolite levels;	chr15:76875927	chr15:76174891~76181486:-
BRCA	cis	rs4727443	0.899	rs6954978	ENSG00000214313.7	AZGP1P1	-11.34	3.44e-28	3.15e-25	-0.34	-0.33	Interstitial lung disease;	chr7:99984589	chr7:99980762~99987535:+
BRCA	cis	rs7044106	0.762	rs4837789	ENSG00000226752.6	PSMD5-AS1	-11.34	3.47e-28	3.17e-25	-0.41	-0.33	Hip circumference adjusted for BMI;	chr9:120663978	chr9:120824828~120854385:+
BRCA	cis	rs4713118	0.516	rs6931858	ENSG00000220721.1	OR1F12	11.34	3.5e-28	3.2e-25	0.44	0.33	Parkinson's disease;	chr6:28110633	chr6:28073316~28074233:+
BRCA	cis	rs875971	0.862	rs7796162	ENSG00000222364.1	RNU6-96P	11.34	3.53e-28	3.22e-25	0.39	0.33	Aortic root size;	chr7:66280771	chr7:66395191~66395286:+
BRCA	cis	rs2243480	1	rs2533288	ENSG00000226824.5	RP4-756H11.3	-11.34	3.54e-28	3.24e-25	-0.65	-0.33	Diabetic kidney disease;	chr7:66591724	chr7:66654538~66669855:+
BRCA	cis	rs9545047	0.604	rs9601226	ENSG00000227676.3	LINC01068	-11.34	3.55e-28	3.24e-25	-0.39	-0.33	Schizophrenia;	chr13:79403400	chr13:79566727~79571436:+
BRCA	cis	rs2729354	0.817	rs2649667	ENSG00000265566.2	RN7SL605P	-11.34	3.59e-28	3.28e-25	-0.49	-0.33	Blood protein levels;	chr11:57503036	chr11:57528085~57528365:-
BRCA	cis	rs7849270	1	rs3124510	ENSG00000268707.1	RP11-247A12.7	11.34	3.59e-28	3.28e-25	0.41	0.33	Blood metabolite ratios;	chr9:129137411	chr9:129170434~129170940:+
BRCA	cis	rs1609391	0.561	rs9289523	ENSG00000239213.4	NCK1-AS1	11.34	3.59e-28	3.28e-25	0.35	0.33	Neuroticism;	chr3:136916747	chr3:136841726~136862054:-
BRCA	cis	rs150992	0.587	rs11960896	ENSG00000248489.1	CTD-2007H13.3	-11.34	3.61e-28	3.29e-25	-0.38	-0.33	Body mass index;	chr5:99014294	chr5:98929171~98995013:+
BRCA	cis	rs9545047	0.604	rs9601217	ENSG00000227676.3	LINC01068	-11.33	3.65e-28	3.33e-25	-0.38	-0.33	Schizophrenia;	chr13:79359797	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs4573813	ENSG00000227676.3	LINC01068	11.33	3.71e-28	3.38e-25	0.39	0.33	Schizophrenia;	chr13:79293357	chr13:79566727~79571436:+
BRCA	cis	rs10256972	0.521	rs10280960	ENSG00000229043.2	AC091729.9	-11.33	3.71e-28	3.39e-25	-0.4	-0.33	Endometriosis;Longevity;	chr7:1064061	chr7:1160374~1165267:+
BRCA	cis	rs875971	0.83	rs778711	ENSG00000222364.1	RNU6-96P	-11.33	3.75e-28	3.42e-25	-0.39	-0.33	Aortic root size;	chr7:66386670	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.862	rs1083554	ENSG00000222364.1	RNU6-96P	-11.33	3.75e-28	3.42e-25	-0.39	-0.33	Aortic root size;	chr7:66387354	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.862	rs778707	ENSG00000222364.1	RNU6-96P	-11.33	3.75e-28	3.42e-25	-0.39	-0.33	Aortic root size;	chr7:66392040	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.862	rs778705	ENSG00000222364.1	RNU6-96P	-11.33	3.75e-28	3.42e-25	-0.39	-0.33	Aortic root size;	chr7:66396128	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.862	rs778697	ENSG00000222364.1	RNU6-96P	-11.33	3.75e-28	3.42e-25	-0.39	-0.33	Aortic root size;	chr7:66405439	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.798	rs7789615	ENSG00000222364.1	RNU6-96P	-11.33	3.75e-28	3.42e-25	-0.39	-0.33	Aortic root size;	chr7:66413674	chr7:66395191~66395286:+
BRCA	cis	rs1062177	0.774	rs2964574	ENSG00000213433.5	RPLP1P6	-11.33	3.76e-28	3.43e-25	-0.42	-0.33	Preschool internalizing problems;	chr5:151776150	chr5:151765859~151766378:-
BRCA	cis	rs9545047	0.604	rs4885625	ENSG00000227676.3	LINC01068	11.33	3.8e-28	3.47e-25	0.39	0.33	Schizophrenia;	chr13:79290355	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs1324873	ENSG00000227676.3	LINC01068	11.33	3.8e-28	3.47e-25	0.39	0.33	Schizophrenia;	chr13:79292246	chr13:79566727~79571436:+
BRCA	cis	rs875971	0.895	rs6460278	ENSG00000222364.1	RNU6-96P	11.33	3.84e-28	3.5e-25	0.39	0.33	Aortic root size;	chr7:66197749	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.862	rs6460279	ENSG00000222364.1	RNU6-96P	11.33	3.84e-28	3.5e-25	0.39	0.33	Aortic root size;	chr7:66197774	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.862	rs28491091	ENSG00000222364.1	RNU6-96P	11.33	3.84e-28	3.5e-25	0.39	0.33	Aortic root size;	chr7:66204077	chr7:66395191~66395286:+
BRCA	cis	rs2404602	0.647	rs12904417	ENSG00000259422.1	RP11-593F23.1	11.33	3.85e-28	3.51e-25	0.43	0.33	Blood metabolite levels;	chr15:76671811	chr15:76174891~76181486:-
BRCA	cis	rs2442825	0.693	rs2728924	ENSG00000206573.7	THUMPD3-AS1	11.33	3.86e-28	3.52e-25	0.3	0.33	Cerebrospinal fluid clusterin levels;	chr3:9381294	chr3:9349689~9398579:-
BRCA	cis	rs150992	0.79	rs40075	ENSG00000248489.1	CTD-2007H13.3	11.33	3.87e-28	3.53e-25	0.37	0.33	Body mass index;	chr5:98976743	chr5:98929171~98995013:+
BRCA	cis	rs10875746	0.855	rs10875728	ENSG00000240399.1	RP1-228P16.1	-11.33	3.91e-28	3.56e-25	-0.43	-0.33	Longevity (90 years and older);	chr12:48032609	chr12:48054813~48055591:-
BRCA	cis	rs2015599	0.584	rs7299283	ENSG00000275476.1	RP11-996F15.4	11.33	3.92e-28	3.57e-25	0.38	0.33	Platelet count;Mean platelet volume;	chr12:29277442	chr12:29277397~29277882:-
BRCA	cis	rs2404602	0.647	rs12903586	ENSG00000259422.1	RP11-593F23.1	-11.33	3.96e-28	3.6e-25	-0.42	-0.33	Blood metabolite levels;	chr15:76875899	chr15:76174891~76181486:-
BRCA	cis	rs9487094	0.961	rs11153175	ENSG00000260273.1	RP11-425D10.10	11.33	3.98e-28	3.62e-25	0.4	0.33	Height;	chr6:109361318	chr6:109382795~109383666:+
BRCA	cis	rs6539288	0.677	rs2216221	ENSG00000260329.1	RP11-412D9.4	-11.33	3.98e-28	3.63e-25	-0.38	-0.33	Total body bone mineral density;	chr12:106933453	chr12:106954029~106955497:-
BRCA	cis	rs11673344	0.77	rs74770693	ENSG00000226686.6	LINC01535	11.33	3.98e-28	3.63e-25	0.48	0.33	Obesity-related traits;	chr19:37135613	chr19:37251912~37265535:+
BRCA	cis	rs2153535	0.58	rs2327051	ENSG00000230939.1	RP11-314C16.1	11.33	3.99e-28	3.63e-25	0.4	0.33	Motion sickness;	chr6:8440917	chr6:8784178~8785445:+
BRCA	cis	rs7044106	0.762	rs7024046	ENSG00000226752.6	PSMD5-AS1	-11.33	3.99e-28	3.63e-25	-0.4	-0.33	Hip circumference adjusted for BMI;	chr9:120656900	chr9:120824828~120854385:+
BRCA	cis	rs9545047	0.604	rs2147566	ENSG00000227676.3	LINC01068	11.33	3.99e-28	3.64e-25	0.38	0.33	Schizophrenia;	chr13:79296580	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs9530906	ENSG00000227676.3	LINC01068	11.33	4.02e-28	3.66e-25	0.38	0.33	Schizophrenia;	chr13:79372401	chr13:79566727~79571436:+
BRCA	cis	rs150992	0.609	rs2927647	ENSG00000248489.1	CTD-2007H13.3	11.32	4.05e-28	3.68e-25	0.37	0.33	Body mass index;	chr5:98990161	chr5:98929171~98995013:+
BRCA	cis	rs875971	0.862	rs801195	ENSG00000222364.1	RNU6-96P	11.32	4.11e-28	3.74e-25	0.39	0.33	Aortic root size;	chr7:66561128	chr7:66395191~66395286:+
BRCA	cis	rs2337406	1	rs10459466	ENSG00000274576.2	IGHV2-70	-11.32	4.12e-28	3.75e-25	-0.4	-0.33	Alzheimer's disease (late onset);	chr14:106689255	chr14:106770577~106771020:-
BRCA	cis	rs7044106	0.718	rs1960421	ENSG00000226752.6	PSMD5-AS1	-11.32	4.15e-28	3.77e-25	-0.41	-0.33	Hip circumference adjusted for BMI;	chr9:120632616	chr9:120824828~120854385:+
BRCA	cis	rs2153535	0.58	rs1577467	ENSG00000230939.1	RP11-314C16.1	-11.32	4.19e-28	3.81e-25	-0.4	-0.33	Motion sickness;	chr6:8444008	chr6:8784178~8785445:+
BRCA	cis	rs1062177	1	rs2915887	ENSG00000213433.5	RPLP1P6	-11.32	4.2e-28	3.82e-25	-0.43	-0.33	Preschool internalizing problems;	chr5:151825943	chr5:151765859~151766378:-
BRCA	cis	rs2015599	0.623	rs1006410	ENSG00000275476.1	RP11-996F15.4	11.32	4.21e-28	3.82e-25	0.38	0.33	Platelet count;Mean platelet volume;	chr12:29282682	chr12:29277397~29277882:-
BRCA	cis	rs1062177	0.826	rs2915873	ENSG00000213433.5	RPLP1P6	-11.32	4.26e-28	3.87e-25	-0.42	-0.33	Preschool internalizing problems;	chr5:151777097	chr5:151765859~151766378:-
BRCA	cis	rs150992	0.79	rs45931	ENSG00000248489.1	CTD-2007H13.3	11.32	4.26e-28	3.87e-25	0.37	0.33	Body mass index;	chr5:98978344	chr5:98929171~98995013:+
BRCA	cis	rs9487094	0.665	rs13207864	ENSG00000260273.1	RP11-425D10.10	11.32	4.26e-28	3.87e-25	0.44	0.33	Height;	chr6:109708527	chr6:109382795~109383666:+
BRCA	cis	rs2015599	0.563	rs11050168	ENSG00000275476.1	RP11-996F15.4	11.32	4.32e-28	3.92e-25	0.38	0.33	Platelet count;Mean platelet volume;	chr12:29273760	chr12:29277397~29277882:-
BRCA	cis	rs7829975	0.623	rs10092965	ENSG00000253893.2	FAM85B	-11.32	4.34e-28	3.94e-25	-0.41	-0.33	Mood instability;	chr8:8515975	chr8:8167819~8226614:-
BRCA	cis	rs10759883	0.627	rs690528	ENSG00000175611.10	LINC00476	11.32	4.36e-28	3.96e-25	0.39	0.33	Nicotine dependence;	chr9:95876006	chr9:95759231~95875977:-
BRCA	cis	rs875971	0.862	rs6978028	ENSG00000222364.1	RNU6-96P	-11.32	4.38e-28	3.98e-25	-0.39	-0.33	Aortic root size;	chr7:66421313	chr7:66395191~66395286:+
BRCA	cis	rs992157	0.56	rs6436048	ENSG00000261338.2	RP11-378A13.1	11.31	4.55e-28	4.13e-25	0.34	0.33	Colorectal cancer;	chr2:218244310	chr2:218255319~218257366:+
BRCA	cis	rs9545047	0.604	rs6563100	ENSG00000227676.3	LINC01068	11.31	4.59e-28	4.17e-25	0.38	0.33	Schizophrenia;	chr13:79382978	chr13:79566727~79571436:+
BRCA	cis	rs875971	0.862	rs2909688	ENSG00000222364.1	RNU6-96P	-11.31	4.6e-28	4.18e-25	-0.39	-0.33	Aortic root size;	chr7:66376625	chr7:66395191~66395286:+
BRCA	cis	rs1062177	1	rs2964584	ENSG00000213433.5	RPLP1P6	-11.31	4.62e-28	4.19e-25	-0.42	-0.33	Preschool internalizing problems;	chr5:151763317	chr5:151765859~151766378:-
BRCA	cis	rs321358	1	rs321365	ENSG00000271584.1	RP11-89C3.4	11.31	4.62e-28	4.2e-25	0.54	0.33	Body mass index;	chr11:111126676	chr11:111091932~111097357:-
BRCA	cis	rs2243480	1	rs316332	ENSG00000226824.5	RP4-756H11.3	-11.31	4.69e-28	4.25e-25	-0.63	-0.33	Diabetic kidney disease;	chr7:66139312	chr7:66654538~66669855:+
BRCA	cis	rs9545047	0.604	rs2025913	ENSG00000227676.3	LINC01068	11.31	4.71e-28	4.27e-25	0.38	0.33	Schizophrenia;	chr13:79357315	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs9545082	ENSG00000227676.3	LINC01068	11.31	4.71e-28	4.27e-25	0.38	0.33	Schizophrenia;	chr13:79358994	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs7332913	ENSG00000227676.3	LINC01068	11.31	4.71e-28	4.27e-25	0.38	0.33	Schizophrenia;	chr13:79359149	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs9545083	ENSG00000227676.3	LINC01068	11.31	4.71e-28	4.27e-25	0.38	0.33	Schizophrenia;	chr13:79360695	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs7322756	ENSG00000227676.3	LINC01068	11.31	4.71e-28	4.27e-25	0.38	0.33	Schizophrenia;	chr13:79361120	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs7324006	ENSG00000227676.3	LINC01068	11.31	4.71e-28	4.27e-25	0.38	0.33	Schizophrenia;	chr13:79361225	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs7322673	ENSG00000227676.3	LINC01068	11.31	4.71e-28	4.27e-25	0.38	0.33	Schizophrenia;	chr13:79361266	chr13:79566727~79571436:+
BRCA	cis	rs6452524	0.901	rs4571449	ENSG00000249664.1	CTD-2227C6.2	11.31	4.75e-28	4.31e-25	0.42	0.33	Hypertension (SNP x SNP interaction);	chr5:83175392	chr5:83012285~83013109:-
BRCA	cis	rs7044106	0.762	rs4142158	ENSG00000226752.6	PSMD5-AS1	-11.31	4.8e-28	4.35e-25	-0.4	-0.33	Hip circumference adjusted for BMI;	chr9:120648541	chr9:120824828~120854385:+
BRCA	cis	rs2729354	0.768	rs2729384	ENSG00000265566.2	RN7SL605P	-11.31	4.84e-28	4.38e-25	-0.48	-0.33	Blood protein levels;	chr11:57491144	chr11:57528085~57528365:-
BRCA	cis	rs7714584	1	rs931058	ENSG00000197083.10	ZNF300P1	11.31	4.84e-28	4.38e-25	0.53	0.33	Crohn's disease;	chr5:150954136	chr5:150930645~150946289:-
BRCA	cis	rs11673344	0.75	rs78241494	ENSG00000226686.6	LINC01535	11.31	4.84e-28	4.39e-25	0.48	0.33	Obesity-related traits;	chr19:37158846	chr19:37251912~37265535:+
BRCA	cis	rs9545047	0.604	rs9574419	ENSG00000227676.3	LINC01068	-11.3	4.99e-28	4.52e-25	-0.39	-0.33	Schizophrenia;	chr13:79402337	chr13:79566727~79571436:+
BRCA	cis	rs8059260	0.736	rs7202408	ENSG00000274038.1	RP11-66H6.4	-11.3	5.04e-28	4.56e-25	-0.53	-0.33	Alcohol consumption over the past year;	chr16:10984758	chr16:11056556~11057034:+
BRCA	cis	rs875971	0.825	rs66981195	ENSG00000222364.1	RNU6-96P	11.3	5.2e-28	4.7e-25	0.39	0.33	Aortic root size;	chr7:66614048	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.862	rs3926380	ENSG00000222364.1	RNU6-96P	11.3	5.2e-28	4.7e-25	0.39	0.33	Aortic root size;	chr7:66615658	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.825	rs1860472	ENSG00000222364.1	RNU6-96P	11.3	5.2e-28	4.7e-25	0.39	0.33	Aortic root size;	chr7:66617736	chr7:66395191~66395286:+
BRCA	cis	rs8059260	0.604	rs9940096	ENSG00000274038.1	RP11-66H6.4	-11.3	5.27e-28	4.76e-25	-0.52	-0.33	Alcohol consumption over the past year;	chr16:11045737	chr16:11056556~11057034:+
BRCA	cis	rs34375054	0.525	rs7133614	ENSG00000279233.1	RP11-158L12.4	11.3	5.32e-28	4.81e-25	0.38	0.33	Post bronchodilator FEV1/FVC ratio;	chr12:125121411	chr12:125138245~125141711:+
BRCA	cis	rs801193	0.636	rs10233806	ENSG00000222364.1	RNU6-96P	11.3	5.33e-28	4.82e-25	0.39	0.33	Aortic root size;	chr7:66653261	chr7:66395191~66395286:+
BRCA	cis	rs673078	0.607	rs7312555	ENSG00000275759.1	RP11-131L12.3	-11.3	5.43e-28	4.91e-25	-0.54	-0.33	Glucose homeostasis traits;	chr12:118414120	chr12:118428281~118428870:+
BRCA	cis	rs6539288	0.63	rs1055332	ENSG00000260329.1	RP11-412D9.4	-11.3	5.44e-28	4.91e-25	-0.37	-0.33	Total body bone mineral density;	chr12:106954847	chr12:106954029~106955497:-
BRCA	cis	rs6539288	0.677	rs2287163	ENSG00000260329.1	RP11-412D9.4	-11.3	5.44e-28	4.91e-25	-0.37	-0.33	Total body bone mineral density;	chr12:106955516	chr12:106954029~106955497:-
BRCA	cis	rs7598759	0.548	rs11693738	ENSG00000181798.2	LINC00471	-11.29	5.46e-28	4.93e-25	-0.4	-0.33	Noise-induced hearing loss;	chr2:231495773	chr2:231508426~231514339:-
BRCA	cis	rs1891275	0.515	rs7092745	ENSG00000228701.1	TNKS2-AS1	-11.29	5.48e-28	4.95e-25	-0.38	-0.33	Intelligence (multi-trait analysis);	chr10:91724063	chr10:91782839~91798291:-
BRCA	cis	rs2404602	0.647	rs11072636	ENSG00000259422.1	RP11-593F23.1	-11.29	5.55e-28	5.01e-25	-0.42	-0.33	Blood metabolite levels;	chr15:76893445	chr15:76174891~76181486:-
BRCA	cis	rs2404602	0.647	rs3812908	ENSG00000259422.1	RP11-593F23.1	11.29	5.59e-28	5.04e-25	0.42	0.33	Blood metabolite levels;	chr15:76883817	chr15:76174891~76181486:-
BRCA	cis	rs7684253	0.565	rs7697176	ENSG00000269949.1	RP11-738E22.3	-11.29	5.67e-28	5.12e-25	-0.38	-0.33	Migraine;	chr4:56956882	chr4:56960927~56961373:-
BRCA	cis	rs9545047	0.604	rs9574416	ENSG00000227676.3	LINC01068	-11.29	5.82e-28	5.25e-25	-0.38	-0.33	Schizophrenia;	chr13:79388577	chr13:79566727~79571436:+
BRCA	cis	rs10256972	0.521	rs871019	ENSG00000229043.2	AC091729.9	-11.29	5.95e-28	5.36e-25	-0.4	-0.33	Endometriosis;Longevity;	chr7:1065594	chr7:1160374~1165267:+
BRCA	cis	rs10875746	0.729	rs1990028	ENSG00000240399.1	RP1-228P16.1	-11.29	5.99e-28	5.4e-25	-0.43	-0.33	Longevity (90 years and older);	chr12:48014230	chr12:48054813~48055591:-
BRCA	cis	rs10759883	0.627	rs689804	ENSG00000175611.10	LINC00476	11.29	6.02e-28	5.43e-25	0.38	0.33	Nicotine dependence;	chr9:95868574	chr9:95759231~95875977:-
BRCA	cis	rs11123170	0.543	rs4849178	ENSG00000274877.1	RP11-65I12.1	-11.29	6.03e-28	5.43e-25	-0.53	-0.33	Renal function-related traits (BUN);	chr2:113225031	chr2:113237595~113240825:+
BRCA	cis	rs9545047	0.589	rs9545090	ENSG00000227676.3	LINC01068	11.28	6.08e-28	5.48e-25	0.38	0.33	Schizophrenia;	chr13:79367276	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs9530902	ENSG00000227676.3	LINC01068	11.28	6.08e-28	5.48e-25	0.38	0.33	Schizophrenia;	chr13:79367748	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs9545092	ENSG00000227676.3	LINC01068	11.28	6.08e-28	5.48e-25	0.38	0.33	Schizophrenia;	chr13:79369809	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.611	rs9545093	ENSG00000227676.3	LINC01068	11.28	6.08e-28	5.48e-25	0.38	0.33	Schizophrenia;	chr13:79371969	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs8001392	ENSG00000227676.3	LINC01068	11.28	6.08e-28	5.48e-25	0.38	0.33	Schizophrenia;	chr13:79374211	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs4146473	ENSG00000227676.3	LINC01068	11.28	6.08e-28	5.48e-25	0.38	0.33	Schizophrenia;	chr13:79374548	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.584	rs1619669	ENSG00000227676.3	LINC01068	11.28	6.08e-28	5.48e-25	0.38	0.33	Schizophrenia;	chr13:79378363	chr13:79566727~79571436:+
BRCA	cis	rs11673344	0.838	rs55856280	ENSG00000226686.6	LINC01535	11.28	6.11e-28	5.5e-25	0.48	0.33	Obesity-related traits;	chr19:37150747	chr19:37251912~37265535:+
BRCA	cis	rs801193	0.569	rs11772819	ENSG00000222364.1	RNU6-96P	-11.28	6.11e-28	5.5e-25	-0.38	-0.33	Aortic root size;	chr7:66752983	chr7:66395191~66395286:+
BRCA	cis	rs801193	0.569	rs7800620	ENSG00000222364.1	RNU6-96P	-11.28	6.11e-28	5.5e-25	-0.38	-0.33	Aortic root size;	chr7:66758701	chr7:66395191~66395286:+
BRCA	cis	rs6539288	0.677	rs7315989	ENSG00000260329.1	RP11-412D9.4	-11.28	6.15e-28	5.54e-25	-0.37	-0.33	Total body bone mineral density;	chr12:106946010	chr12:106954029~106955497:-
BRCA	cis	rs6539288	0.641	rs12318060	ENSG00000260329.1	RP11-412D9.4	-11.28	6.15e-28	5.54e-25	-0.37	-0.33	Total body bone mineral density;	chr12:106946834	chr12:106954029~106955497:-
BRCA	cis	rs6782228	0.606	rs2712404	ENSG00000242551.2	POU5F1P6	11.28	6.17e-28	5.55e-25	0.42	0.33	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128613836	chr3:128674735~128677005:-
BRCA	cis	rs9487094	1	rs12197114	ENSG00000260273.1	RP11-425D10.10	11.28	6.21e-28	5.59e-25	0.4	0.33	Height;	chr6:109414295	chr6:109382795~109383666:+
BRCA	cis	rs875971	0.862	rs6971059	ENSG00000222364.1	RNU6-96P	11.28	6.27e-28	5.64e-25	0.39	0.33	Aortic root size;	chr7:66602045	chr7:66395191~66395286:+
BRCA	cis	rs9545047	0.604	rs9530901	ENSG00000227676.3	LINC01068	11.28	6.39e-28	5.74e-25	0.38	0.33	Schizophrenia;	chr13:79355191	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs4328330	ENSG00000227676.3	LINC01068	11.28	6.39e-28	5.74e-25	0.38	0.33	Schizophrenia;	chr13:79355503	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.567	rs4497554	ENSG00000227676.3	LINC01068	11.28	6.39e-28	5.74e-25	0.38	0.33	Schizophrenia;	chr13:79355651	chr13:79566727~79571436:+
BRCA	cis	rs150992	0.57	rs10050423	ENSG00000248489.1	CTD-2007H13.3	-11.28	6.43e-28	5.78e-25	-0.37	-0.33	Body mass index;	chr5:99006312	chr5:98929171~98995013:+
BRCA	cis	rs1061377	0.748	rs12642261	ENSG00000249207.1	RP11-360F5.1	-11.28	6.48e-28	5.83e-25	-0.37	-0.33	Uric acid levels;	chr4:39096278	chr4:39112677~39126818:-
BRCA	cis	rs2015599	0.623	rs7313552	ENSG00000275476.1	RP11-996F15.4	11.28	6.5e-28	5.84e-25	0.38	0.33	Platelet count;Mean platelet volume;	chr12:29277302	chr12:29277397~29277882:-
BRCA	cis	rs2243480	1	rs4718334	ENSG00000226824.5	RP4-756H11.3	11.28	6.52e-28	5.85e-25	0.64	0.33	Diabetic kidney disease;	chr7:66324467	chr7:66654538~66669855:+
BRCA	cis	rs2404602	0.647	rs907593	ENSG00000259422.1	RP11-593F23.1	-11.28	6.55e-28	5.88e-25	-0.46	-0.33	Blood metabolite levels;	chr15:76904612	chr15:76174891~76181486:-
BRCA	cis	rs7044106	0.762	rs12003646	ENSG00000226752.6	PSMD5-AS1	-11.28	6.56e-28	5.9e-25	-0.4	-0.33	Hip circumference adjusted for BMI;	chr9:120708343	chr9:120824828~120854385:+
BRCA	cis	rs7044106	0.762	rs966396	ENSG00000226752.6	PSMD5-AS1	-11.27	6.71e-28	6.02e-25	-0.4	-0.33	Hip circumference adjusted for BMI;	chr9:120691003	chr9:120824828~120854385:+
BRCA	cis	rs150992	0.587	rs13179812	ENSG00000248489.1	CTD-2007H13.3	-11.27	6.72e-28	6.03e-25	-0.37	-0.33	Body mass index;	chr5:99021029	chr5:98929171~98995013:+
BRCA	cis	rs7580658	0.676	rs4150407	ENSG00000236682.1	AC068282.3	11.27	6.73e-28	6.04e-25	0.43	0.33	Protein C levels;	chr2:127292055	chr2:127389130~127400580:+
BRCA	cis	rs10875746	0.768	rs12305182	ENSG00000240399.1	RP1-228P16.1	-11.27	6.74e-28	6.05e-25	-0.42	-0.33	Longevity (90 years and older);	chr12:48027624	chr12:48054813~48055591:-
BRCA	cis	rs6539288	0.63	rs10778519	ENSG00000260329.1	RP11-412D9.4	-11.27	6.8e-28	6.1e-25	-0.37	-0.33	Total body bone mineral density;	chr12:106963551	chr12:106954029~106955497:-
BRCA	cis	rs875971	0.862	rs6460306	ENSG00000222364.1	RNU6-96P	11.27	6.81e-28	6.11e-25	0.39	0.33	Aortic root size;	chr7:66595806	chr7:66395191~66395286:+
BRCA	cis	rs2404602	0.647	rs8025991	ENSG00000259422.1	RP11-593F23.1	-11.27	6.82e-28	6.12e-25	-0.42	-0.33	Blood metabolite levels;	chr15:76862927	chr15:76174891~76181486:-
BRCA	cis	rs8062405	0.755	rs1074631	ENSG00000259982.1	CDC37P1	-11.27	6.93e-28	6.22e-25	-0.42	-0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28542787	chr16:28700294~28701540:-
BRCA	cis	rs8072100	0.875	rs4794047	ENSG00000228782.6	CTD-2026D20.3	-11.27	6.98e-28	6.26e-25	-0.35	-0.33	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47685639	chr17:47450568~47492492:-
BRCA	cis	rs7829975	0.688	rs7826654	ENSG00000253893.2	FAM85B	-11.27	7.03e-28	6.3e-25	-0.41	-0.33	Mood instability;	chr8:8521596	chr8:8167819~8226614:-
BRCA	cis	rs7829975	0.688	rs7826660	ENSG00000253893.2	FAM85B	-11.27	7.03e-28	6.3e-25	-0.41	-0.33	Mood instability;	chr8:8521597	chr8:8167819~8226614:-
BRCA	cis	rs10129255	0.5	rs10131875	ENSG00000223648.3	IGHV3-64	11.27	7.04e-28	6.31e-25	0.25	0.33	Kawasaki disease;	chr14:106792798	chr14:106643132~106658258:-
BRCA	cis	rs801193	0.569	rs4717315	ENSG00000222364.1	RNU6-96P	-11.27	7.06e-28	6.33e-25	-0.38	-0.33	Aortic root size;	chr7:66713338	chr7:66395191~66395286:+
BRCA	cis	rs9660180	0.846	rs10907195	ENSG00000268575.1	RP1-283E3.8	11.27	7.12e-28	6.38e-25	0.35	0.33	Body mass index;	chr1:1781909	chr1:1702736~1737688:-
BRCA	cis	rs9545047	0.604	rs2182873	ENSG00000227676.3	LINC01068	11.27	7.13e-28	6.39e-25	0.38	0.33	Schizophrenia;	chr13:79356846	chr13:79566727~79571436:+
BRCA	cis	rs2404602	0.684	rs1011083	ENSG00000259422.1	RP11-593F23.1	-11.27	7.15e-28	6.41e-25	-0.42	-0.33	Blood metabolite levels;	chr15:76715186	chr15:76174891~76181486:-
BRCA	cis	rs9545047	0.604	rs9545052	ENSG00000227676.3	LINC01068	11.27	7.18e-28	6.44e-25	0.38	0.33	Schizophrenia;	chr13:79294875	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.588	rs9530913	ENSG00000227676.3	LINC01068	11.27	7.23e-28	6.48e-25	0.38	0.33	Schizophrenia;	chr13:79384539	chr13:79566727~79571436:+
BRCA	cis	rs150992	0.751	rs172874	ENSG00000248489.1	CTD-2007H13.3	11.27	7.28e-28	6.53e-25	0.37	0.33	Body mass index;	chr5:98969402	chr5:98929171~98995013:+
BRCA	cis	rs8177376	1	rs563011	ENSG00000254905.1	RP11-712L6.7	-11.27	7.38e-28	6.61e-25	-0.47	-0.33	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126281527	chr11:126292922~126294254:-
BRCA	cis	rs2153535	0.601	rs4960414	ENSG00000230939.1	RP11-314C16.1	-11.26	7.47e-28	6.69e-25	-0.39	-0.33	Motion sickness;	chr6:8438308	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.542	rs9393012	ENSG00000230939.1	RP11-314C16.1	-11.26	7.47e-28	6.69e-25	-0.39	-0.33	Motion sickness;	chr6:8439576	chr6:8784178~8785445:+
BRCA	cis	rs2404602	0.647	rs35940181	ENSG00000259422.1	RP11-593F23.1	-11.26	7.47e-28	6.69e-25	-0.42	-0.33	Blood metabolite levels;	chr15:76887678	chr15:76174891~76181486:-
BRCA	cis	rs10129255	0.5	rs11628999	ENSG00000223648.3	IGHV3-64	11.26	7.55e-28	6.76e-25	0.25	0.33	Kawasaki disease;	chr14:106800208	chr14:106643132~106658258:-
BRCA	cis	rs875971	0.825	rs10281499	ENSG00000222364.1	RNU6-96P	11.26	7.56e-28	6.76e-25	0.39	0.33	Aortic root size;	chr7:66583979	chr7:66395191~66395286:+
BRCA	cis	rs2153535	0.542	rs6912740	ENSG00000230939.1	RP11-314C16.1	-11.26	7.59e-28	6.79e-25	-0.39	-0.33	Motion sickness;	chr6:8439726	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.542	rs6905925	ENSG00000230939.1	RP11-314C16.1	-11.26	7.59e-28	6.79e-25	-0.39	-0.33	Motion sickness;	chr6:8439797	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.541	rs6905934	ENSG00000230939.1	RP11-314C16.1	-11.26	7.59e-28	6.79e-25	-0.39	-0.33	Motion sickness;	chr6:8439810	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs2327050	ENSG00000230939.1	RP11-314C16.1	-11.26	7.59e-28	6.79e-25	-0.39	-0.33	Motion sickness;	chr6:8440397	chr6:8784178~8785445:+
BRCA	cis	rs7829975	0.688	rs7837587	ENSG00000253893.2	FAM85B	-11.26	7.6e-28	6.8e-25	-0.41	-0.33	Mood instability;	chr8:8521482	chr8:8167819~8226614:-
BRCA	cis	rs11123170	0.64	rs1015754	ENSG00000274877.1	RP11-65I12.1	11.26	7.6e-28	6.8e-25	0.47	0.33	Renal function-related traits (BUN);	chr2:113210413	chr2:113237595~113240825:+
BRCA	cis	rs8062405	0.789	rs1968752	ENSG00000278665.1	RP11-666O2.4	11.26	7.62e-28	6.81e-25	0.34	0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620264	chr16:28599241~28601881:-
BRCA	cis	rs9487094	0.614	rs13191444	ENSG00000260273.1	RP11-425D10.10	11.26	7.69e-28	6.88e-25	0.44	0.33	Height;	chr6:109762861	chr6:109382795~109383666:+
BRCA	cis	rs1062177	0.826	rs2915879	ENSG00000213433.5	RPLP1P6	-11.26	7.85e-28	7.02e-25	-0.42	-0.33	Preschool internalizing problems;	chr5:151767881	chr5:151765859~151766378:-
BRCA	cis	rs10875746	0.729	rs11168357	ENSG00000240399.1	RP1-228P16.1	-11.26	7.95e-28	7.11e-25	-0.44	-0.33	Longevity (90 years and older);	chr12:48018355	chr12:48054813~48055591:-
BRCA	cis	rs10954213	0.525	rs11770589	ENSG00000275106.1	RP11-309L24.10	-11.26	8.01e-28	7.16e-25	-0.42	-0.33	Sjögren's syndrome;	chr7:128949434	chr7:128952527~128953316:-
BRCA	cis	rs2153535	0.58	rs6920779	ENSG00000230939.1	RP11-314C16.1	-11.26	8.07e-28	7.2e-25	-0.39	-0.33	Motion sickness;	chr6:8437391	chr6:8784178~8785445:+
BRCA	cis	rs8059260	0.736	rs113120936	ENSG00000274038.1	RP11-66H6.4	-11.26	8.16e-28	7.29e-25	-0.52	-0.33	Alcohol consumption over the past year;	chr16:10989474	chr16:11056556~11057034:+
BRCA	cis	rs9545047	0.604	rs9530900	ENSG00000227676.3	LINC01068	11.26	8.17e-28	7.3e-25	0.38	0.33	Schizophrenia;	chr13:79355048	chr13:79566727~79571436:+
BRCA	cis	rs172166	0.694	rs203884	ENSG00000220721.1	OR1F12	11.25	8.18e-28	7.3e-25	0.39	0.33	Cardiac Troponin-T levels;	chr6:28109596	chr6:28073316~28074233:+
BRCA	cis	rs7044106	0.762	rs1530370	ENSG00000226752.6	PSMD5-AS1	-11.25	8.25e-28	7.37e-25	-0.41	-0.33	Hip circumference adjusted for BMI;	chr9:120662274	chr9:120824828~120854385:+
BRCA	cis	rs2153535	0.58	rs2327056	ENSG00000230939.1	RP11-314C16.1	-11.25	8.31e-28	7.42e-25	-0.39	-0.33	Motion sickness;	chr6:8443072	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs3938660	ENSG00000230939.1	RP11-314C16.1	-11.25	8.31e-28	7.42e-25	-0.39	-0.33	Motion sickness;	chr6:8443102	chr6:8784178~8785445:+
BRCA	cis	rs2404602	0.735	rs11629888	ENSG00000259422.1	RP11-593F23.1	-11.25	8.32e-28	7.42e-25	-0.44	-0.33	Blood metabolite levels;	chr15:76427539	chr15:76174891~76181486:-
BRCA	cis	rs1062177	0.826	rs2915822	ENSG00000213433.5	RPLP1P6	11.25	8.32e-28	7.43e-25	0.42	0.33	Preschool internalizing problems;	chr5:151751340	chr5:151765859~151766378:-
BRCA	cis	rs321358	1	rs321357	ENSG00000271584.1	RP11-89C3.4	11.25	8.39e-28	7.49e-25	0.54	0.33	Body mass index;	chr11:111125002	chr11:111091932~111097357:-
BRCA	cis	rs9545047	0.604	rs1626333	ENSG00000227676.3	LINC01068	11.25	8.4e-28	7.49e-25	0.38	0.33	Schizophrenia;	chr13:79286932	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.567	rs1856996	ENSG00000227676.3	LINC01068	11.25	8.4e-28	7.49e-25	0.38	0.33	Schizophrenia;	chr13:79287453	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs9545048	ENSG00000227676.3	LINC01068	11.25	8.43e-28	7.52e-25	0.38	0.33	Schizophrenia;	chr13:79285593	chr13:79566727~79571436:+
BRCA	cis	rs7044106	0.762	rs1867254	ENSG00000226752.6	PSMD5-AS1	-11.25	8.48e-28	7.56e-25	-0.4	-0.33	Hip circumference adjusted for BMI;	chr9:120666800	chr9:120824828~120854385:+
BRCA	cis	rs321358	1	rs321353	ENSG00000271584.1	RP11-89C3.4	-11.25	8.51e-28	7.59e-25	-0.54	-0.33	Body mass index;	chr11:111123841	chr11:111091932~111097357:-
BRCA	cis	rs6558530	0.932	rs7842425	ENSG00000253982.1	CTD-2336O2.1	11.25	8.51e-28	7.59e-25	0.36	0.33	Systolic blood pressure;	chr8:1757875	chr8:1761990~1764502:-
BRCA	cis	rs11673344	0.838	rs111827672	ENSG00000226686.6	LINC01535	11.25	8.52e-28	7.6e-25	0.48	0.33	Obesity-related traits;	chr19:37158964	chr19:37251912~37265535:+
BRCA	cis	rs10129255	0.5	rs8004923	ENSG00000223648.3	IGHV3-64	11.25	8.6e-28	7.67e-25	0.25	0.33	Kawasaki disease;	chr14:106785926	chr14:106643132~106658258:-
BRCA	cis	rs11676348	0.846	rs11677534	ENSG00000261338.2	RP11-378A13.1	-11.25	8.7e-28	7.76e-25	-0.35	-0.33	Ulcerative colitis;	chr2:218142337	chr2:218255319~218257366:+
BRCA	cis	rs875971	0.862	rs6460282	ENSG00000222364.1	RNU6-96P	11.25	8.72e-28	7.78e-25	0.39	0.33	Aortic root size;	chr7:66226259	chr7:66395191~66395286:+
BRCA	cis	rs7829975	0.688	rs6601703	ENSG00000253893.2	FAM85B	-11.25	8.76e-28	7.81e-25	-0.41	-0.33	Mood instability;	chr8:8522714	chr8:8167819~8226614:-
BRCA	cis	rs2729354	0.768	rs2584856	ENSG00000265566.2	RN7SL605P	-11.25	8.81e-28	7.85e-25	-0.47	-0.33	Blood protein levels;	chr11:57499839	chr11:57528085~57528365:-
BRCA	cis	rs1609391	0.543	rs9881139	ENSG00000239213.4	NCK1-AS1	11.25	8.85e-28	7.88e-25	0.35	0.33	Neuroticism;	chr3:136915198	chr3:136841726~136862054:-
BRCA	cis	rs11673344	0.832	rs112380313	ENSG00000226686.6	LINC01535	11.25	8.89e-28	7.92e-25	0.47	0.33	Obesity-related traits;	chr19:37027979	chr19:37251912~37265535:+
BRCA	cis	rs11676348	0.846	rs4674259	ENSG00000261338.2	RP11-378A13.1	-11.25	8.93e-28	7.95e-25	-0.35	-0.33	Ulcerative colitis;	chr2:218126282	chr2:218255319~218257366:+
BRCA	cis	rs10129255	0.872	rs8015406	ENSG00000211970.3	IGHV4-61	-11.25	9e-28	8.02e-25	-0.24	-0.33	Kawasaki disease;	chr14:106670611	chr14:106639119~106639657:-
BRCA	cis	rs875971	1	rs2220626	ENSG00000222364.1	RNU6-96P	11.24	9.14e-28	8.14e-25	0.39	0.33	Aortic root size;	chr7:66081075	chr7:66395191~66395286:+
BRCA	cis	rs7044106	0.762	rs10760107	ENSG00000226752.6	PSMD5-AS1	-11.24	9.15e-28	8.14e-25	-0.4	-0.33	Hip circumference adjusted for BMI;	chr9:120621352	chr9:120824828~120854385:+
BRCA	cis	rs10129255	0.5	rs6576232	ENSG00000223648.3	IGHV3-64	11.24	9.17e-28	8.16e-25	0.25	0.33	Kawasaki disease;	chr14:106787090	chr14:106643132~106658258:-
BRCA	cis	rs2153535	0.58	rs1577468	ENSG00000230939.1	RP11-314C16.1	-11.24	9.22e-28	8.21e-25	-0.4	-0.33	Motion sickness;	chr6:8444033	chr6:8784178~8785445:+
BRCA	cis	rs11673344	0.526	rs1871196	ENSG00000226686.6	LINC01535	11.24	9.22e-28	8.21e-25	0.45	0.33	Obesity-related traits;	chr19:37656022	chr19:37251912~37265535:+
BRCA	cis	rs3779195	0.86	rs12704986	ENSG00000272950.1	RP11-307C18.1	11.24	9.24e-28	8.22e-25	0.51	0.33	Sex hormone-binding globulin levels;	chr7:98357118	chr7:98322853~98323430:+
BRCA	cis	rs3779195	0.858	rs3779196	ENSG00000272950.1	RP11-307C18.1	11.24	9.24e-28	8.22e-25	0.51	0.33	Sex hormone-binding globulin levels;	chr7:98360794	chr7:98322853~98323430:+
BRCA	cis	rs3779195	0.789	rs6965424	ENSG00000272950.1	RP11-307C18.1	11.24	9.24e-28	8.22e-25	0.51	0.33	Sex hormone-binding globulin levels;	chr7:98361813	chr7:98322853~98323430:+
BRCA	cis	rs150992	0.721	rs2937706	ENSG00000248489.1	CTD-2007H13.3	11.24	9.29e-28	8.26e-25	0.37	0.33	Body mass index;	chr5:98990434	chr5:98929171~98995013:+
BRCA	cis	rs2739330	0.734	rs2000467	ENSG00000250470.1	AP000351.3	-11.24	9.42e-28	8.38e-25	-0.41	-0.33	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23976904~23977585:-
BRCA	cis	rs801193	0.569	rs2659893	ENSG00000222364.1	RNU6-96P	-11.24	9.5e-28	8.45e-25	-0.38	-0.33	Aortic root size;	chr7:66735006	chr7:66395191~66395286:+
BRCA	cis	rs801193	0.569	rs2659892	ENSG00000222364.1	RNU6-96P	-11.24	9.5e-28	8.45e-25	-0.38	-0.33	Aortic root size;	chr7:66735318	chr7:66395191~66395286:+
BRCA	cis	rs801193	0.569	rs2707847	ENSG00000222364.1	RNU6-96P	-11.24	9.5e-28	8.45e-25	-0.38	-0.33	Aortic root size;	chr7:66737884	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.862	rs6955837	ENSG00000222364.1	RNU6-96P	11.24	9.5e-28	8.45e-25	0.39	0.33	Aortic root size;	chr7:66578155	chr7:66395191~66395286:+
BRCA	cis	rs801193	0.569	rs881285	ENSG00000222364.1	RNU6-96P	11.24	9.51e-28	8.45e-25	0.39	0.33	Aortic root size;	chr7:66654433	chr7:66395191~66395286:+
BRCA	cis	rs9545047	0.604	rs7322901	ENSG00000227676.3	LINC01068	11.24	9.53e-28	8.47e-25	0.38	0.33	Schizophrenia;	chr13:79383505	chr13:79566727~79571436:+
BRCA	cis	rs2153535	0.58	rs915350	ENSG00000230939.1	RP11-314C16.1	-11.24	9.54e-28	8.48e-25	-0.39	-0.33	Motion sickness;	chr6:8443253	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.601	rs9393030	ENSG00000230939.1	RP11-314C16.1	-11.24	9.55e-28	8.48e-25	-0.39	-0.33	Motion sickness;	chr6:8516256	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs9328479	ENSG00000230939.1	RP11-314C16.1	-11.24	9.55e-28	8.48e-25	-0.39	-0.33	Motion sickness;	chr6:8519413	chr6:8784178~8785445:+
BRCA	cis	rs2404602	0.684	rs28895952	ENSG00000259422.1	RP11-593F23.1	-11.24	9.75e-28	8.66e-25	-0.42	-0.33	Blood metabolite levels;	chr15:76564435	chr15:76174891~76181486:-
BRCA	cis	rs2153535	0.58	rs4960411	ENSG00000230939.1	RP11-314C16.1	-11.24	9.77e-28	8.68e-25	-0.39	-0.33	Motion sickness;	chr6:8437998	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs4960412	ENSG00000230939.1	RP11-314C16.1	-11.24	9.77e-28	8.68e-25	-0.39	-0.33	Motion sickness;	chr6:8438028	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs4960413	ENSG00000230939.1	RP11-314C16.1	-11.24	9.77e-28	8.68e-25	-0.39	-0.33	Motion sickness;	chr6:8438233	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs4140586	ENSG00000230939.1	RP11-314C16.1	-11.24	9.84e-28	8.74e-25	-0.39	-0.33	Motion sickness;	chr6:8502959	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.601	rs4140585	ENSG00000230939.1	RP11-314C16.1	-11.24	9.84e-28	8.74e-25	-0.39	-0.33	Motion sickness;	chr6:8503065	chr6:8784178~8785445:+
BRCA	cis	rs321358	1	rs321368	ENSG00000271584.1	RP11-89C3.4	11.24	9.85e-28	8.75e-25	0.55	0.33	Body mass index;	chr11:111129033	chr11:111091932~111097357:-
BRCA	cis	rs321358	1	rs321369	ENSG00000271584.1	RP11-89C3.4	11.24	9.85e-28	8.75e-25	0.55	0.33	Body mass index;	chr11:111129797	chr11:111091932~111097357:-
BRCA	cis	rs321358	1	rs321370	ENSG00000271584.1	RP11-89C3.4	11.24	9.85e-28	8.75e-25	0.55	0.33	Body mass index;	chr11:111129959	chr11:111091932~111097357:-
BRCA	cis	rs9545047	0.604	rs7986306	ENSG00000227676.3	LINC01068	11.24	9.89e-28	8.78e-25	0.38	0.33	Schizophrenia;	chr13:79392530	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs7329331	ENSG00000227676.3	LINC01068	11.24	9.89e-28	8.78e-25	0.38	0.33	Schizophrenia;	chr13:79384986	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs7330479	ENSG00000227676.3	LINC01068	11.24	9.89e-28	8.78e-25	0.38	0.33	Schizophrenia;	chr13:79385058	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs6563104	ENSG00000227676.3	LINC01068	11.24	9.89e-28	8.78e-25	0.38	0.33	Schizophrenia;	chr13:79389718	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs7981500	ENSG00000227676.3	LINC01068	11.24	9.89e-28	8.78e-25	0.38	0.33	Schizophrenia;	chr13:79391461	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs57821487	ENSG00000227676.3	LINC01068	11.24	9.89e-28	8.78e-25	0.38	0.33	Schizophrenia;	chr13:79392810	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs7323246	ENSG00000227676.3	LINC01068	11.24	9.89e-28	8.78e-25	0.38	0.33	Schizophrenia;	chr13:79392903	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs7331766	ENSG00000227676.3	LINC01068	11.24	9.89e-28	8.78e-25	0.38	0.33	Schizophrenia;	chr13:79394076	chr13:79566727~79571436:+
BRCA	cis	rs7044106	0.762	rs1547267	ENSG00000226752.6	PSMD5-AS1	-11.24	9.89e-28	8.78e-25	-0.4	-0.33	Hip circumference adjusted for BMI;	chr9:120646458	chr9:120824828~120854385:+
BRCA	cis	rs6991838	0.584	rs7836349	ENSG00000200714.1	Y_RNA	-11.24	9.89e-28	8.78e-25	-0.38	-0.33	Intelligence (multi-trait analysis);	chr8:65591328	chr8:65592731~65592820:+
BRCA	cis	rs2153535	0.58	rs4404802	ENSG00000230939.1	RP11-314C16.1	-11.24	9.93e-28	8.81e-25	-0.39	-0.33	Motion sickness;	chr6:8441819	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs1932275	ENSG00000230939.1	RP11-314C16.1	-11.24	9.93e-28	8.81e-25	-0.39	-0.33	Motion sickness;	chr6:8442100	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs1932276	ENSG00000230939.1	RP11-314C16.1	-11.24	9.93e-28	8.81e-25	-0.39	-0.33	Motion sickness;	chr6:8442360	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs915352	ENSG00000230939.1	RP11-314C16.1	-11.24	9.93e-28	8.81e-25	-0.39	-0.33	Motion sickness;	chr6:8442533	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs915351	ENSG00000230939.1	RP11-314C16.1	-11.24	9.93e-28	8.81e-25	-0.39	-0.33	Motion sickness;	chr6:8442560	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.601	rs1855765	ENSG00000230939.1	RP11-314C16.1	-11.24	9.93e-28	8.81e-25	-0.39	-0.33	Motion sickness;	chr6:8444092	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs9406143	ENSG00000230939.1	RP11-314C16.1	-11.24	9.93e-28	8.81e-25	-0.39	-0.33	Motion sickness;	chr6:8444350	chr6:8784178~8785445:+
BRCA	cis	rs9545047	0.604	rs7327603	ENSG00000227676.3	LINC01068	11.24	9.93e-28	8.81e-25	0.38	0.33	Schizophrenia;	chr13:79366676	chr13:79566727~79571436:+
BRCA	cis	rs9487094	0.922	rs6916579	ENSG00000260273.1	RP11-425D10.10	11.24	9.94e-28	8.82e-25	0.41	0.33	Height;	chr6:109530435	chr6:109382795~109383666:+
BRCA	cis	rs10256972	0.521	rs7811577	ENSG00000229043.2	AC091729.9	-11.23	1.01e-27	9e-25	-0.39	-0.33	Endometriosis;Longevity;	chr7:1063193	chr7:1160374~1165267:+
BRCA	cis	rs2153535	0.58	rs6597332	ENSG00000230939.1	RP11-314C16.1	-11.23	1.03e-27	9.12e-25	-0.39	-0.33	Motion sickness;	chr6:8504515	chr6:8784178~8785445:+
BRCA	cis	rs321358	1	rs321366	ENSG00000271584.1	RP11-89C3.4	11.23	1.04e-27	9.21e-25	0.55	0.33	Body mass index;	chr11:111128003	chr11:111091932~111097357:-
BRCA	cis	rs7598759	0.548	rs11686485	ENSG00000181798.2	LINC00471	-11.23	1.05e-27	9.33e-25	-0.4	-0.33	Noise-induced hearing loss;	chr2:231495986	chr2:231508426~231514339:-
BRCA	cis	rs6782228	0.675	rs2253151	ENSG00000242551.2	POU5F1P6	-11.23	1.06e-27	9.37e-25	-0.42	-0.33	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128611294	chr3:128674735~128677005:-
BRCA	cis	rs9487094	0.848	rs7372	ENSG00000260273.1	RP11-425D10.10	11.23	1.06e-27	9.39e-25	0.4	0.33	Height;	chr6:109366911	chr6:109382795~109383666:+
BRCA	cis	rs6539288	0.677	rs10735418	ENSG00000260329.1	RP11-412D9.4	-11.23	1.07e-27	9.44e-25	-0.37	-0.33	Total body bone mineral density;	chr12:106949598	chr12:106954029~106955497:-
BRCA	cis	rs9487094	1	rs36035949	ENSG00000260273.1	RP11-425D10.10	11.23	1.07e-27	9.5e-25	0.39	0.33	Height;	chr6:109415411	chr6:109382795~109383666:+
BRCA	cis	rs10875746	0.768	rs4760676	ENSG00000240399.1	RP1-228P16.1	-11.23	1.08e-27	9.55e-25	-0.43	-0.33	Longevity (90 years and older);	chr12:48027880	chr12:48054813~48055591:-
BRCA	cis	rs9487094	0.567	rs13196280	ENSG00000260273.1	RP11-425D10.10	11.23	1.08e-27	9.57e-25	0.44	0.33	Height;	chr6:109764163	chr6:109382795~109383666:+
BRCA	cis	rs2153535	0.58	rs2143355	ENSG00000230939.1	RP11-314C16.1	-11.23	1.09e-27	9.6e-25	-0.39	-0.33	Motion sickness;	chr6:8517623	chr6:8784178~8785445:+
BRCA	cis	rs321358	0.943	rs17537987	ENSG00000271584.1	RP11-89C3.4	11.23	1.09e-27	9.61e-25	0.58	0.33	Body mass index;	chr11:111134144	chr11:111091932~111097357:-
BRCA	cis	rs321358	1	rs73019218	ENSG00000271584.1	RP11-89C3.4	11.23	1.09e-27	9.61e-25	0.58	0.33	Body mass index;	chr11:111134521	chr11:111091932~111097357:-
BRCA	cis	rs6750795	0.765	rs6742387	ENSG00000181798.2	LINC00471	-11.23	1.09e-27	9.62e-25	-0.4	-0.33	Height;	chr2:231490121	chr2:231508426~231514339:-
BRCA	cis	rs7598759	0.548	rs1823328	ENSG00000181798.2	LINC00471	-11.23	1.09e-27	9.62e-25	-0.4	-0.33	Noise-induced hearing loss;	chr2:231490473	chr2:231508426~231514339:-
BRCA	cis	rs1891275	0.515	rs1418161	ENSG00000228701.1	TNKS2-AS1	-11.23	1.1e-27	9.69e-25	-0.38	-0.33	Intelligence (multi-trait analysis);	chr10:91724898	chr10:91782839~91798291:-
BRCA	cis	rs9545047	0.604	rs9318634	ENSG00000227676.3	LINC01068	-11.22	1.11e-27	9.81e-25	-0.38	-0.33	Schizophrenia;	chr13:79369303	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.567	rs4884129	ENSG00000227676.3	LINC01068	11.22	1.12e-27	9.88e-25	0.38	0.33	Schizophrenia;	chr13:79346448	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.567	rs1410336	ENSG00000227676.3	LINC01068	11.22	1.12e-27	9.88e-25	0.38	0.33	Schizophrenia;	chr13:79347598	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs9565492	ENSG00000227676.3	LINC01068	11.22	1.12e-27	9.88e-25	0.38	0.33	Schizophrenia;	chr13:79348554	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs9318625	ENSG00000227676.3	LINC01068	11.22	1.12e-27	9.88e-25	0.38	0.33	Schizophrenia;	chr13:79351429	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs9530899	ENSG00000227676.3	LINC01068	11.22	1.12e-27	9.88e-25	0.38	0.33	Schizophrenia;	chr13:79352461	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs7338677	ENSG00000227676.3	LINC01068	11.22	1.12e-27	9.88e-25	0.38	0.33	Schizophrenia;	chr13:79352580	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs7322744	ENSG00000227676.3	LINC01068	11.22	1.12e-27	9.88e-25	0.38	0.33	Schizophrenia;	chr13:79354070	chr13:79566727~79571436:+
BRCA	cis	rs2153535	0.58	rs2327067	ENSG00000230939.1	RP11-314C16.1	-11.22	1.12e-27	9.9e-25	-0.39	-0.33	Motion sickness;	chr6:8518249	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.541	rs9328477	ENSG00000230939.1	RP11-314C16.1	-11.22	1.12e-27	9.9e-25	-0.39	-0.33	Motion sickness;	chr6:8518876	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs9328478	ENSG00000230939.1	RP11-314C16.1	-11.22	1.12e-27	9.9e-25	-0.39	-0.33	Motion sickness;	chr6:8518950	chr6:8784178~8785445:+
BRCA	cis	rs10129255	0.5	rs7157975	ENSG00000223648.3	IGHV3-64	11.22	1.13e-27	9.94e-25	0.25	0.33	Kawasaki disease;	chr14:106804049	chr14:106643132~106658258:-
BRCA	cis	rs9318086	0.578	rs2077709	ENSG00000205861.10	C1QTNF9B-AS1	11.22	1.13e-27	9.95e-25	0.42	0.33	Myopia (pathological);	chr13:23901934	chr13:23888889~23897263:+
BRCA	cis	rs9545047	0.584	rs7995243	ENSG00000227676.3	LINC01068	-11.22	1.13e-27	1e-24	-0.38	-0.33	Schizophrenia;	chr13:79358645	chr13:79566727~79571436:+
BRCA	cis	rs1062177	1	rs17804178	ENSG00000213433.5	RPLP1P6	-11.22	1.14e-27	1e-24	-0.43	-0.33	Preschool internalizing problems;	chr5:151818168	chr5:151765859~151766378:-
BRCA	cis	rs1062177	1	rs2964612	ENSG00000213433.5	RPLP1P6	-11.22	1.14e-27	1e-24	-0.43	-0.33	Preschool internalizing problems;	chr5:151819189	chr5:151765859~151766378:-
BRCA	cis	rs875971	1	rs697970	ENSG00000222364.1	RNU6-96P	11.22	1.14e-27	1.01e-24	0.39	0.33	Aortic root size;	chr7:66095065	chr7:66395191~66395286:+
BRCA	cis	rs11673344	0.526	rs73035160	ENSG00000226686.6	LINC01535	11.22	1.14e-27	1.01e-24	0.45	0.33	Obesity-related traits;	chr19:37655135	chr19:37251912~37265535:+
BRCA	cis	rs321358	1	rs12419222	ENSG00000271584.1	RP11-89C3.4	11.22	1.16e-27	1.02e-24	0.57	0.33	Body mass index;	chr11:111128439	chr11:111091932~111097357:-
BRCA	cis	rs10759883	0.563	rs12345187	ENSG00000175611.10	LINC00476	11.22	1.16e-27	1.03e-24	0.38	0.33	Nicotine dependence;	chr9:95906088	chr9:95759231~95875977:-
BRCA	cis	rs1891275	0.515	rs7475294	ENSG00000228701.1	TNKS2-AS1	-11.22	1.16e-27	1.03e-24	-0.38	-0.33	Intelligence (multi-trait analysis);	chr10:91748442	chr10:91782839~91798291:-
BRCA	cis	rs150992	0.609	rs366353	ENSG00000248489.1	CTD-2007H13.3	-11.22	1.17e-27	1.03e-24	-0.37	-0.33	Body mass index;	chr5:98995663	chr5:98929171~98995013:+
BRCA	cis	rs875971	0.862	rs6952182	ENSG00000222364.1	RNU6-96P	11.22	1.17e-27	1.03e-24	0.39	0.33	Aortic root size;	chr7:66218330	chr7:66395191~66395286:+
BRCA	cis	rs9487094	0.961	rs12193493	ENSG00000260273.1	RP11-425D10.10	11.22	1.17e-27	1.03e-24	0.4	0.33	Height;	chr6:109371573	chr6:109382795~109383666:+
BRCA	cis	rs853679	0.517	rs17711344	ENSG00000220721.1	OR1F12	-11.22	1.18e-27	1.04e-24	-0.43	-0.33	Depression;	chr6:28109824	chr6:28073316~28074233:+
BRCA	cis	rs2153535	0.58	rs2327064	ENSG00000230939.1	RP11-314C16.1	-11.22	1.18e-27	1.04e-24	-0.39	-0.33	Motion sickness;	chr6:8453819	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs9378556	ENSG00000230939.1	RP11-314C16.1	-11.22	1.19e-27	1.05e-24	-0.39	-0.33	Motion sickness;	chr6:8514462	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs9406171	ENSG00000230939.1	RP11-314C16.1	-11.22	1.19e-27	1.05e-24	-0.39	-0.33	Motion sickness;	chr6:8515129	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.54	rs9378557	ENSG00000230939.1	RP11-314C16.1	-11.22	1.19e-27	1.05e-24	-0.39	-0.33	Motion sickness;	chr6:8517148	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs2143354	ENSG00000230939.1	RP11-314C16.1	-11.22	1.19e-27	1.05e-24	-0.39	-0.33	Motion sickness;	chr6:8517674	chr6:8784178~8785445:+
BRCA	cis	rs62388641	0.802	rs13202504	ENSG00000272279.1	RP11-157J24.2	11.22	1.2e-27	1.06e-24	0.54	0.33	Daytime sleep phenotypes;	chr6:1537640	chr6:1528364~1528911:-
BRCA	cis	rs67311347	0.955	rs9821036	ENSG00000223797.4	ENTPD3-AS1	11.22	1.2e-27	1.06e-24	0.37	0.33	Renal cell carcinoma;	chr3:40337516	chr3:40313802~40453329:-
BRCA	cis	rs11673344	0.832	rs76470527	ENSG00000226686.6	LINC01535	11.22	1.2e-27	1.06e-24	0.47	0.33	Obesity-related traits;	chr19:37035981	chr19:37251912~37265535:+
BRCA	cis	rs9545047	0.604	rs7319212	ENSG00000227676.3	LINC01068	-11.22	1.2e-27	1.06e-24	-0.38	-0.33	Schizophrenia;	chr13:79365404	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs7319252	ENSG00000227676.3	LINC01068	-11.22	1.2e-27	1.06e-24	-0.38	-0.33	Schizophrenia;	chr13:79365471	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs9318633	ENSG00000227676.3	LINC01068	-11.22	1.2e-27	1.06e-24	-0.38	-0.33	Schizophrenia;	chr13:79369113	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs12872328	ENSG00000227676.3	LINC01068	-11.22	1.2e-27	1.06e-24	-0.38	-0.33	Schizophrenia;	chr13:79370489	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs2182010	ENSG00000227676.3	LINC01068	-11.22	1.2e-27	1.06e-24	-0.38	-0.33	Schizophrenia;	chr13:79370618	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs35476664	ENSG00000227676.3	LINC01068	-11.22	1.2e-27	1.06e-24	-0.38	-0.33	Schizophrenia;	chr13:79375462	chr13:79566727~79571436:+
BRCA	cis	rs8059260	0.668	rs7198089	ENSG00000274038.1	RP11-66H6.4	-11.22	1.21e-27	1.06e-24	-0.49	-0.33	Alcohol consumption over the past year;	chr16:11027199	chr16:11056556~11057034:+
BRCA	cis	rs11673344	0.801	rs17707446	ENSG00000226686.6	LINC01535	-11.22	1.21e-27	1.07e-24	-0.47	-0.33	Obesity-related traits;	chr19:37092140	chr19:37251912~37265535:+
BRCA	cis	rs2153535	0.58	rs9406167	ENSG00000230939.1	RP11-314C16.1	-11.22	1.21e-27	1.07e-24	-0.39	-0.33	Motion sickness;	chr6:8502619	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs6941670	ENSG00000230939.1	RP11-314C16.1	-11.22	1.22e-27	1.07e-24	-0.4	-0.33	Motion sickness;	chr6:8446113	chr6:8784178~8785445:+
BRCA	cis	rs2243480	1	rs4718315	ENSG00000226824.5	RP4-756H11.3	11.21	1.23e-27	1.08e-24	0.63	0.33	Diabetic kidney disease;	chr7:66183554	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs4718316	ENSG00000226824.5	RP4-756H11.3	11.21	1.23e-27	1.08e-24	0.63	0.33	Diabetic kidney disease;	chr7:66183744	chr7:66654538~66669855:+
BRCA	cis	rs11673344	0.832	rs56080874	ENSG00000226686.6	LINC01535	11.21	1.23e-27	1.08e-24	0.47	0.33	Obesity-related traits;	chr19:37085487	chr19:37251912~37265535:+
BRCA	cis	rs2243480	1	rs6974723	ENSG00000226824.5	RP4-756H11.3	11.21	1.25e-27	1.1e-24	0.63	0.33	Diabetic kidney disease;	chr7:66172952	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs9769882	ENSG00000226824.5	RP4-756H11.3	11.21	1.25e-27	1.1e-24	0.63	0.33	Diabetic kidney disease;	chr7:66177938	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs6966322	ENSG00000226824.5	RP4-756H11.3	11.21	1.25e-27	1.1e-24	0.63	0.33	Diabetic kidney disease;	chr7:66181767	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs4145008	ENSG00000226824.5	RP4-756H11.3	11.21	1.25e-27	1.1e-24	0.63	0.33	Diabetic kidney disease;	chr7:66182524	chr7:66654538~66669855:+
BRCA	cis	rs6782228	0.606	rs9828893	ENSG00000242551.2	POU5F1P6	-11.21	1.26e-27	1.11e-24	-0.42	-0.33	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128614082	chr3:128674735~128677005:-
BRCA	cis	rs321358	0.945	rs7111445	ENSG00000271584.1	RP11-89C3.4	-11.21	1.26e-27	1.11e-24	-0.55	-0.33	Body mass index;	chr11:111105787	chr11:111091932~111097357:-
BRCA	cis	rs2153535	0.58	rs1932280	ENSG00000230939.1	RP11-314C16.1	-11.21	1.27e-27	1.11e-24	-0.39	-0.33	Motion sickness;	chr6:8473421	chr6:8784178~8785445:+
BRCA	cis	rs8059260	0.668	rs75637865	ENSG00000274038.1	RP11-66H6.4	-11.21	1.28e-27	1.13e-24	-0.53	-0.33	Alcohol consumption over the past year;	chr16:10982439	chr16:11056556~11057034:+
BRCA	cis	rs875971	0.862	rs6964437	ENSG00000222364.1	RNU6-96P	11.21	1.29e-27	1.13e-24	0.39	0.33	Aortic root size;	chr7:66221457	chr7:66395191~66395286:+
BRCA	cis	rs321358	1	rs321358	ENSG00000271584.1	RP11-89C3.4	11.21	1.29e-27	1.13e-24	0.54	0.33	Body mass index;	chr11:111125247	chr11:111091932~111097357:-
BRCA	cis	rs2243480	1	rs6958420	ENSG00000226824.5	RP4-756H11.3	11.21	1.3e-27	1.14e-24	0.63	0.33	Diabetic kidney disease;	chr7:66286184	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs1392104	ENSG00000226824.5	RP4-756H11.3	11.21	1.3e-27	1.14e-24	0.63	0.33	Diabetic kidney disease;	chr7:66294120	chr7:66654538~66669855:+
BRCA	cis	rs7044106	0.762	rs1158553	ENSG00000226752.6	PSMD5-AS1	-11.21	1.32e-27	1.16e-24	-0.4	-0.33	Hip circumference adjusted for BMI;	chr9:120638696	chr9:120824828~120854385:+
BRCA	cis	rs2243480	0.706	rs6460257	ENSG00000226824.5	RP4-756H11.3	-11.21	1.34e-27	1.17e-24	-0.53	-0.33	Diabetic kidney disease;	chr7:65731813	chr7:66654538~66669855:+
BRCA	cis	rs7829975	0.688	rs13270194	ENSG00000253893.2	FAM85B	-11.2	1.36e-27	1.19e-24	-0.41	-0.33	Mood instability;	chr8:8520592	chr8:8167819~8226614:-
BRCA	cis	rs2581828	0.618	rs6792345	ENSG00000242142.1	SERBP1P3	-11.2	1.38e-27	1.21e-24	-0.42	-0.33	Crohn's disease;	chr3:53131178	chr3:53064283~53065091:-
BRCA	cis	rs2581828	0.618	rs6792363	ENSG00000242142.1	SERBP1P3	-11.2	1.38e-27	1.21e-24	-0.42	-0.33	Crohn's disease;	chr3:53131247	chr3:53064283~53065091:-
BRCA	cis	rs2581828	0.618	rs6445565	ENSG00000242142.1	SERBP1P3	-11.2	1.38e-27	1.21e-24	-0.42	-0.33	Crohn's disease;	chr3:53131448	chr3:53064283~53065091:-
BRCA	cis	rs2581828	0.591	rs6445566	ENSG00000242142.1	SERBP1P3	-11.2	1.38e-27	1.21e-24	-0.42	-0.33	Crohn's disease;	chr3:53131611	chr3:53064283~53065091:-
BRCA	cis	rs2581828	0.618	rs13319872	ENSG00000242142.1	SERBP1P3	-11.2	1.38e-27	1.21e-24	-0.42	-0.33	Crohn's disease;	chr3:53132082	chr3:53064283~53065091:-
BRCA	cis	rs2581828	0.618	rs6784207	ENSG00000242142.1	SERBP1P3	-11.2	1.38e-27	1.21e-24	-0.42	-0.33	Crohn's disease;	chr3:53133458	chr3:53064283~53065091:-
BRCA	cis	rs2153535	0.58	rs9406170	ENSG00000230939.1	RP11-314C16.1	-11.2	1.38e-27	1.21e-24	-0.39	-0.33	Motion sickness;	chr6:8513920	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs9379222	ENSG00000230939.1	RP11-314C16.1	-11.2	1.38e-27	1.21e-24	-0.39	-0.33	Motion sickness;	chr6:8514555	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs9406172	ENSG00000230939.1	RP11-314C16.1	-11.2	1.38e-27	1.21e-24	-0.39	-0.33	Motion sickness;	chr6:8515231	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs9406174	ENSG00000230939.1	RP11-314C16.1	-11.2	1.38e-27	1.21e-24	-0.39	-0.33	Motion sickness;	chr6:8516531	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs2143356	ENSG00000230939.1	RP11-314C16.1	-11.2	1.38e-27	1.21e-24	-0.39	-0.33	Motion sickness;	chr6:8517442	chr6:8784178~8785445:+
BRCA	cis	rs9487094	0.961	rs3778475	ENSG00000260273.1	RP11-425D10.10	11.2	1.39e-27	1.22e-24	0.4	0.33	Height;	chr6:109375003	chr6:109382795~109383666:+
BRCA	cis	rs2243480	0.711	rs2420172	ENSG00000226824.5	RP4-756H11.3	11.2	1.41e-27	1.23e-24	0.63	0.33	Diabetic kidney disease;	chr7:66170354	chr7:66654538~66669855:+
BRCA	cis	rs11096990	0.551	rs11724855	ENSG00000249207.1	RP11-360F5.1	-11.2	1.42e-27	1.24e-24	-0.39	-0.33	Cognitive function;	chr4:39163379	chr4:39112677~39126818:-
BRCA	cis	rs2442825	0.693	rs2596913	ENSG00000206573.7	THUMPD3-AS1	11.2	1.42e-27	1.25e-24	0.29	0.33	Cerebrospinal fluid clusterin levels;	chr3:9394788	chr3:9349689~9398579:-
BRCA	cis	rs9545047	0.604	rs7996652	ENSG00000227676.3	LINC01068	11.2	1.44e-27	1.26e-24	0.38	0.33	Schizophrenia;	chr13:79341474	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs9565488	ENSG00000227676.3	LINC01068	11.2	1.44e-27	1.26e-24	0.38	0.33	Schizophrenia;	chr13:79341604	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs7981067	ENSG00000227676.3	LINC01068	11.2	1.45e-27	1.27e-24	0.38	0.33	Schizophrenia;	chr13:79341254	chr13:79566727~79571436:+
BRCA	cis	rs875971	0.825	rs7384021	ENSG00000222364.1	RNU6-96P	11.2	1.45e-27	1.27e-24	0.39	0.33	Aortic root size;	chr7:66612917	chr7:66395191~66395286:+
BRCA	cis	rs801193	0.569	rs3846973	ENSG00000222364.1	RNU6-96P	11.2	1.45e-27	1.27e-24	0.39	0.33	Aortic root size;	chr7:66655048	chr7:66395191~66395286:+
BRCA	cis	rs2243480	1	rs4718317	ENSG00000226824.5	RP4-756H11.3	11.2	1.47e-27	1.29e-24	0.61	0.33	Diabetic kidney disease;	chr7:66183914	chr7:66654538~66669855:+
BRCA	cis	rs2404602	0.71	rs2469541	ENSG00000259422.1	RP11-593F23.1	-11.2	1.49e-27	1.31e-24	-0.41	-0.33	Blood metabolite levels;	chr15:76269777	chr15:76174891~76181486:-
BRCA	cis	rs875971	0.862	rs11765791	ENSG00000222364.1	RNU6-96P	-11.2	1.5e-27	1.31e-24	-0.39	-0.33	Aortic root size;	chr7:66471587	chr7:66395191~66395286:+
BRCA	cis	rs812925	0.512	rs7558954	ENSG00000271889.1	RP11-493E12.1	11.19	1.51e-27	1.32e-24	0.39	0.33	Immature fraction of reticulocytes;	chr2:61157771	chr2:61151433~61162105:-
BRCA	cis	rs10875746	0.768	rs10875724	ENSG00000240399.1	RP1-228P16.1	-11.19	1.51e-27	1.33e-24	-0.43	-0.33	Longevity (90 years and older);	chr12:48026470	chr12:48054813~48055591:-
BRCA	cis	rs9487094	0.885	rs12524273	ENSG00000260273.1	RP11-425D10.10	11.19	1.53e-27	1.34e-24	0.4	0.33	Height;	chr6:109395761	chr6:109382795~109383666:+
BRCA	cis	rs9545047	0.604	rs9574411	ENSG00000227676.3	LINC01068	-11.19	1.56e-27	1.36e-24	-0.38	-0.33	Schizophrenia;	chr13:79354342	chr13:79566727~79571436:+
BRCA	cis	rs67311347	1	rs6762251	ENSG00000223797.4	ENTPD3-AS1	-11.19	1.56e-27	1.36e-24	-0.36	-0.33	Renal cell carcinoma;	chr3:40489645	chr3:40313802~40453329:-
BRCA	cis	rs2153535	0.58	rs6597334	ENSG00000230939.1	RP11-314C16.1	-11.19	1.58e-27	1.38e-24	-0.39	-0.33	Motion sickness;	chr6:8504546	chr6:8784178~8785445:+
BRCA	cis	rs801193	0.548	rs2109297	ENSG00000222364.1	RNU6-96P	11.19	1.58e-27	1.38e-24	0.39	0.33	Aortic root size;	chr7:66657397	chr7:66395191~66395286:+
BRCA	cis	rs7044106	0.762	rs1547268	ENSG00000226752.6	PSMD5-AS1	-11.19	1.59e-27	1.39e-24	-0.4	-0.33	Hip circumference adjusted for BMI;	chr9:120646410	chr9:120824828~120854385:+
BRCA	cis	rs2153535	0.601	rs2327054	ENSG00000230939.1	RP11-314C16.1	-11.19	1.61e-27	1.4e-24	-0.39	-0.33	Motion sickness;	chr6:8442897	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.623	rs2327055	ENSG00000230939.1	RP11-314C16.1	-11.19	1.61e-27	1.4e-24	-0.39	-0.33	Motion sickness;	chr6:8442912	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs7766852	ENSG00000230939.1	RP11-314C16.1	-11.19	1.63e-27	1.42e-24	-0.39	-0.33	Motion sickness;	chr6:8472184	chr6:8784178~8785445:+
BRCA	cis	rs67311347	0.868	rs10865895	ENSG00000223797.4	ENTPD3-AS1	11.19	1.63e-27	1.42e-24	0.37	0.33	Renal cell carcinoma;	chr3:40337186	chr3:40313802~40453329:-
BRCA	cis	rs7201929	1	rs7201929	ENSG00000259982.1	CDC37P1	11.19	1.63e-27	1.43e-24	0.42	0.33	QT interval;	chr16:28860645	chr16:28700294~28701540:-
BRCA	cis	rs9322193	0.607	rs9322229	ENSG00000223701.3	RAET1E-AS1	11.19	1.65e-27	1.44e-24	0.44	0.33	Lung cancer;	chr6:149908949	chr6:149884431~149919508:+
BRCA	cis	rs10129255	1	rs61997605	ENSG00000211970.3	IGHV4-61	-11.19	1.65e-27	1.44e-24	-0.24	-0.33	Kawasaki disease;	chr14:106678368	chr14:106639119~106639657:-
BRCA	cis	rs7849270	0.801	rs10819475	ENSG00000268707.1	RP11-247A12.7	11.18	1.67e-27	1.46e-24	0.42	0.33	Blood metabolite ratios;	chr9:129168561	chr9:129170434~129170940:+
BRCA	cis	rs150992	0.532	rs416750	ENSG00000248489.1	CTD-2007H13.3	11.18	1.67e-27	1.46e-24	0.37	0.33	Body mass index;	chr5:98999046	chr5:98929171~98995013:+
BRCA	cis	rs150992	0.609	rs819232	ENSG00000248489.1	CTD-2007H13.3	11.18	1.67e-27	1.46e-24	0.37	0.33	Body mass index;	chr5:98999416	chr5:98929171~98995013:+
BRCA	cis	rs2442825	0.693	rs2600194	ENSG00000206573.7	THUMPD3-AS1	11.18	1.68e-27	1.46e-24	0.29	0.33	Cerebrospinal fluid clusterin levels;	chr3:9382941	chr3:9349689~9398579:-
BRCA	cis	rs10759883	0.58	rs690495	ENSG00000175611.10	LINC00476	11.18	1.69e-27	1.48e-24	0.38	0.33	Nicotine dependence;	chr9:95893511	chr9:95759231~95875977:-
BRCA	cis	rs2880765	0.566	rs12911430	ENSG00000259295.5	CSPG4P12	11.18	1.69e-27	1.48e-24	0.43	0.33	Coronary artery disease;	chr15:85468033	chr15:85191438~85213905:+
BRCA	cis	rs172166	0.694	rs9295760	ENSG00000220721.1	OR1F12	11.18	1.7e-27	1.48e-24	0.4	0.33	Cardiac Troponin-T levels;	chr6:28179607	chr6:28073316~28074233:+
BRCA	cis	rs875971	0.767	rs12668005	ENSG00000222364.1	RNU6-96P	-11.18	1.7e-27	1.48e-24	-0.39	-0.33	Aortic root size;	chr7:66444034	chr7:66395191~66395286:+
BRCA	cis	rs801193	0.569	rs2013908	ENSG00000222364.1	RNU6-96P	11.18	1.71e-27	1.49e-24	0.39	0.33	Aortic root size;	chr7:66656082	chr7:66395191~66395286:+
BRCA	cis	rs10129255	1	rs8012033	ENSG00000211970.3	IGHV4-61	-11.18	1.71e-27	1.49e-24	-0.24	-0.33	Kawasaki disease;	chr14:106678854	chr14:106639119~106639657:-
BRCA	cis	rs7598759	0.527	rs4973417	ENSG00000181798.2	LINC00471	-11.18	1.74e-27	1.52e-24	-0.4	-0.33	Noise-induced hearing loss;	chr2:231484925	chr2:231508426~231514339:-
BRCA	cis	rs875971	0.789	rs7808013	ENSG00000222364.1	RNU6-96P	11.18	1.74e-27	1.52e-24	0.39	0.33	Aortic root size;	chr7:66606209	chr7:66395191~66395286:+
BRCA	cis	rs812925	0.512	rs1177309	ENSG00000271889.1	RP11-493E12.1	11.18	1.75e-27	1.53e-24	0.39	0.33	Immature fraction of reticulocytes;	chr2:61158113	chr2:61151433~61162105:-
BRCA	cis	rs9322193	0.607	rs4870078	ENSG00000268592.3	RAET1E-AS1	-11.18	1.76e-27	1.53e-24	-0.45	-0.33	Lung cancer;	chr6:149880676	chr6:149863494~149919507:+
BRCA	cis	rs2243480	1	rs10807701	ENSG00000226824.5	RP4-756H11.3	11.18	1.77e-27	1.54e-24	0.63	0.33	Diabetic kidney disease;	chr7:66259699	chr7:66654538~66669855:+
BRCA	cis	rs1609391	0.543	rs6800690	ENSG00000239213.4	NCK1-AS1	11.18	1.77e-27	1.55e-24	0.35	0.33	Neuroticism;	chr3:136904184	chr3:136841726~136862054:-
BRCA	cis	rs1609391	0.543	rs7651085	ENSG00000239213.4	NCK1-AS1	11.18	1.77e-27	1.55e-24	0.35	0.33	Neuroticism;	chr3:136906497	chr3:136841726~136862054:-
BRCA	cis	rs1609391	0.543	rs6761993	ENSG00000239213.4	NCK1-AS1	11.18	1.77e-27	1.55e-24	0.35	0.33	Neuroticism;	chr3:136907060	chr3:136841726~136862054:-
BRCA	cis	rs16863064	0.66	rs1007308	ENSG00000279891.1	FLJ42393	-11.18	1.8e-27	1.57e-24	-0.42	-0.33	Schizophrenia;	chr3:188171935	chr3:188178543~188180812:+
BRCA	cis	rs2153535	0.58	rs2327057	ENSG00000230939.1	RP11-314C16.1	-11.18	1.8e-27	1.57e-24	-0.39	-0.33	Motion sickness;	chr6:8443086	chr6:8784178~8785445:+
BRCA	cis	rs7849270	0.76	rs1075650	ENSG00000268707.1	RP11-247A12.7	11.18	1.81e-27	1.58e-24	0.43	0.33	Blood metabolite ratios;	chr9:129176634	chr9:129170434~129170940:+
BRCA	cis	rs7684253	0.565	rs12641030	ENSG00000269949.1	RP11-738E22.3	-11.18	1.83e-27	1.6e-24	-0.37	-0.33	Migraine;	chr4:56937339	chr4:56960927~56961373:-
BRCA	cis	rs2153535	0.58	rs1932283	ENSG00000230939.1	RP11-314C16.1	-11.17	1.84e-27	1.6e-24	-0.39	-0.33	Motion sickness;	chr6:8477428	chr6:8784178~8785445:+
BRCA	cis	rs801193	0.569	rs6951302	ENSG00000222364.1	RNU6-96P	11.17	1.85e-27	1.61e-24	0.39	0.33	Aortic root size;	chr7:66667525	chr7:66395191~66395286:+
BRCA	cis	rs1555322	0.53	rs2425042	ENSG00000126005.14	MMP24-AS1	-11.17	1.88e-27	1.64e-24	-0.45	-0.33	Attention deficit hyperactivity disorder;	chr20:35278092	chr20:35216462~35278131:-
BRCA	cis	rs9545047	0.564	rs7336186	ENSG00000227676.3	LINC01068	-11.17	1.89e-27	1.64e-24	-0.38	-0.33	Schizophrenia;	chr13:79385497	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs2182009	ENSG00000227676.3	LINC01068	-11.17	1.89e-27	1.64e-24	-0.38	-0.33	Schizophrenia;	chr13:79397781	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs4605023	ENSG00000227676.3	LINC01068	-11.17	1.89e-27	1.64e-24	-0.38	-0.33	Schizophrenia;	chr13:79398700	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs12877507	ENSG00000227676.3	LINC01068	-11.17	1.89e-27	1.64e-24	-0.38	-0.33	Schizophrenia;	chr13:79401822	chr13:79566727~79571436:+
BRCA	cis	rs7849270	0.76	rs882616	ENSG00000268707.1	RP11-247A12.7	11.17	1.89e-27	1.65e-24	0.43	0.33	Blood metabolite ratios;	chr9:129178586	chr9:129170434~129170940:+
BRCA	cis	rs9545047	0.604	rs9565496	ENSG00000227676.3	LINC01068	-11.17	1.9e-27	1.65e-24	-0.38	-0.33	Schizophrenia;	chr13:79398751	chr13:79566727~79571436:+
BRCA	cis	rs10129255	1	rs9324091	ENSG00000211970.3	IGHV4-61	-11.17	1.9e-27	1.65e-24	-0.24	-0.33	Kawasaki disease;	chr14:106676625	chr14:106639119~106639657:-
BRCA	cis	rs9309711	0.506	rs9284794	ENSG00000225234.1	TRAPPC12-AS1	-11.17	1.9e-27	1.66e-24	-0.35	-0.33	Neurofibrillary tangles;	chr2:3488281	chr2:3481242~3482409:-
BRCA	cis	rs2153535	0.58	rs7741403	ENSG00000230939.1	RP11-314C16.1	11.17	1.93e-27	1.68e-24	0.39	0.33	Motion sickness;	chr6:8530345	chr6:8784178~8785445:+
BRCA	cis	rs2188561	1	rs2188561	ENSG00000241764.3	AC002467.7	11.17	1.93e-27	1.68e-24	0.48	0.33	Alcohol consumption;	chr7:107695613	chr7:107742817~107744581:-
BRCA	cis	rs150992	0.609	rs1093794	ENSG00000248489.1	CTD-2007H13.3	-11.17	1.96e-27	1.71e-24	-0.37	-0.33	Body mass index;	chr5:98993334	chr5:98929171~98995013:+
BRCA	cis	rs2015599	0.56	rs11050147	ENSG00000257176.2	RP11-996F15.2	-11.17	1.98e-27	1.72e-24	-0.41	-0.33	Platelet count;Mean platelet volume;	chr12:29242746	chr12:29280418~29317848:-
BRCA	cis	rs150992	0.631	rs112047336	ENSG00000248489.1	CTD-2007H13.3	11.17	1.99e-27	1.73e-24	0.37	0.33	Body mass index;	chr5:98990041	chr5:98929171~98995013:+
BRCA	cis	rs150992	0.609	rs112042355	ENSG00000248489.1	CTD-2007H13.3	11.17	1.99e-27	1.73e-24	0.37	0.33	Body mass index;	chr5:98990046	chr5:98929171~98995013:+
BRCA	cis	rs150992	0.587	rs75001231	ENSG00000248489.1	CTD-2007H13.3	11.17	1.99e-27	1.73e-24	0.37	0.33	Body mass index;	chr5:98990085	chr5:98929171~98995013:+
BRCA	cis	rs8062405	0.721	rs151181	ENSG00000278665.1	RP11-666O2.4	11.17	1.99e-27	1.73e-24	0.35	0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28479196	chr16:28599241~28601881:-
BRCA	cis	rs67311347	1	rs17078941	ENSG00000223797.4	ENTPD3-AS1	-11.17	2.01e-27	1.75e-24	-0.39	-0.33	Renal cell carcinoma;	chr3:40409397	chr3:40313802~40453329:-
BRCA	cis	rs801193	0.591	rs4506088	ENSG00000222364.1	RNU6-96P	11.17	2.02e-27	1.76e-24	0.39	0.33	Aortic root size;	chr7:66670470	chr7:66395191~66395286:+
BRCA	cis	rs9545047	0.567	rs9574420	ENSG00000227676.3	LINC01068	-11.16	2.03e-27	1.76e-24	-0.39	-0.33	Schizophrenia;	chr13:79404342	chr13:79566727~79571436:+
BRCA	cis	rs875971	0.798	rs12698522	ENSG00000222364.1	RNU6-96P	-11.16	2.06e-27	1.79e-24	-0.39	-0.33	Aortic root size;	chr7:66502354	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.83	rs28714531	ENSG00000222364.1	RNU6-96P	-11.16	2.06e-27	1.79e-24	-0.39	-0.33	Aortic root size;	chr7:66503250	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.862	rs12698526	ENSG00000222364.1	RNU6-96P	-11.16	2.06e-27	1.79e-24	-0.39	-0.33	Aortic root size;	chr7:66504118	chr7:66395191~66395286:+
BRCA	cis	rs4722166	0.695	rs7793125	ENSG00000179428.2	AC073072.5	-11.16	2.08e-27	1.8e-24	-0.34	-0.33	Lung cancer;	chr7:22769541	chr7:22725395~22727620:-
BRCA	cis	rs321358	1	rs321352	ENSG00000271584.1	RP11-89C3.4	11.16	2.09e-27	1.81e-24	0.55	0.33	Body mass index;	chr11:111123001	chr11:111091932~111097357:-
BRCA	cis	rs10129255	1	rs8010605	ENSG00000211970.3	IGHV4-61	-11.16	2.09e-27	1.82e-24	-0.24	-0.33	Kawasaki disease;	chr14:106678742	chr14:106639119~106639657:-
BRCA	cis	rs9318086	0.663	rs2312295	ENSG00000205861.10	C1QTNF9B-AS1	-11.16	2.1e-27	1.82e-24	-0.42	-0.33	Myopia (pathological);	chr13:23883605	chr13:23888889~23897263:+
BRCA	cis	rs6539288	0.677	rs11113144	ENSG00000260329.1	RP11-412D9.4	-11.16	2.1e-27	1.83e-24	-0.37	-0.33	Total body bone mineral density;	chr12:106929644	chr12:106954029~106955497:-
BRCA	cis	rs3091242	0.934	rs666686	ENSG00000224183.1	SDHDP6	-11.16	2.12e-27	1.84e-24	-0.39	-0.33	Erythrocyte sedimentation rate;	chr1:25393020	chr1:25294164~25294643:-
BRCA	cis	rs2404602	0.684	rs11072600	ENSG00000259422.1	RP11-593F23.1	-11.16	2.12e-27	1.84e-24	-0.42	-0.33	Blood metabolite levels;	chr15:76575574	chr15:76174891~76181486:-
BRCA	cis	rs9545047	0.547	rs1590465	ENSG00000227676.3	LINC01068	-11.16	2.12e-27	1.84e-24	-0.38	-0.33	Schizophrenia;	chr13:79393998	chr13:79566727~79571436:+
BRCA	cis	rs7849270	0.76	rs419636	ENSG00000268707.1	RP11-247A12.7	11.16	2.13e-27	1.85e-24	0.42	0.33	Blood metabolite ratios;	chr9:129168998	chr9:129170434~129170940:+
BRCA	cis	rs2153535	0.58	rs1928184	ENSG00000230939.1	RP11-314C16.1	-11.16	2.15e-27	1.86e-24	-0.39	-0.33	Motion sickness;	chr6:8531875	chr6:8784178~8785445:+
BRCA	cis	rs2404602	0.684	rs12437981	ENSG00000259422.1	RP11-593F23.1	-11.16	2.15e-27	1.87e-24	-0.42	-0.33	Blood metabolite levels;	chr15:76550060	chr15:76174891~76181486:-
BRCA	cis	rs2153535	0.58	rs7743418	ENSG00000230939.1	RP11-314C16.1	-11.16	2.16e-27	1.87e-24	-0.39	-0.33	Motion sickness;	chr6:8437895	chr6:8784178~8785445:+
BRCA	cis	rs6921919	0.515	rs1339898	ENSG00000216901.1	AL022393.7	11.16	2.16e-27	1.88e-24	0.42	0.33	Autism spectrum disorder or schizophrenia;	chr6:28427729	chr6:28176188~28176674:+
BRCA	cis	rs8062405	0.964	rs62036614	ENSG00000251417.2	RP11-1348G14.4	-11.16	2.17e-27	1.88e-24	-0.4	-0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28813364	chr16:28802743~28817828:+
BRCA	cis	rs10129255	0.957	rs17113284	ENSG00000211970.3	IGHV4-61	11.16	2.17e-27	1.89e-24	0.24	0.33	Kawasaki disease;	chr14:106684476	chr14:106639119~106639657:-
BRCA	cis	rs62103177	0.525	rs10438902	ENSG00000261126.6	RP11-795F19.1	-11.16	2.18e-27	1.89e-24	-0.4	-0.33	Opioid sensitivity;	chr18:79985640	chr18:80046900~80095482:+
BRCA	cis	rs2153535	0.58	rs5001130	ENSG00000230939.1	RP11-314C16.1	-11.16	2.19e-27	1.9e-24	-0.39	-0.33	Motion sickness;	chr6:8442065	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs1577466	ENSG00000230939.1	RP11-314C16.1	-11.16	2.19e-27	1.9e-24	-0.39	-0.33	Motion sickness;	chr6:8443959	chr6:8784178~8785445:+
BRCA	cis	rs1075265	0.588	rs1477258	ENSG00000233266.1	HMGB1P31	11.16	2.19e-27	1.9e-24	0.39	0.33	Chronotype;Morning vs. evening chronotype;	chr2:54000031	chr2:54051334~54051760:+
BRCA	cis	rs2153535	0.58	rs7745043	ENSG00000230939.1	RP11-314C16.1	-11.16	2.2e-27	1.91e-24	-0.39	-0.33	Motion sickness;	chr6:8513274	chr6:8784178~8785445:+
BRCA	cis	rs62103177	0.608	rs4799115	ENSG00000261126.6	RP11-795F19.1	-11.16	2.22e-27	1.93e-24	-0.42	-0.33	Opioid sensitivity;	chr18:79976365	chr18:80046900~80095482:+
BRCA	cis	rs2015599	0.623	rs2288128	ENSG00000275476.1	RP11-996F15.4	11.16	2.23e-27	1.93e-24	0.38	0.33	Platelet count;Mean platelet volume;	chr12:29316054	chr12:29277397~29277882:-
BRCA	cis	rs2015599	0.584	rs2288129	ENSG00000275476.1	RP11-996F15.4	11.16	2.23e-27	1.93e-24	0.38	0.33	Platelet count;Mean platelet volume;	chr12:29316355	chr12:29277397~29277882:-
BRCA	cis	rs2153535	0.58	rs7747306	ENSG00000230939.1	RP11-314C16.1	11.16	2.23e-27	1.93e-24	0.39	0.33	Motion sickness;	chr6:8453430	chr6:8784178~8785445:+
BRCA	cis	rs5760092	0.572	rs738806	ENSG00000218537.1	MIF-AS1	11.15	2.25e-27	1.95e-24	0.47	0.33	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23891985	chr22:23894426~23898930:-
BRCA	cis	rs2243480	1	rs1267820	ENSG00000226824.5	RP4-756H11.3	-11.15	2.29e-27	1.98e-24	-0.64	-0.33	Diabetic kidney disease;	chr7:66585308	chr7:66654538~66669855:+
BRCA	cis	rs11676348	0.791	rs4133195	ENSG00000261338.2	RP11-378A13.1	11.15	2.29e-27	1.98e-24	0.34	0.33	Ulcerative colitis;	chr2:218086522	chr2:218255319~218257366:+
BRCA	cis	rs321358	1	rs321355	ENSG00000271584.1	RP11-89C3.4	11.15	2.29e-27	1.99e-24	0.55	0.33	Body mass index;	chr11:111124273	chr11:111091932~111097357:-
BRCA	cis	rs4423214	0.592	rs10898211	ENSG00000254682.1	RP11-660L16.2	-11.15	2.3e-27	1.99e-24	-0.49	-0.33	Vitamin D levels;	chr11:71499631	chr11:71448674~71452157:+
BRCA	cis	rs10256972	0.616	rs6957733	ENSG00000229043.2	AC091729.9	-11.15	2.31e-27	2e-24	-0.39	-0.33	Endometriosis;Longevity;	chr7:1066691	chr7:1160374~1165267:+
BRCA	cis	rs150992	0.57	rs7710032	ENSG00000248489.1	CTD-2007H13.3	-11.15	2.31e-27	2e-24	-0.37	-0.33	Body mass index;	chr5:99007501	chr5:98929171~98995013:+
BRCA	cis	rs2153535	0.541	rs9505456	ENSG00000230939.1	RP11-314C16.1	-11.15	2.35e-27	2.03e-24	-0.39	-0.33	Motion sickness;	chr6:8478768	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs9505458	ENSG00000230939.1	RP11-314C16.1	-11.15	2.35e-27	2.03e-24	-0.39	-0.33	Motion sickness;	chr6:8478982	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs9379215	ENSG00000230939.1	RP11-314C16.1	-11.15	2.35e-27	2.03e-24	-0.39	-0.33	Motion sickness;	chr6:8480992	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs6597326	ENSG00000230939.1	RP11-314C16.1	-11.15	2.35e-27	2.03e-24	-0.39	-0.33	Motion sickness;	chr6:8481786	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs1414344	ENSG00000230939.1	RP11-314C16.1	-11.15	2.35e-27	2.04e-24	-0.39	-0.33	Motion sickness;	chr6:8471132	chr6:8784178~8785445:+
BRCA	cis	rs2980439	0.525	rs2980508	ENSG00000253893.2	FAM85B	-11.15	2.36e-27	2.04e-24	-0.39	-0.33	Neuroticism;	chr8:8314210	chr8:8167819~8226614:-
BRCA	cis	rs2153535	0.541	rs1414353	ENSG00000230939.1	RP11-314C16.1	-11.15	2.37e-27	2.05e-24	-0.39	-0.33	Motion sickness;	chr6:8485409	chr6:8784178~8785445:+
BRCA	cis	rs150992	0.587	rs4703052	ENSG00000248489.1	CTD-2007H13.3	-11.15	2.37e-27	2.05e-24	-0.36	-0.33	Body mass index;	chr5:99008818	chr5:98929171~98995013:+
BRCA	cis	rs150992	0.609	rs709390	ENSG00000248489.1	CTD-2007H13.3	11.15	2.39e-27	2.06e-24	0.37	0.33	Body mass index;	chr5:98993771	chr5:98929171~98995013:+
BRCA	cis	rs1609391	0.561	rs6439675	ENSG00000239213.4	NCK1-AS1	11.15	2.4e-27	2.08e-24	0.35	0.33	Neuroticism;	chr3:136906594	chr3:136841726~136862054:-
BRCA	cis	rs801193	0.569	rs13242290	ENSG00000222364.1	RNU6-96P	11.15	2.41e-27	2.08e-24	0.38	0.33	Aortic root size;	chr7:66656898	chr7:66395191~66395286:+
BRCA	cis	rs1555322	0.53	rs2425043	ENSG00000126005.14	MMP24-AS1	-11.15	2.41e-27	2.08e-24	-0.43	-0.33	Attention deficit hyperactivity disorder;	chr20:35280899	chr20:35216462~35278131:-
BRCA	cis	rs9545047	0.625	rs9565489	ENSG00000227676.3	LINC01068	11.15	2.42e-27	2.09e-24	0.38	0.33	Schizophrenia;	chr13:79342106	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.625	rs7319320	ENSG00000227676.3	LINC01068	11.15	2.43e-27	2.1e-24	0.38	0.33	Schizophrenia;	chr13:79343072	chr13:79566727~79571436:+
BRCA	cis	rs4713118	0.512	rs2622319	ENSG00000220721.1	OR1F12	11.15	2.43e-27	2.1e-24	0.4	0.33	Parkinson's disease;	chr6:28152623	chr6:28073316~28074233:+
BRCA	cis	rs172166	0.694	rs1150666	ENSG00000220721.1	OR1F12	11.15	2.43e-27	2.1e-24	0.4	0.33	Cardiac Troponin-T levels;	chr6:28156150	chr6:28073316~28074233:+
BRCA	cis	rs6539288	0.677	rs1348566	ENSG00000260329.1	RP11-412D9.4	-11.15	2.43e-27	2.11e-24	-0.37	-0.33	Total body bone mineral density;	chr12:106931870	chr12:106954029~106955497:-
BRCA	cis	rs9545047	0.604	rs3752994	ENSG00000227676.3	LINC01068	11.15	2.44e-27	2.11e-24	0.38	0.33	Schizophrenia;	chr13:79345076	chr13:79566727~79571436:+
BRCA	cis	rs150992	0.861	rs151102	ENSG00000248489.1	CTD-2007H13.3	-11.15	2.46e-27	2.13e-24	-0.36	-0.33	Body mass index;	chr5:98947626	chr5:98929171~98995013:+
BRCA	cis	rs2153535	0.601	rs330105	ENSG00000230939.1	RP11-314C16.1	-11.14	2.52e-27	2.18e-24	-0.39	-0.33	Motion sickness;	chr6:8543748	chr6:8784178~8785445:+
BRCA	cis	rs1609391	0.543	rs1347209	ENSG00000239213.4	NCK1-AS1	11.14	2.53e-27	2.19e-24	0.35	0.33	Neuroticism;	chr3:136907855	chr3:136841726~136862054:-
BRCA	cis	rs9545047	0.604	rs9530915	ENSG00000227676.3	LINC01068	11.14	2.55e-27	2.2e-24	0.38	0.33	Schizophrenia;	chr13:79396512	chr13:79566727~79571436:+
BRCA	cis	rs2243480	0.708	rs35825036	ENSG00000226824.5	RP4-756H11.3	-11.14	2.57e-27	2.22e-24	-0.64	-0.33	Diabetic kidney disease;	chr7:66521515	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs13237037	ENSG00000226824.5	RP4-756H11.3	-11.14	2.57e-27	2.22e-24	-0.64	-0.33	Diabetic kidney disease;	chr7:66532895	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs1796228	ENSG00000226824.5	RP4-756H11.3	-11.14	2.57e-27	2.22e-24	-0.64	-0.33	Diabetic kidney disease;	chr7:66568097	chr7:66654538~66669855:+
BRCA	cis	rs2243480	0.803	rs13224048	ENSG00000226824.5	RP4-756H11.3	-11.14	2.58e-27	2.23e-24	-0.64	-0.33	Diabetic kidney disease;	chr7:66528779	chr7:66654538~66669855:+
BRCA	cis	rs2153535	0.58	rs1410766	ENSG00000230939.1	RP11-314C16.1	-11.14	2.61e-27	2.25e-24	-0.39	-0.33	Motion sickness;	chr6:8525127	chr6:8784178~8785445:+
BRCA	cis	rs9545047	0.604	rs3742117	ENSG00000227676.3	LINC01068	11.14	2.63e-27	2.27e-24	0.37	0.33	Schizophrenia;	chr13:79342498	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.647	rs3742118	ENSG00000227676.3	LINC01068	11.14	2.63e-27	2.27e-24	0.37	0.33	Schizophrenia;	chr13:79342838	chr13:79566727~79571436:+
BRCA	cis	rs1891275	0.515	rs7911755	ENSG00000228701.1	TNKS2-AS1	-11.14	2.64e-27	2.28e-24	-0.38	-0.33	Intelligence (multi-trait analysis);	chr10:91730060	chr10:91782839~91798291:-
BRCA	cis	rs2404602	0.735	rs2436996	ENSG00000259422.1	RP11-593F23.1	-11.14	2.64e-27	2.28e-24	-0.43	-0.33	Blood metabolite levels;	chr15:76525079	chr15:76174891~76181486:-
BRCA	cis	rs1609391	0.543	rs9828009	ENSG00000239213.4	NCK1-AS1	11.14	2.66e-27	2.29e-24	0.35	0.33	Neuroticism;	chr3:136912433	chr3:136841726~136862054:-
BRCA	cis	rs10129255	0.912	rs67410411	ENSG00000211970.3	IGHV4-61	-11.14	2.66e-27	2.3e-24	-0.24	-0.33	Kawasaki disease;	chr14:106680324	chr14:106639119~106639657:-
BRCA	cis	rs1075265	0.633	rs28653587	ENSG00000233266.1	HMGB1P31	11.14	2.68e-27	2.31e-24	0.39	0.33	Chronotype;Morning vs. evening chronotype;	chr2:53992435	chr2:54051334~54051760:+
BRCA	cis	rs875971	0.929	rs4122249	ENSG00000222364.1	RNU6-96P	-11.14	2.68e-27	2.32e-24	-0.38	-0.33	Aortic root size;	chr7:66455949	chr7:66395191~66395286:+
BRCA	cis	rs2153535	0.58	rs2327061	ENSG00000230939.1	RP11-314C16.1	-11.14	2.69e-27	2.32e-24	-0.39	-0.33	Motion sickness;	chr6:8446998	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs7453115	ENSG00000230939.1	RP11-314C16.1	-11.14	2.69e-27	2.32e-24	-0.39	-0.33	Motion sickness;	chr6:8447028	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs6910742	ENSG00000230939.1	RP11-314C16.1	-11.14	2.69e-27	2.32e-24	-0.39	-0.33	Motion sickness;	chr6:8448095	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs7767780	ENSG00000230939.1	RP11-314C16.1	-11.14	2.69e-27	2.32e-24	-0.39	-0.33	Motion sickness;	chr6:8453229	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs6941771	ENSG00000230939.1	RP11-314C16.1	-11.14	2.7e-27	2.33e-24	-0.39	-0.33	Motion sickness;	chr6:8494219	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs6937186	ENSG00000230939.1	RP11-314C16.1	-11.14	2.7e-27	2.33e-24	-0.39	-0.33	Motion sickness;	chr6:8494260	chr6:8784178~8785445:+
BRCA	cis	rs9487094	0.885	rs1358997	ENSG00000260273.1	RP11-425D10.10	11.13	2.75e-27	2.37e-24	0.4	0.33	Height;	chr6:109380457	chr6:109382795~109383666:+
BRCA	cis	rs2243480	1	rs6964245	ENSG00000226824.5	RP4-756H11.3	11.13	2.77e-27	2.38e-24	0.62	0.33	Diabetic kidney disease;	chr7:66253730	chr7:66654538~66669855:+
BRCA	cis	rs12999373	0.501	rs2867134	ENSG00000272342.1	RP13-539J13.1	-11.13	2.8e-27	2.41e-24	-0.38	-0.33	Response to fenofibrate (adiponectin levels);Uric acid levels;	chr2:697499	chr2:739588~740164:-
BRCA	cis	rs812925	0.512	rs1729674	ENSG00000271889.1	RP11-493E12.1	11.13	2.82e-27	2.43e-24	0.39	0.33	Immature fraction of reticulocytes;	chr2:61162602	chr2:61151433~61162105:-
BRCA	cis	rs11676348	0.729	rs13013361	ENSG00000261338.2	RP11-378A13.1	-11.13	2.82e-27	2.43e-24	-0.35	-0.33	Ulcerative colitis;	chr2:218082792	chr2:218255319~218257366:+
BRCA	cis	rs2153535	0.542	rs915353	ENSG00000230939.1	RP11-314C16.1	-11.13	2.83e-27	2.44e-24	-0.39	-0.33	Motion sickness;	chr6:8440137	chr6:8784178~8785445:+
BRCA	cis	rs1609391	0.543	rs2117009	ENSG00000239213.4	NCK1-AS1	-11.13	2.85e-27	2.46e-24	-0.35	-0.33	Neuroticism;	chr3:136914729	chr3:136841726~136862054:-
BRCA	cis	rs2153535	0.58	rs7341381	ENSG00000230939.1	RP11-314C16.1	-11.13	2.87e-27	2.47e-24	-0.39	-0.33	Motion sickness;	chr6:8470304	chr6:8784178~8785445:+
BRCA	cis	rs10759883	0.627	rs689986	ENSG00000175611.10	LINC00476	11.13	2.89e-27	2.49e-24	0.38	0.33	Nicotine dependence;	chr9:95866867	chr9:95759231~95875977:-
BRCA	cis	rs9322193	0.566	rs5024811	ENSG00000223701.3	RAET1E-AS1	-11.13	2.95e-27	2.54e-24	-0.44	-0.33	Lung cancer;	chr6:149924898	chr6:149884431~149919508:+
BRCA	cis	rs8062405	1	rs62036616	ENSG00000251417.2	RP11-1348G14.4	-11.13	2.95e-27	2.54e-24	-0.4	-0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814986	chr16:28802743~28817828:+
BRCA	cis	rs801193	0.548	rs2659891	ENSG00000222364.1	RNU6-96P	-11.13	2.96e-27	2.55e-24	-0.38	-0.33	Aortic root size;	chr7:66736127	chr7:66395191~66395286:+
BRCA	cis	rs801193	0.548	rs7805152	ENSG00000222364.1	RNU6-96P	-11.13	2.96e-27	2.55e-24	-0.38	-0.33	Aortic root size;	chr7:66744266	chr7:66395191~66395286:+
BRCA	cis	rs11123170	0.543	rs2166421	ENSG00000274877.1	RP11-65I12.1	-11.13	2.98e-27	2.56e-24	-0.54	-0.33	Renal function-related traits (BUN);	chr2:113232665	chr2:113237595~113240825:+
BRCA	cis	rs9545047	0.604	rs7983344	ENSG00000227676.3	LINC01068	-11.13	3e-27	2.58e-24	-0.37	-0.33	Schizophrenia;	chr13:79299295	chr13:79566727~79571436:+
BRCA	cis	rs875971	0.862	rs709609	ENSG00000222364.1	RNU6-96P	11.13	3e-27	2.58e-24	0.39	0.33	Aortic root size;	chr7:66095574	chr7:66395191~66395286:+
BRCA	cis	rs5760092	0.572	rs738806	ENSG00000225282.1	AP000350.6	11.12	3.05e-27	2.63e-24	0.44	0.33	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23891985	chr22:23926900~23929574:+
BRCA	cis	rs812925	0.515	rs1177308	ENSG00000271889.1	RP11-493E12.1	11.12	3.05e-27	2.63e-24	0.39	0.33	Immature fraction of reticulocytes;	chr2:61160119	chr2:61151433~61162105:-
BRCA	cis	rs812925	0.553	rs1177307	ENSG00000271889.1	RP11-493E12.1	11.12	3.05e-27	2.63e-24	0.39	0.33	Immature fraction of reticulocytes;	chr2:61160253	chr2:61151433~61162105:-
BRCA	cis	rs7586673	0.93	rs6432667	ENSG00000227403.1	AC009299.3	-11.12	3.08e-27	2.65e-24	-0.45	-0.33	Intelligence (multi-trait analysis);	chr2:161048490	chr2:161244739~161249050:+
BRCA	cis	rs10129255	0.912	rs8011090	ENSG00000211970.3	IGHV4-61	-11.12	3.1e-27	2.67e-24	-0.24	-0.33	Kawasaki disease;	chr14:106678896	chr14:106639119~106639657:-
BRCA	cis	rs2188561	1	rs2712208	ENSG00000241764.3	AC002467.7	11.12	3.12e-27	2.68e-24	0.48	0.33	Alcohol consumption;	chr7:107703317	chr7:107742817~107744581:-
BRCA	cis	rs11673344	0.864	rs1533736	ENSG00000226686.6	LINC01535	11.12	3.12e-27	2.68e-24	0.46	0.33	Obesity-related traits;	chr19:37164074	chr19:37251912~37265535:+
BRCA	cis	rs11673344	0.801	rs56343212	ENSG00000226686.6	LINC01535	11.12	3.13e-27	2.69e-24	0.46	0.33	Obesity-related traits;	chr19:37167684	chr19:37251912~37265535:+
BRCA	cis	rs2243480	1	rs1638734	ENSG00000226824.5	RP4-756H11.3	-11.12	3.22e-27	2.76e-24	-0.64	-0.33	Diabetic kidney disease;	chr7:66632552	chr7:66654538~66669855:+
BRCA	cis	rs4774565	0.724	rs606118	ENSG00000244879.4	GABPB1-AS1	-11.12	3.22e-27	2.77e-24	-0.36	-0.33	Breast cancer;	chr15:50362974	chr15:50354959~50372202:+
BRCA	cis	rs172166	0.694	rs1225716	ENSG00000220721.1	OR1F12	11.12	3.25e-27	2.79e-24	0.4	0.33	Cardiac Troponin-T levels;	chr6:28145968	chr6:28073316~28074233:+
BRCA	cis	rs67311347	0.955	rs6764102	ENSG00000223797.4	ENTPD3-AS1	11.12	3.27e-27	2.81e-24	0.37	0.33	Renal cell carcinoma;	chr3:40336662	chr3:40313802~40453329:-
BRCA	cis	rs9487094	0.626	rs2025148	ENSG00000260273.1	RP11-425D10.10	11.12	3.33e-27	2.86e-24	0.38	0.33	Height;	chr6:109706740	chr6:109382795~109383666:+
BRCA	cis	rs67311347	0.911	rs6776044	ENSG00000223797.4	ENTPD3-AS1	11.11	3.38e-27	2.9e-24	0.37	0.33	Renal cell carcinoma;	chr3:40336012	chr3:40313802~40453329:-
BRCA	cis	rs11105298	1	rs11105298	ENSG00000258302.2	RP11-981P6.1	-11.11	3.38e-27	2.9e-24	-0.37	-0.33	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89482366	chr12:89561129~89594878:+
BRCA	cis	rs9545047	0.604	rs9545085	ENSG00000227676.3	LINC01068	11.11	3.4e-27	2.92e-24	0.38	0.33	Schizophrenia;	chr13:79363969	chr13:79566727~79571436:+
BRCA	cis	rs2153535	0.58	rs2184586	ENSG00000230939.1	RP11-314C16.1	-11.11	3.41e-27	2.92e-24	-0.39	-0.33	Motion sickness;	chr6:8473949	chr6:8784178~8785445:+
BRCA	cis	rs11123170	0.529	rs1015755	ENSG00000274877.1	RP11-65I12.1	-11.11	3.42e-27	2.93e-24	-0.54	-0.33	Renal function-related traits (BUN);	chr2:113210730	chr2:113237595~113240825:+
BRCA	cis	rs10759883	0.563	rs689738	ENSG00000175611.10	LINC00476	11.11	3.44e-27	2.94e-24	0.39	0.33	Nicotine dependence;	chr9:95939738	chr9:95759231~95875977:-
BRCA	cis	rs2442825	0.693	rs2648523	ENSG00000206573.7	THUMPD3-AS1	11.11	3.44e-27	2.95e-24	0.29	0.33	Cerebrospinal fluid clusterin levels;	chr3:9370654	chr3:9349689~9398579:-
BRCA	cis	rs10129255	0.957	rs1024349	ENSG00000211970.3	IGHV4-61	-11.11	3.45e-27	2.95e-24	-0.24	-0.33	Kawasaki disease;	chr14:106689997	chr14:106639119~106639657:-
BRCA	cis	rs10181042	0.581	rs1177285	ENSG00000271889.1	RP11-493E12.1	11.11	3.53e-27	3.02e-24	0.39	0.33	Crohn's disease;	chr2:61123002	chr2:61151433~61162105:-
BRCA	cis	rs1609391	0.543	rs9859810	ENSG00000239213.4	NCK1-AS1	11.11	3.55e-27	3.04e-24	0.35	0.33	Neuroticism;	chr3:136911144	chr3:136841726~136862054:-
BRCA	cis	rs10129255	0.5	rs2027902	ENSG00000223648.3	IGHV3-64	11.11	3.61e-27	3.09e-24	0.25	0.33	Kawasaki disease;	chr14:106807157	chr14:106643132~106658258:-
BRCA	cis	rs67311347	1	rs17078813	ENSG00000223797.4	ENTPD3-AS1	11.11	3.67e-27	3.14e-24	0.39	0.33	Renal cell carcinoma;	chr3:40392671	chr3:40313802~40453329:-
BRCA	cis	rs7829975	0.711	rs12682352	ENSG00000253893.2	FAM85B	-11.1	3.76e-27	3.21e-24	-0.39	-0.33	Mood instability;	chr8:8788736	chr8:8167819~8226614:-
BRCA	cis	rs7684253	0.565	rs13130605	ENSG00000269949.1	RP11-738E22.3	-11.1	3.77e-27	3.22e-24	-0.37	-0.33	Migraine;	chr4:56943905	chr4:56960927~56961373:-
BRCA	cis	rs1555322	0.53	rs7004	ENSG00000126005.14	MMP24-AS1	-11.1	3.81e-27	3.25e-24	-0.45	-0.33	Attention deficit hyperactivity disorder;	chr20:35278950	chr20:35216462~35278131:-
BRCA	cis	rs150992	0.609	rs539024	ENSG00000248489.1	CTD-2007H13.3	11.1	3.81e-27	3.26e-24	0.36	0.33	Body mass index;	chr5:98997103	chr5:98929171~98995013:+
BRCA	cis	rs4308124	0.708	rs10179596	ENSG00000227992.1	AC108463.2	-11.1	3.9e-27	3.33e-24	-0.42	-0.33	Vitiligo;	chr2:111212803	chr2:111203964~111206215:-
BRCA	cis	rs11723261	0.582	rs6599293	ENSG00000275426.1	CH17-262A2.1	11.1	3.99e-27	3.4e-24	0.46	0.33	Immune response to smallpox vaccine (IL-6);	chr4:139246	chr4:149738~150317:+
BRCA	cis	rs2153535	0.58	rs9406169	ENSG00000230939.1	RP11-314C16.1	-11.1	4.09e-27	3.48e-24	-0.38	-0.33	Motion sickness;	chr6:8509237	chr6:8784178~8785445:+
BRCA	cis	rs6452524	1	rs10080123	ENSG00000249664.1	CTD-2227C6.2	-11.09	4.09e-27	3.49e-24	-0.4	-0.33	Hypertension (SNP x SNP interaction);	chr5:83165447	chr5:83012285~83013109:-
BRCA	cis	rs10759883	0.563	rs10739705	ENSG00000175611.10	LINC00476	11.09	4.09e-27	3.49e-24	0.38	0.33	Nicotine dependence;	chr9:95900857	chr9:95759231~95875977:-
BRCA	cis	rs7945705	0.837	rs2742474	ENSG00000254860.4	TMEM9B-AS1	11.09	4.09e-27	3.49e-24	0.29	0.33	Hemoglobin concentration;	chr11:8980542	chr11:8964675~8977527:+
BRCA	cis	rs9660180	0.875	rs4648727	ENSG00000268575.1	RP1-283E3.8	11.09	4.1e-27	3.49e-24	0.34	0.33	Body mass index;	chr1:1844830	chr1:1702736~1737688:-
BRCA	cis	rs2243480	0.901	rs13237344	ENSG00000226824.5	RP4-756H11.3	-11.09	4.14e-27	3.52e-24	-0.64	-0.33	Diabetic kidney disease;	chr7:66557269	chr7:66654538~66669855:+
BRCA	cis	rs875971	1	rs1544549	ENSG00000222364.1	RNU6-96P	11.09	4.16e-27	3.55e-24	0.38	0.33	Aortic root size;	chr7:66625676	chr7:66395191~66395286:+
BRCA	cis	rs9545047	0.553	rs7332004	ENSG00000227676.3	LINC01068	-11.09	4.17e-27	3.55e-24	-0.38	-0.32	Schizophrenia;	chr13:79364128	chr13:79566727~79571436:+
BRCA	cis	rs2442825	0.693	rs1054975	ENSG00000206573.7	THUMPD3-AS1	11.09	4.18e-27	3.56e-24	0.29	0.32	Cerebrospinal fluid clusterin levels;	chr3:9365152	chr3:9349689~9398579:-
BRCA	cis	rs2442825	0.693	rs2728949	ENSG00000206573.7	THUMPD3-AS1	11.09	4.2e-27	3.58e-24	0.29	0.32	Cerebrospinal fluid clusterin levels;	chr3:9364977	chr3:9349689~9398579:-
BRCA	cis	rs150992	0.861	rs428836	ENSG00000248489.1	CTD-2007H13.3	11.09	4.24e-27	3.61e-24	0.36	0.32	Body mass index;	chr5:98951673	chr5:98929171~98995013:+
BRCA	cis	rs858239	0.862	rs1728292	ENSG00000226816.2	AC005082.12	11.09	4.26e-27	3.63e-24	0.38	0.32	Cerebrospinal fluid biomarker levels;	chr7:23223855	chr7:23206013~23208045:+
BRCA	cis	rs17837474	0.656	rs17273	ENSG00000276597.1	TRBV11-3	11.09	4.28e-27	3.64e-24	0.43	0.32	Cancer;	chr7:142407435	chr7:142554836~142555318:+
BRCA	cis	rs1891275	0.515	rs7092884	ENSG00000228701.1	TNKS2-AS1	11.09	4.31e-27	3.67e-24	0.38	0.32	Intelligence (multi-trait analysis);	chr10:91724115	chr10:91782839~91798291:-
BRCA	cis	rs3779195	0.697	rs1688606	ENSG00000272950.1	RP11-307C18.1	11.09	4.42e-27	3.75e-24	0.51	0.32	Sex hormone-binding globulin levels;	chr7:98345539	chr7:98322853~98323430:+
BRCA	cis	rs7684253	0.565	rs6830774	ENSG00000269949.1	RP11-738E22.3	-11.09	4.43e-27	3.76e-24	-0.37	-0.32	Migraine;	chr4:56950140	chr4:56960927~56961373:-
BRCA	cis	rs9545047	0.604	rs9574410	ENSG00000227676.3	LINC01068	-11.09	4.44e-27	3.78e-24	-0.38	-0.32	Schizophrenia;	chr13:79343091	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs2274555	ENSG00000227676.3	LINC01068	-11.09	4.47e-27	3.8e-24	-0.38	-0.32	Schizophrenia;	chr13:79344188	chr13:79566727~79571436:+
BRCA	cis	rs7309	0.935	rs1921309	ENSG00000235724.7	AC009299.2	-11.09	4.48e-27	3.8e-24	-0.37	-0.32	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161192464	chr2:161222785~161308303:-
BRCA	cis	rs9487094	0.885	rs3799839	ENSG00000260273.1	RP11-425D10.10	11.09	4.49e-27	3.81e-24	0.39	0.32	Height;	chr6:109380990	chr6:109382795~109383666:+
BRCA	cis	rs875971	0.862	rs10274883	ENSG00000222364.1	RNU6-96P	11.09	4.49e-27	3.82e-24	0.38	0.32	Aortic root size;	chr7:66651104	chr7:66395191~66395286:+
BRCA	cis	rs2243480	1	rs1553174	ENSG00000226824.5	RP4-756H11.3	11.09	4.52e-27	3.83e-24	0.62	0.32	Diabetic kidney disease;	chr7:66266207	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs10950032	ENSG00000226824.5	RP4-756H11.3	11.09	4.52e-27	3.83e-24	0.62	0.32	Diabetic kidney disease;	chr7:66273604	chr7:66654538~66669855:+
BRCA	cis	rs7684253	0.565	rs13108570	ENSG00000269949.1	RP11-738E22.3	-11.09	4.52e-27	3.84e-24	-0.37	-0.32	Migraine;	chr4:56940917	chr4:56960927~56961373:-
BRCA	cis	rs9545047	0.604	rs9318623	ENSG00000227676.3	LINC01068	-11.08	4.55e-27	3.86e-24	-0.38	-0.32	Schizophrenia;	chr13:79346913	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.564	rs7998837	ENSG00000227676.3	LINC01068	-11.08	4.55e-27	3.86e-24	-0.38	-0.32	Schizophrenia;	chr13:79349190	chr13:79566727~79571436:+
BRCA	cis	rs7945705	0.869	rs2742471	ENSG00000254860.4	TMEM9B-AS1	11.08	4.55e-27	3.86e-24	0.29	0.32	Hemoglobin concentration;	chr11:8982406	chr11:8964675~8977527:+
BRCA	cis	rs1891275	0.515	rs2421694	ENSG00000228701.1	TNKS2-AS1	-11.08	4.62e-27	3.92e-24	-0.38	-0.32	Intelligence (multi-trait analysis);	chr10:91756347	chr10:91782839~91798291:-
BRCA	cis	rs4722166	0.695	rs6946509	ENSG00000179428.2	AC073072.5	-11.08	4.64e-27	3.94e-24	-0.34	-0.32	Lung cancer;	chr7:22769871	chr7:22725395~22727620:-
BRCA	cis	rs2243480	1	rs1546059	ENSG00000226824.5	RP4-756H11.3	11.08	4.65e-27	3.94e-24	0.63	0.32	Diabetic kidney disease;	chr7:66189722	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs2420170	ENSG00000226824.5	RP4-756H11.3	11.08	4.65e-27	3.94e-24	0.63	0.32	Diabetic kidney disease;	chr7:66191066	chr7:66654538~66669855:+
BRCA	cis	rs7586673	0.857	rs16845580	ENSG00000227403.1	AC009299.3	-11.08	4.66e-27	3.95e-24	-0.44	-0.32	Intelligence (multi-trait analysis);	chr2:161064373	chr2:161244739~161249050:+
BRCA	cis	rs673078	0.607	rs17440956	ENSG00000275759.1	RP11-131L12.3	11.08	4.67e-27	3.96e-24	0.52	0.32	Glucose homeostasis traits;	chr12:118394639	chr12:118428281~118428870:+
BRCA	cis	rs9318086	0.624	rs9510909	ENSG00000205861.10	C1QTNF9B-AS1	-11.08	4.71e-27	3.99e-24	-0.42	-0.32	Myopia (pathological);	chr13:23862621	chr13:23888889~23897263:+
BRCA	cis	rs875971	0.545	rs73378304	ENSG00000226824.5	RP4-756H11.3	-11.08	4.74e-27	4.02e-24	-0.43	-0.32	Aortic root size;	chr7:66175760	chr7:66654538~66669855:+
BRCA	cis	rs2153535	0.58	rs9505467	ENSG00000230939.1	RP11-314C16.1	-11.08	4.81e-27	4.07e-24	-0.39	-0.32	Motion sickness;	chr6:8519986	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs1360054	ENSG00000230939.1	RP11-314C16.1	-11.08	4.81e-27	4.07e-24	-0.39	-0.32	Motion sickness;	chr6:8520144	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs9328483	ENSG00000230939.1	RP11-314C16.1	-11.08	4.81e-27	4.07e-24	-0.39	-0.32	Motion sickness;	chr6:8521062	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs9393033	ENSG00000230939.1	RP11-314C16.1	-11.08	4.81e-27	4.07e-24	-0.39	-0.32	Motion sickness;	chr6:8521213	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.541	rs6938688	ENSG00000230939.1	RP11-314C16.1	-11.08	4.81e-27	4.07e-24	-0.39	-0.32	Motion sickness;	chr6:8521396	chr6:8784178~8785445:+
BRCA	cis	rs1075265	0.61	rs6746965	ENSG00000233266.1	HMGB1P31	11.08	4.83e-27	4.09e-24	0.39	0.32	Chronotype;Morning vs. evening chronotype;	chr2:53996388	chr2:54051334~54051760:+
BRCA	cis	rs2153535	0.58	rs6914276	ENSG00000230939.1	RP11-314C16.1	11.08	4.93e-27	4.17e-24	0.39	0.32	Motion sickness;	chr6:8450202	chr6:8784178~8785445:+
BRCA	cis	rs875971	0.862	rs1167408	ENSG00000222364.1	RNU6-96P	11.08	4.98e-27	4.21e-24	0.39	0.32	Aortic root size;	chr7:66091121	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.83	rs1167406	ENSG00000222364.1	RNU6-96P	11.08	4.98e-27	4.21e-24	0.39	0.32	Aortic root size;	chr7:66091949	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.862	rs1167399	ENSG00000222364.1	RNU6-96P	11.08	4.98e-27	4.21e-24	0.39	0.32	Aortic root size;	chr7:66096890	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.862	rs57866200	ENSG00000222364.1	RNU6-96P	11.08	4.98e-27	4.21e-24	0.39	0.32	Aortic root size;	chr7:66100405	chr7:66395191~66395286:+
BRCA	cis	rs4308124	0.708	rs10178095	ENSG00000227992.1	AC108463.2	-11.07	5e-27	4.22e-24	-0.41	-0.32	Vitiligo;	chr2:111214939	chr2:111203964~111206215:-
BRCA	cis	rs1062177	1	rs12654573	ENSG00000213433.5	RPLP1P6	-11.07	5.05e-27	4.27e-24	-0.4	-0.32	Preschool internalizing problems;	chr5:151827912	chr5:151765859~151766378:-
BRCA	cis	rs9318086	0.712	rs9510916	ENSG00000205861.10	C1QTNF9B-AS1	-11.07	5.16e-27	4.36e-24	-0.41	-0.32	Myopia (pathological);	chr13:23868650	chr13:23888889~23897263:+
BRCA	cis	rs801193	0.569	rs6978178	ENSG00000222364.1	RNU6-96P	11.07	5.26e-27	4.44e-24	0.38	0.32	Aortic root size;	chr7:66658097	chr7:66395191~66395286:+
BRCA	cis	rs2153535	0.525	rs1335644	ENSG00000230939.1	RP11-314C16.1	-11.07	5.27e-27	4.44e-24	-0.39	-0.32	Motion sickness;	chr6:8487808	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs9393025	ENSG00000230939.1	RP11-314C16.1	-11.07	5.27e-27	4.44e-24	-0.39	-0.32	Motion sickness;	chr6:8490385	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs1414340	ENSG00000230939.1	RP11-314C16.1	-11.07	5.27e-27	4.44e-24	-0.39	-0.32	Motion sickness;	chr6:8490906	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs1335628	ENSG00000230939.1	RP11-314C16.1	-11.07	5.27e-27	4.44e-24	-0.39	-0.32	Motion sickness;	chr6:8491509	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs6597330	ENSG00000230939.1	RP11-314C16.1	-11.07	5.27e-27	4.44e-24	-0.39	-0.32	Motion sickness;	chr6:8491843	chr6:8784178~8785445:+
BRCA	cis	rs2880765	0.566	rs11630381	ENSG00000259295.5	CSPG4P12	11.07	5.3e-27	4.47e-24	0.43	0.32	Coronary artery disease;	chr15:85469272	chr15:85191438~85213905:+
BRCA	cis	rs2153535	0.58	rs6921964	ENSG00000230939.1	RP11-314C16.1	-11.07	5.31e-27	4.48e-24	-0.39	-0.32	Motion sickness;	chr6:8446162	chr6:8784178~8785445:+
BRCA	cis	rs10759883	0.563	rs1327997	ENSG00000175611.10	LINC00476	11.07	5.34e-27	4.5e-24	0.38	0.32	Nicotine dependence;	chr9:95913600	chr9:95759231~95875977:-
BRCA	cis	rs10759883	0.563	rs1327996	ENSG00000175611.10	LINC00476	11.07	5.34e-27	4.5e-24	0.38	0.32	Nicotine dependence;	chr9:95913710	chr9:95759231~95875977:-
BRCA	cis	rs10759883	0.563	rs617187	ENSG00000175611.10	LINC00476	11.07	5.34e-27	4.5e-24	0.38	0.32	Nicotine dependence;	chr9:95917359	chr9:95759231~95875977:-
BRCA	cis	rs10759883	0.563	rs689619	ENSG00000175611.10	LINC00476	11.07	5.34e-27	4.5e-24	0.38	0.32	Nicotine dependence;	chr9:95921689	chr9:95759231~95875977:-
BRCA	cis	rs10759883	0.563	rs10512245	ENSG00000175611.10	LINC00476	11.07	5.34e-27	4.5e-24	0.38	0.32	Nicotine dependence;	chr9:95929529	chr9:95759231~95875977:-
BRCA	cis	rs7182621	0.639	rs36069387	ENSG00000259363.4	CTD-2054N24.2	-11.07	5.36e-27	4.52e-24	-0.37	-0.32	Colonoscopy-negative controls vs population controls;	chr15:99884540	chr15:99807023~99877148:+
BRCA	cis	rs321358	1	rs321359	ENSG00000271584.1	RP11-89C3.4	11.07	5.41e-27	4.56e-24	0.54	0.32	Body mass index;	chr11:111125257	chr11:111091932~111097357:-
BRCA	cis	rs4308124	0.708	rs28766030	ENSG00000227992.1	AC108463.2	-11.07	5.41e-27	4.56e-24	-0.41	-0.32	Vitiligo;	chr2:111204852	chr2:111203964~111206215:-
BRCA	cis	rs10129255	0.5	rs11627315	ENSG00000223648.3	IGHV3-64	11.07	5.43e-27	4.58e-24	0.25	0.32	Kawasaki disease;	chr14:106802182	chr14:106643132~106658258:-
BRCA	cis	rs2153535	0.58	rs1328862	ENSG00000230939.1	RP11-314C16.1	-11.07	5.47e-27	4.61e-24	-0.39	-0.32	Motion sickness;	chr6:8526448	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.601	rs1928183	ENSG00000230939.1	RP11-314C16.1	-11.07	5.47e-27	4.61e-24	-0.39	-0.32	Motion sickness;	chr6:8529785	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs6597337	ENSG00000230939.1	RP11-314C16.1	-11.07	5.47e-27	4.61e-24	-0.39	-0.32	Motion sickness;	chr6:8531419	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs9505454	ENSG00000230939.1	RP11-314C16.1	-11.07	5.51e-27	4.64e-24	-0.39	-0.32	Motion sickness;	chr6:8478299	chr6:8784178~8785445:+
BRCA	cis	rs321358	1	rs167683	ENSG00000271584.1	RP11-89C3.4	11.06	5.55e-27	4.67e-24	0.55	0.32	Body mass index;	chr11:111123131	chr11:111091932~111097357:-
BRCA	cis	rs2153535	0.58	rs2143357	ENSG00000230939.1	RP11-314C16.1	-11.06	5.62e-27	4.73e-24	-0.39	-0.32	Motion sickness;	chr6:8496963	chr6:8784178~8785445:+
BRCA	cis	rs801193	0.591	rs721717	ENSG00000222364.1	RNU6-96P	11.06	5.73e-27	4.82e-24	0.38	0.32	Aortic root size;	chr7:66665305	chr7:66395191~66395286:+
BRCA	cis	rs4308124	0.708	rs67816163	ENSG00000227992.1	AC108463.2	-11.06	5.73e-27	4.82e-24	-0.41	-0.32	Vitiligo;	chr2:111205733	chr2:111203964~111206215:-
BRCA	cis	rs67311347	0.911	rs6775936	ENSG00000223797.4	ENTPD3-AS1	11.06	5.73e-27	4.83e-24	0.36	0.32	Renal cell carcinoma;	chr3:40335908	chr3:40313802~40453329:-
BRCA	cis	rs321358	1	rs321360	ENSG00000271584.1	RP11-89C3.4	11.06	5.82e-27	4.9e-24	0.54	0.32	Body mass index;	chr11:111125346	chr11:111091932~111097357:-
BRCA	cis	rs1891275	0.515	rs1361552	ENSG00000228701.1	TNKS2-AS1	-11.06	5.83e-27	4.91e-24	-0.38	-0.32	Intelligence (multi-trait analysis);	chr10:91774867	chr10:91782839~91798291:-
BRCA	cis	rs9545047	0.604	rs9565491	ENSG00000227676.3	LINC01068	-11.06	5.84e-27	4.91e-24	-0.37	-0.32	Schizophrenia;	chr13:79346037	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.532	rs9545079	ENSG00000227676.3	LINC01068	11.06	5.87e-27	4.94e-24	0.37	0.32	Schizophrenia;	chr13:79346044	chr13:79566727~79571436:+
BRCA	cis	rs2404602	0.709	rs11072597	ENSG00000259422.1	RP11-593F23.1	-11.06	5.94e-27	5e-24	-0.43	-0.32	Blood metabolite levels;	chr15:76471173	chr15:76174891~76181486:-
BRCA	cis	rs2404602	0.735	rs11857327	ENSG00000259422.1	RP11-593F23.1	-11.06	5.94e-27	5e-24	-0.43	-0.32	Blood metabolite levels;	chr15:76471922	chr15:76174891~76181486:-
BRCA	cis	rs2153535	0.541	rs4637688	ENSG00000230939.1	RP11-314C16.1	-11.06	6.07e-27	5.1e-24	-0.39	-0.32	Motion sickness;	chr6:8446268	chr6:8784178~8785445:+
BRCA	cis	rs812925	0.533	rs35507645	ENSG00000271889.1	RP11-493E12.1	11.05	6.11e-27	5.14e-24	0.39	0.32	Immature fraction of reticulocytes;	chr2:61169631	chr2:61151433~61162105:-
BRCA	cis	rs10129255	0.872	rs1858683	ENSG00000211970.3	IGHV4-61	-11.05	6.14e-27	5.16e-24	-0.24	-0.32	Kawasaki disease;	chr14:106670217	chr14:106639119~106639657:-
BRCA	cis	rs9318086	0.712	rs3794339	ENSG00000205861.10	C1QTNF9B-AS1	-11.05	6.17e-27	5.18e-24	-0.41	-0.32	Myopia (pathological);	chr13:23859926	chr13:23888889~23897263:+
BRCA	cis	rs4308124	0.708	rs6727313	ENSG00000227992.1	AC108463.2	-11.05	6.29e-27	5.28e-24	-0.41	-0.32	Vitiligo;	chr2:111213963	chr2:111203964~111206215:-
BRCA	cis	rs2153535	0.542	rs9505465	ENSG00000230939.1	RP11-314C16.1	-11.05	6.3e-27	5.29e-24	-0.39	-0.32	Motion sickness;	chr6:8510613	chr6:8784178~8785445:+
BRCA	cis	rs2243480	1	rs1873494	ENSG00000226824.5	RP4-756H11.3	11.05	6.32e-27	5.31e-24	0.62	0.32	Diabetic kidney disease;	chr7:66184912	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs6959002	ENSG00000226824.5	RP4-756H11.3	11.05	6.32e-27	5.31e-24	0.62	0.32	Diabetic kidney disease;	chr7:66185509	chr7:66654538~66669855:+
BRCA	cis	rs172166	0.611	rs203883	ENSG00000220721.1	OR1F12	11.05	6.36e-27	5.34e-24	0.39	0.32	Cardiac Troponin-T levels;	chr6:28110578	chr6:28073316~28074233:+
BRCA	cis	rs67311347	0.869	rs9832311	ENSG00000223797.4	ENTPD3-AS1	11.05	6.4e-27	5.37e-24	0.36	0.32	Renal cell carcinoma;	chr3:40339831	chr3:40313802~40453329:-
BRCA	cis	rs2243480	1	rs6958289	ENSG00000226824.5	RP4-756H11.3	11.05	6.41e-27	5.38e-24	0.63	0.32	Diabetic kidney disease;	chr7:66192124	chr7:66654538~66669855:+
BRCA	cis	rs1075265	0.633	rs7564912	ENSG00000233266.1	HMGB1P31	11.05	6.47e-27	5.43e-24	0.39	0.32	Chronotype;Morning vs. evening chronotype;	chr2:53995048	chr2:54051334~54051760:+
BRCA	cis	rs2153535	0.58	rs1120392	ENSG00000230939.1	RP11-314C16.1	-11.05	6.53e-27	5.48e-24	-0.39	-0.32	Motion sickness;	chr6:8486820	chr6:8784178~8785445:+
BRCA	cis	rs4308124	0.708	rs61358692	ENSG00000227992.1	AC108463.2	-11.05	6.55e-27	5.5e-24	-0.41	-0.32	Vitiligo;	chr2:111207582	chr2:111203964~111206215:-
BRCA	cis	rs2404602	0.684	rs1603860	ENSG00000259422.1	RP11-593F23.1	-11.05	6.6e-27	5.54e-24	-0.42	-0.32	Blood metabolite levels;	chr15:76557250	chr15:76174891~76181486:-
BRCA	cis	rs2404602	0.684	rs8037847	ENSG00000259422.1	RP11-593F23.1	-11.05	6.6e-27	5.54e-24	-0.42	-0.32	Blood metabolite levels;	chr15:76564210	chr15:76174891~76181486:-
BRCA	cis	rs2015599	0.623	rs7964831	ENSG00000275476.1	RP11-996F15.4	-11.05	6.63e-27	5.56e-24	-0.37	-0.32	Platelet count;Mean platelet volume;	chr12:29286655	chr12:29277397~29277882:-
BRCA	cis	rs875971	0.862	rs6460307	ENSG00000222364.1	RNU6-96P	-11.05	6.68e-27	5.6e-24	-0.38	-0.32	Aortic root size;	chr7:66595884	chr7:66395191~66395286:+
BRCA	cis	rs6452524	0.904	rs10076056	ENSG00000249664.1	CTD-2227C6.2	-11.04	6.75e-27	5.66e-24	-0.4	-0.32	Hypertension (SNP x SNP interaction);	chr5:83161702	chr5:83012285~83013109:-
BRCA	cis	rs2153535	0.601	rs9379224	ENSG00000230939.1	RP11-314C16.1	-11.04	6.78e-27	5.68e-24	-0.39	-0.32	Motion sickness;	chr6:8538180	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs1932284	ENSG00000230939.1	RP11-314C16.1	-11.04	6.79e-27	5.69e-24	-0.39	-0.32	Motion sickness;	chr6:8477461	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs1932285	ENSG00000230939.1	RP11-314C16.1	-11.04	6.79e-27	5.69e-24	-0.39	-0.32	Motion sickness;	chr6:8477486	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs7775909	ENSG00000230939.1	RP11-314C16.1	-11.04	6.79e-27	5.69e-24	-0.39	-0.32	Motion sickness;	chr6:8477545	chr6:8784178~8785445:+
BRCA	cis	rs1499614	1	rs2707832	ENSG00000226824.5	RP4-756H11.3	-11.04	6.81e-27	5.7e-24	-0.62	-0.32	Gout;	chr7:66671562	chr7:66654538~66669855:+
BRCA	cis	rs34375054	0.526	rs4412800	ENSG00000279233.1	RP11-158L12.4	-11.04	6.82e-27	5.71e-24	-0.38	-0.32	Post bronchodilator FEV1/FVC ratio;	chr12:125190196	chr12:125138245~125141711:+
BRCA	cis	rs9309711	0.544	rs9309712	ENSG00000225234.1	TRAPPC12-AS1	-11.04	6.88e-27	5.76e-24	-0.35	-0.32	Neurofibrillary tangles;	chr2:3487556	chr2:3481242~3482409:-
BRCA	cis	rs2404602	0.66	rs11852777	ENSG00000259422.1	RP11-593F23.1	-11.04	6.88e-27	5.76e-24	-0.42	-0.32	Blood metabolite levels;	chr15:76637451	chr15:76174891~76181486:-
BRCA	cis	rs2153535	0.58	rs1414348	ENSG00000230939.1	RP11-314C16.1	-11.04	6.9e-27	5.78e-24	-0.39	-0.32	Motion sickness;	chr6:8471707	chr6:8784178~8785445:+
BRCA	cis	rs1555322	0.505	rs639763	ENSG00000126005.14	MMP24-AS1	-11.04	6.96e-27	5.82e-24	-0.45	-0.32	Attention deficit hyperactivity disorder;	chr20:35274101	chr20:35216462~35278131:-
BRCA	cis	rs2581828	0.618	rs9828221	ENSG00000242142.1	SERBP1P3	-11.04	6.96e-27	5.82e-24	-0.41	-0.32	Crohn's disease;	chr3:53132643	chr3:53064283~53065091:-
BRCA	cis	rs2712381	0.797	rs62270806	ENSG00000242551.2	POU5F1P6	-11.04	6.96e-27	5.83e-24	-0.41	-0.32	Monocyte count;	chr3:128657426	chr3:128674735~128677005:-
BRCA	cis	rs2880765	0.566	rs17553249	ENSG00000259295.5	CSPG4P12	11.04	7.07e-27	5.92e-24	0.42	0.32	Coronary artery disease;	chr15:85463463	chr15:85191438~85213905:+
BRCA	cis	rs2404602	0.684	rs2047504	ENSG00000259422.1	RP11-593F23.1	-11.04	7.07e-27	5.92e-24	-0.42	-0.32	Blood metabolite levels;	chr15:76591175	chr15:76174891~76181486:-
BRCA	cis	rs1075265	0.597	rs11694711	ENSG00000233266.1	HMGB1P31	11.04	7.07e-27	5.92e-24	0.39	0.32	Chronotype;Morning vs. evening chronotype;	chr2:53971924	chr2:54051334~54051760:+
BRCA	cis	rs7598759	0.548	rs6750795	ENSG00000181798.2	LINC00471	-11.04	7.11e-27	5.95e-24	-0.4	-0.32	Noise-induced hearing loss;	chr2:231513520	chr2:231508426~231514339:-
BRCA	cis	rs6539288	0.691	rs10746071	ENSG00000260329.1	RP11-412D9.4	11.04	7.14e-27	5.97e-24	0.36	0.32	Total body bone mineral density;	chr12:106959817	chr12:106954029~106955497:-
BRCA	cis	rs321358	1	rs73019214	ENSG00000271584.1	RP11-89C3.4	11.04	7.14e-27	5.97e-24	0.57	0.32	Body mass index;	chr11:111131680	chr11:111091932~111097357:-
BRCA	cis	rs1499614	1	rs1638731	ENSG00000226824.5	RP4-756H11.3	-11.04	7.19e-27	6.01e-24	-0.64	-0.32	Gout;	chr7:66679692	chr7:66654538~66669855:+
BRCA	cis	rs1499614	1	rs1882655	ENSG00000226824.5	RP4-756H11.3	11.04	7.19e-27	6.01e-24	0.64	0.32	Gout;	chr7:66682070	chr7:66654538~66669855:+
BRCA	cis	rs1499614	0.831	rs3800822	ENSG00000226824.5	RP4-756H11.3	11.04	7.19e-27	6.01e-24	0.64	0.32	Gout;	chr7:66682162	chr7:66654538~66669855:+
BRCA	cis	rs8062405	1	rs12325113	ENSG00000251417.2	RP11-1348G14.4	-11.04	7.22e-27	6.04e-24	-0.4	-0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28837347	chr16:28802743~28817828:+
BRCA	cis	rs56163509	1	rs56163509	ENSG00000251417.2	RP11-1348G14.4	-11.04	7.22e-27	6.04e-24	-0.4	-0.32	Tonsillectomy;Mean corpuscular volume;	chr16:28853150	chr16:28802743~28817828:+
BRCA	cis	rs11673344	0.526	rs35153242	ENSG00000226686.6	LINC01535	-11.04	7.24e-27	6.05e-24	-0.45	-0.32	Obesity-related traits;	chr19:37660841	chr19:37251912~37265535:+
BRCA	cis	rs2153535	0.58	rs7743995	ENSG00000230939.1	RP11-314C16.1	-11.04	7.25e-27	6.06e-24	-0.39	-0.32	Motion sickness;	chr6:8495979	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs2327060	ENSG00000230939.1	RP11-314C16.1	-11.04	7.28e-27	6.09e-24	-0.39	-0.32	Motion sickness;	chr6:8446878	chr6:8784178~8785445:+
BRCA	cis	rs7829975	0.688	rs7817376	ENSG00000253893.2	FAM85B	11.04	7.29e-27	6.09e-24	0.4	0.32	Mood instability;	chr8:8523020	chr8:8167819~8226614:-
BRCA	cis	rs2404602	0.647	rs62026889	ENSG00000259422.1	RP11-593F23.1	-11.04	7.33e-27	6.12e-24	-0.42	-0.32	Blood metabolite levels;	chr15:76625544	chr15:76174891~76181486:-
BRCA	cis	rs10129255	1	rs11621409	ENSG00000211970.3	IGHV4-61	-11.04	7.38e-27	6.16e-24	-0.25	-0.32	Kawasaki disease;	chr14:106695603	chr14:106639119~106639657:-
BRCA	cis	rs2337406	0.925	rs11851094	ENSG00000274576.2	IGHV2-70	-11.03	7.49e-27	6.26e-24	-0.36	-0.32	Alzheimer's disease (late onset);	chr14:106688967	chr14:106770577~106771020:-
BRCA	cis	rs4308124	0.708	rs2137168	ENSG00000227992.1	AC108463.2	-11.03	7.52e-27	6.28e-24	-0.43	-0.32	Vitiligo;	chr2:111228932	chr2:111203964~111206215:-
BRCA	cis	rs2153535	0.58	rs6929206	ENSG00000230939.1	RP11-314C16.1	-11.03	7.55e-27	6.31e-24	-0.39	-0.32	Motion sickness;	chr6:8447728	chr6:8784178~8785445:+
BRCA	cis	rs812925	0.533	rs60997156	ENSG00000271889.1	RP11-493E12.1	11.03	7.7e-27	6.42e-24	0.39	0.32	Immature fraction of reticulocytes;	chr2:61169404	chr2:61151433~61162105:-
BRCA	cis	rs150992	0.592	rs10038192	ENSG00000248489.1	CTD-2007H13.3	11.03	7.73e-27	6.45e-24	0.37	0.32	Body mass index;	chr5:98989755	chr5:98929171~98995013:+
BRCA	cis	rs150992	0.571	rs10045959	ENSG00000248489.1	CTD-2007H13.3	11.03	7.73e-27	6.45e-24	0.37	0.32	Body mass index;	chr5:98989767	chr5:98929171~98995013:+
BRCA	cis	rs150992	0.571	rs10037147	ENSG00000248489.1	CTD-2007H13.3	11.03	7.73e-27	6.45e-24	0.37	0.32	Body mass index;	chr5:98989768	chr5:98929171~98995013:+
BRCA	cis	rs2153535	0.547	rs9502720	ENSG00000230939.1	RP11-314C16.1	-11.03	7.77e-27	6.48e-24	-0.39	-0.32	Motion sickness;	chr6:8541129	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.547	rs9505475	ENSG00000230939.1	RP11-314C16.1	-11.03	7.77e-27	6.48e-24	-0.39	-0.32	Motion sickness;	chr6:8542657	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.601	rs6906170	ENSG00000230939.1	RP11-314C16.1	-11.03	7.77e-27	6.48e-24	-0.39	-0.32	Motion sickness;	chr6:8542895	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.546	rs1335640	ENSG00000230939.1	RP11-314C16.1	-11.03	7.79e-27	6.49e-24	-0.39	-0.32	Motion sickness;	chr6:8485092	chr6:8784178~8785445:+
BRCA	cis	rs2404602	0.591	rs11635162	ENSG00000259422.1	RP11-593F23.1	-11.03	7.81e-27	6.51e-24	-0.46	-0.32	Blood metabolite levels;	chr15:76658764	chr15:76174891~76181486:-
BRCA	cis	rs7397814	0.558	rs4764447	ENSG00000278635.1	CTD-2318O12.1	11.03	7.91e-27	6.59e-24	0.33	0.32	IgG glycosylation;	chr12:9426513	chr12:9415641~9416718:+
BRCA	cis	rs2188561	1	rs2712207	ENSG00000241764.3	AC002467.7	11.03	7.98e-27	6.64e-24	0.48	0.32	Alcohol consumption;	chr7:107711672	chr7:107742817~107744581:-
BRCA	cis	rs2243480	1	rs1499613	ENSG00000226824.5	RP4-756H11.3	11.03	7.98e-27	6.64e-24	0.62	0.32	Diabetic kidney disease;	chr7:66265873	chr7:66654538~66669855:+
BRCA	cis	rs2153535	0.58	rs9406158	ENSG00000230939.1	RP11-314C16.1	-11.03	7.99e-27	6.65e-24	-0.39	-0.32	Motion sickness;	chr6:8463919	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs9406159	ENSG00000230939.1	RP11-314C16.1	-11.03	7.99e-27	6.65e-24	-0.39	-0.32	Motion sickness;	chr6:8464626	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs1335637	ENSG00000230939.1	RP11-314C16.1	-11.03	7.99e-27	6.65e-24	-0.39	-0.32	Motion sickness;	chr6:8464868	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs9406162	ENSG00000230939.1	RP11-314C16.1	-11.03	7.99e-27	6.65e-24	-0.39	-0.32	Motion sickness;	chr6:8465963	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.541	rs9392222	ENSG00000230939.1	RP11-314C16.1	-11.03	7.99e-27	6.65e-24	-0.39	-0.32	Motion sickness;	chr6:8467416	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.541	rs6932434	ENSG00000230939.1	RP11-314C16.1	-11.03	7.99e-27	6.65e-24	-0.39	-0.32	Motion sickness;	chr6:8467446	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs1034273	ENSG00000230939.1	RP11-314C16.1	-11.03	7.99e-27	6.65e-24	-0.39	-0.32	Motion sickness;	chr6:8467912	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.541	rs9328471	ENSG00000230939.1	RP11-314C16.1	-11.03	7.99e-27	6.65e-24	-0.39	-0.32	Motion sickness;	chr6:8468609	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.601	rs9505451	ENSG00000230939.1	RP11-314C16.1	-11.03	7.99e-27	6.65e-24	-0.39	-0.32	Motion sickness;	chr6:8469717	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs9393023	ENSG00000230939.1	RP11-314C16.1	-11.03	7.99e-27	6.65e-24	-0.39	-0.32	Motion sickness;	chr6:8469761	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs1414346	ENSG00000230939.1	RP11-314C16.1	-11.03	7.99e-27	6.65e-24	-0.39	-0.32	Motion sickness;	chr6:8471341	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs1932279	ENSG00000230939.1	RP11-314C16.1	-11.03	7.99e-27	6.65e-24	-0.39	-0.32	Motion sickness;	chr6:8473420	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs9379213	ENSG00000230939.1	RP11-314C16.1	-11.03	7.99e-27	6.65e-24	-0.39	-0.32	Motion sickness;	chr6:8474712	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.542	rs915354	ENSG00000230939.1	RP11-314C16.1	-11.03	8.02e-27	6.68e-24	-0.39	-0.32	Motion sickness;	chr6:8440124	chr6:8784178~8785445:+
BRCA	cis	rs9318086	0.687	rs9507182	ENSG00000205861.10	C1QTNF9B-AS1	-11.03	8.1e-27	6.73e-24	-0.41	-0.32	Myopia (pathological);	chr13:23868226	chr13:23888889~23897263:+
BRCA	cis	rs2153535	0.58	rs2152348	ENSG00000230939.1	RP11-314C16.1	-11.02	8.23e-27	6.84e-24	-0.39	-0.32	Motion sickness;	chr6:8474068	chr6:8784178~8785445:+
BRCA	cis	rs10759883	0.539	rs10987963	ENSG00000175611.10	LINC00476	11.02	8.28e-27	6.88e-24	0.38	0.32	Nicotine dependence;	chr9:95903798	chr9:95759231~95875977:-
BRCA	cis	rs34375054	0.738	rs10773145	ENSG00000279233.1	RP11-158L12.4	-11.02	8.3e-27	6.89e-24	-0.36	-0.32	Post bronchodilator FEV1/FVC ratio;	chr12:125141057	chr12:125138245~125141711:+
BRCA	cis	rs2153535	0.58	rs7761937	ENSG00000230939.1	RP11-314C16.1	-11.02	8.3e-27	6.9e-24	-0.39	-0.32	Motion sickness;	chr6:8459201	chr6:8784178~8785445:+
BRCA	cis	rs2404602	0.684	rs4886819	ENSG00000259422.1	RP11-593F23.1	-11.02	8.31e-27	6.9e-24	-0.42	-0.32	Blood metabolite levels;	chr15:76609357	chr15:76174891~76181486:-
BRCA	cis	rs6782228	0.606	rs2811490	ENSG00000242551.2	POU5F1P6	-11.02	8.34e-27	6.92e-24	-0.41	-0.32	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128632912	chr3:128674735~128677005:-
BRCA	cis	rs1062177	0.826	rs1549920	ENSG00000213433.5	RPLP1P6	-11.02	8.34e-27	6.93e-24	-0.41	-0.32	Preschool internalizing problems;	chr5:151761283	chr5:151765859~151766378:-
BRCA	cis	rs1555322	0.53	rs6060347	ENSG00000126005.14	MMP24-AS1	-11.02	8.34e-27	6.93e-24	-0.43	-0.32	Attention deficit hyperactivity disorder;	chr20:35286348	chr20:35216462~35278131:-
BRCA	cis	rs11673344	0.67	rs73039188	ENSG00000226686.6	LINC01535	11.02	8.36e-27	6.95e-24	0.46	0.32	Obesity-related traits;	chr19:36922449	chr19:37251912~37265535:+
BRCA	cis	rs6782228	0.606	rs10048945	ENSG00000242551.2	POU5F1P6	-11.02	8.39e-27	6.97e-24	-0.4	-0.32	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128690837	chr3:128674735~128677005:-
BRCA	cis	rs2153535	0.58	rs9505457	ENSG00000230939.1	RP11-314C16.1	-11.02	8.44e-27	7.01e-24	-0.39	-0.32	Motion sickness;	chr6:8478909	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.56	rs9379214	ENSG00000230939.1	RP11-314C16.1	-11.02	8.44e-27	7.01e-24	-0.39	-0.32	Motion sickness;	chr6:8480637	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs2225765	ENSG00000230939.1	RP11-314C16.1	-11.02	8.44e-27	7.01e-24	-0.39	-0.32	Motion sickness;	chr6:8481552	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.526	rs7748404	ENSG00000230939.1	RP11-314C16.1	-11.02	8.46e-27	7.03e-24	-0.39	-0.32	Motion sickness;	chr6:8472267	chr6:8784178~8785445:+
BRCA	cis	rs2442825	0.693	rs2258768	ENSG00000206573.7	THUMPD3-AS1	11.02	8.53e-27	7.08e-24	0.29	0.32	Cerebrospinal fluid clusterin levels;	chr3:9363193	chr3:9349689~9398579:-
BRCA	cis	rs2442825	0.693	rs2648535	ENSG00000206573.7	THUMPD3-AS1	11.02	8.56e-27	7.1e-24	0.29	0.32	Cerebrospinal fluid clusterin levels;	chr3:9366759	chr3:9349689~9398579:-
BRCA	cis	rs2153535	0.58	rs1577472	ENSG00000230939.1	RP11-314C16.1	-11.02	8.56e-27	7.11e-24	-0.39	-0.32	Motion sickness;	chr6:8485982	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.542	rs1120393	ENSG00000230939.1	RP11-314C16.1	-11.02	8.56e-27	7.11e-24	-0.39	-0.32	Motion sickness;	chr6:8486657	chr6:8784178~8785445:+
BRCA	cis	rs992157	0.764	rs2015863	ENSG00000261338.2	RP11-378A13.1	-11.02	8.6e-27	7.13e-24	-0.36	-0.32	Colorectal cancer;	chr2:218320438	chr2:218255319~218257366:+
BRCA	cis	rs2153535	0.562	rs9379211	ENSG00000230939.1	RP11-314C16.1	-11.02	8.61e-27	7.14e-24	-0.39	-0.32	Motion sickness;	chr6:8463694	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs965706	ENSG00000230939.1	RP11-314C16.1	-11.02	8.61e-27	7.14e-24	-0.39	-0.32	Motion sickness;	chr6:8464475	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs6938071	ENSG00000230939.1	RP11-314C16.1	-11.02	8.61e-27	7.14e-24	-0.39	-0.32	Motion sickness;	chr6:8464612	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.601	rs9406160	ENSG00000230939.1	RP11-314C16.1	-11.02	8.61e-27	7.14e-24	-0.39	-0.32	Motion sickness;	chr6:8464674	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs1335636	ENSG00000230939.1	RP11-314C16.1	-11.02	8.61e-27	7.14e-24	-0.39	-0.32	Motion sickness;	chr6:8464814	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs986060	ENSG00000230939.1	RP11-314C16.1	-11.02	8.61e-27	7.14e-24	-0.39	-0.32	Motion sickness;	chr6:8465195	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs9393021	ENSG00000230939.1	RP11-314C16.1	-11.02	8.61e-27	7.14e-24	-0.39	-0.32	Motion sickness;	chr6:8465890	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs9406161	ENSG00000230939.1	RP11-314C16.1	-11.02	8.61e-27	7.14e-24	-0.39	-0.32	Motion sickness;	chr6:8465911	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs9405390	ENSG00000230939.1	RP11-314C16.1	-11.02	8.61e-27	7.14e-24	-0.39	-0.32	Motion sickness;	chr6:8465976	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs9406163	ENSG00000230939.1	RP11-314C16.1	-11.02	8.61e-27	7.14e-24	-0.39	-0.32	Motion sickness;	chr6:8466409	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.504	rs9405393	ENSG00000230939.1	RP11-314C16.1	-11.02	8.61e-27	7.14e-24	-0.39	-0.32	Motion sickness;	chr6:8467199	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs2184584	ENSG00000230939.1	RP11-314C16.1	-11.02	8.61e-27	7.14e-24	-0.39	-0.32	Motion sickness;	chr6:8468174	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.541	rs7774752	ENSG00000230939.1	RP11-314C16.1	-11.02	8.61e-27	7.14e-24	-0.39	-0.32	Motion sickness;	chr6:8468745	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs9505450	ENSG00000230939.1	RP11-314C16.1	-11.02	8.61e-27	7.14e-24	-0.39	-0.32	Motion sickness;	chr6:8469669	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs9406164	ENSG00000230939.1	RP11-314C16.1	-11.02	8.61e-27	7.14e-24	-0.39	-0.32	Motion sickness;	chr6:8469815	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs7341201	ENSG00000230939.1	RP11-314C16.1	-11.02	8.61e-27	7.14e-24	-0.39	-0.32	Motion sickness;	chr6:8470037	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs7341206	ENSG00000230939.1	RP11-314C16.1	-11.02	8.61e-27	7.14e-24	-0.39	-0.32	Motion sickness;	chr6:8470256	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs7341383	ENSG00000230939.1	RP11-314C16.1	-11.02	8.61e-27	7.14e-24	-0.39	-0.32	Motion sickness;	chr6:8470401	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.504	rs9328472	ENSG00000230939.1	RP11-314C16.1	-11.02	8.61e-27	7.14e-24	-0.39	-0.32	Motion sickness;	chr6:8470615	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs1414345	ENSG00000230939.1	RP11-314C16.1	-11.02	8.61e-27	7.14e-24	-0.39	-0.32	Motion sickness;	chr6:8471304	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs1414349	ENSG00000230939.1	RP11-314C16.1	-11.02	8.61e-27	7.14e-24	-0.39	-0.32	Motion sickness;	chr6:8472057	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs1414350	ENSG00000230939.1	RP11-314C16.1	-11.02	8.61e-27	7.14e-24	-0.39	-0.32	Motion sickness;	chr6:8472098	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs9392224	ENSG00000230939.1	RP11-314C16.1	-11.02	8.61e-27	7.14e-24	-0.39	-0.32	Motion sickness;	chr6:8472381	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.542	rs9378553	ENSG00000230939.1	RP11-314C16.1	-11.02	8.61e-27	7.14e-24	-0.39	-0.32	Motion sickness;	chr6:8472399	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.601	rs1855768	ENSG00000230939.1	RP11-314C16.1	-11.02	8.61e-27	7.14e-24	-0.39	-0.32	Motion sickness;	chr6:8472736	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs1932281	ENSG00000230939.1	RP11-314C16.1	-11.02	8.61e-27	7.14e-24	-0.39	-0.32	Motion sickness;	chr6:8473532	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs6900007	ENSG00000230939.1	RP11-314C16.1	-11.02	8.61e-27	7.14e-24	-0.39	-0.32	Motion sickness;	chr6:8473802	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs2184585	ENSG00000230939.1	RP11-314C16.1	-11.02	8.61e-27	7.14e-24	-0.39	-0.32	Motion sickness;	chr6:8473935	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs6902001	ENSG00000230939.1	RP11-314C16.1	-11.02	8.61e-27	7.14e-24	-0.39	-0.32	Motion sickness;	chr6:8476822	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs4960423	ENSG00000230939.1	RP11-314C16.1	-11.02	8.61e-27	7.14e-24	-0.39	-0.32	Motion sickness;	chr6:8476977	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs1932282	ENSG00000230939.1	RP11-314C16.1	-11.02	8.61e-27	7.14e-24	-0.39	-0.32	Motion sickness;	chr6:8477097	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs9505455	ENSG00000230939.1	RP11-314C16.1	-11.02	8.67e-27	7.18e-24	-0.38	-0.32	Motion sickness;	chr6:8478389	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs9379216	ENSG00000230939.1	RP11-314C16.1	-11.02	8.67e-27	7.18e-24	-0.38	-0.32	Motion sickness;	chr6:8481002	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs7450817	ENSG00000230939.1	RP11-314C16.1	-11.02	8.67e-27	7.18e-24	-0.38	-0.32	Motion sickness;	chr6:8481188	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.56	rs2210798	ENSG00000230939.1	RP11-314C16.1	-11.02	8.67e-27	7.18e-24	-0.38	-0.32	Motion sickness;	chr6:8481289	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs6597327	ENSG00000230939.1	RP11-314C16.1	-11.02	8.67e-27	7.18e-24	-0.38	-0.32	Motion sickness;	chr6:8481924	chr6:8784178~8785445:+
BRCA	cis	rs2243480	0.908	rs1532573	ENSG00000226824.5	RP4-756H11.3	11.02	8.69e-27	7.19e-24	0.63	0.32	Diabetic kidney disease;	chr7:66333815	chr7:66654538~66669855:+
BRCA	cis	rs7182621	1	rs7182621	ENSG00000259363.4	CTD-2054N24.2	11.02	8.77e-27	7.26e-24	0.36	0.32	Colonoscopy-negative controls vs population controls;	chr15:99884400	chr15:99807023~99877148:+
BRCA	cis	rs875971	1	rs2420820	ENSG00000222364.1	RNU6-96P	11.02	8.77e-27	7.26e-24	0.38	0.32	Aortic root size;	chr7:66626920	chr7:66395191~66395286:+
BRCA	cis	rs2153535	0.58	rs7763190	ENSG00000230939.1	RP11-314C16.1	-11.02	8.79e-27	7.28e-24	-0.39	-0.32	Motion sickness;	chr6:8483964	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.541	rs1414352	ENSG00000230939.1	RP11-314C16.1	-11.02	8.79e-27	7.28e-24	-0.39	-0.32	Motion sickness;	chr6:8485314	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs1577471	ENSG00000230939.1	RP11-314C16.1	-11.02	8.79e-27	7.28e-24	-0.39	-0.32	Motion sickness;	chr6:8485672	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.601	rs2327091	ENSG00000230939.1	RP11-314C16.1	-11.02	8.83e-27	7.31e-24	-0.39	-0.32	Motion sickness;	chr6:8540136	chr6:8784178~8785445:+
BRCA	cis	rs2880765	0.545	rs11631739	ENSG00000259295.5	CSPG4P12	11.02	8.88e-27	7.35e-24	0.42	0.32	Coronary artery disease;	chr15:85469347	chr15:85191438~85213905:+
BRCA	cis	rs1075265	0.554	rs10168293	ENSG00000233266.1	HMGB1P31	11.02	8.89e-27	7.35e-24	0.39	0.32	Chronotype;Morning vs. evening chronotype;	chr2:53973793	chr2:54051334~54051760:+
BRCA	cis	rs2153535	0.58	rs9378551	ENSG00000230939.1	RP11-314C16.1	-11.02	8.91e-27	7.37e-24	-0.39	-0.32	Motion sickness;	chr6:8463511	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs9378552	ENSG00000230939.1	RP11-314C16.1	-11.02	8.91e-27	7.37e-24	-0.39	-0.32	Motion sickness;	chr6:8463515	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs1034272	ENSG00000230939.1	RP11-314C16.1	-11.02	8.95e-27	7.4e-24	-0.39	-0.32	Motion sickness;	chr6:8469102	chr6:8784178~8785445:+
BRCA	cis	rs10129255	0.828	rs10140989	ENSG00000211970.3	IGHV4-61	-11.02	8.97e-27	7.42e-24	-0.24	-0.32	Kawasaki disease;	chr14:106668657	chr14:106639119~106639657:-
BRCA	cis	rs11673344	0.832	rs56210764	ENSG00000226686.6	LINC01535	11.02	8.99e-27	7.43e-24	0.47	0.32	Obesity-related traits;	chr19:37125970	chr19:37251912~37265535:+
BRCA	cis	rs2337406	1	rs3858878	ENSG00000274576.2	IGHV2-70	-11.01	9.2e-27	7.61e-24	-0.35	-0.32	Alzheimer's disease (late onset);	chr14:106688061	chr14:106770577~106771020:-
BRCA	cis	rs10759883	0.563	rs624075	ENSG00000175611.10	LINC00476	11.01	9.29e-27	7.68e-24	0.38	0.32	Nicotine dependence;	chr9:95902665	chr9:95759231~95875977:-
BRCA	cis	rs4308124	0.708	rs28871990	ENSG00000227992.1	AC108463.2	-11.01	9.35e-27	7.73e-24	-0.41	-0.32	Vitiligo;	chr2:111204864	chr2:111203964~111206215:-
BRCA	cis	rs858239	1	rs199348	ENSG00000226816.2	AC005082.12	11.01	9.39e-27	7.75e-24	0.37	0.32	Cerebrospinal fluid biomarker levels;	chr7:23253479	chr7:23206013~23208045:+
BRCA	cis	rs7772486	0.79	rs9403756	ENSG00000235652.6	RP11-545I5.3	-11.01	9.44e-27	7.8e-24	-0.33	-0.32	Lobe attachment (rater-scored or self-reported);	chr6:145936625	chr6:145799409~145886585:+
BRCA	cis	rs172166	0.694	rs203876	ENSG00000220721.1	OR1F12	11.01	9.5e-27	7.85e-24	0.39	0.32	Cardiac Troponin-T levels;	chr6:28078895	chr6:28073316~28074233:+
BRCA	cis	rs6782228	0.606	rs6775270	ENSG00000242551.2	POU5F1P6	-11.01	9.54e-27	7.87e-24	-0.41	-0.32	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128684655	chr3:128674735~128677005:-
BRCA	cis	rs1499614	1	rs2659903	ENSG00000226824.5	RP4-756H11.3	-11.01	9.55e-27	7.89e-24	-0.63	-0.32	Gout;	chr7:66715944	chr7:66654538~66669855:+
BRCA	cis	rs9660180	0.783	rs1107910	ENSG00000268575.1	RP1-283E3.8	-11.01	9.74e-27	8.04e-24	-0.33	-0.32	Body mass index;	chr1:1760882	chr1:1702736~1737688:-
BRCA	cis	rs2153535	0.58	rs1832100	ENSG00000230939.1	RP11-314C16.1	-11.01	9.85e-27	8.13e-24	-0.38	-0.32	Motion sickness;	chr6:8446723	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs2327058	ENSG00000230939.1	RP11-314C16.1	-11.01	9.85e-27	8.13e-24	-0.38	-0.32	Motion sickness;	chr6:8446785	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.601	rs2327059	ENSG00000230939.1	RP11-314C16.1	-11.01	9.85e-27	8.13e-24	-0.38	-0.32	Motion sickness;	chr6:8446838	chr6:8784178~8785445:+
BRCA	cis	rs4308124	0.679	rs7600458	ENSG00000227992.1	AC108463.2	-11.01	9.9e-27	8.17e-24	-0.41	-0.32	Vitiligo;	chr2:111206013	chr2:111203964~111206215:-
BRCA	cis	rs2153535	0.601	rs9502719	ENSG00000230939.1	RP11-314C16.1	-11.01	9.93e-27	8.19e-24	-0.39	-0.32	Motion sickness;	chr6:8540799	chr6:8784178~8785445:+
BRCA	cis	rs10759883	0.627	rs700962	ENSG00000175611.10	LINC00476	-11.01	1e-26	8.27e-24	-0.37	-0.32	Nicotine dependence;	chr9:95815766	chr9:95759231~95875977:-
BRCA	cis	rs4308124	0.708	rs6749633	ENSG00000227992.1	AC108463.2	11	1.01e-26	8.32e-24	0.41	0.32	Vitiligo;	chr2:111230439	chr2:111203964~111206215:-
BRCA	cis	rs1891275	0.515	rs1080496	ENSG00000228701.1	TNKS2-AS1	11	1.02e-26	8.38e-24	0.37	0.32	Intelligence (multi-trait analysis);	chr10:91684505	chr10:91782839~91798291:-
BRCA	cis	rs2153535	0.58	rs2184582	ENSG00000230939.1	RP11-314C16.1	-11	1.02e-26	8.39e-24	-0.38	-0.32	Motion sickness;	chr6:8447560	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs2184583	ENSG00000230939.1	RP11-314C16.1	-11	1.02e-26	8.39e-24	-0.38	-0.32	Motion sickness;	chr6:8447575	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs9505446	ENSG00000230939.1	RP11-314C16.1	-11	1.02e-26	8.39e-24	-0.38	-0.32	Motion sickness;	chr6:8448458	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs1335633	ENSG00000230939.1	RP11-314C16.1	-11	1.02e-26	8.39e-24	-0.38	-0.32	Motion sickness;	chr6:8448567	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs1115079	ENSG00000230939.1	RP11-314C16.1	-11	1.02e-26	8.39e-24	-0.38	-0.32	Motion sickness;	chr6:8449382	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs1115078	ENSG00000230939.1	RP11-314C16.1	-11	1.02e-26	8.39e-24	-0.38	-0.32	Motion sickness;	chr6:8449405	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs6597322	ENSG00000230939.1	RP11-314C16.1	-11	1.02e-26	8.39e-24	-0.38	-0.32	Motion sickness;	chr6:8449719	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs962590	ENSG00000230939.1	RP11-314C16.1	-11	1.02e-26	8.39e-24	-0.38	-0.32	Motion sickness;	chr6:8450666	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs5001324	ENSG00000230939.1	RP11-314C16.1	-11	1.02e-26	8.39e-24	-0.38	-0.32	Motion sickness;	chr6:8451371	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs5001322	ENSG00000230939.1	RP11-314C16.1	-11	1.02e-26	8.39e-24	-0.38	-0.32	Motion sickness;	chr6:8451375	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs969422	ENSG00000230939.1	RP11-314C16.1	-11	1.02e-26	8.39e-24	-0.38	-0.32	Motion sickness;	chr6:8451547	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs969421	ENSG00000230939.1	RP11-314C16.1	-11	1.02e-26	8.39e-24	-0.38	-0.32	Motion sickness;	chr6:8451716	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.601	rs969420	ENSG00000230939.1	RP11-314C16.1	-11	1.02e-26	8.39e-24	-0.38	-0.32	Motion sickness;	chr6:8451733	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs7741456	ENSG00000230939.1	RP11-314C16.1	-11	1.02e-26	8.39e-24	-0.38	-0.32	Motion sickness;	chr6:8452191	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs7742689	ENSG00000230939.1	RP11-314C16.1	-11	1.02e-26	8.39e-24	-0.38	-0.32	Motion sickness;	chr6:8452200	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs7767756	ENSG00000230939.1	RP11-314C16.1	-11	1.02e-26	8.39e-24	-0.38	-0.32	Motion sickness;	chr6:8453195	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs7767926	ENSG00000230939.1	RP11-314C16.1	-11	1.02e-26	8.39e-24	-0.38	-0.32	Motion sickness;	chr6:8453324	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs9328484	ENSG00000230939.1	RP11-314C16.1	-11	1.03e-26	8.45e-24	-0.39	-0.32	Motion sickness;	chr6:8524610	chr6:8784178~8785445:+
BRCA	cis	rs673078	0.607	rs55929628	ENSG00000275759.1	RP11-131L12.3	-11	1.03e-26	8.45e-24	-0.53	-0.32	Glucose homeostasis traits;	chr12:118371332	chr12:118428281~118428870:+
BRCA	cis	rs2153535	0.601	rs9505472	ENSG00000230939.1	RP11-314C16.1	-11	1.03e-26	8.47e-24	-0.39	-0.32	Motion sickness;	chr6:8538532	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.601	rs9505473	ENSG00000230939.1	RP11-314C16.1	-11	1.03e-26	8.47e-24	-0.39	-0.32	Motion sickness;	chr6:8538544	chr6:8784178~8785445:+
BRCA	cis	rs6782228	0.606	rs2001703	ENSG00000242551.2	POU5F1P6	-11	1.04e-26	8.54e-24	-0.41	-0.32	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128664254	chr3:128674735~128677005:-
BRCA	cis	rs1075265	0.567	rs66773232	ENSG00000233266.1	HMGB1P31	11	1.04e-26	8.6e-24	0.39	0.32	Chronotype;Morning vs. evening chronotype;	chr2:53973970	chr2:54051334~54051760:+
BRCA	cis	rs8062405	1	rs62037369	ENSG00000251417.2	RP11-1348G14.4	-11	1.05e-26	8.61e-24	-0.4	-0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28872520	chr16:28802743~28817828:+
BRCA	cis	rs8062405	0.965	rs7359397	ENSG00000251417.2	RP11-1348G14.4	-11	1.05e-26	8.61e-24	-0.4	-0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28874338	chr16:28802743~28817828:+
BRCA	cis	rs2153535	0.58	rs7341382	ENSG00000230939.1	RP11-314C16.1	-11	1.06e-26	8.69e-24	-0.39	-0.32	Motion sickness;	chr6:8470316	chr6:8784178~8785445:+
BRCA	cis	rs172166	0.611	rs203882	ENSG00000220721.1	OR1F12	11	1.08e-26	8.9e-24	0.39	0.32	Cardiac Troponin-T levels;	chr6:28110724	chr6:28073316~28074233:+
BRCA	cis	rs5760092	0.618	rs5996631	ENSG00000250470.1	AP000351.3	-11	1.09e-26	8.94e-24	-0.44	-0.32	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23976904~23977585:-
BRCA	cis	rs10740039	0.583	rs1904404	ENSG00000254271.1	RP11-131N11.4	-11	1.11e-26	9.08e-24	-0.42	-0.32	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60742428	chr10:60734342~60741828:+
BRCA	cis	rs7309	0.935	rs11884495	ENSG00000235724.7	AC009299.2	-10.99	1.11e-26	9.12e-24	-0.36	-0.32	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161203458	chr2:161222785~161308303:-
BRCA	cis	rs2243480	1	rs313802	ENSG00000226824.5	RP4-756H11.3	-10.99	1.12e-26	9.16e-24	-0.64	-0.32	Diabetic kidney disease;	chr7:66051386	chr7:66654538~66669855:+
BRCA	cis	rs2243480	0.803	rs403089	ENSG00000226824.5	RP4-756H11.3	-10.99	1.12e-26	9.16e-24	-0.64	-0.32	Diabetic kidney disease;	chr7:66052736	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs458291	ENSG00000226824.5	RP4-756H11.3	-10.99	1.12e-26	9.16e-24	-0.64	-0.32	Diabetic kidney disease;	chr7:66055492	chr7:66654538~66669855:+
BRCA	cis	rs321358	1	rs321356	ENSG00000271584.1	RP11-89C3.4	-10.99	1.12e-26	9.16e-24	-0.53	-0.32	Body mass index;	chr11:111124957	chr11:111091932~111097357:-
BRCA	cis	rs2243480	1	rs313803	ENSG00000226824.5	RP4-756H11.3	-10.99	1.13e-26	9.27e-24	-0.64	-0.32	Diabetic kidney disease;	chr7:66049744	chr7:66654538~66669855:+
BRCA	cis	rs1729407	0.774	rs2849167	ENSG00000254851.1	RP11-109L13.1	10.99	1.13e-26	9.29e-24	0.4	0.32	Apolipoprotein A-IV levels;	chr11:116814028	chr11:117135528~117138582:+
BRCA	cis	rs9545047	0.604	rs9574406	ENSG00000227676.3	LINC01068	-10.99	1.14e-26	9.34e-24	-0.37	-0.32	Schizophrenia;	chr13:79338982	chr13:79566727~79571436:+
BRCA	cis	rs7208859	0.623	rs122898	ENSG00000263531.1	RP13-753N3.1	-10.99	1.14e-26	9.36e-24	-0.61	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30578236	chr17:30863921~30864940:-
BRCA	cis	rs10759883	0.563	rs690063	ENSG00000175611.10	LINC00476	10.99	1.17e-26	9.55e-24	0.38	0.32	Nicotine dependence;	chr9:95931019	chr9:95759231~95875977:-
BRCA	cis	rs4380275	0.965	rs12621177	ENSG00000272342.1	RP13-539J13.1	10.99	1.17e-26	9.6e-24	0.41	0.32	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:757786	chr2:739588~740164:-
BRCA	cis	rs150992	0.711	rs170734	ENSG00000248489.1	CTD-2007H13.3	10.99	1.19e-26	9.73e-24	0.37	0.32	Body mass index;	chr5:98811337	chr5:98929171~98995013:+
BRCA	cis	rs11673344	0.838	rs112401881	ENSG00000226686.6	LINC01535	10.99	1.19e-26	9.76e-24	0.47	0.32	Obesity-related traits;	chr19:37156092	chr19:37251912~37265535:+
BRCA	cis	rs2153535	0.58	rs1319169	ENSG00000230939.1	RP11-314C16.1	-10.99	1.2e-26	9.8e-24	-0.38	-0.32	Motion sickness;	chr6:8464223	chr6:8784178~8785445:+
BRCA	cis	rs1499614	1	rs2659913	ENSG00000226824.5	RP4-756H11.3	-10.99	1.2e-26	9.8e-24	-0.63	-0.32	Gout;	chr7:66692349	chr7:66654538~66669855:+
BRCA	cis	rs1499614	1	rs2659911	ENSG00000226824.5	RP4-756H11.3	-10.99	1.2e-26	9.8e-24	-0.63	-0.32	Gout;	chr7:66693433	chr7:66654538~66669855:+
BRCA	cis	rs1499614	1	rs2707838	ENSG00000226824.5	RP4-756H11.3	-10.99	1.2e-26	9.8e-24	-0.63	-0.32	Gout;	chr7:66694214	chr7:66654538~66669855:+
BRCA	cis	rs1499614	1	rs60326618	ENSG00000226824.5	RP4-756H11.3	-10.99	1.2e-26	9.8e-24	-0.63	-0.32	Gout;	chr7:66701371	chr7:66654538~66669855:+
BRCA	cis	rs1499614	1	rs2707830	ENSG00000226824.5	RP4-756H11.3	-10.99	1.2e-26	9.8e-24	-0.63	-0.32	Gout;	chr7:66702658	chr7:66654538~66669855:+
BRCA	cis	rs1499614	1	rs2707828	ENSG00000226824.5	RP4-756H11.3	-10.99	1.2e-26	9.8e-24	-0.63	-0.32	Gout;	chr7:66706390	chr7:66654538~66669855:+
BRCA	cis	rs1499614	0.803	rs1922723	ENSG00000226824.5	RP4-756H11.3	-10.99	1.2e-26	9.8e-24	-0.63	-0.32	Gout;	chr7:66710076	chr7:66654538~66669855:+
BRCA	cis	rs8062405	0.964	rs7187333	ENSG00000251417.2	RP11-1348G14.4	-10.99	1.21e-26	9.87e-24	-0.4	-0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28854595	chr16:28802743~28817828:+
BRCA	cis	rs9318086	0.648	rs9510927	ENSG00000205861.10	C1QTNF9B-AS1	-10.99	1.21e-26	9.93e-24	-0.42	-0.32	Myopia (pathological);	chr13:23893502	chr13:23888889~23897263:+
BRCA	cis	rs2153535	0.58	rs7743686	ENSG00000230939.1	RP11-314C16.1	-10.99	1.21e-26	9.93e-24	-0.38	-0.32	Motion sickness;	chr6:8525878	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.601	rs718504	ENSG00000230939.1	RP11-314C16.1	-10.99	1.21e-26	9.93e-24	-0.38	-0.32	Motion sickness;	chr6:8527279	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.601	rs9328487	ENSG00000230939.1	RP11-314C16.1	-10.99	1.21e-26	9.93e-24	-0.38	-0.32	Motion sickness;	chr6:8529145	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs9328488	ENSG00000230939.1	RP11-314C16.1	-10.99	1.21e-26	9.93e-24	-0.38	-0.32	Motion sickness;	chr6:8529178	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.601	rs7775274	ENSG00000230939.1	RP11-314C16.1	-10.99	1.21e-26	9.93e-24	-0.38	-0.32	Motion sickness;	chr6:8530070	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.521	rs6939827	ENSG00000230939.1	RP11-314C16.1	-10.98	1.23e-26	1e-23	-0.39	-0.32	Motion sickness;	chr6:8461127	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs9393019	ENSG00000230939.1	RP11-314C16.1	-10.98	1.23e-26	1e-23	-0.39	-0.32	Motion sickness;	chr6:8461858	chr6:8784178~8785445:+
BRCA	cis	rs6991838	0.612	rs7842162	ENSG00000200714.1	Y_RNA	10.98	1.23e-26	1.01e-23	0.38	0.32	Intelligence (multi-trait analysis);	chr8:65644057	chr8:65592731~65592820:+
BRCA	cis	rs172166	0.694	rs1631552	ENSG00000220721.1	OR1F12	10.98	1.23e-26	1.01e-23	0.39	0.32	Cardiac Troponin-T levels;	chr6:28121921	chr6:28073316~28074233:+
BRCA	cis	rs10875746	0.951	rs2269935	ENSG00000240399.1	RP1-228P16.1	-10.98	1.24e-26	1.01e-23	-0.45	-0.32	Longevity (90 years and older);	chr12:48122681	chr12:48054813~48055591:-
BRCA	cis	rs9545047	0.532	rs1748768	ENSG00000227676.3	LINC01068	10.98	1.24e-26	1.01e-23	0.37	0.32	Schizophrenia;	chr13:79313276	chr13:79566727~79571436:+
BRCA	cis	rs1075265	0.527	rs10167891	ENSG00000233266.1	HMGB1P31	10.98	1.24e-26	1.01e-23	0.39	0.32	Chronotype;Morning vs. evening chronotype;	chr2:54003658	chr2:54051334~54051760:+
BRCA	cis	rs9545047	0.604	rs1410332	ENSG00000227676.3	LINC01068	10.98	1.25e-26	1.02e-23	0.37	0.32	Schizophrenia;	chr13:79315171	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs9545065	ENSG00000227676.3	LINC01068	10.98	1.25e-26	1.02e-23	0.37	0.32	Schizophrenia;	chr13:79317034	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs3818563	ENSG00000227676.3	LINC01068	10.98	1.25e-26	1.02e-23	0.37	0.32	Schizophrenia;	chr13:79318587	chr13:79566727~79571436:+
BRCA	cis	rs6782228	0.509	rs4481172	ENSG00000242551.2	POU5F1P6	-10.98	1.25e-26	1.02e-23	-0.41	-0.32	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128653814	chr3:128674735~128677005:-
BRCA	cis	rs9545047	0.604	rs1007569	ENSG00000227676.3	LINC01068	10.98	1.25e-26	1.02e-23	0.37	0.32	Schizophrenia;	chr13:79306752	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.584	rs4885626	ENSG00000227676.3	LINC01068	10.98	1.25e-26	1.02e-23	0.37	0.32	Schizophrenia;	chr13:79309765	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs4885627	ENSG00000227676.3	LINC01068	10.98	1.25e-26	1.02e-23	0.37	0.32	Schizophrenia;	chr13:79309786	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs4885628	ENSG00000227676.3	LINC01068	10.98	1.25e-26	1.02e-23	0.37	0.32	Schizophrenia;	chr13:79309830	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.554	rs4885629	ENSG00000227676.3	LINC01068	10.98	1.25e-26	1.02e-23	0.37	0.32	Schizophrenia;	chr13:79309855	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs1927506	ENSG00000227676.3	LINC01068	10.98	1.25e-26	1.02e-23	0.37	0.32	Schizophrenia;	chr13:79311350	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs1409019	ENSG00000227676.3	LINC01068	10.98	1.25e-26	1.02e-23	0.37	0.32	Schizophrenia;	chr13:79312431	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs7317343	ENSG00000227676.3	LINC01068	10.98	1.25e-26	1.02e-23	0.37	0.32	Schizophrenia;	chr13:79312542	chr13:79566727~79571436:+
BRCA	cis	rs172166	0.652	rs476167	ENSG00000220721.1	OR1F12	10.98	1.25e-26	1.02e-23	0.39	0.32	Cardiac Troponin-T levels;	chr6:28098110	chr6:28073316~28074233:+
BRCA	cis	rs9545047	0.604	rs9530897	ENSG00000227676.3	LINC01068	10.98	1.26e-26	1.03e-23	0.37	0.32	Schizophrenia;	chr13:79336420	chr13:79566727~79571436:+
BRCA	cis	rs2404602	0.735	rs2957614	ENSG00000259422.1	RP11-593F23.1	10.98	1.26e-26	1.03e-23	0.41	0.32	Blood metabolite levels;	chr15:76404294	chr15:76174891~76181486:-
BRCA	cis	rs9545047	0.604	rs1748767	ENSG00000227676.3	LINC01068	10.98	1.26e-26	1.03e-23	0.37	0.32	Schizophrenia;	chr13:79313381	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.567	rs1409018	ENSG00000227676.3	LINC01068	10.98	1.26e-26	1.03e-23	0.37	0.32	Schizophrenia;	chr13:79313403	chr13:79566727~79571436:+
BRCA	cis	rs6782228	0.606	rs6787559	ENSG00000242551.2	POU5F1P6	-10.98	1.27e-26	1.03e-23	-0.41	-0.32	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128662243	chr3:128674735~128677005:-
BRCA	cis	rs9318086	0.712	rs1886970	ENSG00000205861.10	C1QTNF9B-AS1	-10.98	1.29e-26	1.05e-23	-0.41	-0.32	Myopia (pathological);	chr13:23866359	chr13:23888889~23897263:+
BRCA	cis	rs2581828	0.618	rs9824325	ENSG00000242142.1	SERBP1P3	-10.98	1.31e-26	1.07e-23	-0.41	-0.32	Crohn's disease;	chr3:53132494	chr3:53064283~53065091:-
BRCA	cis	rs7829975	0.688	rs7827182	ENSG00000253893.2	FAM85B	-10.98	1.31e-26	1.07e-23	-0.4	-0.32	Mood instability;	chr8:8522961	chr8:8167819~8226614:-
BRCA	cis	rs7772486	0.79	rs9485024	ENSG00000235652.6	RP11-545I5.3	-10.98	1.32e-26	1.07e-23	-0.31	-0.32	Lobe attachment (rater-scored or self-reported);	chr6:145821351	chr6:145799409~145886585:+
BRCA	cis	rs7201929	0.801	rs9933198	ENSG00000259982.1	CDC37P1	-10.98	1.34e-26	1.09e-23	-0.43	-0.32	QT interval;	chr16:28877088	chr16:28700294~28701540:-
BRCA	cis	rs10256972	1	rs10256972	ENSG00000229043.2	AC091729.9	10.98	1.35e-26	1.1e-23	0.41	0.32	Endometriosis;Longevity;	chr7:999367	chr7:1160374~1165267:+
BRCA	cis	rs4308124	0.708	rs56693625	ENSG00000227992.1	AC108463.2	-10.97	1.35e-26	1.1e-23	-0.41	-0.32	Vitiligo;	chr2:111207578	chr2:111203964~111206215:-
BRCA	cis	rs2404602	0.735	rs11635463	ENSG00000259422.1	RP11-593F23.1	-10.97	1.36e-26	1.11e-23	-0.43	-0.32	Blood metabolite levels;	chr15:76470645	chr15:76174891~76181486:-
BRCA	cis	rs7945705	0.869	rs7925728	ENSG00000254860.4	TMEM9B-AS1	10.97	1.36e-26	1.11e-23	0.29	0.32	Hemoglobin concentration;	chr11:8991455	chr11:8964675~8977527:+
BRCA	cis	rs11096990	0.551	rs2060005	ENSG00000249207.1	RP11-360F5.1	-10.97	1.38e-26	1.12e-23	-0.38	-0.32	Cognitive function;	chr4:39160901	chr4:39112677~39126818:-
BRCA	cis	rs1061377	0.501	rs62308278	ENSG00000249207.1	RP11-360F5.1	-10.97	1.38e-26	1.12e-23	-0.38	-0.32	Uric acid levels;	chr4:39161038	chr4:39112677~39126818:-
BRCA	cis	rs1499614	1	rs2707840	ENSG00000226824.5	RP4-756H11.3	-10.97	1.38e-26	1.12e-23	-0.63	-0.32	Gout;	chr7:66693028	chr7:66654538~66669855:+
BRCA	cis	rs67383717	0.527	rs10760718	ENSG00000175611.10	LINC00476	10.97	1.4e-26	1.14e-23	0.33	0.32	Parkinson's disease (pesticide exposure interaction);	chr9:96032397	chr9:95759231~95875977:-
BRCA	cis	rs1062177	0.901	rs1549622	ENSG00000213433.5	RPLP1P6	-10.97	1.41e-26	1.15e-23	-0.42	-0.32	Preschool internalizing problems;	chr5:151886488	chr5:151765859~151766378:-
BRCA	cis	rs10875746	0.903	rs11168370	ENSG00000240399.1	RP1-228P16.1	-10.97	1.41e-26	1.15e-23	-0.42	-0.32	Longevity (90 years and older);	chr12:48041497	chr12:48054813~48055591:-
BRCA	cis	rs6782228	0.606	rs6439135	ENSG00000242551.2	POU5F1P6	-10.97	1.41e-26	1.15e-23	-0.41	-0.32	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128639790	chr3:128674735~128677005:-
BRCA	cis	rs10759883	0.627	rs7871709	ENSG00000175611.10	LINC00476	-10.97	1.42e-26	1.15e-23	-0.38	-0.32	Nicotine dependence;	chr9:95798328	chr9:95759231~95875977:-
BRCA	cis	rs11723261	0.582	rs11735742	ENSG00000275426.1	CH17-262A2.1	-10.97	1.42e-26	1.16e-23	-0.45	-0.32	Immune response to smallpox vaccine (IL-6);	chr4:148766	chr4:149738~150317:+
BRCA	cis	rs172166	0.694	rs1770131	ENSG00000220721.1	OR1F12	10.97	1.43e-26	1.16e-23	0.39	0.32	Cardiac Troponin-T levels;	chr6:28118635	chr6:28073316~28074233:+
BRCA	cis	rs4308124	0.708	rs6716091	ENSG00000227992.1	AC108463.2	-10.97	1.43e-26	1.16e-23	-0.41	-0.32	Vitiligo;	chr2:111233556	chr2:111203964~111206215:-
BRCA	cis	rs67311347	0.955	rs4974067	ENSG00000223797.4	ENTPD3-AS1	10.97	1.43e-26	1.16e-23	0.36	0.32	Renal cell carcinoma;	chr3:40333060	chr3:40313802~40453329:-
BRCA	cis	rs1075265	0.633	rs10183655	ENSG00000233266.1	HMGB1P31	10.97	1.44e-26	1.17e-23	0.39	0.32	Chronotype;Morning vs. evening chronotype;	chr2:53983644	chr2:54051334~54051760:+
BRCA	cis	rs4308124	0.708	rs7585313	ENSG00000227992.1	AC108463.2	-10.97	1.44e-26	1.17e-23	-0.41	-0.32	Vitiligo;	chr2:111217626	chr2:111203964~111206215:-
BRCA	cis	rs2153535	0.58	rs6421948	ENSG00000230939.1	RP11-314C16.1	-10.97	1.46e-26	1.19e-23	-0.38	-0.32	Motion sickness;	chr6:8530787	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs6421949	ENSG00000230939.1	RP11-314C16.1	-10.97	1.46e-26	1.19e-23	-0.38	-0.32	Motion sickness;	chr6:8531536	chr6:8784178~8785445:+
BRCA	cis	rs6782228	0.606	rs7650156	ENSG00000242551.2	POU5F1P6	-10.97	1.49e-26	1.21e-23	-0.41	-0.32	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128642712	chr3:128674735~128677005:-
BRCA	cis	rs10740039	0.583	rs1904401	ENSG00000254271.1	RP11-131N11.4	-10.96	1.5e-26	1.22e-23	-0.42	-0.32	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60741809	chr10:60734342~60741828:+
BRCA	cis	rs7309	0.935	rs6432674	ENSG00000235724.7	AC009299.2	-10.96	1.5e-26	1.22e-23	-0.36	-0.32	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161168811	chr2:161222785~161308303:-
BRCA	cis	rs9545047	0.604	rs9545054	ENSG00000227676.3	LINC01068	10.96	1.5e-26	1.22e-23	0.37	0.32	Schizophrenia;	chr13:79298833	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs1752649	ENSG00000227676.3	LINC01068	10.96	1.5e-26	1.22e-23	0.37	0.32	Schizophrenia;	chr13:79331980	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs1749983	ENSG00000227676.3	LINC01068	10.96	1.5e-26	1.22e-23	0.37	0.32	Schizophrenia;	chr13:79332077	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.567	rs1752648	ENSG00000227676.3	LINC01068	10.96	1.5e-26	1.22e-23	0.37	0.32	Schizophrenia;	chr13:79332124	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs1752647	ENSG00000227676.3	LINC01068	10.96	1.5e-26	1.22e-23	0.37	0.32	Schizophrenia;	chr13:79332741	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.532	rs1752646	ENSG00000227676.3	LINC01068	10.96	1.5e-26	1.22e-23	0.37	0.32	Schizophrenia;	chr13:79332752	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs1749988	ENSG00000227676.3	LINC01068	10.96	1.5e-26	1.22e-23	0.37	0.32	Schizophrenia;	chr13:79333103	chr13:79566727~79571436:+
BRCA	cis	rs10759883	0.563	rs686048	ENSG00000175611.10	LINC00476	10.96	1.51e-26	1.22e-23	0.38	0.32	Nicotine dependence;	chr9:95967100	chr9:95759231~95875977:-
BRCA	cis	rs9545047	0.547	rs2876739	ENSG00000227676.3	LINC01068	10.96	1.51e-26	1.22e-23	0.37	0.32	Schizophrenia;	chr13:79299057	chr13:79566727~79571436:+
BRCA	cis	rs10740039	0.583	rs2127352	ENSG00000254271.1	RP11-131N11.4	-10.96	1.53e-26	1.24e-23	-0.42	-0.32	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60742129	chr10:60734342~60741828:+
BRCA	cis	rs2404602	0.684	rs4886816	ENSG00000259422.1	RP11-593F23.1	-10.96	1.56e-26	1.26e-23	-0.42	-0.32	Blood metabolite levels;	chr15:76582366	chr15:76174891~76181486:-
BRCA	cis	rs2404602	0.647	rs907594	ENSG00000259422.1	RP11-593F23.1	-10.96	1.56e-26	1.27e-23	-0.42	-0.32	Blood metabolite levels;	chr15:76905404	chr15:76174891~76181486:-
BRCA	cis	rs2108622	1	rs2108622	ENSG00000267453.5	AC004791.2	-10.96	1.56e-26	1.27e-23	-0.4	-0.32	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15879621	chr19:15851993~15864904:-
BRCA	cis	rs8059260	0.668	rs16957855	ENSG00000274038.1	RP11-66H6.4	-10.96	1.56e-26	1.27e-23	-0.51	-0.32	Alcohol consumption over the past year;	chr16:10977116	chr16:11056556~11057034:+
BRCA	cis	rs9318086	0.712	rs9510917	ENSG00000205861.10	C1QTNF9B-AS1	-10.96	1.57e-26	1.27e-23	-0.41	-0.32	Myopia (pathological);	chr13:23868707	chr13:23888889~23897263:+
BRCA	cis	rs9545047	0.604	rs9530895	ENSG00000227676.3	LINC01068	10.96	1.57e-26	1.27e-23	0.37	0.32	Schizophrenia;	chr13:79334877	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.567	rs9530896	ENSG00000227676.3	LINC01068	10.96	1.57e-26	1.27e-23	0.37	0.32	Schizophrenia;	chr13:79335507	chr13:79566727~79571436:+
BRCA	cis	rs2404602	0.647	rs11631959	ENSG00000259422.1	RP11-593F23.1	-10.96	1.58e-26	1.28e-23	-0.41	-0.32	Blood metabolite levels;	chr15:76747707	chr15:76174891~76181486:-
BRCA	cis	rs2243480	1	rs10247526	ENSG00000226824.5	RP4-756H11.3	10.96	1.6e-26	1.3e-23	0.63	0.32	Diabetic kidney disease;	chr7:66315709	chr7:66654538~66669855:+
BRCA	cis	rs9545047	0.604	rs11620233	ENSG00000227676.3	LINC01068	-10.96	1.61e-26	1.3e-23	-0.38	-0.32	Schizophrenia;	chr13:79373871	chr13:79566727~79571436:+
BRCA	cis	rs9318086	0.648	rs35449605	ENSG00000205861.10	C1QTNF9B-AS1	-10.96	1.63e-26	1.32e-23	-0.42	-0.32	Myopia (pathological);	chr13:23898443	chr13:23888889~23897263:+
BRCA	cis	rs9545047	0.588	rs9530894	ENSG00000227676.3	LINC01068	10.96	1.65e-26	1.33e-23	0.37	0.32	Schizophrenia;	chr13:79334020	chr13:79566727~79571436:+
BRCA	cis	rs10759883	0.539	rs649819	ENSG00000175611.10	LINC00476	10.95	1.65e-26	1.34e-23	0.38	0.32	Nicotine dependence;	chr9:95969323	chr9:95759231~95875977:-
BRCA	cis	rs6991838	0.584	rs7842085	ENSG00000200714.1	Y_RNA	10.95	1.66e-26	1.35e-23	0.38	0.32	Intelligence (multi-trait analysis);	chr8:65636787	chr8:65592731~65592820:+
BRCA	cis	rs172166	0.694	rs203892	ENSG00000220721.1	OR1F12	10.95	1.66e-26	1.35e-23	0.39	0.32	Cardiac Troponin-T levels;	chr6:28099418	chr6:28073316~28074233:+
BRCA	cis	rs172166	0.694	rs188105	ENSG00000220721.1	OR1F12	10.95	1.66e-26	1.35e-23	0.39	0.32	Cardiac Troponin-T levels;	chr6:28103615	chr6:28073316~28074233:+
BRCA	cis	rs1062177	0.855	rs919262	ENSG00000213433.5	RPLP1P6	10.95	1.66e-26	1.35e-23	0.39	0.32	Preschool internalizing problems;	chr5:151886523	chr5:151765859~151766378:-
BRCA	cis	rs9545047	0.625	rs1408657	ENSG00000227676.3	LINC01068	10.95	1.67e-26	1.35e-23	0.37	0.32	Schizophrenia;	chr13:79329315	chr13:79566727~79571436:+
BRCA	cis	rs4380275	1	rs4854376	ENSG00000272342.1	RP13-539J13.1	10.95	1.67e-26	1.35e-23	0.41	0.32	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:763683	chr2:739588~740164:-
BRCA	cis	rs2404602	0.684	rs62026898	ENSG00000259422.1	RP11-593F23.1	-10.95	1.67e-26	1.35e-23	-0.41	-0.32	Blood metabolite levels;	chr15:76652030	chr15:76174891~76181486:-
BRCA	cis	rs2404602	0.647	rs10851889	ENSG00000259422.1	RP11-593F23.1	-10.95	1.67e-26	1.35e-23	-0.42	-0.32	Blood metabolite levels;	chr15:76730995	chr15:76174891~76181486:-
BRCA	cis	rs2404602	0.647	rs11072620	ENSG00000259422.1	RP11-593F23.1	-10.95	1.67e-26	1.35e-23	-0.41	-0.32	Blood metabolite levels;	chr15:76756429	chr15:76174891~76181486:-
BRCA	cis	rs2404602	0.61	rs28823285	ENSG00000259422.1	RP11-593F23.1	-10.95	1.67e-26	1.35e-23	-0.41	-0.32	Blood metabolite levels;	chr15:76758054	chr15:76174891~76181486:-
BRCA	cis	rs2153535	0.623	rs6597338	ENSG00000230939.1	RP11-314C16.1	-10.95	1.68e-26	1.36e-23	-0.38	-0.32	Motion sickness;	chr6:8533275	chr6:8784178~8785445:+
BRCA	cis	rs2243480	1	rs437889	ENSG00000226824.5	RP4-756H11.3	-10.95	1.69e-26	1.37e-23	-0.63	-0.32	Diabetic kidney disease;	chr7:66044247	chr7:66654538~66669855:+
BRCA	cis	rs1891275	0.515	rs7093728	ENSG00000228701.1	TNKS2-AS1	-10.95	1.72e-26	1.39e-23	-0.37	-0.32	Intelligence (multi-trait analysis);	chr10:91683860	chr10:91782839~91798291:-
BRCA	cis	rs2243480	1	rs402418	ENSG00000226824.5	RP4-756H11.3	-10.95	1.72e-26	1.39e-23	-0.63	-0.32	Diabetic kidney disease;	chr7:66044482	chr7:66654538~66669855:+
BRCA	cis	rs2153535	0.58	rs9406165	ENSG00000230939.1	RP11-314C16.1	-10.95	1.76e-26	1.42e-23	-0.38	-0.32	Motion sickness;	chr6:8488604	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.563	rs4428546	ENSG00000230939.1	RP11-314C16.1	-10.95	1.76e-26	1.42e-23	-0.38	-0.32	Motion sickness;	chr6:8490143	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.505	rs1335629	ENSG00000230939.1	RP11-314C16.1	-10.95	1.76e-26	1.42e-23	-0.38	-0.32	Motion sickness;	chr6:8491630	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs763376	ENSG00000230939.1	RP11-314C16.1	-10.95	1.76e-26	1.42e-23	-0.38	-0.32	Motion sickness;	chr6:8492543	chr6:8784178~8785445:+
BRCA	cis	rs1891275	0.515	rs10786010	ENSG00000228701.1	TNKS2-AS1	-10.95	1.77e-26	1.43e-23	-0.37	-0.32	Intelligence (multi-trait analysis);	chr10:91684016	chr10:91782839~91798291:-
BRCA	cis	rs2153535	0.58	rs1855769	ENSG00000230939.1	RP11-314C16.1	-10.95	1.79e-26	1.44e-23	-0.38	-0.32	Motion sickness;	chr6:8472862	chr6:8784178~8785445:+
BRCA	cis	rs1891275	0.515	rs1986941	ENSG00000228701.1	TNKS2-AS1	-10.95	1.8e-26	1.45e-23	-0.37	-0.32	Intelligence (multi-trait analysis);	chr10:91684586	chr10:91782839~91798291:-
BRCA	cis	rs1891275	0.515	rs7098763	ENSG00000228701.1	TNKS2-AS1	-10.95	1.8e-26	1.45e-23	-0.37	-0.32	Intelligence (multi-trait analysis);	chr10:91685070	chr10:91782839~91798291:-
BRCA	cis	rs1891275	0.508	rs7099557	ENSG00000228701.1	TNKS2-AS1	-10.95	1.8e-26	1.45e-23	-0.37	-0.32	Intelligence (multi-trait analysis);	chr10:91685607	chr10:91782839~91798291:-
BRCA	cis	rs2153535	0.58	rs9405391	ENSG00000230939.1	RP11-314C16.1	-10.95	1.81e-26	1.46e-23	-0.38	-0.32	Motion sickness;	chr6:8466315	chr6:8784178~8785445:+
BRCA	cis	rs2243480	1	rs431318	ENSG00000226824.5	RP4-756H11.3	-10.94	1.85e-26	1.49e-23	-0.63	-0.32	Diabetic kidney disease;	chr7:66046610	chr7:66654538~66669855:+
BRCA	cis	rs2153535	0.58	rs4639392	ENSG00000230939.1	RP11-314C16.1	-10.94	1.85e-26	1.49e-23	-0.38	-0.32	Motion sickness;	chr6:8446314	chr6:8784178~8785445:+
BRCA	cis	rs12134133	0.888	rs11580394	ENSG00000274245.1	RP11-357P18.2	10.94	1.86e-26	1.5e-23	0.44	0.32	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207238567	chr1:207372559~207373252:+
BRCA	cis	rs2404602	0.735	rs4886493	ENSG00000259422.1	RP11-593F23.1	-10.94	1.86e-26	1.5e-23	-0.42	-0.32	Blood metabolite levels;	chr15:76386685	chr15:76174891~76181486:-
BRCA	cis	rs2153535	0.58	rs7753192	ENSG00000230939.1	RP11-314C16.1	-10.94	1.87e-26	1.51e-23	-0.38	-0.32	Motion sickness;	chr6:8482404	chr6:8784178~8785445:+
BRCA	cis	rs2729354	0.768	rs2581922	ENSG00000265566.2	RN7SL605P	-10.94	1.87e-26	1.51e-23	-0.46	-0.32	Blood protein levels;	chr11:57497927	chr11:57528085~57528365:-
BRCA	cis	rs2153535	0.58	rs1335641	ENSG00000230939.1	RP11-314C16.1	-10.94	1.89e-26	1.52e-23	-0.38	-0.32	Motion sickness;	chr6:8487627	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs1335643	ENSG00000230939.1	RP11-314C16.1	-10.94	1.89e-26	1.52e-23	-0.38	-0.32	Motion sickness;	chr6:8487788	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs9378554	ENSG00000230939.1	RP11-314C16.1	-10.94	1.89e-26	1.52e-23	-0.38	-0.32	Motion sickness;	chr6:8488235	chr6:8784178~8785445:+
BRCA	cis	rs2243480	1	rs316321	ENSG00000226824.5	RP4-756H11.3	-10.94	1.91e-26	1.54e-23	-0.62	-0.32	Diabetic kidney disease;	chr7:66146626	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs316318	ENSG00000226824.5	RP4-756H11.3	-10.94	1.91e-26	1.54e-23	-0.62	-0.32	Diabetic kidney disease;	chr7:66147917	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs316317	ENSG00000226824.5	RP4-756H11.3	-10.94	1.91e-26	1.54e-23	-0.62	-0.32	Diabetic kidney disease;	chr7:66148650	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs316304	ENSG00000226824.5	RP4-756H11.3	-10.94	1.91e-26	1.54e-23	-0.62	-0.32	Diabetic kidney disease;	chr7:66151907	chr7:66654538~66669855:+
BRCA	cis	rs34779708	0.733	rs16935948	ENSG00000230534.5	RP11-297A16.2	10.93	2.01e-26	1.62e-23	0.4	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35260820	chr10:35098006~35127020:-
BRCA	cis	rs2243480	1	rs4149468	ENSG00000226824.5	RP4-756H11.3	-10.93	2.03e-26	1.63e-23	-0.62	-0.32	Diabetic kidney disease;	chr7:66360703	chr7:66654538~66669855:+
BRCA	cis	rs858239	0.932	rs199355	ENSG00000226816.2	AC005082.12	10.93	2.04e-26	1.64e-23	0.37	0.32	Cerebrospinal fluid biomarker levels;	chr7:23256914	chr7:23206013~23208045:+
BRCA	cis	rs2153535	0.601	rs2015281	ENSG00000230939.1	RP11-314C16.1	-10.93	2.06e-26	1.66e-23	-0.38	-0.32	Motion sickness;	chr6:8539440	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.601	rs9505474	ENSG00000230939.1	RP11-314C16.1	-10.93	2.06e-26	1.66e-23	-0.38	-0.32	Motion sickness;	chr6:8539561	chr6:8784178~8785445:+
BRCA	cis	rs172166	0.694	rs536704	ENSG00000220721.1	OR1F12	10.93	2.07e-26	1.66e-23	0.39	0.32	Cardiac Troponin-T levels;	chr6:28124825	chr6:28073316~28074233:+
BRCA	cis	rs2880765	0.566	rs55899824	ENSG00000259295.5	CSPG4P12	10.93	2.07e-26	1.67e-23	0.42	0.32	Coronary artery disease;	chr15:85460860	chr15:85191438~85213905:+
BRCA	cis	rs6991838	0.584	rs4275254	ENSG00000200714.1	Y_RNA	-10.93	2.08e-26	1.67e-23	-0.37	-0.32	Intelligence (multi-trait analysis);	chr8:65589129	chr8:65592731~65592820:+
BRCA	cis	rs2153535	0.526	rs9406179	ENSG00000230939.1	RP11-314C16.1	-10.93	2.1e-26	1.68e-23	-0.38	-0.32	Motion sickness;	chr6:8537991	chr6:8784178~8785445:+
BRCA	cis	rs9545047	0.625	rs9318621	ENSG00000227676.3	LINC01068	10.93	2.11e-26	1.69e-23	0.37	0.32	Schizophrenia;	chr13:79325662	chr13:79566727~79571436:+
BRCA	cis	rs10129255	0.957	rs2013423	ENSG00000211970.3	IGHV4-61	-10.93	2.11e-26	1.7e-23	-0.23	-0.32	Kawasaki disease;	chr14:106690675	chr14:106639119~106639657:-
BRCA	cis	rs10129255	0.957	rs56134540	ENSG00000211970.3	IGHV4-61	-10.93	2.11e-26	1.7e-23	-0.23	-0.32	Kawasaki disease;	chr14:106691290	chr14:106639119~106639657:-
BRCA	cis	rs2153535	0.601	rs1737581	ENSG00000230939.1	RP11-314C16.1	-10.93	2.14e-26	1.72e-23	-0.38	-0.32	Motion sickness;	chr6:8538905	chr6:8784178~8785445:+
BRCA	cis	rs2276314	1	rs56050783	ENSG00000278986.1	RP11-723J4.3	-10.93	2.16e-26	1.73e-23	-0.41	-0.32	Endometriosis;Drug-induced torsades de pointes;	chr18:35973828	chr18:35972151~35973916:+
BRCA	cis	rs2276314	1	rs58054756	ENSG00000278986.1	RP11-723J4.3	-10.93	2.16e-26	1.73e-23	-0.41	-0.32	Endometriosis;Drug-induced torsades de pointes;	chr18:35974090	chr18:35972151~35973916:+
BRCA	cis	rs1891275	0.55	rs4933694	ENSG00000228701.1	TNKS2-AS1	-10.93	2.2e-26	1.76e-23	-0.37	-0.32	Intelligence (multi-trait analysis);	chr10:91739456	chr10:91782839~91798291:-
BRCA	cis	rs1075265	0.633	rs3731967	ENSG00000233266.1	HMGB1P31	-10.93	2.21e-26	1.77e-23	-0.39	-0.32	Chronotype;Morning vs. evening chronotype;	chr2:53975311	chr2:54051334~54051760:+
BRCA	cis	rs12439619	0.508	rs11856561	ENSG00000278603.1	RP13-608F4.5	10.92	2.22e-26	1.78e-23	0.42	0.32	Intelligence (multi-trait analysis);	chr15:82161415	chr15:82472203~82472426:+
BRCA	cis	rs2581828	0.618	rs1560332	ENSG00000242142.1	SERBP1P3	10.92	2.24e-26	1.8e-23	0.4	0.32	Crohn's disease;	chr3:53130787	chr3:53064283~53065091:-
BRCA	cis	rs2404602	0.647	rs12910081	ENSG00000259422.1	RP11-593F23.1	-10.92	2.25e-26	1.8e-23	-0.42	-0.32	Blood metabolite levels;	chr15:76730618	chr15:76174891~76181486:-
BRCA	cis	rs2115630	0.645	rs1107179	ENSG00000225151.9	GOLGA2P7	-10.92	2.3e-26	1.84e-23	-0.36	-0.32	P wave terminal force;	chr15:84655131	chr15:84199311~84230136:-
BRCA	cis	rs524281	0.861	rs10896081	ENSG00000255320.1	RP11-755F10.1	10.92	2.31e-26	1.85e-23	0.48	0.32	Electroencephalogram traits;	chr11:66112883	chr11:66244840~66246239:-
BRCA	cis	rs11105298	0.891	rs11105302	ENSG00000258302.2	RP11-981P6.1	-10.92	2.31e-26	1.85e-23	-0.35	-0.32	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89497589	chr12:89561129~89594878:+
BRCA	cis	rs2153535	0.58	rs6597318	ENSG00000230939.1	RP11-314C16.1	-10.92	2.33e-26	1.86e-23	-0.38	-0.32	Motion sickness;	chr6:8437056	chr6:8784178~8785445:+
BRCA	cis	rs7849270	0.842	rs184457	ENSG00000268707.1	RP11-247A12.7	10.92	2.33e-26	1.87e-23	0.43	0.32	Blood metabolite ratios;	chr9:129177740	chr9:129170434~129170940:+
BRCA	cis	rs11105298	0.891	rs10858869	ENSG00000258302.2	RP11-981P6.1	10.92	2.35e-26	1.88e-23	0.37	0.32	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89463834	chr12:89561129~89594878:+
BRCA	cis	rs11105298	0.891	rs10858871	ENSG00000258302.2	RP11-981P6.1	10.92	2.35e-26	1.88e-23	0.37	0.32	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89477836	chr12:89561129~89594878:+
BRCA	cis	rs2404602	0.647	rs7178250	ENSG00000259422.1	RP11-593F23.1	-10.92	2.35e-26	1.88e-23	-0.41	-0.32	Blood metabolite levels;	chr15:76806766	chr15:76174891~76181486:-
BRCA	cis	rs9545047	0.604	rs9545076	ENSG00000227676.3	LINC01068	-10.92	2.36e-26	1.89e-23	-0.37	-0.32	Schizophrenia;	chr13:79335983	chr13:79566727~79571436:+
BRCA	cis	rs1499614	1	rs1267817	ENSG00000226824.5	RP4-756H11.3	-10.92	2.38e-26	1.91e-23	-0.63	-0.32	Gout;	chr7:66645053	chr7:66654538~66669855:+
BRCA	cis	rs9545047	0.604	rs3187338	ENSG00000227676.3	LINC01068	10.92	2.39e-26	1.91e-23	0.37	0.32	Schizophrenia;	chr13:79320601	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs9545068	ENSG00000227676.3	LINC01068	10.92	2.39e-26	1.91e-23	0.37	0.32	Schizophrenia;	chr13:79324101	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs7322167	ENSG00000227676.3	LINC01068	10.92	2.39e-26	1.91e-23	0.37	0.32	Schizophrenia;	chr13:79325931	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.604	rs9285309	ENSG00000227676.3	LINC01068	10.92	2.39e-26	1.91e-23	0.37	0.32	Schizophrenia;	chr13:79326707	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.584	rs9545069	ENSG00000227676.3	LINC01068	10.92	2.39e-26	1.91e-23	0.37	0.32	Schizophrenia;	chr13:79328065	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.647	rs7317416	ENSG00000227676.3	LINC01068	10.92	2.39e-26	1.91e-23	0.37	0.32	Schizophrenia;	chr13:79328400	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.588	rs1408658	ENSG00000227676.3	LINC01068	10.92	2.39e-26	1.91e-23	0.37	0.32	Schizophrenia;	chr13:79329294	chr13:79566727~79571436:+
BRCA	cis	rs2153535	0.58	rs9393022	ENSG00000230939.1	RP11-314C16.1	-10.92	2.39e-26	1.91e-23	-0.38	-0.32	Motion sickness;	chr6:8466355	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.601	rs7741024	ENSG00000230939.1	RP11-314C16.1	-10.92	2.41e-26	1.93e-23	-0.38	-0.32	Motion sickness;	chr6:8530080	chr6:8784178~8785445:+
BRCA	cis	rs2243480	0.901	rs778687	ENSG00000226824.5	RP4-756H11.3	-10.92	2.41e-26	1.93e-23	-0.63	-0.32	Diabetic kidney disease;	chr7:66370832	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs778704	ENSG00000226824.5	RP4-756H11.3	-10.92	2.41e-26	1.93e-23	-0.63	-0.32	Diabetic kidney disease;	chr7:66398480	chr7:66654538~66669855:+
BRCA	cis	rs2243480	0.901	rs778693	ENSG00000226824.5	RP4-756H11.3	-10.92	2.41e-26	1.93e-23	-0.63	-0.32	Diabetic kidney disease;	chr7:66407358	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs778691	ENSG00000226824.5	RP4-756H11.3	-10.92	2.41e-26	1.93e-23	-0.63	-0.32	Diabetic kidney disease;	chr7:66408105	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs13235972	ENSG00000226824.5	RP4-756H11.3	-10.92	2.41e-26	1.93e-23	-0.63	-0.32	Diabetic kidney disease;	chr7:66418618	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs34192067	ENSG00000226824.5	RP4-756H11.3	-10.92	2.41e-26	1.93e-23	-0.63	-0.32	Diabetic kidney disease;	chr7:66422670	chr7:66654538~66669855:+
BRCA	cis	rs11096990	0.572	rs35040563	ENSG00000249207.1	RP11-360F5.1	-10.92	2.41e-26	1.93e-23	-0.38	-0.32	Cognitive function;	chr4:39154262	chr4:39112677~39126818:-
BRCA	cis	rs2153535	0.584	rs9502723	ENSG00000230939.1	RP11-314C16.1	-10.91	2.45e-26	1.96e-23	-0.38	-0.32	Motion sickness;	chr6:8541271	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.563	rs1796687	ENSG00000230939.1	RP11-314C16.1	-10.91	2.46e-26	1.96e-23	-0.38	-0.32	Motion sickness;	chr6:8535885	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs6597335	ENSG00000230939.1	RP11-314C16.1	-10.91	2.46e-26	1.97e-23	-0.38	-0.32	Motion sickness;	chr6:8527481	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs9328486	ENSG00000230939.1	RP11-314C16.1	-10.91	2.46e-26	1.97e-23	-0.38	-0.32	Motion sickness;	chr6:8527775	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs2183112	ENSG00000230939.1	RP11-314C16.1	-10.91	2.46e-26	1.97e-23	-0.38	-0.32	Motion sickness;	chr6:8527979	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.601	rs2143353	ENSG00000230939.1	RP11-314C16.1	-10.91	2.46e-26	1.97e-23	-0.38	-0.32	Motion sickness;	chr6:8529878	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.601	rs2143352	ENSG00000230939.1	RP11-314C16.1	-10.91	2.46e-26	1.97e-23	-0.38	-0.32	Motion sickness;	chr6:8530015	chr6:8784178~8785445:+
BRCA	cis	rs2404602	0.647	rs11634266	ENSG00000259422.1	RP11-593F23.1	-10.91	2.46e-26	1.97e-23	-0.41	-0.32	Blood metabolite levels;	chr15:76801120	chr15:76174891~76181486:-
BRCA	cis	rs6452524	0.869	rs10051155	ENSG00000249664.1	CTD-2227C6.2	10.91	2.47e-26	1.97e-23	0.4	0.32	Hypertension (SNP x SNP interaction);	chr5:83160851	chr5:83012285~83013109:-
BRCA	cis	rs6782228	0.585	rs3122175	ENSG00000242551.2	POU5F1P6	-10.91	2.47e-26	1.97e-23	-0.41	-0.32	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128642433	chr3:128674735~128677005:-
BRCA	cis	rs34779708	0.741	rs34397613	ENSG00000230534.5	RP11-297A16.2	10.91	2.5e-26	1.99e-23	0.4	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35261385	chr10:35098006~35127020:-
BRCA	cis	rs6539288	0.63	rs10778520	ENSG00000260329.1	RP11-412D9.4	10.91	2.52e-26	2.01e-23	0.35	0.32	Total body bone mineral density;	chr12:106971095	chr12:106954029~106955497:-
BRCA	cis	rs2283792	0.765	rs34550586	ENSG00000224086.5	LL22NC03-86G7.1	-10.91	2.53e-26	2.02e-23	-0.34	-0.32	Multiple sclerosis;	chr22:21791345	chr22:21938293~21977632:+
BRCA	cis	rs1609391	0.561	rs9817967	ENSG00000239213.4	NCK1-AS1	10.91	2.53e-26	2.02e-23	0.34	0.32	Neuroticism;	chr3:136910648	chr3:136841726~136862054:-
BRCA	cis	rs2404602	0.735	rs11072598	ENSG00000259422.1	RP11-593F23.1	-10.91	2.56e-26	2.04e-23	-0.43	-0.32	Blood metabolite levels;	chr15:76472447	chr15:76174891~76181486:-
BRCA	cis	rs2153535	0.58	rs1119690	ENSG00000230939.1	RP11-314C16.1	-10.91	2.58e-26	2.05e-23	-0.38	-0.32	Motion sickness;	chr6:8460427	chr6:8784178~8785445:+
BRCA	cis	rs2880765	0.631	rs55767890	ENSG00000259295.5	CSPG4P12	10.91	2.58e-26	2.06e-23	0.42	0.32	Coronary artery disease;	chr15:85460911	chr15:85191438~85213905:+
BRCA	cis	rs10129255	0.5	rs8011115	ENSG00000223648.3	IGHV3-64	10.91	2.58e-26	2.06e-23	0.24	0.32	Kawasaki disease;	chr14:106786292	chr14:106643132~106658258:-
BRCA	cis	rs8040855	0.931	rs11855471	ENSG00000259295.5	CSPG4P12	-10.91	2.59e-26	2.07e-23	-0.4	-0.32	Bulimia nervosa;	chr15:85175976	chr15:85191438~85213905:+
BRCA	cis	rs1555322	0.53	rs2250205	ENSG00000126005.14	MMP24-AS1	-10.91	2.61e-26	2.08e-23	-0.43	-0.32	Attention deficit hyperactivity disorder;	chr20:35280121	chr20:35216462~35278131:-
BRCA	cis	rs6782228	0.606	rs2253144	ENSG00000242551.2	POU5F1P6	10.91	2.68e-26	2.13e-23	0.4	0.32	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128611077	chr3:128674735~128677005:-
BRCA	cis	rs8059260	0.736	rs16957872	ENSG00000274038.1	RP11-66H6.4	-10.9	2.7e-26	2.15e-23	-0.5	-0.32	Alcohol consumption over the past year;	chr16:10988835	chr16:11056556~11057034:+
BRCA	cis	rs9545047	0.604	rs7336581	ENSG00000227676.3	LINC01068	10.9	2.71e-26	2.16e-23	0.37	0.32	Schizophrenia;	chr13:79385739	chr13:79566727~79571436:+
BRCA	cis	rs6782228	0.606	rs2811497	ENSG00000242551.2	POU5F1P6	-10.9	2.71e-26	2.16e-23	-0.4	-0.32	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128644489	chr3:128674735~128677005:-
BRCA	cis	rs11105298	0.838	rs10858862	ENSG00000258302.2	RP11-981P6.1	10.9	2.72e-26	2.17e-23	0.37	0.32	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89448276	chr12:89561129~89594878:+
BRCA	cis	rs2153535	0.58	rs2152347	ENSG00000230939.1	RP11-314C16.1	-10.9	2.72e-26	2.17e-23	-0.38	-0.32	Motion sickness;	chr6:8474048	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.563	rs1737584	ENSG00000230939.1	RP11-314C16.1	-10.9	2.73e-26	2.17e-23	-0.38	-0.32	Motion sickness;	chr6:8536509	chr6:8784178~8785445:+
BRCA	cis	rs9545047	0.604	rs7988784	ENSG00000227676.3	LINC01068	-10.9	2.75e-26	2.19e-23	-0.37	-0.32	Schizophrenia;	chr13:79335337	chr13:79566727~79571436:+
BRCA	cis	rs6782228	0.606	rs2811500	ENSG00000242551.2	POU5F1P6	-10.9	2.76e-26	2.2e-23	-0.41	-0.32	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128647413	chr3:128674735~128677005:-
BRCA	cis	rs10129255	0.957	rs10132367	ENSG00000211970.3	IGHV4-61	-10.9	2.76e-26	2.2e-23	-0.23	-0.32	Kawasaki disease;	chr14:106690981	chr14:106639119~106639657:-
BRCA	cis	rs12999373	0.501	rs11127496	ENSG00000272342.1	RP13-539J13.1	10.9	2.77e-26	2.2e-23	0.38	0.32	Response to fenofibrate (adiponectin levels);Uric acid levels;	chr2:694063	chr2:739588~740164:-
BRCA	cis	rs2243480	1	rs2465120	ENSG00000226824.5	RP4-756H11.3	-10.9	2.84e-26	2.26e-23	-0.62	-0.32	Diabetic kidney disease;	chr7:66155987	chr7:66654538~66669855:+
BRCA	cis	rs2243480	0.908	rs2460431	ENSG00000226824.5	RP4-756H11.3	10.9	2.84e-26	2.26e-23	0.62	0.32	Diabetic kidney disease;	chr7:66157859	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs4718309	ENSG00000226824.5	RP4-756H11.3	10.9	2.84e-26	2.26e-23	0.62	0.32	Diabetic kidney disease;	chr7:66162777	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs6460274	ENSG00000226824.5	RP4-756H11.3	10.9	2.84e-26	2.26e-23	0.62	0.32	Diabetic kidney disease;	chr7:66163497	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs7787230	ENSG00000226824.5	RP4-756H11.3	10.9	2.84e-26	2.26e-23	0.62	0.32	Diabetic kidney disease;	chr7:66164112	chr7:66654538~66669855:+
BRCA	cis	rs2337406	1	rs4774173	ENSG00000274576.2	IGHV2-70	-10.9	2.85e-26	2.26e-23	-0.35	-0.32	Alzheimer's disease (late onset);	chr14:106682029	chr14:106770577~106771020:-
BRCA	cis	rs2404602	0.684	rs11854850	ENSG00000259422.1	RP11-593F23.1	-10.9	2.87e-26	2.28e-23	-0.41	-0.32	Blood metabolite levels;	chr15:76552230	chr15:76174891~76181486:-
BRCA	cis	rs6782228	0.606	rs4857919	ENSG00000242551.2	POU5F1P6	-10.9	2.88e-26	2.29e-23	-0.4	-0.32	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128688652	chr3:128674735~128677005:-
BRCA	cis	rs9545047	0.604	rs7331872	ENSG00000227676.3	LINC01068	-10.9	2.92e-26	2.32e-23	-0.38	-0.32	Schizophrenia;	chr13:79388717	chr13:79566727~79571436:+
BRCA	cis	rs7309	0.81	rs11684253	ENSG00000235724.7	AC009299.2	-10.9	2.92e-26	2.32e-23	-0.36	-0.32	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161178025	chr2:161222785~161308303:-
BRCA	cis	rs2404602	0.647	rs12905181	ENSG00000259422.1	RP11-593F23.1	-10.9	2.93e-26	2.33e-23	-0.41	-0.32	Blood metabolite levels;	chr15:76806090	chr15:76174891~76181486:-
BRCA	cis	rs9545047	0.567	rs7988331	ENSG00000227676.3	LINC01068	10.9	2.93e-26	2.33e-23	0.37	0.32	Schizophrenia;	chr13:79299745	chr13:79566727~79571436:+
BRCA	cis	rs1891275	0.508	rs2096079	ENSG00000228701.1	TNKS2-AS1	-10.9	2.93e-26	2.33e-23	-0.37	-0.32	Intelligence (multi-trait analysis);	chr10:91736910	chr10:91782839~91798291:-
BRCA	cis	rs2153535	0.58	rs4451187	ENSG00000230939.1	RP11-314C16.1	-10.9	2.94e-26	2.34e-23	-0.38	-0.32	Motion sickness;	chr6:8473677	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.504	rs4493781	ENSG00000230939.1	RP11-314C16.1	-10.9	2.94e-26	2.34e-23	-0.38	-0.32	Motion sickness;	chr6:8473708	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.541	rs5026687	ENSG00000230939.1	RP11-314C16.1	-10.9	2.94e-26	2.34e-23	-0.38	-0.32	Motion sickness;	chr6:8473724	chr6:8784178~8785445:+
BRCA	cis	rs8062405	0.895	rs62036658	ENSG00000251417.2	RP11-1348G14.4	-10.9	2.96e-26	2.35e-23	-0.4	-0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28839050	chr16:28802743~28817828:+
BRCA	cis	rs2243480	1	rs1979823	ENSG00000226824.5	RP4-756H11.3	10.9	2.97e-26	2.36e-23	0.62	0.32	Diabetic kidney disease;	chr7:66239626	chr7:66654538~66669855:+
BRCA	cis	rs2153535	0.563	rs1737586	ENSG00000230939.1	RP11-314C16.1	-10.9	2.97e-26	2.36e-23	-0.38	-0.32	Motion sickness;	chr6:8535664	chr6:8784178~8785445:+
BRCA	cis	rs9545047	0.604	rs2057573	ENSG00000227676.3	LINC01068	-10.89	3.02e-26	2.4e-23	-0.36	-0.32	Schizophrenia;	chr13:79357736	chr13:79566727~79571436:+
BRCA	cis	rs1499614	0.803	rs1796229	ENSG00000226824.5	RP4-756H11.3	-10.89	3.05e-26	2.42e-23	-0.63	-0.32	Gout;	chr7:66654674	chr7:66654538~66669855:+
BRCA	cis	rs8040855	0.658	rs4842864	ENSG00000259295.5	CSPG4P12	10.89	3.06e-26	2.42e-23	0.42	0.32	Bulimia nervosa;	chr15:85101315	chr15:85191438~85213905:+
BRCA	cis	rs2153535	0.58	rs6921036	ENSG00000230939.1	RP11-314C16.1	-10.89	3.14e-26	2.49e-23	-0.38	-0.32	Motion sickness;	chr6:8455167	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs6926759	ENSG00000230939.1	RP11-314C16.1	-10.89	3.14e-26	2.49e-23	-0.38	-0.32	Motion sickness;	chr6:8455943	chr6:8784178~8785445:+
BRCA	cis	rs10759883	0.587	rs10818899	ENSG00000175611.10	LINC00476	10.89	3.18e-26	2.52e-23	0.38	0.32	Nicotine dependence;	chr9:95860129	chr9:95759231~95875977:-
BRCA	cis	rs1555322	0.53	rs2275275	ENSG00000126005.14	MMP24-AS1	-10.89	3.21e-26	2.54e-23	-0.43	-0.32	Attention deficit hyperactivity disorder;	chr20:35284508	chr20:35216462~35278131:-
BRCA	cis	rs9318086	0.648	rs7331047	ENSG00000205861.10	C1QTNF9B-AS1	-10.89	3.21e-26	2.55e-23	-0.41	-0.32	Myopia (pathological);	chr13:23893203	chr13:23888889~23897263:+
BRCA	cis	rs10256972	0.616	rs6463001	ENSG00000229043.2	AC091729.9	-10.89	3.22e-26	2.55e-23	-0.39	-0.32	Endometriosis;Longevity;	chr7:1068636	chr7:1160374~1165267:+
BRCA	cis	rs2243480	0.901	rs778732	ENSG00000226824.5	RP4-756H11.3	-10.89	3.22e-26	2.55e-23	-0.63	-0.32	Diabetic kidney disease;	chr7:66357373	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.8	rs427557	ENSG00000222364.1	RNU6-96P	-10.89	3.24e-26	2.56e-23	-0.37	-0.32	Aortic root size;	chr7:66054263	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.862	rs6944374	ENSG00000222364.1	RNU6-96P	10.89	3.25e-26	2.57e-23	0.38	0.32	Aortic root size;	chr7:66221942	chr7:66395191~66395286:+
BRCA	cis	rs7617773	0.539	rs13087050	ENSG00000229759.1	MRPS18AP1	10.88	3.29e-26	2.6e-23	0.38	0.32	Coronary artery disease;	chr3:48351310	chr3:48256350~48256938:-
BRCA	cis	rs9322193	0.566	rs3922947	ENSG00000268592.3	RAET1E-AS1	-10.88	3.3e-26	2.61e-23	-0.44	-0.32	Lung cancer;	chr6:149924856	chr6:149863494~149919507:+
BRCA	cis	rs2153535	0.563	rs6942177	ENSG00000230939.1	RP11-314C16.1	10.88	3.33e-26	2.63e-23	0.38	0.32	Motion sickness;	chr6:8534227	chr6:8784178~8785445:+
BRCA	cis	rs11168854	0.93	rs10783302	ENSG00000258017.1	RP11-386G11.10	10.88	3.33e-26	2.63e-23	0.42	0.32	Body mass index;	chr12:49104347	chr12:49127782~49147869:+
BRCA	cis	rs6452524	0.904	rs10474095	ENSG00000249664.1	CTD-2227C6.2	10.88	3.33e-26	2.64e-23	0.4	0.32	Hypertension (SNP x SNP interaction);	chr5:83154887	chr5:83012285~83013109:-
BRCA	cis	rs11673344	0.74	rs113752815	ENSG00000226686.6	LINC01535	10.88	3.34e-26	2.64e-23	0.46	0.32	Obesity-related traits;	chr19:37043829	chr19:37251912~37265535:+
BRCA	cis	rs875971	0.545	rs316328	ENSG00000226824.5	RP4-756H11.3	10.88	3.34e-26	2.64e-23	0.41	0.32	Aortic root size;	chr7:66143851	chr7:66654538~66669855:+
BRCA	cis	rs1555322	0.53	rs2425047	ENSG00000126005.14	MMP24-AS1	10.88	3.36e-26	2.66e-23	0.42	0.32	Attention deficit hyperactivity disorder;	chr20:35283872	chr20:35216462~35278131:-
BRCA	cis	rs6782228	0.606	rs7627549	ENSG00000242551.2	POU5F1P6	-10.88	3.37e-26	2.66e-23	-0.4	-0.32	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128634236	chr3:128674735~128677005:-
BRCA	cis	rs528808	1	rs528808	ENSG00000279170.1	RP1-199J3.6	10.88	3.37e-26	2.67e-23	0.54	0.32	Age-related hearing impairment;	chr6:99656413	chr6:99587611~99589898:+
BRCA	cis	rs8062405	1	rs72793811	ENSG00000251417.2	RP11-1348G14.4	-10.88	3.38e-26	2.67e-23	-0.4	-0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828071	chr16:28802743~28817828:+
BRCA	cis	rs150992	0.587	rs4448016	ENSG00000248489.1	CTD-2007H13.3	10.88	3.38e-26	2.67e-23	0.36	0.32	Body mass index;	chr5:99037904	chr5:98929171~98995013:+
BRCA	cis	rs4380275	0.965	rs12621177	ENSG00000223751.1	AC116609.2	10.88	3.4e-26	2.69e-23	0.42	0.32	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:757786	chr2:742488~747767:+
BRCA	cis	rs2243480	1	rs6964530	ENSG00000226824.5	RP4-756H11.3	10.88	3.41e-26	2.7e-23	0.61	0.32	Diabetic kidney disease;	chr7:66253864	chr7:66654538~66669855:+
BRCA	cis	rs2581828	0.646	rs2564944	ENSG00000242142.1	SERBP1P3	10.88	3.45e-26	2.73e-23	0.38	0.32	Crohn's disease;	chr3:53114439	chr3:53064283~53065091:-
BRCA	cis	rs9322193	0.607	rs4870078	ENSG00000223701.3	RAET1E-AS1	-10.88	3.47e-26	2.74e-23	-0.43	-0.32	Lung cancer;	chr6:149880676	chr6:149884431~149919508:+
BRCA	cis	rs9318086	0.712	rs9318100	ENSG00000205861.10	C1QTNF9B-AS1	10.88	3.47e-26	2.74e-23	0.4	0.32	Myopia (pathological);	chr13:23868343	chr13:23888889~23897263:+
BRCA	cis	rs6782228	0.606	rs1697	ENSG00000242551.2	POU5F1P6	-10.88	3.48e-26	2.75e-23	-0.4	-0.32	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128638009	chr3:128674735~128677005:-
BRCA	cis	rs6782228	0.585	rs6774515	ENSG00000242551.2	POU5F1P6	-10.88	3.49e-26	2.76e-23	-0.4	-0.32	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128697035	chr3:128674735~128677005:-
BRCA	cis	rs11690935	0.595	rs788166	ENSG00000228389.1	AC068039.4	-10.88	3.52e-26	2.78e-23	-0.39	-0.32	Schizophrenia;	chr2:172050761	chr2:171773482~171775844:+
BRCA	cis	rs9545047	0.604	rs6563098	ENSG00000227676.3	LINC01068	10.88	3.53e-26	2.79e-23	0.37	0.32	Schizophrenia;	chr13:79313102	chr13:79566727~79571436:+
BRCA	cis	rs8040855	0.894	rs4843023	ENSG00000259295.5	CSPG4P12	-10.88	3.61e-26	2.85e-23	-0.39	-0.32	Bulimia nervosa;	chr15:85162641	chr15:85191438~85213905:+
BRCA	cis	rs17023223	0.537	rs10923767	ENSG00000231365.4	RP11-418J17.1	-10.88	3.61e-26	2.85e-23	-0.4	-0.32	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119189724	chr1:119140396~119275973:+
BRCA	cis	rs6452524	0.935	rs10043698	ENSG00000249664.1	CTD-2227C6.2	10.87	3.63e-26	2.87e-23	0.4	0.32	Hypertension (SNP x SNP interaction);	chr5:83169100	chr5:83012285~83013109:-
BRCA	cis	rs8062405	0.721	rs151303	ENSG00000278665.1	RP11-666O2.4	10.87	3.71e-26	2.93e-23	0.35	0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28481189	chr16:28599241~28601881:-
BRCA	cis	rs1134634	1	rs1134634	ENSG00000273133.1	RP11-799M12.2	10.87	3.76e-26	2.96e-23	0.38	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15601446	chr4:15563698~15564253:-
BRCA	cis	rs6558530	0.73	rs4875958	ENSG00000253982.1	CTD-2336O2.1	-10.87	3.78e-26	2.98e-23	-0.34	-0.32	Systolic blood pressure;	chr8:1772924	chr8:1761990~1764502:-
BRCA	cis	rs172166	0.694	rs2791332	ENSG00000220721.1	OR1F12	10.87	3.78e-26	2.98e-23	0.39	0.32	Cardiac Troponin-T levels;	chr6:28141010	chr6:28073316~28074233:+
BRCA	cis	rs7580658	0.676	rs4662717	ENSG00000236682.1	AC068282.3	-10.87	3.79e-26	2.99e-23	-0.41	-0.32	Protein C levels;	chr2:127255928	chr2:127389130~127400580:+
BRCA	cis	rs2153535	0.58	rs1119689	ENSG00000230939.1	RP11-314C16.1	-10.87	3.88e-26	3.05e-23	-0.38	-0.32	Motion sickness;	chr6:8460521	chr6:8784178~8785445:+
BRCA	cis	rs6782228	0.606	rs2712405	ENSG00000242551.2	POU5F1P6	-10.87	3.89e-26	3.06e-23	-0.41	-0.32	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128613239	chr3:128674735~128677005:-
BRCA	cis	rs10759883	0.627	rs10985499	ENSG00000175611.10	LINC00476	10.87	3.9e-26	3.07e-23	0.35	0.32	Nicotine dependence;	chr9:95840724	chr9:95759231~95875977:-
BRCA	cis	rs6782228	0.585	rs9841161	ENSG00000242551.2	POU5F1P6	-10.87	3.94e-26	3.1e-23	-0.41	-0.32	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128613027	chr3:128674735~128677005:-
BRCA	cis	rs2243480	0.831	rs57294491	ENSG00000226824.5	RP4-756H11.3	10.87	3.96e-26	3.11e-23	0.62	0.32	Diabetic kidney disease;	chr7:66219914	chr7:66654538~66669855:+
BRCA	cis	rs34779708	0.766	rs7913451	ENSG00000230534.5	RP11-297A16.2	10.87	3.98e-26	3.13e-23	0.4	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35262597	chr10:35098006~35127020:-
BRCA	cis	rs9545047	0.604	rs9565483	ENSG00000227676.3	LINC01068	-10.87	3.98e-26	3.13e-23	-0.37	-0.32	Schizophrenia;	chr13:79294001	chr13:79566727~79571436:+
BRCA	cis	rs10875746	0.669	rs17122812	ENSG00000240399.1	RP1-228P16.1	-10.87	4e-26	3.15e-23	-0.44	-0.32	Longevity (90 years and older);	chr12:48203270	chr12:48054813~48055591:-
BRCA	cis	rs10759883	0.603	rs10760262	ENSG00000175611.10	LINC00476	10.86	4.01e-26	3.15e-23	0.35	0.32	Nicotine dependence;	chr9:95850234	chr9:95759231~95875977:-
BRCA	cis	rs321358	0.895	rs7110930	ENSG00000271584.1	RP11-89C3.4	-10.86	4.02e-26	3.16e-23	-0.5	-0.32	Body mass index;	chr11:111088556	chr11:111091932~111097357:-
BRCA	cis	rs2337406	1	rs4774172	ENSG00000274576.2	IGHV2-70	-10.86	4.02e-26	3.16e-23	-0.34	-0.32	Alzheimer's disease (late onset);	chr14:106681320	chr14:106770577~106771020:-
BRCA	cis	rs1167827	0.71	rs1167836	ENSG00000127957.15	PMS2P3	-10.86	4.03e-26	3.17e-23	-0.33	-0.32	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75539580	chr7:75502930~75528148:-
BRCA	cis	rs8062405	1	rs12446589	ENSG00000251417.2	RP11-1348G14.4	-10.86	4.07e-26	3.2e-23	-0.39	-0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28859641	chr16:28802743~28817828:+
BRCA	cis	rs34779708	0.733	rs7083266	ENSG00000230534.5	RP11-297A16.2	10.86	4.07e-26	3.2e-23	0.4	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35252704	chr10:35098006~35127020:-
BRCA	cis	rs3779195	1	rs3779195	ENSG00000272950.1	RP11-307C18.1	-10.86	4.08e-26	3.21e-23	-0.52	-0.32	Sex hormone-binding globulin levels;	chr7:98364050	chr7:98322853~98323430:+
BRCA	cis	rs7772486	0.79	rs2243665	ENSG00000235652.6	RP11-545I5.3	10.86	4.11e-26	3.23e-23	0.33	0.32	Lobe attachment (rater-scored or self-reported);	chr6:145886984	chr6:145799409~145886585:+
BRCA	cis	rs10759883	0.563	rs690056	ENSG00000175611.10	LINC00476	10.86	4.13e-26	3.25e-23	0.38	0.32	Nicotine dependence;	chr9:95938704	chr9:95759231~95875977:-
BRCA	cis	rs2243480	1	rs466983	ENSG00000226824.5	RP4-756H11.3	-10.86	4.13e-26	3.25e-23	-0.63	-0.32	Diabetic kidney disease;	chr7:66055509	chr7:66654538~66669855:+
BRCA	cis	rs2153535	0.58	rs1832101	ENSG00000230939.1	RP11-314C16.1	-10.86	4.14e-26	3.25e-23	-0.38	-0.32	Motion sickness;	chr6:8459944	chr6:8784178~8785445:+
BRCA	cis	rs6452524	0.904	rs10473867	ENSG00000249664.1	CTD-2227C6.2	10.86	4.15e-26	3.26e-23	0.4	0.32	Hypertension (SNP x SNP interaction);	chr5:83141613	chr5:83012285~83013109:-
BRCA	cis	rs10129255	0.957	rs8005468	ENSG00000211970.3	IGHV4-61	-10.86	4.17e-26	3.28e-23	-0.23	-0.32	Kawasaki disease;	chr14:106686431	chr14:106639119~106639657:-
BRCA	cis	rs2153535	0.623	rs2152346	ENSG00000230939.1	RP11-314C16.1	-10.86	4.17e-26	3.28e-23	-0.38	-0.32	Motion sickness;	chr6:8454419	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.562	rs6901765	ENSG00000230939.1	RP11-314C16.1	-10.86	4.17e-26	3.28e-23	-0.38	-0.32	Motion sickness;	chr6:8455203	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.601	rs9502715	ENSG00000230939.1	RP11-314C16.1	-10.86	4.17e-26	3.28e-23	-0.38	-0.32	Motion sickness;	chr6:8455476	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs6912193	ENSG00000230939.1	RP11-314C16.1	-10.86	4.17e-26	3.28e-23	-0.38	-0.32	Motion sickness;	chr6:8456073	chr6:8784178~8785445:+
BRCA	cis	rs2404602	0.53	rs12915184	ENSG00000259422.1	RP11-593F23.1	-10.86	4.2e-26	3.3e-23	-0.46	-0.32	Blood metabolite levels;	chr15:76673581	chr15:76174891~76181486:-
BRCA	cis	rs2404602	0.647	rs11072619	ENSG00000259422.1	RP11-593F23.1	-10.86	4.2e-26	3.3e-23	-0.41	-0.32	Blood metabolite levels;	chr15:76750901	chr15:76174891~76181486:-
BRCA	cis	rs2153535	0.58	rs2327062	ENSG00000230939.1	RP11-314C16.1	-10.86	4.2e-26	3.3e-23	-0.38	-0.32	Motion sickness;	chr6:8453625	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs4587214	ENSG00000230939.1	RP11-314C16.1	-10.86	4.2e-26	3.3e-23	-0.38	-0.32	Motion sickness;	chr6:8453886	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs6597325	ENSG00000230939.1	RP11-314C16.1	-10.86	4.33e-26	3.4e-23	-0.38	-0.32	Motion sickness;	chr6:8460820	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs6918391	ENSG00000230939.1	RP11-314C16.1	-10.86	4.33e-26	3.4e-23	-0.38	-0.32	Motion sickness;	chr6:8460945	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs9379210	ENSG00000230939.1	RP11-314C16.1	-10.86	4.33e-26	3.4e-23	-0.38	-0.32	Motion sickness;	chr6:8461695	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs9392220	ENSG00000230939.1	RP11-314C16.1	-10.86	4.37e-26	3.43e-23	-0.38	-0.32	Motion sickness;	chr6:8457713	chr6:8784178~8785445:+
BRCA	cis	rs2581828	0.646	rs9867023	ENSG00000242142.1	SERBP1P3	10.86	4.4e-26	3.45e-23	0.39	0.32	Crohn's disease;	chr3:53126116	chr3:53064283~53065091:-
BRCA	cis	rs2153535	0.584	rs9502721	ENSG00000230939.1	RP11-314C16.1	-10.85	4.44e-26	3.49e-23	-0.38	-0.32	Motion sickness;	chr6:8541146	chr6:8784178~8785445:+
BRCA	cis	rs8062405	1	rs12443881	ENSG00000251417.2	RP11-1348G14.4	-10.85	4.47e-26	3.5e-23	-0.39	-0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28830456	chr16:28802743~28817828:+
BRCA	cis	rs2153535	0.58	rs6912374	ENSG00000230939.1	RP11-314C16.1	-10.85	4.48e-26	3.51e-23	-0.38	-0.32	Motion sickness;	chr6:8456190	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.541	rs6908504	ENSG00000230939.1	RP11-314C16.1	-10.85	4.48e-26	3.51e-23	-0.38	-0.32	Motion sickness;	chr6:8456545	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs7755284	ENSG00000230939.1	RP11-314C16.1	-10.85	4.48e-26	3.51e-23	-0.38	-0.32	Motion sickness;	chr6:8457246	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs7769020	ENSG00000230939.1	RP11-314C16.1	-10.85	4.48e-26	3.51e-23	-0.38	-0.32	Motion sickness;	chr6:8457491	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs9379206	ENSG00000230939.1	RP11-314C16.1	-10.85	4.48e-26	3.51e-23	-0.38	-0.32	Motion sickness;	chr6:8457788	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.541	rs9379207	ENSG00000230939.1	RP11-314C16.1	-10.85	4.48e-26	3.51e-23	-0.38	-0.32	Motion sickness;	chr6:8457953	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs9393016	ENSG00000230939.1	RP11-314C16.1	-10.85	4.48e-26	3.51e-23	-0.38	-0.32	Motion sickness;	chr6:8458340	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs4960421	ENSG00000230939.1	RP11-314C16.1	-10.85	4.48e-26	3.51e-23	-0.38	-0.32	Motion sickness;	chr6:8459059	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs4960422	ENSG00000230939.1	RP11-314C16.1	-10.85	4.48e-26	3.51e-23	-0.38	-0.32	Motion sickness;	chr6:8459076	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs7742794	ENSG00000230939.1	RP11-314C16.1	-10.85	4.48e-26	3.51e-23	-0.38	-0.32	Motion sickness;	chr6:8459490	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs9505448	ENSG00000230939.1	RP11-314C16.1	-10.85	4.48e-26	3.51e-23	-0.38	-0.32	Motion sickness;	chr6:8459571	chr6:8784178~8785445:+
BRCA	cis	rs875971	0.83	rs12673450	ENSG00000222364.1	RNU6-96P	-10.85	4.55e-26	3.57e-23	-0.38	-0.32	Aortic root size;	chr7:66544233	chr7:66395191~66395286:+
BRCA	cis	rs11096990	0.613	rs12505690	ENSG00000249207.1	RP11-360F5.1	-10.85	4.57e-26	3.58e-23	-0.38	-0.32	Cognitive function;	chr4:39167425	chr4:39112677~39126818:-
BRCA	cis	rs11723261	0.582	rs7679573	ENSG00000275426.1	CH17-262A2.1	10.85	4.64e-26	3.63e-23	0.46	0.32	Immune response to smallpox vaccine (IL-6);	chr4:157810	chr4:149738~150317:+
BRCA	cis	rs11723261	0.621	rs7440274	ENSG00000275426.1	CH17-262A2.1	-10.85	4.64e-26	3.64e-23	-0.47	-0.32	Immune response to smallpox vaccine (IL-6);	chr4:161923	chr4:149738~150317:+
BRCA	cis	rs4308124	0.708	rs6747657	ENSG00000227992.1	AC108463.2	-10.85	4.65e-26	3.64e-23	-0.39	-0.32	Vitiligo;	chr2:111245586	chr2:111203964~111206215:-
BRCA	cis	rs10759883	0.563	rs682682	ENSG00000175611.10	LINC00476	10.85	4.66e-26	3.65e-23	0.38	0.32	Nicotine dependence;	chr9:95939980	chr9:95759231~95875977:-
BRCA	cis	rs2404602	0.647	rs10152247	ENSG00000259422.1	RP11-593F23.1	-10.85	4.67e-26	3.66e-23	-0.41	-0.32	Blood metabolite levels;	chr15:76649911	chr15:76174891~76181486:-
BRCA	cis	rs9545047	0.625	rs7338170	ENSG00000227676.3	LINC01068	-10.85	4.68e-26	3.67e-23	-0.37	-0.32	Schizophrenia;	chr13:79286030	chr13:79566727~79571436:+
BRCA	cis	rs11676348	1	rs11676348	ENSG00000261338.2	RP11-378A13.1	-10.85	4.69e-26	3.67e-23	-0.33	-0.32	Ulcerative colitis;	chr2:218145423	chr2:218255319~218257366:+
BRCA	cis	rs8040855	0.52	rs11629963	ENSG00000259295.5	CSPG4P12	-10.85	4.72e-26	3.7e-23	-0.48	-0.32	Bulimia nervosa;	chr15:84986808	chr15:85191438~85213905:+
BRCA	cis	rs2581828	0.646	rs6769931	ENSG00000242142.1	SERBP1P3	-10.85	4.72e-26	3.7e-23	-0.39	-0.32	Crohn's disease;	chr3:53126177	chr3:53064283~53065091:-
BRCA	cis	rs2581828	0.646	rs6809973	ENSG00000242142.1	SERBP1P3	-10.85	4.72e-26	3.7e-23	-0.39	-0.32	Crohn's disease;	chr3:53126200	chr3:53064283~53065091:-
BRCA	cis	rs2581828	0.608	rs6769944	ENSG00000242142.1	SERBP1P3	-10.85	4.72e-26	3.7e-23	-0.39	-0.32	Crohn's disease;	chr3:53126227	chr3:53064283~53065091:-
BRCA	cis	rs2581828	0.646	rs9858469	ENSG00000242142.1	SERBP1P3	-10.85	4.72e-26	3.7e-23	-0.39	-0.32	Crohn's disease;	chr3:53128390	chr3:53064283~53065091:-
BRCA	cis	rs2581828	0.646	rs9820324	ENSG00000242142.1	SERBP1P3	-10.85	4.72e-26	3.7e-23	-0.39	-0.32	Crohn's disease;	chr3:53128429	chr3:53064283~53065091:-
BRCA	cis	rs3779195	0.929	rs1635612	ENSG00000272950.1	RP11-307C18.1	10.85	4.76e-26	3.73e-23	0.5	0.32	Sex hormone-binding globulin levels;	chr7:98385737	chr7:98322853~98323430:+
BRCA	cis	rs10759883	0.563	rs12348051	ENSG00000175611.10	LINC00476	10.85	4.78e-26	3.74e-23	0.38	0.32	Nicotine dependence;	chr9:95905928	chr9:95759231~95875977:-
BRCA	cis	rs10759883	0.563	rs689710	ENSG00000175611.10	LINC00476	10.85	4.78e-26	3.74e-23	0.38	0.32	Nicotine dependence;	chr9:95908339	chr9:95759231~95875977:-
BRCA	cis	rs9545047	0.604	rs28579970	ENSG00000227676.3	LINC01068	-10.85	4.79e-26	3.75e-23	-0.37	-0.32	Schizophrenia;	chr13:79308726	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.584	rs9565485	ENSG00000227676.3	LINC01068	-10.85	4.8e-26	3.75e-23	-0.37	-0.32	Schizophrenia;	chr13:79307428	chr13:79566727~79571436:+
BRCA	cis	rs6782228	0.606	rs4857861	ENSG00000242551.2	POU5F1P6	-10.85	4.8e-26	3.76e-23	-0.4	-0.32	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128687924	chr3:128674735~128677005:-
BRCA	cis	rs9545047	0.604	rs9565486	ENSG00000227676.3	LINC01068	-10.85	4.81e-26	3.77e-23	-0.37	-0.32	Schizophrenia;	chr13:79317469	chr13:79566727~79571436:+
BRCA	cis	rs2153535	0.563	rs3117071	ENSG00000230939.1	RP11-314C16.1	-10.85	4.83e-26	3.78e-23	-0.38	-0.32	Motion sickness;	chr6:8537675	chr6:8784178~8785445:+
BRCA	cis	rs9545047	0.604	rs1980883	ENSG00000227676.3	LINC01068	-10.85	4.83e-26	3.78e-23	-0.37	-0.32	Schizophrenia;	chr13:79310629	chr13:79566727~79571436:+
BRCA	cis	rs2243480	1	rs2257790	ENSG00000226824.5	RP4-756H11.3	-10.85	4.86e-26	3.8e-23	-0.61	-0.32	Diabetic kidney disease;	chr7:66135463	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs313813	ENSG00000226824.5	RP4-756H11.3	-10.84	4.9e-26	3.83e-23	-0.63	-0.32	Diabetic kidney disease;	chr7:66038513	chr7:66654538~66669855:+
BRCA	cis	rs17507216	0.56	rs2871011	ENSG00000278603.1	RP13-608F4.5	10.84	4.98e-26	3.89e-23	0.4	0.32	Excessive daytime sleepiness;	chr15:82560792	chr15:82472203~82472426:+
BRCA	cis	rs9318086	0.673	rs7981928	ENSG00000205861.10	C1QTNF9B-AS1	-10.84	4.99e-26	3.9e-23	-0.41	-0.32	Myopia (pathological);	chr13:23861041	chr13:23888889~23897263:+
BRCA	cis	rs2404602	0.735	rs12903874	ENSG00000259422.1	RP11-593F23.1	-10.84	5e-26	3.91e-23	-0.41	-0.32	Blood metabolite levels;	chr15:76400977	chr15:76174891~76181486:-
BRCA	cis	rs10129255	0.957	rs10136817	ENSG00000211970.3	IGHV4-61	-10.84	5.02e-26	3.92e-23	-0.24	-0.32	Kawasaki disease;	chr14:106787730	chr14:106639119~106639657:-
BRCA	cis	rs4423214	0.592	rs3829251	ENSG00000254682.1	RP11-660L16.2	-10.84	5.07e-26	3.96e-23	-0.48	-0.32	Vitamin D levels;	chr11:71483513	chr11:71448674~71452157:+
BRCA	cis	rs172166	0.694	rs203893	ENSG00000220721.1	OR1F12	10.84	5.2e-26	4.06e-23	0.38	0.32	Cardiac Troponin-T levels;	chr6:28094288	chr6:28073316~28074233:+
BRCA	cis	rs1891275	0.515	rs6583784	ENSG00000228701.1	TNKS2-AS1	10.84	5.26e-26	4.11e-23	0.37	0.32	Intelligence (multi-trait analysis);	chr10:91731819	chr10:91782839~91798291:-
BRCA	cis	rs321358	0.895	rs73015151	ENSG00000271584.1	RP11-89C3.4	10.84	5.28e-26	4.12e-23	0.5	0.32	Body mass index;	chr11:111084669	chr11:111091932~111097357:-
BRCA	cis	rs321358	0.895	rs17535886	ENSG00000271584.1	RP11-89C3.4	10.84	5.28e-26	4.12e-23	0.5	0.32	Body mass index;	chr11:111084852	chr11:111091932~111097357:-
BRCA	cis	rs2404602	0.647	rs12910820	ENSG00000259422.1	RP11-593F23.1	-10.84	5.32e-26	4.15e-23	-0.41	-0.32	Blood metabolite levels;	chr15:76730484	chr15:76174891~76181486:-
BRCA	cis	rs875971	0.83	rs427575	ENSG00000222364.1	RNU6-96P	-10.84	5.35e-26	4.17e-23	-0.37	-0.32	Aortic root size;	chr7:66054232	chr7:66395191~66395286:+
BRCA	cis	rs55665837	0.559	rs11023209	ENSG00000251991.1	RNU7-49P	10.84	5.37e-26	4.19e-23	0.35	0.32	Vitamin D levels;	chr11:14401054	chr11:14478892~14478953:+
BRCA	cis	rs2153535	0.541	rs9405386	ENSG00000230939.1	RP11-314C16.1	-10.83	5.41e-26	4.22e-23	-0.38	-0.32	Motion sickness;	chr6:8457834	chr6:8784178~8785445:+
BRCA	cis	rs2404602	0.622	rs11632670	ENSG00000259422.1	RP11-593F23.1	-10.83	5.44e-26	4.24e-23	-0.4	-0.32	Blood metabolite levels;	chr15:76681714	chr15:76174891~76181486:-
BRCA	cis	rs172166	0.694	rs203877	ENSG00000220721.1	OR1F12	10.83	5.49e-26	4.28e-23	0.38	0.32	Cardiac Troponin-T levels;	chr6:28080846	chr6:28073316~28074233:+
BRCA	cis	rs10129255	0.83	rs61997609	ENSG00000211970.3	IGHV4-61	-10.83	5.62e-26	4.38e-23	-0.23	-0.32	Kawasaki disease;	chr14:106692376	chr14:106639119~106639657:-
BRCA	cis	rs10875746	1	rs10875746	ENSG00000240399.1	RP1-228P16.1	-10.83	5.71e-26	4.44e-23	-0.41	-0.32	Longevity (90 years and older);	chr12:48124481	chr12:48054813~48055591:-
BRCA	cis	rs6782228	0.509	rs6780447	ENSG00000242551.2	POU5F1P6	-10.83	5.74e-26	4.47e-23	-0.4	-0.32	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128694965	chr3:128674735~128677005:-
BRCA	cis	rs2153535	0.58	rs6913100	ENSG00000230939.1	RP11-314C16.1	-10.83	5.76e-26	4.49e-23	-0.38	-0.32	Motion sickness;	chr6:8456622	chr6:8784178~8785445:+
BRCA	cis	rs7201929	1	rs7499878	ENSG00000259982.1	CDC37P1	-10.83	5.8e-26	4.52e-23	-0.43	-0.32	QT interval;	chr16:28857143	chr16:28700294~28701540:-
BRCA	cis	rs2243480	1	rs778729	ENSG00000226824.5	RP4-756H11.3	-10.83	5.85e-26	4.55e-23	-0.62	-0.32	Diabetic kidney disease;	chr7:66359432	chr7:66654538~66669855:+
BRCA	cis	rs11690935	0.595	rs788170	ENSG00000228389.1	AC068039.4	-10.83	5.93e-26	4.61e-23	-0.39	-0.32	Schizophrenia;	chr2:172055230	chr2:171773482~171775844:+
BRCA	cis	rs27432	0.608	rs2927619	ENSG00000248734.2	CTD-2260A17.1	10.82	6.09e-26	4.74e-23	0.35	0.32	Psoriasis vulgaris;	chr5:96847014	chr5:96784777~96785999:+
BRCA	cis	rs8062405	1	rs62036622	ENSG00000251417.2	RP11-1348G14.4	-10.82	6.11e-26	4.75e-23	-0.39	-0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28825882	chr16:28802743~28817828:+
BRCA	cis	rs2243480	0.803	rs423187	ENSG00000226824.5	RP4-756H11.3	-10.82	6.33e-26	4.92e-23	-0.63	-0.32	Diabetic kidney disease;	chr7:66044512	chr7:66654538~66669855:+
BRCA	cis	rs2153535	0.601	rs7738877	ENSG00000230939.1	RP11-314C16.1	-10.82	6.4e-26	4.98e-23	-0.38	-0.32	Motion sickness;	chr6:8541997	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs1577470	ENSG00000230939.1	RP11-314C16.1	-10.82	6.5e-26	5.05e-23	-0.38	-0.32	Motion sickness;	chr6:8462193	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.541	rs6923558	ENSG00000230939.1	RP11-314C16.1	-10.81	6.55e-26	5.09e-23	-0.38	-0.32	Motion sickness;	chr6:8461234	chr6:8784178~8785445:+
BRCA	cis	rs875971	0.862	rs4718383	ENSG00000222364.1	RNU6-96P	10.81	6.55e-26	5.09e-23	0.38	0.32	Aortic root size;	chr7:66643422	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.862	rs1860469	ENSG00000222364.1	RNU6-96P	10.81	6.61e-26	5.14e-23	0.38	0.32	Aortic root size;	chr7:66641888	chr7:66395191~66395286:+
BRCA	cis	rs1555322	0.53	rs932562	ENSG00000126005.14	MMP24-AS1	-10.81	6.67e-26	5.18e-23	-0.43	-0.32	Attention deficit hyperactivity disorder;	chr20:35283507	chr20:35216462~35278131:-
BRCA	cis	rs1499614	1	rs2141924	ENSG00000226824.5	RP4-756H11.3	-10.81	6.67e-26	5.18e-23	-0.63	-0.32	Gout;	chr7:66721259	chr7:66654538~66669855:+
BRCA	cis	rs1707322	0.686	rs2991986	ENSG00000280836.1	AL355480.1	10.81	6.71e-26	5.21e-23	0.42	0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45615610	chr1:45581219~45581321:-
BRCA	cis	rs2243480	1	rs7804223	ENSG00000226824.5	RP4-756H11.3	10.81	6.72e-26	5.22e-23	0.62	0.32	Diabetic kidney disease;	chr7:66199572	chr7:66654538~66669855:+
BRCA	cis	rs6782228	0.527	rs7426806	ENSG00000242551.2	POU5F1P6	-10.81	6.74e-26	5.23e-23	-0.4	-0.32	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128694087	chr3:128674735~128677005:-
BRCA	cis	rs2153535	0.58	rs1119688	ENSG00000230939.1	RP11-314C16.1	-10.81	6.76e-26	5.25e-23	-0.38	-0.32	Motion sickness;	chr6:8460617	chr6:8784178~8785445:+
BRCA	cis	rs8040855	0.965	rs6496766	ENSG00000259295.5	CSPG4P12	-10.81	6.79e-26	5.27e-23	-0.39	-0.32	Bulimia nervosa;	chr15:85159144	chr15:85191438~85213905:+
BRCA	cis	rs2153535	0.505	rs1737583	ENSG00000230939.1	RP11-314C16.1	-10.81	6.83e-26	5.3e-23	-0.38	-0.32	Motion sickness;	chr6:8536579	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs718502	ENSG00000230939.1	RP11-314C16.1	-10.81	6.84e-26	5.31e-23	-0.38	-0.32	Motion sickness;	chr6:8527167	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs718503	ENSG00000230939.1	RP11-314C16.1	-10.81	6.84e-26	5.31e-23	-0.38	-0.32	Motion sickness;	chr6:8527230	chr6:8784178~8785445:+
BRCA	cis	rs6782228	0.585	rs2811492	ENSG00000242551.2	POU5F1P6	-10.81	6.89e-26	5.35e-23	-0.4	-0.32	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128637436	chr3:128674735~128677005:-
BRCA	cis	rs6142102	0.602	rs68051854	ENSG00000276073.1	RP5-1125A11.7	-10.81	6.92e-26	5.36e-23	-0.38	-0.32	Skin pigmentation;	chr20:34114150	chr20:33985617~33988989:-
BRCA	cis	rs11105298	0.891	rs10858852	ENSG00000258302.2	RP11-981P6.1	10.81	7.03e-26	5.45e-23	0.36	0.32	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89439561	chr12:89561129~89594878:+
BRCA	cis	rs11105298	0.891	rs4842653	ENSG00000258302.2	RP11-981P6.1	10.81	7.03e-26	5.45e-23	0.36	0.32	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89440336	chr12:89561129~89594878:+
BRCA	cis	rs11105298	0.891	rs4842654	ENSG00000258302.2	RP11-981P6.1	10.81	7.03e-26	5.45e-23	0.36	0.32	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89440651	chr12:89561129~89594878:+
BRCA	cis	rs2153535	0.58	rs6905242	ENSG00000230939.1	RP11-314C16.1	-10.81	7.04e-26	5.46e-23	-0.38	-0.32	Motion sickness;	chr6:8471566	chr6:8784178~8785445:+
BRCA	cis	rs2337406	1	rs1961901	ENSG00000274576.2	IGHV2-70	-10.81	7.09e-26	5.5e-23	-0.34	-0.32	Alzheimer's disease (late onset);	chr14:106680856	chr14:106770577~106771020:-
BRCA	cis	rs10256972	0.933	rs35696159	ENSG00000229043.2	AC091729.9	-10.81	7.11e-26	5.51e-23	-0.41	-0.32	Endometriosis;Longevity;	chr7:1007558	chr7:1160374~1165267:+
BRCA	cis	rs11676348	0.935	rs2230054	ENSG00000261338.2	RP11-378A13.1	-10.81	7.12e-26	5.52e-23	-0.33	-0.32	Ulcerative colitis;	chr2:218135587	chr2:218255319~218257366:+
BRCA	cis	rs2153535	0.58	rs9392223	ENSG00000230939.1	RP11-314C16.1	-10.81	7.14e-26	5.53e-23	-0.38	-0.32	Motion sickness;	chr6:8468417	chr6:8784178~8785445:+
BRCA	cis	rs8062405	0.824	rs62034326	ENSG00000278665.1	RP11-666O2.4	10.81	7.14e-26	5.53e-23	0.33	0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28527972	chr16:28599241~28601881:-
BRCA	cis	rs8062405	0.824	rs4788084	ENSG00000278665.1	RP11-666O2.4	10.81	7.14e-26	5.53e-23	0.33	0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28528527	chr16:28599241~28601881:-
BRCA	cis	rs2243480	1	rs160639	ENSG00000226824.5	RP4-756H11.3	-10.81	7.19e-26	5.57e-23	-0.62	-0.32	Diabetic kidney disease;	chr7:66115000	chr7:66654538~66669855:+
BRCA	cis	rs7240205	0.657	rs1111208	ENSG00000275805.1	RP11-349H17.2	-10.8	7.22e-26	5.59e-23	-0.33	-0.32	Breast cancer;	chr18:26545901	chr18:26565723~26575626:-
BRCA	cis	rs473651	0.935	rs477041	ENSG00000229915.1	AC016999.2	10.8	7.28e-26	5.63e-23	0.39	0.32	Multiple system atrophy;	chr2:238447354	chr2:238427077~238427729:-
BRCA	cis	rs875971	0.658	rs432667	ENSG00000222364.1	RNU6-96P	-10.8	7.44e-26	5.76e-23	-0.37	-0.32	Aortic root size;	chr7:66049646	chr7:66395191~66395286:+
BRCA	cis	rs2153535	0.58	rs6905237	ENSG00000230939.1	RP11-314C16.1	-10.8	7.46e-26	5.77e-23	-0.38	-0.32	Motion sickness;	chr6:8471557	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.542	rs4440510	ENSG00000230939.1	RP11-314C16.1	-10.8	7.46e-26	5.77e-23	-0.38	-0.32	Motion sickness;	chr6:8471585	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.541	rs1414347	ENSG00000230939.1	RP11-314C16.1	-10.8	7.46e-26	5.77e-23	-0.38	-0.32	Motion sickness;	chr6:8471598	chr6:8784178~8785445:+
BRCA	cis	rs1499614	0.901	rs3936	ENSG00000226824.5	RP4-756H11.3	-10.8	7.5e-26	5.8e-23	-0.62	-0.32	Gout;	chr7:66661502	chr7:66654538~66669855:+
BRCA	cis	rs11673344	0.864	rs79407399	ENSG00000226686.6	LINC01535	10.8	7.51e-26	5.81e-23	0.46	0.32	Obesity-related traits;	chr19:37000004	chr19:37251912~37265535:+
BRCA	cis	rs10759883	0.563	rs694230	ENSG00000175611.10	LINC00476	10.8	7.57e-26	5.85e-23	0.37	0.32	Nicotine dependence;	chr9:95954227	chr9:95759231~95875977:-
BRCA	cis	rs2153535	0.546	rs9378559	ENSG00000230939.1	RP11-314C16.1	-10.8	7.72e-26	5.97e-23	-0.38	-0.32	Motion sickness;	chr6:8538825	chr6:8784178~8785445:+
BRCA	cis	rs858239	0.6	rs10488077	ENSG00000226816.2	AC005082.12	10.8	7.78e-26	6.02e-23	0.36	0.32	Cerebrospinal fluid biomarker levels;	chr7:23104563	chr7:23206013~23208045:+
BRCA	cis	rs875971	0.83	rs587360	ENSG00000222364.1	RNU6-96P	-10.8	7.89e-26	6.1e-23	-0.37	-0.32	Aortic root size;	chr7:66057711	chr7:66395191~66395286:+
BRCA	cis	rs2243480	1	rs316326	ENSG00000226824.5	RP4-756H11.3	-10.8	7.9e-26	6.1e-23	-0.61	-0.32	Diabetic kidney disease;	chr7:66144466	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs316325	ENSG00000226824.5	RP4-756H11.3	-10.8	7.9e-26	6.1e-23	-0.61	-0.32	Diabetic kidney disease;	chr7:66144531	chr7:66654538~66669855:+
BRCA	cis	rs10759883	0.627	rs13294931	ENSG00000175611.10	LINC00476	-10.79	7.98e-26	6.17e-23	-0.36	-0.32	Nicotine dependence;	chr9:95833220	chr9:95759231~95875977:-
BRCA	cis	rs875971	0.564	rs313804	ENSG00000222364.1	RNU6-96P	-10.79	8e-26	6.18e-23	-0.37	-0.32	Aortic root size;	chr7:66049635	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.662	rs448725	ENSG00000222364.1	RNU6-96P	-10.79	8e-26	6.18e-23	-0.37	-0.32	Aortic root size;	chr7:66049641	chr7:66395191~66395286:+
BRCA	cis	rs2243480	0.901	rs34807232	ENSG00000226824.5	RP4-756H11.3	-10.79	8.03e-26	6.2e-23	-0.62	-0.32	Diabetic kidney disease;	chr7:66500146	chr7:66654538~66669855:+
BRCA	cis	rs2243480	0.901	rs35823062	ENSG00000226824.5	RP4-756H11.3	-10.79	8.03e-26	6.2e-23	-0.62	-0.32	Diabetic kidney disease;	chr7:66500834	chr7:66654538~66669855:+
BRCA	cis	rs524281	0.731	rs11227439	ENSG00000255320.1	RP11-755F10.1	10.79	8.04e-26	6.21e-23	0.52	0.32	Electroencephalogram traits;	chr11:66258208	chr11:66244840~66246239:-
BRCA	cis	rs4927850	1	rs10881563	ENSG00000231464.1	AC024937.4	10.79	8.07e-26	6.23e-23	0.42	0.32	Pancreatic cancer;	chr3:196023354	chr3:195996738~195998233:+
BRCA	cis	rs10759883	0.539	rs10117340	ENSG00000175611.10	LINC00476	-10.79	8.09e-26	6.25e-23	-0.38	-0.32	Nicotine dependence;	chr9:96032530	chr9:95759231~95875977:-
BRCA	cis	rs2243480	1	rs778679	ENSG00000226824.5	RP4-756H11.3	-10.79	8.15e-26	6.3e-23	-0.62	-0.32	Diabetic kidney disease;	chr7:66375924	chr7:66654538~66669855:+
BRCA	cis	rs7829975	0.714	rs11784052	ENSG00000253893.2	FAM85B	-10.79	8.17e-26	6.3e-23	-0.38	-0.32	Mood instability;	chr8:8814452	chr8:8167819~8226614:-
BRCA	cis	rs1707322	0.686	rs1250	ENSG00000280836.1	AL355480.1	-10.79	8.21e-26	6.33e-23	-0.41	-0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45628355	chr1:45581219~45581321:-
BRCA	cis	rs1823913	0.927	rs35339956	ENSG00000227542.1	AC092614.2	10.79	8.22e-26	6.35e-23	0.41	0.32	Obesity-related traits;	chr2:191261668	chr2:191229165~191246172:-
BRCA	cis	rs10759883	0.627	rs10818574	ENSG00000175611.10	LINC00476	10.79	8.25e-26	6.36e-23	0.36	0.32	Nicotine dependence;	chr9:95836685	chr9:95759231~95875977:-
BRCA	cis	rs1707322	0.686	rs2991987	ENSG00000280836.1	AL355480.1	10.79	8.25e-26	6.36e-23	0.41	0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45615750	chr1:45581219~45581321:-
BRCA	cis	rs4380275	1	rs4854376	ENSG00000223751.1	AC116609.2	10.79	8.44e-26	6.51e-23	0.42	0.32	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:763683	chr2:742488~747767:+
BRCA	cis	rs8062405	0.655	rs7184597	ENSG00000259982.1	CDC37P1	-10.79	8.57e-26	6.6e-23	-0.43	-0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28910488	chr16:28700294~28701540:-
BRCA	cis	rs1499614	1	rs1267818	ENSG00000226824.5	RP4-756H11.3	-10.79	8.6e-26	6.63e-23	-0.62	-0.32	Gout;	chr7:66642037	chr7:66654538~66669855:+
BRCA	cis	rs7714584	1	rs4958842	ENSG00000197083.10	ZNF300P1	10.79	8.72e-26	6.72e-23	0.47	0.32	Crohn's disease;	chr5:150845315	chr5:150930645~150946289:-
BRCA	cis	rs10875746	0.669	rs11168487	ENSG00000240399.1	RP1-228P16.1	-10.78	8.8e-26	6.78e-23	-0.44	-0.32	Longevity (90 years and older);	chr12:48246926	chr12:48054813~48055591:-
BRCA	cis	rs875971	0.825	rs28480509	ENSG00000222364.1	RNU6-96P	10.78	8.86e-26	6.82e-23	0.37	0.32	Aortic root size;	chr7:66634237	chr7:66395191~66395286:+
BRCA	cis	rs2153535	0.563	rs1796688	ENSG00000230939.1	RP11-314C16.1	-10.78	8.92e-26	6.87e-23	-0.38	-0.32	Motion sickness;	chr6:8536190	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.526	rs1796689	ENSG00000230939.1	RP11-314C16.1	-10.78	8.92e-26	6.87e-23	-0.38	-0.32	Motion sickness;	chr6:8536200	chr6:8784178~8785445:+
BRCA	cis	rs2404602	0.575	rs11633309	ENSG00000259422.1	RP11-593F23.1	-10.78	8.98e-26	6.91e-23	-0.46	-0.32	Blood metabolite levels;	chr15:76670008	chr15:76174891~76181486:-
BRCA	cis	rs9545047	0.604	rs9285310	ENSG00000227676.3	LINC01068	-10.78	9.06e-26	6.98e-23	-0.37	-0.32	Schizophrenia;	chr13:79328340	chr13:79566727~79571436:+
BRCA	cis	rs9545047	0.625	rs9593391	ENSG00000227676.3	LINC01068	-10.78	9.06e-26	6.98e-23	-0.37	-0.32	Schizophrenia;	chr13:79329168	chr13:79566727~79571436:+
BRCA	cis	rs2243480	1	rs427044	ENSG00000226824.5	RP4-756H11.3	-10.78	9.1e-26	7.01e-23	-0.62	-0.32	Diabetic kidney disease;	chr7:66043558	chr7:66654538~66669855:+
BRCA	cis	rs9545047	0.604	rs12875039	ENSG00000227676.3	LINC01068	-10.78	9.16e-26	7.05e-23	-0.37	-0.32	Schizophrenia;	chr13:79327449	chr13:79566727~79571436:+
BRCA	cis	rs1823913	0.927	rs56209234	ENSG00000227542.1	AC092614.2	10.78	9.24e-26	7.11e-23	0.41	0.32	Obesity-related traits;	chr2:191261748	chr2:191229165~191246172:-
BRCA	cis	rs6539288	0.677	rs10778518	ENSG00000260329.1	RP11-412D9.4	10.78	9.25e-26	7.12e-23	0.36	0.32	Total body bone mineral density;	chr12:106950172	chr12:106954029~106955497:-
BRCA	cis	rs524281	0.773	rs11227448	ENSG00000255320.1	RP11-755F10.1	10.78	9.39e-26	7.23e-23	0.53	0.32	Electroencephalogram traits;	chr11:66281020	chr11:66244840~66246239:-
BRCA	cis	rs150992	0.587	rs12189335	ENSG00000248489.1	CTD-2007H13.3	-10.78	9.45e-26	7.27e-23	-0.36	-0.32	Body mass index;	chr5:99009311	chr5:98929171~98995013:+
BRCA	cis	rs1062177	0.855	rs919263	ENSG00000213433.5	RPLP1P6	-10.78	9.57e-26	7.36e-23	-0.38	-0.32	Preschool internalizing problems;	chr5:151886292	chr5:151765859~151766378:-
BRCA	cis	rs2153535	0.58	rs4960433	ENSG00000230939.1	RP11-314C16.1	-10.77	9.7e-26	7.46e-23	-0.38	-0.32	Motion sickness;	chr6:8523464	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.58	rs1414342	ENSG00000230939.1	RP11-314C16.1	-10.77	9.72e-26	7.48e-23	-0.38	-0.32	Motion sickness;	chr6:8462319	chr6:8784178~8785445:+
BRCA	cis	rs8062405	0.754	rs62034323	ENSG00000278665.1	RP11-666O2.4	10.77	9.76e-26	7.5e-23	0.33	0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28525152	chr16:28599241~28601881:-
BRCA	cis	rs8062405	0.824	rs62034324	ENSG00000278665.1	RP11-666O2.4	10.77	9.76e-26	7.5e-23	0.33	0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28525441	chr16:28599241~28601881:-
BRCA	cis	rs10759883	0.563	rs589362	ENSG00000175611.10	LINC00476	10.77	9.84e-26	7.56e-23	0.37	0.32	Nicotine dependence;	chr9:95966906	chr9:95759231~95875977:-
BRCA	cis	rs11105298	0.891	rs10858864	ENSG00000258302.2	RP11-981P6.1	10.77	9.88e-26	7.59e-23	0.36	0.32	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89452453	chr12:89561129~89594878:+
BRCA	cis	rs11105298	0.891	rs10858865	ENSG00000258302.2	RP11-981P6.1	10.77	9.88e-26	7.59e-23	0.36	0.32	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89452699	chr12:89561129~89594878:+
BRCA	cis	rs8062405	0.688	rs3924376	ENSG00000259982.1	CDC37P1	-10.77	9.99e-26	7.67e-23	-0.43	-0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28914657	chr16:28700294~28701540:-
BRCA	cis	rs524281	0.773	rs10750781	ENSG00000255320.1	RP11-755F10.1	10.77	1e-25	7.69e-23	0.52	0.32	Electroencephalogram traits;	chr11:66269799	chr11:66244840~66246239:-
BRCA	cis	rs524281	0.773	rs2017969	ENSG00000255320.1	RP11-755F10.1	10.77	1e-25	7.69e-23	0.52	0.32	Electroencephalogram traits;	chr11:66271561	chr11:66244840~66246239:-
BRCA	cis	rs8040855	1	rs6496768	ENSG00000259295.5	CSPG4P12	-10.77	1.01e-25	7.76e-23	-0.39	-0.32	Bulimia nervosa;	chr15:85159701	chr15:85191438~85213905:+
BRCA	cis	rs2153535	0.505	rs9405395	ENSG00000230939.1	RP11-314C16.1	-10.77	1.01e-25	7.77e-23	-0.38	-0.32	Motion sickness;	chr6:8468389	chr6:8784178~8785445:+
BRCA	cis	rs10759883	0.539	rs684455	ENSG00000175611.10	LINC00476	10.77	1.02e-25	7.85e-23	0.37	0.32	Nicotine dependence;	chr9:95964061	chr9:95759231~95875977:-
BRCA	cis	rs58873874	0.737	rs10061544	ENSG00000251405.2	CTB-109A12.1	10.77	1.03e-25	7.91e-23	0.74	0.32	Bipolar disorder (body mass index interaction);	chr5:157383871	chr5:157362615~157460078:-
BRCA	cis	rs58873874	0.737	rs10078836	ENSG00000251405.2	CTB-109A12.1	10.77	1.03e-25	7.91e-23	0.74	0.32	Bipolar disorder (body mass index interaction);	chr5:157384604	chr5:157362615~157460078:-
BRCA	cis	rs11676348	0.901	rs7562334	ENSG00000261338.2	RP11-378A13.1	-10.77	1.04e-25	8.02e-23	-0.33	-0.32	Ulcerative colitis;	chr2:218138637	chr2:218255319~218257366:+
BRCA	cis	rs10759883	0.58	rs10818738	ENSG00000175611.10	LINC00476	10.77	1.05e-25	8.08e-23	0.36	0.32	Nicotine dependence;	chr9:95846938	chr9:95759231~95875977:-
BRCA	cis	rs10759883	0.627	rs10818746	ENSG00000175611.10	LINC00476	10.77	1.05e-25	8.08e-23	0.36	0.32	Nicotine dependence;	chr9:95848031	chr9:95759231~95875977:-
BRCA	cis	rs10759883	0.627	rs10985769	ENSG00000175611.10	LINC00476	10.77	1.05e-25	8.08e-23	0.36	0.32	Nicotine dependence;	chr9:95848094	chr9:95759231~95875977:-
BRCA	cis	rs10740039	0.583	rs2127350	ENSG00000254271.1	RP11-131N11.4	-10.77	1.05e-25	8.08e-23	-0.41	-0.32	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60741079	chr10:60734342~60741828:+
BRCA	cis	rs10740039	0.583	rs2127351	ENSG00000254271.1	RP11-131N11.4	-10.77	1.05e-25	8.08e-23	-0.41	-0.32	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60741425	chr10:60734342~60741828:+
BRCA	cis	rs11105298	0.891	rs11105299	ENSG00000258302.2	RP11-981P6.1	10.76	1.07e-25	8.21e-23	0.36	0.32	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89484166	chr12:89561129~89594878:+
BRCA	cis	rs11105298	0.891	rs1008764	ENSG00000258302.2	RP11-981P6.1	10.76	1.07e-25	8.21e-23	0.36	0.32	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89493872	chr12:89561129~89594878:+
BRCA	cis	rs9318086	0.712	rs12875437	ENSG00000205861.10	C1QTNF9B-AS1	-10.76	1.09e-25	8.37e-23	-0.4	-0.32	Myopia (pathological);	chr13:23879817	chr13:23888889~23897263:+
BRCA	cis	rs6558530	0.836	rs7461159	ENSG00000253982.1	CTD-2336O2.1	10.76	1.09e-25	8.39e-23	0.36	0.32	Systolic blood pressure;	chr8:1768450	chr8:1761990~1764502:-
BRCA	cis	rs9322193	0.607	rs4870078	ENSG00000216906.2	RP11-350J20.9	-10.76	1.11e-25	8.46e-23	-0.43	-0.32	Lung cancer;	chr6:149880676	chr6:149904243~149906418:+
BRCA	cis	rs10759883	0.563	rs671058	ENSG00000175611.10	LINC00476	10.76	1.11e-25	8.52e-23	0.37	0.32	Nicotine dependence;	chr9:95931728	chr9:95759231~95875977:-
BRCA	cis	rs12134133	0.927	rs4844589	ENSG00000274245.1	RP11-357P18.2	10.76	1.13e-25	8.61e-23	0.43	0.32	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207259285	chr1:207372559~207373252:+
BRCA	cis	rs11123694	1	rs11123694	ENSG00000214184.3	AC012487.2	-10.76	1.13e-25	8.65e-23	-0.38	-0.32	Mean platelet volume;	chr2:108448107	chr2:108507515~108534196:-
BRCA	cis	rs6782228	0.565	rs12695509	ENSG00000242551.2	POU5F1P6	-10.76	1.13e-25	8.68e-23	-0.4	-0.32	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128698201	chr3:128674735~128677005:-
BRCA	cis	rs2243480	1	rs4718333	ENSG00000226824.5	RP4-756H11.3	10.76	1.14e-25	8.72e-23	0.62	0.32	Diabetic kidney disease;	chr7:66307771	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs7792391	ENSG00000226824.5	RP4-756H11.3	10.76	1.14e-25	8.72e-23	0.62	0.32	Diabetic kidney disease;	chr7:66308442	chr7:66654538~66669855:+
BRCA	cis	rs17023223	0.537	rs12065809	ENSG00000231365.4	RP11-418J17.1	-10.76	1.14e-25	8.76e-23	-0.4	-0.32	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119181912	chr1:119140396~119275973:+
BRCA	cis	rs8062405	0.755	rs1074631	ENSG00000278665.1	RP11-666O2.4	-10.76	1.15e-25	8.83e-23	-0.35	-0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28542787	chr16:28599241~28601881:-
BRCA	cis	rs10759883	0.627	rs10760261	ENSG00000175611.10	LINC00476	10.76	1.15e-25	8.83e-23	0.35	0.32	Nicotine dependence;	chr9:95850229	chr9:95759231~95875977:-
BRCA	cis	rs6782228	0.565	rs67445542	ENSG00000242551.2	POU5F1P6	-10.76	1.16e-25	8.89e-23	-0.4	-0.32	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128611683	chr3:128674735~128677005:-
BRCA	cis	rs8062405	0.824	rs28698667	ENSG00000278665.1	RP11-666O2.4	10.76	1.17e-25	8.97e-23	0.33	0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28521750	chr16:28599241~28601881:-
BRCA	cis	rs1075265	0.584	rs4671178	ENSG00000233266.1	HMGB1P31	-10.76	1.17e-25	8.97e-23	-0.39	-0.32	Chronotype;Morning vs. evening chronotype;	chr2:54056356	chr2:54051334~54051760:+
BRCA	cis	rs2153535	0.58	rs4365970	ENSG00000230939.1	RP11-314C16.1	10.75	1.21e-25	9.21e-23	0.38	0.32	Motion sickness;	chr6:8453580	chr6:8784178~8785445:+
BRCA	cis	rs6782228	0.527	rs6767383	ENSG00000242551.2	POU5F1P6	-10.75	1.21e-25	9.28e-23	-0.4	-0.32	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128694744	chr3:128674735~128677005:-
BRCA	cis	rs2243480	1	rs316322	ENSG00000226824.5	RP4-756H11.3	-10.75	1.22e-25	9.29e-23	-0.61	-0.32	Diabetic kidney disease;	chr7:66146246	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs316329	ENSG00000226824.5	RP4-756H11.3	-10.75	1.22e-25	9.31e-23	-0.59	-0.32	Diabetic kidney disease;	chr7:66143429	chr7:66654538~66669855:+
BRCA	cis	rs10875746	0.669	rs10875772	ENSG00000240399.1	RP1-228P16.1	-10.75	1.22e-25	9.34e-23	-0.44	-0.32	Longevity (90 years and older);	chr12:48215770	chr12:48054813~48055591:-
BRCA	cis	rs10759883	0.627	rs12343734	ENSG00000175611.10	LINC00476	10.75	1.23e-25	9.43e-23	0.36	0.32	Nicotine dependence;	chr9:95847873	chr9:95759231~95875977:-
BRCA	cis	rs11105298	0.891	rs10858851	ENSG00000258302.2	RP11-981P6.1	10.75	1.25e-25	9.57e-23	0.37	0.32	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89437093	chr12:89561129~89594878:+
BRCA	cis	rs2880765	0.545	rs17553734	ENSG00000259295.5	CSPG4P12	-10.75	1.26e-25	9.59e-23	-0.42	-0.32	Coronary artery disease;	chr15:85469828	chr15:85191438~85213905:+
BRCA	cis	rs11676348	0.967	rs4672873	ENSG00000261338.2	RP11-378A13.1	-10.75	1.26e-25	9.61e-23	-0.33	-0.32	Ulcerative colitis;	chr2:218140487	chr2:218255319~218257366:+
BRCA	cis	rs2404602	0.735	rs283789	ENSG00000259422.1	RP11-593F23.1	10.75	1.27e-25	9.67e-23	0.4	0.32	Blood metabolite levels;	chr15:76485236	chr15:76174891~76181486:-
BRCA	cis	rs7309	0.935	rs10930013	ENSG00000235724.7	AC009299.2	-10.75	1.27e-25	9.68e-23	-0.36	-0.32	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161213814	chr2:161222785~161308303:-
BRCA	cis	rs10759883	0.627	rs11998982	ENSG00000175611.10	LINC00476	10.74	1.3e-25	9.9e-23	0.36	0.32	Nicotine dependence;	chr9:95851142	chr9:95759231~95875977:-
BRCA	cis	rs11676348	0.846	rs13009946	ENSG00000261338.2	RP11-378A13.1	-10.74	1.31e-25	9.97e-23	-0.33	-0.32	Ulcerative colitis;	chr2:218143029	chr2:218255319~218257366:+
BRCA	cis	rs12134133	0.962	rs7526658	ENSG00000274245.1	RP11-357P18.2	10.74	1.31e-25	9.97e-23	0.43	0.32	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207240098	chr1:207372559~207373252:+
BRCA	cis	rs1501911	0.713	rs10479344	ENSG00000248489.1	CTD-2007H13.3	-10.74	1.32e-25	1.01e-22	-0.36	-0.32	Lung function (FEV1/FVC);	chr5:99012676	chr5:98929171~98995013:+
BRCA	cis	rs875971	0.862	rs9791712	ENSG00000222364.1	RNU6-96P	10.74	1.33e-25	1.01e-22	0.37	0.32	Aortic root size;	chr7:66640176	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.862	rs9791713	ENSG00000222364.1	RNU6-96P	10.74	1.33e-25	1.01e-22	0.37	0.32	Aortic root size;	chr7:66640211	chr7:66395191~66395286:+
BRCA	cis	rs11105298	0.891	rs10858872	ENSG00000258302.2	RP11-981P6.1	10.74	1.33e-25	1.01e-22	0.36	0.32	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89479155	chr12:89561129~89594878:+
BRCA	cis	rs17507216	0.56	rs28493687	ENSG00000278603.1	RP13-608F4.5	10.74	1.36e-25	1.03e-22	0.4	0.32	Excessive daytime sleepiness;	chr15:82560062	chr15:82472203~82472426:+
BRCA	cis	rs321358	0.945	rs17458235	ENSG00000271584.1	RP11-89C3.4	-10.74	1.37e-25	1.04e-22	-0.53	-0.32	Body mass index;	chr11:111106114	chr11:111091932~111097357:-
BRCA	cis	rs8062405	1	rs72793812	ENSG00000251417.2	RP11-1348G14.4	-10.74	1.37e-25	1.04e-22	-0.39	-0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28829060	chr16:28802743~28817828:+
BRCA	cis	rs8040855	0.52	rs11629962	ENSG00000259295.5	CSPG4P12	10.74	1.37e-25	1.05e-22	0.48	0.32	Bulimia nervosa;	chr15:84986797	chr15:85191438~85213905:+
BRCA	cis	rs2404602	0.684	rs11072602	ENSG00000259422.1	RP11-593F23.1	-10.74	1.38e-25	1.05e-22	-0.41	-0.32	Blood metabolite levels;	chr15:76581126	chr15:76174891~76181486:-
BRCA	cis	rs6782228	0.606	rs6807019	ENSG00000242551.2	POU5F1P6	-10.74	1.38e-25	1.05e-22	-0.4	-0.32	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128687091	chr3:128674735~128677005:-
BRCA	cis	rs12134133	0.962	rs17258843	ENSG00000274245.1	RP11-357P18.2	10.74	1.4e-25	1.06e-22	0.44	0.32	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207241387	chr1:207372559~207373252:+
BRCA	cis	rs2153535	0.58	rs6927589	ENSG00000230939.1	RP11-314C16.1	10.74	1.41e-25	1.07e-22	0.38	0.32	Motion sickness;	chr6:8456399	chr6:8784178~8785445:+
BRCA	cis	rs10740039	0.549	rs9414741	ENSG00000254271.1	RP11-131N11.4	-10.74	1.41e-25	1.07e-22	-0.41	-0.32	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60738510	chr10:60734342~60741828:+
BRCA	cis	rs9545047	0.604	rs1324870	ENSG00000227676.3	LINC01068	-10.74	1.42e-25	1.08e-22	-0.36	-0.32	Schizophrenia;	chr13:79297911	chr13:79566727~79571436:+
BRCA	cis	rs7240205	0.657	rs1111207	ENSG00000275805.1	RP11-349H17.2	-10.73	1.46e-25	1.11e-22	-0.33	-0.32	Breast cancer;	chr18:26545893	chr18:26565723~26575626:-
BRCA	cis	rs1707322	0.686	rs2275085	ENSG00000280836.1	AL355480.1	10.73	1.47e-25	1.12e-22	0.41	0.32	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45620180	chr1:45581219~45581321:-
BRCA	cis	rs11105298	0.786	rs10858867	ENSG00000258302.2	RP11-981P6.1	10.73	1.49e-25	1.13e-22	0.36	0.32	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89457389	chr12:89561129~89594878:+
BRCA	cis	rs11105298	0.786	rs3803128	ENSG00000258302.2	RP11-981P6.1	10.73	1.49e-25	1.13e-22	0.36	0.32	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89466542	chr12:89561129~89594878:+
BRCA	cis	rs11105298	0.891	rs10506972	ENSG00000258302.2	RP11-981P6.1	10.73	1.49e-25	1.13e-22	0.36	0.32	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89467752	chr12:89561129~89594878:+
BRCA	cis	rs11105298	0.891	rs12228177	ENSG00000258302.2	RP11-981P6.1	10.73	1.49e-25	1.13e-22	0.36	0.32	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89468253	chr12:89561129~89594878:+
BRCA	cis	rs2243480	1	rs1499614	ENSG00000226824.5	RP4-756H11.3	-10.73	1.49e-25	1.13e-22	-0.6	-0.32	Diabetic kidney disease;	chr7:66265811	chr7:66654538~66669855:+
BRCA	cis	rs35160687	0.644	rs10204589	ENSG00000273080.1	RP11-301O19.1	10.73	1.52e-25	1.15e-22	0.37	0.32	Night sleep phenotypes;	chr2:86266100	chr2:86195590~86196049:+
BRCA	cis	rs524281	0.773	rs79770412	ENSG00000255320.1	RP11-755F10.1	10.73	1.52e-25	1.16e-22	0.52	0.32	Electroencephalogram traits;	chr11:66277873	chr11:66244840~66246239:-
BRCA	cis	rs17023223	0.509	rs61806978	ENSG00000231365.4	RP11-418J17.1	-10.73	1.55e-25	1.18e-22	-0.4	-0.32	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119170592	chr1:119140396~119275973:+
BRCA	cis	rs1891275	0.509	rs34190234	ENSG00000228701.1	TNKS2-AS1	-10.73	1.57e-25	1.19e-22	-0.37	-0.32	Intelligence (multi-trait analysis);	chr10:91683317	chr10:91782839~91798291:-
BRCA	cis	rs1891275	0.509	rs76313529	ENSG00000228701.1	TNKS2-AS1	-10.73	1.57e-25	1.19e-22	-0.37	-0.32	Intelligence (multi-trait analysis);	chr10:91683319	chr10:91782839~91798291:-
BRCA	cis	rs524281	0.773	rs10791863	ENSG00000255320.1	RP11-755F10.1	10.73	1.57e-25	1.19e-22	0.52	0.32	Electroencephalogram traits;	chr11:66259887	chr11:66244840~66246239:-
BRCA	cis	rs2442825	0.693	rs2648536	ENSG00000206573.7	THUMPD3-AS1	10.73	1.57e-25	1.19e-22	0.29	0.32	Cerebrospinal fluid clusterin levels;	chr3:9365338	chr3:9349689~9398579:-
BRCA	cis	rs6452524	0.935	rs72767160	ENSG00000249664.1	CTD-2227C6.2	10.72	1.58e-25	1.2e-22	0.39	0.32	Hypertension (SNP x SNP interaction);	chr5:83161102	chr5:83012285~83013109:-
BRCA	cis	rs7945705	0.692	rs11042149	ENSG00000254860.4	TMEM9B-AS1	10.72	1.63e-25	1.24e-22	0.28	0.32	Hemoglobin concentration;	chr11:8989190	chr11:8964675~8977527:+
BRCA	cis	rs4713118	0.513	rs149950	ENSG00000220721.1	OR1F12	10.72	1.64e-25	1.24e-22	0.38	0.32	Parkinson's disease;	chr6:28065261	chr6:28073316~28074233:+
BRCA	cis	rs4713118	0.513	rs149951	ENSG00000220721.1	OR1F12	10.72	1.64e-25	1.24e-22	0.38	0.32	Parkinson's disease;	chr6:28065309	chr6:28073316~28074233:+
BRCA	cis	rs4380275	1	rs7562792	ENSG00000223751.1	AC116609.2	10.72	1.64e-25	1.24e-22	0.42	0.32	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:774469	chr2:742488~747767:+
BRCA	cis	rs11673344	0.636	rs7255595	ENSG00000226686.6	LINC01535	10.72	1.65e-25	1.25e-22	0.45	0.32	Obesity-related traits;	chr19:36896260	chr19:37251912~37265535:+
BRCA	cis	rs2243480	1	rs313814	ENSG00000226824.5	RP4-756H11.3	-10.72	1.66e-25	1.26e-22	-0.62	-0.32	Diabetic kidney disease;	chr7:66038306	chr7:66654538~66669855:+
BRCA	cis	rs10256972	0.967	rs4723338	ENSG00000229043.2	AC091729.9	-10.72	1.68e-25	1.27e-22	-0.4	-0.32	Endometriosis;Longevity;	chr7:996605	chr7:1160374~1165267:+
BRCA	cis	rs6782228	0.606	rs2712381	ENSG00000242551.2	POU5F1P6	-10.72	1.7e-25	1.29e-22	-0.4	-0.32	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128619757	chr3:128674735~128677005:-
BRCA	cis	rs8059260	0.673	rs74985998	ENSG00000274038.1	RP11-66H6.4	-10.72	1.71e-25	1.29e-22	-0.5	-0.32	Alcohol consumption over the past year;	chr16:10967208	chr16:11056556~11057034:+
BRCA	cis	rs1891275	0.515	rs1592051	ENSG00000228701.1	TNKS2-AS1	10.72	1.72e-25	1.3e-22	0.36	0.32	Intelligence (multi-trait analysis);	chr10:91782429	chr10:91782839~91798291:-
BRCA	cis	rs10740039	0.548	rs9415607	ENSG00000254271.1	RP11-131N11.4	-10.71	1.75e-25	1.32e-22	-0.41	-0.32	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60737616	chr10:60734342~60741828:+
BRCA	cis	rs17023223	0.537	rs61806983	ENSG00000231365.4	RP11-418J17.1	-10.71	1.77e-25	1.34e-22	-0.4	-0.31	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119188901	chr1:119140396~119275973:+
BRCA	cis	rs150992	0.587	rs10076291	ENSG00000248489.1	CTD-2007H13.3	-10.71	1.78e-25	1.34e-22	-0.36	-0.31	Body mass index;	chr5:99012954	chr5:98929171~98995013:+
BRCA	cis	rs11673344	0.683	rs11668615	ENSG00000226686.6	LINC01535	10.71	1.78e-25	1.34e-22	0.45	0.31	Obesity-related traits;	chr19:37063632	chr19:37251912~37265535:+
BRCA	cis	rs4380275	0.965	rs4375894	ENSG00000223751.1	AC116609.2	10.71	1.79e-25	1.35e-22	0.42	0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:772567	chr2:742488~747767:+
BRCA	cis	rs6538678	0.746	rs703693	ENSG00000258343.1	RP11-536G4.2	-10.71	1.8e-25	1.36e-22	-0.45	-0.31	Lupus nephritis in systemic lupus erythematosus;	chr12:95866214	chr12:95795345~95858839:-
BRCA	cis	rs9487094	0.67	rs729888	ENSG00000260273.1	RP11-425D10.10	-10.71	1.81e-25	1.36e-22	-0.39	-0.31	Height;	chr6:109636120	chr6:109382795~109383666:+
BRCA	cis	rs10875746	0.669	rs11168499	ENSG00000240399.1	RP1-228P16.1	-10.71	1.82e-25	1.37e-22	-0.43	-0.31	Longevity (90 years and older);	chr12:48268887	chr12:48054813~48055591:-
BRCA	cis	rs7849270	0.801	rs10819474	ENSG00000268707.1	RP11-247A12.7	-10.71	1.84e-25	1.39e-22	-0.4	-0.31	Blood metabolite ratios;	chr9:129168215	chr9:129170434~129170940:+
BRCA	cis	rs2581828	0.646	rs9861233	ENSG00000242142.1	SERBP1P3	-10.71	1.87e-25	1.41e-22	-0.39	-0.31	Crohn's disease;	chr3:53124815	chr3:53064283~53065091:-
BRCA	cis	rs4713118	0.513	rs9368547	ENSG00000220721.1	OR1F12	10.71	1.87e-25	1.41e-22	0.38	0.31	Parkinson's disease;	chr6:28060289	chr6:28073316~28074233:+
BRCA	cis	rs4713118	0.513	rs183244	ENSG00000220721.1	OR1F12	10.71	1.87e-25	1.41e-22	0.38	0.31	Parkinson's disease;	chr6:28064060	chr6:28073316~28074233:+
BRCA	cis	rs4713118	0.513	rs149962	ENSG00000220721.1	OR1F12	10.71	1.88e-25	1.42e-22	0.38	0.31	Parkinson's disease;	chr6:28048140	chr6:28073316~28074233:+
BRCA	cis	rs172166	0.769	rs149965	ENSG00000220721.1	OR1F12	10.71	1.88e-25	1.42e-22	0.38	0.31	Cardiac Troponin-T levels;	chr6:28050911	chr6:28073316~28074233:+
BRCA	cis	rs4380275	1	rs4359695	ENSG00000223751.1	AC116609.2	10.71	1.9e-25	1.43e-22	0.42	0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:774214	chr2:742488~747767:+
BRCA	cis	rs4380275	0.931	rs4538239	ENSG00000223751.1	AC116609.2	10.71	1.9e-25	1.43e-22	0.42	0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:774238	chr2:742488~747767:+
BRCA	cis	rs2243480	0.901	rs12530490	ENSG00000226824.5	RP4-756H11.3	10.71	1.91e-25	1.44e-22	0.61	0.31	Diabetic kidney disease;	chr7:66226660	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs7778911	ENSG00000226824.5	RP4-756H11.3	10.71	1.91e-25	1.44e-22	0.61	0.31	Diabetic kidney disease;	chr7:66229519	chr7:66654538~66669855:+
BRCA	cis	rs12134133	0.962	rs11120512	ENSG00000274245.1	RP11-357P18.2	-10.7	1.92e-25	1.45e-22	-0.43	-0.31	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207240370	chr1:207372559~207373252:+
BRCA	cis	rs7829975	0.667	rs1877119	ENSG00000253893.2	FAM85B	-10.7	1.92e-25	1.45e-22	-0.39	-0.31	Mood instability;	chr8:8849687	chr8:8167819~8226614:-
BRCA	cis	rs4380275	1	rs4450634	ENSG00000223751.1	AC116609.2	10.7	1.92e-25	1.45e-22	0.42	0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:773257	chr2:742488~747767:+
BRCA	cis	rs4380275	1	rs4380275	ENSG00000223751.1	AC116609.2	10.7	1.92e-25	1.45e-22	0.42	0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:773278	chr2:742488~747767:+
BRCA	cis	rs4380275	1	rs73143802	ENSG00000223751.1	AC116609.2	10.7	1.92e-25	1.45e-22	0.42	0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:773826	chr2:742488~747767:+
BRCA	cis	rs524281	0.682	rs4483592	ENSG00000255320.1	RP11-755F10.1	10.7	1.94e-25	1.46e-22	0.51	0.31	Electroencephalogram traits;	chr11:66222968	chr11:66244840~66246239:-
BRCA	cis	rs10759883	0.563	rs689761	ENSG00000175611.10	LINC00476	-10.7	1.94e-25	1.46e-22	-0.37	-0.31	Nicotine dependence;	chr9:95970902	chr9:95759231~95875977:-
BRCA	cis	rs524281	0.773	rs2155030	ENSG00000255320.1	RP11-755F10.1	10.7	1.95e-25	1.47e-22	0.52	0.31	Electroencephalogram traits;	chr11:66263216	chr11:66244840~66246239:-
BRCA	cis	rs524281	0.773	rs2155031	ENSG00000255320.1	RP11-755F10.1	10.7	1.95e-25	1.47e-22	0.52	0.31	Electroencephalogram traits;	chr11:66263456	chr11:66244840~66246239:-
BRCA	cis	rs6723108	0.517	rs1530557	ENSG00000224043.6	CCNT2-AS1	10.7	1.96e-25	1.47e-22	0.4	0.31	Type 2 diabetes;	chr2:134849309	chr2:134735464~134918710:-
BRCA	cis	rs11673344	0.526	rs57654288	ENSG00000226686.6	LINC01535	10.7	1.97e-25	1.48e-22	0.4	0.31	Obesity-related traits;	chr19:37587870	chr19:37251912~37265535:+
BRCA	cis	rs10740039	0.583	rs1904399	ENSG00000254271.1	RP11-131N11.4	-10.7	1.97e-25	1.48e-22	-0.41	-0.31	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60739240	chr10:60734342~60741828:+
BRCA	cis	rs10740039	0.583	rs1904400	ENSG00000254271.1	RP11-131N11.4	-10.7	1.97e-25	1.48e-22	-0.41	-0.31	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60739361	chr10:60734342~60741828:+
BRCA	cis	rs10740039	0.515	rs9414742	ENSG00000254271.1	RP11-131N11.4	-10.7	1.97e-25	1.48e-22	-0.41	-0.31	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60739769	chr10:60734342~60741828:+
BRCA	cis	rs10740039	0.583	rs9415609	ENSG00000254271.1	RP11-131N11.4	-10.7	1.97e-25	1.48e-22	-0.41	-0.31	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60739832	chr10:60734342~60741828:+
BRCA	cis	rs9322193	0.566	rs3922947	ENSG00000223701.3	RAET1E-AS1	-10.7	1.98e-25	1.49e-22	-0.43	-0.31	Lung cancer;	chr6:149924856	chr6:149884431~149919508:+
BRCA	cis	rs17711722	0.528	rs73138179	ENSG00000236529.1	RP13-254B10.1	10.7	1.98e-25	1.49e-22	0.37	0.31	Calcium levels;	chr7:65829495	chr7:65840212~65840596:+
BRCA	cis	rs524281	0.773	rs10791862	ENSG00000255320.1	RP11-755F10.1	10.7	1.99e-25	1.49e-22	0.51	0.31	Electroencephalogram traits;	chr11:66246193	chr11:66244840~66246239:-
BRCA	cis	rs524281	0.773	rs2155198	ENSG00000255320.1	RP11-755F10.1	10.7	1.99e-25	1.49e-22	0.51	0.31	Electroencephalogram traits;	chr11:66246829	chr11:66244840~66246239:-
BRCA	cis	rs7714584	1	rs12652003	ENSG00000197083.10	ZNF300P1	10.7	1.99e-25	1.49e-22	0.47	0.31	Crohn's disease;	chr5:150852383	chr5:150930645~150946289:-
BRCA	cis	rs10759883	0.539	rs10988755	ENSG00000175611.10	LINC00476	10.7	2.05e-25	1.54e-22	0.37	0.31	Nicotine dependence;	chr9:95944085	chr9:95759231~95875977:-
BRCA	cis	rs10759883	0.587	rs603947	ENSG00000175611.10	LINC00476	10.7	2.05e-25	1.54e-22	0.37	0.31	Nicotine dependence;	chr9:95944647	chr9:95759231~95875977:-
BRCA	cis	rs858239	0.6	rs4628176	ENSG00000226816.2	AC005082.12	10.7	2.07e-25	1.56e-22	0.36	0.31	Cerebrospinal fluid biomarker levels;	chr7:23102947	chr7:23206013~23208045:+
BRCA	cis	rs2581828	0.646	rs12630819	ENSG00000242142.1	SERBP1P3	-10.7	2.07e-25	1.56e-22	-0.39	-0.31	Crohn's disease;	chr3:53123286	chr3:53064283~53065091:-
BRCA	cis	rs2581828	0.646	rs12638996	ENSG00000242142.1	SERBP1P3	-10.7	2.07e-25	1.56e-22	-0.39	-0.31	Crohn's disease;	chr3:53123530	chr3:53064283~53065091:-
BRCA	cis	rs1707322	0.686	rs1547924	ENSG00000280836.1	AL355480.1	-10.7	2.1e-25	1.58e-22	-0.41	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45619440	chr1:45581219~45581321:-
BRCA	cis	rs12134133	1	rs7522618	ENSG00000274245.1	RP11-357P18.2	10.7	2.11e-25	1.58e-22	0.42	0.31	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207244081	chr1:207372559~207373252:+
BRCA	cis	rs12134133	1	rs11580382	ENSG00000274245.1	RP11-357P18.2	10.7	2.11e-25	1.58e-22	0.42	0.31	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207245047	chr1:207372559~207373252:+
BRCA	cis	rs524281	0.861	rs10791854	ENSG00000255320.1	RP11-755F10.1	10.69	2.11e-25	1.59e-22	0.47	0.31	Electroencephalogram traits;	chr11:66196072	chr11:66244840~66246239:-
BRCA	cis	rs2739330	0.76	rs1002286	ENSG00000099984.9	GSTT2	10.69	2.13e-25	1.6e-22	0.38	0.31	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23980123~23983911:+
BRCA	cis	rs17023223	0.553	rs11484962	ENSG00000231365.4	RP11-418J17.1	-10.69	2.13e-25	1.6e-22	-0.4	-0.31	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119182563	chr1:119140396~119275973:+
BRCA	cis	rs17023223	0.537	rs55836852	ENSG00000231365.4	RP11-418J17.1	-10.69	2.13e-25	1.6e-22	-0.4	-0.31	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119182778	chr1:119140396~119275973:+
BRCA	cis	rs17023223	0.537	rs66715579	ENSG00000231365.4	RP11-418J17.1	-10.69	2.13e-25	1.6e-22	-0.4	-0.31	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119182809	chr1:119140396~119275973:+
BRCA	cis	rs17023223	0.537	rs11487668	ENSG00000231365.4	RP11-418J17.1	-10.69	2.13e-25	1.6e-22	-0.4	-0.31	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119184173	chr1:119140396~119275973:+
BRCA	cis	rs17023223	0.537	rs10923766	ENSG00000231365.4	RP11-418J17.1	-10.69	2.13e-25	1.6e-22	-0.4	-0.31	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119184309	chr1:119140396~119275973:+
BRCA	cis	rs7945705	0.747	rs2568045	ENSG00000254860.4	TMEM9B-AS1	10.69	2.14e-25	1.61e-22	0.28	0.31	Hemoglobin concentration;	chr11:8982513	chr11:8964675~8977527:+
BRCA	cis	rs10129255	0.912	rs61997792	ENSG00000211970.3	IGHV4-61	-10.69	2.17e-25	1.63e-22	-0.23	-0.31	Kawasaki disease;	chr14:106799304	chr14:106639119~106639657:-
BRCA	cis	rs6452524	0.935	rs5000997	ENSG00000249664.1	CTD-2227C6.2	10.69	2.17e-25	1.63e-22	0.39	0.31	Hypertension (SNP x SNP interaction);	chr5:83164248	chr5:83012285~83013109:-
BRCA	cis	rs2581828	0.646	rs6783748	ENSG00000242142.1	SERBP1P3	-10.69	2.2e-25	1.65e-22	-0.39	-0.31	Crohn's disease;	chr3:53119415	chr3:53064283~53065091:-
BRCA	cis	rs2404602	0.735	rs56246286	ENSG00000259422.1	RP11-593F23.1	-10.69	2.2e-25	1.65e-22	-0.41	-0.31	Blood metabolite levels;	chr15:76398390	chr15:76174891~76181486:-
BRCA	cis	rs8040855	0.52	rs67613323	ENSG00000259295.5	CSPG4P12	10.69	2.22e-25	1.66e-22	0.48	0.31	Bulimia nervosa;	chr15:84986541	chr15:85191438~85213905:+
BRCA	cis	rs4380275	1	rs6548253	ENSG00000223751.1	AC116609.2	10.69	2.23e-25	1.67e-22	0.42	0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:773655	chr2:742488~747767:+
BRCA	cis	rs6142102	0.646	rs2223553	ENSG00000276073.1	RP5-1125A11.7	-10.69	2.25e-25	1.69e-22	-0.37	-0.31	Skin pigmentation;	chr20:34121638	chr20:33985617~33988989:-
BRCA	cis	rs4713118	0.513	rs156738	ENSG00000220721.1	OR1F12	10.68	2.34e-25	1.75e-22	0.38	0.31	Parkinson's disease;	chr6:28046247	chr6:28073316~28074233:+
BRCA	cis	rs6782228	0.606	rs2712419	ENSG00000242551.2	POU5F1P6	-10.68	2.35e-25	1.76e-22	-0.4	-0.31	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128622053	chr3:128674735~128677005:-
BRCA	cis	rs524281	0.773	rs2236651	ENSG00000255320.1	RP11-755F10.1	10.68	2.4e-25	1.79e-22	0.51	0.31	Electroencephalogram traits;	chr11:66233947	chr11:66244840~66246239:-
BRCA	cis	rs524281	0.773	rs10896105	ENSG00000255320.1	RP11-755F10.1	10.68	2.4e-25	1.79e-22	0.51	0.31	Electroencephalogram traits;	chr11:66234789	chr11:66244840~66246239:-
BRCA	cis	rs2153535	0.607	rs9502722	ENSG00000230939.1	RP11-314C16.1	-10.68	2.4e-25	1.79e-22	-0.38	-0.31	Motion sickness;	chr6:8541250	chr6:8784178~8785445:+
BRCA	cis	rs6782228	0.565	rs11719239	ENSG00000242551.2	POU5F1P6	-10.68	2.41e-25	1.8e-22	-0.39	-0.31	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128700211	chr3:128674735~128677005:-
BRCA	cis	rs524281	0.773	rs11227447	ENSG00000255320.1	RP11-755F10.1	10.68	2.41e-25	1.8e-22	0.52	0.31	Electroencephalogram traits;	chr11:66280809	chr11:66244840~66246239:-
BRCA	cis	rs4423214	0.559	rs7949129	ENSG00000254682.1	RP11-660L16.2	-10.68	2.42e-25	1.81e-22	-0.48	-0.31	Vitamin D levels;	chr11:71482089	chr11:71448674~71452157:+
BRCA	cis	rs6782228	0.606	rs2001950	ENSG00000242551.2	POU5F1P6	-10.68	2.43e-25	1.82e-22	-0.39	-0.31	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128700913	chr3:128674735~128677005:-
BRCA	cis	rs6430553	0.929	rs6430547	ENSG00000224043.6	CCNT2-AS1	10.68	2.44e-25	1.82e-22	0.4	0.31	Blood metabolite levels;	chr2:134854852	chr2:134735464~134918710:-
BRCA	cis	rs1075265	0.584	rs1862121	ENSG00000233266.1	HMGB1P31	10.68	2.45e-25	1.83e-22	0.39	0.31	Chronotype;Morning vs. evening chronotype;	chr2:54058102	chr2:54051334~54051760:+
BRCA	cis	rs6782228	0.606	rs2712417	ENSG00000242551.2	POU5F1P6	-10.68	2.46e-25	1.84e-22	-0.4	-0.31	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128626336	chr3:128674735~128677005:-
BRCA	cis	rs17711722	0.503	rs453835	ENSG00000226824.5	RP4-756H11.3	10.68	2.49e-25	1.85e-22	0.4	0.31	Calcium levels;	chr7:66046172	chr7:66654538~66669855:+
BRCA	cis	rs2188561	0.806	rs2712210	ENSG00000241764.3	AC002467.7	10.68	2.49e-25	1.86e-22	0.44	0.31	Alcohol consumption;	chr7:107687407	chr7:107742817~107744581:-
BRCA	cis	rs9545047	0.604	rs1856997	ENSG00000227676.3	LINC01068	10.68	2.53e-25	1.89e-22	0.39	0.31	Schizophrenia;	chr13:79287487	chr13:79566727~79571436:+
BRCA	cis	rs17023223	0.553	rs56234947	ENSG00000231365.4	RP11-418J17.1	-10.68	2.56e-25	1.91e-22	-0.4	-0.31	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119165121	chr1:119140396~119275973:+
BRCA	cis	rs2337406	1	rs11845269	ENSG00000274576.2	IGHV2-70	-10.67	2.59e-25	1.93e-22	-0.34	-0.31	Alzheimer's disease (late onset);	chr14:106683851	chr14:106770577~106771020:-
BRCA	cis	rs4713118	0.513	rs202908	ENSG00000220721.1	OR1F12	10.67	2.6e-25	1.94e-22	0.38	0.31	Parkinson's disease;	chr6:28043773	chr6:28073316~28074233:+
BRCA	cis	rs4380275	0.965	rs4315562	ENSG00000223751.1	AC116609.2	10.67	2.61e-25	1.94e-22	0.42	0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:772723	chr2:742488~747767:+
BRCA	cis	rs321358	0.895	rs17457658	ENSG00000271584.1	RP11-89C3.4	10.67	2.62e-25	1.95e-22	0.49	0.31	Body mass index;	chr11:111089448	chr11:111091932~111097357:-
BRCA	cis	rs524281	0.773	rs7925123	ENSG00000255320.1	RP11-755F10.1	10.67	2.65e-25	1.97e-22	0.51	0.31	Electroencephalogram traits;	chr11:66225742	chr11:66244840~66246239:-
BRCA	cis	rs2153535	0.563	rs7739249	ENSG00000230939.1	RP11-314C16.1	-10.67	2.65e-25	1.97e-22	-0.37	-0.31	Motion sickness;	chr6:8534357	chr6:8784178~8785445:+
BRCA	cis	rs10875746	0.624	rs11168498	ENSG00000240399.1	RP1-228P16.1	-10.67	2.71e-25	2.02e-22	-0.43	-0.31	Longevity (90 years and older);	chr12:48261305	chr12:48054813~48055591:-
BRCA	cis	rs12134133	1	rs7518565	ENSG00000274245.1	RP11-357P18.2	10.67	2.71e-25	2.02e-22	0.43	0.31	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207246998	chr1:207372559~207373252:+
BRCA	cis	rs10740039	0.583	rs2170005	ENSG00000254271.1	RP11-131N11.4	10.67	2.71e-25	2.02e-22	0.41	0.31	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60740842	chr10:60734342~60741828:+
BRCA	cis	rs4713118	0.513	rs149959	ENSG00000220721.1	OR1F12	10.67	2.71e-25	2.02e-22	0.38	0.31	Parkinson's disease;	chr6:28046076	chr6:28073316~28074233:+
BRCA	cis	rs11098499	0.909	rs1809406	ENSG00000245958.5	RP11-33B1.1	-10.67	2.74e-25	2.04e-22	-0.3	-0.31	Corneal astigmatism;	chr4:119455967	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.865	rs2389809	ENSG00000245958.5	RP11-33B1.1	-10.67	2.74e-25	2.04e-22	-0.3	-0.31	Corneal astigmatism;	chr4:119456244	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.909	rs9994810	ENSG00000245958.5	RP11-33B1.1	-10.67	2.74e-25	2.04e-22	-0.3	-0.31	Corneal astigmatism;	chr4:119460435	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.697	rs10020027	ENSG00000245958.5	RP11-33B1.1	-10.67	2.74e-25	2.04e-22	-0.3	-0.31	Corneal astigmatism;	chr4:119460724	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.779	rs7356491	ENSG00000245958.5	RP11-33B1.1	-10.67	2.74e-25	2.04e-22	-0.3	-0.31	Corneal astigmatism;	chr4:119460819	chr4:119454791~119552025:+
BRCA	cis	rs2404602	0.647	rs11072626	ENSG00000259422.1	RP11-593F23.1	-10.67	2.75e-25	2.04e-22	-0.41	-0.31	Blood metabolite levels;	chr15:76798485	chr15:76174891~76181486:-
BRCA	cis	rs150992	0.609	rs451141	ENSG00000248489.1	CTD-2007H13.3	-10.67	2.75e-25	2.05e-22	-0.36	-0.31	Body mass index;	chr5:98991691	chr5:98929171~98995013:+
BRCA	cis	rs6452524	0.935	rs6887915	ENSG00000249664.1	CTD-2227C6.2	10.67	2.76e-25	2.05e-22	0.39	0.31	Hypertension (SNP x SNP interaction);	chr5:83170837	chr5:83012285~83013109:-
BRCA	cis	rs75422866	0.867	rs117022227	ENSG00000257433.4	RP1-197B17.3	10.66	2.83e-25	2.1e-22	0.74	0.31	Pneumonia;	chr12:47633282	chr12:47706085~47742294:+
BRCA	cis	rs11105298	0.891	rs10858889	ENSG00000258302.2	RP11-981P6.1	10.66	2.84e-25	2.11e-22	0.36	0.31	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89508827	chr12:89561129~89594878:+
BRCA	cis	rs524281	0.773	rs2155201	ENSG00000255320.1	RP11-755F10.1	10.66	2.84e-25	2.11e-22	0.51	0.31	Electroencephalogram traits;	chr11:66224873	chr11:66244840~66246239:-
BRCA	cis	rs9545047	0.604	rs12865187	ENSG00000227676.3	LINC01068	-10.66	2.85e-25	2.12e-22	-0.37	-0.31	Schizophrenia;	chr13:79316469	chr13:79566727~79571436:+
BRCA	cis	rs6782228	0.606	rs1127030	ENSG00000242551.2	POU5F1P6	-10.66	2.86e-25	2.13e-22	-0.4	-0.31	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128620110	chr3:128674735~128677005:-
BRCA	cis	rs55665837	0.559	rs11023210	ENSG00000251991.1	RNU7-49P	-10.66	2.87e-25	2.13e-22	-0.35	-0.31	Vitamin D levels;	chr11:14401216	chr11:14478892~14478953:+
BRCA	cis	rs2404602	0.684	rs965818	ENSG00000259422.1	RP11-593F23.1	-10.66	2.87e-25	2.14e-22	-0.4	-0.31	Blood metabolite levels;	chr15:76574444	chr15:76174891~76181486:-
BRCA	cis	rs172166	0.637	rs1071893	ENSG00000220721.1	OR1F12	10.66	2.88e-25	2.14e-22	0.37	0.31	Cardiac Troponin-T levels;	chr6:28199857	chr6:28073316~28074233:+
BRCA	cis	rs11098499	0.738	rs72918577	ENSG00000245958.5	RP11-33B1.1	-10.66	2.88e-25	2.14e-22	-0.3	-0.31	Corneal astigmatism;	chr4:119405546	chr4:119454791~119552025:+
BRCA	cis	rs17023223	0.537	rs6677107	ENSG00000231365.4	RP11-418J17.1	-10.66	2.88e-25	2.14e-22	-0.4	-0.31	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119166142	chr1:119140396~119275973:+
BRCA	cis	rs17023223	0.537	rs12064033	ENSG00000231365.4	RP11-418J17.1	-10.66	2.88e-25	2.14e-22	-0.4	-0.31	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119166935	chr1:119140396~119275973:+
BRCA	cis	rs17023223	0.537	rs12064137	ENSG00000231365.4	RP11-418J17.1	-10.66	2.88e-25	2.14e-22	-0.4	-0.31	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119167126	chr1:119140396~119275973:+
BRCA	cis	rs17023223	0.509	rs56195272	ENSG00000231365.4	RP11-418J17.1	-10.66	2.88e-25	2.14e-22	-0.4	-0.31	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119171374	chr1:119140396~119275973:+
BRCA	cis	rs4713118	0.513	rs149958	ENSG00000220721.1	OR1F12	10.66	2.97e-25	2.2e-22	0.38	0.31	Parkinson's disease;	chr6:28045839	chr6:28073316~28074233:+
BRCA	cis	rs2243480	1	rs410128	ENSG00000226824.5	RP4-756H11.3	-10.66	2.99e-25	2.22e-22	-0.64	-0.31	Diabetic kidney disease;	chr7:66138186	chr7:66654538~66669855:+
BRCA	cis	rs2283792	0.935	rs9610375	ENSG00000224086.5	LL22NC03-86G7.1	-10.66	2.99e-25	2.22e-22	-0.33	-0.31	Multiple sclerosis;	chr22:21832804	chr22:21938293~21977632:+
BRCA	cis	rs9322193	0.607	rs6557165	ENSG00000223701.3	RAET1E-AS1	-10.66	3e-25	2.22e-22	-0.41	-0.31	Lung cancer;	chr6:149906883	chr6:149884431~149919508:+
BRCA	cis	rs4423214	0.592	rs79634040	ENSG00000254682.1	RP11-660L16.2	-10.66	3.01e-25	2.23e-22	-0.48	-0.31	Vitamin D levels;	chr11:71519123	chr11:71448674~71452157:+
BRCA	cis	rs2243480	0.901	rs778730	ENSG00000226824.5	RP4-756H11.3	-10.66	3.01e-25	2.23e-22	-0.62	-0.31	Diabetic kidney disease;	chr7:66358338	chr7:66654538~66669855:+
BRCA	cis	rs992157	0.764	rs10932774	ENSG00000261338.2	RP11-378A13.1	10.66	3.02e-25	2.24e-22	0.34	0.31	Colorectal cancer;	chr2:218326846	chr2:218255319~218257366:+
BRCA	cis	rs11105306	1	rs11105306	ENSG00000258302.2	RP11-981P6.1	10.66	3.03e-25	2.25e-22	0.36	0.31	NT-proBNP levels in acute coronary syndrome;	chr12:89503611	chr12:89561129~89594878:+
BRCA	cis	rs2404602	0.552	rs11630185	ENSG00000259422.1	RP11-593F23.1	-10.66	3.08e-25	2.28e-22	-0.46	-0.31	Blood metabolite levels;	chr15:76667442	chr15:76174891~76181486:-
BRCA	cis	rs17023223	0.537	rs12097967	ENSG00000231365.4	RP11-418J17.1	-10.65	3.12e-25	2.31e-22	-0.4	-0.31	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119160290	chr1:119140396~119275973:+
BRCA	cis	rs6570726	0.846	rs7773939	ENSG00000235652.6	RP11-545I5.3	-10.65	3.12e-25	2.31e-22	-0.32	-0.31	Lobe attachment (rater-scored or self-reported);	chr6:145606248	chr6:145799409~145886585:+
BRCA	cis	rs10759883	0.563	rs7847983	ENSG00000175611.10	LINC00476	10.65	3.14e-25	2.32e-22	0.37	0.31	Nicotine dependence;	chr9:95948046	chr9:95759231~95875977:-
BRCA	cis	rs10759883	0.563	rs10819650	ENSG00000175611.10	LINC00476	10.65	3.14e-25	2.32e-22	0.37	0.31	Nicotine dependence;	chr9:95951161	chr9:95759231~95875977:-
BRCA	cis	rs10759883	0.563	rs10760679	ENSG00000175611.10	LINC00476	10.65	3.14e-25	2.32e-22	0.37	0.31	Nicotine dependence;	chr9:95951511	chr9:95759231~95875977:-
BRCA	cis	rs2015599	0.514	rs10843376	ENSG00000275476.1	RP11-996F15.4	10.65	3.15e-25	2.33e-22	0.36	0.31	Platelet count;Mean platelet volume;	chr12:29283651	chr12:29277397~29277882:-
BRCA	cis	rs7945705	0.712	rs61876274	ENSG00000254860.4	TMEM9B-AS1	-10.65	3.15e-25	2.33e-22	-0.29	-0.31	Hemoglobin concentration;	chr11:8997643	chr11:8964675~8977527:+
BRCA	cis	rs1707322	0.721	rs6699418	ENSG00000280836.1	AL355480.1	-10.65	3.18e-25	2.35e-22	-0.4	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634509	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.721	rs4431884	ENSG00000280836.1	AL355480.1	-10.65	3.18e-25	2.35e-22	-0.4	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45635651	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.65	rs4660879	ENSG00000280836.1	AL355480.1	-10.65	3.18e-25	2.35e-22	-0.4	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45639729	chr1:45581219~45581321:-
BRCA	cis	rs9545047	0.604	rs9565487	ENSG00000227676.3	LINC01068	-10.65	3.19e-25	2.36e-22	-0.37	-0.31	Schizophrenia;	chr13:79332742	chr13:79566727~79571436:+
BRCA	cis	rs6430553	0.929	rs6758113	ENSG00000224043.6	CCNT2-AS1	-10.65	3.23e-25	2.39e-22	-0.4	-0.31	Blood metabolite levels;	chr2:134851677	chr2:134735464~134918710:-
BRCA	cis	rs524281	0.773	rs2282568	ENSG00000255320.1	RP11-755F10.1	10.65	3.29e-25	2.43e-22	0.52	0.31	Electroencephalogram traits;	chr11:66285361	chr11:66244840~66246239:-
BRCA	cis	rs524281	0.861	rs2293121	ENSG00000255320.1	RP11-755F10.1	10.65	3.29e-25	2.43e-22	0.47	0.31	Electroencephalogram traits;	chr11:66193876	chr11:66244840~66246239:-
BRCA	cis	rs524281	0.814	rs10896098	ENSG00000255320.1	RP11-755F10.1	10.65	3.29e-25	2.43e-22	0.47	0.31	Electroencephalogram traits;	chr11:66200945	chr11:66244840~66246239:-
BRCA	cis	rs8040855	0.658	rs12909111	ENSG00000259295.5	CSPG4P12	10.65	3.32e-25	2.46e-22	0.41	0.31	Bulimia nervosa;	chr15:85061095	chr15:85191438~85213905:+
BRCA	cis	rs2243480	0.615	rs34363376	ENSG00000226824.5	RP4-756H11.3	-10.65	3.32e-25	2.46e-22	-0.61	-0.31	Diabetic kidney disease;	chr7:66474549	chr7:66654538~66669855:+
BRCA	cis	rs10875746	0.768	rs4760609	ENSG00000240399.1	RP1-228P16.1	10.65	3.32e-25	2.46e-22	0.39	0.31	Longevity (90 years and older);	chr12:48021974	chr12:48054813~48055591:-
BRCA	cis	rs12134133	0.962	rs7516416	ENSG00000274245.1	RP11-357P18.2	10.65	3.34e-25	2.47e-22	0.43	0.31	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207241050	chr1:207372559~207373252:+
BRCA	cis	rs12134133	0.962	rs6673890	ENSG00000274245.1	RP11-357P18.2	10.65	3.34e-25	2.47e-22	0.43	0.31	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207241788	chr1:207372559~207373252:+
BRCA	cis	rs8062405	0.69	rs62034351	ENSG00000278665.1	RP11-666O2.4	10.65	3.34e-25	2.47e-22	0.36	0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554168	chr16:28599241~28601881:-
BRCA	cis	rs6782228	0.606	rs58977394	ENSG00000242551.2	POU5F1P6	-10.65	3.35e-25	2.47e-22	-0.39	-0.31	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128619074	chr3:128674735~128677005:-
BRCA	cis	rs7772486	0.84	rs2474355	ENSG00000235652.6	RP11-545I5.3	10.65	3.35e-25	2.48e-22	0.32	0.31	Lobe attachment (rater-scored or self-reported);	chr6:145991404	chr6:145799409~145886585:+
BRCA	cis	rs10759883	0.539	rs10988817	ENSG00000175611.10	LINC00476	10.65	3.36e-25	2.48e-22	0.37	0.31	Nicotine dependence;	chr9:95960364	chr9:95759231~95875977:-
BRCA	cis	rs7044106	0.537	rs4434680	ENSG00000226752.6	PSMD5-AS1	-10.65	3.36e-25	2.48e-22	-0.4	-0.31	Hip circumference adjusted for BMI;	chr9:120727410	chr9:120824828~120854385:+
BRCA	cis	rs7586673	0.866	rs7579662	ENSG00000227403.1	AC009299.3	-10.65	3.37e-25	2.49e-22	-0.42	-0.31	Intelligence (multi-trait analysis);	chr2:161059299	chr2:161244739~161249050:+
BRCA	cis	rs2581828	0.646	rs13433700	ENSG00000242142.1	SERBP1P3	-10.64	3.44e-25	2.54e-22	-0.39	-0.31	Crohn's disease;	chr3:53113870	chr3:53064283~53065091:-
BRCA	cis	rs524281	0.731	rs2276036	ENSG00000255320.1	RP11-755F10.1	10.64	3.46e-25	2.55e-22	0.52	0.31	Electroencephalogram traits;	chr11:66265959	chr11:66244840~66246239:-
BRCA	cis	rs673078	0.66	rs61945212	ENSG00000275759.1	RP11-131L12.3	-10.64	3.54e-25	2.61e-22	-0.51	-0.31	Glucose homeostasis traits;	chr12:118252351	chr12:118428281~118428870:+
BRCA	cis	rs150992	0.673	rs161747	ENSG00000248489.1	CTD-2007H13.3	-10.64	3.57e-25	2.63e-22	-0.36	-0.31	Body mass index;	chr5:98920433	chr5:98929171~98995013:+
BRCA	cis	rs2153535	0.504	rs5001323	ENSG00000230939.1	RP11-314C16.1	-10.64	3.6e-25	2.66e-22	-0.37	-0.31	Motion sickness;	chr6:8451372	chr6:8784178~8785445:+
BRCA	cis	rs9399135	0.507	rs7766963	ENSG00000232876.1	CTA-212D2.2	10.64	3.6e-25	2.66e-22	0.38	0.31	Red blood cell count;	chr6:135111745	chr6:135055033~135060550:+
BRCA	cis	rs10759883	0.563	rs623438	ENSG00000175611.10	LINC00476	10.64	3.62e-25	2.67e-22	0.37	0.31	Nicotine dependence;	chr9:95938114	chr9:95759231~95875977:-
BRCA	cis	rs524281	0.773	rs10791861	ENSG00000255320.1	RP11-755F10.1	10.64	3.63e-25	2.68e-22	0.5	0.31	Electroencephalogram traits;	chr11:66240999	chr11:66244840~66246239:-
BRCA	cis	rs2337406	1	rs17113257	ENSG00000274576.2	IGHV2-70	-10.64	3.68e-25	2.71e-22	-0.34	-0.31	Alzheimer's disease (late onset);	chr14:106679574	chr14:106770577~106771020:-
BRCA	cis	rs2243480	1	rs67536397	ENSG00000226824.5	RP4-756H11.3	-10.64	3.7e-25	2.72e-22	-0.61	-0.31	Diabetic kidney disease;	chr7:66482930	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs58669269	ENSG00000226824.5	RP4-756H11.3	-10.64	3.7e-25	2.72e-22	-0.61	-0.31	Diabetic kidney disease;	chr7:66486966	chr7:66654538~66669855:+
BRCA	cis	rs17023223	0.581	rs11811859	ENSG00000231365.4	RP11-418J17.1	-10.64	3.74e-25	2.75e-22	-0.4	-0.31	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119165057	chr1:119140396~119275973:+
BRCA	cis	rs10256972	0.967	rs1881122	ENSG00000229043.2	AC091729.9	-10.64	3.75e-25	2.76e-22	-0.4	-0.31	Endometriosis;Longevity;	chr7:1001310	chr7:1160374~1165267:+
BRCA	cis	rs1707322	0.686	rs3014242	ENSG00000280836.1	AL355480.1	10.64	3.78e-25	2.78e-22	0.41	0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45621905	chr1:45581219~45581321:-
BRCA	cis	rs801193	0.569	rs35070132	ENSG00000222364.1	RNU6-96P	-10.63	3.78e-25	2.78e-22	-0.37	-0.31	Aortic root size;	chr7:66773096	chr7:66395191~66395286:+
BRCA	cis	rs2739330	0.761	rs5760176	ENSG00000099984.9	GSTT2	10.63	3.81e-25	2.8e-22	0.38	0.31	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23980123~23983911:+
BRCA	cis	rs2404602	0.735	rs2454450	ENSG00000259422.1	RP11-593F23.1	-10.63	3.84e-25	2.82e-22	-0.4	-0.31	Blood metabolite levels;	chr15:76538895	chr15:76174891~76181486:-
BRCA	cis	rs11105298	0.891	rs10777162	ENSG00000258302.2	RP11-981P6.1	10.63	3.87e-25	2.84e-22	0.35	0.31	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89436746	chr12:89561129~89594878:+
BRCA	cis	rs7945705	0.747	rs11042150	ENSG00000254860.4	TMEM9B-AS1	10.63	3.88e-25	2.85e-22	0.28	0.31	Hemoglobin concentration;	chr11:8989272	chr11:8964675~8977527:+
BRCA	cis	rs4713118	0.513	rs156739	ENSG00000220721.1	OR1F12	10.63	3.96e-25	2.91e-22	0.38	0.31	Parkinson's disease;	chr6:28045632	chr6:28073316~28074233:+
BRCA	cis	rs1707322	0.686	rs3014239	ENSG00000280836.1	AL355480.1	10.63	3.99e-25	2.93e-22	0.41	0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45624129	chr1:45581219~45581321:-
BRCA	cis	rs11098499	0.908	rs28499576	ENSG00000245958.5	RP11-33B1.1	-10.63	4e-25	2.94e-22	-0.3	-0.31	Corneal astigmatism;	chr4:119465522	chr4:119454791~119552025:+
BRCA	cis	rs6782228	0.606	rs2811489	ENSG00000242551.2	POU5F1P6	10.63	4.03e-25	2.96e-22	0.39	0.31	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128618528	chr3:128674735~128677005:-
BRCA	cis	rs17507216	0.518	rs1877240	ENSG00000278603.1	RP13-608F4.5	10.63	4.03e-25	2.96e-22	0.56	0.31	Excessive daytime sleepiness;	chr15:82770126	chr15:82472203~82472426:+
BRCA	cis	rs2243480	0.711	rs2460426	ENSG00000226824.5	RP4-756H11.3	10.63	4.1e-25	3.01e-22	0.61	0.31	Diabetic kidney disease;	chr7:66158142	chr7:66654538~66669855:+
BRCA	cis	rs524281	0.861	rs2177053	ENSG00000255320.1	RP11-755F10.1	10.63	4.12e-25	3.02e-22	0.47	0.31	Electroencephalogram traits;	chr11:66198674	chr11:66244840~66246239:-
BRCA	cis	rs12134133	1	rs11580387	ENSG00000274245.1	RP11-357P18.2	10.63	4.13e-25	3.03e-22	0.42	0.31	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207245063	chr1:207372559~207373252:+
BRCA	cis	rs7044106	0.762	rs10760110	ENSG00000226752.6	PSMD5-AS1	10.62	4.18e-25	3.06e-22	0.38	0.31	Hip circumference adjusted for BMI;	chr9:120650285	chr9:120824828~120854385:+
BRCA	cis	rs673078	0.66	rs73205531	ENSG00000275759.1	RP11-131L12.3	-10.62	4.2e-25	3.08e-22	-0.52	-0.31	Glucose homeostasis traits;	chr12:118282063	chr12:118428281~118428870:+
BRCA	cis	rs1707322	0.717	rs2275086	ENSG00000280836.1	AL355480.1	10.62	4.22e-25	3.09e-22	0.4	0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45620207	chr1:45581219~45581321:-
BRCA	cis	rs12134133	1	rs4844588	ENSG00000274245.1	RP11-357P18.2	10.62	4.23e-25	3.1e-22	0.42	0.31	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207256323	chr1:207372559~207373252:+
BRCA	cis	rs1707322	0.686	rs1541131	ENSG00000280836.1	AL355480.1	10.62	4.25e-25	3.12e-22	0.4	0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45619262	chr1:45581219~45581321:-
BRCA	cis	rs75422866	0.867	rs73102140	ENSG00000257433.4	RP1-197B17.3	10.62	4.28e-25	3.14e-22	0.74	0.31	Pneumonia;	chr12:47647497	chr12:47706085~47742294:+
BRCA	cis	rs75422866	0.867	rs73102148	ENSG00000257433.4	RP1-197B17.3	10.62	4.28e-25	3.14e-22	0.74	0.31	Pneumonia;	chr12:47648013	chr12:47706085~47742294:+
BRCA	cis	rs75422866	0.867	rs73102151	ENSG00000257433.4	RP1-197B17.3	10.62	4.28e-25	3.14e-22	0.74	0.31	Pneumonia;	chr12:47648023	chr12:47706085~47742294:+
BRCA	cis	rs7044106	0.537	rs10739573	ENSG00000226752.6	PSMD5-AS1	-10.62	4.33e-25	3.17e-22	-0.4	-0.31	Hip circumference adjusted for BMI;	chr9:120727540	chr9:120824828~120854385:+
BRCA	cis	rs321358	0.895	rs7950087	ENSG00000271584.1	RP11-89C3.4	-10.62	4.33e-25	3.17e-22	-0.52	-0.31	Body mass index;	chr11:111082536	chr11:111091932~111097357:-
BRCA	cis	rs75422866	0.867	rs73102188	ENSG00000257433.4	RP1-197B17.3	10.62	4.34e-25	3.18e-22	0.74	0.31	Pneumonia;	chr12:47662993	chr12:47706085~47742294:+
BRCA	cis	rs75422866	0.867	rs73102195	ENSG00000257433.4	RP1-197B17.3	10.62	4.34e-25	3.18e-22	0.74	0.31	Pneumonia;	chr12:47666309	chr12:47706085~47742294:+
BRCA	cis	rs75422866	0.867	rs73102201	ENSG00000257433.4	RP1-197B17.3	10.62	4.34e-25	3.18e-22	0.74	0.31	Pneumonia;	chr12:47669269	chr12:47706085~47742294:+
BRCA	cis	rs75422866	0.867	rs73104104	ENSG00000257433.4	RP1-197B17.3	10.62	4.34e-25	3.18e-22	0.74	0.31	Pneumonia;	chr12:47671986	chr12:47706085~47742294:+
BRCA	cis	rs75422866	0.867	rs73104111	ENSG00000257433.4	RP1-197B17.3	10.62	4.34e-25	3.18e-22	0.74	0.31	Pneumonia;	chr12:47673994	chr12:47706085~47742294:+
BRCA	cis	rs2015599	0.623	rs10843385	ENSG00000275476.1	RP11-996F15.4	-10.62	4.34e-25	3.18e-22	-0.37	-0.31	Platelet count;Mean platelet volume;	chr12:29323100	chr12:29277397~29277882:-
BRCA	cis	rs2581828	0.646	rs9878875	ENSG00000242142.1	SERBP1P3	-10.62	4.35e-25	3.19e-22	-0.38	-0.31	Crohn's disease;	chr3:53122851	chr3:53064283~53065091:-
BRCA	cis	rs10256972	0.967	rs7799110	ENSG00000229043.2	AC091729.9	-10.62	4.35e-25	3.19e-22	-0.39	-0.31	Endometriosis;Longevity;	chr7:999429	chr7:1160374~1165267:+
BRCA	cis	rs10740039	0.583	rs9415608	ENSG00000254271.1	RP11-131N11.4	-10.62	4.36e-25	3.19e-22	-0.42	-0.31	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60737680	chr10:60734342~60741828:+
BRCA	cis	rs524281	0.773	rs4393319	ENSG00000255320.1	RP11-755F10.1	10.62	4.37e-25	3.2e-22	0.5	0.31	Electroencephalogram traits;	chr11:66234407	chr11:66244840~66246239:-
BRCA	cis	rs524281	0.773	rs2236652	ENSG00000255320.1	RP11-755F10.1	10.62	4.37e-25	3.2e-22	0.5	0.31	Electroencephalogram traits;	chr11:66235210	chr11:66244840~66246239:-
BRCA	cis	rs6782228	0.527	rs2712371	ENSG00000242551.2	POU5F1P6	-10.62	4.38e-25	3.21e-22	-0.39	-0.31	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128627371	chr3:128674735~128677005:-
BRCA	cis	rs2564921	0.73	rs2564929	ENSG00000242142.1	SERBP1P3	-10.62	4.44e-25	3.25e-22	-0.38	-0.31	Height;	chr3:53084188	chr3:53064283~53065091:-
BRCA	cis	rs10759883	0.627	rs12000073	ENSG00000175611.10	LINC00476	10.62	4.45e-25	3.26e-22	0.34	0.31	Nicotine dependence;	chr9:95853844	chr9:95759231~95875977:-
BRCA	cis	rs9487094	0.744	rs12661287	ENSG00000260273.1	RP11-425D10.10	10.62	4.47e-25	3.27e-22	0.4	0.31	Height;	chr6:109732047	chr6:109382795~109383666:+
BRCA	cis	rs2243480	0.708	rs13242216	ENSG00000226824.5	RP4-756H11.3	-10.62	4.48e-25	3.28e-22	-0.61	-0.31	Diabetic kidney disease;	chr7:66433290	chr7:66654538~66669855:+
BRCA	cis	rs2442825	0.693	rs2596916	ENSG00000206573.7	THUMPD3-AS1	10.62	4.51e-25	3.3e-22	0.28	0.31	Cerebrospinal fluid clusterin levels;	chr3:9380526	chr3:9349689~9398579:-
BRCA	cis	rs473651	0.935	rs508483	ENSG00000229915.1	AC016999.2	-10.62	4.57e-25	3.34e-22	-0.39	-0.31	Multiple system atrophy;	chr2:238431068	chr2:238427077~238427729:-
BRCA	cis	rs7772486	0.754	rs4896838	ENSG00000235652.6	RP11-545I5.3	-10.61	4.59e-25	3.35e-22	-0.32	-0.31	Lobe attachment (rater-scored or self-reported);	chr6:145694315	chr6:145799409~145886585:+
BRCA	cis	rs2404602	0.709	rs11072591	ENSG00000259422.1	RP11-593F23.1	10.61	4.63e-25	3.38e-22	0.4	0.31	Blood metabolite levels;	chr15:76357221	chr15:76174891~76181486:-
BRCA	cis	rs1707322	0.686	rs3014236	ENSG00000280836.1	AL355480.1	10.61	4.65e-25	3.4e-22	0.41	0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45625633	chr1:45581219~45581321:-
BRCA	cis	rs7586673	0.866	rs747003	ENSG00000227403.1	AC009299.3	10.61	4.71e-25	3.44e-22	0.42	0.31	Intelligence (multi-trait analysis);	chr2:161059898	chr2:161244739~161249050:+
BRCA	cis	rs11098499	0.738	rs28408407	ENSG00000245958.5	RP11-33B1.1	-10.61	4.8e-25	3.5e-22	-0.3	-0.31	Corneal astigmatism;	chr4:119454875	chr4:119454791~119552025:+
BRCA	cis	rs875971	0.545	rs12670811	ENSG00000226824.5	RP4-756H11.3	-10.61	4.81e-25	3.51e-22	-0.43	-0.31	Aortic root size;	chr7:66358032	chr7:66654538~66669855:+
BRCA	cis	rs10759883	0.539	rs966217	ENSG00000175611.10	LINC00476	10.61	4.81e-25	3.51e-22	0.37	0.31	Nicotine dependence;	chr9:95943247	chr9:95759231~95875977:-
BRCA	cis	rs75422866	0.867	rs35044089	ENSG00000257433.4	RP1-197B17.3	10.61	4.91e-25	3.58e-22	0.73	0.31	Pneumonia;	chr12:47610881	chr12:47706085~47742294:+
BRCA	cis	rs75422866	0.867	rs78912815	ENSG00000257433.4	RP1-197B17.3	10.61	4.91e-25	3.58e-22	0.73	0.31	Pneumonia;	chr12:47612065	chr12:47706085~47742294:+
BRCA	cis	rs12134133	1	rs7532664	ENSG00000274245.1	RP11-357P18.2	10.61	4.95e-25	3.61e-22	0.42	0.31	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207253598	chr1:207372559~207373252:+
BRCA	cis	rs12134133	1	rs55638602	ENSG00000274245.1	RP11-357P18.2	10.61	4.95e-25	3.61e-22	0.42	0.31	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207255597	chr1:207372559~207373252:+
BRCA	cis	rs6782228	0.606	rs2811488	ENSG00000242551.2	POU5F1P6	-10.61	5.04e-25	3.67e-22	-0.4	-0.31	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128617674	chr3:128674735~128677005:-
BRCA	cis	rs7621025	0.5	rs9845460	ENSG00000239213.4	NCK1-AS1	10.6	5.1e-25	3.72e-22	0.39	0.31	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136868275	chr3:136841726~136862054:-
BRCA	cis	rs321358	0.895	rs73015171	ENSG00000271584.1	RP11-89C3.4	10.6	5.12e-25	3.73e-22	0.49	0.31	Body mass index;	chr11:111087535	chr11:111091932~111097357:-
BRCA	cis	rs12134133	0.962	rs6682586	ENSG00000274245.1	RP11-357P18.2	10.6	5.14e-25	3.75e-22	0.43	0.31	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207243122	chr1:207372559~207373252:+
BRCA	cis	rs12134133	0.962	rs6668560	ENSG00000274245.1	RP11-357P18.2	10.6	5.14e-25	3.75e-22	0.43	0.31	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207243462	chr1:207372559~207373252:+
BRCA	cis	rs6782228	0.527	rs2811491	ENSG00000242551.2	POU5F1P6	-10.6	5.18e-25	3.78e-22	-0.4	-0.31	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128635107	chr3:128674735~128677005:-
BRCA	cis	rs2153535	0.563	rs1737585	ENSG00000230939.1	RP11-314C16.1	10.6	5.3e-25	3.86e-22	0.37	0.31	Motion sickness;	chr6:8536361	chr6:8784178~8785445:+
BRCA	cis	rs62103177	0.564	rs1715230	ENSG00000261126.6	RP11-795F19.1	10.6	5.32e-25	3.87e-22	0.4	0.31	Opioid sensitivity;	chr18:80090098	chr18:80046900~80095482:+
BRCA	cis	rs858239	0.601	rs764533	ENSG00000226816.2	AC005082.12	10.6	5.34e-25	3.89e-22	0.37	0.31	Cerebrospinal fluid biomarker levels;	chr7:23114256	chr7:23206013~23208045:+
BRCA	cis	rs4713118	0.513	rs149897	ENSG00000220721.1	OR1F12	10.6	5.34e-25	3.89e-22	0.38	0.31	Parkinson's disease;	chr6:28038872	chr6:28073316~28074233:+
BRCA	cis	rs4713118	0.513	rs156734	ENSG00000220721.1	OR1F12	10.6	5.34e-25	3.89e-22	0.38	0.31	Parkinson's disease;	chr6:28039579	chr6:28073316~28074233:+
BRCA	cis	rs2015599	0.601	rs17715086	ENSG00000275476.1	RP11-996F15.4	-10.6	5.34e-25	3.89e-22	-0.37	-0.31	Platelet count;Mean platelet volume;	chr12:29329073	chr12:29277397~29277882:-
BRCA	cis	rs2581828	0.609	rs73088342	ENSG00000242142.1	SERBP1P3	-10.6	5.34e-25	3.89e-22	-0.38	-0.31	Crohn's disease;	chr3:53117648	chr3:53064283~53065091:-
BRCA	cis	rs7945705	0.747	rs1980428	ENSG00000254860.4	TMEM9B-AS1	-10.6	5.36e-25	3.9e-22	-0.28	-0.31	Hemoglobin concentration;	chr11:8988950	chr11:8964675~8977527:+
BRCA	cis	rs9487094	0.922	rs2236582	ENSG00000260273.1	RP11-425D10.10	-10.6	5.37e-25	3.91e-22	-0.38	-0.31	Height;	chr6:109444615	chr6:109382795~109383666:+
BRCA	cis	rs2153535	0.601	rs4140584	ENSG00000230939.1	RP11-314C16.1	10.6	5.44e-25	3.96e-22	0.37	0.31	Motion sickness;	chr6:8540381	chr6:8784178~8785445:+
BRCA	cis	rs1707322	0.686	rs2230658	ENSG00000280836.1	AL355480.1	10.6	5.47e-25	3.98e-22	0.41	0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613182	chr1:45581219~45581321:-
BRCA	cis	rs11096990	0.552	rs7655170	ENSG00000249207.1	RP11-360F5.1	-10.6	5.5e-25	4e-22	-0.37	-0.31	Cognitive function;	chr4:39171984	chr4:39112677~39126818:-
BRCA	cis	rs8062405	0.824	rs153106	ENSG00000278665.1	RP11-666O2.4	10.6	5.51e-25	4.01e-22	0.32	0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28515576	chr16:28599241~28601881:-
BRCA	cis	rs2243480	1	rs316330	ENSG00000226824.5	RP4-756H11.3	-10.59	5.58e-25	4.05e-22	-0.61	-0.31	Diabetic kidney disease;	chr7:66140385	chr7:66654538~66669855:+
BRCA	cis	rs7772486	0.875	rs2777476	ENSG00000235652.6	RP11-545I5.3	10.59	5.6e-25	4.07e-22	0.32	0.31	Lobe attachment (rater-scored or self-reported);	chr6:146023888	chr6:145799409~145886585:+
BRCA	cis	rs10759883	0.563	rs10819668	ENSG00000175611.10	LINC00476	10.59	5.63e-25	4.09e-22	0.37	0.31	Nicotine dependence;	chr9:95959848	chr9:95759231~95875977:-
BRCA	cis	rs150992	0.587	rs1393210	ENSG00000248489.1	CTD-2007H13.3	-10.59	5.63e-25	4.09e-22	-0.35	-0.31	Body mass index;	chr5:99025892	chr5:98929171~98995013:+
BRCA	cis	rs150992	0.587	rs11242567	ENSG00000248489.1	CTD-2007H13.3	-10.59	5.63e-25	4.09e-22	-0.35	-0.31	Body mass index;	chr5:99028686	chr5:98929171~98995013:+
BRCA	cis	rs1062177	0.756	rs2915827	ENSG00000213433.5	RPLP1P6	10.59	5.66e-25	4.12e-22	0.41	0.31	Preschool internalizing problems;	chr5:151740144	chr5:151765859~151766378:-
BRCA	cis	rs465969	1	rs4509157	ENSG00000255389.1	C6orf3	-10.59	5.68e-25	4.12e-22	-0.55	-0.31	Psoriasis;	chr6:111513875	chr6:111599875~111602295:+
BRCA	cis	rs1075265	0.729	rs10201364	ENSG00000233266.1	HMGB1P31	10.59	5.71e-25	4.14e-22	0.37	0.31	Chronotype;Morning vs. evening chronotype;	chr2:53990220	chr2:54051334~54051760:+
BRCA	cis	rs524281	0.861	rs7946917	ENSG00000255320.1	RP11-755F10.1	10.59	5.77e-25	4.19e-22	0.47	0.31	Electroencephalogram traits;	chr11:66189106	chr11:66244840~66246239:-
BRCA	cis	rs524281	0.861	rs10896094	ENSG00000255320.1	RP11-755F10.1	10.59	5.77e-25	4.19e-22	0.47	0.31	Electroencephalogram traits;	chr11:66191735	chr11:66244840~66246239:-
BRCA	cis	rs473651	0.935	rs541013	ENSG00000229915.1	AC016999.2	-10.59	5.84e-25	4.24e-22	-0.39	-0.31	Multiple system atrophy;	chr2:238427851	chr2:238427077~238427729:-
BRCA	cis	rs10129255	1	rs4612959	ENSG00000211970.3	IGHV4-61	-10.59	5.86e-25	4.25e-22	-0.22	-0.31	Kawasaki disease;	chr14:106767055	chr14:106639119~106639657:-
BRCA	cis	rs1707322	0.717	rs1972410	ENSG00000280836.1	AL355480.1	-10.59	5.92e-25	4.3e-22	-0.4	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45615275	chr1:45581219~45581321:-
BRCA	cis	rs10181042	0.612	rs1177282	ENSG00000271889.1	RP11-493E12.1	10.59	5.98e-25	4.34e-22	0.38	0.31	Crohn's disease;	chr2:61130642	chr2:61151433~61162105:-
BRCA	cis	rs465969	0.744	rs6939657	ENSG00000255389.1	C6orf3	-10.59	5.98e-25	4.34e-22	-0.56	-0.31	Psoriasis;	chr6:111521822	chr6:111599875~111602295:+
BRCA	cis	rs4774565	0.762	rs1056682	ENSG00000244879.4	GABPB1-AS1	-10.59	6.01e-25	4.36e-22	-0.34	-0.31	Breast cancer;	chr15:50368004	chr15:50354959~50372202:+
BRCA	cis	rs694739	1	rs499425	ENSG00000236935.1	AP003774.1	-10.59	6.02e-25	4.37e-22	-0.3	-0.31	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64338457	chr11:64325050~64329504:-
BRCA	cis	rs7772486	0.875	rs2748482	ENSG00000235652.6	RP11-545I5.3	10.59	6.11e-25	4.43e-22	0.31	0.31	Lobe attachment (rater-scored or self-reported);	chr6:146015396	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.875	rs1331637	ENSG00000235652.6	RP11-545I5.3	10.59	6.11e-25	4.43e-22	0.31	0.31	Lobe attachment (rater-scored or self-reported);	chr6:146015951	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.846	rs1331636	ENSG00000235652.6	RP11-545I5.3	10.59	6.11e-25	4.43e-22	0.31	0.31	Lobe attachment (rater-scored or self-reported);	chr6:146017690	chr6:145799409~145886585:+
BRCA	cis	rs4380275	1	rs4268954	ENSG00000223751.1	AC116609.2	10.58	6.16e-25	4.46e-22	0.42	0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:772834	chr2:742488~747767:+
BRCA	cis	rs1823874	0.581	rs12910401	ENSG00000182397.13	DNM1P46	-10.58	6.18e-25	4.48e-22	-0.35	-0.31	IgG glycosylation;	chr15:99799692	chr15:99790156~99806927:-
BRCA	cis	rs11673344	0.548	rs2058852	ENSG00000226686.6	LINC01535	10.58	6.24e-25	4.52e-22	0.4	0.31	Obesity-related traits;	chr19:37673701	chr19:37251912~37265535:+
BRCA	cis	rs7772486	0.875	rs1929523	ENSG00000235652.6	RP11-545I5.3	10.58	6.28e-25	4.55e-22	0.31	0.31	Lobe attachment (rater-scored or self-reported);	chr6:146018853	chr6:145799409~145886585:+
BRCA	cis	rs2549794	0.511	rs27645	ENSG00000248734.2	CTD-2260A17.1	10.58	6.28e-25	4.55e-22	0.32	0.31	Crohn's disease;	chr5:96827736	chr5:96784777~96785999:+
BRCA	cis	rs10740039	0.583	rs4948263	ENSG00000254271.1	RP11-131N11.4	-10.58	6.35e-25	4.59e-22	-0.4	-0.31	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60740132	chr10:60734342~60741828:+
BRCA	cis	rs10740039	0.583	rs4948264	ENSG00000254271.1	RP11-131N11.4	-10.58	6.35e-25	4.59e-22	-0.4	-0.31	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60740484	chr10:60734342~60741828:+
BRCA	cis	rs10740039	0.583	rs4948265	ENSG00000254271.1	RP11-131N11.4	-10.58	6.35e-25	4.59e-22	-0.4	-0.31	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60740495	chr10:60734342~60741828:+
BRCA	cis	rs7772486	0.875	rs2224120	ENSG00000235652.6	RP11-545I5.3	10.58	6.43e-25	4.65e-22	0.31	0.31	Lobe attachment (rater-scored or self-reported);	chr6:146022144	chr6:145799409~145886585:+
BRCA	cis	rs1075265	0.584	rs7558126	ENSG00000233266.1	HMGB1P31	10.58	6.43e-25	4.66e-22	0.38	0.31	Chronotype;Morning vs. evening chronotype;	chr2:54053847	chr2:54051334~54051760:+
BRCA	cis	rs7826238	0.623	rs2976893	ENSG00000253893.2	FAM85B	10.58	6.63e-25	4.79e-22	0.39	0.31	Systolic blood pressure;	chr8:8480709	chr8:8167819~8226614:-
BRCA	cis	rs694739	1	rs11231757	ENSG00000236935.1	AP003774.1	10.58	6.67e-25	4.82e-22	0.3	0.31	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64338845	chr11:64325050~64329504:-
BRCA	cis	rs11105298	0.838	rs4842488	ENSG00000258302.2	RP11-981P6.1	10.58	6.69e-25	4.83e-22	0.36	0.31	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89487787	chr12:89561129~89594878:+
BRCA	cis	rs11105298	0.891	rs6538189	ENSG00000258302.2	RP11-981P6.1	10.58	6.69e-25	4.83e-22	0.36	0.31	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89492146	chr12:89561129~89594878:+
BRCA	cis	rs524281	0.731	rs11227433	ENSG00000255320.1	RP11-755F10.1	10.58	6.74e-25	4.87e-22	0.5	0.31	Electroencephalogram traits;	chr11:66237222	chr11:66244840~66246239:-
BRCA	cis	rs524281	0.861	rs10750779	ENSG00000255320.1	RP11-755F10.1	10.57	6.85e-25	4.94e-22	0.47	0.31	Electroencephalogram traits;	chr11:66207120	chr11:66244840~66246239:-
BRCA	cis	rs11123170	0.542	rs11123169	ENSG00000189223.12	PAX8-AS1	10.57	6.9e-25	4.98e-22	0.45	0.31	Renal function-related traits (BUN);	chr2:113209498	chr2:113211522~113276581:+
BRCA	cis	rs1062177	0.756	rs2915815	ENSG00000213433.5	RPLP1P6	10.57	6.91e-25	4.99e-22	0.4	0.31	Preschool internalizing problems;	chr5:151736322	chr5:151765859~151766378:-
BRCA	cis	rs875971	0.545	rs3735147	ENSG00000226824.5	RP4-756H11.3	-10.57	6.98e-25	5.04e-22	-0.43	-0.31	Aortic root size;	chr7:66505541	chr7:66654538~66669855:+
BRCA	cis	rs75422866	0.867	rs73104103	ENSG00000257433.4	RP1-197B17.3	10.57	7.01e-25	5.06e-22	0.73	0.31	Pneumonia;	chr12:47669604	chr12:47706085~47742294:+
BRCA	cis	rs801193	0.548	rs6975044	ENSG00000222364.1	RNU6-96P	-10.57	7.1e-25	5.12e-22	-0.36	-0.31	Aortic root size;	chr7:66762495	chr7:66395191~66395286:+
BRCA	cis	rs524281	0.861	rs10750780	ENSG00000255320.1	RP11-755F10.1	10.57	7.11e-25	5.12e-22	0.47	0.31	Electroencephalogram traits;	chr11:66207121	chr11:66244840~66246239:-
BRCA	cis	rs11690935	0.595	rs788171	ENSG00000228389.1	AC068039.4	-10.57	7.15e-25	5.15e-22	-0.38	-0.31	Schizophrenia;	chr2:172057104	chr2:171773482~171775844:+
BRCA	cis	rs4713118	0.513	rs149941	ENSG00000220721.1	OR1F12	10.57	7.21e-25	5.2e-22	0.38	0.31	Parkinson's disease;	chr6:28033255	chr6:28073316~28074233:+
BRCA	cis	rs6539288	0.63	rs3759316	ENSG00000260329.1	RP11-412D9.4	-10.57	7.21e-25	5.2e-22	-0.35	-0.31	Total body bone mineral density;	chr12:106976432	chr12:106954029~106955497:-
BRCA	cis	rs2581828	0.659	rs9845352	ENSG00000242142.1	SERBP1P3	-10.57	7.23e-25	5.21e-22	-0.38	-0.31	Crohn's disease;	chr3:53108205	chr3:53064283~53065091:-
BRCA	cis	rs2581828	0.659	rs9845484	ENSG00000242142.1	SERBP1P3	-10.57	7.23e-25	5.21e-22	-0.38	-0.31	Crohn's disease;	chr3:53108240	chr3:53064283~53065091:-
BRCA	cis	rs11096990	0.593	rs35552004	ENSG00000249207.1	RP11-360F5.1	-10.57	7.28e-25	5.25e-22	-0.37	-0.31	Cognitive function;	chr4:39170914	chr4:39112677~39126818:-
BRCA	cis	rs11603023	0.772	rs540800	ENSG00000255422.1	AP002954.4	-10.57	7.34e-25	5.28e-22	-0.37	-0.31	Cholesterol, total;	chr11:118694942	chr11:118704607~118750263:+
BRCA	cis	rs783540	0.846	rs2099259	ENSG00000278603.1	RP13-608F4.5	10.57	7.38e-25	5.32e-22	0.39	0.31	Schizophrenia;	chr15:82654937	chr15:82472203~82472426:+
BRCA	cis	rs34779708	0.733	rs3853672	ENSG00000230534.5	RP11-297A16.2	10.57	7.41e-25	5.34e-22	0.39	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35260678	chr10:35098006~35127020:-
BRCA	cis	rs10740039	0.583	rs7917700	ENSG00000254271.1	RP11-131N11.4	-10.56	7.43e-25	5.35e-22	-0.4	-0.31	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60740596	chr10:60734342~60741828:+
BRCA	cis	rs17711722	0.565	rs73372653	ENSG00000224316.1	RP11-479O9.2	10.56	7.45e-25	5.36e-22	0.32	0.31	Calcium levels;	chr7:65977808	chr7:65773620~65802067:+
BRCA	cis	rs12922040	1	rs12922040	ENSG00000263335.1	AF001548.5	-10.56	7.47e-25	5.38e-22	-0.37	-0.31	Serum uric acid levels in response to allopurinol in gout;	chr16:15775609	chr16:15726674~15732993:+
BRCA	cis	rs11723261	0.582	rs6830247	ENSG00000275426.1	CH17-262A2.1	10.56	7.49e-25	5.39e-22	0.44	0.31	Immune response to smallpox vaccine (IL-6);	chr4:156885	chr4:149738~150317:+
BRCA	cis	rs8062405	0.755	rs17707300	ENSG00000278665.1	RP11-666O2.4	10.56	7.51e-25	5.4e-22	0.33	0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28582026	chr16:28599241~28601881:-
BRCA	cis	rs4713118	0.513	rs149972	ENSG00000220721.1	OR1F12	10.56	7.55e-25	5.43e-22	0.38	0.31	Parkinson's disease;	chr6:28015449	chr6:28073316~28074233:+
BRCA	cis	rs4713118	0.513	rs149975	ENSG00000220721.1	OR1F12	10.56	7.55e-25	5.43e-22	0.38	0.31	Parkinson's disease;	chr6:28018562	chr6:28073316~28074233:+
BRCA	cis	rs783540	0.846	rs783539	ENSG00000278603.1	RP13-608F4.5	-10.56	7.64e-25	5.5e-22	-0.39	-0.31	Schizophrenia;	chr15:82585320	chr15:82472203~82472426:+
BRCA	cis	rs1823874	0.581	rs12905599	ENSG00000182397.13	DNM1P46	-10.56	7.65e-25	5.5e-22	-0.36	-0.31	IgG glycosylation;	chr15:99799733	chr15:99790156~99806927:-
BRCA	cis	rs1075265	0.87	rs7569214	ENSG00000233266.1	HMGB1P31	10.56	7.65e-25	5.51e-22	0.37	0.31	Chronotype;Morning vs. evening chronotype;	chr2:53989049	chr2:54051334~54051760:+
BRCA	cis	rs1113500	0.565	rs1777455	ENSG00000226822.1	RP11-356N1.2	-10.56	7.76e-25	5.58e-22	-0.45	-0.31	Growth-regulated protein alpha levels;	chr1:108047666	chr1:108071482~108074519:+
BRCA	cis	rs2404602	0.647	rs7165053	ENSG00000259422.1	RP11-593F23.1	-10.56	7.82e-25	5.62e-22	-0.4	-0.31	Blood metabolite levels;	chr15:76686577	chr15:76174891~76181486:-
BRCA	cis	rs8072100	0.967	rs12452315	ENSG00000228782.6	CTD-2026D20.3	-10.56	7.83e-25	5.63e-22	-0.33	-0.31	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47402080	chr17:47450568~47492492:-
BRCA	cis	rs6142102	0.625	rs4911384	ENSG00000276073.1	RP5-1125A11.7	-10.56	7.88e-25	5.66e-22	-0.36	-0.31	Skin pigmentation;	chr20:33968001	chr20:33985617~33988989:-
BRCA	cis	rs11098499	0.954	rs13107475	ENSG00000245958.5	RP11-33B1.1	-10.56	8.11e-25	5.82e-22	-0.3	-0.31	Corneal astigmatism;	chr4:119471856	chr4:119454791~119552025:+
BRCA	cis	rs783540	0.874	rs10468217	ENSG00000278603.1	RP13-608F4.5	-10.55	8.22e-25	5.9e-22	-0.39	-0.31	Schizophrenia;	chr15:82579329	chr15:82472203~82472426:+
BRCA	cis	rs1862618	0.573	rs832532	ENSG00000271828.1	CTD-2310F14.1	10.55	8.28e-25	5.94e-22	0.45	0.31	Initial pursuit acceleration;	chr5:56926111	chr5:56927874~56929573:+
BRCA	cis	rs875971	0.545	rs1796226	ENSG00000226824.5	RP4-756H11.3	-10.55	8.32e-25	5.97e-22	-0.42	-0.31	Aortic root size;	chr7:66622723	chr7:66654538~66669855:+
BRCA	cis	rs7772486	0.875	rs2748498	ENSG00000235652.6	RP11-545I5.3	10.55	8.34e-25	5.98e-22	0.31	0.31	Lobe attachment (rater-scored or self-reported);	chr6:145998030	chr6:145799409~145886585:+
BRCA	cis	rs9368481	0.743	rs9368480	ENSG00000241549.7	GUSBP2	10.55	8.38e-25	6.01e-22	0.36	0.31	Autism spectrum disorder or schizophrenia;	chr6:26987971	chr6:26871484~26956554:-
BRCA	cis	rs1707322	0.656	rs2991981	ENSG00000280836.1	AL355480.1	10.55	8.38e-25	6.01e-22	0.4	0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45591472	chr1:45581219~45581321:-
BRCA	cis	rs2276314	1	rs2298715	ENSG00000278986.1	RP11-723J4.3	-10.55	8.63e-25	6.19e-22	-0.4	-0.31	Endometriosis;Drug-induced torsades de pointes;	chr18:35972462	chr18:35972151~35973916:+
BRCA	cis	rs2276314	1	rs4573997	ENSG00000278986.1	RP11-723J4.3	-10.55	8.63e-25	6.19e-22	-0.4	-0.31	Endometriosis;Drug-induced torsades de pointes;	chr18:35972605	chr18:35972151~35973916:+
BRCA	cis	rs1707322	0.721	rs4660883	ENSG00000280836.1	AL355480.1	-10.55	8.65e-25	6.2e-22	-0.4	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45770426	chr1:45581219~45581321:-
BRCA	cis	rs6565180	1	rs8049108	ENSG00000273724.1	RP11-347C12.12	-10.55	8.68e-25	6.22e-22	-0.35	-0.31	Tonsillectomy;	chr16:30365165	chr16:30336400~30343336:+
BRCA	cis	rs11105298	0.891	rs10858881	ENSG00000258302.2	RP11-981P6.1	10.55	8.76e-25	6.27e-22	0.35	0.31	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89497697	chr12:89561129~89594878:+
BRCA	cis	rs1499614	0.901	rs2178742	ENSG00000226824.5	RP4-756H11.3	-10.55	8.77e-25	6.28e-22	-0.62	-0.31	Gout;	chr7:66732812	chr7:66654538~66669855:+
BRCA	cis	rs1707322	0.721	rs6429574	ENSG00000280836.1	AL355480.1	-10.54	9.07e-25	6.48e-22	-0.39	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45668382	chr1:45581219~45581321:-
BRCA	cis	rs10875746	0.537	rs4760625	ENSG00000240399.1	RP1-228P16.1	-10.54	9.1e-25	6.5e-22	-0.43	-0.31	Longevity (90 years and older);	chr12:48279960	chr12:48054813~48055591:-
BRCA	cis	rs1707322	0.686	rs2230659	ENSG00000280836.1	AL355480.1	10.54	9.12e-25	6.52e-22	0.4	0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613212	chr1:45581219~45581321:-
BRCA	cis	rs7567389	0.74	rs4536600	ENSG00000236682.1	AC068282.3	-10.54	9.14e-25	6.53e-22	-0.42	-0.31	Self-rated health;	chr2:127244996	chr2:127389130~127400580:+
BRCA	cis	rs2581828	0.646	rs3796351	ENSG00000242142.1	SERBP1P3	10.54	9.14e-25	6.53e-22	0.39	0.31	Crohn's disease;	chr3:53122049	chr3:53064283~53065091:-
BRCA	cis	rs2404602	0.735	rs2461871	ENSG00000259422.1	RP11-593F23.1	-10.54	9.17e-25	6.55e-22	-0.4	-0.31	Blood metabolite levels;	chr15:76530077	chr15:76174891~76181486:-
BRCA	cis	rs2404602	0.552	rs11636612	ENSG00000259422.1	RP11-593F23.1	-10.54	9.2e-25	6.57e-22	-0.45	-0.31	Blood metabolite levels;	chr15:76667189	chr15:76174891~76181486:-
BRCA	cis	rs1891275	0.515	rs10881957	ENSG00000228701.1	TNKS2-AS1	-10.54	9.25e-25	6.61e-22	-0.36	-0.31	Intelligence (multi-trait analysis);	chr10:91742119	chr10:91782839~91798291:-
BRCA	cis	rs2243480	0.803	rs36127118	ENSG00000226824.5	RP4-756H11.3	-10.54	9.41e-25	6.72e-22	-0.6	-0.31	Diabetic kidney disease;	chr7:66100518	chr7:66654538~66669855:+
BRCA	cis	rs17023223	0.537	rs12083510	ENSG00000231365.4	RP11-418J17.1	-10.54	9.48e-25	6.77e-22	-0.4	-0.31	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119203997	chr1:119140396~119275973:+
BRCA	cis	rs7580658	0.864	rs4150441	ENSG00000236682.1	AC068282.3	-10.54	9.66e-25	6.89e-22	-0.41	-0.31	Protein C levels;	chr2:127283339	chr2:127389130~127400580:+
BRCA	cis	rs4713118	0.513	rs149989	ENSG00000220721.1	OR1F12	10.54	9.73e-25	6.94e-22	0.38	0.31	Parkinson's disease;	chr6:28030406	chr6:28073316~28074233:+
BRCA	cis	rs1707322	0.721	rs10789468	ENSG00000280836.1	AL355480.1	-10.54	9.78e-25	6.97e-22	-0.39	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45658886	chr1:45581219~45581321:-
BRCA	cis	rs2455601	0.679	rs2653559	ENSG00000254860.4	TMEM9B-AS1	10.54	9.88e-25	7.04e-22	0.35	0.31	Schizophrenia;	chr11:8878847	chr11:8964675~8977527:+
BRCA	cis	rs1707322	0.686	rs2991977	ENSG00000280836.1	AL355480.1	10.53	9.93e-25	7.08e-22	0.4	0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45588011	chr1:45581219~45581321:-
BRCA	cis	rs10875746	0.669	rs11168510	ENSG00000240399.1	RP1-228P16.1	-10.53	9.97e-25	7.11e-22	-0.43	-0.31	Longevity (90 years and older);	chr12:48291772	chr12:48054813~48055591:-
BRCA	cis	rs2404602	0.662	rs908817	ENSG00000259422.1	RP11-593F23.1	-10.53	9.99e-25	7.12e-22	-0.41	-0.31	Blood metabolite levels;	chr15:76346850	chr15:76174891~76181486:-
BRCA	cis	rs11098499	0.954	rs3733520	ENSG00000245958.5	RP11-33B1.1	-10.53	1e-24	7.13e-22	-0.3	-0.31	Corneal astigmatism;	chr4:119502325	chr4:119454791~119552025:+
BRCA	cis	rs733592	0.507	rs10875739	ENSG00000240399.1	RP1-228P16.1	10.53	1.01e-24	7.18e-22	0.33	0.31	Plateletcrit;	chr12:48087136	chr12:48054813~48055591:-
BRCA	cis	rs8040855	0.627	rs11632899	ENSG00000259295.5	CSPG4P12	10.53	1.02e-24	7.24e-22	0.41	0.31	Bulimia nervosa;	chr15:85057609	chr15:85191438~85213905:+
BRCA	cis	rs7772486	0.875	rs2474353	ENSG00000235652.6	RP11-545I5.3	10.53	1.03e-24	7.33e-22	0.31	0.31	Lobe attachment (rater-scored or self-reported);	chr6:146002747	chr6:145799409~145886585:+
BRCA	cis	rs524281	0.861	rs10791858	ENSG00000255320.1	RP11-755F10.1	10.53	1.03e-24	7.36e-22	0.47	0.31	Electroencephalogram traits;	chr11:66210925	chr11:66244840~66246239:-
BRCA	cis	rs524281	0.817	rs10791859	ENSG00000255320.1	RP11-755F10.1	10.53	1.03e-24	7.36e-22	0.47	0.31	Electroencephalogram traits;	chr11:66210982	chr11:66244840~66246239:-
BRCA	cis	rs2276314	1	rs1540042	ENSG00000278986.1	RP11-723J4.3	-10.53	1.03e-24	7.37e-22	-0.39	-0.31	Endometriosis;Drug-induced torsades de pointes;	chr18:35975273	chr18:35972151~35973916:+
BRCA	cis	rs1075265	0.84	rs2884254	ENSG00000233266.1	HMGB1P31	10.53	1.06e-24	7.51e-22	0.37	0.31	Chronotype;Morning vs. evening chronotype;	chr2:53979326	chr2:54051334~54051760:+
BRCA	cis	rs6538678	0.824	rs4762633	ENSG00000258343.1	RP11-536G4.2	-10.53	1.06e-24	7.55e-22	-0.48	-0.31	Lupus nephritis in systemic lupus erythematosus;	chr12:95860295	chr12:95795345~95858839:-
BRCA	cis	rs10129255	0.913	rs10140943	ENSG00000211970.3	IGHV4-61	-10.53	1.08e-24	7.71e-22	-0.23	-0.31	Kawasaki disease;	chr14:106767441	chr14:106639119~106639657:-
BRCA	cis	rs35160687	0.712	rs11127020	ENSG00000273080.1	RP11-301O19.1	-10.53	1.09e-24	7.75e-22	-0.37	-0.31	Night sleep phenotypes;	chr2:86247421	chr2:86195590~86196049:+
BRCA	cis	rs2243480	1	rs160646	ENSG00000226824.5	RP4-756H11.3	-10.52	1.1e-24	7.81e-22	-0.61	-0.31	Diabetic kidney disease;	chr7:66091293	chr7:66654538~66669855:+
BRCA	cis	rs75422866	0.867	rs73113139	ENSG00000257433.4	RP1-197B17.3	10.52	1.1e-24	7.84e-22	0.73	0.31	Pneumonia;	chr12:47622826	chr12:47706085~47742294:+
BRCA	cis	rs75422866	0.717	rs73113159	ENSG00000257433.4	RP1-197B17.3	10.52	1.1e-24	7.84e-22	0.73	0.31	Pneumonia;	chr12:47631318	chr12:47706085~47742294:+
BRCA	cis	rs75422866	0.717	rs73113161	ENSG00000257433.4	RP1-197B17.3	10.52	1.1e-24	7.84e-22	0.73	0.31	Pneumonia;	chr12:47632361	chr12:47706085~47742294:+
BRCA	cis	rs2581828	0.659	rs4282053	ENSG00000242142.1	SERBP1P3	-10.52	1.11e-24	7.85e-22	-0.39	-0.31	Crohn's disease;	chr3:53107949	chr3:53064283~53065091:-
BRCA	cis	rs875971	0.545	rs11767262	ENSG00000226824.5	RP4-756H11.3	-10.52	1.11e-24	7.86e-22	-0.43	-0.31	Aortic root size;	chr7:66302237	chr7:66654538~66669855:+
BRCA	cis	rs2404602	0.735	rs3765115	ENSG00000259422.1	RP11-593F23.1	-10.52	1.11e-24	7.87e-22	-0.4	-0.31	Blood metabolite levels;	chr15:76381375	chr15:76174891~76181486:-
BRCA	cis	rs7772486	0.79	rs1854900	ENSG00000235652.6	RP11-545I5.3	10.52	1.11e-24	7.89e-22	0.31	0.31	Lobe attachment (rater-scored or self-reported);	chr6:146010246	chr6:145799409~145886585:+
BRCA	cis	rs2739330	0.731	rs5751792	ENSG00000099984.9	GSTT2	-10.52	1.11e-24	7.89e-22	-0.38	-0.31	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23980123~23983911:+
BRCA	cis	rs875971	0.545	rs66594357	ENSG00000226824.5	RP4-756H11.3	-10.52	1.11e-24	7.89e-22	-0.43	-0.31	Aortic root size;	chr7:66327797	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.545	rs1796217	ENSG00000226824.5	RP4-756H11.3	10.52	1.12e-24	7.93e-22	0.43	0.31	Aortic root size;	chr7:66620931	chr7:66654538~66669855:+
BRCA	cis	rs11105298	0.891	rs11105309	ENSG00000258302.2	RP11-981P6.1	10.52	1.13e-24	7.99e-22	0.36	0.31	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89516073	chr12:89561129~89594878:+
BRCA	cis	rs11673344	0.704	rs1667384	ENSG00000226686.6	LINC01535	10.52	1.13e-24	8e-22	0.41	0.31	Obesity-related traits;	chr19:36925852	chr19:37251912~37265535:+
BRCA	cis	rs2404602	0.575	rs11072611	ENSG00000259422.1	RP11-593F23.1	10.52	1.14e-24	8.05e-22	0.42	0.31	Blood metabolite levels;	chr15:76655642	chr15:76174891~76181486:-
BRCA	cis	rs2404602	0.735	rs437131	ENSG00000259422.1	RP11-593F23.1	10.52	1.14e-24	8.1e-22	0.39	0.31	Blood metabolite levels;	chr15:76488710	chr15:76174891~76181486:-
BRCA	cis	rs75422866	0.867	rs73104152	ENSG00000257433.4	RP1-197B17.3	10.52	1.14e-24	8.1e-22	0.74	0.31	Pneumonia;	chr12:47699091	chr12:47706085~47742294:+
BRCA	cis	rs75422866	0.867	rs73104155	ENSG00000257433.4	RP1-197B17.3	10.52	1.14e-24	8.1e-22	0.74	0.31	Pneumonia;	chr12:47700790	chr12:47706085~47742294:+
BRCA	cis	rs10759883	0.539	rs10115110	ENSG00000175611.10	LINC00476	10.52	1.14e-24	8.11e-22	0.37	0.31	Nicotine dependence;	chr9:96033023	chr9:95759231~95875977:-
BRCA	cis	rs524281	0.731	rs476551	ENSG00000255320.1	RP11-755F10.1	10.52	1.15e-24	8.14e-22	0.48	0.31	Electroencephalogram traits;	chr11:66238852	chr11:66244840~66246239:-
BRCA	cis	rs8062405	0.723	rs4788077	ENSG00000278665.1	RP11-666O2.4	10.52	1.15e-24	8.16e-22	0.36	0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28558443	chr16:28599241~28601881:-
BRCA	cis	rs858239	0.6	rs10241208	ENSG00000226816.2	AC005082.12	10.52	1.15e-24	8.16e-22	0.35	0.31	Cerebrospinal fluid biomarker levels;	chr7:23105295	chr7:23206013~23208045:+
BRCA	cis	rs1062177	0.855	rs6896664	ENSG00000213433.5	RPLP1P6	-10.52	1.18e-24	8.37e-22	-0.37	-0.31	Preschool internalizing problems;	chr5:151885713	chr5:151765859~151766378:-
BRCA	cis	rs1891275	0.515	rs2153653	ENSG00000228701.1	TNKS2-AS1	-10.52	1.18e-24	8.37e-22	-0.36	-0.31	Intelligence (multi-trait analysis);	chr10:91736169	chr10:91782839~91798291:-
BRCA	cis	rs858239	0.571	rs6953020	ENSG00000226816.2	AC005082.12	10.52	1.18e-24	8.38e-22	0.36	0.31	Cerebrospinal fluid biomarker levels;	chr7:23132513	chr7:23206013~23208045:+
BRCA	cis	rs6921919	0.515	rs1558205	ENSG00000216901.1	AL022393.7	-10.52	1.19e-24	8.41e-22	-0.4	-0.31	Autism spectrum disorder or schizophrenia;	chr6:28414485	chr6:28176188~28176674:+
BRCA	cis	rs7772486	0.846	rs2748499	ENSG00000235652.6	RP11-545I5.3	10.52	1.2e-24	8.51e-22	0.31	0.31	Lobe attachment (rater-scored or self-reported);	chr6:145993866	chr6:145799409~145886585:+
BRCA	cis	rs8062405	0.824	rs62034319	ENSG00000278665.1	RP11-666O2.4	10.51	1.21e-24	8.56e-22	0.32	0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28520867	chr16:28599241~28601881:-
BRCA	cis	rs875971	0.597	rs11763224	ENSG00000226824.5	RP4-756H11.3	-10.51	1.21e-24	8.56e-22	-0.43	-0.31	Aortic root size;	chr7:66518628	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.545	rs75577046	ENSG00000226824.5	RP4-756H11.3	-10.51	1.22e-24	8.61e-22	-0.43	-0.31	Aortic root size;	chr7:66493729	chr7:66654538~66669855:+
BRCA	cis	rs1707322	0.717	rs2253862	ENSG00000280836.1	AL355480.1	10.51	1.22e-24	8.66e-22	0.4	0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45616288	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.717	rs2991988	ENSG00000280836.1	AL355480.1	10.51	1.22e-24	8.66e-22	0.4	0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45616759	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.717	rs2991989	ENSG00000280836.1	AL355480.1	10.51	1.22e-24	8.66e-22	0.4	0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45617293	chr1:45581219~45581321:-
BRCA	cis	rs732716	0.785	rs9973266	ENSG00000267769.1	CTB-50L17.9	-10.51	1.23e-24	8.69e-22	-0.4	-0.31	Mean corpuscular volume;	chr19:4392718	chr19:4454014~4455286:+
BRCA	cis	rs11098499	0.865	rs4001305	ENSG00000245958.5	RP11-33B1.1	-10.51	1.23e-24	8.69e-22	-0.3	-0.31	Corneal astigmatism;	chr4:119438081	chr4:119454791~119552025:+
BRCA	cis	rs35160687	0.644	rs56394965	ENSG00000273080.1	RP11-301O19.1	-10.51	1.23e-24	8.71e-22	-0.35	-0.31	Night sleep phenotypes;	chr2:86271226	chr2:86195590~86196049:+
BRCA	cis	rs2404602	0.552	rs11072613	ENSG00000259422.1	RP11-593F23.1	-10.51	1.24e-24	8.77e-22	-0.44	-0.31	Blood metabolite levels;	chr15:76669185	chr15:76174891~76181486:-
BRCA	cis	rs1113500	0.541	rs11185241	ENSG00000226822.1	RP11-356N1.2	10.51	1.24e-24	8.79e-22	0.45	0.31	Growth-regulated protein alpha levels;	chr1:108040403	chr1:108071482~108074519:+
BRCA	cis	rs524281	0.773	rs2298468	ENSG00000255320.1	RP11-755F10.1	10.51	1.24e-24	8.81e-22	0.51	0.31	Electroencephalogram traits;	chr11:66275491	chr11:66244840~66246239:-
BRCA	cis	rs75422866	0.867	rs79113930	ENSG00000257433.4	RP1-197B17.3	10.51	1.25e-24	8.85e-22	0.73	0.31	Pneumonia;	chr12:47600628	chr12:47706085~47742294:+
BRCA	cis	rs4728142	0.738	rs3807306	ENSG00000275106.1	RP11-309L24.10	10.51	1.25e-24	8.86e-22	0.39	0.31	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128940626	chr7:128952527~128953316:-
BRCA	cis	rs11105298	0.891	rs6538190	ENSG00000258302.2	RP11-981P6.1	10.51	1.26e-24	8.94e-22	0.35	0.31	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89492165	chr12:89561129~89594878:+
BRCA	cis	rs2015599	0.54	rs12301475	ENSG00000275476.1	RP11-996F15.4	10.51	1.28e-24	9.05e-22	0.36	0.31	Platelet count;Mean platelet volume;	chr12:29253144	chr12:29277397~29277882:-
BRCA	cis	rs10875746	0.579	rs10875778	ENSG00000240399.1	RP1-228P16.1	-10.51	1.29e-24	9.11e-22	-0.43	-0.31	Longevity (90 years and older);	chr12:48230872	chr12:48054813~48055591:-
BRCA	cis	rs10875746	0.669	rs10875779	ENSG00000240399.1	RP1-228P16.1	-10.51	1.29e-24	9.11e-22	-0.43	-0.31	Longevity (90 years and older);	chr12:48236086	chr12:48054813~48055591:-
BRCA	cis	rs2015599	0.623	rs3782510	ENSG00000257176.2	RP11-996F15.2	10.51	1.29e-24	9.15e-22	0.36	0.31	Platelet count;Mean platelet volume;	chr12:29301176	chr12:29280418~29317848:-
BRCA	cis	rs812925	0.511	rs11886950	ENSG00000271889.1	RP11-493E12.1	10.51	1.31e-24	9.23e-22	0.37	0.31	Immature fraction of reticulocytes;	chr2:61172182	chr2:61151433~61162105:-
BRCA	cis	rs11673344	0.77	rs34729406	ENSG00000226686.6	LINC01535	10.5	1.33e-24	9.43e-22	0.44	0.31	Obesity-related traits;	chr19:37012764	chr19:37251912~37265535:+
BRCA	cis	rs321358	0.895	rs73015175	ENSG00000271584.1	RP11-89C3.4	10.5	1.34e-24	9.49e-22	0.51	0.31	Body mass index;	chr11:111088593	chr11:111091932~111097357:-
BRCA	cis	rs321358	0.895	rs17536143	ENSG00000271584.1	RP11-89C3.4	10.5	1.34e-24	9.49e-22	0.51	0.31	Body mass index;	chr11:111088619	chr11:111091932~111097357:-
BRCA	cis	rs321358	0.895	rs12419745	ENSG00000271584.1	RP11-89C3.4	10.5	1.34e-24	9.49e-22	0.51	0.31	Body mass index;	chr11:111090741	chr11:111091932~111097357:-
BRCA	cis	rs4713118	0.513	rs149954	ENSG00000220721.1	OR1F12	10.5	1.37e-24	9.66e-22	0.38	0.31	Parkinson's disease;	chr6:28067468	chr6:28073316~28074233:+
BRCA	cis	rs10740039	0.583	rs2127348	ENSG00000254271.1	RP11-131N11.4	-10.5	1.37e-24	9.7e-22	-0.4	-0.31	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60740945	chr10:60734342~60741828:+
BRCA	cis	rs10740039	0.583	rs2127349	ENSG00000254271.1	RP11-131N11.4	-10.5	1.37e-24	9.7e-22	-0.4	-0.31	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60740947	chr10:60734342~60741828:+
BRCA	cis	rs694739	1	rs1783521	ENSG00000236935.1	AP003774.1	10.5	1.39e-24	9.8e-22	0.3	0.31	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64338819	chr11:64325050~64329504:-
BRCA	cis	rs7772486	0.875	rs2180192	ENSG00000235652.6	RP11-545I5.3	10.5	1.4e-24	9.86e-22	0.32	0.31	Lobe attachment (rater-scored or self-reported);	chr6:146001148	chr6:145799409~145886585:+
BRCA	cis	rs7621025	0.5	rs4678275	ENSG00000239213.4	NCK1-AS1	10.5	1.4e-24	9.88e-22	0.39	0.31	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136934841	chr3:136841726~136862054:-
BRCA	cis	rs12134133	0.752	rs4844579	ENSG00000274245.1	RP11-357P18.2	10.5	1.4e-24	9.88e-22	0.46	0.31	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207204546	chr1:207372559~207373252:+
BRCA	cis	rs1707322	0.721	rs10430124	ENSG00000280836.1	AL355480.1	-10.5	1.42e-24	9.99e-22	-0.4	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755945	chr1:45581219~45581321:-
BRCA	cis	rs875971	0.545	rs4718348	ENSG00000226824.5	RP4-756H11.3	-10.5	1.42e-24	1e-21	-0.43	-0.31	Aortic root size;	chr7:66441589	chr7:66654538~66669855:+
BRCA	cis	rs8062405	0.792	rs12446550	ENSG00000278665.1	RP11-666O2.4	10.5	1.43e-24	1.01e-21	0.32	0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28532060	chr16:28599241~28601881:-
BRCA	cis	rs62103177	0.525	rs8086024	ENSG00000261126.6	RP11-795F19.1	-10.5	1.44e-24	1.01e-21	-0.37	-0.31	Opioid sensitivity;	chr18:79986623	chr18:80046900~80095482:+
BRCA	cis	rs2243480	1	rs316313	ENSG00000226824.5	RP4-756H11.3	-10.5	1.45e-24	1.02e-21	-0.6	-0.31	Diabetic kidney disease;	chr7:66128561	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs316312	ENSG00000226824.5	RP4-756H11.3	-10.5	1.45e-24	1.02e-21	-0.6	-0.31	Diabetic kidney disease;	chr7:66131504	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs419603	ENSG00000226824.5	RP4-756H11.3	-10.5	1.45e-24	1.02e-21	-0.6	-0.31	Diabetic kidney disease;	chr7:66132354	chr7:66654538~66669855:+
BRCA	cis	rs34779708	0.733	rs12254018	ENSG00000230534.5	RP11-297A16.2	10.49	1.46e-24	1.03e-21	0.39	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35261713	chr10:35098006~35127020:-
BRCA	cis	rs17023223	0.537	rs12087987	ENSG00000231365.4	RP11-418J17.1	-10.49	1.46e-24	1.03e-21	-0.39	-0.31	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119192198	chr1:119140396~119275973:+
BRCA	cis	rs2243480	1	rs13310597	ENSG00000226824.5	RP4-756H11.3	-10.49	1.46e-24	1.03e-21	-0.6	-0.31	Diabetic kidney disease;	chr7:66133553	chr7:66654538~66669855:+
BRCA	cis	rs992157	0.764	rs13020391	ENSG00000261338.2	RP11-378A13.1	-10.49	1.46e-24	1.03e-21	-0.35	-0.31	Colorectal cancer;	chr2:218319713	chr2:218255319~218257366:+
BRCA	cis	rs17482078	0.959	rs10062964	ENSG00000248734.2	CTD-2260A17.1	10.49	1.46e-24	1.03e-21	0.43	0.31	Behcet's disease;Blood protein levels;	chr5:96803363	chr5:96784777~96785999:+
BRCA	cis	rs17023223	0.537	rs10923759	ENSG00000231365.4	RP11-418J17.1	10.49	1.48e-24	1.04e-21	0.39	0.31	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119149571	chr1:119140396~119275973:+
BRCA	cis	rs473651	0.904	rs508274	ENSG00000229915.1	AC016999.2	-10.49	1.48e-24	1.04e-21	-0.39	-0.31	Multiple system atrophy;	chr2:238429082	chr2:238427077~238427729:-
BRCA	cis	rs2243480	1	rs387676	ENSG00000226824.5	RP4-756H11.3	-10.49	1.49e-24	1.05e-21	-0.6	-0.31	Diabetic kidney disease;	chr7:66133233	chr7:66654538~66669855:+
BRCA	cis	rs2581828	0.632	rs73088322	ENSG00000242142.1	SERBP1P3	-10.49	1.52e-24	1.07e-21	-0.38	-0.31	Crohn's disease;	chr3:53107500	chr3:53064283~53065091:-
BRCA	cis	rs2581828	0.659	rs73088327	ENSG00000242142.1	SERBP1P3	-10.49	1.52e-24	1.07e-21	-0.38	-0.31	Crohn's disease;	chr3:53107533	chr3:53064283~53065091:-
BRCA	cis	rs6142102	0.625	rs9753690	ENSG00000276073.1	RP5-1125A11.7	-10.49	1.52e-24	1.07e-21	-0.36	-0.31	Skin pigmentation;	chr20:33952995	chr20:33985617~33988989:-
BRCA	cis	rs10740039	0.583	rs9415611	ENSG00000254271.1	RP11-131N11.4	-10.49	1.53e-24	1.07e-21	-0.41	-0.31	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60743440	chr10:60734342~60741828:+
BRCA	cis	rs11123170	0.529	rs112692022	ENSG00000274877.1	RP11-65I12.1	-10.49	1.56e-24	1.1e-21	-0.49	-0.31	Renal function-related traits (BUN);	chr2:113212605	chr2:113237595~113240825:+
BRCA	cis	rs2243480	1	rs465359	ENSG00000226824.5	RP4-756H11.3	-10.49	1.57e-24	1.1e-21	-0.6	-0.31	Diabetic kidney disease;	chr7:66093177	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs462853	ENSG00000226824.5	RP4-756H11.3	-10.49	1.57e-24	1.1e-21	-0.6	-0.31	Diabetic kidney disease;	chr7:66093180	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs160644	ENSG00000226824.5	RP4-756H11.3	-10.49	1.57e-24	1.1e-21	-0.6	-0.31	Diabetic kidney disease;	chr7:66093199	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs160642	ENSG00000226824.5	RP4-756H11.3	-10.49	1.57e-24	1.1e-21	-0.6	-0.31	Diabetic kidney disease;	chr7:66093386	chr7:66654538~66669855:+
BRCA	cis	rs2243480	0.614	rs34032527	ENSG00000226824.5	RP4-756H11.3	-10.49	1.57e-24	1.1e-21	-0.6	-0.31	Diabetic kidney disease;	chr7:66100154	chr7:66654538~66669855:+
BRCA	cis	rs10256972	0.521	rs7457418	ENSG00000229043.2	AC091729.9	-10.49	1.57e-24	1.1e-21	-0.38	-0.31	Endometriosis;Longevity;	chr7:1070619	chr7:1160374~1165267:+
BRCA	cis	rs7772486	0.875	rs2814869	ENSG00000235652.6	RP11-545I5.3	10.49	1.58e-24	1.11e-21	0.31	0.31	Lobe attachment (rater-scored or self-reported);	chr6:145994373	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.875	rs2748501	ENSG00000235652.6	RP11-545I5.3	10.49	1.58e-24	1.11e-21	0.31	0.31	Lobe attachment (rater-scored or self-reported);	chr6:145991122	chr6:145799409~145886585:+
BRCA	cis	rs1062177	0.756	rs2915817	ENSG00000213433.5	RPLP1P6	10.49	1.58e-24	1.11e-21	0.39	0.31	Preschool internalizing problems;	chr5:151735956	chr5:151765859~151766378:-
BRCA	cis	rs2581828	0.646	rs9757079	ENSG00000242142.1	SERBP1P3	-10.49	1.59e-24	1.12e-21	-0.38	-0.31	Crohn's disease;	chr3:53121142	chr3:53064283~53065091:-
BRCA	cis	rs75422866	0.867	rs73102168	ENSG00000257433.4	RP1-197B17.3	10.49	1.6e-24	1.12e-21	0.72	0.31	Pneumonia;	chr12:47654010	chr12:47706085~47742294:+
BRCA	cis	rs10129255	0.957	rs6576233	ENSG00000211970.3	IGHV4-61	-10.48	1.63e-24	1.14e-21	-0.22	-0.31	Kawasaki disease;	chr14:106787239	chr14:106639119~106639657:-
BRCA	cis	rs75422866	1	rs73102120	ENSG00000257433.4	RP1-197B17.3	10.48	1.64e-24	1.15e-21	0.72	0.31	Pneumonia;	chr12:47637280	chr12:47706085~47742294:+
BRCA	cis	rs75422866	0.867	rs12422974	ENSG00000257433.4	RP1-197B17.3	10.48	1.64e-24	1.15e-21	0.72	0.31	Pneumonia;	chr12:47644559	chr12:47706085~47742294:+
BRCA	cis	rs75422866	0.867	rs73102127	ENSG00000257433.4	RP1-197B17.3	10.48	1.64e-24	1.15e-21	0.72	0.31	Pneumonia;	chr12:47645341	chr12:47706085~47742294:+
BRCA	cis	rs75422866	0.867	rs73102166	ENSG00000257433.4	RP1-197B17.3	10.48	1.64e-24	1.15e-21	0.72	0.31	Pneumonia;	chr12:47653769	chr12:47706085~47742294:+
BRCA	cis	rs75422866	0.867	rs73102171	ENSG00000257433.4	RP1-197B17.3	10.48	1.64e-24	1.15e-21	0.72	0.31	Pneumonia;	chr12:47656077	chr12:47706085~47742294:+
BRCA	cis	rs75422866	0.867	rs76100981	ENSG00000257433.4	RP1-197B17.3	10.48	1.64e-24	1.15e-21	0.72	0.31	Pneumonia;	chr12:47660092	chr12:47706085~47742294:+
BRCA	cis	rs34779708	0.733	rs7081597	ENSG00000230534.5	RP11-297A16.2	10.48	1.64e-24	1.15e-21	0.38	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35257403	chr10:35098006~35127020:-
BRCA	cis	rs524281	0.861	rs3953856	ENSG00000255320.1	RP11-755F10.1	10.48	1.64e-24	1.15e-21	0.47	0.31	Electroencephalogram traits;	chr11:66198437	chr11:66244840~66246239:-
BRCA	cis	rs524281	0.861	rs2889313	ENSG00000255320.1	RP11-755F10.1	10.48	1.64e-24	1.15e-21	0.47	0.31	Electroencephalogram traits;	chr11:66198595	chr11:66244840~66246239:-
BRCA	cis	rs858239	0.932	rs1728320	ENSG00000226816.2	AC005082.12	10.48	1.65e-24	1.16e-21	0.36	0.31	Cerebrospinal fluid biomarker levels;	chr7:23280170	chr7:23206013~23208045:+
BRCA	cis	rs55665837	0.701	rs1522633	ENSG00000251991.1	RNU7-49P	10.48	1.66e-24	1.16e-21	0.35	0.31	Vitamin D levels;	chr11:14623692	chr11:14478892~14478953:+
BRCA	cis	rs524281	0.861	rs11227411	ENSG00000255320.1	RP11-755F10.1	10.48	1.66e-24	1.16e-21	0.47	0.31	Electroencephalogram traits;	chr11:66112007	chr11:66244840~66246239:-
BRCA	cis	rs34779708	0.766	rs35308730	ENSG00000230534.5	RP11-297A16.2	10.48	1.67e-24	1.17e-21	0.39	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35260868	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.736	rs34195979	ENSG00000230534.5	RP11-297A16.2	10.48	1.67e-24	1.17e-21	0.39	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35260889	chr10:35098006~35127020:-
BRCA	cis	rs6142102	0.625	rs6142068	ENSG00000276073.1	RP5-1125A11.7	10.48	1.68e-24	1.18e-21	0.35	0.31	Skin pigmentation;	chr20:33969366	chr20:33985617~33988989:-
BRCA	cis	rs6558530	0.897	rs10481354	ENSG00000253982.1	CTD-2336O2.1	-10.48	1.69e-24	1.18e-21	-0.34	-0.31	Systolic blood pressure;	chr8:1755864	chr8:1761990~1764502:-
BRCA	cis	rs321358	0.731	rs484021	ENSG00000271584.1	RP11-89C3.4	10.48	1.69e-24	1.19e-21	0.49	0.31	Body mass index;	chr11:111136353	chr11:111091932~111097357:-
BRCA	cis	rs321358	0.731	rs7112075	ENSG00000271584.1	RP11-89C3.4	10.48	1.69e-24	1.19e-21	0.49	0.31	Body mass index;	chr11:111136407	chr11:111091932~111097357:-
BRCA	cis	rs858239	0.6	rs13438188	ENSG00000226816.2	AC005082.12	-10.48	1.71e-24	1.2e-21	-0.35	-0.31	Cerebrospinal fluid biomarker levels;	chr7:23104578	chr7:23206013~23208045:+
BRCA	cis	rs4774565	0.762	rs17431095	ENSG00000244879.4	GABPB1-AS1	-10.48	1.73e-24	1.21e-21	-0.34	-0.31	Breast cancer;	chr15:50369252	chr15:50354959~50372202:+
BRCA	cis	rs7772486	0.905	rs9373486	ENSG00000235652.6	RP11-545I5.3	-10.48	1.74e-24	1.22e-21	-0.31	-0.31	Lobe attachment (rater-scored or self-reported);	chr6:146124888	chr6:145799409~145886585:+
BRCA	cis	rs10129255	0.957	rs10138532	ENSG00000211970.3	IGHV4-61	-10.48	1.74e-24	1.22e-21	-0.23	-0.31	Kawasaki disease;	chr14:106803901	chr14:106639119~106639657:-
BRCA	cis	rs524281	0.861	rs6591207	ENSG00000255320.1	RP11-755F10.1	10.48	1.76e-24	1.23e-21	0.48	0.31	Electroencephalogram traits;	chr11:66182203	chr11:66244840~66246239:-
BRCA	cis	rs11676348	0.967	rs4674258	ENSG00000261338.2	RP11-378A13.1	-10.48	1.76e-24	1.23e-21	-0.32	-0.31	Ulcerative colitis;	chr2:218125863	chr2:218255319~218257366:+
BRCA	cis	rs673078	0.66	rs76621503	ENSG00000275759.1	RP11-131L12.3	-10.47	1.78e-24	1.24e-21	-0.51	-0.31	Glucose homeostasis traits;	chr12:118179370	chr12:118428281~118428870:+
BRCA	cis	rs4380275	1	rs6548253	ENSG00000272342.1	RP13-539J13.1	10.47	1.78e-24	1.25e-21	0.4	0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:773655	chr2:739588~740164:-
BRCA	cis	rs4713118	0.513	rs149942	ENSG00000220721.1	OR1F12	10.47	1.79e-24	1.25e-21	0.38	0.31	Parkinson's disease;	chr6:28033832	chr6:28073316~28074233:+
BRCA	cis	rs4713118	0.513	rs149944	ENSG00000220721.1	OR1F12	10.47	1.79e-24	1.25e-21	0.38	0.31	Parkinson's disease;	chr6:28035040	chr6:28073316~28074233:+
BRCA	cis	rs4713118	0.513	rs149945	ENSG00000220721.1	OR1F12	10.47	1.79e-24	1.25e-21	0.38	0.31	Parkinson's disease;	chr6:28035075	chr6:28073316~28074233:+
BRCA	cis	rs75422866	0.867	rs73104115	ENSG00000257433.4	RP1-197B17.3	10.47	1.79e-24	1.26e-21	0.73	0.31	Pneumonia;	chr12:47684843	chr12:47706085~47742294:+
BRCA	cis	rs75422866	0.867	rs73104116	ENSG00000257433.4	RP1-197B17.3	10.47	1.79e-24	1.26e-21	0.73	0.31	Pneumonia;	chr12:47685023	chr12:47706085~47742294:+
BRCA	cis	rs6142102	0.625	rs2050208	ENSG00000276073.1	RP5-1125A11.7	-10.47	1.8e-24	1.26e-21	-0.36	-0.31	Skin pigmentation;	chr20:33955767	chr20:33985617~33988989:-
BRCA	cis	rs6558530	0.965	rs6558529	ENSG00000253982.1	CTD-2336O2.1	10.47	1.81e-24	1.27e-21	0.34	0.31	Systolic blood pressure;	chr8:1758040	chr8:1761990~1764502:-
BRCA	cis	rs524281	0.861	rs11607393	ENSG00000255320.1	RP11-755F10.1	10.47	1.82e-24	1.28e-21	0.47	0.31	Electroencephalogram traits;	chr11:66107678	chr11:66244840~66246239:-
BRCA	cis	rs2243480	1	rs422164	ENSG00000226824.5	RP4-756H11.3	-10.47	1.87e-24	1.3e-21	-0.6	-0.31	Diabetic kidney disease;	chr7:66121618	chr7:66654538~66669855:+
BRCA	cis	rs1707322	0.721	rs12043945	ENSG00000280836.1	AL355480.1	-10.47	1.9e-24	1.32e-21	-0.4	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45641250	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.721	rs12091503	ENSG00000280836.1	AL355480.1	-10.47	1.9e-24	1.32e-21	-0.4	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45642196	chr1:45581219~45581321:-
BRCA	cis	rs321358	0.895	rs17457076	ENSG00000271584.1	RP11-89C3.4	10.47	1.91e-24	1.33e-21	0.51	0.31	Body mass index;	chr11:111081030	chr11:111091932~111097357:-
BRCA	cis	rs524281	0.861	rs10896080	ENSG00000255320.1	RP11-755F10.1	10.47	1.91e-24	1.33e-21	0.47	0.31	Electroencephalogram traits;	chr11:66109325	chr11:66244840~66246239:-
BRCA	cis	rs858239	0.6	rs6461691	ENSG00000226816.2	AC005082.12	10.46	1.96e-24	1.37e-21	0.35	0.31	Cerebrospinal fluid biomarker levels;	chr7:23099726	chr7:23206013~23208045:+
BRCA	cis	rs2276314	1	rs2298716	ENSG00000278986.1	RP11-723J4.3	-10.46	1.97e-24	1.37e-21	-0.4	-0.31	Endometriosis;Drug-induced torsades de pointes;	chr18:35972635	chr18:35972151~35973916:+
BRCA	cis	rs35160687	0.644	rs4832271	ENSG00000273080.1	RP11-301O19.1	-10.46	1.98e-24	1.38e-21	-0.35	-0.31	Night sleep phenotypes;	chr2:86278204	chr2:86195590~86196049:+
BRCA	cis	rs2404602	0.735	rs2280306	ENSG00000259422.1	RP11-593F23.1	-10.46	1.99e-24	1.39e-21	-0.4	-0.31	Blood metabolite levels;	chr15:76359917	chr15:76174891~76181486:-
BRCA	cis	rs1707322	0.721	rs11211165	ENSG00000280836.1	AL355480.1	-10.46	2.02e-24	1.41e-21	-0.4	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692234	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.721	rs11211166	ENSG00000280836.1	AL355480.1	-10.46	2.02e-24	1.41e-21	-0.4	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692270	chr1:45581219~45581321:-
BRCA	cis	rs10129255	0.957	rs28887506	ENSG00000211970.3	IGHV4-61	-10.46	2.03e-24	1.42e-21	-0.22	-0.31	Kawasaki disease;	chr14:106785589	chr14:106639119~106639657:-
BRCA	cis	rs11673344	0.698	rs56161518	ENSG00000226686.6	LINC01535	10.46	2.04e-24	1.42e-21	0.45	0.31	Obesity-related traits;	chr19:36978555	chr19:37251912~37265535:+
BRCA	cis	rs34779708	0.733	rs12240638	ENSG00000230534.5	RP11-297A16.2	10.46	2.05e-24	1.43e-21	0.38	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35253682	chr10:35098006~35127020:-
BRCA	cis	rs1823913	0.927	rs13025919	ENSG00000227542.1	AC092614.2	10.46	2.05e-24	1.43e-21	0.4	0.31	Obesity-related traits;	chr2:191260175	chr2:191229165~191246172:-
BRCA	cis	rs2019137	0.589	rs7560701	ENSG00000189223.12	PAX8-AS1	-10.46	2.05e-24	1.43e-21	-0.42	-0.31	Lymphocyte counts;	chr2:113269305	chr2:113211522~113276581:+
BRCA	cis	rs1707322	0.721	rs10890333	ENSG00000280836.1	AL355480.1	-10.46	2.06e-24	1.43e-21	-0.4	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634650	chr1:45581219~45581321:-
BRCA	cis	rs7772486	0.875	rs854146	ENSG00000235652.6	RP11-545I5.3	10.46	2.06e-24	1.44e-21	0.31	0.31	Lobe attachment (rater-scored or self-reported);	chr6:146019897	chr6:145799409~145886585:+
BRCA	cis	rs8062405	0.755	rs56272201	ENSG00000278665.1	RP11-666O2.4	10.46	2.06e-24	1.44e-21	0.35	0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28569364	chr16:28599241~28601881:-
BRCA	cis	rs8062405	0.755	rs62034355	ENSG00000278665.1	RP11-666O2.4	10.46	2.06e-24	1.44e-21	0.35	0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28569717	chr16:28599241~28601881:-
BRCA	cis	rs2404602	0.608	rs17361504	ENSG00000259422.1	RP11-593F23.1	10.46	2.07e-24	1.44e-21	0.38	0.31	Blood metabolite levels;	chr15:76309530	chr15:76174891~76181486:-
BRCA	cis	rs10875746	0.669	rs61940962	ENSG00000240399.1	RP1-228P16.1	-10.46	2.08e-24	1.45e-21	-0.42	-0.31	Longevity (90 years and older);	chr12:48201694	chr12:48054813~48055591:-
BRCA	cis	rs1707322	0.721	rs11211157	ENSG00000280836.1	AL355480.1	-10.46	2.1e-24	1.46e-21	-0.4	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45667172	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.721	rs11211158	ENSG00000280836.1	AL355480.1	-10.46	2.1e-24	1.46e-21	-0.4	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45667178	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.721	rs6429575	ENSG00000280836.1	AL355480.1	-10.46	2.1e-24	1.46e-21	-0.4	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45668544	chr1:45581219~45581321:-
BRCA	cis	rs6142102	0.538	rs6142058	ENSG00000276073.1	RP5-1125A11.7	-10.46	2.1e-24	1.46e-21	-0.36	-0.31	Skin pigmentation;	chr20:33954995	chr20:33985617~33988989:-
BRCA	cis	rs7772486	0.727	rs6941429	ENSG00000235652.6	RP11-545I5.3	10.46	2.11e-24	1.47e-21	0.31	0.31	Lobe attachment (rater-scored or self-reported);	chr6:145631147	chr6:145799409~145886585:+
BRCA	cis	rs17711722	0.51	rs11767457	ENSG00000236529.1	RP13-254B10.1	10.46	2.13e-24	1.48e-21	0.35	0.31	Calcium levels;	chr7:65825628	chr7:65840212~65840596:+
BRCA	cis	rs321358	0.731	rs511835	ENSG00000271584.1	RP11-89C3.4	10.45	2.14e-24	1.49e-21	0.49	0.31	Body mass index;	chr11:111145338	chr11:111091932~111097357:-
BRCA	cis	rs34779708	0.733	rs16935945	ENSG00000230534.5	RP11-297A16.2	10.45	2.16e-24	1.5e-21	0.38	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35251392	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.733	rs12777960	ENSG00000230534.5	RP11-297A16.2	10.45	2.16e-24	1.5e-21	0.38	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35252098	chr10:35098006~35127020:-
BRCA	cis	rs858239	0.6	rs4409314	ENSG00000226816.2	AC005082.12	10.45	2.16e-24	1.51e-21	0.35	0.31	Cerebrospinal fluid biomarker levels;	chr7:23088333	chr7:23206013~23208045:+
BRCA	cis	rs7429990	0.965	rs4599334	ENSG00000229759.1	MRPS18AP1	-10.45	2.17e-24	1.51e-21	-0.37	-0.31	Educational attainment (years of education);	chr3:48024910	chr3:48256350~48256938:-
BRCA	cis	rs783540	0.774	rs28415133	ENSG00000278603.1	RP13-608F4.5	-10.45	2.2e-24	1.53e-21	-0.39	-0.31	Schizophrenia;	chr15:82595963	chr15:82472203~82472426:+
BRCA	cis	rs11123170	0.529	rs1015753	ENSG00000274877.1	RP11-65I12.1	-10.45	2.2e-24	1.53e-21	-0.49	-0.31	Renal function-related traits (BUN);	chr2:113211226	chr2:113237595~113240825:+
BRCA	cis	rs6538678	0.963	rs11108310	ENSG00000258343.1	RP11-536G4.2	-10.45	2.21e-24	1.53e-21	-0.44	-0.31	Lupus nephritis in systemic lupus erythematosus;	chr12:95864164	chr12:95795345~95858839:-
BRCA	cis	rs1167827	0.68	rs1167796	ENSG00000127957.15	PMS2P3	10.45	2.22e-24	1.54e-21	0.31	0.31	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75543861	chr7:75502930~75528148:-
BRCA	cis	rs10129255	0.957	rs8014696	ENSG00000211970.3	IGHV4-61	10.45	2.23e-24	1.55e-21	0.21	0.31	Kawasaki disease;	chr14:106769752	chr14:106639119~106639657:-
BRCA	cis	rs8059260	0.604	rs9302458	ENSG00000274038.1	RP11-66H6.4	-10.45	2.24e-24	1.55e-21	-0.44	-0.31	Alcohol consumption over the past year;	chr16:11050352	chr16:11056556~11057034:+
BRCA	cis	rs524281	0.861	rs11227415	ENSG00000255320.1	RP11-755F10.1	-10.45	2.25e-24	1.56e-21	-0.46	-0.31	Electroencephalogram traits;	chr11:66117988	chr11:66244840~66246239:-
BRCA	cis	rs7772486	0.754	rs9386133	ENSG00000235652.6	RP11-545I5.3	10.45	2.26e-24	1.57e-21	0.31	0.31	Lobe attachment (rater-scored or self-reported);	chr6:145820077	chr6:145799409~145886585:+
BRCA	cis	rs10256972	0.685	rs10263665	ENSG00000229043.2	AC091729.9	-10.45	2.26e-24	1.57e-21	-0.38	-0.31	Endometriosis;Longevity;	chr7:1070992	chr7:1160374~1165267:+
BRCA	cis	rs1062177	0.855	rs1346489	ENSG00000213433.5	RPLP1P6	-10.45	2.29e-24	1.59e-21	-0.36	-0.31	Preschool internalizing problems;	chr5:151886973	chr5:151765859~151766378:-
BRCA	cis	rs8040855	0.603	rs10520585	ENSG00000259295.5	CSPG4P12	-10.45	2.3e-24	1.6e-21	-0.46	-0.31	Bulimia nervosa;	chr15:85118275	chr15:85191438~85213905:+
BRCA	cis	rs1707322	0.721	rs10890336	ENSG00000280836.1	AL355480.1	-10.45	2.31e-24	1.6e-21	-0.4	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45645384	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.721	rs11211151	ENSG00000280836.1	AL355480.1	-10.45	2.31e-24	1.6e-21	-0.4	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45647080	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.721	rs12045096	ENSG00000280836.1	AL355480.1	-10.45	2.31e-24	1.6e-21	-0.4	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45648756	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.721	rs4609469	ENSG00000280836.1	AL355480.1	-10.45	2.31e-24	1.6e-21	-0.4	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45651513	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.721	rs12049027	ENSG00000280836.1	AL355480.1	-10.45	2.31e-24	1.6e-21	-0.4	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45652512	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.752	rs10789467	ENSG00000280836.1	AL355480.1	-10.45	2.31e-24	1.6e-21	-0.4	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45653073	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.721	rs10890337	ENSG00000280836.1	AL355480.1	-10.45	2.31e-24	1.6e-21	-0.4	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45658855	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.752	rs3811435	ENSG00000280836.1	AL355480.1	-10.45	2.31e-24	1.6e-21	-0.4	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45660118	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.721	rs9793568	ENSG00000280836.1	AL355480.1	-10.45	2.31e-24	1.6e-21	-0.4	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45664701	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.685	rs6690926	ENSG00000280836.1	AL355480.1	-10.45	2.31e-24	1.6e-21	-0.4	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45669306	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.752	rs8179402	ENSG00000280836.1	AL355480.1	-10.45	2.31e-24	1.6e-21	-0.4	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45676794	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.752	rs8179296	ENSG00000280836.1	AL355480.1	-10.45	2.31e-24	1.6e-21	-0.4	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45678119	chr1:45581219~45581321:-
BRCA	cis	rs11098499	0.954	rs6849171	ENSG00000245958.5	RP11-33B1.1	-10.45	2.33e-24	1.61e-21	-0.3	-0.31	Corneal astigmatism;	chr4:119488394	chr4:119454791~119552025:+
BRCA	cis	rs7617773	0.539	rs12486935	ENSG00000229759.1	MRPS18AP1	10.44	2.35e-24	1.63e-21	0.37	0.31	Coronary artery disease;	chr3:48348674	chr3:48256350~48256938:-
BRCA	cis	rs7714584	1	rs11957134	ENSG00000197083.10	ZNF300P1	-10.44	2.38e-24	1.65e-21	-0.45	-0.31	Crohn's disease;	chr5:150851388	chr5:150930645~150946289:-
BRCA	cis	rs858239	0.601	rs10239760	ENSG00000226816.2	AC005082.12	10.44	2.42e-24	1.68e-21	0.36	0.31	Cerebrospinal fluid biomarker levels;	chr7:23110331	chr7:23206013~23208045:+
BRCA	cis	rs875971	0.545	rs35459055	ENSG00000226824.5	RP4-756H11.3	-10.44	2.44e-24	1.69e-21	-0.43	-0.31	Aortic root size;	chr7:66479399	chr7:66654538~66669855:+
BRCA	cis	rs765787	0.556	rs10851422	ENSG00000259520.4	CTD-2651B20.3	-10.44	2.44e-24	1.69e-21	-0.38	-0.31	Uric acid levels;	chr15:45221540	chr15:45251580~45279251:-
BRCA	cis	rs7772486	0.754	rs702318	ENSG00000235652.6	RP11-545I5.3	-10.44	2.44e-24	1.69e-21	-0.32	-0.31	Lobe attachment (rater-scored or self-reported);	chr6:145684737	chr6:145799409~145886585:+
BRCA	cis	rs10129255	0.957	rs8009073	ENSG00000211970.3	IGHV4-61	-10.44	2.46e-24	1.7e-21	-0.22	-0.31	Kawasaki disease;	chr14:106777278	chr14:106639119~106639657:-
BRCA	cis	rs4380275	1	rs7562792	ENSG00000272342.1	RP13-539J13.1	10.44	2.46e-24	1.71e-21	0.4	0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:774469	chr2:739588~740164:-
BRCA	cis	rs67311347	1	rs1047855	ENSG00000223797.4	ENTPD3-AS1	-10.44	2.47e-24	1.71e-21	-0.38	-0.31	Renal cell carcinoma;	chr3:40427405	chr3:40313802~40453329:-
BRCA	cis	rs34779708	0.733	rs7087099	ENSG00000230534.5	RP11-297A16.2	10.44	2.55e-24	1.77e-21	0.38	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35253054	chr10:35098006~35127020:-
BRCA	cis	rs875971	0.545	rs2420456	ENSG00000226824.5	RP4-756H11.3	-10.44	2.56e-24	1.77e-21	-0.43	-0.31	Aortic root size;	chr7:66280619	chr7:66654538~66669855:+
BRCA	cis	rs6142102	0.602	rs4911380	ENSG00000276073.1	RP5-1125A11.7	-10.44	2.56e-24	1.77e-21	-0.36	-0.31	Skin pigmentation;	chr20:33958418	chr20:33985617~33988989:-
BRCA	cis	rs2524005	1	rs2524005	ENSG00000227766.1	HCG4P5	-10.44	2.56e-24	1.77e-21	-0.52	-0.31	Bipolar disorder and schizophrenia;	chr6:29931900	chr6:29942075~29943067:-
BRCA	cis	rs858239	0.6	rs10266123	ENSG00000226816.2	AC005082.12	10.43	2.59e-24	1.79e-21	0.35	0.31	Cerebrospinal fluid biomarker levels;	chr7:23096868	chr7:23206013~23208045:+
BRCA	cis	rs2404602	0.735	rs11638767	ENSG00000259422.1	RP11-593F23.1	-10.43	2.59e-24	1.79e-21	-0.4	-0.31	Blood metabolite levels;	chr15:76363597	chr15:76174891~76181486:-
BRCA	cis	rs2153535	0.584	rs62395677	ENSG00000230939.1	RP11-314C16.1	10.43	2.59e-24	1.79e-21	0.37	0.31	Motion sickness;	chr6:8371356	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.584	rs62395678	ENSG00000230939.1	RP11-314C16.1	10.43	2.59e-24	1.79e-21	0.37	0.31	Motion sickness;	chr6:8371456	chr6:8784178~8785445:+
BRCA	cis	rs1113500	0.541	rs11185240	ENSG00000226822.1	RP11-356N1.2	10.43	2.62e-24	1.81e-21	0.45	0.31	Growth-regulated protein alpha levels;	chr1:108040188	chr1:108071482~108074519:+
BRCA	cis	rs667920	0.573	rs9682783	ENSG00000239213.4	NCK1-AS1	10.43	2.65e-24	1.83e-21	0.38	0.31	Coronary artery disease;	chr3:136820847	chr3:136841726~136862054:-
BRCA	cis	rs7580658	0.676	rs12465955	ENSG00000236682.1	AC068282.3	-10.43	2.65e-24	1.83e-21	-0.4	-0.31	Protein C levels;	chr2:127249498	chr2:127389130~127400580:+
BRCA	cis	rs34779708	0.649	rs34421369	ENSG00000230534.5	RP11-297A16.2	10.43	2.65e-24	1.83e-21	0.39	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35261347	chr10:35098006~35127020:-
BRCA	cis	rs11673344	0.526	rs17305823	ENSG00000226686.6	LINC01535	-10.43	2.65e-24	1.83e-21	-0.42	-0.31	Obesity-related traits;	chr19:37644145	chr19:37251912~37265535:+
BRCA	cis	rs2153535	0.584	rs55945625	ENSG00000230939.1	RP11-314C16.1	10.43	2.67e-24	1.84e-21	0.37	0.31	Motion sickness;	chr6:8371134	chr6:8784178~8785445:+
BRCA	cis	rs10129255	0.957	rs8009948	ENSG00000211970.3	IGHV4-61	-10.43	2.68e-24	1.85e-21	-0.24	-0.31	Kawasaki disease;	chr14:106805607	chr14:106639119~106639657:-
BRCA	cis	rs11096990	0.593	rs35937374	ENSG00000249207.1	RP11-360F5.1	-10.43	2.7e-24	1.86e-21	-0.37	-0.31	Cognitive function;	chr4:39184735	chr4:39112677~39126818:-
BRCA	cis	rs62034325	0.697	rs710410	ENSG00000278665.1	RP11-666O2.4	10.43	2.72e-24	1.88e-21	0.35	0.31	Body mass index;	chr16:28592021	chr16:28599241~28601881:-
BRCA	cis	rs4713118	0.621	rs9295756	ENSG00000220721.1	OR1F12	10.43	2.72e-24	1.88e-21	0.41	0.31	Parkinson's disease;	chr6:28065618	chr6:28073316~28074233:+
BRCA	cis	rs62103177	0.608	rs551643	ENSG00000261126.6	RP11-795F19.1	-10.43	2.74e-24	1.89e-21	-0.41	-0.31	Opioid sensitivity;	chr18:80081068	chr18:80046900~80095482:+
BRCA	cis	rs7714584	1	rs11167515	ENSG00000197083.10	ZNF300P1	10.43	2.75e-24	1.9e-21	0.46	0.31	Crohn's disease;	chr5:150859909	chr5:150930645~150946289:-
BRCA	cis	rs673078	0.66	rs17440433	ENSG00000275759.1	RP11-131L12.3	-10.43	2.78e-24	1.92e-21	-0.51	-0.31	Glucose homeostasis traits;	chr12:118201507	chr12:118428281~118428870:+
BRCA	cis	rs6142102	0.502	rs58393429	ENSG00000276073.1	RP5-1125A11.7	-10.43	2.81e-24	1.94e-21	-0.35	-0.31	Skin pigmentation;	chr20:33957996	chr20:33985617~33988989:-
BRCA	cis	rs67180937	0.553	rs1498382	ENSG00000272750.1	RP11-378J18.8	10.43	2.81e-24	1.94e-21	0.44	0.31	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222641495	chr1:222658867~222661512:-
BRCA	cis	rs9545047	0.584	rs12871015	ENSG00000227676.3	LINC01068	-10.43	2.83e-24	1.95e-21	-0.37	-0.31	Schizophrenia;	chr13:79333564	chr13:79566727~79571436:+
BRCA	cis	rs17023223	0.537	rs12081327	ENSG00000231365.4	RP11-418J17.1	-10.43	2.83e-24	1.95e-21	-0.39	-0.31	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119143735	chr1:119140396~119275973:+
BRCA	cis	rs7772486	0.754	rs9399567	ENSG00000235652.6	RP11-545I5.3	10.43	2.83e-24	1.95e-21	0.31	0.31	Lobe attachment (rater-scored or self-reported);	chr6:145826159	chr6:145799409~145886585:+
BRCA	cis	rs34779708	0.733	rs60553075	ENSG00000230534.5	RP11-297A16.2	10.43	2.83e-24	1.95e-21	0.38	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35253534	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.733	rs4007271	ENSG00000230534.5	RP11-297A16.2	10.42	2.85e-24	1.96e-21	0.38	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35257683	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.702	rs4007272	ENSG00000230534.5	RP11-297A16.2	10.42	2.85e-24	1.96e-21	0.38	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35257931	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.733	rs4934740	ENSG00000230534.5	RP11-297A16.2	10.42	2.85e-24	1.96e-21	0.38	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35258213	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.702	rs4244995	ENSG00000230534.5	RP11-297A16.2	10.42	2.85e-24	1.96e-21	0.38	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35258247	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.733	rs4244997	ENSG00000230534.5	RP11-297A16.2	10.42	2.85e-24	1.96e-21	0.38	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35258326	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.733	rs4298846	ENSG00000230534.5	RP11-297A16.2	10.42	2.85e-24	1.96e-21	0.38	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35258452	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.733	rs4391768	ENSG00000230534.5	RP11-297A16.2	10.42	2.85e-24	1.96e-21	0.38	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35258667	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.733	rs7914468	ENSG00000230534.5	RP11-297A16.2	10.42	2.85e-24	1.96e-21	0.38	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35259143	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.733	rs7914560	ENSG00000230534.5	RP11-297A16.2	10.42	2.85e-24	1.96e-21	0.38	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35259171	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.733	rs4444023	ENSG00000230534.5	RP11-297A16.2	10.42	2.85e-24	1.96e-21	0.38	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35259426	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.733	rs12243593	ENSG00000230534.5	RP11-297A16.2	10.42	2.85e-24	1.96e-21	0.38	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35260117	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.733	rs3936502	ENSG00000230534.5	RP11-297A16.2	10.42	2.85e-24	1.96e-21	0.38	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35260290	chr10:35098006~35127020:-
BRCA	cis	rs62103177	0.608	rs613847	ENSG00000261126.6	RP11-795F19.1	-10.42	2.86e-24	1.97e-21	-0.41	-0.31	Opioid sensitivity;	chr18:80087736	chr18:80046900~80095482:+
BRCA	cis	rs62103177	0.608	rs34383580	ENSG00000261126.6	RP11-795F19.1	-10.42	2.86e-24	1.97e-21	-0.41	-0.31	Opioid sensitivity;	chr18:80074960	chr18:80046900~80095482:+
BRCA	cis	rs17023223	0.537	rs12081198	ENSG00000231365.4	RP11-418J17.1	-10.42	2.87e-24	1.97e-21	-0.39	-0.31	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119143481	chr1:119140396~119275973:+
BRCA	cis	rs34779708	0.733	rs7070778	ENSG00000230534.5	RP11-297A16.2	10.42	2.87e-24	1.98e-21	0.38	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35252760	chr10:35098006~35127020:-
BRCA	cis	rs4713118	0.513	rs149955	ENSG00000220721.1	OR1F12	10.42	2.88e-24	1.98e-21	0.37	0.31	Parkinson's disease;	chr6:28068447	chr6:28073316~28074233:+
BRCA	cis	rs4380275	1	rs4450634	ENSG00000272342.1	RP13-539J13.1	10.42	2.88e-24	1.99e-21	0.39	0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:773257	chr2:739588~740164:-
BRCA	cis	rs4380275	1	rs4380275	ENSG00000272342.1	RP13-539J13.1	10.42	2.88e-24	1.99e-21	0.39	0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:773278	chr2:739588~740164:-
BRCA	cis	rs4380275	1	rs73143802	ENSG00000272342.1	RP13-539J13.1	10.42	2.88e-24	1.99e-21	0.39	0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:773826	chr2:739588~740164:-
BRCA	cis	rs2243480	1	rs160633	ENSG00000226824.5	RP4-756H11.3	-10.42	2.9e-24	1.99e-21	-0.62	-0.31	Diabetic kidney disease;	chr7:66063241	chr7:66654538~66669855:+
BRCA	cis	rs10256972	0.9	rs7812072	ENSG00000229043.2	AC091729.9	-10.42	2.92e-24	2.01e-21	-0.4	-0.31	Endometriosis;Longevity;	chr7:1014226	chr7:1160374~1165267:+
BRCA	cis	rs4713118	0.621	rs4713132	ENSG00000220721.1	OR1F12	10.42	2.94e-24	2.02e-21	0.41	0.31	Parkinson's disease;	chr6:28066257	chr6:28073316~28074233:+
BRCA	cis	rs4713118	0.621	rs4713133	ENSG00000220721.1	OR1F12	10.42	2.94e-24	2.02e-21	0.41	0.31	Parkinson's disease;	chr6:28066263	chr6:28073316~28074233:+
BRCA	cis	rs4713118	0.621	rs4713134	ENSG00000220721.1	OR1F12	10.42	2.94e-24	2.02e-21	0.41	0.31	Parkinson's disease;	chr6:28066343	chr6:28073316~28074233:+
BRCA	cis	rs2243480	1	rs464895	ENSG00000226824.5	RP4-756H11.3	-10.42	2.96e-24	2.03e-21	-0.63	-0.31	Diabetic kidney disease;	chr7:66062119	chr7:66654538~66669855:+
BRCA	cis	rs8062405	1	rs7187776	ENSG00000251417.2	RP11-1348G14.4	-10.42	2.98e-24	2.05e-21	-0.34	-0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28846324	chr16:28802743~28817828:+
BRCA	cis	rs2404602	0.53	rs11072614	ENSG00000259422.1	RP11-593F23.1	-10.42	3e-24	2.06e-21	-0.43	-0.31	Blood metabolite levels;	chr15:76674864	chr15:76174891~76181486:-
BRCA	cis	rs34779708	0.706	rs36027395	ENSG00000230534.5	RP11-297A16.2	10.42	3.01e-24	2.07e-21	0.39	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35261395	chr10:35098006~35127020:-
BRCA	cis	rs11105298	0.891	rs10858879	ENSG00000258302.2	RP11-981P6.1	-10.42	3.02e-24	2.07e-21	-0.35	-0.31	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89492801	chr12:89561129~89594878:+
BRCA	cis	rs35160687	0.644	rs28488524	ENSG00000273080.1	RP11-301O19.1	-10.42	3.05e-24	2.1e-21	-0.35	-0.31	Night sleep phenotypes;	chr2:86284021	chr2:86195590~86196049:+
BRCA	cis	rs10875746	0.669	rs61941003	ENSG00000240399.1	RP1-228P16.1	-10.42	3.08e-24	2.11e-21	-0.43	-0.31	Longevity (90 years and older);	chr12:48225842	chr12:48054813~48055591:-
BRCA	cis	rs8062405	0.824	rs240702	ENSG00000278665.1	RP11-666O2.4	10.42	3.08e-24	2.11e-21	0.32	0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28520032	chr16:28599241~28601881:-
BRCA	cis	rs2549794	0.537	rs34755	ENSG00000248734.2	CTD-2260A17.1	-10.42	3.1e-24	2.13e-21	-0.31	-0.31	Crohn's disease;	chr5:96816057	chr5:96784777~96785999:+
BRCA	cis	rs3096299	0.967	rs2911257	ENSG00000274627.1	RP11-104N10.2	10.41	3.12e-24	2.14e-21	0.31	0.31	Multiple myeloma (IgH translocation);	chr16:89417726	chr16:89516797~89522217:+
BRCA	cis	rs62103177	0.525	rs612913	ENSG00000261126.6	RP11-795F19.1	-10.41	3.12e-24	2.14e-21	-0.41	-0.31	Opioid sensitivity;	chr18:80087974	chr18:80046900~80095482:+
BRCA	cis	rs58873874	0.737	rs78738433	ENSG00000251405.2	CTB-109A12.1	10.41	3.12e-24	2.14e-21	0.79	0.31	Bipolar disorder (body mass index interaction);	chr5:157386503	chr5:157362615~157460078:-
BRCA	cis	rs2243480	0.706	rs34466769	ENSG00000226824.5	RP4-756H11.3	-10.41	3.13e-24	2.14e-21	-0.51	-0.31	Diabetic kidney disease;	chr7:65988305	chr7:66654538~66669855:+
BRCA	cis	rs67180937	0.553	rs2133188	ENSG00000272750.1	RP11-378J18.8	10.41	3.14e-24	2.15e-21	0.43	0.31	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222640411	chr1:222658867~222661512:-
BRCA	cis	rs11098499	0.954	rs12510138	ENSG00000245958.5	RP11-33B1.1	-10.41	3.15e-24	2.16e-21	-0.3	-0.31	Corneal astigmatism;	chr4:119502780	chr4:119454791~119552025:+
BRCA	cis	rs34779708	0.733	rs3936503	ENSG00000230534.5	RP11-297A16.2	-10.41	3.17e-24	2.17e-21	-0.38	-0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35260329	chr10:35098006~35127020:-
BRCA	cis	rs11098499	0.618	rs35265692	ENSG00000245958.5	RP11-33B1.1	-10.41	3.19e-24	2.18e-21	-0.3	-0.31	Corneal astigmatism;	chr4:119403980	chr4:119454791~119552025:+
BRCA	cis	rs6921919	0.583	rs35560946	ENSG00000216901.1	AL022393.7	10.41	3.19e-24	2.19e-21	0.4	0.31	Autism spectrum disorder or schizophrenia;	chr6:28427660	chr6:28176188~28176674:+
BRCA	cis	rs10759883	0.627	rs10739622	ENSG00000175611.10	LINC00476	10.41	3.22e-24	2.21e-21	0.34	0.31	Nicotine dependence;	chr9:95852889	chr9:95759231~95875977:-
BRCA	cis	rs10759883	0.627	rs10760269	ENSG00000175611.10	LINC00476	10.41	3.22e-24	2.21e-21	0.34	0.31	Nicotine dependence;	chr9:95852897	chr9:95759231~95875977:-
BRCA	cis	rs34779708	0.733	rs7086715	ENSG00000230534.5	RP11-297A16.2	10.41	3.22e-24	2.21e-21	0.38	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35252912	chr10:35098006~35127020:-
BRCA	cis	rs524281	0.861	rs7941431	ENSG00000255320.1	RP11-755F10.1	10.41	3.23e-24	2.21e-21	0.46	0.31	Electroencephalogram traits;	chr11:66192686	chr11:66244840~66246239:-
BRCA	cis	rs4964805	0.594	rs751448	ENSG00000257681.1	RP11-341G23.4	10.41	3.24e-24	2.22e-21	0.38	0.31	Attention deficit hyperactivity disorder;	chr12:103773407	chr12:103746315~103768858:-
BRCA	cis	rs6142102	0.602	rs6141435	ENSG00000276073.1	RP5-1125A11.7	-10.41	3.25e-24	2.22e-21	-0.35	-0.31	Skin pigmentation;	chr20:33963473	chr20:33985617~33988989:-
BRCA	cis	rs1075265	0.584	rs1833497	ENSG00000233266.1	HMGB1P31	10.41	3.28e-24	2.25e-21	0.38	0.31	Chronotype;Morning vs. evening chronotype;	chr2:54052186	chr2:54051334~54051760:+
BRCA	cis	rs321358	0.731	rs536679	ENSG00000271584.1	RP11-89C3.4	10.41	3.29e-24	2.25e-21	0.49	0.31	Body mass index;	chr11:111142497	chr11:111091932~111097357:-
BRCA	cis	rs321358	0.731	rs502584	ENSG00000271584.1	RP11-89C3.4	10.41	3.29e-24	2.25e-21	0.49	0.31	Body mass index;	chr11:111142620	chr11:111091932~111097357:-
BRCA	cis	rs4380275	1	rs4359695	ENSG00000272342.1	RP13-539J13.1	10.41	3.3e-24	2.26e-21	0.39	0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:774214	chr2:739588~740164:-
BRCA	cis	rs4380275	0.931	rs4538239	ENSG00000272342.1	RP13-539J13.1	10.41	3.3e-24	2.26e-21	0.39	0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:774238	chr2:739588~740164:-
BRCA	cis	rs6142102	0.58	rs9753679	ENSG00000276073.1	RP5-1125A11.7	-10.41	3.3e-24	2.26e-21	-0.36	-0.31	Skin pigmentation;	chr20:33953054	chr20:33985617~33988989:-
BRCA	cis	rs17711722	0.503	rs453835	ENSG00000236529.1	RP13-254B10.1	-10.41	3.31e-24	2.26e-21	-0.35	-0.31	Calcium levels;	chr7:66046172	chr7:65840212~65840596:+
BRCA	cis	rs2404602	0.735	rs2048856	ENSG00000259422.1	RP11-593F23.1	-10.41	3.33e-24	2.28e-21	-0.4	-0.31	Blood metabolite levels;	chr15:76507742	chr15:76174891~76181486:-
BRCA	cis	rs4713118	0.513	rs1225591	ENSG00000220721.1	OR1F12	10.41	3.33e-24	2.28e-21	0.38	0.31	Parkinson's disease;	chr6:28180974	chr6:28073316~28074233:+
BRCA	cis	rs1062177	0.756	rs2915826	ENSG00000213433.5	RPLP1P6	10.41	3.37e-24	2.31e-21	0.4	0.31	Preschool internalizing problems;	chr5:151740402	chr5:151765859~151766378:-
BRCA	cis	rs1062177	0.756	rs2964587	ENSG00000213433.5	RPLP1P6	10.41	3.37e-24	2.31e-21	0.4	0.31	Preschool internalizing problems;	chr5:151740411	chr5:151765859~151766378:-
BRCA	cis	rs524281	0.861	rs7929909	ENSG00000255320.1	RP11-755F10.1	10.41	3.4e-24	2.33e-21	0.46	0.31	Electroencephalogram traits;	chr11:66184227	chr11:66244840~66246239:-
BRCA	cis	rs1707322	0.656	rs3014210	ENSG00000280836.1	AL355480.1	10.41	3.41e-24	2.33e-21	0.39	0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45600936	chr1:45581219~45581321:-
BRCA	cis	rs2276314	1	rs4799832	ENSG00000278986.1	RP11-723J4.3	-10.4	3.44e-24	2.35e-21	-0.39	-0.31	Endometriosis;Drug-induced torsades de pointes;	chr18:35979683	chr18:35972151~35973916:+
BRCA	cis	rs10129255	1	rs10129407	ENSG00000211970.3	IGHV4-61	-10.4	3.44e-24	2.35e-21	-0.22	-0.31	Kawasaki disease;	chr14:106767956	chr14:106639119~106639657:-
BRCA	cis	rs11098499	0.866	rs72676074	ENSG00000245958.5	RP11-33B1.1	-10.4	3.45e-24	2.36e-21	-0.3	-0.31	Corneal astigmatism;	chr4:119438686	chr4:119454791~119552025:+
BRCA	cis	rs7580658	0.75	rs4497825	ENSG00000236682.1	AC068282.3	-10.4	3.48e-24	2.38e-21	-0.4	-0.31	Protein C levels;	chr2:127303477	chr2:127389130~127400580:+
BRCA	cis	rs11105298	0.891	rs11105314	ENSG00000258302.2	RP11-981P6.1	10.4	3.5e-24	2.39e-21	0.35	0.31	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89530782	chr12:89561129~89594878:+
BRCA	cis	rs2404602	0.684	rs3910756	ENSG00000259422.1	RP11-593F23.1	-10.4	3.57e-24	2.44e-21	-0.42	-0.31	Blood metabolite levels;	chr15:76653028	chr15:76174891~76181486:-
BRCA	cis	rs11673344	0.665	rs74435359	ENSG00000226686.6	LINC01535	10.4	3.57e-24	2.44e-21	0.44	0.31	Obesity-related traits;	chr19:36955252	chr19:37251912~37265535:+
BRCA	cis	rs1707322	0.721	rs10890343	ENSG00000280836.1	AL355480.1	-10.4	3.59e-24	2.45e-21	-0.39	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692250	chr1:45581219~45581321:-
BRCA	cis	rs10129255	0.744	rs28517388	ENSG00000211970.3	IGHV4-61	-10.4	3.6e-24	2.46e-21	-0.24	-0.31	Kawasaki disease;	chr14:106704323	chr14:106639119~106639657:-
BRCA	cis	rs2665103	0.589	rs2134046	ENSG00000278603.1	RP13-608F4.5	10.4	3.61e-24	2.47e-21	0.41	0.31	Intelligence (multi-trait analysis);	chr15:82232203	chr15:82472203~82472426:+
BRCA	cis	rs858239	0.601	rs12539331	ENSG00000226816.2	AC005082.12	10.4	3.62e-24	2.47e-21	0.36	0.31	Cerebrospinal fluid biomarker levels;	chr7:23111711	chr7:23206013~23208045:+
BRCA	cis	rs34779708	0.733	rs11010146	ENSG00000230534.5	RP11-297A16.2	10.4	3.63e-24	2.48e-21	0.38	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35252633	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.702	rs7087150	ENSG00000230534.5	RP11-297A16.2	10.4	3.64e-24	2.48e-21	0.38	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35253210	chr10:35098006~35127020:-
BRCA	cis	rs9487094	0.744	rs13220304	ENSG00000260273.1	RP11-425D10.10	10.4	3.67e-24	2.5e-21	0.4	0.31	Height;	chr6:109331033	chr6:109382795~109383666:+
BRCA	cis	rs34779708	0.677	rs112355105	ENSG00000230534.5	RP11-297A16.2	10.4	3.67e-24	2.5e-21	0.39	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35261366	chr10:35098006~35127020:-
BRCA	cis	rs17023223	0.537	rs3934789	ENSG00000231365.4	RP11-418J17.1	-10.4	3.69e-24	2.52e-21	-0.39	-0.31	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119140440	chr1:119140396~119275973:+
BRCA	cis	rs6142102	0.625	rs7263727	ENSG00000276073.1	RP5-1125A11.7	-10.4	3.7e-24	2.53e-21	-0.36	-0.31	Skin pigmentation;	chr20:33953133	chr20:33985617~33988989:-
BRCA	cis	rs6142102	0.625	rs6142056	ENSG00000276073.1	RP5-1125A11.7	-10.4	3.7e-24	2.53e-21	-0.36	-0.31	Skin pigmentation;	chr20:33953349	chr20:33985617~33988989:-
BRCA	cis	rs321358	0.731	rs494921	ENSG00000271584.1	RP11-89C3.4	-10.4	3.71e-24	2.53e-21	-0.48	-0.31	Body mass index;	chr11:111140385	chr11:111091932~111097357:-
BRCA	cis	rs473651	0.935	rs474478	ENSG00000229915.1	AC016999.2	-10.4	3.73e-24	2.54e-21	-0.39	-0.31	Multiple system atrophy;	chr2:238426832	chr2:238427077~238427729:-
BRCA	cis	rs2948294	0.588	rs4840913	ENSG00000253893.2	FAM85B	-10.4	3.76e-24	2.56e-21	-0.42	-0.31	Red cell distribution width;	chr8:8259384	chr8:8167819~8226614:-
BRCA	cis	rs875971	0.545	rs6950988	ENSG00000226824.5	RP4-756H11.3	-10.4	3.76e-24	2.56e-21	-0.42	-0.31	Aortic root size;	chr7:66511428	chr7:66654538~66669855:+
BRCA	cis	rs1113500	0.541	rs6692571	ENSG00000226822.1	RP11-356N1.2	10.39	3.79e-24	2.58e-21	0.44	0.31	Growth-regulated protein alpha levels;	chr1:108034062	chr1:108071482~108074519:+
BRCA	cis	rs11098499	0.954	rs9993199	ENSG00000245958.5	RP11-33B1.1	10.39	3.81e-24	2.6e-21	0.3	0.31	Corneal astigmatism;	chr4:119471718	chr4:119454791~119552025:+
BRCA	cis	rs10759883	0.627	rs816672	ENSG00000175611.10	LINC00476	10.39	3.82e-24	2.6e-21	0.38	0.31	Nicotine dependence;	chr9:95812171	chr9:95759231~95875977:-
BRCA	cis	rs8062405	0.824	rs4788085	ENSG00000278665.1	RP11-666O2.4	10.39	3.87e-24	2.63e-21	0.32	0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28523682	chr16:28599241~28601881:-
BRCA	cis	rs8062405	0.824	rs28772958	ENSG00000278665.1	RP11-666O2.4	10.39	3.87e-24	2.63e-21	0.32	0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28523984	chr16:28599241~28601881:-
BRCA	cis	rs524281	0.814	rs10896093	ENSG00000255320.1	RP11-755F10.1	10.39	3.92e-24	2.67e-21	0.46	0.31	Electroencephalogram traits;	chr11:66190940	chr11:66244840~66246239:-
BRCA	cis	rs11105298	0.891	rs10777184	ENSG00000258302.2	RP11-981P6.1	10.39	3.92e-24	2.67e-21	0.36	0.31	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89525791	chr12:89561129~89594878:+
BRCA	cis	rs6142102	0.625	rs1883707	ENSG00000276073.1	RP5-1125A11.7	10.39	3.92e-24	2.67e-21	0.35	0.31	Skin pigmentation;	chr20:33964781	chr20:33985617~33988989:-
BRCA	cis	rs2243480	1	rs431076	ENSG00000226824.5	RP4-756H11.3	-10.39	3.94e-24	2.68e-21	-0.59	-0.31	Diabetic kidney disease;	chr7:66135333	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs2460422	ENSG00000226824.5	RP4-756H11.3	-10.39	3.94e-24	2.68e-21	-0.59	-0.31	Diabetic kidney disease;	chr7:66136518	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs316334	ENSG00000226824.5	RP4-756H11.3	-10.39	3.94e-24	2.68e-21	-0.59	-0.31	Diabetic kidney disease;	chr7:66137139	chr7:66654538~66669855:+
BRCA	cis	rs34779708	0.733	rs12249814	ENSG00000230534.5	RP11-297A16.2	10.39	3.94e-24	2.68e-21	0.38	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35253829	chr10:35098006~35127020:-
BRCA	cis	rs321358	0.731	rs580656	ENSG00000271584.1	RP11-89C3.4	10.39	3.96e-24	2.69e-21	0.49	0.31	Body mass index;	chr11:111141436	chr11:111091932~111097357:-
BRCA	cis	rs6142102	0.625	rs4243974	ENSG00000276073.1	RP5-1125A11.7	-10.39	3.97e-24	2.7e-21	-0.35	-0.31	Skin pigmentation;	chr20:33960062	chr20:33985617~33988989:-
BRCA	cis	rs6142102	0.625	rs6142062	ENSG00000276073.1	RP5-1125A11.7	-10.39	3.97e-24	2.7e-21	-0.35	-0.31	Skin pigmentation;	chr20:33960706	chr20:33985617~33988989:-
BRCA	cis	rs6142102	0.625	rs6141432	ENSG00000276073.1	RP5-1125A11.7	-10.39	3.97e-24	2.7e-21	-0.35	-0.31	Skin pigmentation;	chr20:33960791	chr20:33985617~33988989:-
BRCA	cis	rs6142102	0.602	rs6141433	ENSG00000276073.1	RP5-1125A11.7	-10.39	3.97e-24	2.7e-21	-0.35	-0.31	Skin pigmentation;	chr20:33961056	chr20:33985617~33988989:-
BRCA	cis	rs875971	0.545	rs6460298	ENSG00000226824.5	RP4-756H11.3	-10.39	4.01e-24	2.72e-21	-0.42	-0.31	Aortic root size;	chr7:66442783	chr7:66654538~66669855:+
BRCA	cis	rs2276314	1	rs2276314	ENSG00000278986.1	RP11-723J4.3	10.39	4.02e-24	2.73e-21	0.39	0.31	Endometriosis;Drug-induced torsades de pointes;	chr18:35977503	chr18:35972151~35973916:+
BRCA	cis	rs11096990	0.574	rs34070258	ENSG00000249207.1	RP11-360F5.1	-10.39	4.09e-24	2.78e-21	-0.37	-0.31	Cognitive function;	chr4:39188132	chr4:39112677~39126818:-
BRCA	cis	rs11096990	0.634	rs3733287	ENSG00000249207.1	RP11-360F5.1	-10.39	4.14e-24	2.81e-21	-0.37	-0.31	Cognitive function;	chr4:39215732	chr4:39112677~39126818:-
BRCA	cis	rs6142102	0.625	rs1883706	ENSG00000276073.1	RP5-1125A11.7	-10.39	4.15e-24	2.82e-21	-0.35	-0.31	Skin pigmentation;	chr20:33965071	chr20:33985617~33988989:-
BRCA	cis	rs6142102	0.625	rs1883705	ENSG00000276073.1	RP5-1125A11.7	-10.39	4.15e-24	2.82e-21	-0.35	-0.31	Skin pigmentation;	chr20:33965072	chr20:33985617~33988989:-
BRCA	cis	rs17023223	0.537	rs61319010	ENSG00000231365.4	RP11-418J17.1	-10.38	4.15e-24	2.82e-21	-0.4	-0.31	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119200388	chr1:119140396~119275973:+
BRCA	cis	rs4862750	0.872	rs6553030	ENSG00000250971.1	RP11-696F12.1	10.38	4.18e-24	2.84e-21	0.32	0.31	Lobe attachment (rater-scored or self-reported);	chr4:186978080	chr4:187060099~187060930:+
BRCA	cis	rs6142102	0.625	rs4012234	ENSG00000276073.1	RP5-1125A11.7	-10.38	4.19e-24	2.85e-21	-0.35	-0.31	Skin pigmentation;	chr20:33965241	chr20:33985617~33988989:-
BRCA	cis	rs6142102	0.649	rs4911382	ENSG00000276073.1	RP5-1125A11.7	-10.38	4.19e-24	2.85e-21	-0.35	-0.31	Skin pigmentation;	chr20:33965289	chr20:33985617~33988989:-
BRCA	cis	rs673078	0.66	rs17512219	ENSG00000275759.1	RP11-131L12.3	-10.38	4.2e-24	2.85e-21	-0.51	-0.31	Glucose homeostasis traits;	chr12:118211468	chr12:118428281~118428870:+
BRCA	cis	rs6142102	0.625	rs6141436	ENSG00000276073.1	RP5-1125A11.7	-10.38	4.21e-24	2.86e-21	-0.35	-0.31	Skin pigmentation;	chr20:33966765	chr20:33985617~33988989:-
BRCA	cis	rs4713118	0.621	rs10484403	ENSG00000220721.1	OR1F12	10.38	4.21e-24	2.86e-21	0.41	0.31	Parkinson's disease;	chr6:28065745	chr6:28073316~28074233:+
BRCA	cis	rs1862618	0.573	rs1550821	ENSG00000271828.1	CTD-2310F14.1	-10.38	4.21e-24	2.86e-21	-0.44	-0.31	Initial pursuit acceleration;	chr5:56946496	chr5:56927874~56929573:+
BRCA	cis	rs858239	0.601	rs10224327	ENSG00000226816.2	AC005082.12	10.38	4.21e-24	2.86e-21	0.35	0.31	Cerebrospinal fluid biomarker levels;	chr7:23122201	chr7:23206013~23208045:+
BRCA	cis	rs1707322	0.721	rs10789470	ENSG00000280836.1	AL355480.1	-10.38	4.22e-24	2.87e-21	-0.4	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692659	chr1:45581219~45581321:-
BRCA	cis	rs2280018	0.526	rs2966129	ENSG00000260735.1	RP11-72I8.1	10.38	4.25e-24	2.89e-21	0.37	0.31	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15059070	chr16:15094411~15109197:+
BRCA	cis	rs150992	0.548	rs12109067	ENSG00000248489.1	CTD-2007H13.3	10.38	4.27e-24	2.9e-21	0.35	0.31	Body mass index;	chr5:99038928	chr5:98929171~98995013:+
BRCA	cis	rs6142102	0.625	rs4911381	ENSG00000276073.1	RP5-1125A11.7	10.38	4.3e-24	2.92e-21	0.35	0.31	Skin pigmentation;	chr20:33962539	chr20:33985617~33988989:-
BRCA	cis	rs2283792	0.819	rs2266965	ENSG00000224086.5	LL22NC03-86G7.1	-10.38	4.3e-24	2.92e-21	-0.32	-0.31	Multiple sclerosis;	chr22:21766866	chr22:21938293~21977632:+
BRCA	cis	rs3779195	0.929	rs4268041	ENSG00000272950.1	RP11-307C18.1	-10.37	4.57e-24	3.09e-21	-0.47	-0.31	Sex hormone-binding globulin levels;	chr7:98376226	chr7:98322853~98323430:+
BRCA	cis	rs8062405	0.789	rs2106480	ENSG00000278665.1	RP11-666O2.4	10.37	4.61e-24	3.12e-21	0.32	0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28526650	chr16:28599241~28601881:-
BRCA	cis	rs11123170	0.529	rs35606997	ENSG00000274877.1	RP11-65I12.1	-10.37	4.61e-24	3.12e-21	-0.48	-0.31	Renal function-related traits (BUN);	chr2:113215773	chr2:113237595~113240825:+
BRCA	cis	rs1707322	0.655	rs3014240	ENSG00000280836.1	AL355480.1	10.37	4.65e-24	3.15e-21	0.4	0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45623553	chr1:45581219~45581321:-
BRCA	cis	rs2280018	0.526	rs2966128	ENSG00000260735.1	RP11-72I8.1	-10.37	4.68e-24	3.16e-21	-0.37	-0.31	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15059532	chr16:15094411~15109197:+
BRCA	cis	rs524281	0.861	rs10896091	ENSG00000255320.1	RP11-755F10.1	10.37	4.68e-24	3.16e-21	0.46	0.31	Electroencephalogram traits;	chr11:66183354	chr11:66244840~66246239:-
BRCA	cis	rs4727443	0.653	rs6465759	ENSG00000214313.7	AZGP1P1	10.37	4.69e-24	3.17e-21	0.31	0.31	Interstitial lung disease;	chr7:99990357	chr7:99980762~99987535:+
BRCA	cis	rs1707322	0.682	rs12037459	ENSG00000280836.1	AL355480.1	-10.37	4.7e-24	3.18e-21	-0.4	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45629287	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.721	rs11211163	ENSG00000280836.1	AL355480.1	-10.37	4.83e-24	3.26e-21	-0.4	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45687876	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.721	rs12037803	ENSG00000280836.1	AL355480.1	-10.37	4.83e-24	3.26e-21	-0.4	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45690820	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.721	rs61784796	ENSG00000280836.1	AL355480.1	-10.37	4.83e-24	3.26e-21	-0.4	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45697584	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.721	rs10749856	ENSG00000280836.1	AL355480.1	-10.37	4.83e-24	3.26e-21	-0.4	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45699174	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.721	rs10890344	ENSG00000280836.1	AL355480.1	-10.37	4.83e-24	3.26e-21	-0.4	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45700418	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.721	rs4564187	ENSG00000280836.1	AL355480.1	-10.37	4.83e-24	3.26e-21	-0.4	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45701189	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.752	rs28438704	ENSG00000280836.1	AL355480.1	-10.37	4.83e-24	3.26e-21	-0.4	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45704872	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.721	rs28442079	ENSG00000280836.1	AL355480.1	-10.37	4.83e-24	3.26e-21	-0.4	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45706329	chr1:45581219~45581321:-
BRCA	cis	rs673078	0.607	rs882927	ENSG00000275759.1	RP11-131L12.3	-10.37	4.84e-24	3.27e-21	-0.45	-0.31	Glucose homeostasis traits;	chr12:118406737	chr12:118428281~118428870:+
BRCA	cis	rs524281	0.861	rs10896087	ENSG00000255320.1	RP11-755F10.1	10.37	4.85e-24	3.27e-21	0.46	0.31	Electroencephalogram traits;	chr11:66157078	chr11:66244840~66246239:-
BRCA	cis	rs524281	0.861	rs4013917	ENSG00000255320.1	RP11-755F10.1	10.37	4.85e-24	3.27e-21	0.46	0.31	Electroencephalogram traits;	chr11:66158714	chr11:66244840~66246239:-
BRCA	cis	rs8062405	0.69	rs762634	ENSG00000278665.1	RP11-666O2.4	10.37	4.85e-24	3.28e-21	0.34	0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28592014	chr16:28599241~28601881:-
BRCA	cis	rs1501911	0.611	rs56180458	ENSG00000248489.1	CTD-2007H13.3	10.37	4.86e-24	3.28e-21	0.35	0.31	Lung function (FEV1/FVC);	chr5:99043633	chr5:98929171~98995013:+
BRCA	cis	rs10740039	0.583	rs9415612	ENSG00000254271.1	RP11-131N11.4	-10.37	4.87e-24	3.29e-21	-0.41	-0.31	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60746638	chr10:60734342~60741828:+
BRCA	cis	rs992157	0.71	rs6719789	ENSG00000261338.2	RP11-378A13.1	-10.37	4.9e-24	3.31e-21	-0.31	-0.31	Colorectal cancer;	chr2:218193087	chr2:218255319~218257366:+
BRCA	cis	rs2243480	0.764	rs2460423	ENSG00000226824.5	RP4-756H11.3	-10.37	4.92e-24	3.32e-21	-0.59	-0.31	Diabetic kidney disease;	chr7:66136229	chr7:66654538~66669855:+
BRCA	cis	rs11105298	0.891	rs10858898	ENSG00000258302.2	RP11-981P6.1	10.37	4.99e-24	3.37e-21	0.36	0.31	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89528334	chr12:89561129~89594878:+
BRCA	cis	rs4727443	0.691	rs6975827	ENSG00000214313.7	AZGP1P1	10.37	4.99e-24	3.37e-21	0.31	0.31	Interstitial lung disease;	chr7:99988175	chr7:99980762~99987535:+
BRCA	cis	rs875971	0.545	rs1547529	ENSG00000226824.5	RP4-756H11.3	-10.36	5.07e-24	3.42e-21	-0.42	-0.31	Aortic root size;	chr7:66258859	chr7:66654538~66669855:+
BRCA	cis	rs858239	0.796	rs433395	ENSG00000226816.2	AC005082.12	10.36	5.08e-24	3.43e-21	0.36	0.31	Cerebrospinal fluid biomarker levels;	chr7:23362336	chr7:23206013~23208045:+
BRCA	cis	rs858239	0.699	rs858260	ENSG00000226816.2	AC005082.12	10.36	5.09e-24	3.43e-21	0.35	0.31	Cerebrospinal fluid biomarker levels;	chr7:23173315	chr7:23206013~23208045:+
BRCA	cis	rs17023223	0.537	rs12086686	ENSG00000231365.4	RP11-418J17.1	-10.36	5.12e-24	3.45e-21	-0.39	-0.31	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119146461	chr1:119140396~119275973:+
BRCA	cis	rs17023223	0.537	rs12085616	ENSG00000231365.4	RP11-418J17.1	-10.36	5.12e-24	3.45e-21	-0.39	-0.31	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119146525	chr1:119140396~119275973:+
BRCA	cis	rs1075265	0.584	rs1862122	ENSG00000233266.1	HMGB1P31	-10.36	5.13e-24	3.46e-21	-0.38	-0.31	Chronotype;Morning vs. evening chronotype;	chr2:54052992	chr2:54051334~54051760:+
BRCA	cis	rs2243480	1	rs313820	ENSG00000226824.5	RP4-756H11.3	-10.36	5.17e-24	3.49e-21	-0.6	-0.31	Diabetic kidney disease;	chr7:66109479	chr7:66654538~66669855:+
BRCA	cis	rs1062177	0.756	rs2964592	ENSG00000213433.5	RPLP1P6	10.36	5.19e-24	3.5e-21	0.38	0.31	Preschool internalizing problems;	chr5:151736127	chr5:151765859~151766378:-
BRCA	cis	rs1823913	0.599	rs13001899	ENSG00000227542.1	AC092614.2	10.36	5.25e-24	3.54e-21	0.38	0.31	Obesity-related traits;	chr2:191285442	chr2:191229165~191246172:-
BRCA	cis	rs6570726	0.791	rs12208019	ENSG00000235652.6	RP11-545I5.3	10.36	5.27e-24	3.55e-21	0.31	0.31	Lobe attachment (rater-scored or self-reported);	chr6:145614436	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.791	rs11155435	ENSG00000235652.6	RP11-545I5.3	10.36	5.27e-24	3.55e-21	0.31	0.31	Lobe attachment (rater-scored or self-reported);	chr6:145617409	chr6:145799409~145886585:+
BRCA	cis	rs4380275	0.965	rs4315562	ENSG00000272342.1	RP13-539J13.1	10.36	5.33e-24	3.59e-21	0.39	0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:772723	chr2:739588~740164:-
BRCA	cis	rs1707322	0.717	rs1135850	ENSG00000280836.1	AL355480.1	-10.36	5.37e-24	3.62e-21	-0.4	-0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45628020	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.686	rs3014235	ENSG00000280836.1	AL355480.1	10.36	5.37e-24	3.62e-21	0.4	0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45625840	chr1:45581219~45581321:-
BRCA	cis	rs6921919	0.583	rs16894108	ENSG00000216901.1	AL022393.7	10.36	5.39e-24	3.63e-21	0.4	0.31	Autism spectrum disorder or schizophrenia;	chr6:28434013	chr6:28176188~28176674:+
BRCA	cis	rs9318086	0.753	rs9553094	ENSG00000205861.10	C1QTNF9B-AS1	10.36	5.51e-24	3.71e-21	0.39	0.31	Myopia (pathological);	chr13:23900474	chr13:23888889~23897263:+
BRCA	cis	rs2276314	1	rs62101367	ENSG00000278986.1	RP11-723J4.3	-10.35	5.52e-24	3.72e-21	-0.39	-0.31	Endometriosis;Drug-induced torsades de pointes;	chr18:35970921	chr18:35972151~35973916:+
BRCA	cis	rs4380275	0.965	rs4375894	ENSG00000272342.1	RP13-539J13.1	10.35	5.61e-24	3.77e-21	0.39	0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:772567	chr2:739588~740164:-
BRCA	cis	rs11096990	0.613	rs6840578	ENSG00000249207.1	RP11-360F5.1	-10.35	5.62e-24	3.78e-21	-0.36	-0.31	Cognitive function;	chr4:39206996	chr4:39112677~39126818:-
BRCA	cis	rs4423214	0.592	rs10898223	ENSG00000254682.1	RP11-660L16.2	-10.35	5.65e-24	3.8e-21	-0.47	-0.31	Vitamin D levels;	chr11:71508218	chr11:71448674~71452157:+
BRCA	cis	rs34779708	0.733	rs59287215	ENSG00000230534.5	RP11-297A16.2	10.35	5.71e-24	3.84e-21	0.38	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35255066	chr10:35098006~35127020:-
BRCA	cis	rs6538678	0.929	rs10735336	ENSG00000258343.1	RP11-536G4.2	-10.35	5.75e-24	3.87e-21	-0.42	-0.31	Lupus nephritis in systemic lupus erythematosus;	chr12:95869661	chr12:95795345~95858839:-
BRCA	cis	rs673078	0.607	rs61943403	ENSG00000275759.1	RP11-131L12.3	-10.35	5.78e-24	3.89e-21	-0.45	-0.31	Glucose homeostasis traits;	chr12:118399887	chr12:118428281~118428870:+
BRCA	cis	rs34779708	0.733	rs61449529	ENSG00000230534.5	RP11-297A16.2	10.35	5.79e-24	3.89e-21	0.38	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35254986	chr10:35098006~35127020:-
BRCA	cis	rs875971	0.545	rs4441996	ENSG00000226824.5	RP4-756H11.3	10.35	5.83e-24	3.92e-21	0.41	0.31	Aortic root size;	chr7:66123233	chr7:66654538~66669855:+
BRCA	cis	rs7849270	1	rs7855278	ENSG00000268707.1	RP11-247A12.7	10.35	5.84e-24	3.92e-21	0.38	0.31	Blood metabolite ratios;	chr9:129159086	chr9:129170434~129170940:+
BRCA	cis	rs7397814	0.558	rs4764447	ENSG00000214776.8	RP11-726G1.1	-10.35	5.84e-24	3.93e-21	-0.35	-0.31	IgG glycosylation;	chr12:9426513	chr12:9467552~9576275:+
BRCA	cis	rs1707322	0.752	rs4660313	ENSG00000280836.1	AL355480.1	10.35	5.86e-24	3.94e-21	0.39	0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45645169	chr1:45581219~45581321:-
BRCA	cis	rs2243480	1	rs313824	ENSG00000226824.5	RP4-756H11.3	-10.35	5.87e-24	3.94e-21	-0.6	-0.31	Diabetic kidney disease;	chr7:66116220	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs186378	ENSG00000226824.5	RP4-756H11.3	-10.35	5.87e-24	3.94e-21	-0.6	-0.31	Diabetic kidney disease;	chr7:66117071	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs160637	ENSG00000226824.5	RP4-756H11.3	-10.35	5.87e-24	3.94e-21	-0.6	-0.31	Diabetic kidney disease;	chr7:66119331	chr7:66654538~66669855:+
BRCA	cis	rs10256972	0.869	rs4720158	ENSG00000229043.2	AC091729.9	-10.35	5.99e-24	4.02e-21	-0.38	-0.31	Endometriosis;Longevity;	chr7:1000689	chr7:1160374~1165267:+
BRCA	cis	rs7829975	0.742	rs1533058	ENSG00000253893.2	FAM85B	-10.35	6e-24	4.03e-21	-0.38	-0.31	Mood instability;	chr8:8827680	chr8:8167819~8226614:-
BRCA	cis	rs2280018	0.526	rs2941257	ENSG00000260735.1	RP11-72I8.1	-10.35	6e-24	4.03e-21	-0.36	-0.31	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15072588	chr16:15094411~15109197:+
BRCA	cis	rs1707322	0.717	rs3014245	ENSG00000280836.1	AL355480.1	10.35	6e-24	4.03e-21	0.4	0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45621241	chr1:45581219~45581321:-
BRCA	cis	rs34779708	0.702	rs35969476	ENSG00000230534.5	RP11-297A16.2	10.35	6.04e-24	4.05e-21	0.38	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35255390	chr10:35098006~35127020:-
BRCA	cis	rs7688540	0.723	rs17521834	ENSG00000275426.1	CH17-262A2.1	-10.35	6.04e-24	4.05e-21	-0.48	-0.31	Facial morphology (factor 6, height of vermillion lower lip);	chr4:231660	chr4:149738~150317:+
BRCA	cis	rs4862750	0.794	rs1030382	ENSG00000250971.1	RP11-696F12.1	10.35	6.05e-24	4.06e-21	0.32	0.31	Lobe attachment (rater-scored or self-reported);	chr4:186982628	chr4:187060099~187060930:+
BRCA	cis	rs1707322	0.506	rs2991983	ENSG00000280836.1	AL355480.1	10.34	6.08e-24	4.08e-21	0.4	0.31	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613719	chr1:45581219~45581321:-
BRCA	cis	rs34779708	0.643	rs4275563	ENSG00000230534.5	RP11-297A16.2	10.34	6.15e-24	4.13e-21	0.38	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35256358	chr10:35098006~35127020:-
BRCA	cis	rs4927850	0.957	rs4927851	ENSG00000231464.1	AC024937.4	10.34	6.19e-24	4.16e-21	0.39	0.31	Pancreatic cancer;	chr3:196024982	chr3:195996738~195998233:+
BRCA	cis	rs2243480	1	rs316327	ENSG00000226824.5	RP4-756H11.3	10.34	6.2e-24	4.16e-21	0.57	0.31	Diabetic kidney disease;	chr7:66144214	chr7:66654538~66669855:+
BRCA	cis	rs524281	0.861	rs7943911	ENSG00000255320.1	RP11-755F10.1	10.34	6.28e-24	4.21e-21	0.46	0.31	Electroencephalogram traits;	chr11:66175583	chr11:66244840~66246239:-
BRCA	cis	rs6570726	0.643	rs9403735	ENSG00000235652.6	RP11-545I5.3	10.34	6.31e-24	4.23e-21	0.31	0.31	Lobe attachment (rater-scored or self-reported);	chr6:145615455	chr6:145799409~145886585:+
BRCA	cis	rs321358	0.731	rs576877	ENSG00000271584.1	RP11-89C3.4	10.34	6.34e-24	4.25e-21	0.49	0.31	Body mass index;	chr11:111147472	chr11:111091932~111097357:-
BRCA	cis	rs4927850	1	rs7630875	ENSG00000231464.1	AC024937.4	10.34	6.35e-24	4.26e-21	0.39	0.31	Pancreatic cancer;	chr3:196026895	chr3:195996738~195998233:+
BRCA	cis	rs858239	0.665	rs6964665	ENSG00000226816.2	AC005082.12	10.34	6.36e-24	4.27e-21	0.35	0.31	Cerebrospinal fluid biomarker levels;	chr7:23171733	chr7:23206013~23208045:+
BRCA	cis	rs875971	0.545	rs1909508	ENSG00000226824.5	RP4-756H11.3	-10.34	6.37e-24	4.28e-21	-0.42	-0.31	Aortic root size;	chr7:66301366	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.545	rs7783889	ENSG00000226824.5	RP4-756H11.3	-10.34	6.38e-24	4.28e-21	-0.42	-0.31	Aortic root size;	chr7:66283366	chr7:66654538~66669855:+
BRCA	cis	rs2665103	0.589	rs3858953	ENSG00000278603.1	RP13-608F4.5	10.34	6.46e-24	4.33e-21	0.39	0.31	Intelligence (multi-trait analysis);	chr15:82238049	chr15:82472203~82472426:+
BRCA	cis	rs6545883	0.524	rs17482440	ENSG00000271889.1	RP11-493E12.1	-10.34	6.5e-24	4.36e-21	-0.36	-0.3	Tuberculosis;	chr2:61321722	chr2:61151433~61162105:-
BRCA	cis	rs2404602	0.698	rs12909656	ENSG00000259422.1	RP11-593F23.1	-10.34	6.51e-24	4.37e-21	-0.39	-0.3	Blood metabolite levels;	chr15:76372037	chr15:76174891~76181486:-
BRCA	cis	rs4862750	0.872	rs13110072	ENSG00000250971.1	RP11-696F12.1	10.34	6.52e-24	4.37e-21	0.32	0.3	Lobe attachment (rater-scored or self-reported);	chr4:186957370	chr4:187060099~187060930:+
BRCA	cis	rs4862750	0.872	rs6825289	ENSG00000250971.1	RP11-696F12.1	10.34	6.52e-24	4.37e-21	0.32	0.3	Lobe attachment (rater-scored or self-reported);	chr4:186957955	chr4:187060099~187060930:+
BRCA	cis	rs321358	0.731	rs559757	ENSG00000271584.1	RP11-89C3.4	10.34	6.53e-24	4.37e-21	0.48	0.3	Body mass index;	chr11:111136885	chr11:111091932~111097357:-
BRCA	cis	rs321358	0.731	rs560503	ENSG00000271584.1	RP11-89C3.4	10.34	6.53e-24	4.37e-21	0.48	0.3	Body mass index;	chr11:111136911	chr11:111091932~111097357:-
BRCA	cis	rs321358	0.731	rs514347	ENSG00000271584.1	RP11-89C3.4	10.34	6.53e-24	4.37e-21	0.48	0.3	Body mass index;	chr11:111137333	chr11:111091932~111097357:-
BRCA	cis	rs321358	0.731	rs565152	ENSG00000271584.1	RP11-89C3.4	10.34	6.53e-24	4.37e-21	0.48	0.3	Body mass index;	chr11:111137443	chr11:111091932~111097357:-
BRCA	cis	rs1062177	0.855	rs6884630	ENSG00000213433.5	RPLP1P6	-10.34	6.53e-24	4.37e-21	-0.37	-0.3	Preschool internalizing problems;	chr5:151889436	chr5:151765859~151766378:-
BRCA	cis	rs34779708	0.801	rs12255409	ENSG00000230534.5	RP11-297A16.2	10.34	6.56e-24	4.4e-21	0.38	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35246497	chr10:35098006~35127020:-
BRCA	cis	rs10740039	0.583	rs2127353	ENSG00000254271.1	RP11-131N11.4	-10.33	6.72e-24	4.5e-21	-0.41	-0.3	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60750206	chr10:60734342~60741828:+
BRCA	cis	rs875971	0.545	rs67775320	ENSG00000226824.5	RP4-756H11.3	-10.33	6.74e-24	4.51e-21	-0.42	-0.3	Aortic root size;	chr7:66193792	chr7:66654538~66669855:+
BRCA	cis	rs6570726	0.791	rs10457788	ENSG00000235652.6	RP11-545I5.3	10.33	6.75e-24	4.52e-21	0.31	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145600000	chr6:145799409~145886585:+
BRCA	cis	rs10875746	0.669	rs10875792	ENSG00000240399.1	RP1-228P16.1	-10.33	6.75e-24	4.52e-21	-0.42	-0.3	Longevity (90 years and older);	chr12:48303640	chr12:48054813~48055591:-
BRCA	cis	rs10875746	0.623	rs10875793	ENSG00000240399.1	RP1-228P16.1	-10.33	6.75e-24	4.52e-21	-0.42	-0.3	Longevity (90 years and older);	chr12:48303647	chr12:48054813~48055591:-
BRCA	cis	rs11673344	0.573	rs73039109	ENSG00000226686.6	LINC01535	10.33	6.8e-24	4.55e-21	0.44	0.3	Obesity-related traits;	chr19:36891073	chr19:37251912~37265535:+
BRCA	cis	rs473651	1	rs473651	ENSG00000229915.1	AC016999.2	-10.33	6.82e-24	4.57e-21	-0.38	-0.3	Multiple system atrophy;	chr2:238426760	chr2:238427077~238427729:-
BRCA	cis	rs1707322	0.685	rs28617418	ENSG00000280836.1	AL355480.1	-10.33	6.88e-24	4.61e-21	-0.4	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45723854	chr1:45581219~45581321:-
BRCA	cis	rs6844153	0.715	rs73813220	ENSG00000240005.4	RP11-293A21.1	-10.33	6.89e-24	4.61e-21	-0.4	-0.3	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26920224	chr4:26859806~26860599:-
BRCA	cis	rs875971	0.545	rs17138149	ENSG00000226824.5	RP4-756H11.3	-10.33	6.94e-24	4.64e-21	-0.42	-0.3	Aortic root size;	chr7:66228193	chr7:66654538~66669855:+
BRCA	cis	rs7580658	0.857	rs11890187	ENSG00000236682.1	AC068282.3	-10.33	6.97e-24	4.66e-21	-0.4	-0.3	Protein C levels;	chr2:127326162	chr2:127389130~127400580:+
BRCA	cis	rs7829975	0.582	rs6982832	ENSG00000253893.2	FAM85B	10.33	7.04e-24	4.71e-21	0.38	0.3	Mood instability;	chr8:8934707	chr8:8167819~8226614:-
BRCA	cis	rs875971	0.545	rs6460276	ENSG00000226824.5	RP4-756H11.3	-10.33	7.08e-24	4.74e-21	-0.42	-0.3	Aortic root size;	chr7:66182290	chr7:66654538~66669855:+
BRCA	cis	rs6142102	0.625	rs4911138	ENSG00000276073.1	RP5-1125A11.7	-10.33	7.09e-24	4.74e-21	-0.35	-0.3	Skin pigmentation;	chr20:33959893	chr20:33985617~33988989:-
BRCA	cis	rs875971	0.545	rs73152714	ENSG00000226824.5	RP4-756H11.3	-10.33	7.13e-24	4.76e-21	-0.42	-0.3	Aortic root size;	chr7:66534641	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.545	rs4718364	ENSG00000226824.5	RP4-756H11.3	-10.33	7.13e-24	4.76e-21	-0.42	-0.3	Aortic root size;	chr7:66536353	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.545	rs801199	ENSG00000226824.5	RP4-756H11.3	10.33	7.13e-24	4.76e-21	0.42	0.3	Aortic root size;	chr7:66560286	chr7:66654538~66669855:+
BRCA	cis	rs321358	0.848	rs78087740	ENSG00000271584.1	RP11-89C3.4	10.33	7.13e-24	4.77e-21	0.51	0.3	Body mass index;	chr11:111079016	chr11:111091932~111097357:-
BRCA	cis	rs321358	0.848	rs73015146	ENSG00000271584.1	RP11-89C3.4	10.33	7.13e-24	4.77e-21	0.51	0.3	Body mass index;	chr11:111079143	chr11:111091932~111097357:-
BRCA	cis	rs10759883	0.563	rs690286	ENSG00000175611.10	LINC00476	10.33	7.15e-24	4.78e-21	0.37	0.3	Nicotine dependence;	chr9:96034685	chr9:95759231~95875977:-
BRCA	cis	rs1823874	0.581	rs9920347	ENSG00000182397.13	DNM1P46	10.33	7.21e-24	4.82e-21	0.34	0.3	IgG glycosylation;	chr15:99799126	chr15:99790156~99806927:-
BRCA	cis	rs55665837	0.559	rs9667144	ENSG00000251991.1	RNU7-49P	-10.33	7.22e-24	4.82e-21	-0.34	-0.3	Vitamin D levels;	chr11:14399555	chr11:14478892~14478953:+
BRCA	cis	rs8059260	0.668	rs74737820	ENSG00000274038.1	RP11-66H6.4	-10.33	7.22e-24	4.82e-21	-0.49	-0.3	Alcohol consumption over the past year;	chr16:10972240	chr16:11056556~11057034:+
BRCA	cis	rs875971	0.545	rs13311962	ENSG00000226824.5	RP4-756H11.3	10.33	7.29e-24	4.86e-21	0.42	0.3	Aortic root size;	chr7:66603142	chr7:66654538~66669855:+
BRCA	cis	rs524281	0.861	rs10750778	ENSG00000255320.1	RP11-755F10.1	10.33	7.29e-24	4.87e-21	0.46	0.3	Electroencephalogram traits;	chr11:66181177	chr11:66244840~66246239:-
BRCA	cis	rs524281	0.861	rs6591208	ENSG00000255320.1	RP11-755F10.1	10.33	7.29e-24	4.87e-21	0.46	0.3	Electroencephalogram traits;	chr11:66182218	chr11:66244840~66246239:-
BRCA	cis	rs8062405	0.965	rs8049439	ENSG00000251417.2	RP11-1348G14.4	-10.33	7.32e-24	4.89e-21	-0.34	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28826194	chr16:28802743~28817828:+
BRCA	cis	rs11098499	0.657	rs71614442	ENSG00000245958.5	RP11-33B1.1	-10.32	7.41e-24	4.94e-21	-0.3	-0.3	Corneal astigmatism;	chr4:119458191	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.954	rs2892848	ENSG00000245958.5	RP11-33B1.1	-10.32	7.41e-24	4.94e-21	-0.3	-0.3	Corneal astigmatism;	chr4:119460186	chr4:119454791~119552025:+
BRCA	cis	rs7772486	0.84	rs2814867	ENSG00000235652.6	RP11-545I5.3	10.32	7.42e-24	4.95e-21	0.31	0.3	Lobe attachment (rater-scored or self-reported);	chr6:146012894	chr6:145799409~145886585:+
BRCA	cis	rs6921919	0.583	rs3800328	ENSG00000216901.1	AL022393.7	10.32	7.44e-24	4.96e-21	0.4	0.3	Autism spectrum disorder or schizophrenia;	chr6:28423066	chr6:28176188~28176674:+
BRCA	cis	rs7829975	0.623	rs10087493	ENSG00000253893.2	FAM85B	10.32	7.45e-24	4.97e-21	0.38	0.3	Mood instability;	chr8:8516047	chr8:8167819~8226614:-
BRCA	cis	rs858239	0.601	rs73272053	ENSG00000226816.2	AC005082.12	10.32	7.45e-24	4.97e-21	0.35	0.3	Cerebrospinal fluid biomarker levels;	chr7:23115906	chr7:23206013~23208045:+
BRCA	cis	rs11603023	0.967	rs494560	ENSG00000255422.1	AP002954.4	10.32	7.51e-24	5.01e-21	0.35	0.3	Cholesterol, total;	chr11:118650844	chr11:118704607~118750263:+
BRCA	cis	rs875971	0.545	rs1638724	ENSG00000226824.5	RP4-756H11.3	10.32	7.55e-24	5.03e-21	0.42	0.3	Aortic root size;	chr7:66575494	chr7:66654538~66669855:+
BRCA	cis	rs4927850	0.918	rs4361313	ENSG00000231464.1	AC024937.4	10.32	7.6e-24	5.06e-21	0.39	0.3	Pancreatic cancer;	chr3:196025389	chr3:195996738~195998233:+
BRCA	cis	rs6723108	0.517	rs6430543	ENSG00000224043.6	CCNT2-AS1	10.32	7.62e-24	5.08e-21	0.39	0.3	Type 2 diabetes;	chr2:134844839	chr2:134735464~134918710:-
BRCA	cis	rs11676348	0.935	rs4674250	ENSG00000261338.2	RP11-378A13.1	-10.32	7.62e-24	5.08e-21	-0.32	-0.3	Ulcerative colitis;	chr2:218112808	chr2:218255319~218257366:+
BRCA	cis	rs1707322	0.721	rs28817701	ENSG00000280836.1	AL355480.1	-10.32	7.65e-24	5.1e-21	-0.4	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45720378	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.691	rs28495425	ENSG00000280836.1	AL355480.1	-10.32	7.65e-24	5.1e-21	-0.4	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45721648	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.691	rs61784803	ENSG00000280836.1	AL355480.1	10.32	7.65e-24	5.1e-21	0.4	0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45713599	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.663	rs3935296	ENSG00000280836.1	AL355480.1	10.32	7.65e-24	5.1e-21	0.4	0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45714798	chr1:45581219~45581321:-
BRCA	cis	rs875971	0.545	rs316306	ENSG00000226824.5	RP4-756H11.3	10.32	7.72e-24	5.14e-21	0.42	0.3	Aortic root size;	chr7:66153687	chr7:66654538~66669855:+
BRCA	cis	rs7580658	0.864	rs4150454	ENSG00000236682.1	AC068282.3	-10.32	7.75e-24	5.16e-21	-0.4	-0.3	Protein C levels;	chr2:127280968	chr2:127389130~127400580:+
BRCA	cis	rs524281	0.861	rs10896077	ENSG00000255320.1	RP11-755F10.1	10.32	7.77e-24	5.18e-21	0.46	0.3	Electroencephalogram traits;	chr11:66084262	chr11:66244840~66246239:-
BRCA	cis	rs7772486	0.754	rs9399561	ENSG00000235652.6	RP11-545I5.3	10.32	7.78e-24	5.18e-21	0.31	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145634551	chr6:145799409~145886585:+
BRCA	cis	rs1707322	0.721	rs6697821	ENSG00000280836.1	AL355480.1	-10.32	7.83e-24	5.21e-21	-0.4	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45751050	chr1:45581219~45581321:-
BRCA	cis	rs11123170	0.503	rs28679654	ENSG00000274877.1	RP11-65I12.1	-10.32	7.83e-24	5.22e-21	-0.48	-0.3	Renal function-related traits (BUN);	chr2:113210040	chr2:113237595~113240825:+
BRCA	cis	rs875971	0.545	rs2707851	ENSG00000226824.5	RP4-756H11.3	10.32	7.87e-24	5.24e-21	0.42	0.3	Aortic root size;	chr7:66624178	chr7:66654538~66669855:+
BRCA	cis	rs1707322	0.717	rs3014246	ENSG00000280836.1	AL355480.1	10.32	7.88e-24	5.24e-21	0.4	0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45620405	chr1:45581219~45581321:-
BRCA	cis	rs1062177	0.724	rs2964590	ENSG00000213433.5	RPLP1P6	10.32	7.92e-24	5.27e-21	0.4	0.3	Preschool internalizing problems;	chr5:151738585	chr5:151765859~151766378:-
BRCA	cis	rs62103177	0.565	rs473119	ENSG00000261126.6	RP11-795F19.1	-10.32	7.93e-24	5.28e-21	-0.4	-0.3	Opioid sensitivity;	chr18:80091557	chr18:80046900~80095482:+
BRCA	cis	rs75422866	0.867	rs73102188	ENSG00000274902.1	RP1-197B17.4	10.32	7.95e-24	5.29e-21	0.81	0.3	Pneumonia;	chr12:47662993	chr12:47731908~47732351:+
BRCA	cis	rs75422866	0.867	rs73102195	ENSG00000274902.1	RP1-197B17.4	10.32	7.95e-24	5.29e-21	0.81	0.3	Pneumonia;	chr12:47666309	chr12:47731908~47732351:+
BRCA	cis	rs75422866	0.867	rs73102201	ENSG00000274902.1	RP1-197B17.4	10.32	7.95e-24	5.29e-21	0.81	0.3	Pneumonia;	chr12:47669269	chr12:47731908~47732351:+
BRCA	cis	rs75422866	0.867	rs73104104	ENSG00000274902.1	RP1-197B17.4	10.32	7.95e-24	5.29e-21	0.81	0.3	Pneumonia;	chr12:47671986	chr12:47731908~47732351:+
BRCA	cis	rs75422866	0.867	rs73104111	ENSG00000274902.1	RP1-197B17.4	10.32	7.95e-24	5.29e-21	0.81	0.3	Pneumonia;	chr12:47673994	chr12:47731908~47732351:+
BRCA	cis	rs75422866	0.867	rs73102140	ENSG00000274902.1	RP1-197B17.4	10.32	7.96e-24	5.3e-21	0.81	0.3	Pneumonia;	chr12:47647497	chr12:47731908~47732351:+
BRCA	cis	rs75422866	0.867	rs73102148	ENSG00000274902.1	RP1-197B17.4	10.32	7.96e-24	5.3e-21	0.81	0.3	Pneumonia;	chr12:47648013	chr12:47731908~47732351:+
BRCA	cis	rs75422866	0.867	rs73102151	ENSG00000274902.1	RP1-197B17.4	10.32	7.96e-24	5.3e-21	0.81	0.3	Pneumonia;	chr12:47648023	chr12:47731908~47732351:+
BRCA	cis	rs11096990	0.634	rs2276888	ENSG00000249207.1	RP11-360F5.1	10.31	8.08e-24	5.37e-21	0.36	0.3	Cognitive function;	chr4:39278287	chr4:39112677~39126818:-
BRCA	cis	rs11096990	0.593	rs7685619	ENSG00000249207.1	RP11-360F5.1	-10.31	8.13e-24	5.41e-21	-0.36	-0.3	Cognitive function;	chr4:39211779	chr4:39112677~39126818:-
BRCA	cis	rs875971	0.528	rs801213	ENSG00000226824.5	RP4-756H11.3	10.31	8.16e-24	5.43e-21	0.42	0.3	Aortic root size;	chr7:66549931	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.545	rs801212	ENSG00000226824.5	RP4-756H11.3	10.31	8.16e-24	5.43e-21	0.42	0.3	Aortic root size;	chr7:66550643	chr7:66654538~66669855:+
BRCA	cis	rs6142102	0.625	rs6142061	ENSG00000276073.1	RP5-1125A11.7	-10.31	8.18e-24	5.44e-21	-0.35	-0.3	Skin pigmentation;	chr20:33960529	chr20:33985617~33988989:-
BRCA	cis	rs1707322	0.691	rs11211174	ENSG00000280836.1	AL355480.1	-10.31	8.2e-24	5.45e-21	-0.4	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755144	chr1:45581219~45581321:-
BRCA	cis	rs2115630	0.691	rs2292462	ENSG00000225151.9	GOLGA2P7	10.31	8.26e-24	5.49e-21	0.34	0.3	P wave terminal force;	chr15:84657523	chr15:84199311~84230136:-
BRCA	cis	rs2404602	0.735	rs2468130	ENSG00000259422.1	RP11-593F23.1	-10.31	8.33e-24	5.54e-21	-0.39	-0.3	Blood metabolite levels;	chr15:76504155	chr15:76174891~76181486:-
BRCA	cis	rs473651	0.935	rs515412	ENSG00000229915.1	AC016999.2	-10.31	8.34e-24	5.54e-21	-0.38	-0.3	Multiple system atrophy;	chr2:238436753	chr2:238427077~238427729:-
BRCA	cis	rs4927850	0.958	rs1975582	ENSG00000231464.1	AC024937.4	10.31	8.34e-24	5.54e-21	0.39	0.3	Pancreatic cancer;	chr3:196024568	chr3:195996738~195998233:+
BRCA	cis	rs2243480	1	rs316307	ENSG00000226824.5	RP4-756H11.3	-10.31	8.39e-24	5.58e-21	-0.6	-0.3	Diabetic kidney disease;	chr7:66105184	chr7:66654538~66669855:+
BRCA	cis	rs7688540	0.771	rs7665727	ENSG00000275426.1	CH17-262A2.1	10.31	8.5e-24	5.64e-21	0.48	0.3	Facial morphology (factor 6, height of vermillion lower lip);	chr4:283268	chr4:149738~150317:+
BRCA	cis	rs4927850	1	rs4927850	ENSG00000231464.1	AC024937.4	-10.31	8.55e-24	5.68e-21	-0.39	-0.3	Pancreatic cancer;	chr3:196024759	chr3:195996738~195998233:+
BRCA	cis	rs875971	0.545	rs6961853	ENSG00000226824.5	RP4-756H11.3	-10.31	8.56e-24	5.69e-21	-0.42	-0.3	Aortic root size;	chr7:66537035	chr7:66654538~66669855:+
BRCA	cis	rs7580658	0.676	rs58475809	ENSG00000236682.1	AC068282.3	-10.31	8.6e-24	5.71e-21	-0.4	-0.3	Protein C levels;	chr2:127245074	chr2:127389130~127400580:+
BRCA	cis	rs11096990	0.613	rs7690414	ENSG00000249207.1	RP11-360F5.1	-10.31	8.81e-24	5.85e-21	-0.36	-0.3	Cognitive function;	chr4:39210669	chr4:39112677~39126818:-
BRCA	cis	rs11098499	0.738	rs34566984	ENSG00000245958.5	RP11-33B1.1	-10.31	8.81e-24	5.85e-21	-0.3	-0.3	Corneal astigmatism;	chr4:119440115	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.954	rs9685777	ENSG00000245958.5	RP11-33B1.1	-10.31	8.81e-24	5.85e-21	-0.3	-0.3	Corneal astigmatism;	chr4:119444810	chr4:119454791~119552025:+
BRCA	cis	rs7772486	0.738	rs9485039	ENSG00000235652.6	RP11-545I5.3	10.31	8.85e-24	5.87e-21	0.31	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145998251	chr6:145799409~145886585:+
BRCA	cis	rs2243480	1	rs316331	ENSG00000226824.5	RP4-756H11.3	10.3	8.88e-24	5.89e-21	0.58	0.3	Diabetic kidney disease;	chr7:66139635	chr7:66654538~66669855:+
BRCA	cis	rs75422866	0.867	rs35044089	ENSG00000274902.1	RP1-197B17.4	10.3	8.94e-24	5.93e-21	0.81	0.3	Pneumonia;	chr12:47610881	chr12:47731908~47732351:+
BRCA	cis	rs75422866	0.867	rs78912815	ENSG00000274902.1	RP1-197B17.4	10.3	8.94e-24	5.93e-21	0.81	0.3	Pneumonia;	chr12:47612065	chr12:47731908~47732351:+
BRCA	cis	rs1707322	0.686	rs3014251	ENSG00000280836.1	AL355480.1	10.3	8.97e-24	5.95e-21	0.4	0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45611756	chr1:45581219~45581321:-
BRCA	cis	rs524281	0.861	rs7931544	ENSG00000255320.1	RP11-755F10.1	10.3	9.01e-24	5.98e-21	0.46	0.3	Electroencephalogram traits;	chr11:66149563	chr11:66244840~66246239:-
BRCA	cis	rs875971	0.545	rs6460281	ENSG00000226824.5	RP4-756H11.3	-10.3	9.02e-24	5.98e-21	-0.42	-0.3	Aortic root size;	chr7:66216128	chr7:66654538~66669855:+
BRCA	cis	rs4713118	0.662	rs156744	ENSG00000220721.1	OR1F12	10.3	9.05e-24	6e-21	0.4	0.3	Parkinson's disease;	chr6:27999496	chr6:28073316~28074233:+
BRCA	cis	rs4713118	0.662	rs149947	ENSG00000220721.1	OR1F12	10.3	9.05e-24	6e-21	0.4	0.3	Parkinson's disease;	chr6:28004655	chr6:28073316~28074233:+
BRCA	cis	rs10875746	0.551	rs11168536	ENSG00000240399.1	RP1-228P16.1	-10.3	9.07e-24	6.01e-21	-0.41	-0.3	Longevity (90 years and older);	chr12:48351268	chr12:48054813~48055591:-
BRCA	cis	rs7945705	0.818	rs2742537	ENSG00000254860.4	TMEM9B-AS1	10.3	9.08e-24	6.02e-21	0.27	0.3	Hemoglobin concentration;	chr11:8886842	chr11:8964675~8977527:+
BRCA	cis	rs858239	0.632	rs1985769	ENSG00000226816.2	AC005082.12	10.3	9.17e-24	6.08e-21	0.35	0.3	Cerebrospinal fluid biomarker levels;	chr7:23082887	chr7:23206013~23208045:+
BRCA	cis	rs858239	0.6	rs28499396	ENSG00000226816.2	AC005082.12	10.3	9.17e-24	6.08e-21	0.35	0.3	Cerebrospinal fluid biomarker levels;	chr7:23084479	chr7:23206013~23208045:+
BRCA	cis	rs858239	0.6	rs7789237	ENSG00000226816.2	AC005082.12	10.3	9.17e-24	6.08e-21	0.35	0.3	Cerebrospinal fluid biomarker levels;	chr7:23085094	chr7:23206013~23208045:+
BRCA	cis	rs17482078	0.959	rs10074694	ENSG00000248734.2	CTD-2260A17.1	10.3	9.21e-24	6.1e-21	0.43	0.3	Behcet's disease;Blood protein levels;	chr5:96801437	chr5:96784777~96785999:+
BRCA	cis	rs17482078	0.959	rs10074708	ENSG00000248734.2	CTD-2260A17.1	10.3	9.21e-24	6.1e-21	0.43	0.3	Behcet's disease;Blood protein levels;	chr5:96801501	chr5:96784777~96785999:+
BRCA	cis	rs11690935	0.571	rs1008151	ENSG00000228389.1	AC068039.4	-10.3	9.25e-24	6.13e-21	-0.38	-0.3	Schizophrenia;	chr2:172047370	chr2:171773482~171775844:+
BRCA	cis	rs524281	0.773	rs11227413	ENSG00000255320.1	RP11-755F10.1	10.3	9.27e-24	6.14e-21	0.46	0.3	Electroencephalogram traits;	chr11:66116225	chr11:66244840~66246239:-
BRCA	cis	rs1707322	0.682	rs28490344	ENSG00000280836.1	AL355480.1	-10.3	9.34e-24	6.19e-21	-0.4	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45732276	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.721	rs28641748	ENSG00000280836.1	AL355480.1	-10.3	9.34e-24	6.19e-21	-0.4	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45747164	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.721	rs4330955	ENSG00000280836.1	AL355480.1	-10.3	9.34e-24	6.19e-21	-0.4	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45751813	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.691	rs12031182	ENSG00000280836.1	AL355480.1	-10.3	9.34e-24	6.19e-21	-0.4	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755327	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.721	rs10430123	ENSG00000280836.1	AL355480.1	-10.3	9.34e-24	6.19e-21	-0.4	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755768	chr1:45581219~45581321:-
BRCA	cis	rs875971	0.545	rs316305	ENSG00000226824.5	RP4-756H11.3	10.3	9.34e-24	6.19e-21	0.42	0.3	Aortic root size;	chr7:66152984	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.545	rs10950027	ENSG00000226824.5	RP4-756H11.3	-10.3	9.45e-24	6.26e-21	-0.42	-0.3	Aortic root size;	chr7:66169164	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.545	rs10950036	ENSG00000226824.5	RP4-756H11.3	-10.3	9.46e-24	6.26e-21	-0.42	-0.3	Aortic root size;	chr7:66353241	chr7:66654538~66669855:+
BRCA	cis	rs1707322	0.717	rs1135812	ENSG00000280836.1	AL355480.1	-10.3	9.48e-24	6.28e-21	-0.39	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45629600	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.752	rs6703748	ENSG00000280836.1	AL355480.1	-10.3	9.48e-24	6.28e-21	-0.39	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45630304	chr1:45581219~45581321:-
BRCA	cis	rs75422866	0.867	rs73104103	ENSG00000274902.1	RP1-197B17.4	10.3	9.55e-24	6.32e-21	0.81	0.3	Pneumonia;	chr12:47669604	chr12:47731908~47732351:+
BRCA	cis	rs875971	0.545	rs73376401	ENSG00000226824.5	RP4-756H11.3	-10.3	9.6e-24	6.35e-21	-0.42	-0.3	Aortic root size;	chr7:66174841	chr7:66654538~66669855:+
BRCA	cis	rs6538678	0.929	rs10745733	ENSG00000258343.1	RP11-536G4.2	-10.3	9.6e-24	6.35e-21	-0.42	-0.3	Lupus nephritis in systemic lupus erythematosus;	chr12:95868728	chr12:95795345~95858839:-
BRCA	cis	rs6538678	0.926	rs10745734	ENSG00000258343.1	RP11-536G4.2	-10.3	9.6e-24	6.35e-21	-0.42	-0.3	Lupus nephritis in systemic lupus erythematosus;	chr12:95868936	chr12:95795345~95858839:-
BRCA	cis	rs1707322	0.721	rs4660314	ENSG00000280836.1	AL355480.1	-10.3	9.63e-24	6.37e-21	-0.4	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45764213	chr1:45581219~45581321:-
BRCA	cis	rs75422866	0.867	rs79113930	ENSG00000274902.1	RP1-197B17.4	10.3	9.63e-24	6.37e-21	0.81	0.3	Pneumonia;	chr12:47600628	chr12:47731908~47732351:+
BRCA	cis	rs7772486	0.701	rs11155438	ENSG00000235652.6	RP11-545I5.3	10.3	9.64e-24	6.38e-21	0.31	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145628976	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.875	rs2814877	ENSG00000235652.6	RP11-545I5.3	10.3	9.71e-24	6.42e-21	0.31	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145978627	chr6:145799409~145886585:+
BRCA	cis	rs11676348	0.935	rs4674248	ENSG00000261338.2	RP11-378A13.1	-10.29	9.77e-24	6.46e-21	-0.32	-0.3	Ulcerative colitis;	chr2:218095408	chr2:218255319~218257366:+
BRCA	cis	rs2404602	0.622	rs4886506	ENSG00000259422.1	RP11-593F23.1	10.29	9.78e-24	6.47e-21	0.39	0.3	Blood metabolite levels;	chr15:76914936	chr15:76174891~76181486:-
BRCA	cis	rs11098499	0.954	rs10034623	ENSG00000245958.5	RP11-33B1.1	-10.29	9.79e-24	6.47e-21	-0.29	-0.3	Corneal astigmatism;	chr4:119476674	chr4:119454791~119552025:+
BRCA	cis	rs7580658	0.895	rs9636237	ENSG00000236682.1	AC068282.3	-10.29	9.82e-24	6.5e-21	-0.4	-0.3	Protein C levels;	chr2:127318446	chr2:127389130~127400580:+
BRCA	cis	rs1862618	0.526	rs2591963	ENSG00000271828.1	CTD-2310F14.1	-10.29	9.84e-24	6.51e-21	-0.44	-0.3	Initial pursuit acceleration;	chr5:56941308	chr5:56927874~56929573:+
BRCA	cis	rs1862618	0.573	rs2591962	ENSG00000271828.1	CTD-2310F14.1	-10.29	9.84e-24	6.51e-21	-0.44	-0.3	Initial pursuit acceleration;	chr5:56941328	chr5:56927874~56929573:+
BRCA	cis	rs2337406	1	rs17113276	ENSG00000274576.2	IGHV2-70	10.29	9.87e-24	6.52e-21	0.33	0.3	Alzheimer's disease (late onset);	chr14:106683485	chr14:106770577~106771020:-
BRCA	cis	rs10256972	0.869	rs1007766	ENSG00000229043.2	AC091729.9	-10.29	1e-23	6.63e-21	-0.39	-0.3	Endometriosis;Longevity;	chr7:995267	chr7:1160374~1165267:+
BRCA	cis	rs11673344	0.668	rs7248693	ENSG00000226686.6	LINC01535	10.29	1.01e-23	6.65e-21	0.43	0.3	Obesity-related traits;	chr19:36991864	chr19:37251912~37265535:+
BRCA	cis	rs6921919	0.583	rs740622	ENSG00000216901.1	AL022393.7	10.29	1.01e-23	6.65e-21	0.4	0.3	Autism spectrum disorder or schizophrenia;	chr6:28430514	chr6:28176188~28176674:+
BRCA	cis	rs6538678	0.929	rs7962359	ENSG00000258343.1	RP11-536G4.2	-10.29	1.02e-23	6.72e-21	-0.43	-0.3	Lupus nephritis in systemic lupus erythematosus;	chr12:95862566	chr12:95795345~95858839:-
BRCA	cis	rs10129255	1	rs10129319	ENSG00000211970.3	IGHV4-61	-10.29	1.02e-23	6.75e-21	-0.22	-0.3	Kawasaki disease;	chr14:106767996	chr14:106639119~106639657:-
BRCA	cis	rs2404602	0.735	rs62028423	ENSG00000259422.1	RP11-593F23.1	-10.29	1.03e-23	6.79e-21	-0.39	-0.3	Blood metabolite levels;	chr15:76462173	chr15:76174891~76181486:-
BRCA	cis	rs11098499	1	rs1011054	ENSG00000245958.5	RP11-33B1.1	10.29	1.03e-23	6.8e-21	0.31	0.3	Corneal astigmatism;	chr4:119281232	chr4:119454791~119552025:+
BRCA	cis	rs11105298	0.891	rs10858894	ENSG00000258302.2	RP11-981P6.1	10.29	1.03e-23	6.81e-21	0.35	0.3	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89520484	chr12:89561129~89594878:+
BRCA	cis	rs11105298	0.891	rs11105310	ENSG00000258302.2	RP11-981P6.1	10.29	1.03e-23	6.81e-21	0.35	0.3	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89524900	chr12:89561129~89594878:+
BRCA	cis	rs2665103	0.61	rs1972460	ENSG00000278603.1	RP13-608F4.5	10.29	1.03e-23	6.82e-21	0.39	0.3	Intelligence (multi-trait analysis);	chr15:82238289	chr15:82472203~82472426:+
BRCA	cis	rs4862750	0.832	rs6836076	ENSG00000250971.1	RP11-696F12.1	10.29	1.04e-23	6.84e-21	0.32	0.3	Lobe attachment (rater-scored or self-reported);	chr4:186978506	chr4:187060099~187060930:+
BRCA	cis	rs4862750	0.872	rs6836781	ENSG00000250971.1	RP11-696F12.1	10.29	1.04e-23	6.84e-21	0.32	0.3	Lobe attachment (rater-scored or self-reported);	chr4:186978547	chr4:187060099~187060930:+
BRCA	cis	rs4862750	0.872	rs11947595	ENSG00000250971.1	RP11-696F12.1	10.29	1.04e-23	6.84e-21	0.32	0.3	Lobe attachment (rater-scored or self-reported);	chr4:186978673	chr4:187060099~187060930:+
BRCA	cis	rs4423214	0.592	rs1790349	ENSG00000254682.1	RP11-660L16.2	-10.29	1.04e-23	6.84e-21	-0.47	-0.3	Vitamin D levels;	chr11:71431304	chr11:71448674~71452157:+
BRCA	cis	rs11096990	0.613	rs4974996	ENSG00000249207.1	RP11-360F5.1	-10.29	1.04e-23	6.85e-21	-0.36	-0.3	Cognitive function;	chr4:39225928	chr4:39112677~39126818:-
BRCA	cis	rs867371	0.502	rs2047679	ENSG00000278603.1	RP13-608F4.5	10.29	1.05e-23	6.95e-21	0.39	0.3	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82239540	chr15:82472203~82472426:+
BRCA	cis	rs11098499	0.909	rs28714195	ENSG00000245958.5	RP11-33B1.1	-10.29	1.06e-23	7.03e-21	-0.29	-0.3	Corneal astigmatism;	chr4:119395795	chr4:119454791~119552025:+
BRCA	cis	rs4862750	0.872	rs7658314	ENSG00000250971.1	RP11-696F12.1	10.28	1.07e-23	7.06e-21	0.32	0.3	Lobe attachment (rater-scored or self-reported);	chr4:186979202	chr4:187060099~187060930:+
BRCA	cis	rs4862750	0.832	rs6419953	ENSG00000250971.1	RP11-696F12.1	10.28	1.07e-23	7.06e-21	0.32	0.3	Lobe attachment (rater-scored or self-reported);	chr4:186979355	chr4:187060099~187060930:+
BRCA	cis	rs858239	0.669	rs12539467	ENSG00000226816.2	AC005082.12	10.28	1.07e-23	7.06e-21	0.36	0.3	Cerebrospinal fluid biomarker levels;	chr7:23076240	chr7:23206013~23208045:+
BRCA	cis	rs673078	0.66	rs61943535	ENSG00000275759.1	RP11-131L12.3	-10.28	1.08e-23	7.11e-21	-0.5	-0.3	Glucose homeostasis traits;	chr12:118168307	chr12:118428281~118428870:+
BRCA	cis	rs7621025	0.5	rs1965107	ENSG00000239213.4	NCK1-AS1	10.28	1.08e-23	7.14e-21	0.38	0.3	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136929801	chr3:136841726~136862054:-
BRCA	cis	rs4862750	0.872	rs4862747	ENSG00000250971.1	RP11-696F12.1	-10.28	1.1e-23	7.24e-21	-0.32	-0.3	Lobe attachment (rater-scored or self-reported);	chr4:186956082	chr4:187060099~187060930:+
BRCA	cis	rs6921919	0.583	rs7740351	ENSG00000216901.1	AL022393.7	10.28	1.11e-23	7.32e-21	0.4	0.3	Autism spectrum disorder or schizophrenia;	chr6:28431635	chr6:28176188~28176674:+
BRCA	cis	rs875971	0.545	rs12671152	ENSG00000226824.5	RP4-756H11.3	-10.28	1.13e-23	7.46e-21	-0.43	-0.3	Aortic root size;	chr7:66311140	chr7:66654538~66669855:+
BRCA	cis	rs11971779	0.648	rs6947309	ENSG00000273391.1	RP11-634H22.1	10.28	1.14e-23	7.5e-21	0.3	0.3	Diisocyanate-induced asthma;	chr7:139351084	chr7:139359032~139359566:-
BRCA	cis	rs11096990	0.613	rs1451821	ENSG00000249207.1	RP11-360F5.1	10.28	1.14e-23	7.52e-21	0.37	0.3	Cognitive function;	chr4:39178797	chr4:39112677~39126818:-
BRCA	cis	rs6700559	1	rs10800720	ENSG00000260088.1	RP11-92G12.3	-10.28	1.14e-23	7.52e-21	-0.39	-0.3	Coronary artery disease;	chr1:200679441	chr1:200669507~200694250:+
BRCA	cis	rs6700559	0.935	rs4072553	ENSG00000260088.1	RP11-92G12.3	-10.28	1.14e-23	7.52e-21	-0.39	-0.3	Coronary artery disease;	chr1:200680036	chr1:200669507~200694250:+
BRCA	cis	rs1707322	0.721	rs12069121	ENSG00000280836.1	AL355480.1	-10.28	1.14e-23	7.53e-21	-0.4	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45766312	chr1:45581219~45581321:-
BRCA	cis	rs875971	0.545	rs316316	ENSG00000226824.5	RP4-756H11.3	10.28	1.15e-23	7.59e-21	0.41	0.3	Aortic root size;	chr7:66149270	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.545	rs75840613	ENSG00000226824.5	RP4-756H11.3	-10.28	1.17e-23	7.69e-21	-0.42	-0.3	Aortic root size;	chr7:66376399	chr7:66654538~66669855:+
BRCA	cis	rs11168351	0.591	rs4258439	ENSG00000240399.1	RP1-228P16.1	-10.28	1.17e-23	7.71e-21	-0.32	-0.3	Bipolar disorder and schizophrenia;	chr12:48074869	chr12:48054813~48055591:-
BRCA	cis	rs1113500	0.573	rs10748507	ENSG00000226822.1	RP11-356N1.2	10.27	1.18e-23	7.79e-21	0.45	0.3	Growth-regulated protein alpha levels;	chr1:108088899	chr1:108071482~108074519:+
BRCA	cis	rs6430553	0.964	rs56383182	ENSG00000224043.6	CCNT2-AS1	-10.27	1.2e-23	7.88e-21	-0.39	-0.3	Blood metabolite levels;	chr2:134850641	chr2:134735464~134918710:-
BRCA	cis	rs6723108	0.534	rs6430546	ENSG00000224043.6	CCNT2-AS1	-10.27	1.2e-23	7.88e-21	-0.39	-0.3	Type 2 diabetes;	chr2:134851231	chr2:134735464~134918710:-
BRCA	cis	rs7772486	0.846	rs2492856	ENSG00000235652.6	RP11-545I5.3	10.27	1.2e-23	7.93e-21	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:146002792	chr6:145799409~145886585:+
BRCA	cis	rs11105298	0.891	rs1054807	ENSG00000258302.2	RP11-981P6.1	10.27	1.22e-23	8e-21	0.35	0.3	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89519642	chr12:89561129~89594878:+
BRCA	cis	rs7688540	0.771	rs79366248	ENSG00000275426.1	CH17-262A2.1	10.27	1.28e-23	8.4e-21	0.47	0.3	Facial morphology (factor 6, height of vermillion lower lip);	chr4:272870	chr4:149738~150317:+
BRCA	cis	rs1707322	0.721	rs11211181	ENSG00000280836.1	AL355480.1	-10.27	1.28e-23	8.42e-21	-0.39	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45771128	chr1:45581219~45581321:-
BRCA	cis	rs524281	0.861	rs12226649	ENSG00000255320.1	RP11-755F10.1	10.27	1.29e-23	8.45e-21	0.46	0.3	Electroencephalogram traits;	chr11:66074576	chr11:66244840~66246239:-
BRCA	cis	rs1707322	0.65	rs4553239	ENSG00000280836.1	AL355480.1	-10.27	1.29e-23	8.47e-21	-0.4	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45684814	chr1:45581219~45581321:-
BRCA	cis	rs11096990	0.613	rs4974990	ENSG00000249207.1	RP11-360F5.1	-10.27	1.29e-23	8.48e-21	-0.36	-0.3	Cognitive function;	chr4:39191645	chr4:39112677~39126818:-
BRCA	cis	rs227275	0.556	rs7676765	ENSG00000246560.2	RP11-10L12.4	-10.26	1.3e-23	8.52e-21	-0.32	-0.3	Allergic disease (asthma, hay fever or eczema);	chr4:103016776	chr4:102828055~102844075:+
BRCA	cis	rs11098499	0.909	rs9759478	ENSG00000245958.5	RP11-33B1.1	-10.26	1.3e-23	8.55e-21	-0.3	-0.3	Corneal astigmatism;	chr4:119446843	chr4:119454791~119552025:+
BRCA	cis	rs7250849	1	rs7250849	ENSG00000273837.1	LLNLR-470E3.1	10.26	1.3e-23	8.55e-21	0.49	0.3	Blood protein levels;	chr19:51655063	chr19:51639478~51639931:-
BRCA	cis	rs6570726	0.791	rs1509214	ENSG00000235652.6	RP11-545I5.3	-10.26	1.31e-23	8.58e-21	-0.31	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145463470	chr6:145799409~145886585:+
BRCA	cis	rs1707322	0.686	rs61784833	ENSG00000280836.1	AL355480.1	-10.26	1.31e-23	8.59e-21	-0.39	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45768100	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.717	rs3014249	ENSG00000280836.1	AL355480.1	10.26	1.31e-23	8.61e-21	0.39	0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613821	chr1:45581219~45581321:-
BRCA	cis	rs4713118	0.621	rs9368548	ENSG00000220721.1	OR1F12	10.26	1.31e-23	8.61e-21	0.41	0.3	Parkinson's disease;	chr6:28066959	chr6:28073316~28074233:+
BRCA	cis	rs7580658	0.864	rs1566823	ENSG00000236682.1	AC068282.3	-10.26	1.32e-23	8.64e-21	-0.4	-0.3	Protein C levels;	chr2:127260616	chr2:127389130~127400580:+
BRCA	cis	rs6921919	0.609	rs67211468	ENSG00000216901.1	AL022393.7	10.26	1.33e-23	8.71e-21	0.4	0.3	Autism spectrum disorder or schizophrenia;	chr6:28424210	chr6:28176188~28176674:+
BRCA	cis	rs321358	0.731	rs539009	ENSG00000271584.1	RP11-89C3.4	10.26	1.34e-23	8.78e-21	0.48	0.3	Body mass index;	chr11:111137694	chr11:111091932~111097357:-
BRCA	cis	rs11096990	0.613	rs35391082	ENSG00000249207.1	RP11-360F5.1	-10.26	1.34e-23	8.8e-21	-0.36	-0.3	Cognitive function;	chr4:39191033	chr4:39112677~39126818:-
BRCA	cis	rs75422866	0.867	rs117022227	ENSG00000274902.1	RP1-197B17.4	10.26	1.34e-23	8.81e-21	0.81	0.3	Pneumonia;	chr12:47633282	chr12:47731908~47732351:+
BRCA	cis	rs150992	0.587	rs6885458	ENSG00000248489.1	CTD-2007H13.3	10.26	1.34e-23	8.82e-21	0.35	0.3	Body mass index;	chr5:99046048	chr5:98929171~98995013:+
BRCA	cis	rs7429990	0.965	rs9854454	ENSG00000229759.1	MRPS18AP1	-10.26	1.35e-23	8.83e-21	-0.34	-0.3	Educational attainment (years of education);	chr3:47971307	chr3:48256350~48256938:-
BRCA	cis	rs524281	0.861	rs918299	ENSG00000255320.1	RP11-755F10.1	10.26	1.35e-23	8.84e-21	0.45	0.3	Electroencephalogram traits;	chr11:66160136	chr11:66244840~66246239:-
BRCA	cis	rs694739	0.796	rs479777	ENSG00000236935.1	AP003774.1	10.26	1.35e-23	8.86e-21	0.29	0.3	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64340005	chr11:64325050~64329504:-
BRCA	cis	rs7772486	0.754	rs6570718	ENSG00000235652.6	RP11-545I5.3	-10.26	1.35e-23	8.86e-21	-0.31	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145767307	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.719	rs2206141	ENSG00000235652.6	RP11-545I5.3	-10.26	1.36e-23	8.9e-21	-0.31	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145765056	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.654	rs6906402	ENSG00000235652.6	RP11-545I5.3	-10.26	1.36e-23	8.9e-21	-0.31	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145768171	chr6:145799409~145886585:+
BRCA	cis	rs17023223	0.537	rs4590715	ENSG00000231365.4	RP11-418J17.1	-10.26	1.36e-23	8.92e-21	-0.39	-0.3	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119207578	chr1:119140396~119275973:+
BRCA	cis	rs7621025	0.5	rs12629000	ENSG00000239213.4	NCK1-AS1	10.26	1.37e-23	8.98e-21	0.38	0.3	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136924729	chr3:136841726~136862054:-
BRCA	cis	rs8072100	0.871	rs7206971	ENSG00000228782.6	CTD-2026D20.3	-10.26	1.38e-23	9.01e-21	-0.33	-0.3	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47347749	chr17:47450568~47492492:-
BRCA	cis	rs7772486	0.754	rs6906258	ENSG00000235652.6	RP11-545I5.3	-10.26	1.38e-23	9.07e-21	-0.31	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145768220	chr6:145799409~145886585:+
BRCA	cis	rs1062177	0.756	rs2964588	ENSG00000213433.5	RPLP1P6	10.26	1.39e-23	9.1e-21	0.39	0.3	Preschool internalizing problems;	chr5:151738825	chr5:151765859~151766378:-
BRCA	cis	rs17023223	0.508	rs12096448	ENSG00000231365.4	RP11-418J17.1	-10.26	1.39e-23	9.11e-21	-0.39	-0.3	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119140767	chr1:119140396~119275973:+
BRCA	cis	rs17023223	0.537	rs4508058	ENSG00000231365.4	RP11-418J17.1	-10.26	1.39e-23	9.11e-21	-0.39	-0.3	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119141627	chr1:119140396~119275973:+
BRCA	cis	rs524281	0.817	rs7115081	ENSG00000255320.1	RP11-755F10.1	10.26	1.39e-23	9.11e-21	0.46	0.3	Electroencephalogram traits;	chr11:66086070	chr11:66244840~66246239:-
BRCA	cis	rs524281	0.861	rs11227403	ENSG00000255320.1	RP11-755F10.1	10.26	1.39e-23	9.11e-21	0.46	0.3	Electroencephalogram traits;	chr11:66090957	chr11:66244840~66246239:-
BRCA	cis	rs524281	0.861	rs1862005	ENSG00000255320.1	RP11-755F10.1	10.26	1.39e-23	9.11e-21	0.46	0.3	Electroencephalogram traits;	chr11:66095931	chr11:66244840~66246239:-
BRCA	cis	rs524281	0.861	rs7935336	ENSG00000255320.1	RP11-755F10.1	10.26	1.39e-23	9.11e-21	0.46	0.3	Electroencephalogram traits;	chr11:66097854	chr11:66244840~66246239:-
BRCA	cis	rs524281	0.861	rs11227409	ENSG00000255320.1	RP11-755F10.1	10.26	1.39e-23	9.11e-21	0.46	0.3	Electroencephalogram traits;	chr11:66103467	chr11:66244840~66246239:-
BRCA	cis	rs524281	0.861	rs11227410	ENSG00000255320.1	RP11-755F10.1	10.26	1.39e-23	9.11e-21	0.46	0.3	Electroencephalogram traits;	chr11:66105925	chr11:66244840~66246239:-
BRCA	cis	rs875971	0.545	rs73148639	ENSG00000226824.5	RP4-756H11.3	-10.26	1.4e-23	9.14e-21	-0.42	-0.3	Aortic root size;	chr7:66390342	chr7:66654538~66669855:+
BRCA	cis	rs7772486	0.719	rs7753770	ENSG00000235652.6	RP11-545I5.3	-10.26	1.41e-23	9.2e-21	-0.31	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145745025	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.655	rs2142981	ENSG00000235652.6	RP11-545I5.3	-10.26	1.41e-23	9.2e-21	-0.31	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145750559	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.72	rs6570713	ENSG00000235652.6	RP11-545I5.3	-10.26	1.41e-23	9.2e-21	-0.31	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145753949	chr6:145799409~145886585:+
BRCA	cis	rs12458462	0.509	rs3786241	ENSG00000274828.1	RP11-567M16.6	10.26	1.41e-23	9.21e-21	0.33	0.3	Monocyte count;	chr18:79734328	chr18:79677287~79679358:-
BRCA	cis	rs875971	0.545	rs316324	ENSG00000226824.5	RP4-756H11.3	10.26	1.41e-23	9.24e-21	0.41	0.3	Aortic root size;	chr7:66145627	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.545	rs316323	ENSG00000226824.5	RP4-756H11.3	10.26	1.41e-23	9.24e-21	0.41	0.3	Aortic root size;	chr7:66146002	chr7:66654538~66669855:+
BRCA	cis	rs7772486	0.754	rs702319	ENSG00000235652.6	RP11-545I5.3	-10.26	1.41e-23	9.24e-21	-0.31	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145684981	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.754	rs857881	ENSG00000235652.6	RP11-545I5.3	-10.26	1.41e-23	9.25e-21	-0.31	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145649657	chr6:145799409~145886585:+
BRCA	cis	rs1113500	0.836	rs1122158	ENSG00000226822.1	RP11-356N1.2	10.26	1.41e-23	9.25e-21	0.39	0.3	Growth-regulated protein alpha levels;	chr1:108046046	chr1:108071482~108074519:+
BRCA	cis	rs2581828	0.618	rs9838517	ENSG00000242142.1	SERBP1P3	-10.26	1.42e-23	9.27e-21	-0.37	-0.3	Crohn's disease;	chr3:53110347	chr3:53064283~53065091:-
BRCA	cis	rs524281	0.637	rs7126075	ENSG00000255320.1	RP11-755F10.1	10.25	1.43e-23	9.32e-21	0.46	0.3	Electroencephalogram traits;	chr11:66173092	chr11:66244840~66246239:-
BRCA	cis	rs524281	0.861	rs2177054	ENSG00000255320.1	RP11-755F10.1	10.25	1.43e-23	9.32e-21	0.46	0.3	Electroencephalogram traits;	chr11:66177141	chr11:66244840~66246239:-
BRCA	cis	rs7829975	0.582	rs6983150	ENSG00000253893.2	FAM85B	10.25	1.43e-23	9.33e-21	0.38	0.3	Mood instability;	chr8:8934916	chr8:8167819~8226614:-
BRCA	cis	rs858239	0.6	rs10233039	ENSG00000226816.2	AC005082.12	10.25	1.43e-23	9.34e-21	0.35	0.3	Cerebrospinal fluid biomarker levels;	chr7:23103494	chr7:23206013~23208045:+
BRCA	cis	rs875971	0.545	rs10950029	ENSG00000226824.5	RP4-756H11.3	-10.25	1.44e-23	9.4e-21	-0.41	-0.3	Aortic root size;	chr7:66169334	chr7:66654538~66669855:+
BRCA	cis	rs524281	0.861	rs7120326	ENSG00000255320.1	RP11-755F10.1	10.25	1.44e-23	9.43e-21	0.45	0.3	Electroencephalogram traits;	chr11:66081785	chr11:66244840~66246239:-
BRCA	cis	rs7772486	0.875	rs854148	ENSG00000235652.6	RP11-545I5.3	10.25	1.47e-23	9.58e-21	0.31	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145989843	chr6:145799409~145886585:+
BRCA	cis	rs35160687	0.644	rs10165626	ENSG00000273080.1	RP11-301O19.1	-10.25	1.47e-23	9.61e-21	-0.35	-0.3	Night sleep phenotypes;	chr2:86309584	chr2:86195590~86196049:+
BRCA	cis	rs4927850	1	rs10881564	ENSG00000231464.1	AC024937.4	10.25	1.48e-23	9.65e-21	0.39	0.3	Pancreatic cancer;	chr3:196023455	chr3:195996738~195998233:+
BRCA	cis	rs4862750	0.794	rs7692427	ENSG00000250971.1	RP11-696F12.1	10.25	1.51e-23	9.83e-21	0.32	0.3	Lobe attachment (rater-scored or self-reported);	chr4:186980573	chr4:187060099~187060930:+
BRCA	cis	rs4862750	0.832	rs9995958	ENSG00000250971.1	RP11-696F12.1	10.25	1.51e-23	9.83e-21	0.32	0.3	Lobe attachment (rater-scored or self-reported);	chr4:186980610	chr4:187060099~187060930:+
BRCA	cis	rs10129255	1	rs10141557	ENSG00000211970.3	IGHV4-61	-10.25	1.51e-23	9.88e-21	-0.22	-0.3	Kawasaki disease;	chr14:106767990	chr14:106639119~106639657:-
BRCA	cis	rs875971	0.545	rs67397473	ENSG00000226824.5	RP4-756H11.3	-10.25	1.54e-23	1e-20	-0.41	-0.3	Aortic root size;	chr7:66168318	chr7:66654538~66669855:+
BRCA	cis	rs17711722	0.523	rs313812	ENSG00000224316.1	RP11-479O9.2	-10.24	1.56e-23	1.02e-20	-0.31	-0.3	Calcium levels;	chr7:66040056	chr7:65773620~65802067:+
BRCA	cis	rs17711722	0.522	rs4642526	ENSG00000224316.1	RP11-479O9.2	10.24	1.57e-23	1.03e-20	0.31	0.3	Calcium levels;	chr7:65751755	chr7:65773620~65802067:+
BRCA	cis	rs11098499	0.954	rs13133522	ENSG00000245958.5	RP11-33B1.1	-10.24	1.58e-23	1.03e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119403269	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.954	rs35091806	ENSG00000245958.5	RP11-33B1.1	-10.24	1.58e-23	1.03e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119404374	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.909	rs35165976	ENSG00000245958.5	RP11-33B1.1	-10.24	1.58e-23	1.03e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119404475	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.954	rs6846442	ENSG00000245958.5	RP11-33B1.1	-10.24	1.58e-23	1.03e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119405168	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.954	rs71614438	ENSG00000245958.5	RP11-33B1.1	-10.24	1.58e-23	1.03e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119450097	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.954	rs66506550	ENSG00000245958.5	RP11-33B1.1	-10.24	1.58e-23	1.03e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119450290	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.909	rs7659501	ENSG00000245958.5	RP11-33B1.1	-10.24	1.58e-23	1.03e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119450397	chr4:119454791~119552025:+
BRCA	cis	rs6430553	0.964	rs60793693	ENSG00000224043.6	CCNT2-AS1	-10.24	1.58e-23	1.03e-20	-0.38	-0.3	Blood metabolite levels;	chr2:134852125	chr2:134735464~134918710:-
BRCA	cis	rs2882667	0.537	rs10057545	ENSG00000253404.1	AC034243.1	10.24	1.59e-23	1.04e-20	0.38	0.3	Age-related hearing impairment (SNP x SNP interaction);	chr5:139095319	chr5:138744434~138753309:-
BRCA	cis	rs6921919	0.583	rs2071965	ENSG00000216901.1	AL022393.7	10.24	1.63e-23	1.06e-20	0.4	0.3	Autism spectrum disorder or schizophrenia;	chr6:28435448	chr6:28176188~28176674:+
BRCA	cis	rs7772486	0.79	rs4280983	ENSG00000235652.6	RP11-545I5.3	-10.24	1.63e-23	1.06e-20	-0.31	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145959654	chr6:145799409~145886585:+
BRCA	cis	rs2665103	0.61	rs56398167	ENSG00000278603.1	RP13-608F4.5	10.24	1.63e-23	1.06e-20	0.39	0.3	Intelligence (multi-trait analysis);	chr15:82237482	chr15:82472203~82472426:+
BRCA	cis	rs321358	0.731	rs516177	ENSG00000271584.1	RP11-89C3.4	10.24	1.64e-23	1.07e-20	0.48	0.3	Body mass index;	chr11:111138173	chr11:111091932~111097357:-
BRCA	cis	rs7772486	0.754	rs2064185	ENSG00000235652.6	RP11-545I5.3	-10.24	1.64e-23	1.07e-20	-0.31	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145745678	chr6:145799409~145886585:+
BRCA	cis	rs34779708	0.766	rs7897088	ENSG00000230534.5	RP11-297A16.2	10.24	1.65e-23	1.07e-20	0.38	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35262639	chr10:35098006~35127020:-
BRCA	cis	rs7772486	0.79	rs4896852	ENSG00000235652.6	RP11-545I5.3	-10.24	1.65e-23	1.08e-20	-0.31	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145963485	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.875	rs2814871	ENSG00000235652.6	RP11-545I5.3	10.24	1.66e-23	1.08e-20	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145991138	chr6:145799409~145886585:+
BRCA	cis	rs11676348	0.805	rs13007219	ENSG00000261338.2	RP11-378A13.1	-10.24	1.69e-23	1.1e-20	-0.32	-0.3	Ulcerative colitis;	chr2:218099136	chr2:218255319~218257366:+
BRCA	cis	rs7580658	0.676	rs2174270	ENSG00000236682.1	AC068282.3	-10.24	1.69e-23	1.1e-20	-0.4	-0.3	Protein C levels;	chr2:127248502	chr2:127389130~127400580:+
BRCA	cis	rs7772486	0.754	rs697053	ENSG00000235652.6	RP11-545I5.3	-10.24	1.69e-23	1.1e-20	-0.31	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145668671	chr6:145799409~145886585:+
BRCA	cis	rs75422866	0.867	rs73102168	ENSG00000274902.1	RP1-197B17.4	10.24	1.69e-23	1.1e-20	0.8	0.3	Pneumonia;	chr12:47654010	chr12:47731908~47732351:+
BRCA	cis	rs6570726	0.791	rs9403734	ENSG00000235652.6	RP11-545I5.3	10.24	1.69e-23	1.1e-20	0.31	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145610323	chr6:145799409~145886585:+
BRCA	cis	rs11971779	0.688	rs8137	ENSG00000273391.1	RP11-634H22.1	-10.24	1.7e-23	1.11e-20	-0.3	-0.3	Diisocyanate-induced asthma;	chr7:139419715	chr7:139359032~139359566:-
BRCA	cis	rs2412819	0.571	rs2729494	ENSG00000249839.1	AC011330.5	10.23	1.72e-23	1.12e-20	0.42	0.3	Lung cancer;	chr15:43837395	chr15:43663654~43684339:-
BRCA	cis	rs875971	0.545	rs2460427	ENSG00000226824.5	RP4-756H11.3	10.23	1.73e-23	1.12e-20	0.41	0.3	Aortic root size;	chr7:66154218	chr7:66654538~66669855:+
BRCA	cis	rs17711722	0.522	rs6957759	ENSG00000224316.1	RP11-479O9.2	10.23	1.74e-23	1.13e-20	0.31	0.3	Calcium levels;	chr7:65806798	chr7:65773620~65802067:+
BRCA	cis	rs7772486	0.701	rs7772717	ENSG00000235652.6	RP11-545I5.3	10.23	1.74e-23	1.13e-20	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145633718	chr6:145799409~145886585:+
BRCA	cis	rs6782228	0.606	rs4634140	ENSG00000242551.2	POU5F1P6	10.23	1.75e-23	1.14e-20	0.37	0.3	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128705613	chr3:128674735~128677005:-
BRCA	cis	rs6142102	0.625	rs6141431	ENSG00000276073.1	RP5-1125A11.7	-10.23	1.76e-23	1.14e-20	-0.35	-0.3	Skin pigmentation;	chr20:33952508	chr20:33985617~33988989:-
BRCA	cis	rs4380275	1	rs4268954	ENSG00000272342.1	RP13-539J13.1	10.23	1.78e-23	1.16e-20	0.39	0.3	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:772834	chr2:739588~740164:-
BRCA	cis	rs2015599	0.525	rs10771514	ENSG00000257176.2	RP11-996F15.2	10.23	1.8e-23	1.17e-20	0.36	0.3	Platelet count;Mean platelet volume;	chr12:29315751	chr12:29280418~29317848:-
BRCA	cis	rs10129255	0.957	rs2007467	ENSG00000211970.3	IGHV4-61	10.23	1.81e-23	1.17e-20	0.22	0.3	Kawasaki disease;	chr14:106771605	chr14:106639119~106639657:-
BRCA	cis	rs75422866	0.867	rs73113143	ENSG00000257433.4	RP1-197B17.3	10.23	1.82e-23	1.18e-20	0.7	0.3	Pneumonia;	chr12:47623060	chr12:47706085~47742294:+
BRCA	cis	rs6538678	0.929	rs10777744	ENSG00000258343.1	RP11-536G4.2	-10.23	1.83e-23	1.19e-20	-0.42	-0.3	Lupus nephritis in systemic lupus erythematosus;	chr12:95864561	chr12:95795345~95858839:-
BRCA	cis	rs75422866	1	rs73102120	ENSG00000274902.1	RP1-197B17.4	10.23	1.86e-23	1.21e-20	0.8	0.3	Pneumonia;	chr12:47637280	chr12:47731908~47732351:+
BRCA	cis	rs75422866	0.867	rs12422974	ENSG00000274902.1	RP1-197B17.4	10.23	1.86e-23	1.21e-20	0.8	0.3	Pneumonia;	chr12:47644559	chr12:47731908~47732351:+
BRCA	cis	rs75422866	0.867	rs73102127	ENSG00000274902.1	RP1-197B17.4	10.23	1.86e-23	1.21e-20	0.8	0.3	Pneumonia;	chr12:47645341	chr12:47731908~47732351:+
BRCA	cis	rs75422866	0.867	rs73102166	ENSG00000274902.1	RP1-197B17.4	10.23	1.86e-23	1.21e-20	0.8	0.3	Pneumonia;	chr12:47653769	chr12:47731908~47732351:+
BRCA	cis	rs75422866	0.867	rs73102171	ENSG00000274902.1	RP1-197B17.4	10.23	1.86e-23	1.21e-20	0.8	0.3	Pneumonia;	chr12:47656077	chr12:47731908~47732351:+
BRCA	cis	rs75422866	0.867	rs76100981	ENSG00000274902.1	RP1-197B17.4	10.23	1.86e-23	1.21e-20	0.8	0.3	Pneumonia;	chr12:47660092	chr12:47731908~47732351:+
BRCA	cis	rs7772486	0.754	rs6915718	ENSG00000235652.6	RP11-545I5.3	-10.23	1.88e-23	1.21e-20	-0.3	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145779540	chr6:145799409~145886585:+
BRCA	cis	rs11603023	0.967	rs7936556	ENSG00000255422.1	AP002954.4	10.22	1.88e-23	1.22e-20	0.35	0.3	Cholesterol, total;	chr11:118630582	chr11:118704607~118750263:+
BRCA	cis	rs1823913	0.599	rs17412635	ENSG00000227542.1	AC092614.2	-10.22	1.89e-23	1.22e-20	-0.36	-0.3	Obesity-related traits;	chr2:191294834	chr2:191229165~191246172:-
BRCA	cis	rs1707322	0.752	rs11211146	ENSG00000280836.1	AL355480.1	-10.22	1.93e-23	1.25e-20	-0.39	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45644122	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.752	rs11211147	ENSG00000280836.1	AL355480.1	-10.22	1.93e-23	1.25e-20	-0.39	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45644422	chr1:45581219~45581321:-
BRCA	cis	rs4423214	0.559	rs10898203	ENSG00000254682.1	RP11-660L16.2	-10.22	1.94e-23	1.25e-20	-0.47	-0.3	Vitamin D levels;	chr11:71492390	chr11:71448674~71452157:+
BRCA	cis	rs7772486	0.875	rs865913	ENSG00000235652.6	RP11-545I5.3	10.22	1.95e-23	1.26e-20	0.31	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145987738	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.875	rs2814873	ENSG00000235652.6	RP11-545I5.3	10.22	1.95e-23	1.26e-20	0.31	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145987796	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.84	rs2777478	ENSG00000235652.6	RP11-545I5.3	10.22	1.95e-23	1.26e-20	0.31	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145987981	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.875	rs2814872	ENSG00000235652.6	RP11-545I5.3	10.22	1.95e-23	1.26e-20	0.31	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145989098	chr6:145799409~145886585:+
BRCA	cis	rs6723108	0.517	rs6430548	ENSG00000224043.6	CCNT2-AS1	-10.22	1.95e-23	1.26e-20	-0.39	-0.3	Type 2 diabetes;	chr2:134854869	chr2:134735464~134918710:-
BRCA	cis	rs11105298	0.891	rs10858909	ENSG00000258302.2	RP11-981P6.1	10.22	1.95e-23	1.26e-20	0.36	0.3	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89541610	chr12:89561129~89594878:+
BRCA	cis	rs1062177	0.724	rs2915828	ENSG00000213433.5	RPLP1P6	10.22	1.99e-23	1.28e-20	0.39	0.3	Preschool internalizing problems;	chr5:151738560	chr5:151765859~151766378:-
BRCA	cis	rs2015599	0.543	rs6487807	ENSG00000257176.2	RP11-996F15.2	10.22	1.99e-23	1.28e-20	0.36	0.3	Platelet count;Mean platelet volume;	chr12:29309291	chr12:29280418~29317848:-
BRCA	cis	rs11098499	0.865	rs11098513	ENSG00000245958.5	RP11-33B1.1	-10.22	2e-23	1.29e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119394920	chr4:119454791~119552025:+
BRCA	cis	rs1707322	0.721	rs28501477	ENSG00000280836.1	AL355480.1	-10.22	2e-23	1.29e-20	-0.39	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45733412	chr1:45581219~45581321:-
BRCA	cis	rs4964805	0.505	rs15918	ENSG00000257681.1	RP11-341G23.4	10.22	2e-23	1.29e-20	0.37	0.3	Attention deficit hyperactivity disorder;	chr12:103773246	chr12:103746315~103768858:-
BRCA	cis	rs11098499	0.697	rs11941899	ENSG00000245958.5	RP11-33B1.1	-10.22	2.02e-23	1.3e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119461603	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.909	rs7681978	ENSG00000245958.5	RP11-33B1.1	-10.22	2.02e-23	1.3e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119462620	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.821	rs28665282	ENSG00000245958.5	RP11-33B1.1	-10.22	2.02e-23	1.3e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119463031	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.738	rs10026493	ENSG00000245958.5	RP11-33B1.1	-10.22	2.02e-23	1.3e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119463039	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.909	rs7681214	ENSG00000245958.5	RP11-33B1.1	-10.22	2.02e-23	1.3e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119464165	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.909	rs28632018	ENSG00000245958.5	RP11-33B1.1	-10.22	2.02e-23	1.3e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119465575	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.908	rs71614449	ENSG00000245958.5	RP11-33B1.1	-10.22	2.02e-23	1.3e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119465900	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.954	rs35063680	ENSG00000245958.5	RP11-33B1.1	-10.22	2.02e-23	1.3e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119465947	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.954	rs34858317	ENSG00000245958.5	RP11-33B1.1	-10.22	2.02e-23	1.3e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119465955	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.954	rs17046116	ENSG00000245958.5	RP11-33B1.1	-10.22	2.02e-23	1.3e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119466104	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.909	rs17046118	ENSG00000245958.5	RP11-33B1.1	-10.22	2.02e-23	1.3e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119466341	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.954	rs7654587	ENSG00000245958.5	RP11-33B1.1	-10.22	2.02e-23	1.3e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119467251	chr4:119454791~119552025:+
BRCA	cis	rs2243480	1	rs781157	ENSG00000226824.5	RP4-756H11.3	-10.22	2.02e-23	1.31e-20	-0.57	-0.3	Diabetic kidney disease;	chr7:66013324	chr7:66654538~66669855:+
BRCA	cis	rs7580658	0.857	rs17015199	ENSG00000236682.1	AC068282.3	-10.22	2.03e-23	1.31e-20	-0.4	-0.3	Protein C levels;	chr2:127336477	chr2:127389130~127400580:+
BRCA	cis	rs7772486	0.79	rs7753696	ENSG00000235652.6	RP11-545I5.3	-10.22	2.04e-23	1.32e-20	-0.31	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145957962	chr6:145799409~145886585:+
BRCA	cis	rs2243480	1	rs160634	ENSG00000226824.5	RP4-756H11.3	10.22	2.06e-23	1.33e-20	0.56	0.3	Diabetic kidney disease;	chr7:66063677	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.545	rs10950025	ENSG00000226824.5	RP4-756H11.3	-10.22	2.06e-23	1.33e-20	-0.41	-0.3	Aortic root size;	chr7:66158946	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.52	rs12666485	ENSG00000226824.5	RP4-756H11.3	-10.22	2.06e-23	1.33e-20	-0.41	-0.3	Aortic root size;	chr7:66160135	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.545	rs67688847	ENSG00000226824.5	RP4-756H11.3	-10.22	2.06e-23	1.33e-20	-0.41	-0.3	Aortic root size;	chr7:66161064	chr7:66654538~66669855:+
BRCA	cis	rs11676348	0.935	rs13007992	ENSG00000261338.2	RP11-378A13.1	-10.22	2.06e-23	1.33e-20	-0.32	-0.3	Ulcerative colitis;	chr2:218099328	chr2:218255319~218257366:+
BRCA	cis	rs694739	0.93	rs574087	ENSG00000236935.1	AP003774.1	10.21	2.09e-23	1.35e-20	0.3	0.3	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64335476	chr11:64325050~64329504:-
BRCA	cis	rs1707322	0.716	rs6694889	ENSG00000280836.1	AL355480.1	-10.21	2.09e-23	1.35e-20	-0.39	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45636134	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.682	rs12041197	ENSG00000280836.1	AL355480.1	-10.21	2.09e-23	1.35e-20	-0.39	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45638792	chr1:45581219~45581321:-
BRCA	cis	rs992157	0.764	rs4672886	ENSG00000261338.2	RP11-378A13.1	-10.21	2.11e-23	1.36e-20	-0.33	-0.3	Colorectal cancer;	chr2:218320822	chr2:218255319~218257366:+
BRCA	cis	rs2439831	0.85	rs12441861	ENSG00000275601.1	AC011330.13	-10.21	2.12e-23	1.37e-20	-0.48	-0.3	Lung cancer in ever smokers;	chr15:43768685	chr15:43642389~43643023:-
BRCA	cis	rs17482078	0.959	rs10043309	ENSG00000248734.2	CTD-2260A17.1	10.21	2.13e-23	1.37e-20	0.42	0.3	Behcet's disease;Blood protein levels;	chr5:96804163	chr5:96784777~96785999:+
BRCA	cis	rs17482078	0.959	rs10041240	ENSG00000248734.2	CTD-2260A17.1	10.21	2.13e-23	1.37e-20	0.42	0.3	Behcet's disease;Blood protein levels;	chr5:96805037	chr5:96784777~96785999:+
BRCA	cis	rs4862750	0.915	rs6835681	ENSG00000250971.1	RP11-696F12.1	10.21	2.15e-23	1.38e-20	0.32	0.3	Lobe attachment (rater-scored or self-reported);	chr4:186982322	chr4:187060099~187060930:+
BRCA	cis	rs6844153	0.68	rs61047003	ENSG00000240005.4	RP11-293A21.1	-10.21	2.16e-23	1.39e-20	-0.39	-0.3	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26937139	chr4:26859806~26860599:-
BRCA	cis	rs2439831	0.702	rs7175032	ENSG00000249839.1	AC011330.5	-10.21	2.17e-23	1.4e-20	-0.5	-0.3	Lung cancer in ever smokers;	chr15:43768038	chr15:43663654~43684339:-
BRCA	cis	rs11098499	0.779	rs28495013	ENSG00000245958.5	RP11-33B1.1	-10.21	2.18e-23	1.4e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119454676	chr4:119454791~119552025:+
BRCA	cis	rs6921919	0.525	rs16894095	ENSG00000216901.1	AL022393.7	10.21	2.18e-23	1.4e-20	0.4	0.3	Autism spectrum disorder or schizophrenia;	chr6:28422453	chr6:28176188~28176674:+
BRCA	cis	rs11098499	0.954	rs11098525	ENSG00000245958.5	RP11-33B1.1	-10.21	2.18e-23	1.41e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119468997	chr4:119454791~119552025:+
BRCA	cis	rs6142102	0.517	rs6142046	ENSG00000276073.1	RP5-1125A11.7	-10.21	2.18e-23	1.41e-20	-0.35	-0.3	Skin pigmentation;	chr20:33926255	chr20:33985617~33988989:-
BRCA	cis	rs733592	0.894	rs886589	ENSG00000240399.1	RP1-228P16.1	-10.21	2.2e-23	1.42e-20	-0.34	-0.3	Plateletcrit;	chr12:48083414	chr12:48054813~48055591:-
BRCA	cis	rs2243480	0.908	rs313822	ENSG00000226824.5	RP4-756H11.3	-10.21	2.21e-23	1.42e-20	-0.6	-0.3	Diabetic kidney disease;	chr7:66108952	chr7:66654538~66669855:+
BRCA	cis	rs1823913	0.599	rs17346475	ENSG00000227542.1	AC092614.2	-10.21	2.21e-23	1.42e-20	-0.37	-0.3	Obesity-related traits;	chr2:191288488	chr2:191229165~191246172:-
BRCA	cis	rs6723108	0.517	rs10928520	ENSG00000224043.6	CCNT2-AS1	-10.21	2.22e-23	1.43e-20	-0.38	-0.3	Type 2 diabetes;	chr2:134846613	chr2:134735464~134918710:-
BRCA	cis	rs11971779	0.68	rs6978680	ENSG00000273391.1	RP11-634H22.1	-10.21	2.22e-23	1.43e-20	-0.3	-0.3	Diisocyanate-induced asthma;	chr7:139427302	chr7:139359032~139359566:-
BRCA	cis	rs7772486	0.719	rs702307	ENSG00000235652.6	RP11-545I5.3	-10.21	2.22e-23	1.43e-20	-0.31	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145672318	chr6:145799409~145886585:+
BRCA	cis	rs524281	0.861	rs10791855	ENSG00000255320.1	RP11-755F10.1	10.21	2.23e-23	1.43e-20	0.45	0.3	Electroencephalogram traits;	chr11:66196266	chr11:66244840~66246239:-
BRCA	cis	rs2276314	1	rs8086395	ENSG00000278986.1	RP11-723J4.3	-10.21	2.23e-23	1.43e-20	-0.38	-0.3	Endometriosis;Drug-induced torsades de pointes;	chr18:35984629	chr18:35972151~35973916:+
BRCA	cis	rs2276314	0.947	rs3898595	ENSG00000278986.1	RP11-723J4.3	-10.21	2.23e-23	1.43e-20	-0.38	-0.3	Endometriosis;Drug-induced torsades de pointes;	chr18:35985922	chr18:35972151~35973916:+
BRCA	cis	rs8062405	0.755	rs56272201	ENSG00000259982.1	CDC37P1	10.21	2.24e-23	1.44e-20	0.41	0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28569364	chr16:28700294~28701540:-
BRCA	cis	rs8062405	0.755	rs62034355	ENSG00000259982.1	CDC37P1	10.21	2.24e-23	1.44e-20	0.41	0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28569717	chr16:28700294~28701540:-
BRCA	cis	rs7688540	0.771	rs11722521	ENSG00000275426.1	CH17-262A2.1	10.21	2.24e-23	1.44e-20	0.47	0.3	Facial morphology (factor 6, height of vermillion lower lip);	chr4:282976	chr4:149738~150317:+
BRCA	cis	rs6545883	0.507	rs4411680	ENSG00000271889.1	RP11-493E12.1	-10.21	2.26e-23	1.45e-20	-0.36	-0.3	Tuberculosis;	chr2:61356970	chr2:61151433~61162105:-
BRCA	cis	rs11105298	0.891	rs10858896	ENSG00000258302.2	RP11-981P6.1	10.21	2.27e-23	1.46e-20	0.35	0.3	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89526407	chr12:89561129~89594878:+
BRCA	cis	rs11105298	0.786	rs10777186	ENSG00000258302.2	RP11-981P6.1	10.21	2.27e-23	1.46e-20	0.35	0.3	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89527500	chr12:89561129~89594878:+
BRCA	cis	rs7772486	0.875	rs864390	ENSG00000235652.6	RP11-545I5.3	10.2	2.27e-23	1.46e-20	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145993899	chr6:145799409~145886585:+
BRCA	cis	rs2882667	0.537	rs13181793	ENSG00000253404.1	AC034243.1	10.2	2.29e-23	1.47e-20	0.38	0.3	Age-related hearing impairment (SNP x SNP interaction);	chr5:139073267	chr5:138744434~138753309:-
BRCA	cis	rs6570726	0.791	rs427128	ENSG00000235652.6	RP11-545I5.3	10.2	2.3e-23	1.48e-20	0.31	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145544781	chr6:145799409~145886585:+
BRCA	cis	rs1707322	0.721	rs4415615	ENSG00000280836.1	AL355480.1	-10.2	2.3e-23	1.48e-20	-0.39	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45666437	chr1:45581219~45581321:-
BRCA	cis	rs2276314	1	rs4799834	ENSG00000278986.1	RP11-723J4.3	-10.2	2.3e-23	1.48e-20	-0.38	-0.3	Endometriosis;Drug-induced torsades de pointes;	chr18:35986280	chr18:35972151~35973916:+
BRCA	cis	rs17023223	0.581	rs10923750	ENSG00000231365.4	RP11-418J17.1	-10.2	2.34e-23	1.5e-20	-0.38	-0.3	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119108172	chr1:119140396~119275973:+
BRCA	cis	rs11673344	0.868	rs1047333	ENSG00000226686.6	LINC01535	10.2	2.35e-23	1.51e-20	0.41	0.3	Obesity-related traits;	chr19:37151263	chr19:37251912~37265535:+
BRCA	cis	rs867371	0.502	rs3759800	ENSG00000278603.1	RP13-608F4.5	-10.2	2.38e-23	1.53e-20	-0.38	-0.3	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82240622	chr15:82472203~82472426:+
BRCA	cis	rs321358	0.731	rs536579	ENSG00000271584.1	RP11-89C3.4	10.2	2.38e-23	1.53e-20	0.48	0.3	Body mass index;	chr11:111145748	chr11:111091932~111097357:-
BRCA	cis	rs867371	0.502	rs8025964	ENSG00000278603.1	RP13-608F4.5	10.2	2.43e-23	1.56e-20	0.39	0.3	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82229429	chr15:82472203~82472426:+
BRCA	cis	rs2439831	0.702	rs2788	ENSG00000249839.1	AC011330.5	-10.2	2.44e-23	1.56e-20	-0.5	-0.3	Lung cancer in ever smokers;	chr15:43772688	chr15:43663654~43684339:-
BRCA	cis	rs2439831	0.85	rs28891769	ENSG00000249839.1	AC011330.5	-10.2	2.44e-23	1.56e-20	-0.5	-0.3	Lung cancer in ever smokers;	chr15:43780662	chr15:43663654~43684339:-
BRCA	cis	rs2439831	0.85	rs28578398	ENSG00000249839.1	AC011330.5	-10.2	2.44e-23	1.56e-20	-0.5	-0.3	Lung cancer in ever smokers;	chr15:43782848	chr15:43663654~43684339:-
BRCA	cis	rs2015599	0.549	rs7956305	ENSG00000257176.2	RP11-996F15.2	10.2	2.44e-23	1.57e-20	0.36	0.3	Platelet count;Mean platelet volume;	chr12:29308639	chr12:29280418~29317848:-
BRCA	cis	rs7772486	0.754	rs4896839	ENSG00000235652.6	RP11-545I5.3	-10.2	2.45e-23	1.57e-20	-0.31	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145698553	chr6:145799409~145886585:+
BRCA	cis	rs2439831	0.702	rs2788	ENSG00000275601.1	AC011330.13	-10.2	2.45e-23	1.57e-20	-0.48	-0.3	Lung cancer in ever smokers;	chr15:43772688	chr15:43642389~43643023:-
BRCA	cis	rs2439831	0.85	rs28891769	ENSG00000275601.1	AC011330.13	-10.2	2.45e-23	1.57e-20	-0.48	-0.3	Lung cancer in ever smokers;	chr15:43780662	chr15:43642389~43643023:-
BRCA	cis	rs2439831	0.85	rs28578398	ENSG00000275601.1	AC011330.13	-10.2	2.45e-23	1.57e-20	-0.48	-0.3	Lung cancer in ever smokers;	chr15:43782848	chr15:43642389~43643023:-
BRCA	cis	rs732716	0.785	rs62129354	ENSG00000267769.1	CTB-50L17.9	-10.2	2.47e-23	1.58e-20	-0.39	-0.3	Mean corpuscular volume;	chr19:4396508	chr19:4454014~4455286:+
BRCA	cis	rs2412819	0.571	rs495880	ENSG00000249839.1	AC011330.5	10.19	2.5e-23	1.6e-20	0.42	0.3	Lung cancer;	chr15:43855067	chr15:43663654~43684339:-
BRCA	cis	rs1823913	0.599	rs10497713	ENSG00000227542.1	AC092614.2	10.19	2.5e-23	1.6e-20	0.36	0.3	Obesity-related traits;	chr2:191279312	chr2:191229165~191246172:-
BRCA	cis	rs2015599	0.56	rs3948497	ENSG00000275476.1	RP11-996F15.4	-10.19	2.5e-23	1.6e-20	-0.36	-0.3	Platelet count;Mean platelet volume;	chr12:29247552	chr12:29277397~29277882:-
BRCA	cis	rs7688540	0.771	rs78343340	ENSG00000275426.1	CH17-262A2.1	10.19	2.51e-23	1.61e-20	0.47	0.3	Facial morphology (factor 6, height of vermillion lower lip);	chr4:273648	chr4:149738~150317:+
BRCA	cis	rs2243480	1	rs781149	ENSG00000226824.5	RP4-756H11.3	-10.19	2.52e-23	1.61e-20	-0.57	-0.3	Diabetic kidney disease;	chr7:66016297	chr7:66654538~66669855:+
BRCA	cis	rs2243480	0.901	rs58207111	ENSG00000226824.5	RP4-756H11.3	-10.19	2.52e-23	1.61e-20	-0.57	-0.3	Diabetic kidney disease;	chr7:66021736	chr7:66654538~66669855:+
BRCA	cis	rs6538678	0.746	rs12820313	ENSG00000258343.1	RP11-536G4.2	-10.19	2.52e-23	1.62e-20	-0.42	-0.3	Lupus nephritis in systemic lupus erythematosus;	chr12:95861926	chr12:95795345~95858839:-
BRCA	cis	rs11098499	0.779	rs80242894	ENSG00000245958.5	RP11-33B1.1	-10.19	2.53e-23	1.62e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119454597	chr4:119454791~119552025:+
BRCA	cis	rs875971	0.545	rs1267814	ENSG00000226824.5	RP4-756H11.3	10.19	2.53e-23	1.62e-20	0.42	0.3	Aortic root size;	chr7:66579422	chr7:66654538~66669855:+
BRCA	cis	rs1707322	0.682	rs10890334	ENSG00000280836.1	AL355480.1	-10.19	2.53e-23	1.62e-20	-0.39	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634706	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.752	rs11211152	ENSG00000280836.1	AL355480.1	-10.19	2.53e-23	1.62e-20	-0.39	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45648485	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.752	rs4607935	ENSG00000280836.1	AL355480.1	-10.19	2.53e-23	1.62e-20	-0.39	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45651489	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.681	rs12048866	ENSG00000280836.1	AL355480.1	-10.19	2.53e-23	1.62e-20	-0.39	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45651820	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.752	rs3811436	ENSG00000280836.1	AL355480.1	-10.19	2.53e-23	1.62e-20	-0.39	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45660208	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.752	rs12024590	ENSG00000280836.1	AL355480.1	-10.19	2.53e-23	1.62e-20	-0.39	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45661824	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.752	rs12027622	ENSG00000280836.1	AL355480.1	-10.19	2.53e-23	1.62e-20	-0.39	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45664580	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.752	rs7529699	ENSG00000280836.1	AL355480.1	-10.19	2.53e-23	1.62e-20	-0.39	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45668962	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.716	rs6699444	ENSG00000280836.1	AL355480.1	-10.19	2.53e-23	1.62e-20	-0.39	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45669448	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.752	rs10430105	ENSG00000280836.1	AL355480.1	-10.19	2.53e-23	1.62e-20	-0.39	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45673204	chr1:45581219~45581321:-
BRCA	cis	rs10875746	0.551	rs10875799	ENSG00000240399.1	RP1-228P16.1	-10.19	2.54e-23	1.62e-20	-0.41	-0.3	Longevity (90 years and older);	chr12:48347096	chr12:48054813~48055591:-
BRCA	cis	rs1707322	0.721	rs7519900	ENSG00000280836.1	AL355480.1	-10.19	2.54e-23	1.63e-20	-0.39	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45769275	chr1:45581219~45581321:-
BRCA	cis	rs733592	0.929	rs4760678	ENSG00000240399.1	RP1-228P16.1	-10.19	2.55e-23	1.63e-20	-0.34	-0.3	Plateletcrit;	chr12:48067798	chr12:48054813~48055591:-
BRCA	cis	rs733592	0.965	rs1978161	ENSG00000240399.1	RP1-228P16.1	-10.19	2.55e-23	1.63e-20	-0.34	-0.3	Plateletcrit;	chr12:48073938	chr12:48054813~48055591:-
BRCA	cis	rs10875746	0.669	rs2279464	ENSG00000240399.1	RP1-228P16.1	-10.19	2.59e-23	1.65e-20	-0.42	-0.3	Longevity (90 years and older);	chr12:48296626	chr12:48054813~48055591:-
BRCA	cis	rs7772486	0.79	rs9497431	ENSG00000235652.6	RP11-545I5.3	-10.19	2.61e-23	1.66e-20	-0.31	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145927041	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.79	rs7753092	ENSG00000235652.6	RP11-545I5.3	-10.19	2.61e-23	1.66e-20	-0.31	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145927727	chr6:145799409~145886585:+
BRCA	cis	rs75422866	0.867	rs75568526	ENSG00000257433.4	RP1-197B17.3	10.19	2.62e-23	1.67e-20	0.69	0.3	Pneumonia;	chr12:47649718	chr12:47706085~47742294:+
BRCA	cis	rs75422866	0.867	rs116302411	ENSG00000257433.4	RP1-197B17.3	10.19	2.62e-23	1.67e-20	0.69	0.3	Pneumonia;	chr12:47649788	chr12:47706085~47742294:+
BRCA	cis	rs75422866	0.867	rs73113117	ENSG00000257433.4	RP1-197B17.3	10.19	2.63e-23	1.68e-20	0.69	0.3	Pneumonia;	chr12:47617299	chr12:47706085~47742294:+
BRCA	cis	rs7772486	0.875	rs2777483	ENSG00000235652.6	RP11-545I5.3	10.19	2.65e-23	1.69e-20	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:146008099	chr6:145799409~145886585:+
BRCA	cis	rs673078	0.615	rs61943528	ENSG00000275759.1	RP11-131L12.3	-10.19	2.66e-23	1.69e-20	-0.5	-0.3	Glucose homeostasis traits;	chr12:118163134	chr12:118428281~118428870:+
BRCA	cis	rs875971	0.545	rs7787063	ENSG00000226824.5	RP4-756H11.3	-10.19	2.66e-23	1.7e-20	-0.41	-0.3	Aortic root size;	chr7:66164012	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.545	rs12673308	ENSG00000226824.5	RP4-756H11.3	-10.19	2.66e-23	1.7e-20	-0.41	-0.3	Aortic root size;	chr7:66166374	chr7:66654538~66669855:+
BRCA	cis	rs732716	0.785	rs34080966	ENSG00000267769.1	CTB-50L17.9	10.19	2.66e-23	1.7e-20	0.37	0.3	Mean corpuscular volume;	chr19:4417848	chr19:4454014~4455286:+
BRCA	cis	rs1707322	0.721	rs10890341	ENSG00000280836.1	AL355480.1	-10.19	2.67e-23	1.71e-20	-0.39	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45681568	chr1:45581219~45581321:-
BRCA	cis	rs7772486	0.754	rs9386134	ENSG00000235652.6	RP11-545I5.3	10.19	2.68e-23	1.71e-20	0.31	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145824372	chr6:145799409~145886585:+
BRCA	cis	rs8072100	0.935	rs78551919	ENSG00000228782.6	CTD-2026D20.3	-10.19	2.69e-23	1.71e-20	-0.32	-0.3	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47548636	chr17:47450568~47492492:-
BRCA	cis	rs11676348	0.904	rs10804264	ENSG00000261338.2	RP11-378A13.1	-10.18	2.74e-23	1.75e-20	-0.32	-0.3	Ulcerative colitis;	chr2:218091086	chr2:218255319~218257366:+
BRCA	cis	rs11105298	0.891	rs11105313	ENSG00000258302.2	RP11-981P6.1	-10.18	2.75e-23	1.76e-20	-0.34	-0.3	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89529599	chr12:89561129~89594878:+
BRCA	cis	rs7580658	0.895	rs4662580	ENSG00000236682.1	AC068282.3	-10.18	2.76e-23	1.76e-20	-0.4	-0.3	Protein C levels;	chr2:127345230	chr2:127389130~127400580:+
BRCA	cis	rs7772486	0.79	rs4075694	ENSG00000235652.6	RP11-545I5.3	-10.18	2.76e-23	1.76e-20	-0.31	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145929972	chr6:145799409~145886585:+
BRCA	cis	rs7580658	0.895	rs4662722	ENSG00000236682.1	AC068282.3	-10.18	2.77e-23	1.77e-20	-0.4	-0.3	Protein C levels;	chr2:127344993	chr2:127389130~127400580:+
BRCA	cis	rs1823913	0.927	rs35530564	ENSG00000227542.1	AC092614.2	10.18	2.78e-23	1.77e-20	0.39	0.3	Obesity-related traits;	chr2:191247324	chr2:191229165~191246172:-
BRCA	cis	rs2439831	0.702	rs7175032	ENSG00000275601.1	AC011330.13	-10.18	2.78e-23	1.77e-20	-0.48	-0.3	Lung cancer in ever smokers;	chr15:43768038	chr15:43642389~43643023:-
BRCA	cis	rs11098499	0.697	rs4560394	ENSG00000245958.5	RP11-33B1.1	-10.18	2.79e-23	1.78e-20	-0.3	-0.3	Corneal astigmatism;	chr4:119392280	chr4:119454791~119552025:+
BRCA	cis	rs7580658	0.864	rs34832797	ENSG00000236682.1	AC068282.3	-10.18	2.8e-23	1.78e-20	-0.4	-0.3	Protein C levels;	chr2:127361865	chr2:127389130~127400580:+
BRCA	cis	rs6921919	0.583	rs740621	ENSG00000216901.1	AL022393.7	10.18	2.8e-23	1.78e-20	0.4	0.3	Autism spectrum disorder or schizophrenia;	chr6:28430010	chr6:28176188~28176674:+
BRCA	cis	rs7201929	1	rs8061877	ENSG00000259982.1	CDC37P1	-10.18	2.81e-23	1.79e-20	-0.39	-0.3	QT interval;	chr16:28845498	chr16:28700294~28701540:-
BRCA	cis	rs11098499	0.908	rs28559989	ENSG00000245958.5	RP11-33B1.1	-10.18	2.82e-23	1.79e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119465472	chr4:119454791~119552025:+
BRCA	cis	rs4964805	0.672	rs11111757	ENSG00000257681.1	RP11-341G23.4	10.18	2.82e-23	1.79e-20	0.37	0.3	Attention deficit hyperactivity disorder;	chr12:103766984	chr12:103746315~103768858:-
BRCA	cis	rs7772486	0.72	rs1890171	ENSG00000235652.6	RP11-545I5.3	-10.18	2.82e-23	1.8e-20	-0.3	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145750978	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.72	rs4896844	ENSG00000235652.6	RP11-545I5.3	-10.18	2.82e-23	1.8e-20	-0.3	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145754088	chr6:145799409~145886585:+
BRCA	cis	rs8091660	0.893	rs1567656	ENSG00000278983.1	RP11-426J5.3	-10.18	2.84e-23	1.81e-20	-0.35	-0.3	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48568420	chr18:48564795~48568342:+
BRCA	cis	rs673078	0.607	rs2036314	ENSG00000275759.1	RP11-131L12.3	-10.18	2.85e-23	1.82e-20	-0.41	-0.3	Glucose homeostasis traits;	chr12:118367132	chr12:118428281~118428870:+
BRCA	cis	rs673078	0.607	rs61943369	ENSG00000275759.1	RP11-131L12.3	-10.18	2.85e-23	1.82e-20	-0.41	-0.3	Glucose homeostasis traits;	chr12:118368145	chr12:118428281~118428870:+
BRCA	cis	rs11690935	0.527	rs7586556	ENSG00000228389.1	AC068039.4	-10.18	2.85e-23	1.82e-20	-0.37	-0.3	Schizophrenia;	chr2:172036983	chr2:171773482~171775844:+
BRCA	cis	rs7772486	0.875	rs2474356	ENSG00000235652.6	RP11-545I5.3	10.18	2.87e-23	1.83e-20	0.31	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145975662	chr6:145799409~145886585:+
BRCA	cis	rs4713118	0.629	rs149899	ENSG00000220721.1	OR1F12	10.18	2.88e-23	1.83e-20	0.39	0.3	Parkinson's disease;	chr6:28052201	chr6:28073316~28074233:+
BRCA	cis	rs4713118	0.629	rs172165	ENSG00000220721.1	OR1F12	10.18	2.88e-23	1.83e-20	0.39	0.3	Parkinson's disease;	chr6:28053036	chr6:28073316~28074233:+
BRCA	cis	rs7772486	0.817	rs2748491	ENSG00000235652.6	RP11-545I5.3	10.18	2.89e-23	1.84e-20	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:146006623	chr6:145799409~145886585:+
BRCA	cis	rs11096990	0.634	rs2381371	ENSG00000249207.1	RP11-360F5.1	-10.18	2.89e-23	1.84e-20	-0.36	-0.3	Cognitive function;	chr4:39271414	chr4:39112677~39126818:-
BRCA	cis	rs7829975	0.617	rs4841072	ENSG00000253893.2	FAM85B	10.18	2.89e-23	1.84e-20	0.37	0.3	Mood instability;	chr8:8933743	chr8:8167819~8226614:-
BRCA	cis	rs11096990	0.593	rs1026235	ENSG00000249207.1	RP11-360F5.1	-10.18	2.89e-23	1.84e-20	-0.36	-0.3	Cognitive function;	chr4:39226629	chr4:39112677~39126818:-
BRCA	cis	rs733592	0.507	rs56129148	ENSG00000240399.1	RP1-228P16.1	-10.18	2.89e-23	1.84e-20	-0.32	-0.3	Plateletcrit;	chr12:48091747	chr12:48054813~48055591:-
BRCA	cis	rs2921073	0.605	rs2976933	ENSG00000253893.2	FAM85B	-10.18	2.91e-23	1.85e-20	-0.39	-0.3	Parkinson's disease;	chr8:8397365	chr8:8167819~8226614:-
BRCA	cis	rs1707322	0.721	rs4559551	ENSG00000280836.1	AL355480.1	-10.18	2.91e-23	1.85e-20	-0.39	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45701861	chr1:45581219~45581321:-
BRCA	cis	rs8072100	0.934	rs8067286	ENSG00000228782.6	CTD-2026D20.3	-10.18	2.92e-23	1.86e-20	-0.32	-0.3	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47517224	chr17:47450568~47492492:-
BRCA	cis	rs6538678	0.895	rs7137751	ENSG00000258343.1	RP11-536G4.2	-10.18	2.94e-23	1.87e-20	-0.45	-0.3	Lupus nephritis in systemic lupus erythematosus;	chr12:95861806	chr12:95795345~95858839:-
BRCA	cis	rs8062405	1	rs80275162	ENSG00000251417.2	RP11-1348G14.4	-10.18	2.94e-23	1.87e-20	-0.36	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28852196	chr16:28802743~28817828:+
BRCA	cis	rs858239	0.601	rs2141307	ENSG00000226816.2	AC005082.12	10.18	2.95e-23	1.88e-20	0.34	0.3	Cerebrospinal fluid biomarker levels;	chr7:23151805	chr7:23206013~23208045:+
BRCA	cis	rs733592	0.507	rs3825403	ENSG00000240399.1	RP1-228P16.1	-10.18	2.96e-23	1.88e-20	-0.32	-0.3	Plateletcrit;	chr12:48063376	chr12:48054813~48055591:-
BRCA	cis	rs733592	0.507	rs10747529	ENSG00000240399.1	RP1-228P16.1	-10.18	2.96e-23	1.88e-20	-0.32	-0.3	Plateletcrit;	chr12:48079586	chr12:48054813~48055591:-
BRCA	cis	rs11098499	0.865	rs28634456	ENSG00000245958.5	RP11-33B1.1	-10.18	2.97e-23	1.89e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119454623	chr4:119454791~119552025:+
BRCA	cis	rs8062405	0.723	rs4788077	ENSG00000259982.1	CDC37P1	10.17	3.02e-23	1.92e-20	0.41	0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28558443	chr16:28700294~28701540:-
BRCA	cis	rs11098499	0.954	rs28572238	ENSG00000245958.5	RP11-33B1.1	-10.17	3.02e-23	1.92e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119395531	chr4:119454791~119552025:+
BRCA	cis	rs1823913	0.927	rs34765012	ENSG00000227542.1	AC092614.2	10.17	3.03e-23	1.92e-20	0.39	0.3	Obesity-related traits;	chr2:191247926	chr2:191229165~191246172:-
BRCA	cis	rs6570726	0.791	rs2096201	ENSG00000235652.6	RP11-545I5.3	10.17	3.05e-23	1.94e-20	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145613137	chr6:145799409~145886585:+
BRCA	cis	rs7688540	0.771	rs11722197	ENSG00000275426.1	CH17-262A2.1	10.17	3.07e-23	1.95e-20	0.47	0.3	Facial morphology (factor 6, height of vermillion lower lip);	chr4:287918	chr4:149738~150317:+
BRCA	cis	rs7688540	0.771	rs11723261	ENSG00000275426.1	CH17-262A2.1	10.17	3.07e-23	1.95e-20	0.47	0.3	Facial morphology (factor 6, height of vermillion lower lip);	chr4:288710	chr4:149738~150317:+
BRCA	cis	rs1113500	0.614	rs12565953	ENSG00000226822.1	RP11-356N1.2	10.17	3.08e-23	1.95e-20	0.44	0.3	Growth-regulated protein alpha levels;	chr1:108064465	chr1:108071482~108074519:+
BRCA	cis	rs7829975	0.522	rs6601689	ENSG00000253893.2	FAM85B	-10.17	3.1e-23	1.97e-20	-0.37	-0.3	Mood instability;	chr8:8314761	chr8:8167819~8226614:-
BRCA	cis	rs7772486	0.79	rs6923545	ENSG00000235652.6	RP11-545I5.3	-10.17	3.11e-23	1.97e-20	-0.31	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145923607	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.754	rs6922507	ENSG00000235652.6	RP11-545I5.3	-10.17	3.11e-23	1.97e-20	-0.31	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145929019	chr6:145799409~145886585:+
BRCA	cis	rs11096990	0.613	rs9997015	ENSG00000249207.1	RP11-360F5.1	10.17	3.11e-23	1.98e-20	0.36	0.3	Cognitive function;	chr4:39222677	chr4:39112677~39126818:-
BRCA	cis	rs4423214	0.559	rs10898201	ENSG00000254682.1	RP11-660L16.2	-10.17	3.12e-23	1.98e-20	-0.46	-0.3	Vitamin D levels;	chr11:71490481	chr11:71448674~71452157:+
BRCA	cis	rs7772486	0.738	rs75288066	ENSG00000235652.6	RP11-545I5.3	10.17	3.12e-23	1.98e-20	0.31	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145998250	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.713	rs79248977	ENSG00000235652.6	RP11-545I5.3	10.17	3.12e-23	1.98e-20	0.31	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145998252	chr6:145799409~145886585:+
BRCA	cis	rs858239	0.601	rs764534	ENSG00000226816.2	AC005082.12	10.17	3.12e-23	1.98e-20	0.35	0.3	Cerebrospinal fluid biomarker levels;	chr7:23114316	chr7:23206013~23208045:+
BRCA	cis	rs858239	0.601	rs2068459	ENSG00000226816.2	AC005082.12	10.17	3.12e-23	1.98e-20	0.35	0.3	Cerebrospinal fluid biomarker levels;	chr7:23114694	chr7:23206013~23208045:+
BRCA	cis	rs11105298	0.891	rs11105325	ENSG00000258302.2	RP11-981P6.1	10.17	3.14e-23	1.99e-20	0.36	0.3	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89544813	chr12:89561129~89594878:+
BRCA	cis	rs858239	0.602	rs6953996	ENSG00000226816.2	AC005082.12	10.17	3.15e-23	2e-20	0.35	0.3	Cerebrospinal fluid biomarker levels;	chr7:23136327	chr7:23206013~23208045:+
BRCA	cis	rs6921919	0.583	rs4642462	ENSG00000216901.1	AL022393.7	10.17	3.16e-23	2e-20	0.39	0.3	Autism spectrum disorder or schizophrenia;	chr6:28421474	chr6:28176188~28176674:+
BRCA	cis	rs75422866	0.717	rs73113159	ENSG00000274902.1	RP1-197B17.4	10.17	3.16e-23	2e-20	0.8	0.3	Pneumonia;	chr12:47631318	chr12:47731908~47732351:+
BRCA	cis	rs75422866	0.717	rs73113161	ENSG00000274902.1	RP1-197B17.4	10.17	3.16e-23	2e-20	0.8	0.3	Pneumonia;	chr12:47632361	chr12:47731908~47732351:+
BRCA	cis	rs8062405	0.824	rs4788083	ENSG00000278665.1	RP11-666O2.4	10.17	3.17e-23	2.01e-20	0.31	0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28534128	chr16:28599241~28601881:-
BRCA	cis	rs4713118	0.597	rs172166	ENSG00000220721.1	OR1F12	10.17	3.2e-23	2.03e-20	0.39	0.3	Parkinson's disease;	chr6:28053042	chr6:28073316~28074233:+
BRCA	cis	rs1823913	0.892	rs35596292	ENSG00000227542.1	AC092614.2	10.17	3.2e-23	2.03e-20	0.39	0.3	Obesity-related traits;	chr2:191246890	chr2:191229165~191246172:-
BRCA	cis	rs6723108	0.517	rs6430553	ENSG00000224043.6	CCNT2-AS1	-10.17	3.22e-23	2.04e-20	-0.38	-0.3	Type 2 diabetes;	chr2:134873830	chr2:134735464~134918710:-
BRCA	cis	rs7580658	0.895	rs7589451	ENSG00000236682.1	AC068282.3	-10.17	3.23e-23	2.04e-20	-0.4	-0.3	Protein C levels;	chr2:127371199	chr2:127389130~127400580:+
BRCA	cis	rs8072100	0.905	rs8077106	ENSG00000228782.6	CTD-2026D20.3	-10.17	3.25e-23	2.06e-20	-0.32	-0.3	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47575925	chr17:47450568~47492492:-
BRCA	cis	rs8072100	0.754	rs8081717	ENSG00000228782.6	CTD-2026D20.3	-10.17	3.25e-23	2.06e-20	-0.32	-0.3	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47576555	chr17:47450568~47492492:-
BRCA	cis	rs11971779	0.68	rs1862879	ENSG00000273391.1	RP11-634H22.1	10.17	3.25e-23	2.06e-20	0.3	0.3	Diisocyanate-induced asthma;	chr7:139335205	chr7:139359032~139359566:-
BRCA	cis	rs2439831	0.85	rs60883262	ENSG00000275601.1	AC011330.13	-10.17	3.27e-23	2.07e-20	-0.48	-0.3	Lung cancer in ever smokers;	chr15:43784305	chr15:43642389~43643023:-
BRCA	cis	rs2581828	0.618	rs7615099	ENSG00000242142.1	SERBP1P3	-10.17	3.29e-23	2.08e-20	-0.37	-0.3	Crohn's disease;	chr3:53109885	chr3:53064283~53065091:-
BRCA	cis	rs11690935	0.571	rs13020884	ENSG00000228389.1	AC068039.4	-10.16	3.3e-23	2.09e-20	-0.37	-0.3	Schizophrenia;	chr2:172036795	chr2:171773482~171775844:+
BRCA	cis	rs7429990	0.93	rs71323371	ENSG00000229759.1	MRPS18AP1	10.16	3.33e-23	2.11e-20	0.36	0.3	Educational attainment (years of education);	chr3:47904327	chr3:48256350~48256938:-
BRCA	cis	rs1707322	0.682	rs3014241	ENSG00000280836.1	AL355480.1	10.16	3.4e-23	2.15e-20	0.39	0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45622207	chr1:45581219~45581321:-
BRCA	cis	rs6558530	0.799	rs62477060	ENSG00000253982.1	CTD-2336O2.1	10.16	3.42e-23	2.17e-20	0.33	0.3	Systolic blood pressure;	chr8:1758332	chr8:1761990~1764502:-
BRCA	cis	rs7429990	0.965	rs319696	ENSG00000229759.1	MRPS18AP1	10.16	3.45e-23	2.18e-20	0.36	0.3	Educational attainment (years of education);	chr3:47902371	chr3:48256350~48256938:-
BRCA	cis	rs1029738	0.659	rs1608553	ENSG00000228649.7	AC005682.5	10.16	3.46e-23	2.19e-20	0.27	0.3	Fibrinogen levels;	chr7:22856612	chr7:22854178~22861579:+
BRCA	cis	rs9601248	0.838	rs6563121	ENSG00000227676.3	LINC01068	-10.16	3.47e-23	2.2e-20	-0.36	-0.3	Major depressive disorder;	chr13:79600865	chr13:79566727~79571436:+
BRCA	cis	rs6700559	1	rs12076877	ENSG00000260088.1	RP11-92G12.3	-10.16	3.48e-23	2.2e-20	-0.39	-0.3	Coronary artery disease;	chr1:200674277	chr1:200669507~200694250:+
BRCA	cis	rs4835473	0.932	rs10857413	ENSG00000251600.4	RP11-673E1.1	10.16	3.51e-23	2.22e-20	0.34	0.3	Immature fraction of reticulocytes;	chr4:143827752	chr4:143912331~143982454:+
BRCA	cis	rs1555322	0.53	rs2425044	ENSG00000126005.14	MMP24-AS1	-10.16	3.52e-23	2.22e-20	-0.41	-0.3	Attention deficit hyperactivity disorder;	chr20:35281932	chr20:35216462~35278131:-
BRCA	cis	rs12134133	0.752	rs61821050	ENSG00000274245.1	RP11-357P18.2	10.16	3.52e-23	2.23e-20	0.44	0.3	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207235253	chr1:207372559~207373252:+
BRCA	cis	rs12134133	0.752	rs61821051	ENSG00000274245.1	RP11-357P18.2	10.16	3.52e-23	2.23e-20	0.44	0.3	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207235624	chr1:207372559~207373252:+
BRCA	cis	rs2439831	0.85	rs3862142	ENSG00000249839.1	AC011330.5	-10.16	3.53e-23	2.23e-20	-0.5	-0.3	Lung cancer in ever smokers;	chr15:43772608	chr15:43663654~43684339:-
BRCA	cis	rs2439831	0.85	rs2277531	ENSG00000249839.1	AC011330.5	-10.16	3.53e-23	2.23e-20	-0.5	-0.3	Lung cancer in ever smokers;	chr15:43776871	chr15:43663654~43684339:-
BRCA	cis	rs7567389	0.704	rs4662714	ENSG00000236682.1	AC068282.3	10.16	3.55e-23	2.24e-20	0.42	0.3	Self-rated health;	chr2:127237637	chr2:127389130~127400580:+
BRCA	cis	rs4927850	1	rs7625570	ENSG00000231464.1	AC024937.4	10.16	3.55e-23	2.24e-20	0.39	0.3	Pancreatic cancer;	chr3:196020527	chr3:195996738~195998233:+
BRCA	cis	rs75422866	0.867	rs73113139	ENSG00000274902.1	RP1-197B17.4	10.16	3.55e-23	2.25e-20	0.8	0.3	Pneumonia;	chr12:47622826	chr12:47731908~47732351:+
BRCA	cis	rs7772486	0.754	rs4895682	ENSG00000235652.6	RP11-545I5.3	-10.16	3.56e-23	2.25e-20	-0.31	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145741725	chr6:145799409~145886585:+
BRCA	cis	rs875971	0.545	rs17138156	ENSG00000226824.5	RP4-756H11.3	-10.16	3.58e-23	2.26e-20	-0.41	-0.3	Aortic root size;	chr7:66249708	chr7:66654538~66669855:+
BRCA	cis	rs10129255	1	rs10129255	ENSG00000211970.3	IGHV4-61	10.16	3.59e-23	2.27e-20	0.21	0.3	Kawasaki disease;	chr14:106767970	chr14:106639119~106639657:-
BRCA	cis	rs4835473	0.831	rs1984809	ENSG00000251600.4	RP11-673E1.1	10.15	3.63e-23	2.29e-20	0.34	0.3	Immature fraction of reticulocytes;	chr4:143825018	chr4:143912331~143982454:+
BRCA	cis	rs4927850	0.881	rs7624638	ENSG00000231464.1	AC024937.4	10.15	3.64e-23	2.3e-20	0.39	0.3	Pancreatic cancer;	chr3:196021858	chr3:195996738~195998233:+
BRCA	cis	rs673078	0.607	rs4766900	ENSG00000275759.1	RP11-131L12.3	-10.15	3.67e-23	2.32e-20	-0.44	-0.3	Glucose homeostasis traits;	chr12:118375139	chr12:118428281~118428870:+
BRCA	cis	rs524281	0.648	rs10896089	ENSG00000255320.1	RP11-755F10.1	10.15	3.71e-23	2.34e-20	0.46	0.3	Electroencephalogram traits;	chr11:66168821	chr11:66244840~66246239:-
BRCA	cis	rs6570726	0.738	rs6917199	ENSG00000235652.6	RP11-545I5.3	10.15	3.73e-23	2.35e-20	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145597184	chr6:145799409~145886585:+
BRCA	cis	rs7580658	0.857	rs2896980	ENSG00000236682.1	AC068282.3	-10.15	3.73e-23	2.36e-20	-0.4	-0.3	Protein C levels;	chr2:127382383	chr2:127389130~127400580:+
BRCA	cis	rs7429990	0.965	rs184388	ENSG00000229759.1	MRPS18AP1	10.15	3.74e-23	2.36e-20	0.36	0.3	Educational attainment (years of education);	chr3:47898136	chr3:48256350~48256938:-
BRCA	cis	rs4774565	0.762	rs7164848	ENSG00000244879.4	GABPB1-AS1	10.15	3.74e-23	2.36e-20	0.31	0.3	Breast cancer;	chr15:50370833	chr15:50354959~50372202:+
BRCA	cis	rs1707322	0.686	rs1084086	ENSG00000280836.1	AL355480.1	10.15	3.74e-23	2.36e-20	0.39	0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45575428	chr1:45581219~45581321:-
BRCA	cis	rs75422866	0.867	rs73104115	ENSG00000274902.1	RP1-197B17.4	10.15	3.74e-23	2.36e-20	0.8	0.3	Pneumonia;	chr12:47684843	chr12:47731908~47732351:+
BRCA	cis	rs75422866	0.867	rs73104116	ENSG00000274902.1	RP1-197B17.4	10.15	3.74e-23	2.36e-20	0.8	0.3	Pneumonia;	chr12:47685023	chr12:47731908~47732351:+
BRCA	cis	rs7772486	0.754	rs1415747	ENSG00000235652.6	RP11-545I5.3	10.15	3.74e-23	2.36e-20	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145756113	chr6:145799409~145886585:+
BRCA	cis	rs6921919	0.583	rs2027361	ENSG00000216901.1	AL022393.7	10.15	3.75e-23	2.37e-20	0.39	0.3	Autism spectrum disorder or schizophrenia;	chr6:28420531	chr6:28176188~28176674:+
BRCA	cis	rs2404602	0.532	rs744336	ENSG00000259422.1	RP11-593F23.1	10.15	3.78e-23	2.38e-20	0.37	0.3	Blood metabolite levels;	chr15:76382283	chr15:76174891~76181486:-
BRCA	cis	rs8040855	0.694	rs12908400	ENSG00000259295.5	CSPG4P12	10.15	3.78e-23	2.38e-20	0.4	0.3	Bulimia nervosa;	chr15:85029945	chr15:85191438~85213905:+
BRCA	cis	rs7429990	0.932	rs34025851	ENSG00000229759.1	MRPS18AP1	10.15	3.82e-23	2.41e-20	0.36	0.3	Educational attainment (years of education);	chr3:47912243	chr3:48256350~48256938:-
BRCA	cis	rs11971779	0.68	rs4077889	ENSG00000273391.1	RP11-634H22.1	10.15	3.84e-23	2.42e-20	0.3	0.3	Diisocyanate-induced asthma;	chr7:139349168	chr7:139359032~139359566:-
BRCA	cis	rs11971779	0.68	rs11980313	ENSG00000273391.1	RP11-634H22.1	10.15	3.84e-23	2.42e-20	0.3	0.3	Diisocyanate-induced asthma;	chr7:139349897	chr7:139359032~139359566:-
BRCA	cis	rs17711722	0.522	rs4642526	ENSG00000236529.1	RP13-254B10.1	10.15	3.87e-23	2.44e-20	0.33	0.3	Calcium levels;	chr7:65751755	chr7:65840212~65840596:+
BRCA	cis	rs72772090	0.539	rs10515250	ENSG00000248734.2	CTD-2260A17.1	-10.15	3.93e-23	2.48e-20	-0.5	-0.3	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96814490	chr5:96784777~96785999:+
BRCA	cis	rs1707322	0.682	rs10890335	ENSG00000280836.1	AL355480.1	-10.15	3.95e-23	2.49e-20	-0.39	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634722	chr1:45581219~45581321:-
BRCA	cis	rs1075265	0.783	rs6545376	ENSG00000233266.1	HMGB1P31	10.15	3.95e-23	2.49e-20	0.36	0.3	Chronotype;Morning vs. evening chronotype;	chr2:53987685	chr2:54051334~54051760:+
BRCA	cis	rs867371	0.502	rs7176926	ENSG00000278603.1	RP13-608F4.5	10.15	3.95e-23	2.49e-20	0.38	0.3	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82245753	chr15:82472203~82472426:+
BRCA	cis	rs3096299	0.967	rs2911256	ENSG00000274627.1	RP11-104N10.2	10.15	3.96e-23	2.5e-20	0.31	0.3	Multiple myeloma (IgH translocation);	chr16:89418688	chr16:89516797~89522217:+
BRCA	cis	rs1707322	0.686	rs2152078	ENSG00000280836.1	AL355480.1	10.14	3.97e-23	2.5e-20	0.39	0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45589928	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.686	rs2991979	ENSG00000280836.1	AL355480.1	10.14	3.97e-23	2.5e-20	0.39	0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45590186	chr1:45581219~45581321:-
BRCA	cis	rs10129255	0.957	rs10136560	ENSG00000211970.3	IGHV4-61	-10.14	3.98e-23	2.5e-20	-0.22	-0.3	Kawasaki disease;	chr14:106787630	chr14:106639119~106639657:-
BRCA	cis	rs8062405	0.72	rs9926245	ENSG00000278665.1	RP11-666O2.4	10.14	3.98e-23	2.51e-20	0.31	0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28544385	chr16:28599241~28601881:-
BRCA	cis	rs7772486	0.738	rs2246334	ENSG00000235652.6	RP11-545I5.3	10.14	4e-23	2.52e-20	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145862499	chr6:145799409~145886585:+
BRCA	cis	rs11098499	0.954	rs10518331	ENSG00000245958.5	RP11-33B1.1	-10.14	4.02e-23	2.53e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119402440	chr4:119454791~119552025:+
BRCA	cis	rs6723108	0.517	rs12473839	ENSG00000224043.6	CCNT2-AS1	-10.14	4.04e-23	2.54e-20	-0.38	-0.3	Type 2 diabetes;	chr2:134880474	chr2:134735464~134918710:-
BRCA	cis	rs6700559	0.873	rs6427840	ENSG00000260088.1	RP11-92G12.3	-10.14	4.06e-23	2.55e-20	-0.4	-0.3	Coronary artery disease;	chr1:200685659	chr1:200669507~200694250:+
BRCA	cis	rs6545883	0.524	rs811871	ENSG00000271889.1	RP11-493E12.1	-10.14	4.07e-23	2.56e-20	-0.36	-0.3	Tuberculosis;	chr2:61350814	chr2:61151433~61162105:-
BRCA	cis	rs7772486	0.875	rs2748485	ENSG00000235652.6	RP11-545I5.3	10.14	4.12e-23	2.59e-20	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:146011285	chr6:145799409~145886585:+
BRCA	cis	rs4835473	0.808	rs1984810	ENSG00000251600.4	RP11-673E1.1	10.14	4.13e-23	2.59e-20	0.34	0.3	Immature fraction of reticulocytes;	chr4:143824970	chr4:143912331~143982454:+
BRCA	cis	rs7580658	0.895	rs62157549	ENSG00000236682.1	AC068282.3	-10.14	4.14e-23	2.6e-20	-0.4	-0.3	Protein C levels;	chr2:127308431	chr2:127389130~127400580:+
BRCA	cis	rs875971	0.545	rs1796222	ENSG00000226824.5	RP4-756H11.3	10.14	4.15e-23	2.61e-20	0.42	0.3	Aortic root size;	chr7:66592167	chr7:66654538~66669855:+
BRCA	cis	rs17711722	0.523	rs365896	ENSG00000224316.1	RP11-479O9.2	-10.14	4.19e-23	2.63e-20	-0.31	-0.3	Calcium levels;	chr7:66045710	chr7:65773620~65802067:+
BRCA	cis	rs858239	0.632	rs6952947	ENSG00000226816.2	AC005082.12	-10.14	4.19e-23	2.63e-20	-0.35	-0.3	Cerebrospinal fluid biomarker levels;	chr7:23081423	chr7:23206013~23208045:+
BRCA	cis	rs2280018	0.526	rs1510148	ENSG00000260735.1	RP11-72I8.1	-10.14	4.23e-23	2.66e-20	-0.36	-0.3	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15073522	chr16:15094411~15109197:+
BRCA	cis	rs10759883	0.539	rs689744	ENSG00000175611.10	LINC00476	10.14	4.24e-23	2.66e-20	0.37	0.3	Nicotine dependence;	chr9:96040417	chr9:95759231~95875977:-
BRCA	cis	rs11098499	0.865	rs9994730	ENSG00000245958.5	RP11-33B1.1	-10.14	4.26e-23	2.67e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119460409	chr4:119454791~119552025:+
BRCA	cis	rs2882667	0.537	rs11743534	ENSG00000253404.1	AC034243.1	10.14	4.3e-23	2.7e-20	0.37	0.3	Age-related hearing impairment (SNP x SNP interaction);	chr5:139073318	chr5:138744434~138753309:-
BRCA	cis	rs11971779	0.616	rs7784192	ENSG00000273391.1	RP11-634H22.1	10.14	4.31e-23	2.7e-20	0.29	0.3	Diisocyanate-induced asthma;	chr7:139354903	chr7:139359032~139359566:-
BRCA	cis	rs465969	1	rs9400478	ENSG00000255389.1	C6orf3	10.14	4.35e-23	2.73e-20	0.67	0.3	Psoriasis;	chr6:111478441	chr6:111599875~111602295:+
BRCA	cis	rs6570726	0.791	rs11155426	ENSG00000235652.6	RP11-545I5.3	10.13	4.37e-23	2.74e-20	0.31	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145495994	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.764	rs376257	ENSG00000235652.6	RP11-545I5.3	10.13	4.37e-23	2.74e-20	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145541813	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.693	rs450921	ENSG00000235652.6	RP11-545I5.3	10.13	4.37e-23	2.74e-20	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145543124	chr6:145799409~145886585:+
BRCA	cis	rs6061231	0.837	rs6121558	ENSG00000273619.1	RP5-908M14.9	-10.13	4.38e-23	2.75e-20	-0.27	-0.3	Colorectal cancer;	chr20:62386309	chr20:62386303~62386970:-
BRCA	cis	rs858239	0.899	rs7794684	ENSG00000226816.2	AC005082.12	10.13	4.43e-23	2.78e-20	0.35	0.3	Cerebrospinal fluid biomarker levels;	chr7:23271186	chr7:23206013~23208045:+
BRCA	cis	rs7772486	0.754	rs2328709	ENSG00000235652.6	RP11-545I5.3	-10.13	4.44e-23	2.78e-20	-0.3	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145785683	chr6:145799409~145886585:+
BRCA	cis	rs227275	0.554	rs223467	ENSG00000246560.2	RP11-10L12.4	10.13	4.44e-23	2.78e-20	0.31	0.3	Allergic disease (asthma, hay fever or eczema);	chr4:102779721	chr4:102828055~102844075:+
BRCA	cis	rs2412819	0.597	rs514311	ENSG00000249839.1	AC011330.5	-10.13	4.44e-23	2.78e-20	-0.42	-0.3	Lung cancer;	chr15:43869376	chr15:43663654~43684339:-
BRCA	cis	rs11690935	0.549	rs62183819	ENSG00000228389.1	AC068039.4	-10.13	4.45e-23	2.79e-20	-0.37	-0.3	Schizophrenia;	chr2:172039610	chr2:171773482~171775844:+
BRCA	cis	rs4835473	0.932	rs6828935	ENSG00000251600.4	RP11-673E1.1	10.13	4.45e-23	2.79e-20	0.34	0.3	Immature fraction of reticulocytes;	chr4:143829113	chr4:143912331~143982454:+
BRCA	cis	rs8059260	0.604	rs16957966	ENSG00000274038.1	RP11-66H6.4	-10.13	4.47e-23	2.8e-20	-0.44	-0.3	Alcohol consumption over the past year;	chr16:11046280	chr16:11056556~11057034:+
BRCA	cis	rs11098499	0.738	rs34965784	ENSG00000245958.5	RP11-33B1.1	-10.13	4.47e-23	2.8e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119440431	chr4:119454791~119552025:+
BRCA	cis	rs7772486	0.754	rs9497401	ENSG00000235652.6	RP11-545I5.3	-10.13	4.47e-23	2.8e-20	-0.3	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145730135	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.754	rs1055212	ENSG00000235652.6	RP11-545I5.3	-10.13	4.47e-23	2.8e-20	-0.3	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145737179	chr6:145799409~145886585:+
BRCA	cis	rs11098499	0.821	rs10032151	ENSG00000245958.5	RP11-33B1.1	-10.13	4.48e-23	2.8e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119470473	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.865	rs10032158	ENSG00000245958.5	RP11-33B1.1	-10.13	4.48e-23	2.8e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119470477	chr4:119454791~119552025:+
BRCA	cis	rs11105298	0.891	rs4842664	ENSG00000258302.2	RP11-981P6.1	10.13	4.49e-23	2.81e-20	0.35	0.3	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89544253	chr12:89561129~89594878:+
BRCA	cis	rs875971	0.798	rs57739047	ENSG00000237310.1	GS1-124K5.4	10.13	4.49e-23	2.81e-20	0.32	0.3	Aortic root size;	chr7:66507579	chr7:66493706~66495474:+
BRCA	cis	rs2439831	0.85	rs7169988	ENSG00000249839.1	AC011330.5	-10.13	4.51e-23	2.82e-20	-0.5	-0.3	Lung cancer in ever smokers;	chr15:43768237	chr15:43663654~43684339:-
BRCA	cis	rs12134133	0.688	rs6540875	ENSG00000274245.1	RP11-357P18.2	10.13	4.51e-23	2.82e-20	0.44	0.3	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207221686	chr1:207372559~207373252:+
BRCA	cis	rs12134133	0.719	rs6696142	ENSG00000274245.1	RP11-357P18.2	10.13	4.51e-23	2.82e-20	0.44	0.3	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207228898	chr1:207372559~207373252:+
BRCA	cis	rs12134133	0.752	rs57003024	ENSG00000274245.1	RP11-357P18.2	10.13	4.51e-23	2.82e-20	0.44	0.3	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207230999	chr1:207372559~207373252:+
BRCA	cis	rs2412819	0.571	rs528764	ENSG00000249839.1	AC011330.5	10.13	4.53e-23	2.83e-20	0.42	0.3	Lung cancer;	chr15:43838650	chr15:43663654~43684339:-
BRCA	cis	rs7829975	0.582	rs448231	ENSG00000253893.2	FAM85B	10.13	4.54e-23	2.84e-20	0.36	0.3	Mood instability;	chr8:8932549	chr8:8167819~8226614:-
BRCA	cis	rs6570726	0.764	rs9399553	ENSG00000235652.6	RP11-545I5.3	10.13	4.57e-23	2.86e-20	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145552528	chr6:145799409~145886585:+
BRCA	cis	rs4713118	0.662	rs9357060	ENSG00000220721.1	OR1F12	10.13	4.58e-23	2.86e-20	0.39	0.3	Parkinson's disease;	chr6:28056708	chr6:28073316~28074233:+
BRCA	cis	rs4713118	0.662	rs9468271	ENSG00000220721.1	OR1F12	10.13	4.58e-23	2.86e-20	0.39	0.3	Parkinson's disease;	chr6:28056792	chr6:28073316~28074233:+
BRCA	cis	rs1707322	0.721	rs6665808	ENSG00000280836.1	AL355480.1	-10.13	4.58e-23	2.87e-20	-0.39	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45696611	chr1:45581219~45581321:-
BRCA	cis	rs6142102	0.625	rs6142051	ENSG00000276073.1	RP5-1125A11.7	-10.13	4.65e-23	2.91e-20	-0.35	-0.3	Skin pigmentation;	chr20:33945212	chr20:33985617~33988989:-
BRCA	cis	rs4713118	0.662	rs149946	ENSG00000220721.1	OR1F12	-10.13	4.66e-23	2.92e-20	-0.39	-0.3	Parkinson's disease;	chr6:28002253	chr6:28073316~28074233:+
BRCA	cis	rs6545883	0.524	rs2694619	ENSG00000271889.1	RP11-493E12.1	-10.13	4.68e-23	2.92e-20	-0.35	-0.3	Tuberculosis;	chr2:61309766	chr2:61151433~61162105:-
BRCA	cis	rs7772486	0.754	rs9390358	ENSG00000235652.6	RP11-545I5.3	10.13	4.73e-23	2.96e-20	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145824542	chr6:145799409~145886585:+
BRCA	cis	rs1707322	0.656	rs9429172	ENSG00000280836.1	AL355480.1	10.13	4.74e-23	2.96e-20	0.39	0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45626804	chr1:45581219~45581321:-
BRCA	cis	rs2276314	0.857	rs8097597	ENSG00000278986.1	RP11-723J4.3	-10.13	4.75e-23	2.97e-20	-0.37	-0.3	Endometriosis;Drug-induced torsades de pointes;	chr18:36039485	chr18:35972151~35973916:+
BRCA	cis	rs2015599	0.525	rs7298031	ENSG00000257176.2	RP11-996F15.2	10.13	4.76e-23	2.98e-20	0.36	0.3	Platelet count;Mean platelet volume;	chr12:29317333	chr12:29280418~29317848:-
BRCA	cis	rs8062405	0.755	rs4788074	ENSG00000278665.1	RP11-666O2.4	-10.13	4.78e-23	2.99e-20	-0.32	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28582276	chr16:28599241~28601881:-
BRCA	cis	rs6570726	0.818	rs437147	ENSG00000235652.6	RP11-545I5.3	10.12	4.8e-23	3e-20	0.31	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145554287	chr6:145799409~145886585:+
BRCA	cis	rs858239	0.6	rs10235786	ENSG00000226816.2	AC005082.12	10.12	4.82e-23	3.01e-20	0.34	0.3	Cerebrospinal fluid biomarker levels;	chr7:23100321	chr7:23206013~23208045:+
BRCA	cis	rs1075265	0.568	rs10865278	ENSG00000233266.1	HMGB1P31	10.12	4.83e-23	3.02e-20	0.37	0.3	Chronotype;Morning vs. evening chronotype;	chr2:54074902	chr2:54051334~54051760:+
BRCA	cis	rs72772090	0.539	rs2042386	ENSG00000248734.2	CTD-2260A17.1	-10.12	4.9e-23	3.06e-20	-0.5	-0.3	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96821080	chr5:96784777~96785999:+
BRCA	cis	rs2276314	0.947	rs4799831	ENSG00000278986.1	RP11-723J4.3	-10.12	4.92e-23	3.07e-20	-0.39	-0.3	Endometriosis;Drug-induced torsades de pointes;	chr18:35974812	chr18:35972151~35973916:+
BRCA	cis	rs11096990	0.613	rs4974995	ENSG00000249207.1	RP11-360F5.1	10.12	4.95e-23	3.09e-20	0.35	0.3	Cognitive function;	chr4:39216503	chr4:39112677~39126818:-
BRCA	cis	rs673078	0.607	rs11068919	ENSG00000275759.1	RP11-131L12.3	-10.12	4.95e-23	3.09e-20	-0.41	-0.3	Glucose homeostasis traits;	chr12:118354925	chr12:118428281~118428870:+
BRCA	cis	rs11098499	0.909	rs78332141	ENSG00000245958.5	RP11-33B1.1	-10.12	4.97e-23	3.1e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119454627	chr4:119454791~119552025:+
BRCA	cis	rs2439831	0.85	rs7174208	ENSG00000249839.1	AC011330.5	-10.12	4.98e-23	3.11e-20	-0.5	-0.3	Lung cancer in ever smokers;	chr15:43760484	chr15:43663654~43684339:-
BRCA	cis	rs2439831	0.85	rs12101756	ENSG00000249839.1	AC011330.5	-10.12	4.98e-23	3.11e-20	-0.5	-0.3	Lung cancer in ever smokers;	chr15:43761689	chr15:43663654~43684339:-
BRCA	cis	rs2404602	0.735	rs11637490	ENSG00000259422.1	RP11-593F23.1	-10.12	4.99e-23	3.11e-20	-0.39	-0.3	Blood metabolite levels;	chr15:76467224	chr15:76174891~76181486:-
BRCA	cis	rs4713118	0.629	rs203890	ENSG00000220721.1	OR1F12	10.12	5.03e-23	3.14e-20	0.39	0.3	Parkinson's disease;	chr6:28054470	chr6:28073316~28074233:+
BRCA	cis	rs11971779	0.715	rs6943973	ENSG00000273391.1	RP11-634H22.1	10.12	5.03e-23	3.14e-20	0.3	0.3	Diisocyanate-induced asthma;	chr7:139345147	chr7:139359032~139359566:-
BRCA	cis	rs1707322	0.685	rs56177313	ENSG00000280836.1	AL355480.1	-10.12	5.04e-23	3.14e-20	-0.39	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45760134	chr1:45581219~45581321:-
BRCA	cis	rs7772486	0.79	rs6924159	ENSG00000235652.6	RP11-545I5.3	-10.12	5.06e-23	3.15e-20	-0.31	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145946737	chr6:145799409~145886585:+
BRCA	cis	rs2015599	0.525	rs7959145	ENSG00000257176.2	RP11-996F15.2	10.12	5.06e-23	3.16e-20	0.36	0.3	Platelet count;Mean platelet volume;	chr12:29330850	chr12:29280418~29317848:-
BRCA	cis	rs2015599	0.525	rs7961943	ENSG00000257176.2	RP11-996F15.2	10.12	5.06e-23	3.16e-20	0.36	0.3	Platelet count;Mean platelet volume;	chr12:29331146	chr12:29280418~29317848:-
BRCA	cis	rs6538678	1	rs6538678	ENSG00000258343.1	RP11-536G4.2	-10.12	5.06e-23	3.16e-20	-0.44	-0.3	Lupus nephritis in systemic lupus erythematosus;	chr12:95867790	chr12:95795345~95858839:-
BRCA	cis	rs11098499	0.505	rs75122014	ENSG00000245958.5	RP11-33B1.1	-10.12	5.07e-23	3.16e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119441271	chr4:119454791~119552025:+
BRCA	cis	rs7688540	0.771	rs11729365	ENSG00000275426.1	CH17-262A2.1	10.12	5.07e-23	3.16e-20	0.46	0.3	Facial morphology (factor 6, height of vermillion lower lip);	chr4:278735	chr4:149738~150317:+
BRCA	cis	rs7772486	0.875	rs2814875	ENSG00000235652.6	RP11-545I5.3	10.12	5.09e-23	3.17e-20	0.31	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145984674	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.875	rs2814874	ENSG00000235652.6	RP11-545I5.3	10.12	5.09e-23	3.17e-20	0.31	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145984759	chr6:145799409~145886585:+
BRCA	cis	rs4964805	0.594	rs3812805	ENSG00000257681.1	RP11-341G23.4	10.12	5.14e-23	3.2e-20	0.36	0.3	Attention deficit hyperactivity disorder;	chr12:103777094	chr12:103746315~103768858:-
BRCA	cis	rs2015599	0.645	rs12578931	ENSG00000275476.1	RP11-996F15.4	-10.12	5.16e-23	3.21e-20	-0.36	-0.3	Platelet count;Mean platelet volume;	chr12:29358608	chr12:29277397~29277882:-
BRCA	cis	rs2015599	0.623	rs4931174	ENSG00000275476.1	RP11-996F15.4	-10.12	5.16e-23	3.21e-20	-0.36	-0.3	Platelet count;Mean platelet volume;	chr12:29360545	chr12:29277397~29277882:-
BRCA	cis	rs6142102	0.625	rs4911137	ENSG00000276073.1	RP5-1125A11.7	-10.12	5.2e-23	3.24e-20	-0.35	-0.3	Skin pigmentation;	chr20:33947657	chr20:33985617~33988989:-
BRCA	cis	rs7772486	0.754	rs697055	ENSG00000235652.6	RP11-545I5.3	10.12	5.22e-23	3.25e-20	0.31	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145682654	chr6:145799409~145886585:+
BRCA	cis	rs34779708	0.801	rs12098720	ENSG00000230534.5	RP11-297A16.2	10.12	5.22e-23	3.25e-20	0.38	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35249755	chr10:35098006~35127020:-
BRCA	cis	rs34779708	0.801	rs34592588	ENSG00000230534.5	RP11-297A16.2	10.12	5.22e-23	3.25e-20	0.38	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35251206	chr10:35098006~35127020:-
BRCA	cis	rs6570726	0.791	rs365747	ENSG00000235652.6	RP11-545I5.3	10.12	5.23e-23	3.26e-20	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145545648	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.764	rs448258	ENSG00000235652.6	RP11-545I5.3	10.12	5.23e-23	3.26e-20	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145548009	chr6:145799409~145886585:+
BRCA	cis	rs875971	0.83	rs6950137	ENSG00000237310.1	GS1-124K5.4	10.12	5.24e-23	3.26e-20	0.32	0.3	Aortic root size;	chr7:66511623	chr7:66493706~66495474:+
BRCA	cis	rs6723108	0.517	rs6711390	ENSG00000224043.6	CCNT2-AS1	-10.12	5.25e-23	3.27e-20	-0.38	-0.3	Type 2 diabetes;	chr2:134871869	chr2:134735464~134918710:-
BRCA	cis	rs11098499	0.954	rs3733524	ENSG00000245958.5	RP11-33B1.1	-10.11	5.26e-23	3.28e-20	-0.31	-0.3	Corneal astigmatism;	chr4:119502574	chr4:119454791~119552025:+
BRCA	cis	rs11123170	0.542	rs28522253	ENSG00000274877.1	RP11-65I12.1	-10.11	5.27e-23	3.28e-20	-0.48	-0.3	Renal function-related traits (BUN);	chr2:113209810	chr2:113237595~113240825:+
BRCA	cis	rs7772486	0.764	rs2265468	ENSG00000235652.6	RP11-545I5.3	10.11	5.29e-23	3.29e-20	0.31	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145897210	chr6:145799409~145886585:+
BRCA	cis	rs875971	0.83	rs6976714	ENSG00000237310.1	GS1-124K5.4	10.11	5.3e-23	3.3e-20	0.32	0.3	Aortic root size;	chr7:66426474	chr7:66493706~66495474:+
BRCA	cis	rs8062405	1	rs1987472	ENSG00000251417.2	RP11-1348G14.4	-10.11	5.34e-23	3.32e-20	-0.35	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814456	chr16:28802743~28817828:+
BRCA	cis	rs8062405	0.895	rs56186137	ENSG00000251417.2	RP11-1348G14.4	-10.11	5.34e-23	3.32e-20	-0.35	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814632	chr16:28802743~28817828:+
BRCA	cis	rs2015599	0.525	rs2016832	ENSG00000257176.2	RP11-996F15.2	10.11	5.36e-23	3.34e-20	0.35	0.3	Platelet count;Mean platelet volume;	chr12:29318199	chr12:29280418~29317848:-
BRCA	cis	rs6565180	1	rs6565180	ENSG00000273724.1	RP11-347C12.12	-10.11	5.37e-23	3.34e-20	-0.34	-0.3	Tonsillectomy;	chr16:30350020	chr16:30336400~30343336:+
BRCA	cis	rs858239	0.676	rs274032	ENSG00000226816.2	AC005082.12	10.11	5.4e-23	3.36e-20	0.35	0.3	Cerebrospinal fluid biomarker levels;	chr7:23334940	chr7:23206013~23208045:+
BRCA	cis	rs10515750	0.643	rs10063413	ENSG00000248544.2	CTB-47B11.3	-10.11	5.41e-23	3.37e-20	-0.54	-0.3	Lung function (FEV1/FVC);	chr5:157384435	chr5:157375741~157384950:-
BRCA	cis	rs6570726	0.791	rs9399558	ENSG00000235652.6	RP11-545I5.3	10.11	5.43e-23	3.38e-20	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145590594	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.791	rs9376953	ENSG00000235652.6	RP11-545I5.3	10.11	5.43e-23	3.38e-20	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145591090	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.791	rs13202312	ENSG00000235652.6	RP11-545I5.3	10.11	5.43e-23	3.38e-20	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145591957	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.791	rs7765675	ENSG00000235652.6	RP11-545I5.3	10.11	5.43e-23	3.38e-20	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145593941	chr6:145799409~145886585:+
BRCA	cis	rs2015599	0.623	rs12581107	ENSG00000275476.1	RP11-996F15.4	-10.11	5.47e-23	3.4e-20	-0.36	-0.3	Platelet count;Mean platelet volume;	chr12:29352358	chr12:29277397~29277882:-
BRCA	cis	rs8062405	0.964	rs11860513	ENSG00000251417.2	RP11-1348G14.4	-10.11	5.52e-23	3.43e-20	-0.35	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814099	chr16:28802743~28817828:+
BRCA	cis	rs17482078	0.959	rs13173167	ENSG00000248734.2	CTD-2260A17.1	10.11	5.54e-23	3.44e-20	0.41	0.3	Behcet's disease;Blood protein levels;	chr5:96795780	chr5:96784777~96785999:+
BRCA	cis	rs17482078	0.959	rs2013717	ENSG00000248734.2	CTD-2260A17.1	10.11	5.54e-23	3.44e-20	0.41	0.3	Behcet's disease;Blood protein levels;	chr5:96798472	chr5:96784777~96785999:+
BRCA	cis	rs17482078	0.918	rs2013671	ENSG00000248734.2	CTD-2260A17.1	10.11	5.54e-23	3.44e-20	0.41	0.3	Behcet's disease;Blood protein levels;	chr5:96798580	chr5:96784777~96785999:+
BRCA	cis	rs17482078	0.959	rs2013633	ENSG00000248734.2	CTD-2260A17.1	10.11	5.54e-23	3.44e-20	0.41	0.3	Behcet's disease;Blood protein levels;	chr5:96798603	chr5:96784777~96785999:+
BRCA	cis	rs11098499	0.865	rs4507344	ENSG00000245958.5	RP11-33B1.1	-10.11	5.58e-23	3.47e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119386330	chr4:119454791~119552025:+
BRCA	cis	rs4927850	1	rs7627706	ENSG00000231464.1	AC024937.4	10.11	5.59e-23	3.47e-20	0.38	0.3	Pancreatic cancer;	chr3:196026482	chr3:195996738~195998233:+
BRCA	cis	rs4927850	0.881	rs7630489	ENSG00000231464.1	AC024937.4	10.11	5.59e-23	3.47e-20	0.38	0.3	Pancreatic cancer;	chr3:196026530	chr3:195996738~195998233:+
BRCA	cis	rs4927850	1	rs7627868	ENSG00000231464.1	AC024937.4	10.11	5.59e-23	3.47e-20	0.38	0.3	Pancreatic cancer;	chr3:196026602	chr3:195996738~195998233:+
BRCA	cis	rs7772486	0.875	rs1330939	ENSG00000235652.6	RP11-545I5.3	10.11	5.66e-23	3.51e-20	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145987382	chr6:145799409~145886585:+
BRCA	cis	rs4927850	1	rs7614767	ENSG00000231464.1	AC024937.4	10.11	5.68e-23	3.53e-20	0.38	0.3	Pancreatic cancer;	chr3:196026580	chr3:195996738~195998233:+
BRCA	cis	rs7772486	0.754	rs9497434	ENSG00000235652.6	RP11-545I5.3	-10.11	5.69e-23	3.53e-20	-0.3	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145939617	chr6:145799409~145886585:+
BRCA	cis	rs6545883	0.507	rs62149712	ENSG00000271889.1	RP11-493E12.1	-10.11	5.71e-23	3.55e-20	-0.36	-0.3	Tuberculosis;	chr2:61374137	chr2:61151433~61162105:-
BRCA	cis	rs2243480	1	rs313807	ENSG00000226824.5	RP4-756H11.3	-10.11	5.73e-23	3.56e-20	-0.57	-0.3	Diabetic kidney disease;	chr7:66034494	chr7:66654538~66669855:+
BRCA	cis	rs6545883	0.542	rs10177225	ENSG00000271889.1	RP11-493E12.1	-10.11	5.76e-23	3.58e-20	-0.36	-0.3	Tuberculosis;	chr2:61367363	chr2:61151433~61162105:-
BRCA	cis	rs11098499	0.909	rs71614422	ENSG00000245958.5	RP11-33B1.1	-10.1	5.77e-23	3.58e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119438185	chr4:119454791~119552025:+
BRCA	cis	rs1823913	0.599	rs58106487	ENSG00000227542.1	AC092614.2	10.1	5.77e-23	3.58e-20	0.36	0.3	Obesity-related traits;	chr2:191292404	chr2:191229165~191246172:-
BRCA	cis	rs2665103	0.632	rs3902959	ENSG00000278603.1	RP13-608F4.5	10.1	5.79e-23	3.6e-20	0.38	0.3	Intelligence (multi-trait analysis);	chr15:82252586	chr15:82472203~82472426:+
BRCA	cis	rs7772486	0.875	rs2748502	ENSG00000235652.6	RP11-545I5.3	10.1	5.82e-23	3.61e-20	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145977103	chr6:145799409~145886585:+
BRCA	cis	rs7829975	0.508	rs4841006	ENSG00000253893.2	FAM85B	10.1	5.82e-23	3.61e-20	0.37	0.3	Mood instability;	chr8:8643964	chr8:8167819~8226614:-
BRCA	cis	rs2882667	0.537	rs7701116	ENSG00000253404.1	AC034243.1	10.1	5.83e-23	3.62e-20	0.37	0.3	Age-related hearing impairment (SNP x SNP interaction);	chr5:139070389	chr5:138744434~138753309:-
BRCA	cis	rs7772486	0.79	rs9390365	ENSG00000235652.6	RP11-545I5.3	-10.1	5.84e-23	3.62e-20	-0.3	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145914490	chr6:145799409~145886585:+
BRCA	cis	rs6545883	0.501	rs935860	ENSG00000271889.1	RP11-493E12.1	10.1	5.87e-23	3.64e-20	0.36	0.3	Tuberculosis;	chr2:61179426	chr2:61151433~61162105:-
BRCA	cis	rs673078	0.607	rs7302387	ENSG00000275759.1	RP11-131L12.3	-10.1	5.87e-23	3.64e-20	-0.51	-0.3	Glucose homeostasis traits;	chr12:118316546	chr12:118428281~118428870:+
BRCA	cis	rs2115630	0.875	rs8039472	ENSG00000225151.9	GOLGA2P7	10.1	5.96e-23	3.7e-20	0.34	0.3	P wave terminal force;	chr15:84818413	chr15:84199311~84230136:-
BRCA	cis	rs6570726	0.791	rs4335004	ENSG00000235652.6	RP11-545I5.3	10.1	5.98e-23	3.71e-20	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145583628	chr6:145799409~145886585:+
BRCA	cis	rs143626010	1	rs143626010	ENSG00000278665.1	RP11-666O2.4	10.1	5.99e-23	3.71e-20	0.32	0.3	Mosquito bite size;	chr16:28528081	chr16:28599241~28601881:-
BRCA	cis	rs8062405	1	rs9972693	ENSG00000251417.2	RP11-1348G14.4	-10.1	6.01e-23	3.72e-20	-0.35	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28848481	chr16:28802743~28817828:+
BRCA	cis	rs8062405	0.964	rs9972768	ENSG00000251417.2	RP11-1348G14.4	-10.1	6.01e-23	3.72e-20	-0.35	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28850413	chr16:28802743~28817828:+
BRCA	cis	rs8062405	0.965	rs62037363	ENSG00000251417.2	RP11-1348G14.4	-10.1	6.01e-23	3.72e-20	-0.35	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28853721	chr16:28802743~28817828:+
BRCA	cis	rs8062405	1	rs7205323	ENSG00000251417.2	RP11-1348G14.4	-10.1	6.01e-23	3.72e-20	-0.35	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28854571	chr16:28802743~28817828:+
BRCA	cis	rs11098499	0.954	rs17009122	ENSG00000245958.5	RP11-33B1.1	-10.1	6.02e-23	3.73e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119441248	chr4:119454791~119552025:+
BRCA	cis	rs7772486	0.79	rs3924498	ENSG00000235652.6	RP11-545I5.3	-10.1	6.03e-23	3.74e-20	-0.3	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145912202	chr6:145799409~145886585:+
BRCA	cis	rs10129255	0.957	rs12589190	ENSG00000211970.3	IGHV4-61	-10.1	6.04e-23	3.74e-20	-0.2	-0.3	Kawasaki disease;	chr14:106783079	chr14:106639119~106639657:-
BRCA	cis	rs11096990	0.613	rs2060805	ENSG00000249207.1	RP11-360F5.1	-10.1	6.11e-23	3.78e-20	-0.36	-0.3	Cognitive function;	chr4:39232788	chr4:39112677~39126818:-
BRCA	cis	rs2439831	0.85	rs12442129	ENSG00000249839.1	AC011330.5	-10.1	6.12e-23	3.79e-20	-0.5	-0.3	Lung cancer in ever smokers;	chr15:43763658	chr15:43663654~43684339:-
BRCA	cis	rs8062405	0.965	rs56040780	ENSG00000251417.2	RP11-1348G14.4	-10.1	6.17e-23	3.82e-20	-0.35	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28850560	chr16:28802743~28817828:+
BRCA	cis	rs2243480	0.901	rs313808	ENSG00000226824.5	RP4-756H11.3	-10.1	6.2e-23	3.84e-20	-0.57	-0.3	Diabetic kidney disease;	chr7:66034886	chr7:66654538~66669855:+
BRCA	cis	rs17711722	0.522	rs62469933	ENSG00000224316.1	RP11-479O9.2	10.1	6.25e-23	3.87e-20	0.3	0.3	Calcium levels;	chr7:65800652	chr7:65773620~65802067:+
BRCA	cis	rs321358	0.731	rs7927998	ENSG00000271584.1	RP11-89C3.4	10.1	6.28e-23	3.88e-20	0.47	0.3	Body mass index;	chr11:111153872	chr11:111091932~111097357:-
BRCA	cis	rs321358	0.731	rs527397	ENSG00000271584.1	RP11-89C3.4	10.1	6.28e-23	3.88e-20	0.47	0.3	Body mass index;	chr11:111159907	chr11:111091932~111097357:-
BRCA	cis	rs1075265	0.84	rs805309	ENSG00000233266.1	HMGB1P31	10.09	6.35e-23	3.92e-20	0.36	0.3	Chronotype;Morning vs. evening chronotype;	chr2:53968877	chr2:54051334~54051760:+
BRCA	cis	rs1707322	0.721	rs11211178	ENSG00000280836.1	AL355480.1	-10.09	6.38e-23	3.94e-20	-0.39	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45761894	chr1:45581219~45581321:-
BRCA	cis	rs8062405	1	rs3088215	ENSG00000251417.2	RP11-1348G14.4	-10.09	6.45e-23	3.98e-20	-0.35	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28842675	chr16:28802743~28817828:+
BRCA	cis	rs8062405	1	rs28403629	ENSG00000251417.2	RP11-1348G14.4	-10.09	6.45e-23	3.98e-20	-0.35	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28843448	chr16:28802743~28817828:+
BRCA	cis	rs8062405	1	rs61737565	ENSG00000251417.2	RP11-1348G14.4	-10.09	6.45e-23	3.98e-20	-0.35	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28844201	chr16:28802743~28817828:+
BRCA	cis	rs8062405	1	rs4788099	ENSG00000251417.2	RP11-1348G14.4	-10.09	6.45e-23	3.98e-20	-0.35	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28844406	chr16:28802743~28817828:+
BRCA	cis	rs11971779	0.68	rs6962186	ENSG00000273391.1	RP11-634H22.1	10.09	6.59e-23	4.07e-20	0.29	0.3	Diisocyanate-induced asthma;	chr7:139350060	chr7:139359032~139359566:-
BRCA	cis	rs1150668	0.796	rs9468372	ENSG00000204709.4	LINC01556	10.09	6.6e-23	4.07e-20	0.37	0.3	Pubertal anthropometrics;	chr6:28411584	chr6:28943877~28944537:+
BRCA	cis	rs465969	0.546	rs77990243	ENSG00000255389.1	C6orf3	-10.09	6.61e-23	4.08e-20	-0.54	-0.3	Psoriasis;	chr6:111513183	chr6:111599875~111602295:+
BRCA	cis	rs2439831	0.85	rs3862142	ENSG00000275601.1	AC011330.13	-10.09	6.63e-23	4.09e-20	-0.47	-0.3	Lung cancer in ever smokers;	chr15:43772608	chr15:43642389~43643023:-
BRCA	cis	rs2439831	0.85	rs2277531	ENSG00000275601.1	AC011330.13	-10.09	6.63e-23	4.09e-20	-0.47	-0.3	Lung cancer in ever smokers;	chr15:43776871	chr15:43642389~43643023:-
BRCA	cis	rs867371	0.502	rs1846908	ENSG00000278603.1	RP13-608F4.5	10.09	6.64e-23	4.1e-20	0.38	0.3	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82230185	chr15:82472203~82472426:+
BRCA	cis	rs2665103	0.655	rs1501367	ENSG00000278603.1	RP13-608F4.5	10.09	6.64e-23	4.1e-20	0.38	0.3	Intelligence (multi-trait analysis);	chr15:82230475	chr15:82472203~82472426:+
BRCA	cis	rs875971	0.862	rs778702	ENSG00000237310.1	GS1-124K5.4	10.09	6.65e-23	4.11e-20	0.32	0.3	Aortic root size;	chr7:66399848	chr7:66493706~66495474:+
BRCA	cis	rs2439831	0.85	rs10163054	ENSG00000249839.1	AC011330.5	-10.09	6.67e-23	4.12e-20	-0.5	-0.3	Lung cancer in ever smokers;	chr15:43755440	chr15:43663654~43684339:-
BRCA	cis	rs11971779	0.68	rs7801613	ENSG00000273391.1	RP11-634H22.1	-10.09	6.7e-23	4.13e-20	-0.29	-0.3	Diisocyanate-induced asthma;	chr7:139355181	chr7:139359032~139359566:-
BRCA	cis	rs7772486	0.875	rs2777477	ENSG00000235652.6	RP11-545I5.3	10.09	6.81e-23	4.2e-20	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145984355	chr6:145799409~145886585:+
BRCA	cis	rs17711722	0.522	rs6957759	ENSG00000236529.1	RP13-254B10.1	10.09	6.82e-23	4.21e-20	0.33	0.3	Calcium levels;	chr7:65806798	chr7:65840212~65840596:+
BRCA	cis	rs7772486	0.79	rs1062068	ENSG00000235652.6	RP11-545I5.3	10.09	6.84e-23	4.22e-20	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145886329	chr6:145799409~145886585:+
BRCA	cis	rs875971	0.862	rs778680	ENSG00000237310.1	GS1-124K5.4	10.09	6.84e-23	4.22e-20	0.32	0.3	Aortic root size;	chr7:66375427	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.862	rs11769079	ENSG00000237310.1	GS1-124K5.4	10.09	6.84e-23	4.22e-20	0.32	0.3	Aortic root size;	chr7:66377141	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.862	rs1695820	ENSG00000237310.1	GS1-124K5.4	10.09	6.84e-23	4.22e-20	0.32	0.3	Aortic root size;	chr7:66379576	chr7:66493706~66495474:+
BRCA	cis	rs4835473	0.932	rs6851999	ENSG00000251600.4	RP11-673E1.1	10.09	6.88e-23	4.24e-20	0.34	0.3	Immature fraction of reticulocytes;	chr4:143742567	chr4:143912331~143982454:+
BRCA	cis	rs11105298	0.891	rs10777163	ENSG00000258302.2	RP11-981P6.1	10.09	6.92e-23	4.27e-20	0.33	0.3	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89436943	chr12:89561129~89594878:+
BRCA	cis	rs2243480	1	rs2462569	ENSG00000226824.5	RP4-756H11.3	10.08	6.94e-23	4.28e-20	0.55	0.3	Diabetic kidney disease;	chr7:66009859	chr7:66654538~66669855:+
BRCA	cis	rs867371	0.502	rs28610286	ENSG00000278603.1	RP13-608F4.5	10.08	7e-23	4.31e-20	0.38	0.3	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82233314	chr15:82472203~82472426:+
BRCA	cis	rs8062405	1	rs62037365	ENSG00000251417.2	RP11-1348G14.4	-10.08	7.01e-23	4.32e-20	-0.35	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28857641	chr16:28802743~28817828:+
BRCA	cis	rs11096990	0.634	rs7666632	ENSG00000249207.1	RP11-360F5.1	-10.08	7.01e-23	4.32e-20	-0.36	-0.3	Cognitive function;	chr4:39238568	chr4:39112677~39126818:-
BRCA	cis	rs67180937	0.504	rs3008625	ENSG00000272750.1	RP11-378J18.8	10.08	7.05e-23	4.34e-20	0.43	0.3	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222646680	chr1:222658867~222661512:-
BRCA	cis	rs10129255	0.957	rs11847726	ENSG00000211970.3	IGHV4-61	-10.08	7.08e-23	4.36e-20	-0.21	-0.3	Kawasaki disease;	chr14:106779116	chr14:106639119~106639657:-
BRCA	cis	rs733592	0.524	rs10875741	ENSG00000240399.1	RP1-228P16.1	-10.08	7.09e-23	4.37e-20	-0.32	-0.3	Plateletcrit;	chr12:48099139	chr12:48054813~48055591:-
BRCA	cis	rs4713118	0.662	rs175954	ENSG00000220721.1	OR1F12	10.08	7.17e-23	4.41e-20	0.39	0.3	Parkinson's disease;	chr6:28043807	chr6:28073316~28074233:+
BRCA	cis	rs1113500	0.836	rs2801220	ENSG00000226822.1	RP11-356N1.2	-10.08	7.21e-23	4.44e-20	-0.39	-0.3	Growth-regulated protein alpha levels;	chr1:108042027	chr1:108071482~108074519:+
BRCA	cis	rs2439831	0.85	rs7168158	ENSG00000249839.1	AC011330.5	-10.08	7.22e-23	4.44e-20	-0.5	-0.3	Lung cancer in ever smokers;	chr15:43758178	chr15:43663654~43684339:-
BRCA	cis	rs8062405	1	rs3888190	ENSG00000251417.2	RP11-1348G14.4	-10.08	7.27e-23	4.48e-20	-0.35	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28878165	chr16:28802743~28817828:+
BRCA	cis	rs673078	0.66	rs7961312	ENSG00000275759.1	RP11-131L12.3	-10.08	7.31e-23	4.5e-20	-0.52	-0.3	Glucose homeostasis traits;	chr12:118324431	chr12:118428281~118428870:+
BRCA	cis	rs748404	0.55	rs12912505	ENSG00000249839.1	AC011330.5	-10.08	7.31e-23	4.5e-20	-0.43	-0.3	Lung cancer;	chr15:43525206	chr15:43663654~43684339:-
BRCA	cis	rs7772486	0.79	rs3923579	ENSG00000235652.6	RP11-545I5.3	-10.08	7.34e-23	4.51e-20	-0.3	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145909096	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.79	rs2247666	ENSG00000235652.6	RP11-545I5.3	10.08	7.34e-23	4.51e-20	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145899273	chr6:145799409~145886585:+
BRCA	cis	rs2882667	0.537	rs6887866	ENSG00000253404.1	AC034243.1	10.08	7.38e-23	4.54e-20	0.37	0.3	Age-related hearing impairment (SNP x SNP interaction);	chr5:139102007	chr5:138744434~138753309:-
BRCA	cis	rs1113500	0.524	rs11185270	ENSG00000226822.1	RP11-356N1.2	10.08	7.38e-23	4.54e-20	0.42	0.3	Growth-regulated protein alpha levels;	chr1:108111740	chr1:108071482~108074519:+
BRCA	cis	rs875971	0.862	rs6962717	ENSG00000237310.1	GS1-124K5.4	10.08	7.38e-23	4.54e-20	0.32	0.3	Aortic root size;	chr7:66418748	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.862	rs1643375	ENSG00000237310.1	GS1-124K5.4	10.08	7.5e-23	4.61e-20	0.32	0.3	Aortic root size;	chr7:66407690	chr7:66493706~66495474:+
BRCA	cis	rs7688540	0.771	rs11723615	ENSG00000275426.1	CH17-262A2.1	10.08	7.51e-23	4.62e-20	0.46	0.3	Facial morphology (factor 6, height of vermillion lower lip);	chr4:283194	chr4:149738~150317:+
BRCA	cis	rs227275	0.525	rs223461	ENSG00000246560.2	RP11-10L12.4	10.08	7.53e-23	4.63e-20	0.31	0.3	Allergic disease (asthma, hay fever or eczema);	chr4:102782372	chr4:102828055~102844075:+
BRCA	cis	rs7567389	0.74	rs1604817	ENSG00000236682.1	AC068282.3	10.08	7.56e-23	4.65e-20	0.42	0.3	Self-rated health;	chr2:127242345	chr2:127389130~127400580:+
BRCA	cis	rs6570726	0.764	rs9403733	ENSG00000235652.6	RP11-545I5.3	10.08	7.61e-23	4.67e-20	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145591175	chr6:145799409~145886585:+
BRCA	cis	rs228614	0.51	rs223397	ENSG00000246560.2	RP11-10L12.4	10.07	7.63e-23	4.68e-20	0.32	0.3	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102821494	chr4:102828055~102844075:+
BRCA	cis	rs7772486	0.79	rs2247429	ENSG00000235652.6	RP11-545I5.3	10.07	7.65e-23	4.7e-20	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145896633	chr6:145799409~145886585:+
BRCA	cis	rs8062405	1	rs4788101	ENSG00000251417.2	RP11-1348G14.4	-10.07	7.67e-23	4.71e-20	-0.35	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28856483	chr16:28802743~28817828:+
BRCA	cis	rs8062405	0.737	rs11861132	ENSG00000251417.2	RP11-1348G14.4	-10.07	7.67e-23	4.71e-20	-0.35	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28860539	chr16:28802743~28817828:+
BRCA	cis	rs8062405	1	rs11861174	ENSG00000251417.2	RP11-1348G14.4	-10.07	7.67e-23	4.71e-20	-0.35	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28860668	chr16:28802743~28817828:+
BRCA	cis	rs8062405	1	rs4788102	ENSG00000251417.2	RP11-1348G14.4	-10.07	7.67e-23	4.71e-20	-0.35	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28862077	chr16:28802743~28817828:+
BRCA	cis	rs8062405	1	rs62037367	ENSG00000251417.2	RP11-1348G14.4	-10.07	7.67e-23	4.71e-20	-0.35	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863226	chr16:28802743~28817828:+
BRCA	cis	rs8062405	1	rs7198606	ENSG00000251417.2	RP11-1348G14.4	-10.07	7.67e-23	4.71e-20	-0.35	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863801	chr16:28802743~28817828:+
BRCA	cis	rs8062405	0.929	rs11864750	ENSG00000251417.2	RP11-1348G14.4	-10.07	7.67e-23	4.71e-20	-0.35	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863883	chr16:28802743~28817828:+
BRCA	cis	rs8062405	0.964	rs7193733	ENSG00000251417.2	RP11-1348G14.4	-10.07	7.67e-23	4.71e-20	-0.35	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28864161	chr16:28802743~28817828:+
BRCA	cis	rs8062405	1	rs8055982	ENSG00000251417.2	RP11-1348G14.4	-10.07	7.67e-23	4.71e-20	-0.35	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28869881	chr16:28802743~28817828:+
BRCA	cis	rs8062405	1	rs7498665	ENSG00000251417.2	RP11-1348G14.4	-10.07	7.67e-23	4.71e-20	-0.35	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28871920	chr16:28802743~28817828:+
BRCA	cis	rs8062405	0.964	rs11864107	ENSG00000251417.2	RP11-1348G14.4	-10.07	7.67e-23	4.71e-20	-0.35	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28874610	chr16:28802743~28817828:+
BRCA	cis	rs6558530	0.836	rs11136424	ENSG00000253982.1	CTD-2336O2.1	10.07	7.68e-23	4.71e-20	0.33	0.3	Systolic blood pressure;	chr8:1768870	chr8:1761990~1764502:-
BRCA	cis	rs2243480	1	rs160655	ENSG00000226824.5	RP4-756H11.3	-10.07	7.68e-23	4.71e-20	-0.59	-0.3	Diabetic kidney disease;	chr7:66068227	chr7:66654538~66669855:+
BRCA	cis	rs2276314	1	rs9304153	ENSG00000278986.1	RP11-723J4.3	-10.07	7.75e-23	4.75e-20	-0.39	-0.3	Endometriosis;Drug-induced torsades de pointes;	chr18:35982187	chr18:35972151~35973916:+
BRCA	cis	rs11971779	0.523	rs10234578	ENSG00000273391.1	RP11-634H22.1	10.07	7.8e-23	4.78e-20	0.29	0.3	Diisocyanate-induced asthma;	chr7:139353242	chr7:139359032~139359566:-
BRCA	cis	rs2276314	1	rs9304154	ENSG00000278986.1	RP11-723J4.3	-10.07	7.8e-23	4.79e-20	-0.39	-0.3	Endometriosis;Drug-induced torsades de pointes;	chr18:35982264	chr18:35972151~35973916:+
BRCA	cis	rs8062405	1	rs62037371	ENSG00000251417.2	RP11-1348G14.4	-10.07	7.82e-23	4.8e-20	-0.35	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28878810	chr16:28802743~28817828:+
BRCA	cis	rs6430553	0.929	rs6714498	ENSG00000224043.6	CCNT2-AS1	10.07	7.83e-23	4.8e-20	0.38	0.3	Blood metabolite levels;	chr2:134893196	chr2:134735464~134918710:-
BRCA	cis	rs712022	1	rs712022	ENSG00000246225.5	RP11-17A1.3	-10.07	7.86e-23	4.82e-20	-0.35	-0.3	Dialysis-related mortality;	chr11:22821609	chr11:22829380~22945393:+
BRCA	cis	rs2439831	0.702	rs7171750	ENSG00000249839.1	AC011330.5	-10.07	7.9e-23	4.84e-20	-0.5	-0.3	Lung cancer in ever smokers;	chr15:43733660	chr15:43663654~43684339:-
BRCA	cis	rs2015599	0.525	rs10743656	ENSG00000257176.2	RP11-996F15.2	10.07	7.94e-23	4.87e-20	0.35	0.3	Platelet count;Mean platelet volume;	chr12:29332516	chr12:29280418~29317848:-
BRCA	cis	rs1874124	0.577	rs2807880	ENSG00000238078.1	LINC01352	10.07	7.95e-23	4.87e-20	0.43	0.3	Cholesterol, total;	chr1:220869661	chr1:220829255~220832429:+
BRCA	cis	rs6430553	0.964	rs62168869	ENSG00000224043.6	CCNT2-AS1	-10.07	7.99e-23	4.9e-20	-0.38	-0.3	Blood metabolite levels;	chr2:134889209	chr2:134735464~134918710:-
BRCA	cis	rs6565180	1	rs68051857	ENSG00000273724.1	RP11-347C12.12	-10.07	8.03e-23	4.92e-20	-0.34	-0.3	Tonsillectomy;	chr16:30348690	chr16:30336400~30343336:+
BRCA	cis	rs10129255	0.957	rs10141009	ENSG00000211970.3	IGHV4-61	-10.07	8.05e-23	4.93e-20	-0.2	-0.3	Kawasaki disease;	chr14:106776695	chr14:106639119~106639657:-
BRCA	cis	rs7772486	0.754	rs2328707	ENSG00000235652.6	RP11-545I5.3	-10.07	8.09e-23	4.96e-20	-0.3	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145732362	chr6:145799409~145886585:+
BRCA	cis	rs10129255	0.957	rs10141052	ENSG00000211970.3	IGHV4-61	-10.07	8.09e-23	4.96e-20	-0.2	-0.3	Kawasaki disease;	chr14:106776528	chr14:106639119~106639657:-
BRCA	cis	rs875971	0.83	rs809025	ENSG00000237310.1	GS1-124K5.4	10.07	8.12e-23	4.97e-20	0.32	0.3	Aortic root size;	chr7:66384832	chr7:66493706~66495474:+
BRCA	cis	rs2276314	0.857	rs28791905	ENSG00000278986.1	RP11-723J4.3	-10.07	8.16e-23	5e-20	-0.38	-0.3	Endometriosis;Drug-induced torsades de pointes;	chr18:36022250	chr18:35972151~35973916:+
BRCA	cis	rs6844153	0.752	rs28497454	ENSG00000240005.4	RP11-293A21.1	-10.07	8.19e-23	5.01e-20	-0.39	-0.3	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26906230	chr4:26859806~26860599:-
BRCA	cis	rs10129255	0.957	rs7493713	ENSG00000211970.3	IGHV4-61	-10.07	8.2e-23	5.02e-20	-0.2	-0.3	Kawasaki disease;	chr14:106783685	chr14:106639119~106639657:-
BRCA	cis	rs10129255	0.912	rs35468694	ENSG00000211970.3	IGHV4-61	-10.07	8.2e-23	5.02e-20	-0.2	-0.3	Kawasaki disease;	chr14:106784199	chr14:106639119~106639657:-
BRCA	cis	rs4713118	0.662	rs9393881	ENSG00000220721.1	OR1F12	10.07	8.26e-23	5.06e-20	0.38	0.3	Parkinson's disease;	chr6:28055973	chr6:28073316~28074233:+
BRCA	cis	rs673078	0.607	rs17512483	ENSG00000275759.1	RP11-131L12.3	10.07	8.29e-23	5.07e-20	0.5	0.3	Glucose homeostasis traits;	chr12:118312380	chr12:118428281~118428870:+
BRCA	cis	rs1707322	0.686	rs2050376	ENSG00000280836.1	AL355480.1	-10.06	8.37e-23	5.12e-20	-0.39	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45612958	chr1:45581219~45581321:-
BRCA	cis	rs1075265	0.87	rs7569370	ENSG00000233266.1	HMGB1P31	10.06	8.37e-23	5.12e-20	0.36	0.3	Chronotype;Morning vs. evening chronotype;	chr2:53989212	chr2:54051334~54051760:+
BRCA	cis	rs10875746	0.551	rs3185921	ENSG00000240399.1	RP1-228P16.1	-10.06	8.43e-23	5.15e-20	-0.4	-0.3	Longevity (90 years and older);	chr12:48340948	chr12:48054813~48055591:-
BRCA	cis	rs6545883	0.507	rs34668697	ENSG00000271889.1	RP11-493E12.1	-10.06	8.49e-23	5.19e-20	-0.36	-0.3	Tuberculosis;	chr2:61341214	chr2:61151433~61162105:-
BRCA	cis	rs2243480	1	rs383402	ENSG00000226824.5	RP4-756H11.3	10.06	8.51e-23	5.2e-20	0.56	0.3	Diabetic kidney disease;	chr7:66121666	chr7:66654538~66669855:+
BRCA	cis	rs1707322	0.627	rs3014213	ENSG00000280836.1	AL355480.1	10.06	8.53e-23	5.21e-20	0.39	0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45579850	chr1:45581219~45581321:-
BRCA	cis	rs7772486	0.79	rs9403749	ENSG00000235652.6	RP11-545I5.3	10.06	8.54e-23	5.22e-20	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145841103	chr6:145799409~145886585:+
BRCA	cis	rs11098499	0.954	rs4309825	ENSG00000245958.5	RP11-33B1.1	10.06	8.66e-23	5.29e-20	0.29	0.3	Corneal astigmatism;	chr4:119393726	chr4:119454791~119552025:+
BRCA	cis	rs4713118	0.662	rs464312	ENSG00000220721.1	OR1F12	10.06	8.74e-23	5.34e-20	0.38	0.3	Parkinson's disease;	chr6:27999813	chr6:28073316~28074233:+
BRCA	cis	rs4713118	0.662	rs469228	ENSG00000220721.1	OR1F12	10.06	8.74e-23	5.34e-20	0.38	0.3	Parkinson's disease;	chr6:28002926	chr6:28073316~28074233:+
BRCA	cis	rs4713118	0.54	rs469227	ENSG00000220721.1	OR1F12	10.06	8.74e-23	5.34e-20	0.38	0.3	Parkinson's disease;	chr6:28002927	chr6:28073316~28074233:+
BRCA	cis	rs4713118	0.662	rs149948	ENSG00000220721.1	OR1F12	10.06	8.74e-23	5.34e-20	0.38	0.3	Parkinson's disease;	chr6:28007039	chr6:28073316~28074233:+
BRCA	cis	rs4713118	0.662	rs149961	ENSG00000220721.1	OR1F12	10.06	8.76e-23	5.35e-20	0.39	0.3	Parkinson's disease;	chr6:28047791	chr6:28073316~28074233:+
BRCA	cis	rs7714584	1	rs1000113	ENSG00000197083.10	ZNF300P1	10.06	8.79e-23	5.37e-20	0.44	0.3	Crohn's disease;	chr5:150860514	chr5:150930645~150946289:-
BRCA	cis	rs6570726	0.791	rs407887	ENSG00000235652.6	RP11-545I5.3	10.06	8.8e-23	5.37e-20	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145522623	chr6:145799409~145886585:+
BRCA	cis	rs1113500	0.548	rs9970655	ENSG00000226822.1	RP11-356N1.2	10.06	8.85e-23	5.4e-20	0.44	0.3	Growth-regulated protein alpha levels;	chr1:108100915	chr1:108071482~108074519:+
BRCA	cis	rs881375	0.715	rs10985073	ENSG00000226752.6	PSMD5-AS1	-10.06	8.89e-23	5.42e-20	-0.35	-0.3	Rheumatoid arthritis;	chr9:120881577	chr9:120824828~120854385:+
BRCA	cis	rs11098499	0.954	rs71629403	ENSG00000245958.5	RP11-33B1.1	-10.06	8.9e-23	5.43e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119451412	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.909	rs28571712	ENSG00000245958.5	RP11-33B1.1	-10.06	8.9e-23	5.43e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119454825	chr4:119454791~119552025:+
BRCA	cis	rs875971	0.545	rs3936065	ENSG00000226824.5	RP4-756H11.3	-10.06	8.93e-23	5.45e-20	-0.42	-0.3	Aortic root size;	chr7:66325577	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.545	rs4718335	ENSG00000226824.5	RP4-756H11.3	-10.06	8.93e-23	5.45e-20	-0.42	-0.3	Aortic root size;	chr7:66339619	chr7:66654538~66669855:+
BRCA	cis	rs6142102	0.58	rs4911139	ENSG00000276073.1	RP5-1125A11.7	-10.06	8.96e-23	5.47e-20	-0.34	-0.3	Skin pigmentation;	chr20:33963729	chr20:33985617~33988989:-
BRCA	cis	rs765787	0.53	rs12592055	ENSG00000259520.4	CTD-2651B20.3	-10.06	9e-23	5.49e-20	-0.37	-0.3	Uric acid levels;	chr15:45222279	chr15:45251580~45279251:-
BRCA	cis	rs8062405	1	rs62037364	ENSG00000251417.2	RP11-1348G14.4	-10.06	9e-23	5.49e-20	-0.35	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28857374	chr16:28802743~28817828:+
BRCA	cis	rs875971	0.545	rs11770063	ENSG00000226824.5	RP4-756H11.3	-10.06	9e-23	5.49e-20	-0.42	-0.3	Aortic root size;	chr7:66318029	chr7:66654538~66669855:+
BRCA	cis	rs10129255	0.957	rs8009464	ENSG00000211970.3	IGHV4-61	-10.06	9.03e-23	5.51e-20	-0.2	-0.3	Kawasaki disease;	chr14:106777611	chr14:106639119~106639657:-
BRCA	cis	rs7772486	0.754	rs9386132	ENSG00000235652.6	RP11-545I5.3	10.06	9.07e-23	5.53e-20	0.31	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145819615	chr6:145799409~145886585:+
BRCA	cis	rs2276314	0.857	rs4799408	ENSG00000278986.1	RP11-723J4.3	10.06	9.07e-23	5.53e-20	0.37	0.3	Endometriosis;Drug-induced torsades de pointes;	chr18:36009019	chr18:35972151~35973916:+
BRCA	cis	rs4964805	0.594	rs4981036	ENSG00000257681.1	RP11-341G23.4	10.06	9.09e-23	5.54e-20	0.35	0.3	Attention deficit hyperactivity disorder;	chr12:103770566	chr12:103746315~103768858:-
BRCA	cis	rs11673344	0.704	rs1644710	ENSG00000226686.6	LINC01535	10.06	9.09e-23	5.54e-20	0.39	0.3	Obesity-related traits;	chr19:36926160	chr19:37251912~37265535:+
BRCA	cis	rs524281	0.861	rs10896085	ENSG00000255320.1	RP11-755F10.1	10.06	9.1e-23	5.55e-20	0.45	0.3	Electroencephalogram traits;	chr11:66146361	chr11:66244840~66246239:-
BRCA	cis	rs875971	0.545	rs73146609	ENSG00000226824.5	RP4-756H11.3	-10.06	9.12e-23	5.56e-20	-0.42	-0.3	Aortic root size;	chr7:66302477	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.545	rs2173571	ENSG00000226824.5	RP4-756H11.3	-10.06	9.12e-23	5.56e-20	-0.42	-0.3	Aortic root size;	chr7:66305392	chr7:66654538~66669855:+
BRCA	cis	rs673078	0.607	rs61943398	ENSG00000275759.1	RP11-131L12.3	-10.06	9.13e-23	5.57e-20	-0.44	-0.3	Glucose homeostasis traits;	chr12:118393280	chr12:118428281~118428870:+
BRCA	cis	rs4713118	0.662	rs9468274	ENSG00000220721.1	OR1F12	10.06	9.13e-23	5.57e-20	0.39	0.3	Parkinson's disease;	chr6:28058299	chr6:28073316~28074233:+
BRCA	cis	rs4713118	0.662	rs9468275	ENSG00000220721.1	OR1F12	10.06	9.13e-23	5.57e-20	0.39	0.3	Parkinson's disease;	chr6:28058358	chr6:28073316~28074233:+
BRCA	cis	rs4713118	0.662	rs9468276	ENSG00000220721.1	OR1F12	10.06	9.13e-23	5.57e-20	0.39	0.3	Parkinson's disease;	chr6:28059910	chr6:28073316~28074233:+
BRCA	cis	rs4713118	0.662	rs9468277	ENSG00000220721.1	OR1F12	10.06	9.13e-23	5.57e-20	0.39	0.3	Parkinson's disease;	chr6:28060612	chr6:28073316~28074233:+
BRCA	cis	rs4713118	0.662	rs9468278	ENSG00000220721.1	OR1F12	10.06	9.13e-23	5.57e-20	0.39	0.3	Parkinson's disease;	chr6:28060704	chr6:28073316~28074233:+
BRCA	cis	rs4713118	0.662	rs13218430	ENSG00000220721.1	OR1F12	10.06	9.13e-23	5.57e-20	0.39	0.3	Parkinson's disease;	chr6:28062059	chr6:28073316~28074233:+
BRCA	cis	rs6570726	0.764	rs366673	ENSG00000235652.6	RP11-545I5.3	10.06	9.14e-23	5.57e-20	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145493492	chr6:145799409~145886585:+
BRCA	cis	rs1113500	0.548	rs17020971	ENSG00000226822.1	RP11-356N1.2	10.06	9.15e-23	5.58e-20	0.42	0.3	Growth-regulated protein alpha levels;	chr1:108112666	chr1:108071482~108074519:+
BRCA	cis	rs11098499	0.954	rs2389803	ENSG00000245958.5	RP11-33B1.1	10.06	9.16e-23	5.58e-20	0.29	0.3	Corneal astigmatism;	chr4:119472356	chr4:119454791~119552025:+
BRCA	cis	rs765787	0.505	rs4439707	ENSG00000259520.4	CTD-2651B20.3	-10.05	9.17e-23	5.59e-20	-0.37	-0.3	Uric acid levels;	chr15:45232018	chr15:45251580~45279251:-
BRCA	cis	rs1707322	0.721	rs61784800	ENSG00000280836.1	AL355480.1	10.05	9.19e-23	5.6e-20	0.38	0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45712440	chr1:45581219~45581321:-
BRCA	cis	rs7580658	0.75	rs6731176	ENSG00000236682.1	AC068282.3	-10.05	9.21e-23	5.61e-20	-0.38	-0.3	Protein C levels;	chr2:127313427	chr2:127389130~127400580:+
BRCA	cis	rs4713118	0.616	rs9348789	ENSG00000220721.1	OR1F12	10.05	9.27e-23	5.65e-20	0.39	0.3	Parkinson's disease;	chr6:28057708	chr6:28073316~28074233:+
BRCA	cis	rs10129255	0.913	rs28861466	ENSG00000211970.3	IGHV4-61	-10.05	9.3e-23	5.67e-20	-0.22	-0.3	Kawasaki disease;	chr14:106718572	chr14:106639119~106639657:-
BRCA	cis	rs1113500	0.836	rs1618973	ENSG00000226822.1	RP11-356N1.2	-10.05	9.39e-23	5.72e-20	-0.39	-0.3	Growth-regulated protein alpha levels;	chr1:108044145	chr1:108071482~108074519:+
BRCA	cis	rs1823913	0.599	rs17511445	ENSG00000227542.1	AC092614.2	-10.05	9.48e-23	5.77e-20	-0.36	-0.3	Obesity-related traits;	chr2:191279831	chr2:191229165~191246172:-
BRCA	cis	rs6782228	0.585	rs2712392	ENSG00000242551.2	POU5F1P6	-10.05	9.51e-23	5.79e-20	-0.37	-0.3	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128705414	chr3:128674735~128677005:-
BRCA	cis	rs6545883	0.507	rs12478192	ENSG00000271889.1	RP11-493E12.1	-10.05	9.51e-23	5.79e-20	-0.36	-0.3	Tuberculosis;	chr2:61364040	chr2:61151433~61162105:-
BRCA	cis	rs1113500	0.614	rs61797342	ENSG00000226822.1	RP11-356N1.2	10.05	9.55e-23	5.81e-20	0.44	0.3	Growth-regulated protein alpha levels;	chr1:108065763	chr1:108071482~108074519:+
BRCA	cis	rs1150668	0.83	rs2859365	ENSG00000204709.4	LINC01556	-10.05	9.59e-23	5.83e-20	-0.37	-0.3	Pubertal anthropometrics;	chr6:28423688	chr6:28943877~28944537:+
BRCA	cis	rs11971779	0.68	rs7779900	ENSG00000273391.1	RP11-634H22.1	10.05	9.64e-23	5.86e-20	0.29	0.3	Diisocyanate-induced asthma;	chr7:139398241	chr7:139359032~139359566:-
BRCA	cis	rs2439831	0.85	rs28595038	ENSG00000249839.1	AC011330.5	-10.05	9.66e-23	5.87e-20	-0.5	-0.3	Lung cancer in ever smokers;	chr15:43752661	chr15:43663654~43684339:-
BRCA	cis	rs10129255	0.957	rs8019272	ENSG00000211970.3	IGHV4-61	-10.05	9.67e-23	5.88e-20	-0.2	-0.3	Kawasaki disease;	chr14:106784709	chr14:106639119~106639657:-
BRCA	cis	rs11098499	0.954	rs3890049	ENSG00000245958.5	RP11-33B1.1	-10.05	9.69e-23	5.89e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119405128	chr4:119454791~119552025:+
BRCA	cis	rs1707322	0.721	rs7520123	ENSG00000280836.1	AL355480.1	-10.05	9.75e-23	5.93e-20	-0.38	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45769547	chr1:45581219~45581321:-
BRCA	cis	rs4713118	0.629	rs203889	ENSG00000220721.1	OR1F12	10.05	9.79e-23	5.95e-20	0.38	0.3	Parkinson's disease;	chr6:28053997	chr6:28073316~28074233:+
BRCA	cis	rs4964805	0.537	rs11111750	ENSG00000257681.1	RP11-341G23.4	10.05	9.94e-23	6.04e-20	0.37	0.3	Attention deficit hyperactivity disorder;	chr12:103761762	chr12:103746315~103768858:-
BRCA	cis	rs11098499	0.954	rs7437420	ENSG00000245958.5	RP11-33B1.1	-10.05	9.95e-23	6.05e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119391748	chr4:119454791~119552025:+
BRCA	cis	rs10129255	0.912	rs6576227	ENSG00000211970.3	IGHV4-61	-10.05	1e-22	6.08e-20	-0.2	-0.3	Kawasaki disease;	chr14:106778202	chr14:106639119~106639657:-
BRCA	cis	rs10129255	0.957	rs6576228	ENSG00000211970.3	IGHV4-61	-10.05	1e-22	6.08e-20	-0.2	-0.3	Kawasaki disease;	chr14:106778401	chr14:106639119~106639657:-
BRCA	cis	rs7772486	0.875	rs2748490	ENSG00000235652.6	RP11-545I5.3	10.05	1e-22	6.1e-20	0.29	0.3	Lobe attachment (rater-scored or self-reported);	chr6:146008545	chr6:145799409~145886585:+
BRCA	cis	rs321358	0.731	rs534858	ENSG00000271584.1	RP11-89C3.4	10.05	1e-22	6.11e-20	0.46	0.3	Body mass index;	chr11:111145583	chr11:111091932~111097357:-
BRCA	cis	rs6570726	0.791	rs447992	ENSG00000235652.6	RP11-545I5.3	10.04	1.01e-22	6.14e-20	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145496048	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.791	rs425999	ENSG00000235652.6	RP11-545I5.3	10.04	1.01e-22	6.14e-20	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145498234	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.791	rs387376	ENSG00000235652.6	RP11-545I5.3	10.04	1.01e-22	6.14e-20	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145501429	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.764	rs1912023	ENSG00000235652.6	RP11-545I5.3	10.04	1.01e-22	6.14e-20	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145503142	chr6:145799409~145886585:+
BRCA	cis	rs1113500	0.548	rs3853495	ENSG00000226822.1	RP11-356N1.2	10.04	1.01e-22	6.15e-20	0.44	0.3	Growth-regulated protein alpha levels;	chr1:108100623	chr1:108071482~108074519:+
BRCA	cis	rs11971779	0.68	rs3924296	ENSG00000273391.1	RP11-634H22.1	10.04	1.01e-22	6.16e-20	0.29	0.3	Diisocyanate-induced asthma;	chr7:139357181	chr7:139359032~139359566:-
BRCA	cis	rs11971779	0.527	rs4379397	ENSG00000273391.1	RP11-634H22.1	10.04	1.01e-22	6.16e-20	0.29	0.3	Diisocyanate-induced asthma;	chr7:139358639	chr7:139359032~139359566:-
BRCA	cis	rs11971779	0.774	rs6467838	ENSG00000273391.1	RP11-634H22.1	10.04	1.01e-22	6.16e-20	0.29	0.3	Diisocyanate-induced asthma;	chr7:139358755	chr7:139359032~139359566:-
BRCA	cis	rs11971779	0.68	rs6961812	ENSG00000273391.1	RP11-634H22.1	10.04	1.01e-22	6.16e-20	0.29	0.3	Diisocyanate-induced asthma;	chr7:139359062	chr7:139359032~139359566:-
BRCA	cis	rs11971779	0.68	rs6962366	ENSG00000273391.1	RP11-634H22.1	10.04	1.01e-22	6.16e-20	0.29	0.3	Diisocyanate-induced asthma;	chr7:139359121	chr7:139359032~139359566:-
BRCA	cis	rs11971779	0.68	rs3924445	ENSG00000273391.1	RP11-634H22.1	10.04	1.01e-22	6.16e-20	0.29	0.3	Diisocyanate-induced asthma;	chr7:139359426	chr7:139359032~139359566:-
BRCA	cis	rs4713118	0.662	rs9380046	ENSG00000220721.1	OR1F12	10.04	1.02e-22	6.17e-20	0.39	0.3	Parkinson's disease;	chr6:28062721	chr6:28073316~28074233:+
BRCA	cis	rs10885997	0.967	rs11197775	ENSG00000266200.5	PNLIPRP2	-10.04	1.02e-22	6.22e-20	-0.37	-0.3	Phospholipid levels (plasma);	chr10:116636627	chr10:116620953~116645143:+
BRCA	cis	rs56046484	0.871	rs7177110	ENSG00000259295.5	CSPG4P12	10.04	1.03e-22	6.24e-20	0.48	0.3	Testicular germ cell tumor;	chr15:85128524	chr15:85191438~85213905:+
BRCA	cis	rs7772486	0.846	rs866473	ENSG00000235652.6	RP11-545I5.3	10.04	1.03e-22	6.26e-20	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:146032278	chr6:145799409~145886585:+
BRCA	cis	rs1707322	0.717	rs11211161	ENSG00000280836.1	AL355480.1	-10.04	1.03e-22	6.26e-20	-0.39	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45682466	chr1:45581219~45581321:-
BRCA	cis	rs4835473	0.897	rs11100812	ENSG00000251600.4	RP11-673E1.1	10.04	1.04e-22	6.29e-20	0.34	0.3	Immature fraction of reticulocytes;	chr4:143790400	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.545	rs10022856	ENSG00000251600.4	RP11-673E1.1	10.04	1.04e-22	6.29e-20	0.34	0.3	Immature fraction of reticulocytes;	chr4:143793157	chr4:143912331~143982454:+
BRCA	cis	rs1707322	0.721	rs10890346	ENSG00000280836.1	AL355480.1	10.04	1.04e-22	6.3e-20	0.39	0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45758220	chr1:45581219~45581321:-
BRCA	cis	rs8072100	1	rs4794048	ENSG00000228782.6	CTD-2026D20.3	10.04	1.05e-22	6.38e-20	0.32	0.3	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47685707	chr17:47450568~47492492:-
BRCA	cis	rs6570726	0.791	rs9403729	ENSG00000235652.6	RP11-545I5.3	10.04	1.05e-22	6.38e-20	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145585871	chr6:145799409~145886585:+
BRCA	cis	rs8062405	1	rs62036616	ENSG00000278665.1	RP11-666O2.4	10.04	1.06e-22	6.43e-20	0.33	0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814986	chr16:28599241~28601881:-
BRCA	cis	rs524281	0.861	rs3825067	ENSG00000255320.1	RP11-755F10.1	-10.04	1.07e-22	6.47e-20	-0.45	-0.3	Electroencephalogram traits;	chr11:66110948	chr11:66244840~66246239:-
BRCA	cis	rs9309711	0.56	rs6548164	ENSG00000225234.1	TRAPPC12-AS1	10.04	1.07e-22	6.49e-20	0.31	0.3	Neurofibrillary tangles;	chr2:3468894	chr2:3481242~3482409:-
BRCA	cis	rs6700559	0.873	rs7542840	ENSG00000260088.1	RP11-92G12.3	-10.04	1.07e-22	6.49e-20	-0.39	-0.3	Coronary artery disease;	chr1:200686558	chr1:200669507~200694250:+
BRCA	cis	rs6700559	0.815	rs7526365	ENSG00000260088.1	RP11-92G12.3	-10.04	1.07e-22	6.49e-20	-0.39	-0.3	Coronary artery disease;	chr1:200688020	chr1:200669507~200694250:+
BRCA	cis	rs6700559	0.873	rs7526482	ENSG00000260088.1	RP11-92G12.3	-10.04	1.07e-22	6.49e-20	-0.39	-0.3	Coronary artery disease;	chr1:200688310	chr1:200669507~200694250:+
BRCA	cis	rs6700559	0.873	rs7526853	ENSG00000260088.1	RP11-92G12.3	-10.04	1.07e-22	6.49e-20	-0.39	-0.3	Coronary artery disease;	chr1:200688529	chr1:200669507~200694250:+
BRCA	cis	rs6700559	0.844	rs61825137	ENSG00000260088.1	RP11-92G12.3	-10.04	1.07e-22	6.49e-20	-0.39	-0.3	Coronary artery disease;	chr1:200689267	chr1:200669507~200694250:+
BRCA	cis	rs6700559	0.873	rs7539646	ENSG00000260088.1	RP11-92G12.3	-10.04	1.07e-22	6.49e-20	-0.39	-0.3	Coronary artery disease;	chr1:200692534	chr1:200669507~200694250:+
BRCA	cis	rs6700559	0.873	rs7519383	ENSG00000260088.1	RP11-92G12.3	-10.04	1.07e-22	6.49e-20	-0.39	-0.3	Coronary artery disease;	chr1:200692968	chr1:200669507~200694250:+
BRCA	cis	rs6700559	0.815	rs12141497	ENSG00000260088.1	RP11-92G12.3	-10.04	1.07e-22	6.49e-20	-0.39	-0.3	Coronary artery disease;	chr1:200693389	chr1:200669507~200694250:+
BRCA	cis	rs6700559	0.873	rs12126708	ENSG00000260088.1	RP11-92G12.3	-10.04	1.07e-22	6.49e-20	-0.39	-0.3	Coronary artery disease;	chr1:200693397	chr1:200669507~200694250:+
BRCA	cis	rs6700559	0.873	rs10920008	ENSG00000260088.1	RP11-92G12.3	-10.04	1.07e-22	6.49e-20	-0.39	-0.3	Coronary artery disease;	chr1:200694546	chr1:200669507~200694250:+
BRCA	cis	rs1113500	0.614	rs1343192	ENSG00000226822.1	RP11-356N1.2	10.04	1.08e-22	6.54e-20	0.44	0.3	Growth-regulated protein alpha levels;	chr1:108071266	chr1:108071482~108074519:+
BRCA	cis	rs35160687	0.623	rs35408390	ENSG00000273080.1	RP11-301O19.1	-10.04	1.08e-22	6.56e-20	-0.36	-0.3	Night sleep phenotypes;	chr2:86244659	chr2:86195590~86196049:+
BRCA	cis	rs2243480	1	rs160652	ENSG00000226824.5	RP4-756H11.3	-10.04	1.09e-22	6.58e-20	-0.6	-0.3	Diabetic kidney disease;	chr7:66073444	chr7:66654538~66669855:+
BRCA	cis	rs7772486	0.754	rs6932863	ENSG00000235652.6	RP11-545I5.3	-10.04	1.09e-22	6.61e-20	-0.3	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145700119	chr6:145799409~145886585:+
BRCA	cis	rs1113500	0.548	rs7541433	ENSG00000226822.1	RP11-356N1.2	10.04	1.09e-22	6.62e-20	0.42	0.3	Growth-regulated protein alpha levels;	chr1:108103019	chr1:108071482~108074519:+
BRCA	cis	rs6750795	0.87	rs6754952	ENSG00000181798.2	LINC00471	10.04	1.1e-22	6.64e-20	0.36	0.3	Height;	chr2:231516534	chr2:231508426~231514339:-
BRCA	cis	rs7772486	0.754	rs4896841	ENSG00000235652.6	RP11-545I5.3	-10.03	1.1e-22	6.68e-20	-0.3	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145720386	chr6:145799409~145886585:+
BRCA	cis	rs2243480	0.803	rs160649	ENSG00000226824.5	RP4-756H11.3	-10.03	1.11e-22	6.68e-20	-0.59	-0.3	Diabetic kidney disease;	chr7:66078212	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs160648	ENSG00000226824.5	RP4-756H11.3	-10.03	1.11e-22	6.68e-20	-0.59	-0.3	Diabetic kidney disease;	chr7:66078397	chr7:66654538~66669855:+
BRCA	cis	rs11971779	0.68	rs17691238	ENSG00000273391.1	RP11-634H22.1	-10.03	1.11e-22	6.69e-20	-0.29	-0.3	Diisocyanate-induced asthma;	chr7:139367538	chr7:139359032~139359566:-
BRCA	cis	rs6545883	0.507	rs2442025	ENSG00000271889.1	RP11-493E12.1	-10.03	1.11e-22	6.71e-20	-0.36	-0.3	Tuberculosis;	chr2:61344310	chr2:61151433~61162105:-
BRCA	cis	rs2412819	0.571	rs28410121	ENSG00000249839.1	AC011330.5	10.03	1.11e-22	6.71e-20	0.41	0.3	Lung cancer;	chr15:43777831	chr15:43663654~43684339:-
BRCA	cis	rs2404602	0.735	rs4886495	ENSG00000259422.1	RP11-593F23.1	10.03	1.11e-22	6.72e-20	0.38	0.3	Blood metabolite levels;	chr15:76446618	chr15:76174891~76181486:-
BRCA	cis	rs732716	0.785	rs56033249	ENSG00000267769.1	CTB-50L17.9	-10.03	1.12e-22	6.77e-20	-0.38	-0.3	Mean corpuscular volume;	chr19:4369450	chr19:4454014~4455286:+
BRCA	cis	rs1862618	0.525	rs2662021	ENSG00000271828.1	CTD-2310F14.1	-10.03	1.12e-22	6.77e-20	-0.43	-0.3	Initial pursuit acceleration;	chr5:56965864	chr5:56927874~56929573:+
BRCA	cis	rs673078	0.607	rs7304342	ENSG00000275759.1	RP11-131L12.3	-10.03	1.12e-22	6.78e-20	-0.44	-0.3	Glucose homeostasis traits;	chr12:118390166	chr12:118428281~118428870:+
BRCA	cis	rs11098499	0.697	rs28655325	ENSG00000245958.5	RP11-33B1.1	-10.03	1.12e-22	6.78e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119451844	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.954	rs6838814	ENSG00000245958.5	RP11-33B1.1	-10.03	1.12e-22	6.78e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119471288	chr4:119454791~119552025:+
BRCA	cis	rs1707322	0.682	rs28508523	ENSG00000280836.1	AL355480.1	-10.03	1.13e-22	6.81e-20	-0.38	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45723953	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.717	rs3014237	ENSG00000280836.1	AL355480.1	10.03	1.13e-22	6.82e-20	0.39	0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45624580	chr1:45581219~45581321:-
BRCA	cis	rs2439831	0.85	rs16950562	ENSG00000249839.1	AC011330.5	-10.03	1.13e-22	6.82e-20	-0.49	-0.3	Lung cancer in ever smokers;	chr15:43744166	chr15:43663654~43684339:-
BRCA	cis	rs6782228	1	rs12495411	ENSG00000242551.2	POU5F1P6	10.03	1.13e-22	6.83e-20	0.42	0.3	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128676852	chr3:128674735~128677005:-
BRCA	cis	rs7429990	0.965	rs9811277	ENSG00000229759.1	MRPS18AP1	10.03	1.14e-22	6.9e-20	0.33	0.3	Educational attainment (years of education);	chr3:47970148	chr3:48256350~48256938:-
BRCA	cis	rs7429990	0.965	rs9814961	ENSG00000229759.1	MRPS18AP1	10.03	1.14e-22	6.9e-20	0.33	0.3	Educational attainment (years of education);	chr3:47976127	chr3:48256350~48256938:-
BRCA	cis	rs6570726	0.791	rs9376945	ENSG00000235652.6	RP11-545I5.3	10.03	1.14e-22	6.9e-20	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145506944	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.755	rs451699	ENSG00000235652.6	RP11-545I5.3	10.03	1.14e-22	6.9e-20	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145509458	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.791	rs401561	ENSG00000235652.6	RP11-545I5.3	10.03	1.14e-22	6.9e-20	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145514781	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.791	rs405206	ENSG00000235652.6	RP11-545I5.3	10.03	1.14e-22	6.9e-20	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145515737	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.791	rs374478	ENSG00000235652.6	RP11-545I5.3	10.03	1.14e-22	6.9e-20	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145518886	chr6:145799409~145886585:+
BRCA	cis	rs10129255	0.785	rs10150044	ENSG00000211970.3	IGHV4-61	-10.03	1.14e-22	6.9e-20	-0.2	-0.3	Kawasaki disease;	chr14:106775695	chr14:106639119~106639657:-
BRCA	cis	rs11098499	0.909	rs28668716	ENSG00000245958.5	RP11-33B1.1	-10.03	1.15e-22	6.92e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119388720	chr4:119454791~119552025:+
BRCA	cis	rs17482078	0.959	rs35983588	ENSG00000248734.2	CTD-2260A17.1	10.03	1.15e-22	6.94e-20	0.41	0.3	Behcet's disease;Blood protein levels;	chr5:96787726	chr5:96784777~96785999:+
BRCA	cis	rs17482078	0.959	rs2287987	ENSG00000248734.2	CTD-2260A17.1	10.03	1.15e-22	6.96e-20	0.41	0.3	Behcet's disease;Blood protein levels;	chr5:96793832	chr5:96784777~96785999:+
BRCA	cis	rs17482078	0.959	rs13168673	ENSG00000248734.2	CTD-2260A17.1	10.03	1.15e-22	6.96e-20	0.41	0.3	Behcet's disease;Blood protein levels;	chr5:96794486	chr5:96784777~96785999:+
BRCA	cis	rs7772486	0.79	rs9497424	ENSG00000235652.6	RP11-545I5.3	-10.03	1.16e-22	6.97e-20	-0.29	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145904135	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.818	rs9390338	ENSG00000235652.6	RP11-545I5.3	10.03	1.16e-22	7e-20	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145587129	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.791	rs6570693	ENSG00000235652.6	RP11-545I5.3	10.03	1.16e-22	7e-20	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145589705	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.791	rs6570694	ENSG00000235652.6	RP11-545I5.3	10.03	1.16e-22	7e-20	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145590068	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.791	rs6570695	ENSG00000235652.6	RP11-545I5.3	10.03	1.16e-22	7e-20	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145590150	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.764	rs9386125	ENSG00000235652.6	RP11-545I5.3	10.03	1.16e-22	7e-20	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145590541	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.791	rs9373466	ENSG00000235652.6	RP11-545I5.3	10.03	1.16e-22	7e-20	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145590880	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.791	rs401331	ENSG00000235652.6	RP11-545I5.3	10.03	1.16e-22	7.01e-20	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145510272	chr6:145799409~145886585:+
BRCA	cis	rs6700559	0.873	rs7545177	ENSG00000260088.1	RP11-92G12.3	-10.03	1.17e-22	7.08e-20	-0.39	-0.3	Coronary artery disease;	chr1:200690727	chr1:200669507~200694250:+
BRCA	cis	rs524281	0.861	rs9645684	ENSG00000255320.1	RP11-755F10.1	10.03	1.18e-22	7.11e-20	0.45	0.3	Electroencephalogram traits;	chr11:66140493	chr11:66244840~66246239:-
BRCA	cis	rs6844153	0.68	rs11729927	ENSG00000240005.4	RP11-293A21.1	-10.03	1.18e-22	7.12e-20	-0.4	-0.3	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26922178	chr4:26859806~26860599:-
BRCA	cis	rs4713118	0.662	rs9380045	ENSG00000220721.1	OR1F12	10.03	1.19e-22	7.15e-20	0.39	0.3	Parkinson's disease;	chr6:28057501	chr6:28073316~28074233:+
BRCA	cis	rs1823913	0.599	rs67342262	ENSG00000227542.1	AC092614.2	10.03	1.19e-22	7.19e-20	0.36	0.3	Obesity-related traits;	chr2:191295612	chr2:191229165~191246172:-
BRCA	cis	rs11098499	0.954	rs59866101	ENSG00000245958.5	RP11-33B1.1	-10.03	1.2e-22	7.2e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119375436	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.618	rs6858383	ENSG00000245958.5	RP11-33B1.1	-10.03	1.2e-22	7.2e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119375617	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.697	rs6832410	ENSG00000245958.5	RP11-33B1.1	-10.03	1.2e-22	7.2e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119375645	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.865	rs1112817	ENSG00000245958.5	RP11-33B1.1	-10.03	1.2e-22	7.2e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119376645	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.779	rs10016060	ENSG00000245958.5	RP11-33B1.1	-10.03	1.2e-22	7.2e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119377257	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.954	rs10005644	ENSG00000245958.5	RP11-33B1.1	-10.03	1.2e-22	7.2e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119377322	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.697	rs10016448	ENSG00000245958.5	RP11-33B1.1	-10.03	1.2e-22	7.2e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119377690	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.657	rs9996569	ENSG00000245958.5	RP11-33B1.1	-10.03	1.2e-22	7.2e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119377849	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.908	rs11729050	ENSG00000245958.5	RP11-33B1.1	-10.03	1.2e-22	7.2e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119378911	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.954	rs28429722	ENSG00000245958.5	RP11-33B1.1	-10.03	1.2e-22	7.2e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119378938	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.954	rs10014845	ENSG00000245958.5	RP11-33B1.1	-10.03	1.2e-22	7.2e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119379922	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.779	rs7674500	ENSG00000245958.5	RP11-33B1.1	-10.03	1.2e-22	7.2e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119382438	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.909	rs28884220	ENSG00000245958.5	RP11-33B1.1	-10.03	1.2e-22	7.2e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119386056	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.909	rs28793658	ENSG00000245958.5	RP11-33B1.1	-10.03	1.2e-22	7.2e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119386059	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.697	rs4373140	ENSG00000245958.5	RP11-33B1.1	-10.03	1.2e-22	7.2e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119386543	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.954	rs13113483	ENSG00000245958.5	RP11-33B1.1	-10.03	1.2e-22	7.2e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119387884	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.542	rs10440343	ENSG00000245958.5	RP11-33B1.1	-10.03	1.2e-22	7.2e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119388632	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.779	rs10011097	ENSG00000245958.5	RP11-33B1.1	-10.03	1.2e-22	7.2e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119389204	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.542	rs7677836	ENSG00000245958.5	RP11-33B1.1	-10.03	1.2e-22	7.2e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119389483	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.909	rs10002083	ENSG00000245958.5	RP11-33B1.1	-10.03	1.2e-22	7.2e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119389997	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.954	rs10024844	ENSG00000245958.5	RP11-33B1.1	-10.03	1.2e-22	7.2e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119390373	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.954	rs4345162	ENSG00000245958.5	RP11-33B1.1	-10.03	1.2e-22	7.2e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119391804	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.657	rs4463052	ENSG00000245958.5	RP11-33B1.1	-10.03	1.2e-22	7.2e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119392103	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.954	rs13151285	ENSG00000245958.5	RP11-33B1.1	-10.03	1.2e-22	7.2e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119393586	chr4:119454791~119552025:+
BRCA	cis	rs2439831	0.85	rs60883262	ENSG00000249839.1	AC011330.5	-10.03	1.21e-22	7.25e-20	-0.49	-0.3	Lung cancer in ever smokers;	chr15:43784305	chr15:43663654~43684339:-
BRCA	cis	rs11098499	0.909	rs11723757	ENSG00000245958.5	RP11-33B1.1	-10.03	1.21e-22	7.25e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119378514	chr4:119454791~119552025:+
BRCA	cis	rs11096990	0.634	rs2381372	ENSG00000249207.1	RP11-360F5.1	-10.02	1.21e-22	7.28e-20	-0.35	-0.3	Cognitive function;	chr4:39271471	chr4:39112677~39126818:-
BRCA	cis	rs7429990	0.965	rs7649981	ENSG00000229759.1	MRPS18AP1	10.02	1.21e-22	7.3e-20	0.33	0.3	Educational attainment (years of education);	chr3:47957847	chr3:48256350~48256938:-
BRCA	cis	rs1113500	0.541	rs9803640	ENSG00000226822.1	RP11-356N1.2	-10.02	1.22e-22	7.36e-20	-0.43	-0.3	Growth-regulated protein alpha levels;	chr1:108033645	chr1:108071482~108074519:+
BRCA	cis	rs227275	0.554	rs223466	ENSG00000246560.2	RP11-10L12.4	10.02	1.24e-22	7.44e-20	0.31	0.3	Allergic disease (asthma, hay fever or eczema);	chr4:102780039	chr4:102828055~102844075:+
BRCA	cis	rs6545883	0.524	rs12992614	ENSG00000271889.1	RP11-493E12.1	-10.02	1.25e-22	7.49e-20	-0.36	-0.3	Tuberculosis;	chr2:61365941	chr2:61151433~61162105:-
BRCA	cis	rs11971779	0.584	rs6962029	ENSG00000273391.1	RP11-634H22.1	10.02	1.25e-22	7.49e-20	0.29	0.3	Diisocyanate-induced asthma;	chr7:139349973	chr7:139359032~139359566:-
BRCA	cis	rs7772486	0.875	rs2207785	ENSG00000235652.6	RP11-545I5.3	10.02	1.25e-22	7.52e-20	0.29	0.3	Lobe attachment (rater-scored or self-reported);	chr6:146011648	chr6:145799409~145886585:+
BRCA	cis	rs2439831	0.85	rs7169988	ENSG00000275601.1	AC011330.13	-10.02	1.26e-22	7.56e-20	-0.47	-0.3	Lung cancer in ever smokers;	chr15:43768237	chr15:43642389~43643023:-
BRCA	cis	rs7688540	0.771	rs74984113	ENSG00000275426.1	CH17-262A2.1	10.02	1.27e-22	7.61e-20	0.46	0.3	Facial morphology (factor 6, height of vermillion lower lip);	chr4:256733	chr4:149738~150317:+
BRCA	cis	rs35160687	0.712	rs11691726	ENSG00000273080.1	RP11-301O19.1	-10.02	1.27e-22	7.62e-20	-0.33	-0.3	Night sleep phenotypes;	chr2:86267147	chr2:86195590~86196049:+
BRCA	cis	rs733592	0.524	rs10875726	ENSG00000240399.1	RP1-228P16.1	-10.02	1.27e-22	7.62e-20	-0.31	-0.3	Plateletcrit;	chr12:48032209	chr12:48054813~48055591:-
BRCA	cis	rs1707322	0.752	rs11211169	ENSG00000280836.1	AL355480.1	-10.02	1.28e-22	7.66e-20	-0.39	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45701037	chr1:45581219~45581321:-
BRCA	cis	rs34787248	1	rs34787248	ENSG00000220721.1	OR1F12	10.02	1.29e-22	7.74e-20	0.43	0.3	Autism spectrum disorder or schizophrenia;	chr6:28230108	chr6:28073316~28074233:+
BRCA	cis	rs10129255	0.957	rs10150241	ENSG00000211970.3	IGHV4-61	10.02	1.29e-22	7.74e-20	0.2	0.3	Kawasaki disease;	chr14:106775945	chr14:106639119~106639657:-
BRCA	cis	rs7772486	0.754	rs9390356	ENSG00000235652.6	RP11-545I5.3	-10.02	1.29e-22	7.75e-20	-0.3	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145797847	chr6:145799409~145886585:+
BRCA	cis	rs6700559	0.967	rs12041320	ENSG00000260088.1	RP11-92G12.3	-10.02	1.3e-22	7.8e-20	-0.39	-0.3	Coronary artery disease;	chr1:200652107	chr1:200669507~200694250:+
BRCA	cis	rs8062405	1	rs8055138	ENSG00000251417.2	RP11-1348G14.4	-10.02	1.31e-22	7.84e-20	-0.35	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28880144	chr16:28802743~28817828:+
BRCA	cis	rs11971779	0.59	rs6944104	ENSG00000273391.1	RP11-634H22.1	10.02	1.31e-22	7.84e-20	0.29	0.3	Diisocyanate-induced asthma;	chr7:139366374	chr7:139359032~139359566:-
BRCA	cis	rs11971779	0.616	rs6944244	ENSG00000273391.1	RP11-634H22.1	10.02	1.31e-22	7.84e-20	0.29	0.3	Diisocyanate-induced asthma;	chr7:139366440	chr7:139359032~139359566:-
BRCA	cis	rs11971779	0.68	rs7799598	ENSG00000273391.1	RP11-634H22.1	10.02	1.31e-22	7.84e-20	0.29	0.3	Diisocyanate-induced asthma;	chr7:139367087	chr7:139359032~139359566:-
BRCA	cis	rs2439831	0.85	rs28718261	ENSG00000249839.1	AC011330.5	-10.02	1.31e-22	7.86e-20	-0.5	-0.3	Lung cancer in ever smokers;	chr15:43751595	chr15:43663654~43684339:-
BRCA	cis	rs8062405	1	rs2008514	ENSG00000251417.2	RP11-1348G14.4	10.02	1.32e-22	7.9e-20	0.34	0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814284	chr16:28802743~28817828:+
BRCA	cis	rs6452524	0.935	rs2386241	ENSG00000249664.1	CTD-2227C6.2	-10.02	1.32e-22	7.9e-20	-0.37	-0.3	Hypertension (SNP x SNP interaction);	chr5:83149872	chr5:83012285~83013109:-
BRCA	cis	rs1707322	0.716	rs10890342	ENSG00000280836.1	AL355480.1	-10.02	1.32e-22	7.91e-20	-0.39	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45691415	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.752	rs6658700	ENSG00000280836.1	AL355480.1	-10.02	1.32e-22	7.91e-20	-0.39	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45694588	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.752	rs12047629	ENSG00000280836.1	AL355480.1	-10.02	1.32e-22	7.91e-20	-0.39	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45697130	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.752	rs11211171	ENSG00000280836.1	AL355480.1	-10.02	1.32e-22	7.91e-20	-0.39	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45702970	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.752	rs28623463	ENSG00000280836.1	AL355480.1	-10.02	1.32e-22	7.91e-20	-0.39	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45705086	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.716	rs28370457	ENSG00000280836.1	AL355480.1	-10.02	1.32e-22	7.91e-20	-0.39	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45706390	chr1:45581219~45581321:-
BRCA	cis	rs875971	0.545	rs7810213	ENSG00000226824.5	RP4-756H11.3	-10.02	1.32e-22	7.93e-20	-0.42	-0.3	Aortic root size;	chr7:66481592	chr7:66654538~66669855:+
BRCA	cis	rs765787	0.53	rs3759892	ENSG00000259520.4	CTD-2651B20.3	-10.01	1.33e-22	7.98e-20	-0.37	-0.3	Uric acid levels;	chr15:45250511	chr15:45251580~45279251:-
BRCA	cis	rs7772486	0.79	rs10223507	ENSG00000235652.6	RP11-545I5.3	-10.01	1.33e-22	7.98e-20	-0.3	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145964068	chr6:145799409~145886585:+
BRCA	cis	rs6565180	1	rs11862806	ENSG00000273724.1	RP11-347C12.12	-10.01	1.34e-22	8.04e-20	-0.34	-0.3	Tonsillectomy;	chr16:30352750	chr16:30336400~30343336:+
BRCA	cis	rs858239	0.899	rs28635122	ENSG00000226816.2	AC005082.12	10.01	1.36e-22	8.13e-20	0.35	0.3	Cerebrospinal fluid biomarker levels;	chr7:23270562	chr7:23206013~23208045:+
BRCA	cis	rs2276314	0.762	rs3826600	ENSG00000278986.1	RP11-723J4.3	-10.01	1.36e-22	8.16e-20	-0.37	-0.3	Endometriosis;Drug-induced torsades de pointes;	chr18:36029090	chr18:35972151~35973916:+
BRCA	cis	rs1075265	0.811	rs805308	ENSG00000233266.1	HMGB1P31	10.01	1.37e-22	8.18e-20	0.36	0.3	Chronotype;Morning vs. evening chronotype;	chr2:53967797	chr2:54051334~54051760:+
BRCA	cis	rs11971779	0.553	rs7799742	ENSG00000273391.1	RP11-634H22.1	10.01	1.38e-22	8.25e-20	0.29	0.3	Diisocyanate-induced asthma;	chr7:139367132	chr7:139359032~139359566:-
BRCA	cis	rs1113500	0.548	rs11185271	ENSG00000226822.1	RP11-356N1.2	10.01	1.38e-22	8.25e-20	0.44	0.3	Growth-regulated protein alpha levels;	chr1:108117311	chr1:108071482~108074519:+
BRCA	cis	rs227275	0.556	rs223398	ENSG00000246560.2	RP11-10L12.4	10.01	1.39e-22	8.3e-20	0.31	0.3	Allergic disease (asthma, hay fever or eczema);	chr4:102821256	chr4:102828055~102844075:+
BRCA	cis	rs465969	0.744	rs3851228	ENSG00000255389.1	C6orf3	10.01	1.39e-22	8.3e-20	0.5	0.3	Psoriasis;	chr6:111526988	chr6:111599875~111602295:+
BRCA	cis	rs853679	0.55	rs34477097	ENSG00000220721.1	OR1F12	10.01	1.39e-22	8.3e-20	0.38	0.3	Depression;	chr6:28229408	chr6:28073316~28074233:+
BRCA	cis	rs11676348	0.935	rs6716276	ENSG00000261338.2	RP11-378A13.1	-10.01	1.39e-22	8.31e-20	-0.31	-0.3	Ulcerative colitis;	chr2:218097482	chr2:218255319~218257366:+
BRCA	cis	rs11971779	0.65	rs10085842	ENSG00000273391.1	RP11-634H22.1	10.01	1.4e-22	8.36e-20	0.29	0.3	Diisocyanate-induced asthma;	chr7:139379836	chr7:139359032~139359566:-
BRCA	cis	rs11971779	0.648	rs28754644	ENSG00000273391.1	RP11-634H22.1	10.01	1.4e-22	8.36e-20	0.29	0.3	Diisocyanate-induced asthma;	chr7:139380311	chr7:139359032~139359566:-
BRCA	cis	rs11971779	0.715	rs6954219	ENSG00000273391.1	RP11-634H22.1	10.01	1.4e-22	8.36e-20	0.29	0.3	Diisocyanate-induced asthma;	chr7:139380364	chr7:139359032~139359566:-
BRCA	cis	rs2581828	0.539	rs114317830	ENSG00000242142.1	SERBP1P3	-10.01	1.4e-22	8.39e-20	-0.37	-0.3	Crohn's disease;	chr3:53126253	chr3:53064283~53065091:-
BRCA	cis	rs2581828	0.539	rs114670283	ENSG00000242142.1	SERBP1P3	-10.01	1.4e-22	8.39e-20	-0.37	-0.3	Crohn's disease;	chr3:53126254	chr3:53064283~53065091:-
BRCA	cis	rs712022	1	rs1019217	ENSG00000246225.5	RP11-17A1.3	10.01	1.4e-22	8.41e-20	0.35	0.3	Dialysis-related mortality;	chr11:22821076	chr11:22829380~22945393:+
BRCA	cis	rs11971779	0.68	rs6962637	ENSG00000273391.1	RP11-634H22.1	10.01	1.41e-22	8.41e-20	0.29	0.3	Diisocyanate-induced asthma;	chr7:139366604	chr7:139359032~139359566:-
BRCA	cis	rs1075265	0.744	rs2909460	ENSG00000233266.1	HMGB1P31	10.01	1.42e-22	8.47e-20	0.36	0.3	Chronotype;Morning vs. evening chronotype;	chr2:53967611	chr2:54051334~54051760:+
BRCA	cis	rs2739330	0.734	rs2000467	ENSG00000231271.1	AP000350.8	-10.01	1.43e-22	8.56e-20	-0.38	-0.3	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23949918~23954042:+
BRCA	cis	rs4964805	0.594	rs3751204	ENSG00000257681.1	RP11-341G23.4	10.01	1.44e-22	8.61e-20	0.35	0.3	Attention deficit hyperactivity disorder;	chr12:103777677	chr12:103746315~103768858:-
BRCA	cis	rs8062405	1	rs4788095	ENSG00000251417.2	RP11-1348G14.4	-10	1.47e-22	8.77e-20	-0.34	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28820038	chr16:28802743~28817828:+
BRCA	cis	rs8062405	0.964	rs72793809	ENSG00000251417.2	RP11-1348G14.4	-10	1.47e-22	8.77e-20	-0.34	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821061	chr16:28802743~28817828:+
BRCA	cis	rs11673344	0.67	rs35011739	ENSG00000226686.6	LINC01535	10	1.47e-22	8.79e-20	0.38	0.3	Obesity-related traits;	chr19:36943328	chr19:37251912~37265535:+
BRCA	cis	rs11673344	0.704	rs540451	ENSG00000226686.6	LINC01535	10	1.47e-22	8.79e-20	0.38	0.3	Obesity-related traits;	chr19:36944619	chr19:37251912~37265535:+
BRCA	cis	rs2439831	0.85	rs12441861	ENSG00000249839.1	AC011330.5	-10	1.47e-22	8.8e-20	-0.49	-0.3	Lung cancer in ever smokers;	chr15:43768685	chr15:43663654~43684339:-
BRCA	cis	rs1707322	0.662	rs11211160	ENSG00000280836.1	AL355480.1	-10	1.48e-22	8.82e-20	-0.38	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45680557	chr1:45581219~45581321:-
BRCA	cis	rs7772486	0.72	rs6901888	ENSG00000235652.6	RP11-545I5.3	-10	1.48e-22	8.83e-20	-0.3	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145702008	chr6:145799409~145886585:+
BRCA	cis	rs1707322	0.691	rs11211175	ENSG00000280836.1	AL355480.1	-10	1.48e-22	8.83e-20	-0.38	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755212	chr1:45581219~45581321:-
BRCA	cis	rs7772486	0.875	rs9322044	ENSG00000235652.6	RP11-545I5.3	10	1.48e-22	8.84e-20	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:146048472	chr6:145799409~145886585:+
BRCA	cis	rs10129255	0.957	rs12590667	ENSG00000211970.3	IGHV4-61	10	1.49e-22	8.93e-20	0.2	0.3	Kawasaki disease;	chr14:106779223	chr14:106639119~106639657:-
BRCA	cis	rs10129255	0.956	rs10137268	ENSG00000211970.3	IGHV4-61	-10	1.5e-22	8.97e-20	-0.22	-0.3	Kawasaki disease;	chr14:106697402	chr14:106639119~106639657:-
BRCA	cis	rs694739	0.734	rs663743	ENSG00000236935.1	AP003774.1	10	1.52e-22	9.06e-20	0.3	0.3	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64340263	chr11:64325050~64329504:-
BRCA	cis	rs11098499	0.954	rs6848389	ENSG00000245958.5	RP11-33B1.1	-10	1.52e-22	9.07e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119481467	chr4:119454791~119552025:+
BRCA	cis	rs10129255	1	rs10134517	ENSG00000211970.3	IGHV4-61	-10	1.53e-22	9.13e-20	-0.21	-0.3	Kawasaki disease;	chr14:106718498	chr14:106639119~106639657:-
BRCA	cis	rs11098499	0.954	rs17005535	ENSG00000245958.5	RP11-33B1.1	-10	1.53e-22	9.15e-20	-0.29	-0.3	Corneal astigmatism;	chr4:119490407	chr4:119454791~119552025:+
BRCA	cis	rs11971779	0.68	rs10229249	ENSG00000273391.1	RP11-634H22.1	10	1.54e-22	9.16e-20	0.29	0.3	Diisocyanate-induced asthma;	chr7:139367764	chr7:139359032~139359566:-
BRCA	cis	rs11971779	0.68	rs11772026	ENSG00000273391.1	RP11-634H22.1	10	1.54e-22	9.16e-20	0.29	0.3	Diisocyanate-induced asthma;	chr7:139367843	chr7:139359032~139359566:-
BRCA	cis	rs11971779	0.68	rs1133067	ENSG00000273391.1	RP11-634H22.1	10	1.54e-22	9.16e-20	0.29	0.3	Diisocyanate-induced asthma;	chr7:139368323	chr7:139359032~139359566:-
BRCA	cis	rs11971779	0.616	rs1133068	ENSG00000273391.1	RP11-634H22.1	10	1.54e-22	9.16e-20	0.29	0.3	Diisocyanate-induced asthma;	chr7:139368397	chr7:139359032~139359566:-
BRCA	cis	rs11971779	0.68	rs6949599	ENSG00000273391.1	RP11-634H22.1	10	1.54e-22	9.16e-20	0.29	0.3	Diisocyanate-induced asthma;	chr7:139369442	chr7:139359032~139359566:-
BRCA	cis	rs11971779	0.616	rs6949963	ENSG00000273391.1	RP11-634H22.1	10	1.54e-22	9.16e-20	0.29	0.3	Diisocyanate-induced asthma;	chr7:139369579	chr7:139359032~139359566:-
BRCA	cis	rs11971779	0.555	rs6950143	ENSG00000273391.1	RP11-634H22.1	10	1.54e-22	9.16e-20	0.29	0.3	Diisocyanate-induced asthma;	chr7:139369672	chr7:139359032~139359566:-
BRCA	cis	rs11971779	0.68	rs6954531	ENSG00000273391.1	RP11-634H22.1	10	1.54e-22	9.16e-20	0.29	0.3	Diisocyanate-induced asthma;	chr7:139369960	chr7:139359032~139359566:-
BRCA	cis	rs11971779	0.68	rs6954547	ENSG00000273391.1	RP11-634H22.1	10	1.54e-22	9.16e-20	0.29	0.3	Diisocyanate-induced asthma;	chr7:139369988	chr7:139359032~139359566:-
BRCA	cis	rs11971779	0.68	rs7788777	ENSG00000273391.1	RP11-634H22.1	10	1.54e-22	9.16e-20	0.29	0.3	Diisocyanate-induced asthma;	chr7:139370447	chr7:139359032~139359566:-
BRCA	cis	rs11971779	0.68	rs6963867	ENSG00000273391.1	RP11-634H22.1	10	1.54e-22	9.16e-20	0.29	0.3	Diisocyanate-induced asthma;	chr7:139375218	chr7:139359032~139359566:-
BRCA	cis	rs875971	0.54	rs4717275	ENSG00000224316.1	RP11-479O9.2	-10	1.54e-22	9.21e-20	-0.3	-0.3	Aortic root size;	chr7:65800193	chr7:65773620~65802067:+
BRCA	cis	rs1150668	0.796	rs2247002	ENSG00000204709.4	LINC01556	10	1.55e-22	9.26e-20	0.37	0.3	Pubertal anthropometrics;	chr6:28430174	chr6:28943877~28944537:+
BRCA	cis	rs17482078	0.959	rs13154629	ENSG00000248734.2	CTD-2260A17.1	10	1.56e-22	9.28e-20	0.41	0.3	Behcet's disease;Blood protein levels;	chr5:96786754	chr5:96784777~96785999:+
BRCA	cis	rs2404602	0.583	rs11072580	ENSG00000259422.1	RP11-593F23.1	10	1.56e-22	9.31e-20	0.36	0.3	Blood metabolite levels;	chr15:76247890	chr15:76174891~76181486:-
BRCA	cis	rs2243480	1	rs4718269	ENSG00000226824.5	RP4-756H11.3	10	1.56e-22	9.31e-20	0.55	0.3	Diabetic kidney disease;	chr7:65735810	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.651	rs2420596	ENSG00000237310.1	GS1-124K5.4	10	1.57e-22	9.33e-20	0.31	0.3	Aortic root size;	chr7:66450996	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.52	rs2420597	ENSG00000237310.1	GS1-124K5.4	10	1.57e-22	9.33e-20	0.31	0.3	Aortic root size;	chr7:66450999	chr7:66493706~66495474:+
BRCA	cis	rs4964805	0.594	rs11111759	ENSG00000257681.1	RP11-341G23.4	10	1.57e-22	9.39e-20	0.36	0.3	Attention deficit hyperactivity disorder;	chr12:103769405	chr12:103746315~103768858:-
BRCA	cis	rs853679	0.628	rs9368560	ENSG00000220721.1	OR1F12	10	1.58e-22	9.43e-20	0.39	0.3	Depression;	chr6:28192182	chr6:28073316~28074233:+
BRCA	cis	rs8072100	0.967	rs2317826	ENSG00000228782.6	CTD-2026D20.3	10	1.58e-22	9.44e-20	0.32	0.3	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47653533	chr17:47450568~47492492:-
BRCA	cis	rs2276314	0.857	rs16967327	ENSG00000278986.1	RP11-723J4.3	-10	1.59e-22	9.49e-20	-0.37	-0.3	Endometriosis;Drug-induced torsades de pointes;	chr18:36007073	chr18:35972151~35973916:+
BRCA	cis	rs7772486	0.875	rs2224121	ENSG00000235652.6	RP11-545I5.3	9.99	1.6e-22	9.53e-20	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:146022078	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.846	rs2748496	ENSG00000235652.6	RP11-545I5.3	9.99	1.6e-22	9.54e-20	0.29	0.3	Lobe attachment (rater-scored or self-reported);	chr6:146000693	chr6:145799409~145886585:+
BRCA	cis	rs2243480	1	rs1167613	ENSG00000226824.5	RP4-756H11.3	-9.99	1.61e-22	9.57e-20	-0.56	-0.3	Diabetic kidney disease;	chr7:66022452	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs313799	ENSG00000226824.5	RP4-756H11.3	-9.99	1.61e-22	9.57e-20	-0.56	-0.3	Diabetic kidney disease;	chr7:66029343	chr7:66654538~66669855:+
BRCA	cis	rs6435862	0.636	rs717548	ENSG00000229267.2	AC072062.1	9.99	1.61e-22	9.61e-20	0.34	0.3	Neuroblastoma (high-risk);	chr2:214812181	chr2:214810229~214963274:+
BRCA	cis	rs7772486	0.754	rs13214277	ENSG00000235652.6	RP11-545I5.3	9.99	1.61e-22	9.61e-20	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145814989	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.791	rs435671	ENSG00000235652.6	RP11-545I5.3	9.99	1.62e-22	9.62e-20	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145560079	chr6:145799409~145886585:+
BRCA	cis	rs7580658	0.637	rs1566822	ENSG00000236682.1	AC068282.3	-9.99	1.62e-22	9.63e-20	-0.4	-0.3	Protein C levels;	chr2:127229815	chr2:127389130~127400580:+
BRCA	cis	rs13256369	0.802	rs11249885	ENSG00000253893.2	FAM85B	-9.99	1.64e-22	9.77e-20	-0.39	-0.3	Obesity-related traits;	chr8:8704498	chr8:8167819~8226614:-
BRCA	cis	rs2439831	0.702	rs8033995	ENSG00000249839.1	AC011330.5	-9.99	1.65e-22	9.8e-20	-0.49	-0.3	Lung cancer in ever smokers;	chr15:43721311	chr15:43663654~43684339:-
BRCA	cis	rs4423214	0.592	rs11233933	ENSG00000254682.1	RP11-660L16.2	-9.99	1.65e-22	9.81e-20	-0.45	-0.3	Vitamin D levels;	chr11:71499024	chr11:71448674~71452157:+
BRCA	cis	rs858239	0.6	rs2072368	ENSG00000226816.2	AC005082.12	9.99	1.65e-22	9.83e-20	0.34	0.3	Cerebrospinal fluid biomarker levels;	chr7:23106493	chr7:23206013~23208045:+
BRCA	cis	rs11098499	0.909	rs10017335	ENSG00000245958.5	RP11-33B1.1	9.99	1.66e-22	9.9e-20	0.29	0.3	Corneal astigmatism;	chr4:119460368	chr4:119454791~119552025:+
BRCA	cis	rs673078	0.66	rs11068917	ENSG00000275759.1	RP11-131L12.3	-9.99	1.67e-22	9.9e-20	-0.39	-0.3	Glucose homeostasis traits;	chr12:118353315	chr12:118428281~118428870:+
BRCA	cis	rs712022	0.967	rs10766971	ENSG00000246225.5	RP11-17A1.3	-9.99	1.67e-22	9.95e-20	-0.34	-0.3	Dialysis-related mortality;	chr11:22832005	chr11:22829380~22945393:+
BRCA	cis	rs6570726	0.791	rs6912079	ENSG00000235652.6	RP11-545I5.3	9.99	1.68e-22	9.98e-20	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145573813	chr6:145799409~145886585:+
BRCA	cis	rs8062405	0.69	rs62034351	ENSG00000259982.1	CDC37P1	9.99	1.68e-22	1e-19	0.4	0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554168	chr16:28700294~28701540:-
BRCA	cis	rs1707322	0.827	rs6683274	ENSG00000280836.1	AL355480.1	-9.99	1.69e-22	1e-19	-0.39	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45775966	chr1:45581219~45581321:-
BRCA	cis	rs17482078	0.879	rs2124921	ENSG00000248734.2	CTD-2260A17.1	9.99	1.69e-22	1e-19	0.41	0.3	Behcet's disease;Blood protein levels;	chr5:96783635	chr5:96784777~96785999:+
BRCA	cis	rs11971779	0.585	rs3922848	ENSG00000273391.1	RP11-634H22.1	9.99	1.71e-22	1.01e-19	0.29	0.3	Diisocyanate-induced asthma;	chr7:139361464	chr7:139359032~139359566:-
BRCA	cis	rs7829975	0.572	rs28730413	ENSG00000253893.2	FAM85B	9.99	1.73e-22	1.03e-19	0.36	0.3	Mood instability;	chr8:8937937	chr8:8167819~8226614:-
BRCA	cis	rs8062405	1	rs62036620	ENSG00000251417.2	RP11-1348G14.4	-9.99	1.74e-22	1.03e-19	-0.34	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821776	chr16:28802743~28817828:+
BRCA	cis	rs8062405	1	rs62036621	ENSG00000251417.2	RP11-1348G14.4	-9.99	1.74e-22	1.03e-19	-0.34	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821978	chr16:28802743~28817828:+
BRCA	cis	rs7772486	0.692	rs1577916	ENSG00000235652.6	RP11-545I5.3	-9.98	1.75e-22	1.04e-19	-0.3	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145748653	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.72	rs7752286	ENSG00000235652.6	RP11-545I5.3	-9.98	1.75e-22	1.04e-19	-0.3	-0.3	Lobe attachment (rater-scored or self-reported);	chr6:145751526	chr6:145799409~145886585:+
BRCA	cis	rs7429990	0.965	rs2053767	ENSG00000229759.1	MRPS18AP1	9.98	1.76e-22	1.04e-19	0.33	0.3	Educational attainment (years of education);	chr3:47958184	chr3:48256350~48256938:-
BRCA	cis	rs9543976	1	rs2031236	ENSG00000261553.4	RP11-29G8.3	-9.98	1.77e-22	1.05e-19	-0.53	-0.3	Diabetic retinopathy;	chr13:75595641	chr13:75549773~75807120:+
BRCA	cis	rs228614	0.51	rs223400	ENSG00000246560.2	RP11-10L12.4	9.98	1.77e-22	1.05e-19	0.32	0.3	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102820439	chr4:102828055~102844075:+
BRCA	cis	rs2243480	1	rs313831	ENSG00000226824.5	RP4-756H11.3	-9.98	1.77e-22	1.05e-19	-0.6	-0.3	Diabetic kidney disease;	chr7:66086239	chr7:66654538~66669855:+
BRCA	cis	rs11673344	0.633	rs519606	ENSG00000226686.6	LINC01535	9.98	1.78e-22	1.06e-19	0.38	0.3	Obesity-related traits;	chr19:36942327	chr19:37251912~37265535:+
BRCA	cis	rs11971779	0.648	rs9656512	ENSG00000273391.1	RP11-634H22.1	9.98	1.78e-22	1.06e-19	0.29	0.3	Diisocyanate-induced asthma;	chr7:139369300	chr7:139359032~139359566:-
BRCA	cis	rs11098499	0.954	rs10008392	ENSG00000245958.5	RP11-33B1.1	-9.98	1.78e-22	1.06e-19	-0.29	-0.3	Corneal astigmatism;	chr4:119397684	chr4:119454791~119552025:+
BRCA	cis	rs34375054	0.66	rs12578446	ENSG00000279233.1	RP11-158L12.4	9.98	1.78e-22	1.06e-19	0.37	0.3	Post bronchodilator FEV1/FVC ratio;	chr12:125121341	chr12:125138245~125141711:+
BRCA	cis	rs7429990	0.965	rs7642590	ENSG00000229759.1	MRPS18AP1	-9.98	1.8e-22	1.07e-19	-0.35	-0.3	Educational attainment (years of education);	chr3:48058260	chr3:48256350~48256938:-
BRCA	cis	rs867371	0.519	rs1566560	ENSG00000278603.1	RP13-608F4.5	9.98	1.81e-22	1.07e-19	0.38	0.3	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82232116	chr15:82472203~82472426:+
BRCA	cis	rs867371	0.519	rs1566559	ENSG00000278603.1	RP13-608F4.5	9.98	1.81e-22	1.07e-19	0.38	0.3	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82232120	chr15:82472203~82472426:+
BRCA	cis	rs6545883	0.507	rs12617371	ENSG00000271889.1	RP11-493E12.1	-9.98	1.81e-22	1.07e-19	-0.36	-0.3	Tuberculosis;	chr2:61341999	chr2:61151433~61162105:-
BRCA	cis	rs56046484	0.797	rs907260	ENSG00000259295.5	CSPG4P12	-9.98	1.82e-22	1.08e-19	-0.49	-0.3	Testicular germ cell tumor;	chr15:85133526	chr15:85191438~85213905:+
BRCA	cis	rs875971	0.862	rs6947339	ENSG00000237310.1	GS1-124K5.4	9.98	1.83e-22	1.09e-19	0.32	0.3	Aortic root size;	chr7:66423483	chr7:66493706~66495474:+
BRCA	cis	rs1075265	0.87	rs1421617	ENSG00000233266.1	HMGB1P31	9.98	1.84e-22	1.09e-19	0.35	0.3	Chronotype;Morning vs. evening chronotype;	chr2:54032995	chr2:54051334~54051760:+
BRCA	cis	rs8062405	0.823	rs7202948	ENSG00000278665.1	RP11-666O2.4	9.98	1.84e-22	1.09e-19	0.3	0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28546968	chr16:28599241~28601881:-
BRCA	cis	rs1707322	0.752	rs61784793	ENSG00000280836.1	AL355480.1	-9.98	1.84e-22	1.09e-19	-0.39	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45683613	chr1:45581219~45581321:-
BRCA	cis	rs6723108	0.517	rs6430552	ENSG00000224043.6	CCNT2-AS1	-9.98	1.85e-22	1.1e-19	-0.38	-0.3	Type 2 diabetes;	chr2:134865238	chr2:134735464~134918710:-
BRCA	cis	rs875971	0.83	rs778715	ENSG00000237310.1	GS1-124K5.4	9.98	1.85e-22	1.1e-19	0.31	0.3	Aortic root size;	chr7:66384222	chr7:66493706~66495474:+
BRCA	cis	rs783540	0.846	rs783534	ENSG00000278603.1	RP13-608F4.5	-9.98	1.85e-22	1.1e-19	-0.37	-0.3	Schizophrenia;	chr15:82581494	chr15:82472203~82472426:+
BRCA	cis	rs858239	0.899	rs2268747	ENSG00000226816.2	AC005082.12	9.98	1.85e-22	1.1e-19	0.35	0.3	Cerebrospinal fluid biomarker levels;	chr7:23273843	chr7:23206013~23208045:+
BRCA	cis	rs733592	0.507	rs7138917	ENSG00000240399.1	RP1-228P16.1	-9.98	1.85e-22	1.1e-19	-0.31	-0.3	Plateletcrit;	chr12:48061472	chr12:48054813~48055591:-
BRCA	cis	rs10759883	0.539	rs7847393	ENSG00000175611.10	LINC00476	9.98	1.86e-22	1.1e-19	0.35	0.3	Nicotine dependence;	chr9:96033431	chr9:95759231~95875977:-
BRCA	cis	rs875971	0.798	rs6460304	ENSG00000237310.1	GS1-124K5.4	9.98	1.86e-22	1.1e-19	0.31	0.3	Aortic root size;	chr7:66499741	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.862	rs6945775	ENSG00000237310.1	GS1-124K5.4	9.98	1.86e-22	1.1e-19	0.31	0.3	Aortic root size;	chr7:66503987	chr7:66493706~66495474:+
BRCA	cis	rs11105298	0.891	rs12369685	ENSG00000258302.2	RP11-981P6.1	9.98	1.86e-22	1.1e-19	0.35	0.3	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89535128	chr12:89561129~89594878:+
BRCA	cis	rs4964805	0.505	rs4981032	ENSG00000257681.1	RP11-341G23.4	9.98	1.87e-22	1.1e-19	0.35	0.3	Attention deficit hyperactivity disorder;	chr12:103772086	chr12:103746315~103768858:-
BRCA	cis	rs4964805	0.594	rs9132	ENSG00000257681.1	RP11-341G23.4	9.98	1.87e-22	1.1e-19	0.35	0.3	Attention deficit hyperactivity disorder;	chr12:103772465	chr12:103746315~103768858:-
BRCA	cis	rs6921919	0.583	rs6928771	ENSG00000216901.1	AL022393.7	9.98	1.87e-22	1.1e-19	0.39	0.3	Autism spectrum disorder or schizophrenia;	chr6:28407432	chr6:28176188~28176674:+
BRCA	cis	rs6921919	0.583	rs6928773	ENSG00000216901.1	AL022393.7	9.98	1.87e-22	1.1e-19	0.39	0.3	Autism spectrum disorder or schizophrenia;	chr6:28407433	chr6:28176188~28176674:+
BRCA	cis	rs228614	0.536	rs223478	ENSG00000246560.2	RP11-10L12.4	9.98	1.87e-22	1.11e-19	0.31	0.3	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102768648	chr4:102828055~102844075:+
BRCA	cis	rs228614	0.536	rs150898	ENSG00000246560.2	RP11-10L12.4	9.98	1.87e-22	1.11e-19	0.31	0.3	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102769234	chr4:102828055~102844075:+
BRCA	cis	rs6570726	0.738	rs7746330	ENSG00000235652.6	RP11-545I5.3	9.98	1.88e-22	1.11e-19	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145578121	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.791	rs12208812	ENSG00000235652.6	RP11-545I5.3	9.98	1.88e-22	1.11e-19	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145579788	chr6:145799409~145886585:+
BRCA	cis	rs228614	0.509	rs223482	ENSG00000246560.2	RP11-10L12.4	9.98	1.88e-22	1.11e-19	0.31	0.3	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102766051	chr4:102828055~102844075:+
BRCA	cis	rs2439831	0.85	rs11070408	ENSG00000249839.1	AC011330.5	-9.98	1.88e-22	1.12e-19	-0.5	-0.3	Lung cancer in ever smokers;	chr15:43742590	chr15:43663654~43684339:-
BRCA	cis	rs7580658	0.817	rs6761447	ENSG00000236682.1	AC068282.3	-9.97	1.92e-22	1.14e-19	-0.39	-0.3	Protein C levels;	chr2:127316997	chr2:127389130~127400580:+
BRCA	cis	rs8062405	0.755	rs55792032	ENSG00000278665.1	RP11-666O2.4	9.97	1.95e-22	1.15e-19	0.31	0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28588090	chr16:28599241~28601881:-
BRCA	cis	rs2276314	0.857	rs72883058	ENSG00000278986.1	RP11-723J4.3	-9.97	1.96e-22	1.16e-19	-0.37	-0.3	Endometriosis;Drug-induced torsades de pointes;	chr18:36032954	chr18:35972151~35973916:+
BRCA	cis	rs10875746	0.551	rs3751273	ENSG00000240399.1	RP1-228P16.1	-9.97	1.96e-22	1.16e-19	-0.4	-0.3	Longevity (90 years and older);	chr12:48345655	chr12:48054813~48055591:-
BRCA	cis	rs8062405	1	rs62036617	ENSG00000251417.2	RP11-1348G14.4	-9.97	1.98e-22	1.17e-19	-0.34	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28816177	chr16:28802743~28817828:+
BRCA	cis	rs4964805	0.594	rs954920	ENSG00000257681.1	RP11-341G23.4	9.97	1.98e-22	1.17e-19	0.36	0.3	Attention deficit hyperactivity disorder;	chr12:103779532	chr12:103746315~103768858:-
BRCA	cis	rs4862750	0.872	rs7671914	ENSG00000250971.1	RP11-696F12.1	9.97	1.99e-22	1.18e-19	0.31	0.3	Lobe attachment (rater-scored or self-reported);	chr4:186957011	chr4:187060099~187060930:+
BRCA	cis	rs11098499	0.909	rs73842633	ENSG00000245958.5	RP11-33B1.1	-9.97	1.99e-22	1.18e-19	-0.29	-0.3	Corneal astigmatism;	chr4:119454309	chr4:119454791~119552025:+
BRCA	cis	rs8062405	0.929	rs11150609	ENSG00000251417.2	RP11-1348G14.4	-9.97	1.99e-22	1.18e-19	-0.35	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28859275	chr16:28802743~28817828:+
BRCA	cis	rs7772486	0.727	rs11155442	ENSG00000235652.6	RP11-545I5.3	9.97	2e-22	1.18e-19	0.3	0.3	Lobe attachment (rater-scored or self-reported);	chr6:145819589	chr6:145799409~145886585:+
BRCA	cis	rs11673344	0.704	rs1726719	ENSG00000226686.6	LINC01535	9.97	2e-22	1.18e-19	0.38	0.3	Obesity-related traits;	chr19:36927130	chr19:37251912~37265535:+
BRCA	cis	rs6921919	0.609	rs9461455	ENSG00000216901.1	AL022393.7	9.97	2e-22	1.18e-19	0.4	0.3	Autism spectrum disorder or schizophrenia;	chr6:28361954	chr6:28176188~28176674:+
BRCA	cis	rs72772090	0.539	rs11743410	ENSG00000248734.2	CTD-2260A17.1	-9.97	2.01e-22	1.19e-19	-0.48	-0.3	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96788750	chr5:96784777~96785999:+
BRCA	cis	rs72772090	0.539	rs11746534	ENSG00000248734.2	CTD-2260A17.1	-9.97	2.01e-22	1.19e-19	-0.48	-0.3	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96789104	chr5:96784777~96785999:+
BRCA	cis	rs72772090	0.539	rs55773007	ENSG00000248734.2	CTD-2260A17.1	-9.97	2.01e-22	1.19e-19	-0.48	-0.3	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96789215	chr5:96784777~96785999:+
BRCA	cis	rs72772090	0.539	rs111886458	ENSG00000248734.2	CTD-2260A17.1	-9.97	2.01e-22	1.19e-19	-0.48	-0.3	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96789344	chr5:96784777~96785999:+
BRCA	cis	rs72772090	0.539	rs10515249	ENSG00000248734.2	CTD-2260A17.1	-9.97	2.01e-22	1.19e-19	-0.48	-0.3	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96789556	chr5:96784777~96785999:+
BRCA	cis	rs72772090	0.539	rs72773947	ENSG00000248734.2	CTD-2260A17.1	-9.97	2.01e-22	1.19e-19	-0.48	-0.3	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96789830	chr5:96784777~96785999:+
BRCA	cis	rs2243480	1	rs35432774	ENSG00000226824.5	RP4-756H11.3	-9.97	2.01e-22	1.19e-19	-0.55	-0.3	Diabetic kidney disease;	chr7:65928032	chr7:66654538~66669855:+
BRCA	cis	rs1113500	1	rs1113500	ENSG00000226822.1	RP11-356N1.2	-9.97	2.03e-22	1.2e-19	-0.39	-0.3	Growth-regulated protein alpha levels;	chr1:108052820	chr1:108071482~108074519:+
BRCA	cis	rs227275	0.554	rs223390	ENSG00000246560.2	RP11-10L12.4	9.97	2.03e-22	1.2e-19	0.31	0.3	Allergic disease (asthma, hay fever or eczema);	chr4:102827640	chr4:102828055~102844075:+
BRCA	cis	rs11105298	0.891	rs3825330	ENSG00000258302.2	RP11-981P6.1	9.97	2.04e-22	1.21e-19	0.34	0.3	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89539933	chr12:89561129~89594878:+
BRCA	cis	rs6545883	0.542	rs2593628	ENSG00000271889.1	RP11-493E12.1	-9.97	2.05e-22	1.21e-19	-0.36	-0.3	Tuberculosis;	chr2:61346152	chr2:61151433~61162105:-
BRCA	cis	rs10129255	0.957	rs4387509	ENSG00000211970.3	IGHV4-61	-9.97	2.07e-22	1.22e-19	-0.22	-0.3	Kawasaki disease;	chr14:106704386	chr14:106639119~106639657:-
BRCA	cis	rs1707322	0.752	rs28890893	ENSG00000280836.1	AL355480.1	-9.97	2.07e-22	1.22e-19	-0.39	-0.3	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45720904	chr1:45581219~45581321:-
BRCA	cis	rs875971	0.862	rs6955837	ENSG00000237310.1	GS1-124K5.4	-9.97	2.09e-22	1.23e-19	-0.31	-0.29	Aortic root size;	chr7:66578155	chr7:66493706~66495474:+
BRCA	cis	rs6782228	1	rs6775011	ENSG00000242551.2	POU5F1P6	9.97	2.09e-22	1.23e-19	0.42	0.29	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128677640	chr3:128674735~128677005:-
BRCA	cis	rs8062405	0.754	rs3859172	ENSG00000278665.1	RP11-666O2.4	9.97	2.1e-22	1.24e-19	0.3	0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554837	chr16:28599241~28601881:-
BRCA	cis	rs875971	0.825	rs10281499	ENSG00000237310.1	GS1-124K5.4	-9.97	2.1e-22	1.24e-19	-0.31	-0.29	Aortic root size;	chr7:66583979	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.862	rs6978028	ENSG00000237310.1	GS1-124K5.4	9.97	2.1e-22	1.24e-19	0.32	0.29	Aortic root size;	chr7:66421313	chr7:66493706~66495474:+
BRCA	cis	rs17023223	0.537	rs12085308	ENSG00000231365.4	RP11-418J17.1	-9.97	2.1e-22	1.24e-19	-0.38	-0.29	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119134930	chr1:119140396~119275973:+
BRCA	cis	rs228614	0.509	rs223476	ENSG00000246560.2	RP11-10L12.4	9.96	2.11e-22	1.25e-19	0.31	0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102771000	chr4:102828055~102844075:+
BRCA	cis	rs228614	0.509	rs150896	ENSG00000246560.2	RP11-10L12.4	9.96	2.11e-22	1.25e-19	0.31	0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102771186	chr4:102828055~102844075:+
BRCA	cis	rs1707322	0.721	rs11211149	ENSG00000280836.1	AL355480.1	-9.96	2.12e-22	1.25e-19	-0.38	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45646546	chr1:45581219~45581321:-
BRCA	cis	rs875971	0.545	rs6970498	ENSG00000226824.5	RP4-756H11.3	-9.96	2.13e-22	1.26e-19	-0.42	-0.29	Aortic root size;	chr7:66275908	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.83	rs778711	ENSG00000237310.1	GS1-124K5.4	9.96	2.14e-22	1.26e-19	0.32	0.29	Aortic root size;	chr7:66386670	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.862	rs1083554	ENSG00000237310.1	GS1-124K5.4	9.96	2.14e-22	1.26e-19	0.32	0.29	Aortic root size;	chr7:66387354	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.862	rs778707	ENSG00000237310.1	GS1-124K5.4	9.96	2.14e-22	1.26e-19	0.32	0.29	Aortic root size;	chr7:66392040	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.862	rs778705	ENSG00000237310.1	GS1-124K5.4	9.96	2.14e-22	1.26e-19	0.32	0.29	Aortic root size;	chr7:66396128	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.862	rs778697	ENSG00000237310.1	GS1-124K5.4	9.96	2.14e-22	1.26e-19	0.32	0.29	Aortic root size;	chr7:66405439	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.798	rs7789615	ENSG00000237310.1	GS1-124K5.4	9.96	2.14e-22	1.26e-19	0.32	0.29	Aortic root size;	chr7:66413674	chr7:66493706~66495474:+
BRCA	cis	rs72772090	0.539	rs116360011	ENSG00000248734.2	CTD-2260A17.1	-9.96	2.14e-22	1.26e-19	-0.49	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96782093	chr5:96784777~96785999:+
BRCA	cis	rs858239	0.601	rs1558313	ENSG00000226816.2	AC005082.12	9.96	2.14e-22	1.26e-19	0.34	0.29	Cerebrospinal fluid biomarker levels;	chr7:23116460	chr7:23206013~23208045:+
BRCA	cis	rs858239	0.601	rs6962526	ENSG00000226816.2	AC005082.12	9.96	2.14e-22	1.26e-19	0.34	0.29	Cerebrospinal fluid biomarker levels;	chr7:23118614	chr7:23206013~23208045:+
BRCA	cis	rs858239	0.539	rs6971673	ENSG00000226816.2	AC005082.12	9.96	2.14e-22	1.26e-19	0.34	0.29	Cerebrospinal fluid biomarker levels;	chr7:23119904	chr7:23206013~23208045:+
BRCA	cis	rs858239	0.601	rs10278700	ENSG00000226816.2	AC005082.12	9.96	2.14e-22	1.26e-19	0.34	0.29	Cerebrospinal fluid biomarker levels;	chr7:23120910	chr7:23206013~23208045:+
BRCA	cis	rs858239	0.601	rs10263110	ENSG00000226816.2	AC005082.12	9.96	2.14e-22	1.26e-19	0.34	0.29	Cerebrospinal fluid biomarker levels;	chr7:23120932	chr7:23206013~23208045:+
BRCA	cis	rs10129255	0.957	rs10140904	ENSG00000211970.3	IGHV4-61	-9.96	2.14e-22	1.26e-19	-0.2	-0.29	Kawasaki disease;	chr14:106776558	chr14:106639119~106639657:-
BRCA	cis	rs4835473	0.932	rs13129702	ENSG00000251600.4	RP11-673E1.1	9.96	2.15e-22	1.27e-19	0.34	0.29	Immature fraction of reticulocytes;	chr4:143785132	chr4:143912331~143982454:+
BRCA	cis	rs875971	0.571	rs78668714	ENSG00000226824.5	RP4-756H11.3	-9.96	2.15e-22	1.27e-19	-0.42	-0.29	Aortic root size;	chr7:66474464	chr7:66654538~66669855:+
BRCA	cis	rs1707322	0.752	rs4660880	ENSG00000280836.1	AL355480.1	-9.96	2.16e-22	1.27e-19	-0.38	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45645368	chr1:45581219~45581321:-
BRCA	cis	rs8062405	1	rs72793812	ENSG00000278665.1	RP11-666O2.4	9.96	2.17e-22	1.27e-19	0.33	0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28829060	chr16:28599241~28601881:-
BRCA	cis	rs6570726	0.764	rs451108	ENSG00000235652.6	RP11-545I5.3	9.96	2.17e-22	1.28e-19	0.3	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145523173	chr6:145799409~145886585:+
BRCA	cis	rs1823913	0.599	rs17511410	ENSG00000227542.1	AC092614.2	9.96	2.19e-22	1.29e-19	0.36	0.29	Obesity-related traits;	chr2:191278043	chr2:191229165~191246172:-
BRCA	cis	rs11971779	0.523	rs10279160	ENSG00000273391.1	RP11-634H22.1	9.96	2.2e-22	1.29e-19	0.29	0.29	Diisocyanate-induced asthma;	chr7:139406015	chr7:139359032~139359566:-
BRCA	cis	rs11971779	0.59	rs4732374	ENSG00000273391.1	RP11-634H22.1	9.96	2.2e-22	1.29e-19	0.29	0.29	Diisocyanate-induced asthma;	chr7:139406707	chr7:139359032~139359566:-
BRCA	cis	rs1707322	0.752	rs12062535	ENSG00000280836.1	AL355480.1	-9.96	2.2e-22	1.3e-19	-0.39	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45757208	chr1:45581219~45581321:-
BRCA	cis	rs6570726	0.791	rs400329	ENSG00000235652.6	RP11-545I5.3	9.96	2.21e-22	1.3e-19	0.3	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145558306	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.764	rs367065	ENSG00000235652.6	RP11-545I5.3	9.96	2.21e-22	1.3e-19	0.3	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145561173	chr6:145799409~145886585:+
BRCA	cis	rs34779708	0.801	rs12246600	ENSG00000230534.5	RP11-297A16.2	9.96	2.23e-22	1.31e-19	0.37	0.29	Inflammatory bowel disease;Crohn's disease;	chr10:35249193	chr10:35098006~35127020:-
BRCA	cis	rs2412819	0.571	rs2930531	ENSG00000249839.1	AC011330.5	9.96	2.23e-22	1.31e-19	0.41	0.29	Lung cancer;	chr15:43829372	chr15:43663654~43684339:-
BRCA	cis	rs11098499	0.954	rs67265404	ENSG00000245958.5	RP11-33B1.1	-9.96	2.24e-22	1.32e-19	-0.29	-0.29	Corneal astigmatism;	chr4:119438115	chr4:119454791~119552025:+
BRCA	cis	rs11690935	0.632	rs12991740	ENSG00000228389.1	AC068039.4	-9.96	2.25e-22	1.32e-19	-0.36	-0.29	Schizophrenia;	chr2:172021092	chr2:171773482~171775844:+
BRCA	cis	rs875971	0.862	rs11763189	ENSG00000237310.1	GS1-124K5.4	9.96	2.26e-22	1.33e-19	0.31	0.29	Aortic root size;	chr7:66518542	chr7:66493706~66495474:+
BRCA	cis	rs801193	0.548	rs2109297	ENSG00000237310.1	GS1-124K5.4	-9.96	2.27e-22	1.33e-19	-0.31	-0.29	Aortic root size;	chr7:66657397	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.571	rs160641	ENSG00000226824.5	RP4-756H11.3	9.96	2.28e-22	1.34e-19	0.41	0.29	Aortic root size;	chr7:66112359	chr7:66654538~66669855:+
BRCA	cis	rs1707322	0.752	rs28719889	ENSG00000280836.1	AL355480.1	-9.96	2.28e-22	1.34e-19	-0.39	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45736611	chr1:45581219~45581321:-
BRCA	cis	rs55794721	0.509	rs873308	ENSG00000224183.1	SDHDP6	9.96	2.29e-22	1.34e-19	0.35	0.29	Mean corpuscular volume;Plateletcrit;	chr1:25432164	chr1:25294164~25294643:-
BRCA	cis	rs7829975	0.742	rs1533059	ENSG00000253893.2	FAM85B	9.96	2.29e-22	1.35e-19	0.37	0.29	Mood instability;	chr8:8827443	chr8:8167819~8226614:-
BRCA	cis	rs10875746	0.551	rs2054904	ENSG00000240399.1	RP1-228P16.1	-9.96	2.3e-22	1.35e-19	-0.4	-0.29	Longevity (90 years and older);	chr12:48330571	chr12:48054813~48055591:-
BRCA	cis	rs17711722	0.51	rs11767457	ENSG00000226824.5	RP4-756H11.3	-9.95	2.31e-22	1.36e-19	-0.38	-0.29	Calcium levels;	chr7:65825628	chr7:66654538~66669855:+
BRCA	cis	rs732716	0.785	rs56272533	ENSG00000267769.1	CTB-50L17.9	-9.95	2.31e-22	1.36e-19	-0.38	-0.29	Mean corpuscular volume;	chr19:4420045	chr19:4454014~4455286:+
BRCA	cis	rs875971	0.862	rs4718377	ENSG00000237310.1	GS1-124K5.4	-9.95	2.31e-22	1.36e-19	-0.31	-0.29	Aortic root size;	chr7:66584691	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.862	rs10278014	ENSG00000237310.1	GS1-124K5.4	-9.95	2.31e-22	1.36e-19	-0.31	-0.29	Aortic root size;	chr7:66586277	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.545	rs6969224	ENSG00000226824.5	RP4-756H11.3	-9.95	2.32e-22	1.36e-19	-0.42	-0.29	Aortic root size;	chr7:66370011	chr7:66654538~66669855:+
BRCA	cis	rs7429990	0.901	rs7431567	ENSG00000229759.1	MRPS18AP1	-9.95	2.33e-22	1.37e-19	-0.36	-0.29	Educational attainment (years of education);	chr3:47986342	chr3:48256350~48256938:-
BRCA	cis	rs4713118	0.629	rs203888	ENSG00000220721.1	OR1F12	9.95	2.34e-22	1.37e-19	0.38	0.29	Parkinson's disease;	chr6:28053811	chr6:28073316~28074233:+
BRCA	cis	rs6545883	0.524	rs2593631	ENSG00000271889.1	RP11-493E12.1	-9.95	2.35e-22	1.38e-19	-0.36	-0.29	Tuberculosis;	chr2:61345151	chr2:61151433~61162105:-
BRCA	cis	rs2337406	0.539	rs2583292	ENSG00000274576.2	IGHV2-70	-9.95	2.36e-22	1.38e-19	-0.31	-0.29	Alzheimer's disease (late onset);	chr14:106649040	chr14:106770577~106771020:-
BRCA	cis	rs17711722	0.522	rs62469933	ENSG00000236529.1	RP13-254B10.1	9.95	2.37e-22	1.39e-19	0.33	0.29	Calcium levels;	chr7:65800652	chr7:65840212~65840596:+
BRCA	cis	rs10129255	0.957	rs10137980	ENSG00000211970.3	IGHV4-61	-9.95	2.38e-22	1.39e-19	-0.2	-0.29	Kawasaki disease;	chr14:106775735	chr14:106639119~106639657:-
BRCA	cis	rs11971779	0.68	rs6467840	ENSG00000273391.1	RP11-634H22.1	9.95	2.38e-22	1.39e-19	0.29	0.29	Diisocyanate-induced asthma;	chr7:139380655	chr7:139359032~139359566:-
BRCA	cis	rs11971779	0.564	rs6467841	ENSG00000273391.1	RP11-634H22.1	9.95	2.38e-22	1.39e-19	0.29	0.29	Diisocyanate-induced asthma;	chr7:139381346	chr7:139359032~139359566:-
BRCA	cis	rs11971779	0.68	rs7792752	ENSG00000273391.1	RP11-634H22.1	9.95	2.38e-22	1.39e-19	0.29	0.29	Diisocyanate-induced asthma;	chr7:139381450	chr7:139359032~139359566:-
BRCA	cis	rs11971779	0.616	rs6974907	ENSG00000273391.1	RP11-634H22.1	9.95	2.38e-22	1.39e-19	0.29	0.29	Diisocyanate-induced asthma;	chr7:139383983	chr7:139359032~139359566:-
BRCA	cis	rs11971779	0.584	rs10236055	ENSG00000273391.1	RP11-634H22.1	9.95	2.38e-22	1.39e-19	0.29	0.29	Diisocyanate-induced asthma;	chr7:139385245	chr7:139359032~139359566:-
BRCA	cis	rs11971779	0.584	rs6942519	ENSG00000273391.1	RP11-634H22.1	9.95	2.38e-22	1.39e-19	0.29	0.29	Diisocyanate-induced asthma;	chr7:139385344	chr7:139359032~139359566:-
BRCA	cis	rs11971779	0.68	rs6467843	ENSG00000273391.1	RP11-634H22.1	9.95	2.38e-22	1.39e-19	0.29	0.29	Diisocyanate-induced asthma;	chr7:139385777	chr7:139359032~139359566:-
BRCA	cis	rs11971779	0.68	rs2355785	ENSG00000273391.1	RP11-634H22.1	9.95	2.38e-22	1.39e-19	0.29	0.29	Diisocyanate-induced asthma;	chr7:139386237	chr7:139359032~139359566:-
BRCA	cis	rs11971779	0.588	rs6972408	ENSG00000273391.1	RP11-634H22.1	9.95	2.38e-22	1.39e-19	0.29	0.29	Diisocyanate-induced asthma;	chr7:139386728	chr7:139359032~139359566:-
BRCA	cis	rs11971779	0.625	rs2355784	ENSG00000273391.1	RP11-634H22.1	9.95	2.38e-22	1.39e-19	0.29	0.29	Diisocyanate-induced asthma;	chr7:139387747	chr7:139359032~139359566:-
BRCA	cis	rs11971779	0.616	rs2883772	ENSG00000273391.1	RP11-634H22.1	9.95	2.38e-22	1.39e-19	0.29	0.29	Diisocyanate-induced asthma;	chr7:139388010	chr7:139359032~139359566:-
BRCA	cis	rs11971779	0.68	rs28579232	ENSG00000273391.1	RP11-634H22.1	9.95	2.38e-22	1.39e-19	0.29	0.29	Diisocyanate-induced asthma;	chr7:139388370	chr7:139359032~139359566:-
BRCA	cis	rs11971779	0.68	rs2355783	ENSG00000273391.1	RP11-634H22.1	9.95	2.38e-22	1.39e-19	0.29	0.29	Diisocyanate-induced asthma;	chr7:139391133	chr7:139359032~139359566:-
BRCA	cis	rs11971779	0.68	rs111461944	ENSG00000273391.1	RP11-634H22.1	9.95	2.38e-22	1.39e-19	0.29	0.29	Diisocyanate-induced asthma;	chr7:139393157	chr7:139359032~139359566:-
BRCA	cis	rs11971779	0.68	rs6467846	ENSG00000273391.1	RP11-634H22.1	9.95	2.38e-22	1.39e-19	0.29	0.29	Diisocyanate-induced asthma;	chr7:139394639	chr7:139359032~139359566:-
BRCA	cis	rs11971779	0.648	rs6467849	ENSG00000273391.1	RP11-634H22.1	9.95	2.38e-22	1.39e-19	0.29	0.29	Diisocyanate-induced asthma;	chr7:139395766	chr7:139359032~139359566:-
BRCA	cis	rs11971779	0.68	rs1986447	ENSG00000273391.1	RP11-634H22.1	9.95	2.38e-22	1.39e-19	0.29	0.29	Diisocyanate-induced asthma;	chr7:139397334	chr7:139359032~139359566:-
BRCA	cis	rs11971779	0.59	rs9642120	ENSG00000273391.1	RP11-634H22.1	9.95	2.38e-22	1.39e-19	0.29	0.29	Diisocyanate-induced asthma;	chr7:139399225	chr7:139359032~139359566:-
BRCA	cis	rs11971779	0.618	rs9640925	ENSG00000273391.1	RP11-634H22.1	9.95	2.38e-22	1.39e-19	0.29	0.29	Diisocyanate-induced asthma;	chr7:139400542	chr7:139359032~139359566:-
BRCA	cis	rs11971779	0.68	rs7804388	ENSG00000273391.1	RP11-634H22.1	9.95	2.38e-22	1.39e-19	0.29	0.29	Diisocyanate-induced asthma;	chr7:139401667	chr7:139359032~139359566:-
BRCA	cis	rs11971779	0.68	rs4732373	ENSG00000273391.1	RP11-634H22.1	9.95	2.38e-22	1.39e-19	0.29	0.29	Diisocyanate-induced asthma;	chr7:139401789	chr7:139359032~139359566:-
BRCA	cis	rs11971779	0.618	rs6943788	ENSG00000273391.1	RP11-634H22.1	9.95	2.38e-22	1.39e-19	0.29	0.29	Diisocyanate-induced asthma;	chr7:139402951	chr7:139359032~139359566:-
BRCA	cis	rs8062405	1	rs55991577	ENSG00000251417.2	RP11-1348G14.4	-9.95	2.39e-22	1.4e-19	-0.34	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28831704	chr16:28802743~28817828:+
BRCA	cis	rs8062405	1	rs56358680	ENSG00000251417.2	RP11-1348G14.4	-9.95	2.39e-22	1.4e-19	-0.34	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28831797	chr16:28802743~28817828:+
BRCA	cis	rs62103177	0.608	rs8088089	ENSG00000261126.6	RP11-795F19.1	-9.95	2.39e-22	1.4e-19	-0.4	-0.29	Opioid sensitivity;	chr18:80073851	chr18:80046900~80095482:+
BRCA	cis	rs7772486	0.754	rs9373476	ENSG00000235652.6	RP11-545I5.3	9.95	2.41e-22	1.41e-19	0.3	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145818605	chr6:145799409~145886585:+
BRCA	cis	rs67180937	0.553	rs2936020	ENSG00000272750.1	RP11-378J18.8	9.95	2.42e-22	1.42e-19	0.43	0.29	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222655754	chr1:222658867~222661512:-
BRCA	cis	rs10875746	0.587	rs9788082	ENSG00000240399.1	RP1-228P16.1	-9.95	2.44e-22	1.43e-19	-0.41	-0.29	Longevity (90 years and older);	chr12:48358273	chr12:48054813~48055591:-
BRCA	cis	rs6921919	0.551	rs13201753	ENSG00000216901.1	AL022393.7	9.95	2.45e-22	1.44e-19	0.39	0.29	Autism spectrum disorder or schizophrenia;	chr6:28363351	chr6:28176188~28176674:+
BRCA	cis	rs875971	0.862	rs778684	ENSG00000237310.1	GS1-124K5.4	9.95	2.45e-22	1.44e-19	0.31	0.29	Aortic root size;	chr7:66371416	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.862	rs3893216	ENSG00000237310.1	GS1-124K5.4	-9.95	2.49e-22	1.46e-19	-0.31	-0.29	Aortic root size;	chr7:66325720	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.862	rs6958294	ENSG00000237310.1	GS1-124K5.4	-9.95	2.49e-22	1.46e-19	-0.31	-0.29	Aortic root size;	chr7:66329809	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.862	rs2088655	ENSG00000237310.1	GS1-124K5.4	-9.95	2.49e-22	1.46e-19	-0.31	-0.29	Aortic root size;	chr7:66330724	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.895	rs10447522	ENSG00000237310.1	GS1-124K5.4	-9.95	2.49e-22	1.46e-19	-0.31	-0.29	Aortic root size;	chr7:66331087	chr7:66493706~66495474:+
BRCA	cis	rs6570726	0.791	rs370654	ENSG00000235652.6	RP11-545I5.3	9.95	2.49e-22	1.46e-19	0.3	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145557869	chr6:145799409~145886585:+
BRCA	cis	rs1707322	0.716	rs28375469	ENSG00000280836.1	AL355480.1	-9.95	2.52e-22	1.47e-19	-0.39	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45729703	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.752	rs28545085	ENSG00000280836.1	AL355480.1	-9.95	2.52e-22	1.47e-19	-0.39	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45736278	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.752	rs28812624	ENSG00000280836.1	AL355480.1	-9.95	2.52e-22	1.47e-19	-0.39	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45738064	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.752	rs28507722	ENSG00000280836.1	AL355480.1	-9.95	2.52e-22	1.47e-19	-0.39	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45740868	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.752	rs28568986	ENSG00000280836.1	AL355480.1	-9.95	2.52e-22	1.47e-19	-0.39	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45742071	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.717	rs28396194	ENSG00000280836.1	AL355480.1	-9.95	2.52e-22	1.47e-19	-0.39	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45747555	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.717	rs28752166	ENSG00000280836.1	AL355480.1	-9.95	2.52e-22	1.47e-19	-0.39	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45747637	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.717	rs10890345	ENSG00000280836.1	AL355480.1	-9.95	2.52e-22	1.47e-19	-0.39	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45748255	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.721	rs10789471	ENSG00000280836.1	AL355480.1	-9.95	2.52e-22	1.47e-19	-0.39	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45749947	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.752	rs11211173	ENSG00000280836.1	AL355480.1	-9.95	2.52e-22	1.47e-19	-0.39	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45753704	chr1:45581219~45581321:-
BRCA	cis	rs6435862	0.593	rs34732883	ENSG00000229267.2	AC072062.1	9.94	2.53e-22	1.48e-19	0.35	0.29	Neuroblastoma (high-risk);	chr2:214809647	chr2:214810229~214963274:+
BRCA	cis	rs4727443	0.932	rs7803714	ENSG00000235713.1	RP4-604G5.3	-9.94	2.54e-22	1.49e-19	-0.33	-0.29	Interstitial lung disease;	chr7:99987527	chr7:99992397~99993050:+
BRCA	cis	rs7772486	0.875	rs2777484	ENSG00000235652.6	RP11-545I5.3	9.94	2.54e-22	1.49e-19	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:146013026	chr6:145799409~145886585:+
BRCA	cis	rs765787	0.53	rs10851423	ENSG00000259520.4	CTD-2651B20.3	-9.94	2.56e-22	1.5e-19	-0.37	-0.29	Uric acid levels;	chr15:45223752	chr15:45251580~45279251:-
BRCA	cis	rs765787	0.53	rs12913123	ENSG00000259520.4	CTD-2651B20.3	-9.94	2.56e-22	1.5e-19	-0.37	-0.29	Uric acid levels;	chr15:45224227	chr15:45251580~45279251:-
BRCA	cis	rs228614	0.51	rs223392	ENSG00000246560.2	RP11-10L12.4	9.94	2.56e-22	1.5e-19	0.31	0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102824599	chr4:102828055~102844075:+
BRCA	cis	rs4964805	0.594	rs10861095	ENSG00000257681.1	RP11-341G23.4	9.94	2.56e-22	1.5e-19	0.35	0.29	Attention deficit hyperactivity disorder;	chr12:103771609	chr12:103746315~103768858:-
BRCA	cis	rs10129255	0.957	rs8022165	ENSG00000211970.3	IGHV4-61	-9.94	2.58e-22	1.51e-19	-0.2	-0.29	Kawasaki disease;	chr14:106781682	chr14:106639119~106639657:-
BRCA	cis	rs673078	0.607	rs884844	ENSG00000275759.1	RP11-131L12.3	-9.94	2.59e-22	1.51e-19	-0.44	-0.29	Glucose homeostasis traits;	chr12:118377033	chr12:118428281~118428870:+
BRCA	cis	rs8062405	0.755	rs4788073	ENSG00000278665.1	RP11-666O2.4	9.94	2.59e-22	1.51e-19	0.31	0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28583228	chr16:28599241~28601881:-
BRCA	cis	rs1707322	0.752	rs28550303	ENSG00000280836.1	AL355480.1	-9.94	2.59e-22	1.52e-19	-0.39	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45723242	chr1:45581219~45581321:-
BRCA	cis	rs11096990	0.613	rs6829660	ENSG00000249207.1	RP11-360F5.1	-9.94	2.59e-22	1.52e-19	-0.35	-0.29	Cognitive function;	chr4:39280943	chr4:39112677~39126818:-
BRCA	cis	rs2276314	0.857	rs62101393	ENSG00000278986.1	RP11-723J4.3	-9.94	2.6e-22	1.52e-19	-0.37	-0.29	Endometriosis;Drug-induced torsades de pointes;	chr18:36012205	chr18:35972151~35973916:+
BRCA	cis	rs2276314	0.857	rs62101394	ENSG00000278986.1	RP11-723J4.3	-9.94	2.6e-22	1.52e-19	-0.37	-0.29	Endometriosis;Drug-induced torsades de pointes;	chr18:36012336	chr18:35972151~35973916:+
BRCA	cis	rs2276314	0.857	rs4799409	ENSG00000278986.1	RP11-723J4.3	-9.94	2.6e-22	1.52e-19	-0.37	-0.29	Endometriosis;Drug-induced torsades de pointes;	chr18:36012639	chr18:35972151~35973916:+
BRCA	cis	rs10129255	0.917	rs8022493	ENSG00000211970.3	IGHV4-61	-9.94	2.61e-22	1.53e-19	-0.2	-0.29	Kawasaki disease;	chr14:106781820	chr14:106639119~106639657:-
BRCA	cis	rs7829975	0.617	rs4841071	ENSG00000253893.2	FAM85B	-9.94	2.62e-22	1.53e-19	-0.37	-0.29	Mood instability;	chr8:8933634	chr8:8167819~8226614:-
BRCA	cis	rs1823913	0.526	rs36028476	ENSG00000227542.1	AC092614.2	9.94	2.64e-22	1.54e-19	0.36	0.29	Obesity-related traits;	chr2:191300595	chr2:191229165~191246172:-
BRCA	cis	rs875971	0.862	rs778736	ENSG00000237310.1	GS1-124K5.4	9.94	2.65e-22	1.55e-19	0.31	0.29	Aortic root size;	chr7:66348861	chr7:66493706~66495474:+
BRCA	cis	rs6545883	0.507	rs59981505	ENSG00000271889.1	RP11-493E12.1	-9.94	2.66e-22	1.55e-19	-0.35	-0.29	Tuberculosis;	chr2:61353394	chr2:61151433~61162105:-
BRCA	cis	rs875971	0.767	rs1643394	ENSG00000237310.1	GS1-124K5.4	9.94	2.67e-22	1.56e-19	0.31	0.29	Aortic root size;	chr7:66371107	chr7:66493706~66495474:+
BRCA	cis	rs6921919	0.583	rs9461459	ENSG00000216901.1	AL022393.7	9.94	2.69e-22	1.57e-19	0.39	0.29	Autism spectrum disorder or schizophrenia;	chr6:28394139	chr6:28176188~28176674:+
BRCA	cis	rs6921919	0.583	rs28360638	ENSG00000216901.1	AL022393.7	9.94	2.69e-22	1.57e-19	0.39	0.29	Autism spectrum disorder or schizophrenia;	chr6:28394552	chr6:28176188~28176674:+
BRCA	cis	rs6921919	0.583	rs9468368	ENSG00000216901.1	AL022393.7	9.94	2.69e-22	1.57e-19	0.39	0.29	Autism spectrum disorder or schizophrenia;	chr6:28397172	chr6:28176188~28176674:+
BRCA	cis	rs11098499	0.954	rs11729521	ENSG00000245958.5	RP11-33B1.1	-9.94	2.69e-22	1.57e-19	-0.29	-0.29	Corneal astigmatism;	chr4:119495633	chr4:119454791~119552025:+
BRCA	cis	rs853679	0.76	rs11967137	ENSG00000220721.1	OR1F12	9.94	2.7e-22	1.58e-19	0.42	0.29	Depression;	chr6:28231986	chr6:28073316~28074233:+
BRCA	cis	rs1707322	0.752	rs11211145	ENSG00000280836.1	AL355480.1	-9.94	2.7e-22	1.58e-19	-0.39	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45642819	chr1:45581219~45581321:-
BRCA	cis	rs2439831	0.85	rs7174208	ENSG00000275601.1	AC011330.13	-9.94	2.71e-22	1.58e-19	-0.47	-0.29	Lung cancer in ever smokers;	chr15:43760484	chr15:43642389~43643023:-
BRCA	cis	rs2439831	0.85	rs12101756	ENSG00000275601.1	AC011330.13	-9.94	2.71e-22	1.58e-19	-0.47	-0.29	Lung cancer in ever smokers;	chr15:43761689	chr15:43642389~43643023:-
BRCA	cis	rs11971779	0.648	rs7799165	ENSG00000273391.1	RP11-634H22.1	9.94	2.71e-22	1.58e-19	0.29	0.29	Diisocyanate-induced asthma;	chr7:139400211	chr7:139359032~139359566:-
BRCA	cis	rs7429990	0.965	rs4296617	ENSG00000229759.1	MRPS18AP1	-9.94	2.72e-22	1.59e-19	-0.36	-0.29	Educational attainment (years of education);	chr3:48026818	chr3:48256350~48256938:-
BRCA	cis	rs1062177	0.756	rs2964591	ENSG00000213433.5	RPLP1P6	9.94	2.72e-22	1.59e-19	0.37	0.29	Preschool internalizing problems;	chr5:151737836	chr5:151765859~151766378:-
BRCA	cis	rs875971	0.825	rs66981195	ENSG00000237310.1	GS1-124K5.4	-9.94	2.72e-22	1.59e-19	-0.31	-0.29	Aortic root size;	chr7:66614048	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.862	rs3926380	ENSG00000237310.1	GS1-124K5.4	-9.94	2.72e-22	1.59e-19	-0.31	-0.29	Aortic root size;	chr7:66615658	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.825	rs1860472	ENSG00000237310.1	GS1-124K5.4	-9.94	2.72e-22	1.59e-19	-0.31	-0.29	Aortic root size;	chr7:66617736	chr7:66493706~66495474:+
BRCA	cis	rs733592	0.931	rs765260	ENSG00000240399.1	RP1-228P16.1	-9.94	2.72e-22	1.59e-19	-0.33	-0.29	Plateletcrit;	chr12:48038153	chr12:48054813~48055591:-
BRCA	cis	rs228614	0.51	rs223410	ENSG00000246560.2	RP11-10L12.4	9.94	2.73e-22	1.59e-19	0.31	0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102813568	chr4:102828055~102844075:+
BRCA	cis	rs11098499	0.865	rs11722183	ENSG00000245958.5	RP11-33B1.1	-9.94	2.73e-22	1.59e-19	-0.29	-0.29	Corneal astigmatism;	chr4:119359442	chr4:119454791~119552025:+
BRCA	cis	rs853679	0.527	rs9461443	ENSG00000220721.1	OR1F12	9.94	2.73e-22	1.59e-19	0.38	0.29	Depression;	chr6:28226851	chr6:28073316~28074233:+
BRCA	cis	rs227275	0.554	rs223485	ENSG00000246560.2	RP11-10L12.4	9.94	2.74e-22	1.6e-19	0.31	0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102764018	chr4:102828055~102844075:+
BRCA	cis	rs6570726	0.791	rs370112	ENSG00000235652.6	RP11-545I5.3	9.94	2.75e-22	1.6e-19	0.3	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145538717	chr6:145799409~145886585:+
BRCA	cis	rs10129255	0.833	rs61997797	ENSG00000211970.3	IGHV4-61	-9.94	2.75e-22	1.6e-19	-0.21	-0.29	Kawasaki disease;	chr14:106815190	chr14:106639119~106639657:-
BRCA	cis	rs875971	0.862	rs1968126	ENSG00000237310.1	GS1-124K5.4	-9.94	2.76e-22	1.61e-19	-0.31	-0.29	Aortic root size;	chr7:66592017	chr7:66493706~66495474:+
BRCA	cis	rs8062405	0.824	rs7191618	ENSG00000278665.1	RP11-666O2.4	9.94	2.76e-22	1.61e-19	0.3	0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554346	chr16:28599241~28601881:-
BRCA	cis	rs10129255	0.957	rs12590735	ENSG00000211970.3	IGHV4-61	-9.94	2.77e-22	1.61e-19	-0.21	-0.29	Kawasaki disease;	chr14:106779660	chr14:106639119~106639657:-
BRCA	cis	rs17482078	0.959	rs13185488	ENSG00000248734.2	CTD-2260A17.1	9.93	2.77e-22	1.62e-19	0.41	0.29	Behcet's disease;Blood protein levels;	chr5:96785480	chr5:96784777~96785999:+
BRCA	cis	rs7429990	0.901	rs6442091	ENSG00000229759.1	MRPS18AP1	-9.93	2.78e-22	1.62e-19	-0.36	-0.29	Educational attainment (years of education);	chr3:48001568	chr3:48256350~48256938:-
BRCA	cis	rs7429990	0.965	rs4858810	ENSG00000229759.1	MRPS18AP1	-9.93	2.78e-22	1.62e-19	-0.36	-0.29	Educational attainment (years of education);	chr3:48002247	chr3:48256350~48256938:-
BRCA	cis	rs17482078	0.959	rs13186739	ENSG00000248734.2	CTD-2260A17.1	9.93	2.79e-22	1.63e-19	0.41	0.29	Behcet's disease;Blood protein levels;	chr5:96785539	chr5:96784777~96785999:+
BRCA	cis	rs1823913	0.599	rs2124095	ENSG00000227542.1	AC092614.2	9.93	2.8e-22	1.63e-19	0.36	0.29	Obesity-related traits;	chr2:191301728	chr2:191229165~191246172:-
BRCA	cis	rs673078	0.607	rs2784	ENSG00000275759.1	RP11-131L12.3	-9.93	2.81e-22	1.63e-19	-0.5	-0.29	Glucose homeostasis traits;	chr12:118311745	chr12:118428281~118428870:+
BRCA	cis	rs673078	0.615	rs61943397	ENSG00000275759.1	RP11-131L12.3	-9.93	2.81e-22	1.64e-19	-0.43	-0.29	Glucose homeostasis traits;	chr12:118390996	chr12:118428281~118428870:+
BRCA	cis	rs75422866	0.867	rs73104152	ENSG00000274902.1	RP1-197B17.4	9.93	2.81e-22	1.64e-19	0.79	0.29	Pneumonia;	chr12:47699091	chr12:47731908~47732351:+
BRCA	cis	rs75422866	0.867	rs73104155	ENSG00000274902.1	RP1-197B17.4	9.93	2.81e-22	1.64e-19	0.79	0.29	Pneumonia;	chr12:47700790	chr12:47731908~47732351:+
BRCA	cis	rs7580658	0.724	rs71414745	ENSG00000236682.1	AC068282.3	-9.93	2.82e-22	1.64e-19	-0.39	-0.29	Protein C levels;	chr2:127235012	chr2:127389130~127400580:+
BRCA	cis	rs17023223	0.537	rs10923754	ENSG00000231365.4	RP11-418J17.1	-9.93	2.82e-22	1.64e-19	-0.38	-0.29	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119126017	chr1:119140396~119275973:+
BRCA	cis	rs875971	0.862	rs6971059	ENSG00000237310.1	GS1-124K5.4	-9.93	2.82e-22	1.64e-19	-0.31	-0.29	Aortic root size;	chr7:66602045	chr7:66493706~66495474:+
BRCA	cis	rs11603023	0.874	rs613243	ENSG00000255422.1	AP002954.4	-9.93	2.82e-22	1.65e-19	-0.34	-0.29	Cholesterol, total;	chr11:118643304	chr11:118704607~118750263:+
BRCA	cis	rs2404602	0.735	rs2461870	ENSG00000259422.1	RP11-593F23.1	-9.93	2.83e-22	1.65e-19	-0.36	-0.29	Blood metabolite levels;	chr15:76521579	chr15:76174891~76181486:-
BRCA	cis	rs875971	0.545	rs73150604	ENSG00000226824.5	RP4-756H11.3	-9.93	2.84e-22	1.66e-19	-0.42	-0.29	Aortic root size;	chr7:66480545	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.825	rs7384021	ENSG00000237310.1	GS1-124K5.4	-9.93	2.84e-22	1.66e-19	-0.31	-0.29	Aortic root size;	chr7:66612917	chr7:66493706~66495474:+
BRCA	cis	rs2404602	0.735	rs2454454	ENSG00000259422.1	RP11-593F23.1	-9.93	2.85e-22	1.66e-19	-0.36	-0.29	Blood metabolite levels;	chr15:76531306	chr15:76174891~76181486:-
BRCA	cis	rs2243480	1	rs313832	ENSG00000226824.5	RP4-756H11.3	-9.93	2.85e-22	1.66e-19	-0.6	-0.29	Diabetic kidney disease;	chr7:66085904	chr7:66654538~66669855:+
BRCA	cis	rs17023223	0.537	rs10923756	ENSG00000231365.4	RP11-418J17.1	-9.93	2.88e-22	1.68e-19	-0.38	-0.29	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119132025	chr1:119140396~119275973:+
BRCA	cis	rs7772486	0.79	rs2265474	ENSG00000235652.6	RP11-545I5.3	9.93	2.89e-22	1.68e-19	0.3	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145860956	chr6:145799409~145886585:+
BRCA	cis	rs10129255	0.957	rs10142918	ENSG00000211970.3	IGHV4-61	-9.93	2.9e-22	1.69e-19	-0.2	-0.29	Kawasaki disease;	chr14:106782206	chr14:106639119~106639657:-
BRCA	cis	rs6570726	0.791	rs443628	ENSG00000235652.6	RP11-545I5.3	9.93	2.92e-22	1.7e-19	0.3	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145562348	chr6:145799409~145886585:+
BRCA	cis	rs72772090	0.539	rs17481856	ENSG00000248734.2	CTD-2260A17.1	-9.93	2.93e-22	1.7e-19	-0.49	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96781104	chr5:96784777~96785999:+
BRCA	cis	rs72772090	0.539	rs72773923	ENSG00000248734.2	CTD-2260A17.1	-9.93	2.93e-22	1.7e-19	-0.49	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96781875	chr5:96784777~96785999:+
BRCA	cis	rs8072100	0.934	rs9905583	ENSG00000228782.6	CTD-2026D20.3	9.93	2.93e-22	1.7e-19	0.32	0.29	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47663650	chr17:47450568~47492492:-
BRCA	cis	rs10759883	0.627	rs690633	ENSG00000175611.10	LINC00476	9.93	2.94e-22	1.71e-19	0.35	0.29	Nicotine dependence;	chr9:95867894	chr9:95759231~95875977:-
BRCA	cis	rs7772486	0.72	rs991507	ENSG00000235652.6	RP11-545I5.3	-9.93	2.95e-22	1.72e-19	-0.3	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145702473	chr6:145799409~145886585:+
BRCA	cis	rs875971	0.789	rs7808013	ENSG00000237310.1	GS1-124K5.4	-9.93	2.95e-22	1.72e-19	-0.31	-0.29	Aortic root size;	chr7:66606209	chr7:66493706~66495474:+
BRCA	cis	rs1707322	0.826	rs10890349	ENSG00000280836.1	AL355480.1	-9.93	2.96e-22	1.72e-19	-0.39	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45784283	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.758	rs10789474	ENSG00000280836.1	AL355480.1	-9.93	2.96e-22	1.72e-19	-0.39	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45784368	chr1:45581219~45581321:-
BRCA	cis	rs875971	0.862	rs6460306	ENSG00000237310.1	GS1-124K5.4	-9.93	2.97e-22	1.73e-19	-0.31	-0.29	Aortic root size;	chr7:66595806	chr7:66493706~66495474:+
BRCA	cis	rs1707322	0.686	rs11211179	ENSG00000280836.1	AL355480.1	-9.93	2.98e-22	1.73e-19	-0.37	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45762410	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.721	rs10157795	ENSG00000280836.1	AL355480.1	-9.93	2.98e-22	1.73e-19	-0.37	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45762520	chr1:45581219~45581321:-
BRCA	cis	rs11096990	0.634	rs17754	ENSG00000249207.1	RP11-360F5.1	-9.93	2.99e-22	1.74e-19	-0.35	-0.29	Cognitive function;	chr4:39287688	chr4:39112677~39126818:-
BRCA	cis	rs8062405	1	rs72793811	ENSG00000278665.1	RP11-666O2.4	9.93	3e-22	1.75e-19	0.33	0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828071	chr16:28599241~28601881:-
BRCA	cis	rs6570726	0.791	rs1509213	ENSG00000235652.6	RP11-545I5.3	-9.93	3.01e-22	1.75e-19	-0.3	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145462224	chr6:145799409~145886585:+
BRCA	cis	rs11105298	0.786	rs10858897	ENSG00000258302.2	RP11-981P6.1	9.93	3.02e-22	1.75e-19	0.34	0.29	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89528255	chr12:89561129~89594878:+
BRCA	cis	rs8062405	0.755	rs62034325	ENSG00000278665.1	RP11-666O2.4	9.93	3.02e-22	1.75e-19	0.32	0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28527319	chr16:28599241~28601881:-
BRCA	cis	rs11105298	0.891	rs11105312	ENSG00000258302.2	RP11-981P6.1	9.92	3.07e-22	1.78e-19	0.34	0.29	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89526956	chr12:89561129~89594878:+
BRCA	cis	rs11105298	0.891	rs10777185	ENSG00000258302.2	RP11-981P6.1	9.92	3.07e-22	1.78e-19	0.34	0.29	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89527498	chr12:89561129~89594878:+
BRCA	cis	rs11098499	0.754	rs1980025	ENSG00000245958.5	RP11-33B1.1	9.92	3.07e-22	1.78e-19	0.27	0.29	Corneal astigmatism;	chr4:119331651	chr4:119454791~119552025:+
BRCA	cis	rs321358	0.731	rs547367	ENSG00000271584.1	RP11-89C3.4	-9.92	3.08e-22	1.79e-19	-0.45	-0.29	Body mass index;	chr11:111165382	chr11:111091932~111097357:-
BRCA	cis	rs11096990	0.634	rs10010352	ENSG00000249207.1	RP11-360F5.1	-9.92	3.09e-22	1.8e-19	-0.35	-0.29	Cognitive function;	chr4:39240657	chr4:39112677~39126818:-
BRCA	cis	rs11105298	0.891	rs10858899	ENSG00000258302.2	RP11-981P6.1	9.92	3.1e-22	1.8e-19	0.34	0.29	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89530034	chr12:89561129~89594878:+
BRCA	cis	rs1823913	0.637	rs1378162	ENSG00000227542.1	AC092614.2	9.92	3.11e-22	1.8e-19	0.36	0.29	Obesity-related traits;	chr2:191298523	chr2:191229165~191246172:-
BRCA	cis	rs7772486	0.79	rs2254257	ENSG00000235652.6	RP11-545I5.3	9.92	3.11e-22	1.81e-19	0.3	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145882588	chr6:145799409~145886585:+
BRCA	cis	rs875971	0.862	rs2909688	ENSG00000237310.1	GS1-124K5.4	9.92	3.11e-22	1.81e-19	0.31	0.29	Aortic root size;	chr7:66376625	chr7:66493706~66495474:+
BRCA	cis	rs4728142	0.593	rs7808907	ENSG00000275106.1	RP11-309L24.10	9.92	3.15e-22	1.83e-19	0.37	0.29	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128944030	chr7:128952527~128953316:-
BRCA	cis	rs72772090	0.539	rs67140788	ENSG00000248734.2	CTD-2260A17.1	-9.92	3.16e-22	1.83e-19	-0.48	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96780582	chr5:96784777~96785999:+
BRCA	cis	rs72772090	0.539	rs72773922	ENSG00000248734.2	CTD-2260A17.1	-9.92	3.16e-22	1.83e-19	-0.48	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96780956	chr5:96784777~96785999:+
BRCA	cis	rs228614	0.51	rs50034	ENSG00000246560.2	RP11-10L12.4	9.92	3.16e-22	1.83e-19	0.31	0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102832214	chr4:102828055~102844075:+
BRCA	cis	rs227275	0.556	rs223380	ENSG00000246560.2	RP11-10L12.4	9.92	3.16e-22	1.83e-19	0.31	0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102833343	chr4:102828055~102844075:+
BRCA	cis	rs227275	0.556	rs223379	ENSG00000246560.2	RP11-10L12.4	9.92	3.16e-22	1.83e-19	0.31	0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102833434	chr4:102828055~102844075:+
BRCA	cis	rs35160687	0.623	rs11127019	ENSG00000273080.1	RP11-301O19.1	-9.92	3.16e-22	1.84e-19	-0.35	-0.29	Night sleep phenotypes;	chr2:86240495	chr2:86195590~86196049:+
BRCA	cis	rs7772486	0.79	rs3924499	ENSG00000235652.6	RP11-545I5.3	-9.92	3.17e-22	1.84e-19	-0.3	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145911842	chr6:145799409~145886585:+
BRCA	cis	rs11098499	0.954	rs10031483	ENSG00000245958.5	RP11-33B1.1	-9.92	3.18e-22	1.85e-19	-0.29	-0.29	Corneal astigmatism;	chr4:119501481	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.954	rs10031665	ENSG00000245958.5	RP11-33B1.1	-9.92	3.18e-22	1.85e-19	-0.29	-0.29	Corneal astigmatism;	chr4:119501697	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.954	rs3733523	ENSG00000245958.5	RP11-33B1.1	-9.92	3.18e-22	1.85e-19	-0.29	-0.29	Corneal astigmatism;	chr4:119502564	chr4:119454791~119552025:+
BRCA	cis	rs858239	0.601	rs11982002	ENSG00000226816.2	AC005082.12	9.92	3.2e-22	1.86e-19	0.34	0.29	Cerebrospinal fluid biomarker levels;	chr7:23123651	chr7:23206013~23208045:+
BRCA	cis	rs10129255	0.957	rs10142859	ENSG00000211970.3	IGHV4-61	-9.92	3.2e-22	1.86e-19	-0.2	-0.29	Kawasaki disease;	chr14:106782238	chr14:106639119~106639657:-
BRCA	cis	rs1707322	0.789	rs7540578	ENSG00000280836.1	AL355480.1	-9.92	3.23e-22	1.87e-19	-0.38	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45786472	chr1:45581219~45581321:-
BRCA	cis	rs6570726	0.791	rs422099	ENSG00000235652.6	RP11-545I5.3	9.92	3.26e-22	1.89e-19	0.3	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145485800	chr6:145799409~145886585:+
BRCA	cis	rs6142102	0.517	rs6142050	ENSG00000276073.1	RP5-1125A11.7	-9.92	3.29e-22	1.9e-19	-0.34	-0.29	Skin pigmentation;	chr20:33939322	chr20:33985617~33988989:-
BRCA	cis	rs1707322	0.752	rs4586014	ENSG00000280836.1	AL355480.1	-9.92	3.3e-22	1.91e-19	-0.38	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45684771	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.648	rs4439382	ENSG00000280836.1	AL355480.1	-9.92	3.3e-22	1.91e-19	-0.38	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45685133	chr1:45581219~45581321:-
BRCA	cis	rs6921919	0.583	rs7759191	ENSG00000216901.1	AL022393.7	9.92	3.31e-22	1.92e-19	0.39	0.29	Autism spectrum disorder or schizophrenia;	chr6:28385657	chr6:28176188~28176674:+
BRCA	cis	rs6921919	0.583	rs7764737	ENSG00000216901.1	AL022393.7	9.92	3.31e-22	1.92e-19	0.39	0.29	Autism spectrum disorder or schizophrenia;	chr6:28386838	chr6:28176188~28176674:+
BRCA	cis	rs6921919	0.583	rs9461458	ENSG00000216901.1	AL022393.7	9.92	3.31e-22	1.92e-19	0.39	0.29	Autism spectrum disorder or schizophrenia;	chr6:28388098	chr6:28176188~28176674:+
BRCA	cis	rs6921919	0.609	rs9468365	ENSG00000216901.1	AL022393.7	9.92	3.31e-22	1.92e-19	0.39	0.29	Autism spectrum disorder or schizophrenia;	chr6:28390189	chr6:28176188~28176674:+
BRCA	cis	rs6921919	0.583	rs1361385	ENSG00000216901.1	AL022393.7	9.92	3.31e-22	1.92e-19	0.39	0.29	Autism spectrum disorder or schizophrenia;	chr6:28390543	chr6:28176188~28176674:+
BRCA	cis	rs6921919	0.583	rs1416918	ENSG00000216901.1	AL022393.7	9.92	3.31e-22	1.92e-19	0.39	0.29	Autism spectrum disorder or schizophrenia;	chr6:28390558	chr6:28176188~28176674:+
BRCA	cis	rs6921919	0.583	rs9468367	ENSG00000216901.1	AL022393.7	9.92	3.31e-22	1.92e-19	0.39	0.29	Autism spectrum disorder or schizophrenia;	chr6:28392469	chr6:28176188~28176674:+
BRCA	cis	rs783540	0.9	rs55924160	ENSG00000278603.1	RP13-608F4.5	-9.91	3.37e-22	1.95e-19	-0.37	-0.29	Schizophrenia;	chr15:82613445	chr15:82472203~82472426:+
BRCA	cis	rs10129255	0.826	rs7150693	ENSG00000211970.3	IGHV4-61	-9.91	3.37e-22	1.95e-19	-0.22	-0.29	Kawasaki disease;	chr14:106705382	chr14:106639119~106639657:-
BRCA	cis	rs10129255	0.869	rs7150549	ENSG00000211970.3	IGHV4-61	-9.91	3.37e-22	1.95e-19	-0.22	-0.29	Kawasaki disease;	chr14:106705441	chr14:106639119~106639657:-
BRCA	cis	rs2243480	1	rs78803505	ENSG00000226824.5	RP4-756H11.3	-9.91	3.39e-22	1.96e-19	-0.55	-0.29	Diabetic kidney disease;	chr7:65917585	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs34577383	ENSG00000226824.5	RP4-756H11.3	-9.91	3.39e-22	1.96e-19	-0.55	-0.29	Diabetic kidney disease;	chr7:65920739	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs55895244	ENSG00000226824.5	RP4-756H11.3	-9.91	3.39e-22	1.96e-19	-0.55	-0.29	Diabetic kidney disease;	chr7:65922691	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs7795242	ENSG00000226824.5	RP4-756H11.3	-9.91	3.39e-22	1.96e-19	-0.55	-0.29	Diabetic kidney disease;	chr7:65925107	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs2177703	ENSG00000226824.5	RP4-756H11.3	-9.91	3.39e-22	1.96e-19	-0.55	-0.29	Diabetic kidney disease;	chr7:65926730	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs56985706	ENSG00000226824.5	RP4-756H11.3	-9.91	3.39e-22	1.96e-19	-0.55	-0.29	Diabetic kidney disease;	chr7:65929575	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs60683927	ENSG00000226824.5	RP4-756H11.3	-9.91	3.39e-22	1.96e-19	-0.55	-0.29	Diabetic kidney disease;	chr7:65929781	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs58062456	ENSG00000226824.5	RP4-756H11.3	-9.91	3.39e-22	1.96e-19	-0.55	-0.29	Diabetic kidney disease;	chr7:65929865	chr7:66654538~66669855:+
BRCA	cis	rs858239	0.867	rs10250602	ENSG00000226816.2	AC005082.12	9.91	3.39e-22	1.96e-19	0.35	0.29	Cerebrospinal fluid biomarker levels;	chr7:23264082	chr7:23206013~23208045:+
BRCA	cis	rs11690935	0.549	rs796839	ENSG00000228389.1	AC068039.4	-9.91	3.41e-22	1.97e-19	-0.36	-0.29	Schizophrenia;	chr2:172051486	chr2:171773482~171775844:+
BRCA	cis	rs11690935	0.549	rs2129475	ENSG00000228389.1	AC068039.4	-9.91	3.41e-22	1.97e-19	-0.36	-0.29	Schizophrenia;	chr2:172052044	chr2:171773482~171775844:+
BRCA	cis	rs1823913	0.599	rs13002286	ENSG00000227542.1	AC092614.2	-9.91	3.47e-22	2e-19	-0.36	-0.29	Obesity-related traits;	chr2:191285626	chr2:191229165~191246172:-
BRCA	cis	rs7772486	0.875	rs2748497	ENSG00000235652.6	RP11-545I5.3	9.91	3.48e-22	2.01e-19	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145998281	chr6:145799409~145886585:+
BRCA	cis	rs1707322	0.789	rs10789473	ENSG00000280836.1	AL355480.1	-9.91	3.48e-22	2.01e-19	-0.38	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45782459	chr1:45581219~45581321:-
BRCA	cis	rs8062405	0.722	rs3785354	ENSG00000278665.1	RP11-666O2.4	9.91	3.5e-22	2.02e-19	0.32	0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28539346	chr16:28599241~28601881:-
BRCA	cis	rs11971779	0.68	rs4732370	ENSG00000273391.1	RP11-634H22.1	-9.91	3.5e-22	2.02e-19	-0.29	-0.29	Diisocyanate-induced asthma;	chr7:139392494	chr7:139359032~139359566:-
BRCA	cis	rs2665103	0.715	rs16973457	ENSG00000278603.1	RP13-608F4.5	9.91	3.52e-22	2.03e-19	0.38	0.29	Intelligence (multi-trait analysis);	chr15:82271650	chr15:82472203~82472426:+
BRCA	cis	rs8062405	0.755	rs4788080	ENSG00000278665.1	RP11-666O2.4	9.91	3.52e-22	2.03e-19	0.32	0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28546760	chr16:28599241~28601881:-
BRCA	cis	rs8062405	0.755	rs4787456	ENSG00000278665.1	RP11-666O2.4	9.91	3.52e-22	2.03e-19	0.32	0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548252	chr16:28599241~28601881:-
BRCA	cis	rs8062405	0.755	rs4788078	ENSG00000278665.1	RP11-666O2.4	9.91	3.52e-22	2.03e-19	0.32	0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548660	chr16:28599241~28601881:-
BRCA	cis	rs2882667	0.537	rs7701338	ENSG00000253404.1	AC034243.1	9.91	3.53e-22	2.04e-19	0.37	0.29	Age-related hearing impairment (SNP x SNP interaction);	chr5:139070305	chr5:138744434~138753309:-
BRCA	cis	rs1707322	0.647	rs6686944	ENSG00000280836.1	AL355480.1	-9.91	3.53e-22	2.04e-19	-0.38	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45690636	chr1:45581219~45581321:-
BRCA	cis	rs875971	0.502	rs11769702	ENSG00000226824.5	RP4-756H11.3	-9.91	3.53e-22	2.04e-19	-0.41	-0.29	Aortic root size;	chr7:66255529	chr7:66654538~66669855:+
BRCA	cis	rs733592	0.524	rs10875727	ENSG00000240399.1	RP1-228P16.1	-9.91	3.55e-22	2.05e-19	-0.31	-0.29	Plateletcrit;	chr12:48032360	chr12:48054813~48055591:-
BRCA	cis	rs72772090	0.539	rs11749811	ENSG00000248734.2	CTD-2260A17.1	-9.91	3.57e-22	2.06e-19	-0.48	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96780221	chr5:96784777~96785999:+
BRCA	cis	rs11098499	0.908	rs7696649	ENSG00000245958.5	RP11-33B1.1	-9.91	3.57e-22	2.06e-19	-0.29	-0.29	Corneal astigmatism;	chr4:119401022	chr4:119454791~119552025:+
BRCA	cis	rs1823913	0.599	rs67781530	ENSG00000227542.1	AC092614.2	9.91	3.59e-22	2.07e-19	0.36	0.29	Obesity-related traits;	chr2:191295608	chr2:191229165~191246172:-
BRCA	cis	rs7429990	0.965	rs6770467	ENSG00000229759.1	MRPS18AP1	-9.91	3.59e-22	2.07e-19	-0.33	-0.29	Educational attainment (years of education);	chr3:47977742	chr3:48256350~48256938:-
BRCA	cis	rs7429990	0.932	rs6770477	ENSG00000229759.1	MRPS18AP1	-9.91	3.59e-22	2.07e-19	-0.33	-0.29	Educational attainment (years of education);	chr3:47977768	chr3:48256350~48256938:-
BRCA	cis	rs7429990	0.965	rs28637561	ENSG00000229759.1	MRPS18AP1	-9.91	3.59e-22	2.07e-19	-0.33	-0.29	Educational attainment (years of education);	chr3:47979528	chr3:48256350~48256938:-
BRCA	cis	rs7429990	0.965	rs7431572	ENSG00000229759.1	MRPS18AP1	-9.91	3.59e-22	2.07e-19	-0.33	-0.29	Educational attainment (years of education);	chr3:47986361	chr3:48256350~48256938:-
BRCA	cis	rs4713118	0.621	rs9295755	ENSG00000220721.1	OR1F12	-9.91	3.6e-22	2.08e-19	-0.39	-0.29	Parkinson's disease;	chr6:28065396	chr6:28073316~28074233:+
BRCA	cis	rs34779708	0.733	rs4102764	ENSG00000230534.5	RP11-297A16.2	9.91	3.62e-22	2.09e-19	0.37	0.29	Inflammatory bowel disease;Crohn's disease;	chr10:35256464	chr10:35098006~35127020:-
BRCA	cis	rs6921919	0.583	rs9468370	ENSG00000216901.1	AL022393.7	9.91	3.63e-22	2.09e-19	0.38	0.29	Autism spectrum disorder or schizophrenia;	chr6:28401163	chr6:28176188~28176674:+
BRCA	cis	rs7829975	0.606	rs891570	ENSG00000253893.2	FAM85B	9.9	3.64e-22	2.1e-19	0.36	0.29	Mood instability;	chr8:8936944	chr8:8167819~8226614:-
BRCA	cis	rs11971779	0.68	rs7783619	ENSG00000273391.1	RP11-634H22.1	9.9	3.65e-22	2.11e-19	0.29	0.29	Diisocyanate-induced asthma;	chr7:139376691	chr7:139359032~139359566:-
BRCA	cis	rs58873874	0.737	rs78565801	ENSG00000251405.2	CTB-109A12.1	9.9	3.65e-22	2.11e-19	0.78	0.29	Bipolar disorder (body mass index interaction);	chr5:157459326	chr5:157362615~157460078:-
BRCA	cis	rs58873874	0.737	rs79951742	ENSG00000251405.2	CTB-109A12.1	9.9	3.65e-22	2.11e-19	0.78	0.29	Bipolar disorder (body mass index interaction);	chr5:157459705	chr5:157362615~157460078:-
BRCA	cis	rs11098499	0.954	rs10006525	ENSG00000245958.5	RP11-33B1.1	-9.9	3.67e-22	2.11e-19	-0.29	-0.29	Corneal astigmatism;	chr4:119487776	chr4:119454791~119552025:+
BRCA	cis	rs6570726	0.791	rs408443	ENSG00000235652.6	RP11-545I5.3	9.9	3.67e-22	2.12e-19	0.3	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145553507	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.791	rs436156	ENSG00000235652.6	RP11-545I5.3	9.9	3.67e-22	2.12e-19	0.3	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145553737	chr6:145799409~145886585:+
BRCA	cis	rs11673344	0.704	rs826262	ENSG00000226686.6	LINC01535	9.9	3.67e-22	2.12e-19	0.38	0.29	Obesity-related traits;	chr19:36928540	chr19:37251912~37265535:+
BRCA	cis	rs228614	0.51	rs223455	ENSG00000246560.2	RP11-10L12.4	9.9	3.67e-22	2.12e-19	0.31	0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102789026	chr4:102828055~102844075:+
BRCA	cis	rs8062405	0.755	rs56209193	ENSG00000278665.1	RP11-666O2.4	9.9	3.68e-22	2.12e-19	0.32	0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28574315	chr16:28599241~28601881:-
BRCA	cis	rs6570726	0.791	rs436498	ENSG00000235652.6	RP11-545I5.3	9.9	3.68e-22	2.12e-19	0.3	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145555211	chr6:145799409~145886585:+
BRCA	cis	rs1113500	0.799	rs1777459	ENSG00000226822.1	RP11-356N1.2	-9.9	3.69e-22	2.13e-19	-0.38	-0.29	Growth-regulated protein alpha levels;	chr1:108042377	chr1:108071482~108074519:+
BRCA	cis	rs6700559	0.873	rs7524025	ENSG00000260088.1	RP11-92G12.3	-9.9	3.69e-22	2.13e-19	-0.38	-0.29	Coronary artery disease;	chr1:200687859	chr1:200669507~200694250:+
BRCA	cis	rs35160687	0.712	rs11674249	ENSG00000273080.1	RP11-301O19.1	-9.9	3.7e-22	2.13e-19	-0.33	-0.29	Night sleep phenotypes;	chr2:86270283	chr2:86195590~86196049:+
BRCA	cis	rs17711722	0.523	rs313812	ENSG00000236529.1	RP13-254B10.1	-9.9	3.71e-22	2.14e-19	-0.33	-0.29	Calcium levels;	chr7:66040056	chr7:65840212~65840596:+
BRCA	cis	rs2439831	0.85	rs28718261	ENSG00000275601.1	AC011330.13	-9.9	3.72e-22	2.15e-19	-0.47	-0.29	Lung cancer in ever smokers;	chr15:43751595	chr15:43642389~43643023:-
BRCA	cis	rs11098499	0.908	rs7695996	ENSG00000245958.5	RP11-33B1.1	-9.9	3.73e-22	2.15e-19	-0.29	-0.29	Corneal astigmatism;	chr4:119400878	chr4:119454791~119552025:+
BRCA	cis	rs17482078	0.918	rs13160231	ENSG00000248734.2	CTD-2260A17.1	9.9	3.77e-22	2.17e-19	0.42	0.29	Behcet's disease;Blood protein levels;	chr5:96818087	chr5:96784777~96785999:+
BRCA	cis	rs6565180	0.962	rs6565183	ENSG00000273724.1	RP11-347C12.12	-9.9	3.79e-22	2.18e-19	-0.34	-0.29	Tonsillectomy;	chr16:30371434	chr16:30336400~30343336:+
BRCA	cis	rs2276314	0.857	rs62101402	ENSG00000278986.1	RP11-723J4.3	-9.9	3.79e-22	2.18e-19	-0.37	-0.29	Endometriosis;Drug-induced torsades de pointes;	chr18:36049472	chr18:35972151~35973916:+
BRCA	cis	rs11098499	0.954	rs2389802	ENSG00000245958.5	RP11-33B1.1	-9.9	3.81e-22	2.19e-19	-0.29	-0.29	Corneal astigmatism;	chr4:119404577	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.954	rs6834796	ENSG00000245958.5	RP11-33B1.1	-9.9	3.84e-22	2.21e-19	-0.29	-0.29	Corneal astigmatism;	chr4:119493538	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.954	rs11734241	ENSG00000245958.5	RP11-33B1.1	-9.9	3.84e-22	2.21e-19	-0.29	-0.29	Corneal astigmatism;	chr4:119495717	chr4:119454791~119552025:+
BRCA	cis	rs875971	0.767	rs12668005	ENSG00000237310.1	GS1-124K5.4	9.9	3.86e-22	2.22e-19	0.31	0.29	Aortic root size;	chr7:66444034	chr7:66493706~66495474:+
BRCA	cis	rs453301	0.686	rs13252797	ENSG00000253893.2	FAM85B	-9.9	3.89e-22	2.24e-19	-0.36	-0.29	Joint mobility (Beighton score);	chr8:9003920	chr8:8167819~8226614:-
BRCA	cis	rs6921919	0.609	rs36018474	ENSG00000216901.1	AL022393.7	9.9	3.9e-22	2.24e-19	0.39	0.29	Autism spectrum disorder or schizophrenia;	chr6:28417752	chr6:28176188~28176674:+
BRCA	cis	rs6921919	0.583	rs13201726	ENSG00000216901.1	AL022393.7	9.9	3.9e-22	2.24e-19	0.39	0.29	Autism spectrum disorder or schizophrenia;	chr6:28417774	chr6:28176188~28176674:+
BRCA	cis	rs228614	0.536	rs223375	ENSG00000246560.2	RP11-10L12.4	9.9	3.9e-22	2.24e-19	0.31	0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102836484	chr4:102828055~102844075:+
BRCA	cis	rs7772486	0.875	rs9376975	ENSG00000235652.6	RP11-545I5.3	9.9	3.92e-22	2.25e-19	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:146034445	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.846	rs9376976	ENSG00000235652.6	RP11-545I5.3	9.9	3.92e-22	2.25e-19	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:146034469	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.875	rs7761033	ENSG00000235652.6	RP11-545I5.3	9.9	3.92e-22	2.25e-19	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:146034970	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.875	rs9403763	ENSG00000235652.6	RP11-545I5.3	9.9	3.92e-22	2.25e-19	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:146036519	chr6:145799409~145886585:+
BRCA	cis	rs228614	0.51	rs223378	ENSG00000246560.2	RP11-10L12.4	9.9	3.92e-22	2.25e-19	0.31	0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102833488	chr4:102828055~102844075:+
BRCA	cis	rs10129255	0.518	rs10150460	ENSG00000211972.2	IGHV3-66	-9.9	3.93e-22	2.26e-19	-0.2	-0.29	Kawasaki disease;	chr14:106677179	chr14:106675017~106675544:-
BRCA	cis	rs11098499	0.954	rs7436506	ENSG00000245958.5	RP11-33B1.1	-9.9	3.94e-22	2.26e-19	-0.29	-0.29	Corneal astigmatism;	chr4:119472614	chr4:119454791~119552025:+
BRCA	cis	rs11105298	0.891	rs12369195	ENSG00000258302.2	RP11-981P6.1	9.9	3.95e-22	2.27e-19	0.34	0.29	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89541195	chr12:89561129~89594878:+
BRCA	cis	rs710216	0.536	rs710222	ENSG00000227533.4	SLC2A1-AS1	9.9	3.96e-22	2.27e-19	0.37	0.29	Red cell distribution width;	chr1:42947982	chr1:42959049~42983358:+
BRCA	cis	rs6921919	0.583	rs6922169	ENSG00000216901.1	AL022393.7	9.9	3.96e-22	2.27e-19	0.39	0.29	Autism spectrum disorder or schizophrenia;	chr6:28415155	chr6:28176188~28176674:+
BRCA	cis	rs6921919	0.559	rs13210866	ENSG00000216901.1	AL022393.7	9.9	3.96e-22	2.27e-19	0.39	0.29	Autism spectrum disorder or schizophrenia;	chr6:28416065	chr6:28176188~28176674:+
BRCA	cis	rs7429990	0.965	rs7430879	ENSG00000229759.1	MRPS18AP1	-9.9	3.97e-22	2.28e-19	-0.33	-0.29	Educational attainment (years of education);	chr3:47997224	chr3:48256350~48256938:-
BRCA	cis	rs733592	1	rs1859440	ENSG00000240399.1	RP1-228P16.1	-9.9	3.97e-22	2.28e-19	-0.32	-0.29	Plateletcrit;	chr12:48033546	chr12:48054813~48055591:-
BRCA	cis	rs11690935	0.632	rs6433323	ENSG00000228389.1	AC068039.4	9.9	3.98e-22	2.28e-19	0.35	0.29	Schizophrenia;	chr2:172008155	chr2:171773482~171775844:+
BRCA	cis	rs875971	0.502	rs1796227	ENSG00000226824.5	RP4-756H11.3	9.9	3.98e-22	2.29e-19	0.41	0.29	Aortic root size;	chr7:66622032	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs778686	ENSG00000237310.1	GS1-124K5.4	9.89	4e-22	2.3e-19	0.31	0.29	Aortic root size;	chr7:66370923	chr7:66493706~66495474:+
BRCA	cis	rs801193	0.569	rs13242290	ENSG00000237310.1	GS1-124K5.4	-9.89	4e-22	2.3e-19	-0.31	-0.29	Aortic root size;	chr7:66656898	chr7:66493706~66495474:+
BRCA	cis	rs6142102	0.517	rs8119076	ENSG00000276073.1	RP5-1125A11.7	-9.89	4.01e-22	2.3e-19	-0.34	-0.29	Skin pigmentation;	chr20:33937909	chr20:33985617~33988989:-
BRCA	cis	rs2276314	0.857	rs28651028	ENSG00000278986.1	RP11-723J4.3	-9.89	4.01e-22	2.3e-19	-0.36	-0.29	Endometriosis;Drug-induced torsades de pointes;	chr18:36058947	chr18:35972151~35973916:+
BRCA	cis	rs7621025	0.5	rs71630059	ENSG00000239213.4	NCK1-AS1	-9.89	4.02e-22	2.31e-19	-0.41	-0.29	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136862769	chr3:136841726~136862054:-
BRCA	cis	rs11673344	0.734	rs2551047	ENSG00000226686.6	LINC01535	9.89	4.03e-22	2.31e-19	0.38	0.29	Obesity-related traits;	chr19:36935174	chr19:37251912~37265535:+
BRCA	cis	rs11673344	0.704	rs551717	ENSG00000226686.6	LINC01535	9.89	4.03e-22	2.31e-19	0.38	0.29	Obesity-related traits;	chr19:36936977	chr19:37251912~37265535:+
BRCA	cis	rs11673344	0.704	rs826290	ENSG00000226686.6	LINC01535	9.89	4.03e-22	2.31e-19	0.38	0.29	Obesity-related traits;	chr19:36937543	chr19:37251912~37265535:+
BRCA	cis	rs11673344	0.67	rs505717	ENSG00000226686.6	LINC01535	9.89	4.03e-22	2.31e-19	0.38	0.29	Obesity-related traits;	chr19:36939414	chr19:37251912~37265535:+
BRCA	cis	rs11673344	0.704	rs544543	ENSG00000226686.6	LINC01535	9.89	4.03e-22	2.31e-19	0.38	0.29	Obesity-related traits;	chr19:36939921	chr19:37251912~37265535:+
BRCA	cis	rs11673344	0.67	rs568654	ENSG00000226686.6	LINC01535	9.89	4.03e-22	2.31e-19	0.38	0.29	Obesity-related traits;	chr19:36940285	chr19:37251912~37265535:+
BRCA	cis	rs6921919	0.525	rs6929825	ENSG00000216901.1	AL022393.7	9.89	4.04e-22	2.32e-19	0.38	0.29	Autism spectrum disorder or schizophrenia;	chr6:28411182	chr6:28176188~28176674:+
BRCA	cis	rs6921919	0.583	rs35599905	ENSG00000216901.1	AL022393.7	9.89	4.04e-22	2.32e-19	0.38	0.29	Autism spectrum disorder or schizophrenia;	chr6:28411886	chr6:28176188~28176674:+
BRCA	cis	rs6921919	0.583	rs1124131	ENSG00000216901.1	AL022393.7	9.89	4.04e-22	2.32e-19	0.38	0.29	Autism spectrum disorder or schizophrenia;	chr6:28412471	chr6:28176188~28176674:+
BRCA	cis	rs6921919	0.583	rs6899389	ENSG00000216901.1	AL022393.7	9.89	4.04e-22	2.32e-19	0.38	0.29	Autism spectrum disorder or schizophrenia;	chr6:28413363	chr6:28176188~28176674:+
BRCA	cis	rs6921919	0.583	rs6922374	ENSG00000216901.1	AL022393.7	9.89	4.04e-22	2.32e-19	0.38	0.29	Autism spectrum disorder or schizophrenia;	chr6:28413495	chr6:28176188~28176674:+
BRCA	cis	rs6921919	0.583	rs6899603	ENSG00000216901.1	AL022393.7	9.89	4.04e-22	2.32e-19	0.38	0.29	Autism spectrum disorder or schizophrenia;	chr6:28413528	chr6:28176188~28176674:+
BRCA	cis	rs6921919	0.583	rs6922429	ENSG00000216901.1	AL022393.7	9.89	4.04e-22	2.32e-19	0.38	0.29	Autism spectrum disorder or schizophrenia;	chr6:28413568	chr6:28176188~28176674:+
BRCA	cis	rs6570726	0.791	rs11759979	ENSG00000235652.6	RP11-545I5.3	9.89	4.05e-22	2.33e-19	0.3	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145597745	chr6:145799409~145886585:+
BRCA	cis	rs8062405	0.755	rs62034358	ENSG00000278665.1	RP11-666O2.4	9.89	4.06e-22	2.33e-19	0.32	0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576276	chr16:28599241~28601881:-
BRCA	cis	rs8062405	0.755	rs12445823	ENSG00000278665.1	RP11-666O2.4	9.89	4.06e-22	2.33e-19	0.32	0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576728	chr16:28599241~28601881:-
BRCA	cis	rs8062405	0.723	rs12445744	ENSG00000278665.1	RP11-666O2.4	9.89	4.06e-22	2.33e-19	0.32	0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28577074	chr16:28599241~28601881:-
BRCA	cis	rs8062405	0.755	rs4787455	ENSG00000278665.1	RP11-666O2.4	9.89	4.06e-22	2.33e-19	0.32	0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28578134	chr16:28599241~28601881:-
BRCA	cis	rs7772486	0.754	rs9373475	ENSG00000235652.6	RP11-545I5.3	9.89	4.06e-22	2.33e-19	0.3	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145805283	chr6:145799409~145886585:+
BRCA	cis	rs875971	0.862	rs778720	ENSG00000237310.1	GS1-124K5.4	-9.89	4.08e-22	2.34e-19	-0.31	-0.29	Aortic root size;	chr7:66381288	chr7:66493706~66495474:+
BRCA	cis	rs8062405	0.755	rs4787457	ENSG00000278665.1	RP11-666O2.4	9.89	4.09e-22	2.34e-19	0.32	0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28544079	chr16:28599241~28601881:-
BRCA	cis	rs858239	0.899	rs10085838	ENSG00000226816.2	AC005082.12	9.89	4.09e-22	2.35e-19	0.35	0.29	Cerebrospinal fluid biomarker levels;	chr7:23258796	chr7:23206013~23208045:+
BRCA	cis	rs11098499	0.954	rs11940028	ENSG00000245958.5	RP11-33B1.1	-9.89	4.1e-22	2.35e-19	-0.29	-0.29	Corneal astigmatism;	chr4:119490752	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.954	rs11935596	ENSG00000245958.5	RP11-33B1.1	-9.89	4.1e-22	2.35e-19	-0.29	-0.29	Corneal astigmatism;	chr4:119491302	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.954	rs12507964	ENSG00000245958.5	RP11-33B1.1	-9.89	4.1e-22	2.35e-19	-0.29	-0.29	Corneal astigmatism;	chr4:119491906	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.909	rs11098530	ENSG00000245958.5	RP11-33B1.1	-9.89	4.1e-22	2.35e-19	-0.29	-0.29	Corneal astigmatism;	chr4:119491999	chr4:119454791~119552025:+
BRCA	cis	rs6570726	0.791	rs6902410	ENSG00000235652.6	RP11-545I5.3	9.89	4.12e-22	2.36e-19	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145584125	chr6:145799409~145886585:+
BRCA	cis	rs35160687	0.712	rs7560886	ENSG00000273080.1	RP11-301O19.1	-9.89	4.13e-22	2.37e-19	-0.33	-0.29	Night sleep phenotypes;	chr2:86265907	chr2:86195590~86196049:+
BRCA	cis	rs8062405	0.964	rs78613234	ENSG00000251417.2	RP11-1348G14.4	-9.89	4.13e-22	2.37e-19	-0.34	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828104	chr16:28802743~28817828:+
BRCA	cis	rs8062405	1	rs62036624	ENSG00000251417.2	RP11-1348G14.4	-9.89	4.13e-22	2.37e-19	-0.34	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828609	chr16:28802743~28817828:+
BRCA	cis	rs6921919	0.583	rs4254981	ENSG00000216901.1	AL022393.7	9.89	4.14e-22	2.37e-19	0.38	0.29	Autism spectrum disorder or schizophrenia;	chr6:28403625	chr6:28176188~28176674:+
BRCA	cis	rs8072100	0.846	rs4264433	ENSG00000228782.6	CTD-2026D20.3	-9.89	4.15e-22	2.38e-19	-0.32	-0.29	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47659909	chr17:47450568~47492492:-
BRCA	cis	rs1823913	0.599	rs2124093	ENSG00000227542.1	AC092614.2	9.89	4.16e-22	2.39e-19	0.35	0.29	Obesity-related traits;	chr2:191288280	chr2:191229165~191246172:-
BRCA	cis	rs6700559	0.683	rs7548530	ENSG00000260088.1	RP11-92G12.3	-9.89	4.21e-22	2.41e-19	-0.38	-0.29	Coronary artery disease;	chr1:200687904	chr1:200669507~200694250:+
BRCA	cis	rs6700559	0.683	rs7526136	ENSG00000260088.1	RP11-92G12.3	-9.89	4.21e-22	2.41e-19	-0.38	-0.29	Coronary artery disease;	chr1:200687911	chr1:200669507~200694250:+
BRCA	cis	rs6700559	0.733	rs7526265	ENSG00000260088.1	RP11-92G12.3	-9.89	4.21e-22	2.41e-19	-0.38	-0.29	Coronary artery disease;	chr1:200687916	chr1:200669507~200694250:+
BRCA	cis	rs11098499	0.954	rs12502423	ENSG00000245958.5	RP11-33B1.1	-9.89	4.22e-22	2.42e-19	-0.29	-0.29	Corneal astigmatism;	chr4:119503017	chr4:119454791~119552025:+
BRCA	cis	rs7945705	0.782	rs2742545	ENSG00000254860.4	TMEM9B-AS1	9.89	4.22e-22	2.42e-19	0.26	0.29	Hemoglobin concentration;	chr11:8862761	chr11:8964675~8977527:+
BRCA	cis	rs7945705	0.84	rs10840136	ENSG00000254860.4	TMEM9B-AS1	9.89	4.22e-22	2.42e-19	0.26	0.29	Hemoglobin concentration;	chr11:8863477	chr11:8964675~8977527:+
BRCA	cis	rs8062405	0.723	rs4788079	ENSG00000278665.1	RP11-666O2.4	9.89	4.23e-22	2.42e-19	0.32	0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548042	chr16:28599241~28601881:-
BRCA	cis	rs4964805	0.58	rs10861097	ENSG00000257681.1	RP11-341G23.4	9.89	4.26e-22	2.44e-19	0.34	0.29	Attention deficit hyperactivity disorder;	chr12:103776696	chr12:103746315~103768858:-
BRCA	cis	rs10129255	0.784	rs7147210	ENSG00000211970.3	IGHV4-61	-9.89	4.27e-22	2.44e-19	-0.22	-0.29	Kawasaki disease;	chr14:106705271	chr14:106639119~106639657:-
BRCA	cis	rs8062405	1	rs62036626	ENSG00000251417.2	RP11-1348G14.4	-9.89	4.28e-22	2.45e-19	-0.34	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28832963	chr16:28802743~28817828:+
BRCA	cis	rs8062405	1	rs62036657	ENSG00000251417.2	RP11-1348G14.4	-9.89	4.28e-22	2.45e-19	-0.34	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28833044	chr16:28802743~28817828:+
BRCA	cis	rs1707322	0.827	rs6694302	ENSG00000280836.1	AL355480.1	-9.89	4.29e-22	2.46e-19	-0.38	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45779973	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.827	rs12125508	ENSG00000280836.1	AL355480.1	-9.89	4.29e-22	2.46e-19	-0.38	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45780338	chr1:45581219~45581321:-
BRCA	cis	rs4835473	0.932	rs10016223	ENSG00000251600.4	RP11-673E1.1	9.89	4.3e-22	2.46e-19	0.34	0.29	Immature fraction of reticulocytes;	chr4:143777429	chr4:143912331~143982454:+
BRCA	cis	rs1707322	0.752	rs6678444	ENSG00000280836.1	AL355480.1	-9.89	4.3e-22	2.46e-19	-0.38	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45764175	chr1:45581219~45581321:-
BRCA	cis	rs7429990	0.965	rs4858887	ENSG00000229759.1	MRPS18AP1	-9.89	4.3e-22	2.46e-19	-0.36	-0.29	Educational attainment (years of education);	chr3:48050527	chr3:48256350~48256938:-
BRCA	cis	rs11673344	0.704	rs1644711	ENSG00000226686.6	LINC01535	9.89	4.32e-22	2.47e-19	0.38	0.29	Obesity-related traits;	chr19:36926420	chr19:37251912~37265535:+
BRCA	cis	rs11673344	0.704	rs485034	ENSG00000226686.6	LINC01535	9.89	4.32e-22	2.47e-19	0.38	0.29	Obesity-related traits;	chr19:36931455	chr19:37251912~37265535:+
BRCA	cis	rs11673344	0.704	rs517110	ENSG00000226686.6	LINC01535	9.89	4.32e-22	2.47e-19	0.38	0.29	Obesity-related traits;	chr19:36931492	chr19:37251912~37265535:+
BRCA	cis	rs1150668	0.796	rs728122	ENSG00000204709.4	LINC01556	9.89	4.33e-22	2.48e-19	0.37	0.29	Pubertal anthropometrics;	chr6:28431347	chr6:28943877~28944537:+
BRCA	cis	rs72772090	0.539	rs56319744	ENSG00000248734.2	CTD-2260A17.1	-9.89	4.35e-22	2.49e-19	-0.49	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96806235	chr5:96784777~96785999:+
BRCA	cis	rs6545883	0.524	rs7561697	ENSG00000271889.1	RP11-493E12.1	-9.89	4.35e-22	2.49e-19	-0.35	-0.29	Tuberculosis;	chr2:61292030	chr2:61151433~61162105:-
BRCA	cis	rs875971	0.862	rs11765791	ENSG00000237310.1	GS1-124K5.4	9.88	4.44e-22	2.54e-19	0.31	0.29	Aortic root size;	chr7:66471587	chr7:66493706~66495474:+
BRCA	cis	rs8062405	1	rs12444171	ENSG00000251417.2	RP11-1348G14.4	-9.88	4.44e-22	2.54e-19	-0.34	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28833930	chr16:28802743~28817828:+
BRCA	cis	rs732716	0.785	rs11666453	ENSG00000267769.1	CTB-50L17.9	-9.88	4.45e-22	2.54e-19	-0.38	-0.29	Mean corpuscular volume;	chr19:4368800	chr19:4454014~4455286:+
BRCA	cis	rs2243480	1	rs34529418	ENSG00000226824.5	RP4-756H11.3	-9.88	4.45e-22	2.55e-19	-0.55	-0.29	Diabetic kidney disease;	chr7:65938222	chr7:66654538~66669855:+
BRCA	cis	rs11098499	0.954	rs11098526	ENSG00000245958.5	RP11-33B1.1	-9.88	4.46e-22	2.55e-19	-0.29	-0.29	Corneal astigmatism;	chr4:119469204	chr4:119454791~119552025:+
BRCA	cis	rs875971	0.825	rs28480509	ENSG00000237310.1	GS1-124K5.4	-9.88	4.46e-22	2.55e-19	-0.31	-0.29	Aortic root size;	chr7:66634237	chr7:66493706~66495474:+
BRCA	cis	rs8062405	1	rs12443881	ENSG00000278665.1	RP11-666O2.4	9.88	4.47e-22	2.55e-19	0.33	0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28830456	chr16:28599241~28601881:-
BRCA	cis	rs1707322	0.717	rs12023439	ENSG00000280836.1	AL355480.1	-9.88	4.47e-22	2.55e-19	-0.38	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45638964	chr1:45581219~45581321:-
BRCA	cis	rs875971	0.862	rs10274883	ENSG00000237310.1	GS1-124K5.4	-9.88	4.47e-22	2.55e-19	-0.31	-0.29	Aortic root size;	chr7:66651104	chr7:66493706~66495474:+
BRCA	cis	rs673078	0.66	rs17619932	ENSG00000275759.1	RP11-131L12.3	-9.88	4.47e-22	2.56e-19	-0.39	-0.29	Glucose homeostasis traits;	chr12:118352228	chr12:118428281~118428870:+
BRCA	cis	rs321358	0.731	rs17459717	ENSG00000271584.1	RP11-89C3.4	9.88	4.52e-22	2.58e-19	0.47	0.29	Body mass index;	chr11:111139862	chr11:111091932~111097357:-
BRCA	cis	rs8062405	1	rs62036622	ENSG00000278665.1	RP11-666O2.4	9.88	4.53e-22	2.59e-19	0.33	0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28825882	chr16:28599241~28601881:-
BRCA	cis	rs12922040	1	rs2075516	ENSG00000263335.1	AF001548.5	9.88	4.56e-22	2.6e-19	0.35	0.29	Serum uric acid levels in response to allopurinol in gout;	chr16:15775668	chr16:15726674~15732993:+
BRCA	cis	rs7772486	0.727	rs10223508	ENSG00000235652.6	RP11-545I5.3	-9.88	4.58e-22	2.62e-19	-0.29	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145964069	chr6:145799409~145886585:+
BRCA	cis	rs10875746	0.624	rs7297298	ENSG00000240399.1	RP1-228P16.1	-9.88	4.6e-22	2.63e-19	-0.4	-0.29	Longevity (90 years and older);	chr12:48278523	chr12:48054813~48055591:-
BRCA	cis	rs7772486	0.875	rs2328712	ENSG00000235652.6	RP11-545I5.3	9.88	4.66e-22	2.66e-19	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:146023427	chr6:145799409~145886585:+
BRCA	cis	rs17711722	0.565	rs4275112	ENSG00000224316.1	RP11-479O9.2	-9.88	4.68e-22	2.67e-19	-0.3	-0.29	Calcium levels;	chr7:65733651	chr7:65773620~65802067:+
BRCA	cis	rs2276314	1	rs4799835	ENSG00000278986.1	RP11-723J4.3	-9.88	4.68e-22	2.67e-19	-0.38	-0.29	Endometriosis;Drug-induced torsades de pointes;	chr18:35991305	chr18:35972151~35973916:+
BRCA	cis	rs8072100	0.967	rs4580230	ENSG00000228782.6	CTD-2026D20.3	9.88	4.7e-22	2.68e-19	0.32	0.29	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47661495	chr17:47450568~47492492:-
BRCA	cis	rs712022	0.872	rs12419860	ENSG00000246225.5	RP11-17A1.3	9.88	4.7e-22	2.68e-19	0.34	0.29	Dialysis-related mortality;	chr11:22824515	chr11:22829380~22945393:+
BRCA	cis	rs10129255	0.833	rs7156689	ENSG00000211970.3	IGHV4-61	-9.88	4.71e-22	2.69e-19	-0.21	-0.29	Kawasaki disease;	chr14:106816039	chr14:106639119~106639657:-
BRCA	cis	rs783540	0.746	rs7165125	ENSG00000278603.1	RP13-608F4.5	-9.88	4.74e-22	2.7e-19	-0.37	-0.29	Schizophrenia;	chr15:82629185	chr15:82472203~82472426:+
BRCA	cis	rs4853012	0.941	rs4852329	ENSG00000257800.1	FNBP1P1	9.88	4.74e-22	2.71e-19	0.34	0.29	Gestational age at birth (maternal effect);	chr2:74127417	chr2:74120680~74123218:+
BRCA	cis	rs227275	0.554	rs223457	ENSG00000246560.2	RP11-10L12.4	9.88	4.75e-22	2.71e-19	0.3	0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102788506	chr4:102828055~102844075:+
BRCA	cis	rs35160687	0.712	rs12988844	ENSG00000273080.1	RP11-301O19.1	-9.88	4.75e-22	2.71e-19	-0.34	-0.29	Night sleep phenotypes;	chr2:86251912	chr2:86195590~86196049:+
BRCA	cis	rs35160687	0.712	rs17438687	ENSG00000273080.1	RP11-301O19.1	-9.88	4.75e-22	2.71e-19	-0.34	-0.29	Night sleep phenotypes;	chr2:86252164	chr2:86195590~86196049:+
BRCA	cis	rs2439831	0.85	rs12442129	ENSG00000275601.1	AC011330.13	-9.88	4.76e-22	2.71e-19	-0.47	-0.29	Lung cancer in ever smokers;	chr15:43763658	chr15:43642389~43643023:-
BRCA	cis	rs6921919	0.609	rs1005127	ENSG00000216901.1	AL022393.7	9.88	4.76e-22	2.72e-19	0.38	0.29	Autism spectrum disorder or schizophrenia;	chr6:28399881	chr6:28176188~28176674:+
BRCA	cis	rs853679	0.515	rs4580862	ENSG00000216901.1	AL022393.7	9.88	4.76e-22	2.72e-19	0.38	0.29	Depression;	chr6:28399886	chr6:28176188~28176674:+
BRCA	cis	rs6921919	0.583	rs4357130	ENSG00000216901.1	AL022393.7	9.88	4.76e-22	2.72e-19	0.38	0.29	Autism spectrum disorder or schizophrenia;	chr6:28399906	chr6:28176188~28176674:+
BRCA	cis	rs875971	0.862	rs13226170	ENSG00000237310.1	GS1-124K5.4	9.88	4.77e-22	2.72e-19	0.31	0.29	Aortic root size;	chr7:66534311	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.862	rs2420611	ENSG00000237310.1	GS1-124K5.4	9.88	4.77e-22	2.72e-19	0.31	0.29	Aortic root size;	chr7:66534333	chr7:66493706~66495474:+
BRCA	cis	rs7772486	0.875	rs2814866	ENSG00000235652.6	RP11-545I5.3	9.88	4.78e-22	2.73e-19	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:146018278	chr6:145799409~145886585:+
BRCA	cis	rs9487094	0.6	rs3799842	ENSG00000260273.1	RP11-425D10.10	9.88	4.79e-22	2.73e-19	0.35	0.29	Height;	chr6:109471826	chr6:109382795~109383666:+
BRCA	cis	rs7811142	0.83	rs6955367	ENSG00000242294.5	STAG3L5P	9.87	4.86e-22	2.77e-19	0.27	0.29	Platelet count;	chr7:100363571	chr7:100336079~100351900:+
BRCA	cis	rs11098499	0.954	rs59394118	ENSG00000245958.5	RP11-33B1.1	-9.87	4.87e-22	2.78e-19	-0.29	-0.29	Corneal astigmatism;	chr4:119374396	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.865	rs9996417	ENSG00000245958.5	RP11-33B1.1	-9.87	4.87e-22	2.78e-19	-0.29	-0.29	Corneal astigmatism;	chr4:119374707	chr4:119454791~119552025:+
BRCA	cis	rs2439831	0.85	rs10163054	ENSG00000275601.1	AC011330.13	-9.87	4.87e-22	2.78e-19	-0.47	-0.29	Lung cancer in ever smokers;	chr15:43755440	chr15:43642389~43643023:-
BRCA	cis	rs6570726	0.791	rs9403730	ENSG00000235652.6	RP11-545I5.3	9.87	4.88e-22	2.78e-19	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145586097	chr6:145799409~145886585:+
BRCA	cis	rs227275	0.531	rs223460	ENSG00000246560.2	RP11-10L12.4	9.87	4.92e-22	2.8e-19	0.31	0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102782903	chr4:102828055~102844075:+
BRCA	cis	rs801193	0.569	rs3846973	ENSG00000237310.1	GS1-124K5.4	-9.87	4.93e-22	2.81e-19	-0.31	-0.29	Aortic root size;	chr7:66655048	chr7:66493706~66495474:+
BRCA	cis	rs801193	0.591	rs721717	ENSG00000237310.1	GS1-124K5.4	-9.87	4.94e-22	2.81e-19	-0.31	-0.29	Aortic root size;	chr7:66665305	chr7:66493706~66495474:+
BRCA	cis	rs673078	0.66	rs117091919	ENSG00000275759.1	RP11-131L12.3	-9.87	4.97e-22	2.83e-19	-0.5	-0.29	Glucose homeostasis traits;	chr12:118273228	chr12:118428281~118428870:+
BRCA	cis	rs673078	0.66	rs7314987	ENSG00000275759.1	RP11-131L12.3	-9.87	4.97e-22	2.83e-19	-0.5	-0.29	Glucose homeostasis traits;	chr12:118274072	chr12:118428281~118428870:+
BRCA	cis	rs801193	0.569	rs2013908	ENSG00000237310.1	GS1-124K5.4	-9.87	4.97e-22	2.83e-19	-0.31	-0.29	Aortic root size;	chr7:66656082	chr7:66493706~66495474:+
BRCA	cis	rs6570726	0.791	rs6570692	ENSG00000235652.6	RP11-545I5.3	9.87	5e-22	2.85e-19	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145583265	chr6:145799409~145886585:+
BRCA	cis	rs1823913	0.561	rs60479498	ENSG00000227542.1	AC092614.2	9.87	5.02e-22	2.86e-19	0.35	0.29	Obesity-related traits;	chr2:191275197	chr2:191229165~191246172:-
BRCA	cis	rs1075265	0.704	rs805402	ENSG00000233266.1	HMGB1P31	9.87	5.02e-22	2.86e-19	0.35	0.29	Chronotype;Morning vs. evening chronotype;	chr2:53889212	chr2:54051334~54051760:+
BRCA	cis	rs58873874	0.737	rs75022277	ENSG00000251405.2	CTB-109A12.1	9.87	5.04e-22	2.87e-19	0.77	0.29	Bipolar disorder (body mass index interaction);	chr5:157454954	chr5:157362615~157460078:-
BRCA	cis	rs7772486	0.727	rs4896843	ENSG00000235652.6	RP11-545I5.3	-9.87	5.06e-22	2.88e-19	-0.3	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145742315	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.764	rs7762562	ENSG00000235652.6	RP11-545I5.3	9.87	5.06e-22	2.88e-19	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145837858	chr6:145799409~145886585:+
BRCA	cis	rs11722779	0.692	rs223414	ENSG00000246560.2	RP11-10L12.4	9.87	5.08e-22	2.89e-19	0.3	0.29	Schizophrenia;	chr4:102811688	chr4:102828055~102844075:+
BRCA	cis	rs858239	0.6	rs7799422	ENSG00000226816.2	AC005082.12	9.87	5.09e-22	2.9e-19	0.34	0.29	Cerebrospinal fluid biomarker levels;	chr7:23088794	chr7:23206013~23208045:+
BRCA	cis	rs6921919	0.583	rs1054372	ENSG00000216901.1	AL022393.7	9.87	5.13e-22	2.92e-19	0.39	0.29	Autism spectrum disorder or schizophrenia;	chr6:28368965	chr6:28176188~28176674:+
BRCA	cis	rs6921919	0.583	rs9468354	ENSG00000216901.1	AL022393.7	9.87	5.13e-22	2.92e-19	0.39	0.29	Autism spectrum disorder or schizophrenia;	chr6:28370024	chr6:28176188~28176674:+
BRCA	cis	rs6921919	0.583	rs7773051	ENSG00000216901.1	AL022393.7	9.87	5.13e-22	2.92e-19	0.39	0.29	Autism spectrum disorder or schizophrenia;	chr6:28372539	chr6:28176188~28176674:+
BRCA	cis	rs6921919	0.583	rs12697938	ENSG00000216901.1	AL022393.7	9.87	5.13e-22	2.92e-19	0.39	0.29	Autism spectrum disorder or schizophrenia;	chr6:28373322	chr6:28176188~28176674:+
BRCA	cis	rs6921919	0.583	rs13437294	ENSG00000216901.1	AL022393.7	9.87	5.13e-22	2.92e-19	0.39	0.29	Autism spectrum disorder or schizophrenia;	chr6:28373758	chr6:28176188~28176674:+
BRCA	cis	rs6921919	0.609	rs9468357	ENSG00000216901.1	AL022393.7	9.87	5.13e-22	2.92e-19	0.39	0.29	Autism spectrum disorder or schizophrenia;	chr6:28374276	chr6:28176188~28176674:+
BRCA	cis	rs6921919	0.583	rs34513104	ENSG00000216901.1	AL022393.7	9.87	5.13e-22	2.92e-19	0.39	0.29	Autism spectrum disorder or schizophrenia;	chr6:28375566	chr6:28176188~28176674:+
BRCA	cis	rs6921919	0.583	rs9461456	ENSG00000216901.1	AL022393.7	9.87	5.13e-22	2.92e-19	0.39	0.29	Autism spectrum disorder or schizophrenia;	chr6:28376039	chr6:28176188~28176674:+
BRCA	cis	rs6921919	0.525	rs9468360	ENSG00000216901.1	AL022393.7	9.87	5.13e-22	2.92e-19	0.39	0.29	Autism spectrum disorder or schizophrenia;	chr6:28376661	chr6:28176188~28176674:+
BRCA	cis	rs6921919	0.583	rs16894021	ENSG00000216901.1	AL022393.7	9.87	5.13e-22	2.92e-19	0.39	0.29	Autism spectrum disorder or schizophrenia;	chr6:28377249	chr6:28176188~28176674:+
BRCA	cis	rs6921919	0.583	rs11751693	ENSG00000216901.1	AL022393.7	9.87	5.13e-22	2.92e-19	0.39	0.29	Autism spectrum disorder or schizophrenia;	chr6:28377306	chr6:28176188~28176674:+
BRCA	cis	rs6921919	0.583	rs7749736	ENSG00000216901.1	AL022393.7	9.87	5.13e-22	2.92e-19	0.39	0.29	Autism spectrum disorder or schizophrenia;	chr6:28378254	chr6:28176188~28176674:+
BRCA	cis	rs6921919	0.525	rs9468361	ENSG00000216901.1	AL022393.7	9.87	5.13e-22	2.92e-19	0.39	0.29	Autism spectrum disorder or schizophrenia;	chr6:28378541	chr6:28176188~28176674:+
BRCA	cis	rs6921919	0.583	rs7775132	ENSG00000216901.1	AL022393.7	9.87	5.13e-22	2.92e-19	0.39	0.29	Autism spectrum disorder or schizophrenia;	chr6:28379236	chr6:28176188~28176674:+
BRCA	cis	rs6921919	0.583	rs3734563	ENSG00000216901.1	AL022393.7	9.87	5.13e-22	2.92e-19	0.39	0.29	Autism spectrum disorder or schizophrenia;	chr6:28381948	chr6:28176188~28176674:+
BRCA	cis	rs6921919	0.583	rs1591913	ENSG00000216901.1	AL022393.7	9.87	5.13e-22	2.92e-19	0.39	0.29	Autism spectrum disorder or schizophrenia;	chr6:28383951	chr6:28176188~28176674:+
BRCA	cis	rs875971	0.798	rs12698522	ENSG00000237310.1	GS1-124K5.4	9.87	5.15e-22	2.93e-19	0.31	0.29	Aortic root size;	chr7:66502354	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.83	rs28714531	ENSG00000237310.1	GS1-124K5.4	9.87	5.15e-22	2.93e-19	0.31	0.29	Aortic root size;	chr7:66503250	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.862	rs12698526	ENSG00000237310.1	GS1-124K5.4	9.87	5.15e-22	2.93e-19	0.31	0.29	Aortic root size;	chr7:66504118	chr7:66493706~66495474:+
BRCA	cis	rs858239	0.899	rs5850	ENSG00000226816.2	AC005082.12	9.87	5.15e-22	2.93e-19	0.35	0.29	Cerebrospinal fluid biomarker levels;	chr7:23274928	chr7:23206013~23208045:+
BRCA	cis	rs732716	0.74	rs62129356	ENSG00000267769.1	CTB-50L17.9	-9.87	5.15e-22	2.93e-19	-0.38	-0.29	Mean corpuscular volume;	chr19:4400317	chr19:4454014~4455286:+
BRCA	cis	rs35160687	0.712	rs2303358	ENSG00000273080.1	RP11-301O19.1	-9.87	5.17e-22	2.94e-19	-0.34	-0.29	Night sleep phenotypes;	chr2:86251541	chr2:86195590~86196049:+
BRCA	cis	rs812925	0.537	rs10208769	ENSG00000271889.1	RP11-493E12.1	-9.87	5.18e-22	2.95e-19	-0.35	-0.29	Immature fraction of reticulocytes;	chr2:61378479	chr2:61151433~61162105:-
BRCA	cis	rs72772090	0.539	rs72773969	ENSG00000248734.2	CTD-2260A17.1	-9.87	5.2e-22	2.95e-19	-0.5	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96809493	chr5:96784777~96785999:+
BRCA	cis	rs7772486	0.846	rs1854901	ENSG00000235652.6	RP11-545I5.3	9.87	5.2e-22	2.95e-19	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:146004549	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.754	rs12199362	ENSG00000235652.6	RP11-545I5.3	9.87	5.2e-22	2.96e-19	0.3	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145797089	chr6:145799409~145886585:+
BRCA	cis	rs1113500	0.614	rs11185243	ENSG00000226822.1	RP11-356N1.2	9.86	5.27e-22	2.99e-19	0.42	0.29	Growth-regulated protein alpha levels;	chr1:108054519	chr1:108071482~108074519:+
BRCA	cis	rs2439831	0.702	rs7171750	ENSG00000275601.1	AC011330.13	-9.86	5.27e-22	2.99e-19	-0.47	-0.29	Lung cancer in ever smokers;	chr15:43733660	chr15:43642389~43643023:-
BRCA	cis	rs4727443	0.899	rs886453	ENSG00000235713.1	RP4-604G5.3	-9.86	5.31e-22	3.02e-19	-0.33	-0.29	Interstitial lung disease;	chr7:99990602	chr7:99992397~99993050:+
BRCA	cis	rs673078	0.607	rs1060964	ENSG00000275759.1	RP11-131L12.3	-9.86	5.32e-22	3.02e-19	-0.42	-0.29	Glucose homeostasis traits;	chr12:118414906	chr12:118428281~118428870:+
BRCA	cis	rs7829975	0.626	rs907183	ENSG00000253893.2	FAM85B	9.86	5.33e-22	3.03e-19	0.37	0.29	Mood instability;	chr8:8872251	chr8:8167819~8226614:-
BRCA	cis	rs875971	0.862	rs7783779	ENSG00000237310.1	GS1-124K5.4	-9.86	5.34e-22	3.03e-19	-0.31	-0.29	Aortic root size;	chr7:66331639	chr7:66493706~66495474:+
BRCA	cis	rs11098499	0.58	rs12509234	ENSG00000245958.5	RP11-33B1.1	-9.86	5.39e-22	3.06e-19	-0.29	-0.29	Corneal astigmatism;	chr4:119398279	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.909	rs10014719	ENSG00000245958.5	RP11-33B1.1	-9.86	5.39e-22	3.06e-19	-0.29	-0.29	Corneal astigmatism;	chr4:119399560	chr4:119454791~119552025:+
BRCA	cis	rs8062405	0.755	rs17640009	ENSG00000278665.1	RP11-666O2.4	9.86	5.4e-22	3.06e-19	0.31	0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28584379	chr16:28599241~28601881:-
BRCA	cis	rs6700559	0.873	rs7542210	ENSG00000260088.1	RP11-92G12.3	-9.86	5.41e-22	3.07e-19	-0.38	-0.29	Coronary artery disease;	chr1:200693087	chr1:200669507~200694250:+
BRCA	cis	rs2019137	0.589	rs7560701	ENSG00000274877.1	RP11-65I12.1	-9.86	5.42e-22	3.08e-19	-0.37	-0.29	Lymphocyte counts;	chr2:113269305	chr2:113237595~113240825:+
BRCA	cis	rs858239	0.899	rs2268745	ENSG00000226816.2	AC005082.12	9.86	5.43e-22	3.08e-19	0.35	0.29	Cerebrospinal fluid biomarker levels;	chr7:23277981	chr7:23206013~23208045:+
BRCA	cis	rs7772486	0.754	rs9497419	ENSG00000235652.6	RP11-545I5.3	9.86	5.44e-22	3.09e-19	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145821473	chr6:145799409~145886585:+
BRCA	cis	rs733592	0.524	rs10875744	ENSG00000240399.1	RP1-228P16.1	9.86	5.44e-22	3.09e-19	0.31	0.29	Plateletcrit;	chr12:48104657	chr12:48054813~48055591:-
BRCA	cis	rs801193	0.569	rs6951302	ENSG00000237310.1	GS1-124K5.4	-9.86	5.44e-22	3.09e-19	-0.31	-0.29	Aortic root size;	chr7:66667525	chr7:66493706~66495474:+
BRCA	cis	rs3779195	0.52	rs17169479	ENSG00000272950.1	RP11-307C18.1	9.86	5.46e-22	3.1e-19	0.48	0.29	Sex hormone-binding globulin levels;	chr7:98238721	chr7:98322853~98323430:+
BRCA	cis	rs11096990	0.634	rs11096988	ENSG00000249207.1	RP11-360F5.1	-9.86	5.46e-22	3.1e-19	-0.35	-0.29	Cognitive function;	chr4:39264081	chr4:39112677~39126818:-
BRCA	cis	rs6570726	0.791	rs621382	ENSG00000235652.6	RP11-545I5.3	9.86	5.47e-22	3.1e-19	0.3	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145478008	chr6:145799409~145886585:+
BRCA	cis	rs8062405	0.755	rs62034350	ENSG00000278665.1	RP11-666O2.4	9.86	5.48e-22	3.11e-19	0.32	0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28550935	chr16:28599241~28601881:-
BRCA	cis	rs1823913	0.599	rs12989203	ENSG00000227542.1	AC092614.2	9.86	5.48e-22	3.11e-19	0.35	0.29	Obesity-related traits;	chr2:191276617	chr2:191229165~191246172:-
BRCA	cis	rs7829975	0.533	rs1039917	ENSG00000253893.2	FAM85B	-9.86	5.53e-22	3.14e-19	-0.37	-0.29	Mood instability;	chr8:8861340	chr8:8167819~8226614:-
BRCA	cis	rs858239	0.601	rs6948469	ENSG00000226816.2	AC005082.12	9.86	5.54e-22	3.14e-19	0.33	0.29	Cerebrospinal fluid biomarker levels;	chr7:23135147	chr7:23206013~23208045:+
BRCA	cis	rs8062405	1	rs56404918	ENSG00000251417.2	RP11-1348G14.4	-9.86	5.54e-22	3.14e-19	-0.34	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835519	chr16:28802743~28817828:+
BRCA	cis	rs8062405	1	rs55719896	ENSG00000251417.2	RP11-1348G14.4	-9.86	5.54e-22	3.14e-19	-0.34	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835545	chr16:28802743~28817828:+
BRCA	cis	rs4964805	0.594	rs10861096	ENSG00000257681.1	RP11-341G23.4	9.86	5.56e-22	3.15e-19	0.34	0.29	Attention deficit hyperactivity disorder;	chr12:103775578	chr12:103746315~103768858:-
BRCA	cis	rs7772486	0.72	rs6931553	ENSG00000235652.6	RP11-545I5.3	-9.86	5.57e-22	3.16e-19	-0.3	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145791212	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.754	rs702306	ENSG00000235652.6	RP11-545I5.3	-9.86	5.58e-22	3.16e-19	-0.3	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145669893	chr6:145799409~145886585:+
BRCA	cis	rs4835473	0.932	rs17018238	ENSG00000251600.4	RP11-673E1.1	-9.86	5.59e-22	3.17e-19	-0.33	-0.29	Immature fraction of reticulocytes;	chr4:143782737	chr4:143912331~143982454:+
BRCA	cis	rs2524005	1	rs2524005	ENSG00000228078.1	HLA-U	-9.86	5.59e-22	3.17e-19	-0.47	-0.29	Bipolar disorder and schizophrenia;	chr6:29931900	chr6:29934101~29934286:+
BRCA	cis	rs801193	0.591	rs4506088	ENSG00000237310.1	GS1-124K5.4	-9.86	5.62e-22	3.18e-19	-0.31	-0.29	Aortic root size;	chr7:66670470	chr7:66493706~66495474:+
BRCA	cis	rs227275	0.554	rs223388	ENSG00000246560.2	RP11-10L12.4	9.86	5.62e-22	3.19e-19	0.3	0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102828287	chr4:102828055~102844075:+
BRCA	cis	rs227275	0.554	rs223386	ENSG00000246560.2	RP11-10L12.4	9.86	5.62e-22	3.19e-19	0.3	0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102829111	chr4:102828055~102844075:+
BRCA	cis	rs227275	0.554	rs223385	ENSG00000246560.2	RP11-10L12.4	9.86	5.62e-22	3.19e-19	0.3	0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102829159	chr4:102828055~102844075:+
BRCA	cis	rs7772486	0.875	rs56181683	ENSG00000235652.6	RP11-545I5.3	-9.86	5.63e-22	3.19e-19	-0.29	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145965484	chr6:145799409~145886585:+
BRCA	cis	rs2243480	1	rs35542501	ENSG00000226824.5	RP4-756H11.3	-9.86	5.67e-22	3.21e-19	-0.55	-0.29	Diabetic kidney disease;	chr7:65966228	chr7:66654538~66669855:+
BRCA	cis	rs2243480	0.708	rs781141	ENSG00000226824.5	RP4-756H11.3	-9.86	5.67e-22	3.21e-19	-0.55	-0.29	Diabetic kidney disease;	chr7:65973566	chr7:66654538~66669855:+
BRCA	cis	rs11105298	0.891	rs10858906	ENSG00000258302.2	RP11-981P6.1	9.86	5.68e-22	3.22e-19	0.34	0.29	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89540697	chr12:89561129~89594878:+
BRCA	cis	rs11673344	0.704	rs571340	ENSG00000226686.6	LINC01535	9.86	5.7e-22	3.23e-19	0.38	0.29	Obesity-related traits;	chr19:36933981	chr19:37251912~37265535:+
BRCA	cis	rs6142102	0.517	rs6059577	ENSG00000276073.1	RP5-1125A11.7	-9.86	5.7e-22	3.23e-19	-0.34	-0.29	Skin pigmentation;	chr20:33939880	chr20:33985617~33988989:-
BRCA	cis	rs8062405	0.755	rs2077031	ENSG00000278665.1	RP11-666O2.4	9.86	5.7e-22	3.23e-19	0.32	0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28591847	chr16:28599241~28601881:-
BRCA	cis	rs11098499	0.954	rs10017543	ENSG00000245958.5	RP11-33B1.1	-9.86	5.71e-22	3.24e-19	-0.29	-0.29	Corneal astigmatism;	chr4:119400265	chr4:119454791~119552025:+
BRCA	cis	rs35160687	0.712	rs4832030	ENSG00000273080.1	RP11-301O19.1	-9.86	5.72e-22	3.24e-19	-0.34	-0.29	Night sleep phenotypes;	chr2:86251746	chr2:86195590~86196049:+
BRCA	cis	rs2243480	1	rs1039664	ENSG00000226824.5	RP4-756H11.3	-9.86	5.74e-22	3.25e-19	-0.55	-0.29	Diabetic kidney disease;	chr7:65984729	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.862	rs801195	ENSG00000237310.1	GS1-124K5.4	-9.86	5.74e-22	3.25e-19	-0.31	-0.29	Aortic root size;	chr7:66561128	chr7:66493706~66495474:+
BRCA	cis	rs1075265	0.568	rs805416	ENSG00000233266.1	HMGB1P31	-9.85	5.75e-22	3.25e-19	-0.35	-0.29	Chronotype;Morning vs. evening chronotype;	chr2:53898121	chr2:54051334~54051760:+
BRCA	cis	rs10129255	0.957	rs11846893	ENSG00000211970.3	IGHV4-61	-9.85	5.81e-22	3.29e-19	-0.2	-0.29	Kawasaki disease;	chr14:106779068	chr14:106639119~106639657:-
BRCA	cis	rs7580658	0.637	rs3902960	ENSG00000236682.1	AC068282.3	-9.85	5.82e-22	3.29e-19	-0.39	-0.29	Protein C levels;	chr2:127230666	chr2:127389130~127400580:+
BRCA	cis	rs733592	1	rs733592	ENSG00000240399.1	RP1-228P16.1	-9.85	5.82e-22	3.3e-19	-0.32	-0.29	Plateletcrit;	chr12:48035993	chr12:48054813~48055591:-
BRCA	cis	rs1823913	0.599	rs55786000	ENSG00000227542.1	AC092614.2	9.85	5.85e-22	3.31e-19	0.35	0.29	Obesity-related traits;	chr2:191284500	chr2:191229165~191246172:-
BRCA	cis	rs6565180	0.888	rs12447833	ENSG00000273724.1	RP11-347C12.12	9.85	5.85e-22	3.31e-19	0.37	0.29	Tonsillectomy;	chr16:30378993	chr16:30336400~30343336:+
BRCA	cis	rs4835473	0.932	rs35164917	ENSG00000251600.4	RP11-673E1.1	9.85	5.86e-22	3.31e-19	0.34	0.29	Immature fraction of reticulocytes;	chr4:143748891	chr4:143912331~143982454:+
BRCA	cis	rs17482078	1	rs17482078	ENSG00000248734.2	CTD-2260A17.1	9.85	5.87e-22	3.32e-19	0.41	0.29	Behcet's disease;Blood protein levels;	chr5:96783162	chr5:96784777~96785999:+
BRCA	cis	rs227275	0.554	rs223395	ENSG00000246560.2	RP11-10L12.4	9.85	5.9e-22	3.34e-19	0.3	0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102823801	chr4:102828055~102844075:+
BRCA	cis	rs7772486	0.875	rs1960885	ENSG00000235652.6	RP11-545I5.3	9.85	5.93e-22	3.35e-19	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:146004794	chr6:145799409~145886585:+
BRCA	cis	rs11096990	0.634	rs6854358	ENSG00000249207.1	RP11-360F5.1	9.85	5.94e-22	3.36e-19	0.34	0.29	Cognitive function;	chr4:39281492	chr4:39112677~39126818:-
BRCA	cis	rs11096990	0.634	rs11736790	ENSG00000249207.1	RP11-360F5.1	-9.85	5.94e-22	3.36e-19	-0.35	-0.29	Cognitive function;	chr4:39254704	chr4:39112677~39126818:-
BRCA	cis	rs228614	0.51	rs223459	ENSG00000246560.2	RP11-10L12.4	9.85	5.96e-22	3.37e-19	0.31	0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102788229	chr4:102828055~102844075:+
BRCA	cis	rs11690935	0.632	rs12052246	ENSG00000228389.1	AC068039.4	-9.85	5.97e-22	3.37e-19	-0.35	-0.29	Schizophrenia;	chr2:172030703	chr2:171773482~171775844:+
BRCA	cis	rs11096990	0.634	rs4975002	ENSG00000249207.1	RP11-360F5.1	9.85	5.98e-22	3.38e-19	0.33	0.29	Cognitive function;	chr4:39286733	chr4:39112677~39126818:-
BRCA	cis	rs1707322	0.721	rs56255771	ENSG00000280836.1	AL355480.1	-9.85	6e-22	3.39e-19	-0.37	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45758647	chr1:45581219~45581321:-
BRCA	cis	rs6844153	0.68	rs6833053	ENSG00000240005.4	RP11-293A21.1	-9.85	6.04e-22	3.41e-19	-0.39	-0.29	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26870838	chr4:26859806~26860599:-
BRCA	cis	rs1823913	0.599	rs34100174	ENSG00000227542.1	AC092614.2	9.85	6.07e-22	3.43e-19	0.35	0.29	Obesity-related traits;	chr2:191283579	chr2:191229165~191246172:-
BRCA	cis	rs875971	0.545	rs1638735	ENSG00000226824.5	RP4-756H11.3	-9.85	6.09e-22	3.44e-19	-0.4	-0.29	Aortic root size;	chr7:66630751	chr7:66654538~66669855:+
BRCA	cis	rs2439831	0.85	rs12441127	ENSG00000249839.1	AC011330.5	-9.85	6.1e-22	3.44e-19	-0.5	-0.29	Lung cancer in ever smokers;	chr15:43728977	chr15:43663654~43684339:-
BRCA	cis	rs875971	0.862	rs801194	ENSG00000237310.1	GS1-124K5.4	-9.85	6.12e-22	3.45e-19	-0.31	-0.29	Aortic root size;	chr7:66563508	chr7:66493706~66495474:+
BRCA	cis	rs858239	0.6	rs2003555	ENSG00000226816.2	AC005082.12	9.85	6.13e-22	3.46e-19	0.34	0.29	Cerebrospinal fluid biomarker levels;	chr7:23083296	chr7:23206013~23208045:+
BRCA	cis	rs858239	0.6	rs7784929	ENSG00000226816.2	AC005082.12	9.85	6.13e-22	3.46e-19	0.34	0.29	Cerebrospinal fluid biomarker levels;	chr7:23084658	chr7:23206013~23208045:+
BRCA	cis	rs11096990	0.634	rs6531703	ENSG00000249207.1	RP11-360F5.1	9.85	6.14e-22	3.47e-19	0.33	0.29	Cognitive function;	chr4:39281786	chr4:39112677~39126818:-
BRCA	cis	rs6570726	0.791	rs7755253	ENSG00000235652.6	RP11-545I5.3	9.85	6.2e-22	3.5e-19	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145537757	chr6:145799409~145886585:+
BRCA	cis	rs2412819	0.571	rs12443084	ENSG00000249839.1	AC011330.5	9.85	6.23e-22	3.52e-19	0.4	0.29	Lung cancer;	chr15:43748767	chr15:43663654~43684339:-
BRCA	cis	rs11098499	0.954	rs3733519	ENSG00000245958.5	RP11-33B1.1	-9.85	6.25e-22	3.53e-19	-0.29	-0.29	Corneal astigmatism;	chr4:119502293	chr4:119454791~119552025:+
BRCA	cis	rs11971779	0.68	rs2355786	ENSG00000273391.1	RP11-634H22.1	-9.85	6.26e-22	3.53e-19	-0.29	-0.29	Diisocyanate-induced asthma;	chr7:139380876	chr7:139359032~139359566:-
BRCA	cis	rs858239	0.6	rs10256359	ENSG00000226816.2	AC005082.12	9.85	6.26e-22	3.53e-19	0.34	0.29	Cerebrospinal fluid biomarker levels;	chr7:23084258	chr7:23206013~23208045:+
BRCA	cis	rs2412819	0.571	rs10163069	ENSG00000249839.1	AC011330.5	9.85	6.29e-22	3.55e-19	0.4	0.29	Lung cancer;	chr15:43755372	chr15:43663654~43684339:-
BRCA	cis	rs875971	0.545	rs2420612	ENSG00000226824.5	RP4-756H11.3	-9.84	6.3e-22	3.56e-19	-0.41	-0.29	Aortic root size;	chr7:66536825	chr7:66654538~66669855:+
BRCA	cis	rs11105298	0.891	rs11105287	ENSG00000258302.2	RP11-981P6.1	9.84	6.33e-22	3.57e-19	0.32	0.29	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89435693	chr12:89561129~89594878:+
BRCA	cis	rs72772090	0.539	rs114006288	ENSG00000248734.2	CTD-2260A17.1	-9.84	6.34e-22	3.58e-19	-0.48	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96782300	chr5:96784777~96785999:+
BRCA	cis	rs72772090	0.539	rs72773932	ENSG00000248734.2	CTD-2260A17.1	-9.84	6.34e-22	3.58e-19	-0.48	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96782444	chr5:96784777~96785999:+
BRCA	cis	rs72772090	0.539	rs11750934	ENSG00000248734.2	CTD-2260A17.1	-9.84	6.34e-22	3.58e-19	-0.48	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96782783	chr5:96784777~96785999:+
BRCA	cis	rs72772090	0.539	rs11738810	ENSG00000248734.2	CTD-2260A17.1	-9.84	6.34e-22	3.58e-19	-0.48	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96783351	chr5:96784777~96785999:+
BRCA	cis	rs72772090	0.539	rs11748519	ENSG00000248734.2	CTD-2260A17.1	-9.84	6.34e-22	3.58e-19	-0.48	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96783624	chr5:96784777~96785999:+
BRCA	cis	rs875971	0.862	rs35378740	ENSG00000237310.1	GS1-124K5.4	9.84	6.37e-22	3.59e-19	0.31	0.29	Aortic root size;	chr7:66522725	chr7:66493706~66495474:+
BRCA	cis	rs6844153	0.627	rs11730235	ENSG00000240005.4	RP11-293A21.1	-9.84	6.4e-22	3.61e-19	-0.39	-0.29	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26922822	chr4:26859806~26860599:-
BRCA	cis	rs7772486	0.79	rs6926657	ENSG00000235652.6	RP11-545I5.3	-9.84	6.42e-22	3.62e-19	-0.3	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145934658	chr6:145799409~145886585:+
BRCA	cis	rs8062405	0.755	rs7186573	ENSG00000278665.1	RP11-666O2.4	9.84	6.46e-22	3.64e-19	0.31	0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576068	chr16:28599241~28601881:-
BRCA	cis	rs4713118	0.662	rs149901	ENSG00000220721.1	OR1F12	9.84	6.57e-22	3.7e-19	0.38	0.29	Parkinson's disease;	chr6:27997725	chr6:28073316~28074233:+
BRCA	cis	rs1823913	0.599	rs34262638	ENSG00000227542.1	AC092614.2	9.84	6.59e-22	3.71e-19	0.35	0.29	Obesity-related traits;	chr2:191279442	chr2:191229165~191246172:-
BRCA	cis	rs228614	0.51	rs223447	ENSG00000246560.2	RP11-10L12.4	9.84	6.59e-22	3.71e-19	0.31	0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102792202	chr4:102828055~102844075:+
BRCA	cis	rs58873874	0.737	rs79339674	ENSG00000251405.2	CTB-109A12.1	9.84	6.6e-22	3.71e-19	0.77	0.29	Bipolar disorder (body mass index interaction);	chr5:157464318	chr5:157362615~157460078:-
BRCA	cis	rs6700559	0.873	rs7526367	ENSG00000260088.1	RP11-92G12.3	-9.84	6.7e-22	3.77e-19	-0.38	-0.29	Coronary artery disease;	chr1:200688025	chr1:200669507~200694250:+
BRCA	cis	rs875971	0.862	rs2024192	ENSG00000237310.1	GS1-124K5.4	-9.84	6.7e-22	3.77e-19	-0.31	-0.29	Aortic root size;	chr7:66576460	chr7:66493706~66495474:+
BRCA	cis	rs30380	0.69	rs27432	ENSG00000248734.2	CTD-2260A17.1	9.84	6.7e-22	3.77e-19	0.33	0.29	Cerebrospinal fluid biomarker levels;	chr5:96783569	chr5:96784777~96785999:+
BRCA	cis	rs858239	0.537	rs6942981	ENSG00000226816.2	AC005082.12	9.84	6.75e-22	3.8e-19	0.34	0.29	Cerebrospinal fluid biomarker levels;	chr7:23191929	chr7:23206013~23208045:+
BRCA	cis	rs4862750	0.914	rs6553028	ENSG00000250971.1	RP11-696F12.1	9.84	6.77e-22	3.81e-19	0.32	0.29	Lobe attachment (rater-scored or self-reported);	chr4:186954892	chr4:187060099~187060930:+
BRCA	cis	rs1823913	0.599	rs17346412	ENSG00000227542.1	AC092614.2	9.84	6.78e-22	3.82e-19	0.35	0.29	Obesity-related traits;	chr2:191285902	chr2:191229165~191246172:-
BRCA	cis	rs1823913	0.599	rs17412239	ENSG00000227542.1	AC092614.2	9.84	6.78e-22	3.82e-19	0.35	0.29	Obesity-related traits;	chr2:191285937	chr2:191229165~191246172:-
BRCA	cis	rs1823913	0.599	rs35098152	ENSG00000227542.1	AC092614.2	9.84	6.78e-22	3.82e-19	0.35	0.29	Obesity-related traits;	chr2:191286658	chr2:191229165~191246172:-
BRCA	cis	rs1075265	0.729	rs7571086	ENSG00000233266.1	HMGB1P31	9.84	6.79e-22	3.82e-19	0.35	0.29	Chronotype;Morning vs. evening chronotype;	chr2:54007899	chr2:54051334~54051760:+
BRCA	cis	rs875971	0.825	rs801202	ENSG00000237310.1	GS1-124K5.4	-9.84	6.79e-22	3.82e-19	-0.31	-0.29	Aortic root size;	chr7:66558942	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.767	rs61348003	ENSG00000237310.1	GS1-124K5.4	9.84	6.79e-22	3.82e-19	0.31	0.29	Aortic root size;	chr7:66540947	chr7:66493706~66495474:+
BRCA	cis	rs227275	0.588	rs223458	ENSG00000246560.2	RP11-10L12.4	9.84	6.8e-22	3.83e-19	0.31	0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102788414	chr4:102828055~102844075:+
BRCA	cis	rs72772090	0.539	rs72773942	ENSG00000248734.2	CTD-2260A17.1	-9.84	6.85e-22	3.85e-19	-0.48	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96787663	chr5:96784777~96785999:+
BRCA	cis	rs732716	0.785	rs55660045	ENSG00000267769.1	CTB-50L17.9	-9.84	6.89e-22	3.87e-19	-0.37	-0.29	Mean corpuscular volume;	chr19:4425308	chr19:4454014~4455286:+
BRCA	cis	rs7772486	0.79	rs2265917	ENSG00000235652.6	RP11-545I5.3	9.83	6.9e-22	3.88e-19	0.3	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145891149	chr6:145799409~145886585:+
BRCA	cis	rs6565180	0.926	rs12446288	ENSG00000273724.1	RP11-347C12.12	9.83	6.91e-22	3.89e-19	0.34	0.29	Tonsillectomy;	chr16:30377388	chr16:30336400~30343336:+
BRCA	cis	rs6570726	0.791	rs9322029	ENSG00000235652.6	RP11-545I5.3	9.83	6.93e-22	3.9e-19	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145585547	chr6:145799409~145886585:+
BRCA	cis	rs228614	0.51	rs223443	ENSG00000246560.2	RP11-10L12.4	9.83	6.94e-22	3.9e-19	0.31	0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102793629	chr4:102828055~102844075:+
BRCA	cis	rs8062405	0.964	rs62036614	ENSG00000278665.1	RP11-666O2.4	9.83	6.98e-22	3.92e-19	0.33	0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28813364	chr16:28599241~28601881:-
BRCA	cis	rs875971	0.545	rs6979636	ENSG00000226824.5	RP4-756H11.3	-9.83	6.98e-22	3.93e-19	-0.4	-0.29	Aortic root size;	chr7:66276638	chr7:66654538~66669855:+
BRCA	cis	rs11105298	0.891	rs4842661	ENSG00000258302.2	RP11-981P6.1	9.83	7.01e-22	3.94e-19	0.35	0.29	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89536622	chr12:89561129~89594878:+
BRCA	cis	rs58873874	0.737	rs76634949	ENSG00000251405.2	CTB-109A12.1	9.83	7.02e-22	3.94e-19	0.77	0.29	Bipolar disorder (body mass index interaction);	chr5:157463391	chr5:157362615~157460078:-
BRCA	cis	rs8062405	1	rs55830740	ENSG00000251417.2	RP11-1348G14.4	-9.83	7.04e-22	3.96e-19	-0.34	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835828	chr16:28802743~28817828:+
BRCA	cis	rs2439831	0.85	rs7168158	ENSG00000275601.1	AC011330.13	-9.83	7.13e-22	4.01e-19	-0.46	-0.29	Lung cancer in ever smokers;	chr15:43758178	chr15:43642389~43643023:-
BRCA	cis	rs227275	0.556	rs223449	ENSG00000246560.2	RP11-10L12.4	9.83	7.15e-22	4.02e-19	0.31	0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102791180	chr4:102828055~102844075:+
BRCA	cis	rs228614	0.51	rs223446	ENSG00000246560.2	RP11-10L12.4	9.83	7.15e-22	4.02e-19	0.31	0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102793025	chr4:102828055~102844075:+
BRCA	cis	rs7772486	0.754	rs864148	ENSG00000235652.6	RP11-545I5.3	-9.83	7.15e-22	4.02e-19	-0.29	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145655539	chr6:145799409~145886585:+
BRCA	cis	rs875971	0.545	rs10261710	ENSG00000226824.5	RP4-756H11.3	-9.83	7.16e-22	4.02e-19	-0.42	-0.29	Aortic root size;	chr7:66249202	chr7:66654538~66669855:+
BRCA	cis	rs1113500	0.614	rs6677839	ENSG00000226822.1	RP11-356N1.2	-9.83	7.19e-22	4.04e-19	-0.42	-0.29	Growth-regulated protein alpha levels;	chr1:108056719	chr1:108071482~108074519:+
BRCA	cis	rs11971779	0.618	rs10085814	ENSG00000273391.1	RP11-634H22.1	9.83	7.23e-22	4.06e-19	0.29	0.29	Diisocyanate-induced asthma;	chr7:139379343	chr7:139359032~139359566:-
BRCA	cis	rs875971	0.862	rs778734	ENSG00000237310.1	GS1-124K5.4	9.83	7.27e-22	4.08e-19	0.31	0.29	Aortic root size;	chr7:66349862	chr7:66493706~66495474:+
BRCA	cis	rs6565180	0.926	rs8046445	ENSG00000273724.1	RP11-347C12.12	-9.83	7.28e-22	4.09e-19	-0.34	-0.29	Tonsillectomy;	chr16:30374941	chr16:30336400~30343336:+
BRCA	cis	rs35160687	0.712	rs4832031	ENSG00000273080.1	RP11-301O19.1	9.83	7.3e-22	4.1e-19	0.34	0.29	Night sleep phenotypes;	chr2:86251857	chr2:86195590~86196049:+
BRCA	cis	rs1823913	0.599	rs35150635	ENSG00000227542.1	AC092614.2	9.83	7.31e-22	4.11e-19	0.35	0.29	Obesity-related traits;	chr2:191287303	chr2:191229165~191246172:-
BRCA	cis	rs6545883	0.524	rs2694618	ENSG00000271889.1	RP11-493E12.1	9.83	7.33e-22	4.11e-19	0.35	0.29	Tuberculosis;	chr2:61309849	chr2:61151433~61162105:-
BRCA	cis	rs2243480	1	rs11538349	ENSG00000226824.5	RP4-756H11.3	-9.83	7.36e-22	4.13e-19	-0.55	-0.29	Diabetic kidney disease;	chr7:65956884	chr7:66654538~66669855:+
BRCA	cis	rs748404	0.723	rs11853991	ENSG00000249839.1	AC011330.5	-9.83	7.4e-22	4.15e-19	-0.35	-0.29	Lung cancer;	chr15:43265351	chr15:43663654~43684339:-
BRCA	cis	rs11098499	0.863	rs12508173	ENSG00000245958.5	RP11-33B1.1	-9.83	7.42e-22	4.17e-19	-0.29	-0.29	Corneal astigmatism;	chr4:119397371	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.908	rs12504149	ENSG00000245958.5	RP11-33B1.1	-9.83	7.42e-22	4.17e-19	-0.29	-0.29	Corneal astigmatism;	chr4:119397422	chr4:119454791~119552025:+
BRCA	cis	rs875971	0.862	rs13232191	ENSG00000237310.1	GS1-124K5.4	9.83	7.43e-22	4.17e-19	0.31	0.29	Aortic root size;	chr7:66521661	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.862	rs10950043	ENSG00000237310.1	GS1-124K5.4	9.83	7.43e-22	4.17e-19	0.31	0.29	Aortic root size;	chr7:66523623	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.862	rs17747530	ENSG00000237310.1	GS1-124K5.4	9.83	7.43e-22	4.17e-19	0.31	0.29	Aortic root size;	chr7:66529742	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.862	rs13536	ENSG00000237310.1	GS1-124K5.4	-9.83	7.43e-22	4.17e-19	-0.31	-0.29	Aortic root size;	chr7:66554203	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.862	rs801209	ENSG00000237310.1	GS1-124K5.4	-9.83	7.43e-22	4.17e-19	-0.31	-0.29	Aortic root size;	chr7:66554403	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.862	rs801206	ENSG00000237310.1	GS1-124K5.4	-9.83	7.43e-22	4.17e-19	-0.31	-0.29	Aortic root size;	chr7:66556979	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.862	rs801204	ENSG00000237310.1	GS1-124K5.4	-9.83	7.43e-22	4.17e-19	-0.31	-0.29	Aortic root size;	chr7:66557934	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.862	rs801203	ENSG00000237310.1	GS1-124K5.4	-9.83	7.43e-22	4.17e-19	-0.31	-0.29	Aortic root size;	chr7:66558025	chr7:66493706~66495474:+
BRCA	cis	rs1075265	0.626	rs805412	ENSG00000233266.1	HMGB1P31	9.83	7.45e-22	4.18e-19	0.35	0.29	Chronotype;Morning vs. evening chronotype;	chr2:53893683	chr2:54051334~54051760:+
BRCA	cis	rs4862750	0.914	rs11945845	ENSG00000250971.1	RP11-696F12.1	9.83	7.45e-22	4.18e-19	0.31	0.29	Lobe attachment (rater-scored or self-reported);	chr4:186952982	chr4:187060099~187060930:+
BRCA	cis	rs2153535	0.606	rs11243253	ENSG00000230939.1	RP11-314C16.1	9.83	7.49e-22	4.2e-19	0.34	0.29	Motion sickness;	chr6:8379960	chr6:8784178~8785445:+
BRCA	cis	rs228614	0.51	rs223470	ENSG00000246560.2	RP11-10L12.4	9.83	7.51e-22	4.21e-19	0.3	0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102778004	chr4:102828055~102844075:+
BRCA	cis	rs875971	0.545	rs4718325	ENSG00000226824.5	RP4-756H11.3	-9.83	7.53e-22	4.22e-19	-0.41	-0.29	Aortic root size;	chr7:66215323	chr7:66654538~66669855:+
BRCA	cis	rs228614	0.51	rs223465	ENSG00000246560.2	RP11-10L12.4	9.82	7.56e-22	4.24e-19	0.3	0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102780174	chr4:102828055~102844075:+
BRCA	cis	rs228614	0.51	rs223464	ENSG00000246560.2	RP11-10L12.4	9.82	7.56e-22	4.24e-19	0.3	0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102780603	chr4:102828055~102844075:+
BRCA	cis	rs673078	0.66	rs61945217	ENSG00000275759.1	RP11-131L12.3	-9.82	7.56e-22	4.24e-19	-0.5	-0.29	Glucose homeostasis traits;	chr12:118261194	chr12:118428281~118428870:+
BRCA	cis	rs8062405	0.754	rs28410083	ENSG00000259982.1	CDC37P1	-9.82	7.59e-22	4.25e-19	-0.36	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620039	chr16:28700294~28701540:-
BRCA	cis	rs8062405	0.789	rs1968751	ENSG00000259982.1	CDC37P1	-9.82	7.59e-22	4.25e-19	-0.36	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620438	chr16:28700294~28701540:-
BRCA	cis	rs80285556	0.51	rs75463146	ENSG00000161643.11	SIGLEC16	9.82	7.59e-22	4.26e-19	0.79	0.29	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:49989087	chr19:49969673~49975814:+
BRCA	cis	rs80285556	1	rs80202648	ENSG00000161643.11	SIGLEC16	9.82	7.59e-22	4.26e-19	0.79	0.29	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:49991129	chr19:49969673~49975814:+
BRCA	cis	rs35160687	0.623	rs718292	ENSG00000273080.1	RP11-301O19.1	9.82	7.59e-22	4.26e-19	0.35	0.29	Night sleep phenotypes;	chr2:86246617	chr2:86195590~86196049:+
BRCA	cis	rs7772486	0.79	rs6917482	ENSG00000235652.6	RP11-545I5.3	-9.82	7.59e-22	4.26e-19	-0.3	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145922445	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.754	rs4566902	ENSG00000235652.6	RP11-545I5.3	-9.82	7.59e-22	4.26e-19	-0.3	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145922992	chr6:145799409~145886585:+
BRCA	cis	rs7945705	0.818	rs2653613	ENSG00000254860.4	TMEM9B-AS1	9.82	7.6e-22	4.26e-19	0.26	0.29	Hemoglobin concentration;	chr11:8857558	chr11:8964675~8977527:+
BRCA	cis	rs2243480	0.803	rs34804747	ENSG00000226824.5	RP4-756H11.3	-9.82	7.62e-22	4.27e-19	-0.55	-0.29	Diabetic kidney disease;	chr7:65947955	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs59794892	ENSG00000226824.5	RP4-756H11.3	-9.82	7.62e-22	4.27e-19	-0.55	-0.29	Diabetic kidney disease;	chr7:65950886	chr7:66654538~66669855:+
BRCA	cis	rs2243480	0.803	rs36004293	ENSG00000226824.5	RP4-756H11.3	-9.82	7.62e-22	4.27e-19	-0.55	-0.29	Diabetic kidney disease;	chr7:65951525	chr7:66654538~66669855:+
BRCA	cis	rs2243480	0.803	rs35268390	ENSG00000226824.5	RP4-756H11.3	-9.82	7.62e-22	4.27e-19	-0.55	-0.29	Diabetic kidney disease;	chr7:65951549	chr7:66654538~66669855:+
BRCA	cis	rs4727443	1	rs6974373	ENSG00000235713.1	RP4-604G5.3	-9.82	7.62e-22	4.27e-19	-0.33	-0.29	Interstitial lung disease;	chr7:99993270	chr7:99992397~99993050:+
BRCA	cis	rs228614	0.51	rs223468	ENSG00000246560.2	RP11-10L12.4	9.82	7.67e-22	4.3e-19	0.3	0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102779265	chr4:102828055~102844075:+
BRCA	cis	rs7773456	0.576	rs4140624	ENSG00000228412.5	RP4-625H18.2	-9.82	7.68e-22	4.3e-19	-0.42	-0.29	Lupus nephritis in systemic lupus erythematosus;	chr6:19818329	chr6:19802164~19804752:-
BRCA	cis	rs8091660	0.929	rs4939780	ENSG00000278983.1	RP11-426J5.3	9.82	7.71e-22	4.32e-19	0.34	0.29	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48568873	chr18:48564795~48568342:+
BRCA	cis	rs801193	0.569	rs881285	ENSG00000237310.1	GS1-124K5.4	-9.82	7.77e-22	4.35e-19	-0.31	-0.29	Aortic root size;	chr7:66654433	chr7:66493706~66495474:+
BRCA	cis	rs1823913	0.599	rs2168166	ENSG00000227542.1	AC092614.2	9.82	7.78e-22	4.36e-19	0.35	0.29	Obesity-related traits;	chr2:191288063	chr2:191229165~191246172:-
BRCA	cis	rs228614	0.51	rs223463	ENSG00000246560.2	RP11-10L12.4	9.82	7.78e-22	4.36e-19	0.31	0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102780620	chr4:102828055~102844075:+
BRCA	cis	rs1062177	0.855	rs6892117	ENSG00000213433.5	RPLP1P6	9.82	7.79e-22	4.36e-19	0.34	0.29	Preschool internalizing problems;	chr5:151885424	chr5:151765859~151766378:-
BRCA	cis	rs11971779	0.68	rs7795520	ENSG00000273391.1	RP11-634H22.1	9.82	7.8e-22	4.37e-19	0.28	0.29	Diisocyanate-induced asthma;	chr7:139394461	chr7:139359032~139359566:-
BRCA	cis	rs2041895	0.527	rs10861681	ENSG00000260329.1	RP11-412D9.4	-9.82	7.82e-22	4.38e-19	-0.36	-0.29	Glaucoma (low intraocular pressure);	chr12:106940484	chr12:106954029~106955497:-
BRCA	cis	rs11723261	0.582	rs4582104	ENSG00000275426.1	CH17-262A2.1	9.82	7.86e-22	4.4e-19	0.39	0.29	Immune response to smallpox vaccine (IL-6);	chr4:143160	chr4:149738~150317:+
BRCA	cis	rs2404602	0.532	rs206205	ENSG00000259422.1	RP11-593F23.1	9.82	7.96e-22	4.46e-19	0.35	0.29	Blood metabolite levels;	chr15:76443750	chr15:76174891~76181486:-
BRCA	cis	rs7429990	0.965	rs7430913	ENSG00000229759.1	MRPS18AP1	-9.82	7.97e-22	4.46e-19	-0.33	-0.29	Educational attainment (years of education);	chr3:47990867	chr3:48256350~48256938:-
BRCA	cis	rs7772486	0.79	rs4435956	ENSG00000235652.6	RP11-545I5.3	-9.82	8e-22	4.48e-19	-0.3	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145911267	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.79	rs6926076	ENSG00000235652.6	RP11-545I5.3	-9.82	8e-22	4.48e-19	-0.3	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145911668	chr6:145799409~145886585:+
BRCA	cis	rs1122900	1	rs1122900	ENSG00000250155.1	CTD-2353F22.1	9.82	8e-22	4.48e-19	0.33	0.29	Aggressive periodontitis;	chr5:36689079	chr5:36666214~36725195:-
BRCA	cis	rs720475	1	rs720475	ENSG00000204959.4	ARHGEF34P	-9.82	8.01e-22	4.48e-19	-0.38	-0.29	Breast cancer;	chr7:144377836	chr7:144272445~144286966:-
BRCA	cis	rs7829975	0.606	rs6422352	ENSG00000253893.2	FAM85B	9.82	8.03e-22	4.49e-19	0.36	0.29	Mood instability;	chr8:8936683	chr8:8167819~8226614:-
BRCA	cis	rs17482078	0.879	rs10050860	ENSG00000248734.2	CTD-2260A17.1	-9.82	8.03e-22	4.5e-19	-0.4	-0.29	Behcet's disease;Blood protein levels;	chr5:96786506	chr5:96784777~96785999:+
BRCA	cis	rs12468226	1	rs76528043	ENSG00000273456.1	RP11-686O6.2	9.82	8.03e-22	4.5e-19	0.44	0.29	Urate levels;	chr2:202466116	chr2:202374932~202375604:-
BRCA	cis	rs12468226	1	rs12468226	ENSG00000273456.1	RP11-686O6.2	9.82	8.03e-22	4.5e-19	0.44	0.29	Urate levels;	chr2:202472278	chr2:202374932~202375604:-
BRCA	cis	rs6570726	0.791	rs446362	ENSG00000235652.6	RP11-545I5.3	9.82	8.04e-22	4.5e-19	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145557580	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.791	rs414600	ENSG00000235652.6	RP11-545I5.3	9.82	8.04e-22	4.5e-19	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145558470	chr6:145799409~145886585:+
BRCA	cis	rs858239	0.541	rs4624924	ENSG00000226816.2	AC005082.12	9.82	8.05e-22	4.51e-19	0.33	0.29	Cerebrospinal fluid biomarker levels;	chr7:23129224	chr7:23206013~23208045:+
BRCA	cis	rs812925	0.537	rs10865324	ENSG00000271889.1	RP11-493E12.1	-9.82	8.06e-22	4.51e-19	-0.35	-0.29	Immature fraction of reticulocytes;	chr2:61394172	chr2:61151433~61162105:-
BRCA	cis	rs6570726	0.791	rs440477	ENSG00000235652.6	RP11-545I5.3	9.82	8.1e-22	4.53e-19	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145533052	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.791	rs385729	ENSG00000235652.6	RP11-545I5.3	9.82	8.1e-22	4.53e-19	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145534329	chr6:145799409~145886585:+
BRCA	cis	rs1707322	0.785	rs10890348	ENSG00000280836.1	AL355480.1	-9.82	8.13e-22	4.55e-19	-0.38	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45776751	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.752	rs7541962	ENSG00000280836.1	AL355480.1	-9.82	8.17e-22	4.57e-19	-0.38	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45769445	chr1:45581219~45581321:-
BRCA	cis	rs858239	0.6	rs1468592	ENSG00000226816.2	AC005082.12	-9.82	8.18e-22	4.57e-19	-0.33	-0.29	Cerebrospinal fluid biomarker levels;	chr7:23101028	chr7:23206013~23208045:+
BRCA	cis	rs7772486	0.79	rs9399571	ENSG00000235652.6	RP11-545I5.3	-9.82	8.2e-22	4.58e-19	-0.3	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145960925	chr6:145799409~145886585:+
BRCA	cis	rs858239	0.537	rs6955115	ENSG00000226816.2	AC005082.12	9.82	8.21e-22	4.59e-19	0.34	0.29	Cerebrospinal fluid biomarker levels;	chr7:23187525	chr7:23206013~23208045:+
BRCA	cis	rs875971	0.755	rs10228885	ENSG00000237310.1	GS1-124K5.4	-9.82	8.22e-22	4.6e-19	-0.31	-0.29	Aortic root size;	chr7:66315542	chr7:66493706~66495474:+
BRCA	cis	rs2439831	0.85	rs10438303	ENSG00000249839.1	AC011330.5	-9.82	8.22e-22	4.6e-19	-0.5	-0.29	Lung cancer in ever smokers;	chr15:43724219	chr15:43663654~43684339:-
BRCA	cis	rs7712401	0.601	rs246285	ENSG00000263432.2	RN7SL689P	-9.82	8.23e-22	4.6e-19	-0.36	-0.29	Mean platelet volume;	chr5:122909273	chr5:123022487~123022783:-
BRCA	cis	rs7772486	0.79	rs2249386	ENSG00000235652.6	RP11-545I5.3	9.82	8.24e-22	4.6e-19	0.3	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145865475	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.818	rs412350	ENSG00000235652.6	RP11-545I5.3	9.82	8.24e-22	4.6e-19	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145531273	chr6:145799409~145886585:+
BRCA	cis	rs3779195	0.524	rs80195155	ENSG00000272950.1	RP11-307C18.1	-9.81	8.29e-22	4.63e-19	-0.48	-0.29	Sex hormone-binding globulin levels;	chr7:98248841	chr7:98322853~98323430:+
BRCA	cis	rs875971	0.862	rs6460307	ENSG00000237310.1	GS1-124K5.4	9.81	8.31e-22	4.64e-19	0.31	0.29	Aortic root size;	chr7:66595884	chr7:66493706~66495474:+
BRCA	cis	rs75422866	0.867	rs73113117	ENSG00000274902.1	RP1-197B17.4	9.81	8.34e-22	4.65e-19	0.76	0.29	Pneumonia;	chr12:47617299	chr12:47731908~47732351:+
BRCA	cis	rs11096990	0.634	rs12651217	ENSG00000249207.1	RP11-360F5.1	-9.81	8.35e-22	4.66e-19	-0.34	-0.29	Cognitive function;	chr4:39271964	chr4:39112677~39126818:-
BRCA	cis	rs7772486	0.79	rs9497427	ENSG00000235652.6	RP11-545I5.3	-9.81	8.37e-22	4.67e-19	-0.29	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145917166	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.875	rs863820	ENSG00000235652.6	RP11-545I5.3	-9.81	8.4e-22	4.68e-19	-0.29	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:146026266	chr6:145799409~145886585:+
BRCA	cis	rs321358	0.731	rs1900556	ENSG00000271584.1	RP11-89C3.4	9.81	8.41e-22	4.69e-19	0.47	0.29	Body mass index;	chr11:111148276	chr11:111091932~111097357:-
BRCA	cis	rs10129255	0.957	rs10136781	ENSG00000211970.3	IGHV4-61	-9.81	8.42e-22	4.69e-19	-0.2	-0.29	Kawasaki disease;	chr14:106780451	chr14:106639119~106639657:-
BRCA	cis	rs875971	0.862	rs4718383	ENSG00000237310.1	GS1-124K5.4	-9.81	8.44e-22	4.71e-19	-0.31	-0.29	Aortic root size;	chr7:66643422	chr7:66493706~66495474:+
BRCA	cis	rs7772486	0.764	rs9399569	ENSG00000235652.6	RP11-545I5.3	-9.81	8.45e-22	4.71e-19	-0.29	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145921806	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.79	rs9403755	ENSG00000235652.6	RP11-545I5.3	-9.81	8.48e-22	4.73e-19	-0.29	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145910334	chr6:145799409~145886585:+
BRCA	cis	rs11098499	0.954	rs12508504	ENSG00000245958.5	RP11-33B1.1	-9.81	8.48e-22	4.73e-19	-0.29	-0.29	Corneal astigmatism;	chr4:119489452	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.909	rs10020034	ENSG00000245958.5	RP11-33B1.1	-9.81	8.49e-22	4.73e-19	-0.29	-0.29	Corneal astigmatism;	chr4:119373176	chr4:119454791~119552025:+
BRCA	cis	rs7580658	0.864	rs10928761	ENSG00000236682.1	AC068282.3	-9.81	8.5e-22	4.74e-19	-0.39	-0.29	Protein C levels;	chr2:127245671	chr2:127389130~127400580:+
BRCA	cis	rs11673344	0.583	rs10421436	ENSG00000226686.6	LINC01535	-9.81	8.56e-22	4.77e-19	-0.36	-0.29	Obesity-related traits;	chr19:37394601	chr19:37251912~37265535:+
BRCA	cis	rs2412819	0.545	rs3862143	ENSG00000249839.1	AC011330.5	9.81	8.57e-22	4.77e-19	0.41	0.29	Lung cancer;	chr15:43779282	chr15:43663654~43684339:-
BRCA	cis	rs10129255	0.789	rs61997796	ENSG00000211970.3	IGHV4-61	-9.81	8.63e-22	4.8e-19	-0.22	-0.29	Kawasaki disease;	chr14:106813798	chr14:106639119~106639657:-
BRCA	cis	rs4862750	0.874	rs6553027	ENSG00000250971.1	RP11-696F12.1	9.81	8.63e-22	4.81e-19	0.32	0.29	Lobe attachment (rater-scored or self-reported);	chr4:186954623	chr4:187060099~187060930:+
BRCA	cis	rs11096990	0.634	rs60016848	ENSG00000249207.1	RP11-360F5.1	9.81	8.74e-22	4.87e-19	0.34	0.29	Cognitive function;	chr4:39281436	chr4:39112677~39126818:-
BRCA	cis	rs11096990	0.577	rs6830736	ENSG00000249207.1	RP11-360F5.1	9.81	8.74e-22	4.87e-19	0.34	0.29	Cognitive function;	chr4:39281467	chr4:39112677~39126818:-
BRCA	cis	rs765787	0.53	rs12910270	ENSG00000259520.4	CTD-2651B20.3	-9.81	8.76e-22	4.87e-19	-0.36	-0.29	Uric acid levels;	chr15:45219888	chr15:45251580~45279251:-
BRCA	cis	rs765787	0.53	rs12440238	ENSG00000259520.4	CTD-2651B20.3	-9.81	8.76e-22	4.87e-19	-0.36	-0.29	Uric acid levels;	chr15:45220707	chr15:45251580~45279251:-
BRCA	cis	rs7772486	0.754	rs4360151	ENSG00000235652.6	RP11-545I5.3	-9.81	8.76e-22	4.88e-19	-0.29	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145933943	chr6:145799409~145886585:+
BRCA	cis	rs1823913	0.599	rs56328712	ENSG00000227542.1	AC092614.2	9.81	8.76e-22	4.88e-19	0.35	0.29	Obesity-related traits;	chr2:191273807	chr2:191229165~191246172:-
BRCA	cis	rs1823913	0.599	rs55862924	ENSG00000227542.1	AC092614.2	9.81	8.76e-22	4.88e-19	0.35	0.29	Obesity-related traits;	chr2:191273809	chr2:191229165~191246172:-
BRCA	cis	rs227275	0.525	rs223462	ENSG00000246560.2	RP11-10L12.4	9.81	8.8e-22	4.89e-19	0.31	0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102780661	chr4:102828055~102844075:+
BRCA	cis	rs11971779	0.68	rs10271297	ENSG00000273391.1	RP11-634H22.1	9.81	8.8e-22	4.9e-19	0.28	0.29	Diisocyanate-induced asthma;	chr7:139367564	chr7:139359032~139359566:-
BRCA	cis	rs875971	0.862	rs1860469	ENSG00000237310.1	GS1-124K5.4	-9.81	8.82e-22	4.9e-19	-0.31	-0.29	Aortic root size;	chr7:66641888	chr7:66493706~66495474:+
BRCA	cis	rs8062405	1	rs4451951	ENSG00000251417.2	RP11-1348G14.4	-9.81	8.82e-22	4.91e-19	-0.34	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28824884	chr16:28802743~28817828:+
BRCA	cis	rs765787	0.53	rs12442533	ENSG00000259520.4	CTD-2651B20.3	-9.81	8.82e-22	4.91e-19	-0.36	-0.29	Uric acid levels;	chr15:45237433	chr15:45251580~45279251:-
BRCA	cis	rs1707322	0.752	rs6662164	ENSG00000280836.1	AL355480.1	-9.81	8.82e-22	4.91e-19	-0.37	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45680558	chr1:45581219~45581321:-
BRCA	cis	rs875971	0.862	rs2088653	ENSG00000237310.1	GS1-124K5.4	-9.81	8.83e-22	4.91e-19	-0.31	-0.29	Aortic root size;	chr7:66343621	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.862	rs6460293	ENSG00000237310.1	GS1-124K5.4	-9.81	8.83e-22	4.91e-19	-0.31	-0.29	Aortic root size;	chr7:66345205	chr7:66493706~66495474:+
BRCA	cis	rs765787	0.53	rs7167731	ENSG00000259520.4	CTD-2651B20.3	-9.81	8.84e-22	4.92e-19	-0.36	-0.29	Uric acid levels;	chr15:45218702	chr15:45251580~45279251:-
BRCA	cis	rs4910157	1	rs4910157	ENSG00000254860.4	TMEM9B-AS1	-9.81	8.84e-22	4.92e-19	-0.27	-0.29	Tonsillectomy;	chr11:8919668	chr11:8964675~8977527:+
BRCA	cis	rs858239	0.537	rs10279691	ENSG00000226816.2	AC005082.12	9.81	8.84e-22	4.92e-19	0.34	0.29	Cerebrospinal fluid biomarker levels;	chr7:23188768	chr7:23206013~23208045:+
BRCA	cis	rs6921919	0.583	rs6907950	ENSG00000216901.1	AL022393.7	9.81	8.84e-22	4.92e-19	0.38	0.29	Autism spectrum disorder or schizophrenia;	chr6:28402469	chr6:28176188~28176674:+
BRCA	cis	rs4862750	0.914	rs1991256	ENSG00000250971.1	RP11-696F12.1	9.81	8.88e-22	4.94e-19	0.31	0.29	Lobe attachment (rater-scored or self-reported);	chr4:186954176	chr4:187060099~187060930:+
BRCA	cis	rs4862750	0.914	rs1991255	ENSG00000250971.1	RP11-696F12.1	9.81	8.88e-22	4.94e-19	0.31	0.29	Lobe attachment (rater-scored or self-reported);	chr4:186954186	chr4:187060099~187060930:+
BRCA	cis	rs75422866	0.867	rs75568526	ENSG00000274902.1	RP1-197B17.4	9.81	8.94e-22	4.97e-19	0.76	0.29	Pneumonia;	chr12:47649718	chr12:47731908~47732351:+
BRCA	cis	rs75422866	0.867	rs116302411	ENSG00000274902.1	RP1-197B17.4	9.81	8.94e-22	4.97e-19	0.76	0.29	Pneumonia;	chr12:47649788	chr12:47731908~47732351:+
BRCA	cis	rs1823913	0.927	rs35092718	ENSG00000227542.1	AC092614.2	9.81	8.97e-22	4.99e-19	0.36	0.29	Obesity-related traits;	chr2:191243882	chr2:191229165~191246172:-
BRCA	cis	rs1075265	0.84	rs10084355	ENSG00000233266.1	HMGB1P31	9.81	9.03e-22	5.01e-19	0.35	0.29	Chronotype;Morning vs. evening chronotype;	chr2:54021711	chr2:54051334~54051760:+
BRCA	cis	rs801193	0.569	rs11761542	ENSG00000237310.1	GS1-124K5.4	9.81	9.03e-22	5.02e-19	0.31	0.29	Aortic root size;	chr7:66753209	chr7:66493706~66495474:+
BRCA	cis	rs2439831	0.85	rs28504496	ENSG00000249839.1	AC011330.5	-9.81	9.03e-22	5.02e-19	-0.5	-0.29	Lung cancer in ever smokers;	chr15:43724685	chr15:43663654~43684339:-
BRCA	cis	rs7772486	0.875	rs2814876	ENSG00000235652.6	RP11-545I5.3	9.81	9.04e-22	5.02e-19	0.3	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145982894	chr6:145799409~145886585:+
BRCA	cis	rs1823913	0.599	rs1378155	ENSG00000227542.1	AC092614.2	9.8	9.07e-22	5.04e-19	0.35	0.29	Obesity-related traits;	chr2:191266610	chr2:191229165~191246172:-
BRCA	cis	rs812925	0.537	rs778146	ENSG00000271889.1	RP11-493E12.1	-9.8	9.08e-22	5.05e-19	-0.35	-0.29	Immature fraction of reticulocytes;	chr2:61379340	chr2:61151433~61162105:-
BRCA	cis	rs228614	0.51	rs223415	ENSG00000246560.2	RP11-10L12.4	9.8	9.09e-22	5.05e-19	0.31	0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102811016	chr4:102828055~102844075:+
BRCA	cis	rs765787	0.53	rs11070444	ENSG00000259520.4	CTD-2651B20.3	-9.8	9.1e-22	5.05e-19	-0.36	-0.29	Uric acid levels;	chr15:45220923	chr15:45251580~45279251:-
BRCA	cis	rs765787	0.53	rs11070445	ENSG00000259520.4	CTD-2651B20.3	-9.8	9.1e-22	5.05e-19	-0.36	-0.29	Uric acid levels;	chr15:45220965	chr15:45251580~45279251:-
BRCA	cis	rs7772486	0.79	rs1062067	ENSG00000235652.6	RP11-545I5.3	9.8	9.12e-22	5.06e-19	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145886427	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.79	rs2256998	ENSG00000235652.6	RP11-545I5.3	9.8	9.12e-22	5.06e-19	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145886521	chr6:145799409~145886585:+
BRCA	cis	rs875971	0.862	rs9791712	ENSG00000237310.1	GS1-124K5.4	-9.8	9.12e-22	5.07e-19	-0.31	-0.29	Aortic root size;	chr7:66640176	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.862	rs9791713	ENSG00000237310.1	GS1-124K5.4	-9.8	9.12e-22	5.07e-19	-0.31	-0.29	Aortic root size;	chr7:66640211	chr7:66493706~66495474:+
BRCA	cis	rs801193	0.569	rs6978178	ENSG00000237310.1	GS1-124K5.4	-9.8	9.16e-22	5.09e-19	-0.31	-0.29	Aortic root size;	chr7:66658097	chr7:66493706~66495474:+
BRCA	cis	rs765787	0.53	rs12904331	ENSG00000259520.4	CTD-2651B20.3	-9.8	9.16e-22	5.09e-19	-0.37	-0.29	Uric acid levels;	chr15:45226095	chr15:45251580~45279251:-
BRCA	cis	rs6921919	0.583	rs2041230	ENSG00000216901.1	AL022393.7	9.8	9.17e-22	5.09e-19	0.38	0.29	Autism spectrum disorder or schizophrenia;	chr6:28397738	chr6:28176188~28176674:+
BRCA	cis	rs8062405	0.679	rs72793818	ENSG00000251417.2	RP11-1348G14.4	-9.8	9.18e-22	5.1e-19	-0.34	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28881816	chr16:28802743~28817828:+
BRCA	cis	rs7772486	0.754	rs6570708	ENSG00000235652.6	RP11-545I5.3	-9.8	9.19e-22	5.1e-19	-0.29	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145668292	chr6:145799409~145886585:+
BRCA	cis	rs1062177	0.906	rs2964573	ENSG00000253921.1	CTB-113P19.3	-9.8	9.22e-22	5.12e-19	-0.4	-0.29	Preschool internalizing problems;	chr5:151780561	chr5:151753992~151767247:+
BRCA	cis	rs17711722	0.523	rs365896	ENSG00000236529.1	RP13-254B10.1	-9.8	9.22e-22	5.12e-19	-0.32	-0.29	Calcium levels;	chr7:66045710	chr7:65840212~65840596:+
BRCA	cis	rs7772486	0.754	rs6921073	ENSG00000235652.6	RP11-545I5.3	9.8	9.24e-22	5.13e-19	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145823241	chr6:145799409~145886585:+
BRCA	cis	rs7811142	0.83	rs11768967	ENSG00000242294.5	STAG3L5P	9.8	9.26e-22	5.14e-19	0.27	0.29	Platelet count;	chr7:100370021	chr7:100336079~100351900:+
BRCA	cis	rs1113500	1	rs1777483	ENSG00000226822.1	RP11-356N1.2	-9.8	9.26e-22	5.14e-19	-0.38	-0.29	Growth-regulated protein alpha levels;	chr1:108066786	chr1:108071482~108074519:+
BRCA	cis	rs7772486	0.692	rs2265915	ENSG00000235652.6	RP11-545I5.3	9.8	9.27e-22	5.15e-19	0.3	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145873196	chr6:145799409~145886585:+
BRCA	cis	rs8072100	1	rs11870935	ENSG00000228782.6	CTD-2026D20.3	-9.8	9.34e-22	5.18e-19	-0.31	-0.29	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47655239	chr17:47450568~47492492:-
BRCA	cis	rs4862750	0.914	rs1346126	ENSG00000250971.1	RP11-696F12.1	9.8	9.36e-22	5.19e-19	0.32	0.29	Lobe attachment (rater-scored or self-reported);	chr4:186955250	chr4:187060099~187060930:+
BRCA	cis	rs7580658	0.724	rs6712213	ENSG00000236682.1	AC068282.3	-9.8	9.43e-22	5.23e-19	-0.39	-0.29	Protein C levels;	chr2:127240654	chr2:127389130~127400580:+
BRCA	cis	rs11098499	0.954	rs10518328	ENSG00000245958.5	RP11-33B1.1	-9.8	9.45e-22	5.24e-19	-0.29	-0.29	Corneal astigmatism;	chr4:119480624	chr4:119454791~119552025:+
BRCA	cis	rs765787	0.53	rs12440321	ENSG00000259520.4	CTD-2651B20.3	-9.8	9.45e-22	5.24e-19	-0.37	-0.29	Uric acid levels;	chr15:45237187	chr15:45251580~45279251:-
BRCA	cis	rs7772486	0.701	rs697056	ENSG00000235652.6	RP11-545I5.3	-9.8	9.49e-22	5.26e-19	-0.3	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145682761	chr6:145799409~145886585:+
BRCA	cis	rs8062405	0.755	rs12447461	ENSG00000278665.1	RP11-666O2.4	9.8	9.57e-22	5.3e-19	0.31	0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28571620	chr16:28599241~28601881:-
BRCA	cis	rs8062405	0.755	rs111693583	ENSG00000278665.1	RP11-666O2.4	9.8	9.57e-22	5.3e-19	0.31	0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28572289	chr16:28599241~28601881:-
BRCA	cis	rs1113500	0.932	rs1343205	ENSG00000226822.1	RP11-356N1.2	9.8	9.57e-22	5.3e-19	0.38	0.29	Growth-regulated protein alpha levels;	chr1:108055251	chr1:108071482~108074519:+
BRCA	cis	rs1075265	0.73	rs11893270	ENSG00000233266.1	HMGB1P31	9.8	9.6e-22	5.32e-19	0.35	0.29	Chronotype;Morning vs. evening chronotype;	chr2:54019828	chr2:54051334~54051760:+
BRCA	cis	rs10129255	0.957	rs12590799	ENSG00000211970.3	IGHV4-61	-9.8	9.6e-22	5.32e-19	-0.2	-0.29	Kawasaki disease;	chr14:106779713	chr14:106639119~106639657:-
BRCA	cis	rs7772486	0.79	rs2265472	ENSG00000235652.6	RP11-545I5.3	9.8	9.65e-22	5.34e-19	0.3	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145899622	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.79	rs2265919	ENSG00000235652.6	RP11-545I5.3	9.8	9.65e-22	5.34e-19	0.3	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145900617	chr6:145799409~145886585:+
BRCA	cis	rs2276314	0.857	rs6507158	ENSG00000278986.1	RP11-723J4.3	-9.8	9.65e-22	5.35e-19	-0.36	-0.29	Endometriosis;Drug-induced torsades de pointes;	chr18:36056103	chr18:35972151~35973916:+
BRCA	cis	rs35160687	0.712	rs11675942	ENSG00000273080.1	RP11-301O19.1	-9.8	9.68e-22	5.37e-19	-0.32	-0.29	Night sleep phenotypes;	chr2:86280565	chr2:86195590~86196049:+
BRCA	cis	rs35160687	0.688	rs4832033	ENSG00000273080.1	RP11-301O19.1	-9.8	9.68e-22	5.37e-19	-0.32	-0.29	Night sleep phenotypes;	chr2:86281640	chr2:86195590~86196049:+
BRCA	cis	rs6921919	0.583	rs11755942	ENSG00000216901.1	AL022393.7	9.8	9.71e-22	5.38e-19	0.38	0.29	Autism spectrum disorder or schizophrenia;	chr6:28401760	chr6:28176188~28176674:+
BRCA	cis	rs2439831	0.85	rs11070408	ENSG00000275601.1	AC011330.13	-9.8	9.81e-22	5.43e-19	-0.47	-0.29	Lung cancer in ever smokers;	chr15:43742590	chr15:43642389~43643023:-
BRCA	cis	rs11723261	0.621	rs6599307	ENSG00000211553.1	AC253576.2	-9.8	9.84e-22	5.45e-19	-0.38	-0.29	Immune response to smallpox vaccine (IL-6);	chr4:149993	chr4:136461~136568:+
BRCA	cis	rs1062177	1	rs973529	ENSG00000253921.1	CTB-113P19.3	-9.8	9.9e-22	5.48e-19	-0.4	-0.29	Preschool internalizing problems;	chr5:151808597	chr5:151753992~151767247:+
BRCA	cis	rs765787	0.53	rs12915027	ENSG00000259520.4	CTD-2651B20.3	-9.79	9.91e-22	5.49e-19	-0.36	-0.29	Uric acid levels;	chr15:45220428	chr15:45251580~45279251:-
BRCA	cis	rs150992	0.587	rs11949103	ENSG00000248489.1	CTD-2007H13.3	-9.79	9.98e-22	5.52e-19	-0.33	-0.29	Body mass index;	chr5:99011939	chr5:98929171~98995013:+
BRCA	cis	rs875971	0.928	rs2036263	ENSG00000237310.1	GS1-124K5.4	-9.79	1e-21	5.54e-19	-0.3	-0.29	Aortic root size;	chr7:66335210	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.862	rs10240949	ENSG00000237310.1	GS1-124K5.4	-9.79	1e-21	5.54e-19	-0.3	-0.29	Aortic root size;	chr7:66339430	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.862	rs7782704	ENSG00000237310.1	GS1-124K5.4	-9.79	1e-21	5.54e-19	-0.3	-0.29	Aortic root size;	chr7:66340379	chr7:66493706~66495474:+
BRCA	cis	rs7772486	0.79	rs2265469	ENSG00000235652.6	RP11-545I5.3	9.79	1e-21	5.54e-19	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145897913	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.79	rs2265918	ENSG00000235652.6	RP11-545I5.3	9.79	1e-21	5.54e-19	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145898028	chr6:145799409~145886585:+
BRCA	cis	rs733592	0.507	rs7299704	ENSG00000240399.1	RP1-228P16.1	9.79	1.01e-21	5.58e-19	0.31	0.29	Plateletcrit;	chr12:48050705	chr12:48054813~48055591:-
BRCA	cis	rs12468226	1	rs74508472	ENSG00000273456.1	RP11-686O6.2	9.79	1.01e-21	5.58e-19	0.43	0.29	Urate levels;	chr2:202517290	chr2:202374932~202375604:-
BRCA	cis	rs853679	0.76	rs2299029	ENSG00000220721.1	OR1F12	9.79	1.01e-21	5.59e-19	0.41	0.29	Depression;	chr6:28231053	chr6:28073316~28074233:+
BRCA	cis	rs4853012	0.838	rs12619982	ENSG00000257800.1	FNBP1P1	9.79	1.01e-21	5.6e-19	0.31	0.29	Gestational age at birth (maternal effect);	chr2:74128895	chr2:74120680~74123218:+
BRCA	cis	rs11096990	0.593	rs7662880	ENSG00000249207.1	RP11-360F5.1	9.79	1.03e-21	5.67e-19	0.33	0.29	Cognitive function;	chr4:39283604	chr4:39112677~39126818:-
BRCA	cis	rs11105298	0.891	rs11105316	ENSG00000258302.2	RP11-981P6.1	9.79	1.03e-21	5.68e-19	0.34	0.29	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89531423	chr12:89561129~89594878:+
BRCA	cis	rs11096990	0.634	rs1451818	ENSG00000249207.1	RP11-360F5.1	-9.79	1.03e-21	5.69e-19	-0.35	-0.29	Cognitive function;	chr4:39257151	chr4:39112677~39126818:-
BRCA	cis	rs6558530	0.932	rs7846610	ENSG00000253982.1	CTD-2336O2.1	9.79	1.03e-21	5.7e-19	0.32	0.29	Systolic blood pressure;	chr8:1758509	chr8:1761990~1764502:-
BRCA	cis	rs6570726	0.791	rs6915094	ENSG00000235652.6	RP11-545I5.3	9.79	1.03e-21	5.71e-19	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145562404	chr6:145799409~145886585:+
BRCA	cis	rs1707322	0.717	rs1547925	ENSG00000280836.1	AL355480.1	9.79	1.04e-21	5.73e-19	0.38	0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45619684	chr1:45581219~45581321:-
BRCA	cis	rs11105298	0.891	rs3741899	ENSG00000258302.2	RP11-981P6.1	9.79	1.05e-21	5.8e-19	0.34	0.29	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89540154	chr12:89561129~89594878:+
BRCA	cis	rs6565180	1	rs11863150	ENSG00000273724.1	RP11-347C12.12	9.79	1.05e-21	5.8e-19	0.33	0.29	Tonsillectomy;	chr16:30374182	chr16:30336400~30343336:+
BRCA	cis	rs72772090	0.539	rs11747896	ENSG00000248734.2	CTD-2260A17.1	9.79	1.05e-21	5.81e-19	0.46	0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96777693	chr5:96784777~96785999:+
BRCA	cis	rs7772486	0.72	rs4896837	ENSG00000235652.6	RP11-545I5.3	-9.79	1.05e-21	5.82e-19	-0.3	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145693032	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.875	rs2814863	ENSG00000235652.6	RP11-545I5.3	-9.79	1.05e-21	5.82e-19	-0.29	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:146026163	chr6:145799409~145886585:+
BRCA	cis	rs875971	0.862	rs6959268	ENSG00000237310.1	GS1-124K5.4	-9.79	1.06e-21	5.83e-19	-0.3	-0.29	Aortic root size;	chr7:66347979	chr7:66493706~66495474:+
BRCA	cis	rs7772486	0.79	rs9497425	ENSG00000235652.6	RP11-545I5.3	-9.79	1.06e-21	5.84e-19	-0.29	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145913061	chr6:145799409~145886585:+
BRCA	cis	rs7945705	0.818	rs2742552	ENSG00000254860.4	TMEM9B-AS1	9.79	1.06e-21	5.86e-19	0.26	0.29	Hemoglobin concentration;	chr11:8855305	chr11:8964675~8977527:+
BRCA	cis	rs11098499	0.954	rs28685688	ENSG00000245958.5	RP11-33B1.1	-9.79	1.06e-21	5.87e-19	-0.29	-0.29	Corneal astigmatism;	chr4:119499179	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.954	rs7687843	ENSG00000245958.5	RP11-33B1.1	-9.79	1.06e-21	5.87e-19	-0.29	-0.29	Corneal astigmatism;	chr4:119500056	chr4:119454791~119552025:+
BRCA	cis	rs673078	0.66	rs61945224	ENSG00000275759.1	RP11-131L12.3	-9.79	1.07e-21	5.88e-19	-0.5	-0.29	Glucose homeostasis traits;	chr12:118288623	chr12:118428281~118428870:+
BRCA	cis	rs673078	0.66	rs61945225	ENSG00000275759.1	RP11-131L12.3	-9.79	1.07e-21	5.88e-19	-0.5	-0.29	Glucose homeostasis traits;	chr12:118288960	chr12:118428281~118428870:+
BRCA	cis	rs11098499	0.954	rs10008459	ENSG00000245958.5	RP11-33B1.1	-9.79	1.07e-21	5.9e-19	-0.28	-0.29	Corneal astigmatism;	chr4:119473076	chr4:119454791~119552025:+
BRCA	cis	rs11673344	0.583	rs10425719	ENSG00000226686.6	LINC01535	-9.79	1.07e-21	5.9e-19	-0.36	-0.29	Obesity-related traits;	chr19:37459896	chr19:37251912~37265535:+
BRCA	cis	rs732716	0.819	rs12459919	ENSG00000267769.1	CTB-50L17.9	-9.79	1.07e-21	5.9e-19	-0.37	-0.29	Mean corpuscular volume;	chr19:4434506	chr19:4454014~4455286:+
BRCA	cis	rs11722779	0.873	rs223384	ENSG00000246560.2	RP11-10L12.4	9.79	1.07e-21	5.9e-19	0.3	0.29	Schizophrenia;	chr4:102829976	chr4:102828055~102844075:+
BRCA	cis	rs227275	0.554	rs223383	ENSG00000246560.2	RP11-10L12.4	9.79	1.07e-21	5.9e-19	0.3	0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102830094	chr4:102828055~102844075:+
BRCA	cis	rs11098499	0.954	rs2306455	ENSG00000245958.5	RP11-33B1.1	-9.79	1.07e-21	5.93e-19	-0.29	-0.29	Corneal astigmatism;	chr4:119500814	chr4:119454791~119552025:+
BRCA	cis	rs765787	0.53	rs12906537	ENSG00000259520.4	CTD-2651B20.3	-9.79	1.08e-21	5.94e-19	-0.37	-0.29	Uric acid levels;	chr15:45227863	chr15:45251580~45279251:-
BRCA	cis	rs765787	0.53	rs12915804	ENSG00000259520.4	CTD-2651B20.3	-9.79	1.08e-21	5.95e-19	-0.36	-0.29	Uric acid levels;	chr15:45220364	chr15:45251580~45279251:-
BRCA	cis	rs765787	0.556	rs12915965	ENSG00000259520.4	CTD-2651B20.3	-9.79	1.08e-21	5.95e-19	-0.36	-0.29	Uric acid levels;	chr15:45220449	chr15:45251580~45279251:-
BRCA	cis	rs7772486	0.79	rs2247206	ENSG00000235652.6	RP11-545I5.3	9.79	1.08e-21	5.95e-19	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145895048	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.764	rs2247211	ENSG00000235652.6	RP11-545I5.3	9.79	1.08e-21	5.95e-19	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145895243	chr6:145799409~145886585:+
BRCA	cis	rs2929278	0.617	rs3986209	ENSG00000249839.1	AC011330.5	9.79	1.08e-21	5.98e-19	0.4	0.29	Schizophrenia;	chr15:43758675	chr15:43663654~43684339:-
BRCA	cis	rs7772486	0.727	rs10447449	ENSG00000235652.6	RP11-545I5.3	9.78	1.09e-21	6.01e-19	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145817571	chr6:145799409~145886585:+
BRCA	cis	rs875971	0.545	rs2279757	ENSG00000226824.5	RP4-756H11.3	-9.78	1.09e-21	6.01e-19	-0.41	-0.29	Aortic root size;	chr7:66363676	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.545	rs11766183	ENSG00000226824.5	RP4-756H11.3	-9.78	1.09e-21	6.01e-19	-0.41	-0.29	Aortic root size;	chr7:66374173	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.545	rs1065265	ENSG00000226824.5	RP4-756H11.3	-9.78	1.09e-21	6.01e-19	-0.41	-0.29	Aortic root size;	chr7:66376216	chr7:66654538~66669855:+
BRCA	cis	rs67180937	0.553	rs2936023	ENSG00000272750.1	RP11-378J18.8	9.78	1.09e-21	6.03e-19	0.42	0.29	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222656989	chr1:222658867~222661512:-
BRCA	cis	rs801193	0.904	rs4718403	ENSG00000222364.1	RNU6-96P	-9.78	1.1e-21	6.04e-19	-0.33	-0.29	Aortic root size;	chr7:66777742	chr7:66395191~66395286:+
BRCA	cis	rs228614	0.51	rs3774987	ENSG00000246560.2	RP11-10L12.4	9.78	1.1e-21	6.04e-19	0.31	0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102799709	chr4:102828055~102844075:+
BRCA	cis	rs732716	0.785	rs62130978	ENSG00000267769.1	CTB-50L17.9	-9.78	1.1e-21	6.05e-19	-0.38	-0.29	Mean corpuscular volume;	chr19:4429010	chr19:4454014~4455286:+
BRCA	cis	rs7772486	0.875	rs9322043	ENSG00000235652.6	RP11-545I5.3	9.78	1.1e-21	6.06e-19	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:146031554	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.875	rs13198450	ENSG00000235652.6	RP11-545I5.3	9.78	1.1e-21	6.08e-19	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:146049388	chr6:145799409~145886585:+
BRCA	cis	rs10971721	0.554	rs55917897	ENSG00000260947.1	RP11-384P7.7	9.78	1.11e-21	6.1e-19	0.59	0.29	Body mass index;	chr9:33795952	chr9:33697459~33700986:+
BRCA	cis	rs8072100	1	rs8065437	ENSG00000228782.6	CTD-2026D20.3	9.78	1.11e-21	6.11e-19	0.31	0.29	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47644287	chr17:47450568~47492492:-
BRCA	cis	rs875971	0.545	rs7811204	ENSG00000226824.5	RP4-756H11.3	-9.78	1.11e-21	6.12e-19	-0.41	-0.29	Aortic root size;	chr7:66387213	chr7:66654538~66669855:+
BRCA	cis	rs11098499	0.954	rs7681544	ENSG00000245958.5	RP11-33B1.1	-9.78	1.11e-21	6.13e-19	-0.29	-0.29	Corneal astigmatism;	chr4:119490100	chr4:119454791~119552025:+
BRCA	cis	rs11096990	0.634	rs6815855	ENSG00000249207.1	RP11-360F5.1	9.78	1.12e-21	6.18e-19	0.33	0.29	Cognitive function;	chr4:39294926	chr4:39112677~39126818:-
BRCA	cis	rs35160687	0.623	rs11689971	ENSG00000273080.1	RP11-301O19.1	-9.78	1.13e-21	6.2e-19	-0.35	-0.29	Night sleep phenotypes;	chr2:86247348	chr2:86195590~86196049:+
BRCA	cis	rs35160687	0.623	rs11127021	ENSG00000273080.1	RP11-301O19.1	-9.78	1.13e-21	6.2e-19	-0.35	-0.29	Night sleep phenotypes;	chr2:86247796	chr2:86195590~86196049:+
BRCA	cis	rs950169	0.58	rs2271431	ENSG00000225151.9	GOLGA2P7	-9.78	1.13e-21	6.22e-19	-0.37	-0.29	Schizophrenia;	chr15:84646233	chr15:84199311~84230136:-
BRCA	cis	rs4835473	0.932	rs28796049	ENSG00000251600.4	RP11-673E1.1	9.78	1.13e-21	6.23e-19	0.33	0.29	Immature fraction of reticulocytes;	chr4:143733990	chr4:143912331~143982454:+
BRCA	cis	rs4853012	0.941	rs7571083	ENSG00000257800.1	FNBP1P1	9.78	1.13e-21	6.24e-19	0.31	0.29	Gestational age at birth (maternal effect);	chr2:74115133	chr2:74120680~74123218:+
BRCA	cis	rs1874124	0.577	rs2807872	ENSG00000238078.1	LINC01352	-9.78	1.14e-21	6.26e-19	-0.4	-0.29	Cholesterol, total;	chr1:220866908	chr1:220829255~220832429:+
BRCA	cis	rs228614	0.536	rs223419	ENSG00000246560.2	RP11-10L12.4	9.78	1.14e-21	6.27e-19	0.31	0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102808586	chr4:102828055~102844075:+
BRCA	cis	rs228614	0.51	rs223434	ENSG00000246560.2	RP11-10L12.4	9.78	1.14e-21	6.28e-19	0.31	0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102799902	chr4:102828055~102844075:+
BRCA	cis	rs1823913	0.599	rs35892286	ENSG00000227542.1	AC092614.2	9.78	1.14e-21	6.3e-19	0.35	0.29	Obesity-related traits;	chr2:191269010	chr2:191229165~191246172:-
BRCA	cis	rs30380	0.734	rs27044	ENSG00000248734.2	CTD-2260A17.1	9.78	1.15e-21	6.3e-19	0.33	0.29	Cerebrospinal fluid biomarker levels;	chr5:96783148	chr5:96784777~96785999:+
BRCA	cis	rs10971721	0.643	rs41315997	ENSG00000260947.1	RP11-384P7.7	9.78	1.15e-21	6.35e-19	0.59	0.29	Body mass index;	chr9:33798840	chr9:33697459~33700986:+
BRCA	cis	rs673078	0.66	rs17512142	ENSG00000275759.1	RP11-131L12.3	-9.78	1.16e-21	6.35e-19	-0.49	-0.29	Glucose homeostasis traits;	chr12:118186186	chr12:118428281~118428870:+
BRCA	cis	rs4964805	0.641	rs11111755	ENSG00000257681.1	RP11-341G23.4	9.78	1.17e-21	6.45e-19	0.35	0.29	Attention deficit hyperactivity disorder;	chr12:103765889	chr12:103746315~103768858:-
BRCA	cis	rs228614	0.51	rs223445	ENSG00000246560.2	RP11-10L12.4	9.78	1.18e-21	6.46e-19	0.31	0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102793337	chr4:102828055~102844075:+
BRCA	cis	rs6570726	0.791	rs365869	ENSG00000235652.6	RP11-545I5.3	9.78	1.18e-21	6.47e-19	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145563615	chr6:145799409~145886585:+
BRCA	cis	rs465969	0.744	rs7758483	ENSG00000255389.1	C6orf3	-9.78	1.18e-21	6.47e-19	-0.57	-0.29	Psoriasis;	chr6:111467945	chr6:111599875~111602295:+
BRCA	cis	rs7772486	0.79	rs9386141	ENSG00000235652.6	RP11-545I5.3	-9.78	1.18e-21	6.5e-19	-0.29	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145947487	chr6:145799409~145886585:+
BRCA	cis	rs6545883	0.524	rs778159	ENSG00000271889.1	RP11-493E12.1	-9.78	1.19e-21	6.52e-19	-0.35	-0.29	Tuberculosis;	chr2:61329609	chr2:61151433~61162105:-
BRCA	cis	rs10971721	0.643	rs12378415	ENSG00000260947.1	RP11-384P7.7	9.77	1.2e-21	6.57e-19	0.59	0.29	Body mass index;	chr9:33797335	chr9:33697459~33700986:+
BRCA	cis	rs858239	0.6	rs7785842	ENSG00000226816.2	AC005082.12	9.77	1.2e-21	6.58e-19	0.33	0.29	Cerebrospinal fluid biomarker levels;	chr7:23102087	chr7:23206013~23208045:+
BRCA	cis	rs4862750	0.872	rs13143414	ENSG00000250971.1	RP11-696F12.1	9.77	1.2e-21	6.6e-19	0.3	0.29	Lobe attachment (rater-scored or self-reported);	chr4:186957059	chr4:187060099~187060930:+
BRCA	cis	rs11105298	0.891	rs3741898	ENSG00000258302.2	RP11-981P6.1	9.77	1.21e-21	6.62e-19	0.34	0.29	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89539986	chr12:89561129~89594878:+
BRCA	cis	rs227275	0.554	rs150895	ENSG00000246560.2	RP11-10L12.4	9.77	1.21e-21	6.64e-19	0.3	0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102791432	chr4:102828055~102844075:+
BRCA	cis	rs11096990	0.634	rs6852967	ENSG00000249207.1	RP11-360F5.1	9.77	1.22e-21	6.67e-19	0.33	0.29	Cognitive function;	chr4:39281526	chr4:39112677~39126818:-
BRCA	cis	rs7772486	0.79	rs4314514	ENSG00000235652.6	RP11-545I5.3	-9.77	1.22e-21	6.71e-19	-0.29	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145938874	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.79	rs9497435	ENSG00000235652.6	RP11-545I5.3	-9.77	1.23e-21	6.74e-19	-0.29	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145944204	chr6:145799409~145886585:+
BRCA	cis	rs227275	0.524	rs150894	ENSG00000246560.2	RP11-10L12.4	9.77	1.25e-21	6.87e-19	0.3	0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102811541	chr4:102828055~102844075:+
BRCA	cis	rs227275	0.525	rs3974604	ENSG00000246560.2	RP11-10L12.4	9.77	1.27e-21	6.95e-19	0.31	0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102928601	chr4:102828055~102844075:+
BRCA	cis	rs9595908	0.865	rs499966	ENSG00000212293.1	SNORA16	-9.77	1.27e-21	6.97e-19	-0.33	-0.29	Body mass index;	chr13:32424473	chr13:32420390~32420516:-
BRCA	cis	rs1823913	0.599	rs6732976	ENSG00000227542.1	AC092614.2	-9.77	1.27e-21	6.98e-19	-0.35	-0.29	Obesity-related traits;	chr2:191281004	chr2:191229165~191246172:-
BRCA	cis	rs8062405	0.69	rs7187604	ENSG00000278665.1	RP11-666O2.4	9.77	1.28e-21	6.99e-19	0.31	0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554632	chr16:28599241~28601881:-
BRCA	cis	rs12468226	0.872	rs1061157	ENSG00000273456.1	RP11-686O6.2	9.77	1.28e-21	6.99e-19	0.44	0.29	Urate levels;	chr2:202556476	chr2:202374932~202375604:-
BRCA	cis	rs7772486	0.79	rs1832362	ENSG00000235652.6	RP11-545I5.3	9.77	1.28e-21	7e-19	0.28	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145858819	chr6:145799409~145886585:+
BRCA	cis	rs2439831	0.85	rs28595038	ENSG00000275601.1	AC011330.13	-9.77	1.28e-21	7.02e-19	-0.47	-0.29	Lung cancer in ever smokers;	chr15:43752661	chr15:43642389~43643023:-
BRCA	cis	rs2665103	0.687	rs11633000	ENSG00000278603.1	RP13-608F4.5	9.77	1.28e-21	7.04e-19	0.37	0.29	Intelligence (multi-trait analysis);	chr15:82269320	chr15:82472203~82472426:+
BRCA	cis	rs2564921	0.57	rs3821831	ENSG00000242142.1	SERBP1P3	-9.77	1.29e-21	7.08e-19	-0.35	-0.29	Height;	chr3:52819385	chr3:53064283~53065091:-
BRCA	cis	rs228614	0.534	rs223387	ENSG00000246560.2	RP11-10L12.4	9.77	1.29e-21	7.08e-19	0.3	0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102828359	chr4:102828055~102844075:+
BRCA	cis	rs11098499	0.618	rs28491261	ENSG00000245958.5	RP11-33B1.1	-9.77	1.3e-21	7.1e-19	-0.28	-0.29	Corneal astigmatism;	chr4:119373745	chr4:119454791~119552025:+
BRCA	cis	rs228614	0.51	rs223358	ENSG00000246560.2	RP11-10L12.4	9.77	1.3e-21	7.12e-19	0.31	0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102849637	chr4:102828055~102844075:+
BRCA	cis	rs7772486	0.701	rs2244308	ENSG00000235652.6	RP11-545I5.3	9.76	1.3e-21	7.13e-19	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145892570	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.79	rs2814880	ENSG00000235652.6	RP11-545I5.3	9.76	1.31e-21	7.19e-19	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145887801	chr6:145799409~145886585:+
BRCA	cis	rs228614	0.536	rs150897	ENSG00000246560.2	RP11-10L12.4	9.76	1.32e-21	7.25e-19	0.31	0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102769309	chr4:102828055~102844075:+
BRCA	cis	rs11096990	0.634	rs12648793	ENSG00000249207.1	RP11-360F5.1	9.76	1.33e-21	7.26e-19	0.33	0.29	Cognitive function;	chr4:39284473	chr4:39112677~39126818:-
BRCA	cis	rs2404602	0.735	rs2436994	ENSG00000259422.1	RP11-593F23.1	-9.76	1.34e-21	7.31e-19	-0.36	-0.29	Blood metabolite levels;	chr15:76508722	chr15:76174891~76181486:-
BRCA	cis	rs7772486	0.875	rs9403764	ENSG00000235652.6	RP11-545I5.3	9.76	1.34e-21	7.31e-19	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:146039446	chr6:145799409~145886585:+
BRCA	cis	rs801193	1	rs3778909	ENSG00000222364.1	RNU6-96P	-9.76	1.34e-21	7.33e-19	-0.33	-0.29	Aortic root size;	chr7:66790659	chr7:66395191~66395286:+
BRCA	cis	rs7772486	0.79	rs2253654	ENSG00000235652.6	RP11-545I5.3	9.76	1.34e-21	7.34e-19	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145878309	chr6:145799409~145886585:+
BRCA	cis	rs858239	0.537	rs2286272	ENSG00000226816.2	AC005082.12	9.76	1.34e-21	7.35e-19	0.34	0.29	Cerebrospinal fluid biomarker levels;	chr7:23184748	chr7:23206013~23208045:+
BRCA	cis	rs228614	0.51	rs223405	ENSG00000246560.2	RP11-10L12.4	9.76	1.35e-21	7.39e-19	0.31	0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102815894	chr4:102828055~102844075:+
BRCA	cis	rs7772486	0.79	rs1133832	ENSG00000235652.6	RP11-545I5.3	-9.76	1.35e-21	7.4e-19	-0.28	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145884468	chr6:145799409~145886585:+
BRCA	cis	rs72772090	0.539	rs3333	ENSG00000248734.2	CTD-2260A17.1	-9.76	1.35e-21	7.4e-19	-0.48	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96779407	chr5:96784777~96785999:+
BRCA	cis	rs11096990	0.634	rs7659894	ENSG00000249207.1	RP11-360F5.1	9.76	1.35e-21	7.41e-19	0.33	0.29	Cognitive function;	chr4:39282815	chr4:39112677~39126818:-
BRCA	cis	rs12468226	1	rs116635509	ENSG00000273456.1	RP11-686O6.2	9.76	1.36e-21	7.43e-19	0.43	0.29	Urate levels;	chr2:202460027	chr2:202374932~202375604:-
BRCA	cis	rs783540	0.9	rs4778686	ENSG00000278603.1	RP13-608F4.5	-9.76	1.36e-21	7.43e-19	-0.37	-0.29	Schizophrenia;	chr15:82642084	chr15:82472203~82472426:+
BRCA	cis	rs7772486	0.79	rs9376971	ENSG00000235652.6	RP11-545I5.3	-9.76	1.36e-21	7.44e-19	-0.29	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145938369	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.72	rs9403757	ENSG00000235652.6	RP11-545I5.3	-9.76	1.36e-21	7.44e-19	-0.29	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145940135	chr6:145799409~145886585:+
BRCA	cis	rs858239	0.57	rs10235467	ENSG00000226816.2	AC005082.12	9.76	1.37e-21	7.49e-19	0.33	0.29	Cerebrospinal fluid biomarker levels;	chr7:23109189	chr7:23206013~23208045:+
BRCA	cis	rs453301	0.653	rs7016139	ENSG00000253893.2	FAM85B	9.76	1.37e-21	7.52e-19	0.37	0.29	Joint mobility (Beighton score);	chr8:9037960	chr8:8167819~8226614:-
BRCA	cis	rs7429990	0.965	rs5012971	ENSG00000229759.1	MRPS18AP1	-9.76	1.38e-21	7.54e-19	-0.33	-0.29	Educational attainment (years of education);	chr3:48033057	chr3:48256350~48256938:-
BRCA	cis	rs7429990	0.813	rs7637622	ENSG00000229759.1	MRPS18AP1	-9.76	1.38e-21	7.54e-19	-0.33	-0.29	Educational attainment (years of education);	chr3:48051561	chr3:48256350~48256938:-
BRCA	cis	rs7429990	0.965	rs7627645	ENSG00000229759.1	MRPS18AP1	-9.76	1.38e-21	7.54e-19	-0.33	-0.29	Educational attainment (years of education);	chr3:48051643	chr3:48256350~48256938:-
BRCA	cis	rs7772486	0.79	rs6570723	ENSG00000235652.6	RP11-545I5.3	9.76	1.38e-21	7.55e-19	0.28	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145830094	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.79	rs6570724	ENSG00000235652.6	RP11-545I5.3	9.76	1.38e-21	7.55e-19	0.28	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145830147	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.79	rs6917135	ENSG00000235652.6	RP11-545I5.3	9.76	1.38e-21	7.55e-19	0.28	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145831290	chr6:145799409~145886585:+
BRCA	cis	rs753274	0.65	rs7257738	ENSG00000267147.2	CTC-548K16.1	-9.76	1.39e-21	7.6e-19	-0.35	-0.29	Tumor necrosis factor beta levels;	chr19:14308109	chr19:14333743~14343916:+
BRCA	cis	rs11105298	0.891	rs10858900	ENSG00000258302.2	RP11-981P6.1	9.76	1.39e-21	7.61e-19	0.34	0.29	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89531304	chr12:89561129~89594878:+
BRCA	cis	rs875971	0.862	rs709609	ENSG00000237310.1	GS1-124K5.4	-9.76	1.4e-21	7.67e-19	-0.31	-0.29	Aortic root size;	chr7:66095574	chr7:66493706~66495474:+
BRCA	cis	rs858239	0.601	rs3735228	ENSG00000226816.2	AC005082.12	9.76	1.41e-21	7.73e-19	0.33	0.29	Cerebrospinal fluid biomarker levels;	chr7:23130808	chr7:23206013~23208045:+
BRCA	cis	rs227275	0.586	rs223448	ENSG00000246560.2	RP11-10L12.4	9.76	1.42e-21	7.75e-19	0.3	0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102792189	chr4:102828055~102844075:+
BRCA	cis	rs228614	0.536	rs223420	ENSG00000246560.2	RP11-10L12.4	9.76	1.42e-21	7.76e-19	0.31	0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102806853	chr4:102828055~102844075:+
BRCA	cis	rs72772090	0.539	rs111237997	ENSG00000248734.2	CTD-2260A17.1	-9.76	1.42e-21	7.77e-19	-0.48	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96779249	chr5:96784777~96785999:+
BRCA	cis	rs227275	0.554	rs223442	ENSG00000246560.2	RP11-10L12.4	9.75	1.43e-21	7.82e-19	0.3	0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102793960	chr4:102828055~102844075:+
BRCA	cis	rs227275	0.554	rs223441	ENSG00000246560.2	RP11-10L12.4	9.75	1.43e-21	7.82e-19	0.3	0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102794228	chr4:102828055~102844075:+
BRCA	cis	rs673078	0.66	rs17512407	ENSG00000275759.1	RP11-131L12.3	-9.75	1.44e-21	7.86e-19	-0.5	-0.29	Glucose homeostasis traits;	chr12:118292705	chr12:118428281~118428870:+
BRCA	cis	rs673078	0.66	rs61946064	ENSG00000275759.1	RP11-131L12.3	-9.75	1.44e-21	7.86e-19	-0.5	-0.29	Glucose homeostasis traits;	chr12:118294495	chr12:118428281~118428870:+
BRCA	cis	rs2882667	0.518	rs10041986	ENSG00000253404.1	AC034243.1	9.75	1.45e-21	7.9e-19	0.35	0.29	Age-related hearing impairment (SNP x SNP interaction);	chr5:139088748	chr5:138744434~138753309:-
BRCA	cis	rs6700559	0.967	rs10919992	ENSG00000260088.1	RP11-92G12.3	-9.75	1.46e-21	7.99e-19	-0.38	-0.29	Coronary artery disease;	chr1:200638338	chr1:200669507~200694250:+
BRCA	cis	rs11096990	0.634	rs2839765	ENSG00000249207.1	RP11-360F5.1	9.75	1.46e-21	7.99e-19	0.33	0.29	Cognitive function;	chr4:39293933	chr4:39112677~39126818:-
BRCA	cis	rs7772486	0.846	rs9373482	ENSG00000235652.6	RP11-545I5.3	9.75	1.47e-21	8.02e-19	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:146041987	chr6:145799409~145886585:+
BRCA	cis	rs7429990	0.965	rs2882668	ENSG00000229759.1	MRPS18AP1	9.75	1.47e-21	8.02e-19	0.33	0.29	Educational attainment (years of education);	chr3:47938816	chr3:48256350~48256938:-
BRCA	cis	rs7811142	0.83	rs7792959	ENSG00000242294.5	STAG3L5P	9.75	1.47e-21	8.02e-19	0.27	0.29	Platelet count;	chr7:100374780	chr7:100336079~100351900:+
BRCA	cis	rs7772486	0.754	rs702324	ENSG00000235652.6	RP11-545I5.3	-9.75	1.47e-21	8.03e-19	-0.31	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145687657	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.79	rs9791313	ENSG00000235652.6	RP11-545I5.3	-9.75	1.48e-21	8.07e-19	-0.29	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145945036	chr6:145799409~145886585:+
BRCA	cis	rs11105298	0.891	rs11105319	ENSG00000258302.2	RP11-981P6.1	9.75	1.48e-21	8.08e-19	0.34	0.29	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89533400	chr12:89561129~89594878:+
BRCA	cis	rs75422866	0.867	rs73113143	ENSG00000274902.1	RP1-197B17.4	9.75	1.48e-21	8.1e-19	0.76	0.29	Pneumonia;	chr12:47623060	chr12:47731908~47732351:+
BRCA	cis	rs1150668	0.83	rs2531831	ENSG00000204709.4	LINC01556	9.75	1.49e-21	8.12e-19	0.36	0.29	Pubertal anthropometrics;	chr6:28420988	chr6:28943877~28944537:+
BRCA	cis	rs1707322	0.685	rs11211177	ENSG00000280836.1	AL355480.1	-9.75	1.49e-21	8.13e-19	-0.38	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45760677	chr1:45581219~45581321:-
BRCA	cis	rs858239	0.712	rs200717	ENSG00000226816.2	AC005082.12	9.75	1.5e-21	8.19e-19	0.33	0.29	Cerebrospinal fluid biomarker levels;	chr7:23352652	chr7:23206013~23208045:+
BRCA	cis	rs875971	0.756	rs2901210	ENSG00000237310.1	GS1-124K5.4	-9.75	1.5e-21	8.2e-19	-0.31	-0.29	Aortic root size;	chr7:66552518	chr7:66493706~66495474:+
BRCA	cis	rs35160687	0.623	rs7569654	ENSG00000273080.1	RP11-301O19.1	-9.75	1.51e-21	8.21e-19	-0.34	-0.29	Night sleep phenotypes;	chr2:86250899	chr2:86195590~86196049:+
BRCA	cis	rs858239	0.6	rs7456915	ENSG00000226816.2	AC005082.12	9.75	1.51e-21	8.25e-19	0.33	0.29	Cerebrospinal fluid biomarker levels;	chr7:23103430	chr7:23206013~23208045:+
BRCA	cis	rs10129255	0.536	rs17113249	ENSG00000211972.2	IGHV3-66	9.75	1.53e-21	8.35e-19	0.2	0.29	Kawasaki disease;	chr14:106678273	chr14:106675017~106675544:-
BRCA	cis	rs227275	0.554	rs223382	ENSG00000246560.2	RP11-10L12.4	9.75	1.54e-21	8.39e-19	0.3	0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102831145	chr4:102828055~102844075:+
BRCA	cis	rs7772486	0.727	rs12190966	ENSG00000235652.6	RP11-545I5.3	9.75	1.54e-21	8.39e-19	0.28	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145825684	chr6:145799409~145886585:+
BRCA	cis	rs8091660	0.929	rs2175564	ENSG00000278983.1	RP11-426J5.3	9.75	1.54e-21	8.42e-19	0.34	0.29	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48570838	chr18:48564795~48568342:+
BRCA	cis	rs11105298	0.891	rs8181784	ENSG00000258302.2	RP11-981P6.1	9.75	1.55e-21	8.43e-19	0.31	0.29	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89434814	chr12:89561129~89594878:+
BRCA	cis	rs1823913	0.599	rs17412094	ENSG00000227542.1	AC092614.2	9.75	1.55e-21	8.43e-19	0.35	0.29	Obesity-related traits;	chr2:191284202	chr2:191229165~191246172:-
BRCA	cis	rs733592	0.507	rs7304428	ENSG00000240399.1	RP1-228P16.1	-9.75	1.55e-21	8.45e-19	-0.31	-0.29	Plateletcrit;	chr12:48100492	chr12:48054813~48055591:-
BRCA	cis	rs858239	0.6	rs7341483	ENSG00000226816.2	AC005082.12	-9.75	1.55e-21	8.46e-19	-0.33	-0.29	Cerebrospinal fluid biomarker levels;	chr7:23088038	chr7:23206013~23208045:+
BRCA	cis	rs72772090	0.539	rs3335	ENSG00000248734.2	CTD-2260A17.1	-9.75	1.55e-21	8.47e-19	-0.48	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96779366	chr5:96784777~96785999:+
BRCA	cis	rs72772090	0.539	rs3334	ENSG00000248734.2	CTD-2260A17.1	-9.75	1.55e-21	8.47e-19	-0.48	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96779381	chr5:96784777~96785999:+
BRCA	cis	rs17711722	0.727	rs1880555	ENSG00000224316.1	RP11-479O9.2	9.74	1.56e-21	8.49e-19	0.29	0.29	Calcium levels;	chr7:65967580	chr7:65773620~65802067:+
BRCA	cis	rs7772486	0.875	rs2777481	ENSG00000235652.6	RP11-545I5.3	9.74	1.56e-21	8.49e-19	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145988900	chr6:145799409~145886585:+
BRCA	cis	rs227275	0.555	rs223403	ENSG00000246560.2	RP11-10L12.4	9.74	1.57e-21	8.53e-19	0.31	0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102817086	chr4:102828055~102844075:+
BRCA	cis	rs227275	0.555	rs223402	ENSG00000246560.2	RP11-10L12.4	9.74	1.57e-21	8.53e-19	0.31	0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102817198	chr4:102828055~102844075:+
BRCA	cis	rs11096990	0.656	rs2066786	ENSG00000249207.1	RP11-360F5.1	-9.74	1.57e-21	8.56e-19	-0.35	-0.29	Cognitive function;	chr4:39300409	chr4:39112677~39126818:-
BRCA	cis	rs4727443	1	rs4727443	ENSG00000235713.1	RP4-604G5.3	-9.74	1.57e-21	8.56e-19	-0.32	-0.29	Interstitial lung disease;	chr7:99995723	chr7:99992397~99993050:+
BRCA	cis	rs228614	0.51	rs223377	ENSG00000246560.2	RP11-10L12.4	9.74	1.57e-21	8.57e-19	0.3	0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102834919	chr4:102828055~102844075:+
BRCA	cis	rs875971	0.545	rs73142233	ENSG00000226824.5	RP4-756H11.3	-9.74	1.58e-21	8.58e-19	-0.41	-0.29	Aortic root size;	chr7:66221293	chr7:66654538~66669855:+
BRCA	cis	rs6570726	0.791	rs392612	ENSG00000235652.6	RP11-545I5.3	-9.74	1.59e-21	8.63e-19	-0.29	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145560450	chr6:145799409~145886585:+
BRCA	cis	rs875971	0.861	rs801215	ENSG00000237310.1	GS1-124K5.4	-9.74	1.59e-21	8.66e-19	-0.31	-0.29	Aortic root size;	chr7:66546951	chr7:66493706~66495474:+
BRCA	cis	rs7772486	0.782	rs7747576	ENSG00000235652.6	RP11-545I5.3	-9.74	1.59e-21	8.66e-19	-0.3	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145956691	chr6:145799409~145886585:+
BRCA	cis	rs8072100	1	rs3809868	ENSG00000228782.6	CTD-2026D20.3	-9.74	1.6e-21	8.68e-19	-0.31	-0.29	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47673230	chr17:47450568~47492492:-
BRCA	cis	rs858239	0.6	rs13438179	ENSG00000226816.2	AC005082.12	9.74	1.6e-21	8.71e-19	0.33	0.29	Cerebrospinal fluid biomarker levels;	chr7:23104232	chr7:23206013~23208045:+
BRCA	cis	rs8072100	1	rs7210738	ENSG00000228782.6	CTD-2026D20.3	-9.74	1.62e-21	8.83e-19	-0.31	-0.29	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47680232	chr17:47450568~47492492:-
BRCA	cis	rs6545883	0.525	rs1177274	ENSG00000271889.1	RP11-493E12.1	9.74	1.63e-21	8.86e-19	0.37	0.29	Tuberculosis;	chr2:61141397	chr2:61151433~61162105:-
BRCA	cis	rs875971	0.862	rs6944374	ENSG00000237310.1	GS1-124K5.4	-9.74	1.63e-21	8.89e-19	-0.31	-0.29	Aortic root size;	chr7:66221942	chr7:66493706~66495474:+
BRCA	cis	rs6545883	0.507	rs2123111	ENSG00000271889.1	RP11-493E12.1	-9.74	1.64e-21	8.89e-19	-0.35	-0.29	Tuberculosis;	chr2:61223319	chr2:61151433~61162105:-
BRCA	cis	rs39841	1	rs39841	ENSG00000248734.2	CTD-2260A17.1	9.74	1.64e-21	8.92e-19	0.32	0.29	Inflammatory skin disease;	chr5:96784466	chr5:96784777~96785999:+
BRCA	cis	rs30380	0.734	rs30376	ENSG00000248734.2	CTD-2260A17.1	9.74	1.64e-21	8.92e-19	0.32	0.29	Cerebrospinal fluid biomarker levels;	chr5:96784555	chr5:96784777~96785999:+
BRCA	cis	rs1075265	0.87	rs6749817	ENSG00000233266.1	HMGB1P31	9.74	1.64e-21	8.93e-19	0.34	0.29	Chronotype;Morning vs. evening chronotype;	chr2:54032396	chr2:54051334~54051760:+
BRCA	cis	rs8177376	0.727	rs601985	ENSG00000254905.1	RP11-712L6.7	9.74	1.65e-21	8.96e-19	0.39	0.29	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126327662	chr11:126292922~126294254:-
BRCA	cis	rs227275	0.556	rs724447	ENSG00000246560.2	RP11-10L12.4	-9.74	1.65e-21	8.98e-19	-0.31	-0.29	Allergic disease (asthma, hay fever or eczema);	chr4:103010149	chr4:102828055~102844075:+
BRCA	cis	rs7309	0.622	rs4664396	ENSG00000227403.1	AC009299.3	9.74	1.65e-21	8.99e-19	0.38	0.29	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161045139	chr2:161244739~161249050:+
BRCA	cis	rs228614	0.536	rs223437	ENSG00000246560.2	RP11-10L12.4	9.74	1.66e-21	9.01e-19	0.3	0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102798736	chr4:102828055~102844075:+
BRCA	cis	rs228614	0.51	rs223435	ENSG00000246560.2	RP11-10L12.4	9.74	1.66e-21	9.01e-19	0.3	0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102799826	chr4:102828055~102844075:+
BRCA	cis	rs228614	0.509	rs223481	ENSG00000246560.2	RP11-10L12.4	9.74	1.66e-21	9.02e-19	0.3	0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102766860	chr4:102828055~102844075:+
BRCA	cis	rs4862750	0.914	rs6553026	ENSG00000250971.1	RP11-696F12.1	9.74	1.66e-21	9.02e-19	0.31	0.29	Lobe attachment (rater-scored or self-reported);	chr4:186954494	chr4:187060099~187060930:+
BRCA	cis	rs6921919	0.583	rs7764722	ENSG00000216901.1	AL022393.7	9.74	1.66e-21	9.03e-19	0.38	0.29	Autism spectrum disorder or schizophrenia;	chr6:28386756	chr6:28176188~28176674:+
BRCA	cis	rs1113500	0.548	rs6583062	ENSG00000226822.1	RP11-356N1.2	9.74	1.67e-21	9.05e-19	0.43	0.29	Growth-regulated protein alpha levels;	chr1:108113841	chr1:108071482~108074519:+
BRCA	cis	rs6921919	0.583	rs6908137	ENSG00000216901.1	AL022393.7	9.74	1.67e-21	9.06e-19	0.38	0.29	Autism spectrum disorder or schizophrenia;	chr6:28402616	chr6:28176188~28176674:+
BRCA	cis	rs4835473	0.932	rs6852195	ENSG00000251600.4	RP11-673E1.1	9.74	1.68e-21	9.11e-19	0.33	0.29	Immature fraction of reticulocytes;	chr4:143742584	chr4:143912331~143982454:+
BRCA	cis	rs1707322	0.691	rs61784799	ENSG00000280836.1	AL355480.1	9.74	1.69e-21	9.19e-19	0.38	0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45712076	chr1:45581219~45581321:-
BRCA	cis	rs875971	0.502	rs2465121	ENSG00000226824.5	RP4-756H11.3	9.74	1.7e-21	9.2e-19	0.41	0.29	Aortic root size;	chr7:66156017	chr7:66654538~66669855:+
BRCA	cis	rs4237845	0.611	rs10877036	ENSG00000257159.1	RP11-58A17.3	-9.73	1.71e-21	9.31e-19	-0.33	-0.29	Intelligence (multi-trait analysis);	chr12:57927867	chr12:57967058~57968399:+
BRCA	cis	rs10129255	0.912	rs8009135	ENSG00000211970.3	IGHV4-61	-9.73	1.72e-21	9.32e-19	-0.2	-0.29	Kawasaki disease;	chr14:106777528	chr14:106639119~106639657:-
BRCA	cis	rs4835473	0.932	rs2127788	ENSG00000251600.4	RP11-673E1.1	9.73	1.72e-21	9.33e-19	0.33	0.29	Immature fraction of reticulocytes;	chr4:143741996	chr4:143912331~143982454:+
BRCA	cis	rs1823913	0.599	rs13027086	ENSG00000227542.1	AC092614.2	9.73	1.72e-21	9.35e-19	0.36	0.29	Obesity-related traits;	chr2:191294058	chr2:191229165~191246172:-
BRCA	cis	rs733592	0.723	rs10875766	ENSG00000240399.1	RP1-228P16.1	9.73	1.72e-21	9.35e-19	0.32	0.29	Plateletcrit;	chr12:48199797	chr12:48054813~48055591:-
BRCA	cis	rs875971	0.862	rs6952182	ENSG00000237310.1	GS1-124K5.4	-9.73	1.73e-21	9.36e-19	-0.31	-0.29	Aortic root size;	chr7:66218330	chr7:66493706~66495474:+
BRCA	cis	rs7829975	0.606	rs11776838	ENSG00000253893.2	FAM85B	9.73	1.74e-21	9.41e-19	0.35	0.29	Mood instability;	chr8:8937291	chr8:8167819~8226614:-
BRCA	cis	rs7847628	0.566	rs10739575	ENSG00000226752.6	PSMD5-AS1	9.73	1.74e-21	9.41e-19	0.44	0.29	Birth weight;	chr9:120843823	chr9:120824828~120854385:+
BRCA	cis	rs6545883	0.524	rs2463101	ENSG00000271889.1	RP11-493E12.1	-9.73	1.74e-21	9.43e-19	-0.35	-0.29	Tuberculosis;	chr2:61347287	chr2:61151433~61162105:-
BRCA	cis	rs858239	0.508	rs10242104	ENSG00000226816.2	AC005082.12	9.73	1.76e-21	9.54e-19	0.34	0.29	Cerebrospinal fluid biomarker levels;	chr7:23180831	chr7:23206013~23208045:+
BRCA	cis	rs11096990	0.6	rs6835337	ENSG00000249207.1	RP11-360F5.1	9.73	1.77e-21	9.57e-19	0.33	0.29	Cognitive function;	chr4:39281189	chr4:39112677~39126818:-
BRCA	cis	rs10515750	0.643	rs10054755	ENSG00000248544.2	CTB-47B11.3	9.73	1.77e-21	9.6e-19	0.53	0.29	Lung function (FEV1/FVC);	chr5:157384037	chr5:157375741~157384950:-
BRCA	cis	rs10515750	0.643	rs10063539	ENSG00000248544.2	CTB-47B11.3	9.73	1.77e-21	9.6e-19	0.53	0.29	Lung function (FEV1/FVC);	chr5:157384666	chr5:157375741~157384950:-
BRCA	cis	rs321358	0.731	rs73003518	ENSG00000271584.1	RP11-89C3.4	9.73	1.77e-21	9.6e-19	0.44	0.29	Body mass index;	chr11:111163933	chr11:111091932~111097357:-
BRCA	cis	rs321358	0.731	rs73003519	ENSG00000271584.1	RP11-89C3.4	9.73	1.77e-21	9.6e-19	0.44	0.29	Body mass index;	chr11:111163943	chr11:111091932~111097357:-
BRCA	cis	rs875971	0.862	rs6964437	ENSG00000237310.1	GS1-124K5.4	-9.73	1.77e-21	9.61e-19	-0.31	-0.29	Aortic root size;	chr7:66221457	chr7:66493706~66495474:+
BRCA	cis	rs3096299	0.967	rs2911255	ENSG00000274627.1	RP11-104N10.2	9.73	1.78e-21	9.65e-19	0.3	0.29	Multiple myeloma (IgH translocation);	chr16:89420729	chr16:89516797~89522217:+
BRCA	cis	rs4862750	0.872	rs6821507	ENSG00000250971.1	RP11-696F12.1	-9.73	1.78e-21	9.65e-19	-0.31	-0.29	Lobe attachment (rater-scored or self-reported);	chr4:186955675	chr4:187060099~187060930:+
BRCA	cis	rs2153535	0.562	rs10458225	ENSG00000230939.1	RP11-314C16.1	9.73	1.78e-21	9.66e-19	0.34	0.29	Motion sickness;	chr6:8385771	chr6:8784178~8785445:+
BRCA	cis	rs4835473	0.932	rs2323200	ENSG00000251600.4	RP11-673E1.1	9.73	1.79e-21	9.7e-19	0.34	0.29	Immature fraction of reticulocytes;	chr4:143765448	chr4:143912331~143982454:+
BRCA	cis	rs783540	0.9	rs12916980	ENSG00000278603.1	RP13-608F4.5	-9.73	1.8e-21	9.72e-19	-0.36	-0.29	Schizophrenia;	chr15:82637696	chr15:82472203~82472426:+
BRCA	cis	rs7772486	0.658	rs9403737	ENSG00000235652.6	RP11-545I5.3	9.73	1.8e-21	9.75e-19	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145641057	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.754	rs4896832	ENSG00000235652.6	RP11-545I5.3	9.73	1.8e-21	9.75e-19	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145643015	chr6:145799409~145886585:+
BRCA	cis	rs8062405	0.691	rs743590	ENSG00000278665.1	RP11-666O2.4	9.73	1.8e-21	9.76e-19	0.31	0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28596909	chr16:28599241~28601881:-
BRCA	cis	rs228614	0.536	rs223418	ENSG00000246560.2	RP11-10L12.4	9.73	1.81e-21	9.77e-19	0.31	0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102809336	chr4:102828055~102844075:+
BRCA	cis	rs7688540	0.8	rs12501727	ENSG00000211553.1	AC253576.2	-9.73	1.82e-21	9.84e-19	-0.36	-0.29	Facial morphology (factor 6, height of vermillion lower lip);	chr4:294285	chr4:136461~136568:+
BRCA	cis	rs7429990	0.965	rs11130154	ENSG00000229759.1	MRPS18AP1	-9.73	1.83e-21	9.87e-19	-0.33	-0.29	Educational attainment (years of education);	chr3:48027752	chr3:48256350~48256938:-
BRCA	cis	rs6700559	0.873	rs7526031	ENSG00000260088.1	RP11-92G12.3	-9.73	1.83e-21	9.92e-19	-0.38	-0.29	Coronary artery disease;	chr1:200695174	chr1:200669507~200694250:+
BRCA	cis	rs7429990	0.901	rs7433678	ENSG00000229759.1	MRPS18AP1	-9.73	1.84e-21	9.94e-19	-0.33	-0.29	Educational attainment (years of education);	chr3:47995588	chr3:48256350~48256938:-
BRCA	cis	rs7044106	0.69	rs10739569	ENSG00000226752.6	PSMD5-AS1	-9.73	1.84e-21	9.97e-19	-0.34	-0.29	Hip circumference adjusted for BMI;	chr9:120598749	chr9:120824828~120854385:+
BRCA	cis	rs1823913	0.637	rs12992372	ENSG00000227542.1	AC092614.2	9.73	1.85e-21	1e-18	0.35	0.29	Obesity-related traits;	chr2:191289251	chr2:191229165~191246172:-
BRCA	cis	rs8072100	0.935	rs12150231	ENSG00000228782.6	CTD-2026D20.3	-9.73	1.85e-21	1e-18	-0.31	-0.29	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47639725	chr17:47450568~47492492:-
BRCA	cis	rs12682352	0.602	rs635594	ENSG00000253893.2	FAM85B	9.73	1.86e-21	1e-18	0.36	0.29	Neuroticism;	chr8:8755877	chr8:8167819~8226614:-
BRCA	cis	rs1062177	1	rs1062177	ENSG00000253921.1	CTB-113P19.3	-9.73	1.86e-21	1.01e-18	-0.4	-0.29	Preschool internalizing problems;	chr5:151805140	chr5:151753992~151767247:+
BRCA	cis	rs858239	0.6	rs6961406	ENSG00000226816.2	AC005082.12	9.73	1.86e-21	1.01e-18	0.33	0.29	Cerebrospinal fluid biomarker levels;	chr7:23095272	chr7:23206013~23208045:+
BRCA	cis	rs858239	0.6	rs6461690	ENSG00000226816.2	AC005082.12	9.73	1.86e-21	1.01e-18	0.33	0.29	Cerebrospinal fluid biomarker levels;	chr7:23095915	chr7:23206013~23208045:+
BRCA	cis	rs858239	0.6	rs6967419	ENSG00000226816.2	AC005082.12	9.73	1.86e-21	1.01e-18	0.33	0.29	Cerebrospinal fluid biomarker levels;	chr7:23096691	chr7:23206013~23208045:+
BRCA	cis	rs2455601	0.744	rs11042107	ENSG00000254860.4	TMEM9B-AS1	9.73	1.86e-21	1.01e-18	0.34	0.29	Schizophrenia;	chr11:8884324	chr11:8964675~8977527:+
BRCA	cis	rs7772486	0.79	rs11760	ENSG00000235652.6	RP11-545I5.3	9.72	1.87e-21	1.01e-18	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145884837	chr6:145799409~145886585:+
BRCA	cis	rs858239	0.6	rs28483572	ENSG00000226816.2	AC005082.12	9.72	1.87e-21	1.01e-18	0.33	0.29	Cerebrospinal fluid biomarker levels;	chr7:23092166	chr7:23206013~23208045:+
BRCA	cis	rs11096990	0.656	rs3733284	ENSG00000249207.1	RP11-360F5.1	9.72	1.88e-21	1.01e-18	0.33	0.29	Cognitive function;	chr4:39299714	chr4:39112677~39126818:-
BRCA	cis	rs7829975	0.535	rs4841005	ENSG00000253893.2	FAM85B	9.72	1.88e-21	1.02e-18	0.36	0.29	Mood instability;	chr8:8643720	chr8:8167819~8226614:-
BRCA	cis	rs957448	1	rs1055800	ENSG00000253704.1	RP11-267M23.4	-9.72	1.88e-21	1.02e-18	-0.33	-0.29	Nonsyndromic cleft lip with cleft palate;	chr8:94510810	chr8:94553722~94569745:+
BRCA	cis	rs4835473	0.9	rs10032963	ENSG00000251600.4	RP11-673E1.1	9.72	1.89e-21	1.02e-18	0.33	0.29	Immature fraction of reticulocytes;	chr4:143733068	chr4:143912331~143982454:+
BRCA	cis	rs11096990	0.656	rs9993224	ENSG00000249207.1	RP11-360F5.1	9.72	1.9e-21	1.03e-18	0.33	0.29	Cognitive function;	chr4:39298578	chr4:39112677~39126818:-
BRCA	cis	rs875971	0.545	rs73142245	ENSG00000226824.5	RP4-756H11.3	-9.72	1.9e-21	1.03e-18	-0.41	-0.29	Aortic root size;	chr7:66226662	chr7:66654538~66669855:+
BRCA	cis	rs8062405	0.69	rs6498089	ENSG00000259982.1	CDC37P1	-9.72	1.9e-21	1.03e-18	-0.36	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28617979	chr16:28700294~28701540:-
BRCA	cis	rs7772486	0.875	rs2777479	ENSG00000235652.6	RP11-545I5.3	9.72	1.91e-21	1.03e-18	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145988042	chr6:145799409~145886585:+
BRCA	cis	rs228614	0.51	rs223472	ENSG00000246560.2	RP11-10L12.4	9.72	1.91e-21	1.03e-18	0.3	0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102774327	chr4:102828055~102844075:+
BRCA	cis	rs227275	0.554	rs223399	ENSG00000246560.2	RP11-10L12.4	9.72	1.92e-21	1.03e-18	0.3	0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102820800	chr4:102828055~102844075:+
BRCA	cis	rs7429990	0.965	rs4858871	ENSG00000229759.1	MRPS18AP1	9.72	1.93e-21	1.04e-18	0.33	0.29	Educational attainment (years of education);	chr3:47911915	chr3:48256350~48256938:-
BRCA	cis	rs801193	0.569	rs2707824	ENSG00000237310.1	GS1-124K5.4	9.72	1.93e-21	1.04e-18	0.3	0.29	Aortic root size;	chr7:66724256	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.502	rs2946580	ENSG00000226824.5	RP4-756H11.3	9.72	1.94e-21	1.05e-18	0.41	0.29	Aortic root size;	chr7:66066855	chr7:66654538~66669855:+
BRCA	cis	rs801193	0.569	rs10950050	ENSG00000237310.1	GS1-124K5.4	9.72	1.94e-21	1.05e-18	0.3	0.29	Aortic root size;	chr7:66774601	chr7:66493706~66495474:+
BRCA	cis	rs11098499	0.865	rs28753180	ENSG00000245958.5	RP11-33B1.1	-9.72	1.95e-21	1.05e-18	-0.28	-0.29	Corneal astigmatism;	chr4:119484212	chr4:119454791~119552025:+
BRCA	cis	rs72772090	0.539	rs55996659	ENSG00000248734.2	CTD-2260A17.1	-9.72	1.97e-21	1.06e-18	-0.48	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96778446	chr5:96784777~96785999:+
BRCA	cis	rs950169	0.545	rs4842841	ENSG00000225151.9	GOLGA2P7	-9.72	1.97e-21	1.06e-18	-0.41	-0.29	Schizophrenia;	chr15:83972373	chr15:84199311~84230136:-
BRCA	cis	rs7684253	0.587	rs4339274	ENSG00000269949.1	RP11-738E22.3	9.72	1.98e-21	1.07e-18	0.33	0.29	Migraine;	chr4:56881468	chr4:56960927~56961373:-
BRCA	cis	rs11098499	0.954	rs4577559	ENSG00000245958.5	RP11-33B1.1	-9.72	1.98e-21	1.07e-18	-0.28	-0.29	Corneal astigmatism;	chr4:119482888	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.954	rs7656252	ENSG00000245958.5	RP11-33B1.1	-9.72	1.98e-21	1.07e-18	-0.28	-0.29	Corneal astigmatism;	chr4:119483113	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.865	rs28845498	ENSG00000245958.5	RP11-33B1.1	-9.72	1.98e-21	1.07e-18	-0.28	-0.29	Corneal astigmatism;	chr4:119484031	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.954	rs56270433	ENSG00000245958.5	RP11-33B1.1	-9.72	1.98e-21	1.07e-18	-0.28	-0.29	Corneal astigmatism;	chr4:119484875	chr4:119454791~119552025:+
BRCA	cis	rs875971	0.862	rs1167408	ENSG00000237310.1	GS1-124K5.4	-9.72	1.99e-21	1.07e-18	-0.31	-0.29	Aortic root size;	chr7:66091121	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.83	rs1167406	ENSG00000237310.1	GS1-124K5.4	-9.72	1.99e-21	1.07e-18	-0.31	-0.29	Aortic root size;	chr7:66091949	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.862	rs1167399	ENSG00000237310.1	GS1-124K5.4	-9.72	1.99e-21	1.07e-18	-0.31	-0.29	Aortic root size;	chr7:66096890	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.862	rs57866200	ENSG00000237310.1	GS1-124K5.4	-9.72	1.99e-21	1.07e-18	-0.31	-0.29	Aortic root size;	chr7:66100405	chr7:66493706~66495474:+
BRCA	cis	rs783540	1	rs1267657	ENSG00000278603.1	RP13-608F4.5	-9.72	2e-21	1.08e-18	-0.37	-0.29	Schizophrenia;	chr15:82546501	chr15:82472203~82472426:+
BRCA	cis	rs783540	1	rs803688	ENSG00000278603.1	RP13-608F4.5	-9.72	2e-21	1.08e-18	-0.37	-0.29	Schizophrenia;	chr15:82548043	chr15:82472203~82472426:+
BRCA	cis	rs7772486	0.79	rs7742333	ENSG00000235652.6	RP11-545I5.3	-9.72	2e-21	1.08e-18	-0.29	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145837893	chr6:145799409~145886585:+
BRCA	cis	rs11096990	0.634	rs12648082	ENSG00000249207.1	RP11-360F5.1	9.72	2.01e-21	1.08e-18	0.33	0.29	Cognitive function;	chr4:39278104	chr4:39112677~39126818:-
BRCA	cis	rs812925	0.519	rs2694627	ENSG00000271889.1	RP11-493E12.1	-9.72	2.01e-21	1.09e-18	-0.35	-0.29	Immature fraction of reticulocytes;	chr2:61398371	chr2:61151433~61162105:-
BRCA	cis	rs10875746	0.551	rs12322347	ENSG00000240399.1	RP1-228P16.1	-9.72	2.02e-21	1.09e-18	-0.4	-0.29	Longevity (90 years and older);	chr12:48313915	chr12:48054813~48055591:-
BRCA	cis	rs10875746	0.551	rs12322348	ENSG00000240399.1	RP1-228P16.1	-9.72	2.02e-21	1.09e-18	-0.4	-0.29	Longevity (90 years and older);	chr12:48313916	chr12:48054813~48055591:-
BRCA	cis	rs1823913	0.637	rs13010441	ENSG00000227542.1	AC092614.2	9.72	2.03e-21	1.09e-18	0.35	0.29	Obesity-related traits;	chr2:191303903	chr2:191229165~191246172:-
BRCA	cis	rs7429990	0.965	rs34380889	ENSG00000229759.1	MRPS18AP1	9.72	2.03e-21	1.1e-18	0.33	0.29	Educational attainment (years of education);	chr3:47905692	chr3:48256350~48256938:-
BRCA	cis	rs733592	0.56	rs2158515	ENSG00000240399.1	RP1-228P16.1	-9.72	2.03e-21	1.1e-18	-0.31	-0.29	Plateletcrit;	chr12:48113885	chr12:48054813~48055591:-
BRCA	cis	rs7772486	0.719	rs4391282	ENSG00000235652.6	RP11-545I5.3	-9.71	2.05e-21	1.1e-18	-0.29	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145955644	chr6:145799409~145886585:+
BRCA	cis	rs875971	0.83	rs12673450	ENSG00000237310.1	GS1-124K5.4	9.71	2.05e-21	1.1e-18	0.31	0.29	Aortic root size;	chr7:66544233	chr7:66493706~66495474:+
BRCA	cis	rs17711722	0.565	rs4717276	ENSG00000224316.1	RP11-479O9.2	9.71	2.05e-21	1.1e-18	0.3	0.29	Calcium levels;	chr7:65829754	chr7:65773620~65802067:+
BRCA	cis	rs4862750	0.914	rs9998558	ENSG00000250971.1	RP11-696F12.1	9.71	2.05e-21	1.11e-18	0.31	0.29	Lobe attachment (rater-scored or self-reported);	chr4:186953537	chr4:187060099~187060930:+
BRCA	cis	rs801193	0.569	rs2659907	ENSG00000237310.1	GS1-124K5.4	9.71	2.06e-21	1.11e-18	0.3	0.29	Aortic root size;	chr7:66699045	chr7:66493706~66495474:+
BRCA	cis	rs17711722	0.565	rs73372653	ENSG00000236529.1	RP13-254B10.1	9.71	2.06e-21	1.11e-18	0.33	0.29	Calcium levels;	chr7:65977808	chr7:65840212~65840596:+
BRCA	cis	rs7772486	0.719	rs702317	ENSG00000235652.6	RP11-545I5.3	-9.71	2.07e-21	1.11e-18	-0.29	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145683874	chr6:145799409~145886585:+
BRCA	cis	rs11098499	0.954	rs17006190	ENSG00000245958.5	RP11-33B1.1	-9.71	2.07e-21	1.12e-18	-0.29	-0.29	Corneal astigmatism;	chr4:119497683	chr4:119454791~119552025:+
BRCA	cis	rs8018967	1	rs8018967	ENSG00000258695.2	RP3-414A15.2	-9.71	2.08e-21	1.12e-18	-0.35	-0.29	Blood metabolite ratios;	chr14:73510230	chr14:73522878~73530610:+
BRCA	cis	rs7429990	0.965	rs7426976	ENSG00000229759.1	MRPS18AP1	-9.71	2.1e-21	1.13e-18	-0.32	-0.29	Educational attainment (years of education);	chr3:47981083	chr3:48256350~48256938:-
BRCA	cis	rs7429990	0.965	rs1013431	ENSG00000229759.1	MRPS18AP1	-9.71	2.1e-21	1.13e-18	-0.32	-0.29	Educational attainment (years of education);	chr3:47987628	chr3:48256350~48256938:-
BRCA	cis	rs7429990	0.932	rs9862913	ENSG00000229759.1	MRPS18AP1	9.71	2.1e-21	1.13e-18	0.32	0.29	Educational attainment (years of education);	chr3:47974682	chr3:48256350~48256938:-
BRCA	cis	rs72772090	0.539	rs17481759	ENSG00000248734.2	CTD-2260A17.1	-9.71	2.1e-21	1.13e-18	-0.48	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96778991	chr5:96784777~96785999:+
BRCA	cis	rs227275	0.554	rs223367	ENSG00000246560.2	RP11-10L12.4	9.71	2.1e-21	1.13e-18	0.3	0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102843836	chr4:102828055~102844075:+
BRCA	cis	rs2404602	0.532	rs284892	ENSG00000259422.1	RP11-593F23.1	9.71	2.12e-21	1.14e-18	0.35	0.29	Blood metabolite levels;	chr15:76428696	chr15:76174891~76181486:-
BRCA	cis	rs1062177	0.95	rs892005	ENSG00000253921.1	CTB-113P19.3	-9.71	2.16e-21	1.16e-18	-0.39	-0.29	Preschool internalizing problems;	chr5:151801060	chr5:151753992~151767247:+
BRCA	cis	rs8062405	0.755	rs7193402	ENSG00000278665.1	RP11-666O2.4	9.71	2.16e-21	1.16e-18	0.31	0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28574806	chr16:28599241~28601881:-
BRCA	cis	rs858239	0.539	rs10254544	ENSG00000226816.2	AC005082.12	9.71	2.16e-21	1.16e-18	0.34	0.29	Cerebrospinal fluid biomarker levels;	chr7:23180616	chr7:23206013~23208045:+
BRCA	cis	rs7684253	0.55	rs4566710	ENSG00000269949.1	RP11-738E22.3	-9.71	2.16e-21	1.16e-18	-0.33	-0.29	Migraine;	chr4:56879297	chr4:56960927~56961373:-
BRCA	cis	rs227275	0.554	rs223436	ENSG00000246560.2	RP11-10L12.4	9.71	2.17e-21	1.17e-18	0.3	0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102798749	chr4:102828055~102844075:+
BRCA	cis	rs227275	0.554	rs223439	ENSG00000246560.2	RP11-10L12.4	9.71	2.19e-21	1.18e-18	0.3	0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102798377	chr4:102828055~102844075:+
BRCA	cis	rs8072100	1	rs4794016	ENSG00000228782.6	CTD-2026D20.3	-9.71	2.21e-21	1.19e-18	-0.31	-0.29	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47648565	chr17:47450568~47492492:-
BRCA	cis	rs801193	1	rs4717319	ENSG00000222364.1	RNU6-96P	-9.71	2.21e-21	1.19e-18	-0.33	-0.29	Aortic root size;	chr7:66777606	chr7:66395191~66395286:+
BRCA	cis	rs801193	0.569	rs13226966	ENSG00000237310.1	GS1-124K5.4	9.71	2.22e-21	1.19e-18	0.3	0.29	Aortic root size;	chr7:66768636	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.862	rs11773628	ENSG00000237310.1	GS1-124K5.4	-9.7	2.24e-21	1.2e-18	-0.3	-0.29	Aortic root size;	chr7:66517644	chr7:66493706~66495474:+
BRCA	cis	rs1823913	0.637	rs2067610	ENSG00000227542.1	AC092614.2	9.7	2.26e-21	1.22e-18	0.35	0.29	Obesity-related traits;	chr2:191299251	chr2:191229165~191246172:-
BRCA	cis	rs875971	0.522	rs2949690	ENSG00000224316.1	RP11-479O9.2	-9.7	2.27e-21	1.22e-18	-0.29	-0.29	Aortic root size;	chr7:66018255	chr7:65773620~65802067:+
BRCA	cis	rs812925	0.519	rs2922089	ENSG00000271889.1	RP11-493E12.1	-9.7	2.29e-21	1.23e-18	-0.35	-0.29	Immature fraction of reticulocytes;	chr2:61397994	chr2:61151433~61162105:-
BRCA	cis	rs11098499	0.909	rs10026736	ENSG00000245958.5	RP11-33B1.1	-9.7	2.29e-21	1.23e-18	-0.29	-0.29	Corneal astigmatism;	chr4:119463167	chr4:119454791~119552025:+
BRCA	cis	rs11096990	0.594	rs2381373	ENSG00000249207.1	RP11-360F5.1	9.7	2.29e-21	1.23e-18	0.33	0.29	Cognitive function;	chr4:39280683	chr4:39112677~39126818:-
BRCA	cis	rs227275	0.556	rs4235407	ENSG00000246560.2	RP11-10L12.4	9.7	2.3e-21	1.23e-18	0.31	0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102897427	chr4:102828055~102844075:+
BRCA	cis	rs8062405	0.789	rs28676837	ENSG00000259982.1	CDC37P1	-9.7	2.31e-21	1.24e-18	-0.36	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28615742	chr16:28700294~28701540:-
BRCA	cis	rs783540	1	rs783540	ENSG00000278603.1	RP13-608F4.5	9.7	2.31e-21	1.24e-18	0.36	0.29	Schizophrenia;	chr15:82585958	chr15:82472203~82472426:+
BRCA	cis	rs1823913	0.622	rs55787447	ENSG00000227542.1	AC092614.2	9.7	2.31e-21	1.24e-18	0.35	0.29	Obesity-related traits;	chr2:191288596	chr2:191229165~191246172:-
BRCA	cis	rs17711722	0.565	rs4275112	ENSG00000236529.1	RP13-254B10.1	-9.7	2.32e-21	1.24e-18	-0.32	-0.29	Calcium levels;	chr7:65733651	chr7:65840212~65840596:+
BRCA	cis	rs801193	0.569	rs4717315	ENSG00000237310.1	GS1-124K5.4	9.7	2.32e-21	1.24e-18	0.3	0.29	Aortic root size;	chr7:66713338	chr7:66493706~66495474:+
BRCA	cis	rs8072100	1	rs4375701	ENSG00000228782.6	CTD-2026D20.3	9.7	2.33e-21	1.25e-18	0.31	0.29	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47634852	chr17:47450568~47492492:-
BRCA	cis	rs11096990	0.634	rs6531704	ENSG00000249207.1	RP11-360F5.1	9.7	2.33e-21	1.25e-18	0.33	0.29	Cognitive function;	chr4:39282126	chr4:39112677~39126818:-
BRCA	cis	rs11096990	0.634	rs745642	ENSG00000249207.1	RP11-360F5.1	9.7	2.34e-21	1.25e-18	0.33	0.29	Cognitive function;	chr4:39279642	chr4:39112677~39126818:-
BRCA	cis	rs875971	0.862	rs6460282	ENSG00000237310.1	GS1-124K5.4	-9.7	2.35e-21	1.26e-18	-0.31	-0.29	Aortic root size;	chr7:66226259	chr7:66493706~66495474:+
BRCA	cis	rs853679	0.76	rs11962305	ENSG00000220721.1	OR1F12	9.7	2.35e-21	1.26e-18	0.41	0.29	Depression;	chr6:28232159	chr6:28073316~28074233:+
BRCA	cis	rs11096990	0.634	rs2086752	ENSG00000249207.1	RP11-360F5.1	9.7	2.35e-21	1.26e-18	0.33	0.29	Cognitive function;	chr4:39280486	chr4:39112677~39126818:-
BRCA	cis	rs8062405	0.54	rs151226	ENSG00000278665.1	RP11-666O2.4	9.7	2.35e-21	1.26e-18	0.28	0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28538502	chr16:28599241~28601881:-
BRCA	cis	rs6570726	0.738	rs4495284	ENSG00000235652.6	RP11-545I5.3	9.7	2.36e-21	1.26e-18	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145595481	chr6:145799409~145886585:+
BRCA	cis	rs227275	0.554	rs223422	ENSG00000246560.2	RP11-10L12.4	9.7	2.37e-21	1.27e-18	0.3	0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102805616	chr4:102828055~102844075:+
BRCA	cis	rs11096990	0.634	rs7654501	ENSG00000249207.1	RP11-360F5.1	9.7	2.37e-21	1.27e-18	0.33	0.29	Cognitive function;	chr4:39282364	chr4:39112677~39126818:-
BRCA	cis	rs228614	0.51	rs223356	ENSG00000246560.2	RP11-10L12.4	9.7	2.37e-21	1.27e-18	0.3	0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102852344	chr4:102828055~102844075:+
BRCA	cis	rs1823913	0.576	rs13011608	ENSG00000227542.1	AC092614.2	9.7	2.37e-21	1.27e-18	0.35	0.29	Obesity-related traits;	chr2:191267097	chr2:191229165~191246172:-
BRCA	cis	rs783540	0.967	rs1145172	ENSG00000278603.1	RP13-608F4.5	-9.7	2.39e-21	1.28e-18	-0.37	-0.29	Schizophrenia;	chr15:82554866	chr15:82472203~82472426:+
BRCA	cis	rs11098499	0.954	rs12499324	ENSG00000245958.5	RP11-33B1.1	-9.7	2.39e-21	1.28e-18	-0.28	-0.29	Corneal astigmatism;	chr4:119472631	chr4:119454791~119552025:+
BRCA	cis	rs875971	0.619	rs2302918	ENSG00000222364.1	RNU6-96P	-9.7	2.41e-21	1.29e-18	-0.34	-0.29	Aortic root size;	chr7:66535945	chr7:66395191~66395286:+
BRCA	cis	rs1113500	0.548	rs3853497	ENSG00000226822.1	RP11-356N1.2	9.7	2.41e-21	1.29e-18	0.43	0.29	Growth-regulated protein alpha levels;	chr1:108114562	chr1:108071482~108074519:+
BRCA	cis	rs7772486	0.79	rs9403750	ENSG00000235652.6	RP11-545I5.3	9.7	2.42e-21	1.29e-18	0.28	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145846626	chr6:145799409~145886585:+
BRCA	cis	rs11096990	0.634	rs746678	ENSG00000249207.1	RP11-360F5.1	9.69	2.45e-21	1.31e-18	0.33	0.29	Cognitive function;	chr4:39279035	chr4:39112677~39126818:-
BRCA	cis	rs11098499	0.863	rs9997631	ENSG00000245958.5	RP11-33B1.1	-9.69	2.45e-21	1.31e-18	-0.28	-0.29	Corneal astigmatism;	chr4:119548840	chr4:119454791~119552025:+
BRCA	cis	rs4862750	0.872	rs6553029	ENSG00000250971.1	RP11-696F12.1	-9.69	2.46e-21	1.31e-18	-0.32	-0.29	Lobe attachment (rater-scored or self-reported);	chr4:186955316	chr4:187060099~187060930:+
BRCA	cis	rs7688540	0.8	rs6837796	ENSG00000211553.1	AC253576.2	-9.69	2.46e-21	1.32e-18	-0.36	-0.29	Facial morphology (factor 6, height of vermillion lower lip);	chr4:278733	chr4:136461~136568:+
BRCA	cis	rs875971	0.66	rs2013222	ENSG00000222364.1	RNU6-96P	9.69	2.48e-21	1.33e-18	0.32	0.29	Aortic root size;	chr7:66570949	chr7:66395191~66395286:+
BRCA	cis	rs7429990	0.965	rs4392441	ENSG00000229759.1	MRPS18AP1	-9.69	2.48e-21	1.33e-18	-0.33	-0.29	Educational attainment (years of education);	chr3:48036211	chr3:48256350~48256938:-
BRCA	cis	rs801193	0.569	rs2659908	ENSG00000237310.1	GS1-124K5.4	9.69	2.53e-21	1.35e-18	0.3	0.29	Aortic root size;	chr7:66695835	chr7:66493706~66495474:+
BRCA	cis	rs8062405	0.558	rs231976	ENSG00000278665.1	RP11-666O2.4	9.69	2.54e-21	1.36e-18	0.28	0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28534266	chr16:28599241~28601881:-
BRCA	cis	rs10759883	0.563	rs625105	ENSG00000175611.10	LINC00476	9.69	2.55e-21	1.36e-18	0.32	0.29	Nicotine dependence;	chr9:96007466	chr9:95759231~95875977:-
BRCA	cis	rs11098499	0.954	rs6822679	ENSG00000245958.5	RP11-33B1.1	-9.69	2.55e-21	1.36e-18	-0.28	-0.29	Corneal astigmatism;	chr4:119481547	chr4:119454791~119552025:+
BRCA	cis	rs11096990	0.634	rs6531706	ENSG00000249207.1	RP11-360F5.1	9.69	2.55e-21	1.36e-18	0.33	0.29	Cognitive function;	chr4:39294547	chr4:39112677~39126818:-
BRCA	cis	rs1113500	0.965	rs10881495	ENSG00000226822.1	RP11-356N1.2	9.69	2.56e-21	1.37e-18	0.38	0.29	Growth-regulated protein alpha levels;	chr1:108068364	chr1:108071482~108074519:+
BRCA	cis	rs875971	0.756	rs4718328	ENSG00000237310.1	GS1-124K5.4	-9.69	2.59e-21	1.38e-18	-0.3	-0.29	Aortic root size;	chr7:66228350	chr7:66493706~66495474:+
BRCA	cis	rs227275	0.554	rs223409	ENSG00000246560.2	RP11-10L12.4	9.69	2.6e-21	1.39e-18	0.3	0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102815023	chr4:102828055~102844075:+
BRCA	cis	rs228614	0.536	rs223475	ENSG00000246560.2	RP11-10L12.4	9.69	2.62e-21	1.4e-18	0.3	0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102771986	chr4:102828055~102844075:+
BRCA	cis	rs228614	0.536	rs223474	ENSG00000246560.2	RP11-10L12.4	9.69	2.62e-21	1.4e-18	0.3	0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102772007	chr4:102828055~102844075:+
BRCA	cis	rs11105298	0.891	rs4842662	ENSG00000258302.2	RP11-981P6.1	9.69	2.62e-21	1.4e-18	0.33	0.29	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89539669	chr12:89561129~89594878:+
BRCA	cis	rs753274	0.65	rs72998945	ENSG00000267147.2	CTC-548K16.1	-9.69	2.63e-21	1.4e-18	-0.34	-0.29	Tumor necrosis factor beta levels;	chr19:14307629	chr19:14333743~14343916:+
BRCA	cis	rs6142102	0.625	rs6142067	ENSG00000276073.1	RP5-1125A11.7	-9.69	2.63e-21	1.4e-18	-0.33	-0.29	Skin pigmentation;	chr20:33968766	chr20:33985617~33988989:-
BRCA	cis	rs875971	0.545	rs73142265	ENSG00000226824.5	RP4-756H11.3	-9.69	2.66e-21	1.42e-18	-0.4	-0.29	Aortic root size;	chr7:66234510	chr7:66654538~66669855:+
BRCA	cis	rs35160687	0.644	rs1863061	ENSG00000273080.1	RP11-301O19.1	-9.68	2.69e-21	1.43e-18	-0.34	-0.29	Night sleep phenotypes;	chr2:86285784	chr2:86195590~86196049:+
BRCA	cis	rs1075265	0.73	rs805392	ENSG00000233266.1	HMGB1P31	9.68	2.7e-21	1.44e-18	0.35	0.29	Chronotype;Morning vs. evening chronotype;	chr2:53877594	chr2:54051334~54051760:+
BRCA	cis	rs1823913	0.538	rs35311234	ENSG00000227542.1	AC092614.2	9.68	2.7e-21	1.44e-18	0.36	0.29	Obesity-related traits;	chr2:191316952	chr2:191229165~191246172:-
BRCA	cis	rs1062177	1	rs2964571	ENSG00000253921.1	CTB-113P19.3	-9.68	2.7e-21	1.44e-18	-0.39	-0.29	Preschool internalizing problems;	chr5:151791695	chr5:151753992~151767247:+
BRCA	cis	rs1062177	1	rs2915869	ENSG00000253921.1	CTB-113P19.3	-9.68	2.7e-21	1.44e-18	-0.39	-0.29	Preschool internalizing problems;	chr5:151791948	chr5:151753992~151767247:+
BRCA	cis	rs17711722	0.727	rs2658585	ENSG00000224316.1	RP11-479O9.2	9.68	2.7e-21	1.44e-18	0.29	0.29	Calcium levels;	chr7:65996954	chr7:65773620~65802067:+
BRCA	cis	rs2243480	1	rs2243480	ENSG00000226824.5	RP4-756H11.3	-9.68	2.72e-21	1.45e-18	-0.57	-0.29	Diabetic kidney disease;	chr7:66134209	chr7:66654538~66669855:+
BRCA	cis	rs1823913	0.599	rs1454754	ENSG00000227542.1	AC092614.2	9.68	2.74e-21	1.46e-18	0.35	0.29	Obesity-related traits;	chr2:191303562	chr2:191229165~191246172:-
BRCA	cis	rs12468226	1	rs75040639	ENSG00000273456.1	RP11-686O6.2	9.68	2.74e-21	1.46e-18	0.43	0.29	Urate levels;	chr2:202486973	chr2:202374932~202375604:-
BRCA	cis	rs11098499	0.908	rs9995234	ENSG00000245958.5	RP11-33B1.1	-9.68	2.74e-21	1.46e-18	-0.29	-0.29	Corneal astigmatism;	chr4:119400672	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.954	rs10006706	ENSG00000245958.5	RP11-33B1.1	-9.68	2.77e-21	1.48e-18	-0.28	-0.29	Corneal astigmatism;	chr4:119487997	chr4:119454791~119552025:+
BRCA	cis	rs1823913	0.599	rs17414109	ENSG00000227542.1	AC092614.2	9.68	2.77e-21	1.48e-18	0.36	0.29	Obesity-related traits;	chr2:191310675	chr2:191229165~191246172:-
BRCA	cis	rs35160687	0.712	rs4832262	ENSG00000273080.1	RP11-301O19.1	-9.68	2.77e-21	1.48e-18	-0.33	-0.29	Night sleep phenotypes;	chr2:86258011	chr2:86195590~86196049:+
BRCA	cis	rs2665103	0.715	rs11639440	ENSG00000278603.1	RP13-608F4.5	9.68	2.78e-21	1.48e-18	0.37	0.29	Intelligence (multi-trait analysis);	chr15:82278705	chr15:82472203~82472426:+
BRCA	cis	rs58873874	0.737	rs11739062	ENSG00000251405.2	CTB-109A12.1	9.68	2.81e-21	1.5e-18	0.74	0.29	Bipolar disorder (body mass index interaction);	chr5:157474693	chr5:157362615~157460078:-
BRCA	cis	rs8062405	0.723	rs762633	ENSG00000278665.1	RP11-666O2.4	9.68	2.82e-21	1.5e-18	0.32	0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28597020	chr16:28599241~28601881:-
BRCA	cis	rs11096990	0.656	rs7686161	ENSG00000249207.1	RP11-360F5.1	9.68	2.83e-21	1.51e-18	0.33	0.29	Cognitive function;	chr4:39283201	chr4:39112677~39126818:-
BRCA	cis	rs8062405	0.723	rs113208333	ENSG00000278665.1	RP11-666O2.4	9.68	2.84e-21	1.51e-18	0.31	0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28594839	chr16:28599241~28601881:-
BRCA	cis	rs227275	0.556	rs223426	ENSG00000246560.2	RP11-10L12.4	9.68	2.85e-21	1.52e-18	0.3	0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102801330	chr4:102828055~102844075:+
BRCA	cis	rs227275	0.554	rs223425	ENSG00000246560.2	RP11-10L12.4	9.68	2.85e-21	1.52e-18	0.3	0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102802836	chr4:102828055~102844075:+
BRCA	cis	rs875971	0.755	rs76288834	ENSG00000237310.1	GS1-124K5.4	-9.68	2.85e-21	1.52e-18	-0.31	-0.29	Aortic root size;	chr7:66604815	chr7:66493706~66495474:+
BRCA	cis	rs11096990	0.634	rs17431358	ENSG00000249207.1	RP11-360F5.1	9.68	2.85e-21	1.52e-18	0.33	0.29	Cognitive function;	chr4:39275676	chr4:39112677~39126818:-
BRCA	cis	rs11096990	0.679	rs6531707	ENSG00000249207.1	RP11-360F5.1	9.68	2.86e-21	1.52e-18	0.33	0.29	Cognitive function;	chr4:39296064	chr4:39112677~39126818:-
BRCA	cis	rs1062177	0.951	rs2915876	ENSG00000253921.1	CTB-113P19.3	-9.68	2.91e-21	1.55e-18	-0.4	-0.29	Preschool internalizing problems;	chr5:151771184	chr5:151753992~151767247:+
BRCA	cis	rs367615	0.918	rs72797472	ENSG00000249476.1	CTD-2587M2.1	9.67	2.94e-21	1.57e-18	0.37	0.29	Colorectal cancer (SNP x SNP interaction);	chr5:109545642	chr5:109237120~109326369:-
BRCA	cis	rs4713118	0.662	rs149900	ENSG00000220721.1	OR1F12	9.67	2.95e-21	1.57e-18	0.38	0.29	Parkinson's disease;	chr6:28046819	chr6:28073316~28074233:+
BRCA	cis	rs4862750	0.872	rs6811569	ENSG00000250971.1	RP11-696F12.1	-9.67	2.96e-21	1.58e-18	-0.3	-0.29	Lobe attachment (rater-scored or self-reported);	chr4:186976834	chr4:187060099~187060930:+
BRCA	cis	rs35160687	0.712	rs6738585	ENSG00000273080.1	RP11-301O19.1	-9.67	2.96e-21	1.58e-18	-0.32	-0.29	Night sleep phenotypes;	chr2:86283161	chr2:86195590~86196049:+
BRCA	cis	rs35160687	0.712	rs6725234	ENSG00000273080.1	RP11-301O19.1	-9.67	2.96e-21	1.58e-18	-0.32	-0.29	Night sleep phenotypes;	chr2:86283165	chr2:86195590~86196049:+
BRCA	cis	rs2243480	0.901	rs2949697	ENSG00000226824.5	RP4-756H11.3	-9.67	2.97e-21	1.58e-18	-0.55	-0.29	Diabetic kidney disease;	chr7:65999249	chr7:66654538~66669855:+
BRCA	cis	rs11722779	0.81	rs223417	ENSG00000246560.2	RP11-10L12.4	9.67	3e-21	1.59e-18	0.3	0.29	Schizophrenia;	chr4:102810568	chr4:102828055~102844075:+
BRCA	cis	rs11722779	0.805	rs223416	ENSG00000246560.2	RP11-10L12.4	9.67	3e-21	1.59e-18	0.3	0.29	Schizophrenia;	chr4:102810580	chr4:102828055~102844075:+
BRCA	cis	rs7829975	0.572	rs7005000	ENSG00000253893.2	FAM85B	9.67	3e-21	1.6e-18	0.35	0.29	Mood instability;	chr8:8939092	chr8:8167819~8226614:-
BRCA	cis	rs2283792	0.765	rs2283793	ENSG00000224086.5	LL22NC03-86G7.1	-9.67	3.01e-21	1.6e-18	-0.31	-0.29	Multiple sclerosis;	chr22:21827189	chr22:21938293~21977632:+
BRCA	cis	rs6538678	0.824	rs7307510	ENSG00000258343.1	RP11-536G4.2	-9.67	3.02e-21	1.6e-18	-0.42	-0.29	Lupus nephritis in systemic lupus erythematosus;	chr12:95843792	chr12:95795345~95858839:-
BRCA	cis	rs858239	0.601	rs7805206	ENSG00000226816.2	AC005082.12	9.67	3.02e-21	1.61e-18	0.32	0.29	Cerebrospinal fluid biomarker levels;	chr7:23120591	chr7:23206013~23208045:+
BRCA	cis	rs732716	0.785	rs11085073	ENSG00000267769.1	CTB-50L17.9	9.67	3.03e-21	1.61e-18	0.36	0.29	Mean corpuscular volume;	chr19:4375165	chr19:4454014~4455286:+
BRCA	cis	rs17023223	0.537	rs12092807	ENSG00000231365.4	RP11-418J17.1	9.67	3.06e-21	1.63e-18	0.37	0.29	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119208021	chr1:119140396~119275973:+
BRCA	cis	rs1113500	0.933	rs11185260	ENSG00000226822.1	RP11-356N1.2	-9.67	3.06e-21	1.63e-18	-0.37	-0.29	Growth-regulated protein alpha levels;	chr1:108092457	chr1:108071482~108074519:+
BRCA	cis	rs7684253	0.587	rs2170073	ENSG00000269949.1	RP11-738E22.3	-9.67	3.07e-21	1.63e-18	-0.33	-0.29	Migraine;	chr4:56880659	chr4:56960927~56961373:-
BRCA	cis	rs7684253	0.587	rs2002154	ENSG00000269949.1	RP11-738E22.3	-9.67	3.08e-21	1.64e-18	-0.33	-0.29	Migraine;	chr4:56879851	chr4:56960927~56961373:-
BRCA	cis	rs6570726	0.689	rs411785	ENSG00000235652.6	RP11-545I5.3	9.67	3.08e-21	1.64e-18	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145567262	chr6:145799409~145886585:+
BRCA	cis	rs12468226	0.872	rs115187557	ENSG00000273456.1	RP11-686O6.2	9.67	3.09e-21	1.64e-18	0.43	0.29	Urate levels;	chr2:202495351	chr2:202374932~202375604:-
BRCA	cis	rs6570726	0.738	rs6925594	ENSG00000235652.6	RP11-545I5.3	9.67	3.09e-21	1.64e-18	0.28	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145577318	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.791	rs11155432	ENSG00000235652.6	RP11-545I5.3	9.67	3.09e-21	1.64e-18	0.28	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145577625	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.791	rs6913727	ENSG00000235652.6	RP11-545I5.3	9.67	3.09e-21	1.64e-18	0.28	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145578690	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.791	rs10872577	ENSG00000235652.6	RP11-545I5.3	9.67	3.09e-21	1.64e-18	0.28	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145579424	chr6:145799409~145886585:+
BRCA	cis	rs875971	0.79	rs10257911	ENSG00000237310.1	GS1-124K5.4	-9.67	3.1e-21	1.64e-18	-0.31	-0.29	Aortic root size;	chr7:66278783	chr7:66493706~66495474:+
BRCA	cis	rs7684253	0.587	rs7670313	ENSG00000269949.1	RP11-738E22.3	-9.67	3.1e-21	1.65e-18	-0.33	-0.29	Migraine;	chr4:56880007	chr4:56960927~56961373:-
BRCA	cis	rs7684253	0.587	rs2170074	ENSG00000269949.1	RP11-738E22.3	-9.67	3.1e-21	1.65e-18	-0.33	-0.29	Migraine;	chr4:56880190	chr4:56960927~56961373:-
BRCA	cis	rs7429990	0.965	rs6772396	ENSG00000229759.1	MRPS18AP1	9.67	3.1e-21	1.65e-18	0.32	0.29	Educational attainment (years of education);	chr3:47918280	chr3:48256350~48256938:-
BRCA	cis	rs35160687	0.644	rs17738058	ENSG00000273080.1	RP11-301O19.1	-9.67	3.11e-21	1.65e-18	-0.34	-0.29	Night sleep phenotypes;	chr2:86286080	chr2:86195590~86196049:+
BRCA	cis	rs2243480	0.908	rs4718273	ENSG00000226824.5	RP4-756H11.3	9.67	3.12e-21	1.66e-18	0.55	0.29	Diabetic kidney disease;	chr7:65751112	chr7:66654538~66669855:+
BRCA	cis	rs1823913	0.637	rs2356354	ENSG00000227542.1	AC092614.2	-9.67	3.13e-21	1.66e-18	-0.35	-0.29	Obesity-related traits;	chr2:191270970	chr2:191229165~191246172:-
BRCA	cis	rs4835473	0.932	rs1842484	ENSG00000251600.4	RP11-673E1.1	9.67	3.14e-21	1.66e-18	0.33	0.29	Immature fraction of reticulocytes;	chr4:143793829	chr4:143912331~143982454:+
BRCA	cis	rs3779195	0.591	rs77968419	ENSG00000272950.1	RP11-307C18.1	-9.67	3.15e-21	1.67e-18	-0.48	-0.29	Sex hormone-binding globulin levels;	chr7:98237168	chr7:98322853~98323430:+
BRCA	cis	rs11971779	0.648	rs6967836	ENSG00000273391.1	RP11-634H22.1	9.67	3.16e-21	1.67e-18	0.28	0.29	Diisocyanate-induced asthma;	chr7:139395198	chr7:139359032~139359566:-
BRCA	cis	rs875971	0.862	rs7796162	ENSG00000237310.1	GS1-124K5.4	-9.67	3.16e-21	1.67e-18	-0.3	-0.29	Aortic root size;	chr7:66280771	chr7:66493706~66495474:+
BRCA	cis	rs11096990	0.656	rs2123027	ENSG00000249207.1	RP11-360F5.1	9.67	3.16e-21	1.68e-18	0.33	0.29	Cognitive function;	chr4:39289493	chr4:39112677~39126818:-
BRCA	cis	rs4835473	0.932	rs7356157	ENSG00000251600.4	RP11-673E1.1	9.67	3.19e-21	1.69e-18	0.33	0.29	Immature fraction of reticulocytes;	chr4:143739233	chr4:143912331~143982454:+
BRCA	cis	rs17482078	0.959	rs13170045	ENSG00000248734.2	CTD-2260A17.1	9.67	3.19e-21	1.69e-18	0.39	0.29	Behcet's disease;Blood protein levels;	chr5:96790082	chr5:96784777~96785999:+
BRCA	cis	rs228614	0.509	rs223486	ENSG00000246560.2	RP11-10L12.4	9.67	3.19e-21	1.69e-18	0.3	0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102763796	chr4:102828055~102844075:+
BRCA	cis	rs17711722	0.565	rs4717276	ENSG00000236529.1	RP13-254B10.1	9.67	3.2e-21	1.7e-18	0.32	0.29	Calcium levels;	chr7:65829754	chr7:65840212~65840596:+
BRCA	cis	rs7429990	0.965	rs13075795	ENSG00000229759.1	MRPS18AP1	-9.66	3.2e-21	1.7e-18	-0.32	-0.29	Educational attainment (years of education);	chr3:47983139	chr3:48256350~48256938:-
BRCA	cis	rs35160687	0.644	rs4832036	ENSG00000273080.1	RP11-301O19.1	-9.66	3.21e-21	1.7e-18	-0.34	-0.29	Night sleep phenotypes;	chr2:86324179	chr2:86195590~86196049:+
BRCA	cis	rs2665103	0.715	rs7403041	ENSG00000278603.1	RP13-608F4.5	-9.66	3.22e-21	1.71e-18	-0.37	-0.29	Intelligence (multi-trait analysis);	chr15:82287841	chr15:82472203~82472426:+
BRCA	cis	rs801193	0.569	rs11772819	ENSG00000237310.1	GS1-124K5.4	9.66	3.22e-21	1.71e-18	0.3	0.29	Aortic root size;	chr7:66752983	chr7:66493706~66495474:+
BRCA	cis	rs801193	0.569	rs7800620	ENSG00000237310.1	GS1-124K5.4	9.66	3.22e-21	1.71e-18	0.3	0.29	Aortic root size;	chr7:66758701	chr7:66493706~66495474:+
BRCA	cis	rs11098499	0.954	rs9998585	ENSG00000245958.5	RP11-33B1.1	-9.66	3.24e-21	1.72e-18	-0.28	-0.29	Corneal astigmatism;	chr4:119475647	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.909	rs6842762	ENSG00000245958.5	RP11-33B1.1	-9.66	3.24e-21	1.72e-18	-0.28	-0.29	Corneal astigmatism;	chr4:119477081	chr4:119454791~119552025:+
BRCA	cis	rs875971	0.651	rs313829	ENSG00000164669.11	INTS4P1	9.66	3.26e-21	1.73e-18	0.39	0.29	Aortic root size;	chr7:66087510	chr7:65141225~65234216:+
BRCA	cis	rs950169	0.579	rs11633088	ENSG00000225151.9	GOLGA2P7	9.66	3.29e-21	1.74e-18	0.39	0.29	Schizophrenia;	chr15:84003429	chr15:84199311~84230136:-
BRCA	cis	rs2243480	1	rs709607	ENSG00000226824.5	RP4-756H11.3	9.66	3.3e-21	1.75e-18	0.54	0.29	Diabetic kidney disease;	chr7:65984554	chr7:66654538~66669855:+
BRCA	cis	rs7945705	0.902	rs10769979	ENSG00000254860.4	TMEM9B-AS1	-9.66	3.3e-21	1.75e-18	-0.27	-0.29	Hemoglobin concentration;	chr11:8989112	chr11:8964675~8977527:+
BRCA	cis	rs367615	0.918	rs10054960	ENSG00000249476.1	CTD-2587M2.1	9.66	3.32e-21	1.76e-18	0.37	0.29	Colorectal cancer (SNP x SNP interaction);	chr5:109530747	chr5:109237120~109326369:-
BRCA	cis	rs6570726	0.791	rs9390336	ENSG00000235652.6	RP11-545I5.3	9.66	3.35e-21	1.77e-18	0.28	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145575687	chr6:145799409~145886585:+
BRCA	cis	rs227275	0.554	rs223424	ENSG00000246560.2	RP11-10L12.4	9.66	3.35e-21	1.78e-18	0.3	0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102804177	chr4:102828055~102844075:+
BRCA	cis	rs227275	0.524	rs223423	ENSG00000246560.2	RP11-10L12.4	9.66	3.35e-21	1.78e-18	0.3	0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102804737	chr4:102828055~102844075:+
BRCA	cis	rs228614	0.51	rs223353	ENSG00000246560.2	RP11-10L12.4	9.66	3.36e-21	1.78e-18	0.3	0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102854547	chr4:102828055~102844075:+
BRCA	cis	rs228614	0.51	rs223352	ENSG00000246560.2	RP11-10L12.4	9.66	3.36e-21	1.78e-18	0.3	0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102855710	chr4:102828055~102844075:+
BRCA	cis	rs783540	0.967	rs1145173	ENSG00000278603.1	RP13-608F4.5	-9.66	3.38e-21	1.79e-18	-0.37	-0.29	Schizophrenia;	chr15:82554675	chr15:82472203~82472426:+
BRCA	cis	rs12468226	1	rs57080353	ENSG00000273456.1	RP11-686O6.2	9.66	3.39e-21	1.79e-18	0.43	0.29	Urate levels;	chr2:202511824	chr2:202374932~202375604:-
BRCA	cis	rs12468226	0.81	rs3736578	ENSG00000273456.1	RP11-686O6.2	9.66	3.39e-21	1.79e-18	0.43	0.29	Urate levels;	chr2:202519989	chr2:202374932~202375604:-
BRCA	cis	rs12468226	1	rs116439150	ENSG00000273456.1	RP11-686O6.2	9.66	3.39e-21	1.79e-18	0.43	0.29	Urate levels;	chr2:202523814	chr2:202374932~202375604:-
BRCA	cis	rs12468226	1	rs12467409	ENSG00000273456.1	RP11-686O6.2	9.66	3.39e-21	1.79e-18	0.43	0.29	Urate levels;	chr2:202529625	chr2:202374932~202375604:-
BRCA	cis	rs801193	0.527	rs2707837	ENSG00000237310.1	GS1-124K5.4	9.66	3.4e-21	1.8e-18	0.3	0.29	Aortic root size;	chr7:66716086	chr7:66493706~66495474:+
BRCA	cis	rs1823913	0.599	rs13035132	ENSG00000227542.1	AC092614.2	9.66	3.4e-21	1.8e-18	0.34	0.29	Obesity-related traits;	chr2:191265275	chr2:191229165~191246172:-
BRCA	cis	rs875971	0.502	rs6460311	ENSG00000226824.5	RP4-756H11.3	9.66	3.41e-21	1.8e-18	0.4	0.29	Aortic root size;	chr7:66646886	chr7:66654538~66669855:+
BRCA	cis	rs1113500	0.933	rs10494089	ENSG00000226822.1	RP11-356N1.2	9.66	3.41e-21	1.8e-18	0.38	0.29	Growth-regulated protein alpha levels;	chr1:108084073	chr1:108071482~108074519:+
BRCA	cis	rs7829975	0.846	rs7005216	ENSG00000253893.2	FAM85B	9.66	3.42e-21	1.81e-18	0.35	0.29	Mood instability;	chr8:8689600	chr8:8167819~8226614:-
BRCA	cis	rs228614	0.51	rs223451	ENSG00000246560.2	RP11-10L12.4	9.66	3.42e-21	1.81e-18	0.3	0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102791032	chr4:102828055~102844075:+
BRCA	cis	rs228614	0.51	rs223450	ENSG00000246560.2	RP11-10L12.4	9.66	3.42e-21	1.81e-18	0.3	0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102791052	chr4:102828055~102844075:+
BRCA	cis	rs6570726	0.791	rs9373463	ENSG00000235652.6	RP11-545I5.3	9.66	3.42e-21	1.81e-18	0.28	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145573626	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.791	rs12205752	ENSG00000235652.6	RP11-545I5.3	9.66	3.42e-21	1.81e-18	0.28	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145574982	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.764	rs2265471	ENSG00000235652.6	RP11-545I5.3	9.66	3.44e-21	1.82e-18	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145899114	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.79	rs2254283	ENSG00000235652.6	RP11-545I5.3	9.66	3.45e-21	1.82e-18	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145883153	chr6:145799409~145886585:+
BRCA	cis	rs875971	0.862	rs1875057	ENSG00000237310.1	GS1-124K5.4	-9.66	3.46e-21	1.83e-18	-0.3	-0.29	Aortic root size;	chr7:66266868	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.862	rs6960446	ENSG00000237310.1	GS1-124K5.4	-9.66	3.46e-21	1.83e-18	-0.3	-0.29	Aortic root size;	chr7:66268272	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.789	rs10260426	ENSG00000237310.1	GS1-124K5.4	-9.66	3.46e-21	1.83e-18	-0.3	-0.29	Aortic root size;	chr7:66271055	chr7:66493706~66495474:+
BRCA	cis	rs1062177	0.694	rs2915816	ENSG00000213433.5	RPLP1P6	9.66	3.46e-21	1.83e-18	0.35	0.29	Preschool internalizing problems;	chr5:151736296	chr5:151765859~151766378:-
BRCA	cis	rs80285556	1	rs17311679	ENSG00000161643.11	SIGLEC16	-9.66	3.46e-21	1.83e-18	-0.74	-0.29	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50018074	chr19:49969673~49975814:+
BRCA	cis	rs7772486	0.72	rs702320	ENSG00000235652.6	RP11-545I5.3	-9.66	3.47e-21	1.83e-18	-0.29	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145685518	chr6:145799409~145886585:+
BRCA	cis	rs8062405	0.789	rs1968752	ENSG00000259982.1	CDC37P1	9.65	3.54e-21	1.87e-18	0.35	0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620264	chr16:28700294~28701540:-
BRCA	cis	rs7829975	0.502	rs7820738	ENSG00000253893.2	FAM85B	9.65	3.55e-21	1.88e-18	0.34	0.29	Mood instability;	chr8:8845097	chr8:8167819~8226614:-
BRCA	cis	rs17711722	0.528	rs73138179	ENSG00000226824.5	RP4-756H11.3	-9.65	3.55e-21	1.88e-18	-0.38	-0.29	Calcium levels;	chr7:65829495	chr7:66654538~66669855:+
BRCA	cis	rs72772090	0.539	rs10515248	ENSG00000248734.2	CTD-2260A17.1	-9.65	3.56e-21	1.88e-18	-0.47	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96776301	chr5:96784777~96785999:+
BRCA	cis	rs72772090	0.539	rs56213813	ENSG00000248734.2	CTD-2260A17.1	-9.65	3.56e-21	1.88e-18	-0.47	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96776580	chr5:96784777~96785999:+
BRCA	cis	rs72772090	0.52	rs56325109	ENSG00000248734.2	CTD-2260A17.1	-9.65	3.56e-21	1.88e-18	-0.47	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96776591	chr5:96784777~96785999:+
BRCA	cis	rs72772090	0.539	rs11747148	ENSG00000248734.2	CTD-2260A17.1	-9.65	3.56e-21	1.88e-18	-0.47	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96777159	chr5:96784777~96785999:+
BRCA	cis	rs7429990	0.932	rs4293721	ENSG00000229759.1	MRPS18AP1	-9.65	3.58e-21	1.89e-18	-0.32	-0.29	Educational attainment (years of education);	chr3:48003647	chr3:48256350~48256938:-
BRCA	cis	rs72772090	0.539	rs11747179	ENSG00000248734.2	CTD-2260A17.1	-9.65	3.58e-21	1.89e-18	-0.47	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96777265	chr5:96784777~96785999:+
BRCA	cis	rs11096990	0.656	rs4580661	ENSG00000249207.1	RP11-360F5.1	9.65	3.59e-21	1.9e-18	0.33	0.29	Cognitive function;	chr4:39294730	chr4:39112677~39126818:-
BRCA	cis	rs4853012	0.941	rs2421752	ENSG00000257800.1	FNBP1P1	9.65	3.61e-21	1.91e-18	0.31	0.29	Gestational age at birth (maternal effect);	chr2:74114488	chr2:74120680~74123218:+
BRCA	cis	rs7772486	0.764	rs7745696	ENSG00000235652.6	RP11-545I5.3	9.65	3.62e-21	1.91e-18	0.28	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145841693	chr6:145799409~145886585:+
BRCA	cis	rs4713118	0.662	rs149969	ENSG00000220721.1	OR1F12	9.65	3.63e-21	1.91e-18	0.36	0.29	Parkinson's disease;	chr6:28009959	chr6:28073316~28074233:+
BRCA	cis	rs881375	0.934	rs1468671	ENSG00000226752.6	PSMD5-AS1	-9.65	3.63e-21	1.92e-18	-0.36	-0.29	Rheumatoid arthritis;	chr9:120895224	chr9:120824828~120854385:+
BRCA	cis	rs17711722	0.701	rs781143	ENSG00000224316.1	RP11-479O9.2	9.65	3.64e-21	1.92e-18	0.29	0.29	Calcium levels;	chr7:65974892	chr7:65773620~65802067:+
BRCA	cis	rs7811142	0.667	rs3873746	ENSG00000242294.5	STAG3L5P	9.65	3.64e-21	1.92e-18	0.27	0.29	Platelet count;	chr7:100337474	chr7:100336079~100351900:+
BRCA	cis	rs875971	0.638	rs10249404	ENSG00000222364.1	RNU6-96P	9.65	3.65e-21	1.93e-18	0.33	0.29	Aortic root size;	chr7:66581737	chr7:66395191~66395286:+
BRCA	cis	rs7772486	0.754	rs697054	ENSG00000235652.6	RP11-545I5.3	9.65	3.65e-21	1.93e-18	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145682634	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.713	rs1986729	ENSG00000235652.6	RP11-545I5.3	9.65	3.66e-21	1.93e-18	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145873695	chr6:145799409~145886585:+
BRCA	cis	rs2439831	0.85	rs16950562	ENSG00000275601.1	AC011330.13	-9.65	3.66e-21	1.93e-18	-0.46	-0.29	Lung cancer in ever smokers;	chr15:43744166	chr15:43642389~43643023:-
BRCA	cis	rs2276314	1	rs16967317	ENSG00000278986.1	RP11-723J4.3	-9.65	3.68e-21	1.94e-18	-0.36	-0.29	Endometriosis;Drug-induced torsades de pointes;	chr18:35993437	chr18:35972151~35973916:+
BRCA	cis	rs11098499	0.754	rs9999724	ENSG00000248280.1	RP11-33B1.2	9.65	3.68e-21	1.94e-18	0.28	0.29	Corneal astigmatism;	chr4:119318789	chr4:119440561~119450157:-
BRCA	cis	rs227275	0.554	rs223381	ENSG00000246560.2	RP11-10L12.4	9.65	3.69e-21	1.95e-18	0.3	0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102832578	chr4:102828055~102844075:+
BRCA	cis	rs35160687	0.644	rs11676515	ENSG00000273080.1	RP11-301O19.1	-9.65	3.7e-21	1.95e-18	-0.34	-0.29	Night sleep phenotypes;	chr2:86268934	chr2:86195590~86196049:+
BRCA	cis	rs9368481	0.761	rs9348746	ENSG00000241549.7	GUSBP2	-9.65	3.7e-21	1.95e-18	-0.33	-0.29	Autism spectrum disorder or schizophrenia;	chr6:27002578	chr6:26871484~26956554:-
BRCA	cis	rs2243480	0.901	rs2456483	ENSG00000226824.5	RP4-756H11.3	-9.65	3.7e-21	1.95e-18	-0.55	-0.29	Diabetic kidney disease;	chr7:65996588	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs1701750	ENSG00000226824.5	RP4-756H11.3	-9.65	3.7e-21	1.95e-18	-0.55	-0.29	Diabetic kidney disease;	chr7:66002158	chr7:66654538~66669855:+
BRCA	cis	rs11159086	0.793	rs1029702	ENSG00000259005.1	RP3-449M8.6	9.65	3.73e-21	1.97e-18	0.43	0.29	Advanced glycation end-product levels;	chr14:74473909	chr14:74474007~74474864:-
BRCA	cis	rs4862750	0.837	rs1863404	ENSG00000250971.1	RP11-696F12.1	9.65	3.73e-21	1.97e-18	0.31	0.29	Lobe attachment (rater-scored or self-reported);	chr4:186953500	chr4:187060099~187060930:+
BRCA	cis	rs875971	0.522	rs709604	ENSG00000224316.1	RP11-479O9.2	-9.65	3.74e-21	1.97e-18	-0.29	-0.29	Aortic root size;	chr7:66032447	chr7:65773620~65802067:+
BRCA	cis	rs228614	0.536	rs223484	ENSG00000246560.2	RP11-10L12.4	9.65	3.75e-21	1.97e-18	0.3	0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102764314	chr4:102828055~102844075:+
BRCA	cis	rs6570726	0.791	rs1280276	ENSG00000235652.6	RP11-545I5.3	9.65	3.75e-21	1.98e-18	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145571214	chr6:145799409~145886585:+
BRCA	cis	rs1075265	0.73	rs805391	ENSG00000233266.1	HMGB1P31	-9.65	3.76e-21	1.98e-18	-0.34	-0.29	Chronotype;Morning vs. evening chronotype;	chr2:53877181	chr2:54051334~54051760:+
BRCA	cis	rs2283792	0.765	rs2266966	ENSG00000224086.5	LL22NC03-86G7.1	-9.65	3.77e-21	1.99e-18	-0.3	-0.29	Multiple sclerosis;	chr22:21767265	chr22:21938293~21977632:+
BRCA	cis	rs12468226	1	rs76021735	ENSG00000273456.1	RP11-686O6.2	9.65	3.78e-21	1.99e-18	0.43	0.29	Urate levels;	chr2:202511476	chr2:202374932~202375604:-
BRCA	cis	rs7811142	0.83	rs10085549	ENSG00000242294.5	STAG3L5P	9.65	3.79e-21	2e-18	0.27	0.29	Platelet count;	chr7:100385512	chr7:100336079~100351900:+
BRCA	cis	rs7688540	0.8	rs9328738	ENSG00000211553.1	AC253576.2	9.65	3.79e-21	2e-18	0.36	0.29	Facial morphology (factor 6, height of vermillion lower lip);	chr4:284407	chr4:136461~136568:+
BRCA	cis	rs35160687	0.712	rs4832261	ENSG00000273080.1	RP11-301O19.1	9.65	3.81e-21	2e-18	0.33	0.29	Night sleep phenotypes;	chr2:86257375	chr2:86195590~86196049:+
BRCA	cis	rs12468226	0.81	rs77090459	ENSG00000273456.1	RP11-686O6.2	9.65	3.82e-21	2.01e-18	0.43	0.29	Urate levels;	chr2:202542132	chr2:202374932~202375604:-
BRCA	cis	rs35160687	0.644	rs4832265	ENSG00000273080.1	RP11-301O19.1	-9.65	3.82e-21	2.01e-18	-0.34	-0.29	Night sleep phenotypes;	chr2:86261142	chr2:86195590~86196049:+
BRCA	cis	rs2243480	1	rs1701758	ENSG00000226824.5	RP4-756H11.3	-9.65	3.82e-21	2.01e-18	-0.55	-0.29	Diabetic kidney disease;	chr7:66005214	chr7:66654538~66669855:+
BRCA	cis	rs11098499	0.908	rs11098527	ENSG00000245958.5	RP11-33B1.1	-9.64	3.83e-21	2.02e-18	-0.28	-0.29	Corneal astigmatism;	chr4:119478751	chr4:119454791~119552025:+
BRCA	cis	rs2439831	0.85	rs16950562	ENSG00000205771.5	CATSPER2P1	-9.64	3.84e-21	2.02e-18	-0.49	-0.29	Lung cancer in ever smokers;	chr15:43744166	chr15:43726918~43747094:-
BRCA	cis	rs1062177	1	rs2347596	ENSG00000253921.1	CTB-113P19.3	-9.64	3.89e-21	2.05e-18	-0.39	-0.29	Preschool internalizing problems;	chr5:151799638	chr5:151753992~151767247:+
BRCA	cis	rs7688540	0.8	rs6857106	ENSG00000211553.1	AC253576.2	9.64	3.89e-21	2.05e-18	0.35	0.29	Facial morphology (factor 6, height of vermillion lower lip);	chr4:255641	chr4:136461~136568:+
BRCA	cis	rs6570726	0.755	rs2103633	ENSG00000235652.6	RP11-545I5.3	9.64	3.91e-21	2.06e-18	0.28	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145572885	chr6:145799409~145886585:+
BRCA	cis	rs11673344	0.704	rs1726724	ENSG00000226686.6	LINC01535	9.64	3.91e-21	2.06e-18	0.37	0.29	Obesity-related traits;	chr19:36925890	chr19:37251912~37265535:+
BRCA	cis	rs875971	0.862	rs1167390	ENSG00000237310.1	GS1-124K5.4	-9.64	3.91e-21	2.06e-18	-0.3	-0.29	Aortic root size;	chr7:66110906	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.862	rs35034167	ENSG00000237310.1	GS1-124K5.4	-9.64	3.91e-21	2.06e-18	-0.3	-0.29	Aortic root size;	chr7:66115179	chr7:66493706~66495474:+
BRCA	cis	rs321358	0.731	rs73003515	ENSG00000271584.1	RP11-89C3.4	9.64	3.94e-21	2.07e-18	0.46	0.29	Body mass index;	chr11:111160734	chr11:111091932~111097357:-
BRCA	cis	rs748404	0.589	rs62020616	ENSG00000249839.1	AC011330.5	-9.64	3.97e-21	2.09e-18	-0.41	-0.29	Lung cancer;	chr15:43558554	chr15:43663654~43684339:-
BRCA	cis	rs748404	0.626	rs60367691	ENSG00000249839.1	AC011330.5	-9.64	3.97e-21	2.09e-18	-0.41	-0.29	Lung cancer;	chr15:43559201	chr15:43663654~43684339:-
BRCA	cis	rs3779195	0.585	rs58699591	ENSG00000272950.1	RP11-307C18.1	-9.64	4.02e-21	2.11e-18	-0.47	-0.29	Sex hormone-binding globulin levels;	chr7:98247392	chr7:98322853~98323430:+
BRCA	cis	rs7429990	0.965	rs7427418	ENSG00000229759.1	MRPS18AP1	-9.64	4.02e-21	2.12e-18	-0.32	-0.29	Educational attainment (years of education);	chr3:47981217	chr3:48256350~48256938:-
BRCA	cis	rs7429990	0.965	rs13074973	ENSG00000229759.1	MRPS18AP1	-9.64	4.02e-21	2.12e-18	-0.32	-0.29	Educational attainment (years of education);	chr3:47986654	chr3:48256350~48256938:-
BRCA	cis	rs801193	0.548	rs2659891	ENSG00000237310.1	GS1-124K5.4	9.64	4.04e-21	2.12e-18	0.3	0.29	Aortic root size;	chr7:66736127	chr7:66493706~66495474:+
BRCA	cis	rs801193	0.548	rs7805152	ENSG00000237310.1	GS1-124K5.4	9.64	4.04e-21	2.12e-18	0.3	0.29	Aortic root size;	chr7:66744266	chr7:66493706~66495474:+
BRCA	cis	rs858239	0.6	rs7776644	ENSG00000226816.2	AC005082.12	9.64	4.04e-21	2.13e-18	0.34	0.29	Cerebrospinal fluid biomarker levels;	chr7:23079688	chr7:23206013~23208045:+
BRCA	cis	rs801193	0.569	rs7782587	ENSG00000237310.1	GS1-124K5.4	9.64	4.05e-21	2.13e-18	0.3	0.29	Aortic root size;	chr7:66701485	chr7:66493706~66495474:+
BRCA	cis	rs801193	0.548	rs6975044	ENSG00000237310.1	GS1-124K5.4	9.64	4.06e-21	2.13e-18	0.3	0.29	Aortic root size;	chr7:66762495	chr7:66493706~66495474:+
BRCA	cis	rs11096990	0.656	rs3796513	ENSG00000249207.1	RP11-360F5.1	9.64	4.06e-21	2.13e-18	0.33	0.29	Cognitive function;	chr4:39289462	chr4:39112677~39126818:-
BRCA	cis	rs11096990	0.634	rs10029074	ENSG00000249207.1	RP11-360F5.1	9.64	4.06e-21	2.13e-18	0.33	0.29	Cognitive function;	chr4:39290882	chr4:39112677~39126818:-
BRCA	cis	rs11096990	0.634	rs1564710	ENSG00000249207.1	RP11-360F5.1	9.64	4.06e-21	2.13e-18	0.33	0.29	Cognitive function;	chr4:39291178	chr4:39112677~39126818:-
BRCA	cis	rs875971	0.825	rs6951503	ENSG00000237310.1	GS1-124K5.4	-9.64	4.07e-21	2.14e-18	-0.31	-0.29	Aortic root size;	chr7:66253949	chr7:66493706~66495474:+
BRCA	cis	rs227275	0.554	rs149576	ENSG00000246560.2	RP11-10L12.4	9.64	4.07e-21	2.14e-18	0.3	0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102811411	chr4:102828055~102844075:+
BRCA	cis	rs7772486	0.846	rs7755440	ENSG00000235652.6	RP11-545I5.3	9.64	4.08e-21	2.15e-18	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:146054770	chr6:145799409~145886585:+
BRCA	cis	rs80285556	1	rs79602855	ENSG00000161643.11	SIGLEC16	9.64	4.12e-21	2.16e-18	0.75	0.29	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50022468	chr19:49969673~49975814:+
BRCA	cis	rs321358	0.731	rs7939631	ENSG00000271584.1	RP11-89C3.4	9.64	4.13e-21	2.17e-18	0.46	0.29	Body mass index;	chr11:111153506	chr11:111091932~111097357:-
BRCA	cis	rs1113500	0.933	rs3909076	ENSG00000226822.1	RP11-356N1.2	9.64	4.14e-21	2.17e-18	0.38	0.29	Growth-regulated protein alpha levels;	chr1:108089138	chr1:108071482~108074519:+
BRCA	cis	rs875971	0.862	rs1612452	ENSG00000237310.1	GS1-124K5.4	-9.64	4.14e-21	2.18e-18	-0.3	-0.29	Aortic root size;	chr7:66108909	chr7:66493706~66495474:+
BRCA	cis	rs10875746	0.551	rs1471998	ENSG00000240399.1	RP1-228P16.1	-9.64	4.17e-21	2.19e-18	-0.39	-0.29	Longevity (90 years and older);	chr12:48318219	chr12:48054813~48055591:-
BRCA	cis	rs35160687	0.644	rs1863056	ENSG00000273080.1	RP11-301O19.1	-9.63	4.19e-21	2.2e-18	-0.34	-0.29	Night sleep phenotypes;	chr2:86264122	chr2:86195590~86196049:+
BRCA	cis	rs1062177	1	rs72802204	ENSG00000253921.1	CTB-113P19.3	-9.63	4.19e-21	2.2e-18	-0.39	-0.29	Preschool internalizing problems;	chr5:151803622	chr5:151753992~151767247:+
BRCA	cis	rs9438901	0.655	rs609320	ENSG00000261349.1	RP3-465N24.5	9.63	4.19e-21	2.2e-18	0.45	0.29	Red cell distribution width;	chr1:25390874	chr1:25266102~25267136:-
BRCA	cis	rs13392177	0.672	rs4674270	ENSG00000261338.2	RP11-378A13.1	-9.63	4.19e-21	2.2e-18	-0.3	-0.29	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218188418	chr2:218255319~218257366:+
BRCA	cis	rs67180937	0.553	rs3008629	ENSG00000272750.1	RP11-378J18.8	9.63	4.2e-21	2.21e-18	0.44	0.29	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222662588	chr1:222658867~222661512:-
BRCA	cis	rs7772486	0.686	rs857883	ENSG00000235652.6	RP11-545I5.3	-9.63	4.21e-21	2.21e-18	-0.29	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145648078	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.686	rs857882	ENSG00000235652.6	RP11-545I5.3	-9.63	4.21e-21	2.21e-18	-0.29	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145648580	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.686	rs857877	ENSG00000235652.6	RP11-545I5.3	-9.63	4.21e-21	2.21e-18	-0.29	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145655094	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.754	rs1415746	ENSG00000235652.6	RP11-545I5.3	-9.63	4.22e-21	2.21e-18	-0.29	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145755971	chr6:145799409~145886585:+
BRCA	cis	rs2243480	0.901	rs1701759	ENSG00000226824.5	RP4-756H11.3	-9.63	4.22e-21	2.22e-18	-0.55	-0.29	Diabetic kidney disease;	chr7:66005945	chr7:66654538~66669855:+
BRCA	cis	rs2412819	0.571	rs11070411	ENSG00000249839.1	AC011330.5	9.63	4.23e-21	2.22e-18	0.41	0.29	Lung cancer;	chr15:43766436	chr15:43663654~43684339:-
BRCA	cis	rs6570726	0.764	rs9322028	ENSG00000235652.6	RP11-545I5.3	9.63	4.23e-21	2.22e-18	0.28	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145574661	chr6:145799409~145886585:+
BRCA	cis	rs812925	0.519	rs10199672	ENSG00000271889.1	RP11-493E12.1	-9.63	4.24e-21	2.22e-18	-0.35	-0.29	Immature fraction of reticulocytes;	chr2:61400499	chr2:61151433~61162105:-
BRCA	cis	rs7772486	0.875	rs9390377	ENSG00000235652.6	RP11-545I5.3	9.63	4.25e-21	2.23e-18	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:146065796	chr6:145799409~145886585:+
BRCA	cis	rs4820294	0.669	rs9622678	ENSG00000233360.4	Z83844.1	9.63	4.26e-21	2.23e-18	0.32	0.29	Fat distribution (HIV);	chr22:37661331	chr22:37641832~37658377:-
BRCA	cis	rs227275	0.554	rs223404	ENSG00000246560.2	RP11-10L12.4	9.63	4.28e-21	2.24e-18	0.3	0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102816951	chr4:102828055~102844075:+
BRCA	cis	rs11098499	0.754	rs878376	ENSG00000248280.1	RP11-33B1.2	9.63	4.3e-21	2.26e-18	0.28	0.29	Corneal astigmatism;	chr4:119316547	chr4:119440561~119450157:-
BRCA	cis	rs2243480	1	rs4718270	ENSG00000226824.5	RP4-756H11.3	-9.63	4.31e-21	2.26e-18	-0.55	-0.29	Diabetic kidney disease;	chr7:65737415	chr7:66654538~66669855:+
BRCA	cis	rs17482078	0.959	rs71630754	ENSG00000248734.2	CTD-2260A17.1	9.63	4.33e-21	2.27e-18	0.4	0.29	Behcet's disease;Blood protein levels;	chr5:96791235	chr5:96784777~96785999:+
BRCA	cis	rs72772090	0.539	rs11741100	ENSG00000248734.2	CTD-2260A17.1	-9.63	4.33e-21	2.27e-18	-0.47	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96777541	chr5:96784777~96785999:+
BRCA	cis	rs2274273	0.84	rs943590	ENSG00000258413.1	RP11-665C16.6	-9.63	4.34e-21	2.28e-18	-0.36	-0.29	Protein biomarker;	chr14:55271878	chr14:55262767~55272075:-
BRCA	cis	rs321358	0.731	rs73021576	ENSG00000271584.1	RP11-89C3.4	9.63	4.36e-21	2.29e-18	0.46	0.29	Body mass index;	chr11:111155690	chr11:111091932~111097357:-
BRCA	cis	rs2041895	0.565	rs10861679	ENSG00000260329.1	RP11-412D9.4	-9.63	4.37e-21	2.29e-18	-0.35	-0.29	Glaucoma (low intraocular pressure);	chr12:106929137	chr12:106954029~106955497:-
BRCA	cis	rs11105298	0.891	rs10858902	ENSG00000258302.2	RP11-981P6.1	9.63	4.38e-21	2.3e-18	0.33	0.29	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89534012	chr12:89561129~89594878:+
BRCA	cis	rs11105298	0.891	rs10858903	ENSG00000258302.2	RP11-981P6.1	9.63	4.38e-21	2.3e-18	0.33	0.29	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89534195	chr12:89561129~89594878:+
BRCA	cis	rs7429990	0.932	rs2166772	ENSG00000229759.1	MRPS18AP1	-9.63	4.4e-21	2.31e-18	-0.32	-0.29	Educational attainment (years of education);	chr3:48006384	chr3:48256350~48256938:-
BRCA	cis	rs7772486	0.817	rs12198065	ENSG00000235652.6	RP11-545I5.3	9.63	4.41e-21	2.31e-18	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:146064150	chr6:145799409~145886585:+
BRCA	cis	rs35160687	0.644	rs4832264	ENSG00000273080.1	RP11-301O19.1	-9.63	4.41e-21	2.31e-18	-0.34	-0.29	Night sleep phenotypes;	chr2:86259711	chr2:86195590~86196049:+
BRCA	cis	rs801193	0.569	rs2659893	ENSG00000237310.1	GS1-124K5.4	9.63	4.42e-21	2.32e-18	0.3	0.29	Aortic root size;	chr7:66735006	chr7:66493706~66495474:+
BRCA	cis	rs801193	0.569	rs2659892	ENSG00000237310.1	GS1-124K5.4	9.63	4.42e-21	2.32e-18	0.3	0.29	Aortic root size;	chr7:66735318	chr7:66493706~66495474:+
BRCA	cis	rs801193	0.569	rs2707847	ENSG00000237310.1	GS1-124K5.4	9.63	4.42e-21	2.32e-18	0.3	0.29	Aortic root size;	chr7:66737884	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.505	rs6955582	ENSG00000224316.1	RP11-479O9.2	9.63	4.43e-21	2.32e-18	0.28	0.29	Aortic root size;	chr7:65966699	chr7:65773620~65802067:+
BRCA	cis	rs11098499	0.954	rs12506546	ENSG00000245958.5	RP11-33B1.1	-9.63	4.43e-21	2.32e-18	-0.28	-0.29	Corneal astigmatism;	chr4:119380463	chr4:119454791~119552025:+
BRCA	cis	rs7429990	0.965	rs2166770	ENSG00000229759.1	MRPS18AP1	9.63	4.44e-21	2.33e-18	0.32	0.29	Educational attainment (years of education);	chr3:47964183	chr3:48256350~48256938:-
BRCA	cis	rs875971	0.862	rs778724	ENSG00000237310.1	GS1-124K5.4	9.63	4.45e-21	2.33e-18	0.3	0.29	Aortic root size;	chr7:66364304	chr7:66493706~66495474:+
BRCA	cis	rs367615	0.918	rs10070104	ENSG00000249476.1	CTD-2587M2.1	-9.63	4.48e-21	2.34e-18	-0.36	-0.29	Colorectal cancer (SNP x SNP interaction);	chr5:109530737	chr5:109237120~109326369:-
BRCA	cis	rs13392177	0.684	rs6720449	ENSG00000261338.2	RP11-378A13.1	-9.63	4.5e-21	2.36e-18	-0.3	-0.29	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218216255	chr2:218255319~218257366:+
BRCA	cis	rs875971	0.545	rs1796219	ENSG00000226824.5	RP4-756H11.3	9.63	4.5e-21	2.36e-18	0.41	0.29	Aortic root size;	chr7:66645977	chr7:66654538~66669855:+
BRCA	cis	rs524281	0.861	rs7937281	ENSG00000255320.1	RP11-755F10.1	9.63	4.51e-21	2.36e-18	0.41	0.29	Electroencephalogram traits;	chr11:66182603	chr11:66244840~66246239:-
BRCA	cis	rs957448	1	rs1992370	ENSG00000253704.1	RP11-267M23.4	9.63	4.55e-21	2.38e-18	0.34	0.29	Nonsyndromic cleft lip with cleft palate;	chr8:94546466	chr8:94553722~94569745:+
BRCA	cis	rs8062405	1	rs1987472	ENSG00000278665.1	RP11-666O2.4	9.63	4.56e-21	2.39e-18	0.3	0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814456	chr16:28599241~28601881:-
BRCA	cis	rs8062405	0.895	rs56186137	ENSG00000278665.1	RP11-666O2.4	9.63	4.56e-21	2.39e-18	0.3	0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814632	chr16:28599241~28601881:-
BRCA	cis	rs1707322	0.752	rs11211168	ENSG00000280836.1	AL355480.1	-9.62	4.58e-21	2.4e-18	-0.37	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45697975	chr1:45581219~45581321:-
BRCA	cis	rs875971	0.895	rs6460278	ENSG00000237310.1	GS1-124K5.4	-9.62	4.59e-21	2.4e-18	-0.3	-0.29	Aortic root size;	chr7:66197749	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.862	rs6460279	ENSG00000237310.1	GS1-124K5.4	-9.62	4.59e-21	2.4e-18	-0.3	-0.29	Aortic root size;	chr7:66197774	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.862	rs28491091	ENSG00000237310.1	GS1-124K5.4	-9.62	4.59e-21	2.4e-18	-0.3	-0.29	Aortic root size;	chr7:66204077	chr7:66493706~66495474:+
BRCA	cis	rs853679	0.76	rs9468317	ENSG00000220721.1	OR1F12	9.62	4.63e-21	2.42e-18	0.4	0.29	Depression;	chr6:28230678	chr6:28073316~28074233:+
BRCA	cis	rs875971	0.862	rs4149461	ENSG00000237310.1	GS1-124K5.4	-9.62	4.64e-21	2.43e-18	-0.3	-0.29	Aortic root size;	chr7:66279745	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.862	rs4236208	ENSG00000237310.1	GS1-124K5.4	-9.62	4.67e-21	2.44e-18	-0.3	-0.29	Aortic root size;	chr7:66284091	chr7:66493706~66495474:+
BRCA	cis	rs11159086	0.793	rs1029703	ENSG00000259005.1	RP3-449M8.6	9.62	4.67e-21	2.44e-18	0.43	0.29	Advanced glycation end-product levels;	chr14:74473899	chr14:74474007~74474864:-
BRCA	cis	rs10740039	0.729	rs6479728	ENSG00000254271.1	RP11-131N11.4	-9.62	4.68e-21	2.44e-18	-0.37	-0.29	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60731043	chr10:60734342~60741828:+
BRCA	cis	rs7429990	0.932	rs6442101	ENSG00000229759.1	MRPS18AP1	-9.62	4.68e-21	2.44e-18	-0.35	-0.29	Educational attainment (years of education);	chr3:48089403	chr3:48256350~48256938:-
BRCA	cis	rs6570726	0.764	rs9403731	ENSG00000235652.6	RP11-545I5.3	9.62	4.71e-21	2.46e-18	0.28	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145586801	chr6:145799409~145886585:+
BRCA	cis	rs1113500	0.933	rs11185255	ENSG00000226822.1	RP11-356N1.2	9.62	4.71e-21	2.46e-18	0.37	0.29	Growth-regulated protein alpha levels;	chr1:108090569	chr1:108071482~108074519:+
BRCA	cis	rs11673344	0.704	rs484001	ENSG00000226686.6	LINC01535	9.62	4.71e-21	2.46e-18	0.37	0.29	Obesity-related traits;	chr19:36931320	chr19:37251912~37265535:+
BRCA	cis	rs801193	1	rs3800812	ENSG00000222364.1	RNU6-96P	-9.62	4.72e-21	2.46e-18	-0.33	-0.29	Aortic root size;	chr7:66758474	chr7:66395191~66395286:+
BRCA	cis	rs801193	1	rs4279493	ENSG00000222364.1	RNU6-96P	-9.62	4.72e-21	2.46e-18	-0.33	-0.29	Aortic root size;	chr7:66761633	chr7:66395191~66395286:+
BRCA	cis	rs7811142	0.83	rs6975660	ENSG00000242294.5	STAG3L5P	9.62	4.73e-21	2.47e-18	0.27	0.29	Platelet count;	chr7:100377643	chr7:100336079~100351900:+
BRCA	cis	rs7811142	0.83	rs73401443	ENSG00000242294.5	STAG3L5P	9.62	4.73e-21	2.47e-18	0.27	0.29	Platelet count;	chr7:100379959	chr7:100336079~100351900:+
BRCA	cis	rs875971	0.862	rs10282433	ENSG00000237310.1	GS1-124K5.4	-9.62	4.74e-21	2.47e-18	-0.3	-0.29	Aortic root size;	chr7:66256452	chr7:66493706~66495474:+
BRCA	cis	rs227275	0.554	rs223371	ENSG00000246560.2	RP11-10L12.4	9.62	4.75e-21	2.48e-18	0.3	0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102838032	chr4:102828055~102844075:+
BRCA	cis	rs11096990	0.634	rs10019594	ENSG00000249207.1	RP11-360F5.1	9.62	4.75e-21	2.48e-18	0.33	0.29	Cognitive function;	chr4:39287127	chr4:39112677~39126818:-
BRCA	cis	rs858239	0.601	rs6461693	ENSG00000226816.2	AC005082.12	-9.62	4.76e-21	2.48e-18	-0.33	-0.29	Cerebrospinal fluid biomarker levels;	chr7:23120514	chr7:23206013~23208045:+
BRCA	cis	rs11098499	0.909	rs2127821	ENSG00000245958.5	RP11-33B1.1	-9.62	4.78e-21	2.49e-18	-0.28	-0.29	Corneal astigmatism;	chr4:119473380	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.863	rs3736115	ENSG00000245958.5	RP11-33B1.1	9.62	4.79e-21	2.5e-18	0.28	0.29	Corneal astigmatism;	chr4:119567548	chr4:119454791~119552025:+
BRCA	cis	rs2274273	0.837	rs7146748	ENSG00000258413.1	RP11-665C16.6	-9.62	4.84e-21	2.53e-18	-0.36	-0.29	Protein biomarker;	chr14:55280368	chr14:55262767~55272075:-
BRCA	cis	rs227275	0.527	rs223338	ENSG00000246560.2	RP11-10L12.4	9.62	4.87e-21	2.54e-18	0.3	0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102864959	chr4:102828055~102844075:+
BRCA	cis	rs11971779	0.68	rs6960876	ENSG00000273391.1	RP11-634H22.1	-9.62	4.88e-21	2.54e-18	-0.28	-0.29	Diisocyanate-induced asthma;	chr7:139427430	chr7:139359032~139359566:-
BRCA	cis	rs1113500	0.933	rs3893034	ENSG00000226822.1	RP11-356N1.2	9.62	4.89e-21	2.55e-18	0.38	0.29	Growth-regulated protein alpha levels;	chr1:108089556	chr1:108071482~108074519:+
BRCA	cis	rs812925	0.537	rs2463097	ENSG00000271889.1	RP11-493E12.1	-9.62	4.89e-21	2.55e-18	-0.35	-0.29	Immature fraction of reticulocytes;	chr2:61387166	chr2:61151433~61162105:-
BRCA	cis	rs12468226	1	rs16839149	ENSG00000273456.1	RP11-686O6.2	9.62	4.92e-21	2.56e-18	0.42	0.29	Urate levels;	chr2:202427621	chr2:202374932~202375604:-
BRCA	cis	rs62103177	0.525	rs62101233	ENSG00000261126.6	RP11-795F19.1	9.62	4.92e-21	2.57e-18	0.38	0.29	Opioid sensitivity;	chr18:79964288	chr18:80046900~80095482:+
BRCA	cis	rs875971	0.862	rs908915	ENSG00000237310.1	GS1-124K5.4	-9.62	4.93e-21	2.57e-18	-0.3	-0.29	Aortic root size;	chr7:66149664	chr7:66493706~66495474:+
BRCA	cis	rs858239	0.601	rs987257	ENSG00000226816.2	AC005082.12	9.62	4.93e-21	2.57e-18	0.33	0.29	Cerebrospinal fluid biomarker levels;	chr7:23108221	chr7:23206013~23208045:+
BRCA	cis	rs11096990	0.656	rs7693837	ENSG00000249207.1	RP11-360F5.1	-9.62	4.93e-21	2.57e-18	-0.33	-0.29	Cognitive function;	chr4:39301481	chr4:39112677~39126818:-
BRCA	cis	rs9368481	0.761	rs9379952	ENSG00000241549.7	GUSBP2	-9.62	4.94e-21	2.58e-18	-0.33	-0.29	Autism spectrum disorder or schizophrenia;	chr6:27020121	chr6:26871484~26956554:-
BRCA	cis	rs367615	0.918	rs4270746	ENSG00000249476.1	CTD-2587M2.1	9.62	4.95e-21	2.58e-18	0.37	0.29	Colorectal cancer (SNP x SNP interaction);	chr5:109541138	chr5:109237120~109326369:-
BRCA	cis	rs6782228	1	rs35604103	ENSG00000242551.2	POU5F1P6	9.62	4.95e-21	2.58e-18	0.41	0.29	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128616009	chr3:128674735~128677005:-
BRCA	cis	rs473651	0.692	rs579511	ENSG00000229915.1	AC016999.2	-9.62	4.96e-21	2.59e-18	-0.36	-0.29	Multiple system atrophy;	chr2:238426273	chr2:238427077~238427729:-
BRCA	cis	rs7924176	0.502	rs12784355	ENSG00000213731.2	RAB5CP1	-9.62	4.97e-21	2.59e-18	-0.32	-0.29	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74386487	chr10:74423435~74424014:-
BRCA	cis	rs875971	0.66	rs801192	ENSG00000222364.1	RNU6-96P	9.62	5e-21	2.61e-18	0.33	0.29	Aortic root size;	chr7:66566965	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.66	rs801190	ENSG00000222364.1	RNU6-96P	9.62	5e-21	2.61e-18	0.33	0.29	Aortic root size;	chr7:66568046	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.66	rs3857686	ENSG00000222364.1	RNU6-96P	9.62	5e-21	2.61e-18	0.33	0.29	Aortic root size;	chr7:66571204	chr7:66395191~66395286:+
BRCA	cis	rs1062177	0.547	rs2915818	ENSG00000213433.5	RPLP1P6	9.61	5.02e-21	2.62e-18	0.36	0.29	Preschool internalizing problems;	chr5:151735729	chr5:151765859~151766378:-
BRCA	cis	rs1113500	0.933	rs745795	ENSG00000226822.1	RP11-356N1.2	9.61	5.02e-21	2.62e-18	0.38	0.29	Growth-regulated protein alpha levels;	chr1:108086723	chr1:108071482~108074519:+
BRCA	cis	rs1113500	0.933	rs2077259	ENSG00000226822.1	RP11-356N1.2	9.61	5.02e-21	2.62e-18	0.38	0.29	Growth-regulated protein alpha levels;	chr1:108086929	chr1:108071482~108074519:+
BRCA	cis	rs1061377	0.513	rs6840214	ENSG00000249207.1	RP11-360F5.1	9.61	5.04e-21	2.63e-18	0.36	0.29	Uric acid levels;	chr4:39118999	chr4:39112677~39126818:-
BRCA	cis	rs7772486	0.754	rs6937661	ENSG00000235652.6	RP11-545I5.3	-9.61	5.05e-21	2.63e-18	-0.29	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145792163	chr6:145799409~145886585:+
BRCA	cis	rs11096990	0.634	rs4975001	ENSG00000249207.1	RP11-360F5.1	9.61	5.07e-21	2.64e-18	0.33	0.29	Cognitive function;	chr4:39264844	chr4:39112677~39126818:-
BRCA	cis	rs875971	0.825	rs4587224	ENSG00000237310.1	GS1-124K5.4	-9.61	5.08e-21	2.64e-18	-0.3	-0.29	Aortic root size;	chr7:66271195	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.792	rs6971752	ENSG00000237310.1	GS1-124K5.4	-9.61	5.08e-21	2.64e-18	-0.3	-0.29	Aortic root size;	chr7:66272999	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.862	rs10950033	ENSG00000237310.1	GS1-124K5.4	-9.61	5.08e-21	2.64e-18	-0.3	-0.29	Aortic root size;	chr7:66274686	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.862	rs11760844	ENSG00000237310.1	GS1-124K5.4	-9.61	5.08e-21	2.64e-18	-0.3	-0.29	Aortic root size;	chr7:66274896	chr7:66493706~66495474:+
BRCA	cis	rs35160687	0.644	rs36079379	ENSG00000273080.1	RP11-301O19.1	-9.61	5.08e-21	2.65e-18	-0.34	-0.29	Night sleep phenotypes;	chr2:86318837	chr2:86195590~86196049:+
BRCA	cis	rs6570726	0.791	rs6923074	ENSG00000235652.6	RP11-545I5.3	9.61	5.09e-21	2.65e-18	0.28	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145572196	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.755	rs2092296	ENSG00000235652.6	RP11-545I5.3	9.61	5.09e-21	2.65e-18	0.28	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145572548	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.755	rs2092297	ENSG00000235652.6	RP11-545I5.3	9.61	5.09e-21	2.65e-18	0.28	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145572629	chr6:145799409~145886585:+
BRCA	cis	rs7811142	0.562	rs7786844	ENSG00000242294.5	STAG3L5P	9.61	5.13e-21	2.67e-18	0.27	0.29	Platelet count;	chr7:100336385	chr7:100336079~100351900:+
BRCA	cis	rs7429990	0.965	rs9846062	ENSG00000229759.1	MRPS18AP1	9.61	5.16e-21	2.69e-18	0.32	0.29	Educational attainment (years of education);	chr3:47957476	chr3:48256350~48256938:-
BRCA	cis	rs228614	0.51	rs4699033	ENSG00000246560.2	RP11-10L12.4	9.61	5.17e-21	2.69e-18	0.3	0.29	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102897577	chr4:102828055~102844075:+
BRCA	cis	rs6142102	0.517	rs6059580	ENSG00000276073.1	RP5-1125A11.7	-9.61	5.17e-21	2.69e-18	-0.33	-0.29	Skin pigmentation;	chr20:33940067	chr20:33985617~33988989:-
BRCA	cis	rs2882667	0.556	rs6873733	ENSG00000253404.1	AC034243.1	9.61	5.17e-21	2.69e-18	0.35	0.29	Age-related hearing impairment (SNP x SNP interaction);	chr5:139067628	chr5:138744434~138753309:-
BRCA	cis	rs875971	0.638	rs3898855	ENSG00000222364.1	RNU6-96P	9.61	5.19e-21	2.7e-18	0.33	0.29	Aortic root size;	chr7:66571411	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.638	rs10278816	ENSG00000222364.1	RNU6-96P	9.61	5.19e-21	2.7e-18	0.33	0.29	Aortic root size;	chr7:66572000	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.66	rs10281080	ENSG00000222364.1	RNU6-96P	9.61	5.19e-21	2.7e-18	0.33	0.29	Aortic root size;	chr7:66577454	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.66	rs10950044	ENSG00000222364.1	RNU6-96P	9.61	5.19e-21	2.7e-18	0.33	0.29	Aortic root size;	chr7:66577989	chr7:66395191~66395286:+
BRCA	cis	rs2243480	1	rs35058610	ENSG00000226824.5	RP4-756H11.3	-9.61	5.21e-21	2.71e-18	-0.54	-0.29	Diabetic kidney disease;	chr7:65925938	chr7:66654538~66669855:+
BRCA	cis	rs1426063	1	rs1426063	ENSG00000260265.1	RP11-44F21.5	-9.61	5.22e-21	2.72e-18	-0.46	-0.29	QT interval;	chr4:75105711	chr4:75081702~75084717:-
BRCA	cis	rs1113500	0.933	rs12132785	ENSG00000226822.1	RP11-356N1.2	9.61	5.25e-21	2.73e-18	0.37	0.29	Growth-regulated protein alpha levels;	chr1:108090461	chr1:108071482~108074519:+
BRCA	cis	rs783540	0.869	rs783533	ENSG00000278603.1	RP13-608F4.5	-9.61	5.27e-21	2.74e-18	-0.35	-0.29	Schizophrenia;	chr15:82581437	chr15:82472203~82472426:+
BRCA	cis	rs732716	0.785	rs11667543	ENSG00000267769.1	CTB-50L17.9	-9.61	5.28e-21	2.75e-18	-0.37	-0.29	Mean corpuscular volume;	chr19:4374853	chr19:4454014~4455286:+
BRCA	cis	rs8059260	0.542	rs11860851	ENSG00000274038.1	RP11-66H6.4	-9.61	5.28e-21	2.75e-18	-0.43	-0.29	Alcohol consumption over the past year;	chr16:11033893	chr16:11056556~11057034:+
BRCA	cis	rs1113500	0.933	rs10881498	ENSG00000226822.1	RP11-356N1.2	9.61	5.29e-21	2.75e-18	0.37	0.29	Growth-regulated protein alpha levels;	chr1:108092362	chr1:108071482~108074519:+
BRCA	cis	rs367615	0.918	rs4576198	ENSG00000249476.1	CTD-2587M2.1	9.61	5.31e-21	2.76e-18	0.37	0.29	Colorectal cancer (SNP x SNP interaction);	chr5:109531649	chr5:109237120~109326369:-
BRCA	cis	rs2243480	0.831	rs7806717	ENSG00000226824.5	RP4-756H11.3	9.61	5.35e-21	2.78e-18	0.54	0.29	Diabetic kidney disease;	chr7:65928187	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs34933526	ENSG00000226824.5	RP4-756H11.3	-9.61	5.35e-21	2.78e-18	-0.54	-0.29	Diabetic kidney disease;	chr7:65918212	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs6949812	ENSG00000226824.5	RP4-756H11.3	-9.61	5.35e-21	2.78e-18	-0.54	-0.29	Diabetic kidney disease;	chr7:65922114	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs6970243	ENSG00000226824.5	RP4-756H11.3	-9.61	5.35e-21	2.78e-18	-0.54	-0.29	Diabetic kidney disease;	chr7:65923503	chr7:66654538~66669855:+
BRCA	cis	rs2243480	0.708	rs35310401	ENSG00000226824.5	RP4-756H11.3	-9.61	5.35e-21	2.78e-18	-0.54	-0.29	Diabetic kidney disease;	chr7:65925372	chr7:66654538~66669855:+
BRCA	cis	rs11098499	0.909	rs11723839	ENSG00000245958.5	RP11-33B1.1	-9.61	5.36e-21	2.79e-18	-0.28	-0.29	Corneal astigmatism;	chr4:119378518	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.779	rs7699346	ENSG00000245958.5	RP11-33B1.1	-9.61	5.36e-21	2.79e-18	-0.28	-0.29	Corneal astigmatism;	chr4:119389387	chr4:119454791~119552025:+
BRCA	cis	rs875971	0.789	rs28815324	ENSG00000226824.5	RP4-756H11.3	9.61	5.37e-21	2.79e-18	0.4	0.29	Aortic root size;	chr7:66100789	chr7:66654538~66669855:+
BRCA	cis	rs7772486	0.686	rs9376961	ENSG00000235652.6	RP11-545I5.3	9.61	5.4e-21	2.81e-18	0.29	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145727601	chr6:145799409~145886585:+
BRCA	cis	rs6921919	0.525	rs11760133	ENSG00000216901.1	AL022393.7	9.61	5.4e-21	2.81e-18	0.38	0.29	Autism spectrum disorder or schizophrenia;	chr6:28418962	chr6:28176188~28176674:+
BRCA	cis	rs875971	0.66	rs801211	ENSG00000222364.1	RNU6-96P	9.61	5.41e-21	2.81e-18	0.33	0.29	Aortic root size;	chr7:66550702	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.638	rs801205	ENSG00000222364.1	RNU6-96P	9.61	5.41e-21	2.81e-18	0.33	0.29	Aortic root size;	chr7:66557157	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.617	rs810400	ENSG00000222364.1	RNU6-96P	9.61	5.41e-21	2.81e-18	0.33	0.29	Aortic root size;	chr7:66557902	chr7:66395191~66395286:+
BRCA	cis	rs858239	0.601	rs73272048	ENSG00000226816.2	AC005082.12	9.61	5.43e-21	2.82e-18	0.33	0.29	Cerebrospinal fluid biomarker levels;	chr7:23113034	chr7:23206013~23208045:+
BRCA	cis	rs10129255	0.5	rs2105991	ENSG00000211972.2	IGHV3-66	9.61	5.43e-21	2.82e-18	0.2	0.29	Kawasaki disease;	chr14:106682022	chr14:106675017~106675544:-
BRCA	cis	rs4835473	0.838	rs6832094	ENSG00000251600.4	RP11-673E1.1	-9.61	5.45e-21	2.83e-18	-0.33	-0.29	Immature fraction of reticulocytes;	chr4:143795388	chr4:143912331~143982454:+
BRCA	cis	rs6570726	0.791	rs383841	ENSG00000235652.6	RP11-545I5.3	-9.6	5.49e-21	2.85e-18	-0.29	-0.29	Lobe attachment (rater-scored or self-reported);	chr6:145567193	chr6:145799409~145886585:+
BRCA	cis	rs7743045	0.548	rs2357023	ENSG00000253194.1	RP11-351A11.1	-9.6	5.49e-21	2.85e-18	-0.36	-0.29	Mean platelet volume;	chr6:119023364	chr6:118934785~119031541:+
BRCA	cis	rs11098499	0.863	rs10018280	ENSG00000245958.5	RP11-33B1.1	-9.6	5.51e-21	2.86e-18	-0.28	-0.29	Corneal astigmatism;	chr4:119556984	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.863	rs6534141	ENSG00000245958.5	RP11-33B1.1	-9.6	5.51e-21	2.86e-18	-0.28	-0.29	Corneal astigmatism;	chr4:119564068	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.863	rs2127823	ENSG00000245958.5	RP11-33B1.1	-9.6	5.51e-21	2.86e-18	-0.28	-0.29	Corneal astigmatism;	chr4:119564515	chr4:119454791~119552025:+
BRCA	cis	rs227275	0.556	rs11722779	ENSG00000246560.2	RP11-10L12.4	9.6	5.51e-21	2.86e-18	0.3	0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102906331	chr4:102828055~102844075:+
BRCA	cis	rs858239	0.601	rs6461702	ENSG00000226816.2	AC005082.12	9.6	5.52e-21	2.87e-18	0.34	0.29	Cerebrospinal fluid biomarker levels;	chr7:23209654	chr7:23206013~23208045:+
BRCA	cis	rs4727443	0.966	rs66748925	ENSG00000235713.1	RP4-604G5.3	-9.6	5.54e-21	2.88e-18	-0.32	-0.29	Interstitial lung disease;	chr7:99992220	chr7:99992397~99993050:+
BRCA	cis	rs453301	0.658	rs13271797	ENSG00000253893.2	FAM85B	9.6	5.55e-21	2.88e-18	0.36	0.29	Joint mobility (Beighton score);	chr8:9028444	chr8:8167819~8226614:-
BRCA	cis	rs1062177	1	rs2964578	ENSG00000253921.1	CTB-113P19.3	-9.6	5.55e-21	2.88e-18	-0.4	-0.29	Preschool internalizing problems;	chr5:151767637	chr5:151753992~151767247:+
BRCA	cis	rs7429990	1	rs1684942	ENSG00000229759.1	MRPS18AP1	9.6	5.55e-21	2.88e-18	0.33	0.29	Educational attainment (years of education);	chr3:47859213	chr3:48256350~48256938:-
BRCA	cis	rs1062177	1	rs2915877	ENSG00000253921.1	CTB-113P19.3	-9.6	5.62e-21	2.91e-18	-0.39	-0.29	Preschool internalizing problems;	chr5:151771040	chr5:151753992~151767247:+
BRCA	cis	rs1062177	1	rs2964576	ENSG00000253921.1	CTB-113P19.3	-9.6	5.62e-21	2.91e-18	-0.39	-0.29	Preschool internalizing problems;	chr5:151771041	chr5:151753992~151767247:+
BRCA	cis	rs7772486	0.79	rs9376968	ENSG00000235652.6	RP11-545I5.3	9.6	5.62e-21	2.91e-18	0.28	0.29	Lobe attachment (rater-scored or self-reported);	chr6:145859228	chr6:145799409~145886585:+
BRCA	cis	rs875971	0.66	rs62465434	ENSG00000222364.1	RNU6-96P	-9.6	5.62e-21	2.91e-18	-0.33	-0.29	Aortic root size;	chr7:66540165	chr7:66395191~66395286:+
BRCA	cis	rs7429990	0.965	rs319685	ENSG00000229759.1	MRPS18AP1	9.6	5.62e-21	2.92e-18	0.32	0.29	Educational attainment (years of education);	chr3:47890494	chr3:48256350~48256938:-
BRCA	cis	rs875971	0.66	rs28698552	ENSG00000222364.1	RNU6-96P	-9.6	5.63e-21	2.92e-18	-0.33	-0.29	Aortic root size;	chr7:66540031	chr7:66395191~66395286:+
BRCA	cis	rs11098499	0.754	rs714899	ENSG00000248280.1	RP11-33B1.2	9.6	5.64e-21	2.92e-18	0.28	0.29	Corneal astigmatism;	chr4:119321880	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.863	rs1010739	ENSG00000245958.5	RP11-33B1.1	-9.6	5.65e-21	2.93e-18	-0.29	-0.29	Corneal astigmatism;	chr4:119542316	chr4:119454791~119552025:+
BRCA	cis	rs875971	0.508	rs6947808	ENSG00000222364.1	RNU6-96P	9.6	5.71e-21	2.96e-18	0.33	0.29	Aortic root size;	chr7:66580095	chr7:66395191~66395286:+
BRCA	cis	rs227275	0.554	rs223363	ENSG00000246560.2	RP11-10L12.4	9.6	5.72e-21	2.97e-18	0.3	0.29	Allergic disease (asthma, hay fever or eczema);	chr4:102846182	chr4:102828055~102844075:+
BRCA	cis	rs6890270	1	rs6890270	ENSG00000271828.1	CTD-2310F14.1	9.6	5.75e-21	2.98e-18	0.41	0.29	Breast cancer;	chr5:56964779	chr5:56927874~56929573:+
BRCA	cis	rs858239	0.6	rs9691762	ENSG00000226816.2	AC005082.12	9.6	5.75e-21	2.98e-18	0.32	0.29	Cerebrospinal fluid biomarker levels;	chr7:23086303	chr7:23206013~23208045:+
BRCA	cis	rs875971	0.66	rs13224319	ENSG00000222364.1	RNU6-96P	-9.6	5.76e-21	2.99e-18	-0.33	-0.29	Aortic root size;	chr7:66542376	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.66	rs801217	ENSG00000222364.1	RNU6-96P	9.6	5.76e-21	2.99e-18	0.33	0.29	Aortic root size;	chr7:66545590	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.638	rs801216	ENSG00000222364.1	RNU6-96P	9.6	5.76e-21	2.99e-18	0.33	0.29	Aortic root size;	chr7:66546680	chr7:66395191~66395286:+
BRCA	cis	rs6538678	0.833	rs1898178	ENSG00000258343.1	RP11-536G4.2	-9.6	5.83e-21	3.02e-18	-0.39	-0.28	Lupus nephritis in systemic lupus erythematosus;	chr12:95887554	chr12:95795345~95858839:-
BRCA	cis	rs6538678	0.833	rs1898177	ENSG00000258343.1	RP11-536G4.2	-9.6	5.83e-21	3.02e-18	-0.39	-0.28	Lupus nephritis in systemic lupus erythematosus;	chr12:95887568	chr12:95795345~95858839:-
BRCA	cis	rs4964805	0.641	rs10861094	ENSG00000257681.1	RP11-341G23.4	9.6	5.86e-21	3.03e-18	0.34	0.28	Attention deficit hyperactivity disorder;	chr12:103765938	chr12:103746315~103768858:-
BRCA	cis	rs875971	0.545	rs313830	ENSG00000226824.5	RP4-756H11.3	9.6	5.88e-21	3.05e-18	0.4	0.28	Aortic root size;	chr7:66086944	chr7:66654538~66669855:+
BRCA	cis	rs7772486	0.686	rs9403739	ENSG00000235652.6	RP11-545I5.3	-9.6	5.91e-21	3.06e-18	-0.29	-0.28	Lobe attachment (rater-scored or self-reported);	chr6:145694221	chr6:145799409~145886585:+
BRCA	cis	rs11098499	0.954	rs6849561	ENSG00000245958.5	RP11-33B1.1	9.6	5.91e-21	3.06e-18	0.29	0.28	Corneal astigmatism;	chr4:119488539	chr4:119454791~119552025:+
BRCA	cis	rs875971	0.862	rs10276077	ENSG00000237310.1	GS1-124K5.4	-9.6	5.93e-21	3.07e-18	-0.3	-0.28	Aortic root size;	chr7:66263424	chr7:66493706~66495474:+
BRCA	cis	rs35160687	0.644	rs2113615	ENSG00000273080.1	RP11-301O19.1	-9.6	5.93e-21	3.07e-18	-0.34	-0.28	Night sleep phenotypes;	chr2:86290479	chr2:86195590~86196049:+
BRCA	cis	rs812925	0.519	rs2694638	ENSG00000271889.1	RP11-493E12.1	-9.6	5.95e-21	3.08e-18	-0.35	-0.28	Immature fraction of reticulocytes;	chr2:61408228	chr2:61151433~61162105:-
BRCA	cis	rs875971	0.545	rs313828	ENSG00000226824.5	RP4-756H11.3	9.6	5.96e-21	3.09e-18	0.4	0.28	Aortic root size;	chr7:66087627	chr7:66654538~66669855:+
BRCA	cis	rs7772486	0.754	rs702304	ENSG00000235652.6	RP11-545I5.3	-9.6	5.97e-21	3.09e-18	-0.29	-0.28	Lobe attachment (rater-scored or self-reported);	chr6:145669661	chr6:145799409~145886585:+
BRCA	cis	rs7924176	0.58	rs7912162	ENSG00000213731.2	RAB5CP1	-9.59	5.98e-21	3.09e-18	-0.32	-0.28	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74162005	chr10:74423435~74424014:-
BRCA	cis	rs6844153	0.752	rs58968032	ENSG00000240005.4	RP11-293A21.1	-9.59	5.98e-21	3.1e-18	-0.4	-0.28	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26884674	chr4:26859806~26860599:-
BRCA	cis	rs35160687	0.623	rs1863060	ENSG00000273080.1	RP11-301O19.1	-9.59	6.01e-21	3.11e-18	-0.34	-0.28	Night sleep phenotypes;	chr2:86284333	chr2:86195590~86196049:+
BRCA	cis	rs11098499	0.863	rs3775858	ENSG00000245958.5	RP11-33B1.1	-9.59	6.04e-21	3.12e-18	-0.28	-0.28	Corneal astigmatism;	chr4:119564873	chr4:119454791~119552025:+
BRCA	cis	rs1061377	1	rs9996285	ENSG00000249685.1	RP11-360F5.3	9.59	6.05e-21	3.13e-18	0.34	0.28	Uric acid levels;	chr4:39130556	chr4:39133913~39135608:+
BRCA	cis	rs227275	0.554	rs223316	ENSG00000246560.2	RP11-10L12.4	9.59	6.09e-21	3.15e-18	0.3	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102881949	chr4:102828055~102844075:+
BRCA	cis	rs875971	0.619	rs12533585	ENSG00000222364.1	RNU6-96P	-9.59	6.12e-21	3.17e-18	-0.33	-0.28	Aortic root size;	chr7:66519618	chr7:66395191~66395286:+
BRCA	cis	rs227275	0.525	rs1080081	ENSG00000246560.2	RP11-10L12.4	9.59	6.13e-21	3.17e-18	0.31	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:103029268	chr4:102828055~102844075:+
BRCA	cis	rs227275	0.525	rs4699049	ENSG00000246560.2	RP11-10L12.4	9.59	6.13e-21	3.17e-18	0.31	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:103030467	chr4:102828055~102844075:+
BRCA	cis	rs1113500	0.933	rs11185256	ENSG00000226822.1	RP11-356N1.2	9.59	6.13e-21	3.17e-18	0.37	0.28	Growth-regulated protein alpha levels;	chr1:108091335	chr1:108071482~108074519:+
BRCA	cis	rs2404602	0.503	rs284909	ENSG00000259422.1	RP11-593F23.1	9.59	6.14e-21	3.18e-18	0.35	0.28	Blood metabolite levels;	chr15:76444287	chr15:76174891~76181486:-
BRCA	cis	rs1062177	1	rs2964585	ENSG00000253921.1	CTB-113P19.3	-9.59	6.14e-21	3.18e-18	-0.39	-0.28	Preschool internalizing problems;	chr5:151762334	chr5:151753992~151767247:+
BRCA	cis	rs4835473	0.932	rs4383567	ENSG00000251600.4	RP11-673E1.1	9.59	6.17e-21	3.19e-18	0.33	0.28	Immature fraction of reticulocytes;	chr4:143788873	chr4:143912331~143982454:+
BRCA	cis	rs1823913	0.637	rs13382985	ENSG00000227542.1	AC092614.2	-9.59	6.18e-21	3.2e-18	-0.34	-0.28	Obesity-related traits;	chr2:191306335	chr2:191229165~191246172:-
BRCA	cis	rs1555322	0.53	rs8122819	ENSG00000126005.14	MMP24-AS1	-9.59	6.18e-21	3.2e-18	-0.38	-0.28	Attention deficit hyperactivity disorder;	chr20:35293783	chr20:35216462~35278131:-
BRCA	cis	rs1113500	0.933	rs11185261	ENSG00000226822.1	RP11-356N1.2	9.59	6.29e-21	3.25e-18	0.37	0.28	Growth-regulated protein alpha levels;	chr1:108096081	chr1:108071482~108074519:+
BRCA	cis	rs1113500	0.897	rs4628530	ENSG00000226822.1	RP11-356N1.2	9.59	6.29e-21	3.25e-18	0.37	0.28	Growth-regulated protein alpha levels;	chr1:108096086	chr1:108071482~108074519:+
BRCA	cis	rs801193	1	rs10234018	ENSG00000222364.1	RNU6-96P	9.59	6.31e-21	3.26e-18	0.33	0.28	Aortic root size;	chr7:66681297	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.66	rs12698534	ENSG00000222364.1	RNU6-96P	-9.59	6.32e-21	3.27e-18	-0.33	-0.28	Aortic root size;	chr7:66521858	chr7:66395191~66395286:+
BRCA	cis	rs2243480	1	rs6460260	ENSG00000226824.5	RP4-756H11.3	9.59	6.35e-21	3.28e-18	0.55	0.28	Diabetic kidney disease;	chr7:65750468	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs6460261	ENSG00000226824.5	RP4-756H11.3	9.59	6.35e-21	3.28e-18	0.55	0.28	Diabetic kidney disease;	chr7:65750593	chr7:66654538~66669855:+
BRCA	cis	rs6921919	0.583	rs16894060	ENSG00000216901.1	AL022393.7	9.59	6.35e-21	3.28e-18	0.38	0.28	Autism spectrum disorder or schizophrenia;	chr6:28394694	chr6:28176188~28176674:+
BRCA	cis	rs11676348	0.751	rs6715591	ENSG00000261338.2	RP11-378A13.1	-9.59	6.36e-21	3.29e-18	-0.3	-0.28	Ulcerative colitis;	chr2:218155148	chr2:218255319~218257366:+
BRCA	cis	rs2284378	0.515	rs6059579	ENSG00000276073.1	RP5-1125A11.7	-9.59	6.36e-21	3.29e-18	-0.33	-0.28	Breast cancer;	chr20:33940059	chr20:33985617~33988989:-
BRCA	cis	rs8062405	0.723	rs62031562	ENSG00000278665.1	RP11-666O2.4	9.59	6.37e-21	3.29e-18	0.31	0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28598008	chr16:28599241~28601881:-
BRCA	cis	rs673078	0.66	rs78690826	ENSG00000275759.1	RP11-131L12.3	-9.59	6.38e-21	3.29e-18	-0.49	-0.28	Glucose homeostasis traits;	chr12:118176693	chr12:118428281~118428870:+
BRCA	cis	rs881375	0.654	rs10760126	ENSG00000226752.6	PSMD5-AS1	-9.59	6.38e-21	3.3e-18	-0.34	-0.28	Rheumatoid arthritis;	chr9:120900340	chr9:120824828~120854385:+
BRCA	cis	rs881375	0.678	rs4836834	ENSG00000226752.6	PSMD5-AS1	-9.59	6.38e-21	3.3e-18	-0.34	-0.28	Rheumatoid arthritis;	chr9:120903623	chr9:120824828~120854385:+
BRCA	cis	rs2412819	0.597	rs7181912	ENSG00000249839.1	AC011330.5	9.59	6.4e-21	3.3e-18	0.4	0.28	Lung cancer;	chr15:43770676	chr15:43663654~43684339:-
BRCA	cis	rs1823913	0.599	rs4146103	ENSG00000227542.1	AC092614.2	9.59	6.41e-21	3.31e-18	0.34	0.28	Obesity-related traits;	chr2:191272000	chr2:191229165~191246172:-
BRCA	cis	rs12220777	1	rs11201799	ENSG00000230091.5	TMEM254-AS1	-9.59	6.43e-21	3.32e-18	-0.53	-0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80122198	chr10:80046860~80078912:-
BRCA	cis	rs72772090	0.539	rs11739020	ENSG00000248734.2	CTD-2260A17.1	9.59	6.45e-21	3.33e-18	0.45	0.28	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96778134	chr5:96784777~96785999:+
BRCA	cis	rs17711722	0.701	rs781145	ENSG00000224316.1	RP11-479O9.2	9.59	6.48e-21	3.35e-18	0.28	0.28	Calcium levels;	chr7:65975383	chr7:65773620~65802067:+
BRCA	cis	rs9318086	0.935	rs9553083	ENSG00000205861.10	C1QTNF9B-AS1	9.59	6.48e-21	3.35e-18	0.35	0.28	Myopia (pathological);	chr13:23867386	chr13:23888889~23897263:+
BRCA	cis	rs11096990	0.634	rs6829064	ENSG00000249207.1	RP11-360F5.1	9.59	6.49e-21	3.35e-18	0.33	0.28	Cognitive function;	chr4:39290192	chr4:39112677~39126818:-
BRCA	cis	rs524281	0.684	rs7946447	ENSG00000255320.1	RP11-755F10.1	9.59	6.51e-21	3.36e-18	0.42	0.28	Electroencephalogram traits;	chr11:66096867	chr11:66244840~66246239:-
BRCA	cis	rs17711722	1	rs17711722	ENSG00000224316.1	RP11-479O9.2	-9.59	6.51e-21	3.36e-18	-0.28	-0.28	Calcium levels;	chr7:65806210	chr7:65773620~65802067:+
BRCA	cis	rs6558530	0.932	rs6558531	ENSG00000253982.1	CTD-2336O2.1	9.58	6.55e-21	3.38e-18	0.32	0.28	Systolic blood pressure;	chr8:1759400	chr8:1761990~1764502:-
BRCA	cis	rs1707322	0.821	rs10749857	ENSG00000280836.1	AL355480.1	-9.58	6.67e-21	3.44e-18	-0.37	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45782471	chr1:45581219~45581321:-
BRCA	cis	rs875971	0.895	rs12531677	ENSG00000237310.1	GS1-124K5.4	-9.58	6.67e-21	3.44e-18	-0.3	-0.28	Aortic root size;	chr7:66304099	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.862	rs7798630	ENSG00000237310.1	GS1-124K5.4	-9.58	6.67e-21	3.44e-18	-0.3	-0.28	Aortic root size;	chr7:66306492	chr7:66493706~66495474:+
BRCA	cis	rs6452524	0.766	rs2252179	ENSG00000249664.1	CTD-2227C6.2	-9.58	6.68e-21	3.45e-18	-0.35	-0.28	Hypertension (SNP x SNP interaction);	chr5:83145630	chr5:83012285~83013109:-
BRCA	cis	rs2243480	0.901	rs57126451	ENSG00000226824.5	RP4-756H11.3	-9.58	6.73e-21	3.47e-18	-0.54	-0.28	Diabetic kidney disease;	chr7:65951319	chr7:66654538~66669855:+
BRCA	cis	rs11096990	0.634	rs11947159	ENSG00000249207.1	RP11-360F5.1	9.58	6.81e-21	3.51e-18	0.33	0.28	Cognitive function;	chr4:39286900	chr4:39112677~39126818:-
BRCA	cis	rs10875746	0.669	rs11168459	ENSG00000240399.1	RP1-228P16.1	-9.58	6.93e-21	3.57e-18	-0.38	-0.28	Longevity (90 years and older);	chr12:48202458	chr12:48054813~48055591:-
BRCA	cis	rs875971	0.862	rs4718330	ENSG00000237310.1	GS1-124K5.4	-9.58	7e-21	3.61e-18	-0.3	-0.28	Aortic root size;	chr7:66250256	chr7:66493706~66495474:+
BRCA	cis	rs7772486	0.875	rs2748483	ENSG00000235652.6	RP11-545I5.3	-9.58	7.12e-21	3.67e-18	-0.28	-0.28	Lobe attachment (rater-scored or self-reported);	chr6:146014424	chr6:145799409~145886585:+
BRCA	cis	rs34375054	0.66	rs900411	ENSG00000279233.1	RP11-158L12.4	9.57	7.15e-21	3.69e-18	0.33	0.28	Post bronchodilator FEV1/FVC ratio;	chr12:125128293	chr12:125138245~125141711:+
BRCA	cis	rs1823913	0.599	rs1378156	ENSG00000227542.1	AC092614.2	-9.57	7.16e-21	3.69e-18	-0.35	-0.28	Obesity-related traits;	chr2:191272466	chr2:191229165~191246172:-
BRCA	cis	rs11690935	0.688	rs7600835	ENSG00000228389.1	AC068039.4	9.57	7.16e-21	3.69e-18	0.35	0.28	Schizophrenia;	chr2:171665317	chr2:171773482~171775844:+
BRCA	cis	rs228614	0.51	rs6830407	ENSG00000246560.2	RP11-10L12.4	9.57	7.16e-21	3.69e-18	0.3	0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102895366	chr4:102828055~102844075:+
BRCA	cis	rs2111504	0.806	rs2903738	ENSG00000267213.4	AC007773.2	-9.57	7.21e-21	3.71e-18	-0.37	-0.28	Bipolar disorder;	chr19:32455137	chr19:32390050~32405560:-
BRCA	cis	rs1113500	0.509	rs17020915	ENSG00000226822.1	RP11-356N1.2	9.57	7.24e-21	3.73e-18	0.42	0.28	Growth-regulated protein alpha levels;	chr1:108104384	chr1:108071482~108074519:+
BRCA	cis	rs875971	0.862	rs880166	ENSG00000237310.1	GS1-124K5.4	-9.57	7.25e-21	3.73e-18	-0.3	-0.28	Aortic root size;	chr7:66205775	chr7:66493706~66495474:+
BRCA	cis	rs6452524	0.692	rs1382367	ENSG00000249664.1	CTD-2227C6.2	-9.57	7.26e-21	3.74e-18	-0.35	-0.28	Hypertension (SNP x SNP interaction);	chr5:83155393	chr5:83012285~83013109:-
BRCA	cis	rs228614	0.51	rs223453	ENSG00000246560.2	RP11-10L12.4	9.57	7.29e-21	3.75e-18	0.29	0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102789895	chr4:102828055~102844075:+
BRCA	cis	rs35160687	0.644	rs2367232	ENSG00000273080.1	RP11-301O19.1	-9.57	7.3e-21	3.76e-18	-0.34	-0.28	Night sleep phenotypes;	chr2:86314368	chr2:86195590~86196049:+
BRCA	cis	rs7924176	0.564	rs6480727	ENSG00000213731.2	RAB5CP1	-9.57	7.31e-21	3.76e-18	-0.32	-0.28	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74243315	chr10:74423435~74424014:-
BRCA	cis	rs801193	1	rs2659906	ENSG00000222364.1	RNU6-96P	-9.57	7.33e-21	3.77e-18	-0.32	-0.28	Aortic root size;	chr7:66700323	chr7:66395191~66395286:+
BRCA	cis	rs6570726	0.791	rs398408	ENSG00000235652.6	RP11-545I5.3	9.57	7.33e-21	3.77e-18	0.29	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145479884	chr6:145799409~145886585:+
BRCA	cis	rs2243480	1	rs1723267	ENSG00000226824.5	RP4-756H11.3	-9.57	7.34e-21	3.77e-18	-0.54	-0.28	Diabetic kidney disease;	chr7:66008327	chr7:66654538~66669855:+
BRCA	cis	rs7688540	0.8	rs2353599	ENSG00000211553.1	AC253576.2	-9.57	7.35e-21	3.78e-18	-0.35	-0.28	Facial morphology (factor 6, height of vermillion lower lip);	chr4:286637	chr4:136461~136568:+
BRCA	cis	rs1823913	0.599	rs12988037	ENSG00000227542.1	AC092614.2	9.57	7.36e-21	3.78e-18	0.34	0.28	Obesity-related traits;	chr2:191306419	chr2:191229165~191246172:-
BRCA	cis	rs2243480	0.901	rs35087093	ENSG00000226824.5	RP4-756H11.3	-9.57	7.42e-21	3.82e-18	-0.54	-0.28	Diabetic kidney disease;	chr7:65940221	chr7:66654538~66669855:+
BRCA	cis	rs1075265	0.749	rs805380	ENSG00000233266.1	HMGB1P31	9.57	7.43e-21	3.82e-18	0.34	0.28	Chronotype;Morning vs. evening chronotype;	chr2:53867284	chr2:54051334~54051760:+
BRCA	cis	rs228614	0.51	rs223452	ENSG00000246560.2	RP11-10L12.4	9.57	7.43e-21	3.82e-18	0.3	0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102790277	chr4:102828055~102844075:+
BRCA	cis	rs765787	0.53	rs2899378	ENSG00000259520.4	CTD-2651B20.3	-9.57	7.48e-21	3.84e-18	-0.36	-0.28	Uric acid levels;	chr15:45245386	chr15:45251580~45279251:-
BRCA	cis	rs1062177	1	rs17741826	ENSG00000253921.1	CTB-113P19.3	9.57	7.49e-21	3.85e-18	0.39	0.28	Preschool internalizing problems;	chr5:151769701	chr5:151753992~151767247:+
BRCA	cis	rs765787	0.53	rs12904265	ENSG00000259520.4	CTD-2651B20.3	-9.57	7.52e-21	3.87e-18	-0.36	-0.28	Uric acid levels;	chr15:45234515	chr15:45251580~45279251:-
BRCA	cis	rs875971	0.66	rs10272357	ENSG00000222364.1	RNU6-96P	9.57	7.58e-21	3.9e-18	0.33	0.28	Aortic root size;	chr7:66598087	chr7:66395191~66395286:+
BRCA	cis	rs7829975	0.54	rs2976909	ENSG00000254153.1	CTA-398F10.2	-9.57	7.68e-21	3.95e-18	-0.36	-0.28	Mood instability;	chr8:8489180	chr8:8456909~8461337:-
BRCA	cis	rs875971	0.862	rs11984115	ENSG00000237310.1	GS1-124K5.4	-9.57	7.71e-21	3.96e-18	-0.3	-0.28	Aortic root size;	chr7:66308872	chr7:66493706~66495474:+
BRCA	cis	rs10262624	1	rs7792262	ENSG00000234286.1	AC006026.13	9.57	7.72e-21	3.97e-18	0.33	0.28	Schizophrenia;	chr7:23876124	chr7:23680195~23680786:-
BRCA	cis	rs2243480	1	rs35396113	ENSG00000226824.5	RP4-756H11.3	-9.57	7.76e-21	3.98e-18	-0.55	-0.28	Diabetic kidney disease;	chr7:66030474	chr7:66654538~66669855:+
BRCA	cis	rs1862618	0.525	rs832403	ENSG00000271828.1	CTD-2310F14.1	-9.57	7.8e-21	4e-18	-0.42	-0.28	Initial pursuit acceleration;	chr5:56970165	chr5:56927874~56929573:+
BRCA	cis	rs7772486	0.79	rs7753833	ENSG00000235652.6	RP11-545I5.3	9.56	7.81e-21	4.01e-18	0.28	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145840296	chr6:145799409~145886585:+
BRCA	cis	rs1061377	0.513	rs2712000	ENSG00000249207.1	RP11-360F5.1	-9.56	7.87e-21	4.04e-18	-0.36	-0.28	Uric acid levels;	chr4:39135462	chr4:39112677~39126818:-
BRCA	cis	rs6570726	0.791	rs418701	ENSG00000235652.6	RP11-545I5.3	9.56	7.89e-21	4.05e-18	0.28	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145568856	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.791	rs1280275	ENSG00000235652.6	RP11-545I5.3	9.56	7.89e-21	4.05e-18	0.28	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145571266	chr6:145799409~145886585:+
BRCA	cis	rs875971	0.505	rs1723275	ENSG00000224316.1	RP11-479O9.2	-9.56	7.93e-21	4.07e-18	-0.28	-0.28	Aortic root size;	chr7:66039646	chr7:65773620~65802067:+
BRCA	cis	rs7924176	0.549	rs2395076	ENSG00000213731.2	RAB5CP1	-9.56	7.99e-21	4.1e-18	-0.31	-0.28	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74172081	chr10:74423435~74424014:-
BRCA	cis	rs957448	1	rs72674852	ENSG00000253704.1	RP11-267M23.4	9.56	8.01e-21	4.11e-18	0.34	0.28	Nonsyndromic cleft lip with cleft palate;	chr8:94536523	chr8:94553722~94569745:+
BRCA	cis	rs8177376	0.727	rs645852	ENSG00000254905.1	RP11-712L6.7	9.56	8.05e-21	4.13e-18	0.38	0.28	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126327509	chr11:126292922~126294254:-
BRCA	cis	rs8177376	0.727	rs646775	ENSG00000254905.1	RP11-712L6.7	9.56	8.05e-21	4.13e-18	0.38	0.28	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126327704	chr11:126292922~126294254:-
BRCA	cis	rs6570726	0.791	rs6900040	ENSG00000235652.6	RP11-545I5.3	9.56	8.07e-21	4.14e-18	0.28	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145571998	chr6:145799409~145886585:+
BRCA	cis	rs2404602	0.552	rs4886823	ENSG00000259422.1	RP11-593F23.1	-9.56	8.09e-21	4.15e-18	-0.38	-0.28	Blood metabolite levels;	chr15:76673061	chr15:76174891~76181486:-
BRCA	cis	rs1113500	0.548	rs11185269	ENSG00000226822.1	RP11-356N1.2	9.56	8.1e-21	4.15e-18	0.42	0.28	Growth-regulated protein alpha levels;	chr1:108105014	chr1:108071482~108074519:+
BRCA	cis	rs7924176	0.601	rs7089391	ENSG00000213731.2	RAB5CP1	-9.56	8.15e-21	4.18e-18	-0.31	-0.28	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74177762	chr10:74423435~74424014:-
BRCA	cis	rs4853012	0.793	rs6707619	ENSG00000257800.1	FNBP1P1	9.56	8.17e-21	4.19e-18	0.29	0.28	Gestational age at birth (maternal effect);	chr2:74117529	chr2:74120680~74123218:+
BRCA	cis	rs35160687	0.644	rs4832272	ENSG00000273080.1	RP11-301O19.1	-9.56	8.18e-21	4.19e-18	-0.34	-0.28	Night sleep phenotypes;	chr2:86289088	chr2:86195590~86196049:+
BRCA	cis	rs35160687	0.644	rs57270703	ENSG00000273080.1	RP11-301O19.1	-9.56	8.18e-21	4.19e-18	-0.34	-0.28	Night sleep phenotypes;	chr2:86289750	chr2:86195590~86196049:+
BRCA	cis	rs7188445	0.736	rs4243177	ENSG00000261390.4	RP11-345M22.2	9.56	8.2e-21	4.2e-18	0.35	0.28	Urate levels;	chr16:79669932	chr16:79715232~79770563:-
BRCA	cis	rs72772090	0.539	rs11738115	ENSG00000248734.2	CTD-2260A17.1	9.56	8.23e-21	4.22e-18	0.47	0.28	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96777368	chr5:96784777~96785999:+
BRCA	cis	rs875971	0.862	rs10263690	ENSG00000237310.1	GS1-124K5.4	-9.56	8.24e-21	4.23e-18	-0.3	-0.28	Aortic root size;	chr7:66301466	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.862	rs10250544	ENSG00000237310.1	GS1-124K5.4	-9.56	8.24e-21	4.23e-18	-0.3	-0.28	Aortic root size;	chr7:66301574	chr7:66493706~66495474:+
BRCA	cis	rs227275	0.556	rs6815526	ENSG00000246560.2	RP11-10L12.4	9.56	8.28e-21	4.24e-18	0.3	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102899729	chr4:102828055~102844075:+
BRCA	cis	rs227275	0.556	rs6824070	ENSG00000246560.2	RP11-10L12.4	9.56	8.28e-21	4.24e-18	0.3	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102901676	chr4:102828055~102844075:+
BRCA	cis	rs11722779	0.935	rs6856176	ENSG00000246560.2	RP11-10L12.4	9.56	8.28e-21	4.24e-18	0.3	0.28	Schizophrenia;	chr4:102902574	chr4:102828055~102844075:+
BRCA	cis	rs1113500	0.836	rs1539553	ENSG00000226822.1	RP11-356N1.2	-9.56	8.29e-21	4.25e-18	-0.37	-0.28	Growth-regulated protein alpha levels;	chr1:108047376	chr1:108071482~108074519:+
BRCA	cis	rs227275	0.554	rs223357	ENSG00000246560.2	RP11-10L12.4	9.56	8.31e-21	4.26e-18	0.3	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102851095	chr4:102828055~102844075:+
BRCA	cis	rs227275	0.554	rs223421	ENSG00000246560.2	RP11-10L12.4	9.56	8.32e-21	4.26e-18	0.29	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102805861	chr4:102828055~102844075:+
BRCA	cis	rs321358	0.707	rs73021578	ENSG00000271584.1	RP11-89C3.4	9.56	8.36e-21	4.28e-18	0.45	0.28	Body mass index;	chr11:111156211	chr11:111091932~111097357:-
BRCA	cis	rs12468226	1	rs76284304	ENSG00000273456.1	RP11-686O6.2	9.56	8.47e-21	4.33e-18	0.42	0.28	Urate levels;	chr2:202427116	chr2:202374932~202375604:-
BRCA	cis	rs11098499	0.863	rs6858592	ENSG00000245958.5	RP11-33B1.1	-9.56	8.51e-21	4.35e-18	-0.28	-0.28	Corneal astigmatism;	chr4:119537537	chr4:119454791~119552025:+
BRCA	cis	rs80285556	1	rs77187281	ENSG00000161643.11	SIGLEC16	9.55	8.54e-21	4.37e-18	0.77	0.28	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50004410	chr19:49969673~49975814:+
BRCA	cis	rs11673344	0.932	rs76350084	ENSG00000226686.6	LINC01535	9.55	8.58e-21	4.39e-18	0.37	0.28	Obesity-related traits;	chr19:37187917	chr19:37251912~37265535:+
BRCA	cis	rs11098499	0.754	rs938056	ENSG00000248280.1	RP11-33B1.2	9.55	8.6e-21	4.4e-18	0.28	0.28	Corneal astigmatism;	chr4:119316298	chr4:119440561~119450157:-
BRCA	cis	rs801193	1	rs7788576	ENSG00000222364.1	RNU6-96P	9.55	8.65e-21	4.42e-18	0.33	0.28	Aortic root size;	chr7:66683315	chr7:66395191~66395286:+
BRCA	cis	rs1707322	0.821	rs11211182	ENSG00000280836.1	AL355480.1	-9.55	8.65e-21	4.43e-18	-0.37	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45774498	chr1:45581219~45581321:-
BRCA	cis	rs227275	0.524	rs223337	ENSG00000246560.2	RP11-10L12.4	9.55	8.69e-21	4.44e-18	0.3	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102865214	chr4:102828055~102844075:+
BRCA	cis	rs3779195	0.585	rs56694862	ENSG00000272950.1	RP11-307C18.1	-9.55	8.7e-21	4.45e-18	-0.5	-0.28	Sex hormone-binding globulin levels;	chr7:98267808	chr7:98322853~98323430:+
BRCA	cis	rs2243480	0.711	rs1626926	ENSG00000226824.5	RP4-756H11.3	-9.55	8.72e-21	4.46e-18	-0.54	-0.28	Diabetic kidney disease;	chr7:65970805	chr7:66654538~66669855:+
BRCA	cis	rs227275	0.554	rs223314	ENSG00000246560.2	RP11-10L12.4	9.55	8.74e-21	4.47e-18	0.3	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102884642	chr4:102828055~102844075:+
BRCA	cis	rs228614	0.51	rs7254	ENSG00000246560.2	RP11-10L12.4	9.55	8.74e-21	4.47e-18	0.3	0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102888488	chr4:102828055~102844075:+
BRCA	cis	rs11722779	0.566	rs6822658	ENSG00000246560.2	RP11-10L12.4	9.55	8.74e-21	4.47e-18	0.3	0.28	Schizophrenia;	chr4:102891964	chr4:102828055~102844075:+
BRCA	cis	rs228614	0.51	rs6823625	ENSG00000246560.2	RP11-10L12.4	9.55	8.74e-21	4.47e-18	0.3	0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102892437	chr4:102828055~102844075:+
BRCA	cis	rs228614	0.51	rs6846762	ENSG00000246560.2	RP11-10L12.4	9.55	8.74e-21	4.47e-18	0.3	0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102892577	chr4:102828055~102844075:+
BRCA	cis	rs228614	0.51	rs4699032	ENSG00000246560.2	RP11-10L12.4	9.55	8.74e-21	4.47e-18	0.3	0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102892724	chr4:102828055~102844075:+
BRCA	cis	rs4835473	0.932	rs1839448	ENSG00000251600.4	RP11-673E1.1	9.55	8.8e-21	4.5e-18	0.33	0.28	Immature fraction of reticulocytes;	chr4:143752113	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs10021860	ENSG00000251600.4	RP11-673E1.1	9.55	8.8e-21	4.5e-18	0.33	0.28	Immature fraction of reticulocytes;	chr4:143754593	chr4:143912331~143982454:+
BRCA	cis	rs35160687	0.644	rs4610056	ENSG00000273080.1	RP11-301O19.1	-9.55	8.83e-21	4.51e-18	-0.34	-0.28	Night sleep phenotypes;	chr2:86326127	chr2:86195590~86196049:+
BRCA	cis	rs35160687	0.644	rs7595785	ENSG00000273080.1	RP11-301O19.1	-9.55	8.83e-21	4.51e-18	-0.34	-0.28	Night sleep phenotypes;	chr2:86329282	chr2:86195590~86196049:+
BRCA	cis	rs4713118	0.662	rs149970	ENSG00000220721.1	OR1F12	9.55	8.84e-21	4.52e-18	0.37	0.28	Parkinson's disease;	chr6:28012442	chr6:28073316~28074233:+
BRCA	cis	rs801193	1	rs11773829	ENSG00000222364.1	RNU6-96P	9.55	8.85e-21	4.52e-18	0.33	0.28	Aortic root size;	chr7:66676087	chr7:66395191~66395286:+
BRCA	cis	rs9807989	0.507	rs13021177	ENSG00000234389.1	AC007278.3	9.55	8.88e-21	4.54e-18	0.26	0.28	Asthma;	chr2:102440033	chr2:102438713~102440475:+
BRCA	cis	rs1062177	1	rs41494545	ENSG00000253921.1	CTB-113P19.3	9.55	8.89e-21	4.54e-18	0.39	0.28	Preschool internalizing problems;	chr5:151855533	chr5:151753992~151767247:+
BRCA	cis	rs875971	0.545	rs73136346	ENSG00000226824.5	RP4-756H11.3	9.55	8.9e-21	4.55e-18	0.4	0.28	Aortic root size;	chr7:66101095	chr7:66654538~66669855:+
BRCA	cis	rs4862750	0.914	rs1863405	ENSG00000250971.1	RP11-696F12.1	-9.55	8.96e-21	4.58e-18	-0.3	-0.28	Lobe attachment (rater-scored or self-reported);	chr4:186953374	chr4:187060099~187060930:+
BRCA	cis	rs3779195	0.524	rs76976120	ENSG00000272950.1	RP11-307C18.1	-9.55	9.05e-21	4.62e-18	-0.49	-0.28	Sex hormone-binding globulin levels;	chr7:98264860	chr7:98322853~98323430:+
BRCA	cis	rs801193	0.761	rs2659888	ENSG00000222364.1	RNU6-96P	-9.55	9.05e-21	4.62e-18	-0.33	-0.28	Aortic root size;	chr7:66765184	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.862	rs2901152	ENSG00000237310.1	GS1-124K5.4	-9.55	9.06e-21	4.63e-18	-0.3	-0.28	Aortic root size;	chr7:66300017	chr7:66493706~66495474:+
BRCA	cis	rs7772486	0.686	rs1292334	ENSG00000235652.6	RP11-545I5.3	9.55	9.09e-21	4.64e-18	0.29	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145647152	chr6:145799409~145886585:+
BRCA	cis	rs9318086	0.935	rs2025701	ENSG00000205861.10	C1QTNF9B-AS1	-9.55	9.15e-21	4.67e-18	-0.35	-0.28	Myopia (pathological);	chr13:23866442	chr13:23888889~23897263:+
BRCA	cis	rs7580658	0.521	rs2404535	ENSG00000236682.1	AC068282.3	9.55	9.23e-21	4.71e-18	0.37	0.28	Protein C levels;	chr2:127190133	chr2:127389130~127400580:+
BRCA	cis	rs801193	1	rs2707856	ENSG00000222364.1	RNU6-96P	-9.55	9.24e-21	4.72e-18	-0.32	-0.28	Aortic root size;	chr7:66746023	chr7:66395191~66395286:+
BRCA	cis	rs1185460	1	rs7127212	ENSG00000271751.1	RP11-110I1.14	9.55	9.28e-21	4.74e-18	0.36	0.28	Coronary artery disease;	chr11:119082492	chr11:119065263~119065677:-
BRCA	cis	rs4853012	0.838	rs72915068	ENSG00000257800.1	FNBP1P1	9.55	9.29e-21	4.74e-18	0.29	0.28	Gestational age at birth (maternal effect);	chr2:74129058	chr2:74120680~74123218:+
BRCA	cis	rs2243480	1	rs34136756	ENSG00000226824.5	RP4-756H11.3	-9.54	9.34e-21	4.77e-18	-0.54	-0.28	Diabetic kidney disease;	chr7:65916269	chr7:66654538~66669855:+
BRCA	cis	rs1707322	0.752	rs11488313	ENSG00000280836.1	AL355480.1	-9.54	9.36e-21	4.77e-18	-0.37	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45759108	chr1:45581219~45581321:-
BRCA	cis	rs853679	0.723	rs9366718	ENSG00000220721.1	OR1F12	9.54	9.39e-21	4.79e-18	0.41	0.28	Depression;	chr6:28237724	chr6:28073316~28074233:+
BRCA	cis	rs2243480	1	rs781156	ENSG00000226824.5	RP4-756H11.3	-9.54	9.41e-21	4.8e-18	-0.54	-0.28	Diabetic kidney disease;	chr7:66014154	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs451396	ENSG00000226824.5	RP4-756H11.3	-9.54	9.41e-21	4.8e-18	-0.54	-0.28	Diabetic kidney disease;	chr7:66019087	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs1715235	ENSG00000226824.5	RP4-756H11.3	-9.54	9.41e-21	4.8e-18	-0.54	-0.28	Diabetic kidney disease;	chr7:66023407	chr7:66654538~66669855:+
BRCA	cis	rs7772486	0.875	rs10872583	ENSG00000235652.6	RP11-545I5.3	-9.54	9.45e-21	4.82e-18	-0.28	-0.28	Lobe attachment (rater-scored or self-reported);	chr6:146075563	chr6:145799409~145886585:+
BRCA	cis	rs2243480	1	rs781142	ENSG00000226824.5	RP4-756H11.3	-9.54	9.5e-21	4.84e-18	-0.54	-0.28	Diabetic kidney disease;	chr7:65973791	chr7:66654538~66669855:+
BRCA	cis	rs2739330	0.76	rs5751761	ENSG00000099984.9	GSTT2	9.54	9.53e-21	4.86e-18	0.35	0.28	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23980123~23983911:+
BRCA	cis	rs4853012	0.838	rs4452177	ENSG00000257800.1	FNBP1P1	9.54	9.53e-21	4.86e-18	0.29	0.28	Gestational age at birth (maternal effect);	chr2:74118079	chr2:74120680~74123218:+
BRCA	cis	rs228614	0.51	rs223412	ENSG00000246560.2	RP11-10L12.4	9.54	9.54e-21	4.87e-18	0.3	0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102812443	chr4:102828055~102844075:+
BRCA	cis	rs2243480	1	rs313809	ENSG00000226824.5	RP4-756H11.3	-9.54	9.55e-21	4.87e-18	-0.55	-0.28	Diabetic kidney disease;	chr7:66034996	chr7:66654538~66669855:+
BRCA	cis	rs3779195	0.585	rs73709460	ENSG00000272950.1	RP11-307C18.1	-9.54	9.58e-21	4.88e-18	-0.49	-0.28	Sex hormone-binding globulin levels;	chr7:98265942	chr7:98322853~98323430:+
BRCA	cis	rs875971	0.862	rs6460302	ENSG00000237310.1	GS1-124K5.4	9.54	9.6e-21	4.89e-18	0.3	0.28	Aortic root size;	chr7:66495270	chr7:66493706~66495474:+
BRCA	cis	rs7829975	0.606	rs10112585	ENSG00000253893.2	FAM85B	9.54	9.65e-21	4.92e-18	0.35	0.28	Mood instability;	chr8:8937520	chr8:8167819~8226614:-
BRCA	cis	rs10129255	0.5	rs9324092	ENSG00000211972.2	IGHV3-66	-9.54	9.67e-21	4.93e-18	-0.2	-0.28	Kawasaki disease;	chr14:106683806	chr14:106675017~106675544:-
BRCA	cis	rs4835473	0.932	rs13152209	ENSG00000251600.4	RP11-673E1.1	9.54	9.69e-21	4.94e-18	0.33	0.28	Immature fraction of reticulocytes;	chr4:143776088	chr4:143912331~143982454:+
BRCA	cis	rs7772486	0.875	rs2492855	ENSG00000235652.6	RP11-545I5.3	9.54	9.69e-21	4.94e-18	0.28	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145975790	chr6:145799409~145886585:+
BRCA	cis	rs875971	0.545	rs221986	ENSG00000226824.5	RP4-756H11.3	9.54	9.7e-21	4.94e-18	0.4	0.28	Aortic root size;	chr7:66105323	chr7:66654538~66669855:+
BRCA	cis	rs227275	0.525	rs17215211	ENSG00000246560.2	RP11-10L12.4	9.54	9.76e-21	4.97e-18	0.3	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:103025961	chr4:102828055~102844075:+
BRCA	cis	rs7772486	0.79	rs2485632	ENSG00000235652.6	RP11-545I5.3	9.54	9.78e-21	4.98e-18	0.29	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145872092	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.79	rs2253307	ENSG00000235652.6	RP11-545I5.3	9.54	9.78e-21	4.98e-18	0.29	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145875045	chr6:145799409~145886585:+
BRCA	cis	rs6430553	0.894	rs6730306	ENSG00000224043.6	CCNT2-AS1	-9.54	9.8e-21	4.99e-18	-0.36	-0.28	Blood metabolite levels;	chr2:134851597	chr2:134735464~134918710:-
BRCA	cis	rs875971	0.638	rs6460305	ENSG00000222364.1	RNU6-96P	9.54	9.89e-21	5.04e-18	0.33	0.28	Aortic root size;	chr7:66595421	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.862	rs7786892	ENSG00000237310.1	GS1-124K5.4	-9.54	9.89e-21	5.04e-18	-0.3	-0.28	Aortic root size;	chr7:66163889	chr7:66493706~66495474:+
BRCA	cis	rs9506514	0.509	rs9509279	ENSG00000222726.1	RNU2-7P	9.54	9.91e-21	5.05e-18	0.34	0.28	Coronary artery calcification;	chr13:20559580	chr13:20612161~20612338:+
BRCA	cis	rs4820294	0.669	rs7287340	ENSG00000233360.4	Z83844.1	9.54	9.93e-21	5.06e-18	0.32	0.28	Fat distribution (HIV);	chr22:37658318	chr22:37641832~37658377:-
BRCA	cis	rs4820294	0.669	rs7287358	ENSG00000233360.4	Z83844.1	9.54	9.93e-21	5.06e-18	0.32	0.28	Fat distribution (HIV);	chr22:37658396	chr22:37641832~37658377:-
BRCA	cis	rs7429990	0.965	rs7619882	ENSG00000229759.1	MRPS18AP1	9.54	9.99e-21	5.09e-18	0.32	0.28	Educational attainment (years of education);	chr3:47943334	chr3:48256350~48256938:-
BRCA	cis	rs875971	0.862	rs10261398	ENSG00000237310.1	GS1-124K5.4	-9.54	1e-20	5.11e-18	-0.3	-0.28	Aortic root size;	chr7:66285177	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.862	rs10224872	ENSG00000237310.1	GS1-124K5.4	-9.54	1e-20	5.11e-18	-0.3	-0.28	Aortic root size;	chr7:66294786	chr7:66493706~66495474:+
BRCA	cis	rs11098499	0.866	rs10518329	ENSG00000245958.5	RP11-33B1.1	-9.54	1.01e-20	5.12e-18	-0.27	-0.28	Corneal astigmatism;	chr4:119480680	chr4:119454791~119552025:+
BRCA	cis	rs2276314	0.857	rs56230698	ENSG00000278986.1	RP11-723J4.3	-9.54	1.01e-20	5.12e-18	-0.36	-0.28	Endometriosis;Drug-induced torsades de pointes;	chr18:36048922	chr18:35972151~35973916:+
BRCA	cis	rs8062405	0.723	rs35175818	ENSG00000278665.1	RP11-666O2.4	9.54	1.01e-20	5.15e-18	0.31	0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28597425	chr16:28599241~28601881:-
BRCA	cis	rs113835537	0.529	rs11227495	ENSG00000255517.5	CTD-3074O7.5	-9.54	1.01e-20	5.16e-18	-0.37	-0.28	Airway imaging phenotypes;	chr11:66495772	chr11:66473490~66480233:-
BRCA	cis	rs228614	0.51	rs223362	ENSG00000246560.2	RP11-10L12.4	9.54	1.02e-20	5.17e-18	0.3	0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102848077	chr4:102828055~102844075:+
BRCA	cis	rs2067615	0.524	rs7959062	ENSG00000260329.1	RP11-412D9.4	-9.53	1.02e-20	5.2e-18	-0.31	-0.28	Heart rate;	chr12:106713556	chr12:106954029~106955497:-
BRCA	cis	rs7924176	0.601	rs12414280	ENSG00000213731.2	RAB5CP1	-9.53	1.02e-20	5.2e-18	-0.31	-0.28	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74174642	chr10:74423435~74424014:-
BRCA	cis	rs4853012	0.838	rs72911122	ENSG00000257800.1	FNBP1P1	9.53	1.02e-20	5.21e-18	0.29	0.28	Gestational age at birth (maternal effect);	chr2:74116992	chr2:74120680~74123218:+
BRCA	cis	rs875971	0.508	rs10242423	ENSG00000222364.1	RNU6-96P	9.53	1.02e-20	5.21e-18	0.33	0.28	Aortic root size;	chr7:66594188	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.508	rs10253883	ENSG00000222364.1	RNU6-96P	9.53	1.02e-20	5.21e-18	0.33	0.28	Aortic root size;	chr7:66596151	chr7:66395191~66395286:+
BRCA	cis	rs1062177	1	rs892006	ENSG00000253921.1	CTB-113P19.3	-9.53	1.03e-20	5.21e-18	-0.38	-0.28	Preschool internalizing problems;	chr5:151801329	chr5:151753992~151767247:+
BRCA	cis	rs11096990	0.593	rs6531700	ENSG00000249207.1	RP11-360F5.1	9.53	1.03e-20	5.23e-18	0.33	0.28	Cognitive function;	chr4:39269265	chr4:39112677~39126818:-
BRCA	cis	rs875971	0.522	rs1968127	ENSG00000222364.1	RNU6-96P	9.53	1.03e-20	5.23e-18	0.33	0.28	Aortic root size;	chr7:66591816	chr7:66395191~66395286:+
BRCA	cis	rs7924176	0.58	rs12360119	ENSG00000213731.2	RAB5CP1	-9.53	1.03e-20	5.24e-18	-0.31	-0.28	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74255558	chr10:74423435~74424014:-
BRCA	cis	rs858239	0.601	rs4140959	ENSG00000226816.2	AC005082.12	9.53	1.04e-20	5.28e-18	0.33	0.28	Cerebrospinal fluid biomarker levels;	chr7:23131157	chr7:23206013~23208045:+
BRCA	cis	rs875971	0.862	rs4718319	ENSG00000237310.1	GS1-124K5.4	-9.53	1.04e-20	5.29e-18	-0.3	-0.28	Aortic root size;	chr7:66187797	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.723	rs28391294	ENSG00000237310.1	GS1-124K5.4	-9.53	1.04e-20	5.29e-18	-0.3	-0.28	Aortic root size;	chr7:66189328	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.83	rs6967708	ENSG00000237310.1	GS1-124K5.4	-9.53	1.04e-20	5.29e-18	-0.3	-0.28	Aortic root size;	chr7:66192326	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.895	rs7782806	ENSG00000237310.1	GS1-124K5.4	-9.53	1.04e-20	5.29e-18	-0.3	-0.28	Aortic root size;	chr7:66192910	chr7:66493706~66495474:+
BRCA	cis	rs1113500	0.966	rs11185249	ENSG00000226822.1	RP11-356N1.2	9.53	1.04e-20	5.31e-18	0.38	0.28	Growth-regulated protein alpha levels;	chr1:108069024	chr1:108071482~108074519:+
BRCA	cis	rs957448	1	rs72674861	ENSG00000253704.1	RP11-267M23.4	9.53	1.05e-20	5.31e-18	0.34	0.28	Nonsyndromic cleft lip with cleft palate;	chr8:94550051	chr8:94553722~94569745:+
BRCA	cis	rs227275	0.556	rs10015289	ENSG00000246560.2	RP11-10L12.4	9.53	1.05e-20	5.33e-18	0.3	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102984956	chr4:102828055~102844075:+
BRCA	cis	rs7772486	0.79	rs2249147	ENSG00000235652.6	RP11-545I5.3	9.53	1.05e-20	5.33e-18	0.28	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145863863	chr6:145799409~145886585:+
BRCA	cis	rs957448	1	rs16916874	ENSG00000253704.1	RP11-267M23.4	9.53	1.06e-20	5.37e-18	0.34	0.28	Nonsyndromic cleft lip with cleft palate;	chr8:94537749	chr8:94553722~94569745:+
BRCA	cis	rs227275	0.556	rs6852141	ENSG00000246560.2	RP11-10L12.4	9.53	1.06e-20	5.38e-18	0.3	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102986439	chr4:102828055~102844075:+
BRCA	cis	rs228614	0.509	rs4455415	ENSG00000246560.2	RP11-10L12.4	9.53	1.06e-20	5.38e-18	0.3	0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102993663	chr4:102828055~102844075:+
BRCA	cis	rs227275	0.525	rs6853193	ENSG00000246560.2	RP11-10L12.4	9.53	1.06e-20	5.38e-18	0.3	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102994888	chr4:102828055~102844075:+
BRCA	cis	rs6921919	0.583	rs9468355	ENSG00000216901.1	AL022393.7	9.53	1.06e-20	5.4e-18	0.37	0.28	Autism spectrum disorder or schizophrenia;	chr6:28374100	chr6:28176188~28176674:+
BRCA	cis	rs1823913	0.562	rs17347499	ENSG00000227542.1	AC092614.2	9.53	1.06e-20	5.41e-18	0.35	0.28	Obesity-related traits;	chr2:191301116	chr2:191229165~191246172:-
BRCA	cis	rs35160687	0.712	rs1863057	ENSG00000273080.1	RP11-301O19.1	-9.53	1.07e-20	5.43e-18	-0.34	-0.28	Night sleep phenotypes;	chr2:86274978	chr2:86195590~86196049:+
BRCA	cis	rs6565180	1	rs11646130	ENSG00000273724.1	RP11-347C12.12	-9.53	1.07e-20	5.43e-18	-0.35	-0.28	Tonsillectomy;	chr16:30365638	chr16:30336400~30343336:+
BRCA	cis	rs1062177	1	rs2915882	ENSG00000253921.1	CTB-113P19.3	-9.53	1.07e-20	5.44e-18	-0.39	-0.28	Preschool internalizing problems;	chr5:151765875	chr5:151753992~151767247:+
BRCA	cis	rs1823913	0.927	rs35092718	ENSG00000280083.1	RP11-317J9.1	-9.53	1.07e-20	5.44e-18	-0.33	-0.28	Obesity-related traits;	chr2:191243882	chr2:191154118~191156070:-
BRCA	cis	rs801193	1	rs2707836	ENSG00000222364.1	RNU6-96P	-9.53	1.07e-20	5.45e-18	-0.32	-0.28	Aortic root size;	chr7:66695448	chr7:66395191~66395286:+
BRCA	cis	rs801193	0.844	rs7779971	ENSG00000222364.1	RNU6-96P	-9.53	1.07e-20	5.45e-18	-0.32	-0.28	Aortic root size;	chr7:66696803	chr7:66395191~66395286:+
BRCA	cis	rs7772486	0.748	rs2748484	ENSG00000235652.6	RP11-545I5.3	9.53	1.08e-20	5.48e-18	0.28	0.28	Lobe attachment (rater-scored or self-reported);	chr6:146012517	chr6:145799409~145886585:+
BRCA	cis	rs875971	0.54	rs1723268	ENSG00000224316.1	RP11-479O9.2	9.53	1.08e-20	5.49e-18	0.28	0.28	Aortic root size;	chr7:66008093	chr7:65773620~65802067:+
BRCA	cis	rs1823913	0.927	rs13013390	ENSG00000227542.1	AC092614.2	9.53	1.08e-20	5.5e-18	0.35	0.28	Obesity-related traits;	chr2:191262001	chr2:191229165~191246172:-
BRCA	cis	rs2243480	0.901	rs2900904	ENSG00000226824.5	RP4-756H11.3	-9.53	1.08e-20	5.5e-18	-0.54	-0.28	Diabetic kidney disease;	chr7:65739282	chr7:66654538~66669855:+
BRCA	cis	rs11722779	0.844	rs10003326	ENSG00000246560.2	RP11-10L12.4	9.53	1.08e-20	5.51e-18	0.3	0.28	Schizophrenia;	chr4:102948193	chr4:102828055~102844075:+
BRCA	cis	rs6545883	0.525	rs1621048	ENSG00000271889.1	RP11-493E12.1	-9.53	1.09e-20	5.52e-18	-0.36	-0.28	Tuberculosis;	chr2:61137081	chr2:61151433~61162105:-
BRCA	cis	rs7772486	0.875	rs1331640	ENSG00000235652.6	RP11-545I5.3	9.53	1.09e-20	5.52e-18	0.29	0.28	Lobe attachment (rater-scored or self-reported);	chr6:146106114	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.79	rs2254288	ENSG00000235652.6	RP11-545I5.3	9.53	1.09e-20	5.53e-18	0.28	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145883334	chr6:145799409~145886585:+
BRCA	cis	rs801193	0.967	rs2707853	ENSG00000222364.1	RNU6-96P	-9.53	1.09e-20	5.54e-18	-0.33	-0.28	Aortic root size;	chr7:66749023	chr7:66395191~66395286:+
BRCA	cis	rs17482078	0.918	rs28513759	ENSG00000248734.2	CTD-2260A17.1	9.53	1.1e-20	5.59e-18	0.42	0.28	Behcet's disease;Blood protein levels;	chr5:96825366	chr5:96784777~96785999:+
BRCA	cis	rs875971	0.52	rs160645	ENSG00000226824.5	RP4-756H11.3	9.52	1.12e-20	5.67e-18	0.4	0.28	Aortic root size;	chr7:66091320	chr7:66654538~66669855:+
BRCA	cis	rs4853012	0.838	rs60705299	ENSG00000257800.1	FNBP1P1	9.52	1.12e-20	5.69e-18	0.28	0.28	Gestational age at birth (maternal effect);	chr2:74118243	chr2:74120680~74123218:+
BRCA	cis	rs11096990	0.576	rs2008679	ENSG00000249207.1	RP11-360F5.1	9.52	1.13e-20	5.72e-18	0.33	0.28	Cognitive function;	chr4:39266385	chr4:39112677~39126818:-
BRCA	cis	rs524281	0.861	rs10896090	ENSG00000255320.1	RP11-755F10.1	9.52	1.13e-20	5.73e-18	0.46	0.28	Electroencephalogram traits;	chr11:66177715	chr11:66244840~66246239:-
BRCA	cis	rs7811142	1	rs68116612	ENSG00000242294.5	STAG3L5P	9.52	1.13e-20	5.74e-18	0.26	0.28	Platelet count;	chr7:100408870	chr7:100336079~100351900:+
BRCA	cis	rs17711722	0.503	rs453835	ENSG00000224316.1	RP11-479O9.2	-9.52	1.13e-20	5.74e-18	-0.3	-0.28	Calcium levels;	chr7:66046172	chr7:65773620~65802067:+
BRCA	cis	rs4835473	0.932	rs5016159	ENSG00000251600.4	RP11-673E1.1	9.52	1.14e-20	5.75e-18	0.32	0.28	Immature fraction of reticulocytes;	chr4:143738362	chr4:143912331~143982454:+
BRCA	cis	rs11098499	0.908	rs1002152	ENSG00000245958.5	RP11-33B1.1	-9.52	1.14e-20	5.77e-18	-0.28	-0.28	Corneal astigmatism;	chr4:119352232	chr4:119454791~119552025:+
BRCA	cis	rs801193	0.773	rs801207	ENSG00000222364.1	RNU6-96P	9.52	1.14e-20	5.79e-18	0.33	0.28	Aortic root size;	chr7:66555603	chr7:66395191~66395286:+
BRCA	cis	rs812925	0.537	rs778153	ENSG00000271889.1	RP11-493E12.1	-9.52	1.14e-20	5.8e-18	-0.34	-0.28	Immature fraction of reticulocytes;	chr2:61381517	chr2:61151433~61162105:-
BRCA	cis	rs1062177	1	rs2915880	ENSG00000253921.1	CTB-113P19.3	-9.52	1.15e-20	5.83e-18	-0.39	-0.28	Preschool internalizing problems;	chr5:151767773	chr5:151753992~151767247:+
BRCA	cis	rs875971	0.543	rs801191	ENSG00000222364.1	RNU6-96P	9.52	1.15e-20	5.84e-18	0.32	0.28	Aortic root size;	chr7:66567968	chr7:66395191~66395286:+
BRCA	cis	rs858239	0.899	rs1881203	ENSG00000226816.2	AC005082.12	9.52	1.15e-20	5.85e-18	0.33	0.28	Cerebrospinal fluid biomarker levels;	chr7:23253189	chr7:23206013~23208045:+
BRCA	cis	rs6142102	0.961	rs6120487	ENSG00000276073.1	RP5-1125A11.7	-9.52	1.16e-20	5.86e-18	-0.33	-0.28	Skin pigmentation;	chr20:34034802	chr20:33985617~33988989:-
BRCA	cis	rs2243480	1	rs35046236	ENSG00000226824.5	RP4-756H11.3	-9.52	1.16e-20	5.89e-18	-0.53	-0.28	Diabetic kidney disease;	chr7:65943626	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs36068983	ENSG00000226824.5	RP4-756H11.3	-9.52	1.16e-20	5.89e-18	-0.53	-0.28	Diabetic kidney disease;	chr7:65944004	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs68189316	ENSG00000226824.5	RP4-756H11.3	-9.52	1.16e-20	5.89e-18	-0.53	-0.28	Diabetic kidney disease;	chr7:65944182	chr7:66654538~66669855:+
BRCA	cis	rs9287719	0.967	rs12464817	ENSG00000234818.1	AC092687.5	9.52	1.17e-20	5.94e-18	0.33	0.28	Prostate cancer;	chr2:10567086	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs4669593	ENSG00000234818.1	AC092687.5	9.52	1.18e-20	5.99e-18	0.33	0.28	Prostate cancer;	chr2:10561782	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs3814388	ENSG00000234818.1	AC092687.5	9.52	1.18e-20	5.99e-18	0.33	0.28	Prostate cancer;	chr2:10561973	chr2:10589166~10604830:+
BRCA	cis	rs7924176	0.564	rs12572820	ENSG00000213731.2	RAB5CP1	-9.52	1.19e-20	6.01e-18	-0.31	-0.28	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74117387	chr10:74423435~74424014:-
BRCA	cis	rs858239	0.6	rs2072369	ENSG00000226816.2	AC005082.12	9.52	1.19e-20	6.03e-18	0.32	0.28	Cerebrospinal fluid biomarker levels;	chr7:23106570	chr7:23206013~23208045:+
BRCA	cis	rs801193	1	rs62466793	ENSG00000222364.1	RNU6-96P	-9.52	1.2e-20	6.06e-18	-0.32	-0.28	Aortic root size;	chr7:66726530	chr7:66395191~66395286:+
BRCA	cis	rs7772486	0.754	rs10872580	ENSG00000235652.6	RP11-545I5.3	-9.52	1.2e-20	6.07e-18	-0.28	-0.28	Lobe attachment (rater-scored or self-reported);	chr6:145819145	chr6:145799409~145886585:+
BRCA	cis	rs11722779	0.903	rs13130741	ENSG00000246560.2	RP11-10L12.4	9.52	1.2e-20	6.08e-18	0.3	0.28	Schizophrenia;	chr4:103035799	chr4:102828055~102844075:+
BRCA	cis	rs957448	1	rs957447	ENSG00000253704.1	RP11-267M23.4	9.52	1.21e-20	6.11e-18	0.34	0.28	Nonsyndromic cleft lip with cleft palate;	chr8:94528995	chr8:94553722~94569745:+
BRCA	cis	rs11098499	0.954	rs1480931	ENSG00000245958.5	RP11-33B1.1	-9.51	1.22e-20	6.16e-18	-0.28	-0.28	Corneal astigmatism;	chr4:119474654	chr4:119454791~119552025:+
BRCA	cis	rs227275	0.525	rs223332	ENSG00000246560.2	RP11-10L12.4	9.51	1.22e-20	6.17e-18	0.3	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102869029	chr4:102828055~102844075:+
BRCA	cis	rs12134133	0.752	rs6673080	ENSG00000274245.1	RP11-357P18.2	9.51	1.22e-20	6.18e-18	0.4	0.28	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207216859	chr1:207372559~207373252:+
BRCA	cis	rs228614	0.536	rs223327	ENSG00000246560.2	RP11-10L12.4	9.51	1.24e-20	6.25e-18	0.3	0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102873560	chr4:102828055~102844075:+
BRCA	cis	rs228614	0.51	rs223326	ENSG00000246560.2	RP11-10L12.4	9.51	1.24e-20	6.25e-18	0.3	0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102873770	chr4:102828055~102844075:+
BRCA	cis	rs12458462	0.892	rs2007483	ENSG00000274828.1	RP11-567M16.6	9.51	1.25e-20	6.34e-18	0.32	0.28	Monocyte count;	chr18:79716131	chr18:79677287~79679358:-
BRCA	cis	rs875971	0.522	rs2008188	ENSG00000224316.1	RP11-479O9.2	9.51	1.25e-20	6.34e-18	0.28	0.28	Aortic root size;	chr7:65964026	chr7:65773620~65802067:+
BRCA	cis	rs7772486	0.875	rs854145	ENSG00000235652.6	RP11-545I5.3	9.51	1.25e-20	6.34e-18	0.28	0.28	Lobe attachment (rater-scored or self-reported);	chr6:146028514	chr6:145799409~145886585:+
BRCA	cis	rs4853012	0.838	rs4563249	ENSG00000257800.1	FNBP1P1	9.51	1.25e-20	6.34e-18	0.28	0.28	Gestational age at birth (maternal effect);	chr2:74126889	chr2:74120680~74123218:+
BRCA	cis	rs1113500	0.933	rs4590700	ENSG00000226822.1	RP11-356N1.2	9.51	1.25e-20	6.34e-18	0.37	0.28	Growth-regulated protein alpha levels;	chr1:108095722	chr1:108071482~108074519:+
BRCA	cis	rs4835473	0.932	rs17018500	ENSG00000251600.4	RP11-673E1.1	-9.51	1.26e-20	6.37e-18	-0.32	-0.28	Immature fraction of reticulocytes;	chr4:143824849	chr4:143912331~143982454:+
BRCA	cis	rs875971	0.862	rs949930	ENSG00000237310.1	GS1-124K5.4	-9.51	1.26e-20	6.38e-18	-0.3	-0.28	Aortic root size;	chr7:66301835	chr7:66493706~66495474:+
BRCA	cis	rs801193	1	rs6958520	ENSG00000222364.1	RNU6-96P	-9.51	1.27e-20	6.44e-18	-0.32	-0.28	Aortic root size;	chr7:66686466	chr7:66395191~66395286:+
BRCA	cis	rs8012947	1	rs7153897	ENSG00000279636.2	LINC00216	-9.51	1.27e-20	6.44e-18	-0.31	-0.28	Alcohol consumption in current drinkers;	chr14:58295479	chr14:58288033~58289158:+
BRCA	cis	rs875971	0.66	rs7807930	ENSG00000222364.1	RNU6-96P	9.51	1.28e-20	6.48e-18	0.33	0.28	Aortic root size;	chr7:66622178	chr7:66395191~66395286:+
BRCA	cis	rs496547	0.719	rs476246	ENSG00000255239.1	AP002954.6	-9.51	1.29e-20	6.5e-18	-0.33	-0.28	Hip minimal joint space width;	chr11:118747211	chr11:118688039~118690600:-
BRCA	cis	rs9287719	0.935	rs61424402	ENSG00000234818.1	AC092687.5	9.51	1.29e-20	6.52e-18	0.33	0.28	Prostate cancer;	chr2:10618245	chr2:10589166~10604830:+
BRCA	cis	rs881375	0.678	rs7031752	ENSG00000226752.6	PSMD5-AS1	-9.51	1.31e-20	6.59e-18	-0.34	-0.28	Rheumatoid arthritis;	chr9:120901204	chr9:120824828~120854385:+
BRCA	cis	rs227275	0.525	rs13113923	ENSG00000246560.2	RP11-10L12.4	9.51	1.31e-20	6.59e-18	0.3	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102918936	chr4:102828055~102844075:+
BRCA	cis	rs1075265	0.749	rs805375	ENSG00000233266.1	HMGB1P31	9.51	1.31e-20	6.6e-18	0.34	0.28	Chronotype;Morning vs. evening chronotype;	chr2:53863268	chr2:54051334~54051760:+
BRCA	cis	rs765787	0.53	rs2899379	ENSG00000259520.4	CTD-2651B20.3	-9.51	1.31e-20	6.62e-18	-0.36	-0.28	Uric acid levels;	chr15:45242601	chr15:45251580~45279251:-
BRCA	cis	rs12468226	1	rs16839090	ENSG00000273456.1	RP11-686O6.2	9.51	1.32e-20	6.64e-18	0.42	0.28	Urate levels;	chr2:202348338	chr2:202374932~202375604:-
BRCA	cis	rs12701220	0.655	rs7778968	ENSG00000229043.2	AC091729.9	-9.51	1.32e-20	6.67e-18	-0.4	-0.28	Bronchopulmonary dysplasia;	chr7:1104986	chr7:1160374~1165267:+
BRCA	cis	rs35160687	0.623	rs13005014	ENSG00000273080.1	RP11-301O19.1	-9.51	1.33e-20	6.69e-18	-0.34	-0.28	Night sleep phenotypes;	chr2:86260093	chr2:86195590~86196049:+
BRCA	cis	rs10875746	0.551	rs1471997	ENSG00000240399.1	RP1-228P16.1	-9.51	1.33e-20	6.69e-18	-0.38	-0.28	Longevity (90 years and older);	chr12:48329812	chr12:48054813~48055591:-
BRCA	cis	rs2243480	1	rs56016656	ENSG00000226824.5	RP4-756H11.3	-9.51	1.33e-20	6.69e-18	-0.54	-0.28	Diabetic kidney disease;	chr7:65918494	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs56291018	ENSG00000226824.5	RP4-756H11.3	-9.51	1.33e-20	6.69e-18	-0.54	-0.28	Diabetic kidney disease;	chr7:65925352	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs36033484	ENSG00000226824.5	RP4-756H11.3	-9.51	1.33e-20	6.69e-18	-0.54	-0.28	Diabetic kidney disease;	chr7:65925571	chr7:66654538~66669855:+
BRCA	cis	rs783540	0.967	rs7494860	ENSG00000278603.1	RP13-608F4.5	9.51	1.33e-20	6.7e-18	0.35	0.28	Schizophrenia;	chr15:82665667	chr15:82472203~82472426:+
BRCA	cis	rs6545883	0.507	rs6545855	ENSG00000271889.1	RP11-493E12.1	-9.51	1.33e-20	6.7e-18	-0.34	-0.28	Tuberculosis;	chr2:61305725	chr2:61151433~61162105:-
BRCA	cis	rs2439831	0.85	rs12441861	ENSG00000205771.5	CATSPER2P1	-9.5	1.33e-20	6.71e-18	-0.48	-0.28	Lung cancer in ever smokers;	chr15:43768685	chr15:43726918~43747094:-
BRCA	cis	rs2276314	0.857	rs28435069	ENSG00000278986.1	RP11-723J4.3	-9.5	1.33e-20	6.72e-18	-0.35	-0.28	Endometriosis;Drug-induced torsades de pointes;	chr18:36048512	chr18:35972151~35973916:+
BRCA	cis	rs2276314	0.857	rs8087539	ENSG00000278986.1	RP11-723J4.3	-9.5	1.33e-20	6.72e-18	-0.35	-0.28	Endometriosis;Drug-induced torsades de pointes;	chr18:36051574	chr18:35972151~35973916:+
BRCA	cis	rs2243480	1	rs1723270	ENSG00000226824.5	RP4-756H11.3	-9.5	1.33e-20	6.73e-18	-0.54	-0.28	Diabetic kidney disease;	chr7:66004843	chr7:66654538~66669855:+
BRCA	cis	rs6782228	0.876	rs34198449	ENSG00000242551.2	POU5F1P6	9.5	1.34e-20	6.74e-18	0.41	0.28	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128662427	chr3:128674735~128677005:-
BRCA	cis	rs7924176	0.502	rs1874151	ENSG00000213731.2	RAB5CP1	-9.5	1.34e-20	6.75e-18	-0.31	-0.28	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74107856	chr10:74423435~74424014:-
BRCA	cis	rs11096990	0.656	rs2123028	ENSG00000249207.1	RP11-360F5.1	9.5	1.34e-20	6.78e-18	0.33	0.28	Cognitive function;	chr4:39301859	chr4:39112677~39126818:-
BRCA	cis	rs35160687	0.644	rs11680025	ENSG00000273080.1	RP11-301O19.1	-9.5	1.35e-20	6.81e-18	-0.33	-0.28	Night sleep phenotypes;	chr2:86318215	chr2:86195590~86196049:+
BRCA	cis	rs801193	1	rs2659889	ENSG00000222364.1	RNU6-96P	-9.5	1.36e-20	6.84e-18	-0.33	-0.28	Aortic root size;	chr7:66752125	chr7:66395191~66395286:+
BRCA	cis	rs1062177	0.826	rs2053063	ENSG00000253921.1	CTB-113P19.3	-9.5	1.36e-20	6.86e-18	-0.38	-0.28	Preschool internalizing problems;	chr5:151787203	chr5:151753992~151767247:+
BRCA	cis	rs12468226	1	rs115170232	ENSG00000273456.1	RP11-686O6.2	9.5	1.36e-20	6.88e-18	0.42	0.28	Urate levels;	chr2:202416790	chr2:202374932~202375604:-
BRCA	cis	rs7924176	0.601	rs7093532	ENSG00000213731.2	RAB5CP1	-9.5	1.37e-20	6.9e-18	-0.31	-0.28	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74178282	chr10:74423435~74424014:-
BRCA	cis	rs8062405	1	rs62036617	ENSG00000278665.1	RP11-666O2.4	9.5	1.37e-20	6.93e-18	0.3	0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28816177	chr16:28599241~28601881:-
BRCA	cis	rs7772486	0.597	rs7746618	ENSG00000235652.6	RP11-545I5.3	-9.5	1.38e-20	6.96e-18	-0.31	-0.28	Lobe attachment (rater-scored or self-reported);	chr6:145960231	chr6:145799409~145886585:+
BRCA	cis	rs875971	0.825	rs1000464	ENSG00000237310.1	GS1-124K5.4	-9.5	1.38e-20	6.96e-18	-0.3	-0.28	Aortic root size;	chr7:66312922	chr7:66493706~66495474:+
BRCA	cis	rs35160687	0.644	rs4832274	ENSG00000273080.1	RP11-301O19.1	-9.5	1.38e-20	6.97e-18	-0.34	-0.28	Night sleep phenotypes;	chr2:86301961	chr2:86195590~86196049:+
BRCA	cis	rs1062177	1	rs2915887	ENSG00000253921.1	CTB-113P19.3	-9.5	1.39e-20	6.99e-18	-0.39	-0.28	Preschool internalizing problems;	chr5:151825943	chr5:151753992~151767247:+
BRCA	cis	rs11098499	0.954	rs878373	ENSG00000248280.1	RP11-33B1.2	9.5	1.39e-20	7e-18	0.29	0.28	Corneal astigmatism;	chr4:119316329	chr4:119440561~119450157:-
BRCA	cis	rs367615	0.918	rs17161895	ENSG00000249476.1	CTD-2587M2.1	9.5	1.39e-20	7.02e-18	0.36	0.28	Colorectal cancer (SNP x SNP interaction);	chr5:109520130	chr5:109237120~109326369:-
BRCA	cis	rs1062177	1	rs12653926	ENSG00000253921.1	CTB-113P19.3	-9.5	1.4e-20	7.03e-18	-0.4	-0.28	Preschool internalizing problems;	chr5:151870687	chr5:151753992~151767247:+
BRCA	cis	rs1062177	1	rs6890099	ENSG00000253921.1	CTB-113P19.3	-9.5	1.4e-20	7.05e-18	-0.39	-0.28	Preschool internalizing problems;	chr5:151772401	chr5:151753992~151767247:+
BRCA	cis	rs11722779	0.844	rs3974602	ENSG00000246560.2	RP11-10L12.4	9.5	1.41e-20	7.08e-18	0.3	0.28	Schizophrenia;	chr4:102928840	chr4:102828055~102844075:+
BRCA	cis	rs875971	0.522	rs4718285	ENSG00000224316.1	RP11-479O9.2	9.5	1.41e-20	7.09e-18	0.28	0.28	Aortic root size;	chr7:65827018	chr7:65773620~65802067:+
BRCA	cis	rs1113500	0.933	rs11185250	ENSG00000226822.1	RP11-356N1.2	9.5	1.41e-20	7.1e-18	0.37	0.28	Growth-regulated protein alpha levels;	chr1:108073795	chr1:108071482~108074519:+
BRCA	cis	rs1113500	0.933	rs1419003	ENSG00000226822.1	RP11-356N1.2	9.5	1.41e-20	7.1e-18	0.37	0.28	Growth-regulated protein alpha levels;	chr1:108074333	chr1:108071482~108074519:+
BRCA	cis	rs801193	0.569	rs35070132	ENSG00000237310.1	GS1-124K5.4	9.5	1.42e-20	7.16e-18	0.3	0.28	Aortic root size;	chr7:66773096	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.619	rs10278371	ENSG00000222364.1	RNU6-96P	9.5	1.42e-20	7.17e-18	0.33	0.28	Aortic root size;	chr7:66586553	chr7:66395191~66395286:+
BRCA	cis	rs7829975	0.682	rs7013471	ENSG00000253893.2	FAM85B	9.5	1.43e-20	7.19e-18	0.35	0.28	Mood instability;	chr8:8829815	chr8:8167819~8226614:-
BRCA	cis	rs2243480	1	rs12698509	ENSG00000226824.5	RP4-756H11.3	-9.5	1.43e-20	7.2e-18	-0.53	-0.28	Diabetic kidney disease;	chr7:65953889	chr7:66654538~66669855:+
BRCA	cis	rs7772486	0.875	rs7739371	ENSG00000235652.6	RP11-545I5.3	9.5	1.43e-20	7.21e-18	0.29	0.28	Lobe attachment (rater-scored or self-reported);	chr6:146103217	chr6:145799409~145886585:+
BRCA	cis	rs72772090	0.539	rs11740375	ENSG00000248734.2	CTD-2260A17.1	-9.5	1.44e-20	7.23e-18	-0.46	-0.28	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96777193	chr5:96784777~96785999:+
BRCA	cis	rs2111504	0.806	rs10421787	ENSG00000267213.4	AC007773.2	-9.5	1.44e-20	7.24e-18	-0.37	-0.28	Bipolar disorder;	chr19:32460316	chr19:32390050~32405560:-
BRCA	cis	rs1113500	0.933	rs1414674	ENSG00000226822.1	RP11-356N1.2	9.5	1.44e-20	7.25e-18	0.37	0.28	Growth-regulated protein alpha levels;	chr1:108083325	chr1:108071482~108074519:+
BRCA	cis	rs367615	0.84	rs113540823	ENSG00000249476.1	CTD-2587M2.1	9.5	1.44e-20	7.25e-18	0.37	0.28	Colorectal cancer (SNP x SNP interaction);	chr5:109543383	chr5:109237120~109326369:-
BRCA	cis	rs367615	0.879	rs56689485	ENSG00000249476.1	CTD-2587M2.1	9.5	1.44e-20	7.25e-18	0.37	0.28	Colorectal cancer (SNP x SNP interaction);	chr5:109544127	chr5:109237120~109326369:-
BRCA	cis	rs858239	0.601	rs6980224	ENSG00000226816.2	AC005082.12	9.5	1.45e-20	7.27e-18	0.32	0.28	Cerebrospinal fluid biomarker levels;	chr7:23109518	chr7:23206013~23208045:+
BRCA	cis	rs7580658	0.637	rs4560059	ENSG00000236682.1	AC068282.3	-9.5	1.45e-20	7.29e-18	-0.37	-0.28	Protein C levels;	chr2:127214652	chr2:127389130~127400580:+
BRCA	cis	rs9287719	0.967	rs6432121	ENSG00000234818.1	AC092687.5	9.49	1.46e-20	7.34e-18	0.33	0.28	Prostate cancer;	chr2:10613678	chr2:10589166~10604830:+
BRCA	cis	rs1113500	0.933	rs61797345	ENSG00000226822.1	RP11-356N1.2	9.49	1.48e-20	7.44e-18	0.37	0.28	Growth-regulated protein alpha levels;	chr1:108081106	chr1:108071482~108074519:+
BRCA	cis	rs17711722	0.675	rs6947132	ENSG00000224316.1	RP11-479O9.2	-9.49	1.48e-20	7.44e-18	-0.28	-0.28	Calcium levels;	chr7:65808508	chr7:65773620~65802067:+
BRCA	cis	rs367615	0.918	rs17161889	ENSG00000249476.1	CTD-2587M2.1	-9.49	1.5e-20	7.51e-18	-0.35	-0.28	Colorectal cancer (SNP x SNP interaction);	chr5:109519550	chr5:109237120~109326369:-
BRCA	cis	rs2439831	0.85	rs28504496	ENSG00000275601.1	AC011330.13	-9.49	1.5e-20	7.54e-18	-0.46	-0.28	Lung cancer in ever smokers;	chr15:43724685	chr15:43642389~43643023:-
BRCA	cis	rs1113500	0.933	rs61797344	ENSG00000226822.1	RP11-356N1.2	9.49	1.51e-20	7.6e-18	0.37	0.28	Growth-regulated protein alpha levels;	chr1:108079958	chr1:108071482~108074519:+
BRCA	cis	rs1075265	0.704	rs805405	ENSG00000233266.1	HMGB1P31	9.49	1.52e-20	7.63e-18	0.34	0.28	Chronotype;Morning vs. evening chronotype;	chr2:53891014	chr2:54051334~54051760:+
BRCA	cis	rs957448	1	rs2381885	ENSG00000253704.1	RP11-267M23.4	9.49	1.53e-20	7.66e-18	0.34	0.28	Nonsyndromic cleft lip with cleft palate;	chr8:94499974	chr8:94553722~94569745:+
BRCA	cis	rs1823913	0.599	rs55685315	ENSG00000227542.1	AC092614.2	9.49	1.53e-20	7.67e-18	0.34	0.28	Obesity-related traits;	chr2:191306451	chr2:191229165~191246172:-
BRCA	cis	rs2404602	0.583	rs2456076	ENSG00000259422.1	RP11-593F23.1	-9.49	1.53e-20	7.67e-18	-0.34	-0.28	Blood metabolite levels;	chr15:76265212	chr15:76174891~76181486:-
BRCA	cis	rs858239	0.539	rs6461695	ENSG00000226816.2	AC005082.12	9.49	1.53e-20	7.7e-18	0.33	0.28	Cerebrospinal fluid biomarker levels;	chr7:23158165	chr7:23206013~23208045:+
BRCA	cis	rs7924176	0.601	rs10824107	ENSG00000213731.2	RAB5CP1	-9.49	1.53e-20	7.7e-18	-0.31	-0.28	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74202041	chr10:74423435~74424014:-
BRCA	cis	rs875971	0.545	rs2707851	ENSG00000237310.1	GS1-124K5.4	-9.49	1.54e-20	7.7e-18	-0.33	-0.28	Aortic root size;	chr7:66624178	chr7:66493706~66495474:+
BRCA	cis	rs7189233	0.531	rs8043918	ENSG00000279344.1	RP11-44F14.7	9.49	1.54e-20	7.72e-18	0.29	0.28	Intelligence (multi-trait analysis);	chr16:53479121	chr16:53478957~53481550:-
BRCA	cis	rs10262624	0.967	rs10229233	ENSG00000234286.1	AC006026.13	-9.49	1.54e-20	7.72e-18	-0.33	-0.28	Schizophrenia;	chr7:23867900	chr7:23680195~23680786:-
BRCA	cis	rs10262624	1	rs10245161	ENSG00000234286.1	AC006026.13	-9.49	1.54e-20	7.72e-18	-0.33	-0.28	Schizophrenia;	chr7:23868073	chr7:23680195~23680786:-
BRCA	cis	rs2015599	0.56	rs11050147	ENSG00000275476.1	RP11-996F15.4	-9.49	1.54e-20	7.73e-18	-0.34	-0.28	Platelet count;Mean platelet volume;	chr12:29242746	chr12:29277397~29277882:-
BRCA	cis	rs75422866	0.867	rs73102125	ENSG00000274902.1	RP1-197B17.4	9.49	1.55e-20	7.75e-18	0.71	0.28	Pneumonia;	chr12:47637869	chr12:47731908~47732351:+
BRCA	cis	rs75422866	0.867	rs12426849	ENSG00000274902.1	RP1-197B17.4	9.49	1.55e-20	7.75e-18	0.71	0.28	Pneumonia;	chr12:47638975	chr12:47731908~47732351:+
BRCA	cis	rs75422866	0.867	rs117950951	ENSG00000274902.1	RP1-197B17.4	9.49	1.55e-20	7.75e-18	0.71	0.28	Pneumonia;	chr12:47639794	chr12:47731908~47732351:+
BRCA	cis	rs75422866	0.867	rs7954764	ENSG00000274902.1	RP1-197B17.4	9.49	1.55e-20	7.75e-18	0.71	0.28	Pneumonia;	chr12:47641136	chr12:47731908~47732351:+
BRCA	cis	rs17711722	0.74	rs7809991	ENSG00000224316.1	RP11-479O9.2	9.49	1.55e-20	7.76e-18	0.28	0.28	Calcium levels;	chr7:65941231	chr7:65773620~65802067:+
BRCA	cis	rs6538678	0.818	rs7976294	ENSG00000258343.1	RP11-536G4.2	-9.49	1.56e-20	7.8e-18	-0.42	-0.28	Lupus nephritis in systemic lupus erythematosus;	chr12:95876868	chr12:95795345~95858839:-
BRCA	cis	rs6538678	0.818	rs1036429	ENSG00000258343.1	RP11-536G4.2	-9.49	1.56e-20	7.8e-18	-0.42	-0.28	Lupus nephritis in systemic lupus erythematosus;	chr12:95877650	chr12:95795345~95858839:-
BRCA	cis	rs875971	0.862	rs2420174	ENSG00000237310.1	GS1-124K5.4	-9.49	1.56e-20	7.84e-18	-0.3	-0.28	Aortic root size;	chr7:66180374	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.862	rs2420173	ENSG00000237310.1	GS1-124K5.4	-9.49	1.56e-20	7.84e-18	-0.3	-0.28	Aortic root size;	chr7:66180412	chr7:66493706~66495474:+
BRCA	cis	rs228614	0.51	rs223313	ENSG00000246560.2	RP11-10L12.4	9.49	1.56e-20	7.84e-18	0.3	0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102886563	chr4:102828055~102844075:+
BRCA	cis	rs2243480	1	rs1964692	ENSG00000226824.5	RP4-756H11.3	-9.49	1.57e-20	7.85e-18	-0.54	-0.28	Diabetic kidney disease;	chr7:65989196	chr7:66654538~66669855:+
BRCA	cis	rs858239	0.899	rs28458177	ENSG00000226816.2	AC005082.12	9.49	1.57e-20	7.86e-18	0.33	0.28	Cerebrospinal fluid biomarker levels;	chr7:23255253	chr7:23206013~23208045:+
BRCA	cis	rs11098499	0.954	rs10017371	ENSG00000245958.5	RP11-33B1.1	-9.49	1.57e-20	7.88e-18	-0.28	-0.28	Corneal astigmatism;	chr4:119372621	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.909	rs1546504	ENSG00000248280.1	RP11-33B1.2	9.49	1.58e-20	7.9e-18	0.29	0.28	Corneal astigmatism;	chr4:119320024	chr4:119440561~119450157:-
BRCA	cis	rs875971	0.862	rs12537823	ENSG00000237310.1	GS1-124K5.4	9.49	1.58e-20	7.9e-18	0.3	0.28	Aortic root size;	chr7:66255897	chr7:66493706~66495474:+
BRCA	cis	rs1862618	0.525	rs2662016	ENSG00000271828.1	CTD-2310F14.1	-9.48	1.59e-20	7.95e-18	-0.41	-0.28	Initial pursuit acceleration;	chr5:56973220	chr5:56927874~56929573:+
BRCA	cis	rs7924176	0.601	rs7099026	ENSG00000213731.2	RAB5CP1	-9.48	1.59e-20	7.95e-18	-0.31	-0.28	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74128770	chr10:74423435~74424014:-
BRCA	cis	rs7811142	0.83	rs6979910	ENSG00000242294.5	STAG3L5P	9.48	1.59e-20	7.96e-18	0.27	0.28	Platelet count;	chr7:100343007	chr7:100336079~100351900:+
BRCA	cis	rs801193	0.967	rs2707841	ENSG00000222364.1	RNU6-96P	-9.48	1.59e-20	7.96e-18	-0.32	-0.28	Aortic root size;	chr7:66692033	chr7:66395191~66395286:+
BRCA	cis	rs801193	1	rs4717310	ENSG00000222364.1	RNU6-96P	-9.48	1.59e-20	7.96e-18	-0.32	-0.28	Aortic root size;	chr7:66696020	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.862	rs6460290	ENSG00000237310.1	GS1-124K5.4	-9.48	1.6e-20	8e-18	-0.29	-0.28	Aortic root size;	chr7:66344119	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.522	rs1701760	ENSG00000224316.1	RP11-479O9.2	9.48	1.6e-20	8.03e-18	0.28	0.28	Aortic root size;	chr7:66008701	chr7:65773620~65802067:+
BRCA	cis	rs10262624	0.935	rs6966641	ENSG00000234286.1	AC006026.13	-9.48	1.61e-20	8.08e-18	-0.32	-0.28	Schizophrenia;	chr7:23866979	chr7:23680195~23680786:-
BRCA	cis	rs858239	0.539	rs2103281	ENSG00000226816.2	AC005082.12	9.48	1.61e-20	8.08e-18	0.32	0.28	Cerebrospinal fluid biomarker levels;	chr7:23154612	chr7:23206013~23208045:+
BRCA	cis	rs712022	0.837	rs2159668	ENSG00000246225.5	RP11-17A1.3	9.48	1.62e-20	8.12e-18	0.33	0.28	Dialysis-related mortality;	chr11:22817914	chr11:22829380~22945393:+
BRCA	cis	rs10262624	0.901	rs6966655	ENSG00000234286.1	AC006026.13	-9.48	1.62e-20	8.12e-18	-0.33	-0.28	Schizophrenia;	chr7:23867010	chr7:23680195~23680786:-
BRCA	cis	rs1555322	0.53	rs6058224	ENSG00000126005.14	MMP24-AS1	-9.48	1.62e-20	8.13e-18	-0.37	-0.28	Attention deficit hyperactivity disorder;	chr20:35293971	chr20:35216462~35278131:-
BRCA	cis	rs228614	0.536	rs223477	ENSG00000246560.2	RP11-10L12.4	9.48	1.63e-20	8.15e-18	0.3	0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102769099	chr4:102828055~102844075:+
BRCA	cis	rs2337406	0.587	rs10139664	ENSG00000274576.2	IGHV2-70	-9.48	1.63e-20	8.16e-18	-0.3	-0.28	Alzheimer's disease (late onset);	chr14:106647254	chr14:106770577~106771020:-
BRCA	cis	rs35160687	0.623	rs4832263	ENSG00000273080.1	RP11-301O19.1	-9.48	1.63e-20	8.16e-18	-0.33	-0.28	Night sleep phenotypes;	chr2:86258034	chr2:86195590~86196049:+
BRCA	cis	rs2439831	0.702	rs8033995	ENSG00000275601.1	AC011330.13	-9.48	1.63e-20	8.16e-18	-0.45	-0.28	Lung cancer in ever smokers;	chr15:43721311	chr15:43642389~43643023:-
BRCA	cis	rs7250849	0.565	rs11883221	ENSG00000273837.1	LLNLR-470E3.1	-9.48	1.64e-20	8.19e-18	-0.37	-0.28	Blood protein levels;	chr19:51665579	chr19:51639478~51639931:-
BRCA	cis	rs6142102	0.886	rs6142098	ENSG00000276073.1	RP5-1125A11.7	-9.48	1.64e-20	8.19e-18	-0.33	-0.28	Skin pigmentation;	chr20:34100488	chr20:33985617~33988989:-
BRCA	cis	rs367615	0.918	rs10067984	ENSG00000249476.1	CTD-2587M2.1	9.48	1.64e-20	8.2e-18	0.37	0.28	Colorectal cancer (SNP x SNP interaction);	chr5:109536983	chr5:109237120~109326369:-
BRCA	cis	rs6750795	0.542	rs1797388	ENSG00000181798.2	LINC00471	-9.48	1.64e-20	8.23e-18	-0.34	-0.28	Height;	chr2:231551270	chr2:231508426~231514339:-
BRCA	cis	rs858239	0.508	rs7805071	ENSG00000226816.2	AC005082.12	9.48	1.64e-20	8.23e-18	0.33	0.28	Cerebrospinal fluid biomarker levels;	chr7:23150593	chr7:23206013~23208045:+
BRCA	cis	rs67311347	0.713	rs9861194	ENSG00000223797.4	ENTPD3-AS1	9.48	1.65e-20	8.24e-18	0.32	0.28	Renal cell carcinoma;	chr3:40267734	chr3:40313802~40453329:-
BRCA	cis	rs1075265	0.818	rs12713253	ENSG00000233266.1	HMGB1P31	9.48	1.65e-20	8.24e-18	0.34	0.28	Chronotype;Morning vs. evening chronotype;	chr2:54037323	chr2:54051334~54051760:+
BRCA	cis	rs957448	1	rs10956915	ENSG00000253704.1	RP11-267M23.4	9.48	1.66e-20	8.29e-18	0.33	0.28	Nonsyndromic cleft lip with cleft palate;	chr8:94502362	chr8:94553722~94569745:+
BRCA	cis	rs7924176	0.564	rs11000920	ENSG00000213731.2	RAB5CP1	-9.48	1.66e-20	8.3e-18	-0.31	-0.28	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74208443	chr10:74423435~74424014:-
BRCA	cis	rs11992186	0.505	rs7845203	ENSG00000253893.2	FAM85B	-9.48	1.67e-20	8.33e-18	-0.35	-0.28	Neuroticism;	chr8:8287918	chr8:8167819~8226614:-
BRCA	cis	rs2243480	1	rs7794661	ENSG00000226824.5	RP4-756H11.3	-9.48	1.68e-20	8.4e-18	-0.53	-0.28	Diabetic kidney disease;	chr7:65924743	chr7:66654538~66669855:+
BRCA	cis	rs4853012	0.838	rs59570457	ENSG00000257800.1	FNBP1P1	9.48	1.69e-20	8.45e-18	0.29	0.28	Gestational age at birth (maternal effect);	chr2:74117155	chr2:74120680~74123218:+
BRCA	cis	rs875971	0.571	rs160647	ENSG00000226824.5	RP4-756H11.3	9.48	1.69e-20	8.46e-18	0.4	0.28	Aortic root size;	chr7:66089365	chr7:66654538~66669855:+
BRCA	cis	rs1075265	0.68	rs6715488	ENSG00000233266.1	HMGB1P31	9.48	1.69e-20	8.47e-18	0.34	0.28	Chronotype;Morning vs. evening chronotype;	chr2:54004130	chr2:54051334~54051760:+
BRCA	cis	rs950169	0.614	rs765524	ENSG00000225151.9	GOLGA2P7	-9.48	1.7e-20	8.49e-18	-0.39	-0.28	Schizophrenia;	chr15:84013030	chr15:84199311~84230136:-
BRCA	cis	rs17711722	0.64	rs13237956	ENSG00000224316.1	RP11-479O9.2	9.48	1.7e-20	8.51e-18	0.28	0.28	Calcium levels;	chr7:65853042	chr7:65773620~65802067:+
BRCA	cis	rs1062177	1	rs17804178	ENSG00000253921.1	CTB-113P19.3	-9.48	1.71e-20	8.54e-18	-0.39	-0.28	Preschool internalizing problems;	chr5:151818168	chr5:151753992~151767247:+
BRCA	cis	rs1062177	1	rs2964612	ENSG00000253921.1	CTB-113P19.3	-9.48	1.71e-20	8.54e-18	-0.39	-0.28	Preschool internalizing problems;	chr5:151819189	chr5:151753992~151767247:+
BRCA	cis	rs801193	0.935	rs3800820	ENSG00000222364.1	RNU6-96P	9.48	1.71e-20	8.56e-18	0.33	0.28	Aortic root size;	chr7:66682191	chr7:66395191~66395286:+
BRCA	cis	rs11159086	0.793	rs12432412	ENSG00000259005.1	RP3-449M8.6	9.48	1.71e-20	8.57e-18	0.42	0.28	Advanced glycation end-product levels;	chr14:74474294	chr14:74474007~74474864:-
BRCA	cis	rs11159086	0.793	rs1029700	ENSG00000259005.1	RP3-449M8.6	9.48	1.71e-20	8.57e-18	0.42	0.28	Advanced glycation end-product levels;	chr14:74474309	chr14:74474007~74474864:-
BRCA	cis	rs11159086	0.793	rs1029699	ENSG00000259005.1	RP3-449M8.6	9.48	1.71e-20	8.57e-18	0.42	0.28	Advanced glycation end-product levels;	chr14:74474790	chr14:74474007~74474864:-
BRCA	cis	rs875971	0.862	rs28470208	ENSG00000237310.1	GS1-124K5.4	-9.48	1.72e-20	8.59e-18	-0.3	-0.28	Aortic root size;	chr7:66119713	chr7:66493706~66495474:+
BRCA	cis	rs11089937	0.626	rs4820337	ENSG00000211638.2	IGLV8-61	9.48	1.72e-20	8.59e-18	0.28	0.28	Periodontitis (PAL4Q3);	chr22:22164374	chr22:22098700~22099212:+
BRCA	cis	rs11098499	0.754	rs17595608	ENSG00000248280.1	RP11-33B1.2	9.48	1.72e-20	8.61e-18	0.28	0.28	Corneal astigmatism;	chr4:119329351	chr4:119440561~119450157:-
BRCA	cis	rs10759883	0.563	rs657451	ENSG00000175611.10	LINC00476	-9.48	1.73e-20	8.65e-18	-0.31	-0.28	Nicotine dependence;	chr9:96003496	chr9:95759231~95875977:-
BRCA	cis	rs7429990	0.932	rs7620736	ENSG00000229759.1	MRPS18AP1	-9.47	1.74e-20	8.69e-18	-0.32	-0.28	Educational attainment (years of education);	chr3:48068479	chr3:48256350~48256938:-
BRCA	cis	rs6782228	1	rs7429360	ENSG00000242551.2	POU5F1P6	9.47	1.74e-20	8.7e-18	0.41	0.28	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128645954	chr3:128674735~128677005:-
BRCA	cis	rs858239	0.508	rs7805085	ENSG00000226816.2	AC005082.12	9.47	1.75e-20	8.72e-18	0.33	0.28	Cerebrospinal fluid biomarker levels;	chr7:23150624	chr7:23206013~23208045:+
BRCA	cis	rs524281	0.861	rs9736673	ENSG00000255320.1	RP11-755F10.1	9.47	1.75e-20	8.72e-18	0.42	0.28	Electroencephalogram traits;	chr11:66156553	chr11:66244840~66246239:-
BRCA	cis	rs228614	0.543	rs223330	ENSG00000246560.2	RP11-10L12.4	9.47	1.75e-20	8.76e-18	0.3	0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102872502	chr4:102828055~102844075:+
BRCA	cis	rs228614	0.51	rs223329	ENSG00000246560.2	RP11-10L12.4	9.47	1.75e-20	8.76e-18	0.3	0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102873031	chr4:102828055~102844075:+
BRCA	cis	rs113835537	0.559	rs11227498	ENSG00000255517.5	CTD-3074O7.5	-9.47	1.76e-20	8.77e-18	-0.37	-0.28	Airway imaging phenotypes;	chr11:66502243	chr11:66473490~66480233:-
BRCA	cis	rs465969	0.744	rs9400477	ENSG00000255389.1	C6orf3	9.47	1.78e-20	8.88e-18	0.57	0.28	Psoriasis;	chr6:111469440	chr6:111599875~111602295:+
BRCA	cis	rs1062177	1	rs62377945	ENSG00000253921.1	CTB-113P19.3	-9.47	1.78e-20	8.89e-18	-0.39	-0.28	Preschool internalizing problems;	chr5:151828443	chr5:151753992~151767247:+
BRCA	cis	rs801193	1	rs62466794	ENSG00000222364.1	RNU6-96P	-9.47	1.78e-20	8.9e-18	-0.32	-0.28	Aortic root size;	chr7:66726592	chr7:66395191~66395286:+
BRCA	cis	rs228614	0.51	rs223324	ENSG00000246560.2	RP11-10L12.4	9.47	1.79e-20	8.92e-18	0.3	0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102876177	chr4:102828055~102844075:+
BRCA	cis	rs875971	0.522	rs10807697	ENSG00000224316.1	RP11-479O9.2	9.47	1.79e-20	8.94e-18	0.28	0.28	Aortic root size;	chr7:65951183	chr7:65773620~65802067:+
BRCA	cis	rs1823913	0.599	rs13015653	ENSG00000227542.1	AC092614.2	9.47	1.79e-20	8.94e-18	0.34	0.28	Obesity-related traits;	chr2:191306813	chr2:191229165~191246172:-
BRCA	cis	rs1823913	0.599	rs12994212	ENSG00000227542.1	AC092614.2	9.47	1.79e-20	8.94e-18	0.34	0.28	Obesity-related traits;	chr2:191306910	chr2:191229165~191246172:-
BRCA	cis	rs1823913	0.599	rs12994236	ENSG00000227542.1	AC092614.2	9.47	1.79e-20	8.94e-18	0.34	0.28	Obesity-related traits;	chr2:191306991	chr2:191229165~191246172:-
BRCA	cis	rs1823913	0.599	rs35495506	ENSG00000227542.1	AC092614.2	9.47	1.79e-20	8.94e-18	0.34	0.28	Obesity-related traits;	chr2:191307551	chr2:191229165~191246172:-
BRCA	cis	rs1823913	0.599	rs34691559	ENSG00000227542.1	AC092614.2	9.47	1.79e-20	8.94e-18	0.34	0.28	Obesity-related traits;	chr2:191307688	chr2:191229165~191246172:-
BRCA	cis	rs1823913	0.561	rs55790432	ENSG00000227542.1	AC092614.2	9.47	1.79e-20	8.94e-18	0.34	0.28	Obesity-related traits;	chr2:191307722	chr2:191229165~191246172:-
BRCA	cis	rs2276314	0.857	rs9304155	ENSG00000278986.1	RP11-723J4.3	-9.47	1.8e-20	8.96e-18	-0.35	-0.28	Endometriosis;Drug-induced torsades de pointes;	chr18:36005747	chr18:35972151~35973916:+
BRCA	cis	rs12468226	1	rs12472408	ENSG00000273456.1	RP11-686O6.2	9.47	1.8e-20	9e-18	0.42	0.28	Urate levels;	chr2:202413973	chr2:202374932~202375604:-
BRCA	cis	rs957448	0.904	rs56302978	ENSG00000253704.1	RP11-267M23.4	9.47	1.81e-20	9e-18	0.33	0.28	Nonsyndromic cleft lip with cleft palate;	chr8:94505883	chr8:94553722~94569745:+
BRCA	cis	rs6570726	0.791	rs9373464	ENSG00000235652.6	RP11-545I5.3	9.47	1.81e-20	9.04e-18	0.28	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145586031	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.875	rs6570736	ENSG00000235652.6	RP11-545I5.3	9.47	1.82e-20	9.06e-18	0.28	0.28	Lobe attachment (rater-scored or self-reported);	chr6:146067184	chr6:145799409~145886585:+
BRCA	cis	rs7688540	0.8	rs12506277	ENSG00000211553.1	AC253576.2	-9.47	1.82e-20	9.07e-18	-0.36	-0.28	Facial morphology (factor 6, height of vermillion lower lip);	chr4:293860	chr4:136461~136568:+
BRCA	cis	rs11098499	0.863	rs10004484	ENSG00000245958.5	RP11-33B1.1	-9.47	1.82e-20	9.08e-18	-0.27	-0.28	Corneal astigmatism;	chr4:119521273	chr4:119454791~119552025:+
BRCA	cis	rs2243480	1	rs34560516	ENSG00000226824.5	RP4-756H11.3	-9.47	1.82e-20	9.09e-18	-0.54	-0.28	Diabetic kidney disease;	chr7:65939105	chr7:66654538~66669855:+
BRCA	cis	rs11098499	0.754	rs66900435	ENSG00000248280.1	RP11-33B1.2	9.47	1.83e-20	9.13e-18	0.28	0.28	Corneal astigmatism;	chr4:119328270	chr4:119440561~119450157:-
BRCA	cis	rs465969	1	rs34382476	ENSG00000255389.1	C6orf3	-9.47	1.84e-20	9.15e-18	-0.58	-0.28	Psoriasis;	chr6:111423551	chr6:111599875~111602295:+
BRCA	cis	rs2404602	0.583	rs2469542	ENSG00000259422.1	RP11-593F23.1	-9.47	1.84e-20	9.19e-18	-0.34	-0.28	Blood metabolite levels;	chr15:76265135	chr15:76174891~76181486:-
BRCA	cis	rs11676348	0.808	rs12694430	ENSG00000261338.2	RP11-378A13.1	-9.47	1.85e-20	9.2e-18	-0.3	-0.28	Ulcerative colitis;	chr2:218151076	chr2:218255319~218257366:+
BRCA	cis	rs801193	0.839	rs12534943	ENSG00000222364.1	RNU6-96P	9.47	1.85e-20	9.22e-18	0.32	0.28	Aortic root size;	chr7:66605533	chr7:66395191~66395286:+
BRCA	cis	rs2274273	0.673	rs2209808	ENSG00000258413.1	RP11-665C16.6	-9.47	1.85e-20	9.22e-18	-0.36	-0.28	Protein biomarker;	chr14:55340977	chr14:55262767~55272075:-
BRCA	cis	rs7772486	0.79	rs2253768	ENSG00000235652.6	RP11-545I5.3	9.47	1.85e-20	9.23e-18	0.28	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145878786	chr6:145799409~145886585:+
BRCA	cis	rs7580658	0.637	rs4662710	ENSG00000236682.1	AC068282.3	-9.47	1.85e-20	9.23e-18	-0.38	-0.28	Protein C levels;	chr2:127219241	chr2:127389130~127400580:+
BRCA	cis	rs227275	0.556	rs28367331	ENSG00000246560.2	RP11-10L12.4	9.47	1.85e-20	9.24e-18	0.3	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102900734	chr4:102828055~102844075:+
BRCA	cis	rs2439831	0.85	rs10438303	ENSG00000275601.1	AC011330.13	-9.46	1.89e-20	9.43e-18	-0.46	-0.28	Lung cancer in ever smokers;	chr15:43724219	chr15:43642389~43643023:-
BRCA	cis	rs875971	0.508	rs10258739	ENSG00000222364.1	RNU6-96P	9.46	1.9e-20	9.44e-18	0.32	0.28	Aortic root size;	chr7:66597948	chr7:66395191~66395286:+
BRCA	cis	rs783540	0.869	rs783521	ENSG00000278603.1	RP13-608F4.5	-9.46	1.9e-20	9.44e-18	-0.35	-0.28	Schizophrenia;	chr15:82611694	chr15:82472203~82472426:+
BRCA	cis	rs783540	0.835	rs783522	ENSG00000278603.1	RP13-608F4.5	-9.46	1.9e-20	9.44e-18	-0.35	-0.28	Schizophrenia;	chr15:82611862	chr15:82472203~82472426:+
BRCA	cis	rs1113500	0.933	rs12035689	ENSG00000226822.1	RP11-356N1.2	9.46	1.9e-20	9.48e-18	0.37	0.28	Growth-regulated protein alpha levels;	chr1:108094134	chr1:108071482~108074519:+
BRCA	cis	rs1113500	0.862	rs3853494	ENSG00000226822.1	RP11-356N1.2	9.46	1.9e-20	9.48e-18	0.37	0.28	Growth-regulated protein alpha levels;	chr1:108094712	chr1:108071482~108074519:+
BRCA	cis	rs6750795	0.569	rs1797387	ENSG00000181798.2	LINC00471	-9.46	1.91e-20	9.51e-18	-0.34	-0.28	Height;	chr2:231549981	chr2:231508426~231514339:-
BRCA	cis	rs67180937	0.553	rs2088514	ENSG00000272750.1	RP11-378J18.8	-9.46	1.91e-20	9.52e-18	-0.4	-0.28	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222658030	chr1:222658867~222661512:-
BRCA	cis	rs1113500	0.933	rs10785833	ENSG00000226822.1	RP11-356N1.2	9.46	1.92e-20	9.55e-18	0.37	0.28	Growth-regulated protein alpha levels;	chr1:108096460	chr1:108071482~108074519:+
BRCA	cis	rs1113500	0.702	rs11185262	ENSG00000226822.1	RP11-356N1.2	9.46	1.92e-20	9.55e-18	0.37	0.28	Growth-regulated protein alpha levels;	chr1:108097120	chr1:108071482~108074519:+
BRCA	cis	rs11098499	0.909	rs1546502	ENSG00000248280.1	RP11-33B1.2	9.46	1.93e-20	9.59e-18	0.29	0.28	Corneal astigmatism;	chr4:119314743	chr4:119440561~119450157:-
BRCA	cis	rs8062405	1	rs4788095	ENSG00000278665.1	RP11-666O2.4	9.46	1.94e-20	9.67e-18	0.3	0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28820038	chr16:28599241~28601881:-
BRCA	cis	rs8062405	0.964	rs72793809	ENSG00000278665.1	RP11-666O2.4	9.46	1.94e-20	9.67e-18	0.3	0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821061	chr16:28599241~28601881:-
BRCA	cis	rs116175783	0.557	rs62194490	ENSG00000227403.1	AC009299.3	9.46	1.96e-20	9.77e-18	0.49	0.28	Intelligence (multi-trait analysis);	chr2:161344287	chr2:161244739~161249050:+
BRCA	cis	rs8062405	0.964	rs11860513	ENSG00000278665.1	RP11-666O2.4	9.46	1.97e-20	9.77e-18	0.3	0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814099	chr16:28599241~28601881:-
BRCA	cis	rs9287719	0.967	rs6712304	ENSG00000234818.1	AC092687.5	9.46	1.97e-20	9.77e-18	0.33	0.28	Prostate cancer;	chr2:10614249	chr2:10589166~10604830:+
BRCA	cis	rs9287719	1	rs9679122	ENSG00000234818.1	AC092687.5	9.46	1.97e-20	9.79e-18	0.33	0.28	Prostate cancer;	chr2:10611584	chr2:10589166~10604830:+
BRCA	cis	rs11096990	0.634	rs2062229	ENSG00000249207.1	RP11-360F5.1	-9.46	1.97e-20	9.81e-18	-0.32	-0.28	Cognitive function;	chr4:39285146	chr4:39112677~39126818:-
BRCA	cis	rs875971	0.516	rs6945322	ENSG00000224316.1	RP11-479O9.2	9.46	2e-20	9.93e-18	0.28	0.28	Aortic root size;	chr7:65871069	chr7:65773620~65802067:+
BRCA	cis	rs11676348	0.808	rs1008563	ENSG00000261338.2	RP11-378A13.1	-9.46	2e-20	9.95e-18	-0.3	-0.28	Ulcerative colitis;	chr2:218162165	chr2:218255319~218257366:+
BRCA	cis	rs4820294	0.646	rs9622675	ENSG00000233360.4	Z83844.1	9.46	2e-20	9.95e-18	0.32	0.28	Fat distribution (HIV);	chr22:37657658	chr22:37641832~37658377:-
BRCA	cis	rs4835473	0.801	rs35839125	ENSG00000251600.4	RP11-673E1.1	-9.46	2.01e-20	9.97e-18	-0.32	-0.28	Immature fraction of reticulocytes;	chr4:143792351	chr4:143912331~143982454:+
BRCA	cis	rs1789	0.592	rs1558572	ENSG00000273133.1	RP11-799M12.2	-9.46	2.01e-20	9.98e-18	-0.37	-0.28	Blood protein levels;	chr4:15537121	chr4:15563698~15564253:-
BRCA	cis	rs72772090	0.539	rs11750464	ENSG00000248734.2	CTD-2260A17.1	9.46	2.01e-20	1e-17	0.45	0.28	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96777327	chr5:96784777~96785999:+
BRCA	cis	rs11722779	0.903	rs6830193	ENSG00000246560.2	RP11-10L12.4	9.46	2.01e-20	1e-17	0.3	0.28	Schizophrenia;	chr4:102955457	chr4:102828055~102844075:+
BRCA	cis	rs4835473	0.932	rs5016158	ENSG00000251600.4	RP11-673E1.1	-9.46	2.02e-20	1e-17	-0.32	-0.28	Immature fraction of reticulocytes;	chr4:143738472	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs5016157	ENSG00000251600.4	RP11-673E1.1	-9.46	2.02e-20	1e-17	-0.32	-0.28	Immature fraction of reticulocytes;	chr4:143738587	chr4:143912331~143982454:+
BRCA	cis	rs875971	0.508	rs10950045	ENSG00000222364.1	RNU6-96P	9.46	2.04e-20	1.01e-17	0.32	0.28	Aortic root size;	chr7:66601386	chr7:66395191~66395286:+
BRCA	cis	rs801193	0.839	rs6968619	ENSG00000222364.1	RNU6-96P	9.46	2.04e-20	1.01e-17	0.32	0.28	Aortic root size;	chr7:66603880	chr7:66395191~66395286:+
BRCA	cis	rs801193	0.805	rs12532355	ENSG00000222364.1	RNU6-96P	9.46	2.04e-20	1.01e-17	0.32	0.28	Aortic root size;	chr7:66605597	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.66	rs79009421	ENSG00000222364.1	RNU6-96P	9.46	2.06e-20	1.02e-17	0.33	0.28	Aortic root size;	chr7:66603522	chr7:66395191~66395286:+
BRCA	cis	rs2111504	0.806	rs10403559	ENSG00000267213.4	AC007773.2	-9.46	2.06e-20	1.02e-17	-0.36	-0.28	Bipolar disorder;	chr19:32462195	chr19:32390050~32405560:-
BRCA	cis	rs1062177	1	rs2915878	ENSG00000253921.1	CTB-113P19.3	-9.46	2.06e-20	1.02e-17	-0.38	-0.28	Preschool internalizing problems;	chr5:151770101	chr5:151753992~151767247:+
BRCA	cis	rs6565180	0.962	rs11642676	ENSG00000273724.1	RP11-347C12.12	-9.46	2.06e-20	1.02e-17	-0.35	-0.28	Tonsillectomy;	chr16:30360334	chr16:30336400~30343336:+
BRCA	cis	rs2243480	1	rs1723269	ENSG00000226824.5	RP4-756H11.3	-9.45	2.07e-20	1.03e-17	-0.54	-0.28	Diabetic kidney disease;	chr7:66007799	chr7:66654538~66669855:+
BRCA	cis	rs8059260	0.736	rs74391397	ENSG00000274038.1	RP11-66H6.4	-9.45	2.08e-20	1.03e-17	-0.51	-0.28	Alcohol consumption over the past year;	chr16:10975570	chr16:11056556~11057034:+
BRCA	cis	rs875971	0.505	rs2462573	ENSG00000224316.1	RP11-479O9.2	-9.45	2.08e-20	1.03e-17	-0.28	-0.28	Aortic root size;	chr7:66042405	chr7:65773620~65802067:+
BRCA	cis	rs2067615	0.56	rs1882542	ENSG00000260329.1	RP11-412D9.4	-9.45	2.09e-20	1.03e-17	-0.3	-0.28	Heart rate;	chr12:106676271	chr12:106954029~106955497:-
BRCA	cis	rs875971	0.862	rs4368860	ENSG00000237310.1	GS1-124K5.4	-9.45	2.11e-20	1.04e-17	-0.29	-0.28	Aortic root size;	chr7:66143495	chr7:66493706~66495474:+
BRCA	cis	rs1062177	1	rs62394155	ENSG00000253921.1	CTB-113P19.3	-9.45	2.11e-20	1.05e-17	-0.4	-0.28	Preschool internalizing problems;	chr5:151868508	chr5:151753992~151767247:+
BRCA	cis	rs6750795	0.569	rs1667308	ENSG00000181798.2	LINC00471	-9.45	2.11e-20	1.05e-17	-0.33	-0.28	Height;	chr2:231541633	chr2:231508426~231514339:-
BRCA	cis	rs13392177	0.66	rs62185964	ENSG00000261338.2	RP11-378A13.1	-9.45	2.12e-20	1.05e-17	-0.29	-0.28	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218209022	chr2:218255319~218257366:+
BRCA	cis	rs13392177	0.684	rs62185965	ENSG00000261338.2	RP11-378A13.1	-9.45	2.12e-20	1.05e-17	-0.29	-0.28	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218209056	chr2:218255319~218257366:+
BRCA	cis	rs1113500	0.897	rs55980437	ENSG00000226822.1	RP11-356N1.2	9.45	2.13e-20	1.05e-17	0.37	0.28	Growth-regulated protein alpha levels;	chr1:108096876	chr1:108071482~108074519:+
BRCA	cis	rs1062177	1	rs12515762	ENSG00000253921.1	CTB-113P19.3	-9.45	2.13e-20	1.06e-17	-0.39	-0.28	Preschool internalizing problems;	chr5:151830361	chr5:151753992~151767247:+
BRCA	cis	rs875971	0.66	rs7807944	ENSG00000222364.1	RNU6-96P	9.45	2.14e-20	1.06e-17	0.32	0.28	Aortic root size;	chr7:66622208	chr7:66395191~66395286:+
BRCA	cis	rs4727443	0.899	rs6954978	ENSG00000235713.1	RP4-604G5.3	-9.45	2.14e-20	1.06e-17	-0.32	-0.28	Interstitial lung disease;	chr7:99984589	chr7:99992397~99993050:+
BRCA	cis	rs7772486	0.875	rs9322045	ENSG00000235652.6	RP11-545I5.3	9.45	2.15e-20	1.06e-17	0.28	0.28	Lobe attachment (rater-scored or self-reported);	chr6:146063814	chr6:145799409~145886585:+
BRCA	cis	rs13392177	0.684	rs11682371	ENSG00000261338.2	RP11-378A13.1	-9.45	2.15e-20	1.07e-17	-0.29	-0.28	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218214790	chr2:218255319~218257366:+
BRCA	cis	rs35160687	0.712	rs9677502	ENSG00000273080.1	RP11-301O19.1	-9.45	2.16e-20	1.07e-17	-0.32	-0.28	Night sleep phenotypes;	chr2:86253815	chr2:86195590~86196049:+
BRCA	cis	rs875971	0.862	rs7809814	ENSG00000237310.1	GS1-124K5.4	-9.45	2.17e-20	1.07e-17	-0.29	-0.28	Aortic root size;	chr7:66150410	chr7:66493706~66495474:+
BRCA	cis	rs7772486	0.84	rs11155451	ENSG00000235652.6	RP11-545I5.3	9.45	2.18e-20	1.08e-17	0.29	0.28	Lobe attachment (rater-scored or self-reported);	chr6:146101388	chr6:145799409~145886585:+
BRCA	cis	rs228614	0.509	rs223480	ENSG00000246560.2	RP11-10L12.4	9.45	2.18e-20	1.08e-17	0.3	0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102766881	chr4:102828055~102844075:+
BRCA	cis	rs801193	0.967	rs2707849	ENSG00000222364.1	RNU6-96P	-9.45	2.2e-20	1.09e-17	-0.32	-0.28	Aortic root size;	chr7:66687725	chr7:66395191~66395286:+
BRCA	cis	rs465969	1	rs35856111	ENSG00000255389.1	C6orf3	-9.45	2.21e-20	1.09e-17	-0.58	-0.28	Psoriasis;	chr6:111452265	chr6:111599875~111602295:+
BRCA	cis	rs875971	0.66	rs6460308	ENSG00000222364.1	RNU6-96P	9.45	2.21e-20	1.09e-17	0.32	0.28	Aortic root size;	chr7:66619753	chr7:66395191~66395286:+
BRCA	cis	rs7580658	0.521	rs35577992	ENSG00000236682.1	AC068282.3	-9.45	2.21e-20	1.1e-17	-0.37	-0.28	Protein C levels;	chr2:127183748	chr2:127389130~127400580:+
BRCA	cis	rs4835473	0.75	rs12498381	ENSG00000251600.4	RP11-673E1.1	-9.45	2.23e-20	1.1e-17	-0.32	-0.28	Immature fraction of reticulocytes;	chr4:143793928	chr4:143912331~143982454:+
BRCA	cis	rs3779195	0.585	rs7777991	ENSG00000272950.1	RP11-307C18.1	-9.45	2.24e-20	1.11e-17	-0.46	-0.28	Sex hormone-binding globulin levels;	chr7:98236445	chr7:98322853~98323430:+
BRCA	cis	rs2243480	1	rs34970380	ENSG00000226824.5	RP4-756H11.3	-9.45	2.24e-20	1.11e-17	-0.54	-0.28	Diabetic kidney disease;	chr7:65966506	chr7:66654538~66669855:+
BRCA	cis	rs11722779	0.935	rs11938650	ENSG00000246560.2	RP11-10L12.4	9.45	2.25e-20	1.11e-17	0.3	0.28	Schizophrenia;	chr4:103021639	chr4:102828055~102844075:+
BRCA	cis	rs9287719	0.839	rs11683335	ENSG00000234818.1	AC092687.5	9.45	2.25e-20	1.11e-17	0.33	0.28	Prostate cancer;	chr2:10616539	chr2:10589166~10604830:+
BRCA	cis	rs7429990	0.93	rs7374516	ENSG00000229759.1	MRPS18AP1	9.45	2.25e-20	1.11e-17	0.31	0.28	Educational attainment (years of education);	chr3:47961150	chr3:48256350~48256938:-
BRCA	cis	rs6750795	0.569	rs1667305	ENSG00000181798.2	LINC00471	-9.44	2.26e-20	1.12e-17	-0.33	-0.28	Height;	chr2:231539118	chr2:231508426~231514339:-
BRCA	cis	rs7429990	0.965	rs6791834	ENSG00000229759.1	MRPS18AP1	-9.44	2.26e-20	1.12e-17	-0.32	-0.28	Educational attainment (years of education);	chr3:48073598	chr3:48256350~48256938:-
BRCA	cis	rs7429990	0.965	rs34750113	ENSG00000229759.1	MRPS18AP1	9.44	2.27e-20	1.13e-17	0.34	0.28	Educational attainment (years of education);	chr3:47944902	chr3:48256350~48256938:-
BRCA	cis	rs812925	0.502	rs13028833	ENSG00000271889.1	RP11-493E12.1	-9.44	2.27e-20	1.13e-17	-0.34	-0.28	Immature fraction of reticulocytes;	chr2:61417194	chr2:61151433~61162105:-
BRCA	cis	rs801193	0.935	rs2659899	ENSG00000222364.1	RNU6-96P	-9.44	2.28e-20	1.13e-17	-0.32	-0.28	Aortic root size;	chr7:66721734	chr7:66395191~66395286:+
BRCA	cis	rs853679	0.567	rs7740429	ENSG00000216901.1	AL022393.7	9.44	2.28e-20	1.13e-17	0.4	0.28	Depression;	chr6:28431469	chr6:28176188~28176674:+
BRCA	cis	rs9287719	0.967	rs10203664	ENSG00000234818.1	AC092687.5	9.44	2.28e-20	1.13e-17	0.33	0.28	Prostate cancer;	chr2:10612251	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.934	rs10201077	ENSG00000234818.1	AC092687.5	9.44	2.28e-20	1.13e-17	0.33	0.28	Prostate cancer;	chr2:10612300	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs9287720	ENSG00000234818.1	AC092687.5	9.44	2.28e-20	1.13e-17	0.33	0.28	Prostate cancer;	chr2:10612538	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.87	rs10167676	ENSG00000234818.1	AC092687.5	9.44	2.28e-20	1.13e-17	0.33	0.28	Prostate cancer;	chr2:10613014	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs12995159	ENSG00000234818.1	AC092687.5	9.44	2.28e-20	1.13e-17	0.33	0.28	Prostate cancer;	chr2:10613197	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs12995602	ENSG00000234818.1	AC092687.5	9.44	2.28e-20	1.13e-17	0.33	0.28	Prostate cancer;	chr2:10613416	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs6432119	ENSG00000234818.1	AC092687.5	9.44	2.28e-20	1.13e-17	0.33	0.28	Prostate cancer;	chr2:10613561	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs6432120	ENSG00000234818.1	AC092687.5	9.44	2.28e-20	1.13e-17	0.33	0.28	Prostate cancer;	chr2:10613645	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs6432122	ENSG00000234818.1	AC092687.5	9.44	2.28e-20	1.13e-17	0.33	0.28	Prostate cancer;	chr2:10613718	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs6712406	ENSG00000234818.1	AC092687.5	9.44	2.28e-20	1.13e-17	0.33	0.28	Prostate cancer;	chr2:10614294	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs10195802	ENSG00000234818.1	AC092687.5	9.44	2.28e-20	1.13e-17	0.33	0.28	Prostate cancer;	chr2:10614406	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs7566875	ENSG00000234818.1	AC092687.5	9.44	2.28e-20	1.13e-17	0.33	0.28	Prostate cancer;	chr2:10614666	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.934	rs4371336	ENSG00000234818.1	AC092687.5	9.44	2.28e-20	1.13e-17	0.33	0.28	Prostate cancer;	chr2:10615597	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs4405729	ENSG00000234818.1	AC092687.5	9.44	2.28e-20	1.13e-17	0.33	0.28	Prostate cancer;	chr2:10615653	chr2:10589166~10604830:+
BRCA	cis	rs11098499	0.866	rs7665125	ENSG00000245958.5	RP11-33B1.1	-9.44	2.28e-20	1.13e-17	-0.26	-0.28	Corneal astigmatism;	chr4:119480924	chr4:119454791~119552025:+
BRCA	cis	rs10129255	0.5	rs4774008	ENSG00000211972.2	IGHV3-66	9.44	2.29e-20	1.13e-17	0.2	0.28	Kawasaki disease;	chr14:106681273	chr14:106675017~106675544:-
BRCA	cis	rs1113500	0.933	rs10881500	ENSG00000226822.1	RP11-356N1.2	9.44	2.3e-20	1.14e-17	0.37	0.28	Growth-regulated protein alpha levels;	chr1:108096273	chr1:108071482~108074519:+
BRCA	cis	rs1113500	0.897	rs10785832	ENSG00000226822.1	RP11-356N1.2	9.44	2.3e-20	1.14e-17	0.37	0.28	Growth-regulated protein alpha levels;	chr1:108096277	chr1:108071482~108074519:+
BRCA	cis	rs2015599	0.623	rs3782510	ENSG00000275476.1	RP11-996F15.4	9.44	2.3e-20	1.14e-17	0.31	0.28	Platelet count;Mean platelet volume;	chr12:29301176	chr12:29277397~29277882:-
BRCA	cis	rs801193	1	rs2659909	ENSG00000222364.1	RNU6-96P	-9.44	2.31e-20	1.14e-17	-0.32	-0.28	Aortic root size;	chr7:66695292	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.862	rs709596	ENSG00000237310.1	GS1-124K5.4	9.44	2.31e-20	1.14e-17	0.29	0.28	Aortic root size;	chr7:66360926	chr7:66493706~66495474:+
BRCA	cis	rs858239	0.539	rs10247268	ENSG00000226816.2	AC005082.12	9.44	2.31e-20	1.14e-17	0.33	0.28	Cerebrospinal fluid biomarker levels;	chr7:23147560	chr7:23206013~23208045:+
BRCA	cis	rs858239	0.539	rs6461694	ENSG00000226816.2	AC005082.12	9.44	2.31e-20	1.14e-17	0.33	0.28	Cerebrospinal fluid biomarker levels;	chr7:23148160	chr7:23206013~23208045:+
BRCA	cis	rs9287719	0.934	rs6710033	ENSG00000234818.1	AC092687.5	9.44	2.33e-20	1.15e-17	0.33	0.28	Prostate cancer;	chr2:10617551	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs4669598	ENSG00000234818.1	AC092687.5	9.44	2.33e-20	1.15e-17	0.33	0.28	Prostate cancer;	chr2:10617712	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs4669599	ENSG00000234818.1	AC092687.5	9.44	2.33e-20	1.15e-17	0.33	0.28	Prostate cancer;	chr2:10617903	chr2:10589166~10604830:+
BRCA	cis	rs13256369	0.708	rs11249886	ENSG00000253893.2	FAM85B	-9.44	2.33e-20	1.15e-17	-0.4	-0.28	Obesity-related traits;	chr8:8704511	chr8:8167819~8226614:-
BRCA	cis	rs812925	0.537	rs10196146	ENSG00000271889.1	RP11-493E12.1	-9.44	2.34e-20	1.16e-17	-0.34	-0.28	Immature fraction of reticulocytes;	chr2:61378244	chr2:61151433~61162105:-
BRCA	cis	rs2243480	1	rs937108	ENSG00000226824.5	RP4-756H11.3	-9.44	2.34e-20	1.16e-17	-0.53	-0.28	Diabetic kidney disease;	chr7:65963465	chr7:66654538~66669855:+
BRCA	cis	rs228614	0.51	rs223349	ENSG00000246560.2	RP11-10L12.4	9.44	2.36e-20	1.17e-17	0.3	0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102857277	chr4:102828055~102844075:+
BRCA	cis	rs1062177	0.826	rs2915873	ENSG00000253921.1	CTB-113P19.3	-9.44	2.37e-20	1.17e-17	-0.38	-0.28	Preschool internalizing problems;	chr5:151777097	chr5:151753992~151767247:+
BRCA	cis	rs2283792	0.765	rs5999752	ENSG00000224086.5	LL22NC03-86G7.1	-9.44	2.38e-20	1.17e-17	-0.3	-0.28	Multiple sclerosis;	chr22:21833894	chr22:21938293~21977632:+
BRCA	cis	rs11098499	0.863	rs9884402	ENSG00000245958.5	RP11-33B1.1	-9.44	2.38e-20	1.17e-17	-0.28	-0.28	Corneal astigmatism;	chr4:119568827	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.731	rs9995026	ENSG00000245958.5	RP11-33B1.1	-9.44	2.38e-20	1.17e-17	-0.28	-0.28	Corneal astigmatism;	chr4:119569344	chr4:119454791~119552025:+
BRCA	cis	rs8062405	0.755	rs4788076	ENSG00000278665.1	RP11-666O2.4	9.44	2.38e-20	1.18e-17	0.31	0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28558684	chr16:28599241~28601881:-
BRCA	cis	rs4835473	0.932	rs13139738	ENSG00000251600.4	RP11-673E1.1	-9.44	2.39e-20	1.18e-17	-0.32	-0.28	Immature fraction of reticulocytes;	chr4:143738828	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs17018165	ENSG00000251600.4	RP11-673E1.1	-9.44	2.39e-20	1.18e-17	-0.32	-0.28	Immature fraction of reticulocytes;	chr4:143738849	chr4:143912331~143982454:+
BRCA	cis	rs1061377	0.513	rs2566162	ENSG00000249207.1	RP11-360F5.1	-9.44	2.39e-20	1.18e-17	-0.36	-0.28	Uric acid levels;	chr4:39126453	chr4:39112677~39126818:-
BRCA	cis	rs7924176	0.601	rs10824072	ENSG00000213731.2	RAB5CP1	-9.44	2.44e-20	1.2e-17	-0.31	-0.28	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74114134	chr10:74423435~74424014:-
BRCA	cis	rs11098499	0.954	rs10006877	ENSG00000248280.1	RP11-33B1.2	9.44	2.44e-20	1.2e-17	0.29	0.28	Corneal astigmatism;	chr4:119321638	chr4:119440561~119450157:-
BRCA	cis	rs7924176	0.564	rs10762588	ENSG00000213731.2	RAB5CP1	-9.44	2.44e-20	1.2e-17	-0.31	-0.28	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74226087	chr10:74423435~74424014:-
BRCA	cis	rs7429990	0.965	rs35689209	ENSG00000229759.1	MRPS18AP1	-9.44	2.45e-20	1.21e-17	-0.32	-0.28	Educational attainment (years of education);	chr3:48078273	chr3:48256350~48256938:-
BRCA	cis	rs9287719	0.967	rs7563894	ENSG00000234818.1	AC092687.5	9.44	2.46e-20	1.21e-17	0.33	0.28	Prostate cancer;	chr2:10614523	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs7566767	ENSG00000234818.1	AC092687.5	9.44	2.46e-20	1.21e-17	0.33	0.28	Prostate cancer;	chr2:10614537	chr2:10589166~10604830:+
BRCA	cis	rs465969	0.793	rs7752225	ENSG00000255389.1	C6orf3	9.43	2.48e-20	1.22e-17	0.58	0.28	Psoriasis;	chr6:111459412	chr6:111599875~111602295:+
BRCA	cis	rs11722779	0.935	rs3857200	ENSG00000246560.2	RP11-10L12.4	9.43	2.48e-20	1.22e-17	0.3	0.28	Schizophrenia;	chr4:103001864	chr4:102828055~102844075:+
BRCA	cis	rs4862750	0.914	rs9995391	ENSG00000250971.1	RP11-696F12.1	-9.43	2.48e-20	1.23e-17	-0.3	-0.28	Lobe attachment (rater-scored or self-reported);	chr4:186952595	chr4:187060099~187060930:+
BRCA	cis	rs8062405	1	rs62036620	ENSG00000278665.1	RP11-666O2.4	9.43	2.49e-20	1.23e-17	0.3	0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821776	chr16:28599241~28601881:-
BRCA	cis	rs8062405	1	rs62036621	ENSG00000278665.1	RP11-666O2.4	9.43	2.49e-20	1.23e-17	0.3	0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821978	chr16:28599241~28601881:-
BRCA	cis	rs858239	0.601	rs6971002	ENSG00000226816.2	AC005082.12	9.43	2.51e-20	1.24e-17	0.32	0.28	Cerebrospinal fluid biomarker levels;	chr7:23132685	chr7:23206013~23208045:+
BRCA	cis	rs2243480	1	rs781150	ENSG00000226824.5	RP4-756H11.3	-9.43	2.53e-20	1.25e-17	-0.54	-0.28	Diabetic kidney disease;	chr7:66015986	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs313798	ENSG00000226824.5	RP4-756H11.3	-9.43	2.53e-20	1.25e-17	-0.54	-0.28	Diabetic kidney disease;	chr7:66028044	chr7:66654538~66669855:+
BRCA	cis	rs6545883	0.56	rs11677775	ENSG00000271889.1	RP11-493E12.1	-9.43	2.53e-20	1.25e-17	-0.34	-0.28	Tuberculosis;	chr2:61275975	chr2:61151433~61162105:-
BRCA	cis	rs950169	0.58	rs11634322	ENSG00000225151.9	GOLGA2P7	-9.43	2.55e-20	1.26e-17	-0.36	-0.28	Schizophrenia;	chr15:84628978	chr15:84199311~84230136:-
BRCA	cis	rs2111504	0.806	rs7252443	ENSG00000267213.4	AC007773.2	-9.43	2.57e-20	1.26e-17	-0.36	-0.28	Bipolar disorder;	chr19:32449827	chr19:32390050~32405560:-
BRCA	cis	rs875971	0.54	rs781152	ENSG00000224316.1	RP11-479O9.2	9.43	2.58e-20	1.27e-17	0.28	0.28	Aortic root size;	chr7:66014585	chr7:65773620~65802067:+
BRCA	cis	rs17711722	0.727	rs781151	ENSG00000224316.1	RP11-479O9.2	9.43	2.58e-20	1.27e-17	0.28	0.28	Calcium levels;	chr7:66014891	chr7:65773620~65802067:+
BRCA	cis	rs227275	0.554	rs223454	ENSG00000246560.2	RP11-10L12.4	9.43	2.59e-20	1.27e-17	0.29	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102789773	chr4:102828055~102844075:+
BRCA	cis	rs9287719	0.967	rs10203785	ENSG00000234818.1	AC092687.5	9.43	2.59e-20	1.27e-17	0.33	0.28	Prostate cancer;	chr2:10612382	chr2:10589166~10604830:+
BRCA	cis	rs2933343	0.951	rs789220	ENSG00000231305.3	RP11-723O4.2	-9.43	2.6e-20	1.28e-17	-0.34	-0.28	IgG glycosylation;	chr3:128873292	chr3:128861313~128871540:-
BRCA	cis	rs4266144	0.821	rs4325879	ENSG00000244515.1	KRT18P34	-9.43	2.61e-20	1.29e-17	-0.39	-0.28	Coronary artery disease;	chr3:157134195	chr3:157162663~157163932:-
BRCA	cis	rs13256369	0.901	rs12681298	ENSG00000253893.2	FAM85B	9.43	2.63e-20	1.29e-17	0.39	0.28	Obesity-related traits;	chr8:8708725	chr8:8167819~8226614:-
BRCA	cis	rs2283792	0.765	rs9610374	ENSG00000224086.5	LL22NC03-86G7.1	-9.43	2.63e-20	1.3e-17	-0.3	-0.28	Multiple sclerosis;	chr22:21832514	chr22:21938293~21977632:+
BRCA	cis	rs4835473	0.932	rs13121861	ENSG00000251600.4	RP11-673E1.1	-9.43	2.64e-20	1.3e-17	-0.32	-0.28	Immature fraction of reticulocytes;	chr4:143814007	chr4:143912331~143982454:+
BRCA	cis	rs6538678	0.777	rs10745736	ENSG00000258343.1	RP11-536G4.2	-9.43	2.64e-20	1.3e-17	-0.42	-0.28	Lupus nephritis in systemic lupus erythematosus;	chr12:95889308	chr12:95795345~95858839:-
BRCA	cis	rs812925	0.537	rs2593620	ENSG00000271889.1	RP11-493E12.1	-9.43	2.65e-20	1.3e-17	-0.34	-0.28	Immature fraction of reticulocytes;	chr2:61386126	chr2:61151433~61162105:-
BRCA	cis	rs858239	0.539	rs4559148	ENSG00000226816.2	AC005082.12	9.43	2.66e-20	1.31e-17	0.33	0.28	Cerebrospinal fluid biomarker levels;	chr7:23146348	chr7:23206013~23208045:+
BRCA	cis	rs8062405	0.558	rs151228	ENSG00000278665.1	RP11-666O2.4	9.43	2.67e-20	1.31e-17	0.28	0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28551705	chr16:28599241~28601881:-
BRCA	cis	rs1062177	0.774	rs2964574	ENSG00000253921.1	CTB-113P19.3	-9.43	2.67e-20	1.31e-17	-0.38	-0.28	Preschool internalizing problems;	chr5:151776150	chr5:151753992~151767247:+
BRCA	cis	rs801193	1	rs2659912	ENSG00000222364.1	RNU6-96P	-9.43	2.68e-20	1.32e-17	-0.32	-0.28	Aortic root size;	chr7:66693012	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.522	rs4502988	ENSG00000224316.1	RP11-479O9.2	9.43	2.69e-20	1.32e-17	0.28	0.28	Aortic root size;	chr7:65832759	chr7:65773620~65802067:+
BRCA	cis	rs4964805	0.594	rs4964830	ENSG00000257681.1	RP11-341G23.4	-9.42	2.69e-20	1.32e-17	-0.34	-0.28	Attention deficit hyperactivity disorder;	chr12:103775130	chr12:103746315~103768858:-
BRCA	cis	rs10129255	0.957	rs2007467	ENSG00000223648.3	IGHV3-64	-9.42	2.71e-20	1.33e-17	-0.24	-0.28	Kawasaki disease;	chr14:106771605	chr14:106643132~106658258:-
BRCA	cis	rs6545883	0.507	rs10169662	ENSG00000271889.1	RP11-493E12.1	-9.42	2.72e-20	1.34e-17	-0.33	-0.28	Tuberculosis;	chr2:61280801	chr2:61151433~61162105:-
BRCA	cis	rs858239	0.508	rs2390754	ENSG00000226816.2	AC005082.12	9.42	2.73e-20	1.34e-17	0.33	0.28	Cerebrospinal fluid biomarker levels;	chr7:23150875	chr7:23206013~23208045:+
BRCA	cis	rs1075265	0.692	rs805361	ENSG00000233266.1	HMGB1P31	9.42	2.73e-20	1.34e-17	0.34	0.28	Chronotype;Morning vs. evening chronotype;	chr2:53938709	chr2:54051334~54051760:+
BRCA	cis	rs6565180	0.963	rs4787642	ENSG00000273724.1	RP11-347C12.12	-9.42	2.74e-20	1.35e-17	-0.33	-0.28	Tonsillectomy;	chr16:30348087	chr16:30336400~30343336:+
BRCA	cis	rs2412819	0.559	rs8040336	ENSG00000205771.5	CATSPER2P1	-9.42	2.74e-20	1.35e-17	-0.33	-0.28	Lung cancer;	chr15:43761419	chr15:43726918~43747094:-
BRCA	cis	rs58873874	0.737	rs11749762	ENSG00000251405.2	CTB-109A12.1	9.42	2.74e-20	1.35e-17	0.67	0.28	Bipolar disorder (body mass index interaction);	chr5:157474607	chr5:157362615~157460078:-
BRCA	cis	rs858239	0.899	rs10262243	ENSG00000226816.2	AC005082.12	9.42	2.78e-20	1.36e-17	0.33	0.28	Cerebrospinal fluid biomarker levels;	chr7:23251368	chr7:23206013~23208045:+
BRCA	cis	rs10129255	0.518	rs7143784	ENSG00000211972.2	IGHV3-66	9.42	2.8e-20	1.38e-17	0.19	0.28	Kawasaki disease;	chr14:106687277	chr14:106675017~106675544:-
BRCA	cis	rs950169	0.58	rs17598114	ENSG00000225151.9	GOLGA2P7	-9.42	2.82e-20	1.38e-17	-0.36	-0.28	Schizophrenia;	chr15:84628086	chr15:84199311~84230136:-
BRCA	cis	rs875971	0.638	rs7793569	ENSG00000222364.1	RNU6-96P	9.42	2.82e-20	1.38e-17	0.32	0.28	Aortic root size;	chr7:66651646	chr7:66395191~66395286:+
BRCA	cis	rs801193	1	rs3857688	ENSG00000222364.1	RNU6-96P	9.42	2.82e-20	1.38e-17	0.32	0.28	Aortic root size;	chr7:66662819	chr7:66395191~66395286:+
BRCA	cis	rs801193	1	rs2286684	ENSG00000222364.1	RNU6-96P	9.42	2.82e-20	1.38e-17	0.32	0.28	Aortic root size;	chr7:66664843	chr7:66395191~66395286:+
BRCA	cis	rs801193	0.935	rs2286683	ENSG00000222364.1	RNU6-96P	9.42	2.82e-20	1.38e-17	0.32	0.28	Aortic root size;	chr7:66664856	chr7:66395191~66395286:+
BRCA	cis	rs801193	1	rs10274773	ENSG00000222364.1	RNU6-96P	9.42	2.82e-20	1.38e-17	0.32	0.28	Aortic root size;	chr7:66668591	chr7:66395191~66395286:+
BRCA	cis	rs1823913	0.66	rs1454752	ENSG00000227542.1	AC092614.2	-9.42	2.83e-20	1.39e-17	-0.34	-0.28	Obesity-related traits;	chr2:191298668	chr2:191229165~191246172:-
BRCA	cis	rs4835473	0.868	rs62337291	ENSG00000251600.4	RP11-673E1.1	-9.42	2.83e-20	1.39e-17	-0.32	-0.28	Immature fraction of reticulocytes;	chr4:143807903	chr4:143912331~143982454:+
BRCA	cis	rs10262624	0.935	rs4722283	ENSG00000234286.1	AC006026.13	9.42	2.84e-20	1.39e-17	0.32	0.28	Schizophrenia;	chr7:23866595	chr7:23680195~23680786:-
BRCA	cis	rs2274273	0.87	rs66696758	ENSG00000258413.1	RP11-665C16.6	-9.42	2.86e-20	1.4e-17	-0.35	-0.28	Protein biomarker;	chr14:55299791	chr14:55262767~55272075:-
BRCA	cis	rs2274273	0.87	rs7153645	ENSG00000258413.1	RP11-665C16.6	-9.42	2.86e-20	1.4e-17	-0.35	-0.28	Protein biomarker;	chr14:55304800	chr14:55262767~55272075:-
BRCA	cis	rs2274273	0.901	rs7147136	ENSG00000258413.1	RP11-665C16.6	-9.42	2.86e-20	1.4e-17	-0.35	-0.28	Protein biomarker;	chr14:55359970	chr14:55262767~55272075:-
BRCA	cis	rs4820294	0.669	rs9622677	ENSG00000233360.4	Z83844.1	9.42	2.87e-20	1.41e-17	0.32	0.28	Fat distribution (HIV);	chr22:37658255	chr22:37641832~37658377:-
BRCA	cis	rs875971	0.638	rs35986979	ENSG00000222364.1	RNU6-96P	9.42	2.87e-20	1.41e-17	0.32	0.28	Aortic root size;	chr7:66624003	chr7:66395191~66395286:+
BRCA	cis	rs4853012	0.941	rs60291089	ENSG00000257800.1	FNBP1P1	9.42	2.88e-20	1.41e-17	0.28	0.28	Gestational age at birth (maternal effect);	chr2:74117763	chr2:74120680~74123218:+
BRCA	cis	rs4853012	0.838	rs58759652	ENSG00000257800.1	FNBP1P1	9.42	2.88e-20	1.41e-17	0.28	0.28	Gestational age at birth (maternal effect);	chr2:74117775	chr2:74120680~74123218:+
BRCA	cis	rs957448	1	rs1055797	ENSG00000253704.1	RP11-267M23.4	9.42	2.88e-20	1.41e-17	0.33	0.28	Nonsyndromic cleft lip with cleft palate;	chr8:94511005	chr8:94553722~94569745:+
BRCA	cis	rs13392177	0.647	rs6718220	ENSG00000261338.2	RP11-378A13.1	-9.42	2.88e-20	1.41e-17	-0.29	-0.28	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218201795	chr2:218255319~218257366:+
BRCA	cis	rs2276314	0.857	rs59649576	ENSG00000278986.1	RP11-723J4.3	-9.42	2.89e-20	1.42e-17	-0.35	-0.28	Endometriosis;Drug-induced torsades de pointes;	chr18:36036112	chr18:35972151~35973916:+
BRCA	cis	rs11159086	0.793	rs11621693	ENSG00000259005.1	RP3-449M8.6	9.42	2.93e-20	1.44e-17	0.42	0.28	Advanced glycation end-product levels;	chr14:74472631	chr14:74474007~74474864:-
BRCA	cis	rs4853012	0.887	rs77148265	ENSG00000257800.1	FNBP1P1	9.41	2.94e-20	1.44e-17	0.3	0.28	Gestational age at birth (maternal effect);	chr2:74112392	chr2:74120680~74123218:+
BRCA	cis	rs801193	1	rs7785213	ENSG00000222364.1	RNU6-96P	9.41	2.94e-20	1.44e-17	0.32	0.28	Aortic root size;	chr7:66673991	chr7:66395191~66395286:+
BRCA	cis	rs228614	0.51	rs65671	ENSG00000246560.2	RP11-10L12.4	9.41	2.95e-20	1.44e-17	0.29	0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102801081	chr4:102828055~102844075:+
BRCA	cis	rs2067615	0.579	rs1073261	ENSG00000260329.1	RP11-412D9.4	-9.41	2.95e-20	1.45e-17	-0.3	-0.28	Heart rate;	chr12:106742164	chr12:106954029~106955497:-
BRCA	cis	rs801193	1	rs2003301	ENSG00000222364.1	RNU6-96P	9.41	2.97e-20	1.46e-17	0.32	0.28	Aortic root size;	chr7:66682669	chr7:66395191~66395286:+
BRCA	cis	rs858239	0.6	rs10256524	ENSG00000226816.2	AC005082.12	9.41	2.97e-20	1.46e-17	0.32	0.28	Cerebrospinal fluid biomarker levels;	chr7:23105328	chr7:23206013~23208045:+
BRCA	cis	rs1113500	0.933	rs11185259	ENSG00000226822.1	RP11-356N1.2	-9.41	2.98e-20	1.46e-17	-0.37	-0.28	Growth-regulated protein alpha levels;	chr1:108092440	chr1:108071482~108074519:+
BRCA	cis	rs2439831	0.85	rs12441127	ENSG00000275601.1	AC011330.13	-9.41	2.99e-20	1.46e-17	-0.46	-0.28	Lung cancer in ever smokers;	chr15:43728977	chr15:43642389~43643023:-
BRCA	cis	rs465969	1	rs17090837	ENSG00000255389.1	C6orf3	-9.41	3e-20	1.47e-17	-0.57	-0.28	Psoriasis;	chr6:111430650	chr6:111599875~111602295:+
BRCA	cis	rs465969	1	rs35208445	ENSG00000255389.1	C6orf3	-9.41	3e-20	1.47e-17	-0.57	-0.28	Psoriasis;	chr6:111434944	chr6:111599875~111602295:+
BRCA	cis	rs465969	1	rs35248830	ENSG00000255389.1	C6orf3	-9.41	3e-20	1.47e-17	-0.57	-0.28	Psoriasis;	chr6:111435547	chr6:111599875~111602295:+
BRCA	cis	rs465969	1	rs35151650	ENSG00000255389.1	C6orf3	-9.41	3e-20	1.47e-17	-0.57	-0.28	Psoriasis;	chr6:111436524	chr6:111599875~111602295:+
BRCA	cis	rs465969	0.744	rs34089926	ENSG00000255389.1	C6orf3	-9.41	3e-20	1.47e-17	-0.57	-0.28	Psoriasis;	chr6:111439043	chr6:111599875~111602295:+
BRCA	cis	rs465969	1	rs4580915	ENSG00000255389.1	C6orf3	-9.41	3e-20	1.47e-17	-0.57	-0.28	Psoriasis;	chr6:111439561	chr6:111599875~111602295:+
BRCA	cis	rs227275	0.525	rs7660298	ENSG00000246560.2	RP11-10L12.4	9.41	3e-20	1.47e-17	0.3	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:103039611	chr4:102828055~102844075:+
BRCA	cis	rs7811142	0.775	rs1059129	ENSG00000242294.5	STAG3L5P	9.41	3.01e-20	1.47e-17	0.27	0.28	Platelet count;	chr7:100328899	chr7:100336079~100351900:+
BRCA	cis	rs881375	0.692	rs2072438	ENSG00000226752.6	PSMD5-AS1	-9.41	3.03e-20	1.48e-17	-0.33	-0.28	Rheumatoid arthritis;	chr9:120889023	chr9:120824828~120854385:+
BRCA	cis	rs6545883	0.525	rs2049747	ENSG00000271889.1	RP11-493E12.1	-9.41	3.03e-20	1.48e-17	-0.35	-0.28	Tuberculosis;	chr2:61137019	chr2:61151433~61162105:-
BRCA	cis	rs2067615	0.579	rs10778510	ENSG00000260329.1	RP11-412D9.4	9.41	3.05e-20	1.49e-17	0.3	0.28	Heart rate;	chr12:106769187	chr12:106954029~106955497:-
BRCA	cis	rs7044106	0.708	rs1324472	ENSG00000226752.6	PSMD5-AS1	-9.41	3.07e-20	1.5e-17	-0.34	-0.28	Hip circumference adjusted for BMI;	chr9:120612832	chr9:120824828~120854385:+
BRCA	cis	rs10129255	0.5	rs1024350	ENSG00000211972.2	IGHV3-66	9.41	3.09e-20	1.51e-17	0.19	0.28	Kawasaki disease;	chr14:106685105	chr14:106675017~106675544:-
BRCA	cis	rs2921036	0.529	rs2979192	ENSG00000253893.2	FAM85B	-9.41	3.1e-20	1.52e-17	-0.37	-0.28	Neuroticism;	chr8:8480637	chr8:8167819~8226614:-
BRCA	cis	rs6538678	0.864	rs4762249	ENSG00000258343.1	RP11-536G4.2	9.41	3.1e-20	1.52e-17	0.38	0.28	Lupus nephritis in systemic lupus erythematosus;	chr12:95884183	chr12:95795345~95858839:-
BRCA	cis	rs7429990	0.965	rs777015	ENSG00000229759.1	MRPS18AP1	9.41	3.1e-20	1.52e-17	0.32	0.28	Educational attainment (years of education);	chr3:47895582	chr3:48256350~48256938:-
BRCA	cis	rs858239	0.6	rs28646184	ENSG00000226816.2	AC005082.12	9.41	3.12e-20	1.52e-17	0.32	0.28	Cerebrospinal fluid biomarker levels;	chr7:23099976	chr7:23206013~23208045:+
BRCA	cis	rs11098499	0.863	rs1155576	ENSG00000245958.5	RP11-33B1.1	-9.41	3.12e-20	1.52e-17	-0.27	-0.28	Corneal astigmatism;	chr4:119529004	chr4:119454791~119552025:+
BRCA	cis	rs812925	0.502	rs778150	ENSG00000271889.1	RP11-493E12.1	-9.41	3.12e-20	1.53e-17	-0.34	-0.28	Immature fraction of reticulocytes;	chr2:61381237	chr2:61151433~61162105:-
BRCA	cis	rs7429990	0.965	rs1550914	ENSG00000229759.1	MRPS18AP1	9.41	3.12e-20	1.53e-17	0.31	0.28	Educational attainment (years of education);	chr3:47953678	chr3:48256350~48256938:-
BRCA	cis	rs853679	0.567	rs13209596	ENSG00000216901.1	AL022393.7	9.41	3.12e-20	1.53e-17	0.4	0.28	Depression;	chr6:28428413	chr6:28176188~28176674:+
BRCA	cis	rs2882667	0.537	rs7704790	ENSG00000253404.1	AC034243.1	9.41	3.12e-20	1.53e-17	0.35	0.28	Age-related hearing impairment (SNP x SNP interaction);	chr5:139074407	chr5:138744434~138753309:-
BRCA	cis	rs4660456	0.913	rs12743517	ENSG00000237899.1	RP4-739H11.3	9.41	3.13e-20	1.53e-17	0.4	0.28	Platelet count;	chr1:40759682	chr1:40669089~40687588:-
BRCA	cis	rs801193	0.844	rs732465	ENSG00000222364.1	RNU6-96P	-9.41	3.15e-20	1.54e-17	-0.32	-0.28	Aortic root size;	chr7:66533463	chr7:66395191~66395286:+
BRCA	cis	rs11098499	0.754	rs1980027	ENSG00000248280.1	RP11-33B1.2	9.41	3.16e-20	1.54e-17	0.28	0.28	Corneal astigmatism;	chr4:119330422	chr4:119440561~119450157:-
BRCA	cis	rs7429990	0.864	rs6442081	ENSG00000229759.1	MRPS18AP1	-9.41	3.16e-20	1.54e-17	-0.31	-0.28	Educational attainment (years of education);	chr3:47728890	chr3:48256350~48256938:-
BRCA	cis	rs80285556	0.655	rs17311832	ENSG00000161643.11	SIGLEC16	9.41	3.16e-20	1.55e-17	0.77	0.28	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50022059	chr19:49969673~49975814:+
BRCA	cis	rs80285556	1	rs80314222	ENSG00000161643.11	SIGLEC16	9.41	3.16e-20	1.55e-17	0.77	0.28	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50022257	chr19:49969673~49975814:+
BRCA	cis	rs7429990	0.965	rs319682	ENSG00000229759.1	MRPS18AP1	9.41	3.16e-20	1.55e-17	0.32	0.28	Educational attainment (years of education);	chr3:47873628	chr3:48256350~48256938:-
BRCA	cis	rs321358	0.731	rs1517578	ENSG00000271584.1	RP11-89C3.4	9.41	3.17e-20	1.55e-17	0.45	0.28	Body mass index;	chr11:111150750	chr11:111091932~111097357:-
BRCA	cis	rs2274273	0.934	rs10140869	ENSG00000258413.1	RP11-665C16.6	-9.41	3.17e-20	1.55e-17	-0.35	-0.28	Protein biomarker;	chr14:55328565	chr14:55262767~55272075:-
BRCA	cis	rs13256369	0.802	rs11249887	ENSG00000253893.2	FAM85B	-9.41	3.17e-20	1.55e-17	-0.39	-0.28	Obesity-related traits;	chr8:8704674	chr8:8167819~8226614:-
BRCA	cis	rs875971	0.893	rs62465470	ENSG00000237310.1	GS1-124K5.4	-9.41	3.17e-20	1.55e-17	-0.29	-0.28	Aortic root size;	chr7:66136231	chr7:66493706~66495474:+
BRCA	cis	rs11159086	0.793	rs1029701	ENSG00000259005.1	RP3-449M8.6	9.41	3.19e-20	1.56e-17	0.41	0.28	Advanced glycation end-product levels;	chr14:74474112	chr14:74474007~74474864:-
BRCA	cis	rs7945705	0.902	rs10769980	ENSG00000254860.4	TMEM9B-AS1	-9.41	3.19e-20	1.56e-17	-0.27	-0.28	Hemoglobin concentration;	chr11:8992633	chr11:8964675~8977527:+
BRCA	cis	rs858239	0.539	rs2390757	ENSG00000226816.2	AC005082.12	9.41	3.2e-20	1.56e-17	0.33	0.28	Cerebrospinal fluid biomarker levels;	chr7:23151873	chr7:23206013~23208045:+
BRCA	cis	rs7772486	0.597	rs6570732	ENSG00000235652.6	RP11-545I5.3	-9.4	3.24e-20	1.58e-17	-0.3	-0.28	Lobe attachment (rater-scored or self-reported);	chr6:145924015	chr6:145799409~145886585:+
BRCA	cis	rs7829975	0.659	rs4382480	ENSG00000253893.2	FAM85B	-9.4	3.25e-20	1.59e-17	-0.35	-0.28	Mood instability;	chr8:8863963	chr8:8167819~8226614:-
BRCA	cis	rs9287719	0.967	rs10929688	ENSG00000234818.1	AC092687.5	9.4	3.27e-20	1.6e-17	0.33	0.28	Prostate cancer;	chr2:10616524	chr2:10589166~10604830:+
BRCA	cis	rs875971	0.66	rs801193	ENSG00000222364.1	RNU6-96P	9.4	3.27e-20	1.6e-17	0.32	0.28	Aortic root size;	chr7:66565625	chr7:66395191~66395286:+
BRCA	cis	rs7772486	0.686	rs9403746	ENSG00000235652.6	RP11-545I5.3	-9.4	3.28e-20	1.6e-17	-0.28	-0.28	Lobe attachment (rater-scored or self-reported);	chr6:145782632	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.79	rs2253764	ENSG00000235652.6	RP11-545I5.3	9.4	3.29e-20	1.61e-17	0.27	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145878745	chr6:145799409~145886585:+
BRCA	cis	rs875971	0.54	rs736270	ENSG00000224316.1	RP11-479O9.2	9.4	3.29e-20	1.61e-17	0.28	0.28	Aortic root size;	chr7:65963835	chr7:65773620~65802067:+
BRCA	cis	rs227275	0.556	rs11731885	ENSG00000246560.2	RP11-10L12.4	9.4	3.29e-20	1.61e-17	0.3	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:103010913	chr4:102828055~102844075:+
BRCA	cis	rs1113500	0.862	rs2336128	ENSG00000226822.1	RP11-356N1.2	9.4	3.3e-20	1.61e-17	0.37	0.28	Growth-regulated protein alpha levels;	chr1:108098117	chr1:108071482~108074519:+
BRCA	cis	rs2404602	1	rs2404741	ENSG00000259422.1	RP11-593F23.1	9.4	3.33e-20	1.62e-17	0.35	0.28	Blood metabolite levels;	chr15:76559394	chr15:76174891~76181486:-
BRCA	cis	rs2404602	1	rs2404740	ENSG00000259422.1	RP11-593F23.1	9.4	3.33e-20	1.62e-17	0.35	0.28	Blood metabolite levels;	chr15:76559802	chr15:76174891~76181486:-
BRCA	cis	rs3096299	0.933	rs28608022	ENSG00000274627.1	RP11-104N10.2	9.4	3.34e-20	1.63e-17	0.29	0.28	Multiple myeloma (IgH translocation);	chr16:89387884	chr16:89516797~89522217:+
BRCA	cis	rs4835473	0.9	rs4835303	ENSG00000251600.4	RP11-673E1.1	-9.4	3.35e-20	1.63e-17	-0.32	-0.28	Immature fraction of reticulocytes;	chr4:143821533	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs4835034	ENSG00000251600.4	RP11-673E1.1	-9.4	3.35e-20	1.63e-17	-0.32	-0.28	Immature fraction of reticulocytes;	chr4:143821538	chr4:143912331~143982454:+
BRCA	cis	rs801193	1	rs2420824	ENSG00000222364.1	RNU6-96P	9.4	3.36e-20	1.64e-17	0.32	0.28	Aortic root size;	chr7:66666129	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.545	rs1909508	ENSG00000237310.1	GS1-124K5.4	9.4	3.36e-20	1.64e-17	0.33	0.28	Aortic root size;	chr7:66301366	chr7:66493706~66495474:+
BRCA	cis	rs17711722	0.727	rs35850374	ENSG00000224316.1	RP11-479O9.2	9.4	3.36e-20	1.64e-17	0.28	0.28	Calcium levels;	chr7:65892789	chr7:65773620~65802067:+
BRCA	cis	rs2274273	0.84	rs72715769	ENSG00000258413.1	RP11-665C16.6	-9.4	3.4e-20	1.66e-17	-0.35	-0.28	Protein biomarker;	chr14:55295711	chr14:55262767~55272075:-
BRCA	cis	rs13392177	0.684	rs11695527	ENSG00000261338.2	RP11-378A13.1	9.4	3.42e-20	1.67e-17	0.29	0.28	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218203380	chr2:218255319~218257366:+
BRCA	cis	rs9847710	0.696	rs2564932	ENSG00000242142.1	SERBP1P3	-9.4	3.44e-20	1.67e-17	-0.34	-0.28	Ulcerative colitis;	chr3:52987994	chr3:53064283~53065091:-
BRCA	cis	rs875971	0.522	rs34973832	ENSG00000224316.1	RP11-479O9.2	9.4	3.44e-20	1.67e-17	0.28	0.28	Aortic root size;	chr7:65931217	chr7:65773620~65802067:+
BRCA	cis	rs1134634	0.52	rs4698408	ENSG00000273133.1	RP11-799M12.2	-9.4	3.45e-20	1.68e-17	-0.36	-0.28	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15657425	chr4:15563698~15564253:-
BRCA	cis	rs7829975	0.658	rs907181	ENSG00000253893.2	FAM85B	-9.4	3.46e-20	1.69e-17	-0.34	-0.28	Mood instability;	chr8:8845365	chr8:8167819~8226614:-
BRCA	cis	rs2067615	0.524	rs1882543	ENSG00000260329.1	RP11-412D9.4	9.4	3.47e-20	1.69e-17	0.31	0.28	Heart rate;	chr12:106673382	chr12:106954029~106955497:-
BRCA	cis	rs1113500	0.933	rs10785834	ENSG00000226822.1	RP11-356N1.2	9.4	3.47e-20	1.69e-17	0.37	0.28	Growth-regulated protein alpha levels;	chr1:108096479	chr1:108071482~108074519:+
BRCA	cis	rs4835473	0.932	rs4835305	ENSG00000251600.4	RP11-673E1.1	-9.4	3.47e-20	1.69e-17	-0.32	-0.28	Immature fraction of reticulocytes;	chr4:143823646	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs11721700	ENSG00000251600.4	RP11-673E1.1	-9.4	3.47e-20	1.69e-17	-0.32	-0.28	Immature fraction of reticulocytes;	chr4:143824264	chr4:143912331~143982454:+
BRCA	cis	rs227275	0.554	rs223333	ENSG00000246560.2	RP11-10L12.4	9.4	3.48e-20	1.7e-17	0.29	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102868653	chr4:102828055~102844075:+
BRCA	cis	rs10262624	0.935	rs8180700	ENSG00000234286.1	AC006026.13	-9.4	3.49e-20	1.7e-17	-0.32	-0.28	Schizophrenia;	chr7:23870323	chr7:23680195~23680786:-
BRCA	cis	rs11722779	0.844	rs7694724	ENSG00000246560.2	RP11-10L12.4	9.4	3.49e-20	1.7e-17	0.3	0.28	Schizophrenia;	chr4:103041375	chr4:102828055~102844075:+
BRCA	cis	rs4853012	0.838	rs6707729	ENSG00000257800.1	FNBP1P1	9.4	3.49e-20	1.7e-17	0.28	0.28	Gestational age at birth (maternal effect);	chr2:74117558	chr2:74120680~74123218:+
BRCA	cis	rs957448	1	rs72674843	ENSG00000253704.1	RP11-267M23.4	9.4	3.49e-20	1.7e-17	0.34	0.28	Nonsyndromic cleft lip with cleft palate;	chr8:94520772	chr8:94553722~94569745:+
BRCA	cis	rs875971	0.505	rs1167385	ENSG00000224316.1	RP11-479O9.2	-9.39	3.52e-20	1.71e-17	-0.28	-0.28	Aortic root size;	chr7:66048321	chr7:65773620~65802067:+
BRCA	cis	rs7250849	0.565	rs7255319	ENSG00000273837.1	LLNLR-470E3.1	9.39	3.52e-20	1.72e-17	0.37	0.28	Blood protein levels;	chr19:51664653	chr19:51639478~51639931:-
BRCA	cis	rs801193	1	rs1553610	ENSG00000222364.1	RNU6-96P	-9.39	3.54e-20	1.72e-17	-0.32	-0.28	Aortic root size;	chr7:66732246	chr7:66395191~66395286:+
BRCA	cis	rs801193	1	rs2707845	ENSG00000222364.1	RNU6-96P	-9.39	3.54e-20	1.72e-17	-0.32	-0.28	Aortic root size;	chr7:66733811	chr7:66395191~66395286:+
BRCA	cis	rs801193	1	rs2707850	ENSG00000222364.1	RNU6-96P	-9.39	3.54e-20	1.72e-17	-0.32	-0.28	Aortic root size;	chr7:66738883	chr7:66395191~66395286:+
BRCA	cis	rs801193	0.967	rs1110414	ENSG00000222364.1	RNU6-96P	-9.39	3.54e-20	1.72e-17	-0.32	-0.28	Aortic root size;	chr7:66740595	chr7:66395191~66395286:+
BRCA	cis	rs801193	1	rs7783924	ENSG00000222364.1	RNU6-96P	-9.39	3.54e-20	1.72e-17	-0.32	-0.28	Aortic root size;	chr7:66744070	chr7:66395191~66395286:+
BRCA	cis	rs801193	1	rs7789184	ENSG00000222364.1	RNU6-96P	-9.39	3.54e-20	1.72e-17	-0.32	-0.28	Aortic root size;	chr7:66745208	chr7:66395191~66395286:+
BRCA	cis	rs801193	1	rs2707854	ENSG00000222364.1	RNU6-96P	-9.39	3.54e-20	1.72e-17	-0.32	-0.28	Aortic root size;	chr7:66747610	chr7:66395191~66395286:+
BRCA	cis	rs8062405	0.54	rs480400	ENSG00000278665.1	RP11-666O2.4	9.39	3.54e-20	1.72e-17	0.28	0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28563294	chr16:28599241~28601881:-
BRCA	cis	rs2276314	0.857	rs28396546	ENSG00000278986.1	RP11-723J4.3	-9.39	3.54e-20	1.72e-17	-0.36	-0.28	Endometriosis;Drug-induced torsades de pointes;	chr18:36059061	chr18:35972151~35973916:+
BRCA	cis	rs8062405	1	rs55991577	ENSG00000278665.1	RP11-666O2.4	9.39	3.54e-20	1.72e-17	0.3	0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28831704	chr16:28599241~28601881:-
BRCA	cis	rs8062405	1	rs56358680	ENSG00000278665.1	RP11-666O2.4	9.39	3.54e-20	1.72e-17	0.3	0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28831797	chr16:28599241~28601881:-
BRCA	cis	rs9368481	0.761	rs9357030	ENSG00000241549.7	GUSBP2	-9.39	3.54e-20	1.72e-17	-0.32	-0.28	Autism spectrum disorder or schizophrenia;	chr6:27017247	chr6:26871484~26956554:-
BRCA	cis	rs7429990	0.965	rs4858880	ENSG00000229759.1	MRPS18AP1	-9.39	3.55e-20	1.73e-17	-0.32	-0.28	Educational attainment (years of education);	chr3:48062959	chr3:48256350~48256938:-
BRCA	cis	rs453301	0.658	rs3855900	ENSG00000253893.2	FAM85B	9.39	3.57e-20	1.73e-17	0.35	0.28	Joint mobility (Beighton score);	chr8:9044411	chr8:8167819~8226614:-
BRCA	cis	rs4835473	0.932	rs2323190	ENSG00000251600.4	RP11-673E1.1	-9.39	3.59e-20	1.74e-17	-0.32	-0.28	Immature fraction of reticulocytes;	chr4:143744282	chr4:143912331~143982454:+
BRCA	cis	rs7429990	0.93	rs11130152	ENSG00000229759.1	MRPS18AP1	-9.39	3.59e-20	1.74e-17	-0.32	-0.28	Educational attainment (years of education);	chr3:48014919	chr3:48256350~48256938:-
BRCA	cis	rs228614	0.51	rs223328	ENSG00000246560.2	RP11-10L12.4	9.39	3.6e-20	1.75e-17	0.29	0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102873379	chr4:102828055~102844075:+
BRCA	cis	rs228614	0.536	rs223325	ENSG00000246560.2	RP11-10L12.4	9.39	3.6e-20	1.75e-17	0.29	0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102875751	chr4:102828055~102844075:+
BRCA	cis	rs1075265	0.584	rs10164409	ENSG00000233266.1	HMGB1P31	9.39	3.61e-20	1.75e-17	0.34	0.28	Chronotype;Morning vs. evening chronotype;	chr2:53940867	chr2:54051334~54051760:+
BRCA	cis	rs875971	0.545	rs73376394	ENSG00000237310.1	GS1-124K5.4	9.39	3.62e-20	1.76e-17	0.33	0.28	Aortic root size;	chr7:66172694	chr7:66493706~66495474:+
BRCA	cis	rs11098499	0.754	rs10213554	ENSG00000248280.1	RP11-33B1.2	-9.39	3.62e-20	1.76e-17	-0.28	-0.28	Corneal astigmatism;	chr4:119339630	chr4:119440561~119450157:-
BRCA	cis	rs7429990	0.965	rs2631721	ENSG00000229759.1	MRPS18AP1	9.39	3.66e-20	1.78e-17	0.32	0.28	Educational attainment (years of education);	chr3:47881807	chr3:48256350~48256938:-
BRCA	cis	rs673078	0.607	rs16948230	ENSG00000275759.1	RP11-131L12.3	-9.39	3.66e-20	1.78e-17	-0.43	-0.28	Glucose homeostasis traits;	chr12:118277086	chr12:118428281~118428870:+
BRCA	cis	rs227275	0.554	rs223359	ENSG00000246560.2	RP11-10L12.4	9.39	3.67e-20	1.78e-17	0.29	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102849422	chr4:102828055~102844075:+
BRCA	cis	rs12468226	0.935	rs75597391	ENSG00000273456.1	RP11-686O6.2	9.39	3.67e-20	1.79e-17	0.42	0.28	Urate levels;	chr2:202398850	chr2:202374932~202375604:-
BRCA	cis	rs35160687	0.712	rs11681689	ENSG00000273080.1	RP11-301O19.1	-9.39	3.68e-20	1.79e-17	-0.32	-0.28	Night sleep phenotypes;	chr2:86256039	chr2:86195590~86196049:+
BRCA	cis	rs35160687	0.688	rs12466728	ENSG00000273080.1	RP11-301O19.1	-9.39	3.68e-20	1.79e-17	-0.32	-0.28	Night sleep phenotypes;	chr2:86256976	chr2:86195590~86196049:+
BRCA	cis	rs35160687	0.666	rs36104799	ENSG00000273080.1	RP11-301O19.1	-9.39	3.68e-20	1.79e-17	-0.32	-0.28	Night sleep phenotypes;	chr2:86257000	chr2:86195590~86196049:+
BRCA	cis	rs35160687	0.666	rs7583074	ENSG00000273080.1	RP11-301O19.1	-9.39	3.68e-20	1.79e-17	-0.32	-0.28	Night sleep phenotypes;	chr2:86257069	chr2:86195590~86196049:+
BRCA	cis	rs11096990	0.634	rs7564	ENSG00000249207.1	RP11-360F5.1	9.39	3.71e-20	1.8e-17	0.32	0.28	Cognitive function;	chr4:39285702	chr4:39112677~39126818:-
BRCA	cis	rs4835473	0.932	rs62339580	ENSG00000251600.4	RP11-673E1.1	-9.39	3.71e-20	1.8e-17	-0.32	-0.28	Immature fraction of reticulocytes;	chr4:143785090	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs62339581	ENSG00000251600.4	RP11-673E1.1	-9.39	3.71e-20	1.8e-17	-0.32	-0.28	Immature fraction of reticulocytes;	chr4:143785172	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs7666368	ENSG00000251600.4	RP11-673E1.1	-9.39	3.71e-20	1.8e-17	-0.32	-0.28	Immature fraction of reticulocytes;	chr4:143785372	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs7690428	ENSG00000251600.4	RP11-673E1.1	-9.39	3.71e-20	1.8e-17	-0.32	-0.28	Immature fraction of reticulocytes;	chr4:143785400	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs34781605	ENSG00000251600.4	RP11-673E1.1	-9.39	3.71e-20	1.8e-17	-0.32	-0.28	Immature fraction of reticulocytes;	chr4:143785486	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.9	rs11100810	ENSG00000251600.4	RP11-673E1.1	-9.39	3.71e-20	1.8e-17	-0.32	-0.28	Immature fraction of reticulocytes;	chr4:143787518	chr4:143912331~143982454:+
BRCA	cis	rs7772486	0.79	rs2253880	ENSG00000235652.6	RP11-545I5.3	9.39	3.73e-20	1.81e-17	0.27	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145879638	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.79	rs2814879	ENSG00000235652.6	RP11-545I5.3	9.39	3.73e-20	1.81e-17	0.27	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145880607	chr6:145799409~145886585:+
BRCA	cis	rs875971	0.638	rs6960778	ENSG00000222364.1	RNU6-96P	9.39	3.73e-20	1.81e-17	0.32	0.28	Aortic root size;	chr7:66606610	chr7:66395191~66395286:+
BRCA	cis	rs9640161	0.75	rs3800780	ENSG00000261305.1	RP4-584D14.7	9.39	3.74e-20	1.82e-17	0.42	0.28	Blood protein levels;Circulating chemerin levels;	chr7:150330195	chr7:150341771~150342607:+
BRCA	cis	rs1062177	1	rs2964584	ENSG00000253921.1	CTB-113P19.3	-9.39	3.76e-20	1.82e-17	-0.38	-0.28	Preschool internalizing problems;	chr5:151763317	chr5:151753992~151767247:+
BRCA	cis	rs2276314	0.857	rs62101376	ENSG00000278986.1	RP11-723J4.3	-9.39	3.77e-20	1.83e-17	-0.36	-0.28	Endometriosis;Drug-induced torsades de pointes;	chr18:36002992	chr18:35972151~35973916:+
BRCA	cis	rs6750795	0.569	rs1667313	ENSG00000181798.2	LINC00471	-9.39	3.79e-20	1.84e-17	-0.33	-0.28	Height;	chr2:231543307	chr2:231508426~231514339:-
BRCA	cis	rs113835537	0.529	rs17147644	ENSG00000255517.5	CTD-3074O7.5	-9.39	3.82e-20	1.85e-17	-0.37	-0.28	Airway imaging phenotypes;	chr11:66489189	chr11:66473490~66480233:-
BRCA	cis	rs858239	0.6	rs1115941	ENSG00000226816.2	AC005082.12	9.38	3.82e-20	1.86e-17	0.32	0.28	Cerebrospinal fluid biomarker levels;	chr7:23097569	chr7:23206013~23208045:+
BRCA	cis	rs4835473	0.778	rs6856553	ENSG00000251600.4	RP11-673E1.1	-9.38	3.83e-20	1.86e-17	-0.32	-0.28	Immature fraction of reticulocytes;	chr4:143825973	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.868	rs11737787	ENSG00000251600.4	RP11-673E1.1	-9.38	3.83e-20	1.86e-17	-0.32	-0.28	Immature fraction of reticulocytes;	chr4:143826498	chr4:143912331~143982454:+
BRCA	cis	rs11098499	0.955	rs1511015	ENSG00000245958.5	RP11-33B1.1	-9.38	3.86e-20	1.87e-17	-0.27	-0.28	Corneal astigmatism;	chr4:119249318	chr4:119454791~119552025:+
BRCA	cis	rs4835473	0.808	rs13134564	ENSG00000251600.4	RP11-673E1.1	-9.38	3.86e-20	1.87e-17	-0.32	-0.28	Immature fraction of reticulocytes;	chr4:143738763	chr4:143912331~143982454:+
BRCA	cis	rs748404	0.589	rs3862138	ENSG00000249839.1	AC011330.5	-9.38	3.86e-20	1.87e-17	-0.4	-0.28	Lung cancer;	chr15:43523801	chr15:43663654~43684339:-
BRCA	cis	rs7712401	0.601	rs2126935	ENSG00000263432.2	RN7SL689P	-9.38	3.87e-20	1.88e-17	-0.35	-0.28	Mean platelet volume;	chr5:122977876	chr5:123022487~123022783:-
BRCA	cis	rs7580658	0.545	rs59318157	ENSG00000236682.1	AC068282.3	-9.38	3.89e-20	1.89e-17	-0.36	-0.28	Protein C levels;	chr2:127192498	chr2:127389130~127400580:+
BRCA	cis	rs801193	0.935	rs2659916	ENSG00000222364.1	RNU6-96P	-9.38	3.89e-20	1.89e-17	-0.32	-0.28	Aortic root size;	chr7:66686365	chr7:66395191~66395286:+
BRCA	cis	rs9287719	0.967	rs6727768	ENSG00000234818.1	AC092687.5	9.38	3.91e-20	1.89e-17	0.32	0.28	Prostate cancer;	chr2:10617353	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs10167129	ENSG00000234818.1	AC092687.5	9.38	3.91e-20	1.89e-17	0.32	0.28	Prostate cancer;	chr2:10618449	chr2:10589166~10604830:+
BRCA	cis	rs6844153	0.752	rs73811400	ENSG00000240005.4	RP11-293A21.1	-9.38	3.91e-20	1.9e-17	-0.36	-0.28	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26887701	chr4:26859806~26860599:-
BRCA	cis	rs9287719	0.967	rs6432126	ENSG00000234818.1	AC092687.5	9.38	3.97e-20	1.92e-17	0.32	0.28	Prostate cancer;	chr2:10616975	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.904	rs55738250	ENSG00000234818.1	AC092687.5	9.38	3.97e-20	1.92e-17	0.32	0.28	Prostate cancer;	chr2:10617006	chr2:10589166~10604830:+
BRCA	cis	rs1075265	0.87	rs17268179	ENSG00000233266.1	HMGB1P31	9.38	3.97e-20	1.92e-17	0.33	0.28	Chronotype;Morning vs. evening chronotype;	chr2:54036876	chr2:54051334~54051760:+
BRCA	cis	rs6570726	0.791	rs1935612	ENSG00000235652.6	RP11-545I5.3	9.38	3.98e-20	1.93e-17	0.28	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145584954	chr6:145799409~145886585:+
BRCA	cis	rs881375	0.715	rs11794516	ENSG00000226752.6	PSMD5-AS1	-9.38	3.98e-20	1.93e-17	-0.33	-0.28	Rheumatoid arthritis;	chr9:120877952	chr9:120824828~120854385:+
BRCA	cis	rs7580658	0.929	rs4150477	ENSG00000236682.1	AC068282.3	9.38	4.01e-20	1.94e-17	0.37	0.28	Protein C levels;	chr2:127274970	chr2:127389130~127400580:+
BRCA	cis	rs6565180	1	rs12930787	ENSG00000273724.1	RP11-347C12.12	-9.38	4.02e-20	1.95e-17	-0.33	-0.28	Tonsillectomy;	chr16:30369982	chr16:30336400~30343336:+
BRCA	cis	rs7772486	0.79	rs9376970	ENSG00000235652.6	RP11-545I5.3	-9.38	4.05e-20	1.96e-17	-0.28	-0.28	Lobe attachment (rater-scored or self-reported);	chr6:145920336	chr6:145799409~145886585:+
BRCA	cis	rs11098499	0.754	rs9991959	ENSG00000245958.5	RP11-33B1.1	9.38	4.07e-20	1.97e-17	0.26	0.28	Corneal astigmatism;	chr4:119332618	chr4:119454791~119552025:+
BRCA	cis	rs950169	0.544	rs62021193	ENSG00000225151.9	GOLGA2P7	-9.38	4.08e-20	1.98e-17	-0.36	-0.28	Schizophrenia;	chr15:84627352	chr15:84199311~84230136:-
BRCA	cis	rs9287719	0.967	rs9679581	ENSG00000234818.1	AC092687.5	9.38	4.09e-20	1.98e-17	0.32	0.28	Prostate cancer;	chr2:10611610	chr2:10589166~10604830:+
BRCA	cis	rs8062405	1	rs62037369	ENSG00000278665.1	RP11-666O2.4	9.38	4.11e-20	1.99e-17	0.32	0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28872520	chr16:28599241~28601881:-
BRCA	cis	rs8062405	0.965	rs7359397	ENSG00000278665.1	RP11-666O2.4	9.38	4.11e-20	1.99e-17	0.32	0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28874338	chr16:28599241~28601881:-
BRCA	cis	rs4835473	0.808	rs4054643	ENSG00000251600.4	RP11-673E1.1	-9.38	4.12e-20	1.99e-17	-0.32	-0.28	Immature fraction of reticulocytes;	chr4:143787329	chr4:143912331~143982454:+
BRCA	cis	rs6142102	0.602	rs2268086	ENSG00000275784.1	RP5-1125A11.6	9.38	4.13e-20	2e-17	0.31	0.28	Skin pigmentation;	chr20:34060932	chr20:33989480~33991818:-
BRCA	cis	rs465969	1	rs7750803	ENSG00000255389.1	C6orf3	9.38	4.15e-20	2.01e-17	0.58	0.28	Psoriasis;	chr6:111478910	chr6:111599875~111602295:+
BRCA	cis	rs1823913	0.599	rs13427761	ENSG00000227542.1	AC092614.2	-9.37	4.17e-20	2.02e-17	-0.34	-0.28	Obesity-related traits;	chr2:191269256	chr2:191229165~191246172:-
BRCA	cis	rs9287719	0.967	rs6721739	ENSG00000234818.1	AC092687.5	-9.37	4.17e-20	2.02e-17	-0.32	-0.28	Prostate cancer;	chr2:10611120	chr2:10589166~10604830:+
BRCA	cis	rs858239	0.539	rs4377861	ENSG00000226816.2	AC005082.12	9.37	4.19e-20	2.03e-17	0.33	0.28	Cerebrospinal fluid biomarker levels;	chr7:23146350	chr7:23206013~23208045:+
BRCA	cis	rs2439831	0.85	rs7169988	ENSG00000205771.5	CATSPER2P1	-9.37	4.22e-20	2.04e-17	-0.48	-0.28	Lung cancer in ever smokers;	chr15:43768237	chr15:43726918~43747094:-
BRCA	cis	rs957448	0.948	rs11992893	ENSG00000253704.1	RP11-267M23.4	9.37	4.24e-20	2.05e-17	0.33	0.28	Nonsyndromic cleft lip with cleft palate;	chr8:94508473	chr8:94553722~94569745:+
BRCA	cis	rs957448	1	rs1048029	ENSG00000253704.1	RP11-267M23.4	9.37	4.24e-20	2.05e-17	0.33	0.28	Nonsyndromic cleft lip with cleft palate;	chr8:94510149	chr8:94553722~94569745:+
BRCA	cis	rs11098499	0.826	rs4472123	ENSG00000248280.1	RP11-33B1.2	9.37	4.28e-20	2.07e-17	0.28	0.28	Corneal astigmatism;	chr4:119315475	chr4:119440561~119450157:-
BRCA	cis	rs1075265	0.749	rs805379	ENSG00000233266.1	HMGB1P31	9.37	4.28e-20	2.07e-17	0.34	0.28	Chronotype;Morning vs. evening chronotype;	chr2:53865847	chr2:54051334~54051760:+
BRCA	cis	rs8062405	1	rs12325113	ENSG00000278665.1	RP11-666O2.4	9.37	4.3e-20	2.08e-17	0.32	0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28837347	chr16:28599241~28601881:-
BRCA	cis	rs56163509	1	rs56163509	ENSG00000278665.1	RP11-666O2.4	9.37	4.3e-20	2.08e-17	0.32	0.28	Tonsillectomy;Mean corpuscular volume;	chr16:28853150	chr16:28599241~28601881:-
BRCA	cis	rs2243480	1	rs34193460	ENSG00000226824.5	RP4-756H11.3	-9.37	4.3e-20	2.08e-17	-0.54	-0.28	Diabetic kidney disease;	chr7:65928123	chr7:66654538~66669855:+
BRCA	cis	rs7429990	0.965	rs4858881	ENSG00000229759.1	MRPS18AP1	-9.37	4.3e-20	2.08e-17	-0.32	-0.28	Educational attainment (years of education);	chr3:48082306	chr3:48256350~48256938:-
BRCA	cis	rs7429990	0.932	rs810334	ENSG00000229759.1	MRPS18AP1	9.37	4.32e-20	2.09e-17	0.32	0.28	Educational attainment (years of education);	chr3:47893813	chr3:48256350~48256938:-
BRCA	cis	rs9543976	1	rs73223968	ENSG00000261553.4	RP11-29G8.3	-9.37	4.33e-20	2.09e-17	-0.52	-0.28	Diabetic retinopathy;	chr13:75567585	chr13:75549773~75807120:+
BRCA	cis	rs9543976	1	rs2296146	ENSG00000261553.4	RP11-29G8.3	-9.37	4.33e-20	2.09e-17	-0.52	-0.28	Diabetic retinopathy;	chr13:75569436	chr13:75549773~75807120:+
BRCA	cis	rs2243480	1	rs35820085	ENSG00000226824.5	RP4-756H11.3	-9.37	4.35e-20	2.1e-17	-0.54	-0.28	Diabetic kidney disease;	chr7:65977771	chr7:66654538~66669855:+
BRCA	cis	rs881375	0.678	rs10760129	ENSG00000226752.6	PSMD5-AS1	-9.37	4.35e-20	2.11e-17	-0.33	-0.28	Rheumatoid arthritis;	chr9:120937905	chr9:120824828~120854385:+
BRCA	cis	rs1075265	0.836	rs1421622	ENSG00000233266.1	HMGB1P31	-9.37	4.35e-20	2.11e-17	-0.33	-0.28	Chronotype;Morning vs. evening chronotype;	chr2:54062644	chr2:54051334~54051760:+
BRCA	cis	rs2274273	0.934	rs17740741	ENSG00000258413.1	RP11-665C16.6	-9.37	4.36e-20	2.11e-17	-0.35	-0.28	Protein biomarker;	chr14:55295994	chr14:55262767~55272075:-
BRCA	cis	rs2274273	0.901	rs68046603	ENSG00000258413.1	RP11-665C16.6	-9.37	4.36e-20	2.11e-17	-0.35	-0.28	Protein biomarker;	chr14:55296085	chr14:55262767~55272075:-
BRCA	cis	rs17711722	0.528	rs73138179	ENSG00000224316.1	RP11-479O9.2	9.37	4.36e-20	2.11e-17	0.3	0.28	Calcium levels;	chr7:65829495	chr7:65773620~65802067:+
BRCA	cis	rs11098499	1	rs10029750	ENSG00000245958.5	RP11-33B1.1	-9.37	4.36e-20	2.11e-17	-0.27	-0.28	Corneal astigmatism;	chr4:119251388	chr4:119454791~119552025:+
BRCA	cis	rs2274273	0.773	rs10147765	ENSG00000258413.1	RP11-665C16.6	-9.37	4.37e-20	2.11e-17	-0.35	-0.28	Protein biomarker;	chr14:55361108	chr14:55262767~55272075:-
BRCA	cis	rs35160687	0.712	rs6705366	ENSG00000273080.1	RP11-301O19.1	-9.37	4.38e-20	2.12e-17	-0.32	-0.28	Night sleep phenotypes;	chr2:86257659	chr2:86195590~86196049:+
BRCA	cis	rs2243480	0.803	rs55700941	ENSG00000226824.5	RP4-756H11.3	-9.37	4.4e-20	2.13e-17	-0.54	-0.28	Diabetic kidney disease;	chr7:65924813	chr7:66654538~66669855:+
BRCA	cis	rs8062405	1	rs4451951	ENSG00000278665.1	RP11-666O2.4	9.37	4.43e-20	2.14e-17	0.3	0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28824884	chr16:28599241~28601881:-
BRCA	cis	rs17711722	0.51	rs11767457	ENSG00000224316.1	RP11-479O9.2	9.37	4.44e-20	2.14e-17	0.29	0.28	Calcium levels;	chr7:65825628	chr7:65773620~65802067:+
BRCA	cis	rs10262624	1	rs10238070	ENSG00000234286.1	AC006026.13	-9.37	4.46e-20	2.16e-17	-0.32	-0.28	Schizophrenia;	chr7:23870172	chr7:23680195~23680786:-
BRCA	cis	rs2274273	0.87	rs10139083	ENSG00000258413.1	RP11-665C16.6	-9.37	4.47e-20	2.16e-17	-0.35	-0.28	Protein biomarker;	chr14:55316017	chr14:55262767~55272075:-
BRCA	cis	rs748404	0.589	rs62020612	ENSG00000249839.1	AC011330.5	-9.37	4.47e-20	2.16e-17	-0.4	-0.28	Lung cancer;	chr15:43525881	chr15:43663654~43684339:-
BRCA	cis	rs2274273	0.901	rs12050099	ENSG00000258413.1	RP11-665C16.6	-9.37	4.5e-20	2.17e-17	-0.35	-0.28	Protein biomarker;	chr14:55297613	chr14:55262767~55272075:-
BRCA	cis	rs2274273	0.87	rs10145203	ENSG00000258413.1	RP11-665C16.6	-9.37	4.54e-20	2.19e-17	-0.35	-0.28	Protein biomarker;	chr14:55317740	chr14:55262767~55272075:-
BRCA	cis	rs12468226	0.873	rs78798541	ENSG00000273456.1	RP11-686O6.2	9.37	4.54e-20	2.19e-17	0.43	0.28	Urate levels;	chr2:202194708	chr2:202374932~202375604:-
BRCA	cis	rs4835473	0.932	rs6827971	ENSG00000251600.4	RP11-673E1.1	-9.36	4.58e-20	2.21e-17	-0.32	-0.28	Immature fraction of reticulocytes;	chr4:143822126	chr4:143912331~143982454:+
BRCA	cis	rs2404602	1	rs2896954	ENSG00000259422.1	RP11-593F23.1	9.36	4.62e-20	2.23e-17	0.35	0.28	Blood metabolite levels;	chr15:76559351	chr15:76174891~76181486:-
BRCA	cis	rs1075265	0.756	rs809280	ENSG00000233266.1	HMGB1P31	9.36	4.62e-20	2.23e-17	0.34	0.28	Chronotype;Morning vs. evening chronotype;	chr2:53921270	chr2:54051334~54051760:+
BRCA	cis	rs1113500	0.897	rs11185263	ENSG00000226822.1	RP11-356N1.2	9.36	4.65e-20	2.24e-17	0.36	0.28	Growth-regulated protein alpha levels;	chr1:108097182	chr1:108071482~108074519:+
BRCA	cis	rs2276314	0.947	rs16967319	ENSG00000278986.1	RP11-723J4.3	-9.36	4.68e-20	2.26e-17	-0.36	-0.28	Endometriosis;Drug-induced torsades de pointes;	chr18:35993562	chr18:35972151~35973916:+
BRCA	cis	rs13256369	0.755	rs12680167	ENSG00000253893.2	FAM85B	-9.36	4.7e-20	2.27e-17	-0.39	-0.28	Obesity-related traits;	chr8:8704957	chr8:8167819~8226614:-
BRCA	cis	rs7429990	0.965	rs11707679	ENSG00000229759.1	MRPS18AP1	9.36	4.7e-20	2.27e-17	0.34	0.28	Educational attainment (years of education);	chr3:47915016	chr3:48256350~48256938:-
BRCA	cis	rs11098499	0.863	rs2306457	ENSG00000245958.5	RP11-33B1.1	-9.36	4.73e-20	2.28e-17	-0.28	-0.28	Corneal astigmatism;	chr4:119551684	chr4:119454791~119552025:+
BRCA	cis	rs1075265	0.783	rs805424	ENSG00000233266.1	HMGB1P31	9.36	4.76e-20	2.3e-17	0.33	0.28	Chronotype;Morning vs. evening chronotype;	chr2:53901098	chr2:54051334~54051760:+
BRCA	cis	rs858239	0.601	rs15775	ENSG00000226816.2	AC005082.12	9.36	4.76e-20	2.3e-17	0.32	0.28	Cerebrospinal fluid biomarker levels;	chr7:23125082	chr7:23206013~23208045:+
BRCA	cis	rs1061377	0.513	rs2711994	ENSG00000249207.1	RP11-360F5.1	9.36	4.76e-20	2.3e-17	0.36	0.28	Uric acid levels;	chr4:39148121	chr4:39112677~39126818:-
BRCA	cis	rs6565180	0.926	rs4787643	ENSG00000273724.1	RP11-347C12.12	9.36	4.79e-20	2.31e-17	0.34	0.28	Tonsillectomy;	chr16:30382339	chr16:30336400~30343336:+
BRCA	cis	rs6565180	0.926	rs4788409	ENSG00000273724.1	RP11-347C12.12	9.36	4.79e-20	2.31e-17	0.34	0.28	Tonsillectomy;	chr16:30382450	chr16:30336400~30343336:+
BRCA	cis	rs875971	0.545	rs10950036	ENSG00000237310.1	GS1-124K5.4	9.36	4.81e-20	2.32e-17	0.33	0.28	Aortic root size;	chr7:66353241	chr7:66493706~66495474:+
BRCA	cis	rs6142102	0.961	rs6087557	ENSG00000276073.1	RP5-1125A11.7	-9.36	4.84e-20	2.33e-17	-0.33	-0.28	Skin pigmentation;	chr20:34110469	chr20:33985617~33988989:-
BRCA	cis	rs6061231	0.798	rs2427308	ENSG00000273619.1	RP5-908M14.9	-9.36	4.84e-20	2.33e-17	-0.27	-0.28	Colorectal cancer;	chr20:62394395	chr20:62386303~62386970:-
BRCA	cis	rs4820294	0.669	rs1894532	ENSG00000233360.4	Z83844.1	9.36	4.84e-20	2.33e-17	0.32	0.28	Fat distribution (HIV);	chr22:37663743	chr22:37641832~37658377:-
BRCA	cis	rs8012947	0.848	rs1190982	ENSG00000279636.2	LINC00216	-9.36	4.84e-20	2.33e-17	-0.3	-0.28	Alcohol consumption in current drinkers;	chr14:58349121	chr14:58288033~58289158:+
BRCA	cis	rs801193	0.935	rs11772264	ENSG00000222364.1	RNU6-96P	-9.36	4.84e-20	2.33e-17	-0.32	-0.28	Aortic root size;	chr7:66711400	chr7:66395191~66395286:+
BRCA	cis	rs7580658	0.891	rs3768866	ENSG00000236682.1	AC068282.3	-9.36	4.86e-20	2.34e-17	-0.37	-0.28	Protein C levels;	chr2:127287839	chr2:127389130~127400580:+
BRCA	cis	rs875971	0.545	rs6950988	ENSG00000237310.1	GS1-124K5.4	9.36	4.87e-20	2.34e-17	0.33	0.28	Aortic root size;	chr7:66511428	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.66	rs10215132	ENSG00000222364.1	RNU6-96P	9.36	4.87e-20	2.35e-17	0.32	0.28	Aortic root size;	chr7:66589419	chr7:66395191~66395286:+
BRCA	cis	rs227275	0.527	rs223308	ENSG00000246560.2	RP11-10L12.4	9.36	4.89e-20	2.35e-17	0.29	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102891342	chr4:102828055~102844075:+
BRCA	cis	rs9287719	0.967	rs10206225	ENSG00000234818.1	AC092687.5	9.36	4.89e-20	2.35e-17	0.32	0.28	Prostate cancer;	chr2:10618531	chr2:10589166~10604830:+
BRCA	cis	rs7429990	0.965	rs35199727	ENSG00000229759.1	MRPS18AP1	9.36	4.9e-20	2.36e-17	0.34	0.28	Educational attainment (years of education);	chr3:47905218	chr3:48256350~48256938:-
BRCA	cis	rs6545883	0.558	rs7587389	ENSG00000271889.1	RP11-493E12.1	-9.36	4.9e-20	2.36e-17	-0.34	-0.28	Tuberculosis;	chr2:61422656	chr2:61151433~61162105:-
BRCA	cis	rs11159086	0.793	rs11845370	ENSG00000259005.1	RP3-449M8.6	9.36	4.91e-20	2.36e-17	0.42	0.28	Advanced glycation end-product levels;	chr14:74481587	chr14:74474007~74474864:-
BRCA	cis	rs11159086	0.793	rs3784035	ENSG00000259005.1	RP3-449M8.6	9.36	4.91e-20	2.36e-17	0.42	0.28	Advanced glycation end-product levels;	chr14:74482221	chr14:74474007~74474864:-
BRCA	cis	rs11159086	0.793	rs10148268	ENSG00000259005.1	RP3-449M8.6	9.36	4.91e-20	2.36e-17	0.42	0.28	Advanced glycation end-product levels;	chr14:74484261	chr14:74474007~74474864:-
BRCA	cis	rs9847710	0.733	rs2581790	ENSG00000242142.1	SERBP1P3	9.36	4.91e-20	2.36e-17	0.34	0.28	Ulcerative colitis;	chr3:53067764	chr3:53064283~53065091:-
BRCA	cis	rs10262624	1	rs17347505	ENSG00000234286.1	AC006026.13	-9.36	4.92e-20	2.37e-17	-0.32	-0.28	Schizophrenia;	chr7:23875664	chr7:23680195~23680786:-
BRCA	cis	rs10262624	1	rs12671584	ENSG00000234286.1	AC006026.13	-9.36	4.92e-20	2.37e-17	-0.32	-0.28	Schizophrenia;	chr7:23875803	chr7:23680195~23680786:-
BRCA	cis	rs228614	0.51	rs170565	ENSG00000246560.2	RP11-10L12.4	9.36	4.93e-20	2.37e-17	0.29	0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102798277	chr4:102828055~102844075:+
BRCA	cis	rs858239	0.57	rs10271613	ENSG00000226816.2	AC005082.12	9.36	4.94e-20	2.38e-17	0.32	0.28	Cerebrospinal fluid biomarker levels;	chr7:23122967	chr7:23206013~23208045:+
BRCA	cis	rs6844153	0.752	rs10029307	ENSG00000240005.4	RP11-293A21.1	-9.36	4.94e-20	2.38e-17	-0.37	-0.28	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26902591	chr4:26859806~26860599:-
BRCA	cis	rs4237845	0.611	rs4583019	ENSG00000257159.1	RP11-58A17.3	9.36	4.95e-20	2.38e-17	0.33	0.28	Intelligence (multi-trait analysis);	chr12:57922962	chr12:57967058~57968399:+
BRCA	cis	rs8062405	1	rs12446589	ENSG00000278665.1	RP11-666O2.4	9.35	4.99e-20	2.4e-17	0.31	0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28859641	chr16:28599241~28601881:-
BRCA	cis	rs11159086	0.729	rs8015872	ENSG00000259005.1	RP3-449M8.6	9.35	5.01e-20	2.41e-17	0.41	0.28	Advanced glycation end-product levels;	chr14:74475529	chr14:74474007~74474864:-
BRCA	cis	rs875971	0.545	rs10950027	ENSG00000237310.1	GS1-124K5.4	9.35	5.02e-20	2.41e-17	0.33	0.28	Aortic root size;	chr7:66169164	chr7:66493706~66495474:+
BRCA	cis	rs7772486	0.597	rs6912351	ENSG00000235652.6	RP11-545I5.3	-9.35	5.04e-20	2.42e-17	-0.3	-0.28	Lobe attachment (rater-scored or self-reported);	chr6:145942935	chr6:145799409~145886585:+
BRCA	cis	rs12468226	0.873	rs79071680	ENSG00000273456.1	RP11-686O6.2	9.35	5.07e-20	2.44e-17	0.44	0.28	Urate levels;	chr2:202191520	chr2:202374932~202375604:-
BRCA	cis	rs12468226	0.873	rs79860867	ENSG00000273456.1	RP11-686O6.2	9.35	5.07e-20	2.44e-17	0.44	0.28	Urate levels;	chr2:202192397	chr2:202374932~202375604:-
BRCA	cis	rs11159086	0.793	rs12433382	ENSG00000259005.1	RP3-449M8.6	9.35	5.1e-20	2.45e-17	0.42	0.28	Advanced glycation end-product levels;	chr14:74482940	chr14:74474007~74474864:-
BRCA	cis	rs35160687	0.644	rs11127024	ENSG00000273080.1	RP11-301O19.1	-9.35	5.13e-20	2.47e-17	-0.33	-0.28	Night sleep phenotypes;	chr2:86278330	chr2:86195590~86196049:+
BRCA	cis	rs227275	0.554	rs223339	ENSG00000246560.2	RP11-10L12.4	9.35	5.14e-20	2.47e-17	0.29	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102864700	chr4:102828055~102844075:+
BRCA	cis	rs7580658	0.637	rs4580338	ENSG00000236682.1	AC068282.3	-9.35	5.19e-20	2.49e-17	-0.37	-0.28	Protein C levels;	chr2:127217361	chr2:127389130~127400580:+
BRCA	cis	rs12468226	1	rs79919139	ENSG00000273456.1	RP11-686O6.2	9.35	5.22e-20	2.51e-17	0.42	0.28	Urate levels;	chr2:202382786	chr2:202374932~202375604:-
BRCA	cis	rs875971	0.522	rs4718286	ENSG00000224316.1	RP11-479O9.2	9.35	5.22e-20	2.51e-17	0.28	0.28	Aortic root size;	chr7:65827777	chr7:65773620~65802067:+
BRCA	cis	rs17711722	0.585	rs6942660	ENSG00000224316.1	RP11-479O9.2	9.35	5.22e-20	2.51e-17	0.28	0.28	Calcium levels;	chr7:65837419	chr7:65773620~65802067:+
BRCA	cis	rs853679	0.567	rs9969098	ENSG00000216901.1	AL022393.7	9.35	5.27e-20	2.53e-17	0.4	0.28	Depression;	chr6:28430971	chr6:28176188~28176674:+
BRCA	cis	rs853679	0.567	rs16894106	ENSG00000216901.1	AL022393.7	9.35	5.27e-20	2.53e-17	0.4	0.28	Depression;	chr6:28432562	chr6:28176188~28176674:+
BRCA	cis	rs801193	1	rs1553609	ENSG00000222364.1	RNU6-96P	-9.35	5.27e-20	2.53e-17	-0.32	-0.28	Aortic root size;	chr7:66732152	chr7:66395191~66395286:+
BRCA	cis	rs6565180	0.791	rs4247355	ENSG00000273724.1	RP11-347C12.12	9.35	5.3e-20	2.54e-17	0.34	0.28	Tonsillectomy;	chr16:30380778	chr16:30336400~30343336:+
BRCA	cis	rs55665837	1	rs4412729	ENSG00000251991.1	RNU7-49P	9.35	5.33e-20	2.56e-17	0.32	0.28	Vitamin D levels;	chr11:14417454	chr11:14478892~14478953:+
BRCA	cis	rs858239	0.601	rs10278776	ENSG00000226816.2	AC005082.12	9.35	5.36e-20	2.57e-17	0.32	0.28	Cerebrospinal fluid biomarker levels;	chr7:23130140	chr7:23206013~23208045:+
BRCA	cis	rs858239	0.632	rs13438452	ENSG00000226816.2	AC005082.12	9.35	5.37e-20	2.58e-17	0.32	0.28	Cerebrospinal fluid biomarker levels;	chr7:23134563	chr7:23206013~23208045:+
BRCA	cis	rs9807989	0.507	rs6734762	ENSG00000234389.1	AC007278.3	9.35	5.39e-20	2.59e-17	0.25	0.28	Asthma;	chr2:102446466	chr2:102438713~102440475:+
BRCA	cis	rs858239	0.57	rs6968242	ENSG00000226816.2	AC005082.12	9.35	5.39e-20	2.59e-17	0.32	0.28	Cerebrospinal fluid biomarker levels;	chr7:23127792	chr7:23206013~23208045:+
BRCA	cis	rs1113500	0.862	rs11185264	ENSG00000226822.1	RP11-356N1.2	9.35	5.39e-20	2.59e-17	0.37	0.28	Growth-regulated protein alpha levels;	chr1:108097884	chr1:108071482~108074519:+
BRCA	cis	rs8072100	0.817	rs9912101	ENSG00000228782.6	CTD-2026D20.3	9.35	5.4e-20	2.59e-17	0.3	0.28	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47469712	chr17:47450568~47492492:-
BRCA	cis	rs875971	0.505	rs1167386	ENSG00000224316.1	RP11-479O9.2	-9.34	5.49e-20	2.63e-17	-0.28	-0.28	Aortic root size;	chr7:66048109	chr7:65773620~65802067:+
BRCA	cis	rs2243480	1	rs34815098	ENSG00000226824.5	RP4-756H11.3	-9.34	5.49e-20	2.63e-17	-0.53	-0.28	Diabetic kidney disease;	chr7:65827267	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs35735127	ENSG00000226824.5	RP4-756H11.3	-9.34	5.49e-20	2.63e-17	-0.53	-0.28	Diabetic kidney disease;	chr7:65835436	chr7:66654538~66669855:+
BRCA	cis	rs2243480	0.901	rs35256305	ENSG00000226824.5	RP4-756H11.3	-9.34	5.49e-20	2.63e-17	-0.53	-0.28	Diabetic kidney disease;	chr7:65841418	chr7:66654538~66669855:+
BRCA	cis	rs2243480	0.803	rs34004500	ENSG00000226824.5	RP4-756H11.3	-9.34	5.49e-20	2.63e-17	-0.53	-0.28	Diabetic kidney disease;	chr7:65847191	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs35825738	ENSG00000226824.5	RP4-756H11.3	-9.34	5.49e-20	2.63e-17	-0.53	-0.28	Diabetic kidney disease;	chr7:65853040	chr7:66654538~66669855:+
BRCA	cis	rs9287719	0.967	rs6709466	ENSG00000234818.1	AC092687.5	9.34	5.55e-20	2.66e-17	0.32	0.28	Prostate cancer;	chr2:10608131	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs6719701	ENSG00000234818.1	AC092687.5	9.34	5.55e-20	2.66e-17	0.32	0.28	Prostate cancer;	chr2:10608157	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.934	rs6432115	ENSG00000234818.1	AC092687.5	9.34	5.55e-20	2.66e-17	0.32	0.28	Prostate cancer;	chr2:10608217	chr2:10589166~10604830:+
BRCA	cis	rs2067615	0.579	rs10861667	ENSG00000260329.1	RP11-412D9.4	-9.34	5.57e-20	2.67e-17	-0.3	-0.28	Heart rate;	chr12:106800998	chr12:106954029~106955497:-
BRCA	cis	rs6539288	0.5	rs11113116	ENSG00000260329.1	RP11-412D9.4	-9.34	5.57e-20	2.67e-17	-0.3	-0.28	Total body bone mineral density;	chr12:106802151	chr12:106954029~106955497:-
BRCA	cis	rs2243480	1	rs160643	ENSG00000226824.5	RP4-756H11.3	-9.34	5.57e-20	2.67e-17	-0.5	-0.28	Diabetic kidney disease;	chr7:66093235	chr7:66654538~66669855:+
BRCA	cis	rs950169	0.58	rs17532346	ENSG00000225151.9	GOLGA2P7	-9.34	5.57e-20	2.67e-17	-0.36	-0.28	Schizophrenia;	chr15:84628264	chr15:84199311~84230136:-
BRCA	cis	rs9640161	0.75	rs11764936	ENSG00000261305.1	RP4-584D14.7	9.34	5.58e-20	2.68e-17	0.42	0.28	Blood protein levels;Circulating chemerin levels;	chr7:150328826	chr7:150341771~150342607:+
BRCA	cis	rs801193	1	rs6975195	ENSG00000222364.1	RNU6-96P	9.34	5.58e-20	2.68e-17	0.32	0.28	Aortic root size;	chr7:66659787	chr7:66395191~66395286:+
BRCA	cis	rs1075265	0.87	rs1363062	ENSG00000233266.1	HMGB1P31	9.34	5.63e-20	2.7e-17	0.33	0.28	Chronotype;Morning vs. evening chronotype;	chr2:54054625	chr2:54051334~54051760:+
BRCA	cis	rs11098499	0.954	rs12505469	ENSG00000248280.1	RP11-33B1.2	9.34	5.64e-20	2.7e-17	0.29	0.28	Corneal astigmatism;	chr4:119328430	chr4:119440561~119450157:-
BRCA	cis	rs748404	0.666	rs12906017	ENSG00000249839.1	AC011330.5	-9.34	5.67e-20	2.72e-17	-0.41	-0.28	Lung cancer;	chr15:43504710	chr15:43663654~43684339:-
BRCA	cis	rs1113500	0.933	rs10881497	ENSG00000226822.1	RP11-356N1.2	-9.34	5.71e-20	2.73e-17	-0.36	-0.28	Growth-regulated protein alpha levels;	chr1:108091893	chr1:108071482~108074519:+
BRCA	cis	rs17711722	0.701	rs55773927	ENSG00000224316.1	RP11-479O9.2	9.34	5.71e-20	2.74e-17	0.28	0.28	Calcium levels;	chr7:65872915	chr7:65773620~65802067:+
BRCA	cis	rs673078	0.571	rs7954330	ENSG00000275759.1	RP11-131L12.3	-9.34	5.72e-20	2.74e-17	-0.44	-0.28	Glucose homeostasis traits;	chr12:118275284	chr12:118428281~118428870:+
BRCA	cis	rs9640161	0.711	rs3800781	ENSG00000261305.1	RP4-584D14.7	9.34	5.74e-20	2.75e-17	0.42	0.28	Blood protein levels;Circulating chemerin levels;	chr7:150330235	chr7:150341771~150342607:+
BRCA	cis	rs748404	0.666	rs12906481	ENSG00000249839.1	AC011330.5	-9.34	5.74e-20	2.75e-17	-0.41	-0.28	Lung cancer;	chr15:43467356	chr15:43663654~43684339:-
BRCA	cis	rs748404	0.666	rs35958032	ENSG00000249839.1	AC011330.5	-9.34	5.74e-20	2.75e-17	-0.41	-0.28	Lung cancer;	chr15:43494397	chr15:43663654~43684339:-
BRCA	cis	rs9287719	0.934	rs6721510	ENSG00000234818.1	AC092687.5	9.34	5.76e-20	2.76e-17	0.32	0.28	Prostate cancer;	chr2:10610920	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs6721514	ENSG00000234818.1	AC092687.5	9.34	5.76e-20	2.76e-17	0.32	0.28	Prostate cancer;	chr2:10610936	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.934	rs6706763	ENSG00000234818.1	AC092687.5	9.34	5.76e-20	2.76e-17	0.32	0.28	Prostate cancer;	chr2:10611281	chr2:10589166~10604830:+
BRCA	cis	rs2274273	0.901	rs17674563	ENSG00000258413.1	RP11-665C16.6	-9.34	5.8e-20	2.78e-17	-0.35	-0.28	Protein biomarker;	chr14:55364407	chr14:55262767~55272075:-
BRCA	cis	rs875971	0.545	rs73378304	ENSG00000222364.1	RNU6-96P	-9.34	5.83e-20	2.79e-17	-0.35	-0.28	Aortic root size;	chr7:66175760	chr7:66395191~66395286:+
BRCA	cis	rs7429990	0.965	rs319684	ENSG00000229759.1	MRPS18AP1	9.34	5.83e-20	2.79e-17	0.32	0.28	Educational attainment (years of education);	chr3:47890784	chr3:48256350~48256938:-
BRCA	cis	rs881375	0.715	rs7858209	ENSG00000226752.6	PSMD5-AS1	-9.34	5.83e-20	2.79e-17	-0.32	-0.28	Rheumatoid arthritis;	chr9:120883482	chr9:120824828~120854385:+
BRCA	cis	rs881375	0.715	rs10760119	ENSG00000226752.6	PSMD5-AS1	-9.34	5.83e-20	2.79e-17	-0.32	-0.28	Rheumatoid arthritis;	chr9:120883782	chr9:120824828~120854385:+
BRCA	cis	rs2276314	0.857	rs62101379	ENSG00000278986.1	RP11-723J4.3	-9.34	5.85e-20	2.8e-17	-0.36	-0.28	Endometriosis;Drug-induced torsades de pointes;	chr18:36004939	chr18:35972151~35973916:+
BRCA	cis	rs11098499	0.908	rs2017057	ENSG00000248280.1	RP11-33B1.2	9.34	5.87e-20	2.81e-17	0.29	0.28	Corneal astigmatism;	chr4:119336556	chr4:119440561~119450157:-
BRCA	cis	rs2243480	1	rs57057549	ENSG00000226824.5	RP4-756H11.3	-9.34	5.88e-20	2.81e-17	-0.53	-0.28	Diabetic kidney disease;	chr7:65940751	chr7:66654538~66669855:+
BRCA	cis	rs11123170	0.542	rs11123169	ENSG00000274877.1	RP11-65I12.1	9.34	5.9e-20	2.82e-17	0.38	0.28	Renal function-related traits (BUN);	chr2:113209498	chr2:113237595~113240825:+
BRCA	cis	rs7924176	0.564	rs4564273	ENSG00000213731.2	RAB5CP1	-9.34	5.9e-20	2.82e-17	-0.31	-0.28	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74230154	chr10:74423435~74424014:-
BRCA	cis	rs2067615	0.579	rs10778509	ENSG00000260329.1	RP11-412D9.4	-9.34	5.91e-20	2.83e-17	-0.3	-0.28	Heart rate;	chr12:106769140	chr12:106954029~106955497:-
BRCA	cis	rs62012628	0.527	rs12438008	ENSG00000261143.1	ADAMTS7P3	-9.33	5.92e-20	2.83e-17	-0.36	-0.28	Diastolic blood pressure;	chr15:78792338	chr15:77976042~77993057:+
BRCA	cis	rs9287719	0.87	rs728135	ENSG00000234818.1	AC092687.5	9.33	5.93e-20	2.84e-17	0.32	0.28	Prostate cancer;	chr2:10605006	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs2884233	ENSG00000234818.1	AC092687.5	9.33	5.93e-20	2.84e-17	0.32	0.28	Prostate cancer;	chr2:10605177	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.839	rs12692415	ENSG00000234818.1	AC092687.5	9.33	5.93e-20	2.84e-17	0.32	0.28	Prostate cancer;	chr2:10605348	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.934	rs12692416	ENSG00000234818.1	AC092687.5	9.33	5.93e-20	2.84e-17	0.32	0.28	Prostate cancer;	chr2:10605501	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs12692417	ENSG00000234818.1	AC092687.5	9.33	5.93e-20	2.84e-17	0.32	0.28	Prostate cancer;	chr2:10605592	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.934	rs12692418	ENSG00000234818.1	AC092687.5	9.33	5.93e-20	2.84e-17	0.32	0.28	Prostate cancer;	chr2:10605744	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs6755548	ENSG00000234818.1	AC092687.5	9.33	5.93e-20	2.84e-17	0.32	0.28	Prostate cancer;	chr2:10606000	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs6761678	ENSG00000234818.1	AC092687.5	9.33	5.93e-20	2.84e-17	0.32	0.28	Prostate cancer;	chr2:10606215	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs6759100	ENSG00000234818.1	AC092687.5	9.33	5.93e-20	2.84e-17	0.32	0.28	Prostate cancer;	chr2:10606584	chr2:10589166~10604830:+
BRCA	cis	rs13392177	0.66	rs10932762	ENSG00000261338.2	RP11-378A13.1	-9.33	5.94e-20	2.84e-17	-0.29	-0.28	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218211490	chr2:218255319~218257366:+
BRCA	cis	rs11098499	0.69	rs34818745	ENSG00000245958.5	RP11-33B1.1	-9.33	5.98e-20	2.86e-17	-0.27	-0.28	Corneal astigmatism;	chr4:119335900	chr4:119454791~119552025:+
BRCA	cis	rs1134634	0.52	rs2041671	ENSG00000273133.1	RP11-799M12.2	-9.33	6e-20	2.87e-17	-0.36	-0.28	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15550575	chr4:15563698~15564253:-
BRCA	cis	rs4988958	0.565	rs3755265	ENSG00000234389.1	AC007278.3	9.33	6.01e-20	2.88e-17	0.26	0.28	Asthma (childhood onset);	chr2:102436356	chr2:102438713~102440475:+
BRCA	cis	rs1823913	0.599	rs13020656	ENSG00000227542.1	AC092614.2	9.33	6.06e-20	2.9e-17	0.34	0.28	Obesity-related traits;	chr2:191314197	chr2:191229165~191246172:-
BRCA	cis	rs9287719	0.967	rs6432116	ENSG00000234818.1	AC092687.5	9.33	6.07e-20	2.9e-17	0.32	0.28	Prostate cancer;	chr2:10608489	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs2110776	ENSG00000234818.1	AC092687.5	9.33	6.07e-20	2.9e-17	0.32	0.28	Prostate cancer;	chr2:10608684	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs2110778	ENSG00000234818.1	AC092687.5	9.33	6.07e-20	2.9e-17	0.32	0.28	Prostate cancer;	chr2:10608844	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs6432117	ENSG00000234818.1	AC092687.5	9.33	6.07e-20	2.9e-17	0.32	0.28	Prostate cancer;	chr2:10609233	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs6432118	ENSG00000234818.1	AC092687.5	9.33	6.07e-20	2.9e-17	0.32	0.28	Prostate cancer;	chr2:10609315	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.935	rs728283	ENSG00000234818.1	AC092687.5	9.33	6.07e-20	2.9e-17	0.32	0.28	Prostate cancer;	chr2:10609964	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs728282	ENSG00000234818.1	AC092687.5	9.33	6.07e-20	2.9e-17	0.32	0.28	Prostate cancer;	chr2:10610177	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs728281	ENSG00000234818.1	AC092687.5	9.33	6.07e-20	2.9e-17	0.32	0.28	Prostate cancer;	chr2:10610229	chr2:10589166~10604830:+
BRCA	cis	rs11096990	0.634	rs1057807	ENSG00000249207.1	RP11-360F5.1	9.33	6.09e-20	2.91e-17	0.32	0.28	Cognitive function;	chr4:39287853	chr4:39112677~39126818:-
BRCA	cis	rs858239	0.601	rs4599714	ENSG00000226816.2	AC005082.12	9.33	6.09e-20	2.91e-17	0.32	0.28	Cerebrospinal fluid biomarker levels;	chr7:23129182	chr7:23206013~23208045:+
BRCA	cis	rs6782228	1	rs34890930	ENSG00000242551.2	POU5F1P6	9.33	6.12e-20	2.92e-17	0.39	0.28	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128610380	chr3:128674735~128677005:-
BRCA	cis	rs2337406	0.587	rs10129888	ENSG00000274576.2	IGHV2-70	-9.33	6.13e-20	2.93e-17	-0.29	-0.28	Alzheimer's disease (late onset);	chr14:106647421	chr14:106770577~106771020:-
BRCA	cis	rs9287719	0.967	rs6432114	ENSG00000234818.1	AC092687.5	9.33	6.16e-20	2.94e-17	0.32	0.28	Prostate cancer;	chr2:10604804	chr2:10589166~10604830:+
BRCA	cis	rs4366055	1	rs4366055	ENSG00000253704.1	RP11-267M23.4	9.33	6.17e-20	2.95e-17	0.31	0.28	Body mass index;	chr8:94495100	chr8:94553722~94569745:+
BRCA	cis	rs783540	0.934	rs8043401	ENSG00000278603.1	RP13-608F4.5	9.33	6.21e-20	2.97e-17	0.35	0.28	Schizophrenia;	chr15:82687507	chr15:82472203~82472426:+
BRCA	cis	rs1707322	0.963	rs6429581	ENSG00000280836.1	AL355480.1	-9.33	6.23e-20	2.97e-17	-0.36	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45853424	chr1:45581219~45581321:-
BRCA	cis	rs4862750	0.624	rs34414639	ENSG00000250971.1	RP11-696F12.1	9.33	6.25e-20	2.99e-17	0.3	0.28	Lobe attachment (rater-scored or self-reported);	chr4:186952263	chr4:187060099~187060930:+
BRCA	cis	rs8062405	0.964	rs7187333	ENSG00000278665.1	RP11-666O2.4	9.33	6.26e-20	2.99e-17	0.31	0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28854595	chr16:28599241~28601881:-
BRCA	cis	rs465969	0.546	rs7772141	ENSG00000255389.1	C6orf3	9.33	6.27e-20	2.99e-17	0.56	0.28	Psoriasis;	chr6:111472358	chr6:111599875~111602295:+
BRCA	cis	rs465969	0.793	rs7776047	ENSG00000255389.1	C6orf3	9.33	6.27e-20	2.99e-17	0.56	0.28	Psoriasis;	chr6:111472391	chr6:111599875~111602295:+
BRCA	cis	rs11722779	0.838	rs6821247	ENSG00000246560.2	RP11-10L12.4	9.33	6.27e-20	2.99e-17	0.29	0.28	Schizophrenia;	chr4:102913483	chr4:102828055~102844075:+
BRCA	cis	rs673078	0.66	rs7973455	ENSG00000275759.1	RP11-131L12.3	-9.33	6.28e-20	3e-17	-0.43	-0.28	Glucose homeostasis traits;	chr12:118247490	chr12:118428281~118428870:+
BRCA	cis	rs6782228	1	rs6782407	ENSG00000242551.2	POU5F1P6	9.33	6.32e-20	3.02e-17	0.4	0.28	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128619905	chr3:128674735~128677005:-
BRCA	cis	rs881375	1	rs1953126	ENSG00000226752.6	PSMD5-AS1	-9.33	6.34e-20	3.02e-17	-0.33	-0.28	Rheumatoid arthritis;	chr9:120878222	chr9:120824828~120854385:+
BRCA	cis	rs858239	0.632	rs7811903	ENSG00000226816.2	AC005082.12	9.33	6.34e-20	3.03e-17	0.32	0.28	Cerebrospinal fluid biomarker levels;	chr7:23079437	chr7:23206013~23208045:+
BRCA	cis	rs7772486	0.846	rs9403767	ENSG00000235652.6	RP11-545I5.3	9.33	6.35e-20	3.03e-17	0.29	0.28	Lobe attachment (rater-scored or self-reported);	chr6:146081250	chr6:145799409~145886585:+
BRCA	cis	rs783540	0.809	rs3970696	ENSG00000278603.1	RP13-608F4.5	9.33	6.36e-20	3.03e-17	0.34	0.28	Schizophrenia;	chr15:82595006	chr15:82472203~82472426:+
BRCA	cis	rs11676348	0.808	rs4674261	ENSG00000261338.2	RP11-378A13.1	-9.33	6.38e-20	3.04e-17	-0.29	-0.28	Ulcerative colitis;	chr2:218140286	chr2:218255319~218257366:+
BRCA	cis	rs11096990	0.634	rs3733281	ENSG00000249207.1	RP11-360F5.1	9.33	6.38e-20	3.04e-17	0.32	0.28	Cognitive function;	chr4:39270293	chr4:39112677~39126818:-
BRCA	cis	rs7772486	0.686	rs857880	ENSG00000235652.6	RP11-545I5.3	-9.32	6.45e-20	3.08e-17	-0.28	-0.28	Lobe attachment (rater-scored or self-reported);	chr6:145649979	chr6:145799409~145886585:+
BRCA	cis	rs11673344	0.832	rs11084871	ENSG00000226686.6	LINC01535	9.32	6.5e-20	3.1e-17	0.37	0.28	Obesity-related traits;	chr19:37042023	chr19:37251912~37265535:+
BRCA	cis	rs9287719	0.967	rs963831	ENSG00000234818.1	AC092687.5	9.32	6.52e-20	3.11e-17	0.32	0.28	Prostate cancer;	chr2:10605058	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs728134	ENSG00000234818.1	AC092687.5	9.32	6.52e-20	3.11e-17	0.32	0.28	Prostate cancer;	chr2:10605061	chr2:10589166~10604830:+
BRCA	cis	rs7945705	0.902	rs2012696	ENSG00000254860.4	TMEM9B-AS1	-9.32	6.52e-20	3.11e-17	-0.26	-0.28	Hemoglobin concentration;	chr11:8974271	chr11:8964675~8977527:+
BRCA	cis	rs7688540	0.8	rs10023604	ENSG00000211553.1	AC253576.2	-9.32	6.57e-20	3.13e-17	-0.35	-0.28	Facial morphology (factor 6, height of vermillion lower lip);	chr4:287249	chr4:136461~136568:+
BRCA	cis	rs11676348	0.838	rs17844697	ENSG00000261338.2	RP11-378A13.1	-9.32	6.6e-20	3.14e-17	-0.29	-0.28	Ulcerative colitis;	chr2:218134532	chr2:218255319~218257366:+
BRCA	cis	rs6570726	0.791	rs378937	ENSG00000235652.6	RP11-545I5.3	9.32	6.6e-20	3.15e-17	0.28	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145513609	chr6:145799409~145886585:+
BRCA	cis	rs2276314	0.857	rs3737474	ENSG00000278986.1	RP11-723J4.3	-9.32	6.61e-20	3.15e-17	-0.36	-0.28	Endometriosis;Drug-induced torsades de pointes;	chr18:36033632	chr18:35972151~35973916:+
BRCA	cis	rs6782228	1	rs11711038	ENSG00000242551.2	POU5F1P6	9.32	6.63e-20	3.16e-17	0.41	0.28	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128675467	chr3:128674735~128677005:-
BRCA	cis	rs11098499	0.863	rs12498539	ENSG00000245958.5	RP11-33B1.1	-9.32	6.63e-20	3.16e-17	-0.27	-0.28	Corneal astigmatism;	chr4:119547215	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.863	rs3822194	ENSG00000245958.5	RP11-33B1.1	-9.32	6.63e-20	3.16e-17	-0.27	-0.28	Corneal astigmatism;	chr4:119550493	chr4:119454791~119552025:+
BRCA	cis	rs12682352	0.715	rs332039	ENSG00000253893.2	FAM85B	-9.32	6.69e-20	3.19e-17	-0.36	-0.28	Neuroticism;	chr8:8866141	chr8:8167819~8226614:-
BRCA	cis	rs465969	1	rs17510733	ENSG00000255389.1	C6orf3	-9.32	6.71e-20	3.2e-17	-0.57	-0.28	Psoriasis;	chr6:111389715	chr6:111599875~111602295:+
BRCA	cis	rs8062405	0.964	rs78613234	ENSG00000278665.1	RP11-666O2.4	9.32	6.75e-20	3.21e-17	0.3	0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828104	chr16:28599241~28601881:-
BRCA	cis	rs8062405	1	rs62036624	ENSG00000278665.1	RP11-666O2.4	9.32	6.75e-20	3.21e-17	0.3	0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828609	chr16:28599241~28601881:-
BRCA	cis	rs858239	0.57	rs10242166	ENSG00000226816.2	AC005082.12	9.32	6.78e-20	3.23e-17	0.32	0.28	Cerebrospinal fluid biomarker levels;	chr7:23123180	chr7:23206013~23208045:+
BRCA	cis	rs2933343	1	rs1683811	ENSG00000231305.3	RP11-723O4.2	9.32	6.79e-20	3.23e-17	0.34	0.28	IgG glycosylation;	chr3:128893270	chr3:128861313~128871540:-
BRCA	cis	rs875971	0.545	rs6460281	ENSG00000237310.1	GS1-124K5.4	9.32	6.8e-20	3.24e-17	0.33	0.28	Aortic root size;	chr7:66216128	chr7:66493706~66495474:+
BRCA	cis	rs4835473	0.932	rs17694797	ENSG00000251600.4	RP11-673E1.1	-9.32	6.82e-20	3.25e-17	-0.32	-0.28	Immature fraction of reticulocytes;	chr4:143778812	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs35947975	ENSG00000251600.4	RP11-673E1.1	-9.32	6.82e-20	3.25e-17	-0.32	-0.28	Immature fraction of reticulocytes;	chr4:143778969	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs1375987	ENSG00000251600.4	RP11-673E1.1	-9.32	6.82e-20	3.25e-17	-0.32	-0.28	Immature fraction of reticulocytes;	chr4:143779622	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs7687151	ENSG00000251600.4	RP11-673E1.1	-9.32	6.82e-20	3.25e-17	-0.32	-0.28	Immature fraction of reticulocytes;	chr4:143781681	chr4:143912331~143982454:+
BRCA	cis	rs9847710	0.67	rs36051354	ENSG00000242142.1	SERBP1P3	9.32	6.88e-20	3.27e-17	0.34	0.28	Ulcerative colitis;	chr3:52951996	chr3:53064283~53065091:-
BRCA	cis	rs113835537	0.529	rs11227509	ENSG00000255517.5	CTD-3074O7.5	-9.32	6.89e-20	3.28e-17	-0.36	-0.28	Airway imaging phenotypes;	chr11:66513723	chr11:66473490~66480233:-
BRCA	cis	rs113835537	0.529	rs11227510	ENSG00000255517.5	CTD-3074O7.5	-9.32	6.89e-20	3.28e-17	-0.36	-0.28	Airway imaging phenotypes;	chr11:66513749	chr11:66473490~66480233:-
BRCA	cis	rs113835537	0.529	rs11227512	ENSG00000255517.5	CTD-3074O7.5	-9.32	6.89e-20	3.28e-17	-0.36	-0.28	Airway imaging phenotypes;	chr11:66513820	chr11:66473490~66480233:-
BRCA	cis	rs113835537	0.529	rs2298806	ENSG00000255517.5	CTD-3074O7.5	-9.32	6.89e-20	3.28e-17	-0.36	-0.28	Airway imaging phenotypes;	chr11:66514624	chr11:66473490~66480233:-
BRCA	cis	rs113835537	0.529	rs2276406	ENSG00000255517.5	CTD-3074O7.5	-9.32	6.89e-20	3.28e-17	-0.36	-0.28	Airway imaging phenotypes;	chr11:66515786	chr11:66473490~66480233:-
BRCA	cis	rs7829975	0.742	rs12547493	ENSG00000253893.2	FAM85B	9.32	6.89e-20	3.28e-17	0.35	0.28	Mood instability;	chr8:8804024	chr8:8167819~8226614:-
BRCA	cis	rs2221433	1	rs1110269	ENSG00000260310.1	RP11-27M24.2	-9.32	6.92e-20	3.29e-17	-0.33	-0.28	Eating disorders;	chr16:10578731	chr16:10576499~10578183:-
BRCA	cis	rs2933343	1	rs2929859	ENSG00000231305.3	RP11-723O4.2	9.32	6.96e-20	3.31e-17	0.34	0.28	IgG glycosylation;	chr3:128889498	chr3:128861313~128871540:-
BRCA	cis	rs11159086	0.793	rs10147316	ENSG00000259005.1	RP3-449M8.6	9.32	6.99e-20	3.32e-17	0.41	0.28	Advanced glycation end-product levels;	chr14:74475688	chr14:74474007~74474864:-
BRCA	cis	rs11159086	0.838	rs10147963	ENSG00000259005.1	RP3-449M8.6	9.32	6.99e-20	3.32e-17	0.41	0.28	Advanced glycation end-product levels;	chr14:74476091	chr14:74474007~74474864:-
BRCA	cis	rs875971	0.825	rs1129531	ENSG00000237310.1	GS1-124K5.4	-9.32	6.99e-20	3.32e-17	-0.29	-0.28	Aortic root size;	chr7:66154117	chr7:66493706~66495474:+
BRCA	cis	rs1075265	0.704	rs6711217	ENSG00000233266.1	HMGB1P31	9.32	7.01e-20	3.33e-17	0.33	0.28	Chronotype;Morning vs. evening chronotype;	chr2:54017892	chr2:54051334~54051760:+
BRCA	cis	rs7829975	0.567	rs6601273	ENSG00000253893.2	FAM85B	9.32	7.03e-20	3.34e-17	0.34	0.28	Mood instability;	chr8:8939009	chr8:8167819~8226614:-
BRCA	cis	rs13256369	0.802	rs13281933	ENSG00000253893.2	FAM85B	-9.31	7.04e-20	3.35e-17	-0.39	-0.28	Obesity-related traits;	chr8:8705155	chr8:8167819~8226614:-
BRCA	cis	rs801193	1	rs7782320	ENSG00000222364.1	RNU6-96P	-9.31	7.09e-20	3.37e-17	-0.32	-0.28	Aortic root size;	chr7:66712111	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.545	rs66594357	ENSG00000237310.1	GS1-124K5.4	9.31	7.09e-20	3.37e-17	0.33	0.28	Aortic root size;	chr7:66327797	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.545	rs1796217	ENSG00000237310.1	GS1-124K5.4	-9.31	7.11e-20	3.38e-17	-0.33	-0.28	Aortic root size;	chr7:66620931	chr7:66493706~66495474:+
BRCA	cis	rs12701220	0.655	rs34344742	ENSG00000229043.2	AC091729.9	-9.31	7.12e-20	3.38e-17	-0.39	-0.28	Bronchopulmonary dysplasia;	chr7:1109652	chr7:1160374~1165267:+
BRCA	cis	rs858239	0.601	rs1981665	ENSG00000226816.2	AC005082.12	9.31	7.16e-20	3.4e-17	0.32	0.28	Cerebrospinal fluid biomarker levels;	chr7:23128350	chr7:23206013~23208045:+
BRCA	cis	rs6782228	1	rs35871360	ENSG00000242551.2	POU5F1P6	9.31	7.17e-20	3.41e-17	0.4	0.28	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128617286	chr3:128674735~128677005:-
BRCA	cis	rs2243480	0.901	rs73148097	ENSG00000226824.5	RP4-756H11.3	-9.31	7.21e-20	3.43e-17	-0.53	-0.28	Diabetic kidney disease;	chr7:65966800	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs906134	ENSG00000226824.5	RP4-756H11.3	-9.31	7.21e-20	3.43e-17	-0.53	-0.28	Diabetic kidney disease;	chr7:65979301	chr7:66654538~66669855:+
BRCA	cis	rs10262624	1	rs2106747	ENSG00000234286.1	AC006026.13	-9.31	7.23e-20	3.43e-17	-0.32	-0.28	Schizophrenia;	chr7:23871880	chr7:23680195~23680786:-
BRCA	cis	rs4820294	0.669	rs12628135	ENSG00000233360.4	Z83844.1	9.31	7.25e-20	3.44e-17	0.31	0.28	Fat distribution (HIV);	chr22:37669648	chr22:37641832~37658377:-
BRCA	cis	rs858239	0.536	rs6956974	ENSG00000226816.2	AC005082.12	-9.31	7.25e-20	3.44e-17	-0.32	-0.28	Cerebrospinal fluid biomarker levels;	chr7:23212699	chr7:23206013~23208045:+
BRCA	cis	rs2243480	0.803	rs35480979	ENSG00000226824.5	RP4-756H11.3	-9.31	7.29e-20	3.46e-17	-0.53	-0.28	Diabetic kidney disease;	chr7:65892097	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs35391607	ENSG00000226824.5	RP4-756H11.3	-9.31	7.29e-20	3.46e-17	-0.53	-0.28	Diabetic kidney disease;	chr7:65895842	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs13220979	ENSG00000226824.5	RP4-756H11.3	-9.31	7.29e-20	3.46e-17	-0.53	-0.28	Diabetic kidney disease;	chr7:65898217	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs34974928	ENSG00000226824.5	RP4-756H11.3	-9.31	7.29e-20	3.46e-17	-0.53	-0.28	Diabetic kidney disease;	chr7:65899019	chr7:66654538~66669855:+
BRCA	cis	rs465969	0.744	rs13220692	ENSG00000255389.1	C6orf3	-9.31	7.33e-20	3.48e-17	-0.57	-0.28	Psoriasis;	chr6:111455836	chr6:111599875~111602295:+
BRCA	cis	rs957448	1	rs12678305	ENSG00000253704.1	RP11-267M23.4	9.31	7.34e-20	3.48e-17	0.33	0.28	Nonsyndromic cleft lip with cleft palate;	chr8:94508911	chr8:94553722~94569745:+
BRCA	cis	rs1823913	0.637	rs4853575	ENSG00000227542.1	AC092614.2	-9.31	7.34e-20	3.49e-17	-0.33	-0.28	Obesity-related traits;	chr2:191296149	chr2:191229165~191246172:-
BRCA	cis	rs10262624	1	rs2106748	ENSG00000234286.1	AC006026.13	-9.31	7.35e-20	3.49e-17	-0.32	-0.28	Schizophrenia;	chr7:23871694	chr7:23680195~23680786:-
BRCA	cis	rs227275	0.525	rs28445579	ENSG00000246560.2	RP11-10L12.4	9.31	7.37e-20	3.5e-17	0.29	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:103016438	chr4:102828055~102844075:+
BRCA	cis	rs2439831	0.702	rs2788	ENSG00000205771.5	CATSPER2P1	-9.31	7.38e-20	3.5e-17	-0.48	-0.28	Lung cancer in ever smokers;	chr15:43772688	chr15:43726918~43747094:-
BRCA	cis	rs2439831	0.85	rs28891769	ENSG00000205771.5	CATSPER2P1	-9.31	7.38e-20	3.5e-17	-0.48	-0.28	Lung cancer in ever smokers;	chr15:43780662	chr15:43726918~43747094:-
BRCA	cis	rs2439831	0.85	rs28578398	ENSG00000205771.5	CATSPER2P1	-9.31	7.38e-20	3.5e-17	-0.48	-0.28	Lung cancer in ever smokers;	chr15:43782848	chr15:43726918~43747094:-
BRCA	cis	rs957448	0.948	rs1470153	ENSG00000253704.1	RP11-267M23.4	9.31	7.4e-20	3.51e-17	0.33	0.28	Nonsyndromic cleft lip with cleft palate;	chr8:94514587	chr8:94553722~94569745:+
BRCA	cis	rs1075265	0.73	rs6711105	ENSG00000233266.1	HMGB1P31	9.31	7.41e-20	3.52e-17	0.33	0.28	Chronotype;Morning vs. evening chronotype;	chr2:54017775	chr2:54051334~54051760:+
BRCA	cis	rs7429990	0.864	rs3772399	ENSG00000229759.1	MRPS18AP1	-9.31	7.42e-20	3.52e-17	-0.31	-0.28	Educational attainment (years of education);	chr3:47826237	chr3:48256350~48256938:-
BRCA	cis	rs7580658	0.891	rs55998967	ENSG00000236682.1	AC068282.3	-9.31	7.43e-20	3.53e-17	-0.37	-0.28	Protein C levels;	chr2:127291098	chr2:127389130~127400580:+
BRCA	cis	rs6558530	1	rs6558530	ENSG00000253982.1	CTD-2336O2.1	9.31	7.44e-20	3.53e-17	0.32	0.28	Systolic blood pressure;	chr8:1758041	chr8:1761990~1764502:-
BRCA	cis	rs2439831	0.85	rs60883262	ENSG00000205771.5	CATSPER2P1	-9.31	7.44e-20	3.53e-17	-0.48	-0.28	Lung cancer in ever smokers;	chr15:43784305	chr15:43726918~43747094:-
BRCA	cis	rs7772486	0.875	rs1125461	ENSG00000235652.6	RP11-545I5.3	9.31	7.46e-20	3.54e-17	0.28	0.28	Lobe attachment (rater-scored or self-reported);	chr6:146096517	chr6:145799409~145886585:+
BRCA	cis	rs2439831	0.702	rs8033995	ENSG00000205771.5	CATSPER2P1	-9.31	7.48e-20	3.55e-17	-0.48	-0.28	Lung cancer in ever smokers;	chr15:43721311	chr15:43726918~43747094:-
BRCA	cis	rs7924176	0.601	rs10824073	ENSG00000213731.2	RAB5CP1	-9.31	7.53e-20	3.57e-17	-0.3	-0.28	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74115458	chr10:74423435~74424014:-
BRCA	cis	rs2067615	0.579	rs7964605	ENSG00000260329.1	RP11-412D9.4	9.31	7.54e-20	3.58e-17	0.3	0.28	Heart rate;	chr12:106811635	chr12:106954029~106955497:-
BRCA	cis	rs35160687	0.712	rs11691807	ENSG00000273080.1	RP11-301O19.1	-9.31	7.55e-20	3.58e-17	-0.32	-0.28	Night sleep phenotypes;	chr2:86255898	chr2:86195590~86196049:+
BRCA	cis	rs2274273	0.868	rs9919926	ENSG00000258413.1	RP11-665C16.6	-9.31	7.6e-20	3.6e-17	-0.35	-0.28	Protein biomarker;	chr14:55347172	chr14:55262767~55272075:-
BRCA	cis	rs6570726	0.846	rs7762536	ENSG00000235652.6	RP11-545I5.3	9.31	7.6e-20	3.6e-17	0.28	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145602009	chr6:145799409~145886585:+
BRCA	cis	rs1707322	1	rs785467	ENSG00000280836.1	AL355480.1	9.31	7.6e-20	3.6e-17	0.36	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46055887	chr1:45581219~45581321:-
BRCA	cis	rs2274273	0.934	rs10144418	ENSG00000258413.1	RP11-665C16.6	-9.31	7.62e-20	3.61e-17	-0.35	-0.28	Protein biomarker;	chr14:55350990	chr14:55262767~55272075:-
BRCA	cis	rs7772486	0.875	rs6934467	ENSG00000235652.6	RP11-545I5.3	9.3	7.68e-20	3.64e-17	0.28	0.28	Lobe attachment (rater-scored or self-reported);	chr6:146089393	chr6:145799409~145886585:+
BRCA	cis	rs8062405	1	rs2008514	ENSG00000278665.1	RP11-666O2.4	-9.3	7.7e-20	3.65e-17	-0.29	-0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814284	chr16:28599241~28601881:-
BRCA	cis	rs4835473	0.932	rs7356305	ENSG00000251600.4	RP11-673E1.1	9.3	7.7e-20	3.65e-17	0.32	0.28	Immature fraction of reticulocytes;	chr4:143737850	chr4:143912331~143982454:+
BRCA	cis	rs9287719	0.967	rs4668691	ENSG00000234818.1	AC092687.5	9.3	7.71e-20	3.66e-17	0.32	0.28	Prostate cancer;	chr2:10600368	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.934	rs10181806	ENSG00000234818.1	AC092687.5	9.3	7.71e-20	3.66e-17	0.32	0.28	Prostate cancer;	chr2:10601015	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs11687023	ENSG00000234818.1	AC092687.5	9.3	7.71e-20	3.66e-17	0.32	0.28	Prostate cancer;	chr2:10601286	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs10454738	ENSG00000234818.1	AC092687.5	9.3	7.71e-20	3.66e-17	0.32	0.28	Prostate cancer;	chr2:10601923	chr2:10589166~10604830:+
BRCA	cis	rs875971	0.545	rs75840613	ENSG00000237310.1	GS1-124K5.4	9.3	7.73e-20	3.66e-17	0.33	0.28	Aortic root size;	chr7:66376399	chr7:66493706~66495474:+
BRCA	cis	rs2933343	0.951	rs796862	ENSG00000231305.3	RP11-723O4.2	9.3	7.73e-20	3.66e-17	0.34	0.28	IgG glycosylation;	chr3:128874197	chr3:128861313~128871540:-
BRCA	cis	rs7772486	0.875	rs9399572	ENSG00000235652.6	RP11-545I5.3	9.3	7.76e-20	3.68e-17	0.28	0.28	Lobe attachment (rater-scored or self-reported);	chr6:146041809	chr6:145799409~145886585:+
BRCA	cis	rs4835473	0.838	rs34819068	ENSG00000251600.4	RP11-673E1.1	-9.3	7.77e-20	3.68e-17	-0.32	-0.28	Immature fraction of reticulocytes;	chr4:143787330	chr4:143912331~143982454:+
BRCA	cis	rs10262624	1	rs10262624	ENSG00000234286.1	AC006026.13	-9.3	7.77e-20	3.68e-17	-0.32	-0.28	Schizophrenia;	chr7:23876057	chr7:23680195~23680786:-
BRCA	cis	rs2274273	0.87	rs17741542	ENSG00000258413.1	RP11-665C16.6	9.3	7.82e-20	3.71e-17	0.35	0.28	Protein biomarker;	chr14:55339143	chr14:55262767~55272075:-
BRCA	cis	rs875971	0.545	rs73148639	ENSG00000237310.1	GS1-124K5.4	9.3	7.85e-20	3.72e-17	0.33	0.28	Aortic root size;	chr7:66390342	chr7:66493706~66495474:+
BRCA	cis	rs7937890	0.559	rs2597196	ENSG00000251991.1	RNU7-49P	-9.3	7.86e-20	3.72e-17	-0.3	-0.28	Mitochondrial DNA levels;	chr11:14470055	chr11:14478892~14478953:+
BRCA	cis	rs7945705	0.935	rs1883098	ENSG00000254860.4	TMEM9B-AS1	9.3	7.86e-20	3.72e-17	0.25	0.28	Hemoglobin concentration;	chr11:8869047	chr11:8964675~8977527:+
BRCA	cis	rs2933343	1	rs789232	ENSG00000231305.3	RP11-723O4.2	9.3	7.87e-20	3.73e-17	0.34	0.28	IgG glycosylation;	chr3:128884237	chr3:128861313~128871540:-
BRCA	cis	rs67311347	1	rs1119179	ENSG00000223797.4	ENTPD3-AS1	-9.3	7.88e-20	3.73e-17	-0.32	-0.28	Renal cell carcinoma;	chr3:40383438	chr3:40313802~40453329:-
BRCA	cis	rs6570726	0.791	rs952406	ENSG00000235652.6	RP11-545I5.3	9.3	7.89e-20	3.74e-17	0.28	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145604480	chr6:145799409~145886585:+
BRCA	cis	rs4718428	0.672	rs13241598	ENSG00000232546.1	RP11-458F8.1	-9.3	7.91e-20	3.74e-17	-0.26	-0.28	Corneal structure;	chr7:66835665	chr7:66848496~66858136:+
BRCA	cis	rs227275	0.556	rs4699044	ENSG00000246560.2	RP11-10L12.4	9.3	7.98e-20	3.78e-17	0.29	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102976939	chr4:102828055~102844075:+
BRCA	cis	rs9287719	0.967	rs6759714	ENSG00000234818.1	AC092687.5	9.3	7.98e-20	3.78e-17	0.32	0.28	Prostate cancer;	chr2:10607081	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs6744854	ENSG00000234818.1	AC092687.5	9.3	7.98e-20	3.78e-17	0.32	0.28	Prostate cancer;	chr2:10607120	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs6759740	ENSG00000234818.1	AC092687.5	9.3	7.98e-20	3.78e-17	0.32	0.28	Prostate cancer;	chr2:10607145	chr2:10589166~10604830:+
BRCA	cis	rs801193	1	rs10252765	ENSG00000222364.1	RNU6-96P	-9.3	7.98e-20	3.78e-17	-0.32	-0.28	Aortic root size;	chr7:66763745	chr7:66395191~66395286:+
BRCA	cis	rs6538678	0.895	rs4762637	ENSG00000258343.1	RP11-536G4.2	-9.3	8.01e-20	3.79e-17	-0.39	-0.28	Lupus nephritis in systemic lupus erythematosus;	chr12:95888877	chr12:95795345~95858839:-
BRCA	cis	rs7772486	0.875	rs9403770	ENSG00000235652.6	RP11-545I5.3	9.3	8.03e-20	3.8e-17	0.28	0.28	Lobe attachment (rater-scored or self-reported);	chr6:146102198	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.875	rs11155452	ENSG00000235652.6	RP11-545I5.3	9.3	8.03e-20	3.8e-17	0.28	0.28	Lobe attachment (rater-scored or self-reported);	chr6:146103495	chr6:145799409~145886585:+
BRCA	cis	rs319690	1	rs319690	ENSG00000229759.1	MRPS18AP1	9.3	8.04e-20	3.8e-17	0.31	0.28	Diastolic blood pressure;Systolic blood pressure;Blood pressure;	chr3:47885994	chr3:48256350~48256938:-
BRCA	cis	rs13256369	0.851	rs11786125	ENSG00000253893.2	FAM85B	-9.3	8.06e-20	3.82e-17	-0.39	-0.28	Obesity-related traits;	chr8:8707060	chr8:8167819~8226614:-
BRCA	cis	rs2274273	0.84	rs11547116	ENSG00000258413.1	RP11-665C16.6	-9.3	8.1e-20	3.83e-17	-0.35	-0.28	Protein biomarker;	chr14:55271447	chr14:55262767~55272075:-
BRCA	cis	rs9287719	0.967	rs6748036	ENSG00000234818.1	AC092687.5	9.3	8.12e-20	3.84e-17	0.32	0.28	Prostate cancer;	chr2:10577363	chr2:10589166~10604830:+
BRCA	cis	rs783540	0.9	rs783525	ENSG00000278603.1	RP13-608F4.5	-9.3	8.14e-20	3.85e-17	-0.35	-0.28	Schizophrenia;	chr15:82615878	chr15:82472203~82472426:+
BRCA	cis	rs6570726	0.764	rs9403726	ENSG00000235652.6	RP11-545I5.3	9.3	8.15e-20	3.86e-17	0.27	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145580550	chr6:145799409~145886585:+
BRCA	cis	rs8012947	1	rs10147580	ENSG00000279636.2	LINC00216	-9.3	8.16e-20	3.86e-17	-0.3	-0.28	Alcohol consumption in current drinkers;	chr14:58247422	chr14:58288033~58289158:+
BRCA	cis	rs4835473	0.932	rs1450236	ENSG00000251600.4	RP11-673E1.1	-9.3	8.17e-20	3.86e-17	-0.32	-0.28	Immature fraction of reticulocytes;	chr4:143783069	chr4:143912331~143982454:+
BRCA	cis	rs875971	0.545	rs6460276	ENSG00000237310.1	GS1-124K5.4	9.3	8.17e-20	3.87e-17	0.33	0.28	Aortic root size;	chr7:66182290	chr7:66493706~66495474:+
BRCA	cis	rs2933343	1	rs789227	ENSG00000231305.3	RP11-723O4.2	9.3	8.18e-20	3.87e-17	0.34	0.28	IgG glycosylation;	chr3:128881742	chr3:128861313~128871540:-
BRCA	cis	rs1075265	0.704	rs805410	ENSG00000233266.1	HMGB1P31	9.3	8.19e-20	3.87e-17	0.33	0.28	Chronotype;Morning vs. evening chronotype;	chr2:53893360	chr2:54051334~54051760:+
BRCA	cis	rs11098499	0.691	rs10028773	ENSG00000245958.5	RP11-33B1.1	9.3	8.21e-20	3.88e-17	0.25	0.28	Corneal astigmatism;	chr4:119344104	chr4:119454791~119552025:+
BRCA	cis	rs6558530	0.897	rs7838456	ENSG00000253982.1	CTD-2336O2.1	9.3	8.23e-20	3.89e-17	0.32	0.28	Systolic blood pressure;	chr8:1759425	chr8:1761990~1764502:-
BRCA	cis	rs11722779	0.935	rs7681629	ENSG00000246560.2	RP11-10L12.4	9.3	8.23e-20	3.89e-17	0.29	0.28	Schizophrenia;	chr4:102974407	chr4:102828055~102844075:+
BRCA	cis	rs11722779	0.844	rs17033381	ENSG00000246560.2	RP11-10L12.4	9.3	8.23e-20	3.89e-17	0.29	0.28	Schizophrenia;	chr4:102974952	chr4:102828055~102844075:+
BRCA	cis	rs227275	0.556	rs4699045	ENSG00000246560.2	RP11-10L12.4	9.3	8.23e-20	3.89e-17	0.29	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102977009	chr4:102828055~102844075:+
BRCA	cis	rs11098499	0.954	rs1546505	ENSG00000248280.1	RP11-33B1.2	9.3	8.25e-20	3.9e-17	0.28	0.28	Corneal astigmatism;	chr4:119320069	chr4:119440561~119450157:-
BRCA	cis	rs11159086	0.793	rs8021664	ENSG00000259005.1	RP3-449M8.6	9.3	8.31e-20	3.93e-17	0.41	0.28	Advanced glycation end-product levels;	chr14:74476592	chr14:74474007~74474864:-
BRCA	cis	rs10262624	0.967	rs2390848	ENSG00000234286.1	AC006026.13	-9.3	8.32e-20	3.93e-17	-0.32	-0.28	Schizophrenia;	chr7:23872755	chr7:23680195~23680786:-
BRCA	cis	rs9287719	0.967	rs6432113	ENSG00000234818.1	AC092687.5	-9.3	8.35e-20	3.95e-17	-0.32	-0.28	Prostate cancer;	chr2:10604763	chr2:10589166~10604830:+
BRCA	cis	rs7772486	0.817	rs9386145	ENSG00000235652.6	RP11-545I5.3	9.3	8.35e-20	3.95e-17	0.28	0.28	Lobe attachment (rater-scored or self-reported);	chr6:146042383	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.875	rs9390372	ENSG00000235652.6	RP11-545I5.3	9.3	8.35e-20	3.95e-17	0.28	0.28	Lobe attachment (rater-scored or self-reported);	chr6:146042502	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.875	rs9373483	ENSG00000235652.6	RP11-545I5.3	9.3	8.35e-20	3.95e-17	0.28	0.28	Lobe attachment (rater-scored or self-reported);	chr6:146043058	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.875	rs7766595	ENSG00000235652.6	RP11-545I5.3	9.3	8.35e-20	3.95e-17	0.28	0.28	Lobe attachment (rater-scored or self-reported);	chr6:146043371	chr6:145799409~145886585:+
BRCA	cis	rs321358	0.731	rs7940380	ENSG00000271584.1	RP11-89C3.4	9.3	8.36e-20	3.95e-17	0.44	0.28	Body mass index;	chr11:111149974	chr11:111091932~111097357:-
BRCA	cis	rs227275	0.554	rs223319	ENSG00000246560.2	RP11-10L12.4	9.29	8.4e-20	3.97e-17	0.29	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102881157	chr4:102828055~102844075:+
BRCA	cis	rs228614	0.509	rs223318	ENSG00000246560.2	RP11-10L12.4	9.29	8.4e-20	3.97e-17	0.29	0.28	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102881422	chr4:102828055~102844075:+
BRCA	cis	rs227275	0.554	rs223315	ENSG00000246560.2	RP11-10L12.4	9.29	8.4e-20	3.97e-17	0.29	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102884286	chr4:102828055~102844075:+
BRCA	cis	rs875971	0.522	rs6960048	ENSG00000224316.1	RP11-479O9.2	9.29	8.45e-20	3.99e-17	0.28	0.28	Aortic root size;	chr7:65943052	chr7:65773620~65802067:+
BRCA	cis	rs853679	0.76	rs9357067	ENSG00000220721.1	OR1F12	9.29	8.46e-20	4e-17	0.39	0.28	Depression;	chr6:28242515	chr6:28073316~28074233:+
BRCA	cis	rs10262624	1	rs10950973	ENSG00000234286.1	AC006026.13	-9.29	8.46e-20	4e-17	-0.32	-0.28	Schizophrenia;	chr7:23877658	chr7:23680195~23680786:-
BRCA	cis	rs10262624	1	rs10950974	ENSG00000234286.1	AC006026.13	-9.29	8.46e-20	4e-17	-0.32	-0.28	Schizophrenia;	chr7:23877661	chr7:23680195~23680786:-
BRCA	cis	rs75422866	0.867	rs73102125	ENSG00000257433.4	RP1-197B17.3	9.29	8.47e-20	4e-17	0.62	0.28	Pneumonia;	chr12:47637869	chr12:47706085~47742294:+
BRCA	cis	rs75422866	0.867	rs12426849	ENSG00000257433.4	RP1-197B17.3	9.29	8.47e-20	4e-17	0.62	0.28	Pneumonia;	chr12:47638975	chr12:47706085~47742294:+
BRCA	cis	rs75422866	0.867	rs117950951	ENSG00000257433.4	RP1-197B17.3	9.29	8.47e-20	4e-17	0.62	0.28	Pneumonia;	chr12:47639794	chr12:47706085~47742294:+
BRCA	cis	rs75422866	0.867	rs7954764	ENSG00000257433.4	RP1-197B17.3	9.29	8.47e-20	4e-17	0.62	0.28	Pneumonia;	chr12:47641136	chr12:47706085~47742294:+
BRCA	cis	rs11722779	0.935	rs6533046	ENSG00000246560.2	RP11-10L12.4	9.29	8.48e-20	4e-17	0.29	0.28	Schizophrenia;	chr4:102965917	chr4:102828055~102844075:+
BRCA	cis	rs55665837	0.539	rs10766196	ENSG00000251991.1	RNU7-49P	9.29	8.49e-20	4.01e-17	0.31	0.28	Vitamin D levels;	chr11:14891585	chr11:14478892~14478953:+
BRCA	cis	rs1075265	0.704	rs10084374	ENSG00000233266.1	HMGB1P31	9.29	8.56e-20	4.04e-17	0.33	0.28	Chronotype;Morning vs. evening chronotype;	chr2:54022175	chr2:54051334~54051760:+
BRCA	cis	rs6952407	1	rs6952407	ENSG00000222364.1	RNU6-96P	9.29	8.57e-20	4.04e-17	0.32	0.28	Cotinine glucuronidation;	chr7:66580525	chr7:66395191~66395286:+
BRCA	cis	rs7811142	0.943	rs111757992	ENSG00000242294.5	STAG3L5P	9.29	8.57e-20	4.05e-17	0.26	0.28	Platelet count;	chr7:100418731	chr7:100336079~100351900:+
BRCA	cis	rs10262624	0.967	rs7792734	ENSG00000234286.1	AC006026.13	-9.29	8.61e-20	4.06e-17	-0.32	-0.28	Schizophrenia;	chr7:23876429	chr7:23680195~23680786:-
BRCA	cis	rs2276314	1	rs1789513	ENSG00000278986.1	RP11-723J4.3	9.29	8.65e-20	4.08e-17	0.36	0.28	Endometriosis;Drug-induced torsades de pointes;	chr18:35965667	chr18:35972151~35973916:+
BRCA	cis	rs801193	0.844	rs2244022	ENSG00000222364.1	RNU6-96P	-9.29	8.69e-20	4.1e-17	-0.32	-0.28	Aortic root size;	chr7:66737443	chr7:66395191~66395286:+
BRCA	cis	rs11159086	0.793	rs8015894	ENSG00000259005.1	RP3-449M8.6	9.29	8.74e-20	4.12e-17	0.41	0.28	Advanced glycation end-product levels;	chr14:74491917	chr14:74474007~74474864:-
BRCA	cis	rs10262624	1	rs2390847	ENSG00000234286.1	AC006026.13	-9.29	8.77e-20	4.14e-17	-0.32	-0.28	Schizophrenia;	chr7:23872082	chr7:23680195~23680786:-
BRCA	cis	rs2439831	0.702	rs7175032	ENSG00000205771.5	CATSPER2P1	-9.29	8.77e-20	4.14e-17	-0.48	-0.28	Lung cancer in ever smokers;	chr15:43768038	chr15:43726918~43747094:-
BRCA	cis	rs17023223	0.581	rs61808932	ENSG00000231365.4	RP11-418J17.1	-9.29	8.79e-20	4.14e-17	-0.36	-0.28	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119101197	chr1:119140396~119275973:+
BRCA	cis	rs11159086	0.793	rs28378078	ENSG00000259005.1	RP3-449M8.6	9.29	8.79e-20	4.15e-17	0.41	0.28	Advanced glycation end-product levels;	chr14:74487940	chr14:74474007~74474864:-
BRCA	cis	rs4835473	0.643	rs34680080	ENSG00000251600.4	RP11-673E1.1	-9.29	8.83e-20	4.16e-17	-0.32	-0.28	Immature fraction of reticulocytes;	chr4:143797290	chr4:143912331~143982454:+
BRCA	cis	rs3096299	0.838	rs4785561	ENSG00000274627.1	RP11-104N10.2	9.29	8.88e-20	4.19e-17	0.29	0.28	Multiple myeloma (IgH translocation);	chr16:89362644	chr16:89516797~89522217:+
BRCA	cis	rs9287719	0.967	rs6706542	ENSG00000234818.1	AC092687.5	9.29	8.97e-20	4.23e-17	0.32	0.28	Prostate cancer;	chr2:10602365	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs2287061	ENSG00000234818.1	AC092687.5	9.29	8.97e-20	4.23e-17	0.32	0.28	Prostate cancer;	chr2:10603027	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs2287062	ENSG00000234818.1	AC092687.5	9.29	8.97e-20	4.23e-17	0.32	0.28	Prostate cancer;	chr2:10603065	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.935	rs1309	ENSG00000234818.1	AC092687.5	9.29	8.97e-20	4.23e-17	0.32	0.28	Prostate cancer;	chr2:10603420	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs3815521	ENSG00000234818.1	AC092687.5	9.29	8.97e-20	4.23e-17	0.32	0.28	Prostate cancer;	chr2:10603528	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs10929686	ENSG00000234818.1	AC092687.5	9.29	8.97e-20	4.23e-17	0.32	0.28	Prostate cancer;	chr2:10603579	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs4613248	ENSG00000234818.1	AC092687.5	9.29	8.97e-20	4.23e-17	0.32	0.28	Prostate cancer;	chr2:10603925	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs10191883	ENSG00000234818.1	AC092687.5	9.29	8.97e-20	4.23e-17	0.32	0.28	Prostate cancer;	chr2:10604010	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.934	rs4629131	ENSG00000234818.1	AC092687.5	9.29	8.97e-20	4.23e-17	0.32	0.28	Prostate cancer;	chr2:10604033	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.901	rs4555317	ENSG00000234818.1	AC092687.5	9.29	8.97e-20	4.23e-17	0.32	0.28	Prostate cancer;	chr2:10604121	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs4555318	ENSG00000234818.1	AC092687.5	9.29	8.97e-20	4.23e-17	0.32	0.28	Prostate cancer;	chr2:10604169	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.934	rs4622695	ENSG00000234818.1	AC092687.5	9.29	8.97e-20	4.23e-17	0.32	0.28	Prostate cancer;	chr2:10604201	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.934	rs6432111	ENSG00000234818.1	AC092687.5	9.29	8.97e-20	4.23e-17	0.32	0.28	Prostate cancer;	chr2:10604494	chr2:10589166~10604830:+
BRCA	cis	rs2243480	1	rs2961102	ENSG00000226824.5	RP4-756H11.3	-9.29	8.98e-20	4.23e-17	-0.53	-0.28	Diabetic kidney disease;	chr7:65959671	chr7:66654538~66669855:+
BRCA	cis	rs10262624	0.967	rs13244145	ENSG00000234286.1	AC006026.13	-9.29	8.99e-20	4.24e-17	-0.32	-0.28	Schizophrenia;	chr7:23878123	chr7:23680195~23680786:-
BRCA	cis	rs7772486	0.875	rs7739418	ENSG00000235652.6	RP11-545I5.3	9.29	9.01e-20	4.24e-17	0.27	0.28	Lobe attachment (rater-scored or self-reported);	chr6:146038052	chr6:145799409~145886585:+
BRCA	cis	rs6545883	0.524	rs12713435	ENSG00000271889.1	RP11-493E12.1	-9.29	9.06e-20	4.27e-17	-0.33	-0.28	Tuberculosis;	chr2:61272654	chr2:61151433~61162105:-
BRCA	cis	rs10262624	1	rs9769098	ENSG00000234286.1	AC006026.13	-9.29	9.09e-20	4.28e-17	-0.32	-0.28	Schizophrenia;	chr7:23877113	chr7:23680195~23680786:-
BRCA	cis	rs10262624	0.967	rs12333669	ENSG00000234286.1	AC006026.13	-9.29	9.09e-20	4.28e-17	-0.32	-0.28	Schizophrenia;	chr7:23877267	chr7:23680195~23680786:-
BRCA	cis	rs10262624	0.935	rs10487596	ENSG00000234286.1	AC006026.13	-9.29	9.09e-20	4.28e-17	-0.32	-0.28	Schizophrenia;	chr7:23877458	chr7:23680195~23680786:-
BRCA	cis	rs10262624	1	rs10950975	ENSG00000234286.1	AC006026.13	-9.29	9.09e-20	4.28e-17	-0.32	-0.28	Schizophrenia;	chr7:23877861	chr7:23680195~23680786:-
BRCA	cis	rs875971	0.862	rs10256544	ENSG00000237310.1	GS1-124K5.4	9.29	9.11e-20	4.29e-17	0.29	0.28	Aortic root size;	chr7:66210141	chr7:66493706~66495474:+
BRCA	cis	rs6921919	0.848	rs56131013	ENSG00000216901.1	AL022393.7	9.29	9.11e-20	4.29e-17	0.4	0.28	Autism spectrum disorder or schizophrenia;	chr6:28352900	chr6:28176188~28176674:+
BRCA	cis	rs11098499	1	rs28374891	ENSG00000245958.5	RP11-33B1.1	-9.29	9.12e-20	4.3e-17	-0.27	-0.28	Corneal astigmatism;	chr4:119262395	chr4:119454791~119552025:+
BRCA	cis	rs7829975	0.606	rs7819827	ENSG00000253893.2	FAM85B	9.28	9.13e-20	4.3e-17	0.34	0.28	Mood instability;	chr8:8939545	chr8:8167819~8226614:-
BRCA	cis	rs7829975	0.573	rs7842359	ENSG00000253893.2	FAM85B	9.28	9.13e-20	4.3e-17	0.34	0.28	Mood instability;	chr8:8939568	chr8:8167819~8226614:-
BRCA	cis	rs8072100	0.817	rs6505049	ENSG00000228782.6	CTD-2026D20.3	-9.28	9.17e-20	4.32e-17	-0.3	-0.28	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47598415	chr17:47450568~47492492:-
BRCA	cis	rs11098499	0.954	rs6820115	ENSG00000245958.5	RP11-33B1.1	-9.28	9.18e-20	4.32e-17	-0.26	-0.28	Corneal astigmatism;	chr4:119477027	chr4:119454791~119552025:+
BRCA	cis	rs11676348	0.808	rs4674267	ENSG00000261338.2	RP11-378A13.1	-9.28	9.2e-20	4.33e-17	-0.3	-0.28	Ulcerative colitis;	chr2:218181714	chr2:218255319~218257366:+
BRCA	cis	rs4862750	0.914	rs1346127	ENSG00000250971.1	RP11-696F12.1	-9.28	9.23e-20	4.35e-17	-0.3	-0.28	Lobe attachment (rater-scored or self-reported);	chr4:186955235	chr4:187060099~187060930:+
BRCA	cis	rs1113500	0.862	rs2336129	ENSG00000226822.1	RP11-356N1.2	-9.28	9.24e-20	4.35e-17	-0.36	-0.28	Growth-regulated protein alpha levels;	chr1:108098047	chr1:108071482~108074519:+
BRCA	cis	rs2243480	0.808	rs12698508	ENSG00000226824.5	RP4-756H11.3	-9.28	9.25e-20	4.36e-17	-0.53	-0.28	Diabetic kidney disease;	chr7:65946971	chr7:66654538~66669855:+
BRCA	cis	rs11159086	0.793	rs11850070	ENSG00000259005.1	RP3-449M8.6	9.28	9.27e-20	4.36e-17	0.41	0.28	Advanced glycation end-product levels;	chr14:74487575	chr14:74474007~74474864:-
BRCA	cis	rs2243480	1	rs73150014	ENSG00000226824.5	RP4-756H11.3	-9.28	9.29e-20	4.37e-17	-0.53	-0.28	Diabetic kidney disease;	chr7:65985932	chr7:66654538~66669855:+
BRCA	cis	rs10262624	1	rs12671624	ENSG00000234286.1	AC006026.13	-9.28	9.3e-20	4.38e-17	-0.32	-0.28	Schizophrenia;	chr7:23875794	chr7:23680195~23680786:-
BRCA	cis	rs875971	0.545	rs1796226	ENSG00000237310.1	GS1-124K5.4	9.28	9.32e-20	4.39e-17	0.32	0.28	Aortic root size;	chr7:66622723	chr7:66493706~66495474:+
BRCA	cis	rs10262624	1	rs2023787	ENSG00000234286.1	AC006026.13	-9.28	9.41e-20	4.43e-17	-0.32	-0.28	Schizophrenia;	chr7:23875521	chr7:23680195~23680786:-
BRCA	cis	rs17711722	0.701	rs4467826	ENSG00000224316.1	RP11-479O9.2	9.28	9.43e-20	4.44e-17	0.27	0.28	Calcium levels;	chr7:65903721	chr7:65773620~65802067:+
BRCA	cis	rs227275	0.525	rs1383733	ENSG00000246560.2	RP11-10L12.4	9.28	9.44e-20	4.44e-17	0.29	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102995297	chr4:102828055~102844075:+
BRCA	cis	rs465969	1	rs459048	ENSG00000255389.1	C6orf3	-9.28	9.45e-20	4.45e-17	-0.56	-0.28	Psoriasis;	chr6:111368429	chr6:111599875~111602295:+
BRCA	cis	rs465969	1	rs479343	ENSG00000255389.1	C6orf3	-9.28	9.45e-20	4.45e-17	-0.56	-0.28	Psoriasis;	chr6:111369701	chr6:111599875~111602295:+
BRCA	cis	rs465969	0.744	rs458017	ENSG00000255389.1	C6orf3	-9.28	9.45e-20	4.45e-17	-0.56	-0.28	Psoriasis;	chr6:111374888	chr6:111599875~111602295:+
BRCA	cis	rs465969	1	rs13213522	ENSG00000255389.1	C6orf3	-9.28	9.45e-20	4.45e-17	-0.56	-0.28	Psoriasis;	chr6:111384138	chr6:111599875~111602295:+
BRCA	cis	rs9368481	0.729	rs9379950	ENSG00000241549.7	GUSBP2	-9.28	9.53e-20	4.48e-17	-0.32	-0.28	Autism spectrum disorder or schizophrenia;	chr6:26993769	chr6:26871484~26956554:-
BRCA	cis	rs765787	0.53	rs12903149	ENSG00000259520.4	CTD-2651B20.3	-9.28	9.54e-20	4.49e-17	-0.35	-0.28	Uric acid levels;	chr15:45246878	chr15:45251580~45279251:-
BRCA	cis	rs12908161	0.959	rs17598603	ENSG00000225151.9	GOLGA2P7	9.28	9.54e-20	4.49e-17	0.35	0.28	Schizophrenia;	chr15:84656980	chr15:84199311~84230136:-
BRCA	cis	rs6782228	1	rs12635488	ENSG00000242551.2	POU5F1P6	9.28	9.55e-20	4.49e-17	0.43	0.28	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128633535	chr3:128674735~128677005:-
BRCA	cis	rs11096990	0.656	rs6531709	ENSG00000249207.1	RP11-360F5.1	9.28	9.59e-20	4.51e-17	0.32	0.28	Cognitive function;	chr4:39300629	chr4:39112677~39126818:-
BRCA	cis	rs35160687	0.712	rs7568971	ENSG00000273080.1	RP11-301O19.1	-9.28	9.66e-20	4.54e-17	-0.32	-0.28	Night sleep phenotypes;	chr2:86260917	chr2:86195590~86196049:+
BRCA	cis	rs35160687	0.712	rs12476826	ENSG00000273080.1	RP11-301O19.1	-9.28	9.66e-20	4.54e-17	-0.32	-0.28	Night sleep phenotypes;	chr2:86262397	chr2:86195590~86196049:+
BRCA	cis	rs35160687	0.712	rs4832270	ENSG00000273080.1	RP11-301O19.1	-9.28	9.66e-20	4.54e-17	-0.32	-0.28	Night sleep phenotypes;	chr2:86263065	chr2:86195590~86196049:+
BRCA	cis	rs35160687	0.712	rs6547668	ENSG00000273080.1	RP11-301O19.1	-9.28	9.66e-20	4.54e-17	-0.32	-0.28	Night sleep phenotypes;	chr2:86263538	chr2:86195590~86196049:+
BRCA	cis	rs858239	0.601	rs10255228	ENSG00000226816.2	AC005082.12	9.28	9.69e-20	4.56e-17	0.32	0.28	Cerebrospinal fluid biomarker levels;	chr7:23119244	chr7:23206013~23208045:+
BRCA	cis	rs12908161	0.96	rs17599989	ENSG00000225151.9	GOLGA2P7	-9.28	9.81e-20	4.61e-17	-0.35	-0.28	Schizophrenia;	chr15:84742305	chr15:84199311~84230136:-
BRCA	cis	rs853679	0.76	rs967005	ENSG00000220721.1	OR1F12	9.28	9.83e-20	4.62e-17	0.39	0.28	Depression;	chr6:28242910	chr6:28073316~28074233:+
BRCA	cis	rs957448	1	rs60655325	ENSG00000253704.1	RP11-267M23.4	9.28	9.84e-20	4.62e-17	0.33	0.28	Nonsyndromic cleft lip with cleft palate;	chr8:94552606	chr8:94553722~94569745:+
BRCA	cis	rs6061231	0.724	rs1570027	ENSG00000273619.1	RP5-908M14.9	-9.28	9.86e-20	4.64e-17	-0.26	-0.28	Colorectal cancer;	chr20:62393540	chr20:62386303~62386970:-
BRCA	cis	rs673078	0.607	rs6490177	ENSG00000275759.1	RP11-131L12.3	-9.28	9.91e-20	4.66e-17	-0.36	-0.28	Glucose homeostasis traits;	chr12:118358280	chr12:118428281~118428870:+
BRCA	cis	rs1075265	0.692	rs805318	ENSG00000233266.1	HMGB1P31	9.28	9.92e-20	4.66e-17	0.33	0.28	Chronotype;Morning vs. evening chronotype;	chr2:53907915	chr2:54051334~54051760:+
BRCA	cis	rs10262624	1	rs2023786	ENSG00000234286.1	AC006026.13	-9.28	9.95e-20	4.67e-17	-0.32	-0.28	Schizophrenia;	chr7:23875534	chr7:23680195~23680786:-
BRCA	cis	rs875971	0.895	rs4145009	ENSG00000237310.1	GS1-124K5.4	-9.27	9.95e-20	4.68e-17	-0.29	-0.28	Aortic root size;	chr7:66261628	chr7:66493706~66495474:+
BRCA	cis	rs13256369	0.755	rs12550057	ENSG00000253893.2	FAM85B	-9.27	9.99e-20	4.69e-17	-0.39	-0.28	Obesity-related traits;	chr8:8704758	chr8:8167819~8226614:-
BRCA	cis	rs1075265	0.669	rs805317	ENSG00000233266.1	HMGB1P31	9.27	1e-19	4.71e-17	0.33	0.28	Chronotype;Morning vs. evening chronotype;	chr2:53907867	chr2:54051334~54051760:+
BRCA	cis	rs858239	0.539	rs6975852	ENSG00000226816.2	AC005082.12	9.27	1.01e-19	4.72e-17	0.32	0.28	Cerebrospinal fluid biomarker levels;	chr7:23147035	chr7:23206013~23208045:+
BRCA	cis	rs858239	0.6	rs7790157	ENSG00000226816.2	AC005082.12	9.27	1.01e-19	4.74e-17	0.31	0.28	Cerebrospinal fluid biomarker levels;	chr7:23087379	chr7:23206013~23208045:+
BRCA	cis	rs881375	0.967	rs7046108	ENSG00000226752.6	PSMD5-AS1	9.27	1.01e-19	4.75e-17	0.33	0.28	Rheumatoid arthritis;	chr9:120898061	chr9:120824828~120854385:+
BRCA	cis	rs9807989	0.507	rs2110659	ENSG00000234389.1	AC007278.3	9.27	1.01e-19	4.75e-17	0.25	0.28	Asthma;	chr2:102427407	chr2:102438713~102440475:+
BRCA	cis	rs9807989	0.507	rs7605284	ENSG00000234389.1	AC007278.3	9.27	1.01e-19	4.75e-17	0.25	0.28	Asthma;	chr2:102427715	chr2:102438713~102440475:+
BRCA	cis	rs4988958	0.584	rs12712149	ENSG00000234389.1	AC007278.3	9.27	1.01e-19	4.75e-17	0.25	0.28	Asthma (childhood onset);	chr2:102428733	chr2:102438713~102440475:+
BRCA	cis	rs4988958	0.584	rs7559845	ENSG00000234389.1	AC007278.3	9.27	1.01e-19	4.75e-17	0.25	0.28	Asthma (childhood onset);	chr2:102429754	chr2:102438713~102440475:+
BRCA	cis	rs11098499	0.863	rs3822195	ENSG00000245958.5	RP11-33B1.1	-9.27	1.02e-19	4.77e-17	-0.27	-0.28	Corneal astigmatism;	chr4:119550505	chr4:119454791~119552025:+
BRCA	cis	rs9368481	1	rs9368481	ENSG00000241549.7	GUSBP2	-9.27	1.02e-19	4.77e-17	-0.32	-0.28	Autism spectrum disorder or schizophrenia;	chr6:26993982	chr6:26871484~26956554:-
BRCA	cis	rs4835473	0.838	rs56033497	ENSG00000251600.4	RP11-673E1.1	-9.27	1.02e-19	4.81e-17	-0.32	-0.28	Immature fraction of reticulocytes;	chr4:143792341	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs11100806	ENSG00000251600.4	RP11-673E1.1	9.27	1.03e-19	4.82e-17	0.32	0.28	Immature fraction of reticulocytes;	chr4:143761006	chr4:143912331~143982454:+
BRCA	cis	rs1075265	0.783	rs698858	ENSG00000233266.1	HMGB1P31	9.27	1.03e-19	4.84e-17	0.34	0.28	Chronotype;Morning vs. evening chronotype;	chr2:53943333	chr2:54051334~54051760:+
BRCA	cis	rs4718428	0.662	rs34577323	ENSG00000232546.1	RP11-458F8.1	-9.27	1.03e-19	4.85e-17	-0.26	-0.28	Corneal structure;	chr7:66845054	chr7:66848496~66858136:+
BRCA	cis	rs465969	1	rs463543	ENSG00000255389.1	C6orf3	-9.27	1.04e-19	4.86e-17	-0.56	-0.28	Psoriasis;	chr6:111346349	chr6:111599875~111602295:+
BRCA	cis	rs4718428	0.705	rs4718422	ENSG00000232546.1	RP11-458F8.1	-9.27	1.04e-19	4.86e-17	-0.26	-0.28	Corneal structure;	chr7:66894282	chr7:66848496~66858136:+
BRCA	cis	rs9807989	0.507	rs6758936	ENSG00000234389.1	AC007278.3	-9.27	1.04e-19	4.88e-17	-0.25	-0.28	Asthma;	chr2:102374909	chr2:102438713~102440475:+
BRCA	cis	rs8062405	0.755	rs4149398	ENSG00000278665.1	RP11-666O2.4	9.27	1.04e-19	4.88e-17	0.3	0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28597617	chr16:28599241~28601881:-
BRCA	cis	rs1823913	0.614	rs4853463	ENSG00000227542.1	AC092614.2	-9.27	1.04e-19	4.9e-17	-0.33	-0.28	Obesity-related traits;	chr2:191278699	chr2:191229165~191246172:-
BRCA	cis	rs10875746	0.669	rs1021313	ENSG00000240399.1	RP1-228P16.1	-9.27	1.05e-19	4.91e-17	-0.36	-0.28	Longevity (90 years and older);	chr12:48244258	chr12:48054813~48055591:-
BRCA	cis	rs875971	0.545	rs1638724	ENSG00000237310.1	GS1-124K5.4	-9.27	1.05e-19	4.91e-17	-0.33	-0.28	Aortic root size;	chr7:66575494	chr7:66493706~66495474:+
BRCA	cis	rs748404	0.666	rs12899865	ENSG00000249839.1	AC011330.5	-9.27	1.05e-19	4.91e-17	-0.39	-0.28	Lung cancer;	chr15:43448819	chr15:43663654~43684339:-
BRCA	cis	rs227275	0.525	rs7685399	ENSG00000246560.2	RP11-10L12.4	9.27	1.05e-19	4.91e-17	0.29	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102991926	chr4:102828055~102844075:+
BRCA	cis	rs227275	0.525	rs2866417	ENSG00000246560.2	RP11-10L12.4	9.27	1.05e-19	4.91e-17	0.29	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102993481	chr4:102828055~102844075:+
BRCA	cis	rs11673344	0.864	rs703530	ENSG00000226686.6	LINC01535	9.27	1.05e-19	4.93e-17	0.35	0.28	Obesity-related traits;	chr19:37010016	chr19:37251912~37265535:+
BRCA	cis	rs4722166	0.568	rs1880241	ENSG00000179428.2	AC073072.5	-9.27	1.05e-19	4.94e-17	-0.28	-0.28	Lung cancer;	chr7:22719850	chr7:22725395~22727620:-
BRCA	cis	rs2276314	0.857	rs28431958	ENSG00000278986.1	RP11-723J4.3	-9.27	1.06e-19	4.98e-17	-0.36	-0.28	Endometriosis;Drug-induced torsades de pointes;	chr18:35998438	chr18:35972151~35973916:+
BRCA	cis	rs875971	0.545	rs1267814	ENSG00000237310.1	GS1-124K5.4	-9.27	1.06e-19	4.98e-17	-0.33	-0.28	Aortic root size;	chr7:66579422	chr7:66493706~66495474:+
BRCA	cis	rs748404	0.666	rs16957715	ENSG00000249839.1	AC011330.5	-9.27	1.07e-19	4.99e-17	-0.39	-0.28	Lung cancer;	chr15:43416539	chr15:43663654~43684339:-
BRCA	cis	rs35160687	0.712	rs6745235	ENSG00000273080.1	RP11-301O19.1	-9.27	1.07e-19	5.01e-17	-0.32	-0.28	Night sleep phenotypes;	chr2:86259960	chr2:86195590~86196049:+
BRCA	cis	rs5751614	0.537	rs3788358	ENSG00000230701.2	FBXW4P1	9.27	1.08e-19	5.04e-17	0.35	0.28	Height;	chr22:23274168	chr22:23262767~23265005:+
BRCA	cis	rs11673344	0.864	rs1879497	ENSG00000226686.6	LINC01535	9.27	1.08e-19	5.04e-17	0.37	0.28	Obesity-related traits;	chr19:37141975	chr19:37251912~37265535:+
BRCA	cis	rs227275	0.525	rs9917919	ENSG00000246560.2	RP11-10L12.4	9.27	1.08e-19	5.06e-17	0.28	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:102918497	chr4:102828055~102844075:+
BRCA	cis	rs56046484	0.956	rs35204319	ENSG00000259295.5	CSPG4P12	9.27	1.08e-19	5.06e-17	0.48	0.28	Testicular germ cell tumor;	chr15:85107246	chr15:85191438~85213905:+
BRCA	cis	rs783540	0.934	rs1594511	ENSG00000278603.1	RP13-608F4.5	-9.27	1.08e-19	5.07e-17	-0.35	-0.28	Schizophrenia;	chr15:82638312	chr15:82472203~82472426:+
BRCA	cis	rs11722779	0.935	rs7676736	ENSG00000246560.2	RP11-10L12.4	9.27	1.08e-19	5.07e-17	0.29	0.28	Schizophrenia;	chr4:103016729	chr4:102828055~102844075:+
BRCA	cis	rs9807989	0.507	rs4479442	ENSG00000234389.1	AC007278.3	9.27	1.08e-19	5.08e-17	0.25	0.28	Asthma;	chr2:102437614	chr2:102438713~102440475:+
BRCA	cis	rs11098499	0.955	rs1551	ENSG00000245958.5	RP11-33B1.1	-9.26	1.09e-19	5.11e-17	-0.27	-0.28	Corneal astigmatism;	chr4:119237345	chr4:119454791~119552025:+
BRCA	cis	rs1823913	0.599	rs34840299	ENSG00000227542.1	AC092614.2	9.26	1.1e-19	5.13e-17	0.33	0.28	Obesity-related traits;	chr2:191280379	chr2:191229165~191246172:-
BRCA	cis	rs6921919	0.848	rs6903652	ENSG00000216901.1	AL022393.7	9.26	1.1e-19	5.14e-17	0.4	0.28	Autism spectrum disorder or schizophrenia;	chr6:28354343	chr6:28176188~28176674:+
BRCA	cis	rs7811142	0.943	rs28660238	ENSG00000242294.5	STAG3L5P	9.26	1.1e-19	5.16e-17	0.26	0.28	Platelet count;	chr7:100425685	chr7:100336079~100351900:+
BRCA	cis	rs7772486	0.875	rs7766463	ENSG00000235652.6	RP11-545I5.3	9.26	1.1e-19	5.17e-17	0.28	0.28	Lobe attachment (rater-scored or self-reported);	chr6:146043317	chr6:145799409~145886585:+
BRCA	cis	rs10875746	0.551	rs2054903	ENSG00000240399.1	RP1-228P16.1	-9.26	1.11e-19	5.18e-17	-0.37	-0.28	Longevity (90 years and older);	chr12:48330710	chr12:48054813~48055591:-
BRCA	cis	rs957448	1	rs7829886	ENSG00000253704.1	RP11-267M23.4	9.26	1.11e-19	5.2e-17	0.31	0.28	Nonsyndromic cleft lip with cleft palate;	chr8:94485160	chr8:94553722~94569745:+
BRCA	cis	rs13256369	0.951	rs12679360	ENSG00000253893.2	FAM85B	9.26	1.12e-19	5.22e-17	0.38	0.28	Obesity-related traits;	chr8:8708759	chr8:8167819~8226614:-
BRCA	cis	rs10129255	0.53	rs11624912	ENSG00000211972.2	IGHV3-66	9.26	1.12e-19	5.22e-17	0.19	0.28	Kawasaki disease;	chr14:106673891	chr14:106675017~106675544:-
BRCA	cis	rs6142102	0.961	rs2268089	ENSG00000276073.1	RP5-1125A11.7	-9.26	1.12e-19	5.23e-17	-0.32	-0.28	Skin pigmentation;	chr20:34079492	chr20:33985617~33988989:-
BRCA	cis	rs7811142	1	rs28490152	ENSG00000242294.5	STAG3L5P	9.26	1.12e-19	5.24e-17	0.26	0.28	Platelet count;	chr7:100423359	chr7:100336079~100351900:+
BRCA	cis	rs1707322	1	rs10890381	ENSG00000280836.1	AL355480.1	-9.26	1.12e-19	5.25e-17	-0.36	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45986099	chr1:45581219~45581321:-
BRCA	cis	rs2243480	1	rs7456042	ENSG00000226824.5	RP4-756H11.3	-9.26	1.12e-19	5.26e-17	-0.52	-0.28	Diabetic kidney disease;	chr7:65834791	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs73142121	ENSG00000226824.5	RP4-756H11.3	-9.26	1.12e-19	5.26e-17	-0.52	-0.28	Diabetic kidney disease;	chr7:65846219	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs34702770	ENSG00000226824.5	RP4-756H11.3	-9.26	1.12e-19	5.26e-17	-0.52	-0.28	Diabetic kidney disease;	chr7:65879836	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs34637256	ENSG00000226824.5	RP4-756H11.3	-9.26	1.12e-19	5.26e-17	-0.52	-0.28	Diabetic kidney disease;	chr7:65895144	chr7:66654538~66669855:+
BRCA	cis	rs801193	0.591	rs9986881	ENSG00000236529.1	RP13-254B10.1	9.26	1.13e-19	5.28e-17	0.31	0.28	Aortic root size;	chr7:66708053	chr7:65840212~65840596:+
BRCA	cis	rs11603023	0.625	rs633683	ENSG00000255422.1	AP002954.4	-9.26	1.13e-19	5.28e-17	-0.32	-0.28	Cholesterol, total;	chr11:118634025	chr11:118704607~118750263:+
BRCA	cis	rs9807989	0.507	rs6755905	ENSG00000234389.1	AC007278.3	9.26	1.13e-19	5.29e-17	0.25	0.28	Asthma;	chr2:102431747	chr2:102438713~102440475:+
BRCA	cis	rs4988958	0.527	rs6756161	ENSG00000234389.1	AC007278.3	9.26	1.13e-19	5.29e-17	0.25	0.28	Asthma (childhood onset);	chr2:102431957	chr2:102438713~102440475:+
BRCA	cis	rs9807989	0.507	rs6726985	ENSG00000234389.1	AC007278.3	9.26	1.13e-19	5.29e-17	0.25	0.28	Asthma;	chr2:102432120	chr2:102438713~102440475:+
BRCA	cis	rs9807989	0.507	rs2310300	ENSG00000234389.1	AC007278.3	9.26	1.13e-19	5.29e-17	0.25	0.28	Asthma;	chr2:102432614	chr2:102438713~102440475:+
BRCA	cis	rs9807989	0.507	rs7581119	ENSG00000234389.1	AC007278.3	9.26	1.13e-19	5.29e-17	0.25	0.28	Asthma;	chr2:102433405	chr2:102438713~102440475:+
BRCA	cis	rs4835473	0.808	rs2060653	ENSG00000251600.4	RP11-673E1.1	-9.26	1.13e-19	5.3e-17	-0.32	-0.28	Immature fraction of reticulocytes;	chr4:143739132	chr4:143912331~143982454:+
BRCA	cis	rs2439831	0.85	rs3862142	ENSG00000205771.5	CATSPER2P1	-9.26	1.14e-19	5.33e-17	-0.47	-0.28	Lung cancer in ever smokers;	chr15:43772608	chr15:43726918~43747094:-
BRCA	cis	rs2439831	0.85	rs2277531	ENSG00000205771.5	CATSPER2P1	-9.26	1.14e-19	5.33e-17	-0.47	-0.28	Lung cancer in ever smokers;	chr15:43776871	chr15:43726918~43747094:-
BRCA	cis	rs858239	0.601	rs929507	ENSG00000226816.2	AC005082.12	9.26	1.14e-19	5.34e-17	0.31	0.28	Cerebrospinal fluid biomarker levels;	chr7:23127045	chr7:23206013~23208045:+
BRCA	cis	rs858239	0.601	rs929508	ENSG00000226816.2	AC005082.12	9.26	1.14e-19	5.34e-17	0.31	0.28	Cerebrospinal fluid biomarker levels;	chr7:23127090	chr7:23206013~23208045:+
BRCA	cis	rs11098499	0.954	rs1480931	ENSG00000248280.1	RP11-33B1.2	9.26	1.14e-19	5.35e-17	0.28	0.28	Corneal astigmatism;	chr4:119474654	chr4:119440561~119450157:-
BRCA	cis	rs4988958	0.565	rs6732138	ENSG00000234389.1	AC007278.3	9.26	1.15e-19	5.37e-17	0.25	0.28	Asthma (childhood onset);	chr2:102393202	chr2:102438713~102440475:+
BRCA	cis	rs858239	0.601	rs1034963	ENSG00000226816.2	AC005082.12	9.26	1.15e-19	5.38e-17	0.31	0.28	Cerebrospinal fluid biomarker levels;	chr7:23108854	chr7:23206013~23208045:+
BRCA	cis	rs875971	0.642	rs35526611	ENSG00000222364.1	RNU6-96P	9.26	1.15e-19	5.38e-17	0.32	0.28	Aortic root size;	chr7:66629021	chr7:66395191~66395286:+
BRCA	cis	rs11098499	0.955	rs6815725	ENSG00000245958.5	RP11-33B1.1	-9.26	1.15e-19	5.38e-17	-0.27	-0.28	Corneal astigmatism;	chr4:119237255	chr4:119454791~119552025:+
BRCA	cis	rs11098499	1	rs6837898	ENSG00000245958.5	RP11-33B1.1	-9.26	1.15e-19	5.39e-17	-0.27	-0.28	Corneal astigmatism;	chr4:119257999	chr4:119454791~119552025:+
BRCA	cis	rs113835537	0.529	rs78999944	ENSG00000255517.5	CTD-3074O7.5	-9.26	1.15e-19	5.39e-17	-0.36	-0.28	Airway imaging phenotypes;	chr11:66483757	chr11:66473490~66480233:-
BRCA	cis	rs4237845	0.611	rs7298370	ENSG00000257159.1	RP11-58A17.3	9.26	1.15e-19	5.39e-17	0.33	0.28	Intelligence (multi-trait analysis);	chr12:57925114	chr12:57967058~57968399:+
BRCA	cis	rs889312	0.532	rs16886165	ENSG00000271828.1	CTD-2310F14.1	9.26	1.15e-19	5.4e-17	0.38	0.28	Breast cancer (early onset);Breast cancer;	chr5:56727256	chr5:56927874~56929573:+
BRCA	cis	rs9287719	0.967	rs4470306	ENSG00000234818.1	AC092687.5	9.26	1.16e-19	5.4e-17	0.32	0.28	Prostate cancer;	chr2:10603872	chr2:10589166~10604830:+
BRCA	cis	rs10759883	0.563	rs666093	ENSG00000175611.10	LINC00476	9.26	1.16e-19	5.43e-17	0.31	0.28	Nicotine dependence;	chr9:95983820	chr9:95759231~95875977:-
BRCA	cis	rs10759883	0.563	rs667705	ENSG00000175611.10	LINC00476	9.26	1.16e-19	5.43e-17	0.31	0.28	Nicotine dependence;	chr9:95984132	chr9:95759231~95875977:-
BRCA	cis	rs9807989	0.524	rs6759479	ENSG00000234389.1	AC007278.3	9.26	1.17e-19	5.45e-17	0.25	0.28	Asthma;	chr2:102423587	chr2:102438713~102440475:+
BRCA	cis	rs9807989	0.507	rs6543133	ENSG00000234389.1	AC007278.3	9.26	1.17e-19	5.45e-17	0.25	0.28	Asthma;	chr2:102423717	chr2:102438713~102440475:+
BRCA	cis	rs13256369	0.951	rs13259955	ENSG00000253893.2	FAM85B	-9.26	1.17e-19	5.46e-17	-0.39	-0.28	Obesity-related traits;	chr8:8708375	chr8:8167819~8226614:-
BRCA	cis	rs812925	0.519	rs2463099	ENSG00000271889.1	RP11-493E12.1	-9.26	1.17e-19	5.49e-17	-0.34	-0.28	Immature fraction of reticulocytes;	chr2:61391176	chr2:61151433~61162105:-
BRCA	cis	rs4988958	0.565	rs3771154	ENSG00000234389.1	AC007278.3	9.26	1.17e-19	5.49e-17	0.25	0.28	Asthma (childhood onset);	chr2:102422900	chr2:102438713~102440475:+
BRCA	cis	rs7924176	0.601	rs2131957	ENSG00000213731.2	RAB5CP1	-9.26	1.18e-19	5.49e-17	-0.3	-0.28	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74107171	chr10:74423435~74424014:-
BRCA	cis	rs2439831	0.85	rs3825783	ENSG00000249839.1	AC011330.5	-9.26	1.18e-19	5.49e-17	-0.48	-0.28	Lung cancer in ever smokers;	chr15:43810111	chr15:43663654~43684339:-
BRCA	cis	rs7811142	1	rs11766752	ENSG00000242294.5	STAG3L5P	9.26	1.18e-19	5.5e-17	0.26	0.28	Platelet count;	chr7:100475669	chr7:100336079~100351900:+
BRCA	cis	rs7429990	0.965	rs319686	ENSG00000229759.1	MRPS18AP1	9.26	1.18e-19	5.52e-17	0.31	0.28	Educational attainment (years of education);	chr3:47888930	chr3:48256350~48256938:-
BRCA	cis	rs55665837	0.539	rs12794714	ENSG00000251991.1	RNU7-49P	9.25	1.19e-19	5.54e-17	0.31	0.28	Vitamin D levels;	chr11:14892029	chr11:14478892~14478953:+
BRCA	cis	rs673078	0.66	rs17512574	ENSG00000275759.1	RP11-131L12.3	-9.25	1.19e-19	5.56e-17	-0.4	-0.28	Glucose homeostasis traits;	chr12:118350198	chr12:118428281~118428870:+
BRCA	cis	rs858239	0.536	rs6961109	ENSG00000226816.2	AC005082.12	9.25	1.19e-19	5.57e-17	0.32	0.28	Cerebrospinal fluid biomarker levels;	chr7:23212794	chr7:23206013~23208045:+
BRCA	cis	rs1062177	1	rs12518722	ENSG00000253921.1	CTB-113P19.3	-9.25	1.2e-19	5.6e-17	-0.38	-0.28	Preschool internalizing problems;	chr5:151851899	chr5:151753992~151767247:+
BRCA	cis	rs3096299	0.967	rs2965935	ENSG00000274627.1	RP11-104N10.2	-9.25	1.2e-19	5.61e-17	-0.28	-0.28	Multiple myeloma (IgH translocation);	chr16:89414866	chr16:89516797~89522217:+
BRCA	cis	rs113835537	0.529	rs11550299	ENSG00000255517.5	CTD-3074O7.5	-9.25	1.21e-19	5.63e-17	-0.36	-0.28	Airway imaging phenotypes;	chr11:66486614	chr11:66473490~66480233:-
BRCA	cis	rs7429990	1	rs1665982	ENSG00000229759.1	MRPS18AP1	-9.25	1.22e-19	5.67e-17	-0.36	-0.28	Educational attainment (years of education);	chr3:47863589	chr3:48256350~48256938:-
BRCA	cis	rs4988958	0.525	rs3771159	ENSG00000234389.1	AC007278.3	9.25	1.22e-19	5.67e-17	0.25	0.28	Asthma (childhood onset);	chr2:102388498	chr2:102438713~102440475:+
BRCA	cis	rs9807989	0.501	rs11903946	ENSG00000234389.1	AC007278.3	9.25	1.22e-19	5.67e-17	0.25	0.28	Asthma;	chr2:102388870	chr2:102438713~102440475:+
BRCA	cis	rs9807989	0.507	rs6749014	ENSG00000234389.1	AC007278.3	9.25	1.22e-19	5.67e-17	0.25	0.28	Asthma;	chr2:102389988	chr2:102438713~102440475:+
BRCA	cis	rs2439831	0.85	rs2228368	ENSG00000249839.1	AC011330.5	-9.25	1.22e-19	5.68e-17	-0.46	-0.28	Lung cancer in ever smokers;	chr15:43809812	chr15:43663654~43684339:-
BRCA	cis	rs6435862	0.5	rs12477063	ENSG00000229267.2	AC072062.1	9.25	1.22e-19	5.7e-17	0.32	0.28	Neuroblastoma (high-risk);	chr2:214808940	chr2:214810229~214963274:+
BRCA	cis	rs9807989	0.507	rs6706002	ENSG00000234389.1	AC007278.3	9.25	1.23e-19	5.72e-17	0.25	0.28	Asthma;	chr2:102389644	chr2:102438713~102440475:+
BRCA	cis	rs1062177	0.756	rs2964591	ENSG00000253921.1	CTB-113P19.3	9.25	1.23e-19	5.73e-17	0.37	0.28	Preschool internalizing problems;	chr5:151737836	chr5:151753992~151767247:+
BRCA	cis	rs783540	0.967	rs783529	ENSG00000278603.1	RP13-608F4.5	-9.25	1.23e-19	5.74e-17	-0.35	-0.28	Schizophrenia;	chr15:82599231	chr15:82472203~82472426:+
BRCA	cis	rs6570726	0.791	rs7765687	ENSG00000235652.6	RP11-545I5.3	9.25	1.23e-19	5.75e-17	0.27	0.28	Lobe attachment (rater-scored or self-reported);	chr6:145593964	chr6:145799409~145886585:+
BRCA	cis	rs11098499	0.863	rs1552095	ENSG00000248280.1	RP11-33B1.2	9.25	1.24e-19	5.78e-17	0.29	0.28	Corneal astigmatism;	chr4:119539151	chr4:119440561~119450157:-
BRCA	cis	rs950169	0.58	rs11634320	ENSG00000225151.9	GOLGA2P7	9.25	1.24e-19	5.79e-17	0.34	0.28	Schizophrenia;	chr15:84628952	chr15:84199311~84230136:-
BRCA	cis	rs9287719	0.967	rs4284804	ENSG00000234818.1	AC092687.5	9.25	1.24e-19	5.79e-17	0.32	0.28	Prostate cancer;	chr2:10581998	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.935	rs10803723	ENSG00000234818.1	AC092687.5	9.25	1.24e-19	5.79e-17	0.32	0.28	Prostate cancer;	chr2:10582751	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.935	rs6751075	ENSG00000234818.1	AC092687.5	9.25	1.24e-19	5.79e-17	0.32	0.28	Prostate cancer;	chr2:10583420	chr2:10589166~10604830:+
BRCA	cis	rs1555322	0.53	rs2425053	ENSG00000126005.14	MMP24-AS1	-9.25	1.24e-19	5.79e-17	-0.37	-0.28	Attention deficit hyperactivity disorder;	chr20:35294017	chr20:35216462~35278131:-
BRCA	cis	rs9807989	0.507	rs2058659	ENSG00000234389.1	AC007278.3	-9.25	1.24e-19	5.79e-17	-0.25	-0.28	Asthma;	chr2:102438096	chr2:102438713~102440475:+
BRCA	cis	rs9287719	0.934	rs6727884	ENSG00000234818.1	AC092687.5	-9.25	1.25e-19	5.81e-17	-0.32	-0.28	Prostate cancer;	chr2:10617431	chr2:10589166~10604830:+
BRCA	cis	rs11098499	0.913	rs11098496	ENSG00000245958.5	RP11-33B1.1	-9.25	1.25e-19	5.83e-17	-0.27	-0.28	Corneal astigmatism;	chr4:119246311	chr4:119454791~119552025:+
BRCA	cis	rs10875746	0.669	rs10467101	ENSG00000240399.1	RP1-228P16.1	-9.25	1.25e-19	5.83e-17	-0.36	-0.28	Longevity (90 years and older);	chr12:48213954	chr12:48054813~48055591:-
BRCA	cis	rs1062177	0.855	rs6896664	ENSG00000253921.1	CTB-113P19.3	-9.25	1.25e-19	5.84e-17	-0.35	-0.28	Preschool internalizing problems;	chr5:151885713	chr5:151753992~151767247:+
BRCA	cis	rs1075265	0.692	rs805358	ENSG00000233266.1	HMGB1P31	9.25	1.25e-19	5.84e-17	0.34	0.28	Chronotype;Morning vs. evening chronotype;	chr2:53934885	chr2:54051334~54051760:+
BRCA	cis	rs1707322	1	rs12097761	ENSG00000280836.1	AL355480.1	-9.25	1.25e-19	5.84e-17	-0.36	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45825490	chr1:45581219~45581321:-
BRCA	cis	rs6545883	0.525	rs1729662	ENSG00000271889.1	RP11-493E12.1	9.25	1.25e-19	5.85e-17	0.35	0.28	Tuberculosis;	chr2:61164170	chr2:61151433~61162105:-
BRCA	cis	rs875971	0.522	rs7784623	ENSG00000224316.1	RP11-479O9.2	9.25	1.26e-19	5.86e-17	0.27	0.28	Aortic root size;	chr7:65930047	chr7:65773620~65802067:+
BRCA	cis	rs12701220	0.604	rs12702122	ENSG00000229043.2	AC091729.9	-9.25	1.26e-19	5.86e-17	-0.39	-0.28	Bronchopulmonary dysplasia;	chr7:1109858	chr7:1160374~1165267:+
BRCA	cis	rs13256369	0.802	rs13255789	ENSG00000253893.2	FAM85B	-9.25	1.26e-19	5.87e-17	-0.39	-0.28	Obesity-related traits;	chr8:8705281	chr8:8167819~8226614:-
BRCA	cis	rs2067615	0.579	rs10861663	ENSG00000260329.1	RP11-412D9.4	-9.25	1.26e-19	5.88e-17	-0.3	-0.28	Heart rate;	chr12:106789811	chr12:106954029~106955497:-
BRCA	cis	rs853679	0.825	rs8180562	ENSG00000220721.1	OR1F12	9.25	1.27e-19	5.91e-17	0.51	0.28	Depression;	chr6:28173682	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.882	rs9380064	ENSG00000220721.1	OR1F12	9.25	1.27e-19	5.91e-17	0.51	0.28	Depression;	chr6:28175340	chr6:28073316~28074233:+
BRCA	cis	rs9807989	0.507	rs1420096	ENSG00000234389.1	AC007278.3	9.25	1.27e-19	5.91e-17	0.25	0.28	Asthma;	chr2:102394452	chr2:102438713~102440475:+
BRCA	cis	rs1823913	0.637	rs4853583	ENSG00000227542.1	AC092614.2	-9.25	1.28e-19	5.94e-17	-0.33	-0.28	Obesity-related traits;	chr2:191304648	chr2:191229165~191246172:-
BRCA	cis	rs4853012	0.941	rs78128123	ENSG00000257800.1	FNBP1P1	9.25	1.28e-19	5.97e-17	0.32	0.28	Gestational age at birth (maternal effect);	chr2:74120398	chr2:74120680~74123218:+
BRCA	cis	rs673078	0.66	rs73205526	ENSG00000275759.1	RP11-131L12.3	-9.25	1.28e-19	5.98e-17	-0.43	-0.28	Glucose homeostasis traits;	chr12:118273172	chr12:118428281~118428870:+
BRCA	cis	rs2274273	0.837	rs10141552	ENSG00000258413.1	RP11-665C16.6	9.25	1.29e-19	5.99e-17	0.34	0.28	Protein biomarker;	chr14:55279373	chr14:55262767~55272075:-
BRCA	cis	rs13256369	0.756	rs13280759	ENSG00000253893.2	FAM85B	-9.24	1.29e-19	6.01e-17	-0.39	-0.28	Obesity-related traits;	chr8:8705485	chr8:8167819~8226614:-
BRCA	cis	rs4862750	0.881	rs6813866	ENSG00000250971.1	RP11-696F12.1	9.24	1.29e-19	6.02e-17	0.29	0.28	Lobe attachment (rater-scored or self-reported);	chr4:186951007	chr4:187060099~187060930:+
BRCA	cis	rs4718428	0.705	rs13231140	ENSG00000232546.1	RP11-458F8.1	-9.24	1.29e-19	6.03e-17	-0.26	-0.28	Corneal structure;	chr7:66896631	chr7:66848496~66858136:+
BRCA	cis	rs881375	0.669	rs73541868	ENSG00000226752.6	PSMD5-AS1	-9.24	1.3e-19	6.04e-17	-0.32	-0.28	Rheumatoid arthritis;	chr9:120876986	chr9:120824828~120854385:+
BRCA	cis	rs1075265	0.783	rs805359	ENSG00000233266.1	HMGB1P31	9.24	1.3e-19	6.04e-17	0.33	0.28	Chronotype;Morning vs. evening chronotype;	chr2:53935317	chr2:54051334~54051760:+
BRCA	cis	rs875971	0.545	rs1547529	ENSG00000237310.1	GS1-124K5.4	9.24	1.3e-19	6.07e-17	0.33	0.28	Aortic root size;	chr7:66258859	chr7:66493706~66495474:+
BRCA	cis	rs13256369	0.851	rs13254997	ENSG00000253893.2	FAM85B	-9.24	1.31e-19	6.09e-17	-0.39	-0.28	Obesity-related traits;	chr8:8706243	chr8:8167819~8226614:-
BRCA	cis	rs2067615	0.524	rs9971765	ENSG00000260329.1	RP11-412D9.4	-9.24	1.31e-19	6.1e-17	-0.31	-0.28	Heart rate;	chr12:106698521	chr12:106954029~106955497:-
BRCA	cis	rs853679	0.699	rs9468318	ENSG00000220721.1	OR1F12	9.24	1.31e-19	6.11e-17	0.39	0.28	Depression;	chr6:28241753	chr6:28073316~28074233:+
BRCA	cis	rs1823913	0.637	rs2883912	ENSG00000227542.1	AC092614.2	-9.24	1.32e-19	6.13e-17	-0.33	-0.28	Obesity-related traits;	chr2:191284290	chr2:191229165~191246172:-
BRCA	cis	rs875971	0.545	rs35459055	ENSG00000237310.1	GS1-124K5.4	9.24	1.33e-19	6.18e-17	0.33	0.28	Aortic root size;	chr7:66479399	chr7:66493706~66495474:+
BRCA	cis	rs712039	0.652	rs829161	ENSG00000276054.1	RP11-378E13.3	-9.24	1.33e-19	6.19e-17	-0.39	-0.28	Tuberculosis;	chr17:37403775	chr17:37386886~37387926:+
BRCA	cis	rs1075265	0.669	rs805330	ENSG00000233266.1	HMGB1P31	9.24	1.33e-19	6.19e-17	0.34	0.28	Chronotype;Morning vs. evening chronotype;	chr2:53921194	chr2:54051334~54051760:+
BRCA	cis	rs957448	1	rs28817653	ENSG00000253704.1	RP11-267M23.4	9.24	1.33e-19	6.2e-17	0.33	0.28	Nonsyndromic cleft lip with cleft palate;	chr8:94557822	chr8:94553722~94569745:+
BRCA	cis	rs11098499	0.954	rs12499324	ENSG00000248280.1	RP11-33B1.2	9.24	1.34e-19	6.21e-17	0.28	0.28	Corneal astigmatism;	chr4:119472631	chr4:119440561~119450157:-
BRCA	cis	rs11098499	1	rs12506395	ENSG00000245958.5	RP11-33B1.1	-9.24	1.34e-19	6.24e-17	-0.27	-0.28	Corneal astigmatism;	chr4:119263939	chr4:119454791~119552025:+
BRCA	cis	rs1707322	1	rs10789479	ENSG00000280836.1	AL355480.1	-9.24	1.34e-19	6.25e-17	-0.36	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45886828	chr1:45581219~45581321:-
BRCA	cis	rs2243480	1	rs67728539	ENSG00000226824.5	RP4-756H11.3	-9.24	1.35e-19	6.26e-17	-0.52	-0.28	Diabetic kidney disease;	chr7:65913137	chr7:66654538~66669855:+
BRCA	cis	rs875971	0.545	rs3735147	ENSG00000237310.1	GS1-124K5.4	9.24	1.35e-19	6.26e-17	0.33	0.28	Aortic root size;	chr7:66505541	chr7:66493706~66495474:+
BRCA	cis	rs853679	0.76	rs9368563	ENSG00000220721.1	OR1F12	9.24	1.35e-19	6.27e-17	0.39	0.28	Depression;	chr6:28240780	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.76	rs9295768	ENSG00000220721.1	OR1F12	9.24	1.35e-19	6.27e-17	0.39	0.28	Depression;	chr6:28241324	chr6:28073316~28074233:+
BRCA	cis	rs17711722	0.653	rs2460421	ENSG00000236529.1	RP13-254B10.1	-9.24	1.35e-19	6.27e-17	-0.3	-0.28	Calcium levels;	chr7:66026136	chr7:65840212~65840596:+
BRCA	cis	rs10875746	0.669	rs61941006	ENSG00000240399.1	RP1-228P16.1	-9.24	1.35e-19	6.28e-17	-0.36	-0.28	Longevity (90 years and older);	chr12:48237350	chr12:48054813~48055591:-
BRCA	cis	rs11673344	0.864	rs703535	ENSG00000226686.6	LINC01535	9.24	1.35e-19	6.29e-17	0.35	0.28	Obesity-related traits;	chr19:37014838	chr19:37251912~37265535:+
BRCA	cis	rs11098499	0.82	rs6829903	ENSG00000245958.5	RP11-33B1.1	-9.24	1.36e-19	6.3e-17	-0.27	-0.28	Corneal astigmatism;	chr4:119585729	chr4:119454791~119552025:+
BRCA	cis	rs1061377	0.513	rs2566166	ENSG00000249207.1	RP11-360F5.1	9.24	1.36e-19	6.33e-17	0.35	0.28	Uric acid levels;	chr4:39148404	chr4:39112677~39126818:-
BRCA	cis	rs4988958	0.565	rs12712146	ENSG00000234389.1	AC007278.3	9.24	1.36e-19	6.33e-17	0.25	0.28	Asthma (childhood onset);	chr2:102392254	chr2:102438713~102440475:+
BRCA	cis	rs9287719	0.967	rs12622765	ENSG00000234818.1	AC092687.5	9.24	1.37e-19	6.35e-17	0.32	0.28	Prostate cancer;	chr2:10588205	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs759402	ENSG00000234818.1	AC092687.5	9.24	1.37e-19	6.35e-17	0.32	0.28	Prostate cancer;	chr2:10589428	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs759403	ENSG00000234818.1	AC092687.5	9.24	1.37e-19	6.35e-17	0.32	0.28	Prostate cancer;	chr2:10589771	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs11674433	ENSG00000234818.1	AC092687.5	9.24	1.37e-19	6.35e-17	0.32	0.28	Prostate cancer;	chr2:10590713	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs2024431	ENSG00000234818.1	AC092687.5	9.24	1.37e-19	6.35e-17	0.32	0.28	Prostate cancer;	chr2:10591201	chr2:10589166~10604830:+
BRCA	cis	rs9318086	0.935	rs9652080	ENSG00000205861.10	C1QTNF9B-AS1	9.24	1.38e-19	6.41e-17	0.34	0.28	Myopia (pathological);	chr13:23861287	chr13:23888889~23897263:+
BRCA	cis	rs9807989	0.507	rs10439410	ENSG00000234389.1	AC007278.3	-9.24	1.38e-19	6.42e-17	-0.25	-0.28	Asthma;	chr2:102374328	chr2:102438713~102440475:+
BRCA	cis	rs2276314	0.802	rs58906216	ENSG00000278986.1	RP11-723J4.3	-9.24	1.38e-19	6.42e-17	-0.35	-0.28	Endometriosis;Drug-induced torsades de pointes;	chr18:36050334	chr18:35972151~35973916:+
BRCA	cis	rs2276314	0.857	rs6507157	ENSG00000278986.1	RP11-723J4.3	-9.24	1.38e-19	6.42e-17	-0.35	-0.28	Endometriosis;Drug-induced torsades de pointes;	chr18:36051740	chr18:35972151~35973916:+
BRCA	cis	rs1113500	0.933	rs4517375	ENSG00000226822.1	RP11-356N1.2	-9.24	1.39e-19	6.46e-17	-0.36	-0.28	Growth-regulated protein alpha levels;	chr1:108095708	chr1:108071482~108074519:+
BRCA	cis	rs9287719	0.901	rs10210859	ENSG00000234818.1	AC092687.5	9.24	1.39e-19	6.47e-17	0.32	0.28	Prostate cancer;	chr2:10593803	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs715247	ENSG00000234818.1	AC092687.5	9.24	1.39e-19	6.47e-17	0.32	0.28	Prostate cancer;	chr2:10596165	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs715246	ENSG00000234818.1	AC092687.5	9.24	1.39e-19	6.47e-17	0.32	0.28	Prostate cancer;	chr2:10596229	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs2010073	ENSG00000234818.1	AC092687.5	9.24	1.39e-19	6.47e-17	0.32	0.28	Prostate cancer;	chr2:10596352	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs2010080	ENSG00000234818.1	AC092687.5	9.24	1.39e-19	6.47e-17	0.32	0.28	Prostate cancer;	chr2:10596426	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.901	rs6432109	ENSG00000234818.1	AC092687.5	9.24	1.39e-19	6.47e-17	0.32	0.28	Prostate cancer;	chr2:10596695	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.934	rs6432110	ENSG00000234818.1	AC092687.5	9.24	1.39e-19	6.47e-17	0.32	0.28	Prostate cancer;	chr2:10597892	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs7605461	ENSG00000234818.1	AC092687.5	9.24	1.39e-19	6.47e-17	0.32	0.28	Prostate cancer;	chr2:10598008	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs7593496	ENSG00000234818.1	AC092687.5	9.24	1.39e-19	6.47e-17	0.32	0.28	Prostate cancer;	chr2:10598050	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs7608498	ENSG00000234818.1	AC092687.5	9.24	1.39e-19	6.47e-17	0.32	0.28	Prostate cancer;	chr2:10598302	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs7582775	ENSG00000234818.1	AC092687.5	9.24	1.39e-19	6.47e-17	0.32	0.28	Prostate cancer;	chr2:10598323	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs6750891	ENSG00000234818.1	AC092687.5	9.24	1.39e-19	6.47e-17	0.32	0.28	Prostate cancer;	chr2:10598437	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs6733416	ENSG00000234818.1	AC092687.5	9.24	1.39e-19	6.47e-17	0.32	0.28	Prostate cancer;	chr2:10598558	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs6751398	ENSG00000234818.1	AC092687.5	9.24	1.39e-19	6.47e-17	0.32	0.28	Prostate cancer;	chr2:10598846	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.901	rs13034017	ENSG00000234818.1	AC092687.5	9.24	1.39e-19	6.47e-17	0.32	0.28	Prostate cancer;	chr2:10599466	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs13034061	ENSG00000234818.1	AC092687.5	9.24	1.39e-19	6.47e-17	0.32	0.28	Prostate cancer;	chr2:10599525	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.935	rs7600495	ENSG00000234818.1	AC092687.5	9.24	1.39e-19	6.47e-17	0.32	0.28	Prostate cancer;	chr2:10599674	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs7600587	ENSG00000234818.1	AC092687.5	9.24	1.39e-19	6.47e-17	0.32	0.28	Prostate cancer;	chr2:10599725	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.839	rs7600695	ENSG00000234818.1	AC092687.5	9.24	1.39e-19	6.47e-17	0.32	0.28	Prostate cancer;	chr2:10599819	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs7587114	ENSG00000234818.1	AC092687.5	9.24	1.39e-19	6.47e-17	0.32	0.28	Prostate cancer;	chr2:10599837	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs7600728	ENSG00000234818.1	AC092687.5	9.24	1.39e-19	6.47e-17	0.32	0.28	Prostate cancer;	chr2:10599873	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs7600820	ENSG00000234818.1	AC092687.5	9.24	1.39e-19	6.47e-17	0.32	0.28	Prostate cancer;	chr2:10599918	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs7587231	ENSG00000234818.1	AC092687.5	9.24	1.39e-19	6.47e-17	0.32	0.28	Prostate cancer;	chr2:10599967	chr2:10589166~10604830:+
BRCA	cis	rs7772486	0.625	rs2050027	ENSG00000235652.6	RP11-545I5.3	-9.24	1.4e-19	6.48e-17	-0.27	-0.28	Lobe attachment (rater-scored or self-reported);	chr6:145794977	chr6:145799409~145886585:+
BRCA	cis	rs875971	0.522	rs1617484	ENSG00000164669.11	INTS4P1	-9.24	1.4e-19	6.48e-17	-0.34	-0.28	Aortic root size;	chr7:65998108	chr7:65141225~65234216:+
BRCA	cis	rs9287719	0.967	rs4519489	ENSG00000234818.1	AC092687.5	9.24	1.4e-19	6.51e-17	0.32	0.28	Prostate cancer;	chr2:10598961	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs4453662	ENSG00000234818.1	AC092687.5	9.24	1.4e-19	6.51e-17	0.32	0.28	Prostate cancer;	chr2:10599002	chr2:10589166~10604830:+
BRCA	cis	rs227275	0.525	rs4698874	ENSG00000246560.2	RP11-10L12.4	9.24	1.41e-19	6.52e-17	0.29	0.28	Allergic disease (asthma, hay fever or eczema);	chr4:103009354	chr4:102828055~102844075:+
BRCA	cis	rs11098499	0.863	rs3775854	ENSG00000245958.5	RP11-33B1.1	-9.23	1.41e-19	6.54e-17	-0.27	-0.28	Corneal astigmatism;	chr4:119550816	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.863	rs6853998	ENSG00000245958.5	RP11-33B1.1	-9.23	1.41e-19	6.54e-17	-0.27	-0.28	Corneal astigmatism;	chr4:119554705	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.863	rs6858777	ENSG00000245958.5	RP11-33B1.1	-9.23	1.41e-19	6.54e-17	-0.27	-0.28	Corneal astigmatism;	chr4:119554811	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.863	rs11731756	ENSG00000245958.5	RP11-33B1.1	-9.23	1.41e-19	6.54e-17	-0.27	-0.28	Corneal astigmatism;	chr4:119557541	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.863	rs34308924	ENSG00000245958.5	RP11-33B1.1	-9.23	1.41e-19	6.54e-17	-0.27	-0.28	Corneal astigmatism;	chr4:119560276	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.863	rs2170276	ENSG00000245958.5	RP11-33B1.1	-9.23	1.41e-19	6.54e-17	-0.27	-0.28	Corneal astigmatism;	chr4:119564669	chr4:119454791~119552025:+
BRCA	cis	rs1823913	0.892	rs35596292	ENSG00000280083.1	RP11-317J9.1	-9.23	1.41e-19	6.55e-17	-0.34	-0.28	Obesity-related traits;	chr2:191246890	chr2:191154118~191156070:-
BRCA	cis	rs13256369	0.851	rs13256611	ENSG00000253893.2	FAM85B	-9.23	1.41e-19	6.55e-17	-0.39	-0.28	Obesity-related traits;	chr8:8706831	chr8:8167819~8226614:-
BRCA	cis	rs11159086	0.793	rs1860108	ENSG00000259005.1	RP3-449M8.6	9.23	1.41e-19	6.56e-17	0.41	0.28	Advanced glycation end-product levels;	chr14:74478562	chr14:74474007~74474864:-
BRCA	cis	rs8012947	0.958	rs7158746	ENSG00000279636.2	LINC00216	-9.23	1.42e-19	6.57e-17	-0.3	-0.28	Alcohol consumption in current drinkers;	chr14:58254081	chr14:58288033~58289158:+
BRCA	cis	rs9438901	0.655	rs609320	ENSG00000224183.1	SDHDP6	9.23	1.42e-19	6.58e-17	0.46	0.28	Red cell distribution width;	chr1:25390874	chr1:25294164~25294643:-
BRCA	cis	rs1823913	0.637	rs4853569	ENSG00000227542.1	AC092614.2	-9.23	1.42e-19	6.59e-17	-0.33	-0.28	Obesity-related traits;	chr2:191266970	chr2:191229165~191246172:-
BRCA	cis	rs7429990	0.965	rs796566	ENSG00000229759.1	MRPS18AP1	9.23	1.42e-19	6.6e-17	0.31	0.28	Educational attainment (years of education);	chr3:47896864	chr3:48256350~48256938:-
BRCA	cis	rs9287719	0.967	rs7355649	ENSG00000234818.1	AC092687.5	9.23	1.43e-19	6.63e-17	0.32	0.28	Prostate cancer;	chr2:10607968	chr2:10589166~10604830:+
BRCA	cis	rs957448	1	rs16916881	ENSG00000253704.1	RP11-267M23.4	9.23	1.43e-19	6.65e-17	0.33	0.27	Nonsyndromic cleft lip with cleft palate;	chr8:94554042	chr8:94553722~94569745:+
BRCA	cis	rs1113500	0.933	rs4593854	ENSG00000226822.1	RP11-356N1.2	9.23	1.44e-19	6.65e-17	0.36	0.27	Growth-regulated protein alpha levels;	chr1:108095897	chr1:108071482~108074519:+
BRCA	cis	rs7772486	0.686	rs9399564	ENSG00000235652.6	RP11-545I5.3	-9.23	1.44e-19	6.68e-17	-0.27	-0.27	Lobe attachment (rater-scored or self-reported);	chr6:145757771	chr6:145799409~145886585:+
BRCA	cis	rs853679	0.76	rs9393910	ENSG00000220721.1	OR1F12	9.23	1.44e-19	6.68e-17	0.39	0.27	Depression;	chr6:28240414	chr6:28073316~28074233:+
BRCA	cis	rs4718428	0.705	rs4717328	ENSG00000232546.1	RP11-458F8.1	-9.23	1.45e-19	6.71e-17	-0.26	-0.27	Corneal structure;	chr7:66887678	chr7:66848496~66858136:+
BRCA	cis	rs4835473	0.864	rs67749935	ENSG00000251600.4	RP11-673E1.1	-9.23	1.45e-19	6.73e-17	-0.32	-0.27	Immature fraction of reticulocytes;	chr4:143739852	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.9	rs66934100	ENSG00000251600.4	RP11-673E1.1	-9.23	1.45e-19	6.73e-17	-0.32	-0.27	Immature fraction of reticulocytes;	chr4:143739872	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs4325971	ENSG00000251600.4	RP11-673E1.1	-9.23	1.45e-19	6.73e-17	-0.32	-0.27	Immature fraction of reticulocytes;	chr4:143740167	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs4637344	ENSG00000251600.4	RP11-673E1.1	-9.23	1.45e-19	6.73e-17	-0.32	-0.27	Immature fraction of reticulocytes;	chr4:143740434	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs13143879	ENSG00000251600.4	RP11-673E1.1	-9.23	1.45e-19	6.73e-17	-0.32	-0.27	Immature fraction of reticulocytes;	chr4:143740901	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs36086465	ENSG00000251600.4	RP11-673E1.1	-9.23	1.45e-19	6.73e-17	-0.32	-0.27	Immature fraction of reticulocytes;	chr4:143742738	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs873430	ENSG00000251600.4	RP11-673E1.1	-9.23	1.45e-19	6.73e-17	-0.32	-0.27	Immature fraction of reticulocytes;	chr4:143742953	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs873431	ENSG00000251600.4	RP11-673E1.1	-9.23	1.45e-19	6.73e-17	-0.32	-0.27	Immature fraction of reticulocytes;	chr4:143743035	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs899903	ENSG00000251600.4	RP11-673E1.1	-9.23	1.45e-19	6.73e-17	-0.32	-0.27	Immature fraction of reticulocytes;	chr4:143743551	chr4:143912331~143982454:+
BRCA	cis	rs1707322	0.963	rs10789478	ENSG00000280836.1	AL355480.1	-9.23	1.45e-19	6.73e-17	-0.36	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45884834	chr1:45581219~45581321:-
BRCA	cis	rs881375	1	rs1609810	ENSG00000226752.6	PSMD5-AS1	-9.23	1.45e-19	6.73e-17	-0.33	-0.27	Rheumatoid arthritis;	chr9:120880073	chr9:120824828~120854385:+
BRCA	cis	rs1823913	0.637	rs6741454	ENSG00000227542.1	AC092614.2	-9.23	1.46e-19	6.76e-17	-0.33	-0.27	Obesity-related traits;	chr2:191269520	chr2:191229165~191246172:-
BRCA	cis	rs9368481	0.761	rs9357028	ENSG00000241549.7	GUSBP2	-9.23	1.46e-19	6.77e-17	-0.32	-0.27	Autism spectrum disorder or schizophrenia;	chr6:26999445	chr6:26871484~26956554:-
BRCA	cis	rs875971	0.545	rs316316	ENSG00000237310.1	GS1-124K5.4	-9.23	1.46e-19	6.77e-17	-0.32	-0.27	Aortic root size;	chr7:66149270	chr7:66493706~66495474:+
BRCA	cis	rs13256369	0.951	rs10503394	ENSG00000253893.2	FAM85B	-9.23	1.46e-19	6.78e-17	-0.39	-0.27	Obesity-related traits;	chr8:8708265	chr8:8167819~8226614:-
BRCA	cis	rs11098499	0.955	rs11931312	ENSG00000245958.5	RP11-33B1.1	-9.23	1.46e-19	6.79e-17	-0.27	-0.27	Corneal astigmatism;	chr4:119237868	chr4:119454791~119552025:+
BRCA	cis	rs957448	1	rs2381882	ENSG00000253704.1	RP11-267M23.4	9.23	1.47e-19	6.81e-17	0.33	0.27	Nonsyndromic cleft lip with cleft palate;	chr8:94535496	chr8:94553722~94569745:+
BRCA	cis	rs4835473	0.778	rs75562808	ENSG00000251600.4	RP11-673E1.1	-9.23	1.47e-19	6.82e-17	-0.32	-0.27	Immature fraction of reticulocytes;	chr4:143779065	chr4:143912331~143982454:+
BRCA	cis	rs11098499	0.954	rs1022145	ENSG00000248280.1	RP11-33B1.2	9.23	1.48e-19	6.85e-17	0.28	0.27	Corneal astigmatism;	chr4:119309824	chr4:119440561~119450157:-
BRCA	cis	rs7772486	0.625	rs9390355	ENSG00000235652.6	RP11-545I5.3	-9.23	1.48e-19	6.86e-17	-0.27	-0.27	Lobe attachment (rater-scored or self-reported);	chr6:145791806	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.658	rs4895683	ENSG00000235652.6	RP11-545I5.3	-9.23	1.48e-19	6.86e-17	-0.27	-0.27	Lobe attachment (rater-scored or self-reported);	chr6:145792518	chr6:145799409~145886585:+
BRCA	cis	rs7811142	1	rs67239991	ENSG00000242294.5	STAG3L5P	9.23	1.49e-19	6.88e-17	0.26	0.27	Platelet count;	chr7:100448881	chr7:100336079~100351900:+
BRCA	cis	rs1823913	0.614	rs6755243	ENSG00000227542.1	AC092614.2	-9.23	1.49e-19	6.9e-17	-0.33	-0.27	Obesity-related traits;	chr2:191269810	chr2:191229165~191246172:-
BRCA	cis	rs748404	0.666	rs12908460	ENSG00000249839.1	AC011330.5	-9.23	1.49e-19	6.9e-17	-0.4	-0.27	Lung cancer;	chr15:43413472	chr15:43663654~43684339:-
BRCA	cis	rs748404	0.666	rs2230451	ENSG00000249839.1	AC011330.5	-9.23	1.49e-19	6.9e-17	-0.4	-0.27	Lung cancer;	chr15:43415610	chr15:43663654~43684339:-
BRCA	cis	rs748404	0.666	rs62021180	ENSG00000249839.1	AC011330.5	-9.23	1.49e-19	6.9e-17	-0.4	-0.27	Lung cancer;	chr15:43420139	chr15:43663654~43684339:-
BRCA	cis	rs875971	0.545	rs2420456	ENSG00000237310.1	GS1-124K5.4	9.23	1.49e-19	6.92e-17	0.33	0.27	Aortic root size;	chr7:66280619	chr7:66493706~66495474:+
BRCA	cis	rs4835473	0.932	rs4443230	ENSG00000251600.4	RP11-673E1.1	-9.23	1.5e-19	6.93e-17	-0.32	-0.27	Immature fraction of reticulocytes;	chr4:143740372	chr4:143912331~143982454:+
BRCA	cis	rs13256369	0.951	rs13260947	ENSG00000253893.2	FAM85B	-9.23	1.5e-19	6.94e-17	-0.39	-0.27	Obesity-related traits;	chr8:8708373	chr8:8167819~8226614:-
BRCA	cis	rs4835473	0.932	rs10030428	ENSG00000251600.4	RP11-673E1.1	9.23	1.5e-19	6.94e-17	0.31	0.27	Immature fraction of reticulocytes;	chr4:143762699	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs5015757	ENSG00000251600.4	RP11-673E1.1	9.23	1.5e-19	6.95e-17	0.32	0.27	Immature fraction of reticulocytes;	chr4:143738144	chr4:143912331~143982454:+
BRCA	cis	rs4988958	0.565	rs10206291	ENSG00000234389.1	AC007278.3	9.23	1.51e-19	6.97e-17	0.25	0.27	Asthma (childhood onset);	chr2:102422403	chr2:102438713~102440475:+
BRCA	cis	rs950169	0.579	rs881983	ENSG00000225151.9	GOLGA2P7	-9.23	1.51e-19	6.98e-17	-0.39	-0.27	Schizophrenia;	chr15:83978556	chr15:84199311~84230136:-
BRCA	cis	rs6142102	0.961	rs2284389	ENSG00000276073.1	RP5-1125A11.7	-9.23	1.51e-19	6.99e-17	-0.32	-0.27	Skin pigmentation;	chr20:34069035	chr20:33985617~33988989:-
BRCA	cis	rs875971	0.545	rs75577046	ENSG00000237310.1	GS1-124K5.4	9.23	1.51e-19	6.99e-17	0.33	0.27	Aortic root size;	chr7:66493729	chr7:66493706~66495474:+
BRCA	cis	rs11673344	0.764	rs513406	ENSG00000226686.6	LINC01535	9.23	1.51e-19	7e-17	0.35	0.27	Obesity-related traits;	chr19:36948245	chr19:37251912~37265535:+
BRCA	cis	rs11673344	0.734	rs496872	ENSG00000226686.6	LINC01535	9.23	1.51e-19	7e-17	0.35	0.27	Obesity-related traits;	chr19:36948579	chr19:37251912~37265535:+
BRCA	cis	rs9287719	0.781	rs6714795	ENSG00000234818.1	AC092687.5	9.23	1.52e-19	7.01e-17	0.32	0.27	Prostate cancer;	chr2:10619008	chr2:10589166~10604830:+
BRCA	cis	rs853679	0.567	rs16894091	ENSG00000216901.1	AL022393.7	-9.23	1.52e-19	7.01e-17	-0.39	-0.27	Depression;	chr6:28422360	chr6:28176188~28176674:+
BRCA	cis	rs113835537	0.529	rs4930379	ENSG00000255517.5	CTD-3074O7.5	-9.23	1.53e-19	7.06e-17	-0.36	-0.27	Airway imaging phenotypes;	chr11:66488203	chr11:66473490~66480233:-
BRCA	cis	rs113835537	0.529	rs4930183	ENSG00000255517.5	CTD-3074O7.5	-9.23	1.53e-19	7.06e-17	-0.36	-0.27	Airway imaging phenotypes;	chr11:66488261	chr11:66473490~66480233:-
BRCA	cis	rs13256369	0.851	rs13258283	ENSG00000253893.2	FAM85B	-9.23	1.53e-19	7.08e-17	-0.39	-0.27	Obesity-related traits;	chr8:8706120	chr8:8167819~8226614:-
BRCA	cis	rs13256369	0.851	rs13249700	ENSG00000253893.2	FAM85B	-9.23	1.53e-19	7.08e-17	-0.39	-0.27	Obesity-related traits;	chr8:8706127	chr8:8167819~8226614:-
BRCA	cis	rs13256369	0.851	rs13255061	ENSG00000253893.2	FAM85B	-9.23	1.53e-19	7.08e-17	-0.39	-0.27	Obesity-related traits;	chr8:8706324	chr8:8167819~8226614:-
BRCA	cis	rs13256369	0.851	rs12541477	ENSG00000253893.2	FAM85B	-9.23	1.53e-19	7.08e-17	-0.39	-0.27	Obesity-related traits;	chr8:8706385	chr8:8167819~8226614:-
BRCA	cis	rs6921919	0.806	rs213230	ENSG00000216901.1	AL022393.7	9.22	1.54e-19	7.1e-17	0.38	0.27	Autism spectrum disorder or schizophrenia;	chr6:28362487	chr6:28176188~28176674:+
BRCA	cis	rs11098499	0.863	rs7669520	ENSG00000245958.5	RP11-33B1.1	-9.22	1.54e-19	7.11e-17	-0.27	-0.27	Corneal astigmatism;	chr4:119594123	chr4:119454791~119552025:+
BRCA	cis	rs2221433	1	rs2354423	ENSG00000260310.1	RP11-27M24.2	9.22	1.54e-19	7.12e-17	0.32	0.27	Eating disorders;	chr16:10578271	chr16:10576499~10578183:-
BRCA	cis	rs11159086	0.793	rs9285594	ENSG00000259005.1	RP3-449M8.6	9.22	1.54e-19	7.12e-17	0.41	0.27	Advanced glycation end-product levels;	chr14:74489253	chr14:74474007~74474864:-
BRCA	cis	rs11159086	0.793	rs4903229	ENSG00000259005.1	RP3-449M8.6	9.22	1.54e-19	7.12e-17	0.41	0.27	Advanced glycation end-product levels;	chr14:74489865	chr14:74474007~74474864:-
BRCA	cis	rs11159086	0.793	rs8016972	ENSG00000259005.1	RP3-449M8.6	9.22	1.54e-19	7.12e-17	0.41	0.27	Advanced glycation end-product levels;	chr14:74491833	chr14:74474007~74474864:-
BRCA	cis	rs673078	0.66	rs75752792	ENSG00000275759.1	RP11-131L12.3	-9.22	1.54e-19	7.13e-17	-0.43	-0.27	Glucose homeostasis traits;	chr12:118187005	chr12:118428281~118428870:+
BRCA	cis	rs673078	0.66	rs75571641	ENSG00000275759.1	RP11-131L12.3	-9.22	1.54e-19	7.13e-17	-0.43	-0.27	Glucose homeostasis traits;	chr12:118187012	chr12:118428281~118428870:+
BRCA	cis	rs2404602	1	rs12148786	ENSG00000259422.1	RP11-593F23.1	9.22	1.55e-19	7.18e-17	0.34	0.27	Blood metabolite levels;	chr15:76508021	chr15:76174891~76181486:-
BRCA	cis	rs11159086	0.793	rs10150696	ENSG00000259005.1	RP3-449M8.6	9.22	1.56e-19	7.19e-17	0.41	0.27	Advanced glycation end-product levels;	chr14:74476723	chr14:74474007~74474864:-
BRCA	cis	rs1707322	0.963	rs4630155	ENSG00000280836.1	AL355480.1	-9.22	1.56e-19	7.23e-17	-0.36	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45791438	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.963	rs12076580	ENSG00000280836.1	AL355480.1	-9.22	1.56e-19	7.23e-17	-0.36	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45792487	chr1:45581219~45581321:-
BRCA	cis	rs9368481	0.554	rs2754603	ENSG00000241549.7	GUSBP2	-9.22	1.57e-19	7.23e-17	-0.32	-0.27	Autism spectrum disorder or schizophrenia;	chr6:26997360	chr6:26871484~26956554:-
BRCA	cis	rs13256369	0.756	rs13282580	ENSG00000253893.2	FAM85B	-9.22	1.57e-19	7.24e-17	-0.39	-0.27	Obesity-related traits;	chr8:8705393	chr8:8167819~8226614:-
BRCA	cis	rs673078	0.66	rs56708462	ENSG00000275759.1	RP11-131L12.3	-9.22	1.57e-19	7.25e-17	-0.43	-0.27	Glucose homeostasis traits;	chr12:118284135	chr12:118428281~118428870:+
BRCA	cis	rs2276314	0.802	rs9963714	ENSG00000278986.1	RP11-723J4.3	-9.22	1.57e-19	7.25e-17	-0.36	-0.27	Endometriosis;Drug-induced torsades de pointes;	chr18:36012093	chr18:35972151~35973916:+
BRCA	cis	rs2276314	0.802	rs4799838	ENSG00000278986.1	RP11-723J4.3	-9.22	1.57e-19	7.25e-17	-0.36	-0.27	Endometriosis;Drug-induced torsades de pointes;	chr18:36017567	chr18:35972151~35973916:+
BRCA	cis	rs2276314	0.748	rs4799839	ENSG00000278986.1	RP11-723J4.3	-9.22	1.57e-19	7.25e-17	-0.36	-0.27	Endometriosis;Drug-induced torsades de pointes;	chr18:36017568	chr18:35972151~35973916:+
BRCA	cis	rs2276314	0.857	rs28375959	ENSG00000278986.1	RP11-723J4.3	-9.22	1.57e-19	7.25e-17	-0.36	-0.27	Endometriosis;Drug-induced torsades de pointes;	chr18:36021571	chr18:35972151~35973916:+
BRCA	cis	rs783540	1	rs1259180	ENSG00000278603.1	RP13-608F4.5	-9.22	1.57e-19	7.26e-17	-0.34	-0.27	Schizophrenia;	chr15:82575930	chr15:82472203~82472426:+
BRCA	cis	rs7945705	0.935	rs2653567	ENSG00000254860.4	TMEM9B-AS1	9.22	1.58e-19	7.3e-17	0.25	0.27	Hemoglobin concentration;	chr11:8868083	chr11:8964675~8977527:+
BRCA	cis	rs80285556	1	rs17661933	ENSG00000161643.11	SIGLEC16	-9.22	1.59e-19	7.33e-17	-0.66	-0.27	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50031263	chr19:49969673~49975814:+
BRCA	cis	rs7945705	0.818	rs1988708	ENSG00000254860.4	TMEM9B-AS1	9.22	1.59e-19	7.36e-17	0.25	0.27	Hemoglobin concentration;	chr11:8861346	chr11:8964675~8977527:+
BRCA	cis	rs875971	0.545	rs6460298	ENSG00000237310.1	GS1-124K5.4	9.22	1.61e-19	7.43e-17	0.33	0.27	Aortic root size;	chr7:66442783	chr7:66493706~66495474:+
BRCA	cis	rs7945705	0.935	rs2568062	ENSG00000254860.4	TMEM9B-AS1	9.22	1.62e-19	7.46e-17	0.25	0.27	Hemoglobin concentration;	chr11:8866398	chr11:8964675~8977527:+
BRCA	cis	rs9318086	0.904	rs9580769	ENSG00000205861.10	C1QTNF9B-AS1	9.22	1.62e-19	7.48e-17	0.34	0.27	Myopia (pathological);	chr13:23865585	chr13:23888889~23897263:+
BRCA	cis	rs4835473	0.932	rs56277406	ENSG00000251600.4	RP11-673E1.1	-9.22	1.62e-19	7.49e-17	-0.32	-0.27	Immature fraction of reticulocytes;	chr4:143740620	chr4:143912331~143982454:+
BRCA	cis	rs858239	0.601	rs28673077	ENSG00000226816.2	AC005082.12	9.22	1.63e-19	7.51e-17	0.33	0.27	Cerebrospinal fluid biomarker levels;	chr7:23211235	chr7:23206013~23208045:+
BRCA	cis	rs7811142	1	rs4472444	ENSG00000242294.5	STAG3L5P	9.22	1.63e-19	7.52e-17	0.26	0.27	Platelet count;	chr7:100473135	chr7:100336079~100351900:+
BRCA	cis	rs7811142	1	rs7809801	ENSG00000242294.5	STAG3L5P	9.22	1.63e-19	7.52e-17	0.26	0.27	Platelet count;	chr7:100474408	chr7:100336079~100351900:+
BRCA	cis	rs2067615	0.579	rs3910854	ENSG00000260329.1	RP11-412D9.4	-9.22	1.63e-19	7.52e-17	-0.3	-0.27	Heart rate;	chr12:106771891	chr12:106954029~106955497:-
BRCA	cis	rs9287719	0.967	rs10929682	ENSG00000234818.1	AC092687.5	9.22	1.63e-19	7.53e-17	0.32	0.27	Prostate cancer;	chr2:10592063	chr2:10589166~10604830:+
BRCA	cis	rs9807989	0.507	rs3755266	ENSG00000234389.1	AC007278.3	9.22	1.64e-19	7.54e-17	0.25	0.27	Asthma;	chr2:102426252	chr2:102438713~102440475:+
BRCA	cis	rs465969	1	rs459888	ENSG00000255389.1	C6orf3	9.22	1.64e-19	7.55e-17	0.53	0.27	Psoriasis;	chr6:111329953	chr6:111599875~111602295:+
BRCA	cis	rs11673344	0.864	rs826322	ENSG00000226686.6	LINC01535	9.22	1.64e-19	7.58e-17	0.35	0.27	Obesity-related traits;	chr19:37013694	chr19:37251912~37265535:+
BRCA	cis	rs7772486	0.686	rs4896828	ENSG00000235652.6	RP11-545I5.3	9.22	1.65e-19	7.6e-17	0.27	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145632203	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.686	rs6570701	ENSG00000235652.6	RP11-545I5.3	9.22	1.65e-19	7.6e-17	0.27	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145632954	chr6:145799409~145886585:+
BRCA	cis	rs6750795	0.507	rs1667320	ENSG00000181798.2	LINC00471	-9.22	1.65e-19	7.61e-17	-0.33	-0.27	Height;	chr2:231553603	chr2:231508426~231514339:-
BRCA	cis	rs1707322	1	rs4606257	ENSG00000280836.1	AL355480.1	-9.22	1.67e-19	7.68e-17	-0.36	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45841596	chr1:45581219~45581321:-
BRCA	cis	rs765787	0.53	rs12439643	ENSG00000259520.4	CTD-2651B20.3	-9.22	1.67e-19	7.7e-17	-0.35	-0.27	Uric acid levels;	chr15:45237569	chr15:45251580~45279251:-
BRCA	cis	rs7580658	0.724	rs6712551	ENSG00000236682.1	AC068282.3	-9.21	1.7e-19	7.84e-17	-0.37	-0.27	Protein C levels;	chr2:127240909	chr2:127389130~127400580:+
BRCA	cis	rs1075265	0.836	rs1363063	ENSG00000233266.1	HMGB1P31	9.21	1.7e-19	7.84e-17	0.33	0.27	Chronotype;Morning vs. evening chronotype;	chr2:54047433	chr2:54051334~54051760:+
BRCA	cis	rs9287719	0.967	rs4669596	ENSG00000234818.1	AC092687.5	9.21	1.7e-19	7.85e-17	0.32	0.27	Prostate cancer;	chr2:10580446	chr2:10589166~10604830:+
BRCA	cis	rs889312	0.504	rs62355900	ENSG00000271828.1	CTD-2310F14.1	9.21	1.71e-19	7.86e-17	0.42	0.27	Breast cancer (early onset);Breast cancer;	chr5:56756868	chr5:56927874~56929573:+
BRCA	cis	rs4835473	0.897	rs2060654	ENSG00000251600.4	RP11-673E1.1	-9.21	1.71e-19	7.86e-17	-0.32	-0.27	Immature fraction of reticulocytes;	chr4:143739155	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs2060655	ENSG00000251600.4	RP11-673E1.1	-9.21	1.71e-19	7.86e-17	-0.32	-0.27	Immature fraction of reticulocytes;	chr4:143739159	chr4:143912331~143982454:+
BRCA	cis	rs67311347	0.713	rs4974018	ENSG00000223797.4	ENTPD3-AS1	9.21	1.71e-19	7.86e-17	0.31	0.27	Renal cell carcinoma;	chr3:40265928	chr3:40313802~40453329:-
BRCA	cis	rs1823913	0.927	rs35530564	ENSG00000280083.1	RP11-317J9.1	-9.21	1.71e-19	7.89e-17	-0.34	-0.27	Obesity-related traits;	chr2:191247324	chr2:191154118~191156070:-
BRCA	cis	rs6538678	0.864	rs10777747	ENSG00000258343.1	RP11-536G4.2	-9.21	1.72e-19	7.94e-17	-0.37	-0.27	Lupus nephritis in systemic lupus erythematosus;	chr12:95870192	chr12:95795345~95858839:-
BRCA	cis	rs2274273	0.934	rs10137307	ENSG00000258413.1	RP11-665C16.6	-9.21	1.72e-19	7.94e-17	-0.35	-0.27	Protein biomarker;	chr14:55378467	chr14:55262767~55272075:-
BRCA	cis	rs9847710	0.708	rs2581811	ENSG00000242142.1	SERBP1P3	9.21	1.73e-19	7.97e-17	0.34	0.27	Ulcerative colitis;	chr3:53051785	chr3:53064283~53065091:-
BRCA	cis	rs227275	0.525	rs13150426	ENSG00000246560.2	RP11-10L12.4	9.21	1.73e-19	7.97e-17	0.29	0.27	Allergic disease (asthma, hay fever or eczema);	chr4:103013743	chr4:102828055~102844075:+
BRCA	cis	rs11763147	1	rs11763147	ENSG00000224316.1	RP11-479O9.2	-9.21	1.74e-19	8e-17	-0.27	-0.27	Corneal structure;	chr7:65861834	chr7:65773620~65802067:+
BRCA	cis	rs1823913	0.637	rs921737	ENSG00000227542.1	AC092614.2	-9.21	1.75e-19	8.04e-17	-0.33	-0.27	Obesity-related traits;	chr2:191286097	chr2:191229165~191246172:-
BRCA	cis	rs7429990	0.965	rs800762	ENSG00000229759.1	MRPS18AP1	9.21	1.75e-19	8.05e-17	0.31	0.27	Educational attainment (years of education);	chr3:47864080	chr3:48256350~48256938:-
BRCA	cis	rs113835537	0.529	rs7950407	ENSG00000255517.5	CTD-3074O7.5	-9.21	1.75e-19	8.06e-17	-0.35	-0.27	Airway imaging phenotypes;	chr11:66490535	chr11:66473490~66480233:-
BRCA	cis	rs7811142	0.943	rs111493473	ENSG00000242294.5	STAG3L5P	9.21	1.76e-19	8.1e-17	0.26	0.27	Platelet count;	chr7:100452119	chr7:100336079~100351900:+
BRCA	cis	rs2439831	0.85	rs8042868	ENSG00000249839.1	AC011330.5	-9.21	1.77e-19	8.13e-17	-0.48	-0.27	Lung cancer in ever smokers;	chr15:43647444	chr15:43663654~43684339:-
BRCA	cis	rs7772486	0.641	rs2748489	ENSG00000235652.6	RP11-545I5.3	9.21	1.77e-19	8.14e-17	0.3	0.27	Lobe attachment (rater-scored or self-reported);	chr6:146010151	chr6:145799409~145886585:+
BRCA	cis	rs783540	0.835	rs8030185	ENSG00000278603.1	RP13-608F4.5	9.21	1.77e-19	8.14e-17	0.35	0.27	Schizophrenia;	chr15:82722785	chr15:82472203~82472426:+
BRCA	cis	rs858267	0.661	rs7786708	ENSG00000230658.1	KLHL7-AS1	-9.21	1.77e-19	8.16e-17	-0.64	-0.27	Blood protein levels;	chr7:23075797	chr7:23101228~23105703:-
BRCA	cis	rs673078	0.615	rs16948204	ENSG00000275759.1	RP11-131L12.3	-9.21	1.78e-19	8.17e-17	-0.43	-0.27	Glucose homeostasis traits;	chr12:118258252	chr12:118428281~118428870:+
BRCA	cis	rs673078	0.66	rs7303417	ENSG00000275759.1	RP11-131L12.3	-9.21	1.78e-19	8.17e-17	-0.43	-0.27	Glucose homeostasis traits;	chr12:118258859	chr12:118428281~118428870:+
BRCA	cis	rs673078	0.66	rs7965350	ENSG00000275759.1	RP11-131L12.3	-9.21	1.78e-19	8.17e-17	-0.43	-0.27	Glucose homeostasis traits;	chr12:118266710	chr12:118428281~118428870:+
BRCA	cis	rs673078	0.66	rs17433217	ENSG00000275759.1	RP11-131L12.3	-9.21	1.78e-19	8.17e-17	-0.43	-0.27	Glucose homeostasis traits;	chr12:118269076	chr12:118428281~118428870:+
BRCA	cis	rs7772486	0.686	rs4896827	ENSG00000235652.6	RP11-545I5.3	9.21	1.79e-19	8.22e-17	0.27	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145632202	chr6:145799409~145886585:+
BRCA	cis	rs227275	0.525	rs4699046	ENSG00000246560.2	RP11-10L12.4	9.21	1.79e-19	8.22e-17	0.29	0.27	Allergic disease (asthma, hay fever or eczema);	chr4:103004514	chr4:102828055~102844075:+
BRCA	cis	rs227275	0.525	rs4699047	ENSG00000246560.2	RP11-10L12.4	9.21	1.79e-19	8.22e-17	0.29	0.27	Allergic disease (asthma, hay fever or eczema);	chr4:103005385	chr4:102828055~102844075:+
BRCA	cis	rs227275	0.525	rs28778380	ENSG00000246560.2	RP11-10L12.4	9.21	1.79e-19	8.22e-17	0.29	0.27	Allergic disease (asthma, hay fever or eczema);	chr4:103006416	chr4:102828055~102844075:+
BRCA	cis	rs2067615	0.579	rs12312782	ENSG00000260329.1	RP11-412D9.4	-9.21	1.79e-19	8.22e-17	-0.3	-0.27	Heart rate;	chr12:106741869	chr12:106954029~106955497:-
BRCA	cis	rs875971	0.545	rs313828	ENSG00000237310.1	GS1-124K5.4	-9.21	1.79e-19	8.23e-17	-0.33	-0.27	Aortic root size;	chr7:66087627	chr7:66493706~66495474:+
BRCA	cis	rs7772486	0.875	rs9390371	ENSG00000235652.6	RP11-545I5.3	9.21	1.79e-19	8.24e-17	0.27	0.27	Lobe attachment (rater-scored or self-reported);	chr6:146042044	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.875	rs6909827	ENSG00000235652.6	RP11-545I5.3	9.21	1.79e-19	8.24e-17	0.27	0.27	Lobe attachment (rater-scored or self-reported);	chr6:146044602	chr6:145799409~145886585:+
BRCA	cis	rs12701220	0.655	rs12702117	ENSG00000229043.2	AC091729.9	-9.21	1.79e-19	8.24e-17	-0.39	-0.27	Bronchopulmonary dysplasia;	chr7:1109066	chr7:1160374~1165267:+
BRCA	cis	rs2274273	0.868	rs1572611	ENSG00000258413.1	RP11-665C16.6	-9.21	1.79e-19	8.25e-17	-0.35	-0.27	Protein biomarker;	chr14:55367156	chr14:55262767~55272075:-
BRCA	cis	rs11096990	0.634	rs6531702	ENSG00000249207.1	RP11-360F5.1	-9.21	1.81e-19	8.31e-17	-0.32	-0.27	Cognitive function;	chr4:39273774	chr4:39112677~39126818:-
BRCA	cis	rs4835473	0.9	rs4257605	ENSG00000251600.4	RP11-673E1.1	-9.21	1.82e-19	8.36e-17	-0.32	-0.27	Immature fraction of reticulocytes;	chr4:143740081	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs4498094	ENSG00000251600.4	RP11-673E1.1	-9.21	1.82e-19	8.36e-17	-0.32	-0.27	Immature fraction of reticulocytes;	chr4:143740097	chr4:143912331~143982454:+
BRCA	cis	rs673078	0.66	rs7970481	ENSG00000275759.1	RP11-131L12.3	-9.21	1.82e-19	8.37e-17	-0.43	-0.27	Glucose homeostasis traits;	chr12:118242112	chr12:118428281~118428870:+
BRCA	cis	rs673078	0.66	rs58113338	ENSG00000275759.1	RP11-131L12.3	-9.21	1.82e-19	8.37e-17	-0.43	-0.27	Glucose homeostasis traits;	chr12:118251335	chr12:118428281~118428870:+
BRCA	cis	rs1075265	0.756	rs805367	ENSG00000233266.1	HMGB1P31	9.2	1.82e-19	8.37e-17	0.33	0.27	Chronotype;Morning vs. evening chronotype;	chr2:53943956	chr2:54051334~54051760:+
BRCA	cis	rs465969	1	rs17510761	ENSG00000255389.1	C6orf3	-9.2	1.83e-19	8.4e-17	-0.56	-0.27	Psoriasis;	chr6:111387380	chr6:111599875~111602295:+
BRCA	cis	rs465969	1	rs78945802	ENSG00000255389.1	C6orf3	-9.2	1.83e-19	8.4e-17	-0.56	-0.27	Psoriasis;	chr6:111407143	chr6:111599875~111602295:+
BRCA	cis	rs465969	1	rs17072683	ENSG00000255389.1	C6orf3	-9.2	1.83e-19	8.4e-17	-0.56	-0.27	Psoriasis;	chr6:111410007	chr6:111599875~111602295:+
BRCA	cis	rs11722779	0.838	rs4533776	ENSG00000246560.2	RP11-10L12.4	9.2	1.84e-19	8.46e-17	0.28	0.27	Schizophrenia;	chr4:102912732	chr4:102828055~102844075:+
BRCA	cis	rs30380	0.69	rs2911139	ENSG00000248734.2	CTD-2260A17.1	9.2	1.84e-19	8.47e-17	0.31	0.27	Cerebrospinal fluid biomarker levels;	chr5:96843890	chr5:96784777~96785999:+
BRCA	cis	rs4835473	0.808	rs2060652	ENSG00000251600.4	RP11-673E1.1	-9.2	1.85e-19	8.47e-17	-0.32	-0.27	Immature fraction of reticulocytes;	chr4:143739129	chr4:143912331~143982454:+
BRCA	cis	rs4718428	0.705	rs62465692	ENSG00000232546.1	RP11-458F8.1	-9.2	1.85e-19	8.48e-17	-0.25	-0.27	Corneal structure;	chr7:66830758	chr7:66848496~66858136:+
BRCA	cis	rs9847710	0.683	rs2581818	ENSG00000242142.1	SERBP1P3	9.2	1.85e-19	8.49e-17	0.33	0.27	Ulcerative colitis;	chr3:53037636	chr3:53064283~53065091:-
BRCA	cis	rs4835473	0.808	rs62339607	ENSG00000251600.4	RP11-673E1.1	-9.2	1.88e-19	8.62e-17	-0.32	-0.27	Immature fraction of reticulocytes;	chr4:143791474	chr4:143912331~143982454:+
BRCA	cis	rs11159086	0.793	rs11625502	ENSG00000259005.1	RP3-449M8.6	9.2	1.88e-19	8.63e-17	0.42	0.27	Advanced glycation end-product levels;	chr14:74468309	chr14:74474007~74474864:-
BRCA	cis	rs7580658	0.724	rs6712446	ENSG00000236682.1	AC068282.3	-9.2	1.89e-19	8.67e-17	-0.37	-0.27	Protein C levels;	chr2:127240823	chr2:127389130~127400580:+
BRCA	cis	rs9807989	0.507	rs11465721	ENSG00000234389.1	AC007278.3	9.2	1.89e-19	8.68e-17	0.25	0.27	Asthma;	chr2:102446780	chr2:102438713~102440475:+
BRCA	cis	rs116175783	0.557	rs1267058	ENSG00000227403.1	AC009299.3	-9.2	1.89e-19	8.69e-17	-0.48	-0.27	Intelligence (multi-trait analysis);	chr2:161264934	chr2:161244739~161249050:+
BRCA	cis	rs1075265	0.589	rs2542571	ENSG00000233266.1	HMGB1P31	9.2	1.91e-19	8.77e-17	0.32	0.27	Chronotype;Morning vs. evening chronotype;	chr2:53814846	chr2:54051334~54051760:+
BRCA	cis	rs7580658	0.637	rs12463909	ENSG00000236682.1	AC068282.3	9.2	1.92e-19	8.79e-17	0.36	0.27	Protein C levels;	chr2:127214162	chr2:127389130~127400580:+
BRCA	cis	rs12468226	1	rs74766638	ENSG00000273456.1	RP11-686O6.2	9.2	1.92e-19	8.83e-17	0.41	0.27	Urate levels;	chr2:202445168	chr2:202374932~202375604:-
BRCA	cis	rs1823913	0.599	rs6736071	ENSG00000227542.1	AC092614.2	-9.2	1.93e-19	8.84e-17	-0.33	-0.27	Obesity-related traits;	chr2:191287265	chr2:191229165~191246172:-
BRCA	cis	rs1061377	0.965	rs3733275	ENSG00000249685.1	RP11-360F5.3	9.2	1.93e-19	8.84e-17	0.33	0.27	Uric acid levels;	chr4:39121077	chr4:39133913~39135608:+
BRCA	cis	rs30380	0.69	rs2042381	ENSG00000248734.2	CTD-2260A17.1	9.2	1.93e-19	8.85e-17	0.3	0.27	Cerebrospinal fluid biomarker levels;	chr5:96852963	chr5:96784777~96785999:+
BRCA	cis	rs12130219	0.588	rs2282302	ENSG00000237975.5	FLG-AS1	9.2	1.94e-19	8.91e-17	0.4	0.27	Inflammatory skin disease;	chr1:152356893	chr1:152168125~152445456:+
BRCA	cis	rs11098499	0.954	rs6822679	ENSG00000248280.1	RP11-33B1.2	9.2	1.94e-19	8.92e-17	0.28	0.27	Corneal astigmatism;	chr4:119481547	chr4:119440561~119450157:-
BRCA	cis	rs2404602	1	rs12441433	ENSG00000259422.1	RP11-593F23.1	9.2	1.95e-19	8.96e-17	0.34	0.27	Blood metabolite levels;	chr15:76523674	chr15:76174891~76181486:-
BRCA	cis	rs9847710	0.733	rs2581809	ENSG00000242142.1	SERBP1P3	9.2	1.95e-19	8.96e-17	0.34	0.27	Ulcerative colitis;	chr3:53055667	chr3:53064283~53065091:-
BRCA	cis	rs9807989	0.507	rs1833174	ENSG00000234389.1	AC007278.3	9.2	1.97e-19	9.01e-17	0.25	0.27	Asthma;	chr2:102418383	chr2:102438713~102440475:+
BRCA	cis	rs11159086	0.793	rs28612392	ENSG00000259005.1	RP3-449M8.6	9.2	1.97e-19	9.02e-17	0.42	0.27	Advanced glycation end-product levels;	chr14:74467894	chr14:74474007~74474864:-
BRCA	cis	rs891378	0.837	rs11120688	ENSG00000274245.1	RP11-357P18.2	9.2	1.97e-19	9.03e-17	0.41	0.27	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207312770	chr1:207372559~207373252:+
BRCA	cis	rs875971	0.545	rs67397473	ENSG00000237310.1	GS1-124K5.4	9.2	1.97e-19	9.04e-17	0.32	0.27	Aortic root size;	chr7:66168318	chr7:66493706~66495474:+
BRCA	cis	rs11098499	0.863	rs3775843	ENSG00000245958.5	RP11-33B1.1	-9.2	1.98e-19	9.09e-17	-0.27	-0.27	Corneal astigmatism;	chr4:119506689	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.863	rs3775844	ENSG00000245958.5	RP11-33B1.1	-9.2	1.98e-19	9.09e-17	-0.27	-0.27	Corneal astigmatism;	chr4:119506878	chr4:119454791~119552025:+
BRCA	cis	rs858239	0.6	rs6961131	ENSG00000226816.2	AC005082.12	9.19	1.98e-19	9.1e-17	0.31	0.27	Cerebrospinal fluid biomarker levels;	chr7:23095171	chr7:23206013~23208045:+
BRCA	cis	rs6570726	0.764	rs4263604	ENSG00000235652.6	RP11-545I5.3	9.19	1.99e-19	9.11e-17	0.27	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145595561	chr6:145799409~145886585:+
BRCA	cis	rs6545883	0.503	rs1665272	ENSG00000271889.1	RP11-493E12.1	9.19	1.99e-19	9.13e-17	0.34	0.27	Tuberculosis;	chr2:61152151	chr2:61151433~61162105:-
BRCA	cis	rs3743772	0.5	rs8045574	ENSG00000279722.1	RP11-44F14.6	-9.19	1.99e-19	9.13e-17	-0.42	-0.27	Depressive symptoms (SSRI exposure interaction);	chr16:53395293	chr16:53487607~53489943:-
BRCA	cis	rs9847710	0.733	rs2581808	ENSG00000242142.1	SERBP1P3	9.19	1.99e-19	9.13e-17	0.34	0.27	Ulcerative colitis;	chr3:53055429	chr3:53064283~53065091:-
BRCA	cis	rs7826238	0.502	rs10503377	ENSG00000253893.2	FAM85B	-9.19	2e-19	9.16e-17	-0.38	-0.27	Systolic blood pressure;	chr8:8520912	chr8:8167819~8226614:-
BRCA	cis	rs9807989	0.507	rs10208196	ENSG00000234389.1	AC007278.3	9.19	2e-19	9.16e-17	0.25	0.27	Asthma;	chr2:102379885	chr2:102438713~102440475:+
BRCA	cis	rs9807989	0.507	rs3213732	ENSG00000234389.1	AC007278.3	9.19	2e-19	9.16e-17	0.25	0.27	Asthma;	chr2:102381819	chr2:102438713~102440475:+
BRCA	cis	rs9807989	0.507	rs10204757	ENSG00000234389.1	AC007278.3	9.19	2e-19	9.16e-17	0.25	0.27	Asthma;	chr2:102382514	chr2:102438713~102440475:+
BRCA	cis	rs9807989	0.524	rs7591246	ENSG00000234389.1	AC007278.3	9.19	2e-19	9.16e-17	0.25	0.27	Asthma;	chr2:102382943	chr2:102438713~102440475:+
BRCA	cis	rs4988958	0.565	rs6760621	ENSG00000234389.1	AC007278.3	9.19	2e-19	9.16e-17	0.25	0.27	Asthma (childhood onset);	chr2:102383492	chr2:102438713~102440475:+
BRCA	cis	rs4988958	0.527	rs11465641	ENSG00000234389.1	AC007278.3	9.19	2e-19	9.16e-17	0.25	0.27	Asthma (childhood onset);	chr2:102384408	chr2:102438713~102440475:+
BRCA	cis	rs783540	1	rs783531	ENSG00000278603.1	RP13-608F4.5	-9.19	2.01e-19	9.19e-17	-0.34	-0.27	Schizophrenia;	chr15:82580370	chr15:82472203~82472426:+
BRCA	cis	rs783540	0.934	rs783532	ENSG00000278603.1	RP13-608F4.5	-9.19	2.01e-19	9.19e-17	-0.34	-0.27	Schizophrenia;	chr15:82580618	chr15:82472203~82472426:+
BRCA	cis	rs6570726	0.791	rs11155433	ENSG00000235652.6	RP11-545I5.3	-9.19	2.01e-19	9.21e-17	-0.27	-0.27	Lobe attachment (rater-scored or self-reported);	chr6:145586695	chr6:145799409~145886585:+
BRCA	cis	rs673078	0.66	rs7962185	ENSG00000275759.1	RP11-131L12.3	-9.19	2.02e-19	9.23e-17	-0.43	-0.27	Glucose homeostasis traits;	chr12:118287842	chr12:118428281~118428870:+
BRCA	cis	rs875971	0.545	rs801199	ENSG00000237310.1	GS1-124K5.4	-9.19	2.03e-19	9.29e-17	-0.32	-0.27	Aortic root size;	chr7:66560286	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.545	rs73152714	ENSG00000237310.1	GS1-124K5.4	9.19	2.03e-19	9.29e-17	0.32	0.27	Aortic root size;	chr7:66534641	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.545	rs4718364	ENSG00000237310.1	GS1-124K5.4	9.19	2.03e-19	9.29e-17	0.32	0.27	Aortic root size;	chr7:66536353	chr7:66493706~66495474:+
BRCA	cis	rs113835537	0.529	rs2279864	ENSG00000255517.5	CTD-3074O7.5	-9.19	2.03e-19	9.3e-17	-0.36	-0.27	Airway imaging phenotypes;	chr11:66480373	chr11:66473490~66480233:-
BRCA	cis	rs56046484	0.956	rs17540501	ENSG00000259295.5	CSPG4P12	9.19	2.04e-19	9.32e-17	0.48	0.27	Testicular germ cell tumor;	chr15:85094870	chr15:85191438~85213905:+
BRCA	cis	rs56046484	1	rs12911330	ENSG00000259295.5	CSPG4P12	9.19	2.04e-19	9.33e-17	0.48	0.27	Testicular germ cell tumor;	chr15:85087103	chr15:85191438~85213905:+
BRCA	cis	rs56046484	0.956	rs34919315	ENSG00000259295.5	CSPG4P12	9.19	2.04e-19	9.33e-17	0.48	0.27	Testicular germ cell tumor;	chr15:85088675	chr15:85191438~85213905:+
BRCA	cis	rs2243480	1	rs4548056	ENSG00000226824.5	RP4-756H11.3	-9.19	2.05e-19	9.37e-17	-0.52	-0.27	Diabetic kidney disease;	chr7:65833886	chr7:66654538~66669855:+
BRCA	cis	rs6570726	0.577	rs441982	ENSG00000235652.6	RP11-545I5.3	9.19	2.05e-19	9.37e-17	0.3	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145521712	chr6:145799409~145886585:+
BRCA	cis	rs925255	0.591	rs7559046	ENSG00000270210.1	RP11-373D23.3	9.19	2.06e-19	9.41e-17	0.35	0.27	Inflammatory bowel disease;Crohn's disease;	chr2:28421803	chr2:28425945~28426719:+
BRCA	cis	rs2274273	0.774	rs17128440	ENSG00000258413.1	RP11-665C16.6	-9.19	2.06e-19	9.43e-17	-0.34	-0.27	Protein biomarker;	chr14:55395194	chr14:55262767~55272075:-
BRCA	cis	rs11673344	0.864	rs2263167	ENSG00000226686.6	LINC01535	9.19	2.06e-19	9.44e-17	0.35	0.27	Obesity-related traits;	chr19:37030025	chr19:37251912~37265535:+
BRCA	cis	rs7924176	0.601	rs3180427	ENSG00000213731.2	RAB5CP1	-9.19	2.06e-19	9.45e-17	-0.3	-0.27	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74121589	chr10:74423435~74424014:-
BRCA	cis	rs1823913	0.637	rs4853578	ENSG00000227542.1	AC092614.2	9.19	2.08e-19	9.51e-17	0.33	0.27	Obesity-related traits;	chr2:191297215	chr2:191229165~191246172:-
BRCA	cis	rs4835473	0.932	rs5016160	ENSG00000251600.4	RP11-673E1.1	9.19	2.1e-19	9.57e-17	0.32	0.27	Immature fraction of reticulocytes;	chr4:143738305	chr4:143912331~143982454:+
BRCA	cis	rs9903692	0.954	rs8080662	ENSG00000278765.1	RP5-890E16.5	-9.19	2.1e-19	9.61e-17	-0.34	-0.27	Pulse pressure;	chr17:48113457	chr17:48066704~48067293:-
BRCA	cis	rs2276314	1	rs9956938	ENSG00000278986.1	RP11-723J4.3	-9.19	2.12e-19	9.69e-17	-0.36	-0.27	Endometriosis;Drug-induced torsades de pointes;	chr18:35987098	chr18:35972151~35973916:+
BRCA	cis	rs2274273	0.837	rs59871474	ENSG00000258413.1	RP11-665C16.6	-9.19	2.12e-19	9.7e-17	-0.34	-0.27	Protein biomarker;	chr14:55312645	chr14:55262767~55272075:-
BRCA	cis	rs4835473	0.932	rs13133444	ENSG00000251600.4	RP11-673E1.1	9.19	2.12e-19	9.7e-17	0.32	0.27	Immature fraction of reticulocytes;	chr4:143738191	chr4:143912331~143982454:+
BRCA	cis	rs881375	1	rs10818480	ENSG00000226752.6	PSMD5-AS1	-9.19	2.13e-19	9.74e-17	-0.33	-0.27	Rheumatoid arthritis;	chr9:120880892	chr9:120824828~120854385:+
BRCA	cis	rs367615	0.704	rs7704824	ENSG00000249476.1	CTD-2587M2.1	9.19	2.13e-19	9.75e-17	0.3	0.27	Colorectal cancer (SNP x SNP interaction);	chr5:109514577	chr5:109237120~109326369:-
BRCA	cis	rs7429990	0.866	rs3732529	ENSG00000229759.1	MRPS18AP1	9.19	2.14e-19	9.76e-17	0.31	0.27	Educational attainment (years of education);	chr3:47928619	chr3:48256350~48256938:-
BRCA	cis	rs9287719	0.781	rs12472807	ENSG00000234818.1	AC092687.5	9.19	2.15e-19	9.84e-17	0.32	0.27	Prostate cancer;	chr2:10641479	chr2:10589166~10604830:+
BRCA	cis	rs11098499	0.955	rs35197422	ENSG00000245958.5	RP11-33B1.1	-9.19	2.15e-19	9.84e-17	-0.27	-0.27	Corneal astigmatism;	chr4:119248159	chr4:119454791~119552025:+
BRCA	cis	rs2067615	0.524	rs10778499	ENSG00000260329.1	RP11-412D9.4	-9.19	2.16e-19	9.85e-17	-0.3	-0.27	Heart rate;	chr12:106674609	chr12:106954029~106955497:-
BRCA	cis	rs1075265	0.626	rs805320	ENSG00000233266.1	HMGB1P31	9.19	2.16e-19	9.87e-17	0.34	0.27	Chronotype;Morning vs. evening chronotype;	chr2:53911305	chr2:54051334~54051760:+
BRCA	cis	rs6570726	0.791	rs414297	ENSG00000235652.6	RP11-545I5.3	9.18	2.17e-19	9.91e-17	0.27	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145566420	chr6:145799409~145886585:+
BRCA	cis	rs875971	0.522	rs1917563	ENSG00000224316.1	RP11-479O9.2	-9.18	2.18e-19	9.93e-17	-0.27	-0.27	Aortic root size;	chr7:65950660	chr7:65773620~65802067:+
BRCA	cis	rs673078	0.66	rs61945206	ENSG00000275759.1	RP11-131L12.3	-9.18	2.18e-19	9.94e-17	-0.43	-0.27	Glucose homeostasis traits;	chr12:118238295	chr12:118428281~118428870:+
BRCA	cis	rs9847710	0.696	rs2581821	ENSG00000242142.1	SERBP1P3	9.18	2.18e-19	9.95e-17	0.34	0.27	Ulcerative colitis;	chr3:52987572	chr3:53064283~53065091:-
BRCA	cis	rs7429990	0.965	rs1060407	ENSG00000229759.1	MRPS18AP1	9.18	2.2e-19	1e-16	0.33	0.27	Educational attainment (years of education);	chr3:47916547	chr3:48256350~48256938:-
BRCA	cis	rs9368481	0.761	rs12661756	ENSG00000241549.7	GUSBP2	9.18	2.2e-19	1e-16	0.31	0.27	Autism spectrum disorder or schizophrenia;	chr6:27035704	chr6:26871484~26956554:-
BRCA	cis	rs6570726	0.599	rs455001	ENSG00000235652.6	RP11-545I5.3	9.18	2.2e-19	1.01e-16	0.3	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145533314	chr6:145799409~145886585:+
BRCA	cis	rs1062177	1	rs12654573	ENSG00000253921.1	CTB-113P19.3	-9.18	2.21e-19	1.01e-16	-0.36	-0.27	Preschool internalizing problems;	chr5:151827912	chr5:151753992~151767247:+
BRCA	cis	rs1823913	0.927	rs34765012	ENSG00000280083.1	RP11-317J9.1	-9.18	2.22e-19	1.01e-16	-0.34	-0.27	Obesity-related traits;	chr2:191247926	chr2:191154118~191156070:-
BRCA	cis	rs13256369	0.802	rs11249888	ENSG00000253893.2	FAM85B	-9.18	2.24e-19	1.02e-16	-0.39	-0.27	Obesity-related traits;	chr8:8707424	chr8:8167819~8226614:-
BRCA	cis	rs13256369	0.851	rs11249889	ENSG00000253893.2	FAM85B	-9.18	2.24e-19	1.02e-16	-0.39	-0.27	Obesity-related traits;	chr8:8707482	chr8:8167819~8226614:-
BRCA	cis	rs1707322	0.963	rs4508055	ENSG00000280836.1	AL355480.1	-9.18	2.26e-19	1.03e-16	-0.36	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45792059	chr1:45581219~45581321:-
BRCA	cis	rs227275	0.525	rs4699037	ENSG00000246560.2	RP11-10L12.4	9.18	2.26e-19	1.03e-16	0.28	0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102957010	chr4:102828055~102844075:+
BRCA	cis	rs227275	0.556	rs3857198	ENSG00000246560.2	RP11-10L12.4	9.18	2.26e-19	1.03e-16	0.28	0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102957720	chr4:102828055~102844075:+
BRCA	cis	rs227275	0.525	rs4699039	ENSG00000246560.2	RP11-10L12.4	9.18	2.26e-19	1.03e-16	0.28	0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102958354	chr4:102828055~102844075:+
BRCA	cis	rs1062177	0.826	rs2915879	ENSG00000253921.1	CTB-113P19.3	-9.18	2.27e-19	1.04e-16	-0.37	-0.27	Preschool internalizing problems;	chr5:151767881	chr5:151753992~151767247:+
BRCA	cis	rs1075265	0.704	rs9631059	ENSG00000233266.1	HMGB1P31	9.18	2.29e-19	1.04e-16	0.33	0.27	Chronotype;Morning vs. evening chronotype;	chr2:54015160	chr2:54051334~54051760:+
BRCA	cis	rs11098499	0.82	rs11737395	ENSG00000245958.5	RP11-33B1.1	-9.18	2.29e-19	1.04e-16	-0.27	-0.27	Corneal astigmatism;	chr4:119599549	chr4:119454791~119552025:+
BRCA	cis	rs7085104	0.7	rs10786712	ENSG00000213061.2	PFN1P11	-9.18	2.3e-19	1.05e-16	-0.35	-0.27	Immature fraction of reticulocytes;Schizophrenia;	chr10:102836639	chr10:102838011~102845473:-
BRCA	cis	rs1823913	0.637	rs4853573	ENSG00000227542.1	AC092614.2	-9.18	2.3e-19	1.05e-16	-0.33	-0.27	Obesity-related traits;	chr2:191295866	chr2:191229165~191246172:-
BRCA	cis	rs227275	0.525	rs2086499	ENSG00000246560.2	RP11-10L12.4	9.18	2.32e-19	1.05e-16	0.29	0.27	Allergic disease (asthma, hay fever or eczema);	chr4:103008672	chr4:102828055~102844075:+
BRCA	cis	rs13392177	0.637	rs61041183	ENSG00000261338.2	RP11-378A13.1	9.18	2.32e-19	1.06e-16	0.28	0.27	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218191657	chr2:218255319~218257366:+
BRCA	cis	rs1823913	0.637	rs4853465	ENSG00000227542.1	AC092614.2	-9.18	2.33e-19	1.06e-16	-0.33	-0.27	Obesity-related traits;	chr2:191294768	chr2:191229165~191246172:-
BRCA	cis	rs641862	1	rs641862	ENSG00000229152.2	ANKRD10-IT1	9.18	2.33e-19	1.06e-16	0.36	0.27	Obesity-related traits;	chr13:110137885	chr13:110894639~110899172:-
BRCA	cis	rs10875746	0.669	rs10783244	ENSG00000240399.1	RP1-228P16.1	-9.18	2.33e-19	1.06e-16	-0.36	-0.27	Longevity (90 years and older);	chr12:48271206	chr12:48054813~48055591:-
BRCA	cis	rs2404602	0.532	rs12591100	ENSG00000259422.1	RP11-593F23.1	-9.18	2.34e-19	1.06e-16	-0.34	-0.27	Blood metabolite levels;	chr15:76408460	chr15:76174891~76181486:-
BRCA	cis	rs2439831	0.85	rs3742982	ENSG00000249839.1	AC011330.5	-9.18	2.34e-19	1.06e-16	-0.46	-0.27	Lung cancer in ever smokers;	chr15:43884483	chr15:43663654~43684339:-
BRCA	cis	rs1075265	0.73	rs7597188	ENSG00000233266.1	HMGB1P31	9.18	2.34e-19	1.06e-16	0.33	0.27	Chronotype;Morning vs. evening chronotype;	chr2:54014732	chr2:54051334~54051760:+
BRCA	cis	rs11098499	0.955	rs1397608	ENSG00000245958.5	RP11-33B1.1	-9.18	2.35e-19	1.07e-16	-0.27	-0.27	Corneal astigmatism;	chr4:119240589	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.955	rs7685268	ENSG00000245958.5	RP11-33B1.1	-9.18	2.35e-19	1.07e-16	-0.27	-0.27	Corneal astigmatism;	chr4:119241033	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.955	rs7684942	ENSG00000245958.5	RP11-33B1.1	-9.18	2.35e-19	1.07e-16	-0.27	-0.27	Corneal astigmatism;	chr4:119241046	chr4:119454791~119552025:+
BRCA	cis	rs11673344	0.864	rs2562606	ENSG00000226686.6	LINC01535	9.18	2.35e-19	1.07e-16	0.35	0.27	Obesity-related traits;	chr19:37029628	chr19:37251912~37265535:+
BRCA	cis	rs7580658	0.724	rs12623948	ENSG00000236682.1	AC068282.3	-9.17	2.37e-19	1.08e-16	-0.36	-0.27	Protein C levels;	chr2:127243766	chr2:127389130~127400580:+
BRCA	cis	rs6570726	0.846	rs372904	ENSG00000235652.6	RP11-545I5.3	9.17	2.38e-19	1.08e-16	0.27	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145566289	chr6:145799409~145886585:+
BRCA	cis	rs1823913	0.614	rs4853466	ENSG00000227542.1	AC092614.2	-9.17	2.42e-19	1.1e-16	-0.33	-0.27	Obesity-related traits;	chr2:191295943	chr2:191229165~191246172:-
BRCA	cis	rs875971	0.571	rs160641	ENSG00000237310.1	GS1-124K5.4	-9.17	2.42e-19	1.1e-16	-0.32	-0.27	Aortic root size;	chr7:66112359	chr7:66493706~66495474:+
BRCA	cis	rs2439831	0.85	rs12440573	ENSG00000249839.1	AC011330.5	-9.17	2.42e-19	1.1e-16	-0.47	-0.27	Lung cancer in ever smokers;	chr15:43816799	chr15:43663654~43684339:-
BRCA	cis	rs10129255	0.5	rs2105989	ENSG00000211972.2	IGHV3-66	9.17	2.42e-19	1.1e-16	0.2	0.27	Kawasaki disease;	chr14:106682199	chr14:106675017~106675544:-
BRCA	cis	rs11673344	0.502	rs62108306	ENSG00000226686.6	LINC01535	9.17	2.43e-19	1.1e-16	0.35	0.27	Obesity-related traits;	chr19:37691789	chr19:37251912~37265535:+
BRCA	cis	rs2439831	0.85	rs28590651	ENSG00000249839.1	AC011330.5	-9.17	2.43e-19	1.1e-16	-0.45	-0.27	Lung cancer in ever smokers;	chr15:43820818	chr15:43663654~43684339:-
BRCA	cis	rs11098499	0.954	rs10518328	ENSG00000248280.1	RP11-33B1.2	9.17	2.43e-19	1.1e-16	0.28	0.27	Corneal astigmatism;	chr4:119480624	chr4:119440561~119450157:-
BRCA	cis	rs858239	0.568	rs6970694	ENSG00000226816.2	AC005082.12	9.17	2.43e-19	1.11e-16	0.32	0.27	Cerebrospinal fluid biomarker levels;	chr7:23211209	chr7:23206013~23208045:+
BRCA	cis	rs7772486	0.686	rs2328708	ENSG00000235652.6	RP11-545I5.3	-9.17	2.44e-19	1.11e-16	-0.27	-0.27	Lobe attachment (rater-scored or self-reported);	chr6:145774603	chr6:145799409~145886585:+
BRCA	cis	rs8062405	1	rs12444171	ENSG00000278665.1	RP11-666O2.4	9.17	2.44e-19	1.11e-16	0.29	0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28833930	chr16:28599241~28601881:-
BRCA	cis	rs11676348	0.774	rs57545959	ENSG00000261338.2	RP11-378A13.1	9.17	2.45e-19	1.11e-16	0.29	0.27	Ulcerative colitis;	chr2:218182995	chr2:218255319~218257366:+
BRCA	cis	rs6538678	0.895	rs1436124	ENSG00000258343.1	RP11-536G4.2	-9.17	2.45e-19	1.11e-16	-0.4	-0.27	Lupus nephritis in systemic lupus erythematosus;	chr12:95889654	chr12:95795345~95858839:-
BRCA	cis	rs9807989	0.507	rs2293224	ENSG00000234389.1	AC007278.3	9.17	2.45e-19	1.11e-16	0.25	0.27	Asthma;	chr2:102419319	chr2:102438713~102440475:+
BRCA	cis	rs9807989	0.507	rs6743516	ENSG00000234389.1	AC007278.3	9.17	2.45e-19	1.11e-16	0.25	0.27	Asthma;	chr2:102419875	chr2:102438713~102440475:+
BRCA	cis	rs4988958	0.565	rs1420100	ENSG00000234389.1	AC007278.3	9.17	2.45e-19	1.11e-16	0.25	0.27	Asthma (childhood onset);	chr2:102420542	chr2:102438713~102440475:+
BRCA	cis	rs875971	0.545	rs6961853	ENSG00000237310.1	GS1-124K5.4	9.17	2.45e-19	1.11e-16	0.32	0.27	Aortic root size;	chr7:66537035	chr7:66493706~66495474:+
BRCA	cis	rs2439831	0.702	rs7171750	ENSG00000205771.5	CATSPER2P1	-9.17	2.46e-19	1.12e-16	-0.47	-0.27	Lung cancer in ever smokers;	chr15:43733660	chr15:43726918~43747094:-
BRCA	cis	rs875971	0.862	rs1983372	ENSG00000237310.1	GS1-124K5.4	-9.17	2.46e-19	1.12e-16	-0.28	-0.27	Aortic root size;	chr7:66146364	chr7:66493706~66495474:+
BRCA	cis	rs1061377	1	rs2890659	ENSG00000249685.1	RP11-360F5.3	9.17	2.47e-19	1.12e-16	0.33	0.27	Uric acid levels;	chr4:39125401	chr4:39133913~39135608:+
BRCA	cis	rs6570726	0.791	rs9497357	ENSG00000235652.6	RP11-545I5.3	9.17	2.47e-19	1.12e-16	0.27	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145591752	chr6:145799409~145886585:+
BRCA	cis	rs7811142	0.666	rs28401739	ENSG00000242294.5	STAG3L5P	9.17	2.47e-19	1.12e-16	0.26	0.27	Platelet count;	chr7:100308061	chr7:100336079~100351900:+
BRCA	cis	rs11673344	0.8	rs826323	ENSG00000226686.6	LINC01535	9.17	2.49e-19	1.13e-16	0.35	0.27	Obesity-related traits;	chr19:37014051	chr19:37251912~37265535:+
BRCA	cis	rs35160687	0.644	rs11687392	ENSG00000273080.1	RP11-301O19.1	-9.17	2.49e-19	1.13e-16	-0.32	-0.27	Night sleep phenotypes;	chr2:86275540	chr2:86195590~86196049:+
BRCA	cis	rs858239	0.6	rs2014768	ENSG00000226816.2	AC005082.12	9.17	2.49e-19	1.13e-16	0.31	0.27	Cerebrospinal fluid biomarker levels;	chr7:23082821	chr7:23206013~23208045:+
BRCA	cis	rs858239	0.6	rs6978827	ENSG00000226816.2	AC005082.12	9.17	2.49e-19	1.13e-16	0.31	0.27	Cerebrospinal fluid biomarker levels;	chr7:23085925	chr7:23206013~23208045:+
BRCA	cis	rs858239	0.6	rs6960001	ENSG00000226816.2	AC005082.12	9.17	2.49e-19	1.13e-16	0.31	0.27	Cerebrospinal fluid biomarker levels;	chr7:23091257	chr7:23206013~23208045:+
BRCA	cis	rs858239	0.6	rs10237755	ENSG00000226816.2	AC005082.12	9.17	2.49e-19	1.13e-16	0.31	0.27	Cerebrospinal fluid biomarker levels;	chr7:23091945	chr7:23206013~23208045:+
BRCA	cis	rs812925	0.537	rs778139	ENSG00000271889.1	RP11-493E12.1	-9.17	2.51e-19	1.14e-16	-0.33	-0.27	Immature fraction of reticulocytes;	chr2:61457429	chr2:61151433~61162105:-
BRCA	cis	rs9287719	0.746	rs6742448	ENSG00000234818.1	AC092687.5	9.17	2.52e-19	1.14e-16	0.32	0.27	Prostate cancer;	chr2:10619000	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.781	rs6732671	ENSG00000234818.1	AC092687.5	9.17	2.52e-19	1.14e-16	0.32	0.27	Prostate cancer;	chr2:10619023	chr2:10589166~10604830:+
BRCA	cis	rs3096299	0.933	rs2965823	ENSG00000274627.1	RP11-104N10.2	9.17	2.52e-19	1.15e-16	0.28	0.27	Multiple myeloma (IgH translocation);	chr16:89388516	chr16:89516797~89522217:+
BRCA	cis	rs11673344	0.864	rs2562595	ENSG00000226686.6	LINC01535	9.17	2.52e-19	1.15e-16	0.35	0.27	Obesity-related traits;	chr19:37023964	chr19:37251912~37265535:+
BRCA	cis	rs11673344	0.832	rs8101407	ENSG00000226686.6	LINC01535	9.17	2.52e-19	1.15e-16	0.35	0.27	Obesity-related traits;	chr19:37024444	chr19:37251912~37265535:+
BRCA	cis	rs12682352	0.602	rs4841044	ENSG00000253893.2	FAM85B	9.17	2.53e-19	1.15e-16	0.35	0.27	Neuroticism;	chr8:8807430	chr8:8167819~8226614:-
BRCA	cis	rs6142102	0.602	rs932388	ENSG00000275784.1	RP5-1125A11.6	-9.17	2.53e-19	1.15e-16	-0.31	-0.27	Skin pigmentation;	chr20:34069572	chr20:33989480~33991818:-
BRCA	cis	rs12594515	0.6	rs12903858	ENSG00000273972.1	CTD-2306A12.1	-9.17	2.54e-19	1.15e-16	-0.31	-0.27	Weight;Waist circumference;	chr15:45679968	chr15:45702640~45703183:+
BRCA	cis	rs1707322	1	rs4660332	ENSG00000280836.1	AL355480.1	-9.17	2.54e-19	1.15e-16	-0.36	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45995746	chr1:45581219~45581321:-
BRCA	cis	rs783540	0.934	rs783530	ENSG00000278603.1	RP13-608F4.5	-9.17	2.54e-19	1.15e-16	-0.35	-0.27	Schizophrenia;	chr15:82597799	chr15:82472203~82472426:+
BRCA	cis	rs12468226	0.938	rs12464254	ENSG00000273456.1	RP11-686O6.2	9.17	2.54e-19	1.15e-16	0.41	0.27	Urate levels;	chr2:202301641	chr2:202374932~202375604:-
BRCA	cis	rs858239	0.6	rs10256361	ENSG00000226816.2	AC005082.12	9.17	2.55e-19	1.16e-16	0.31	0.27	Cerebrospinal fluid biomarker levels;	chr7:23084266	chr7:23206013~23208045:+
BRCA	cis	rs4853012	0.539	rs9789534	ENSG00000217702.2	RP11-287D1.4	9.17	2.55e-19	1.16e-16	0.4	0.27	Gestational age at birth (maternal effect);	chr2:74135863	chr2:74130583~74135395:+
BRCA	cis	rs56046484	0.912	rs12914674	ENSG00000259295.5	CSPG4P12	9.17	2.56e-19	1.16e-16	0.47	0.27	Testicular germ cell tumor;	chr15:85119829	chr15:85191438~85213905:+
BRCA	cis	rs1134634	0.52	rs73127647	ENSG00000273133.1	RP11-799M12.2	-9.17	2.56e-19	1.16e-16	-0.35	-0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15639969	chr4:15563698~15564253:-
BRCA	cis	rs881375	0.678	rs10985102	ENSG00000226752.6	PSMD5-AS1	-9.16	2.58e-19	1.17e-16	-0.32	-0.27	Rheumatoid arthritis;	chr9:120945219	chr9:120824828~120854385:+
BRCA	cis	rs7772486	0.686	rs702305	ENSG00000235652.6	RP11-545I5.3	-9.16	2.58e-19	1.17e-16	-0.27	-0.27	Lobe attachment (rater-scored or self-reported);	chr6:145652704	chr6:145799409~145886585:+
BRCA	cis	rs9807989	0.507	rs4851004	ENSG00000234389.1	AC007278.3	-9.16	2.58e-19	1.17e-16	-0.25	-0.27	Asthma;	chr2:102393077	chr2:102438713~102440475:+
BRCA	cis	rs1823913	0.637	rs897197	ENSG00000227542.1	AC092614.2	-9.16	2.58e-19	1.17e-16	-0.33	-0.27	Obesity-related traits;	chr2:191281456	chr2:191229165~191246172:-
BRCA	cis	rs875971	0.545	rs1638735	ENSG00000237310.1	GS1-124K5.4	9.16	2.59e-19	1.17e-16	0.32	0.27	Aortic root size;	chr7:66630751	chr7:66493706~66495474:+
BRCA	cis	rs228614	0.514	rs59550147	ENSG00000246560.2	RP11-10L12.4	9.16	2.61e-19	1.18e-16	0.28	0.27	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102914239	chr4:102828055~102844075:+
BRCA	cis	rs10875746	0.669	rs11168496	ENSG00000240399.1	RP1-228P16.1	-9.16	2.63e-19	1.19e-16	-0.35	-0.27	Longevity (90 years and older);	chr12:48257072	chr12:48054813~48055591:-
BRCA	cis	rs950169	0.614	rs12911536	ENSG00000225151.9	GOLGA2P7	-9.16	2.63e-19	1.19e-16	-0.39	-0.27	Schizophrenia;	chr15:84004278	chr15:84199311~84230136:-
BRCA	cis	rs9807989	0.507	rs7584093	ENSG00000234389.1	AC007278.3	9.16	2.64e-19	1.2e-16	0.25	0.27	Asthma;	chr2:102381261	chr2:102438713~102440475:+
BRCA	cis	rs6844153	0.752	rs28520489	ENSG00000240005.4	RP11-293A21.1	-9.16	2.64e-19	1.2e-16	-0.36	-0.27	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26896082	chr4:26859806~26860599:-
BRCA	cis	rs8062405	1	rs62036626	ENSG00000278665.1	RP11-666O2.4	9.16	2.65e-19	1.2e-16	0.29	0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28832963	chr16:28599241~28601881:-
BRCA	cis	rs8062405	1	rs62036657	ENSG00000278665.1	RP11-666O2.4	9.16	2.65e-19	1.2e-16	0.29	0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28833044	chr16:28599241~28601881:-
BRCA	cis	rs7429990	0.932	rs6803741	ENSG00000229759.1	MRPS18AP1	-9.16	2.65e-19	1.2e-16	-0.32	-0.27	Educational attainment (years of education);	chr3:48082050	chr3:48256350~48256938:-
BRCA	cis	rs227275	0.525	rs10028116	ENSG00000246560.2	RP11-10L12.4	9.16	2.66e-19	1.2e-16	0.28	0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102931421	chr4:102828055~102844075:+
BRCA	cis	rs7811142	0.943	rs67196635	ENSG00000242294.5	STAG3L5P	9.16	2.67e-19	1.21e-16	0.26	0.27	Platelet count;	chr7:100427941	chr7:100336079~100351900:+
BRCA	cis	rs7811142	1	rs6962151	ENSG00000242294.5	STAG3L5P	9.16	2.67e-19	1.21e-16	0.26	0.27	Platelet count;	chr7:100430861	chr7:100336079~100351900:+
BRCA	cis	rs1062177	1	rs2016409	ENSG00000253921.1	CTB-113P19.3	9.16	2.67e-19	1.21e-16	0.39	0.27	Preschool internalizing problems;	chr5:151746763	chr5:151753992~151767247:+
BRCA	cis	rs2067615	0.56	rs2044304	ENSG00000260329.1	RP11-412D9.4	-9.16	2.68e-19	1.22e-16	-0.3	-0.27	Heart rate;	chr12:106790585	chr12:106954029~106955497:-
BRCA	cis	rs9287719	0.781	rs6714413	ENSG00000234818.1	AC092687.5	9.16	2.69e-19	1.22e-16	0.32	0.27	Prostate cancer;	chr2:10618733	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.753	rs2018512	ENSG00000234818.1	AC092687.5	9.16	2.69e-19	1.22e-16	0.32	0.27	Prostate cancer;	chr2:10619153	chr2:10589166~10604830:+
BRCA	cis	rs1061377	0.965	rs1046655	ENSG00000249685.1	RP11-360F5.3	9.16	2.7e-19	1.22e-16	0.33	0.27	Uric acid levels;	chr4:39126127	chr4:39133913~39135608:+
BRCA	cis	rs1061377	1	rs7694760	ENSG00000249685.1	RP11-360F5.3	9.16	2.7e-19	1.22e-16	0.33	0.27	Uric acid levels;	chr4:39126481	chr4:39133913~39135608:+
BRCA	cis	rs10129255	0.872	rs8015406	ENSG00000223648.3	IGHV3-64	9.16	2.71e-19	1.23e-16	0.24	0.27	Kawasaki disease;	chr14:106670611	chr14:106643132~106658258:-
BRCA	cis	rs56046484	0.956	rs35045545	ENSG00000259295.5	CSPG4P12	9.16	2.72e-19	1.23e-16	0.47	0.27	Testicular germ cell tumor;	chr15:85121720	chr15:85191438~85213905:+
BRCA	cis	rs1075265	0.73	rs7597189	ENSG00000233266.1	HMGB1P31	9.16	2.74e-19	1.24e-16	0.33	0.27	Chronotype;Morning vs. evening chronotype;	chr2:54014733	chr2:54051334~54051760:+
BRCA	cis	rs1061377	1	rs13182	ENSG00000249685.1	RP11-360F5.3	9.16	2.75e-19	1.25e-16	0.33	0.27	Uric acid levels;	chr4:39121293	chr4:39133913~39135608:+
BRCA	cis	rs7772486	0.817	rs2144477	ENSG00000235652.6	RP11-545I5.3	9.16	2.75e-19	1.25e-16	0.28	0.27	Lobe attachment (rater-scored or self-reported);	chr6:146085112	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.875	rs9403768	ENSG00000235652.6	RP11-545I5.3	9.16	2.75e-19	1.25e-16	0.28	0.27	Lobe attachment (rater-scored or self-reported);	chr6:146085322	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.875	rs12194437	ENSG00000235652.6	RP11-545I5.3	9.16	2.75e-19	1.25e-16	0.28	0.27	Lobe attachment (rater-scored or self-reported);	chr6:146090304	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.875	rs6938972	ENSG00000235652.6	RP11-545I5.3	9.16	2.77e-19	1.25e-16	0.28	0.27	Lobe attachment (rater-scored or self-reported);	chr6:146089472	chr6:145799409~145886585:+
BRCA	cis	rs11673344	0.864	rs703537	ENSG00000226686.6	LINC01535	9.16	2.77e-19	1.25e-16	0.35	0.27	Obesity-related traits;	chr19:37016827	chr19:37251912~37265535:+
BRCA	cis	rs6545883	0.524	rs4599092	ENSG00000271889.1	RP11-493E12.1	-9.16	2.77e-19	1.25e-16	-0.33	-0.27	Tuberculosis;	chr2:61271833	chr2:61151433~61162105:-
BRCA	cis	rs1075265	0.756	rs805423	ENSG00000233266.1	HMGB1P31	9.16	2.79e-19	1.26e-16	0.33	0.27	Chronotype;Morning vs. evening chronotype;	chr2:53899904	chr2:54051334~54051760:+
BRCA	cis	rs1134634	0.52	rs4698403	ENSG00000273133.1	RP11-799M12.2	-9.16	2.79e-19	1.26e-16	-0.35	-0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15628204	chr4:15563698~15564253:-
BRCA	cis	rs9287719	0.967	rs7592691	ENSG00000234818.1	AC092687.5	9.16	2.79e-19	1.26e-16	0.32	0.27	Prostate cancer;	chr2:10597300	chr2:10589166~10604830:+
BRCA	cis	rs1075265	0.568	rs3095756	ENSG00000233266.1	HMGB1P31	9.15	2.8e-19	1.27e-16	0.33	0.27	Chronotype;Morning vs. evening chronotype;	chr2:53822332	chr2:54051334~54051760:+
BRCA	cis	rs7945705	0.935	rs2568061	ENSG00000254860.4	TMEM9B-AS1	9.15	2.8e-19	1.27e-16	0.25	0.27	Hemoglobin concentration;	chr11:8864713	chr11:8964675~8977527:+
BRCA	cis	rs6142102	0.602	rs4911402	ENSG00000275784.1	RP5-1125A11.6	-9.15	2.82e-19	1.28e-16	-0.31	-0.27	Skin pigmentation;	chr20:34079839	chr20:33989480~33991818:-
BRCA	cis	rs11098499	0.865	rs28753180	ENSG00000248280.1	RP11-33B1.2	9.15	2.82e-19	1.28e-16	0.28	0.27	Corneal astigmatism;	chr4:119484212	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.955	rs1511019	ENSG00000245958.5	RP11-33B1.1	-9.15	2.82e-19	1.28e-16	-0.27	-0.27	Corneal astigmatism;	chr4:119244852	chr4:119454791~119552025:+
BRCA	cis	rs2274273	0.934	rs10139337	ENSG00000258413.1	RP11-665C16.6	-9.15	2.82e-19	1.28e-16	-0.35	-0.27	Protein biomarker;	chr14:55275395	chr14:55262767~55272075:-
BRCA	cis	rs11673344	0.864	rs79927931	ENSG00000226686.6	LINC01535	9.15	2.83e-19	1.28e-16	0.36	0.27	Obesity-related traits;	chr19:37012241	chr19:37251912~37265535:+
BRCA	cis	rs2243480	1	rs73142122	ENSG00000226824.5	RP4-756H11.3	-9.15	2.83e-19	1.28e-16	-0.53	-0.27	Diabetic kidney disease;	chr7:65846311	chr7:66654538~66669855:+
BRCA	cis	rs2243480	0.901	rs73142137	ENSG00000226824.5	RP4-756H11.3	-9.15	2.83e-19	1.28e-16	-0.53	-0.27	Diabetic kidney disease;	chr7:65878455	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs13247184	ENSG00000226824.5	RP4-756H11.3	-9.15	2.83e-19	1.28e-16	-0.53	-0.27	Diabetic kidney disease;	chr7:65893941	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs35283677	ENSG00000226824.5	RP4-756H11.3	-9.15	2.83e-19	1.28e-16	-0.53	-0.27	Diabetic kidney disease;	chr7:65894246	chr7:66654538~66669855:+
BRCA	cis	rs2243480	1	rs35421653	ENSG00000226824.5	RP4-756H11.3	-9.15	2.83e-19	1.28e-16	-0.53	-0.27	Diabetic kidney disease;	chr7:65898442	chr7:66654538~66669855:+
BRCA	cis	rs6921919	0.789	rs11970439	ENSG00000216901.1	AL022393.7	9.15	2.84e-19	1.28e-16	0.39	0.27	Autism spectrum disorder or schizophrenia;	chr6:28335687	chr6:28176188~28176674:+
BRCA	cis	rs7772486	0.875	rs10457793	ENSG00000235652.6	RP11-545I5.3	9.15	2.85e-19	1.29e-16	0.28	0.27	Lobe attachment (rater-scored or self-reported);	chr6:146094267	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.875	rs10457794	ENSG00000235652.6	RP11-545I5.3	9.15	2.85e-19	1.29e-16	0.28	0.27	Lobe attachment (rater-scored or self-reported);	chr6:146094472	chr6:145799409~145886585:+
BRCA	cis	rs227275	0.525	rs4623004	ENSG00000246560.2	RP11-10L12.4	9.15	2.86e-19	1.29e-16	0.28	0.27	Allergic disease (asthma, hay fever or eczema);	chr4:103000141	chr4:102828055~102844075:+
BRCA	cis	rs35160687	0.644	rs1863058	ENSG00000273080.1	RP11-301O19.1	-9.15	2.86e-19	1.29e-16	-0.32	-0.27	Night sleep phenotypes;	chr2:86282144	chr2:86195590~86196049:+
BRCA	cis	rs2439831	0.85	rs28684672	ENSG00000249839.1	AC011330.5	-9.15	2.87e-19	1.3e-16	-0.47	-0.27	Lung cancer in ever smokers;	chr15:43815464	chr15:43663654~43684339:-
BRCA	cis	rs1707322	0.964	rs12067716	ENSG00000280836.1	AL355480.1	-9.15	2.87e-19	1.3e-16	-0.36	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45968756	chr1:45581219~45581321:-
BRCA	cis	rs13256369	0.851	rs11249890	ENSG00000253893.2	FAM85B	-9.15	2.87e-19	1.3e-16	-0.39	-0.27	Obesity-related traits;	chr8:8707735	chr8:8167819~8226614:-
BRCA	cis	rs2283792	0.765	rs5999749	ENSG00000224086.5	LL22NC03-86G7.1	9.15	2.88e-19	1.3e-16	0.29	0.27	Multiple sclerosis;	chr22:21833371	chr22:21938293~21977632:+
BRCA	cis	rs11098499	0.954	rs9998585	ENSG00000248280.1	RP11-33B1.2	9.15	2.91e-19	1.32e-16	0.28	0.27	Corneal astigmatism;	chr4:119475647	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.909	rs6842762	ENSG00000248280.1	RP11-33B1.2	9.15	2.91e-19	1.32e-16	0.28	0.27	Corneal astigmatism;	chr4:119477081	chr4:119440561~119450157:-
BRCA	cis	rs2274273	0.87	rs8021583	ENSG00000258413.1	RP11-665C16.6	-9.15	2.92e-19	1.32e-16	-0.34	-0.27	Protein biomarker;	chr14:55282889	chr14:55262767~55272075:-
BRCA	cis	rs7937890	0.559	rs2597208	ENSG00000251991.1	RNU7-49P	9.15	2.94e-19	1.33e-16	0.3	0.27	Mitochondrial DNA levels;	chr11:14450783	chr11:14478892~14478953:+
BRCA	cis	rs11098499	0.954	rs2306455	ENSG00000248280.1	RP11-33B1.2	9.15	2.95e-19	1.33e-16	0.28	0.27	Corneal astigmatism;	chr4:119500814	chr4:119440561~119450157:-
BRCA	cis	rs783540	0.935	rs2278355	ENSG00000278603.1	RP13-608F4.5	9.15	2.95e-19	1.33e-16	0.35	0.27	Schizophrenia;	chr15:82662403	chr15:82472203~82472426:+
BRCA	cis	rs11722779	0.901	rs28674656	ENSG00000246560.2	RP11-10L12.4	9.15	2.97e-19	1.34e-16	0.28	0.27	Schizophrenia;	chr4:102944396	chr4:102828055~102844075:+
BRCA	cis	rs10875746	0.669	rs10875767	ENSG00000240399.1	RP1-228P16.1	-9.15	2.97e-19	1.34e-16	-0.36	-0.27	Longevity (90 years and older);	chr12:48205474	chr12:48054813~48055591:-
BRCA	cis	rs2243480	1	rs34703416	ENSG00000226824.5	RP4-756H11.3	-9.15	3e-19	1.35e-16	-0.52	-0.27	Diabetic kidney disease;	chr7:65835655	chr7:66654538~66669855:+
BRCA	cis	rs11676348	0.741	rs12694425	ENSG00000261338.2	RP11-378A13.1	9.15	3e-19	1.36e-16	0.29	0.27	Ulcerative colitis;	chr2:218077590	chr2:218255319~218257366:+
BRCA	cis	rs1062177	0.826	rs1549920	ENSG00000253921.1	CTB-113P19.3	-9.15	3.01e-19	1.36e-16	-0.37	-0.27	Preschool internalizing problems;	chr5:151761283	chr5:151753992~151767247:+
BRCA	cis	rs881375	0.967	rs3761849	ENSG00000226752.6	PSMD5-AS1	-9.15	3.03e-19	1.37e-16	-0.33	-0.27	Rheumatoid arthritis;	chr9:120928679	chr9:120824828~120854385:+
BRCA	cis	rs72772090	0.539	rs17405676	ENSG00000248734.2	CTD-2260A17.1	-9.15	3.04e-19	1.37e-16	-0.45	-0.27	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96846912	chr5:96784777~96785999:+
BRCA	cis	rs1061377	1	rs4974998	ENSG00000249685.1	RP11-360F5.3	9.15	3.04e-19	1.37e-16	0.33	0.27	Uric acid levels;	chr4:39109129	chr4:39133913~39135608:+
BRCA	cis	rs7945705	0.875	rs2653616	ENSG00000254860.4	TMEM9B-AS1	9.15	3.04e-19	1.37e-16	0.25	0.27	Hemoglobin concentration;	chr11:8864345	chr11:8964675~8977527:+
BRCA	cis	rs7429990	0.93	rs13075457	ENSG00000229759.1	MRPS18AP1	-9.15	3.04e-19	1.37e-16	-0.32	-0.27	Educational attainment (years of education);	chr3:48013063	chr3:48256350~48256938:-
BRCA	cis	rs2274273	0.84	rs1045002	ENSG00000258413.1	RP11-665C16.6	-9.14	3.05e-19	1.38e-16	-0.34	-0.27	Protein biomarker;	chr14:55351799	chr14:55262767~55272075:-
BRCA	cis	rs875971	0.545	rs17138156	ENSG00000237310.1	GS1-124K5.4	9.14	3.05e-19	1.38e-16	0.32	0.27	Aortic root size;	chr7:66249708	chr7:66493706~66495474:+
BRCA	cis	rs56046484	0.956	rs34889576	ENSG00000259295.5	CSPG4P12	9.14	3.07e-19	1.38e-16	0.47	0.27	Testicular germ cell tumor;	chr15:85121445	chr15:85191438~85213905:+
BRCA	cis	rs56046484	0.956	rs34076898	ENSG00000259295.5	CSPG4P12	9.14	3.07e-19	1.38e-16	0.47	0.27	Testicular germ cell tumor;	chr15:85121569	chr15:85191438~85213905:+
BRCA	cis	rs56046484	0.956	rs35533990	ENSG00000259295.5	CSPG4P12	9.14	3.07e-19	1.38e-16	0.47	0.27	Testicular germ cell tumor;	chr15:85121590	chr15:85191438~85213905:+
BRCA	cis	rs9807989	0.507	rs1420094	ENSG00000234389.1	AC007278.3	9.14	3.07e-19	1.38e-16	0.25	0.27	Asthma;	chr2:102399227	chr2:102438713~102440475:+
BRCA	cis	rs2243480	1	rs3885839	ENSG00000226824.5	RP4-756H11.3	-9.14	3.08e-19	1.39e-16	-0.53	-0.27	Diabetic kidney disease;	chr7:65825416	chr7:66654538~66669855:+
BRCA	cis	rs113835537	0.529	rs80100524	ENSG00000255517.5	CTD-3074O7.5	-9.14	3.08e-19	1.39e-16	-0.36	-0.27	Airway imaging phenotypes;	chr11:66478465	chr11:66473490~66480233:-
BRCA	cis	rs11098499	0.954	rs4577559	ENSG00000248280.1	RP11-33B1.2	9.14	3.1e-19	1.4e-16	0.28	0.27	Corneal astigmatism;	chr4:119482888	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.954	rs7656252	ENSG00000248280.1	RP11-33B1.2	9.14	3.1e-19	1.4e-16	0.28	0.27	Corneal astigmatism;	chr4:119483113	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.865	rs28845498	ENSG00000248280.1	RP11-33B1.2	9.14	3.1e-19	1.4e-16	0.28	0.27	Corneal astigmatism;	chr4:119484031	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.954	rs56270433	ENSG00000248280.1	RP11-33B1.2	9.14	3.1e-19	1.4e-16	0.28	0.27	Corneal astigmatism;	chr4:119484875	chr4:119440561~119450157:-
BRCA	cis	rs1061377	1	rs9990742	ENSG00000249685.1	RP11-360F5.3	9.14	3.1e-19	1.4e-16	0.33	0.27	Uric acid levels;	chr4:39119794	chr4:39133913~39135608:+
BRCA	cis	rs3096299	0.967	rs2965827	ENSG00000274627.1	RP11-104N10.2	-9.14	3.11e-19	1.4e-16	-0.28	-0.27	Multiple myeloma (IgH translocation);	chr16:89390942	chr16:89516797~89522217:+
BRCA	cis	rs875971	0.545	rs73376401	ENSG00000237310.1	GS1-124K5.4	9.14	3.11e-19	1.4e-16	0.32	0.27	Aortic root size;	chr7:66174841	chr7:66493706~66495474:+
BRCA	cis	rs7772486	0.622	rs1292333	ENSG00000235652.6	RP11-545I5.3	-9.14	3.11e-19	1.4e-16	-0.27	-0.27	Lobe attachment (rater-scored or self-reported);	chr6:145661208	chr6:145799409~145886585:+
BRCA	cis	rs2067615	0.579	rs9651957	ENSG00000260329.1	RP11-412D9.4	-9.14	3.11e-19	1.4e-16	-0.3	-0.27	Heart rate;	chr12:106776350	chr12:106954029~106955497:-
BRCA	cis	rs7772486	0.686	rs857875	ENSG00000235652.6	RP11-545I5.3	-9.14	3.12e-19	1.41e-16	-0.27	-0.27	Lobe attachment (rater-scored or self-reported);	chr6:145658897	chr6:145799409~145886585:+
BRCA	cis	rs1862618	0.627	rs744023	ENSG00000271828.1	CTD-2310F14.1	9.14	3.15e-19	1.42e-16	0.41	0.27	Initial pursuit acceleration;	chr5:56901251	chr5:56927874~56929573:+
BRCA	cis	rs875971	0.522	rs1880556	ENSG00000224316.1	RP11-479O9.2	9.14	3.15e-19	1.42e-16	0.27	0.27	Aortic root size;	chr7:65967557	chr7:65773620~65802067:+
BRCA	cis	rs35160687	0.644	rs4832276	ENSG00000273080.1	RP11-301O19.1	9.14	3.16e-19	1.42e-16	0.32	0.27	Night sleep phenotypes;	chr2:86317895	chr2:86195590~86196049:+
BRCA	cis	rs1061377	0.932	rs35464499	ENSG00000249685.1	RP11-360F5.3	9.14	3.16e-19	1.42e-16	0.33	0.27	Uric acid levels;	chr4:39127670	chr4:39133913~39135608:+
BRCA	cis	rs1061377	1	rs4974931	ENSG00000249685.1	RP11-360F5.3	9.14	3.18e-19	1.43e-16	0.33	0.27	Uric acid levels;	chr4:39108896	chr4:39133913~39135608:+
BRCA	cis	rs4814920	0.756	rs1543472	ENSG00000275142.1	RP5-999L4.2	9.14	3.19e-19	1.44e-16	0.42	0.27	Bipolar disorder (body mass index interaction);	chr20:19867383	chr20:19871891~19872284:+
BRCA	cis	rs11722779	0.869	rs223350	ENSG00000246560.2	RP11-10L12.4	9.14	3.2e-19	1.44e-16	0.29	0.27	Schizophrenia;	chr4:102856899	chr4:102828055~102844075:+
BRCA	cis	rs6142102	0.602	rs4911145	ENSG00000275784.1	RP5-1125A11.6	9.14	3.21e-19	1.44e-16	0.31	0.27	Skin pigmentation;	chr20:34027417	chr20:33989480~33991818:-
BRCA	cis	rs875971	0.545	rs7783889	ENSG00000237310.1	GS1-124K5.4	9.14	3.23e-19	1.46e-16	0.32	0.27	Aortic root size;	chr7:66283366	chr7:66493706~66495474:+
BRCA	cis	rs6570726	0.577	rs403345	ENSG00000235652.6	RP11-545I5.3	9.14	3.23e-19	1.46e-16	0.3	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145524035	chr6:145799409~145886585:+
BRCA	cis	rs10129255	0.872	rs1858683	ENSG00000223648.3	IGHV3-64	9.14	3.24e-19	1.46e-16	0.24	0.27	Kawasaki disease;	chr14:106670217	chr14:106643132~106658258:-
BRCA	cis	rs7945705	0.902	rs2568059	ENSG00000254860.4	TMEM9B-AS1	9.14	3.24e-19	1.46e-16	0.25	0.27	Hemoglobin concentration;	chr11:8862614	chr11:8964675~8977527:+
BRCA	cis	rs7924176	0.601	rs10824071	ENSG00000213731.2	RAB5CP1	-9.14	3.25e-19	1.46e-16	-0.31	-0.27	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74113881	chr10:74423435~74424014:-
BRCA	cis	rs875971	0.597	rs11763224	ENSG00000237310.1	GS1-124K5.4	9.14	3.25e-19	1.46e-16	0.32	0.27	Aortic root size;	chr7:66518628	chr7:66493706~66495474:+
BRCA	cis	rs72772090	0.539	rs35898772	ENSG00000248734.2	CTD-2260A17.1	-9.14	3.25e-19	1.46e-16	-0.45	-0.27	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96843982	chr5:96784777~96785999:+
BRCA	cis	rs2243480	0.901	rs3813708	ENSG00000226824.5	RP4-756H11.3	-9.14	3.26e-19	1.47e-16	-0.53	-0.27	Diabetic kidney disease;	chr7:65840645	chr7:66654538~66669855:+
BRCA	cis	rs7924176	0.601	rs4638254	ENSG00000213731.2	RAB5CP1	-9.14	3.26e-19	1.47e-16	-0.3	-0.27	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74152974	chr10:74423435~74424014:-
BRCA	cis	rs80285556	1	rs76812330	ENSG00000161643.11	SIGLEC16	9.14	3.27e-19	1.47e-16	0.69	0.27	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50028603	chr19:49969673~49975814:+
BRCA	cis	rs6570726	0.791	rs6914203	ENSG00000235652.6	RP11-545I5.3	9.14	3.27e-19	1.47e-16	0.27	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145578839	chr6:145799409~145886585:+
BRCA	cis	rs1075265	0.589	rs2253760	ENSG00000233266.1	HMGB1P31	9.14	3.28e-19	1.47e-16	0.32	0.27	Chronotype;Morning vs. evening chronotype;	chr2:53806851	chr2:54051334~54051760:+
BRCA	cis	rs11098499	0.863	rs3822190	ENSG00000245958.5	RP11-33B1.1	-9.14	3.28e-19	1.48e-16	-0.27	-0.27	Corneal astigmatism;	chr4:119506943	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.863	rs3822191	ENSG00000245958.5	RP11-33B1.1	-9.14	3.28e-19	1.48e-16	-0.27	-0.27	Corneal astigmatism;	chr4:119506946	chr4:119454791~119552025:+
BRCA	cis	rs1061377	1	rs1897136	ENSG00000249685.1	RP11-360F5.3	9.14	3.28e-19	1.48e-16	0.33	0.27	Uric acid levels;	chr4:39131242	chr4:39133913~39135608:+
BRCA	cis	rs1061377	1	rs1897137	ENSG00000249685.1	RP11-360F5.3	9.14	3.28e-19	1.48e-16	0.33	0.27	Uric acid levels;	chr4:39131387	chr4:39133913~39135608:+
BRCA	cis	rs1061377	1	rs7681116	ENSG00000249685.1	RP11-360F5.3	9.14	3.28e-19	1.48e-16	0.33	0.27	Uric acid levels;	chr4:39133015	chr4:39133913~39135608:+
BRCA	cis	rs321358	0.731	rs1517581	ENSG00000271584.1	RP11-89C3.4	9.14	3.29e-19	1.48e-16	0.43	0.27	Body mass index;	chr11:111164533	chr11:111091932~111097357:-
BRCA	cis	rs4988958	0.527	rs3771155	ENSG00000234389.1	AC007278.3	9.14	3.29e-19	1.48e-16	0.25	0.27	Asthma (childhood onset);	chr2:102421366	chr2:102438713~102440475:+
BRCA	cis	rs11676348	0.808	rs61700947	ENSG00000261338.2	RP11-378A13.1	9.14	3.3e-19	1.48e-16	0.3	0.27	Ulcerative colitis;	chr2:218181448	chr2:218255319~218257366:+
BRCA	cis	rs881375	0.967	rs1930778	ENSG00000226752.6	PSMD5-AS1	-9.14	3.3e-19	1.48e-16	-0.32	-0.27	Rheumatoid arthritis;	chr9:120879091	chr9:120824828~120854385:+
BRCA	cis	rs950169	0.614	rs12903883	ENSG00000225151.9	GOLGA2P7	-9.14	3.3e-19	1.49e-16	-0.39	-0.27	Schizophrenia;	chr15:84011801	chr15:84199311~84230136:-
BRCA	cis	rs6142102	0.602	rs11696338	ENSG00000275784.1	RP5-1125A11.6	-9.14	3.3e-19	1.49e-16	-0.31	-0.27	Skin pigmentation;	chr20:34099805	chr20:33989480~33991818:-
BRCA	cis	rs35160687	0.644	rs9309635	ENSG00000273080.1	RP11-301O19.1	9.14	3.31e-19	1.49e-16	0.32	0.27	Night sleep phenotypes;	chr2:86272279	chr2:86195590~86196049:+
BRCA	cis	rs11098499	0.954	rs12502423	ENSG00000248280.1	RP11-33B1.2	9.13	3.33e-19	1.5e-16	0.28	0.27	Corneal astigmatism;	chr4:119503017	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.863	rs6835635	ENSG00000245958.5	RP11-33B1.1	-9.13	3.34e-19	1.5e-16	-0.28	-0.27	Corneal astigmatism;	chr4:119537712	chr4:119454791~119552025:+
BRCA	cis	rs9287719	0.967	rs7570118	ENSG00000234818.1	AC092687.5	9.13	3.35e-19	1.5e-16	0.32	0.27	Prostate cancer;	chr2:10577881	chr2:10589166~10604830:+
BRCA	cis	rs6545883	0.56	rs11677776	ENSG00000271889.1	RP11-493E12.1	-9.13	3.36e-19	1.51e-16	-0.33	-0.27	Tuberculosis;	chr2:61275978	chr2:61151433~61162105:-
BRCA	cis	rs7811142	0.943	rs67483801	ENSG00000242294.5	STAG3L5P	9.13	3.36e-19	1.51e-16	0.26	0.27	Platelet count;	chr7:100434135	chr7:100336079~100351900:+
BRCA	cis	rs7811142	1	rs11761784	ENSG00000242294.5	STAG3L5P	9.13	3.36e-19	1.51e-16	0.26	0.27	Platelet count;	chr7:100442347	chr7:100336079~100351900:+
BRCA	cis	rs321358	0.697	rs522188	ENSG00000271584.1	RP11-89C3.4	-9.13	3.36e-19	1.51e-16	-0.39	-0.27	Body mass index;	chr11:111169869	chr11:111091932~111097357:-
BRCA	cis	rs10181042	0.514	rs1177289	ENSG00000271889.1	RP11-493E12.1	9.13	3.37e-19	1.51e-16	0.35	0.27	Crohn's disease;	chr2:61126121	chr2:61151433~61162105:-
BRCA	cis	rs783540	0.967	rs1259183	ENSG00000278603.1	RP13-608F4.5	-9.13	3.37e-19	1.51e-16	-0.34	-0.27	Schizophrenia;	chr15:82610683	chr15:82472203~82472426:+
BRCA	cis	rs12458462	0.859	rs2242177	ENSG00000274828.1	RP11-567M16.6	9.13	3.37e-19	1.51e-16	0.32	0.27	Monocyte count;	chr18:79717379	chr18:79677287~79679358:-
BRCA	cis	rs6570726	0.599	rs4398765	ENSG00000235652.6	RP11-545I5.3	9.13	3.37e-19	1.51e-16	0.3	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145613870	chr6:145799409~145886585:+
BRCA	cis	rs1134634	0.52	rs10008889	ENSG00000273133.1	RP11-799M12.2	-9.13	3.38e-19	1.52e-16	-0.35	-0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15622896	chr4:15563698~15564253:-
BRCA	cis	rs4237845	0.622	rs10783859	ENSG00000257159.1	RP11-58A17.3	9.13	3.4e-19	1.53e-16	0.32	0.27	Intelligence (multi-trait analysis);	chr12:57939011	chr12:57967058~57968399:+
BRCA	cis	rs12458462	0.859	rs35493271	ENSG00000274828.1	RP11-567M16.6	9.13	3.42e-19	1.54e-16	0.32	0.27	Monocyte count;	chr18:79688793	chr18:79677287~79679358:-
BRCA	cis	rs7772486	0.846	rs2892453	ENSG00000235652.6	RP11-545I5.3	9.13	3.42e-19	1.54e-16	0.27	0.27	Lobe attachment (rater-scored or self-reported);	chr6:146056581	chr6:145799409~145886585:+
BRCA	cis	rs11673344	0.765	rs826296	ENSG00000226686.6	LINC01535	9.13	3.43e-19	1.54e-16	0.35	0.27	Obesity-related traits;	chr19:36947384	chr19:37251912~37265535:+
BRCA	cis	rs11098499	0.908	rs11098527	ENSG00000248280.1	RP11-33B1.2	9.13	3.45e-19	1.55e-16	0.28	0.27	Corneal astigmatism;	chr4:119478751	chr4:119440561~119450157:-
BRCA	cis	rs875971	0.545	rs7787063	ENSG00000237310.1	GS1-124K5.4	9.13	3.46e-19	1.55e-16	0.32	0.27	Aortic root size;	chr7:66164012	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.545	rs12673308	ENSG00000237310.1	GS1-124K5.4	9.13	3.46e-19	1.55e-16	0.32	0.27	Aortic root size;	chr7:66166374	chr7:66493706~66495474:+
BRCA	cis	rs9807989	0.507	rs2041739	ENSG00000234389.1	AC007278.3	-9.13	3.46e-19	1.55e-16	-0.25	-0.27	Asthma;	chr2:102377873	chr2:102438713~102440475:+
BRCA	cis	rs4835473	0.932	rs13147386	ENSG00000251600.4	RP11-673E1.1	9.13	3.47e-19	1.56e-16	0.32	0.27	Immature fraction of reticulocytes;	chr4:143736586	chr4:143912331~143982454:+
BRCA	cis	rs783540	1	rs11637433	ENSG00000278603.1	RP13-608F4.5	9.13	3.49e-19	1.56e-16	0.34	0.27	Schizophrenia;	chr15:82652585	chr15:82472203~82472426:+
BRCA	cis	rs227275	0.525	rs7698608	ENSG00000246560.2	RP11-10L12.4	9.13	3.49e-19	1.57e-16	0.28	0.27	Allergic disease (asthma, hay fever or eczema);	chr4:103016817	chr4:102828055~102844075:+
BRCA	cis	rs7772486	0.654	rs1011597	ENSG00000235652.6	RP11-545I5.3	-9.13	3.51e-19	1.57e-16	-0.27	-0.27	Lobe attachment (rater-scored or self-reported);	chr6:145754536	chr6:145799409~145886585:+
BRCA	cis	rs72772090	0.539	rs72775810	ENSG00000248734.2	CTD-2260A17.1	-9.13	3.51e-19	1.57e-16	-0.46	-0.27	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96849604	chr5:96784777~96785999:+
BRCA	cis	rs2439831	0.85	rs28718261	ENSG00000205771.5	CATSPER2P1	-9.13	3.51e-19	1.58e-16	-0.47	-0.27	Lung cancer in ever smokers;	chr15:43751595	chr15:43726918~43747094:-
BRCA	cis	rs1061377	1	rs7664078	ENSG00000249685.1	RP11-360F5.3	9.13	3.53e-19	1.58e-16	0.33	0.27	Uric acid levels;	chr4:39116583	chr4:39133913~39135608:+
BRCA	cis	rs1113500	0.897	rs2336127	ENSG00000226822.1	RP11-356N1.2	9.13	3.53e-19	1.58e-16	0.36	0.27	Growth-regulated protein alpha levels;	chr1:108098248	chr1:108071482~108074519:+
BRCA	cis	rs6844153	0.752	rs12644073	ENSG00000240005.4	RP11-293A21.1	-9.13	3.58e-19	1.6e-16	-0.35	-0.27	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26895436	chr4:26859806~26860599:-
BRCA	cis	rs7772486	0.875	rs10872582	ENSG00000235652.6	RP11-545I5.3	9.13	3.59e-19	1.61e-16	0.27	0.27	Lobe attachment (rater-scored or self-reported);	chr6:146051925	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.837	rs2474354	ENSG00000235652.6	RP11-545I5.3	9.13	3.61e-19	1.62e-16	0.27	0.27	Lobe attachment (rater-scored or self-reported);	chr6:146002659	chr6:145799409~145886585:+
BRCA	cis	rs67311347	1	rs6599094	ENSG00000223797.4	ENTPD3-AS1	9.12	3.62e-19	1.62e-16	0.3	0.27	Renal cell carcinoma;	chr3:40358102	chr3:40313802~40453329:-
BRCA	cis	rs950169	0.545	rs4354897	ENSG00000225151.9	GOLGA2P7	-9.12	3.63e-19	1.63e-16	-0.39	-0.27	Schizophrenia;	chr15:83976219	chr15:84199311~84230136:-
BRCA	cis	rs881375	0.678	rs10760125	ENSG00000226752.6	PSMD5-AS1	-9.12	3.63e-19	1.63e-16	-0.32	-0.27	Rheumatoid arthritis;	chr9:120900312	chr9:120824828~120854385:+
BRCA	cis	rs881375	0.678	rs9886724	ENSG00000226752.6	PSMD5-AS1	-9.12	3.63e-19	1.63e-16	-0.32	-0.27	Rheumatoid arthritis;	chr9:120902741	chr9:120824828~120854385:+
BRCA	cis	rs9847710	0.67	rs2564933	ENSG00000242142.1	SERBP1P3	9.12	3.63e-19	1.63e-16	0.33	0.27	Ulcerative colitis;	chr3:52989357	chr3:53064283~53065091:-
BRCA	cis	rs9807989	0.507	rs6745614	ENSG00000234389.1	AC007278.3	9.12	3.65e-19	1.63e-16	0.25	0.27	Asthma;	chr2:102374753	chr2:102438713~102440475:+
BRCA	cis	rs10262624	0.564	rs58051142	ENSG00000234286.1	AC006026.13	-9.12	3.65e-19	1.63e-16	-0.32	-0.27	Schizophrenia;	chr7:23866047	chr7:23680195~23680786:-
BRCA	cis	rs4835473	0.932	rs34950821	ENSG00000251600.4	RP11-673E1.1	-9.12	3.65e-19	1.63e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143738174	chr4:143912331~143982454:+
BRCA	cis	rs881375	0.631	rs10739577	ENSG00000226752.6	PSMD5-AS1	-9.12	3.65e-19	1.64e-16	-0.32	-0.27	Rheumatoid arthritis;	chr9:120906576	chr9:120824828~120854385:+
BRCA	cis	rs7772486	0.875	rs2073287	ENSG00000235652.6	RP11-545I5.3	9.12	3.66e-19	1.64e-16	0.27	0.27	Lobe attachment (rater-scored or self-reported);	chr6:146029128	chr6:145799409~145886585:+
BRCA	cis	rs1318937	1	rs3773469	ENSG00000224660.1	SH3BP5-AS1	9.12	3.67e-19	1.64e-16	0.28	0.27	Alcohol dependence;Alcohol and nicotine co-dependence;	chr3:15266733	chr3:15254184~15264493:+
BRCA	cis	rs7811142	1	rs1000215	ENSG00000242294.5	STAG3L5P	9.12	3.67e-19	1.65e-16	0.25	0.27	Platelet count;	chr7:100406920	chr7:100336079~100351900:+
BRCA	cis	rs875971	0.502	rs2946580	ENSG00000237310.1	GS1-124K5.4	-9.12	3.68e-19	1.65e-16	-0.33	-0.27	Aortic root size;	chr7:66066855	chr7:66493706~66495474:+
BRCA	cis	rs4862750	0.914	rs6814259	ENSG00000250971.1	RP11-696F12.1	9.12	3.71e-19	1.66e-16	0.28	0.27	Lobe attachment (rater-scored or self-reported);	chr4:186951183	chr4:187060099~187060930:+
BRCA	cis	rs853679	0.882	rs9468300	ENSG00000220721.1	OR1F12	9.12	3.72e-19	1.67e-16	0.5	0.27	Depression;	chr6:28159062	chr6:28073316~28074233:+
BRCA	cis	rs12468226	0.938	rs3731700	ENSG00000273456.1	RP11-686O6.2	9.12	3.73e-19	1.67e-16	0.41	0.27	Urate levels;	chr2:202291213	chr2:202374932~202375604:-
BRCA	cis	rs1061377	1	rs7657926	ENSG00000249685.1	RP11-360F5.3	9.12	3.74e-19	1.67e-16	0.33	0.27	Uric acid levels;	chr4:39132443	chr4:39133913~39135608:+
BRCA	cis	rs1061377	1	rs11096982	ENSG00000249685.1	RP11-360F5.3	9.12	3.74e-19	1.67e-16	0.33	0.27	Uric acid levels;	chr4:39133247	chr4:39133913~39135608:+
BRCA	cis	rs1061377	1	rs11727875	ENSG00000249685.1	RP11-360F5.3	9.12	3.74e-19	1.67e-16	0.33	0.27	Uric acid levels;	chr4:39133699	chr4:39133913~39135608:+
BRCA	cis	rs875971	0.545	rs17138149	ENSG00000237310.1	GS1-124K5.4	9.12	3.75e-19	1.68e-16	0.32	0.27	Aortic root size;	chr7:66228193	chr7:66493706~66495474:+
BRCA	cis	rs853679	0.882	rs3757188	ENSG00000220721.1	OR1F12	9.12	3.75e-19	1.68e-16	0.5	0.27	Depression;	chr6:28139579	chr6:28073316~28074233:+
BRCA	cis	rs7811142	1	rs112317829	ENSG00000242294.5	STAG3L5P	9.12	3.76e-19	1.68e-16	0.26	0.27	Platelet count;	chr7:100445550	chr7:100336079~100351900:+
BRCA	cis	rs9807989	0.507	rs4851571	ENSG00000234389.1	AC007278.3	9.12	3.76e-19	1.68e-16	0.25	0.27	Asthma;	chr2:102402540	chr2:102438713~102440475:+
BRCA	cis	rs9807989	0.507	rs4851572	ENSG00000234389.1	AC007278.3	9.12	3.76e-19	1.68e-16	0.25	0.27	Asthma;	chr2:102402571	chr2:102438713~102440475:+
BRCA	cis	rs1061377	1	rs34771104	ENSG00000249685.1	RP11-360F5.3	9.12	3.76e-19	1.68e-16	0.33	0.27	Uric acid levels;	chr4:39127432	chr4:39133913~39135608:+
BRCA	cis	rs4835473	0.932	rs4835278	ENSG00000251600.4	RP11-673E1.1	-9.12	3.77e-19	1.69e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143788433	chr4:143912331~143982454:+
BRCA	cis	rs1134634	0.52	rs3822298	ENSG00000273133.1	RP11-799M12.2	-9.12	3.78e-19	1.69e-16	-0.36	-0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15554780	chr4:15563698~15564253:-
BRCA	cis	rs748404	0.666	rs12907870	ENSG00000249839.1	AC011330.5	-9.12	3.79e-19	1.69e-16	-0.39	-0.27	Lung cancer;	chr15:43453971	chr15:43663654~43684339:-
BRCA	cis	rs673078	0.66	rs16948193	ENSG00000275759.1	RP11-131L12.3	-9.12	3.8e-19	1.7e-16	-0.43	-0.27	Glucose homeostasis traits;	chr12:118227115	chr12:118428281~118428870:+
BRCA	cis	rs673078	0.66	rs61945187	ENSG00000275759.1	RP11-131L12.3	-9.12	3.8e-19	1.7e-16	-0.43	-0.27	Glucose homeostasis traits;	chr12:118228989	chr12:118428281~118428870:+
BRCA	cis	rs11673344	0.864	rs8107192	ENSG00000226686.6	LINC01535	9.12	3.81e-19	1.71e-16	0.36	0.27	Obesity-related traits;	chr19:37008725	chr19:37251912~37265535:+
BRCA	cis	rs1823913	0.637	rs11686185	ENSG00000227542.1	AC092614.2	-9.12	3.81e-19	1.71e-16	-0.32	-0.27	Obesity-related traits;	chr2:191289282	chr2:191229165~191246172:-
BRCA	cis	rs783540	1	rs6603033	ENSG00000278603.1	RP13-608F4.5	9.12	3.82e-19	1.71e-16	0.34	0.27	Schizophrenia;	chr15:82667123	chr15:82472203~82472426:+
BRCA	cis	rs7712401	0.601	rs246268	ENSG00000263432.2	RN7SL689P	9.12	3.82e-19	1.71e-16	0.34	0.27	Mean platelet volume;	chr5:122920647	chr5:123022487~123022783:-
BRCA	cis	rs7899628	1	rs7899628	ENSG00000276742.1	RP11-500G22.4	-9.12	3.82e-19	1.71e-16	-0.35	-0.27	Breast cancer;	chr10:121904429	chr10:121956782~121957098:+
BRCA	cis	rs55665837	0.539	rs10832310	ENSG00000251991.1	RNU7-49P	9.12	3.83e-19	1.71e-16	0.31	0.27	Vitamin D levels;	chr11:14856896	chr11:14478892~14478953:+
BRCA	cis	rs8062405	1	rs8062405	ENSG00000278665.1	RP11-666O2.4	-9.12	3.83e-19	1.71e-16	-0.28	-0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28826585	chr16:28599241~28601881:-
BRCA	cis	rs11098499	0.789	rs9991166	ENSG00000248280.1	RP11-33B1.2	9.12	3.83e-19	1.71e-16	0.27	0.27	Corneal astigmatism;	chr4:119316696	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.708	rs10005237	ENSG00000248280.1	RP11-33B1.2	9.12	3.83e-19	1.71e-16	0.27	0.27	Corneal astigmatism;	chr4:119316742	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.754	rs10213267	ENSG00000248280.1	RP11-33B1.2	9.12	3.83e-19	1.71e-16	0.27	0.27	Corneal astigmatism;	chr4:119317919	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.754	rs10212775	ENSG00000248280.1	RP11-33B1.2	9.12	3.83e-19	1.71e-16	0.27	0.27	Corneal astigmatism;	chr4:119318089	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.754	rs2964	ENSG00000248280.1	RP11-33B1.2	9.12	3.83e-19	1.71e-16	0.27	0.27	Corneal astigmatism;	chr4:119318976	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.754	rs1511025	ENSG00000248280.1	RP11-33B1.2	9.12	3.83e-19	1.71e-16	0.27	0.27	Corneal astigmatism;	chr4:119319083	chr4:119440561~119450157:-
BRCA	cis	rs2439831	0.85	rs3736180	ENSG00000249839.1	AC011330.5	-9.12	3.84e-19	1.72e-16	-0.47	-0.27	Lung cancer in ever smokers;	chr15:43814426	chr15:43663654~43684339:-
BRCA	cis	rs1061377	1	rs35437629	ENSG00000249685.1	RP11-360F5.3	9.12	3.84e-19	1.72e-16	0.33	0.27	Uric acid levels;	chr4:39131712	chr4:39133913~39135608:+
BRCA	cis	rs11673344	1	rs11673344	ENSG00000226686.6	LINC01535	9.12	3.84e-19	1.72e-16	0.36	0.27	Obesity-related traits;	chr19:37194064	chr19:37251912~37265535:+
BRCA	cis	rs925255	0.743	rs7589485	ENSG00000270210.1	RP11-373D23.3	9.12	3.85e-19	1.72e-16	0.35	0.27	Inflammatory bowel disease;Crohn's disease;	chr2:28422253	chr2:28425945~28426719:+
BRCA	cis	rs11098499	0.575	rs907204	ENSG00000248280.1	RP11-33B1.2	9.12	3.87e-19	1.73e-16	0.27	0.27	Corneal astigmatism;	chr4:119317499	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.575	rs907205	ENSG00000248280.1	RP11-33B1.2	9.12	3.87e-19	1.73e-16	0.27	0.27	Corneal astigmatism;	chr4:119317509	chr4:119440561~119450157:-
BRCA	cis	rs7772486	0.686	rs4895684	ENSG00000235652.6	RP11-545I5.3	-9.12	3.88e-19	1.73e-16	-0.27	-0.27	Lobe attachment (rater-scored or self-reported);	chr6:145792887	chr6:145799409~145886585:+
BRCA	cis	rs12468226	1	rs16839077	ENSG00000273456.1	RP11-686O6.2	9.12	3.88e-19	1.73e-16	0.4	0.27	Urate levels;	chr2:202343970	chr2:202374932~202375604:-
BRCA	cis	rs6504950	0.925	rs244348	ENSG00000275710.1	RP11-257O5.4	9.12	3.88e-19	1.74e-16	0.33	0.27	Breast cancer;	chr17:55118930	chr17:54964474~54964679:+
BRCA	cis	rs1061377	0.965	rs11728058	ENSG00000249685.1	RP11-360F5.3	9.12	3.89e-19	1.74e-16	0.33	0.27	Uric acid levels;	chr4:39128224	chr4:39133913~39135608:+
BRCA	cis	rs1061377	1	rs17508864	ENSG00000249685.1	RP11-360F5.3	9.12	3.89e-19	1.74e-16	0.33	0.27	Uric acid levels;	chr4:39129025	chr4:39133913~39135608:+
BRCA	cis	rs1707322	1	rs7539800	ENSG00000280836.1	AL355480.1	9.12	3.9e-19	1.74e-16	0.35	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45796457	chr1:45581219~45581321:-
BRCA	cis	rs875971	0.545	rs313830	ENSG00000237310.1	GS1-124K5.4	-9.12	3.91e-19	1.74e-16	-0.33	-0.27	Aortic root size;	chr7:66086944	chr7:66493706~66495474:+
BRCA	cis	rs11098499	0.662	rs13108589	ENSG00000245958.5	RP11-33B1.1	-9.12	3.91e-19	1.75e-16	-0.26	-0.27	Corneal astigmatism;	chr4:119346947	chr4:119454791~119552025:+
BRCA	cis	rs13256369	0.901	rs12679831	ENSG00000253893.2	FAM85B	-9.12	3.91e-19	1.75e-16	-0.39	-0.27	Obesity-related traits;	chr8:8708901	chr8:8167819~8226614:-
BRCA	cis	rs13256369	0.901	rs12681327	ENSG00000253893.2	FAM85B	-9.12	3.91e-19	1.75e-16	-0.39	-0.27	Obesity-related traits;	chr8:8708904	chr8:8167819~8226614:-
BRCA	cis	rs1185460	0.546	rs2508948	ENSG00000271751.1	RP11-110I1.14	9.12	3.92e-19	1.75e-16	0.35	0.27	Coronary artery disease;	chr11:119080932	chr11:119065263~119065677:-
BRCA	cis	rs2274273	0.901	rs8011288	ENSG00000258413.1	RP11-665C16.6	-9.12	3.92e-19	1.75e-16	-0.34	-0.27	Protein biomarker;	chr14:55268394	chr14:55262767~55272075:-
BRCA	cis	rs150992	0.504	rs11745405	ENSG00000248489.1	CTD-2007H13.3	-9.12	3.93e-19	1.75e-16	-0.34	-0.27	Body mass index;	chr5:99047700	chr5:98929171~98995013:+
BRCA	cis	rs11098499	0.754	rs878372	ENSG00000248280.1	RP11-33B1.2	9.12	3.94e-19	1.76e-16	0.27	0.27	Corneal astigmatism;	chr4:119317625	chr4:119440561~119450157:-
BRCA	cis	rs1075265	0.605	rs805418	ENSG00000233266.1	HMGB1P31	9.11	3.94e-19	1.76e-16	0.34	0.27	Chronotype;Morning vs. evening chronotype;	chr2:53898634	chr2:54051334~54051760:+
BRCA	cis	rs1823913	0.599	rs13399251	ENSG00000227542.1	AC092614.2	9.11	3.95e-19	1.76e-16	0.33	0.27	Obesity-related traits;	chr2:191268758	chr2:191229165~191246172:-
BRCA	cis	rs2015599	0.525	rs10771514	ENSG00000275476.1	RP11-996F15.4	9.11	3.95e-19	1.76e-16	0.31	0.27	Platelet count;Mean platelet volume;	chr12:29315751	chr12:29277397~29277882:-
BRCA	cis	rs3096299	0.933	rs2965934	ENSG00000274627.1	RP11-104N10.2	9.11	3.96e-19	1.77e-16	0.28	0.27	Multiple myeloma (IgH translocation);	chr16:89414821	chr16:89516797~89522217:+
BRCA	cis	rs1823913	0.637	rs12624271	ENSG00000227542.1	AC092614.2	-9.11	3.99e-19	1.78e-16	-0.33	-0.27	Obesity-related traits;	chr2:191288586	chr2:191229165~191246172:-
BRCA	cis	rs1707322	1	rs1707317	ENSG00000280836.1	AL355480.1	9.11	3.99e-19	1.78e-16	0.35	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46044970	chr1:45581219~45581321:-
BRCA	cis	rs673078	0.66	rs73205512	ENSG00000275759.1	RP11-131L12.3	-9.11	4.01e-19	1.79e-16	-0.43	-0.27	Glucose homeostasis traits;	chr12:118235770	chr12:118428281~118428870:+
BRCA	cis	rs12468226	0.873	rs12472035	ENSG00000273456.1	RP11-686O6.2	9.11	4.01e-19	1.79e-16	0.42	0.27	Urate levels;	chr2:202221970	chr2:202374932~202375604:-
BRCA	cis	rs12458462	0.892	rs2242175	ENSG00000274828.1	RP11-567M16.6	9.11	4.02e-19	1.79e-16	0.32	0.27	Monocyte count;	chr18:79704406	chr18:79677287~79679358:-
BRCA	cis	rs1823913	0.927	rs13025919	ENSG00000280083.1	RP11-317J9.1	-9.11	4.04e-19	1.8e-16	-0.33	-0.27	Obesity-related traits;	chr2:191260175	chr2:191154118~191156070:-
BRCA	cis	rs12468226	0.938	rs80315897	ENSG00000273456.1	RP11-686O6.2	9.11	4.04e-19	1.8e-16	0.41	0.27	Urate levels;	chr2:202318044	chr2:202374932~202375604:-
BRCA	cis	rs11096990	0.656	rs6531710	ENSG00000249207.1	RP11-360F5.1	9.11	4.07e-19	1.82e-16	0.32	0.27	Cognitive function;	chr4:39300658	chr4:39112677~39126818:-
BRCA	cis	rs748404	0.666	rs12900259	ENSG00000249839.1	AC011330.5	-9.11	4.09e-19	1.82e-16	-0.39	-0.27	Lung cancer;	chr15:43427369	chr15:43663654~43684339:-
BRCA	cis	rs748404	0.666	rs34921640	ENSG00000249839.1	AC011330.5	-9.11	4.09e-19	1.82e-16	-0.39	-0.27	Lung cancer;	chr15:43429187	chr15:43663654~43684339:-
BRCA	cis	rs748404	0.666	rs62020574	ENSG00000249839.1	AC011330.5	-9.11	4.09e-19	1.82e-16	-0.39	-0.27	Lung cancer;	chr15:43429380	chr15:43663654~43684339:-
BRCA	cis	rs12468226	0.938	rs12471060	ENSG00000273456.1	RP11-686O6.2	9.11	4.1e-19	1.83e-16	0.41	0.27	Urate levels;	chr2:202309597	chr2:202374932~202375604:-
BRCA	cis	rs2274273	0.901	rs10140801	ENSG00000258413.1	RP11-665C16.6	-9.11	4.1e-19	1.83e-16	-0.36	-0.27	Protein biomarker;	chr14:55263686	chr14:55262767~55272075:-
BRCA	cis	rs11098499	0.954	rs10031483	ENSG00000248280.1	RP11-33B1.2	9.11	4.11e-19	1.83e-16	0.28	0.27	Corneal astigmatism;	chr4:119501481	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.954	rs10031665	ENSG00000248280.1	RP11-33B1.2	9.11	4.11e-19	1.83e-16	0.28	0.27	Corneal astigmatism;	chr4:119501697	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.954	rs3733523	ENSG00000248280.1	RP11-33B1.2	9.11	4.11e-19	1.83e-16	0.28	0.27	Corneal astigmatism;	chr4:119502564	chr4:119440561~119450157:-
BRCA	cis	rs875971	0.545	rs10950025	ENSG00000237310.1	GS1-124K5.4	9.11	4.12e-19	1.84e-16	0.32	0.27	Aortic root size;	chr7:66158946	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.52	rs12666485	ENSG00000237310.1	GS1-124K5.4	9.11	4.12e-19	1.84e-16	0.32	0.27	Aortic root size;	chr7:66160135	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.545	rs67688847	ENSG00000237310.1	GS1-124K5.4	9.11	4.12e-19	1.84e-16	0.32	0.27	Aortic root size;	chr7:66161064	chr7:66493706~66495474:+
BRCA	cis	rs113835537	0.529	rs2305535	ENSG00000255517.5	CTD-3074O7.5	9.11	4.12e-19	1.84e-16	0.36	0.27	Airway imaging phenotypes;	chr11:66504766	chr11:66473490~66480233:-
BRCA	cis	rs1134634	0.52	rs872678	ENSG00000273133.1	RP11-799M12.2	-9.11	4.16e-19	1.85e-16	-0.35	-0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15654075	chr4:15563698~15564253:-
BRCA	cis	rs1061377	1	rs1982009	ENSG00000249685.1	RP11-360F5.3	9.11	4.16e-19	1.86e-16	0.33	0.27	Uric acid levels;	chr4:39123253	chr4:39133913~39135608:+
BRCA	cis	rs1061377	0.965	rs1138494	ENSG00000249685.1	RP11-360F5.3	9.11	4.16e-19	1.86e-16	0.33	0.27	Uric acid levels;	chr4:39123315	chr4:39133913~39135608:+
BRCA	cis	rs11676348	0.71	rs11894169	ENSG00000261338.2	RP11-378A13.1	9.11	4.17e-19	1.86e-16	0.3	0.27	Ulcerative colitis;	chr2:218182123	chr2:218255319~218257366:+
BRCA	cis	rs875971	1	rs10244498	ENSG00000237310.1	GS1-124K5.4	9.11	4.19e-19	1.87e-16	0.29	0.27	Aortic root size;	chr7:66651069	chr7:66493706~66495474:+
BRCA	cis	rs11676348	0.873	rs10210012	ENSG00000261338.2	RP11-378A13.1	-9.11	4.2e-19	1.87e-16	-0.29	-0.27	Ulcerative colitis;	chr2:218148611	chr2:218255319~218257366:+
BRCA	cis	rs7712401	0.601	rs431878	ENSG00000263432.2	RN7SL689P	-9.11	4.21e-19	1.87e-16	-0.35	-0.27	Mean platelet volume;	chr5:122926096	chr5:123022487~123022783:-
BRCA	cis	rs4988958	0.565	rs885088	ENSG00000234389.1	AC007278.3	9.11	4.24e-19	1.89e-16	0.25	0.27	Asthma (childhood onset);	chr2:102422584	chr2:102438713~102440475:+
BRCA	cis	rs881375	0.967	rs2239658	ENSG00000226752.6	PSMD5-AS1	-9.11	4.24e-19	1.89e-16	-0.33	-0.27	Rheumatoid arthritis;	chr9:120909559	chr9:120824828~120854385:+
BRCA	cis	rs6921919	0.789	rs6912584	ENSG00000216901.1	AL022393.7	9.11	4.26e-19	1.9e-16	0.39	0.27	Autism spectrum disorder or schizophrenia;	chr6:28341813	chr6:28176188~28176674:+
BRCA	cis	rs9807989	0.524	rs4851576	ENSG00000234389.1	AC007278.3	9.11	4.26e-19	1.9e-16	0.25	0.27	Asthma;	chr2:102412435	chr2:102438713~102440475:+
BRCA	cis	rs9807989	0.507	rs4851577	ENSG00000234389.1	AC007278.3	9.11	4.26e-19	1.9e-16	0.25	0.27	Asthma;	chr2:102412461	chr2:102438713~102440475:+
BRCA	cis	rs9807989	0.507	rs4851579	ENSG00000234389.1	AC007278.3	9.11	4.26e-19	1.9e-16	0.25	0.27	Asthma;	chr2:102412524	chr2:102438713~102440475:+
BRCA	cis	rs9807989	0.507	rs1592459	ENSG00000234389.1	AC007278.3	9.11	4.26e-19	1.9e-16	0.25	0.27	Asthma;	chr2:102415109	chr2:102438713~102440475:+
BRCA	cis	rs9807989	0.507	rs2160201	ENSG00000234389.1	AC007278.3	9.11	4.26e-19	1.9e-16	0.25	0.27	Asthma;	chr2:102417501	chr2:102438713~102440475:+
BRCA	cis	rs875971	0.545	rs13311962	ENSG00000237310.1	GS1-124K5.4	-9.11	4.27e-19	1.9e-16	-0.32	-0.27	Aortic root size;	chr7:66603142	chr7:66493706~66495474:+
BRCA	cis	rs673078	0.66	rs61945190	ENSG00000275759.1	RP11-131L12.3	-9.11	4.27e-19	1.9e-16	-0.43	-0.27	Glucose homeostasis traits;	chr12:118231345	chr12:118428281~118428870:+
BRCA	cis	rs812925	0.502	rs2084318	ENSG00000271889.1	RP11-493E12.1	-9.11	4.29e-19	1.91e-16	-0.33	-0.27	Immature fraction of reticulocytes;	chr2:61425466	chr2:61151433~61162105:-
BRCA	cis	rs4988958	0.548	rs6543127	ENSG00000234389.1	AC007278.3	9.1	4.29e-19	1.91e-16	0.25	0.27	Asthma (childhood onset);	chr2:102411841	chr2:102438713~102440475:+
BRCA	cis	rs7773456	0.576	rs6924929	ENSG00000228412.5	RP4-625H18.2	-9.1	4.3e-19	1.92e-16	-0.39	-0.27	Lupus nephritis in systemic lupus erythematosus;	chr6:19812381	chr6:19802164~19804752:-
BRCA	cis	rs673078	0.66	rs17512177	ENSG00000275759.1	RP11-131L12.3	-9.1	4.3e-19	1.92e-16	-0.43	-0.27	Glucose homeostasis traits;	chr12:118192335	chr12:118428281~118428870:+
BRCA	cis	rs673078	0.66	rs17512198	ENSG00000275759.1	RP11-131L12.3	-9.1	4.3e-19	1.92e-16	-0.43	-0.27	Glucose homeostasis traits;	chr12:118194217	chr12:118428281~118428870:+
BRCA	cis	rs1113500	0.524	rs12145813	ENSG00000226822.1	RP11-356N1.2	9.1	4.32e-19	1.92e-16	0.39	0.27	Growth-regulated protein alpha levels;	chr1:108027282	chr1:108071482~108074519:+
BRCA	cis	rs12468226	0.873	rs59293950	ENSG00000273456.1	RP11-686O6.2	9.1	4.32e-19	1.92e-16	0.42	0.27	Urate levels;	chr2:202214069	chr2:202374932~202375604:-
BRCA	cis	rs1823913	0.599	rs7598639	ENSG00000227542.1	AC092614.2	9.1	4.32e-19	1.92e-16	0.33	0.27	Obesity-related traits;	chr2:191267958	chr2:191229165~191246172:-
BRCA	cis	rs17772222	0.958	rs74074098	ENSG00000258983.2	RP11-507K2.2	9.1	4.33e-19	1.93e-16	0.32	0.27	Coronary artery calcification;	chr14:88484213	chr14:88499334~88515502:+
BRCA	cis	rs875971	0.66	rs1860470	ENSG00000222364.1	RNU6-96P	9.1	4.34e-19	1.93e-16	0.32	0.27	Aortic root size;	chr7:66638707	chr7:66395191~66395286:+
BRCA	cis	rs4862750	0.914	rs6837117	ENSG00000250971.1	RP11-696F12.1	9.1	4.36e-19	1.94e-16	0.28	0.27	Lobe attachment (rater-scored or self-reported);	chr4:186951225	chr4:187060099~187060930:+
BRCA	cis	rs4835473	0.932	rs2323191	ENSG00000251600.4	RP11-673E1.1	-9.1	4.36e-19	1.94e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143744472	chr4:143912331~143982454:+
BRCA	cis	rs5751614	0.537	rs5996508	ENSG00000230701.2	FBXW4P1	9.1	4.36e-19	1.94e-16	0.35	0.27	Height;	chr22:23270441	chr22:23262767~23265005:+
BRCA	cis	rs12701220	0.655	rs7784403	ENSG00000229043.2	AC091729.9	-9.1	4.4e-19	1.96e-16	-0.38	-0.27	Bronchopulmonary dysplasia;	chr7:1113441	chr7:1160374~1165267:+
BRCA	cis	rs2274273	0.805	rs11628437	ENSG00000258413.1	RP11-665C16.6	-9.1	4.43e-19	1.97e-16	-0.34	-0.27	Protein biomarker;	chr14:55308750	chr14:55262767~55272075:-
BRCA	cis	rs10875746	0.624	rs10875777	ENSG00000240399.1	RP1-228P16.1	-9.1	4.43e-19	1.97e-16	-0.36	-0.27	Longevity (90 years and older);	chr12:48228288	chr12:48054813~48055591:-
BRCA	cis	rs7429990	0.932	rs60446735	ENSG00000229759.1	MRPS18AP1	9.1	4.45e-19	1.98e-16	0.31	0.27	Educational attainment (years of education);	chr3:47929958	chr3:48256350~48256938:-
BRCA	cis	rs2283792	0.765	rs9607285	ENSG00000224086.5	LL22NC03-86G7.1	-9.1	4.46e-19	1.99e-16	-0.29	-0.27	Multiple sclerosis;	chr22:21808704	chr22:21938293~21977632:+
BRCA	cis	rs11098499	0.754	rs1546503	ENSG00000248280.1	RP11-33B1.2	9.1	4.47e-19	1.99e-16	0.27	0.27	Corneal astigmatism;	chr4:119320012	chr4:119440561~119450157:-
BRCA	cis	rs55665837	0.539	rs731042	ENSG00000251991.1	RNU7-49P	9.1	4.48e-19	1.99e-16	0.31	0.27	Vitamin D levels;	chr11:14853429	chr11:14478892~14478953:+
BRCA	cis	rs11098499	0.863	rs17050695	ENSG00000245958.5	RP11-33B1.1	-9.1	4.48e-19	1.99e-16	-0.26	-0.27	Corneal astigmatism;	chr4:119568372	chr4:119454791~119552025:+
BRCA	cis	rs4660456	0.869	rs7518344	ENSG00000237899.1	RP4-739H11.3	9.1	4.49e-19	2e-16	0.4	0.27	Platelet count;	chr1:40708327	chr1:40669089~40687588:-
BRCA	cis	rs4660456	0.827	rs10736404	ENSG00000237899.1	RP4-739H11.3	9.1	4.49e-19	2e-16	0.4	0.27	Platelet count;	chr1:40710331	chr1:40669089~40687588:-
BRCA	cis	rs11098499	0.954	rs3733519	ENSG00000248280.1	RP11-33B1.2	9.1	4.49e-19	2e-16	0.28	0.27	Corneal astigmatism;	chr4:119502293	chr4:119440561~119450157:-
BRCA	cis	rs673078	0.66	rs7977403	ENSG00000275759.1	RP11-131L12.3	-9.1	4.49e-19	2e-16	-0.42	-0.27	Glucose homeostasis traits;	chr12:118233446	chr12:118428281~118428870:+
BRCA	cis	rs2067615	0.579	rs4964489	ENSG00000260329.1	RP11-412D9.4	-9.1	4.5e-19	2e-16	-0.29	-0.27	Heart rate;	chr12:106778030	chr12:106954029~106955497:-
BRCA	cis	rs6545883	0.507	rs4672427	ENSG00000271889.1	RP11-493E12.1	-9.1	4.5e-19	2e-16	-0.33	-0.27	Tuberculosis;	chr2:61242115	chr2:61151433~61162105:-
BRCA	cis	rs875971	0.66	rs3764903	ENSG00000222364.1	RNU6-96P	9.1	4.51e-19	2.01e-16	0.32	0.27	Aortic root size;	chr7:66633495	chr7:66395191~66395286:+
BRCA	cis	rs367615	0.659	rs13435970	ENSG00000249476.1	CTD-2587M2.1	9.1	4.52e-19	2.01e-16	0.34	0.27	Colorectal cancer (SNP x SNP interaction);	chr5:109548959	chr5:109237120~109326369:-
BRCA	cis	rs881375	1	rs7037140	ENSG00000226752.6	PSMD5-AS1	-9.1	4.52e-19	2.01e-16	-0.33	-0.27	Rheumatoid arthritis;	chr9:120894049	chr9:120824828~120854385:+
BRCA	cis	rs58873874	0.737	rs10476052	ENSG00000251405.2	CTB-109A12.1	9.1	4.52e-19	2.01e-16	0.69	0.27	Bipolar disorder (body mass index interaction);	chr5:157473526	chr5:157362615~157460078:-
BRCA	cis	rs1061377	0.803	rs6857761	ENSG00000249685.1	RP11-360F5.3	9.1	4.52e-19	2.01e-16	0.33	0.27	Uric acid levels;	chr4:39118353	chr4:39133913~39135608:+
BRCA	cis	rs12701220	0.553	rs7782024	ENSG00000229043.2	AC091729.9	-9.1	4.55e-19	2.02e-16	-0.38	-0.27	Bronchopulmonary dysplasia;	chr7:1117866	chr7:1160374~1165267:+
BRCA	cis	rs1061377	1	rs9998867	ENSG00000249685.1	RP11-360F5.3	9.1	4.56e-19	2.02e-16	0.33	0.27	Uric acid levels;	chr4:39117542	chr4:39133913~39135608:+
BRCA	cis	rs6782228	1	rs11718130	ENSG00000242551.2	POU5F1P6	9.1	4.56e-19	2.03e-16	0.43	0.27	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128611184	chr3:128674735~128677005:-
BRCA	cis	rs4835473	0.838	rs13134571	ENSG00000251600.4	RP11-673E1.1	-9.1	4.56e-19	2.03e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143738771	chr4:143912331~143982454:+
BRCA	cis	rs5751614	0.557	rs5759666	ENSG00000230701.2	FBXW4P1	9.1	4.58e-19	2.03e-16	0.34	0.27	Height;	chr22:23260155	chr22:23262767~23265005:+
BRCA	cis	rs12188164	0.61	rs6555242	ENSG00000225138.6	CTD-2228K2.7	9.1	4.58e-19	2.03e-16	0.31	0.27	Cystic fibrosis severity;	chr5:416431	chr5:473236~480884:+
BRCA	cis	rs2439831	0.85	rs28564774	ENSG00000249839.1	AC011330.5	-9.1	4.58e-19	2.04e-16	-0.46	-0.27	Lung cancer in ever smokers;	chr15:43833277	chr15:43663654~43684339:-
BRCA	cis	rs6142102	0.961	rs1055857	ENSG00000276073.1	RP5-1125A11.7	-9.1	4.59e-19	2.04e-16	-0.32	-0.27	Skin pigmentation;	chr20:34026067	chr20:33985617~33988989:-
BRCA	cis	rs4835473	0.932	rs2060656	ENSG00000251600.4	RP11-673E1.1	-9.1	4.62e-19	2.05e-16	-0.32	-0.27	Immature fraction of reticulocytes;	chr4:143739330	chr4:143912331~143982454:+
BRCA	cis	rs465969	0.655	rs13203984	ENSG00000255389.1	C6orf3	-9.1	4.63e-19	2.06e-16	-0.55	-0.27	Psoriasis;	chr6:111388538	chr6:111599875~111602295:+
BRCA	cis	rs875971	0.528	rs801213	ENSG00000237310.1	GS1-124K5.4	-9.1	4.63e-19	2.06e-16	-0.32	-0.27	Aortic root size;	chr7:66549931	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.545	rs801212	ENSG00000237310.1	GS1-124K5.4	-9.1	4.63e-19	2.06e-16	-0.32	-0.27	Aortic root size;	chr7:66550643	chr7:66493706~66495474:+
BRCA	cis	rs2274273	0.805	rs28660594	ENSG00000258413.1	RP11-665C16.6	-9.1	4.64e-19	2.06e-16	-0.34	-0.27	Protein biomarker;	chr14:55379456	chr14:55262767~55272075:-
BRCA	cis	rs2404602	0.569	rs2469249	ENSG00000259422.1	RP11-593F23.1	-9.1	4.65e-19	2.06e-16	-0.38	-0.27	Blood metabolite levels;	chr15:76479721	chr15:76174891~76181486:-
BRCA	cis	rs11098499	0.708	rs1546506	ENSG00000248280.1	RP11-33B1.2	9.1	4.66e-19	2.07e-16	0.27	0.27	Corneal astigmatism;	chr4:119320085	chr4:119440561~119450157:-
BRCA	cis	rs875971	0.545	rs316306	ENSG00000237310.1	GS1-124K5.4	-9.1	4.66e-19	2.07e-16	-0.32	-0.27	Aortic root size;	chr7:66153687	chr7:66493706~66495474:+
BRCA	cis	rs6142102	0.581	rs4911148	ENSG00000275784.1	RP5-1125A11.6	-9.09	4.68e-19	2.08e-16	-0.31	-0.27	Skin pigmentation;	chr20:34080438	chr20:33989480~33991818:-
BRCA	cis	rs1061377	0.965	rs10018622	ENSG00000249685.1	RP11-360F5.3	9.09	4.68e-19	2.08e-16	0.33	0.27	Uric acid levels;	chr4:39133944	chr4:39133913~39135608:+
BRCA	cis	rs801193	0.904	rs4718405	ENSG00000222364.1	RNU6-96P	-9.09	4.69e-19	2.08e-16	-0.3	-0.27	Aortic root size;	chr7:66789659	chr7:66395191~66395286:+
BRCA	cis	rs7773456	0.533	rs9350190	ENSG00000228412.5	RP4-625H18.2	-9.09	4.7e-19	2.09e-16	-0.39	-0.27	Lupus nephritis in systemic lupus erythematosus;	chr6:19811429	chr6:19802164~19804752:-
BRCA	cis	rs11098499	0.754	rs11732087	ENSG00000248280.1	RP11-33B1.2	9.09	4.7e-19	2.09e-16	0.27	0.27	Corneal astigmatism;	chr4:119318676	chr4:119440561~119450157:-
BRCA	cis	rs227275	0.525	rs6533052	ENSG00000246560.2	RP11-10L12.4	9.09	4.72e-19	2.1e-16	0.28	0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102990624	chr4:102828055~102844075:+
BRCA	cis	rs957448	1	rs957448	ENSG00000253704.1	RP11-267M23.4	9.09	4.72e-19	2.1e-16	0.31	0.27	Nonsyndromic cleft lip with cleft palate;	chr8:94529074	chr8:94553722~94569745:+
BRCA	cis	rs227275	0.525	rs3974485	ENSG00000246560.2	RP11-10L12.4	9.09	4.72e-19	2.1e-16	0.28	0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102993283	chr4:102828055~102844075:+
BRCA	cis	rs6570726	0.791	rs379040	ENSG00000235652.6	RP11-545I5.3	9.09	4.74e-19	2.1e-16	0.27	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145567899	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.686	rs7744014	ENSG00000235652.6	RP11-545I5.3	9.09	4.74e-19	2.11e-16	0.27	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145802682	chr6:145799409~145886585:+
BRCA	cis	rs8012947	1	rs10142973	ENSG00000279636.2	LINC00216	-9.09	4.75e-19	2.11e-16	-0.3	-0.27	Alcohol consumption in current drinkers;	chr14:58332400	chr14:58288033~58289158:+
BRCA	cis	rs7945705	0.902	rs7479407	ENSG00000254860.4	TMEM9B-AS1	-9.09	4.76e-19	2.11e-16	-0.25	-0.27	Hemoglobin concentration;	chr11:9001874	chr11:8964675~8977527:+
BRCA	cis	rs11098499	0.954	rs28685688	ENSG00000248280.1	RP11-33B1.2	9.09	4.76e-19	2.11e-16	0.28	0.27	Corneal astigmatism;	chr4:119499179	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.954	rs7687843	ENSG00000248280.1	RP11-33B1.2	9.09	4.76e-19	2.11e-16	0.28	0.27	Corneal astigmatism;	chr4:119500056	chr4:119440561~119450157:-
BRCA	cis	rs10262624	1	rs13244265	ENSG00000234286.1	AC006026.13	-9.09	4.79e-19	2.13e-16	-0.31	-0.27	Schizophrenia;	chr7:23878284	chr7:23680195~23680786:-
BRCA	cis	rs227275	0.556	rs6842179	ENSG00000246560.2	RP11-10L12.4	9.09	4.8e-19	2.13e-16	0.29	0.27	Allergic disease (asthma, hay fever or eczema);	chr4:103018363	chr4:102828055~102844075:+
BRCA	cis	rs881375	1	rs10760118	ENSG00000226752.6	PSMD5-AS1	-9.09	4.8e-19	2.13e-16	-0.32	-0.27	Rheumatoid arthritis;	chr9:120879338	chr9:120824828~120854385:+
BRCA	cis	rs875971	0.52	rs160645	ENSG00000237310.1	GS1-124K5.4	-9.09	4.81e-19	2.13e-16	-0.33	-0.27	Aortic root size;	chr7:66091320	chr7:66493706~66495474:+
BRCA	cis	rs11673344	0.864	rs8108727	ENSG00000226686.6	LINC01535	9.09	4.82e-19	2.14e-16	0.36	0.27	Obesity-related traits;	chr19:37090622	chr19:37251912~37265535:+
BRCA	cis	rs1134634	0.52	rs75099653	ENSG00000273133.1	RP11-799M12.2	-9.09	4.87e-19	2.16e-16	-0.35	-0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15626397	chr4:15563698~15564253:-
BRCA	cis	rs7772486	0.534	rs34541797	ENSG00000235652.6	RP11-545I5.3	9.09	4.87e-19	2.16e-16	0.29	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145884168	chr6:145799409~145886585:+
BRCA	cis	rs2439831	0.85	rs28504496	ENSG00000205771.5	CATSPER2P1	-9.09	4.89e-19	2.17e-16	-0.48	-0.27	Lung cancer in ever smokers;	chr15:43724685	chr15:43726918~43747094:-
BRCA	cis	rs1707322	1	rs1612419	ENSG00000280836.1	AL355480.1	9.09	4.9e-19	2.17e-16	0.35	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46081273	chr1:45581219~45581321:-
BRCA	cis	rs1061377	1	rs2163273	ENSG00000249685.1	RP11-360F5.3	9.09	4.92e-19	2.18e-16	0.33	0.27	Uric acid levels;	chr4:39112835	chr4:39133913~39135608:+
BRCA	cis	rs9807989	0.507	rs1420105	ENSG00000234389.1	AC007278.3	9.09	4.92e-19	2.18e-16	0.25	0.27	Asthma;	chr2:102418659	chr2:102438713~102440475:+
BRCA	cis	rs748404	0.666	rs7177146	ENSG00000249839.1	AC011330.5	-9.09	4.94e-19	2.19e-16	-0.4	-0.27	Lung cancer;	chr15:43506110	chr15:43663654~43684339:-
BRCA	cis	rs875971	0.545	rs1796219	ENSG00000237310.1	GS1-124K5.4	-9.09	4.95e-19	2.2e-16	-0.33	-0.27	Aortic root size;	chr7:66645977	chr7:66493706~66495474:+
BRCA	cis	rs10181042	0.514	rs1177283	ENSG00000271889.1	RP11-493E12.1	9.09	4.96e-19	2.2e-16	0.35	0.27	Crohn's disease;	chr2:61121669	chr2:61151433~61162105:-
BRCA	cis	rs7567389	0.744	rs6430934	ENSG00000236682.1	AC068282.3	9.09	4.97e-19	2.2e-16	0.39	0.27	Self-rated health;	chr2:127243257	chr2:127389130~127400580:+
BRCA	cis	rs1075265	0.783	rs718872	ENSG00000233266.1	HMGB1P31	9.09	4.97e-19	2.2e-16	0.33	0.27	Chronotype;Morning vs. evening chronotype;	chr2:53946569	chr2:54051334~54051760:+
BRCA	cis	rs2729354	0.514	rs1967179	ENSG00000265566.2	RN7SL605P	-9.09	4.97e-19	2.2e-16	-0.34	-0.27	Blood protein levels;	chr11:57581010	chr11:57528085~57528365:-
BRCA	cis	rs8062405	1	rs56404918	ENSG00000278665.1	RP11-666O2.4	9.09	4.99e-19	2.21e-16	0.29	0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835519	chr16:28599241~28601881:-
BRCA	cis	rs8062405	1	rs55719896	ENSG00000278665.1	RP11-666O2.4	9.09	4.99e-19	2.21e-16	0.29	0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835545	chr16:28599241~28601881:-
BRCA	cis	rs5751614	0.537	rs9608093	ENSG00000230701.2	FBXW4P1	9.09	5e-19	2.21e-16	0.35	0.27	Height;	chr22:23271352	chr22:23262767~23265005:+
BRCA	cis	rs4988958	0.584	rs7589142	ENSG00000234389.1	AC007278.3	9.09	5.03e-19	2.23e-16	0.25	0.27	Asthma (childhood onset);	chr2:102408200	chr2:102438713~102440475:+
BRCA	cis	rs10262624	1	rs17347692	ENSG00000234286.1	AC006026.13	-9.09	5.03e-19	2.23e-16	-0.31	-0.27	Schizophrenia;	chr7:23878748	chr7:23680195~23680786:-
BRCA	cis	rs55665837	0.539	rs10832311	ENSG00000251991.1	RNU7-49P	9.09	5.03e-19	2.23e-16	0.31	0.27	Vitamin D levels;	chr11:14860380	chr11:14478892~14478953:+
BRCA	cis	rs7772486	0.686	rs9386131	ENSG00000235652.6	RP11-545I5.3	9.09	5.04e-19	2.23e-16	0.27	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145800472	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.686	rs7739735	ENSG00000235652.6	RP11-545I5.3	9.09	5.04e-19	2.23e-16	0.27	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145802400	chr6:145799409~145886585:+
BRCA	cis	rs11673344	0.832	rs77772684	ENSG00000226686.6	LINC01535	9.09	5.06e-19	2.24e-16	0.36	0.27	Obesity-related traits;	chr19:37055838	chr19:37251912~37265535:+
BRCA	cis	rs12458462	0.812	rs34583578	ENSG00000274828.1	RP11-567M16.6	9.09	5.09e-19	2.25e-16	0.32	0.27	Monocyte count;	chr18:79731070	chr18:79677287~79679358:-
BRCA	cis	rs673078	0.66	rs10507286	ENSG00000275759.1	RP11-131L12.3	-9.08	5.09e-19	2.25e-16	-0.43	-0.27	Glucose homeostasis traits;	chr12:118197101	chr12:118428281~118428870:+
BRCA	cis	rs11098499	0.909	rs2127821	ENSG00000248280.1	RP11-33B1.2	9.08	5.1e-19	2.26e-16	0.28	0.27	Corneal astigmatism;	chr4:119473380	chr4:119440561~119450157:-
BRCA	cis	rs12458462	0.787	rs56006341	ENSG00000274828.1	RP11-567M16.6	9.08	5.1e-19	2.26e-16	0.31	0.27	Monocyte count;	chr18:79679844	chr18:79677287~79679358:-
BRCA	cis	rs875971	0.545	rs67775320	ENSG00000237310.1	GS1-124K5.4	9.08	5.12e-19	2.27e-16	0.32	0.27	Aortic root size;	chr7:66193792	chr7:66493706~66495474:+
BRCA	cis	rs6538678	0.864	rs7308921	ENSG00000258343.1	RP11-536G4.2	9.08	5.12e-19	2.27e-16	0.36	0.27	Lupus nephritis in systemic lupus erythematosus;	chr12:95870757	chr12:95795345~95858839:-
BRCA	cis	rs8012947	0.959	rs10132929	ENSG00000279636.2	LINC00216	-9.08	5.16e-19	2.28e-16	-0.29	-0.27	Alcohol consumption in current drinkers;	chr14:58292289	chr14:58288033~58289158:+
BRCA	cis	rs8012947	0.959	rs7146801	ENSG00000279636.2	LINC00216	-9.08	5.16e-19	2.28e-16	-0.29	-0.27	Alcohol consumption in current drinkers;	chr14:58292769	chr14:58288033~58289158:+
BRCA	cis	rs116175783	0.557	rs62188136	ENSG00000227403.1	AC009299.3	9.08	5.17e-19	2.29e-16	0.48	0.27	Intelligence (multi-trait analysis);	chr2:161399439	chr2:161244739~161249050:+
BRCA	cis	rs2274273	0.84	rs11626751	ENSG00000258413.1	RP11-665C16.6	-9.08	5.18e-19	2.29e-16	-0.34	-0.27	Protein biomarker;	chr14:55368509	chr14:55262767~55272075:-
BRCA	cis	rs12468226	0.873	rs12470401	ENSG00000273456.1	RP11-686O6.2	9.08	5.2e-19	2.3e-16	0.42	0.27	Urate levels;	chr2:202236436	chr2:202374932~202375604:-
BRCA	cis	rs1061377	1	rs9997089	ENSG00000249685.1	RP11-360F5.3	9.08	5.2e-19	2.3e-16	0.33	0.27	Uric acid levels;	chr4:39119263	chr4:39133913~39135608:+
BRCA	cis	rs1061377	1	rs28465556	ENSG00000249685.1	RP11-360F5.3	9.08	5.2e-19	2.3e-16	0.33	0.27	Uric acid levels;	chr4:39119569	chr4:39133913~39135608:+
BRCA	cis	rs1061377	1	rs10027813	ENSG00000249685.1	RP11-360F5.3	9.08	5.2e-19	2.3e-16	0.33	0.27	Uric acid levels;	chr4:39119818	chr4:39133913~39135608:+
BRCA	cis	rs1061377	1	rs9990755	ENSG00000249685.1	RP11-360F5.3	9.08	5.2e-19	2.3e-16	0.33	0.27	Uric acid levels;	chr4:39119819	chr4:39133913~39135608:+
BRCA	cis	rs1061377	1	rs7676008	ENSG00000249685.1	RP11-360F5.3	9.08	5.2e-19	2.3e-16	0.33	0.27	Uric acid levels;	chr4:39120154	chr4:39133913~39135608:+
BRCA	cis	rs1061377	1	rs7655122	ENSG00000249685.1	RP11-360F5.3	9.08	5.2e-19	2.3e-16	0.33	0.27	Uric acid levels;	chr4:39120396	chr4:39133913~39135608:+
BRCA	cis	rs12458462	0.892	rs12456692	ENSG00000274828.1	RP11-567M16.6	9.08	5.2e-19	2.3e-16	0.32	0.27	Monocyte count;	chr18:79722189	chr18:79677287~79679358:-
BRCA	cis	rs8062405	1	rs55830740	ENSG00000278665.1	RP11-666O2.4	9.08	5.21e-19	2.3e-16	0.29	0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835828	chr16:28599241~28601881:-
BRCA	cis	rs4660456	0.913	rs1494	ENSG00000237899.1	RP4-739H11.3	9.08	5.21e-19	2.3e-16	0.4	0.27	Platelet count;	chr1:40706176	chr1:40669089~40687588:-
BRCA	cis	rs4660456	0.826	rs3767952	ENSG00000237899.1	RP4-739H11.3	-9.08	5.25e-19	2.32e-16	-0.4	-0.27	Platelet count;	chr1:40765360	chr1:40669089~40687588:-
BRCA	cis	rs227275	0.525	rs724446	ENSG00000246560.2	RP11-10L12.4	9.08	5.26e-19	2.33e-16	0.28	0.27	Allergic disease (asthma, hay fever or eczema);	chr4:103010206	chr4:102828055~102844075:+
BRCA	cis	rs2274273	0.87	rs11625001	ENSG00000258413.1	RP11-665C16.6	-9.08	5.27e-19	2.33e-16	-0.34	-0.27	Protein biomarker;	chr14:55291442	chr14:55262767~55272075:-
BRCA	cis	rs1134634	0.52	rs28522268	ENSG00000273133.1	RP11-799M12.2	-9.08	5.29e-19	2.34e-16	-0.36	-0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15601844	chr4:15563698~15564253:-
BRCA	cis	rs6142102	0.602	rs6142069	ENSG00000275784.1	RP5-1125A11.6	-9.08	5.29e-19	2.34e-16	-0.31	-0.27	Skin pigmentation;	chr20:33972736	chr20:33989480~33991818:-
BRCA	cis	rs1061377	1	rs7685082	ENSG00000249685.1	RP11-360F5.3	9.08	5.3e-19	2.34e-16	0.33	0.27	Uric acid levels;	chr4:39116472	chr4:39133913~39135608:+
BRCA	cis	rs11098499	0.954	rs17006190	ENSG00000248280.1	RP11-33B1.2	9.08	5.3e-19	2.34e-16	0.28	0.27	Corneal astigmatism;	chr4:119497683	chr4:119440561~119450157:-
BRCA	cis	rs11673344	0.864	rs7256876	ENSG00000226686.6	LINC01535	9.08	5.31e-19	2.35e-16	0.36	0.27	Obesity-related traits;	chr19:37088570	chr19:37251912~37265535:+
BRCA	cis	rs6142102	0.602	rs4911396	ENSG00000275784.1	RP5-1125A11.6	-9.08	5.32e-19	2.35e-16	-0.31	-0.27	Skin pigmentation;	chr20:33992139	chr20:33989480~33991818:-
BRCA	cis	rs2067615	0.56	rs10467028	ENSG00000260329.1	RP11-412D9.4	-9.08	5.35e-19	2.36e-16	-0.29	-0.27	Heart rate;	chr12:106682627	chr12:106954029~106955497:-
BRCA	cis	rs2439831	0.85	rs10163054	ENSG00000205771.5	CATSPER2P1	-9.08	5.35e-19	2.37e-16	-0.47	-0.27	Lung cancer in ever smokers;	chr15:43755440	chr15:43726918~43747094:-
BRCA	cis	rs2439831	0.85	rs11070408	ENSG00000205771.5	CATSPER2P1	-9.08	5.37e-19	2.37e-16	-0.47	-0.27	Lung cancer in ever smokers;	chr15:43742590	chr15:43726918~43747094:-
BRCA	cis	rs1900504	0.584	rs2915754	ENSG00000266200.5	PNLIPRP2	-9.08	5.39e-19	2.38e-16	-0.35	-0.27	Tonsillectomy;	chr10:116605306	chr10:116620953~116645143:+
BRCA	cis	rs11676348	0.772	rs7422358	ENSG00000261338.2	RP11-378A13.1	-9.08	5.4e-19	2.38e-16	-0.28	-0.27	Ulcerative colitis;	chr2:218088055	chr2:218255319~218257366:+
BRCA	cis	rs11098499	0.913	rs10010696	ENSG00000245958.5	RP11-33B1.1	-9.08	5.4e-19	2.38e-16	-0.27	-0.27	Corneal astigmatism;	chr4:119243148	chr4:119454791~119552025:+
BRCA	cis	rs11676348	0.774	rs11683524	ENSG00000261338.2	RP11-378A13.1	-9.08	5.4e-19	2.39e-16	-0.29	-0.27	Ulcerative colitis;	chr2:218119881	chr2:218255319~218257366:+
BRCA	cis	rs4835473	0.9	rs7698963	ENSG00000251600.4	RP11-673E1.1	9.08	5.4e-19	2.39e-16	0.31	0.27	Immature fraction of reticulocytes;	chr4:143733190	chr4:143912331~143982454:+
BRCA	cis	rs4660456	0.913	rs7542019	ENSG00000237899.1	RP4-739H11.3	9.08	5.41e-19	2.39e-16	0.4	0.27	Platelet count;	chr1:40704039	chr1:40669089~40687588:-
BRCA	cis	rs4835473	0.9	rs1375982	ENSG00000251600.4	RP11-673E1.1	-9.08	5.43e-19	2.4e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143745764	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.9	rs4835237	ENSG00000251600.4	RP11-673E1.1	-9.08	5.43e-19	2.4e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143746349	chr4:143912331~143982454:+
BRCA	cis	rs875971	0.571	rs160647	ENSG00000237310.1	GS1-124K5.4	-9.08	5.44e-19	2.4e-16	-0.32	-0.27	Aortic root size;	chr7:66089365	chr7:66493706~66495474:+
BRCA	cis	rs881375	0.935	rs7034390	ENSG00000226752.6	PSMD5-AS1	-9.08	5.45e-19	2.41e-16	-0.32	-0.27	Rheumatoid arthritis;	chr9:120884210	chr9:120824828~120854385:+
BRCA	cis	rs11098499	0.954	rs11722872	ENSG00000248280.1	RP11-33B1.2	9.08	5.5e-19	2.43e-16	0.28	0.27	Corneal astigmatism;	chr4:119311875	chr4:119440561~119450157:-
BRCA	cis	rs1061377	1	rs1036038	ENSG00000249685.1	RP11-360F5.3	9.08	5.51e-19	2.43e-16	0.33	0.27	Uric acid levels;	chr4:39111383	chr4:39133913~39135608:+
BRCA	cis	rs1061377	1	rs1560396	ENSG00000249685.1	RP11-360F5.3	9.08	5.51e-19	2.43e-16	0.33	0.27	Uric acid levels;	chr4:39112092	chr4:39133913~39135608:+
BRCA	cis	rs1061377	1	rs1560397	ENSG00000249685.1	RP11-360F5.3	9.08	5.51e-19	2.43e-16	0.33	0.27	Uric acid levels;	chr4:39112265	chr4:39133913~39135608:+
BRCA	cis	rs1061377	1	rs2381285	ENSG00000249685.1	RP11-360F5.3	9.08	5.51e-19	2.43e-16	0.33	0.27	Uric acid levels;	chr4:39112775	chr4:39133913~39135608:+
BRCA	cis	rs1061377	1	rs62310332	ENSG00000249685.1	RP11-360F5.3	9.08	5.51e-19	2.43e-16	0.33	0.27	Uric acid levels;	chr4:39112939	chr4:39133913~39135608:+
BRCA	cis	rs1061377	0.965	rs3796510	ENSG00000249685.1	RP11-360F5.3	9.08	5.51e-19	2.43e-16	0.33	0.27	Uric acid levels;	chr4:39113309	chr4:39133913~39135608:+
BRCA	cis	rs1061377	0.932	rs6855118	ENSG00000249685.1	RP11-360F5.3	9.08	5.51e-19	2.43e-16	0.33	0.27	Uric acid levels;	chr4:39114322	chr4:39133913~39135608:+
BRCA	cis	rs1061377	1	rs6829234	ENSG00000249685.1	RP11-360F5.3	9.08	5.51e-19	2.43e-16	0.33	0.27	Uric acid levels;	chr4:39114586	chr4:39133913~39135608:+
BRCA	cis	rs1061377	1	rs6812540	ENSG00000249685.1	RP11-360F5.3	9.08	5.51e-19	2.43e-16	0.33	0.27	Uric acid levels;	chr4:39114803	chr4:39133913~39135608:+
BRCA	cis	rs321358	0.731	rs12421339	ENSG00000271584.1	RP11-89C3.4	9.07	5.55e-19	2.45e-16	0.42	0.27	Body mass index;	chr11:111168744	chr11:111091932~111097357:-
BRCA	cis	rs1061377	1	rs2381284	ENSG00000249685.1	RP11-360F5.3	9.07	5.56e-19	2.45e-16	0.33	0.27	Uric acid levels;	chr4:39117976	chr4:39133913~39135608:+
BRCA	cis	rs1061377	1	rs9999327	ENSG00000249685.1	RP11-360F5.3	9.07	5.57e-19	2.46e-16	0.33	0.27	Uric acid levels;	chr4:39110111	chr4:39133913~39135608:+
BRCA	cis	rs1061377	0.965	rs6833654	ENSG00000249685.1	RP11-360F5.3	9.07	5.57e-19	2.46e-16	0.33	0.27	Uric acid levels;	chr4:39110701	chr4:39133913~39135608:+
BRCA	cis	rs4660456	0.913	rs16827569	ENSG00000237899.1	RP4-739H11.3	-9.07	5.59e-19	2.46e-16	-0.4	-0.27	Platelet count;	chr1:40761655	chr1:40669089~40687588:-
BRCA	cis	rs12134133	0.752	rs6683677	ENSG00000274245.1	RP11-357P18.2	9.07	5.6e-19	2.47e-16	0.39	0.27	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207228335	chr1:207372559~207373252:+
BRCA	cis	rs881375	0.631	rs2416808	ENSG00000226752.6	PSMD5-AS1	-9.07	5.6e-19	2.47e-16	-0.32	-0.27	Rheumatoid arthritis;	chr9:120944005	chr9:120824828~120854385:+
BRCA	cis	rs9807989	0.524	rs2110662	ENSG00000234389.1	AC007278.3	9.07	5.6e-19	2.47e-16	0.25	0.27	Asthma;	chr2:102403679	chr2:102438713~102440475:+
BRCA	cis	rs1061377	1	rs9998481	ENSG00000249685.1	RP11-360F5.3	9.07	5.61e-19	2.47e-16	0.33	0.27	Uric acid levels;	chr4:39117215	chr4:39133913~39135608:+
BRCA	cis	rs9807989	0.524	rs7594402	ENSG00000234389.1	AC007278.3	9.07	5.62e-19	2.48e-16	0.25	0.27	Asthma;	chr2:102404807	chr2:102438713~102440475:+
BRCA	cis	rs9807989	0.507	rs6710034	ENSG00000234389.1	AC007278.3	9.07	5.62e-19	2.48e-16	0.25	0.27	Asthma;	chr2:102407218	chr2:102438713~102440475:+
BRCA	cis	rs11098499	0.754	rs12506610	ENSG00000248280.1	RP11-33B1.2	9.07	5.62e-19	2.48e-16	0.27	0.27	Corneal astigmatism;	chr4:119320504	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.743	rs10003567	ENSG00000248280.1	RP11-33B1.2	9.07	5.62e-19	2.48e-16	0.27	0.27	Corneal astigmatism;	chr4:119320519	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.754	rs10006259	ENSG00000248280.1	RP11-33B1.2	9.07	5.62e-19	2.48e-16	0.27	0.27	Corneal astigmatism;	chr4:119320990	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.754	rs28652763	ENSG00000248280.1	RP11-33B1.2	9.07	5.62e-19	2.48e-16	0.27	0.27	Corneal astigmatism;	chr4:119321157	chr4:119440561~119450157:-
BRCA	cis	rs13256369	1	rs10110591	ENSG00000253893.2	FAM85B	9.07	5.62e-19	2.48e-16	0.37	0.27	Obesity-related traits;	chr8:8719098	chr8:8167819~8226614:-
BRCA	cis	rs12468226	0.873	rs1474267	ENSG00000273456.1	RP11-686O6.2	-9.07	5.63e-19	2.48e-16	-0.39	-0.27	Urate levels;	chr2:202178596	chr2:202374932~202375604:-
BRCA	cis	rs9807989	0.507	rs1035129	ENSG00000234389.1	AC007278.3	9.07	5.64e-19	2.49e-16	0.25	0.27	Asthma;	chr2:102403325	chr2:102438713~102440475:+
BRCA	cis	rs881375	1	rs6478486	ENSG00000226752.6	PSMD5-AS1	-9.07	5.65e-19	2.49e-16	-0.33	-0.27	Rheumatoid arthritis;	chr9:120893051	chr9:120824828~120854385:+
BRCA	cis	rs7430456	0.839	rs9824506	ENSG00000228221.4	LINC00578	-9.07	5.65e-19	2.49e-16	-0.34	-0.27	Breast cancer;	chr3:177751431	chr3:177441921~177752305:+
BRCA	cis	rs8062405	0.895	rs62036658	ENSG00000278665.1	RP11-666O2.4	9.07	5.66e-19	2.49e-16	0.31	0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28839050	chr16:28599241~28601881:-
BRCA	cis	rs881375	1	rs10117059	ENSG00000226752.6	PSMD5-AS1	-9.07	5.67e-19	2.5e-16	-0.33	-0.27	Rheumatoid arthritis;	chr9:120891199	chr9:120824828~120854385:+
BRCA	cis	rs1707322	0.964	rs785499	ENSG00000280836.1	AL355480.1	9.07	5.7e-19	2.51e-16	0.36	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46126748	chr1:45581219~45581321:-
BRCA	cis	rs11168351	0.517	rs10875754	ENSG00000240399.1	RP1-228P16.1	9.07	5.7e-19	2.51e-16	0.29	0.27	Bipolar disorder and schizophrenia;	chr12:48164139	chr12:48054813~48055591:-
BRCA	cis	rs4835473	0.9	rs13119630	ENSG00000251600.4	RP11-673E1.1	-9.07	5.7e-19	2.51e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143773901	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs1450233	ENSG00000251600.4	RP11-673E1.1	-9.07	5.7e-19	2.51e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143774710	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs4308330	ENSG00000251600.4	RP11-673E1.1	-9.07	5.7e-19	2.51e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143774761	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs11725708	ENSG00000251600.4	RP11-673E1.1	-9.07	5.7e-19	2.51e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143775683	chr4:143912331~143982454:+
BRCA	cis	rs875971	1	rs709597	ENSG00000237310.1	GS1-124K5.4	-9.07	5.71e-19	2.52e-16	-0.28	-0.27	Aortic root size;	chr7:66360996	chr7:66493706~66495474:+
BRCA	cis	rs67311347	0.866	rs2371183	ENSG00000223797.4	ENTPD3-AS1	-9.07	5.72e-19	2.52e-16	-0.29	-0.27	Renal cell carcinoma;	chr3:40292756	chr3:40313802~40453329:-
BRCA	cis	rs4835473	0.932	rs4615131	ENSG00000251600.4	RP11-673E1.1	-9.07	5.79e-19	2.55e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143740295	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs4499657	ENSG00000251600.4	RP11-673E1.1	-9.07	5.79e-19	2.55e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143740316	chr4:143912331~143982454:+
BRCA	cis	rs11098499	0.955	rs1511018	ENSG00000245958.5	RP11-33B1.1	-9.07	5.84e-19	2.57e-16	-0.27	-0.27	Corneal astigmatism;	chr4:119240425	chr4:119454791~119552025:+
BRCA	cis	rs2067615	0.579	rs10778502	ENSG00000260329.1	RP11-412D9.4	-9.07	5.85e-19	2.58e-16	-0.3	-0.27	Heart rate;	chr12:106696423	chr12:106954029~106955497:-
BRCA	cis	rs4835473	0.932	rs12512202	ENSG00000251600.4	RP11-673E1.1	-9.07	5.9e-19	2.6e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143771248	chr4:143912331~143982454:+
BRCA	cis	rs783540	0.934	rs7182403	ENSG00000278603.1	RP13-608F4.5	-9.07	5.93e-19	2.61e-16	-0.34	-0.27	Schizophrenia;	chr15:82628862	chr15:82472203~82472426:+
BRCA	cis	rs2274273	0.87	rs11625423	ENSG00000258413.1	RP11-665C16.6	-9.07	5.94e-19	2.61e-16	-0.34	-0.27	Protein biomarker;	chr14:55329195	chr14:55262767~55272075:-
BRCA	cis	rs6142102	0.961	rs1883524	ENSG00000276073.1	RP5-1125A11.7	-9.07	5.96e-19	2.62e-16	-0.32	-0.27	Skin pigmentation;	chr20:34038301	chr20:33985617~33988989:-
BRCA	cis	rs11676348	0.774	rs13397673	ENSG00000261338.2	RP11-378A13.1	-9.07	5.96e-19	2.62e-16	-0.29	-0.27	Ulcerative colitis;	chr2:218183059	chr2:218255319~218257366:+
BRCA	cis	rs875971	0.545	rs2460427	ENSG00000237310.1	GS1-124K5.4	-9.07	5.98e-19	2.63e-16	-0.32	-0.27	Aortic root size;	chr7:66154218	chr7:66493706~66495474:+
BRCA	cis	rs1823913	0.637	rs4853574	ENSG00000227542.1	AC092614.2	-9.07	6.01e-19	2.64e-16	-0.32	-0.27	Obesity-related traits;	chr2:191296113	chr2:191229165~191246172:-
BRCA	cis	rs66887589	0.72	rs11724758	ENSG00000248280.1	RP11-33B1.2	9.07	6.01e-19	2.64e-16	0.25	0.27	Diastolic blood pressure;	chr4:119318723	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.863	rs13134665	ENSG00000245958.5	RP11-33B1.1	-9.06	6.04e-19	2.66e-16	-0.27	-0.27	Corneal astigmatism;	chr4:119505275	chr4:119454791~119552025:+
BRCA	cis	rs1823913	0.927	rs56209234	ENSG00000280083.1	RP11-317J9.1	-9.06	6.05e-19	2.66e-16	-0.33	-0.27	Obesity-related traits;	chr2:191261748	chr2:191154118~191156070:-
BRCA	cis	rs4718428	0.705	rs13220977	ENSG00000232546.1	RP11-458F8.1	9.06	6.06e-19	2.67e-16	0.24	0.27	Corneal structure;	chr7:66872661	chr7:66848496~66858136:+
BRCA	cis	rs1707322	1	rs785493	ENSG00000280836.1	AL355480.1	9.06	6.07e-19	2.67e-16	0.36	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46119187	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.964	rs785496	ENSG00000280836.1	AL355480.1	9.06	6.07e-19	2.67e-16	0.36	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46122334	chr1:45581219~45581321:-
BRCA	cis	rs1707322	1	rs785497	ENSG00000280836.1	AL355480.1	9.06	6.07e-19	2.67e-16	0.36	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46126231	chr1:45581219~45581321:-
BRCA	cis	rs11098499	0.909	rs11723839	ENSG00000248280.1	RP11-33B1.2	9.06	6.07e-19	2.67e-16	0.28	0.27	Corneal astigmatism;	chr4:119378518	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.779	rs7699346	ENSG00000248280.1	RP11-33B1.2	9.06	6.07e-19	2.67e-16	0.28	0.27	Corneal astigmatism;	chr4:119389387	chr4:119440561~119450157:-
BRCA	cis	rs9847710	0.733	rs9818819	ENSG00000242142.1	SERBP1P3	9.06	6.08e-19	2.67e-16	0.33	0.27	Ulcerative colitis;	chr3:53042739	chr3:53064283~53065091:-
BRCA	cis	rs925255	0.713	rs9309662	ENSG00000270210.1	RP11-373D23.3	-9.06	6.09e-19	2.68e-16	-0.34	-0.27	Inflammatory bowel disease;Crohn's disease;	chr2:28407025	chr2:28425945~28426719:+
BRCA	cis	rs10262624	1	rs4722286	ENSG00000234286.1	AC006026.13	9.06	6.13e-19	2.7e-16	0.31	0.27	Schizophrenia;	chr7:23874005	chr7:23680195~23680786:-
BRCA	cis	rs7772486	0.686	rs1337839	ENSG00000235652.6	RP11-545I5.3	-9.06	6.13e-19	2.7e-16	-0.27	-0.27	Lobe attachment (rater-scored or self-reported);	chr6:145689103	chr6:145799409~145886585:+
BRCA	cis	rs12594515	0.548	rs12912226	ENSG00000273972.1	CTD-2306A12.1	-9.06	6.14e-19	2.7e-16	-0.36	-0.27	Weight;Waist circumference;	chr15:45693510	chr15:45702640~45703183:+
BRCA	cis	rs58873874	0.737	rs10476050	ENSG00000251405.2	CTB-109A12.1	9.06	6.17e-19	2.71e-16	0.68	0.27	Bipolar disorder (body mass index interaction);	chr5:157471866	chr5:157362615~157460078:-
BRCA	cis	rs2067615	0.579	rs10861665	ENSG00000260329.1	RP11-412D9.4	-9.06	6.18e-19	2.72e-16	-0.29	-0.27	Heart rate;	chr12:106800058	chr12:106954029~106955497:-
BRCA	cis	rs7937890	0.532	rs2575827	ENSG00000251991.1	RNU7-49P	9.06	6.19e-19	2.72e-16	0.3	0.27	Mitochondrial DNA levels;	chr11:14453969	chr11:14478892~14478953:+
BRCA	cis	rs150992	0.536	rs10479348	ENSG00000248489.1	CTD-2007H13.3	-9.06	6.2e-19	2.72e-16	-0.36	-0.27	Body mass index;	chr5:99013022	chr5:98929171~98995013:+
BRCA	cis	rs2067615	0.579	rs11113119	ENSG00000260329.1	RP11-412D9.4	-9.06	6.2e-19	2.73e-16	-0.29	-0.27	Heart rate;	chr12:106806278	chr12:106954029~106955497:-
BRCA	cis	rs2274273	0.84	rs66486619	ENSG00000258413.1	RP11-665C16.6	-9.06	6.21e-19	2.73e-16	-0.34	-0.27	Protein biomarker;	chr14:55402837	chr14:55262767~55272075:-
BRCA	cis	rs2439831	0.85	rs28513374	ENSG00000249839.1	AC011330.5	-9.06	6.25e-19	2.74e-16	-0.46	-0.27	Lung cancer in ever smokers;	chr15:43833297	chr15:43663654~43684339:-
BRCA	cis	rs2274273	0.804	rs28428911	ENSG00000258413.1	RP11-665C16.6	-9.06	6.28e-19	2.76e-16	-0.34	-0.27	Protein biomarker;	chr14:55376878	chr14:55262767~55272075:-
BRCA	cis	rs748404	0.666	rs72709879	ENSG00000249839.1	AC011330.5	-9.06	6.29e-19	2.76e-16	-0.39	-0.27	Lung cancer;	chr15:43507777	chr15:43663654~43684339:-
BRCA	cis	rs875971	0.545	rs221986	ENSG00000237310.1	GS1-124K5.4	-9.06	6.29e-19	2.76e-16	-0.32	-0.27	Aortic root size;	chr7:66105323	chr7:66493706~66495474:+
BRCA	cis	rs1707322	1	rs785510	ENSG00000280836.1	AL355480.1	9.06	6.3e-19	2.77e-16	0.35	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46062946	chr1:45581219~45581321:-
BRCA	cis	rs748404	0.666	rs35326382	ENSG00000249839.1	AC011330.5	-9.06	6.3e-19	2.77e-16	-0.39	-0.27	Lung cancer;	chr15:43338686	chr15:43663654~43684339:-
BRCA	cis	rs10262624	0.967	rs35988560	ENSG00000234286.1	AC006026.13	-9.06	6.32e-19	2.77e-16	-0.31	-0.27	Schizophrenia;	chr7:23878561	chr7:23680195~23680786:-
BRCA	cis	rs9287719	0.967	rs6744599	ENSG00000234818.1	AC092687.5	-9.06	6.32e-19	2.78e-16	-0.32	-0.27	Prostate cancer;	chr2:10606887	chr2:10589166~10604830:+
BRCA	cis	rs1075265	0.744	rs10203576	ENSG00000233266.1	HMGB1P31	9.06	6.33e-19	2.78e-16	0.32	0.27	Chronotype;Morning vs. evening chronotype;	chr2:54060939	chr2:54051334~54051760:+
BRCA	cis	rs7937890	0.504	rs2575847	ENSG00000251991.1	RNU7-49P	9.06	6.35e-19	2.79e-16	0.3	0.27	Mitochondrial DNA levels;	chr11:14449626	chr11:14478892~14478953:+
BRCA	cis	rs7937890	0.559	rs2575825	ENSG00000251991.1	RNU7-49P	9.06	6.35e-19	2.79e-16	0.3	0.27	Mitochondrial DNA levels;	chr11:14450550	chr11:14478892~14478953:+
BRCA	cis	rs10875746	0.625	rs2898065	ENSG00000240399.1	RP1-228P16.1	-9.06	6.35e-19	2.79e-16	-0.35	-0.27	Longevity (90 years and older);	chr12:48250836	chr12:48054813~48055591:-
BRCA	cis	rs4727443	0.691	rs6975827	ENSG00000235713.1	RP4-604G5.3	9.06	6.36e-19	2.79e-16	0.3	0.27	Interstitial lung disease;	chr7:99988175	chr7:99992397~99993050:+
BRCA	cis	rs11673344	0.966	rs111927298	ENSG00000226686.6	LINC01535	9.06	6.38e-19	2.8e-16	0.35	0.27	Obesity-related traits;	chr19:37193034	chr19:37251912~37265535:+
BRCA	cis	rs2067615	0.579	rs10507214	ENSG00000260329.1	RP11-412D9.4	-9.06	6.4e-19	2.81e-16	-0.29	-0.27	Heart rate;	chr12:106800683	chr12:106954029~106955497:-
BRCA	cis	rs1061377	0.965	rs7677729	ENSG00000249685.1	RP11-360F5.3	9.06	6.41e-19	2.81e-16	0.32	0.27	Uric acid levels;	chr4:39120370	chr4:39133913~39135608:+
BRCA	cis	rs1061377	1	rs3796511	ENSG00000249685.1	RP11-360F5.3	9.06	6.41e-19	2.81e-16	0.32	0.27	Uric acid levels;	chr4:39120586	chr4:39133913~39135608:+
BRCA	cis	rs1061377	1	rs3733274	ENSG00000249685.1	RP11-360F5.3	9.06	6.41e-19	2.81e-16	0.32	0.27	Uric acid levels;	chr4:39120957	chr4:39133913~39135608:+
BRCA	cis	rs9847710	0.696	rs2581822	ENSG00000242142.1	SERBP1P3	9.06	6.41e-19	2.81e-16	0.33	0.27	Ulcerative colitis;	chr3:52987733	chr3:53064283~53065091:-
BRCA	cis	rs11673344	0.536	rs7259272	ENSG00000226686.6	LINC01535	9.06	6.43e-19	2.82e-16	0.34	0.27	Obesity-related traits;	chr19:37692214	chr19:37251912~37265535:+
BRCA	cis	rs1823913	0.637	rs10931493	ENSG00000227542.1	AC092614.2	9.06	6.44e-19	2.83e-16	0.32	0.27	Obesity-related traits;	chr2:191288142	chr2:191229165~191246172:-
BRCA	cis	rs11722779	0.935	rs3857199	ENSG00000246560.2	RP11-10L12.4	9.06	6.47e-19	2.84e-16	0.28	0.27	Schizophrenia;	chr4:102957991	chr4:102828055~102844075:+
BRCA	cis	rs10875746	0.669	rs11168516	ENSG00000240399.1	RP1-228P16.1	-9.06	6.48e-19	2.84e-16	-0.36	-0.27	Longevity (90 years and older);	chr12:48308282	chr12:48054813~48055591:-
BRCA	cis	rs7580658	0.963	rs12463451	ENSG00000236682.1	AC068282.3	-9.06	6.49e-19	2.84e-16	-0.36	-0.27	Protein C levels;	chr2:127296307	chr2:127389130~127400580:+
BRCA	cis	rs7580658	0.963	rs4233584	ENSG00000236682.1	AC068282.3	-9.06	6.49e-19	2.84e-16	-0.36	-0.27	Protein C levels;	chr2:127302587	chr2:127389130~127400580:+
BRCA	cis	rs6570726	0.62	rs12201226	ENSG00000235652.6	RP11-545I5.3	9.06	6.49e-19	2.85e-16	0.29	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145592283	chr6:145799409~145886585:+
BRCA	cis	rs11098499	0.863	rs6833334	ENSG00000245958.5	RP11-33B1.1	-9.06	6.5e-19	2.85e-16	-0.27	-0.27	Corneal astigmatism;	chr4:119583072	chr4:119454791~119552025:+
BRCA	cis	rs11722779	0.873	rs6533041	ENSG00000246560.2	RP11-10L12.4	9.06	6.5e-19	2.85e-16	0.28	0.27	Schizophrenia;	chr4:102951615	chr4:102828055~102844075:+
BRCA	cis	rs7772486	0.688	rs1884364	ENSG00000235652.6	RP11-545I5.3	9.06	6.52e-19	2.86e-16	0.29	0.27	Lobe attachment (rater-scored or self-reported);	chr6:146016681	chr6:145799409~145886585:+
BRCA	cis	rs1707322	0.927	rs6690386	ENSG00000280836.1	AL355480.1	-9.06	6.53e-19	2.86e-16	-0.36	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45787339	chr1:45581219~45581321:-
BRCA	cis	rs4727443	0.653	rs6465759	ENSG00000235713.1	RP4-604G5.3	9.06	6.53e-19	2.86e-16	0.3	0.27	Interstitial lung disease;	chr7:99990357	chr7:99992397~99993050:+
BRCA	cis	rs6142102	0.602	rs2268079	ENSG00000275784.1	RP5-1125A11.6	-9.06	6.54e-19	2.87e-16	-0.31	-0.27	Skin pigmentation;	chr20:34008944	chr20:33989480~33991818:-
BRCA	cis	rs9287719	0.901	rs55861579	ENSG00000234818.1	AC092687.5	9.05	6.6e-19	2.89e-16	0.32	0.27	Prostate cancer;	chr2:10623214	chr2:10589166~10604830:+
BRCA	cis	rs2283792	0.765	rs9340	ENSG00000224086.5	LL22NC03-86G7.1	-9.05	6.62e-19	2.9e-16	-0.29	-0.27	Multiple sclerosis;	chr22:21761064	chr22:21938293~21977632:+
BRCA	cis	rs875971	0.502	rs6460311	ENSG00000237310.1	GS1-124K5.4	-9.05	6.62e-19	2.9e-16	-0.33	-0.27	Aortic root size;	chr7:66646886	chr7:66493706~66495474:+
BRCA	cis	rs4835473	0.897	rs13145976	ENSG00000251600.4	RP11-673E1.1	-9.05	6.66e-19	2.92e-16	-0.32	-0.27	Immature fraction of reticulocytes;	chr4:143735710	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.897	rs13114071	ENSG00000251600.4	RP11-673E1.1	-9.05	6.66e-19	2.92e-16	-0.32	-0.27	Immature fraction of reticulocytes;	chr4:143735728	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.897	rs13140654	ENSG00000251600.4	RP11-673E1.1	-9.05	6.66e-19	2.92e-16	-0.32	-0.27	Immature fraction of reticulocytes;	chr4:143735733	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.897	rs6537167	ENSG00000251600.4	RP11-673E1.1	9.05	6.67e-19	2.92e-16	0.32	0.27	Immature fraction of reticulocytes;	chr4:143691323	chr4:143912331~143982454:+
BRCA	cis	rs9807989	0.507	rs3732124	ENSG00000234389.1	AC007278.3	-9.05	6.67e-19	2.92e-16	-0.25	-0.27	Asthma;	chr2:102401592	chr2:102438713~102440475:+
BRCA	cis	rs1823913	0.927	rs35339956	ENSG00000280083.1	RP11-317J9.1	-9.05	6.68e-19	2.93e-16	-0.33	-0.27	Obesity-related traits;	chr2:191261668	chr2:191154118~191156070:-
BRCA	cis	rs4835473	0.932	rs17018200	ENSG00000251600.4	RP11-673E1.1	-9.05	6.71e-19	2.94e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143760866	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs11100805	ENSG00000251600.4	RP11-673E1.1	-9.05	6.71e-19	2.94e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143760979	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.9	rs5015759	ENSG00000251600.4	RP11-673E1.1	-9.05	6.71e-19	2.94e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143738050	chr4:143912331~143982454:+
BRCA	cis	rs4718428	0.705	rs4717331	ENSG00000232546.1	RP11-458F8.1	-9.05	6.72e-19	2.94e-16	-0.25	-0.27	Corneal structure;	chr7:66913899	chr7:66848496~66858136:+
BRCA	cis	rs11098499	0.863	rs13140391	ENSG00000245958.5	RP11-33B1.1	-9.05	6.72e-19	2.94e-16	-0.27	-0.27	Corneal astigmatism;	chr4:119582282	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.863	rs13140409	ENSG00000245958.5	RP11-33B1.1	-9.05	6.72e-19	2.94e-16	-0.27	-0.27	Corneal astigmatism;	chr4:119582305	chr4:119454791~119552025:+
BRCA	cis	rs131777	0.708	rs131749	ENSG00000205559.3	CHKB-AS1	9.05	6.73e-19	2.95e-16	0.33	0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr22:50586195	chr22:50583026~50583877:+
BRCA	cis	rs1823913	0.637	rs1947456	ENSG00000227542.1	AC092614.2	-9.05	6.73e-19	2.95e-16	-0.32	-0.27	Obesity-related traits;	chr2:191298759	chr2:191229165~191246172:-
BRCA	cis	rs7937890	0.559	rs2597206	ENSG00000251991.1	RNU7-49P	9.05	6.74e-19	2.95e-16	0.3	0.27	Mitochondrial DNA levels;	chr11:14455992	chr11:14478892~14478953:+
BRCA	cis	rs227275	0.525	rs11097796	ENSG00000246560.2	RP11-10L12.4	9.05	6.75e-19	2.95e-16	0.28	0.27	Allergic disease (asthma, hay fever or eczema);	chr4:103002401	chr4:102828055~102844075:+
BRCA	cis	rs227275	0.525	rs11097797	ENSG00000246560.2	RP11-10L12.4	9.05	6.75e-19	2.95e-16	0.28	0.27	Allergic disease (asthma, hay fever or eczema);	chr4:103002507	chr4:102828055~102844075:+
BRCA	cis	rs227275	0.525	rs13117110	ENSG00000246560.2	RP11-10L12.4	9.05	6.75e-19	2.95e-16	0.28	0.27	Allergic disease (asthma, hay fever or eczema);	chr4:103003981	chr4:102828055~102844075:+
BRCA	cis	rs227275	0.525	rs13144033	ENSG00000246560.2	RP11-10L12.4	9.05	6.75e-19	2.95e-16	0.28	0.27	Allergic disease (asthma, hay fever or eczema);	chr4:103004032	chr4:102828055~102844075:+
BRCA	cis	rs227275	0.525	rs10029073	ENSG00000246560.2	RP11-10L12.4	9.05	6.75e-19	2.95e-16	0.28	0.27	Allergic disease (asthma, hay fever or eczema);	chr4:103006991	chr4:102828055~102844075:+
BRCA	cis	rs875971	0.66	rs1860468	ENSG00000222364.1	RNU6-96P	9.05	6.77e-19	2.96e-16	0.31	0.27	Aortic root size;	chr7:66642265	chr7:66395191~66395286:+
BRCA	cis	rs1707322	0.963	rs12145287	ENSG00000280836.1	AL355480.1	-9.05	6.77e-19	2.96e-16	-0.35	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45859330	chr1:45581219~45581321:-
BRCA	cis	rs4718428	0.672	rs36038499	ENSG00000232546.1	RP11-458F8.1	-9.05	6.8e-19	2.98e-16	-0.25	-0.27	Corneal structure;	chr7:66824628	chr7:66848496~66858136:+
BRCA	cis	rs11673344	0.864	rs8104919	ENSG00000226686.6	LINC01535	9.05	6.8e-19	2.98e-16	0.35	0.27	Obesity-related traits;	chr19:37012881	chr19:37251912~37265535:+
BRCA	cis	rs9847710	0.733	rs7613013	ENSG00000242142.1	SERBP1P3	9.05	6.83e-19	2.99e-16	0.33	0.27	Ulcerative colitis;	chr3:53043790	chr3:53064283~53065091:-
BRCA	cis	rs2276314	0.857	rs28530656	ENSG00000278986.1	RP11-723J4.3	9.05	6.86e-19	3e-16	0.34	0.27	Endometriosis;Drug-induced torsades de pointes;	chr18:36008737	chr18:35972151~35973916:+
BRCA	cis	rs6142102	0.923	rs3787230	ENSG00000276073.1	RP5-1125A11.7	-9.05	6.87e-19	3.01e-16	-0.32	-0.27	Skin pigmentation;	chr20:34052466	chr20:33985617~33988989:-
BRCA	cis	rs2439831	0.702	rs2467402	ENSG00000249839.1	AC011330.5	9.05	6.9e-19	3.02e-16	0.42	0.27	Lung cancer in ever smokers;	chr15:43732292	chr15:43663654~43684339:-
BRCA	cis	rs11098499	0.863	rs11098532	ENSG00000245958.5	RP11-33B1.1	-9.05	6.9e-19	3.02e-16	-0.27	-0.27	Corneal astigmatism;	chr4:119569571	chr4:119454791~119552025:+
BRCA	cis	rs11673344	0.864	rs55792845	ENSG00000226686.6	LINC01535	9.05	6.92e-19	3.03e-16	0.35	0.27	Obesity-related traits;	chr19:37007783	chr19:37251912~37265535:+
BRCA	cis	rs11673344	0.864	rs11670216	ENSG00000226686.6	LINC01535	9.05	6.92e-19	3.03e-16	0.35	0.27	Obesity-related traits;	chr19:37012526	chr19:37251912~37265535:+
BRCA	cis	rs4835473	0.932	rs6537183	ENSG00000251600.4	RP11-673E1.1	-9.05	6.92e-19	3.03e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143770441	chr4:143912331~143982454:+
BRCA	cis	rs11098499	0.754	rs12711071	ENSG00000245958.5	RP11-33B1.1	-9.05	6.93e-19	3.03e-16	-0.25	-0.27	Corneal astigmatism;	chr4:119319779	chr4:119454791~119552025:+
BRCA	cis	rs1134634	0.52	rs1473166	ENSG00000273133.1	RP11-799M12.2	-9.05	6.93e-19	3.03e-16	-0.36	-0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15555868	chr4:15563698~15564253:-
BRCA	cis	rs10262624	0.967	rs13235406	ENSG00000234286.1	AC006026.13	-9.05	6.96e-19	3.04e-16	-0.31	-0.27	Schizophrenia;	chr7:23879212	chr7:23680195~23680786:-
BRCA	cis	rs9287719	0.81	rs1990612	ENSG00000234818.1	AC092687.5	9.05	6.96e-19	3.05e-16	0.31	0.27	Prostate cancer;	chr2:10641818	chr2:10589166~10604830:+
BRCA	cis	rs1823913	0.637	rs6750360	ENSG00000227542.1	AC092614.2	-9.05	6.97e-19	3.05e-16	-0.32	-0.27	Obesity-related traits;	chr2:191303089	chr2:191229165~191246172:-
BRCA	cis	rs1823913	0.637	rs11677694	ENSG00000227542.1	AC092614.2	-9.05	6.97e-19	3.05e-16	-0.32	-0.27	Obesity-related traits;	chr2:191303203	chr2:191229165~191246172:-
BRCA	cis	rs1823913	0.571	rs6737307	ENSG00000227542.1	AC092614.2	-9.05	6.97e-19	3.05e-16	-0.32	-0.27	Obesity-related traits;	chr2:191303247	chr2:191229165~191246172:-
BRCA	cis	rs1823913	0.637	rs4853582	ENSG00000227542.1	AC092614.2	-9.05	6.97e-19	3.05e-16	-0.32	-0.27	Obesity-related traits;	chr2:191303483	chr2:191229165~191246172:-
BRCA	cis	rs1823913	0.637	rs35200176	ENSG00000227542.1	AC092614.2	-9.05	6.97e-19	3.05e-16	-0.32	-0.27	Obesity-related traits;	chr2:191303534	chr2:191229165~191246172:-
BRCA	cis	rs1823913	0.637	rs17348013	ENSG00000227542.1	AC092614.2	-9.05	6.97e-19	3.05e-16	-0.32	-0.27	Obesity-related traits;	chr2:191303726	chr2:191229165~191246172:-
BRCA	cis	rs7580658	0.545	rs885275	ENSG00000236682.1	AC068282.3	-9.05	7e-19	3.06e-16	-0.35	-0.27	Protein C levels;	chr2:127193519	chr2:127389130~127400580:+
BRCA	cis	rs2041895	0.509	rs1838445	ENSG00000260329.1	RP11-412D9.4	-9.05	7.02e-19	3.07e-16	-0.33	-0.27	Glaucoma (low intraocular pressure);	chr12:106920807	chr12:106954029~106955497:-
BRCA	cis	rs7773456	0.533	rs9368127	ENSG00000228412.5	RP4-625H18.2	-9.05	7.02e-19	3.07e-16	-0.39	-0.27	Lupus nephritis in systemic lupus erythematosus;	chr6:19811760	chr6:19802164~19804752:-
BRCA	cis	rs6991838	0.831	rs11992528	ENSG00000272010.1	CTD-3025N20.3	9.05	7.06e-19	3.09e-16	0.29	0.27	Intelligence (multi-trait analysis);	chr8:65561644	chr8:65591850~65592472:-
BRCA	cis	rs4718428	0.705	rs4717331	ENSG00000273142.1	RP11-458F8.4	-9.05	7.1e-19	3.1e-16	-0.26	-0.27	Corneal structure;	chr7:66913899	chr7:66902857~66906297:+
BRCA	cis	rs11673344	0.764	rs519551	ENSG00000226686.6	LINC01535	9.05	7.11e-19	3.11e-16	0.35	0.27	Obesity-related traits;	chr19:36965046	chr19:37251912~37265535:+
BRCA	cis	rs11098499	0.954	rs6849561	ENSG00000248280.1	RP11-33B1.2	-9.05	7.12e-19	3.11e-16	-0.29	-0.27	Corneal astigmatism;	chr4:119488539	chr4:119440561~119450157:-
BRCA	cis	rs7772486	0.558	rs62435775	ENSG00000235652.6	RP11-545I5.3	9.05	7.12e-19	3.11e-16	0.29	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145815279	chr6:145799409~145886585:+
BRCA	cis	rs1823913	0.637	rs1349938	ENSG00000227542.1	AC092614.2	-9.05	7.14e-19	3.12e-16	-0.32	-0.27	Obesity-related traits;	chr2:191299970	chr2:191229165~191246172:-
BRCA	cis	rs1823913	0.592	rs1349939	ENSG00000227542.1	AC092614.2	-9.05	7.14e-19	3.12e-16	-0.32	-0.27	Obesity-related traits;	chr2:191300079	chr2:191229165~191246172:-
BRCA	cis	rs1823913	0.614	rs6434459	ENSG00000227542.1	AC092614.2	-9.05	7.14e-19	3.12e-16	-0.32	-0.27	Obesity-related traits;	chr2:191300886	chr2:191229165~191246172:-
BRCA	cis	rs1823913	0.592	rs7588555	ENSG00000227542.1	AC092614.2	-9.05	7.14e-19	3.12e-16	-0.32	-0.27	Obesity-related traits;	chr2:191300912	chr2:191229165~191246172:-
BRCA	cis	rs1823913	0.637	rs4853581	ENSG00000227542.1	AC092614.2	-9.05	7.14e-19	3.12e-16	-0.32	-0.27	Obesity-related traits;	chr2:191301533	chr2:191229165~191246172:-
BRCA	cis	rs1823913	0.614	rs7565987	ENSG00000227542.1	AC092614.2	-9.05	7.14e-19	3.12e-16	-0.32	-0.27	Obesity-related traits;	chr2:191301815	chr2:191229165~191246172:-
BRCA	cis	rs1823913	0.614	rs1973067	ENSG00000227542.1	AC092614.2	-9.05	7.14e-19	3.12e-16	-0.32	-0.27	Obesity-related traits;	chr2:191302021	chr2:191229165~191246172:-
BRCA	cis	rs1823913	0.637	rs1973068	ENSG00000227542.1	AC092614.2	-9.05	7.14e-19	3.12e-16	-0.32	-0.27	Obesity-related traits;	chr2:191302227	chr2:191229165~191246172:-
BRCA	cis	rs1823913	0.637	rs7569231	ENSG00000227542.1	AC092614.2	-9.05	7.14e-19	3.12e-16	-0.32	-0.27	Obesity-related traits;	chr2:191302373	chr2:191229165~191246172:-
BRCA	cis	rs1823913	0.637	rs6434461	ENSG00000227542.1	AC092614.2	-9.05	7.14e-19	3.12e-16	-0.32	-0.27	Obesity-related traits;	chr2:191302661	chr2:191229165~191246172:-
BRCA	cis	rs1823913	0.614	rs6434462	ENSG00000227542.1	AC092614.2	-9.05	7.14e-19	3.12e-16	-0.32	-0.27	Obesity-related traits;	chr2:191302705	chr2:191229165~191246172:-
BRCA	cis	rs4835473	0.932	rs6843671	ENSG00000251600.4	RP11-673E1.1	-9.04	7.16e-19	3.13e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143772041	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.9	rs35395070	ENSG00000251600.4	RP11-673E1.1	-9.04	7.16e-19	3.13e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143772283	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.9	rs34614750	ENSG00000251600.4	RP11-673E1.1	-9.04	7.16e-19	3.13e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143772369	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs35002497	ENSG00000251600.4	RP11-673E1.1	-9.04	7.16e-19	3.13e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143772952	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs6858195	ENSG00000251600.4	RP11-673E1.1	-9.04	7.16e-19	3.13e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143768444	chr4:143912331~143982454:+
BRCA	cis	rs1061377	1	rs10026775	ENSG00000249685.1	RP11-360F5.3	9.04	7.16e-19	3.13e-16	0.33	0.27	Uric acid levels;	chr4:39115155	chr4:39133913~39135608:+
BRCA	cis	rs1061377	1	rs3733276	ENSG00000249685.1	RP11-360F5.3	9.04	7.16e-19	3.13e-16	0.33	0.27	Uric acid levels;	chr4:39115291	chr4:39133913~39135608:+
BRCA	cis	rs1061377	1	rs3733277	ENSG00000249685.1	RP11-360F5.3	9.04	7.16e-19	3.13e-16	0.33	0.27	Uric acid levels;	chr4:39115483	chr4:39133913~39135608:+
BRCA	cis	rs1061377	1	rs3733278	ENSG00000249685.1	RP11-360F5.3	9.04	7.16e-19	3.13e-16	0.33	0.27	Uric acid levels;	chr4:39115615	chr4:39133913~39135608:+
BRCA	cis	rs1061377	1	rs3733279	ENSG00000249685.1	RP11-360F5.3	9.04	7.16e-19	3.13e-16	0.33	0.27	Uric acid levels;	chr4:39115625	chr4:39133913~39135608:+
BRCA	cis	rs72772090	0.539	rs72775809	ENSG00000248734.2	CTD-2260A17.1	-9.04	7.19e-19	3.14e-16	-0.45	-0.27	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96847853	chr5:96784777~96785999:+
BRCA	cis	rs11971779	0.688	rs1862880	ENSG00000273391.1	RP11-634H22.1	9.04	7.23e-19	3.16e-16	0.27	0.27	Diisocyanate-induced asthma;	chr7:139335354	chr7:139359032~139359566:-
BRCA	cis	rs11098499	0.866	rs12501602	ENSG00000245958.5	RP11-33B1.1	-9.04	7.26e-19	3.17e-16	-0.26	-0.27	Corneal astigmatism;	chr4:119366780	chr4:119454791~119552025:+
BRCA	cis	rs4718428	0.705	rs12536410	ENSG00000232546.1	RP11-458F8.1	-9.04	7.27e-19	3.18e-16	-0.25	-0.27	Corneal structure;	chr7:66789303	chr7:66848496~66858136:+
BRCA	cis	rs7829975	0.509	rs7838674	ENSG00000253893.2	FAM85B	9.04	7.28e-19	3.18e-16	0.33	0.27	Mood instability;	chr8:8939563	chr8:8167819~8226614:-
BRCA	cis	rs453301	0.686	rs6748	ENSG00000253893.2	FAM85B	9.04	7.29e-19	3.18e-16	0.34	0.27	Joint mobility (Beighton score);	chr8:9033292	chr8:8167819~8226614:-
BRCA	cis	rs748404	0.666	rs34633582	ENSG00000249839.1	AC011330.5	-9.04	7.3e-19	3.19e-16	-0.39	-0.27	Lung cancer;	chr15:43462683	chr15:43663654~43684339:-
BRCA	cis	rs7772486	0.641	rs2777485	ENSG00000235652.6	RP11-545I5.3	9.04	7.31e-19	3.19e-16	0.29	0.27	Lobe attachment (rater-scored or self-reported);	chr6:146013241	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.597	rs2246132	ENSG00000235652.6	RP11-545I5.3	9.04	7.31e-19	3.19e-16	0.29	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145861379	chr6:145799409~145886585:+
BRCA	cis	rs10262624	1	rs11767124	ENSG00000234286.1	AC006026.13	-9.04	7.32e-19	3.19e-16	-0.31	-0.27	Schizophrenia;	chr7:23879461	chr7:23680195~23680786:-
BRCA	cis	rs10129255	0.5	rs10143242	ENSG00000211972.2	IGHV3-66	9.04	7.32e-19	3.2e-16	0.19	0.27	Kawasaki disease;	chr14:106681814	chr14:106675017~106675544:-
BRCA	cis	rs11098499	0.866	rs6847778	ENSG00000245958.5	RP11-33B1.1	-9.04	7.36e-19	3.21e-16	-0.26	-0.27	Corneal astigmatism;	chr4:119372427	chr4:119454791~119552025:+
BRCA	cis	rs12458462	0.892	rs35928863	ENSG00000274828.1	RP11-567M16.6	9.04	7.36e-19	3.21e-16	0.31	0.27	Monocyte count;	chr18:79678956	chr18:79677287~79679358:-
BRCA	cis	rs10028773	0.7	rs7671797	ENSG00000248280.1	RP11-33B1.2	9.04	7.37e-19	3.22e-16	0.27	0.27	Educational attainment;	chr4:119327002	chr4:119440561~119450157:-
BRCA	cis	rs7772486	0.754	rs702323	ENSG00000235652.6	RP11-545I5.3	-9.04	7.41e-19	3.23e-16	-0.27	-0.27	Lobe attachment (rater-scored or self-reported);	chr6:145687138	chr6:145799409~145886585:+
BRCA	cis	rs875971	0.522	rs7784623	ENSG00000164669.11	INTS4P1	-9.04	7.42e-19	3.24e-16	-0.33	-0.27	Aortic root size;	chr7:65930047	chr7:65141225~65234216:+
BRCA	cis	rs1823913	0.599	rs1823912	ENSG00000227542.1	AC092614.2	9.04	7.42e-19	3.24e-16	0.32	0.27	Obesity-related traits;	chr2:191266388	chr2:191229165~191246172:-
BRCA	cis	rs1823913	0.614	rs11693878	ENSG00000227542.1	AC092614.2	-9.04	7.43e-19	3.24e-16	-0.32	-0.27	Obesity-related traits;	chr2:191299399	chr2:191229165~191246172:-
BRCA	cis	rs1823913	0.637	rs10931494	ENSG00000227542.1	AC092614.2	-9.04	7.43e-19	3.24e-16	-0.32	-0.27	Obesity-related traits;	chr2:191299442	chr2:191229165~191246172:-
BRCA	cis	rs1823913	0.637	rs10931495	ENSG00000227542.1	AC092614.2	-9.04	7.43e-19	3.24e-16	-0.32	-0.27	Obesity-related traits;	chr2:191299447	chr2:191229165~191246172:-
BRCA	cis	rs1823913	0.637	rs12623156	ENSG00000227542.1	AC092614.2	-9.04	7.43e-19	3.24e-16	-0.32	-0.27	Obesity-related traits;	chr2:191299661	chr2:191229165~191246172:-
BRCA	cis	rs7937890	0.559	rs2597197	ENSG00000251991.1	RNU7-49P	9.04	7.44e-19	3.24e-16	0.3	0.27	Mitochondrial DNA levels;	chr11:14468286	chr11:14478892~14478953:+
BRCA	cis	rs9287719	0.967	rs12467642	ENSG00000234818.1	AC092687.5	9.04	7.45e-19	3.25e-16	0.31	0.27	Prostate cancer;	chr2:10621358	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs12464908	ENSG00000234818.1	AC092687.5	9.04	7.45e-19	3.25e-16	0.31	0.27	Prostate cancer;	chr2:10621370	chr2:10589166~10604830:+
BRCA	cis	rs748404	0.666	rs16957730	ENSG00000249839.1	AC011330.5	-9.04	7.45e-19	3.25e-16	-0.39	-0.27	Lung cancer;	chr15:43438288	chr15:43663654~43684339:-
BRCA	cis	rs10181042	0.514	rs1177288	ENSG00000271889.1	RP11-493E12.1	9.04	7.47e-19	3.26e-16	0.34	0.27	Crohn's disease;	chr2:61125850	chr2:61151433~61162105:-
BRCA	cis	rs6142102	0.961	rs6119447	ENSG00000276073.1	RP5-1125A11.7	-9.04	7.47e-19	3.26e-16	-0.32	-0.27	Skin pigmentation;	chr20:34080770	chr20:33985617~33988989:-
BRCA	cis	rs4835473	0.9	rs34569841	ENSG00000251600.4	RP11-673E1.1	-9.04	7.51e-19	3.27e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143738060	chr4:143912331~143982454:+
BRCA	cis	rs7429990	0.965	rs62260764	ENSG00000229759.1	MRPS18AP1	9.04	7.52e-19	3.28e-16	0.37	0.27	Educational attainment (years of education);	chr3:47949010	chr3:48256350~48256938:-
BRCA	cis	rs7712401	0.715	rs6880480	ENSG00000263432.2	RN7SL689P	-9.04	7.53e-19	3.28e-16	-0.35	-0.27	Mean platelet volume;	chr5:123019031	chr5:123022487~123022783:-
BRCA	cis	rs4660456	0.913	rs954654	ENSG00000237899.1	RP4-739H11.3	-9.04	7.53e-19	3.28e-16	-0.4	-0.27	Platelet count;	chr1:40764979	chr1:40669089~40687588:-
BRCA	cis	rs465969	1	rs9387010	ENSG00000255389.1	C6orf3	9.04	7.55e-19	3.29e-16	0.52	0.27	Psoriasis;	chr6:111384741	chr6:111599875~111602295:+
BRCA	cis	rs7937890	0.532	rs2575833	ENSG00000251991.1	RNU7-49P	9.04	7.55e-19	3.29e-16	0.3	0.27	Mitochondrial DNA levels;	chr11:14470959	chr11:14478892~14478953:+
BRCA	cis	rs11098499	0.954	rs6847248	ENSG00000245958.5	RP11-33B1.1	-9.04	7.56e-19	3.3e-16	-0.29	-0.27	Corneal astigmatism;	chr4:119304800	chr4:119454791~119552025:+
BRCA	cis	rs17711722	0.565	rs4275112	ENSG00000234585.5	CCT6P3	-9.04	7.57e-19	3.3e-16	-0.27	-0.27	Calcium levels;	chr7:65733651	chr7:65038354~65074713:+
BRCA	cis	rs9287719	0.967	rs7563816	ENSG00000234818.1	AC092687.5	9.04	7.58e-19	3.3e-16	0.31	0.27	Prostate cancer;	chr2:10623274	chr2:10589166~10604830:+
BRCA	cis	rs1823913	0.637	rs12622194	ENSG00000227542.1	AC092614.2	-9.04	7.58e-19	3.3e-16	-0.32	-0.27	Obesity-related traits;	chr2:191298680	chr2:191229165~191246172:-
BRCA	cis	rs1823913	0.637	rs13019567	ENSG00000227542.1	AC092614.2	-9.04	7.58e-19	3.3e-16	-0.32	-0.27	Obesity-related traits;	chr2:191298736	chr2:191229165~191246172:-
BRCA	cis	rs4835473	0.868	rs56115009	ENSG00000251600.4	RP11-673E1.1	-9.04	7.58e-19	3.3e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143761073	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.9	rs10857406	ENSG00000251600.4	RP11-673E1.1	-9.04	7.58e-19	3.3e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143761216	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs10857407	ENSG00000251600.4	RP11-673E1.1	-9.04	7.58e-19	3.3e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143761226	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs10857408	ENSG00000251600.4	RP11-673E1.1	-9.04	7.58e-19	3.3e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143761333	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.9	rs10857409	ENSG00000251600.4	RP11-673E1.1	-9.04	7.58e-19	3.3e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143761461	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs10857410	ENSG00000251600.4	RP11-673E1.1	-9.04	7.58e-19	3.3e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143761566	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs10857411	ENSG00000251600.4	RP11-673E1.1	-9.04	7.58e-19	3.3e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143761599	chr4:143912331~143982454:+
BRCA	cis	rs5751614	0.537	rs11090228	ENSG00000230701.2	FBXW4P1	9.04	7.59e-19	3.31e-16	0.34	0.27	Height;	chr22:23289452	chr22:23262767~23265005:+
BRCA	cis	rs8012947	0.92	rs7154498	ENSG00000279636.2	LINC00216	-9.04	7.6e-19	3.31e-16	-0.29	-0.27	Alcohol consumption in current drinkers;	chr14:58295814	chr14:58288033~58289158:+
BRCA	cis	rs8012947	0.92	rs7155825	ENSG00000279636.2	LINC00216	-9.04	7.6e-19	3.31e-16	-0.29	-0.27	Alcohol consumption in current drinkers;	chr14:58295819	chr14:58288033~58289158:+
BRCA	cis	rs4660456	0.913	rs656230	ENSG00000237899.1	RP4-739H11.3	9.04	7.61e-19	3.31e-16	0.4	0.27	Platelet count;	chr1:40692701	chr1:40669089~40687588:-
BRCA	cis	rs9847710	0.733	rs11923593	ENSG00000242142.1	SERBP1P3	9.04	7.62e-19	3.32e-16	0.34	0.27	Ulcerative colitis;	chr3:53054774	chr3:53064283~53065091:-
BRCA	cis	rs7937890	0.559	rs2575831	ENSG00000251991.1	RNU7-49P	9.04	7.63e-19	3.32e-16	0.3	0.27	Mitochondrial DNA levels;	chr11:14464648	chr11:14478892~14478953:+
BRCA	cis	rs1823913	0.637	rs4853579	ENSG00000227542.1	AC092614.2	-9.04	7.64e-19	3.33e-16	-0.32	-0.27	Obesity-related traits;	chr2:191297413	chr2:191229165~191246172:-
BRCA	cis	rs5751614	0.537	rs2227939	ENSG00000230701.2	FBXW4P1	9.04	7.65e-19	3.33e-16	0.34	0.27	Height;	chr22:23289614	chr22:23262767~23265005:+
BRCA	cis	rs4835473	0.932	rs17762299	ENSG00000251600.4	RP11-673E1.1	-9.04	7.65e-19	3.33e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143777196	chr4:143912331~143982454:+
BRCA	cis	rs875971	0.522	rs1917563	ENSG00000164669.11	INTS4P1	9.04	7.67e-19	3.34e-16	0.33	0.27	Aortic root size;	chr7:65950660	chr7:65141225~65234216:+
BRCA	cis	rs925255	0.743	rs7600164	ENSG00000270210.1	RP11-373D23.3	9.04	7.69e-19	3.35e-16	0.34	0.27	Inflammatory bowel disease;Crohn's disease;	chr2:28421995	chr2:28425945~28426719:+
BRCA	cis	rs10759883	0.563	rs10819720	ENSG00000175611.10	LINC00476	9.04	7.72e-19	3.36e-16	0.31	0.27	Nicotine dependence;	chr9:96021506	chr9:95759231~95875977:-
BRCA	cis	rs7937890	0.559	rs2597201	ENSG00000251991.1	RNU7-49P	9.04	7.74e-19	3.37e-16	0.3	0.27	Mitochondrial DNA levels;	chr11:14463858	chr11:14478892~14478953:+
BRCA	cis	rs7937890	0.532	rs2575832	ENSG00000251991.1	RNU7-49P	9.04	7.74e-19	3.37e-16	0.3	0.27	Mitochondrial DNA levels;	chr11:14467264	chr11:14478892~14478953:+
BRCA	cis	rs7688540	0.74	rs28784663	ENSG00000211553.1	AC253576.2	-9.04	7.76e-19	3.38e-16	-0.36	-0.27	Facial morphology (factor 6, height of vermillion lower lip);	chr4:293257	chr4:136461~136568:+
BRCA	cis	rs55665837	0.54	rs10832299	ENSG00000251991.1	RNU7-49P	9.04	7.77e-19	3.38e-16	0.3	0.27	Vitamin D levels;	chr11:14747846	chr11:14478892~14478953:+
BRCA	cis	rs62355901	0.739	rs61055995	ENSG00000271828.1	CTD-2310F14.1	9.04	7.77e-19	3.38e-16	0.38	0.27	Breast cancer;	chr5:56723237	chr5:56927874~56929573:+
BRCA	cis	rs2067615	0.56	rs10431462	ENSG00000260329.1	RP11-412D9.4	-9.04	7.78e-19	3.39e-16	-0.29	-0.27	Heart rate;	chr12:106712768	chr12:106954029~106955497:-
BRCA	cis	rs875971	0.545	rs11767262	ENSG00000237310.1	GS1-124K5.4	9.03	7.79e-19	3.39e-16	0.32	0.27	Aortic root size;	chr7:66302237	chr7:66493706~66495474:+
BRCA	cis	rs10262624	1	rs17347733	ENSG00000234286.1	AC006026.13	-9.03	7.85e-19	3.42e-16	-0.31	-0.27	Schizophrenia;	chr7:23878891	chr7:23680195~23680786:-
BRCA	cis	rs1707322	1	rs11211232	ENSG00000280836.1	AL355480.1	-9.03	7.86e-19	3.42e-16	-0.35	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45945474	chr1:45581219~45581321:-
BRCA	cis	rs853679	0.882	rs4713139	ENSG00000220721.1	OR1F12	9.03	7.86e-19	3.42e-16	0.49	0.27	Depression;	chr6:28124907	chr6:28073316~28074233:+
BRCA	cis	rs7688540	0.8	rs12510827	ENSG00000211553.1	AC253576.2	-9.03	7.91e-19	3.44e-16	-0.35	-0.27	Facial morphology (factor 6, height of vermillion lower lip);	chr4:259015	chr4:136461~136568:+
BRCA	cis	rs3813579	0.654	rs4480821	ENSG00000261390.4	RP11-345M22.2	-9.03	7.91e-19	3.44e-16	-0.34	-0.27	Thyroid volume;	chr16:79711416	chr16:79715232~79770563:-
BRCA	cis	rs11098499	0.863	rs7664986	ENSG00000245958.5	RP11-33B1.1	-9.03	7.92e-19	3.45e-16	-0.27	-0.27	Corneal astigmatism;	chr4:119508797	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.818	rs10008791	ENSG00000245958.5	RP11-33B1.1	-9.03	7.92e-19	3.45e-16	-0.27	-0.27	Corneal astigmatism;	chr4:119510314	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.863	rs11736416	ENSG00000245958.5	RP11-33B1.1	-9.03	7.92e-19	3.45e-16	-0.27	-0.27	Corneal astigmatism;	chr4:119510506	chr4:119454791~119552025:+
BRCA	cis	rs1061377	1	rs2163272	ENSG00000249685.1	RP11-360F5.3	9.03	7.93e-19	3.45e-16	0.32	0.27	Uric acid levels;	chr4:39112790	chr4:39133913~39135608:+
BRCA	cis	rs72772090	0.539	rs72775807	ENSG00000248734.2	CTD-2260A17.1	-9.03	7.93e-19	3.45e-16	-0.44	-0.27	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96844058	chr5:96784777~96785999:+
BRCA	cis	rs2015599	0.549	rs7956305	ENSG00000275476.1	RP11-996F15.4	9.03	7.98e-19	3.47e-16	0.31	0.27	Platelet count;Mean platelet volume;	chr12:29308639	chr12:29277397~29277882:-
BRCA	cis	rs2439831	0.85	rs7174208	ENSG00000205771.5	CATSPER2P1	-9.03	7.98e-19	3.47e-16	-0.46	-0.27	Lung cancer in ever smokers;	chr15:43760484	chr15:43726918~43747094:-
BRCA	cis	rs2439831	0.85	rs12101756	ENSG00000205771.5	CATSPER2P1	-9.03	7.98e-19	3.47e-16	-0.46	-0.27	Lung cancer in ever smokers;	chr15:43761689	chr15:43726918~43747094:-
BRCA	cis	rs227275	0.525	rs7672319	ENSG00000246560.2	RP11-10L12.4	9.03	7.99e-19	3.47e-16	0.28	0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102990002	chr4:102828055~102844075:+
BRCA	cis	rs227275	0.525	rs6533051	ENSG00000246560.2	RP11-10L12.4	9.03	7.99e-19	3.47e-16	0.28	0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102990065	chr4:102828055~102844075:+
BRCA	cis	rs9807989	0.507	rs10200952	ENSG00000234389.1	AC007278.3	9.03	8e-19	3.48e-16	0.25	0.27	Asthma;	chr2:102411191	chr2:102438713~102440475:+
BRCA	cis	rs2439831	0.85	rs16977798	ENSG00000249839.1	AC011330.5	-9.03	8.01e-19	3.48e-16	-0.44	-0.27	Lung cancer in ever smokers;	chr15:43859750	chr15:43663654~43684339:-
BRCA	cis	rs7712401	0.601	rs30022	ENSG00000263432.2	RN7SL689P	9.03	8.03e-19	3.49e-16	0.34	0.27	Mean platelet volume;	chr5:122950021	chr5:123022487~123022783:-
BRCA	cis	rs7712401	0.546	rs30021	ENSG00000263432.2	RN7SL689P	9.03	8.03e-19	3.49e-16	0.34	0.27	Mean platelet volume;	chr5:122950199	chr5:123022487~123022783:-
BRCA	cis	rs7712401	0.601	rs246328	ENSG00000263432.2	RN7SL689P	9.03	8.03e-19	3.49e-16	0.34	0.27	Mean platelet volume;	chr5:122951933	chr5:123022487~123022783:-
BRCA	cis	rs4718428	0.705	rs12698547	ENSG00000232546.1	RP11-458F8.1	-9.03	8.07e-19	3.51e-16	-0.25	-0.27	Corneal structure;	chr7:66813271	chr7:66848496~66858136:+
BRCA	cis	rs7120173	1	rs7120173	ENSG00000254851.1	RP11-109L13.1	9.03	8.07e-19	3.51e-16	0.41	0.27	Visceral adipose tissue adjusted for BMI;	chr11:116958937	chr11:117135528~117138582:+
BRCA	cis	rs9807989	0.507	rs10203558	ENSG00000234389.1	AC007278.3	9.03	8.09e-19	3.51e-16	0.25	0.27	Asthma;	chr2:102411180	chr2:102438713~102440475:+
BRCA	cis	rs875971	0.522	rs2008188	ENSG00000164669.11	INTS4P1	-9.03	8.13e-19	3.53e-16	-0.33	-0.27	Aortic root size;	chr7:65964026	chr7:65141225~65234216:+
BRCA	cis	rs11098499	1	rs13435802	ENSG00000245958.5	RP11-33B1.1	9.03	8.15e-19	3.54e-16	0.27	0.27	Corneal astigmatism;	chr4:119256805	chr4:119454791~119552025:+
BRCA	cis	rs2439831	0.85	rs28595038	ENSG00000205771.5	CATSPER2P1	-9.03	8.16e-19	3.55e-16	-0.47	-0.27	Lung cancer in ever smokers;	chr15:43752661	chr15:43726918~43747094:-
BRCA	cis	rs11722779	0.933	rs7695096	ENSG00000246560.2	RP11-10L12.4	9.03	8.22e-19	3.57e-16	0.29	0.27	Schizophrenia;	chr4:103011399	chr4:102828055~102844075:+
BRCA	cis	rs875971	0.789	rs28815324	ENSG00000237310.1	GS1-124K5.4	-9.03	8.23e-19	3.57e-16	-0.32	-0.27	Aortic root size;	chr7:66100789	chr7:66493706~66495474:+
BRCA	cis	rs58873874	0.737	rs11745566	ENSG00000251405.2	CTB-109A12.1	9.03	8.23e-19	3.58e-16	0.68	0.27	Bipolar disorder (body mass index interaction);	chr5:157464945	chr5:157362615~157460078:-
BRCA	cis	rs2041895	0.527	rs10861678	ENSG00000260329.1	RP11-412D9.4	-9.03	8.24e-19	3.58e-16	-0.34	-0.27	Glaucoma (low intraocular pressure);	chr12:106925883	chr12:106954029~106955497:-
BRCA	cis	rs113835537	0.559	rs74933537	ENSG00000255517.5	CTD-3074O7.5	-9.03	8.27e-19	3.59e-16	-0.35	-0.27	Airway imaging phenotypes;	chr11:66507487	chr11:66473490~66480233:-
BRCA	cis	rs7772486	0.902	rs2144476	ENSG00000235652.6	RP11-545I5.3	9.03	8.28e-19	3.59e-16	0.27	0.27	Lobe attachment (rater-scored or self-reported);	chr6:146001348	chr6:145799409~145886585:+
BRCA	cis	rs875971	0.522	rs10807697	ENSG00000164669.11	INTS4P1	-9.03	8.28e-19	3.6e-16	-0.33	-0.27	Aortic root size;	chr7:65951183	chr7:65141225~65234216:+
BRCA	cis	rs7945705	0.902	rs2016942	ENSG00000254860.4	TMEM9B-AS1	-9.03	8.29e-19	3.6e-16	-0.26	-0.27	Hemoglobin concentration;	chr11:8917240	chr11:8964675~8977527:+
BRCA	cis	rs783540	0.867	rs7167880	ENSG00000278603.1	RP13-608F4.5	-9.03	8.3e-19	3.6e-16	-0.34	-0.27	Schizophrenia;	chr15:82625685	chr15:82472203~82472426:+
BRCA	cis	rs1707322	1	rs12124847	ENSG00000280836.1	AL355480.1	-9.03	8.33e-19	3.62e-16	-0.35	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45915178	chr1:45581219~45581321:-
BRCA	cis	rs1134634	0.52	rs2160044	ENSG00000273133.1	RP11-799M12.2	-9.03	8.34e-19	3.62e-16	-0.36	-0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15556720	chr4:15563698~15564253:-
BRCA	cis	rs748404	0.666	rs72709850	ENSG00000249839.1	AC011330.5	-9.03	8.36e-19	3.63e-16	-0.39	-0.27	Lung cancer;	chr15:43462486	chr15:43663654~43684339:-
BRCA	cis	rs7937890	0.559	rs2575853	ENSG00000251991.1	RNU7-49P	9.03	8.36e-19	3.63e-16	0.3	0.27	Mitochondrial DNA levels;	chr11:14512417	chr11:14478892~14478953:+
BRCA	cis	rs4835473	0.932	rs1993015	ENSG00000251600.4	RP11-673E1.1	-9.03	8.38e-19	3.63e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143760202	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.9	rs1993016	ENSG00000251600.4	RP11-673E1.1	-9.03	8.38e-19	3.63e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143760217	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs1993017	ENSG00000251600.4	RP11-673E1.1	-9.03	8.38e-19	3.63e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143760285	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.9	rs1375983	ENSG00000251600.4	RP11-673E1.1	-9.03	8.38e-19	3.63e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143760423	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs1375984	ENSG00000251600.4	RP11-673E1.1	-9.03	8.38e-19	3.63e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143760510	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs1375985	ENSG00000251600.4	RP11-673E1.1	-9.03	8.38e-19	3.63e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143760556	chr4:143912331~143982454:+
BRCA	cis	rs11098499	0.954	rs11722872	ENSG00000245958.5	RP11-33B1.1	-9.03	8.39e-19	3.64e-16	-0.27	-0.27	Corneal astigmatism;	chr4:119311875	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.754	rs12510269	ENSG00000248280.1	RP11-33B1.2	9.03	8.4e-19	3.64e-16	0.26	0.27	Corneal astigmatism;	chr4:119320491	chr4:119440561~119450157:-
BRCA	cis	rs227275	0.556	rs3886723	ENSG00000246560.2	RP11-10L12.4	9.03	8.45e-19	3.66e-16	0.28	0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102983013	chr4:102828055~102844075:+
BRCA	cis	rs4835473	0.9	rs5015758	ENSG00000251600.4	RP11-673E1.1	-9.03	8.45e-19	3.67e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143738052	chr4:143912331~143982454:+
BRCA	cis	rs11971779	0.68	rs11768023	ENSG00000273391.1	RP11-634H22.1	9.03	8.45e-19	3.67e-16	0.26	0.27	Diisocyanate-induced asthma;	chr7:139369649	chr7:139359032~139359566:-
BRCA	cis	rs12701220	0.655	rs10241018	ENSG00000229043.2	AC091729.9	-9.03	8.47e-19	3.67e-16	-0.38	-0.27	Bronchopulmonary dysplasia;	chr7:1105138	chr7:1160374~1165267:+
BRCA	cis	rs748404	0.666	rs35158584	ENSG00000249839.1	AC011330.5	-9.02	8.49e-19	3.69e-16	-0.39	-0.27	Lung cancer;	chr15:43392876	chr15:43663654~43684339:-
BRCA	cis	rs12458462	0.851	rs3859317	ENSG00000274828.1	RP11-567M16.6	9.02	8.51e-19	3.69e-16	0.31	0.27	Monocyte count;	chr18:79683093	chr18:79677287~79679358:-
BRCA	cis	rs12468226	0.938	rs80282360	ENSG00000273456.1	RP11-686O6.2	9.02	8.53e-19	3.7e-16	0.41	0.27	Urate levels;	chr2:202275121	chr2:202374932~202375604:-
BRCA	cis	rs7945705	0.935	rs2653593	ENSG00000254860.4	TMEM9B-AS1	9.02	8.55e-19	3.71e-16	0.24	0.27	Hemoglobin concentration;	chr11:8855770	chr11:8964675~8977527:+
BRCA	cis	rs950169	0.579	rs12913054	ENSG00000225151.9	GOLGA2P7	-9.02	8.56e-19	3.71e-16	-0.39	-0.27	Schizophrenia;	chr15:83995704	chr15:84199311~84230136:-
BRCA	cis	rs11098499	0.954	rs10008459	ENSG00000248280.1	RP11-33B1.2	9.02	8.57e-19	3.71e-16	0.28	0.27	Corneal astigmatism;	chr4:119473076	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.863	rs3775845	ENSG00000245958.5	RP11-33B1.1	-9.02	8.57e-19	3.72e-16	-0.27	-0.27	Corneal astigmatism;	chr4:119511292	chr4:119454791~119552025:+
BRCA	cis	rs12468226	0.938	rs12463937	ENSG00000273456.1	RP11-686O6.2	9.02	8.58e-19	3.72e-16	0.4	0.27	Urate levels;	chr2:202246543	chr2:202374932~202375604:-
BRCA	cis	rs227275	0.554	rs9307281	ENSG00000246560.2	RP11-10L12.4	9.02	8.58e-19	3.72e-16	0.28	0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102934971	chr4:102828055~102844075:+
BRCA	cis	rs11722779	0.903	rs6533037	ENSG00000246560.2	RP11-10L12.4	9.02	8.58e-19	3.72e-16	0.28	0.27	Schizophrenia;	chr4:102935865	chr4:102828055~102844075:+
BRCA	cis	rs11722779	0.903	rs4530634	ENSG00000246560.2	RP11-10L12.4	9.02	8.58e-19	3.72e-16	0.28	0.27	Schizophrenia;	chr4:102937924	chr4:102828055~102844075:+
BRCA	cis	rs227275	0.525	rs7676943	ENSG00000246560.2	RP11-10L12.4	9.02	8.58e-19	3.72e-16	0.28	0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102938135	chr4:102828055~102844075:+
BRCA	cis	rs227275	0.525	rs6419160	ENSG00000246560.2	RP11-10L12.4	9.02	8.58e-19	3.72e-16	0.28	0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102938648	chr4:102828055~102844075:+
BRCA	cis	rs11722779	0.838	rs3974494	ENSG00000246560.2	RP11-10L12.4	9.02	8.58e-19	3.72e-16	0.28	0.27	Schizophrenia;	chr4:102945323	chr4:102828055~102844075:+
BRCA	cis	rs11673344	0.864	rs56208574	ENSG00000226686.6	LINC01535	9.02	8.59e-19	3.72e-16	0.35	0.27	Obesity-related traits;	chr19:37007843	chr19:37251912~37265535:+
BRCA	cis	rs2067615	0.599	rs10778508	ENSG00000260329.1	RP11-412D9.4	9.02	8.6e-19	3.73e-16	0.29	0.27	Heart rate;	chr12:106765627	chr12:106954029~106955497:-
BRCA	cis	rs11098499	0.954	rs6834796	ENSG00000248280.1	RP11-33B1.2	9.02	8.62e-19	3.73e-16	0.28	0.27	Corneal astigmatism;	chr4:119493538	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.954	rs11734241	ENSG00000248280.1	RP11-33B1.2	9.02	8.62e-19	3.73e-16	0.28	0.27	Corneal astigmatism;	chr4:119495717	chr4:119440561~119450157:-
BRCA	cis	rs4660456	0.913	rs6661855	ENSG00000237899.1	RP4-739H11.3	9.02	8.62e-19	3.74e-16	0.4	0.27	Platelet count;	chr1:40703245	chr1:40669089~40687588:-
BRCA	cis	rs11098499	0.954	rs6857105	ENSG00000248280.1	RP11-33B1.2	9.02	8.62e-19	3.74e-16	0.28	0.27	Corneal astigmatism;	chr4:119301143	chr4:119440561~119450157:-
BRCA	cis	rs2274273	0.87	rs59629906	ENSG00000258413.1	RP11-665C16.6	-9.02	8.67e-19	3.76e-16	-0.34	-0.27	Protein biomarker;	chr14:55314471	chr14:55262767~55272075:-
BRCA	cis	rs2015599	0.543	rs6487807	ENSG00000275476.1	RP11-996F15.4	9.02	8.69e-19	3.76e-16	0.31	0.27	Platelet count;Mean platelet volume;	chr12:29309291	chr12:29277397~29277882:-
BRCA	cis	rs6142102	0.58	rs6142101	ENSG00000275784.1	RP5-1125A11.6	-9.02	8.69e-19	3.76e-16	-0.31	-0.27	Skin pigmentation;	chr20:34110039	chr20:33989480~33991818:-
BRCA	cis	rs67981189	0.542	rs17109053	ENSG00000269927.1	RP6-91H8.3	9.02	8.69e-19	3.77e-16	0.36	0.27	Schizophrenia;	chr14:71142981	chr14:71141125~71143253:-
BRCA	cis	rs875971	0.545	rs316305	ENSG00000237310.1	GS1-124K5.4	-9.02	8.72e-19	3.78e-16	-0.31	-0.27	Aortic root size;	chr7:66152984	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.505	rs1167386	ENSG00000222364.1	RNU6-96P	9.02	8.72e-19	3.78e-16	0.31	0.27	Aortic root size;	chr7:66048109	chr7:66395191~66395286:+
BRCA	cis	rs227275	0.525	rs7688940	ENSG00000246560.2	RP11-10L12.4	9.02	8.75e-19	3.79e-16	0.28	0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102994153	chr4:102828055~102844075:+
BRCA	cis	rs227275	0.556	rs6821173	ENSG00000246560.2	RP11-10L12.4	9.02	8.76e-19	3.79e-16	0.28	0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102966404	chr4:102828055~102844075:+
BRCA	cis	rs1061377	1	rs7673299	ENSG00000249685.1	RP11-360F5.3	9.02	8.77e-19	3.8e-16	0.33	0.27	Uric acid levels;	chr4:39109138	chr4:39133913~39135608:+
BRCA	cis	rs1823913	0.614	rs4853576	ENSG00000227542.1	AC092614.2	-9.02	8.79e-19	3.81e-16	-0.32	-0.27	Obesity-related traits;	chr2:191296618	chr2:191229165~191246172:-
BRCA	cis	rs11098499	0.663	rs9996501	ENSG00000248280.1	RP11-33B1.2	9.02	8.8e-19	3.81e-16	0.27	0.27	Corneal astigmatism;	chr4:119317763	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.697	rs28458294	ENSG00000248280.1	RP11-33B1.2	9.02	8.8e-19	3.81e-16	0.27	0.27	Corneal astigmatism;	chr4:119317769	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.663	rs28369503	ENSG00000248280.1	RP11-33B1.2	9.02	8.8e-19	3.81e-16	0.27	0.27	Corneal astigmatism;	chr4:119317770	chr4:119440561~119450157:-
BRCA	cis	rs4660456	0.913	rs2361650	ENSG00000237899.1	RP4-739H11.3	-9.02	8.8e-19	3.81e-16	-0.4	-0.27	Platelet count;	chr1:40764678	chr1:40669089~40687588:-
BRCA	cis	rs7772486	0.902	rs2748500	ENSG00000235652.6	RP11-545I5.3	9.02	8.8e-19	3.81e-16	0.26	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145993716	chr6:145799409~145886585:+
BRCA	cis	rs1707322	1	rs785490	ENSG00000280836.1	AL355480.1	9.02	8.83e-19	3.82e-16	0.36	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46111452	chr1:45581219~45581321:-
BRCA	cis	rs66887589	0.72	rs2036858	ENSG00000248280.1	RP11-33B1.2	9.02	8.84e-19	3.83e-16	0.25	0.27	Diastolic blood pressure;	chr4:119328082	chr4:119440561~119450157:-
BRCA	cis	rs116175783	0.557	rs16845844	ENSG00000227403.1	AC009299.3	-9.02	8.88e-19	3.84e-16	-0.47	-0.27	Intelligence (multi-trait analysis);	chr2:161408759	chr2:161244739~161249050:+
BRCA	cis	rs4835473	0.932	rs34886773	ENSG00000251600.4	RP11-673E1.1	-9.02	8.88e-19	3.85e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143764678	chr4:143912331~143982454:+
BRCA	cis	rs321358	0.731	rs17460676	ENSG00000271584.1	RP11-89C3.4	9.02	8.94e-19	3.87e-16	0.42	0.27	Body mass index;	chr11:111166625	chr11:111091932~111097357:-
BRCA	cis	rs6782228	1	rs6801509	ENSG00000242551.2	POU5F1P6	9.02	8.96e-19	3.88e-16	0.4	0.27	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128645426	chr3:128674735~128677005:-
BRCA	cis	rs11098499	0.954	rs7436506	ENSG00000248280.1	RP11-33B1.2	9.02	8.98e-19	3.89e-16	0.28	0.27	Corneal astigmatism;	chr4:119472614	chr4:119440561~119450157:-
BRCA	cis	rs748404	0.666	rs16957680	ENSG00000249839.1	AC011330.5	-9.02	8.98e-19	3.89e-16	-0.39	-0.27	Lung cancer;	chr15:43396207	chr15:43663654~43684339:-
BRCA	cis	rs7937890	0.559	rs4369365	ENSG00000251991.1	RNU7-49P	9.02	8.99e-19	3.89e-16	0.3	0.27	Mitochondrial DNA levels;	chr11:14422969	chr11:14478892~14478953:+
BRCA	cis	rs6142102	0.602	rs10485503	ENSG00000275784.1	RP5-1125A11.6	-9.02	9e-19	3.9e-16	-0.31	-0.27	Skin pigmentation;	chr20:33970036	chr20:33989480~33991818:-
BRCA	cis	rs2067615	0.579	rs10861655	ENSG00000260329.1	RP11-412D9.4	9.02	9.01e-19	3.9e-16	0.29	0.27	Heart rate;	chr12:106735641	chr12:106954029~106955497:-
BRCA	cis	rs58873874	0.737	rs78832945	ENSG00000251405.2	CTB-109A12.1	9.02	9.02e-19	3.9e-16	0.66	0.27	Bipolar disorder (body mass index interaction);	chr5:157475805	chr5:157362615~157460078:-
BRCA	cis	rs7772486	0.623	rs9485021	ENSG00000235652.6	RP11-545I5.3	-9.02	9.02e-19	3.9e-16	-0.27	-0.27	Lobe attachment (rater-scored or self-reported);	chr6:145747661	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.654	rs6928007	ENSG00000235652.6	RP11-545I5.3	-9.02	9.02e-19	3.9e-16	-0.27	-0.27	Lobe attachment (rater-scored or self-reported);	chr6:145753805	chr6:145799409~145886585:+
BRCA	cis	rs2274273	0.805	rs28612464	ENSG00000258413.1	RP11-665C16.6	-9.02	9.05e-19	3.91e-16	-0.34	-0.27	Protein biomarker;	chr14:55349693	chr14:55262767~55272075:-
BRCA	cis	rs2274273	0.773	rs28430823	ENSG00000258413.1	RP11-665C16.6	-9.02	9.05e-19	3.91e-16	-0.34	-0.27	Protein biomarker;	chr14:55349842	chr14:55262767~55272075:-
BRCA	cis	rs2274273	0.87	rs17741831	ENSG00000258413.1	RP11-665C16.6	-9.02	9.05e-19	3.91e-16	-0.34	-0.27	Protein biomarker;	chr14:55349997	chr14:55262767~55272075:-
BRCA	cis	rs4862750	0.957	rs2375916	ENSG00000250971.1	RP11-696F12.1	9.02	9.05e-19	3.91e-16	0.28	0.27	Lobe attachment (rater-scored or self-reported);	chr4:186982769	chr4:187060099~187060930:+
BRCA	cis	rs6683071	0.54	rs1391558	ENSG00000272750.1	RP11-378J18.8	9.02	9.07e-19	3.92e-16	0.42	0.27	Cognitive performance;	chr1:222674687	chr1:222658867~222661512:-
BRCA	cis	rs4988958	0.565	rs1035125	ENSG00000234389.1	AC007278.3	9.02	9.07e-19	3.92e-16	0.25	0.27	Asthma (childhood onset);	chr2:102417379	chr2:102438713~102440475:+
BRCA	cis	rs9287719	0.81	rs7601748	ENSG00000234818.1	AC092687.5	9.02	9.08e-19	3.93e-16	0.31	0.27	Prostate cancer;	chr2:10645320	chr2:10589166~10604830:+
BRCA	cis	rs4718428	0.705	rs68168107	ENSG00000232546.1	RP11-458F8.1	-9.02	9.09e-19	3.93e-16	-0.25	-0.27	Corneal structure;	chr7:66790251	chr7:66848496~66858136:+
BRCA	cis	rs227275	0.525	rs11737544	ENSG00000246560.2	RP11-10L12.4	9.02	9.13e-19	3.95e-16	0.28	0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102983877	chr4:102828055~102844075:+
BRCA	cis	rs1707322	1	rs785507	ENSG00000280836.1	AL355480.1	9.02	9.13e-19	3.95e-16	0.35	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46075886	chr1:45581219~45581321:-
BRCA	cis	rs9807989	0.507	rs1592458	ENSG00000234389.1	AC007278.3	9.02	9.14e-19	3.95e-16	0.25	0.27	Asthma;	chr2:102415289	chr2:102438713~102440475:+
BRCA	cis	rs2933343	1	rs789227	ENSG00000261159.1	RP11-723O4.9	9.02	9.15e-19	3.96e-16	0.32	0.27	IgG glycosylation;	chr3:128881742	chr3:128859716~128860526:-
BRCA	cis	rs1061377	1	rs35116118	ENSG00000249685.1	RP11-360F5.3	9.02	9.16e-19	3.96e-16	0.33	0.27	Uric acid levels;	chr4:39127293	chr4:39133913~39135608:+
BRCA	cis	rs11098499	0.863	rs7699064	ENSG00000245958.5	RP11-33B1.1	9.02	9.18e-19	3.97e-16	0.27	0.27	Corneal astigmatism;	chr4:119507154	chr4:119454791~119552025:+
BRCA	cis	rs4835473	0.9	rs58106929	ENSG00000251600.4	RP11-673E1.1	9.02	9.19e-19	3.97e-16	0.31	0.27	Immature fraction of reticulocytes;	chr4:143733166	chr4:143912331~143982454:+
BRCA	cis	rs2933343	1	rs789213	ENSG00000231305.3	RP11-723O4.2	-9.02	9.2e-19	3.98e-16	-0.33	-0.27	IgG glycosylation;	chr3:128897516	chr3:128861313~128871540:-
BRCA	cis	rs367615	0.731	rs58241713	ENSG00000249476.1	CTD-2587M2.1	9.02	9.2e-19	3.98e-16	0.3	0.27	Colorectal cancer (SNP x SNP interaction);	chr5:109517963	chr5:109237120~109326369:-
BRCA	cis	rs8012947	1	rs7154212	ENSG00000279636.2	LINC00216	-9.01	9.22e-19	3.99e-16	-0.29	-0.27	Alcohol consumption in current drinkers;	chr14:58295491	chr14:58288033~58289158:+
BRCA	cis	rs5751614	0.537	rs9608100	ENSG00000230701.2	FBXW4P1	9.01	9.24e-19	3.99e-16	0.34	0.27	Height;	chr22:23290070	chr22:23262767~23265005:+
BRCA	cis	rs2280018	0.526	rs2966129	ENSG00000188599.16	NPIPP1	9.01	9.24e-19	4e-16	0.24	0.27	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15059070	chr16:15104312~15123498:-
BRCA	cis	rs4660456	0.913	rs16827552	ENSG00000237899.1	RP4-739H11.3	-9.01	9.26e-19	4e-16	-0.4	-0.27	Platelet count;	chr1:40758336	chr1:40669089~40687588:-
BRCA	cis	rs748404	0.666	rs36078097	ENSG00000249839.1	AC011330.5	-9.01	9.26e-19	4e-16	-0.39	-0.27	Lung cancer;	chr15:43466209	chr15:43663654~43684339:-
BRCA	cis	rs748404	0.666	rs7181783	ENSG00000249839.1	AC011330.5	-9.01	9.26e-19	4e-16	-0.39	-0.27	Lung cancer;	chr15:43469723	chr15:43663654~43684339:-
BRCA	cis	rs748404	0.666	rs35903301	ENSG00000249839.1	AC011330.5	-9.01	9.26e-19	4e-16	-0.39	-0.27	Lung cancer;	chr15:43472332	chr15:43663654~43684339:-
BRCA	cis	rs748404	0.666	rs34002293	ENSG00000249839.1	AC011330.5	-9.01	9.26e-19	4e-16	-0.39	-0.27	Lung cancer;	chr15:43472401	chr15:43663654~43684339:-
BRCA	cis	rs748404	0.666	rs34181131	ENSG00000249839.1	AC011330.5	-9.01	9.26e-19	4e-16	-0.39	-0.27	Lung cancer;	chr15:43478527	chr15:43663654~43684339:-
BRCA	cis	rs748404	0.666	rs7173383	ENSG00000249839.1	AC011330.5	-9.01	9.26e-19	4e-16	-0.39	-0.27	Lung cancer;	chr15:43480838	chr15:43663654~43684339:-
BRCA	cis	rs748404	0.666	rs55801120	ENSG00000249839.1	AC011330.5	-9.01	9.26e-19	4e-16	-0.39	-0.27	Lung cancer;	chr15:43495042	chr15:43663654~43684339:-
BRCA	cis	rs748404	0.666	rs12911740	ENSG00000249839.1	AC011330.5	-9.01	9.26e-19	4e-16	-0.39	-0.27	Lung cancer;	chr15:43498254	chr15:43663654~43684339:-
BRCA	cis	rs881375	0.967	rs1014529	ENSG00000226752.6	PSMD5-AS1	-9.01	9.28e-19	4.01e-16	-0.32	-0.27	Rheumatoid arthritis;	chr9:120922665	chr9:120824828~120854385:+
BRCA	cis	rs55665837	0.502	rs12795794	ENSG00000251991.1	RNU7-49P	9.01	9.29e-19	4.01e-16	0.31	0.27	Vitamin D levels;	chr11:14825327	chr11:14478892~14478953:+
BRCA	cis	rs1134634	0.52	rs7661102	ENSG00000273133.1	RP11-799M12.2	-9.01	9.32e-19	4.03e-16	-0.35	-0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15596914	chr4:15563698~15564253:-
BRCA	cis	rs55665837	0.52	rs10766189	ENSG00000251991.1	RNU7-49P	9.01	9.35e-19	4.04e-16	0.3	0.27	Vitamin D levels;	chr11:14712377	chr11:14478892~14478953:+
BRCA	cis	rs11673344	0.864	rs7256213	ENSG00000226686.6	LINC01535	9.01	9.35e-19	4.04e-16	0.35	0.27	Obesity-related traits;	chr19:37020589	chr19:37251912~37265535:+
BRCA	cis	rs2439831	0.85	rs12441984	ENSG00000249839.1	AC011330.5	-9.01	9.36e-19	4.04e-16	-0.46	-0.27	Lung cancer in ever smokers;	chr15:43834087	chr15:43663654~43684339:-
BRCA	cis	rs11098499	0.722	rs1814814	ENSG00000245958.5	RP11-33B1.1	-9.01	9.37e-19	4.05e-16	-0.25	-0.27	Corneal astigmatism;	chr4:119336969	chr4:119454791~119552025:+
BRCA	cis	rs1134634	0.52	rs56041141	ENSG00000273133.1	RP11-799M12.2	-9.01	9.39e-19	4.06e-16	-0.35	-0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15598222	chr4:15563698~15564253:-
BRCA	cis	rs7772486	0.686	rs9497395	ENSG00000235652.6	RP11-545I5.3	-9.01	9.4e-19	4.06e-16	-0.27	-0.27	Lobe attachment (rater-scored or self-reported);	chr6:145692456	chr6:145799409~145886585:+
BRCA	cis	rs5751614	0.537	rs5759681	ENSG00000230701.2	FBXW4P1	-9.01	9.41e-19	4.06e-16	-0.34	-0.27	Height;	chr22:23287365	chr22:23262767~23265005:+
BRCA	cis	rs8396	1	rs9410	ENSG00000271817.2	U3	9.01	9.43e-19	4.07e-16	0.3	0.27	Blood metabolite levels;Blood protein levels;Acylcarnitine levels;Metabolite levels;Metabolic traits;	chr4:158710839	chr4:158700691~158700909:+
BRCA	cis	rs7937890	0.559	rs2597188	ENSG00000251991.1	RNU7-49P	9.01	9.44e-19	4.07e-16	0.3	0.27	Mitochondrial DNA levels;	chr11:14495360	chr11:14478892~14478953:+
BRCA	cis	rs7937890	0.559	rs2597187	ENSG00000251991.1	RNU7-49P	9.01	9.44e-19	4.07e-16	0.3	0.27	Mitochondrial DNA levels;	chr11:14495473	chr11:14478892~14478953:+
BRCA	cis	rs9318086	0.935	rs9652081	ENSG00000205861.10	C1QTNF9B-AS1	9.01	9.45e-19	4.08e-16	0.34	0.27	Myopia (pathological);	chr13:23861371	chr13:23888889~23897263:+
BRCA	cis	rs875971	0.522	rs6960048	ENSG00000164669.11	INTS4P1	-9.01	9.45e-19	4.08e-16	-0.33	-0.27	Aortic root size;	chr7:65943052	chr7:65141225~65234216:+
BRCA	cis	rs17711722	0.74	rs7809991	ENSG00000164669.11	INTS4P1	-9.01	9.48e-19	4.09e-16	-0.33	-0.27	Calcium levels;	chr7:65941231	chr7:65141225~65234216:+
BRCA	cis	rs8177376	0.727	rs240555	ENSG00000254905.1	RP11-712L6.7	9.01	9.48e-19	4.09e-16	0.35	0.27	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126332190	chr11:126292922~126294254:-
BRCA	cis	rs875971	0.505	rs2462573	ENSG00000222364.1	RNU6-96P	9.01	9.53e-19	4.12e-16	0.31	0.27	Aortic root size;	chr7:66042405	chr7:66395191~66395286:+
BRCA	cis	rs7772486	0.686	rs1337841	ENSG00000235652.6	RP11-545I5.3	-9.01	9.56e-19	4.12e-16	-0.27	-0.27	Lobe attachment (rater-scored or self-reported);	chr6:145738351	chr6:145799409~145886585:+
BRCA	cis	rs875971	0.505	rs1167385	ENSG00000222364.1	RNU6-96P	9.01	9.58e-19	4.13e-16	0.31	0.27	Aortic root size;	chr7:66048321	chr7:66395191~66395286:+
BRCA	cis	rs6142102	0.58	rs761233	ENSG00000275784.1	RP5-1125A11.6	-9.01	9.59e-19	4.14e-16	-0.31	-0.27	Skin pigmentation;	chr20:33981080	chr20:33989480~33991818:-
BRCA	cis	rs7937890	0.559	rs2034480	ENSG00000251991.1	RNU7-49P	9.01	9.62e-19	4.15e-16	0.3	0.27	Mitochondrial DNA levels;	chr11:14445377	chr11:14478892~14478953:+
BRCA	cis	rs6142102	0.602	rs4911395	ENSG00000275784.1	RP5-1125A11.6	-9.01	9.65e-19	4.16e-16	-0.31	-0.27	Skin pigmentation;	chr20:33992095	chr20:33989480~33991818:-
BRCA	cis	rs801193	1	rs2659915	ENSG00000222364.1	RNU6-96P	-9.01	9.67e-19	4.17e-16	-0.31	-0.27	Aortic root size;	chr7:66688114	chr7:66395191~66395286:+
BRCA	cis	rs12682352	0.652	rs1567398	ENSG00000253893.2	FAM85B	9.01	9.69e-19	4.18e-16	0.33	0.27	Neuroticism;	chr8:8869294	chr8:8167819~8226614:-
BRCA	cis	rs748404	0.626	rs62021176	ENSG00000249839.1	AC011330.5	-9.01	9.7e-19	4.19e-16	-0.39	-0.27	Lung cancer;	chr15:43388014	chr15:43663654~43684339:-
BRCA	cis	rs748404	0.666	rs7180812	ENSG00000249839.1	AC011330.5	-9.01	9.71e-19	4.19e-16	-0.39	-0.27	Lung cancer;	chr15:43403033	chr15:43663654~43684339:-
BRCA	cis	rs4835473	0.9	rs7689374	ENSG00000251600.4	RP11-673E1.1	-9.01	9.73e-19	4.2e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143769567	chr4:143912331~143982454:+
BRCA	cis	rs4718428	0.607	rs66954441	ENSG00000232546.1	RP11-458F8.1	-9.01	9.76e-19	4.21e-16	-0.25	-0.27	Corneal structure;	chr7:66904222	chr7:66848496~66858136:+
BRCA	cis	rs8396	1	rs9918016	ENSG00000271817.2	U3	9.01	9.79e-19	4.22e-16	0.3	0.27	Blood metabolite levels;Blood protein levels;Acylcarnitine levels;Metabolite levels;Metabolic traits;	chr4:158700845	chr4:158700691~158700909:+
BRCA	cis	rs1900504	0.584	rs3010501	ENSG00000266200.5	PNLIPRP2	-9.01	9.82e-19	4.23e-16	-0.34	-0.27	Tonsillectomy;	chr10:116604130	chr10:116620953~116645143:+
BRCA	cis	rs4660456	0.826	rs2744802	ENSG00000237899.1	RP4-739H11.3	9.01	9.84e-19	4.24e-16	0.4	0.27	Platelet count;	chr1:40687577	chr1:40669089~40687588:-
BRCA	cis	rs1707322	1	rs4660335	ENSG00000280836.1	AL355480.1	-9.01	9.87e-19	4.26e-16	-0.35	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46009046	chr1:45581219~45581321:-
BRCA	cis	rs2274273	0.87	rs67514154	ENSG00000258413.1	RP11-665C16.6	-9.01	9.89e-19	4.26e-16	-0.34	-0.27	Protein biomarker;	chr14:55300664	chr14:55262767~55272075:-
BRCA	cis	rs11098499	0.691	rs9996644	ENSG00000248280.1	RP11-33B1.2	9.01	9.93e-19	4.28e-16	0.27	0.27	Corneal astigmatism;	chr4:119317722	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.691	rs9996494	ENSG00000248280.1	RP11-33B1.2	9.01	9.93e-19	4.28e-16	0.27	0.27	Corneal astigmatism;	chr4:119317725	chr4:119440561~119450157:-
BRCA	cis	rs9640161	0.659	rs7806429	ENSG00000261305.1	RP4-584D14.7	9.01	9.95e-19	4.29e-16	0.38	0.27	Blood protein levels;Circulating chemerin levels;	chr7:150316304	chr7:150341771~150342607:+
BRCA	cis	rs11098499	0.954	rs7681544	ENSG00000248280.1	RP11-33B1.2	9.01	9.96e-19	4.29e-16	0.28	0.27	Corneal astigmatism;	chr4:119490100	chr4:119440561~119450157:-
BRCA	cis	rs7580658	0.929	rs4150496	ENSG00000236682.1	AC068282.3	-9.01	9.96e-19	4.29e-16	-0.36	-0.27	Protein C levels;	chr2:127271927	chr2:127389130~127400580:+
BRCA	cis	rs957448	1	rs72674855	ENSG00000253704.1	RP11-267M23.4	9.01	9.97e-19	4.3e-16	0.3	0.27	Nonsyndromic cleft lip with cleft palate;	chr8:94536706	chr8:94553722~94569745:+
BRCA	cis	rs2933343	1	rs1683811	ENSG00000261159.1	RP11-723O4.9	9.01	9.98e-19	4.3e-16	0.32	0.27	IgG glycosylation;	chr3:128893270	chr3:128859716~128860526:-
BRCA	cis	rs2439831	0.85	rs10438303	ENSG00000205771.5	CATSPER2P1	-9.01	9.99e-19	4.31e-16	-0.47	-0.27	Lung cancer in ever smokers;	chr15:43724219	chr15:43726918~43747094:-
BRCA	cis	rs11098499	0.754	rs2036860	ENSG00000248280.1	RP11-33B1.2	9.01	1e-18	4.31e-16	0.27	0.27	Corneal astigmatism;	chr4:119327779	chr4:119440561~119450157:-
BRCA	cis	rs7580658	0.929	rs11886231	ENSG00000236682.1	AC068282.3	-9.01	1e-18	4.32e-16	-0.36	-0.27	Protein C levels;	chr2:127270554	chr2:127389130~127400580:+
BRCA	cis	rs4835473	0.932	rs34697602	ENSG00000251600.4	RP11-673E1.1	-9	1.01e-18	4.34e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143762499	chr4:143912331~143982454:+
BRCA	cis	rs11676348	0.772	rs6738953	ENSG00000261338.2	RP11-378A13.1	-9	1.01e-18	4.34e-16	-0.28	-0.27	Ulcerative colitis;	chr2:218085313	chr2:218255319~218257366:+
BRCA	cis	rs11971779	0.715	rs10954646	ENSG00000273391.1	RP11-634H22.1	-9	1.01e-18	4.36e-16	-0.26	-0.27	Diisocyanate-induced asthma;	chr7:139376323	chr7:139359032~139359566:-
BRCA	cis	rs321358	0.731	rs17460781	ENSG00000271584.1	RP11-89C3.4	9	1.01e-18	4.36e-16	0.41	0.27	Body mass index;	chr11:111169966	chr11:111091932~111097357:-
BRCA	cis	rs9287719	0.967	rs6432112	ENSG00000234818.1	AC092687.5	-9	1.01e-18	4.37e-16	-0.31	-0.27	Prostate cancer;	chr2:10604748	chr2:10589166~10604830:+
BRCA	cis	rs17772222	0.837	rs1864748	ENSG00000258983.2	RP11-507K2.2	9	1.02e-18	4.39e-16	0.31	0.27	Coronary artery calcification;	chr14:88488847	chr14:88499334~88515502:+
BRCA	cis	rs2933343	1	rs789232	ENSG00000261159.1	RP11-723O4.9	9	1.02e-18	4.4e-16	0.32	0.27	IgG glycosylation;	chr3:128884237	chr3:128859716~128860526:-
BRCA	cis	rs8396	1	rs6536365	ENSG00000271817.2	U3	9	1.02e-18	4.4e-16	0.3	0.27	Blood metabolite levels;Blood protein levels;Acylcarnitine levels;Metabolite levels;Metabolic traits;	chr4:158711141	chr4:158700691~158700909:+
BRCA	cis	rs6142102	0.961	rs8119937	ENSG00000276073.1	RP5-1125A11.7	-9	1.02e-18	4.4e-16	-0.31	-0.27	Skin pigmentation;	chr20:34057745	chr20:33985617~33988989:-
BRCA	cis	rs783540	0.967	rs55972423	ENSG00000278603.1	RP13-608F4.5	-9	1.03e-18	4.42e-16	-0.34	-0.27	Schizophrenia;	chr15:82590203	chr15:82472203~82472426:+
BRCA	cis	rs853679	0.882	rs9461432	ENSG00000220721.1	OR1F12	9	1.03e-18	4.42e-16	0.49	0.27	Depression;	chr6:28119105	chr6:28073316~28074233:+
BRCA	cis	rs783540	0.967	rs2567635	ENSG00000278603.1	RP13-608F4.5	-9	1.03e-18	4.44e-16	-0.34	-0.27	Schizophrenia;	chr15:82593431	chr15:82472203~82472426:+
BRCA	cis	rs783540	0.933	rs2567636	ENSG00000278603.1	RP13-608F4.5	-9	1.03e-18	4.44e-16	-0.34	-0.27	Schizophrenia;	chr15:82594678	chr15:82472203~82472426:+
BRCA	cis	rs1061377	1	rs1036037	ENSG00000249685.1	RP11-360F5.3	9	1.03e-18	4.44e-16	0.32	0.27	Uric acid levels;	chr4:39111272	chr4:39133913~39135608:+
BRCA	cis	rs801193	1	rs2055682	ENSG00000222364.1	RNU6-96P	-9	1.03e-18	4.45e-16	-0.31	-0.27	Aortic root size;	chr7:66795302	chr7:66395191~66395286:+
BRCA	cis	rs12134133	0.752	rs6540874	ENSG00000274245.1	RP11-357P18.2	9	1.04e-18	4.48e-16	0.39	0.27	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207221638	chr1:207372559~207373252:+
BRCA	cis	rs673078	0.66	rs16948234	ENSG00000275759.1	RP11-131L12.3	9	1.04e-18	4.49e-16	0.42	0.27	Glucose homeostasis traits;	chr12:118282464	chr12:118428281~118428870:+
BRCA	cis	rs950169	0.579	rs62027818	ENSG00000225151.9	GOLGA2P7	-9	1.05e-18	4.5e-16	-0.39	-0.27	Schizophrenia;	chr15:83992393	chr15:84199311~84230136:-
BRCA	cis	rs6142102	0.961	rs2377957	ENSG00000276073.1	RP5-1125A11.7	-9	1.05e-18	4.52e-16	-0.31	-0.27	Skin pigmentation;	chr20:33966667	chr20:33985617~33988989:-
BRCA	cis	rs7580658	0.724	rs4662711	ENSG00000236682.1	AC068282.3	-9	1.05e-18	4.52e-16	-0.36	-0.27	Protein C levels;	chr2:127233264	chr2:127389130~127400580:+
BRCA	cis	rs11098499	0.954	rs11729521	ENSG00000248280.1	RP11-33B1.2	9	1.05e-18	4.52e-16	0.28	0.27	Corneal astigmatism;	chr4:119495633	chr4:119440561~119450157:-
BRCA	cis	rs2243480	1	rs73142162	ENSG00000226824.5	RP4-756H11.3	-9	1.05e-18	4.53e-16	-0.52	-0.27	Diabetic kidney disease;	chr7:65909309	chr7:66654538~66669855:+
BRCA	cis	rs1075265	0.836	rs11687324	ENSG00000233266.1	HMGB1P31	9	1.05e-18	4.53e-16	0.32	0.27	Chronotype;Morning vs. evening chronotype;	chr2:54046589	chr2:54051334~54051760:+
BRCA	cis	rs1061377	1	rs4974997	ENSG00000249685.1	RP11-360F5.3	9	1.05e-18	4.53e-16	0.33	0.27	Uric acid levels;	chr4:39109151	chr4:39133913~39135608:+
BRCA	cis	rs12594515	0.591	rs35554150	ENSG00000273972.1	CTD-2306A12.1	-9	1.06e-18	4.56e-16	-0.35	-0.27	Weight;Waist circumference;	chr15:45698100	chr15:45702640~45703183:+
BRCA	cis	rs9318086	0.776	rs1326130	ENSG00000205861.10	C1QTNF9B-AS1	-9	1.06e-18	4.56e-16	-0.34	-0.27	Myopia (pathological);	chr13:23873525	chr13:23888889~23897263:+
BRCA	cis	rs2933343	1	rs2929859	ENSG00000261159.1	RP11-723O4.9	9	1.06e-18	4.56e-16	0.32	0.27	IgG glycosylation;	chr3:128889498	chr3:128859716~128860526:-
BRCA	cis	rs875971	0.545	rs73136346	ENSG00000237310.1	GS1-124K5.4	-9	1.06e-18	4.57e-16	-0.32	-0.27	Aortic root size;	chr7:66101095	chr7:66493706~66495474:+
BRCA	cis	rs1198872	0.563	rs1686497	ENSG00000272275.1	RP11-791G15.2	-9	1.07e-18	4.59e-16	-0.34	-0.27	Cardiac Troponin-T levels;	chr2:10821058	chr2:10767875~10770058:-
BRCA	cis	rs6142102	0.602	rs1054534	ENSG00000275784.1	RP5-1125A11.6	-9	1.07e-18	4.59e-16	-0.31	-0.27	Skin pigmentation;	chr20:34017521	chr20:33989480~33991818:-
BRCA	cis	rs55665837	0.54	rs3206554	ENSG00000251991.1	RNU7-49P	9	1.07e-18	4.59e-16	0.3	0.27	Vitamin D levels;	chr11:14776399	chr11:14478892~14478953:+
BRCA	cis	rs10129255	0.518	rs2006284	ENSG00000211972.2	IGHV3-66	9	1.07e-18	4.61e-16	0.19	0.27	Kawasaki disease;	chr14:106676185	chr14:106675017~106675544:-
BRCA	cis	rs748404	0.666	rs12913977	ENSG00000249839.1	AC011330.5	-9	1.07e-18	4.62e-16	-0.39	-0.27	Lung cancer;	chr15:43438913	chr15:43663654~43684339:-
BRCA	cis	rs748404	0.666	rs12914122	ENSG00000249839.1	AC011330.5	-9	1.07e-18	4.62e-16	-0.39	-0.27	Lung cancer;	chr15:43438956	chr15:43663654~43684339:-
BRCA	cis	rs748404	0.666	rs34697113	ENSG00000249839.1	AC011330.5	-9	1.07e-18	4.62e-16	-0.39	-0.27	Lung cancer;	chr15:43442041	chr15:43663654~43684339:-
BRCA	cis	rs7937890	0.505	rs4403769	ENSG00000251991.1	RNU7-49P	9	1.07e-18	4.62e-16	0.29	0.27	Mitochondrial DNA levels;	chr11:14428630	chr11:14478892~14478953:+
BRCA	cis	rs875971	0.522	rs34973832	ENSG00000164669.11	INTS4P1	-9	1.08e-18	4.66e-16	-0.33	-0.27	Aortic root size;	chr7:65931217	chr7:65141225~65234216:+
BRCA	cis	rs733592	0.504	rs2261608	ENSG00000240399.1	RP1-228P16.1	9	1.09e-18	4.68e-16	0.3	0.27	Plateletcrit;	chr12:48327851	chr12:48054813~48055591:-
BRCA	cis	rs881375	0.967	rs1860823	ENSG00000226752.6	PSMD5-AS1	-9	1.09e-18	4.68e-16	-0.32	-0.27	Rheumatoid arthritis;	chr9:120897026	chr9:120824828~120854385:+
BRCA	cis	rs881375	0.967	rs1860824	ENSG00000226752.6	PSMD5-AS1	-9	1.09e-18	4.68e-16	-0.32	-0.27	Rheumatoid arthritis;	chr9:120897061	chr9:120824828~120854385:+
BRCA	cis	rs1823913	0.637	rs4853577	ENSG00000227542.1	AC092614.2	-8.99	1.1e-18	4.71e-16	-0.32	-0.27	Obesity-related traits;	chr2:191297118	chr2:191229165~191246172:-
BRCA	cis	rs4835473	0.9	rs35230778	ENSG00000251600.4	RP11-673E1.1	-8.99	1.1e-18	4.71e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143734336	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.9	rs34772566	ENSG00000251600.4	RP11-673E1.1	-8.99	1.1e-18	4.71e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143734355	chr4:143912331~143982454:+
BRCA	cis	rs227275	0.525	rs3974608	ENSG00000246560.2	RP11-10L12.4	8.99	1.1e-18	4.71e-16	0.28	0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102925641	chr4:102828055~102844075:+
BRCA	cis	rs4835473	0.932	rs3872	ENSG00000251600.4	RP11-673E1.1	8.99	1.11e-18	4.77e-16	0.32	0.27	Immature fraction of reticulocytes;	chr4:143968788	chr4:143912331~143982454:+
BRCA	cis	rs950169	0.579	rs12912716	ENSG00000225151.9	GOLGA2P7	-8.99	1.11e-18	4.78e-16	-0.39	-0.27	Schizophrenia;	chr15:83995511	chr15:84199311~84230136:-
BRCA	cis	rs7937890	0.532	rs2256884	ENSG00000251991.1	RNU7-49P	8.99	1.12e-18	4.81e-16	0.3	0.27	Mitochondrial DNA levels;	chr11:14454856	chr11:14478892~14478953:+
BRCA	cis	rs11098499	0.754	rs7672594	ENSG00000248280.1	RP11-33B1.2	8.99	1.12e-18	4.82e-16	0.26	0.27	Corneal astigmatism;	chr4:119327388	chr4:119440561~119450157:-
BRCA	cis	rs11673344	0.764	rs472226	ENSG00000226686.6	LINC01535	8.99	1.13e-18	4.83e-16	0.34	0.27	Obesity-related traits;	chr19:36967811	chr19:37251912~37265535:+
BRCA	cis	rs4835473	0.932	rs1597442	ENSG00000251600.4	RP11-673E1.1	-8.99	1.13e-18	4.85e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143764359	chr4:143912331~143982454:+
BRCA	cis	rs11098499	0.82	rs13128602	ENSG00000248280.1	RP11-33B1.2	-8.99	1.13e-18	4.85e-16	-0.28	-0.27	Corneal astigmatism;	chr4:119538211	chr4:119440561~119450157:-
BRCA	cis	rs7811142	0.943	rs28578163	ENSG00000242294.5	STAG3L5P	8.99	1.14e-18	4.87e-16	0.25	0.27	Platelet count;	chr7:100447131	chr7:100336079~100351900:+
BRCA	cis	rs7772486	0.686	rs6933161	ENSG00000235652.6	RP11-545I5.3	-8.99	1.14e-18	4.88e-16	-0.27	-0.27	Lobe attachment (rater-scored or self-reported);	chr6:145760233	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.686	rs9399565	ENSG00000235652.6	RP11-545I5.3	-8.99	1.14e-18	4.88e-16	-0.27	-0.27	Lobe attachment (rater-scored or self-reported);	chr6:145760770	chr6:145799409~145886585:+
BRCA	cis	rs11098499	0.866	rs11098506	ENSG00000245958.5	RP11-33B1.1	-8.99	1.14e-18	4.9e-16	-0.25	-0.27	Corneal astigmatism;	chr4:119363816	chr4:119454791~119552025:+
BRCA	cis	rs1707322	1	rs6672115	ENSG00000280836.1	AL355480.1	-8.99	1.14e-18	4.91e-16	-0.35	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45807207	chr1:45581219~45581321:-
BRCA	cis	rs875971	0.505	rs1723275	ENSG00000222364.1	RNU6-96P	8.99	1.15e-18	4.91e-16	0.31	0.27	Aortic root size;	chr7:66039646	chr7:66395191~66395286:+
BRCA	cis	rs4835473	0.897	rs7656786	ENSG00000251600.4	RP11-673E1.1	-8.99	1.15e-18	4.91e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143759455	chr4:143912331~143982454:+
BRCA	cis	rs11159086	0.793	rs10139029	ENSG00000259005.1	RP3-449M8.6	8.99	1.15e-18	4.91e-16	0.41	0.27	Advanced glycation end-product levels;	chr14:74492284	chr14:74474007~74474864:-
BRCA	cis	rs853679	0.567	rs6905380	ENSG00000216901.1	AL022393.7	8.99	1.15e-18	4.93e-16	0.39	0.27	Depression;	chr6:28407125	chr6:28176188~28176674:+
BRCA	cis	rs7580658	0.545	rs12477559	ENSG00000236682.1	AC068282.3	-8.99	1.15e-18	4.95e-16	-0.34	-0.27	Protein C levels;	chr2:127194221	chr2:127389130~127400580:+
BRCA	cis	rs8059260	0.736	rs16957854	ENSG00000274038.1	RP11-66H6.4	-8.99	1.16e-18	4.96e-16	-0.48	-0.27	Alcohol consumption over the past year;	chr16:10976466	chr16:11056556~11057034:+
BRCA	cis	rs4835473	0.932	rs11100808	ENSG00000251600.4	RP11-673E1.1	-8.99	1.16e-18	4.97e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143762728	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs7661407	ENSG00000251600.4	RP11-673E1.1	-8.99	1.16e-18	4.97e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143762982	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs1562777	ENSG00000251600.4	RP11-673E1.1	-8.99	1.16e-18	4.97e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143763676	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs1562778	ENSG00000251600.4	RP11-673E1.1	-8.99	1.16e-18	4.97e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143763816	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs1562779	ENSG00000251600.4	RP11-673E1.1	-8.99	1.16e-18	4.97e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143763999	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs1597441	ENSG00000251600.4	RP11-673E1.1	-8.99	1.16e-18	4.97e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143764158	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs1597443	ENSG00000251600.4	RP11-673E1.1	-8.99	1.16e-18	4.97e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143764406	chr4:143912331~143982454:+
BRCA	cis	rs2015599	0.525	rs7959145	ENSG00000275476.1	RP11-996F15.4	8.99	1.16e-18	4.98e-16	0.31	0.27	Platelet count;Mean platelet volume;	chr12:29330850	chr12:29277397~29277882:-
BRCA	cis	rs2015599	0.525	rs7961943	ENSG00000275476.1	RP11-996F15.4	8.99	1.16e-18	4.98e-16	0.31	0.27	Platelet count;Mean platelet volume;	chr12:29331146	chr12:29277397~29277882:-
BRCA	cis	rs10875746	0.669	rs4760701	ENSG00000240399.1	RP1-228P16.1	-8.99	1.17e-18	5.02e-16	-0.34	-0.27	Longevity (90 years and older);	chr12:48304735	chr12:48054813~48055591:-
BRCA	cis	rs4927850	0.709	rs6783079	ENSG00000231464.1	AC024937.4	8.99	1.18e-18	5.05e-16	0.4	0.27	Pancreatic cancer;	chr3:195925837	chr3:195996738~195998233:+
BRCA	cis	rs4927850	0.709	rs6765762	ENSG00000231464.1	AC024937.4	8.99	1.18e-18	5.05e-16	0.4	0.27	Pancreatic cancer;	chr3:195925980	chr3:195996738~195998233:+
BRCA	cis	rs4835473	0.9	rs7687976	ENSG00000251600.4	RP11-673E1.1	-8.99	1.18e-18	5.06e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143749171	chr4:143912331~143982454:+
BRCA	cis	rs7772486	0.79	rs2250387	ENSG00000235652.6	RP11-545I5.3	8.99	1.18e-18	5.06e-16	0.27	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145884097	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.536	rs9373467	ENSG00000235652.6	RP11-545I5.3	8.99	1.18e-18	5.07e-16	0.3	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145634469	chr6:145799409~145886585:+
BRCA	cis	rs897984	0.609	rs17839567	ENSG00000260911.2	RP11-196G11.2	8.99	1.18e-18	5.07e-16	0.24	0.27	Dementia with Lewy bodies;	chr16:31046624	chr16:31043150~31049868:+
BRCA	cis	rs1061377	1	rs10018049	ENSG00000249685.1	RP11-360F5.3	8.99	1.18e-18	5.07e-16	0.32	0.27	Uric acid levels;	chr4:39115781	chr4:39133913~39135608:+
BRCA	cis	rs11971779	0.793	rs11543827	ENSG00000273391.1	RP11-634H22.1	8.99	1.19e-18	5.09e-16	0.28	0.27	Diisocyanate-induced asthma;	chr7:139347947	chr7:139359032~139359566:-
BRCA	cis	rs2404602	0.716	rs8039545	ENSG00000259422.1	RP11-593F23.1	8.99	1.19e-18	5.09e-16	0.34	0.27	Blood metabolite levels;	chr15:76414906	chr15:76174891~76181486:-
BRCA	cis	rs2404602	0.716	rs7164060	ENSG00000259422.1	RP11-593F23.1	8.99	1.19e-18	5.09e-16	0.34	0.27	Blood metabolite levels;	chr15:76415353	chr15:76174891~76181486:-
BRCA	cis	rs7772486	0.875	rs9373485	ENSG00000235652.6	RP11-545I5.3	8.99	1.19e-18	5.09e-16	0.27	0.27	Lobe attachment (rater-scored or self-reported);	chr6:146080293	chr6:145799409~145886585:+
BRCA	cis	rs2067615	0.579	rs3782709	ENSG00000260329.1	RP11-412D9.4	-8.98	1.19e-18	5.09e-16	-0.29	-0.27	Heart rate;	chr12:106811975	chr12:106954029~106955497:-
BRCA	cis	rs1075265	0.749	rs805436	ENSG00000233266.1	HMGB1P31	8.98	1.19e-18	5.1e-16	0.33	0.27	Chronotype;Morning vs. evening chronotype;	chr2:53837843	chr2:54051334~54051760:+
BRCA	cis	rs453301	0.606	rs7462373	ENSG00000253893.2	FAM85B	8.98	1.19e-18	5.1e-16	0.34	0.27	Joint mobility (Beighton score);	chr8:9041808	chr8:8167819~8226614:-
BRCA	cis	rs10463554	0.963	rs17154959	ENSG00000175749.11	EIF3KP1	8.98	1.19e-18	5.1e-16	0.37	0.27	Parkinson's disease;	chr5:103020587	chr5:103032376~103033031:+
BRCA	cis	rs1707322	1	rs4134387	ENSG00000280836.1	AL355480.1	-8.98	1.19e-18	5.11e-16	-0.35	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45929486	chr1:45581219~45581321:-
BRCA	cis	rs9318086	0.901	rs7336730	ENSG00000205861.10	C1QTNF9B-AS1	8.98	1.19e-18	5.11e-16	0.34	0.27	Myopia (pathological);	chr13:23877965	chr13:23888889~23897263:+
BRCA	cis	rs881375	1	rs4323544	ENSG00000226752.6	PSMD5-AS1	-8.98	1.2e-18	5.12e-16	-0.32	-0.27	Rheumatoid arthritis;	chr9:120885099	chr9:120824828~120854385:+
BRCA	cis	rs2067615	0.579	rs1811458	ENSG00000260329.1	RP11-412D9.4	-8.98	1.2e-18	5.15e-16	-0.29	-0.27	Heart rate;	chr12:106809905	chr12:106954029~106955497:-
BRCA	cis	rs4835473	0.9	rs56084616	ENSG00000251600.4	RP11-673E1.1	-8.98	1.2e-18	5.15e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143746697	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.966	rs11722639	ENSG00000251600.4	RP11-673E1.1	-8.98	1.2e-18	5.15e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143746884	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.966	rs11722673	ENSG00000251600.4	RP11-673E1.1	-8.98	1.2e-18	5.15e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143746946	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs6821979	ENSG00000251600.4	RP11-673E1.1	-8.98	1.2e-18	5.15e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143748091	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs6838887	ENSG00000251600.4	RP11-673E1.1	-8.98	1.2e-18	5.15e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143748130	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs1982392	ENSG00000251600.4	RP11-673E1.1	-8.98	1.2e-18	5.15e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143748604	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs1982393	ENSG00000251600.4	RP11-673E1.1	-8.98	1.2e-18	5.15e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143748736	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs9683880	ENSG00000251600.4	RP11-673E1.1	-8.98	1.2e-18	5.15e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143748787	chr4:143912331~143982454:+
BRCA	cis	rs875971	0.545	rs10950029	ENSG00000237310.1	GS1-124K5.4	8.98	1.21e-18	5.18e-16	0.31	0.27	Aortic root size;	chr7:66169334	chr7:66493706~66495474:+
BRCA	cis	rs2439831	0.85	rs7168158	ENSG00000205771.5	CATSPER2P1	-8.98	1.21e-18	5.19e-16	-0.46	-0.27	Lung cancer in ever smokers;	chr15:43758178	chr15:43726918~43747094:-
BRCA	cis	rs8062405	1	rs80275162	ENSG00000278665.1	RP11-666O2.4	8.98	1.22e-18	5.21e-16	0.29	0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28852196	chr16:28599241~28601881:-
BRCA	cis	rs783540	0.934	rs36109438	ENSG00000278603.1	RP13-608F4.5	-8.98	1.22e-18	5.22e-16	-0.34	-0.27	Schizophrenia;	chr15:82595709	chr15:82472203~82472426:+
BRCA	cis	rs4835473	0.932	rs1006406	ENSG00000251600.4	RP11-673E1.1	-8.98	1.23e-18	5.27e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143761710	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs1562776	ENSG00000251600.4	RP11-673E1.1	-8.98	1.23e-18	5.27e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143761999	chr4:143912331~143982454:+
BRCA	cis	rs11098499	0.954	rs11940028	ENSG00000248280.1	RP11-33B1.2	8.98	1.24e-18	5.29e-16	0.28	0.27	Corneal astigmatism;	chr4:119490752	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.954	rs11935596	ENSG00000248280.1	RP11-33B1.2	8.98	1.24e-18	5.29e-16	0.28	0.27	Corneal astigmatism;	chr4:119491302	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.954	rs12507964	ENSG00000248280.1	RP11-33B1.2	8.98	1.24e-18	5.29e-16	0.28	0.27	Corneal astigmatism;	chr4:119491906	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.909	rs11098530	ENSG00000248280.1	RP11-33B1.2	8.98	1.24e-18	5.29e-16	0.28	0.27	Corneal astigmatism;	chr4:119491999	chr4:119440561~119450157:-
BRCA	cis	rs11722779	0.815	rs223347	ENSG00000246560.2	RP11-10L12.4	8.98	1.24e-18	5.31e-16	0.29	0.27	Schizophrenia;	chr4:102858815	chr4:102828055~102844075:+
BRCA	cis	rs13256369	0.951	rs13270852	ENSG00000253893.2	FAM85B	-8.98	1.24e-18	5.32e-16	-0.38	-0.27	Obesity-related traits;	chr8:8709343	chr8:8167819~8226614:-
BRCA	cis	rs113835537	0.529	rs7950790	ENSG00000255517.5	CTD-3074O7.5	-8.98	1.24e-18	5.32e-16	-0.34	-0.27	Airway imaging phenotypes;	chr11:66490582	chr11:66473490~66480233:-
BRCA	cis	rs1134634	0.52	rs16892140	ENSG00000273133.1	RP11-799M12.2	-8.98	1.25e-18	5.33e-16	-0.35	-0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15546927	chr4:15563698~15564253:-
BRCA	cis	rs11673344	0.864	rs7247589	ENSG00000226686.6	LINC01535	8.98	1.25e-18	5.33e-16	0.35	0.27	Obesity-related traits;	chr19:37019879	chr19:37251912~37265535:+
BRCA	cis	rs4835473	0.868	rs971391	ENSG00000251600.4	RP11-673E1.1	-8.98	1.25e-18	5.34e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143751324	chr4:143912331~143982454:+
BRCA	cis	rs13256369	0.708	rs10903310	ENSG00000253893.2	FAM85B	8.98	1.26e-18	5.39e-16	0.39	0.27	Obesity-related traits;	chr8:8732177	chr8:8167819~8226614:-
BRCA	cis	rs116175783	0.557	rs1733180	ENSG00000227403.1	AC009299.3	-8.98	1.26e-18	5.4e-16	-0.47	-0.27	Intelligence (multi-trait analysis);	chr2:161277119	chr2:161244739~161249050:+
BRCA	cis	rs11971779	0.648	rs59791374	ENSG00000273391.1	RP11-634H22.1	8.98	1.26e-18	5.4e-16	0.26	0.27	Diisocyanate-induced asthma;	chr7:139432216	chr7:139359032~139359566:-
BRCA	cis	rs7580658	0.929	rs2276583	ENSG00000236682.1	AC068282.3	-8.98	1.26e-18	5.41e-16	-0.36	-0.27	Protein C levels;	chr2:127257108	chr2:127389130~127400580:+
BRCA	cis	rs4718428	0.705	rs28648401	ENSG00000232546.1	RP11-458F8.1	-8.98	1.27e-18	5.43e-16	-0.25	-0.27	Corneal structure;	chr7:66902145	chr7:66848496~66858136:+
BRCA	cis	rs4835473	0.9	rs935732	ENSG00000251600.4	RP11-673E1.1	-8.98	1.27e-18	5.44e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143759164	chr4:143912331~143982454:+
BRCA	cis	rs1707322	1	rs4074225	ENSG00000280836.1	AL355480.1	-8.98	1.27e-18	5.45e-16	-0.35	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45926692	chr1:45581219~45581321:-
BRCA	cis	rs4660456	0.913	rs34212676	ENSG00000237899.1	RP4-739H11.3	-8.98	1.27e-18	5.45e-16	-0.4	-0.27	Platelet count;	chr1:40766522	chr1:40669089~40687588:-
BRCA	cis	rs10740039	0.768	rs920646	ENSG00000254271.1	RP11-131N11.4	8.98	1.27e-18	5.45e-16	0.36	0.27	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60703767	chr10:60734342~60741828:+
BRCA	cis	rs11098499	0.863	rs59732491	ENSG00000245958.5	RP11-33B1.1	-8.98	1.28e-18	5.48e-16	-0.27	-0.27	Corneal astigmatism;	chr4:119568433	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.863	rs11723090	ENSG00000245958.5	RP11-33B1.1	-8.98	1.28e-18	5.48e-16	-0.27	-0.27	Corneal astigmatism;	chr4:119569437	chr4:119454791~119552025:+
BRCA	cis	rs4835473	0.838	rs4271960	ENSG00000251600.4	RP11-673E1.1	-8.98	1.28e-18	5.48e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143763591	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.808	rs2323198	ENSG00000251600.4	RP11-673E1.1	-8.98	1.28e-18	5.48e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143763595	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.9	rs2323199	ENSG00000251600.4	RP11-673E1.1	-8.98	1.28e-18	5.48e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143763606	chr4:143912331~143982454:+
BRCA	cis	rs2015599	0.525	rs2016832	ENSG00000275476.1	RP11-996F15.4	8.98	1.29e-18	5.5e-16	0.31	0.27	Platelet count;Mean platelet volume;	chr12:29318199	chr12:29277397~29277882:-
BRCA	cis	rs875971	0.522	rs781144	ENSG00000224316.1	RP11-479O9.2	8.98	1.29e-18	5.5e-16	0.26	0.27	Aortic root size;	chr7:65975357	chr7:65773620~65802067:+
BRCA	cis	rs7945705	0.905	rs2568054	ENSG00000254860.4	TMEM9B-AS1	8.98	1.29e-18	5.51e-16	0.24	0.27	Hemoglobin concentration;	chr11:8854482	chr11:8964675~8977527:+
BRCA	cis	rs9807989	0.524	rs6543126	ENSG00000234389.1	AC007278.3	8.98	1.29e-18	5.52e-16	0.25	0.27	Asthma;	chr2:102410644	chr2:102438713~102440475:+
BRCA	cis	rs7937890	0.559	rs2597219	ENSG00000251991.1	RNU7-49P	8.97	1.3e-18	5.53e-16	0.3	0.27	Mitochondrial DNA levels;	chr11:14509320	chr11:14478892~14478953:+
BRCA	cis	rs7937890	0.559	rs2575852	ENSG00000251991.1	RNU7-49P	8.97	1.3e-18	5.53e-16	0.3	0.27	Mitochondrial DNA levels;	chr11:14511822	chr11:14478892~14478953:+
BRCA	cis	rs7937890	0.531	rs2597216	ENSG00000251991.1	RNU7-49P	8.97	1.3e-18	5.53e-16	0.3	0.27	Mitochondrial DNA levels;	chr11:14512370	chr11:14478892~14478953:+
BRCA	cis	rs7937890	0.559	rs1548074	ENSG00000251991.1	RNU7-49P	8.97	1.3e-18	5.53e-16	0.3	0.27	Mitochondrial DNA levels;	chr11:14513279	chr11:14478892~14478953:+
BRCA	cis	rs875971	0.522	rs1617484	ENSG00000224316.1	RP11-479O9.2	8.97	1.3e-18	5.55e-16	0.27	0.27	Aortic root size;	chr7:65998108	chr7:65773620~65802067:+
BRCA	cis	rs7208859	0.623	rs9895785	ENSG00000266490.1	CTD-2349P21.9	-8.97	1.3e-18	5.55e-16	-0.39	-0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780690	chr17:30792372~30792833:+
BRCA	cis	rs4835473	0.9	rs7683287	ENSG00000251600.4	RP11-673E1.1	-8.97	1.3e-18	5.57e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143749270	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.712	rs2198000	ENSG00000251600.4	RP11-673E1.1	-8.97	1.3e-18	5.57e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143750005	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.9	rs2198002	ENSG00000251600.4	RP11-673E1.1	-8.97	1.3e-18	5.57e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143750028	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs6853460	ENSG00000251600.4	RP11-673E1.1	-8.97	1.3e-18	5.57e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143750392	chr4:143912331~143982454:+
BRCA	cis	rs7772486	0.875	rs9322046	ENSG00000235652.6	RP11-545I5.3	8.97	1.3e-18	5.57e-16	0.26	0.27	Lobe attachment (rater-scored or self-reported);	chr6:146072489	chr6:145799409~145886585:+
BRCA	cis	rs4835473	0.897	rs7681903	ENSG00000251600.4	RP11-673E1.1	-8.97	1.31e-18	5.6e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143759326	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.897	rs7656753	ENSG00000251600.4	RP11-673E1.1	-8.97	1.31e-18	5.6e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143759414	chr4:143912331~143982454:+
BRCA	cis	rs11971779	0.59	rs59602547	ENSG00000273391.1	RP11-634H22.1	8.97	1.31e-18	5.6e-16	0.26	0.27	Diisocyanate-induced asthma;	chr7:139432277	chr7:139359032~139359566:-
BRCA	cis	rs10740039	0.768	rs7895268	ENSG00000254271.1	RP11-131N11.4	8.97	1.32e-18	5.64e-16	0.35	0.27	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60703479	chr10:60734342~60741828:+
BRCA	cis	rs10262624	1	rs10257777	ENSG00000234286.1	AC006026.13	-8.97	1.32e-18	5.65e-16	-0.31	-0.27	Schizophrenia;	chr7:23871362	chr7:23680195~23680786:-
BRCA	cis	rs7085104	0.66	rs7902804	ENSG00000213061.2	PFN1P11	8.97	1.33e-18	5.66e-16	0.35	0.27	Immature fraction of reticulocytes;Schizophrenia;	chr10:102825648	chr10:102838011~102845473:-
BRCA	cis	rs7429990	0.965	rs319692	ENSG00000229759.1	MRPS18AP1	8.97	1.33e-18	5.68e-16	0.31	0.27	Educational attainment (years of education);	chr3:47882827	chr3:48256350~48256938:-
BRCA	cis	rs6558530	0.692	rs6558522	ENSG00000253982.1	CTD-2336O2.1	-8.97	1.33e-18	5.69e-16	-0.32	-0.27	Systolic blood pressure;	chr8:1754204	chr8:1761990~1764502:-
BRCA	cis	rs1501911	0.509	rs692759	ENSG00000248489.1	CTD-2007H13.3	-8.97	1.34e-18	5.72e-16	-0.3	-0.27	Lung function (FEV1/FVC);	chr5:98856841	chr5:98929171~98995013:+
BRCA	cis	rs150992	0.536	rs179053	ENSG00000248489.1	CTD-2007H13.3	8.97	1.34e-18	5.72e-16	0.35	0.27	Body mass index;	chr5:98979890	chr5:98929171~98995013:+
BRCA	cis	rs6142102	0.961	rs4911392	ENSG00000276073.1	RP5-1125A11.7	-8.97	1.34e-18	5.73e-16	-0.31	-0.27	Skin pigmentation;	chr20:33982712	chr20:33985617~33988989:-
BRCA	cis	rs6142102	0.961	rs4911393	ENSG00000276073.1	RP5-1125A11.7	-8.97	1.34e-18	5.73e-16	-0.31	-0.27	Skin pigmentation;	chr20:33983120	chr20:33985617~33988989:-
BRCA	cis	rs875971	0.545	rs316324	ENSG00000237310.1	GS1-124K5.4	-8.97	1.34e-18	5.74e-16	-0.31	-0.27	Aortic root size;	chr7:66145627	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.545	rs316323	ENSG00000237310.1	GS1-124K5.4	-8.97	1.34e-18	5.74e-16	-0.31	-0.27	Aortic root size;	chr7:66146002	chr7:66493706~66495474:+
BRCA	cis	rs881375	0.678	rs7021049	ENSG00000226752.6	PSMD5-AS1	-8.97	1.35e-18	5.74e-16	-0.32	-0.27	Rheumatoid arthritis;	chr9:120921704	chr9:120824828~120854385:+
BRCA	cis	rs9807989	0.507	rs2287033	ENSG00000234389.1	AC007278.3	-8.97	1.35e-18	5.75e-16	-0.24	-0.27	Asthma;	chr2:102394777	chr2:102438713~102440475:+
BRCA	cis	rs4835473	0.932	rs13119602	ENSG00000251600.4	RP11-673E1.1	-8.97	1.35e-18	5.76e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143736621	chr4:143912331~143982454:+
BRCA	cis	rs17711722	0.727	rs1880555	ENSG00000236529.1	RP13-254B10.1	8.97	1.35e-18	5.77e-16	0.29	0.27	Calcium levels;	chr7:65967580	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.545	rs4441996	ENSG00000164669.11	INTS4P1	8.97	1.36e-18	5.78e-16	0.37	0.27	Aortic root size;	chr7:66123233	chr7:65141225~65234216:+
BRCA	cis	rs7429990	0.965	rs319689	ENSG00000229759.1	MRPS18AP1	8.97	1.36e-18	5.8e-16	0.3	0.27	Educational attainment (years of education);	chr3:47886677	chr3:48256350~48256938:-
BRCA	cis	rs2274273	0.84	rs10136596	ENSG00000258413.1	RP11-665C16.6	-8.97	1.36e-18	5.82e-16	-0.33	-0.27	Protein biomarker;	chr14:55370055	chr14:55262767~55272075:-
BRCA	cis	rs10760123	1	rs10760123	ENSG00000226752.6	PSMD5-AS1	-8.97	1.37e-18	5.82e-16	-0.32	-0.27	Allergic disease (asthma, hay fever or eczema);	chr9:120888256	chr9:120824828~120854385:+
BRCA	cis	rs881375	0.967	rs2270231	ENSG00000226752.6	PSMD5-AS1	-8.97	1.37e-18	5.82e-16	-0.32	-0.27	Rheumatoid arthritis;	chr9:120888704	chr9:120824828~120854385:+
BRCA	cis	rs881375	1	rs881375	ENSG00000226752.6	PSMD5-AS1	-8.97	1.37e-18	5.82e-16	-0.32	-0.27	Rheumatoid arthritis;	chr9:120890620	chr9:120824828~120854385:+
BRCA	cis	rs7937890	0.531	rs2575828	ENSG00000251991.1	RNU7-49P	8.97	1.38e-18	5.86e-16	0.3	0.27	Mitochondrial DNA levels;	chr11:14462646	chr11:14478892~14478953:+
BRCA	cis	rs7937890	0.559	rs2575829	ENSG00000251991.1	RNU7-49P	8.97	1.38e-18	5.86e-16	0.3	0.27	Mitochondrial DNA levels;	chr11:14463475	chr11:14478892~14478953:+
BRCA	cis	rs7937890	0.559	rs2597200	ENSG00000251991.1	RNU7-49P	8.97	1.38e-18	5.86e-16	0.3	0.27	Mitochondrial DNA levels;	chr11:14464054	chr11:14478892~14478953:+
BRCA	cis	rs7937890	0.559	rs2575830	ENSG00000251991.1	RNU7-49P	8.97	1.38e-18	5.86e-16	0.3	0.27	Mitochondrial DNA levels;	chr11:14464056	chr11:14478892~14478953:+
BRCA	cis	rs1062177	0.855	rs1346489	ENSG00000253921.1	CTB-113P19.3	-8.97	1.38e-18	5.88e-16	-0.34	-0.27	Preschool internalizing problems;	chr5:151886973	chr5:151753992~151767247:+
BRCA	cis	rs875971	0.545	rs73376394	ENSG00000226824.5	RP4-756H11.3	-8.97	1.38e-18	5.9e-16	-0.36	-0.27	Aortic root size;	chr7:66172694	chr7:66654538~66669855:+
BRCA	cis	rs765787	0.53	rs12905246	ENSG00000259520.4	CTD-2651B20.3	-8.97	1.4e-18	5.95e-16	-0.34	-0.27	Uric acid levels;	chr15:45208643	chr15:45251580~45279251:-
BRCA	cis	rs11098499	0.754	rs2036857	ENSG00000248280.1	RP11-33B1.2	8.97	1.4e-18	5.96e-16	0.26	0.27	Corneal astigmatism;	chr4:119328085	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.754	rs2036856	ENSG00000248280.1	RP11-33B1.2	8.97	1.4e-18	5.96e-16	0.26	0.27	Corneal astigmatism;	chr4:119328133	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.754	rs4443261	ENSG00000248280.1	RP11-33B1.2	8.97	1.4e-18	5.96e-16	0.26	0.27	Corneal astigmatism;	chr4:119328146	chr4:119440561~119450157:-
BRCA	cis	rs11673344	0.808	rs57916401	ENSG00000226686.6	LINC01535	8.97	1.4e-18	5.96e-16	0.35	0.27	Obesity-related traits;	chr19:37153149	chr19:37251912~37265535:+
BRCA	cis	rs5751614	0.537	rs5759682	ENSG00000230701.2	FBXW4P1	8.97	1.41e-18	5.99e-16	0.34	0.27	Height;	chr22:23288992	chr22:23262767~23265005:+
BRCA	cis	rs2439831	0.85	rs12441127	ENSG00000205771.5	CATSPER2P1	-8.96	1.41e-18	6e-16	-0.47	-0.27	Lung cancer in ever smokers;	chr15:43728977	chr15:43726918~43747094:-
BRCA	cis	rs875971	0.545	rs73378304	ENSG00000237310.1	GS1-124K5.4	8.96	1.41e-18	6e-16	0.31	0.27	Aortic root size;	chr7:66175760	chr7:66493706~66495474:+
BRCA	cis	rs7712401	0.601	rs30026	ENSG00000263432.2	RN7SL689P	8.96	1.42e-18	6.03e-16	0.34	0.27	Mean platelet volume;	chr5:122948873	chr5:123022487~123022783:-
BRCA	cis	rs453301	0.686	rs10217044	ENSG00000253893.2	FAM85B	8.96	1.42e-18	6.05e-16	0.34	0.27	Joint mobility (Beighton score);	chr8:9037242	chr8:8167819~8226614:-
BRCA	cis	rs4835473	0.932	rs1597444	ENSG00000251600.4	RP11-673E1.1	-8.96	1.42e-18	6.05e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143764547	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.9	rs60038202	ENSG00000251600.4	RP11-673E1.1	-8.96	1.42e-18	6.05e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143764662	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs1450230	ENSG00000251600.4	RP11-673E1.1	-8.96	1.42e-18	6.05e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143765118	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs34683160	ENSG00000251600.4	RP11-673E1.1	-8.96	1.42e-18	6.05e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143765227	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.9	rs72946226	ENSG00000251600.4	RP11-673E1.1	-8.96	1.42e-18	6.05e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143765238	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs34230433	ENSG00000251600.4	RP11-673E1.1	-8.96	1.42e-18	6.05e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143765253	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs7696869	ENSG00000251600.4	RP11-673E1.1	-8.96	1.42e-18	6.05e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143765855	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs7698287	ENSG00000251600.4	RP11-673E1.1	-8.96	1.42e-18	6.05e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143765859	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs4835279	ENSG00000251600.4	RP11-673E1.1	-8.96	1.42e-18	6.06e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143788917	chr4:143912331~143982454:+
BRCA	cis	rs2015599	0.525	rs7298031	ENSG00000275476.1	RP11-996F15.4	8.96	1.43e-18	6.07e-16	0.31	0.27	Platelet count;Mean platelet volume;	chr12:29317333	chr12:29277397~29277882:-
BRCA	cis	rs4718428	0.662	rs34577323	ENSG00000273142.1	RP11-458F8.4	-8.96	1.43e-18	6.09e-16	-0.26	-0.27	Corneal structure;	chr7:66845054	chr7:66902857~66906297:+
BRCA	cis	rs7937890	0.561	rs2575849	ENSG00000251991.1	RNU7-49P	8.96	1.43e-18	6.1e-16	0.3	0.27	Mitochondrial DNA levels;	chr11:14518093	chr11:14478892~14478953:+
BRCA	cis	rs2439831	0.85	rs7169322	ENSG00000249839.1	AC011330.5	-8.96	1.44e-18	6.11e-16	-0.45	-0.27	Lung cancer in ever smokers;	chr15:43838816	chr15:43663654~43684339:-
BRCA	cis	rs2439831	0.85	rs28707214	ENSG00000249839.1	AC011330.5	-8.96	1.44e-18	6.11e-16	-0.45	-0.27	Lung cancer in ever smokers;	chr15:43839425	chr15:43663654~43684339:-
BRCA	cis	rs9807989	0.507	rs1420097	ENSG00000234389.1	AC007278.3	-8.96	1.44e-18	6.14e-16	-0.24	-0.27	Asthma;	chr2:102392894	chr2:102438713~102440475:+
BRCA	cis	rs897984	0.609	rs35468353	ENSG00000260911.2	RP11-196G11.2	8.96	1.44e-18	6.15e-16	0.24	0.27	Dementia with Lewy bodies;	chr16:31045112	chr16:31043150~31049868:+
BRCA	cis	rs897984	0.609	rs11862744	ENSG00000260911.2	RP11-196G11.2	8.96	1.44e-18	6.15e-16	0.24	0.27	Dementia with Lewy bodies;	chr16:31046479	chr16:31043150~31049868:+
BRCA	cis	rs11098499	0.954	rs12506546	ENSG00000248280.1	RP11-33B1.2	8.96	1.45e-18	6.16e-16	0.28	0.27	Corneal astigmatism;	chr4:119380463	chr4:119440561~119450157:-
BRCA	cis	rs4835473	0.932	rs12513130	ENSG00000251600.4	RP11-673E1.1	-8.96	1.45e-18	6.18e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143758666	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.868	rs7681891	ENSG00000251600.4	RP11-673E1.1	-8.96	1.45e-18	6.18e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143759289	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.771	rs34069296	ENSG00000251600.4	RP11-673E1.1	-8.96	1.45e-18	6.18e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143759656	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.897	rs7687915	ENSG00000251600.4	RP11-673E1.1	-8.96	1.45e-18	6.18e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143759801	chr4:143912331~143982454:+
BRCA	cis	rs2276314	0.793	rs77590522	ENSG00000278986.1	RP11-723J4.3	-8.96	1.46e-18	6.2e-16	-0.36	-0.27	Endometriosis;Drug-induced torsades de pointes;	chr18:36049447	chr18:35972151~35973916:+
BRCA	cis	rs7580658	0.963	rs12622436	ENSG00000236682.1	AC068282.3	-8.96	1.46e-18	6.2e-16	-0.36	-0.27	Protein C levels;	chr2:127324106	chr2:127389130~127400580:+
BRCA	cis	rs12468226	0.935	rs113188021	ENSG00000273456.1	RP11-686O6.2	8.96	1.46e-18	6.2e-16	0.4	0.27	Urate levels;	chr2:202336237	chr2:202374932~202375604:-
BRCA	cis	rs12468226	1	rs6731027	ENSG00000273456.1	RP11-686O6.2	8.96	1.46e-18	6.2e-16	0.4	0.27	Urate levels;	chr2:202337443	chr2:202374932~202375604:-
BRCA	cis	rs7937890	0.507	rs4463820	ENSG00000251991.1	RNU7-49P	8.96	1.46e-18	6.2e-16	0.3	0.27	Mitochondrial DNA levels;	chr11:14534796	chr11:14478892~14478953:+
BRCA	cis	rs4835473	0.932	rs34257944	ENSG00000251600.4	RP11-673E1.1	-8.96	1.46e-18	6.2e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143736443	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.868	rs35243309	ENSG00000251600.4	RP11-673E1.1	-8.96	1.46e-18	6.21e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143755116	chr4:143912331~143982454:+
BRCA	cis	rs11673344	0.966	rs56330606	ENSG00000226686.6	LINC01535	8.96	1.46e-18	6.22e-16	0.35	0.27	Obesity-related traits;	chr19:37183051	chr19:37251912~37265535:+
BRCA	cis	rs11098499	0.954	rs6848389	ENSG00000248280.1	RP11-33B1.2	8.96	1.46e-18	6.23e-16	0.27	0.27	Corneal astigmatism;	chr4:119481467	chr4:119440561~119450157:-
BRCA	cis	rs783540	0.967	rs4779044	ENSG00000278603.1	RP13-608F4.5	8.96	1.47e-18	6.24e-16	0.34	0.27	Schizophrenia;	chr15:82670601	chr15:82472203~82472426:+
BRCA	cis	rs11098499	0.908	rs2017057	ENSG00000245958.5	RP11-33B1.1	-8.96	1.47e-18	6.24e-16	-0.26	-0.27	Corneal astigmatism;	chr4:119336556	chr4:119454791~119552025:+
BRCA	cis	rs17772222	0.876	rs12587528	ENSG00000258983.2	RP11-507K2.2	8.96	1.47e-18	6.24e-16	0.31	0.27	Coronary artery calcification;	chr14:88487652	chr14:88499334~88515502:+
BRCA	cis	rs11098499	0.687	rs71610270	ENSG00000245958.5	RP11-33B1.1	-8.96	1.47e-18	6.26e-16	-0.25	-0.27	Corneal astigmatism;	chr4:119366281	chr4:119454791~119552025:+
BRCA	cis	rs1075265	0.568	rs2542577	ENSG00000233266.1	HMGB1P31	8.96	1.47e-18	6.26e-16	0.32	0.27	Chronotype;Morning vs. evening chronotype;	chr2:53822111	chr2:54051334~54051760:+
BRCA	cis	rs1707322	0.964	rs7512395	ENSG00000280836.1	AL355480.1	-8.96	1.48e-18	6.31e-16	-0.35	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45895505	chr1:45581219~45581321:-
BRCA	cis	rs4835473	0.932	rs34618381	ENSG00000251600.4	RP11-673E1.1	-8.96	1.49e-18	6.32e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143762612	chr4:143912331~143982454:+
BRCA	cis	rs2333194	0.844	rs17182286	ENSG00000258408.1	NT5CP2	-8.96	1.49e-18	6.33e-16	-0.3	-0.27	Bipolar disorder with mood-incongruent psychosis;	chr14:73282200	chr14:73539221~73539781:-
BRCA	cis	rs7937890	0.531	rs2575859	ENSG00000251991.1	RNU7-49P	8.96	1.49e-18	6.33e-16	0.3	0.27	Mitochondrial DNA levels;	chr11:14489190	chr11:14478892~14478953:+
BRCA	cis	rs7772486	0.869	rs2777473	ENSG00000235652.6	RP11-545I5.3	8.96	1.49e-18	6.34e-16	0.26	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145980358	chr6:145799409~145886585:+
BRCA	cis	rs783540	0.967	rs34186444	ENSG00000278603.1	RP13-608F4.5	-8.96	1.49e-18	6.34e-16	-0.34	-0.27	Schizophrenia;	chr15:82618749	chr15:82472203~82472426:+
BRCA	cis	rs1729407	0.814	rs2542051	ENSG00000254851.1	RP11-109L13.1	8.96	1.51e-18	6.4e-16	0.32	0.27	Apolipoprotein A-IV levels;	chr11:116827022	chr11:117135528~117138582:+
BRCA	cis	rs2439831	0.85	rs12442129	ENSG00000205771.5	CATSPER2P1	-8.96	1.51e-18	6.41e-16	-0.46	-0.27	Lung cancer in ever smokers;	chr15:43763658	chr15:43726918~43747094:-
BRCA	cis	rs1045529	0.524	rs34251783	ENSG00000253893.2	FAM85B	8.96	1.51e-18	6.41e-16	0.34	0.27	Myopia (pathological);Myopia;	chr8:9033866	chr8:8167819~8226614:-
BRCA	cis	rs957448	1	rs12680965	ENSG00000253704.1	RP11-267M23.4	8.96	1.52e-18	6.46e-16	0.32	0.27	Nonsyndromic cleft lip with cleft palate;	chr8:94554069	chr8:94553722~94569745:+
BRCA	cis	rs11098499	0.955	rs11944880	ENSG00000245958.5	RP11-33B1.1	8.96	1.53e-18	6.48e-16	0.26	0.27	Corneal astigmatism;	chr4:119238179	chr4:119454791~119552025:+
BRCA	cis	rs8396	0.96	rs6839534	ENSG00000271817.2	U3	8.95	1.53e-18	6.5e-16	0.3	0.27	Blood metabolite levels;Blood protein levels;Acylcarnitine levels;Metabolite levels;Metabolic traits;	chr4:158716843	chr4:158700691~158700909:+
BRCA	cis	rs8059260	0.604	rs34573672	ENSG00000274038.1	RP11-66H6.4	-8.95	1.53e-18	6.51e-16	-0.43	-0.27	Alcohol consumption over the past year;	chr16:11111882	chr16:11056556~11057034:+
BRCA	cis	rs11098499	0.865	rs10213221	ENSG00000248280.1	RP11-33B1.2	8.95	1.54e-18	6.53e-16	0.26	0.27	Corneal astigmatism;	chr4:119334771	chr4:119440561~119450157:-
BRCA	cis	rs13256369	0.802	rs11249884	ENSG00000253893.2	FAM85B	8.95	1.54e-18	6.54e-16	0.38	0.27	Obesity-related traits;	chr8:8704042	chr8:8167819~8226614:-
BRCA	cis	rs1075265	0.704	rs10181999	ENSG00000233266.1	HMGB1P31	8.95	1.55e-18	6.57e-16	0.32	0.27	Chronotype;Morning vs. evening chronotype;	chr2:54025360	chr2:54051334~54051760:+
BRCA	cis	rs12458462	0.892	rs58675823	ENSG00000274828.1	RP11-567M16.6	8.95	1.55e-18	6.58e-16	0.31	0.27	Monocyte count;	chr18:79703672	chr18:79677287~79679358:-
BRCA	cis	rs3814244	0.569	rs11177008	ENSG00000236946.2	HNRNPA1P70	-8.95	1.55e-18	6.58e-16	-0.23	-0.27	Itch intensity from mosquito bite adjusted by bite size;	chr12:68021024	chr12:68035767~68036853:+
BRCA	cis	rs11098499	0.754	rs28643450	ENSG00000248280.1	RP11-33B1.2	8.95	1.55e-18	6.59e-16	0.26	0.27	Corneal astigmatism;	chr4:119324087	chr4:119440561~119450157:-
BRCA	cis	rs4964805	0.865	rs4964780	ENSG00000257681.1	RP11-341G23.4	8.95	1.55e-18	6.59e-16	0.34	0.27	Attention deficit hyperactivity disorder;	chr12:103813081	chr12:103746315~103768858:-
BRCA	cis	rs5751614	0.537	rs5759679	ENSG00000230701.2	FBXW4P1	8.95	1.56e-18	6.62e-16	0.33	0.27	Height;	chr22:23286826	chr22:23262767~23265005:+
BRCA	cis	rs4835473	0.801	rs76574827	ENSG00000251600.4	RP11-673E1.1	-8.95	1.56e-18	6.62e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143737303	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.832	rs62337616	ENSG00000251600.4	RP11-673E1.1	-8.95	1.56e-18	6.62e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143737307	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.832	rs66717029	ENSG00000251600.4	RP11-673E1.1	-8.95	1.56e-18	6.62e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143737318	chr4:143912331~143982454:+
BRCA	cis	rs4660456	0.913	rs4660449	ENSG00000237899.1	RP4-739H11.3	8.95	1.56e-18	6.62e-16	0.39	0.27	Platelet count;	chr1:40739780	chr1:40669089~40687588:-
BRCA	cis	rs1061377	1	rs3796509	ENSG00000249685.1	RP11-360F5.3	8.95	1.56e-18	6.63e-16	0.32	0.27	Uric acid levels;	chr4:39108566	chr4:39133913~39135608:+
BRCA	cis	rs673078	0.66	rs61945180	ENSG00000275759.1	RP11-131L12.3	-8.95	1.56e-18	6.63e-16	-0.42	-0.27	Glucose homeostasis traits;	chr12:118216335	chr12:118428281~118428870:+
BRCA	cis	rs673078	0.66	rs61945181	ENSG00000275759.1	RP11-131L12.3	-8.95	1.56e-18	6.63e-16	-0.42	-0.27	Glucose homeostasis traits;	chr12:118216651	chr12:118428281~118428870:+
BRCA	cis	rs4835473	0.864	rs17750354	ENSG00000251600.4	RP11-673E1.1	-8.95	1.56e-18	6.63e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143737352	chr4:143912331~143982454:+
BRCA	cis	rs7945705	0.869	rs11042154	ENSG00000254860.4	TMEM9B-AS1	8.95	1.57e-18	6.64e-16	0.26	0.27	Hemoglobin concentration;	chr11:9008153	chr11:8964675~8977527:+
BRCA	cis	rs4835473	0.897	rs34380794	ENSG00000251600.4	RP11-673E1.1	-8.95	1.57e-18	6.65e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143735800	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.75	rs56372690	ENSG00000251600.4	RP11-673E1.1	-8.95	1.57e-18	6.65e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143735816	chr4:143912331~143982454:+
BRCA	cis	rs2404602	0.716	rs7164813	ENSG00000259422.1	RP11-593F23.1	8.95	1.57e-18	6.66e-16	0.34	0.27	Blood metabolite levels;	chr15:76415725	chr15:76174891~76181486:-
BRCA	cis	rs11673344	0.832	rs76781063	ENSG00000226686.6	LINC01535	8.95	1.58e-18	6.68e-16	0.35	0.27	Obesity-related traits;	chr19:37036040	chr19:37251912~37265535:+
BRCA	cis	rs4835473	0.9	rs35419968	ENSG00000251600.4	RP11-673E1.1	-8.95	1.58e-18	6.71e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143734583	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.868	rs66634585	ENSG00000251600.4	RP11-673E1.1	-8.95	1.58e-18	6.71e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143734608	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.868	rs35016507	ENSG00000251600.4	RP11-673E1.1	-8.95	1.58e-18	6.71e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143734617	chr4:143912331~143982454:+
BRCA	cis	rs881375	1	rs6478484	ENSG00000226752.6	PSMD5-AS1	-8.95	1.59e-18	6.72e-16	-0.32	-0.27	Rheumatoid arthritis;	chr9:120890102	chr9:120824828~120854385:+
BRCA	cis	rs4835473	0.932	rs11721495	ENSG00000251600.4	RP11-673E1.1	-8.95	1.59e-18	6.73e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143767216	chr4:143912331~143982454:+
BRCA	cis	rs11098499	0.909	rs79026312	ENSG00000248280.1	RP11-33B1.2	8.95	1.59e-18	6.75e-16	0.28	0.27	Corneal astigmatism;	chr4:119519522	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.909	rs35111518	ENSG00000248280.1	RP11-33B1.2	8.95	1.59e-18	6.75e-16	0.28	0.27	Corneal astigmatism;	chr4:119519527	chr4:119440561~119450157:-
BRCA	cis	rs4835473	0.897	rs17693780	ENSG00000251600.4	RP11-673E1.1	-8.95	1.6e-18	6.76e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143737563	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.897	rs35556180	ENSG00000251600.4	RP11-673E1.1	-8.95	1.6e-18	6.76e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143737595	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.897	rs35377051	ENSG00000251600.4	RP11-673E1.1	-8.95	1.6e-18	6.76e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143737627	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.864	rs17018131	ENSG00000251600.4	RP11-673E1.1	-8.95	1.6e-18	6.76e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143737647	chr4:143912331~143982454:+
BRCA	cis	rs55665837	0.539	rs11023350	ENSG00000251991.1	RNU7-49P	8.95	1.6e-18	6.79e-16	0.31	0.27	Vitamin D levels;	chr11:14839971	chr11:14478892~14478953:+
BRCA	cis	rs7772486	0.558	rs9376965	ENSG00000235652.6	RP11-545I5.3	8.95	1.61e-18	6.83e-16	0.29	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145808919	chr6:145799409~145886585:+
BRCA	cis	rs853679	0.513	rs13437444	ENSG00000220721.1	OR1F12	8.95	1.62e-18	6.84e-16	0.4	0.27	Depression;	chr6:28103220	chr6:28073316~28074233:+
BRCA	cis	rs7829975	0.54	rs2976909	ENSG00000253893.2	FAM85B	8.95	1.62e-18	6.85e-16	0.35	0.27	Mood instability;	chr8:8489180	chr8:8167819~8226614:-
BRCA	cis	rs6921919	0.789	rs17301128	ENSG00000216901.1	AL022393.7	8.95	1.62e-18	6.85e-16	0.38	0.27	Autism spectrum disorder or schizophrenia;	chr6:28340257	chr6:28176188~28176674:+
BRCA	cis	rs227275	0.525	rs6533050	ENSG00000246560.2	RP11-10L12.4	8.95	1.62e-18	6.86e-16	0.28	0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102979044	chr4:102828055~102844075:+
BRCA	cis	rs11098499	0.754	rs4107728	ENSG00000248280.1	RP11-33B1.2	8.95	1.63e-18	6.91e-16	0.26	0.27	Corneal astigmatism;	chr4:119332755	chr4:119440561~119450157:-
BRCA	cis	rs807029	0.533	rs3824783	ENSG00000272572.1	RP11-179B2.2	-8.95	1.65e-18	6.97e-16	-0.34	-0.27	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100991094	chr10:100911103~100912739:-
BRCA	cis	rs8012947	0.959	rs2233752	ENSG00000279636.2	LINC00216	-8.95	1.65e-18	6.98e-16	-0.29	-0.27	Alcohol consumption in current drinkers;	chr14:58288762	chr14:58288033~58289158:+
BRCA	cis	rs7772486	0.686	rs9497396	ENSG00000235652.6	RP11-545I5.3	-8.95	1.65e-18	7e-16	-0.27	-0.27	Lobe attachment (rater-scored or self-reported);	chr6:145693827	chr6:145799409~145886585:+
BRCA	cis	rs67311347	1	rs9835219	ENSG00000223797.4	ENTPD3-AS1	8.95	1.66e-18	7.02e-16	0.3	0.27	Renal cell carcinoma;	chr3:40382602	chr3:40313802~40453329:-
BRCA	cis	rs150992	0.536	rs161729	ENSG00000248489.1	CTD-2007H13.3	8.95	1.66e-18	7.03e-16	0.35	0.27	Body mass index;	chr5:98982477	chr5:98929171~98995013:+
BRCA	cis	rs11098499	0.775	rs10021601	ENSG00000245958.5	RP11-33B1.1	-8.94	1.67e-18	7.08e-16	-0.25	-0.27	Corneal astigmatism;	chr4:119361408	chr4:119454791~119552025:+
BRCA	cis	rs2274273	0.87	rs11851169	ENSG00000258413.1	RP11-665C16.6	-8.94	1.68e-18	7.09e-16	-0.33	-0.27	Protein biomarker;	chr14:55349214	chr14:55262767~55272075:-
BRCA	cis	rs881375	0.967	rs7875829	ENSG00000226752.6	PSMD5-AS1	-8.94	1.68e-18	7.12e-16	-0.32	-0.27	Rheumatoid arthritis;	chr9:120898120	chr9:120824828~120854385:+
BRCA	cis	rs881375	0.867	rs10818484	ENSG00000226752.6	PSMD5-AS1	-8.94	1.68e-18	7.12e-16	-0.32	-0.27	Rheumatoid arthritis;	chr9:120898916	chr9:120824828~120854385:+
BRCA	cis	rs1061377	0.965	rs7669376	ENSG00000249685.1	RP11-360F5.3	8.94	1.69e-18	7.15e-16	0.32	0.27	Uric acid levels;	chr4:39116717	chr4:39133913~39135608:+
BRCA	cis	rs56046484	0.956	rs34105012	ENSG00000259295.5	CSPG4P12	8.94	1.7e-18	7.2e-16	0.47	0.27	Testicular germ cell tumor;	chr15:85048455	chr15:85191438~85213905:+
BRCA	cis	rs4835473	0.932	rs6853676	ENSG00000251600.4	RP11-673E1.1	-8.94	1.71e-18	7.2e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143750495	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs6848393	ENSG00000251600.4	RP11-673E1.1	-8.94	1.71e-18	7.2e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143750537	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs971390	ENSG00000251600.4	RP11-673E1.1	-8.94	1.71e-18	7.2e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143751264	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs971392	ENSG00000251600.4	RP11-673E1.1	-8.94	1.71e-18	7.2e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143751384	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.838	rs35978782	ENSG00000251600.4	RP11-673E1.1	-8.94	1.71e-18	7.2e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143751713	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs34060266	ENSG00000251600.4	RP11-673E1.1	-8.94	1.71e-18	7.2e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143751766	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs35300159	ENSG00000251600.4	RP11-673E1.1	-8.94	1.71e-18	7.2e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143751768	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs13139419	ENSG00000251600.4	RP11-673E1.1	-8.94	1.71e-18	7.2e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143751862	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.868	rs13106052	ENSG00000251600.4	RP11-673E1.1	-8.94	1.71e-18	7.2e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143751995	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs13134401	ENSG00000251600.4	RP11-673E1.1	-8.94	1.71e-18	7.2e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143752008	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs13106287	ENSG00000251600.4	RP11-673E1.1	-8.94	1.71e-18	7.2e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143752091	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs13134679	ENSG00000251600.4	RP11-673E1.1	-8.94	1.71e-18	7.2e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143752187	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs13108134	ENSG00000251600.4	RP11-673E1.1	-8.94	1.71e-18	7.2e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143752213	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.9	rs34406317	ENSG00000251600.4	RP11-673E1.1	-8.94	1.71e-18	7.2e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143752237	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs35863996	ENSG00000251600.4	RP11-673E1.1	-8.94	1.71e-18	7.2e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143752260	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs6836896	ENSG00000251600.4	RP11-673E1.1	-8.94	1.71e-18	7.2e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143752404	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs2874983	ENSG00000251600.4	RP11-673E1.1	-8.94	1.71e-18	7.2e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143752589	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs2874984	ENSG00000251600.4	RP11-673E1.1	-8.94	1.71e-18	7.2e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143752622	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.9	rs2323192	ENSG00000251600.4	RP11-673E1.1	-8.94	1.71e-18	7.2e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143752646	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs2323193	ENSG00000251600.4	RP11-673E1.1	-8.94	1.71e-18	7.2e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143752812	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs34152627	ENSG00000251600.4	RP11-673E1.1	-8.94	1.71e-18	7.2e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143753205	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs35670108	ENSG00000251600.4	RP11-673E1.1	-8.94	1.71e-18	7.2e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143753280	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.9	rs6832005	ENSG00000251600.4	RP11-673E1.1	-8.94	1.71e-18	7.2e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143754284	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.838	rs55963933	ENSG00000251600.4	RP11-673E1.1	-8.94	1.71e-18	7.2e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143755048	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.9	rs34790336	ENSG00000251600.4	RP11-673E1.1	-8.94	1.71e-18	7.2e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143755284	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs35740243	ENSG00000251600.4	RP11-673E1.1	-8.94	1.71e-18	7.2e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143755395	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs4395452	ENSG00000251600.4	RP11-673E1.1	-8.94	1.71e-18	7.2e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143755678	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.741	rs6537180	ENSG00000251600.4	RP11-673E1.1	-8.94	1.71e-18	7.2e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143755984	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.741	rs6537181	ENSG00000251600.4	RP11-673E1.1	-8.94	1.71e-18	7.2e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143755995	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.9	rs6814065	ENSG00000251600.4	RP11-673E1.1	-8.94	1.71e-18	7.2e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143756233	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.9	rs6816347	ENSG00000251600.4	RP11-673E1.1	-8.94	1.71e-18	7.2e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143756674	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.808	rs6847256	ENSG00000251600.4	RP11-673E1.1	-8.94	1.71e-18	7.2e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143757032	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.868	rs57413073	ENSG00000251600.4	RP11-673E1.1	-8.94	1.71e-18	7.2e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143757852	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs34732468	ENSG00000251600.4	RP11-673E1.1	-8.94	1.71e-18	7.2e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143758009	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs12510395	ENSG00000251600.4	RP11-673E1.1	-8.94	1.71e-18	7.2e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143758107	chr4:143912331~143982454:+
BRCA	cis	rs11098499	0.955	rs13114751	ENSG00000245958.5	RP11-33B1.1	-8.94	1.71e-18	7.21e-16	-0.27	-0.27	Corneal astigmatism;	chr4:119235462	chr4:119454791~119552025:+
BRCA	cis	rs6570726	0.62	rs367693	ENSG00000235652.6	RP11-545I5.3	8.94	1.71e-18	7.22e-16	0.29	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145494813	chr6:145799409~145886585:+
BRCA	cis	rs10861661	0.569	rs10778514	ENSG00000260329.1	RP11-412D9.4	-8.94	1.71e-18	7.22e-16	-0.32	-0.27	Triglyceride levels;	chr12:106909799	chr12:106954029~106955497:-
BRCA	cis	rs12468226	1	rs113877751	ENSG00000273456.1	RP11-686O6.2	8.94	1.71e-18	7.22e-16	0.39	0.27	Urate levels;	chr2:202329998	chr2:202374932~202375604:-
BRCA	cis	rs12468226	0.935	rs113021930	ENSG00000273456.1	RP11-686O6.2	8.94	1.71e-18	7.22e-16	0.39	0.27	Urate levels;	chr2:202330448	chr2:202374932~202375604:-
BRCA	cis	rs12468226	1	rs113491584	ENSG00000273456.1	RP11-686O6.2	8.94	1.71e-18	7.22e-16	0.39	0.27	Urate levels;	chr2:202331724	chr2:202374932~202375604:-
BRCA	cis	rs875971	0.54	rs4717275	ENSG00000236529.1	RP13-254B10.1	-8.94	1.71e-18	7.23e-16	-0.29	-0.27	Aortic root size;	chr7:65800193	chr7:65840212~65840596:+
BRCA	cis	rs2274273	0.837	rs56949365	ENSG00000258413.1	RP11-665C16.6	-8.94	1.72e-18	7.27e-16	-0.34	-0.27	Protein biomarker;	chr14:55323360	chr14:55262767~55272075:-
BRCA	cis	rs2274273	0.87	rs4496026	ENSG00000258413.1	RP11-665C16.6	-8.94	1.72e-18	7.27e-16	-0.34	-0.27	Protein biomarker;	chr14:55323794	chr14:55262767~55272075:-
BRCA	cis	rs2274273	0.87	rs4366639	ENSG00000258413.1	RP11-665C16.6	-8.94	1.72e-18	7.27e-16	-0.34	-0.27	Protein biomarker;	chr14:55323798	chr14:55262767~55272075:-
BRCA	cis	rs6061231	0.793	rs6061512	ENSG00000273619.1	RP5-908M14.9	-8.94	1.72e-18	7.27e-16	-0.25	-0.27	Colorectal cancer;	chr20:62401873	chr20:62386303~62386970:-
BRCA	cis	rs1707322	1	rs10890382	ENSG00000280836.1	AL355480.1	-8.94	1.73e-18	7.28e-16	-0.35	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46004002	chr1:45581219~45581321:-
BRCA	cis	rs1707322	1	rs1622208	ENSG00000280836.1	AL355480.1	8.94	1.73e-18	7.29e-16	0.35	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46032703	chr1:45581219~45581321:-
BRCA	cis	rs55665837	0.54	rs7938266	ENSG00000251991.1	RNU7-49P	8.94	1.73e-18	7.3e-16	0.3	0.27	Vitamin D levels;	chr11:14687778	chr11:14478892~14478953:+
BRCA	cis	rs6570726	0.846	rs9376954	ENSG00000235652.6	RP11-545I5.3	8.94	1.74e-18	7.33e-16	0.26	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145622601	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.846	rs2144478	ENSG00000235652.6	RP11-545I5.3	8.94	1.74e-18	7.33e-16	0.26	0.27	Lobe attachment (rater-scored or self-reported);	chr6:146060309	chr6:145799409~145886585:+
BRCA	cis	rs11971779	0.941	rs6954453	ENSG00000273391.1	RP11-634H22.1	8.94	1.74e-18	7.35e-16	0.3	0.27	Diisocyanate-induced asthma;	chr7:139347048	chr7:139359032~139359566:-
BRCA	cis	rs13256369	0.802	rs12681326	ENSG00000253893.2	FAM85B	-8.94	1.74e-18	7.35e-16	-0.38	-0.27	Obesity-related traits;	chr8:8708879	chr8:8167819~8226614:-
BRCA	cis	rs6782228	0.848	rs3935016	ENSG00000242551.2	POU5F1P6	8.94	1.74e-18	7.35e-16	0.37	0.27	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128701591	chr3:128674735~128677005:-
BRCA	cis	rs6782228	0.848	rs6439141	ENSG00000242551.2	POU5F1P6	8.94	1.74e-18	7.35e-16	0.37	0.27	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128701691	chr3:128674735~128677005:-
BRCA	cis	rs56046484	0.956	rs35885781	ENSG00000259295.5	CSPG4P12	8.94	1.74e-18	7.36e-16	0.47	0.27	Testicular germ cell tumor;	chr15:85047852	chr15:85191438~85213905:+
BRCA	cis	rs9287719	0.967	rs6735074	ENSG00000234818.1	AC092687.5	-8.94	1.74e-18	7.36e-16	-0.31	-0.27	Prostate cancer;	chr2:10594640	chr2:10589166~10604830:+
BRCA	cis	rs150992	0.571	rs34488	ENSG00000248489.1	CTD-2007H13.3	8.94	1.75e-18	7.38e-16	0.35	0.27	Body mass index;	chr5:98977773	chr5:98929171~98995013:+
BRCA	cis	rs11098499	0.779	rs10857066	ENSG00000245958.5	RP11-33B1.1	-8.94	1.75e-18	7.39e-16	-0.25	-0.27	Corneal astigmatism;	chr4:119365441	chr4:119454791~119552025:+
BRCA	cis	rs2274273	0.87	rs7153612	ENSG00000258413.1	RP11-665C16.6	-8.94	1.75e-18	7.4e-16	-0.34	-0.27	Protein biomarker;	chr14:55322044	chr14:55262767~55272075:-
BRCA	cis	rs11098499	0.754	rs12513083	ENSG00000248280.1	RP11-33B1.2	8.94	1.76e-18	7.4e-16	0.26	0.27	Corneal astigmatism;	chr4:119328457	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.754	rs12509621	ENSG00000248280.1	RP11-33B1.2	8.94	1.76e-18	7.4e-16	0.26	0.27	Corneal astigmatism;	chr4:119328505	chr4:119440561~119450157:-
BRCA	cis	rs10129255	0.957	rs8009464	ENSG00000223648.3	IGHV3-64	8.94	1.76e-18	7.42e-16	0.22	0.27	Kawasaki disease;	chr14:106777611	chr14:106643132~106658258:-
BRCA	cis	rs6142102	0.961	rs2235596	ENSG00000276073.1	RP5-1125A11.7	8.94	1.76e-18	7.43e-16	0.31	0.27	Skin pigmentation;	chr20:34096503	chr20:33985617~33988989:-
BRCA	cis	rs7937890	0.559	rs6486197	ENSG00000251991.1	RNU7-49P	8.94	1.77e-18	7.45e-16	0.3	0.27	Mitochondrial DNA levels;	chr11:14508328	chr11:14478892~14478953:+
BRCA	cis	rs1075265	0.783	rs805438	ENSG00000233266.1	HMGB1P31	8.94	1.78e-18	7.49e-16	0.32	0.27	Chronotype;Morning vs. evening chronotype;	chr2:53829051	chr2:54051334~54051760:+
BRCA	cis	rs80285556	1	rs55914901	ENSG00000161643.11	SIGLEC16	8.94	1.78e-18	7.49e-16	0.69	0.27	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50025089	chr19:49969673~49975814:+
BRCA	cis	rs6570726	0.846	rs9399559	ENSG00000235652.6	RP11-545I5.3	8.94	1.78e-18	7.52e-16	0.26	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145624642	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.686	rs9390349	ENSG00000235652.6	RP11-545I5.3	-8.94	1.8e-18	7.57e-16	-0.26	-0.27	Lobe attachment (rater-scored or self-reported);	chr6:145733294	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.686	rs2072911	ENSG00000235652.6	RP11-545I5.3	-8.94	1.8e-18	7.57e-16	-0.26	-0.27	Lobe attachment (rater-scored or self-reported);	chr6:145735665	chr6:145799409~145886585:+
BRCA	cis	rs2933343	0.951	rs789217	ENSG00000231305.3	RP11-723O4.2	8.94	1.8e-18	7.59e-16	0.33	0.27	IgG glycosylation;	chr3:128874358	chr3:128861313~128871540:-
BRCA	cis	rs11676348	0.772	rs10932745	ENSG00000261338.2	RP11-378A13.1	-8.94	1.81e-18	7.63e-16	-0.28	-0.27	Ulcerative colitis;	chr2:218078253	chr2:218255319~218257366:+
BRCA	cis	rs1707322	0.964	rs785516	ENSG00000280836.1	AL355480.1	8.93	1.81e-18	7.64e-16	0.35	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46099086	chr1:45581219~45581321:-
BRCA	cis	rs1707322	1	rs785517	ENSG00000280836.1	AL355480.1	8.93	1.81e-18	7.64e-16	0.35	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46101863	chr1:45581219~45581321:-
BRCA	cis	rs1707322	1	rs785484	ENSG00000280836.1	AL355480.1	8.93	1.81e-18	7.64e-16	0.35	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46108343	chr1:45581219~45581321:-
BRCA	cis	rs748404	0.666	rs12905220	ENSG00000249839.1	AC011330.5	-8.93	1.81e-18	7.64e-16	-0.39	-0.27	Lung cancer;	chr15:43465641	chr15:43663654~43684339:-
BRCA	cis	rs150992	0.536	rs161730	ENSG00000248489.1	CTD-2007H13.3	8.93	1.82e-18	7.65e-16	0.35	0.27	Body mass index;	chr5:98982631	chr5:98929171~98995013:+
BRCA	cis	rs11098499	0.954	rs1546505	ENSG00000245958.5	RP11-33B1.1	-8.93	1.82e-18	7.65e-16	-0.26	-0.27	Corneal astigmatism;	chr4:119320069	chr4:119454791~119552025:+
BRCA	cis	rs925255	0.747	rs6547850	ENSG00000270210.1	RP11-373D23.3	-8.93	1.82e-18	7.66e-16	-0.34	-0.27	Inflammatory bowel disease;Crohn's disease;	chr2:28406476	chr2:28425945~28426719:+
BRCA	cis	rs11098499	0.955	rs4145951	ENSG00000245958.5	RP11-33B1.1	-8.93	1.82e-18	7.66e-16	-0.27	-0.27	Corneal astigmatism;	chr4:119234662	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.955	rs35916640	ENSG00000245958.5	RP11-33B1.1	-8.93	1.82e-18	7.66e-16	-0.27	-0.27	Corneal astigmatism;	chr4:119234697	chr4:119454791~119552025:+
BRCA	cis	rs889312	0.532	rs16886181	ENSG00000271828.1	CTD-2310F14.1	8.93	1.82e-18	7.66e-16	0.39	0.27	Breast cancer (early onset);Breast cancer;	chr5:56733416	chr5:56927874~56929573:+
BRCA	cis	rs4835473	0.838	rs4583708	ENSG00000251600.4	RP11-673E1.1	-8.93	1.82e-18	7.67e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143735610	chr4:143912331~143982454:+
BRCA	cis	rs11722779	0.935	rs3974481	ENSG00000246560.2	RP11-10L12.4	8.93	1.82e-18	7.67e-16	0.28	0.27	Schizophrenia;	chr4:102956834	chr4:102828055~102844075:+
BRCA	cis	rs2933343	0.951	rs796862	ENSG00000261159.1	RP11-723O4.9	8.93	1.83e-18	7.71e-16	0.31	0.27	IgG glycosylation;	chr3:128874197	chr3:128859716~128860526:-
BRCA	cis	rs11098499	0.866	rs6857892	ENSG00000245958.5	RP11-33B1.1	-8.93	1.83e-18	7.71e-16	-0.25	-0.27	Corneal astigmatism;	chr4:119361541	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.909	rs28581362	ENSG00000245958.5	RP11-33B1.1	-8.93	1.83e-18	7.71e-16	-0.25	-0.27	Corneal astigmatism;	chr4:119362393	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.82	rs12503082	ENSG00000245958.5	RP11-33B1.1	-8.93	1.83e-18	7.71e-16	-0.25	-0.27	Corneal astigmatism;	chr4:119363162	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.866	rs12499602	ENSG00000245958.5	RP11-33B1.1	-8.93	1.83e-18	7.71e-16	-0.25	-0.27	Corneal astigmatism;	chr4:119363232	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.774	rs11098505	ENSG00000245958.5	RP11-33B1.1	-8.93	1.83e-18	7.71e-16	-0.25	-0.27	Corneal astigmatism;	chr4:119363472	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.866	rs13105020	ENSG00000245958.5	RP11-33B1.1	-8.93	1.83e-18	7.71e-16	-0.25	-0.27	Corneal astigmatism;	chr4:119364533	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.866	rs6824111	ENSG00000245958.5	RP11-33B1.1	-8.93	1.83e-18	7.71e-16	-0.25	-0.27	Corneal astigmatism;	chr4:119364813	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.775	rs10029303	ENSG00000245958.5	RP11-33B1.1	-8.93	1.83e-18	7.71e-16	-0.25	-0.27	Corneal astigmatism;	chr4:119365600	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.866	rs9995136	ENSG00000245958.5	RP11-33B1.1	-8.93	1.83e-18	7.71e-16	-0.25	-0.27	Corneal astigmatism;	chr4:119365690	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.866	rs13125526	ENSG00000245958.5	RP11-33B1.1	-8.93	1.83e-18	7.71e-16	-0.25	-0.27	Corneal astigmatism;	chr4:119366864	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.866	rs12513310	ENSG00000245958.5	RP11-33B1.1	-8.93	1.83e-18	7.71e-16	-0.25	-0.27	Corneal astigmatism;	chr4:119366884	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.866	rs12510451	ENSG00000245958.5	RP11-33B1.1	-8.93	1.83e-18	7.71e-16	-0.25	-0.27	Corneal astigmatism;	chr4:119367988	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.774	rs73842616	ENSG00000245958.5	RP11-33B1.1	-8.93	1.83e-18	7.71e-16	-0.25	-0.27	Corneal astigmatism;	chr4:119369528	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.645	rs72676059	ENSG00000245958.5	RP11-33B1.1	-8.93	1.83e-18	7.71e-16	-0.25	-0.27	Corneal astigmatism;	chr4:119369673	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.569	rs55845118	ENSG00000245958.5	RP11-33B1.1	-8.93	1.83e-18	7.71e-16	-0.25	-0.27	Corneal astigmatism;	chr4:119369758	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.866	rs7677068	ENSG00000245958.5	RP11-33B1.1	-8.93	1.83e-18	7.71e-16	-0.25	-0.27	Corneal astigmatism;	chr4:119370549	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.866	rs9991221	ENSG00000245958.5	RP11-33B1.1	-8.93	1.83e-18	7.71e-16	-0.25	-0.27	Corneal astigmatism;	chr4:119370952	chr4:119454791~119552025:+
BRCA	cis	rs11673344	0.711	rs112857724	ENSG00000226686.6	LINC01535	8.93	1.83e-18	7.72e-16	0.35	0.27	Obesity-related traits;	chr19:37030176	chr19:37251912~37265535:+
BRCA	cis	rs11971779	0.793	rs4732366	ENSG00000273391.1	RP11-634H22.1	8.93	1.84e-18	7.75e-16	0.27	0.27	Diisocyanate-induced asthma;	chr7:139343099	chr7:139359032~139359566:-
BRCA	cis	rs11098499	0.697	rs35280960	ENSG00000248280.1	RP11-33B1.2	8.93	1.84e-18	7.76e-16	0.27	0.27	Corneal astigmatism;	chr4:119335904	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.863	rs11098531	ENSG00000245958.5	RP11-33B1.1	-8.93	1.84e-18	7.76e-16	-0.27	-0.27	Corneal astigmatism;	chr4:119543846	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.863	rs28718422	ENSG00000245958.5	RP11-33B1.1	-8.93	1.84e-18	7.76e-16	-0.27	-0.27	Corneal astigmatism;	chr4:119545149	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.818	rs12498599	ENSG00000245958.5	RP11-33B1.1	-8.93	1.84e-18	7.76e-16	-0.27	-0.27	Corneal astigmatism;	chr4:119547348	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.863	rs10009626	ENSG00000245958.5	RP11-33B1.1	-8.93	1.84e-18	7.76e-16	-0.27	-0.27	Corneal astigmatism;	chr4:119548850	chr4:119454791~119552025:+
BRCA	cis	rs17608059	0.524	rs9897978	ENSG00000236088.8	COX10-AS1	8.93	1.85e-18	7.77e-16	0.3	0.27	Temperament;	chr17:13996939	chr17:13756478~14069495:-
BRCA	cis	rs807029	0.577	rs11190787	ENSG00000272572.1	RP11-179B2.2	-8.93	1.85e-18	7.79e-16	-0.34	-0.27	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100998868	chr10:100911103~100912739:-
BRCA	cis	rs2933343	0.951	rs1055128	ENSG00000231305.3	RP11-723O4.2	8.93	1.85e-18	7.79e-16	0.33	0.27	IgG glycosylation;	chr3:128872205	chr3:128861313~128871540:-
BRCA	cis	rs881375	0.678	rs10760130	ENSG00000226752.6	PSMD5-AS1	-8.93	1.85e-18	7.79e-16	-0.32	-0.27	Rheumatoid arthritis;	chr9:120939712	chr9:120824828~120854385:+
BRCA	cis	rs875971	1	rs697970	ENSG00000237310.1	GS1-124K5.4	-8.93	1.85e-18	7.8e-16	-0.28	-0.27	Aortic root size;	chr7:66095065	chr7:66493706~66495474:+
BRCA	cis	rs11098499	0.564	rs11098507	ENSG00000245958.5	RP11-33B1.1	-8.93	1.86e-18	7.81e-16	-0.25	-0.27	Corneal astigmatism;	chr4:119367131	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.863	rs34868248	ENSG00000248280.1	RP11-33B1.2	8.93	1.87e-18	7.85e-16	0.28	0.27	Corneal astigmatism;	chr4:119521275	chr4:119440561~119450157:-
BRCA	cis	rs10875746	0.669	rs11168508	ENSG00000240399.1	RP1-228P16.1	-8.93	1.87e-18	7.85e-16	-0.35	-0.27	Longevity (90 years and older);	chr12:48289728	chr12:48054813~48055591:-
BRCA	cis	rs6570726	0.846	rs1935616	ENSG00000235652.6	RP11-545I5.3	8.93	1.88e-18	7.89e-16	0.26	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145622376	chr6:145799409~145886585:+
BRCA	cis	rs7727544	0.735	rs272881	ENSG00000233006.5	AC034220.3	8.93	1.88e-18	7.89e-16	0.19	0.27	Blood metabolite levels;	chr5:132333571	chr5:132311285~132369916:-
BRCA	cis	rs7727544	0.735	rs272879	ENSG00000233006.5	AC034220.3	8.93	1.88e-18	7.89e-16	0.19	0.27	Blood metabolite levels;	chr5:132334853	chr5:132311285~132369916:-
BRCA	cis	rs638893	0.578	rs500254	ENSG00000278376.1	RP11-158I9.8	8.93	1.88e-18	7.9e-16	0.37	0.27	Vitiligo;	chr11:118808071	chr11:118791254~118793137:+
BRCA	cis	rs7937890	0.559	rs10766184	ENSG00000251991.1	RNU7-49P	8.93	1.89e-18	7.92e-16	0.3	0.27	Mitochondrial DNA levels;	chr11:14521031	chr11:14478892~14478953:+
BRCA	cis	rs9506514	0.722	rs11147813	ENSG00000222726.1	RNU2-7P	8.93	1.89e-18	7.93e-16	0.31	0.27	Coronary artery calcification;	chr13:20684419	chr13:20612161~20612338:+
BRCA	cis	rs11098499	0.955	rs35434465	ENSG00000245958.5	RP11-33B1.1	-8.93	1.89e-18	7.95e-16	-0.27	-0.27	Corneal astigmatism;	chr4:119248223	chr4:119454791~119552025:+
BRCA	cis	rs858239	0.6	rs7776649	ENSG00000226816.2	AC005082.12	8.93	1.89e-18	7.96e-16	0.31	0.27	Cerebrospinal fluid biomarker levels;	chr7:23079698	chr7:23206013~23208045:+
BRCA	cis	rs4835473	0.932	rs12509642	ENSG00000251600.4	RP11-673E1.1	-8.93	1.9e-18	7.98e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143737080	chr4:143912331~143982454:+
BRCA	cis	rs7429990	0.833	rs6777632	ENSG00000229759.1	MRPS18AP1	-8.93	1.9e-18	7.99e-16	-0.3	-0.27	Educational attainment (years of education);	chr3:47748775	chr3:48256350~48256938:-
BRCA	cis	rs881375	0.715	rs10818482	ENSG00000226752.6	PSMD5-AS1	8.93	1.91e-18	8.01e-16	0.31	0.27	Rheumatoid arthritis;	chr9:120885807	chr9:120824828~120854385:+
BRCA	cis	rs7945705	0.875	rs2568065	ENSG00000254860.4	TMEM9B-AS1	8.93	1.91e-18	8.03e-16	0.24	0.27	Hemoglobin concentration;	chr11:8868101	chr11:8964675~8977527:+
BRCA	cis	rs7772486	0.686	rs1415744	ENSG00000235652.6	RP11-545I5.3	8.93	1.91e-18	8.03e-16	0.26	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145701395	chr6:145799409~145886585:+
BRCA	cis	rs6142102	0.602	rs4911399	ENSG00000275784.1	RP5-1125A11.6	-8.93	1.92e-18	8.06e-16	-0.3	-0.27	Skin pigmentation;	chr20:34035612	chr20:33989480~33991818:-
BRCA	cis	rs6558530	0.73	rs7014327	ENSG00000253982.1	CTD-2336O2.1	8.93	1.92e-18	8.07e-16	0.3	0.27	Systolic blood pressure;	chr8:1775886	chr8:1761990~1764502:-
BRCA	cis	rs7617773	0.817	rs9830016	ENSG00000228638.1	FCF1P2	-8.93	1.92e-18	8.07e-16	-0.28	-0.27	Coronary artery disease;	chr3:48241004	chr3:48290793~48291375:-
BRCA	cis	rs881375	0.867	rs6478487	ENSG00000226752.6	PSMD5-AS1	-8.93	1.92e-18	8.08e-16	-0.32	-0.27	Rheumatoid arthritis;	chr9:120910499	chr9:120824828~120854385:+
BRCA	cis	rs7429990	0.864	rs4274776	ENSG00000229759.1	MRPS18AP1	8.93	1.93e-18	8.09e-16	0.3	0.27	Educational attainment (years of education);	chr3:47605868	chr3:48256350~48256938:-
BRCA	cis	rs7429990	0.864	rs6786001	ENSG00000229759.1	MRPS18AP1	-8.93	1.95e-18	8.18e-16	-0.3	-0.27	Educational attainment (years of education);	chr3:47718500	chr3:48256350~48256938:-
BRCA	cis	rs7429990	0.864	rs35148469	ENSG00000229759.1	MRPS18AP1	-8.93	1.95e-18	8.18e-16	-0.3	-0.27	Educational attainment (years of education);	chr3:47739873	chr3:48256350~48256938:-
BRCA	cis	rs7429990	0.864	rs6442082	ENSG00000229759.1	MRPS18AP1	-8.93	1.95e-18	8.18e-16	-0.3	-0.27	Educational attainment (years of education);	chr3:47743991	chr3:48256350~48256938:-
BRCA	cis	rs7727544	0.735	rs272884	ENSG00000233006.5	AC034220.3	8.93	1.96e-18	8.22e-16	0.19	0.27	Blood metabolite levels;	chr5:132332961	chr5:132311285~132369916:-
BRCA	cis	rs881375	0.933	rs7859805	ENSG00000226752.6	PSMD5-AS1	-8.92	1.97e-18	8.26e-16	-0.32	-0.27	Rheumatoid arthritis;	chr9:120901845	chr9:120824828~120854385:+
BRCA	cis	rs881375	0.967	rs10435843	ENSG00000226752.6	PSMD5-AS1	-8.92	1.97e-18	8.26e-16	-0.32	-0.27	Rheumatoid arthritis;	chr9:120905755	chr9:120824828~120854385:+
BRCA	cis	rs881375	0.967	rs10435844	ENSG00000226752.6	PSMD5-AS1	-8.92	1.97e-18	8.26e-16	-0.32	-0.27	Rheumatoid arthritis;	chr9:120905921	chr9:120824828~120854385:+
BRCA	cis	rs881375	0.967	rs7848332	ENSG00000226752.6	PSMD5-AS1	-8.92	1.97e-18	8.26e-16	-0.32	-0.27	Rheumatoid arthritis;	chr9:120907218	chr9:120824828~120854385:+
BRCA	cis	rs11098499	0.954	rs12508504	ENSG00000248280.1	RP11-33B1.2	8.92	1.97e-18	8.26e-16	0.27	0.27	Corneal astigmatism;	chr4:119489452	chr4:119440561~119450157:-
BRCA	cis	rs11676348	0.805	rs12694428	ENSG00000261338.2	RP11-378A13.1	-8.92	1.98e-18	8.3e-16	-0.28	-0.27	Ulcerative colitis;	chr2:218094097	chr2:218255319~218257366:+
BRCA	cis	rs10129255	0.5	rs8014529	ENSG00000211972.2	IGHV3-66	8.92	1.98e-18	8.32e-16	0.18	0.27	Kawasaki disease;	chr14:106784065	chr14:106675017~106675544:-
BRCA	cis	rs11098499	0.789	rs1980024	ENSG00000245958.5	RP11-33B1.1	-8.92	1.99e-18	8.34e-16	-0.25	-0.27	Corneal astigmatism;	chr4:119331892	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.754	rs34425882	ENSG00000245958.5	RP11-33B1.1	-8.92	1.99e-18	8.34e-16	-0.25	-0.27	Corneal astigmatism;	chr4:119332022	chr4:119454791~119552025:+
BRCA	cis	rs55665837	0.54	rs12416696	ENSG00000251991.1	RNU7-49P	8.92	2e-18	8.39e-16	0.3	0.27	Vitamin D levels;	chr11:14769343	chr11:14478892~14478953:+
BRCA	cis	rs67311347	1	rs7642552	ENSG00000223797.4	ENTPD3-AS1	8.92	2e-18	8.39e-16	0.3	0.27	Renal cell carcinoma;	chr3:40383325	chr3:40313802~40453329:-
BRCA	cis	rs11098499	0.954	rs12505469	ENSG00000245958.5	RP11-33B1.1	-8.92	2.01e-18	8.41e-16	-0.26	-0.27	Corneal astigmatism;	chr4:119328430	chr4:119454791~119552025:+
BRCA	cis	rs11159086	0.793	rs10139122	ENSG00000259005.1	RP3-449M8.6	8.92	2.01e-18	8.42e-16	0.4	0.27	Advanced glycation end-product levels;	chr14:74492353	chr14:74474007~74474864:-
BRCA	cis	rs783540	0.867	rs11855735	ENSG00000278603.1	RP13-608F4.5	8.92	2.01e-18	8.43e-16	0.33	0.27	Schizophrenia;	chr15:82627794	chr15:82472203~82472426:+
BRCA	cis	rs11676348	0.772	rs11687200	ENSG00000261338.2	RP11-378A13.1	-8.92	2.02e-18	8.47e-16	-0.28	-0.27	Ulcerative colitis;	chr2:218079892	chr2:218255319~218257366:+
BRCA	cis	rs881375	0.933	rs4837799	ENSG00000226752.6	PSMD5-AS1	-8.92	2.03e-18	8.52e-16	-0.32	-0.27	Rheumatoid arthritis;	chr9:120906048	chr9:120824828~120854385:+
BRCA	cis	rs763567	0.933	rs608930	ENSG00000271811.1	RP1-79C4.4	8.92	2.03e-18	8.52e-16	0.29	0.27	Tonsillectomy;	chr1:170648165	chr1:170667381~170669425:+
BRCA	cis	rs11722779	0.873	rs223346	ENSG00000246560.2	RP11-10L12.4	8.92	2.04e-18	8.54e-16	0.28	0.27	Schizophrenia;	chr4:102859339	chr4:102828055~102844075:+
BRCA	cis	rs12468226	1	rs112306637	ENSG00000273456.1	RP11-686O6.2	8.92	2.04e-18	8.54e-16	0.39	0.27	Urate levels;	chr2:202334195	chr2:202374932~202375604:-
BRCA	cis	rs55665837	0.54	rs11023302	ENSG00000251991.1	RNU7-49P	8.92	2.04e-18	8.55e-16	0.3	0.27	Vitamin D levels;	chr11:14672389	chr11:14478892~14478953:+
BRCA	cis	rs8012947	1	rs10133305	ENSG00000279636.2	LINC00216	-8.92	2.04e-18	8.56e-16	-0.29	-0.27	Alcohol consumption in current drinkers;	chr14:58294411	chr14:58288033~58289158:+
BRCA	cis	rs7429990	0.786	rs13064183	ENSG00000229759.1	MRPS18AP1	-8.92	2.05e-18	8.59e-16	-0.3	-0.27	Educational attainment (years of education);	chr3:47745405	chr3:48256350~48256938:-
BRCA	cis	rs11098499	0.863	rs1383532	ENSG00000245958.5	RP11-33B1.1	8.92	2.05e-18	8.6e-16	0.26	0.27	Corneal astigmatism;	chr4:119513249	chr4:119454791~119552025:+
BRCA	cis	rs7937890	0.559	rs2575836	ENSG00000251991.1	RNU7-49P	8.92	2.06e-18	8.62e-16	0.3	0.27	Mitochondrial DNA levels;	chr11:14476318	chr11:14478892~14478953:+
BRCA	cis	rs4237845	0.586	rs4760174	ENSG00000257159.1	RP11-58A17.3	8.92	2.06e-18	8.62e-16	0.31	0.27	Intelligence (multi-trait analysis);	chr12:57926653	chr12:57967058~57968399:+
BRCA	cis	rs7712401	0.623	rs26372	ENSG00000263432.2	RN7SL689P	-8.92	2.08e-18	8.71e-16	-0.34	-0.27	Mean platelet volume;	chr5:122870752	chr5:123022487~123022783:-
BRCA	cis	rs6782228	0.883	rs6439142	ENSG00000242551.2	POU5F1P6	8.92	2.08e-18	8.71e-16	0.37	0.27	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128701714	chr3:128674735~128677005:-
BRCA	cis	rs4862750	0.957	rs6858853	ENSG00000250971.1	RP11-696F12.1	-8.92	2.09e-18	8.73e-16	-0.28	-0.27	Lobe attachment (rater-scored or self-reported);	chr4:186982258	chr4:187060099~187060930:+
BRCA	cis	rs1134634	0.52	rs4393989	ENSG00000273133.1	RP11-799M12.2	-8.92	2.09e-18	8.73e-16	-0.35	-0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15614276	chr4:15563698~15564253:-
BRCA	cis	rs1134634	0.52	rs10003739	ENSG00000273133.1	RP11-799M12.2	-8.92	2.09e-18	8.73e-16	-0.35	-0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15617063	chr4:15563698~15564253:-
BRCA	cis	rs11098499	0.863	rs3733525	ENSG00000248280.1	RP11-33B1.2	8.92	2.09e-18	8.74e-16	0.28	0.27	Corneal astigmatism;	chr4:119525893	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.863	rs3775847	ENSG00000248280.1	RP11-33B1.2	8.92	2.09e-18	8.74e-16	0.28	0.27	Corneal astigmatism;	chr4:119526487	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.863	rs3775848	ENSG00000248280.1	RP11-33B1.2	8.92	2.09e-18	8.74e-16	0.28	0.27	Corneal astigmatism;	chr4:119526569	chr4:119440561~119450157:-
BRCA	cis	rs881375	0.967	rs1008382	ENSG00000226752.6	PSMD5-AS1	-8.92	2.1e-18	8.78e-16	-0.32	-0.27	Rheumatoid arthritis;	chr9:120918977	chr9:120824828~120854385:+
BRCA	cis	rs17772222	0.958	rs1816372	ENSG00000258983.2	RP11-507K2.2	8.92	2.1e-18	8.8e-16	0.31	0.27	Coronary artery calcification;	chr14:88507033	chr14:88499334~88515502:+
BRCA	cis	rs11098499	0.754	rs7672372	ENSG00000248280.1	RP11-33B1.2	8.92	2.1e-18	8.8e-16	0.27	0.27	Corneal astigmatism;	chr4:119327251	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.908	rs1002152	ENSG00000248280.1	RP11-33B1.2	8.92	2.11e-18	8.81e-16	0.27	0.27	Corneal astigmatism;	chr4:119352232	chr4:119440561~119450157:-
BRCA	cis	rs55665837	0.54	rs10128681	ENSG00000251991.1	RNU7-49P	8.92	2.12e-18	8.85e-16	0.3	0.27	Vitamin D levels;	chr11:14680030	chr11:14478892~14478953:+
BRCA	cis	rs4718428	0.672	rs36038499	ENSG00000273142.1	RP11-458F8.4	-8.92	2.12e-18	8.86e-16	-0.26	-0.27	Corneal structure;	chr7:66824628	chr7:66902857~66906297:+
BRCA	cis	rs7772486	0.875	rs6930975	ENSG00000235652.6	RP11-545I5.3	8.92	2.12e-18	8.87e-16	0.26	0.27	Lobe attachment (rater-scored or self-reported);	chr6:146065975	chr6:145799409~145886585:+
BRCA	cis	rs8012947	1	rs12323535	ENSG00000279636.2	LINC00216	-8.92	2.13e-18	8.89e-16	-0.29	-0.27	Alcohol consumption in current drinkers;	chr14:58303137	chr14:58288033~58289158:+
BRCA	cis	rs8012947	1	rs10145481	ENSG00000279636.2	LINC00216	-8.92	2.13e-18	8.89e-16	-0.29	-0.27	Alcohol consumption in current drinkers;	chr14:58303671	chr14:58288033~58289158:+
BRCA	cis	rs8012947	0.959	rs1951204	ENSG00000279636.2	LINC00216	-8.92	2.13e-18	8.89e-16	-0.29	-0.27	Alcohol consumption in current drinkers;	chr14:58303983	chr14:58288033~58289158:+
BRCA	cis	rs12468226	1	rs7597469	ENSG00000273456.1	RP11-686O6.2	8.92	2.13e-18	8.89e-16	0.39	0.27	Urate levels;	chr2:202329547	chr2:202374932~202375604:-
BRCA	cis	rs4660456	0.913	rs2780950	ENSG00000237899.1	RP4-739H11.3	8.92	2.13e-18	8.91e-16	0.4	0.27	Platelet count;	chr1:40686937	chr1:40669089~40687588:-
BRCA	cis	rs1075265	0.756	rs2160931	ENSG00000233266.1	HMGB1P31	8.92	2.13e-18	8.92e-16	0.33	0.27	Chronotype;Morning vs. evening chronotype;	chr2:53712411	chr2:54051334~54051760:+
BRCA	cis	rs10262624	0.901	rs6977550	ENSG00000234286.1	AC006026.13	-8.92	2.14e-18	8.95e-16	-0.31	-0.27	Schizophrenia;	chr7:23865825	chr7:23680195~23680786:-
BRCA	cis	rs75422866	0.51	rs75424057	ENSG00000274902.1	RP1-197B17.4	8.91	2.14e-18	8.96e-16	0.68	0.27	Pneumonia;	chr12:47737294	chr12:47731908~47732351:+
BRCA	cis	rs11098499	0.722	rs28713555	ENSG00000248280.1	RP11-33B1.2	8.91	2.15e-18	8.99e-16	0.26	0.27	Corneal astigmatism;	chr4:119330840	chr4:119440561~119450157:-
BRCA	cis	rs4835473	0.932	rs13135034	ENSG00000251600.4	RP11-673E1.1	8.91	2.15e-18	8.99e-16	0.31	0.27	Immature fraction of reticulocytes;	chr4:143738247	chr4:143912331~143982454:+
BRCA	cis	rs8012947	1	rs4595719	ENSG00000279636.2	LINC00216	-8.91	2.16e-18	9.03e-16	-0.29	-0.27	Alcohol consumption in current drinkers;	chr14:58302084	chr14:58288033~58289158:+
BRCA	cis	rs1061377	1	rs10030904	ENSG00000249685.1	RP11-360F5.3	8.91	2.18e-18	9.09e-16	0.32	0.27	Uric acid levels;	chr4:39113603	chr4:39133913~39135608:+
BRCA	cis	rs1134634	0.52	rs7682586	ENSG00000273133.1	RP11-799M12.2	-8.91	2.18e-18	9.09e-16	-0.35	-0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15624620	chr4:15563698~15564253:-
BRCA	cis	rs11971779	0.818	rs12056045	ENSG00000273391.1	RP11-634H22.1	8.91	2.19e-18	9.14e-16	0.3	0.27	Diisocyanate-induced asthma;	chr7:139340684	chr7:139359032~139359566:-
BRCA	cis	rs7937890	0.504	rs2575822	ENSG00000251991.1	RNU7-49P	8.91	2.19e-18	9.15e-16	0.3	0.27	Mitochondrial DNA levels;	chr11:14498305	chr11:14478892~14478953:+
BRCA	cis	rs7937890	0.559	rs2575823	ENSG00000251991.1	RNU7-49P	8.91	2.19e-18	9.15e-16	0.3	0.27	Mitochondrial DNA levels;	chr11:14499808	chr11:14478892~14478953:+
BRCA	cis	rs7937890	0.559	rs2597221	ENSG00000251991.1	RNU7-49P	8.91	2.19e-18	9.15e-16	0.3	0.27	Mitochondrial DNA levels;	chr11:14505529	chr11:14478892~14478953:+
BRCA	cis	rs10875746	0.669	rs10875770	ENSG00000240399.1	RP1-228P16.1	-8.91	2.19e-18	9.15e-16	-0.35	-0.27	Longevity (90 years and older);	chr12:48206737	chr12:48054813~48055591:-
BRCA	cis	rs11098499	0.657	rs10434028	ENSG00000245958.5	RP11-33B1.1	-8.91	2.2e-18	9.19e-16	-0.25	-0.27	Corneal astigmatism;	chr4:119373309	chr4:119454791~119552025:+
BRCA	cis	rs7429990	0.864	rs13098128	ENSG00000229759.1	MRPS18AP1	-8.91	2.2e-18	9.19e-16	-0.3	-0.27	Educational attainment (years of education);	chr3:47756066	chr3:48256350~48256938:-
BRCA	cis	rs7429990	0.864	rs6442085	ENSG00000229759.1	MRPS18AP1	-8.91	2.2e-18	9.19e-16	-0.3	-0.27	Educational attainment (years of education);	chr3:47760080	chr3:48256350~48256938:-
BRCA	cis	rs10129255	0.957	rs10150241	ENSG00000223648.3	IGHV3-64	-8.91	2.2e-18	9.2e-16	-0.22	-0.27	Kawasaki disease;	chr14:106775945	chr14:106643132~106658258:-
BRCA	cis	rs6683071	0.688	rs2936049	ENSG00000272750.1	RP11-378J18.8	8.91	2.21e-18	9.22e-16	0.41	0.27	Cognitive performance;	chr1:222684825	chr1:222658867~222661512:-
BRCA	cis	rs875971	1	rs2420820	ENSG00000237310.1	GS1-124K5.4	-8.91	2.22e-18	9.25e-16	-0.28	-0.27	Aortic root size;	chr7:66626920	chr7:66493706~66495474:+
BRCA	cis	rs11673344	0.864	rs7259513	ENSG00000226686.6	LINC01535	8.91	2.22e-18	9.28e-16	0.35	0.27	Obesity-related traits;	chr19:37085802	chr19:37251912~37265535:+
BRCA	cis	rs55665837	0.54	rs4144487	ENSG00000251991.1	RNU7-49P	8.91	2.23e-18	9.29e-16	0.3	0.27	Vitamin D levels;	chr11:14728905	chr11:14478892~14478953:+
BRCA	cis	rs55665837	0.54	rs12788030	ENSG00000251991.1	RNU7-49P	8.91	2.23e-18	9.29e-16	0.3	0.27	Vitamin D levels;	chr11:14743138	chr11:14478892~14478953:+
BRCA	cis	rs7937890	0.535	rs2575857	ENSG00000251991.1	RNU7-49P	8.91	2.23e-18	9.32e-16	0.3	0.27	Mitochondrial DNA levels;	chr11:14479750	chr11:14478892~14478953:+
BRCA	cis	rs2067615	0.579	rs66716938	ENSG00000260329.1	RP11-412D9.4	-8.91	2.23e-18	9.32e-16	-0.29	-0.27	Heart rate;	chr12:106803047	chr12:106954029~106955497:-
BRCA	cis	rs7772486	0.686	rs9390357	ENSG00000235652.6	RP11-545I5.3	8.91	2.25e-18	9.37e-16	0.26	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145808211	chr6:145799409~145886585:+
BRCA	cis	rs7580658	0.929	rs4662575	ENSG00000236682.1	AC068282.3	-8.91	2.25e-18	9.38e-16	-0.35	-0.27	Protein C levels;	chr2:127264639	chr2:127389130~127400580:+
BRCA	cis	rs1134634	0.52	rs73125606	ENSG00000273133.1	RP11-799M12.2	-8.91	2.26e-18	9.41e-16	-0.35	-0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15545691	chr4:15563698~15564253:-
BRCA	cis	rs1134634	0.52	rs10025837	ENSG00000273133.1	RP11-799M12.2	-8.91	2.26e-18	9.41e-16	-0.35	-0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15548362	chr4:15563698~15564253:-
BRCA	cis	rs4835473	0.864	rs13117932	ENSG00000251600.4	RP11-673E1.1	-8.91	2.26e-18	9.43e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143735873	chr4:143912331~143982454:+
BRCA	cis	rs6142102	0.602	rs2300209	ENSG00000275784.1	RP5-1125A11.6	-8.91	2.28e-18	9.49e-16	-0.3	-0.27	Skin pigmentation;	chr20:34055294	chr20:33989480~33991818:-
BRCA	cis	rs4718428	0.705	rs4718424	ENSG00000232546.1	RP11-458F8.1	-8.91	2.28e-18	9.5e-16	-0.25	-0.27	Corneal structure;	chr7:66911108	chr7:66848496~66858136:+
BRCA	cis	rs6570726	0.818	rs952405	ENSG00000235652.6	RP11-545I5.3	8.91	2.28e-18	9.52e-16	0.26	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145604816	chr6:145799409~145886585:+
BRCA	cis	rs10463554	0.927	rs185387	ENSG00000175749.11	EIF3KP1	8.91	2.28e-18	9.52e-16	0.36	0.27	Parkinson's disease;	chr5:103084315	chr5:103032376~103033031:+
BRCA	cis	rs10463554	0.927	rs257315	ENSG00000175749.11	EIF3KP1	8.91	2.28e-18	9.52e-16	0.36	0.27	Parkinson's disease;	chr5:103085725	chr5:103032376~103033031:+
BRCA	cis	rs4835473	0.932	rs12512652	ENSG00000251600.4	RP11-673E1.1	-8.91	2.29e-18	9.53e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143736787	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.897	rs35598237	ENSG00000251600.4	RP11-673E1.1	-8.91	2.29e-18	9.54e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143735961	chr4:143912331~143982454:+
BRCA	cis	rs4718428	0.672	rs12530806	ENSG00000232546.1	RP11-458F8.1	-8.91	2.29e-18	9.56e-16	-0.25	-0.27	Corneal structure;	chr7:66925737	chr7:66848496~66858136:+
BRCA	cis	rs7937890	0.559	rs2597217	ENSG00000251991.1	RNU7-49P	8.91	2.3e-18	9.59e-16	0.3	0.27	Mitochondrial DNA levels;	chr11:14511337	chr11:14478892~14478953:+
BRCA	cis	rs453301	0.719	rs34004903	ENSG00000253893.2	FAM85B	8.91	2.31e-18	9.62e-16	0.34	0.27	Joint mobility (Beighton score);	chr8:9035094	chr8:8167819~8226614:-
BRCA	cis	rs12468226	1	rs111252524	ENSG00000273456.1	RP11-686O6.2	8.91	2.31e-18	9.63e-16	0.39	0.27	Urate levels;	chr2:202334465	chr2:202374932~202375604:-
BRCA	cis	rs12468226	1	rs112753638	ENSG00000273456.1	RP11-686O6.2	8.91	2.31e-18	9.63e-16	0.39	0.27	Urate levels;	chr2:202334496	chr2:202374932~202375604:-
BRCA	cis	rs875971	0.545	rs12671152	ENSG00000237310.1	GS1-124K5.4	8.91	2.32e-18	9.64e-16	0.32	0.27	Aortic root size;	chr7:66311140	chr7:66493706~66495474:+
BRCA	cis	rs11971779	0.793	rs11764426	ENSG00000273391.1	RP11-634H22.1	8.91	2.32e-18	9.65e-16	0.27	0.27	Diisocyanate-induced asthma;	chr7:139339304	chr7:139359032~139359566:-
BRCA	cis	rs875971	0.502	rs1796227	ENSG00000237310.1	GS1-124K5.4	-8.91	2.33e-18	9.69e-16	-0.32	-0.27	Aortic root size;	chr7:66622032	chr7:66493706~66495474:+
BRCA	cis	rs1823913	0.637	rs979967	ENSG00000227542.1	AC092614.2	8.9	2.33e-18	9.71e-16	0.32	0.27	Obesity-related traits;	chr2:191304695	chr2:191229165~191246172:-
BRCA	cis	rs8062405	1	rs62037364	ENSG00000278665.1	RP11-666O2.4	8.9	2.33e-18	9.71e-16	0.28	0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28857374	chr16:28599241~28601881:-
BRCA	cis	rs10463554	0.892	rs158401	ENSG00000175749.11	EIF3KP1	8.9	2.34e-18	9.75e-16	0.36	0.27	Parkinson's disease;	chr5:103079764	chr5:103032376~103033031:+
BRCA	cis	rs10463554	0.927	rs257304	ENSG00000175749.11	EIF3KP1	8.9	2.34e-18	9.75e-16	0.36	0.27	Parkinson's disease;	chr5:103081114	chr5:103032376~103033031:+
BRCA	cis	rs9640161	0.75	rs11769348	ENSG00000261305.1	RP4-584D14.7	-8.9	2.34e-18	9.75e-16	-0.41	-0.27	Blood protein levels;Circulating chemerin levels;	chr7:150329664	chr7:150341771~150342607:+
BRCA	cis	rs4660456	0.83	rs12566786	ENSG00000237899.1	RP4-739H11.3	-8.9	2.35e-18	9.79e-16	-0.39	-0.27	Platelet count;	chr1:40742709	chr1:40669089~40687588:-
BRCA	cis	rs4660456	0.871	rs2274957	ENSG00000237899.1	RP4-739H11.3	-8.9	2.35e-18	9.79e-16	-0.39	-0.27	Platelet count;	chr1:40747290	chr1:40669089~40687588:-
BRCA	cis	rs4660456	0.913	rs4660173	ENSG00000237899.1	RP4-739H11.3	-8.9	2.35e-18	9.79e-16	-0.39	-0.27	Platelet count;	chr1:40747876	chr1:40669089~40687588:-
BRCA	cis	rs4660456	0.913	rs4660452	ENSG00000237899.1	RP4-739H11.3	-8.9	2.35e-18	9.79e-16	-0.39	-0.27	Platelet count;	chr1:40748519	chr1:40669089~40687588:-
BRCA	cis	rs55665837	0.54	rs4757261	ENSG00000251991.1	RNU7-49P	8.9	2.35e-18	9.8e-16	0.3	0.27	Vitamin D levels;	chr11:14648256	chr11:14478892~14478953:+
BRCA	cis	rs4835473	0.669	rs75704080	ENSG00000251600.4	RP11-673E1.1	-8.9	2.36e-18	9.83e-16	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143779066	chr4:143912331~143982454:+
BRCA	cis	rs58873874	0.737	rs9313608	ENSG00000251405.2	CTB-109A12.1	-8.9	2.36e-18	9.83e-16	-0.67	-0.27	Bipolar disorder (body mass index interaction);	chr5:157473039	chr5:157362615~157460078:-
BRCA	cis	rs2439831	0.702	rs2467402	ENSG00000205771.5	CATSPER2P1	8.9	2.37e-18	9.88e-16	0.42	0.27	Lung cancer in ever smokers;	chr15:43732292	chr15:43726918~43747094:-
BRCA	cis	rs10262624	0.967	rs2188845	ENSG00000234286.1	AC006026.13	-8.9	2.38e-18	9.9e-16	-0.31	-0.27	Schizophrenia;	chr7:23882391	chr7:23680195~23680786:-
BRCA	cis	rs11971779	0.941	rs28395455	ENSG00000273391.1	RP11-634H22.1	8.9	2.4e-18	9.97e-16	0.29	0.27	Diisocyanate-induced asthma;	chr7:139351240	chr7:139359032~139359566:-
BRCA	cis	rs7772486	0.686	rs1569540	ENSG00000235652.6	RP11-545I5.3	-8.9	2.4e-18	9.97e-16	-0.26	-0.27	Lobe attachment (rater-scored or self-reported);	chr6:145747976	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.686	rs2142983	ENSG00000235652.6	RP11-545I5.3	-8.9	2.4e-18	9.97e-16	-0.26	-0.27	Lobe attachment (rater-scored or self-reported);	chr6:145748565	chr6:145799409~145886585:+
BRCA	cis	rs7429990	0.747	rs6442083	ENSG00000229759.1	MRPS18AP1	-8.9	2.41e-18	1e-15	-0.3	-0.27	Educational attainment (years of education);	chr3:47744305	chr3:48256350~48256938:-
BRCA	cis	rs67311347	1	rs9332450	ENSG00000223797.4	ENTPD3-AS1	-8.9	2.41e-18	1e-15	-0.29	-0.27	Renal cell carcinoma;	chr3:40416550	chr3:40313802~40453329:-
BRCA	cis	rs12458462	0.892	rs3786228	ENSG00000274828.1	RP11-567M16.6	-8.9	2.42e-18	1e-15	-0.31	-0.27	Monocyte count;	chr18:79704170	chr18:79677287~79679358:-
BRCA	cis	rs11098499	0.954	rs10006706	ENSG00000248280.1	RP11-33B1.2	8.9	2.42e-18	1.01e-15	0.27	0.27	Corneal astigmatism;	chr4:119487997	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.913	rs35271032	ENSG00000245958.5	RP11-33B1.1	-8.9	2.42e-18	1.01e-15	-0.27	-0.27	Corneal astigmatism;	chr4:119235504	chr4:119454791~119552025:+
BRCA	cis	rs202072	0.729	rs202030	ENSG00000272379.1	RP1-257A7.5	8.9	2.43e-18	1.01e-15	0.46	0.27	HIV-1 viral setpoint;	chr6:13291920	chr6:13290018~13290490:-
BRCA	cis	rs1134634	0.52	rs10022610	ENSG00000273133.1	RP11-799M12.2	-8.9	2.44e-18	1.01e-15	-0.35	-0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15635864	chr4:15563698~15564253:-
BRCA	cis	rs11971779	0.941	rs4732368	ENSG00000273391.1	RP11-634H22.1	8.9	2.44e-18	1.01e-15	0.3	0.27	Diisocyanate-induced asthma;	chr7:139349461	chr7:139359032~139359566:-
BRCA	cis	rs13256369	1	rs12550458	ENSG00000253893.2	FAM85B	-8.9	2.44e-18	1.01e-15	-0.38	-0.27	Obesity-related traits;	chr8:8710322	chr8:8167819~8226614:-
BRCA	cis	rs7772486	0.686	rs1011596	ENSG00000235652.6	RP11-545I5.3	8.9	2.44e-18	1.01e-15	0.26	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145755297	chr6:145799409~145886585:+
BRCA	cis	rs55665837	0.54	rs10219313	ENSG00000251991.1	RNU7-49P	8.9	2.45e-18	1.02e-15	0.3	0.27	Vitamin D levels;	chr11:14728303	chr11:14478892~14478953:+
BRCA	cis	rs55665837	0.519	rs10832297	ENSG00000251991.1	RNU7-49P	8.9	2.45e-18	1.02e-15	0.3	0.27	Vitamin D levels;	chr11:14736191	chr11:14478892~14478953:+
BRCA	cis	rs748404	0.666	rs7183708	ENSG00000249839.1	AC011330.5	-8.9	2.45e-18	1.02e-15	-0.38	-0.27	Lung cancer;	chr15:43355226	chr15:43663654~43684339:-
BRCA	cis	rs10800713	0.607	rs6682828	ENSG00000260088.1	RP11-92G12.3	-8.9	2.45e-18	1.02e-15	-0.34	-0.27	Tandem gait;	chr1:200537968	chr1:200669507~200694250:+
BRCA	cis	rs75422866	0.51	rs75424057	ENSG00000257433.4	RP1-197B17.3	8.9	2.47e-18	1.03e-15	0.6	0.27	Pneumonia;	chr12:47737294	chr12:47706085~47742294:+
BRCA	cis	rs227275	0.525	rs5028609	ENSG00000246560.2	RP11-10L12.4	8.9	2.47e-18	1.03e-15	0.28	0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102959294	chr4:102828055~102844075:+
BRCA	cis	rs227275	0.525	rs6815540	ENSG00000246560.2	RP11-10L12.4	8.9	2.47e-18	1.03e-15	0.28	0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102959922	chr4:102828055~102844075:+
BRCA	cis	rs227275	0.525	rs4698867	ENSG00000246560.2	RP11-10L12.4	8.9	2.47e-18	1.03e-15	0.28	0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102961049	chr4:102828055~102844075:+
BRCA	cis	rs227275	0.525	rs7663876	ENSG00000246560.2	RP11-10L12.4	8.9	2.47e-18	1.03e-15	0.28	0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102966174	chr4:102828055~102844075:+
BRCA	cis	rs673078	0.66	rs61945183	ENSG00000275759.1	RP11-131L12.3	-8.9	2.48e-18	1.03e-15	-0.42	-0.27	Glucose homeostasis traits;	chr12:118221966	chr12:118428281~118428870:+
BRCA	cis	rs4718428	0.672	rs13241598	ENSG00000273142.1	RP11-458F8.4	-8.9	2.51e-18	1.04e-15	-0.26	-0.27	Corneal structure;	chr7:66835665	chr7:66902857~66906297:+
BRCA	cis	rs748404	0.666	rs55748552	ENSG00000249839.1	AC011330.5	-8.9	2.52e-18	1.04e-15	-0.38	-0.27	Lung cancer;	chr15:43359428	chr15:43663654~43684339:-
BRCA	cis	rs748404	0.63	rs35278805	ENSG00000249839.1	AC011330.5	-8.9	2.52e-18	1.04e-15	-0.38	-0.27	Lung cancer;	chr15:43361124	chr15:43663654~43684339:-
BRCA	cis	rs11098499	0.908	rs7696649	ENSG00000248280.1	RP11-33B1.2	8.9	2.52e-18	1.05e-15	0.27	0.27	Corneal astigmatism;	chr4:119401022	chr4:119440561~119450157:-
BRCA	cis	rs56046484	0.956	rs34054841	ENSG00000259295.5	CSPG4P12	8.9	2.52e-18	1.05e-15	0.47	0.27	Testicular germ cell tumor;	chr15:85058115	chr15:85191438~85213905:+
BRCA	cis	rs1062177	0.826	rs2915822	ENSG00000253921.1	CTB-113P19.3	8.9	2.53e-18	1.05e-15	0.36	0.27	Preschool internalizing problems;	chr5:151751340	chr5:151753992~151767247:+
BRCA	cis	rs10463554	0.927	rs158396	ENSG00000175749.11	EIF3KP1	8.9	2.53e-18	1.05e-15	0.36	0.27	Parkinson's disease;	chr5:103076015	chr5:103032376~103033031:+
BRCA	cis	rs10463554	0.927	rs257312	ENSG00000175749.11	EIF3KP1	8.89	2.54e-18	1.05e-15	0.36	0.27	Parkinson's disease;	chr5:103083923	chr5:103032376~103033031:+
BRCA	cis	rs10463554	0.892	rs257313	ENSG00000175749.11	EIF3KP1	8.89	2.54e-18	1.05e-15	0.36	0.27	Parkinson's disease;	chr5:103084943	chr5:103032376~103033031:+
BRCA	cis	rs6570726	0.557	rs403956	ENSG00000235652.6	RP11-545I5.3	8.89	2.54e-18	1.06e-15	0.29	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145508820	chr6:145799409~145886585:+
BRCA	cis	rs6700559	0.81	rs10919991	ENSG00000260088.1	RP11-92G12.3	-8.89	2.55e-18	1.06e-15	-0.34	-0.27	Coronary artery disease;	chr1:200627217	chr1:200669507~200694250:+
BRCA	cis	rs7580658	0.963	rs867304	ENSG00000236682.1	AC068282.3	-8.89	2.55e-18	1.06e-15	-0.35	-0.27	Protein C levels;	chr2:127320912	chr2:127389130~127400580:+
BRCA	cis	rs2067615	0.56	rs10861671	ENSG00000260329.1	RP11-412D9.4	-8.89	2.57e-18	1.07e-15	-0.29	-0.27	Heart rate;	chr12:106827149	chr12:106954029~106955497:-
BRCA	cis	rs17711722	0.565	rs4717276	ENSG00000234585.5	CCT6P3	8.89	2.57e-18	1.07e-15	0.26	0.27	Calcium levels;	chr7:65829754	chr7:65038354~65074713:+
BRCA	cis	rs321358	0.895	rs17536059	ENSG00000271584.1	RP11-89C3.4	-8.89	2.58e-18	1.07e-15	-0.41	-0.27	Body mass index;	chr11:111086611	chr11:111091932~111097357:-
BRCA	cis	rs875971	0.505	rs6955582	ENSG00000164669.11	INTS4P1	-8.89	2.58e-18	1.07e-15	-0.33	-0.27	Aortic root size;	chr7:65966699	chr7:65141225~65234216:+
BRCA	cis	rs4660456	0.913	rs7551747	ENSG00000237899.1	RP4-739H11.3	8.89	2.58e-18	1.07e-15	0.39	0.27	Platelet count;	chr1:40699407	chr1:40669089~40687588:-
BRCA	cis	rs875971	0.54	rs4717275	ENSG00000164669.11	INTS4P1	8.89	2.59e-18	1.07e-15	0.33	0.27	Aortic root size;	chr7:65800193	chr7:65141225~65234216:+
BRCA	cis	rs6700559	0.742	rs10399790	ENSG00000260088.1	RP11-92G12.3	-8.89	2.6e-18	1.08e-15	-0.34	-0.27	Coronary artery disease;	chr1:200626241	chr1:200669507~200694250:+
BRCA	cis	rs1061377	0.513	rs2566163	ENSG00000249207.1	RP11-360F5.1	-8.89	2.6e-18	1.08e-15	-0.35	-0.27	Uric acid levels;	chr4:39128345	chr4:39112677~39126818:-
BRCA	cis	rs881375	0.967	rs7034492	ENSG00000226752.6	PSMD5-AS1	-8.89	2.6e-18	1.08e-15	-0.31	-0.27	Rheumatoid arthritis;	chr9:120924933	chr9:120824828~120854385:+
BRCA	cis	rs4835473	0.9	rs13137885	ENSG00000251600.4	RP11-673E1.1	-8.89	2.6e-18	1.08e-15	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143734212	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.9	rs13105550	ENSG00000251600.4	RP11-673E1.1	-8.89	2.6e-18	1.08e-15	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143734220	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.9	rs13105571	ENSG00000251600.4	RP11-673E1.1	-8.89	2.6e-18	1.08e-15	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143734241	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.9	rs36083417	ENSG00000251600.4	RP11-673E1.1	-8.89	2.6e-18	1.08e-15	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143734253	chr4:143912331~143982454:+
BRCA	cis	rs2933343	0.859	rs789247	ENSG00000231305.3	RP11-723O4.2	8.89	2.61e-18	1.08e-15	0.32	0.27	IgG glycosylation;	chr3:128861742	chr3:128861313~128871540:-
BRCA	cis	rs7772486	0.902	rs2777480	ENSG00000235652.6	RP11-545I5.3	8.89	2.62e-18	1.09e-15	0.26	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145988847	chr6:145799409~145886585:+
BRCA	cis	rs1707322	1	rs6677777	ENSG00000280836.1	AL355480.1	-8.89	2.63e-18	1.09e-15	-0.35	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46010164	chr1:45581219~45581321:-
BRCA	cis	rs1198872	0.563	rs1106185	ENSG00000272275.1	RP11-791G15.2	8.89	2.63e-18	1.09e-15	0.34	0.27	Cardiac Troponin-T levels;	chr2:10823444	chr2:10767875~10770058:-
BRCA	cis	rs7160336	0.555	rs8021337	ENSG00000259065.1	RP5-1021I20.1	-8.89	2.63e-18	1.09e-15	-0.32	-0.27	Blood protein levels;	chr14:74184738	chr14:73787360~73803270:+
BRCA	cis	rs10129255	0.828	rs10140989	ENSG00000223648.3	IGHV3-64	8.89	2.63e-18	1.09e-15	0.24	0.27	Kawasaki disease;	chr14:106668657	chr14:106643132~106658258:-
BRCA	cis	rs11722779	0.775	rs223341	ENSG00000246560.2	RP11-10L12.4	8.89	2.64e-18	1.09e-15	0.28	0.27	Schizophrenia;	chr4:102862343	chr4:102828055~102844075:+
BRCA	cis	rs2067615	0.524	rs10778504	ENSG00000260329.1	RP11-412D9.4	-8.89	2.64e-18	1.09e-15	-0.29	-0.27	Heart rate;	chr12:106726646	chr12:106954029~106955497:-
BRCA	cis	rs896854	0.625	rs7823886	ENSG00000253528.2	RP11-347C18.4	8.89	2.64e-18	1.09e-15	0.27	0.27	Type 2 diabetes;	chr8:94974231	chr8:94974573~94974853:-
BRCA	cis	rs875971	1	rs1544549	ENSG00000237310.1	GS1-124K5.4	-8.89	2.64e-18	1.09e-15	-0.28	-0.27	Aortic root size;	chr7:66625676	chr7:66493706~66495474:+
BRCA	cis	rs56046484	0.956	rs12908535	ENSG00000259295.5	CSPG4P12	8.89	2.65e-18	1.1e-15	0.47	0.27	Testicular germ cell tumor;	chr15:85058294	chr15:85191438~85213905:+
BRCA	cis	rs11098499	0.754	rs7672778	ENSG00000248280.1	RP11-33B1.2	8.89	2.67e-18	1.1e-15	0.26	0.27	Corneal astigmatism;	chr4:119327430	chr4:119440561~119450157:-
BRCA	cis	rs1075265	0.73	rs7601692	ENSG00000233266.1	HMGB1P31	8.89	2.67e-18	1.11e-15	0.33	0.27	Chronotype;Morning vs. evening chronotype;	chr2:53705532	chr2:54051334~54051760:+
BRCA	cis	rs4660456	0.826	rs507914	ENSG00000237899.1	RP4-739H11.3	8.89	2.68e-18	1.11e-15	0.4	0.27	Platelet count;	chr1:40686529	chr1:40669089~40687588:-
BRCA	cis	rs227275	0.554	rs223334	ENSG00000246560.2	RP11-10L12.4	-8.89	2.68e-18	1.11e-15	-0.28	-0.27	Allergic disease (asthma, hay fever or eczema);	chr4:102867054	chr4:102828055~102844075:+
BRCA	cis	rs2015599	0.525	rs10743656	ENSG00000275476.1	RP11-996F15.4	8.89	2.69e-18	1.11e-15	0.3	0.27	Platelet count;Mean platelet volume;	chr12:29332516	chr12:29277397~29277882:-
BRCA	cis	rs812925	0.502	rs2053750	ENSG00000271889.1	RP11-493E12.1	-8.89	2.7e-18	1.12e-15	-0.32	-0.27	Immature fraction of reticulocytes;	chr2:61429138	chr2:61151433~61162105:-
BRCA	cis	rs1113500	0.509	rs1619485	ENSG00000226822.1	RP11-356N1.2	-8.89	2.7e-18	1.12e-15	-0.34	-0.27	Growth-regulated protein alpha levels;	chr1:108065725	chr1:108071482~108074519:+
BRCA	cis	rs925255	0.747	rs6547851	ENSG00000270210.1	RP11-373D23.3	-8.89	2.7e-18	1.12e-15	-0.34	-0.27	Inflammatory bowel disease;Crohn's disease;	chr2:28406500	chr2:28425945~28426719:+
BRCA	cis	rs7085104	0.66	rs3781286	ENSG00000213061.2	PFN1P11	8.89	2.7e-18	1.12e-15	0.34	0.27	Immature fraction of reticulocytes;Schizophrenia;	chr10:102835962	chr10:102838011~102845473:-
BRCA	cis	rs2067615	0.524	rs10778498	ENSG00000260329.1	RP11-412D9.4	-8.89	2.7e-18	1.12e-15	-0.29	-0.27	Heart rate;	chr12:106669562	chr12:106954029~106955497:-
BRCA	cis	rs10463554	0.926	rs26429	ENSG00000175749.11	EIF3KP1	-8.89	2.72e-18	1.12e-15	-0.36	-0.27	Parkinson's disease;	chr5:103030349	chr5:103032376~103033031:+
BRCA	cis	rs4835473	0.897	rs17693768	ENSG00000251600.4	RP11-673E1.1	-8.89	2.72e-18	1.12e-15	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143737503	chr4:143912331~143982454:+
BRCA	cis	rs7580658	0.963	rs9789510	ENSG00000236682.1	AC068282.3	-8.89	2.73e-18	1.13e-15	-0.36	-0.27	Protein C levels;	chr2:127379436	chr2:127389130~127400580:+
BRCA	cis	rs875971	0.545	rs12670811	ENSG00000237310.1	GS1-124K5.4	8.89	2.73e-18	1.13e-15	0.32	0.27	Aortic root size;	chr7:66358032	chr7:66493706~66495474:+
BRCA	cis	rs11676348	0.772	rs11676275	ENSG00000261338.2	RP11-378A13.1	-8.89	2.73e-18	1.13e-15	-0.28	-0.27	Ulcerative colitis;	chr2:218080085	chr2:218255319~218257366:+
BRCA	cis	rs55665837	0.519	rs1451677	ENSG00000251991.1	RNU7-49P	8.89	2.73e-18	1.13e-15	0.3	0.27	Vitamin D levels;	chr11:14724466	chr11:14478892~14478953:+
BRCA	cis	rs55665837	0.54	rs10766192	ENSG00000251991.1	RNU7-49P	8.89	2.75e-18	1.14e-15	0.3	0.27	Vitamin D levels;	chr11:14790140	chr11:14478892~14478953:+
BRCA	cis	rs55665837	0.54	rs10832294	ENSG00000251991.1	RNU7-49P	8.89	2.75e-18	1.14e-15	0.3	0.27	Vitamin D levels;	chr11:14725881	chr11:14478892~14478953:+
BRCA	cis	rs11098499	1	rs35643470	ENSG00000245958.5	RP11-33B1.1	-8.88	2.75e-18	1.14e-15	-0.26	-0.27	Corneal astigmatism;	chr4:119263793	chr4:119454791~119552025:+
BRCA	cis	rs2041895	0.509	rs2024518	ENSG00000260329.1	RP11-412D9.4	-8.88	2.76e-18	1.14e-15	-0.32	-0.27	Glaucoma (low intraocular pressure);	chr12:106903124	chr12:106954029~106955497:-
BRCA	cis	rs853679	0.567	rs13196606	ENSG00000216901.1	AL022393.7	8.88	2.76e-18	1.14e-15	0.38	0.27	Depression;	chr6:28402301	chr6:28176188~28176674:+
BRCA	cis	rs881375	0.967	rs7034653	ENSG00000226752.6	PSMD5-AS1	-8.88	2.78e-18	1.15e-15	-0.31	-0.27	Rheumatoid arthritis;	chr9:120925094	chr9:120824828~120854385:+
BRCA	cis	rs4835473	0.932	rs12513087	ENSG00000251600.4	RP11-673E1.1	-8.88	2.79e-18	1.15e-15	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143758551	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs12513119	ENSG00000251600.4	RP11-673E1.1	-8.88	2.79e-18	1.15e-15	-0.31	-0.27	Immature fraction of reticulocytes;	chr4:143758619	chr4:143912331~143982454:+
BRCA	cis	rs881375	1	rs10760121	ENSG00000226752.6	PSMD5-AS1	-8.88	2.79e-18	1.16e-15	-0.32	-0.27	Rheumatoid arthritis;	chr9:120885637	chr9:120824828~120854385:+
BRCA	cis	rs62388641	0.813	rs34114087	ENSG00000272279.1	RP11-157J24.2	8.88	2.8e-18	1.16e-15	0.41	0.27	Daytime sleep phenotypes;	chr6:1553203	chr6:1528364~1528911:-
BRCA	cis	rs11159086	0.793	rs10136668	ENSG00000259005.1	RP3-449M8.6	8.88	2.8e-18	1.16e-15	0.4	0.27	Advanced glycation end-product levels;	chr14:74492183	chr14:74474007~74474864:-
BRCA	cis	rs7772486	0.623	rs735535	ENSG00000235652.6	RP11-545I5.3	-8.88	2.8e-18	1.16e-15	-0.27	-0.27	Lobe attachment (rater-scored or self-reported);	chr6:145715693	chr6:145799409~145886585:+
BRCA	cis	rs11098499	0.955	rs56386062	ENSG00000245958.5	RP11-33B1.1	-8.88	2.83e-18	1.17e-15	-0.26	-0.27	Corneal astigmatism;	chr4:119233980	chr4:119454791~119552025:+
BRCA	cis	rs6570726	0.846	rs6914304	ENSG00000235652.6	RP11-545I5.3	8.88	2.85e-18	1.18e-15	0.26	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145599881	chr6:145799409~145886585:+
BRCA	cis	rs4660456	0.913	rs12567925	ENSG00000237899.1	RP4-739H11.3	-8.88	2.87e-18	1.18e-15	-0.39	-0.27	Platelet count;	chr1:40751428	chr1:40669089~40687588:-
BRCA	cis	rs4660456	0.913	rs12728776	ENSG00000237899.1	RP4-739H11.3	-8.88	2.87e-18	1.18e-15	-0.39	-0.27	Platelet count;	chr1:40751718	chr1:40669089~40687588:-
BRCA	cis	rs4660456	0.913	rs16827532	ENSG00000237899.1	RP4-739H11.3	-8.88	2.87e-18	1.18e-15	-0.39	-0.27	Platelet count;	chr1:40755064	chr1:40669089~40687588:-
BRCA	cis	rs4660456	0.913	rs12729696	ENSG00000237899.1	RP4-739H11.3	-8.88	2.87e-18	1.18e-15	-0.39	-0.27	Platelet count;	chr1:40755099	chr1:40669089~40687588:-
BRCA	cis	rs3758911	0.861	rs1388170	ENSG00000255353.1	RP11-382M14.1	-8.88	2.87e-18	1.19e-15	-0.35	-0.27	Coronary artery disease;	chr11:107272130	chr11:107176286~107177530:+
BRCA	cis	rs62355901	0.83	rs12653202	ENSG00000271828.1	CTD-2310F14.1	8.88	2.87e-18	1.19e-15	0.37	0.27	Breast cancer;	chr5:56721091	chr5:56927874~56929573:+
BRCA	cis	rs62388641	0.813	rs62390562	ENSG00000272279.1	RP11-157J24.2	8.88	2.88e-18	1.19e-15	0.41	0.27	Daytime sleep phenotypes;	chr6:1551467	chr6:1528364~1528911:-
BRCA	cis	rs62388641	0.813	rs55821127	ENSG00000272279.1	RP11-157J24.2	8.88	2.89e-18	1.19e-15	0.41	0.27	Daytime sleep phenotypes;	chr6:1550635	chr6:1528364~1528911:-
BRCA	cis	rs7772486	0.597	rs2485631	ENSG00000235652.6	RP11-545I5.3	8.88	2.89e-18	1.19e-15	0.28	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145868941	chr6:145799409~145886585:+
BRCA	cis	rs1113500	0.565	rs11185226	ENSG00000226822.1	RP11-356N1.2	8.88	2.9e-18	1.2e-15	0.39	0.27	Growth-regulated protein alpha levels;	chr1:108005429	chr1:108071482~108074519:+
BRCA	cis	rs7772486	0.817	rs9322047	ENSG00000235652.6	RP11-545I5.3	8.88	2.91e-18	1.2e-15	0.27	0.27	Lobe attachment (rater-scored or self-reported);	chr6:146079258	chr6:145799409~145886585:+
BRCA	cis	rs748404	0.626	rs57938858	ENSG00000249839.1	AC011330.5	-8.88	2.91e-18	1.2e-15	-0.39	-0.27	Lung cancer;	chr15:43520259	chr15:43663654~43684339:-
BRCA	cis	rs1075265	0.548	rs2542575	ENSG00000233266.1	HMGB1P31	8.88	2.91e-18	1.2e-15	0.32	0.27	Chronotype;Morning vs. evening chronotype;	chr2:53821221	chr2:54051334~54051760:+
BRCA	cis	rs4718428	0.705	rs68168107	ENSG00000273142.1	RP11-458F8.4	-8.88	2.94e-18	1.21e-15	-0.26	-0.27	Corneal structure;	chr7:66790251	chr7:66902857~66906297:+
BRCA	cis	rs875971	0.83	rs4718358	ENSG00000237310.1	GS1-124K5.4	8.88	2.94e-18	1.21e-15	0.28	0.27	Aortic root size;	chr7:66508681	chr7:66493706~66495474:+
BRCA	cis	rs1113500	0.565	rs1781071	ENSG00000226822.1	RP11-356N1.2	8.88	2.96e-18	1.22e-15	0.37	0.27	Growth-regulated protein alpha levels;	chr1:108028412	chr1:108071482~108074519:+
BRCA	cis	rs11098499	0.754	rs1511017	ENSG00000248280.1	RP11-33B1.2	8.88	2.96e-18	1.22e-15	0.26	0.27	Corneal astigmatism;	chr4:119329650	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.789	rs12498994	ENSG00000248280.1	RP11-33B1.2	8.88	2.96e-18	1.22e-15	0.26	0.27	Corneal astigmatism;	chr4:119329663	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.754	rs12507565	ENSG00000248280.1	RP11-33B1.2	8.88	2.96e-18	1.22e-15	0.26	0.27	Corneal astigmatism;	chr4:119329966	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.826	rs12511640	ENSG00000248280.1	RP11-33B1.2	8.88	2.96e-18	1.22e-15	0.26	0.27	Corneal astigmatism;	chr4:119330093	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.754	rs1980026	ENSG00000248280.1	RP11-33B1.2	8.88	2.96e-18	1.22e-15	0.26	0.27	Corneal astigmatism;	chr4:119330488	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.743	rs11098501	ENSG00000248280.1	RP11-33B1.2	8.88	2.96e-18	1.22e-15	0.26	0.27	Corneal astigmatism;	chr4:119330862	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.754	rs11098502	ENSG00000248280.1	RP11-33B1.2	8.88	2.96e-18	1.22e-15	0.26	0.27	Corneal astigmatism;	chr4:119330908	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.708	rs11732686	ENSG00000248280.1	RP11-33B1.2	8.88	2.96e-18	1.22e-15	0.26	0.27	Corneal astigmatism;	chr4:119331175	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.754	rs11724409	ENSG00000248280.1	RP11-33B1.2	8.88	2.96e-18	1.22e-15	0.26	0.27	Corneal astigmatism;	chr4:119331206	chr4:119440561~119450157:-
BRCA	cis	rs853679	0.882	rs4713140	ENSG00000220721.1	OR1F12	8.88	2.96e-18	1.22e-15	0.48	0.27	Depression;	chr6:28129415	chr6:28073316~28074233:+
BRCA	cis	rs7621025	0.5	rs16844241	ENSG00000239213.4	NCK1-AS1	-8.88	2.97e-18	1.22e-15	-0.35	-0.27	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136916329	chr3:136841726~136862054:-
BRCA	cis	rs875971	0.522	rs1701760	ENSG00000236529.1	RP13-254B10.1	8.88	2.97e-18	1.23e-15	0.29	0.27	Aortic root size;	chr7:66008701	chr7:65840212~65840596:+
BRCA	cis	rs2404602	0.967	rs12148805	ENSG00000259422.1	RP11-593F23.1	8.88	2.98e-18	1.23e-15	0.33	0.27	Blood metabolite levels;	chr15:76508318	chr15:76174891~76181486:-
BRCA	cis	rs783540	0.934	rs803747	ENSG00000278603.1	RP13-608F4.5	-8.88	2.98e-18	1.23e-15	-0.34	-0.27	Schizophrenia;	chr15:82589345	chr15:82472203~82472426:+
BRCA	cis	rs3814244	0.569	rs2051993	ENSG00000236946.2	HNRNPA1P70	-8.87	3e-18	1.24e-15	-0.23	-0.27	Itch intensity from mosquito bite adjusted by bite size;	chr12:68019898	chr12:68035767~68036853:+
BRCA	cis	rs55665837	0.502	rs4757269	ENSG00000251991.1	RNU7-49P	8.87	3e-18	1.24e-15	0.3	0.27	Vitamin D levels;	chr11:14814646	chr11:14478892~14478953:+
BRCA	cis	rs881375	0.9	rs2241003	ENSG00000226752.6	PSMD5-AS1	-8.87	3.03e-18	1.25e-15	-0.31	-0.27	Rheumatoid arthritis;	chr9:120904499	chr9:120824828~120854385:+
BRCA	cis	rs875971	0.522	rs1880556	ENSG00000236529.1	RP13-254B10.1	8.87	3.04e-18	1.25e-15	0.28	0.27	Aortic root size;	chr7:65967557	chr7:65840212~65840596:+
BRCA	cis	rs2439831	0.85	rs28524541	ENSG00000249839.1	AC011330.5	-8.87	3.04e-18	1.25e-15	-0.44	-0.27	Lung cancer in ever smokers;	chr15:43832633	chr15:43663654~43684339:-
BRCA	cis	rs10129255	0.5	rs6576231	ENSG00000211972.2	IGHV3-66	8.87	3.06e-18	1.26e-15	0.18	0.27	Kawasaki disease;	chr14:106783693	chr14:106675017~106675544:-
BRCA	cis	rs6844153	0.752	rs11737218	ENSG00000240005.4	RP11-293A21.1	8.87	3.07e-18	1.27e-15	0.34	0.27	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26884151	chr4:26859806~26860599:-
BRCA	cis	rs11098499	0.954	rs71629403	ENSG00000248280.1	RP11-33B1.2	8.87	3.09e-18	1.27e-15	0.27	0.26	Corneal astigmatism;	chr4:119451412	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.909	rs28571712	ENSG00000248280.1	RP11-33B1.2	8.87	3.09e-18	1.27e-15	0.27	0.26	Corneal astigmatism;	chr4:119454825	chr4:119440561~119450157:-
BRCA	cis	rs801193	0.636	rs10233806	ENSG00000237310.1	GS1-124K5.4	-8.87	3.09e-18	1.27e-15	-0.28	-0.26	Aortic root size;	chr7:66653261	chr7:66493706~66495474:+
BRCA	cis	rs11098499	0.954	rs1022145	ENSG00000245958.5	RP11-33B1.1	-8.87	3.1e-18	1.27e-15	-0.26	-0.26	Corneal astigmatism;	chr4:119309824	chr4:119454791~119552025:+
BRCA	cis	rs10028773	0.7	rs7690338	ENSG00000248280.1	RP11-33B1.2	8.87	3.11e-18	1.28e-15	0.26	0.26	Educational attainment;	chr4:119335313	chr4:119440561~119450157:-
BRCA	cis	rs1134634	0.52	rs12645849	ENSG00000273133.1	RP11-799M12.2	-8.87	3.11e-18	1.28e-15	-0.35	-0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15627457	chr4:15563698~15564253:-
BRCA	cis	rs875971	0.545	rs4718348	ENSG00000237310.1	GS1-124K5.4	8.87	3.12e-18	1.29e-15	0.32	0.26	Aortic root size;	chr7:66441589	chr7:66493706~66495474:+
BRCA	cis	rs11098499	0.619	rs28502463	ENSG00000248280.1	RP11-33B1.2	8.87	3.12e-18	1.29e-15	0.26	0.26	Corneal astigmatism;	chr4:119335868	chr4:119440561~119450157:-
BRCA	cis	rs1707322	1	rs10789485	ENSG00000280836.1	AL355480.1	-8.87	3.14e-18	1.29e-15	-0.35	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45941636	chr1:45581219~45581321:-
BRCA	cis	rs7772486	0.632	rs9386128	ENSG00000235652.6	RP11-545I5.3	-8.87	3.14e-18	1.29e-15	-0.26	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145727917	chr6:145799409~145886585:+
BRCA	cis	rs881375	0.933	rs4837804	ENSG00000226752.6	PSMD5-AS1	-8.87	3.15e-18	1.3e-15	-0.31	-0.26	Rheumatoid arthritis;	chr9:120943026	chr9:120824828~120854385:+
BRCA	cis	rs881375	0.967	rs7039505	ENSG00000226752.6	PSMD5-AS1	-8.87	3.15e-18	1.3e-15	-0.31	-0.26	Rheumatoid arthritis;	chr9:120943667	chr9:120824828~120854385:+
BRCA	cis	rs2067615	0.542	rs11113120	ENSG00000260329.1	RP11-412D9.4	-8.87	3.16e-18	1.3e-15	-0.29	-0.26	Heart rate;	chr12:106809682	chr12:106954029~106955497:-
BRCA	cis	rs11098499	0.738	rs28687057	ENSG00000245958.5	RP11-33B1.1	-8.87	3.17e-18	1.3e-15	-0.25	-0.26	Corneal astigmatism;	chr4:119359657	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.775	rs67281037	ENSG00000245958.5	RP11-33B1.1	-8.87	3.17e-18	1.3e-15	-0.25	-0.26	Corneal astigmatism;	chr4:119360002	chr4:119454791~119552025:+
BRCA	cis	rs10028773	0.506	rs12374346	ENSG00000245958.5	RP11-33B1.1	-8.87	3.17e-18	1.3e-15	-0.25	-0.26	Educational attainment;	chr4:119360550	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.866	rs12374244	ENSG00000245958.5	RP11-33B1.1	-8.87	3.17e-18	1.3e-15	-0.25	-0.26	Corneal astigmatism;	chr4:119360817	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.866	rs12374352	ENSG00000245958.5	RP11-33B1.1	-8.87	3.17e-18	1.3e-15	-0.25	-0.26	Corneal astigmatism;	chr4:119360822	chr4:119454791~119552025:+
BRCA	cis	rs875971	0.522	rs2949690	ENSG00000236529.1	RP13-254B10.1	-8.87	3.17e-18	1.3e-15	-0.29	-0.26	Aortic root size;	chr7:66018255	chr7:65840212~65840596:+
BRCA	cis	rs2115630	1	rs58581703	ENSG00000225151.9	GOLGA2P7	8.87	3.18e-18	1.31e-15	0.29	0.26	P wave terminal force;	chr15:84733704	chr15:84199311~84230136:-
BRCA	cis	rs875971	0.522	rs9530	ENSG00000224316.1	RP11-479O9.2	8.87	3.18e-18	1.31e-15	0.27	0.26	Aortic root size;	chr7:65960907	chr7:65773620~65802067:+
BRCA	cis	rs1823874	0.924	rs4965542	ENSG00000182397.13	DNM1P46	-8.87	3.18e-18	1.31e-15	-0.28	-0.26	IgG glycosylation;	chr15:99816414	chr15:99790156~99806927:-
BRCA	cis	rs11098499	0.954	rs10006525	ENSG00000248280.1	RP11-33B1.2	8.87	3.19e-18	1.31e-15	0.27	0.26	Corneal astigmatism;	chr4:119487776	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.754	rs17049949	ENSG00000248280.1	RP11-33B1.2	8.87	3.19e-18	1.31e-15	0.26	0.26	Corneal astigmatism;	chr4:119334135	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.754	rs7689729	ENSG00000248280.1	RP11-33B1.2	8.87	3.19e-18	1.31e-15	0.26	0.26	Corneal astigmatism;	chr4:119335037	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.865	rs3956464	ENSG00000248280.1	RP11-33B1.2	8.87	3.19e-18	1.31e-15	0.26	0.26	Corneal astigmatism;	chr4:119335609	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.648	rs2002047	ENSG00000248280.1	RP11-33B1.2	8.87	3.19e-18	1.31e-15	0.26	0.26	Corneal astigmatism;	chr4:119336073	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.775	rs2002049	ENSG00000248280.1	RP11-33B1.2	8.87	3.19e-18	1.31e-15	0.26	0.26	Corneal astigmatism;	chr4:119336262	chr4:119440561~119450157:-
BRCA	cis	rs11673344	0.864	rs11667146	ENSG00000226686.6	LINC01535	8.87	3.19e-18	1.31e-15	0.35	0.26	Obesity-related traits;	chr19:37004493	chr19:37251912~37265535:+
BRCA	cis	rs13256369	0.901	rs4841015	ENSG00000253893.2	FAM85B	-8.87	3.2e-18	1.31e-15	-0.38	-0.26	Obesity-related traits;	chr8:8709630	chr8:8167819~8226614:-
BRCA	cis	rs2243480	1	rs73142166	ENSG00000226824.5	RP4-756H11.3	-8.87	3.2e-18	1.32e-15	-0.51	-0.26	Diabetic kidney disease;	chr7:65910845	chr7:66654538~66669855:+
BRCA	cis	rs11098499	0.863	rs10013305	ENSG00000248280.1	RP11-33B1.2	8.87	3.21e-18	1.32e-15	0.28	0.26	Corneal astigmatism;	chr4:119529269	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.863	rs3775849	ENSG00000248280.1	RP11-33B1.2	8.87	3.21e-18	1.32e-15	0.28	0.26	Corneal astigmatism;	chr4:119529753	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.818	rs7688802	ENSG00000248280.1	RP11-33B1.2	8.87	3.21e-18	1.32e-15	0.28	0.26	Corneal astigmatism;	chr4:119530513	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.863	rs7695620	ENSG00000248280.1	RP11-33B1.2	8.87	3.21e-18	1.32e-15	0.28	0.26	Corneal astigmatism;	chr4:119531621	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.863	rs12502389	ENSG00000248280.1	RP11-33B1.2	8.87	3.21e-18	1.32e-15	0.28	0.26	Corneal astigmatism;	chr4:119533036	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.821	rs3775852	ENSG00000248280.1	RP11-33B1.2	8.87	3.21e-18	1.32e-15	0.28	0.26	Corneal astigmatism;	chr4:119533401	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.82	rs6534140	ENSG00000248280.1	RP11-33B1.2	8.87	3.21e-18	1.32e-15	0.28	0.26	Corneal astigmatism;	chr4:119534156	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.863	rs7657849	ENSG00000248280.1	RP11-33B1.2	8.87	3.21e-18	1.32e-15	0.28	0.26	Corneal astigmatism;	chr4:119534339	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.863	rs10034450	ENSG00000248280.1	RP11-33B1.2	8.87	3.21e-18	1.32e-15	0.28	0.26	Corneal astigmatism;	chr4:119534494	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.863	rs1480939	ENSG00000248280.1	RP11-33B1.2	8.87	3.21e-18	1.32e-15	0.28	0.26	Corneal astigmatism;	chr4:119535772	chr4:119440561~119450157:-
BRCA	cis	rs748404	0.666	rs34591748	ENSG00000249839.1	AC011330.5	-8.87	3.23e-18	1.33e-15	-0.39	-0.26	Lung cancer;	chr15:43334917	chr15:43663654~43684339:-
BRCA	cis	rs7429990	0.864	rs7618758	ENSG00000229759.1	MRPS18AP1	-8.87	3.23e-18	1.33e-15	-0.3	-0.26	Educational attainment (years of education);	chr3:47720993	chr3:48256350~48256938:-
BRCA	cis	rs812925	0.519	rs1186706	ENSG00000271889.1	RP11-493E12.1	8.87	3.23e-18	1.33e-15	0.32	0.26	Immature fraction of reticulocytes;	chr2:61446259	chr2:61151433~61162105:-
BRCA	cis	rs13256369	1	rs885000	ENSG00000253893.2	FAM85B	-8.87	3.24e-18	1.33e-15	-0.38	-0.26	Obesity-related traits;	chr8:8711365	chr8:8167819~8226614:-
BRCA	cis	rs1823913	0.637	rs1470962	ENSG00000227542.1	AC092614.2	-8.87	3.24e-18	1.33e-15	-0.31	-0.26	Obesity-related traits;	chr2:191270271	chr2:191229165~191246172:-
BRCA	cis	rs7772486	0.566	rs735536	ENSG00000235652.6	RP11-545I5.3	-8.87	3.24e-18	1.33e-15	-0.26	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145715696	chr6:145799409~145886585:+
BRCA	cis	rs4718428	0.705	rs12536410	ENSG00000273142.1	RP11-458F8.4	-8.87	3.25e-18	1.33e-15	-0.26	-0.26	Corneal structure;	chr7:66789303	chr7:66902857~66906297:+
BRCA	cis	rs4862750	0.957	rs4861733	ENSG00000250971.1	RP11-696F12.1	8.87	3.25e-18	1.34e-15	0.27	0.26	Lobe attachment (rater-scored or self-reported);	chr4:186982779	chr4:187060099~187060930:+
BRCA	cis	rs881375	0.933	rs1548784	ENSG00000226752.6	PSMD5-AS1	-8.86	3.26e-18	1.34e-15	-0.31	-0.26	Rheumatoid arthritis;	chr9:120923002	chr9:120824828~120854385:+
BRCA	cis	rs1900504	0.584	rs2915756	ENSG00000266200.5	PNLIPRP2	-8.86	3.26e-18	1.34e-15	-0.33	-0.26	Tonsillectomy;	chr10:116603428	chr10:116620953~116645143:+
BRCA	cis	rs4660456	0.913	rs12567755	ENSG00000237899.1	RP4-739H11.3	-8.86	3.28e-18	1.35e-15	-0.39	-0.26	Platelet count;	chr1:40751813	chr1:40669089~40687588:-
BRCA	cis	rs7937890	0.559	rs2167160	ENSG00000251991.1	RNU7-49P	8.86	3.29e-18	1.35e-15	0.29	0.26	Mitochondrial DNA levels;	chr11:14485903	chr11:14478892~14478953:+
BRCA	cis	rs11971779	0.68	rs11764236	ENSG00000273391.1	RP11-634H22.1	8.86	3.29e-18	1.35e-15	0.26	0.26	Diisocyanate-induced asthma;	chr7:139433768	chr7:139359032~139359566:-
BRCA	cis	rs11971779	0.648	rs66463279	ENSG00000273391.1	RP11-634H22.1	8.86	3.29e-18	1.35e-15	0.26	0.26	Diisocyanate-induced asthma;	chr7:139433915	chr7:139359032~139359566:-
BRCA	cis	rs11098499	1	rs7659194	ENSG00000245958.5	RP11-33B1.1	-8.86	3.3e-18	1.35e-15	-0.26	-0.26	Corneal astigmatism;	chr4:119285992	chr4:119454791~119552025:+
BRCA	cis	rs4660456	0.913	rs2780952	ENSG00000237899.1	RP4-739H11.3	8.86	3.31e-18	1.36e-15	0.4	0.26	Platelet count;	chr1:40689711	chr1:40669089~40687588:-
BRCA	cis	rs11673344	0.8	rs8108214	ENSG00000226686.6	LINC01535	-8.86	3.31e-18	1.36e-15	-0.34	-0.26	Obesity-related traits;	chr19:37025184	chr19:37251912~37265535:+
BRCA	cis	rs2067615	0.524	rs9804754	ENSG00000260329.1	RP11-412D9.4	-8.86	3.31e-18	1.36e-15	-0.29	-0.26	Heart rate;	chr12:106689253	chr12:106954029~106955497:-
BRCA	cis	rs11763147	1	rs11763147	ENSG00000164669.11	INTS4P1	8.86	3.32e-18	1.36e-15	0.32	0.26	Corneal structure;	chr7:65861834	chr7:65141225~65234216:+
BRCA	cis	rs6558530	0.73	rs10100341	ENSG00000253982.1	CTD-2336O2.1	8.86	3.32e-18	1.36e-15	0.31	0.26	Systolic blood pressure;	chr8:1775583	chr8:1761990~1764502:-
BRCA	cis	rs55665837	0.54	rs1007392	ENSG00000251991.1	RNU7-49P	8.86	3.32e-18	1.36e-15	0.3	0.26	Vitamin D levels;	chr11:14753045	chr11:14478892~14478953:+
BRCA	cis	rs897984	0.609	rs12445650	ENSG00000260911.2	RP11-196G11.2	8.86	3.32e-18	1.36e-15	0.24	0.26	Dementia with Lewy bodies;	chr16:31033576	chr16:31043150~31049868:+
BRCA	cis	rs7772486	0.558	rs2142978	ENSG00000235652.6	RP11-545I5.3	-8.86	3.33e-18	1.37e-15	-0.29	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145690925	chr6:145799409~145886585:+
BRCA	cis	rs8062405	0.965	rs56040780	ENSG00000278665.1	RP11-666O2.4	8.86	3.35e-18	1.37e-15	0.28	0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28850560	chr16:28599241~28601881:-
BRCA	cis	rs4718428	0.705	rs62465692	ENSG00000273142.1	RP11-458F8.4	-8.86	3.37e-18	1.38e-15	-0.26	-0.26	Corneal structure;	chr7:66830758	chr7:66902857~66906297:+
BRCA	cis	rs4972806	0.739	rs10834	ENSG00000226363.3	HAGLROS	-8.86	3.38e-18	1.39e-15	-0.37	-0.26	IgG glycosylation;	chr2:176177359	chr2:176177717~176179008:+
BRCA	cis	rs4718428	0.705	rs4717328	ENSG00000273142.1	RP11-458F8.4	-8.86	3.39e-18	1.39e-15	-0.26	-0.26	Corneal structure;	chr7:66887678	chr7:66902857~66906297:+
BRCA	cis	rs2276314	0.857	rs7237599	ENSG00000278986.1	RP11-723J4.3	-8.86	3.4e-18	1.39e-15	-0.33	-0.26	Endometriosis;Drug-induced torsades de pointes;	chr18:36059433	chr18:35972151~35973916:+
BRCA	cis	rs6545883	0.791	rs2600665	ENSG00000271889.1	RP11-493E12.1	8.86	3.4e-18	1.4e-15	0.34	0.26	Tuberculosis;	chr2:61178660	chr2:61151433~61162105:-
BRCA	cis	rs11098499	0.863	rs1010740	ENSG00000245958.5	RP11-33B1.1	8.86	3.43e-18	1.4e-15	0.27	0.26	Corneal astigmatism;	chr4:119542254	chr4:119454791~119552025:+
BRCA	cis	rs4718428	0.705	rs4718422	ENSG00000273142.1	RP11-458F8.4	-8.86	3.44e-18	1.41e-15	-0.26	-0.26	Corneal structure;	chr7:66894282	chr7:66902857~66906297:+
BRCA	cis	rs250518	0.708	rs258893	ENSG00000272081.1	CTD-2376I4.2	8.86	3.44e-18	1.41e-15	0.32	0.26	Mean corpuscular hemoglobin concentration;	chr5:73009376	chr5:72955206~72955699:-
BRCA	cis	rs783540	0.967	rs783526	ENSG00000278603.1	RP13-608F4.5	-8.86	3.45e-18	1.42e-15	-0.33	-0.26	Schizophrenia;	chr15:82617044	chr15:82472203~82472426:+
BRCA	cis	rs11971779	0.793	rs11772447	ENSG00000273391.1	RP11-634H22.1	8.86	3.46e-18	1.42e-15	0.27	0.26	Diisocyanate-induced asthma;	chr7:139348843	chr7:139359032~139359566:-
BRCA	cis	rs11098499	0.954	rs11098526	ENSG00000248280.1	RP11-33B1.2	8.86	3.46e-18	1.42e-15	0.27	0.26	Corneal astigmatism;	chr4:119469204	chr4:119440561~119450157:-
BRCA	cis	rs4660456	0.913	rs6667368	ENSG00000237899.1	RP4-739H11.3	8.86	3.46e-18	1.42e-15	0.4	0.26	Platelet count;	chr1:40694887	chr1:40669089~40687588:-
BRCA	cis	rs6061231	0.793	rs2427320	ENSG00000273619.1	RP5-908M14.9	-8.86	3.47e-18	1.42e-15	-0.25	-0.26	Colorectal cancer;	chr20:62401667	chr20:62386303~62386970:-
BRCA	cis	rs7772486	0.686	rs9497380	ENSG00000235652.6	RP11-545I5.3	8.86	3.47e-18	1.42e-15	0.26	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145634169	chr6:145799409~145886585:+
BRCA	cis	rs1823913	0.513	rs4334520	ENSG00000227542.1	AC092614.2	8.86	3.48e-18	1.43e-15	0.34	0.26	Obesity-related traits;	chr2:191329200	chr2:191229165~191246172:-
BRCA	cis	rs11098499	0.754	rs10213554	ENSG00000245958.5	RP11-33B1.1	8.86	3.48e-18	1.43e-15	0.25	0.26	Corneal astigmatism;	chr4:119339630	chr4:119454791~119552025:+
BRCA	cis	rs17023223	0.537	rs2645295	ENSG00000231365.4	RP11-418J17.1	-8.86	3.49e-18	1.43e-15	-0.33	-0.26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119039825	chr1:119140396~119275973:+
BRCA	cis	rs7772486	0.597	rs1970306	ENSG00000235652.6	RP11-545I5.3	8.86	3.49e-18	1.43e-15	0.28	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145833407	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.597	rs9386136	ENSG00000235652.6	RP11-545I5.3	8.86	3.49e-18	1.43e-15	0.28	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145837164	chr6:145799409~145886585:+
BRCA	cis	rs10463554	0.927	rs158250	ENSG00000175749.11	EIF3KP1	8.86	3.5e-18	1.43e-15	0.36	0.26	Parkinson's disease;	chr5:103071075	chr5:103032376~103033031:+
BRCA	cis	rs10463554	0.927	rs464702	ENSG00000175749.11	EIF3KP1	8.86	3.5e-18	1.43e-15	0.36	0.26	Parkinson's disease;	chr5:103071180	chr5:103032376~103033031:+
BRCA	cis	rs8062405	1	rs62037371	ENSG00000278665.1	RP11-666O2.4	8.86	3.5e-18	1.43e-15	0.28	0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28878810	chr16:28599241~28601881:-
BRCA	cis	rs5751614	0.557	rs16802	ENSG00000230701.2	FBXW4P1	-8.86	3.51e-18	1.44e-15	-0.33	-0.26	Height;	chr22:23290326	chr22:23262767~23265005:+
BRCA	cis	rs7772486	0.558	rs7753273	ENSG00000235652.6	RP11-545I5.3	-8.86	3.51e-18	1.44e-15	-0.28	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145744903	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.59	rs1890170	ENSG00000235652.6	RP11-545I5.3	-8.86	3.51e-18	1.44e-15	-0.28	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145750703	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.641	rs2253757	ENSG00000235652.6	RP11-545I5.3	8.86	3.52e-18	1.44e-15	0.28	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145878550	chr6:145799409~145886585:+
BRCA	cis	rs2283792	0.765	rs1063311	ENSG00000224086.5	LL22NC03-86G7.1	-8.86	3.52e-18	1.44e-15	-0.28	-0.26	Multiple sclerosis;	chr22:21762178	chr22:21938293~21977632:+
BRCA	cis	rs807029	0.533	rs3740487	ENSG00000272572.1	RP11-179B2.2	-8.86	3.53e-18	1.45e-15	-0.34	-0.26	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100991026	chr10:100911103~100912739:-
BRCA	cis	rs858239	0.698	rs4265084	ENSG00000226816.2	AC005082.12	8.86	3.54e-18	1.45e-15	0.31	0.26	Cerebrospinal fluid biomarker levels;	chr7:23367621	chr7:23206013~23208045:+
BRCA	cis	rs7250849	0.688	rs16982907	ENSG00000273837.1	LLNLR-470E3.1	-8.85	3.54e-18	1.45e-15	-0.36	-0.26	Blood protein levels;	chr19:51659782	chr19:51639478~51639931:-
BRCA	cis	rs1061377	1	rs12499266	ENSG00000249685.1	RP11-360F5.3	-8.85	3.55e-18	1.45e-15	-0.32	-0.26	Uric acid levels;	chr4:39118133	chr4:39133913~39135608:+
BRCA	cis	rs4835473	0.712	rs12509607	ENSG00000251600.4	RP11-673E1.1	-8.85	3.55e-18	1.45e-15	-0.31	-0.26	Immature fraction of reticulocytes;	chr4:143736894	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.712	rs12498218	ENSG00000251600.4	RP11-673E1.1	-8.85	3.55e-18	1.45e-15	-0.31	-0.26	Immature fraction of reticulocytes;	chr4:143736900	chr4:143912331~143982454:+
BRCA	cis	rs8012947	0.92	rs2348071	ENSG00000279636.2	LINC00216	-8.85	3.55e-18	1.46e-15	-0.29	-0.26	Alcohol consumption in current drinkers;	chr14:58263908	chr14:58288033~58289158:+
BRCA	cis	rs17711722	0.653	rs2460421	ENSG00000224316.1	RP11-479O9.2	-8.85	3.56e-18	1.46e-15	-0.27	-0.26	Calcium levels;	chr7:66026136	chr7:65773620~65802067:+
BRCA	cis	rs6046396	1	rs6046396	ENSG00000275142.1	RP5-999L4.2	8.85	3.57e-18	1.46e-15	0.33	0.26	Bipolar disorder and schizophrenia;	chr20:19871859	chr20:19871891~19872284:+
BRCA	cis	rs7250849	0.736	rs12459542	ENSG00000273837.1	LLNLR-470E3.1	-8.85	3.57e-18	1.46e-15	-0.37	-0.26	Blood protein levels;	chr19:51660025	chr19:51639478~51639931:-
BRCA	cis	rs7772486	0.641	rs9390370	ENSG00000235652.6	RP11-545I5.3	8.85	3.58e-18	1.46e-15	0.29	0.26	Lobe attachment (rater-scored or self-reported);	chr6:146036433	chr6:145799409~145886585:+
BRCA	cis	rs783540	0.843	rs9652567	ENSG00000278603.1	RP13-608F4.5	8.85	3.58e-18	1.47e-15	0.34	0.26	Schizophrenia;	chr15:82699762	chr15:82472203~82472426:+
BRCA	cis	rs807029	0.533	rs3740485	ENSG00000272572.1	RP11-179B2.2	-8.85	3.59e-18	1.47e-15	-0.34	-0.26	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100990864	chr10:100911103~100912739:-
BRCA	cis	rs807029	0.533	rs3740486	ENSG00000272572.1	RP11-179B2.2	-8.85	3.59e-18	1.47e-15	-0.34	-0.26	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100990866	chr10:100911103~100912739:-
BRCA	cis	rs957448	1	rs1023767	ENSG00000253704.1	RP11-267M23.4	8.85	3.59e-18	1.47e-15	0.3	0.26	Nonsyndromic cleft lip with cleft palate;	chr8:94518741	chr8:94553722~94569745:+
BRCA	cis	rs524281	0.506	rs560393	ENSG00000255320.1	RP11-755F10.1	8.85	3.6e-18	1.47e-15	0.37	0.26	Electroencephalogram traits;	chr11:66238006	chr11:66244840~66246239:-
BRCA	cis	rs2067615	0.579	rs1922435	ENSG00000260329.1	RP11-412D9.4	-8.85	3.62e-18	1.48e-15	-0.29	-0.26	Heart rate;	chr12:106688677	chr12:106954029~106955497:-
BRCA	cis	rs228614	0.517	rs3886722	ENSG00000246560.2	RP11-10L12.4	8.85	3.62e-18	1.48e-15	0.27	0.26	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102983084	chr4:102828055~102844075:+
BRCA	cis	rs10129255	0.5	rs12101190	ENSG00000211972.2	IGHV3-66	8.85	3.63e-18	1.48e-15	0.18	0.26	Kawasaki disease;	chr14:106784149	chr14:106675017~106675544:-
BRCA	cis	rs10129255	0.518	rs8004895	ENSG00000211972.2	IGHV3-66	8.85	3.63e-18	1.48e-15	0.18	0.26	Kawasaki disease;	chr14:106785139	chr14:106675017~106675544:-
BRCA	cis	rs4660456	0.913	rs2780953	ENSG00000237899.1	RP4-739H11.3	8.85	3.63e-18	1.48e-15	0.39	0.26	Platelet count;	chr1:40694105	chr1:40669089~40687588:-
BRCA	cis	rs227275	0.525	rs10032234	ENSG00000246560.2	RP11-10L12.4	8.85	3.63e-18	1.49e-15	0.27	0.26	Allergic disease (asthma, hay fever or eczema);	chr4:102980538	chr4:102828055~102844075:+
BRCA	cis	rs227275	0.525	rs28845922	ENSG00000246560.2	RP11-10L12.4	8.85	3.63e-18	1.49e-15	0.27	0.26	Allergic disease (asthma, hay fever or eczema);	chr4:102981959	chr4:102828055~102844075:+
BRCA	cis	rs11098499	0.863	rs6534139	ENSG00000248280.1	RP11-33B1.2	-8.85	3.64e-18	1.49e-15	-0.28	-0.26	Corneal astigmatism;	chr4:119528301	chr4:119440561~119450157:-
BRCA	cis	rs7937890	0.559	rs2575838	ENSG00000251991.1	RNU7-49P	8.85	3.64e-18	1.49e-15	0.29	0.26	Mitochondrial DNA levels;	chr11:14476675	chr11:14478892~14478953:+
BRCA	cis	rs4835473	0.864	rs5015762	ENSG00000251600.4	RP11-673E1.1	-8.85	3.65e-18	1.49e-15	-0.31	-0.26	Immature fraction of reticulocytes;	chr4:143737773	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.864	rs5015761	ENSG00000251600.4	RP11-673E1.1	-8.85	3.65e-18	1.49e-15	-0.31	-0.26	Immature fraction of reticulocytes;	chr4:143737791	chr4:143912331~143982454:+
BRCA	cis	rs2404602	0.716	rs12441247	ENSG00000259422.1	RP11-593F23.1	8.85	3.65e-18	1.49e-15	0.34	0.26	Blood metabolite levels;	chr15:76519975	chr15:76174891~76181486:-
BRCA	cis	rs7829975	0.686	rs907180	ENSG00000253893.2	FAM85B	-8.85	3.67e-18	1.5e-15	-0.32	-0.26	Mood instability;	chr8:8845317	chr8:8167819~8226614:-
BRCA	cis	rs7772486	0.806	rs7740785	ENSG00000235652.6	RP11-545I5.3	8.85	3.67e-18	1.5e-15	0.26	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145850163	chr6:145799409~145886585:+
BRCA	cis	rs4835473	0.932	rs35655934	ENSG00000251600.4	RP11-673E1.1	-8.85	3.67e-18	1.5e-15	-0.31	-0.26	Immature fraction of reticulocytes;	chr4:143734697	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.897	rs35515006	ENSG00000251600.4	RP11-673E1.1	-8.85	3.67e-18	1.5e-15	-0.31	-0.26	Immature fraction of reticulocytes;	chr4:143734705	chr4:143912331~143982454:+
BRCA	cis	rs4660456	0.913	rs657149	ENSG00000237899.1	RP4-739H11.3	8.85	3.68e-18	1.5e-15	0.39	0.26	Platelet count;	chr1:40692486	chr1:40669089~40687588:-
BRCA	cis	rs2067615	0.524	rs4964186	ENSG00000260329.1	RP11-412D9.4	-8.85	3.69e-18	1.51e-15	-0.29	-0.26	Heart rate;	chr12:106686457	chr12:106954029~106955497:-
BRCA	cis	rs11676348	0.712	rs12694426	ENSG00000261338.2	RP11-378A13.1	-8.85	3.7e-18	1.51e-15	-0.28	-0.26	Ulcerative colitis;	chr2:218077628	chr2:218255319~218257366:+
BRCA	cis	rs2404602	0.716	rs4079681	ENSG00000259422.1	RP11-593F23.1	8.85	3.7e-18	1.51e-15	0.34	0.26	Blood metabolite levels;	chr15:76402889	chr15:76174891~76181486:-
BRCA	cis	rs673078	0.66	rs7974718	ENSG00000275759.1	RP11-131L12.3	-8.85	3.7e-18	1.51e-15	-0.37	-0.26	Glucose homeostasis traits;	chr12:118243258	chr12:118428281~118428870:+
BRCA	cis	rs1134634	0.52	rs10034328	ENSG00000273133.1	RP11-799M12.2	-8.85	3.7e-18	1.51e-15	-0.35	-0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15616764	chr4:15563698~15564253:-
BRCA	cis	rs1134634	0.52	rs28661857	ENSG00000273133.1	RP11-799M12.2	-8.85	3.7e-18	1.51e-15	-0.35	-0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15589842	chr4:15563698~15564253:-
BRCA	cis	rs72627509	0.951	rs6554401	ENSG00000269949.1	RP11-738E22.3	8.85	3.71e-18	1.52e-15	0.39	0.26	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56959170	chr4:56960927~56961373:-
BRCA	cis	rs453301	0.658	rs6983877	ENSG00000253893.2	FAM85B	8.85	3.72e-18	1.52e-15	0.33	0.26	Joint mobility (Beighton score);	chr8:9047129	chr8:8167819~8226614:-
BRCA	cis	rs2933343	0.903	rs2638846	ENSG00000231305.3	RP11-723O4.2	8.85	3.73e-18	1.52e-15	0.32	0.26	IgG glycosylation;	chr3:128868320	chr3:128861313~128871540:-
BRCA	cis	rs6142102	0.961	rs2300204	ENSG00000276073.1	RP5-1125A11.7	-8.85	3.73e-18	1.52e-15	-0.31	-0.26	Skin pigmentation;	chr20:34000967	chr20:33985617~33988989:-
BRCA	cis	rs67311347	0.605	rs1880762	ENSG00000223797.4	ENTPD3-AS1	8.85	3.75e-18	1.53e-15	0.29	0.26	Renal cell carcinoma;	chr3:40241724	chr3:40313802~40453329:-
BRCA	cis	rs881375	0.967	rs10733648	ENSG00000226752.6	PSMD5-AS1	-8.85	3.78e-18	1.54e-15	-0.31	-0.26	Rheumatoid arthritis;	chr9:120938501	chr9:120824828~120854385:+
BRCA	cis	rs7772486	0.806	rs2265477	ENSG00000235652.6	RP11-545I5.3	8.85	3.79e-18	1.55e-15	0.26	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145891202	chr6:145799409~145886585:+
BRCA	cis	rs11098499	0.909	rs73842633	ENSG00000248280.1	RP11-33B1.2	8.85	3.8e-18	1.55e-15	0.27	0.26	Corneal astigmatism;	chr4:119454309	chr4:119440561~119450157:-
BRCA	cis	rs4718428	0.607	rs66954441	ENSG00000273142.1	RP11-458F8.4	-8.84	3.86e-18	1.57e-15	-0.25	-0.26	Corneal structure;	chr7:66904222	chr7:66902857~66906297:+
BRCA	cis	rs11098499	0.954	rs3890049	ENSG00000248280.1	RP11-33B1.2	8.84	3.86e-18	1.57e-15	0.27	0.26	Corneal astigmatism;	chr4:119405128	chr4:119440561~119450157:-
BRCA	cis	rs11722779	0.844	rs223345	ENSG00000246560.2	RP11-10L12.4	8.84	3.87e-18	1.58e-15	0.28	0.26	Schizophrenia;	chr4:102859366	chr4:102828055~102844075:+
BRCA	cis	rs11722779	0.873	rs223344	ENSG00000246560.2	RP11-10L12.4	8.84	3.87e-18	1.58e-15	0.28	0.26	Schizophrenia;	chr4:102859765	chr4:102828055~102844075:+
BRCA	cis	rs10463554	0.892	rs13340345	ENSG00000175749.11	EIF3KP1	8.84	3.87e-18	1.58e-15	0.36	0.26	Parkinson's disease;	chr5:103003518	chr5:103032376~103033031:+
BRCA	cis	rs10463554	0.927	rs464720	ENSG00000175749.11	EIF3KP1	8.84	3.88e-18	1.58e-15	0.36	0.26	Parkinson's disease;	chr5:103071183	chr5:103032376~103033031:+
BRCA	cis	rs11098499	0.863	rs2306456	ENSG00000245958.5	RP11-33B1.1	-8.84	3.9e-18	1.59e-15	-0.26	-0.26	Corneal astigmatism;	chr4:119551267	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.863	rs11947234	ENSG00000245958.5	RP11-33B1.1	-8.84	3.9e-18	1.59e-15	-0.26	-0.26	Corneal astigmatism;	chr4:119553704	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.863	rs11933966	ENSG00000245958.5	RP11-33B1.1	-8.84	3.9e-18	1.59e-15	-0.26	-0.26	Corneal astigmatism;	chr4:119555560	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.863	rs36040693	ENSG00000245958.5	RP11-33B1.1	-8.84	3.9e-18	1.59e-15	-0.26	-0.26	Corneal astigmatism;	chr4:119556461	chr4:119454791~119552025:+
BRCA	cis	rs10129255	0.5	rs59939897	ENSG00000211972.2	IGHV3-66	8.84	3.9e-18	1.59e-15	0.18	0.26	Kawasaki disease;	chr14:106783414	chr14:106675017~106675544:-
BRCA	cis	rs8012947	1	rs2180871	ENSG00000279636.2	LINC00216	-8.84	3.91e-18	1.59e-15	-0.29	-0.26	Alcohol consumption in current drinkers;	chr14:58272819	chr14:58288033~58289158:+
BRCA	cis	rs1198872	0.563	rs2005011	ENSG00000272275.1	RP11-791G15.2	-8.84	3.91e-18	1.59e-15	-0.34	-0.26	Cardiac Troponin-T levels;	chr2:10823799	chr2:10767875~10770058:-
BRCA	cis	rs1198872	0.563	rs2008967	ENSG00000272275.1	RP11-791G15.2	-8.84	3.91e-18	1.59e-15	-0.34	-0.26	Cardiac Troponin-T levels;	chr2:10824167	chr2:10767875~10770058:-
BRCA	cis	rs897984	0.572	rs112906665	ENSG00000260911.2	RP11-196G11.2	8.84	3.91e-18	1.6e-15	0.24	0.26	Dementia with Lewy bodies;	chr16:31028818	chr16:31043150~31049868:+
BRCA	cis	rs11098499	0.863	rs1383533	ENSG00000245958.5	RP11-33B1.1	-8.84	3.92e-18	1.6e-15	-0.26	-0.26	Corneal astigmatism;	chr4:119513421	chr4:119454791~119552025:+
BRCA	cis	rs881375	0.902	rs2900180	ENSG00000226752.6	PSMD5-AS1	-8.84	3.92e-18	1.6e-15	-0.31	-0.26	Rheumatoid arthritis;	chr9:120944104	chr9:120824828~120854385:+
BRCA	cis	rs11673344	0.832	rs8104296	ENSG00000226686.6	LINC01535	8.84	3.93e-18	1.6e-15	0.35	0.26	Obesity-related traits;	chr19:37025634	chr19:37251912~37265535:+
BRCA	cis	rs11098499	0.909	rs1546502	ENSG00000245958.5	RP11-33B1.1	-8.84	3.94e-18	1.6e-15	-0.26	-0.26	Corneal astigmatism;	chr4:119314743	chr4:119454791~119552025:+
BRCA	cis	rs8012947	1	rs941752	ENSG00000279636.2	LINC00216	-8.84	3.95e-18	1.61e-15	-0.29	-0.26	Alcohol consumption in current drinkers;	chr14:58332643	chr14:58288033~58289158:+
BRCA	cis	rs11098499	0.954	rs10006877	ENSG00000245958.5	RP11-33B1.1	-8.84	3.96e-18	1.61e-15	-0.26	-0.26	Corneal astigmatism;	chr4:119321638	chr4:119454791~119552025:+
BRCA	cis	rs11098499	1	rs11098499	ENSG00000245958.5	RP11-33B1.1	-8.84	3.96e-18	1.61e-15	-0.26	-0.26	Corneal astigmatism;	chr4:119266456	chr4:119454791~119552025:+
BRCA	cis	rs1501911	0.588	rs709389	ENSG00000248489.1	CTD-2007H13.3	8.84	3.96e-18	1.61e-15	0.33	0.26	Lung function (FEV1/FVC);	chr5:98994011	chr5:98929171~98995013:+
BRCA	cis	rs13256369	0.851	rs13271698	ENSG00000253893.2	FAM85B	-8.84	3.98e-18	1.62e-15	-0.38	-0.26	Obesity-related traits;	chr8:8710029	chr8:8167819~8226614:-
BRCA	cis	rs875971	0.898	rs6977501	ENSG00000237310.1	GS1-124K5.4	-8.84	3.98e-18	1.62e-15	-0.28	-0.26	Aortic root size;	chr7:66228355	chr7:66493706~66495474:+
BRCA	cis	rs7580658	0.963	rs4233583	ENSG00000236682.1	AC068282.3	-8.84	3.98e-18	1.62e-15	-0.35	-0.26	Protein C levels;	chr2:127302492	chr2:127389130~127400580:+
BRCA	cis	rs4835473	0.9	rs67600034	ENSG00000251600.4	RP11-673E1.1	-8.84	3.98e-18	1.62e-15	-0.31	-0.26	Immature fraction of reticulocytes;	chr4:143734670	chr4:143912331~143982454:+
BRCA	cis	rs13256369	0.851	rs13267036	ENSG00000253893.2	FAM85B	-8.84	3.99e-18	1.62e-15	-0.38	-0.26	Obesity-related traits;	chr8:8709175	chr8:8167819~8226614:-
BRCA	cis	rs116175783	0.557	rs62188138	ENSG00000227403.1	AC009299.3	8.84	3.99e-18	1.62e-15	0.46	0.26	Intelligence (multi-trait analysis);	chr2:161410935	chr2:161244739~161249050:+
BRCA	cis	rs116175783	0.557	rs6710414	ENSG00000227403.1	AC009299.3	8.84	3.99e-18	1.62e-15	0.46	0.26	Intelligence (multi-trait analysis);	chr2:161412004	chr2:161244739~161249050:+
BRCA	cis	rs7712401	0.601	rs30038	ENSG00000263432.2	RN7SL689P	8.84	3.99e-18	1.62e-15	0.33	0.26	Mean platelet volume;	chr5:122941667	chr5:123022487~123022783:-
BRCA	cis	rs1707322	0.929	rs785513	ENSG00000280836.1	AL355480.1	8.84	4.01e-18	1.63e-15	0.34	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46072648	chr1:45581219~45581321:-
BRCA	cis	rs67981189	0.529	rs2526868	ENSG00000269927.1	RP6-91H8.3	-8.84	4.01e-18	1.63e-15	-0.35	-0.26	Schizophrenia;	chr14:70923672	chr14:71141125~71143253:-
BRCA	cis	rs8062405	1	rs3888190	ENSG00000278665.1	RP11-666O2.4	8.84	4.02e-18	1.63e-15	0.28	0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28878165	chr16:28599241~28601881:-
BRCA	cis	rs4835473	0.897	rs55635947	ENSG00000251600.4	RP11-673E1.1	-8.84	4.02e-18	1.63e-15	-0.31	-0.26	Immature fraction of reticulocytes;	chr4:143736218	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.897	rs56334914	ENSG00000251600.4	RP11-673E1.1	-8.84	4.02e-18	1.63e-15	-0.31	-0.26	Immature fraction of reticulocytes;	chr4:143736291	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.897	rs56324738	ENSG00000251600.4	RP11-673E1.1	-8.84	4.02e-18	1.63e-15	-0.31	-0.26	Immature fraction of reticulocytes;	chr4:143736297	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs55862664	ENSG00000251600.4	RP11-673E1.1	-8.84	4.02e-18	1.63e-15	-0.31	-0.26	Immature fraction of reticulocytes;	chr4:143736311	chr4:143912331~143982454:+
BRCA	cis	rs7937890	0.559	rs2575837	ENSG00000251991.1	RNU7-49P	8.84	4.05e-18	1.65e-15	0.29	0.26	Mitochondrial DNA levels;	chr11:14476455	chr11:14478892~14478953:+
BRCA	cis	rs812925	0.555	rs12616433	ENSG00000271889.1	RP11-493E12.1	8.84	4.05e-18	1.65e-15	0.32	0.26	Immature fraction of reticulocytes;	chr2:61469353	chr2:61151433~61162105:-
BRCA	cis	rs6570726	0.577	rs406868	ENSG00000235652.6	RP11-545I5.3	8.84	4.06e-18	1.65e-15	0.29	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145488847	chr6:145799409~145886585:+
BRCA	cis	rs5751614	0.517	rs928780	ENSG00000230701.2	FBXW4P1	8.84	4.06e-18	1.65e-15	0.33	0.26	Height;	chr22:23257682	chr22:23262767~23265005:+
BRCA	cis	rs11098499	0.731	rs6846966	ENSG00000245958.5	RP11-33B1.1	-8.84	4.08e-18	1.66e-15	-0.25	-0.26	Corneal astigmatism;	chr4:119372053	chr4:119454791~119552025:+
BRCA	cis	rs17772222	0.916	rs77306894	ENSG00000258983.2	RP11-507K2.2	8.84	4.09e-18	1.66e-15	0.31	0.26	Coronary artery calcification;	chr14:88494507	chr14:88499334~88515502:+
BRCA	cis	rs17711722	0.727	rs2658585	ENSG00000236529.1	RP13-254B10.1	8.84	4.1e-18	1.67e-15	0.29	0.26	Calcium levels;	chr7:65996954	chr7:65840212~65840596:+
BRCA	cis	rs1075265	0.749	rs10203095	ENSG00000233266.1	HMGB1P31	8.84	4.11e-18	1.67e-15	0.32	0.26	Chronotype;Morning vs. evening chronotype;	chr2:53737150	chr2:54051334~54051760:+
BRCA	cis	rs11098499	0.691	rs9996644	ENSG00000245958.5	RP11-33B1.1	-8.84	4.12e-18	1.68e-15	-0.25	-0.26	Corneal astigmatism;	chr4:119317722	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.691	rs9996494	ENSG00000245958.5	RP11-33B1.1	-8.84	4.12e-18	1.68e-15	-0.25	-0.26	Corneal astigmatism;	chr4:119317725	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.909	rs10026736	ENSG00000248280.1	RP11-33B1.2	8.84	4.13e-18	1.68e-15	0.28	0.26	Corneal astigmatism;	chr4:119463167	chr4:119440561~119450157:-
BRCA	cis	rs6570726	0.791	rs6902404	ENSG00000235652.6	RP11-545I5.3	8.84	4.15e-18	1.68e-15	0.26	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145584118	chr6:145799409~145886585:+
BRCA	cis	rs11098499	0.789	rs10212719	ENSG00000248280.1	RP11-33B1.2	8.84	4.16e-18	1.69e-15	0.26	0.26	Corneal astigmatism;	chr4:119333282	chr4:119440561~119450157:-
BRCA	cis	rs12468226	1	rs6739198	ENSG00000273456.1	RP11-686O6.2	8.84	4.16e-18	1.69e-15	0.37	0.26	Urate levels;	chr2:202492273	chr2:202374932~202375604:-
BRCA	cis	rs4835473	0.932	rs34525847	ENSG00000251600.4	RP11-673E1.1	-8.83	4.21e-18	1.71e-15	-0.31	-0.26	Immature fraction of reticulocytes;	chr4:143734970	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs35277115	ENSG00000251600.4	RP11-673E1.1	-8.83	4.21e-18	1.71e-15	-0.31	-0.26	Immature fraction of reticulocytes;	chr4:143735001	chr4:143912331~143982454:+
BRCA	cis	rs6570726	0.846	rs4896824	ENSG00000235652.6	RP11-545I5.3	8.83	4.24e-18	1.72e-15	0.26	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145605912	chr6:145799409~145886585:+
BRCA	cis	rs8062405	1	rs4788101	ENSG00000278665.1	RP11-666O2.4	8.83	4.24e-18	1.72e-15	0.28	0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28856483	chr16:28599241~28601881:-
BRCA	cis	rs8062405	0.737	rs11861132	ENSG00000278665.1	RP11-666O2.4	8.83	4.24e-18	1.72e-15	0.28	0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28860539	chr16:28599241~28601881:-
BRCA	cis	rs8062405	1	rs11861174	ENSG00000278665.1	RP11-666O2.4	8.83	4.24e-18	1.72e-15	0.28	0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28860668	chr16:28599241~28601881:-
BRCA	cis	rs8062405	1	rs4788102	ENSG00000278665.1	RP11-666O2.4	8.83	4.24e-18	1.72e-15	0.28	0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28862077	chr16:28599241~28601881:-
BRCA	cis	rs8062405	1	rs62037367	ENSG00000278665.1	RP11-666O2.4	8.83	4.24e-18	1.72e-15	0.28	0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863226	chr16:28599241~28601881:-
BRCA	cis	rs8062405	1	rs7198606	ENSG00000278665.1	RP11-666O2.4	8.83	4.24e-18	1.72e-15	0.28	0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863801	chr16:28599241~28601881:-
BRCA	cis	rs8062405	0.929	rs11864750	ENSG00000278665.1	RP11-666O2.4	8.83	4.24e-18	1.72e-15	0.28	0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863883	chr16:28599241~28601881:-
BRCA	cis	rs8062405	0.964	rs7193733	ENSG00000278665.1	RP11-666O2.4	8.83	4.24e-18	1.72e-15	0.28	0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28864161	chr16:28599241~28601881:-
BRCA	cis	rs8062405	1	rs8055982	ENSG00000278665.1	RP11-666O2.4	8.83	4.24e-18	1.72e-15	0.28	0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28869881	chr16:28599241~28601881:-
BRCA	cis	rs8062405	1	rs7498665	ENSG00000278665.1	RP11-666O2.4	8.83	4.24e-18	1.72e-15	0.28	0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28871920	chr16:28599241~28601881:-
BRCA	cis	rs8062405	0.964	rs11864107	ENSG00000278665.1	RP11-666O2.4	8.83	4.24e-18	1.72e-15	0.28	0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28874610	chr16:28599241~28601881:-
BRCA	cis	rs2404602	0.716	rs12917430	ENSG00000259422.1	RP11-593F23.1	8.83	4.27e-18	1.73e-15	0.33	0.26	Blood metabolite levels;	chr15:76382019	chr15:76174891~76181486:-
BRCA	cis	rs838147	0.563	rs281379	ENSG00000232871.7	SEC1P	8.83	4.27e-18	1.73e-15	0.3	0.26	Dietary macronutrient intake;	chr19:48711017	chr19:48638071~48682245:+
BRCA	cis	rs6496932	0.563	rs2344083	ENSG00000259295.5	CSPG4P12	-8.83	4.28e-18	1.73e-15	-0.31	-0.26	Central corneal thickness;Corneal structure;	chr15:85354201	chr15:85191438~85213905:+
BRCA	cis	rs1823874	0.962	rs12906206	ENSG00000182397.13	DNM1P46	-8.83	4.31e-18	1.75e-15	-0.28	-0.26	IgG glycosylation;	chr15:99818921	chr15:99790156~99806927:-
BRCA	cis	rs11098499	0.865	rs9994730	ENSG00000248280.1	RP11-33B1.2	8.83	4.34e-18	1.76e-15	0.27	0.26	Corneal astigmatism;	chr4:119460409	chr4:119440561~119450157:-
BRCA	cis	rs8062405	0.929	rs11150609	ENSG00000278665.1	RP11-666O2.4	8.83	4.34e-18	1.76e-15	0.28	0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28859275	chr16:28599241~28601881:-
BRCA	cis	rs1823913	0.637	rs10931497	ENSG00000227542.1	AC092614.2	-8.83	4.35e-18	1.76e-15	-0.32	-0.26	Obesity-related traits;	chr2:191306254	chr2:191229165~191246172:-
BRCA	cis	rs853679	0.882	rs2743555	ENSG00000220721.1	OR1F12	8.83	4.38e-18	1.78e-15	0.42	0.26	Depression;	chr6:28273304	chr6:28073316~28074233:+
BRCA	cis	rs7160336	0.515	rs7152352	ENSG00000259065.1	RP5-1021I20.1	-8.83	4.38e-18	1.78e-15	-0.3	-0.26	Blood protein levels;	chr14:74144568	chr14:73787360~73803270:+
BRCA	cis	rs11098499	0.754	rs1814813	ENSG00000245958.5	RP11-33B1.1	8.83	4.39e-18	1.78e-15	0.24	0.26	Corneal astigmatism;	chr4:119337052	chr4:119454791~119552025:+
BRCA	cis	rs8062405	1	rs9972693	ENSG00000278665.1	RP11-666O2.4	8.83	4.39e-18	1.78e-15	0.28	0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28848481	chr16:28599241~28601881:-
BRCA	cis	rs8062405	0.964	rs9972768	ENSG00000278665.1	RP11-666O2.4	8.83	4.39e-18	1.78e-15	0.28	0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28850413	chr16:28599241~28601881:-
BRCA	cis	rs8062405	0.965	rs62037363	ENSG00000278665.1	RP11-666O2.4	8.83	4.39e-18	1.78e-15	0.28	0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28853721	chr16:28599241~28601881:-
BRCA	cis	rs8062405	1	rs7205323	ENSG00000278665.1	RP11-666O2.4	8.83	4.39e-18	1.78e-15	0.28	0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28854571	chr16:28599241~28601881:-
BRCA	cis	rs13256369	1	rs12545771	ENSG00000253893.2	FAM85B	-8.83	4.39e-18	1.78e-15	-0.38	-0.26	Obesity-related traits;	chr8:8710467	chr8:8167819~8226614:-
BRCA	cis	rs1823874	1	rs1823874	ENSG00000182397.13	DNM1P46	-8.83	4.4e-18	1.78e-15	-0.28	-0.26	IgG glycosylation;	chr15:99817230	chr15:99790156~99806927:-
BRCA	cis	rs10463554	0.963	rs3776857	ENSG00000175749.11	EIF3KP1	8.83	4.4e-18	1.78e-15	0.36	0.26	Parkinson's disease;	chr5:103022456	chr5:103032376~103033031:+
BRCA	cis	rs11098499	0.644	rs3986377	ENSG00000248280.1	RP11-33B1.2	8.83	4.41e-18	1.79e-15	0.25	0.26	Corneal astigmatism;	chr4:119339115	chr4:119440561~119450157:-
BRCA	cis	rs10028773	0.556	rs4473640	ENSG00000248280.1	RP11-33B1.2	8.83	4.41e-18	1.79e-15	0.25	0.26	Educational attainment;	chr4:119339282	chr4:119440561~119450157:-
BRCA	cis	rs4862750	0.914	rs11943333	ENSG00000250971.1	RP11-696F12.1	8.83	4.43e-18	1.8e-15	0.27	0.26	Lobe attachment (rater-scored or self-reported);	chr4:186951301	chr4:187060099~187060930:+
BRCA	cis	rs748404	0.666	rs7181634	ENSG00000249839.1	AC011330.5	-8.83	4.43e-18	1.8e-15	-0.38	-0.26	Lung cancer;	chr15:43351703	chr15:43663654~43684339:-
BRCA	cis	rs1707322	1	rs7553924	ENSG00000280836.1	AL355480.1	-8.83	4.44e-18	1.8e-15	-0.33	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45886952	chr1:45581219~45581321:-
BRCA	cis	rs1707322	1	rs4641257	ENSG00000280836.1	AL355480.1	-8.83	4.44e-18	1.8e-15	-0.33	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45887917	chr1:45581219~45581321:-
BRCA	cis	rs1707322	1	rs6693336	ENSG00000280836.1	AL355480.1	-8.83	4.44e-18	1.8e-15	-0.33	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45888923	chr1:45581219~45581321:-
BRCA	cis	rs2067615	0.579	rs6539283	ENSG00000260329.1	RP11-412D9.4	-8.83	4.44e-18	1.8e-15	-0.29	-0.26	Heart rate;	chr12:106829211	chr12:106954029~106955497:-
BRCA	cis	rs748404	0.626	rs17780920	ENSG00000249839.1	AC011330.5	-8.83	4.46e-18	1.81e-15	-0.38	-0.26	Lung cancer;	chr15:43370164	chr15:43663654~43684339:-
BRCA	cis	rs10895987	0.531	rs7943007	ENSG00000254614.2	AP003068.23	-8.83	4.46e-18	1.81e-15	-0.35	-0.26	Blood protein levels;	chr11:65089626	chr11:65177606~65181834:-
BRCA	cis	rs8012947	1	rs7154076	ENSG00000279636.2	LINC00216	-8.83	4.46e-18	1.81e-15	-0.29	-0.26	Alcohol consumption in current drinkers;	chr14:58295564	chr14:58288033~58289158:+
BRCA	cis	rs13256369	0.901	rs13251887	ENSG00000253893.2	FAM85B	-8.83	4.48e-18	1.81e-15	-0.38	-0.26	Obesity-related traits;	chr8:8711168	chr8:8167819~8226614:-
BRCA	cis	rs17711722	0.727	rs35850374	ENSG00000164669.11	INTS4P1	-8.83	4.49e-18	1.82e-15	-0.32	-0.26	Calcium levels;	chr7:65892789	chr7:65141225~65234216:+
BRCA	cis	rs8062405	1	rs3088215	ENSG00000278665.1	RP11-666O2.4	8.83	4.49e-18	1.82e-15	0.28	0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28842675	chr16:28599241~28601881:-
BRCA	cis	rs8062405	1	rs28403629	ENSG00000278665.1	RP11-666O2.4	8.83	4.49e-18	1.82e-15	0.28	0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28843448	chr16:28599241~28601881:-
BRCA	cis	rs8062405	1	rs61737565	ENSG00000278665.1	RP11-666O2.4	8.83	4.49e-18	1.82e-15	0.28	0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28844201	chr16:28599241~28601881:-
BRCA	cis	rs8062405	1	rs4788099	ENSG00000278665.1	RP11-666O2.4	8.83	4.49e-18	1.82e-15	0.28	0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28844406	chr16:28599241~28601881:-
BRCA	cis	rs7772486	0.686	rs9376956	ENSG00000235652.6	RP11-545I5.3	8.83	4.49e-18	1.82e-15	0.26	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145628708	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.658	rs6570706	ENSG00000235652.6	RP11-545I5.3	8.83	4.49e-18	1.82e-15	0.26	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145641786	chr6:145799409~145886585:+
BRCA	cis	rs11098499	0.955	rs13113112	ENSG00000245958.5	RP11-33B1.1	-8.83	4.5e-18	1.82e-15	-0.27	-0.26	Corneal astigmatism;	chr4:119234885	chr4:119454791~119552025:+
BRCA	cis	rs10463554	0.927	rs257316	ENSG00000175749.11	EIF3KP1	-8.83	4.5e-18	1.82e-15	-0.38	-0.26	Parkinson's disease;	chr5:103086739	chr5:103032376~103033031:+
BRCA	cis	rs7429990	0.864	rs6806860	ENSG00000229759.1	MRPS18AP1	-8.83	4.5e-18	1.82e-15	-0.3	-0.26	Educational attainment (years of education);	chr3:47708218	chr3:48256350~48256938:-
BRCA	cis	rs7429990	0.864	rs17079785	ENSG00000229759.1	MRPS18AP1	-8.83	4.5e-18	1.82e-15	-0.3	-0.26	Educational attainment (years of education);	chr3:47743160	chr3:48256350~48256938:-
BRCA	cis	rs7772486	0.624	rs6930154	ENSG00000235652.6	RP11-545I5.3	-8.83	4.51e-18	1.82e-15	-0.26	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145704526	chr6:145799409~145886585:+
BRCA	cis	rs380904	0.552	rs10099003	ENSG00000254859.1	RP11-661A12.5	-8.83	4.51e-18	1.82e-15	-0.4	-0.26	Venous thromboembolism (SNP x SNP interaction);	chr8:143563290	chr8:143541973~143549729:-
BRCA	cis	rs8062405	1	rs8062405	ENSG00000251417.2	RP11-1348G14.4	8.83	4.51e-18	1.82e-15	0.3	0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28826585	chr16:28802743~28817828:+
BRCA	cis	rs2404602	0.716	rs117129193	ENSG00000259422.1	RP11-593F23.1	8.83	4.51e-18	1.83e-15	0.33	0.26	Blood metabolite levels;	chr15:76364462	chr15:76174891~76181486:-
BRCA	cis	rs875971	0.964	rs778735	ENSG00000237310.1	GS1-124K5.4	8.83	4.52e-18	1.83e-15	0.27	0.26	Aortic root size;	chr7:66349822	chr7:66493706~66495474:+
BRCA	cis	rs881375	0.933	rs10818485	ENSG00000226752.6	PSMD5-AS1	-8.83	4.52e-18	1.83e-15	-0.32	-0.26	Rheumatoid arthritis;	chr9:120905538	chr9:120824828~120854385:+
BRCA	cis	rs17772222	0.958	rs59136503	ENSG00000258983.2	RP11-507K2.2	8.82	4.55e-18	1.84e-15	0.31	0.26	Coronary artery calcification;	chr14:88501921	chr14:88499334~88515502:+
BRCA	cis	rs4835473	0.932	rs2218791	ENSG00000251600.4	RP11-673E1.1	-8.82	4.55e-18	1.84e-15	-0.3	-0.26	Immature fraction of reticulocytes;	chr4:143749300	chr4:143912331~143982454:+
BRCA	cis	rs17711722	0.701	rs4467826	ENSG00000164669.11	INTS4P1	-8.82	4.56e-18	1.85e-15	-0.32	-0.26	Calcium levels;	chr7:65903721	chr7:65141225~65234216:+
BRCA	cis	rs6142102	0.961	rs6120519	ENSG00000276073.1	RP5-1125A11.7	-8.82	4.56e-18	1.85e-15	-0.31	-0.26	Skin pigmentation;	chr20:34100307	chr20:33985617~33988989:-
BRCA	cis	rs783540	0.967	rs1864699	ENSG00000278603.1	RP13-608F4.5	8.82	4.57e-18	1.85e-15	0.33	0.26	Schizophrenia;	chr15:82654567	chr15:82472203~82472426:+
BRCA	cis	rs2041895	0.509	rs1035236	ENSG00000260329.1	RP11-412D9.4	-8.82	4.58e-18	1.85e-15	-0.33	-0.26	Glaucoma (low intraocular pressure);	chr12:106917019	chr12:106954029~106955497:-
BRCA	cis	rs2041895	0.509	rs10861676	ENSG00000260329.1	RP11-412D9.4	-8.82	4.58e-18	1.85e-15	-0.33	-0.26	Glaucoma (low intraocular pressure);	chr12:106917457	chr12:106954029~106955497:-
BRCA	cis	rs853679	0.538	rs13199081	ENSG00000216901.1	AL022393.7	8.82	4.58e-18	1.85e-15	0.38	0.26	Depression;	chr6:28364057	chr6:28176188~28176674:+
BRCA	cis	rs4660456	0.913	rs2361651	ENSG00000237899.1	RP4-739H11.3	8.82	4.58e-18	1.85e-15	0.39	0.26	Platelet count;	chr1:40764542	chr1:40669089~40687588:-
BRCA	cis	rs11098499	0.789	rs10212719	ENSG00000245958.5	RP11-33B1.1	-8.82	4.58e-18	1.85e-15	-0.25	-0.26	Corneal astigmatism;	chr4:119333282	chr4:119454791~119552025:+
BRCA	cis	rs881375	0.967	rs758959	ENSG00000226752.6	PSMD5-AS1	-8.82	4.59e-18	1.85e-15	-0.32	-0.26	Rheumatoid arthritis;	chr9:120914421	chr9:120824828~120854385:+
BRCA	cis	rs7945705	0.967	rs10840141	ENSG00000254860.4	TMEM9B-AS1	-8.82	4.64e-18	1.88e-15	-0.25	-0.26	Hemoglobin concentration;	chr11:8880671	chr11:8964675~8977527:+
BRCA	cis	rs7428	0.527	rs7607284	ENSG00000246575.2	AC093162.5	8.82	4.66e-18	1.88e-15	0.28	0.26	Ear protrusion;	chr2:85320253	chr2:85315041~85316529:+
BRCA	cis	rs7428	0.527	rs4459734	ENSG00000246575.2	AC093162.5	8.82	4.66e-18	1.88e-15	0.28	0.26	Ear protrusion;	chr2:85320306	chr2:85315041~85316529:+
BRCA	cis	rs526231	0.578	rs42860	ENSG00000175749.11	EIF3KP1	8.82	4.66e-18	1.88e-15	0.36	0.26	Primary biliary cholangitis;	chr5:103092414	chr5:103032376~103033031:+
BRCA	cis	rs10463554	0.927	rs34806	ENSG00000175749.11	EIF3KP1	8.82	4.66e-18	1.88e-15	0.36	0.26	Parkinson's disease;	chr5:103092733	chr5:103032376~103033031:+
BRCA	cis	rs875971	1	rs6979382	ENSG00000237310.1	GS1-124K5.4	8.82	4.69e-18	1.89e-15	0.27	0.26	Aortic root size;	chr7:66421388	chr7:66493706~66495474:+
BRCA	cis	rs875971	1	rs6961990	ENSG00000237310.1	GS1-124K5.4	8.82	4.69e-18	1.89e-15	0.27	0.26	Aortic root size;	chr7:66423583	chr7:66493706~66495474:+
BRCA	cis	rs150992	0.505	rs167798	ENSG00000248489.1	CTD-2007H13.3	8.82	4.7e-18	1.9e-15	0.35	0.26	Body mass index;	chr5:98972150	chr5:98929171~98995013:+
BRCA	cis	rs4964805	0.913	rs36034617	ENSG00000257681.1	RP11-341G23.4	8.82	4.73e-18	1.91e-15	0.33	0.26	Attention deficit hyperactivity disorder;	chr12:103809837	chr12:103746315~103768858:-
BRCA	cis	rs11673344	0.864	rs55921822	ENSG00000226686.6	LINC01535	8.82	4.74e-18	1.91e-15	0.34	0.26	Obesity-related traits;	chr19:37005910	chr19:37251912~37265535:+
BRCA	cis	rs17023223	0.509	rs10923740	ENSG00000231365.4	RP11-418J17.1	-8.82	4.76e-18	1.92e-15	-0.35	-0.26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119057664	chr1:119140396~119275973:+
BRCA	cis	rs858239	0.6	rs7787110	ENSG00000226816.2	AC005082.12	8.82	4.78e-18	1.93e-15	0.3	0.26	Cerebrospinal fluid biomarker levels;	chr7:23098855	chr7:23206013~23208045:+
BRCA	cis	rs11098499	0.863	rs2291185	ENSG00000245958.5	RP11-33B1.1	-8.82	4.78e-18	1.93e-15	-0.26	-0.26	Corneal astigmatism;	chr4:119513678	chr4:119454791~119552025:+
BRCA	cis	rs853679	0.567	rs3799499	ENSG00000216901.1	AL022393.7	8.82	4.78e-18	1.93e-15	0.37	0.26	Depression;	chr6:28386473	chr6:28176188~28176674:+
BRCA	cis	rs853679	0.567	rs2232427	ENSG00000216901.1	AL022393.7	8.82	4.78e-18	1.93e-15	0.37	0.26	Depression;	chr6:28391932	chr6:28176188~28176674:+
BRCA	cis	rs17711722	1	rs17711722	ENSG00000236529.1	RP13-254B10.1	-8.82	4.79e-18	1.93e-15	-0.29	-0.26	Calcium levels;	chr7:65806210	chr7:65840212~65840596:+
BRCA	cis	rs7430456	0.874	rs7428501	ENSG00000228221.4	LINC00578	8.82	4.8e-18	1.94e-15	0.33	0.26	Breast cancer;	chr3:177751974	chr3:177441921~177752305:+
BRCA	cis	rs4660456	0.871	rs7549789	ENSG00000237899.1	RP4-739H11.3	-8.82	4.8e-18	1.94e-15	-0.38	-0.26	Platelet count;	chr1:40759362	chr1:40669089~40687588:-
BRCA	cis	rs881375	0.967	rs2416805	ENSG00000226752.6	PSMD5-AS1	-8.82	4.81e-18	1.94e-15	-0.32	-0.26	Rheumatoid arthritis;	chr9:120914204	chr9:120824828~120854385:+
BRCA	cis	rs10971721	0.822	rs72727332	ENSG00000260947.1	RP11-384P7.7	8.82	4.81e-18	1.94e-15	0.47	0.26	Body mass index;	chr9:33929479	chr9:33697459~33700986:+
BRCA	cis	rs9640161	0.75	rs73170185	ENSG00000261305.1	RP4-584D14.7	8.82	4.82e-18	1.94e-15	0.41	0.26	Blood protein levels;Circulating chemerin levels;	chr7:150333102	chr7:150341771~150342607:+
BRCA	cis	rs7429990	0.864	rs12495204	ENSG00000229759.1	MRPS18AP1	-8.82	4.83e-18	1.95e-15	-0.3	-0.26	Educational attainment (years of education);	chr3:47720540	chr3:48256350~48256938:-
BRCA	cis	rs7429990	0.864	rs7612219	ENSG00000229759.1	MRPS18AP1	-8.82	4.83e-18	1.95e-15	-0.3	-0.26	Educational attainment (years of education);	chr3:47739676	chr3:48256350~48256938:-
BRCA	cis	rs7429990	0.864	rs7637372	ENSG00000229759.1	MRPS18AP1	-8.82	4.83e-18	1.95e-15	-0.3	-0.26	Educational attainment (years of education);	chr3:47750385	chr3:48256350~48256938:-
BRCA	cis	rs2041895	0.509	rs7970139	ENSG00000260329.1	RP11-412D9.4	-8.82	4.85e-18	1.96e-15	-0.33	-0.26	Glaucoma (low intraocular pressure);	chr12:106918652	chr12:106954029~106955497:-
BRCA	cis	rs748404	0.626	rs35992154	ENSG00000249839.1	AC011330.5	-8.82	4.85e-18	1.96e-15	-0.38	-0.26	Lung cancer;	chr15:43345669	chr15:43663654~43684339:-
BRCA	cis	rs1501911	0.509	rs327786	ENSG00000248489.1	CTD-2007H13.3	8.82	4.88e-18	1.97e-15	0.29	0.26	Lung function (FEV1/FVC);	chr5:98878301	chr5:98929171~98995013:+
BRCA	cis	rs2243480	0.908	rs55876148	ENSG00000226824.5	RP4-756H11.3	-8.82	4.88e-18	1.97e-15	-0.51	-0.26	Diabetic kidney disease;	chr7:65914813	chr7:66654538~66669855:+
BRCA	cis	rs13030978	0.505	rs72916554	ENSG00000227542.1	AC092614.2	8.82	4.9e-18	1.98e-15	0.34	0.26	Liver enzyme levels (gamma-glutamyl transferase);	chr2:191330532	chr2:191229165~191246172:-
BRCA	cis	rs8062405	1	rs8055138	ENSG00000278665.1	RP11-666O2.4	8.82	4.91e-18	1.98e-15	0.28	0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28880144	chr16:28599241~28601881:-
BRCA	cis	rs7772486	0.806	rs4075695	ENSG00000235652.6	RP11-545I5.3	-8.82	4.92e-18	1.98e-15	-0.26	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145929823	chr6:145799409~145886585:+
BRCA	cis	rs2404602	1	rs12594212	ENSG00000259422.1	RP11-593F23.1	8.82	4.92e-18	1.99e-15	0.33	0.26	Blood metabolite levels;	chr15:76509673	chr15:76174891~76181486:-
BRCA	cis	rs881375	0.967	rs10739579	ENSG00000226752.6	PSMD5-AS1	-8.82	4.93e-18	1.99e-15	-0.31	-0.26	Rheumatoid arthritis;	chr9:120932510	chr9:120824828~120854385:+
BRCA	cis	rs881375	0.678	rs10818488	ENSG00000226752.6	PSMD5-AS1	-8.81	4.94e-18	1.99e-15	-0.3	-0.26	Rheumatoid arthritis;	chr9:120942809	chr9:120824828~120854385:+
BRCA	cis	rs1823913	0.614	rs12616167	ENSG00000227542.1	AC092614.2	-8.81	4.94e-18	1.99e-15	-0.32	-0.26	Obesity-related traits;	chr2:191311274	chr2:191229165~191246172:-
BRCA	cis	rs875971	0.895	rs7788984	ENSG00000237310.1	GS1-124K5.4	8.81	4.94e-18	1.99e-15	0.27	0.26	Aortic root size;	chr7:66450629	chr7:66493706~66495474:+
BRCA	cis	rs11673344	0.764	rs524802	ENSG00000226686.6	LINC01535	8.81	4.95e-18	2e-15	0.34	0.26	Obesity-related traits;	chr19:36956045	chr19:37251912~37265535:+
BRCA	cis	rs673078	0.66	rs16948197	ENSG00000275759.1	RP11-131L12.3	8.81	4.96e-18	2e-15	0.41	0.26	Glucose homeostasis traits;	chr12:118239135	chr12:118428281~118428870:+
BRCA	cis	rs5751614	0.537	rs7292656	ENSG00000230701.2	FBXW4P1	8.81	4.97e-18	2e-15	0.33	0.26	Height;	chr22:23287415	chr22:23262767~23265005:+
BRCA	cis	rs11676348	0.774	rs4672870	ENSG00000261338.2	RP11-378A13.1	-8.81	4.99e-18	2.01e-15	-0.28	-0.26	Ulcerative colitis;	chr2:218077193	chr2:218255319~218257366:+
BRCA	cis	rs1707322	1	rs4539075	ENSG00000280836.1	AL355480.1	-8.81	4.99e-18	2.01e-15	-0.33	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45892338	chr1:45581219~45581321:-
BRCA	cis	rs1061377	0.722	rs34803689	ENSG00000249685.1	RP11-360F5.3	8.81	5e-18	2.01e-15	0.32	0.26	Uric acid levels;	chr4:39116665	chr4:39133913~39135608:+
BRCA	cis	rs10971721	0.822	rs10971791	ENSG00000260947.1	RP11-384P7.7	8.81	5e-18	2.01e-15	0.48	0.26	Body mass index;	chr9:33920912	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.822	rs10971792	ENSG00000260947.1	RP11-384P7.7	8.81	5e-18	2.01e-15	0.48	0.26	Body mass index;	chr9:33920955	chr9:33697459~33700986:+
BRCA	cis	rs11098499	0.863	rs58452170	ENSG00000248280.1	RP11-33B1.2	8.81	5.01e-18	2.02e-15	0.28	0.26	Corneal astigmatism;	chr4:119538519	chr4:119440561~119450157:-
BRCA	cis	rs4718428	0.705	rs4718424	ENSG00000273142.1	RP11-458F8.4	-8.81	5.03e-18	2.03e-15	-0.25	-0.26	Corneal structure;	chr7:66911108	chr7:66902857~66906297:+
BRCA	cis	rs12468226	1	rs58288071	ENSG00000273456.1	RP11-686O6.2	8.81	5.04e-18	2.03e-15	0.4	0.26	Urate levels;	chr2:202350016	chr2:202374932~202375604:-
BRCA	cis	rs7428	0.545	rs7572750	ENSG00000246575.2	AC093162.5	8.81	5.05e-18	2.03e-15	0.28	0.26	Ear protrusion;	chr2:85325063	chr2:85315041~85316529:+
BRCA	cis	rs11098499	0.554	rs2175381	ENSG00000245958.5	RP11-33B1.1	-8.81	5.07e-18	2.04e-15	-0.24	-0.26	Corneal astigmatism;	chr4:119344812	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.599	rs3864142	ENSG00000245958.5	RP11-33B1.1	-8.81	5.07e-18	2.04e-15	-0.24	-0.26	Corneal astigmatism;	chr4:119345036	chr4:119454791~119552025:+
BRCA	cis	rs7580658	0.545	rs885276	ENSG00000236682.1	AC068282.3	-8.81	5.13e-18	2.06e-15	-0.34	-0.26	Protein C levels;	chr2:127193328	chr2:127389130~127400580:+
BRCA	cis	rs113835537	0.529	rs2305532	ENSG00000255517.5	CTD-3074O7.5	-8.81	5.13e-18	2.06e-15	-0.35	-0.26	Airway imaging phenotypes;	chr11:66531123	chr11:66473490~66480233:-
BRCA	cis	rs113835537	0.529	rs2305533	ENSG00000255517.5	CTD-3074O7.5	-8.81	5.13e-18	2.06e-15	-0.35	-0.26	Airway imaging phenotypes;	chr11:66531152	chr11:66473490~66480233:-
BRCA	cis	rs11098499	0.605	rs6833140	ENSG00000245958.5	RP11-33B1.1	-8.81	5.15e-18	2.07e-15	-0.24	-0.26	Corneal astigmatism;	chr4:119345667	chr4:119454791~119552025:+
BRCA	cis	rs7580658	0.963	rs10803585	ENSG00000236682.1	AC068282.3	-8.81	5.16e-18	2.07e-15	-0.35	-0.26	Protein C levels;	chr2:127372532	chr2:127389130~127400580:+
BRCA	cis	rs7580658	0.963	rs2090574	ENSG00000236682.1	AC068282.3	-8.81	5.16e-18	2.07e-15	-0.35	-0.26	Protein C levels;	chr2:127373815	chr2:127389130~127400580:+
BRCA	cis	rs11098499	0.863	rs7678400	ENSG00000248280.1	RP11-33B1.2	8.81	5.16e-18	2.07e-15	0.28	0.26	Corneal astigmatism;	chr4:119540802	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.863	rs1480936	ENSG00000248280.1	RP11-33B1.2	8.81	5.16e-18	2.07e-15	0.28	0.26	Corneal astigmatism;	chr4:119541706	chr4:119440561~119450157:-
BRCA	cis	rs7580658	0.963	rs62157555	ENSG00000236682.1	AC068282.3	-8.81	5.17e-18	2.08e-15	-0.35	-0.26	Protein C levels;	chr2:127349600	chr2:127389130~127400580:+
BRCA	cis	rs4835473	0.932	rs66474962	ENSG00000251600.4	RP11-673E1.1	-8.81	5.18e-18	2.08e-15	-0.31	-0.26	Immature fraction of reticulocytes;	chr4:143735145	chr4:143912331~143982454:+
BRCA	cis	rs12468226	0.817	rs6722588	ENSG00000273456.1	RP11-686O6.2	-8.81	5.18e-18	2.08e-15	-0.4	-0.26	Urate levels;	chr2:202187163	chr2:202374932~202375604:-
BRCA	cis	rs1113500	0.527	rs1777482	ENSG00000226822.1	RP11-356N1.2	-8.81	5.19e-18	2.09e-15	-0.34	-0.26	Growth-regulated protein alpha levels;	chr1:108068752	chr1:108071482~108074519:+
BRCA	cis	rs7580658	0.963	rs12479003	ENSG00000236682.1	AC068282.3	-8.81	5.19e-18	2.09e-15	-0.35	-0.26	Protein C levels;	chr2:127360977	chr2:127389130~127400580:+
BRCA	cis	rs17023223	0.537	rs2794310	ENSG00000231365.4	RP11-418J17.1	-8.81	5.19e-18	2.09e-15	-0.34	-0.26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119019307	chr1:119140396~119275973:+
BRCA	cis	rs875971	1	rs1981798	ENSG00000237310.1	GS1-124K5.4	8.81	5.2e-18	2.09e-15	0.27	0.26	Aortic root size;	chr7:66489916	chr7:66493706~66495474:+
BRCA	cis	rs1198872	0.571	rs902130	ENSG00000272275.1	RP11-791G15.2	-8.81	5.2e-18	2.09e-15	-0.33	-0.26	Cardiac Troponin-T levels;	chr2:10770843	chr2:10767875~10770058:-
BRCA	cis	rs7429990	0.864	rs3915654	ENSG00000229759.1	MRPS18AP1	-8.81	5.23e-18	2.1e-15	-0.29	-0.26	Educational attainment (years of education);	chr3:47827132	chr3:48256350~48256938:-
BRCA	cis	rs11673344	0.704	rs510757	ENSG00000226686.6	LINC01535	-8.81	5.25e-18	2.11e-15	-0.34	-0.26	Obesity-related traits;	chr19:36931900	chr19:37251912~37265535:+
BRCA	cis	rs8012947	0.877	rs10136481	ENSG00000279636.2	LINC00216	-8.81	5.28e-18	2.12e-15	-0.28	-0.26	Alcohol consumption in current drinkers;	chr14:58302690	chr14:58288033~58289158:+
BRCA	cis	rs11098499	0.863	rs10030660	ENSG00000248280.1	RP11-33B1.2	8.81	5.28e-18	2.12e-15	0.28	0.26	Corneal astigmatism;	chr4:119515549	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.863	rs13149407	ENSG00000248280.1	RP11-33B1.2	8.81	5.28e-18	2.12e-15	0.28	0.26	Corneal astigmatism;	chr4:119516670	chr4:119440561~119450157:-
BRCA	cis	rs783540	0.967	rs783527	ENSG00000278603.1	RP13-608F4.5	-8.81	5.28e-18	2.12e-15	-0.33	-0.26	Schizophrenia;	chr15:82617096	chr15:82472203~82472426:+
BRCA	cis	rs1707322	1	rs12403666	ENSG00000280836.1	AL355480.1	-8.81	5.28e-18	2.12e-15	-0.34	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45965949	chr1:45581219~45581321:-
BRCA	cis	rs4820294	0.669	rs35662099	ENSG00000233360.4	Z83844.1	8.81	5.3e-18	2.13e-15	0.29	0.26	Fat distribution (HIV);	chr22:37657902	chr22:37641832~37658377:-
BRCA	cis	rs4660456	0.913	rs569159	ENSG00000237899.1	RP4-739H11.3	-8.81	5.31e-18	2.13e-15	-0.4	-0.26	Platelet count;	chr1:40701862	chr1:40669089~40687588:-
BRCA	cis	rs812925	0.519	rs1186696	ENSG00000271889.1	RP11-493E12.1	8.81	5.32e-18	2.14e-15	0.32	0.26	Immature fraction of reticulocytes;	chr2:61433348	chr2:61151433~61162105:-
BRCA	cis	rs11673344	0.864	rs8106386	ENSG00000226686.6	LINC01535	-8.81	5.33e-18	2.14e-15	-0.34	-0.26	Obesity-related traits;	chr19:37012997	chr19:37251912~37265535:+
BRCA	cis	rs17023223	0.581	rs12064109	ENSG00000231365.4	RP11-418J17.1	-8.81	5.34e-18	2.14e-15	-0.35	-0.26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119099673	chr1:119140396~119275973:+
BRCA	cis	rs1062177	0.855	rs919262	ENSG00000253921.1	CTB-113P19.3	8.81	5.34e-18	2.14e-15	0.34	0.26	Preschool internalizing problems;	chr5:151886523	chr5:151753992~151767247:+
BRCA	cis	rs1075265	0.811	rs805322	ENSG00000233266.1	HMGB1P31	-8.81	5.35e-18	2.15e-15	-0.32	-0.26	Chronotype;Morning vs. evening chronotype;	chr2:53912758	chr2:54051334~54051760:+
BRCA	cis	rs783540	1	rs698500	ENSG00000278603.1	RP13-608F4.5	-8.8	5.38e-18	2.16e-15	-0.33	-0.26	Schizophrenia;	chr15:82569019	chr15:82472203~82472426:+
BRCA	cis	rs1707322	1	rs34694458	ENSG00000280836.1	AL355480.1	-8.8	5.38e-18	2.16e-15	-0.33	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45867024	chr1:45581219~45581321:-
BRCA	cis	rs1075265	0.704	rs13417926	ENSG00000233266.1	HMGB1P31	8.8	5.39e-18	2.16e-15	0.32	0.26	Chronotype;Morning vs. evening chronotype;	chr2:53825520	chr2:54051334~54051760:+
BRCA	cis	rs10028773	0.6	rs4001390	ENSG00000245958.5	RP11-33B1.1	-8.8	5.4e-18	2.17e-15	-0.24	-0.26	Educational attainment;	chr4:119344628	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.691	rs2136911	ENSG00000245958.5	RP11-33B1.1	-8.8	5.4e-18	2.17e-15	-0.24	-0.26	Corneal astigmatism;	chr4:119344704	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.779	rs6815934	ENSG00000245958.5	RP11-33B1.1	-8.8	5.4e-18	2.17e-15	-0.24	-0.26	Corneal astigmatism;	chr4:119346155	chr4:119454791~119552025:+
BRCA	cis	rs10028773	0.568	rs6838457	ENSG00000245958.5	RP11-33B1.1	-8.8	5.4e-18	2.17e-15	-0.24	-0.26	Educational attainment;	chr4:119346212	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.535	rs10005542	ENSG00000245958.5	RP11-33B1.1	-8.8	5.4e-18	2.17e-15	-0.24	-0.26	Corneal astigmatism;	chr4:119347147	chr4:119454791~119552025:+
BRCA	cis	rs858239	0.738	rs13225593	ENSG00000226816.2	AC005082.12	8.8	5.4e-18	2.17e-15	0.31	0.26	Cerebrospinal fluid biomarker levels;	chr7:23220688	chr7:23206013~23208045:+
BRCA	cis	rs6570726	0.846	rs6570698	ENSG00000235652.6	RP11-545I5.3	8.8	5.4e-18	2.17e-15	0.26	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145597499	chr6:145799409~145886585:+
BRCA	cis	rs853679	1	rs11965538	ENSG00000220721.1	OR1F12	8.8	5.42e-18	2.17e-15	0.41	0.26	Depression;	chr6:28272137	chr6:28073316~28074233:+
BRCA	cis	rs10463554	0.89	rs26428	ENSG00000175749.11	EIF3KP1	-8.8	5.42e-18	2.18e-15	-0.36	-0.26	Parkinson's disease;	chr5:103030780	chr5:103032376~103033031:+
BRCA	cis	rs8012947	0.727	rs10135729	ENSG00000279636.2	LINC00216	-8.8	5.43e-18	2.18e-15	-0.29	-0.26	Alcohol consumption in current drinkers;	chr14:58277859	chr14:58288033~58289158:+
BRCA	cis	rs10463554	0.963	rs6596530	ENSG00000175749.11	EIF3KP1	8.8	5.43e-18	2.18e-15	0.36	0.26	Parkinson's disease;	chr5:103035736	chr5:103032376~103033031:+
BRCA	cis	rs8072100	0.817	rs7213086	ENSG00000228782.6	CTD-2026D20.3	8.8	5.43e-18	2.18e-15	0.29	0.26	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47674944	chr17:47450568~47492492:-
BRCA	cis	rs11098499	0.863	rs3775841	ENSG00000245958.5	RP11-33B1.1	-8.8	5.44e-18	2.18e-15	-0.26	-0.26	Corneal astigmatism;	chr4:119504622	chr4:119454791~119552025:+
BRCA	cis	rs2404602	0.716	rs56351018	ENSG00000259422.1	RP11-593F23.1	8.8	5.45e-18	2.19e-15	0.33	0.26	Blood metabolite levels;	chr15:76532250	chr15:76174891~76181486:-
BRCA	cis	rs4835473	0.932	rs13130345	ENSG00000251600.4	RP11-673E1.1	8.8	5.47e-18	2.19e-15	0.32	0.26	Immature fraction of reticulocytes;	chr4:143920939	chr4:143912331~143982454:+
BRCA	cis	rs12468226	1	rs7565875	ENSG00000273456.1	RP11-686O6.2	8.8	5.48e-18	2.19e-15	0.37	0.26	Urate levels;	chr2:202516412	chr2:202374932~202375604:-
BRCA	cis	rs7580658	0.963	rs6732279	ENSG00000236682.1	AC068282.3	-8.8	5.49e-18	2.2e-15	-0.35	-0.26	Protein C levels;	chr2:127331964	chr2:127389130~127400580:+
BRCA	cis	rs4964805	0.865	rs67825151	ENSG00000257681.1	RP11-341G23.4	8.8	5.49e-18	2.2e-15	0.34	0.26	Attention deficit hyperactivity disorder;	chr12:103811666	chr12:103746315~103768858:-
BRCA	cis	rs2439831	0.85	rs28858500	ENSG00000249839.1	AC011330.5	-8.8	5.49e-18	2.2e-15	-0.43	-0.26	Lung cancer in ever smokers;	chr15:43864744	chr15:43663654~43684339:-
BRCA	cis	rs11098499	0.661	rs10015965	ENSG00000245958.5	RP11-33B1.1	-8.8	5.49e-18	2.2e-15	-0.24	-0.26	Corneal astigmatism;	chr4:119347082	chr4:119454791~119552025:+
BRCA	cis	rs6700559	0.81	rs10919990	ENSG00000260088.1	RP11-92G12.3	-8.8	5.5e-18	2.2e-15	-0.34	-0.26	Coronary artery disease;	chr1:200627076	chr1:200669507~200694250:+
BRCA	cis	rs7429990	0.864	rs6768699	ENSG00000229759.1	MRPS18AP1	-8.8	5.5e-18	2.21e-15	-0.3	-0.26	Educational attainment (years of education);	chr3:47711258	chr3:48256350~48256938:-
BRCA	cis	rs75422866	0.51	rs73105829	ENSG00000274902.1	RP1-197B17.4	8.8	5.52e-18	2.21e-15	0.67	0.26	Pneumonia;	chr12:47734162	chr12:47731908~47732351:+
BRCA	cis	rs11098499	0.754	rs1511017	ENSG00000245958.5	RP11-33B1.1	-8.8	5.53e-18	2.21e-15	-0.25	-0.26	Corneal astigmatism;	chr4:119329650	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.789	rs12498994	ENSG00000245958.5	RP11-33B1.1	-8.8	5.53e-18	2.21e-15	-0.25	-0.26	Corneal astigmatism;	chr4:119329663	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.754	rs12507565	ENSG00000245958.5	RP11-33B1.1	-8.8	5.53e-18	2.21e-15	-0.25	-0.26	Corneal astigmatism;	chr4:119329966	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.826	rs12511640	ENSG00000245958.5	RP11-33B1.1	-8.8	5.53e-18	2.21e-15	-0.25	-0.26	Corneal astigmatism;	chr4:119330093	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.754	rs1980026	ENSG00000245958.5	RP11-33B1.1	-8.8	5.53e-18	2.21e-15	-0.25	-0.26	Corneal astigmatism;	chr4:119330488	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.743	rs11098501	ENSG00000245958.5	RP11-33B1.1	-8.8	5.53e-18	2.21e-15	-0.25	-0.26	Corneal astigmatism;	chr4:119330862	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.754	rs11098502	ENSG00000245958.5	RP11-33B1.1	-8.8	5.53e-18	2.21e-15	-0.25	-0.26	Corneal astigmatism;	chr4:119330908	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.708	rs11732686	ENSG00000245958.5	RP11-33B1.1	-8.8	5.53e-18	2.21e-15	-0.25	-0.26	Corneal astigmatism;	chr4:119331175	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.754	rs11724409	ENSG00000245958.5	RP11-33B1.1	-8.8	5.53e-18	2.21e-15	-0.25	-0.26	Corneal astigmatism;	chr4:119331206	chr4:119454791~119552025:+
BRCA	cis	rs2455601	0.608	rs11042104	ENSG00000254860.4	TMEM9B-AS1	-8.8	5.55e-18	2.22e-15	-0.25	-0.26	Schizophrenia;	chr11:8869377	chr11:8964675~8977527:+
BRCA	cis	rs7772486	0.641	rs960385	ENSG00000235652.6	RP11-545I5.3	8.8	5.55e-18	2.22e-15	0.28	0.26	Lobe attachment (rater-scored or self-reported);	chr6:146049938	chr6:145799409~145886585:+
BRCA	cis	rs6844153	0.752	rs6815719	ENSG00000240005.4	RP11-293A21.1	-8.8	5.56e-18	2.23e-15	-0.34	-0.26	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26880232	chr4:26859806~26860599:-
BRCA	cis	rs11098499	0.863	rs1480940	ENSG00000248280.1	RP11-33B1.2	8.8	5.58e-18	2.24e-15	0.28	0.26	Corneal astigmatism;	chr4:119536527	chr4:119440561~119450157:-
BRCA	cis	rs7428	0.527	rs1554110	ENSG00000246575.2	AC093162.5	8.8	5.59e-18	2.24e-15	0.28	0.26	Ear protrusion;	chr2:85320840	chr2:85315041~85316529:+
BRCA	cis	rs4835473	0.9	rs35311036	ENSG00000251600.4	RP11-673E1.1	-8.8	5.59e-18	2.24e-15	-0.31	-0.26	Immature fraction of reticulocytes;	chr4:143734397	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.9	rs35906127	ENSG00000251600.4	RP11-673E1.1	-8.8	5.59e-18	2.24e-15	-0.31	-0.26	Immature fraction of reticulocytes;	chr4:143734400	chr4:143912331~143982454:+
BRCA	cis	rs2041895	0.509	rs7976343	ENSG00000260329.1	RP11-412D9.4	-8.8	5.61e-18	2.24e-15	-0.32	-0.26	Glaucoma (low intraocular pressure);	chr12:106902250	chr12:106954029~106955497:-
BRCA	cis	rs17711722	0.701	rs781143	ENSG00000236529.1	RP13-254B10.1	8.8	5.61e-18	2.24e-15	0.29	0.26	Calcium levels;	chr7:65974892	chr7:65840212~65840596:+
BRCA	cis	rs11098499	0.789	rs1980024	ENSG00000248280.1	RP11-33B1.2	8.8	5.63e-18	2.25e-15	0.26	0.26	Corneal astigmatism;	chr4:119331892	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.754	rs34425882	ENSG00000248280.1	RP11-33B1.2	8.8	5.63e-18	2.25e-15	0.26	0.26	Corneal astigmatism;	chr4:119332022	chr4:119440561~119450157:-
BRCA	cis	rs11673344	0.73	rs826314	ENSG00000226686.6	LINC01535	8.8	5.63e-18	2.25e-15	0.34	0.26	Obesity-related traits;	chr19:36959533	chr19:37251912~37265535:+
BRCA	cis	rs2404602	1	rs6495206	ENSG00000259422.1	RP11-593F23.1	8.8	5.65e-18	2.26e-15	0.32	0.26	Blood metabolite levels;	chr15:76578622	chr15:76174891~76181486:-
BRCA	cis	rs4835473	0.9	rs4285038	ENSG00000251600.4	RP11-673E1.1	-8.8	5.66e-18	2.26e-15	-0.3	-0.26	Immature fraction of reticulocytes;	chr4:143763637	chr4:143912331~143982454:+
BRCA	cis	rs11098499	0.863	rs58452170	ENSG00000245958.5	RP11-33B1.1	-8.8	5.66e-18	2.26e-15	-0.26	-0.26	Corneal astigmatism;	chr4:119538519	chr4:119454791~119552025:+
BRCA	cis	rs202072	0.729	rs202040	ENSG00000272379.1	RP1-257A7.5	8.8	5.66e-18	2.27e-15	0.45	0.26	HIV-1 viral setpoint;	chr6:13288303	chr6:13290018~13290490:-
BRCA	cis	rs10463554	0.963	rs3776860	ENSG00000175749.11	EIF3KP1	8.8	5.67e-18	2.27e-15	0.36	0.26	Parkinson's disease;	chr5:103014266	chr5:103032376~103033031:+
BRCA	cis	rs875971	0.545	rs2279757	ENSG00000237310.1	GS1-124K5.4	8.8	5.67e-18	2.27e-15	0.32	0.26	Aortic root size;	chr7:66363676	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.545	rs11766183	ENSG00000237310.1	GS1-124K5.4	8.8	5.67e-18	2.27e-15	0.32	0.26	Aortic root size;	chr7:66374173	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.545	rs1065265	ENSG00000237310.1	GS1-124K5.4	8.8	5.67e-18	2.27e-15	0.32	0.26	Aortic root size;	chr7:66376216	chr7:66493706~66495474:+
BRCA	cis	rs11098499	0.954	rs10017543	ENSG00000248280.1	RP11-33B1.2	8.8	5.68e-18	2.27e-15	0.27	0.26	Corneal astigmatism;	chr4:119400265	chr4:119440561~119450157:-
BRCA	cis	rs17023223	0.537	rs2794311	ENSG00000231365.4	RP11-418J17.1	8.8	5.71e-18	2.28e-15	0.33	0.26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119053326	chr1:119140396~119275973:+
BRCA	cis	rs9287719	0.967	rs1541573	ENSG00000234818.1	AC092687.5	8.8	5.72e-18	2.29e-15	0.31	0.26	Prostate cancer;	chr2:10633259	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.967	rs1541574	ENSG00000234818.1	AC092687.5	8.8	5.72e-18	2.29e-15	0.31	0.26	Prostate cancer;	chr2:10633382	chr2:10589166~10604830:+
BRCA	cis	rs853679	0.824	rs34712084	ENSG00000220721.1	OR1F12	8.8	5.73e-18	2.29e-15	0.5	0.26	Depression;	chr6:28076050	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.824	rs1321505	ENSG00000220721.1	OR1F12	8.8	5.73e-18	2.29e-15	0.5	0.26	Depression;	chr6:28085045	chr6:28073316~28074233:+
BRCA	cis	rs4718428	0.705	rs13231140	ENSG00000273142.1	RP11-458F8.4	-8.8	5.73e-18	2.29e-15	-0.25	-0.26	Corneal structure;	chr7:66896631	chr7:66902857~66906297:+
BRCA	cis	rs4862750	0.957	rs1030381	ENSG00000250971.1	RP11-696F12.1	8.8	5.74e-18	2.29e-15	0.27	0.26	Lobe attachment (rater-scored or self-reported);	chr4:186982414	chr4:187060099~187060930:+
BRCA	cis	rs11098499	0.863	rs1552092	ENSG00000245958.5	RP11-33B1.1	-8.8	5.74e-18	2.3e-15	-0.26	-0.26	Corneal astigmatism;	chr4:119567341	chr4:119454791~119552025:+
BRCA	cis	rs10971721	0.822	rs72727329	ENSG00000260947.1	RP11-384P7.7	8.8	5.76e-18	2.3e-15	0.47	0.26	Body mass index;	chr9:33921666	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.822	rs11848	ENSG00000260947.1	RP11-384P7.7	8.8	5.76e-18	2.3e-15	0.47	0.26	Body mass index;	chr9:33921921	chr9:33697459~33700986:+
BRCA	cis	rs2404602	0.716	rs12437627	ENSG00000259422.1	RP11-593F23.1	8.8	5.77e-18	2.31e-15	0.33	0.26	Blood metabolite levels;	chr15:76552709	chr15:76174891~76181486:-
BRCA	cis	rs10875746	0.669	rs9634261	ENSG00000240399.1	RP1-228P16.1	-8.8	5.79e-18	2.31e-15	-0.34	-0.26	Longevity (90 years and older);	chr12:48293088	chr12:48054813~48055591:-
BRCA	cis	rs7429990	0.833	rs4858801	ENSG00000229759.1	MRPS18AP1	-8.8	5.8e-18	2.32e-15	-0.3	-0.26	Educational attainment (years of education);	chr3:47599432	chr3:48256350~48256938:-
BRCA	cis	rs55665837	0.523	rs10832301	ENSG00000251991.1	RNU7-49P	8.8	5.81e-18	2.32e-15	0.29	0.26	Vitamin D levels;	chr11:14767418	chr11:14478892~14478953:+
BRCA	cis	rs7773456	0.74	rs6917179	ENSG00000228412.5	RP4-625H18.2	-8.79	5.83e-18	2.33e-15	-0.36	-0.26	Lupus nephritis in systemic lupus erythematosus;	chr6:19817570	chr6:19802164~19804752:-
BRCA	cis	rs11098499	0.754	rs17049949	ENSG00000245958.5	RP11-33B1.1	-8.79	5.84e-18	2.33e-15	-0.25	-0.26	Corneal astigmatism;	chr4:119334135	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.754	rs7689729	ENSG00000245958.5	RP11-33B1.1	-8.79	5.84e-18	2.33e-15	-0.25	-0.26	Corneal astigmatism;	chr4:119335037	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.865	rs3956464	ENSG00000245958.5	RP11-33B1.1	-8.79	5.84e-18	2.33e-15	-0.25	-0.26	Corneal astigmatism;	chr4:119335609	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.648	rs2002047	ENSG00000245958.5	RP11-33B1.1	-8.79	5.84e-18	2.33e-15	-0.25	-0.26	Corneal astigmatism;	chr4:119336073	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.775	rs2002049	ENSG00000245958.5	RP11-33B1.1	-8.79	5.84e-18	2.33e-15	-0.25	-0.26	Corneal astigmatism;	chr4:119336262	chr4:119454791~119552025:+
BRCA	cis	rs1707322	1	rs6429588	ENSG00000280836.1	AL355480.1	-8.79	5.84e-18	2.33e-15	-0.34	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45988386	chr1:45581219~45581321:-
BRCA	cis	rs4835473	0.864	rs13145791	ENSG00000251600.4	RP11-673E1.1	-8.79	5.84e-18	2.33e-15	-0.31	-0.26	Immature fraction of reticulocytes;	chr4:143735688	chr4:143912331~143982454:+
BRCA	cis	rs7772486	0.659	rs9376957	ENSG00000235652.6	RP11-545I5.3	-8.79	5.85e-18	2.34e-15	-0.26	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145689928	chr6:145799409~145886585:+
BRCA	cis	rs1707322	1	rs11211217	ENSG00000280836.1	AL355480.1	-8.79	5.86e-18	2.34e-15	-0.33	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45882557	chr1:45581219~45581321:-
BRCA	cis	rs10971721	0.822	rs72727344	ENSG00000260947.1	RP11-384P7.7	8.79	5.87e-18	2.34e-15	0.47	0.26	Body mass index;	chr9:33939122	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.822	rs10971807	ENSG00000260947.1	RP11-384P7.7	8.79	5.87e-18	2.34e-15	0.47	0.26	Body mass index;	chr9:33939557	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.822	rs72727345	ENSG00000260947.1	RP11-384P7.7	8.79	5.87e-18	2.34e-15	0.47	0.26	Body mass index;	chr9:33940200	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.822	rs72727346	ENSG00000260947.1	RP11-384P7.7	8.79	5.87e-18	2.34e-15	0.47	0.26	Body mass index;	chr9:33940420	chr9:33697459~33700986:+
BRCA	cis	rs11098499	0.863	rs1010740	ENSG00000248280.1	RP11-33B1.2	-8.79	5.88e-18	2.35e-15	-0.28	-0.26	Corneal astigmatism;	chr4:119542254	chr4:119440561~119450157:-
BRCA	cis	rs75422866	0.51	rs73105803	ENSG00000274902.1	RP1-197B17.4	8.79	5.89e-18	2.35e-15	0.66	0.26	Pneumonia;	chr12:47722135	chr12:47731908~47732351:+
BRCA	cis	rs75422866	0.51	rs73105812	ENSG00000274902.1	RP1-197B17.4	8.79	5.89e-18	2.35e-15	0.66	0.26	Pneumonia;	chr12:47724404	chr12:47731908~47732351:+
BRCA	cis	rs75422866	0.51	rs74733564	ENSG00000274902.1	RP1-197B17.4	8.79	5.89e-18	2.35e-15	0.66	0.26	Pneumonia;	chr12:47724644	chr12:47731908~47732351:+
BRCA	cis	rs75422866	0.51	rs73105814	ENSG00000274902.1	RP1-197B17.4	8.79	5.89e-18	2.35e-15	0.66	0.26	Pneumonia;	chr12:47725817	chr12:47731908~47732351:+
BRCA	cis	rs4835473	0.932	rs7696106	ENSG00000251600.4	RP11-673E1.1	-8.79	5.89e-18	2.35e-15	-0.31	-0.26	Immature fraction of reticulocytes;	chr4:143765454	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs7680045	ENSG00000251600.4	RP11-673E1.1	-8.79	5.89e-18	2.35e-15	-0.31	-0.26	Immature fraction of reticulocytes;	chr4:143765470	chr4:143912331~143982454:+
BRCA	cis	rs4718428	0.705	rs28648401	ENSG00000273142.1	RP11-458F8.4	-8.79	5.93e-18	2.37e-15	-0.25	-0.26	Corneal structure;	chr7:66902145	chr7:66902857~66906297:+
BRCA	cis	rs1501911	0.509	rs34487	ENSG00000248489.1	CTD-2007H13.3	8.79	5.94e-18	2.37e-15	0.29	0.26	Lung function (FEV1/FVC);	chr5:98872725	chr5:98929171~98995013:+
BRCA	cis	rs710216	0.536	rs710221	ENSG00000227533.4	SLC2A1-AS1	8.79	5.94e-18	2.37e-15	0.34	0.26	Red cell distribution width;	chr1:42948529	chr1:42959049~42983358:+
BRCA	cis	rs1062177	0.855	rs6884630	ENSG00000253921.1	CTB-113P19.3	-8.79	5.95e-18	2.38e-15	-0.34	-0.26	Preschool internalizing problems;	chr5:151889436	chr5:151753992~151767247:+
BRCA	cis	rs7580658	0.545	rs67996371	ENSG00000236682.1	AC068282.3	-8.79	5.96e-18	2.38e-15	-0.34	-0.26	Protein C levels;	chr2:127195841	chr2:127389130~127400580:+
BRCA	cis	rs881375	0.678	rs10118357	ENSG00000226752.6	PSMD5-AS1	-8.79	5.96e-18	2.38e-15	-0.31	-0.26	Rheumatoid arthritis;	chr9:120917790	chr9:120824828~120854385:+
BRCA	cis	rs6545883	0.525	rs1729658	ENSG00000271889.1	RP11-493E12.1	8.79	5.97e-18	2.38e-15	0.33	0.26	Tuberculosis;	chr2:61146385	chr2:61151433~61162105:-
BRCA	cis	rs17772222	0.958	rs2297128	ENSG00000258983.2	RP11-507K2.2	8.79	5.98e-18	2.39e-15	0.3	0.26	Coronary artery calcification;	chr14:88469910	chr14:88499334~88515502:+
BRCA	cis	rs10129255	1	rs8010605	ENSG00000223648.3	IGHV3-64	8.79	6.01e-18	2.4e-15	0.23	0.26	Kawasaki disease;	chr14:106678742	chr14:106643132~106658258:-
BRCA	cis	rs8012947	1	rs1885134	ENSG00000279636.2	LINC00216	-8.79	6.01e-18	2.4e-15	-0.29	-0.26	Alcohol consumption in current drinkers;	chr14:58270812	chr14:58288033~58289158:+
BRCA	cis	rs1707322	1	rs10890380	ENSG00000280836.1	AL355480.1	-8.79	6.01e-18	2.4e-15	-0.34	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45983797	chr1:45581219~45581321:-
BRCA	cis	rs7429990	0.864	rs61620099	ENSG00000229759.1	MRPS18AP1	-8.79	6.02e-18	2.4e-15	-0.3	-0.26	Educational attainment (years of education);	chr3:47600755	chr3:48256350~48256938:-
BRCA	cis	rs7773456	0.576	rs12206194	ENSG00000228412.5	RP4-625H18.2	8.79	6.02e-18	2.4e-15	0.37	0.26	Lupus nephritis in systemic lupus erythematosus;	chr6:19819677	chr6:19802164~19804752:-
BRCA	cis	rs453301	0.686	rs1045527	ENSG00000253893.2	FAM85B	8.79	6.03e-18	2.41e-15	0.33	0.26	Joint mobility (Beighton score);	chr8:9032531	chr8:8167819~8226614:-
BRCA	cis	rs10463554	0.926	rs3776858	ENSG00000175749.11	EIF3KP1	8.79	6.04e-18	2.41e-15	0.36	0.26	Parkinson's disease;	chr5:103021790	chr5:103032376~103033031:+
BRCA	cis	rs748404	0.666	rs35160541	ENSG00000249839.1	AC011330.5	-8.79	6.07e-18	2.42e-15	-0.38	-0.26	Lung cancer;	chr15:43365601	chr15:43663654~43684339:-
BRCA	cis	rs11673344	0.764	rs547483	ENSG00000226686.6	LINC01535	-8.79	6.1e-18	2.43e-15	-0.34	-0.26	Obesity-related traits;	chr19:36950463	chr19:37251912~37265535:+
BRCA	cis	rs10971721	0.822	rs10971793	ENSG00000260947.1	RP11-384P7.7	8.79	6.1e-18	2.43e-15	0.48	0.26	Body mass index;	chr9:33922628	chr9:33697459~33700986:+
BRCA	cis	rs11098499	0.754	rs12513083	ENSG00000245958.5	RP11-33B1.1	-8.79	6.1e-18	2.43e-15	-0.25	-0.26	Corneal astigmatism;	chr4:119328457	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.754	rs12509621	ENSG00000245958.5	RP11-33B1.1	-8.79	6.1e-18	2.43e-15	-0.25	-0.26	Corneal astigmatism;	chr4:119328505	chr4:119454791~119552025:+
BRCA	cis	rs11690935	0.632	rs6737308	ENSG00000228389.1	AC068039.4	-8.79	6.12e-18	2.44e-15	-0.32	-0.26	Schizophrenia;	chr2:172007137	chr2:171773482~171775844:+
BRCA	cis	rs7712401	0.601	rs2910136	ENSG00000263432.2	RN7SL689P	-8.79	6.14e-18	2.45e-15	-0.33	-0.26	Mean platelet volume;	chr5:122918322	chr5:123022487~123022783:-
BRCA	cis	rs748404	0.666	rs17780417	ENSG00000249839.1	AC011330.5	-8.79	6.14e-18	2.45e-15	-0.38	-0.26	Lung cancer;	chr15:43347264	chr15:43663654~43684339:-
BRCA	cis	rs72772090	0.539	rs11750671	ENSG00000248734.2	CTD-2260A17.1	-8.79	6.18e-18	2.46e-15	-0.45	-0.26	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96852779	chr5:96784777~96785999:+
BRCA	cis	rs10028773	0.7	rs7690338	ENSG00000245958.5	RP11-33B1.1	-8.79	6.18e-18	2.46e-15	-0.25	-0.26	Educational attainment;	chr4:119335313	chr4:119454791~119552025:+
BRCA	cis	rs7829975	0.533	rs13274028	ENSG00000253893.2	FAM85B	-8.79	6.19e-18	2.47e-15	-0.33	-0.26	Mood instability;	chr8:8871683	chr8:8167819~8226614:-
BRCA	cis	rs8012947	0.959	rs4520767	ENSG00000279636.2	LINC00216	-8.79	6.21e-18	2.48e-15	-0.28	-0.26	Alcohol consumption in current drinkers;	chr14:58302220	chr14:58288033~58289158:+
BRCA	cis	rs875971	0.545	rs12671152	ENSG00000222364.1	RNU6-96P	-8.79	6.21e-18	2.48e-15	-0.35	-0.26	Aortic root size;	chr7:66311140	chr7:66395191~66395286:+
BRCA	cis	rs2115630	0.967	rs8028490	ENSG00000225151.9	GOLGA2P7	8.79	6.22e-18	2.48e-15	0.29	0.26	P wave terminal force;	chr15:84734657	chr15:84199311~84230136:-
BRCA	cis	rs7429990	0.694	rs7645846	ENSG00000229759.1	MRPS18AP1	-8.79	6.24e-18	2.49e-15	-0.3	-0.26	Educational attainment (years of education);	chr3:47740829	chr3:48256350~48256938:-
BRCA	cis	rs8062405	1	rs62037365	ENSG00000278665.1	RP11-666O2.4	8.79	6.26e-18	2.49e-15	0.28	0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28857641	chr16:28599241~28601881:-
BRCA	cis	rs7580658	0.534	rs2089109	ENSG00000236682.1	AC068282.3	-8.79	6.31e-18	2.51e-15	-0.33	-0.26	Protein C levels;	chr2:127193882	chr2:127389130~127400580:+
BRCA	cis	rs4835473	0.9	rs35670120	ENSG00000251600.4	RP11-673E1.1	-8.79	6.31e-18	2.51e-15	-0.31	-0.26	Immature fraction of reticulocytes;	chr4:143787041	chr4:143912331~143982454:+
BRCA	cis	rs875971	0.545	rs11770063	ENSG00000237310.1	GS1-124K5.4	8.79	6.32e-18	2.52e-15	0.32	0.26	Aortic root size;	chr7:66318029	chr7:66493706~66495474:+
BRCA	cis	rs9543976	0.623	rs6562915	ENSG00000261553.4	RP11-29G8.3	8.78	6.33e-18	2.52e-15	0.41	0.26	Diabetic retinopathy;	chr13:75596750	chr13:75549773~75807120:+
BRCA	cis	rs2067615	0.56	rs12298717	ENSG00000260329.1	RP11-412D9.4	8.78	6.34e-18	2.52e-15	0.29	0.26	Heart rate;	chr12:106706105	chr12:106954029~106955497:-
BRCA	cis	rs7923609	0.578	rs3858121	ENSG00000232075.1	MRPL35P2	-8.78	6.34e-18	2.52e-15	-0.33	-0.26	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63640237	chr10:63634317~63634827:-
BRCA	cis	rs4835473	0.868	rs4629390	ENSG00000251600.4	RP11-673E1.1	-8.78	6.38e-18	2.54e-15	-0.3	-0.26	Immature fraction of reticulocytes;	chr4:143735302	chr4:143912331~143982454:+
BRCA	cis	rs11098499	0.908	rs7695996	ENSG00000248280.1	RP11-33B1.2	8.78	6.39e-18	2.55e-15	0.27	0.26	Corneal astigmatism;	chr4:119400878	chr4:119440561~119450157:-
BRCA	cis	rs853679	0.567	rs7774981	ENSG00000216901.1	AL022393.7	8.78	6.41e-18	2.55e-15	0.38	0.26	Depression;	chr6:28379133	chr6:28176188~28176674:+
BRCA	cis	rs853679	0.567	rs7754960	ENSG00000216901.1	AL022393.7	8.78	6.41e-18	2.55e-15	0.38	0.26	Depression;	chr6:28379168	chr6:28176188~28176674:+
BRCA	cis	rs17711722	0.701	rs781143	ENSG00000164669.11	INTS4P1	-8.78	6.42e-18	2.55e-15	-0.32	-0.26	Calcium levels;	chr7:65974892	chr7:65141225~65234216:+
BRCA	cis	rs228614	0.51	rs150893	ENSG00000246560.2	RP11-10L12.4	-8.78	6.44e-18	2.56e-15	-0.27	-0.26	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102817075	chr4:102828055~102844075:+
BRCA	cis	rs11673344	0.734	rs1667343	ENSG00000226686.6	LINC01535	8.78	6.47e-18	2.57e-15	0.34	0.26	Obesity-related traits;	chr19:36978196	chr19:37251912~37265535:+
BRCA	cis	rs858239	0.72	rs10227559	ENSG00000226816.2	AC005082.12	8.78	6.48e-18	2.58e-15	0.31	0.26	Cerebrospinal fluid biomarker levels;	chr7:23232525	chr7:23206013~23208045:+
BRCA	cis	rs2688482	0.557	rs3103952	ENSG00000224769.1	AC069213.1	8.78	6.48e-18	2.58e-15	0.49	0.26	Lung disease severity in cystic fibrosis;	chr3:195795819	chr3:195614947~195620233:+
BRCA	cis	rs7580658	0.963	rs12052483	ENSG00000236682.1	AC068282.3	-8.78	6.48e-18	2.58e-15	-0.35	-0.26	Protein C levels;	chr2:127379244	chr2:127389130~127400580:+
BRCA	cis	rs7580658	0.926	rs4662725	ENSG00000236682.1	AC068282.3	-8.78	6.48e-18	2.58e-15	-0.35	-0.26	Protein C levels;	chr2:127383744	chr2:127389130~127400580:+
BRCA	cis	rs11098499	0.73	rs12505735	ENSG00000245958.5	RP11-33B1.1	-8.78	6.52e-18	2.59e-15	-0.26	-0.26	Corneal astigmatism;	chr4:119611801	chr4:119454791~119552025:+
BRCA	cis	rs853679	0.567	rs1005126	ENSG00000216901.1	AL022393.7	8.78	6.55e-18	2.6e-15	0.37	0.26	Depression;	chr6:28399846	chr6:28176188~28176674:+
BRCA	cis	rs56046484	0.871	rs62021230	ENSG00000259295.5	CSPG4P12	8.78	6.55e-18	2.6e-15	0.47	0.26	Testicular germ cell tumor;	chr15:85040721	chr15:85191438~85213905:+
BRCA	cis	rs858239	0.539	rs7791200	ENSG00000226816.2	AC005082.12	8.78	6.55e-18	2.61e-15	0.31	0.26	Cerebrospinal fluid biomarker levels;	chr7:23142502	chr7:23206013~23208045:+
BRCA	cis	rs881375	0.678	rs1014530	ENSG00000226752.6	PSMD5-AS1	-8.78	6.55e-18	2.61e-15	-0.3	-0.26	Rheumatoid arthritis;	chr9:120922814	chr9:120824828~120854385:+
BRCA	cis	rs72772090	0.539	rs72775817	ENSG00000248734.2	CTD-2260A17.1	-8.78	6.57e-18	2.61e-15	-0.44	-0.26	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96855006	chr5:96784777~96785999:+
BRCA	cis	rs72772090	0.539	rs72775818	ENSG00000248734.2	CTD-2260A17.1	-8.78	6.57e-18	2.61e-15	-0.44	-0.26	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96857512	chr5:96784777~96785999:+
BRCA	cis	rs950169	0.512	rs4374136	ENSG00000225151.9	GOLGA2P7	-8.78	6.57e-18	2.61e-15	-0.38	-0.26	Schizophrenia;	chr15:83976255	chr15:84199311~84230136:-
BRCA	cis	rs875971	0.545	rs4718325	ENSG00000237310.1	GS1-124K5.4	8.78	6.63e-18	2.64e-15	0.32	0.26	Aortic root size;	chr7:66215323	chr7:66493706~66495474:+
BRCA	cis	rs75422866	0.51	rs73105829	ENSG00000257433.4	RP1-197B17.3	8.78	6.63e-18	2.64e-15	0.59	0.26	Pneumonia;	chr12:47734162	chr12:47706085~47742294:+
BRCA	cis	rs11098499	0.954	rs17005535	ENSG00000248280.1	RP11-33B1.2	8.78	6.64e-18	2.64e-15	0.27	0.26	Corneal astigmatism;	chr4:119490407	chr4:119440561~119450157:-
BRCA	cis	rs4964805	0.865	rs4964289	ENSG00000257681.1	RP11-341G23.4	8.78	6.67e-18	2.65e-15	0.33	0.26	Attention deficit hyperactivity disorder;	chr12:103810413	chr12:103746315~103768858:-
BRCA	cis	rs7772486	0.686	rs2179323	ENSG00000235652.6	RP11-545I5.3	-8.78	6.68e-18	2.65e-15	-0.26	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145661650	chr6:145799409~145886585:+
BRCA	cis	rs896854	0.846	rs7845219	ENSG00000253528.2	RP11-347C18.4	8.78	6.74e-18	2.68e-15	0.28	0.26	Type 2 diabetes;	chr8:94925274	chr8:94974573~94974853:-
BRCA	cis	rs783540	0.934	rs4779050	ENSG00000278603.1	RP13-608F4.5	8.78	6.75e-18	2.68e-15	0.33	0.26	Schizophrenia;	chr15:82699986	chr15:82472203~82472426:+
BRCA	cis	rs11098499	0.909	rs1546504	ENSG00000245958.5	RP11-33B1.1	-8.78	6.77e-18	2.69e-15	-0.26	-0.26	Corneal astigmatism;	chr4:119320024	chr4:119454791~119552025:+
BRCA	cis	rs11673344	0.864	rs8110696	ENSG00000226686.6	LINC01535	8.78	6.77e-18	2.69e-15	0.34	0.26	Obesity-related traits;	chr19:37009449	chr19:37251912~37265535:+
BRCA	cis	rs202072	0.729	rs8541	ENSG00000272379.1	RP1-257A7.5	8.78	6.79e-18	2.7e-15	0.45	0.26	HIV-1 viral setpoint;	chr6:13290006	chr6:13290018~13290490:-
BRCA	cis	rs4660456	0.871	rs669072	ENSG00000237899.1	RP4-739H11.3	8.78	6.8e-18	2.7e-15	0.4	0.26	Platelet count;	chr1:40679946	chr1:40669089~40687588:-
BRCA	cis	rs11098499	0.58	rs12509234	ENSG00000248280.1	RP11-33B1.2	8.78	6.8e-18	2.7e-15	0.27	0.26	Corneal astigmatism;	chr4:119398279	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.909	rs10014719	ENSG00000248280.1	RP11-33B1.2	8.78	6.8e-18	2.7e-15	0.27	0.26	Corneal astigmatism;	chr4:119399560	chr4:119440561~119450157:-
BRCA	cis	rs6782228	0.848	rs6439140	ENSG00000242551.2	POU5F1P6	8.78	6.81e-18	2.71e-15	0.36	0.26	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128699917	chr3:128674735~128677005:-
BRCA	cis	rs11673344	0.764	rs826303	ENSG00000226686.6	LINC01535	8.78	6.82e-18	2.71e-15	0.34	0.26	Obesity-related traits;	chr19:36951549	chr19:37251912~37265535:+
BRCA	cis	rs11723261	0.621	rs6599307	ENSG00000275426.1	CH17-262A2.1	8.78	6.82e-18	2.71e-15	0.35	0.26	Immune response to smallpox vaccine (IL-6);	chr4:149993	chr4:149738~150317:+
BRCA	cis	rs875971	1	rs937495	ENSG00000237310.1	GS1-124K5.4	-8.78	6.85e-18	2.72e-15	-0.27	-0.26	Aortic root size;	chr7:66314811	chr7:66493706~66495474:+
BRCA	cis	rs875971	1	rs2036264	ENSG00000237310.1	GS1-124K5.4	-8.78	6.85e-18	2.72e-15	-0.27	-0.26	Aortic root size;	chr7:66334917	chr7:66493706~66495474:+
BRCA	cis	rs875971	1	rs7783613	ENSG00000237310.1	GS1-124K5.4	-8.78	6.85e-18	2.72e-15	-0.27	-0.26	Aortic root size;	chr7:66340274	chr7:66493706~66495474:+
BRCA	cis	rs7580658	0.926	rs79789049	ENSG00000236682.1	AC068282.3	-8.78	6.87e-18	2.73e-15	-0.35	-0.26	Protein C levels;	chr2:127387896	chr2:127389130~127400580:+
BRCA	cis	rs7772486	0.776	rs4316025	ENSG00000235652.6	RP11-545I5.3	-8.77	6.9e-18	2.74e-15	-0.26	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145916896	chr6:145799409~145886585:+
BRCA	cis	rs881375	0.967	rs1930781	ENSG00000226752.6	PSMD5-AS1	-8.77	6.91e-18	2.74e-15	-0.31	-0.26	Rheumatoid arthritis;	chr9:120925556	chr9:120824828~120854385:+
BRCA	cis	rs881375	0.967	rs2416806	ENSG00000226752.6	PSMD5-AS1	-8.77	6.91e-18	2.74e-15	-0.31	-0.26	Rheumatoid arthritis;	chr9:120928014	chr9:120824828~120854385:+
BRCA	cis	rs1062177	0.855	rs919263	ENSG00000253921.1	CTB-113P19.3	-8.77	6.91e-18	2.74e-15	-0.34	-0.26	Preschool internalizing problems;	chr5:151886292	chr5:151753992~151767247:+
BRCA	cis	rs10463554	0.927	rs12055075	ENSG00000175749.11	EIF3KP1	8.77	6.93e-18	2.75e-15	0.36	0.26	Parkinson's disease;	chr5:103044553	chr5:103032376~103033031:+
BRCA	cis	rs1061377	1	rs7685468	ENSG00000249685.1	RP11-360F5.3	8.77	6.93e-18	2.75e-15	0.32	0.26	Uric acid levels;	chr4:39116649	chr4:39133913~39135608:+
BRCA	cis	rs30380	0.69	rs2216752	ENSG00000248734.2	CTD-2260A17.1	-8.77	6.93e-18	2.75e-15	-0.29	-0.26	Cerebrospinal fluid biomarker levels;	chr5:96849764	chr5:96784777~96785999:+
BRCA	cis	rs7772486	0.686	rs857879	ENSG00000235652.6	RP11-545I5.3	-8.77	6.94e-18	2.75e-15	-0.26	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145652907	chr6:145799409~145886585:+
BRCA	cis	rs2404602	1	rs1117367	ENSG00000259422.1	RP11-593F23.1	8.77	6.94e-18	2.76e-15	0.32	0.26	Blood metabolite levels;	chr15:76579989	chr15:76174891~76181486:-
BRCA	cis	rs11098499	0.954	rs17009122	ENSG00000248280.1	RP11-33B1.2	8.77	6.96e-18	2.76e-15	0.27	0.26	Corneal astigmatism;	chr4:119441248	chr4:119440561~119450157:-
BRCA	cis	rs227275	0.525	rs4596243	ENSG00000246560.2	RP11-10L12.4	8.77	6.99e-18	2.78e-15	0.27	0.26	Allergic disease (asthma, hay fever or eczema);	chr4:102964411	chr4:102828055~102844075:+
BRCA	cis	rs10129255	0.957	rs10137980	ENSG00000223648.3	IGHV3-64	8.77	7.02e-18	2.79e-15	0.22	0.26	Kawasaki disease;	chr14:106775735	chr14:106643132~106658258:-
BRCA	cis	rs10262624	0.935	rs6955725	ENSG00000234286.1	AC006026.13	-8.77	7.04e-18	2.79e-15	-0.31	-0.26	Schizophrenia;	chr7:23865523	chr7:23680195~23680786:-
BRCA	cis	rs6570726	0.599	rs9376951	ENSG00000235652.6	RP11-545I5.3	8.77	7.04e-18	2.79e-15	0.28	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145577775	chr6:145799409~145886585:+
BRCA	cis	rs11098499	0.954	rs10017371	ENSG00000248280.1	RP11-33B1.2	8.77	7.05e-18	2.8e-15	0.27	0.26	Corneal astigmatism;	chr4:119372621	chr4:119440561~119450157:-
BRCA	cis	rs4835473	0.932	rs1597445	ENSG00000251600.4	RP11-673E1.1	-8.77	7.05e-18	2.8e-15	-0.3	-0.26	Immature fraction of reticulocytes;	chr4:143768543	chr4:143912331~143982454:+
BRCA	cis	rs17711722	0.528	rs73138179	ENSG00000273024.4	INTS4P2	-8.77	7.06e-18	2.8e-15	-0.31	-0.26	Calcium levels;	chr7:65829495	chr7:65647864~65715661:+
BRCA	cis	rs17711722	0.701	rs781145	ENSG00000236529.1	RP13-254B10.1	8.77	7.06e-18	2.8e-15	0.29	0.26	Calcium levels;	chr7:65975383	chr7:65840212~65840596:+
BRCA	cis	rs8012947	0.959	rs7147470	ENSG00000279636.2	LINC00216	-8.77	7.08e-18	2.81e-15	-0.28	-0.26	Alcohol consumption in current drinkers;	chr14:58292948	chr14:58288033~58289158:+
BRCA	cis	rs875971	0.545	rs7811204	ENSG00000237310.1	GS1-124K5.4	8.77	7.09e-18	2.81e-15	0.32	0.26	Aortic root size;	chr7:66387213	chr7:66493706~66495474:+
BRCA	cis	rs881375	0.967	rs1930780	ENSG00000226752.6	PSMD5-AS1	-8.77	7.12e-18	2.82e-15	-0.31	-0.26	Rheumatoid arthritis;	chr9:120923941	chr9:120824828~120854385:+
BRCA	cis	rs881375	0.678	rs7037195	ENSG00000226752.6	PSMD5-AS1	-8.77	7.12e-18	2.82e-15	-0.3	-0.26	Rheumatoid arthritis;	chr9:120921722	chr9:120824828~120854385:+
BRCA	cis	rs7615952	0.932	rs13065725	ENSG00000171084.14	FAM86JP	8.77	7.13e-18	2.83e-15	0.46	0.26	Blood pressure (smoking interaction);	chr3:125913446	chr3:125916620~125930024:+
BRCA	cis	rs7772486	0.875	rs9403765	ENSG00000235652.6	RP11-545I5.3	-8.77	7.2e-18	2.85e-15	-0.26	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:146046905	chr6:145799409~145886585:+
BRCA	cis	rs11098499	0.697	rs28655325	ENSG00000248280.1	RP11-33B1.2	8.77	7.2e-18	2.85e-15	0.27	0.26	Corneal astigmatism;	chr4:119451844	chr4:119440561~119450157:-
BRCA	cis	rs2274273	0.87	rs10139000	ENSG00000258413.1	RP11-665C16.6	-8.77	7.22e-18	2.86e-15	-0.33	-0.26	Protein biomarker;	chr14:55383158	chr14:55262767~55272075:-
BRCA	cis	rs897984	0.571	rs7184567	ENSG00000260911.2	RP11-196G11.2	8.77	7.25e-18	2.88e-15	0.24	0.26	Dementia with Lewy bodies;	chr16:31009757	chr16:31043150~31049868:+
BRCA	cis	rs10129255	0.536	rs10142951	ENSG00000211972.2	IGHV3-66	8.77	7.26e-18	2.88e-15	0.18	0.26	Kawasaki disease;	chr14:106782337	chr14:106675017~106675544:-
BRCA	cis	rs11673344	0.864	rs7260386	ENSG00000226686.6	LINC01535	8.77	7.28e-18	2.89e-15	0.34	0.26	Obesity-related traits;	chr19:37158656	chr19:37251912~37265535:+
BRCA	cis	rs4835473	0.932	rs34653324	ENSG00000251600.4	RP11-673E1.1	-8.77	7.3e-18	2.89e-15	-0.3	-0.26	Immature fraction of reticulocytes;	chr4:143735058	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs35947648	ENSG00000251600.4	RP11-673E1.1	-8.77	7.3e-18	2.89e-15	-0.3	-0.26	Immature fraction of reticulocytes;	chr4:143735092	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.838	rs35800634	ENSG00000251600.4	RP11-673E1.1	-8.77	7.3e-18	2.89e-15	-0.3	-0.26	Immature fraction of reticulocytes;	chr4:143735199	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.838	rs34505330	ENSG00000251600.4	RP11-673E1.1	-8.77	7.3e-18	2.89e-15	-0.3	-0.26	Immature fraction of reticulocytes;	chr4:143735206	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs4597770	ENSG00000251600.4	RP11-673E1.1	-8.77	7.3e-18	2.89e-15	-0.3	-0.26	Immature fraction of reticulocytes;	chr4:143735239	chr4:143912331~143982454:+
BRCA	cis	rs9640161	0.789	rs3735172	ENSG00000261305.1	RP4-584D14.7	-8.77	7.3e-18	2.89e-15	-0.38	-0.26	Blood protein levels;Circulating chemerin levels;	chr7:150331869	chr7:150341771~150342607:+
BRCA	cis	rs6142102	0.646	rs2223553	ENSG00000275784.1	RP5-1125A11.6	-8.77	7.31e-18	2.9e-15	-0.31	-0.26	Skin pigmentation;	chr20:34121638	chr20:33989480~33991818:-
BRCA	cis	rs7772486	0.624	rs9485018	ENSG00000235652.6	RP11-545I5.3	-8.77	7.32e-18	2.9e-15	-0.26	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145704595	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.686	rs1045820	ENSG00000235652.6	RP11-545I5.3	8.77	7.32e-18	2.9e-15	0.26	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145625944	chr6:145799409~145886585:+
BRCA	cis	rs11098499	0.78	rs10013652	ENSG00000245958.5	RP11-33B1.1	-8.77	7.33e-18	2.9e-15	-0.25	-0.26	Corneal astigmatism;	chr4:119371101	chr4:119454791~119552025:+
BRCA	cis	rs453301	0.658	rs12114954	ENSG00000253893.2	FAM85B	8.77	7.33e-18	2.9e-15	0.33	0.26	Joint mobility (Beighton score);	chr8:9047352	chr8:8167819~8226614:-
BRCA	cis	rs783540	1	rs11631963	ENSG00000278603.1	RP13-608F4.5	8.77	7.35e-18	2.91e-15	0.33	0.26	Schizophrenia;	chr15:82649451	chr15:82472203~82472426:+
BRCA	cis	rs875971	0.54	rs1723268	ENSG00000236529.1	RP13-254B10.1	8.77	7.38e-18	2.92e-15	0.29	0.26	Aortic root size;	chr7:66008093	chr7:65840212~65840596:+
BRCA	cis	rs1823913	0.637	rs11688994	ENSG00000227542.1	AC092614.2	8.77	7.42e-18	2.94e-15	0.31	0.26	Obesity-related traits;	chr2:191266242	chr2:191229165~191246172:-
BRCA	cis	rs2404602	0.716	rs56216512	ENSG00000259422.1	RP11-593F23.1	8.77	7.43e-18	2.94e-15	0.33	0.26	Blood metabolite levels;	chr15:76394595	chr15:76174891~76181486:-
BRCA	cis	rs5751614	0.557	rs928781	ENSG00000230701.2	FBXW4P1	-8.77	7.43e-18	2.94e-15	-0.32	-0.26	Height;	chr22:23257826	chr22:23262767~23265005:+
BRCA	cis	rs10129255	0.5	rs8022547	ENSG00000211972.2	IGHV3-66	8.77	7.43e-18	2.94e-15	0.18	0.26	Kawasaki disease;	chr14:106781985	chr14:106675017~106675544:-
BRCA	cis	rs1707322	1	rs785469	ENSG00000280836.1	AL355480.1	8.76	7.48e-18	2.96e-15	0.33	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46055419	chr1:45581219~45581321:-
BRCA	cis	rs1707322	1	rs785468	ENSG00000280836.1	AL355480.1	8.76	7.48e-18	2.96e-15	0.33	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46055845	chr1:45581219~45581321:-
BRCA	cis	rs13256369	1	rs883648	ENSG00000253893.2	FAM85B	-8.76	7.49e-18	2.97e-15	-0.38	-0.26	Obesity-related traits;	chr8:8712011	chr8:8167819~8226614:-
BRCA	cis	rs11722779	0.658	rs6533044	ENSG00000246560.2	RP11-10L12.4	8.76	7.49e-18	2.97e-15	0.27	0.26	Schizophrenia;	chr4:102965261	chr4:102828055~102844075:+
BRCA	cis	rs11673344	0.864	rs12151313	ENSG00000226686.6	LINC01535	8.76	7.51e-18	2.97e-15	0.34	0.26	Obesity-related traits;	chr19:37072309	chr19:37251912~37265535:+
BRCA	cis	rs5751614	1	rs2267018	ENSG00000230701.2	FBXW4P1	8.76	7.51e-18	2.97e-15	0.29	0.26	Height;	chr22:23246006	chr22:23262767~23265005:+
BRCA	cis	rs7772486	0.714	rs1883365	ENSG00000235652.6	RP11-545I5.3	-8.76	7.53e-18	2.98e-15	-0.26	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145755613	chr6:145799409~145886585:+
BRCA	cis	rs8059260	0.604	rs12929596	ENSG00000274038.1	RP11-66H6.4	-8.76	7.53e-18	2.98e-15	-0.43	-0.26	Alcohol consumption over the past year;	chr16:11105495	chr16:11056556~11057034:+
BRCA	cis	rs7772486	0.686	rs1004752	ENSG00000235652.6	RP11-545I5.3	-8.76	7.57e-18	3e-15	-0.26	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145716686	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.686	rs9390347	ENSG00000235652.6	RP11-545I5.3	-8.76	7.57e-18	3e-15	-0.26	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145723611	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.686	rs9390348	ENSG00000235652.6	RP11-545I5.3	-8.76	7.57e-18	3e-15	-0.26	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145723612	chr6:145799409~145886585:+
BRCA	cis	rs4835473	0.9	rs12505665	ENSG00000251600.4	RP11-673E1.1	-8.76	7.61e-18	3.01e-15	-0.31	-0.26	Immature fraction of reticulocytes;	chr4:143758515	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.9	rs12509716	ENSG00000251600.4	RP11-673E1.1	-8.76	7.61e-18	3.01e-15	-0.31	-0.26	Immature fraction of reticulocytes;	chr4:143758520	chr4:143912331~143982454:+
BRCA	cis	rs17711722	0.701	rs55773927	ENSG00000164669.11	INTS4P1	-8.76	7.63e-18	3.02e-15	-0.32	-0.26	Calcium levels;	chr7:65872915	chr7:65141225~65234216:+
BRCA	cis	rs11098499	0.863	rs12508173	ENSG00000248280.1	RP11-33B1.2	8.76	7.65e-18	3.03e-15	0.27	0.26	Corneal astigmatism;	chr4:119397371	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.908	rs12504149	ENSG00000248280.1	RP11-33B1.2	8.76	7.65e-18	3.03e-15	0.27	0.26	Corneal astigmatism;	chr4:119397422	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.863	rs3822192	ENSG00000245958.5	RP11-33B1.1	-8.76	7.67e-18	3.03e-15	-0.27	-0.26	Corneal astigmatism;	chr4:119524565	chr4:119454791~119552025:+
BRCA	cis	rs7712401	0.601	rs30048	ENSG00000263432.2	RN7SL689P	8.76	7.68e-18	3.04e-15	0.33	0.26	Mean platelet volume;	chr5:122934698	chr5:123022487~123022783:-
BRCA	cis	rs10971721	0.822	rs72725368	ENSG00000260947.1	RP11-384P7.7	8.76	7.71e-18	3.05e-15	0.48	0.26	Body mass index;	chr9:33815457	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.822	rs72725370	ENSG00000260947.1	RP11-384P7.7	8.76	7.71e-18	3.05e-15	0.48	0.26	Body mass index;	chr9:33818459	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.554	rs10971712	ENSG00000260947.1	RP11-384P7.7	8.76	7.71e-18	3.05e-15	0.48	0.26	Body mass index;	chr9:33820940	chr9:33697459~33700986:+
BRCA	cis	rs853679	0.882	rs9468287	ENSG00000220721.1	OR1F12	8.76	7.72e-18	3.05e-15	0.49	0.26	Depression;	chr6:28111963	chr6:28073316~28074233:+
BRCA	cis	rs17711722	0.727	rs1880555	ENSG00000164669.11	INTS4P1	-8.76	7.74e-18	3.06e-15	-0.32	-0.26	Calcium levels;	chr7:65967580	chr7:65141225~65234216:+
BRCA	cis	rs11971779	0.715	rs11772771	ENSG00000273391.1	RP11-634H22.1	8.76	7.74e-18	3.06e-15	0.26	0.26	Diisocyanate-induced asthma;	chr7:139374057	chr7:139359032~139359566:-
BRCA	cis	rs881375	0.967	rs7864019	ENSG00000226752.6	PSMD5-AS1	-8.76	7.78e-18	3.07e-15	-0.31	-0.26	Rheumatoid arthritis;	chr9:120930590	chr9:120824828~120854385:+
BRCA	cis	rs2439831	0.85	rs11856795	ENSG00000249839.1	AC011330.5	-8.76	7.79e-18	3.08e-15	-0.44	-0.26	Lung cancer in ever smokers;	chr15:43868384	chr15:43663654~43684339:-
BRCA	cis	rs875971	0.545	rs4441996	ENSG00000237310.1	GS1-124K5.4	-8.76	7.79e-18	3.08e-15	-0.3	-0.26	Aortic root size;	chr7:66123233	chr7:66493706~66495474:+
BRCA	cis	rs9640161	0.702	rs11765692	ENSG00000261305.1	RP4-584D14.7	8.76	7.8e-18	3.08e-15	0.38	0.26	Blood protein levels;Circulating chemerin levels;	chr7:150329478	chr7:150341771~150342607:+
BRCA	cis	rs13256369	0.95	rs12548792	ENSG00000253893.2	FAM85B	-8.76	7.81e-18	3.09e-15	-0.37	-0.26	Obesity-related traits;	chr8:8710521	chr8:8167819~8226614:-
BRCA	cis	rs6844153	0.752	rs7681462	ENSG00000240005.4	RP11-293A21.1	-8.76	7.82e-18	3.09e-15	-0.35	-0.26	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26894272	chr4:26859806~26860599:-
BRCA	cis	rs748404	0.666	rs34178146	ENSG00000249839.1	AC011330.5	-8.76	7.83e-18	3.09e-15	-0.38	-0.26	Lung cancer;	chr15:43384406	chr15:43663654~43684339:-
BRCA	cis	rs1707322	0.827	rs10890347	ENSG00000280836.1	AL355480.1	8.76	7.85e-18	3.1e-15	0.35	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45776660	chr1:45581219~45581321:-
BRCA	cis	rs11971779	0.646	rs58682779	ENSG00000273391.1	RP11-634H22.1	8.76	7.86e-18	3.11e-15	0.29	0.26	Diisocyanate-induced asthma;	chr7:139399966	chr7:139359032~139359566:-
BRCA	cis	rs10971721	0.822	rs72727335	ENSG00000260947.1	RP11-384P7.7	8.76	7.88e-18	3.11e-15	0.46	0.26	Body mass index;	chr9:33931720	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.822	rs72727336	ENSG00000260947.1	RP11-384P7.7	8.76	7.88e-18	3.11e-15	0.46	0.26	Body mass index;	chr9:33931795	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.822	rs10971802	ENSG00000260947.1	RP11-384P7.7	8.76	7.88e-18	3.11e-15	0.46	0.26	Body mass index;	chr9:33933284	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.822	rs10971803	ENSG00000260947.1	RP11-384P7.7	8.76	7.88e-18	3.11e-15	0.46	0.26	Body mass index;	chr9:33933289	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.822	rs41314578	ENSG00000260947.1	RP11-384P7.7	8.76	7.88e-18	3.11e-15	0.46	0.26	Body mass index;	chr9:33933943	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.822	rs56274755	ENSG00000260947.1	RP11-384P7.7	8.76	7.88e-18	3.11e-15	0.46	0.26	Body mass index;	chr9:33934273	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.822	rs118115128	ENSG00000260947.1	RP11-384P7.7	8.76	7.88e-18	3.11e-15	0.46	0.26	Body mass index;	chr9:33935451	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.822	rs72727340	ENSG00000260947.1	RP11-384P7.7	8.76	7.88e-18	3.11e-15	0.46	0.26	Body mass index;	chr9:33936736	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.822	rs72727341	ENSG00000260947.1	RP11-384P7.7	8.76	7.88e-18	3.11e-15	0.46	0.26	Body mass index;	chr9:33936878	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.822	rs72727342	ENSG00000260947.1	RP11-384P7.7	8.76	7.88e-18	3.11e-15	0.46	0.26	Body mass index;	chr9:33938084	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.822	rs117733169	ENSG00000260947.1	RP11-384P7.7	8.76	7.88e-18	3.11e-15	0.46	0.26	Body mass index;	chr9:33938101	chr9:33697459~33700986:+
BRCA	cis	rs11098499	0.663	rs9996501	ENSG00000245958.5	RP11-33B1.1	-8.76	7.91e-18	3.12e-15	-0.25	-0.26	Corneal astigmatism;	chr4:119317763	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.697	rs28458294	ENSG00000245958.5	RP11-33B1.1	-8.76	7.91e-18	3.12e-15	-0.25	-0.26	Corneal astigmatism;	chr4:119317769	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.663	rs28369503	ENSG00000245958.5	RP11-33B1.1	-8.76	7.91e-18	3.12e-15	-0.25	-0.26	Corneal astigmatism;	chr4:119317770	chr4:119454791~119552025:+
BRCA	cis	rs875971	0.545	rs6460298	ENSG00000222364.1	RNU6-96P	-8.76	7.93e-18	3.13e-15	-0.34	-0.26	Aortic root size;	chr7:66442783	chr7:66395191~66395286:+
BRCA	cis	rs7772486	0.776	rs2265467	ENSG00000235652.6	RP11-545I5.3	8.76	7.94e-18	3.13e-15	0.26	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145897203	chr6:145799409~145886585:+
BRCA	cis	rs11098499	0.754	rs12711071	ENSG00000248280.1	RP11-33B1.2	8.76	7.96e-18	3.14e-15	0.26	0.26	Corneal astigmatism;	chr4:119319779	chr4:119440561~119450157:-
BRCA	cis	rs10262624	0.935	rs6955884	ENSG00000234286.1	AC006026.13	-8.76	7.97e-18	3.15e-15	-0.31	-0.26	Schizophrenia;	chr7:23865654	chr7:23680195~23680786:-
BRCA	cis	rs11098499	0.644	rs34835603	ENSG00000248280.1	RP11-33B1.2	8.76	8e-18	3.16e-15	0.26	0.26	Corneal astigmatism;	chr4:119632273	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.615	rs28850368	ENSG00000248280.1	RP11-33B1.2	8.76	8e-18	3.16e-15	0.26	0.26	Corneal astigmatism;	chr4:119633158	chr4:119440561~119450157:-
BRCA	cis	rs1707322	1	rs7531911	ENSG00000280836.1	AL355480.1	-8.76	8.01e-18	3.16e-15	-0.33	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45864751	chr1:45581219~45581321:-
BRCA	cis	rs1707322	1	rs10890359	ENSG00000280836.1	AL355480.1	-8.76	8.01e-18	3.16e-15	-0.33	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45870963	chr1:45581219~45581321:-
BRCA	cis	rs748404	0.666	rs34515241	ENSG00000249839.1	AC011330.5	-8.76	8.02e-18	3.17e-15	-0.38	-0.26	Lung cancer;	chr15:43342011	chr15:43663654~43684339:-
BRCA	cis	rs11098499	0.619	rs28502463	ENSG00000245958.5	RP11-33B1.1	-8.76	8.03e-18	3.17e-15	-0.25	-0.26	Corneal astigmatism;	chr4:119335868	chr4:119454791~119552025:+
BRCA	cis	rs6142102	0.602	rs68051854	ENSG00000275784.1	RP5-1125A11.6	-8.76	8.03e-18	3.17e-15	-0.31	-0.26	Skin pigmentation;	chr20:34114150	chr20:33989480~33991818:-
BRCA	cis	rs6545883	0.862	rs778141	ENSG00000271889.1	RP11-493E12.1	8.76	8.09e-18	3.19e-15	0.34	0.26	Tuberculosis;	chr2:61455043	chr2:61151433~61162105:-
BRCA	cis	rs11098499	0.754	rs10212714	ENSG00000248280.1	RP11-33B1.2	8.75	8.12e-18	3.2e-15	0.26	0.26	Corneal astigmatism;	chr4:119333147	chr4:119440561~119450157:-
BRCA	cis	rs1075265	0.901	rs7591194	ENSG00000233266.1	HMGB1P31	-8.75	8.14e-18	3.21e-15	-0.31	-0.26	Chronotype;Morning vs. evening chronotype;	chr2:54086699	chr2:54051334~54051760:+
BRCA	cis	rs807029	0.533	rs2295716	ENSG00000272572.1	RP11-179B2.2	-8.75	8.15e-18	3.22e-15	-0.34	-0.26	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100984457	chr10:100911103~100912739:-
BRCA	cis	rs11023332	0.832	rs10832289	ENSG00000251991.1	RNU7-49P	-8.75	8.17e-18	3.22e-15	-0.29	-0.26	Vitamin D levels;Adiponectin levels;	chr11:14647950	chr11:14478892~14478953:+
BRCA	cis	rs1075265	0.655	rs13432632	ENSG00000233266.1	HMGB1P31	8.75	8.18e-18	3.23e-15	0.32	0.26	Chronotype;Morning vs. evening chronotype;	chr2:53713586	chr2:54051334~54051760:+
BRCA	cis	rs11098499	0.954	rs10008392	ENSG00000248280.1	RP11-33B1.2	8.75	8.19e-18	3.23e-15	0.27	0.26	Corneal astigmatism;	chr4:119397684	chr4:119440561~119450157:-
BRCA	cis	rs1707322	1	rs11211219	ENSG00000280836.1	AL355480.1	-8.75	8.21e-18	3.24e-15	-0.33	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45893806	chr1:45581219~45581321:-
BRCA	cis	rs202072	0.729	rs202038	ENSG00000272379.1	RP1-257A7.5	-8.75	8.22e-18	3.24e-15	-0.42	-0.26	HIV-1 viral setpoint;	chr6:13288416	chr6:13290018~13290490:-
BRCA	cis	rs950880	0.677	rs4851585	ENSG00000234389.1	AC007278.3	-8.75	8.27e-18	3.26e-15	-0.26	-0.26	Serum protein levels (sST2);	chr2:102446294	chr2:102438713~102440475:+
BRCA	cis	rs17711722	0.701	rs4467826	ENSG00000222364.1	RNU6-96P	-8.75	8.28e-18	3.27e-15	-0.3	-0.26	Calcium levels;	chr7:65903721	chr7:66395191~66395286:+
BRCA	cis	rs4964805	0.865	rs35371470	ENSG00000257681.1	RP11-341G23.4	8.75	8.29e-18	3.27e-15	0.33	0.26	Attention deficit hyperactivity disorder;	chr12:103809942	chr12:103746315~103768858:-
BRCA	cis	rs720475	0.732	rs17195725	ENSG00000204959.4	ARHGEF34P	8.75	8.29e-18	3.27e-15	0.35	0.26	Breast cancer;	chr7:144440044	chr7:144272445~144286966:-
BRCA	cis	rs2404602	0.569	rs283793	ENSG00000259422.1	RP11-593F23.1	8.75	8.32e-18	3.28e-15	0.35	0.26	Blood metabolite levels;	chr15:76482411	chr15:76174891~76181486:-
BRCA	cis	rs4862750	1	rs4862750	ENSG00000250971.1	RP11-696F12.1	8.75	8.33e-18	3.28e-15	0.27	0.26	Lobe attachment (rater-scored or self-reported);	chr4:186982889	chr4:187060099~187060930:+
BRCA	cis	rs4862750	1	rs4862751	ENSG00000250971.1	RP11-696F12.1	8.75	8.33e-18	3.28e-15	0.27	0.26	Lobe attachment (rater-scored or self-reported);	chr4:186982896	chr4:187060099~187060930:+
BRCA	cis	rs7772486	0.686	rs2092263	ENSG00000235652.6	RP11-545I5.3	-8.75	8.35e-18	3.29e-15	-0.26	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145708551	chr6:145799409~145886585:+
BRCA	cis	rs4660456	0.913	rs3767950	ENSG00000237899.1	RP4-739H11.3	-8.75	8.36e-18	3.3e-15	-0.39	-0.26	Platelet count;	chr1:40767541	chr1:40669089~40687588:-
BRCA	cis	rs6545883	0.801	rs778142	ENSG00000271889.1	RP11-493E12.1	8.75	8.36e-18	3.3e-15	0.34	0.26	Tuberculosis;	chr2:61454293	chr2:61151433~61162105:-
BRCA	cis	rs812925	0.502	rs6545868	ENSG00000271889.1	RP11-493E12.1	-8.75	8.36e-18	3.3e-15	-0.32	-0.26	Immature fraction of reticulocytes;	chr2:61428230	chr2:61151433~61162105:-
BRCA	cis	rs9640161	0.742	rs2159236	ENSG00000261305.1	RP4-584D14.7	8.75	8.39e-18	3.31e-15	0.39	0.26	Blood protein levels;Circulating chemerin levels;	chr7:150320125	chr7:150341771~150342607:+
BRCA	cis	rs11098499	0.754	rs1849457	ENSG00000248280.1	RP11-33B1.2	8.75	8.4e-18	3.31e-15	0.26	0.26	Corneal astigmatism;	chr4:119333200	chr4:119440561~119450157:-
BRCA	cis	rs10129255	0.957	rs28887506	ENSG00000223648.3	IGHV3-64	8.75	8.4e-18	3.31e-15	0.23	0.26	Kawasaki disease;	chr14:106785589	chr14:106643132~106658258:-
BRCA	cis	rs4927850	0.752	rs7624460	ENSG00000231464.1	AC024937.4	8.75	8.43e-18	3.32e-15	0.33	0.26	Pancreatic cancer;	chr3:196021659	chr3:195996738~195998233:+
BRCA	cis	rs801193	0.66	rs2659914	ENSG00000237310.1	GS1-124K5.4	8.75	8.53e-18	3.36e-15	0.27	0.26	Aortic root size;	chr7:66691927	chr7:66493706~66495474:+
BRCA	cis	rs801193	0.591	rs2707839	ENSG00000237310.1	GS1-124K5.4	8.75	8.53e-18	3.36e-15	0.27	0.26	Aortic root size;	chr7:66728097	chr7:66493706~66495474:+
BRCA	cis	rs7772486	0.875	rs1331644	ENSG00000235652.6	RP11-545I5.3	8.75	8.54e-18	3.37e-15	0.26	0.26	Lobe attachment (rater-scored or self-reported);	chr6:146077524	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.806	rs2247317	ENSG00000235652.6	RP11-545I5.3	8.75	8.55e-18	3.37e-15	0.26	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145896434	chr6:145799409~145886585:+
BRCA	cis	rs875971	0.545	rs73150604	ENSG00000237310.1	GS1-124K5.4	8.75	8.56e-18	3.37e-15	0.32	0.26	Aortic root size;	chr7:66480545	chr7:66493706~66495474:+
BRCA	cis	rs881375	0.678	rs1930782	ENSG00000226752.6	PSMD5-AS1	-8.75	8.6e-18	3.39e-15	-0.3	-0.26	Rheumatoid arthritis;	chr9:120925627	chr9:120824828~120854385:+
BRCA	cis	rs10129255	0.957	rs12590735	ENSG00000223648.3	IGHV3-64	8.75	8.62e-18	3.39e-15	0.22	0.26	Kawasaki disease;	chr14:106779660	chr14:106643132~106658258:-
BRCA	cis	rs881375	0.702	rs3761847	ENSG00000226752.6	PSMD5-AS1	-8.75	8.72e-18	3.43e-15	-0.3	-0.26	Rheumatoid arthritis;	chr9:120927961	chr9:120824828~120854385:+
BRCA	cis	rs6545883	0.895	rs2442029	ENSG00000271889.1	RP11-493E12.1	8.75	8.73e-18	3.44e-15	0.35	0.26	Tuberculosis;	chr2:61452417	chr2:61151433~61162105:-
BRCA	cis	rs6545883	0.929	rs2256615	ENSG00000271889.1	RP11-493E12.1	8.75	8.73e-18	3.44e-15	0.35	0.26	Tuberculosis;	chr2:61452759	chr2:61151433~61162105:-
BRCA	cis	rs8012947	1	rs11158203	ENSG00000279636.2	LINC00216	-8.75	8.73e-18	3.44e-15	-0.28	-0.26	Alcohol consumption in current drinkers;	chr14:58303305	chr14:58288033~58289158:+
BRCA	cis	rs8012947	1	rs10145280	ENSG00000279636.2	LINC00216	-8.75	8.73e-18	3.44e-15	-0.28	-0.26	Alcohol consumption in current drinkers;	chr14:58303337	chr14:58288033~58289158:+
BRCA	cis	rs17711722	0.675	rs6947132	ENSG00000236529.1	RP13-254B10.1	-8.75	8.74e-18	3.44e-15	-0.28	-0.26	Calcium levels;	chr7:65808508	chr7:65840212~65840596:+
BRCA	cis	rs11098499	0.955	rs13129661	ENSG00000245958.5	RP11-33B1.1	-8.75	8.74e-18	3.44e-15	-0.26	-0.26	Corneal astigmatism;	chr4:119231754	chr4:119454791~119552025:+
BRCA	cis	rs875971	0.502	rs11769702	ENSG00000237310.1	GS1-124K5.4	8.75	8.76e-18	3.45e-15	0.32	0.26	Aortic root size;	chr7:66255529	chr7:66493706~66495474:+
BRCA	cis	rs7772486	0.686	rs9485019	ENSG00000235652.6	RP11-545I5.3	-8.75	8.76e-18	3.45e-15	-0.26	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145725245	chr6:145799409~145886585:+
BRCA	cis	rs11098499	0.662	rs13108589	ENSG00000248280.1	RP11-33B1.2	8.75	8.77e-18	3.45e-15	0.26	0.26	Corneal astigmatism;	chr4:119346947	chr4:119440561~119450157:-
BRCA	cis	rs11673344	0.618	rs4420645	ENSG00000226686.6	LINC01535	8.74	8.82e-18	3.47e-15	0.34	0.26	Obesity-related traits;	chr19:37054086	chr19:37251912~37265535:+
BRCA	cis	rs2243480	1	rs4718317	ENSG00000273142.1	RP11-458F8.4	8.74	8.82e-18	3.47e-15	0.35	0.26	Diabetic kidney disease;	chr7:66183914	chr7:66902857~66906297:+
BRCA	cis	rs1707322	0.964	rs6675259	ENSG00000280836.1	AL355480.1	8.74	8.85e-18	3.48e-15	0.34	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46036623	chr1:45581219~45581321:-
BRCA	cis	rs875971	0.545	rs4718348	ENSG00000222364.1	RNU6-96P	-8.74	8.9e-18	3.5e-15	-0.35	-0.26	Aortic root size;	chr7:66441589	chr7:66395191~66395286:+
BRCA	cis	rs4835473	0.932	rs10025527	ENSG00000251600.4	RP11-673E1.1	8.74	8.91e-18	3.5e-15	0.31	0.26	Immature fraction of reticulocytes;	chr4:143968391	chr4:143912331~143982454:+
BRCA	cis	rs10129255	0.957	rs11847726	ENSG00000223648.3	IGHV3-64	8.74	8.93e-18	3.51e-15	0.22	0.26	Kawasaki disease;	chr14:106779116	chr14:106643132~106658258:-
BRCA	cis	rs10463554	0.927	rs34811	ENSG00000175749.11	EIF3KP1	8.74	8.96e-18	3.52e-15	0.36	0.26	Parkinson's disease;	chr5:103096117	chr5:103032376~103033031:+
BRCA	cis	rs11098499	0.863	rs7678400	ENSG00000245958.5	RP11-33B1.1	-8.74	8.96e-18	3.52e-15	-0.26	-0.26	Corneal astigmatism;	chr4:119540802	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.863	rs1480936	ENSG00000245958.5	RP11-33B1.1	-8.74	8.96e-18	3.52e-15	-0.26	-0.26	Corneal astigmatism;	chr4:119541706	chr4:119454791~119552025:+
BRCA	cis	rs10463554	0.892	rs257305	ENSG00000175749.11	EIF3KP1	8.74	8.97e-18	3.52e-15	0.37	0.26	Parkinson's disease;	chr5:103081533	chr5:103032376~103033031:+
BRCA	cis	rs10463554	0.927	rs257306	ENSG00000175749.11	EIF3KP1	8.74	8.97e-18	3.52e-15	0.37	0.26	Parkinson's disease;	chr5:103081770	chr5:103032376~103033031:+
BRCA	cis	rs10463554	0.892	rs257307	ENSG00000175749.11	EIF3KP1	8.74	8.97e-18	3.52e-15	0.37	0.26	Parkinson's disease;	chr5:103081805	chr5:103032376~103033031:+
BRCA	cis	rs10463554	0.927	rs257308	ENSG00000175749.11	EIF3KP1	8.74	8.97e-18	3.52e-15	0.37	0.26	Parkinson's disease;	chr5:103082557	chr5:103032376~103033031:+
BRCA	cis	rs10463554	0.927	rs257311	ENSG00000175749.11	EIF3KP1	8.74	8.97e-18	3.52e-15	0.37	0.26	Parkinson's disease;	chr5:103083394	chr5:103032376~103033031:+
BRCA	cis	rs10463554	0.927	rs257314	ENSG00000175749.11	EIF3KP1	8.74	8.97e-18	3.52e-15	0.37	0.26	Parkinson's disease;	chr5:103085391	chr5:103032376~103033031:+
BRCA	cis	rs4845875	0.53	rs4846048	ENSG00000242349.4	NPPA-AS1	-8.74	8.98e-18	3.53e-15	-0.3	-0.26	Midregional pro atrial natriuretic peptide levels;	chr1:11786195	chr1:11841017~11848079:+
BRCA	cis	rs17772222	0.917	rs1998670	ENSG00000258983.2	RP11-507K2.2	8.74	8.98e-18	3.53e-15	0.3	0.26	Coronary artery calcification;	chr14:88504581	chr14:88499334~88515502:+
BRCA	cis	rs11098499	0.909	rs71614422	ENSG00000248280.1	RP11-33B1.2	8.74	9e-18	3.54e-15	0.27	0.26	Corneal astigmatism;	chr4:119438185	chr4:119440561~119450157:-
BRCA	cis	rs4718428	0.705	rs3800817	ENSG00000273142.1	RP11-458F8.4	-8.74	9.03e-18	3.55e-15	-0.25	-0.26	Corneal structure;	chr7:66798563	chr7:66902857~66906297:+
BRCA	cis	rs9506514	0.722	rs11147813	ENSG00000238286.1	SLC35E1P1	8.74	9.04e-18	3.55e-15	0.27	0.26	Coronary artery calcification;	chr13:20684419	chr13:20607268~20608131:+
BRCA	cis	rs1075265	0.572	rs3770405	ENSG00000233266.1	HMGB1P31	8.74	9.05e-18	3.55e-15	0.32	0.26	Chronotype;Morning vs. evening chronotype;	chr2:53694884	chr2:54051334~54051760:+
BRCA	cis	rs11098499	0.505	rs75122014	ENSG00000248280.1	RP11-33B1.2	8.74	9.05e-18	3.56e-15	0.27	0.26	Corneal astigmatism;	chr4:119441271	chr4:119440561~119450157:-
BRCA	cis	rs453301	0.686	rs2409120	ENSG00000253893.2	FAM85B	8.74	9.08e-18	3.57e-15	0.33	0.26	Joint mobility (Beighton score);	chr8:9025061	chr8:8167819~8226614:-
BRCA	cis	rs6570726	0.791	rs441290	ENSG00000235652.6	RP11-545I5.3	8.74	9.11e-18	3.58e-15	0.26	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145562047	chr6:145799409~145886585:+
BRCA	cis	rs11098499	0.82	rs13128602	ENSG00000245958.5	RP11-33B1.1	8.74	9.11e-18	3.58e-15	0.26	0.26	Corneal astigmatism;	chr4:119538211	chr4:119454791~119552025:+
BRCA	cis	rs8059260	0.604	rs12928945	ENSG00000274038.1	RP11-66H6.4	-8.74	9.12e-18	3.58e-15	-0.43	-0.26	Alcohol consumption over the past year;	chr16:11106309	chr16:11056556~11057034:+
BRCA	cis	rs875971	0.522	rs709604	ENSG00000236529.1	RP13-254B10.1	-8.74	9.12e-18	3.58e-15	-0.28	-0.26	Aortic root size;	chr7:66032447	chr7:65840212~65840596:+
BRCA	cis	rs56046484	0.956	rs12904410	ENSG00000259295.5	CSPG4P12	8.74	9.15e-18	3.59e-15	0.45	0.26	Testicular germ cell tumor;	chr15:85066557	chr15:85191438~85213905:+
BRCA	cis	rs853679	1	rs6901575	ENSG00000220721.1	OR1F12	8.74	9.18e-18	3.6e-15	0.41	0.26	Depression;	chr6:28283207	chr6:28073316~28074233:+
BRCA	cis	rs11098499	0.863	rs1552092	ENSG00000248280.1	RP11-33B1.2	8.74	9.21e-18	3.61e-15	0.27	0.26	Corneal astigmatism;	chr4:119567341	chr4:119440561~119450157:-
BRCA	cis	rs6545883	0.826	rs1186697	ENSG00000271889.1	RP11-493E12.1	8.74	9.21e-18	3.61e-15	0.35	0.26	Tuberculosis;	chr2:61434282	chr2:61151433~61162105:-
BRCA	cis	rs807029	0.533	rs722435	ENSG00000272572.1	RP11-179B2.2	-8.74	9.22e-18	3.62e-15	-0.34	-0.26	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100985305	chr10:100911103~100912739:-
BRCA	cis	rs881375	0.967	rs876445	ENSG00000226752.6	PSMD5-AS1	-8.74	9.22e-18	3.62e-15	-0.31	-0.26	Rheumatoid arthritis;	chr9:120914824	chr9:120824828~120854385:+
BRCA	cis	rs881375	0.967	rs2109895	ENSG00000226752.6	PSMD5-AS1	-8.74	9.22e-18	3.62e-15	-0.31	-0.26	Rheumatoid arthritis;	chr9:120915549	chr9:120824828~120854385:+
BRCA	cis	rs875971	0.545	rs2420612	ENSG00000237310.1	GS1-124K5.4	8.74	9.23e-18	3.62e-15	0.32	0.26	Aortic root size;	chr7:66536825	chr7:66493706~66495474:+
BRCA	cis	rs17711722	0.701	rs781145	ENSG00000164669.11	INTS4P1	-8.74	9.28e-18	3.64e-15	-0.32	-0.26	Calcium levels;	chr7:65975383	chr7:65141225~65234216:+
BRCA	cis	rs10463554	0.963	rs12655592	ENSG00000175749.11	EIF3KP1	8.74	9.29e-18	3.65e-15	0.36	0.26	Parkinson's disease;	chr5:103043715	chr5:103032376~103033031:+
BRCA	cis	rs10463554	0.963	rs12054848	ENSG00000175749.11	EIF3KP1	8.74	9.29e-18	3.65e-15	0.36	0.26	Parkinson's disease;	chr5:103044736	chr5:103032376~103033031:+
BRCA	cis	rs10463554	0.963	rs11242484	ENSG00000175749.11	EIF3KP1	8.74	9.29e-18	3.65e-15	0.36	0.26	Parkinson's disease;	chr5:103046172	chr5:103032376~103033031:+
BRCA	cis	rs10463554	0.892	rs10434791	ENSG00000175749.11	EIF3KP1	8.74	9.29e-18	3.65e-15	0.36	0.26	Parkinson's disease;	chr5:103053768	chr5:103032376~103033031:+
BRCA	cis	rs10463554	0.963	rs34382	ENSG00000175749.11	EIF3KP1	8.74	9.29e-18	3.65e-15	0.36	0.26	Parkinson's disease;	chr5:103060521	chr5:103032376~103033031:+
BRCA	cis	rs10463554	0.963	rs34380	ENSG00000175749.11	EIF3KP1	8.74	9.29e-18	3.65e-15	0.36	0.26	Parkinson's disease;	chr5:103061245	chr5:103032376~103033031:+
BRCA	cis	rs6700559	0.81	rs10399615	ENSG00000260088.1	RP11-92G12.3	8.74	9.31e-18	3.65e-15	0.33	0.26	Coronary artery disease;	chr1:200626145	chr1:200669507~200694250:+
BRCA	cis	rs2404602	0.716	rs17364076	ENSG00000259422.1	RP11-593F23.1	8.74	9.33e-18	3.66e-15	0.33	0.26	Blood metabolite levels;	chr15:76468550	chr15:76174891~76181486:-
BRCA	cis	rs875971	0.522	rs781144	ENSG00000236529.1	RP13-254B10.1	8.74	9.39e-18	3.68e-15	0.28	0.26	Aortic root size;	chr7:65975357	chr7:65840212~65840596:+
BRCA	cis	rs694739	0.595	rs11542299	ENSG00000236935.1	AP003774.1	8.74	9.41e-18	3.69e-15	0.25	0.26	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64371333	chr11:64325050~64329504:-
BRCA	cis	rs875971	0.545	rs75577046	ENSG00000222364.1	RNU6-96P	-8.74	9.41e-18	3.69e-15	-0.34	-0.26	Aortic root size;	chr7:66493729	chr7:66395191~66395286:+
BRCA	cis	rs2067615	0.524	rs10778500	ENSG00000260329.1	RP11-412D9.4	-8.74	9.49e-18	3.72e-15	-0.29	-0.26	Heart rate;	chr12:106680632	chr12:106954029~106955497:-
BRCA	cis	rs12468226	1	rs13389798	ENSG00000273456.1	RP11-686O6.2	8.73	9.57e-18	3.75e-15	0.38	0.26	Urate levels;	chr2:202348370	chr2:202374932~202375604:-
BRCA	cis	rs7772486	0.875	rs969694	ENSG00000235652.6	RP11-545I5.3	8.73	9.59e-18	3.76e-15	0.26	0.26	Lobe attachment (rater-scored or self-reported);	chr6:146073519	chr6:145799409~145886585:+
BRCA	cis	rs2439831	0.702	rs9989313	ENSG00000249839.1	AC011330.5	-8.73	9.61e-18	3.77e-15	-0.44	-0.26	Lung cancer in ever smokers;	chr15:43860619	chr15:43663654~43684339:-
BRCA	cis	rs7085104	0.7	rs743572	ENSG00000213061.2	PFN1P11	8.73	9.62e-18	3.77e-15	0.34	0.26	Immature fraction of reticulocytes;Schizophrenia;	chr10:102837395	chr10:102838011~102845473:-
BRCA	cis	rs4660456	0.564	rs34320811	ENSG00000237899.1	RP4-739H11.3	-8.73	9.65e-18	3.78e-15	-0.38	-0.26	Platelet count;	chr1:40763288	chr1:40669089~40687588:-
BRCA	cis	rs10463554	0.927	rs34373	ENSG00000175749.11	EIF3KP1	8.73	9.7e-18	3.8e-15	0.37	0.26	Parkinson's disease;	chr5:103068590	chr5:103032376~103033031:+
BRCA	cis	rs10463554	0.927	rs158253	ENSG00000175749.11	EIF3KP1	8.73	9.7e-18	3.8e-15	0.37	0.26	Parkinson's disease;	chr5:103069502	chr5:103032376~103033031:+
BRCA	cis	rs7772486	0.686	rs4896833	ENSG00000235652.6	RP11-545I5.3	8.73	9.72e-18	3.81e-15	0.26	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145644537	chr6:145799409~145886585:+
BRCA	cis	rs858239	0.539	rs57864591	ENSG00000226816.2	AC005082.12	8.73	9.73e-18	3.81e-15	0.31	0.26	Cerebrospinal fluid biomarker levels;	chr7:23144805	chr7:23206013~23208045:+
BRCA	cis	rs10129255	1	rs8012033	ENSG00000223648.3	IGHV3-64	8.73	9.78e-18	3.83e-15	0.23	0.26	Kawasaki disease;	chr14:106678854	chr14:106643132~106658258:-
BRCA	cis	rs4660456	0.912	rs658806	ENSG00000237899.1	RP4-739H11.3	8.73	9.79e-18	3.83e-15	0.39	0.26	Platelet count;	chr1:40683312	chr1:40669089~40687588:-
BRCA	cis	rs4660456	0.913	rs489222	ENSG00000237899.1	RP4-739H11.3	8.73	9.79e-18	3.83e-15	0.39	0.26	Platelet count;	chr1:40683422	chr1:40669089~40687588:-
BRCA	cis	rs4660456	0.871	rs671704	ENSG00000237899.1	RP4-739H11.3	8.73	9.79e-18	3.83e-15	0.39	0.26	Platelet count;	chr1:40683974	chr1:40669089~40687588:-
BRCA	cis	rs7772486	0.686	rs9403741	ENSG00000235652.6	RP11-545I5.3	-8.73	9.83e-18	3.85e-15	-0.26	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145709412	chr6:145799409~145886585:+
BRCA	cis	rs2404602	1	rs12594541	ENSG00000259422.1	RP11-593F23.1	8.73	9.84e-18	3.86e-15	0.32	0.26	Blood metabolite levels;	chr15:76542027	chr15:76174891~76181486:-
BRCA	cis	rs858239	0.806	rs10268610	ENSG00000226816.2	AC005082.12	8.73	9.88e-18	3.87e-15	0.31	0.26	Cerebrospinal fluid biomarker levels;	chr7:23235145	chr7:23206013~23208045:+
BRCA	cis	rs875971	0.54	rs1723268	ENSG00000164669.11	INTS4P1	-8.73	9.91e-18	3.88e-15	-0.32	-0.26	Aortic root size;	chr7:66008093	chr7:65141225~65234216:+
BRCA	cis	rs7615952	0.673	rs9821905	ENSG00000171084.14	FAM86JP	-8.73	9.95e-18	3.89e-15	-0.52	-0.26	Blood pressure (smoking interaction);	chr3:125902007	chr3:125916620~125930024:+
BRCA	cis	rs2067615	0.524	rs10778503	ENSG00000260329.1	RP11-412D9.4	-8.73	9.95e-18	3.9e-15	-0.29	-0.26	Heart rate;	chr12:106696838	chr12:106954029~106955497:-
BRCA	cis	rs2067615	0.524	rs1922433	ENSG00000260329.1	RP11-412D9.4	-8.73	9.98e-18	3.91e-15	-0.29	-0.26	Heart rate;	chr12:106683394	chr12:106954029~106955497:-
BRCA	cis	rs2067615	0.524	rs10467029	ENSG00000260329.1	RP11-412D9.4	-8.73	9.98e-18	3.91e-15	-0.29	-0.26	Heart rate;	chr12:106684670	chr12:106954029~106955497:-
BRCA	cis	rs2933343	0.951	rs789220	ENSG00000261159.1	RP11-723O4.9	-8.73	1e-17	3.92e-15	-0.3	-0.26	IgG glycosylation;	chr3:128873292	chr3:128859716~128860526:-
BRCA	cis	rs10129255	0.833	rs7156689	ENSG00000223648.3	IGHV3-64	8.73	1e-17	3.92e-15	0.23	0.26	Kawasaki disease;	chr14:106816039	chr14:106643132~106658258:-
BRCA	cis	rs150992	0.603	rs246251	ENSG00000248489.1	CTD-2007H13.3	8.73	1e-17	3.93e-15	0.34	0.26	Body mass index;	chr5:98942362	chr5:98929171~98995013:+
BRCA	cis	rs801193	0.66	rs974239	ENSG00000237310.1	GS1-124K5.4	8.73	1e-17	3.93e-15	0.28	0.26	Aortic root size;	chr7:66748504	chr7:66493706~66495474:+
BRCA	cis	rs11098499	0.954	rs878373	ENSG00000245958.5	RP11-33B1.1	-8.73	1.01e-17	3.94e-15	-0.26	-0.26	Corneal astigmatism;	chr4:119316329	chr4:119454791~119552025:+
BRCA	cis	rs4927850	0.723	rs7630825	ENSG00000231464.1	AC024937.4	8.73	1.01e-17	3.94e-15	0.33	0.26	Pancreatic cancer;	chr3:196026869	chr3:195996738~195998233:+
BRCA	cis	rs2858942	0.602	rs1211375	ENSG00000268836.1	LA16c-OS12.2	-8.73	1.01e-17	3.94e-15	-0.26	-0.26	Mean corpuscular hemoglobin;	chr16:190281	chr16:185748~186294:-
BRCA	cis	rs2933343	0.951	rs789251	ENSG00000231305.3	RP11-723O4.2	8.73	1.01e-17	3.95e-15	0.32	0.26	IgG glycosylation;	chr3:128857927	chr3:128861313~128871540:-
BRCA	cis	rs11971779	0.941	rs7800795	ENSG00000273391.1	RP11-634H22.1	8.73	1.01e-17	3.95e-15	0.29	0.26	Diisocyanate-induced asthma;	chr7:139395602	chr7:139359032~139359566:-
BRCA	cis	rs881375	0.933	rs7028641	ENSG00000226752.6	PSMD5-AS1	-8.73	1.01e-17	3.95e-15	-0.31	-0.26	Rheumatoid arthritis;	chr9:120928863	chr9:120824828~120854385:+
BRCA	cis	rs932287	0.666	rs10840161	ENSG00000254860.4	TMEM9B-AS1	-8.73	1.01e-17	3.96e-15	-0.25	-0.26	Colonoscopy-negative controls vs population controls;	chr11:9032277	chr11:8964675~8977527:+
BRCA	cis	rs875971	0.545	rs1796226	ENSG00000222364.1	RNU6-96P	-8.73	1.01e-17	3.96e-15	-0.34	-0.26	Aortic root size;	chr7:66622723	chr7:66395191~66395286:+
BRCA	cis	rs8070463	0.515	rs11655943	ENSG00000228782.6	CTD-2026D20.3	8.73	1.01e-17	3.97e-15	0.28	0.26	Multiple sclerosis;Ankylosing spondylitis;	chr17:47308274	chr17:47450568~47492492:-
BRCA	cis	rs1707322	1	rs4660331	ENSG00000280836.1	AL355480.1	-8.73	1.01e-17	3.97e-15	-0.33	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45993111	chr1:45581219~45581321:-
BRCA	cis	rs1707322	1	rs12097799	ENSG00000280836.1	AL355480.1	-8.73	1.01e-17	3.97e-15	-0.33	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45994214	chr1:45581219~45581321:-
BRCA	cis	rs11098499	0.708	rs1546506	ENSG00000245958.5	RP11-33B1.1	-8.73	1.02e-17	3.97e-15	-0.24	-0.26	Corneal astigmatism;	chr4:119320085	chr4:119454791~119552025:+
BRCA	cis	rs881375	0.678	rs10760128	ENSG00000226752.6	PSMD5-AS1	-8.73	1.02e-17	3.98e-15	-0.31	-0.26	Rheumatoid arthritis;	chr9:120934047	chr9:120824828~120854385:+
BRCA	cis	rs7772486	0.558	rs702322	ENSG00000235652.6	RP11-545I5.3	-8.73	1.02e-17	3.99e-15	-0.29	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145686030	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.577	rs9497315	ENSG00000235652.6	RP11-545I5.3	-8.73	1.03e-17	4.01e-15	-0.29	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145470831	chr6:145799409~145886585:+
BRCA	cis	rs10129255	0.957	rs10132367	ENSG00000223648.3	IGHV3-64	8.73	1.03e-17	4.02e-15	0.23	0.26	Kawasaki disease;	chr14:106690981	chr14:106643132~106658258:-
BRCA	cis	rs10463554	0.927	rs158245	ENSG00000175749.11	EIF3KP1	8.73	1.03e-17	4.03e-15	0.37	0.26	Parkinson's disease;	chr5:103073801	chr5:103032376~103033031:+
BRCA	cis	rs453301	0.631	rs17700611	ENSG00000253893.2	FAM85B	8.73	1.03e-17	4.04e-15	0.34	0.26	Joint mobility (Beighton score);	chr8:8936144	chr8:8167819~8226614:-
BRCA	cis	rs10463554	0.963	rs61418746	ENSG00000175749.11	EIF3KP1	8.73	1.03e-17	4.04e-15	0.36	0.26	Parkinson's disease;	chr5:103043914	chr5:103032376~103033031:+
BRCA	cis	rs10463554	0.963	rs62364875	ENSG00000175749.11	EIF3KP1	8.73	1.03e-17	4.04e-15	0.36	0.26	Parkinson's disease;	chr5:103056486	chr5:103032376~103033031:+
BRCA	cis	rs10463554	0.857	rs34376	ENSG00000175749.11	EIF3KP1	8.72	1.04e-17	4.07e-15	0.37	0.26	Parkinson's disease;	chr5:103065409	chr5:103032376~103033031:+
BRCA	cis	rs10463554	0.927	rs34375	ENSG00000175749.11	EIF3KP1	8.72	1.04e-17	4.07e-15	0.37	0.26	Parkinson's disease;	chr5:103065419	chr5:103032376~103033031:+
BRCA	cis	rs17023223	0.537	rs2765542	ENSG00000231365.4	RP11-418J17.1	-8.72	1.05e-17	4.09e-15	-0.34	-0.26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119017703	chr1:119140396~119275973:+
BRCA	cis	rs11098499	0.754	rs12506610	ENSG00000245958.5	RP11-33B1.1	-8.72	1.05e-17	4.11e-15	-0.25	-0.26	Corneal astigmatism;	chr4:119320504	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.743	rs10003567	ENSG00000245958.5	RP11-33B1.1	-8.72	1.05e-17	4.11e-15	-0.25	-0.26	Corneal astigmatism;	chr4:119320519	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.754	rs10006259	ENSG00000245958.5	RP11-33B1.1	-8.72	1.05e-17	4.11e-15	-0.25	-0.26	Corneal astigmatism;	chr4:119320990	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.754	rs28652763	ENSG00000245958.5	RP11-33B1.1	-8.72	1.05e-17	4.11e-15	-0.25	-0.26	Corneal astigmatism;	chr4:119321157	chr4:119454791~119552025:+
BRCA	cis	rs11673344	0.764	rs474017	ENSG00000226686.6	LINC01535	8.72	1.05e-17	4.12e-15	0.33	0.26	Obesity-related traits;	chr19:36963217	chr19:37251912~37265535:+
BRCA	cis	rs8012947	1	rs11628909	ENSG00000279636.2	LINC00216	8.72	1.06e-17	4.13e-15	0.29	0.26	Alcohol consumption in current drinkers;	chr14:58352508	chr14:58288033~58289158:+
BRCA	cis	rs875971	0.505	rs1723275	ENSG00000164669.11	INTS4P1	8.72	1.06e-17	4.13e-15	0.32	0.26	Aortic root size;	chr7:66039646	chr7:65141225~65234216:+
BRCA	cis	rs875971	0.545	rs3936065	ENSG00000237310.1	GS1-124K5.4	8.72	1.06e-17	4.13e-15	0.31	0.26	Aortic root size;	chr7:66325577	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.545	rs4718335	ENSG00000237310.1	GS1-124K5.4	8.72	1.06e-17	4.13e-15	0.31	0.26	Aortic root size;	chr7:66339619	chr7:66493706~66495474:+
BRCA	cis	rs7727544	0.735	rs272875	ENSG00000233006.5	AC034220.3	8.72	1.06e-17	4.13e-15	0.19	0.26	Blood metabolite levels;	chr5:132339195	chr5:132311285~132369916:-
BRCA	cis	rs10463554	0.927	rs468844	ENSG00000175749.11	EIF3KP1	8.72	1.06e-17	4.13e-15	0.37	0.26	Parkinson's disease;	chr5:103087872	chr5:103032376~103033031:+
BRCA	cis	rs10463554	0.927	rs469094	ENSG00000175749.11	EIF3KP1	8.72	1.06e-17	4.13e-15	0.37	0.26	Parkinson's disease;	chr5:103087875	chr5:103032376~103033031:+
BRCA	cis	rs11673344	0.536	rs62108291	ENSG00000226686.6	LINC01535	8.72	1.06e-17	4.13e-15	0.34	0.26	Obesity-related traits;	chr19:37659457	chr19:37251912~37265535:+
BRCA	cis	rs881375	0.933	rs7031096	ENSG00000226752.6	PSMD5-AS1	-8.72	1.06e-17	4.14e-15	-0.31	-0.26	Rheumatoid arthritis;	chr9:120932664	chr9:120824828~120854385:+
BRCA	cis	rs881375	0.967	rs10739580	ENSG00000226752.6	PSMD5-AS1	-8.72	1.06e-17	4.14e-15	-0.31	-0.26	Rheumatoid arthritis;	chr9:120933004	chr9:120824828~120854385:+
BRCA	cis	rs2439831	0.85	rs28413704	ENSG00000249839.1	AC011330.5	-8.72	1.06e-17	4.14e-15	-0.44	-0.26	Lung cancer in ever smokers;	chr15:43856229	chr15:43663654~43684339:-
BRCA	cis	rs6545883	0.929	rs1186700	ENSG00000271889.1	RP11-493E12.1	8.72	1.06e-17	4.15e-15	0.35	0.26	Tuberculosis;	chr2:61436237	chr2:61151433~61162105:-
BRCA	cis	rs17023223	0.509	rs7542832	ENSG00000231365.4	RP11-418J17.1	-8.72	1.06e-17	4.15e-15	-0.34	-0.26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119220106	chr1:119140396~119275973:+
BRCA	cis	rs7772486	0.686	rs1292337	ENSG00000235652.6	RP11-545I5.3	-8.72	1.07e-17	4.16e-15	-0.26	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145646671	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.818	rs9399555	ENSG00000235652.6	RP11-545I5.3	8.72	1.07e-17	4.17e-15	0.26	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145556418	chr6:145799409~145886585:+
BRCA	cis	rs2067615	0.507	rs11113083	ENSG00000260329.1	RP11-412D9.4	-8.72	1.07e-17	4.18e-15	-0.29	-0.26	Heart rate;	chr12:106679538	chr12:106954029~106955497:-
BRCA	cis	rs10463554	0.963	rs1011454	ENSG00000175749.11	EIF3KP1	8.72	1.07e-17	4.19e-15	0.36	0.26	Parkinson's disease;	chr5:103032551	chr5:103032376~103033031:+
BRCA	cis	rs7428	0.527	rs1061782	ENSG00000246575.2	AC093162.5	-8.72	1.07e-17	4.19e-15	-0.27	-0.26	Ear protrusion;	chr2:85319492	chr2:85315041~85316529:+
BRCA	cis	rs11676348	0.772	rs12471105	ENSG00000261338.2	RP11-378A13.1	-8.72	1.08e-17	4.2e-15	-0.28	-0.26	Ulcerative colitis;	chr2:218085486	chr2:218255319~218257366:+
BRCA	cis	rs7246657	0.722	rs2909098	ENSG00000267422.1	CTD-2554C21.1	8.72	1.08e-17	4.22e-15	0.39	0.26	Coronary artery calcification;	chr19:37713347	chr19:37779686~37792865:+
BRCA	cis	rs2933343	1	rs2630252	ENSG00000231305.3	RP11-723O4.2	8.72	1.08e-17	4.23e-15	0.33	0.26	IgG glycosylation;	chr3:128905929	chr3:128861313~128871540:-
BRCA	cis	rs11098499	0.754	rs4107728	ENSG00000245958.5	RP11-33B1.1	-8.72	1.09e-17	4.24e-15	-0.25	-0.26	Corneal astigmatism;	chr4:119332755	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.754	rs11732087	ENSG00000245958.5	RP11-33B1.1	-8.72	1.09e-17	4.25e-15	-0.25	-0.26	Corneal astigmatism;	chr4:119318676	chr4:119454791~119552025:+
BRCA	cis	rs897984	0.609	rs4889609	ENSG00000260911.2	RP11-196G11.2	8.72	1.09e-17	4.25e-15	0.24	0.26	Dementia with Lewy bodies;	chr16:31015106	chr16:31043150~31049868:+
BRCA	cis	rs7429990	0.833	rs11716582	ENSG00000229759.1	MRPS18AP1	-8.72	1.09e-17	4.25e-15	-0.29	-0.26	Educational attainment (years of education);	chr3:47592269	chr3:48256350~48256938:-
BRCA	cis	rs4964805	0.626	rs4964827	ENSG00000257681.1	RP11-341G23.4	8.72	1.09e-17	4.25e-15	0.33	0.26	Attention deficit hyperactivity disorder;	chr12:103783303	chr12:103746315~103768858:-
BRCA	cis	rs1707322	0.964	rs10890358	ENSG00000280836.1	AL355480.1	-8.72	1.09e-17	4.26e-15	-0.33	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45853353	chr1:45581219~45581321:-
BRCA	cis	rs11673344	0.73	rs475026	ENSG00000226686.6	LINC01535	8.72	1.09e-17	4.27e-15	0.33	0.26	Obesity-related traits;	chr19:36968115	chr19:37251912~37265535:+
BRCA	cis	rs7712401	0.601	rs28892	ENSG00000263432.2	RN7SL689P	-8.72	1.1e-17	4.28e-15	-0.34	-0.26	Mean platelet volume;	chr5:122948131	chr5:123022487~123022783:-
BRCA	cis	rs11690935	0.632	rs62183783	ENSG00000228389.1	AC068039.4	-8.72	1.1e-17	4.3e-15	-0.32	-0.26	Schizophrenia;	chr2:172000868	chr2:171773482~171775844:+
BRCA	cis	rs6545883	0.895	rs796597	ENSG00000271889.1	RP11-493E12.1	8.72	1.11e-17	4.33e-15	0.35	0.26	Tuberculosis;	chr2:61453925	chr2:61151433~61162105:-
BRCA	cis	rs6142102	0.961	rs4911405	ENSG00000276073.1	RP5-1125A11.7	-8.72	1.11e-17	4.33e-15	-0.33	-0.26	Skin pigmentation;	chr20:34087161	chr20:33985617~33988989:-
BRCA	cis	rs853679	0.567	rs6905380	ENSG00000204709.4	LINC01556	8.72	1.11e-17	4.35e-15	0.39	0.26	Depression;	chr6:28407125	chr6:28943877~28944537:+
BRCA	cis	rs875971	0.545	rs73142233	ENSG00000237310.1	GS1-124K5.4	8.72	1.12e-17	4.35e-15	0.31	0.26	Aortic root size;	chr7:66221293	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.964	rs697969	ENSG00000237310.1	GS1-124K5.4	-8.72	1.12e-17	4.36e-15	-0.27	-0.26	Aortic root size;	chr7:66093491	chr7:66493706~66495474:+
BRCA	cis	rs875971	1	rs1182882	ENSG00000237310.1	GS1-124K5.4	-8.72	1.12e-17	4.36e-15	-0.27	-0.26	Aortic root size;	chr7:66097076	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.522	rs4502988	ENSG00000236529.1	RP13-254B10.1	8.72	1.12e-17	4.37e-15	0.28	0.26	Aortic root size;	chr7:65832759	chr7:65840212~65840596:+
BRCA	cis	rs11098499	0.863	rs7699064	ENSG00000248280.1	RP11-33B1.2	-8.72	1.12e-17	4.38e-15	-0.27	-0.26	Corneal astigmatism;	chr4:119507154	chr4:119440561~119450157:-
BRCA	cis	rs4718428	0.705	rs10267335	ENSG00000232546.1	RP11-458F8.1	-8.72	1.12e-17	4.38e-15	-0.24	-0.26	Corneal structure;	chr7:66938233	chr7:66848496~66858136:+
BRCA	cis	rs4660456	0.913	rs3754179	ENSG00000237899.1	RP4-739H11.3	-8.72	1.12e-17	4.38e-15	-0.39	-0.26	Platelet count;	chr1:40768464	chr1:40669089~40687588:-
BRCA	cis	rs6142102	1	rs6142102	ENSG00000276073.1	RP5-1125A11.7	-8.72	1.12e-17	4.39e-15	-0.31	-0.26	Skin pigmentation;	chr20:34116821	chr20:33985617~33988989:-
BRCA	cis	rs8059260	0.544	rs35347079	ENSG00000274038.1	RP11-66H6.4	-8.72	1.13e-17	4.39e-15	-0.43	-0.26	Alcohol consumption over the past year;	chr16:11099696	chr16:11056556~11057034:+
BRCA	cis	rs11673344	0.734	rs1644638	ENSG00000226686.6	LINC01535	8.72	1.13e-17	4.39e-15	0.33	0.26	Obesity-related traits;	chr19:36970513	chr19:37251912~37265535:+
BRCA	cis	rs3814244	0.528	rs56393928	ENSG00000236946.2	HNRNPA1P70	-8.71	1.13e-17	4.41e-15	-0.22	-0.26	Itch intensity from mosquito bite adjusted by bite size;	chr12:68029927	chr12:68035767~68036853:+
BRCA	cis	rs17772222	0.958	rs2274737	ENSG00000258983.2	RP11-507K2.2	8.71	1.13e-17	4.41e-15	0.3	0.26	Coronary artery calcification;	chr14:88469307	chr14:88499334~88515502:+
BRCA	cis	rs875971	0.516	rs6945322	ENSG00000236529.1	RP13-254B10.1	8.71	1.13e-17	4.42e-15	0.28	0.26	Aortic root size;	chr7:65871069	chr7:65840212~65840596:+
BRCA	cis	rs1061377	1	rs6829450	ENSG00000249685.1	RP11-360F5.3	8.71	1.14e-17	4.42e-15	0.32	0.26	Uric acid levels;	chr4:39114721	chr4:39133913~39135608:+
BRCA	cis	rs150992	0.504	rs7723242	ENSG00000248489.1	CTD-2007H13.3	-8.71	1.14e-17	4.43e-15	-0.35	-0.26	Body mass index;	chr5:99023408	chr5:98929171~98995013:+
BRCA	cis	rs11673344	0.801	rs112263309	ENSG00000226686.6	LINC01535	8.71	1.14e-17	4.44e-15	0.34	0.26	Obesity-related traits;	chr19:37160333	chr19:37251912~37265535:+
BRCA	cis	rs1134634	0.52	rs28528670	ENSG00000273133.1	RP11-799M12.2	-8.71	1.14e-17	4.44e-15	-0.34	-0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15591295	chr4:15563698~15564253:-
BRCA	cis	rs7615952	0.932	rs9841157	ENSG00000171084.14	FAM86JP	8.71	1.14e-17	4.44e-15	0.46	0.26	Blood pressure (smoking interaction);	chr3:125916812	chr3:125916620~125930024:+
BRCA	cis	rs7615952	0.551	rs12695470	ENSG00000171084.14	FAM86JP	8.71	1.14e-17	4.44e-15	0.46	0.26	Blood pressure (smoking interaction);	chr3:125916875	chr3:125916620~125930024:+
BRCA	cis	rs228614	0.51	rs223438	ENSG00000246560.2	RP11-10L12.4	-8.71	1.15e-17	4.46e-15	-0.27	-0.26	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102798584	chr4:102828055~102844075:+
BRCA	cis	rs7772486	0.654	rs702321	ENSG00000235652.6	RP11-545I5.3	-8.71	1.15e-17	4.47e-15	-0.26	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145685559	chr6:145799409~145886585:+
BRCA	cis	rs2404602	1	rs12443137	ENSG00000259422.1	RP11-593F23.1	8.71	1.15e-17	4.47e-15	0.32	0.26	Blood metabolite levels;	chr15:76548491	chr15:76174891~76181486:-
BRCA	cis	rs899997	0.814	rs28661610	ENSG00000261143.1	ADAMTS7P3	-8.71	1.15e-17	4.47e-15	-0.37	-0.26	Coronary artery disease or large artery stroke;	chr15:78692975	chr15:77976042~77993057:+
BRCA	cis	rs1707322	1	rs34444543	ENSG00000280836.1	AL355480.1	-8.71	1.15e-17	4.48e-15	-0.33	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45893190	chr1:45581219~45581321:-
BRCA	cis	rs10463554	0.927	rs158399	ENSG00000175749.11	EIF3KP1	8.71	1.15e-17	4.48e-15	0.37	0.26	Parkinson's disease;	chr5:103077564	chr5:103032376~103033031:+
BRCA	cis	rs10463554	0.927	rs158404	ENSG00000175749.11	EIF3KP1	8.71	1.15e-17	4.48e-15	0.37	0.26	Parkinson's disease;	chr5:103080206	chr5:103032376~103033031:+
BRCA	cis	rs875971	0.545	rs6970498	ENSG00000237310.1	GS1-124K5.4	8.71	1.15e-17	4.49e-15	0.32	0.26	Aortic root size;	chr7:66275908	chr7:66493706~66495474:+
BRCA	cis	rs7712401	0.601	rs173480	ENSG00000263432.2	RN7SL689P	8.71	1.16e-17	4.51e-15	0.33	0.26	Mean platelet volume;	chr5:122918436	chr5:123022487~123022783:-
BRCA	cis	rs950880	0.71	rs7597017	ENSG00000234389.1	AC007278.3	-8.71	1.16e-17	4.51e-15	-0.25	-0.26	Serum protein levels (sST2);	chr2:102445656	chr2:102438713~102440475:+
BRCA	cis	rs875971	1	rs2220626	ENSG00000237310.1	GS1-124K5.4	-8.71	1.16e-17	4.52e-15	-0.28	-0.26	Aortic root size;	chr7:66081075	chr7:66493706~66495474:+
BRCA	cis	rs11098499	0.754	rs7672778	ENSG00000245958.5	RP11-33B1.1	-8.71	1.16e-17	4.52e-15	-0.25	-0.26	Corneal astigmatism;	chr4:119327430	chr4:119454791~119552025:+
BRCA	cis	rs10971721	0.822	rs10971794	ENSG00000260947.1	RP11-384P7.7	8.71	1.16e-17	4.52e-15	0.47	0.26	Body mass index;	chr9:33924314	chr9:33697459~33700986:+
BRCA	cis	rs8072100	0.817	rs9905581	ENSG00000228782.6	CTD-2026D20.3	8.71	1.16e-17	4.53e-15	0.28	0.26	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47469819	chr17:47450568~47492492:-
BRCA	cis	rs11098499	0.863	rs34868248	ENSG00000245958.5	RP11-33B1.1	-8.71	1.16e-17	4.53e-15	-0.26	-0.26	Corneal astigmatism;	chr4:119521275	chr4:119454791~119552025:+
BRCA	cis	rs9807989	0.507	rs6710528	ENSG00000234389.1	AC007278.3	-8.71	1.17e-17	4.54e-15	-0.24	-0.26	Asthma;	chr2:102399682	chr2:102438713~102440475:+
BRCA	cis	rs11673344	0.528	rs578655	ENSG00000226686.6	LINC01535	8.71	1.17e-17	4.55e-15	0.33	0.26	Obesity-related traits;	chr19:36919855	chr19:37251912~37265535:+
BRCA	cis	rs67981189	0.529	rs2526857	ENSG00000269927.1	RP6-91H8.3	-8.71	1.17e-17	4.55e-15	-0.34	-0.26	Schizophrenia;	chr14:70945909	chr14:71141125~71143253:-
BRCA	cis	rs8396	1	rs8396	ENSG00000271817.2	U3	-8.71	1.17e-17	4.56e-15	-0.29	-0.26	Blood metabolite levels;Blood protein levels;Acylcarnitine levels;Metabolite levels;Metabolic traits;	chr4:158709665	chr4:158700691~158700909:+
BRCA	cis	rs1134634	0.52	rs28419165	ENSG00000273133.1	RP11-799M12.2	-8.71	1.18e-17	4.58e-15	-0.35	-0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15587722	chr4:15563698~15564253:-
BRCA	cis	rs56205728	0.606	rs3784397	ENSG00000273855.1	RP11-133K1.12	8.71	1.18e-17	4.58e-15	0.29	0.26	Schizophrenia;	chr15:40304643	chr15:40285468~40285909:-
BRCA	cis	rs11673344	0.764	rs1644643	ENSG00000226686.6	LINC01535	8.71	1.18e-17	4.59e-15	0.33	0.26	Obesity-related traits;	chr19:36972269	chr19:37251912~37265535:+
BRCA	cis	rs11673344	0.764	rs1644645	ENSG00000226686.6	LINC01535	8.71	1.18e-17	4.59e-15	0.33	0.26	Obesity-related traits;	chr19:36972528	chr19:37251912~37265535:+
BRCA	cis	rs896854	0.654	rs4735339	ENSG00000253528.2	RP11-347C18.4	8.71	1.18e-17	4.6e-15	0.27	0.26	Type 2 diabetes;	chr8:94962145	chr8:94974573~94974853:-
BRCA	cis	rs113835537	0.529	rs7943327	ENSG00000255517.5	CTD-3074O7.5	-8.71	1.18e-17	4.61e-15	-0.33	-0.26	Airway imaging phenotypes;	chr11:66489110	chr11:66473490~66480233:-
BRCA	cis	rs7615952	0.673	rs35955861	ENSG00000171084.14	FAM86JP	8.71	1.19e-17	4.64e-15	0.52	0.26	Blood pressure (smoking interaction);	chr3:125907358	chr3:125916620~125930024:+
BRCA	cis	rs11098499	0.779	rs28495013	ENSG00000248280.1	RP11-33B1.2	8.71	1.19e-17	4.64e-15	0.27	0.26	Corneal astigmatism;	chr4:119454676	chr4:119440561~119450157:-
BRCA	cis	rs11673344	0.931	rs73622783	ENSG00000226686.6	LINC01535	8.71	1.19e-17	4.64e-15	0.34	0.26	Obesity-related traits;	chr19:37165155	chr19:37251912~37265535:+
BRCA	cis	rs748404	0.626	rs72707530	ENSG00000249839.1	AC011330.5	-8.71	1.2e-17	4.65e-15	-0.38	-0.26	Lung cancer;	chr15:43353622	chr15:43663654~43684339:-
BRCA	cis	rs7772486	0.806	rs4243478	ENSG00000235652.6	RP11-545I5.3	-8.71	1.2e-17	4.66e-15	-0.26	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145963424	chr6:145799409~145886585:+
BRCA	cis	rs860818	1	rs858234	ENSG00000226816.2	AC005082.12	-8.71	1.2e-17	4.66e-15	-0.55	-0.26	Initial pursuit acceleration;	chr7:23201196	chr7:23206013~23208045:+
BRCA	cis	rs7246657	0.722	rs2972430	ENSG00000267422.1	CTD-2554C21.1	8.71	1.2e-17	4.66e-15	0.39	0.26	Coronary artery calcification;	chr19:37691210	chr19:37779686~37792865:+
BRCA	cis	rs10463554	0.857	rs158397	ENSG00000175749.11	EIF3KP1	8.71	1.2e-17	4.67e-15	0.37	0.26	Parkinson's disease;	chr5:103076497	chr5:103032376~103033031:+
BRCA	cis	rs11098499	0.78	rs7692994	ENSG00000245958.5	RP11-33B1.1	-8.71	1.2e-17	4.67e-15	-0.25	-0.26	Corneal astigmatism;	chr4:119506334	chr4:119454791~119552025:+
BRCA	cis	rs7085104	0.684	rs7092690	ENSG00000213061.2	PFN1P11	8.71	1.2e-17	4.67e-15	0.34	0.26	Immature fraction of reticulocytes;Schizophrenia;	chr10:102849608	chr10:102838011~102845473:-
BRCA	cis	rs17711722	0.675	rs6947132	ENSG00000164669.11	INTS4P1	8.71	1.2e-17	4.68e-15	0.32	0.26	Calcium levels;	chr7:65808508	chr7:65141225~65234216:+
BRCA	cis	rs11098499	0.738	rs34566984	ENSG00000248280.1	RP11-33B1.2	8.71	1.21e-17	4.69e-15	0.27	0.26	Corneal astigmatism;	chr4:119440115	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.954	rs9685777	ENSG00000248280.1	RP11-33B1.2	8.71	1.21e-17	4.69e-15	0.27	0.26	Corneal astigmatism;	chr4:119444810	chr4:119440561~119450157:-
BRCA	cis	rs896854	0.654	rs28591375	ENSG00000253528.2	RP11-347C18.4	8.71	1.21e-17	4.7e-15	0.27	0.26	Type 2 diabetes;	chr8:94961409	chr8:94974573~94974853:-
BRCA	cis	rs8012947	0.959	rs10137327	ENSG00000279636.2	LINC00216	-8.71	1.21e-17	4.7e-15	-0.29	-0.26	Alcohol consumption in current drinkers;	chr14:58287183	chr14:58288033~58289158:+
BRCA	cis	rs56046484	0.956	rs2174218	ENSG00000259295.5	CSPG4P12	-8.71	1.21e-17	4.7e-15	-0.43	-0.26	Testicular germ cell tumor;	chr15:85081425	chr15:85191438~85213905:+
BRCA	cis	rs858239	0.511	rs10256996	ENSG00000226816.2	AC005082.12	-8.71	1.22e-17	4.72e-15	-0.29	-0.26	Cerebrospinal fluid biomarker levels;	chr7:23105676	chr7:23206013~23208045:+
BRCA	cis	rs13068223	0.584	rs345985	ENSG00000243926.1	TIPARP-AS1	-8.71	1.22e-17	4.74e-15	-0.27	-0.26	Age-related hearing impairment (SNP x SNP interaction);	chr3:156679385	chr3:156671862~156674378:-
BRCA	cis	rs891378	0.793	rs12021745	ENSG00000274245.1	RP11-357P18.2	8.7	1.22e-17	4.76e-15	0.39	0.26	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207293254	chr1:207372559~207373252:+
BRCA	cis	rs4722166	0.704	rs4321884	ENSG00000179428.2	AC073072.5	-8.7	1.23e-17	4.76e-15	-0.28	-0.26	Lung cancer;	chr7:22701840	chr7:22725395~22727620:-
BRCA	cis	rs896854	0.654	rs28716845	ENSG00000253528.2	RP11-347C18.4	8.7	1.23e-17	4.77e-15	0.27	0.26	Type 2 diabetes;	chr8:94962257	chr8:94974573~94974853:-
BRCA	cis	rs75422866	0.51	rs35784744	ENSG00000274902.1	RP1-197B17.4	8.7	1.24e-17	4.8e-15	0.66	0.26	Pneumonia;	chr12:47729646	chr12:47731908~47732351:+
BRCA	cis	rs4718428	0.705	rs12698547	ENSG00000273142.1	RP11-458F8.4	-8.7	1.24e-17	4.81e-15	-0.25	-0.26	Corneal structure;	chr7:66813271	chr7:66902857~66906297:+
BRCA	cis	rs7727544	0.66	rs272886	ENSG00000233006.5	AC034220.3	8.7	1.24e-17	4.82e-15	0.19	0.26	Blood metabolite levels;	chr5:132330147	chr5:132311285~132369916:-
BRCA	cis	rs10129255	0.5	rs6576230	ENSG00000211972.2	IGHV3-66	8.7	1.24e-17	4.82e-15	0.18	0.26	Kawasaki disease;	chr14:106778539	chr14:106675017~106675544:-
BRCA	cis	rs2280018	0.526	rs2966128	ENSG00000188599.16	NPIPP1	-8.7	1.24e-17	4.83e-15	-0.23	-0.26	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15059532	chr16:15104312~15123498:-
BRCA	cis	rs875971	0.545	rs12670811	ENSG00000222364.1	RNU6-96P	-8.7	1.25e-17	4.85e-15	-0.34	-0.26	Aortic root size;	chr7:66358032	chr7:66395191~66395286:+
BRCA	cis	rs2810114	1	rs2810114	ENSG00000269927.1	RP6-91H8.3	-8.7	1.25e-17	4.87e-15	-0.34	-0.26	Alcohol dependence;	chr14:70928887	chr14:71141125~71143253:-
BRCA	cis	rs7772486	0.875	rs11755334	ENSG00000235652.6	RP11-545I5.3	8.7	1.26e-17	4.88e-15	0.26	0.26	Lobe attachment (rater-scored or self-reported);	chr6:146078161	chr6:145799409~145886585:+
BRCA	cis	rs7923609	0.578	rs10740138	ENSG00000232075.1	MRPL35P2	-8.7	1.26e-17	4.9e-15	-0.33	-0.26	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63635373	chr10:63634317~63634827:-
BRCA	cis	rs7085104	0.7	rs7096183	ENSG00000213061.2	PFN1P11	8.7	1.26e-17	4.91e-15	0.34	0.26	Immature fraction of reticulocytes;Schizophrenia;	chr10:102849709	chr10:102838011~102845473:-
BRCA	cis	rs7615952	0.551	rs6438945	ENSG00000171084.14	FAM86JP	8.7	1.27e-17	4.91e-15	0.46	0.26	Blood pressure (smoking interaction);	chr3:125915630	chr3:125916620~125930024:+
BRCA	cis	rs6844153	0.752	rs12650172	ENSG00000240005.4	RP11-293A21.1	-8.7	1.27e-17	4.93e-15	-0.34	-0.26	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26872784	chr4:26859806~26860599:-
BRCA	cis	rs6844153	0.752	rs12641261	ENSG00000240005.4	RP11-293A21.1	-8.7	1.27e-17	4.93e-15	-0.34	-0.26	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26872814	chr4:26859806~26860599:-
BRCA	cis	rs58873874	0.737	rs9313608	ENSG00000248544.2	CTB-47B11.3	-8.7	1.27e-17	4.94e-15	-0.61	-0.26	Bipolar disorder (body mass index interaction);	chr5:157473039	chr5:157375741~157384950:-
BRCA	cis	rs17711722	0.64	rs13237956	ENSG00000164669.11	INTS4P1	-8.7	1.28e-17	4.95e-15	-0.32	-0.26	Calcium levels;	chr7:65853042	chr7:65141225~65234216:+
BRCA	cis	rs875971	0.545	rs7810213	ENSG00000237310.1	GS1-124K5.4	8.7	1.28e-17	4.95e-15	0.31	0.26	Aortic root size;	chr7:66481592	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.545	rs35459055	ENSG00000222364.1	RNU6-96P	-8.7	1.28e-17	4.96e-15	-0.34	-0.26	Aortic root size;	chr7:66479399	chr7:66395191~66395286:+
BRCA	cis	rs12682352	0.579	rs7006589	ENSG00000253893.2	FAM85B	-8.7	1.28e-17	4.96e-15	-0.33	-0.26	Neuroticism;	chr8:8810976	chr8:8167819~8226614:-
BRCA	cis	rs17711722	0.74	rs7809991	ENSG00000236529.1	RP13-254B10.1	8.7	1.28e-17	4.97e-15	0.28	0.26	Calcium levels;	chr7:65941231	chr7:65840212~65840596:+
BRCA	cis	rs858239	0.601	rs6461693	ENSG00000230042.1	AK3P3	8.7	1.29e-17	4.99e-15	0.29	0.26	Cerebrospinal fluid biomarker levels;	chr7:23120514	chr7:23129178~23129841:+
BRCA	cis	rs11098499	0.738	rs34965784	ENSG00000248280.1	RP11-33B1.2	8.7	1.29e-17	5e-15	0.26	0.26	Corneal astigmatism;	chr4:119440431	chr4:119440561~119450157:-
BRCA	cis	rs7772486	0.686	rs6570705	ENSG00000235652.6	RP11-545I5.3	8.7	1.29e-17	5.01e-15	0.26	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145640065	chr6:145799409~145886585:+
BRCA	cis	rs2404602	0.716	rs17460201	ENSG00000259422.1	RP11-593F23.1	-8.7	1.3e-17	5.03e-15	-0.33	-0.26	Blood metabolite levels;	chr15:76381286	chr15:76174891~76181486:-
BRCA	cis	rs4718428	0.705	rs3800817	ENSG00000232546.1	RP11-458F8.1	-8.7	1.3e-17	5.04e-15	-0.24	-0.26	Corneal structure;	chr7:66798563	chr7:66848496~66858136:+
BRCA	cis	rs11971779	1	rs75919582	ENSG00000273391.1	RP11-634H22.1	8.7	1.3e-17	5.05e-15	0.31	0.26	Diisocyanate-induced asthma;	chr7:139370173	chr7:139359032~139359566:-
BRCA	cis	rs4853012	0.775	rs12465641	ENSG00000257800.1	FNBP1P1	-8.7	1.31e-17	5.07e-15	-0.27	-0.26	Gestational age at birth (maternal effect);	chr2:74110588	chr2:74120680~74123218:+
BRCA	cis	rs748404	0.666	rs10518812	ENSG00000249839.1	AC011330.5	8.7	1.32e-17	5.1e-15	0.38	0.26	Lung cancer;	chr15:43360739	chr15:43663654~43684339:-
BRCA	cis	rs7772486	0.651	rs1292338	ENSG00000235652.6	RP11-545I5.3	-8.7	1.32e-17	5.11e-15	-0.26	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145646335	chr6:145799409~145886585:+
BRCA	cis	rs10463554	0.892	rs158252	ENSG00000175749.11	EIF3KP1	8.7	1.32e-17	5.11e-15	0.37	0.26	Parkinson's disease;	chr5:103070546	chr5:103032376~103033031:+
BRCA	cis	rs10463554	0.927	rs154369	ENSG00000175749.11	EIF3KP1	8.7	1.32e-17	5.11e-15	0.37	0.26	Parkinson's disease;	chr5:103071140	chr5:103032376~103033031:+
BRCA	cis	rs10463554	0.892	rs158246	ENSG00000175749.11	EIF3KP1	8.7	1.32e-17	5.11e-15	0.37	0.26	Parkinson's disease;	chr5:103073145	chr5:103032376~103033031:+
BRCA	cis	rs7429990	0.864	rs7631950	ENSG00000229759.1	MRPS18AP1	-8.7	1.32e-17	5.12e-15	-0.29	-0.26	Educational attainment (years of education);	chr3:47591865	chr3:48256350~48256938:-
BRCA	cis	rs11971779	0.941	rs1127424	ENSG00000273391.1	RP11-634H22.1	8.7	1.32e-17	5.12e-15	0.29	0.26	Diisocyanate-induced asthma;	chr7:139422914	chr7:139359032~139359566:-
BRCA	cis	rs17711722	0.503	rs453835	ENSG00000273024.4	INTS4P2	8.7	1.32e-17	5.13e-15	0.3	0.26	Calcium levels;	chr7:66046172	chr7:65647864~65715661:+
BRCA	cis	rs4718428	0.672	rs12530806	ENSG00000273142.1	RP11-458F8.4	-8.7	1.33e-17	5.13e-15	-0.25	-0.26	Corneal structure;	chr7:66925737	chr7:66902857~66906297:+
BRCA	cis	rs2404602	0.716	rs1946650	ENSG00000259422.1	RP11-593F23.1	8.7	1.33e-17	5.14e-15	0.33	0.26	Blood metabolite levels;	chr15:76556122	chr15:76174891~76181486:-
BRCA	cis	rs7615952	0.576	rs17523380	ENSG00000250012.1	RP11-124N2.1	-8.7	1.33e-17	5.14e-15	-0.33	-0.26	Blood pressure (smoking interaction);	chr3:126084031	chr3:126084220~126095349:+
BRCA	cis	rs11098499	0.644	rs7676296	ENSG00000248280.1	RP11-33B1.2	8.69	1.33e-17	5.15e-15	0.26	0.26	Corneal astigmatism;	chr4:119634532	chr4:119440561~119450157:-
BRCA	cis	rs67981189	0.501	rs2810104	ENSG00000269927.1	RP6-91H8.3	8.69	1.33e-17	5.15e-15	0.34	0.26	Schizophrenia;	chr14:70958096	chr14:71141125~71143253:-
BRCA	cis	rs11971779	0.816	rs11979272	ENSG00000273391.1	RP11-634H22.1	8.69	1.33e-17	5.15e-15	0.29	0.26	Diisocyanate-induced asthma;	chr7:139389323	chr7:139359032~139359566:-
BRCA	cis	rs11098499	0.722	rs28713555	ENSG00000245958.5	RP11-33B1.1	-8.69	1.33e-17	5.15e-15	-0.25	-0.26	Corneal astigmatism;	chr4:119330840	chr4:119454791~119552025:+
BRCA	cis	rs1707322	1	rs4298677	ENSG00000280836.1	AL355480.1	-8.69	1.33e-17	5.16e-15	-0.33	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45840947	chr1:45581219~45581321:-
BRCA	cis	rs2439831	0.85	rs61390361	ENSG00000249839.1	AC011330.5	-8.69	1.34e-17	5.17e-15	-0.44	-0.26	Lung cancer in ever smokers;	chr15:43867644	chr15:43663654~43684339:-
BRCA	cis	rs897984	0.572	rs4889526	ENSG00000260911.2	RP11-196G11.2	8.69	1.34e-17	5.18e-15	0.24	0.26	Dementia with Lewy bodies;	chr16:31019023	chr16:31043150~31049868:+
BRCA	cis	rs3758911	0.964	rs10890702	ENSG00000255353.1	RP11-382M14.1	8.69	1.34e-17	5.18e-15	0.33	0.26	Coronary artery disease;	chr11:107310159	chr11:107176286~107177530:+
BRCA	cis	rs7772486	0.875	rs10457795	ENSG00000235652.6	RP11-545I5.3	8.69	1.34e-17	5.19e-15	0.26	0.26	Lobe attachment (rater-scored or self-reported);	chr6:146094529	chr6:145799409~145886585:+
BRCA	cis	rs7246657	0.722	rs2909093	ENSG00000267422.1	CTD-2554C21.1	8.69	1.34e-17	5.2e-15	0.39	0.26	Coronary artery calcification;	chr19:37708561	chr19:37779686~37792865:+
BRCA	cis	rs7772486	0.806	rs4075696	ENSG00000235652.6	RP11-545I5.3	-8.69	1.35e-17	5.21e-15	-0.26	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145929811	chr6:145799409~145886585:+
BRCA	cis	rs875971	0.516	rs6945322	ENSG00000164669.11	INTS4P1	-8.69	1.35e-17	5.22e-15	-0.32	-0.26	Aortic root size;	chr7:65871069	chr7:65141225~65234216:+
BRCA	cis	rs11673344	0.832	rs2011475	ENSG00000226686.6	LINC01535	8.69	1.35e-17	5.22e-15	0.34	0.26	Obesity-related traits;	chr19:37054712	chr19:37251912~37265535:+
BRCA	cis	rs11098499	0.954	rs11098525	ENSG00000248280.1	RP11-33B1.2	8.69	1.35e-17	5.22e-15	0.27	0.26	Corneal astigmatism;	chr4:119468997	chr4:119440561~119450157:-
BRCA	cis	rs10463554	0.927	rs40061	ENSG00000175749.11	EIF3KP1	8.69	1.35e-17	5.24e-15	0.37	0.26	Parkinson's disease;	chr5:103067412	chr5:103032376~103033031:+
BRCA	cis	rs12682352	0.602	rs11783966	ENSG00000253893.2	FAM85B	8.69	1.35e-17	5.24e-15	0.32	0.26	Neuroticism;	chr8:8807637	chr8:8167819~8226614:-
BRCA	cis	rs875971	0.571	rs78668714	ENSG00000237310.1	GS1-124K5.4	8.69	1.35e-17	5.24e-15	0.31	0.26	Aortic root size;	chr7:66474464	chr7:66493706~66495474:+
BRCA	cis	rs1707322	0.964	rs785508	ENSG00000280836.1	AL355480.1	8.69	1.36e-17	5.25e-15	0.33	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46061487	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.964	rs785509	ENSG00000280836.1	AL355480.1	8.69	1.36e-17	5.25e-15	0.33	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46061628	chr1:45581219~45581321:-
BRCA	cis	rs524281	0.506	rs512421	ENSG00000255320.1	RP11-755F10.1	8.69	1.36e-17	5.27e-15	0.36	0.26	Electroencephalogram traits;	chr11:66217697	chr11:66244840~66246239:-
BRCA	cis	rs58873874	1	rs75720504	ENSG00000251405.2	CTB-109A12.1	8.69	1.37e-17	5.29e-15	0.66	0.26	Bipolar disorder (body mass index interaction);	chr5:157508965	chr5:157362615~157460078:-
BRCA	cis	rs875971	0.545	rs1796222	ENSG00000237310.1	GS1-124K5.4	-8.69	1.37e-17	5.29e-15	-0.31	-0.26	Aortic root size;	chr7:66592167	chr7:66493706~66495474:+
BRCA	cis	rs61270009	0.955	rs4916897	ENSG00000247828.6	TMEM161B-AS1	8.69	1.37e-17	5.3e-15	0.33	0.26	Depressive symptoms;	chr5:88285771	chr5:88268895~88436685:+
BRCA	cis	rs875971	0.505	rs2462573	ENSG00000164669.11	INTS4P1	8.69	1.37e-17	5.31e-15	0.32	0.26	Aortic root size;	chr7:66042405	chr7:65141225~65234216:+
BRCA	cis	rs4835473	0.932	rs1375986	ENSG00000251600.4	RP11-673E1.1	-8.69	1.38e-17	5.32e-15	-0.3	-0.26	Immature fraction of reticulocytes;	chr4:143746048	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.868	rs35420625	ENSG00000251600.4	RP11-673E1.1	-8.69	1.38e-17	5.32e-15	-0.3	-0.26	Immature fraction of reticulocytes;	chr4:143746089	chr4:143912331~143982454:+
BRCA	cis	rs6142102	0.625	rs6142068	ENSG00000275784.1	RP5-1125A11.6	8.69	1.38e-17	5.32e-15	0.29	0.26	Skin pigmentation;	chr20:33969366	chr20:33989480~33991818:-
BRCA	cis	rs11673344	0.764	rs529468	ENSG00000226686.6	LINC01535	8.69	1.38e-17	5.32e-15	0.33	0.26	Obesity-related traits;	chr19:36955298	chr19:37251912~37265535:+
BRCA	cis	rs26232	0.583	rs26430	ENSG00000175749.11	EIF3KP1	-8.69	1.38e-17	5.33e-15	-0.35	-0.26	Rheumatoid arthritis;	chr5:103030228	chr5:103032376~103033031:+
BRCA	cis	rs11673344	0.764	rs826304	ENSG00000226686.6	LINC01535	8.69	1.38e-17	5.33e-15	0.33	0.26	Obesity-related traits;	chr19:36952681	chr19:37251912~37265535:+
BRCA	cis	rs11098499	0.954	rs67265404	ENSG00000248280.1	RP11-33B1.2	8.69	1.38e-17	5.34e-15	0.27	0.26	Corneal astigmatism;	chr4:119438115	chr4:119440561~119450157:-
BRCA	cis	rs2404602	0.716	rs17362383	ENSG00000259422.1	RP11-593F23.1	8.69	1.38e-17	5.34e-15	0.33	0.26	Blood metabolite levels;	chr15:76358361	chr15:76174891~76181486:-
BRCA	cis	rs875971	0.522	rs10807697	ENSG00000236529.1	RP13-254B10.1	8.69	1.39e-17	5.36e-15	0.28	0.26	Aortic root size;	chr7:65951183	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.666	rs13242072	ENSG00000222364.1	RNU6-96P	8.69	1.39e-17	5.39e-15	0.3	0.26	Aortic root size;	chr7:66301001	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.522	rs4718285	ENSG00000236529.1	RP13-254B10.1	8.69	1.4e-17	5.4e-15	0.28	0.26	Aortic root size;	chr7:65827018	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.522	rs1617484	ENSG00000236529.1	RP13-254B10.1	8.69	1.4e-17	5.43e-15	0.28	0.26	Aortic root size;	chr7:65998108	chr7:65840212~65840596:+
BRCA	cis	rs4835473	0.832	rs35398499	ENSG00000251600.4	RP11-673E1.1	-8.69	1.41e-17	5.43e-15	-0.31	-0.26	Immature fraction of reticulocytes;	chr4:143737715	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.832	rs35763177	ENSG00000251600.4	RP11-673E1.1	-8.69	1.41e-17	5.43e-15	-0.31	-0.26	Immature fraction of reticulocytes;	chr4:143737717	chr4:143912331~143982454:+
BRCA	cis	rs875971	0.545	rs11767262	ENSG00000222364.1	RNU6-96P	-8.69	1.41e-17	5.44e-15	-0.34	-0.26	Aortic root size;	chr7:66302237	chr7:66395191~66395286:+
BRCA	cis	rs7085104	0.7	rs6163	ENSG00000213061.2	PFN1P11	8.69	1.41e-17	5.44e-15	0.34	0.26	Immature fraction of reticulocytes;Schizophrenia;	chr10:102837167	chr10:102838011~102845473:-
BRCA	cis	rs17023223	0.537	rs17023174	ENSG00000231365.4	RP11-418J17.1	-8.69	1.41e-17	5.45e-15	-0.33	-0.26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119050678	chr1:119140396~119275973:+
BRCA	cis	rs875971	0.522	rs1701760	ENSG00000164669.11	INTS4P1	-8.69	1.41e-17	5.46e-15	-0.32	-0.26	Aortic root size;	chr7:66008701	chr7:65141225~65234216:+
BRCA	cis	rs7246657	0.722	rs2287229	ENSG00000267422.1	CTD-2554C21.1	8.69	1.42e-17	5.47e-15	0.39	0.26	Coronary artery calcification;	chr19:37697751	chr19:37779686~37792865:+
BRCA	cis	rs10463554	0.963	rs1595553	ENSG00000175749.11	EIF3KP1	8.69	1.42e-17	5.48e-15	0.36	0.26	Parkinson's disease;	chr5:103043164	chr5:103032376~103033031:+
BRCA	cis	rs875971	1	rs11974264	ENSG00000237310.1	GS1-124K5.4	-8.69	1.42e-17	5.49e-15	-0.27	-0.26	Aortic root size;	chr7:66182595	chr7:66493706~66495474:+
BRCA	cis	rs4660456	0.913	rs556875	ENSG00000237899.1	RP4-739H11.3	-8.69	1.42e-17	5.49e-15	-0.38	-0.26	Platelet count;	chr1:40688571	chr1:40669089~40687588:-
BRCA	cis	rs875971	0.545	rs4441996	ENSG00000222364.1	RNU6-96P	8.69	1.42e-17	5.49e-15	0.33	0.26	Aortic root size;	chr7:66123233	chr7:66395191~66395286:+
BRCA	cis	rs10129255	0.5	rs34326748	ENSG00000211972.2	IGHV3-66	8.69	1.43e-17	5.51e-15	0.18	0.26	Kawasaki disease;	chr14:106782523	chr14:106675017~106675544:-
BRCA	cis	rs10129255	0.5	rs10143385	ENSG00000211972.2	IGHV3-66	8.69	1.43e-17	5.51e-15	0.18	0.26	Kawasaki disease;	chr14:106782559	chr14:106675017~106675544:-
BRCA	cis	rs11098499	0.863	rs2291185	ENSG00000248280.1	RP11-33B1.2	8.69	1.43e-17	5.53e-15	0.27	0.26	Corneal astigmatism;	chr4:119513678	chr4:119440561~119450157:-
BRCA	cis	rs10971721	0.822	rs12376279	ENSG00000260947.1	RP11-384P7.7	8.69	1.44e-17	5.55e-15	0.48	0.26	Body mass index;	chr9:33804256	chr9:33697459~33700986:+
BRCA	cis	rs11098499	0.691	rs12510133	ENSG00000245958.5	RP11-33B1.1	-8.69	1.44e-17	5.55e-15	-0.24	-0.26	Corneal astigmatism;	chr4:119350189	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.754	rs12506487	ENSG00000245958.5	RP11-33B1.1	-8.69	1.44e-17	5.55e-15	-0.24	-0.26	Corneal astigmatism;	chr4:119350206	chr4:119454791~119552025:+
BRCA	cis	rs17711722	1	rs17711722	ENSG00000164669.11	INTS4P1	8.69	1.44e-17	5.55e-15	0.32	0.26	Calcium levels;	chr7:65806210	chr7:65141225~65234216:+
BRCA	cis	rs11098499	0.865	rs10213221	ENSG00000245958.5	RP11-33B1.1	-8.69	1.44e-17	5.55e-15	-0.25	-0.26	Corneal astigmatism;	chr4:119334771	chr4:119454791~119552025:+
BRCA	cis	rs10129255	0.518	rs11847766	ENSG00000211972.2	IGHV3-66	8.69	1.44e-17	5.56e-15	0.18	0.26	Kawasaki disease;	chr14:106779186	chr14:106675017~106675544:-
BRCA	cis	rs1707322	1	rs10890376	ENSG00000280836.1	AL355480.1	-8.68	1.44e-17	5.57e-15	-0.34	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45940910	chr1:45581219~45581321:-
BRCA	cis	rs807029	0.533	rs67813203	ENSG00000272572.1	RP11-179B2.2	-8.68	1.45e-17	5.58e-15	-0.34	-0.26	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100978794	chr10:100911103~100912739:-
BRCA	cis	rs881375	0.967	rs2109896	ENSG00000226752.6	PSMD5-AS1	-8.68	1.45e-17	5.59e-15	-0.31	-0.26	Rheumatoid arthritis;	chr9:120920828	chr9:120824828~120854385:+
BRCA	cis	rs11098499	0.863	rs13134665	ENSG00000248280.1	RP11-33B1.2	8.68	1.45e-17	5.6e-15	0.27	0.26	Corneal astigmatism;	chr4:119505275	chr4:119440561~119450157:-
BRCA	cis	rs801193	0.636	rs2659895	ENSG00000237310.1	GS1-124K5.4	8.68	1.45e-17	5.61e-15	0.27	0.26	Aortic root size;	chr7:66731484	chr7:66493706~66495474:+
BRCA	cis	rs1501911	0.588	rs819227	ENSG00000248489.1	CTD-2007H13.3	-8.68	1.47e-17	5.65e-15	-0.33	-0.26	Lung function (FEV1/FVC);	chr5:98994161	chr5:98929171~98995013:+
BRCA	cis	rs4964805	0.626	rs11111771	ENSG00000257681.1	RP11-341G23.4	-8.68	1.47e-17	5.68e-15	-0.33	-0.26	Attention deficit hyperactivity disorder;	chr12:103785493	chr12:103746315~103768858:-
BRCA	cis	rs875971	0.545	rs73142245	ENSG00000237310.1	GS1-124K5.4	8.68	1.48e-17	5.69e-15	0.31	0.26	Aortic root size;	chr7:66226662	chr7:66493706~66495474:+
BRCA	cis	rs7246657	0.722	rs2075284	ENSG00000267422.1	CTD-2554C21.1	8.68	1.48e-17	5.71e-15	0.39	0.26	Coronary artery calcification;	chr19:37698715	chr19:37779686~37792865:+
BRCA	cis	rs10129255	0.912	rs8009135	ENSG00000223648.3	IGHV3-64	8.68	1.49e-17	5.74e-15	0.22	0.26	Kawasaki disease;	chr14:106777528	chr14:106643132~106658258:-
BRCA	cis	rs61270009	0.863	rs6452782	ENSG00000247828.6	TMEM161B-AS1	8.68	1.49e-17	5.75e-15	0.33	0.26	Depressive symptoms;	chr5:88376887	chr5:88268895~88436685:+
BRCA	cis	rs9903692	0.954	rs2109984	ENSG00000278765.1	RP5-890E16.5	8.68	1.49e-17	5.75e-15	0.32	0.26	Pulse pressure;	chr17:48093737	chr17:48066704~48067293:-
BRCA	cis	rs11098499	0.863	rs2306456	ENSG00000248280.1	RP11-33B1.2	8.68	1.5e-17	5.77e-15	0.27	0.26	Corneal astigmatism;	chr4:119551267	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.863	rs11947234	ENSG00000248280.1	RP11-33B1.2	8.68	1.5e-17	5.77e-15	0.27	0.26	Corneal astigmatism;	chr4:119553704	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.863	rs11933966	ENSG00000248280.1	RP11-33B1.2	8.68	1.5e-17	5.77e-15	0.27	0.26	Corneal astigmatism;	chr4:119555560	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.863	rs36040693	ENSG00000248280.1	RP11-33B1.2	8.68	1.5e-17	5.77e-15	0.27	0.26	Corneal astigmatism;	chr4:119556461	chr4:119440561~119450157:-
BRCA	cis	rs2933343	1	rs1683776	ENSG00000231305.3	RP11-723O4.2	8.68	1.5e-17	5.77e-15	0.33	0.26	IgG glycosylation;	chr3:128903917	chr3:128861313~128871540:-
BRCA	cis	rs2439831	0.85	rs7179388	ENSG00000249839.1	AC011330.5	-8.68	1.5e-17	5.78e-15	-0.46	-0.26	Lung cancer in ever smokers;	chr15:43831747	chr15:43663654~43684339:-
BRCA	cis	rs875971	0.522	rs4718286	ENSG00000164669.11	INTS4P1	-8.68	1.5e-17	5.78e-15	-0.32	-0.26	Aortic root size;	chr7:65827777	chr7:65141225~65234216:+
BRCA	cis	rs17711722	0.585	rs6942660	ENSG00000164669.11	INTS4P1	-8.68	1.5e-17	5.78e-15	-0.32	-0.26	Calcium levels;	chr7:65837419	chr7:65141225~65234216:+
BRCA	cis	rs4820294	0.77	rs7285699	ENSG00000233360.4	Z83844.1	8.68	1.5e-17	5.79e-15	0.29	0.26	Fat distribution (HIV);	chr22:37670549	chr22:37641832~37658377:-
BRCA	cis	rs858239	0.738	rs7807879	ENSG00000226816.2	AC005082.12	8.68	1.5e-17	5.8e-15	0.31	0.26	Cerebrospinal fluid biomarker levels;	chr7:23220969	chr7:23206013~23208045:+
BRCA	cis	rs35160687	0.712	rs2303359	ENSG00000273080.1	RP11-301O19.1	-8.68	1.51e-17	5.8e-15	-0.29	-0.26	Night sleep phenotypes;	chr2:86251547	chr2:86195590~86196049:+
BRCA	cis	rs783540	1	rs7496954	ENSG00000278603.1	RP13-608F4.5	8.68	1.51e-17	5.81e-15	0.33	0.26	Schizophrenia;	chr15:82676784	chr15:82472203~82472426:+
BRCA	cis	rs9640161	0.711	rs60268791	ENSG00000261305.1	RP4-584D14.7	8.68	1.52e-17	5.84e-15	0.38	0.26	Blood protein levels;Circulating chemerin levels;	chr7:150326711	chr7:150341771~150342607:+
BRCA	cis	rs875971	0.545	rs6979636	ENSG00000237310.1	GS1-124K5.4	8.68	1.52e-17	5.85e-15	0.31	0.26	Aortic root size;	chr7:66276638	chr7:66493706~66495474:+
BRCA	cis	rs7615952	0.673	rs7632557	ENSG00000171084.14	FAM86JP	8.68	1.52e-17	5.86e-15	0.45	0.26	Blood pressure (smoking interaction);	chr3:125916038	chr3:125916620~125930024:+
BRCA	cis	rs8062405	0.679	rs72793818	ENSG00000278665.1	RP11-666O2.4	8.68	1.53e-17	5.89e-15	0.28	0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28881816	chr16:28599241~28601881:-
BRCA	cis	rs11098499	0.722	rs10025925	ENSG00000245958.5	RP11-33B1.1	-8.68	1.53e-17	5.91e-15	-0.24	-0.26	Corneal astigmatism;	chr4:119350589	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.731	rs10015579	ENSG00000245958.5	RP11-33B1.1	-8.68	1.53e-17	5.91e-15	-0.24	-0.26	Corneal astigmatism;	chr4:119350647	chr4:119454791~119552025:+
BRCA	cis	rs2404602	0.631	rs9646213	ENSG00000259422.1	RP11-593F23.1	8.68	1.54e-17	5.92e-15	0.33	0.26	Blood metabolite levels;	chr15:76515331	chr15:76174891~76181486:-
BRCA	cis	rs896854	0.654	rs6982393	ENSG00000253528.2	RP11-347C18.4	8.68	1.54e-17	5.92e-15	0.27	0.26	Type 2 diabetes;	chr8:94968480	chr8:94974573~94974853:-
BRCA	cis	rs875971	0.577	rs35072105	ENSG00000222364.1	RNU6-96P	8.68	1.54e-17	5.93e-15	0.3	0.26	Aortic root size;	chr7:66144830	chr7:66395191~66395286:+
BRCA	cis	rs9640161	0.75	rs11765644	ENSG00000261305.1	RP4-584D14.7	8.68	1.55e-17	5.96e-15	0.4	0.26	Blood protein levels;Circulating chemerin levels;	chr7:150329250	chr7:150341771~150342607:+
BRCA	cis	rs2404602	0.716	rs7179142	ENSG00000259422.1	RP11-593F23.1	8.68	1.55e-17	5.97e-15	0.33	0.26	Blood metabolite levels;	chr15:76405927	chr15:76174891~76181486:-
BRCA	cis	rs11098499	0.644	rs17517414	ENSG00000248280.1	RP11-33B1.2	8.68	1.56e-17	5.98e-15	0.25	0.26	Corneal astigmatism;	chr4:119340946	chr4:119440561~119450157:-
BRCA	cis	rs783540	0.967	rs17158390	ENSG00000278603.1	RP13-608F4.5	-8.68	1.56e-17	5.98e-15	-0.33	-0.26	Schizophrenia;	chr15:82624277	chr15:82472203~82472426:+
BRCA	cis	rs17023223	0.537	rs7532510	ENSG00000231365.4	RP11-418J17.1	-8.68	1.56e-17	6e-15	-0.34	-0.26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119051613	chr1:119140396~119275973:+
BRCA	cis	rs10129255	0.5	rs8006888	ENSG00000211972.2	IGHV3-66	8.68	1.56e-17	6.01e-15	0.18	0.26	Kawasaki disease;	chr14:106782219	chr14:106675017~106675544:-
BRCA	cis	rs10463554	0.963	rs62362546	ENSG00000175749.11	EIF3KP1	8.67	1.57e-17	6.03e-15	0.36	0.26	Parkinson's disease;	chr5:103015615	chr5:103032376~103033031:+
BRCA	cis	rs748404	0.666	rs60018990	ENSG00000249839.1	AC011330.5	-8.67	1.57e-17	6.03e-15	-0.37	-0.26	Lung cancer;	chr15:43504606	chr15:43663654~43684339:-
BRCA	cis	rs875971	0.505	rs6955582	ENSG00000222364.1	RNU6-96P	-8.67	1.57e-17	6.04e-15	-0.3	-0.26	Aortic root size;	chr7:65966699	chr7:66395191~66395286:+
BRCA	cis	rs875971	1	rs1540651	ENSG00000237310.1	GS1-124K5.4	-8.67	1.57e-17	6.04e-15	-0.27	-0.26	Aortic root size;	chr7:66185134	chr7:66493706~66495474:+
BRCA	cis	rs881375	0.9	rs1008383	ENSG00000226752.6	PSMD5-AS1	-8.67	1.58e-17	6.06e-15	-0.31	-0.26	Rheumatoid arthritis;	chr9:120921301	chr9:120824828~120854385:+
BRCA	cis	rs11098499	0.863	rs1383532	ENSG00000248280.1	RP11-33B1.2	-8.67	1.58e-17	6.09e-15	-0.27	-0.26	Corneal astigmatism;	chr4:119513249	chr4:119440561~119450157:-
BRCA	cis	rs7772486	0.754	rs6570703	ENSG00000235652.6	RP11-545I5.3	8.67	1.59e-17	6.1e-15	0.26	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145635916	chr6:145799409~145886585:+
BRCA	cis	rs11673344	0.864	rs2562587	ENSG00000226686.6	LINC01535	8.67	1.59e-17	6.11e-15	0.34	0.26	Obesity-related traits;	chr19:37019357	chr19:37251912~37265535:+
BRCA	cis	rs875971	0.522	rs4718285	ENSG00000222364.1	RNU6-96P	-8.67	1.59e-17	6.11e-15	-0.3	-0.26	Aortic root size;	chr7:65827018	chr7:66395191~66395286:+
BRCA	cis	rs4964805	0.913	rs35945096	ENSG00000257681.1	RP11-341G23.4	8.67	1.59e-17	6.12e-15	0.32	0.26	Attention deficit hyperactivity disorder;	chr12:103808151	chr12:103746315~103768858:-
BRCA	cis	rs11098499	0.863	rs7664986	ENSG00000248280.1	RP11-33B1.2	8.67	1.59e-17	6.13e-15	0.27	0.26	Corneal astigmatism;	chr4:119508797	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.818	rs10008791	ENSG00000248280.1	RP11-33B1.2	8.67	1.59e-17	6.13e-15	0.27	0.26	Corneal astigmatism;	chr4:119510314	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.863	rs11736416	ENSG00000248280.1	RP11-33B1.2	8.67	1.59e-17	6.13e-15	0.27	0.26	Corneal astigmatism;	chr4:119510506	chr4:119440561~119450157:-
BRCA	cis	rs17772222	0.958	rs60878614	ENSG00000258983.2	RP11-507K2.2	8.67	1.59e-17	6.13e-15	0.3	0.26	Coronary artery calcification;	chr14:88513871	chr14:88499334~88515502:+
BRCA	cis	rs11098499	0.954	rs10518331	ENSG00000248280.1	RP11-33B1.2	8.67	1.6e-17	6.13e-15	0.26	0.26	Corneal astigmatism;	chr4:119402440	chr4:119440561~119450157:-
BRCA	cis	rs1707322	1	rs4524994	ENSG00000280836.1	AL355480.1	-8.67	1.6e-17	6.13e-15	-0.33	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45904591	chr1:45581219~45581321:-
BRCA	cis	rs11157436	0.918	rs7159024	ENSG00000211812.1	TRAV26-2	-8.67	1.6e-17	6.15e-15	-0.23	-0.26	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22228760	chr14:22202583~22203368:+
BRCA	cis	rs367615	0.959	rs17161951	ENSG00000249476.1	CTD-2587M2.1	-8.67	1.6e-17	6.15e-15	-0.32	-0.26	Colorectal cancer (SNP x SNP interaction);	chr5:109594889	chr5:109237120~109326369:-
BRCA	cis	rs875971	0.54	rs781152	ENSG00000236529.1	RP13-254B10.1	8.67	1.6e-17	6.16e-15	0.29	0.26	Aortic root size;	chr7:66014585	chr7:65840212~65840596:+
BRCA	cis	rs17711722	0.727	rs781151	ENSG00000236529.1	RP13-254B10.1	8.67	1.6e-17	6.16e-15	0.29	0.26	Calcium levels;	chr7:66014891	chr7:65840212~65840596:+
BRCA	cis	rs11098499	0.569	rs10023641	ENSG00000248280.1	RP11-33B1.2	8.67	1.61e-17	6.18e-15	0.25	0.26	Corneal astigmatism;	chr4:119337255	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.754	rs878372	ENSG00000245958.5	RP11-33B1.1	-8.67	1.61e-17	6.18e-15	-0.24	-0.26	Corneal astigmatism;	chr4:119317625	chr4:119454791~119552025:+
BRCA	cis	rs1823913	0.637	rs4853584	ENSG00000227542.1	AC092614.2	-8.67	1.63e-17	6.24e-15	-0.31	-0.26	Obesity-related traits;	chr2:191310596	chr2:191229165~191246172:-
BRCA	cis	rs950880	0.71	rs11123927	ENSG00000234389.1	AC007278.3	-8.67	1.63e-17	6.25e-15	-0.25	-0.26	Serum protein levels (sST2);	chr2:102442343	chr2:102438713~102440475:+
BRCA	cis	rs875971	0.522	rs2949690	ENSG00000164669.11	INTS4P1	8.67	1.63e-17	6.26e-15	0.32	0.26	Aortic root size;	chr7:66018255	chr7:65141225~65234216:+
BRCA	cis	rs7429990	0.803	rs11130145	ENSG00000229759.1	MRPS18AP1	-8.67	1.63e-17	6.27e-15	-0.29	-0.26	Educational attainment (years of education);	chr3:47661780	chr3:48256350~48256938:-
BRCA	cis	rs7429990	0.864	rs6772301	ENSG00000229759.1	MRPS18AP1	-8.67	1.63e-17	6.27e-15	-0.29	-0.26	Educational attainment (years of education);	chr3:47682366	chr3:48256350~48256938:-
BRCA	cis	rs7429990	0.864	rs2133601	ENSG00000229759.1	MRPS18AP1	-8.67	1.63e-17	6.27e-15	-0.29	-0.26	Educational attainment (years of education);	chr3:47692525	chr3:48256350~48256938:-
BRCA	cis	rs7429990	0.864	rs6792497	ENSG00000229759.1	MRPS18AP1	-8.67	1.63e-17	6.27e-15	-0.29	-0.26	Educational attainment (years of education);	chr3:47693684	chr3:48256350~48256938:-
BRCA	cis	rs11098499	0.863	rs3775843	ENSG00000248280.1	RP11-33B1.2	8.67	1.63e-17	6.27e-15	0.27	0.26	Corneal astigmatism;	chr4:119506689	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.863	rs3775844	ENSG00000248280.1	RP11-33B1.2	8.67	1.63e-17	6.27e-15	0.27	0.26	Corneal astigmatism;	chr4:119506878	chr4:119440561~119450157:-
BRCA	cis	rs3814244	0.528	rs12228471	ENSG00000236946.2	HNRNPA1P70	-8.67	1.63e-17	6.27e-15	-0.22	-0.26	Itch intensity from mosquito bite adjusted by bite size;	chr12:68027842	chr12:68035767~68036853:+
BRCA	cis	rs7429990	0.864	rs12636863	ENSG00000229759.1	MRPS18AP1	-8.67	1.64e-17	6.28e-15	-0.29	-0.26	Educational attainment (years of education);	chr3:47638629	chr3:48256350~48256938:-
BRCA	cis	rs17711722	0.64	rs13237956	ENSG00000236529.1	RP13-254B10.1	8.67	1.64e-17	6.28e-15	0.28	0.26	Calcium levels;	chr7:65853042	chr7:65840212~65840596:+
BRCA	cis	rs10129255	1	rs61997605	ENSG00000223648.3	IGHV3-64	8.67	1.64e-17	6.31e-15	0.23	0.26	Kawasaki disease;	chr14:106678368	chr14:106643132~106658258:-
BRCA	cis	rs2067615	0.524	rs4964483	ENSG00000260329.1	RP11-412D9.4	-8.67	1.65e-17	6.32e-15	-0.29	-0.26	Heart rate;	chr12:106705279	chr12:106954029~106955497:-
BRCA	cis	rs875971	0.545	rs3735147	ENSG00000222364.1	RNU6-96P	-8.67	1.65e-17	6.32e-15	-0.34	-0.26	Aortic root size;	chr7:66505541	chr7:66395191~66395286:+
BRCA	cis	rs896854	0.596	rs7823059	ENSG00000253528.2	RP11-347C18.4	8.67	1.65e-17	6.32e-15	0.27	0.26	Type 2 diabetes;	chr8:94962733	chr8:94974573~94974853:-
BRCA	cis	rs896854	0.653	rs13266313	ENSG00000253528.2	RP11-347C18.4	8.67	1.65e-17	6.32e-15	0.27	0.26	Type 2 diabetes;	chr8:94963074	chr8:94974573~94974853:-
BRCA	cis	rs896854	0.654	rs4735340	ENSG00000253528.2	RP11-347C18.4	8.67	1.65e-17	6.32e-15	0.27	0.26	Type 2 diabetes;	chr8:94964023	chr8:94974573~94974853:-
BRCA	cis	rs4718428	0.705	rs10267335	ENSG00000273142.1	RP11-458F8.4	-8.67	1.65e-17	6.33e-15	-0.25	-0.26	Corneal structure;	chr7:66938233	chr7:66902857~66906297:+
BRCA	cis	rs875971	0.522	rs2008188	ENSG00000236529.1	RP13-254B10.1	8.67	1.66e-17	6.35e-15	0.28	0.26	Aortic root size;	chr7:65964026	chr7:65840212~65840596:+
BRCA	cis	rs11098499	0.722	rs17595727	ENSG00000248280.1	RP11-33B1.2	-8.67	1.66e-17	6.38e-15	-0.25	-0.26	Corneal astigmatism;	chr4:119340919	chr4:119440561~119450157:-
BRCA	cis	rs17711722	0.727	rs35850374	ENSG00000236529.1	RP13-254B10.1	8.67	1.66e-17	6.38e-15	0.28	0.26	Calcium levels;	chr7:65892789	chr7:65840212~65840596:+
BRCA	cis	rs10463554	0.927	rs34831	ENSG00000175749.11	EIF3KP1	8.67	1.66e-17	6.38e-15	0.37	0.26	Parkinson's disease;	chr5:103108385	chr5:103032376~103033031:+
BRCA	cis	rs7429990	0.864	rs11130143	ENSG00000229759.1	MRPS18AP1	-8.67	1.67e-17	6.39e-15	-0.29	-0.26	Educational attainment (years of education);	chr3:47614943	chr3:48256350~48256938:-
BRCA	cis	rs113835537	0.529	rs11821155	ENSG00000255517.5	CTD-3074O7.5	8.67	1.67e-17	6.39e-15	0.33	0.26	Airway imaging phenotypes;	chr11:66478866	chr11:66473490~66480233:-
BRCA	cis	rs67981189	0.529	rs61990379	ENSG00000269927.1	RP6-91H8.3	8.67	1.67e-17	6.39e-15	0.34	0.26	Schizophrenia;	chr14:71000353	chr14:71141125~71143253:-
BRCA	cis	rs1707322	1	rs10158032	ENSG00000280836.1	AL355480.1	-8.67	1.67e-17	6.39e-15	-0.33	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45867029	chr1:45581219~45581321:-
BRCA	cis	rs17711722	0.701	rs55773927	ENSG00000236529.1	RP13-254B10.1	8.67	1.67e-17	6.41e-15	0.28	0.26	Calcium levels;	chr7:65872915	chr7:65840212~65840596:+
BRCA	cis	rs881375	0.678	rs3761846	ENSG00000226752.6	PSMD5-AS1	-8.67	1.68e-17	6.42e-15	-0.3	-0.26	Rheumatoid arthritis;	chr9:120927319	chr9:120824828~120854385:+
BRCA	cis	rs7429990	0.864	rs13086149	ENSG00000229759.1	MRPS18AP1	-8.67	1.68e-17	6.46e-15	-0.29	-0.26	Educational attainment (years of education);	chr3:47784158	chr3:48256350~48256938:-
BRCA	cis	rs11098499	0.863	rs1480940	ENSG00000245958.5	RP11-33B1.1	-8.67	1.69e-17	6.46e-15	-0.26	-0.26	Corneal astigmatism;	chr4:119536527	chr4:119454791~119552025:+
BRCA	cis	rs881375	0.933	rs2239657	ENSG00000226752.6	PSMD5-AS1	8.67	1.69e-17	6.47e-15	0.31	0.26	Rheumatoid arthritis;	chr9:120909242	chr9:120824828~120854385:+
BRCA	cis	rs8072100	0.817	rs9892497	ENSG00000228782.6	CTD-2026D20.3	8.67	1.69e-17	6.49e-15	0.28	0.26	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47468553	chr17:47450568~47492492:-
BRCA	cis	rs1707322	1	rs7547189	ENSG00000280836.1	AL355480.1	-8.67	1.69e-17	6.49e-15	-0.33	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45853842	chr1:45581219~45581321:-
BRCA	cis	rs1707322	1	rs7547284	ENSG00000280836.1	AL355480.1	-8.67	1.69e-17	6.49e-15	-0.33	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45853893	chr1:45581219~45581321:-
BRCA	cis	rs1707322	1	rs11211205	ENSG00000280836.1	AL355480.1	-8.67	1.69e-17	6.49e-15	-0.33	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45856202	chr1:45581219~45581321:-
BRCA	cis	rs783540	0.967	rs783523	ENSG00000278603.1	RP13-608F4.5	8.67	1.7e-17	6.51e-15	0.33	0.26	Schizophrenia;	chr15:82614804	chr15:82472203~82472426:+
BRCA	cis	rs6545883	0.929	rs778140	ENSG00000271889.1	RP11-493E12.1	8.66	1.7e-17	6.52e-15	0.34	0.26	Tuberculosis;	chr2:61455841	chr2:61151433~61162105:-
BRCA	cis	rs150992	0.537	rs1604450	ENSG00000248489.1	CTD-2007H13.3	-8.66	1.7e-17	6.52e-15	-0.34	-0.26	Body mass index;	chr5:99036274	chr5:98929171~98995013:+
BRCA	cis	rs150992	0.504	rs7719649	ENSG00000248489.1	CTD-2007H13.3	8.66	1.7e-17	6.52e-15	0.34	0.26	Body mass index;	chr5:99036711	chr5:98929171~98995013:+
BRCA	cis	rs13230714	1	rs13230714	ENSG00000204959.4	ARHGEF34P	-8.66	1.7e-17	6.53e-15	-0.33	-0.26	Breast cancer;	chr7:144477198	chr7:144272445~144286966:-
BRCA	cis	rs17711722	0.727	rs2658585	ENSG00000164669.11	INTS4P1	-8.66	1.7e-17	6.53e-15	-0.32	-0.26	Calcium levels;	chr7:65996954	chr7:65141225~65234216:+
BRCA	cis	rs1075265	0.933	rs7560947	ENSG00000233266.1	HMGB1P31	8.66	1.71e-17	6.53e-15	0.31	0.26	Chronotype;Morning vs. evening chronotype;	chr2:54087473	chr2:54051334~54051760:+
BRCA	cis	rs10463554	0.963	rs6883113	ENSG00000175749.11	EIF3KP1	8.66	1.71e-17	6.54e-15	0.36	0.26	Parkinson's disease;	chr5:103042185	chr5:103032376~103033031:+
BRCA	cis	rs12468226	1	rs16824599	ENSG00000273456.1	RP11-686O6.2	8.66	1.71e-17	6.57e-15	0.4	0.26	Urate levels;	chr2:202358243	chr2:202374932~202375604:-
BRCA	cis	rs950880	0.71	rs4851582	ENSG00000234389.1	AC007278.3	-8.66	1.72e-17	6.57e-15	-0.26	-0.26	Serum protein levels (sST2);	chr2:102435098	chr2:102438713~102440475:+
BRCA	cis	rs10463554	0.926	rs5855	ENSG00000175749.11	EIF3KP1	-8.66	1.72e-17	6.57e-15	-0.35	-0.26	Parkinson's disease;	chr5:103029482	chr5:103032376~103033031:+
BRCA	cis	rs1707322	1	rs10890353	ENSG00000280836.1	AL355480.1	-8.66	1.72e-17	6.58e-15	-0.33	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45832711	chr1:45581219~45581321:-
BRCA	cis	rs1707322	1	rs11211222	ENSG00000280836.1	AL355480.1	-8.66	1.73e-17	6.62e-15	-0.33	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45902085	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.963	rs9787412	ENSG00000280836.1	AL355480.1	-8.66	1.73e-17	6.62e-15	-0.33	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45905924	chr1:45581219~45581321:-
BRCA	cis	rs1707322	1	rs4660896	ENSG00000280836.1	AL355480.1	-8.66	1.73e-17	6.62e-15	-0.33	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45906744	chr1:45581219~45581321:-
BRCA	cis	rs1707322	1	rs12133129	ENSG00000280836.1	AL355480.1	-8.66	1.73e-17	6.62e-15	-0.33	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45907676	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.963	rs4553121	ENSG00000280836.1	AL355480.1	-8.66	1.73e-17	6.62e-15	-0.33	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45909581	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.963	rs6690652	ENSG00000280836.1	AL355480.1	-8.66	1.73e-17	6.62e-15	-0.33	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45911020	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.964	rs6697830	ENSG00000280836.1	AL355480.1	-8.66	1.73e-17	6.62e-15	-0.33	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45824805	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.928	rs7527244	ENSG00000280836.1	AL355480.1	-8.66	1.73e-17	6.63e-15	-0.33	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45903100	chr1:45581219~45581321:-
BRCA	cis	rs10463554	0.892	rs34830	ENSG00000175749.11	EIF3KP1	8.66	1.73e-17	6.64e-15	0.37	0.26	Parkinson's disease;	chr5:103108349	chr5:103032376~103033031:+
BRCA	cis	rs7085104	0.632	rs4290163	ENSG00000213061.2	PFN1P11	8.66	1.74e-17	6.64e-15	0.34	0.26	Immature fraction of reticulocytes;Schizophrenia;	chr10:102851169	chr10:102838011~102845473:-
BRCA	cis	rs7429990	0.864	rs2140335	ENSG00000229759.1	MRPS18AP1	-8.66	1.74e-17	6.64e-15	-0.29	-0.26	Educational attainment (years of education);	chr3:47663625	chr3:48256350~48256938:-
BRCA	cis	rs1707322	1	rs785465	ENSG00000280836.1	AL355480.1	-8.66	1.74e-17	6.67e-15	-0.33	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46056905	chr1:45581219~45581321:-
BRCA	cis	rs2810114	0.916	rs2526851	ENSG00000269927.1	RP6-91H8.3	-8.66	1.74e-17	6.67e-15	-0.34	-0.26	Alcohol dependence;	chr14:70949563	chr14:71141125~71143253:-
BRCA	cis	rs17711722	0.522	rs4642526	ENSG00000234585.5	CCT6P3	8.66	1.75e-17	6.69e-15	0.25	0.26	Calcium levels;	chr7:65751755	chr7:65038354~65074713:+
BRCA	cis	rs7712401	0.601	rs246265	ENSG00000263432.2	RN7SL689P	8.66	1.75e-17	6.71e-15	0.33	0.26	Mean platelet volume;	chr5:122919255	chr5:123022487~123022783:-
BRCA	cis	rs11098499	0.754	rs7672594	ENSG00000245958.5	RP11-33B1.1	-8.66	1.76e-17	6.72e-15	-0.24	-0.26	Corneal astigmatism;	chr4:119327388	chr4:119454791~119552025:+
BRCA	cis	rs113835537	0.529	rs11824771	ENSG00000255517.5	CTD-3074O7.5	-8.66	1.76e-17	6.73e-15	-0.33	-0.26	Airway imaging phenotypes;	chr11:66495079	chr11:66473490~66480233:-
BRCA	cis	rs2243480	1	rs10807702	ENSG00000273142.1	RP11-458F8.4	-8.66	1.76e-17	6.74e-15	-0.36	-0.26	Diabetic kidney disease;	chr7:66302856	chr7:66902857~66906297:+
BRCA	cis	rs10971721	0.749	rs72725371	ENSG00000260947.1	RP11-384P7.7	8.66	1.76e-17	6.74e-15	0.48	0.26	Body mass index;	chr9:33825013	chr9:33697459~33700986:+
BRCA	cis	rs875971	0.545	rs6969224	ENSG00000237310.1	GS1-124K5.4	8.66	1.76e-17	6.74e-15	0.32	0.26	Aortic root size;	chr7:66370011	chr7:66493706~66495474:+
BRCA	cis	rs10510102	0.872	rs12259144	ENSG00000276742.1	RP11-500G22.4	8.66	1.77e-17	6.75e-15	0.45	0.26	Breast cancer;	chr10:121965433	chr10:121956782~121957098:+
BRCA	cis	rs11098499	0.863	rs3775845	ENSG00000248280.1	RP11-33B1.2	8.66	1.77e-17	6.75e-15	0.27	0.26	Corneal astigmatism;	chr4:119511292	chr4:119440561~119450157:-
BRCA	cis	rs198389	0.589	rs535107	ENSG00000242349.4	NPPA-AS1	8.66	1.78e-17	6.8e-15	0.28	0.26	B-type natriuretic peptide levels;NT-proBNP levels in acute coronary syndrome;	chr1:11829411	chr1:11841017~11848079:+
BRCA	cis	rs875971	0.522	rs34973832	ENSG00000236529.1	RP13-254B10.1	8.66	1.78e-17	6.8e-15	0.28	0.26	Aortic root size;	chr7:65931217	chr7:65840212~65840596:+
BRCA	cis	rs10463554	0.927	rs158403	ENSG00000175749.11	EIF3KP1	8.66	1.78e-17	6.81e-15	0.37	0.26	Parkinson's disease;	chr5:103080064	chr5:103032376~103033031:+
BRCA	cis	rs801193	0.613	rs2659900	ENSG00000237310.1	GS1-124K5.4	8.66	1.79e-17	6.84e-15	0.27	0.26	Aortic root size;	chr7:66719456	chr7:66493706~66495474:+
BRCA	cis	rs11098499	0.863	rs10019674	ENSG00000245958.5	RP11-33B1.1	8.66	1.79e-17	6.85e-15	0.26	0.26	Corneal astigmatism;	chr4:119522334	chr4:119454791~119552025:+
BRCA	cis	rs4835473	0.932	rs13134327	ENSG00000251600.4	RP11-673E1.1	8.66	1.8e-17	6.86e-15	0.3	0.26	Immature fraction of reticulocytes;	chr4:143738642	chr4:143912331~143982454:+
BRCA	cis	rs7429990	0.864	rs1403578	ENSG00000229759.1	MRPS18AP1	-8.66	1.8e-17	6.86e-15	-0.29	-0.26	Educational attainment (years of education);	chr3:47617997	chr3:48256350~48256938:-
BRCA	cis	rs7429990	0.864	rs868255	ENSG00000229759.1	MRPS18AP1	-8.66	1.8e-17	6.86e-15	-0.29	-0.26	Educational attainment (years of education);	chr3:47619074	chr3:48256350~48256938:-
BRCA	cis	rs7429990	0.864	rs4858842	ENSG00000229759.1	MRPS18AP1	-8.66	1.8e-17	6.86e-15	-0.29	-0.26	Educational attainment (years of education);	chr3:47619574	chr3:48256350~48256938:-
BRCA	cis	rs896854	0.967	rs10956933	ENSG00000253528.2	RP11-347C18.4	8.66	1.8e-17	6.86e-15	0.27	0.26	Type 2 diabetes;	chr8:94955460	chr8:94974573~94974853:-
BRCA	cis	rs875971	0.522	rs709604	ENSG00000164669.11	INTS4P1	8.66	1.8e-17	6.86e-15	0.32	0.26	Aortic root size;	chr7:66032447	chr7:65141225~65234216:+
BRCA	cis	rs17023223	0.537	rs56708249	ENSG00000231365.4	RP11-418J17.1	-8.66	1.8e-17	6.88e-15	-0.33	-0.26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119050582	chr1:119140396~119275973:+
BRCA	cis	rs7429990	0.864	rs13085978	ENSG00000229759.1	MRPS18AP1	8.66	1.8e-17	6.88e-15	0.31	0.26	Educational attainment (years of education);	chr3:47608585	chr3:48256350~48256938:-
BRCA	cis	rs2933343	1	rs876755	ENSG00000261159.1	RP11-723O4.9	8.66	1.8e-17	6.89e-15	0.31	0.26	IgG glycosylation;	chr3:128909090	chr3:128859716~128860526:-
BRCA	cis	rs7772486	0.875	rs7767660	ENSG00000235652.6	RP11-545I5.3	8.66	1.81e-17	6.92e-15	0.26	0.26	Lobe attachment (rater-scored or self-reported);	chr6:146115414	chr6:145799409~145886585:+
BRCA	cis	rs10129255	0.957	rs1024349	ENSG00000223648.3	IGHV3-64	8.66	1.82e-17	6.95e-15	0.23	0.26	Kawasaki disease;	chr14:106689997	chr14:106643132~106658258:-
BRCA	cis	rs34375054	0.558	rs12578774	ENSG00000279233.1	RP11-158L12.4	-8.66	1.82e-17	6.96e-15	-0.31	-0.26	Post bronchodilator FEV1/FVC ratio;	chr12:125197215	chr12:125138245~125141711:+
BRCA	cis	rs1707322	0.963	rs10890373	ENSG00000280836.1	AL355480.1	-8.66	1.82e-17	6.96e-15	-0.34	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45928083	chr1:45581219~45581321:-
BRCA	cis	rs10971721	0.731	rs12377117	ENSG00000260947.1	RP11-384P7.7	8.66	1.83e-17	6.98e-15	0.47	0.26	Body mass index;	chr9:33806586	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.73	rs72725361	ENSG00000260947.1	RP11-384P7.7	8.66	1.83e-17	6.98e-15	0.47	0.26	Body mass index;	chr9:33806615	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.822	rs12376664	ENSG00000260947.1	RP11-384P7.7	8.66	1.83e-17	6.98e-15	0.47	0.26	Body mass index;	chr9:33808705	chr9:33697459~33700986:+
BRCA	cis	rs1707322	0.928	rs10732844	ENSG00000280836.1	AL355480.1	-8.66	1.83e-17	6.99e-15	-0.33	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45907016	chr1:45581219~45581321:-
BRCA	cis	rs11098499	0.575	rs907204	ENSG00000245958.5	RP11-33B1.1	-8.66	1.83e-17	7e-15	-0.24	-0.26	Corneal astigmatism;	chr4:119317499	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.575	rs907205	ENSG00000245958.5	RP11-33B1.1	-8.66	1.83e-17	7e-15	-0.24	-0.26	Corneal astigmatism;	chr4:119317509	chr4:119454791~119552025:+
BRCA	cis	rs2933343	1	rs789237	ENSG00000231305.3	RP11-723O4.2	8.66	1.84e-17	7.02e-15	0.32	0.26	IgG glycosylation;	chr3:128918118	chr3:128861313~128871540:-
BRCA	cis	rs11098499	0.691	rs28396837	ENSG00000245958.5	RP11-33B1.1	-8.66	1.84e-17	7.03e-15	-0.24	-0.26	Corneal astigmatism;	chr4:119350386	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.629	rs28369518	ENSG00000245958.5	RP11-33B1.1	-8.66	1.84e-17	7.03e-15	-0.24	-0.26	Corneal astigmatism;	chr4:119350475	chr4:119454791~119552025:+
BRCA	cis	rs8003054	0.589	rs999692	ENSG00000258515.1	RP11-203M5.7	-8.65	1.85e-17	7.07e-15	-0.22	-0.26	Facial morphology (factor 1, breadth of lateral portion of upper face);	chr14:20449506	chr14:20451305~20451918:+
BRCA	cis	rs1707322	1	rs6661500	ENSG00000280836.1	AL355480.1	-8.65	1.86e-17	7.09e-15	-0.33	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45999990	chr1:45581219~45581321:-
BRCA	cis	rs11098499	0.954	rs13133522	ENSG00000248280.1	RP11-33B1.2	8.65	1.86e-17	7.09e-15	0.26	0.26	Corneal astigmatism;	chr4:119403269	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.954	rs35091806	ENSG00000248280.1	RP11-33B1.2	8.65	1.86e-17	7.09e-15	0.26	0.26	Corneal astigmatism;	chr4:119404374	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.909	rs35165976	ENSG00000248280.1	RP11-33B1.2	8.65	1.86e-17	7.09e-15	0.26	0.26	Corneal astigmatism;	chr4:119404475	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.954	rs6846442	ENSG00000248280.1	RP11-33B1.2	8.65	1.86e-17	7.09e-15	0.26	0.26	Corneal astigmatism;	chr4:119405168	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.954	rs71614438	ENSG00000248280.1	RP11-33B1.2	8.65	1.86e-17	7.09e-15	0.26	0.26	Corneal astigmatism;	chr4:119450097	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.954	rs66506550	ENSG00000248280.1	RP11-33B1.2	8.65	1.86e-17	7.09e-15	0.26	0.26	Corneal astigmatism;	chr4:119450290	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.909	rs7659501	ENSG00000248280.1	RP11-33B1.2	8.65	1.86e-17	7.09e-15	0.26	0.26	Corneal astigmatism;	chr4:119450397	chr4:119440561~119450157:-
BRCA	cis	rs1707322	1	rs12060274	ENSG00000280836.1	AL355480.1	-8.65	1.86e-17	7.1e-15	-0.33	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45825390	chr1:45581219~45581321:-
BRCA	cis	rs875971	0.505	rs1167385	ENSG00000164669.11	INTS4P1	8.65	1.86e-17	7.1e-15	0.32	0.26	Aortic root size;	chr7:66048321	chr7:65141225~65234216:+
BRCA	cis	rs4660456	0.711	rs12409109	ENSG00000237899.1	RP4-739H11.3	-8.65	1.87e-17	7.11e-15	-0.39	-0.26	Platelet count;	chr1:40727216	chr1:40669089~40687588:-
BRCA	cis	rs10129255	0.957	rs2013423	ENSG00000223648.3	IGHV3-64	8.65	1.87e-17	7.12e-15	0.23	0.26	Kawasaki disease;	chr14:106690675	chr14:106643132~106658258:-
BRCA	cis	rs10129255	0.957	rs56134540	ENSG00000223648.3	IGHV3-64	8.65	1.87e-17	7.12e-15	0.23	0.26	Kawasaki disease;	chr14:106691290	chr14:106643132~106658258:-
BRCA	cis	rs783540	0.843	rs28374463	ENSG00000278603.1	RP13-608F4.5	-8.65	1.88e-17	7.15e-15	-0.33	-0.26	Schizophrenia;	chr15:82630613	chr15:82472203~82472426:+
BRCA	cis	rs7246657	0.722	rs968073	ENSG00000267422.1	CTD-2554C21.1	8.65	1.88e-17	7.15e-15	0.39	0.26	Coronary artery calcification;	chr19:37701120	chr19:37779686~37792865:+
BRCA	cis	rs11098499	0.754	rs10212714	ENSG00000245958.5	RP11-33B1.1	-8.65	1.88e-17	7.16e-15	-0.25	-0.26	Corneal astigmatism;	chr4:119333147	chr4:119454791~119552025:+
BRCA	cis	rs4835473	0.932	rs5015760	ENSG00000251600.4	RP11-673E1.1	-8.65	1.88e-17	7.18e-15	-0.3	-0.26	Immature fraction of reticulocytes;	chr4:143737955	chr4:143912331~143982454:+
BRCA	cis	rs7615952	0.673	rs35001498	ENSG00000171084.14	FAM86JP	8.65	1.89e-17	7.2e-15	0.52	0.26	Blood pressure (smoking interaction);	chr3:125909801	chr3:125916620~125930024:+
BRCA	cis	rs10971721	0.822	rs12376145	ENSG00000260947.1	RP11-384P7.7	8.65	1.89e-17	7.2e-15	0.47	0.26	Body mass index;	chr9:34050408	chr9:33697459~33700986:+
BRCA	cis	rs66887589	0.777	rs1814815	ENSG00000248280.1	RP11-33B1.2	8.65	1.89e-17	7.22e-15	0.24	0.26	Diastolic blood pressure;	chr4:119336936	chr4:119440561~119450157:-
BRCA	cis	rs7429990	0.833	rs2293226	ENSG00000229759.1	MRPS18AP1	8.65	1.9e-17	7.23e-15	0.29	0.26	Educational attainment (years of education);	chr3:47585292	chr3:48256350~48256938:-
BRCA	cis	rs2404602	0.967	rs2083762	ENSG00000259422.1	RP11-593F23.1	8.65	1.9e-17	7.24e-15	0.32	0.26	Blood metabolite levels;	chr15:76615035	chr15:76174891~76181486:-
BRCA	cis	rs10129255	0.912	rs67410411	ENSG00000223648.3	IGHV3-64	8.65	1.91e-17	7.29e-15	0.23	0.26	Kawasaki disease;	chr14:106680324	chr14:106643132~106658258:-
BRCA	cis	rs875971	0.571	rs78668714	ENSG00000222364.1	RNU6-96P	-8.65	1.92e-17	7.29e-15	-0.35	-0.26	Aortic root size;	chr7:66474464	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.545	rs316306	ENSG00000222364.1	RNU6-96P	8.65	1.92e-17	7.3e-15	0.34	0.26	Aortic root size;	chr7:66153687	chr7:66395191~66395286:+
BRCA	cis	rs11098499	0.863	rs10013305	ENSG00000245958.5	RP11-33B1.1	-8.65	1.93e-17	7.33e-15	-0.26	-0.26	Corneal astigmatism;	chr4:119529269	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.863	rs3775849	ENSG00000245958.5	RP11-33B1.1	-8.65	1.93e-17	7.33e-15	-0.26	-0.26	Corneal astigmatism;	chr4:119529753	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.818	rs7688802	ENSG00000245958.5	RP11-33B1.1	-8.65	1.93e-17	7.33e-15	-0.26	-0.26	Corneal astigmatism;	chr4:119530513	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.863	rs7695620	ENSG00000245958.5	RP11-33B1.1	-8.65	1.93e-17	7.33e-15	-0.26	-0.26	Corneal astigmatism;	chr4:119531621	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.863	rs12502389	ENSG00000245958.5	RP11-33B1.1	-8.65	1.93e-17	7.33e-15	-0.26	-0.26	Corneal astigmatism;	chr4:119533036	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.821	rs3775852	ENSG00000245958.5	RP11-33B1.1	-8.65	1.93e-17	7.33e-15	-0.26	-0.26	Corneal astigmatism;	chr4:119533401	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.82	rs6534140	ENSG00000245958.5	RP11-33B1.1	-8.65	1.93e-17	7.33e-15	-0.26	-0.26	Corneal astigmatism;	chr4:119534156	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.863	rs7657849	ENSG00000245958.5	RP11-33B1.1	-8.65	1.93e-17	7.33e-15	-0.26	-0.26	Corneal astigmatism;	chr4:119534339	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.863	rs10034450	ENSG00000245958.5	RP11-33B1.1	-8.65	1.93e-17	7.33e-15	-0.26	-0.26	Corneal astigmatism;	chr4:119534494	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.863	rs1480939	ENSG00000245958.5	RP11-33B1.1	-8.65	1.93e-17	7.33e-15	-0.26	-0.26	Corneal astigmatism;	chr4:119535772	chr4:119454791~119552025:+
BRCA	cis	rs7712401	0.601	rs193539	ENSG00000263432.2	RN7SL689P	8.65	1.93e-17	7.33e-15	0.33	0.26	Mean platelet volume;	chr5:122921922	chr5:123022487~123022783:-
BRCA	cis	rs11971779	0.68	rs4728465	ENSG00000273391.1	RP11-634H22.1	8.65	1.93e-17	7.35e-15	0.26	0.26	Diisocyanate-induced asthma;	chr7:139384315	chr7:139359032~139359566:-
BRCA	cis	rs11971779	0.715	rs55714903	ENSG00000273391.1	RP11-634H22.1	8.65	1.93e-17	7.35e-15	0.26	0.26	Diisocyanate-induced asthma;	chr7:139389844	chr7:139359032~139359566:-
BRCA	cis	rs2243480	0.901	rs778730	ENSG00000273142.1	RP11-458F8.4	-8.65	1.94e-17	7.36e-15	-0.36	-0.26	Diabetic kidney disease;	chr7:66358338	chr7:66902857~66906297:+
BRCA	cis	rs1198872	0.526	rs57282335	ENSG00000272275.1	RP11-791G15.2	-8.65	1.94e-17	7.38e-15	-0.35	-0.26	Cardiac Troponin-T levels;	chr2:10788081	chr2:10767875~10770058:-
BRCA	cis	rs673078	0.66	rs17440364	ENSG00000275759.1	RP11-131L12.3	-8.65	1.95e-17	7.4e-15	-0.4	-0.26	Glucose homeostasis traits;	chr12:118186613	chr12:118428281~118428870:+
BRCA	cis	rs66887589	0.777	rs2017058	ENSG00000248280.1	RP11-33B1.2	8.65	1.95e-17	7.42e-15	0.24	0.26	Diastolic blood pressure;	chr4:119336584	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.863	rs10030660	ENSG00000245958.5	RP11-33B1.1	-8.65	1.95e-17	7.42e-15	-0.26	-0.26	Corneal astigmatism;	chr4:119515549	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.863	rs13149407	ENSG00000245958.5	RP11-33B1.1	-8.65	1.95e-17	7.42e-15	-0.26	-0.26	Corneal astigmatism;	chr4:119516670	chr4:119454791~119552025:+
BRCA	cis	rs1707322	1	rs785480	ENSG00000280836.1	AL355480.1	-8.65	1.95e-17	7.43e-15	-0.33	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46026492	chr1:45581219~45581321:-
BRCA	cis	rs11098499	0.691	rs10010355	ENSG00000248280.1	RP11-33B1.2	8.65	1.96e-17	7.44e-15	0.25	0.26	Corneal astigmatism;	chr4:119339888	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.691	rs9307471	ENSG00000248280.1	RP11-33B1.2	8.65	1.96e-17	7.44e-15	0.25	0.26	Corneal astigmatism;	chr4:119340107	chr4:119440561~119450157:-
BRCA	cis	rs4266144	0.821	rs56237906	ENSG00000244515.1	KRT18P34	-8.65	1.96e-17	7.46e-15	-0.34	-0.26	Coronary artery disease;	chr3:157134684	chr3:157162663~157163932:-
BRCA	cis	rs801193	0.967	rs34356500	ENSG00000222364.1	RNU6-96P	-8.65	1.97e-17	7.48e-15	-0.29	-0.26	Aortic root size;	chr7:66771620	chr7:66395191~66395286:+
BRCA	cis	rs6570726	0.846	rs6570700	ENSG00000235652.6	RP11-545I5.3	8.65	1.98e-17	7.51e-15	0.26	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145610416	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.846	rs870491	ENSG00000235652.6	RP11-545I5.3	8.65	1.98e-17	7.51e-15	0.26	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145612254	chr6:145799409~145886585:+
BRCA	cis	rs875971	0.545	rs2460427	ENSG00000222364.1	RNU6-96P	8.65	1.98e-17	7.52e-15	0.34	0.26	Aortic root size;	chr7:66154218	chr7:66395191~66395286:+
BRCA	cis	rs2404602	0.716	rs12907805	ENSG00000259422.1	RP11-593F23.1	8.65	1.98e-17	7.53e-15	0.33	0.26	Blood metabolite levels;	chr15:76398265	chr15:76174891~76181486:-
BRCA	cis	rs10463554	0.927	rs34824	ENSG00000175749.11	EIF3KP1	8.65	1.98e-17	7.53e-15	0.37	0.26	Parkinson's disease;	chr5:103103227	chr5:103032376~103033031:+
BRCA	cis	rs748404	0.666	rs8027748	ENSG00000249839.1	AC011330.5	-8.65	1.98e-17	7.54e-15	-0.38	-0.26	Lung cancer;	chr15:43447622	chr15:43663654~43684339:-
BRCA	cis	rs10129255	0.5	rs7161740	ENSG00000211972.2	IGHV3-66	8.65	1.99e-17	7.55e-15	0.18	0.26	Kawasaki disease;	chr14:106776119	chr14:106675017~106675544:-
BRCA	cis	rs5751614	0.557	rs5759665	ENSG00000230701.2	FBXW4P1	8.65	1.99e-17	7.56e-15	0.32	0.26	Height;	chr22:23260033	chr22:23262767~23265005:+
BRCA	cis	rs10463554	0.963	rs11242485	ENSG00000175749.11	EIF3KP1	8.65	1.99e-17	7.57e-15	0.36	0.26	Parkinson's disease;	chr5:103046330	chr5:103032376~103033031:+
BRCA	cis	rs875971	0.545	rs73146609	ENSG00000222364.1	RNU6-96P	-8.65	1.99e-17	7.57e-15	-0.35	-0.26	Aortic root size;	chr7:66302477	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.545	rs2173571	ENSG00000222364.1	RNU6-96P	-8.65	1.99e-17	7.57e-15	-0.35	-0.26	Aortic root size;	chr7:66305392	chr7:66395191~66395286:+
BRCA	cis	rs11098499	0.754	rs1546503	ENSG00000245958.5	RP11-33B1.1	-8.65	2e-17	7.59e-15	-0.24	-0.26	Corneal astigmatism;	chr4:119320012	chr4:119454791~119552025:+
BRCA	cis	rs875971	0.545	rs7810213	ENSG00000222364.1	RNU6-96P	-8.65	2e-17	7.6e-15	-0.35	-0.26	Aortic root size;	chr7:66481592	chr7:66395191~66395286:+
BRCA	cis	rs7712401	0.562	rs384483	ENSG00000263432.2	RN7SL689P	-8.65	2e-17	7.6e-15	-0.31	-0.26	Mean platelet volume;	chr5:122925878	chr5:123022487~123022783:-
BRCA	cis	rs2274273	0.87	rs3783652	ENSG00000258413.1	RP11-665C16.6	-8.65	2e-17	7.6e-15	-0.33	-0.26	Protein biomarker;	chr14:55387490	chr14:55262767~55272075:-
BRCA	cis	rs9640161	0.659	rs77354576	ENSG00000261305.1	RP4-584D14.7	8.64	2.01e-17	7.62e-15	0.37	0.26	Blood protein levels;Circulating chemerin levels;	chr7:150316211	chr7:150341771~150342607:+
BRCA	cis	rs67981189	0.529	rs2526858	ENSG00000269927.1	RP6-91H8.3	-8.64	2.01e-17	7.64e-15	-0.34	-0.26	Schizophrenia;	chr14:70945623	chr14:71141125~71143253:-
BRCA	cis	rs11098499	0.863	rs1383533	ENSG00000248280.1	RP11-33B1.2	8.64	2.02e-17	7.66e-15	0.27	0.26	Corneal astigmatism;	chr4:119513421	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.779	rs80242894	ENSG00000248280.1	RP11-33B1.2	8.64	2.02e-17	7.67e-15	0.26	0.26	Corneal astigmatism;	chr4:119454597	chr4:119440561~119450157:-
BRCA	cis	rs7773456	0.74	rs4140625	ENSG00000228412.5	RP4-625H18.2	-8.64	2.02e-17	7.68e-15	-0.35	-0.26	Lupus nephritis in systemic lupus erythematosus;	chr6:19818109	chr6:19802164~19804752:-
BRCA	cis	rs10129255	0.912	rs8011090	ENSG00000223648.3	IGHV3-64	8.64	2.03e-17	7.72e-15	0.23	0.26	Kawasaki disease;	chr14:106678896	chr14:106643132~106658258:-
BRCA	cis	rs11976180	0.517	rs6949375	ENSG00000204959.4	ARHGEF34P	8.64	2.03e-17	7.73e-15	0.43	0.26	Obesity-related traits;	chr7:144076758	chr7:144272445~144286966:-
BRCA	cis	rs17711722	0.64	rs13237956	ENSG00000222364.1	RNU6-96P	-8.64	2.04e-17	7.73e-15	-0.3	-0.26	Calcium levels;	chr7:65853042	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.505	rs1167386	ENSG00000164669.11	INTS4P1	8.64	2.04e-17	7.75e-15	0.32	0.26	Aortic root size;	chr7:66048109	chr7:65141225~65234216:+
BRCA	cis	rs867371	0.656	rs2665103	ENSG00000278603.1	RP13-608F4.5	-8.64	2.04e-17	7.75e-15	-0.33	-0.26	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82140374	chr15:82472203~82472426:+
BRCA	cis	rs4835473	0.932	rs12505628	ENSG00000251600.4	RP11-673E1.1	-8.64	2.04e-17	7.76e-15	-0.3	-0.26	Immature fraction of reticulocytes;	chr4:143758468	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.9	rs12505663	ENSG00000251600.4	RP11-673E1.1	-8.64	2.04e-17	7.76e-15	-0.3	-0.26	Immature fraction of reticulocytes;	chr4:143758491	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.868	rs12513078	ENSG00000251600.4	RP11-673E1.1	-8.64	2.04e-17	7.76e-15	-0.3	-0.26	Immature fraction of reticulocytes;	chr4:143758494	chr4:143912331~143982454:+
BRCA	cis	rs11673344	0.73	rs1644641	ENSG00000226686.6	LINC01535	8.64	2.05e-17	7.76e-15	0.34	0.26	Obesity-related traits;	chr19:36971237	chr19:37251912~37265535:+
BRCA	cis	rs881375	0.9	rs1930786	ENSG00000226752.6	PSMD5-AS1	-8.64	2.05e-17	7.76e-15	-0.3	-0.26	Rheumatoid arthritis;	chr9:120929191	chr9:120824828~120854385:+
BRCA	cis	rs875971	0.545	rs67397473	ENSG00000222364.1	RNU6-96P	-8.64	2.06e-17	7.8e-15	-0.34	-0.26	Aortic root size;	chr7:66168318	chr7:66395191~66395286:+
BRCA	cis	rs7429990	0.864	rs2047559	ENSG00000229759.1	MRPS18AP1	-8.64	2.06e-17	7.82e-15	-0.29	-0.26	Educational attainment (years of education);	chr3:47704695	chr3:48256350~48256938:-
BRCA	cis	rs10463554	0.963	rs34772	ENSG00000175749.11	EIF3KP1	8.64	2.06e-17	7.82e-15	0.37	0.26	Parkinson's disease;	chr5:103114808	chr5:103032376~103033031:+
BRCA	cis	rs11098499	0.789	rs9991166	ENSG00000245958.5	RP11-33B1.1	-8.64	2.07e-17	7.83e-15	-0.24	-0.26	Corneal astigmatism;	chr4:119316696	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.708	rs10005237	ENSG00000245958.5	RP11-33B1.1	-8.64	2.07e-17	7.83e-15	-0.24	-0.26	Corneal astigmatism;	chr4:119316742	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.754	rs10213267	ENSG00000245958.5	RP11-33B1.1	-8.64	2.07e-17	7.83e-15	-0.24	-0.26	Corneal astigmatism;	chr4:119317919	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.754	rs10212775	ENSG00000245958.5	RP11-33B1.1	-8.64	2.07e-17	7.83e-15	-0.24	-0.26	Corneal astigmatism;	chr4:119318089	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.754	rs2964	ENSG00000245958.5	RP11-33B1.1	-8.64	2.07e-17	7.83e-15	-0.24	-0.26	Corneal astigmatism;	chr4:119318976	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.754	rs1511025	ENSG00000245958.5	RP11-33B1.1	-8.64	2.07e-17	7.83e-15	-0.24	-0.26	Corneal astigmatism;	chr4:119319083	chr4:119454791~119552025:+
BRCA	cis	rs4835473	0.9	rs4835009	ENSG00000251600.4	RP11-673E1.1	-8.64	2.08e-17	7.89e-15	-0.3	-0.26	Immature fraction of reticulocytes;	chr4:143746130	chr4:143912331~143982454:+
BRCA	cis	rs150992	0.504	rs6878136	ENSG00000248489.1	CTD-2007H13.3	-8.64	2.08e-17	7.89e-15	-0.34	-0.26	Body mass index;	chr5:99022487	chr5:98929171~98995013:+
BRCA	cis	rs11098499	0.754	rs1980027	ENSG00000245958.5	RP11-33B1.1	-8.64	2.08e-17	7.9e-15	-0.25	-0.26	Corneal astigmatism;	chr4:119330422	chr4:119454791~119552025:+
BRCA	cis	rs1707322	1	rs6682683	ENSG00000280836.1	AL355480.1	-8.64	2.09e-17	7.91e-15	-0.33	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45876665	chr1:45581219~45581321:-
BRCA	cis	rs875971	1	rs1167612	ENSG00000237310.1	GS1-124K5.4	-8.64	2.09e-17	7.92e-15	-0.27	-0.26	Aortic root size;	chr7:66102989	chr7:66493706~66495474:+
BRCA	cis	rs7429990	0.864	rs7621236	ENSG00000229759.1	MRPS18AP1	-8.64	2.1e-17	7.94e-15	-0.29	-0.26	Educational attainment (years of education);	chr3:47646677	chr3:48256350~48256938:-
BRCA	cis	rs7429990	0.864	rs7624474	ENSG00000229759.1	MRPS18AP1	-8.64	2.1e-17	7.94e-15	-0.29	-0.26	Educational attainment (years of education);	chr3:47647786	chr3:48256350~48256938:-
BRCA	cis	rs7429990	0.864	rs4858846	ENSG00000229759.1	MRPS18AP1	-8.64	2.1e-17	7.94e-15	-0.29	-0.26	Educational attainment (years of education);	chr3:47654591	chr3:48256350~48256938:-
BRCA	cis	rs875971	0.522	rs4502988	ENSG00000164669.11	INTS4P1	-8.64	2.1e-17	7.96e-15	-0.32	-0.26	Aortic root size;	chr7:65832759	chr7:65141225~65234216:+
BRCA	cis	rs2280018	0.526	rs2941257	ENSG00000188599.16	NPIPP1	-8.64	2.11e-17	7.98e-15	-0.23	-0.26	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15072588	chr16:15104312~15123498:-
BRCA	cis	rs62355901	0.599	rs10513090	ENSG00000271828.1	CTD-2310F14.1	-8.64	2.11e-17	8.01e-15	-0.45	-0.26	Breast cancer;	chr5:56758238	chr5:56927874~56929573:+
BRCA	cis	rs55665837	0.539	rs10500804	ENSG00000251991.1	RNU7-49P	8.64	2.12e-17	8.02e-15	0.29	0.26	Vitamin D levels;	chr11:14888727	chr11:14478892~14478953:+
BRCA	cis	rs9640161	0.75	rs59211922	ENSG00000261305.1	RP4-584D14.7	8.64	2.13e-17	8.05e-15	0.37	0.26	Blood protein levels;Circulating chemerin levels;	chr7:150326701	chr7:150341771~150342607:+
BRCA	cis	rs950776	0.593	rs588765	ENSG00000261762.1	RP11-650L12.2	-8.64	2.13e-17	8.06e-15	-0.28	-0.26	Sudden cardiac arrest;	chr15:78573083	chr15:78589123~78591276:-
BRCA	cis	rs1707322	1	rs3922887	ENSG00000280836.1	AL355480.1	-8.64	2.14e-17	8.12e-15	-0.33	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46008130	chr1:45581219~45581321:-
BRCA	cis	rs1707322	1	rs3922886	ENSG00000280836.1	AL355480.1	-8.64	2.14e-17	8.12e-15	-0.33	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46008230	chr1:45581219~45581321:-
BRCA	cis	rs193541	0.632	rs30023	ENSG00000263432.2	RN7SL689P	8.64	2.15e-17	8.13e-15	0.35	0.26	Glucose homeostasis traits;	chr5:122949604	chr5:123022487~123022783:-
BRCA	cis	rs875971	0.545	rs66594357	ENSG00000222364.1	RNU6-96P	-8.64	2.15e-17	8.13e-15	-0.34	-0.26	Aortic root size;	chr7:66327797	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.522	rs4718285	ENSG00000164669.11	INTS4P1	-8.64	2.16e-17	8.17e-15	-0.32	-0.26	Aortic root size;	chr7:65827018	chr7:65141225~65234216:+
BRCA	cis	rs881375	0.678	rs10739581	ENSG00000226752.6	PSMD5-AS1	-8.64	2.16e-17	8.18e-15	-0.3	-0.26	Rheumatoid arthritis;	chr9:120934593	chr9:120824828~120854385:+
BRCA	cis	rs11098499	0.954	rs6838814	ENSG00000248280.1	RP11-33B1.2	8.63	2.18e-17	8.27e-15	0.26	0.26	Corneal astigmatism;	chr4:119471288	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.863	rs11098531	ENSG00000248280.1	RP11-33B1.2	8.63	2.2e-17	8.34e-15	0.27	0.26	Corneal astigmatism;	chr4:119543846	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.863	rs28718422	ENSG00000248280.1	RP11-33B1.2	8.63	2.2e-17	8.34e-15	0.27	0.26	Corneal astigmatism;	chr4:119545149	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.818	rs12498599	ENSG00000248280.1	RP11-33B1.2	8.63	2.2e-17	8.34e-15	0.27	0.26	Corneal astigmatism;	chr4:119547348	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.863	rs10009626	ENSG00000248280.1	RP11-33B1.2	8.63	2.2e-17	8.34e-15	0.27	0.26	Corneal astigmatism;	chr4:119548850	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.644	rs7693919	ENSG00000248280.1	RP11-33B1.2	8.63	2.21e-17	8.35e-15	0.26	0.26	Corneal astigmatism;	chr4:119619416	chr4:119440561~119450157:-
BRCA	cis	rs875971	0.965	rs6971509	ENSG00000237310.1	GS1-124K5.4	-8.63	2.21e-17	8.36e-15	-0.27	-0.26	Aortic root size;	chr7:66249983	chr7:66493706~66495474:+
BRCA	cis	rs10463554	0.892	rs464591	ENSG00000175749.11	EIF3KP1	8.63	2.21e-17	8.37e-15	0.37	0.26	Parkinson's disease;	chr5:103111600	chr5:103032376~103033031:+
BRCA	cis	rs7429990	0.727	rs61675361	ENSG00000229759.1	MRPS18AP1	8.63	2.21e-17	8.38e-15	0.31	0.26	Educational attainment (years of education);	chr3:47610630	chr3:48256350~48256938:-
BRCA	cis	rs3814244	0.528	rs2870960	ENSG00000236946.2	HNRNPA1P70	-8.63	2.21e-17	8.38e-15	-0.22	-0.26	Itch intensity from mosquito bite adjusted by bite size;	chr12:68032848	chr12:68035767~68036853:+
BRCA	cis	rs66887589	0.748	rs28439855	ENSG00000248280.1	RP11-33B1.2	8.63	2.21e-17	8.38e-15	0.24	0.26	Diastolic blood pressure;	chr4:119341101	chr4:119440561~119450157:-
BRCA	cis	rs7923609	0.578	rs10761789	ENSG00000232075.1	MRPL35P2	-8.63	2.22e-17	8.38e-15	-0.33	-0.26	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63636804	chr10:63634317~63634827:-
BRCA	cis	rs55757919	1	rs55757919	ENSG00000237595.3	RP11-112L6.3	8.63	2.22e-17	8.38e-15	0.38	0.26	Monocyte percentage of white cells;	chr20:50132011	chr20:50162765~50166102:-
BRCA	cis	rs12701220	0.655	rs6955290	ENSG00000229043.2	AC091729.9	8.63	2.22e-17	8.39e-15	0.36	0.26	Bronchopulmonary dysplasia;	chr7:1111430	chr7:1160374~1165267:+
BRCA	cis	rs1707322	1	rs10890355	ENSG00000280836.1	AL355480.1	-8.63	2.22e-17	8.39e-15	-0.33	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45851676	chr1:45581219~45581321:-
BRCA	cis	rs1707322	1	rs11211204	ENSG00000280836.1	AL355480.1	-8.63	2.22e-17	8.39e-15	-0.33	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45852192	chr1:45581219~45581321:-
BRCA	cis	rs150992	0.504	rs7719562	ENSG00000248489.1	CTD-2007H13.3	-8.63	2.23e-17	8.42e-15	-0.34	-0.26	Body mass index;	chr5:99029419	chr5:98929171~98995013:+
BRCA	cis	rs1789	0.592	rs1125378	ENSG00000273133.1	RP11-799M12.2	-8.63	2.23e-17	8.44e-15	-0.34	-0.26	Blood protein levels;	chr4:15538867	chr4:15563698~15564253:-
BRCA	cis	rs11098499	0.754	rs9991959	ENSG00000248280.1	RP11-33B1.2	-8.63	2.23e-17	8.44e-15	-0.25	-0.26	Corneal astigmatism;	chr4:119332618	chr4:119440561~119450157:-
BRCA	cis	rs950880	0.71	rs10490203	ENSG00000234389.1	AC007278.3	-8.63	2.24e-17	8.47e-15	-0.25	-0.26	Serum protein levels (sST2);	chr2:102442777	chr2:102438713~102440475:+
BRCA	cis	rs11098499	0.754	rs12510269	ENSG00000245958.5	RP11-33B1.1	-8.63	2.24e-17	8.48e-15	-0.24	-0.26	Corneal astigmatism;	chr4:119320491	chr4:119454791~119552025:+
BRCA	cis	rs10129255	0.5	rs6576225	ENSG00000211972.2	IGHV3-66	8.63	2.24e-17	8.49e-15	0.18	0.26	Kawasaki disease;	chr14:106778120	chr14:106675017~106675544:-
BRCA	cis	rs10129255	0.5	rs6576226	ENSG00000211972.2	IGHV3-66	8.63	2.24e-17	8.49e-15	0.18	0.26	Kawasaki disease;	chr14:106778135	chr14:106675017~106675544:-
BRCA	cis	rs10463554	0.824	rs3776868	ENSG00000175749.11	EIF3KP1	8.63	2.26e-17	8.55e-15	0.35	0.26	Parkinson's disease;	chr5:102963012	chr5:103032376~103033031:+
BRCA	cis	rs6570726	0.846	rs6899900	ENSG00000235652.6	RP11-545I5.3	8.63	2.26e-17	8.56e-15	0.25	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145562737	chr6:145799409~145886585:+
BRCA	cis	rs11098499	0.754	rs66900435	ENSG00000245958.5	RP11-33B1.1	-8.63	2.26e-17	8.56e-15	-0.25	-0.26	Corneal astigmatism;	chr4:119328270	chr4:119454791~119552025:+
BRCA	cis	rs1075265	0.935	rs6545384	ENSG00000233266.1	HMGB1P31	8.63	2.26e-17	8.56e-15	0.31	0.26	Chronotype;Morning vs. evening chronotype;	chr2:54073927	chr2:54051334~54051760:+
BRCA	cis	rs9287719	0.837	rs4233883	ENSG00000234818.1	AC092687.5	8.63	2.27e-17	8.58e-15	0.3	0.26	Prostate cancer;	chr2:10615470	chr2:10589166~10604830:+
BRCA	cis	rs7937890	0.559	rs1116739	ENSG00000251991.1	RNU7-49P	8.63	2.28e-17	8.61e-15	0.29	0.26	Mitochondrial DNA levels;	chr11:14467636	chr11:14478892~14478953:+
BRCA	cis	rs7429990	0.828	rs11712152	ENSG00000229759.1	MRPS18AP1	8.63	2.28e-17	8.63e-15	0.31	0.26	Educational attainment (years of education);	chr3:47655314	chr3:48256350~48256938:-
BRCA	cis	rs6921919	0.887	rs7766356	ENSG00000216901.1	AL022393.7	8.63	2.29e-17	8.64e-15	0.44	0.26	Autism spectrum disorder or schizophrenia;	chr6:28432761	chr6:28176188~28176674:+
BRCA	cis	rs11023332	1	rs11023332	ENSG00000251991.1	RNU7-49P	8.63	2.29e-17	8.67e-15	0.29	0.26	Vitamin D levels;Adiponectin levels;	chr11:14762564	chr11:14478892~14478953:+
BRCA	cis	rs4835473	0.932	rs11721523	ENSG00000251600.4	RP11-673E1.1	-8.63	2.3e-17	8.7e-15	-0.3	-0.26	Immature fraction of reticulocytes;	chr4:143767301	chr4:143912331~143982454:+
BRCA	cis	rs11098499	0.57	rs6832740	ENSG00000248280.1	RP11-33B1.2	8.63	2.3e-17	8.71e-15	0.26	0.26	Corneal astigmatism;	chr4:119624981	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.644	rs6855918	ENSG00000248280.1	RP11-33B1.2	8.63	2.3e-17	8.71e-15	0.26	0.26	Corneal astigmatism;	chr4:119625144	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.722	rs10006192	ENSG00000248280.1	RP11-33B1.2	8.63	2.31e-17	8.72e-15	0.25	0.26	Corneal astigmatism;	chr4:119341867	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.615	rs28551750	ENSG00000248280.1	RP11-33B1.2	8.63	2.31e-17	8.72e-15	0.25	0.26	Corneal astigmatism;	chr4:119343746	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.691	rs9995716	ENSG00000248280.1	RP11-33B1.2	8.63	2.31e-17	8.72e-15	0.25	0.26	Corneal astigmatism;	chr4:119343841	chr4:119440561~119450157:-
BRCA	cis	rs2688482	0.512	rs3103953	ENSG00000224769.1	AC069213.1	-8.63	2.31e-17	8.73e-15	-0.48	-0.26	Lung disease severity in cystic fibrosis;	chr3:195793726	chr3:195614947~195620233:+
BRCA	cis	rs11098499	0.863	rs3733525	ENSG00000245958.5	RP11-33B1.1	-8.63	2.32e-17	8.77e-15	-0.26	-0.26	Corneal astigmatism;	chr4:119525893	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.863	rs3775847	ENSG00000245958.5	RP11-33B1.1	-8.63	2.32e-17	8.77e-15	-0.26	-0.26	Corneal astigmatism;	chr4:119526487	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.863	rs3775848	ENSG00000245958.5	RP11-33B1.1	-8.63	2.32e-17	8.77e-15	-0.26	-0.26	Corneal astigmatism;	chr4:119526569	chr4:119454791~119552025:+
BRCA	cis	rs6570726	0.791	rs4896820	ENSG00000235652.6	RP11-545I5.3	8.63	2.32e-17	8.77e-15	0.25	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145573821	chr6:145799409~145886585:+
BRCA	cis	rs875971	0.522	rs34973832	ENSG00000222364.1	RNU6-96P	-8.63	2.33e-17	8.78e-15	-0.3	-0.26	Aortic root size;	chr7:65931217	chr7:66395191~66395286:+
BRCA	cis	rs10971721	0.822	rs10971818	ENSG00000260947.1	RP11-384P7.7	-8.63	2.33e-17	8.79e-15	-0.43	-0.26	Body mass index;	chr9:33952155	chr9:33697459~33700986:+
BRCA	cis	rs67981189	0.529	rs2526872	ENSG00000269927.1	RP6-91H8.3	-8.63	2.33e-17	8.79e-15	-0.34	-0.26	Schizophrenia;	chr14:70918168	chr14:71141125~71143253:-
BRCA	cis	rs2439831	0.557	rs13329084	ENSG00000249839.1	AC011330.5	8.63	2.33e-17	8.8e-15	0.5	0.26	Lung cancer in ever smokers;	chr15:43858865	chr15:43663654~43684339:-
BRCA	cis	rs1707322	0.964	rs7546237	ENSG00000280836.1	AL355480.1	-8.63	2.33e-17	8.81e-15	-0.33	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45819938	chr1:45581219~45581321:-
BRCA	cis	rs783540	0.967	rs1269134	ENSG00000278603.1	RP13-608F4.5	-8.63	2.34e-17	8.83e-15	-0.33	-0.26	Schizophrenia;	chr15:82613877	chr15:82472203~82472426:+
BRCA	cis	rs11098499	0.691	rs17009144	ENSG00000245958.5	RP11-33B1.1	8.63	2.34e-17	8.83e-15	0.24	0.26	Corneal astigmatism;	chr4:119349640	chr4:119454791~119552025:+
BRCA	cis	rs62445005	1	rs62445005	ENSG00000211699.2	TRGV3	8.63	2.34e-17	8.85e-15	0.3	0.26	Shingles;	chr7:38346957	chr7:38358512~38359162:-
BRCA	cis	rs10463554	0.963	rs257319	ENSG00000175749.11	EIF3KP1	8.63	2.35e-17	8.89e-15	0.36	0.26	Parkinson's disease;	chr5:103110123	chr5:103032376~103033031:+
BRCA	cis	rs10463554	0.927	rs39666	ENSG00000175749.11	EIF3KP1	8.63	2.35e-17	8.89e-15	0.36	0.26	Parkinson's disease;	chr5:103111423	chr5:103032376~103033031:+
BRCA	cis	rs10463554	0.927	rs34769	ENSG00000175749.11	EIF3KP1	8.63	2.35e-17	8.89e-15	0.36	0.26	Parkinson's disease;	chr5:103111523	chr5:103032376~103033031:+
BRCA	cis	rs875971	0.516	rs6945322	ENSG00000222364.1	RNU6-96P	-8.62	2.36e-17	8.9e-15	-0.3	-0.26	Aortic root size;	chr7:65871069	chr7:66395191~66395286:+
BRCA	cis	rs11098499	0.954	rs7437420	ENSG00000248280.1	RP11-33B1.2	8.62	2.36e-17	8.9e-15	0.26	0.26	Corneal astigmatism;	chr4:119391748	chr4:119440561~119450157:-
BRCA	cis	rs2115630	0.967	rs10438428	ENSG00000225151.9	GOLGA2P7	8.62	2.37e-17	8.93e-15	0.28	0.26	P wave terminal force;	chr15:84787514	chr15:84199311~84230136:-
BRCA	cis	rs11098499	0.821	rs10032151	ENSG00000248280.1	RP11-33B1.2	8.62	2.37e-17	8.94e-15	0.26	0.26	Corneal astigmatism;	chr4:119470473	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.865	rs10032158	ENSG00000248280.1	RP11-33B1.2	8.62	2.37e-17	8.94e-15	0.26	0.26	Corneal astigmatism;	chr4:119470477	chr4:119440561~119450157:-
BRCA	cis	rs5760092	0.618	rs5996631	ENSG00000099984.9	GSTT2	8.62	2.38e-17	8.97e-15	0.35	0.26	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23980123~23983911:+
BRCA	cis	rs10129255	0.556	rs8010005	ENSG00000211972.2	IGHV3-66	8.62	2.39e-17	9e-15	0.18	0.26	Kawasaki disease;	chr14:106777987	chr14:106675017~106675544:-
BRCA	cis	rs10129255	0.556	rs6576224	ENSG00000211972.2	IGHV3-66	8.62	2.39e-17	9e-15	0.18	0.26	Kawasaki disease;	chr14:106777997	chr14:106675017~106675544:-
BRCA	cis	rs10129255	0.518	rs8010020	ENSG00000211972.2	IGHV3-66	8.62	2.39e-17	9e-15	0.18	0.26	Kawasaki disease;	chr14:106778016	chr14:106675017~106675544:-
BRCA	cis	rs55665837	0.54	rs12290926	ENSG00000251991.1	RNU7-49P	8.62	2.4e-17	9.07e-15	0.29	0.26	Vitamin D levels;	chr11:14673500	chr11:14478892~14478953:+
BRCA	cis	rs6570726	0.764	rs4896821	ENSG00000235652.6	RP11-545I5.3	8.62	2.41e-17	9.1e-15	0.25	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145575045	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.686	rs10872579	ENSG00000235652.6	RP11-545I5.3	8.62	2.42e-17	9.12e-15	0.26	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145644876	chr6:145799409~145886585:+
BRCA	cis	rs10971721	0.822	rs72727351	ENSG00000260947.1	RP11-384P7.7	8.62	2.43e-17	9.15e-15	0.46	0.26	Body mass index;	chr9:33950434	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.822	rs72727353	ENSG00000260947.1	RP11-384P7.7	8.62	2.43e-17	9.15e-15	0.46	0.26	Body mass index;	chr9:33950824	chr9:33697459~33700986:+
BRCA	cis	rs11098499	0.644	rs28787668	ENSG00000248280.1	RP11-33B1.2	8.62	2.44e-17	9.21e-15	0.26	0.26	Corneal astigmatism;	chr4:119633532	chr4:119440561~119450157:-
BRCA	cis	rs638893	0.842	rs480791	ENSG00000278376.1	RP11-158I9.8	-8.62	2.45e-17	9.24e-15	-0.37	-0.26	Vitiligo;	chr11:118833546	chr11:118791254~118793137:+
BRCA	cis	rs7085104	0.7	rs10883785	ENSG00000213061.2	PFN1P11	8.62	2.48e-17	9.33e-15	0.33	0.26	Immature fraction of reticulocytes;Schizophrenia;	chr10:102843831	chr10:102838011~102845473:-
BRCA	cis	rs7688540	0.771	rs7674560	ENSG00000275426.1	CH17-262A2.1	8.62	2.48e-17	9.34e-15	0.38	0.26	Facial morphology (factor 6, height of vermillion lower lip);	chr4:269530	chr4:149738~150317:+
BRCA	cis	rs10971721	0.731	rs10971782	ENSG00000260947.1	RP11-384P7.7	8.62	2.48e-17	9.36e-15	0.46	0.26	Body mass index;	chr9:33909466	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.908	rs10971787	ENSG00000260947.1	RP11-384P7.7	8.62	2.48e-17	9.36e-15	0.46	0.26	Body mass index;	chr9:33914414	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.822	rs72727327	ENSG00000260947.1	RP11-384P7.7	8.62	2.48e-17	9.36e-15	0.46	0.26	Body mass index;	chr9:33918818	chr9:33697459~33700986:+
BRCA	cis	rs6545883	0.562	rs777588	ENSG00000271889.1	RP11-493E12.1	8.62	2.48e-17	9.36e-15	0.32	0.26	Tuberculosis;	chr2:61199685	chr2:61151433~61162105:-
BRCA	cis	rs3096299	0.933	rs2965824	ENSG00000274627.1	RP11-104N10.2	8.62	2.48e-17	9.36e-15	0.27	0.26	Multiple myeloma (IgH translocation);	chr16:89388898	chr16:89516797~89522217:+
BRCA	cis	rs1707322	1	rs6675222	ENSG00000280836.1	AL355480.1	-8.62	2.5e-17	9.4e-15	-0.33	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45860904	chr1:45581219~45581321:-
BRCA	cis	rs1707322	1	rs4660895	ENSG00000280836.1	AL355480.1	-8.62	2.5e-17	9.4e-15	-0.33	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45864067	chr1:45581219~45581321:-
BRCA	cis	rs1707322	1	rs4660318	ENSG00000280836.1	AL355480.1	-8.62	2.5e-17	9.4e-15	-0.33	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45869204	chr1:45581219~45581321:-
BRCA	cis	rs1707322	1	rs10890360	ENSG00000280836.1	AL355480.1	-8.62	2.5e-17	9.4e-15	-0.33	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45872772	chr1:45581219~45581321:-
BRCA	cis	rs67981189	0.529	rs2526850	ENSG00000269927.1	RP6-91H8.3	-8.62	2.51e-17	9.46e-15	-0.34	-0.26	Schizophrenia;	chr14:70950532	chr14:71141125~71143253:-
BRCA	cis	rs75422866	0.51	rs35784744	ENSG00000257433.4	RP1-197B17.3	8.62	2.52e-17	9.49e-15	0.57	0.26	Pneumonia;	chr12:47729646	chr12:47706085~47742294:+
BRCA	cis	rs2153535	0.967	rs10484750	ENSG00000230939.1	RP11-314C16.1	8.62	2.53e-17	9.53e-15	0.29	0.26	Motion sickness;	chr6:8378376	chr6:8784178~8785445:+
BRCA	cis	rs7085104	0.632	rs7096475	ENSG00000213061.2	PFN1P11	8.62	2.53e-17	9.53e-15	0.33	0.26	Immature fraction of reticulocytes;Schizophrenia;	chr10:102849919	chr10:102838011~102845473:-
BRCA	cis	rs6570726	0.791	rs4332001	ENSG00000235652.6	RP11-545I5.3	8.62	2.54e-17	9.55e-15	0.25	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145613705	chr6:145799409~145886585:+
BRCA	cis	rs4660456	0.913	rs3767951	ENSG00000237899.1	RP4-739H11.3	-8.62	2.54e-17	9.55e-15	-0.38	-0.26	Platelet count;	chr1:40767359	chr1:40669089~40687588:-
BRCA	cis	rs10510102	0.872	rs11814703	ENSG00000276742.1	RP11-500G22.4	8.62	2.54e-17	9.55e-15	0.45	0.26	Breast cancer;	chr10:121964774	chr10:121956782~121957098:+
BRCA	cis	rs11971779	0.711	rs6961204	ENSG00000273391.1	RP11-634H22.1	8.62	2.54e-17	9.56e-15	0.28	0.26	Diisocyanate-induced asthma;	chr7:139362653	chr7:139359032~139359566:-
BRCA	cis	rs1061377	0.861	rs35739603	ENSG00000249685.1	RP11-360F5.3	8.62	2.54e-17	9.57e-15	0.32	0.26	Uric acid levels;	chr4:39107938	chr4:39133913~39135608:+
BRCA	cis	rs875971	1	rs7792762	ENSG00000237310.1	GS1-124K5.4	8.62	2.55e-17	9.58e-15	0.27	0.26	Aortic root size;	chr7:66539151	chr7:66493706~66495474:+
BRCA	cis	rs17711722	0.675	rs6947132	ENSG00000222364.1	RNU6-96P	8.62	2.55e-17	9.61e-15	0.3	0.26	Calcium levels;	chr7:65808508	chr7:66395191~66395286:+
BRCA	cis	rs7429990	0.864	rs7637950	ENSG00000229759.1	MRPS18AP1	-8.61	2.56e-17	9.63e-15	-0.29	-0.26	Educational attainment (years of education);	chr3:47758204	chr3:48256350~48256938:-
BRCA	cis	rs2115630	0.967	rs11073731	ENSG00000225151.9	GOLGA2P7	8.61	2.56e-17	9.64e-15	0.29	0.26	P wave terminal force;	chr15:84811882	chr15:84199311~84230136:-
BRCA	cis	rs11098499	0.657	rs71614442	ENSG00000248280.1	RP11-33B1.2	8.61	2.56e-17	9.64e-15	0.26	0.26	Corneal astigmatism;	chr4:119458191	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.954	rs2892848	ENSG00000248280.1	RP11-33B1.2	8.61	2.56e-17	9.64e-15	0.26	0.26	Corneal astigmatism;	chr4:119460186	chr4:119440561~119450157:-
BRCA	cis	rs2274273	0.84	rs10142448	ENSG00000258413.1	RP11-665C16.6	8.61	2.57e-17	9.65e-15	0.31	0.26	Protein biomarker;	chr14:55371390	chr14:55262767~55272075:-
BRCA	cis	rs11098499	0.722	rs7673476	ENSG00000245958.5	RP11-33B1.1	-8.61	2.57e-17	9.67e-15	-0.24	-0.26	Corneal astigmatism;	chr4:119327528	chr4:119454791~119552025:+
BRCA	cis	rs875971	0.545	rs73142265	ENSG00000237310.1	GS1-124K5.4	8.61	2.58e-17	9.69e-15	0.31	0.26	Aortic root size;	chr7:66234510	chr7:66493706~66495474:+
BRCA	cis	rs11098499	0.739	rs10031033	ENSG00000245958.5	RP11-33B1.1	-8.61	2.58e-17	9.71e-15	-0.25	-0.26	Corneal astigmatism;	chr4:119230297	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.754	rs2036860	ENSG00000245958.5	RP11-33B1.1	-8.61	2.6e-17	9.76e-15	-0.24	-0.26	Corneal astigmatism;	chr4:119327779	chr4:119454791~119552025:+
BRCA	cis	rs9640161	0.789	rs4554381	ENSG00000261305.1	RP4-584D14.7	8.61	2.6e-17	9.76e-15	0.37	0.26	Blood protein levels;Circulating chemerin levels;	chr7:150328478	chr7:150341771~150342607:+
BRCA	cis	rs26232	0.52	rs26432	ENSG00000175749.11	EIF3KP1	-8.61	2.6e-17	9.77e-15	-0.35	-0.26	Rheumatoid arthritis;	chr5:103030006	chr5:103032376~103033031:+
BRCA	cis	rs896854	0.967	rs10808671	ENSG00000253528.2	RP11-347C18.4	8.61	2.6e-17	9.77e-15	0.27	0.26	Type 2 diabetes;	chr8:94955144	chr8:94974573~94974853:-
BRCA	cis	rs875971	1	rs11971949	ENSG00000237310.1	GS1-124K5.4	-8.61	2.6e-17	9.77e-15	-0.27	-0.26	Aortic root size;	chr7:66161027	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.545	rs316328	ENSG00000237310.1	GS1-124K5.4	-8.61	2.6e-17	9.78e-15	-0.29	-0.26	Aortic root size;	chr7:66143851	chr7:66493706~66495474:+
BRCA	cis	rs7429990	0.76	rs319694	ENSG00000229759.1	MRPS18AP1	8.61	2.61e-17	9.82e-15	0.3	0.26	Educational attainment (years of education);	chr3:47843463	chr3:48256350~48256938:-
BRCA	cis	rs11098499	0.73	rs78971550	ENSG00000245958.5	RP11-33B1.1	-8.61	2.62e-17	9.85e-15	-0.25	-0.26	Corneal astigmatism;	chr4:119359886	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.645	rs78422072	ENSG00000245958.5	RP11-33B1.1	-8.61	2.62e-17	9.85e-15	-0.25	-0.26	Corneal astigmatism;	chr4:119359887	chr4:119454791~119552025:+
BRCA	cis	rs8012947	1	rs1984549	ENSG00000279636.2	LINC00216	-8.61	2.63e-17	9.88e-15	-0.28	-0.26	Alcohol consumption in current drinkers;	chr14:58322121	chr14:58288033~58289158:+
BRCA	cis	rs11098499	0.954	rs6847248	ENSG00000248280.1	RP11-33B1.2	8.61	2.64e-17	9.91e-15	0.29	0.26	Corneal astigmatism;	chr4:119304800	chr4:119440561~119450157:-
BRCA	cis	rs7429990	0.864	rs883662	ENSG00000229759.1	MRPS18AP1	8.61	2.64e-17	9.92e-15	0.31	0.26	Educational attainment (years of education);	chr3:47619342	chr3:48256350~48256938:-
BRCA	cis	rs2404602	0.967	rs7174096	ENSG00000259422.1	RP11-593F23.1	8.61	2.64e-17	9.92e-15	0.32	0.26	Blood metabolite levels;	chr15:76780059	chr15:76174891~76181486:-
BRCA	cis	rs2404602	1	rs2404602	ENSG00000259422.1	RP11-593F23.1	8.61	2.65e-17	9.95e-15	0.31	0.26	Blood metabolite levels;	chr15:76738451	chr15:76174891~76181486:-
BRCA	cis	rs8012947	1	rs8009579	ENSG00000279636.2	LINC00216	-8.61	2.65e-17	9.97e-15	-0.28	-0.26	Alcohol consumption in current drinkers;	chr14:58246841	chr14:58288033~58289158:+
BRCA	cis	rs1707322	1	rs785478	ENSG00000280836.1	AL355480.1	8.61	2.66e-17	9.99e-15	0.32	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46025963	chr1:45581219~45581321:-
BRCA	cis	rs75422866	0.51	rs73105803	ENSG00000257433.4	RP1-197B17.3	8.61	2.66e-17	1e-14	0.57	0.26	Pneumonia;	chr12:47722135	chr12:47706085~47742294:+
BRCA	cis	rs75422866	0.51	rs73105812	ENSG00000257433.4	RP1-197B17.3	8.61	2.66e-17	1e-14	0.57	0.26	Pneumonia;	chr12:47724404	chr12:47706085~47742294:+
BRCA	cis	rs75422866	0.51	rs74733564	ENSG00000257433.4	RP1-197B17.3	8.61	2.66e-17	1e-14	0.57	0.26	Pneumonia;	chr12:47724644	chr12:47706085~47742294:+
BRCA	cis	rs75422866	0.51	rs73105814	ENSG00000257433.4	RP1-197B17.3	8.61	2.66e-17	1e-14	0.57	0.26	Pneumonia;	chr12:47725817	chr12:47706085~47742294:+
BRCA	cis	rs10028773	0.666	rs12498657	ENSG00000248280.1	RP11-33B1.2	8.61	2.66e-17	1e-14	0.25	0.26	Educational attainment;	chr4:119341711	chr4:119440561~119450157:-
BRCA	cis	rs10875746	0.669	rs10431526	ENSG00000240399.1	RP1-228P16.1	-8.61	2.67e-17	1e-14	-0.34	-0.26	Longevity (90 years and older);	chr12:48296360	chr12:48054813~48055591:-
BRCA	cis	rs6545883	0.655	rs11893880	ENSG00000271889.1	RP11-493E12.1	8.61	2.67e-17	1e-14	0.32	0.26	Tuberculosis;	chr2:61194884	chr2:61151433~61162105:-
BRCA	cis	rs113835537	0.529	rs4930378	ENSG00000255517.5	CTD-3074O7.5	-8.61	2.68e-17	1.01e-14	-0.33	-0.26	Airway imaging phenotypes;	chr11:66488044	chr11:66473490~66480233:-
BRCA	cis	rs524281	0.506	rs2298466	ENSG00000255320.1	RP11-755F10.1	8.61	2.68e-17	1.01e-14	0.36	0.26	Electroencephalogram traits;	chr11:66243809	chr11:66244840~66246239:-
BRCA	cis	rs950880	0.71	rs4851583	ENSG00000234389.1	AC007278.3	-8.61	2.68e-17	1.01e-14	-0.25	-0.26	Serum protein levels (sST2);	chr2:102443840	chr2:102438713~102440475:+
BRCA	cis	rs950880	0.71	rs11694360	ENSG00000234389.1	AC007278.3	-8.61	2.68e-17	1.01e-14	-0.25	-0.26	Serum protein levels (sST2);	chr2:102444687	chr2:102438713~102440475:+
BRCA	cis	rs10463554	0.892	rs59292735	ENSG00000175749.11	EIF3KP1	8.61	2.69e-17	1.01e-14	0.36	0.26	Parkinson's disease;	chr5:103047047	chr5:103032376~103033031:+
BRCA	cis	rs1023500	0.596	rs133369	ENSG00000205702.9	CYP2D7	8.61	2.69e-17	1.01e-14	0.23	0.26	Schizophrenia;	chr22:42067810	chr22:42140203~42144577:-
BRCA	cis	rs853679	1	rs2799077	ENSG00000220721.1	OR1F12	8.61	2.7e-17	1.01e-14	0.41	0.26	Depression;	chr6:28266819	chr6:28073316~28074233:+
BRCA	cis	rs6545883	0.759	rs777585	ENSG00000271889.1	RP11-493E12.1	-8.61	2.7e-17	1.01e-14	-0.33	-0.26	Tuberculosis;	chr2:61185424	chr2:61151433~61162105:-
BRCA	cis	rs10129255	0.785	rs10150044	ENSG00000223648.3	IGHV3-64	8.61	2.71e-17	1.02e-14	0.21	0.26	Kawasaki disease;	chr14:106775695	chr14:106643132~106658258:-
BRCA	cis	rs2933343	0.951	rs789218	ENSG00000231305.3	RP11-723O4.2	8.61	2.71e-17	1.02e-14	0.32	0.26	IgG glycosylation;	chr3:128873827	chr3:128861313~128871540:-
BRCA	cis	rs3814244	0.528	rs17104682	ENSG00000236946.2	HNRNPA1P70	8.61	2.73e-17	1.02e-14	0.22	0.26	Itch intensity from mosquito bite adjusted by bite size;	chr12:68033256	chr12:68035767~68036853:+
BRCA	cis	rs10971721	0.822	rs10971773	ENSG00000260947.1	RP11-384P7.7	8.61	2.74e-17	1.03e-14	0.46	0.26	Body mass index;	chr9:33898781	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.822	rs10971774	ENSG00000260947.1	RP11-384P7.7	8.61	2.74e-17	1.03e-14	0.46	0.26	Body mass index;	chr9:33900111	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.822	rs72727318	ENSG00000260947.1	RP11-384P7.7	8.61	2.74e-17	1.03e-14	0.46	0.26	Body mass index;	chr9:33901802	chr9:33697459~33700986:+
BRCA	cis	rs6991838	0.831	rs11992528	ENSG00000200714.1	Y_RNA	8.61	2.76e-17	1.04e-14	0.3	0.26	Intelligence (multi-trait analysis);	chr8:65561644	chr8:65592731~65592820:+
BRCA	cis	rs2115630	1	rs6496452	ENSG00000225151.9	GOLGA2P7	8.61	2.76e-17	1.04e-14	0.28	0.26	P wave terminal force;	chr15:84829414	chr15:84199311~84230136:-
BRCA	cis	rs7684253	0.587	rs9685436	ENSG00000269949.1	RP11-738E22.3	-8.61	2.77e-17	1.04e-14	-0.31	-0.26	Migraine;	chr4:56881195	chr4:56960927~56961373:-
BRCA	cis	rs9543976	0.623	rs9543990	ENSG00000261553.4	RP11-29G8.3	8.61	2.77e-17	1.04e-14	0.41	0.26	Diabetic retinopathy;	chr13:75598298	chr13:75549773~75807120:+
BRCA	cis	rs11098499	0.754	rs28643450	ENSG00000245958.5	RP11-33B1.1	-8.6	2.77e-17	1.04e-14	-0.24	-0.26	Corneal astigmatism;	chr4:119324087	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.698	rs4422403	ENSG00000248280.1	RP11-33B1.2	8.6	2.78e-17	1.04e-14	0.25	0.26	Corneal astigmatism;	chr4:119337039	chr4:119440561~119450157:-
BRCA	cis	rs897984	0.542	rs59061704	ENSG00000260911.2	RP11-196G11.2	8.6	2.79e-17	1.05e-14	0.23	0.26	Dementia with Lewy bodies;	chr16:31051383	chr16:31043150~31049868:+
BRCA	cis	rs950173	1	rs13000153	ENSG00000228389.1	AC068039.4	8.6	2.79e-17	1.05e-14	0.5	0.26	Hippocampal volume;	chr2:171729557	chr2:171773482~171775844:+
BRCA	cis	rs2067615	0.599	rs1579808	ENSG00000260329.1	RP11-412D9.4	8.6	2.79e-17	1.05e-14	0.28	0.26	Heart rate;	chr12:106846169	chr12:106954029~106955497:-
BRCA	cis	rs875971	0.545	rs73150604	ENSG00000222364.1	RNU6-96P	-8.6	2.79e-17	1.05e-14	-0.35	-0.26	Aortic root size;	chr7:66480545	chr7:66395191~66395286:+
BRCA	cis	rs7712401	0.601	rs246287	ENSG00000263432.2	RN7SL689P	8.6	2.79e-17	1.05e-14	0.32	0.26	Mean platelet volume;	chr5:122909731	chr5:123022487~123022783:-
BRCA	cis	rs6142102	0.625	rs4911384	ENSG00000275784.1	RP5-1125A11.6	-8.6	2.8e-17	1.05e-14	-0.3	-0.26	Skin pigmentation;	chr20:33968001	chr20:33989480~33991818:-
BRCA	cis	rs12458462	1	rs12458462	ENSG00000274828.1	RP11-567M16.6	8.6	2.8e-17	1.05e-14	0.31	0.26	Monocyte count;	chr18:79712436	chr18:79677287~79679358:-
BRCA	cis	rs10129255	0.5	rs2027902	ENSG00000211972.2	IGHV3-66	8.6	2.8e-17	1.05e-14	0.18	0.26	Kawasaki disease;	chr14:106807157	chr14:106675017~106675544:-
BRCA	cis	rs11098499	0.865	rs28634456	ENSG00000248280.1	RP11-33B1.2	8.6	2.8e-17	1.05e-14	0.26	0.26	Corneal astigmatism;	chr4:119454623	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.954	rs59394118	ENSG00000248280.1	RP11-33B1.2	8.6	2.81e-17	1.05e-14	0.26	0.26	Corneal astigmatism;	chr4:119374396	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.865	rs9996417	ENSG00000248280.1	RP11-33B1.2	8.6	2.81e-17	1.05e-14	0.26	0.26	Corneal astigmatism;	chr4:119374707	chr4:119440561~119450157:-
BRCA	cis	rs10129255	0.912	rs6576227	ENSG00000223648.3	IGHV3-64	8.6	2.82e-17	1.05e-14	0.21	0.26	Kawasaki disease;	chr14:106778202	chr14:106643132~106658258:-
BRCA	cis	rs10129255	0.957	rs6576228	ENSG00000223648.3	IGHV3-64	8.6	2.82e-17	1.05e-14	0.21	0.26	Kawasaki disease;	chr14:106778401	chr14:106643132~106658258:-
BRCA	cis	rs875971	0.522	rs4718286	ENSG00000236529.1	RP13-254B10.1	8.6	2.83e-17	1.06e-14	0.28	0.26	Aortic root size;	chr7:65827777	chr7:65840212~65840596:+
BRCA	cis	rs17711722	0.585	rs6942660	ENSG00000236529.1	RP13-254B10.1	8.6	2.83e-17	1.06e-14	0.28	0.26	Calcium levels;	chr7:65837419	chr7:65840212~65840596:+
BRCA	cis	rs858239	0.57	rs10235467	ENSG00000230042.1	AK3P3	-8.6	2.83e-17	1.06e-14	-0.29	-0.26	Cerebrospinal fluid biomarker levels;	chr7:23109189	chr7:23129178~23129841:+
BRCA	cis	rs11098499	0.909	rs78332141	ENSG00000248280.1	RP11-33B1.2	8.6	2.83e-17	1.06e-14	0.26	0.26	Corneal astigmatism;	chr4:119454627	chr4:119440561~119450157:-
BRCA	cis	rs875971	0.502	rs2465121	ENSG00000237310.1	GS1-124K5.4	-8.6	2.84e-17	1.06e-14	-0.31	-0.26	Aortic root size;	chr7:66156017	chr7:66493706~66495474:+
BRCA	cis	rs9847710	0.524	rs11712910	ENSG00000242142.1	SERBP1P3	8.6	2.84e-17	1.06e-14	0.34	0.26	Ulcerative colitis;	chr3:53060178	chr3:53064283~53065091:-
BRCA	cis	rs673078	0.607	rs10082823	ENSG00000275759.1	RP11-131L12.3	-8.6	2.84e-17	1.07e-14	-0.33	-0.26	Glucose homeostasis traits;	chr12:118365386	chr12:118428281~118428870:+
BRCA	cis	rs6472827	0.645	rs2956056	ENSG00000253983.2	RP1-16A9.1	8.6	2.85e-17	1.07e-14	0.35	0.26	Uterine fibroids;	chr8:74199608	chr8:74199396~74208441:+
BRCA	cis	rs7429990	0.864	rs12635438	ENSG00000229759.1	MRPS18AP1	8.6	2.86e-17	1.07e-14	0.31	0.26	Educational attainment (years of education);	chr3:47693210	chr3:48256350~48256938:-
BRCA	cis	rs11098499	0.754	rs17595608	ENSG00000245958.5	RP11-33B1.1	-8.6	2.86e-17	1.07e-14	-0.24	-0.26	Corneal astigmatism;	chr4:119329351	chr4:119454791~119552025:+
BRCA	cis	rs875971	0.522	rs9530	ENSG00000164669.11	INTS4P1	-8.6	2.87e-17	1.08e-14	-0.32	-0.26	Aortic root size;	chr7:65960907	chr7:65141225~65234216:+
BRCA	cis	rs2404602	1	rs2120107	ENSG00000259422.1	RP11-593F23.1	8.6	2.88e-17	1.08e-14	0.31	0.26	Blood metabolite levels;	chr15:76577448	chr15:76174891~76181486:-
BRCA	cis	rs1501911	0.545	rs4703345	ENSG00000248489.1	CTD-2007H13.3	-8.6	2.89e-17	1.08e-14	-0.34	-0.26	Lung function (FEV1/FVC);	chr5:99016679	chr5:98929171~98995013:+
BRCA	cis	rs10463554	0.927	rs34821	ENSG00000175749.11	EIF3KP1	8.6	2.9e-17	1.09e-14	0.36	0.26	Parkinson's disease;	chr5:103101913	chr5:103032376~103033031:+
BRCA	cis	rs6570726	0.577	rs399502	ENSG00000235652.6	RP11-545I5.3	8.6	2.9e-17	1.09e-14	0.28	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145484738	chr6:145799409~145886585:+
BRCA	cis	rs10129255	0.833	rs61997797	ENSG00000223648.3	IGHV3-64	8.6	2.9e-17	1.09e-14	0.23	0.26	Kawasaki disease;	chr14:106815190	chr14:106643132~106658258:-
BRCA	cis	rs858239	0.601	rs987257	ENSG00000230042.1	AK3P3	-8.6	2.9e-17	1.09e-14	-0.29	-0.26	Cerebrospinal fluid biomarker levels;	chr7:23108221	chr7:23129178~23129841:+
BRCA	cis	rs6570726	0.846	rs453834	ENSG00000235652.6	RP11-545I5.3	8.6	2.91e-17	1.09e-14	0.25	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145565125	chr6:145799409~145886585:+
BRCA	cis	rs853679	0.766	rs9368561	ENSG00000220721.1	OR1F12	8.6	2.92e-17	1.09e-14	0.48	0.26	Depression;	chr6:28200565	chr6:28073316~28074233:+
BRCA	cis	rs6061231	0.837	rs6061235	ENSG00000273619.1	RP5-908M14.9	-8.6	2.92e-17	1.09e-14	-0.24	-0.26	Colorectal cancer;	chr20:62403468	chr20:62386303~62386970:-
BRCA	cis	rs875971	0.545	rs67775320	ENSG00000222364.1	RNU6-96P	-8.6	2.92e-17	1.09e-14	-0.34	-0.26	Aortic root size;	chr7:66193792	chr7:66395191~66395286:+
BRCA	cis	rs932287	0.54	rs4910442	ENSG00000254860.4	TMEM9B-AS1	-8.6	2.92e-17	1.09e-14	-0.25	-0.26	Colonoscopy-negative controls vs population controls;	chr11:9022790	chr11:8964675~8977527:+
BRCA	cis	rs11971779	0.938	rs28477480	ENSG00000273391.1	RP11-634H22.1	-8.6	2.94e-17	1.1e-14	-0.28	-0.26	Diisocyanate-induced asthma;	chr7:139351312	chr7:139359032~139359566:-
BRCA	cis	rs853679	1	rs1419183	ENSG00000220721.1	OR1F12	8.6	2.94e-17	1.1e-14	0.4	0.26	Depression;	chr6:28275017	chr6:28073316~28074233:+
BRCA	cis	rs2404602	0.679	rs12899871	ENSG00000259422.1	RP11-593F23.1	8.6	2.96e-17	1.11e-14	0.33	0.26	Blood metabolite levels;	chr15:76465006	chr15:76174891~76181486:-
BRCA	cis	rs1134634	0.52	rs4280724	ENSG00000273133.1	RP11-799M12.2	-8.6	2.98e-17	1.12e-14	-0.34	-0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15574128	chr4:15563698~15564253:-
BRCA	cis	rs10463554	0.963	rs62364874	ENSG00000175749.11	EIF3KP1	8.6	2.99e-17	1.12e-14	0.36	0.26	Parkinson's disease;	chr5:103056475	chr5:103032376~103033031:+
BRCA	cis	rs10463554	0.963	rs62364876	ENSG00000175749.11	EIF3KP1	8.6	2.99e-17	1.12e-14	0.36	0.26	Parkinson's disease;	chr5:103058454	chr5:103032376~103033031:+
BRCA	cis	rs10463554	0.963	rs158254	ENSG00000175749.11	EIF3KP1	8.6	2.99e-17	1.12e-14	0.36	0.26	Parkinson's disease;	chr5:103059179	chr5:103032376~103033031:+
BRCA	cis	rs11676348	0.712	rs11687434	ENSG00000261338.2	RP11-378A13.1	-8.6	3e-17	1.12e-14	-0.27	-0.26	Ulcerative colitis;	chr2:218080420	chr2:218255319~218257366:+
BRCA	cis	rs67981189	0.529	rs2810097	ENSG00000269927.1	RP6-91H8.3	-8.6	3e-17	1.12e-14	-0.34	-0.26	Schizophrenia;	chr14:70967397	chr14:71141125~71143253:-
BRCA	cis	rs11098499	0.82	rs28535956	ENSG00000245958.5	RP11-33B1.1	8.6	3.01e-17	1.12e-14	0.26	0.26	Corneal astigmatism;	chr4:119615703	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.754	rs2036857	ENSG00000245958.5	RP11-33B1.1	-8.59	3.01e-17	1.13e-14	-0.24	-0.26	Corneal astigmatism;	chr4:119328085	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.754	rs2036856	ENSG00000245958.5	RP11-33B1.1	-8.59	3.01e-17	1.13e-14	-0.24	-0.26	Corneal astigmatism;	chr4:119328133	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.754	rs4443261	ENSG00000245958.5	RP11-33B1.1	-8.59	3.01e-17	1.13e-14	-0.24	-0.26	Corneal astigmatism;	chr4:119328146	chr4:119454791~119552025:+
BRCA	cis	rs875971	0.545	rs11770063	ENSG00000222364.1	RNU6-96P	-8.59	3.02e-17	1.13e-14	-0.34	-0.26	Aortic root size;	chr7:66318029	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.545	rs6950988	ENSG00000222364.1	RNU6-96P	-8.59	3.02e-17	1.13e-14	-0.34	-0.26	Aortic root size;	chr7:66511428	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.545	rs3936065	ENSG00000222364.1	RNU6-96P	-8.59	3.03e-17	1.13e-14	-0.34	-0.26	Aortic root size;	chr7:66325577	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.545	rs4718335	ENSG00000222364.1	RNU6-96P	-8.59	3.03e-17	1.13e-14	-0.34	-0.26	Aortic root size;	chr7:66339619	chr7:66395191~66395286:+
BRCA	cis	rs11098499	0.863	rs3775841	ENSG00000248280.1	RP11-33B1.2	8.59	3.03e-17	1.13e-14	0.27	0.26	Corneal astigmatism;	chr4:119504622	chr4:119440561~119450157:-
BRCA	cis	rs2067615	0.579	rs4964492	ENSG00000260329.1	RP11-412D9.4	-8.59	3.04e-17	1.14e-14	-0.28	-0.26	Heart rate;	chr12:106828996	chr12:106954029~106955497:-
BRCA	cis	rs875971	0.545	rs10950027	ENSG00000222364.1	RNU6-96P	-8.59	3.05e-17	1.14e-14	-0.33	-0.26	Aortic root size;	chr7:66169164	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.54	rs736270	ENSG00000164669.11	INTS4P1	-8.59	3.06e-17	1.14e-14	-0.32	-0.26	Aortic root size;	chr7:65963835	chr7:65141225~65234216:+
BRCA	cis	rs2404602	0.716	rs17363713	ENSG00000259422.1	RP11-593F23.1	8.59	3.07e-17	1.14e-14	0.33	0.26	Blood metabolite levels;	chr15:76453787	chr15:76174891~76181486:-
BRCA	cis	rs113835537	0.529	rs11227514	ENSG00000255517.5	CTD-3074O7.5	-8.59	3.07e-17	1.15e-14	-0.33	-0.26	Airway imaging phenotypes;	chr11:66519156	chr11:66473490~66480233:-
BRCA	cis	rs11098499	0.691	rs12502524	ENSG00000245958.5	RP11-33B1.1	-8.59	3.08e-17	1.15e-14	-0.24	-0.26	Corneal astigmatism;	chr4:119350259	chr4:119454791~119552025:+
BRCA	cis	rs10463554	0.889	rs34775	ENSG00000175749.11	EIF3KP1	8.59	3.09e-17	1.15e-14	0.37	0.26	Parkinson's disease;	chr5:103115572	chr5:103032376~103033031:+
BRCA	cis	rs7727544	0.735	rs4705933	ENSG00000233006.5	AC034220.3	8.59	3.09e-17	1.15e-14	0.19	0.26	Blood metabolite levels;	chr5:132342719	chr5:132311285~132369916:-
BRCA	cis	rs7727544	0.735	rs272867	ENSG00000233006.5	AC034220.3	8.59	3.09e-17	1.15e-14	0.19	0.26	Blood metabolite levels;	chr5:132345364	chr5:132311285~132369916:-
BRCA	cis	rs875971	0.577	rs35072105	ENSG00000224316.1	RP11-479O9.2	-8.59	3.09e-17	1.15e-14	-0.26	-0.26	Aortic root size;	chr7:66144830	chr7:65773620~65802067:+
BRCA	cis	rs950173	1	rs950173	ENSG00000228389.1	AC068039.4	8.59	3.1e-17	1.16e-14	0.52	0.26	Hippocampal volume;	chr2:171713909	chr2:171773482~171775844:+
BRCA	cis	rs950880	0.71	rs56166614	ENSG00000234389.1	AC007278.3	-8.59	3.12e-17	1.16e-14	-0.25	-0.26	Serum protein levels (sST2);	chr2:102439636	chr2:102438713~102440475:+
BRCA	cis	rs1075265	0.716	rs7573991	ENSG00000233266.1	HMGB1P31	8.59	3.13e-17	1.17e-14	0.31	0.26	Chronotype;Morning vs. evening chronotype;	chr2:53726830	chr2:54051334~54051760:+
BRCA	cis	rs7428	0.527	rs1053560	ENSG00000246575.2	AC093162.5	8.59	3.13e-17	1.17e-14	0.27	0.26	Ear protrusion;	chr2:85319069	chr2:85315041~85316529:+
BRCA	cis	rs11098499	0.818	rs55825515	ENSG00000248280.1	RP11-33B1.2	8.59	3.13e-17	1.17e-14	0.27	0.26	Corneal astigmatism;	chr4:119565247	chr4:119440561~119450157:-
BRCA	cis	rs6570726	0.846	rs439035	ENSG00000235652.6	RP11-545I5.3	8.59	3.14e-17	1.17e-14	0.25	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145566854	chr6:145799409~145886585:+
BRCA	cis	rs9640161	0.789	rs10952250	ENSG00000261305.1	RP4-584D14.7	8.59	3.14e-17	1.17e-14	0.37	0.26	Blood protein levels;Circulating chemerin levels;	chr7:150328877	chr7:150341771~150342607:+
BRCA	cis	rs6142102	0.961	rs2284386	ENSG00000276073.1	RP5-1125A11.7	-8.59	3.14e-17	1.17e-14	-0.3	-0.26	Skin pigmentation;	chr20:34056590	chr20:33985617~33988989:-
BRCA	cis	rs11673344	0.764	rs10424584	ENSG00000226686.6	LINC01535	8.59	3.15e-17	1.18e-14	0.34	0.26	Obesity-related traits;	chr19:36975986	chr19:37251912~37265535:+
BRCA	cis	rs17023223	0.537	rs2765530	ENSG00000231365.4	RP11-418J17.1	-8.59	3.16e-17	1.18e-14	-0.33	-0.26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119041773	chr1:119140396~119275973:+
BRCA	cis	rs10463554	0.963	rs34381	ENSG00000175749.11	EIF3KP1	8.59	3.17e-17	1.18e-14	0.36	0.26	Parkinson's disease;	chr5:103060852	chr5:103032376~103033031:+
BRCA	cis	rs4604732	0.536	rs4925674	ENSG00000227135.1	GCSAML-AS1	-8.59	3.18e-17	1.18e-14	-0.4	-0.26	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247473604	chr1:247524679~247526752:-
BRCA	cis	rs10028773	0.546	rs13117947	ENSG00000248280.1	RP11-33B1.2	8.59	3.18e-17	1.19e-14	0.24	0.26	Educational attainment;	chr4:119335905	chr4:119440561~119450157:-
BRCA	cis	rs1707322	1	rs4073847	ENSG00000280836.1	AL355480.1	8.59	3.19e-17	1.19e-14	0.33	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45997340	chr1:45581219~45581321:-
BRCA	cis	rs2117029	0.767	rs12580349	ENSG00000258017.1	RP11-386G11.10	8.59	3.22e-17	1.2e-14	0.35	0.26	Intelligence (multi-trait analysis);	chr12:49042941	chr12:49127782~49147869:+
BRCA	cis	rs10129255	0.957	rs8009948	ENSG00000223648.3	IGHV3-64	8.59	3.23e-17	1.2e-14	0.24	0.26	Kawasaki disease;	chr14:106805607	chr14:106643132~106658258:-
BRCA	cis	rs58873874	0.737	rs10476050	ENSG00000248544.2	CTB-47B11.3	8.59	3.24e-17	1.21e-14	0.6	0.26	Bipolar disorder (body mass index interaction);	chr5:157471866	chr5:157375741~157384950:-
BRCA	cis	rs2404602	0.716	rs1588961	ENSG00000259422.1	RP11-593F23.1	8.59	3.25e-17	1.21e-14	0.33	0.26	Blood metabolite levels;	chr15:76460357	chr15:76174891~76181486:-
BRCA	cis	rs1707322	1	rs6695421	ENSG00000280836.1	AL355480.1	-8.59	3.26e-17	1.21e-14	-0.33	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45914535	chr1:45581219~45581321:-
BRCA	cis	rs2276314	0.857	rs9960670	ENSG00000278986.1	RP11-723J4.3	-8.59	3.26e-17	1.21e-14	-0.34	-0.26	Endometriosis;Drug-induced torsades de pointes;	chr18:35997749	chr18:35972151~35973916:+
BRCA	cis	rs1707322	1	rs11211223	ENSG00000280836.1	AL355480.1	-8.58	3.26e-17	1.22e-14	-0.33	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45914933	chr1:45581219~45581321:-
BRCA	cis	rs2404602	0.716	rs2164101	ENSG00000259422.1	RP11-593F23.1	8.58	3.27e-17	1.22e-14	0.33	0.26	Blood metabolite levels;	chr15:76456776	chr15:76174891~76181486:-
BRCA	cis	rs10510102	0.688	rs74570569	ENSG00000276742.1	RP11-500G22.4	8.58	3.28e-17	1.22e-14	0.44	0.26	Breast cancer;	chr10:121945347	chr10:121956782~121957098:+
BRCA	cis	rs875971	0.522	rs709604	ENSG00000222364.1	RNU6-96P	8.58	3.3e-17	1.23e-14	0.3	0.26	Aortic root size;	chr7:66032447	chr7:66395191~66395286:+
BRCA	cis	rs526231	0.511	rs3776861	ENSG00000175749.11	EIF3KP1	8.58	3.3e-17	1.23e-14	0.36	0.26	Primary biliary cholangitis;	chr5:103013958	chr5:103032376~103033031:+
BRCA	cis	rs193541	0.556	rs30024	ENSG00000263432.2	RN7SL689P	8.58	3.31e-17	1.23e-14	0.35	0.26	Glucose homeostasis traits;	chr5:122949465	chr5:123022487~123022783:-
BRCA	cis	rs11673344	0.764	rs16971873	ENSG00000226686.6	LINC01535	8.58	3.31e-17	1.23e-14	0.34	0.26	Obesity-related traits;	chr19:36978521	chr19:37251912~37265535:+
BRCA	cis	rs11098499	0.954	rs3733524	ENSG00000248280.1	RP11-33B1.2	8.58	3.31e-17	1.23e-14	0.28	0.26	Corneal astigmatism;	chr4:119502574	chr4:119440561~119450157:-
BRCA	cis	rs10971721	0.822	rs7856487	ENSG00000260947.1	RP11-384P7.7	8.58	3.32e-17	1.24e-14	0.44	0.26	Body mass index;	chr9:33870942	chr9:33697459~33700986:+
BRCA	cis	rs7772486	0.558	rs9497403	ENSG00000235652.6	RP11-545I5.3	-8.58	3.32e-17	1.24e-14	-0.28	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145733559	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.727	rs2235481	ENSG00000235652.6	RP11-545I5.3	-8.58	3.32e-17	1.24e-14	-0.28	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145735712	chr6:145799409~145886585:+
BRCA	cis	rs694739	0.726	rs516124	ENSG00000236935.1	AP003774.1	8.58	3.32e-17	1.24e-14	0.25	0.26	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64360951	chr11:64325050~64329504:-
BRCA	cis	rs4964805	0.802	rs11111778	ENSG00000257681.1	RP11-341G23.4	8.58	3.33e-17	1.24e-14	0.33	0.26	Attention deficit hyperactivity disorder;	chr12:103791653	chr12:103746315~103768858:-
BRCA	cis	rs13256369	1	rs13266699	ENSG00000253893.2	FAM85B	8.58	3.33e-17	1.24e-14	0.36	0.26	Obesity-related traits;	chr8:8712803	chr8:8167819~8226614:-
BRCA	cis	rs875971	0.545	rs1638724	ENSG00000222364.1	RNU6-96P	8.58	3.33e-17	1.24e-14	0.34	0.26	Aortic root size;	chr7:66575494	chr7:66395191~66395286:+
BRCA	cis	rs26232	0.526	rs61654927	ENSG00000175749.11	EIF3KP1	8.58	3.35e-17	1.24e-14	0.36	0.26	Rheumatoid arthritis;	chr5:103047021	chr5:103032376~103033031:+
BRCA	cis	rs1075265	0.783	rs805439	ENSG00000233266.1	HMGB1P31	8.58	3.36e-17	1.25e-14	0.31	0.26	Chronotype;Morning vs. evening chronotype;	chr2:53829437	chr2:54051334~54051760:+
BRCA	cis	rs875971	0.545	rs73376401	ENSG00000222364.1	RNU6-96P	-8.58	3.36e-17	1.25e-14	-0.33	-0.26	Aortic root size;	chr7:66174841	chr7:66395191~66395286:+
BRCA	cis	rs7615952	0.604	rs9837847	ENSG00000171084.14	FAM86JP	8.58	3.37e-17	1.25e-14	0.51	0.26	Blood pressure (smoking interaction);	chr3:125905076	chr3:125916620~125930024:+
BRCA	cis	rs10129255	0.518	rs8009594	ENSG00000211972.2	IGHV3-66	8.58	3.38e-17	1.26e-14	0.18	0.26	Kawasaki disease;	chr14:106777494	chr14:106675017~106675544:-
BRCA	cis	rs10129255	0.83	rs61997609	ENSG00000223648.3	IGHV3-64	8.58	3.38e-17	1.26e-14	0.23	0.26	Kawasaki disease;	chr14:106692376	chr14:106643132~106658258:-
BRCA	cis	rs11098499	0.863	rs13136462	ENSG00000248280.1	RP11-33B1.2	8.58	3.39e-17	1.26e-14	0.27	0.26	Corneal astigmatism;	chr4:119622018	chr4:119440561~119450157:-
BRCA	cis	rs2404602	0.692	rs2117369	ENSG00000259422.1	RP11-593F23.1	8.58	3.39e-17	1.26e-14	0.33	0.26	Blood metabolite levels;	chr15:76456520	chr15:76174891~76181486:-
BRCA	cis	rs7772486	0.686	rs1292336	ENSG00000235652.6	RP11-545I5.3	-8.58	3.39e-17	1.26e-14	-0.25	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145646682	chr6:145799409~145886585:+
BRCA	cis	rs694739	0.628	rs538147	ENSG00000236935.1	AP003774.1	8.58	3.39e-17	1.26e-14	0.24	0.26	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64362250	chr11:64325050~64329504:-
BRCA	cis	rs4835473	0.932	rs4585249	ENSG00000251600.4	RP11-673E1.1	-8.58	3.39e-17	1.26e-14	-0.3	-0.26	Immature fraction of reticulocytes;	chr4:143981173	chr4:143912331~143982454:+
BRCA	cis	rs875971	0.558	rs4433015	ENSG00000224316.1	RP11-479O9.2	-8.58	3.4e-17	1.26e-14	-0.26	-0.26	Aortic root size;	chr7:66174736	chr7:65773620~65802067:+
BRCA	cis	rs4266144	1	rs4561781	ENSG00000244515.1	KRT18P34	8.58	3.4e-17	1.26e-14	0.31	0.26	Coronary artery disease;	chr3:157135154	chr3:157162663~157163932:-
BRCA	cis	rs4934494	0.911	rs7098233	ENSG00000240996.1	RP11-80H5.7	8.58	3.41e-17	1.27e-14	0.3	0.26	Red blood cell count;	chr10:89663111	chr10:89694295~89697928:-
BRCA	cis	rs875971	0.545	rs7787063	ENSG00000222364.1	RNU6-96P	-8.58	3.41e-17	1.27e-14	-0.33	-0.26	Aortic root size;	chr7:66164012	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.545	rs12673308	ENSG00000222364.1	RNU6-96P	-8.58	3.41e-17	1.27e-14	-0.33	-0.26	Aortic root size;	chr7:66166374	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.522	rs9530	ENSG00000236529.1	RP13-254B10.1	8.58	3.42e-17	1.27e-14	0.28	0.26	Aortic root size;	chr7:65960907	chr7:65840212~65840596:+
BRCA	cis	rs673078	0.66	rs76842574	ENSG00000275759.1	RP11-131L12.3	-8.58	3.43e-17	1.27e-14	-0.33	-0.26	Glucose homeostasis traits;	chr12:118371789	chr12:118428281~118428870:+
BRCA	cis	rs812925	0.519	rs967968	ENSG00000271889.1	RP11-493E12.1	-8.58	3.43e-17	1.27e-14	-0.31	-0.26	Immature fraction of reticulocytes;	chr2:61428921	chr2:61151433~61162105:-
BRCA	cis	rs2933343	1	rs876755	ENSG00000231305.3	RP11-723O4.2	8.58	3.43e-17	1.28e-14	0.32	0.26	IgG glycosylation;	chr3:128909090	chr3:128861313~128871540:-
BRCA	cis	rs11098499	0.82	rs28578366	ENSG00000245958.5	RP11-33B1.1	8.58	3.43e-17	1.28e-14	0.25	0.26	Corneal astigmatism;	chr4:119615750	chr4:119454791~119552025:+
BRCA	cis	rs10463554	0.927	rs7717343	ENSG00000175749.11	EIF3KP1	8.58	3.45e-17	1.28e-14	0.35	0.26	Parkinson's disease;	chr5:103026279	chr5:103032376~103033031:+
BRCA	cis	rs10463554	0.963	rs7721530	ENSG00000175749.11	EIF3KP1	8.58	3.45e-17	1.28e-14	0.35	0.26	Parkinson's disease;	chr5:103026488	chr5:103032376~103033031:+
BRCA	cis	rs1707322	1	rs11211200	ENSG00000280836.1	AL355480.1	-8.58	3.46e-17	1.28e-14	-0.32	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45822680	chr1:45581219~45581321:-
BRCA	cis	rs950880	0.71	rs66566526	ENSG00000234389.1	AC007278.3	-8.58	3.48e-17	1.29e-14	-0.26	-0.26	Serum protein levels (sST2);	chr2:102431342	chr2:102438713~102440475:+
BRCA	cis	rs801193	0.967	rs2420827	ENSG00000222364.1	RNU6-96P	8.58	3.48e-17	1.29e-14	0.3	0.26	Aortic root size;	chr7:66682114	chr7:66395191~66395286:+
BRCA	cis	rs6570726	0.846	rs426874	ENSG00000235652.6	RP11-545I5.3	8.58	3.48e-17	1.29e-14	0.25	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145559494	chr6:145799409~145886585:+
BRCA	cis	rs10129255	0.5	rs988134	ENSG00000211972.2	IGHV3-66	8.58	3.49e-17	1.3e-14	0.18	0.26	Kawasaki disease;	chr14:106776698	chr14:106675017~106675544:-
BRCA	cis	rs10129255	0.5	rs988133	ENSG00000211972.2	IGHV3-66	8.58	3.49e-17	1.3e-14	0.18	0.26	Kawasaki disease;	chr14:106776724	chr14:106675017~106675544:-
BRCA	cis	rs150992	0.504	rs4583911	ENSG00000248489.1	CTD-2007H13.3	-8.58	3.5e-17	1.3e-14	-0.34	-0.26	Body mass index;	chr5:99031401	chr5:98929171~98995013:+
BRCA	cis	rs61270009	0.955	rs35300532	ENSG00000247828.6	TMEM161B-AS1	8.58	3.5e-17	1.3e-14	0.32	0.26	Depressive symptoms;	chr5:88293219	chr5:88268895~88436685:+
BRCA	cis	rs950880	0.71	rs17027179	ENSG00000234389.1	AC007278.3	-8.58	3.51e-17	1.3e-14	-0.25	-0.26	Serum protein levels (sST2);	chr2:102440699	chr2:102438713~102440475:+
BRCA	cis	rs10971721	0.822	rs72729316	ENSG00000260947.1	RP11-384P7.7	8.58	3.52e-17	1.31e-14	0.46	0.26	Body mass index;	chr9:34008175	chr9:33697459~33700986:+
BRCA	cis	rs72627509	0.904	rs3796529	ENSG00000269949.1	RP11-738E22.3	8.58	3.53e-17	1.31e-14	0.37	0.26	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56931248	chr4:56960927~56961373:-
BRCA	cis	rs11098499	0.82	rs2389885	ENSG00000245958.5	RP11-33B1.1	-8.58	3.53e-17	1.31e-14	-0.27	-0.26	Corneal astigmatism;	chr4:119612776	chr4:119454791~119552025:+
BRCA	cis	rs1134634	0.52	rs7665390	ENSG00000273133.1	RP11-799M12.2	-8.58	3.54e-17	1.31e-14	-0.34	-0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15576115	chr4:15563698~15564253:-
BRCA	cis	rs1707322	1	rs1707322	ENSG00000280836.1	AL355480.1	-8.57	3.55e-17	1.32e-14	-0.32	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46039475	chr1:45581219~45581321:-
BRCA	cis	rs11098499	0.909	rs79026312	ENSG00000245958.5	RP11-33B1.1	-8.57	3.56e-17	1.32e-14	-0.26	-0.26	Corneal astigmatism;	chr4:119519522	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.909	rs35111518	ENSG00000245958.5	RP11-33B1.1	-8.57	3.56e-17	1.32e-14	-0.26	-0.26	Corneal astigmatism;	chr4:119519527	chr4:119454791~119552025:+
BRCA	cis	rs11673344	0.764	rs565721	ENSG00000226686.6	LINC01535	8.57	3.56e-17	1.32e-14	0.33	0.26	Obesity-related traits;	chr19:36964929	chr19:37251912~37265535:+
BRCA	cis	rs8012947	1	rs8011191	ENSG00000279636.2	LINC00216	-8.57	3.57e-17	1.32e-14	-0.28	-0.26	Alcohol consumption in current drinkers;	chr14:58250295	chr14:58288033~58289158:+
BRCA	cis	rs4727443	0.866	rs2897075	ENSG00000214313.7	AZGP1P1	-8.57	3.57e-17	1.33e-14	-0.26	-0.26	Interstitial lung disease;	chr7:100032719	chr7:99980762~99987535:+
BRCA	cis	rs7429990	0.864	rs12492915	ENSG00000229759.1	MRPS18AP1	-8.57	3.58e-17	1.33e-14	-0.29	-0.26	Educational attainment (years of education);	chr3:47636545	chr3:48256350~48256938:-
BRCA	cis	rs10129255	1	rs9324091	ENSG00000223648.3	IGHV3-64	8.57	3.58e-17	1.33e-14	0.23	0.26	Kawasaki disease;	chr14:106676625	chr14:106643132~106658258:-
BRCA	cis	rs875971	0.522	rs7784623	ENSG00000236529.1	RP13-254B10.1	8.57	3.6e-17	1.33e-14	0.28	0.26	Aortic root size;	chr7:65930047	chr7:65840212~65840596:+
BRCA	cis	rs1707322	1	rs4660889	ENSG00000280836.1	AL355480.1	-8.57	3.62e-17	1.34e-14	-0.32	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45831659	chr1:45581219~45581321:-
BRCA	cis	rs67311347	1	rs112619360	ENSG00000223797.4	ENTPD3-AS1	8.57	3.62e-17	1.34e-14	0.29	0.26	Renal cell carcinoma;	chr3:40391154	chr3:40313802~40453329:-
BRCA	cis	rs2933343	1	rs6785869	ENSG00000261159.1	RP11-723O4.9	8.57	3.62e-17	1.34e-14	0.31	0.26	IgG glycosylation;	chr3:128924301	chr3:128859716~128860526:-
BRCA	cis	rs2933343	1	rs1683778	ENSG00000261159.1	RP11-723O4.9	8.57	3.62e-17	1.34e-14	0.31	0.26	IgG glycosylation;	chr3:128925752	chr3:128859716~128860526:-
BRCA	cis	rs4927850	0.752	rs7618864	ENSG00000231464.1	AC024937.4	8.57	3.63e-17	1.35e-14	0.33	0.26	Pancreatic cancer;	chr3:196022690	chr3:195996738~195998233:+
BRCA	cis	rs7615952	0.611	rs9681518	ENSG00000171084.14	FAM86JP	8.57	3.63e-17	1.35e-14	0.51	0.26	Blood pressure (smoking interaction);	chr3:125896287	chr3:125916620~125930024:+
BRCA	cis	rs875971	1	rs6963646	ENSG00000237310.1	GS1-124K5.4	-8.57	3.63e-17	1.35e-14	-0.27	-0.26	Aortic root size;	chr7:66220780	chr7:66493706~66495474:+
BRCA	cis	rs10129255	0.957	rs11846893	ENSG00000223648.3	IGHV3-64	8.57	3.65e-17	1.35e-14	0.21	0.26	Kawasaki disease;	chr14:106779068	chr14:106643132~106658258:-
BRCA	cis	rs2067615	0.524	rs7309351	ENSG00000260329.1	RP11-412D9.4	8.57	3.65e-17	1.35e-14	0.28	0.26	Heart rate;	chr12:106683654	chr12:106954029~106955497:-
BRCA	cis	rs10463554	0.963	rs13340364	ENSG00000175749.11	EIF3KP1	8.57	3.66e-17	1.36e-14	0.35	0.26	Parkinson's disease;	chr5:103003406	chr5:103032376~103033031:+
BRCA	cis	rs1707322	0.964	rs1768802	ENSG00000280836.1	AL355480.1	8.57	3.67e-17	1.36e-14	0.32	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46082196	chr1:45581219~45581321:-
BRCA	cis	rs1707322	1	rs1588663	ENSG00000280836.1	AL355480.1	8.57	3.67e-17	1.36e-14	0.32	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46083153	chr1:45581219~45581321:-
BRCA	cis	rs1707322	1	rs1768801	ENSG00000280836.1	AL355480.1	8.57	3.67e-17	1.36e-14	0.32	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46083465	chr1:45581219~45581321:-
BRCA	cis	rs1707322	1	rs1768800	ENSG00000280836.1	AL355480.1	8.57	3.67e-17	1.36e-14	0.32	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46083516	chr1:45581219~45581321:-
BRCA	cis	rs58873874	0.737	rs10476052	ENSG00000248544.2	CTB-47B11.3	8.57	3.67e-17	1.36e-14	0.61	0.26	Bipolar disorder (body mass index interaction);	chr5:157473526	chr5:157375741~157384950:-
BRCA	cis	rs58873874	0.737	rs11739062	ENSG00000248544.2	CTB-47B11.3	8.57	3.68e-17	1.36e-14	0.61	0.26	Bipolar disorder (body mass index interaction);	chr5:157474693	chr5:157375741~157384950:-
BRCA	cis	rs2041895	0.509	rs10861674	ENSG00000260329.1	RP11-412D9.4	-8.57	3.68e-17	1.37e-14	-0.32	-0.26	Glaucoma (low intraocular pressure);	chr12:106910259	chr12:106954029~106955497:-
BRCA	cis	rs2276314	0.857	rs28379448	ENSG00000278986.1	RP11-723J4.3	-8.57	3.7e-17	1.37e-14	-0.34	-0.26	Endometriosis;Drug-induced torsades de pointes;	chr18:36024401	chr18:35972151~35973916:+
BRCA	cis	rs7429990	0.864	rs6774170	ENSG00000229759.1	MRPS18AP1	-8.57	3.7e-17	1.37e-14	-0.29	-0.26	Educational attainment (years of education);	chr3:47615977	chr3:48256350~48256938:-
BRCA	cis	rs875971	0.505	rs1723275	ENSG00000236529.1	RP13-254B10.1	-8.57	3.71e-17	1.37e-14	-0.28	-0.26	Aortic root size;	chr7:66039646	chr7:65840212~65840596:+
BRCA	cis	rs881375	0.678	rs2269060	ENSG00000226752.6	PSMD5-AS1	-8.57	3.71e-17	1.37e-14	-0.29	-0.26	Rheumatoid arthritis;	chr9:120921291	chr9:120824828~120854385:+
BRCA	cis	rs17023223	0.537	rs2794312	ENSG00000231365.4	RP11-418J17.1	-8.57	3.73e-17	1.38e-14	-0.33	-0.26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119048423	chr1:119140396~119275973:+
BRCA	cis	rs17023223	0.537	rs2765532	ENSG00000231365.4	RP11-418J17.1	-8.57	3.73e-17	1.38e-14	-0.33	-0.26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119048923	chr1:119140396~119275973:+
BRCA	cis	rs11098499	0.697	rs11941899	ENSG00000248280.1	RP11-33B1.2	8.57	3.74e-17	1.38e-14	0.26	0.26	Corneal astigmatism;	chr4:119461603	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.909	rs7681978	ENSG00000248280.1	RP11-33B1.2	8.57	3.74e-17	1.38e-14	0.26	0.26	Corneal astigmatism;	chr4:119462620	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.821	rs28665282	ENSG00000248280.1	RP11-33B1.2	8.57	3.74e-17	1.38e-14	0.26	0.26	Corneal astigmatism;	chr4:119463031	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.738	rs10026493	ENSG00000248280.1	RP11-33B1.2	8.57	3.74e-17	1.38e-14	0.26	0.26	Corneal astigmatism;	chr4:119463039	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.909	rs7681214	ENSG00000248280.1	RP11-33B1.2	8.57	3.74e-17	1.38e-14	0.26	0.26	Corneal astigmatism;	chr4:119464165	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.909	rs28632018	ENSG00000248280.1	RP11-33B1.2	8.57	3.74e-17	1.38e-14	0.26	0.26	Corneal astigmatism;	chr4:119465575	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.908	rs71614449	ENSG00000248280.1	RP11-33B1.2	8.57	3.74e-17	1.38e-14	0.26	0.26	Corneal astigmatism;	chr4:119465900	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.954	rs35063680	ENSG00000248280.1	RP11-33B1.2	8.57	3.74e-17	1.38e-14	0.26	0.26	Corneal astigmatism;	chr4:119465947	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.954	rs34858317	ENSG00000248280.1	RP11-33B1.2	8.57	3.74e-17	1.38e-14	0.26	0.26	Corneal astigmatism;	chr4:119465955	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.954	rs17046116	ENSG00000248280.1	RP11-33B1.2	8.57	3.74e-17	1.38e-14	0.26	0.26	Corneal astigmatism;	chr4:119466104	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.909	rs17046118	ENSG00000248280.1	RP11-33B1.2	8.57	3.74e-17	1.38e-14	0.26	0.26	Corneal astigmatism;	chr4:119466341	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.954	rs7654587	ENSG00000248280.1	RP11-33B1.2	8.57	3.74e-17	1.38e-14	0.26	0.26	Corneal astigmatism;	chr4:119467251	chr4:119440561~119450157:-
BRCA	cis	rs58873874	0.737	rs79339674	ENSG00000248544.2	CTB-47B11.3	8.57	3.74e-17	1.39e-14	0.63	0.26	Bipolar disorder (body mass index interaction);	chr5:157464318	chr5:157375741~157384950:-
BRCA	cis	rs2243480	1	rs958550	ENSG00000273142.1	RP11-458F8.4	8.57	3.75e-17	1.39e-14	0.34	0.26	Diabetic kidney disease;	chr7:66170692	chr7:66902857~66906297:+
BRCA	cis	rs4308124	0.708	rs2137168	ENSG00000230499.1	AC108463.1	-8.57	3.75e-17	1.39e-14	-0.34	-0.26	Vitiligo;	chr2:111228932	chr2:111195963~111206494:+
BRCA	cis	rs11098499	0.863	rs3822190	ENSG00000248280.1	RP11-33B1.2	8.57	3.75e-17	1.39e-14	0.27	0.26	Corneal astigmatism;	chr4:119506943	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.863	rs3822191	ENSG00000248280.1	RP11-33B1.2	8.57	3.75e-17	1.39e-14	0.27	0.26	Corneal astigmatism;	chr4:119506946	chr4:119440561~119450157:-
BRCA	cis	rs1707322	1	rs2458400	ENSG00000280836.1	AL355480.1	8.57	3.76e-17	1.39e-14	0.32	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46065126	chr1:45581219~45581321:-
BRCA	cis	rs10463554	0.667	rs57714862	ENSG00000175749.11	EIF3KP1	8.57	3.77e-17	1.4e-14	0.35	0.26	Parkinson's disease;	chr5:103047025	chr5:103032376~103033031:+
BRCA	cis	rs113835537	0.597	rs57288351	ENSG00000255517.5	CTD-3074O7.5	-8.57	3.78e-17	1.4e-14	-0.34	-0.26	Airway imaging phenotypes;	chr11:66540018	chr11:66473490~66480233:-
BRCA	cis	rs10971721	0.822	rs72727350	ENSG00000260947.1	RP11-384P7.7	8.57	3.78e-17	1.4e-14	0.46	0.26	Body mass index;	chr9:33944732	chr9:33697459~33700986:+
BRCA	cis	rs2933343	1	rs1680790	ENSG00000261159.1	RP11-723O4.9	8.57	3.79e-17	1.4e-14	0.31	0.26	IgG glycosylation;	chr3:128907010	chr3:128859716~128860526:-
BRCA	cis	rs10463554	0.927	rs34799	ENSG00000175749.11	EIF3KP1	8.57	3.8e-17	1.41e-14	0.37	0.26	Parkinson's disease;	chr5:103090498	chr5:103032376~103033031:+
BRCA	cis	rs10463554	0.927	rs34800	ENSG00000175749.11	EIF3KP1	8.57	3.8e-17	1.41e-14	0.37	0.26	Parkinson's disease;	chr5:103090799	chr5:103032376~103033031:+
BRCA	cis	rs11157436	0.958	rs6572313	ENSG00000211812.1	TRAV26-2	-8.57	3.81e-17	1.41e-14	-0.24	-0.26	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22214070	chr14:22202583~22203368:+
BRCA	cis	rs875971	0.543	rs801191	ENSG00000237310.1	GS1-124K5.4	-8.57	3.82e-17	1.41e-14	-0.27	-0.26	Aortic root size;	chr7:66567968	chr7:66493706~66495474:+
BRCA	cis	rs4308124	0.708	rs67816163	ENSG00000230499.1	AC108463.1	-8.57	3.83e-17	1.42e-14	-0.33	-0.26	Vitiligo;	chr2:111205733	chr2:111195963~111206494:+
BRCA	cis	rs10463554	0.927	rs34825	ENSG00000175749.11	EIF3KP1	8.56	3.85e-17	1.42e-14	0.36	0.26	Parkinson's disease;	chr5:103103614	chr5:103032376~103033031:+
BRCA	cis	rs10463554	0.963	rs34826	ENSG00000175749.11	EIF3KP1	8.56	3.85e-17	1.42e-14	0.36	0.26	Parkinson's disease;	chr5:103106044	chr5:103032376~103033031:+
BRCA	cis	rs375066	0.935	rs421512	ENSG00000267058.1	RP11-15A1.3	-8.56	3.88e-17	1.43e-14	-0.3	-0.26	Breast cancer;	chr19:43911428	chr19:43891804~43901805:-
BRCA	cis	rs950880	0.71	rs55645612	ENSG00000234389.1	AC007278.3	-8.56	3.88e-17	1.44e-14	-0.25	-0.26	Serum protein levels (sST2);	chr2:102439201	chr2:102438713~102440475:+
BRCA	cis	rs1707322	1	rs7517560	ENSG00000280836.1	AL355480.1	-8.56	3.88e-17	1.44e-14	-0.33	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45960271	chr1:45581219~45581321:-
BRCA	cis	rs7429990	0.864	rs11130146	ENSG00000229759.1	MRPS18AP1	-8.56	3.89e-17	1.44e-14	-0.29	-0.26	Educational attainment (years of education);	chr3:47666322	chr3:48256350~48256938:-
BRCA	cis	rs7429990	0.864	rs13063042	ENSG00000229759.1	MRPS18AP1	-8.56	3.89e-17	1.44e-14	-0.29	-0.26	Educational attainment (years of education);	chr3:47683825	chr3:48256350~48256938:-
BRCA	cis	rs1707322	1	rs785470	ENSG00000280836.1	AL355480.1	8.56	3.89e-17	1.44e-14	0.32	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46053950	chr1:45581219~45581321:-
BRCA	cis	rs10971721	0.822	rs72727362	ENSG00000260947.1	RP11-384P7.7	8.56	3.9e-17	1.44e-14	0.46	0.26	Body mass index;	chr9:33957324	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.822	rs72727367	ENSG00000260947.1	RP11-384P7.7	8.56	3.9e-17	1.44e-14	0.46	0.26	Body mass index;	chr9:33965180	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.822	rs72727369	ENSG00000260947.1	RP11-384P7.7	8.56	3.9e-17	1.44e-14	0.46	0.26	Body mass index;	chr9:33965777	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.822	rs10971826	ENSG00000260947.1	RP11-384P7.7	8.56	3.9e-17	1.44e-14	0.46	0.26	Body mass index;	chr9:33972035	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.822	rs10971827	ENSG00000260947.1	RP11-384P7.7	8.56	3.9e-17	1.44e-14	0.46	0.26	Body mass index;	chr9:33972469	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.822	rs10971828	ENSG00000260947.1	RP11-384P7.7	8.56	3.9e-17	1.44e-14	0.46	0.26	Body mass index;	chr9:33973417	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.822	rs72727378	ENSG00000260947.1	RP11-384P7.7	8.56	3.9e-17	1.44e-14	0.46	0.26	Body mass index;	chr9:33975792	chr9:33697459~33700986:+
BRCA	cis	rs11098499	0.909	rs11723757	ENSG00000248280.1	RP11-33B1.2	8.56	3.9e-17	1.44e-14	0.26	0.26	Corneal astigmatism;	chr4:119378514	chr4:119440561~119450157:-
BRCA	cis	rs875971	0.502	rs2465121	ENSG00000222364.1	RNU6-96P	8.56	3.91e-17	1.44e-14	0.34	0.26	Aortic root size;	chr7:66156017	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.838	rs2173570	ENSG00000237310.1	GS1-124K5.4	-8.56	3.91e-17	1.45e-14	-0.27	-0.26	Aortic root size;	chr7:66297976	chr7:66493706~66495474:+
BRCA	cis	rs526231	0.511	rs11951374	ENSG00000175749.11	EIF3KP1	8.56	3.91e-17	1.45e-14	0.36	0.26	Primary biliary cholangitis;	chr5:103020094	chr5:103032376~103033031:+
BRCA	cis	rs950776	0.518	rs55690619	ENSG00000261762.1	RP11-650L12.2	-8.56	3.93e-17	1.45e-14	-0.28	-0.26	Sudden cardiac arrest;	chr15:78541270	chr15:78589123~78591276:-
BRCA	cis	rs11098499	0.754	rs714899	ENSG00000245958.5	RP11-33B1.1	-8.56	3.93e-17	1.45e-14	-0.24	-0.26	Corneal astigmatism;	chr4:119321880	chr4:119454791~119552025:+
BRCA	cis	rs7428	0.527	rs6547612	ENSG00000246575.2	AC093162.5	8.56	3.94e-17	1.45e-14	0.27	0.26	Ear protrusion;	chr2:85324061	chr2:85315041~85316529:+
BRCA	cis	rs875971	0.545	rs10950025	ENSG00000222364.1	RNU6-96P	-8.56	3.94e-17	1.45e-14	-0.33	-0.26	Aortic root size;	chr7:66158946	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.52	rs12666485	ENSG00000222364.1	RNU6-96P	-8.56	3.94e-17	1.45e-14	-0.33	-0.26	Aortic root size;	chr7:66160135	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.545	rs67688847	ENSG00000222364.1	RNU6-96P	-8.56	3.94e-17	1.45e-14	-0.33	-0.26	Aortic root size;	chr7:66161064	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.545	rs10950036	ENSG00000222364.1	RNU6-96P	-8.56	3.94e-17	1.46e-14	-0.34	-0.26	Aortic root size;	chr7:66353241	chr7:66395191~66395286:+
BRCA	cis	rs10463554	0.927	rs34802	ENSG00000175749.11	EIF3KP1	8.56	3.95e-17	1.46e-14	0.37	0.26	Parkinson's disease;	chr5:103091301	chr5:103032376~103033031:+
BRCA	cis	rs526231	0.508	rs34805	ENSG00000175749.11	EIF3KP1	8.56	3.95e-17	1.46e-14	0.37	0.26	Primary biliary cholangitis;	chr5:103092608	chr5:103032376~103033031:+
BRCA	cis	rs4660456	0.913	rs4660448	ENSG00000237899.1	RP4-739H11.3	-8.56	3.95e-17	1.46e-14	-0.38	-0.26	Platelet count;	chr1:40724682	chr1:40669089~40687588:-
BRCA	cis	rs4660456	0.913	rs7532802	ENSG00000237899.1	RP4-739H11.3	-8.56	3.95e-17	1.46e-14	-0.38	-0.26	Platelet count;	chr1:40725528	chr1:40669089~40687588:-
BRCA	cis	rs4660456	0.913	rs2361648	ENSG00000237899.1	RP4-739H11.3	-8.56	3.95e-17	1.46e-14	-0.38	-0.26	Platelet count;	chr1:40726825	chr1:40669089~40687588:-
BRCA	cis	rs4660456	0.913	rs6675886	ENSG00000237899.1	RP4-739H11.3	-8.56	3.95e-17	1.46e-14	-0.38	-0.26	Platelet count;	chr1:40727955	chr1:40669089~40687588:-
BRCA	cis	rs4660456	0.913	rs35881320	ENSG00000237899.1	RP4-739H11.3	-8.56	3.95e-17	1.46e-14	-0.38	-0.26	Platelet count;	chr1:40733893	chr1:40669089~40687588:-
BRCA	cis	rs4660456	0.871	rs34512220	ENSG00000237899.1	RP4-739H11.3	-8.56	3.95e-17	1.46e-14	-0.38	-0.26	Platelet count;	chr1:40733912	chr1:40669089~40687588:-
BRCA	cis	rs4660456	0.913	rs6664044	ENSG00000237899.1	RP4-739H11.3	-8.56	3.95e-17	1.46e-14	-0.38	-0.26	Platelet count;	chr1:40735089	chr1:40669089~40687588:-
BRCA	cis	rs4660456	0.913	rs6702983	ENSG00000237899.1	RP4-739H11.3	-8.56	3.95e-17	1.46e-14	-0.38	-0.26	Platelet count;	chr1:40735585	chr1:40669089~40687588:-
BRCA	cis	rs4660456	0.913	rs12566733	ENSG00000237899.1	RP4-739H11.3	-8.56	3.95e-17	1.46e-14	-0.38	-0.26	Platelet count;	chr1:40736067	chr1:40669089~40687588:-
BRCA	cis	rs7429990	0.833	rs883661	ENSG00000229759.1	MRPS18AP1	-8.56	3.96e-17	1.46e-14	-0.29	-0.26	Educational attainment (years of education);	chr3:47618611	chr3:48256350~48256938:-
BRCA	cis	rs17023223	0.537	rs2645302	ENSG00000231365.4	RP11-418J17.1	-8.56	3.97e-17	1.47e-14	-0.33	-0.26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119047775	chr1:119140396~119275973:+
BRCA	cis	rs375066	0.935	rs373168	ENSG00000267058.1	RP11-15A1.3	-8.56	3.98e-17	1.47e-14	-0.29	-0.26	Breast cancer;	chr19:43926717	chr19:43891804~43901805:-
BRCA	cis	rs858239	0.601	rs11982002	ENSG00000230042.1	AK3P3	-8.56	3.98e-17	1.47e-14	-0.29	-0.26	Cerebrospinal fluid biomarker levels;	chr7:23123651	chr7:23129178~23129841:+
BRCA	cis	rs7429990	0.833	rs2030596	ENSG00000229759.1	MRPS18AP1	-8.56	3.98e-17	1.47e-14	-0.29	-0.26	Educational attainment (years of education);	chr3:47701712	chr3:48256350~48256938:-
BRCA	cis	rs10463554	0.927	rs34795	ENSG00000175749.11	EIF3KP1	8.56	4.01e-17	1.48e-14	0.37	0.26	Parkinson's disease;	chr5:103088716	chr5:103032376~103033031:+
BRCA	cis	rs10463554	0.927	rs34796	ENSG00000175749.11	EIF3KP1	8.56	4.01e-17	1.48e-14	0.37	0.26	Parkinson's disease;	chr5:103088725	chr5:103032376~103033031:+
BRCA	cis	rs526231	0.543	rs26819	ENSG00000175749.11	EIF3KP1	8.56	4.01e-17	1.48e-14	0.37	0.26	Primary biliary cholangitis;	chr5:103193700	chr5:103032376~103033031:+
BRCA	cis	rs526231	0.615	rs26818	ENSG00000175749.11	EIF3KP1	8.56	4.01e-17	1.48e-14	0.37	0.26	Primary biliary cholangitis;	chr5:103194018	chr5:103032376~103033031:+
BRCA	cis	rs10971721	0.822	rs72727389	ENSG00000260947.1	RP11-384P7.7	8.56	4.01e-17	1.48e-14	0.46	0.26	Body mass index;	chr9:33987030	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.822	rs72727399	ENSG00000260947.1	RP11-384P7.7	8.56	4.01e-17	1.48e-14	0.46	0.26	Body mass index;	chr9:33997271	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.686	rs10971839	ENSG00000260947.1	RP11-384P7.7	8.56	4.01e-17	1.48e-14	0.46	0.26	Body mass index;	chr9:33998410	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.822	rs72729305	ENSG00000260947.1	RP11-384P7.7	8.56	4.01e-17	1.48e-14	0.46	0.26	Body mass index;	chr9:34000293	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.822	rs10971845	ENSG00000260947.1	RP11-384P7.7	8.56	4.01e-17	1.48e-14	0.46	0.26	Body mass index;	chr9:34009879	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.822	rs10971847	ENSG00000260947.1	RP11-384P7.7	8.56	4.01e-17	1.48e-14	0.46	0.26	Body mass index;	chr9:34011460	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.822	rs10971848	ENSG00000260947.1	RP11-384P7.7	8.56	4.01e-17	1.48e-14	0.46	0.26	Body mass index;	chr9:34012504	chr9:33697459~33700986:+
BRCA	cis	rs35160687	0.712	rs12052607	ENSG00000273080.1	RP11-301O19.1	-8.56	4.02e-17	1.48e-14	-0.29	-0.26	Night sleep phenotypes;	chr2:86279394	chr2:86195590~86196049:+
BRCA	cis	rs35160687	0.712	rs1863059	ENSG00000273080.1	RP11-301O19.1	-8.56	4.03e-17	1.49e-14	-0.29	-0.26	Night sleep phenotypes;	chr2:86282265	chr2:86195590~86196049:+
BRCA	cis	rs2439831	0.702	rs16977724	ENSG00000249839.1	AC011330.5	-8.56	4.03e-17	1.49e-14	-0.46	-0.26	Lung cancer in ever smokers;	chr15:43859101	chr15:43663654~43684339:-
BRCA	cis	rs875971	0.651	rs313829	ENSG00000222364.1	RNU6-96P	8.56	4.04e-17	1.49e-14	0.33	0.26	Aortic root size;	chr7:66087510	chr7:66395191~66395286:+
BRCA	cis	rs17023223	0.537	rs2645305	ENSG00000231365.4	RP11-418J17.1	-8.56	4.04e-17	1.49e-14	-0.33	-0.26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119018742	chr1:119140396~119275973:+
BRCA	cis	rs10463554	0.963	rs67068617	ENSG00000175749.11	EIF3KP1	8.56	4.04e-17	1.49e-14	0.36	0.26	Parkinson's disease;	chr5:103039977	chr5:103032376~103033031:+
BRCA	cis	rs10129255	0.556	rs6576222	ENSG00000211972.2	IGHV3-66	8.56	4.04e-17	1.49e-14	0.18	0.26	Kawasaki disease;	chr14:106776442	chr14:106675017~106675544:-
BRCA	cis	rs3758911	0.929	rs10749894	ENSG00000255353.1	RP11-382M14.1	-8.56	4.05e-17	1.49e-14	-0.34	-0.26	Coronary artery disease;	chr11:107309586	chr11:107176286~107177530:+
BRCA	cis	rs11971779	0.941	rs74299967	ENSG00000273391.1	RP11-634H22.1	8.56	4.06e-17	1.5e-14	0.29	0.26	Diisocyanate-induced asthma;	chr7:139359023	chr7:139359032~139359566:-
BRCA	cis	rs10129255	0.536	rs6576223	ENSG00000211972.2	IGHV3-66	8.56	4.07e-17	1.5e-14	0.18	0.26	Kawasaki disease;	chr14:106776448	chr14:106675017~106675544:-
BRCA	cis	rs6570726	0.846	rs409553	ENSG00000235652.6	RP11-545I5.3	8.56	4.07e-17	1.5e-14	0.25	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145565827	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.846	rs371186	ENSG00000235652.6	RP11-545I5.3	8.56	4.07e-17	1.5e-14	0.25	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145565835	chr6:145799409~145886585:+
BRCA	cis	rs2404602	0.716	rs8030411	ENSG00000259422.1	RP11-593F23.1	8.56	4.09e-17	1.51e-14	0.32	0.26	Blood metabolite levels;	chr15:76407514	chr15:76174891~76181486:-
BRCA	cis	rs2933343	1	rs876756	ENSG00000261159.1	RP11-723O4.9	8.56	4.1e-17	1.51e-14	0.31	0.26	IgG glycosylation;	chr3:128908780	chr3:128859716~128860526:-
BRCA	cis	rs10463554	0.892	rs34816	ENSG00000175749.11	EIF3KP1	8.56	4.11e-17	1.52e-14	0.37	0.26	Parkinson's disease;	chr5:103098941	chr5:103032376~103033031:+
BRCA	cis	rs875971	0.577	rs34888281	ENSG00000224316.1	RP11-479O9.2	-8.56	4.12e-17	1.52e-14	-0.26	-0.26	Aortic root size;	chr7:66120784	chr7:65773620~65802067:+
BRCA	cis	rs12458462	0.892	rs2242174	ENSG00000274828.1	RP11-567M16.6	8.56	4.13e-17	1.52e-14	0.3	0.26	Monocyte count;	chr18:79698037	chr18:79677287~79679358:-
BRCA	cis	rs7945705	0.967	rs10769968	ENSG00000254860.4	TMEM9B-AS1	-8.56	4.13e-17	1.52e-14	-0.24	-0.26	Hemoglobin concentration;	chr11:8886036	chr11:8964675~8977527:+
BRCA	cis	rs11098499	0.908	rs28559989	ENSG00000248280.1	RP11-33B1.2	8.56	4.13e-17	1.52e-14	0.26	0.26	Corneal astigmatism;	chr4:119465472	chr4:119440561~119450157:-
BRCA	cis	rs6570726	0.72	rs412623	ENSG00000235652.6	RP11-545I5.3	8.56	4.13e-17	1.52e-14	0.25	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145562121	chr6:145799409~145886585:+
BRCA	cis	rs375066	0.935	rs399098	ENSG00000267058.1	RP11-15A1.3	-8.56	4.15e-17	1.53e-14	-0.3	-0.26	Breast cancer;	chr19:43914672	chr19:43891804~43901805:-
BRCA	cis	rs10129255	0.957	rs10140904	ENSG00000223648.3	IGHV3-64	8.56	4.16e-17	1.53e-14	0.21	0.26	Kawasaki disease;	chr14:106776558	chr14:106643132~106658258:-
BRCA	cis	rs2404602	1	rs4886818	ENSG00000259422.1	RP11-593F23.1	8.56	4.16e-17	1.53e-14	0.32	0.26	Blood metabolite levels;	chr15:76588598	chr15:76174891~76181486:-
BRCA	cis	rs13256369	0.826	rs7846050	ENSG00000253893.2	FAM85B	-8.56	4.16e-17	1.53e-14	-0.36	-0.26	Obesity-related traits;	chr8:8718159	chr8:8167819~8226614:-
BRCA	cis	rs875971	0.545	rs6460276	ENSG00000222364.1	RNU6-96P	-8.55	4.18e-17	1.54e-14	-0.33	-0.26	Aortic root size;	chr7:66182290	chr7:66395191~66395286:+
BRCA	cis	rs17023223	0.537	rs2765531	ENSG00000231365.4	RP11-418J17.1	-8.55	4.21e-17	1.55e-14	-0.33	-0.26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119042874	chr1:119140396~119275973:+
BRCA	cis	rs17023223	0.537	rs2794313	ENSG00000231365.4	RP11-418J17.1	-8.55	4.21e-17	1.55e-14	-0.33	-0.26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119044817	chr1:119140396~119275973:+
BRCA	cis	rs1275468	0.798	rs10879928	ENSG00000257497.2	RP11-585P4.5	8.55	4.21e-17	1.55e-14	0.35	0.26	Polycystic ovary syndrome;	chr12:75531996	chr12:75483454~75489820:-
BRCA	cis	rs10129255	0.518	rs7143784	ENSG00000280411.1	IGHV1-69-2	-8.55	4.22e-17	1.55e-14	-0.17	-0.26	Kawasaki disease;	chr14:106687277	chr14:106762092~106762588:-
BRCA	cis	rs875971	0.528	rs801213	ENSG00000222364.1	RNU6-96P	8.55	4.22e-17	1.56e-14	0.34	0.26	Aortic root size;	chr7:66549931	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.545	rs801212	ENSG00000222364.1	RNU6-96P	8.55	4.22e-17	1.56e-14	0.34	0.26	Aortic root size;	chr7:66550643	chr7:66395191~66395286:+
BRCA	cis	rs3758911	0.894	rs10890698	ENSG00000255353.1	RP11-382M14.1	-8.55	4.23e-17	1.56e-14	-0.34	-0.26	Coronary artery disease;	chr11:107308080	chr11:107176286~107177530:+
BRCA	cis	rs3758911	0.929	rs10890700	ENSG00000255353.1	RP11-382M14.1	-8.55	4.23e-17	1.56e-14	-0.34	-0.26	Coronary artery disease;	chr11:107308243	chr11:107176286~107177530:+
BRCA	cis	rs3758911	0.964	rs10789599	ENSG00000255353.1	RP11-382M14.1	-8.55	4.23e-17	1.56e-14	-0.34	-0.26	Coronary artery disease;	chr11:107309145	chr11:107176286~107177530:+
BRCA	cis	rs10510102	0.872	rs7076727	ENSG00000276742.1	RP11-500G22.4	8.55	4.23e-17	1.56e-14	0.44	0.26	Breast cancer;	chr10:121947000	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.745	rs7076882	ENSG00000276742.1	RP11-500G22.4	8.55	4.23e-17	1.56e-14	0.44	0.26	Breast cancer;	chr10:121947039	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.872	rs7077035	ENSG00000276742.1	RP11-500G22.4	8.55	4.23e-17	1.56e-14	0.44	0.26	Breast cancer;	chr10:121947130	chr10:121956782~121957098:+
BRCA	cis	rs875971	0.545	rs316305	ENSG00000222364.1	RNU6-96P	8.55	4.25e-17	1.56e-14	0.33	0.26	Aortic root size;	chr7:66152984	chr7:66395191~66395286:+
BRCA	cis	rs13256369	1	rs9329166	ENSG00000253893.2	FAM85B	-8.55	4.26e-17	1.57e-14	-0.35	-0.26	Obesity-related traits;	chr8:8719145	chr8:8167819~8226614:-
BRCA	cis	rs7429990	0.833	rs870622	ENSG00000229759.1	MRPS18AP1	-8.55	4.26e-17	1.57e-14	-0.29	-0.26	Educational attainment (years of education);	chr3:47618683	chr3:48256350~48256938:-
BRCA	cis	rs7772486	0.641	rs67882056	ENSG00000235652.6	RP11-545I5.3	8.55	4.3e-17	1.58e-14	0.28	0.26	Lobe attachment (rater-scored or self-reported);	chr6:146095165	chr6:145799409~145886585:+
BRCA	cis	rs11098499	0.82	rs13122709	ENSG00000248280.1	RP11-33B1.2	8.55	4.32e-17	1.59e-14	0.27	0.26	Corneal astigmatism;	chr4:119634201	chr4:119440561~119450157:-
BRCA	cis	rs875971	0.545	rs6969224	ENSG00000222364.1	RNU6-96P	-8.55	4.32e-17	1.59e-14	-0.35	-0.26	Aortic root size;	chr7:66370011	chr7:66395191~66395286:+
BRCA	cis	rs61270009	0.955	rs12655529	ENSG00000247828.6	TMEM161B-AS1	8.55	4.32e-17	1.59e-14	0.33	0.26	Depressive symptoms;	chr5:88280980	chr5:88268895~88436685:+
BRCA	cis	rs2153535	1	rs2153535	ENSG00000230939.1	RP11-314C16.1	8.55	4.35e-17	1.6e-14	0.29	0.26	Motion sickness;	chr6:8369446	chr6:8784178~8785445:+
BRCA	cis	rs11673344	0.582	rs114437741	ENSG00000226686.6	LINC01535	8.55	4.37e-17	1.61e-14	0.33	0.26	Obesity-related traits;	chr19:36955379	chr19:37251912~37265535:+
BRCA	cis	rs7429990	0.864	rs12633604	ENSG00000229759.1	MRPS18AP1	-8.55	4.37e-17	1.61e-14	-0.29	-0.26	Educational attainment (years of education);	chr3:47673308	chr3:48256350~48256938:-
BRCA	cis	rs11098499	0.954	rs2389802	ENSG00000248280.1	RP11-33B1.2	8.55	4.38e-17	1.61e-14	0.26	0.26	Corneal astigmatism;	chr4:119404577	chr4:119440561~119450157:-
BRCA	cis	rs875971	0.545	rs75840613	ENSG00000222364.1	RNU6-96P	-8.55	4.38e-17	1.61e-14	-0.34	-0.26	Aortic root size;	chr7:66376399	chr7:66395191~66395286:+
BRCA	cis	rs17711722	0.51	rs11767457	ENSG00000273024.4	INTS4P2	-8.55	4.4e-17	1.62e-14	-0.3	-0.26	Calcium levels;	chr7:65825628	chr7:65647864~65715661:+
BRCA	cis	rs3096299	0.9	rs3114867	ENSG00000274627.1	RP11-104N10.2	8.55	4.4e-17	1.62e-14	0.26	0.26	Multiple myeloma (IgH translocation);	chr16:89362559	chr16:89516797~89522217:+
BRCA	cis	rs3758911	0.929	rs1843	ENSG00000255353.1	RP11-382M14.1	-8.55	4.4e-17	1.62e-14	-0.34	-0.26	Coronary artery disease;	chr11:107312219	chr11:107176286~107177530:+
BRCA	cis	rs11098499	0.535	rs7671759	ENSG00000248280.1	RP11-33B1.2	8.55	4.41e-17	1.62e-14	0.26	0.26	Corneal astigmatism;	chr4:119326939	chr4:119440561~119450157:-
BRCA	cis	rs897984	0.645	rs58726213	ENSG00000260911.2	RP11-196G11.2	8.55	4.43e-17	1.63e-14	0.23	0.26	Dementia with Lewy bodies;	chr16:31033362	chr16:31043150~31049868:+
BRCA	cis	rs4660456	0.913	rs552147	ENSG00000237899.1	RP4-739H11.3	-8.55	4.43e-17	1.63e-14	-0.39	-0.26	Platelet count;	chr1:40689141	chr1:40669089~40687588:-
BRCA	cis	rs11763147	1	rs11763147	ENSG00000236529.1	RP13-254B10.1	-8.55	4.44e-17	1.63e-14	-0.27	-0.26	Corneal structure;	chr7:65861834	chr7:65840212~65840596:+
BRCA	cis	rs10754283	0.756	rs17441836	ENSG00000231613.1	RP5-943J3.1	8.55	4.45e-17	1.64e-14	0.3	0.26	Amyotrophic lateral sclerosis (sporadic);	chr1:89669874	chr1:89788914~89790492:+
BRCA	cis	rs2810114	0.916	rs2810099	ENSG00000269927.1	RP6-91H8.3	-8.55	4.46e-17	1.64e-14	-0.34	-0.26	Alcohol dependence;	chr14:70965704	chr14:71141125~71143253:-
BRCA	cis	rs4308124	0.708	rs28766030	ENSG00000230499.1	AC108463.1	-8.55	4.46e-17	1.64e-14	-0.33	-0.26	Vitiligo;	chr2:111204852	chr2:111195963~111206494:+
BRCA	cis	rs1134634	0.52	rs11943107	ENSG00000273133.1	RP11-799M12.2	-8.55	4.47e-17	1.64e-14	-0.34	-0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15573042	chr4:15563698~15564253:-
BRCA	cis	rs807029	0.533	rs67692077	ENSG00000272572.1	RP11-179B2.2	-8.55	4.47e-17	1.64e-14	-0.33	-0.26	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100980514	chr10:100911103~100912739:-
BRCA	cis	rs807029	0.533	rs12571302	ENSG00000272572.1	RP11-179B2.2	-8.55	4.47e-17	1.64e-14	-0.33	-0.26	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100983006	chr10:100911103~100912739:-
BRCA	cis	rs807029	0.533	rs2863095	ENSG00000272572.1	RP11-179B2.2	-8.55	4.47e-17	1.64e-14	-0.33	-0.26	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100986746	chr10:100911103~100912739:-
BRCA	cis	rs896854	0.967	rs13257021	ENSG00000253528.2	RP11-347C18.4	8.55	4.49e-17	1.65e-14	0.27	0.26	Type 2 diabetes;	chr8:94953467	chr8:94974573~94974853:-
BRCA	cis	rs1707322	1	rs10890350	ENSG00000280836.1	AL355480.1	-8.55	4.51e-17	1.66e-14	-0.33	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45796706	chr1:45581219~45581321:-
BRCA	cis	rs10129255	0.957	rs10141009	ENSG00000223648.3	IGHV3-64	8.55	4.51e-17	1.66e-14	0.21	0.26	Kawasaki disease;	chr14:106776695	chr14:106643132~106658258:-
BRCA	cis	rs3758911	0.861	rs10890688	ENSG00000255353.1	RP11-382M14.1	-8.55	4.51e-17	1.66e-14	-0.34	-0.26	Coronary artery disease;	chr11:107272020	chr11:107176286~107177530:+
BRCA	cis	rs4660456	0.913	rs12727412	ENSG00000237899.1	RP4-739H11.3	-8.54	4.51e-17	1.66e-14	-0.38	-0.26	Platelet count;	chr1:40723243	chr1:40669089~40687588:-
BRCA	cis	rs4660456	0.913	rs6668453	ENSG00000237899.1	RP4-739H11.3	-8.54	4.51e-17	1.66e-14	-0.38	-0.26	Platelet count;	chr1:40733299	chr1:40669089~40687588:-
BRCA	cis	rs193541	0.632	rs30063	ENSG00000263432.2	RN7SL689P	8.54	4.53e-17	1.66e-14	0.35	0.26	Glucose homeostasis traits;	chr5:122959998	chr5:123022487~123022783:-
BRCA	cis	rs950776	0.518	rs4886571	ENSG00000261762.1	RP11-650L12.2	-8.54	4.54e-17	1.67e-14	-0.28	-0.26	Sudden cardiac arrest;	chr15:78541416	chr15:78589123~78591276:-
BRCA	cis	rs7772486	0.641	rs9390374	ENSG00000235652.6	RP11-545I5.3	8.54	4.54e-17	1.67e-14	0.28	0.26	Lobe attachment (rater-scored or self-reported);	chr6:146047039	chr6:145799409~145886585:+
BRCA	cis	rs11098499	0.818	rs55825515	ENSG00000245958.5	RP11-33B1.1	-8.54	4.54e-17	1.67e-14	-0.26	-0.26	Corneal astigmatism;	chr4:119565247	chr4:119454791~119552025:+
BRCA	cis	rs2404602	0.716	rs12592171	ENSG00000259422.1	RP11-593F23.1	8.54	4.57e-17	1.68e-14	0.33	0.26	Blood metabolite levels;	chr15:76462792	chr15:76174891~76181486:-
BRCA	cis	rs10463554	0.927	rs34810	ENSG00000175749.11	EIF3KP1	8.54	4.58e-17	1.68e-14	0.37	0.26	Parkinson's disease;	chr5:103095045	chr5:103032376~103033031:+
BRCA	cis	rs11098499	0.954	rs12510138	ENSG00000248280.1	RP11-33B1.2	8.54	4.6e-17	1.69e-14	0.26	0.26	Corneal astigmatism;	chr4:119502780	chr4:119440561~119450157:-
BRCA	cis	rs7568498	0.564	rs10490563	ENSG00000227403.1	AC009299.3	8.54	4.6e-17	1.69e-14	0.37	0.26	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);	chr2:161057657	chr2:161244739~161249050:+
BRCA	cis	rs150992	0.569	rs326482	ENSG00000248489.1	CTD-2007H13.3	8.54	4.62e-17	1.7e-14	0.33	0.26	Body mass index;	chr5:98951115	chr5:98929171~98995013:+
BRCA	cis	rs2404602	0.716	rs8025134	ENSG00000259422.1	RP11-593F23.1	8.54	4.63e-17	1.7e-14	0.33	0.26	Blood metabolite levels;	chr15:76489388	chr15:76174891~76181486:-
BRCA	cis	rs11971779	0.793	rs4728464	ENSG00000273391.1	RP11-634H22.1	-8.54	4.64e-17	1.7e-14	-0.26	-0.26	Diisocyanate-induced asthma;	chr7:139332924	chr7:139359032~139359566:-
BRCA	cis	rs2439831	0.85	rs3816792	ENSG00000249839.1	AC011330.5	8.54	4.64e-17	1.7e-14	0.42	0.26	Lung cancer in ever smokers;	chr15:43824788	chr15:43663654~43684339:-
BRCA	cis	rs10971721	0.731	rs10971857	ENSG00000260947.1	RP11-384P7.7	8.54	4.64e-17	1.7e-14	0.46	0.26	Body mass index;	chr9:34021621	chr9:33697459~33700986:+
BRCA	cis	rs875971	0.965	rs28682868	ENSG00000237310.1	GS1-124K5.4	-8.54	4.68e-17	1.72e-14	-0.27	-0.26	Aortic root size;	chr7:66224822	chr7:66493706~66495474:+
BRCA	cis	rs1075265	0.722	rs7596349	ENSG00000233266.1	HMGB1P31	8.54	4.68e-17	1.72e-14	0.31	0.26	Chronotype;Morning vs. evening chronotype;	chr2:53709123	chr2:54051334~54051760:+
BRCA	cis	rs801193	0.66	rs10950049	ENSG00000237310.1	GS1-124K5.4	8.54	4.69e-17	1.72e-14	0.27	0.26	Aortic root size;	chr7:66765873	chr7:66493706~66495474:+
BRCA	cis	rs17711722	1	rs17711722	ENSG00000222364.1	RNU6-96P	8.54	4.7e-17	1.72e-14	0.29	0.26	Calcium levels;	chr7:65806210	chr7:66395191~66395286:+
BRCA	cis	rs1707322	0.963	rs11211202	ENSG00000280836.1	AL355480.1	-8.54	4.72e-17	1.73e-14	-0.32	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45826710	chr1:45581219~45581321:-
BRCA	cis	rs1707322	1	rs10890365	ENSG00000280836.1	AL355480.1	-8.54	4.73e-17	1.73e-14	-0.32	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45893676	chr1:45581219~45581321:-
BRCA	cis	rs7246657	0.722	rs2909102	ENSG00000267422.1	CTD-2554C21.1	8.54	4.73e-17	1.74e-14	0.38	0.26	Coronary artery calcification;	chr19:37676463	chr19:37779686~37792865:+
BRCA	cis	rs4934494	0.727	rs1590566	ENSG00000240996.1	RP11-80H5.7	-8.54	4.74e-17	1.74e-14	-0.3	-0.26	Red blood cell count;	chr10:89778781	chr10:89694295~89697928:-
BRCA	cis	rs875971	0.545	rs6961853	ENSG00000222364.1	RNU6-96P	-8.54	4.77e-17	1.75e-14	-0.34	-0.26	Aortic root size;	chr7:66537035	chr7:66395191~66395286:+
BRCA	cis	rs4660456	0.83	rs12742219	ENSG00000237899.1	RP4-739H11.3	-8.54	4.77e-17	1.75e-14	-0.38	-0.26	Platelet count;	chr1:40728665	chr1:40669089~40687588:-
BRCA	cis	rs7429990	0.864	rs11130144	ENSG00000229759.1	MRPS18AP1	-8.54	4.78e-17	1.75e-14	-0.29	-0.26	Educational attainment (years of education);	chr3:47626444	chr3:48256350~48256938:-
BRCA	cis	rs10129255	0.957	rs10141052	ENSG00000223648.3	IGHV3-64	8.54	4.79e-17	1.75e-14	0.21	0.26	Kawasaki disease;	chr14:106776528	chr14:106643132~106658258:-
BRCA	cis	rs2286503	0.901	rs2286505	ENSG00000228649.7	AC005682.5	8.54	4.79e-17	1.76e-14	0.22	0.26	Fibrinogen;	chr7:22815221	chr7:22854178~22861579:+
BRCA	cis	rs67981189	0.529	rs2158996	ENSG00000269927.1	RP6-91H8.3	8.54	4.84e-17	1.77e-14	0.34	0.26	Schizophrenia;	chr14:71062882	chr14:71141125~71143253:-
BRCA	cis	rs875971	0.628	rs6974355	ENSG00000222364.1	RNU6-96P	-8.54	4.85e-17	1.78e-14	-0.3	-0.26	Aortic root size;	chr7:66376994	chr7:66395191~66395286:+
BRCA	cis	rs1501911	0.566	rs709387	ENSG00000248489.1	CTD-2007H13.3	8.54	4.86e-17	1.78e-14	0.33	0.26	Lung function (FEV1/FVC);	chr5:98994337	chr5:98929171~98995013:+
BRCA	cis	rs7246657	0.722	rs1564208	ENSG00000267422.1	CTD-2554C21.1	-8.54	4.87e-17	1.78e-14	-0.38	-0.26	Coronary artery calcification;	chr19:37550319	chr19:37779686~37792865:+
BRCA	cis	rs2933343	1	rs1680795	ENSG00000231305.3	RP11-723O4.2	8.54	4.87e-17	1.78e-14	0.32	0.26	IgG glycosylation;	chr3:128901545	chr3:128861313~128871540:-
BRCA	cis	rs7429990	0.864	rs6785669	ENSG00000229759.1	MRPS18AP1	-8.54	4.87e-17	1.78e-14	-0.29	-0.26	Educational attainment (years of education);	chr3:47715771	chr3:48256350~48256938:-
BRCA	cis	rs7429990	0.833	rs6442079	ENSG00000229759.1	MRPS18AP1	-8.54	4.87e-17	1.78e-14	-0.29	-0.26	Educational attainment (years of education);	chr3:47721044	chr3:48256350~48256938:-
BRCA	cis	rs7429990	0.864	rs13094264	ENSG00000229759.1	MRPS18AP1	-8.54	4.87e-17	1.78e-14	-0.29	-0.26	Educational attainment (years of education);	chr3:47722723	chr3:48256350~48256938:-
BRCA	cis	rs7429990	0.864	rs4858851	ENSG00000229759.1	MRPS18AP1	-8.54	4.87e-17	1.78e-14	-0.29	-0.26	Educational attainment (years of education);	chr3:47724165	chr3:48256350~48256938:-
BRCA	cis	rs7429990	0.833	rs34777284	ENSG00000229759.1	MRPS18AP1	-8.54	4.87e-17	1.78e-14	-0.29	-0.26	Educational attainment (years of education);	chr3:47726585	chr3:48256350~48256938:-
BRCA	cis	rs7429990	0.833	rs7649393	ENSG00000229759.1	MRPS18AP1	-8.54	4.87e-17	1.78e-14	-0.29	-0.26	Educational attainment (years of education);	chr3:47727501	chr3:48256350~48256938:-
BRCA	cis	rs7429990	0.864	rs7638103	ENSG00000229759.1	MRPS18AP1	-8.54	4.87e-17	1.78e-14	-0.29	-0.26	Educational attainment (years of education);	chr3:47727585	chr3:48256350~48256938:-
BRCA	cis	rs7429990	0.864	rs11130148	ENSG00000229759.1	MRPS18AP1	-8.54	4.87e-17	1.78e-14	-0.29	-0.26	Educational attainment (years of education);	chr3:47729797	chr3:48256350~48256938:-
BRCA	cis	rs11098499	0.908	rs9995234	ENSG00000248280.1	RP11-33B1.2	8.54	4.88e-17	1.79e-14	0.27	0.26	Corneal astigmatism;	chr4:119400672	chr4:119440561~119450157:-
BRCA	cis	rs9903692	0.954	rs9899461	ENSG00000278765.1	RP5-890E16.5	-8.54	4.88e-17	1.79e-14	-0.33	-0.26	Pulse pressure;	chr17:48051991	chr17:48066704~48067293:-
BRCA	cis	rs10510102	0.748	rs11200297	ENSG00000276742.1	RP11-500G22.4	8.54	4.88e-17	1.79e-14	0.43	0.26	Breast cancer;	chr10:121972916	chr10:121956782~121957098:+
BRCA	cis	rs11098499	0.82	rs28394116	ENSG00000245958.5	RP11-33B1.1	-8.54	4.89e-17	1.79e-14	-0.25	-0.26	Corneal astigmatism;	chr4:119603128	chr4:119454791~119552025:+
BRCA	cis	rs694739	0.628	rs11606081	ENSG00000236935.1	AP003774.1	8.53	4.9e-17	1.79e-14	0.24	0.26	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64370403	chr11:64325050~64329504:-
BRCA	cis	rs6430549	0.518	rs41521049	ENSG00000224043.6	CCNT2-AS1	-8.53	4.91e-17	1.8e-14	-0.35	-0.26	Hematocrit;	chr2:134935499	chr2:134735464~134918710:-
BRCA	cis	rs8072100	0.817	rs12449647	ENSG00000228782.6	CTD-2026D20.3	8.53	4.91e-17	1.8e-14	0.28	0.26	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47471592	chr17:47450568~47492492:-
BRCA	cis	rs4308124	0.679	rs7600458	ENSG00000230499.1	AC108463.1	-8.53	4.92e-17	1.8e-14	-0.33	-0.26	Vitiligo;	chr2:111206013	chr2:111195963~111206494:+
BRCA	cis	rs10510102	0.872	rs7916008	ENSG00000276742.1	RP11-500G22.4	8.53	4.92e-17	1.8e-14	0.43	0.26	Breast cancer;	chr10:121943578	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.872	rs7916380	ENSG00000276742.1	RP11-500G22.4	8.53	4.92e-17	1.8e-14	0.43	0.26	Breast cancer;	chr10:121943773	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.808	rs7920024	ENSG00000276742.1	RP11-500G22.4	8.53	4.92e-17	1.8e-14	0.43	0.26	Breast cancer;	chr10:121944063	chr10:121956782~121957098:+
BRCA	cis	rs1707322	1	rs9429186	ENSG00000280836.1	AL355480.1	8.53	4.94e-17	1.81e-14	0.32	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46074015	chr1:45581219~45581321:-
BRCA	cis	rs2439831	0.85	rs9944216	ENSG00000249839.1	AC011330.5	8.53	4.94e-17	1.81e-14	0.42	0.26	Lung cancer in ever smokers;	chr15:43868575	chr15:43663654~43684339:-
BRCA	cis	rs10971721	0.822	rs10971850	ENSG00000260947.1	RP11-384P7.7	8.53	4.96e-17	1.81e-14	0.46	0.26	Body mass index;	chr9:34013910	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.731	rs10814061	ENSG00000260947.1	RP11-384P7.7	8.53	4.96e-17	1.81e-14	0.46	0.26	Body mass index;	chr9:34014032	chr9:33697459~33700986:+
BRCA	cis	rs748404	0.629	rs34657657	ENSG00000249839.1	AC011330.5	-8.53	4.97e-17	1.82e-14	-0.38	-0.26	Lung cancer;	chr15:43315763	chr15:43663654~43684339:-
BRCA	cis	rs748404	0.626	rs62019432	ENSG00000249839.1	AC011330.5	-8.53	4.97e-17	1.82e-14	-0.38	-0.26	Lung cancer;	chr15:43316482	chr15:43663654~43684339:-
BRCA	cis	rs7429990	0.864	rs7613934	ENSG00000229759.1	MRPS18AP1	-8.53	4.98e-17	1.82e-14	-0.29	-0.26	Educational attainment (years of education);	chr3:47640681	chr3:48256350~48256938:-
BRCA	cis	rs801193	0.66	rs1016265	ENSG00000237310.1	GS1-124K5.4	8.53	4.98e-17	1.82e-14	0.27	0.26	Aortic root size;	chr7:66749580	chr7:66493706~66495474:+
BRCA	cis	rs801193	0.66	rs4610622	ENSG00000237310.1	GS1-124K5.4	8.53	4.98e-17	1.82e-14	0.27	0.26	Aortic root size;	chr7:66759510	chr7:66493706~66495474:+
BRCA	cis	rs6545883	0.929	rs2593635	ENSG00000271889.1	RP11-493E12.1	-8.53	4.98e-17	1.82e-14	-0.34	-0.26	Tuberculosis;	chr2:61407571	chr2:61151433~61162105:-
BRCA	cis	rs7945705	0.902	rs10743095	ENSG00000254860.4	TMEM9B-AS1	-8.53	5e-17	1.83e-14	-0.24	-0.26	Hemoglobin concentration;	chr11:8915437	chr11:8964675~8977527:+
BRCA	cis	rs875971	0.706	rs1643374	ENSG00000222364.1	RNU6-96P	-8.53	5.04e-17	1.84e-14	-0.3	-0.26	Aortic root size;	chr7:66407695	chr7:66395191~66395286:+
BRCA	cis	rs9516	0.564	rs10898993	ENSG00000254974.1	RP11-702H23.2	8.53	5.06e-17	1.85e-14	0.3	0.26	Facial morphology (factor 15, philtrum width);	chr11:74463919	chr11:74485580~74486051:-
BRCA	cis	rs10129255	0.957	rs12590799	ENSG00000223648.3	IGHV3-64	8.53	5.11e-17	1.87e-14	0.21	0.26	Kawasaki disease;	chr14:106779713	chr14:106643132~106658258:-
BRCA	cis	rs6472827	0.645	rs2956053	ENSG00000253983.2	RP1-16A9.1	8.53	5.13e-17	1.88e-14	0.35	0.26	Uterine fibroids;	chr8:74200205	chr8:74199396~74208441:+
BRCA	cis	rs10971721	0.822	rs10971838	ENSG00000260947.1	RP11-384P7.7	8.53	5.15e-17	1.88e-14	0.46	0.26	Body mass index;	chr9:33997948	chr9:33697459~33700986:+
BRCA	cis	rs113835537	0.529	rs11227525	ENSG00000255517.5	CTD-3074O7.5	-8.53	5.15e-17	1.88e-14	-0.34	-0.26	Airway imaging phenotypes;	chr11:66540594	chr11:66473490~66480233:-
BRCA	cis	rs2404602	1	rs12898430	ENSG00000259422.1	RP11-593F23.1	8.53	5.16e-17	1.88e-14	0.31	0.26	Blood metabolite levels;	chr15:76582582	chr15:76174891~76181486:-
BRCA	cis	rs10246939	0.579	rs10464444	ENSG00000228775.6	WEE2-AS1	-8.53	5.17e-17	1.89e-14	-0.28	-0.26	Bitter taste perception;	chr7:141832387	chr7:141704338~141738346:-
BRCA	cis	rs10463554	0.927	rs34776	ENSG00000175749.11	EIF3KP1	8.53	5.19e-17	1.9e-14	0.36	0.26	Parkinson's disease;	chr5:103116090	chr5:103032376~103033031:+
BRCA	cis	rs10463554	0.667	rs34782	ENSG00000175749.11	EIF3KP1	8.53	5.19e-17	1.9e-14	0.36	0.26	Parkinson's disease;	chr5:103118766	chr5:103032376~103033031:+
BRCA	cis	rs12468226	0.873	rs3181153	ENSG00000273456.1	RP11-686O6.2	-8.53	5.22e-17	1.9e-14	-0.38	-0.26	Urate levels;	chr2:202205155	chr2:202374932~202375604:-
BRCA	cis	rs801193	0.66	rs2659897	ENSG00000237310.1	GS1-124K5.4	-8.53	5.24e-17	1.91e-14	-0.27	-0.26	Aortic root size;	chr7:66722728	chr7:66493706~66495474:+
BRCA	cis	rs807029	0.577	rs3740488	ENSG00000272572.1	RP11-179B2.2	-8.53	5.25e-17	1.92e-14	-0.33	-0.26	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100994276	chr10:100911103~100912739:-
BRCA	cis	rs6545883	0.826	rs777591	ENSG00000271889.1	RP11-493E12.1	8.53	5.26e-17	1.92e-14	0.33	0.26	Tuberculosis;	chr2:61190482	chr2:61151433~61162105:-
BRCA	cis	rs875971	0.545	rs2420456	ENSG00000222364.1	RNU6-96P	-8.53	5.28e-17	1.93e-14	-0.34	-0.26	Aortic root size;	chr7:66280619	chr7:66395191~66395286:+
BRCA	cis	rs9640161	0.742	rs11767726	ENSG00000261305.1	RP4-584D14.7	-8.53	5.28e-17	1.93e-14	-0.36	-0.26	Blood protein levels;Circulating chemerin levels;	chr7:150321007	chr7:150341771~150342607:+
BRCA	cis	rs10463554	0.824	rs427430	ENSG00000175749.11	EIF3KP1	8.53	5.29e-17	1.93e-14	0.37	0.26	Parkinson's disease;	chr5:103096320	chr5:103032376~103033031:+
BRCA	cis	rs4718428	0.672	rs4718412	ENSG00000273142.1	RP11-458F8.4	8.52	5.31e-17	1.94e-14	0.25	0.26	Corneal structure;	chr7:66821880	chr7:66902857~66906297:+
BRCA	cis	rs10971721	0.822	rs12380173	ENSG00000260947.1	RP11-384P7.7	8.52	5.31e-17	1.94e-14	0.46	0.26	Body mass index;	chr9:34018500	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.822	rs12377970	ENSG00000260947.1	RP11-384P7.7	8.52	5.31e-17	1.94e-14	0.46	0.26	Body mass index;	chr9:34021269	chr9:33697459~33700986:+
BRCA	cis	rs375066	0.935	rs429027	ENSG00000267058.1	RP11-15A1.3	-8.52	5.32e-17	1.94e-14	-0.29	-0.26	Breast cancer;	chr19:43891337	chr19:43891804~43901805:-
BRCA	cis	rs4266144	0.632	rs56268334	ENSG00000244515.1	KRT18P34	-8.52	5.32e-17	1.94e-14	-0.37	-0.26	Coronary artery disease;	chr3:157130235	chr3:157162663~157163932:-
BRCA	cis	rs875971	0.545	rs316324	ENSG00000222364.1	RNU6-96P	8.52	5.35e-17	1.95e-14	0.33	0.26	Aortic root size;	chr7:66145627	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.545	rs316323	ENSG00000222364.1	RNU6-96P	8.52	5.35e-17	1.95e-14	0.33	0.26	Aortic root size;	chr7:66146002	chr7:66395191~66395286:+
BRCA	cis	rs17711722	0.522	rs6957759	ENSG00000234585.5	CCT6P3	8.52	5.37e-17	1.96e-14	0.25	0.26	Calcium levels;	chr7:65806798	chr7:65038354~65074713:+
BRCA	cis	rs4964805	0.626	rs11111767	ENSG00000257681.1	RP11-341G23.4	-8.52	5.39e-17	1.97e-14	-0.32	-0.26	Attention deficit hyperactivity disorder;	chr12:103782468	chr12:103746315~103768858:-
BRCA	cis	rs11098499	0.754	rs7672372	ENSG00000245958.5	RP11-33B1.1	-8.52	5.39e-17	1.97e-14	-0.24	-0.26	Corneal astigmatism;	chr4:119327251	chr4:119454791~119552025:+
BRCA	cis	rs9595908	0.865	rs743760	ENSG00000212293.1	SNORA16	-8.52	5.4e-17	1.97e-14	-0.33	-0.26	Body mass index;	chr13:32496990	chr13:32420390~32420516:-
BRCA	cis	rs2404602	1	rs2056544	ENSG00000259422.1	RP11-593F23.1	8.52	5.4e-17	1.97e-14	0.32	0.26	Blood metabolite levels;	chr15:76533662	chr15:76174891~76181486:-
BRCA	cis	rs1707322	1	rs1707337	ENSG00000280836.1	AL355480.1	8.52	5.42e-17	1.98e-14	0.32	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46043097	chr1:45581219~45581321:-
BRCA	cis	rs1707322	1	rs1768807	ENSG00000280836.1	AL355480.1	8.52	5.42e-17	1.98e-14	0.32	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46044898	chr1:45581219~45581321:-
BRCA	cis	rs4835473	0.932	rs7693772	ENSG00000251600.4	RP11-673E1.1	8.52	5.44e-17	1.98e-14	0.3	0.26	Immature fraction of reticulocytes;	chr4:143965614	chr4:143912331~143982454:+
BRCA	cis	rs950880	0.71	rs17027071	ENSG00000234389.1	AC007278.3	-8.52	5.45e-17	1.99e-14	-0.26	-0.26	Serum protein levels (sST2);	chr2:102396214	chr2:102438713~102440475:+
BRCA	cis	rs11673344	0.528	rs573294	ENSG00000226686.6	LINC01535	8.52	5.48e-17	2e-14	0.33	0.26	Obesity-related traits;	chr19:36919260	chr19:37251912~37265535:+
BRCA	cis	rs11673344	0.528	rs579452	ENSG00000226686.6	LINC01535	8.52	5.49e-17	2e-14	0.33	0.26	Obesity-related traits;	chr19:36919936	chr19:37251912~37265535:+
BRCA	cis	rs11673344	0.528	rs491326	ENSG00000226686.6	LINC01535	8.52	5.49e-17	2e-14	0.33	0.26	Obesity-related traits;	chr19:36920037	chr19:37251912~37265535:+
BRCA	cis	rs11673344	0.528	rs563786	ENSG00000226686.6	LINC01535	8.52	5.49e-17	2e-14	0.33	0.26	Obesity-related traits;	chr19:36922012	chr19:37251912~37265535:+
BRCA	cis	rs897984	0.609	rs55979739	ENSG00000260911.2	RP11-196G11.2	8.52	5.49e-17	2e-14	0.23	0.26	Dementia with Lewy bodies;	chr16:31037834	chr16:31043150~31049868:+
BRCA	cis	rs897984	0.609	rs732172	ENSG00000260911.2	RP11-196G11.2	8.52	5.49e-17	2e-14	0.23	0.26	Dementia with Lewy bodies;	chr16:31038712	chr16:31043150~31049868:+
BRCA	cis	rs2404602	0.716	rs67888330	ENSG00000259422.1	RP11-593F23.1	8.52	5.49e-17	2e-14	0.32	0.26	Blood metabolite levels;	chr15:76460142	chr15:76174891~76181486:-
BRCA	cis	rs9918079	0.884	rs11728037	ENSG00000273133.1	RP11-799M12.2	-8.52	5.49e-17	2e-14	-0.38	-0.26	Obesity-related traits;	chr4:15593275	chr4:15563698~15564253:-
BRCA	cis	rs1707322	1	rs946527	ENSG00000280836.1	AL355480.1	-8.52	5.49e-17	2e-14	-0.32	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46020298	chr1:45581219~45581321:-
BRCA	cis	rs11971779	0.68	rs66491565	ENSG00000273391.1	RP11-634H22.1	8.52	5.5e-17	2e-14	0.25	0.26	Diisocyanate-induced asthma;	chr7:139404231	chr7:139359032~139359566:-
BRCA	cis	rs17711722	0.701	rs4467826	ENSG00000236529.1	RP13-254B10.1	8.52	5.5e-17	2.01e-14	0.28	0.26	Calcium levels;	chr7:65903721	chr7:65840212~65840596:+
BRCA	cis	rs9640161	0.663	rs1916932	ENSG00000261305.1	RP4-584D14.7	8.52	5.52e-17	2.01e-14	0.37	0.26	Blood protein levels;Circulating chemerin levels;	chr7:150324555	chr7:150341771~150342607:+
BRCA	cis	rs801193	0.773	rs801207	ENSG00000237310.1	GS1-124K5.4	-8.52	5.54e-17	2.02e-14	-0.26	-0.26	Aortic root size;	chr7:66555603	chr7:66493706~66495474:+
BRCA	cis	rs7568498	0.564	rs9287807	ENSG00000227403.1	AC009299.3	8.52	5.54e-17	2.02e-14	0.37	0.26	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);	chr2:161058850	chr2:161244739~161249050:+
BRCA	cis	rs11098499	0.863	rs3822192	ENSG00000248280.1	RP11-33B1.2	8.52	5.55e-17	2.02e-14	0.27	0.26	Corneal astigmatism;	chr4:119524565	chr4:119440561~119450157:-
BRCA	cis	rs56205728	0.606	rs2898991	ENSG00000273855.1	RP11-133K1.12	8.52	5.56e-17	2.03e-14	0.28	0.26	Schizophrenia;	chr15:40304367	chr15:40285468~40285909:-
BRCA	cis	rs853679	1	rs1778511	ENSG00000220721.1	OR1F12	-8.52	5.56e-17	2.03e-14	-0.4	-0.26	Depression;	chr6:28261633	chr6:28073316~28074233:+
BRCA	cis	rs3758911	0.964	rs10789603	ENSG00000255353.1	RP11-382M14.1	-8.52	5.58e-17	2.03e-14	-0.34	-0.26	Coronary artery disease;	chr11:107311050	chr11:107176286~107177530:+
BRCA	cis	rs1823913	0.637	rs6722183	ENSG00000227542.1	AC092614.2	-8.52	5.59e-17	2.03e-14	-0.31	-0.26	Obesity-related traits;	chr2:191333203	chr2:191229165~191246172:-
BRCA	cis	rs875971	0.545	rs73148639	ENSG00000222364.1	RNU6-96P	-8.52	5.6e-17	2.04e-14	-0.33	-0.26	Aortic root size;	chr7:66390342	chr7:66395191~66395286:+
BRCA	cis	rs4964805	0.58	rs1866292	ENSG00000257681.1	RP11-341G23.4	8.52	5.6e-17	2.04e-14	0.33	0.26	Attention deficit hyperactivity disorder;	chr12:103780414	chr12:103746315~103768858:-
BRCA	cis	rs7246657	0.663	rs10408619	ENSG00000267422.1	CTD-2554C21.1	-8.52	5.61e-17	2.04e-14	-0.38	-0.26	Coronary artery calcification;	chr19:37579573	chr19:37779686~37792865:+
BRCA	cis	rs7772486	0.875	rs9322048	ENSG00000235652.6	RP11-545I5.3	8.52	5.64e-17	2.05e-14	0.25	0.26	Lobe attachment (rater-scored or self-reported);	chr6:146079303	chr6:145799409~145886585:+
BRCA	cis	rs3758911	0.861	rs1388171	ENSG00000255353.1	RP11-382M14.1	-8.52	5.65e-17	2.06e-14	-0.34	-0.26	Coronary artery disease;	chr11:107272411	chr11:107176286~107177530:+
BRCA	cis	rs7429990	0.803	rs13081356	ENSG00000229759.1	MRPS18AP1	-8.52	5.68e-17	2.07e-14	-0.29	-0.26	Educational attainment (years of education);	chr3:47660067	chr3:48256350~48256938:-
BRCA	cis	rs10129255	0.5	rs9324092	ENSG00000211970.3	IGHV4-61	8.52	5.69e-17	2.07e-14	0.17	0.26	Kawasaki disease;	chr14:106683806	chr14:106639119~106639657:-
BRCA	cis	rs10129255	0.957	rs8022165	ENSG00000223648.3	IGHV3-64	8.52	5.7e-17	2.08e-14	0.21	0.26	Kawasaki disease;	chr14:106781682	chr14:106643132~106658258:-
BRCA	cis	rs12468226	0.938	rs56684065	ENSG00000273456.1	RP11-686O6.2	8.52	5.71e-17	2.08e-14	0.38	0.26	Urate levels;	chr2:202289528	chr2:202374932~202375604:-
BRCA	cis	rs12468226	0.938	rs1474001	ENSG00000273456.1	RP11-686O6.2	8.52	5.71e-17	2.08e-14	0.38	0.26	Urate levels;	chr2:202290230	chr2:202374932~202375604:-
BRCA	cis	rs12468226	0.938	rs76664732	ENSG00000273456.1	RP11-686O6.2	8.52	5.71e-17	2.08e-14	0.38	0.26	Urate levels;	chr2:202296298	chr2:202374932~202375604:-
BRCA	cis	rs4308124	0.708	rs28871990	ENSG00000230499.1	AC108463.1	-8.52	5.73e-17	2.09e-14	-0.33	-0.26	Vitiligo;	chr2:111204864	chr2:111195963~111206494:+
BRCA	cis	rs1707322	1	rs785498	ENSG00000280836.1	AL355480.1	8.51	5.76e-17	2.09e-14	0.33	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46126742	chr1:45581219~45581321:-
BRCA	cis	rs6142102	0.625	rs6142067	ENSG00000275784.1	RP5-1125A11.6	-8.51	5.77e-17	2.1e-14	-0.29	-0.26	Skin pigmentation;	chr20:33968766	chr20:33989480~33991818:-
BRCA	cis	rs1707322	0.896	rs809774	ENSG00000280836.1	AL355480.1	8.51	5.77e-17	2.1e-14	0.33	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46094572	chr1:45581219~45581321:-
BRCA	cis	rs6545883	0.718	rs2694624	ENSG00000271889.1	RP11-493E12.1	8.51	5.77e-17	2.1e-14	0.33	0.26	Tuberculosis;	chr2:61445178	chr2:61151433~61162105:-
BRCA	cis	rs875971	0.505	rs6955582	ENSG00000236529.1	RP13-254B10.1	8.51	5.78e-17	2.1e-14	0.28	0.26	Aortic root size;	chr7:65966699	chr7:65840212~65840596:+
BRCA	cis	rs858239	0.509	rs6975524	ENSG00000226816.2	AC005082.12	8.51	5.81e-17	2.11e-14	0.3	0.26	Cerebrospinal fluid biomarker levels;	chr7:23146833	chr7:23206013~23208045:+
BRCA	cis	rs858239	0.539	rs6955726	ENSG00000226816.2	AC005082.12	8.51	5.81e-17	2.11e-14	0.3	0.26	Cerebrospinal fluid biomarker levels;	chr7:23147072	chr7:23206013~23208045:+
BRCA	cis	rs858239	0.539	rs6956828	ENSG00000226816.2	AC005082.12	8.51	5.81e-17	2.11e-14	0.3	0.26	Cerebrospinal fluid biomarker levels;	chr7:23147728	chr7:23206013~23208045:+
BRCA	cis	rs150992	0.603	rs326481	ENSG00000248489.1	CTD-2007H13.3	8.51	5.82e-17	2.12e-14	0.33	0.26	Body mass index;	chr5:98949581	chr5:98929171~98995013:+
BRCA	cis	rs2286503	0.966	rs2286507	ENSG00000228649.7	AC005682.5	8.51	5.84e-17	2.12e-14	0.22	0.26	Fibrinogen;	chr7:22815141	chr7:22854178~22861579:+
BRCA	cis	rs11098499	0.675	rs11098534	ENSG00000248280.1	RP11-33B1.2	8.51	5.85e-17	2.13e-14	0.25	0.26	Corneal astigmatism;	chr4:119635617	chr4:119440561~119450157:-
BRCA	cis	rs17711722	0.701	rs781143	ENSG00000222364.1	RNU6-96P	-8.51	5.85e-17	2.13e-14	-0.29	-0.26	Calcium levels;	chr7:65974892	chr7:66395191~66395286:+
BRCA	cis	rs2933343	1	rs1683782	ENSG00000261159.1	RP11-723O4.9	8.51	5.85e-17	2.13e-14	0.3	0.26	IgG glycosylation;	chr3:128921434	chr3:128859716~128860526:-
BRCA	cis	rs783540	0.967	rs2870966	ENSG00000278603.1	RP13-608F4.5	-8.51	5.86e-17	2.13e-14	-0.32	-0.25	Schizophrenia;	chr15:82626493	chr15:82472203~82472426:+
BRCA	cis	rs2274273	0.84	rs7144737	ENSG00000258413.1	RP11-665C16.6	-8.51	5.86e-17	2.13e-14	-0.32	-0.25	Protein biomarker;	chr14:55356228	chr14:55262767~55272075:-
BRCA	cis	rs113835537	0.529	rs10896125	ENSG00000255517.5	CTD-3074O7.5	-8.51	5.86e-17	2.13e-14	-0.33	-0.25	Airway imaging phenotypes;	chr11:66521262	chr11:66473490~66480233:-
BRCA	cis	rs875971	0.545	rs73152714	ENSG00000222364.1	RNU6-96P	-8.51	5.86e-17	2.13e-14	-0.33	-0.25	Aortic root size;	chr7:66534641	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.545	rs4718364	ENSG00000222364.1	RNU6-96P	-8.51	5.86e-17	2.13e-14	-0.33	-0.25	Aortic root size;	chr7:66536353	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.545	rs801199	ENSG00000222364.1	RNU6-96P	8.51	5.86e-17	2.13e-14	0.33	0.25	Aortic root size;	chr7:66560286	chr7:66395191~66395286:+
BRCA	cis	rs56046484	0.956	rs17541572	ENSG00000259295.5	CSPG4P12	-8.51	5.88e-17	2.14e-14	-0.44	-0.25	Testicular germ cell tumor;	chr15:85122016	chr15:85191438~85213905:+
BRCA	cis	rs11971779	0.752	rs4732371	ENSG00000273391.1	RP11-634H22.1	8.51	5.88e-17	2.14e-14	0.25	0.25	Diisocyanate-induced asthma;	chr7:139392571	chr7:139359032~139359566:-
BRCA	cis	rs4718428	0.672	rs4718412	ENSG00000232546.1	RP11-458F8.1	8.51	5.89e-17	2.14e-14	0.24	0.25	Corneal structure;	chr7:66821880	chr7:66848496~66858136:+
BRCA	cis	rs7428	0.527	rs4832164	ENSG00000246575.2	AC093162.5	8.51	5.9e-17	2.14e-14	0.27	0.25	Ear protrusion;	chr2:85319809	chr2:85315041~85316529:+
BRCA	cis	rs875971	0.545	rs1547529	ENSG00000222364.1	RNU6-96P	-8.51	5.9e-17	2.14e-14	-0.33	-0.25	Aortic root size;	chr7:66258859	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.597	rs11763224	ENSG00000222364.1	RNU6-96P	-8.51	5.9e-17	2.15e-14	-0.34	-0.25	Aortic root size;	chr7:66518628	chr7:66395191~66395286:+
BRCA	cis	rs11098499	0.866	rs3756156	ENSG00000245958.5	RP11-33B1.1	-8.51	5.91e-17	2.15e-14	-0.25	-0.25	Corneal astigmatism;	chr4:119603686	chr4:119454791~119552025:+
BRCA	cis	rs7674212	0.507	rs223361	ENSG00000246560.2	RP11-10L12.4	8.51	5.92e-17	2.15e-14	0.28	0.25	Type 2 diabetes;	chr4:102848147	chr4:102828055~102844075:+
BRCA	cis	rs10129255	0.917	rs8022493	ENSG00000223648.3	IGHV3-64	8.51	5.92e-17	2.15e-14	0.21	0.25	Kawasaki disease;	chr14:106781820	chr14:106643132~106658258:-
BRCA	cis	rs858239	0.539	rs4504540	ENSG00000226816.2	AC005082.12	8.51	5.92e-17	2.15e-14	0.3	0.25	Cerebrospinal fluid biomarker levels;	chr7:23146579	chr7:23206013~23208045:+
BRCA	cis	rs4853012	0.838	rs61521879	ENSG00000257800.1	FNBP1P1	8.51	5.94e-17	2.16e-14	0.25	0.25	Gestational age at birth (maternal effect);	chr2:74119081	chr2:74120680~74123218:+
BRCA	cis	rs8072100	0.875	rs12451409	ENSG00000228782.6	CTD-2026D20.3	8.51	5.96e-17	2.17e-14	0.28	0.25	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47467490	chr17:47450568~47492492:-
BRCA	cis	rs1707322	0.89	rs2297883	ENSG00000280836.1	AL355480.1	8.51	5.98e-17	2.17e-14	0.32	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46045815	chr1:45581219~45581321:-
BRCA	cis	rs7712401	0.502	rs30066	ENSG00000263432.2	RN7SL689P	8.51	5.99e-17	2.18e-14	0.35	0.25	Mean platelet volume;	chr5:122958007	chr5:123022487~123022783:-
BRCA	cis	rs11098499	0.954	rs59866101	ENSG00000248280.1	RP11-33B1.2	8.51	6e-17	2.18e-14	0.26	0.25	Corneal astigmatism;	chr4:119375436	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.618	rs6858383	ENSG00000248280.1	RP11-33B1.2	8.51	6e-17	2.18e-14	0.26	0.25	Corneal astigmatism;	chr4:119375617	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.697	rs6832410	ENSG00000248280.1	RP11-33B1.2	8.51	6e-17	2.18e-14	0.26	0.25	Corneal astigmatism;	chr4:119375645	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.865	rs1112817	ENSG00000248280.1	RP11-33B1.2	8.51	6e-17	2.18e-14	0.26	0.25	Corneal astigmatism;	chr4:119376645	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.779	rs10016060	ENSG00000248280.1	RP11-33B1.2	8.51	6e-17	2.18e-14	0.26	0.25	Corneal astigmatism;	chr4:119377257	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.954	rs10005644	ENSG00000248280.1	RP11-33B1.2	8.51	6e-17	2.18e-14	0.26	0.25	Corneal astigmatism;	chr4:119377322	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.697	rs10016448	ENSG00000248280.1	RP11-33B1.2	8.51	6e-17	2.18e-14	0.26	0.25	Corneal astigmatism;	chr4:119377690	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.657	rs9996569	ENSG00000248280.1	RP11-33B1.2	8.51	6e-17	2.18e-14	0.26	0.25	Corneal astigmatism;	chr4:119377849	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.908	rs11729050	ENSG00000248280.1	RP11-33B1.2	8.51	6e-17	2.18e-14	0.26	0.25	Corneal astigmatism;	chr4:119378911	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.954	rs28429722	ENSG00000248280.1	RP11-33B1.2	8.51	6e-17	2.18e-14	0.26	0.25	Corneal astigmatism;	chr4:119378938	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.954	rs10014845	ENSG00000248280.1	RP11-33B1.2	8.51	6e-17	2.18e-14	0.26	0.25	Corneal astigmatism;	chr4:119379922	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.779	rs7674500	ENSG00000248280.1	RP11-33B1.2	8.51	6e-17	2.18e-14	0.26	0.25	Corneal astigmatism;	chr4:119382438	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.909	rs28884220	ENSG00000248280.1	RP11-33B1.2	8.51	6e-17	2.18e-14	0.26	0.25	Corneal astigmatism;	chr4:119386056	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.909	rs28793658	ENSG00000248280.1	RP11-33B1.2	8.51	6e-17	2.18e-14	0.26	0.25	Corneal astigmatism;	chr4:119386059	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.697	rs4373140	ENSG00000248280.1	RP11-33B1.2	8.51	6e-17	2.18e-14	0.26	0.25	Corneal astigmatism;	chr4:119386543	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.954	rs13113483	ENSG00000248280.1	RP11-33B1.2	8.51	6e-17	2.18e-14	0.26	0.25	Corneal astigmatism;	chr4:119387884	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.542	rs10440343	ENSG00000248280.1	RP11-33B1.2	8.51	6e-17	2.18e-14	0.26	0.25	Corneal astigmatism;	chr4:119388632	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.779	rs10011097	ENSG00000248280.1	RP11-33B1.2	8.51	6e-17	2.18e-14	0.26	0.25	Corneal astigmatism;	chr4:119389204	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.542	rs7677836	ENSG00000248280.1	RP11-33B1.2	8.51	6e-17	2.18e-14	0.26	0.25	Corneal astigmatism;	chr4:119389483	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.909	rs10002083	ENSG00000248280.1	RP11-33B1.2	8.51	6e-17	2.18e-14	0.26	0.25	Corneal astigmatism;	chr4:119389997	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.954	rs10024844	ENSG00000248280.1	RP11-33B1.2	8.51	6e-17	2.18e-14	0.26	0.25	Corneal astigmatism;	chr4:119390373	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.954	rs4345162	ENSG00000248280.1	RP11-33B1.2	8.51	6e-17	2.18e-14	0.26	0.25	Corneal astigmatism;	chr4:119391804	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.657	rs4463052	ENSG00000248280.1	RP11-33B1.2	8.51	6e-17	2.18e-14	0.26	0.25	Corneal astigmatism;	chr4:119392103	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.954	rs13151285	ENSG00000248280.1	RP11-33B1.2	8.51	6e-17	2.18e-14	0.26	0.25	Corneal astigmatism;	chr4:119393586	chr4:119440561~119450157:-
BRCA	cis	rs4727443	0.866	rs13238380	ENSG00000214313.7	AZGP1P1	-8.51	6.01e-17	2.18e-14	-0.26	-0.25	Interstitial lung disease;	chr7:100031438	chr7:99980762~99987535:+
BRCA	cis	rs2439831	0.85	rs8032649	ENSG00000249839.1	AC011330.5	8.51	6.01e-17	2.18e-14	0.43	0.25	Lung cancer in ever smokers;	chr15:43842724	chr15:43663654~43684339:-
BRCA	cis	rs2337406	0.587	rs10150642	ENSG00000274576.2	IGHV2-70	8.51	6.03e-17	2.19e-14	0.26	0.25	Alzheimer's disease (late onset);	chr14:106647269	chr14:106770577~106771020:-
BRCA	cis	rs1823913	0.637	rs4613316	ENSG00000227542.1	AC092614.2	8.51	6.03e-17	2.19e-14	0.31	0.25	Obesity-related traits;	chr2:191326074	chr2:191229165~191246172:-
BRCA	cis	rs1707322	1	rs12077546	ENSG00000280836.1	AL355480.1	-8.51	6.04e-17	2.19e-14	-0.33	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45966134	chr1:45581219~45581321:-
BRCA	cis	rs1707322	1	rs12124291	ENSG00000280836.1	AL355480.1	-8.51	6.04e-17	2.19e-14	-0.33	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45966460	chr1:45581219~45581321:-
BRCA	cis	rs2933343	1	rs1680790	ENSG00000231305.3	RP11-723O4.2	8.51	6.05e-17	2.19e-14	0.32	0.25	IgG glycosylation;	chr3:128907010	chr3:128861313~128871540:-
BRCA	cis	rs2115630	1	rs6496441	ENSG00000225151.9	GOLGA2P7	8.51	6.05e-17	2.19e-14	0.28	0.25	P wave terminal force;	chr15:84820117	chr15:84199311~84230136:-
BRCA	cis	rs4964805	0.672	rs4964823	ENSG00000257681.1	RP11-341G23.4	8.51	6.09e-17	2.21e-14	0.32	0.25	Attention deficit hyperactivity disorder;	chr12:103787642	chr12:103746315~103768858:-
BRCA	cis	rs12468226	0.938	rs114177656	ENSG00000273456.1	RP11-686O6.2	8.51	6.11e-17	2.21e-14	0.37	0.25	Urate levels;	chr2:202291596	chr2:202374932~202375604:-
BRCA	cis	rs7688540	0.771	rs10027325	ENSG00000275426.1	CH17-262A2.1	8.51	6.11e-17	2.21e-14	0.36	0.25	Facial morphology (factor 6, height of vermillion lower lip);	chr4:288819	chr4:149738~150317:+
BRCA	cis	rs7688540	0.771	rs1986557	ENSG00000275426.1	CH17-262A2.1	8.51	6.11e-17	2.21e-14	0.36	0.25	Facial morphology (factor 6, height of vermillion lower lip);	chr4:289329	chr4:149738~150317:+
BRCA	cis	rs4853012	0.838	rs6715351	ENSG00000257800.1	FNBP1P1	8.51	6.11e-17	2.22e-14	0.25	0.25	Gestational age at birth (maternal effect);	chr2:74118992	chr2:74120680~74123218:+
BRCA	cis	rs4845875	0.559	rs4846047	ENSG00000242349.4	NPPA-AS1	8.51	6.13e-17	2.22e-14	0.3	0.25	Midregional pro atrial natriuretic peptide levels;	chr1:11783575	chr1:11841017~11848079:+
BRCA	cis	rs1900504	0.614	rs2915761	ENSG00000266200.5	PNLIPRP2	-8.51	6.14e-17	2.23e-14	-0.34	-0.25	Tonsillectomy;	chr10:116601682	chr10:116620953~116645143:+
BRCA	cis	rs10971721	0.822	rs10971866	ENSG00000260947.1	RP11-384P7.7	8.51	6.14e-17	2.23e-14	0.46	0.25	Body mass index;	chr9:34043163	chr9:33697459~33700986:+
BRCA	cis	rs801193	0.844	rs732465	ENSG00000237310.1	GS1-124K5.4	8.51	6.15e-17	2.23e-14	0.26	0.25	Aortic root size;	chr7:66533463	chr7:66493706~66495474:+
BRCA	cis	rs7727544	0.709	rs441969	ENSG00000233006.5	AC034220.3	8.51	6.18e-17	2.24e-14	0.19	0.25	Blood metabolite levels;	chr5:132366428	chr5:132311285~132369916:-
BRCA	cis	rs6921919	1	rs6921919	ENSG00000216901.1	AL022393.7	8.51	6.18e-17	2.24e-14	0.39	0.25	Autism spectrum disorder or schizophrenia;	chr6:28357424	chr6:28176188~28176674:+
BRCA	cis	rs875971	0.545	rs73146609	ENSG00000237310.1	GS1-124K5.4	8.51	6.21e-17	2.25e-14	0.31	0.25	Aortic root size;	chr7:66302477	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.545	rs2173571	ENSG00000237310.1	GS1-124K5.4	8.51	6.21e-17	2.25e-14	0.31	0.25	Aortic root size;	chr7:66305392	chr7:66493706~66495474:+
BRCA	cis	rs1113500	0.73	rs1361829	ENSG00000226822.1	RP11-356N1.2	-8.5	6.24e-17	2.26e-14	-0.33	-0.25	Growth-regulated protein alpha levels;	chr1:108051273	chr1:108071482~108074519:+
BRCA	cis	rs858239	0.539	rs4294098	ENSG00000226816.2	AC005082.12	8.5	6.24e-17	2.26e-14	0.3	0.25	Cerebrospinal fluid biomarker levels;	chr7:23146376	chr7:23206013~23208045:+
BRCA	cis	rs875971	0.571	rs160641	ENSG00000164669.11	INTS4P1	8.5	6.26e-17	2.27e-14	0.35	0.25	Aortic root size;	chr7:66112359	chr7:65141225~65234216:+
BRCA	cis	rs7430456	1	rs7430456	ENSG00000228221.4	LINC00578	-8.5	6.29e-17	2.28e-14	-0.31	-0.25	Breast cancer;	chr3:177768082	chr3:177441921~177752305:+
BRCA	cis	rs4934494	0.822	rs3962370	ENSG00000240996.1	RP11-80H5.7	-8.5	6.29e-17	2.28e-14	-0.29	-0.25	Red blood cell count;	chr10:89777763	chr10:89694295~89697928:-
BRCA	cis	rs1113500	0.73	rs1781080	ENSG00000226822.1	RP11-356N1.2	-8.5	6.3e-17	2.28e-14	-0.33	-0.25	Growth-regulated protein alpha levels;	chr1:108050793	chr1:108071482~108074519:+
BRCA	cis	rs7772486	0.686	rs702314	ENSG00000235652.6	RP11-545I5.3	-8.5	6.34e-17	2.29e-14	-0.25	-0.25	Lobe attachment (rater-scored or self-reported);	chr6:145682374	chr6:145799409~145886585:+
BRCA	cis	rs42648	0.869	rs3810891	ENSG00000225498.1	AC002064.5	8.5	6.34e-17	2.3e-14	0.24	0.25	Homocysteine levels;	chr7:90279537	chr7:90312496~90322592:+
BRCA	cis	rs4308124	0.708	rs6749633	ENSG00000230499.1	AC108463.1	8.5	6.34e-17	2.3e-14	0.32	0.25	Vitiligo;	chr2:111230439	chr2:111195963~111206494:+
BRCA	cis	rs7772486	0.846	rs1474871	ENSG00000235652.6	RP11-545I5.3	8.5	6.35e-17	2.3e-14	0.25	0.25	Lobe attachment (rater-scored or self-reported);	chr6:146085158	chr6:145799409~145886585:+
BRCA	cis	rs950880	0.71	rs11123929	ENSG00000234389.1	AC007278.3	-8.5	6.36e-17	2.3e-14	-0.25	-0.25	Serum protein levels (sST2);	chr2:102450683	chr2:102438713~102440475:+
BRCA	cis	rs11098499	0.697	rs35280960	ENSG00000245958.5	RP11-33B1.1	-8.5	6.37e-17	2.31e-14	-0.24	-0.25	Corneal astigmatism;	chr4:119335904	chr4:119454791~119552025:+
BRCA	cis	rs10971721	0.822	rs10971867	ENSG00000260947.1	RP11-384P7.7	8.5	6.38e-17	2.31e-14	0.46	0.25	Body mass index;	chr9:34046758	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.822	rs72729361	ENSG00000260947.1	RP11-384P7.7	8.5	6.38e-17	2.31e-14	0.46	0.25	Body mass index;	chr9:34047525	chr9:33697459~33700986:+
BRCA	cis	rs10510102	0.872	rs12246728	ENSG00000276742.1	RP11-500G22.4	8.5	6.4e-17	2.32e-14	0.44	0.25	Breast cancer;	chr10:121966618	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.872	rs12261371	ENSG00000276742.1	RP11-500G22.4	8.5	6.4e-17	2.32e-14	0.44	0.25	Breast cancer;	chr10:121966686	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.872	rs11200292	ENSG00000276742.1	RP11-500G22.4	8.5	6.4e-17	2.32e-14	0.44	0.25	Breast cancer;	chr10:121967383	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.808	rs17102804	ENSG00000276742.1	RP11-500G22.4	8.5	6.4e-17	2.32e-14	0.44	0.25	Breast cancer;	chr10:121968365	chr10:121956782~121957098:+
BRCA	cis	rs694739	0.595	rs11606015	ENSG00000236935.1	AP003774.1	8.5	6.41e-17	2.32e-14	0.24	0.25	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64369405	chr11:64325050~64329504:-
BRCA	cis	rs1707322	0.835	rs946525	ENSG00000280836.1	AL355480.1	8.5	6.41e-17	2.32e-14	0.32	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46021605	chr1:45581219~45581321:-
BRCA	cis	rs1707322	1	rs946524	ENSG00000280836.1	AL355480.1	8.5	6.41e-17	2.32e-14	0.32	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46021888	chr1:45581219~45581321:-
BRCA	cis	rs881375	0.934	rs2159778	ENSG00000226752.6	PSMD5-AS1	-8.5	6.44e-17	2.33e-14	-0.3	-0.25	Rheumatoid arthritis;	chr9:120915851	chr9:120824828~120854385:+
BRCA	cis	rs12188164	0.515	rs2672744	ENSG00000225138.6	CTD-2228K2.7	-8.5	6.44e-17	2.33e-14	-0.29	-0.25	Cystic fibrosis severity;	chr5:410932	chr5:473236~480884:+
BRCA	cis	rs8059260	0.604	rs35715760	ENSG00000274038.1	RP11-66H6.4	-8.5	6.5e-17	2.35e-14	-0.42	-0.25	Alcohol consumption over the past year;	chr16:11102091	chr16:11056556~11057034:+
BRCA	cis	rs8072100	0.875	rs7208530	ENSG00000228782.6	CTD-2026D20.3	8.5	6.52e-17	2.36e-14	0.28	0.25	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47466741	chr17:47450568~47492492:-
BRCA	cis	rs2115630	1	rs8037423	ENSG00000225151.9	GOLGA2P7	8.5	6.53e-17	2.36e-14	0.28	0.25	P wave terminal force;	chr15:84812263	chr15:84199311~84230136:-
BRCA	cis	rs4835473	0.932	rs7683686	ENSG00000251600.4	RP11-673E1.1	-8.5	6.55e-17	2.37e-14	-0.28	-0.25	Immature fraction of reticulocytes;	chr4:143784352	chr4:143912331~143982454:+
BRCA	cis	rs3758911	0.861	rs11212112	ENSG00000255353.1	RP11-382M14.1	-8.5	6.59e-17	2.38e-14	-0.34	-0.25	Coronary artery disease;	chr11:107272667	chr11:107176286~107177530:+
BRCA	cis	rs1707322	1	rs4454479	ENSG00000280836.1	AL355480.1	-8.5	6.6e-17	2.39e-14	-0.32	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45957883	chr1:45581219~45581321:-
BRCA	cis	rs10971721	0.822	rs117703548	ENSG00000260947.1	RP11-384P7.7	8.5	6.61e-17	2.39e-14	0.46	0.25	Body mass index;	chr9:34041199	chr9:33697459~33700986:+
BRCA	cis	rs7208859	0.524	rs73988172	ENSG00000266490.1	CTD-2349P21.9	8.5	6.61e-17	2.39e-14	0.37	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759314	chr17:30792372~30792833:+
BRCA	cis	rs694739	0.628	rs508168	ENSG00000236935.1	AP003774.1	8.5	6.62e-17	2.39e-14	0.24	0.25	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64367963	chr11:64325050~64329504:-
BRCA	cis	rs10129255	0.957	rs10136781	ENSG00000223648.3	IGHV3-64	8.5	6.64e-17	2.4e-14	0.21	0.25	Kawasaki disease;	chr14:106780451	chr14:106643132~106658258:-
BRCA	cis	rs7429990	0.864	rs35698005	ENSG00000229759.1	MRPS18AP1	-8.5	6.64e-17	2.4e-14	-0.29	-0.25	Educational attainment (years of education);	chr3:47800558	chr3:48256350~48256938:-
BRCA	cis	rs10971721	0.822	rs10971817	ENSG00000260947.1	RP11-384P7.7	8.5	6.67e-17	2.41e-14	0.45	0.25	Body mass index;	chr9:33951886	chr9:33697459~33700986:+
BRCA	cis	rs526231	0.543	rs257310	ENSG00000175749.11	EIF3KP1	8.5	6.68e-17	2.42e-14	0.37	0.25	Primary biliary cholangitis;	chr5:103083149	chr5:103032376~103033031:+
BRCA	cis	rs1707322	1	rs4660336	ENSG00000280836.1	AL355480.1	8.5	6.69e-17	2.42e-14	0.32	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46022304	chr1:45581219~45581321:-
BRCA	cis	rs7772486	0.806	rs2253648	ENSG00000235652.6	RP11-545I5.3	8.5	6.69e-17	2.42e-14	0.25	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145878160	chr6:145799409~145886585:+
BRCA	cis	rs7428	0.527	rs7608892	ENSG00000246575.2	AC093162.5	8.5	6.71e-17	2.42e-14	0.27	0.25	Ear protrusion;	chr2:85315595	chr2:85315041~85316529:+
BRCA	cis	rs10510102	0.872	rs12265369	ENSG00000276742.1	RP11-500G22.4	8.5	6.71e-17	2.43e-14	0.44	0.25	Breast cancer;	chr10:121968455	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.872	rs12265542	ENSG00000276742.1	RP11-500G22.4	8.5	6.71e-17	2.43e-14	0.44	0.25	Breast cancer;	chr10:121968740	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.872	rs11200293	ENSG00000276742.1	RP11-500G22.4	8.5	6.71e-17	2.43e-14	0.44	0.25	Breast cancer;	chr10:121969195	chr10:121956782~121957098:+
BRCA	cis	rs72627509	0.951	rs17087335	ENSG00000269949.1	RP11-738E22.3	8.5	6.71e-17	2.43e-14	0.39	0.25	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56972417	chr4:56960927~56961373:-
BRCA	cis	rs6472827	0.645	rs2956055	ENSG00000253983.2	RP1-16A9.1	8.5	6.72e-17	2.43e-14	0.35	0.25	Uterine fibroids;	chr8:74199718	chr8:74199396~74208441:+
BRCA	cis	rs375066	0.901	rs376069	ENSG00000267058.1	RP11-15A1.3	-8.5	6.72e-17	2.43e-14	-0.29	-0.25	Breast cancer;	chr19:43913143	chr19:43891804~43901805:-
BRCA	cis	rs67981189	0.546	rs2810075	ENSG00000269927.1	RP6-91H8.3	-8.5	6.72e-17	2.43e-14	-0.34	-0.25	Schizophrenia;	chr14:70908363	chr14:71141125~71143253:-
BRCA	cis	rs26232	0.521	rs11958562	ENSG00000175749.11	EIF3KP1	8.5	6.73e-17	2.43e-14	0.35	0.25	Rheumatoid arthritis;	chr5:103027357	chr5:103032376~103033031:+
BRCA	cis	rs7674212	0.507	rs223413	ENSG00000246560.2	RP11-10L12.4	-8.5	6.74e-17	2.44e-14	-0.27	-0.25	Type 2 diabetes;	chr4:102811709	chr4:102828055~102844075:+
BRCA	cis	rs7727544	0.735	rs272860	ENSG00000233006.5	AC034220.3	8.5	6.75e-17	2.44e-14	0.19	0.25	Blood metabolite levels;	chr5:132348482	chr5:132311285~132369916:-
BRCA	cis	rs4835473	0.932	rs2323417	ENSG00000251600.4	RP11-673E1.1	8.5	6.75e-17	2.44e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143969108	chr4:143912331~143982454:+
BRCA	cis	rs17023223	0.537	rs1325938	ENSG00000231365.4	RP11-418J17.1	-8.5	6.76e-17	2.44e-14	-0.32	-0.25	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119040019	chr1:119140396~119275973:+
BRCA	cis	rs8012947	1	rs8012947	ENSG00000279636.2	LINC00216	-8.49	6.76e-17	2.44e-14	-0.28	-0.25	Alcohol consumption in current drinkers;	chr14:58317737	chr14:58288033~58289158:+
BRCA	cis	rs1707322	0.963	rs1768815	ENSG00000280836.1	AL355480.1	8.49	6.76e-17	2.44e-14	0.32	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46062931	chr1:45581219~45581321:-
BRCA	cis	rs1707322	1	rs785506	ENSG00000280836.1	AL355480.1	8.49	6.77e-17	2.44e-14	0.32	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46074980	chr1:45581219~45581321:-
BRCA	cis	rs875971	0.558	rs4433015	ENSG00000222364.1	RNU6-96P	8.49	6.77e-17	2.44e-14	0.29	0.25	Aortic root size;	chr7:66174736	chr7:66395191~66395286:+
BRCA	cis	rs1707322	1	rs6671754	ENSG00000280836.1	AL355480.1	-8.49	6.78e-17	2.45e-14	-0.33	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45968318	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.963	rs6666763	ENSG00000280836.1	AL355480.1	-8.49	6.78e-17	2.45e-14	-0.33	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45970779	chr1:45581219~45581321:-
BRCA	cis	rs1707322	1	rs4489497	ENSG00000280836.1	AL355480.1	-8.49	6.78e-17	2.45e-14	-0.33	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45973026	chr1:45581219~45581321:-
BRCA	cis	rs1707322	1	rs11211235	ENSG00000280836.1	AL355480.1	-8.49	6.78e-17	2.45e-14	-0.33	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45974703	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.893	rs9919275	ENSG00000280836.1	AL355480.1	-8.49	6.78e-17	2.45e-14	-0.33	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45975688	chr1:45581219~45581321:-
BRCA	cis	rs1707322	1	rs11211236	ENSG00000280836.1	AL355480.1	-8.49	6.78e-17	2.45e-14	-0.33	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45978095	chr1:45581219~45581321:-
BRCA	cis	rs1707322	1	rs4660328	ENSG00000280836.1	AL355480.1	-8.49	6.78e-17	2.45e-14	-0.33	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45979159	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.928	rs61785614	ENSG00000280836.1	AL355480.1	-8.49	6.78e-17	2.45e-14	-0.33	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45980375	chr1:45581219~45581321:-
BRCA	cis	rs1707322	1	rs9793167	ENSG00000280836.1	AL355480.1	-8.49	6.78e-17	2.45e-14	-0.33	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45981128	chr1:45581219~45581321:-
BRCA	cis	rs1707322	1	rs11211237	ENSG00000280836.1	AL355480.1	-8.49	6.78e-17	2.45e-14	-0.33	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45981657	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.963	rs11211238	ENSG00000280836.1	AL355480.1	-8.49	6.78e-17	2.45e-14	-0.33	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45983743	chr1:45581219~45581321:-
BRCA	cis	rs1707322	1	rs4460583	ENSG00000280836.1	AL355480.1	-8.49	6.78e-17	2.45e-14	-0.33	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45984246	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.963	rs4459051	ENSG00000280836.1	AL355480.1	-8.49	6.78e-17	2.45e-14	-0.33	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45985531	chr1:45581219~45581321:-
BRCA	cis	rs1707322	1	rs11211239	ENSG00000280836.1	AL355480.1	-8.49	6.78e-17	2.45e-14	-0.33	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45986275	chr1:45581219~45581321:-
BRCA	cis	rs17023223	0.537	rs12072768	ENSG00000231365.4	RP11-418J17.1	-8.49	6.8e-17	2.45e-14	-0.32	-0.25	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119051295	chr1:119140396~119275973:+
BRCA	cis	rs765787	0.505	rs12593605	ENSG00000259520.4	CTD-2651B20.3	-8.49	6.8e-17	2.45e-14	-0.33	-0.25	Uric acid levels;	chr15:45205250	chr15:45251580~45279251:-
BRCA	cis	rs8012947	0.959	rs6573196	ENSG00000279636.2	LINC00216	-8.49	6.82e-17	2.46e-14	-0.28	-0.25	Alcohol consumption in current drinkers;	chr14:58255821	chr14:58288033~58289158:+
BRCA	cis	rs6860806	0.507	rs272878	ENSG00000233006.5	AC034220.3	-8.49	6.83e-17	2.46e-14	-0.2	-0.25	Breast cancer;	chr5:132336076	chr5:132311285~132369916:-
BRCA	cis	rs17772222	0.958	rs17203789	ENSG00000258983.2	RP11-507K2.2	8.49	6.84e-17	2.47e-14	0.29	0.25	Coronary artery calcification;	chr14:88541362	chr14:88499334~88515502:+
BRCA	cis	rs875971	0.522	rs4718286	ENSG00000222364.1	RNU6-96P	-8.49	6.85e-17	2.47e-14	-0.29	-0.25	Aortic root size;	chr7:65827777	chr7:66395191~66395286:+
BRCA	cis	rs17711722	0.585	rs6942660	ENSG00000222364.1	RNU6-96P	-8.49	6.85e-17	2.47e-14	-0.29	-0.25	Calcium levels;	chr7:65837419	chr7:66395191~66395286:+
BRCA	cis	rs858239	0.601	rs15775	ENSG00000230042.1	AK3P3	-8.49	6.91e-17	2.49e-14	-0.29	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23125082	chr7:23129178~23129841:+
BRCA	cis	rs7727544	0.661	rs273900	ENSG00000233006.5	AC034220.3	8.49	6.93e-17	2.5e-14	0.19	0.25	Blood metabolite levels;	chr5:132358913	chr5:132311285~132369916:-
BRCA	cis	rs1707322	1	rs11211248	ENSG00000280836.1	AL355480.1	-8.49	6.98e-17	2.51e-14	-0.32	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46011172	chr1:45581219~45581321:-
BRCA	cis	rs11763147	1	rs11763147	ENSG00000222364.1	RNU6-96P	8.49	7e-17	2.52e-14	0.29	0.25	Corneal structure;	chr7:65861834	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.545	rs6460281	ENSG00000222364.1	RNU6-96P	-8.49	7.03e-17	2.53e-14	-0.33	-0.25	Aortic root size;	chr7:66216128	chr7:66395191~66395286:+
BRCA	cis	rs881375	0.933	rs7021206	ENSG00000226752.6	PSMD5-AS1	8.49	7.06e-17	2.54e-14	0.3	0.25	Rheumatoid arthritis;	chr9:120921879	chr9:120824828~120854385:+
BRCA	cis	rs11098499	0.874	rs13139045	ENSG00000245958.5	RP11-33B1.1	-8.49	7.07e-17	2.55e-14	-0.24	-0.25	Corneal astigmatism;	chr4:119247433	chr4:119454791~119552025:+
BRCA	cis	rs10971721	0.908	rs72729329	ENSG00000260947.1	RP11-384P7.7	8.49	7.09e-17	2.56e-14	0.46	0.25	Body mass index;	chr9:34022884	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.908	rs10971858	ENSG00000260947.1	RP11-384P7.7	8.49	7.09e-17	2.56e-14	0.46	0.25	Body mass index;	chr9:34023693	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.822	rs72729341	ENSG00000260947.1	RP11-384P7.7	8.49	7.09e-17	2.56e-14	0.46	0.25	Body mass index;	chr9:34031693	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.822	rs72729344	ENSG00000260947.1	RP11-384P7.7	8.49	7.09e-17	2.56e-14	0.46	0.25	Body mass index;	chr9:34034032	chr9:33697459~33700986:+
BRCA	cis	rs17711722	0.727	rs2658585	ENSG00000222364.1	RNU6-96P	-8.49	7.1e-17	2.56e-14	-0.29	-0.25	Calcium levels;	chr7:65996954	chr7:66395191~66395286:+
BRCA	cis	rs860818	1	rs858253	ENSG00000226816.2	AC005082.12	8.49	7.1e-17	2.56e-14	0.57	0.25	Initial pursuit acceleration;	chr7:23178101	chr7:23206013~23208045:+
BRCA	cis	rs4803480	0.542	rs7255742	ENSG00000270164.1	LINC01480	-8.49	7.12e-17	2.56e-14	-0.29	-0.25	Schizophrenia;	chr19:41543459	chr19:41535183~41536904:+
BRCA	cis	rs8059260	0.877	rs6498146	ENSG00000274038.1	RP11-66H6.4	8.49	7.13e-17	2.57e-14	0.32	0.25	Alcohol consumption over the past year;	chr16:11012850	chr16:11056556~11057034:+
BRCA	cis	rs1062177	0.901	rs1549622	ENSG00000253921.1	CTB-113P19.3	-8.49	7.13e-17	2.57e-14	-0.35	-0.25	Preschool internalizing problems;	chr5:151886488	chr5:151753992~151767247:+
BRCA	cis	rs875971	0.522	rs1880556	ENSG00000222364.1	RNU6-96P	-8.49	7.14e-17	2.57e-14	-0.29	-0.25	Aortic root size;	chr7:65967557	chr7:66395191~66395286:+
BRCA	cis	rs7945705	0.87	rs4929922	ENSG00000254860.4	TMEM9B-AS1	8.49	7.15e-17	2.58e-14	0.25	0.25	Hemoglobin concentration;	chr11:8954229	chr11:8964675~8977527:+
BRCA	cis	rs4835473	0.831	rs4125544	ENSG00000251600.4	RP11-673E1.1	8.49	7.19e-17	2.59e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143962542	chr4:143912331~143982454:+
BRCA	cis	rs4660456	0.913	rs2223486	ENSG00000237899.1	RP4-739H11.3	-8.49	7.19e-17	2.59e-14	-0.37	-0.25	Platelet count;	chr1:40693557	chr1:40669089~40687588:-
BRCA	cis	rs1499614	1	rs1638731	ENSG00000273142.1	RP11-458F8.4	-8.49	7.21e-17	2.6e-14	-0.36	-0.25	Gout;	chr7:66679692	chr7:66902857~66906297:+
BRCA	cis	rs1499614	1	rs1882655	ENSG00000273142.1	RP11-458F8.4	8.49	7.21e-17	2.6e-14	0.36	0.25	Gout;	chr7:66682070	chr7:66902857~66906297:+
BRCA	cis	rs1499614	0.831	rs3800822	ENSG00000273142.1	RP11-458F8.4	8.49	7.21e-17	2.6e-14	0.36	0.25	Gout;	chr7:66682162	chr7:66902857~66906297:+
BRCA	cis	rs925255	0.682	rs7590263	ENSG00000270210.1	RP11-373D23.3	8.49	7.22e-17	2.6e-14	0.32	0.25	Inflammatory bowel disease;Crohn's disease;	chr2:28422935	chr2:28425945~28426719:+
BRCA	cis	rs4660456	0.913	rs2744799	ENSG00000237899.1	RP4-739H11.3	8.49	7.23e-17	2.6e-14	0.38	0.25	Platelet count;	chr1:40719862	chr1:40669089~40687588:-
BRCA	cis	rs61270009	0.955	rs12659252	ENSG00000247828.6	TMEM161B-AS1	8.49	7.24e-17	2.61e-14	0.32	0.25	Depressive symptoms;	chr5:88297472	chr5:88268895~88436685:+
BRCA	cis	rs61270009	0.955	rs6872223	ENSG00000247828.6	TMEM161B-AS1	8.49	7.24e-17	2.61e-14	0.32	0.25	Depressive symptoms;	chr5:88306555	chr5:88268895~88436685:+
BRCA	cis	rs7208859	0.573	rs56031503	ENSG00000266490.1	CTD-2349P21.9	8.49	7.24e-17	2.61e-14	0.37	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748647	chr17:30792372~30792833:+
BRCA	cis	rs116175783	0.557	rs62188123	ENSG00000227403.1	AC009299.3	8.49	7.25e-17	2.61e-14	0.46	0.25	Intelligence (multi-trait analysis);	chr2:161385335	chr2:161244739~161249050:+
BRCA	cis	rs858239	0.601	rs4140959	ENSG00000230042.1	AK3P3	-8.49	7.25e-17	2.61e-14	-0.29	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23131157	chr7:23129178~23129841:+
BRCA	cis	rs2933343	1	rs876756	ENSG00000231305.3	RP11-723O4.2	8.49	7.28e-17	2.62e-14	0.32	0.25	IgG glycosylation;	chr3:128908780	chr3:128861313~128871540:-
BRCA	cis	rs3758911	0.861	rs11212113	ENSG00000255353.1	RP11-382M14.1	-8.49	7.3e-17	2.63e-14	-0.34	-0.25	Coronary artery disease;	chr11:107272776	chr11:107176286~107177530:+
BRCA	cis	rs11098499	0.865	rs4507344	ENSG00000248280.1	RP11-33B1.2	8.49	7.3e-17	2.63e-14	0.26	0.25	Corneal astigmatism;	chr4:119386330	chr4:119440561~119450157:-
BRCA	cis	rs875971	0.505	rs1167385	ENSG00000236529.1	RP13-254B10.1	-8.49	7.31e-17	2.63e-14	-0.28	-0.25	Aortic root size;	chr7:66048321	chr7:65840212~65840596:+
BRCA	cis	rs6570726	0.846	rs6919684	ENSG00000235652.6	RP11-545I5.3	8.49	7.32e-17	2.63e-14	0.25	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145562665	chr6:145799409~145886585:+
BRCA	cis	rs11673344	0.931	rs1234251	ENSG00000226686.6	LINC01535	8.48	7.33e-17	2.64e-14	0.33	0.25	Obesity-related traits;	chr19:37180354	chr19:37251912~37265535:+
BRCA	cis	rs801193	1	rs17566701	ENSG00000222364.1	RNU6-96P	-8.48	7.34e-17	2.64e-14	-0.29	-0.25	Aortic root size;	chr7:66728196	chr7:66395191~66395286:+
BRCA	cis	rs17772222	0.958	rs76559451	ENSG00000258983.2	RP11-507K2.2	8.48	7.35e-17	2.64e-14	0.29	0.25	Coronary artery calcification;	chr14:88523193	chr14:88499334~88515502:+
BRCA	cis	rs4835473	0.932	rs12512649	ENSG00000251600.4	RP11-673E1.1	-8.48	7.39e-17	2.66e-14	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143736745	chr4:143912331~143982454:+
BRCA	cis	rs875971	0.545	rs316328	ENSG00000222364.1	RNU6-96P	8.48	7.4e-17	2.66e-14	0.31	0.25	Aortic root size;	chr7:66143851	chr7:66395191~66395286:+
BRCA	cis	rs1707322	1	rs1707338	ENSG00000280836.1	AL355480.1	8.48	7.43e-17	2.67e-14	0.32	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46046309	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.964	rs1707339	ENSG00000280836.1	AL355480.1	8.48	7.43e-17	2.67e-14	0.32	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46047507	chr1:45581219~45581321:-
BRCA	cis	rs1707322	1	rs1768818	ENSG00000280836.1	AL355480.1	8.48	7.43e-17	2.67e-14	0.32	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46048614	chr1:45581219~45581321:-
BRCA	cis	rs1707322	1	rs1768817	ENSG00000280836.1	AL355480.1	8.48	7.43e-17	2.67e-14	0.32	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46048862	chr1:45581219~45581321:-
BRCA	cis	rs896854	0.967	rs896853	ENSG00000253528.2	RP11-347C18.4	8.48	7.45e-17	2.68e-14	0.26	0.25	Type 2 diabetes;	chr8:94948627	chr8:94974573~94974853:-
BRCA	cis	rs6539288	0.674	rs989560	ENSG00000260329.1	RP11-412D9.4	-8.48	7.5e-17	2.7e-14	-0.28	-0.25	Total body bone mineral density;	chr12:106891973	chr12:106954029~106955497:-
BRCA	cis	rs4718428	0.705	rs11028	ENSG00000232546.1	RP11-458F8.1	-8.48	7.5e-17	2.7e-14	-0.23	-0.25	Corneal structure;	chr7:66811230	chr7:66848496~66858136:+
BRCA	cis	rs7773456	0.711	rs9358277	ENSG00000228412.5	RP4-625H18.2	-8.48	7.5e-17	2.7e-14	-0.36	-0.25	Lupus nephritis in systemic lupus erythematosus;	chr6:19816398	chr6:19802164~19804752:-
BRCA	cis	rs2115630	0.905	rs1975277	ENSG00000225151.9	GOLGA2P7	8.48	7.55e-17	2.71e-14	0.28	0.25	P wave terminal force;	chr15:84786327	chr15:84199311~84230136:-
BRCA	cis	rs11673344	0.796	rs9676450	ENSG00000226686.6	LINC01535	8.48	7.56e-17	2.71e-14	0.33	0.25	Obesity-related traits;	chr19:36998505	chr19:37251912~37265535:+
BRCA	cis	rs925255	0.711	rs12478126	ENSG00000270210.1	RP11-373D23.3	8.48	7.58e-17	2.72e-14	0.32	0.25	Inflammatory bowel disease;Crohn's disease;	chr2:28423081	chr2:28425945~28426719:+
BRCA	cis	rs10129255	0.957	rs17113284	ENSG00000223648.3	IGHV3-64	-8.48	7.58e-17	2.72e-14	-0.22	-0.25	Kawasaki disease;	chr14:106684476	chr14:106643132~106658258:-
BRCA	cis	rs17023223	0.537	rs2361272	ENSG00000231365.4	RP11-418J17.1	-8.48	7.61e-17	2.73e-14	-0.32	-0.25	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119060794	chr1:119140396~119275973:+
BRCA	cis	rs10971721	0.822	rs72725392	ENSG00000260947.1	RP11-384P7.7	8.48	7.61e-17	2.73e-14	0.45	0.25	Body mass index;	chr9:33867780	chr9:33697459~33700986:+
BRCA	cis	rs12468226	0.938	rs79117531	ENSG00000273456.1	RP11-686O6.2	8.48	7.7e-17	2.77e-14	0.37	0.25	Urate levels;	chr2:202307690	chr2:202374932~202375604:-
BRCA	cis	rs858239	0.799	rs10279941	ENSG00000226816.2	AC005082.12	8.48	7.71e-17	2.77e-14	0.3	0.25	Cerebrospinal fluid biomarker levels;	chr7:23330889	chr7:23206013~23208045:+
BRCA	cis	rs8059260	0.668	rs7199305	ENSG00000274038.1	RP11-66H6.4	8.48	7.71e-17	2.77e-14	0.37	0.25	Alcohol consumption over the past year;	chr16:11006476	chr16:11056556~11057034:+
BRCA	cis	rs4727443	0.866	rs13243708	ENSG00000214313.7	AZGP1P1	-8.48	7.73e-17	2.78e-14	-0.26	-0.25	Interstitial lung disease;	chr7:100018668	chr7:99980762~99987535:+
BRCA	cis	rs526231	0.543	rs26820	ENSG00000175749.11	EIF3KP1	8.48	7.74e-17	2.78e-14	0.37	0.25	Primary biliary cholangitis;	chr5:103192391	chr5:103032376~103033031:+
BRCA	cis	rs1113500	0.73	rs1777456	ENSG00000226822.1	RP11-356N1.2	-8.48	7.8e-17	2.8e-14	-0.33	-0.25	Growth-regulated protein alpha levels;	chr1:108045850	chr1:108071482~108074519:+
BRCA	cis	rs10129255	0.957	rs8009073	ENSG00000223648.3	IGHV3-64	8.48	7.8e-17	2.8e-14	0.22	0.25	Kawasaki disease;	chr14:106777278	chr14:106643132~106658258:-
BRCA	cis	rs11098499	0.954	rs2389803	ENSG00000248280.1	RP11-33B1.2	-8.48	7.84e-17	2.82e-14	-0.26	-0.25	Corneal astigmatism;	chr4:119472356	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.754	rs9999724	ENSG00000245958.5	RP11-33B1.1	-8.48	7.87e-17	2.82e-14	-0.24	-0.25	Corneal astigmatism;	chr4:119318789	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.618	rs28491261	ENSG00000248280.1	RP11-33B1.2	8.48	7.91e-17	2.84e-14	0.26	0.25	Corneal astigmatism;	chr4:119373745	chr4:119440561~119450157:-
BRCA	cis	rs7727544	0.709	rs272852	ENSG00000233006.5	AC034220.3	8.48	7.92e-17	2.84e-14	0.19	0.25	Blood metabolite levels;	chr5:132353074	chr5:132311285~132369916:-
BRCA	cis	rs11971779	0.941	rs7802779	ENSG00000273391.1	RP11-634H22.1	8.47	7.94e-17	2.85e-14	0.26	0.25	Diisocyanate-induced asthma;	chr7:139437833	chr7:139359032~139359566:-
BRCA	cis	rs694739	0.541	rs61886926	ENSG00000236935.1	AP003774.1	8.47	7.94e-17	2.85e-14	0.24	0.25	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64366080	chr11:64325050~64329504:-
BRCA	cis	rs694739	0.628	rs617051	ENSG00000236935.1	AP003774.1	8.47	7.94e-17	2.85e-14	0.24	0.25	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64366166	chr11:64325050~64329504:-
BRCA	cis	rs1707322	1	rs7527079	ENSG00000280836.1	AL355480.1	-8.47	7.97e-17	2.86e-14	-0.32	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45947778	chr1:45581219~45581321:-
BRCA	cis	rs1707322	1	rs34446427	ENSG00000280836.1	AL355480.1	-8.47	7.97e-17	2.86e-14	-0.32	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45951983	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.963	rs4660900	ENSG00000280836.1	AL355480.1	-8.47	7.97e-17	2.86e-14	-0.32	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45953933	chr1:45581219~45581321:-
BRCA	cis	rs881375	0.967	rs1008381	ENSG00000226752.6	PSMD5-AS1	-8.47	7.97e-17	2.86e-14	-0.3	-0.25	Rheumatoid arthritis;	chr9:120918838	chr9:120824828~120854385:+
BRCA	cis	rs875971	0.508	rs10950045	ENSG00000237310.1	GS1-124K5.4	-8.47	7.98e-17	2.86e-14	-0.26	-0.25	Aortic root size;	chr7:66601386	chr7:66493706~66495474:+
BRCA	cis	rs801193	0.839	rs6968619	ENSG00000237310.1	GS1-124K5.4	-8.47	7.98e-17	2.86e-14	-0.26	-0.25	Aortic root size;	chr7:66603880	chr7:66493706~66495474:+
BRCA	cis	rs801193	0.805	rs12532355	ENSG00000237310.1	GS1-124K5.4	-8.47	7.98e-17	2.86e-14	-0.26	-0.25	Aortic root size;	chr7:66605597	chr7:66493706~66495474:+
BRCA	cis	rs2274273	0.87	rs8013713	ENSG00000258413.1	RP11-665C16.6	8.47	7.98e-17	2.86e-14	0.32	0.25	Protein biomarker;	chr14:55374534	chr14:55262767~55272075:-
BRCA	cis	rs875971	1	rs2420168	ENSG00000237310.1	GS1-124K5.4	-8.47	8e-17	2.87e-14	-0.26	-0.25	Aortic root size;	chr7:66165644	chr7:66493706~66495474:+
BRCA	cis	rs17772222	0.958	rs12436326	ENSG00000258983.2	RP11-507K2.2	8.47	8.02e-17	2.88e-14	0.29	0.25	Coronary artery calcification;	chr14:88533632	chr14:88499334~88515502:+
BRCA	cis	rs34375054	0.624	rs7132026	ENSG00000279233.1	RP11-158L12.4	-8.47	8.02e-17	2.88e-14	-0.32	-0.25	Post bronchodilator FEV1/FVC ratio;	chr12:125193550	chr12:125138245~125141711:+
BRCA	cis	rs875971	1	rs6945843	ENSG00000237310.1	GS1-124K5.4	-8.47	8.1e-17	2.9e-14	-0.26	-0.25	Aortic root size;	chr7:66269796	chr7:66493706~66495474:+
BRCA	cis	rs367615	0.879	rs2201015	ENSG00000249476.1	CTD-2587M2.1	8.47	8.12e-17	2.91e-14	0.31	0.25	Colorectal cancer (SNP x SNP interaction);	chr5:109611749	chr5:109237120~109326369:-
BRCA	cis	rs2243480	1	rs6958420	ENSG00000273142.1	RP11-458F8.4	8.47	8.13e-17	2.91e-14	0.35	0.25	Diabetic kidney disease;	chr7:66286184	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs1392104	ENSG00000273142.1	RP11-458F8.4	8.47	8.13e-17	2.91e-14	0.35	0.25	Diabetic kidney disease;	chr7:66294120	chr7:66902857~66906297:+
BRCA	cis	rs1167827	0.68	rs1167796	ENSG00000278416.1	PMS2L2	-8.47	8.13e-17	2.91e-14	-0.34	-0.25	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75543861	chr7:75344015~75359550:-
BRCA	cis	rs875971	0.545	rs7811204	ENSG00000222364.1	RNU6-96P	-8.47	8.14e-17	2.92e-14	-0.34	-0.25	Aortic root size;	chr7:66387213	chr7:66395191~66395286:+
BRCA	cis	rs8059260	0.544	rs34846673	ENSG00000274038.1	RP11-66H6.4	-8.47	8.14e-17	2.92e-14	-0.41	-0.25	Alcohol consumption over the past year;	chr16:11102829	chr16:11056556~11057034:+
BRCA	cis	rs375066	0.935	rs388685	ENSG00000267058.1	RP11-15A1.3	-8.47	8.16e-17	2.93e-14	-0.3	-0.25	Breast cancer;	chr19:43914528	chr19:43891804~43901805:-
BRCA	cis	rs2115630	1	rs7183401	ENSG00000225151.9	GOLGA2P7	8.47	8.21e-17	2.94e-14	0.27	0.25	P wave terminal force;	chr15:84828713	chr15:84199311~84230136:-
BRCA	cis	rs10129255	0.518	rs8009612	ENSG00000211972.2	IGHV3-66	8.47	8.21e-17	2.94e-14	0.18	0.25	Kawasaki disease;	chr14:106777510	chr14:106675017~106675544:-
BRCA	cis	rs10971721	0.822	rs72725387	ENSG00000260947.1	RP11-384P7.7	8.47	8.33e-17	2.98e-14	0.45	0.25	Body mass index;	chr9:33863673	chr9:33697459~33700986:+
BRCA	cis	rs453301	0.658	rs6986044	ENSG00000253893.2	FAM85B	8.47	8.36e-17	2.99e-14	0.32	0.25	Joint mobility (Beighton score);	chr8:9017276	chr8:8167819~8226614:-
BRCA	cis	rs875971	0.545	rs316316	ENSG00000222364.1	RNU6-96P	8.47	8.37e-17	3e-14	0.33	0.25	Aortic root size;	chr7:66149270	chr7:66395191~66395286:+
BRCA	cis	rs67981189	0.529	rs17108862	ENSG00000269927.1	RP6-91H8.3	8.47	8.38e-17	3e-14	0.33	0.25	Schizophrenia;	chr14:70997949	chr14:71141125~71143253:-
BRCA	cis	rs4713118	0.629	rs203887	ENSG00000220721.1	OR1F12	8.47	8.39e-17	3e-14	0.34	0.25	Parkinson's disease;	chr6:28053491	chr6:28073316~28074233:+
BRCA	cis	rs4787484	0.593	rs12917712	ENSG00000214725.6	CDIPT-AS1	8.47	8.39e-17	3e-14	0.31	0.25	Response to taxane treatment (placlitaxel);	chr16:29871169	chr16:29863593~29868053:+
BRCA	cis	rs2117029	0.737	rs34436857	ENSG00000258017.1	RP11-386G11.10	-8.47	8.43e-17	3.02e-14	-0.35	-0.25	Intelligence (multi-trait analysis);	chr12:49045738	chr12:49127782~49147869:+
BRCA	cis	rs10971721	0.749	rs10971741	ENSG00000260947.1	RP11-384P7.7	8.47	8.44e-17	3.02e-14	0.45	0.25	Body mass index;	chr9:33856869	chr9:33697459~33700986:+
BRCA	cis	rs875971	0.545	rs6970498	ENSG00000222364.1	RNU6-96P	-8.47	8.44e-17	3.02e-14	-0.34	-0.25	Aortic root size;	chr7:66275908	chr7:66395191~66395286:+
BRCA	cis	rs193541	0.586	rs11241662	ENSG00000263432.2	RN7SL689P	-8.47	8.46e-17	3.03e-14	-0.33	-0.25	Glucose homeostasis traits;	chr5:122846280	chr5:123022487~123022783:-
BRCA	cis	rs9368481	0.761	rs7775041	ENSG00000241549.7	GUSBP2	-8.47	8.48e-17	3.04e-14	-0.29	-0.25	Autism spectrum disorder or schizophrenia;	chr6:27041733	chr6:26871484~26956554:-
BRCA	cis	rs875971	0.522	rs781144	ENSG00000164669.11	INTS4P1	-8.47	8.49e-17	3.04e-14	-0.31	-0.25	Aortic root size;	chr7:65975357	chr7:65141225~65234216:+
BRCA	cis	rs13230714	0.858	rs714429	ENSG00000204959.4	ARHGEF34P	-8.47	8.51e-17	3.04e-14	-0.31	-0.25	Breast cancer;	chr7:144456641	chr7:144272445~144286966:-
BRCA	cis	rs8012947	0.565	rs4901852	ENSG00000279636.2	LINC00216	8.47	8.51e-17	3.05e-14	0.26	0.25	Alcohol consumption in current drinkers;	chr14:58355211	chr14:58288033~58289158:+
BRCA	cis	rs4835473	0.864	rs2089837	ENSG00000251600.4	RP11-673E1.1	8.47	8.52e-17	3.05e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143965038	chr4:143912331~143982454:+
BRCA	cis	rs1167827	0.71	rs1167836	ENSG00000278416.1	PMS2L2	8.47	8.54e-17	3.06e-14	0.35	0.25	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75539580	chr7:75344015~75359550:-
BRCA	cis	rs12468226	0.938	rs16841867	ENSG00000273456.1	RP11-686O6.2	8.47	8.55e-17	3.06e-14	0.37	0.25	Urate levels;	chr2:202303512	chr2:202374932~202375604:-
BRCA	cis	rs12468226	0.938	rs16839065	ENSG00000273456.1	RP11-686O6.2	8.47	8.55e-17	3.06e-14	0.37	0.25	Urate levels;	chr2:202308774	chr2:202374932~202375604:-
BRCA	cis	rs12468226	0.938	rs114922024	ENSG00000273456.1	RP11-686O6.2	8.47	8.55e-17	3.06e-14	0.37	0.25	Urate levels;	chr2:202315958	chr2:202374932~202375604:-
BRCA	cis	rs12468226	0.938	rs77261109	ENSG00000273456.1	RP11-686O6.2	8.47	8.55e-17	3.06e-14	0.37	0.25	Urate levels;	chr2:202316233	chr2:202374932~202375604:-
BRCA	cis	rs12468226	0.938	rs12466003	ENSG00000273456.1	RP11-686O6.2	8.47	8.55e-17	3.06e-14	0.37	0.25	Urate levels;	chr2:202317317	chr2:202374932~202375604:-
BRCA	cis	rs2933343	0.951	rs1055128	ENSG00000261159.1	RP11-723O4.9	8.47	8.56e-17	3.06e-14	0.3	0.25	IgG glycosylation;	chr3:128872205	chr3:128859716~128860526:-
BRCA	cis	rs72627509	1	rs57265257	ENSG00000269949.1	RP11-738E22.3	8.47	8.57e-17	3.06e-14	0.39	0.25	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56973114	chr4:56960927~56961373:-
BRCA	cis	rs4964805	0.913	rs11111795	ENSG00000257681.1	RP11-341G23.4	8.47	8.58e-17	3.07e-14	0.31	0.25	Attention deficit hyperactivity disorder;	chr12:103811052	chr12:103746315~103768858:-
BRCA	cis	rs1707322	0.964	rs785483	ENSG00000280836.1	AL355480.1	8.47	8.6e-17	3.07e-14	0.32	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46093499	chr1:45581219~45581321:-
BRCA	cis	rs10129255	1	rs11627342	ENSG00000223648.3	IGHV3-64	8.46	8.61e-17	3.08e-14	0.23	0.25	Kawasaki disease;	chr14:106675823	chr14:106643132~106658258:-
BRCA	cis	rs5751614	0.62	rs1811017	ENSG00000230701.2	FBXW4P1	8.46	8.64e-17	3.09e-14	0.31	0.25	Height;	chr22:23264771	chr22:23262767~23265005:+
BRCA	cis	rs7772486	0.603	rs2223411	ENSG00000235652.6	RP11-545I5.3	-8.46	8.64e-17	3.09e-14	-0.27	-0.25	Lobe attachment (rater-scored or self-reported);	chr6:145707631	chr6:145799409~145886585:+
BRCA	cis	rs7208859	0.623	rs7503335	ENSG00000266490.1	CTD-2349P21.9	8.46	8.66e-17	3.1e-14	0.37	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30746944	chr17:30792372~30792833:+
BRCA	cis	rs875971	0.545	rs13311962	ENSG00000222364.1	RNU6-96P	8.46	8.68e-17	3.1e-14	0.33	0.25	Aortic root size;	chr7:66603142	chr7:66395191~66395286:+
BRCA	cis	rs453301	0.686	rs3989373	ENSG00000253893.2	FAM85B	8.46	8.69e-17	3.11e-14	0.31	0.25	Joint mobility (Beighton score);	chr8:9053798	chr8:8167819~8226614:-
BRCA	cis	rs858239	0.57	rs10242166	ENSG00000230042.1	AK3P3	-8.46	8.69e-17	3.11e-14	-0.29	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23123180	chr7:23129178~23129841:+
BRCA	cis	rs858239	0.539	rs6955969	ENSG00000226816.2	AC005082.12	8.46	8.7e-17	3.11e-14	0.3	0.25	Cerebrospinal fluid biomarker levels;	chr7:23147080	chr7:23206013~23208045:+
BRCA	cis	rs526231	0.543	rs158244	ENSG00000175749.11	EIF3KP1	8.46	8.71e-17	3.11e-14	0.37	0.25	Primary biliary cholangitis;	chr5:103075062	chr5:103032376~103033031:+
BRCA	cis	rs2380205	0.5	rs688388	ENSG00000232807.2	RP11-536K7.3	-8.46	8.73e-17	3.12e-14	-0.26	-0.25	Breast cancer;	chr10:5918667	chr10:5934270~5945900:-
BRCA	cis	rs17023223	0.537	rs2645301	ENSG00000231365.4	RP11-418J17.1	-8.46	8.73e-17	3.12e-14	-0.32	-0.25	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119047797	chr1:119140396~119275973:+
BRCA	cis	rs4308124	0.708	rs56693625	ENSG00000230499.1	AC108463.1	-8.46	8.74e-17	3.12e-14	-0.32	-0.25	Vitiligo;	chr2:111207578	chr2:111195963~111206494:+
BRCA	cis	rs875971	0.545	rs7783889	ENSG00000222364.1	RNU6-96P	-8.46	8.75e-17	3.13e-14	-0.33	-0.25	Aortic root size;	chr7:66283366	chr7:66395191~66395286:+
BRCA	cis	rs2810114	0.76	rs2810105	ENSG00000269927.1	RP6-91H8.3	-8.46	8.77e-17	3.14e-14	-0.33	-0.25	Alcohol dependence;	chr14:70957934	chr14:71141125~71143253:-
BRCA	cis	rs858239	0.601	rs10255228	ENSG00000230042.1	AK3P3	-8.46	8.81e-17	3.15e-14	-0.29	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23119244	chr7:23129178~23129841:+
BRCA	cis	rs2933343	1	rs1683782	ENSG00000231305.3	RP11-723O4.2	8.46	8.82e-17	3.15e-14	0.32	0.25	IgG glycosylation;	chr3:128921434	chr3:128861313~128871540:-
BRCA	cis	rs10129255	0.957	rs10142859	ENSG00000223648.3	IGHV3-64	8.46	8.84e-17	3.16e-14	0.21	0.25	Kawasaki disease;	chr14:106782238	chr14:106643132~106658258:-
BRCA	cis	rs6142102	0.961	rs4911408	ENSG00000276073.1	RP5-1125A11.7	-8.46	8.84e-17	3.16e-14	-0.31	-0.25	Skin pigmentation;	chr20:34112760	chr20:33985617~33988989:-
BRCA	cis	rs4835473	0.639	rs28674022	ENSG00000251600.4	RP11-673E1.1	8.46	8.84e-17	3.16e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143966409	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.864	rs28423022	ENSG00000251600.4	RP11-673E1.1	8.46	8.84e-17	3.16e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143966416	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.864	rs35888177	ENSG00000251600.4	RP11-673E1.1	8.46	8.84e-17	3.16e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143966863	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs10033382	ENSG00000251600.4	RP11-673E1.1	8.46	8.84e-17	3.16e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143967103	chr4:143912331~143982454:+
BRCA	cis	rs858239	0.601	rs6980224	ENSG00000230042.1	AK3P3	-8.46	8.87e-17	3.17e-14	-0.29	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23109518	chr7:23129178~23129841:+
BRCA	cis	rs375066	0.901	rs438517	ENSG00000267058.1	RP11-15A1.3	-8.46	8.88e-17	3.17e-14	-0.29	-0.25	Breast cancer;	chr19:43915506	chr19:43891804~43901805:-
BRCA	cis	rs375066	0.935	rs446674	ENSG00000267058.1	RP11-15A1.3	-8.46	8.88e-17	3.17e-14	-0.29	-0.25	Breast cancer;	chr19:43916855	chr19:43891804~43901805:-
BRCA	cis	rs10463554	1	rs3776864	ENSG00000175749.11	EIF3KP1	8.46	8.88e-17	3.17e-14	0.36	0.25	Parkinson's disease;	chr5:102992164	chr5:103032376~103033031:+
BRCA	cis	rs11098499	0.82	rs13122709	ENSG00000245958.5	RP11-33B1.1	-8.46	8.92e-17	3.18e-14	-0.25	-0.25	Corneal astigmatism;	chr4:119634201	chr4:119454791~119552025:+
BRCA	cis	rs875971	0.505	rs1167386	ENSG00000236529.1	RP13-254B10.1	-8.46	8.92e-17	3.19e-14	-0.28	-0.25	Aortic root size;	chr7:66048109	chr7:65840212~65840596:+
BRCA	cis	rs61270009	0.955	rs4916898	ENSG00000247828.6	TMEM161B-AS1	8.46	8.92e-17	3.19e-14	0.32	0.25	Depressive symptoms;	chr5:88290245	chr5:88268895~88436685:+
BRCA	cis	rs11098499	1	rs11098500	ENSG00000245958.5	RP11-33B1.1	-8.46	8.93e-17	3.19e-14	-0.25	-0.25	Corneal astigmatism;	chr4:119298084	chr4:119454791~119552025:+
BRCA	cis	rs4727443	0.866	rs12531809	ENSG00000214313.7	AZGP1P1	-8.46	8.93e-17	3.19e-14	-0.26	-0.25	Interstitial lung disease;	chr7:100022850	chr7:99980762~99987535:+
BRCA	cis	rs11098499	0.722	rs17595727	ENSG00000245958.5	RP11-33B1.1	8.46	8.94e-17	3.19e-14	0.23	0.25	Corneal astigmatism;	chr4:119340919	chr4:119454791~119552025:+
BRCA	cis	rs875971	0.545	rs2279757	ENSG00000222364.1	RNU6-96P	-8.46	8.97e-17	3.2e-14	-0.34	-0.25	Aortic root size;	chr7:66363676	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.545	rs11766183	ENSG00000222364.1	RNU6-96P	-8.46	8.97e-17	3.2e-14	-0.34	-0.25	Aortic root size;	chr7:66374173	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.545	rs1065265	ENSG00000222364.1	RNU6-96P	-8.46	8.97e-17	3.2e-14	-0.34	-0.25	Aortic root size;	chr7:66376216	chr7:66395191~66395286:+
BRCA	cis	rs858239	0.601	rs1558313	ENSG00000230042.1	AK3P3	-8.46	9e-17	3.21e-14	-0.29	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23116460	chr7:23129178~23129841:+
BRCA	cis	rs858239	0.601	rs6962526	ENSG00000230042.1	AK3P3	-8.46	9e-17	3.21e-14	-0.29	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23118614	chr7:23129178~23129841:+
BRCA	cis	rs858239	0.539	rs6971673	ENSG00000230042.1	AK3P3	-8.46	9e-17	3.21e-14	-0.29	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23119904	chr7:23129178~23129841:+
BRCA	cis	rs858239	0.601	rs10278700	ENSG00000230042.1	AK3P3	-8.46	9e-17	3.21e-14	-0.29	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23120910	chr7:23129178~23129841:+
BRCA	cis	rs858239	0.601	rs10263110	ENSG00000230042.1	AK3P3	-8.46	9e-17	3.21e-14	-0.29	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23120932	chr7:23129178~23129841:+
BRCA	cis	rs875971	0.508	rs6947808	ENSG00000237310.1	GS1-124K5.4	-8.46	9e-17	3.21e-14	-0.26	-0.25	Aortic root size;	chr7:66580095	chr7:66493706~66495474:+
BRCA	cis	rs7246657	0.722	rs2909105	ENSG00000267422.1	CTD-2554C21.1	8.46	9.04e-17	3.23e-14	0.37	0.25	Coronary artery calcification;	chr19:37677005	chr19:37779686~37792865:+
BRCA	cis	rs10246939	0.544	rs6955562	ENSG00000228775.6	WEE2-AS1	8.46	9.07e-17	3.24e-14	0.29	0.25	Bitter taste perception;	chr7:141886641	chr7:141704338~141738346:-
BRCA	cis	rs801193	0.548	rs2659904	ENSG00000237310.1	GS1-124K5.4	8.46	9.07e-17	3.24e-14	0.27	0.25	Aortic root size;	chr7:66713615	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.929	rs4122249	ENSG00000237310.1	GS1-124K5.4	8.46	9.09e-17	3.24e-14	0.26	0.25	Aortic root size;	chr7:66455949	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.545	rs2707851	ENSG00000222364.1	RNU6-96P	8.46	9.14e-17	3.26e-14	0.33	0.25	Aortic root size;	chr7:66624178	chr7:66395191~66395286:+
BRCA	cis	rs11098499	0.754	rs1849457	ENSG00000245958.5	RP11-33B1.1	-8.46	9.14e-17	3.26e-14	-0.24	-0.25	Corneal astigmatism;	chr4:119333200	chr4:119454791~119552025:+
BRCA	cis	rs10129255	0.518	rs10136903	ENSG00000211972.2	IGHV3-66	8.46	9.16e-17	3.27e-14	0.18	0.25	Kawasaki disease;	chr14:106778866	chr14:106675017~106675544:-
BRCA	cis	rs12468226	0.938	rs4675274	ENSG00000273456.1	RP11-686O6.2	-8.46	9.17e-17	3.27e-14	-0.37	-0.25	Urate levels;	chr2:202243145	chr2:202374932~202375604:-
BRCA	cis	rs748404	1	rs66651343	ENSG00000249839.1	AC011330.5	-8.46	9.17e-17	3.27e-14	-0.36	-0.25	Lung cancer;	chr15:43265806	chr15:43663654~43684339:-
BRCA	cis	rs250518	0.926	rs6896898	ENSG00000272081.1	CTD-2376I4.2	8.46	9.24e-17	3.3e-14	0.32	0.25	Mean corpuscular hemoglobin concentration;	chr5:72795174	chr5:72955206~72955699:-
BRCA	cis	rs875971	0.508	rs10242423	ENSG00000237310.1	GS1-124K5.4	-8.46	9.24e-17	3.3e-14	-0.26	-0.25	Aortic root size;	chr7:66594188	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.508	rs10253883	ENSG00000237310.1	GS1-124K5.4	-8.46	9.24e-17	3.3e-14	-0.26	-0.25	Aortic root size;	chr7:66596151	chr7:66493706~66495474:+
BRCA	cis	rs11098499	0.909	rs28668716	ENSG00000248280.1	RP11-33B1.2	8.46	9.24e-17	3.3e-14	0.26	0.25	Corneal astigmatism;	chr4:119388720	chr4:119440561~119450157:-
BRCA	cis	rs72772090	0.634	rs17401901	ENSG00000248734.2	CTD-2260A17.1	-8.46	9.25e-17	3.3e-14	-0.4	-0.25	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96756221	chr5:96784777~96785999:+
BRCA	cis	rs72772090	0.634	rs72773906	ENSG00000248734.2	CTD-2260A17.1	-8.46	9.25e-17	3.3e-14	-0.4	-0.25	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96756570	chr5:96784777~96785999:+
BRCA	cis	rs10510102	0.872	rs12240306	ENSG00000276742.1	RP11-500G22.4	8.46	9.25e-17	3.3e-14	0.44	0.25	Breast cancer;	chr10:121963391	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.872	rs12240308	ENSG00000276742.1	RP11-500G22.4	8.46	9.25e-17	3.3e-14	0.44	0.25	Breast cancer;	chr10:121963407	chr10:121956782~121957098:+
BRCA	cis	rs7727544	0.735	rs273914	ENSG00000233006.5	AC034220.3	8.46	9.25e-17	3.3e-14	0.18	0.25	Blood metabolite levels;	chr5:132324738	chr5:132311285~132369916:-
BRCA	cis	rs875971	0.545	rs17138156	ENSG00000222364.1	RNU6-96P	-8.46	9.26e-17	3.3e-14	-0.33	-0.25	Aortic root size;	chr7:66249708	chr7:66395191~66395286:+
BRCA	cis	rs10971721	0.822	rs72729357	ENSG00000260947.1	RP11-384P7.7	8.46	9.26e-17	3.3e-14	0.46	0.25	Body mass index;	chr9:34041170	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.731	rs10971750	ENSG00000260947.1	RP11-384P7.7	8.46	9.26e-17	3.3e-14	0.45	0.25	Body mass index;	chr9:33869783	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.822	rs10971753	ENSG00000260947.1	RP11-384P7.7	8.46	9.26e-17	3.3e-14	0.45	0.25	Body mass index;	chr9:33870438	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.822	rs10971754	ENSG00000260947.1	RP11-384P7.7	8.46	9.26e-17	3.3e-14	0.45	0.25	Body mass index;	chr9:33871714	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.822	rs10971755	ENSG00000260947.1	RP11-384P7.7	8.46	9.26e-17	3.3e-14	0.45	0.25	Body mass index;	chr9:33872007	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.822	rs72725398	ENSG00000260947.1	RP11-384P7.7	8.46	9.26e-17	3.3e-14	0.45	0.25	Body mass index;	chr9:33875920	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.822	rs10971758	ENSG00000260947.1	RP11-384P7.7	8.46	9.26e-17	3.3e-14	0.45	0.25	Body mass index;	chr9:33876071	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.731	rs72725402	ENSG00000260947.1	RP11-384P7.7	8.46	9.26e-17	3.3e-14	0.45	0.25	Body mass index;	chr9:33878358	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.731	rs72727303	ENSG00000260947.1	RP11-384P7.7	8.46	9.26e-17	3.3e-14	0.45	0.25	Body mass index;	chr9:33878378	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.822	rs10971763	ENSG00000260947.1	RP11-384P7.7	8.46	9.26e-17	3.3e-14	0.45	0.25	Body mass index;	chr9:33879779	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.822	rs10971764	ENSG00000260947.1	RP11-384P7.7	8.46	9.26e-17	3.3e-14	0.45	0.25	Body mass index;	chr9:33880102	chr9:33697459~33700986:+
BRCA	cis	rs13256369	1	rs13256369	ENSG00000253893.2	FAM85B	-8.46	9.28e-17	3.31e-14	-0.35	-0.25	Obesity-related traits;	chr8:8719869	chr8:8167819~8226614:-
BRCA	cis	rs875971	0.545	rs17138149	ENSG00000222364.1	RNU6-96P	-8.46	9.28e-17	3.31e-14	-0.33	-0.25	Aortic root size;	chr7:66228193	chr7:66395191~66395286:+
BRCA	cis	rs9660180	0.875	rs4648727	ENSG00000231050.1	RP1-140A9.1	-8.46	9.3e-17	3.31e-14	-0.29	-0.25	Body mass index;	chr1:1844830	chr1:1891471~1892658:+
BRCA	cis	rs72627509	0.857	rs56155140	ENSG00000269949.1	RP11-738E22.3	8.46	9.3e-17	3.32e-14	0.37	0.25	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56958285	chr4:56960927~56961373:-
BRCA	cis	rs801193	0.967	rs3800823	ENSG00000222364.1	RNU6-96P	8.46	9.32e-17	3.32e-14	0.29	0.25	Aortic root size;	chr7:66682123	chr7:66395191~66395286:+
BRCA	cis	rs1707322	0.896	rs785512	ENSG00000280836.1	AL355480.1	8.45	9.35e-17	3.33e-14	0.32	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46068871	chr1:45581219~45581321:-
BRCA	cis	rs17711722	0.701	rs781145	ENSG00000222364.1	RNU6-96P	-8.45	9.36e-17	3.34e-14	-0.29	-0.25	Calcium levels;	chr7:65975383	chr7:66395191~66395286:+
BRCA	cis	rs113835537	0.597	rs2305534	ENSG00000255517.5	CTD-3074O7.5	-8.45	9.37e-17	3.34e-14	-0.34	-0.25	Airway imaging phenotypes;	chr11:66545732	chr11:66473490~66480233:-
BRCA	cis	rs875971	0.522	rs1880556	ENSG00000164669.11	INTS4P1	-8.45	9.38e-17	3.34e-14	-0.31	-0.25	Aortic root size;	chr7:65967557	chr7:65141225~65234216:+
BRCA	cis	rs10510102	0.872	rs11200268	ENSG00000276742.1	RP11-500G22.4	8.45	9.38e-17	3.34e-14	0.43	0.25	Breast cancer;	chr10:121932661	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.872	rs11200269	ENSG00000276742.1	RP11-500G22.4	8.45	9.38e-17	3.34e-14	0.43	0.25	Breast cancer;	chr10:121934021	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.872	rs11498944	ENSG00000276742.1	RP11-500G22.4	8.45	9.38e-17	3.34e-14	0.43	0.25	Breast cancer;	chr10:121938748	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.81	rs12267347	ENSG00000276742.1	RP11-500G22.4	8.45	9.38e-17	3.34e-14	0.43	0.25	Breast cancer;	chr10:121939110	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.808	rs12253007	ENSG00000276742.1	RP11-500G22.4	8.45	9.38e-17	3.34e-14	0.43	0.25	Breast cancer;	chr10:121939360	chr10:121956782~121957098:+
BRCA	cis	rs8012947	1	rs6573197	ENSG00000279636.2	LINC00216	-8.45	9.39e-17	3.35e-14	-0.28	-0.25	Alcohol consumption in current drinkers;	chr14:58257490	chr14:58288033~58289158:+
BRCA	cis	rs11971779	0.938	rs11981688	ENSG00000273391.1	RP11-634H22.1	8.45	9.4e-17	3.35e-14	0.28	0.25	Diisocyanate-induced asthma;	chr7:139404149	chr7:139359032~139359566:-
BRCA	cis	rs6545883	0.929	rs2121660	ENSG00000271889.1	RP11-493E12.1	-8.45	9.41e-17	3.35e-14	-0.34	-0.25	Tuberculosis;	chr2:61425923	chr2:61151433~61162105:-
BRCA	cis	rs321358	0.731	rs7926634	ENSG00000271584.1	RP11-89C3.4	-8.45	9.42e-17	3.36e-14	-0.39	-0.25	Body mass index;	chr11:111149618	chr11:111091932~111097357:-
BRCA	cis	rs17711722	0.522	rs62469933	ENSG00000234585.5	CCT6P3	8.45	9.44e-17	3.36e-14	0.25	0.25	Calcium levels;	chr7:65800652	chr7:65038354~65074713:+
BRCA	cis	rs6700559	0.81	rs7521550	ENSG00000260088.1	RP11-92G12.3	-8.45	9.44e-17	3.36e-14	-0.32	-0.25	Coronary artery disease;	chr1:200623235	chr1:200669507~200694250:+
BRCA	cis	rs7580658	0.509	rs12477653	ENSG00000236682.1	AC068282.3	-8.45	9.45e-17	3.36e-14	-0.32	-0.25	Protein C levels;	chr2:127194505	chr2:127389130~127400580:+
BRCA	cis	rs7580658	0.545	rs13001179	ENSG00000236682.1	AC068282.3	-8.45	9.45e-17	3.36e-14	-0.32	-0.25	Protein C levels;	chr2:127194617	chr2:127389130~127400580:+
BRCA	cis	rs7580658	0.545	rs13001184	ENSG00000236682.1	AC068282.3	-8.45	9.45e-17	3.36e-14	-0.32	-0.25	Protein C levels;	chr2:127194630	chr2:127389130~127400580:+
BRCA	cis	rs875971	0.54	rs35510581	ENSG00000222364.1	RNU6-96P	8.45	9.45e-17	3.37e-14	0.29	0.25	Aortic root size;	chr7:66113790	chr7:66395191~66395286:+
BRCA	cis	rs67981189	0.501	rs3829954	ENSG00000269927.1	RP6-91H8.3	8.45	9.46e-17	3.37e-14	0.33	0.25	Schizophrenia;	chr14:70988823	chr14:71141125~71143253:-
BRCA	cis	rs6545883	0.542	rs7584500	ENSG00000271889.1	RP11-493E12.1	8.45	9.47e-17	3.37e-14	0.31	0.25	Tuberculosis;	chr2:61464980	chr2:61151433~61162105:-
BRCA	cis	rs113835537	0.529	rs11227499	ENSG00000255517.5	CTD-3074O7.5	-8.45	9.47e-17	3.37e-14	-0.31	-0.25	Airway imaging phenotypes;	chr11:66505353	chr11:66473490~66480233:-
BRCA	cis	rs1113500	0.58	rs1781058	ENSG00000226822.1	RP11-356N1.2	8.45	9.52e-17	3.39e-14	0.33	0.25	Growth-regulated protein alpha levels;	chr1:108021437	chr1:108071482~108074519:+
BRCA	cis	rs8012947	0.917	rs57044214	ENSG00000279636.2	LINC00216	8.45	9.55e-17	3.4e-14	0.29	0.25	Alcohol consumption in current drinkers;	chr14:58367191	chr14:58288033~58289158:+
BRCA	cis	rs10971721	0.822	rs56253239	ENSG00000260947.1	RP11-384P7.7	8.45	9.58e-17	3.41e-14	0.45	0.25	Body mass index;	chr9:33860068	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.822	rs115554740	ENSG00000260947.1	RP11-384P7.7	8.45	9.58e-17	3.41e-14	0.45	0.25	Body mass index;	chr9:33860888	chr9:33697459~33700986:+
BRCA	cis	rs8072100	0.748	rs9908016	ENSG00000228782.6	CTD-2026D20.3	8.45	9.6e-17	3.42e-14	0.27	0.25	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47473995	chr17:47450568~47492492:-
BRCA	cis	rs8072100	0.782	rs28507314	ENSG00000228782.6	CTD-2026D20.3	8.45	9.6e-17	3.42e-14	0.27	0.25	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47474036	chr17:47450568~47492492:-
BRCA	cis	rs12468226	0.938	rs76501067	ENSG00000273456.1	RP11-686O6.2	8.45	9.61e-17	3.42e-14	0.37	0.25	Urate levels;	chr2:202318042	chr2:202374932~202375604:-
BRCA	cis	rs10129255	1	rs10129319	ENSG00000223648.3	IGHV3-64	8.45	9.61e-17	3.42e-14	0.22	0.25	Kawasaki disease;	chr14:106767996	chr14:106643132~106658258:-
BRCA	cis	rs875971	1	rs55962648	ENSG00000237310.1	GS1-124K5.4	-8.45	9.65e-17	3.43e-14	-0.26	-0.25	Aortic root size;	chr7:66160764	chr7:66493706~66495474:+
BRCA	cis	rs6142102	0.625	rs4911381	ENSG00000275784.1	RP5-1125A11.6	8.45	9.65e-17	3.43e-14	0.29	0.25	Skin pigmentation;	chr20:33962539	chr20:33989480~33991818:-
BRCA	cis	rs1874124	0.577	rs2807872	ENSG00000257551.1	HLX-AS1	-8.45	9.66e-17	3.44e-14	-0.35	-0.25	Cholesterol, total;	chr1:220866908	chr1:220832763~220880140:-
BRCA	cis	rs11098499	0.78	rs12504773	ENSG00000245958.5	RP11-33B1.1	-8.45	9.67e-17	3.44e-14	-0.26	-0.25	Corneal astigmatism;	chr4:119640994	chr4:119454791~119552025:+
BRCA	cis	rs42648	0.869	rs3810890	ENSG00000225498.1	AC002064.5	8.45	9.7e-17	3.45e-14	0.24	0.25	Homocysteine levels;	chr7:90279519	chr7:90312496~90322592:+
BRCA	cis	rs42648	0.837	rs10262603	ENSG00000225498.1	AC002064.5	8.45	9.7e-17	3.45e-14	0.24	0.25	Homocysteine levels;	chr7:90280128	chr7:90312496~90322592:+
BRCA	cis	rs2404602	0.716	rs17461634	ENSG00000259422.1	RP11-593F23.1	8.45	9.75e-17	3.47e-14	0.32	0.25	Blood metabolite levels;	chr15:76471766	chr15:76174891~76181486:-
BRCA	cis	rs1707322	1	rs6429580	ENSG00000280836.1	AL355480.1	-8.45	9.81e-17	3.49e-14	-0.32	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45809976	chr1:45581219~45581321:-
BRCA	cis	rs10971721	0.731	rs72725388	ENSG00000260947.1	RP11-384P7.7	8.45	9.82e-17	3.49e-14	0.45	0.25	Body mass index;	chr9:33864624	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.822	rs117687546	ENSG00000260947.1	RP11-384P7.7	8.45	9.82e-17	3.49e-14	0.45	0.25	Body mass index;	chr9:33864931	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.822	rs56370320	ENSG00000260947.1	RP11-384P7.7	8.45	9.82e-17	3.49e-14	0.45	0.25	Body mass index;	chr9:33865630	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.822	rs56172788	ENSG00000260947.1	RP11-384P7.7	8.45	9.82e-17	3.49e-14	0.45	0.25	Body mass index;	chr9:33865752	chr9:33697459~33700986:+
BRCA	cis	rs7727544	0.735	rs272894	ENSG00000233006.5	AC034220.3	8.45	9.82e-17	3.49e-14	0.18	0.25	Blood metabolite levels;	chr5:132326767	chr5:132311285~132369916:-
BRCA	cis	rs13256369	1	rs9329165	ENSG00000253893.2	FAM85B	8.45	9.83e-17	3.49e-14	0.35	0.25	Obesity-related traits;	chr8:8719132	chr8:8167819~8226614:-
BRCA	cis	rs2179367	0.881	rs2744432	ENSG00000231760.4	RP11-350J20.5	-8.45	9.88e-17	3.51e-14	-0.33	-0.25	Dupuytren's disease;	chr6:149422735	chr6:149796151~149826294:-
BRCA	cis	rs1062177	0.756	rs2915827	ENSG00000253921.1	CTB-113P19.3	8.45	9.9e-17	3.52e-14	0.35	0.25	Preschool internalizing problems;	chr5:151740144	chr5:151753992~151767247:+
BRCA	cis	rs720475	1	rs720475	ENSG00000170356.8	OR2A20P	8.45	9.96e-17	3.54e-14	0.38	0.25	Breast cancer;	chr7:144377836	chr7:144250045~144252957:-
BRCA	cis	rs1707322	1	rs11211243	ENSG00000280836.1	AL355480.1	-8.45	9.97e-17	3.54e-14	-0.32	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45989761	chr1:45581219~45581321:-
BRCA	cis	rs1707322	1	rs11211244	ENSG00000280836.1	AL355480.1	-8.45	9.97e-17	3.54e-14	-0.32	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45991001	chr1:45581219~45581321:-
BRCA	cis	rs7712401	0.562	rs30046	ENSG00000263432.2	RN7SL689P	8.45	9.98e-17	3.54e-14	0.32	0.25	Mean platelet volume;	chr5:122935538	chr5:123022487~123022783:-
BRCA	cis	rs875971	0.522	rs7784623	ENSG00000222364.1	RNU6-96P	-8.45	9.99e-17	3.55e-14	-0.29	-0.25	Aortic root size;	chr7:65930047	chr7:66395191~66395286:+
BRCA	cis	rs2933343	1	rs2630252	ENSG00000261159.1	RP11-723O4.9	8.45	1e-16	3.55e-14	0.3	0.25	IgG glycosylation;	chr3:128905929	chr3:128859716~128860526:-
BRCA	cis	rs1113500	0.633	rs1777451	ENSG00000226822.1	RP11-356N1.2	-8.45	1e-16	3.55e-14	-0.33	-0.25	Growth-regulated protein alpha levels;	chr1:108035560	chr1:108071482~108074519:+
BRCA	cis	rs875971	0.502	rs2946580	ENSG00000164669.11	INTS4P1	8.45	1e-16	3.56e-14	0.36	0.25	Aortic root size;	chr7:66066855	chr7:65141225~65234216:+
BRCA	cis	rs11673344	0.528	rs476194	ENSG00000226686.6	LINC01535	8.45	1.01e-16	3.58e-14	0.33	0.25	Obesity-related traits;	chr19:36919831	chr19:37251912~37265535:+
BRCA	cis	rs4308124	0.708	rs10178095	ENSG00000230499.1	AC108463.1	-8.45	1.01e-16	3.58e-14	-0.32	-0.25	Vitiligo;	chr2:111214939	chr2:111195963~111206494:+
BRCA	cis	rs193541	0.545	rs12518979	ENSG00000263432.2	RN7SL689P	-8.44	1.01e-16	3.59e-14	-0.33	-0.25	Glucose homeostasis traits;	chr5:122846092	chr5:123022487~123022783:-
BRCA	cis	rs375066	0.935	rs423765	ENSG00000267058.1	RP11-15A1.3	-8.44	1.01e-16	3.59e-14	-0.29	-0.25	Breast cancer;	chr19:43912047	chr19:43891804~43901805:-
BRCA	cis	rs4835473	0.932	rs11100824	ENSG00000251600.4	RP11-673E1.1	8.44	1.02e-16	3.61e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143964845	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.592	rs11100825	ENSG00000251600.4	RP11-673E1.1	8.44	1.02e-16	3.61e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143964903	chr4:143912331~143982454:+
BRCA	cis	rs11098499	0.863	rs11098532	ENSG00000248280.1	RP11-33B1.2	8.44	1.02e-16	3.61e-14	0.26	0.25	Corneal astigmatism;	chr4:119569571	chr4:119440561~119450157:-
BRCA	cis	rs375066	0.868	rs368079	ENSG00000267058.1	RP11-15A1.3	-8.44	1.02e-16	3.62e-14	-0.29	-0.25	Breast cancer;	chr19:43889204	chr19:43891804~43901805:-
BRCA	cis	rs858239	0.539	rs6976957	ENSG00000226816.2	AC005082.12	8.44	1.02e-16	3.62e-14	0.29	0.25	Cerebrospinal fluid biomarker levels;	chr7:23147714	chr7:23206013~23208045:+
BRCA	cis	rs1707322	1	rs11211190	ENSG00000280836.1	AL355480.1	-8.44	1.02e-16	3.63e-14	-0.32	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45800583	chr1:45581219~45581321:-
BRCA	cis	rs42648	0.869	rs10266179	ENSG00000225498.1	AC002064.5	8.44	1.03e-16	3.64e-14	0.24	0.25	Homocysteine levels;	chr7:90280668	chr7:90312496~90322592:+
BRCA	cis	rs4308124	0.708	rs61358692	ENSG00000230499.1	AC108463.1	-8.44	1.03e-16	3.65e-14	-0.32	-0.25	Vitiligo;	chr2:111207582	chr2:111195963~111206494:+
BRCA	cis	rs2933343	1	rs6785869	ENSG00000231305.3	RP11-723O4.2	8.44	1.03e-16	3.66e-14	0.32	0.25	IgG glycosylation;	chr3:128924301	chr3:128861313~128871540:-
BRCA	cis	rs2933343	1	rs1683778	ENSG00000231305.3	RP11-723O4.2	8.44	1.03e-16	3.66e-14	0.32	0.25	IgG glycosylation;	chr3:128925752	chr3:128861313~128871540:-
BRCA	cis	rs2115630	1	rs11854291	ENSG00000225151.9	GOLGA2P7	8.44	1.03e-16	3.66e-14	0.28	0.25	P wave terminal force;	chr15:84820477	chr15:84199311~84230136:-
BRCA	cis	rs1501911	0.588	rs709386	ENSG00000248489.1	CTD-2007H13.3	8.44	1.03e-16	3.66e-14	0.33	0.25	Lung function (FEV1/FVC);	chr5:98994346	chr5:98929171~98995013:+
BRCA	cis	rs10129255	0.957	rs10136817	ENSG00000223648.3	IGHV3-64	8.44	1.03e-16	3.67e-14	0.23	0.25	Kawasaki disease;	chr14:106787730	chr14:106643132~106658258:-
BRCA	cis	rs11976180	0.517	rs6949375	ENSG00000170356.8	OR2A20P	-8.44	1.04e-16	3.68e-14	-0.47	-0.25	Obesity-related traits;	chr7:144076758	chr7:144250045~144252957:-
BRCA	cis	rs4835473	0.864	rs12507633	ENSG00000251600.4	RP11-673E1.1	8.44	1.04e-16	3.69e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143962730	chr4:143912331~143982454:+
BRCA	cis	rs11098499	0.863	rs13136462	ENSG00000245958.5	RP11-33B1.1	-8.44	1.04e-16	3.7e-14	-0.25	-0.25	Corneal astigmatism;	chr4:119622018	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.909	rs9759478	ENSG00000248280.1	RP11-33B1.2	8.44	1.04e-16	3.7e-14	0.26	0.25	Corneal astigmatism;	chr4:119446843	chr4:119440561~119450157:-
BRCA	cis	rs8059260	0.544	rs7205916	ENSG00000274038.1	RP11-66H6.4	-8.44	1.04e-16	3.7e-14	-0.38	-0.25	Alcohol consumption over the past year;	chr16:11095399	chr16:11056556~11057034:+
BRCA	cis	rs113835537	0.597	rs11227527	ENSG00000255517.5	CTD-3074O7.5	-8.44	1.05e-16	3.72e-14	-0.33	-0.25	Airway imaging phenotypes;	chr11:66545555	chr11:66473490~66480233:-
BRCA	cis	rs11098499	0.865	rs11098513	ENSG00000248280.1	RP11-33B1.2	8.44	1.05e-16	3.73e-14	0.26	0.25	Corneal astigmatism;	chr4:119394920	chr4:119440561~119450157:-
BRCA	cis	rs875971	0.545	rs2420612	ENSG00000222364.1	RNU6-96P	-8.44	1.05e-16	3.74e-14	-0.34	-0.25	Aortic root size;	chr7:66536825	chr7:66395191~66395286:+
BRCA	cis	rs3864261	0.515	rs55769858	ENSG00000272081.1	CTD-2376I4.2	8.44	1.06e-16	3.75e-14	0.32	0.25	Discordance in emotional problems in monozygotic twins;	chr5:72984937	chr5:72955206~72955699:-
BRCA	cis	rs1707322	1	rs4660905	ENSG00000280836.1	AL355480.1	8.44	1.06e-16	3.75e-14	0.32	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45995915	chr1:45581219~45581321:-
BRCA	cis	rs11673344	0.83	rs3745770	ENSG00000226686.6	LINC01535	8.44	1.06e-16	3.76e-14	0.33	0.25	Obesity-related traits;	chr19:36997663	chr19:37251912~37265535:+
BRCA	cis	rs11673344	0.797	rs3745768	ENSG00000226686.6	LINC01535	8.44	1.06e-16	3.76e-14	0.33	0.25	Obesity-related traits;	chr19:36997907	chr19:37251912~37265535:+
BRCA	cis	rs13230714	0.858	rs2888075	ENSG00000204959.4	ARHGEF34P	8.44	1.06e-16	3.77e-14	0.31	0.25	Breast cancer;	chr7:144456786	chr7:144272445~144286966:-
BRCA	cis	rs10463554	0.892	rs158408	ENSG00000175749.11	EIF3KP1	8.44	1.07e-16	3.79e-14	0.34	0.25	Parkinson's disease;	chr5:103071670	chr5:103032376~103033031:+
BRCA	cis	rs7665090	0.51	rs223498	ENSG00000246560.2	RP11-10L12.4	-8.44	1.07e-16	3.79e-14	-0.27	-0.25	Primary biliary cholangitis;	chr4:102730805	chr4:102828055~102844075:+
BRCA	cis	rs56804039	1	rs17616779	ENSG00000253893.2	FAM85B	-8.44	1.08e-16	3.83e-14	-0.39	-0.25	Cervical cancer;	chr8:8524864	chr8:8167819~8226614:-
BRCA	cis	rs6822297	0.504	rs10010180	ENSG00000240005.4	RP11-293A21.1	8.44	1.08e-16	3.83e-14	0.3	0.25	Obesity-related traits;	chr4:26984359	chr4:26859806~26860599:-
BRCA	cis	rs1707322	1	rs10890378	ENSG00000280836.1	AL355480.1	8.44	1.09e-16	3.85e-14	0.32	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45944985	chr1:45581219~45581321:-
BRCA	cis	rs1707322	1	rs7532204	ENSG00000280836.1	AL355480.1	8.44	1.09e-16	3.86e-14	0.32	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46019403	chr1:45581219~45581321:-
BRCA	cis	rs7085104	0.632	rs3781287	ENSG00000213061.2	PFN1P11	8.44	1.09e-16	3.86e-14	0.32	0.25	Immature fraction of reticulocytes;Schizophrenia;	chr10:102835663	chr10:102838011~102845473:-
BRCA	cis	rs8012947	1	rs10151828	ENSG00000279636.2	LINC00216	-8.44	1.09e-16	3.86e-14	-0.28	-0.25	Alcohol consumption in current drinkers;	chr14:58282711	chr14:58288033~58289158:+
BRCA	cis	rs1707322	1	rs4660903	ENSG00000280836.1	AL355480.1	-8.44	1.09e-16	3.86e-14	-0.32	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45991929	chr1:45581219~45581321:-
BRCA	cis	rs10129255	0.957	rs10142918	ENSG00000223648.3	IGHV3-64	8.44	1.09e-16	3.86e-14	0.21	0.25	Kawasaki disease;	chr14:106782206	chr14:106643132~106658258:-
BRCA	cis	rs4722166	1	rs4722166	ENSG00000179428.2	AC073072.5	-8.44	1.09e-16	3.87e-14	-0.3	-0.25	Lung cancer;	chr7:22699143	chr7:22725395~22727620:-
BRCA	cis	rs13256369	1	rs13282915	ENSG00000253893.2	FAM85B	-8.43	1.1e-16	3.88e-14	-0.35	-0.25	Obesity-related traits;	chr8:8713381	chr8:8167819~8226614:-
BRCA	cis	rs8062405	0.965	rs8049439	ENSG00000278665.1	RP11-666O2.4	8.43	1.1e-16	3.88e-14	0.26	0.25	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28826194	chr16:28599241~28601881:-
BRCA	cis	rs4835473	0.897	rs35599924	ENSG00000251600.4	RP11-673E1.1	8.43	1.1e-16	3.88e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143980602	chr4:143912331~143982454:+
BRCA	cis	rs12468226	0.938	rs10931993	ENSG00000273456.1	RP11-686O6.2	8.43	1.1e-16	3.9e-14	0.37	0.25	Urate levels;	chr2:202243017	chr2:202374932~202375604:-
BRCA	cis	rs858239	0.601	rs1034963	ENSG00000230042.1	AK3P3	-8.43	1.1e-16	3.9e-14	-0.29	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23108854	chr7:23129178~23129841:+
BRCA	cis	rs67981189	0.529	rs8014273	ENSG00000269927.1	RP6-91H8.3	8.43	1.1e-16	3.91e-14	0.33	0.25	Schizophrenia;	chr14:71043113	chr14:71141125~71143253:-
BRCA	cis	rs113835537	0.529	rs11227501	ENSG00000255517.5	CTD-3074O7.5	-8.43	1.11e-16	3.92e-14	-0.32	-0.25	Airway imaging phenotypes;	chr11:66506601	chr11:66473490~66480233:-
BRCA	cis	rs1501911	0.566	rs709388	ENSG00000248489.1	CTD-2007H13.3	8.43	1.11e-16	3.93e-14	0.33	0.25	Lung function (FEV1/FVC);	chr5:98994037	chr5:98929171~98995013:+
BRCA	cis	rs7246657	0.722	rs1564206	ENSG00000267422.1	CTD-2554C21.1	-8.43	1.11e-16	3.93e-14	-0.37	-0.25	Coronary artery calcification;	chr19:37549174	chr19:37779686~37792865:+
BRCA	cis	rs375066	0.935	rs371875	ENSG00000267058.1	RP11-15A1.3	-8.43	1.11e-16	3.93e-14	-0.29	-0.25	Breast cancer;	chr19:43889105	chr19:43891804~43901805:-
BRCA	cis	rs7569084	0.687	rs12614851	ENSG00000204929.10	AC074391.1	8.43	1.11e-16	3.95e-14	0.34	0.25	Sum eosinophil basophil counts;	chr2:65458050	chr2:65436711~66084639:+
BRCA	cis	rs67981189	0.529	rs17108808	ENSG00000269927.1	RP6-91H8.3	8.43	1.12e-16	3.96e-14	0.33	0.25	Schizophrenia;	chr14:70974835	chr14:71141125~71143253:-
BRCA	cis	rs875971	1	rs9986696	ENSG00000237310.1	GS1-124K5.4	-8.43	1.13e-16	3.98e-14	-0.26	-0.25	Aortic root size;	chr7:66239589	chr7:66493706~66495474:+
BRCA	cis	rs6921919	0.945	rs7765989	ENSG00000216901.1	AL022393.7	8.43	1.13e-16	3.99e-14	0.39	0.25	Autism spectrum disorder or schizophrenia;	chr6:28432518	chr6:28176188~28176674:+
BRCA	cis	rs17711722	0.727	rs35850374	ENSG00000222364.1	RNU6-96P	-8.43	1.13e-16	4e-14	-0.29	-0.25	Calcium levels;	chr7:65892789	chr7:66395191~66395286:+
BRCA	cis	rs13256369	1	rs4840352	ENSG00000253893.2	FAM85B	-8.43	1.14e-16	4.03e-14	-0.36	-0.25	Obesity-related traits;	chr8:8715998	chr8:8167819~8226614:-
BRCA	cis	rs6545883	0.929	rs778155	ENSG00000271889.1	RP11-493E12.1	-8.43	1.14e-16	4.03e-14	-0.34	-0.25	Tuberculosis;	chr2:61420766	chr2:61151433~61162105:-
BRCA	cis	rs875971	0.505	rs2462573	ENSG00000236529.1	RP13-254B10.1	-8.43	1.14e-16	4.03e-14	-0.28	-0.25	Aortic root size;	chr7:66042405	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.545	rs1267814	ENSG00000222364.1	RNU6-96P	8.43	1.14e-16	4.04e-14	0.33	0.25	Aortic root size;	chr7:66579422	chr7:66395191~66395286:+
BRCA	cis	rs526231	0.543	rs40092	ENSG00000175749.11	EIF3KP1	8.43	1.15e-16	4.07e-14	0.37	0.25	Primary biliary cholangitis;	chr5:103088509	chr5:103032376~103033031:+
BRCA	cis	rs4835473	0.897	rs12649594	ENSG00000251600.4	RP11-673E1.1	8.43	1.15e-16	4.08e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143989307	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.864	rs13101482	ENSG00000251600.4	RP11-673E1.1	8.43	1.15e-16	4.08e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143989463	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.864	rs13135472	ENSG00000251600.4	RP11-673E1.1	8.43	1.15e-16	4.08e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143989465	chr4:143912331~143982454:+
BRCA	cis	rs2348418	0.765	rs6487665	ENSG00000247934.4	RP11-967K21.1	8.43	1.16e-16	4.09e-14	0.28	0.25	Lung function (FEV1);Lung function (FVC);	chr12:28177726	chr12:28163298~28190738:-
BRCA	cis	rs10510102	0.872	rs79865971	ENSG00000276742.1	RP11-500G22.4	8.43	1.16e-16	4.1e-14	0.43	0.25	Breast cancer;	chr10:121941208	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.872	rs74318512	ENSG00000276742.1	RP11-500G22.4	8.43	1.16e-16	4.1e-14	0.43	0.25	Breast cancer;	chr10:121941465	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.872	rs12257207	ENSG00000276742.1	RP11-500G22.4	8.43	1.16e-16	4.1e-14	0.43	0.25	Breast cancer;	chr10:121941737	chr10:121956782~121957098:+
BRCA	cis	rs1707322	0.963	rs10890371	ENSG00000280836.1	AL355480.1	-8.43	1.16e-16	4.11e-14	-0.32	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45925225	chr1:45581219~45581321:-
BRCA	cis	rs1707322	1	rs10890372	ENSG00000280836.1	AL355480.1	-8.43	1.16e-16	4.11e-14	-0.32	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45925348	chr1:45581219~45581321:-
BRCA	cis	rs11098499	1	rs6849889	ENSG00000245958.5	RP11-33B1.1	-8.43	1.17e-16	4.12e-14	-0.25	-0.25	Corneal astigmatism;	chr4:119265193	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.913	rs68128210	ENSG00000245958.5	RP11-33B1.1	-8.43	1.17e-16	4.13e-14	-0.26	-0.25	Corneal astigmatism;	chr4:119216664	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.913	rs13126596	ENSG00000245958.5	RP11-33B1.1	-8.43	1.17e-16	4.13e-14	-0.26	-0.25	Corneal astigmatism;	chr4:119219574	chr4:119454791~119552025:+
BRCA	cis	rs8012947	1	rs1957038	ENSG00000279636.2	LINC00216	-8.43	1.17e-16	4.14e-14	-0.28	-0.25	Alcohol consumption in current drinkers;	chr14:58299899	chr14:58288033~58289158:+
BRCA	cis	rs375066	0.935	rs426534	ENSG00000267058.1	RP11-15A1.3	-8.43	1.17e-16	4.15e-14	-0.29	-0.25	Breast cancer;	chr19:43908431	chr19:43891804~43901805:-
BRCA	cis	rs7811142	0.83	rs7341507	ENSG00000242294.5	STAG3L5P	8.43	1.17e-16	4.15e-14	0.25	0.25	Platelet count;	chr7:100353692	chr7:100336079~100351900:+
BRCA	cis	rs10129255	0.957	rs10138532	ENSG00000223648.3	IGHV3-64	8.43	1.18e-16	4.15e-14	0.23	0.25	Kawasaki disease;	chr14:106803901	chr14:106643132~106658258:-
BRCA	cis	rs7250849	0.529	rs73052877	ENSG00000273837.1	LLNLR-470E3.1	-8.43	1.18e-16	4.15e-14	-0.34	-0.25	Blood protein levels;	chr19:51662744	chr19:51639478~51639931:-
BRCA	cis	rs1707322	1	rs6657720	ENSG00000280836.1	AL355480.1	-8.43	1.18e-16	4.17e-14	-0.32	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45920597	chr1:45581219~45581321:-
BRCA	cis	rs1707322	1	rs7526369	ENSG00000280836.1	AL355480.1	-8.43	1.18e-16	4.17e-14	-0.32	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45924888	chr1:45581219~45581321:-
BRCA	cis	rs2280018	0.526	rs1510148	ENSG00000188599.16	NPIPP1	-8.43	1.18e-16	4.17e-14	-0.22	-0.25	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15073522	chr16:15104312~15123498:-
BRCA	cis	rs4835473	0.932	rs6852502	ENSG00000251600.4	RP11-673E1.1	8.42	1.19e-16	4.19e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143987174	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.897	rs7682204	ENSG00000251600.4	RP11-673E1.1	8.42	1.2e-16	4.24e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143966306	chr4:143912331~143982454:+
BRCA	cis	rs875971	0.965	rs7794930	ENSG00000237310.1	GS1-124K5.4	-8.42	1.2e-16	4.24e-14	-0.26	-0.25	Aortic root size;	chr7:66313559	chr7:66493706~66495474:+
BRCA	cis	rs2933343	1	rs1683776	ENSG00000261159.1	RP11-723O4.9	8.42	1.2e-16	4.24e-14	0.3	0.25	IgG glycosylation;	chr3:128903917	chr3:128859716~128860526:-
BRCA	cis	rs4835473	0.932	rs4260486	ENSG00000251600.4	RP11-673E1.1	8.42	1.2e-16	4.25e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143987556	chr4:143912331~143982454:+
BRCA	cis	rs13256369	1	rs873063	ENSG00000253893.2	FAM85B	-8.42	1.2e-16	4.25e-14	-0.36	-0.25	Obesity-related traits;	chr8:8714937	chr8:8167819~8226614:-
BRCA	cis	rs4835473	0.663	rs1511423	ENSG00000251600.4	RP11-673E1.1	8.42	1.21e-16	4.26e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143990136	chr4:143912331~143982454:+
BRCA	cis	rs2439831	0.85	rs12442297	ENSG00000249839.1	AC011330.5	-8.42	1.21e-16	4.26e-14	-0.44	-0.25	Lung cancer in ever smokers;	chr15:43876272	chr15:43663654~43684339:-
BRCA	cis	rs11098499	0.863	rs10019674	ENSG00000248280.1	RP11-33B1.2	-8.42	1.21e-16	4.27e-14	-0.27	-0.25	Corneal astigmatism;	chr4:119522334	chr4:119440561~119450157:-
BRCA	cis	rs526231	0.543	rs246900	ENSG00000175749.11	EIF3KP1	8.42	1.21e-16	4.28e-14	0.37	0.25	Primary biliary cholangitis;	chr5:103198928	chr5:103032376~103033031:+
BRCA	cis	rs7569084	0.687	rs12993075	ENSG00000204929.10	AC074391.1	8.42	1.21e-16	4.28e-14	0.34	0.25	Sum eosinophil basophil counts;	chr2:65431010	chr2:65436711~66084639:+
BRCA	cis	rs4934494	1	rs4934494	ENSG00000240996.1	RP11-80H5.7	-8.42	1.21e-16	4.28e-14	-0.3	-0.25	Red blood cell count;	chr10:89687662	chr10:89694295~89697928:-
BRCA	cis	rs2028299	1	rs4932148	ENSG00000259677.1	RP11-493E3.1	8.42	1.22e-16	4.29e-14	0.33	0.25	Type 2 diabetes;	chr15:89851124	chr15:89876540~89877285:+
BRCA	cis	rs6472827	0.595	rs2936684	ENSG00000253983.2	RP1-16A9.1	8.42	1.22e-16	4.3e-14	0.35	0.25	Uterine fibroids;	chr8:74201522	chr8:74199396~74208441:+
BRCA	cis	rs7772486	0.875	rs6570738	ENSG00000235652.6	RP11-545I5.3	8.42	1.22e-16	4.3e-14	0.25	0.25	Lobe attachment (rater-scored or self-reported);	chr6:146091559	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.875	rs1412080	ENSG00000235652.6	RP11-545I5.3	8.42	1.22e-16	4.3e-14	0.25	0.25	Lobe attachment (rater-scored or self-reported);	chr6:146096168	chr6:145799409~145886585:+
BRCA	cis	rs2933343	0.859	rs789247	ENSG00000261159.1	RP11-723O4.9	8.42	1.23e-16	4.32e-14	0.3	0.25	IgG glycosylation;	chr3:128861742	chr3:128859716~128860526:-
BRCA	cis	rs17023223	0.537	rs17023185	ENSG00000231365.4	RP11-418J17.1	-8.42	1.23e-16	4.33e-14	-0.33	-0.25	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119068164	chr1:119140396~119275973:+
BRCA	cis	rs1707322	1	rs6687301	ENSG00000280836.1	AL355480.1	-8.42	1.23e-16	4.33e-14	-0.32	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45917180	chr1:45581219~45581321:-
BRCA	cis	rs10463554	0.963	rs26817	ENSG00000175749.11	EIF3KP1	-8.42	1.23e-16	4.33e-14	-0.34	-0.25	Parkinson's disease;	chr5:103204665	chr5:103032376~103033031:+
BRCA	cis	rs950776	0.518	rs4243083	ENSG00000261762.1	RP11-650L12.2	-8.42	1.24e-16	4.37e-14	-0.28	-0.25	Sudden cardiac arrest;	chr15:78541488	chr15:78589123~78591276:-
BRCA	cis	rs4835473	0.8	rs2089839	ENSG00000251600.4	RP11-673E1.1	8.42	1.25e-16	4.41e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143980955	chr4:143912331~143982454:+
BRCA	cis	rs11673344	0.796	rs16971886	ENSG00000226686.6	LINC01535	8.42	1.25e-16	4.41e-14	0.33	0.25	Obesity-related traits;	chr19:36997073	chr19:37251912~37265535:+
BRCA	cis	rs2243480	1	rs6958289	ENSG00000273142.1	RP11-458F8.4	8.42	1.25e-16	4.41e-14	0.35	0.25	Diabetic kidney disease;	chr7:66192124	chr7:66902857~66906297:+
BRCA	cis	rs1113500	0.73	rs1781077	ENSG00000226822.1	RP11-356N1.2	-8.42	1.25e-16	4.41e-14	-0.32	-0.25	Growth-regulated protein alpha levels;	chr1:108046967	chr1:108071482~108074519:+
BRCA	cis	rs9903692	0.954	rs6847	ENSG00000278765.1	RP5-890E16.5	-8.42	1.25e-16	4.42e-14	-0.32	-0.25	Pulse pressure;	chr17:48070445	chr17:48066704~48067293:-
BRCA	cis	rs7684253	0.548	rs13106200	ENSG00000269949.1	RP11-738E22.3	-8.42	1.26e-16	4.43e-14	-0.3	-0.25	Migraine;	chr4:56852029	chr4:56960927~56961373:-
BRCA	cis	rs4964805	1	rs73192052	ENSG00000257681.1	RP11-341G23.4	8.42	1.26e-16	4.43e-14	0.33	0.25	Attention deficit hyperactivity disorder;	chr12:103797076	chr12:103746315~103768858:-
BRCA	cis	rs896854	0.631	rs10097617	ENSG00000253528.2	RP11-347C18.4	8.42	1.26e-16	4.44e-14	0.26	0.25	Type 2 diabetes;	chr8:94949398	chr8:94974573~94974853:-
BRCA	cis	rs375066	0.935	rs425217	ENSG00000267058.1	RP11-15A1.3	-8.42	1.26e-16	4.45e-14	-0.29	-0.25	Breast cancer;	chr19:43889823	chr19:43891804~43901805:-
BRCA	cis	rs9660180	0.846	rs10907195	ENSG00000231050.1	RP1-140A9.1	-8.42	1.27e-16	4.46e-14	-0.28	-0.25	Body mass index;	chr1:1781909	chr1:1891471~1892658:+
BRCA	cis	rs8072100	0.748	rs9912592	ENSG00000228782.6	CTD-2026D20.3	8.42	1.27e-16	4.46e-14	0.27	0.25	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47479579	chr17:47450568~47492492:-
BRCA	cis	rs67981189	0.519	rs2526879	ENSG00000269927.1	RP6-91H8.3	-8.42	1.27e-16	4.47e-14	-0.33	-0.25	Schizophrenia;	chr14:70910501	chr14:71141125~71143253:-
BRCA	cis	rs526231	0.511	rs17154942	ENSG00000175749.11	EIF3KP1	-8.42	1.27e-16	4.47e-14	-0.37	-0.25	Primary biliary cholangitis;	chr5:103017014	chr5:103032376~103033031:+
BRCA	cis	rs56205728	0.606	rs3784398	ENSG00000273855.1	RP11-133K1.12	8.42	1.27e-16	4.48e-14	0.28	0.25	Schizophrenia;	chr15:40304665	chr15:40285468~40285909:-
BRCA	cis	rs10510102	0.872	rs12246693	ENSG00000276742.1	RP11-500G22.4	8.42	1.27e-16	4.49e-14	0.43	0.25	Breast cancer;	chr10:121957373	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.872	rs12248806	ENSG00000276742.1	RP11-500G22.4	8.42	1.27e-16	4.49e-14	0.43	0.25	Breast cancer;	chr10:121958638	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.872	rs12255832	ENSG00000276742.1	RP11-500G22.4	8.42	1.27e-16	4.49e-14	0.43	0.25	Breast cancer;	chr10:121958762	chr10:121956782~121957098:+
BRCA	cis	rs7246657	0.55	rs9941475	ENSG00000267422.1	CTD-2554C21.1	-8.42	1.28e-16	4.5e-14	-0.37	-0.25	Coronary artery calcification;	chr19:37573615	chr19:37779686~37792865:+
BRCA	cis	rs7246657	0.765	rs4803262	ENSG00000267422.1	CTD-2554C21.1	-8.42	1.28e-16	4.5e-14	-0.37	-0.25	Coronary artery calcification;	chr19:37575858	chr19:37779686~37792865:+
BRCA	cis	rs7246657	0.712	rs4803263	ENSG00000267422.1	CTD-2554C21.1	-8.42	1.28e-16	4.5e-14	-0.37	-0.25	Coronary artery calcification;	chr19:37575880	chr19:37779686~37792865:+
BRCA	cis	rs7246657	0.722	rs10412510	ENSG00000267422.1	CTD-2554C21.1	-8.42	1.28e-16	4.5e-14	-0.37	-0.25	Coronary artery calcification;	chr19:37585043	chr19:37779686~37792865:+
BRCA	cis	rs7246657	0.722	rs3829688	ENSG00000267422.1	CTD-2554C21.1	-8.42	1.28e-16	4.5e-14	-0.37	-0.25	Coronary artery calcification;	chr19:37586199	chr19:37779686~37792865:+
BRCA	cis	rs7246657	0.722	rs13744	ENSG00000267422.1	CTD-2554C21.1	-8.42	1.28e-16	4.5e-14	-0.37	-0.25	Coronary artery calcification;	chr19:37587011	chr19:37779686~37792865:+
BRCA	cis	rs7246657	0.722	rs10403173	ENSG00000267422.1	CTD-2554C21.1	-8.42	1.28e-16	4.5e-14	-0.37	-0.25	Coronary artery calcification;	chr19:37587779	chr19:37779686~37792865:+
BRCA	cis	rs7246657	0.679	rs12461113	ENSG00000267422.1	CTD-2554C21.1	-8.42	1.28e-16	4.5e-14	-0.37	-0.25	Coronary artery calcification;	chr19:37592287	chr19:37779686~37792865:+
BRCA	cis	rs7246657	0.639	rs12459015	ENSG00000267422.1	CTD-2554C21.1	-8.42	1.28e-16	4.5e-14	-0.37	-0.25	Coronary artery calcification;	chr19:37592288	chr19:37779686~37792865:+
BRCA	cis	rs17711722	0.701	rs55773927	ENSG00000222364.1	RNU6-96P	-8.42	1.28e-16	4.51e-14	-0.29	-0.25	Calcium levels;	chr7:65872915	chr7:66395191~66395286:+
BRCA	cis	rs4835473	0.932	rs1849118	ENSG00000251600.4	RP11-673E1.1	8.42	1.28e-16	4.52e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143989822	chr4:143912331~143982454:+
BRCA	cis	rs11971779	0.715	rs7787398	ENSG00000273391.1	RP11-634H22.1	8.41	1.28e-16	4.52e-14	0.25	0.25	Diisocyanate-induced asthma;	chr7:139377100	chr7:139359032~139359566:-
BRCA	cis	rs10129255	0.789	rs61997796	ENSG00000223648.3	IGHV3-64	8.41	1.29e-16	4.54e-14	0.23	0.25	Kawasaki disease;	chr14:106813798	chr14:106643132~106658258:-
BRCA	cis	rs932287	0.505	rs2742536	ENSG00000254860.4	TMEM9B-AS1	8.41	1.29e-16	4.54e-14	0.23	0.25	Colonoscopy-negative controls vs population controls;	chr11:8888269	chr11:8964675~8977527:+
BRCA	cis	rs875971	0.545	rs6979636	ENSG00000222364.1	RNU6-96P	-8.41	1.29e-16	4.54e-14	-0.33	-0.25	Aortic root size;	chr7:66276638	chr7:66395191~66395286:+
BRCA	cis	rs67981189	0.529	rs2810096	ENSG00000269927.1	RP6-91H8.3	-8.41	1.29e-16	4.54e-14	-0.33	-0.25	Schizophrenia;	chr14:70968583	chr14:71141125~71143253:-
BRCA	cis	rs1707322	1	rs7519181	ENSG00000280836.1	AL355480.1	-8.41	1.29e-16	4.54e-14	-0.32	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45922157	chr1:45581219~45581321:-
BRCA	cis	rs10510102	0.872	rs11200267	ENSG00000276742.1	RP11-500G22.4	8.41	1.29e-16	4.55e-14	0.43	0.25	Breast cancer;	chr10:121929851	chr10:121956782~121957098:+
BRCA	cis	rs526231	0.511	rs7731395	ENSG00000175749.11	EIF3KP1	8.41	1.3e-16	4.56e-14	0.35	0.25	Primary biliary cholangitis;	chr5:103026057	chr5:103032376~103033031:+
BRCA	cis	rs11098499	0.954	rs3733520	ENSG00000248280.1	RP11-33B1.2	8.41	1.3e-16	4.57e-14	0.26	0.25	Corneal astigmatism;	chr4:119502325	chr4:119440561~119450157:-
BRCA	cis	rs13631	0.697	rs1018330	ENSG00000268996.3	MAN1B1-AS1	8.41	1.3e-16	4.58e-14	0.25	0.25	Cerebrospinal fluid biomarker levels;	chr9:137085933	chr9:137084946~137086817:-
BRCA	cis	rs10246939	0.579	rs12703413	ENSG00000228775.6	WEE2-AS1	-8.41	1.3e-16	4.59e-14	-0.29	-0.25	Bitter taste perception;	chr7:141847047	chr7:141704338~141738346:-
BRCA	cis	rs10246939	0.579	rs6969430	ENSG00000228775.6	WEE2-AS1	8.41	1.3e-16	4.59e-14	0.28	0.25	Bitter taste perception;	chr7:141831340	chr7:141704338~141738346:-
BRCA	cis	rs4835473	0.864	rs4257604	ENSG00000251600.4	RP11-673E1.1	8.41	1.31e-16	4.61e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143980261	chr4:143912331~143982454:+
BRCA	cis	rs2933343	0.951	rs789218	ENSG00000261159.1	RP11-723O4.9	8.41	1.31e-16	4.62e-14	0.3	0.25	IgG glycosylation;	chr3:128873827	chr3:128859716~128860526:-
BRCA	cis	rs10129255	0.957	rs8014696	ENSG00000223648.3	IGHV3-64	-8.41	1.31e-16	4.62e-14	-0.21	-0.25	Kawasaki disease;	chr14:106769752	chr14:106643132~106658258:-
BRCA	cis	rs4835473	0.897	rs11931330	ENSG00000251600.4	RP11-673E1.1	8.41	1.31e-16	4.62e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143970808	chr4:143912331~143982454:+
BRCA	cis	rs875971	0.54	rs4717275	ENSG00000222364.1	RNU6-96P	8.41	1.32e-16	4.64e-14	0.29	0.25	Aortic root size;	chr7:65800193	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.522	rs6960048	ENSG00000236529.1	RP13-254B10.1	8.41	1.32e-16	4.64e-14	0.27	0.25	Aortic root size;	chr7:65943052	chr7:65840212~65840596:+
BRCA	cis	rs957448	1	rs56716157	ENSG00000253704.1	RP11-267M23.4	8.41	1.32e-16	4.65e-14	0.32	0.25	Nonsyndromic cleft lip with cleft palate;	chr8:94530644	chr8:94553722~94569745:+
BRCA	cis	rs7727544	0.735	rs273913	ENSG00000233006.5	AC034220.3	8.41	1.33e-16	4.66e-14	0.19	0.25	Blood metabolite levels;	chr5:132325463	chr5:132311285~132369916:-
BRCA	cis	rs2041895	0.509	rs2072559	ENSG00000260329.1	RP11-412D9.4	-8.41	1.33e-16	4.69e-14	-0.32	-0.25	Glaucoma (low intraocular pressure);	chr12:106913509	chr12:106954029~106955497:-
BRCA	cis	rs7569084	0.687	rs6755006	ENSG00000204929.10	AC074391.1	-8.41	1.33e-16	4.69e-14	-0.34	-0.25	Sum eosinophil basophil counts;	chr2:65426008	chr2:65436711~66084639:+
BRCA	cis	rs7569084	0.687	rs6755128	ENSG00000204929.10	AC074391.1	-8.41	1.33e-16	4.69e-14	-0.34	-0.25	Sum eosinophil basophil counts;	chr2:65426065	chr2:65436711~66084639:+
BRCA	cis	rs4835473	0.663	rs4835115	ENSG00000251600.4	RP11-673E1.1	8.41	1.33e-16	4.69e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143979308	chr4:143912331~143982454:+
BRCA	cis	rs58873874	0.737	rs11749762	ENSG00000248544.2	CTB-47B11.3	8.41	1.34e-16	4.69e-14	0.57	0.25	Bipolar disorder (body mass index interaction);	chr5:157474607	chr5:157375741~157384950:-
BRCA	cis	rs12468226	0.938	rs116109808	ENSG00000273456.1	RP11-686O6.2	8.41	1.34e-16	4.7e-14	0.38	0.25	Urate levels;	chr2:202287356	chr2:202374932~202375604:-
BRCA	cis	rs12468226	0.873	rs78175596	ENSG00000273456.1	RP11-686O6.2	8.41	1.34e-16	4.7e-14	0.38	0.25	Urate levels;	chr2:202287993	chr2:202374932~202375604:-
BRCA	cis	rs12468226	0.938	rs74454549	ENSG00000273456.1	RP11-686O6.2	8.41	1.34e-16	4.7e-14	0.38	0.25	Urate levels;	chr2:202288044	chr2:202374932~202375604:-
BRCA	cis	rs2404602	1	rs11072603	ENSG00000259422.1	RP11-593F23.1	8.41	1.34e-16	4.71e-14	0.31	0.25	Blood metabolite levels;	chr15:76588797	chr15:76174891~76181486:-
BRCA	cis	rs4835473	0.83	rs7692672	ENSG00000251600.4	RP11-673E1.1	8.41	1.34e-16	4.72e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143971048	chr4:143912331~143982454:+
BRCA	cis	rs875971	0.66	rs10263935	ENSG00000222364.1	RNU6-96P	-8.41	1.35e-16	4.73e-14	-0.29	-0.25	Aortic root size;	chr7:66631041	chr7:66395191~66395286:+
BRCA	cis	rs858239	0.73	rs10255155	ENSG00000226816.2	AC005082.12	-8.41	1.35e-16	4.74e-14	-0.29	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23362528	chr7:23206013~23208045:+
BRCA	cis	rs12468226	0.938	rs116601501	ENSG00000273456.1	RP11-686O6.2	8.41	1.35e-16	4.75e-14	0.38	0.25	Urate levels;	chr2:202274567	chr2:202374932~202375604:-
BRCA	cis	rs12468226	0.938	rs78928733	ENSG00000273456.1	RP11-686O6.2	8.41	1.35e-16	4.75e-14	0.38	0.25	Urate levels;	chr2:202283787	chr2:202374932~202375604:-
BRCA	cis	rs11098499	0.863	rs13140391	ENSG00000248280.1	RP11-33B1.2	8.41	1.36e-16	4.77e-14	0.26	0.25	Corneal astigmatism;	chr4:119582282	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.863	rs13140409	ENSG00000248280.1	RP11-33B1.2	8.41	1.36e-16	4.77e-14	0.26	0.25	Corneal astigmatism;	chr4:119582305	chr4:119440561~119450157:-
BRCA	cis	rs2933343	1	rs1680795	ENSG00000261159.1	RP11-723O4.9	8.41	1.36e-16	4.78e-14	0.31	0.25	IgG glycosylation;	chr3:128901545	chr3:128859716~128860526:-
BRCA	cis	rs875971	0.545	rs1909508	ENSG00000222364.1	RNU6-96P	-8.41	1.36e-16	4.78e-14	-0.33	-0.25	Aortic root size;	chr7:66301366	chr7:66395191~66395286:+
BRCA	cis	rs4835473	0.524	rs4404495	ENSG00000251600.4	RP11-673E1.1	8.41	1.36e-16	4.78e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143979791	chr4:143912331~143982454:+
BRCA	cis	rs853679	1	rs1778508	ENSG00000220721.1	OR1F12	-8.41	1.36e-16	4.79e-14	-0.4	-0.25	Depression;	chr6:28262103	chr6:28073316~28074233:+
BRCA	cis	rs13256369	1	rs1109619	ENSG00000253893.2	FAM85B	-8.41	1.37e-16	4.8e-14	-0.36	-0.25	Obesity-related traits;	chr8:8714106	chr8:8167819~8226614:-
BRCA	cis	rs6142102	0.625	rs6141436	ENSG00000275784.1	RP5-1125A11.6	-8.41	1.37e-16	4.82e-14	-0.29	-0.25	Skin pigmentation;	chr20:33966765	chr20:33989480~33991818:-
BRCA	cis	rs524281	0.731	rs7931167	ENSG00000255320.1	RP11-755F10.1	-8.41	1.37e-16	4.82e-14	-0.41	-0.25	Electroencephalogram traits;	chr11:66036279	chr11:66244840~66246239:-
BRCA	cis	rs897984	0.609	rs57576577	ENSG00000260911.2	RP11-196G11.2	8.41	1.38e-16	4.84e-14	0.23	0.25	Dementia with Lewy bodies;	chr16:31025046	chr16:31043150~31049868:+
BRCA	cis	rs13256369	1	rs13267501	ENSG00000253893.2	FAM85B	-8.41	1.38e-16	4.84e-14	-0.36	-0.25	Obesity-related traits;	chr8:8716548	chr8:8167819~8226614:-
BRCA	cis	rs13256369	0.95	rs13270006	ENSG00000253893.2	FAM85B	-8.41	1.38e-16	4.84e-14	-0.36	-0.25	Obesity-related traits;	chr8:8716687	chr8:8167819~8226614:-
BRCA	cis	rs10510102	0.872	rs12247367	ENSG00000276742.1	RP11-500G22.4	8.41	1.38e-16	4.85e-14	0.43	0.25	Breast cancer;	chr10:121961556	chr10:121956782~121957098:+
BRCA	cis	rs6545883	0.826	rs777590	ENSG00000271889.1	RP11-493E12.1	8.41	1.39e-16	4.88e-14	0.32	0.25	Tuberculosis;	chr2:61190010	chr2:61151433~61162105:-
BRCA	cis	rs1499614	1	rs2141924	ENSG00000273142.1	RP11-458F8.4	-8.4	1.39e-16	4.88e-14	-0.36	-0.25	Gout;	chr7:66721259	chr7:66902857~66906297:+
BRCA	cis	rs4835473	0.897	rs2089835	ENSG00000251600.4	RP11-673E1.1	8.4	1.39e-16	4.89e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143965127	chr4:143912331~143982454:+
BRCA	cis	rs673078	0.66	rs11068891	ENSG00000275759.1	RP11-131L12.3	8.4	1.4e-16	4.9e-14	0.35	0.25	Glucose homeostasis traits;	chr12:118259814	chr12:118428281~118428870:+
BRCA	cis	rs6569038	0.557	rs9401118	ENSG00000253194.1	RP11-351A11.1	-8.4	1.4e-16	4.92e-14	-0.32	-0.25	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr6:119053584	chr6:118934785~119031541:+
BRCA	cis	rs6142102	0.625	rs4012234	ENSG00000275784.1	RP5-1125A11.6	-8.4	1.4e-16	4.92e-14	-0.29	-0.25	Skin pigmentation;	chr20:33965241	chr20:33989480~33991818:-
BRCA	cis	rs6142102	0.649	rs4911382	ENSG00000275784.1	RP5-1125A11.6	-8.4	1.4e-16	4.92e-14	-0.29	-0.25	Skin pigmentation;	chr20:33965289	chr20:33989480~33991818:-
BRCA	cis	rs6545883	0.63	rs12998475	ENSG00000271889.1	RP11-493E12.1	-8.4	1.4e-16	4.92e-14	-0.32	-0.25	Tuberculosis;	chr2:61210352	chr2:61151433~61162105:-
BRCA	cis	rs853679	1	rs7740487	ENSG00000220721.1	OR1F12	8.4	1.41e-16	4.94e-14	0.41	0.25	Depression;	chr6:28248708	chr6:28073316~28074233:+
BRCA	cis	rs4718428	0.705	rs11028	ENSG00000273142.1	RP11-458F8.4	-8.4	1.41e-16	4.94e-14	-0.24	-0.25	Corneal structure;	chr7:66811230	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs1546059	ENSG00000273142.1	RP11-458F8.4	8.4	1.41e-16	4.94e-14	0.35	0.25	Diabetic kidney disease;	chr7:66189722	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs2420170	ENSG00000273142.1	RP11-458F8.4	8.4	1.41e-16	4.94e-14	0.35	0.25	Diabetic kidney disease;	chr7:66191066	chr7:66902857~66906297:+
BRCA	cis	rs875971	1	rs1565531	ENSG00000237310.1	GS1-124K5.4	-8.4	1.41e-16	4.95e-14	-0.26	-0.25	Aortic root size;	chr7:66198126	chr7:66493706~66495474:+
BRCA	cis	rs11098499	0.913	rs67073020	ENSG00000245958.5	RP11-33B1.1	-8.4	1.42e-16	4.99e-14	-0.26	-0.25	Corneal astigmatism;	chr4:119231402	chr4:119454791~119552025:+
BRCA	cis	rs6921919	0.887	rs16894116	ENSG00000216901.1	AL022393.7	8.4	1.42e-16	4.99e-14	0.39	0.25	Autism spectrum disorder or schizophrenia;	chr6:28447190	chr6:28176188~28176674:+
BRCA	cis	rs4853012	0.838	rs4429500	ENSG00000257800.1	FNBP1P1	8.4	1.43e-16	5.01e-14	0.24	0.25	Gestational age at birth (maternal effect);	chr2:74118209	chr2:74120680~74123218:+
BRCA	cis	rs17023223	0.581	rs2765529	ENSG00000231365.4	RP11-418J17.1	-8.4	1.43e-16	5.01e-14	-0.32	-0.25	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119039277	chr1:119140396~119275973:+
BRCA	cis	rs673078	0.66	rs17440336	ENSG00000275759.1	RP11-131L12.3	8.4	1.43e-16	5.01e-14	0.39	0.25	Glucose homeostasis traits;	chr12:118163305	chr12:118428281~118428870:+
BRCA	cis	rs6142102	0.625	rs1883706	ENSG00000275784.1	RP5-1125A11.6	-8.4	1.43e-16	5.03e-14	-0.29	-0.25	Skin pigmentation;	chr20:33965071	chr20:33989480~33991818:-
BRCA	cis	rs6142102	0.625	rs1883705	ENSG00000275784.1	RP5-1125A11.6	-8.4	1.43e-16	5.03e-14	-0.29	-0.25	Skin pigmentation;	chr20:33965072	chr20:33989480~33991818:-
BRCA	cis	rs875971	0.545	rs73142265	ENSG00000222364.1	RNU6-96P	-8.4	1.44e-16	5.03e-14	-0.34	-0.25	Aortic root size;	chr7:66234510	chr7:66395191~66395286:+
BRCA	cis	rs6545883	0.895	rs4430924	ENSG00000271889.1	RP11-493E12.1	8.4	1.45e-16	5.07e-14	0.34	0.25	Tuberculosis;	chr2:61476721	chr2:61151433~61162105:-
BRCA	cis	rs858239	0.57	rs6968242	ENSG00000230042.1	AK3P3	-8.4	1.45e-16	5.07e-14	-0.28	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23127792	chr7:23129178~23129841:+
BRCA	cis	rs4835473	0.766	rs6537222	ENSG00000251600.4	RP11-673E1.1	8.4	1.45e-16	5.08e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143971459	chr4:143912331~143982454:+
BRCA	cis	rs9640161	0.789	rs28432021	ENSG00000261305.1	RP4-584D14.7	8.4	1.45e-16	5.08e-14	0.37	0.25	Blood protein levels;Circulating chemerin levels;	chr7:150349146	chr7:150341771~150342607:+
BRCA	cis	rs858239	0.831	rs7796541	ENSG00000226816.2	AC005082.12	8.4	1.45e-16	5.09e-14	0.29	0.25	Cerebrospinal fluid biomarker levels;	chr7:23349454	chr7:23206013~23208045:+
BRCA	cis	rs875971	1	rs778706	ENSG00000237310.1	GS1-124K5.4	8.4	1.45e-16	5.1e-14	0.26	0.25	Aortic root size;	chr7:66395437	chr7:66493706~66495474:+
BRCA	cis	rs147858478	1	rs147858478	ENSG00000233006.5	AC034220.3	8.4	1.46e-16	5.11e-14	0.18	0.25	High light scatter reticulocyte percentage of red cells;	chr5:132347099	chr5:132311285~132369916:-
BRCA	cis	rs11098499	0.954	rs28572238	ENSG00000248280.1	RP11-33B1.2	8.4	1.46e-16	5.12e-14	0.26	0.25	Corneal astigmatism;	chr4:119395531	chr4:119440561~119450157:-
BRCA	cis	rs4835473	0.932	rs1849112	ENSG00000251600.4	RP11-673E1.1	8.4	1.46e-16	5.12e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143962502	chr4:143912331~143982454:+
BRCA	cis	rs4308124	0.708	rs6727313	ENSG00000230499.1	AC108463.1	-8.4	1.46e-16	5.13e-14	-0.32	-0.25	Vitiligo;	chr2:111213963	chr2:111195963~111206494:+
BRCA	cis	rs4835473	0.771	rs4261935	ENSG00000251600.4	RP11-673E1.1	8.4	1.47e-16	5.14e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143979751	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.75	rs57610804	ENSG00000251600.4	RP11-673E1.1	8.4	1.48e-16	5.17e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143974341	chr4:143912331~143982454:+
BRCA	cis	rs6545883	0.894	rs7602859	ENSG00000271889.1	RP11-493E12.1	-8.4	1.48e-16	5.18e-14	-0.33	-0.25	Tuberculosis;	chr2:61231071	chr2:61151433~61162105:-
BRCA	cis	rs2933343	1	rs789237	ENSG00000261159.1	RP11-723O4.9	8.4	1.49e-16	5.21e-14	0.3	0.25	IgG glycosylation;	chr3:128918118	chr3:128859716~128860526:-
BRCA	cis	rs4835473	0.549	rs11940719	ENSG00000251600.4	RP11-673E1.1	8.4	1.49e-16	5.22e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143970855	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.9	rs6537223	ENSG00000251600.4	RP11-673E1.1	8.4	1.49e-16	5.22e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143971541	chr4:143912331~143982454:+
BRCA	cis	rs67981189	0.529	rs8181986	ENSG00000269927.1	RP6-91H8.3	8.4	1.49e-16	5.22e-14	0.33	0.25	Schizophrenia;	chr14:71115527	chr14:71141125~71143253:-
BRCA	cis	rs950169	0.519	rs7237	ENSG00000225151.9	GOLGA2P7	-8.4	1.5e-16	5.26e-14	-0.33	-0.25	Schizophrenia;	chr15:84643346	chr15:84199311~84230136:-
BRCA	cis	rs4308124	0.708	rs10179596	ENSG00000230499.1	AC108463.1	-8.39	1.51e-16	5.27e-14	-0.32	-0.25	Vitiligo;	chr2:111212803	chr2:111195963~111206494:+
BRCA	cis	rs11098499	0.739	rs7441137	ENSG00000245958.5	RP11-33B1.1	8.39	1.51e-16	5.29e-14	0.25	0.25	Corneal astigmatism;	chr4:119212066	chr4:119454791~119552025:+
BRCA	cis	rs6472827	0.645	rs2977070	ENSG00000253983.2	RP1-16A9.1	-8.39	1.51e-16	5.29e-14	-0.35	-0.25	Uterine fibroids;	chr8:74200535	chr8:74199396~74208441:+
BRCA	cis	rs6142102	0.923	rs6059635	ENSG00000276073.1	RP5-1125A11.7	-8.39	1.51e-16	5.29e-14	-0.3	-0.25	Skin pigmentation;	chr20:34025687	chr20:33985617~33988989:-
BRCA	cis	rs10510102	0.872	rs11200277	ENSG00000276742.1	RP11-500G22.4	8.39	1.52e-16	5.31e-14	0.43	0.25	Breast cancer;	chr10:121944295	chr10:121956782~121957098:+
BRCA	cis	rs875971	1	rs11974219	ENSG00000237310.1	GS1-124K5.4	-8.39	1.52e-16	5.33e-14	-0.26	-0.25	Aortic root size;	chr7:66182423	chr7:66493706~66495474:+
BRCA	cis	rs8012947	1	rs10145437	ENSG00000279636.2	LINC00216	-8.39	1.53e-16	5.34e-14	-0.28	-0.25	Alcohol consumption in current drinkers;	chr14:58294485	chr14:58288033~58289158:+
BRCA	cis	rs1113500	0.73	rs1777457	ENSG00000226822.1	RP11-356N1.2	-8.39	1.54e-16	5.37e-14	-0.32	-0.25	Growth-regulated protein alpha levels;	chr1:108045573	chr1:108071482~108074519:+
BRCA	cis	rs6142102	0.602	rs6141435	ENSG00000275784.1	RP5-1125A11.6	-8.39	1.54e-16	5.38e-14	-0.29	-0.25	Skin pigmentation;	chr20:33963473	chr20:33989480~33991818:-
BRCA	cis	rs10463554	0.927	rs257317	ENSG00000175749.11	EIF3KP1	8.39	1.55e-16	5.42e-14	0.34	0.25	Parkinson's disease;	chr5:103086881	chr5:103032376~103033031:+
BRCA	cis	rs67981189	0.529	rs8010063	ENSG00000269927.1	RP6-91H8.3	8.39	1.56e-16	5.44e-14	0.33	0.25	Schizophrenia;	chr14:71043408	chr14:71141125~71143253:-
BRCA	cis	rs2404602	0.716	rs12594577	ENSG00000259422.1	RP11-593F23.1	8.39	1.56e-16	5.44e-14	0.32	0.25	Blood metabolite levels;	chr15:76536452	chr15:76174891~76181486:-
BRCA	cis	rs950880	0.645	rs56044378	ENSG00000234389.1	AC007278.3	-8.39	1.56e-16	5.46e-14	-0.25	-0.25	Serum protein levels (sST2);	chr2:102448907	chr2:102438713~102440475:+
BRCA	cis	rs7809950	1	rs2107713	ENSG00000238832.1	snoU109	-8.39	1.56e-16	5.46e-14	-0.33	-0.25	Coronary artery disease;	chr7:107591924	chr7:107603363~107603507:+
BRCA	cis	rs6142102	0.886	rs4911147	ENSG00000276073.1	RP5-1125A11.7	-8.39	1.56e-16	5.46e-14	-0.3	-0.25	Skin pigmentation;	chr20:34079801	chr20:33985617~33988989:-
BRCA	cis	rs1707322	0.865	rs785501	ENSG00000280836.1	AL355480.1	8.39	1.57e-16	5.47e-14	0.32	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46113939	chr1:45581219~45581321:-
BRCA	cis	rs875971	1	rs6460292	ENSG00000237310.1	GS1-124K5.4	-8.39	1.57e-16	5.49e-14	-0.26	-0.25	Aortic root size;	chr7:66345088	chr7:66493706~66495474:+
BRCA	cis	rs75422866	0.541	rs12425816	ENSG00000274902.1	RP1-197B17.4	8.39	1.58e-16	5.52e-14	0.64	0.25	Pneumonia;	chr12:47731419	chr12:47731908~47732351:+
BRCA	cis	rs11098499	0.909	rs28714195	ENSG00000248280.1	RP11-33B1.2	8.39	1.58e-16	5.52e-14	0.26	0.25	Corneal astigmatism;	chr4:119395795	chr4:119440561~119450157:-
BRCA	cis	rs3758911	0.929	rs10749895	ENSG00000255353.1	RP11-382M14.1	-8.39	1.58e-16	5.53e-14	-0.33	-0.25	Coronary artery disease;	chr11:107310855	chr11:107176286~107177530:+
BRCA	cis	rs763567	0.933	rs623752	ENSG00000271811.1	RP1-79C4.4	8.39	1.59e-16	5.54e-14	0.27	0.25	Tonsillectomy;	chr1:170649150	chr1:170667381~170669425:+
BRCA	cis	rs875971	0.522	rs4502988	ENSG00000222364.1	RNU6-96P	-8.39	1.59e-16	5.54e-14	-0.29	-0.25	Aortic root size;	chr7:65832759	chr7:66395191~66395286:+
BRCA	cis	rs13256369	1	rs873064	ENSG00000253893.2	FAM85B	-8.39	1.59e-16	5.55e-14	-0.35	-0.25	Obesity-related traits;	chr8:8714870	chr8:8167819~8226614:-
BRCA	cis	rs3758911	0.929	rs10789600	ENSG00000255353.1	RP11-382M14.1	-8.39	1.59e-16	5.55e-14	-0.34	-0.25	Coronary artery disease;	chr11:107310335	chr11:107176286~107177530:+
BRCA	cis	rs193541	0.564	rs407230	ENSG00000263432.2	RN7SL689P	-8.39	1.59e-16	5.55e-14	-0.34	-0.25	Glucose homeostasis traits;	chr5:123010032	chr5:123022487~123022783:-
BRCA	cis	rs193541	0.593	rs154499	ENSG00000263432.2	RN7SL689P	8.39	1.59e-16	5.55e-14	0.34	0.25	Glucose homeostasis traits;	chr5:122883971	chr5:123022487~123022783:-
BRCA	cis	rs950776	0.593	rs6495306	ENSG00000261762.1	RP11-650L12.2	-8.39	1.59e-16	5.57e-14	-0.27	-0.25	Sudden cardiac arrest;	chr15:78573551	chr15:78589123~78591276:-
BRCA	cis	rs748404	0.666	rs12911569	ENSG00000249839.1	AC011330.5	-8.39	1.6e-16	5.57e-14	-0.38	-0.25	Lung cancer;	chr15:43305099	chr15:43663654~43684339:-
BRCA	cis	rs11673344	0.931	rs7256746	ENSG00000226686.6	LINC01535	8.39	1.61e-16	5.62e-14	0.32	0.25	Obesity-related traits;	chr19:37175073	chr19:37251912~37265535:+
BRCA	cis	rs7246657	0.722	rs954504	ENSG00000267422.1	CTD-2554C21.1	-8.39	1.61e-16	5.62e-14	-0.37	-0.25	Coronary artery calcification;	chr19:37554492	chr19:37779686~37792865:+
BRCA	cis	rs7246657	0.722	rs8110865	ENSG00000267422.1	CTD-2554C21.1	-8.39	1.61e-16	5.62e-14	-0.37	-0.25	Coronary artery calcification;	chr19:37556485	chr19:37779686~37792865:+
BRCA	cis	rs7246657	0.678	rs4802024	ENSG00000267422.1	CTD-2554C21.1	-8.39	1.61e-16	5.62e-14	-0.37	-0.25	Coronary artery calcification;	chr19:37561291	chr19:37779686~37792865:+
BRCA	cis	rs7246657	0.722	rs4802029	ENSG00000267422.1	CTD-2554C21.1	-8.39	1.61e-16	5.62e-14	-0.37	-0.25	Coronary artery calcification;	chr19:37564710	chr19:37779686~37792865:+
BRCA	cis	rs7246657	0.722	rs28512414	ENSG00000267422.1	CTD-2554C21.1	-8.39	1.61e-16	5.62e-14	-0.37	-0.25	Coronary artery calcification;	chr19:37565672	chr19:37779686~37792865:+
BRCA	cis	rs7246657	0.722	rs6508736	ENSG00000267422.1	CTD-2554C21.1	-8.39	1.61e-16	5.62e-14	-0.37	-0.25	Coronary artery calcification;	chr19:37570855	chr19:37779686~37792865:+
BRCA	cis	rs875971	0.54	rs35510581	ENSG00000224316.1	RP11-479O9.2	-8.39	1.61e-16	5.63e-14	-0.25	-0.25	Aortic root size;	chr7:66113790	chr7:65773620~65802067:+
BRCA	cis	rs4835473	0.932	rs4516663	ENSG00000251600.4	RP11-673E1.1	8.39	1.61e-16	5.63e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143980791	chr4:143912331~143982454:+
BRCA	cis	rs17023223	0.537	rs7525871	ENSG00000231365.4	RP11-418J17.1	-8.39	1.62e-16	5.64e-14	-0.33	-0.25	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119079271	chr1:119140396~119275973:+
BRCA	cis	rs6142102	0.625	rs1883707	ENSG00000275784.1	RP5-1125A11.6	8.39	1.62e-16	5.64e-14	0.29	0.25	Skin pigmentation;	chr20:33964781	chr20:33989480~33991818:-
BRCA	cis	rs12468226	0.938	rs115418918	ENSG00000273456.1	RP11-686O6.2	8.39	1.62e-16	5.64e-14	0.37	0.25	Urate levels;	chr2:202315145	chr2:202374932~202375604:-
BRCA	cis	rs4835473	0.798	rs34353812	ENSG00000251600.4	RP11-673E1.1	8.39	1.62e-16	5.65e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143973949	chr4:143912331~143982454:+
BRCA	cis	rs10246939	0.579	rs35647444	ENSG00000228775.6	WEE2-AS1	8.39	1.63e-16	5.68e-14	0.28	0.25	Bitter taste perception;	chr7:141833957	chr7:141704338~141738346:-
BRCA	cis	rs2688482	0.557	rs2550236	ENSG00000224769.1	AC069213.1	8.39	1.63e-16	5.69e-14	0.45	0.25	Lung disease severity in cystic fibrosis;	chr3:195795450	chr3:195614947~195620233:+
BRCA	cis	rs4964805	0.913	rs12229276	ENSG00000257681.1	RP11-341G23.4	-8.39	1.63e-16	5.69e-14	-0.3	-0.25	Attention deficit hyperactivity disorder;	chr12:103810993	chr12:103746315~103768858:-
BRCA	cis	rs6921919	0.832	rs17312661	ENSG00000204709.4	LINC01556	8.38	1.64e-16	5.72e-14	0.43	0.25	Autism spectrum disorder or schizophrenia;	chr6:28332559	chr6:28943877~28944537:+
BRCA	cis	rs189798	0.592	rs10111263	ENSG00000253893.2	FAM85B	8.38	1.64e-16	5.73e-14	0.34	0.25	Myopia (pathological);	chr8:9111923	chr8:8167819~8226614:-
BRCA	cis	rs11723261	0.582	rs4582104	ENSG00000211553.1	AC253576.2	-8.38	1.65e-16	5.75e-14	-0.34	-0.25	Immune response to smallpox vaccine (IL-6);	chr4:143160	chr4:136461~136568:+
BRCA	cis	rs6921919	1	rs6922111	ENSG00000216901.1	AL022393.7	8.38	1.65e-16	5.75e-14	0.37	0.25	Autism spectrum disorder or schizophrenia;	chr6:28357531	chr6:28176188~28176674:+
BRCA	cis	rs4835473	0.831	rs10428468	ENSG00000251600.4	RP11-673E1.1	8.38	1.65e-16	5.75e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143974104	chr4:143912331~143982454:+
BRCA	cis	rs1707322	0.964	rs796773	ENSG00000280836.1	AL355480.1	8.38	1.65e-16	5.76e-14	0.32	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46098803	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.896	rs785518	ENSG00000280836.1	AL355480.1	8.38	1.65e-16	5.76e-14	0.32	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46102750	chr1:45581219~45581321:-
BRCA	cis	rs1707322	1	rs785519	ENSG00000280836.1	AL355480.1	8.38	1.65e-16	5.76e-14	0.32	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46102890	chr1:45581219~45581321:-
BRCA	cis	rs7811142	0.83	rs6948685	ENSG00000242294.5	STAG3L5P	8.38	1.65e-16	5.77e-14	0.25	0.25	Platelet count;	chr7:100372565	chr7:100336079~100351900:+
BRCA	cis	rs1075265	0.749	rs2692518	ENSG00000233266.1	HMGB1P31	8.38	1.65e-16	5.77e-14	0.3	0.25	Chronotype;Morning vs. evening chronotype;	chr2:53804746	chr2:54051334~54051760:+
BRCA	cis	rs875971	0.545	rs313830	ENSG00000164669.11	INTS4P1	8.38	1.65e-16	5.77e-14	0.36	0.25	Aortic root size;	chr7:66086944	chr7:65141225~65234216:+
BRCA	cis	rs17023223	0.537	rs1325940	ENSG00000231365.4	RP11-418J17.1	-8.38	1.66e-16	5.78e-14	-0.32	-0.25	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119044064	chr1:119140396~119275973:+
BRCA	cis	rs11098499	0.874	rs9995277	ENSG00000245958.5	RP11-33B1.1	-8.38	1.66e-16	5.79e-14	-0.26	-0.25	Corneal astigmatism;	chr4:119187448	chr4:119454791~119552025:+
BRCA	cis	rs860818	0.793	rs1406080	ENSG00000226816.2	AC005082.12	-8.38	1.66e-16	5.79e-14	-0.57	-0.25	Initial pursuit acceleration;	chr7:23153985	chr7:23206013~23208045:+
BRCA	cis	rs12999373	0.501	rs2867134	ENSG00000223751.1	AC116609.2	-8.38	1.66e-16	5.79e-14	-0.31	-0.25	Response to fenofibrate (adiponectin levels);Uric acid levels;	chr2:697499	chr2:742488~747767:+
BRCA	cis	rs10971721	0.908	rs10971722	ENSG00000260947.1	RP11-384P7.7	8.38	1.66e-16	5.79e-14	0.45	0.25	Body mass index;	chr9:33828166	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.822	rs10971723	ENSG00000260947.1	RP11-384P7.7	8.38	1.66e-16	5.79e-14	0.45	0.25	Body mass index;	chr9:33829604	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.908	rs12376055	ENSG00000260947.1	RP11-384P7.7	8.38	1.66e-16	5.79e-14	0.45	0.25	Body mass index;	chr9:33831957	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.908	rs55684780	ENSG00000260947.1	RP11-384P7.7	8.38	1.66e-16	5.79e-14	0.45	0.25	Body mass index;	chr9:33833210	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.908	rs10971728	ENSG00000260947.1	RP11-384P7.7	8.38	1.66e-16	5.79e-14	0.45	0.25	Body mass index;	chr9:33834635	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.642	rs114466241	ENSG00000260947.1	RP11-384P7.7	8.38	1.66e-16	5.79e-14	0.45	0.25	Body mass index;	chr9:33835731	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.731	rs12378261	ENSG00000260947.1	RP11-384P7.7	8.38	1.66e-16	5.79e-14	0.45	0.25	Body mass index;	chr9:33837174	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.822	rs72725374	ENSG00000260947.1	RP11-384P7.7	8.38	1.66e-16	5.79e-14	0.45	0.25	Body mass index;	chr9:33840651	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.749	rs72725375	ENSG00000260947.1	RP11-384P7.7	8.38	1.66e-16	5.79e-14	0.45	0.25	Body mass index;	chr9:33840706	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.822	rs72725376	ENSG00000260947.1	RP11-384P7.7	8.38	1.66e-16	5.79e-14	0.45	0.25	Body mass index;	chr9:33841931	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.822	rs72725377	ENSG00000260947.1	RP11-384P7.7	8.38	1.66e-16	5.79e-14	0.45	0.25	Body mass index;	chr9:33842228	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.822	rs72725378	ENSG00000260947.1	RP11-384P7.7	8.38	1.66e-16	5.79e-14	0.45	0.25	Body mass index;	chr9:33842896	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.822	rs72725381	ENSG00000260947.1	RP11-384P7.7	8.38	1.66e-16	5.79e-14	0.45	0.25	Body mass index;	chr9:33851167	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.642	rs10971736	ENSG00000260947.1	RP11-384P7.7	8.38	1.66e-16	5.79e-14	0.45	0.25	Body mass index;	chr9:33854376	chr9:33697459~33700986:+
BRCA	cis	rs10740039	0.804	rs10821824	ENSG00000254271.1	RP11-131N11.4	8.38	1.66e-16	5.8e-14	0.33	0.25	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60690449	chr10:60734342~60741828:+
BRCA	cis	rs7208859	0.623	rs9898084	ENSG00000266490.1	CTD-2349P21.9	8.38	1.67e-16	5.83e-14	0.36	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30755316	chr17:30792372~30792833:+
BRCA	cis	rs10028773	0.7	rs7671797	ENSG00000245958.5	RP11-33B1.1	-8.38	1.68e-16	5.84e-14	-0.24	-0.25	Educational attainment;	chr4:119327002	chr4:119454791~119552025:+
BRCA	cis	rs1075265	0.901	rs1058320	ENSG00000233266.1	HMGB1P31	8.38	1.68e-16	5.85e-14	0.3	0.25	Chronotype;Morning vs. evening chronotype;	chr2:54085016	chr2:54051334~54051760:+
BRCA	cis	rs250518	0.926	rs1509131	ENSG00000272081.1	CTD-2376I4.2	8.38	1.68e-16	5.86e-14	0.32	0.25	Mean corpuscular hemoglobin concentration;	chr5:72797651	chr5:72955206~72955699:-
BRCA	cis	rs875971	0.54	rs736270	ENSG00000222364.1	RNU6-96P	-8.38	1.68e-16	5.87e-14	-0.29	-0.25	Aortic root size;	chr7:65963835	chr7:66395191~66395286:+
BRCA	cis	rs1075265	0.933	rs2287642	ENSG00000233266.1	HMGB1P31	8.38	1.69e-16	5.88e-14	0.3	0.25	Chronotype;Morning vs. evening chronotype;	chr2:54108447	chr2:54051334~54051760:+
BRCA	cis	rs13256369	0.76	rs7816171	ENSG00000253893.2	FAM85B	-8.38	1.69e-16	5.88e-14	-0.35	-0.25	Obesity-related traits;	chr8:8718325	chr8:8167819~8226614:-
BRCA	cis	rs13256369	0.76	rs7839473	ENSG00000253893.2	FAM85B	-8.38	1.69e-16	5.88e-14	-0.35	-0.25	Obesity-related traits;	chr8:8718326	chr8:8167819~8226614:-
BRCA	cis	rs1707322	0.929	rs785500	ENSG00000280836.1	AL355480.1	8.38	1.69e-16	5.89e-14	0.32	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46127372	chr1:45581219~45581321:-
BRCA	cis	rs250518	0.926	rs6875887	ENSG00000272081.1	CTD-2376I4.2	8.38	1.69e-16	5.9e-14	0.32	0.25	Mean corpuscular hemoglobin concentration;	chr5:72795067	chr5:72955206~72955699:-
BRCA	cis	rs250518	0.926	rs6876549	ENSG00000272081.1	CTD-2376I4.2	8.38	1.69e-16	5.9e-14	0.32	0.25	Mean corpuscular hemoglobin concentration;	chr5:72795463	chr5:72955206~72955699:-
BRCA	cis	rs250518	0.926	rs6897422	ENSG00000272081.1	CTD-2376I4.2	8.38	1.69e-16	5.9e-14	0.32	0.25	Mean corpuscular hemoglobin concentration;	chr5:72795532	chr5:72955206~72955699:-
BRCA	cis	rs250518	0.926	rs6452687	ENSG00000272081.1	CTD-2376I4.2	8.38	1.69e-16	5.9e-14	0.32	0.25	Mean corpuscular hemoglobin concentration;	chr5:72795688	chr5:72955206~72955699:-
BRCA	cis	rs250518	0.926	rs6452690	ENSG00000272081.1	CTD-2376I4.2	8.38	1.69e-16	5.9e-14	0.32	0.25	Mean corpuscular hemoglobin concentration;	chr5:72795785	chr5:72955206~72955699:-
BRCA	cis	rs1062177	0.855	rs6892117	ENSG00000253921.1	CTB-113P19.3	8.38	1.69e-16	5.9e-14	0.31	0.25	Preschool internalizing problems;	chr5:151885424	chr5:151753992~151767247:+
BRCA	cis	rs113835537	0.559	rs11227497	ENSG00000255517.5	CTD-3074O7.5	-8.38	1.7e-16	5.91e-14	-0.32	-0.25	Airway imaging phenotypes;	chr11:66501993	chr11:66473490~66480233:-
BRCA	cis	rs61270009	0.955	rs78909929	ENSG00000247828.6	TMEM161B-AS1	8.38	1.7e-16	5.91e-14	0.32	0.25	Depressive symptoms;	chr5:88344154	chr5:88268895~88436685:+
BRCA	cis	rs875971	0.964	rs60193905	ENSG00000237310.1	GS1-124K5.4	8.38	1.7e-16	5.92e-14	0.26	0.25	Aortic root size;	chr7:66506273	chr7:66493706~66495474:+
BRCA	cis	rs10971721	0.822	rs12380143	ENSG00000260947.1	RP11-384P7.7	8.38	1.7e-16	5.93e-14	0.45	0.25	Body mass index;	chr9:33847588	chr9:33697459~33700986:+
BRCA	cis	rs10971721	0.822	rs10971735	ENSG00000260947.1	RP11-384P7.7	8.38	1.7e-16	5.93e-14	0.45	0.25	Body mass index;	chr9:33851801	chr9:33697459~33700986:+
BRCA	cis	rs7246657	0.722	rs2291002	ENSG00000267422.1	CTD-2554C21.1	-8.38	1.7e-16	5.94e-14	-0.37	-0.25	Coronary artery calcification;	chr19:37543024	chr19:37779686~37792865:+
BRCA	cis	rs7246657	0.722	rs10404031	ENSG00000267422.1	CTD-2554C21.1	-8.38	1.7e-16	5.94e-14	-0.37	-0.25	Coronary artery calcification;	chr19:37545052	chr19:37779686~37792865:+
BRCA	cis	rs7246657	0.722	rs10406379	ENSG00000267422.1	CTD-2554C21.1	-8.38	1.7e-16	5.94e-14	-0.37	-0.25	Coronary artery calcification;	chr19:37545823	chr19:37779686~37792865:+
BRCA	cis	rs6142102	0.538	rs6142058	ENSG00000275784.1	RP5-1125A11.6	-8.38	1.71e-16	5.95e-14	-0.29	-0.25	Skin pigmentation;	chr20:33954995	chr20:33989480~33991818:-
BRCA	cis	rs3758911	0.964	rs10789602	ENSG00000255353.1	RP11-382M14.1	-8.38	1.71e-16	5.95e-14	-0.33	-0.25	Coronary artery disease;	chr11:107310729	chr11:107176286~107177530:+
BRCA	cis	rs1707322	1	rs7538978	ENSG00000280836.1	AL355480.1	8.38	1.71e-16	5.96e-14	0.32	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46039382	chr1:45581219~45581321:-
BRCA	cis	rs1075265	0.756	rs698854	ENSG00000233266.1	HMGB1P31	8.38	1.72e-16	5.98e-14	0.3	0.25	Chronotype;Morning vs. evening chronotype;	chr2:53826784	chr2:54051334~54051760:+
BRCA	cis	rs7712401	0.601	rs30039	ENSG00000263432.2	RN7SL689P	-8.38	1.72e-16	5.99e-14	-0.32	-0.25	Mean platelet volume;	chr5:122941484	chr5:123022487~123022783:-
BRCA	cis	rs72772090	0.634	rs12186366	ENSG00000248734.2	CTD-2260A17.1	-8.38	1.73e-16	6.01e-14	-0.4	-0.25	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96753146	chr5:96784777~96785999:+
BRCA	cis	rs13256369	1	rs10103769	ENSG00000253893.2	FAM85B	-8.38	1.73e-16	6.01e-14	-0.35	-0.25	Obesity-related traits;	chr8:8715526	chr8:8167819~8226614:-
BRCA	cis	rs10028773	0.666	rs12498657	ENSG00000245958.5	RP11-33B1.1	-8.38	1.73e-16	6.02e-14	-0.23	-0.25	Educational attainment;	chr4:119341711	chr4:119454791~119552025:+
BRCA	cis	rs3814244	0.528	rs7306466	ENSG00000236946.2	HNRNPA1P70	-8.38	1.73e-16	6.03e-14	-0.21	-0.25	Itch intensity from mosquito bite adjusted by bite size;	chr12:68014942	chr12:68035767~68036853:+
BRCA	cis	rs13403656	1	rs13403656	ENSG00000240350.2	AC017002.1	8.38	1.74e-16	6.05e-14	0.34	0.25	Allergic disease (asthma, hay fever or eczema);	chr2:111511550	chr2:111491273~111570974:+
BRCA	cis	rs875971	0.522	rs781144	ENSG00000222364.1	RNU6-96P	-8.38	1.74e-16	6.06e-14	-0.29	-0.25	Aortic root size;	chr7:65975357	chr7:66395191~66395286:+
BRCA	cis	rs860818	0.793	rs2091491	ENSG00000226816.2	AC005082.12	-8.38	1.74e-16	6.06e-14	-0.56	-0.25	Initial pursuit acceleration;	chr7:23153930	chr7:23206013~23208045:+
BRCA	cis	rs7811142	0.83	rs3087502	ENSG00000242294.5	STAG3L5P	8.38	1.76e-16	6.11e-14	0.25	0.25	Platelet count;	chr7:100357741	chr7:100336079~100351900:+
BRCA	cis	rs7811142	0.83	rs61735533	ENSG00000242294.5	STAG3L5P	8.38	1.76e-16	6.11e-14	0.25	0.25	Platelet count;	chr7:100358243	chr7:100336079~100351900:+
BRCA	cis	rs11098499	0.78	rs7680914	ENSG00000245958.5	RP11-33B1.1	-8.38	1.76e-16	6.12e-14	-0.25	-0.25	Corneal astigmatism;	chr4:119641898	chr4:119454791~119552025:+
BRCA	cis	rs7772486	0.875	rs13204280	ENSG00000235652.6	RP11-545I5.3	8.37	1.77e-16	6.16e-14	0.25	0.25	Lobe attachment (rater-scored or self-reported);	chr6:146094232	chr6:145799409~145886585:+
BRCA	cis	rs858239	0.57	rs10271613	ENSG00000230042.1	AK3P3	-8.37	1.78e-16	6.19e-14	-0.28	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23122967	chr7:23129178~23129841:+
BRCA	cis	rs11098499	0.722	rs10006192	ENSG00000245958.5	RP11-33B1.1	-8.37	1.79e-16	6.23e-14	-0.23	-0.25	Corneal astigmatism;	chr4:119341867	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.615	rs28551750	ENSG00000245958.5	RP11-33B1.1	-8.37	1.79e-16	6.23e-14	-0.23	-0.25	Corneal astigmatism;	chr4:119343746	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.691	rs9995716	ENSG00000245958.5	RP11-33B1.1	-8.37	1.79e-16	6.23e-14	-0.23	-0.25	Corneal astigmatism;	chr4:119343841	chr4:119454791~119552025:+
BRCA	cis	rs4835473	0.932	rs13148097	ENSG00000251600.4	RP11-673E1.1	8.37	1.79e-16	6.23e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143976238	chr4:143912331~143982454:+
BRCA	cis	rs1075265	0.749	rs2357693	ENSG00000233266.1	HMGB1P31	8.37	1.79e-16	6.23e-14	0.3	0.25	Chronotype;Morning vs. evening chronotype;	chr2:53735699	chr2:54051334~54051760:+
BRCA	cis	rs13256369	1	rs4841016	ENSG00000253893.2	FAM85B	-8.37	1.79e-16	6.23e-14	-0.35	-0.25	Obesity-related traits;	chr8:8715051	chr8:8167819~8226614:-
BRCA	cis	rs7569084	0.687	rs934731	ENSG00000204929.10	AC074391.1	8.37	1.79e-16	6.24e-14	0.33	0.25	Sum eosinophil basophil counts;	chr2:65456353	chr2:65436711~66084639:+
BRCA	cis	rs875971	0.522	rs6960048	ENSG00000222364.1	RNU6-96P	-8.37	1.8e-16	6.26e-14	-0.29	-0.25	Aortic root size;	chr7:65943052	chr7:66395191~66395286:+
BRCA	cis	rs7772486	0.875	rs1412081	ENSG00000235652.6	RP11-545I5.3	8.37	1.8e-16	6.27e-14	0.25	0.25	Lobe attachment (rater-scored or self-reported);	chr6:146088597	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.875	rs10457792	ENSG00000235652.6	RP11-545I5.3	8.37	1.8e-16	6.27e-14	0.25	0.25	Lobe attachment (rater-scored or self-reported);	chr6:146091279	chr6:145799409~145886585:+
BRCA	cis	rs4835473	0.932	rs1849115	ENSG00000251600.4	RP11-673E1.1	8.37	1.8e-16	6.27e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143989687	chr4:143912331~143982454:+
BRCA	cis	rs11098499	1	rs3749591	ENSG00000245958.5	RP11-33B1.1	-8.37	1.81e-16	6.29e-14	-0.26	-0.25	Corneal astigmatism;	chr4:119292875	chr4:119454791~119552025:+
BRCA	cis	rs6504622	0.755	rs4074249	ENSG00000262879.4	RP11-156P1.3	-8.37	1.81e-16	6.3e-14	-0.26	-0.25	Orofacial clefts;	chr17:47072043	chr17:46984045~47100323:-
BRCA	cis	rs8059260	0.544	rs12925161	ENSG00000274038.1	RP11-66H6.4	-8.37	1.82e-16	6.31e-14	-0.39	-0.25	Alcohol consumption over the past year;	chr16:11112719	chr16:11056556~11057034:+
BRCA	cis	rs12468226	0.873	rs60722019	ENSG00000273456.1	RP11-686O6.2	8.37	1.82e-16	6.31e-14	0.37	0.25	Urate levels;	chr2:202282060	chr2:202374932~202375604:-
BRCA	cis	rs17772222	0.958	rs10134008	ENSG00000258983.2	RP11-507K2.2	8.37	1.82e-16	6.31e-14	0.29	0.25	Coronary artery calcification;	chr14:88549183	chr14:88499334~88515502:+
BRCA	cis	rs10246939	0.543	rs9640359	ENSG00000228775.6	WEE2-AS1	8.37	1.82e-16	6.34e-14	0.28	0.25	Bitter taste perception;	chr7:141844399	chr7:141704338~141738346:-
BRCA	cis	rs4835473	0.615	rs6857432	ENSG00000251600.4	RP11-673E1.1	8.37	1.83e-16	6.36e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143971912	chr4:143912331~143982454:+
BRCA	cis	rs730566	0.64	rs6442112	ENSG00000229759.1	MRPS18AP1	8.37	1.84e-16	6.38e-14	0.32	0.25	Prion diseases;	chr3:48274544	chr3:48256350~48256938:-
BRCA	cis	rs11673344	0.667	rs504549	ENSG00000226686.6	LINC01535	8.37	1.84e-16	6.39e-14	0.33	0.25	Obesity-related traits;	chr19:36946299	chr19:37251912~37265535:+
BRCA	cis	rs950776	0.518	rs8025429	ENSG00000261762.1	RP11-650L12.2	-8.37	1.84e-16	6.4e-14	-0.28	-0.25	Sudden cardiac arrest;	chr15:78544020	chr15:78589123~78591276:-
BRCA	cis	rs950776	0.518	rs4886572	ENSG00000261762.1	RP11-650L12.2	-8.37	1.84e-16	6.4e-14	-0.28	-0.25	Sudden cardiac arrest;	chr15:78545110	chr15:78589123~78591276:-
BRCA	cis	rs4835473	0.932	rs4835471	ENSG00000251600.4	RP11-673E1.1	8.37	1.84e-16	6.4e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143982153	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.897	rs4835119	ENSG00000251600.4	RP11-673E1.1	8.37	1.84e-16	6.4e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143982210	chr4:143912331~143982454:+
BRCA	cis	rs858239	0.601	rs3735228	ENSG00000230042.1	AK3P3	-8.37	1.85e-16	6.42e-14	-0.29	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23130808	chr7:23129178~23129841:+
BRCA	cis	rs875971	0.545	rs221986	ENSG00000164669.11	INTS4P1	8.37	1.85e-16	6.43e-14	0.35	0.25	Aortic root size;	chr7:66105323	chr7:65141225~65234216:+
BRCA	cis	rs6545883	0.894	rs2694639	ENSG00000271889.1	RP11-493E12.1	-8.37	1.86e-16	6.44e-14	-0.33	-0.25	Tuberculosis;	chr2:61368156	chr2:61151433~61162105:-
BRCA	cis	rs193541	0.632	rs34486978	ENSG00000263432.2	RN7SL689P	-8.37	1.86e-16	6.46e-14	-0.34	-0.25	Glucose homeostasis traits;	chr5:122976848	chr5:123022487~123022783:-
BRCA	cis	rs875971	0.508	rs10258739	ENSG00000237310.1	GS1-124K5.4	-8.37	1.86e-16	6.47e-14	-0.26	-0.25	Aortic root size;	chr7:66597948	chr7:66493706~66495474:+
BRCA	cis	rs11098499	0.863	rs59732491	ENSG00000248280.1	RP11-33B1.2	8.37	1.87e-16	6.47e-14	0.26	0.25	Corneal astigmatism;	chr4:119568433	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.863	rs11723090	ENSG00000248280.1	RP11-33B1.2	8.37	1.87e-16	6.47e-14	0.26	0.25	Corneal astigmatism;	chr4:119569437	chr4:119440561~119450157:-
BRCA	cis	rs1062177	0.756	rs2915817	ENSG00000253921.1	CTB-113P19.3	8.37	1.87e-16	6.49e-14	0.34	0.25	Preschool internalizing problems;	chr5:151735956	chr5:151753992~151767247:+
BRCA	cis	rs875971	1	rs709595	ENSG00000237310.1	GS1-124K5.4	8.37	1.87e-16	6.5e-14	0.26	0.25	Aortic root size;	chr7:66352346	chr7:66493706~66495474:+
BRCA	cis	rs875971	1	rs811880	ENSG00000237310.1	GS1-124K5.4	8.37	1.87e-16	6.5e-14	0.26	0.25	Aortic root size;	chr7:66353659	chr7:66493706~66495474:+
BRCA	cis	rs2842992	0.915	rs2842980	ENSG00000237927.1	RP3-393E18.2	-8.37	1.88e-16	6.54e-14	-0.36	-0.25	Age-related macular degeneration (geographic atrophy);	chr6:159679084	chr6:159586955~159589169:-
BRCA	cis	rs6545883	0.894	rs10177303	ENSG00000271889.1	RP11-493E12.1	-8.37	1.88e-16	6.54e-14	-0.33	-0.25	Tuberculosis;	chr2:61367324	chr2:61151433~61162105:-
BRCA	cis	rs783540	0.934	rs4779053	ENSG00000278603.1	RP13-608F4.5	8.37	1.89e-16	6.55e-14	0.32	0.25	Schizophrenia;	chr15:82702846	chr15:82472203~82472426:+
BRCA	cis	rs6142102	0.625	rs2050208	ENSG00000275784.1	RP5-1125A11.6	-8.37	1.89e-16	6.55e-14	-0.29	-0.25	Skin pigmentation;	chr20:33955767	chr20:33989480~33991818:-
BRCA	cis	rs7246657	0.722	rs4802051	ENSG00000267422.1	CTD-2554C21.1	-8.37	1.89e-16	6.57e-14	-0.37	-0.25	Coronary artery calcification;	chr19:37581427	chr19:37779686~37792865:+
BRCA	cis	rs7246657	0.663	rs4803276	ENSG00000267422.1	CTD-2554C21.1	-8.37	1.89e-16	6.57e-14	-0.37	-0.25	Coronary artery calcification;	chr19:37581429	chr19:37779686~37792865:+
BRCA	cis	rs7429990	0.833	rs3755637	ENSG00000229759.1	MRPS18AP1	-8.37	1.89e-16	6.57e-14	-0.28	-0.25	Educational attainment (years of education);	chr3:47580720	chr3:48256350~48256938:-
BRCA	cis	rs2933343	0.951	rs789251	ENSG00000261159.1	RP11-723O4.9	8.37	1.9e-16	6.57e-14	0.29	0.25	IgG glycosylation;	chr3:128857927	chr3:128859716~128860526:-
BRCA	cis	rs875971	1	rs778726	ENSG00000237310.1	GS1-124K5.4	8.37	1.9e-16	6.61e-14	0.26	0.25	Aortic root size;	chr7:66363744	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.767	rs1695815	ENSG00000237310.1	GS1-124K5.4	8.37	1.9e-16	6.61e-14	0.26	0.25	Aortic root size;	chr7:66366357	chr7:66493706~66495474:+
BRCA	cis	rs875971	1	rs778685	ENSG00000237310.1	GS1-124K5.4	8.37	1.9e-16	6.61e-14	0.26	0.25	Aortic root size;	chr7:66371189	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.929	rs778682	ENSG00000237310.1	GS1-124K5.4	8.37	1.9e-16	6.61e-14	0.26	0.25	Aortic root size;	chr7:66372947	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.964	rs11765965	ENSG00000237310.1	GS1-124K5.4	8.37	1.9e-16	6.61e-14	0.26	0.25	Aortic root size;	chr7:66377234	chr7:66493706~66495474:+
BRCA	cis	rs150992	0.568	rs34498	ENSG00000248489.1	CTD-2007H13.3	8.36	1.91e-16	6.63e-14	0.32	0.25	Body mass index;	chr5:98960690	chr5:98929171~98995013:+
BRCA	cis	rs6545883	0.929	rs10193666	ENSG00000271889.1	RP11-493E12.1	-8.36	1.91e-16	6.63e-14	-0.33	-0.25	Tuberculosis;	chr2:61402273	chr2:61151433~61162105:-
BRCA	cis	rs67311347	1	rs72861689	ENSG00000223797.4	ENTPD3-AS1	8.36	1.92e-16	6.65e-14	0.28	0.25	Renal cell carcinoma;	chr3:40394399	chr3:40313802~40453329:-
BRCA	cis	rs10463554	0.892	rs66505956	ENSG00000175749.11	EIF3KP1	8.36	1.92e-16	6.67e-14	0.34	0.25	Parkinson's disease;	chr5:102943853	chr5:103032376~103033031:+
BRCA	cis	rs4835473	0.831	rs7689328	ENSG00000251600.4	RP11-673E1.1	8.36	1.93e-16	6.68e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143973768	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.831	rs7694353	ENSG00000251600.4	RP11-673E1.1	8.36	1.93e-16	6.68e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143973787	chr4:143912331~143982454:+
BRCA	cis	rs765787	0.53	rs12323957	ENSG00000259520.4	CTD-2651B20.3	-8.36	1.93e-16	6.68e-14	-0.32	-0.25	Uric acid levels;	chr15:45198575	chr15:45251580~45279251:-
BRCA	cis	rs875971	0.545	rs4718325	ENSG00000222364.1	RNU6-96P	-8.36	1.93e-16	6.69e-14	-0.33	-0.25	Aortic root size;	chr7:66215323	chr7:66395191~66395286:+
BRCA	cis	rs5751614	0.577	rs2330369	ENSG00000230701.2	FBXW4P1	8.36	1.93e-16	6.69e-14	0.3	0.25	Height;	chr22:23265255	chr22:23262767~23265005:+
BRCA	cis	rs875971	1	rs2087647	ENSG00000237310.1	GS1-124K5.4	-8.36	1.93e-16	6.7e-14	-0.26	-0.25	Aortic root size;	chr7:66128201	chr7:66493706~66495474:+
BRCA	cis	rs7569084	0.687	rs1344891	ENSG00000204929.10	AC074391.1	8.36	1.93e-16	6.7e-14	0.34	0.25	Sum eosinophil basophil counts;	chr2:65458890	chr2:65436711~66084639:+
BRCA	cis	rs72627509	0.951	rs72606404	ENSG00000269949.1	RP11-738E22.3	8.36	1.94e-16	6.71e-14	0.39	0.25	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56975047	chr4:56960927~56961373:-
BRCA	cis	rs6142102	0.961	rs8123521	ENSG00000276073.1	RP5-1125A11.7	-8.36	1.94e-16	6.71e-14	-0.3	-0.25	Skin pigmentation;	chr20:34081079	chr20:33985617~33988989:-
BRCA	cis	rs1075265	0.73	rs4413193	ENSG00000233266.1	HMGB1P31	8.36	1.94e-16	6.73e-14	0.31	0.25	Chronotype;Morning vs. evening chronotype;	chr2:53710901	chr2:54051334~54051760:+
BRCA	cis	rs875971	0.502	rs11769702	ENSG00000222364.1	RNU6-96P	-8.36	1.94e-16	6.74e-14	-0.34	-0.25	Aortic root size;	chr7:66255529	chr7:66395191~66395286:+
BRCA	cis	rs10463554	0.927	rs34820	ENSG00000175749.11	EIF3KP1	8.36	1.95e-16	6.75e-14	0.34	0.25	Parkinson's disease;	chr5:103101164	chr5:103032376~103033031:+
BRCA	cis	rs2933343	1	rs2933343	ENSG00000261159.1	RP11-723O4.9	8.36	1.95e-16	6.75e-14	0.3	0.25	IgG glycosylation;	chr3:128939649	chr3:128859716~128860526:-
BRCA	cis	rs375066	0.935	rs4803662	ENSG00000267058.1	RP11-15A1.3	-8.36	1.95e-16	6.76e-14	-0.29	-0.25	Breast cancer;	chr19:43855412	chr19:43891804~43901805:-
BRCA	cis	rs875971	1	rs4718307	ENSG00000237310.1	GS1-124K5.4	-8.36	1.95e-16	6.76e-14	-0.26	-0.25	Aortic root size;	chr7:66146001	chr7:66493706~66495474:+
BRCA	cis	rs875971	1	rs7801282	ENSG00000237310.1	GS1-124K5.4	-8.36	1.95e-16	6.76e-14	-0.26	-0.25	Aortic root size;	chr7:66148700	chr7:66493706~66495474:+
BRCA	cis	rs8059260	0.604	rs9652600	ENSG00000274038.1	RP11-66H6.4	-8.36	1.96e-16	6.78e-14	-0.4	-0.25	Alcohol consumption over the past year;	chr16:11080157	chr16:11056556~11057034:+
BRCA	cis	rs375066	0.935	rs368089	ENSG00000267058.1	RP11-15A1.3	-8.36	1.96e-16	6.8e-14	-0.29	-0.25	Breast cancer;	chr19:43894932	chr19:43891804~43901805:-
BRCA	cis	rs77204473	0.744	rs17120344	ENSG00000254851.1	RP11-109L13.1	-8.36	1.97e-16	6.82e-14	-0.61	-0.25	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117125629	chr11:117135528~117138582:+
BRCA	cis	rs7246657	0.606	rs2972439	ENSG00000267422.1	CTD-2554C21.1	8.36	1.98e-16	6.86e-14	0.37	0.25	Coronary artery calcification;	chr19:37721680	chr19:37779686~37792865:+
BRCA	cis	rs7246657	0.722	rs2909100	ENSG00000267422.1	CTD-2554C21.1	8.36	1.98e-16	6.86e-14	0.37	0.25	Coronary artery calcification;	chr19:37721779	chr19:37779686~37792865:+
BRCA	cis	rs11098499	0.913	rs56122576	ENSG00000245958.5	RP11-33B1.1	-8.36	1.98e-16	6.86e-14	-0.26	-0.25	Corneal astigmatism;	chr4:119208181	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.874	rs6832670	ENSG00000245958.5	RP11-33B1.1	-8.36	1.98e-16	6.87e-14	-0.26	-0.25	Corneal astigmatism;	chr4:119197637	chr4:119454791~119552025:+
BRCA	cis	rs4727443	0.866	rs35228488	ENSG00000214313.7	AZGP1P1	-8.36	1.99e-16	6.89e-14	-0.26	-0.25	Interstitial lung disease;	chr7:100020229	chr7:99980762~99987535:+
BRCA	cis	rs8012947	0.545	rs1190980	ENSG00000279636.2	LINC00216	-8.36	2e-16	6.91e-14	-0.26	-0.25	Alcohol consumption in current drinkers;	chr14:58348088	chr14:58288033~58289158:+
BRCA	cis	rs4835473	0.639	rs5029916	ENSG00000251600.4	RP11-673E1.1	8.36	2e-16	6.94e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143990684	chr4:143912331~143982454:+
BRCA	cis	rs150992	0.603	rs161732	ENSG00000248489.1	CTD-2007H13.3	-8.36	2.01e-16	6.94e-14	-0.32	-0.25	Body mass index;	chr5:98941418	chr5:98929171~98995013:+
BRCA	cis	rs2439831	0.85	rs16977798	ENSG00000205771.5	CATSPER2P1	-8.36	2.01e-16	6.95e-14	-0.42	-0.25	Lung cancer in ever smokers;	chr15:43859750	chr15:43726918~43747094:-
BRCA	cis	rs12468226	0.938	rs57571703	ENSG00000273456.1	RP11-686O6.2	8.36	2.01e-16	6.95e-14	0.37	0.25	Urate levels;	chr2:202281997	chr2:202374932~202375604:-
BRCA	cis	rs12468226	0.938	rs77062060	ENSG00000273456.1	RP11-686O6.2	8.36	2.01e-16	6.95e-14	0.37	0.25	Urate levels;	chr2:202285639	chr2:202374932~202375604:-
BRCA	cis	rs4803480	0.543	rs7257282	ENSG00000270164.1	LINC01480	-8.36	2.02e-16	6.98e-14	-0.3	-0.25	Schizophrenia;	chr19:41536585	chr19:41535183~41536904:+
BRCA	cis	rs812925	0.559	rs2600667	ENSG00000271889.1	RP11-493E12.1	8.36	2.02e-16	6.98e-14	0.33	0.25	Immature fraction of reticulocytes;	chr2:61177796	chr2:61151433~61162105:-
BRCA	cis	rs9527	0.637	rs12219247	ENSG00000213061.2	PFN1P11	8.36	2.02e-16	6.99e-14	0.33	0.25	Arsenic metabolism;	chr10:102853604	chr10:102838011~102845473:-
BRCA	cis	rs6545883	0.826	rs777593	ENSG00000271889.1	RP11-493E12.1	8.36	2.02e-16	7e-14	0.33	0.25	Tuberculosis;	chr2:61191968	chr2:61151433~61162105:-
BRCA	cis	rs8012947	1	rs9743908	ENSG00000279636.2	LINC00216	-8.36	2.03e-16	7.01e-14	-0.28	-0.25	Alcohol consumption in current drinkers;	chr14:58256828	chr14:58288033~58289158:+
BRCA	cis	rs8030379	0.811	rs7162542	ENSG00000230373.7	GOLGA6L5P	-8.36	2.03e-16	7.02e-14	-0.27	-0.25	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83845538	chr15:84507885~84516814:-
BRCA	cis	rs7569084	0.663	rs11126037	ENSG00000204929.10	AC074391.1	8.36	2.03e-16	7.03e-14	0.34	0.25	Sum eosinophil basophil counts;	chr2:65436024	chr2:65436711~66084639:+
BRCA	cis	rs753274	0.562	rs888876	ENSG00000267147.2	CTC-548K16.1	8.36	2.03e-16	7.04e-14	0.28	0.25	Tumor necrosis factor beta levels;	chr19:14305981	chr19:14333743~14343916:+
BRCA	cis	rs17023223	0.537	rs17023171	ENSG00000231365.4	RP11-418J17.1	-8.36	2.04e-16	7.07e-14	-0.32	-0.25	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119050645	chr1:119140396~119275973:+
BRCA	cis	rs4835473	0.897	rs3874	ENSG00000251600.4	RP11-673E1.1	8.36	2.05e-16	7.09e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143968795	chr4:143912331~143982454:+
BRCA	cis	rs8012947	1	rs8009527	ENSG00000279636.2	LINC00216	-8.36	2.05e-16	7.09e-14	-0.28	-0.25	Alcohol consumption in current drinkers;	chr14:58285394	chr14:58288033~58289158:+
BRCA	cis	rs875971	0.964	rs1643388	ENSG00000237310.1	GS1-124K5.4	8.36	2.05e-16	7.1e-14	0.26	0.25	Aortic root size;	chr7:66379575	chr7:66493706~66495474:+
BRCA	cis	rs875971	1	rs778722	ENSG00000237310.1	GS1-124K5.4	8.36	2.05e-16	7.1e-14	0.26	0.25	Aortic root size;	chr7:66379841	chr7:66493706~66495474:+
BRCA	cis	rs2933343	0.903	rs2638846	ENSG00000261159.1	RP11-723O4.9	8.36	2.05e-16	7.1e-14	0.29	0.25	IgG glycosylation;	chr3:128868320	chr3:128859716~128860526:-
BRCA	cis	rs858239	0.601	rs929507	ENSG00000230042.1	AK3P3	-8.36	2.06e-16	7.11e-14	-0.28	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23127045	chr7:23129178~23129841:+
BRCA	cis	rs858239	0.601	rs929508	ENSG00000230042.1	AK3P3	-8.36	2.06e-16	7.11e-14	-0.28	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23127090	chr7:23129178~23129841:+
BRCA	cis	rs10740039	0.671	rs7919726	ENSG00000254271.1	RP11-131N11.4	8.36	2.06e-16	7.11e-14	0.33	0.25	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60689748	chr10:60734342~60741828:+
BRCA	cis	rs1707322	0.964	rs10437063	ENSG00000280836.1	AL355480.1	-8.36	2.06e-16	7.12e-14	-0.32	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45807994	chr1:45581219~45581321:-
BRCA	cis	rs1707322	1	rs6676982	ENSG00000280836.1	AL355480.1	-8.36	2.06e-16	7.12e-14	-0.32	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45809729	chr1:45581219~45581321:-
BRCA	cis	rs11191419	1	rs11191419	ENSG00000213061.2	PFN1P11	8.36	2.06e-16	7.13e-14	0.33	0.25	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr10:102852578	chr10:102838011~102845473:-
BRCA	cis	rs12468226	0.938	rs76658848	ENSG00000273456.1	RP11-686O6.2	8.36	2.07e-16	7.15e-14	0.37	0.25	Urate levels;	chr2:202275548	chr2:202374932~202375604:-
BRCA	cis	rs367615	0.959	rs4957830	ENSG00000249476.1	CTD-2587M2.1	8.35	2.07e-16	7.15e-14	0.32	0.25	Colorectal cancer (SNP x SNP interaction);	chr5:109576057	chr5:109237120~109326369:-
BRCA	cis	rs4948102	0.595	rs7793921	ENSG00000226278.1	PSPHP1	-8.35	2.07e-16	7.16e-14	-0.27	-0.25	Plasma homocysteine levels (post-methionine load test);	chr7:56053188	chr7:55764797~55773288:+
BRCA	cis	rs875971	0.964	rs55748098	ENSG00000237310.1	GS1-124K5.4	-8.35	2.08e-16	7.18e-14	-0.26	-0.25	Aortic root size;	chr7:66298631	chr7:66493706~66495474:+
BRCA	cis	rs875971	1	rs6958484	ENSG00000237310.1	GS1-124K5.4	-8.35	2.09e-16	7.21e-14	-0.26	-0.25	Aortic root size;	chr7:66134459	chr7:66493706~66495474:+
BRCA	cis	rs7131987	0.565	rs7137141	ENSG00000257176.2	RP11-996F15.2	8.35	2.09e-16	7.22e-14	0.29	0.25	QT interval;	chr12:29272168	chr12:29280418~29317848:-
BRCA	cis	rs1113500	0.73	rs1618693	ENSG00000226822.1	RP11-356N1.2	-8.35	2.09e-16	7.22e-14	-0.32	-0.25	Growth-regulated protein alpha levels;	chr1:108048961	chr1:108071482~108074519:+
BRCA	cis	rs1113500	0.698	rs1781078	ENSG00000226822.1	RP11-356N1.2	-8.35	2.09e-16	7.22e-14	-0.32	-0.25	Growth-regulated protein alpha levels;	chr1:108049020	chr1:108071482~108074519:+
BRCA	cis	rs9543976	0.557	rs6562916	ENSG00000261553.4	RP11-29G8.3	8.35	2.09e-16	7.23e-14	0.4	0.25	Diabetic retinopathy;	chr13:75597086	chr13:75549773~75807120:+
BRCA	cis	rs9543976	0.623	rs4885322	ENSG00000261553.4	RP11-29G8.3	8.35	2.09e-16	7.23e-14	0.4	0.25	Diabetic retinopathy;	chr13:75597195	chr13:75549773~75807120:+
BRCA	cis	rs113835537	0.529	rs2277302	ENSG00000255517.5	CTD-3074O7.5	-8.35	2.09e-16	7.23e-14	-0.32	-0.25	Airway imaging phenotypes;	chr11:66473411	chr11:66473490~66480233:-
BRCA	cis	rs875971	1	rs6961717	ENSG00000237310.1	GS1-124K5.4	-8.35	2.1e-16	7.27e-14	-0.26	-0.25	Aortic root size;	chr7:66122550	chr7:66493706~66495474:+
BRCA	cis	rs11098499	0.535	rs7671759	ENSG00000245958.5	RP11-33B1.1	-8.35	2.1e-16	7.27e-14	-0.24	-0.25	Corneal astigmatism;	chr4:119326939	chr4:119454791~119552025:+
BRCA	cis	rs524281	0.638	rs4261293	ENSG00000255320.1	RP11-755F10.1	-8.35	2.11e-16	7.27e-14	-0.41	-0.25	Electroencephalogram traits;	chr11:66037664	chr11:66244840~66246239:-
BRCA	cis	rs6142102	0.961	rs6059587	ENSG00000276073.1	RP5-1125A11.7	-8.35	2.11e-16	7.28e-14	-0.31	-0.25	Skin pigmentation;	chr20:33955120	chr20:33985617~33988989:-
BRCA	cis	rs4727443	0.866	rs6963345	ENSG00000214313.7	AZGP1P1	-8.35	2.11e-16	7.29e-14	-0.26	-0.25	Interstitial lung disease;	chr7:100020983	chr7:99980762~99987535:+
BRCA	cis	rs4835473	0.932	rs6826862	ENSG00000251600.4	RP11-673E1.1	8.35	2.11e-16	7.29e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143978180	chr4:143912331~143982454:+
BRCA	cis	rs8059260	0.544	rs16958051	ENSG00000274038.1	RP11-66H6.4	8.35	2.11e-16	7.3e-14	0.37	0.25	Alcohol consumption over the past year;	chr16:11097362	chr16:11056556~11057034:+
BRCA	cis	rs113835537	0.529	rs11227511	ENSG00000255517.5	CTD-3074O7.5	-8.35	2.11e-16	7.3e-14	-0.32	-0.25	Airway imaging phenotypes;	chr11:66513773	chr11:66473490~66480233:-
BRCA	cis	rs11098499	0.82	rs28394116	ENSG00000248280.1	RP11-33B1.2	8.35	2.12e-16	7.32e-14	0.26	0.25	Corneal astigmatism;	chr4:119603128	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.954	rs10034623	ENSG00000248280.1	RP11-33B1.2	8.35	2.12e-16	7.33e-14	0.25	0.25	Corneal astigmatism;	chr4:119476674	chr4:119440561~119450157:-
BRCA	cis	rs9907295	0.688	rs2526327	ENSG00000270977.1	AC015849.16	8.35	2.12e-16	7.33e-14	0.34	0.25	Fibroblast growth factor basic levels;	chr17:35929902	chr17:35893707~35911023:-
BRCA	cis	rs321358	0.731	rs555063	ENSG00000271584.1	RP11-89C3.4	8.35	2.13e-16	7.36e-14	0.34	0.25	Body mass index;	chr11:111168621	chr11:111091932~111097357:-
BRCA	cis	rs875971	1	rs10257427	ENSG00000237310.1	GS1-124K5.4	-8.35	2.13e-16	7.36e-14	-0.26	-0.25	Aortic root size;	chr7:66278221	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.964	rs778721	ENSG00000237310.1	GS1-124K5.4	8.35	2.13e-16	7.36e-14	0.26	0.25	Aortic root size;	chr7:66380410	chr7:66493706~66495474:+
BRCA	cis	rs1075265	0.611	rs3770403	ENSG00000233266.1	HMGB1P31	8.35	2.14e-16	7.39e-14	0.31	0.25	Chronotype;Morning vs. evening chronotype;	chr2:53695688	chr2:54051334~54051760:+
BRCA	cis	rs1707322	1	rs4390216	ENSG00000280836.1	AL355480.1	-8.35	2.14e-16	7.39e-14	-0.32	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45800784	chr1:45581219~45581321:-
BRCA	cis	rs1707322	1	rs785486	ENSG00000280836.1	AL355480.1	8.35	2.14e-16	7.4e-14	0.32	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46109476	chr1:45581219~45581321:-
BRCA	cis	rs17023223	0.537	rs1343723	ENSG00000231365.4	RP11-418J17.1	-8.35	2.14e-16	7.4e-14	-0.31	-0.25	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119062431	chr1:119140396~119275973:+
BRCA	cis	rs1707322	1	rs785504	ENSG00000280836.1	AL355480.1	8.35	2.15e-16	7.41e-14	0.32	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46130024	chr1:45581219~45581321:-
BRCA	cis	rs4964805	0.913	rs7134701	ENSG00000257681.1	RP11-341G23.4	8.35	2.15e-16	7.42e-14	0.31	0.25	Attention deficit hyperactivity disorder;	chr12:103808913	chr12:103746315~103768858:-
BRCA	cis	rs10129255	0.5	rs1024350	ENSG00000280411.1	IGHV1-69-2	-8.35	2.16e-16	7.44e-14	-0.17	-0.25	Kawasaki disease;	chr14:106685105	chr14:106762092~106762588:-
BRCA	cis	rs6472827	0.645	rs2936683	ENSG00000253983.2	RP1-16A9.1	8.35	2.16e-16	7.45e-14	0.34	0.25	Uterine fibroids;	chr8:74201004	chr8:74199396~74208441:+
BRCA	cis	rs6472827	0.645	rs16836	ENSG00000253983.2	RP1-16A9.1	8.35	2.16e-16	7.45e-14	0.34	0.25	Uterine fibroids;	chr8:74201827	chr8:74199396~74208441:+
BRCA	cis	rs11098499	0.71	rs6851130	ENSG00000245958.5	RP11-33B1.1	8.35	2.17e-16	7.47e-14	0.25	0.25	Corneal astigmatism;	chr4:119212557	chr4:119454791~119552025:+
BRCA	cis	rs35160687	0.623	rs2276625	ENSG00000273080.1	RP11-301O19.1	8.35	2.17e-16	7.47e-14	0.29	0.25	Night sleep phenotypes;	chr2:86254712	chr2:86195590~86196049:+
BRCA	cis	rs2115630	1	rs2879828	ENSG00000225151.9	GOLGA2P7	8.35	2.17e-16	7.48e-14	0.27	0.25	P wave terminal force;	chr15:84818746	chr15:84199311~84230136:-
BRCA	cis	rs1134634	0.52	rs741180	ENSG00000273133.1	RP11-799M12.2	-8.35	2.17e-16	7.5e-14	-0.32	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15561787	chr4:15563698~15564253:-
BRCA	cis	rs875971	0.52	rs160645	ENSG00000164669.11	INTS4P1	8.35	2.18e-16	7.51e-14	0.35	0.25	Aortic root size;	chr7:66091320	chr7:65141225~65234216:+
BRCA	cis	rs7772486	0.875	rs932522	ENSG00000235652.6	RP11-545I5.3	-8.35	2.18e-16	7.52e-14	-0.25	-0.25	Lobe attachment (rater-scored or self-reported);	chr6:146052890	chr6:145799409~145886585:+
BRCA	cis	rs4835473	0.742	rs1838519	ENSG00000251600.4	RP11-673E1.1	8.35	2.18e-16	7.53e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143972242	chr4:143912331~143982454:+
BRCA	cis	rs6142102	0.923	rs4911379	ENSG00000276073.1	RP5-1125A11.7	-8.35	2.2e-16	7.59e-14	-0.3	-0.25	Skin pigmentation;	chr20:33947499	chr20:33985617~33988989:-
BRCA	cis	rs6539288	0.933	rs10746070	ENSG00000260329.1	RP11-412D9.4	-8.35	2.2e-16	7.59e-14	-0.29	-0.25	Total body bone mineral density;	chr12:106910681	chr12:106954029~106955497:-
BRCA	cis	rs807029	0.577	rs11190786	ENSG00000272572.1	RP11-179B2.2	-8.35	2.2e-16	7.6e-14	-0.32	-0.25	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100997685	chr10:100911103~100912739:-
BRCA	cis	rs807029	0.577	rs7902510	ENSG00000272572.1	RP11-179B2.2	-8.35	2.2e-16	7.6e-14	-0.32	-0.25	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100998177	chr10:100911103~100912739:-
BRCA	cis	rs807029	0.577	rs7903239	ENSG00000272572.1	RP11-179B2.2	-8.35	2.2e-16	7.6e-14	-0.32	-0.25	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100998580	chr10:100911103~100912739:-
BRCA	cis	rs2117029	1	rs11168827	ENSG00000258017.1	RP11-386G11.10	8.35	2.2e-16	7.6e-14	0.34	0.25	Intelligence (multi-trait analysis);	chr12:49025894	chr12:49127782~49147869:+
BRCA	cis	rs7674212	0.581	rs13150953	ENSG00000246560.2	RP11-10L12.4	8.35	2.21e-16	7.63e-14	0.27	0.25	Type 2 diabetes;	chr4:103021341	chr4:102828055~102844075:+
BRCA	cis	rs7674212	0.556	rs13151569	ENSG00000246560.2	RP11-10L12.4	8.35	2.21e-16	7.63e-14	0.27	0.25	Type 2 diabetes;	chr4:103021633	chr4:102828055~102844075:+
BRCA	cis	rs950880	0.71	rs4851570	ENSG00000234389.1	AC007278.3	-8.35	2.23e-16	7.67e-14	-0.25	-0.25	Serum protein levels (sST2);	chr2:102389927	chr2:102438713~102440475:+
BRCA	cis	rs58873874	0.579	rs80253028	ENSG00000251405.2	CTB-109A12.1	8.35	2.23e-16	7.68e-14	0.55	0.25	Bipolar disorder (body mass index interaction);	chr5:157340020	chr5:157362615~157460078:-
BRCA	cis	rs4718428	0.705	rs2901311	ENSG00000232546.1	RP11-458F8.1	-8.35	2.23e-16	7.7e-14	-0.24	-0.25	Corneal structure;	chr7:66950082	chr7:66848496~66858136:+
BRCA	cis	rs2933343	1	rs789213	ENSG00000261159.1	RP11-723O4.9	-8.35	2.24e-16	7.71e-14	-0.29	-0.25	IgG glycosylation;	chr3:128897516	chr3:128859716~128860526:-
BRCA	cis	rs950880	0.71	rs11678975	ENSG00000234389.1	AC007278.3	-8.35	2.24e-16	7.71e-14	-0.26	-0.25	Serum protein levels (sST2);	chr2:102427279	chr2:102438713~102440475:+
BRCA	cis	rs17023223	0.537	rs12086549	ENSG00000231365.4	RP11-418J17.1	8.35	2.24e-16	7.72e-14	0.33	0.25	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119071714	chr1:119140396~119275973:+
BRCA	cis	rs4835473	0.932	rs34617134	ENSG00000251600.4	RP11-673E1.1	8.34	2.24e-16	7.73e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143983606	chr4:143912331~143982454:+
BRCA	cis	rs875971	0.965	rs9969301	ENSG00000237310.1	GS1-124K5.4	-8.34	2.25e-16	7.75e-14	-0.26	-0.25	Aortic root size;	chr7:66316668	chr7:66493706~66495474:+
BRCA	cis	rs375066	0.935	rs422457	ENSG00000267058.1	RP11-15A1.3	-8.34	2.25e-16	7.76e-14	-0.29	-0.25	Breast cancer;	chr19:43905259	chr19:43891804~43901805:-
BRCA	cis	rs11098499	0.863	rs1552095	ENSG00000245958.5	RP11-33B1.1	-8.34	2.25e-16	7.76e-14	-0.25	-0.25	Corneal astigmatism;	chr4:119539151	chr4:119454791~119552025:+
BRCA	cis	rs1140227	0.502	rs10789304	ENSG00000235358.1	RP11-399E6.1	8.34	2.25e-16	7.76e-14	0.37	0.25	Intelligence (multi-trait analysis);	chr1:41121740	chr1:41242373~41284861:+
BRCA	cis	rs73186030	0.546	rs73188388	ENSG00000272758.4	RP11-299J3.8	8.34	2.26e-16	7.8e-14	0.35	0.25	Serum parathyroid hormone levels;	chr3:122399229	chr3:122416207~122443180:+
BRCA	cis	rs10510102	0.872	rs12258234	ENSG00000276742.1	RP11-500G22.4	8.34	2.27e-16	7.8e-14	0.43	0.25	Breast cancer;	chr10:121952828	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.515	rs11200285	ENSG00000276742.1	RP11-500G22.4	8.34	2.27e-16	7.8e-14	0.43	0.25	Breast cancer;	chr10:121953931	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.872	rs75831447	ENSG00000276742.1	RP11-500G22.4	8.34	2.27e-16	7.8e-14	0.43	0.25	Breast cancer;	chr10:121953963	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.63	rs79960726	ENSG00000276742.1	RP11-500G22.4	8.34	2.27e-16	7.8e-14	0.43	0.25	Breast cancer;	chr10:121954358	chr10:121956782~121957098:+
BRCA	cis	rs7811142	0.83	rs78256546	ENSG00000242294.5	STAG3L5P	8.34	2.27e-16	7.8e-14	0.25	0.25	Platelet count;	chr7:100355347	chr7:100336079~100351900:+
BRCA	cis	rs4862750	0.872	rs4862748	ENSG00000250971.1	RP11-696F12.1	-8.34	2.27e-16	7.81e-14	-0.26	-0.25	Lobe attachment (rater-scored or self-reported);	chr4:186956234	chr4:187060099~187060930:+
BRCA	cis	rs11098499	0.909	rs10020034	ENSG00000248280.1	RP11-33B1.2	8.34	2.27e-16	7.82e-14	0.26	0.25	Corneal astigmatism;	chr4:119373176	chr4:119440561~119450157:-
BRCA	cis	rs4835473	0.932	rs28377887	ENSG00000251600.4	RP11-673E1.1	8.34	2.27e-16	7.83e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143977075	chr4:143912331~143982454:+
BRCA	cis	rs1075265	0.756	rs2542576	ENSG00000233266.1	HMGB1P31	8.34	2.27e-16	7.83e-14	0.3	0.25	Chronotype;Morning vs. evening chronotype;	chr2:53821659	chr2:54051334~54051760:+
BRCA	cis	rs1874124	0.577	rs2807880	ENSG00000257551.1	HLX-AS1	8.34	2.28e-16	7.84e-14	0.36	0.25	Cholesterol, total;	chr1:220869661	chr1:220832763~220880140:-
BRCA	cis	rs875971	0.522	rs2008188	ENSG00000222364.1	RNU6-96P	-8.34	2.28e-16	7.84e-14	-0.29	-0.25	Aortic root size;	chr7:65964026	chr7:66395191~66395286:+
BRCA	cis	rs17023223	0.537	rs1057991	ENSG00000231365.4	RP11-418J17.1	-8.34	2.28e-16	7.84e-14	-0.32	-0.25	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119032547	chr1:119140396~119275973:+
BRCA	cis	rs17023223	0.537	rs1057990	ENSG00000231365.4	RP11-418J17.1	-8.34	2.28e-16	7.84e-14	-0.32	-0.25	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119032609	chr1:119140396~119275973:+
BRCA	cis	rs4835473	0.932	rs6847869	ENSG00000251600.4	RP11-673E1.1	8.34	2.28e-16	7.84e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143982881	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.897	rs6846984	ENSG00000251600.4	RP11-673E1.1	8.34	2.28e-16	7.84e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143983098	chr4:143912331~143982454:+
BRCA	cis	rs6472827	0.645	rs7009750	ENSG00000253983.2	RP1-16A9.1	8.34	2.28e-16	7.85e-14	0.34	0.25	Uterine fibroids;	chr8:74199894	chr8:74199396~74208441:+
BRCA	cis	rs11098499	0.739	rs9884728	ENSG00000245958.5	RP11-33B1.1	8.34	2.29e-16	7.87e-14	0.25	0.25	Corneal astigmatism;	chr4:119205924	chr4:119454791~119552025:+
BRCA	cis	rs113835537	0.529	rs57634456	ENSG00000255517.5	CTD-3074O7.5	-8.34	2.29e-16	7.9e-14	-0.33	-0.25	Airway imaging phenotypes;	chr11:66483367	chr11:66473490~66480233:-
BRCA	cis	rs875971	1	rs10215948	ENSG00000237310.1	GS1-124K5.4	-8.34	2.3e-16	7.9e-14	-0.26	-0.25	Aortic root size;	chr7:66282799	chr7:66493706~66495474:+
BRCA	cis	rs860818	0.557	rs2178138	ENSG00000226816.2	AC005082.12	-8.34	2.3e-16	7.91e-14	-0.57	-0.25	Initial pursuit acceleration;	chr7:23154414	chr7:23206013~23208045:+
BRCA	cis	rs860818	0.793	rs1358441	ENSG00000226816.2	AC005082.12	-8.34	2.3e-16	7.91e-14	-0.57	-0.25	Initial pursuit acceleration;	chr7:23154850	chr7:23206013~23208045:+
BRCA	cis	rs860818	0.557	rs6961136	ENSG00000226816.2	AC005082.12	-8.34	2.3e-16	7.91e-14	-0.57	-0.25	Initial pursuit acceleration;	chr7:23155343	chr7:23206013~23208045:+
BRCA	cis	rs860818	0.793	rs12700418	ENSG00000226816.2	AC005082.12	-8.34	2.3e-16	7.91e-14	-0.57	-0.25	Initial pursuit acceleration;	chr7:23155701	chr7:23206013~23208045:+
BRCA	cis	rs860818	0.793	rs6966420	ENSG00000226816.2	AC005082.12	-8.34	2.3e-16	7.91e-14	-0.57	-0.25	Initial pursuit acceleration;	chr7:23156346	chr7:23206013~23208045:+
BRCA	cis	rs860818	0.793	rs4722227	ENSG00000226816.2	AC005082.12	-8.34	2.3e-16	7.91e-14	-0.57	-0.25	Initial pursuit acceleration;	chr7:23156399	chr7:23206013~23208045:+
BRCA	cis	rs860818	0.793	rs6966929	ENSG00000226816.2	AC005082.12	-8.34	2.3e-16	7.91e-14	-0.57	-0.25	Initial pursuit acceleration;	chr7:23156455	chr7:23206013~23208045:+
BRCA	cis	rs860818	0.546	rs4722228	ENSG00000226816.2	AC005082.12	-8.34	2.3e-16	7.91e-14	-0.57	-0.25	Initial pursuit acceleration;	chr7:23156479	chr7:23206013~23208045:+
BRCA	cis	rs860818	0.793	rs4722229	ENSG00000226816.2	AC005082.12	-8.34	2.3e-16	7.91e-14	-0.57	-0.25	Initial pursuit acceleration;	chr7:23156485	chr7:23206013~23208045:+
BRCA	cis	rs860818	0.793	rs4722230	ENSG00000226816.2	AC005082.12	-8.34	2.3e-16	7.91e-14	-0.57	-0.25	Initial pursuit acceleration;	chr7:23157572	chr7:23206013~23208045:+
BRCA	cis	rs11098499	0.874	rs10022508	ENSG00000245958.5	RP11-33B1.1	-8.34	2.3e-16	7.93e-14	-0.26	-0.25	Corneal astigmatism;	chr4:119194073	chr4:119454791~119552025:+
BRCA	cis	rs72627509	0.904	rs17081933	ENSG00000269949.1	RP11-738E22.3	8.34	2.31e-16	7.95e-14	0.38	0.25	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56956703	chr4:56960927~56961373:-
BRCA	cis	rs673078	0.66	rs61945176	ENSG00000275759.1	RP11-131L12.3	-8.34	2.31e-16	7.96e-14	-0.35	-0.25	Glucose homeostasis traits;	chr12:118204735	chr12:118428281~118428870:+
BRCA	cis	rs17711722	0.727	rs1880555	ENSG00000222364.1	RNU6-96P	-8.34	2.31e-16	7.97e-14	-0.29	-0.25	Calcium levels;	chr7:65967580	chr7:66395191~66395286:+
BRCA	cis	rs73219805	1	rs17310286	ENSG00000228451.3	SDAD1P1	8.34	2.33e-16	8.01e-14	0.34	0.25	Schizophrenia;	chr8:26411516	chr8:26379259~26382953:-
BRCA	cis	rs11971779	0.838	rs11764161	ENSG00000273391.1	RP11-634H22.1	8.34	2.34e-16	8.04e-14	0.27	0.25	Diisocyanate-induced asthma;	chr7:139430452	chr7:139359032~139359566:-
BRCA	cis	rs4934494	0.911	rs6586213	ENSG00000240996.1	RP11-80H5.7	-8.34	2.35e-16	8.07e-14	-0.3	-0.25	Red blood cell count;	chr10:89656327	chr10:89694295~89697928:-
BRCA	cis	rs11098499	0.754	rs10518300	ENSG00000245958.5	RP11-33B1.1	8.34	2.35e-16	8.09e-14	0.24	0.25	Corneal astigmatism;	chr4:119328344	chr4:119454791~119552025:+
BRCA	cis	rs6142102	0.602	rs4911380	ENSG00000275784.1	RP5-1125A11.6	-8.34	2.36e-16	8.11e-14	-0.29	-0.25	Skin pigmentation;	chr20:33958418	chr20:33989480~33991818:-
BRCA	cis	rs10129255	0.912	rs61997792	ENSG00000223648.3	IGHV3-64	8.34	2.36e-16	8.12e-14	0.22	0.25	Kawasaki disease;	chr14:106799304	chr14:106643132~106658258:-
BRCA	cis	rs113835537	0.529	rs11227500	ENSG00000255517.5	CTD-3074O7.5	-8.34	2.37e-16	8.14e-14	-0.32	-0.25	Airway imaging phenotypes;	chr11:66505762	chr11:66473490~66480233:-
BRCA	cis	rs7246657	0.722	rs1531549	ENSG00000267422.1	CTD-2554C21.1	-8.34	2.37e-16	8.15e-14	-0.37	-0.25	Coronary artery calcification;	chr19:37597108	chr19:37779686~37792865:+
BRCA	cis	rs1134634	0.52	rs16892152	ENSG00000273133.1	RP11-799M12.2	-8.34	2.38e-16	8.17e-14	-0.34	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15559630	chr4:15563698~15564253:-
BRCA	cis	rs10129255	0.957	rs12589190	ENSG00000223648.3	IGHV3-64	8.34	2.38e-16	8.18e-14	0.21	0.25	Kawasaki disease;	chr14:106783079	chr14:106643132~106658258:-
BRCA	cis	rs202072	0.72	rs1550526	ENSG00000272379.1	RP1-257A7.5	8.34	2.38e-16	8.18e-14	0.44	0.25	HIV-1 viral setpoint;	chr6:13295283	chr6:13290018~13290490:-
BRCA	cis	rs375066	0.934	rs411803	ENSG00000267058.1	RP11-15A1.3	8.34	2.39e-16	8.21e-14	0.28	0.25	Breast cancer;	chr19:43928688	chr19:43891804~43901805:-
BRCA	cis	rs875971	0.522	rs10807697	ENSG00000222364.1	RNU6-96P	-8.34	2.39e-16	8.21e-14	-0.29	-0.25	Aortic root size;	chr7:65951183	chr7:66395191~66395286:+
BRCA	cis	rs8072100	0.902	rs12051716	ENSG00000228782.6	CTD-2026D20.3	-8.34	2.39e-16	8.23e-14	-0.27	-0.25	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47505029	chr17:47450568~47492492:-
BRCA	cis	rs6921919	0.945	rs61289879	ENSG00000216901.1	AL022393.7	8.34	2.4e-16	8.23e-14	0.39	0.25	Autism spectrum disorder or schizophrenia;	chr6:28451385	chr6:28176188~28176674:+
BRCA	cis	rs67981189	0.57	rs67188216	ENSG00000269927.1	RP6-91H8.3	8.34	2.4e-16	8.23e-14	0.33	0.25	Schizophrenia;	chr14:71042607	chr14:71141125~71143253:-
BRCA	cis	rs6545883	0.929	rs10200055	ENSG00000271889.1	RP11-493E12.1	-8.34	2.4e-16	8.24e-14	-0.32	-0.25	Tuberculosis;	chr2:61400882	chr2:61151433~61162105:-
BRCA	cis	rs526231	0.543	rs34832	ENSG00000175749.11	EIF3KP1	8.34	2.4e-16	8.26e-14	0.37	0.25	Primary biliary cholangitis;	chr5:103108891	chr5:103032376~103033031:+
BRCA	cis	rs1707322	0.963	rs12022335	ENSG00000280836.1	AL355480.1	-8.34	2.41e-16	8.27e-14	-0.32	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45937060	chr1:45581219~45581321:-
BRCA	cis	rs9543976	0.623	rs4885323	ENSG00000261553.4	RP11-29G8.3	8.34	2.41e-16	8.27e-14	0.39	0.25	Diabetic retinopathy;	chr13:75598278	chr13:75549773~75807120:+
BRCA	cis	rs1707322	1	rs4660906	ENSG00000280836.1	AL355480.1	-8.34	2.41e-16	8.28e-14	-0.32	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46005188	chr1:45581219~45581321:-
BRCA	cis	rs875971	0.545	rs313828	ENSG00000164669.11	INTS4P1	8.34	2.42e-16	8.3e-14	0.35	0.25	Aortic root size;	chr7:66087627	chr7:65141225~65234216:+
BRCA	cis	rs4934494	0.911	rs7081788	ENSG00000240996.1	RP11-80H5.7	-8.34	2.42e-16	8.3e-14	-0.29	-0.25	Red blood cell count;	chr10:89648999	chr10:89694295~89697928:-
BRCA	cis	rs801193	0.839	rs12534943	ENSG00000237310.1	GS1-124K5.4	-8.34	2.42e-16	8.31e-14	-0.26	-0.25	Aortic root size;	chr7:66605533	chr7:66493706~66495474:+
BRCA	cis	rs858239	0.539	rs10280815	ENSG00000226816.2	AC005082.12	8.34	2.42e-16	8.31e-14	0.29	0.25	Cerebrospinal fluid biomarker levels;	chr7:23148751	chr7:23206013~23208045:+
BRCA	cis	rs858239	0.539	rs10225608	ENSG00000226816.2	AC005082.12	8.34	2.42e-16	8.31e-14	0.29	0.25	Cerebrospinal fluid biomarker levels;	chr7:23149289	chr7:23206013~23208045:+
BRCA	cis	rs11098499	0.874	rs17839089	ENSG00000245958.5	RP11-33B1.1	-8.34	2.42e-16	8.32e-14	-0.26	-0.25	Corneal astigmatism;	chr4:119189914	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.874	rs6826823	ENSG00000245958.5	RP11-33B1.1	-8.34	2.42e-16	8.32e-14	-0.26	-0.25	Corneal astigmatism;	chr4:119190943	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.874	rs12509054	ENSG00000245958.5	RP11-33B1.1	-8.34	2.42e-16	8.32e-14	-0.26	-0.25	Corneal astigmatism;	chr4:119193920	chr4:119454791~119552025:+
BRCA	cis	rs375066	0.901	rs1050054	ENSG00000267058.1	RP11-15A1.3	-8.33	2.43e-16	8.34e-14	-0.28	-0.25	Breast cancer;	chr19:43872529	chr19:43891804~43901805:-
BRCA	cis	rs1823913	0.927	rs13013390	ENSG00000280083.1	RP11-317J9.1	-8.33	2.43e-16	8.36e-14	-0.29	-0.25	Obesity-related traits;	chr2:191262001	chr2:191154118~191156070:-
BRCA	cis	rs30380	1	rs27710	ENSG00000248734.2	CTD-2260A17.1	-8.33	2.44e-16	8.36e-14	-0.26	-0.25	Cerebrospinal fluid biomarker levels;	chr5:96790494	chr5:96784777~96785999:+
BRCA	cis	rs875971	0.965	rs10267430	ENSG00000237310.1	GS1-124K5.4	-8.33	2.44e-16	8.38e-14	-0.26	-0.25	Aortic root size;	chr7:66278036	chr7:66493706~66495474:+
BRCA	cis	rs6142102	0.625	rs9753690	ENSG00000275784.1	RP5-1125A11.6	-8.33	2.45e-16	8.42e-14	-0.29	-0.25	Skin pigmentation;	chr20:33952995	chr20:33989480~33991818:-
BRCA	cis	rs11673344	0.764	rs569371	ENSG00000226686.6	LINC01535	8.33	2.46e-16	8.44e-14	0.32	0.25	Obesity-related traits;	chr19:36963095	chr19:37251912~37265535:+
BRCA	cis	rs375066	0.935	rs384522	ENSG00000267058.1	RP11-15A1.3	-8.33	2.46e-16	8.45e-14	-0.28	-0.25	Breast cancer;	chr19:43900892	chr19:43891804~43901805:-
BRCA	cis	rs6545883	0.86	rs6545847	ENSG00000271889.1	RP11-493E12.1	-8.33	2.47e-16	8.48e-14	-0.32	-0.25	Tuberculosis;	chr2:61218198	chr2:61151433~61162105:-
BRCA	cis	rs801193	0.844	rs2244022	ENSG00000237310.1	GS1-124K5.4	8.33	2.48e-16	8.5e-14	0.26	0.25	Aortic root size;	chr7:66737443	chr7:66493706~66495474:+
BRCA	cis	rs4835473	0.932	rs1511425	ENSG00000251600.4	RP11-673E1.1	8.33	2.48e-16	8.5e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143985122	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs1849120	ENSG00000251600.4	RP11-673E1.1	8.33	2.48e-16	8.5e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143985337	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs4835476	ENSG00000251600.4	RP11-673E1.1	8.33	2.48e-16	8.5e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143985517	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs1828502	ENSG00000251600.4	RP11-673E1.1	8.33	2.48e-16	8.5e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143985797	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs7668698	ENSG00000251600.4	RP11-673E1.1	8.33	2.48e-16	8.5e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143986333	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs6537231	ENSG00000251600.4	RP11-673E1.1	8.33	2.48e-16	8.5e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143986489	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs1877234	ENSG00000251600.4	RP11-673E1.1	8.33	2.48e-16	8.5e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143986774	chr4:143912331~143982454:+
BRCA	cis	rs11098499	1	rs13116504	ENSG00000245958.5	RP11-33B1.1	-8.33	2.49e-16	8.53e-14	-0.25	-0.25	Corneal astigmatism;	chr4:119288257	chr4:119454791~119552025:+
BRCA	cis	rs375066	0.869	rs379785	ENSG00000267058.1	RP11-15A1.3	-8.33	2.5e-16	8.56e-14	-0.28	-0.25	Breast cancer;	chr19:43923949	chr19:43891804~43901805:-
BRCA	cis	rs7429990	0.864	rs13091913	ENSG00000229759.1	MRPS18AP1	-8.33	2.5e-16	8.56e-14	-0.28	-0.25	Educational attainment (years of education);	chr3:47762307	chr3:48256350~48256938:-
BRCA	cis	rs10129255	0.957	rs7493713	ENSG00000223648.3	IGHV3-64	8.33	2.51e-16	8.6e-14	0.21	0.25	Kawasaki disease;	chr14:106783685	chr14:106643132~106658258:-
BRCA	cis	rs10129255	0.912	rs35468694	ENSG00000223648.3	IGHV3-64	8.33	2.51e-16	8.6e-14	0.21	0.25	Kawasaki disease;	chr14:106784199	chr14:106643132~106658258:-
BRCA	cis	rs375066	0.935	rs398964	ENSG00000267058.1	RP11-15A1.3	-8.33	2.51e-16	8.6e-14	-0.28	-0.25	Breast cancer;	chr19:43909732	chr19:43891804~43901805:-
BRCA	cis	rs375066	0.901	rs372491	ENSG00000267058.1	RP11-15A1.3	-8.33	2.51e-16	8.6e-14	-0.28	-0.25	Breast cancer;	chr19:43897641	chr19:43891804~43901805:-
BRCA	cis	rs375066	0.868	rs453950	ENSG00000267058.1	RP11-15A1.3	-8.33	2.51e-16	8.6e-14	-0.28	-0.25	Breast cancer;	chr19:43898903	chr19:43891804~43901805:-
BRCA	cis	rs375066	0.934	rs440784	ENSG00000267058.1	RP11-15A1.3	-8.33	2.51e-16	8.6e-14	-0.28	-0.25	Breast cancer;	chr19:43900190	chr19:43891804~43901805:-
BRCA	cis	rs375066	0.901	rs374307	ENSG00000267058.1	RP11-15A1.3	-8.33	2.51e-16	8.6e-14	-0.28	-0.25	Breast cancer;	chr19:43900246	chr19:43891804~43901805:-
BRCA	cis	rs375066	0.967	rs441344	ENSG00000267058.1	RP11-15A1.3	-8.33	2.51e-16	8.6e-14	-0.28	-0.25	Breast cancer;	chr19:43900530	chr19:43891804~43901805:-
BRCA	cis	rs375066	0.935	rs398099	ENSG00000267058.1	RP11-15A1.3	-8.33	2.51e-16	8.6e-14	-0.28	-0.25	Breast cancer;	chr19:43901129	chr19:43891804~43901805:-
BRCA	cis	rs375066	0.935	rs385321	ENSG00000267058.1	RP11-15A1.3	-8.33	2.51e-16	8.6e-14	-0.28	-0.25	Breast cancer;	chr19:43901135	chr19:43891804~43901805:-
BRCA	cis	rs375066	0.967	rs376328	ENSG00000267058.1	RP11-15A1.3	-8.33	2.51e-16	8.6e-14	-0.28	-0.25	Breast cancer;	chr19:43903335	chr19:43891804~43901805:-
BRCA	cis	rs375066	0.935	rs365556	ENSG00000267058.1	RP11-15A1.3	-8.33	2.51e-16	8.6e-14	-0.28	-0.25	Breast cancer;	chr19:43904047	chr19:43891804~43901805:-
BRCA	cis	rs375066	0.901	rs451945	ENSG00000267058.1	RP11-15A1.3	-8.33	2.51e-16	8.6e-14	-0.28	-0.25	Breast cancer;	chr19:43904601	chr19:43891804~43901805:-
BRCA	cis	rs375066	0.934	rs454813	ENSG00000267058.1	RP11-15A1.3	-8.33	2.51e-16	8.6e-14	-0.28	-0.25	Breast cancer;	chr19:43904821	chr19:43891804~43901805:-
BRCA	cis	rs375066	0.967	rs417400	ENSG00000267058.1	RP11-15A1.3	-8.33	2.51e-16	8.6e-14	-0.28	-0.25	Breast cancer;	chr19:43906694	chr19:43891804~43901805:-
BRCA	cis	rs375066	0.901	rs376457	ENSG00000267058.1	RP11-15A1.3	-8.33	2.51e-16	8.6e-14	-0.28	-0.25	Breast cancer;	chr19:43908605	chr19:43891804~43901805:-
BRCA	cis	rs375066	0.935	rs430667	ENSG00000267058.1	RP11-15A1.3	-8.33	2.51e-16	8.6e-14	-0.28	-0.25	Breast cancer;	chr19:43909101	chr19:43891804~43901805:-
BRCA	cis	rs375066	0.935	rs439665	ENSG00000267058.1	RP11-15A1.3	-8.33	2.51e-16	8.6e-14	-0.28	-0.25	Breast cancer;	chr19:43910315	chr19:43891804~43901805:-
BRCA	cis	rs875971	0.545	rs73142245	ENSG00000222364.1	RNU6-96P	-8.33	2.51e-16	8.6e-14	-0.33	-0.25	Aortic root size;	chr7:66226662	chr7:66395191~66395286:+
BRCA	cis	rs7246657	0.639	rs3112434	ENSG00000267422.1	CTD-2554C21.1	8.33	2.52e-16	8.64e-14	0.37	0.25	Coronary artery calcification;	chr19:37707247	chr19:37779686~37792865:+
BRCA	cis	rs807029	0.577	rs3740489	ENSG00000272572.1	RP11-179B2.2	-8.33	2.52e-16	8.64e-14	-0.32	-0.25	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100994481	chr10:100911103~100912739:-
BRCA	cis	rs526231	0.511	rs1011453	ENSG00000175749.11	EIF3KP1	8.33	2.52e-16	8.65e-14	0.36	0.25	Primary biliary cholangitis;	chr5:103032323	chr5:103032376~103033031:+
BRCA	cis	rs950880	0.71	rs3771150	ENSG00000234389.1	AC007278.3	-8.33	2.53e-16	8.67e-14	-0.26	-0.25	Serum protein levels (sST2);	chr2:102444391	chr2:102438713~102440475:+
BRCA	cis	rs950880	0.71	rs11693955	ENSG00000234389.1	AC007278.3	-8.33	2.53e-16	8.68e-14	-0.25	-0.25	Serum protein levels (sST2);	chr2:102412705	chr2:102438713~102440475:+
BRCA	cis	rs4835473	0.932	rs4305468	ENSG00000251600.4	RP11-673E1.1	-8.33	2.53e-16	8.68e-14	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143987315	chr4:143912331~143982454:+
BRCA	cis	rs375066	0.935	rs432454	ENSG00000267058.1	RP11-15A1.3	-8.33	2.54e-16	8.69e-14	-0.29	-0.25	Breast cancer;	chr19:43894679	chr19:43891804~43901805:-
BRCA	cis	rs35160687	0.509	rs13024436	ENSG00000273080.1	RP11-301O19.1	-8.33	2.54e-16	8.7e-14	-0.31	-0.25	Night sleep phenotypes;	chr2:86307398	chr2:86195590~86196049:+
BRCA	cis	rs1707322	0.963	rs10789484	ENSG00000280836.1	AL355480.1	-8.33	2.54e-16	8.7e-14	-0.32	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45941306	chr1:45581219~45581321:-
BRCA	cis	rs950880	0.614	rs60038017	ENSG00000234389.1	AC007278.3	-8.33	2.54e-16	8.72e-14	-0.25	-0.25	Serum protein levels (sST2);	chr2:102459541	chr2:102438713~102440475:+
BRCA	cis	rs198389	0.617	rs503040	ENSG00000242349.4	NPPA-AS1	-8.33	2.55e-16	8.72e-14	-0.27	-0.25	B-type natriuretic peptide levels;NT-proBNP levels in acute coronary syndrome;	chr1:11830638	chr1:11841017~11848079:+
BRCA	cis	rs858239	0.539	rs6945510	ENSG00000226816.2	AC005082.12	8.33	2.55e-16	8.73e-14	0.29	0.25	Cerebrospinal fluid biomarker levels;	chr7:23152621	chr7:23206013~23208045:+
BRCA	cis	rs4718428	0.705	rs2901311	ENSG00000273142.1	RP11-458F8.4	-8.33	2.56e-16	8.76e-14	-0.24	-0.25	Corneal structure;	chr7:66950082	chr7:66902857~66906297:+
BRCA	cis	rs12701220	0.655	rs34696066	ENSG00000229043.2	AC091729.9	-8.33	2.56e-16	8.76e-14	-0.36	-0.25	Bronchopulmonary dysplasia;	chr7:1101283	chr7:1160374~1165267:+
BRCA	cis	rs4934494	0.911	rs34486602	ENSG00000240996.1	RP11-80H5.7	-8.33	2.56e-16	8.76e-14	-0.29	-0.25	Red blood cell count;	chr10:89655895	chr10:89694295~89697928:-
BRCA	cis	rs8059260	0.604	rs34215426	ENSG00000274038.1	RP11-66H6.4	-8.33	2.57e-16	8.82e-14	-0.39	-0.25	Alcohol consumption over the past year;	chr16:11113614	chr16:11056556~11057034:+
BRCA	cis	rs4948102	0.595	rs10255049	ENSG00000226278.1	PSPHP1	-8.33	2.58e-16	8.83e-14	-0.27	-0.25	Plasma homocysteine levels (post-methionine load test);	chr7:56053611	chr7:55764797~55773288:+
BRCA	cis	rs4835473	0.932	rs4835118	ENSG00000251600.4	RP11-673E1.1	8.33	2.58e-16	8.83e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143981994	chr4:143912331~143982454:+
BRCA	cis	rs375066	0.935	rs454559	ENSG00000267058.1	RP11-15A1.3	-8.33	2.58e-16	8.84e-14	-0.29	-0.25	Breast cancer;	chr19:43924968	chr19:43891804~43901805:-
BRCA	cis	rs858239	0.601	rs1981665	ENSG00000230042.1	AK3P3	-8.33	2.58e-16	8.85e-14	-0.28	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23128350	chr7:23129178~23129841:+
BRCA	cis	rs875971	1	rs6957199	ENSG00000237310.1	GS1-124K5.4	8.33	2.59e-16	8.88e-14	0.26	0.25	Aortic root size;	chr7:66513532	chr7:66493706~66495474:+
BRCA	cis	rs10246939	0.543	rs9640204	ENSG00000228775.6	WEE2-AS1	8.33	2.6e-16	8.91e-14	0.27	0.25	Bitter taste perception;	chr7:141844300	chr7:141704338~141738346:-
BRCA	cis	rs1062177	0.756	rs2915826	ENSG00000253921.1	CTB-113P19.3	8.33	2.61e-16	8.94e-14	0.35	0.25	Preschool internalizing problems;	chr5:151740402	chr5:151753992~151767247:+
BRCA	cis	rs1062177	0.756	rs2964587	ENSG00000253921.1	CTB-113P19.3	8.33	2.61e-16	8.94e-14	0.35	0.25	Preschool internalizing problems;	chr5:151740411	chr5:151753992~151767247:+
BRCA	cis	rs11098499	0.874	rs6822498	ENSG00000245958.5	RP11-33B1.1	-8.33	2.61e-16	8.95e-14	-0.26	-0.25	Corneal astigmatism;	chr4:119199028	chr4:119454791~119552025:+
BRCA	cis	rs875971	0.545	rs1796222	ENSG00000222364.1	RNU6-96P	8.33	2.62e-16	8.95e-14	0.33	0.25	Aortic root size;	chr7:66592167	chr7:66395191~66395286:+
BRCA	cis	rs4835473	0.864	rs2323418	ENSG00000251600.4	RP11-673E1.1	8.33	2.62e-16	8.98e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143969141	chr4:143912331~143982454:+
BRCA	cis	rs2286503	0.966	rs6949233	ENSG00000228649.7	AC005682.5	8.32	2.63e-16	8.99e-14	0.21	0.25	Fibrinogen;	chr7:22818572	chr7:22854178~22861579:+
BRCA	cis	rs11098499	0.954	rs4309825	ENSG00000248280.1	RP11-33B1.2	-8.32	2.63e-16	8.99e-14	-0.25	-0.25	Corneal astigmatism;	chr4:119393726	chr4:119440561~119450157:-
BRCA	cis	rs10129255	0.957	rs10136560	ENSG00000223648.3	IGHV3-64	8.32	2.65e-16	9.07e-14	0.22	0.25	Kawasaki disease;	chr14:106787630	chr14:106643132~106658258:-
BRCA	cis	rs4835473	0.932	rs4835472	ENSG00000251600.4	RP11-673E1.1	8.32	2.66e-16	9.09e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143982398	chr4:143912331~143982454:+
BRCA	cis	rs17711722	0.74	rs7809991	ENSG00000222364.1	RNU6-96P	-8.32	2.66e-16	9.11e-14	-0.29	-0.25	Calcium levels;	chr7:65941231	chr7:66395191~66395286:+
BRCA	cis	rs10129255	0.957	rs8019272	ENSG00000223648.3	IGHV3-64	8.32	2.67e-16	9.12e-14	0.21	0.25	Kawasaki disease;	chr14:106784709	chr14:106643132~106658258:-
BRCA	cis	rs875971	0.545	rs73142233	ENSG00000222364.1	RNU6-96P	-8.32	2.67e-16	9.13e-14	-0.33	-0.25	Aortic root size;	chr7:66221293	chr7:66395191~66395286:+
BRCA	cis	rs67981189	0.542	rs1012725	ENSG00000269927.1	RP6-91H8.3	-8.32	2.67e-16	9.13e-14	-0.35	-0.25	Schizophrenia;	chr14:71138994	chr14:71141125~71143253:-
BRCA	cis	rs75422866	0.541	rs12425816	ENSG00000257433.4	RP1-197B17.3	8.32	2.69e-16	9.19e-14	0.56	0.25	Pneumonia;	chr12:47731419	chr12:47706085~47742294:+
BRCA	cis	rs35160687	0.509	rs35723061	ENSG00000273080.1	RP11-301O19.1	-8.32	2.69e-16	9.2e-14	-0.31	-0.25	Night sleep phenotypes;	chr2:86321965	chr2:86195590~86196049:+
BRCA	cis	rs17711722	0.565	rs73372653	ENSG00000234585.5	CCT6P3	8.32	2.69e-16	9.21e-14	0.25	0.25	Calcium levels;	chr7:65977808	chr7:65038354~65074713:+
BRCA	cis	rs6472827	0.645	rs2977069	ENSG00000253983.2	RP1-16A9.1	8.32	2.7e-16	9.22e-14	0.34	0.25	Uterine fibroids;	chr8:74199550	chr8:74199396~74208441:+
BRCA	cis	rs875971	0.571	rs160647	ENSG00000164669.11	INTS4P1	8.32	2.7e-16	9.23e-14	0.35	0.25	Aortic root size;	chr7:66089365	chr7:65141225~65234216:+
BRCA	cis	rs6472827	0.645	rs2936685	ENSG00000253983.2	RP1-16A9.1	8.32	2.7e-16	9.24e-14	0.35	0.25	Uterine fibroids;	chr8:74202449	chr8:74199396~74208441:+
BRCA	cis	rs375066	0.935	rs384329	ENSG00000267058.1	RP11-15A1.3	-8.32	2.72e-16	9.32e-14	-0.28	-0.25	Breast cancer;	chr19:43919829	chr19:43891804~43901805:-
BRCA	cis	rs3758911	0.964	rs10890703	ENSG00000255353.1	RP11-382M14.1	-8.32	2.73e-16	9.33e-14	-0.34	-0.25	Coronary artery disease;	chr11:107310403	chr11:107176286~107177530:+
BRCA	cis	rs250518	0.926	rs7709640	ENSG00000272081.1	CTD-2376I4.2	8.32	2.74e-16	9.38e-14	0.32	0.25	Mean corpuscular hemoglobin concentration;	chr5:72791653	chr5:72955206~72955699:-
BRCA	cis	rs7246657	0.722	rs2972437	ENSG00000267422.1	CTD-2554C21.1	-8.32	2.75e-16	9.38e-14	-0.37	-0.25	Coronary artery calcification;	chr19:37719610	chr19:37779686~37792865:+
BRCA	cis	rs11098499	0.78	rs12504773	ENSG00000248280.1	RP11-33B1.2	8.32	2.75e-16	9.39e-14	0.26	0.25	Corneal astigmatism;	chr4:119640994	chr4:119440561~119450157:-
BRCA	cis	rs2933343	0.909	rs1683817	ENSG00000231305.3	RP11-723O4.2	8.32	2.75e-16	9.4e-14	0.32	0.25	IgG glycosylation;	chr3:128932693	chr3:128861313~128871540:-
BRCA	cis	rs867371	1	rs7180584	ENSG00000259429.4	UBE2Q2P2	-8.32	2.75e-16	9.4e-14	-0.25	-0.25	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82163493	chr15:82355142~82420075:+
BRCA	cis	rs11907546	1	rs11907546	ENSG00000276073.1	RP5-1125A11.7	-8.32	2.75e-16	9.4e-14	-0.3	-0.25	Cancer (pleiotropy);Cancer;	chr20:34131991	chr20:33985617~33988989:-
BRCA	cis	rs853679	0.567	rs13209596	ENSG00000204709.4	LINC01556	8.32	2.75e-16	9.41e-14	0.37	0.25	Depression;	chr6:28428413	chr6:28943877~28944537:+
BRCA	cis	rs11098499	1	rs58601355	ENSG00000245958.5	RP11-33B1.1	-8.32	2.76e-16	9.44e-14	-0.25	-0.25	Corneal astigmatism;	chr4:119265212	chr4:119454791~119552025:+
BRCA	cis	rs58873874	0.737	rs75022277	ENSG00000248544.2	CTB-47B11.3	8.32	2.76e-16	9.44e-14	0.62	0.25	Bipolar disorder (body mass index interaction);	chr5:157454954	chr5:157375741~157384950:-
BRCA	cis	rs867371	1	rs7180584	ENSG00000255769.6	GOLGA2P10	-8.32	2.76e-16	9.44e-14	-0.29	-0.25	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82163493	chr15:82472993~82513950:-
BRCA	cis	rs7429990	0.965	rs7651237	ENSG00000229759.1	MRPS18AP1	-8.32	2.76e-16	9.44e-14	-0.32	-0.25	Educational attainment (years of education);	chr3:48064038	chr3:48256350~48256938:-
BRCA	cis	rs1075265	0.547	rs6743627	ENSG00000233266.1	HMGB1P31	-8.32	2.77e-16	9.46e-14	-0.31	-0.25	Chronotype;Morning vs. evening chronotype;	chr2:53687024	chr2:54051334~54051760:+
BRCA	cis	rs375066	0.935	rs367283	ENSG00000267058.1	RP11-15A1.3	-8.32	2.78e-16	9.48e-14	-0.28	-0.25	Breast cancer;	chr19:43901975	chr19:43891804~43901805:-
BRCA	cis	rs11098499	0.78	rs7680914	ENSG00000248280.1	RP11-33B1.2	8.32	2.78e-16	9.51e-14	0.26	0.25	Corneal astigmatism;	chr4:119641898	chr4:119440561~119450157:-
BRCA	cis	rs858239	0.539	rs1358442	ENSG00000226816.2	AC005082.12	8.32	2.79e-16	9.53e-14	0.29	0.25	Cerebrospinal fluid biomarker levels;	chr7:23150120	chr7:23206013~23208045:+
BRCA	cis	rs7246657	0.663	rs4803287	ENSG00000267422.1	CTD-2554C21.1	-8.32	2.81e-16	9.61e-14	-0.37	-0.25	Coronary artery calcification;	chr19:37588534	chr19:37779686~37792865:+
BRCA	cis	rs11673344	0.764	rs10403679	ENSG00000226686.6	LINC01535	8.32	2.82e-16	9.62e-14	0.33	0.25	Obesity-related traits;	chr19:36980810	chr19:37251912~37265535:+
BRCA	cis	rs4266144	1	rs4266144	ENSG00000244515.1	KRT18P34	-8.32	2.82e-16	9.63e-14	-0.31	-0.25	Coronary artery disease;	chr3:157134803	chr3:157162663~157163932:-
BRCA	cis	rs7569084	0.663	rs4671128	ENSG00000204929.10	AC074391.1	8.32	2.83e-16	9.66e-14	0.32	0.25	Sum eosinophil basophil counts;	chr2:65438130	chr2:65436711~66084639:+
BRCA	cis	rs6142102	1	rs2143230	ENSG00000276073.1	RP5-1125A11.7	-8.32	2.83e-16	9.66e-14	-0.3	-0.25	Skin pigmentation;	chr20:34136539	chr20:33985617~33988989:-
BRCA	cis	rs875971	0.867	rs1002053	ENSG00000237310.1	GS1-124K5.4	-8.32	2.84e-16	9.7e-14	-0.26	-0.25	Aortic root size;	chr7:66333558	chr7:66493706~66495474:+
BRCA	cis	rs4835473	0.932	rs7667092	ENSG00000251600.4	RP11-673E1.1	8.32	2.84e-16	9.7e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143968604	chr4:143912331~143982454:+
BRCA	cis	rs11098499	0.874	rs6851169	ENSG00000245958.5	RP11-33B1.1	-8.31	2.84e-16	9.7e-14	-0.26	-0.25	Corneal astigmatism;	chr4:119196355	chr4:119454791~119552025:+
BRCA	cis	rs6545883	0.929	rs778154	ENSG00000271889.1	RP11-493E12.1	-8.31	2.84e-16	9.7e-14	-0.33	-0.25	Tuberculosis;	chr2:61419496	chr2:61151433~61162105:-
BRCA	cis	rs7085104	0.7	rs3740397	ENSG00000213061.2	PFN1P11	8.31	2.84e-16	9.71e-14	0.33	0.25	Immature fraction of reticulocytes;Schizophrenia;	chr10:102832918	chr10:102838011~102845473:-
BRCA	cis	rs11976180	0.569	rs12703565	ENSG00000170356.8	OR2A20P	-8.31	2.85e-16	9.71e-14	-0.47	-0.25	Obesity-related traits;	chr7:144057308	chr7:144250045~144252957:-
BRCA	cis	rs875971	0.964	rs778723	ENSG00000237310.1	GS1-124K5.4	8.31	2.85e-16	9.72e-14	0.26	0.25	Aortic root size;	chr7:66364510	chr7:66493706~66495474:+
BRCA	cis	rs2286503	1	rs2286498	ENSG00000228649.7	AC005682.5	-8.31	2.85e-16	9.73e-14	-0.21	-0.25	Fibrinogen;	chr7:22817885	chr7:22854178~22861579:+
BRCA	cis	rs875971	1	rs2077593	ENSG00000237310.1	GS1-124K5.4	8.31	2.86e-16	9.76e-14	0.26	0.25	Aortic root size;	chr7:66427543	chr7:66493706~66495474:+
BRCA	cis	rs4835473	0.736	rs11724009	ENSG00000251600.4	RP11-673E1.1	8.31	2.86e-16	9.76e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143984291	chr4:143912331~143982454:+
BRCA	cis	rs4323050	0.514	rs28647406	ENSG00000251600.4	RP11-673E1.1	8.31	2.86e-16	9.76e-14	0.3	0.25	High light scatter reticulocyte percentage of red cells;	chr4:143984437	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.604	rs11938387	ENSG00000251600.4	RP11-673E1.1	8.31	2.86e-16	9.76e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143984476	chr4:143912331~143982454:+
BRCA	cis	rs2933343	0.951	rs789217	ENSG00000261159.1	RP11-723O4.9	8.31	2.87e-16	9.8e-14	0.3	0.25	IgG glycosylation;	chr3:128874358	chr3:128859716~128860526:-
BRCA	cis	rs8100891	1	rs8100891	ENSG00000267213.4	AC007773.2	-8.31	2.89e-16	9.84e-14	-0.3	-0.25	Neuroticism;	chr19:32338607	chr19:32390050~32405560:-
BRCA	cis	rs4845875	0.564	rs2151655	ENSG00000242349.4	NPPA-AS1	8.31	2.89e-16	9.86e-14	0.29	0.25	Midregional pro atrial natriuretic peptide levels;	chr1:11785461	chr1:11841017~11848079:+
BRCA	cis	rs375066	0.935	rs448823	ENSG00000267058.1	RP11-15A1.3	-8.31	2.9e-16	9.87e-14	-0.28	-0.25	Breast cancer;	chr19:43902139	chr19:43891804~43901805:-
BRCA	cis	rs375066	0.868	rs448829	ENSG00000267058.1	RP11-15A1.3	-8.31	2.9e-16	9.87e-14	-0.28	-0.25	Breast cancer;	chr19:43902169	chr19:43891804~43901805:-
BRCA	cis	rs375066	0.935	rs388706	ENSG00000267058.1	RP11-15A1.3	-8.31	2.9e-16	9.89e-14	-0.28	-0.25	Breast cancer;	chr19:43914541	chr19:43891804~43901805:-
BRCA	cis	rs6539288	0.803	rs7307895	ENSG00000260329.1	RP11-412D9.4	-8.31	2.9e-16	9.89e-14	-0.28	-0.25	Total body bone mineral density;	chr12:106938348	chr12:106954029~106955497:-
BRCA	cis	rs7674212	0.556	rs6533039	ENSG00000246560.2	RP11-10L12.4	8.31	2.9e-16	9.9e-14	0.27	0.25	Type 2 diabetes;	chr4:102938381	chr4:102828055~102844075:+
BRCA	cis	rs10510102	0.872	rs116521083	ENSG00000276742.1	RP11-500G22.4	8.31	2.91e-16	9.91e-14	0.42	0.25	Breast cancer;	chr10:121950611	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.81	rs34738294	ENSG00000276742.1	RP11-500G22.4	8.31	2.91e-16	9.91e-14	0.42	0.25	Breast cancer;	chr10:121951357	chr10:121956782~121957098:+
BRCA	cis	rs875971	0.929	rs6970860	ENSG00000237310.1	GS1-124K5.4	8.31	2.91e-16	9.91e-14	0.26	0.25	Aortic root size;	chr7:66511647	chr7:66493706~66495474:+
BRCA	cis	rs4835473	0.932	rs4287958	ENSG00000251600.4	RP11-673E1.1	8.31	2.91e-16	9.92e-14	0.3	0.25	Immature fraction of reticulocytes;	chr4:143987719	chr4:143912331~143982454:+
BRCA	cis	rs875971	0.545	rs1796217	ENSG00000222364.1	RNU6-96P	8.31	2.91e-16	9.93e-14	0.33	0.25	Aortic root size;	chr7:66620931	chr7:66395191~66395286:+
BRCA	cis	rs2243480	1	rs2533288	ENSG00000273142.1	RP11-458F8.4	-8.31	2.92e-16	9.95e-14	-0.35	-0.25	Diabetic kidney disease;	chr7:66591724	chr7:66902857~66906297:+
BRCA	cis	rs11098499	0.913	rs10006304	ENSG00000245958.5	RP11-33B1.1	-8.31	2.92e-16	9.96e-14	-0.26	-0.25	Corneal astigmatism;	chr4:119203150	chr4:119454791~119552025:+
BRCA	cis	rs13256369	1	rs7004438	ENSG00000253893.2	FAM85B	-8.31	2.94e-16	1e-13	-0.35	-0.25	Obesity-related traits;	chr8:8716869	chr8:8167819~8226614:-
BRCA	cis	rs875971	0.545	rs10261710	ENSG00000237310.1	GS1-124K5.4	8.31	2.94e-16	1e-13	0.3	0.25	Aortic root size;	chr7:66249202	chr7:66493706~66495474:+
BRCA	cis	rs375066	1	rs375066	ENSG00000267058.1	RP11-15A1.3	-8.31	2.94e-16	1e-13	-0.28	-0.25	Breast cancer;	chr19:43919418	chr19:43891804~43901805:-
BRCA	cis	rs10256972	0.647	rs10233430	ENSG00000229043.2	AC091729.9	-8.31	2.95e-16	1.01e-13	-0.31	-0.25	Endometriosis;Longevity;	chr7:1012028	chr7:1160374~1165267:+
BRCA	cis	rs950880	0.71	rs56117144	ENSG00000234389.1	AC007278.3	-8.31	2.95e-16	1.01e-13	-0.25	-0.25	Serum protein levels (sST2);	chr2:102458191	chr2:102438713~102440475:+
BRCA	cis	rs950880	0.71	rs57081652	ENSG00000234389.1	AC007278.3	-8.31	2.95e-16	1.01e-13	-0.25	-0.25	Serum protein levels (sST2);	chr2:102458921	chr2:102438713~102440475:+
BRCA	cis	rs1185460	0.546	rs17075	ENSG00000271751.1	RP11-110I1.14	8.31	2.97e-16	1.01e-13	0.31	0.25	Coronary artery disease;	chr11:119088621	chr11:119065263~119065677:-
BRCA	cis	rs58873874	0.737	rs76634949	ENSG00000248544.2	CTB-47B11.3	8.31	2.97e-16	1.01e-13	0.62	0.25	Bipolar disorder (body mass index interaction);	chr5:157463391	chr5:157375741~157384950:-
BRCA	cis	rs10129255	0.913	rs10140943	ENSG00000223648.3	IGHV3-64	8.31	2.98e-16	1.02e-13	0.22	0.25	Kawasaki disease;	chr14:106767441	chr14:106643132~106658258:-
BRCA	cis	rs375066	0.935	rs387689	ENSG00000267058.1	RP11-15A1.3	-8.31	2.99e-16	1.02e-13	-0.28	-0.25	Breast cancer;	chr19:43915959	chr19:43891804~43901805:-
BRCA	cis	rs375066	0.935	rs398193	ENSG00000267058.1	RP11-15A1.3	-8.31	2.99e-16	1.02e-13	-0.28	-0.25	Breast cancer;	chr19:43916268	chr19:43891804~43901805:-
BRCA	cis	rs375066	0.935	rs450308	ENSG00000267058.1	RP11-15A1.3	-8.31	2.99e-16	1.02e-13	-0.28	-0.25	Breast cancer;	chr19:43918206	chr19:43891804~43901805:-
BRCA	cis	rs375066	0.935	rs424729	ENSG00000267058.1	RP11-15A1.3	-8.31	2.99e-16	1.02e-13	-0.28	-0.25	Breast cancer;	chr19:43918650	chr19:43891804~43901805:-
BRCA	cis	rs375066	0.935	rs423320	ENSG00000267058.1	RP11-15A1.3	-8.31	2.99e-16	1.02e-13	-0.28	-0.25	Breast cancer;	chr19:43918830	chr19:43891804~43901805:-
BRCA	cis	rs375066	0.935	rs423752	ENSG00000267058.1	RP11-15A1.3	-8.31	2.99e-16	1.02e-13	-0.28	-0.25	Breast cancer;	chr19:43919043	chr19:43891804~43901805:-
BRCA	cis	rs375066	0.868	rs370190	ENSG00000267058.1	RP11-15A1.3	-8.31	3.03e-16	1.03e-13	-0.28	-0.25	Breast cancer;	chr19:43920102	chr19:43891804~43901805:-
BRCA	cis	rs375066	0.935	rs413093	ENSG00000267058.1	RP11-15A1.3	-8.31	3.03e-16	1.03e-13	-0.28	-0.25	Breast cancer;	chr19:43922113	chr19:43891804~43901805:-
BRCA	cis	rs56804039	1	rs59620654	ENSG00000253893.2	FAM85B	8.31	3.04e-16	1.04e-13	0.38	0.25	Cervical cancer;	chr8:8525122	chr8:8167819~8226614:-
BRCA	cis	rs6142102	0.502	rs58393429	ENSG00000275784.1	RP5-1125A11.6	-8.31	3.04e-16	1.04e-13	-0.29	-0.25	Skin pigmentation;	chr20:33957996	chr20:33989480~33991818:-
BRCA	cis	rs10971721	0.822	rs10971788	ENSG00000260947.1	RP11-384P7.7	8.31	3.06e-16	1.04e-13	0.44	0.25	Body mass index;	chr9:33915087	chr9:33697459~33700986:+
BRCA	cis	rs7569084	0.687	rs4671663	ENSG00000204929.10	AC074391.1	8.31	3.06e-16	1.04e-13	0.34	0.25	Sum eosinophil basophil counts;	chr2:65434400	chr2:65436711~66084639:+
BRCA	cis	rs526231	0.511	rs62362558	ENSG00000175749.11	EIF3KP1	8.31	3.07e-16	1.04e-13	0.36	0.25	Primary biliary cholangitis;	chr5:103032789	chr5:103032376~103033031:+
BRCA	cis	rs526231	0.511	rs4421079	ENSG00000175749.11	EIF3KP1	8.31	3.07e-16	1.04e-13	0.36	0.25	Primary biliary cholangitis;	chr5:103033372	chr5:103032376~103033031:+
BRCA	cis	rs2742234	0.59	rs2505506	ENSG00000273008.1	RP11-351D16.3	-8.31	3.07e-16	1.05e-13	-0.31	-0.25	Hirschsprung disease;	chr10:43150406	chr10:43136824~43138334:-
BRCA	cis	rs526231	0.578	rs34794	ENSG00000175749.11	EIF3KP1	8.31	3.07e-16	1.05e-13	0.36	0.25	Primary biliary cholangitis;	chr5:103087664	chr5:103032376~103033031:+
BRCA	cis	rs6142102	1	rs12480839	ENSG00000276073.1	RP5-1125A11.7	-8.3	3.09e-16	1.05e-13	-0.3	-0.25	Skin pigmentation;	chr20:34139624	chr20:33985617~33988989:-
BRCA	cis	rs12701220	0.553	rs13245507	ENSG00000229043.2	AC091729.9	-8.3	3.09e-16	1.05e-13	-0.38	-0.25	Bronchopulmonary dysplasia;	chr7:1124058	chr7:1160374~1165267:+
BRCA	cis	rs950776	0.518	rs2292117	ENSG00000261762.1	RP11-650L12.2	8.3	3.09e-16	1.05e-13	0.28	0.25	Sudden cardiac arrest;	chr15:78542347	chr15:78589123~78591276:-
BRCA	cis	rs10463554	0.927	rs11952361	ENSG00000175749.11	EIF3KP1	8.3	3.09e-16	1.05e-13	0.34	0.25	Parkinson's disease;	chr5:102952216	chr5:103032376~103033031:+
BRCA	cis	rs375066	0.935	rs408549	ENSG00000267058.1	RP11-15A1.3	-8.3	3.09e-16	1.05e-13	-0.28	-0.25	Breast cancer;	chr19:43921467	chr19:43891804~43901805:-
BRCA	cis	rs375066	0.935	rs398388	ENSG00000267058.1	RP11-15A1.3	-8.3	3.09e-16	1.05e-13	-0.28	-0.25	Breast cancer;	chr19:43921530	chr19:43891804~43901805:-
BRCA	cis	rs375066	0.935	rs403137	ENSG00000267058.1	RP11-15A1.3	-8.3	3.09e-16	1.05e-13	-0.28	-0.25	Breast cancer;	chr19:43923474	chr19:43891804~43901805:-
BRCA	cis	rs375066	0.935	rs428505	ENSG00000267058.1	RP11-15A1.3	-8.3	3.09e-16	1.05e-13	-0.28	-0.25	Breast cancer;	chr19:43924759	chr19:43891804~43901805:-
BRCA	cis	rs375066	0.935	rs367741	ENSG00000267058.1	RP11-15A1.3	-8.3	3.09e-16	1.05e-13	-0.28	-0.25	Breast cancer;	chr19:43925028	chr19:43891804~43901805:-
BRCA	cis	rs6545883	0.929	rs2252662	ENSG00000271889.1	RP11-493E12.1	8.3	3.09e-16	1.05e-13	0.32	0.25	Tuberculosis;	chr2:61443596	chr2:61151433~61162105:-
BRCA	cis	rs2933343	0.909	rs1683817	ENSG00000261159.1	RP11-723O4.9	8.3	3.09e-16	1.05e-13	0.3	0.25	IgG glycosylation;	chr3:128932693	chr3:128859716~128860526:-
BRCA	cis	rs250518	0.926	rs6873718	ENSG00000272081.1	CTD-2376I4.2	8.3	3.09e-16	1.05e-13	0.32	0.25	Mean corpuscular hemoglobin concentration;	chr5:72747581	chr5:72955206~72955699:-
BRCA	cis	rs7811142	0.83	rs1063945	ENSG00000242294.5	STAG3L5P	8.3	3.1e-16	1.05e-13	0.25	0.25	Platelet count;	chr7:100332824	chr7:100336079~100351900:+
BRCA	cis	rs10129255	0.518	rs12590732	ENSG00000211972.2	IGHV3-66	-8.3	3.1e-16	1.06e-13	-0.17	-0.25	Kawasaki disease;	chr14:106779612	chr14:106675017~106675544:-
BRCA	cis	rs875971	0.545	rs73136346	ENSG00000164669.11	INTS4P1	8.3	3.1e-16	1.06e-13	0.35	0.25	Aortic root size;	chr7:66101095	chr7:65141225~65234216:+
BRCA	cis	rs950880	0.71	rs17027060	ENSG00000234389.1	AC007278.3	-8.3	3.11e-16	1.06e-13	-0.25	-0.25	Serum protein levels (sST2);	chr2:102391107	chr2:102438713~102440475:+
BRCA	cis	rs2720460	0.502	rs223374	ENSG00000246560.2	RP11-10L12.4	8.3	3.11e-16	1.06e-13	0.27	0.25	Testicular germ cell tumor;	chr4:102837144	chr4:102828055~102844075:+
BRCA	cis	rs7927771	1	rs12419692	ENSG00000280615.1	Y_RNA	8.3	3.14e-16	1.07e-13	0.3	0.25	Subjective well-being;	chr11:47603162	chr11:47614898~47614994:-
BRCA	cis	rs6921919	0.887	rs7766356	ENSG00000204709.4	LINC01556	8.3	3.14e-16	1.07e-13	0.43	0.25	Autism spectrum disorder or schizophrenia;	chr6:28432761	chr6:28943877~28944537:+
BRCA	cis	rs1707322	1	rs12077974	ENSG00000280836.1	AL355480.1	-8.3	3.15e-16	1.07e-13	-0.32	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45918469	chr1:45581219~45581321:-
BRCA	cis	rs11098499	0.874	rs7661020	ENSG00000245958.5	RP11-33B1.1	-8.3	3.15e-16	1.07e-13	-0.26	-0.25	Corneal astigmatism;	chr4:119185827	chr4:119454791~119552025:+
BRCA	cis	rs193541	0.555	rs2438151	ENSG00000263432.2	RN7SL689P	8.3	3.16e-16	1.07e-13	0.34	0.25	Glucose homeostasis traits;	chr5:122863502	chr5:123022487~123022783:-
BRCA	cis	rs10246939	0.579	rs9640205	ENSG00000228775.6	WEE2-AS1	8.3	3.16e-16	1.07e-13	0.28	0.25	Bitter taste perception;	chr7:141844400	chr7:141704338~141738346:-
BRCA	cis	rs61270009	0.818	rs4916718	ENSG00000247828.6	TMEM161B-AS1	8.3	3.16e-16	1.07e-13	0.32	0.25	Depressive symptoms;	chr5:88316825	chr5:88268895~88436685:+
BRCA	cis	rs11098499	0.739	rs4833612	ENSG00000245958.5	RP11-33B1.1	8.3	3.16e-16	1.07e-13	0.24	0.25	Corneal astigmatism;	chr4:119226441	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.739	rs10013032	ENSG00000245958.5	RP11-33B1.1	8.3	3.16e-16	1.07e-13	0.24	0.25	Corneal astigmatism;	chr4:119228264	chr4:119454791~119552025:+
BRCA	cis	rs950880	0.71	rs17027230	ENSG00000234389.1	AC007278.3	-8.3	3.16e-16	1.08e-13	-0.24	-0.25	Serum protein levels (sST2);	chr2:102462870	chr2:102438713~102440475:+
BRCA	cis	rs950776	0.518	rs2869544	ENSG00000261762.1	RP11-650L12.2	-8.3	3.17e-16	1.08e-13	-0.27	-0.25	Sudden cardiac arrest;	chr15:78547058	chr15:78589123~78591276:-
BRCA	cis	rs42648	0.869	rs1015403	ENSG00000225498.1	AC002064.5	8.3	3.18e-16	1.08e-13	0.24	0.25	Homocysteine levels;	chr7:90284388	chr7:90312496~90322592:+
BRCA	cis	rs860818	1	rs858238	ENSG00000226816.2	AC005082.12	8.3	3.18e-16	1.08e-13	0.54	0.25	Initial pursuit acceleration;	chr7:23199514	chr7:23206013~23208045:+
BRCA	cis	rs801193	1	rs13239306	ENSG00000222364.1	RNU6-96P	8.3	3.19e-16	1.08e-13	0.29	0.25	Aortic root size;	chr7:66671030	chr7:66395191~66395286:+
BRCA	cis	rs6545883	0.894	rs4672431	ENSG00000271889.1	RP11-493E12.1	-8.3	3.2e-16	1.09e-13	-0.32	-0.25	Tuberculosis;	chr2:61292787	chr2:61151433~61162105:-
BRCA	cis	rs858239	0.541	rs4624924	ENSG00000230042.1	AK3P3	-8.3	3.2e-16	1.09e-13	-0.28	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23129224	chr7:23129178~23129841:+
BRCA	cis	rs950880	0.71	rs12905	ENSG00000234389.1	AC007278.3	-8.3	3.21e-16	1.09e-13	-0.26	-0.25	Serum protein levels (sST2);	chr2:102343547	chr2:102438713~102440475:+
BRCA	cis	rs858239	0.539	rs28624974	ENSG00000226816.2	AC005082.12	8.3	3.21e-16	1.09e-13	0.29	0.25	Cerebrospinal fluid biomarker levels;	chr7:23149317	chr7:23206013~23208045:+
BRCA	cis	rs113835537	0.529	rs11227502	ENSG00000255517.5	CTD-3074O7.5	-8.3	3.22e-16	1.09e-13	-0.32	-0.25	Airway imaging phenotypes;	chr11:66506677	chr11:66473490~66480233:-
BRCA	cis	rs6472827	0.571	rs2936692	ENSG00000253983.2	RP1-16A9.1	8.3	3.22e-16	1.1e-13	0.34	0.25	Uterine fibroids;	chr8:74199039	chr8:74199396~74208441:+
BRCA	cis	rs6142102	0.625	rs4243974	ENSG00000275784.1	RP5-1125A11.6	-8.3	3.23e-16	1.1e-13	-0.29	-0.25	Skin pigmentation;	chr20:33960062	chr20:33989480~33991818:-
BRCA	cis	rs6142102	0.625	rs6142062	ENSG00000275784.1	RP5-1125A11.6	-8.3	3.23e-16	1.1e-13	-0.29	-0.25	Skin pigmentation;	chr20:33960706	chr20:33989480~33991818:-
BRCA	cis	rs6142102	0.625	rs6141432	ENSG00000275784.1	RP5-1125A11.6	-8.3	3.23e-16	1.1e-13	-0.29	-0.25	Skin pigmentation;	chr20:33960791	chr20:33989480~33991818:-
BRCA	cis	rs6142102	0.602	rs6141433	ENSG00000275784.1	RP5-1125A11.6	-8.3	3.23e-16	1.1e-13	-0.29	-0.25	Skin pigmentation;	chr20:33961056	chr20:33989480~33991818:-
BRCA	cis	rs2911132	1	rs2911140	ENSG00000248734.2	CTD-2260A17.1	8.3	3.23e-16	1.1e-13	0.3	0.25	Urate levels (BMI interaction);	chr5:96844240	chr5:96784777~96785999:+
BRCA	cis	rs875971	1	rs3735148	ENSG00000237310.1	GS1-124K5.4	8.3	3.23e-16	1.1e-13	0.26	0.25	Aortic root size;	chr7:66506022	chr7:66493706~66495474:+
BRCA	cis	rs2243480	0.711	rs2460426	ENSG00000273142.1	RP11-458F8.4	8.3	3.23e-16	1.1e-13	0.34	0.25	Diabetic kidney disease;	chr7:66158142	chr7:66902857~66906297:+
BRCA	cis	rs2028299	0.919	rs3759831	ENSG00000259677.1	RP11-493E3.1	8.3	3.25e-16	1.1e-13	0.34	0.25	Type 2 diabetes;	chr15:89871410	chr15:89876540~89877285:+
BRCA	cis	rs6545883	0.859	rs7561672	ENSG00000271889.1	RP11-493E12.1	-8.3	3.26e-16	1.11e-13	-0.32	-0.25	Tuberculosis;	chr2:61291959	chr2:61151433~61162105:-
BRCA	cis	rs8012947	1	rs7149735	ENSG00000279636.2	LINC00216	-8.3	3.26e-16	1.11e-13	-0.27	-0.25	Alcohol consumption in current drinkers;	chr14:58289703	chr14:58288033~58289158:+
BRCA	cis	rs8012947	0.959	rs6573198	ENSG00000279636.2	LINC00216	-8.3	3.26e-16	1.11e-13	-0.27	-0.25	Alcohol consumption in current drinkers;	chr14:58293044	chr14:58288033~58289158:+
BRCA	cis	rs10129255	0.518	rs2006284	ENSG00000280411.1	IGHV1-69-2	-8.3	3.26e-16	1.11e-13	-0.17	-0.25	Kawasaki disease;	chr14:106676185	chr14:106762092~106762588:-
BRCA	cis	rs6142102	0.923	rs6057961	ENSG00000276073.1	RP5-1125A11.7	-8.3	3.27e-16	1.11e-13	-0.3	-0.25	Skin pigmentation;	chr20:33986005	chr20:33985617~33988989:-
BRCA	cis	rs4835473	0.932	rs1988206	ENSG00000251600.4	RP11-673E1.1	8.3	3.27e-16	1.11e-13	0.3	0.25	Immature fraction of reticulocytes;	chr4:143991344	chr4:143912331~143982454:+
BRCA	cis	rs7246657	0.722	rs10410588	ENSG00000267422.1	CTD-2554C21.1	-8.3	3.27e-16	1.11e-13	-0.37	-0.25	Coronary artery calcification;	chr19:37551508	chr19:37779686~37792865:+
BRCA	cis	rs748404	0.666	rs7176923	ENSG00000249839.1	AC011330.5	-8.3	3.28e-16	1.11e-13	-0.38	-0.25	Lung cancer;	chr15:43317679	chr15:43663654~43684339:-
BRCA	cis	rs2153535	0.869	rs11962457	ENSG00000230939.1	RP11-314C16.1	8.3	3.29e-16	1.12e-13	0.29	0.25	Motion sickness;	chr6:8375622	chr6:8784178~8785445:+
BRCA	cis	rs4835473	0.897	rs4835474	ENSG00000251600.4	RP11-673E1.1	8.3	3.31e-16	1.12e-13	0.3	0.25	Immature fraction of reticulocytes;	chr4:143982444	chr4:143912331~143982454:+
BRCA	cis	rs875971	0.522	rs1917563	ENSG00000222364.1	RNU6-96P	8.3	3.31e-16	1.12e-13	0.29	0.25	Aortic root size;	chr7:65950660	chr7:66395191~66395286:+
BRCA	cis	rs7246657	0.722	rs2927746	ENSG00000267422.1	CTD-2554C21.1	8.29	3.33e-16	1.13e-13	0.37	0.25	Coronary artery calcification;	chr19:37665669	chr19:37779686~37792865:+
BRCA	cis	rs11098499	0.739	rs2203039	ENSG00000245958.5	RP11-33B1.1	8.29	3.34e-16	1.13e-13	0.24	0.25	Corneal astigmatism;	chr4:119211192	chr4:119454791~119552025:+
BRCA	cis	rs875971	0.895	rs12698520	ENSG00000237310.1	GS1-124K5.4	8.29	3.36e-16	1.14e-13	0.26	0.25	Aortic root size;	chr7:66453720	chr7:66493706~66495474:+
BRCA	cis	rs6545883	0.894	rs2694643	ENSG00000271889.1	RP11-493E12.1	8.29	3.36e-16	1.14e-13	0.32	0.25	Tuberculosis;	chr2:61377248	chr2:61151433~61162105:-
BRCA	cis	rs250518	0.926	rs34919293	ENSG00000272081.1	CTD-2376I4.2	8.29	3.37e-16	1.14e-13	0.32	0.25	Mean corpuscular hemoglobin concentration;	chr5:72756687	chr5:72955206~72955699:-
BRCA	cis	rs4835473	0.8	rs13124170	ENSG00000251600.4	RP11-673E1.1	8.29	3.37e-16	1.14e-13	0.3	0.25	Immature fraction of reticulocytes;	chr4:143975951	chr4:143912331~143982454:+
BRCA	cis	rs6545883	0.894	rs778148	ENSG00000271889.1	RP11-493E12.1	-8.29	3.37e-16	1.14e-13	-0.32	-0.25	Tuberculosis;	chr2:61379731	chr2:61151433~61162105:-
BRCA	cis	rs42648	0.869	rs6948139	ENSG00000225498.1	AC002064.5	8.29	3.37e-16	1.14e-13	0.24	0.25	Homocysteine levels;	chr7:90308467	chr7:90312496~90322592:+
BRCA	cis	rs42648	0.837	rs6970750	ENSG00000225498.1	AC002064.5	8.29	3.37e-16	1.14e-13	0.24	0.25	Homocysteine levels;	chr7:90308877	chr7:90312496~90322592:+
BRCA	cis	rs875971	0.502	rs1796227	ENSG00000222364.1	RNU6-96P	8.29	3.4e-16	1.15e-13	0.33	0.25	Aortic root size;	chr7:66622032	chr7:66395191~66395286:+
BRCA	cis	rs526231	0.543	rs158395	ENSG00000175749.11	EIF3KP1	8.29	3.4e-16	1.15e-13	0.36	0.25	Primary biliary cholangitis;	chr5:103075685	chr5:103032376~103033031:+
BRCA	cis	rs526231	0.543	rs158400	ENSG00000175749.11	EIF3KP1	8.29	3.4e-16	1.15e-13	0.36	0.25	Primary biliary cholangitis;	chr5:103077628	chr5:103032376~103033031:+
BRCA	cis	rs526231	0.543	rs257302	ENSG00000175749.11	EIF3KP1	8.29	3.4e-16	1.15e-13	0.36	0.25	Primary biliary cholangitis;	chr5:103080426	chr5:103032376~103033031:+
BRCA	cis	rs526231	0.543	rs257303	ENSG00000175749.11	EIF3KP1	8.29	3.4e-16	1.15e-13	0.36	0.25	Primary biliary cholangitis;	chr5:103081023	chr5:103032376~103033031:+
BRCA	cis	rs7246657	0.654	rs10407568	ENSG00000267422.1	CTD-2554C21.1	-8.29	3.4e-16	1.15e-13	-0.37	-0.25	Coronary artery calcification;	chr19:37632108	chr19:37779686~37792865:+
BRCA	cis	rs807029	0.577	rs3740490	ENSG00000272572.1	RP11-179B2.2	-8.29	3.41e-16	1.15e-13	-0.32	-0.25	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100996986	chr10:100911103~100912739:-
BRCA	cis	rs10510102	0.872	rs7907815	ENSG00000276742.1	RP11-500G22.4	8.29	3.41e-16	1.16e-13	0.42	0.25	Breast cancer;	chr10:121965951	chr10:121956782~121957098:+
BRCA	cis	rs3762637	1	rs7615673	ENSG00000272758.4	RP11-299J3.8	-8.29	3.43e-16	1.16e-13	-0.36	-0.25	LDL cholesterol levels;	chr3:122406697	chr3:122416207~122443180:+
BRCA	cis	rs5850	0.557	rs10270788	ENSG00000226816.2	AC005082.12	8.29	3.44e-16	1.17e-13	0.29	0.25	Blood protein levels;	chr7:23149381	chr7:23206013~23208045:+
BRCA	cis	rs858239	0.539	rs28716381	ENSG00000226816.2	AC005082.12	8.29	3.44e-16	1.17e-13	0.29	0.25	Cerebrospinal fluid biomarker levels;	chr7:23149396	chr7:23206013~23208045:+
BRCA	cis	rs7674212	0.507	rs223471	ENSG00000246560.2	RP11-10L12.4	8.29	3.45e-16	1.17e-13	0.27	0.25	Type 2 diabetes;	chr4:102777629	chr4:102828055~102844075:+
BRCA	cis	rs1499614	1	rs2707840	ENSG00000273142.1	RP11-458F8.4	-8.29	3.46e-16	1.17e-13	-0.35	-0.25	Gout;	chr7:66693028	chr7:66902857~66906297:+
BRCA	cis	rs67981189	0.529	rs61990387	ENSG00000269927.1	RP6-91H8.3	8.29	3.46e-16	1.17e-13	0.33	0.25	Schizophrenia;	chr14:71024850	chr14:71141125~71143253:-
BRCA	cis	rs7246657	0.722	rs1975937	ENSG00000267422.1	CTD-2554C21.1	-8.29	3.47e-16	1.17e-13	-0.37	-0.25	Coronary artery calcification;	chr19:37601031	chr19:37779686~37792865:+
BRCA	cis	rs2439831	0.85	rs28590651	ENSG00000205771.5	CATSPER2P1	-8.29	3.48e-16	1.18e-13	-0.43	-0.25	Lung cancer in ever smokers;	chr15:43820818	chr15:43726918~43747094:-
BRCA	cis	rs6570726	0.791	rs6918814	ENSG00000235652.6	RP11-545I5.3	8.29	3.49e-16	1.18e-13	0.24	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145584892	chr6:145799409~145886585:+
BRCA	cis	rs227275	0.526	rs223497	ENSG00000246560.2	RP11-10L12.4	8.29	3.5e-16	1.19e-13	0.27	0.25	Allergic disease (asthma, hay fever or eczema);	chr4:102732819	chr4:102828055~102844075:+
BRCA	cis	rs10246939	0.505	rs6967189	ENSG00000228775.6	WEE2-AS1	8.29	3.51e-16	1.19e-13	0.29	0.25	Bitter taste perception;	chr7:141826220	chr7:141704338~141738346:-
BRCA	cis	rs11098499	0.69	rs34818745	ENSG00000248280.1	RP11-33B1.2	8.29	3.51e-16	1.19e-13	0.25	0.25	Corneal astigmatism;	chr4:119335900	chr4:119440561~119450157:-
BRCA	cis	rs4835473	0.932	rs4125545	ENSG00000251600.4	RP11-673E1.1	8.29	3.52e-16	1.19e-13	0.3	0.25	Immature fraction of reticulocytes;	chr4:143988650	chr4:143912331~143982454:+
BRCA	cis	rs17772222	0.917	rs2004329	ENSG00000258983.2	RP11-507K2.2	8.29	3.52e-16	1.19e-13	0.28	0.25	Coronary artery calcification;	chr14:88532965	chr14:88499334~88515502:+
BRCA	cis	rs875971	0.571	rs160641	ENSG00000222364.1	RNU6-96P	8.29	3.52e-16	1.19e-13	0.32	0.25	Aortic root size;	chr7:66112359	chr7:66395191~66395286:+
BRCA	cis	rs250518	0.926	rs1912005	ENSG00000272081.1	CTD-2376I4.2	-8.29	3.53e-16	1.19e-13	-0.32	-0.25	Mean corpuscular hemoglobin concentration;	chr5:72772227	chr5:72955206~72955699:-
BRCA	cis	rs526231	0.543	rs34808	ENSG00000175749.11	EIF3KP1	8.29	3.54e-16	1.2e-13	0.37	0.25	Primary biliary cholangitis;	chr5:103093484	chr5:103032376~103033031:+
BRCA	cis	rs7246657	0.722	rs35863684	ENSG00000267422.1	CTD-2554C21.1	-8.29	3.55e-16	1.2e-13	-0.36	-0.25	Coronary artery calcification;	chr19:37618876	chr19:37779686~37792865:+
BRCA	cis	rs17772222	0.917	rs10143767	ENSG00000258983.2	RP11-507K2.2	8.29	3.57e-16	1.21e-13	0.28	0.25	Coronary artery calcification;	chr14:88514867	chr14:88499334~88515502:+
BRCA	cis	rs1062177	0.756	rs2964588	ENSG00000253921.1	CTB-113P19.3	8.29	3.58e-16	1.21e-13	0.34	0.25	Preschool internalizing problems;	chr5:151738825	chr5:151753992~151767247:+
BRCA	cis	rs9880211	1	rs9812579	ENSG00000239213.4	NCK1-AS1	8.29	3.6e-16	1.22e-13	0.33	0.25	Height;Body mass index;	chr3:136432408	chr3:136841726~136862054:-
BRCA	cis	rs2243480	0.831	rs57294491	ENSG00000273142.1	RP11-458F8.4	8.29	3.6e-16	1.22e-13	0.35	0.25	Diabetic kidney disease;	chr7:66219914	chr7:66902857~66906297:+
BRCA	cis	rs6545883	0.929	rs10190332	ENSG00000271889.1	RP11-493E12.1	-8.28	3.61e-16	1.22e-13	-0.32	-0.25	Tuberculosis;	chr2:61392132	chr2:61151433~61162105:-
BRCA	cis	rs2286503	1	rs2286501	ENSG00000228649.7	AC005682.5	8.28	3.62e-16	1.22e-13	0.21	0.25	Fibrinogen;	chr7:22817166	chr7:22854178~22861579:+
BRCA	cis	rs10463554	0.927	rs34798	ENSG00000175749.11	EIF3KP1	8.28	3.63e-16	1.23e-13	0.38	0.25	Parkinson's disease;	chr5:103090047	chr5:103032376~103033031:+
BRCA	cis	rs7811142	0.83	rs41280971	ENSG00000242294.5	STAG3L5P	8.28	3.64e-16	1.23e-13	0.24	0.25	Platelet count;	chr7:100356834	chr7:100336079~100351900:+
BRCA	cis	rs7811142	0.83	rs11761426	ENSG00000242294.5	STAG3L5P	8.28	3.64e-16	1.23e-13	0.24	0.25	Platelet count;	chr7:100359270	chr7:100336079~100351900:+
BRCA	cis	rs7811142	0.83	rs77861211	ENSG00000242294.5	STAG3L5P	8.28	3.64e-16	1.23e-13	0.24	0.25	Platelet count;	chr7:100364473	chr7:100336079~100351900:+
BRCA	cis	rs375066	0.935	rs430308	ENSG00000267058.1	RP11-15A1.3	-8.28	3.64e-16	1.23e-13	-0.28	-0.25	Breast cancer;	chr19:43896223	chr19:43891804~43901805:-
BRCA	cis	rs6545883	0.929	rs2694625	ENSG00000271889.1	RP11-493E12.1	-8.28	3.65e-16	1.23e-13	-0.33	-0.25	Tuberculosis;	chr2:61388920	chr2:61151433~61162105:-
BRCA	cis	rs7520050	0.778	rs2934857	ENSG00000280836.1	AL355480.1	-8.28	3.66e-16	1.24e-13	-0.29	-0.25	Reticulocyte count;Red blood cell count;	chr1:45573940	chr1:45581219~45581321:-
BRCA	cis	rs7429990	0.803	rs6773732	ENSG00000229759.1	MRPS18AP1	-8.28	3.66e-16	1.24e-13	-0.28	-0.25	Educational attainment (years of education);	chr3:47677772	chr3:48256350~48256938:-
BRCA	cis	rs7429990	0.864	rs7429162	ENSG00000229759.1	MRPS18AP1	-8.28	3.66e-16	1.24e-13	-0.28	-0.25	Educational attainment (years of education);	chr3:47683845	chr3:48256350~48256938:-
BRCA	cis	rs7429990	0.864	rs4410463	ENSG00000229759.1	MRPS18AP1	-8.28	3.66e-16	1.24e-13	-0.28	-0.25	Educational attainment (years of education);	chr3:47693907	chr3:48256350~48256938:-
BRCA	cis	rs858239	0.539	rs2178140	ENSG00000226816.2	AC005082.12	8.28	3.68e-16	1.24e-13	0.29	0.25	Cerebrospinal fluid biomarker levels;	chr7:23152006	chr7:23206013~23208045:+
BRCA	cis	rs950880	0.71	rs1135354	ENSG00000234389.1	AC007278.3	-8.28	3.69e-16	1.24e-13	-0.25	-0.25	Serum protein levels (sST2);	chr2:102397842	chr2:102438713~102440475:+
BRCA	cis	rs13256369	1	rs4841017	ENSG00000253893.2	FAM85B	-8.28	3.69e-16	1.25e-13	-0.34	-0.25	Obesity-related traits;	chr8:8719583	chr8:8167819~8226614:-
BRCA	cis	rs860818	1	rs858252	ENSG00000226816.2	AC005082.12	8.28	3.7e-16	1.25e-13	0.57	0.25	Initial pursuit acceleration;	chr7:23178253	chr7:23206013~23208045:+
BRCA	cis	rs860818	1	rs858250	ENSG00000226816.2	AC005082.12	8.28	3.7e-16	1.25e-13	0.57	0.25	Initial pursuit acceleration;	chr7:23178941	chr7:23206013~23208045:+
BRCA	cis	rs875971	0.564	rs313804	ENSG00000237310.1	GS1-124K5.4	8.28	3.7e-16	1.25e-13	0.26	0.25	Aortic root size;	chr7:66049635	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.662	rs448725	ENSG00000237310.1	GS1-124K5.4	8.28	3.7e-16	1.25e-13	0.26	0.25	Aortic root size;	chr7:66049641	chr7:66493706~66495474:+
BRCA	cis	rs10515750	0.656	rs112839393	ENSG00000251405.2	CTB-109A12.1	8.28	3.71e-16	1.25e-13	0.55	0.25	Lung function (FEV1/FVC);	chr5:157282304	chr5:157362615~157460078:-
BRCA	cis	rs375066	0.901	rs368316	ENSG00000267058.1	RP11-15A1.3	-8.28	3.72e-16	1.26e-13	-0.29	-0.25	Breast cancer;	chr19:43927742	chr19:43891804~43901805:-
BRCA	cis	rs7246657	0.722	rs8100646	ENSG00000267422.1	CTD-2554C21.1	-8.28	3.74e-16	1.26e-13	-0.37	-0.25	Coronary artery calcification;	chr19:37617042	chr19:37779686~37792865:+
BRCA	cis	rs4835473	0.798	rs11100829	ENSG00000251600.4	RP11-673E1.1	8.28	3.74e-16	1.26e-13	0.3	0.25	Immature fraction of reticulocytes;	chr4:143984761	chr4:143912331~143982454:+
BRCA	cis	rs1134634	0.52	rs11932730	ENSG00000273133.1	RP11-799M12.2	8.28	3.75e-16	1.26e-13	0.32	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15564135	chr4:15563698~15564253:-
BRCA	cis	rs7712401	0.56	rs13168225	ENSG00000263432.2	RN7SL689P	-8.28	3.76e-16	1.27e-13	-0.33	-0.25	Mean platelet volume;	chr5:123011569	chr5:123022487~123022783:-
BRCA	cis	rs7569084	0.687	rs11126038	ENSG00000204929.10	AC074391.1	8.28	3.76e-16	1.27e-13	0.33	0.25	Sum eosinophil basophil counts;	chr2:65436100	chr2:65436711~66084639:+
BRCA	cis	rs7569084	0.663	rs11694714	ENSG00000204929.10	AC074391.1	8.28	3.76e-16	1.27e-13	0.33	0.25	Sum eosinophil basophil counts;	chr2:65436802	chr2:65436711~66084639:+
BRCA	cis	rs7429990	0.864	rs13061412	ENSG00000229759.1	MRPS18AP1	-8.28	3.76e-16	1.27e-13	-0.28	-0.25	Educational attainment (years of education);	chr3:47660092	chr3:48256350~48256938:-
BRCA	cis	rs11098499	0.909	rs28555550	ENSG00000245958.5	RP11-33B1.1	-8.28	3.77e-16	1.27e-13	-0.25	-0.25	Corneal astigmatism;	chr4:119289885	chr4:119454791~119552025:+
BRCA	cis	rs11098499	1	rs28419773	ENSG00000245958.5	RP11-33B1.1	-8.28	3.77e-16	1.27e-13	-0.25	-0.25	Corneal astigmatism;	chr4:119289906	chr4:119454791~119552025:+
BRCA	cis	rs867371	1	rs6495642	ENSG00000255769.6	GOLGA2P10	-8.28	3.77e-16	1.27e-13	-0.29	-0.25	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82165156	chr15:82472993~82513950:-
BRCA	cis	rs858239	0.601	rs764533	ENSG00000230042.1	AK3P3	-8.28	3.78e-16	1.27e-13	-0.29	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23114256	chr7:23129178~23129841:+
BRCA	cis	rs2243480	1	rs4718315	ENSG00000273142.1	RP11-458F8.4	8.28	3.82e-16	1.29e-13	0.34	0.25	Diabetic kidney disease;	chr7:66183554	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs4718316	ENSG00000273142.1	RP11-458F8.4	8.28	3.82e-16	1.29e-13	0.34	0.25	Diabetic kidney disease;	chr7:66183744	chr7:66902857~66906297:+
BRCA	cis	rs4835473	0.8	rs1849122	ENSG00000251600.4	RP11-673E1.1	8.28	3.84e-16	1.3e-13	0.3	0.25	Immature fraction of reticulocytes;	chr4:143978699	chr4:143912331~143982454:+
BRCA	cis	rs7615952	0.932	rs13325495	ENSG00000171084.14	FAM86JP	8.28	3.85e-16	1.3e-13	0.44	0.25	Blood pressure (smoking interaction);	chr3:125918573	chr3:125916620~125930024:+
BRCA	cis	rs10740039	0.768	rs10761549	ENSG00000254271.1	RP11-131N11.4	8.28	3.85e-16	1.3e-13	0.33	0.25	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60701902	chr10:60734342~60741828:+
BRCA	cis	rs875971	0.929	rs778692	ENSG00000237310.1	GS1-124K5.4	8.28	3.86e-16	1.3e-13	0.26	0.25	Aortic root size;	chr7:66407462	chr7:66493706~66495474:+
BRCA	cis	rs875971	1	rs4718343	ENSG00000237310.1	GS1-124K5.4	8.28	3.86e-16	1.3e-13	0.26	0.25	Aortic root size;	chr7:66409301	chr7:66493706~66495474:+
BRCA	cis	rs875971	1	rs1968225	ENSG00000237310.1	GS1-124K5.4	8.28	3.86e-16	1.3e-13	0.26	0.25	Aortic root size;	chr7:66409786	chr7:66493706~66495474:+
BRCA	cis	rs875971	1	rs6460295	ENSG00000237310.1	GS1-124K5.4	8.28	3.86e-16	1.3e-13	0.26	0.25	Aortic root size;	chr7:66417741	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.964	rs6978721	ENSG00000237310.1	GS1-124K5.4	8.28	3.86e-16	1.3e-13	0.26	0.25	Aortic root size;	chr7:66418217	chr7:66493706~66495474:+
BRCA	cis	rs858239	0.539	rs10279194	ENSG00000226816.2	AC005082.12	8.28	3.86e-16	1.3e-13	0.29	0.25	Cerebrospinal fluid biomarker levels;	chr7:23151464	chr7:23206013~23208045:+
BRCA	cis	rs858239	0.539	rs3950345	ENSG00000226816.2	AC005082.12	8.28	3.86e-16	1.3e-13	0.29	0.25	Cerebrospinal fluid biomarker levels;	chr7:23151495	chr7:23206013~23208045:+
BRCA	cis	rs858239	0.539	rs2178139	ENSG00000226816.2	AC005082.12	8.28	3.86e-16	1.3e-13	0.29	0.25	Cerebrospinal fluid biomarker levels;	chr7:23152017	chr7:23206013~23208045:+
BRCA	cis	rs858239	0.539	rs2141306	ENSG00000226816.2	AC005082.12	8.28	3.86e-16	1.3e-13	0.29	0.25	Cerebrospinal fluid biomarker levels;	chr7:23152045	chr7:23206013~23208045:+
BRCA	cis	rs3864261	0.515	rs57149385	ENSG00000272081.1	CTD-2376I4.2	8.28	3.86e-16	1.3e-13	0.31	0.25	Discordance in emotional problems in monozygotic twins;	chr5:73060354	chr5:72955206~72955699:-
BRCA	cis	rs3864261	0.515	rs10942539	ENSG00000272081.1	CTD-2376I4.2	8.28	3.86e-16	1.3e-13	0.31	0.25	Discordance in emotional problems in monozygotic twins;	chr5:73061259	chr5:72955206~72955699:-
BRCA	cis	rs4835473	0.868	rs62337303	ENSG00000251600.4	RP11-673E1.1	-8.28	3.87e-16	1.3e-13	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143824967	chr4:143912331~143982454:+
BRCA	cis	rs4323050	0.546	rs13124157	ENSG00000251600.4	RP11-673E1.1	8.28	3.88e-16	1.31e-13	0.3	0.25	High light scatter reticulocyte percentage of red cells;	chr4:143975741	chr4:143912331~143982454:+
BRCA	cis	rs853679	1	rs1679709	ENSG00000220721.1	OR1F12	-8.27	3.9e-16	1.31e-13	-0.39	-0.25	Depression;	chr6:28260564	chr6:28073316~28074233:+
BRCA	cis	rs6539288	0.803	rs2374651	ENSG00000260329.1	RP11-412D9.4	-8.27	3.9e-16	1.32e-13	-0.28	-0.25	Total body bone mineral density;	chr12:106934346	chr12:106954029~106955497:-
BRCA	cis	rs11023332	0.8	rs12271890	ENSG00000251991.1	RNU7-49P	8.27	3.91e-16	1.32e-13	0.28	0.25	Vitamin D levels;Adiponectin levels;	chr11:14913140	chr11:14478892~14478953:+
BRCA	cis	rs2243480	0.908	rs1532573	ENSG00000273142.1	RP11-458F8.4	8.27	3.91e-16	1.32e-13	0.35	0.25	Diabetic kidney disease;	chr7:66333815	chr7:66902857~66906297:+
BRCA	cis	rs42648	0.869	rs6970376	ENSG00000225498.1	AC002064.5	-8.27	3.92e-16	1.32e-13	-0.24	-0.25	Homocysteine levels;	chr7:90308772	chr7:90312496~90322592:+
BRCA	cis	rs6142102	0.625	rs4911138	ENSG00000275784.1	RP5-1125A11.6	-8.27	3.92e-16	1.32e-13	-0.29	-0.25	Skin pigmentation;	chr20:33959893	chr20:33989480~33991818:-
BRCA	cis	rs11098499	0.739	rs951570	ENSG00000245958.5	RP11-33B1.1	8.27	3.92e-16	1.32e-13	0.24	0.25	Corneal astigmatism;	chr4:119229312	chr4:119454791~119552025:+
BRCA	cis	rs7674212	0.507	rs223331	ENSG00000246560.2	RP11-10L12.4	8.27	3.93e-16	1.32e-13	0.27	0.25	Type 2 diabetes;	chr4:102872408	chr4:102828055~102844075:+
BRCA	cis	rs2742234	0.59	rs741968	ENSG00000273008.1	RP11-351D16.3	-8.27	3.93e-16	1.32e-13	-0.32	-0.25	Hirschsprung disease;	chr10:43116260	chr10:43136824~43138334:-
BRCA	cis	rs7927771	0.965	rs35184771	ENSG00000280615.1	Y_RNA	-8.27	3.93e-16	1.33e-13	-0.31	-0.25	Subjective well-being;	chr11:47453637	chr11:47614898~47614994:-
BRCA	cis	rs2243480	1	rs10247526	ENSG00000273142.1	RP11-458F8.4	8.27	3.95e-16	1.33e-13	0.35	0.25	Diabetic kidney disease;	chr7:66315709	chr7:66902857~66906297:+
BRCA	cis	rs2243480	0.908	rs2460431	ENSG00000273142.1	RP11-458F8.4	8.27	3.95e-16	1.33e-13	0.34	0.25	Diabetic kidney disease;	chr7:66157859	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs4718309	ENSG00000273142.1	RP11-458F8.4	8.27	3.95e-16	1.33e-13	0.34	0.25	Diabetic kidney disease;	chr7:66162777	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs6460274	ENSG00000273142.1	RP11-458F8.4	8.27	3.95e-16	1.33e-13	0.34	0.25	Diabetic kidney disease;	chr7:66163497	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs7787230	ENSG00000273142.1	RP11-458F8.4	8.27	3.95e-16	1.33e-13	0.34	0.25	Diabetic kidney disease;	chr7:66164112	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs2465120	ENSG00000273142.1	RP11-458F8.4	-8.27	3.95e-16	1.33e-13	-0.34	-0.25	Diabetic kidney disease;	chr7:66155987	chr7:66902857~66906297:+
BRCA	cis	rs7246657	0.722	rs8103647	ENSG00000267422.1	CTD-2554C21.1	-8.27	3.96e-16	1.33e-13	-0.37	-0.25	Coronary artery calcification;	chr19:37609551	chr19:37779686~37792865:+
BRCA	cis	rs11098499	0.863	rs6833334	ENSG00000248280.1	RP11-33B1.2	8.27	3.96e-16	1.33e-13	0.26	0.25	Corneal astigmatism;	chr4:119583072	chr4:119440561~119450157:-
BRCA	cis	rs6570726	0.577	rs867056	ENSG00000235652.6	RP11-545I5.3	-8.27	3.96e-16	1.33e-13	-0.27	-0.25	Lobe attachment (rater-scored or self-reported);	chr6:145463669	chr6:145799409~145886585:+
BRCA	cis	rs10246939	0.543	rs11765575	ENSG00000228775.6	WEE2-AS1	8.27	3.97e-16	1.34e-13	0.27	0.25	Bitter taste perception;	chr7:141838168	chr7:141704338~141738346:-
BRCA	cis	rs875971	0.54	rs1723268	ENSG00000222364.1	RNU6-96P	-8.27	3.97e-16	1.34e-13	-0.29	-0.25	Aortic root size;	chr7:66008093	chr7:66395191~66395286:+
BRCA	cis	rs4713118	0.699	rs200978	ENSG00000220721.1	OR1F12	8.27	3.98e-16	1.34e-13	0.33	0.25	Parkinson's disease;	chr6:27885390	chr6:28073316~28074233:+
BRCA	cis	rs42648	0.777	rs4728878	ENSG00000225498.1	AC002064.5	8.27	3.99e-16	1.34e-13	0.24	0.25	Homocysteine levels;	chr7:90294918	chr7:90312496~90322592:+
BRCA	cis	rs42648	0.837	rs13239439	ENSG00000225498.1	AC002064.5	8.27	3.99e-16	1.34e-13	0.24	0.25	Homocysteine levels;	chr7:90295086	chr7:90312496~90322592:+
BRCA	cis	rs42648	0.837	rs7786771	ENSG00000225498.1	AC002064.5	8.27	3.99e-16	1.34e-13	0.24	0.25	Homocysteine levels;	chr7:90295453	chr7:90312496~90322592:+
BRCA	cis	rs8062405	0.824	rs240702	ENSG00000251417.2	RP11-1348G14.4	-8.27	4e-16	1.35e-13	-0.28	-0.25	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28520032	chr16:28802743~28817828:+
BRCA	cis	rs6142102	0.847	rs4911413	ENSG00000276073.1	RP5-1125A11.7	-8.27	4e-16	1.35e-13	-0.3	-0.25	Skin pigmentation;	chr20:34133969	chr20:33985617~33988989:-
BRCA	cis	rs875971	0.522	rs1917563	ENSG00000236529.1	RP13-254B10.1	-8.27	4.01e-16	1.35e-13	-0.27	-0.25	Aortic root size;	chr7:65950660	chr7:65840212~65840596:+
BRCA	cis	rs11098499	0.532	rs12512646	ENSG00000248280.1	RP11-33B1.2	8.27	4.01e-16	1.35e-13	0.25	0.25	Corneal astigmatism;	chr4:119664578	chr4:119440561~119450157:-
BRCA	cis	rs1015362	0.869	rs6088411	ENSG00000276073.1	RP5-1125A11.7	8.27	4.01e-16	1.35e-13	0.3	0.25	Freckles;Red vs. non-red hair color;Skin sensitivity to sun;Burning and freckling;	chr20:34152101	chr20:33985617~33988989:-
BRCA	cis	rs853679	1	rs853694	ENSG00000220721.1	OR1F12	8.27	4.02e-16	1.35e-13	0.39	0.25	Depression;	chr6:28311323	chr6:28073316~28074233:+
BRCA	cis	rs875971	1	rs12532998	ENSG00000237310.1	GS1-124K5.4	8.27	4.02e-16	1.35e-13	0.26	0.25	Aortic root size;	chr7:66502472	chr7:66493706~66495474:+
BRCA	cis	rs896854	0.967	rs2879813	ENSG00000253528.2	RP11-347C18.4	8.27	4.02e-16	1.35e-13	0.26	0.25	Type 2 diabetes;	chr8:94948719	chr8:94974573~94974853:-
BRCA	cis	rs867371	1	rs7181655	ENSG00000255769.6	GOLGA2P10	-8.27	4.03e-16	1.36e-13	-0.29	-0.25	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82163275	chr15:82472993~82513950:-
BRCA	cis	rs6142102	0.961	rs2235597	ENSG00000276073.1	RP5-1125A11.7	-8.27	4.03e-16	1.36e-13	-0.3	-0.25	Skin pigmentation;	chr20:34077808	chr20:33985617~33988989:-
BRCA	cis	rs9368481	0.761	rs6918835	ENSG00000241549.7	GUSBP2	-8.27	4.03e-16	1.36e-13	-0.29	-0.25	Autism spectrum disorder or schizophrenia;	chr6:27050048	chr6:26871484~26956554:-
BRCA	cis	rs11098499	0.691	rs12502524	ENSG00000248280.1	RP11-33B1.2	8.27	4.03e-16	1.36e-13	0.24	0.25	Corneal astigmatism;	chr4:119350259	chr4:119440561~119450157:-
BRCA	cis	rs6545883	0.894	rs778143	ENSG00000271889.1	RP11-493E12.1	8.27	4.03e-16	1.36e-13	0.32	0.25	Tuberculosis;	chr2:61354755	chr2:61151433~61162105:-
BRCA	cis	rs1499614	1	rs2659913	ENSG00000273142.1	RP11-458F8.4	-8.27	4.04e-16	1.36e-13	-0.35	-0.25	Gout;	chr7:66692349	chr7:66902857~66906297:+
BRCA	cis	rs1499614	1	rs2659911	ENSG00000273142.1	RP11-458F8.4	-8.27	4.04e-16	1.36e-13	-0.35	-0.25	Gout;	chr7:66693433	chr7:66902857~66906297:+
BRCA	cis	rs1499614	1	rs2707838	ENSG00000273142.1	RP11-458F8.4	-8.27	4.04e-16	1.36e-13	-0.35	-0.25	Gout;	chr7:66694214	chr7:66902857~66906297:+
BRCA	cis	rs1499614	1	rs60326618	ENSG00000273142.1	RP11-458F8.4	-8.27	4.04e-16	1.36e-13	-0.35	-0.25	Gout;	chr7:66701371	chr7:66902857~66906297:+
BRCA	cis	rs1499614	1	rs2707830	ENSG00000273142.1	RP11-458F8.4	-8.27	4.04e-16	1.36e-13	-0.35	-0.25	Gout;	chr7:66702658	chr7:66902857~66906297:+
BRCA	cis	rs1499614	1	rs2707828	ENSG00000273142.1	RP11-458F8.4	-8.27	4.04e-16	1.36e-13	-0.35	-0.25	Gout;	chr7:66706390	chr7:66902857~66906297:+
BRCA	cis	rs1499614	0.803	rs1922723	ENSG00000273142.1	RP11-458F8.4	-8.27	4.04e-16	1.36e-13	-0.35	-0.25	Gout;	chr7:66710076	chr7:66902857~66906297:+
BRCA	cis	rs694739	0.628	rs645078	ENSG00000236935.1	AP003774.1	8.27	4.07e-16	1.37e-13	0.23	0.25	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64367826	chr11:64325050~64329504:-
BRCA	cis	rs375066	0.935	rs406968	ENSG00000267058.1	RP11-15A1.3	-8.27	4.07e-16	1.37e-13	-0.28	-0.25	Breast cancer;	chr19:43914191	chr19:43891804~43901805:-
BRCA	cis	rs375066	0.935	rs10406290	ENSG00000267058.1	RP11-15A1.3	-8.27	4.07e-16	1.37e-13	-0.29	-0.25	Breast cancer;	chr19:43874725	chr19:43891804~43901805:-
BRCA	cis	rs13068223	0.74	rs237250	ENSG00000243926.1	TIPARP-AS1	8.27	4.07e-16	1.37e-13	0.26	0.25	Age-related hearing impairment (SNP x SNP interaction);	chr3:156726594	chr3:156671862~156674378:-
BRCA	cis	rs867371	1	rs6495642	ENSG00000259429.4	UBE2Q2P2	-8.27	4.08e-16	1.37e-13	-0.25	-0.25	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82165156	chr15:82355142~82420075:+
BRCA	cis	rs2028299	1	rs1371135	ENSG00000259677.1	RP11-493E3.1	8.27	4.08e-16	1.37e-13	0.33	0.25	Type 2 diabetes;	chr15:89848038	chr15:89876540~89877285:+
BRCA	cis	rs6545883	0.929	rs2593627	ENSG00000271889.1	RP11-493E12.1	-8.27	4.1e-16	1.38e-13	-0.32	-0.25	Tuberculosis;	chr2:61391439	chr2:61151433~61162105:-
BRCA	cis	rs2933343	1	rs1680784	ENSG00000261159.1	RP11-723O4.9	8.27	4.1e-16	1.38e-13	0.3	0.25	IgG glycosylation;	chr3:128925615	chr3:128859716~128860526:-
BRCA	cis	rs2243480	1	rs6974723	ENSG00000273142.1	RP11-458F8.4	8.27	4.1e-16	1.38e-13	0.34	0.25	Diabetic kidney disease;	chr7:66172952	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs9769882	ENSG00000273142.1	RP11-458F8.4	8.27	4.1e-16	1.38e-13	0.34	0.25	Diabetic kidney disease;	chr7:66177938	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs6966322	ENSG00000273142.1	RP11-458F8.4	8.27	4.1e-16	1.38e-13	0.34	0.25	Diabetic kidney disease;	chr7:66181767	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs4145008	ENSG00000273142.1	RP11-458F8.4	8.27	4.1e-16	1.38e-13	0.34	0.25	Diabetic kidney disease;	chr7:66182524	chr7:66902857~66906297:+
BRCA	cis	rs67981189	0.529	rs17093738	ENSG00000269927.1	RP6-91H8.3	8.27	4.11e-16	1.38e-13	0.33	0.25	Schizophrenia;	chr14:71119931	chr14:71141125~71143253:-
BRCA	cis	rs875971	1	rs4717292	ENSG00000237310.1	GS1-124K5.4	8.27	4.12e-16	1.38e-13	0.26	0.25	Aortic root size;	chr7:66430611	chr7:66493706~66495474:+
BRCA	cis	rs875971	1	rs35149210	ENSG00000237310.1	GS1-124K5.4	8.27	4.12e-16	1.38e-13	0.26	0.25	Aortic root size;	chr7:66464938	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.964	rs6945019	ENSG00000237310.1	GS1-124K5.4	8.27	4.12e-16	1.38e-13	0.26	0.25	Aortic root size;	chr7:66457471	chr7:66493706~66495474:+
BRCA	cis	rs250518	0.926	rs3846650	ENSG00000272081.1	CTD-2376I4.2	8.27	4.13e-16	1.39e-13	0.32	0.25	Mean corpuscular hemoglobin concentration;	chr5:72768560	chr5:72955206~72955699:-
BRCA	cis	rs526231	0.543	rs27361	ENSG00000175749.11	EIF3KP1	8.27	4.13e-16	1.39e-13	0.36	0.25	Primary biliary cholangitis;	chr5:103213266	chr5:103032376~103033031:+
BRCA	cis	rs875971	0.522	rs2949690	ENSG00000222364.1	RNU6-96P	8.27	4.13e-16	1.39e-13	0.29	0.25	Aortic root size;	chr7:66018255	chr7:66395191~66395286:+
BRCA	cis	rs6570726	0.599	rs9403725	ENSG00000235652.6	RP11-545I5.3	-8.27	4.13e-16	1.39e-13	-0.27	-0.25	Lobe attachment (rater-scored or self-reported);	chr6:145576486	chr6:145799409~145886585:+
BRCA	cis	rs526231	0.543	rs34809	ENSG00000175749.11	EIF3KP1	8.27	4.15e-16	1.39e-13	0.37	0.25	Primary biliary cholangitis;	chr5:103094413	chr5:103032376~103033031:+
BRCA	cis	rs897984	0.609	rs1108431	ENSG00000260911.2	RP11-196G11.2	8.27	4.15e-16	1.39e-13	0.23	0.25	Dementia with Lewy bodies;	chr16:31043286	chr16:31043150~31049868:+
BRCA	cis	rs2243480	0.803	rs13224048	ENSG00000273142.1	RP11-458F8.4	-8.27	4.15e-16	1.4e-13	-0.34	-0.25	Diabetic kidney disease;	chr7:66528779	chr7:66902857~66906297:+
BRCA	cis	rs875971	0.895	rs778700	ENSG00000237310.1	GS1-124K5.4	8.27	4.16e-16	1.4e-13	0.26	0.25	Aortic root size;	chr7:66401463	chr7:66493706~66495474:+
BRCA	cis	rs875971	1	rs778699	ENSG00000237310.1	GS1-124K5.4	8.27	4.16e-16	1.4e-13	0.26	0.25	Aortic root size;	chr7:66403303	chr7:66493706~66495474:+
BRCA	cis	rs11098499	0.874	rs12502503	ENSG00000245958.5	RP11-33B1.1	-8.27	4.17e-16	1.4e-13	-0.26	-0.25	Corneal astigmatism;	chr4:119195100	chr4:119454791~119552025:+
BRCA	cis	rs7246657	0.722	rs2927747	ENSG00000267422.1	CTD-2554C21.1	8.27	4.18e-16	1.4e-13	0.37	0.25	Coronary artery calcification;	chr19:37668629	chr19:37779686~37792865:+
BRCA	cis	rs7429990	0.864	rs883663	ENSG00000229759.1	MRPS18AP1	-8.27	4.18e-16	1.41e-13	-0.28	-0.25	Educational attainment (years of education);	chr3:47619306	chr3:48256350~48256938:-
BRCA	cis	rs526231	0.543	rs34783	ENSG00000175749.11	EIF3KP1	8.27	4.19e-16	1.41e-13	0.37	0.25	Primary biliary cholangitis;	chr5:103121337	chr5:103032376~103033031:+
BRCA	cis	rs1707322	1	rs11211228	ENSG00000280836.1	AL355480.1	-8.27	4.2e-16	1.41e-13	-0.32	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45934168	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.963	rs11211229	ENSG00000280836.1	AL355480.1	-8.27	4.2e-16	1.41e-13	-0.32	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45934845	chr1:45581219~45581321:-
BRCA	cis	rs1707322	1	rs9803784	ENSG00000280836.1	AL355480.1	-8.27	4.2e-16	1.41e-13	-0.32	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45936235	chr1:45581219~45581321:-
BRCA	cis	rs904251	0.523	rs1757191	ENSG00000204110.6	RP1-153P14.8	-8.27	4.21e-16	1.41e-13	-0.27	-0.25	Cognitive performance;	chr6:37515095	chr6:37507348~37535616:+
BRCA	cis	rs2274273	0.84	rs6573020	ENSG00000258413.1	RP11-665C16.6	-8.27	4.21e-16	1.41e-13	-0.31	-0.25	Protein biomarker;	chr14:55404734	chr14:55262767~55272075:-
BRCA	cis	rs858239	0.539	rs4365988	ENSG00000226816.2	AC005082.12	8.26	4.22e-16	1.42e-13	0.29	0.25	Cerebrospinal fluid biomarker levels;	chr7:23151252	chr7:23206013~23208045:+
BRCA	cis	rs7811142	0.83	rs28495773	ENSG00000242294.5	STAG3L5P	8.26	4.22e-16	1.42e-13	0.25	0.25	Platelet count;	chr7:100345960	chr7:100336079~100351900:+
BRCA	cis	rs10463554	0.963	rs72785733	ENSG00000175749.11	EIF3KP1	8.26	4.22e-16	1.42e-13	0.36	0.25	Parkinson's disease;	chr5:103038488	chr5:103032376~103033031:+
BRCA	cis	rs13256369	1	rs13271966	ENSG00000253893.2	FAM85B	-8.26	4.22e-16	1.42e-13	-0.35	-0.25	Obesity-related traits;	chr8:8717962	chr8:8167819~8226614:-
BRCA	cis	rs113835537	0.529	rs61561111	ENSG00000255517.5	CTD-3074O7.5	-8.26	4.23e-16	1.42e-13	-0.32	-0.25	Airway imaging phenotypes;	chr11:66508452	chr11:66473490~66480233:-
BRCA	cis	rs6142102	0.961	rs4911390	ENSG00000276073.1	RP5-1125A11.7	-8.26	4.23e-16	1.42e-13	-0.3	-0.25	Skin pigmentation;	chr20:33977401	chr20:33985617~33988989:-
BRCA	cis	rs11105298	0.891	rs11105318	ENSG00000258302.2	RP11-981P6.1	8.26	4.23e-16	1.42e-13	0.3	0.25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89532881	chr12:89561129~89594878:+
BRCA	cis	rs904251	0.523	rs2776872	ENSG00000204110.6	RP1-153P14.8	-8.26	4.23e-16	1.42e-13	-0.27	-0.25	Cognitive performance;	chr6:37515011	chr6:37507348~37535616:+
BRCA	cis	rs7811142	0.775	rs1636980	ENSG00000242294.5	STAG3L5P	-8.26	4.23e-16	1.42e-13	-0.25	-0.25	Platelet count;	chr7:100341241	chr7:100336079~100351900:+
BRCA	cis	rs858239	0.6	rs2072368	ENSG00000230042.1	AK3P3	-8.26	4.25e-16	1.43e-13	-0.28	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23106493	chr7:23129178~23129841:+
BRCA	cis	rs17772222	0.958	rs1123421	ENSG00000258983.2	RP11-507K2.2	8.26	4.26e-16	1.43e-13	0.28	0.25	Coronary artery calcification;	chr14:88524651	chr14:88499334~88515502:+
BRCA	cis	rs11976180	1	rs2961115	ENSG00000170356.8	OR2A20P	-8.26	4.26e-16	1.43e-13	-0.34	-0.25	Obesity-related traits;	chr7:144056278	chr7:144250045~144252957:-
BRCA	cis	rs11098499	0.644	rs17517414	ENSG00000245958.5	RP11-33B1.1	-8.26	4.27e-16	1.43e-13	-0.23	-0.25	Corneal astigmatism;	chr4:119340946	chr4:119454791~119552025:+
BRCA	cis	rs524281	0.731	rs12576969	ENSG00000255320.1	RP11-755F10.1	-8.26	4.28e-16	1.44e-13	-0.4	-0.25	Electroencephalogram traits;	chr11:66035007	chr11:66244840~66246239:-
BRCA	cis	rs11098499	0.874	rs28452522	ENSG00000245958.5	RP11-33B1.1	-8.26	4.28e-16	1.44e-13	-0.26	-0.25	Corneal astigmatism;	chr4:119189629	chr4:119454791~119552025:+
BRCA	cis	rs673078	0.615	rs73222058	ENSG00000275759.1	RP11-131L12.3	-8.26	4.29e-16	1.44e-13	-0.34	-0.25	Glucose homeostasis traits;	chr12:118221066	chr12:118428281~118428870:+
BRCA	cis	rs8072100	0.967	rs8072644	ENSG00000228782.6	CTD-2026D20.3	-8.26	4.3e-16	1.44e-13	-0.27	-0.25	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47575998	chr17:47450568~47492492:-
BRCA	cis	rs7569084	0.663	rs1437461	ENSG00000204929.10	AC074391.1	8.26	4.3e-16	1.44e-13	0.34	0.25	Sum eosinophil basophil counts;	chr2:65452578	chr2:65436711~66084639:+
BRCA	cis	rs7569084	0.687	rs7562559	ENSG00000204929.10	AC074391.1	8.26	4.3e-16	1.44e-13	0.34	0.25	Sum eosinophil basophil counts;	chr2:65452719	chr2:65436711~66084639:+
BRCA	cis	rs58873874	0.737	rs78832945	ENSG00000248544.2	CTB-47B11.3	8.26	4.3e-16	1.44e-13	0.57	0.25	Bipolar disorder (body mass index interaction);	chr5:157475805	chr5:157375741~157384950:-
BRCA	cis	rs375066	0.935	rs376032	ENSG00000267058.1	RP11-15A1.3	-8.26	4.31e-16	1.45e-13	-0.29	-0.25	Breast cancer;	chr19:43903412	chr19:43891804~43901805:-
BRCA	cis	rs875971	0.929	rs10950041	ENSG00000237310.1	GS1-124K5.4	8.26	4.32e-16	1.45e-13	0.26	0.25	Aortic root size;	chr7:66508888	chr7:66493706~66495474:+
BRCA	cis	rs867371	1	rs7181655	ENSG00000259429.4	UBE2Q2P2	-8.26	4.33e-16	1.45e-13	-0.25	-0.25	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82163275	chr15:82355142~82420075:+
BRCA	cis	rs875971	0.862	rs1981799	ENSG00000237310.1	GS1-124K5.4	8.26	4.34e-16	1.46e-13	0.26	0.25	Aortic root size;	chr7:66490572	chr7:66493706~66495474:+
BRCA	cis	rs950880	0.71	rs3821203	ENSG00000234389.1	AC007278.3	-8.26	4.34e-16	1.46e-13	-0.25	-0.25	Serum protein levels (sST2);	chr2:102380412	chr2:102438713~102440475:+
BRCA	cis	rs11690935	0.55	rs7584187	ENSG00000228389.1	AC068039.4	8.26	4.35e-16	1.46e-13	0.3	0.25	Schizophrenia;	chr2:172001198	chr2:171773482~171775844:+
BRCA	cis	rs11098499	0.82	rs28578366	ENSG00000248280.1	RP11-33B1.2	-8.26	4.35e-16	1.46e-13	-0.26	-0.25	Corneal astigmatism;	chr4:119615750	chr4:119440561~119450157:-
BRCA	cis	rs801193	0.901	rs4273746	ENSG00000222364.1	RNU6-96P	8.26	4.35e-16	1.46e-13	0.29	0.25	Aortic root size;	chr7:66836124	chr7:66395191~66395286:+
BRCA	cis	rs4835473	0.897	rs4835095	ENSG00000251600.4	RP11-673E1.1	8.26	4.37e-16	1.47e-13	0.29	0.25	Immature fraction of reticulocytes;	chr4:143960431	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.831	rs2667353	ENSG00000251600.4	RP11-673E1.1	8.26	4.37e-16	1.47e-13	0.29	0.25	Immature fraction of reticulocytes;	chr4:143960462	chr4:143912331~143982454:+
BRCA	cis	rs858239	0.632	rs13438452	ENSG00000230042.1	AK3P3	-8.26	4.37e-16	1.47e-13	-0.28	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23134563	chr7:23129178~23129841:+
BRCA	cis	rs10129255	0.957	rs12590667	ENSG00000223648.3	IGHV3-64	-8.26	4.38e-16	1.47e-13	-0.2	-0.25	Kawasaki disease;	chr14:106779223	chr14:106643132~106658258:-
BRCA	cis	rs10246939	0.543	rs9640357	ENSG00000228775.6	WEE2-AS1	8.26	4.39e-16	1.47e-13	0.27	0.25	Bitter taste perception;	chr7:141843298	chr7:141704338~141738346:-
BRCA	cis	rs2742234	0.59	rs2505557	ENSG00000273008.1	RP11-351D16.3	-8.26	4.4e-16	1.47e-13	-0.32	-0.25	Hirschsprung disease;	chr10:43170568	chr10:43136824~43138334:-
BRCA	cis	rs7945705	0.902	rs1560569	ENSG00000254860.4	TMEM9B-AS1	8.26	4.4e-16	1.47e-13	0.23	0.25	Hemoglobin concentration;	chr11:8918340	chr11:8964675~8977527:+
BRCA	cis	rs950880	0.71	rs3771162	ENSG00000234389.1	AC007278.3	-8.26	4.42e-16	1.48e-13	-0.25	-0.25	Serum protein levels (sST2);	chr2:102380714	chr2:102438713~102440475:+
BRCA	cis	rs950880	0.71	rs11465633	ENSG00000234389.1	AC007278.3	-8.26	4.42e-16	1.48e-13	-0.25	-0.25	Serum protein levels (sST2);	chr2:102381273	chr2:102438713~102440475:+
BRCA	cis	rs950880	0.71	rs1035130	ENSG00000234389.1	AC007278.3	-8.26	4.42e-16	1.48e-13	-0.25	-0.25	Serum protein levels (sST2);	chr2:102384942	chr2:102438713~102440475:+
BRCA	cis	rs6142102	0.961	rs973409	ENSG00000276073.1	RP5-1125A11.7	-8.26	4.42e-16	1.48e-13	-0.31	-0.25	Skin pigmentation;	chr20:33948558	chr20:33985617~33988989:-
BRCA	cis	rs7569084	0.687	rs11692813	ENSG00000204929.10	AC074391.1	8.26	4.44e-16	1.49e-13	0.33	0.25	Sum eosinophil basophil counts;	chr2:65435172	chr2:65436711~66084639:+
BRCA	cis	rs875971	0.895	rs10755833	ENSG00000237310.1	GS1-124K5.4	8.26	4.45e-16	1.49e-13	0.26	0.25	Aortic root size;	chr7:66448930	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.895	rs1833495	ENSG00000237310.1	GS1-124K5.4	8.26	4.45e-16	1.49e-13	0.26	0.25	Aortic root size;	chr7:66456608	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.964	rs6945032	ENSG00000237310.1	GS1-124K5.4	8.26	4.45e-16	1.49e-13	0.26	0.25	Aortic root size;	chr7:66457499	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.929	rs12673810	ENSG00000237310.1	GS1-124K5.4	8.26	4.45e-16	1.49e-13	0.26	0.25	Aortic root size;	chr7:66458866	chr7:66493706~66495474:+
BRCA	cis	rs875971	1	rs6961155	ENSG00000237310.1	GS1-124K5.4	8.26	4.45e-16	1.49e-13	0.26	0.25	Aortic root size;	chr7:66468308	chr7:66493706~66495474:+
BRCA	cis	rs875971	1	rs7789768	ENSG00000237310.1	GS1-124K5.4	8.26	4.45e-16	1.49e-13	0.26	0.25	Aortic root size;	chr7:66473993	chr7:66493706~66495474:+
BRCA	cis	rs875971	1	rs1363055	ENSG00000237310.1	GS1-124K5.4	8.26	4.45e-16	1.49e-13	0.26	0.25	Aortic root size;	chr7:66478288	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.964	rs9691480	ENSG00000237310.1	GS1-124K5.4	8.26	4.45e-16	1.49e-13	0.26	0.25	Aortic root size;	chr7:66479319	chr7:66493706~66495474:+
BRCA	cis	rs7811142	0.83	rs11769057	ENSG00000242294.5	STAG3L5P	8.26	4.46e-16	1.49e-13	0.24	0.25	Platelet count;	chr7:100367038	chr7:100336079~100351900:+
BRCA	cis	rs7772486	0.875	rs1331639	ENSG00000235652.6	RP11-545I5.3	-8.26	4.46e-16	1.49e-13	-0.25	-0.25	Lobe attachment (rater-scored or self-reported);	chr6:146110733	chr6:145799409~145886585:+
BRCA	cis	rs720475	0.732	rs7784282	ENSG00000204959.4	ARHGEF34P	-8.26	4.49e-16	1.5e-13	-0.32	-0.25	Breast cancer;	chr7:144431561	chr7:144272445~144286966:-
BRCA	cis	rs10246939	0.543	rs35836873	ENSG00000228775.6	WEE2-AS1	8.26	4.49e-16	1.5e-13	0.27	0.25	Bitter taste perception;	chr7:141844010	chr7:141704338~141738346:-
BRCA	cis	rs10246939	0.543	rs9640358	ENSG00000228775.6	WEE2-AS1	8.26	4.49e-16	1.5e-13	0.27	0.25	Bitter taste perception;	chr7:141844082	chr7:141704338~141738346:-
BRCA	cis	rs6545883	0.894	rs2600660	ENSG00000271889.1	RP11-493E12.1	-8.26	4.49e-16	1.5e-13	-0.32	-0.25	Tuberculosis;	chr2:61322465	chr2:61151433~61162105:-
BRCA	cis	rs7429990	0.833	rs6442072	ENSG00000229759.1	MRPS18AP1	-8.26	4.5e-16	1.51e-13	-0.28	-0.25	Educational attainment (years of education);	chr3:47642960	chr3:48256350~48256938:-
BRCA	cis	rs8062405	0.698	rs7188071	ENSG00000251417.2	RP11-1348G14.4	8.26	4.51e-16	1.51e-13	0.3	0.25	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28906323	chr16:28802743~28817828:+
BRCA	cis	rs6142102	0.812	rs2377955	ENSG00000276073.1	RP5-1125A11.7	-8.26	4.51e-16	1.51e-13	-0.31	-0.25	Skin pigmentation;	chr20:33937564	chr20:33985617~33988989:-
BRCA	cis	rs58873874	0.737	rs11745566	ENSG00000248544.2	CTB-47B11.3	8.26	4.52e-16	1.51e-13	0.59	0.25	Bipolar disorder (body mass index interaction);	chr5:157464945	chr5:157375741~157384950:-
BRCA	cis	rs250518	0.926	rs34749191	ENSG00000272081.1	CTD-2376I4.2	8.26	4.53e-16	1.52e-13	0.32	0.25	Mean corpuscular hemoglobin concentration;	chr5:72749431	chr5:72955206~72955699:-
BRCA	cis	rs2243480	0.901	rs778687	ENSG00000273142.1	RP11-458F8.4	-8.26	4.54e-16	1.52e-13	-0.35	-0.25	Diabetic kidney disease;	chr7:66370832	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs778704	ENSG00000273142.1	RP11-458F8.4	-8.26	4.54e-16	1.52e-13	-0.35	-0.25	Diabetic kidney disease;	chr7:66398480	chr7:66902857~66906297:+
BRCA	cis	rs2243480	0.901	rs778693	ENSG00000273142.1	RP11-458F8.4	-8.26	4.54e-16	1.52e-13	-0.35	-0.25	Diabetic kidney disease;	chr7:66407358	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs778691	ENSG00000273142.1	RP11-458F8.4	-8.26	4.54e-16	1.52e-13	-0.35	-0.25	Diabetic kidney disease;	chr7:66408105	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs13235972	ENSG00000273142.1	RP11-458F8.4	-8.26	4.54e-16	1.52e-13	-0.35	-0.25	Diabetic kidney disease;	chr7:66418618	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs34192067	ENSG00000273142.1	RP11-458F8.4	-8.26	4.54e-16	1.52e-13	-0.35	-0.25	Diabetic kidney disease;	chr7:66422670	chr7:66902857~66906297:+
BRCA	cis	rs11098499	0.691	rs28396837	ENSG00000248280.1	RP11-33B1.2	8.26	4.54e-16	1.52e-13	0.24	0.25	Corneal astigmatism;	chr4:119350386	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.629	rs28369518	ENSG00000248280.1	RP11-33B1.2	8.26	4.54e-16	1.52e-13	0.24	0.25	Corneal astigmatism;	chr4:119350475	chr4:119440561~119450157:-
BRCA	cis	rs2742234	0.59	rs2293020	ENSG00000273008.1	RP11-351D16.3	8.25	4.57e-16	1.53e-13	0.31	0.25	Hirschsprung disease;	chr10:43197439	chr10:43136824~43138334:-
BRCA	cis	rs858239	0.676	rs3807459	ENSG00000226816.2	AC005082.12	8.25	4.59e-16	1.54e-13	0.28	0.25	Cerebrospinal fluid biomarker levels;	chr7:23350132	chr7:23206013~23208045:+
BRCA	cis	rs4718428	0.705	rs13227468	ENSG00000232546.1	RP11-458F8.1	-8.25	4.6e-16	1.54e-13	-0.23	-0.25	Corneal structure;	chr7:66968576	chr7:66848496~66858136:+
BRCA	cis	rs950880	0.71	rs17027037	ENSG00000234389.1	AC007278.3	-8.25	4.62e-16	1.54e-13	-0.25	-0.25	Serum protein levels (sST2);	chr2:102378424	chr2:102438713~102440475:+
BRCA	cis	rs950880	0.71	rs2080289	ENSG00000234389.1	AC007278.3	-8.25	4.62e-16	1.54e-13	-0.25	-0.25	Serum protein levels (sST2);	chr2:102378560	chr2:102438713~102440475:+
BRCA	cis	rs4835473	0.742	rs6537238	ENSG00000251600.4	RP11-673E1.1	8.25	4.63e-16	1.55e-13	0.3	0.25	Immature fraction of reticulocytes;	chr4:143996463	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs1473055	ENSG00000251600.4	RP11-673E1.1	8.25	4.63e-16	1.55e-13	0.3	0.25	Immature fraction of reticulocytes;	chr4:143997714	chr4:143912331~143982454:+
BRCA	cis	rs10463554	0.892	rs6871715	ENSG00000175749.11	EIF3KP1	8.25	4.63e-16	1.55e-13	0.33	0.25	Parkinson's disease;	chr5:102930398	chr5:103032376~103033031:+
BRCA	cis	rs875971	0.929	rs12535036	ENSG00000237310.1	GS1-124K5.4	8.25	4.64e-16	1.55e-13	0.26	0.25	Aortic root size;	chr7:66499076	chr7:66493706~66495474:+
BRCA	cis	rs875971	1	rs6970030	ENSG00000237310.1	GS1-124K5.4	8.25	4.64e-16	1.55e-13	0.26	0.25	Aortic root size;	chr7:66503692	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.928	rs6970357	ENSG00000237310.1	GS1-124K5.4	8.25	4.64e-16	1.55e-13	0.26	0.25	Aortic root size;	chr7:66503891	chr7:66493706~66495474:+
BRCA	cis	rs7621025	0.5	rs9845460	ENSG00000273486.1	RP11-731C17.2	8.25	4.64e-16	1.55e-13	0.31	0.25	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136868275	chr3:136837338~136839021:-
BRCA	cis	rs11098499	0.874	rs13123591	ENSG00000245958.5	RP11-33B1.1	-8.25	4.64e-16	1.55e-13	-0.26	-0.25	Corneal astigmatism;	chr4:119184835	chr4:119454791~119552025:+
BRCA	cis	rs875971	0.964	rs6978429	ENSG00000237310.1	GS1-124K5.4	8.25	4.65e-16	1.56e-13	0.26	0.25	Aortic root size;	chr7:66494889	chr7:66493706~66495474:+
BRCA	cis	rs875971	1	rs4718357	ENSG00000237310.1	GS1-124K5.4	8.25	4.65e-16	1.56e-13	0.26	0.25	Aortic root size;	chr7:66495891	chr7:66493706~66495474:+
BRCA	cis	rs367615	0.842	rs2578484	ENSG00000249476.1	CTD-2587M2.1	-8.25	4.66e-16	1.56e-13	-0.3	-0.25	Colorectal cancer (SNP x SNP interaction);	chr5:109615107	chr5:109237120~109326369:-
BRCA	cis	rs9532669	0.926	rs2039119	ENSG00000168852.11	TPTE2P5	-8.25	4.67e-16	1.56e-13	-0.24	-0.25	Cervical cancer;	chr13:40872432	chr13:40822296~40921749:-
BRCA	cis	rs875971	1	rs7789554	ENSG00000237310.1	GS1-124K5.4	8.25	4.68e-16	1.56e-13	0.26	0.25	Aortic root size;	chr7:66481051	chr7:66493706~66495474:+
BRCA	cis	rs875971	1	rs4717300	ENSG00000237310.1	GS1-124K5.4	8.25	4.68e-16	1.56e-13	0.26	0.25	Aortic root size;	chr7:66482393	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.895	rs1974769	ENSG00000237310.1	GS1-124K5.4	8.25	4.68e-16	1.56e-13	0.26	0.25	Aortic root size;	chr7:66485627	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.895	rs6460300	ENSG00000237310.1	GS1-124K5.4	8.25	4.68e-16	1.56e-13	0.26	0.25	Aortic root size;	chr7:66487937	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.862	rs7803416	ENSG00000237310.1	GS1-124K5.4	8.25	4.68e-16	1.56e-13	0.26	0.25	Aortic root size;	chr7:66489212	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.964	rs2277911	ENSG00000237310.1	GS1-124K5.4	8.25	4.68e-16	1.56e-13	0.26	0.25	Aortic root size;	chr7:66493638	chr7:66493706~66495474:+
BRCA	cis	rs11976180	1	rs1320894	ENSG00000170356.8	OR2A20P	-8.25	4.71e-16	1.57e-13	-0.34	-0.25	Obesity-related traits;	chr7:144054709	chr7:144250045~144252957:-
BRCA	cis	rs11976180	1	rs2951369	ENSG00000170356.8	OR2A20P	-8.25	4.71e-16	1.57e-13	-0.34	-0.25	Obesity-related traits;	chr7:144055545	chr7:144250045~144252957:-
BRCA	cis	rs10463554	0.892	rs11952337	ENSG00000175749.11	EIF3KP1	8.25	4.71e-16	1.57e-13	0.33	0.25	Parkinson's disease;	chr5:102928043	chr5:103032376~103033031:+
BRCA	cis	rs3762637	0.941	rs6788746	ENSG00000272758.4	RP11-299J3.8	-8.25	4.71e-16	1.57e-13	-0.37	-0.25	LDL cholesterol levels;	chr3:122387896	chr3:122416207~122443180:+
BRCA	cis	rs2933343	1	rs1680784	ENSG00000231305.3	RP11-723O4.2	8.25	4.72e-16	1.58e-13	0.31	0.25	IgG glycosylation;	chr3:128925615	chr3:128861313~128871540:-
BRCA	cis	rs10740039	0.804	rs894383	ENSG00000254271.1	RP11-131N11.4	8.25	4.72e-16	1.58e-13	0.33	0.25	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60683359	chr10:60734342~60741828:+
BRCA	cis	rs732716	0.785	rs9973266	ENSG00000267980.1	AC007292.6	-8.25	4.73e-16	1.58e-13	-0.33	-0.25	Mean corpuscular volume;	chr19:4392718	chr19:4363789~4364640:+
BRCA	cis	rs7674212	0.531	rs4698875	ENSG00000246560.2	RP11-10L12.4	8.25	4.73e-16	1.58e-13	0.27	0.25	Type 2 diabetes;	chr4:103012211	chr4:102828055~102844075:+
BRCA	cis	rs858239	0.571	rs6953020	ENSG00000230042.1	AK3P3	-8.25	4.74e-16	1.58e-13	-0.29	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23132513	chr7:23129178~23129841:+
BRCA	cis	rs950776	0.518	rs1979907	ENSG00000261762.1	RP11-650L12.2	-8.25	4.74e-16	1.58e-13	-0.27	-0.25	Sudden cardiac arrest;	chr15:78549897	chr15:78589123~78591276:-
BRCA	cis	rs2243480	0.901	rs778732	ENSG00000273142.1	RP11-458F8.4	-8.25	4.74e-16	1.58e-13	-0.35	-0.25	Diabetic kidney disease;	chr7:66357373	chr7:66902857~66906297:+
BRCA	cis	rs875971	0.545	rs10950029	ENSG00000222364.1	RNU6-96P	-8.25	4.74e-16	1.58e-13	-0.32	-0.25	Aortic root size;	chr7:66169334	chr7:66395191~66395286:+
BRCA	cis	rs10129255	1	rs4612959	ENSG00000223648.3	IGHV3-64	8.25	4.74e-16	1.58e-13	0.21	0.25	Kawasaki disease;	chr14:106767055	chr14:106643132~106658258:-
BRCA	cis	rs897984	0.609	rs732173	ENSG00000260911.2	RP11-196G11.2	8.25	4.75e-16	1.59e-13	0.23	0.25	Dementia with Lewy bodies;	chr16:31038702	chr16:31043150~31049868:+
BRCA	cis	rs8012947	1	rs56208804	ENSG00000279636.2	LINC00216	-8.25	4.75e-16	1.59e-13	-0.27	-0.25	Alcohol consumption in current drinkers;	chr14:58313408	chr14:58288033~58289158:+
BRCA	cis	rs7811142	0.83	rs73401450	ENSG00000242294.5	STAG3L5P	8.25	4.75e-16	1.59e-13	0.24	0.25	Platelet count;	chr7:100384236	chr7:100336079~100351900:+
BRCA	cis	rs4835473	0.831	rs4452380	ENSG00000251600.4	RP11-673E1.1	8.25	4.77e-16	1.59e-13	0.3	0.25	Immature fraction of reticulocytes;	chr4:143972856	chr4:143912331~143982454:+
BRCA	cis	rs6142102	0.58	rs4911139	ENSG00000275784.1	RP5-1125A11.6	-8.25	4.78e-16	1.6e-13	-0.28	-0.25	Skin pigmentation;	chr20:33963729	chr20:33989480~33991818:-
BRCA	cis	rs4718428	0.705	rs13227468	ENSG00000273142.1	RP11-458F8.4	-8.25	4.79e-16	1.6e-13	-0.24	-0.25	Corneal structure;	chr7:66968576	chr7:66902857~66906297:+
BRCA	cis	rs4835473	0.897	rs7662736	ENSG00000251600.4	RP11-673E1.1	8.25	4.79e-16	1.6e-13	0.29	0.25	Immature fraction of reticulocytes;	chr4:143958036	chr4:143912331~143982454:+
BRCA	cis	rs2439831	0.702	rs28699233	ENSG00000249839.1	AC011330.5	-8.25	4.8e-16	1.6e-13	-0.47	-0.25	Lung cancer in ever smokers;	chr15:43830668	chr15:43663654~43684339:-
BRCA	cis	rs7250849	0.529	rs16982912	ENSG00000273837.1	LLNLR-470E3.1	-8.25	4.81e-16	1.6e-13	-0.33	-0.25	Blood protein levels;	chr19:51661874	chr19:51639478~51639931:-
BRCA	cis	rs11098499	0.691	rs12510133	ENSG00000248280.1	RP11-33B1.2	8.25	4.81e-16	1.61e-13	0.24	0.25	Corneal astigmatism;	chr4:119350189	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.754	rs12506487	ENSG00000248280.1	RP11-33B1.2	8.25	4.81e-16	1.61e-13	0.24	0.25	Corneal astigmatism;	chr4:119350206	chr4:119440561~119450157:-
BRCA	cis	rs875971	1	rs2420591	ENSG00000237310.1	GS1-124K5.4	8.25	4.82e-16	1.61e-13	0.26	0.25	Aortic root size;	chr7:66447394	chr7:66493706~66495474:+
BRCA	cis	rs7429990	0.864	rs2049301	ENSG00000229759.1	MRPS18AP1	-8.25	4.83e-16	1.61e-13	-0.28	-0.25	Educational attainment (years of education);	chr3:47681369	chr3:48256350~48256938:-
BRCA	cis	rs2243480	1	rs1873494	ENSG00000273142.1	RP11-458F8.4	8.25	4.84e-16	1.62e-13	0.34	0.25	Diabetic kidney disease;	chr7:66184912	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs6959002	ENSG00000273142.1	RP11-458F8.4	8.25	4.84e-16	1.62e-13	0.34	0.25	Diabetic kidney disease;	chr7:66185509	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs7804223	ENSG00000273142.1	RP11-458F8.4	8.25	4.85e-16	1.62e-13	0.34	0.25	Diabetic kidney disease;	chr7:66199572	chr7:66902857~66906297:+
BRCA	cis	rs6545883	0.894	rs6545867	ENSG00000271889.1	RP11-493E12.1	-8.25	4.85e-16	1.62e-13	-0.32	-0.25	Tuberculosis;	chr2:61423892	chr2:61151433~61162105:-
BRCA	cis	rs10129255	1	rs10129255	ENSG00000223648.3	IGHV3-64	-8.25	4.86e-16	1.62e-13	-0.21	-0.25	Kawasaki disease;	chr14:106767970	chr14:106643132~106658258:-
BRCA	cis	rs2115630	0.755	rs7169629	ENSG00000225151.9	GOLGA2P7	-8.25	4.87e-16	1.62e-13	-0.26	-0.25	P wave terminal force;	chr15:84648043	chr15:84199311~84230136:-
BRCA	cis	rs6142102	0.961	rs4911389	ENSG00000276073.1	RP5-1125A11.7	-8.25	4.87e-16	1.63e-13	-0.3	-0.25	Skin pigmentation;	chr20:33977235	chr20:33985617~33988989:-
BRCA	cis	rs875971	0.964	rs12668936	ENSG00000237310.1	GS1-124K5.4	8.25	4.88e-16	1.63e-13	0.26	0.25	Aortic root size;	chr7:66449417	chr7:66493706~66495474:+
BRCA	cis	rs10740039	0.804	rs1372714	ENSG00000254271.1	RP11-131N11.4	8.25	4.88e-16	1.63e-13	0.33	0.25	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60686640	chr10:60734342~60741828:+
BRCA	cis	rs1075232	1	rs72722829	ENSG00000270055.1	CTD-3092A11.2	-8.25	4.88e-16	1.63e-13	-0.57	-0.25	Survival in colorectal cancer (non-distant metastatic);	chr15:31346911	chr15:30487963~30490313:+
BRCA	cis	rs860818	1	rs1626853	ENSG00000226816.2	AC005082.12	8.25	4.89e-16	1.63e-13	0.54	0.25	Initial pursuit acceleration;	chr7:23195723	chr7:23206013~23208045:+
BRCA	cis	rs198389	0.589	rs198391	ENSG00000242349.4	NPPA-AS1	8.25	4.9e-16	1.63e-13	0.26	0.25	B-type natriuretic peptide levels;NT-proBNP levels in acute coronary syndrome;	chr1:11816360	chr1:11841017~11848079:+
BRCA	cis	rs6545883	0.894	rs4672436	ENSG00000271889.1	RP11-493E12.1	-8.25	4.9e-16	1.63e-13	-0.32	-0.25	Tuberculosis;	chr2:61376222	chr2:61151433~61162105:-
BRCA	cis	rs6545883	0.859	rs35760550	ENSG00000271889.1	RP11-493E12.1	-8.25	4.9e-16	1.63e-13	-0.32	-0.25	Tuberculosis;	chr2:61376730	chr2:61151433~61162105:-
BRCA	cis	rs6545883	0.859	rs62149714	ENSG00000271889.1	RP11-493E12.1	-8.25	4.9e-16	1.63e-13	-0.32	-0.25	Tuberculosis;	chr2:61376734	chr2:61151433~61162105:-
BRCA	cis	rs11098499	1	rs11726229	ENSG00000245958.5	RP11-33B1.1	-8.25	4.9e-16	1.63e-13	-0.25	-0.25	Corneal astigmatism;	chr4:119290425	chr4:119454791~119552025:+
BRCA	cis	rs7727544	0.735	rs2631370	ENSG00000233006.5	AC034220.3	-8.25	4.9e-16	1.63e-13	-0.18	-0.25	Blood metabolite levels;	chr5:132368084	chr5:132311285~132369916:-
BRCA	cis	rs6700559	0.654	rs66717951	ENSG00000260088.1	RP11-92G12.3	8.25	4.92e-16	1.64e-13	0.3	0.25	Coronary artery disease;	chr1:200626437	chr1:200669507~200694250:+
BRCA	cis	rs1167827	1	rs1167827	ENSG00000278416.1	PMS2L2	8.24	4.95e-16	1.65e-13	0.32	0.25	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75533848	chr7:75344015~75359550:-
BRCA	cis	rs7246657	0.722	rs2972458	ENSG00000267422.1	CTD-2554C21.1	8.24	4.95e-16	1.65e-13	0.37	0.25	Coronary artery calcification;	chr19:37644502	chr19:37779686~37792865:+
BRCA	cis	rs526231	0.543	rs27698	ENSG00000175749.11	EIF3KP1	-8.24	4.96e-16	1.65e-13	-0.36	-0.25	Primary biliary cholangitis;	chr5:103190474	chr5:103032376~103033031:+
BRCA	cis	rs7569084	0.64	rs11126039	ENSG00000204929.10	AC074391.1	8.24	4.98e-16	1.66e-13	0.33	0.25	Sum eosinophil basophil counts;	chr2:65457953	chr2:65436711~66084639:+
BRCA	cis	rs4835473	1	rs4835473	ENSG00000251600.4	RP11-673E1.1	8.24	4.99e-16	1.66e-13	0.3	0.25	Immature fraction of reticulocytes;	chr4:143982419	chr4:143912331~143982454:+
BRCA	cis	rs8062405	0.824	rs153106	ENSG00000251417.2	RP11-1348G14.4	-8.24	5e-16	1.67e-13	-0.28	-0.25	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28515576	chr16:28802743~28817828:+
BRCA	cis	rs11023332	0.706	rs10766197	ENSG00000251991.1	RNU7-49P	8.24	5.01e-16	1.67e-13	0.28	0.25	Vitamin D levels;Adiponectin levels;	chr11:14900334	chr11:14478892~14478953:+
BRCA	cis	rs7772486	0.875	rs10457796	ENSG00000235652.6	RP11-545I5.3	8.24	5.02e-16	1.67e-13	0.25	0.25	Lobe attachment (rater-scored or self-reported);	chr6:146094951	chr6:145799409~145886585:+
BRCA	cis	rs4323050	0.51	rs4254715	ENSG00000251600.4	RP11-673E1.1	8.24	5.02e-16	1.67e-13	0.3	0.25	High light scatter reticulocyte percentage of red cells;	chr4:143993140	chr4:143912331~143982454:+
BRCA	cis	rs4323050	0.51	rs4273414	ENSG00000251600.4	RP11-673E1.1	8.24	5.02e-16	1.67e-13	0.3	0.25	High light scatter reticulocyte percentage of red cells;	chr4:143993142	chr4:143912331~143982454:+
BRCA	cis	rs7927771	0.832	rs10838704	ENSG00000280615.1	Y_RNA	-8.24	5.03e-16	1.68e-13	-0.31	-0.25	Subjective well-being;	chr11:47403166	chr11:47614898~47614994:-
BRCA	cis	rs9637599	0.967	rs7656367	ENSG00000246375.2	RP11-10L7.1	8.24	5.05e-16	1.68e-13	0.32	0.25	Metabolite levels (small molecules and protein measures);	chr4:88275669	chr4:88284942~88331421:+
BRCA	cis	rs10510102	0.748	rs4589226	ENSG00000276742.1	RP11-500G22.4	8.24	5.06e-16	1.68e-13	0.42	0.25	Breast cancer;	chr10:121951073	chr10:121956782~121957098:+
BRCA	cis	rs9880211	0.898	rs9866840	ENSG00000239213.4	NCK1-AS1	8.24	5.07e-16	1.69e-13	0.31	0.25	Height;Body mass index;	chr3:136310416	chr3:136841726~136862054:-
BRCA	cis	rs853679	1	rs68141011	ENSG00000220721.1	OR1F12	8.24	5.07e-16	1.69e-13	0.4	0.25	Depression;	chr6:28250019	chr6:28073316~28074233:+
BRCA	cis	rs853679	1	rs13200462	ENSG00000220721.1	OR1F12	8.24	5.07e-16	1.69e-13	0.4	0.25	Depression;	chr6:28250421	chr6:28073316~28074233:+
BRCA	cis	rs526231	0.543	rs34377	ENSG00000175749.11	EIF3KP1	8.24	5.08e-16	1.69e-13	0.36	0.25	Primary biliary cholangitis;	chr5:103064852	chr5:103032376~103033031:+
BRCA	cis	rs858239	0.539	rs6965833	ENSG00000226816.2	AC005082.12	8.24	5.08e-16	1.69e-13	0.29	0.25	Cerebrospinal fluid biomarker levels;	chr7:23152747	chr7:23206013~23208045:+
BRCA	cis	rs858239	0.539	rs6949363	ENSG00000226816.2	AC005082.12	8.24	5.08e-16	1.69e-13	0.29	0.25	Cerebrospinal fluid biomarker levels;	chr7:23152775	chr7:23206013~23208045:+
BRCA	cis	rs1061377	1	rs12646251	ENSG00000249685.1	RP11-360F5.3	8.24	5.09e-16	1.69e-13	0.31	0.25	Uric acid levels;	chr4:39132751	chr4:39133913~39135608:+
BRCA	cis	rs950880	0.71	rs66919607	ENSG00000234389.1	AC007278.3	-8.24	5.09e-16	1.69e-13	-0.25	-0.25	Serum protein levels (sST2);	chr2:102392509	chr2:102438713~102440475:+
BRCA	cis	rs858239	0.539	rs2141305	ENSG00000226816.2	AC005082.12	8.24	5.1e-16	1.7e-13	0.29	0.25	Cerebrospinal fluid biomarker levels;	chr7:23152280	chr7:23206013~23208045:+
BRCA	cis	rs10129255	0.518	rs7143784	ENSG00000211970.3	IGHV4-61	-8.24	5.12e-16	1.71e-13	-0.16	-0.25	Kawasaki disease;	chr14:106687277	chr14:106639119~106639657:-
BRCA	cis	rs4835473	0.771	rs4443231	ENSG00000251600.4	RP11-673E1.1	8.24	5.13e-16	1.71e-13	0.3	0.25	Immature fraction of reticulocytes;	chr4:143979501	chr4:143912331~143982454:+
BRCA	cis	rs6545883	0.859	rs2694644	ENSG00000271889.1	RP11-493E12.1	-8.24	5.13e-16	1.71e-13	-0.32	-0.25	Tuberculosis;	chr2:61377721	chr2:61151433~61162105:-
BRCA	cis	rs2921036	0.545	rs4840975	ENSG00000253893.2	FAM85B	8.24	5.15e-16	1.71e-13	0.32	0.25	Neuroticism;	chr8:8505748	chr8:8167819~8226614:-
BRCA	cis	rs7811142	0.779	rs111312383	ENSG00000242294.5	STAG3L5P	8.24	5.15e-16	1.72e-13	0.25	0.25	Platelet count;	chr7:100307702	chr7:100336079~100351900:+
BRCA	cis	rs526231	0.511	rs17155009	ENSG00000175749.11	EIF3KP1	8.24	5.17e-16	1.72e-13	0.35	0.25	Primary biliary cholangitis;	chr5:103038440	chr5:103032376~103033031:+
BRCA	cis	rs26232	0.521	rs67019105	ENSG00000175749.11	EIF3KP1	8.24	5.17e-16	1.72e-13	0.35	0.25	Rheumatoid arthritis;	chr5:103038459	chr5:103032376~103033031:+
BRCA	cis	rs950776	0.518	rs8053	ENSG00000261762.1	RP11-650L12.2	-8.24	5.18e-16	1.72e-13	-0.27	-0.25	Sudden cardiac arrest;	chr15:78548878	chr15:78589123~78591276:-
BRCA	cis	rs1113500	0.748	rs1781048	ENSG00000226822.1	RP11-356N1.2	8.24	5.19e-16	1.73e-13	0.33	0.25	Growth-regulated protein alpha levels;	chr1:108012428	chr1:108071482~108074519:+
BRCA	cis	rs950880	0.71	rs55883125	ENSG00000234389.1	AC007278.3	-8.24	5.19e-16	1.73e-13	-0.25	-0.25	Serum protein levels (sST2);	chr2:102407871	chr2:102438713~102440475:+
BRCA	cis	rs11976180	1	rs2951363	ENSG00000170356.8	OR2A20P	-8.24	5.22e-16	1.74e-13	-0.34	-0.25	Obesity-related traits;	chr7:144057631	chr7:144250045~144252957:-
BRCA	cis	rs7085104	0.7	rs7096183	ENSG00000236937.2	PTGES3P4	8.24	5.24e-16	1.74e-13	0.31	0.25	Immature fraction of reticulocytes;Schizophrenia;	chr10:102849709	chr10:102845595~102845950:+
BRCA	cis	rs56804039	1	rs34154295	ENSG00000253893.2	FAM85B	8.24	5.26e-16	1.75e-13	0.37	0.25	Cervical cancer;	chr8:8525967	chr8:8167819~8226614:-
BRCA	cis	rs6142102	1	rs4911410	ENSG00000276073.1	RP5-1125A11.7	-8.24	5.27e-16	1.75e-13	-0.29	-0.25	Skin pigmentation;	chr20:34123168	chr20:33985617~33988989:-
BRCA	cis	rs3864261	0.515	rs12186995	ENSG00000272081.1	CTD-2376I4.2	8.24	5.28e-16	1.75e-13	0.31	0.25	Discordance in emotional problems in monozygotic twins;	chr5:73039500	chr5:72955206~72955699:-
BRCA	cis	rs13256369	1	rs10098234	ENSG00000253893.2	FAM85B	-8.24	5.28e-16	1.76e-13	-0.34	-0.25	Obesity-related traits;	chr8:8719182	chr8:8167819~8226614:-
BRCA	cis	rs11098499	0.866	rs3756156	ENSG00000248280.1	RP11-33B1.2	8.24	5.29e-16	1.76e-13	0.26	0.25	Corneal astigmatism;	chr4:119603686	chr4:119440561~119450157:-
BRCA	cis	rs950880	0.71	rs2270298	ENSG00000234389.1	AC007278.3	-8.24	5.3e-16	1.76e-13	-0.25	-0.25	Serum protein levels (sST2);	chr2:102375619	chr2:102438713~102440475:+
BRCA	cis	rs6545883	0.929	rs1186711	ENSG00000271889.1	RP11-493E12.1	8.24	5.3e-16	1.76e-13	0.33	0.25	Tuberculosis;	chr2:61461370	chr2:61151433~61162105:-
BRCA	cis	rs8012947	1	rs1951202	ENSG00000279636.2	LINC00216	8.24	5.32e-16	1.77e-13	0.27	0.25	Alcohol consumption in current drinkers;	chr14:58312699	chr14:58288033~58289158:+
BRCA	cis	rs858239	0.601	rs10278776	ENSG00000230042.1	AK3P3	-8.23	5.34e-16	1.78e-13	-0.28	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23130140	chr7:23129178~23129841:+
BRCA	cis	rs11098499	0.863	rs6835635	ENSG00000248280.1	RP11-33B1.2	8.23	5.37e-16	1.78e-13	0.26	0.25	Corneal astigmatism;	chr4:119537712	chr4:119440561~119450157:-
BRCA	cis	rs9640161	0.789	rs1464752	ENSG00000261305.1	RP4-584D14.7	8.23	5.37e-16	1.79e-13	0.37	0.25	Blood protein levels;Circulating chemerin levels;	chr7:150324195	chr7:150341771~150342607:+
BRCA	cis	rs858239	0.601	rs4599714	ENSG00000230042.1	AK3P3	-8.23	5.38e-16	1.79e-13	-0.28	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23129182	chr7:23129178~23129841:+
BRCA	cis	rs8062405	0.789	rs1968752	ENSG00000251417.2	RP11-1348G14.4	-8.23	5.38e-16	1.79e-13	-0.28	-0.25	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620264	chr16:28802743~28817828:+
BRCA	cis	rs3762637	1	rs7615930	ENSG00000272758.4	RP11-299J3.8	-8.23	5.38e-16	1.79e-13	-0.35	-0.25	LDL cholesterol levels;	chr3:122406903	chr3:122416207~122443180:+
BRCA	cis	rs10463554	0.963	rs32850	ENSG00000175749.11	EIF3KP1	8.23	5.38e-16	1.79e-13	0.33	0.25	Parkinson's disease;	chr5:103134325	chr5:103032376~103033031:+
BRCA	cis	rs13256369	1	rs10088439	ENSG00000253893.2	FAM85B	-8.23	5.39e-16	1.79e-13	-0.34	-0.25	Obesity-related traits;	chr8:8719189	chr8:8167819~8226614:-
BRCA	cis	rs2243480	0.708	rs35825036	ENSG00000273142.1	RP11-458F8.4	-8.23	5.39e-16	1.79e-13	-0.34	-0.25	Diabetic kidney disease;	chr7:66521515	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs13237037	ENSG00000273142.1	RP11-458F8.4	-8.23	5.39e-16	1.79e-13	-0.34	-0.25	Diabetic kidney disease;	chr7:66532895	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs1796228	ENSG00000273142.1	RP11-458F8.4	-8.23	5.39e-16	1.79e-13	-0.34	-0.25	Diabetic kidney disease;	chr7:66568097	chr7:66902857~66906297:+
BRCA	cis	rs1075232	1	rs16956707	ENSG00000270055.1	CTD-3092A11.2	-8.23	5.4e-16	1.79e-13	-0.57	-0.25	Survival in colorectal cancer (non-distant metastatic);	chr15:31349430	chr15:30487963~30490313:+
BRCA	cis	rs11023332	0.706	rs11023380	ENSG00000251991.1	RNU7-49P	8.23	5.4e-16	1.79e-13	0.28	0.25	Vitamin D levels;Adiponectin levels;	chr11:14908512	chr11:14478892~14478953:+
BRCA	cis	rs6142102	0.625	rs7263727	ENSG00000275784.1	RP5-1125A11.6	-8.23	5.4e-16	1.8e-13	-0.28	-0.25	Skin pigmentation;	chr20:33953133	chr20:33989480~33991818:-
BRCA	cis	rs6142102	0.625	rs6142056	ENSG00000275784.1	RP5-1125A11.6	-8.23	5.4e-16	1.8e-13	-0.28	-0.25	Skin pigmentation;	chr20:33953349	chr20:33989480~33991818:-
BRCA	cis	rs7085104	0.684	rs7092690	ENSG00000236937.2	PTGES3P4	8.23	5.41e-16	1.8e-13	0.31	0.25	Immature fraction of reticulocytes;Schizophrenia;	chr10:102849608	chr10:102845595~102845950:+
BRCA	cis	rs10463554	0.927	rs56361326	ENSG00000175749.11	EIF3KP1	8.23	5.41e-16	1.8e-13	0.33	0.25	Parkinson's disease;	chr5:103054184	chr5:103032376~103033031:+
BRCA	cis	rs58873874	0.737	rs12654973	ENSG00000251405.2	CTB-109A12.1	8.23	5.42e-16	1.8e-13	0.55	0.25	Bipolar disorder (body mass index interaction);	chr5:157280938	chr5:157362615~157460078:-
BRCA	cis	rs58873874	0.579	rs74804793	ENSG00000251405.2	CTB-109A12.1	8.23	5.42e-16	1.8e-13	0.55	0.25	Bipolar disorder (body mass index interaction);	chr5:157281515	chr5:157362615~157460078:-
BRCA	cis	rs3758911	0.861	rs10749890	ENSG00000255353.1	RP11-382M14.1	-8.23	5.44e-16	1.81e-13	-0.34	-0.25	Coronary artery disease;	chr11:107278357	chr11:107176286~107177530:+
BRCA	cis	rs1075265	0.756	rs1075264	ENSG00000233266.1	HMGB1P31	8.23	5.48e-16	1.82e-13	0.3	0.25	Chronotype;Morning vs. evening chronotype;	chr2:54127916	chr2:54051334~54051760:+
BRCA	cis	rs12701220	0.503	rs13222294	ENSG00000229043.2	AC091729.9	-8.23	5.48e-16	1.82e-13	-0.38	-0.25	Bronchopulmonary dysplasia;	chr7:1133333	chr7:1160374~1165267:+
BRCA	cis	rs4308124	0.708	rs7585313	ENSG00000230499.1	AC108463.1	-8.23	5.5e-16	1.83e-13	-0.32	-0.25	Vitiligo;	chr2:111217626	chr2:111195963~111206494:+
BRCA	cis	rs6142102	0.961	rs6088355	ENSG00000276073.1	RP5-1125A11.7	-8.23	5.51e-16	1.83e-13	-0.3	-0.25	Skin pigmentation;	chr20:33958081	chr20:33985617~33988989:-
BRCA	cis	rs7085104	0.632	rs6162	ENSG00000213061.2	PFN1P11	8.23	5.51e-16	1.83e-13	0.32	0.25	Immature fraction of reticulocytes;Schizophrenia;	chr10:102837224	chr10:102838011~102845473:-
BRCA	cis	rs7598759	0.679	rs6437018	ENSG00000181798.2	LINC00471	-8.23	5.54e-16	1.84e-13	-0.3	-0.25	Noise-induced hearing loss;	chr2:231462980	chr2:231508426~231514339:-
BRCA	cis	rs7598759	0.679	rs6437019	ENSG00000181798.2	LINC00471	-8.23	5.54e-16	1.84e-13	-0.3	-0.25	Noise-induced hearing loss;	chr2:231462996	chr2:231508426~231514339:-
BRCA	cis	rs7580658	0.545	rs13006847	ENSG00000236682.1	AC068282.3	8.23	5.58e-16	1.85e-13	0.31	0.25	Protein C levels;	chr2:127194687	chr2:127389130~127400580:+
BRCA	cis	rs4835473	0.932	rs1849128	ENSG00000251600.4	RP11-673E1.1	8.23	5.58e-16	1.85e-13	0.3	0.25	Immature fraction of reticulocytes;	chr4:143992582	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.771	rs2175452	ENSG00000251600.4	RP11-673E1.1	8.23	5.58e-16	1.85e-13	0.3	0.25	Immature fraction of reticulocytes;	chr4:143992887	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.8	rs2175451	ENSG00000251600.4	RP11-673E1.1	8.23	5.58e-16	1.85e-13	0.3	0.25	Immature fraction of reticulocytes;	chr4:143992964	chr4:143912331~143982454:+
BRCA	cis	rs2243480	1	rs2707844	ENSG00000273142.1	RP11-458F8.4	-8.23	5.59e-16	1.85e-13	-0.34	-0.25	Diabetic kidney disease;	chr7:66594522	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs1796220	ENSG00000273142.1	RP11-458F8.4	-8.23	5.59e-16	1.85e-13	-0.34	-0.25	Diabetic kidney disease;	chr7:66597113	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs2707831	ENSG00000273142.1	RP11-458F8.4	-8.23	5.59e-16	1.85e-13	-0.34	-0.25	Diabetic kidney disease;	chr7:66597524	chr7:66902857~66906297:+
BRCA	cis	rs10129255	1	rs10141557	ENSG00000223648.3	IGHV3-64	8.23	5.6e-16	1.86e-13	0.22	0.25	Kawasaki disease;	chr14:106767990	chr14:106643132~106658258:-
BRCA	cis	rs6700559	0.654	rs2809346	ENSG00000260088.1	RP11-92G12.3	8.23	5.6e-16	1.86e-13	0.3	0.25	Coronary artery disease;	chr1:200627089	chr1:200669507~200694250:+
BRCA	cis	rs7569084	0.687	rs11675538	ENSG00000204929.10	AC074391.1	8.23	5.63e-16	1.87e-13	0.33	0.25	Sum eosinophil basophil counts;	chr2:65459327	chr2:65436711~66084639:+
BRCA	cis	rs1062177	0.756	rs2964592	ENSG00000253921.1	CTB-113P19.3	8.23	5.64e-16	1.87e-13	0.33	0.25	Preschool internalizing problems;	chr5:151736127	chr5:151753992~151767247:+
BRCA	cis	rs6142102	0.961	rs4911401	ENSG00000276073.1	RP5-1125A11.7	-8.23	5.65e-16	1.87e-13	-0.3	-0.25	Skin pigmentation;	chr20:34066756	chr20:33985617~33988989:-
BRCA	cis	rs8012947	0.959	rs3945957	ENSG00000279636.2	LINC00216	-8.23	5.65e-16	1.87e-13	-0.27	-0.25	Alcohol consumption in current drinkers;	chr14:58316335	chr14:58288033~58289158:+
BRCA	cis	rs8062405	0.824	rs62034319	ENSG00000251417.2	RP11-1348G14.4	-8.23	5.65e-16	1.87e-13	-0.28	-0.25	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28520867	chr16:28802743~28817828:+
BRCA	cis	rs1501911	0.611	rs7712408	ENSG00000248489.1	CTD-2007H13.3	-8.23	5.66e-16	1.88e-13	-0.31	-0.25	Lung function (FEV1/FVC);	chr5:99020633	chr5:98929171~98995013:+
BRCA	cis	rs375066	0.868	rs378112	ENSG00000267058.1	RP11-15A1.3	-8.23	5.67e-16	1.88e-13	-0.28	-0.25	Breast cancer;	chr19:43917777	chr19:43891804~43901805:-
BRCA	cis	rs375066	0.868	rs378109	ENSG00000267058.1	RP11-15A1.3	-8.23	5.67e-16	1.88e-13	-0.28	-0.25	Breast cancer;	chr19:43917785	chr19:43891804~43901805:-
BRCA	cis	rs950776	0.593	rs481134	ENSG00000261762.1	RP11-650L12.2	8.23	5.68e-16	1.88e-13	0.27	0.25	Sudden cardiac arrest;	chr15:78585221	chr15:78589123~78591276:-
BRCA	cis	rs526231	0.543	rs26523	ENSG00000175749.11	EIF3KP1	8.23	5.69e-16	1.89e-13	0.37	0.25	Primary biliary cholangitis;	chr5:103120550	chr5:103032376~103033031:+
BRCA	cis	rs250518	0.926	rs34426717	ENSG00000272081.1	CTD-2376I4.2	8.23	5.69e-16	1.89e-13	0.31	0.25	Mean corpuscular hemoglobin concentration;	chr5:72752640	chr5:72955206~72955699:-
BRCA	cis	rs367615	0.959	rs2201016	ENSG00000249476.1	CTD-2587M2.1	8.23	5.71e-16	1.89e-13	0.31	0.25	Colorectal cancer (SNP x SNP interaction);	chr5:109611586	chr5:109237120~109326369:-
BRCA	cis	rs891378	0.876	rs1367067	ENSG00000274245.1	RP11-357P18.2	8.23	5.72e-16	1.9e-13	0.37	0.25	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207269019	chr1:207372559~207373252:+
BRCA	cis	rs10463554	0.75	rs26257	ENSG00000175749.11	EIF3KP1	8.23	5.73e-16	1.9e-13	0.36	0.25	Parkinson's disease;	chr5:103214830	chr5:103032376~103033031:+
BRCA	cis	rs42648	0.869	rs12374728	ENSG00000225498.1	AC002064.5	8.23	5.74e-16	1.9e-13	0.24	0.25	Homocysteine levels;	chr7:90312570	chr7:90312496~90322592:+
BRCA	cis	rs875971	1	rs778696	ENSG00000237310.1	GS1-124K5.4	8.23	5.74e-16	1.9e-13	0.26	0.25	Aortic root size;	chr7:66405826	chr7:66493706~66495474:+
BRCA	cis	rs875971	1	rs778694	ENSG00000237310.1	GS1-124K5.4	8.23	5.74e-16	1.9e-13	0.26	0.25	Aortic root size;	chr7:66406571	chr7:66493706~66495474:+
BRCA	cis	rs875971	1	rs4718344	ENSG00000237310.1	GS1-124K5.4	8.23	5.74e-16	1.9e-13	0.26	0.25	Aortic root size;	chr7:66409394	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.737	rs7803424	ENSG00000237310.1	GS1-124K5.4	8.23	5.74e-16	1.9e-13	0.26	0.25	Aortic root size;	chr7:66415618	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.83	rs7799834	ENSG00000237310.1	GS1-124K5.4	8.23	5.74e-16	1.9e-13	0.26	0.25	Aortic root size;	chr7:66415707	chr7:66493706~66495474:+
BRCA	cis	rs73186030	0.546	rs73188320	ENSG00000272758.4	RP11-299J3.8	8.23	5.75e-16	1.91e-13	0.35	0.25	Serum parathyroid hormone levels;	chr3:122391694	chr3:122416207~122443180:+
BRCA	cis	rs202072	0.72	rs4602719	ENSG00000272379.1	RP1-257A7.5	8.23	5.76e-16	1.91e-13	0.44	0.25	HIV-1 viral setpoint;	chr6:13295270	chr6:13290018~13290490:-
BRCA	cis	rs4835473	0.831	rs1912743	ENSG00000251600.4	RP11-673E1.1	8.23	5.76e-16	1.91e-13	0.3	0.25	Immature fraction of reticulocytes;	chr4:143993705	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.614	rs4487293	ENSG00000251600.4	RP11-673E1.1	8.23	5.76e-16	1.91e-13	0.3	0.25	Immature fraction of reticulocytes;	chr4:143993880	chr4:143912331~143982454:+
BRCA	cis	rs860818	0.793	rs1881202	ENSG00000226816.2	AC005082.12	-8.22	5.77e-16	1.91e-13	-0.55	-0.25	Initial pursuit acceleration;	chr7:23153889	chr7:23206013~23208045:+
BRCA	cis	rs2243480	0.711	rs2420172	ENSG00000273142.1	RP11-458F8.4	8.22	5.78e-16	1.91e-13	0.34	0.25	Diabetic kidney disease;	chr7:66170354	chr7:66902857~66906297:+
BRCA	cis	rs1499614	1	rs2659903	ENSG00000273142.1	RP11-458F8.4	-8.22	5.79e-16	1.92e-13	-0.35	-0.25	Gout;	chr7:66715944	chr7:66902857~66906297:+
BRCA	cis	rs6545883	0.929	rs1209434	ENSG00000271889.1	RP11-493E12.1	8.22	5.8e-16	1.92e-13	0.32	0.25	Tuberculosis;	chr2:61445823	chr2:61151433~61162105:-
BRCA	cis	rs6142102	0.58	rs9753679	ENSG00000275784.1	RP5-1125A11.6	-8.22	5.81e-16	1.92e-13	-0.28	-0.25	Skin pigmentation;	chr20:33953054	chr20:33989480~33991818:-
BRCA	cis	rs2933343	0.859	rs789245	ENSG00000231305.3	RP11-723O4.2	8.22	5.81e-16	1.92e-13	0.31	0.25	IgG glycosylation;	chr3:128864737	chr3:128861313~128871540:-
BRCA	cis	rs6142102	0.961	rs4911407	ENSG00000276073.1	RP5-1125A11.7	-8.22	5.83e-16	1.93e-13	-0.3	-0.25	Skin pigmentation;	chr20:34095759	chr20:33985617~33988989:-
BRCA	cis	rs11098499	0.954	rs6849171	ENSG00000248280.1	RP11-33B1.2	8.22	5.85e-16	1.94e-13	0.25	0.25	Corneal astigmatism;	chr4:119488394	chr4:119440561~119450157:-
BRCA	cis	rs950880	0.71	rs55742125	ENSG00000234389.1	AC007278.3	-8.22	5.87e-16	1.94e-13	-0.25	-0.25	Serum protein levels (sST2);	chr2:102403322	chr2:102438713~102440475:+
BRCA	cis	rs9880211	0.948	rs13316214	ENSG00000239213.4	NCK1-AS1	8.22	5.88e-16	1.95e-13	0.32	0.25	Height;Body mass index;	chr3:136439379	chr3:136841726~136862054:-
BRCA	cis	rs7674212	0.556	rs223401	ENSG00000246560.2	RP11-10L12.4	8.22	5.88e-16	1.95e-13	0.27	0.25	Type 2 diabetes;	chr4:102817815	chr4:102828055~102844075:+
BRCA	cis	rs950880	0.645	rs4851006	ENSG00000234389.1	AC007278.3	-8.22	5.89e-16	1.95e-13	-0.25	-0.25	Serum protein levels (sST2);	chr2:102408278	chr2:102438713~102440475:+
BRCA	cis	rs875971	0.789	rs28815324	ENSG00000164669.11	INTS4P1	8.22	5.89e-16	1.95e-13	0.35	0.25	Aortic root size;	chr7:66100789	chr7:65141225~65234216:+
BRCA	cis	rs858239	0.571	rs2390755	ENSG00000226816.2	AC005082.12	8.22	5.92e-16	1.96e-13	0.29	0.25	Cerebrospinal fluid biomarker levels;	chr7:23151097	chr7:23206013~23208045:+
BRCA	cis	rs9880211	0.948	rs34282798	ENSG00000239213.4	NCK1-AS1	8.22	5.95e-16	1.97e-13	0.32	0.25	Height;Body mass index;	chr3:136424515	chr3:136841726~136862054:-
BRCA	cis	rs11976180	1	rs2951364	ENSG00000170356.8	OR2A20P	-8.22	5.97e-16	1.97e-13	-0.34	-0.25	Obesity-related traits;	chr7:144057390	chr7:144250045~144252957:-
BRCA	cis	rs6545883	0.929	rs1186707	ENSG00000271889.1	RP11-493E12.1	8.22	5.97e-16	1.97e-13	0.32	0.25	Tuberculosis;	chr2:61446385	chr2:61151433~61162105:-
BRCA	cis	rs9640161	0.789	rs6964110	ENSG00000261305.1	RP4-584D14.7	8.22	5.98e-16	1.98e-13	0.36	0.25	Blood protein levels;Circulating chemerin levels;	chr7:150344747	chr7:150341771~150342607:+
BRCA	cis	rs10129255	0.5	rs1024350	ENSG00000211970.3	IGHV4-61	-8.22	5.98e-16	1.98e-13	-0.16	-0.25	Kawasaki disease;	chr14:106685105	chr14:106639119~106639657:-
BRCA	cis	rs6142102	0.961	rs1555075	ENSG00000276073.1	RP5-1125A11.7	-8.22	5.99e-16	1.98e-13	-0.3	-0.25	Skin pigmentation;	chr20:34022595	chr20:33985617~33988989:-
BRCA	cis	rs11676348	0.772	rs12694427	ENSG00000261338.2	RP11-378A13.1	-8.22	5.99e-16	1.98e-13	-0.26	-0.25	Ulcerative colitis;	chr2:218080322	chr2:218255319~218257366:+
BRCA	cis	rs35160687	0.545	rs1863050	ENSG00000273080.1	RP11-301O19.1	-8.22	6e-16	1.98e-13	-0.3	-0.25	Night sleep phenotypes;	chr2:86331253	chr2:86195590~86196049:+
BRCA	cis	rs198389	0.589	rs12404124	ENSG00000242349.4	NPPA-AS1	-8.22	6.01e-16	1.99e-13	-0.26	-0.25	B-type natriuretic peptide levels;NT-proBNP levels in acute coronary syndrome;	chr1:11813812	chr1:11841017~11848079:+
BRCA	cis	rs2933343	1	rs2933343	ENSG00000231305.3	RP11-723O4.2	8.22	6.02e-16	1.99e-13	0.31	0.25	IgG glycosylation;	chr3:128939649	chr3:128861313~128871540:-
BRCA	cis	rs193541	0.593	rs154517	ENSG00000263432.2	RN7SL689P	8.22	6.02e-16	1.99e-13	0.33	0.25	Glucose homeostasis traits;	chr5:122854130	chr5:123022487~123022783:-
BRCA	cis	rs10256972	0.669	rs10229964	ENSG00000229043.2	AC091729.9	-8.22	6.04e-16	2e-13	-0.31	-0.25	Endometriosis;Longevity;	chr7:1012140	chr7:1160374~1165267:+
BRCA	cis	rs10246939	0.505	rs34726057	ENSG00000228775.6	WEE2-AS1	8.22	6.05e-16	2e-13	0.29	0.25	Bitter taste perception;	chr7:141832117	chr7:141704338~141738346:-
BRCA	cis	rs853679	0.567	rs7740429	ENSG00000204709.4	LINC01556	8.22	6.06e-16	2e-13	0.37	0.25	Depression;	chr6:28431469	chr6:28943877~28944537:+
BRCA	cis	rs524281	0.731	rs10791841	ENSG00000255320.1	RP11-755F10.1	8.22	6.1e-16	2.01e-13	0.42	0.25	Electroencephalogram traits;	chr11:66041116	chr11:66244840~66246239:-
BRCA	cis	rs8012947	1	rs2348072	ENSG00000279636.2	LINC00216	-8.22	6.11e-16	2.02e-13	-0.27	-0.25	Alcohol consumption in current drinkers;	chr14:58277034	chr14:58288033~58289158:+
BRCA	cis	rs526231	0.543	rs34766	ENSG00000175749.11	EIF3KP1	8.22	6.13e-16	2.02e-13	0.36	0.25	Primary biliary cholangitis;	chr5:103175219	chr5:103032376~103033031:+
BRCA	cis	rs7811142	0.83	rs11761253	ENSG00000242294.5	STAG3L5P	8.22	6.13e-16	2.03e-13	0.25	0.25	Platelet count;	chr7:100341698	chr7:100336079~100351900:+
BRCA	cis	rs875971	1	rs6460296	ENSG00000237310.1	GS1-124K5.4	8.22	6.13e-16	2.03e-13	0.25	0.25	Aortic root size;	chr7:66430152	chr7:66493706~66495474:+
BRCA	cis	rs7615952	0.599	rs6779141	ENSG00000250012.1	RP11-124N2.1	-8.22	6.16e-16	2.03e-13	-0.34	-0.25	Blood pressure (smoking interaction);	chr3:125991152	chr3:126084220~126095349:+
BRCA	cis	rs56046484	0.913	rs17611290	ENSG00000259295.5	CSPG4P12	8.22	6.16e-16	2.03e-13	0.43	0.25	Testicular germ cell tumor;	chr15:85031188	chr15:85191438~85213905:+
BRCA	cis	rs56046484	0.913	rs12906544	ENSG00000259295.5	CSPG4P12	8.22	6.16e-16	2.03e-13	0.43	0.25	Testicular germ cell tumor;	chr15:85032832	chr15:85191438~85213905:+
BRCA	cis	rs950880	0.677	rs17027087	ENSG00000234389.1	AC007278.3	-8.22	6.17e-16	2.04e-13	-0.25	-0.25	Serum protein levels (sST2);	chr2:102399458	chr2:102438713~102440475:+
BRCA	cis	rs875971	1	rs6958271	ENSG00000237310.1	GS1-124K5.4	8.22	6.18e-16	2.04e-13	0.26	0.25	Aortic root size;	chr7:66514344	chr7:66493706~66495474:+
BRCA	cis	rs875971	1	rs6958277	ENSG00000237310.1	GS1-124K5.4	8.22	6.18e-16	2.04e-13	0.26	0.25	Aortic root size;	chr7:66514362	chr7:66493706~66495474:+
BRCA	cis	rs2028299	1	rs2351706	ENSG00000259677.1	RP11-493E3.1	8.22	6.18e-16	2.04e-13	0.33	0.25	Type 2 diabetes;	chr15:89840883	chr15:89876540~89877285:+
BRCA	cis	rs4835473	0.864	rs1849132	ENSG00000251600.4	RP11-673E1.1	8.22	6.19e-16	2.04e-13	0.29	0.25	Immature fraction of reticulocytes;	chr4:143958309	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.9	rs13123407	ENSG00000251600.4	RP11-673E1.1	8.22	6.19e-16	2.04e-13	0.29	0.25	Immature fraction of reticulocytes;	chr4:143958713	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.897	rs61611095	ENSG00000251600.4	RP11-673E1.1	8.22	6.19e-16	2.04e-13	0.29	0.25	Immature fraction of reticulocytes;	chr4:143958802	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.9	rs4835449	ENSG00000251600.4	RP11-673E1.1	8.22	6.19e-16	2.04e-13	0.29	0.25	Immature fraction of reticulocytes;	chr4:143958830	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs1838516	ENSG00000251600.4	RP11-673E1.1	8.22	6.19e-16	2.04e-13	0.29	0.25	Immature fraction of reticulocytes;	chr4:143962082	chr4:143912331~143982454:+
BRCA	cis	rs9368481	0.729	rs10946881	ENSG00000241549.7	GUSBP2	8.22	6.19e-16	2.04e-13	0.29	0.25	Autism spectrum disorder or schizophrenia;	chr6:26946832	chr6:26871484~26956554:-
BRCA	cis	rs17023223	0.537	rs2645292	ENSG00000231365.4	RP11-418J17.1	-8.22	6.19e-16	2.05e-13	-0.31	-0.25	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119030571	chr1:119140396~119275973:+
BRCA	cis	rs2115630	1	rs4633690	ENSG00000225151.9	GOLGA2P7	8.22	6.21e-16	2.05e-13	0.27	0.25	P wave terminal force;	chr15:84818729	chr15:84199311~84230136:-
BRCA	cis	rs7727544	0.735	rs272842	ENSG00000233006.5	AC034220.3	8.22	6.22e-16	2.06e-13	0.18	0.25	Blood metabolite levels;	chr5:132320824	chr5:132311285~132369916:-
BRCA	cis	rs11098499	0.738	rs28408407	ENSG00000248280.1	RP11-33B1.2	8.22	6.24e-16	2.06e-13	0.25	0.25	Corneal astigmatism;	chr4:119454875	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.697	rs4560394	ENSG00000248280.1	RP11-33B1.2	8.21	6.24e-16	2.06e-13	0.25	0.25	Corneal astigmatism;	chr4:119392280	chr4:119440561~119450157:-
BRCA	cis	rs807029	0.544	rs55646950	ENSG00000272572.1	RP11-179B2.2	-8.21	6.26e-16	2.06e-13	-0.32	-0.25	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:101001239	chr10:100911103~100912739:-
BRCA	cis	rs1075265	0.572	rs2193682	ENSG00000233266.1	HMGB1P31	8.21	6.26e-16	2.06e-13	0.31	0.25	Chronotype;Morning vs. evening chronotype;	chr2:53695119	chr2:54051334~54051760:+
BRCA	cis	rs875971	0.545	rs10261710	ENSG00000222364.1	RNU6-96P	-8.21	6.28e-16	2.07e-13	-0.33	-0.25	Aortic root size;	chr7:66249202	chr7:66395191~66395286:+
BRCA	cis	rs10463554	0.963	rs26816	ENSG00000175749.11	EIF3KP1	8.21	6.31e-16	2.08e-13	0.33	0.25	Parkinson's disease;	chr5:103204821	chr5:103032376~103033031:+
BRCA	cis	rs875971	0.895	rs3857684	ENSG00000237310.1	GS1-124K5.4	8.21	6.33e-16	2.09e-13	0.26	0.25	Aortic root size;	chr7:66473171	chr7:66493706~66495474:+
BRCA	cis	rs6142102	0.961	rs2268088	ENSG00000276073.1	RP5-1125A11.7	-8.21	6.33e-16	2.09e-13	-0.3	-0.25	Skin pigmentation;	chr20:34061258	chr20:33985617~33988989:-
BRCA	cis	rs6142102	0.961	rs2284388	ENSG00000276073.1	RP5-1125A11.7	-8.21	6.33e-16	2.09e-13	-0.3	-0.25	Skin pigmentation;	chr20:34067935	chr20:33985617~33988989:-
BRCA	cis	rs9880211	0.948	rs9857966	ENSG00000239213.4	NCK1-AS1	8.21	6.34e-16	2.09e-13	0.32	0.25	Height;Body mass index;	chr3:136560548	chr3:136841726~136862054:-
BRCA	cis	rs1075265	0.756	rs6751105	ENSG00000233266.1	HMGB1P31	8.21	6.35e-16	2.1e-13	0.3	0.25	Chronotype;Morning vs. evening chronotype;	chr2:54129214	chr2:54051334~54051760:+
BRCA	cis	rs11098499	0.722	rs7673476	ENSG00000248280.1	RP11-33B1.2	8.21	6.36e-16	2.1e-13	0.24	0.25	Corneal astigmatism;	chr4:119327528	chr4:119440561~119450157:-
BRCA	cis	rs8062405	0.789	rs28676837	ENSG00000251417.2	RP11-1348G14.4	8.21	6.36e-16	2.1e-13	0.29	0.25	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28615742	chr16:28802743~28817828:+
BRCA	cis	rs853679	0.567	rs9969098	ENSG00000204709.4	LINC01556	8.21	6.37e-16	2.1e-13	0.37	0.25	Depression;	chr6:28430971	chr6:28943877~28944537:+
BRCA	cis	rs853679	0.567	rs16894106	ENSG00000204709.4	LINC01556	8.21	6.37e-16	2.1e-13	0.37	0.25	Depression;	chr6:28432562	chr6:28943877~28944537:+
BRCA	cis	rs10510102	0.808	rs11200296	ENSG00000276742.1	RP11-500G22.4	8.21	6.38e-16	2.1e-13	0.43	0.25	Breast cancer;	chr10:121971956	chr10:121956782~121957098:+
BRCA	cis	rs875971	0.54	rs736270	ENSG00000236529.1	RP13-254B10.1	8.21	6.39e-16	2.11e-13	0.27	0.25	Aortic root size;	chr7:65963835	chr7:65840212~65840596:+
BRCA	cis	rs875971	1	rs12698523	ENSG00000237310.1	GS1-124K5.4	8.21	6.4e-16	2.11e-13	0.26	0.25	Aortic root size;	chr7:66503126	chr7:66493706~66495474:+
BRCA	cis	rs7927771	1	rs12363232	ENSG00000280615.1	Y_RNA	-8.21	6.41e-16	2.11e-13	-0.31	-0.25	Subjective well-being;	chr11:47602338	chr11:47614898~47614994:-
BRCA	cis	rs6921919	0.945	rs16901847	ENSG00000204709.4	LINC01556	8.21	6.42e-16	2.12e-13	0.39	0.25	Autism spectrum disorder or schizophrenia;	chr6:28408074	chr6:28943877~28944537:+
BRCA	cis	rs526231	0.543	rs34770	ENSG00000175749.11	EIF3KP1	8.21	6.43e-16	2.12e-13	0.36	0.25	Primary biliary cholangitis;	chr5:103111942	chr5:103032376~103033031:+
BRCA	cis	rs8012947	1	rs12878264	ENSG00000279636.2	LINC00216	-8.21	6.45e-16	2.13e-13	-0.27	-0.25	Alcohol consumption in current drinkers;	chr14:58254250	chr14:58288033~58289158:+
BRCA	cis	rs11976180	1	rs13226728	ENSG00000170356.8	OR2A20P	-8.21	6.46e-16	2.13e-13	-0.34	-0.25	Obesity-related traits;	chr7:144049485	chr7:144250045~144252957:-
BRCA	cis	rs11098499	0.588	rs2389874	ENSG00000248280.1	RP11-33B1.2	-8.21	6.46e-16	2.13e-13	-0.24	-0.25	Corneal astigmatism;	chr4:119633836	chr4:119440561~119450157:-
BRCA	cis	rs9640161	0.75	rs1983440	ENSG00000261305.1	RP4-584D14.7	8.21	6.47e-16	2.13e-13	0.37	0.25	Blood protein levels;Circulating chemerin levels;	chr7:150326852	chr7:150341771~150342607:+
BRCA	cis	rs10129255	0.536	rs17113249	ENSG00000280411.1	IGHV1-69-2	-8.21	6.48e-16	2.14e-13	-0.16	-0.25	Kawasaki disease;	chr14:106678273	chr14:106762092~106762588:-
BRCA	cis	rs1134634	0.52	rs4280723	ENSG00000273133.1	RP11-799M12.2	8.21	6.48e-16	2.14e-13	0.32	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15574095	chr4:15563698~15564253:-
BRCA	cis	rs732716	0.889	rs62129355	ENSG00000267769.1	CTB-50L17.9	-8.21	6.48e-16	2.14e-13	-0.3	-0.25	Mean corpuscular volume;	chr19:4397037	chr19:4454014~4455286:+
BRCA	cis	rs2742234	0.656	rs1864400	ENSG00000273008.1	RP11-351D16.3	-8.21	6.48e-16	2.14e-13	-0.31	-0.25	Hirschsprung disease;	chr10:43114918	chr10:43136824~43138334:-
BRCA	cis	rs6142102	0.812	rs4911375	ENSG00000276073.1	RP5-1125A11.7	-8.21	6.48e-16	2.14e-13	-0.3	-0.25	Skin pigmentation;	chr20:33928216	chr20:33985617~33988989:-
BRCA	cis	rs7580658	0.613	rs6754999	ENSG00000236682.1	AC068282.3	-8.21	6.5e-16	2.14e-13	-0.34	-0.25	Protein C levels;	chr2:127437811	chr2:127389130~127400580:+
BRCA	cis	rs3762637	1	rs9836309	ENSG00000272758.4	RP11-299J3.8	-8.21	6.5e-16	2.14e-13	-0.37	-0.25	LDL cholesterol levels;	chr3:122416348	chr3:122416207~122443180:+
BRCA	cis	rs3762637	0.941	rs9873842	ENSG00000272758.4	RP11-299J3.8	-8.21	6.5e-16	2.14e-13	-0.37	-0.25	LDL cholesterol levels;	chr3:122416484	chr3:122416207~122443180:+
BRCA	cis	rs3762637	1	rs12633461	ENSG00000272758.4	RP11-299J3.8	-8.21	6.5e-16	2.14e-13	-0.37	-0.25	LDL cholesterol levels;	chr3:122417050	chr3:122416207~122443180:+
BRCA	cis	rs4308124	0.708	rs6716091	ENSG00000230499.1	AC108463.1	-8.21	6.53e-16	2.15e-13	-0.31	-0.25	Vitiligo;	chr2:111233556	chr2:111195963~111206494:+
BRCA	cis	rs2288884	0.515	rs73053909	ENSG00000275055.1	CTC-471J1.11	-8.21	6.53e-16	2.15e-13	-0.28	-0.25	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52032864	chr19:52049007~52049754:+
BRCA	cis	rs1707322	0.927	rs11211194	ENSG00000280836.1	AL355480.1	-8.21	6.54e-16	2.15e-13	-0.32	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45816412	chr1:45581219~45581321:-
BRCA	cis	rs17826219	0.789	rs4794873	ENSG00000263531.1	RP13-753N3.1	8.21	6.56e-16	2.16e-13	0.46	0.25	Body mass index;	chr17:30421334	chr17:30863921~30864940:-
BRCA	cis	rs1707322	1	rs10890370	ENSG00000280836.1	AL355480.1	-8.21	6.56e-16	2.16e-13	-0.32	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45923545	chr1:45581219~45581321:-
BRCA	cis	rs2288884	0.537	rs7254131	ENSG00000275055.1	CTC-471J1.11	-8.21	6.57e-16	2.16e-13	-0.28	-0.25	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52035774	chr19:52049007~52049754:+
BRCA	cis	rs875971	0.658	rs432667	ENSG00000237310.1	GS1-124K5.4	8.21	6.57e-16	2.17e-13	0.26	0.25	Aortic root size;	chr7:66049646	chr7:66493706~66495474:+
BRCA	cis	rs250518	0.926	rs11953054	ENSG00000272081.1	CTD-2376I4.2	8.21	6.58e-16	2.17e-13	0.31	0.25	Mean corpuscular hemoglobin concentration;	chr5:72746876	chr5:72955206~72955699:-
BRCA	cis	rs9402682	0.77	rs2210366	ENSG00000232876.1	CTA-212D2.2	8.21	6.59e-16	2.17e-13	0.33	0.25	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr6:135094070	chr6:135055033~135060550:+
BRCA	cis	rs875971	0.502	rs6460311	ENSG00000222364.1	RNU6-96P	8.21	6.59e-16	2.17e-13	0.33	0.25	Aortic root size;	chr7:66646886	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.895	rs4718349	ENSG00000237310.1	GS1-124K5.4	8.21	6.59e-16	2.17e-13	0.25	0.25	Aortic root size;	chr7:66444024	chr7:66493706~66495474:+
BRCA	cis	rs875971	1	rs2042133	ENSG00000237310.1	GS1-124K5.4	8.21	6.59e-16	2.17e-13	0.25	0.25	Aortic root size;	chr7:66466935	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.964	rs2161065	ENSG00000237310.1	GS1-124K5.4	8.21	6.59e-16	2.17e-13	0.25	0.25	Aortic root size;	chr7:66467918	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.862	rs12698521	ENSG00000237310.1	GS1-124K5.4	8.21	6.59e-16	2.17e-13	0.25	0.25	Aortic root size;	chr7:66474502	chr7:66493706~66495474:+
BRCA	cis	rs6142102	0.961	rs761235	ENSG00000276073.1	RP5-1125A11.7	-8.21	6.62e-16	2.18e-13	-0.31	-0.25	Skin pigmentation;	chr20:33946602	chr20:33985617~33988989:-
BRCA	cis	rs1707322	0.928	rs6681068	ENSG00000280836.1	AL355480.1	-8.21	6.62e-16	2.18e-13	-0.31	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45932710	chr1:45581219~45581321:-
BRCA	cis	rs2115630	0.967	rs12595786	ENSG00000225151.9	GOLGA2P7	8.21	6.64e-16	2.19e-13	0.27	0.25	P wave terminal force;	chr15:84793439	chr15:84199311~84230136:-
BRCA	cis	rs4835473	0.77	rs4835096	ENSG00000251600.4	RP11-673E1.1	8.21	6.65e-16	2.19e-13	0.29	0.25	Immature fraction of reticulocytes;	chr4:143960685	chr4:143912331~143982454:+
BRCA	cis	rs11098499	0.739	rs6534130	ENSG00000245958.5	RP11-33B1.1	8.21	6.65e-16	2.19e-13	0.24	0.25	Corneal astigmatism;	chr4:119210184	chr4:119454791~119552025:+
BRCA	cis	rs7246657	0.722	rs2927739	ENSG00000267422.1	CTD-2554C21.1	8.21	6.68e-16	2.2e-13	0.36	0.25	Coronary artery calcification;	chr19:37658429	chr19:37779686~37792865:+
BRCA	cis	rs6061231	1	rs6061231	ENSG00000273619.1	RP5-908M14.9	-8.21	6.7e-16	2.2e-13	-0.22	-0.25	Colorectal cancer;	chr20:62381861	chr20:62386303~62386970:-
BRCA	cis	rs30380	0.573	rs469783	ENSG00000248734.2	CTD-2260A17.1	8.21	6.72e-16	2.21e-13	0.26	0.25	Cerebrospinal fluid biomarker levels;	chr5:96785820	chr5:96784777~96785999:+
BRCA	cis	rs9368481	0.645	rs10456350	ENSG00000241549.7	GUSBP2	8.2	6.76e-16	2.22e-13	0.28	0.25	Autism spectrum disorder or schizophrenia;	chr6:27007802	chr6:26871484~26956554:-
BRCA	cis	rs524281	0.682	rs6591202	ENSG00000255320.1	RP11-755F10.1	-8.2	6.77e-16	2.23e-13	-0.4	-0.25	Electroencephalogram traits;	chr11:66038622	chr11:66244840~66246239:-
BRCA	cis	rs524281	0.731	rs6591203	ENSG00000255320.1	RP11-755F10.1	-8.2	6.77e-16	2.23e-13	-0.4	-0.25	Electroencephalogram traits;	chr11:66038758	chr11:66244840~66246239:-
BRCA	cis	rs9876781	0.507	rs1824362	ENSG00000229759.1	MRPS18AP1	-8.2	6.78e-16	2.23e-13	-0.28	-0.25	Longevity;	chr3:48360459	chr3:48256350~48256938:-
BRCA	cis	rs7246657	0.722	rs10402671	ENSG00000267422.1	CTD-2554C21.1	-8.2	6.81e-16	2.24e-13	-0.36	-0.25	Coronary artery calcification;	chr19:37626185	chr19:37779686~37792865:+
BRCA	cis	rs7246657	0.722	rs10417576	ENSG00000267422.1	CTD-2554C21.1	-8.2	6.81e-16	2.24e-13	-0.36	-0.25	Coronary artery calcification;	chr19:37628311	chr19:37779686~37792865:+
BRCA	cis	rs3762637	0.882	rs9818537	ENSG00000272758.4	RP11-299J3.8	-8.2	6.81e-16	2.24e-13	-0.36	-0.25	LDL cholesterol levels;	chr3:122367610	chr3:122416207~122443180:+
BRCA	cis	rs250518	0.926	rs4267846	ENSG00000272081.1	CTD-2376I4.2	8.2	6.84e-16	2.25e-13	0.31	0.25	Mean corpuscular hemoglobin concentration;	chr5:72735617	chr5:72955206~72955699:-
BRCA	cis	rs250518	0.926	rs2338788	ENSG00000272081.1	CTD-2376I4.2	8.2	6.84e-16	2.25e-13	0.31	0.25	Mean corpuscular hemoglobin concentration;	chr5:72737690	chr5:72955206~72955699:-
BRCA	cis	rs7085104	0.552	rs11191414	ENSG00000213061.2	PFN1P11	8.2	6.85e-16	2.25e-13	0.32	0.25	Immature fraction of reticulocytes;Schizophrenia;	chr10:102841808	chr10:102838011~102845473:-
BRCA	cis	rs875971	1	rs12533997	ENSG00000237310.1	GS1-124K5.4	8.2	6.86e-16	2.26e-13	0.25	0.25	Aortic root size;	chr7:66500390	chr7:66493706~66495474:+
BRCA	cis	rs4835473	0.932	rs4835126	ENSG00000251600.4	RP11-673E1.1	8.2	6.87e-16	2.26e-13	0.3	0.25	Immature fraction of reticulocytes;	chr4:143997740	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.699	rs4835127	ENSG00000251600.4	RP11-673E1.1	8.2	6.87e-16	2.26e-13	0.3	0.25	Immature fraction of reticulocytes;	chr4:143997972	chr4:143912331~143982454:+
BRCA	cis	rs7429990	0.864	rs2882611	ENSG00000229759.1	MRPS18AP1	-8.2	6.87e-16	2.26e-13	-0.28	-0.25	Educational attainment (years of education);	chr3:47651532	chr3:48256350~48256938:-
BRCA	cis	rs7085104	0.7	rs10786712	ENSG00000236937.2	PTGES3P4	-8.2	6.88e-16	2.26e-13	-0.31	-0.25	Immature fraction of reticulocytes;Schizophrenia;	chr10:102836639	chr10:102845595~102845950:+
BRCA	cis	rs6504622	0.72	rs4968304	ENSG00000262879.4	RP11-156P1.3	-8.2	6.88e-16	2.26e-13	-0.25	-0.25	Orofacial clefts;	chr17:47063235	chr17:46984045~47100323:-
BRCA	cis	rs8012947	1	rs6573199	ENSG00000279636.2	LINC00216	-8.2	6.91e-16	2.27e-13	-0.27	-0.25	Alcohol consumption in current drinkers;	chr14:58318063	chr14:58288033~58289158:+
BRCA	cis	rs875971	1	rs778710	ENSG00000237310.1	GS1-124K5.4	8.2	6.91e-16	2.27e-13	0.25	0.25	Aortic root size;	chr7:66389847	chr7:66493706~66495474:+
BRCA	cis	rs11098499	0.722	rs10025925	ENSG00000248280.1	RP11-33B1.2	8.2	6.92e-16	2.27e-13	0.24	0.25	Corneal astigmatism;	chr4:119350589	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.731	rs10015579	ENSG00000248280.1	RP11-33B1.2	8.2	6.92e-16	2.27e-13	0.24	0.25	Corneal astigmatism;	chr4:119350647	chr4:119440561~119450157:-
BRCA	cis	rs748404	1	rs748404	ENSG00000249839.1	AC011330.5	-8.2	6.92e-16	2.27e-13	-0.35	-0.25	Lung cancer;	chr15:43267033	chr15:43663654~43684339:-
BRCA	cis	rs7727544	0.636	rs2631365	ENSG00000233006.5	AC034220.3	-8.2	6.93e-16	2.28e-13	-0.18	-0.25	Blood metabolite levels;	chr5:132370257	chr5:132311285~132369916:-
BRCA	cis	rs6539288	0.803	rs7305715	ENSG00000260329.1	RP11-412D9.4	-8.2	6.94e-16	2.28e-13	-0.28	-0.25	Total body bone mineral density;	chr12:106932774	chr12:106954029~106955497:-
BRCA	cis	rs7927771	0.864	rs112060627	ENSG00000280615.1	Y_RNA	-8.2	6.95e-16	2.28e-13	-0.3	-0.25	Subjective well-being;	chr11:47405405	chr11:47614898~47614994:-
BRCA	cis	rs7927771	0.864	rs7107726	ENSG00000280615.1	Y_RNA	-8.2	6.95e-16	2.28e-13	-0.3	-0.25	Subjective well-being;	chr11:47407694	chr11:47614898~47614994:-
BRCA	cis	rs6545883	0.826	rs2694651	ENSG00000271889.1	RP11-493E12.1	-8.2	6.95e-16	2.28e-13	-0.32	-0.25	Tuberculosis;	chr2:61361507	chr2:61151433~61162105:-
BRCA	cis	rs61270009	0.955	rs4916899	ENSG00000247828.6	TMEM161B-AS1	8.2	6.96e-16	2.29e-13	0.31	0.25	Depressive symptoms;	chr5:88292209	chr5:88268895~88436685:+
BRCA	cis	rs4835473	0.932	rs4835120	ENSG00000251600.4	RP11-673E1.1	8.2	6.96e-16	2.29e-13	0.3	0.25	Immature fraction of reticulocytes;	chr4:143982370	chr4:143912331~143982454:+
BRCA	cis	rs904251	0.523	rs2797798	ENSG00000204110.6	RP1-153P14.8	-8.2	6.97e-16	2.29e-13	-0.27	-0.25	Cognitive performance;	chr6:37513661	chr6:37507348~37535616:+
BRCA	cis	rs6539288	0.901	rs7974499	ENSG00000260329.1	RP11-412D9.4	-8.2	6.97e-16	2.29e-13	-0.28	-0.25	Total body bone mineral density;	chr12:106947607	chr12:106954029~106955497:-
BRCA	cis	rs7598759	0.712	rs12991636	ENSG00000181798.2	LINC00471	-8.2	6.99e-16	2.3e-13	-0.3	-0.25	Noise-induced hearing loss;	chr2:231468955	chr2:231508426~231514339:-
BRCA	cis	rs9880211	1	rs34757183	ENSG00000239213.4	NCK1-AS1	8.2	7e-16	2.3e-13	0.32	0.25	Height;Body mass index;	chr3:136424826	chr3:136841726~136862054:-
BRCA	cis	rs2274273	0.837	rs8008119	ENSG00000258413.1	RP11-665C16.6	-8.2	7.03e-16	2.31e-13	-0.31	-0.25	Protein biomarker;	chr14:55364510	chr14:55262767~55272075:-
BRCA	cis	rs748404	1	rs17779494	ENSG00000249839.1	AC011330.5	8.2	7.05e-16	2.32e-13	0.35	0.25	Lung cancer;	chr15:43287025	chr15:43663654~43684339:-
BRCA	cis	rs950880	0.71	rs56331791	ENSG00000234389.1	AC007278.3	-8.2	7.08e-16	2.32e-13	-0.25	-0.25	Serum protein levels (sST2);	chr2:102431697	chr2:102438713~102440475:+
BRCA	cis	rs7429990	0.833	rs1486915	ENSG00000229759.1	MRPS18AP1	-8.2	7.09e-16	2.33e-13	-0.28	-0.25	Educational attainment (years of education);	chr3:47781053	chr3:48256350~48256938:-
BRCA	cis	rs11976180	1	rs1320893	ENSG00000170356.8	OR2A20P	-8.2	7.12e-16	2.34e-13	-0.34	-0.25	Obesity-related traits;	chr7:144055019	chr7:144250045~144252957:-
BRCA	cis	rs8062405	0.655	rs7184597	ENSG00000251417.2	RP11-1348G14.4	8.2	7.13e-16	2.34e-13	0.31	0.25	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28910488	chr16:28802743~28817828:+
BRCA	cis	rs7674212	0.581	rs11946020	ENSG00000246560.2	RP11-10L12.4	8.2	7.14e-16	2.34e-13	0.26	0.25	Type 2 diabetes;	chr4:103023585	chr4:102828055~102844075:+
BRCA	cis	rs375066	0.901	rs12977303	ENSG00000267058.1	RP11-15A1.3	-8.2	7.15e-16	2.35e-13	-0.29	-0.25	Breast cancer;	chr19:43873517	chr19:43891804~43901805:-
BRCA	cis	rs2243480	1	rs4718334	ENSG00000273142.1	RP11-458F8.4	8.2	7.17e-16	2.35e-13	0.34	0.25	Diabetic kidney disease;	chr7:66324467	chr7:66902857~66906297:+
BRCA	cis	rs26232	0.521	rs3776855	ENSG00000175749.11	EIF3KP1	8.2	7.17e-16	2.36e-13	0.36	0.25	Rheumatoid arthritis;	chr5:103023111	chr5:103032376~103033031:+
BRCA	cis	rs858239	0.601	rs6948469	ENSG00000230042.1	AK3P3	-8.2	7.18e-16	2.36e-13	-0.28	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23135147	chr7:23129178~23129841:+
BRCA	cis	rs6061231	1	rs67941642	ENSG00000273619.1	RP5-908M14.9	-8.2	7.19e-16	2.36e-13	-0.21	-0.25	Colorectal cancer;	chr20:62383052	chr20:62386303~62386970:-
BRCA	cis	rs4835473	0.771	rs4835097	ENSG00000251600.4	RP11-673E1.1	8.2	7.21e-16	2.37e-13	0.29	0.25	Immature fraction of reticulocytes;	chr4:143960687	chr4:143912331~143982454:+
BRCA	cis	rs3762637	1	rs9879508	ENSG00000272758.4	RP11-299J3.8	-8.2	7.21e-16	2.37e-13	-0.37	-0.25	LDL cholesterol levels;	chr3:122417633	chr3:122416207~122443180:+
BRCA	cis	rs8062405	0.754	rs62034323	ENSG00000251417.2	RP11-1348G14.4	-8.2	7.22e-16	2.37e-13	-0.28	-0.25	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28525152	chr16:28802743~28817828:+
BRCA	cis	rs8062405	0.824	rs62034324	ENSG00000251417.2	RP11-1348G14.4	-8.2	7.22e-16	2.37e-13	-0.28	-0.25	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28525441	chr16:28802743~28817828:+
BRCA	cis	rs3758911	0.861	rs10890689	ENSG00000255353.1	RP11-382M14.1	-8.2	7.26e-16	2.38e-13	-0.34	-0.25	Coronary artery disease;	chr11:107275626	chr11:107176286~107177530:+
BRCA	cis	rs201673768	1	rs201673768	ENSG00000240399.1	RP1-228P16.1	8.2	7.27e-16	2.38e-13	0.28	0.25	Platelet count;	chr12:48305834	chr12:48054813~48055591:-
BRCA	cis	rs6539288	0.901	rs4964506	ENSG00000260329.1	RP11-412D9.4	-8.2	7.28e-16	2.39e-13	-0.28	-0.25	Total body bone mineral density;	chr12:106953307	chr12:106954029~106955497:-
BRCA	cis	rs6539288	0.901	rs4964507	ENSG00000260329.1	RP11-412D9.4	-8.2	7.28e-16	2.39e-13	-0.28	-0.25	Total body bone mineral density;	chr12:106954979	chr12:106954029~106955497:-
BRCA	cis	rs2028299	1	rs3960018	ENSG00000259677.1	RP11-493E3.1	8.19	7.3e-16	2.39e-13	0.33	0.25	Type 2 diabetes;	chr15:89840075	chr15:89876540~89877285:+
BRCA	cis	rs7927771	0.725	rs11039265	ENSG00000280615.1	Y_RNA	-8.19	7.34e-16	2.41e-13	-0.31	-0.25	Subjective well-being;	chr11:47501662	chr11:47614898~47614994:-
BRCA	cis	rs2286503	1	rs2286503	ENSG00000228649.7	AC005682.5	8.19	7.34e-16	2.41e-13	0.21	0.25	Fibrinogen;	chr7:22816987	chr7:22854178~22861579:+
BRCA	cis	rs6545883	0.894	rs12615783	ENSG00000271889.1	RP11-493E12.1	-8.19	7.35e-16	2.41e-13	-0.32	-0.25	Tuberculosis;	chr2:61213812	chr2:61151433~61162105:-
BRCA	cis	rs62355900	0.627	rs16886403	ENSG00000271828.1	CTD-2310F14.1	8.19	7.35e-16	2.41e-13	0.42	0.25	Endometriosis;	chr5:56843419	chr5:56927874~56929573:+
BRCA	cis	rs7811142	0.72	rs7795656	ENSG00000242294.5	STAG3L5P	8.19	7.4e-16	2.43e-13	0.24	0.25	Platelet count;	chr7:100352674	chr7:100336079~100351900:+
BRCA	cis	rs875971	0.964	rs778708	ENSG00000237310.1	GS1-124K5.4	8.19	7.42e-16	2.43e-13	0.25	0.25	Aortic root size;	chr7:66391332	chr7:66493706~66495474:+
BRCA	cis	rs3758911	0.861	rs11212116	ENSG00000255353.1	RP11-382M14.1	-8.19	7.43e-16	2.44e-13	-0.34	-0.25	Coronary artery disease;	chr11:107276621	chr11:107176286~107177530:+
BRCA	cis	rs11098499	0.644	rs10050092	ENSG00000248280.1	RP11-33B1.2	8.19	7.43e-16	2.44e-13	0.24	0.25	Corneal astigmatism;	chr4:119610930	chr4:119440561~119450157:-
BRCA	cis	rs6142102	0.961	rs6057957	ENSG00000276073.1	RP5-1125A11.7	-8.19	7.45e-16	2.44e-13	-0.3	-0.25	Skin pigmentation;	chr20:33962052	chr20:33985617~33988989:-
BRCA	cis	rs526231	0.511	rs28062	ENSG00000175749.11	EIF3KP1	8.19	7.45e-16	2.44e-13	0.36	0.25	Primary biliary cholangitis;	chr5:103204500	chr5:103032376~103033031:+
BRCA	cis	rs7598759	0.679	rs10202701	ENSG00000181798.2	LINC00471	8.19	7.46e-16	2.45e-13	0.3	0.25	Noise-induced hearing loss;	chr2:231463970	chr2:231508426~231514339:-
BRCA	cis	rs2993535	1	rs1586660	ENSG00000233626.2	RP11-565J7.1	8.19	7.48e-16	2.45e-13	0.52	0.25	Hip circumference adjusted for BMI;	chr1:212093189	chr1:211936249~211936634:+
BRCA	cis	rs3758911	0.861	rs11212114	ENSG00000255353.1	RP11-382M14.1	8.19	7.51e-16	2.46e-13	0.33	0.25	Coronary artery disease;	chr11:107274940	chr11:107176286~107177530:+
BRCA	cis	rs11098499	0.863	rs3775854	ENSG00000248280.1	RP11-33B1.2	8.19	7.51e-16	2.46e-13	0.25	0.25	Corneal astigmatism;	chr4:119550816	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.863	rs6853998	ENSG00000248280.1	RP11-33B1.2	8.19	7.51e-16	2.46e-13	0.25	0.25	Corneal astigmatism;	chr4:119554705	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.863	rs6858777	ENSG00000248280.1	RP11-33B1.2	8.19	7.51e-16	2.46e-13	0.25	0.25	Corneal astigmatism;	chr4:119554811	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.863	rs11731756	ENSG00000248280.1	RP11-33B1.2	8.19	7.51e-16	2.46e-13	0.25	0.25	Corneal astigmatism;	chr4:119557541	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.863	rs34308924	ENSG00000248280.1	RP11-33B1.2	8.19	7.51e-16	2.46e-13	0.25	0.25	Corneal astigmatism;	chr4:119560276	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.863	rs2170276	ENSG00000248280.1	RP11-33B1.2	8.19	7.51e-16	2.46e-13	0.25	0.25	Corneal astigmatism;	chr4:119564669	chr4:119440561~119450157:-
BRCA	cis	rs4835473	0.932	rs1877235	ENSG00000251600.4	RP11-673E1.1	-8.19	7.52e-16	2.47e-13	-0.29	-0.25	Immature fraction of reticulocytes;	chr4:143986961	chr4:143912331~143982454:+
BRCA	cis	rs11098499	0.863	rs6534139	ENSG00000245958.5	RP11-33B1.1	8.19	7.55e-16	2.47e-13	0.25	0.25	Corneal astigmatism;	chr4:119528301	chr4:119454791~119552025:+
BRCA	cis	rs7772486	0.846	rs6908063	ENSG00000235652.6	RP11-545I5.3	8.19	7.56e-16	2.48e-13	0.24	0.25	Lobe attachment (rater-scored or self-reported);	chr6:146082482	chr6:145799409~145886585:+
BRCA	cis	rs1062177	0.756	rs2915815	ENSG00000253921.1	CTB-113P19.3	8.19	7.57e-16	2.48e-13	0.34	0.25	Preschool internalizing problems;	chr5:151736322	chr5:151753992~151767247:+
BRCA	cis	rs4718428	0.705	rs13220977	ENSG00000273142.1	RP11-458F8.4	8.19	7.59e-16	2.49e-13	0.23	0.25	Corneal structure;	chr7:66872661	chr7:66902857~66906297:+
BRCA	cis	rs10463554	0.759	rs461609	ENSG00000175749.11	EIF3KP1	8.19	7.59e-16	2.49e-13	0.35	0.25	Parkinson's disease;	chr5:103111601	chr5:103032376~103033031:+
BRCA	cis	rs2274273	0.84	rs10150760	ENSG00000258413.1	RP11-665C16.6	8.19	7.59e-16	2.49e-13	0.3	0.25	Protein biomarker;	chr14:55354830	chr14:55262767~55272075:-
BRCA	cis	rs11098499	0.865	rs11722183	ENSG00000248280.1	RP11-33B1.2	8.19	7.64e-16	2.5e-13	0.25	0.25	Corneal astigmatism;	chr4:119359442	chr4:119440561~119450157:-
BRCA	cis	rs904251	0.523	rs2776870	ENSG00000204110.6	RP1-153P14.8	-8.19	7.65e-16	2.5e-13	-0.27	-0.25	Cognitive performance;	chr6:37513588	chr6:37507348~37535616:+
BRCA	cis	rs11976180	1	rs2951368	ENSG00000170356.8	OR2A20P	-8.19	7.65e-16	2.51e-13	-0.34	-0.25	Obesity-related traits;	chr7:144055728	chr7:144250045~144252957:-
BRCA	cis	rs6142102	0.924	rs6059662	ENSG00000276073.1	RP5-1125A11.7	8.19	7.66e-16	2.51e-13	0.31	0.25	Skin pigmentation;	chr20:34087921	chr20:33985617~33988989:-
BRCA	cis	rs6504622	0.755	rs11079750	ENSG00000262879.4	RP11-156P1.3	-8.19	7.7e-16	2.52e-13	-0.25	-0.25	Orofacial clefts;	chr17:47072149	chr17:46984045~47100323:-
BRCA	cis	rs875971	1	rs7781698	ENSG00000237310.1	GS1-124K5.4	8.19	7.71e-16	2.52e-13	0.25	0.25	Aortic root size;	chr7:66431325	chr7:66493706~66495474:+
BRCA	cis	rs42648	0.869	rs12704518	ENSG00000225498.1	AC002064.5	8.19	7.71e-16	2.53e-13	0.24	0.25	Homocysteine levels;	chr7:90285074	chr7:90312496~90322592:+
BRCA	cis	rs11098499	0.738	rs72918577	ENSG00000248280.1	RP11-33B1.2	8.19	7.73e-16	2.53e-13	0.25	0.25	Corneal astigmatism;	chr4:119405546	chr4:119440561~119450157:-
BRCA	cis	rs9880211	0.948	rs9820621	ENSG00000239213.4	NCK1-AS1	8.19	7.73e-16	2.53e-13	0.33	0.25	Height;Body mass index;	chr3:136391671	chr3:136841726~136862054:-
BRCA	cis	rs7246657	0.722	rs10409605	ENSG00000267422.1	CTD-2554C21.1	-8.19	7.74e-16	2.53e-13	-0.36	-0.25	Coronary artery calcification;	chr19:37632236	chr19:37779686~37792865:+
BRCA	cis	rs250518	0.926	rs3846644	ENSG00000272081.1	CTD-2376I4.2	8.19	7.74e-16	2.53e-13	0.31	0.25	Mean corpuscular hemoglobin concentration;	chr5:72727276	chr5:72955206~72955699:-
BRCA	cis	rs7569084	0.687	rs1437462	ENSG00000204929.10	AC074391.1	8.19	7.75e-16	2.54e-13	0.33	0.25	Sum eosinophil basophil counts;	chr2:65449559	chr2:65436711~66084639:+
BRCA	cis	rs3096299	0.933	rs889576	ENSG00000274627.1	RP11-104N10.2	-8.19	7.78e-16	2.55e-13	-0.26	-0.25	Multiple myeloma (IgH translocation);	chr16:89363245	chr16:89516797~89522217:+
BRCA	cis	rs7811142	0.83	rs7792525	ENSG00000242294.5	STAG3L5P	8.19	7.78e-16	2.55e-13	0.25	0.25	Platelet count;	chr7:100374499	chr7:100336079~100351900:+
BRCA	cis	rs61270009	0.955	rs1367233	ENSG00000247828.6	TMEM161B-AS1	8.19	7.8e-16	2.55e-13	0.32	0.25	Depressive symptoms;	chr5:88301195	chr5:88268895~88436685:+
BRCA	cis	rs61270009	0.955	rs11740776	ENSG00000247828.6	TMEM161B-AS1	8.19	7.8e-16	2.55e-13	0.32	0.25	Depressive symptoms;	chr5:88303489	chr5:88268895~88436685:+
BRCA	cis	rs61270009	0.955	rs4916717	ENSG00000247828.6	TMEM161B-AS1	8.19	7.8e-16	2.55e-13	0.32	0.25	Depressive symptoms;	chr5:88305802	chr5:88268895~88436685:+
BRCA	cis	rs950776	0.593	rs555018	ENSG00000261762.1	RP11-650L12.2	-8.19	7.83e-16	2.56e-13	-0.27	-0.25	Sudden cardiac arrest;	chr15:78586900	chr15:78589123~78591276:-
BRCA	cis	rs673078	0.66	rs2280711	ENSG00000275759.1	RP11-131L12.3	-8.18	7.89e-16	2.58e-13	-0.34	-0.25	Glucose homeostasis traits;	chr12:118212149	chr12:118428281~118428870:+
BRCA	cis	rs667920	0.573	rs9682783	ENSG00000273486.1	RP11-731C17.2	8.18	7.92e-16	2.59e-13	0.31	0.25	Coronary artery disease;	chr3:136820847	chr3:136837338~136839021:-
BRCA	cis	rs7674212	0.507	rs6843738	ENSG00000246560.2	RP11-10L12.4	8.18	7.92e-16	2.59e-13	0.27	0.25	Type 2 diabetes;	chr4:103014844	chr4:102828055~102844075:+
BRCA	cis	rs1499614	0.901	rs2178742	ENSG00000273142.1	RP11-458F8.4	-8.18	7.92e-16	2.59e-13	-0.35	-0.25	Gout;	chr7:66732812	chr7:66902857~66906297:+
BRCA	cis	rs10771431	1	rs11611670	ENSG00000111788.10	RP11-22B23.1	8.18	7.96e-16	2.6e-13	0.23	0.25	Breast size;	chr12:9232939	chr12:9277235~9313241:+
BRCA	cis	rs7772486	0.681	rs9390343	ENSG00000235652.6	RP11-545I5.3	-8.18	7.99e-16	2.61e-13	-0.24	-0.25	Lobe attachment (rater-scored or self-reported);	chr6:145689391	chr6:145799409~145886585:+
BRCA	cis	rs3762637	1	rs9858558	ENSG00000272758.4	RP11-299J3.8	-8.18	8e-16	2.62e-13	-0.37	-0.25	LDL cholesterol levels;	chr3:122420895	chr3:122416207~122443180:+
BRCA	cis	rs11098499	0.863	rs3822195	ENSG00000248280.1	RP11-33B1.2	8.18	8e-16	2.62e-13	0.25	0.25	Corneal astigmatism;	chr4:119550505	chr4:119440561~119450157:-
BRCA	cis	rs7809950	1	rs3801944	ENSG00000238832.1	snoU109	8.18	8.02e-16	2.62e-13	0.32	0.25	Coronary artery disease;	chr7:107615103	chr7:107603363~107603507:+
BRCA	cis	rs7429990	0.828	rs6792350	ENSG00000229759.1	MRPS18AP1	-8.18	8.06e-16	2.63e-13	-0.28	-0.25	Educational attainment (years of education);	chr3:47797451	chr3:48256350~48256938:-
BRCA	cis	rs7429990	0.864	rs4858860	ENSG00000229759.1	MRPS18AP1	-8.18	8.06e-16	2.63e-13	-0.28	-0.25	Educational attainment (years of education);	chr3:47817344	chr3:48256350~48256938:-
BRCA	cis	rs6142102	0.625	rs6142051	ENSG00000275784.1	RP5-1125A11.6	-8.18	8.07e-16	2.64e-13	-0.28	-0.25	Skin pigmentation;	chr20:33945212	chr20:33989480~33991818:-
BRCA	cis	rs74233809	1	rs11191560	ENSG00000213277.3	MARCKSL1P1	8.18	8.07e-16	2.64e-13	0.45	0.25	Birth weight;	chr10:103109281	chr10:103175554~103176094:+
BRCA	cis	rs6142102	0.625	rs6142061	ENSG00000275784.1	RP5-1125A11.6	-8.18	8.07e-16	2.64e-13	-0.28	-0.25	Skin pigmentation;	chr20:33960529	chr20:33989480~33991818:-
BRCA	cis	rs42648	0.869	rs1015402	ENSG00000225498.1	AC002064.5	8.18	8.08e-16	2.64e-13	0.24	0.25	Homocysteine levels;	chr7:90283955	chr7:90312496~90322592:+
BRCA	cis	rs2286503	1	rs2286499	ENSG00000228649.7	AC005682.5	8.18	8.09e-16	2.64e-13	0.21	0.25	Fibrinogen;	chr7:22817858	chr7:22854178~22861579:+
BRCA	cis	rs7945705	0.846	rs2742540	ENSG00000254860.4	TMEM9B-AS1	-8.18	8.11e-16	2.65e-13	-0.22	-0.25	Hemoglobin concentration;	chr11:8877981	chr11:8964675~8977527:+
BRCA	cis	rs10971721	0.731	rs10971819	ENSG00000260947.1	RP11-384P7.7	8.18	8.11e-16	2.65e-13	0.44	0.25	Body mass index;	chr9:33954149	chr9:33697459~33700986:+
BRCA	cis	rs8012947	1	rs7155580	ENSG00000279636.2	LINC00216	-8.18	8.14e-16	2.66e-13	-0.27	-0.25	Alcohol consumption in current drinkers;	chr14:58304914	chr14:58288033~58289158:+
BRCA	cis	rs526231	0.543	rs152134	ENSG00000175749.11	EIF3KP1	8.18	8.15e-16	2.66e-13	0.36	0.25	Primary biliary cholangitis;	chr5:103176745	chr5:103032376~103033031:+
BRCA	cis	rs6782228	0.883	rs11712115	ENSG00000242551.2	POU5F1P6	8.18	8.15e-16	2.66e-13	0.34	0.25	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128685426	chr3:128674735~128677005:-
BRCA	cis	rs202072	0.72	rs454563	ENSG00000272379.1	RP1-257A7.5	8.18	8.2e-16	2.68e-13	0.43	0.25	HIV-1 viral setpoint;	chr6:13295304	chr6:13290018~13290490:-
BRCA	cis	rs875971	0.929	rs34406470	ENSG00000237310.1	GS1-124K5.4	8.18	8.2e-16	2.68e-13	0.26	0.25	Aortic root size;	chr7:66464969	chr7:66493706~66495474:+
BRCA	cis	rs7580658	0.613	rs12478656	ENSG00000236682.1	AC068282.3	-8.18	8.21e-16	2.68e-13	-0.33	-0.25	Protein C levels;	chr2:127438944	chr2:127389130~127400580:+
BRCA	cis	rs58873874	0.737	rs78565801	ENSG00000248544.2	CTB-47B11.3	8.18	8.22e-16	2.69e-13	0.61	0.25	Bipolar disorder (body mass index interaction);	chr5:157459326	chr5:157375741~157384950:-
BRCA	cis	rs58873874	0.737	rs79951742	ENSG00000248544.2	CTB-47B11.3	8.18	8.22e-16	2.69e-13	0.61	0.25	Bipolar disorder (body mass index interaction);	chr5:157459705	chr5:157375741~157384950:-
BRCA	cis	rs7927771	0.864	rs3781625	ENSG00000280615.1	Y_RNA	-8.18	8.22e-16	2.69e-13	-0.3	-0.25	Subjective well-being;	chr11:47421529	chr11:47614898~47614994:-
BRCA	cis	rs7809950	1	rs2237672	ENSG00000238832.1	snoU109	-8.18	8.24e-16	2.69e-13	-0.32	-0.25	Coronary artery disease;	chr7:107491118	chr7:107603363~107603507:+
BRCA	cis	rs11159086	1	rs8006909	ENSG00000259005.1	RP3-449M8.6	8.18	8.25e-16	2.69e-13	0.39	0.25	Advanced glycation end-product levels;	chr14:74478085	chr14:74474007~74474864:-
BRCA	cis	rs9640161	0.789	rs1464753	ENSG00000261305.1	RP4-584D14.7	8.18	8.25e-16	2.69e-13	0.37	0.25	Blood protein levels;Circulating chemerin levels;	chr7:150324261	chr7:150341771~150342607:+
BRCA	cis	rs4964805	0.626	rs869993	ENSG00000257681.1	RP11-341G23.4	8.18	8.26e-16	2.7e-13	0.3	0.25	Attention deficit hyperactivity disorder;	chr12:103781360	chr12:103746315~103768858:-
BRCA	cis	rs526231	0.543	rs34807	ENSG00000175749.11	EIF3KP1	8.18	8.28e-16	2.7e-13	0.36	0.25	Primary biliary cholangitis;	chr5:103092818	chr5:103032376~103033031:+
BRCA	cis	rs526231	0.543	rs28025	ENSG00000175749.11	EIF3KP1	8.18	8.29e-16	2.71e-13	0.36	0.25	Primary biliary cholangitis;	chr5:103201678	chr5:103032376~103033031:+
BRCA	cis	rs10510102	0.935	rs11200201	ENSG00000276742.1	RP11-500G22.4	8.18	8.29e-16	2.71e-13	0.39	0.25	Breast cancer;	chr10:121864790	chr10:121956782~121957098:+
BRCA	cis	rs7569084	0.687	rs1370394	ENSG00000204929.10	AC074391.1	8.18	8.3e-16	2.71e-13	0.33	0.25	Sum eosinophil basophil counts;	chr2:65453176	chr2:65436711~66084639:+
BRCA	cis	rs904251	0.504	rs2797795	ENSG00000204110.6	RP1-153P14.8	-8.18	8.3e-16	2.71e-13	-0.27	-0.25	Cognitive performance;	chr6:37512907	chr6:37507348~37535616:+
BRCA	cis	rs30380	1	rs26510	ENSG00000248734.2	CTD-2260A17.1	8.18	8.31e-16	2.71e-13	0.26	0.25	Cerebrospinal fluid biomarker levels;	chr5:96790207	chr5:96784777~96785999:+
BRCA	cis	rs896854	0.902	rs726816	ENSG00000253528.2	RP11-347C18.4	8.18	8.34e-16	2.72e-13	0.26	0.25	Type 2 diabetes;	chr8:94956185	chr8:94974573~94974853:-
BRCA	cis	rs11098499	0.754	rs878376	ENSG00000245958.5	RP11-33B1.1	-8.18	8.34e-16	2.72e-13	-0.23	-0.25	Corneal astigmatism;	chr4:119316547	chr4:119454791~119552025:+
BRCA	cis	rs7160336	0.628	rs12893501	ENSG00000259065.1	RP5-1021I20.1	8.18	8.35e-16	2.73e-13	0.3	0.25	Blood protein levels;	chr14:73990459	chr14:73787360~73803270:+
BRCA	cis	rs26232	0.521	rs40508	ENSG00000175749.11	EIF3KP1	8.18	8.4e-16	2.74e-13	0.35	0.25	Rheumatoid arthritis;	chr5:103108234	chr5:103032376~103033031:+
BRCA	cis	rs748404	0.666	rs66629206	ENSG00000249839.1	AC011330.5	-8.18	8.43e-16	2.75e-13	-0.37	-0.25	Lung cancer;	chr15:43458804	chr15:43663654~43684339:-
BRCA	cis	rs12468226	0.679	rs6435133	ENSG00000273456.1	RP11-686O6.2	-8.18	8.43e-16	2.75e-13	-0.36	-0.25	Urate levels;	chr2:202209237	chr2:202374932~202375604:-
BRCA	cis	rs12468226	0.817	rs12693965	ENSG00000273456.1	RP11-686O6.2	-8.18	8.43e-16	2.75e-13	-0.36	-0.25	Urate levels;	chr2:202210188	chr2:202374932~202375604:-
BRCA	cis	rs12468226	0.873	rs3769817	ENSG00000273456.1	RP11-686O6.2	-8.18	8.43e-16	2.75e-13	-0.36	-0.25	Urate levels;	chr2:202214584	chr2:202374932~202375604:-
BRCA	cis	rs12468226	0.873	rs6435134	ENSG00000273456.1	RP11-686O6.2	-8.18	8.43e-16	2.75e-13	-0.36	-0.25	Urate levels;	chr2:202214857	chr2:202374932~202375604:-
BRCA	cis	rs12468226	0.817	rs6435135	ENSG00000273456.1	RP11-686O6.2	-8.18	8.43e-16	2.75e-13	-0.36	-0.25	Urate levels;	chr2:202217469	chr2:202374932~202375604:-
BRCA	cis	rs7684253	0.548	rs13108002	ENSG00000269949.1	RP11-738E22.3	-8.18	8.45e-16	2.76e-13	-0.3	-0.25	Migraine;	chr4:56852087	chr4:56960927~56961373:-
BRCA	cis	rs526231	0.543	rs8488	ENSG00000175749.11	EIF3KP1	8.18	8.47e-16	2.76e-13	0.36	0.25	Primary biliary cholangitis;	chr5:103203051	chr5:103032376~103033031:+
BRCA	cis	rs11098499	0.754	rs1980025	ENSG00000248280.1	RP11-33B1.2	-8.18	8.51e-16	2.78e-13	-0.24	-0.25	Corneal astigmatism;	chr4:119331651	chr4:119440561~119450157:-
BRCA	cis	rs10129255	0.536	rs8004835	ENSG00000280411.1	IGHV1-69-2	-8.18	8.52e-16	2.78e-13	-0.16	-0.25	Kawasaki disease;	chr14:106686361	chr14:106762092~106762588:-
BRCA	cis	rs4835473	0.932	rs4835013	ENSG00000251600.4	RP11-673E1.1	8.17	8.55e-16	2.79e-13	0.29	0.25	Immature fraction of reticulocytes;	chr4:143748485	chr4:143912331~143982454:+
BRCA	cis	rs2288884	0.515	rs17779341	ENSG00000275055.1	CTC-471J1.11	-8.17	8.56e-16	2.79e-13	-0.28	-0.25	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52047148	chr19:52049007~52049754:+
BRCA	cis	rs2348418	0.733	rs10771414	ENSG00000247934.4	RP11-967K21.1	8.17	8.57e-16	2.8e-13	0.28	0.25	Lung function (FEV1);Lung function (FVC);	chr12:28241369	chr12:28163298~28190738:-
BRCA	cis	rs67981189	0.558	rs56043821	ENSG00000269927.1	RP6-91H8.3	8.17	8.6e-16	2.8e-13	0.33	0.25	Schizophrenia;	chr14:71103835	chr14:71141125~71143253:-
BRCA	cis	rs2439831	0.702	rs2467402	ENSG00000275601.1	AC011330.13	8.17	8.6e-16	2.8e-13	0.36	0.25	Lung cancer in ever smokers;	chr15:43732292	chr15:43642389~43643023:-
BRCA	cis	rs10129255	1	rs10129407	ENSG00000223648.3	IGHV3-64	8.17	8.65e-16	2.82e-13	0.21	0.25	Kawasaki disease;	chr14:106767956	chr14:106643132~106658258:-
BRCA	cis	rs6472827	0.645	rs2956024	ENSG00000253983.2	RP1-16A9.1	8.17	8.65e-16	2.82e-13	0.34	0.25	Uterine fibroids;	chr8:74191465	chr8:74199396~74208441:+
BRCA	cis	rs2243480	1	rs316321	ENSG00000273142.1	RP11-458F8.4	-8.17	8.66e-16	2.82e-13	-0.34	-0.25	Diabetic kidney disease;	chr7:66146626	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs316318	ENSG00000273142.1	RP11-458F8.4	-8.17	8.66e-16	2.82e-13	-0.34	-0.25	Diabetic kidney disease;	chr7:66147917	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs316317	ENSG00000273142.1	RP11-458F8.4	-8.17	8.66e-16	2.82e-13	-0.34	-0.25	Diabetic kidney disease;	chr7:66148650	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs316304	ENSG00000273142.1	RP11-458F8.4	-8.17	8.66e-16	2.82e-13	-0.34	-0.25	Diabetic kidney disease;	chr7:66151907	chr7:66902857~66906297:+
BRCA	cis	rs847577	0.677	rs1495525	ENSG00000272950.1	RP11-307C18.1	-8.17	8.68e-16	2.83e-13	-0.32	-0.25	Breast cancer;	chr7:98196920	chr7:98322853~98323430:+
BRCA	cis	rs6545883	0.86	rs6749226	ENSG00000271889.1	RP11-493E12.1	-8.17	8.69e-16	2.83e-13	-0.32	-0.25	Tuberculosis;	chr2:61282648	chr2:61151433~61162105:-
BRCA	cis	rs2439831	0.85	rs3816792	ENSG00000275601.1	AC011330.13	8.17	8.7e-16	2.84e-13	0.38	0.25	Lung cancer in ever smokers;	chr15:43824788	chr15:43642389~43643023:-
BRCA	cis	rs61776719	0.875	rs10890238	ENSG00000212541.1	RNU6-510P	-8.17	8.7e-16	2.84e-13	-0.29	-0.25	Coronary artery disease;	chr1:37979982	chr1:37991462~37991569:+
BRCA	cis	rs113835537	0.529	rs79798028	ENSG00000255517.5	CTD-3074O7.5	-8.17	8.72e-16	2.84e-13	-0.31	-0.25	Airway imaging phenotypes;	chr11:66431891	chr11:66473490~66480233:-
BRCA	cis	rs10129255	0.518	rs10136903	ENSG00000280411.1	IGHV1-69-2	-8.17	8.74e-16	2.85e-13	-0.16	-0.25	Kawasaki disease;	chr14:106778866	chr14:106762092~106762588:-
BRCA	cis	rs4237845	1	rs4237845	ENSG00000257159.1	RP11-58A17.3	-8.17	8.74e-16	2.85e-13	-0.28	-0.25	Intelligence (multi-trait analysis);	chr12:57908653	chr12:57967058~57968399:+
BRCA	cis	rs367615	1	rs367615	ENSG00000249476.1	CTD-2587M2.1	-8.17	8.75e-16	2.85e-13	-0.3	-0.25	Colorectal cancer (SNP x SNP interaction);	chr5:109613236	chr5:109237120~109326369:-
BRCA	cis	rs526231	0.543	rs3776863	ENSG00000175749.11	EIF3KP1	8.17	8.76e-16	2.86e-13	0.35	0.25	Primary biliary cholangitis;	chr5:102992165	chr5:103032376~103033031:+
BRCA	cis	rs526231	0.543	rs17154913	ENSG00000175749.11	EIF3KP1	8.17	8.76e-16	2.86e-13	0.35	0.25	Primary biliary cholangitis;	chr5:102992786	chr5:103032376~103033031:+
BRCA	cis	rs193541	0.632	rs154503	ENSG00000263432.2	RN7SL689P	8.17	8.78e-16	2.86e-13	0.33	0.25	Glucose homeostasis traits;	chr5:122868804	chr5:123022487~123022783:-
BRCA	cis	rs10463554	0.963	rs3776859	ENSG00000175749.11	EIF3KP1	8.17	8.79e-16	2.86e-13	0.33	0.25	Parkinson's disease;	chr5:103016330	chr5:103032376~103033031:+
BRCA	cis	rs10463554	0.963	rs17154953	ENSG00000175749.11	EIF3KP1	8.17	8.79e-16	2.86e-13	0.33	0.25	Parkinson's disease;	chr5:103019557	chr5:103032376~103033031:+
BRCA	cis	rs8062405	0.824	rs28698667	ENSG00000251417.2	RP11-1348G14.4	-8.17	8.79e-16	2.87e-13	-0.28	-0.25	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28521750	chr16:28802743~28817828:+
BRCA	cis	rs6142102	0.625	rs4911137	ENSG00000275784.1	RP5-1125A11.6	-8.17	8.79e-16	2.87e-13	-0.28	-0.25	Skin pigmentation;	chr20:33947657	chr20:33989480~33991818:-
BRCA	cis	rs950880	0.71	rs55927292	ENSG00000234389.1	AC007278.3	-8.17	8.81e-16	2.87e-13	-0.25	-0.25	Serum protein levels (sST2);	chr2:102348401	chr2:102438713~102440475:+
BRCA	cis	rs7809950	1	rs67982599	ENSG00000238832.1	snoU109	-8.17	8.81e-16	2.87e-13	-0.32	-0.25	Coronary artery disease;	chr7:107459659	chr7:107603363~107603507:+
BRCA	cis	rs7809950	1	rs987391	ENSG00000238832.1	snoU109	-8.17	8.81e-16	2.87e-13	-0.32	-0.25	Coronary artery disease;	chr7:107460349	chr7:107603363~107603507:+
BRCA	cis	rs11976180	1	rs2951372	ENSG00000170356.8	OR2A20P	-8.17	8.81e-16	2.87e-13	-0.34	-0.25	Obesity-related traits;	chr7:144052410	chr7:144250045~144252957:-
BRCA	cis	rs375066	0.967	rs436249	ENSG00000267058.1	RP11-15A1.3	-8.17	8.84e-16	2.88e-13	-0.28	-0.25	Breast cancer;	chr19:43895413	chr19:43891804~43901805:-
BRCA	cis	rs7809950	0.798	rs10281535	ENSG00000238832.1	snoU109	8.17	8.85e-16	2.88e-13	0.32	0.25	Coronary artery disease;	chr7:107589173	chr7:107603363~107603507:+
BRCA	cis	rs7809950	0.954	rs2189839	ENSG00000238832.1	snoU109	8.17	8.85e-16	2.88e-13	0.32	0.25	Coronary artery disease;	chr7:107589581	chr7:107603363~107603507:+
BRCA	cis	rs3758911	0.861	rs10890692	ENSG00000255353.1	RP11-382M14.1	-8.17	8.86e-16	2.89e-13	-0.33	-0.25	Coronary artery disease;	chr11:107277053	chr11:107176286~107177530:+
BRCA	cis	rs11098499	0.826	rs4472123	ENSG00000245958.5	RP11-33B1.1	-8.17	8.89e-16	2.9e-13	-0.23	-0.25	Corneal astigmatism;	chr4:119315475	chr4:119454791~119552025:+
BRCA	cis	rs61270009	0.955	rs11743103	ENSG00000247828.6	TMEM161B-AS1	-8.17	8.89e-16	2.9e-13	-0.31	-0.25	Depressive symptoms;	chr5:88380145	chr5:88268895~88436685:+
BRCA	cis	rs11690935	0.55	rs6746701	ENSG00000228389.1	AC068039.4	-8.17	8.91e-16	2.9e-13	-0.3	-0.25	Schizophrenia;	chr2:172004347	chr2:171773482~171775844:+
BRCA	cis	rs7712401	0.601	rs36180885	ENSG00000263432.2	RN7SL689P	-8.17	8.95e-16	2.91e-13	-0.33	-0.25	Mean platelet volume;	chr5:123020708	chr5:123022487~123022783:-
BRCA	cis	rs11098499	1	rs11098500	ENSG00000248280.1	RP11-33B1.2	8.17	8.95e-16	2.92e-13	0.25	0.25	Corneal astigmatism;	chr4:119298084	chr4:119440561~119450157:-
BRCA	cis	rs853679	0.882	rs9393908	ENSG00000220721.1	OR1F12	8.17	8.96e-16	2.92e-13	0.46	0.25	Depression;	chr6:28223052	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.882	rs9366717	ENSG00000220721.1	OR1F12	8.17	8.96e-16	2.92e-13	0.46	0.25	Depression;	chr6:28223279	chr6:28073316~28074233:+
BRCA	cis	rs6539288	0.674	rs4964494	ENSG00000260329.1	RP11-412D9.4	-8.17	8.96e-16	2.92e-13	-0.26	-0.25	Total body bone mineral density;	chr12:106890682	chr12:106954029~106955497:-
BRCA	cis	rs9640161	0.742	rs2108853	ENSG00000261305.1	RP4-584D14.7	8.17	8.97e-16	2.92e-13	0.36	0.25	Blood protein levels;Circulating chemerin levels;	chr7:150320500	chr7:150341771~150342607:+
BRCA	cis	rs6545883	0.894	rs778157	ENSG00000271889.1	RP11-493E12.1	8.17	8.98e-16	2.92e-13	0.31	0.25	Tuberculosis;	chr2:61327154	chr2:61151433~61162105:-
BRCA	cis	rs59482735	1	rs59482735	ENSG00000226752.6	PSMD5-AS1	-8.17	8.98e-16	2.93e-13	-0.31	-0.25	Prostate-specific antigen levels;	chr9:120881148	chr9:120824828~120854385:+
BRCA	cis	rs7085104	0.632	rs7097872	ENSG00000213061.2	PFN1P11	8.17	9.01e-16	2.93e-13	0.32	0.25	Immature fraction of reticulocytes;Schizophrenia;	chr10:102846879	chr10:102838011~102845473:-
BRCA	cis	rs13256369	1	rs12547721	ENSG00000253893.2	FAM85B	-8.17	9.03e-16	2.94e-13	-0.34	-0.25	Obesity-related traits;	chr8:8713161	chr8:8167819~8226614:-
BRCA	cis	rs526231	0.511	rs73179850	ENSG00000175749.11	EIF3KP1	8.17	9.04e-16	2.94e-13	0.36	0.25	Primary biliary cholangitis;	chr5:103012873	chr5:103032376~103033031:+
BRCA	cis	rs1707322	1	rs1707303	ENSG00000280836.1	AL355480.1	8.17	9.07e-16	2.95e-13	0.32	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46132601	chr1:45581219~45581321:-
BRCA	cis	rs30380	1	rs27529	ENSG00000248734.2	CTD-2260A17.1	8.17	9.08e-16	2.95e-13	0.26	0.25	Cerebrospinal fluid biomarker levels;	chr5:96790605	chr5:96784777~96785999:+
BRCA	cis	rs42648	0.869	rs1015404	ENSG00000225498.1	AC002064.5	8.17	9.14e-16	2.97e-13	0.23	0.25	Homocysteine levels;	chr7:90284632	chr7:90312496~90322592:+
BRCA	cis	rs4964805	1	rs11111791	ENSG00000257681.1	RP11-341G23.4	8.17	9.14e-16	2.97e-13	0.32	0.25	Attention deficit hyperactivity disorder;	chr12:103799493	chr12:103746315~103768858:-
BRCA	cis	rs11976180	0.569	rs12703565	ENSG00000204959.4	ARHGEF34P	8.17	9.16e-16	2.98e-13	0.41	0.25	Obesity-related traits;	chr7:144057308	chr7:144272445~144286966:-
BRCA	cis	rs7811142	1	rs7783550	ENSG00000242294.5	STAG3L5P	-8.17	9.16e-16	2.98e-13	-0.24	-0.25	Platelet count;	chr7:100390182	chr7:100336079~100351900:+
BRCA	cis	rs11098499	0.954	rs13107475	ENSG00000248280.1	RP11-33B1.2	8.17	9.18e-16	2.99e-13	0.25	0.25	Corneal astigmatism;	chr4:119471856	chr4:119440561~119450157:-
BRCA	cis	rs6545883	0.825	rs4672426	ENSG00000271889.1	RP11-493E12.1	-8.17	9.2e-16	2.99e-13	-0.31	-0.25	Tuberculosis;	chr2:61230013	chr2:61151433~61162105:-
BRCA	cis	rs6545883	0.86	rs4671399	ENSG00000271889.1	RP11-493E12.1	-8.17	9.2e-16	2.99e-13	-0.31	-0.25	Tuberculosis;	chr2:61231383	chr2:61151433~61162105:-
BRCA	cis	rs7674212	0.507	rs223322	ENSG00000246560.2	RP11-10L12.4	8.17	9.21e-16	3e-13	0.27	0.25	Type 2 diabetes;	chr4:102879037	chr4:102828055~102844075:+
BRCA	cis	rs860818	1	rs858243	ENSG00000226816.2	AC005082.12	8.16	9.22e-16	3e-13	0.54	0.25	Initial pursuit acceleration;	chr7:23184738	chr7:23206013~23208045:+
BRCA	cis	rs193541	0.632	rs152038	ENSG00000263432.2	RN7SL689P	8.16	9.24e-16	3.01e-13	0.33	0.25	Glucose homeostasis traits;	chr5:122860151	chr5:123022487~123022783:-
BRCA	cis	rs7085104	0.7	rs743572	ENSG00000236937.2	PTGES3P4	8.16	9.29e-16	3.02e-13	0.31	0.25	Immature fraction of reticulocytes;Schizophrenia;	chr10:102837395	chr10:102845595~102845950:+
BRCA	cis	rs7811142	0.83	rs11771936	ENSG00000242294.5	STAG3L5P	8.16	9.29e-16	3.02e-13	0.25	0.25	Platelet count;	chr7:100345660	chr7:100336079~100351900:+
BRCA	cis	rs7811142	0.779	rs77370288	ENSG00000242294.5	STAG3L5P	8.16	9.29e-16	3.02e-13	0.25	0.25	Platelet count;	chr7:100350274	chr7:100336079~100351900:+
BRCA	cis	rs4835473	0.715	rs4538428	ENSG00000251600.4	RP11-673E1.1	8.16	9.29e-16	3.02e-13	0.3	0.25	Immature fraction of reticulocytes;	chr4:143992751	chr4:143912331~143982454:+
BRCA	cis	rs193541	0.632	rs154512	ENSG00000263432.2	RN7SL689P	8.16	9.32e-16	3.03e-13	0.33	0.25	Glucose homeostasis traits;	chr5:122859345	chr5:123022487~123022783:-
BRCA	cis	rs11098499	0.73	rs12505735	ENSG00000248280.1	RP11-33B1.2	8.16	9.34e-16	3.04e-13	0.25	0.25	Corneal astigmatism;	chr4:119611801	chr4:119440561~119450157:-
BRCA	cis	rs2348418	0.703	rs10843122	ENSG00000247934.4	RP11-967K21.1	-8.16	9.35e-16	3.04e-13	-0.28	-0.25	Lung function (FEV1);Lung function (FVC);	chr12:28174153	chr12:28163298~28190738:-
BRCA	cis	rs2976388	0.609	rs1469811	ENSG00000253741.1	CTD-2292P10.4	-8.16	9.36e-16	3.04e-13	-0.27	-0.25	Urinary tract infection frequency;	chr8:142706581	chr8:142702252~142726973:-
BRCA	cis	rs11098499	0.866	rs72676074	ENSG00000248280.1	RP11-33B1.2	8.16	9.4e-16	3.06e-13	0.25	0.25	Corneal astigmatism;	chr4:119438686	chr4:119440561~119450157:-
BRCA	cis	rs1061377	0.748	rs35904472	ENSG00000249685.1	RP11-360F5.3	8.16	9.44e-16	3.07e-13	0.3	0.25	Uric acid levels;	chr4:39094901	chr4:39133913~39135608:+
BRCA	cis	rs1061377	0.748	rs10856841	ENSG00000249685.1	RP11-360F5.3	8.16	9.44e-16	3.07e-13	0.3	0.25	Uric acid levels;	chr4:39095240	chr4:39133913~39135608:+
BRCA	cis	rs9640161	0.789	rs10282458	ENSG00000261305.1	RP4-584D14.7	8.16	9.45e-16	3.07e-13	0.36	0.25	Blood protein levels;Circulating chemerin levels;	chr7:150348213	chr7:150341771~150342607:+
BRCA	cis	rs7674212	0.531	rs4699048	ENSG00000246560.2	RP11-10L12.4	8.16	9.46e-16	3.08e-13	0.26	0.25	Type 2 diabetes;	chr4:103005570	chr4:102828055~102844075:+
BRCA	cis	rs7731783	1	rs7731783	ENSG00000247679.2	RP11-1277A3.1	8.16	9.48e-16	3.08e-13	0.26	0.25	Methadone dose in opioid dependence;	chr5:177633311	chr5:177611253~177619754:+
BRCA	cis	rs7772486	0.875	rs9399573	ENSG00000235652.6	RP11-545I5.3	8.16	9.5e-16	3.09e-13	0.24	0.25	Lobe attachment (rater-scored or self-reported);	chr6:146082119	chr6:145799409~145886585:+
BRCA	cis	rs7598759	0.679	rs6740843	ENSG00000181798.2	LINC00471	-8.16	9.5e-16	3.09e-13	-0.29	-0.25	Noise-induced hearing loss;	chr2:231467428	chr2:231508426~231514339:-
BRCA	cis	rs950880	0.71	rs17027006	ENSG00000234389.1	AC007278.3	8.16	9.52e-16	3.09e-13	0.25	0.25	Serum protein levels (sST2);	chr2:102348872	chr2:102438713~102440475:+
BRCA	cis	rs7727544	0.735	rs2569266	ENSG00000233006.5	AC034220.3	-8.16	9.53e-16	3.09e-13	-0.18	-0.25	Blood metabolite levels;	chr5:132371099	chr5:132311285~132369916:-
BRCA	cis	rs11098499	0.909	rs1809406	ENSG00000248280.1	RP11-33B1.2	8.16	9.58e-16	3.11e-13	0.25	0.25	Corneal astigmatism;	chr4:119455967	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.865	rs2389809	ENSG00000248280.1	RP11-33B1.2	8.16	9.58e-16	3.11e-13	0.25	0.25	Corneal astigmatism;	chr4:119456244	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.909	rs9994810	ENSG00000248280.1	RP11-33B1.2	8.16	9.58e-16	3.11e-13	0.25	0.25	Corneal astigmatism;	chr4:119460435	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.697	rs10020027	ENSG00000248280.1	RP11-33B1.2	8.16	9.58e-16	3.11e-13	0.25	0.25	Corneal astigmatism;	chr4:119460724	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.779	rs7356491	ENSG00000248280.1	RP11-33B1.2	8.16	9.58e-16	3.11e-13	0.25	0.25	Corneal astigmatism;	chr4:119460819	chr4:119440561~119450157:-
BRCA	cis	rs73186030	0.546	rs73188327	ENSG00000272758.4	RP11-299J3.8	8.16	9.58e-16	3.11e-13	0.34	0.25	Serum parathyroid hormone levels;	chr3:122394819	chr3:122416207~122443180:+
BRCA	cis	rs950880	0.71	rs4851011	ENSG00000234389.1	AC007278.3	8.16	9.63e-16	3.13e-13	0.25	0.25	Serum protein levels (sST2);	chr2:102473219	chr2:102438713~102440475:+
BRCA	cis	rs8012947	1	rs1885133	ENSG00000279636.2	LINC00216	-8.16	9.64e-16	3.13e-13	-0.27	-0.25	Alcohol consumption in current drinkers;	chr14:58270684	chr14:58288033~58289158:+
BRCA	cis	rs2236295	0.814	rs1848797	ENSG00000238280.1	RP11-436D10.3	-8.16	9.66e-16	3.14e-13	-0.34	-0.25	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks);	chr10:62793174	chr10:62793562~62805887:-
BRCA	cis	rs7684253	0.548	rs62308071	ENSG00000269949.1	RP11-738E22.3	-8.16	9.69e-16	3.15e-13	-0.29	-0.25	Migraine;	chr4:56850720	chr4:56960927~56961373:-
BRCA	cis	rs950880	0.71	rs10490204	ENSG00000234389.1	AC007278.3	-8.16	9.69e-16	3.15e-13	-0.25	-0.25	Serum protein levels (sST2);	chr2:102440074	chr2:102438713~102440475:+
BRCA	cis	rs2880765	0.835	rs7178991	ENSG00000259295.5	CSPG4P12	8.16	9.73e-16	3.16e-13	0.3	0.25	Coronary artery disease;	chr15:85507713	chr15:85191438~85213905:+
BRCA	cis	rs6921919	0.887	rs16894116	ENSG00000204709.4	LINC01556	8.16	9.73e-16	3.16e-13	0.39	0.25	Autism spectrum disorder or schizophrenia;	chr6:28447190	chr6:28943877~28944537:+
BRCA	cis	rs6545883	0.86	rs6545848	ENSG00000271889.1	RP11-493E12.1	-8.16	9.8e-16	3.18e-13	-0.31	-0.24	Tuberculosis;	chr2:61234048	chr2:61151433~61162105:-
BRCA	cis	rs9309711	0.922	rs11679058	ENSG00000225234.1	TRAPPC12-AS1	-8.16	9.81e-16	3.19e-13	-0.29	-0.24	Neurofibrillary tangles;	chr2:3480042	chr2:3481242~3482409:-
BRCA	cis	rs7621025	0.5	rs4678275	ENSG00000273486.1	RP11-731C17.2	8.16	9.85e-16	3.2e-13	0.31	0.24	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136934841	chr3:136837338~136839021:-
BRCA	cis	rs904251	0.523	rs2797794	ENSG00000204110.6	RP1-153P14.8	-8.16	9.86e-16	3.2e-13	-0.27	-0.24	Cognitive performance;	chr6:37512828	chr6:37507348~37535616:+
BRCA	cis	rs904251	0.523	rs2776920	ENSG00000204110.6	RP1-153P14.8	-8.16	9.86e-16	3.2e-13	-0.27	-0.24	Cognitive performance;	chr6:37512829	chr6:37507348~37535616:+
BRCA	cis	rs11098499	0.691	rs10010355	ENSG00000245958.5	RP11-33B1.1	-8.16	9.89e-16	3.21e-13	-0.23	-0.24	Corneal astigmatism;	chr4:119339888	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.691	rs9307471	ENSG00000245958.5	RP11-33B1.1	-8.16	9.89e-16	3.21e-13	-0.23	-0.24	Corneal astigmatism;	chr4:119340107	chr4:119454791~119552025:+
BRCA	cis	rs7598759	0.712	rs6740474	ENSG00000181798.2	LINC00471	-8.16	9.89e-16	3.21e-13	-0.29	-0.24	Noise-induced hearing loss;	chr2:231467120	chr2:231508426~231514339:-
BRCA	cis	rs7598759	0.712	rs6727510	ENSG00000181798.2	LINC00471	-8.16	9.89e-16	3.21e-13	-0.29	-0.24	Noise-induced hearing loss;	chr2:231467305	chr2:231508426~231514339:-
BRCA	cis	rs7598759	0.675	rs6727530	ENSG00000181798.2	LINC00471	-8.16	9.89e-16	3.21e-13	-0.29	-0.24	Noise-induced hearing loss;	chr2:231467347	chr2:231508426~231514339:-
BRCA	cis	rs7598759	0.712	rs10933372	ENSG00000181798.2	LINC00471	-8.16	9.89e-16	3.21e-13	-0.29	-0.24	Noise-induced hearing loss;	chr2:231467614	chr2:231508426~231514339:-
BRCA	cis	rs7598759	0.712	rs997400	ENSG00000181798.2	LINC00471	-8.16	9.89e-16	3.21e-13	-0.29	-0.24	Noise-induced hearing loss;	chr2:231468136	chr2:231508426~231514339:-
BRCA	cis	rs526231	0.511	rs158402	ENSG00000175749.11	EIF3KP1	8.16	9.89e-16	3.21e-13	0.35	0.24	Primary biliary cholangitis;	chr5:103079821	chr5:103032376~103033031:+
BRCA	cis	rs7598759	0.712	rs6727372	ENSG00000181798.2	LINC00471	-8.16	9.93e-16	3.22e-13	-0.29	-0.24	Noise-induced hearing loss;	chr2:231467195	chr2:231508426~231514339:-
BRCA	cis	rs7598759	0.588	rs6737291	ENSG00000181798.2	LINC00471	-8.16	9.94e-16	3.22e-13	-0.29	-0.24	Noise-induced hearing loss;	chr2:231464848	chr2:231508426~231514339:-
BRCA	cis	rs10463554	0.759	rs34815	ENSG00000175749.11	EIF3KP1	8.15	9.97e-16	3.24e-13	0.36	0.24	Parkinson's disease;	chr5:103098561	chr5:103032376~103033031:+
BRCA	cis	rs11976180	1	rs13243677	ENSG00000170356.8	OR2A20P	-8.15	9.99e-16	3.24e-13	-0.34	-0.24	Obesity-related traits;	chr7:144049479	chr7:144250045~144252957:-
BRCA	cis	rs12468226	0.808	rs77251002	ENSG00000273456.1	RP11-686O6.2	8.15	1e-15	3.25e-13	0.39	0.24	Urate levels;	chr2:202150236	chr2:202374932~202375604:-
BRCA	cis	rs860818	1	rs1637216	ENSG00000226816.2	AC005082.12	8.15	1e-15	3.25e-13	0.53	0.24	Initial pursuit acceleration;	chr7:23196510	chr7:23206013~23208045:+
BRCA	cis	rs7927771	1	rs4752797	ENSG00000280615.1	Y_RNA	-8.15	1e-15	3.25e-13	-0.3	-0.24	Subjective well-being;	chr11:47852812	chr11:47614898~47614994:-
BRCA	cis	rs12468226	0.873	rs2350358	ENSG00000273456.1	RP11-686O6.2	-8.15	1e-15	3.25e-13	-0.34	-0.24	Urate levels;	chr2:202199771	chr2:202374932~202375604:-
BRCA	cis	rs11673344	0.764	rs13345491	ENSG00000226686.6	LINC01535	8.15	1.01e-15	3.26e-13	0.32	0.24	Obesity-related traits;	chr19:36982197	chr19:37251912~37265535:+
BRCA	cis	rs526231	0.575	rs55652053	ENSG00000175749.11	EIF3KP1	8.15	1.01e-15	3.26e-13	0.35	0.24	Primary biliary cholangitis;	chr5:103001466	chr5:103032376~103033031:+
BRCA	cis	rs11098499	0.691	rs17009144	ENSG00000248280.1	RP11-33B1.2	-8.15	1.01e-15	3.26e-13	-0.23	-0.24	Corneal astigmatism;	chr4:119349640	chr4:119440561~119450157:-
BRCA	cis	rs9880211	1	rs9883189	ENSG00000239213.4	NCK1-AS1	8.15	1.01e-15	3.27e-13	0.32	0.24	Height;Body mass index;	chr3:136570624	chr3:136841726~136862054:-
BRCA	cis	rs1799949	1	rs8070085	ENSG00000267681.1	CTD-3199J23.6	8.15	1.01e-15	3.27e-13	0.29	0.24	Menopause (age at onset);	chr17:43189967	chr17:43144956~43145255:+
BRCA	cis	rs7809950	1	rs7793613	ENSG00000238832.1	snoU109	-8.15	1.01e-15	3.28e-13	-0.33	-0.24	Coronary artery disease;	chr7:107610039	chr7:107603363~107603507:+
BRCA	cis	rs61270009	0.955	rs4916719	ENSG00000247828.6	TMEM161B-AS1	8.15	1.02e-15	3.29e-13	0.31	0.24	Depressive symptoms;	chr5:88327844	chr5:88268895~88436685:+
BRCA	cis	rs3758911	0.828	rs10890701	ENSG00000255353.1	RP11-382M14.1	-8.15	1.02e-15	3.3e-13	-0.33	-0.24	Coronary artery disease;	chr11:107309216	chr11:107176286~107177530:+
BRCA	cis	rs6142102	0.961	rs2284379	ENSG00000276073.1	RP5-1125A11.7	-8.15	1.02e-15	3.31e-13	-0.3	-0.24	Skin pigmentation;	chr20:34006836	chr20:33985617~33988989:-
BRCA	cis	rs6142102	0.961	rs6059649	ENSG00000276073.1	RP5-1125A11.7	-8.15	1.02e-15	3.31e-13	-0.3	-0.24	Skin pigmentation;	chr20:34056071	chr20:33985617~33988989:-
BRCA	cis	rs10463554	0.727	rs34768	ENSG00000175749.11	EIF3KP1	8.15	1.02e-15	3.31e-13	0.36	0.24	Parkinson's disease;	chr5:103155798	chr5:103032376~103033031:+
BRCA	cis	rs9368481	0.678	rs62402024	ENSG00000241549.7	GUSBP2	8.15	1.02e-15	3.31e-13	0.28	0.24	Autism spectrum disorder or schizophrenia;	chr6:26956197	chr6:26871484~26956554:-
BRCA	cis	rs1707322	1	rs10890375	ENSG00000280836.1	AL355480.1	-8.15	1.03e-15	3.33e-13	-0.31	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45940909	chr1:45581219~45581321:-
BRCA	cis	rs1707322	1	rs10890377	ENSG00000280836.1	AL355480.1	-8.15	1.03e-15	3.33e-13	-0.31	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45940922	chr1:45581219~45581321:-
BRCA	cis	rs6558530	0.64	rs7844748	ENSG00000253982.1	CTD-2336O2.1	-8.15	1.03e-15	3.35e-13	-0.3	-0.24	Systolic blood pressure;	chr8:1754177	chr8:1761990~1764502:-
BRCA	cis	rs2117029	0.862	rs10875915	ENSG00000258017.1	RP11-386G11.10	-8.15	1.03e-15	3.35e-13	-0.32	-0.24	Intelligence (multi-trait analysis);	chr12:49036311	chr12:49127782~49147869:+
BRCA	cis	rs2911132	1	rs2549803	ENSG00000248734.2	CTD-2260A17.1	8.15	1.03e-15	3.35e-13	0.3	0.24	Urate levels (BMI interaction);	chr5:96839226	chr5:96784777~96785999:+
BRCA	cis	rs11098499	0.644	rs3806808	ENSG00000248280.1	RP11-33B1.2	8.15	1.04e-15	3.37e-13	0.24	0.24	Corneal astigmatism;	chr4:119629930	chr4:119440561~119450157:-
BRCA	cis	rs250518	0.926	rs7723498	ENSG00000272081.1	CTD-2376I4.2	8.15	1.04e-15	3.38e-13	0.31	0.24	Mean corpuscular hemoglobin concentration;	chr5:72791470	chr5:72955206~72955699:-
BRCA	cis	rs7674212	0.531	rs6816370	ENSG00000246560.2	RP11-10L12.4	8.15	1.04e-15	3.38e-13	0.27	0.24	Type 2 diabetes;	chr4:103018276	chr4:102828055~102844075:+
BRCA	cis	rs113835537	0.529	rs11227503	ENSG00000255517.5	CTD-3074O7.5	-8.15	1.04e-15	3.38e-13	-0.31	-0.24	Airway imaging phenotypes;	chr11:66507771	chr11:66473490~66480233:-
BRCA	cis	rs113835537	0.529	rs4542420	ENSG00000255517.5	CTD-3074O7.5	-8.15	1.04e-15	3.38e-13	-0.31	-0.24	Airway imaging phenotypes;	chr11:66510139	chr11:66473490~66480233:-
BRCA	cis	rs1707322	1	rs4660334	ENSG00000280836.1	AL355480.1	-8.15	1.05e-15	3.39e-13	-0.31	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45996454	chr1:45581219~45581321:-
BRCA	cis	rs6539288	0.901	rs4964505	ENSG00000260329.1	RP11-412D9.4	-8.15	1.05e-15	3.4e-13	-0.28	-0.24	Total body bone mineral density;	chr12:106948062	chr12:106954029~106955497:-
BRCA	cis	rs7927771	1	rs1317149	ENSG00000280615.1	Y_RNA	-8.15	1.05e-15	3.41e-13	-0.3	-0.24	Subjective well-being;	chr11:47465333	chr11:47614898~47614994:-
BRCA	cis	rs6545883	0.894	rs2694632	ENSG00000271889.1	RP11-493E12.1	-8.15	1.06e-15	3.42e-13	-0.31	-0.24	Tuberculosis;	chr2:61331547	chr2:61151433~61162105:-
BRCA	cis	rs7674212	0.507	rs223317	ENSG00000246560.2	RP11-10L12.4	8.15	1.06e-15	3.42e-13	0.27	0.24	Type 2 diabetes;	chr4:102881667	chr4:102828055~102844075:+
BRCA	cis	rs9880211	0.948	rs9813691	ENSG00000239213.4	NCK1-AS1	8.15	1.06e-15	3.42e-13	0.32	0.24	Height;Body mass index;	chr3:136541880	chr3:136841726~136862054:-
BRCA	cis	rs1075265	0.656	rs2542574	ENSG00000233266.1	HMGB1P31	8.15	1.06e-15	3.43e-13	0.29	0.24	Chronotype;Morning vs. evening chronotype;	chr2:53820295	chr2:54051334~54051760:+
BRCA	cis	rs10463554	0.856	rs26427	ENSG00000175749.11	EIF3KP1	-8.15	1.06e-15	3.43e-13	-0.33	-0.24	Parkinson's disease;	chr5:103031079	chr5:103032376~103033031:+
BRCA	cis	rs950880	0.744	rs3771156	ENSG00000234389.1	AC007278.3	-8.15	1.06e-15	3.44e-13	-0.25	-0.24	Serum protein levels (sST2);	chr2:102420217	chr2:102438713~102440475:+
BRCA	cis	rs6472827	0.645	rs2956052	ENSG00000253983.2	RP1-16A9.1	8.15	1.06e-15	3.44e-13	0.34	0.24	Uterine fibroids;	chr8:74200423	chr8:74199396~74208441:+
BRCA	cis	rs72627509	0.857	rs2227901	ENSG00000269949.1	RP11-738E22.3	-8.15	1.07e-15	3.45e-13	-0.36	-0.24	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56932023	chr4:56960927~56961373:-
BRCA	cis	rs7569084	0.687	rs7577452	ENSG00000204929.10	AC074391.1	8.15	1.07e-15	3.45e-13	0.33	0.24	Sum eosinophil basophil counts;	chr2:65456694	chr2:65436711~66084639:+
BRCA	cis	rs2274273	0.84	rs28493647	ENSG00000258413.1	RP11-665C16.6	-8.15	1.07e-15	3.45e-13	-0.3	-0.24	Protein biomarker;	chr14:55357745	chr14:55262767~55272075:-
BRCA	cis	rs2274273	0.84	rs17674463	ENSG00000258413.1	RP11-665C16.6	-8.15	1.07e-15	3.45e-13	-0.3	-0.24	Protein biomarker;	chr14:55358145	chr14:55262767~55272075:-
BRCA	cis	rs10129255	0.556	rs9324093	ENSG00000280411.1	IGHV1-69-2	-8.15	1.07e-15	3.46e-13	-0.16	-0.24	Kawasaki disease;	chr14:106683893	chr14:106762092~106762588:-
BRCA	cis	rs11098499	0.863	rs12498539	ENSG00000248280.1	RP11-33B1.2	8.15	1.07e-15	3.46e-13	0.25	0.24	Corneal astigmatism;	chr4:119547215	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.863	rs3822194	ENSG00000248280.1	RP11-33B1.2	8.15	1.07e-15	3.46e-13	0.25	0.24	Corneal astigmatism;	chr4:119550493	chr4:119440561~119450157:-
BRCA	cis	rs853679	1	rs853679	ENSG00000220721.1	OR1F12	8.15	1.07e-15	3.46e-13	0.38	0.24	Depression;	chr6:28329086	chr6:28073316~28074233:+
BRCA	cis	rs853679	1	rs853678	ENSG00000220721.1	OR1F12	8.15	1.07e-15	3.46e-13	0.38	0.24	Depression;	chr6:28329536	chr6:28073316~28074233:+
BRCA	cis	rs526231	0.512	rs34797	ENSG00000175749.11	EIF3KP1	8.14	1.08e-15	3.5e-13	0.36	0.24	Primary biliary cholangitis;	chr5:103090023	chr5:103032376~103033031:+
BRCA	cis	rs526231	0.543	rs34801	ENSG00000175749.11	EIF3KP1	8.14	1.08e-15	3.5e-13	0.36	0.24	Primary biliary cholangitis;	chr5:103090809	chr5:103032376~103033031:+
BRCA	cis	rs6545883	0.894	rs6709441	ENSG00000271889.1	RP11-493E12.1	-8.14	1.08e-15	3.5e-13	-0.32	-0.24	Tuberculosis;	chr2:61209795	chr2:61151433~61162105:-
BRCA	cis	rs1789	0.503	rs13133213	ENSG00000273133.1	RP11-799M12.2	-8.14	1.08e-15	3.51e-13	-0.29	-0.24	Blood protein levels;	chr4:15645171	chr4:15563698~15564253:-
BRCA	cis	rs2911132	1	rs2617433	ENSG00000248734.2	CTD-2260A17.1	8.14	1.08e-15	3.51e-13	0.3	0.24	Urate levels (BMI interaction);	chr5:96840738	chr5:96784777~96785999:+
BRCA	cis	rs8062405	0.755	rs62031607	ENSG00000251417.2	RP11-1348G14.4	-8.14	1.08e-15	3.51e-13	-0.3	-0.24	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620209	chr16:28802743~28817828:+
BRCA	cis	rs58873874	0.579	rs35536103	ENSG00000251405.2	CTB-109A12.1	8.14	1.09e-15	3.51e-13	0.54	0.24	Bipolar disorder (body mass index interaction);	chr5:157308391	chr5:157362615~157460078:-
BRCA	cis	rs950880	0.71	rs1474309	ENSG00000234389.1	AC007278.3	-8.14	1.09e-15	3.52e-13	-0.24	-0.24	Serum protein levels (sST2);	chr2:102474542	chr2:102438713~102440475:+
BRCA	cis	rs875971	0.8	rs427557	ENSG00000237310.1	GS1-124K5.4	8.14	1.09e-15	3.53e-13	0.26	0.24	Aortic root size;	chr7:66054263	chr7:66493706~66495474:+
BRCA	cis	rs73186030	0.546	rs55857899	ENSG00000272758.4	RP11-299J3.8	8.14	1.1e-15	3.54e-13	0.34	0.24	Serum parathyroid hormone levels;	chr3:122390705	chr3:122416207~122443180:+
BRCA	cis	rs12701220	0.604	rs34904312	ENSG00000229043.2	AC091729.9	-8.14	1.1e-15	3.54e-13	-0.35	-0.24	Bronchopulmonary dysplasia;	chr7:1096247	chr7:1160374~1165267:+
BRCA	cis	rs8072100	0.967	rs7219303	ENSG00000228782.6	CTD-2026D20.3	-8.14	1.1e-15	3.55e-13	-0.26	-0.24	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47660335	chr17:47450568~47492492:-
BRCA	cis	rs6142102	0.625	rs6141431	ENSG00000275784.1	RP5-1125A11.6	-8.14	1.1e-15	3.57e-13	-0.28	-0.24	Skin pigmentation;	chr20:33952508	chr20:33989480~33991818:-
BRCA	cis	rs11976180	1	rs2961144	ENSG00000170356.8	OR2A20P	8.14	1.11e-15	3.57e-13	0.34	0.24	Obesity-related traits;	chr7:144050777	chr7:144250045~144252957:-
BRCA	cis	rs875971	0.862	rs9791712	ENSG00000232559.3	GS1-124K5.12	-8.14	1.11e-15	3.58e-13	-0.3	-0.24	Aortic root size;	chr7:66640176	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.862	rs9791713	ENSG00000232559.3	GS1-124K5.12	-8.14	1.11e-15	3.58e-13	-0.3	-0.24	Aortic root size;	chr7:66640211	chr7:66554588~66576923:-
BRCA	cis	rs860818	1	rs1637223	ENSG00000226816.2	AC005082.12	8.14	1.11e-15	3.58e-13	0.54	0.24	Initial pursuit acceleration;	chr7:23189050	chr7:23206013~23208045:+
BRCA	cis	rs860818	0.744	rs1728319	ENSG00000226816.2	AC005082.12	8.14	1.11e-15	3.58e-13	0.54	0.24	Initial pursuit acceleration;	chr7:23191580	chr7:23206013~23208045:+
BRCA	cis	rs2243480	1	rs313824	ENSG00000273142.1	RP11-458F8.4	-8.14	1.11e-15	3.59e-13	-0.34	-0.24	Diabetic kidney disease;	chr7:66116220	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs186378	ENSG00000273142.1	RP11-458F8.4	-8.14	1.11e-15	3.59e-13	-0.34	-0.24	Diabetic kidney disease;	chr7:66117071	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs160637	ENSG00000273142.1	RP11-458F8.4	-8.14	1.11e-15	3.59e-13	-0.34	-0.24	Diabetic kidney disease;	chr7:66119331	chr7:66902857~66906297:+
BRCA	cis	rs6142102	0.961	rs6059596	ENSG00000276073.1	RP5-1125A11.7	-8.14	1.11e-15	3.59e-13	-0.3	-0.24	Skin pigmentation;	chr20:33969313	chr20:33985617~33988989:-
BRCA	cis	rs9368481	0.761	rs4358615	ENSG00000241549.7	GUSBP2	8.14	1.12e-15	3.61e-13	0.28	0.24	Autism spectrum disorder or schizophrenia;	chr6:27030788	chr6:26871484~26956554:-
BRCA	cis	rs6472827	0.645	rs1532577	ENSG00000253983.2	RP1-16A9.1	8.14	1.12e-15	3.61e-13	0.34	0.24	Uterine fibroids;	chr8:74193907	chr8:74199396~74208441:+
BRCA	cis	rs4835473	0.932	rs13147170	ENSG00000251600.4	RP11-673E1.1	8.14	1.12e-15	3.62e-13	0.3	0.24	Immature fraction of reticulocytes;	chr4:143975848	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs13147184	ENSG00000251600.4	RP11-673E1.1	8.14	1.12e-15	3.62e-13	0.3	0.24	Immature fraction of reticulocytes;	chr4:143975873	chr4:143912331~143982454:+
BRCA	cis	rs526231	0.512	rs28022	ENSG00000175749.11	EIF3KP1	8.14	1.12e-15	3.62e-13	0.36	0.24	Primary biliary cholangitis;	chr5:103128663	chr5:103032376~103033031:+
BRCA	cis	rs11098499	0.863	rs2306457	ENSG00000248280.1	RP11-33B1.2	8.14	1.12e-15	3.62e-13	0.25	0.24	Corneal astigmatism;	chr4:119551684	chr4:119440561~119450157:-
BRCA	cis	rs881375	0.526	rs1930785	ENSG00000226752.6	PSMD5-AS1	-8.14	1.12e-15	3.63e-13	-0.28	-0.24	Rheumatoid arthritis;	chr9:120928959	chr9:120824828~120854385:+
BRCA	cis	rs807029	0.577	rs750866	ENSG00000272572.1	RP11-179B2.2	-8.14	1.13e-15	3.64e-13	-0.32	-0.24	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:101001701	chr10:100911103~100912739:-
BRCA	cis	rs6545883	0.929	rs2264100	ENSG00000271889.1	RP11-493E12.1	8.14	1.13e-15	3.64e-13	0.32	0.24	Tuberculosis;	chr2:61443694	chr2:61151433~61162105:-
BRCA	cis	rs9880211	1	rs17200216	ENSG00000239213.4	NCK1-AS1	8.14	1.13e-15	3.64e-13	0.32	0.24	Height;Body mass index;	chr3:136348390	chr3:136841726~136862054:-
BRCA	cis	rs875971	0.825	rs28480509	ENSG00000232559.3	GS1-124K5.12	-8.14	1.14e-15	3.67e-13	-0.3	-0.24	Aortic root size;	chr7:66634237	chr7:66554588~66576923:-
BRCA	cis	rs526231	0.543	rs7714539	ENSG00000175749.11	EIF3KP1	8.14	1.14e-15	3.67e-13	0.35	0.24	Primary biliary cholangitis;	chr5:102993174	chr5:103032376~103033031:+
BRCA	cis	rs526231	0.543	rs60633061	ENSG00000175749.11	EIF3KP1	8.14	1.14e-15	3.67e-13	0.35	0.24	Primary biliary cholangitis;	chr5:102994345	chr5:103032376~103033031:+
BRCA	cis	rs950880	0.71	rs17027255	ENSG00000234389.1	AC007278.3	-8.14	1.14e-15	3.68e-13	-0.24	-0.24	Serum protein levels (sST2);	chr2:102473668	chr2:102438713~102440475:+
BRCA	cis	rs2274273	0.87	rs2016931	ENSG00000258413.1	RP11-665C16.6	-8.14	1.14e-15	3.68e-13	-0.3	-0.24	Protein biomarker;	chr14:55375614	chr14:55262767~55272075:-
BRCA	cis	rs10129255	0.5	rs8011115	ENSG00000211972.2	IGHV3-66	8.14	1.14e-15	3.69e-13	0.17	0.24	Kawasaki disease;	chr14:106786292	chr14:106675017~106675544:-
BRCA	cis	rs6545883	0.895	rs2256617	ENSG00000271889.1	RP11-493E12.1	8.14	1.14e-15	3.69e-13	0.32	0.24	Tuberculosis;	chr2:61452789	chr2:61151433~61162105:-
BRCA	cis	rs2179367	0.959	rs9322178	ENSG00000231760.4	RP11-350J20.5	8.14	1.15e-15	3.7e-13	0.31	0.24	Dupuytren's disease;	chr6:149372131	chr6:149796151~149826294:-
BRCA	cis	rs10463554	0.963	rs257115	ENSG00000175749.11	EIF3KP1	8.14	1.15e-15	3.7e-13	0.33	0.24	Parkinson's disease;	chr5:103196107	chr5:103032376~103033031:+
BRCA	cis	rs13256369	1	rs4840351	ENSG00000253893.2	FAM85B	-8.14	1.15e-15	3.7e-13	-0.34	-0.24	Obesity-related traits;	chr8:8715638	chr8:8167819~8226614:-
BRCA	cis	rs11098499	0.866	rs12501602	ENSG00000248280.1	RP11-33B1.2	8.14	1.15e-15	3.72e-13	0.25	0.24	Corneal astigmatism;	chr4:119366780	chr4:119440561~119450157:-
BRCA	cis	rs7927771	0.826	rs2293578	ENSG00000280615.1	Y_RNA	-8.14	1.15e-15	3.72e-13	-0.3	-0.24	Subjective well-being;	chr11:47415852	chr11:47614898~47614994:-
BRCA	cis	rs4835473	0.8	rs1849133	ENSG00000251600.4	RP11-673E1.1	8.14	1.15e-15	3.72e-13	0.29	0.24	Immature fraction of reticulocytes;	chr4:143958262	chr4:143912331~143982454:+
BRCA	cis	rs526231	0.511	rs6881612	ENSG00000175749.11	EIF3KP1	8.13	1.17e-15	3.76e-13	0.35	0.24	Primary biliary cholangitis;	chr5:103041309	chr5:103032376~103033031:+
BRCA	cis	rs7684253	0.548	rs922570	ENSG00000269949.1	RP11-738E22.3	-8.13	1.17e-15	3.77e-13	-0.29	-0.24	Migraine;	chr4:56851192	chr4:56960927~56961373:-
BRCA	cis	rs10129255	0.5	rs2105989	ENSG00000211970.3	IGHV4-61	-8.13	1.17e-15	3.78e-13	-0.16	-0.24	Kawasaki disease;	chr14:106682199	chr14:106639119~106639657:-
BRCA	cis	rs4835473	0.897	rs6835827	ENSG00000251600.4	RP11-673E1.1	8.13	1.17e-15	3.78e-13	0.29	0.24	Immature fraction of reticulocytes;	chr4:143712803	chr4:143912331~143982454:+
BRCA	cis	rs2243480	1	rs313820	ENSG00000273142.1	RP11-458F8.4	-8.13	1.18e-15	3.79e-13	-0.34	-0.24	Diabetic kidney disease;	chr7:66109479	chr7:66902857~66906297:+
BRCA	cis	rs6545883	0.602	rs11125871	ENSG00000271889.1	RP11-493E12.1	-8.13	1.18e-15	3.8e-13	-0.31	-0.24	Tuberculosis;	chr2:61242991	chr2:61151433~61162105:-
BRCA	cis	rs1185460	1	rs15818	ENSG00000271751.1	RP11-110I1.14	-8.13	1.18e-15	3.8e-13	-0.31	-0.24	Coronary artery disease;	chr11:119081463	chr11:119065263~119065677:-
BRCA	cis	rs875971	0.577	rs34888281	ENSG00000222364.1	RNU6-96P	8.13	1.18e-15	3.81e-13	0.29	0.24	Aortic root size;	chr7:66120784	chr7:66395191~66395286:+
BRCA	cis	rs7772486	0.875	rs6913797	ENSG00000235652.6	RP11-545I5.3	8.13	1.18e-15	3.82e-13	0.24	0.24	Lobe attachment (rater-scored or self-reported);	chr6:146092622	chr6:145799409~145886585:+
BRCA	cis	rs72772090	0.634	rs10515246	ENSG00000248734.2	CTD-2260A17.1	-8.13	1.18e-15	3.82e-13	-0.39	-0.24	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96763561	chr5:96784777~96785999:+
BRCA	cis	rs6545883	0.894	rs6739427	ENSG00000271889.1	RP11-493E12.1	-8.13	1.19e-15	3.83e-13	-0.31	-0.24	Tuberculosis;	chr2:61225744	chr2:61151433~61162105:-
BRCA	cis	rs7927771	0.864	rs55927797	ENSG00000280615.1	Y_RNA	-8.13	1.19e-15	3.83e-13	-0.29	-0.24	Subjective well-being;	chr11:47424741	chr11:47614898~47614994:-
BRCA	cis	rs2028299	0.919	rs12440156	ENSG00000259677.1	RP11-493E3.1	8.13	1.19e-15	3.84e-13	0.33	0.24	Type 2 diabetes;	chr15:89877441	chr15:89876540~89877285:+
BRCA	cis	rs526231	0.543	rs4386712	ENSG00000175749.11	EIF3KP1	8.13	1.2e-15	3.85e-13	0.35	0.24	Primary biliary cholangitis;	chr5:103033530	chr5:103032376~103033031:+
BRCA	cis	rs526231	0.511	rs56235607	ENSG00000175749.11	EIF3KP1	8.13	1.2e-15	3.85e-13	0.35	0.24	Primary biliary cholangitis;	chr5:103036902	chr5:103032376~103033031:+
BRCA	cis	rs526231	0.511	rs55741939	ENSG00000175749.11	EIF3KP1	8.13	1.2e-15	3.85e-13	0.35	0.24	Primary biliary cholangitis;	chr5:103036984	chr5:103032376~103033031:+
BRCA	cis	rs875971	0.522	rs1701760	ENSG00000222364.1	RNU6-96P	-8.13	1.2e-15	3.85e-13	-0.28	-0.24	Aortic root size;	chr7:66008701	chr7:66395191~66395286:+
BRCA	cis	rs1707322	1	rs10789486	ENSG00000280836.1	AL355480.1	-8.13	1.2e-15	3.86e-13	-0.31	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45942995	chr1:45581219~45581321:-
BRCA	cis	rs42648	0.869	rs42611	ENSG00000225498.1	AC002064.5	8.13	1.2e-15	3.87e-13	0.23	0.24	Homocysteine levels;	chr7:90320746	chr7:90312496~90322592:+
BRCA	cis	rs2842992	0.915	rs1967802	ENSG00000237927.1	RP3-393E18.2	-8.13	1.2e-15	3.87e-13	-0.35	-0.24	Age-related macular degeneration (geographic atrophy);	chr6:159676759	chr6:159586955~159589169:-
BRCA	cis	rs4835473	0.8	rs1849117	ENSG00000251600.4	RP11-673E1.1	8.13	1.2e-15	3.88e-13	0.29	0.24	Immature fraction of reticulocytes;	chr4:143989791	chr4:143912331~143982454:+
BRCA	cis	rs2243480	1	rs2420171	ENSG00000273142.1	RP11-458F8.4	8.13	1.21e-15	3.88e-13	0.34	0.24	Diabetic kidney disease;	chr7:66172773	chr7:66902857~66906297:+
BRCA	cis	rs12468226	0.873	rs6435138	ENSG00000273456.1	RP11-686O6.2	-8.13	1.21e-15	3.89e-13	-0.36	-0.24	Urate levels;	chr2:202234310	chr2:202374932~202375604:-
BRCA	cis	rs2243480	1	rs6964245	ENSG00000273142.1	RP11-458F8.4	8.13	1.21e-15	3.89e-13	0.33	0.24	Diabetic kidney disease;	chr7:66253730	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs1267820	ENSG00000273142.1	RP11-458F8.4	-8.13	1.21e-15	3.91e-13	-0.34	-0.24	Diabetic kidney disease;	chr7:66585308	chr7:66902857~66906297:+
BRCA	cis	rs7714584	1	rs3900064	ENSG00000197083.10	ZNF300P1	-8.13	1.22e-15	3.92e-13	-0.34	-0.24	Crohn's disease;	chr5:150884852	chr5:150930645~150946289:-
BRCA	cis	rs11098499	0.754	rs938056	ENSG00000245958.5	RP11-33B1.1	-8.13	1.22e-15	3.92e-13	-0.23	-0.24	Corneal astigmatism;	chr4:119316298	chr4:119454791~119552025:+
BRCA	cis	rs6545883	0.86	rs777589	ENSG00000271889.1	RP11-493E12.1	8.13	1.22e-15	3.92e-13	0.31	0.24	Tuberculosis;	chr2:61198486	chr2:61151433~61162105:-
BRCA	cis	rs7246657	0.722	rs16958861	ENSG00000267422.1	CTD-2554C21.1	-8.13	1.22e-15	3.93e-13	-0.36	-0.24	Coronary artery calcification;	chr19:37633278	chr19:37779686~37792865:+
BRCA	cis	rs875971	0.522	rs9530	ENSG00000222364.1	RNU6-96P	-8.13	1.22e-15	3.94e-13	-0.29	-0.24	Aortic root size;	chr7:65960907	chr7:66395191~66395286:+
BRCA	cis	rs7927771	0.864	rs11604680	ENSG00000280615.1	Y_RNA	-8.13	1.23e-15	3.96e-13	-0.31	-0.24	Subjective well-being;	chr11:47435988	chr11:47614898~47614994:-
BRCA	cis	rs17818399	0.548	rs1989720	ENSG00000279254.1	RP11-536C12.1	-8.13	1.23e-15	3.97e-13	-0.29	-0.24	Height;	chr2:46627225	chr2:46668870~46670778:+
BRCA	cis	rs2348418	0.765	rs2078016	ENSG00000247934.4	RP11-967K21.1	-8.13	1.24e-15	3.98e-13	-0.27	-0.24	Lung function (FEV1);Lung function (FVC);	chr12:28180174	chr12:28163298~28190738:-
BRCA	cis	rs875971	0.545	rs1796219	ENSG00000222364.1	RNU6-96P	8.13	1.24e-15	3.99e-13	0.33	0.24	Aortic root size;	chr7:66645977	chr7:66395191~66395286:+
BRCA	cis	rs72627509	0.857	rs781658	ENSG00000269949.1	RP11-738E22.3	8.13	1.25e-15	4.01e-13	0.35	0.24	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56913401	chr4:56960927~56961373:-
BRCA	cis	rs113835537	0.529	rs2279865	ENSG00000255517.5	CTD-3074O7.5	-8.13	1.25e-15	4.04e-13	-0.31	-0.24	Airway imaging phenotypes;	chr11:66435554	chr11:66473490~66480233:-
BRCA	cis	rs113835537	0.502	rs7104378	ENSG00000255517.5	CTD-3074O7.5	-8.13	1.25e-15	4.04e-13	-0.31	-0.24	Airway imaging phenotypes;	chr11:66449204	chr11:66473490~66480233:-
BRCA	cis	rs526231	0.511	rs10434792	ENSG00000175749.11	EIF3KP1	8.13	1.26e-15	4.05e-13	0.35	0.24	Primary biliary cholangitis;	chr5:103053898	chr5:103032376~103033031:+
BRCA	cis	rs526231	0.511	rs10434793	ENSG00000175749.11	EIF3KP1	8.13	1.26e-15	4.05e-13	0.35	0.24	Primary biliary cholangitis;	chr5:103054111	chr5:103032376~103033031:+
BRCA	cis	rs526231	0.511	rs12109860	ENSG00000175749.11	EIF3KP1	8.13	1.26e-15	4.05e-13	0.35	0.24	Primary biliary cholangitis;	chr5:103057408	chr5:103032376~103033031:+
BRCA	cis	rs72627509	0.951	rs72627508	ENSG00000269949.1	RP11-738E22.3	8.13	1.26e-15	4.05e-13	0.38	0.24	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56965398	chr4:56960927~56961373:-
BRCA	cis	rs13256369	1	rs10095733	ENSG00000253893.2	FAM85B	-8.12	1.26e-15	4.05e-13	-0.34	-0.24	Obesity-related traits;	chr8:8717136	chr8:8167819~8226614:-
BRCA	cis	rs2439831	0.618	rs8023508	ENSG00000275601.1	AC011330.13	8.12	1.26e-15	4.06e-13	0.35	0.24	Lung cancer in ever smokers;	chr15:43883905	chr15:43642389~43643023:-
BRCA	cis	rs526231	0.543	rs34765	ENSG00000175749.11	EIF3KP1	8.12	1.26e-15	4.06e-13	0.35	0.24	Primary biliary cholangitis;	chr5:103171160	chr5:103032376~103033031:+
BRCA	cis	rs526231	0.543	rs183752	ENSG00000175749.11	EIF3KP1	8.12	1.26e-15	4.06e-13	0.35	0.24	Primary biliary cholangitis;	chr5:103172108	chr5:103032376~103033031:+
BRCA	cis	rs9368481	0.7	rs6911401	ENSG00000241549.7	GUSBP2	8.12	1.27e-15	4.08e-13	0.28	0.24	Autism spectrum disorder or schizophrenia;	chr6:26945435	chr6:26871484~26956554:-
BRCA	cis	rs9880211	1	rs9823373	ENSG00000239213.4	NCK1-AS1	8.12	1.27e-15	4.09e-13	0.32	0.24	Height;Body mass index;	chr3:136448185	chr3:136841726~136862054:-
BRCA	cis	rs75422866	0.867	rs7304743	ENSG00000257433.4	RP1-197B17.3	-8.12	1.27e-15	4.1e-13	-0.49	-0.24	Pneumonia;	chr12:47683658	chr12:47706085~47742294:+
BRCA	cis	rs9880211	0.528	rs75685279	ENSG00000273486.1	RP11-731C17.2	8.12	1.27e-15	4.1e-13	0.3	0.24	Height;Body mass index;	chr3:136715991	chr3:136837338~136839021:-
BRCA	cis	rs10246939	0.505	rs892354	ENSG00000228775.6	WEE2-AS1	8.12	1.28e-15	4.1e-13	0.29	0.24	Bitter taste perception;	chr7:141844934	chr7:141704338~141738346:-
BRCA	cis	rs950880	0.71	rs3732123	ENSG00000234389.1	AC007278.3	-8.12	1.28e-15	4.1e-13	-0.24	-0.24	Serum protein levels (sST2);	chr2:102401617	chr2:102438713~102440475:+
BRCA	cis	rs7809950	1	rs3801948	ENSG00000238832.1	snoU109	-8.12	1.28e-15	4.13e-13	-0.32	-0.24	Coronary artery disease;	chr7:107598002	chr7:107603363~107603507:+
BRCA	cis	rs7674212	0.556	rs34475639	ENSG00000246560.2	RP11-10L12.4	8.12	1.28e-15	4.13e-13	0.27	0.24	Type 2 diabetes;	chr4:103033694	chr4:102828055~102844075:+
BRCA	cis	rs8012947	0.565	rs7151036	ENSG00000279636.2	LINC00216	8.12	1.29e-15	4.13e-13	0.25	0.24	Alcohol consumption in current drinkers;	chr14:58356315	chr14:58288033~58289158:+
BRCA	cis	rs72627509	0.68	rs66790703	ENSG00000269949.1	RP11-738E22.3	8.12	1.29e-15	4.14e-13	0.35	0.24	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56907742	chr4:56960927~56961373:-
BRCA	cis	rs2933343	0.951	rs7648327	ENSG00000231305.3	RP11-723O4.2	8.12	1.29e-15	4.14e-13	0.3	0.24	IgG glycosylation;	chr3:128851865	chr3:128861313~128871540:-
BRCA	cis	rs77204473	1	rs2186844	ENSG00000254851.1	RP11-109L13.1	-8.12	1.29e-15	4.14e-13	-0.55	-0.24	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117026197	chr11:117135528~117138582:+
BRCA	cis	rs526231	0.511	rs27896	ENSG00000175749.11	EIF3KP1	8.12	1.29e-15	4.14e-13	0.36	0.24	Primary biliary cholangitis;	chr5:103152867	chr5:103032376~103033031:+
BRCA	cis	rs10246939	0.505	rs9640203	ENSG00000228775.6	WEE2-AS1	8.12	1.29e-15	4.14e-13	0.29	0.24	Bitter taste perception;	chr7:141844295	chr7:141704338~141738346:-
BRCA	cis	rs10463554	0.963	rs26261	ENSG00000175749.11	EIF3KP1	8.12	1.29e-15	4.14e-13	0.33	0.24	Parkinson's disease;	chr5:103209992	chr5:103032376~103033031:+
BRCA	cis	rs853679	1	rs853685	ENSG00000220721.1	OR1F12	8.12	1.29e-15	4.14e-13	0.38	0.24	Depression;	chr6:28321008	chr6:28073316~28074233:+
BRCA	cis	rs10129255	0.5	rs4774008	ENSG00000211970.3	IGHV4-61	-8.12	1.29e-15	4.14e-13	-0.16	-0.24	Kawasaki disease;	chr14:106681273	chr14:106639119~106639657:-
BRCA	cis	rs11098499	0.532	rs4504231	ENSG00000248280.1	RP11-33B1.2	8.12	1.3e-15	4.17e-13	0.25	0.24	Corneal astigmatism;	chr4:119665736	chr4:119440561~119450157:-
BRCA	cis	rs7927771	0.8	rs35996350	ENSG00000280615.1	Y_RNA	-8.12	1.3e-15	4.17e-13	-0.29	-0.24	Subjective well-being;	chr11:47367672	chr11:47614898~47614994:-
BRCA	cis	rs9880211	1	rs28634226	ENSG00000239213.4	NCK1-AS1	8.12	1.3e-15	4.17e-13	0.32	0.24	Height;Body mass index;	chr3:136411040	chr3:136841726~136862054:-
BRCA	cis	rs950880	0.71	rs11123928	ENSG00000234389.1	AC007278.3	-8.12	1.3e-15	4.18e-13	-0.24	-0.24	Serum protein levels (sST2);	chr2:102444826	chr2:102438713~102440475:+
BRCA	cis	rs77204473	0.744	rs2170317	ENSG00000254851.1	RP11-109L13.1	8.12	1.31e-15	4.2e-13	0.49	0.24	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117200024	chr11:117135528~117138582:+
BRCA	cis	rs8062405	1	rs7187776	ENSG00000278665.1	RP11-666O2.4	8.12	1.31e-15	4.2e-13	0.25	0.24	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28846324	chr16:28599241~28601881:-
BRCA	cis	rs58873874	0.737	rs78738433	ENSG00000248544.2	CTB-47B11.3	8.12	1.31e-15	4.21e-13	0.59	0.24	Bipolar disorder (body mass index interaction);	chr5:157386503	chr5:157375741~157384950:-
BRCA	cis	rs10129255	0.5	rs2105991	ENSG00000280411.1	IGHV1-69-2	-8.12	1.31e-15	4.22e-13	-0.16	-0.24	Kawasaki disease;	chr14:106682022	chr14:106762092~106762588:-
BRCA	cis	rs7580658	0.521	rs7605733	ENSG00000236682.1	AC068282.3	-8.12	1.31e-15	4.22e-13	-0.32	-0.24	Protein C levels;	chr2:127174211	chr2:127389130~127400580:+
BRCA	cis	rs526231	0.543	rs34767	ENSG00000175749.11	EIF3KP1	8.12	1.31e-15	4.22e-13	0.36	0.24	Primary biliary cholangitis;	chr5:103153807	chr5:103032376~103033031:+
BRCA	cis	rs3762637	1	rs6777596	ENSG00000272758.4	RP11-299J3.8	-8.12	1.31e-15	4.22e-13	-0.37	-0.24	LDL cholesterol levels;	chr3:122414474	chr3:122416207~122443180:+
BRCA	cis	rs9880211	0.898	rs34031772	ENSG00000239213.4	NCK1-AS1	8.12	1.31e-15	4.22e-13	0.31	0.24	Height;Body mass index;	chr3:136299299	chr3:136841726~136862054:-
BRCA	cis	rs853679	1	rs1679732	ENSG00000220721.1	OR1F12	-8.12	1.32e-15	4.23e-13	-0.38	-0.24	Depression;	chr6:28253486	chr6:28073316~28074233:+
BRCA	cis	rs17711722	0.51	rs11767457	ENSG00000234585.5	CCT6P3	8.12	1.32e-15	4.23e-13	0.25	0.24	Calcium levels;	chr7:65825628	chr7:65038354~65074713:+
BRCA	cis	rs720475	0.695	rs62483108	ENSG00000204959.4	ARHGEF34P	-8.12	1.32e-15	4.23e-13	-0.33	-0.24	Breast cancer;	chr7:144442326	chr7:144272445~144286966:-
BRCA	cis	rs526231	0.511	rs3756582	ENSG00000175749.11	EIF3KP1	8.12	1.32e-15	4.24e-13	0.35	0.24	Primary biliary cholangitis;	chr5:103003848	chr5:103032376~103033031:+
BRCA	cis	rs526231	0.511	rs1826673	ENSG00000175749.11	EIF3KP1	8.12	1.32e-15	4.24e-13	0.35	0.24	Primary biliary cholangitis;	chr5:103010212	chr5:103032376~103033031:+
BRCA	cis	rs526231	0.511	rs62362545	ENSG00000175749.11	EIF3KP1	8.12	1.32e-15	4.24e-13	0.35	0.24	Primary biliary cholangitis;	chr5:103011748	chr5:103032376~103033031:+
BRCA	cis	rs526231	0.511	rs3910557	ENSG00000175749.11	EIF3KP1	8.12	1.32e-15	4.24e-13	0.35	0.24	Primary biliary cholangitis;	chr5:103014767	chr5:103032376~103033031:+
BRCA	cis	rs526231	0.511	rs2288389	ENSG00000175749.11	EIF3KP1	8.12	1.32e-15	4.24e-13	0.35	0.24	Primary biliary cholangitis;	chr5:103018104	chr5:103032376~103033031:+
BRCA	cis	rs6142102	0.961	rs6088360	ENSG00000276073.1	RP5-1125A11.7	-8.12	1.32e-15	4.24e-13	-0.3	-0.24	Skin pigmentation;	chr20:33969383	chr20:33985617~33988989:-
BRCA	cis	rs9880211	0.948	rs1604793	ENSG00000239213.4	NCK1-AS1	8.12	1.32e-15	4.25e-13	0.33	0.24	Height;Body mass index;	chr3:136462228	chr3:136841726~136862054:-
BRCA	cis	rs250518	0.926	rs3916445	ENSG00000272081.1	CTD-2376I4.2	8.12	1.33e-15	4.26e-13	0.31	0.24	Mean corpuscular hemoglobin concentration;	chr5:72773821	chr5:72955206~72955699:-
BRCA	cis	rs7727544	0.735	rs270605	ENSG00000233006.5	AC034220.3	8.12	1.34e-15	4.3e-13	0.18	0.24	Blood metabolite levels;	chr5:132316118	chr5:132311285~132369916:-
BRCA	cis	rs860818	1	rs858242	ENSG00000226816.2	AC005082.12	8.12	1.34e-15	4.32e-13	0.54	0.24	Initial pursuit acceleration;	chr7:23185723	chr7:23206013~23208045:+
BRCA	cis	rs860818	1	rs1637220	ENSG00000226816.2	AC005082.12	8.12	1.34e-15	4.32e-13	0.54	0.24	Initial pursuit acceleration;	chr7:23193232	chr7:23206013~23208045:+
BRCA	cis	rs860818	1	rs6955117	ENSG00000226816.2	AC005082.12	8.12	1.34e-15	4.32e-13	0.54	0.24	Initial pursuit acceleration;	chr7:23194521	chr7:23206013~23208045:+
BRCA	cis	rs3758911	0.861	rs10454489	ENSG00000255353.1	RP11-382M14.1	-8.12	1.35e-15	4.32e-13	-0.33	-0.24	Coronary artery disease;	chr11:107279206	chr11:107176286~107177530:+
BRCA	cis	rs6545883	0.825	rs7578139	ENSG00000271889.1	RP11-493E12.1	-8.12	1.35e-15	4.33e-13	-0.31	-0.24	Tuberculosis;	chr2:61336986	chr2:61151433~61162105:-
BRCA	cis	rs2742234	0.578	rs2435354	ENSG00000273008.1	RP11-351D16.3	-8.12	1.35e-15	4.34e-13	-0.31	-0.24	Hirschsprung disease;	chr10:43156997	chr10:43136824~43138334:-
BRCA	cis	rs12701220	0.655	rs10215292	ENSG00000229043.2	AC091729.9	-8.12	1.35e-15	4.34e-13	-0.35	-0.24	Bronchopulmonary dysplasia;	chr7:1095627	chr7:1160374~1165267:+
BRCA	cis	rs6570726	0.818	rs437978	ENSG00000235652.6	RP11-545I5.3	8.12	1.36e-15	4.35e-13	0.24	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145487998	chr6:145799409~145886585:+
BRCA	cis	rs13256369	1	rs12550762	ENSG00000253893.2	FAM85B	-8.12	1.36e-15	4.36e-13	-0.34	-0.24	Obesity-related traits;	chr8:8719025	chr8:8167819~8226614:-
BRCA	cis	rs4835473	0.715	rs1849124	ENSG00000251600.4	RP11-673E1.1	8.12	1.36e-15	4.36e-13	0.29	0.24	Immature fraction of reticulocytes;	chr4:143978494	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.689	rs1849123	ENSG00000251600.4	RP11-673E1.1	8.12	1.36e-15	4.36e-13	0.29	0.24	Immature fraction of reticulocytes;	chr4:143978495	chr4:143912331~143982454:+
BRCA	cis	rs8062405	0.688	rs3924376	ENSG00000251417.2	RP11-1348G14.4	8.11	1.36e-15	4.36e-13	0.31	0.24	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28914657	chr16:28802743~28817828:+
BRCA	cis	rs73173548	0.502	rs4451795	ENSG00000247828.6	TMEM161B-AS1	8.11	1.37e-15	4.38e-13	0.31	0.24	Macular telangiectasia type 2;	chr5:88422879	chr5:88268895~88436685:+
BRCA	cis	rs6545883	0.929	rs3821222	ENSG00000271889.1	RP11-493E12.1	8.11	1.37e-15	4.39e-13	0.31	0.24	Tuberculosis;	chr2:61486391	chr2:61151433~61162105:-
BRCA	cis	rs720475	0.732	rs62483106	ENSG00000204959.4	ARHGEF34P	-8.11	1.38e-15	4.42e-13	-0.32	-0.24	Breast cancer;	chr7:144439533	chr7:144272445~144286966:-
BRCA	cis	rs7727544	0.735	rs274558	ENSG00000233006.5	AC034220.3	-8.11	1.38e-15	4.43e-13	-0.18	-0.24	Blood metabolite levels;	chr5:132385482	chr5:132311285~132369916:-
BRCA	cis	rs7727544	0.735	rs274557	ENSG00000233006.5	AC034220.3	-8.11	1.38e-15	4.43e-13	-0.18	-0.24	Blood metabolite levels;	chr5:132385512	chr5:132311285~132369916:-
BRCA	cis	rs950776	0.518	rs12902493	ENSG00000261762.1	RP11-650L12.2	8.11	1.38e-15	4.44e-13	0.27	0.24	Sudden cardiac arrest;	chr15:78526933	chr15:78589123~78591276:-
BRCA	cis	rs6142102	0.527	rs1015362	ENSG00000276073.1	RP5-1125A11.7	8.11	1.39e-15	4.46e-13	0.3	0.24	Skin pigmentation;	chr20:34150806	chr20:33985617~33988989:-
BRCA	cis	rs11098499	0.698	rs4422403	ENSG00000245958.5	RP11-33B1.1	-8.11	1.4e-15	4.47e-13	-0.22	-0.24	Corneal astigmatism;	chr4:119337039	chr4:119454791~119552025:+
BRCA	cis	rs375066	0.935	rs425221	ENSG00000267058.1	RP11-15A1.3	8.11	1.4e-15	4.49e-13	0.28	0.24	Breast cancer;	chr19:43914392	chr19:43891804~43901805:-
BRCA	cis	rs10129255	0.701	rs2005643	ENSG00000223648.3	IGHV3-64	8.11	1.41e-15	4.51e-13	0.2	0.24	Kawasaki disease;	chr14:106676288	chr14:106643132~106658258:-
BRCA	cis	rs6472827	0.622	rs2956023	ENSG00000253983.2	RP1-16A9.1	8.11	1.41e-15	4.51e-13	0.33	0.24	Uterine fibroids;	chr8:74193978	chr8:74199396~74208441:+
BRCA	cis	rs904251	0.523	rs2797796	ENSG00000204110.6	RP1-153P14.8	-8.11	1.41e-15	4.53e-13	-0.27	-0.24	Cognitive performance;	chr6:37513110	chr6:37507348~37535616:+
BRCA	cis	rs6142102	0.961	rs909884	ENSG00000276073.1	RP5-1125A11.7	-8.11	1.42e-15	4.53e-13	-0.3	-0.24	Skin pigmentation;	chr20:34058257	chr20:33985617~33988989:-
BRCA	cis	rs7727544	0.735	rs274566	ENSG00000233006.5	AC034220.3	-8.11	1.42e-15	4.54e-13	-0.18	-0.24	Blood metabolite levels;	chr5:132379319	chr5:132311285~132369916:-
BRCA	cis	rs4308124	0.708	rs6747657	ENSG00000230499.1	AC108463.1	-8.11	1.42e-15	4.54e-13	-0.3	-0.24	Vitiligo;	chr2:111245586	chr2:111195963~111206494:+
BRCA	cis	rs193541	0.632	rs2910135	ENSG00000263432.2	RN7SL689P	8.11	1.42e-15	4.54e-13	0.32	0.24	Glucose homeostasis traits;	chr5:122894095	chr5:123022487~123022783:-
BRCA	cis	rs6472827	0.645	rs2956058	ENSG00000253983.2	RP1-16A9.1	8.11	1.42e-15	4.55e-13	0.33	0.24	Uterine fibroids;	chr8:74197824	chr8:74199396~74208441:+
BRCA	cis	rs3758911	0.861	rs10890690	ENSG00000255353.1	RP11-382M14.1	-8.11	1.42e-15	4.55e-13	-0.33	-0.24	Coronary artery disease;	chr11:107276174	chr11:107176286~107177530:+
BRCA	cis	rs3762637	0.941	rs9863712	ENSG00000272758.4	RP11-299J3.8	-8.11	1.42e-15	4.56e-13	-0.36	-0.24	LDL cholesterol levels;	chr3:122381059	chr3:122416207~122443180:+
BRCA	cis	rs8062405	0.754	rs151179	ENSG00000251417.2	RP11-1348G14.4	-8.11	1.42e-15	4.56e-13	-0.29	-0.24	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28475735	chr16:28802743~28817828:+
BRCA	cis	rs2243480	1	rs6964530	ENSG00000273142.1	RP11-458F8.4	8.11	1.43e-15	4.57e-13	0.33	0.24	Diabetic kidney disease;	chr7:66253864	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs1979823	ENSG00000273142.1	RP11-458F8.4	8.11	1.43e-15	4.57e-13	0.34	0.24	Diabetic kidney disease;	chr7:66239626	chr7:66902857~66906297:+
BRCA	cis	rs2041895	0.509	rs12368448	ENSG00000260329.1	RP11-412D9.4	8.11	1.43e-15	4.59e-13	0.3	0.24	Glaucoma (low intraocular pressure);	chr12:106923018	chr12:106954029~106955497:-
BRCA	cis	rs875971	0.929	rs778712	ENSG00000237310.1	GS1-124K5.4	8.11	1.43e-15	4.59e-13	0.25	0.24	Aortic root size;	chr7:66384991	chr7:66493706~66495474:+
BRCA	cis	rs6504622	0.721	rs8077021	ENSG00000262879.4	RP11-156P1.3	-8.11	1.44e-15	4.6e-13	-0.25	-0.24	Orofacial clefts;	chr17:47061937	chr17:46984045~47100323:-
BRCA	cis	rs30380	1	rs246454	ENSG00000248734.2	CTD-2260A17.1	8.11	1.44e-15	4.6e-13	0.26	0.24	Cerebrospinal fluid biomarker levels;	chr5:96787561	chr5:96784777~96785999:+
BRCA	cis	rs9880211	1	rs9878078	ENSG00000239213.4	NCK1-AS1	8.11	1.44e-15	4.62e-13	0.32	0.24	Height;Body mass index;	chr3:136518731	chr3:136841726~136862054:-
BRCA	cis	rs875971	0.83	rs427575	ENSG00000237310.1	GS1-124K5.4	8.11	1.44e-15	4.62e-13	0.26	0.24	Aortic root size;	chr7:66054232	chr7:66493706~66495474:+
BRCA	cis	rs12220777	0.585	rs11201146	ENSG00000230091.5	TMEM254-AS1	-8.11	1.45e-15	4.66e-13	-0.45	-0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80007581	chr10:80046860~80078912:-
BRCA	cis	rs72627509	0.904	rs56281640	ENSG00000269949.1	RP11-738E22.3	8.11	1.46e-15	4.66e-13	0.35	0.24	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56899650	chr4:56960927~56961373:-
BRCA	cis	rs11098499	0.644	rs2389880	ENSG00000248280.1	RP11-33B1.2	8.11	1.46e-15	4.68e-13	0.24	0.24	Corneal astigmatism;	chr4:119638715	chr4:119440561~119450157:-
BRCA	cis	rs2243480	1	rs10807701	ENSG00000273142.1	RP11-458F8.4	8.11	1.46e-15	4.68e-13	0.33	0.24	Diabetic kidney disease;	chr7:66259699	chr7:66902857~66906297:+
BRCA	cis	rs526231	0.543	rs62362544	ENSG00000175749.11	EIF3KP1	8.11	1.46e-15	4.68e-13	0.35	0.24	Primary biliary cholangitis;	chr5:102998543	chr5:103032376~103033031:+
BRCA	cis	rs6545883	0.894	rs2694649	ENSG00000271889.1	RP11-493E12.1	-8.11	1.47e-15	4.69e-13	-0.31	-0.24	Tuberculosis;	chr2:61346691	chr2:61151433~61162105:-
BRCA	cis	rs9880211	0.948	rs34135127	ENSG00000239213.4	NCK1-AS1	8.1	1.48e-15	4.72e-13	0.32	0.24	Height;Body mass index;	chr3:136507656	chr3:136841726~136862054:-
BRCA	cis	rs4835473	0.831	rs4323050	ENSG00000251600.4	RP11-673E1.1	8.1	1.48e-15	4.73e-13	0.3	0.24	Immature fraction of reticulocytes;	chr4:143992106	chr4:143912331~143982454:+
BRCA	cis	rs867371	0.929	rs7176075	ENSG00000255769.6	GOLGA2P10	-8.1	1.48e-15	4.73e-13	-0.28	-0.24	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82178998	chr15:82472993~82513950:-
BRCA	cis	rs2439831	0.85	rs3742982	ENSG00000275601.1	AC011330.13	-8.1	1.48e-15	4.73e-13	-0.39	-0.24	Lung cancer in ever smokers;	chr15:43884483	chr15:43642389~43643023:-
BRCA	cis	rs7246657	0.722	rs3101746	ENSG00000267422.1	CTD-2554C21.1	8.1	1.48e-15	4.74e-13	0.36	0.24	Coronary artery calcification;	chr19:37655499	chr19:37779686~37792865:+
BRCA	cis	rs1134634	0.52	rs13121363	ENSG00000273133.1	RP11-799M12.2	8.1	1.49e-15	4.76e-13	0.31	0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15567369	chr4:15563698~15564253:-
BRCA	cis	rs1134634	0.52	rs13116304	ENSG00000273133.1	RP11-799M12.2	8.1	1.49e-15	4.76e-13	0.31	0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15567523	chr4:15563698~15564253:-
BRCA	cis	rs250518	0.926	rs6452683	ENSG00000272081.1	CTD-2376I4.2	8.1	1.49e-15	4.77e-13	0.31	0.24	Mean corpuscular hemoglobin concentration;	chr5:72787076	chr5:72955206~72955699:-
BRCA	cis	rs7927771	0.965	rs56400411	ENSG00000280615.1	Y_RNA	-8.1	1.51e-15	4.81e-13	-0.3	-0.24	Subjective well-being;	chr11:47564824	chr11:47614898~47614994:-
BRCA	cis	rs4713118	0.614	rs9468209	ENSG00000216901.1	AL022393.7	8.1	1.51e-15	4.82e-13	0.3	0.24	Parkinson's disease;	chr6:27726642	chr6:28176188~28176674:+
BRCA	cis	rs2286503	1	rs1029740	ENSG00000228649.7	AC005682.5	8.1	1.51e-15	4.83e-13	0.21	0.24	Fibrinogen;	chr7:22833967	chr7:22854178~22861579:+
BRCA	cis	rs3762637	1	rs9843165	ENSG00000272758.4	RP11-299J3.8	-8.1	1.51e-15	4.83e-13	-0.35	-0.24	LDL cholesterol levels;	chr3:122412264	chr3:122416207~122443180:+
BRCA	cis	rs11098499	0.569	rs10023641	ENSG00000245958.5	RP11-33B1.1	-8.1	1.51e-15	4.84e-13	-0.22	-0.24	Corneal astigmatism;	chr4:119337255	chr4:119454791~119552025:+
BRCA	cis	rs950880	0.71	rs3821204	ENSG00000234389.1	AC007278.3	-8.1	1.51e-15	4.84e-13	-0.25	-0.24	Serum protein levels (sST2);	chr2:102343821	chr2:102438713~102440475:+
BRCA	cis	rs1062177	0.724	rs2915828	ENSG00000253921.1	CTB-113P19.3	8.1	1.52e-15	4.85e-13	0.34	0.24	Preschool internalizing problems;	chr5:151738560	chr5:151753992~151767247:+
BRCA	cis	rs6142102	0.812	rs6120440	ENSG00000276073.1	RP5-1125A11.7	8.1	1.52e-15	4.85e-13	0.3	0.24	Skin pigmentation;	chr20:33929779	chr20:33985617~33988989:-
BRCA	cis	rs2179367	0.959	rs652807	ENSG00000231760.4	RP11-350J20.5	-8.1	1.52e-15	4.85e-13	-0.31	-0.24	Dupuytren's disease;	chr6:149416359	chr6:149796151~149826294:-
BRCA	cis	rs56046484	0.871	rs34978449	ENSG00000259295.5	CSPG4P12	8.1	1.52e-15	4.85e-13	0.43	0.24	Testicular germ cell tumor;	chr15:85036917	chr15:85191438~85213905:+
BRCA	cis	rs9880211	1	rs35899944	ENSG00000239213.4	NCK1-AS1	8.1	1.52e-15	4.86e-13	0.32	0.24	Height;Body mass index;	chr3:136510215	chr3:136841726~136862054:-
BRCA	cis	rs7674212	0.531	rs7665026	ENSG00000246560.2	RP11-10L12.4	8.1	1.52e-15	4.87e-13	0.26	0.24	Type 2 diabetes;	chr4:103015491	chr4:102828055~102844075:+
BRCA	cis	rs73186030	0.546	rs67818421	ENSG00000272758.4	RP11-299J3.8	8.1	1.53e-15	4.88e-13	0.33	0.24	Serum parathyroid hormone levels;	chr3:122389871	chr3:122416207~122443180:+
BRCA	cis	rs73186030	0.546	rs9857972	ENSG00000272758.4	RP11-299J3.8	8.1	1.53e-15	4.88e-13	0.33	0.24	Serum parathyroid hormone levels;	chr3:122390602	chr3:122416207~122443180:+
BRCA	cis	rs17711722	0.528	rs73138179	ENSG00000234585.5	CCT6P3	8.1	1.54e-15	4.91e-13	0.25	0.24	Calcium levels;	chr7:65829495	chr7:65038354~65074713:+
BRCA	cis	rs2742234	0.59	rs2257767	ENSG00000273008.1	RP11-351D16.3	-8.1	1.54e-15	4.91e-13	-0.31	-0.24	Hirschsprung disease;	chr10:43162363	chr10:43136824~43138334:-
BRCA	cis	rs875971	0.789	rs28815324	ENSG00000222364.1	RNU6-96P	8.1	1.54e-15	4.92e-13	0.32	0.24	Aortic root size;	chr7:66100789	chr7:66395191~66395286:+
BRCA	cis	rs7621025	0.5	rs71630059	ENSG00000273486.1	RP11-731C17.2	-8.1	1.54e-15	4.92e-13	-0.34	-0.24	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136862769	chr3:136837338~136839021:-
BRCA	cis	rs6545883	0.894	rs2694642	ENSG00000271889.1	RP11-493E12.1	-8.1	1.54e-15	4.93e-13	-0.32	-0.24	Tuberculosis;	chr2:61369045	chr2:61151433~61162105:-
BRCA	cis	rs8062405	0.69	rs6498089	ENSG00000251417.2	RP11-1348G14.4	8.1	1.55e-15	4.94e-13	0.28	0.24	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28617979	chr16:28802743~28817828:+
BRCA	cis	rs7569084	0.687	rs35839762	ENSG00000204929.10	AC074391.1	8.1	1.55e-15	4.94e-13	0.32	0.24	Sum eosinophil basophil counts;	chr2:65441318	chr2:65436711~66084639:+
BRCA	cis	rs453301	0.686	rs6987107	ENSG00000253893.2	FAM85B	8.1	1.55e-15	4.96e-13	0.3	0.24	Joint mobility (Beighton score);	chr8:9036071	chr8:8167819~8226614:-
BRCA	cis	rs2439831	0.85	rs2228368	ENSG00000205771.5	CATSPER2P1	-8.1	1.55e-15	4.97e-13	-0.42	-0.24	Lung cancer in ever smokers;	chr15:43809812	chr15:43726918~43747094:-
BRCA	cis	rs11098499	0.731	rs6846966	ENSG00000248280.1	RP11-33B1.2	8.1	1.56e-15	4.97e-13	0.24	0.24	Corneal astigmatism;	chr4:119372053	chr4:119440561~119450157:-
BRCA	cis	rs10463554	0.526	rs114525197	ENSG00000175749.11	EIF3KP1	8.1	1.56e-15	4.97e-13	0.35	0.24	Parkinson's disease;	chr5:103107341	chr5:103032376~103033031:+
BRCA	cis	rs11098499	0.618	rs35265692	ENSG00000248280.1	RP11-33B1.2	8.1	1.56e-15	4.98e-13	0.25	0.24	Corneal astigmatism;	chr4:119403980	chr4:119440561~119450157:-
BRCA	cis	rs7927771	0.965	rs34958982	ENSG00000280615.1	Y_RNA	-8.1	1.56e-15	4.98e-13	-0.3	-0.24	Subjective well-being;	chr11:47525494	chr11:47614898~47614994:-
BRCA	cis	rs7927771	0.929	rs66749409	ENSG00000280615.1	Y_RNA	-8.1	1.56e-15	4.98e-13	-0.3	-0.24	Subjective well-being;	chr11:47546522	chr11:47614898~47614994:-
BRCA	cis	rs7927771	0.894	rs12798346	ENSG00000280615.1	Y_RNA	-8.1	1.56e-15	4.98e-13	-0.3	-0.24	Subjective well-being;	chr11:47561569	chr11:47614898~47614994:-
BRCA	cis	rs6142102	0.961	rs6059651	ENSG00000276073.1	RP5-1125A11.7	-8.1	1.56e-15	4.98e-13	-0.3	-0.24	Skin pigmentation;	chr20:34057246	chr20:33985617~33988989:-
BRCA	cis	rs66887589	0.87	rs10518336	ENSG00000248280.1	RP11-33B1.2	8.1	1.56e-15	4.99e-13	0.23	0.24	Diastolic blood pressure;	chr4:119601779	chr4:119440561~119450157:-
BRCA	cis	rs7927771	1	rs35624992	ENSG00000280615.1	Y_RNA	-8.1	1.57e-15	5.01e-13	-0.3	-0.24	Subjective well-being;	chr11:47594246	chr11:47614898~47614994:-
BRCA	cis	rs2028299	1	rs2351707	ENSG00000259677.1	RP11-493E3.1	8.1	1.57e-15	5.02e-13	0.33	0.24	Type 2 diabetes;	chr15:89840813	chr15:89876540~89877285:+
BRCA	cis	rs950776	0.616	rs647041	ENSG00000261762.1	RP11-650L12.2	-8.1	1.57e-15	5.02e-13	-0.26	-0.24	Sudden cardiac arrest;	chr15:78588139	chr15:78589123~78591276:-
BRCA	cis	rs6545883	0.894	rs9677047	ENSG00000271889.1	RP11-493E12.1	-8.1	1.58e-15	5.03e-13	-0.32	-0.24	Tuberculosis;	chr2:61358160	chr2:61151433~61162105:-
BRCA	cis	rs4835473	0.932	rs6813011	ENSG00000251600.4	RP11-673E1.1	8.1	1.58e-15	5.03e-13	0.29	0.24	Immature fraction of reticulocytes;	chr4:143914496	chr4:143912331~143982454:+
BRCA	cis	rs72627509	0.904	rs58408429	ENSG00000269949.1	RP11-738E22.3	8.1	1.58e-15	5.03e-13	0.36	0.24	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56903658	chr4:56960927~56961373:-
BRCA	cis	rs9438901	0.614	rs2375278	ENSG00000261349.1	RP3-465N24.5	8.1	1.58e-15	5.03e-13	0.38	0.24	Red cell distribution width;	chr1:25202547	chr1:25266102~25267136:-
BRCA	cis	rs7809950	1	rs10243340	ENSG00000238832.1	snoU109	-8.1	1.58e-15	5.04e-13	-0.32	-0.24	Coronary artery disease;	chr7:107450510	chr7:107603363~107603507:+
BRCA	cis	rs30380	1	rs30187	ENSG00000248734.2	CTD-2260A17.1	8.09	1.59e-15	5.06e-13	0.26	0.24	Cerebrospinal fluid biomarker levels;	chr5:96788627	chr5:96784777~96785999:+
BRCA	cis	rs858239	0.6	rs28646184	ENSG00000230042.1	AK3P3	-8.09	1.59e-15	5.07e-13	-0.27	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23099976	chr7:23129178~23129841:+
BRCA	cis	rs72627509	0.767	rs6853156	ENSG00000269949.1	RP11-738E22.3	8.09	1.59e-15	5.08e-13	0.36	0.24	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56908677	chr4:56960927~56961373:-
BRCA	cis	rs2243480	1	rs4149468	ENSG00000273142.1	RP11-458F8.4	-8.09	1.59e-15	5.08e-13	-0.34	-0.24	Diabetic kidney disease;	chr7:66360703	chr7:66902857~66906297:+
BRCA	cis	rs10129255	0.5	rs2105991	ENSG00000211970.3	IGHV4-61	-8.09	1.59e-15	5.08e-13	-0.16	-0.24	Kawasaki disease;	chr14:106682022	chr14:106639119~106639657:-
BRCA	cis	rs11098499	0.644	rs10009566	ENSG00000248280.1	RP11-33B1.2	8.09	1.59e-15	5.09e-13	0.24	0.24	Corneal astigmatism;	chr4:119637453	chr4:119440561~119450157:-
BRCA	cis	rs10510102	0.872	rs28586586	ENSG00000276742.1	RP11-500G22.4	8.09	1.6e-15	5.09e-13	0.41	0.24	Breast cancer;	chr10:121950228	chr10:121956782~121957098:+
BRCA	cis	rs7712401	0.623	rs7723798	ENSG00000263432.2	RN7SL689P	8.09	1.6e-15	5.09e-13	0.31	0.24	Mean platelet volume;	chr5:123034022	chr5:123022487~123022783:-
BRCA	cis	rs526231	0.511	rs45518833	ENSG00000175749.11	EIF3KP1	8.09	1.6e-15	5.09e-13	0.35	0.24	Primary biliary cholangitis;	chr5:103007286	chr5:103032376~103033031:+
BRCA	cis	rs12468226	0.938	rs6435139	ENSG00000273456.1	RP11-686O6.2	-8.09	1.6e-15	5.1e-13	-0.35	-0.24	Urate levels;	chr2:202255145	chr2:202374932~202375604:-
BRCA	cis	rs7927771	0.832	rs1317164	ENSG00000280615.1	Y_RNA	-8.09	1.61e-15	5.13e-13	-0.3	-0.24	Subjective well-being;	chr11:47398206	chr11:47614898~47614994:-
BRCA	cis	rs897984	0.542	rs7197717	ENSG00000260911.2	RP11-196G11.2	8.09	1.61e-15	5.13e-13	0.22	0.24	Dementia with Lewy bodies;	chr16:31071754	chr16:31043150~31049868:+
BRCA	cis	rs7927771	0.864	rs60075622	ENSG00000280615.1	Y_RNA	-8.09	1.61e-15	5.13e-13	-0.29	-0.24	Subjective well-being;	chr11:47427550	chr11:47614898~47614994:-
BRCA	cis	rs77204473	1	rs12294657	ENSG00000254851.1	RP11-109L13.1	8.09	1.61e-15	5.13e-13	0.56	0.24	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116936652	chr11:117135528~117138582:+
BRCA	cis	rs77204473	1	rs77136879	ENSG00000254851.1	RP11-109L13.1	8.09	1.61e-15	5.13e-13	0.56	0.24	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116937737	chr11:117135528~117138582:+
BRCA	cis	rs77204473	1	rs7480278	ENSG00000254851.1	RP11-109L13.1	8.09	1.61e-15	5.13e-13	0.56	0.24	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116939073	chr11:117135528~117138582:+
BRCA	cis	rs77204473	1	rs80015203	ENSG00000254851.1	RP11-109L13.1	8.09	1.61e-15	5.13e-13	0.56	0.24	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116940190	chr11:117135528~117138582:+
BRCA	cis	rs77204473	1	rs117877581	ENSG00000254851.1	RP11-109L13.1	8.09	1.61e-15	5.13e-13	0.56	0.24	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116940238	chr11:117135528~117138582:+
BRCA	cis	rs77204473	1	rs116597701	ENSG00000254851.1	RP11-109L13.1	8.09	1.61e-15	5.13e-13	0.56	0.24	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116940771	chr11:117135528~117138582:+
BRCA	cis	rs77204473	1	rs78066444	ENSG00000254851.1	RP11-109L13.1	8.09	1.61e-15	5.13e-13	0.56	0.24	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116941342	chr11:117135528~117138582:+
BRCA	cis	rs7927771	1	rs11039255	ENSG00000280615.1	Y_RNA	-8.09	1.61e-15	5.14e-13	-0.3	-0.24	Subjective well-being;	chr11:47474194	chr11:47614898~47614994:-
BRCA	cis	rs367615	0.918	rs13173339	ENSG00000249476.1	CTD-2587M2.1	8.09	1.61e-15	5.14e-13	0.29	0.24	Colorectal cancer (SNP x SNP interaction);	chr5:109535617	chr5:109237120~109326369:-
BRCA	cis	rs6061231	1	rs11908473	ENSG00000273619.1	RP5-908M14.9	-8.09	1.62e-15	5.17e-13	-0.21	-0.24	Colorectal cancer;	chr20:62382714	chr20:62386303~62386970:-
BRCA	cis	rs9880211	0.898	rs9870825	ENSG00000239213.4	NCK1-AS1	8.09	1.63e-15	5.18e-13	0.32	0.24	Height;Body mass index;	chr3:136346878	chr3:136841726~136862054:-
BRCA	cis	rs7809950	1	rs7778270	ENSG00000238832.1	snoU109	8.09	1.64e-15	5.22e-13	0.32	0.24	Coronary artery disease;	chr7:107584222	chr7:107603363~107603507:+
BRCA	cis	rs10129255	0.536	rs10139058	ENSG00000280411.1	IGHV1-69-2	-8.09	1.65e-15	5.26e-13	-0.16	-0.24	Kawasaki disease;	chr14:106685899	chr14:106762092~106762588:-
BRCA	cis	rs10800713	0.954	rs4623737	ENSG00000260088.1	RP11-92G12.3	-8.09	1.65e-15	5.26e-13	-0.29	-0.24	Tandem gait;	chr1:200594578	chr1:200669507~200694250:+
BRCA	cis	rs7927771	0.965	rs4752845	ENSG00000280615.1	Y_RNA	-8.09	1.65e-15	5.26e-13	-0.3	-0.24	Subjective well-being;	chr11:47518145	chr11:47614898~47614994:-
BRCA	cis	rs3762637	0.941	rs74467988	ENSG00000272758.4	RP11-299J3.8	-8.09	1.65e-15	5.27e-13	-0.36	-0.24	LDL cholesterol levels;	chr3:122364293	chr3:122416207~122443180:+
BRCA	cis	rs13256369	1	rs7820159	ENSG00000253893.2	FAM85B	-8.09	1.66e-15	5.29e-13	-0.35	-0.24	Obesity-related traits;	chr8:8718705	chr8:8167819~8226614:-
BRCA	cis	rs11098499	0.82	rs28535956	ENSG00000248280.1	RP11-33B1.2	-8.09	1.66e-15	5.29e-13	-0.26	-0.24	Corneal astigmatism;	chr4:119615703	chr4:119440561~119450157:-
BRCA	cis	rs8062405	0.754	rs28410083	ENSG00000251417.2	RP11-1348G14.4	8.09	1.66e-15	5.29e-13	0.28	0.24	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620039	chr16:28802743~28817828:+
BRCA	cis	rs8062405	0.789	rs1968751	ENSG00000251417.2	RP11-1348G14.4	8.09	1.66e-15	5.29e-13	0.28	0.24	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620438	chr16:28802743~28817828:+
BRCA	cis	rs8062405	0.824	rs62034326	ENSG00000251417.2	RP11-1348G14.4	-8.09	1.67e-15	5.31e-13	-0.28	-0.24	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28527972	chr16:28802743~28817828:+
BRCA	cis	rs8062405	0.824	rs4788084	ENSG00000251417.2	RP11-1348G14.4	-8.09	1.67e-15	5.31e-13	-0.28	-0.24	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28528527	chr16:28802743~28817828:+
BRCA	cis	rs7586673	0.893	rs889925	ENSG00000235724.7	AC009299.2	-8.09	1.68e-15	5.34e-13	-0.28	-0.24	Intelligence (multi-trait analysis);	chr2:161115086	chr2:161222785~161308303:-
BRCA	cis	rs7586673	0.93	rs2884364	ENSG00000235724.7	AC009299.2	-8.09	1.68e-15	5.34e-13	-0.28	-0.24	Intelligence (multi-trait analysis);	chr2:161121136	chr2:161222785~161308303:-
BRCA	cis	rs66887589	0.592	rs62320740	ENSG00000248280.1	RP11-33B1.2	8.09	1.68e-15	5.34e-13	0.23	0.24	Diastolic blood pressure;	chr4:119358331	chr4:119440561~119450157:-
BRCA	cis	rs7772486	0.686	rs9373473	ENSG00000235652.6	RP11-545I5.3	8.09	1.68e-15	5.35e-13	0.24	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145761146	chr6:145799409~145886585:+
BRCA	cis	rs860818	1	rs2529002	ENSG00000226816.2	AC005082.12	8.09	1.69e-15	5.37e-13	0.54	0.24	Initial pursuit acceleration;	chr7:23193704	chr7:23206013~23208045:+
BRCA	cis	rs755249	1	rs61779359	ENSG00000228060.1	RP11-69E11.8	-8.09	1.69e-15	5.38e-13	-0.29	-0.24	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39544563	chr1:39565160~39573203:+
BRCA	cis	rs755249	0.959	rs61781363	ENSG00000228060.1	RP11-69E11.8	-8.09	1.69e-15	5.38e-13	-0.29	-0.24	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39546761	chr1:39565160~39573203:+
BRCA	cis	rs755249	1	rs4660808	ENSG00000228060.1	RP11-69E11.8	-8.09	1.69e-15	5.38e-13	-0.29	-0.24	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39552837	chr1:39565160~39573203:+
BRCA	cis	rs755249	1	rs61781364	ENSG00000228060.1	RP11-69E11.8	-8.09	1.69e-15	5.38e-13	-0.29	-0.24	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39553919	chr1:39565160~39573203:+
BRCA	cis	rs193541	0.632	rs6595413	ENSG00000263432.2	RN7SL689P	8.09	1.69e-15	5.38e-13	0.33	0.24	Glucose homeostasis traits;	chr5:122821254	chr5:123022487~123022783:-
BRCA	cis	rs2742234	0.541	rs1059484	ENSG00000273008.1	RP11-351D16.3	-8.09	1.69e-15	5.38e-13	-0.31	-0.24	Hirschsprung disease;	chr10:43184352	chr10:43136824~43138334:-
BRCA	cis	rs17265703	0.524	rs12107092	ENSG00000272758.4	RP11-299J3.8	8.09	1.69e-15	5.39e-13	0.33	0.24	Phosphorus levels;	chr3:122405001	chr3:122416207~122443180:+
BRCA	cis	rs9309711	0.922	rs13385119	ENSG00000225234.1	TRAPPC12-AS1	-8.09	1.69e-15	5.39e-13	-0.28	-0.24	Neurofibrillary tangles;	chr2:3480750	chr2:3481242~3482409:-
BRCA	cis	rs783540	0.867	rs10906984	ENSG00000278603.1	RP13-608F4.5	8.09	1.7e-15	5.42e-13	0.31	0.24	Schizophrenia;	chr15:82697544	chr15:82472203~82472426:+
BRCA	cis	rs8059260	0.799	rs7194545	ENSG00000274038.1	RP11-66H6.4	-8.09	1.71e-15	5.45e-13	-0.32	-0.24	Alcohol consumption over the past year;	chr16:11030439	chr16:11056556~11057034:+
BRCA	cis	rs6142102	0.961	rs2056990	ENSG00000276073.1	RP5-1125A11.7	-8.08	1.73e-15	5.49e-13	-0.3	-0.24	Skin pigmentation;	chr20:34035658	chr20:33985617~33988989:-
BRCA	cis	rs4835473	0.8	rs1849134	ENSG00000251600.4	RP11-673E1.1	8.08	1.73e-15	5.49e-13	0.29	0.24	Immature fraction of reticulocytes;	chr4:143958260	chr4:143912331~143982454:+
BRCA	cis	rs6545883	0.894	rs6545845	ENSG00000271889.1	RP11-493E12.1	-8.08	1.73e-15	5.51e-13	-0.31	-0.24	Tuberculosis;	chr2:61209909	chr2:61151433~61162105:-
BRCA	cis	rs875971	0.545	rs221986	ENSG00000222364.1	RNU6-96P	8.08	1.74e-15	5.53e-13	0.32	0.24	Aortic root size;	chr7:66105323	chr7:66395191~66395286:+
BRCA	cis	rs11098499	0.526	rs10026625	ENSG00000248280.1	RP11-33B1.2	8.08	1.74e-15	5.53e-13	0.23	0.24	Corneal astigmatism;	chr4:119358981	chr4:119440561~119450157:-
BRCA	cis	rs9640161	0.742	rs2159235	ENSG00000261305.1	RP4-584D14.7	8.08	1.74e-15	5.54e-13	0.35	0.24	Blood protein levels;Circulating chemerin levels;	chr7:150320139	chr7:150341771~150342607:+
BRCA	cis	rs526231	0.543	rs34779	ENSG00000175749.11	EIF3KP1	8.08	1.74e-15	5.54e-13	0.35	0.24	Primary biliary cholangitis;	chr5:103117064	chr5:103032376~103033031:+
BRCA	cis	rs526231	0.547	rs34780	ENSG00000175749.11	EIF3KP1	8.08	1.74e-15	5.54e-13	0.35	0.24	Primary biliary cholangitis;	chr5:103117853	chr5:103032376~103033031:+
BRCA	cis	rs10463554	0.759	rs34781	ENSG00000175749.11	EIF3KP1	8.08	1.74e-15	5.54e-13	0.35	0.24	Parkinson's disease;	chr5:103118735	chr5:103032376~103033031:+
BRCA	cis	rs7429990	0.864	rs3888	ENSG00000229759.1	MRPS18AP1	-8.08	1.76e-15	5.58e-13	-0.27	-0.24	Educational attainment (years of education);	chr3:47816085	chr3:48256350~48256938:-
BRCA	cis	rs1707322	0.963	rs34907901	ENSG00000280836.1	AL355480.1	-8.08	1.77e-15	5.63e-13	-0.32	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45939542	chr1:45581219~45581321:-
BRCA	cis	rs2243480	1	rs4718333	ENSG00000273142.1	RP11-458F8.4	8.08	1.78e-15	5.67e-13	0.34	0.24	Diabetic kidney disease;	chr7:66307771	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs7792391	ENSG00000273142.1	RP11-458F8.4	8.08	1.78e-15	5.67e-13	0.34	0.24	Diabetic kidney disease;	chr7:66308442	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs1553174	ENSG00000273142.1	RP11-458F8.4	8.08	1.79e-15	5.68e-13	0.33	0.24	Diabetic kidney disease;	chr7:66266207	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs10950032	ENSG00000273142.1	RP11-458F8.4	8.08	1.79e-15	5.68e-13	0.33	0.24	Diabetic kidney disease;	chr7:66273604	chr7:66902857~66906297:+
BRCA	cis	rs11971779	0.68	rs73154134	ENSG00000273391.1	RP11-634H22.1	8.08	1.79e-15	5.69e-13	0.24	0.24	Diisocyanate-induced asthma;	chr7:139355205	chr7:139359032~139359566:-
BRCA	cis	rs6142102	0.961	rs4911144	ENSG00000276073.1	RP5-1125A11.7	-8.08	1.79e-15	5.7e-13	-0.3	-0.24	Skin pigmentation;	chr20:34026565	chr20:33985617~33988989:-
BRCA	cis	rs3762637	0.941	rs79493664	ENSG00000272758.4	RP11-299J3.8	-8.08	1.8e-15	5.7e-13	-0.36	-0.24	LDL cholesterol levels;	chr3:122390699	chr3:122416207~122443180:+
BRCA	cis	rs853679	1	rs9986596	ENSG00000220721.1	OR1F12	8.08	1.8e-15	5.71e-13	0.39	0.24	Depression;	chr6:28251883	chr6:28073316~28074233:+
BRCA	cis	rs1062177	0.724	rs2964590	ENSG00000253921.1	CTB-113P19.3	8.08	1.8e-15	5.72e-13	0.34	0.24	Preschool internalizing problems;	chr5:151738585	chr5:151753992~151767247:+
BRCA	cis	rs9543976	0.623	rs7996884	ENSG00000261553.4	RP11-29G8.3	8.08	1.81e-15	5.75e-13	0.39	0.24	Diabetic retinopathy;	chr13:75598608	chr13:75549773~75807120:+
BRCA	cis	rs42648	0.869	rs42613	ENSG00000225498.1	AC002064.5	8.08	1.82e-15	5.77e-13	0.23	0.24	Homocysteine levels;	chr7:90320989	chr7:90312496~90322592:+
BRCA	cis	rs42648	0.837	rs42615	ENSG00000225498.1	AC002064.5	8.08	1.82e-15	5.77e-13	0.23	0.24	Homocysteine levels;	chr7:90321187	chr7:90312496~90322592:+
BRCA	cis	rs7274963	0.685	rs56039768	ENSG00000236474.1	GCNT1P1	8.08	1.82e-15	5.77e-13	0.33	0.24	Body mass index;	chr20:18360253	chr20:18420160~18421454:-
BRCA	cis	rs748404	1	rs12911132	ENSG00000249839.1	AC011330.5	-8.08	1.82e-15	5.77e-13	-0.34	-0.24	Lung cancer;	chr15:43268238	chr15:43663654~43684339:-
BRCA	cis	rs950880	0.71	rs11681718	ENSG00000234389.1	AC007278.3	-8.08	1.82e-15	5.78e-13	-0.25	-0.24	Serum protein levels (sST2);	chr2:102434684	chr2:102438713~102440475:+
BRCA	cis	rs7246657	0.722	rs2927742	ENSG00000267422.1	CTD-2554C21.1	8.08	1.83e-15	5.81e-13	0.36	0.24	Coronary artery calcification;	chr19:37642717	chr19:37779686~37792865:+
BRCA	cis	rs2028299	1	rs6496609	ENSG00000259677.1	RP11-493E3.1	8.08	1.83e-15	5.81e-13	0.33	0.24	Type 2 diabetes;	chr15:89836400	chr15:89876540~89877285:+
BRCA	cis	rs6142102	0.923	rs4911394	ENSG00000276073.1	RP5-1125A11.7	-8.08	1.83e-15	5.82e-13	-0.3	-0.24	Skin pigmentation;	chr20:33989521	chr20:33985617~33988989:-
BRCA	cis	rs8177876	0.822	rs12443549	ENSG00000261838.4	RP11-303E16.6	-8.08	1.85e-15	5.86e-13	-0.5	-0.24	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81070596	chr16:81069854~81076598:+
BRCA	cis	rs72627509	0.904	rs17081935	ENSG00000269949.1	RP11-738E22.3	8.07	1.85e-15	5.87e-13	0.37	0.24	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56957310	chr4:56960927~56961373:-
BRCA	cis	rs2911132	1	rs2911132	ENSG00000248734.2	CTD-2260A17.1	8.07	1.85e-15	5.88e-13	0.29	0.24	Urate levels (BMI interaction);	chr5:96851285	chr5:96784777~96785999:+
BRCA	cis	rs17818399	0.62	rs6739397	ENSG00000279254.1	RP11-536C12.1	-8.07	1.85e-15	5.88e-13	-0.29	-0.24	Height;	chr2:46631182	chr2:46668870~46670778:+
BRCA	cis	rs2243480	0.901	rs12530490	ENSG00000273142.1	RP11-458F8.4	8.07	1.86e-15	5.89e-13	0.34	0.24	Diabetic kidney disease;	chr7:66226660	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs7778911	ENSG00000273142.1	RP11-458F8.4	8.07	1.86e-15	5.89e-13	0.34	0.24	Diabetic kidney disease;	chr7:66229519	chr7:66902857~66906297:+
BRCA	cis	rs875971	0.545	rs73136346	ENSG00000222364.1	RNU6-96P	8.07	1.86e-15	5.9e-13	0.32	0.24	Aortic root size;	chr7:66101095	chr7:66395191~66395286:+
BRCA	cis	rs7809950	0.953	rs2237670	ENSG00000238832.1	snoU109	-8.07	1.86e-15	5.9e-13	-0.32	-0.24	Coronary artery disease;	chr7:107491040	chr7:107603363~107603507:+
BRCA	cis	rs3762637	0.941	rs28679619	ENSG00000272758.4	RP11-299J3.8	-8.07	1.86e-15	5.9e-13	-0.36	-0.24	LDL cholesterol levels;	chr3:122381502	chr3:122416207~122443180:+
BRCA	cis	rs7665147	1	rs7665147	ENSG00000269949.1	RP11-738E22.3	8.07	1.87e-15	5.91e-13	0.35	0.24	Platelet count;	chr4:56901161	chr4:56960927~56961373:-
BRCA	cis	rs6496932	0.563	rs2344083	ENSG00000259295.5	CSPG4P12	8.07	1.87e-15	5.92e-13	0.32	0.24	Central corneal thickness;Corneal structure;	chr15:85354201	chr15:85191438~85213905:+
BRCA	cis	rs193541	0.632	rs4835896	ENSG00000263432.2	RN7SL689P	-8.07	1.87e-15	5.92e-13	-0.33	-0.24	Glucose homeostasis traits;	chr5:122785545	chr5:123022487~123022783:-
BRCA	cis	rs26232	0.521	rs3776856	ENSG00000175749.11	EIF3KP1	8.07	1.87e-15	5.93e-13	0.35	0.24	Rheumatoid arthritis;	chr5:103023102	chr5:103032376~103033031:+
BRCA	cis	rs8072100	0.967	rs8074149	ENSG00000228782.6	CTD-2026D20.3	-8.07	1.87e-15	5.94e-13	-0.26	-0.24	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47506009	chr17:47450568~47492492:-
BRCA	cis	rs7727544	0.735	rs274559	ENSG00000233006.5	AC034220.3	-8.07	1.87e-15	5.94e-13	-0.18	-0.24	Blood metabolite levels;	chr5:132384378	chr5:132311285~132369916:-
BRCA	cis	rs7927771	0.864	rs755555	ENSG00000280615.1	Y_RNA	-8.07	1.87e-15	5.94e-13	-0.3	-0.24	Subjective well-being;	chr11:47410415	chr11:47614898~47614994:-
BRCA	cis	rs8072100	0.875	rs9635762	ENSG00000228782.6	CTD-2026D20.3	-8.07	1.87e-15	5.94e-13	-0.26	-0.24	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47571080	chr17:47450568~47492492:-
BRCA	cis	rs875971	0.862	rs1860469	ENSG00000232559.3	GS1-124K5.12	-8.07	1.88e-15	5.96e-13	-0.3	-0.24	Aortic root size;	chr7:66641888	chr7:66554588~66576923:-
BRCA	cis	rs7927771	0.864	rs2868459	ENSG00000280615.1	Y_RNA	-8.07	1.88e-15	5.97e-13	-0.29	-0.24	Subjective well-being;	chr11:47433421	chr11:47614898~47614994:-
BRCA	cis	rs30380	1	rs30379	ENSG00000248734.2	CTD-2260A17.1	8.07	1.89e-15	6e-13	0.26	0.24	Cerebrospinal fluid biomarker levels;	chr5:96786556	chr5:96784777~96785999:+
BRCA	cis	rs30380	1	rs30380	ENSG00000248734.2	CTD-2260A17.1	8.07	1.89e-15	6e-13	0.26	0.24	Cerebrospinal fluid biomarker levels;	chr5:96786577	chr5:96784777~96785999:+
BRCA	cis	rs11690935	0.55	rs6718013	ENSG00000228389.1	AC068039.4	-8.07	1.9e-15	6.01e-13	-0.29	-0.24	Schizophrenia;	chr2:172004277	chr2:171773482~171775844:+
BRCA	cis	rs526231	0.543	rs34785	ENSG00000175749.11	EIF3KP1	8.07	1.9e-15	6.01e-13	0.35	0.24	Primary biliary cholangitis;	chr5:103122399	chr5:103032376~103033031:+
BRCA	cis	rs526231	0.578	rs34786	ENSG00000175749.11	EIF3KP1	8.07	1.9e-15	6.01e-13	0.35	0.24	Primary biliary cholangitis;	chr5:103122409	chr5:103032376~103033031:+
BRCA	cis	rs10129255	0.5	rs9324092	ENSG00000280411.1	IGHV1-69-2	8.07	1.9e-15	6.02e-13	0.16	0.24	Kawasaki disease;	chr14:106683806	chr14:106762092~106762588:-
BRCA	cis	rs6539288	0.745	rs2041895	ENSG00000260329.1	RP11-412D9.4	-8.07	1.9e-15	6.03e-13	-0.27	-0.24	Total body bone mineral density;	chr12:106956310	chr12:106954029~106955497:-
BRCA	cis	rs9880211	1	rs9869630	ENSG00000239213.4	NCK1-AS1	8.07	1.91e-15	6.04e-13	0.31	0.24	Height;Body mass index;	chr3:136529177	chr3:136841726~136862054:-
BRCA	cis	rs8072100	0.935	rs8070759	ENSG00000228782.6	CTD-2026D20.3	-8.07	1.91e-15	6.04e-13	-0.26	-0.24	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47561394	chr17:47450568~47492492:-
BRCA	cis	rs853679	0.666	rs200956	ENSG00000220721.1	OR1F12	8.07	1.91e-15	6.04e-13	0.36	0.24	Depression;	chr6:27871968	chr6:28073316~28074233:+
BRCA	cis	rs2742234	0.59	rs2503848	ENSG00000273008.1	RP11-351D16.3	-8.07	1.92e-15	6.07e-13	-0.31	-0.24	Hirschsprung disease;	chr10:43177337	chr10:43136824~43138334:-
BRCA	cis	rs2742234	0.59	rs2435383	ENSG00000273008.1	RP11-351D16.3	-8.07	1.92e-15	6.07e-13	-0.31	-0.24	Hirschsprung disease;	chr10:43180223	chr10:43136824~43138334:-
BRCA	cis	rs12550612	0.614	rs4268128	ENSG00000253616.4	RP11-875O11.3	8.07	1.92e-15	6.08e-13	0.36	0.24	Myeloid white cell count;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;White blood cell count;Sum neutrophil eosinophil counts;	chr8:23080343	chr8:23071377~23074488:-
BRCA	cis	rs8072100	0.764	rs2644349	ENSG00000228782.6	CTD-2026D20.3	-8.07	1.92e-15	6.08e-13	-0.26	-0.24	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47564377	chr17:47450568~47492492:-
BRCA	cis	rs6921919	0.832	rs17312661	ENSG00000216901.1	AL022393.7	8.07	1.92e-15	6.09e-13	0.4	0.24	Autism spectrum disorder or schizophrenia;	chr6:28332559	chr6:28176188~28176674:+
BRCA	cis	rs193541	0.632	rs1460040	ENSG00000263432.2	RN7SL689P	8.07	1.93e-15	6.1e-13	0.32	0.24	Glucose homeostasis traits;	chr5:122769537	chr5:123022487~123022783:-
BRCA	cis	rs67981189	0.529	rs61990380	ENSG00000269927.1	RP6-91H8.3	8.07	1.93e-15	6.11e-13	0.32	0.24	Schizophrenia;	chr14:71005229	chr14:71141125~71143253:-
BRCA	cis	rs9640161	0.789	rs1464751	ENSG00000261305.1	RP4-584D14.7	8.07	1.93e-15	6.12e-13	0.36	0.24	Blood protein levels;Circulating chemerin levels;	chr7:150324193	chr7:150341771~150342607:+
BRCA	cis	rs11098499	0.532	rs4833624	ENSG00000248280.1	RP11-33B1.2	8.07	1.94e-15	6.13e-13	0.25	0.24	Corneal astigmatism;	chr4:119664342	chr4:119440561~119450157:-
BRCA	cis	rs4964805	0.865	rs11111796	ENSG00000257681.1	RP11-341G23.4	8.07	1.94e-15	6.13e-13	0.3	0.24	Attention deficit hyperactivity disorder;	chr12:103812150	chr12:103746315~103768858:-
BRCA	cis	rs7927771	0.69	rs35496532	ENSG00000280615.1	Y_RNA	-8.07	1.94e-15	6.14e-13	-0.29	-0.24	Subjective well-being;	chr11:47428787	chr11:47614898~47614994:-
BRCA	cis	rs10510102	0.688	rs11812208	ENSG00000276742.1	RP11-500G22.4	8.07	1.94e-15	6.14e-13	0.42	0.24	Breast cancer;	chr10:121924831	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.935	rs77447688	ENSG00000276742.1	RP11-500G22.4	8.07	1.94e-15	6.14e-13	0.42	0.24	Breast cancer;	chr10:121925721	chr10:121956782~121957098:+
BRCA	cis	rs2273788	0.793	rs34492085	ENSG00000204173.9	LRRC37A5P	8.07	1.94e-15	6.15e-13	0.34	0.24	Monocyte count;	chr9:111584381	chr9:111602831~111631289:-
BRCA	cis	rs7772486	0.743	rs9403742	ENSG00000235652.6	RP11-545I5.3	8.07	1.95e-15	6.17e-13	0.24	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145739057	chr6:145799409~145886585:+
BRCA	cis	rs8072100	0.87	rs10432035	ENSG00000228782.6	CTD-2026D20.3	-8.07	1.95e-15	6.18e-13	-0.26	-0.24	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47547547	chr17:47450568~47492492:-
BRCA	cis	rs9880211	1	rs28811905	ENSG00000239213.4	NCK1-AS1	8.07	1.96e-15	6.19e-13	0.32	0.24	Height;Body mass index;	chr3:136533210	chr3:136841726~136862054:-
BRCA	cis	rs875971	0.862	rs4718383	ENSG00000232559.3	GS1-124K5.12	-8.07	1.97e-15	6.22e-13	-0.3	-0.24	Aortic root size;	chr7:66643422	chr7:66554588~66576923:-
BRCA	cis	rs7809950	1	rs1544336	ENSG00000238832.1	snoU109	-8.07	1.97e-15	6.23e-13	-0.32	-0.24	Coronary artery disease;	chr7:107441970	chr7:107603363~107603507:+
BRCA	cis	rs7927771	0.77	rs11039203	ENSG00000280615.1	Y_RNA	-8.07	1.98e-15	6.25e-13	-0.29	-0.24	Subjective well-being;	chr11:47363046	chr11:47614898~47614994:-
BRCA	cis	rs7927771	0.832	rs67116452	ENSG00000280615.1	Y_RNA	-8.07	1.98e-15	6.25e-13	-0.29	-0.24	Subjective well-being;	chr11:47363643	chr11:47614898~47614994:-
BRCA	cis	rs875971	0.83	rs587360	ENSG00000237310.1	GS1-124K5.4	8.07	1.98e-15	6.27e-13	0.25	0.24	Aortic root size;	chr7:66057711	chr7:66493706~66495474:+
BRCA	cis	rs62402013	1	rs62402013	ENSG00000241549.7	GUSBP2	8.07	1.98e-15	6.28e-13	0.28	0.24	Schizophrenia;	chr6:26947221	chr6:26871484~26956554:-
BRCA	cis	rs6921919	0.945	rs61289879	ENSG00000204709.4	LINC01556	8.07	1.99e-15	6.28e-13	0.39	0.24	Autism spectrum disorder or schizophrenia;	chr6:28451385	chr6:28943877~28944537:+
BRCA	cis	rs7927771	0.864	rs11600581	ENSG00000280615.1	Y_RNA	-8.07	1.99e-15	6.3e-13	-0.29	-0.24	Subjective well-being;	chr11:47426946	chr11:47614898~47614994:-
BRCA	cis	rs4934494	0.768	rs11330	ENSG00000240996.1	RP11-80H5.7	8.07	2e-15	6.31e-13	0.3	0.24	Red blood cell count;	chr10:89634322	chr10:89694295~89697928:-
BRCA	cis	rs11098499	0.644	rs28787668	ENSG00000245958.5	RP11-33B1.1	-8.06	2e-15	6.33e-13	-0.23	-0.24	Corneal astigmatism;	chr4:119633532	chr4:119454791~119552025:+
BRCA	cis	rs858239	0.601	rs73272048	ENSG00000230042.1	AK3P3	-8.06	2.02e-15	6.38e-13	-0.28	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23113034	chr7:23129178~23129841:+
BRCA	cis	rs4845875	0.513	rs198397	ENSG00000242349.4	NPPA-AS1	-8.06	2.04e-15	6.43e-13	-0.26	-0.24	Midregional pro atrial natriuretic peptide levels;	chr1:11823275	chr1:11841017~11848079:+
BRCA	cis	rs904251	0.523	rs1776454	ENSG00000204110.6	RP1-153P14.8	-8.06	2.05e-15	6.48e-13	-0.26	-0.24	Cognitive performance;	chr6:37514323	chr6:37507348~37535616:+
BRCA	cis	rs6142102	0.961	rs4911385	ENSG00000276073.1	RP5-1125A11.7	-8.06	2.06e-15	6.51e-13	-0.29	-0.24	Skin pigmentation;	chr20:33970787	chr20:33985617~33988989:-
BRCA	cis	rs11971779	0.68	rs4728467	ENSG00000273391.1	RP11-634H22.1	8.06	2.07e-15	6.55e-13	0.24	0.24	Diisocyanate-induced asthma;	chr7:139435816	chr7:139359032~139359566:-
BRCA	cis	rs9880211	1	rs9841529	ENSG00000239213.4	NCK1-AS1	8.06	2.07e-15	6.55e-13	0.32	0.24	Height;Body mass index;	chr3:136418441	chr3:136841726~136862054:-
BRCA	cis	rs2274273	0.624	rs67795323	ENSG00000258413.1	RP11-665C16.6	-8.06	2.08e-15	6.56e-13	-0.32	-0.24	Protein biomarker;	chr14:55331115	chr14:55262767~55272075:-
BRCA	cis	rs2274273	0.624	rs8005450	ENSG00000258413.1	RP11-665C16.6	-8.06	2.08e-15	6.56e-13	-0.32	-0.24	Protein biomarker;	chr14:55332447	chr14:55262767~55272075:-
BRCA	cis	rs367615	1	rs58931051	ENSG00000249476.1	CTD-2587M2.1	8.06	2.08e-15	6.56e-13	0.31	0.24	Colorectal cancer (SNP x SNP interaction);	chr5:109572031	chr5:109237120~109326369:-
BRCA	cis	rs193541	0.632	rs2407402	ENSG00000263432.2	RN7SL689P	8.06	2.08e-15	6.57e-13	0.33	0.24	Glucose homeostasis traits;	chr5:122771410	chr5:123022487~123022783:-
BRCA	cis	rs58873874	0.579	rs77042939	ENSG00000251405.2	CTB-109A12.1	8.06	2.08e-15	6.59e-13	0.56	0.24	Bipolar disorder (body mass index interaction);	chr5:157303027	chr5:157362615~157460078:-
BRCA	cis	rs4934494	0.813	rs34928397	ENSG00000240996.1	RP11-80H5.7	-8.06	2.09e-15	6.61e-13	-0.32	-0.24	Red blood cell count;	chr10:89766842	chr10:89694295~89697928:-
BRCA	cis	rs17023223	0.553	rs72691108	ENSG00000231365.4	RP11-418J17.1	-8.06	2.1e-15	6.63e-13	-0.34	-0.24	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119219552	chr1:119140396~119275973:+
BRCA	cis	rs6921919	0.848	rs6903652	ENSG00000204709.4	LINC01556	8.06	2.1e-15	6.64e-13	0.36	0.24	Autism spectrum disorder or schizophrenia;	chr6:28354343	chr6:28943877~28944537:+
BRCA	cis	rs9880211	1	rs9828088	ENSG00000239213.4	NCK1-AS1	8.06	2.11e-15	6.65e-13	0.31	0.24	Height;Body mass index;	chr3:136528948	chr3:136841726~136862054:-
BRCA	cis	rs17818399	0.633	rs2242033	ENSG00000279254.1	RP11-536C12.1	-8.06	2.11e-15	6.65e-13	-0.29	-0.24	Height;	chr2:46615271	chr2:46668870~46670778:+
BRCA	cis	rs9880211	1	rs9818056	ENSG00000239213.4	NCK1-AS1	8.06	2.11e-15	6.65e-13	0.31	0.24	Height;Body mass index;	chr3:136491232	chr3:136841726~136862054:-
BRCA	cis	rs2115630	1	rs1030863	ENSG00000225151.9	GOLGA2P7	8.06	2.11e-15	6.66e-13	0.26	0.24	P wave terminal force;	chr15:84739404	chr15:84199311~84230136:-
BRCA	cis	rs2179367	0.959	rs628488	ENSG00000231760.4	RP11-350J20.5	8.06	2.11e-15	6.67e-13	0.31	0.24	Dupuytren's disease;	chr6:149398264	chr6:149796151~149826294:-
BRCA	cis	rs2742234	0.91	rs2505505	ENSG00000273008.1	RP11-351D16.3	-8.06	2.12e-15	6.68e-13	-0.28	-0.24	Hirschsprung disease;	chr10:43152773	chr10:43136824~43138334:-
BRCA	cis	rs6545883	0.826	rs2694617	ENSG00000271889.1	RP11-493E12.1	-8.06	2.13e-15	6.71e-13	-0.31	-0.24	Tuberculosis;	chr2:61310079	chr2:61151433~61162105:-
BRCA	cis	rs9527	0.637	rs7096169	ENSG00000213061.2	PFN1P11	8.06	2.13e-15	6.72e-13	0.32	0.24	Arsenic metabolism;	chr10:102858938	chr10:102838011~102845473:-
BRCA	cis	rs11098499	0.908	rs28499576	ENSG00000248280.1	RP11-33B1.2	8.06	2.15e-15	6.79e-13	0.24	0.24	Corneal astigmatism;	chr4:119465522	chr4:119440561~119450157:-
BRCA	cis	rs66887589	0.807	rs7694483	ENSG00000248280.1	RP11-33B1.2	8.06	2.16e-15	6.81e-13	0.23	0.24	Diastolic blood pressure;	chr4:119484774	chr4:119440561~119450157:-
BRCA	cis	rs7674212	0.507	rs223413	ENSG00000251288.2	RP11-10L12.2	8.05	2.16e-15	6.82e-13	0.29	0.24	Type 2 diabetes;	chr4:102811709	chr4:102751401~102752641:+
BRCA	cis	rs11159086	1	rs8006958	ENSG00000259005.1	RP3-449M8.6	8.05	2.17e-15	6.86e-13	0.38	0.24	Advanced glycation end-product levels;	chr14:74478148	chr14:74474007~74474864:-
BRCA	cis	rs7927771	0.832	rs56030824	ENSG00000280615.1	Y_RNA	-8.05	2.18e-15	6.88e-13	-0.31	-0.24	Subjective well-being;	chr11:47375802	chr11:47614898~47614994:-
BRCA	cis	rs9880211	0.948	rs9844666	ENSG00000239213.4	NCK1-AS1	8.05	2.18e-15	6.88e-13	0.32	0.24	Height;Body mass index;	chr3:136255374	chr3:136841726~136862054:-
BRCA	cis	rs7809950	1	rs2808	ENSG00000238832.1	snoU109	8.05	2.18e-15	6.88e-13	0.31	0.24	Coronary artery disease;	chr7:107620411	chr7:107603363~107603507:+
BRCA	cis	rs9595908	0.931	rs9595630	ENSG00000212293.1	SNORA16	-8.05	2.19e-15	6.89e-13	-0.29	-0.24	Body mass index;	chr13:32491306	chr13:32420390~32420516:-
BRCA	cis	rs10971721	0.822	rs307673	ENSG00000260947.1	RP11-384P7.7	8.05	2.19e-15	6.91e-13	0.43	0.24	Body mass index;	chr9:33968821	chr9:33697459~33700986:+
BRCA	cis	rs6142102	0.812	rs761238	ENSG00000276073.1	RP5-1125A11.7	8.05	2.19e-15	6.92e-13	0.29	0.24	Skin pigmentation;	chr20:33932182	chr20:33985617~33988989:-
BRCA	cis	rs375066	0.935	rs11673020	ENSG00000267058.1	RP11-15A1.3	-8.05	2.19e-15	6.92e-13	-0.27	-0.24	Breast cancer;	chr19:43870479	chr19:43891804~43901805:-
BRCA	cis	rs11098499	0.604	rs17051352	ENSG00000248280.1	RP11-33B1.2	8.05	2.2e-15	6.93e-13	0.26	0.24	Corneal astigmatism;	chr4:119660272	chr4:119440561~119450157:-
BRCA	cis	rs1075265	0.522	rs7584474	ENSG00000233266.1	HMGB1P31	8.05	2.2e-15	6.93e-13	0.3	0.24	Chronotype;Morning vs. evening chronotype;	chr2:53674874	chr2:54051334~54051760:+
BRCA	cis	rs7246657	0.678	rs2972446	ENSG00000267422.1	CTD-2554C21.1	8.05	2.22e-15	6.99e-13	0.36	0.24	Coronary artery calcification;	chr19:37638992	chr19:37779686~37792865:+
BRCA	cis	rs720475	0.732	rs62483107	ENSG00000204959.4	ARHGEF34P	-8.05	2.22e-15	6.99e-13	-0.32	-0.24	Breast cancer;	chr7:144442144	chr7:144272445~144286966:-
BRCA	cis	rs7811142	0.83	rs6945952	ENSG00000242294.5	STAG3L5P	8.05	2.22e-15	7.01e-13	0.24	0.24	Platelet count;	chr7:100384152	chr7:100336079~100351900:+
BRCA	cis	rs7811142	0.83	rs73401451	ENSG00000242294.5	STAG3L5P	8.05	2.22e-15	7.01e-13	0.24	0.24	Platelet count;	chr7:100384272	chr7:100336079~100351900:+
BRCA	cis	rs9880211	0.948	rs34913797	ENSG00000239213.4	NCK1-AS1	8.05	2.22e-15	7.01e-13	0.33	0.24	Height;Body mass index;	chr3:136408728	chr3:136841726~136862054:-
BRCA	cis	rs6570726	0.846	rs446031	ENSG00000235652.6	RP11-545I5.3	8.05	2.22e-15	7.01e-13	0.24	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145564456	chr6:145799409~145886585:+
BRCA	cis	rs526231	0.511	rs58344084	ENSG00000175749.11	EIF3KP1	8.05	2.22e-15	7.01e-13	0.35	0.24	Primary biliary cholangitis;	chr5:103042508	chr5:103032376~103033031:+
BRCA	cis	rs904251	0.523	rs1776455	ENSG00000204110.6	RP1-153P14.8	-8.05	2.22e-15	7.01e-13	-0.26	-0.24	Cognitive performance;	chr6:37515147	chr6:37507348~37535616:+
BRCA	cis	rs755249	1	rs4660293	ENSG00000228060.1	RP11-69E11.8	8.05	2.22e-15	7.01e-13	0.29	0.24	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39562508	chr1:39565160~39573203:+
BRCA	cis	rs11690935	0.589	rs6729945	ENSG00000228389.1	AC068039.4	-8.05	2.24e-15	7.05e-13	-0.29	-0.24	Schizophrenia;	chr2:171999788	chr2:171773482~171775844:+
BRCA	cis	rs2115630	1	rs10220733	ENSG00000225151.9	GOLGA2P7	8.05	2.24e-15	7.07e-13	0.26	0.24	P wave terminal force;	chr15:84737633	chr15:84199311~84230136:-
BRCA	cis	rs2179367	0.959	rs579789	ENSG00000231760.4	RP11-350J20.5	8.05	2.24e-15	7.07e-13	0.31	0.24	Dupuytren's disease;	chr6:149358235	chr6:149796151~149826294:-
BRCA	cis	rs2179367	0.959	rs489551	ENSG00000231760.4	RP11-350J20.5	8.05	2.24e-15	7.07e-13	0.31	0.24	Dupuytren's disease;	chr6:149368321	chr6:149796151~149826294:-
BRCA	cis	rs9880211	1	rs67949818	ENSG00000239213.4	NCK1-AS1	8.05	2.25e-15	7.08e-13	0.32	0.24	Height;Body mass index;	chr3:136494136	chr3:136841726~136862054:-
BRCA	cis	rs56804039	1	rs11780966	ENSG00000253893.2	FAM85B	8.05	2.26e-15	7.11e-13	0.36	0.24	Cervical cancer;	chr8:8525886	chr8:8167819~8226614:-
BRCA	cis	rs9309711	0.922	rs13431788	ENSG00000225234.1	TRAPPC12-AS1	-8.05	2.26e-15	7.11e-13	-0.28	-0.24	Neurofibrillary tangles;	chr2:3479141	chr2:3481242~3482409:-
BRCA	cis	rs11023332	0.706	rs11023379	ENSG00000251991.1	RNU7-49P	8.05	2.27e-15	7.14e-13	0.27	0.24	Vitamin D levels;Adiponectin levels;	chr11:14908414	chr11:14478892~14478953:+
BRCA	cis	rs10463554	0.963	rs40322	ENSG00000175749.11	EIF3KP1	8.05	2.27e-15	7.16e-13	0.33	0.24	Parkinson's disease;	chr5:103111253	chr5:103032376~103033031:+
BRCA	cis	rs7085104	0.7	rs6163	ENSG00000236937.2	PTGES3P4	8.05	2.28e-15	7.17e-13	0.31	0.24	Immature fraction of reticulocytes;Schizophrenia;	chr10:102837167	chr10:102845595~102845950:+
BRCA	cis	rs7809950	0.954	rs2712193	ENSG00000238832.1	snoU109	-8.05	2.28e-15	7.18e-13	-0.32	-0.24	Coronary artery disease;	chr7:107485440	chr7:107603363~107603507:+
BRCA	cis	rs10129255	1	rs11621409	ENSG00000223648.3	IGHV3-64	8.05	2.28e-15	7.19e-13	0.22	0.24	Kawasaki disease;	chr14:106695603	chr14:106643132~106658258:-
BRCA	cis	rs3758911	0.964	rs10789601	ENSG00000255353.1	RP11-382M14.1	-8.05	2.29e-15	7.2e-13	-0.33	-0.24	Coronary artery disease;	chr11:107310693	chr11:107176286~107177530:+
BRCA	cis	rs1823913	0.503	rs35868016	ENSG00000227542.1	AC092614.2	8.05	2.3e-15	7.25e-13	0.3	0.24	Obesity-related traits;	chr2:191344082	chr2:191229165~191246172:-
BRCA	cis	rs30380	0.922	rs246453	ENSG00000248734.2	CTD-2260A17.1	8.05	2.31e-15	7.27e-13	0.26	0.24	Cerebrospinal fluid biomarker levels;	chr5:96787633	chr5:96784777~96785999:+
BRCA	cis	rs950776	0.684	rs11637635	ENSG00000261762.1	RP11-650L12.2	-8.05	2.31e-15	7.28e-13	-0.27	-0.24	Sudden cardiac arrest;	chr15:78584808	chr15:78589123~78591276:-
BRCA	cis	rs3758911	1	rs10789618	ENSG00000255353.1	RP11-382M14.1	-8.05	2.32e-15	7.3e-13	-0.31	-0.24	Coronary artery disease;	chr11:107319003	chr11:107176286~107177530:+
BRCA	cis	rs732716	0.785	rs56033249	ENSG00000267980.1	AC007292.6	-8.05	2.32e-15	7.3e-13	-0.33	-0.24	Mean corpuscular volume;	chr19:4369450	chr19:4363789~4364640:+
BRCA	cis	rs1501911	0.611	rs10041261	ENSG00000248489.1	CTD-2007H13.3	-8.05	2.32e-15	7.3e-13	-0.3	-0.24	Lung function (FEV1/FVC);	chr5:99023435	chr5:98929171~98995013:+
BRCA	cis	rs7246657	0.722	rs2972447	ENSG00000267422.1	CTD-2554C21.1	8.05	2.33e-15	7.32e-13	0.36	0.24	Coronary artery calcification;	chr19:37638835	chr19:37779686~37792865:+
BRCA	cis	rs9880211	0.898	rs28877020	ENSG00000239213.4	NCK1-AS1	8.04	2.34e-15	7.36e-13	0.32	0.24	Height;Body mass index;	chr3:136676874	chr3:136841726~136862054:-
BRCA	cis	rs6545883	0.894	rs2600672	ENSG00000271889.1	RP11-493E12.1	8.04	2.34e-15	7.37e-13	0.31	0.24	Tuberculosis;	chr2:61309605	chr2:61151433~61162105:-
BRCA	cis	rs3762637	0.882	rs9856011	ENSG00000272758.4	RP11-299J3.8	-8.04	2.34e-15	7.37e-13	-0.36	-0.24	LDL cholesterol levels;	chr3:122374723	chr3:122416207~122443180:+
BRCA	cis	rs3762637	1	rs12630576	ENSG00000272758.4	RP11-299J3.8	-8.04	2.35e-15	7.39e-13	-0.35	-0.24	LDL cholesterol levels;	chr3:122420670	chr3:122416207~122443180:+
BRCA	cis	rs73173548	0.502	rs12187348	ENSG00000247828.6	TMEM161B-AS1	8.04	2.36e-15	7.41e-13	0.32	0.24	Macular telangiectasia type 2;	chr5:88424724	chr5:88268895~88436685:+
BRCA	cis	rs858239	0.601	rs6971002	ENSG00000230042.1	AK3P3	-8.04	2.36e-15	7.43e-13	-0.28	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23132685	chr7:23129178~23129841:+
BRCA	cis	rs7621025	0.5	rs1965107	ENSG00000273486.1	RP11-731C17.2	8.04	2.37e-15	7.44e-13	0.31	0.24	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136929801	chr3:136837338~136839021:-
BRCA	cis	rs6545883	0.894	rs778158	ENSG00000271889.1	RP11-493E12.1	-8.04	2.37e-15	7.45e-13	-0.31	-0.24	Tuberculosis;	chr2:61328286	chr2:61151433~61162105:-
BRCA	cis	rs7615952	0.641	rs12488180	ENSG00000250012.1	RP11-124N2.1	-8.04	2.37e-15	7.46e-13	-0.33	-0.24	Blood pressure (smoking interaction);	chr3:126063393	chr3:126084220~126095349:+
BRCA	cis	rs6545883	0.859	rs13004855	ENSG00000271889.1	RP11-493E12.1	-8.04	2.38e-15	7.47e-13	-0.32	-0.24	Tuberculosis;	chr2:61277937	chr2:61151433~61162105:-
BRCA	cis	rs113835537	0.529	rs57207756	ENSG00000255517.5	CTD-3074O7.5	-8.04	2.38e-15	7.47e-13	-0.33	-0.24	Airway imaging phenotypes;	chr11:66502889	chr11:66473490~66480233:-
BRCA	cis	rs113835537	0.529	rs17496250	ENSG00000255517.5	CTD-3074O7.5	-8.04	2.38e-15	7.47e-13	-0.33	-0.24	Airway imaging phenotypes;	chr11:66503303	chr11:66473490~66480233:-
BRCA	cis	rs858239	0.6	rs7787110	ENSG00000230042.1	AK3P3	-8.04	2.38e-15	7.48e-13	-0.27	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23098855	chr7:23129178~23129841:+
BRCA	cis	rs10463554	0.553	rs72785712	ENSG00000175749.11	EIF3KP1	8.04	2.39e-15	7.5e-13	0.35	0.24	Parkinson's disease;	chr5:102988693	chr5:103032376~103033031:+
BRCA	cis	rs875971	0.502	rs2946580	ENSG00000222364.1	RNU6-96P	8.04	2.39e-15	7.52e-13	0.32	0.24	Aortic root size;	chr7:66066855	chr7:66395191~66395286:+
BRCA	cis	rs1501911	0.611	rs2221268	ENSG00000248489.1	CTD-2007H13.3	-8.04	2.39e-15	7.52e-13	-0.3	-0.24	Lung function (FEV1/FVC);	chr5:99021711	chr5:98929171~98995013:+
BRCA	cis	rs7927771	0.832	rs11039212	ENSG00000280615.1	Y_RNA	8.04	2.4e-15	7.53e-13	0.29	0.24	Subjective well-being;	chr11:47371752	chr11:47614898~47614994:-
BRCA	cis	rs72627509	0.904	rs781663	ENSG00000269949.1	RP11-738E22.3	8.04	2.4e-15	7.54e-13	0.35	0.24	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56915588	chr4:56960927~56961373:-
BRCA	cis	rs904251	0.523	rs2776871	ENSG00000204110.6	RP1-153P14.8	-8.04	2.4e-15	7.54e-13	-0.26	-0.24	Cognitive performance;	chr6:37513983	chr6:37507348~37535616:+
BRCA	cis	rs9880211	1	rs28641809	ENSG00000239213.4	NCK1-AS1	8.04	2.41e-15	7.57e-13	0.32	0.24	Height;Body mass index;	chr3:136571647	chr3:136841726~136862054:-
BRCA	cis	rs6844153	0.887	rs6835631	ENSG00000240005.4	RP11-293A21.1	8.04	2.41e-15	7.58e-13	0.35	0.24	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26946864	chr4:26859806~26860599:-
BRCA	cis	rs11159086	1	rs11159086	ENSG00000259005.1	RP3-449M8.6	8.04	2.41e-15	7.58e-13	0.37	0.24	Advanced glycation end-product levels;	chr14:74495572	chr14:74474007~74474864:-
BRCA	cis	rs12701220	0.553	rs9639882	ENSG00000229043.2	AC091729.9	-8.04	2.42e-15	7.61e-13	-0.35	-0.24	Bronchopulmonary dysplasia;	chr7:1094095	chr7:1160374~1165267:+
BRCA	cis	rs875971	1	rs875971	ENSG00000237310.1	GS1-124K5.4	-8.04	2.43e-15	7.63e-13	-0.25	-0.24	Aortic root size;	chr7:66152608	chr7:66493706~66495474:+
BRCA	cis	rs193541	0.632	rs1363200	ENSG00000263432.2	RN7SL689P	8.04	2.43e-15	7.64e-13	0.33	0.24	Glucose homeostasis traits;	chr5:122828107	chr5:123022487~123022783:-
BRCA	cis	rs10129255	0.5	rs10143242	ENSG00000211970.3	IGHV4-61	-8.04	2.43e-15	7.64e-13	-0.16	-0.24	Kawasaki disease;	chr14:106681814	chr14:106639119~106639657:-
BRCA	cis	rs10751647	0.804	rs3809112	ENSG00000251661.3	RP11-326C3.11	-8.04	2.44e-15	7.66e-13	-0.26	-0.24	Monocyte count;	chr11:307036	chr11:318640~325631:+
BRCA	cis	rs4713118	0.699	rs200969	ENSG00000220721.1	OR1F12	8.04	2.44e-15	7.66e-13	0.32	0.24	Parkinson's disease;	chr6:27891675	chr6:28073316~28074233:+
BRCA	cis	rs6545883	0.894	rs7566035	ENSG00000271889.1	RP11-493E12.1	-8.04	2.44e-15	7.67e-13	-0.31	-0.24	Tuberculosis;	chr2:61293680	chr2:61151433~61162105:-
BRCA	cis	rs11690935	0.55	rs62183784	ENSG00000228389.1	AC068039.4	-8.04	2.45e-15	7.7e-13	-0.29	-0.24	Schizophrenia;	chr2:172001789	chr2:171773482~171775844:+
BRCA	cis	rs6504622	0.755	rs11653838	ENSG00000262879.4	RP11-156P1.3	-8.04	2.46e-15	7.71e-13	-0.25	-0.24	Orofacial clefts;	chr17:47006317	chr17:46984045~47100323:-
BRCA	cis	rs375066	0.935	rs10414702	ENSG00000267058.1	RP11-15A1.3	-8.04	2.46e-15	7.72e-13	-0.27	-0.24	Breast cancer;	chr19:43876384	chr19:43891804~43901805:-
BRCA	cis	rs375066	0.935	rs10421518	ENSG00000267058.1	RP11-15A1.3	-8.04	2.46e-15	7.72e-13	-0.27	-0.24	Breast cancer;	chr19:43877134	chr19:43891804~43901805:-
BRCA	cis	rs375066	0.87	rs7258418	ENSG00000267058.1	RP11-15A1.3	-8.04	2.46e-15	7.72e-13	-0.27	-0.24	Breast cancer;	chr19:43878931	chr19:43891804~43901805:-
BRCA	cis	rs897984	0.542	rs8061047	ENSG00000260911.2	RP11-196G11.2	8.04	2.48e-15	7.77e-13	0.22	0.24	Dementia with Lewy bodies;	chr16:31057639	chr16:31043150~31049868:+
BRCA	cis	rs11690935	0.55	rs62183801	ENSG00000228389.1	AC068039.4	-8.04	2.48e-15	7.78e-13	-0.29	-0.24	Schizophrenia;	chr2:172002567	chr2:171773482~171775844:+
BRCA	cis	rs853679	0.76	rs9393909	ENSG00000220721.1	OR1F12	-8.04	2.48e-15	7.78e-13	-0.35	-0.24	Depression;	chr6:28239422	chr6:28073316~28074233:+
BRCA	cis	rs7246657	0.722	rs12979640	ENSG00000267422.1	CTD-2554C21.1	8.04	2.49e-15	7.8e-13	0.36	0.24	Coronary artery calcification;	chr19:37688255	chr19:37779686~37792865:+
BRCA	cis	rs2880765	0.835	rs4281668	ENSG00000259295.5	CSPG4P12	8.04	2.49e-15	7.8e-13	0.3	0.24	Coronary artery disease;	chr15:85504055	chr15:85191438~85213905:+
BRCA	cis	rs11690935	0.55	rs62183785	ENSG00000228389.1	AC068039.4	-8.04	2.49e-15	7.81e-13	-0.29	-0.24	Schizophrenia;	chr2:172002068	chr2:171773482~171775844:+
BRCA	cis	rs11690935	0.531	rs62183800	ENSG00000228389.1	AC068039.4	-8.04	2.49e-15	7.81e-13	-0.29	-0.24	Schizophrenia;	chr2:172002365	chr2:171773482~171775844:+
BRCA	cis	rs7927771	0.864	rs2053979	ENSG00000280615.1	Y_RNA	-8.04	2.5e-15	7.83e-13	-0.29	-0.24	Subjective well-being;	chr11:47417893	chr11:47614898~47614994:-
BRCA	cis	rs11098499	1	rs11726229	ENSG00000248280.1	RP11-33B1.2	8.04	2.51e-15	7.89e-13	0.25	0.24	Corneal astigmatism;	chr4:119290425	chr4:119440561~119450157:-
BRCA	cis	rs6142102	0.923	rs4911383	ENSG00000276073.1	RP5-1125A11.7	-8.04	2.52e-15	7.9e-13	-0.3	-0.24	Skin pigmentation;	chr20:33967973	chr20:33985617~33988989:-
BRCA	cis	rs858239	0.539	rs870476	ENSG00000226816.2	AC005082.12	8.03	2.53e-15	7.92e-13	0.28	0.24	Cerebrospinal fluid biomarker levels;	chr7:23153652	chr7:23206013~23208045:+
BRCA	cis	rs6545883	0.86	rs13023037	ENSG00000271889.1	RP11-493E12.1	-8.03	2.53e-15	7.92e-13	-0.31	-0.24	Tuberculosis;	chr2:61393854	chr2:61151433~61162105:-
BRCA	cis	rs10740039	0.804	rs1837950	ENSG00000254271.1	RP11-131N11.4	-8.03	2.53e-15	7.94e-13	-0.32	-0.24	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60685207	chr10:60734342~60741828:+
BRCA	cis	rs9640161	0.742	rs2108854	ENSG00000261305.1	RP4-584D14.7	-8.03	2.53e-15	7.94e-13	-0.35	-0.24	Blood protein levels;Circulating chemerin levels;	chr7:150320319	chr7:150341771~150342607:+
BRCA	cis	rs950880	0.593	rs887971	ENSG00000234389.1	AC007278.3	-8.03	2.54e-15	7.96e-13	-0.24	-0.24	Serum protein levels (sST2);	chr2:102424707	chr2:102438713~102440475:+
BRCA	cis	rs375066	0.934	rs2191564	ENSG00000267058.1	RP11-15A1.3	-8.03	2.54e-15	7.97e-13	-0.27	-0.24	Breast cancer;	chr19:43863459	chr19:43891804~43901805:-
BRCA	cis	rs375066	0.935	rs397913	ENSG00000267058.1	RP11-15A1.3	8.03	2.54e-15	7.97e-13	0.27	0.24	Breast cancer;	chr19:43894788	chr19:43891804~43901805:-
BRCA	cis	rs7809950	1	rs2520277	ENSG00000238832.1	snoU109	-8.03	2.54e-15	7.97e-13	-0.31	-0.24	Coronary artery disease;	chr7:107489789	chr7:107603363~107603507:+
BRCA	cis	rs11098499	0.644	rs3986377	ENSG00000245958.5	RP11-33B1.1	-8.03	2.55e-15	7.98e-13	-0.22	-0.24	Corneal astigmatism;	chr4:119339115	chr4:119454791~119552025:+
BRCA	cis	rs10028773	0.556	rs4473640	ENSG00000245958.5	RP11-33B1.1	-8.03	2.55e-15	7.98e-13	-0.22	-0.24	Educational attainment;	chr4:119339282	chr4:119454791~119552025:+
BRCA	cis	rs867371	1	rs1846911	ENSG00000255769.6	GOLGA2P10	-8.03	2.55e-15	8e-13	-0.28	-0.24	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82176309	chr15:82472993~82513950:-
BRCA	cis	rs73173548	0.502	rs10452479	ENSG00000247828.6	TMEM161B-AS1	8.03	2.55e-15	8e-13	0.31	0.24	Macular telangiectasia type 2;	chr5:88445131	chr5:88268895~88436685:+
BRCA	cis	rs4889609	0.834	rs72785520	ENSG00000260911.2	RP11-196G11.2	8.03	2.56e-15	8.03e-13	0.22	0.24	Response to metformin (IC50);	chr16:31059457	chr16:31043150~31049868:+
BRCA	cis	rs250518	0.926	rs6875670	ENSG00000272081.1	CTD-2376I4.2	8.03	2.58e-15	8.09e-13	0.3	0.24	Mean corpuscular hemoglobin concentration;	chr5:72785943	chr5:72955206~72955699:-
BRCA	cis	rs7674212	0.531	rs4698876	ENSG00000246560.2	RP11-10L12.4	8.03	2.59e-15	8.12e-13	0.26	0.24	Type 2 diabetes;	chr4:103012410	chr4:102828055~102844075:+
BRCA	cis	rs61270009	0.955	rs4916905	ENSG00000247828.6	TMEM161B-AS1	8.03	2.59e-15	8.13e-13	0.31	0.24	Depressive symptoms;	chr5:88362244	chr5:88268895~88436685:+
BRCA	cis	rs375066	0.806	rs415168	ENSG00000267058.1	RP11-15A1.3	-8.03	2.6e-15	8.14e-13	-0.28	-0.24	Breast cancer;	chr19:43898422	chr19:43891804~43901805:-
BRCA	cis	rs2348418	0.733	rs7294486	ENSG00000247934.4	RP11-967K21.1	-8.03	2.6e-15	8.14e-13	-0.27	-0.24	Lung function (FEV1);Lung function (FVC);	chr12:28181989	chr12:28163298~28190738:-
BRCA	cis	rs6545883	0.894	rs778144	ENSG00000271889.1	RP11-493E12.1	-8.03	2.62e-15	8.22e-13	-0.31	-0.24	Tuberculosis;	chr2:61355993	chr2:61151433~61162105:-
BRCA	cis	rs61270009	0.738	rs73171756	ENSG00000247828.6	TMEM161B-AS1	8.03	2.63e-15	8.23e-13	0.31	0.24	Depressive symptoms;	chr5:88446454	chr5:88268895~88436685:+
BRCA	cis	rs9543976	0.623	rs7982517	ENSG00000261553.4	RP11-29G8.3	8.03	2.63e-15	8.24e-13	0.38	0.24	Diabetic retinopathy;	chr13:75587903	chr13:75549773~75807120:+
BRCA	cis	rs6472827	0.595	rs2977068	ENSG00000253983.2	RP1-16A9.1	8.03	2.63e-15	8.25e-13	0.33	0.24	Uterine fibroids;	chr8:74192817	chr8:74199396~74208441:+
BRCA	cis	rs2179367	0.959	rs9373592	ENSG00000231760.4	RP11-350J20.5	8.03	2.63e-15	8.25e-13	0.31	0.24	Dupuytren's disease;	chr6:149412119	chr6:149796151~149826294:-
BRCA	cis	rs73186030	0.546	rs55780469	ENSG00000272758.4	RP11-299J3.8	8.03	2.64e-15	8.27e-13	0.33	0.24	Serum parathyroid hormone levels;	chr3:122388590	chr3:122416207~122443180:+
BRCA	cis	rs6921919	0.945	rs16901847	ENSG00000216901.1	AL022393.7	8.03	2.64e-15	8.28e-13	0.37	0.24	Autism spectrum disorder or schizophrenia;	chr6:28408074	chr6:28176188~28176674:+
BRCA	cis	rs58873874	0.579	rs56666304	ENSG00000251405.2	CTB-109A12.1	8.03	2.65e-15	8.29e-13	0.52	0.24	Bipolar disorder (body mass index interaction);	chr5:157286520	chr5:157362615~157460078:-
BRCA	cis	rs11098499	0.644	rs7676296	ENSG00000245958.5	RP11-33B1.1	-8.03	2.66e-15	8.31e-13	-0.23	-0.24	Corneal astigmatism;	chr4:119634532	chr4:119454791~119552025:+
BRCA	cis	rs7927771	0.8	rs12146565	ENSG00000280615.1	Y_RNA	-8.03	2.67e-15	8.35e-13	-0.31	-0.24	Subjective well-being;	chr11:47377412	chr11:47614898~47614994:-
BRCA	cis	rs4820294	1	rs62236668	ENSG00000233360.4	Z83844.1	8.03	2.67e-15	8.36e-13	0.29	0.24	Fat distribution (HIV);	chr22:37667863	chr22:37641832~37658377:-
BRCA	cis	rs2243480	0.901	rs13237344	ENSG00000273142.1	RP11-458F8.4	-8.03	2.67e-15	8.36e-13	-0.34	-0.24	Diabetic kidney disease;	chr7:66557269	chr7:66902857~66906297:+
BRCA	cis	rs7809950	1	rs17154077	ENSG00000238832.1	snoU109	8.03	2.68e-15	8.39e-13	0.31	0.24	Coronary artery disease;	chr7:107437496	chr7:107603363~107603507:+
BRCA	cis	rs2439831	0.85	rs3825783	ENSG00000205771.5	CATSPER2P1	-8.03	2.69e-15	8.41e-13	-0.43	-0.24	Lung cancer in ever smokers;	chr15:43810111	chr15:43726918~43747094:-
BRCA	cis	rs10129255	0.518	rs11847766	ENSG00000280411.1	IGHV1-69-2	-8.03	2.69e-15	8.42e-13	-0.16	-0.24	Kawasaki disease;	chr14:106779186	chr14:106762092~106762588:-
BRCA	cis	rs2179367	0.959	rs237034	ENSG00000231760.4	RP11-350J20.5	8.03	2.69e-15	8.42e-13	0.31	0.24	Dupuytren's disease;	chr6:149390726	chr6:149796151~149826294:-
BRCA	cis	rs193541	0.632	rs7735618	ENSG00000263432.2	RN7SL689P	8.03	2.69e-15	8.42e-13	0.32	0.24	Glucose homeostasis traits;	chr5:122840550	chr5:123022487~123022783:-
BRCA	cis	rs4820294	1	rs713835	ENSG00000233360.4	Z83844.1	8.03	2.69e-15	8.42e-13	0.29	0.24	Fat distribution (HIV);	chr22:37668643	chr22:37641832~37658377:-
BRCA	cis	rs4820294	1	rs739139	ENSG00000233360.4	Z83844.1	8.03	2.69e-15	8.42e-13	0.29	0.24	Fat distribution (HIV);	chr22:37671004	chr22:37641832~37658377:-
BRCA	cis	rs10510102	0.688	rs76573813	ENSG00000276742.1	RP11-500G22.4	8.03	2.7e-15	8.45e-13	0.41	0.24	Breast cancer;	chr10:121928955	chr10:121956782~121957098:+
BRCA	cis	rs526231	0.543	rs34784	ENSG00000175749.11	EIF3KP1	8.03	2.7e-15	8.45e-13	0.35	0.24	Primary biliary cholangitis;	chr5:103121626	chr5:103032376~103033031:+
BRCA	cis	rs526231	0.543	rs34787	ENSG00000175749.11	EIF3KP1	8.03	2.7e-15	8.45e-13	0.35	0.24	Primary biliary cholangitis;	chr5:103123199	chr5:103032376~103033031:+
BRCA	cis	rs526231	0.543	rs34789	ENSG00000175749.11	EIF3KP1	8.03	2.7e-15	8.45e-13	0.35	0.24	Primary biliary cholangitis;	chr5:103125035	chr5:103032376~103033031:+
BRCA	cis	rs526231	0.543	rs26525	ENSG00000175749.11	EIF3KP1	8.03	2.7e-15	8.45e-13	0.35	0.24	Primary biliary cholangitis;	chr5:103129219	chr5:103032376~103033031:+
BRCA	cis	rs526231	0.543	rs32851	ENSG00000175749.11	EIF3KP1	8.03	2.7e-15	8.45e-13	0.35	0.24	Primary biliary cholangitis;	chr5:103132967	chr5:103032376~103033031:+
BRCA	cis	rs526231	0.543	rs32849	ENSG00000175749.11	EIF3KP1	8.03	2.7e-15	8.45e-13	0.35	0.24	Primary biliary cholangitis;	chr5:103134339	chr5:103032376~103033031:+
BRCA	cis	rs1075265	0.575	rs2692531	ENSG00000233266.1	HMGB1P31	8.03	2.71e-15	8.47e-13	0.29	0.24	Chronotype;Morning vs. evening chronotype;	chr2:53776640	chr2:54051334~54051760:+
BRCA	cis	rs7927771	0.826	rs7925389	ENSG00000280615.1	Y_RNA	-8.03	2.71e-15	8.47e-13	-0.29	-0.24	Subjective well-being;	chr11:47445238	chr11:47614898~47614994:-
BRCA	cis	rs3762637	1	rs11932	ENSG00000272758.4	RP11-299J3.8	8.03	2.71e-15	8.48e-13	0.32	0.24	LDL cholesterol levels;	chr3:122422288	chr3:122416207~122443180:+
BRCA	cis	rs11098499	0.865	rs4001305	ENSG00000248280.1	RP11-33B1.2	8.02	2.73e-15	8.52e-13	0.24	0.24	Corneal astigmatism;	chr4:119438081	chr4:119440561~119450157:-
BRCA	cis	rs62246343	0.605	rs34665459	ENSG00000206573.7	THUMPD3-AS1	-8.02	2.73e-15	8.52e-13	-0.25	-0.24	Fibrinogen levels;	chr3:9423041	chr3:9349689~9398579:-
BRCA	cis	rs1499614	1	rs1267817	ENSG00000273142.1	RP11-458F8.4	-8.02	2.73e-15	8.53e-13	-0.34	-0.24	Gout;	chr7:66645053	chr7:66902857~66906297:+
BRCA	cis	rs526231	0.543	rs34791	ENSG00000175749.11	EIF3KP1	8.02	2.73e-15	8.54e-13	0.35	0.24	Primary biliary cholangitis;	chr5:103126400	chr5:103032376~103033031:+
BRCA	cis	rs7927771	0.832	rs11601173	ENSG00000280615.1	Y_RNA	-8.02	2.73e-15	8.54e-13	-0.29	-0.24	Subjective well-being;	chr11:47379507	chr11:47614898~47614994:-
BRCA	cis	rs7927771	0.832	rs11607981	ENSG00000280615.1	Y_RNA	-8.02	2.73e-15	8.54e-13	-0.29	-0.24	Subjective well-being;	chr11:47379509	chr11:47614898~47614994:-
BRCA	cis	rs7927771	0.832	rs11601603	ENSG00000280615.1	Y_RNA	-8.02	2.73e-15	8.54e-13	-0.29	-0.24	Subjective well-being;	chr11:47379620	chr11:47614898~47614994:-
BRCA	cis	rs1499614	0.901	rs3936	ENSG00000273142.1	RP11-458F8.4	-8.02	2.73e-15	8.55e-13	-0.34	-0.24	Gout;	chr7:66661502	chr7:66902857~66906297:+
BRCA	cis	rs2842992	0.872	rs2758328	ENSG00000237927.1	RP3-393E18.2	-8.02	2.74e-15	8.55e-13	-0.34	-0.24	Age-related macular degeneration (geographic atrophy);	chr6:159669699	chr6:159586955~159589169:-
BRCA	cis	rs77204473	1	rs35184536	ENSG00000254851.1	RP11-109L13.1	8.02	2.74e-15	8.57e-13	0.61	0.24	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116908097	chr11:117135528~117138582:+
BRCA	cis	rs6545883	0.929	rs2593625	ENSG00000271889.1	RP11-493E12.1	8.02	2.74e-15	8.57e-13	0.32	0.24	Tuberculosis;	chr2:61441634	chr2:61151433~61162105:-
BRCA	cis	rs2243480	1	rs160639	ENSG00000273142.1	RP11-458F8.4	-8.02	2.76e-15	8.61e-13	-0.33	-0.24	Diabetic kidney disease;	chr7:66115000	chr7:66902857~66906297:+
BRCA	cis	rs58873874	0.579	rs56666304	ENSG00000248544.2	CTB-47B11.3	8.02	2.77e-15	8.65e-13	0.48	0.24	Bipolar disorder (body mass index interaction);	chr5:157286520	chr5:157375741~157384950:-
BRCA	cis	rs11098499	0.738	rs28687057	ENSG00000248280.1	RP11-33B1.2	8.02	2.78e-15	8.67e-13	0.24	0.24	Corneal astigmatism;	chr4:119359657	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.775	rs67281037	ENSG00000248280.1	RP11-33B1.2	8.02	2.78e-15	8.67e-13	0.24	0.24	Corneal astigmatism;	chr4:119360002	chr4:119440561~119450157:-
BRCA	cis	rs10028773	0.506	rs12374346	ENSG00000248280.1	RP11-33B1.2	8.02	2.78e-15	8.67e-13	0.24	0.24	Educational attainment;	chr4:119360550	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.866	rs12374244	ENSG00000248280.1	RP11-33B1.2	8.02	2.78e-15	8.67e-13	0.24	0.24	Corneal astigmatism;	chr4:119360817	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.866	rs12374352	ENSG00000248280.1	RP11-33B1.2	8.02	2.78e-15	8.67e-13	0.24	0.24	Corneal astigmatism;	chr4:119360822	chr4:119440561~119450157:-
BRCA	cis	rs8062405	0.721	rs151303	ENSG00000251417.2	RP11-1348G14.4	-8.02	2.78e-15	8.69e-13	-0.29	-0.24	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28481189	chr16:28802743~28817828:+
BRCA	cis	rs2179367	0.959	rs9373589	ENSG00000231760.4	RP11-350J20.5	8.02	2.79e-15	8.71e-13	0.31	0.24	Dupuytren's disease;	chr6:149386152	chr6:149796151~149826294:-
BRCA	cis	rs79349575	0.716	rs46522	ENSG00000248278.1	SUMO2P17	8.02	2.79e-15	8.72e-13	0.3	0.24	Type 2 diabetes;	chr17:48911235	chr17:48874860~48908983:-
BRCA	cis	rs10129255	0.53	rs11624912	ENSG00000280411.1	IGHV1-69-2	-8.02	2.8e-15	8.75e-13	-0.16	-0.24	Kawasaki disease;	chr14:106673891	chr14:106762092~106762588:-
BRCA	cis	rs7826238	0.72	rs12546760	ENSG00000253893.2	FAM85B	8.02	2.81e-15	8.77e-13	0.29	0.24	Systolic blood pressure;	chr8:8517326	chr8:8167819~8226614:-
BRCA	cis	rs2742234	0.91	rs2503866	ENSG00000273008.1	RP11-351D16.3	-8.02	2.82e-15	8.8e-13	-0.27	-0.24	Hirschsprung disease;	chr10:43150813	chr10:43136824~43138334:-
BRCA	cis	rs17772222	1	rs3814855	ENSG00000258983.2	RP11-507K2.2	8.02	2.82e-15	8.81e-13	0.28	0.24	Coronary artery calcification;	chr14:88467016	chr14:88499334~88515502:+
BRCA	cis	rs950880	0.71	rs873022	ENSG00000234389.1	AC007278.3	-8.02	2.83e-15	8.85e-13	-0.25	-0.24	Serum protein levels (sST2);	chr2:102339223	chr2:102438713~102440475:+
BRCA	cis	rs1075232	0.826	rs16956738	ENSG00000270055.1	CTD-3092A11.2	8.02	2.84e-15	8.88e-13	0.51	0.24	Survival in colorectal cancer (non-distant metastatic);	chr15:31444028	chr15:30487963~30490313:+
BRCA	cis	rs950776	0.518	rs3813571	ENSG00000261762.1	RP11-650L12.2	8.02	2.85e-15	8.88e-13	0.27	0.24	Sudden cardiac arrest;	chr15:78540450	chr15:78589123~78591276:-
BRCA	cis	rs2243480	0.901	rs34807232	ENSG00000273142.1	RP11-458F8.4	-8.02	2.85e-15	8.89e-13	-0.34	-0.24	Diabetic kidney disease;	chr7:66500146	chr7:66902857~66906297:+
BRCA	cis	rs2243480	0.901	rs35823062	ENSG00000273142.1	RP11-458F8.4	-8.02	2.85e-15	8.89e-13	-0.34	-0.24	Diabetic kidney disease;	chr7:66500834	chr7:66902857~66906297:+
BRCA	cis	rs7598759	0.617	rs6437017	ENSG00000181798.2	LINC00471	-8.02	2.87e-15	8.94e-13	-0.29	-0.24	Noise-induced hearing loss;	chr2:231462873	chr2:231508426~231514339:-
BRCA	cis	rs6142102	0.961	rs4911146	ENSG00000276073.1	RP5-1125A11.7	-8.02	2.87e-15	8.96e-13	-0.29	-0.24	Skin pigmentation;	chr20:34052241	chr20:33985617~33988989:-
BRCA	cis	rs2742234	0.955	rs2503841	ENSG00000273008.1	RP11-351D16.3	-8.02	2.87e-15	8.96e-13	-0.28	-0.24	Hirschsprung disease;	chr10:43180273	chr10:43136824~43138334:-
BRCA	cis	rs7621025	0.5	rs12629000	ENSG00000273486.1	RP11-731C17.2	8.02	2.87e-15	8.96e-13	0.31	0.24	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136924729	chr3:136837338~136839021:-
BRCA	cis	rs2028299	0.839	rs3844575	ENSG00000259677.1	RP11-493E3.1	8.02	2.88e-15	8.98e-13	0.34	0.24	Type 2 diabetes;	chr15:89900515	chr15:89876540~89877285:+
BRCA	cis	rs11690935	0.55	rs6730085	ENSG00000228389.1	AC068039.4	-8.02	2.88e-15	9e-13	-0.29	-0.24	Schizophrenia;	chr2:171999938	chr2:171773482~171775844:+
BRCA	cis	rs61270009	0.955	rs12657757	ENSG00000247828.6	TMEM161B-AS1	-8.02	2.89e-15	9e-13	-0.31	-0.24	Depressive symptoms;	chr5:88280952	chr5:88268895~88436685:+
BRCA	cis	rs2028299	0.839	rs2279848	ENSG00000259677.1	RP11-493E3.1	8.02	2.89e-15	9e-13	0.34	0.24	Type 2 diabetes;	chr15:89901449	chr15:89876540~89877285:+
BRCA	cis	rs7684253	0.526	rs34112167	ENSG00000269949.1	RP11-738E22.3	-8.02	2.89e-15	9.02e-13	-0.29	-0.24	Migraine;	chr4:56853383	chr4:56960927~56961373:-
BRCA	cis	rs11098499	0.866	rs6847778	ENSG00000248280.1	RP11-33B1.2	8.02	2.89e-15	9.02e-13	0.24	0.24	Corneal astigmatism;	chr4:119372427	chr4:119440561~119450157:-
BRCA	cis	rs2439831	0.85	rs28590651	ENSG00000275601.1	AC011330.13	-8.02	2.9e-15	9.04e-13	-0.38	-0.24	Lung cancer in ever smokers;	chr15:43820818	chr15:43642389~43643023:-
BRCA	cis	rs4835473	0.932	rs6826665	ENSG00000251600.4	RP11-673E1.1	-8.02	2.9e-15	9.05e-13	-0.3	-0.24	Immature fraction of reticulocytes;	chr4:143795140	chr4:143912331~143982454:+
BRCA	cis	rs7085104	0.7	rs10883785	ENSG00000236937.2	PTGES3P4	8.02	2.91e-15	9.07e-13	0.31	0.24	Immature fraction of reticulocytes;Schizophrenia;	chr10:102843831	chr10:102845595~102845950:+
BRCA	cis	rs10971721	0.822	rs10971739	ENSG00000260947.1	RP11-384P7.7	8.02	2.91e-15	9.08e-13	0.4	0.24	Body mass index;	chr9:33855467	chr9:33697459~33700986:+
BRCA	cis	rs6558530	0.666	rs6558526	ENSG00000253982.1	CTD-2336O2.1	8.02	2.92e-15	9.1e-13	0.29	0.24	Systolic blood pressure;	chr8:1754406	chr8:1761990~1764502:-
BRCA	cis	rs7927771	0.832	rs4752990	ENSG00000280615.1	Y_RNA	-8.02	2.92e-15	9.1e-13	-0.3	-0.24	Subjective well-being;	chr11:47388842	chr11:47614898~47614994:-
BRCA	cis	rs6545883	0.895	rs2421192	ENSG00000271889.1	RP11-493E12.1	-8.02	2.93e-15	9.13e-13	-0.31	-0.24	Tuberculosis;	chr2:61416496	chr2:61151433~61162105:-
BRCA	cis	rs13256369	0.95	rs13248096	ENSG00000253893.2	FAM85B	-8.01	2.94e-15	9.17e-13	-0.34	-0.24	Obesity-related traits;	chr8:8719966	chr8:8167819~8226614:-
BRCA	cis	rs6921919	0.515	rs1339898	ENSG00000204709.4	LINC01556	8.01	2.94e-15	9.17e-13	0.32	0.24	Autism spectrum disorder or schizophrenia;	chr6:28427729	chr6:28943877~28944537:+
BRCA	cis	rs2348418	0.765	rs10843119	ENSG00000247934.4	RP11-967K21.1	-8.01	2.95e-15	9.18e-13	-0.27	-0.24	Lung function (FEV1);Lung function (FVC);	chr12:28164675	chr12:28163298~28190738:-
BRCA	cis	rs72627509	0.904	rs7687767	ENSG00000269949.1	RP11-738E22.3	-8.01	2.96e-15	9.21e-13	-0.35	-0.24	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56958766	chr4:56960927~56961373:-
BRCA	cis	rs7772486	0.743	rs9390344	ENSG00000235652.6	RP11-545I5.3	-8.01	2.97e-15	9.24e-13	-0.24	-0.24	Lobe attachment (rater-scored or self-reported);	chr6:145691619	chr6:145799409~145886585:+
BRCA	cis	rs10129255	0.5	rs10143242	ENSG00000280411.1	IGHV1-69-2	-8.01	2.97e-15	9.25e-13	-0.16	-0.24	Kawasaki disease;	chr14:106681814	chr14:106762092~106762588:-
BRCA	cis	rs867371	1	rs9944197	ENSG00000255769.6	GOLGA2P10	-8.01	2.97e-15	9.26e-13	-0.27	-0.24	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82158261	chr15:82472993~82513950:-
BRCA	cis	rs6545883	0.929	rs2593626	ENSG00000271889.1	RP11-493E12.1	8.01	2.97e-15	9.26e-13	0.31	0.24	Tuberculosis;	chr2:61438049	chr2:61151433~61162105:-
BRCA	cis	rs6545883	0.929	rs2592352	ENSG00000271889.1	RP11-493E12.1	8.01	2.97e-15	9.26e-13	0.31	0.24	Tuberculosis;	chr2:61438201	chr2:61151433~61162105:-
BRCA	cis	rs61270009	0.955	rs12515274	ENSG00000247828.6	TMEM161B-AS1	8.01	2.98e-15	9.28e-13	0.31	0.24	Depressive symptoms;	chr5:88359845	chr5:88268895~88436685:+
BRCA	cis	rs6921919	1	rs35875412	ENSG00000216901.1	AL022393.7	8.01	2.99e-15	9.31e-13	0.37	0.24	Autism spectrum disorder or schizophrenia;	chr6:28364041	chr6:28176188~28176674:+
BRCA	cis	rs61270009	0.955	rs12657776	ENSG00000247828.6	TMEM161B-AS1	8.01	2.99e-15	9.32e-13	0.31	0.24	Depressive symptoms;	chr5:88365776	chr5:88268895~88436685:+
BRCA	cis	rs2243480	0.522	rs12698511	ENSG00000226824.5	RP4-756H11.3	-8.01	3.02e-15	9.39e-13	-0.56	-0.24	Diabetic kidney disease;	chr7:66009932	chr7:66654538~66669855:+
BRCA	cis	rs7580658	0.613	rs12463538	ENSG00000236682.1	AC068282.3	-8.01	3.02e-15	9.4e-13	-0.33	-0.24	Protein C levels;	chr2:127439278	chr2:127389130~127400580:+
BRCA	cis	rs9880211	1	rs6771002	ENSG00000239213.4	NCK1-AS1	8.01	3.03e-15	9.43e-13	0.31	0.24	Height;Body mass index;	chr3:136522186	chr3:136841726~136862054:-
BRCA	cis	rs13068223	0.74	rs343999	ENSG00000243926.1	TIPARP-AS1	-8.01	3.04e-15	9.45e-13	-0.25	-0.24	Age-related hearing impairment (SNP x SNP interaction);	chr3:156734050	chr3:156671862~156674378:-
BRCA	cis	rs950880	0.71	rs56386507	ENSG00000234389.1	AC007278.3	-8.01	3.04e-15	9.47e-13	-0.25	-0.24	Serum protein levels (sST2);	chr2:102354705	chr2:102438713~102440475:+
BRCA	cis	rs7809950	0.784	rs7803102	ENSG00000238832.1	snoU109	8.01	3.04e-15	9.47e-13	0.32	0.24	Coronary artery disease;	chr7:107608484	chr7:107603363~107603507:+
BRCA	cis	rs1499614	0.803	rs1796229	ENSG00000273142.1	RP11-458F8.4	-8.01	3.04e-15	9.47e-13	-0.34	-0.24	Gout;	chr7:66654674	chr7:66902857~66906297:+
BRCA	cis	rs950776	0.518	rs952215	ENSG00000261762.1	RP11-650L12.2	-8.01	3.05e-15	9.48e-13	-0.27	-0.24	Sudden cardiac arrest;	chr15:78526811	chr15:78589123~78591276:-
BRCA	cis	rs6700559	0.81	rs2809344	ENSG00000260088.1	RP11-92G12.3	8.01	3.05e-15	9.5e-13	0.3	0.24	Coronary artery disease;	chr1:200627478	chr1:200669507~200694250:+
BRCA	cis	rs193541	0.593	rs1035372	ENSG00000263432.2	RN7SL689P	8.01	3.06e-15	9.51e-13	0.32	0.24	Glucose homeostasis traits;	chr5:122833753	chr5:123022487~123022783:-
BRCA	cis	rs4835473	0.932	rs6849896	ENSG00000251600.4	RP11-673E1.1	-8.01	3.07e-15	9.57e-13	-0.29	-0.24	Immature fraction of reticulocytes;	chr4:143794927	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.838	rs35998817	ENSG00000251600.4	RP11-673E1.1	-8.01	3.07e-15	9.57e-13	-0.29	-0.24	Immature fraction of reticulocytes;	chr4:143795355	chr4:143912331~143982454:+
BRCA	cis	rs2117029	1	rs10875913	ENSG00000258017.1	RP11-386G11.10	-8.01	3.08e-15	9.57e-13	-0.31	-0.24	Intelligence (multi-trait analysis);	chr12:49025525	chr12:49127782~49147869:+
BRCA	cis	rs6844153	0.887	rs62302535	ENSG00000240005.4	RP11-293A21.1	-8.01	3.09e-15	9.6e-13	-0.36	-0.24	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26957254	chr4:26859806~26860599:-
BRCA	cis	rs30380	1	rs30378	ENSG00000248734.2	CTD-2260A17.1	8.01	3.09e-15	9.62e-13	0.26	0.24	Cerebrospinal fluid biomarker levels;	chr5:96786290	chr5:96784777~96785999:+
BRCA	cis	rs2179367	0.959	rs9390677	ENSG00000231760.4	RP11-350J20.5	8.01	3.09e-15	9.62e-13	0.31	0.24	Dupuytren's disease;	chr6:149389361	chr6:149796151~149826294:-
BRCA	cis	rs8062405	0.792	rs12446550	ENSG00000251417.2	RP11-1348G14.4	-8.01	3.1e-15	9.63e-13	-0.28	-0.24	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28532060	chr16:28802743~28817828:+
BRCA	cis	rs11690935	0.55	rs11676438	ENSG00000228389.1	AC068039.4	-8.01	3.1e-15	9.64e-13	-0.29	-0.24	Schizophrenia;	chr2:171970147	chr2:171773482~171775844:+
BRCA	cis	rs11098499	0.863	rs1010739	ENSG00000248280.1	RP11-33B1.2	8.01	3.11e-15	9.68e-13	0.25	0.24	Corneal astigmatism;	chr4:119542316	chr4:119440561~119450157:-
BRCA	cis	rs925255	0.817	rs12624279	ENSG00000270210.1	RP11-373D23.3	-8.01	3.11e-15	9.69e-13	-0.32	-0.24	Inflammatory bowel disease;Crohn's disease;	chr2:28411923	chr2:28425945~28426719:+
BRCA	cis	rs7927771	0.896	rs12794570	ENSG00000280615.1	Y_RNA	-8.01	3.12e-15	9.7e-13	-0.3	-0.24	Subjective well-being;	chr11:47636762	chr11:47614898~47614994:-
BRCA	cis	rs11098499	0.866	rs6857892	ENSG00000248280.1	RP11-33B1.2	8.01	3.12e-15	9.71e-13	0.24	0.24	Corneal astigmatism;	chr4:119361541	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.909	rs28581362	ENSG00000248280.1	RP11-33B1.2	8.01	3.12e-15	9.71e-13	0.24	0.24	Corneal astigmatism;	chr4:119362393	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.82	rs12503082	ENSG00000248280.1	RP11-33B1.2	8.01	3.12e-15	9.71e-13	0.24	0.24	Corneal astigmatism;	chr4:119363162	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.866	rs12499602	ENSG00000248280.1	RP11-33B1.2	8.01	3.12e-15	9.71e-13	0.24	0.24	Corneal astigmatism;	chr4:119363232	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.774	rs11098505	ENSG00000248280.1	RP11-33B1.2	8.01	3.12e-15	9.71e-13	0.24	0.24	Corneal astigmatism;	chr4:119363472	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.866	rs13105020	ENSG00000248280.1	RP11-33B1.2	8.01	3.12e-15	9.71e-13	0.24	0.24	Corneal astigmatism;	chr4:119364533	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.866	rs6824111	ENSG00000248280.1	RP11-33B1.2	8.01	3.12e-15	9.71e-13	0.24	0.24	Corneal astigmatism;	chr4:119364813	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.775	rs10029303	ENSG00000248280.1	RP11-33B1.2	8.01	3.12e-15	9.71e-13	0.24	0.24	Corneal astigmatism;	chr4:119365600	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.866	rs9995136	ENSG00000248280.1	RP11-33B1.2	8.01	3.12e-15	9.71e-13	0.24	0.24	Corneal astigmatism;	chr4:119365690	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.866	rs13125526	ENSG00000248280.1	RP11-33B1.2	8.01	3.12e-15	9.71e-13	0.24	0.24	Corneal astigmatism;	chr4:119366864	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.866	rs12513310	ENSG00000248280.1	RP11-33B1.2	8.01	3.12e-15	9.71e-13	0.24	0.24	Corneal astigmatism;	chr4:119366884	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.866	rs12510451	ENSG00000248280.1	RP11-33B1.2	8.01	3.12e-15	9.71e-13	0.24	0.24	Corneal astigmatism;	chr4:119367988	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.774	rs73842616	ENSG00000248280.1	RP11-33B1.2	8.01	3.12e-15	9.71e-13	0.24	0.24	Corneal astigmatism;	chr4:119369528	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.645	rs72676059	ENSG00000248280.1	RP11-33B1.2	8.01	3.12e-15	9.71e-13	0.24	0.24	Corneal astigmatism;	chr4:119369673	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.569	rs55845118	ENSG00000248280.1	RP11-33B1.2	8.01	3.12e-15	9.71e-13	0.24	0.24	Corneal astigmatism;	chr4:119369758	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.866	rs7677068	ENSG00000248280.1	RP11-33B1.2	8.01	3.12e-15	9.71e-13	0.24	0.24	Corneal astigmatism;	chr4:119370549	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.866	rs9991221	ENSG00000248280.1	RP11-33B1.2	8.01	3.12e-15	9.71e-13	0.24	0.24	Corneal astigmatism;	chr4:119370952	chr4:119440561~119450157:-
BRCA	cis	rs867371	1	rs1501372	ENSG00000255769.6	GOLGA2P10	-8.01	3.13e-15	9.73e-13	-0.28	-0.24	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82176114	chr15:82472993~82513950:-
BRCA	cis	rs6545883	0.894	rs10496092	ENSG00000271889.1	RP11-493E12.1	-8.01	3.14e-15	9.76e-13	-0.31	-0.24	Tuberculosis;	chr2:61297544	chr2:61151433~61162105:-
BRCA	cis	rs858239	0.6	rs2072369	ENSG00000230042.1	AK3P3	-8.01	3.14e-15	9.77e-13	-0.27	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23106570	chr7:23129178~23129841:+
BRCA	cis	rs875971	0.52	rs160645	ENSG00000222364.1	RNU6-96P	8.01	3.15e-15	9.78e-13	0.32	0.24	Aortic root size;	chr7:66091320	chr7:66395191~66395286:+
BRCA	cis	rs11098499	0.909	rs28555550	ENSG00000248280.1	RP11-33B1.2	8.01	3.16e-15	9.81e-13	0.25	0.24	Corneal astigmatism;	chr4:119289885	chr4:119440561~119450157:-
BRCA	cis	rs11098499	1	rs28419773	ENSG00000248280.1	RP11-33B1.2	8.01	3.16e-15	9.81e-13	0.25	0.24	Corneal astigmatism;	chr4:119289906	chr4:119440561~119450157:-
BRCA	cis	rs12468226	0.938	rs3843338	ENSG00000273456.1	RP11-686O6.2	-8	3.19e-15	9.89e-13	-0.34	-0.24	Urate levels;	chr2:202246102	chr2:202374932~202375604:-
BRCA	cis	rs9880211	0.528	rs75685279	ENSG00000239213.4	NCK1-AS1	8	3.2e-15	9.94e-13	0.3	0.24	Height;Body mass index;	chr3:136715991	chr3:136841726~136862054:-
BRCA	cis	rs1075265	0.572	rs62139835	ENSG00000233266.1	HMGB1P31	8	3.21e-15	9.95e-13	0.29	0.24	Chronotype;Morning vs. evening chronotype;	chr2:53682307	chr2:54051334~54051760:+
BRCA	cis	rs9287719	0.753	rs1990613	ENSG00000234818.1	AC092687.5	-8	3.21e-15	9.96e-13	-0.27	-0.24	Prostate cancer;	chr2:10641849	chr2:10589166~10604830:+
BRCA	cis	rs9880211	0.948	rs17298525	ENSG00000239213.4	NCK1-AS1	8	3.22e-15	1e-12	0.32	0.24	Height;Body mass index;	chr3:136474183	chr3:136841726~136862054:-
BRCA	cis	rs6545883	0.894	rs6734628	ENSG00000271889.1	RP11-493E12.1	-8	3.22e-15	1e-12	-0.32	-0.24	Tuberculosis;	chr2:61224125	chr2:61151433~61162105:-
BRCA	cis	rs75422866	0.867	rs7303895	ENSG00000257433.4	RP1-197B17.3	8	3.23e-15	1e-12	0.49	0.24	Pneumonia;	chr12:47683290	chr12:47706085~47742294:+
BRCA	cis	rs73173548	0.502	rs10505856	ENSG00000247828.6	TMEM161B-AS1	8	3.23e-15	1e-12	0.31	0.24	Macular telangiectasia type 2;	chr5:88440636	chr5:88268895~88436685:+
BRCA	cis	rs42648	0.869	rs2027965	ENSG00000225498.1	AC002064.5	8	3.23e-15	1e-12	0.23	0.24	Homocysteine levels;	chr7:90283199	chr7:90312496~90322592:+
BRCA	cis	rs1075265	0.68	rs805396	ENSG00000233266.1	HMGB1P31	8	3.24e-15	1.01e-12	0.29	0.24	Chronotype;Morning vs. evening chronotype;	chr2:53882314	chr2:54051334~54051760:+
BRCA	cis	rs2028299	0.959	rs893617	ENSG00000259677.1	RP11-493E3.1	8	3.24e-15	1.01e-12	0.32	0.24	Type 2 diabetes;	chr15:89838046	chr15:89876540~89877285:+
BRCA	cis	rs56804039	1	rs11777086	ENSG00000253893.2	FAM85B	8	3.25e-15	1.01e-12	0.36	0.24	Cervical cancer;	chr8:8526969	chr8:8167819~8226614:-
BRCA	cis	rs79040073	0.53	rs2078024	ENSG00000259531.2	RP11-295H24.3	8	3.25e-15	1.01e-12	0.37	0.24	Lung cancer in ever smokers;	chr15:49329413	chr15:49365124~49366685:-
BRCA	cis	rs904251	0.523	rs10947675	ENSG00000204110.6	RP1-153P14.8	-8	3.25e-15	1.01e-12	-0.27	-0.24	Cognitive performance;	chr6:37512196	chr6:37507348~37535616:+
BRCA	cis	rs6545883	0.831	rs1186704	ENSG00000271889.1	RP11-493E12.1	8	3.26e-15	1.01e-12	0.31	0.24	Tuberculosis;	chr2:61445856	chr2:61151433~61162105:-
BRCA	cis	rs1552244	0.882	rs13089863	ENSG00000180385.7	EMC3-AS1	-8	3.28e-15	1.02e-12	-0.32	-0.24	Alzheimer's disease;	chr3:9990575	chr3:9986893~10006990:+
BRCA	cis	rs2274273	0.905	rs8007614	ENSG00000258413.1	RP11-665C16.6	-8	3.28e-15	1.02e-12	-0.3	-0.24	Protein biomarker;	chr14:55119857	chr14:55262767~55272075:-
BRCA	cis	rs380904	0.519	rs10102146	ENSG00000254859.1	RP11-661A12.5	8	3.29e-15	1.02e-12	0.39	0.24	Venous thromboembolism (SNP x SNP interaction);	chr8:143566986	chr8:143541973~143549729:-
BRCA	cis	rs10246939	0.529	rs60165685	ENSG00000228775.6	WEE2-AS1	8	3.32e-15	1.03e-12	0.27	0.24	Bitter taste perception;	chr7:141861190	chr7:141704338~141738346:-
BRCA	cis	rs4842666	0.915	rs12579302	ENSG00000258302.2	RP11-981P6.1	-8	3.32e-15	1.03e-12	-0.29	-0.24	Blood pressure;	chr12:89656726	chr12:89561129~89594878:+
BRCA	cis	rs11098499	0.644	rs10012252	ENSG00000248280.1	RP11-33B1.2	8	3.33e-15	1.03e-12	0.24	0.24	Corneal astigmatism;	chr4:119637984	chr4:119440561~119450157:-
BRCA	cis	rs858239	0.6	rs1115941	ENSG00000230042.1	AK3P3	-8	3.33e-15	1.03e-12	-0.27	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23097569	chr7:23129178~23129841:+
BRCA	cis	rs950880	0.71	rs67723747	ENSG00000234389.1	AC007278.3	-8	3.34e-15	1.03e-12	-0.25	-0.24	Serum protein levels (sST2);	chr2:102353347	chr2:102438713~102440475:+
BRCA	cis	rs2439831	0.85	rs9944216	ENSG00000205771.5	CATSPER2P1	8	3.34e-15	1.04e-12	0.4	0.24	Lung cancer in ever smokers;	chr15:43868575	chr15:43726918~43747094:-
BRCA	cis	rs2243480	1	rs1499613	ENSG00000273142.1	RP11-458F8.4	8	3.35e-15	1.04e-12	0.33	0.24	Diabetic kidney disease;	chr7:66265873	chr7:66902857~66906297:+
BRCA	cis	rs12468226	0.817	rs2350360	ENSG00000273456.1	RP11-686O6.2	-8	3.35e-15	1.04e-12	-0.35	-0.24	Urate levels;	chr2:202222980	chr2:202374932~202375604:-
BRCA	cis	rs2742234	0.59	rs2503863	ENSG00000273008.1	RP11-351D16.3	-8	3.36e-15	1.04e-12	-0.31	-0.24	Hirschsprung disease;	chr10:43171950	chr10:43136824~43138334:-
BRCA	cis	rs3758785	0.679	rs13447595	ENSG00000255893.1	RP11-685N10.1	-8	3.36e-15	1.04e-12	-0.32	-0.24	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);	chr11:94489524	chr11:94472908~94473570:-
BRCA	cis	rs11690935	0.55	rs55653103	ENSG00000228389.1	AC068039.4	-8	3.37e-15	1.04e-12	-0.29	-0.24	Schizophrenia;	chr2:171996909	chr2:171773482~171775844:+
BRCA	cis	rs9543976	0.623	rs6562913	ENSG00000261553.4	RP11-29G8.3	8	3.37e-15	1.04e-12	0.38	0.24	Diabetic retinopathy;	chr13:75593297	chr13:75549773~75807120:+
BRCA	cis	rs67981189	0.647	rs36555	ENSG00000269927.1	RP6-91H8.3	-8	3.38e-15	1.05e-12	-0.32	-0.24	Schizophrenia;	chr14:70897844	chr14:71141125~71143253:-
BRCA	cis	rs7246657	0.943	rs713256	ENSG00000276846.1	CTD-3220F14.3	8	3.38e-15	1.05e-12	0.34	0.24	Coronary artery calcification;	chr19:37374463	chr19:37314868~37315620:-
BRCA	cis	rs9309711	0.883	rs13429373	ENSG00000225234.1	TRAPPC12-AS1	-8	3.38e-15	1.05e-12	-0.29	-0.24	Neurofibrillary tangles;	chr2:3473243	chr2:3481242~3482409:-
BRCA	cis	rs2911132	1	rs2911130	ENSG00000248734.2	CTD-2260A17.1	8	3.39e-15	1.05e-12	0.29	0.24	Urate levels (BMI interaction);	chr5:96847724	chr5:96784777~96785999:+
BRCA	cis	rs2028299	0.839	rs2279849	ENSG00000259677.1	RP11-493E3.1	8	3.4e-15	1.05e-12	0.34	0.24	Type 2 diabetes;	chr15:89901407	chr15:89876540~89877285:+
BRCA	cis	rs250518	0.926	rs7734796	ENSG00000272081.1	CTD-2376I4.2	8	3.41e-15	1.06e-12	0.31	0.24	Mean corpuscular hemoglobin concentration;	chr5:72781261	chr5:72955206~72955699:-
BRCA	cis	rs12188164	0.58	rs2672755	ENSG00000225138.6	CTD-2228K2.7	-8	3.41e-15	1.06e-12	-0.26	-0.24	Cystic fibrosis severity;	chr5:457134	chr5:473236~480884:+
BRCA	cis	rs287982	0.935	rs287978	ENSG00000269973.1	RP11-95D17.1	8	3.42e-15	1.06e-12	0.29	0.24	Nonsyndromic cleft lip with cleft palate;	chr2:9830405	chr2:9936360~9939590:+
BRCA	cis	rs116175783	0.557	rs2042487	ENSG00000227403.1	AC009299.3	8	3.42e-15	1.06e-12	0.45	0.24	Intelligence (multi-trait analysis);	chr2:161293734	chr2:161244739~161249050:+
BRCA	cis	rs10510102	0.872	rs10887032	ENSG00000276742.1	RP11-500G22.4	-8	3.42e-15	1.06e-12	-0.41	-0.24	Breast cancer;	chr10:121955887	chr10:121956782~121957098:+
BRCA	cis	rs7927771	0.832	rs55677087	ENSG00000280615.1	Y_RNA	-7.99	3.42e-15	1.06e-12	-0.3	-0.24	Subjective well-being;	chr11:47376163	chr11:47614898~47614994:-
BRCA	cis	rs2028299	0.959	rs748508	ENSG00000259677.1	RP11-493E3.1	7.99	3.42e-15	1.06e-12	0.32	0.24	Type 2 diabetes;	chr15:89838026	chr15:89876540~89877285:+
BRCA	cis	rs11098499	0.644	rs10050092	ENSG00000245958.5	RP11-33B1.1	-7.99	3.46e-15	1.07e-12	-0.23	-0.24	Corneal astigmatism;	chr4:119610930	chr4:119454791~119552025:+
BRCA	cis	rs867371	1	rs8037224	ENSG00000255769.6	GOLGA2P10	-7.99	3.46e-15	1.07e-12	-0.27	-0.24	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82172189	chr15:82472993~82513950:-
BRCA	cis	rs1075265	0.783	rs6708095	ENSG00000233266.1	HMGB1P31	7.99	3.47e-15	1.07e-12	0.29	0.24	Chronotype;Morning vs. evening chronotype;	chr2:53710365	chr2:54051334~54051760:+
BRCA	cis	rs10129255	0.536	rs6576223	ENSG00000280411.1	IGHV1-69-2	-7.99	3.48e-15	1.08e-12	-0.16	-0.24	Kawasaki disease;	chr14:106776448	chr14:106762092~106762588:-
BRCA	cis	rs3762637	1	rs3762637	ENSG00000272758.4	RP11-299J3.8	-7.99	3.48e-15	1.08e-12	-0.35	-0.24	LDL cholesterol levels;	chr3:122426477	chr3:122416207~122443180:+
BRCA	cis	rs11098499	0.687	rs71610270	ENSG00000248280.1	RP11-33B1.2	7.99	3.49e-15	1.08e-12	0.24	0.24	Corneal astigmatism;	chr4:119366281	chr4:119440561~119450157:-
BRCA	cis	rs9880211	0.948	rs13321721	ENSG00000239213.4	NCK1-AS1	7.99	3.5e-15	1.08e-12	0.32	0.24	Height;Body mass index;	chr3:136490708	chr3:136841726~136862054:-
BRCA	cis	rs4835473	0.897	rs4423826	ENSG00000251600.4	RP11-673E1.1	7.99	3.5e-15	1.08e-12	0.29	0.24	Immature fraction of reticulocytes;	chr4:143992165	chr4:143912331~143982454:+
BRCA	cis	rs720475	0.732	rs17172978	ENSG00000204959.4	ARHGEF34P	-7.99	3.52e-15	1.09e-12	-0.32	-0.24	Breast cancer;	chr7:144429551	chr7:144272445~144286966:-
BRCA	cis	rs7772486	0.713	rs2328704	ENSG00000235652.6	RP11-545I5.3	-7.99	3.52e-15	1.09e-12	-0.24	-0.24	Lobe attachment (rater-scored or self-reported);	chr6:145699358	chr6:145799409~145886585:+
BRCA	cis	rs10463554	0.963	rs26253	ENSG00000175749.11	EIF3KP1	7.99	3.52e-15	1.09e-12	0.33	0.24	Parkinson's disease;	chr5:103221266	chr5:103032376~103033031:+
BRCA	cis	rs10129255	0.556	rs6576222	ENSG00000280411.1	IGHV1-69-2	-7.99	3.52e-15	1.09e-12	-0.16	-0.24	Kawasaki disease;	chr14:106776442	chr14:106762092~106762588:-
BRCA	cis	rs755249	0.727	rs16826349	ENSG00000237624.1	OXCT2P1	7.99	3.52e-15	1.09e-12	0.29	0.24	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39573264	chr1:39514956~39516490:+
BRCA	cis	rs6545883	0.894	rs2694634	ENSG00000271889.1	RP11-493E12.1	-7.99	3.53e-15	1.09e-12	-0.31	-0.24	Tuberculosis;	chr2:61324300	chr2:61151433~61162105:-
BRCA	cis	rs10129255	0.5	rs988134	ENSG00000280411.1	IGHV1-69-2	-7.99	3.53e-15	1.09e-12	-0.16	-0.24	Kawasaki disease;	chr14:106776698	chr14:106762092~106762588:-
BRCA	cis	rs10129255	0.5	rs988133	ENSG00000280411.1	IGHV1-69-2	-7.99	3.53e-15	1.09e-12	-0.16	-0.24	Kawasaki disease;	chr14:106776724	chr14:106762092~106762588:-
BRCA	cis	rs8059260	0.935	rs7203687	ENSG00000274038.1	RP11-66H6.4	-7.99	3.54e-15	1.09e-12	-0.31	-0.24	Alcohol consumption over the past year;	chr16:11013063	chr16:11056556~11057034:+
BRCA	cis	rs950880	0.71	rs12469506	ENSG00000234389.1	AC007278.3	-7.99	3.54e-15	1.1e-12	-0.25	-0.24	Serum protein levels (sST2);	chr2:102349411	chr2:102438713~102440475:+
BRCA	cis	rs9880211	1	rs13092193	ENSG00000239213.4	NCK1-AS1	7.99	3.55e-15	1.1e-12	0.31	0.24	Height;Body mass index;	chr3:136521524	chr3:136841726~136862054:-
BRCA	cis	rs375066	0.935	rs396874	ENSG00000267058.1	RP11-15A1.3	-7.99	3.56e-15	1.1e-12	-0.27	-0.24	Breast cancer;	chr19:43893073	chr19:43891804~43901805:-
BRCA	cis	rs4835473	0.9	rs10025455	ENSG00000251600.4	RP11-673E1.1	-7.99	3.56e-15	1.1e-12	-0.3	-0.24	Immature fraction of reticulocytes;	chr4:143998417	chr4:143912331~143982454:+
BRCA	cis	rs10129255	0.53	rs11624912	ENSG00000211970.3	IGHV4-61	-7.99	3.56e-15	1.1e-12	-0.16	-0.24	Kawasaki disease;	chr14:106673891	chr14:106639119~106639657:-
BRCA	cis	rs30380	1	rs151964	ENSG00000248734.2	CTD-2260A17.1	7.99	3.56e-15	1.1e-12	0.25	0.24	Cerebrospinal fluid biomarker levels;	chr5:96787963	chr5:96784777~96785999:+
BRCA	cis	rs11098499	0.564	rs11098507	ENSG00000248280.1	RP11-33B1.2	7.99	3.58e-15	1.11e-12	0.24	0.24	Corneal astigmatism;	chr4:119367131	chr4:119440561~119450157:-
BRCA	cis	rs1062177	0.547	rs2915818	ENSG00000253921.1	CTB-113P19.3	7.99	3.58e-15	1.11e-12	0.32	0.24	Preschool internalizing problems;	chr5:151735729	chr5:151753992~151767247:+
BRCA	cis	rs7586673	0.93	rs7591506	ENSG00000235724.7	AC009299.2	-7.99	3.59e-15	1.11e-12	-0.28	-0.24	Intelligence (multi-trait analysis);	chr2:161104414	chr2:161222785~161308303:-
BRCA	cis	rs7085104	0.632	rs4290163	ENSG00000236937.2	PTGES3P4	7.99	3.59e-15	1.11e-12	0.31	0.24	Immature fraction of reticulocytes;Schizophrenia;	chr10:102851169	chr10:102845595~102845950:+
BRCA	cis	rs6921919	0.789	rs11970439	ENSG00000204709.4	LINC01556	7.99	3.59e-15	1.11e-12	0.35	0.24	Autism spectrum disorder or schizophrenia;	chr6:28335687	chr6:28943877~28944537:+
BRCA	cis	rs10129255	0.518	rs8009594	ENSG00000280411.1	IGHV1-69-2	-7.99	3.6e-15	1.11e-12	-0.16	-0.24	Kawasaki disease;	chr14:106777494	chr14:106762092~106762588:-
BRCA	cis	rs526231	0.511	rs34823	ENSG00000175749.11	EIF3KP1	-7.99	3.6e-15	1.11e-12	-0.35	-0.24	Primary biliary cholangitis;	chr5:103102587	chr5:103032376~103033031:+
BRCA	cis	rs2274273	0.588	rs9919923	ENSG00000258413.1	RP11-665C16.6	-7.99	3.61e-15	1.12e-12	-0.32	-0.24	Protein biomarker;	chr14:55347181	chr14:55262767~55272075:-
BRCA	cis	rs2274273	0.588	rs9919932	ENSG00000258413.1	RP11-665C16.6	-7.99	3.61e-15	1.12e-12	-0.32	-0.24	Protein biomarker;	chr14:55347362	chr14:55262767~55272075:-
BRCA	cis	rs2933343	0.951	rs7648327	ENSG00000261159.1	RP11-723O4.9	7.99	3.61e-15	1.12e-12	0.28	0.24	IgG glycosylation;	chr3:128851865	chr3:128859716~128860526:-
BRCA	cis	rs7809950	1	rs10274041	ENSG00000238832.1	snoU109	7.99	3.62e-15	1.12e-12	0.31	0.24	Coronary artery disease;	chr7:107621111	chr7:107603363~107603507:+
BRCA	cis	rs7809950	1	rs2395883	ENSG00000238832.1	snoU109	-7.99	3.62e-15	1.12e-12	-0.32	-0.24	Coronary artery disease;	chr7:107449225	chr7:107603363~107603507:+
BRCA	cis	rs2842992	0.915	rs2842985	ENSG00000237927.1	RP3-393E18.2	-7.99	3.63e-15	1.12e-12	-0.35	-0.24	Age-related macular degeneration (geographic atrophy);	chr6:159664402	chr6:159586955~159589169:-
BRCA	cis	rs891378	0.785	rs6540876	ENSG00000274245.1	RP11-357P18.2	-7.99	3.64e-15	1.12e-12	-0.31	-0.24	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207222873	chr1:207372559~207373252:+
BRCA	cis	rs74233809	1	rs79082900	ENSG00000213277.3	MARCKSL1P1	7.99	3.64e-15	1.12e-12	0.46	0.24	Birth weight;	chr10:103117545	chr10:103175554~103176094:+
BRCA	cis	rs11992186	0.597	rs77717027	ENSG00000253893.2	FAM85B	7.99	3.64e-15	1.13e-12	0.3	0.24	Neuroticism;	chr8:8734122	chr8:8167819~8226614:-
BRCA	cis	rs7927771	0.864	rs4752838	ENSG00000280615.1	Y_RNA	-7.99	3.66e-15	1.13e-12	-0.29	-0.24	Subjective well-being;	chr11:47444454	chr11:47614898~47614994:-
BRCA	cis	rs7927771	0.965	rs3817335	ENSG00000280615.1	Y_RNA	-7.99	3.66e-15	1.13e-12	-0.29	-0.24	Subjective well-being;	chr11:47622339	chr11:47614898~47614994:-
BRCA	cis	rs67311347	0.544	rs2123998	ENSG00000223797.4	ENTPD3-AS1	-7.99	3.66e-15	1.13e-12	-0.26	-0.24	Renal cell carcinoma;	chr3:40317514	chr3:40313802~40453329:-
BRCA	cis	rs10246939	0.505	rs10952508	ENSG00000228775.6	WEE2-AS1	7.99	3.67e-15	1.13e-12	0.28	0.24	Bitter taste perception;	chr7:141879415	chr7:141704338~141738346:-
BRCA	cis	rs7927771	1	rs10838738	ENSG00000280615.1	Y_RNA	-7.99	3.67e-15	1.13e-12	-0.3	-0.24	Subjective well-being;	chr11:47641497	chr11:47614898~47614994:-
BRCA	cis	rs26232	0.551	rs26431	ENSG00000175749.11	EIF3KP1	-7.99	3.68e-15	1.14e-12	-0.34	-0.24	Rheumatoid arthritis;	chr5:103030090	chr5:103032376~103033031:+
BRCA	cis	rs11098499	0.739	rs9996382	ENSG00000245958.5	RP11-33B1.1	-7.99	3.69e-15	1.14e-12	-0.23	-0.24	Corneal astigmatism;	chr4:119229857	chr4:119454791~119552025:+
BRCA	cis	rs950776	0.714	rs660652	ENSG00000261762.1	RP11-650L12.2	-7.98	3.71e-15	1.15e-12	-0.27	-0.24	Sudden cardiac arrest;	chr15:78595490	chr15:78589123~78591276:-
BRCA	cis	rs950776	0.714	rs472054	ENSG00000261762.1	RP11-650L12.2	-7.98	3.72e-15	1.15e-12	-0.27	-0.24	Sudden cardiac arrest;	chr15:78595652	chr15:78589123~78591276:-
BRCA	cis	rs2439831	0.85	rs3742982	ENSG00000205771.5	CATSPER2P1	-7.98	3.72e-15	1.15e-12	-0.41	-0.24	Lung cancer in ever smokers;	chr15:43884483	chr15:43726918~43747094:-
BRCA	cis	rs11098499	0.604	rs10022185	ENSG00000248280.1	RP11-33B1.2	7.98	3.73e-15	1.15e-12	0.26	0.24	Corneal astigmatism;	chr4:119650610	chr4:119440561~119450157:-
BRCA	cis	rs11690935	0.589	rs62183782	ENSG00000228389.1	AC068039.4	-7.98	3.73e-15	1.15e-12	-0.29	-0.24	Schizophrenia;	chr2:172000102	chr2:171773482~171775844:+
BRCA	cis	rs77204473	1	rs12418208	ENSG00000254851.1	RP11-109L13.1	7.98	3.73e-15	1.15e-12	0.57	0.24	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116916917	chr11:117135528~117138582:+
BRCA	cis	rs77204473	1	rs1006176	ENSG00000254851.1	RP11-109L13.1	7.98	3.73e-15	1.15e-12	0.57	0.24	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116917417	chr11:117135528~117138582:+
BRCA	cis	rs10740039	0.729	rs7091383	ENSG00000254271.1	RP11-131N11.4	7.98	3.73e-15	1.15e-12	0.32	0.24	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60676419	chr10:60734342~60741828:+
BRCA	cis	rs720475	0.732	rs73159066	ENSG00000204959.4	ARHGEF34P	-7.98	3.77e-15	1.16e-12	-0.32	-0.24	Breast cancer;	chr7:144426495	chr7:144272445~144286966:-
BRCA	cis	rs673078	0.66	rs17586342	ENSG00000275759.1	RP11-131L12.3	-7.98	3.78e-15	1.17e-12	-0.33	-0.24	Glucose homeostasis traits;	chr12:118162399	chr12:118428281~118428870:+
BRCA	cis	rs453301	0.658	rs9329175	ENSG00000253893.2	FAM85B	7.98	3.79e-15	1.17e-12	0.29	0.24	Joint mobility (Beighton score);	chr8:9009151	chr8:8167819~8226614:-
BRCA	cis	rs3762637	1	rs55853677	ENSG00000272758.4	RP11-299J3.8	-7.98	3.79e-15	1.17e-12	-0.34	-0.24	LDL cholesterol levels;	chr3:122421769	chr3:122416207~122443180:+
BRCA	cis	rs1075265	0.722	rs2111623	ENSG00000233266.1	HMGB1P31	-7.98	3.8e-15	1.17e-12	-0.29	-0.24	Chronotype;Morning vs. evening chronotype;	chr2:53757820	chr2:54051334~54051760:+
BRCA	cis	rs61270009	0.955	rs4916907	ENSG00000247828.6	TMEM161B-AS1	7.98	3.83e-15	1.18e-12	0.31	0.24	Depressive symptoms;	chr5:88364163	chr5:88268895~88436685:+
BRCA	cis	rs6545883	0.894	rs12620105	ENSG00000271889.1	RP11-493E12.1	-7.98	3.84e-15	1.18e-12	-0.31	-0.24	Tuberculosis;	chr2:61285186	chr2:61151433~61162105:-
BRCA	cis	rs3762637	1	rs76599189	ENSG00000272758.4	RP11-299J3.8	-7.98	3.84e-15	1.18e-12	-0.35	-0.24	LDL cholesterol levels;	chr3:122405229	chr3:122416207~122443180:+
BRCA	cis	rs848490	0.674	rs17807185	ENSG00000214293.7	APTR	7.98	3.85e-15	1.19e-12	0.28	0.24	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77678978	chr7:77657660~77696265:-
BRCA	cis	rs925255	0.81	rs7574996	ENSG00000270210.1	RP11-373D23.3	7.98	3.85e-15	1.19e-12	0.3	0.24	Inflammatory bowel disease;Crohn's disease;	chr2:28420656	chr2:28425945~28426719:+
BRCA	cis	rs7809950	1	rs2250414	ENSG00000238832.1	snoU109	-7.98	3.86e-15	1.19e-12	-0.31	-0.24	Coronary artery disease;	chr7:107500542	chr7:107603363~107603507:+
BRCA	cis	rs7809950	1	rs2520249	ENSG00000238832.1	snoU109	-7.98	3.86e-15	1.19e-12	-0.31	-0.24	Coronary artery disease;	chr7:107506303	chr7:107603363~107603507:+
BRCA	cis	rs867371	1	rs8041868	ENSG00000255769.6	GOLGA2P10	-7.98	3.86e-15	1.19e-12	-0.27	-0.24	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82179985	chr15:82472993~82513950:-
BRCA	cis	rs10129255	0.5	rs11627315	ENSG00000211972.2	IGHV3-66	7.98	3.87e-15	1.19e-12	0.17	0.24	Kawasaki disease;	chr14:106802182	chr14:106675017~106675544:-
BRCA	cis	rs4835473	0.722	rs7666296	ENSG00000251600.4	RP11-673E1.1	-7.98	3.88e-15	1.2e-12	-0.3	-0.24	Immature fraction of reticulocytes;	chr4:143999004	chr4:143912331~143982454:+
BRCA	cis	rs932287	0.858	rs7109896	ENSG00000254860.4	TMEM9B-AS1	-7.98	3.92e-15	1.21e-12	-0.22	-0.24	Colonoscopy-negative controls vs population controls;	chr11:9032975	chr11:8964675~8977527:+
BRCA	cis	rs899997	0.862	rs57260218	ENSG00000261143.1	ADAMTS7P3	-7.98	3.92e-15	1.21e-12	-0.33	-0.24	Coronary artery disease or large artery stroke;	chr15:78681430	chr15:77976042~77993057:+
BRCA	cis	rs6061231	1	rs13043313	ENSG00000273619.1	RP5-908M14.9	-7.98	3.92e-15	1.21e-12	-0.21	-0.24	Colorectal cancer;	chr20:62383213	chr20:62386303~62386970:-
BRCA	cis	rs2028299	1	rs7111	ENSG00000259677.1	RP11-493E3.1	7.98	3.94e-15	1.21e-12	0.32	0.24	Type 2 diabetes;	chr15:89830641	chr15:89876540~89877285:+
BRCA	cis	rs2028299	1	rs2028299	ENSG00000259677.1	RP11-493E3.1	7.98	3.94e-15	1.21e-12	0.32	0.24	Type 2 diabetes;	chr15:89831025	chr15:89876540~89877285:+
BRCA	cis	rs116175783	0.557	rs16845829	ENSG00000227403.1	AC009299.3	7.97	3.99e-15	1.23e-12	0.45	0.24	Intelligence (multi-trait analysis);	chr2:161399960	chr2:161244739~161249050:+
BRCA	cis	rs116175783	0.557	rs72877940	ENSG00000227403.1	AC009299.3	7.97	3.99e-15	1.23e-12	0.45	0.24	Intelligence (multi-trait analysis);	chr2:161403965	chr2:161244739~161249050:+
BRCA	cis	rs3758911	0.828	rs10890697	ENSG00000255353.1	RP11-382M14.1	-7.97	3.99e-15	1.23e-12	-0.32	-0.24	Coronary artery disease;	chr11:107307915	chr11:107176286~107177530:+
BRCA	cis	rs11976180	1	rs6464574	ENSG00000170356.8	OR2A20P	-7.97	4e-15	1.23e-12	-0.35	-0.24	Obesity-related traits;	chr7:144051164	chr7:144250045~144252957:-
BRCA	cis	rs10246939	0.579	rs58093678	ENSG00000228775.6	WEE2-AS1	7.97	4.02e-15	1.24e-12	0.27	0.24	Bitter taste perception;	chr7:141856719	chr7:141704338~141738346:-
BRCA	cis	rs11098499	0.779	rs10857066	ENSG00000248280.1	RP11-33B1.2	7.97	4.03e-15	1.24e-12	0.24	0.24	Corneal astigmatism;	chr4:119365441	chr4:119440561~119450157:-
BRCA	cis	rs6921919	0.945	rs7765989	ENSG00000204709.4	LINC01556	7.97	4.03e-15	1.24e-12	0.38	0.24	Autism spectrum disorder or schizophrenia;	chr6:28432518	chr6:28943877~28944537:+
BRCA	cis	rs6921919	0.515	rs1558205	ENSG00000204709.4	LINC01556	-7.97	4.03e-15	1.24e-12	-0.32	-0.24	Autism spectrum disorder or schizophrenia;	chr6:28414485	chr6:28943877~28944537:+
BRCA	cis	rs3758911	0.861	rs11212117	ENSG00000255353.1	RP11-382M14.1	-7.97	4.03e-15	1.24e-12	-0.33	-0.24	Coronary artery disease;	chr11:107276757	chr11:107176286~107177530:+
BRCA	cis	rs7131987	0.527	rs7308534	ENSG00000257176.2	RP11-996F15.2	7.97	4.03e-15	1.24e-12	0.28	0.24	QT interval;	chr12:29300269	chr12:29280418~29317848:-
BRCA	cis	rs9660180	0.783	rs1107910	ENSG00000231050.1	RP1-140A9.1	7.97	4.03e-15	1.24e-12	0.27	0.24	Body mass index;	chr1:1760882	chr1:1891471~1892658:+
BRCA	cis	rs66887589	0.777	rs10015883	ENSG00000248280.1	RP11-33B1.2	7.97	4.04e-15	1.24e-12	0.22	0.24	Diastolic blood pressure;	chr4:119346991	chr4:119440561~119450157:-
BRCA	cis	rs1075265	0.547	rs7587217	ENSG00000233266.1	HMGB1P31	7.97	4.05e-15	1.25e-12	0.29	0.24	Chronotype;Morning vs. evening chronotype;	chr2:53675029	chr2:54051334~54051760:+
BRCA	cis	rs2439831	0.85	rs3736180	ENSG00000205771.5	CATSPER2P1	-7.97	4.05e-15	1.25e-12	-0.42	-0.24	Lung cancer in ever smokers;	chr15:43814426	chr15:43726918~43747094:-
BRCA	cis	rs732716	0.785	rs11666453	ENSG00000267980.1	AC007292.6	-7.97	4.07e-15	1.25e-12	-0.33	-0.24	Mean corpuscular volume;	chr19:4368800	chr19:4363789~4364640:+
BRCA	cis	rs2742234	0.59	rs2435377	ENSG00000273008.1	RP11-351D16.3	7.97	4.08e-15	1.26e-12	0.3	0.24	Hirschsprung disease;	chr10:43188152	chr10:43136824~43138334:-
BRCA	cis	rs116175783	0.557	rs7349280	ENSG00000227403.1	AC009299.3	7.97	4.09e-15	1.26e-12	0.45	0.24	Intelligence (multi-trait analysis);	chr2:161354120	chr2:161244739~161249050:+
BRCA	cis	rs4820294	0.961	rs62236664	ENSG00000233360.4	Z83844.1	7.97	4.11e-15	1.27e-12	0.29	0.24	Fat distribution (HIV);	chr22:37663420	chr22:37641832~37658377:-
BRCA	cis	rs10129255	0.5	rs7161740	ENSG00000280411.1	IGHV1-69-2	-7.97	4.12e-15	1.27e-12	-0.16	-0.24	Kawasaki disease;	chr14:106776119	chr14:106762092~106762588:-
BRCA	cis	rs11723261	0.582	rs6830247	ENSG00000211553.1	AC253576.2	-7.97	4.12e-15	1.27e-12	-0.34	-0.24	Immune response to smallpox vaccine (IL-6);	chr4:156885	chr4:136461~136568:+
BRCA	cis	rs904251	0.6	rs9380673	ENSG00000204110.6	RP1-153P14.8	-7.97	4.12e-15	1.27e-12	-0.27	-0.24	Cognitive performance;	chr6:37447349	chr6:37507348~37535616:+
BRCA	cis	rs10740039	0.766	rs2119917	ENSG00000254271.1	RP11-131N11.4	7.97	4.13e-15	1.27e-12	0.32	0.24	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60677626	chr10:60734342~60741828:+
BRCA	cis	rs2842992	0.915	rs1322427	ENSG00000237927.1	RP3-393E18.2	-7.97	4.14e-15	1.27e-12	-0.34	-0.24	Age-related macular degeneration (geographic atrophy);	chr6:159654422	chr6:159586955~159589169:-
BRCA	cis	rs56804039	1	rs7017341	ENSG00000253893.2	FAM85B	7.97	4.15e-15	1.28e-12	0.36	0.24	Cervical cancer;	chr8:8524154	chr8:8167819~8226614:-
BRCA	cis	rs74233809	1	rs12220375	ENSG00000213277.3	MARCKSL1P1	7.97	4.15e-15	1.28e-12	0.46	0.24	Birth weight;	chr10:103141734	chr10:103175554~103176094:+
BRCA	cis	rs6545883	0.894	rs12622458	ENSG00000271889.1	RP11-493E12.1	-7.97	4.16e-15	1.28e-12	-0.31	-0.24	Tuberculosis;	chr2:61296419	chr2:61151433~61162105:-
BRCA	cis	rs17818399	0.708	rs1531133	ENSG00000279254.1	RP11-536C12.1	-7.97	4.16e-15	1.28e-12	-0.29	-0.24	Height;	chr2:46616492	chr2:46668870~46670778:+
BRCA	cis	rs6539288	0.803	rs4479083	ENSG00000260329.1	RP11-412D9.4	-7.97	4.17e-15	1.28e-12	-0.27	-0.24	Total body bone mineral density;	chr12:106927467	chr12:106954029~106955497:-
BRCA	cis	rs526231	0.511	rs17154965	ENSG00000175749.11	EIF3KP1	7.97	4.18e-15	1.29e-12	0.35	0.24	Primary biliary cholangitis;	chr5:103023862	chr5:103032376~103033031:+
BRCA	cis	rs2439831	0.85	rs28684672	ENSG00000205771.5	CATSPER2P1	-7.97	4.18e-15	1.29e-12	-0.42	-0.24	Lung cancer in ever smokers;	chr15:43815464	chr15:43726918~43747094:-
BRCA	cis	rs875971	0.898	rs6977501	ENSG00000232559.3	GS1-124K5.12	-7.97	4.2e-15	1.29e-12	-0.29	-0.24	Aortic root size;	chr7:66228355	chr7:66554588~66576923:-
BRCA	cis	rs9880211	0.898	rs13434116	ENSG00000239213.4	NCK1-AS1	7.97	4.2e-15	1.29e-12	0.32	0.24	Height;Body mass index;	chr3:136634232	chr3:136841726~136862054:-
BRCA	cis	rs2028299	0.959	rs2165069	ENSG00000259677.1	RP11-493E3.1	7.97	4.22e-15	1.3e-12	0.33	0.24	Type 2 diabetes;	chr15:89863887	chr15:89876540~89877285:+
BRCA	cis	rs12664251	0.638	rs2782573	ENSG00000253194.1	RP11-351A11.1	-7.97	4.22e-15	1.3e-12	-0.29	-0.24	Schizophrenia;	chr6:119031549	chr6:118934785~119031541:+
BRCA	cis	rs7809950	1	rs2057837	ENSG00000238832.1	snoU109	7.97	4.24e-15	1.3e-12	0.32	0.24	Coronary artery disease;	chr7:107582280	chr7:107603363~107603507:+
BRCA	cis	rs6570726	0.599	rs426371	ENSG00000235652.6	RP11-545I5.3	-7.97	4.24e-15	1.3e-12	-0.26	-0.24	Lobe attachment (rater-scored or self-reported);	chr6:145565333	chr6:145799409~145886585:+
BRCA	cis	rs375066	0.967	rs8104290	ENSG00000267058.1	RP11-15A1.3	-7.97	4.25e-15	1.31e-12	-0.27	-0.24	Breast cancer;	chr19:43863186	chr19:43891804~43901805:-
BRCA	cis	rs11098499	0.955	rs35434465	ENSG00000248280.1	RP11-33B1.2	7.97	4.25e-15	1.31e-12	0.25	0.24	Corneal astigmatism;	chr4:119248223	chr4:119440561~119450157:-
BRCA	cis	rs10463554	0.927	rs6862616	ENSG00000175749.11	EIF3KP1	7.97	4.25e-15	1.31e-12	0.33	0.24	Parkinson's disease;	chr5:102910334	chr5:103032376~103033031:+
BRCA	cis	rs867371	1	rs7173339	ENSG00000255769.6	GOLGA2P10	-7.97	4.26e-15	1.31e-12	-0.28	-0.24	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82175253	chr15:82472993~82513950:-
BRCA	cis	rs17711722	0.653	rs2460421	ENSG00000237310.1	GS1-124K5.4	-7.97	4.27e-15	1.31e-12	-0.25	-0.24	Calcium levels;	chr7:66026136	chr7:66493706~66495474:+
BRCA	cis	rs858239	0.6	rs10256524	ENSG00000230042.1	AK3P3	-7.97	4.29e-15	1.32e-12	-0.27	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23105328	chr7:23129178~23129841:+
BRCA	cis	rs10129255	0.957	rs8005468	ENSG00000223648.3	IGHV3-64	7.97	4.29e-15	1.32e-12	0.2	0.24	Kawasaki disease;	chr14:106686431	chr14:106643132~106658258:-
BRCA	cis	rs875971	1	rs2420820	ENSG00000232559.3	GS1-124K5.12	-7.97	4.29e-15	1.32e-12	-0.29	-0.24	Aortic root size;	chr7:66626920	chr7:66554588~66576923:-
BRCA	cis	rs2274273	0.624	rs7152390	ENSG00000258413.1	RP11-665C16.6	-7.97	4.3e-15	1.32e-12	-0.32	-0.24	Protein biomarker;	chr14:55344983	chr14:55262767~55272075:-
BRCA	cis	rs2028299	0.959	rs12912009	ENSG00000259677.1	RP11-493E3.1	7.97	4.3e-15	1.32e-12	0.31	0.24	Type 2 diabetes;	chr15:89885916	chr15:89876540~89877285:+
BRCA	cis	rs11098499	0.863	rs9884402	ENSG00000248280.1	RP11-33B1.2	7.97	4.3e-15	1.32e-12	0.25	0.24	Corneal astigmatism;	chr4:119568827	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.731	rs9995026	ENSG00000248280.1	RP11-33B1.2	7.97	4.3e-15	1.32e-12	0.25	0.24	Corneal astigmatism;	chr4:119569344	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.754	rs1814813	ENSG00000248280.1	RP11-33B1.2	-7.97	4.3e-15	1.32e-12	-0.23	-0.24	Corneal astigmatism;	chr4:119337052	chr4:119440561~119450157:-
BRCA	cis	rs12220777	1	rs12220777	ENSG00000230091.5	TMEM254-AS1	-7.96	4.31e-15	1.32e-12	-0.45	-0.24	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80028348	chr10:80046860~80078912:-
BRCA	cis	rs1823913	0.503	rs35282329	ENSG00000227542.1	AC092614.2	7.96	4.31e-15	1.32e-12	0.3	0.24	Obesity-related traits;	chr2:191343925	chr2:191229165~191246172:-
BRCA	cis	rs9601248	0.967	rs9545145	ENSG00000227676.3	LINC01068	-7.96	4.32e-15	1.33e-12	-0.28	-0.24	Major depressive disorder;	chr13:79599625	chr13:79566727~79571436:+
BRCA	cis	rs1075265	0.547	rs7557799	ENSG00000233266.1	HMGB1P31	-7.96	4.32e-15	1.33e-12	-0.29	-0.24	Chronotype;Morning vs. evening chronotype;	chr2:53674760	chr2:54051334~54051760:+
BRCA	cis	rs10129255	0.556	rs8010005	ENSG00000280411.1	IGHV1-69-2	-7.96	4.33e-15	1.33e-12	-0.16	-0.24	Kawasaki disease;	chr14:106777987	chr14:106762092~106762588:-
BRCA	cis	rs10129255	0.556	rs6576224	ENSG00000280411.1	IGHV1-69-2	-7.96	4.33e-15	1.33e-12	-0.16	-0.24	Kawasaki disease;	chr14:106777997	chr14:106762092~106762588:-
BRCA	cis	rs10129255	0.518	rs8010020	ENSG00000280411.1	IGHV1-69-2	-7.96	4.33e-15	1.33e-12	-0.16	-0.24	Kawasaki disease;	chr14:106778016	chr14:106762092~106762588:-
BRCA	cis	rs4842666	0.915	rs17249754	ENSG00000258302.2	RP11-981P6.1	-7.96	4.36e-15	1.34e-12	-0.28	-0.24	Blood pressure;	chr12:89666809	chr12:89561129~89594878:+
BRCA	cis	rs10129255	0.518	rs10150460	ENSG00000280411.1	IGHV1-69-2	7.96	4.36e-15	1.34e-12	0.16	0.24	Kawasaki disease;	chr14:106677179	chr14:106762092~106762588:-
BRCA	cis	rs867371	1	rs7173339	ENSG00000259429.4	UBE2Q2P2	-7.96	4.36e-15	1.34e-12	-0.24	-0.24	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82175253	chr15:82355142~82420075:+
BRCA	cis	rs7927771	0.965	rs1064608	ENSG00000280615.1	Y_RNA	-7.96	4.37e-15	1.34e-12	-0.3	-0.24	Subjective well-being;	chr11:47618877	chr11:47614898~47614994:-
BRCA	cis	rs7927771	0.8	rs55876153	ENSG00000280615.1	Y_RNA	-7.96	4.37e-15	1.34e-12	-0.3	-0.24	Subjective well-being;	chr11:47395085	chr11:47614898~47614994:-
BRCA	cis	rs6569038	0.669	rs2884078	ENSG00000253194.1	RP11-351A11.1	-7.96	4.37e-15	1.34e-12	-0.3	-0.24	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr6:119065019	chr6:118934785~119031541:+
BRCA	cis	rs867371	1	rs11855089	ENSG00000259429.4	UBE2Q2P2	-7.96	4.39e-15	1.35e-12	-0.24	-0.24	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82154924	chr15:82355142~82420075:+
BRCA	cis	rs1823913	0.503	rs34716486	ENSG00000227542.1	AC092614.2	7.96	4.4e-15	1.35e-12	0.3	0.24	Obesity-related traits;	chr2:191343335	chr2:191229165~191246172:-
BRCA	cis	rs10129255	0.957	rs17113284	ENSG00000211972.2	IGHV3-66	-7.96	4.41e-15	1.35e-12	-0.19	-0.24	Kawasaki disease;	chr14:106684476	chr14:106675017~106675544:-
BRCA	cis	rs6545883	0.894	rs35292974	ENSG00000271889.1	RP11-493E12.1	-7.96	4.42e-15	1.36e-12	-0.3	-0.24	Tuberculosis;	chr2:61294912	chr2:61151433~61162105:-
BRCA	cis	rs11098499	0.604	rs2389887	ENSG00000248280.1	RP11-33B1.2	7.96	4.43e-15	1.36e-12	0.26	0.24	Corneal astigmatism;	chr4:119649489	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.604	rs34278750	ENSG00000248280.1	RP11-33B1.2	7.96	4.43e-15	1.36e-12	0.26	0.24	Corneal astigmatism;	chr4:119649981	chr4:119440561~119450157:-
BRCA	cis	rs9543976	0.623	rs8192756	ENSG00000261553.4	RP11-29G8.3	7.96	4.45e-15	1.36e-12	0.38	0.24	Diabetic retinopathy;	chr13:75590802	chr13:75549773~75807120:+
BRCA	cis	rs9543976	0.623	rs3783028	ENSG00000261553.4	RP11-29G8.3	7.96	4.45e-15	1.36e-12	0.38	0.24	Diabetic retinopathy;	chr13:75591146	chr13:75549773~75807120:+
BRCA	cis	rs9880211	1	rs9880211	ENSG00000239213.4	NCK1-AS1	7.96	4.45e-15	1.37e-12	0.31	0.24	Height;Body mass index;	chr3:136388707	chr3:136841726~136862054:-
BRCA	cis	rs11971779	1	rs11971779	ENSG00000273391.1	RP11-634H22.1	-7.96	4.46e-15	1.37e-12	-0.27	-0.24	Diisocyanate-induced asthma;	chr7:139355512	chr7:139359032~139359566:-
BRCA	cis	rs74233809	1	rs12217501	ENSG00000213277.3	MARCKSL1P1	7.96	4.47e-15	1.37e-12	0.46	0.24	Birth weight;	chr10:103092132	chr10:103175554~103176094:+
BRCA	cis	rs1185460	0.546	rs549893	ENSG00000271751.1	RP11-110I1.14	7.96	4.47e-15	1.37e-12	0.3	0.24	Coronary artery disease;	chr11:119089022	chr11:119065263~119065677:-
BRCA	cis	rs6545883	0.894	rs2177962	ENSG00000271889.1	RP11-493E12.1	-7.96	4.47e-15	1.37e-12	-0.31	-0.24	Tuberculosis;	chr2:61360935	chr2:61151433~61162105:-
BRCA	cis	rs2742234	0.59	rs2435337	ENSG00000273008.1	RP11-351D16.3	-7.96	4.47e-15	1.37e-12	-0.3	-0.24	Hirschsprung disease;	chr10:43166388	chr10:43136824~43138334:-
BRCA	cis	rs8012947	0.527	rs1190981	ENSG00000279636.2	LINC00216	-7.96	4.5e-15	1.38e-12	-0.25	-0.24	Alcohol consumption in current drinkers;	chr14:58348357	chr14:58288033~58289158:+
BRCA	cis	rs7208859	0.623	rs3794796	ENSG00000266490.1	CTD-2349P21.9	7.96	4.54e-15	1.39e-12	0.37	0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30803862	chr17:30792372~30792833:+
BRCA	cis	rs11098499	0.566	rs17051356	ENSG00000248280.1	RP11-33B1.2	7.96	4.54e-15	1.39e-12	0.26	0.24	Corneal astigmatism;	chr4:119664153	chr4:119440561~119450157:-
BRCA	cis	rs10463554	0.963	rs27970	ENSG00000175749.11	EIF3KP1	7.96	4.54e-15	1.39e-12	0.33	0.24	Parkinson's disease;	chr5:103151019	chr5:103032376~103033031:+
BRCA	cis	rs867371	1	rs7166570	ENSG00000259429.4	UBE2Q2P2	-7.96	4.56e-15	1.4e-12	-0.24	-0.24	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82173880	chr15:82355142~82420075:+
BRCA	cis	rs2712381	0.517	rs62273237	ENSG00000242551.2	POU5F1P6	-7.96	4.56e-15	1.4e-12	-0.29	-0.24	Monocyte count;	chr3:128591264	chr3:128674735~128677005:-
BRCA	cis	rs2348418	0.765	rs10843120	ENSG00000247934.4	RP11-967K21.1	-7.96	4.57e-15	1.4e-12	-0.27	-0.24	Lung function (FEV1);Lung function (FVC);	chr12:28165881	chr12:28163298~28190738:-
BRCA	cis	rs61270009	0.955	rs11741675	ENSG00000247828.6	TMEM161B-AS1	7.96	4.57e-15	1.4e-12	0.31	0.24	Depressive symptoms;	chr5:88332984	chr5:88268895~88436685:+
BRCA	cis	rs867371	1	rs1174543	ENSG00000259429.4	UBE2Q2P2	7.96	4.57e-15	1.4e-12	0.24	0.24	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82155732	chr15:82355142~82420075:+
BRCA	cis	rs10129255	0.5	rs8006888	ENSG00000280411.1	IGHV1-69-2	-7.96	4.57e-15	1.4e-12	-0.16	-0.24	Kawasaki disease;	chr14:106782219	chr14:106762092~106762588:-
BRCA	cis	rs61270009	0.955	rs4916904	ENSG00000247828.6	TMEM161B-AS1	7.96	4.58e-15	1.4e-12	0.31	0.24	Depressive symptoms;	chr5:88338780	chr5:88268895~88436685:+
BRCA	cis	rs867371	1	rs9944197	ENSG00000259429.4	UBE2Q2P2	-7.96	4.58e-15	1.4e-12	-0.24	-0.24	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82158261	chr15:82355142~82420075:+
BRCA	cis	rs812925	0.714	rs1900573	ENSG00000271889.1	RP11-493E12.1	-7.96	4.59e-15	1.41e-12	-0.32	-0.24	Immature fraction of reticulocytes;	chr2:61369777	chr2:61151433~61162105:-
BRCA	cis	rs875971	0.571	rs160647	ENSG00000222364.1	RNU6-96P	7.96	4.59e-15	1.41e-12	0.32	0.24	Aortic root size;	chr7:66089365	chr7:66395191~66395286:+
BRCA	cis	rs4820294	1	rs732856	ENSG00000233360.4	Z83844.1	-7.96	4.61e-15	1.41e-12	-0.28	-0.24	Fat distribution (HIV);	chr22:37664684	chr22:37641832~37658377:-
BRCA	cis	rs74233809	1	rs12413046	ENSG00000213277.3	MARCKSL1P1	7.96	4.64e-15	1.42e-12	0.46	0.24	Birth weight;	chr10:103111447	chr10:103175554~103176094:+
BRCA	cis	rs74233809	1	rs10883832	ENSG00000213277.3	MARCKSL1P1	7.96	4.64e-15	1.42e-12	0.46	0.24	Birth weight;	chr10:103111522	chr10:103175554~103176094:+
BRCA	cis	rs801193	1	rs13239306	ENSG00000237310.1	GS1-124K5.4	-7.96	4.64e-15	1.42e-12	-0.25	-0.24	Aortic root size;	chr7:66671030	chr7:66493706~66495474:+
BRCA	cis	rs11098499	0.866	rs11098506	ENSG00000248280.1	RP11-33B1.2	7.95	4.65e-15	1.42e-12	0.24	0.24	Corneal astigmatism;	chr4:119363816	chr4:119440561~119450157:-
BRCA	cis	rs2404602	0.692	rs3110382	ENSG00000259422.1	RP11-593F23.1	-7.95	4.66e-15	1.43e-12	-0.29	-0.24	Blood metabolite levels;	chr15:76856347	chr15:76174891~76181486:-
BRCA	cis	rs7674212	0.556	rs223401	ENSG00000251288.2	RP11-10L12.2	-7.95	4.67e-15	1.43e-12	-0.29	-0.24	Type 2 diabetes;	chr4:102817815	chr4:102751401~102752641:+
BRCA	cis	rs1707322	1	rs1613296	ENSG00000280836.1	AL355480.1	7.95	4.69e-15	1.44e-12	0.3	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46081180	chr1:45581219~45581321:-
BRCA	cis	rs6570726	0.818	rs399516	ENSG00000235652.6	RP11-545I5.3	7.95	4.69e-15	1.44e-12	0.23	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145489713	chr6:145799409~145886585:+
BRCA	cis	rs17818399	0.62	rs1598517	ENSG00000279254.1	RP11-536C12.1	-7.95	4.7e-15	1.44e-12	-0.29	-0.24	Height;	chr2:46630262	chr2:46668870~46670778:+
BRCA	cis	rs66887589	0.592	rs28580295	ENSG00000248280.1	RP11-33B1.2	7.95	4.7e-15	1.44e-12	0.22	0.24	Diastolic blood pressure;	chr4:119357718	chr4:119440561~119450157:-
BRCA	cis	rs853679	0.567	rs16894091	ENSG00000204709.4	LINC01556	-7.95	4.7e-15	1.44e-12	-0.35	-0.24	Depression;	chr6:28422360	chr6:28943877~28944537:+
BRCA	cis	rs9880211	0.948	rs9813691	ENSG00000273486.1	RP11-731C17.2	7.95	4.71e-15	1.44e-12	0.32	0.24	Height;Body mass index;	chr3:136541880	chr3:136837338~136839021:-
BRCA	cis	rs867371	1	rs2088858	ENSG00000255769.6	GOLGA2P10	-7.95	4.71e-15	1.44e-12	-0.27	-0.24	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82182408	chr15:82472993~82513950:-
BRCA	cis	rs867371	1	rs4778982	ENSG00000255769.6	GOLGA2P10	-7.95	4.71e-15	1.44e-12	-0.27	-0.24	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82182931	chr15:82472993~82513950:-
BRCA	cis	rs867371	1	rs2867579	ENSG00000255769.6	GOLGA2P10	-7.95	4.71e-15	1.44e-12	-0.27	-0.24	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82183043	chr15:82472993~82513950:-
BRCA	cis	rs867371	1	rs881308	ENSG00000255769.6	GOLGA2P10	-7.95	4.71e-15	1.44e-12	-0.27	-0.24	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82183456	chr15:82472993~82513950:-
BRCA	cis	rs10463554	0.963	rs34773	ENSG00000175749.11	EIF3KP1	7.95	4.73e-15	1.45e-12	0.32	0.24	Parkinson's disease;	chr5:103114872	chr5:103032376~103033031:+
BRCA	cis	rs950880	0.71	rs3771171	ENSG00000234389.1	AC007278.3	-7.95	4.73e-15	1.45e-12	-0.25	-0.24	Serum protein levels (sST2);	chr2:102369490	chr2:102438713~102440475:+
BRCA	cis	rs801193	1	rs2659915	ENSG00000237310.1	GS1-124K5.4	7.95	4.73e-15	1.45e-12	0.25	0.24	Aortic root size;	chr7:66688114	chr7:66493706~66495474:+
BRCA	cis	rs867371	1	rs8037224	ENSG00000259429.4	UBE2Q2P2	-7.95	4.75e-15	1.45e-12	-0.24	-0.24	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82172189	chr15:82355142~82420075:+
BRCA	cis	rs42648	0.837	rs3761804	ENSG00000225498.1	AC002064.5	7.95	4.77e-15	1.46e-12	0.23	0.24	Homocysteine levels;	chr7:90286024	chr7:90312496~90322592:+
BRCA	cis	rs9880211	0.948	rs9872178	ENSG00000239213.4	NCK1-AS1	7.95	4.77e-15	1.46e-12	0.31	0.24	Height;Body mass index;	chr3:136267596	chr3:136841726~136862054:-
BRCA	cis	rs6545883	0.929	rs9679557	ENSG00000271889.1	RP11-493E12.1	7.95	4.79e-15	1.47e-12	0.31	0.24	Tuberculosis;	chr2:61482214	chr2:61151433~61162105:-
BRCA	cis	rs7580658	0.68	rs2069931	ENSG00000236682.1	AC068282.3	-7.95	4.79e-15	1.47e-12	-0.33	-0.24	Protein C levels;	chr2:127427993	chr2:127389130~127400580:+
BRCA	cis	rs7246657	0.663	rs9304568	ENSG00000267422.1	CTD-2554C21.1	-7.95	4.82e-15	1.48e-12	-0.35	-0.24	Coronary artery calcification;	chr19:37563606	chr19:37779686~37792865:+
BRCA	cis	rs10463554	0.963	rs257318	ENSG00000175749.11	EIF3KP1	7.95	4.82e-15	1.48e-12	0.32	0.24	Parkinson's disease;	chr5:103109766	chr5:103032376~103033031:+
BRCA	cis	rs858239	0.6	rs7790157	ENSG00000230042.1	AK3P3	-7.95	4.84e-15	1.48e-12	-0.27	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23087379	chr7:23129178~23129841:+
BRCA	cis	rs17818399	0.62	rs7598578	ENSG00000279254.1	RP11-536C12.1	-7.95	4.84e-15	1.48e-12	-0.29	-0.24	Height;	chr2:46629946	chr2:46668870~46670778:+
BRCA	cis	rs875971	0.651	rs313829	ENSG00000237310.1	GS1-124K5.4	-7.95	4.85e-15	1.48e-12	-0.27	-0.24	Aortic root size;	chr7:66087510	chr7:66493706~66495474:+
BRCA	cis	rs2742234	1	rs2742234	ENSG00000273008.1	RP11-351D16.3	7.95	4.87e-15	1.49e-12	0.27	0.24	Hirschsprung disease;	chr10:43117161	chr10:43136824~43138334:-
BRCA	cis	rs12664251	0.66	rs794257	ENSG00000253194.1	RP11-351A11.1	-7.95	4.87e-15	1.49e-12	-0.29	-0.24	Schizophrenia;	chr6:119032047	chr6:118934785~119031541:+
BRCA	cis	rs6142102	0.923	rs6059586	ENSG00000276073.1	RP5-1125A11.7	-7.95	4.87e-15	1.49e-12	-0.28	-0.24	Skin pigmentation;	chr20:33952695	chr20:33985617~33988989:-
BRCA	cis	rs9368481	0.761	rs4713062	ENSG00000241549.7	GUSBP2	-7.95	4.88e-15	1.49e-12	-0.28	-0.24	Autism spectrum disorder or schizophrenia;	chr6:26980416	chr6:26871484~26956554:-
BRCA	cis	rs2274273	0.6	rs10134317	ENSG00000258413.1	RP11-665C16.6	-7.95	4.88e-15	1.49e-12	-0.32	-0.24	Protein biomarker;	chr14:55326730	chr14:55262767~55272075:-
BRCA	cis	rs6921919	1	rs35875412	ENSG00000204709.4	LINC01556	7.95	4.89e-15	1.49e-12	0.38	0.24	Autism spectrum disorder or schizophrenia;	chr6:28364041	chr6:28943877~28944537:+
BRCA	cis	rs10463554	0.963	rs26821	ENSG00000175749.11	EIF3KP1	7.95	4.92e-15	1.5e-12	0.33	0.24	Parkinson's disease;	chr5:103184699	chr5:103032376~103033031:+
BRCA	cis	rs867371	0.892	rs4344697	ENSG00000255769.6	GOLGA2P10	-7.95	4.92e-15	1.5e-12	-0.28	-0.24	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82252873	chr15:82472993~82513950:-
BRCA	cis	rs2742234	0.955	rs2503865	ENSG00000273008.1	RP11-351D16.3	-7.95	4.93e-15	1.51e-12	-0.27	-0.24	Hirschsprung disease;	chr10:43164088	chr10:43136824~43138334:-
BRCA	cis	rs58873874	0.579	rs11551374	ENSG00000251405.2	CTB-109A12.1	7.95	4.95e-15	1.51e-12	0.51	0.24	Bipolar disorder (body mass index interaction);	chr5:157326249	chr5:157362615~157460078:-
BRCA	cis	rs925255	0.81	rs1396733	ENSG00000270210.1	RP11-373D23.3	-7.95	4.95e-15	1.51e-12	-0.3	-0.24	Inflammatory bowel disease;Crohn's disease;	chr2:28419880	chr2:28425945~28426719:+
BRCA	cis	rs875971	0.862	rs6971059	ENSG00000232559.3	GS1-124K5.12	-7.95	4.96e-15	1.51e-12	-0.29	-0.24	Aortic root size;	chr7:66602045	chr7:66554588~66576923:-
BRCA	cis	rs2115630	1	rs55646601	ENSG00000225151.9	GOLGA2P7	7.95	4.96e-15	1.51e-12	0.26	0.24	P wave terminal force;	chr15:84780337	chr15:84199311~84230136:-
BRCA	cis	rs453301	0.686	rs11785634	ENSG00000253893.2	FAM85B	7.95	4.99e-15	1.52e-12	0.3	0.24	Joint mobility (Beighton score);	chr8:9035087	chr8:8167819~8226614:-
BRCA	cis	rs11098499	0.566	rs7664440	ENSG00000248280.1	RP11-33B1.2	7.95	5e-15	1.53e-12	0.26	0.24	Corneal astigmatism;	chr4:119657385	chr4:119440561~119450157:-
BRCA	cis	rs9880211	1	rs9837158	ENSG00000239213.4	NCK1-AS1	7.94	5.01e-15	1.53e-12	0.31	0.24	Height;Body mass index;	chr3:136354321	chr3:136841726~136862054:-
BRCA	cis	rs250518	0.888	rs6870112	ENSG00000272081.1	CTD-2376I4.2	7.94	5.03e-15	1.53e-12	0.3	0.24	Mean corpuscular hemoglobin concentration;	chr5:72725093	chr5:72955206~72955699:-
BRCA	cis	rs875971	0.545	rs313828	ENSG00000222364.1	RNU6-96P	7.94	5.04e-15	1.54e-12	0.32	0.24	Aortic root size;	chr7:66087627	chr7:66395191~66395286:+
BRCA	cis	rs6545883	0.894	rs2121661	ENSG00000271889.1	RP11-493E12.1	-7.94	5.06e-15	1.54e-12	-0.31	-0.24	Tuberculosis;	chr2:61334523	chr2:61151433~61162105:-
BRCA	cis	rs875971	1	rs697970	ENSG00000232559.3	GS1-124K5.12	-7.94	5.06e-15	1.55e-12	-0.29	-0.24	Aortic root size;	chr7:66095065	chr7:66554588~66576923:-
BRCA	cis	rs867371	1	rs13380317	ENSG00000255769.6	GOLGA2P10	7.94	5.07e-15	1.55e-12	0.27	0.24	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82214449	chr15:82472993~82513950:-
BRCA	cis	rs6472827	0.794	rs4439117	ENSG00000253983.2	RP1-16A9.1	7.94	5.08e-15	1.55e-12	0.37	0.24	Uterine fibroids;	chr8:74207475	chr8:74199396~74208441:+
BRCA	cis	rs875971	0.825	rs66981195	ENSG00000232559.3	GS1-124K5.12	-7.94	5.08e-15	1.55e-12	-0.29	-0.24	Aortic root size;	chr7:66614048	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.862	rs3926380	ENSG00000232559.3	GS1-124K5.12	-7.94	5.08e-15	1.55e-12	-0.29	-0.24	Aortic root size;	chr7:66615658	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.825	rs1860472	ENSG00000232559.3	GS1-124K5.12	-7.94	5.08e-15	1.55e-12	-0.29	-0.24	Aortic root size;	chr7:66617736	chr7:66554588~66576923:-
BRCA	cis	rs9543976	0.623	rs7139740	ENSG00000261553.4	RP11-29G8.3	7.94	5.08e-15	1.55e-12	0.38	0.24	Diabetic retinopathy;	chr13:75592806	chr13:75549773~75807120:+
BRCA	cis	rs7674212	0.531	rs10006474	ENSG00000246560.2	RP11-10L12.4	7.94	5.09e-15	1.55e-12	0.25	0.24	Type 2 diabetes;	chr4:103006890	chr4:102828055~102844075:+
BRCA	cis	rs440932	1	rs365309	ENSG00000253893.2	FAM85B	7.94	5.09e-15	1.55e-12	0.32	0.24	High light scatter reticulocyte percentage of red cells;	chr8:9169430	chr8:8167819~8226614:-
BRCA	cis	rs2115630	0.967	rs7171167	ENSG00000225151.9	GOLGA2P7	7.94	5.09e-15	1.55e-12	0.26	0.24	P wave terminal force;	chr15:84695892	chr15:84199311~84230136:-
BRCA	cis	rs1075265	0.756	rs3821081	ENSG00000233266.1	HMGB1P31	-7.94	5.13e-15	1.56e-12	-0.29	-0.24	Chronotype;Morning vs. evening chronotype;	chr2:53738252	chr2:54051334~54051760:+
BRCA	cis	rs9876781	0.56	rs2362451	ENSG00000229759.1	MRPS18AP1	-7.94	5.15e-15	1.57e-12	-0.26	-0.24	Longevity;	chr3:48358338	chr3:48256350~48256938:-
BRCA	cis	rs7674212	0.531	rs2866416	ENSG00000246560.2	RP11-10L12.4	7.94	5.15e-15	1.57e-12	0.26	0.24	Type 2 diabetes;	chr4:102959554	chr4:102828055~102844075:+
BRCA	cis	rs11098499	0.775	rs10021601	ENSG00000248280.1	RP11-33B1.2	7.94	5.15e-15	1.57e-12	0.24	0.24	Corneal astigmatism;	chr4:119361408	chr4:119440561~119450157:-
BRCA	cis	rs7809950	0.773	rs62483722	ENSG00000238832.1	snoU109	-7.94	5.16e-15	1.57e-12	-0.31	-0.24	Coronary artery disease;	chr7:107545904	chr7:107603363~107603507:+
BRCA	cis	rs7809950	0.906	rs62483723	ENSG00000238832.1	snoU109	-7.94	5.16e-15	1.57e-12	-0.31	-0.24	Coronary artery disease;	chr7:107545913	chr7:107603363~107603507:+
BRCA	cis	rs7246657	0.678	rs2927740	ENSG00000267422.1	CTD-2554C21.1	7.94	5.16e-15	1.57e-12	0.35	0.24	Coronary artery calcification;	chr19:37650065	chr19:37779686~37792865:+
BRCA	cis	rs113835537	0.529	rs10501397	ENSG00000255517.5	CTD-3074O7.5	-7.94	5.17e-15	1.58e-12	-0.3	-0.24	Airway imaging phenotypes;	chr11:66505505	chr11:66473490~66480233:-
BRCA	cis	rs3758911	0.828	rs10890695	ENSG00000255353.1	RP11-382M14.1	-7.94	5.18e-15	1.58e-12	-0.32	-0.24	Coronary artery disease;	chr11:107294923	chr11:107176286~107177530:+
BRCA	cis	rs3758911	0.861	rs11212142	ENSG00000255353.1	RP11-382M14.1	-7.94	5.18e-15	1.58e-12	-0.32	-0.24	Coronary artery disease;	chr11:107302994	chr11:107176286~107177530:+
BRCA	cis	rs3758911	0.861	rs10789597	ENSG00000255353.1	RP11-382M14.1	-7.94	5.18e-15	1.58e-12	-0.32	-0.24	Coronary artery disease;	chr11:107304314	chr11:107176286~107177530:+
BRCA	cis	rs3758911	0.861	rs12285607	ENSG00000255353.1	RP11-382M14.1	-7.94	5.18e-15	1.58e-12	-0.32	-0.24	Coronary artery disease;	chr11:107304608	chr11:107176286~107177530:+
BRCA	cis	rs3758911	0.861	rs10890696	ENSG00000255353.1	RP11-382M14.1	-7.94	5.18e-15	1.58e-12	-0.32	-0.24	Coronary artery disease;	chr11:107306487	chr11:107176286~107177530:+
BRCA	cis	rs526231	0.543	rs62362541	ENSG00000175749.11	EIF3KP1	7.94	5.19e-15	1.58e-12	0.35	0.24	Primary biliary cholangitis;	chr5:102986744	chr5:103032376~103033031:+
BRCA	cis	rs58873874	0.579	rs75099611	ENSG00000251405.2	CTB-109A12.1	7.94	5.19e-15	1.58e-12	0.53	0.24	Bipolar disorder (body mass index interaction);	chr5:157312920	chr5:157362615~157460078:-
BRCA	cis	rs847577	0.575	rs41278842	ENSG00000272950.1	RP11-307C18.1	-7.94	5.2e-15	1.58e-12	-0.31	-0.24	Breast cancer;	chr7:98186687	chr7:98322853~98323430:+
BRCA	cis	rs2439831	0.85	rs8042868	ENSG00000275601.1	AC011330.13	-7.94	5.21e-15	1.59e-12	-0.4	-0.24	Lung cancer in ever smokers;	chr15:43647444	chr15:43642389~43643023:-
BRCA	cis	rs4835473	0.722	rs7662277	ENSG00000251600.4	RP11-673E1.1	-7.94	5.24e-15	1.6e-12	-0.29	-0.24	Immature fraction of reticulocytes;	chr4:143999485	chr4:143912331~143982454:+
BRCA	cis	rs3762637	1	rs13321097	ENSG00000272758.4	RP11-299J3.8	-7.94	5.25e-15	1.6e-12	-0.36	-0.24	LDL cholesterol levels;	chr3:122443160	chr3:122416207~122443180:+
BRCA	cis	rs3762637	0.941	rs112768052	ENSG00000272758.4	RP11-299J3.8	-7.94	5.25e-15	1.6e-12	-0.36	-0.24	LDL cholesterol levels;	chr3:122450537	chr3:122416207~122443180:+
BRCA	cis	rs2439831	0.85	rs8042868	ENSG00000205771.5	CATSPER2P1	-7.94	5.26e-15	1.6e-12	-0.43	-0.24	Lung cancer in ever smokers;	chr15:43647444	chr15:43726918~43747094:-
BRCA	cis	rs10129255	0.5	rs6576230	ENSG00000280411.1	IGHV1-69-2	-7.94	5.27e-15	1.6e-12	-0.16	-0.24	Kawasaki disease;	chr14:106778539	chr14:106762092~106762588:-
BRCA	cis	rs56804039	1	rs6986470	ENSG00000253893.2	FAM85B	7.94	5.27e-15	1.6e-12	0.36	0.24	Cervical cancer;	chr8:8523920	chr8:8167819~8226614:-
BRCA	cis	rs1075265	0.611	rs11684084	ENSG00000233266.1	HMGB1P31	7.94	5.27e-15	1.61e-12	0.3	0.24	Chronotype;Morning vs. evening chronotype;	chr2:53695806	chr2:54051334~54051760:+
BRCA	cis	rs858239	0.632	rs6952947	ENSG00000230042.1	AK3P3	7.94	5.29e-15	1.61e-12	0.27	0.24	Cerebrospinal fluid biomarker levels;	chr7:23081423	chr7:23129178~23129841:+
BRCA	cis	rs10971721	0.584	rs10971938	ENSG00000260947.1	RP11-384P7.7	-7.94	5.29e-15	1.61e-12	-0.4	-0.24	Body mass index;	chr9:34120722	chr9:33697459~33700986:+
BRCA	cis	rs3758911	0.796	rs112617433	ENSG00000255353.1	RP11-382M14.1	-7.94	5.29e-15	1.61e-12	-0.33	-0.24	Coronary artery disease;	chr11:107282855	chr11:107176286~107177530:+
BRCA	cis	rs3758911	0.861	rs7929343	ENSG00000255353.1	RP11-382M14.1	-7.94	5.29e-15	1.61e-12	-0.33	-0.24	Coronary artery disease;	chr11:107285183	chr11:107176286~107177530:+
BRCA	cis	rs3758911	0.861	rs7929345	ENSG00000255353.1	RP11-382M14.1	-7.94	5.29e-15	1.61e-12	-0.33	-0.24	Coronary artery disease;	chr11:107285185	chr11:107176286~107177530:+
BRCA	cis	rs77204473	0.744	rs17120523	ENSG00000254851.1	RP11-109L13.1	7.94	5.3e-15	1.61e-12	0.6	0.24	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117223875	chr11:117135528~117138582:+
BRCA	cis	rs7927771	0.793	rs12803525	ENSG00000280615.1	Y_RNA	-7.94	5.3e-15	1.61e-12	-0.29	-0.24	Subjective well-being;	chr11:47391924	chr11:47614898~47614994:-
BRCA	cis	rs10510102	1	rs10510102	ENSG00000276742.1	RP11-500G22.4	-7.94	5.31e-15	1.62e-12	-0.38	-0.24	Breast cancer;	chr10:121865675	chr10:121956782~121957098:+
BRCA	cis	rs2404602	0.669	rs17464903	ENSG00000259422.1	RP11-593F23.1	7.94	5.32e-15	1.62e-12	0.3	0.24	Blood metabolite levels;	chr15:76903145	chr15:76174891~76181486:-
BRCA	cis	rs1061377	0.748	rs13117988	ENSG00000249685.1	RP11-360F5.3	7.94	5.32e-15	1.62e-12	0.29	0.24	Uric acid levels;	chr4:39092219	chr4:39133913~39135608:+
BRCA	cis	rs30380	1	rs469758	ENSG00000248734.2	CTD-2260A17.1	7.94	5.36e-15	1.63e-12	0.25	0.24	Cerebrospinal fluid biomarker levels;	chr5:96786011	chr5:96784777~96785999:+
BRCA	cis	rs4934494	0.727	rs36019294	ENSG00000240996.1	RP11-80H5.7	-7.94	5.36e-15	1.63e-12	-0.3	-0.24	Red blood cell count;	chr10:89777822	chr10:89694295~89697928:-
BRCA	cis	rs2439831	0.85	rs16977798	ENSG00000275601.1	AC011330.13	-7.94	5.37e-15	1.63e-12	-0.37	-0.24	Lung cancer in ever smokers;	chr15:43859750	chr15:43642389~43643023:-
BRCA	cis	rs783540	0.934	rs10400906	ENSG00000278603.1	RP13-608F4.5	7.94	5.37e-15	1.63e-12	0.3	0.24	Schizophrenia;	chr15:82628387	chr15:82472203~82472426:+
BRCA	cis	rs858239	0.6	rs6961131	ENSG00000230042.1	AK3P3	-7.94	5.37e-15	1.63e-12	-0.27	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23095171	chr7:23129178~23129841:+
BRCA	cis	rs10463554	1	rs12659870	ENSG00000175749.11	EIF3KP1	7.94	5.4e-15	1.64e-12	0.32	0.24	Parkinson's disease;	chr5:103000867	chr5:103032376~103033031:+
BRCA	cis	rs755249	0.727	rs2242500	ENSG00000237624.1	OXCT2P1	7.94	5.4e-15	1.64e-12	0.29	0.24	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39572230	chr1:39514956~39516490:+
BRCA	cis	rs6674176	0.597	rs2352990	ENSG00000237950.1	RP11-7O11.3	7.94	5.4e-15	1.64e-12	0.29	0.24	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43927604	chr1:43944370~43946551:-
BRCA	cis	rs17213965	0.925	rs62030569	ENSG00000207425.1	Y_RNA	-7.94	5.4e-15	1.64e-12	-0.38	-0.24	Waist-hip ratio;	chr16:15786892	chr16:14915457~14915556:-
BRCA	cis	rs6569038	0.669	rs7764418	ENSG00000253194.1	RP11-351A11.1	7.93	5.41e-15	1.65e-12	0.31	0.24	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr6:119062817	chr6:118934785~119031541:+
BRCA	cis	rs11098499	0.554	rs2175381	ENSG00000248280.1	RP11-33B1.2	7.93	5.42e-15	1.65e-12	0.23	0.24	Corneal astigmatism;	chr4:119344812	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.599	rs3864142	ENSG00000248280.1	RP11-33B1.2	7.93	5.42e-15	1.65e-12	0.23	0.24	Corneal astigmatism;	chr4:119345036	chr4:119440561~119450157:-
BRCA	cis	rs2803122	0.501	rs10811140	ENSG00000273226.1	RP11-513M16.8	-7.93	5.42e-15	1.65e-12	-0.3	-0.24	Pulse pressure;	chr9:19230401	chr9:19375451~19375996:+
BRCA	cis	rs7246657	0.722	rs16958863	ENSG00000267422.1	CTD-2554C21.1	-7.93	5.43e-15	1.65e-12	-0.35	-0.24	Coronary artery calcification;	chr19:37633334	chr19:37779686~37792865:+
BRCA	cis	rs526231	0.511	rs55896090	ENSG00000175749.11	EIF3KP1	7.93	5.44e-15	1.65e-12	0.34	0.24	Primary biliary cholangitis;	chr5:103026300	chr5:103032376~103033031:+
BRCA	cis	rs10463554	0.927	rs62362489	ENSG00000175749.11	EIF3KP1	7.93	5.49e-15	1.67e-12	0.33	0.24	Parkinson's disease;	chr5:102909841	chr5:103032376~103033031:+
BRCA	cis	rs875971	0.789	rs7808013	ENSG00000232559.3	GS1-124K5.12	-7.93	5.5e-15	1.67e-12	-0.29	-0.24	Aortic root size;	chr7:66606209	chr7:66554588~66576923:-
BRCA	cis	rs10129255	0.518	rs12590732	ENSG00000211970.3	IGHV4-61	7.93	5.5e-15	1.67e-12	0.15	0.24	Kawasaki disease;	chr14:106779612	chr14:106639119~106639657:-
BRCA	cis	rs56046484	0.826	rs35816571	ENSG00000259295.5	CSPG4P12	7.93	5.54e-15	1.68e-12	0.43	0.24	Testicular germ cell tumor;	chr15:85010891	chr15:85191438~85213905:+
BRCA	cis	rs375066	0.935	rs397346	ENSG00000267058.1	RP11-15A1.3	-7.93	5.55e-15	1.69e-12	-0.27	-0.24	Breast cancer;	chr19:43894963	chr19:43891804~43901805:-
BRCA	cis	rs6142102	0.961	rs1007090	ENSG00000276073.1	RP5-1125A11.7	-7.93	5.55e-15	1.69e-12	-0.29	-0.24	Skin pigmentation;	chr20:33995065	chr20:33985617~33988989:-
BRCA	cis	rs6142102	0.923	rs2284377	ENSG00000276073.1	RP5-1125A11.7	-7.93	5.55e-15	1.69e-12	-0.29	-0.24	Skin pigmentation;	chr20:33998876	chr20:33985617~33988989:-
BRCA	cis	rs6142102	0.961	rs2284378	ENSG00000276073.1	RP5-1125A11.7	-7.93	5.55e-15	1.69e-12	-0.29	-0.24	Skin pigmentation;	chr20:34000289	chr20:33985617~33988989:-
BRCA	cis	rs6142102	0.961	rs2268080	ENSG00000276073.1	RP5-1125A11.7	-7.93	5.55e-15	1.69e-12	-0.29	-0.24	Skin pigmentation;	chr20:34009910	chr20:33985617~33988989:-
BRCA	cis	rs2742234	1	rs1864395	ENSG00000273008.1	RP11-351D16.3	-7.93	5.55e-15	1.69e-12	-0.27	-0.24	Hirschsprung disease;	chr10:43160249	chr10:43136824~43138334:-
BRCA	cis	rs3758911	0.765	rs10789592	ENSG00000255353.1	RP11-382M14.1	-7.93	5.55e-15	1.69e-12	-0.33	-0.24	Coronary artery disease;	chr11:107283589	chr11:107176286~107177530:+
BRCA	cis	rs2243480	0.908	rs313822	ENSG00000273142.1	RP11-458F8.4	-7.93	5.56e-15	1.69e-12	-0.34	-0.24	Diabetic kidney disease;	chr7:66108952	chr7:66902857~66906297:+
BRCA	cis	rs6142102	0.517	rs6059580	ENSG00000275784.1	RP5-1125A11.6	-7.93	5.57e-15	1.69e-12	-0.27	-0.24	Skin pigmentation;	chr20:33940067	chr20:33989480~33991818:-
BRCA	cis	rs10510102	0.935	rs7083278	ENSG00000276742.1	RP11-500G22.4	7.93	5.59e-15	1.7e-12	0.4	0.24	Breast cancer;	chr10:121853758	chr10:121956782~121957098:+
BRCA	cis	rs9880211	1	rs13071220	ENSG00000239213.4	NCK1-AS1	7.93	5.61e-15	1.7e-12	0.31	0.24	Height;Body mass index;	chr3:136595277	chr3:136841726~136862054:-
BRCA	cis	rs61270009	0.955	rs2410766	ENSG00000247828.6	TMEM161B-AS1	7.93	5.64e-15	1.71e-12	0.31	0.24	Depressive symptoms;	chr5:88405666	chr5:88268895~88436685:+
BRCA	cis	rs875971	0.825	rs7384021	ENSG00000232559.3	GS1-124K5.12	-7.93	5.64e-15	1.71e-12	-0.29	-0.24	Aortic root size;	chr7:66612917	chr7:66554588~66576923:-
BRCA	cis	rs10463554	0.963	rs1552916	ENSG00000175749.11	EIF3KP1	7.93	5.65e-15	1.71e-12	0.32	0.24	Parkinson's disease;	chr5:103002036	chr5:103032376~103033031:+
BRCA	cis	rs10129255	0.5	rs8011115	ENSG00000280411.1	IGHV1-69-2	-7.93	5.66e-15	1.72e-12	-0.16	-0.24	Kawasaki disease;	chr14:106786292	chr14:106762092~106762588:-
BRCA	cis	rs4934494	0.636	rs34408087	ENSG00000240996.1	RP11-80H5.7	-7.93	5.67e-15	1.72e-12	-0.3	-0.24	Red blood cell count;	chr10:89783794	chr10:89694295~89697928:-
BRCA	cis	rs732716	0.785	rs34080966	ENSG00000267980.1	AC007292.6	7.93	5.67e-15	1.72e-12	0.31	0.24	Mean corpuscular volume;	chr19:4417848	chr19:4363789~4364640:+
BRCA	cis	rs4835473	0.932	rs13152443	ENSG00000251600.4	RP11-673E1.1	-7.93	5.68e-15	1.72e-12	-0.3	-0.24	Immature fraction of reticulocytes;	chr4:143742492	chr4:143912331~143982454:+
BRCA	cis	rs6921919	0.789	rs6912584	ENSG00000204709.4	LINC01556	7.93	5.69e-15	1.73e-12	0.35	0.24	Autism spectrum disorder or schizophrenia;	chr6:28341813	chr6:28943877~28944537:+
BRCA	cis	rs17023223	0.537	rs6662165	ENSG00000231365.4	RP11-418J17.1	-7.93	5.69e-15	1.73e-12	-0.32	-0.24	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119071448	chr1:119140396~119275973:+
BRCA	cis	rs2179367	0.959	rs562428	ENSG00000231760.4	RP11-350J20.5	7.93	5.69e-15	1.73e-12	0.31	0.24	Dupuytren's disease;	chr6:149326389	chr6:149796151~149826294:-
BRCA	cis	rs12468226	0.606	rs10445793	ENSG00000273456.1	RP11-686O6.2	7.93	5.7e-15	1.73e-12	0.32	0.24	Urate levels;	chr2:202190799	chr2:202374932~202375604:-
BRCA	cis	rs4964805	0.77	rs11111779	ENSG00000257681.1	RP11-341G23.4	7.93	5.71e-15	1.73e-12	0.29	0.24	Attention deficit hyperactivity disorder;	chr12:103791718	chr12:103746315~103768858:-
BRCA	cis	rs950169	0.58	rs17532346	ENSG00000259728.4	LINC00933	7.93	5.72e-15	1.74e-12	0.31	0.24	Schizophrenia;	chr15:84628264	chr15:84570649~84580175:+
BRCA	cis	rs1823913	0.503	rs35672076	ENSG00000227542.1	AC092614.2	7.93	5.73e-15	1.74e-12	0.3	0.24	Obesity-related traits;	chr2:191343907	chr2:191229165~191246172:-
BRCA	cis	rs3758911	1	rs10789616	ENSG00000255353.1	RP11-382M14.1	-7.93	5.73e-15	1.74e-12	-0.31	-0.24	Coronary artery disease;	chr11:107318365	chr11:107176286~107177530:+
BRCA	cis	rs10463554	0.963	rs11955683	ENSG00000175749.11	EIF3KP1	7.93	5.73e-15	1.74e-12	0.32	0.24	Parkinson's disease;	chr5:102990992	chr5:103032376~103033031:+
BRCA	cis	rs7809950	1	rs2520260	ENSG00000238832.1	snoU109	-7.93	5.75e-15	1.75e-12	-0.31	-0.24	Coronary artery disease;	chr7:107532349	chr7:107603363~107603507:+
BRCA	cis	rs7809950	1	rs12668402	ENSG00000238832.1	snoU109	-7.93	5.75e-15	1.75e-12	-0.31	-0.24	Coronary artery disease;	chr7:107532575	chr7:107603363~107603507:+
BRCA	cis	rs4835473	0.9	rs71612420	ENSG00000251600.4	RP11-673E1.1	-7.93	5.76e-15	1.75e-12	-0.29	-0.24	Immature fraction of reticulocytes;	chr4:143779107	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.9	rs13134869	ENSG00000251600.4	RP11-673E1.1	-7.93	5.76e-15	1.75e-12	-0.29	-0.24	Immature fraction of reticulocytes;	chr4:143782301	chr4:143912331~143982454:+
BRCA	cis	rs2280018	1	rs2280017	ENSG00000260735.1	RP11-72I8.1	7.93	5.76e-15	1.75e-12	0.26	0.24	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15057504	chr16:15094411~15109197:+
BRCA	cis	rs875971	0.798	rs6460304	ENSG00000232559.3	GS1-124K5.12	7.93	5.76e-15	1.75e-12	0.29	0.24	Aortic root size;	chr7:66499741	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.862	rs6945775	ENSG00000232559.3	GS1-124K5.12	7.93	5.76e-15	1.75e-12	0.29	0.24	Aortic root size;	chr7:66503987	chr7:66554588~66576923:-
BRCA	cis	rs8072100	0.967	rs11871606	ENSG00000228782.6	CTD-2026D20.3	-7.93	5.76e-15	1.75e-12	-0.25	-0.24	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47655408	chr17:47450568~47492492:-
BRCA	cis	rs56804039	1	rs56804039	ENSG00000253893.2	FAM85B	7.93	5.78e-15	1.75e-12	0.36	0.24	Cervical cancer;	chr8:8523519	chr8:8167819~8226614:-
BRCA	cis	rs10129255	0.956	rs10137268	ENSG00000223648.3	IGHV3-64	7.93	5.79e-15	1.76e-12	0.21	0.24	Kawasaki disease;	chr14:106697402	chr14:106643132~106658258:-
BRCA	cis	rs11098499	0.954	rs6857105	ENSG00000245958.5	RP11-33B1.1	-7.93	5.79e-15	1.76e-12	-0.23	-0.24	Corneal astigmatism;	chr4:119301143	chr4:119454791~119552025:+
BRCA	cis	rs904251	0.6	rs2270687	ENSG00000204110.6	RP1-153P14.8	-7.93	5.8e-15	1.76e-12	-0.27	-0.24	Cognitive performance;	chr6:37450487	chr6:37507348~37535616:+
BRCA	cis	rs77204473	0.744	rs17120293	ENSG00000254851.1	RP11-109L13.1	7.93	5.82e-15	1.76e-12	0.53	0.24	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117074130	chr11:117135528~117138582:+
BRCA	cis	rs2742234	0.59	rs2503864	ENSG00000273008.1	RP11-351D16.3	-7.93	5.82e-15	1.77e-12	-0.3	-0.24	Hirschsprung disease;	chr10:43171319	chr10:43136824~43138334:-
BRCA	cis	rs7811142	1	rs76913697	ENSG00000242294.5	STAG3L5P	7.93	5.83e-15	1.77e-12	0.23	0.24	Platelet count;	chr7:100405149	chr7:100336079~100351900:+
BRCA	cis	rs17023223	0.537	rs10802075	ENSG00000231365.4	RP11-418J17.1	-7.92	5.86e-15	1.78e-12	-0.32	-0.24	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119084604	chr1:119140396~119275973:+
BRCA	cis	rs2274273	0.588	rs11158037	ENSG00000258413.1	RP11-665C16.6	-7.92	5.87e-15	1.78e-12	-0.32	-0.24	Protein biomarker;	chr14:55365434	chr14:55262767~55272075:-
BRCA	cis	rs7927771	1	rs4752856	ENSG00000280615.1	Y_RNA	-7.92	5.88e-15	1.78e-12	-0.3	-0.24	Subjective well-being;	chr11:47626490	chr11:47614898~47614994:-
BRCA	cis	rs26232	0.583	rs26434	ENSG00000175749.11	EIF3KP1	-7.92	5.91e-15	1.79e-12	-0.34	-0.24	Rheumatoid arthritis;	chr5:103027698	chr5:103032376~103033031:+
BRCA	cis	rs74233809	1	rs11191505	ENSG00000213277.3	MARCKSL1P1	7.92	5.93e-15	1.8e-12	0.46	0.24	Birth weight;	chr10:103007134	chr10:103175554~103176094:+
BRCA	cis	rs7727544	0.735	rs274568	ENSG00000233006.5	AC034220.3	-7.92	5.93e-15	1.8e-12	-0.18	-0.24	Blood metabolite levels;	chr5:132377886	chr5:132311285~132369916:-
BRCA	cis	rs375066	0.935	rs417699	ENSG00000267058.1	RP11-15A1.3	-7.92	5.94e-15	1.8e-12	-0.27	-0.24	Breast cancer;	chr19:43913423	chr19:43891804~43901805:-
BRCA	cis	rs10129255	0.5	rs4774008	ENSG00000280411.1	IGHV1-69-2	-7.92	5.95e-15	1.8e-12	-0.16	-0.24	Kawasaki disease;	chr14:106681273	chr14:106762092~106762588:-
BRCA	cis	rs10129255	0.5	rs7157975	ENSG00000211972.2	IGHV3-66	7.92	5.96e-15	1.81e-12	0.16	0.24	Kawasaki disease;	chr14:106804049	chr14:106675017~106675544:-
BRCA	cis	rs17772222	1	rs17772222	ENSG00000258983.2	RP11-507K2.2	-7.92	5.96e-15	1.81e-12	-0.27	-0.24	Coronary artery calcification;	chr14:88360138	chr14:88499334~88515502:+
BRCA	cis	rs950880	0.71	rs4140785	ENSG00000234389.1	AC007278.3	-7.92	5.96e-15	1.81e-12	-0.24	-0.24	Serum protein levels (sST2);	chr2:102472057	chr2:102438713~102440475:+
BRCA	cis	rs7688540	0.723	rs9684973	ENSG00000275426.1	CH17-262A2.1	7.92	5.97e-15	1.81e-12	0.33	0.24	Facial morphology (factor 6, height of vermillion lower lip);	chr4:245032	chr4:149738~150317:+
BRCA	cis	rs13068223	0.74	rs344003	ENSG00000243926.1	TIPARP-AS1	-7.92	5.99e-15	1.82e-12	-0.25	-0.24	Age-related hearing impairment (SNP x SNP interaction);	chr3:156739931	chr3:156671862~156674378:-
BRCA	cis	rs250518	0.852	rs3846640	ENSG00000272081.1	CTD-2376I4.2	7.92	5.99e-15	1.82e-12	0.3	0.24	Mean corpuscular hemoglobin concentration;	chr5:72724139	chr5:72955206~72955699:-
BRCA	cis	rs858239	0.6	rs7776649	ENSG00000230042.1	AK3P3	-7.92	6.04e-15	1.83e-12	-0.27	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23079698	chr7:23129178~23129841:+
BRCA	cis	rs2880765	0.835	rs7174323	ENSG00000259295.5	CSPG4P12	7.92	6.08e-15	1.84e-12	0.29	0.24	Coronary artery disease;	chr15:85506488	chr15:85191438~85213905:+
BRCA	cis	rs526231	0.511	rs55810112	ENSG00000175749.11	EIF3KP1	7.92	6.1e-15	1.85e-12	0.34	0.24	Primary biliary cholangitis;	chr5:103026645	chr5:103032376~103033031:+
BRCA	cis	rs77204473	1	rs79711490	ENSG00000254851.1	RP11-109L13.1	7.92	6.14e-15	1.86e-12	0.55	0.24	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116914625	chr11:117135528~117138582:+
BRCA	cis	rs11098499	0.78	rs10013652	ENSG00000248280.1	RP11-33B1.2	7.92	6.14e-15	1.86e-12	0.24	0.24	Corneal astigmatism;	chr4:119371101	chr4:119440561~119450157:-
BRCA	cis	rs7927771	0.864	rs4752999	ENSG00000280615.1	Y_RNA	-7.92	6.15e-15	1.86e-12	-0.29	-0.24	Subjective well-being;	chr11:47407014	chr11:47614898~47614994:-
BRCA	cis	rs7246657	0.941	rs7259618	ENSG00000276846.1	CTD-3220F14.3	7.92	6.18e-15	1.87e-12	0.34	0.24	Coronary artery calcification;	chr19:37259817	chr19:37314868~37315620:-
BRCA	cis	rs2179367	0.959	rs544947	ENSG00000231760.4	RP11-350J20.5	7.92	6.2e-15	1.88e-12	0.31	0.24	Dupuytren's disease;	chr6:149402412	chr6:149796151~149826294:-
BRCA	cis	rs62355901	0.505	rs62358079	ENSG00000271828.1	CTD-2310F14.1	7.92	6.2e-15	1.88e-12	0.5	0.24	Breast cancer;	chr5:56858020	chr5:56927874~56929573:+
BRCA	cis	rs875971	0.545	rs313830	ENSG00000222364.1	RNU6-96P	7.92	6.22e-15	1.88e-12	0.32	0.24	Aortic root size;	chr7:66086944	chr7:66395191~66395286:+
BRCA	cis	rs62355901	0.545	rs57850701	ENSG00000271828.1	CTD-2310F14.1	7.92	6.24e-15	1.89e-12	0.42	0.24	Breast cancer;	chr5:56728529	chr5:56927874~56929573:+
BRCA	cis	rs62355901	0.599	rs62355875	ENSG00000271828.1	CTD-2310F14.1	7.92	6.24e-15	1.89e-12	0.42	0.24	Breast cancer;	chr5:56729353	chr5:56927874~56929573:+
BRCA	cis	rs62355901	0.599	rs62355876	ENSG00000271828.1	CTD-2310F14.1	7.92	6.24e-15	1.89e-12	0.42	0.24	Breast cancer;	chr5:56729373	chr5:56927874~56929573:+
BRCA	cis	rs10740039	0.883	rs10994468	ENSG00000254271.1	RP11-131N11.4	7.92	6.24e-15	1.89e-12	0.32	0.24	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60666533	chr10:60734342~60741828:+
BRCA	cis	rs11976180	1	rs2961118	ENSG00000170356.8	OR2A20P	-7.92	6.25e-15	1.89e-12	-0.33	-0.24	Obesity-related traits;	chr7:144058350	chr7:144250045~144252957:-
BRCA	cis	rs9880211	1	rs28718456	ENSG00000239213.4	NCK1-AS1	7.92	6.28e-15	1.9e-12	0.31	0.24	Height;Body mass index;	chr3:136485164	chr3:136841726~136862054:-
BRCA	cis	rs113835537	0.529	rs3892818	ENSG00000255517.5	CTD-3074O7.5	-7.91	6.32e-15	1.91e-12	-0.3	-0.24	Airway imaging phenotypes;	chr11:66472720	chr11:66473490~66480233:-
BRCA	cis	rs2439831	0.85	rs11856795	ENSG00000205771.5	CATSPER2P1	-7.91	6.33e-15	1.91e-12	-0.41	-0.24	Lung cancer in ever smokers;	chr15:43868384	chr15:43726918~43747094:-
BRCA	cis	rs9880211	0.848	rs71336069	ENSG00000239213.4	NCK1-AS1	7.91	6.36e-15	1.92e-12	0.31	0.24	Height;Body mass index;	chr3:136633024	chr3:136841726~136862054:-
BRCA	cis	rs2274273	0.624	rs68138420	ENSG00000258413.1	RP11-665C16.6	-7.91	6.36e-15	1.93e-12	-0.32	-0.24	Protein biomarker;	chr14:55311249	chr14:55262767~55272075:-
BRCA	cis	rs7131987	0.565	rs7137141	ENSG00000275476.1	RP11-996F15.4	7.91	6.38e-15	1.93e-12	0.27	0.24	QT interval;	chr12:29272168	chr12:29277397~29277882:-
BRCA	cis	rs10463554	1	rs3776862	ENSG00000175749.11	EIF3KP1	7.91	6.38e-15	1.93e-12	0.32	0.24	Parkinson's disease;	chr5:102996017	chr5:103032376~103033031:+
BRCA	cis	rs867371	1	rs13380319	ENSG00000255769.6	GOLGA2P10	-7.91	6.39e-15	1.93e-12	-0.27	-0.24	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82214526	chr15:82472993~82513950:-
BRCA	cis	rs12468226	0.702	rs114634431	ENSG00000273456.1	RP11-686O6.2	7.91	6.39e-15	1.93e-12	0.37	0.24	Urate levels;	chr2:202142530	chr2:202374932~202375604:-
BRCA	cis	rs2742234	0.518	rs1254967	ENSG00000273008.1	RP11-351D16.3	7.91	6.42e-15	1.94e-12	0.31	0.24	Hirschsprung disease;	chr10:43194943	chr10:43136824~43138334:-
BRCA	cis	rs780096	0.546	rs1528533	ENSG00000234072.1	AC074117.10	-7.91	6.42e-15	1.94e-12	-0.23	-0.24	Total body bone mineral density;	chr2:27372889	chr2:27356246~27367622:+
BRCA	cis	rs7637701	0.517	rs3851992	ENSG00000243926.1	TIPARP-AS1	7.91	6.42e-15	1.94e-12	0.25	0.24	Breast cancer;	chr3:156681391	chr3:156671862~156674378:-
BRCA	cis	rs2274273	0.624	rs7151754	ENSG00000258413.1	RP11-665C16.6	-7.91	6.43e-15	1.94e-12	-0.32	-0.24	Protein biomarker;	chr14:55321783	chr14:55262767~55272075:-
BRCA	cis	rs1075265	0.636	rs2193683	ENSG00000233266.1	HMGB1P31	7.91	6.44e-15	1.95e-12	0.3	0.24	Chronotype;Morning vs. evening chronotype;	chr2:53695319	chr2:54051334~54051760:+
BRCA	cis	rs875971	0.666	rs13242072	ENSG00000224316.1	RP11-479O9.2	-7.91	6.45e-15	1.95e-12	-0.24	-0.24	Aortic root size;	chr7:66301001	chr7:65773620~65802067:+
BRCA	cis	rs11098499	0.954	rs9993199	ENSG00000248280.1	RP11-33B1.2	-7.91	6.45e-15	1.95e-12	-0.24	-0.24	Corneal astigmatism;	chr4:119471718	chr4:119440561~119450157:-
BRCA	cis	rs3758911	1	rs11212153	ENSG00000255353.1	RP11-382M14.1	-7.91	6.45e-15	1.95e-12	-0.31	-0.24	Coronary artery disease;	chr11:107319234	chr11:107176286~107177530:+
BRCA	cis	rs2842992	0.83	rs2758320	ENSG00000237927.1	RP3-393E18.2	-7.91	6.46e-15	1.95e-12	-0.34	-0.24	Age-related macular degeneration (geographic atrophy);	chr6:159649644	chr6:159586955~159589169:-
BRCA	cis	rs1113500	0.805	rs11185244	ENSG00000226822.1	RP11-356N1.2	7.91	6.48e-15	1.96e-12	0.31	0.24	Growth-regulated protein alpha levels;	chr1:108058525	chr1:108071482~108074519:+
BRCA	cis	rs1113500	0.814	rs1592282	ENSG00000226822.1	RP11-356N1.2	7.91	6.48e-15	1.96e-12	0.31	0.24	Growth-regulated protein alpha levels;	chr1:108058743	chr1:108071482~108074519:+
BRCA	cis	rs10463554	0.889	rs34822	ENSG00000175749.11	EIF3KP1	7.91	6.49e-15	1.96e-12	0.32	0.24	Parkinson's disease;	chr5:103102007	chr5:103032376~103033031:+
BRCA	cis	rs950880	0.645	rs11679889	ENSG00000234389.1	AC007278.3	-7.91	6.49e-15	1.96e-12	-0.25	-0.24	Serum protein levels (sST2);	chr2:102324549	chr2:102438713~102440475:+
BRCA	cis	rs875971	1	rs1544549	ENSG00000232559.3	GS1-124K5.12	-7.91	6.5e-15	1.96e-12	-0.29	-0.24	Aortic root size;	chr7:66625676	chr7:66554588~66576923:-
BRCA	cis	rs465969	0.793	rs34288099	ENSG00000255389.1	C6orf3	-7.91	6.5e-15	1.96e-12	-0.39	-0.24	Psoriasis;	chr6:111424034	chr6:111599875~111602295:+
BRCA	cis	rs8072100	0.701	rs10163469	ENSG00000228782.6	CTD-2026D20.3	-7.91	6.51e-15	1.97e-12	-0.26	-0.24	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47610401	chr17:47450568~47492492:-
BRCA	cis	rs12468226	0.606	rs79092351	ENSG00000273456.1	RP11-686O6.2	7.91	6.52e-15	1.97e-12	0.31	0.24	Urate levels;	chr2:202204388	chr2:202374932~202375604:-
BRCA	cis	rs9399135	0.517	rs1883354	ENSG00000232876.1	CTA-212D2.2	7.91	6.55e-15	1.98e-12	0.29	0.24	Red blood cell count;	chr6:135136403	chr6:135055033~135060550:+
BRCA	cis	rs2742234	0.554	rs1270015	ENSG00000273008.1	RP11-351D16.3	7.91	6.58e-15	1.99e-12	0.31	0.24	Hirschsprung disease;	chr10:43202792	chr10:43136824~43138334:-
BRCA	cis	rs6921919	0.848	rs56131013	ENSG00000204709.4	LINC01556	7.91	6.59e-15	1.99e-12	0.35	0.24	Autism spectrum disorder or schizophrenia;	chr6:28352900	chr6:28943877~28944537:+
BRCA	cis	rs867371	1	rs7166570	ENSG00000255769.6	GOLGA2P10	-7.91	6.59e-15	1.99e-12	-0.27	-0.24	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82173880	chr15:82472993~82513950:-
BRCA	cis	rs638893	0.528	rs521910	ENSG00000278376.1	RP11-158I9.8	7.91	6.61e-15	2e-12	0.31	0.24	Vitiligo;	chr11:118739920	chr11:118791254~118793137:+
BRCA	cis	rs2274273	0.588	rs7158791	ENSG00000258413.1	RP11-665C16.6	-7.91	6.64e-15	2e-12	-0.32	-0.24	Protein biomarker;	chr14:55361889	chr14:55262767~55272075:-
BRCA	cis	rs9880211	1	rs9883189	ENSG00000273486.1	RP11-731C17.2	7.91	6.64e-15	2e-12	0.32	0.24	Height;Body mass index;	chr3:136570624	chr3:136837338~136839021:-
BRCA	cis	rs10028773	0.6	rs4001390	ENSG00000248280.1	RP11-33B1.2	7.91	6.65e-15	2.01e-12	0.23	0.24	Educational attainment;	chr4:119344628	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.691	rs2136911	ENSG00000248280.1	RP11-33B1.2	7.91	6.65e-15	2.01e-12	0.23	0.24	Corneal astigmatism;	chr4:119344704	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.779	rs6815934	ENSG00000248280.1	RP11-33B1.2	7.91	6.65e-15	2.01e-12	0.23	0.24	Corneal astigmatism;	chr4:119346155	chr4:119440561~119450157:-
BRCA	cis	rs10028773	0.568	rs6838457	ENSG00000248280.1	RP11-33B1.2	7.91	6.65e-15	2.01e-12	0.23	0.24	Educational attainment;	chr4:119346212	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.535	rs10005542	ENSG00000248280.1	RP11-33B1.2	7.91	6.65e-15	2.01e-12	0.23	0.24	Corneal astigmatism;	chr4:119347147	chr4:119440561~119450157:-
BRCA	cis	rs4820294	1	rs62236667	ENSG00000233360.4	Z83844.1	7.91	6.66e-15	2.01e-12	0.29	0.24	Fat distribution (HIV);	chr22:37665513	chr22:37641832~37658377:-
BRCA	cis	rs2439831	0.85	rs61390361	ENSG00000205771.5	CATSPER2P1	-7.91	6.67e-15	2.01e-12	-0.41	-0.24	Lung cancer in ever smokers;	chr15:43867644	chr15:43726918~43747094:-
BRCA	cis	rs4835473	0.868	rs7683365	ENSG00000251600.4	RP11-673E1.1	-7.91	6.67e-15	2.01e-12	-0.29	-0.24	Immature fraction of reticulocytes;	chr4:143999443	chr4:143912331~143982454:+
BRCA	cis	rs867371	1	rs8041924	ENSG00000255769.6	GOLGA2P10	-7.91	6.71e-15	2.02e-12	-0.27	-0.24	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82181320	chr15:82472993~82513950:-
BRCA	cis	rs2274273	0.624	rs7140628	ENSG00000258413.1	RP11-665C16.6	-7.91	6.74e-15	2.03e-12	-0.32	-0.24	Protein biomarker;	chr14:55293963	chr14:55262767~55272075:-
BRCA	cis	rs6545883	0.929	rs6705235	ENSG00000271889.1	RP11-493E12.1	7.91	6.76e-15	2.04e-12	0.3	0.24	Tuberculosis;	chr2:61486445	chr2:61151433~61162105:-
BRCA	cis	rs10129255	0.536	rs10142951	ENSG00000280411.1	IGHV1-69-2	-7.91	6.77e-15	2.04e-12	-0.16	-0.24	Kawasaki disease;	chr14:106782337	chr14:106762092~106762588:-
BRCA	cis	rs11098499	0.82	rs11737395	ENSG00000248280.1	RP11-33B1.2	7.91	6.77e-15	2.04e-12	0.25	0.24	Corneal astigmatism;	chr4:119599549	chr4:119440561~119450157:-
BRCA	cis	rs6539288	0.933	rs10861673	ENSG00000260329.1	RP11-412D9.4	-7.91	6.78e-15	2.04e-12	-0.27	-0.24	Total body bone mineral density;	chr12:106906293	chr12:106954029~106955497:-
BRCA	cis	rs113835537	0.529	rs3741360	ENSG00000255517.5	CTD-3074O7.5	-7.9	6.81e-15	2.05e-12	-0.31	-0.24	Airway imaging phenotypes;	chr11:66532877	chr11:66473490~66480233:-
BRCA	cis	rs1113500	0.787	rs4571989	ENSG00000226822.1	RP11-356N1.2	7.9	6.81e-15	2.05e-12	0.3	0.24	Growth-regulated protein alpha levels;	chr1:108088722	chr1:108071482~108074519:+
BRCA	cis	rs10463554	1	rs11949145	ENSG00000175749.11	EIF3KP1	7.9	6.86e-15	2.07e-12	0.32	0.24	Parkinson's disease;	chr5:102994552	chr5:103032376~103033031:+
BRCA	cis	rs3758911	0.828	rs11212141	ENSG00000255353.1	RP11-382M14.1	-7.9	6.86e-15	2.07e-12	-0.33	-0.24	Coronary artery disease;	chr11:107298200	chr11:107176286~107177530:+
BRCA	cis	rs61270009	0.955	rs11748768	ENSG00000247828.6	TMEM161B-AS1	7.9	6.86e-15	2.07e-12	0.3	0.24	Depressive symptoms;	chr5:88354818	chr5:88268895~88436685:+
BRCA	cis	rs61270009	0.955	rs11750391	ENSG00000247828.6	TMEM161B-AS1	7.9	6.86e-15	2.07e-12	0.3	0.24	Depressive symptoms;	chr5:88356255	chr5:88268895~88436685:+
BRCA	cis	rs7085104	0.66	rs3781286	ENSG00000236937.2	PTGES3P4	7.9	6.88e-15	2.07e-12	0.3	0.24	Immature fraction of reticulocytes;Schizophrenia;	chr10:102835962	chr10:102845595~102845950:+
BRCA	cis	rs7811142	0.779	rs28680963	ENSG00000242294.5	STAG3L5P	7.9	6.88e-15	2.07e-12	0.24	0.24	Platelet count;	chr7:100307852	chr7:100336079~100351900:+
BRCA	cis	rs2274273	0.624	rs4580079	ENSG00000258413.1	RP11-665C16.6	-7.9	6.9e-15	2.08e-12	-0.32	-0.24	Protein biomarker;	chr14:55313648	chr14:55262767~55272075:-
BRCA	cis	rs9880211	0.898	rs9866840	ENSG00000273486.1	RP11-731C17.2	7.9	6.91e-15	2.08e-12	0.31	0.24	Height;Body mass index;	chr3:136310416	chr3:136837338~136839021:-
BRCA	cis	rs11098499	0.863	rs7669520	ENSG00000248280.1	RP11-33B1.2	7.9	6.92e-15	2.09e-12	0.25	0.24	Corneal astigmatism;	chr4:119594123	chr4:119440561~119450157:-
BRCA	cis	rs10463554	0.824	rs34818	ENSG00000175749.11	EIF3KP1	7.9	6.93e-15	2.09e-12	0.33	0.24	Parkinson's disease;	chr5:103100407	chr5:103032376~103033031:+
BRCA	cis	rs9880211	0.948	rs6806123	ENSG00000239213.4	NCK1-AS1	7.9	6.94e-15	2.09e-12	0.32	0.24	Height;Body mass index;	chr3:136586634	chr3:136841726~136862054:-
BRCA	cis	rs1609391	0.561	rs9289523	ENSG00000273486.1	RP11-731C17.2	7.9	6.94e-15	2.09e-12	0.26	0.24	Neuroticism;	chr3:136916747	chr3:136837338~136839021:-
BRCA	cis	rs4403732	1	rs4237333	ENSG00000230526.1	RP11-472G21.2	7.9	6.97e-15	2.1e-12	0.35	0.24	Coronary artery disease;	chr10:71877468	chr10:71878356~71879107:+
BRCA	cis	rs3758911	1	rs1046094	ENSG00000255353.1	RP11-382M14.1	-7.9	6.98e-15	2.1e-12	-0.31	-0.24	Coronary artery disease;	chr11:107326530	chr11:107176286~107177530:+
BRCA	cis	rs9880211	0.8	rs34324561	ENSG00000239213.4	NCK1-AS1	7.9	6.98e-15	2.1e-12	0.31	0.24	Height;Body mass index;	chr3:136382400	chr3:136841726~136862054:-
BRCA	cis	rs867371	0.929	rs7176075	ENSG00000259429.4	UBE2Q2P2	-7.9	7e-15	2.11e-12	-0.23	-0.24	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82178998	chr15:82355142~82420075:+
BRCA	cis	rs6545883	0.791	rs4672445	ENSG00000271889.1	RP11-493E12.1	-7.9	7e-15	2.11e-12	-0.31	-0.24	Tuberculosis;	chr2:61427873	chr2:61151433~61162105:-
BRCA	cis	rs8072100	0.967	rs4793842	ENSG00000228782.6	CTD-2026D20.3	-7.9	7.01e-15	2.11e-12	-0.26	-0.24	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47594140	chr17:47450568~47492492:-
BRCA	cis	rs8072100	0.967	rs8075411	ENSG00000228782.6	CTD-2026D20.3	-7.9	7.01e-15	2.11e-12	-0.26	-0.24	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47599394	chr17:47450568~47492492:-
BRCA	cis	rs6558530	0.626	rs6558524	ENSG00000253982.1	CTD-2336O2.1	7.9	7.03e-15	2.12e-12	0.29	0.24	Systolic blood pressure;	chr8:1754346	chr8:1761990~1764502:-
BRCA	cis	rs6558530	0.692	rs6558525	ENSG00000253982.1	CTD-2336O2.1	7.9	7.03e-15	2.12e-12	0.29	0.24	Systolic blood pressure;	chr8:1754357	chr8:1761990~1764502:-
BRCA	cis	rs3758911	1	rs10789617	ENSG00000255353.1	RP11-382M14.1	-7.9	7.04e-15	2.12e-12	-0.31	-0.24	Coronary artery disease;	chr11:107318968	chr11:107176286~107177530:+
BRCA	cis	rs10129255	0.957	rs8009073	ENSG00000211972.2	IGHV3-66	7.9	7.04e-15	2.12e-12	0.18	0.24	Kawasaki disease;	chr14:106777278	chr14:106675017~106675544:-
BRCA	cis	rs2742234	0.59	rs2505553	ENSG00000273008.1	RP11-351D16.3	-7.9	7.05e-15	2.12e-12	-0.3	-0.24	Hirschsprung disease;	chr10:43185803	chr10:43136824~43138334:-
BRCA	cis	rs7809950	0.953	rs28687365	ENSG00000238832.1	snoU109	-7.9	7.06e-15	2.12e-12	-0.31	-0.24	Coronary artery disease;	chr7:107466267	chr7:107603363~107603507:+
BRCA	cis	rs6142102	0.961	rs4911411	ENSG00000276073.1	RP5-1125A11.7	-7.9	7.06e-15	2.12e-12	-0.28	-0.24	Skin pigmentation;	chr20:34128036	chr20:33985617~33988989:-
BRCA	cis	rs17482078	0.885	rs10045403	ENSG00000248734.2	CTD-2260A17.1	7.9	7.07e-15	2.13e-12	0.31	0.24	Behcet's disease;Blood protein levels;	chr5:96812030	chr5:96784777~96785999:+
BRCA	cis	rs73173548	0.502	rs6865693	ENSG00000247828.6	TMEM161B-AS1	7.9	7.07e-15	2.13e-12	0.31	0.24	Macular telangiectasia type 2;	chr5:88419422	chr5:88268895~88436685:+
BRCA	cis	rs4835473	0.897	rs2590034	ENSG00000251600.4	RP11-673E1.1	7.9	7.11e-15	2.14e-12	0.28	0.24	Immature fraction of reticulocytes;	chr4:143926778	chr4:143912331~143982454:+
BRCA	cis	rs812925	0.859	rs2593624	ENSG00000271889.1	RP11-493E12.1	-7.9	7.11e-15	2.14e-12	-0.31	-0.24	Immature fraction of reticulocytes;	chr2:61325349	chr2:61151433~61162105:-
BRCA	cis	rs2243480	1	rs67536397	ENSG00000273142.1	RP11-458F8.4	-7.9	7.12e-15	2.14e-12	-0.33	-0.24	Diabetic kidney disease;	chr7:66482930	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs58669269	ENSG00000273142.1	RP11-458F8.4	-7.9	7.12e-15	2.14e-12	-0.33	-0.24	Diabetic kidney disease;	chr7:66486966	chr7:66902857~66906297:+
BRCA	cis	rs77204473	1	rs17120132	ENSG00000254851.1	RP11-109L13.1	7.9	7.12e-15	2.14e-12	0.55	0.24	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116902602	chr11:117135528~117138582:+
BRCA	cis	rs77204473	1	rs17120136	ENSG00000254851.1	RP11-109L13.1	7.9	7.12e-15	2.14e-12	0.55	0.24	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116903045	chr11:117135528~117138582:+
BRCA	cis	rs77204473	1	rs78694306	ENSG00000254851.1	RP11-109L13.1	7.9	7.12e-15	2.14e-12	0.55	0.24	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116903528	chr11:117135528~117138582:+
BRCA	cis	rs77204473	1	rs115971514	ENSG00000254851.1	RP11-109L13.1	7.9	7.12e-15	2.14e-12	0.55	0.24	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116903783	chr11:117135528~117138582:+
BRCA	cis	rs77204473	1	rs12280030	ENSG00000254851.1	RP11-109L13.1	7.9	7.12e-15	2.14e-12	0.55	0.24	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116904480	chr11:117135528~117138582:+
BRCA	cis	rs6545883	0.862	rs11691734	ENSG00000271889.1	RP11-493E12.1	7.9	7.12e-15	2.14e-12	0.31	0.24	Tuberculosis;	chr2:61475331	chr2:61151433~61162105:-
BRCA	cis	rs6142102	0.962	rs2206448	ENSG00000276073.1	RP5-1125A11.7	-7.9	7.13e-15	2.14e-12	-0.28	-0.24	Skin pigmentation;	chr20:34121719	chr20:33985617~33988989:-
BRCA	cis	rs11159086	1	rs3759745	ENSG00000259005.1	RP3-449M8.6	7.9	7.15e-15	2.15e-12	0.37	0.24	Advanced glycation end-product levels;	chr14:74495967	chr14:74474007~74474864:-
BRCA	cis	rs867371	1	rs2088858	ENSG00000259429.4	UBE2Q2P2	-7.9	7.16e-15	2.15e-12	-0.23	-0.24	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82182408	chr15:82355142~82420075:+
BRCA	cis	rs867371	1	rs4778982	ENSG00000259429.4	UBE2Q2P2	-7.9	7.16e-15	2.15e-12	-0.23	-0.24	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82182931	chr15:82355142~82420075:+
BRCA	cis	rs867371	1	rs2867579	ENSG00000259429.4	UBE2Q2P2	-7.9	7.16e-15	2.15e-12	-0.23	-0.24	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82183043	chr15:82355142~82420075:+
BRCA	cis	rs867371	1	rs881308	ENSG00000259429.4	UBE2Q2P2	-7.9	7.16e-15	2.15e-12	-0.23	-0.24	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82183456	chr15:82355142~82420075:+
BRCA	cis	rs6539288	0.901	rs4964193	ENSG00000260329.1	RP11-412D9.4	-7.9	7.17e-15	2.16e-12	-0.27	-0.24	Total body bone mineral density;	chr12:106927970	chr12:106954029~106955497:-
BRCA	cis	rs7927771	1	rs4752857	ENSG00000280615.1	Y_RNA	-7.9	7.21e-15	2.17e-12	-0.3	-0.24	Subjective well-being;	chr11:47634200	chr11:47614898~47614994:-
BRCA	cis	rs950776	0.684	rs692780	ENSG00000261762.1	RP11-650L12.2	-7.9	7.21e-15	2.17e-12	-0.27	-0.24	Sudden cardiac arrest;	chr15:78584163	chr15:78589123~78591276:-
BRCA	cis	rs3758911	0.861	rs10789621	ENSG00000255353.1	RP11-382M14.1	7.9	7.22e-15	2.17e-12	0.31	0.24	Coronary artery disease;	chr11:107388345	chr11:107176286~107177530:+
BRCA	cis	rs17428076	0.514	rs3821095	ENSG00000228389.1	AC068039.4	7.9	7.22e-15	2.17e-12	0.29	0.24	Myopia;	chr2:171827496	chr2:171773482~171775844:+
BRCA	cis	rs10463554	0.963	rs34829	ENSG00000175749.11	EIF3KP1	7.9	7.22e-15	2.17e-12	0.32	0.24	Parkinson's disease;	chr5:103108260	chr5:103032376~103033031:+
BRCA	cis	rs193541	0.632	rs7729834	ENSG00000263432.2	RN7SL689P	7.9	7.25e-15	2.18e-12	0.32	0.24	Glucose homeostasis traits;	chr5:122786464	chr5:123022487~123022783:-
BRCA	cis	rs2274273	0.624	rs7157308	ENSG00000258413.1	RP11-665C16.6	-7.9	7.25e-15	2.18e-12	-0.32	-0.24	Protein biomarker;	chr14:55315325	chr14:55262767~55272075:-
BRCA	cis	rs6545883	0.894	rs6760075	ENSG00000271889.1	RP11-493E12.1	-7.9	7.27e-15	2.18e-12	-0.31	-0.24	Tuberculosis;	chr2:61385746	chr2:61151433~61162105:-
BRCA	cis	rs10800713	0.908	rs6686605	ENSG00000260088.1	RP11-92G12.3	-7.89	7.33e-15	2.2e-12	-0.33	-0.24	Tandem gait;	chr1:200539440	chr1:200669507~200694250:+
BRCA	cis	rs2028299	0.879	rs8034631	ENSG00000259677.1	RP11-493E3.1	7.89	7.33e-15	2.2e-12	0.31	0.24	Type 2 diabetes;	chr15:89879433	chr15:89876540~89877285:+
BRCA	cis	rs2439831	0.85	rs28524541	ENSG00000275601.1	AC011330.13	-7.89	7.35e-15	2.21e-12	-0.38	-0.24	Lung cancer in ever smokers;	chr15:43832633	chr15:43642389~43643023:-
BRCA	cis	rs7674212	0.507	rs223471	ENSG00000251288.2	RP11-10L12.2	-7.89	7.37e-15	2.21e-12	-0.29	-0.24	Type 2 diabetes;	chr4:102777629	chr4:102751401~102752641:+
BRCA	cis	rs3758911	1	rs10789615	ENSG00000255353.1	RP11-382M14.1	-7.89	7.38e-15	2.22e-12	-0.31	-0.24	Coronary artery disease;	chr11:107318088	chr11:107176286~107177530:+
BRCA	cis	rs56804039	1	rs58361948	ENSG00000253893.2	FAM85B	7.89	7.38e-15	2.22e-12	0.36	0.24	Cervical cancer;	chr8:8523485	chr8:8167819~8226614:-
BRCA	cis	rs6142102	0.778	rs6059581	ENSG00000276073.1	RP5-1125A11.7	-7.89	7.41e-15	2.23e-12	-0.29	-0.24	Skin pigmentation;	chr20:33940582	chr20:33985617~33988989:-
BRCA	cis	rs11098499	0.605	rs6833140	ENSG00000248280.1	RP11-33B1.2	7.89	7.43e-15	2.23e-12	0.23	0.24	Corneal astigmatism;	chr4:119345667	chr4:119440561~119450157:-
BRCA	cis	rs4663866	0.505	rs3739064	ENSG00000186235.9	AC016757.3	7.89	7.45e-15	2.24e-12	0.36	0.24	Irritable bowel syndrome;	chr2:238267745	chr2:238224552~238231677:-
BRCA	cis	rs10463554	0.963	rs34774	ENSG00000175749.11	EIF3KP1	7.89	7.45e-15	2.24e-12	0.33	0.24	Parkinson's disease;	chr5:103115116	chr5:103032376~103033031:+
BRCA	cis	rs4934494	0.727	rs67827533	ENSG00000240996.1	RP11-80H5.7	-7.89	7.49e-15	2.25e-12	-0.3	-0.24	Red blood cell count;	chr10:89745626	chr10:89694295~89697928:-
BRCA	cis	rs11098499	0.661	rs10015965	ENSG00000248280.1	RP11-33B1.2	7.89	7.49e-15	2.25e-12	0.23	0.24	Corneal astigmatism;	chr4:119347082	chr4:119440561~119450157:-
BRCA	cis	rs77204473	1	rs12273762	ENSG00000254851.1	RP11-109L13.1	7.89	7.51e-15	2.25e-12	0.55	0.24	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116906347	chr11:117135528~117138582:+
BRCA	cis	rs77204473	1	rs9651681	ENSG00000254851.1	RP11-109L13.1	7.89	7.51e-15	2.25e-12	0.55	0.24	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116907349	chr11:117135528~117138582:+
BRCA	cis	rs875971	0.545	rs10950029	ENSG00000224316.1	RP11-479O9.2	7.89	7.52e-15	2.26e-12	0.27	0.24	Aortic root size;	chr7:66169334	chr7:65773620~65802067:+
BRCA	cis	rs6545883	0.894	rs7572603	ENSG00000271889.1	RP11-493E12.1	-7.89	7.52e-15	2.26e-12	-0.3	-0.24	Tuberculosis;	chr2:61325010	chr2:61151433~61162105:-
BRCA	cis	rs61270009	0.955	rs410354	ENSG00000247828.6	TMEM161B-AS1	-7.89	7.52e-15	2.26e-12	-0.3	-0.24	Depressive symptoms;	chr5:88254467	chr5:88268895~88436685:+
BRCA	cis	rs61270009	0.955	rs780404	ENSG00000247828.6	TMEM161B-AS1	-7.89	7.52e-15	2.26e-12	-0.3	-0.24	Depressive symptoms;	chr5:88256675	chr5:88268895~88436685:+
BRCA	cis	rs61270009	0.955	rs375514	ENSG00000247828.6	TMEM161B-AS1	-7.89	7.52e-15	2.26e-12	-0.3	-0.24	Depressive symptoms;	chr5:88259477	chr5:88268895~88436685:+
BRCA	cis	rs6142102	0.886	rs6059583	ENSG00000276073.1	RP5-1125A11.7	-7.89	7.53e-15	2.26e-12	-0.3	-0.24	Skin pigmentation;	chr20:33944308	chr20:33985617~33988989:-
BRCA	cis	rs4835473	0.932	rs35017645	ENSG00000251600.4	RP11-673E1.1	-7.89	7.54e-15	2.26e-12	-0.3	-0.24	Immature fraction of reticulocytes;	chr4:143760196	chr4:143912331~143982454:+
BRCA	cis	rs10246939	0.579	rs17133534	ENSG00000228775.6	WEE2-AS1	7.89	7.54e-15	2.26e-12	0.26	0.24	Bitter taste perception;	chr7:141860855	chr7:141704338~141738346:-
BRCA	cis	rs11971779	0.838	rs58074268	ENSG00000273391.1	RP11-634H22.1	7.89	7.55e-15	2.27e-12	0.25	0.24	Diisocyanate-induced asthma;	chr7:139424179	chr7:139359032~139359566:-
BRCA	cis	rs4927850	0.752	rs7618864	ENSG00000242086.7	LINC00969	7.89	7.56e-15	2.27e-12	0.26	0.24	Pancreatic cancer;	chr3:196022690	chr3:195658062~195739964:+
BRCA	cis	rs950880	0.71	rs3771177	ENSG00000234389.1	AC007278.3	-7.89	7.57e-15	2.27e-12	-0.25	-0.24	Serum protein levels (sST2);	chr2:102339400	chr2:102438713~102440475:+
BRCA	cis	rs10129255	0.957	rs10132367	ENSG00000211972.2	IGHV3-66	7.89	7.58e-15	2.27e-12	0.19	0.24	Kawasaki disease;	chr14:106690981	chr14:106675017~106675544:-
BRCA	cis	rs2274273	0.624	rs67386901	ENSG00000258413.1	RP11-665C16.6	-7.89	7.58e-15	2.27e-12	-0.31	-0.24	Protein biomarker;	chr14:55290646	chr14:55262767~55272075:-
BRCA	cis	rs4835473	0.932	rs62337619	ENSG00000251600.4	RP11-673E1.1	-7.89	7.58e-15	2.27e-12	-0.3	-0.24	Immature fraction of reticulocytes;	chr4:143742083	chr4:143912331~143982454:+
BRCA	cis	rs10463554	0.963	rs34771	ENSG00000175749.11	EIF3KP1	7.89	7.63e-15	2.29e-12	0.33	0.24	Parkinson's disease;	chr5:103114713	chr5:103032376~103033031:+
BRCA	cis	rs875971	0.545	rs67397473	ENSG00000224316.1	RP11-479O9.2	7.89	7.64e-15	2.29e-12	0.27	0.24	Aortic root size;	chr7:66168318	chr7:65773620~65802067:+
BRCA	cis	rs950880	0.668	rs3732126	ENSG00000234389.1	AC007278.3	-7.89	7.66e-15	2.3e-12	-0.25	-0.24	Serum protein levels (sST2);	chr2:102397502	chr2:102438713~102440475:+
BRCA	cis	rs950880	0.71	rs3732125	ENSG00000234389.1	AC007278.3	-7.89	7.66e-15	2.3e-12	-0.25	-0.24	Serum protein levels (sST2);	chr2:102397503	chr2:102438713~102440475:+
BRCA	cis	rs4934494	0.723	rs17127001	ENSG00000240996.1	RP11-80H5.7	-7.89	7.66e-15	2.3e-12	-0.3	-0.24	Red blood cell count;	chr10:89762932	chr10:89694295~89697928:-
BRCA	cis	rs858239	0.6	rs2014768	ENSG00000230042.1	AK3P3	-7.89	7.71e-15	2.31e-12	-0.27	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23082821	chr7:23129178~23129841:+
BRCA	cis	rs858239	0.6	rs6978827	ENSG00000230042.1	AK3P3	-7.89	7.71e-15	2.31e-12	-0.27	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23085925	chr7:23129178~23129841:+
BRCA	cis	rs858239	0.6	rs6960001	ENSG00000230042.1	AK3P3	-7.89	7.71e-15	2.31e-12	-0.27	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23091257	chr7:23129178~23129841:+
BRCA	cis	rs858239	0.6	rs10237755	ENSG00000230042.1	AK3P3	-7.89	7.71e-15	2.31e-12	-0.27	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23091945	chr7:23129178~23129841:+
BRCA	cis	rs30380	0.688	rs27524	ENSG00000272109.1	CTD-2260A17.3	-7.89	7.71e-15	2.31e-12	-0.3	-0.24	Cerebrospinal fluid biomarker levels;	chr5:96766240	chr5:96804353~96806105:+
BRCA	cis	rs61270009	0.955	rs377958	ENSG00000247828.6	TMEM161B-AS1	-7.89	7.74e-15	2.32e-12	-0.3	-0.24	Depressive symptoms;	chr5:88267571	chr5:88268895~88436685:+
BRCA	cis	rs61270009	0.913	rs402114	ENSG00000247828.6	TMEM161B-AS1	-7.89	7.74e-15	2.32e-12	-0.3	-0.24	Depressive symptoms;	chr5:88268106	chr5:88268895~88436685:+
BRCA	cis	rs293748	0.882	rs158793	ENSG00000250155.1	CTD-2353F22.1	-7.89	7.78e-15	2.33e-12	-0.34	-0.24	Obesity-related traits;	chr5:36884988	chr5:36666214~36725195:-
BRCA	cis	rs1061377	1	rs13109200	ENSG00000249685.1	RP11-360F5.3	7.89	7.79e-15	2.33e-12	0.29	0.24	Uric acid levels;	chr4:39124396	chr4:39133913~39135608:+
BRCA	cis	rs1061377	1	rs13144374	ENSG00000249685.1	RP11-360F5.3	7.89	7.79e-15	2.33e-12	0.29	0.24	Uric acid levels;	chr4:39128859	chr4:39133913~39135608:+
BRCA	cis	rs4820294	1	rs62236665	ENSG00000233360.4	Z83844.1	7.89	7.79e-15	2.33e-12	0.29	0.24	Fat distribution (HIV);	chr22:37663840	chr22:37641832~37658377:-
BRCA	cis	rs867371	1	rs1392976	ENSG00000259429.4	UBE2Q2P2	7.89	7.81e-15	2.34e-12	0.23	0.24	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82153834	chr15:82355142~82420075:+
BRCA	cis	rs2976388	0.609	rs2717550	ENSG00000253741.1	CTD-2292P10.4	-7.89	7.84e-15	2.35e-12	-0.26	-0.24	Urinary tract infection frequency;	chr8:142706390	chr8:142702252~142726973:-
BRCA	cis	rs10129255	0.5	rs10131875	ENSG00000211972.2	IGHV3-66	7.89	7.84e-15	2.35e-12	0.16	0.24	Kawasaki disease;	chr14:106792798	chr14:106675017~106675544:-
BRCA	cis	rs58873874	0.522	rs111370613	ENSG00000251405.2	CTB-109A12.1	7.89	7.84e-15	2.35e-12	0.54	0.24	Bipolar disorder (body mass index interaction);	chr5:157271128	chr5:157362615~157460078:-
BRCA	cis	rs62246343	0.564	rs17050383	ENSG00000206573.7	THUMPD3-AS1	-7.89	7.85e-15	2.35e-12	-0.27	-0.24	Fibrinogen levels;	chr3:9472896	chr3:9349689~9398579:-
BRCA	cis	rs2439831	0.85	rs9944216	ENSG00000275601.1	AC011330.13	7.89	7.86e-15	2.35e-12	0.37	0.24	Lung cancer in ever smokers;	chr15:43868575	chr15:43642389~43643023:-
BRCA	cis	rs1113500	0.787	rs12047429	ENSG00000226822.1	RP11-356N1.2	7.89	7.86e-15	2.36e-12	0.3	0.24	Growth-regulated protein alpha levels;	chr1:108090617	chr1:108071482~108074519:+
BRCA	cis	rs7712401	0.511	rs30068	ENSG00000263432.2	RN7SL689P	7.89	7.88e-15	2.36e-12	0.29	0.24	Mean platelet volume;	chr5:122957914	chr5:123022487~123022783:-
BRCA	cis	rs10800713	0.954	rs4504918	ENSG00000260088.1	RP11-92G12.3	7.88	7.91e-15	2.37e-12	0.34	0.24	Tandem gait;	chr1:200588639	chr1:200669507~200694250:+
BRCA	cis	rs875971	0.83	rs6950137	ENSG00000232559.3	GS1-124K5.12	7.88	7.92e-15	2.37e-12	0.29	0.24	Aortic root size;	chr7:66511623	chr7:66554588~66576923:-
BRCA	cis	rs2976388	0.609	rs1594999	ENSG00000253741.1	CTD-2292P10.4	-7.88	7.95e-15	2.38e-12	-0.26	-0.24	Urinary tract infection frequency;	chr8:142709156	chr8:142702252~142726973:-
BRCA	cis	rs2976388	0.609	rs2263092	ENSG00000253741.1	CTD-2292P10.4	-7.88	8.01e-15	2.4e-12	-0.26	-0.24	Urinary tract infection frequency;	chr8:142708548	chr8:142702252~142726973:-
BRCA	cis	rs293748	0.713	rs158789	ENSG00000250155.1	CTD-2353F22.1	-7.88	8.01e-15	2.4e-12	-0.33	-0.24	Obesity-related traits;	chr5:36834955	chr5:36666214~36725195:-
BRCA	cis	rs10463554	0.963	rs40093	ENSG00000175749.11	EIF3KP1	7.88	8.02e-15	2.4e-12	0.32	0.24	Parkinson's disease;	chr5:103104121	chr5:103032376~103033031:+
BRCA	cis	rs380904	0.517	rs11775744	ENSG00000254859.1	RP11-661A12.5	-7.88	8.02e-15	2.4e-12	-0.37	-0.24	Venous thromboembolism (SNP x SNP interaction);	chr8:143567022	chr8:143541973~143549729:-
BRCA	cis	rs875971	0.798	rs57739047	ENSG00000232559.3	GS1-124K5.12	7.88	8.02e-15	2.4e-12	0.29	0.24	Aortic root size;	chr7:66507579	chr7:66554588~66576923:-
BRCA	cis	rs7809950	0.953	rs2520267	ENSG00000238832.1	snoU109	-7.88	8.03e-15	2.4e-12	-0.31	-0.24	Coronary artery disease;	chr7:107547052	chr7:107603363~107603507:+
BRCA	cis	rs9880211	1	rs6774964	ENSG00000239213.4	NCK1-AS1	7.88	8.03e-15	2.4e-12	0.31	0.24	Height;Body mass index;	chr3:136556740	chr3:136841726~136862054:-
BRCA	cis	rs9880211	1	rs6775314	ENSG00000239213.4	NCK1-AS1	7.88	8.03e-15	2.4e-12	0.31	0.24	Height;Body mass index;	chr3:136557106	chr3:136841726~136862054:-
BRCA	cis	rs10129255	0.5	rs8004923	ENSG00000211972.2	IGHV3-66	7.88	8.06e-15	2.41e-12	0.16	0.24	Kawasaki disease;	chr14:106785926	chr14:106675017~106675544:-
BRCA	cis	rs10129255	0.5	rs59939897	ENSG00000280411.1	IGHV1-69-2	-7.88	8.12e-15	2.43e-12	-0.16	-0.24	Kawasaki disease;	chr14:106783414	chr14:106762092~106762588:-
BRCA	cis	rs7162943	0.708	rs293365	ENSG00000260123.1	RP11-326A19.4	-7.88	8.13e-15	2.43e-12	-0.27	-0.24	Mean platelet volume;	chr15:89070777	chr15:89041223~89082819:+
BRCA	cis	rs896854	0.738	rs1713669	ENSG00000253528.2	RP11-347C18.4	7.88	8.13e-15	2.43e-12	0.26	0.24	Type 2 diabetes;	chr8:94946409	chr8:94974573~94974853:-
BRCA	cis	rs2439831	0.85	rs12440573	ENSG00000205771.5	CATSPER2P1	-7.88	8.14e-15	2.44e-12	-0.42	-0.24	Lung cancer in ever smokers;	chr15:43816799	chr15:43726918~43747094:-
BRCA	cis	rs4845875	0.626	rs4845882	ENSG00000242349.4	NPPA-AS1	7.88	8.15e-15	2.44e-12	0.26	0.24	Midregional pro atrial natriuretic peptide levels;	chr1:11783110	chr1:11841017~11848079:+
BRCA	cis	rs58873874	0.579	rs11738062	ENSG00000251405.2	CTB-109A12.1	7.88	8.15e-15	2.44e-12	0.48	0.24	Bipolar disorder (body mass index interaction);	chr5:157358059	chr5:157362615~157460078:-
BRCA	cis	rs10129255	0.5	rs11628999	ENSG00000211972.2	IGHV3-66	7.88	8.19e-15	2.45e-12	0.16	0.24	Kawasaki disease;	chr14:106800208	chr14:106675017~106675544:-
BRCA	cis	rs904251	0.504	rs12202664	ENSG00000204110.6	RP1-153P14.8	-7.88	8.2e-15	2.45e-12	-0.26	-0.24	Cognitive performance;	chr6:37513422	chr6:37507348~37535616:+
BRCA	cis	rs9880211	1	rs4038586	ENSG00000239213.4	NCK1-AS1	7.88	8.2e-15	2.45e-12	0.31	0.24	Height;Body mass index;	chr3:136644449	chr3:136841726~136862054:-
BRCA	cis	rs9880211	1	rs6767889	ENSG00000239213.4	NCK1-AS1	7.88	8.2e-15	2.45e-12	0.31	0.24	Height;Body mass index;	chr3:136646613	chr3:136841726~136862054:-
BRCA	cis	rs58873874	1	rs75720504	ENSG00000248544.2	CTB-47B11.3	7.88	8.21e-15	2.46e-12	0.56	0.24	Bipolar disorder (body mass index interaction);	chr5:157508965	chr5:157375741~157384950:-
BRCA	cis	rs8028182	0.537	rs4371118	ENSG00000260269.4	CTD-2323K18.1	-7.88	8.22e-15	2.46e-12	-0.38	-0.24	Sudden cardiac arrest;	chr15:75606549	chr15:75527150~75601205:-
BRCA	cis	rs10129255	0.5	rs6576232	ENSG00000211972.2	IGHV3-66	7.88	8.25e-15	2.47e-12	0.16	0.24	Kawasaki disease;	chr14:106787090	chr14:106675017~106675544:-
BRCA	cis	rs6142102	0.517	rs6142046	ENSG00000275784.1	RP5-1125A11.6	-7.88	8.26e-15	2.47e-12	-0.27	-0.24	Skin pigmentation;	chr20:33926255	chr20:33989480~33991818:-
BRCA	cis	rs42648	0.869	rs1134956	ENSG00000225498.1	AC002064.5	7.88	8.27e-15	2.47e-12	0.23	0.24	Homocysteine levels;	chr7:90309366	chr7:90312496~90322592:+
BRCA	cis	rs3781264	0.595	rs6583937	ENSG00000273450.1	RP11-76P2.4	7.88	8.27e-15	2.47e-12	0.31	0.24	Esophageal cancer and gastric cancer;	chr10:94323695	chr10:94314907~94315327:-
BRCA	cis	rs7246657	1	rs12709812	ENSG00000276846.1	CTD-3220F14.3	-7.88	8.28e-15	2.47e-12	-0.33	-0.24	Coronary artery calcification;	chr19:37303948	chr19:37314868~37315620:-
BRCA	cis	rs2274273	0.588	rs58296156	ENSG00000258413.1	RP11-665C16.6	-7.88	8.31e-15	2.48e-12	-0.32	-0.24	Protein biomarker;	chr14:55361609	chr14:55262767~55272075:-
BRCA	cis	rs2274273	0.588	rs2297816	ENSG00000258413.1	RP11-665C16.6	-7.88	8.36e-15	2.5e-12	-0.31	-0.24	Protein biomarker;	chr14:55366320	chr14:55262767~55272075:-
BRCA	cis	rs10246939	0.553	rs34894166	ENSG00000228775.6	WEE2-AS1	7.88	8.37e-15	2.5e-12	0.26	0.24	Bitter taste perception;	chr7:141852158	chr7:141704338~141738346:-
BRCA	cis	rs10129255	0.5	rs6576231	ENSG00000280411.1	IGHV1-69-2	-7.88	8.38e-15	2.5e-12	-0.16	-0.24	Kawasaki disease;	chr14:106783693	chr14:106762092~106762588:-
BRCA	cis	rs875971	0.862	rs778702	ENSG00000232559.3	GS1-124K5.12	7.88	8.39e-15	2.51e-12	0.29	0.24	Aortic root size;	chr7:66399848	chr7:66554588~66576923:-
BRCA	cis	rs4266144	0.558	rs4680339	ENSG00000244515.1	KRT18P34	7.88	8.4e-15	2.51e-12	0.27	0.24	Coronary artery disease;	chr3:157117630	chr3:157162663~157163932:-
BRCA	cis	rs1061377	1	rs1061377	ENSG00000249685.1	RP11-360F5.3	7.88	8.46e-15	2.53e-12	0.29	0.24	Uric acid levels;	chr4:39123130	chr4:39133913~39135608:+
BRCA	cis	rs17264034	0.861	rs1508798	ENSG00000250786.1	SNHG18	-7.88	8.47e-15	2.53e-12	-0.32	-0.24	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9556582	chr5:9546200~9550609:+
BRCA	cis	rs4835473	0.932	rs7664248	ENSG00000251600.4	RP11-673E1.1	7.88	8.48e-15	2.53e-12	0.28	0.24	Immature fraction of reticulocytes;	chr4:143732554	chr4:143912331~143982454:+
BRCA	cis	rs1113500	0.814	rs893983	ENSG00000226822.1	RP11-356N1.2	-7.88	8.5e-15	2.54e-12	-0.3	-0.24	Growth-regulated protein alpha levels;	chr1:108087716	chr1:108071482~108074519:+
BRCA	cis	rs11976180	1	rs6464573	ENSG00000170356.8	OR2A20P	7.88	8.51e-15	2.54e-12	0.33	0.24	Obesity-related traits;	chr7:144051005	chr7:144250045~144252957:-
BRCA	cis	rs42648	0.869	rs42609	ENSG00000225498.1	AC002064.5	7.87	8.53e-15	2.55e-12	0.23	0.24	Homocysteine levels;	chr7:90320541	chr7:90312496~90322592:+
BRCA	cis	rs2274273	0.905	rs8007620	ENSG00000258413.1	RP11-665C16.6	-7.87	8.56e-15	2.56e-12	-0.3	-0.24	Protein biomarker;	chr14:55119869	chr14:55262767~55272075:-
BRCA	cis	rs9876781	1	rs9849509	ENSG00000244380.1	RP11-24C3.2	7.87	8.57e-15	2.56e-12	0.27	0.24	Longevity;	chr3:48442021	chr3:48440352~48446656:-
BRCA	cis	rs9876781	1	rs60512868	ENSG00000244380.1	RP11-24C3.2	7.87	8.57e-15	2.56e-12	0.27	0.24	Longevity;	chr3:48442035	chr3:48440352~48446656:-
BRCA	cis	rs7580658	0.68	rs6710535	ENSG00000236682.1	AC068282.3	7.87	8.58e-15	2.56e-12	0.33	0.24	Protein C levels;	chr2:127433384	chr2:127389130~127400580:+
BRCA	cis	rs7927771	1	rs11605774	ENSG00000280615.1	Y_RNA	-7.87	8.58e-15	2.56e-12	-0.3	-0.24	Subjective well-being;	chr11:47811241	chr11:47614898~47614994:-
BRCA	cis	rs4835473	0.897	rs11727223	ENSG00000251600.4	RP11-673E1.1	7.87	8.58e-15	2.56e-12	0.3	0.24	Immature fraction of reticulocytes;	chr4:143707090	chr4:143912331~143982454:+
BRCA	cis	rs10463554	0.963	rs187427	ENSG00000175749.11	EIF3KP1	7.87	8.59e-15	2.57e-12	0.33	0.24	Parkinson's disease;	chr5:103177102	chr5:103032376~103033031:+
BRCA	cis	rs74233809	1	rs11191555	ENSG00000213277.3	MARCKSL1P1	7.87	8.59e-15	2.57e-12	0.45	0.24	Birth weight;	chr10:103097766	chr10:103175554~103176094:+
BRCA	cis	rs74233809	1	rs11191557	ENSG00000213277.3	MARCKSL1P1	7.87	8.59e-15	2.57e-12	0.45	0.24	Birth weight;	chr10:103104857	chr10:103175554~103176094:+
BRCA	cis	rs74233809	1	rs11191558	ENSG00000213277.3	MARCKSL1P1	7.87	8.59e-15	2.57e-12	0.45	0.24	Birth weight;	chr10:103104921	chr10:103175554~103176094:+
BRCA	cis	rs13068223	0.792	rs344034	ENSG00000243926.1	TIPARP-AS1	-7.87	8.6e-15	2.57e-12	-0.25	-0.24	Age-related hearing impairment (SNP x SNP interaction);	chr3:156745215	chr3:156671862~156674378:-
BRCA	cis	rs950880	0.71	rs17026974	ENSG00000234389.1	AC007278.3	7.87	8.62e-15	2.57e-12	0.24	0.24	Serum protein levels (sST2);	chr2:102335900	chr2:102438713~102440475:+
BRCA	cis	rs9880211	1	rs28750366	ENSG00000239213.4	NCK1-AS1	7.87	8.65e-15	2.58e-12	0.31	0.24	Height;Body mass index;	chr3:136642213	chr3:136841726~136862054:-
BRCA	cis	rs62246343	0.605	rs17050395	ENSG00000206573.7	THUMPD3-AS1	-7.87	8.65e-15	2.58e-12	-0.24	-0.24	Fibrinogen levels;	chr3:9492290	chr3:9349689~9398579:-
BRCA	cis	rs293748	0.771	rs151945	ENSG00000250155.1	CTD-2353F22.1	-7.87	8.65e-15	2.58e-12	-0.33	-0.24	Obesity-related traits;	chr5:36838494	chr5:36666214~36725195:-
BRCA	cis	rs853679	1	rs853676	ENSG00000220721.1	OR1F12	7.87	8.65e-15	2.58e-12	0.37	0.24	Depression;	chr6:28331910	chr6:28073316~28074233:+
BRCA	cis	rs10129255	0.957	rs4387509	ENSG00000223648.3	IGHV3-64	7.87	8.65e-15	2.58e-12	0.21	0.24	Kawasaki disease;	chr14:106704386	chr14:106643132~106658258:-
BRCA	cis	rs2274273	0.588	rs7154831	ENSG00000258413.1	RP11-665C16.6	-7.87	8.65e-15	2.58e-12	-0.31	-0.24	Protein biomarker;	chr14:55357247	chr14:55262767~55272075:-
BRCA	cis	rs875971	0.651	rs2420596	ENSG00000232559.3	GS1-124K5.12	7.87	8.68e-15	2.59e-12	0.29	0.24	Aortic root size;	chr7:66450996	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.52	rs2420597	ENSG00000232559.3	GS1-124K5.12	7.87	8.68e-15	2.59e-12	0.29	0.24	Aortic root size;	chr7:66450999	chr7:66554588~66576923:-
BRCA	cis	rs9880211	0.948	rs13326151	ENSG00000239213.4	NCK1-AS1	7.87	8.69e-15	2.59e-12	0.31	0.24	Height;Body mass index;	chr3:136542902	chr3:136841726~136862054:-
BRCA	cis	rs8100891	0.922	rs7255223	ENSG00000267213.4	AC007773.2	7.87	8.71e-15	2.6e-12	0.28	0.24	Neuroticism;	chr19:32333404	chr19:32390050~32405560:-
BRCA	cis	rs7811142	1	rs67163493	ENSG00000242294.5	STAG3L5P	7.87	8.72e-15	2.6e-12	0.23	0.24	Platelet count;	chr7:100426215	chr7:100336079~100351900:+
BRCA	cis	rs526231	0.543	rs75913944	ENSG00000175749.11	EIF3KP1	7.87	8.75e-15	2.61e-12	0.34	0.24	Primary biliary cholangitis;	chr5:103143799	chr5:103032376~103033031:+
BRCA	cis	rs9880211	0.948	rs9844666	ENSG00000273486.1	RP11-731C17.2	7.87	8.76e-15	2.61e-12	0.32	0.24	Height;Body mass index;	chr3:136255374	chr3:136837338~136839021:-
BRCA	cis	rs7429990	0.864	rs1403579	ENSG00000229759.1	MRPS18AP1	7.87	8.76e-15	2.61e-12	0.28	0.24	Educational attainment (years of education);	chr3:47617889	chr3:48256350~48256938:-
BRCA	cis	rs11009175	0.556	rs2093345	ENSG00000273038.2	RP11-479G22.8	-7.87	8.8e-15	2.63e-12	-0.35	-0.24	Depression (quantitative trait);	chr10:33037255	chr10:32887255~32889311:-
BRCA	cis	rs10129255	0.5	rs34326748	ENSG00000280411.1	IGHV1-69-2	-7.87	8.81e-15	2.63e-12	-0.16	-0.24	Kawasaki disease;	chr14:106782523	chr14:106762092~106762588:-
BRCA	cis	rs10129255	0.5	rs10143385	ENSG00000280411.1	IGHV1-69-2	-7.87	8.81e-15	2.63e-12	-0.16	-0.24	Kawasaki disease;	chr14:106782559	chr14:106762092~106762588:-
BRCA	cis	rs3762637	1	rs7626861	ENSG00000272758.4	RP11-299J3.8	-7.87	8.82e-15	2.63e-12	-0.35	-0.24	LDL cholesterol levels;	chr3:122436349	chr3:122416207~122443180:+
BRCA	cis	rs3762637	1	rs9842736	ENSG00000272758.4	RP11-299J3.8	-7.87	8.82e-15	2.63e-12	-0.35	-0.24	LDL cholesterol levels;	chr3:122442254	chr3:122416207~122443180:+
BRCA	cis	rs9309711	0.772	rs9752251	ENSG00000225234.1	TRAPPC12-AS1	-7.87	8.83e-15	2.63e-12	-0.28	-0.24	Neurofibrillary tangles;	chr2:3486098	chr2:3481242~3482409:-
BRCA	cis	rs3814244	0.832	rs11177006	ENSG00000236946.2	HNRNPA1P70	-7.87	8.86e-15	2.64e-12	-0.2	-0.24	Itch intensity from mosquito bite adjusted by bite size;	chr12:68019317	chr12:68035767~68036853:+
BRCA	cis	rs10510102	0.872	rs7906271	ENSG00000276742.1	RP11-500G22.4	-7.87	8.88e-15	2.65e-12	-0.39	-0.24	Breast cancer;	chr10:121948207	chr10:121956782~121957098:+
BRCA	cis	rs3762637	1	rs78381804	ENSG00000272758.4	RP11-299J3.8	-7.87	8.89e-15	2.65e-12	-0.36	-0.24	LDL cholesterol levels;	chr3:122503415	chr3:122416207~122443180:+
BRCA	cis	rs3758911	1	rs10789619	ENSG00000255353.1	RP11-382M14.1	-7.87	8.9e-15	2.65e-12	-0.31	-0.24	Coronary artery disease;	chr11:107324570	chr11:107176286~107177530:+
BRCA	cis	rs3758911	0.964	rs11212157	ENSG00000255353.1	RP11-382M14.1	-7.87	8.9e-15	2.65e-12	-0.31	-0.24	Coronary artery disease;	chr11:107324572	chr11:107176286~107177530:+
BRCA	cis	rs13256369	1	rs7843488	ENSG00000253893.2	FAM85B	-7.87	8.9e-15	2.65e-12	-0.34	-0.24	Obesity-related traits;	chr8:8718707	chr8:8167819~8226614:-
BRCA	cis	rs7617773	0.817	rs936426	ENSG00000228638.1	FCF1P2	-7.87	8.92e-15	2.66e-12	-0.25	-0.24	Coronary artery disease;	chr3:48173763	chr3:48290793~48291375:-
BRCA	cis	rs853679	1	rs6905391	ENSG00000220721.1	OR1F12	7.87	8.93e-15	2.66e-12	0.37	0.24	Depression;	chr6:28294909	chr6:28073316~28074233:+
BRCA	cis	rs77204473	1	rs74881320	ENSG00000254851.1	RP11-109L13.1	7.87	8.95e-15	2.67e-12	0.56	0.24	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116895209	chr11:117135528~117138582:+
BRCA	cis	rs6545883	0.862	rs1880866	ENSG00000271889.1	RP11-493E12.1	7.87	8.96e-15	2.67e-12	0.31	0.24	Tuberculosis;	chr2:61471837	chr2:61151433~61162105:-
BRCA	cis	rs2712431	0.554	rs2010054	ENSG00000242551.2	POU5F1P6	-7.87	8.97e-15	2.67e-12	-0.29	-0.24	Monocyte chemoattractant protein-1 levels;	chr3:128586459	chr3:128674735~128677005:-
BRCA	cis	rs7621025	0.5	rs16844241	ENSG00000273486.1	RP11-731C17.2	-7.87	8.99e-15	2.68e-12	-0.32	-0.24	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136916329	chr3:136837338~136839021:-
BRCA	cis	rs1476670	0.565	rs2108201	ENSG00000230615.5	RP5-1198O20.4	-7.87	9.01e-15	2.69e-12	-0.32	-0.24	Eotaxin levels;	chr1:44049211	chr1:44030443~44115913:+
BRCA	cis	rs3758911	0.861	rs10789594	ENSG00000255353.1	RP11-382M14.1	-7.87	9.02e-15	2.69e-12	-0.32	-0.24	Coronary artery disease;	chr11:107290391	chr11:107176286~107177530:+
BRCA	cis	rs3758911	1	rs12146472	ENSG00000255353.1	RP11-382M14.1	-7.87	9.03e-15	2.69e-12	-0.31	-0.24	Coronary artery disease;	chr11:107323450	chr11:107176286~107177530:+
BRCA	cis	rs3758911	1	rs12146473	ENSG00000255353.1	RP11-382M14.1	-7.87	9.03e-15	2.69e-12	-0.31	-0.24	Coronary artery disease;	chr11:107323540	chr11:107176286~107177530:+
BRCA	cis	rs6750795	0.746	rs2916579	ENSG00000181798.2	LINC00471	-7.87	9.03e-15	2.69e-12	-0.29	-0.24	Height;	chr2:231556448	chr2:231508426~231514339:-
BRCA	cis	rs9880211	1	rs12695649	ENSG00000239213.4	NCK1-AS1	7.87	9.04e-15	2.69e-12	0.31	0.24	Height;Body mass index;	chr3:136553074	chr3:136841726~136862054:-
BRCA	cis	rs9928842	0.771	rs2870471	ENSG00000280152.1	RP11-331F4.5	-7.87	9.05e-15	2.7e-12	-0.3	-0.24	Alcoholic chronic pancreatitis;	chr16:75240384	chr16:75245994~75250077:-
BRCA	cis	rs293748	0.825	rs468022	ENSG00000250155.1	CTD-2353F22.1	-7.87	9.07e-15	2.7e-12	-0.34	-0.24	Obesity-related traits;	chr5:36988150	chr5:36666214~36725195:-
BRCA	cis	rs26232	0.583	rs154258	ENSG00000175749.11	EIF3KP1	-7.87	9.08e-15	2.7e-12	-0.34	-0.24	Rheumatoid arthritis;	chr5:103027919	chr5:103032376~103033031:+
BRCA	cis	rs2034650	0.544	rs661488	ENSG00000223313.1	RNU6-516P	7.87	9.08e-15	2.7e-12	0.3	0.24	Interstitial lung disease;	chr15:40429221	chr15:40529570~40529673:+
BRCA	cis	rs7635879	0.702	rs4687494	ENSG00000230102.6	RP11-407B7.1	-7.87	9.1e-15	2.71e-12	-0.28	-0.24	Breastfeeding duration;	chr3:194010581	chr3:194005259~194070970:-
BRCA	cis	rs7246657	0.943	rs7408563	ENSG00000276846.1	CTD-3220F14.3	7.87	9.1e-15	2.71e-12	0.33	0.24	Coronary artery calcification;	chr19:37317683	chr19:37314868~37315620:-
BRCA	cis	rs875971	0.83	rs809025	ENSG00000232559.3	GS1-124K5.12	7.87	9.11e-15	2.71e-12	0.29	0.24	Aortic root size;	chr7:66384832	chr7:66554588~66576923:-
BRCA	cis	rs2933343	0.859	rs789245	ENSG00000261159.1	RP11-723O4.9	7.87	9.13e-15	2.72e-12	0.28	0.24	IgG glycosylation;	chr3:128864737	chr3:128859716~128860526:-
BRCA	cis	rs2117029	1	rs10783301	ENSG00000258017.1	RP11-386G11.10	-7.87	9.14e-15	2.72e-12	-0.3	-0.24	Intelligence (multi-trait analysis);	chr12:49045593	chr12:49127782~49147869:+
BRCA	cis	rs293748	0.882	rs151946	ENSG00000250155.1	CTD-2353F22.1	-7.87	9.15e-15	2.73e-12	-0.34	-0.24	Obesity-related traits;	chr5:36884064	chr5:36666214~36725195:-
BRCA	cis	rs3762637	0.941	rs77599736	ENSG00000272758.4	RP11-299J3.8	-7.87	9.16e-15	2.73e-12	-0.36	-0.24	LDL cholesterol levels;	chr3:122460662	chr3:122416207~122443180:+
BRCA	cis	rs3762637	0.943	rs10439995	ENSG00000272758.4	RP11-299J3.8	-7.87	9.16e-15	2.73e-12	-0.36	-0.24	LDL cholesterol levels;	chr3:122470313	chr3:122416207~122443180:+
BRCA	cis	rs3762637	0.882	rs7630833	ENSG00000272758.4	RP11-299J3.8	-7.87	9.16e-15	2.73e-12	-0.36	-0.24	LDL cholesterol levels;	chr3:122471577	chr3:122416207~122443180:+
BRCA	cis	rs2274273	0.624	rs66551709	ENSG00000258413.1	RP11-665C16.6	-7.87	9.17e-15	2.73e-12	-0.31	-0.24	Protein biomarker;	chr14:55324304	chr14:55262767~55272075:-
BRCA	cis	rs526231	0.543	rs246916	ENSG00000175749.11	EIF3KP1	7.87	9.19e-15	2.74e-12	0.35	0.24	Primary biliary cholangitis;	chr5:103221814	chr5:103032376~103033031:+
BRCA	cis	rs4964805	0.954	rs4964812	ENSG00000257681.1	RP11-341G23.4	7.86	9.22e-15	2.75e-12	0.29	0.24	Attention deficit hyperactivity disorder;	chr12:103795837	chr12:103746315~103768858:-
BRCA	cis	rs301901	1	rs158624	ENSG00000250155.1	CTD-2353F22.1	-7.86	9.23e-15	2.75e-12	-0.26	-0.24	Height;	chr5:36865567	chr5:36666214~36725195:-
BRCA	cis	rs193541	0.632	rs10037044	ENSG00000263432.2	RN7SL689P	-7.86	9.26e-15	2.76e-12	-0.32	-0.24	Glucose homeostasis traits;	chr5:122787604	chr5:123022487~123022783:-
BRCA	cis	rs950880	0.71	rs17027258	ENSG00000234389.1	AC007278.3	-7.86	9.27e-15	2.76e-12	-0.23	-0.24	Serum protein levels (sST2);	chr2:102475081	chr2:102438713~102440475:+
BRCA	cis	rs6750795	0.746	rs1667301	ENSG00000181798.2	LINC00471	-7.86	9.35e-15	2.78e-12	-0.29	-0.24	Height;	chr2:231559006	chr2:231508426~231514339:-
BRCA	cis	rs3096299	0.967	rs2965932	ENSG00000274627.1	RP11-104N10.2	-7.86	9.36e-15	2.79e-12	-0.25	-0.24	Multiple myeloma (IgH translocation);	chr16:89410643	chr16:89516797~89522217:+
BRCA	cis	rs11976180	1	rs2961119	ENSG00000170356.8	OR2A20P	-7.86	9.39e-15	2.8e-12	-0.33	-0.24	Obesity-related traits;	chr7:144058759	chr7:144250045~144252957:-
BRCA	cis	rs9880211	0.846	rs73230043	ENSG00000239213.4	NCK1-AS1	7.86	9.4e-15	2.8e-12	0.3	0.24	Height;Body mass index;	chr3:136688317	chr3:136841726~136862054:-
BRCA	cis	rs10129255	0.5	rs8014529	ENSG00000280411.1	IGHV1-69-2	-7.86	9.42e-15	2.8e-12	-0.16	-0.24	Kawasaki disease;	chr14:106784065	chr14:106762092~106762588:-
BRCA	cis	rs7811142	1	rs11771241	ENSG00000242294.5	STAG3L5P	7.86	9.43e-15	2.81e-12	0.23	0.24	Platelet count;	chr7:100397162	chr7:100336079~100351900:+
BRCA	cis	rs7712401	0.765	rs4349713	ENSG00000263432.2	RN7SL689P	7.86	9.45e-15	2.81e-12	0.3	0.24	Mean platelet volume;	chr5:123055931	chr5:123022487~123022783:-
BRCA	cis	rs875971	0.862	rs6962717	ENSG00000232559.3	GS1-124K5.12	7.86	9.47e-15	2.82e-12	0.29	0.24	Aortic root size;	chr7:66418748	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.965	rs6971509	ENSG00000232559.3	GS1-124K5.12	-7.86	9.47e-15	2.82e-12	-0.28	-0.24	Aortic root size;	chr7:66249983	chr7:66554588~66576923:-
BRCA	cis	rs13068223	0.663	rs12107178	ENSG00000243926.1	TIPARP-AS1	7.86	9.53e-15	2.84e-12	0.25	0.24	Age-related hearing impairment (SNP x SNP interaction);	chr3:156756735	chr3:156671862~156674378:-
BRCA	cis	rs58873874	0.579	rs10037386	ENSG00000251405.2	CTB-109A12.1	7.86	9.53e-15	2.84e-12	0.49	0.24	Bipolar disorder (body mass index interaction);	chr5:157342641	chr5:157362615~157460078:-
BRCA	cis	rs9399135	0.517	rs1041478	ENSG00000232876.1	CTA-212D2.2	-7.86	9.56e-15	2.84e-12	-0.29	-0.24	Red blood cell count;	chr6:135130059	chr6:135055033~135060550:+
BRCA	cis	rs3758911	0.964	rs10890715	ENSG00000255353.1	RP11-382M14.1	-7.86	9.6e-15	2.86e-12	-0.31	-0.24	Coronary artery disease;	chr11:107322457	chr11:107176286~107177530:+
BRCA	cis	rs375066	0.935	rs108775	ENSG00000267058.1	RP11-15A1.3	-7.86	9.61e-15	2.86e-12	-0.27	-0.24	Breast cancer;	chr19:43901770	chr19:43891804~43901805:-
BRCA	cis	rs9880211	1	rs12695645	ENSG00000239213.4	NCK1-AS1	7.86	9.64e-15	2.87e-12	0.31	0.24	Height;Body mass index;	chr3:136272039	chr3:136841726~136862054:-
BRCA	cis	rs193541	0.593	rs246309	ENSG00000263432.2	RN7SL689P	7.86	9.66e-15	2.87e-12	0.32	0.24	Glucose homeostasis traits;	chr5:122934024	chr5:123022487~123022783:-
BRCA	cis	rs2243480	1	rs778679	ENSG00000273142.1	RP11-458F8.4	-7.86	9.67e-15	2.88e-12	-0.33	-0.24	Diabetic kidney disease;	chr7:66375924	chr7:66902857~66906297:+
BRCA	cis	rs812925	0.784	rs6735081	ENSG00000271889.1	RP11-493E12.1	-7.86	9.71e-15	2.89e-12	-0.3	-0.24	Immature fraction of reticulocytes;	chr2:61233582	chr2:61151433~61162105:-
BRCA	cis	rs2243480	1	rs778729	ENSG00000273142.1	RP11-458F8.4	-7.86	9.73e-15	2.89e-12	-0.33	-0.24	Diabetic kidney disease;	chr7:66359432	chr7:66902857~66906297:+
BRCA	cis	rs10463554	0.963	rs26262	ENSG00000175749.11	EIF3KP1	7.86	9.75e-15	2.9e-12	0.33	0.24	Parkinson's disease;	chr5:103209462	chr5:103032376~103033031:+
BRCA	cis	rs453301	0.606	rs6601279	ENSG00000253893.2	FAM85B	7.86	9.76e-15	2.9e-12	0.3	0.24	Joint mobility (Beighton score);	chr8:9050721	chr8:8167819~8226614:-
BRCA	cis	rs453301	0.606	rs6981060	ENSG00000253893.2	FAM85B	7.86	9.76e-15	2.9e-12	0.3	0.24	Joint mobility (Beighton score);	chr8:9050725	chr8:8167819~8226614:-
BRCA	cis	rs4835473	0.932	rs13134808	ENSG00000251600.4	RP11-673E1.1	-7.86	9.76e-15	2.9e-12	-0.29	-0.24	Immature fraction of reticulocytes;	chr4:143798339	chr4:143912331~143982454:+
BRCA	cis	rs11098499	0.82	rs6829903	ENSG00000248280.1	RP11-33B1.2	7.86	9.78e-15	2.91e-12	0.24	0.24	Corneal astigmatism;	chr4:119585729	chr4:119440561~119450157:-
BRCA	cis	rs11690935	0.55	rs4280427	ENSG00000228389.1	AC068039.4	-7.86	9.79e-15	2.91e-12	-0.29	-0.24	Schizophrenia;	chr2:171956692	chr2:171773482~171775844:+
BRCA	cis	rs11690935	0.531	rs4280428	ENSG00000228389.1	AC068039.4	-7.86	9.79e-15	2.91e-12	-0.29	-0.24	Schizophrenia;	chr2:171956693	chr2:171773482~171775844:+
BRCA	cis	rs2028299	0.919	rs8026131	ENSG00000259677.1	RP11-493E3.1	7.86	9.79e-15	2.91e-12	0.31	0.24	Type 2 diabetes;	chr15:89874767	chr15:89876540~89877285:+
BRCA	cis	rs2028299	0.879	rs986505	ENSG00000259677.1	RP11-493E3.1	7.86	9.79e-15	2.91e-12	0.31	0.24	Type 2 diabetes;	chr15:89875181	chr15:89876540~89877285:+
BRCA	cis	rs17264034	0.861	rs56344213	ENSG00000250786.1	SNHG18	7.86	9.8e-15	2.91e-12	0.33	0.24	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9553756	chr5:9546200~9550609:+
BRCA	cis	rs1499614	1	rs2707832	ENSG00000273142.1	RP11-458F8.4	-7.86	9.83e-15	2.92e-12	-0.32	-0.24	Gout;	chr7:66671562	chr7:66902857~66906297:+
BRCA	cis	rs6545883	0.894	rs4672423	ENSG00000271889.1	RP11-493E12.1	-7.86	9.84e-15	2.92e-12	-0.31	-0.24	Tuberculosis;	chr2:61208140	chr2:61151433~61162105:-
BRCA	cis	rs7927771	0.832	rs11605672	ENSG00000280615.1	Y_RNA	-7.86	9.86e-15	2.93e-12	-0.29	-0.24	Subjective well-being;	chr11:47392182	chr11:47614898~47614994:-
BRCA	cis	rs3814244	0.54	rs2159064	ENSG00000236946.2	HNRNPA1P70	7.86	9.89e-15	2.94e-12	0.19	0.24	Itch intensity from mosquito bite adjusted by bite size;	chr12:68017126	chr12:68035767~68036853:+
BRCA	cis	rs17023223	0.537	rs3936018	ENSG00000231365.4	RP11-418J17.1	-7.86	9.9e-15	2.94e-12	-0.33	-0.24	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119139747	chr1:119140396~119275973:+
BRCA	cis	rs2115630	1	rs11854313	ENSG00000225151.9	GOLGA2P7	7.85	9.92e-15	2.94e-12	0.26	0.24	P wave terminal force;	chr15:84760817	chr15:84199311~84230136:-
BRCA	cis	rs4266144	0.544	rs6805781	ENSG00000244515.1	KRT18P34	7.85	9.93e-15	2.95e-12	0.28	0.24	Coronary artery disease;	chr3:157112780	chr3:157162663~157163932:-
BRCA	cis	rs1823913	0.526	rs35340557	ENSG00000227542.1	AC092614.2	7.85	9.93e-15	2.95e-12	0.29	0.24	Obesity-related traits;	chr2:191338688	chr2:191229165~191246172:-
BRCA	cis	rs1823913	0.503	rs35562914	ENSG00000227542.1	AC092614.2	7.85	9.93e-15	2.95e-12	0.29	0.24	Obesity-related traits;	chr2:191338969	chr2:191229165~191246172:-
BRCA	cis	rs11118620	0.622	rs11118618	ENSG00000257551.1	HLX-AS1	7.85	9.93e-15	2.95e-12	0.3	0.24	Heart failure;	chr1:220838204	chr1:220832763~220880140:-
BRCA	cis	rs113835537	0.529	rs11227515	ENSG00000255517.5	CTD-3074O7.5	-7.85	9.94e-15	2.95e-12	-0.3	-0.24	Airway imaging phenotypes;	chr11:66519912	chr11:66473490~66480233:-
BRCA	cis	rs875971	0.619	rs2302918	ENSG00000237310.1	GS1-124K5.4	7.85	9.95e-15	2.95e-12	0.25	0.24	Aortic root size;	chr7:66535945	chr7:66493706~66495474:+
BRCA	cis	rs4934494	0.768	rs1926139	ENSG00000240996.1	RP11-80H5.7	-7.85	9.96e-15	2.95e-12	-0.3	-0.24	Red blood cell count;	chr10:89753395	chr10:89694295~89697928:-
BRCA	cis	rs4934494	0.727	rs55823491	ENSG00000240996.1	RP11-80H5.7	-7.85	9.96e-15	2.95e-12	-0.3	-0.24	Red blood cell count;	chr10:89757598	chr10:89694295~89697928:-
BRCA	cis	rs4934494	0.727	rs12570750	ENSG00000240996.1	RP11-80H5.7	-7.85	9.96e-15	2.95e-12	-0.3	-0.24	Red blood cell count;	chr10:89761273	chr10:89694295~89697928:-
BRCA	cis	rs62432291	0.681	rs378547	ENSG00000235086.1	FNDC1-IT1	7.85	9.96e-15	2.96e-12	0.32	0.24	Joint mobility (Beighton score);	chr6:159241493	chr6:159240786~159243329:+
BRCA	cis	rs897984	0.542	rs6565217	ENSG00000260911.2	RP11-196G11.2	7.85	9.98e-15	2.96e-12	0.21	0.24	Dementia with Lewy bodies;	chr16:31072003	chr16:31043150~31049868:+
BRCA	cis	rs10463554	0.963	rs26524	ENSG00000175749.11	EIF3KP1	7.85	9.98e-15	2.96e-12	0.32	0.24	Parkinson's disease;	chr5:103120600	chr5:103032376~103033031:+
BRCA	cis	rs524281	0.731	rs9326365	ENSG00000255320.1	RP11-755F10.1	-7.85	9.99e-15	2.96e-12	-0.38	-0.24	Electroencephalogram traits;	chr11:66040414	chr11:66244840~66246239:-
BRCA	cis	rs287982	1	rs1119633	ENSG00000269973.1	RP11-95D17.1	-7.85	9.99e-15	2.96e-12	-0.29	-0.24	Nonsyndromic cleft lip with cleft palate;	chr2:9827403	chr2:9936360~9939590:+
BRCA	cis	rs287982	0.935	rs1119632	ENSG00000269973.1	RP11-95D17.1	-7.85	9.99e-15	2.96e-12	-0.29	-0.24	Nonsyndromic cleft lip with cleft palate;	chr2:9827535	chr2:9936360~9939590:+
BRCA	cis	rs2034650	0.563	rs12914315	ENSG00000223313.1	RNU6-516P	-7.85	1e-14	2.97e-12	-0.28	-0.24	Interstitial lung disease;	chr15:40421679	chr15:40529570~40529673:+
BRCA	cis	rs7927771	0.832	rs10838697	ENSG00000280615.1	Y_RNA	-7.85	1.01e-14	2.99e-12	-0.29	-0.24	Subjective well-being;	chr11:47362933	chr11:47614898~47614994:-
BRCA	cis	rs1061377	1	rs36090629	ENSG00000249685.1	RP11-360F5.3	7.85	1.01e-14	2.99e-12	0.28	0.24	Uric acid levels;	chr4:39137195	chr4:39133913~39135608:+
BRCA	cis	rs1061377	0.87	rs73238544	ENSG00000249685.1	RP11-360F5.3	7.85	1.01e-14	2.99e-12	0.28	0.24	Uric acid levels;	chr4:39137343	chr4:39133913~39135608:+
BRCA	cis	rs10463554	0.963	rs32840	ENSG00000175749.11	EIF3KP1	7.85	1.01e-14	3e-12	0.32	0.24	Parkinson's disease;	chr5:103143446	chr5:103032376~103033031:+
BRCA	cis	rs9880211	1	rs6768743	ENSG00000239213.4	NCK1-AS1	-7.85	1.01e-14	3e-12	-0.3	-0.24	Height;Body mass index;	chr3:136486165	chr3:136841726~136862054:-
BRCA	cis	rs9880211	1	rs67949818	ENSG00000273486.1	RP11-731C17.2	7.85	1.01e-14	3e-12	0.31	0.24	Height;Body mass index;	chr3:136494136	chr3:136837338~136839021:-
BRCA	cis	rs4713118	0.669	rs200997	ENSG00000216901.1	AL022393.7	7.85	1.01e-14	3e-12	0.31	0.24	Parkinson's disease;	chr6:27844037	chr6:28176188~28176674:+
BRCA	cis	rs11159086	1	rs4903232	ENSG00000259005.1	RP3-449M8.6	7.85	1.01e-14	3e-12	0.36	0.24	Advanced glycation end-product levels;	chr14:74496585	chr14:74474007~74474864:-
BRCA	cis	rs919433	1	rs1346649	ENSG00000231621.1	AC013264.2	7.85	1.01e-14	3e-12	0.22	0.24	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197301393	chr2:197197991~197199273:+
BRCA	cis	rs6545883	0.895	rs7588814	ENSG00000271889.1	RP11-493E12.1	7.85	1.01e-14	3e-12	0.31	0.24	Tuberculosis;	chr2:61468454	chr2:61151433~61162105:-
BRCA	cis	rs875971	0.862	rs1643375	ENSG00000232559.3	GS1-124K5.12	7.85	1.02e-14	3.01e-12	0.29	0.24	Aortic root size;	chr7:66407690	chr7:66554588~66576923:-
BRCA	cis	rs4934494	0.727	rs12783845	ENSG00000240996.1	RP11-80H5.7	-7.85	1.02e-14	3.02e-12	-0.3	-0.24	Red blood cell count;	chr10:89722872	chr10:89694295~89697928:-
BRCA	cis	rs8072100	0.967	rs8078880	ENSG00000228782.6	CTD-2026D20.3	-7.85	1.02e-14	3.03e-12	-0.25	-0.24	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47599160	chr17:47450568~47492492:-
BRCA	cis	rs4835473	0.932	rs36018946	ENSG00000251600.4	RP11-673E1.1	-7.85	1.02e-14	3.03e-12	-0.29	-0.24	Immature fraction of reticulocytes;	chr4:143980942	chr4:143912331~143982454:+
BRCA	cis	rs875971	0.545	rs10950027	ENSG00000224316.1	RP11-479O9.2	7.85	1.03e-14	3.04e-12	0.27	0.24	Aortic root size;	chr7:66169164	chr7:65773620~65802067:+
BRCA	cis	rs9880211	0.898	rs9870825	ENSG00000273486.1	RP11-731C17.2	7.85	1.03e-14	3.04e-12	0.32	0.24	Height;Body mass index;	chr3:136346878	chr3:136837338~136839021:-
BRCA	cis	rs14027	0.921	rs7813651	ENSG00000279347.1	RP11-85I17.2	-7.85	1.03e-14	3.04e-12	-0.25	-0.24	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119839119	chr8:119838736~119840385:-
BRCA	cis	rs380904	0.519	rs1377663	ENSG00000254859.1	RP11-661A12.5	-7.85	1.03e-14	3.05e-12	-0.37	-0.24	Venous thromboembolism (SNP x SNP interaction);	chr8:143562617	chr8:143541973~143549729:-
BRCA	cis	rs2274273	0.84	rs3742569	ENSG00000258413.1	RP11-665C16.6	-7.85	1.03e-14	3.06e-12	-0.29	-0.24	Protein biomarker;	chr14:55351988	chr14:55262767~55272075:-
BRCA	cis	rs9880211	0.898	rs35304385	ENSG00000239213.4	NCK1-AS1	7.85	1.04e-14	3.06e-12	0.31	0.24	Height;Body mass index;	chr3:136667411	chr3:136841726~136862054:-
BRCA	cis	rs74233809	1	rs11191548	ENSG00000213277.3	MARCKSL1P1	-7.85	1.04e-14	3.07e-12	-0.43	-0.24	Birth weight;	chr10:103086421	chr10:103175554~103176094:+
BRCA	cis	rs79040073	0.53	rs73392262	ENSG00000259531.2	RP11-295H24.3	7.85	1.04e-14	3.07e-12	0.35	0.24	Lung cancer in ever smokers;	chr15:49229513	chr15:49365124~49366685:-
BRCA	cis	rs957448	0.554	rs12541408	ENSG00000253704.1	RP11-267M23.4	7.85	1.04e-14	3.07e-12	0.25	0.24	Nonsyndromic cleft lip with cleft palate;	chr8:94573579	chr8:94553722~94569745:+
BRCA	cis	rs4835473	0.932	rs13105102	ENSG00000251600.4	RP11-673E1.1	-7.85	1.04e-14	3.08e-12	-0.29	-0.24	Immature fraction of reticulocytes;	chr4:143819046	chr4:143912331~143982454:+
BRCA	cis	rs6545883	0.794	rs778152	ENSG00000271889.1	RP11-493E12.1	-7.85	1.04e-14	3.08e-12	-0.3	-0.24	Tuberculosis;	chr2:61381405	chr2:61151433~61162105:-
BRCA	cis	rs2439831	0.85	rs28858500	ENSG00000275601.1	AC011330.13	-7.85	1.04e-14	3.09e-12	-0.37	-0.24	Lung cancer in ever smokers;	chr15:43864744	chr15:43642389~43643023:-
BRCA	cis	rs8062405	0.721	rs151181	ENSG00000251417.2	RP11-1348G14.4	-7.85	1.05e-14	3.1e-12	-0.28	-0.24	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28479196	chr16:28802743~28817828:+
BRCA	cis	rs7580658	0.68	rs12468304	ENSG00000236682.1	AC068282.3	7.85	1.05e-14	3.11e-12	0.31	0.24	Protein C levels;	chr2:127436236	chr2:127389130~127400580:+
BRCA	cis	rs6472827	0.904	rs2956031	ENSG00000253983.2	RP1-16A9.1	7.85	1.06e-14	3.12e-12	0.37	0.24	Uterine fibroids;	chr8:74203074	chr8:74199396~74208441:+
BRCA	cis	rs74233809	1	rs12412038	ENSG00000213277.3	MARCKSL1P1	7.85	1.06e-14	3.13e-12	0.45	0.24	Birth weight;	chr10:103096405	chr10:103175554~103176094:+
BRCA	cis	rs12468226	0.752	rs77319662	ENSG00000273456.1	RP11-686O6.2	7.85	1.06e-14	3.13e-12	0.36	0.24	Urate levels;	chr2:202126928	chr2:202374932~202375604:-
BRCA	cis	rs9880211	0.898	rs1052620	ENSG00000239213.4	NCK1-AS1	7.85	1.06e-14	3.13e-12	0.33	0.24	Height;Body mass index;	chr3:136855679	chr3:136841726~136862054:-
BRCA	cis	rs9527	0.571	rs10786715	ENSG00000213061.2	PFN1P11	7.84	1.07e-14	3.16e-12	0.31	0.24	Arsenic metabolism;	chr10:102860978	chr10:102838011~102845473:-
BRCA	cis	rs4660456	0.913	rs2744808	ENSG00000237899.1	RP4-739H11.3	-7.84	1.07e-14	3.17e-12	-0.35	-0.24	Platelet count;	chr1:40712271	chr1:40669089~40687588:-
BRCA	cis	rs2439831	0.85	rs3825783	ENSG00000275601.1	AC011330.13	-7.84	1.07e-14	3.17e-12	-0.39	-0.24	Lung cancer in ever smokers;	chr15:43810111	chr15:43642389~43643023:-
BRCA	cis	rs2243480	0.522	rs1638736	ENSG00000226824.5	RP4-756H11.3	-7.84	1.07e-14	3.18e-12	-0.55	-0.24	Diabetic kidney disease;	chr7:66627321	chr7:66654538~66669855:+
BRCA	cis	rs10246939	0.505	rs13236432	ENSG00000228775.6	WEE2-AS1	7.84	1.08e-14	3.18e-12	0.28	0.24	Bitter taste perception;	chr7:141850980	chr7:141704338~141738346:-
BRCA	cis	rs113835537	0.529	rs17065	ENSG00000255517.5	CTD-3074O7.5	-7.84	1.08e-14	3.19e-12	-0.32	-0.24	Airway imaging phenotypes;	chr11:66509564	chr11:66473490~66480233:-
BRCA	cis	rs10463554	0.963	rs154355	ENSG00000175749.11	EIF3KP1	7.84	1.09e-14	3.22e-12	0.32	0.24	Parkinson's disease;	chr5:103163177	chr5:103032376~103033031:+
BRCA	cis	rs26232	0.517	rs154356	ENSG00000175749.11	EIF3KP1	7.84	1.09e-14	3.22e-12	0.32	0.24	Rheumatoid arthritis;	chr5:103163440	chr5:103032376~103033031:+
BRCA	cis	rs812925	0.855	rs777592	ENSG00000271889.1	RP11-493E12.1	7.84	1.09e-14	3.23e-12	0.3	0.24	Immature fraction of reticulocytes;	chr2:61191208	chr2:61151433~61162105:-
BRCA	cis	rs867371	1	rs8041924	ENSG00000259429.4	UBE2Q2P2	-7.84	1.09e-14	3.23e-12	-0.23	-0.24	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82181320	chr15:82355142~82420075:+
BRCA	cis	rs250518	0.926	rs13157511	ENSG00000272081.1	CTD-2376I4.2	-7.84	1.09e-14	3.23e-12	-0.3	-0.24	Mean corpuscular hemoglobin concentration;	chr5:72775976	chr5:72955206~72955699:-
BRCA	cis	rs58873874	0.522	rs77458926	ENSG00000251405.2	CTB-109A12.1	7.84	1.09e-14	3.23e-12	0.54	0.24	Bipolar disorder (body mass index interaction);	chr5:157271198	chr5:157362615~157460078:-
BRCA	cis	rs10463554	0.926	rs34778	ENSG00000175749.11	EIF3KP1	7.84	1.1e-14	3.24e-12	0.32	0.24	Parkinson's disease;	chr5:103116852	chr5:103032376~103033031:+
BRCA	cis	rs4820294	1	rs78974622	ENSG00000233360.4	Z83844.1	7.84	1.1e-14	3.24e-12	0.29	0.24	Fat distribution (HIV);	chr22:37663918	chr22:37641832~37658377:-
BRCA	cis	rs875971	0.545	rs67775320	ENSG00000224316.1	RP11-479O9.2	7.84	1.1e-14	3.25e-12	0.27	0.24	Aortic root size;	chr7:66193792	chr7:65773620~65802067:+
BRCA	cis	rs72627509	0.638	rs7658601	ENSG00000269949.1	RP11-738E22.3	7.84	1.1e-14	3.25e-12	0.36	0.24	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56915181	chr4:56960927~56961373:-
BRCA	cis	rs8005677	1	rs1956880	ENSG00000279656.1	RP11-298I3.6	7.84	1.1e-14	3.26e-12	0.28	0.24	Cognitive ability (multi-trait analysis);	chr14:22924798	chr14:23023083~23024217:-
BRCA	cis	rs11098499	0.82	rs2389885	ENSG00000248280.1	RP11-33B1.2	7.84	1.11e-14	3.27e-12	0.26	0.24	Corneal astigmatism;	chr4:119612776	chr4:119440561~119450157:-
BRCA	cis	rs3758911	0.964	rs10789614	ENSG00000255353.1	RP11-382M14.1	-7.84	1.11e-14	3.27e-12	-0.31	-0.24	Coronary artery disease;	chr11:107318047	chr11:107176286~107177530:+
BRCA	cis	rs6504622	0.755	rs7216950	ENSG00000262879.4	RP11-156P1.3	-7.84	1.11e-14	3.28e-12	-0.24	-0.24	Orofacial clefts;	chr17:47011089	chr17:46984045~47100323:-
BRCA	cis	rs875971	0.83	rs6976714	ENSG00000232559.3	GS1-124K5.12	7.84	1.11e-14	3.28e-12	0.29	0.24	Aortic root size;	chr7:66426474	chr7:66554588~66576923:-
BRCA	cis	rs58873874	0.579	rs10040318	ENSG00000248544.2	CTB-47B11.3	7.84	1.11e-14	3.28e-12	0.45	0.24	Bipolar disorder (body mass index interaction);	chr5:157283016	chr5:157375741~157384950:-
BRCA	cis	rs4835473	0.838	rs34521499	ENSG00000251600.4	RP11-673E1.1	-7.84	1.11e-14	3.28e-12	-0.3	-0.24	Immature fraction of reticulocytes;	chr4:143777628	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.9	rs34264936	ENSG00000251600.4	RP11-673E1.1	-7.84	1.11e-14	3.28e-12	-0.3	-0.24	Immature fraction of reticulocytes;	chr4:143780294	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.9	rs13140028	ENSG00000251600.4	RP11-673E1.1	-7.84	1.11e-14	3.28e-12	-0.3	-0.24	Immature fraction of reticulocytes;	chr4:143782195	chr4:143912331~143982454:+
BRCA	cis	rs13068223	0.716	rs344067	ENSG00000243926.1	TIPARP-AS1	-7.84	1.11e-14	3.29e-12	-0.25	-0.24	Age-related hearing impairment (SNP x SNP interaction);	chr3:156723825	chr3:156671862~156674378:-
BRCA	cis	rs17213965	0.852	rs4781691	ENSG00000207425.1	Y_RNA	-7.84	1.11e-14	3.29e-12	-0.39	-0.24	Waist-hip ratio;	chr16:15783798	chr16:14915457~14915556:-
BRCA	cis	rs3762637	1	rs7644540	ENSG00000272758.4	RP11-299J3.8	-7.84	1.12e-14	3.3e-12	-0.35	-0.24	LDL cholesterol levels;	chr3:122491205	chr3:122416207~122443180:+
BRCA	cis	rs875971	1	rs6946143	ENSG00000237310.1	GS1-124K5.4	7.84	1.12e-14	3.3e-12	0.25	0.24	Aortic root size;	chr7:66114735	chr7:66493706~66495474:+
BRCA	cis	rs11976180	1	rs2371244	ENSG00000170356.8	OR2A20P	-7.84	1.12e-14	3.3e-12	-0.33	-0.24	Obesity-related traits;	chr7:144060518	chr7:144250045~144252957:-
BRCA	cis	rs2348418	0.733	rs2169754	ENSG00000247934.4	RP11-967K21.1	-7.84	1.12e-14	3.31e-12	-0.27	-0.24	Lung function (FEV1);Lung function (FVC);	chr12:28187712	chr12:28163298~28190738:-
BRCA	cis	rs2300206	1	rs2300206	ENSG00000276073.1	RP5-1125A11.7	-7.84	1.12e-14	3.31e-12	-0.29	-0.24	Cancer (pleiotropy);Cancer;	chr20:34002002	chr20:33985617~33988989:-
BRCA	cis	rs7474896	0.806	rs1779150	ENSG00000226578.1	RP11-258F22.1	-7.84	1.12e-14	3.31e-12	-0.5	-0.24	Obesity (extreme);	chr10:37749759	chr10:37775371~37784131:-
BRCA	cis	rs8062405	0.789	rs2106480	ENSG00000251417.2	RP11-1348G14.4	-7.84	1.12e-14	3.32e-12	-0.27	-0.24	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28526650	chr16:28802743~28817828:+
BRCA	cis	rs3762637	0.943	rs9822345	ENSG00000272758.4	RP11-299J3.8	-7.84	1.13e-14	3.32e-12	-0.35	-0.24	LDL cholesterol levels;	chr3:122526751	chr3:122416207~122443180:+
BRCA	cis	rs1061377	1	rs7675782	ENSG00000249685.1	RP11-360F5.3	7.84	1.13e-14	3.32e-12	0.28	0.24	Uric acid levels;	chr4:39120048	chr4:39133913~39135608:+
BRCA	cis	rs875971	0.862	rs778680	ENSG00000232559.3	GS1-124K5.12	7.84	1.13e-14	3.33e-12	0.29	0.24	Aortic root size;	chr7:66375427	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.862	rs11769079	ENSG00000232559.3	GS1-124K5.12	7.84	1.13e-14	3.33e-12	0.29	0.24	Aortic root size;	chr7:66377141	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.862	rs1695820	ENSG00000232559.3	GS1-124K5.12	7.84	1.13e-14	3.33e-12	0.29	0.24	Aortic root size;	chr7:66379576	chr7:66554588~66576923:-
BRCA	cis	rs77204473	1	rs17120131	ENSG00000254851.1	RP11-109L13.1	7.84	1.13e-14	3.33e-12	0.55	0.24	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116901770	chr11:117135528~117138582:+
BRCA	cis	rs7811142	1	rs11771419	ENSG00000242294.5	STAG3L5P	7.84	1.13e-14	3.34e-12	0.23	0.24	Platelet count;	chr7:100390780	chr7:100336079~100351900:+
BRCA	cis	rs11723261	0.582	rs11735742	ENSG00000211553.1	AC253576.2	7.84	1.13e-14	3.34e-12	0.33	0.24	Immune response to smallpox vaccine (IL-6);	chr4:148766	chr4:136461~136568:+
BRCA	cis	rs2115630	1	rs11073730	ENSG00000225151.9	GOLGA2P7	7.84	1.13e-14	3.34e-12	0.26	0.24	P wave terminal force;	chr15:84811365	chr15:84199311~84230136:-
BRCA	cis	rs2288884	0.537	rs9636140	ENSG00000275055.1	CTC-471J1.11	-7.84	1.13e-14	3.35e-12	-0.28	-0.24	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52056610	chr19:52049007~52049754:+
BRCA	cis	rs9876781	1	rs7636044	ENSG00000244380.1	RP11-24C3.2	7.84	1.14e-14	3.36e-12	0.27	0.24	Longevity;	chr3:48443151	chr3:48440352~48446656:-
BRCA	cis	rs9876781	1	rs4490383	ENSG00000244380.1	RP11-24C3.2	7.84	1.14e-14	3.36e-12	0.27	0.24	Longevity;	chr3:48443275	chr3:48440352~48446656:-
BRCA	cis	rs10129255	0.5	rs6576225	ENSG00000280411.1	IGHV1-69-2	-7.84	1.14e-14	3.36e-12	-0.16	-0.24	Kawasaki disease;	chr14:106778120	chr14:106762092~106762588:-
BRCA	cis	rs10129255	0.5	rs6576226	ENSG00000280411.1	IGHV1-69-2	-7.84	1.14e-14	3.36e-12	-0.16	-0.24	Kawasaki disease;	chr14:106778135	chr14:106762092~106762588:-
BRCA	cis	rs2028299	0.92	rs10852123	ENSG00000259677.1	RP11-493E3.1	7.84	1.14e-14	3.36e-12	0.34	0.24	Type 2 diabetes;	chr15:89885662	chr15:89876540~89877285:+
BRCA	cis	rs6545883	0.929	rs1186710	ENSG00000271889.1	RP11-493E12.1	7.84	1.14e-14	3.36e-12	0.31	0.24	Tuberculosis;	chr2:61461592	chr2:61151433~61162105:-
BRCA	cis	rs7811142	0.83	rs705866	ENSG00000242294.5	STAG3L5P	7.84	1.14e-14	3.36e-12	0.25	0.24	Platelet count;	chr7:100367662	chr7:100336079~100351900:+
BRCA	cis	rs7927771	0.832	rs6485753	ENSG00000280615.1	Y_RNA	7.84	1.14e-14	3.36e-12	0.29	0.24	Subjective well-being;	chr11:47388649	chr11:47614898~47614994:-
BRCA	cis	rs875971	0.66	rs801193	ENSG00000237310.1	GS1-124K5.4	-7.84	1.14e-14	3.37e-12	-0.25	-0.24	Aortic root size;	chr7:66565625	chr7:66493706~66495474:+
BRCA	cis	rs10463554	1	rs1593842	ENSG00000175749.11	EIF3KP1	7.84	1.15e-14	3.38e-12	0.32	0.24	Parkinson's disease;	chr5:102999018	chr5:103032376~103033031:+
BRCA	cis	rs7927771	0.832	rs4752993	ENSG00000280615.1	Y_RNA	7.84	1.15e-14	3.38e-12	0.29	0.24	Subjective well-being;	chr11:47389400	chr11:47614898~47614994:-
BRCA	cis	rs2028299	0.92	rs4932265	ENSG00000259677.1	RP11-493E3.1	7.84	1.15e-14	3.39e-12	0.33	0.24	Type 2 diabetes;	chr15:89880061	chr15:89876540~89877285:+
BRCA	cis	rs6504622	0.755	rs12942936	ENSG00000262879.4	RP11-156P1.3	-7.83	1.15e-14	3.4e-12	-0.24	-0.24	Orofacial clefts;	chr17:47075062	chr17:46984045~47100323:-
BRCA	cis	rs10028773	0.515	rs9994651	ENSG00000248280.1	RP11-33B1.2	7.83	1.15e-14	3.4e-12	0.23	0.24	Educational attainment;	chr4:119666648	chr4:119440561~119450157:-
BRCA	cis	rs10129255	0.5	rs12101190	ENSG00000280411.1	IGHV1-69-2	-7.83	1.15e-14	3.4e-12	-0.16	-0.24	Kawasaki disease;	chr14:106784149	chr14:106762092~106762588:-
BRCA	cis	rs10129255	0.518	rs8004895	ENSG00000280411.1	IGHV1-69-2	-7.83	1.15e-14	3.4e-12	-0.16	-0.24	Kawasaki disease;	chr14:106785139	chr14:106762092~106762588:-
BRCA	cis	rs875971	0.545	rs7787063	ENSG00000224316.1	RP11-479O9.2	7.83	1.15e-14	3.4e-12	0.27	0.24	Aortic root size;	chr7:66164012	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.545	rs12673308	ENSG00000224316.1	RP11-479O9.2	7.83	1.15e-14	3.4e-12	0.27	0.24	Aortic root size;	chr7:66166374	chr7:65773620~65802067:+
BRCA	cis	rs1061377	1	rs28607301	ENSG00000249685.1	RP11-360F5.3	7.83	1.16e-14	3.41e-12	0.28	0.24	Uric acid levels;	chr4:39136460	chr4:39133913~39135608:+
BRCA	cis	rs287982	1	rs287980	ENSG00000269973.1	RP11-95D17.1	7.83	1.16e-14	3.41e-12	0.29	0.24	Nonsyndromic cleft lip with cleft palate;	chr2:9831237	chr2:9936360~9939590:+
BRCA	cis	rs2274273	0.624	rs7150234	ENSG00000258413.1	RP11-665C16.6	-7.83	1.16e-14	3.41e-12	-0.31	-0.24	Protein biomarker;	chr14:55335463	chr14:55262767~55272075:-
BRCA	cis	rs10129255	0.5	rs8022547	ENSG00000280411.1	IGHV1-69-2	-7.83	1.16e-14	3.42e-12	-0.15	-0.24	Kawasaki disease;	chr14:106781985	chr14:106762092~106762588:-
BRCA	cis	rs950880	0.71	rs2160202	ENSG00000234389.1	AC007278.3	-7.83	1.16e-14	3.42e-12	-0.24	-0.24	Serum protein levels (sST2);	chr2:102369694	chr2:102438713~102440475:+
BRCA	cis	rs812925	0.893	rs778160	ENSG00000271889.1	RP11-493E12.1	7.83	1.16e-14	3.42e-12	0.32	0.24	Immature fraction of reticulocytes;	chr2:61330029	chr2:61151433~61162105:-
BRCA	cis	rs875971	0.756	rs4718328	ENSG00000232559.3	GS1-124K5.12	-7.83	1.16e-14	3.42e-12	-0.28	-0.24	Aortic root size;	chr7:66228350	chr7:66554588~66576923:-
BRCA	cis	rs801193	0.66	rs1962050	ENSG00000237310.1	GS1-124K5.4	-7.83	1.16e-14	3.43e-12	-0.24	-0.24	Aortic root size;	chr7:66775021	chr7:66493706~66495474:+
BRCA	cis	rs925255	0.817	rs7606480	ENSG00000270210.1	RP11-373D23.3	-7.83	1.17e-14	3.43e-12	-0.31	-0.24	Inflammatory bowel disease;Crohn's disease;	chr2:28409510	chr2:28425945~28426719:+
BRCA	cis	rs8040855	0.624	rs12903975	ENSG00000259295.5	CSPG4P12	7.83	1.17e-14	3.44e-12	0.3	0.24	Bulimia nervosa;	chr15:85006004	chr15:85191438~85213905:+
BRCA	cis	rs2993535	1	rs3010029	ENSG00000233626.2	RP11-565J7.1	-7.83	1.17e-14	3.44e-12	-0.48	-0.24	Hip circumference adjusted for BMI;	chr1:212024502	chr1:211936249~211936634:+
BRCA	cis	rs9880211	0.948	rs17298525	ENSG00000273486.1	RP11-731C17.2	7.83	1.17e-14	3.45e-12	0.32	0.24	Height;Body mass index;	chr3:136474183	chr3:136837338~136839021:-
BRCA	cis	rs6142102	0.517	rs6059577	ENSG00000275784.1	RP5-1125A11.6	-7.83	1.17e-14	3.45e-12	-0.27	-0.24	Skin pigmentation;	chr20:33939880	chr20:33989480~33991818:-
BRCA	cis	rs780096	0.545	rs6716894	ENSG00000234072.1	AC074117.10	-7.83	1.17e-14	3.45e-12	-0.23	-0.24	Total body bone mineral density;	chr2:27360406	chr2:27356246~27367622:+
BRCA	cis	rs10129255	0.509	rs756583	ENSG00000280411.1	IGHV1-69-2	-7.83	1.17e-14	3.46e-12	-0.16	-0.24	Kawasaki disease;	chr14:106680002	chr14:106762092~106762588:-
BRCA	cis	rs10129255	0.536	rs3944157	ENSG00000280411.1	IGHV1-69-2	-7.83	1.18e-14	3.47e-12	-0.16	-0.24	Kawasaki disease;	chr14:106682286	chr14:106762092~106762588:-
BRCA	cis	rs9649213	0.574	rs60077733	ENSG00000272950.1	RP11-307C18.1	7.83	1.18e-14	3.47e-12	0.32	0.24	Prostate cancer (SNP x SNP interaction);	chr7:98340825	chr7:98322853~98323430:+
BRCA	cis	rs3758911	0.861	rs7131522	ENSG00000255353.1	RP11-382M14.1	-7.83	1.18e-14	3.48e-12	-0.32	-0.24	Coronary artery disease;	chr11:107293773	chr11:107176286~107177530:+
BRCA	cis	rs4835473	0.9	rs7667544	ENSG00000251600.4	RP11-673E1.1	-7.83	1.19e-14	3.49e-12	-0.29	-0.24	Immature fraction of reticulocytes;	chr4:143793802	chr4:143912331~143982454:+
BRCA	cis	rs7615952	0.641	rs7632497	ENSG00000250012.1	RP11-124N2.1	-7.83	1.19e-14	3.5e-12	-0.32	-0.24	Blood pressure (smoking interaction);	chr3:126064243	chr3:126084220~126095349:+
BRCA	cis	rs7615952	0.641	rs12487875	ENSG00000250012.1	RP11-124N2.1	-7.83	1.19e-14	3.5e-12	-0.32	-0.24	Blood pressure (smoking interaction);	chr3:126068381	chr3:126084220~126095349:+
BRCA	cis	rs10463554	0.926	rs26433	ENSG00000175749.11	EIF3KP1	7.83	1.19e-14	3.51e-12	0.31	0.24	Parkinson's disease;	chr5:103028154	chr5:103032376~103033031:+
BRCA	cis	rs875971	0.545	rs10950025	ENSG00000224316.1	RP11-479O9.2	7.83	1.2e-14	3.52e-12	0.27	0.24	Aortic root size;	chr7:66158946	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.52	rs12666485	ENSG00000224316.1	RP11-479O9.2	7.83	1.2e-14	3.52e-12	0.27	0.24	Aortic root size;	chr7:66160135	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.545	rs67688847	ENSG00000224316.1	RP11-479O9.2	7.83	1.2e-14	3.52e-12	0.27	0.24	Aortic root size;	chr7:66161064	chr7:65773620~65802067:+
BRCA	cis	rs73173548	0.502	rs6452789	ENSG00000247828.6	TMEM161B-AS1	7.83	1.2e-14	3.53e-12	0.31	0.24	Macular telangiectasia type 2;	chr5:88429498	chr5:88268895~88436685:+
BRCA	cis	rs7772486	0.743	rs62433835	ENSG00000235652.6	RP11-545I5.3	-7.83	1.2e-14	3.54e-12	-0.23	-0.24	Lobe attachment (rater-scored or self-reported);	chr6:145711552	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.743	rs2092262	ENSG00000235652.6	RP11-545I5.3	-7.83	1.2e-14	3.54e-12	-0.23	-0.24	Lobe attachment (rater-scored or self-reported);	chr6:145715969	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.682	rs1337840	ENSG00000235652.6	RP11-545I5.3	-7.83	1.2e-14	3.54e-12	-0.23	-0.24	Lobe attachment (rater-scored or self-reported);	chr6:145721422	chr6:145799409~145886585:+
BRCA	cis	rs858239	0.6	rs10256361	ENSG00000230042.1	AK3P3	-7.83	1.21e-14	3.56e-12	-0.27	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23084266	chr7:23129178~23129841:+
BRCA	cis	rs7246657	0.722	rs11083432	ENSG00000267422.1	CTD-2554C21.1	7.83	1.21e-14	3.56e-12	0.34	0.24	Coronary artery calcification;	chr19:37691732	chr19:37779686~37792865:+
BRCA	cis	rs4835473	0.9	rs13133239	ENSG00000251600.4	RP11-673E1.1	-7.83	1.21e-14	3.56e-12	-0.29	-0.24	Immature fraction of reticulocytes;	chr4:143818894	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.9	rs13106488	ENSG00000251600.4	RP11-673E1.1	-7.83	1.21e-14	3.56e-12	-0.29	-0.24	Immature fraction of reticulocytes;	chr4:143818969	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs35271123	ENSG00000251600.4	RP11-673E1.1	-7.83	1.21e-14	3.56e-12	-0.29	-0.24	Immature fraction of reticulocytes;	chr4:143819629	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs1383443	ENSG00000251600.4	RP11-673E1.1	-7.83	1.21e-14	3.56e-12	-0.29	-0.24	Immature fraction of reticulocytes;	chr4:143819940	chr4:143912331~143982454:+
BRCA	cis	rs1061377	1	rs1036036	ENSG00000249685.1	RP11-360F5.3	7.83	1.21e-14	3.57e-12	0.28	0.24	Uric acid levels;	chr4:39111104	chr4:39133913~39135608:+
BRCA	cis	rs6740322	0.696	rs10188539	ENSG00000234936.1	AC010883.5	7.83	1.22e-14	3.57e-12	0.26	0.24	Coronary artery disease;	chr2:43257536	chr2:43229573~43233394:+
BRCA	cis	rs3758911	1	rs10890716	ENSG00000255353.1	RP11-382M14.1	-7.83	1.22e-14	3.58e-12	-0.3	-0.24	Coronary artery disease;	chr11:107324310	chr11:107176286~107177530:+
BRCA	cis	rs950776	0.518	rs1504545	ENSG00000261762.1	RP11-650L12.2	-7.83	1.22e-14	3.58e-12	-0.27	-0.24	Sudden cardiac arrest;	chr15:78526129	chr15:78589123~78591276:-
BRCA	cis	rs6539288	0.933	rs1444583	ENSG00000260329.1	RP11-412D9.4	7.83	1.23e-14	3.6e-12	0.27	0.24	Total body bone mineral density;	chr12:106919068	chr12:106954029~106955497:-
BRCA	cis	rs875971	0.54	rs781152	ENSG00000164669.11	INTS4P1	-7.83	1.23e-14	3.61e-12	-0.29	-0.24	Aortic root size;	chr7:66014585	chr7:65141225~65234216:+
BRCA	cis	rs17711722	0.727	rs781151	ENSG00000164669.11	INTS4P1	-7.83	1.23e-14	3.61e-12	-0.29	-0.24	Calcium levels;	chr7:66014891	chr7:65141225~65234216:+
BRCA	cis	rs2439831	0.85	rs2228368	ENSG00000275601.1	AC011330.13	-7.83	1.23e-14	3.61e-12	-0.38	-0.24	Lung cancer in ever smokers;	chr15:43809812	chr15:43642389~43643023:-
BRCA	cis	rs950880	0.71	rs3732129	ENSG00000234389.1	AC007278.3	-7.83	1.23e-14	3.62e-12	-0.25	-0.24	Serum protein levels (sST2);	chr2:102341072	chr2:102438713~102440475:+
BRCA	cis	rs293748	0.882	rs158794	ENSG00000250155.1	CTD-2353F22.1	-7.83	1.24e-14	3.63e-12	-0.34	-0.24	Obesity-related traits;	chr5:36882986	chr5:36666214~36725195:-
BRCA	cis	rs8005677	1	rs8014936	ENSG00000279656.1	RP11-298I3.6	7.83	1.24e-14	3.64e-12	0.28	0.24	Cognitive ability (multi-trait analysis);	chr14:22905936	chr14:23023083~23024217:-
BRCA	cis	rs8005677	1	rs8016061	ENSG00000279656.1	RP11-298I3.6	7.83	1.24e-14	3.64e-12	0.28	0.24	Cognitive ability (multi-trait analysis);	chr14:22906600	chr14:23023083~23024217:-
BRCA	cis	rs3779195	0.584	rs1688605	ENSG00000272950.1	RP11-307C18.1	-7.82	1.25e-14	3.66e-12	-0.39	-0.24	Sex hormone-binding globulin levels;	chr7:98410534	chr7:98322853~98323430:+
BRCA	cis	rs7927771	0.832	rs7924485	ENSG00000280615.1	Y_RNA	7.82	1.25e-14	3.67e-12	0.29	0.24	Subjective well-being;	chr11:47397578	chr11:47614898~47614994:-
BRCA	cis	rs73173548	0.502	rs4144466	ENSG00000247828.6	TMEM161B-AS1	7.82	1.25e-14	3.68e-12	0.31	0.24	Macular telangiectasia type 2;	chr5:88412379	chr5:88268895~88436685:+
BRCA	cis	rs6504622	0.755	rs34774205	ENSG00000262879.4	RP11-156P1.3	-7.82	1.26e-14	3.69e-12	-0.24	-0.24	Orofacial clefts;	chr17:47083453	chr17:46984045~47100323:-
BRCA	cis	rs950169	0.58	rs17598114	ENSG00000259728.4	LINC00933	7.82	1.26e-14	3.7e-12	0.31	0.24	Schizophrenia;	chr15:84628086	chr15:84570649~84580175:+
BRCA	cis	rs950880	0.71	rs11693204	ENSG00000234389.1	AC007278.3	-7.82	1.26e-14	3.7e-12	-0.24	-0.24	Serum protein levels (sST2);	chr2:102319514	chr2:102438713~102440475:+
BRCA	cis	rs6539288	0.933	rs10778513	ENSG00000260329.1	RP11-412D9.4	-7.82	1.26e-14	3.7e-12	-0.27	-0.24	Total body bone mineral density;	chr12:106908405	chr12:106954029~106955497:-
BRCA	cis	rs6142102	0.517	rs6142050	ENSG00000275784.1	RP5-1125A11.6	-7.82	1.27e-14	3.73e-12	-0.27	-0.24	Skin pigmentation;	chr20:33939322	chr20:33989480~33991818:-
BRCA	cis	rs867371	1	rs8041868	ENSG00000259429.4	UBE2Q2P2	-7.82	1.27e-14	3.74e-12	-0.23	-0.24	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82179985	chr15:82355142~82420075:+
BRCA	cis	rs2742234	0.666	rs715106	ENSG00000273008.1	RP11-351D16.3	-7.82	1.28e-14	3.74e-12	-0.3	-0.24	Hirschsprung disease;	chr10:43121303	chr10:43136824~43138334:-
BRCA	cis	rs113835537	0.529	rs75683511	ENSG00000255517.5	CTD-3074O7.5	-7.82	1.28e-14	3.75e-12	-0.32	-0.24	Airway imaging phenotypes;	chr11:66507555	chr11:66473490~66480233:-
BRCA	cis	rs7615952	0.641	rs4422257	ENSG00000250012.1	RP11-124N2.1	-7.82	1.29e-14	3.77e-12	-0.32	-0.24	Blood pressure (smoking interaction);	chr3:126055520	chr3:126084220~126095349:+
BRCA	cis	rs7615952	0.641	rs66520539	ENSG00000250012.1	RP11-124N2.1	-7.82	1.29e-14	3.77e-12	-0.32	-0.24	Blood pressure (smoking interaction);	chr3:126061531	chr3:126084220~126095349:+
BRCA	cis	rs524281	0.692	rs2302884	ENSG00000255320.1	RP11-755F10.1	7.82	1.29e-14	3.79e-12	0.35	0.24	Electroencephalogram traits;	chr11:66056613	chr11:66244840~66246239:-
BRCA	cis	rs2060793	0.519	rs2597212	ENSG00000251991.1	RNU7-49P	-7.82	1.3e-14	3.8e-12	-0.25	-0.24	Vitamin D levels;	chr11:14560216	chr11:14478892~14478953:+
BRCA	cis	rs526231	0.543	rs7709726	ENSG00000175749.11	EIF3KP1	-7.82	1.3e-14	3.81e-12	-0.32	-0.24	Primary biliary cholangitis;	chr5:102991759	chr5:103032376~103033031:+
BRCA	cis	rs875971	0.862	rs4718330	ENSG00000232559.3	GS1-124K5.12	-7.82	1.3e-14	3.81e-12	-0.28	-0.24	Aortic root size;	chr7:66250256	chr7:66554588~66576923:-
BRCA	cis	rs42648	0.905	rs42622	ENSG00000225498.1	AC002064.5	7.82	1.3e-14	3.81e-12	0.23	0.24	Homocysteine levels;	chr7:90327510	chr7:90312496~90322592:+
BRCA	cis	rs42648	0.935	rs42624	ENSG00000225498.1	AC002064.5	7.82	1.3e-14	3.81e-12	0.23	0.24	Homocysteine levels;	chr7:90328227	chr7:90312496~90322592:+
BRCA	cis	rs950880	0.71	rs12470867	ENSG00000234389.1	AC007278.3	-7.82	1.31e-14	3.82e-12	-0.24	-0.24	Serum protein levels (sST2);	chr2:102309906	chr2:102438713~102440475:+
BRCA	cis	rs3758911	1	rs10789611	ENSG00000255353.1	RP11-382M14.1	-7.82	1.31e-14	3.83e-12	-0.3	-0.24	Coronary artery disease;	chr11:107316810	chr11:107176286~107177530:+
BRCA	cis	rs3758911	1	rs10789612	ENSG00000255353.1	RP11-382M14.1	-7.82	1.31e-14	3.83e-12	-0.3	-0.24	Coronary artery disease;	chr11:107316931	chr11:107176286~107177530:+
BRCA	cis	rs3758911	1	rs10890707	ENSG00000255353.1	RP11-382M14.1	-7.82	1.31e-14	3.83e-12	-0.3	-0.24	Coronary artery disease;	chr11:107317153	chr11:107176286~107177530:+
BRCA	cis	rs3758911	1	rs10890708	ENSG00000255353.1	RP11-382M14.1	-7.82	1.31e-14	3.83e-12	-0.3	-0.24	Coronary artery disease;	chr11:107317315	chr11:107176286~107177530:+
BRCA	cis	rs3758911	0.964	rs10890709	ENSG00000255353.1	RP11-382M14.1	-7.82	1.31e-14	3.83e-12	-0.3	-0.24	Coronary artery disease;	chr11:107317378	chr11:107176286~107177530:+
BRCA	cis	rs3758911	0.964	rs10890711	ENSG00000255353.1	RP11-382M14.1	-7.82	1.31e-14	3.83e-12	-0.3	-0.24	Coronary artery disease;	chr11:107317424	chr11:107176286~107177530:+
BRCA	cis	rs3758911	0.964	rs12290112	ENSG00000255353.1	RP11-382M14.1	-7.82	1.31e-14	3.83e-12	-0.3	-0.24	Coronary artery disease;	chr11:107317487	chr11:107176286~107177530:+
BRCA	cis	rs3758911	0.964	rs12270655	ENSG00000255353.1	RP11-382M14.1	-7.82	1.31e-14	3.83e-12	-0.3	-0.24	Coronary artery disease;	chr11:107317507	chr11:107176286~107177530:+
BRCA	cis	rs3758911	0.964	rs10890712	ENSG00000255353.1	RP11-382M14.1	-7.82	1.31e-14	3.83e-12	-0.3	-0.24	Coronary artery disease;	chr11:107317583	chr11:107176286~107177530:+
BRCA	cis	rs10129255	0.536	rs17113249	ENSG00000211970.3	IGHV4-61	-7.82	1.31e-14	3.83e-12	-0.15	-0.24	Kawasaki disease;	chr14:106678273	chr14:106639119~106639657:-
BRCA	cis	rs7809950	0.954	rs12673675	ENSG00000238832.1	snoU109	-7.82	1.31e-14	3.83e-12	-0.31	-0.24	Coronary artery disease;	chr7:107472775	chr7:107603363~107603507:+
BRCA	cis	rs8005677	1	rs8005677	ENSG00000279656.1	RP11-298I3.6	7.82	1.31e-14	3.83e-12	0.28	0.24	Cognitive ability (multi-trait analysis);	chr14:22907469	chr14:23023083~23024217:-
BRCA	cis	rs4820294	1	rs7291867	ENSG00000233360.4	Z83844.1	7.82	1.31e-14	3.85e-12	0.29	0.24	Fat distribution (HIV);	chr22:37666105	chr22:37641832~37658377:-
BRCA	cis	rs9880211	0.948	rs34135127	ENSG00000273486.1	RP11-731C17.2	7.82	1.32e-14	3.85e-12	0.32	0.24	Height;Body mass index;	chr3:136507656	chr3:136837338~136839021:-
BRCA	cis	rs1823913	0.525	rs7424440	ENSG00000227542.1	AC092614.2	7.82	1.32e-14	3.85e-12	0.29	0.24	Obesity-related traits;	chr2:191337919	chr2:191229165~191246172:-
BRCA	cis	rs10129255	0.826	rs7150693	ENSG00000223648.3	IGHV3-64	7.82	1.32e-14	3.86e-12	0.21	0.24	Kawasaki disease;	chr14:106705382	chr14:106643132~106658258:-
BRCA	cis	rs10129255	0.869	rs7150549	ENSG00000223648.3	IGHV3-64	7.82	1.32e-14	3.86e-12	0.21	0.24	Kawasaki disease;	chr14:106705441	chr14:106643132~106658258:-
BRCA	cis	rs3758911	0.929	rs55837508	ENSG00000255353.1	RP11-382M14.1	-7.82	1.32e-14	3.87e-12	-0.3	-0.24	Coronary artery disease;	chr11:107323756	chr11:107176286~107177530:+
BRCA	cis	rs867371	1	rs1846911	ENSG00000259429.4	UBE2Q2P2	-7.82	1.32e-14	3.87e-12	-0.23	-0.24	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82176309	chr15:82355142~82420075:+
BRCA	cis	rs875971	0.862	rs6955837	ENSG00000232559.3	GS1-124K5.12	-7.82	1.33e-14	3.89e-12	-0.29	-0.24	Aortic root size;	chr7:66578155	chr7:66554588~66576923:-
BRCA	cis	rs73173548	0.502	rs12516483	ENSG00000247828.6	TMEM161B-AS1	7.82	1.33e-14	3.9e-12	0.31	0.24	Macular telangiectasia type 2;	chr5:88454718	chr5:88268895~88436685:+
BRCA	cis	rs4934494	0.681	rs34591435	ENSG00000240996.1	RP11-80H5.7	-7.82	1.34e-14	3.91e-12	-0.29	-0.24	Red blood cell count;	chr10:89721691	chr10:89694295~89697928:-
BRCA	cis	rs1113500	0.787	rs473704	ENSG00000226822.1	RP11-356N1.2	-7.81	1.34e-14	3.92e-12	-0.3	-0.24	Growth-regulated protein alpha levels;	chr1:108094688	chr1:108071482~108074519:+
BRCA	cis	rs950880	0.71	rs56043441	ENSG00000234389.1	AC007278.3	-7.81	1.34e-14	3.93e-12	-0.23	-0.24	Serum protein levels (sST2);	chr2:102470923	chr2:102438713~102440475:+
BRCA	cis	rs9527	0.571	rs7096249	ENSG00000213061.2	PFN1P11	7.81	1.34e-14	3.93e-12	0.31	0.24	Arsenic metabolism;	chr10:102858767	chr10:102838011~102845473:-
BRCA	cis	rs4835473	0.932	rs13117421	ENSG00000251600.4	RP11-673E1.1	-7.81	1.35e-14	3.94e-12	-0.3	-0.24	Immature fraction of reticulocytes;	chr4:143769405	chr4:143912331~143982454:+
BRCA	cis	rs2243480	1	rs160652	ENSG00000273142.1	RP11-458F8.4	-7.81	1.35e-14	3.94e-12	-0.34	-0.24	Diabetic kidney disease;	chr7:66073444	chr7:66902857~66906297:+
BRCA	cis	rs11098499	0.57	rs6832740	ENSG00000245958.5	RP11-33B1.1	-7.81	1.36e-14	3.96e-12	-0.22	-0.24	Corneal astigmatism;	chr4:119624981	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.644	rs6855918	ENSG00000245958.5	RP11-33B1.1	-7.81	1.36e-14	3.96e-12	-0.22	-0.24	Corneal astigmatism;	chr4:119625144	chr4:119454791~119552025:+
BRCA	cis	rs7811142	1	rs11763414	ENSG00000242294.5	STAG3L5P	7.81	1.36e-14	3.96e-12	0.23	0.24	Platelet count;	chr7:100419221	chr7:100336079~100351900:+
BRCA	cis	rs875971	1	rs6956179	ENSG00000237310.1	GS1-124K5.4	-7.81	1.36e-14	3.97e-12	-0.24	-0.24	Aortic root size;	chr7:66341672	chr7:66493706~66495474:+
BRCA	cis	rs847577	0.646	rs10270222	ENSG00000272950.1	RP11-307C18.1	-7.81	1.36e-14	3.97e-12	-0.3	-0.24	Breast cancer;	chr7:98152487	chr7:98322853~98323430:+
BRCA	cis	rs9368481	0.761	rs3931464	ENSG00000241549.7	GUSBP2	7.81	1.36e-14	3.97e-12	0.27	0.24	Autism spectrum disorder or schizophrenia;	chr6:26972077	chr6:26871484~26956554:-
BRCA	cis	rs2439831	0.618	rs8023508	ENSG00000249839.1	AC011330.5	7.81	1.36e-14	3.98e-12	0.35	0.24	Lung cancer in ever smokers;	chr15:43883905	chr15:43663654~43684339:-
BRCA	cis	rs6472827	0.953	rs35446151	ENSG00000253983.2	RP1-16A9.1	-7.81	1.36e-14	3.98e-12	-0.36	-0.24	Uterine fibroids;	chr8:74209236	chr8:74199396~74208441:+
BRCA	cis	rs875971	0.862	rs4718377	ENSG00000232559.3	GS1-124K5.12	-7.81	1.37e-14	4e-12	-0.29	-0.24	Aortic root size;	chr7:66584691	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.862	rs10278014	ENSG00000232559.3	GS1-124K5.12	-7.81	1.37e-14	4e-12	-0.29	-0.24	Aortic root size;	chr7:66586277	chr7:66554588~66576923:-
BRCA	cis	rs250518	0.926	rs4321733	ENSG00000272081.1	CTD-2376I4.2	7.81	1.37e-14	4e-12	0.3	0.24	Mean corpuscular hemoglobin concentration;	chr5:72759145	chr5:72955206~72955699:-
BRCA	cis	rs250518	0.926	rs4618410	ENSG00000272081.1	CTD-2376I4.2	7.81	1.37e-14	4e-12	0.3	0.24	Mean corpuscular hemoglobin concentration;	chr5:72759146	chr5:72955206~72955699:-
BRCA	cis	rs2028299	1	rs8031576	ENSG00000259677.1	RP11-493E3.1	7.81	1.37e-14	4e-12	0.31	0.24	Type 2 diabetes;	chr15:89836982	chr15:89876540~89877285:+
BRCA	cis	rs9543976	0.623	rs4611344	ENSG00000261553.4	RP11-29G8.3	7.81	1.37e-14	4e-12	0.38	0.24	Diabetic retinopathy;	chr13:75601192	chr13:75549773~75807120:+
BRCA	cis	rs2911132	0.628	rs2032890	ENSG00000248734.2	CTD-2260A17.1	7.81	1.37e-14	4.01e-12	0.28	0.24	Urate levels (BMI interaction);	chr5:96785448	chr5:96784777~96785999:+
BRCA	cis	rs193541	0.632	rs154504	ENSG00000263432.2	RN7SL689P	7.81	1.37e-14	4.01e-12	0.31	0.24	Glucose homeostasis traits;	chr5:122868391	chr5:123022487~123022783:-
BRCA	cis	rs17213965	0.852	rs4781692	ENSG00000207425.1	Y_RNA	7.81	1.38e-14	4.02e-12	0.39	0.24	Waist-hip ratio;	chr16:15784296	chr16:14915457~14915556:-
BRCA	cis	rs2842992	0.872	rs9456440	ENSG00000237927.1	RP3-393E18.2	-7.81	1.38e-14	4.03e-12	-0.33	-0.24	Age-related macular degeneration (geographic atrophy);	chr6:159653431	chr6:159586955~159589169:-
BRCA	cis	rs9543976	0.623	rs6562918	ENSG00000261553.4	RP11-29G8.3	7.81	1.39e-14	4.05e-12	0.38	0.24	Diabetic retinopathy;	chr13:75600441	chr13:75549773~75807120:+
BRCA	cis	rs3745672	1	rs73509026	ENSG00000219665.7	CTD-2006C1.2	-7.81	1.39e-14	4.06e-12	-0.61	-0.24	Multiple sclerosis;	chr19:11948652	chr19:11987617~12046275:+
BRCA	cis	rs950880	0.71	rs2287034	ENSG00000234389.1	AC007278.3	7.81	1.39e-14	4.06e-12	0.24	0.24	Serum protein levels (sST2);	chr2:102394128	chr2:102438713~102440475:+
BRCA	cis	rs867371	1	rs1501372	ENSG00000259429.4	UBE2Q2P2	-7.81	1.39e-14	4.07e-12	-0.23	-0.24	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82176114	chr15:82355142~82420075:+
BRCA	cis	rs2439831	0.85	rs28524541	ENSG00000205771.5	CATSPER2P1	-7.81	1.39e-14	4.07e-12	-0.4	-0.24	Lung cancer in ever smokers;	chr15:43832633	chr15:43726918~43747094:-
BRCA	cis	rs957448	0.554	rs12682601	ENSG00000253704.1	RP11-267M23.4	7.81	1.4e-14	4.08e-12	0.26	0.24	Nonsyndromic cleft lip with cleft palate;	chr8:94582492	chr8:94553722~94569745:+
BRCA	cis	rs10463554	0.892	rs17154860	ENSG00000175749.11	EIF3KP1	7.81	1.4e-14	4.09e-12	0.32	0.24	Parkinson's disease;	chr5:102955441	chr5:103032376~103033031:+
BRCA	cis	rs17772222	0.876	rs56144430	ENSG00000258983.2	RP11-507K2.2	7.81	1.4e-14	4.09e-12	0.27	0.24	Coronary artery calcification;	chr14:88622013	chr14:88499334~88515502:+
BRCA	cis	rs2742234	0.59	rs2435376	ENSG00000273008.1	RP11-351D16.3	-7.81	1.41e-14	4.11e-12	-0.3	-0.24	Hirschsprung disease;	chr10:43189515	chr10:43136824~43138334:-
BRCA	cis	rs2742234	0.579	rs2503881	ENSG00000273008.1	RP11-351D16.3	-7.81	1.41e-14	4.11e-12	-0.3	-0.24	Hirschsprung disease;	chr10:43190578	chr10:43136824~43138334:-
BRCA	cis	rs10129255	0.784	rs7147210	ENSG00000223648.3	IGHV3-64	7.81	1.41e-14	4.11e-12	0.21	0.24	Kawasaki disease;	chr14:106705271	chr14:106643132~106658258:-
BRCA	cis	rs4753788	0.511	rs12224337	ENSG00000255353.1	RP11-382M14.1	-7.81	1.41e-14	4.12e-12	-0.28	-0.24	Coronary artery disease;	chr11:107269351	chr11:107176286~107177530:+
BRCA	cis	rs867371	1	rs11855089	ENSG00000255769.6	GOLGA2P10	-7.81	1.41e-14	4.12e-12	-0.27	-0.24	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82154924	chr15:82472993~82513950:-
BRCA	cis	rs61270009	0.863	rs35339529	ENSG00000247828.6	TMEM161B-AS1	7.81	1.41e-14	4.12e-12	0.3	0.24	Depressive symptoms;	chr5:88360284	chr5:88268895~88436685:+
BRCA	cis	rs2911132	0.967	rs2042380	ENSG00000248734.2	CTD-2260A17.1	7.81	1.41e-14	4.13e-12	0.27	0.24	Urate levels (BMI interaction);	chr5:96851563	chr5:96784777~96785999:+
BRCA	cis	rs875971	0.825	rs10281499	ENSG00000232559.3	GS1-124K5.12	-7.81	1.41e-14	4.13e-12	-0.29	-0.24	Aortic root size;	chr7:66583979	chr7:66554588~66576923:-
BRCA	cis	rs2880765	0.835	rs4842887	ENSG00000259295.5	CSPG4P12	7.81	1.41e-14	4.13e-12	0.28	0.24	Coronary artery disease;	chr15:85492579	chr15:85191438~85213905:+
BRCA	cis	rs4835473	0.868	rs1828503	ENSG00000251600.4	RP11-673E1.1	-7.81	1.42e-14	4.15e-12	-0.29	-0.24	Immature fraction of reticulocytes;	chr4:143993354	chr4:143912331~143982454:+
BRCA	cis	rs7615952	0.641	rs7618515	ENSG00000250012.1	RP11-124N2.1	-7.81	1.43e-14	4.17e-12	-0.32	-0.24	Blood pressure (smoking interaction);	chr3:126071735	chr3:126084220~126095349:+
BRCA	cis	rs875971	0.83	rs778715	ENSG00000232559.3	GS1-124K5.12	7.81	1.43e-14	4.17e-12	0.29	0.24	Aortic root size;	chr7:66384222	chr7:66554588~66576923:-
BRCA	cis	rs293748	0.771	rs181755	ENSG00000250155.1	CTD-2353F22.1	-7.81	1.43e-14	4.17e-12	-0.33	-0.24	Obesity-related traits;	chr5:36839162	chr5:36666214~36725195:-
BRCA	cis	rs1062177	0.694	rs2915816	ENSG00000253921.1	CTB-113P19.3	7.81	1.43e-14	4.18e-12	0.31	0.24	Preschool internalizing problems;	chr5:151736296	chr5:151753992~151767247:+
BRCA	cis	rs11098499	0.644	rs7693919	ENSG00000245958.5	RP11-33B1.1	-7.81	1.44e-14	4.19e-12	-0.22	-0.24	Corneal astigmatism;	chr4:119619416	chr4:119454791~119552025:+
BRCA	cis	rs875971	0.522	rs1617484	ENSG00000222364.1	RNU6-96P	-7.81	1.44e-14	4.19e-12	-0.27	-0.24	Aortic root size;	chr7:65998108	chr7:66395191~66395286:+
BRCA	cis	rs2179367	0.92	rs638407	ENSG00000231760.4	RP11-350J20.5	7.81	1.44e-14	4.19e-12	0.3	0.24	Dupuytren's disease;	chr6:149417214	chr6:149796151~149826294:-
BRCA	cis	rs4835473	0.897	rs12508285	ENSG00000251600.4	RP11-673E1.1	-7.81	1.44e-14	4.19e-12	-0.29	-0.24	Immature fraction of reticulocytes;	chr4:143792642	chr4:143912331~143982454:+
BRCA	cis	rs526231	0.543	rs246915	ENSG00000175749.11	EIF3KP1	7.81	1.44e-14	4.2e-12	0.35	0.24	Primary biliary cholangitis;	chr5:103222343	chr5:103032376~103033031:+
BRCA	cis	rs4934494	0.727	rs12572012	ENSG00000240996.1	RP11-80H5.7	-7.8	1.44e-14	4.21e-12	-0.29	-0.24	Red blood cell count;	chr10:89727892	chr10:89694295~89697928:-
BRCA	cis	rs4934494	0.727	rs3758388	ENSG00000240996.1	RP11-80H5.7	-7.8	1.44e-14	4.21e-12	-0.29	-0.24	Red blood cell count;	chr10:89729222	chr10:89694295~89697928:-
BRCA	cis	rs4934494	0.727	rs12783582	ENSG00000240996.1	RP11-80H5.7	-7.8	1.44e-14	4.21e-12	-0.29	-0.24	Red blood cell count;	chr10:89735210	chr10:89694295~89697928:-
BRCA	cis	rs875971	0.755	rs76288834	ENSG00000232559.3	GS1-124K5.12	-7.8	1.45e-14	4.21e-12	-0.29	-0.24	Aortic root size;	chr7:66604815	chr7:66554588~66576923:-
BRCA	cis	rs732716	0.785	rs11667543	ENSG00000267980.1	AC007292.6	-7.8	1.45e-14	4.22e-12	-0.32	-0.24	Mean corpuscular volume;	chr19:4374853	chr19:4363789~4364640:+
BRCA	cis	rs2028299	0.879	rs3803534	ENSG00000259677.1	RP11-493E3.1	7.8	1.45e-14	4.22e-12	0.33	0.24	Type 2 diabetes;	chr15:89898638	chr15:89876540~89877285:+
BRCA	cis	rs2179367	0.632	rs11155645	ENSG00000231760.4	RP11-350J20.5	7.8	1.45e-14	4.22e-12	0.34	0.24	Dupuytren's disease;	chr6:149360056	chr6:149796151~149826294:-
BRCA	cis	rs2179367	0.632	rs9498332	ENSG00000231760.4	RP11-350J20.5	7.8	1.45e-14	4.22e-12	0.34	0.24	Dupuytren's disease;	chr6:149367490	chr6:149796151~149826294:-
BRCA	cis	rs2179367	0.632	rs9498333	ENSG00000231760.4	RP11-350J20.5	7.8	1.45e-14	4.22e-12	0.34	0.24	Dupuytren's disease;	chr6:149368196	chr6:149796151~149826294:-
BRCA	cis	rs875971	0.862	rs11763189	ENSG00000232559.3	GS1-124K5.12	7.8	1.45e-14	4.24e-12	0.28	0.23	Aortic root size;	chr7:66518542	chr7:66554588~66576923:-
BRCA	cis	rs2243480	1	rs316329	ENSG00000273142.1	RP11-458F8.4	-7.8	1.45e-14	4.24e-12	-0.31	-0.23	Diabetic kidney disease;	chr7:66143429	chr7:66902857~66906297:+
BRCA	cis	rs77204473	1	rs11216186	ENSG00000254851.1	RP11-109L13.1	7.8	1.46e-14	4.24e-12	0.56	0.23	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116913976	chr11:117135528~117138582:+
BRCA	cis	rs4835473	0.9	rs12503074	ENSG00000251600.4	RP11-673E1.1	-7.8	1.46e-14	4.25e-12	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143812560	chr4:143912331~143982454:+
BRCA	cis	rs7811142	0.83	rs11765869	ENSG00000242294.5	STAG3L5P	7.8	1.46e-14	4.25e-12	0.25	0.23	Platelet count;	chr7:100367166	chr7:100336079~100351900:+
BRCA	cis	rs2115630	0.967	rs11073702	ENSG00000225151.9	GOLGA2P7	7.8	1.46e-14	4.26e-12	0.25	0.23	P wave terminal force;	chr15:84766840	chr15:84199311~84230136:-
BRCA	cis	rs293748	0.713	rs2937116	ENSG00000250155.1	CTD-2353F22.1	-7.8	1.47e-14	4.28e-12	-0.33	-0.23	Obesity-related traits;	chr5:36824900	chr5:36666214~36725195:-
BRCA	cis	rs812925	0.659	rs2167565	ENSG00000271889.1	RP11-493E12.1	-7.8	1.47e-14	4.28e-12	-0.3	-0.23	Immature fraction of reticulocytes;	chr2:61249323	chr2:61151433~61162105:-
BRCA	cis	rs2742234	0.59	rs1254965	ENSG00000273008.1	RP11-351D16.3	7.8	1.47e-14	4.29e-12	0.3	0.23	Hirschsprung disease;	chr10:43194405	chr10:43136824~43138334:-
BRCA	cis	rs2742234	0.59	rs2115817	ENSG00000273008.1	RP11-351D16.3	-7.8	1.47e-14	4.29e-12	-0.3	-0.23	Hirschsprung disease;	chr10:43191104	chr10:43136824~43138334:-
BRCA	cis	rs11098499	0.909	rs10017335	ENSG00000248280.1	RP11-33B1.2	-7.8	1.47e-14	4.29e-12	-0.24	-0.23	Corneal astigmatism;	chr4:119460368	chr4:119440561~119450157:-
BRCA	cis	rs11976180	1	rs4726669	ENSG00000170356.8	OR2A20P	-7.8	1.47e-14	4.29e-12	-0.33	-0.23	Obesity-related traits;	chr7:144061098	chr7:144250045~144252957:-
BRCA	cis	rs250518	0.926	rs11747669	ENSG00000272081.1	CTD-2376I4.2	7.8	1.47e-14	4.3e-12	0.3	0.23	Mean corpuscular hemoglobin concentration;	chr5:72760354	chr5:72955206~72955699:-
BRCA	cis	rs6504622	0.755	rs34038545	ENSG00000262879.4	RP11-156P1.3	-7.8	1.48e-14	4.3e-12	-0.24	-0.23	Orofacial clefts;	chr17:47067541	chr17:46984045~47100323:-
BRCA	cis	rs2439831	0.85	rs28858500	ENSG00000205771.5	CATSPER2P1	-7.8	1.48e-14	4.32e-12	-0.4	-0.23	Lung cancer in ever smokers;	chr15:43864744	chr15:43726918~43747094:-
BRCA	cis	rs875971	0.862	rs4236208	ENSG00000232559.3	GS1-124K5.12	-7.8	1.49e-14	4.33e-12	-0.28	-0.23	Aortic root size;	chr7:66284091	chr7:66554588~66576923:-
BRCA	cis	rs113835537	0.529	rs12099041	ENSG00000255517.5	CTD-3074O7.5	-7.8	1.49e-14	4.34e-12	-0.3	-0.23	Airway imaging phenotypes;	chr11:66465302	chr11:66473490~66480233:-
BRCA	cis	rs113835537	0.529	rs57691879	ENSG00000255517.5	CTD-3074O7.5	-7.8	1.49e-14	4.34e-12	-0.3	-0.23	Airway imaging phenotypes;	chr11:66469133	chr11:66473490~66480233:-
BRCA	cis	rs6952407	1	rs6952407	ENSG00000224316.1	RP11-479O9.2	-7.8	1.49e-14	4.34e-12	-0.23	-0.23	Cotinine glucuronidation;	chr7:66580525	chr7:65773620~65802067:+
BRCA	cis	rs10129255	0.719	rs7156660	ENSG00000223648.3	IGHV3-64	7.8	1.49e-14	4.35e-12	0.2	0.23	Kawasaki disease;	chr14:106673171	chr14:106643132~106658258:-
BRCA	cis	rs11098499	1	rs35643470	ENSG00000248280.1	RP11-33B1.2	7.8	1.5e-14	4.35e-12	0.24	0.23	Corneal astigmatism;	chr4:119263793	chr4:119440561~119450157:-
BRCA	cis	rs7809950	1	rs10234355	ENSG00000238832.1	snoU109	-7.8	1.5e-14	4.36e-12	-0.31	-0.23	Coronary artery disease;	chr7:107446072	chr7:107603363~107603507:+
BRCA	cis	rs7809950	1	rs4727680	ENSG00000238832.1	snoU109	-7.8	1.5e-14	4.36e-12	-0.31	-0.23	Coronary artery disease;	chr7:107446962	chr7:107603363~107603507:+
BRCA	cis	rs950880	0.677	rs56224165	ENSG00000234389.1	AC007278.3	-7.8	1.5e-14	4.36e-12	-0.24	-0.23	Serum protein levels (sST2);	chr2:102308763	chr2:102438713~102440475:+
BRCA	cis	rs77204473	1	rs11216185	ENSG00000254851.1	RP11-109L13.1	7.8	1.5e-14	4.36e-12	0.55	0.23	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116912258	chr11:117135528~117138582:+
BRCA	cis	rs13068223	0.74	rs344028	ENSG00000243926.1	TIPARP-AS1	7.8	1.5e-14	4.37e-12	0.24	0.23	Age-related hearing impairment (SNP x SNP interaction);	chr3:156747980	chr3:156671862~156674378:-
BRCA	cis	rs2179367	0.632	rs10155766	ENSG00000231760.4	RP11-350J20.5	7.8	1.5e-14	4.37e-12	0.34	0.23	Dupuytren's disease;	chr6:149364577	chr6:149796151~149826294:-
BRCA	cis	rs950169	0.544	rs62021193	ENSG00000259728.4	LINC00933	7.8	1.5e-14	4.38e-12	0.31	0.23	Schizophrenia;	chr15:84627352	chr15:84570649~84580175:+
BRCA	cis	rs897984	0.511	rs7196726	ENSG00000260911.2	RP11-196G11.2	7.8	1.5e-14	4.38e-12	0.21	0.23	Dementia with Lewy bodies;	chr16:31080754	chr16:31043150~31049868:+
BRCA	cis	rs4934494	0.727	rs2418929	ENSG00000240996.1	RP11-80H5.7	-7.8	1.5e-14	4.38e-12	-0.29	-0.23	Red blood cell count;	chr10:89741720	chr10:89694295~89697928:-
BRCA	cis	rs4835473	0.932	rs1580002	ENSG00000251600.4	RP11-673E1.1	-7.8	1.51e-14	4.39e-12	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143766507	chr4:143912331~143982454:+
BRCA	cis	rs9876781	1	rs13076076	ENSG00000244380.1	RP11-24C3.2	7.8	1.51e-14	4.4e-12	0.27	0.23	Longevity;	chr3:48437629	chr3:48440352~48446656:-
BRCA	cis	rs7674212	0.507	rs10516495	ENSG00000246560.2	RP11-10L12.4	7.8	1.52e-14	4.41e-12	0.26	0.23	Type 2 diabetes;	chr4:102978933	chr4:102828055~102844075:+
BRCA	cis	rs860818	1	rs858249	ENSG00000226816.2	AC005082.12	-7.8	1.52e-14	4.41e-12	-0.5	-0.23	Initial pursuit acceleration;	chr7:23181020	chr7:23206013~23208045:+
BRCA	cis	rs2742234	0.59	rs1254962	ENSG00000273008.1	RP11-351D16.3	7.8	1.52e-14	4.42e-12	0.3	0.23	Hirschsprung disease;	chr10:43201544	chr10:43136824~43138334:-
BRCA	cis	rs2742234	0.541	rs1254959	ENSG00000273008.1	RP11-351D16.3	7.8	1.52e-14	4.42e-12	0.3	0.23	Hirschsprung disease;	chr10:43205531	chr10:43136824~43138334:-
BRCA	cis	rs2742234	0.541	rs1254958	ENSG00000273008.1	RP11-351D16.3	7.8	1.52e-14	4.42e-12	0.3	0.23	Hirschsprung disease;	chr10:43206695	chr10:43136824~43138334:-
BRCA	cis	rs4835473	0.932	rs7669198	ENSG00000251600.4	RP11-673E1.1	-7.8	1.53e-14	4.45e-12	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143821229	chr4:143912331~143982454:+
BRCA	cis	rs4934494	0.681	rs1129777	ENSG00000240996.1	RP11-80H5.7	-7.8	1.53e-14	4.45e-12	-0.29	-0.23	Red blood cell count;	chr10:89709168	chr10:89694295~89697928:-
BRCA	cis	rs4934494	0.727	rs3824607	ENSG00000240996.1	RP11-80H5.7	-7.8	1.53e-14	4.45e-12	-0.29	-0.23	Red blood cell count;	chr10:89711258	chr10:89694295~89697928:-
BRCA	cis	rs4934494	0.681	rs3740035	ENSG00000240996.1	RP11-80H5.7	-7.8	1.53e-14	4.45e-12	-0.29	-0.23	Red blood cell count;	chr10:89716708	chr10:89694295~89697928:-
BRCA	cis	rs9543976	0.545	rs2328963	ENSG00000261553.4	RP11-29G8.3	7.8	1.54e-14	4.47e-12	0.38	0.23	Diabetic retinopathy;	chr13:75601390	chr13:75549773~75807120:+
BRCA	cis	rs4835473	0.868	rs13105118	ENSG00000251600.4	RP11-673E1.1	-7.8	1.54e-14	4.47e-12	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143819077	chr4:143912331~143982454:+
BRCA	cis	rs12468226	0.689	rs17651413	ENSG00000273456.1	RP11-686O6.2	7.8	1.54e-14	4.47e-12	0.36	0.23	Urate levels;	chr2:202104086	chr2:202374932~202375604:-
BRCA	cis	rs6142102	0.812	rs6059554	ENSG00000276073.1	RP5-1125A11.7	-7.8	1.54e-14	4.49e-12	-0.29	-0.23	Skin pigmentation;	chr20:33926286	chr20:33985617~33988989:-
BRCA	cis	rs12188164	0.543	rs7728027	ENSG00000225138.6	CTD-2228K2.7	-7.8	1.55e-14	4.5e-12	-0.25	-0.23	Cystic fibrosis severity;	chr5:459828	chr5:473236~480884:+
BRCA	cis	rs10129255	0.518	rs8009612	ENSG00000280411.1	IGHV1-69-2	-7.8	1.55e-14	4.51e-12	-0.15	-0.23	Kawasaki disease;	chr14:106777510	chr14:106762092~106762588:-
BRCA	cis	rs2179367	0.632	rs6920383	ENSG00000231760.4	RP11-350J20.5	7.8	1.55e-14	4.51e-12	0.34	0.23	Dupuytren's disease;	chr6:149356361	chr6:149796151~149826294:-
BRCA	cis	rs193541	0.53	rs2045626	ENSG00000263432.2	RN7SL689P	7.79	1.56e-14	4.54e-12	0.31	0.23	Glucose homeostasis traits;	chr5:122745558	chr5:123022487~123022783:-
BRCA	cis	rs113835537	0.529	rs3819247	ENSG00000255517.5	CTD-3074O7.5	-7.79	1.57e-14	4.55e-12	-0.31	-0.23	Airway imaging phenotypes;	chr11:66526308	chr11:66473490~66480233:-
BRCA	cis	rs2243480	1	rs316326	ENSG00000273142.1	RP11-458F8.4	-7.79	1.57e-14	4.55e-12	-0.32	-0.23	Diabetic kidney disease;	chr7:66144466	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs316325	ENSG00000273142.1	RP11-458F8.4	-7.79	1.57e-14	4.55e-12	-0.32	-0.23	Diabetic kidney disease;	chr7:66144531	chr7:66902857~66906297:+
BRCA	cis	rs755249	1	rs2293476	ENSG00000228060.1	RP11-69E11.8	7.79	1.57e-14	4.56e-12	0.28	0.23	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39571175	chr1:39565160~39573203:+
BRCA	cis	rs4713118	0.615	rs9295747	ENSG00000216901.1	AL022393.7	-7.79	1.57e-14	4.57e-12	-0.3	-0.23	Parkinson's disease;	chr6:27769214	chr6:28176188~28176674:+
BRCA	cis	rs9880211	1	rs9828976	ENSG00000239213.4	NCK1-AS1	7.79	1.58e-14	4.59e-12	0.31	0.23	Height;Body mass index;	chr3:136817993	chr3:136841726~136862054:-
BRCA	cis	rs8062405	0.824	rs4788085	ENSG00000251417.2	RP11-1348G14.4	-7.79	1.58e-14	4.61e-12	-0.27	-0.23	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28523682	chr16:28802743~28817828:+
BRCA	cis	rs8062405	0.824	rs28772958	ENSG00000251417.2	RP11-1348G14.4	-7.79	1.58e-14	4.61e-12	-0.27	-0.23	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28523984	chr16:28802743~28817828:+
BRCA	cis	rs2243480	1	rs313813	ENSG00000273142.1	RP11-458F8.4	-7.79	1.59e-14	4.62e-12	-0.33	-0.23	Diabetic kidney disease;	chr7:66038513	chr7:66902857~66906297:+
BRCA	cis	rs6142102	1	rs4911409	ENSG00000276073.1	RP5-1125A11.7	-7.79	1.59e-14	4.62e-12	-0.28	-0.23	Skin pigmentation;	chr20:34122904	chr20:33985617~33988989:-
BRCA	cis	rs9880211	1	rs35899944	ENSG00000273486.1	RP11-731C17.2	7.79	1.59e-14	4.62e-12	0.31	0.23	Height;Body mass index;	chr3:136510215	chr3:136837338~136839021:-
BRCA	cis	rs7772486	0.875	rs6914813	ENSG00000235652.6	RP11-545I5.3	7.79	1.59e-14	4.62e-12	0.24	0.23	Lobe attachment (rater-scored or self-reported);	chr6:146076662	chr6:145799409~145886585:+
BRCA	cis	rs7927771	0.832	rs4752994	ENSG00000280615.1	Y_RNA	7.79	1.59e-14	4.62e-12	0.29	0.23	Subjective well-being;	chr11:47389514	chr11:47614898~47614994:-
BRCA	cis	rs7927771	0.832	rs10769262	ENSG00000280615.1	Y_RNA	7.79	1.59e-14	4.62e-12	0.29	0.23	Subjective well-being;	chr11:47390030	chr11:47614898~47614994:-
BRCA	cis	rs10463554	0.892	rs1561404	ENSG00000175749.11	EIF3KP1	7.79	1.59e-14	4.62e-12	0.33	0.23	Parkinson's disease;	chr5:102963647	chr5:103032376~103033031:+
BRCA	cis	rs875971	0.545	rs316306	ENSG00000224316.1	RP11-479O9.2	-7.79	1.59e-14	4.63e-12	-0.26	-0.23	Aortic root size;	chr7:66153687	chr7:65773620~65802067:+
BRCA	cis	rs6142102	0.961	rs1319363	ENSG00000276073.1	RP5-1125A11.7	-7.79	1.59e-14	4.63e-12	-0.29	-0.23	Skin pigmentation;	chr20:33954070	chr20:33985617~33988989:-
BRCA	cis	rs4835473	0.838	rs6838981	ENSG00000251600.4	RP11-673E1.1	-7.79	1.6e-14	4.64e-12	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143826484	chr4:143912331~143982454:+
BRCA	cis	rs7811142	0.72	rs112622797	ENSG00000242294.5	STAG3L5P	7.79	1.6e-14	4.64e-12	0.25	0.23	Platelet count;	chr7:100319793	chr7:100336079~100351900:+
BRCA	cis	rs3758911	0.964	rs11212158	ENSG00000255353.1	RP11-382M14.1	-7.79	1.6e-14	4.66e-12	-0.31	-0.23	Coronary artery disease;	chr11:107325745	chr11:107176286~107177530:+
BRCA	cis	rs56046484	0.871	rs35000527	ENSG00000259295.5	CSPG4P12	7.79	1.61e-14	4.66e-12	0.42	0.23	Testicular germ cell tumor;	chr15:85010550	chr15:85191438~85213905:+
BRCA	cis	rs853679	1	rs1936365	ENSG00000220721.1	OR1F12	-7.79	1.61e-14	4.67e-12	-0.36	-0.23	Depression;	chr6:28300675	chr6:28073316~28074233:+
BRCA	cis	rs4934494	0.834	rs1359624	ENSG00000240996.1	RP11-80H5.7	-7.79	1.61e-14	4.67e-12	-0.26	-0.23	Red blood cell count;	chr10:89635671	chr10:89694295~89697928:-
BRCA	cis	rs4835473	0.932	rs11734290	ENSG00000251600.4	RP11-673E1.1	-7.79	1.61e-14	4.68e-12	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143823636	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs11734383	ENSG00000251600.4	RP11-673E1.1	-7.79	1.61e-14	4.68e-12	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143824093	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.868	rs11735295	ENSG00000251600.4	RP11-673E1.1	-7.79	1.61e-14	4.68e-12	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143824150	chr4:143912331~143982454:+
BRCA	cis	rs1113500	0.636	rs3853493	ENSG00000226822.1	RP11-356N1.2	7.79	1.61e-14	4.68e-12	0.3	0.23	Growth-regulated protein alpha levels;	chr1:108094571	chr1:108071482~108074519:+
BRCA	cis	rs10463554	0.963	rs28301	ENSG00000175749.11	EIF3KP1	7.79	1.61e-14	4.68e-12	0.32	0.23	Parkinson's disease;	chr5:103105778	chr5:103032376~103033031:+
BRCA	cis	rs4835473	0.932	rs17695238	ENSG00000251600.4	RP11-673E1.1	-7.79	1.61e-14	4.69e-12	-0.3	-0.23	Immature fraction of reticulocytes;	chr4:143820720	chr4:143912331~143982454:+
BRCA	cis	rs7809950	0.862	rs12112877	ENSG00000238832.1	snoU109	-7.79	1.62e-14	4.7e-12	-0.31	-0.23	Coronary artery disease;	chr7:107300879	chr7:107603363~107603507:+
BRCA	cis	rs7615952	0.641	rs12495947	ENSG00000250012.1	RP11-124N2.1	-7.79	1.62e-14	4.7e-12	-0.32	-0.23	Blood pressure (smoking interaction);	chr3:126052855	chr3:126084220~126095349:+
BRCA	cis	rs7615952	0.641	rs6805074	ENSG00000250012.1	RP11-124N2.1	-7.79	1.62e-14	4.7e-12	-0.32	-0.23	Blood pressure (smoking interaction);	chr3:126053431	chr3:126084220~126095349:+
BRCA	cis	rs847577	0.677	rs951988	ENSG00000272950.1	RP11-307C18.1	-7.79	1.63e-14	4.73e-12	-0.3	-0.23	Breast cancer;	chr7:98133162	chr7:98322853~98323430:+
BRCA	cis	rs2742234	0.541	rs10793422	ENSG00000273008.1	RP11-351D16.3	7.79	1.63e-14	4.74e-12	0.3	0.23	Hirschsprung disease;	chr10:43208426	chr10:43136824~43138334:-
BRCA	cis	rs6570726	0.967	rs6903252	ENSG00000235652.6	RP11-545I5.3	7.79	1.63e-14	4.74e-12	0.23	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145601641	chr6:145799409~145886585:+
BRCA	cis	rs7829975	0.688	rs7817376	ENSG00000254153.1	CTA-398F10.2	-7.79	1.63e-14	4.74e-12	-0.28	-0.23	Mood instability;	chr8:8523020	chr8:8456909~8461337:-
BRCA	cis	rs1113500	0.73	rs1343203	ENSG00000226822.1	RP11-356N1.2	7.79	1.64e-14	4.75e-12	0.31	0.23	Growth-regulated protein alpha levels;	chr1:108048560	chr1:108071482~108074519:+
BRCA	cis	rs6545883	0.929	rs2421203	ENSG00000271889.1	RP11-493E12.1	7.79	1.64e-14	4.75e-12	0.3	0.23	Tuberculosis;	chr2:61442113	chr2:61151433~61162105:-
BRCA	cis	rs2274273	0.564	rs3783649	ENSG00000258413.1	RP11-665C16.6	-7.79	1.64e-14	4.76e-12	-0.31	-0.23	Protein biomarker;	chr14:55367692	chr14:55262767~55272075:-
BRCA	cis	rs6921919	1	rs6921919	ENSG00000204709.4	LINC01556	7.79	1.64e-14	4.76e-12	0.37	0.23	Autism spectrum disorder or schizophrenia;	chr6:28357424	chr6:28943877~28944537:+
BRCA	cis	rs287982	0.8	rs9973905	ENSG00000269973.1	RP11-95D17.1	-7.79	1.64e-14	4.77e-12	-0.29	-0.23	Nonsyndromic cleft lip with cleft palate;	chr2:9820726	chr2:9936360~9939590:+
BRCA	cis	rs875971	0.545	rs73376401	ENSG00000224316.1	RP11-479O9.2	7.79	1.65e-14	4.78e-12	0.26	0.23	Aortic root size;	chr7:66174841	chr7:65773620~65802067:+
BRCA	cis	rs11159086	1	rs4903233	ENSG00000259005.1	RP3-449M8.6	7.79	1.65e-14	4.78e-12	0.36	0.23	Advanced glycation end-product levels;	chr14:74497291	chr14:74474007~74474864:-
BRCA	cis	rs7927771	0.8	rs11039200	ENSG00000280615.1	Y_RNA	-7.79	1.65e-14	4.79e-12	-0.3	-0.23	Subjective well-being;	chr11:47358095	chr11:47614898~47614994:-
BRCA	cis	rs2880765	0.835	rs7161880	ENSG00000259295.5	CSPG4P12	7.79	1.65e-14	4.79e-12	0.29	0.23	Coronary artery disease;	chr15:85475515	chr15:85191438~85213905:+
BRCA	cis	rs2179367	0.537	rs12192159	ENSG00000231760.4	RP11-350J20.5	7.79	1.66e-14	4.81e-12	0.36	0.23	Dupuytren's disease;	chr6:149445969	chr6:149796151~149826294:-
BRCA	cis	rs34779708	0.766	rs7897088	ENSG00000271335.4	RP11-324I22.4	7.79	1.66e-14	4.81e-12	0.24	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35262639	chr10:35314552~35336401:-
BRCA	cis	rs867371	1	rs1392976	ENSG00000255769.6	GOLGA2P10	7.79	1.66e-14	4.81e-12	0.27	0.23	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82153834	chr15:82472993~82513950:-
BRCA	cis	rs2274273	0.967	rs10147667	ENSG00000258413.1	RP11-665C16.6	7.79	1.66e-14	4.82e-12	0.29	0.23	Protein biomarker;	chr14:55104131	chr14:55262767~55272075:-
BRCA	cis	rs2028299	0.919	rs7174878	ENSG00000259677.1	RP11-493E3.1	7.79	1.67e-14	4.83e-12	0.33	0.23	Type 2 diabetes;	chr15:89891656	chr15:89876540~89877285:+
BRCA	cis	rs6545883	0.894	rs12997538	ENSG00000271889.1	RP11-493E12.1	-7.79	1.67e-14	4.84e-12	-0.31	-0.23	Tuberculosis;	chr2:61337114	chr2:61151433~61162105:-
BRCA	cis	rs11098499	0.562	rs13101722	ENSG00000248280.1	RP11-33B1.2	-7.79	1.67e-14	4.84e-12	-0.23	-0.23	Corneal astigmatism;	chr4:119634820	chr4:119440561~119450157:-
BRCA	cis	rs42648	0.869	rs10251227	ENSG00000225498.1	AC002064.5	7.79	1.67e-14	4.84e-12	0.23	0.23	Homocysteine levels;	chr7:90262972	chr7:90312496~90322592:+
BRCA	cis	rs7208859	0.573	rs55661352	ENSG00000266490.1	CTD-2349P21.9	7.79	1.67e-14	4.84e-12	0.37	0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30718610	chr17:30792372~30792833:+
BRCA	cis	rs2274273	0.624	rs7147247	ENSG00000258413.1	RP11-665C16.6	-7.79	1.67e-14	4.84e-12	-0.31	-0.23	Protein biomarker;	chr14:55310995	chr14:55262767~55272075:-
BRCA	cis	rs10129255	0.518	rs12590732	ENSG00000280411.1	IGHV1-69-2	7.78	1.68e-14	4.86e-12	0.15	0.23	Kawasaki disease;	chr14:106779612	chr14:106762092~106762588:-
BRCA	cis	rs17711722	0.565	rs4275112	ENSG00000273024.4	INTS4P2	7.78	1.68e-14	4.86e-12	0.27	0.23	Calcium levels;	chr7:65733651	chr7:65647864~65715661:+
BRCA	cis	rs293748	0.882	rs16903459	ENSG00000250155.1	CTD-2353F22.1	-7.78	1.68e-14	4.86e-12	-0.33	-0.23	Obesity-related traits;	chr5:37031314	chr5:36666214~36725195:-
BRCA	cis	rs867371	1	rs1174543	ENSG00000255769.6	GOLGA2P10	7.78	1.68e-14	4.87e-12	0.27	0.23	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82155732	chr15:82472993~82513950:-
BRCA	cis	rs6545883	0.894	rs2593633	ENSG00000271889.1	RP11-493E12.1	-7.78	1.69e-14	4.89e-12	-0.3	-0.23	Tuberculosis;	chr2:61344378	chr2:61151433~61162105:-
BRCA	cis	rs4835473	0.932	rs35055653	ENSG00000251600.4	RP11-673E1.1	-7.78	1.69e-14	4.89e-12	-0.3	-0.23	Immature fraction of reticulocytes;	chr4:143754836	chr4:143912331~143982454:+
BRCA	cis	rs2742234	0.541	rs12416428	ENSG00000273008.1	RP11-351D16.3	7.78	1.69e-14	4.91e-12	0.31	0.23	Hirschsprung disease;	chr10:43213550	chr10:43136824~43138334:-
BRCA	cis	rs2742234	0.541	rs11238476	ENSG00000273008.1	RP11-351D16.3	7.78	1.69e-14	4.91e-12	0.31	0.23	Hirschsprung disease;	chr10:43215988	chr10:43136824~43138334:-
BRCA	cis	rs875971	0.838	rs2173570	ENSG00000232559.3	GS1-124K5.12	-7.78	1.7e-14	4.93e-12	-0.28	-0.23	Aortic root size;	chr7:66297976	chr7:66554588~66576923:-
BRCA	cis	rs2742234	0.59	rs1254960	ENSG00000273008.1	RP11-351D16.3	7.78	1.7e-14	4.93e-12	0.3	0.23	Hirschsprung disease;	chr10:43204209	chr10:43136824~43138334:-
BRCA	cis	rs10463554	0.892	rs1837256	ENSG00000175749.11	EIF3KP1	7.78	1.7e-14	4.93e-12	0.33	0.23	Parkinson's disease;	chr5:102968852	chr5:103032376~103033031:+
BRCA	cis	rs9880211	1	rs9878078	ENSG00000273486.1	RP11-731C17.2	7.78	1.7e-14	4.93e-12	0.31	0.23	Height;Body mass index;	chr3:136518731	chr3:136837338~136839021:-
BRCA	cis	rs2243480	1	rs316332	ENSG00000273142.1	RP11-458F8.4	-7.78	1.71e-14	4.94e-12	-0.32	-0.23	Diabetic kidney disease;	chr7:66139312	chr7:66902857~66906297:+
BRCA	cis	rs12188164	0.543	rs890972	ENSG00000225138.6	CTD-2228K2.7	-7.78	1.71e-14	4.95e-12	-0.25	-0.23	Cystic fibrosis severity;	chr5:462350	chr5:473236~480884:+
BRCA	cis	rs12188164	0.543	rs2434694	ENSG00000225138.6	CTD-2228K2.7	-7.78	1.71e-14	4.95e-12	-0.25	-0.23	Cystic fibrosis severity;	chr5:462619	chr5:473236~480884:+
BRCA	cis	rs9876781	1	rs2290822	ENSG00000244380.1	RP11-24C3.2	7.78	1.71e-14	4.95e-12	0.27	0.23	Longevity;	chr3:48431794	chr3:48440352~48446656:-
BRCA	cis	rs10463554	0.892	rs1560040	ENSG00000175749.11	EIF3KP1	7.78	1.71e-14	4.97e-12	0.33	0.23	Parkinson's disease;	chr5:102964363	chr5:103032376~103033031:+
BRCA	cis	rs4835473	0.932	rs34324222	ENSG00000251600.4	RP11-673E1.1	-7.78	1.72e-14	4.98e-12	-0.3	-0.23	Immature fraction of reticulocytes;	chr4:143784572	chr4:143912331~143982454:+
BRCA	cis	rs2243480	0.708	rs13242216	ENSG00000273142.1	RP11-458F8.4	-7.78	1.73e-14	5.01e-12	-0.33	-0.23	Diabetic kidney disease;	chr7:66433290	chr7:66902857~66906297:+
BRCA	cis	rs8012947	0.651	rs8008129	ENSG00000279636.2	LINC00216	7.78	1.73e-14	5.01e-12	0.25	0.23	Alcohol consumption in current drinkers;	chr14:58362314	chr14:58288033~58289158:+
BRCA	cis	rs7811142	0.83	rs6965458	ENSG00000242294.5	STAG3L5P	7.78	1.73e-14	5.02e-12	0.25	0.23	Platelet count;	chr7:100375779	chr7:100336079~100351900:+
BRCA	cis	rs875971	0.66	rs10263935	ENSG00000237310.1	GS1-124K5.4	7.78	1.74e-14	5.03e-12	0.24	0.23	Aortic root size;	chr7:66631041	chr7:66493706~66495474:+
BRCA	cis	rs3762637	0.943	rs3817040	ENSG00000272758.4	RP11-299J3.8	-7.78	1.74e-14	5.04e-12	-0.33	-0.23	LDL cholesterol levels;	chr3:122535922	chr3:122416207~122443180:+
BRCA	cis	rs2720460	0.502	rs223374	ENSG00000251288.2	RP11-10L12.2	-7.78	1.74e-14	5.04e-12	-0.29	-0.23	Testicular germ cell tumor;	chr4:102837144	chr4:102751401~102752641:+
BRCA	cis	rs61270009	0.955	rs13172095	ENSG00000247828.6	TMEM161B-AS1	-7.78	1.75e-14	5.07e-12	-0.3	-0.23	Depressive symptoms;	chr5:88295130	chr5:88268895~88436685:+
BRCA	cis	rs4835473	0.9	rs13101531	ENSG00000251600.4	RP11-673E1.1	-7.78	1.75e-14	5.07e-12	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143982197	chr4:143912331~143982454:+
BRCA	cis	rs2179367	0.509	rs9485390	ENSG00000231760.4	RP11-350J20.5	7.78	1.75e-14	5.08e-12	0.34	0.23	Dupuytren's disease;	chr6:149421004	chr6:149796151~149826294:-
BRCA	cis	rs113835537	0.529	rs7928882	ENSG00000255517.5	CTD-3074O7.5	-7.78	1.76e-14	5.09e-12	-0.3	-0.23	Airway imaging phenotypes;	chr11:66467294	chr11:66473490~66480233:-
BRCA	cis	rs7674212	0.581	rs10516496	ENSG00000246560.2	RP11-10L12.4	7.78	1.76e-14	5.1e-12	0.25	0.23	Type 2 diabetes;	chr4:103021008	chr4:102828055~102844075:+
BRCA	cis	rs875971	0.862	rs10261398	ENSG00000232559.3	GS1-124K5.12	-7.78	1.77e-14	5.12e-12	-0.28	-0.23	Aortic root size;	chr7:66285177	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.862	rs10224872	ENSG00000232559.3	GS1-124K5.12	-7.78	1.77e-14	5.12e-12	-0.28	-0.23	Aortic root size;	chr7:66294786	chr7:66554588~66576923:-
BRCA	cis	rs6545883	0.894	rs1186703	ENSG00000271889.1	RP11-493E12.1	7.78	1.77e-14	5.12e-12	0.3	0.23	Tuberculosis;	chr2:61445830	chr2:61151433~61162105:-
BRCA	cis	rs904251	0.523	rs2797799	ENSG00000204110.6	RP1-153P14.8	-7.78	1.77e-14	5.13e-12	-0.26	-0.23	Cognitive performance;	chr6:37515844	chr6:37507348~37535616:+
BRCA	cis	rs17772222	0.917	rs4635267	ENSG00000258983.2	RP11-507K2.2	7.78	1.78e-14	5.15e-12	0.27	0.23	Coronary artery calcification;	chr14:88621922	chr14:88499334~88515502:+
BRCA	cis	rs7615952	0.599	rs67566088	ENSG00000250012.1	RP11-124N2.1	-7.78	1.78e-14	5.16e-12	-0.32	-0.23	Blood pressure (smoking interaction);	chr3:126050130	chr3:126084220~126095349:+
BRCA	cis	rs2028299	0.92	rs8027198	ENSG00000259677.1	RP11-493E3.1	7.78	1.78e-14	5.16e-12	0.33	0.23	Type 2 diabetes;	chr15:89883457	chr15:89876540~89877285:+
BRCA	cis	rs12468226	0.752	rs79058237	ENSG00000273456.1	RP11-686O6.2	7.78	1.8e-14	5.2e-12	0.36	0.23	Urate levels;	chr2:202140247	chr2:202374932~202375604:-
BRCA	cis	rs12701220	0.696	rs12112029	ENSG00000229043.2	AC091729.9	-7.78	1.8e-14	5.21e-12	-0.34	-0.23	Bronchopulmonary dysplasia;	chr7:1098253	chr7:1160374~1165267:+
BRCA	cis	rs875971	0.862	rs6944374	ENSG00000232559.3	GS1-124K5.12	-7.77	1.81e-14	5.23e-12	-0.29	-0.23	Aortic root size;	chr7:66221942	chr7:66554588~66576923:-
BRCA	cis	rs526231	0.543	rs34379	ENSG00000175749.11	EIF3KP1	-7.77	1.81e-14	5.24e-12	-0.33	-0.23	Primary biliary cholangitis;	chr5:103062994	chr5:103032376~103033031:+
BRCA	cis	rs9880211	1	rs9826454	ENSG00000239213.4	NCK1-AS1	7.77	1.81e-14	5.24e-12	0.3	0.23	Height;Body mass index;	chr3:136234378	chr3:136841726~136862054:-
BRCA	cis	rs7811142	0.83	rs76798830	ENSG00000242294.5	STAG3L5P	7.77	1.81e-14	5.25e-12	0.25	0.23	Platelet count;	chr7:100355205	chr7:100336079~100351900:+
BRCA	cis	rs8072100	0.967	rs3760370	ENSG00000228782.6	CTD-2026D20.3	-7.77	1.82e-14	5.25e-12	-0.25	-0.23	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47618466	chr17:47450568~47492492:-
BRCA	cis	rs2284378	0.515	rs6059579	ENSG00000275784.1	RP5-1125A11.6	-7.77	1.82e-14	5.25e-12	-0.27	-0.23	Breast cancer;	chr20:33940059	chr20:33989480~33991818:-
BRCA	cis	rs72627509	0.904	rs12645070	ENSG00000269949.1	RP11-738E22.3	7.77	1.82e-14	5.25e-12	0.35	0.23	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56903940	chr4:56960927~56961373:-
BRCA	cis	rs11976180	1	rs7777389	ENSG00000170356.8	OR2A20P	-7.77	1.82e-14	5.25e-12	-0.33	-0.23	Obesity-related traits;	chr7:144047709	chr7:144250045~144252957:-
BRCA	cis	rs11976180	1	rs67239267	ENSG00000170356.8	OR2A20P	-7.77	1.82e-14	5.25e-12	-0.33	-0.23	Obesity-related traits;	chr7:144048023	chr7:144250045~144252957:-
BRCA	cis	rs4835473	0.9	rs6834494	ENSG00000251600.4	RP11-673E1.1	-7.77	1.82e-14	5.26e-12	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143822257	chr4:143912331~143982454:+
BRCA	cis	rs2274273	0.624	rs78205412	ENSG00000258413.1	RP11-665C16.6	-7.77	1.82e-14	5.26e-12	-0.31	-0.23	Protein biomarker;	chr14:55314532	chr14:55262767~55272075:-
BRCA	cis	rs7809950	1	rs7782057	ENSG00000238832.1	snoU109	-7.77	1.82e-14	5.27e-12	-0.31	-0.23	Coronary artery disease;	chr7:107458432	chr7:107603363~107603507:+
BRCA	cis	rs3758911	0.828	rs10789598	ENSG00000255353.1	RP11-382M14.1	-7.77	1.83e-14	5.28e-12	-0.32	-0.23	Coronary artery disease;	chr11:107307878	chr11:107176286~107177530:+
BRCA	cis	rs3758911	0.861	rs11212143	ENSG00000255353.1	RP11-382M14.1	-7.77	1.83e-14	5.28e-12	-0.32	-0.23	Coronary artery disease;	chr11:107308554	chr11:107176286~107177530:+
BRCA	cis	rs1075265	0.749	rs6738369	ENSG00000233266.1	HMGB1P31	7.77	1.83e-14	5.29e-12	0.28	0.23	Chronotype;Morning vs. evening chronotype;	chr2:53756547	chr2:54051334~54051760:+
BRCA	cis	rs950880	0.71	rs56258475	ENSG00000234389.1	AC007278.3	-7.77	1.83e-14	5.29e-12	-0.24	-0.23	Serum protein levels (sST2);	chr2:102382852	chr2:102438713~102440475:+
BRCA	cis	rs1185460	1	rs4614	ENSG00000271751.1	RP11-110I1.14	-7.77	1.83e-14	5.3e-12	-0.3	-0.23	Coronary artery disease;	chr11:119081661	chr11:119065263~119065677:-
BRCA	cis	rs6539288	0.933	rs1037012	ENSG00000260329.1	RP11-412D9.4	-7.77	1.83e-14	5.3e-12	-0.27	-0.23	Total body bone mineral density;	chr12:106908899	chr12:106954029~106955497:-
BRCA	cis	rs9543976	0.623	rs7317250	ENSG00000261553.4	RP11-29G8.3	7.77	1.83e-14	5.3e-12	0.37	0.23	Diabetic retinopathy;	chr13:75593005	chr13:75549773~75807120:+
BRCA	cis	rs867371	1	rs6495643	ENSG00000255769.6	GOLGA2P10	-7.77	1.85e-14	5.33e-12	-0.27	-0.23	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82186913	chr15:82472993~82513950:-
BRCA	cis	rs3762637	1	rs16845530	ENSG00000272758.4	RP11-299J3.8	-7.77	1.85e-14	5.33e-12	-0.33	-0.23	LDL cholesterol levels;	chr3:122423600	chr3:122416207~122443180:+
BRCA	cis	rs2115630	0.905	rs6496401	ENSG00000225151.9	GOLGA2P7	7.77	1.86e-14	5.37e-12	0.25	0.23	P wave terminal force;	chr15:84754562	chr15:84199311~84230136:-
BRCA	cis	rs2348418	0.733	rs9651832	ENSG00000247934.4	RP11-967K21.1	-7.77	1.86e-14	5.37e-12	-0.27	-0.23	Lung function (FEV1);Lung function (FVC);	chr12:28242489	chr12:28163298~28190738:-
BRCA	cis	rs7615952	0.641	rs12491577	ENSG00000250012.1	RP11-124N2.1	-7.77	1.86e-14	5.38e-12	-0.32	-0.23	Blood pressure (smoking interaction);	chr3:126012288	chr3:126084220~126095349:+
BRCA	cis	rs6545883	0.868	rs28749199	ENSG00000271889.1	RP11-493E12.1	7.77	1.87e-14	5.39e-12	0.31	0.23	Tuberculosis;	chr2:61599917	chr2:61151433~61162105:-
BRCA	cis	rs4835473	0.808	rs6831401	ENSG00000251600.4	RP11-673E1.1	-7.77	1.87e-14	5.4e-12	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143801038	chr4:143912331~143982454:+
BRCA	cis	rs11098499	0.604	rs2389882	ENSG00000245958.5	RP11-33B1.1	-7.77	1.88e-14	5.42e-12	-0.23	-0.23	Corneal astigmatism;	chr4:119645578	chr4:119454791~119552025:+
BRCA	cis	rs11098499	1	rs11098499	ENSG00000248280.1	RP11-33B1.2	7.77	1.88e-14	5.42e-12	0.24	0.23	Corneal astigmatism;	chr4:119266456	chr4:119440561~119450157:-
BRCA	cis	rs10463554	1	rs12656131	ENSG00000175749.11	EIF3KP1	-7.77	1.88e-14	5.43e-12	-0.32	-0.23	Parkinson's disease;	chr5:102990174	chr5:103032376~103033031:+
BRCA	cis	rs9527	0.571	rs12219246	ENSG00000213061.2	PFN1P11	7.77	1.89e-14	5.46e-12	0.31	0.23	Arsenic metabolism;	chr10:102853598	chr10:102838011~102845473:-
BRCA	cis	rs10463554	0.963	rs34828	ENSG00000175749.11	EIF3KP1	7.77	1.89e-14	5.46e-12	0.32	0.23	Parkinson's disease;	chr5:103107209	chr5:103032376~103033031:+
BRCA	cis	rs919433	1	rs112572902	ENSG00000231621.1	AC013264.2	7.77	1.9e-14	5.47e-12	0.22	0.23	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197310455	chr2:197197991~197199273:+
BRCA	cis	rs7927771	0.965	rs12787112	ENSG00000280615.1	Y_RNA	-7.77	1.9e-14	5.49e-12	-0.29	-0.23	Subjective well-being;	chr11:47665595	chr11:47614898~47614994:-
BRCA	cis	rs875971	0.619	rs10278371	ENSG00000224316.1	RP11-479O9.2	-7.77	1.91e-14	5.5e-12	-0.24	-0.23	Aortic root size;	chr7:66586553	chr7:65773620~65802067:+
BRCA	cis	rs899997	0.862	rs8043123	ENSG00000261143.1	ADAMTS7P3	-7.77	1.91e-14	5.51e-12	-0.32	-0.23	Coronary artery disease or large artery stroke;	chr15:78681051	chr15:77976042~77993057:+
BRCA	cis	rs6539288	0.899	rs7298423	ENSG00000260329.1	RP11-412D9.4	-7.77	1.92e-14	5.53e-12	-0.27	-0.23	Total body bone mineral density;	chr12:106908202	chr12:106954029~106955497:-
BRCA	cis	rs250518	0.926	rs2338791	ENSG00000272081.1	CTD-2376I4.2	7.77	1.92e-14	5.55e-12	0.3	0.23	Mean corpuscular hemoglobin concentration;	chr5:72770970	chr5:72955206~72955699:-
BRCA	cis	rs919433	0.929	rs1366836	ENSG00000231621.1	AC013264.2	7.77	1.92e-14	5.55e-12	0.22	0.23	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197307424	chr2:197197991~197199273:+
BRCA	cis	rs875971	0.767	rs1643394	ENSG00000232559.3	GS1-124K5.12	7.77	1.93e-14	5.56e-12	0.28	0.23	Aortic root size;	chr7:66371107	chr7:66554588~66576923:-
BRCA	cis	rs9813712	0.596	rs2587988	ENSG00000228252.7	COL6A4P2	-7.77	1.93e-14	5.56e-12	-0.28	-0.23	Response to amphetamines;	chr3:130201415	chr3:130212823~130273806:+
BRCA	cis	rs875971	0.862	rs6460307	ENSG00000232559.3	GS1-124K5.12	7.77	1.94e-14	5.59e-12	0.28	0.23	Aortic root size;	chr7:66595884	chr7:66554588~66576923:-
BRCA	cis	rs42648	0.567	rs12669304	ENSG00000225498.1	AC002064.5	7.77	1.94e-14	5.6e-12	0.22	0.23	Homocysteine levels;	chr7:90261726	chr7:90312496~90322592:+
BRCA	cis	rs293748	0.771	rs245587	ENSG00000250155.1	CTD-2353F22.1	-7.77	1.94e-14	5.6e-12	-0.33	-0.23	Obesity-related traits;	chr5:36839445	chr5:36666214~36725195:-
BRCA	cis	rs2115630	0.754	rs12595321	ENSG00000225151.9	GOLGA2P7	7.77	1.94e-14	5.6e-12	0.26	0.23	P wave terminal force;	chr15:84788038	chr15:84199311~84230136:-
BRCA	cis	rs7246657	1	rs35398388	ENSG00000276846.1	CTD-3220F14.3	7.76	1.95e-14	5.61e-12	0.33	0.23	Coronary artery calcification;	chr19:37249456	chr19:37314868~37315620:-
BRCA	cis	rs7246657	1	rs7247672	ENSG00000276846.1	CTD-3220F14.3	7.76	1.95e-14	5.61e-12	0.33	0.23	Coronary artery calcification;	chr19:37253026	chr19:37314868~37315620:-
BRCA	cis	rs7246657	1	rs8110011	ENSG00000276846.1	CTD-3220F14.3	7.76	1.95e-14	5.61e-12	0.33	0.23	Coronary artery calcification;	chr19:37254911	chr19:37314868~37315620:-
BRCA	cis	rs875971	1	rs11974264	ENSG00000232559.3	GS1-124K5.12	-7.76	1.95e-14	5.62e-12	-0.28	-0.23	Aortic root size;	chr7:66182595	chr7:66554588~66576923:-
BRCA	cis	rs10483853	0.525	rs10138789	ENSG00000258695.2	RP3-414A15.2	-7.76	1.95e-14	5.63e-12	-0.37	-0.23	Coronary artery calcification;	chr14:73497574	chr14:73522878~73530610:+
BRCA	cis	rs293748	0.605	rs13188136	ENSG00000250155.1	CTD-2353F22.1	-7.76	1.96e-14	5.65e-12	-0.31	-0.23	Obesity-related traits;	chr5:37117132	chr5:36666214~36725195:-
BRCA	cis	rs9880211	0.948	rs9857966	ENSG00000273486.1	RP11-731C17.2	7.76	1.96e-14	5.65e-12	0.31	0.23	Height;Body mass index;	chr3:136560548	chr3:136837338~136839021:-
BRCA	cis	rs58873874	0.579	rs3815829	ENSG00000251405.2	CTB-109A12.1	7.76	1.96e-14	5.66e-12	0.52	0.23	Bipolar disorder (body mass index interaction);	chr5:157300684	chr5:157362615~157460078:-
BRCA	cis	rs516805	0.961	rs510283	ENSG00000279114.1	RP3-425C14.5	-7.76	1.96e-14	5.66e-12	-0.24	-0.23	Lymphocyte counts;	chr6:122451547	chr6:122471923~122484161:+
BRCA	cis	rs8005677	1	rs1956881	ENSG00000279656.1	RP11-298I3.6	7.76	1.96e-14	5.66e-12	0.28	0.23	Cognitive ability (multi-trait analysis);	chr14:22924860	chr14:23023083~23024217:-
BRCA	cis	rs14027	0.921	rs35496588	ENSG00000279347.1	RP11-85I17.2	7.76	1.97e-14	5.68e-12	0.25	0.23	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119842461	chr8:119838736~119840385:-
BRCA	cis	rs8005677	1	rs8006396	ENSG00000279656.1	RP11-298I3.6	7.76	1.97e-14	5.69e-12	0.28	0.23	Cognitive ability (multi-trait analysis);	chr14:22911641	chr14:23023083~23024217:-
BRCA	cis	rs8005677	1	rs4982706	ENSG00000279656.1	RP11-298I3.6	7.76	1.97e-14	5.69e-12	0.28	0.23	Cognitive ability (multi-trait analysis);	chr14:22912488	chr14:23023083~23024217:-
BRCA	cis	rs9880211	1	rs17200216	ENSG00000273486.1	RP11-731C17.2	7.76	1.97e-14	5.69e-12	0.31	0.23	Height;Body mass index;	chr3:136348390	chr3:136837338~136839021:-
BRCA	cis	rs12188164	0.525	rs2561665	ENSG00000225138.6	CTD-2228K2.7	-7.76	1.97e-14	5.69e-12	-0.25	-0.23	Cystic fibrosis severity;	chr5:460020	chr5:473236~480884:+
BRCA	cis	rs950169	0.58	rs11634322	ENSG00000259728.4	LINC00933	7.76	1.97e-14	5.69e-12	0.3	0.23	Schizophrenia;	chr15:84628978	chr15:84570649~84580175:+
BRCA	cis	rs4934494	0.681	rs12572928	ENSG00000240996.1	RP11-80H5.7	-7.76	1.97e-14	5.69e-12	-0.3	-0.23	Red blood cell count;	chr10:89793792	chr10:89694295~89697928:-
BRCA	cis	rs2243480	1	rs316330	ENSG00000273142.1	RP11-458F8.4	-7.76	1.98e-14	5.71e-12	-0.32	-0.23	Diabetic kidney disease;	chr7:66140385	chr7:66902857~66906297:+
BRCA	cis	rs526231	0.511	rs26255	ENSG00000175749.11	EIF3KP1	7.76	1.98e-14	5.71e-12	0.34	0.23	Primary biliary cholangitis;	chr5:103218399	chr5:103032376~103033031:+
BRCA	cis	rs12701220	0.655	rs7799656	ENSG00000229043.2	AC091729.9	-7.76	1.99e-14	5.72e-12	-0.33	-0.23	Bronchopulmonary dysplasia;	chr7:1100879	chr7:1160374~1165267:+
BRCA	cis	rs7131987	0.565	rs10743652	ENSG00000257176.2	RP11-996F15.2	7.76	2e-14	5.75e-12	0.28	0.23	QT interval;	chr12:29255074	chr12:29280418~29317848:-
BRCA	cis	rs858239	0.632	rs7811903	ENSG00000230042.1	AK3P3	-7.76	2.01e-14	5.79e-12	-0.27	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23079437	chr7:23129178~23129841:+
BRCA	cis	rs42648	0.935	rs42635	ENSG00000225498.1	AC002064.5	7.76	2.01e-14	5.8e-12	0.23	0.23	Homocysteine levels;	chr7:90336884	chr7:90312496~90322592:+
BRCA	cis	rs2243480	1	rs383402	ENSG00000273142.1	RP11-458F8.4	7.76	2.02e-14	5.8e-12	0.32	0.23	Diabetic kidney disease;	chr7:66121666	chr7:66902857~66906297:+
BRCA	cis	rs6472827	0.645	rs2977067	ENSG00000253983.2	RP1-16A9.1	7.76	2.02e-14	5.81e-12	0.32	0.23	Uterine fibroids;	chr8:74190596	chr8:74199396~74208441:+
BRCA	cis	rs2880765	0.835	rs11074276	ENSG00000259295.5	CSPG4P12	7.76	2.02e-14	5.82e-12	0.28	0.23	Coronary artery disease;	chr15:85487132	chr15:85191438~85213905:+
BRCA	cis	rs2880765	0.835	rs7164106	ENSG00000259295.5	CSPG4P12	7.76	2.02e-14	5.82e-12	0.28	0.23	Coronary artery disease;	chr15:85489359	chr15:85191438~85213905:+
BRCA	cis	rs2880765	0.835	rs1872074	ENSG00000259295.5	CSPG4P12	7.76	2.02e-14	5.82e-12	0.28	0.23	Coronary artery disease;	chr15:85489953	chr15:85191438~85213905:+
BRCA	cis	rs875971	0.545	rs6460276	ENSG00000224316.1	RP11-479O9.2	7.76	2.02e-14	5.82e-12	0.26	0.23	Aortic root size;	chr7:66182290	chr7:65773620~65802067:+
BRCA	cis	rs858239	0.6	rs7776644	ENSG00000230042.1	AK3P3	-7.76	2.05e-14	5.9e-12	-0.27	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23079688	chr7:23129178~23129841:+
BRCA	cis	rs11098499	1	rs13116504	ENSG00000248280.1	RP11-33B1.2	7.76	2.06e-14	5.94e-12	0.24	0.23	Corneal astigmatism;	chr4:119288257	chr4:119440561~119450157:-
BRCA	cis	rs2060793	0.519	rs10766187	ENSG00000251991.1	RNU7-49P	7.76	2.06e-14	5.94e-12	0.25	0.23	Vitamin D levels;	chr11:14603836	chr11:14478892~14478953:+
BRCA	cis	rs42648	0.905	rs42641	ENSG00000225498.1	AC002064.5	7.76	2.07e-14	5.94e-12	0.23	0.23	Homocysteine levels;	chr7:90343450	chr7:90312496~90322592:+
BRCA	cis	rs1609391	0.561	rs6439675	ENSG00000273486.1	RP11-731C17.2	7.76	2.07e-14	5.95e-12	0.25	0.23	Neuroticism;	chr3:136906594	chr3:136837338~136839021:-
BRCA	cis	rs7809950	1	rs2712200	ENSG00000238832.1	snoU109	-7.76	2.07e-14	5.96e-12	-0.31	-0.23	Coronary artery disease;	chr7:107501990	chr7:107603363~107603507:+
BRCA	cis	rs7809950	0.953	rs3094383	ENSG00000238832.1	snoU109	-7.76	2.07e-14	5.96e-12	-0.31	-0.23	Coronary artery disease;	chr7:107502719	chr7:107603363~107603507:+
BRCA	cis	rs2274273	0.624	rs7151581	ENSG00000258413.1	RP11-665C16.6	7.76	2.07e-14	5.96e-12	0.31	0.23	Protein biomarker;	chr14:55321727	chr14:55262767~55272075:-
BRCA	cis	rs2880765	0.835	rs7180213	ENSG00000259295.5	CSPG4P12	7.76	2.08e-14	5.97e-12	0.28	0.23	Coronary artery disease;	chr15:85477956	chr15:85191438~85213905:+
BRCA	cis	rs7131987	0.527	rs7308534	ENSG00000275476.1	RP11-996F15.4	7.76	2.08e-14	5.98e-12	0.27	0.23	QT interval;	chr12:29300269	chr12:29277397~29277882:-
BRCA	cis	rs2243480	1	rs160646	ENSG00000273142.1	RP11-458F8.4	-7.76	2.08e-14	5.98e-12	-0.33	-0.23	Diabetic kidney disease;	chr7:66091293	chr7:66902857~66906297:+
BRCA	cis	rs2274273	0.624	rs11848575	ENSG00000258413.1	RP11-665C16.6	-7.76	2.09e-14	6.01e-12	-0.31	-0.23	Protein biomarker;	chr14:55289070	chr14:55262767~55272075:-
BRCA	cis	rs4948102	0.595	rs10255049	ENSG00000273720.1	RP11-613E4.4	-7.76	2.09e-14	6.01e-12	-0.28	-0.23	Plasma homocysteine levels (post-methionine load test);	chr7:56053611	chr7:55743073~55743457:+
BRCA	cis	rs867371	0.762	rs12905578	ENSG00000259429.4	UBE2Q2P2	7.75	2.1e-14	6.04e-12	0.24	0.23	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82288923	chr15:82355142~82420075:+
BRCA	cis	rs13068223	0.669	rs168247	ENSG00000243926.1	TIPARP-AS1	-7.75	2.1e-14	6.04e-12	-0.25	-0.23	Age-related hearing impairment (SNP x SNP interaction);	chr3:156722397	chr3:156671862~156674378:-
BRCA	cis	rs875971	0.862	rs778684	ENSG00000232559.3	GS1-124K5.12	7.75	2.1e-14	6.05e-12	0.28	0.23	Aortic root size;	chr7:66371416	chr7:66554588~66576923:-
BRCA	cis	rs250518	0.926	rs266428	ENSG00000272081.1	CTD-2376I4.2	-7.75	2.11e-14	6.06e-12	-0.3	-0.23	Mean corpuscular hemoglobin concentration;	chr5:72832940	chr5:72955206~72955699:-
BRCA	cis	rs780096	0.546	rs1060525	ENSG00000234072.1	AC074117.10	-7.75	2.11e-14	6.06e-12	-0.23	-0.23	Total body bone mineral density;	chr2:27412715	chr2:27356246~27367622:+
BRCA	cis	rs1440410	0.835	rs4594668	ENSG00000250326.1	RP11-284M14.1	7.75	2.11e-14	6.06e-12	0.26	0.23	Ischemic stroke;	chr4:143129293	chr4:142933195~143184861:-
BRCA	cis	rs8005677	1	rs4981446	ENSG00000279656.1	RP11-298I3.6	7.75	2.11e-14	6.07e-12	0.28	0.23	Cognitive ability (multi-trait analysis);	chr14:22912204	chr14:23023083~23024217:-
BRCA	cis	rs42648	0.748	rs6972119	ENSG00000225498.1	AC002064.5	7.75	2.11e-14	6.07e-12	0.22	0.23	Homocysteine levels;	chr7:90264694	chr7:90312496~90322592:+
BRCA	cis	rs7811142	1	rs11764818	ENSG00000242294.5	STAG3L5P	7.75	2.12e-14	6.08e-12	0.23	0.23	Platelet count;	chr7:100445432	chr7:100336079~100351900:+
BRCA	cis	rs2243480	1	rs465359	ENSG00000273142.1	RP11-458F8.4	-7.75	2.12e-14	6.08e-12	-0.32	-0.23	Diabetic kidney disease;	chr7:66093177	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs462853	ENSG00000273142.1	RP11-458F8.4	-7.75	2.12e-14	6.08e-12	-0.32	-0.23	Diabetic kidney disease;	chr7:66093180	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs160644	ENSG00000273142.1	RP11-458F8.4	-7.75	2.12e-14	6.08e-12	-0.32	-0.23	Diabetic kidney disease;	chr7:66093199	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs160642	ENSG00000273142.1	RP11-458F8.4	-7.75	2.12e-14	6.08e-12	-0.32	-0.23	Diabetic kidney disease;	chr7:66093386	chr7:66902857~66906297:+
BRCA	cis	rs2243480	0.614	rs34032527	ENSG00000273142.1	RP11-458F8.4	-7.75	2.12e-14	6.08e-12	-0.32	-0.23	Diabetic kidney disease;	chr7:66100154	chr7:66902857~66906297:+
BRCA	cis	rs62445005	1	rs62445005	ENSG00000211698.2	TRGV4	7.75	2.12e-14	6.09e-12	0.28	0.23	Shingles;	chr7:38346957	chr7:38353715~38354517:-
BRCA	cis	rs12680842	0.883	rs13265241	ENSG00000253704.1	RP11-267M23.4	7.75	2.12e-14	6.1e-12	0.25	0.23	Body mass index;	chr8:94575129	chr8:94553722~94569745:+
BRCA	cis	rs287982	1	rs13404815	ENSG00000269973.1	RP11-95D17.1	-7.75	2.12e-14	6.1e-12	-0.29	-0.23	Nonsyndromic cleft lip with cleft palate;	chr2:9827637	chr2:9936360~9939590:+
BRCA	cis	rs287982	1	rs2656329	ENSG00000269973.1	RP11-95D17.1	-7.75	2.12e-14	6.1e-12	-0.29	-0.23	Nonsyndromic cleft lip with cleft palate;	chr2:9828215	chr2:9936360~9939590:+
BRCA	cis	rs6539288	0.899	rs7956807	ENSG00000260329.1	RP11-412D9.4	-7.75	2.13e-14	6.12e-12	-0.27	-0.23	Total body bone mineral density;	chr12:106906748	chr12:106954029~106955497:-
BRCA	cis	rs6700559	0.81	rs2808250	ENSG00000260088.1	RP11-92G12.3	-7.75	2.13e-14	6.12e-12	-0.29	-0.23	Coronary artery disease;	chr1:200623419	chr1:200669507~200694250:+
BRCA	cis	rs2243480	0.615	rs34363376	ENSG00000273142.1	RP11-458F8.4	-7.75	2.14e-14	6.14e-12	-0.33	-0.23	Diabetic kidney disease;	chr7:66474549	chr7:66902857~66906297:+
BRCA	cis	rs113835537	0.529	rs74869459	ENSG00000255517.5	CTD-3074O7.5	-7.75	2.14e-14	6.15e-12	-0.3	-0.23	Airway imaging phenotypes;	chr11:66529098	chr11:66473490~66480233:-
BRCA	cis	rs11098499	0.675	rs11098534	ENSG00000245958.5	RP11-33B1.1	-7.75	2.14e-14	6.15e-12	-0.22	-0.23	Corneal astigmatism;	chr4:119635617	chr4:119454791~119552025:+
BRCA	cis	rs7246657	0.943	rs7258692	ENSG00000276846.1	CTD-3220F14.3	7.75	2.14e-14	6.15e-12	0.32	0.23	Coronary artery calcification;	chr19:37327927	chr19:37314868~37315620:-
BRCA	cis	rs3762637	1	rs9882100	ENSG00000272758.4	RP11-299J3.8	-7.75	2.15e-14	6.17e-12	-0.34	-0.23	LDL cholesterol levels;	chr3:122451061	chr3:122416207~122443180:+
BRCA	cis	rs4948102	0.595	rs7793921	ENSG00000273720.1	RP11-613E4.4	-7.75	2.15e-14	6.17e-12	-0.28	-0.23	Plasma homocysteine levels (post-methionine load test);	chr7:56053188	chr7:55743073~55743457:+
BRCA	cis	rs42648	0.935	rs42621	ENSG00000225498.1	AC002064.5	7.75	2.15e-14	6.17e-12	0.23	0.23	Homocysteine levels;	chr7:90327170	chr7:90312496~90322592:+
BRCA	cis	rs2439831	0.702	rs9989313	ENSG00000205771.5	CATSPER2P1	-7.75	2.15e-14	6.17e-12	-0.4	-0.23	Lung cancer in ever smokers;	chr15:43860619	chr15:43726918~43747094:-
BRCA	cis	rs712022	0.534	rs7927085	ENSG00000246225.5	RP11-17A1.3	-7.75	2.15e-14	6.17e-12	-0.28	-0.23	Dialysis-related mortality;	chr11:22852337	chr11:22829380~22945393:+
BRCA	cis	rs9876781	1	rs11130171	ENSG00000244380.1	RP11-24C3.2	7.75	2.16e-14	6.2e-12	0.26	0.23	Longevity;	chr3:48421052	chr3:48440352~48446656:-
BRCA	cis	rs9876781	1	rs9883927	ENSG00000244380.1	RP11-24C3.2	7.75	2.16e-14	6.2e-12	0.26	0.23	Longevity;	chr3:48422302	chr3:48440352~48446656:-
BRCA	cis	rs10129255	0.957	rs2013423	ENSG00000211972.2	IGHV3-66	7.75	2.16e-14	6.2e-12	0.18	0.23	Kawasaki disease;	chr14:106690675	chr14:106675017~106675544:-
BRCA	cis	rs10129255	0.957	rs56134540	ENSG00000211972.2	IGHV3-66	7.75	2.16e-14	6.2e-12	0.18	0.23	Kawasaki disease;	chr14:106691290	chr14:106675017~106675544:-
BRCA	cis	rs79040073	0.563	rs7167852	ENSG00000259531.2	RP11-295H24.3	7.75	2.16e-14	6.21e-12	0.35	0.23	Lung cancer in ever smokers;	chr15:49250004	chr15:49365124~49366685:-
BRCA	cis	rs6545883	0.894	rs2463102	ENSG00000271889.1	RP11-493E12.1	-7.75	2.16e-14	6.21e-12	-0.3	-0.23	Tuberculosis;	chr2:61344160	chr2:61151433~61162105:-
BRCA	cis	rs801193	0.548	rs2109297	ENSG00000232559.3	GS1-124K5.12	-7.75	2.17e-14	6.22e-12	-0.28	-0.23	Aortic root size;	chr7:66657397	chr7:66554588~66576923:-
BRCA	cis	rs904251	0.504	rs1757188	ENSG00000204110.6	RP1-153P14.8	-7.75	2.17e-14	6.22e-12	-0.26	-0.23	Cognitive performance;	chr6:37516032	chr6:37507348~37535616:+
BRCA	cis	rs11098499	1	rs7659194	ENSG00000248280.1	RP11-33B1.2	7.75	2.17e-14	6.22e-12	0.24	0.23	Corneal astigmatism;	chr4:119285992	chr4:119440561~119450157:-
BRCA	cis	rs61270009	0.955	rs12654702	ENSG00000247828.6	TMEM161B-AS1	7.75	2.17e-14	6.23e-12	0.3	0.23	Depressive symptoms;	chr5:88402882	chr5:88268895~88436685:+
BRCA	cis	rs61270009	0.955	rs12523282	ENSG00000247828.6	TMEM161B-AS1	7.75	2.17e-14	6.23e-12	0.3	0.23	Depressive symptoms;	chr5:88407679	chr5:88268895~88436685:+
BRCA	cis	rs61270009	0.955	rs12651891	ENSG00000247828.6	TMEM161B-AS1	7.75	2.17e-14	6.23e-12	0.3	0.23	Depressive symptoms;	chr5:88408187	chr5:88268895~88436685:+
BRCA	cis	rs780096	0.587	rs4665969	ENSG00000234072.1	AC074117.10	7.75	2.18e-14	6.26e-12	0.22	0.23	Total body bone mineral density;	chr2:27352086	chr2:27356246~27367622:+
BRCA	cis	rs847577	0.677	rs10242903	ENSG00000272950.1	RP11-307C18.1	-7.75	2.19e-14	6.27e-12	-0.29	-0.23	Breast cancer;	chr7:98112483	chr7:98322853~98323430:+
BRCA	cis	rs10129255	0.83	rs61997609	ENSG00000211972.2	IGHV3-66	7.75	2.19e-14	6.28e-12	0.19	0.23	Kawasaki disease;	chr14:106692376	chr14:106675017~106675544:-
BRCA	cis	rs7809950	1	rs2237673	ENSG00000238832.1	snoU109	-7.75	2.19e-14	6.29e-12	-0.31	-0.23	Coronary artery disease;	chr7:107491135	chr7:107603363~107603507:+
BRCA	cis	rs6142102	0.923	rs2268078	ENSG00000276073.1	RP5-1125A11.7	-7.75	2.19e-14	6.29e-12	-0.29	-0.23	Skin pigmentation;	chr20:34008898	chr20:33985617~33988989:-
BRCA	cis	rs9876781	1	rs9817615	ENSG00000244380.1	RP11-24C3.2	7.75	2.19e-14	6.29e-12	0.26	0.23	Longevity;	chr3:48429347	chr3:48440352~48446656:-
BRCA	cis	rs919433	1	rs6741380	ENSG00000231621.1	AC013264.2	-7.75	2.19e-14	6.29e-12	-0.22	-0.23	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197300397	chr2:197197991~197199273:+
BRCA	cis	rs891378	0.785	rs7516640	ENSG00000274245.1	RP11-357P18.2	7.75	2.19e-14	6.29e-12	0.29	0.23	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207236069	chr1:207372559~207373252:+
BRCA	cis	rs6142102	0.778	rs6059555	ENSG00000276073.1	RP5-1125A11.7	-7.75	2.2e-14	6.31e-12	-0.29	-0.23	Skin pigmentation;	chr20:33926518	chr20:33985617~33988989:-
BRCA	cis	rs77204473	0.744	rs10892068	ENSG00000254851.1	RP11-109L13.1	-7.75	2.2e-14	6.31e-12	-0.51	-0.23	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117057830	chr11:117135528~117138582:+
BRCA	cis	rs2742234	0.91	rs2505513	ENSG00000273008.1	RP11-351D16.3	-7.75	2.2e-14	6.33e-12	-0.27	-0.23	Hirschsprung disease;	chr10:43138089	chr10:43136824~43138334:-
BRCA	cis	rs7809950	1	rs17154104	ENSG00000238832.1	snoU109	-7.75	2.21e-14	6.33e-12	-0.31	-0.23	Coronary artery disease;	chr7:107450253	chr7:107603363~107603507:+
BRCA	cis	rs6539288	0.933	rs4964498	ENSG00000260329.1	RP11-412D9.4	-7.75	2.21e-14	6.34e-12	-0.27	-0.23	Total body bone mineral density;	chr12:106912945	chr12:106954029~106955497:-
BRCA	cis	rs4835473	0.778	rs2622380	ENSG00000251600.4	RP11-673E1.1	-7.75	2.21e-14	6.34e-12	-0.28	-0.23	Immature fraction of reticulocytes;	chr4:143814571	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs35792820	ENSG00000251600.4	RP11-673E1.1	-7.75	2.21e-14	6.34e-12	-0.28	-0.23	Immature fraction of reticulocytes;	chr4:143814806	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.864	rs62337300	ENSG00000251600.4	RP11-673E1.1	-7.75	2.21e-14	6.34e-12	-0.28	-0.23	Immature fraction of reticulocytes;	chr4:143815897	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs7697498	ENSG00000251600.4	RP11-673E1.1	-7.75	2.21e-14	6.34e-12	-0.28	-0.23	Immature fraction of reticulocytes;	chr4:143816854	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs7656455	ENSG00000251600.4	RP11-673E1.1	-7.75	2.21e-14	6.34e-12	-0.28	-0.23	Immature fraction of reticulocytes;	chr4:143817005	chr4:143912331~143982454:+
BRCA	cis	rs11023332	0.617	rs1879888	ENSG00000251991.1	RNU7-49P	7.75	2.22e-14	6.36e-12	0.24	0.23	Vitamin D levels;Adiponectin levels;	chr11:14657701	chr11:14478892~14478953:+
BRCA	cis	rs2028299	0.959	rs12594808	ENSG00000259677.1	RP11-493E3.1	7.75	2.22e-14	6.37e-12	0.31	0.23	Type 2 diabetes;	chr15:89857652	chr15:89876540~89877285:+
BRCA	cis	rs875971	1	rs1540651	ENSG00000232559.3	GS1-124K5.12	-7.75	2.23e-14	6.39e-12	-0.28	-0.23	Aortic root size;	chr7:66185134	chr7:66554588~66576923:-
BRCA	cis	rs950776	0.616	rs12901300	ENSG00000261762.1	RP11-650L12.2	7.75	2.23e-14	6.4e-12	0.25	0.23	Sudden cardiac arrest;	chr15:78600610	chr15:78589123~78591276:-
BRCA	cis	rs8005677	1	rs10148215	ENSG00000279656.1	RP11-298I3.6	7.75	2.23e-14	6.41e-12	0.28	0.23	Cognitive ability (multi-trait analysis);	chr14:22913136	chr14:23023083~23024217:-
BRCA	cis	rs2033711	0.755	rs4801587	ENSG00000269473.1	CTD-2619J13.19	7.75	2.24e-14	6.41e-12	0.28	0.23	Uric acid clearance;	chr19:58425312	chr19:58440448~58445849:+
BRCA	cis	rs2034650	0.544	rs11070272	ENSG00000223313.1	RNU6-516P	7.75	2.24e-14	6.42e-12	0.3	0.23	Interstitial lung disease;	chr15:40433064	chr15:40529570~40529673:+
BRCA	cis	rs875971	0.545	rs6460281	ENSG00000224316.1	RP11-479O9.2	7.74	2.27e-14	6.49e-12	0.26	0.23	Aortic root size;	chr7:66216128	chr7:65773620~65802067:+
BRCA	cis	rs875971	1	rs3981131	ENSG00000237310.1	GS1-124K5.4	7.74	2.27e-14	6.5e-12	0.24	0.23	Aortic root size;	chr7:66486690	chr7:66493706~66495474:+
BRCA	cis	rs6569038	0.557	rs9387629	ENSG00000253194.1	RP11-351A11.1	7.74	2.27e-14	6.5e-12	0.29	0.23	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr6:119035036	chr6:118934785~119031541:+
BRCA	cis	rs950880	0.71	rs17027166	ENSG00000234389.1	AC007278.3	-7.74	2.28e-14	6.52e-12	-0.24	-0.23	Serum protein levels (sST2);	chr2:102438960	chr2:102438713~102440475:+
BRCA	cis	rs12712135	0.706	rs6543114	ENSG00000234389.1	AC007278.3	-7.74	2.28e-14	6.53e-12	-0.24	-0.23	Blood protein levels;	chr2:102309534	chr2:102438713~102440475:+
BRCA	cis	rs16978956	0.592	rs16990336	ENSG00000236474.1	GCNT1P1	7.74	2.28e-14	6.53e-12	0.33	0.23	Body mass index;	chr20:18348968	chr20:18420160~18421454:-
BRCA	cis	rs891378	0.785	rs55957981	ENSG00000274245.1	RP11-357P18.2	-7.74	2.29e-14	6.55e-12	-0.3	-0.23	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207205594	chr1:207372559~207373252:+
BRCA	cis	rs17818399	0.597	rs13385693	ENSG00000279254.1	RP11-536C12.1	-7.74	2.29e-14	6.55e-12	-0.28	-0.23	Height;	chr2:46640019	chr2:46668870~46670778:+
BRCA	cis	rs2742234	0.541	rs11238479	ENSG00000273008.1	RP11-351D16.3	7.74	2.29e-14	6.55e-12	0.3	0.23	Hirschsprung disease;	chr10:43221975	chr10:43136824~43138334:-
BRCA	cis	rs9649213	0.613	rs6961129	ENSG00000272950.1	RP11-307C18.1	7.74	2.29e-14	6.57e-12	0.3	0.23	Prostate cancer (SNP x SNP interaction);	chr7:98346230	chr7:98322853~98323430:+
BRCA	cis	rs11098499	0.754	rs10518300	ENSG00000248280.1	RP11-33B1.2	-7.74	2.29e-14	6.57e-12	-0.23	-0.23	Corneal astigmatism;	chr4:119328344	chr4:119440561~119450157:-
BRCA	cis	rs56046484	0.62	rs34585903	ENSG00000259295.5	CSPG4P12	7.74	2.29e-14	6.57e-12	0.43	0.23	Testicular germ cell tumor;	chr15:84984893	chr15:85191438~85213905:+
BRCA	cis	rs10200159	1	rs6739788	ENSG00000272606.1	RP11-554J4.1	7.74	2.3e-14	6.58e-12	0.44	0.23	Vitiligo;	chr2:55635220	chr2:55617909~55618373:+
BRCA	cis	rs77204473	1	rs12286581	ENSG00000254851.1	RP11-109L13.1	7.74	2.3e-14	6.58e-12	0.54	0.23	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116878028	chr11:117135528~117138582:+
BRCA	cis	rs2439831	0.85	rs28564774	ENSG00000205771.5	CATSPER2P1	-7.74	2.3e-14	6.58e-12	-0.41	-0.23	Lung cancer in ever smokers;	chr15:43833277	chr15:43726918~43747094:-
BRCA	cis	rs6539288	0.933	rs2053205	ENSG00000260329.1	RP11-412D9.4	-7.74	2.3e-14	6.59e-12	-0.27	-0.23	Total body bone mineral density;	chr12:106912489	chr12:106954029~106955497:-
BRCA	cis	rs6539288	0.933	rs759605	ENSG00000260329.1	RP11-412D9.4	-7.74	2.3e-14	6.59e-12	-0.27	-0.23	Total body bone mineral density;	chr12:106913401	chr12:106954029~106955497:-
BRCA	cis	rs6539288	0.933	rs759604	ENSG00000260329.1	RP11-412D9.4	-7.74	2.3e-14	6.59e-12	-0.27	-0.23	Total body bone mineral density;	chr12:106913518	chr12:106954029~106955497:-
BRCA	cis	rs6539288	0.899	rs759603	ENSG00000260329.1	RP11-412D9.4	-7.74	2.3e-14	6.59e-12	-0.27	-0.23	Total body bone mineral density;	chr12:106913613	chr12:106954029~106955497:-
BRCA	cis	rs6539288	0.933	rs2075289	ENSG00000260329.1	RP11-412D9.4	-7.74	2.3e-14	6.59e-12	-0.27	-0.23	Total body bone mineral density;	chr12:106913860	chr12:106954029~106955497:-
BRCA	cis	rs3758785	0.737	rs12270338	ENSG00000255893.1	RP11-685N10.1	7.74	2.3e-14	6.59e-12	0.3	0.23	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);	chr11:94414298	chr11:94472908~94473570:-
BRCA	cis	rs2439831	0.85	rs12442297	ENSG00000205771.5	CATSPER2P1	-7.74	2.3e-14	6.59e-12	-0.42	-0.23	Lung cancer in ever smokers;	chr15:43876272	chr15:43726918~43747094:-
BRCA	cis	rs8012947	0.565	rs12891852	ENSG00000279636.2	LINC00216	-7.74	2.31e-14	6.61e-12	-0.24	-0.23	Alcohol consumption in current drinkers;	chr14:58330922	chr14:58288033~58289158:+
BRCA	cis	rs7811142	0.775	rs6946768	ENSG00000242294.5	STAG3L5P	7.74	2.31e-14	6.61e-12	0.24	0.23	Platelet count;	chr7:100356770	chr7:100336079~100351900:+
BRCA	cis	rs7809950	0.954	rs2520243	ENSG00000238832.1	snoU109	-7.74	2.31e-14	6.62e-12	-0.31	-0.23	Coronary artery disease;	chr7:107496528	chr7:107603363~107603507:+
BRCA	cis	rs2033711	0.87	rs1465789	ENSG00000269473.1	CTD-2619J13.19	7.74	2.32e-14	6.64e-12	0.28	0.23	Uric acid clearance;	chr19:58434689	chr19:58440448~58445849:+
BRCA	cis	rs2179367	0.632	rs11155642	ENSG00000231760.4	RP11-350J20.5	7.74	2.32e-14	6.64e-12	0.34	0.23	Dupuytren's disease;	chr6:149332984	chr6:149796151~149826294:-
BRCA	cis	rs9532669	0.511	rs3783164	ENSG00000176268.5	CYCSP34	-7.74	2.33e-14	6.66e-12	-0.26	-0.23	Cervical cancer;	chr13:40806227	chr13:40863599~40863902:-
BRCA	cis	rs2179367	0.632	rs7349921	ENSG00000231760.4	RP11-350J20.5	7.74	2.33e-14	6.66e-12	0.34	0.23	Dupuytren's disease;	chr6:149392727	chr6:149796151~149826294:-
BRCA	cis	rs2179367	0.632	rs60153446	ENSG00000231760.4	RP11-350J20.5	7.74	2.33e-14	6.66e-12	0.34	0.23	Dupuytren's disease;	chr6:149393186	chr6:149796151~149826294:-
BRCA	cis	rs2179367	0.632	rs61259243	ENSG00000231760.4	RP11-350J20.5	7.74	2.33e-14	6.66e-12	0.34	0.23	Dupuytren's disease;	chr6:149393457	chr6:149796151~149826294:-
BRCA	cis	rs2179367	0.632	rs62426115	ENSG00000231760.4	RP11-350J20.5	7.74	2.33e-14	6.66e-12	0.34	0.23	Dupuytren's disease;	chr6:149393718	chr6:149796151~149826294:-
BRCA	cis	rs2179367	0.632	rs68080376	ENSG00000231760.4	RP11-350J20.5	7.74	2.33e-14	6.66e-12	0.34	0.23	Dupuytren's disease;	chr6:149393873	chr6:149796151~149826294:-
BRCA	cis	rs287982	1	rs287979	ENSG00000269973.1	RP11-95D17.1	7.74	2.33e-14	6.67e-12	0.28	0.23	Nonsyndromic cleft lip with cleft palate;	chr2:9830838	chr2:9936360~9939590:+
BRCA	cis	rs2880765	0.835	rs7180923	ENSG00000259295.5	CSPG4P12	7.74	2.33e-14	6.67e-12	0.28	0.23	Coronary artery disease;	chr15:85507659	chr15:85191438~85213905:+
BRCA	cis	rs3758911	1	rs11212164	ENSG00000255353.1	RP11-382M14.1	-7.74	2.33e-14	6.68e-12	-0.3	-0.23	Coronary artery disease;	chr11:107328113	chr11:107176286~107177530:+
BRCA	cis	rs9880211	1	rs28811905	ENSG00000273486.1	RP11-731C17.2	7.74	2.34e-14	6.69e-12	0.31	0.23	Height;Body mass index;	chr3:136533210	chr3:136837338~136839021:-
BRCA	cis	rs875971	0.862	rs1167408	ENSG00000232559.3	GS1-124K5.12	-7.74	2.34e-14	6.69e-12	-0.29	-0.23	Aortic root size;	chr7:66091121	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.83	rs1167406	ENSG00000232559.3	GS1-124K5.12	-7.74	2.34e-14	6.69e-12	-0.29	-0.23	Aortic root size;	chr7:66091949	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.862	rs1167399	ENSG00000232559.3	GS1-124K5.12	-7.74	2.34e-14	6.69e-12	-0.29	-0.23	Aortic root size;	chr7:66096890	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.862	rs57866200	ENSG00000232559.3	GS1-124K5.12	-7.74	2.34e-14	6.69e-12	-0.29	-0.23	Aortic root size;	chr7:66100405	chr7:66554588~66576923:-
BRCA	cis	rs10050311	0.79	rs72667724	ENSG00000251411.1	RP11-397E7.4	-7.74	2.34e-14	6.7e-12	-0.35	-0.23	Insulin-related traits;	chr4:86929931	chr4:86913266~86914817:-
BRCA	cis	rs2153535	0.935	rs11243254	ENSG00000230939.1	RP11-314C16.1	7.74	2.34e-14	6.71e-12	0.27	0.23	Motion sickness;	chr6:8381009	chr6:8784178~8785445:+
BRCA	cis	rs6539288	0.705	rs1053051	ENSG00000260329.1	RP11-412D9.4	-7.74	2.34e-14	6.71e-12	-0.26	-0.23	Total body bone mineral density;	chr12:106973447	chr12:106954029~106955497:-
BRCA	cis	rs875971	0.862	rs10282433	ENSG00000232559.3	GS1-124K5.12	-7.74	2.34e-14	6.71e-12	-0.28	-0.23	Aortic root size;	chr7:66256452	chr7:66554588~66576923:-
BRCA	cis	rs1075265	0.621	rs2542593	ENSG00000233266.1	HMGB1P31	7.74	2.35e-14	6.72e-12	0.28	0.23	Chronotype;Morning vs. evening chronotype;	chr2:53804299	chr2:54051334~54051760:+
BRCA	cis	rs6597981	0.592	rs10902218	ENSG00000255142.1	AP006621.6	-7.74	2.35e-14	6.72e-12	-0.2	-0.23	Breast cancer;	chr11:743813	chr11:781645~782105:+
BRCA	cis	rs2274273	0.624	rs7159824	ENSG00000258413.1	RP11-665C16.6	-7.74	2.36e-14	6.74e-12	-0.31	-0.23	Protein biomarker;	chr14:55305818	chr14:55262767~55272075:-
BRCA	cis	rs9880211	0.898	rs28877020	ENSG00000273486.1	RP11-731C17.2	7.74	2.36e-14	6.75e-12	0.31	0.23	Height;Body mass index;	chr3:136676874	chr3:136837338~136839021:-
BRCA	cis	rs287982	1	rs56154233	ENSG00000269973.1	RP11-95D17.1	-7.74	2.36e-14	6.76e-12	-0.29	-0.23	Nonsyndromic cleft lip with cleft palate;	chr2:9829098	chr2:9936360~9939590:+
BRCA	cis	rs113835537	0.529	rs117112180	ENSG00000255517.5	CTD-3074O7.5	-7.74	2.36e-14	6.76e-12	-0.32	-0.23	Airway imaging phenotypes;	chr11:66525802	chr11:66473490~66480233:-
BRCA	cis	rs2179367	0.632	rs9498344	ENSG00000231760.4	RP11-350J20.5	7.74	2.36e-14	6.76e-12	0.34	0.23	Dupuytren's disease;	chr6:149401053	chr6:149796151~149826294:-
BRCA	cis	rs3758911	0.894	rs10749902	ENSG00000255353.1	RP11-382M14.1	-7.74	2.37e-14	6.77e-12	-0.31	-0.23	Coronary artery disease;	chr11:107324855	chr11:107176286~107177530:+
BRCA	cis	rs8005677	0.926	rs34344888	ENSG00000279656.1	RP11-298I3.6	7.74	2.37e-14	6.77e-12	0.28	0.23	Cognitive ability (multi-trait analysis);	chr14:22918376	chr14:23023083~23024217:-
BRCA	cis	rs8005677	0.962	rs34917191	ENSG00000279656.1	RP11-298I3.6	7.74	2.37e-14	6.77e-12	0.28	0.23	Cognitive ability (multi-trait analysis);	chr14:22918419	chr14:23023083~23024217:-
BRCA	cis	rs8005677	1	rs1951119	ENSG00000279656.1	RP11-298I3.6	7.74	2.37e-14	6.77e-12	0.28	0.23	Cognitive ability (multi-trait analysis);	chr14:22919117	chr14:23023083~23024217:-
BRCA	cis	rs8005677	1	rs2295683	ENSG00000279656.1	RP11-298I3.6	7.74	2.37e-14	6.77e-12	0.28	0.23	Cognitive ability (multi-trait analysis);	chr14:22919173	chr14:23023083~23024217:-
BRCA	cis	rs8005677	1	rs4981449	ENSG00000279656.1	RP11-298I3.6	7.74	2.37e-14	6.77e-12	0.28	0.23	Cognitive ability (multi-trait analysis);	chr14:22919662	chr14:23023083~23024217:-
BRCA	cis	rs867371	0.964	rs7169961	ENSG00000255769.6	GOLGA2P10	-7.74	2.37e-14	6.77e-12	-0.27	-0.23	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82186588	chr15:82472993~82513950:-
BRCA	cis	rs17772222	0.874	rs61984746	ENSG00000258983.2	RP11-507K2.2	7.74	2.37e-14	6.78e-12	0.27	0.23	Coronary artery calcification;	chr14:88668136	chr14:88499334~88515502:+
BRCA	cis	rs2348418	0.703	rs12368149	ENSG00000247934.4	RP11-967K21.1	-7.74	2.38e-14	6.8e-12	-0.26	-0.23	Lung function (FEV1);Lung function (FVC);	chr12:28168625	chr12:28163298~28190738:-
BRCA	cis	rs867371	1	rs13380319	ENSG00000259429.4	UBE2Q2P2	-7.74	2.39e-14	6.83e-12	-0.23	-0.23	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82214526	chr15:82355142~82420075:+
BRCA	cis	rs74233809	1	rs11191515	ENSG00000213277.3	MARCKSL1P1	7.74	2.39e-14	6.83e-12	0.46	0.23	Birth weight;	chr10:103016770	chr10:103175554~103176094:+
BRCA	cis	rs4835473	0.932	rs17763107	ENSG00000251600.4	RP11-673E1.1	-7.74	2.39e-14	6.83e-12	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143828512	chr4:143912331~143982454:+
BRCA	cis	rs4713118	0.615	rs57252182	ENSG00000216901.1	AL022393.7	7.74	2.39e-14	6.84e-12	0.3	0.23	Parkinson's disease;	chr6:27752470	chr6:28176188~28176674:+
BRCA	cis	rs56046484	0.75	rs62022525	ENSG00000259295.5	CSPG4P12	7.74	2.4e-14	6.86e-12	0.43	0.23	Testicular germ cell tumor;	chr15:84980447	chr15:85191438~85213905:+
BRCA	cis	rs9402682	0.668	rs2026938	ENSG00000232876.1	CTA-212D2.2	-7.74	2.41e-14	6.88e-12	-0.33	-0.23	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr6:135122871	chr6:135055033~135060550:+
BRCA	cis	rs4835473	0.778	rs6853798	ENSG00000251600.4	RP11-673E1.1	-7.74	2.41e-14	6.88e-12	-0.28	-0.23	Immature fraction of reticulocytes;	chr4:143801153	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.9	rs12502940	ENSG00000251600.4	RP11-673E1.1	-7.74	2.41e-14	6.88e-12	-0.28	-0.23	Immature fraction of reticulocytes;	chr4:143812117	chr4:143912331~143982454:+
BRCA	cis	rs10463554	0.963	rs34777	ENSG00000175749.11	EIF3KP1	7.74	2.41e-14	6.89e-12	0.32	0.23	Parkinson's disease;	chr5:103116554	chr5:103032376~103033031:+
BRCA	cis	rs7520050	0.807	rs5021934	ENSG00000280836.1	AL355480.1	7.74	2.42e-14	6.9e-12	0.27	0.23	Reticulocyte count;Red blood cell count;	chr1:45643632	chr1:45581219~45581321:-
BRCA	cis	rs950880	0.593	rs887972	ENSG00000234389.1	AC007278.3	-7.74	2.42e-14	6.9e-12	-0.24	-0.23	Serum protein levels (sST2);	chr2:102424485	chr2:102438713~102440475:+
BRCA	cis	rs4835473	0.932	rs28668841	ENSG00000251600.4	RP11-673E1.1	-7.74	2.42e-14	6.91e-12	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143982530	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs9685306	ENSG00000251600.4	RP11-673E1.1	-7.74	2.42e-14	6.91e-12	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143748843	chr4:143912331~143982454:+
BRCA	cis	rs9880211	1	rs9809988	ENSG00000239213.4	NCK1-AS1	7.74	2.42e-14	6.91e-12	0.31	0.23	Height;Body mass index;	chr3:136803379	chr3:136841726~136862054:-
BRCA	cis	rs9527	0.637	rs7085104	ENSG00000213061.2	PFN1P11	7.74	2.42e-14	6.92e-12	0.31	0.23	Arsenic metabolism;	chr10:102869116	chr10:102838011~102845473:-
BRCA	cis	rs2179367	0.632	rs12196656	ENSG00000231760.4	RP11-350J20.5	7.74	2.42e-14	6.93e-12	0.34	0.23	Dupuytren's disease;	chr6:149383104	chr6:149796151~149826294:-
BRCA	cis	rs2179367	0.632	rs12211570	ENSG00000231760.4	RP11-350J20.5	7.74	2.42e-14	6.93e-12	0.34	0.23	Dupuytren's disease;	chr6:149383616	chr6:149796151~149826294:-
BRCA	cis	rs2179367	0.568	rs11155647	ENSG00000231760.4	RP11-350J20.5	7.74	2.42e-14	6.93e-12	0.34	0.23	Dupuytren's disease;	chr6:149384499	chr6:149796151~149826294:-
BRCA	cis	rs7772486	0.743	rs9376955	ENSG00000235652.6	RP11-545I5.3	7.74	2.43e-14	6.95e-12	0.23	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145628268	chr6:145799409~145886585:+
BRCA	cis	rs7772486	0.805	rs4896831	ENSG00000235652.6	RP11-545I5.3	7.74	2.43e-14	6.95e-12	0.23	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145638345	chr6:145799409~145886585:+
BRCA	cis	rs875971	0.798	rs12698522	ENSG00000232559.3	GS1-124K5.12	7.73	2.43e-14	6.95e-12	0.28	0.23	Aortic root size;	chr7:66502354	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.83	rs28714531	ENSG00000232559.3	GS1-124K5.12	7.73	2.43e-14	6.95e-12	0.28	0.23	Aortic root size;	chr7:66503250	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.862	rs12698526	ENSG00000232559.3	GS1-124K5.12	7.73	2.43e-14	6.95e-12	0.28	0.23	Aortic root size;	chr7:66504118	chr7:66554588~66576923:-
BRCA	cis	rs7811142	1	rs11773661	ENSG00000242294.5	STAG3L5P	7.73	2.44e-14	6.98e-12	0.23	0.23	Platelet count;	chr7:100475446	chr7:100336079~100351900:+
BRCA	cis	rs858239	0.6	rs2003555	ENSG00000230042.1	AK3P3	-7.73	2.45e-14	6.99e-12	-0.27	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23083296	chr7:23129178~23129841:+
BRCA	cis	rs858239	0.6	rs7784929	ENSG00000230042.1	AK3P3	-7.73	2.45e-14	6.99e-12	-0.27	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23084658	chr7:23129178~23129841:+
BRCA	cis	rs7615952	0.599	rs2270986	ENSG00000250012.1	RP11-124N2.1	-7.73	2.45e-14	7e-12	-0.32	-0.23	Blood pressure (smoking interaction);	chr3:125982256	chr3:126084220~126095349:+
BRCA	cis	rs7615952	0.599	rs12496921	ENSG00000250012.1	RP11-124N2.1	-7.73	2.45e-14	7e-12	-0.32	-0.23	Blood pressure (smoking interaction);	chr3:125983105	chr3:126084220~126095349:+
BRCA	cis	rs11098499	0.644	rs34835603	ENSG00000245958.5	RP11-33B1.1	-7.73	2.45e-14	7e-12	-0.22	-0.23	Corneal astigmatism;	chr4:119632273	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.615	rs28850368	ENSG00000245958.5	RP11-33B1.1	-7.73	2.45e-14	7e-12	-0.22	-0.23	Corneal astigmatism;	chr4:119633158	chr4:119454791~119552025:+
BRCA	cis	rs10246939	0.579	rs13232651	ENSG00000228775.6	WEE2-AS1	7.73	2.46e-14	7.01e-12	0.26	0.23	Bitter taste perception;	chr7:141862624	chr7:141704338~141738346:-
BRCA	cis	rs763512	0.532	rs3110626	ENSG00000276054.1	RP11-378E13.3	-7.73	2.46e-14	7.01e-12	-0.34	-0.23	3-hydroxypropylmercapturic acid levels in smokers;	chr17:37536300	chr17:37386886~37387926:+
BRCA	cis	rs287982	0.8	rs13429581	ENSG00000269973.1	RP11-95D17.1	-7.73	2.46e-14	7.01e-12	-0.29	-0.23	Nonsyndromic cleft lip with cleft palate;	chr2:9823314	chr2:9936360~9939590:+
BRCA	cis	rs875971	0.964	rs778735	ENSG00000232559.3	GS1-124K5.12	7.73	2.46e-14	7.02e-12	0.28	0.23	Aortic root size;	chr7:66349822	chr7:66554588~66576923:-
BRCA	cis	rs10463554	0.963	rs11242483	ENSG00000175749.11	EIF3KP1	7.73	2.46e-14	7.04e-12	0.32	0.23	Parkinson's disease;	chr5:102988062	chr5:103032376~103033031:+
BRCA	cis	rs875971	0.862	rs778686	ENSG00000232559.3	GS1-124K5.12	7.73	2.47e-14	7.04e-12	0.28	0.23	Aortic root size;	chr7:66370923	chr7:66554588~66576923:-
BRCA	cis	rs11098499	0.955	rs1511019	ENSG00000248280.1	RP11-33B1.2	7.73	2.47e-14	7.04e-12	0.24	0.23	Corneal astigmatism;	chr4:119244852	chr4:119440561~119450157:-
BRCA	cis	rs3758911	0.828	rs11212138	ENSG00000255353.1	RP11-382M14.1	-7.73	2.47e-14	7.04e-12	-0.32	-0.23	Coronary artery disease;	chr11:107294553	chr11:107176286~107177530:+
BRCA	cis	rs526231	0.543	rs152123	ENSG00000175749.11	EIF3KP1	-7.73	2.47e-14	7.05e-12	-0.35	-0.23	Primary biliary cholangitis;	chr5:103196218	chr5:103032376~103033031:+
BRCA	cis	rs2243480	0.522	rs73150635	ENSG00000226824.5	RP4-756H11.3	-7.73	2.47e-14	7.05e-12	-0.56	-0.23	Diabetic kidney disease;	chr7:66507503	chr7:66654538~66669855:+
BRCA	cis	rs1275468	0.798	rs1275474	ENSG00000257497.2	RP11-585P4.5	-7.73	2.48e-14	7.06e-12	-0.32	-0.23	Polycystic ovary syndrome;	chr12:75525870	chr12:75483454~75489820:-
BRCA	cis	rs2880765	0.835	rs4842884	ENSG00000259295.5	CSPG4P12	7.73	2.48e-14	7.08e-12	0.28	0.23	Coronary artery disease;	chr15:85491943	chr15:85191438~85213905:+
BRCA	cis	rs250518	0.926	rs6897924	ENSG00000272081.1	CTD-2376I4.2	7.73	2.48e-14	7.09e-12	0.3	0.23	Mean corpuscular hemoglobin concentration;	chr5:72765713	chr5:72955206~72955699:-
BRCA	cis	rs10022462	0.933	rs10516806	ENSG00000246375.2	RP11-10L7.1	7.73	2.49e-14	7.12e-12	0.3	0.23	Breast cancer;Blood metabolite levels;	chr4:88325062	chr4:88284942~88331421:+
BRCA	cis	rs875971	0.545	rs73378304	ENSG00000224316.1	RP11-479O9.2	7.73	2.5e-14	7.14e-12	0.26	0.23	Aortic root size;	chr7:66175760	chr7:65773620~65802067:+
BRCA	cis	rs3762637	0.823	rs59569049	ENSG00000272758.4	RP11-299J3.8	-7.73	2.51e-14	7.17e-12	-0.33	-0.23	LDL cholesterol levels;	chr3:122519941	chr3:122416207~122443180:+
BRCA	cis	rs11098499	0.604	rs2389886	ENSG00000248280.1	RP11-33B1.2	7.73	2.52e-14	7.18e-12	0.25	0.23	Corneal astigmatism;	chr4:119649267	chr4:119440561~119450157:-
BRCA	cis	rs9880211	0.904	rs9857833	ENSG00000239213.4	NCK1-AS1	7.73	2.52e-14	7.19e-12	0.3	0.23	Height;Body mass index;	chr3:136685625	chr3:136841726~136862054:-
BRCA	cis	rs12468226	0.873	rs6761131	ENSG00000273456.1	RP11-686O6.2	-7.73	2.52e-14	7.2e-12	-0.34	-0.23	Urate levels;	chr2:202237675	chr2:202374932~202375604:-
BRCA	cis	rs8072100	0.935	rs4793978	ENSG00000228782.6	CTD-2026D20.3	-7.73	2.53e-14	7.21e-12	-0.25	-0.23	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47620809	chr17:47450568~47492492:-
BRCA	cis	rs8062405	0.754	rs3859172	ENSG00000251417.2	RP11-1348G14.4	-7.73	2.54e-14	7.23e-12	-0.26	-0.23	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554837	chr16:28802743~28817828:+
BRCA	cis	rs8072100	0.935	rs12943464	ENSG00000228782.6	CTD-2026D20.3	-7.73	2.54e-14	7.24e-12	-0.25	-0.23	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47612985	chr17:47450568~47492492:-
BRCA	cis	rs7809950	1	rs2894475	ENSG00000238832.1	snoU109	-7.73	2.54e-14	7.26e-12	-0.3	-0.23	Coronary artery disease;	chr7:107622113	chr7:107603363~107603507:+
BRCA	cis	rs4964805	1	rs11111792	ENSG00000257681.1	RP11-341G23.4	7.73	2.55e-14	7.27e-12	0.29	0.23	Attention deficit hyperactivity disorder;	chr12:103801079	chr12:103746315~103768858:-
BRCA	cis	rs4835473	0.932	rs1450235	ENSG00000251600.4	RP11-673E1.1	7.73	2.55e-14	7.27e-12	0.29	0.23	Immature fraction of reticulocytes;	chr4:143782927	chr4:143912331~143982454:+
BRCA	cis	rs113835537	0.529	rs75003264	ENSG00000255517.5	CTD-3074O7.5	-7.73	2.55e-14	7.28e-12	-0.32	-0.23	Airway imaging phenotypes;	chr11:66488628	chr11:66473490~66480233:-
BRCA	cis	rs72627509	0.857	rs55762216	ENSG00000269949.1	RP11-738E22.3	7.73	2.56e-14	7.29e-12	0.35	0.23	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56899565	chr4:56960927~56961373:-
BRCA	cis	rs732716	0.785	rs11085073	ENSG00000267980.1	AC007292.6	7.73	2.56e-14	7.3e-12	0.31	0.23	Mean corpuscular volume;	chr19:4375165	chr19:4363789~4364640:+
BRCA	cis	rs7811142	1	rs67315960	ENSG00000242294.5	STAG3L5P	7.73	2.57e-14	7.32e-12	0.23	0.23	Platelet count;	chr7:100417501	chr7:100336079~100351900:+
BRCA	cis	rs7306456	0.623	rs10902513	ENSG00000256576.2	RP13-977J11.2	7.73	2.57e-14	7.32e-12	0.25	0.23	Anti-saccade response;	chr12:132208942	chr12:132186735~132189695:-
BRCA	cis	rs17772222	0.917	rs17260408	ENSG00000258983.2	RP11-507K2.2	7.73	2.57e-14	7.32e-12	0.27	0.23	Coronary artery calcification;	chr14:88715464	chr14:88499334~88515502:+
BRCA	cis	rs17772222	0.917	rs8021690	ENSG00000258983.2	RP11-507K2.2	7.73	2.57e-14	7.32e-12	0.27	0.23	Coronary artery calcification;	chr14:88717806	chr14:88499334~88515502:+
BRCA	cis	rs2243480	1	rs313832	ENSG00000273142.1	RP11-458F8.4	-7.73	2.58e-14	7.34e-12	-0.34	-0.23	Diabetic kidney disease;	chr7:66085904	chr7:66902857~66906297:+
BRCA	cis	rs2274273	0.624	rs10129505	ENSG00000258413.1	RP11-665C16.6	-7.73	2.59e-14	7.39e-12	-0.31	-0.23	Protein biomarker;	chr14:55309657	chr14:55262767~55272075:-
BRCA	cis	rs7432375	0.566	rs835636	ENSG00000239213.4	NCK1-AS1	7.73	2.6e-14	7.4e-12	0.24	0.23	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136955658	chr3:136841726~136862054:-
BRCA	cis	rs293748	0.882	rs13177875	ENSG00000250155.1	CTD-2353F22.1	-7.73	2.61e-14	7.42e-12	-0.33	-0.23	Obesity-related traits;	chr5:37078226	chr5:36666214~36725195:-
BRCA	cis	rs2179367	0.632	rs763590	ENSG00000231760.4	RP11-350J20.5	7.73	2.61e-14	7.43e-12	0.34	0.23	Dupuytren's disease;	chr6:149398831	chr6:149796151~149826294:-
BRCA	cis	rs2179367	0.632	rs17506789	ENSG00000231760.4	RP11-350J20.5	7.73	2.61e-14	7.43e-12	0.34	0.23	Dupuytren's disease;	chr6:149399710	chr6:149796151~149826294:-
BRCA	cis	rs2179367	0.586	rs34097428	ENSG00000231760.4	RP11-350J20.5	7.73	2.61e-14	7.43e-12	0.34	0.23	Dupuytren's disease;	chr6:149399822	chr6:149796151~149826294:-
BRCA	cis	rs2179367	0.632	rs12154153	ENSG00000231760.4	RP11-350J20.5	7.73	2.61e-14	7.43e-12	0.34	0.23	Dupuytren's disease;	chr6:149401686	chr6:149796151~149826294:-
BRCA	cis	rs875971	0.545	rs2460427	ENSG00000224316.1	RP11-479O9.2	-7.73	2.61e-14	7.45e-12	-0.26	-0.23	Aortic root size;	chr7:66154218	chr7:65773620~65802067:+
BRCA	cis	rs6565180	0.632	rs8050812	ENSG00000273724.1	RP11-347C12.12	-7.73	2.62e-14	7.45e-12	-0.3	-0.23	Tonsillectomy;	chr16:30374516	chr16:30336400~30343336:+
BRCA	cis	rs17772222	0.917	rs17188207	ENSG00000258983.2	RP11-507K2.2	7.72	2.62e-14	7.47e-12	0.27	0.23	Coronary artery calcification;	chr14:88699579	chr14:88499334~88515502:+
BRCA	cis	rs9649213	0.574	rs7802560	ENSG00000272950.1	RP11-307C18.1	-7.72	2.62e-14	7.47e-12	-0.3	-0.23	Prostate cancer (SNP x SNP interaction);	chr7:98274494	chr7:98322853~98323430:+
BRCA	cis	rs7811142	1	rs6975729	ENSG00000242294.5	STAG3L5P	7.72	2.62e-14	7.47e-12	0.23	0.23	Platelet count;	chr7:100430564	chr7:100336079~100351900:+
BRCA	cis	rs2439831	0.85	rs28513374	ENSG00000205771.5	CATSPER2P1	-7.72	2.63e-14	7.49e-12	-0.41	-0.23	Lung cancer in ever smokers;	chr15:43833297	chr15:43726918~43747094:-
BRCA	cis	rs875971	1	rs937495	ENSG00000232559.3	GS1-124K5.12	-7.72	2.64e-14	7.5e-12	-0.28	-0.23	Aortic root size;	chr7:66314811	chr7:66554588~66576923:-
BRCA	cis	rs875971	1	rs2036264	ENSG00000232559.3	GS1-124K5.12	-7.72	2.64e-14	7.5e-12	-0.28	-0.23	Aortic root size;	chr7:66334917	chr7:66554588~66576923:-
BRCA	cis	rs875971	1	rs7783613	ENSG00000232559.3	GS1-124K5.12	-7.72	2.64e-14	7.5e-12	-0.28	-0.23	Aortic root size;	chr7:66340274	chr7:66554588~66576923:-
BRCA	cis	rs10129255	0.957	rs2007467	ENSG00000211972.2	IGHV3-66	-7.72	2.65e-14	7.53e-12	-0.18	-0.23	Kawasaki disease;	chr14:106771605	chr14:106675017~106675544:-
BRCA	cis	rs6142102	1	rs4911414	ENSG00000276073.1	RP5-1125A11.7	-7.72	2.65e-14	7.54e-12	-0.29	-0.23	Skin pigmentation;	chr20:34141638	chr20:33985617~33988989:-
BRCA	cis	rs8062405	0.69	rs762634	ENSG00000251417.2	RP11-1348G14.4	-7.72	2.65e-14	7.54e-12	-0.29	-0.23	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28592014	chr16:28802743~28817828:+
BRCA	cis	rs7520050	0.807	rs3013594	ENSG00000280836.1	AL355480.1	-7.72	2.65e-14	7.54e-12	-0.27	-0.23	Reticulocyte count;Red blood cell count;	chr1:45672328	chr1:45581219~45581321:-
BRCA	cis	rs957448	0.607	rs12680842	ENSG00000253704.1	RP11-267M23.4	7.72	2.65e-14	7.54e-12	0.25	0.23	Nonsyndromic cleft lip with cleft palate;	chr8:94570378	chr8:94553722~94569745:+
BRCA	cis	rs3758911	0.861	rs2355840	ENSG00000255353.1	RP11-382M14.1	-7.72	2.65e-14	7.55e-12	-0.32	-0.23	Coronary artery disease;	chr11:107287251	chr11:107176286~107177530:+
BRCA	cis	rs3758911	0.861	rs11212132	ENSG00000255353.1	RP11-382M14.1	-7.72	2.65e-14	7.55e-12	-0.32	-0.23	Coronary artery disease;	chr11:107288576	chr11:107176286~107177530:+
BRCA	cis	rs2243480	1	rs316322	ENSG00000273142.1	RP11-458F8.4	-7.72	2.66e-14	7.58e-12	-0.32	-0.23	Diabetic kidney disease;	chr7:66146246	chr7:66902857~66906297:+
BRCA	cis	rs957448	0.554	rs72674877	ENSG00000253704.1	RP11-267M23.4	7.72	2.67e-14	7.61e-12	0.25	0.23	Nonsyndromic cleft lip with cleft palate;	chr8:94580479	chr8:94553722~94569745:+
BRCA	cis	rs2033711	0.87	rs3764534	ENSG00000269473.1	CTD-2619J13.19	7.72	2.68e-14	7.63e-12	0.28	0.23	Uric acid clearance;	chr19:58417769	chr19:58440448~58445849:+
BRCA	cis	rs7811142	0.887	rs4074838	ENSG00000242294.5	STAG3L5P	7.72	2.69e-14	7.65e-12	0.23	0.23	Platelet count;	chr7:100435042	chr7:100336079~100351900:+
BRCA	cis	rs287982	0.932	rs9973577	ENSG00000269973.1	RP11-95D17.1	-7.72	2.69e-14	7.67e-12	-0.29	-0.23	Nonsyndromic cleft lip with cleft palate;	chr2:9820574	chr2:9936360~9939590:+
BRCA	cis	rs7811142	1	rs7811142	ENSG00000242294.5	STAG3L5P	7.72	2.69e-14	7.67e-12	0.23	0.23	Platelet count;	chr7:100467820	chr7:100336079~100351900:+
BRCA	cis	rs858239	0.6	rs6961406	ENSG00000230042.1	AK3P3	-7.72	2.7e-14	7.67e-12	-0.27	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23095272	chr7:23129178~23129841:+
BRCA	cis	rs858239	0.6	rs6461690	ENSG00000230042.1	AK3P3	-7.72	2.7e-14	7.67e-12	-0.27	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23095915	chr7:23129178~23129841:+
BRCA	cis	rs858239	0.6	rs6967419	ENSG00000230042.1	AK3P3	-7.72	2.7e-14	7.67e-12	-0.27	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23096691	chr7:23129178~23129841:+
BRCA	cis	rs2880765	0.835	rs11638498	ENSG00000259295.5	CSPG4P12	7.72	2.7e-14	7.69e-12	0.28	0.23	Coronary artery disease;	chr15:85479787	chr15:85191438~85213905:+
BRCA	cis	rs2179367	0.586	rs9498341	ENSG00000231760.4	RP11-350J20.5	7.72	2.71e-14	7.7e-12	0.34	0.23	Dupuytren's disease;	chr6:149379737	chr6:149796151~149826294:-
BRCA	cis	rs2179367	0.632	rs9498342	ENSG00000231760.4	RP11-350J20.5	7.72	2.71e-14	7.7e-12	0.34	0.23	Dupuytren's disease;	chr6:149379806	chr6:149796151~149826294:-
BRCA	cis	rs2179367	0.632	rs12191079	ENSG00000231760.4	RP11-350J20.5	7.72	2.71e-14	7.7e-12	0.34	0.23	Dupuytren's disease;	chr6:149380333	chr6:149796151~149826294:-
BRCA	cis	rs2179367	0.632	rs12204461	ENSG00000231760.4	RP11-350J20.5	7.72	2.71e-14	7.7e-12	0.34	0.23	Dupuytren's disease;	chr6:149380399	chr6:149796151~149826294:-
BRCA	cis	rs2279440	0.85	rs3872707	ENSG00000206573.7	THUMPD3-AS1	-7.72	2.71e-14	7.71e-12	-0.26	-0.23	Glucose homeostasis traits;	chr3:9472332	chr3:9349689~9398579:-
BRCA	cis	rs2179367	0.632	rs9498338	ENSG00000231760.4	RP11-350J20.5	7.72	2.71e-14	7.71e-12	0.34	0.23	Dupuytren's disease;	chr6:149376428	chr6:149796151~149826294:-
BRCA	cis	rs2179367	0.632	rs9498336	ENSG00000231760.4	RP11-350J20.5	7.72	2.72e-14	7.74e-12	0.34	0.23	Dupuytren's disease;	chr6:149374208	chr6:149796151~149826294:-
BRCA	cis	rs2179367	0.632	rs1980774	ENSG00000231760.4	RP11-350J20.5	7.72	2.72e-14	7.74e-12	0.34	0.23	Dupuytren's disease;	chr6:149375030	chr6:149796151~149826294:-
BRCA	cis	rs2179367	0.632	rs9498337	ENSG00000231760.4	RP11-350J20.5	7.72	2.72e-14	7.74e-12	0.34	0.23	Dupuytren's disease;	chr6:149375970	chr6:149796151~149826294:-
BRCA	cis	rs3762637	0.943	rs7629285	ENSG00000272758.4	RP11-299J3.8	7.72	2.73e-14	7.75e-12	0.33	0.23	LDL cholesterol levels;	chr3:122546892	chr3:122416207~122443180:+
BRCA	cis	rs524281	0.647	rs2302883	ENSG00000255320.1	RP11-755F10.1	7.72	2.73e-14	7.75e-12	0.35	0.23	Electroencephalogram traits;	chr11:66057523	chr11:66244840~66246239:-
BRCA	cis	rs673078	0.66	rs7136216	ENSG00000275759.1	RP11-131L12.3	-7.72	2.73e-14	7.75e-12	-0.31	-0.23	Glucose homeostasis traits;	chr12:118170475	chr12:118428281~118428870:+
BRCA	cis	rs79040073	0.53	rs8025550	ENSG00000259531.2	RP11-295H24.3	-7.72	2.73e-14	7.76e-12	-0.35	-0.23	Lung cancer in ever smokers;	chr15:49222870	chr15:49365124~49366685:-
BRCA	cis	rs2742234	0.503	rs1254968	ENSG00000273008.1	RP11-351D16.3	7.72	2.73e-14	7.77e-12	0.3	0.23	Hirschsprung disease;	chr10:43196243	chr10:43136824~43138334:-
BRCA	cis	rs875971	0.862	rs6964437	ENSG00000232559.3	GS1-124K5.12	-7.72	2.74e-14	7.79e-12	-0.28	-0.23	Aortic root size;	chr7:66221457	chr7:66554588~66576923:-
BRCA	cis	rs2028299	0.92	rs4932261	ENSG00000259677.1	RP11-493E3.1	7.72	2.74e-14	7.8e-12	0.31	0.23	Type 2 diabetes;	chr15:89887164	chr15:89876540~89877285:+
BRCA	cis	rs4845875	0.557	rs4846054	ENSG00000242349.4	NPPA-AS1	7.72	2.74e-14	7.8e-12	0.25	0.23	Midregional pro atrial natriuretic peptide levels;	chr1:11809173	chr1:11841017~11848079:+
BRCA	cis	rs11098499	0.73	rs78971550	ENSG00000248280.1	RP11-33B1.2	7.72	2.74e-14	7.8e-12	0.24	0.23	Corneal astigmatism;	chr4:119359886	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.645	rs78422072	ENSG00000248280.1	RP11-33B1.2	7.72	2.74e-14	7.8e-12	0.24	0.23	Corneal astigmatism;	chr4:119359887	chr4:119440561~119450157:-
BRCA	cis	rs293748	0.771	rs35899185	ENSG00000250155.1	CTD-2353F22.1	-7.72	2.75e-14	7.81e-12	-0.33	-0.23	Obesity-related traits;	chr5:36795884	chr5:36666214~36725195:-
BRCA	cis	rs2033711	0.84	rs10423138	ENSG00000269473.1	CTD-2619J13.19	7.72	2.75e-14	7.81e-12	0.28	0.23	Uric acid clearance;	chr19:58416935	chr19:58440448~58445849:+
BRCA	cis	rs11039389	1	rs11039389	ENSG00000280615.1	Y_RNA	-7.72	2.75e-14	7.81e-12	-0.29	-0.23	Neuroticism;	chr11:47774510	chr11:47614898~47614994:-
BRCA	cis	rs250518	0.692	rs10074296	ENSG00000272081.1	CTD-2376I4.2	7.72	2.75e-14	7.83e-12	0.3	0.23	Mean corpuscular hemoglobin concentration;	chr5:72791089	chr5:72955206~72955699:-
BRCA	cis	rs957448	0.554	rs10956919	ENSG00000253704.1	RP11-267M23.4	7.72	2.76e-14	7.83e-12	0.25	0.23	Nonsyndromic cleft lip with cleft palate;	chr8:94572945	chr8:94553722~94569745:+
BRCA	cis	rs4845875	0.53	rs6667720	ENSG00000242349.4	NPPA-AS1	-7.72	2.76e-14	7.84e-12	-0.27	-0.23	Midregional pro atrial natriuretic peptide levels;	chr1:11771558	chr1:11841017~11848079:+
BRCA	cis	rs56046484	0.871	rs12900736	ENSG00000259295.5	CSPG4P12	7.72	2.76e-14	7.84e-12	0.42	0.23	Testicular germ cell tumor;	chr15:85014909	chr15:85191438~85213905:+
BRCA	cis	rs56046484	0.871	rs12904958	ENSG00000259295.5	CSPG4P12	7.72	2.76e-14	7.84e-12	0.42	0.23	Testicular germ cell tumor;	chr15:85014956	chr15:85191438~85213905:+
BRCA	cis	rs56046484	0.871	rs34493704	ENSG00000259295.5	CSPG4P12	7.72	2.76e-14	7.84e-12	0.42	0.23	Testicular germ cell tumor;	chr15:85015539	chr15:85191438~85213905:+
BRCA	cis	rs293748	0.657	rs16903342	ENSG00000250155.1	CTD-2353F22.1	-7.72	2.77e-14	7.86e-12	-0.33	-0.23	Obesity-related traits;	chr5:36792480	chr5:36666214~36725195:-
BRCA	cis	rs293748	0.657	rs72732585	ENSG00000250155.1	CTD-2353F22.1	-7.72	2.77e-14	7.86e-12	-0.33	-0.23	Obesity-related traits;	chr5:36792493	chr5:36666214~36725195:-
BRCA	cis	rs11098499	0.691	rs10028773	ENSG00000248280.1	RP11-33B1.2	-7.72	2.77e-14	7.87e-12	-0.22	-0.23	Corneal astigmatism;	chr4:119344104	chr4:119440561~119450157:-
BRCA	cis	rs848490	0.674	rs7803449	ENSG00000214293.7	APTR	7.72	2.77e-14	7.88e-12	0.27	0.23	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77679660	chr7:77657660~77696265:-
BRCA	cis	rs4835473	0.868	rs35809032	ENSG00000251600.4	RP11-673E1.1	-7.72	2.78e-14	7.89e-12	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143824797	chr4:143912331~143982454:+
BRCA	cis	rs875971	1	rs10244498	ENSG00000232559.3	GS1-124K5.12	7.72	2.78e-14	7.89e-12	0.28	0.23	Aortic root size;	chr7:66651069	chr7:66554588~66576923:-
BRCA	cis	rs293748	0.771	rs13184774	ENSG00000250155.1	CTD-2353F22.1	-7.72	2.78e-14	7.9e-12	-0.33	-0.23	Obesity-related traits;	chr5:36803578	chr5:36666214~36725195:-
BRCA	cis	rs293748	0.713	rs292162	ENSG00000250155.1	CTD-2353F22.1	-7.72	2.78e-14	7.9e-12	-0.33	-0.23	Obesity-related traits;	chr5:36803778	chr5:36666214~36725195:-
BRCA	cis	rs293748	0.771	rs292166	ENSG00000250155.1	CTD-2353F22.1	-7.72	2.78e-14	7.9e-12	-0.33	-0.23	Obesity-related traits;	chr5:36805367	chr5:36666214~36725195:-
BRCA	cis	rs2179367	0.632	rs9498329	ENSG00000231760.4	RP11-350J20.5	7.72	2.78e-14	7.91e-12	0.34	0.23	Dupuytren's disease;	chr6:149349941	chr6:149796151~149826294:-
BRCA	cis	rs2404602	0.716	rs284895	ENSG00000259422.1	RP11-593F23.1	-7.72	2.79e-14	7.93e-12	-0.29	-0.23	Blood metabolite levels;	chr15:76458884	chr15:76174891~76181486:-
BRCA	cis	rs7927771	1	rs2290850	ENSG00000280615.1	Y_RNA	-7.72	2.8e-14	7.94e-12	-0.29	-0.23	Subjective well-being;	chr11:47786222	chr11:47614898~47614994:-
BRCA	cis	rs858239	0.6	rs28483572	ENSG00000230042.1	AK3P3	-7.72	2.81e-14	7.99e-12	-0.27	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23092166	chr7:23129178~23129841:+
BRCA	cis	rs4835473	0.618	rs7666297	ENSG00000251600.4	RP11-673E1.1	-7.72	2.81e-14	7.99e-12	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143999005	chr4:143912331~143982454:+
BRCA	cis	rs2274273	0.624	rs11158034	ENSG00000258413.1	RP11-665C16.6	-7.72	2.81e-14	7.99e-12	-0.31	-0.23	Protein biomarker;	chr14:55286842	chr14:55262767~55272075:-
BRCA	cis	rs2033711	0.87	rs4801270	ENSG00000269473.1	CTD-2619J13.19	7.72	2.81e-14	7.99e-12	0.28	0.23	Uric acid clearance;	chr19:58421395	chr19:58440448~58445849:+
BRCA	cis	rs2115630	0.967	rs28595395	ENSG00000225151.9	GOLGA2P7	7.72	2.82e-14	8e-12	0.25	0.23	P wave terminal force;	chr15:84791721	chr15:84199311~84230136:-
BRCA	cis	rs2243480	1	rs313831	ENSG00000273142.1	RP11-458F8.4	-7.72	2.82e-14	8e-12	-0.34	-0.23	Diabetic kidney disease;	chr7:66086239	chr7:66902857~66906297:+
BRCA	cis	rs1707322	0.896	rs946528	ENSG00000280836.1	AL355480.1	7.72	2.82e-14	8.01e-12	0.29	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46019890	chr1:45581219~45581321:-
BRCA	cis	rs896854	0.738	rs481887	ENSG00000253528.2	RP11-347C18.4	-7.71	2.82e-14	8.02e-12	-0.26	-0.23	Type 2 diabetes;	chr8:94955610	chr8:94974573~94974853:-
BRCA	cis	rs74233809	1	rs943037	ENSG00000213277.3	MARCKSL1P1	7.71	2.83e-14	8.03e-12	0.44	0.23	Birth weight;	chr10:103076162	chr10:103175554~103176094:+
BRCA	cis	rs7927771	1	rs7120333	ENSG00000280615.1	Y_RNA	-7.71	2.84e-14	8.05e-12	-0.29	-0.23	Subjective well-being;	chr11:47795889	chr11:47614898~47614994:-
BRCA	cis	rs287982	0.932	rs11887231	ENSG00000269973.1	RP11-95D17.1	-7.71	2.84e-14	8.05e-12	-0.28	-0.23	Nonsyndromic cleft lip with cleft palate;	chr2:9826987	chr2:9936360~9939590:+
BRCA	cis	rs950776	0.616	rs56276142	ENSG00000261762.1	RP11-650L12.2	7.71	2.84e-14	8.06e-12	0.25	0.23	Sudden cardiac arrest;	chr15:78597453	chr15:78589123~78591276:-
BRCA	cis	rs875971	0.545	rs17138156	ENSG00000224316.1	RP11-479O9.2	7.71	2.84e-14	8.06e-12	0.26	0.23	Aortic root size;	chr7:66249708	chr7:65773620~65802067:+
BRCA	cis	rs56046484	0.871	rs71397837	ENSG00000259295.5	CSPG4P12	7.71	2.84e-14	8.07e-12	0.42	0.23	Testicular germ cell tumor;	chr15:85020330	chr15:85191438~85213905:+
BRCA	cis	rs56046484	0.871	rs62021203	ENSG00000259295.5	CSPG4P12	7.71	2.84e-14	8.07e-12	0.42	0.23	Testicular germ cell tumor;	chr15:85020846	chr15:85191438~85213905:+
BRCA	cis	rs2179367	0.632	rs9498334	ENSG00000231760.4	RP11-350J20.5	7.71	2.85e-14	8.08e-12	0.34	0.23	Dupuytren's disease;	chr6:149370902	chr6:149796151~149826294:-
BRCA	cis	rs2274273	0.6	rs35112084	ENSG00000258413.1	RP11-665C16.6	-7.71	2.85e-14	8.09e-12	-0.31	-0.23	Protein biomarker;	chr14:55314382	chr14:55262767~55272075:-
BRCA	cis	rs2179367	0.632	rs9498335	ENSG00000231760.4	RP11-350J20.5	7.71	2.86e-14	8.12e-12	0.34	0.23	Dupuytren's disease;	chr6:149372648	chr6:149796151~149826294:-
BRCA	cis	rs957448	0.554	rs12540967	ENSG00000253704.1	RP11-267M23.4	7.71	2.87e-14	8.15e-12	0.25	0.23	Nonsyndromic cleft lip with cleft palate;	chr8:94576862	chr8:94553722~94569745:+
BRCA	cis	rs957448	0.554	rs4735297	ENSG00000253704.1	RP11-267M23.4	7.71	2.87e-14	8.15e-12	0.25	0.23	Nonsyndromic cleft lip with cleft palate;	chr8:94577112	chr8:94553722~94569745:+
BRCA	cis	rs2946504	0.906	rs2946511	ENSG00000251468.2	RP11-369K16.1	7.71	2.87e-14	8.15e-12	0.28	0.23	Type 2 diabetes;	chr8:12949796	chr8:12958387~12962200:+
BRCA	cis	rs7945705	0.52	rs1984791	ENSG00000254860.4	TMEM9B-AS1	-7.71	2.87e-14	8.16e-12	-0.23	-0.23	Hemoglobin concentration;	chr11:9013480	chr11:8964675~8977527:+
BRCA	cis	rs950776	0.616	rs6495307	ENSG00000261762.1	RP11-650L12.2	7.71	2.88e-14	8.18e-12	0.25	0.23	Sudden cardiac arrest;	chr15:78597979	chr15:78589123~78591276:-
BRCA	cis	rs875971	0.862	rs4149461	ENSG00000232559.3	GS1-124K5.12	-7.71	2.88e-14	8.18e-12	-0.28	-0.23	Aortic root size;	chr7:66279745	chr7:66554588~66576923:-
BRCA	cis	rs2303759	0.918	rs7251704	ENSG00000268686.1	AC010524.2	-7.71	2.88e-14	8.18e-12	-0.36	-0.23	Multiple sclerosis;	chr19:49387616	chr19:49368705~49388081:-
BRCA	cis	rs9527	0.637	rs7096169	ENSG00000236937.2	PTGES3P4	7.71	2.89e-14	8.19e-12	0.3	0.23	Arsenic metabolism;	chr10:102858938	chr10:102845595~102845950:+
BRCA	cis	rs17772222	0.917	rs58550317	ENSG00000258983.2	RP11-507K2.2	7.71	2.89e-14	8.19e-12	0.27	0.23	Coronary artery calcification;	chr14:88775243	chr14:88499334~88515502:+
BRCA	cis	rs2742234	0.59	rs2435338	ENSG00000273008.1	RP11-351D16.3	-7.71	2.89e-14	8.2e-12	-0.29	-0.23	Hirschsprung disease;	chr10:43146667	chr10:43136824~43138334:-
BRCA	cis	rs2742234	0.59	rs2435339	ENSG00000273008.1	RP11-351D16.3	-7.71	2.89e-14	8.2e-12	-0.29	-0.23	Hirschsprung disease;	chr10:43146725	chr10:43136824~43138334:-
BRCA	cis	rs7615952	0.599	rs1875683	ENSG00000250012.1	RP11-124N2.1	-7.71	2.89e-14	8.2e-12	-0.32	-0.23	Blood pressure (smoking interaction);	chr3:126013638	chr3:126084220~126095349:+
BRCA	cis	rs2274273	0.624	rs11848456	ENSG00000258413.1	RP11-665C16.6	-7.71	2.9e-14	8.21e-12	-0.31	-0.23	Protein biomarker;	chr14:55288674	chr14:55262767~55272075:-
BRCA	cis	rs7809950	0.954	rs2520247	ENSG00000238832.1	snoU109	-7.71	2.9e-14	8.22e-12	-0.3	-0.23	Coronary artery disease;	chr7:107503501	chr7:107603363~107603507:+
BRCA	cis	rs801193	1	rs7785213	ENSG00000237310.1	GS1-124K5.4	-7.71	2.9e-14	8.22e-12	-0.24	-0.23	Aortic root size;	chr7:66673991	chr7:66493706~66495474:+
BRCA	cis	rs58873874	0.737	rs10061544	ENSG00000248544.2	CTB-47B11.3	7.71	2.9e-14	8.22e-12	0.51	0.23	Bipolar disorder (body mass index interaction);	chr5:157383871	chr5:157375741~157384950:-
BRCA	cis	rs58873874	0.737	rs10078836	ENSG00000248544.2	CTB-47B11.3	7.71	2.9e-14	8.22e-12	0.51	0.23	Bipolar disorder (body mass index interaction);	chr5:157384604	chr5:157375741~157384950:-
BRCA	cis	rs6597981	0.604	rs7945912	ENSG00000255142.1	AP006621.6	7.71	2.91e-14	8.24e-12	0.2	0.23	Breast cancer;	chr11:750849	chr11:781645~782105:+
BRCA	cis	rs12468226	0.752	rs116078354	ENSG00000273456.1	RP11-686O6.2	7.71	2.91e-14	8.24e-12	0.36	0.23	Urate levels;	chr2:202136356	chr2:202374932~202375604:-
BRCA	cis	rs6472827	0.953	rs4449781	ENSG00000253983.2	RP1-16A9.1	-7.71	2.91e-14	8.24e-12	-0.35	-0.23	Uterine fibroids;	chr8:74209309	chr8:74199396~74208441:+
BRCA	cis	rs6142102	0.778	rs4911374	ENSG00000276073.1	RP5-1125A11.7	-7.71	2.91e-14	8.25e-12	-0.29	-0.23	Skin pigmentation;	chr20:33928195	chr20:33985617~33988989:-
BRCA	cis	rs4835473	0.932	rs11736609	ENSG00000251600.4	RP11-673E1.1	-7.71	2.91e-14	8.25e-12	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143832876	chr4:143912331~143982454:+
BRCA	cis	rs42648	0.837	rs10262472	ENSG00000225498.1	AC002064.5	7.71	2.91e-14	8.25e-12	0.22	0.23	Homocysteine levels;	chr7:90271069	chr7:90312496~90322592:+
BRCA	cis	rs2742234	0.518	rs2505514	ENSG00000273008.1	RP11-351D16.3	-7.71	2.91e-14	8.26e-12	-0.3	-0.23	Hirschsprung disease;	chr10:43137800	chr10:43136824~43138334:-
BRCA	cis	rs2280018	0.963	rs12928424	ENSG00000260735.1	RP11-72I8.1	-7.71	2.92e-14	8.27e-12	-0.26	-0.23	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15056916	chr16:15094411~15109197:+
BRCA	cis	rs66887589	0.837	rs7661498	ENSG00000248280.1	RP11-33B1.2	7.71	2.93e-14	8.31e-12	0.22	0.23	Diastolic blood pressure;	chr4:119486953	chr4:119440561~119450157:-
BRCA	cis	rs516805	0.961	rs471620	ENSG00000279114.1	RP3-425C14.5	-7.71	2.94e-14	8.33e-12	-0.24	-0.23	Lymphocyte counts;	chr6:122473532	chr6:122471923~122484161:+
BRCA	cis	rs8062405	0.755	rs56272201	ENSG00000251417.2	RP11-1348G14.4	-7.71	2.94e-14	8.34e-12	-0.29	-0.23	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28569364	chr16:28802743~28817828:+
BRCA	cis	rs8062405	0.755	rs62034355	ENSG00000251417.2	RP11-1348G14.4	-7.71	2.94e-14	8.34e-12	-0.29	-0.23	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28569717	chr16:28802743~28817828:+
BRCA	cis	rs3758911	1	rs10749901	ENSG00000255353.1	RP11-382M14.1	-7.71	2.96e-14	8.4e-12	-0.3	-0.23	Coronary artery disease;	chr11:107324776	chr11:107176286~107177530:+
BRCA	cis	rs6539288	0.899	rs4964192	ENSG00000260329.1	RP11-412D9.4	-7.71	2.97e-14	8.41e-12	-0.26	-0.23	Total body bone mineral density;	chr12:106915014	chr12:106954029~106955497:-
BRCA	cis	rs10129255	0.5	rs2105989	ENSG00000280411.1	IGHV1-69-2	-7.71	2.97e-14	8.41e-12	-0.16	-0.23	Kawasaki disease;	chr14:106682199	chr14:106762092~106762588:-
BRCA	cis	rs875971	0.862	rs778734	ENSG00000232559.3	GS1-124K5.12	7.71	2.97e-14	8.41e-12	0.28	0.23	Aortic root size;	chr7:66349862	chr7:66554588~66576923:-
BRCA	cis	rs2742234	0.554	rs1254963	ENSG00000273008.1	RP11-351D16.3	7.71	2.97e-14	8.42e-12	0.3	0.23	Hirschsprung disease;	chr10:43200638	chr10:43136824~43138334:-
BRCA	cis	rs6539288	0.933	rs4964497	ENSG00000260329.1	RP11-412D9.4	-7.71	2.97e-14	8.42e-12	-0.27	-0.23	Total body bone mineral density;	chr12:106910711	chr12:106954029~106955497:-
BRCA	cis	rs875971	0.862	rs6952182	ENSG00000232559.3	GS1-124K5.12	-7.71	2.99e-14	8.46e-12	-0.28	-0.23	Aortic root size;	chr7:66218330	chr7:66554588~66576923:-
BRCA	cis	rs2243480	1	rs1638734	ENSG00000273142.1	RP11-458F8.4	-7.71	2.99e-14	8.46e-12	-0.32	-0.23	Diabetic kidney disease;	chr7:66632552	chr7:66902857~66906297:+
BRCA	cis	rs801193	0.569	rs6978178	ENSG00000232559.3	GS1-124K5.12	-7.71	3e-14	8.49e-12	-0.28	-0.23	Aortic root size;	chr7:66658097	chr7:66554588~66576923:-
BRCA	cis	rs56804039	1	rs67180327	ENSG00000253893.2	FAM85B	7.71	3.01e-14	8.51e-12	0.35	0.23	Cervical cancer;	chr8:8523244	chr8:8167819~8226614:-
BRCA	cis	rs287982	1	rs287977	ENSG00000269973.1	RP11-95D17.1	7.71	3.01e-14	8.52e-12	0.28	0.23	Nonsyndromic cleft lip with cleft palate;	chr2:9829889	chr2:9936360~9939590:+
BRCA	cis	rs801193	0.569	rs6951302	ENSG00000232559.3	GS1-124K5.12	-7.71	3.01e-14	8.52e-12	-0.28	-0.23	Aortic root size;	chr7:66667525	chr7:66554588~66576923:-
BRCA	cis	rs10050311	0.79	rs76583174	ENSG00000251411.1	RP11-397E7.4	-7.71	3.03e-14	8.57e-12	-0.35	-0.23	Insulin-related traits;	chr4:86917234	chr4:86913266~86914817:-
BRCA	cis	rs2243480	1	rs466983	ENSG00000273142.1	RP11-458F8.4	-7.71	3.03e-14	8.58e-12	-0.33	-0.23	Diabetic kidney disease;	chr7:66055509	chr7:66902857~66906297:+
BRCA	cis	rs2274273	0.624	rs1972221	ENSG00000258413.1	RP11-665C16.6	-7.7	3.04e-14	8.6e-12	-0.31	-0.23	Protein biomarker;	chr14:55318663	chr14:55262767~55272075:-
BRCA	cis	rs875971	0.862	rs1968126	ENSG00000232559.3	GS1-124K5.12	-7.7	3.04e-14	8.6e-12	-0.28	-0.23	Aortic root size;	chr7:66592017	chr7:66554588~66576923:-
BRCA	cis	rs853679	0.538	rs13199081	ENSG00000204709.4	LINC01556	7.7	3.04e-14	8.61e-12	0.34	0.23	Depression;	chr6:28364057	chr6:28943877~28944537:+
BRCA	cis	rs11671005	0.611	rs56026876	ENSG00000252334.1	RNU6-1337P	7.7	3.04e-14	8.62e-12	0.37	0.23	Mean platelet volume;	chr19:58494790	chr19:58483749~58483843:-
BRCA	cis	rs801193	0.591	rs4506088	ENSG00000232559.3	GS1-124K5.12	-7.7	3.05e-14	8.62e-12	-0.28	-0.23	Aortic root size;	chr7:66670470	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.862	rs6460282	ENSG00000232559.3	GS1-124K5.12	-7.7	3.05e-14	8.62e-12	-0.28	-0.23	Aortic root size;	chr7:66226259	chr7:66554588~66576923:-
BRCA	cis	rs4835473	0.897	rs4835454	ENSG00000251600.4	RP11-673E1.1	7.7	3.06e-14	8.65e-12	0.28	0.23	Immature fraction of reticulocytes;	chr4:143730081	chr4:143912331~143982454:+
BRCA	cis	rs11971779	0.878	rs4732378	ENSG00000273391.1	RP11-634H22.1	7.7	3.06e-14	8.67e-12	0.26	0.23	Diisocyanate-induced asthma;	chr7:139435649	chr7:139359032~139359566:-
BRCA	cis	rs8062405	0.723	rs4788077	ENSG00000251417.2	RP11-1348G14.4	-7.7	3.07e-14	8.69e-12	-0.29	-0.23	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28558443	chr16:28802743~28817828:+
BRCA	cis	rs919433	0.817	rs10931780	ENSG00000231621.1	AC013264.2	7.7	3.07e-14	8.7e-12	0.21	0.23	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197310573	chr2:197197991~197199273:+
BRCA	cis	rs42648	0.935	rs2188232	ENSG00000225498.1	AC002064.5	7.7	3.08e-14	8.72e-12	0.22	0.23	Homocysteine levels;	chr7:90329000	chr7:90312496~90322592:+
BRCA	cis	rs42648	0.935	rs2188233	ENSG00000225498.1	AC002064.5	7.7	3.08e-14	8.72e-12	0.22	0.23	Homocysteine levels;	chr7:90329001	chr7:90312496~90322592:+
BRCA	cis	rs957448	0.554	rs12680855	ENSG00000253704.1	RP11-267M23.4	7.7	3.09e-14	8.74e-12	0.25	0.23	Nonsyndromic cleft lip with cleft palate;	chr8:94570427	chr8:94553722~94569745:+
BRCA	cis	rs293748	0.515	rs12658479	ENSG00000250155.1	CTD-2353F22.1	7.7	3.09e-14	8.74e-12	0.3	0.23	Obesity-related traits;	chr5:37206519	chr5:36666214~36725195:-
BRCA	cis	rs732716	0.785	rs56272533	ENSG00000267980.1	AC007292.6	-7.7	3.09e-14	8.75e-12	-0.31	-0.23	Mean corpuscular volume;	chr19:4420045	chr19:4363789~4364640:+
BRCA	cis	rs4964805	1	rs4964794	ENSG00000257681.1	RP11-341G23.4	7.7	3.09e-14	8.75e-12	0.29	0.23	Attention deficit hyperactivity disorder;	chr12:103800640	chr12:103746315~103768858:-
BRCA	cis	rs801193	1	rs10252765	ENSG00000237310.1	GS1-124K5.4	7.7	3.1e-14	8.77e-12	0.24	0.23	Aortic root size;	chr7:66763745	chr7:66493706~66495474:+
BRCA	cis	rs897984	0.542	rs3751855	ENSG00000260911.2	RP11-196G11.2	7.7	3.1e-14	8.77e-12	0.21	0.23	Dementia with Lewy bodies;	chr16:31079888	chr16:31043150~31049868:+
BRCA	cis	rs9880211	1	rs9828088	ENSG00000273486.1	RP11-731C17.2	7.7	3.11e-14	8.79e-12	0.3	0.23	Height;Body mass index;	chr3:136528948	chr3:136837338~136839021:-
BRCA	cis	rs919433	1	rs6761919	ENSG00000231621.1	AC013264.2	7.7	3.11e-14	8.79e-12	0.21	0.23	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197298604	chr2:197197991~197199273:+
BRCA	cis	rs7927771	0.965	rs17788930	ENSG00000280615.1	Y_RNA	-7.7	3.11e-14	8.79e-12	-0.29	-0.23	Subjective well-being;	chr11:47731223	chr11:47614898~47614994:-
BRCA	cis	rs293748	0.771	rs34920909	ENSG00000250155.1	CTD-2353F22.1	-7.7	3.11e-14	8.79e-12	-0.32	-0.23	Obesity-related traits;	chr5:36792614	chr5:36666214~36725195:-
BRCA	cis	rs293748	0.771	rs59889951	ENSG00000250155.1	CTD-2353F22.1	-7.7	3.11e-14	8.79e-12	-0.32	-0.23	Obesity-related traits;	chr5:36793150	chr5:36666214~36725195:-
BRCA	cis	rs7927771	1	rs34128973	ENSG00000280615.1	Y_RNA	-7.7	3.11e-14	8.8e-12	-0.29	-0.23	Subjective well-being;	chr11:47829824	chr11:47614898~47614994:-
BRCA	cis	rs2179367	0.959	rs480034	ENSG00000231760.4	RP11-350J20.5	-7.7	3.11e-14	8.8e-12	-0.3	-0.23	Dupuytren's disease;	chr6:149414294	chr6:149796151~149826294:-
BRCA	cis	rs732716	0.785	rs62129354	ENSG00000267980.1	AC007292.6	-7.7	3.12e-14	8.81e-12	-0.31	-0.23	Mean corpuscular volume;	chr19:4396508	chr19:4363789~4364640:+
BRCA	cis	rs12999373	0.501	rs11127496	ENSG00000223751.1	AC116609.2	7.7	3.12e-14	8.81e-12	0.29	0.23	Response to fenofibrate (adiponectin levels);Uric acid levels;	chr2:694063	chr2:742488~747767:+
BRCA	cis	rs7927771	1	rs12418852	ENSG00000280615.1	Y_RNA	-7.7	3.12e-14	8.82e-12	-0.29	-0.23	Subjective well-being;	chr11:47847301	chr11:47614898~47614994:-
BRCA	cis	rs9438901	0.614	rs2375278	ENSG00000224183.1	SDHDP6	7.7	3.12e-14	8.82e-12	0.39	0.23	Red cell distribution width;	chr1:25202547	chr1:25294164~25294643:-
BRCA	cis	rs801193	0.591	rs721717	ENSG00000232559.3	GS1-124K5.12	-7.7	3.13e-14	8.84e-12	-0.28	-0.23	Aortic root size;	chr7:66665305	chr7:66554588~66576923:-
BRCA	cis	rs780096	0.545	rs2280737	ENSG00000234072.1	AC074117.10	-7.7	3.13e-14	8.86e-12	-0.22	-0.23	Total body bone mineral density;	chr2:27366943	chr2:27356246~27367622:+
BRCA	cis	rs34034915	1	rs34034915	ENSG00000216901.1	AL022393.7	7.7	3.14e-14	8.87e-12	0.29	0.23	Hepatitis A;	chr6:27752924	chr6:28176188~28176674:+
BRCA	cis	rs4713118	0.527	rs36042294	ENSG00000216901.1	AL022393.7	7.7	3.14e-14	8.87e-12	0.29	0.23	Parkinson's disease;	chr6:27752933	chr6:28176188~28176674:+
BRCA	cis	rs293748	0.771	rs151947	ENSG00000250155.1	CTD-2353F22.1	-7.7	3.14e-14	8.88e-12	-0.32	-0.23	Obesity-related traits;	chr5:36865491	chr5:36666214~36725195:-
BRCA	cis	rs957448	0.687	rs10104041	ENSG00000253704.1	RP11-267M23.4	7.7	3.14e-14	8.88e-12	0.25	0.23	Nonsyndromic cleft lip with cleft palate;	chr8:94559374	chr8:94553722~94569745:+
BRCA	cis	rs1861628	1	rs2712172	ENSG00000237930.1	AC007563.4	-7.7	3.15e-14	8.91e-12	-0.3	-0.23	Serum thyroid-stimulating hormone levels;Hypothyroidism;	chr2:216756010	chr2:216785774~216786144:-
BRCA	cis	rs4835473	0.897	rs2323194	ENSG00000251600.4	RP11-673E1.1	-7.7	3.16e-14	8.92e-12	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143752879	chr4:143912331~143982454:+
BRCA	cis	rs14027	1	rs14027	ENSG00000279347.1	RP11-85I17.2	-7.7	3.16e-14	8.93e-12	-0.24	-0.23	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119834349	chr8:119838736~119840385:-
BRCA	cis	rs3814244	0.528	rs12582272	ENSG00000236946.2	HNRNPA1P70	-7.7	3.16e-14	8.93e-12	-0.2	-0.23	Itch intensity from mosquito bite adjusted by bite size;	chr12:68006298	chr12:68035767~68036853:+
BRCA	cis	rs7246657	0.722	rs2972438	ENSG00000267422.1	CTD-2554C21.1	-7.7	3.16e-14	8.94e-12	-0.34	-0.23	Coronary artery calcification;	chr19:37719946	chr19:37779686~37792865:+
BRCA	cis	rs10463554	0.892	rs66759661	ENSG00000175749.11	EIF3KP1	7.7	3.17e-14	8.94e-12	0.32	0.23	Parkinson's disease;	chr5:102925894	chr5:103032376~103033031:+
BRCA	cis	rs8062405	0.824	rs7191618	ENSG00000251417.2	RP11-1348G14.4	-7.7	3.17e-14	8.96e-12	-0.26	-0.23	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554346	chr16:28802743~28817828:+
BRCA	cis	rs875971	0.862	rs7796162	ENSG00000232559.3	GS1-124K5.12	-7.7	3.18e-14	8.98e-12	-0.28	-0.23	Aortic root size;	chr7:66280771	chr7:66554588~66576923:-
BRCA	cis	rs293748	0.771	rs66868318	ENSG00000250155.1	CTD-2353F22.1	-7.7	3.18e-14	8.99e-12	-0.32	-0.23	Obesity-related traits;	chr5:36826119	chr5:36666214~36725195:-
BRCA	cis	rs10028773	0.515	rs9994488	ENSG00000248280.1	RP11-33B1.2	7.7	3.19e-14	9.01e-12	0.23	0.23	Educational attainment;	chr4:119666626	chr4:119440561~119450157:-
BRCA	cis	rs7267979	0.789	rs2260197	ENSG00000274973.1	RP13-401N8.7	-7.7	3.19e-14	9.02e-12	-0.27	-0.23	Liver enzyme levels (alkaline phosphatase);	chr20:25303707	chr20:25845497~25845862:+
BRCA	cis	rs919433	0.929	rs7592511	ENSG00000231621.1	AC013264.2	7.7	3.19e-14	9.02e-12	0.21	0.23	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197313250	chr2:197197991~197199273:+
BRCA	cis	rs11976180	0.517	rs6949375	ENSG00000244479.5	OR2A1-AS1	7.7	3.19e-14	9.02e-12	0.41	0.23	Obesity-related traits;	chr7:144076758	chr7:144251264~144356181:-
BRCA	cis	rs9880211	0.948	rs13326151	ENSG00000273486.1	RP11-731C17.2	7.7	3.2e-14	9.03e-12	0.31	0.23	Height;Body mass index;	chr3:136542902	chr3:136837338~136839021:-
BRCA	cis	rs10200159	1	rs9309267	ENSG00000272606.1	RP11-554J4.1	-7.7	3.21e-14	9.05e-12	-0.44	-0.23	Vitiligo;	chr2:55623198	chr2:55617909~55618373:+
BRCA	cis	rs6545883	0.895	rs2177961	ENSG00000271889.1	RP11-493E12.1	-7.7	3.21e-14	9.07e-12	-0.3	-0.23	Tuberculosis;	chr2:61333129	chr2:61151433~61162105:-
BRCA	cis	rs9880211	0.948	rs9820621	ENSG00000273486.1	RP11-731C17.2	7.7	3.21e-14	9.07e-12	0.32	0.23	Height;Body mass index;	chr3:136391671	chr3:136837338~136839021:-
BRCA	cis	rs10463554	0.857	rs3776873	ENSG00000175749.11	EIF3KP1	7.7	3.21e-14	9.07e-12	0.32	0.23	Parkinson's disease;	chr5:102946768	chr5:103032376~103033031:+
BRCA	cis	rs3758911	0.828	rs1490946	ENSG00000255353.1	RP11-382M14.1	-7.7	3.21e-14	9.08e-12	-0.31	-0.23	Coronary artery disease;	chr11:107325374	chr11:107176286~107177530:+
BRCA	cis	rs2274273	0.588	rs7155054	ENSG00000258413.1	RP11-665C16.6	-7.7	3.22e-14	9.1e-12	-0.3	-0.23	Protein biomarker;	chr14:55283944	chr14:55262767~55272075:-
BRCA	cis	rs3814244	0.528	rs11177002	ENSG00000236946.2	HNRNPA1P70	-7.7	3.23e-14	9.11e-12	-0.2	-0.23	Itch intensity from mosquito bite adjusted by bite size;	chr12:68003377	chr12:68035767~68036853:+
BRCA	cis	rs801193	0.569	rs2013908	ENSG00000232559.3	GS1-124K5.12	-7.7	3.23e-14	9.11e-12	-0.28	-0.23	Aortic root size;	chr7:66656082	chr7:66554588~66576923:-
BRCA	cis	rs12200782	0.53	rs6929908	ENSG00000241549.7	GUSBP2	7.7	3.23e-14	9.12e-12	0.31	0.23	Small cell lung carcinoma;	chr6:26555061	chr6:26871484~26956554:-
BRCA	cis	rs6921919	0.583	rs6928771	ENSG00000204709.4	LINC01556	7.7	3.23e-14	9.12e-12	0.31	0.23	Autism spectrum disorder or schizophrenia;	chr6:28407432	chr6:28943877~28944537:+
BRCA	cis	rs6921919	0.583	rs6928773	ENSG00000204709.4	LINC01556	7.7	3.23e-14	9.12e-12	0.31	0.23	Autism spectrum disorder or schizophrenia;	chr6:28407433	chr6:28943877~28944537:+
BRCA	cis	rs250518	0.926	rs10069567	ENSG00000272081.1	CTD-2376I4.2	7.7	3.23e-14	9.12e-12	0.29	0.23	Mean corpuscular hemoglobin concentration;	chr5:72771877	chr5:72955206~72955699:-
BRCA	cis	rs2880765	0.835	rs4842886	ENSG00000259295.5	CSPG4P12	7.7	3.23e-14	9.12e-12	0.28	0.23	Coronary artery disease;	chr15:85492542	chr15:85191438~85213905:+
BRCA	cis	rs12908161	0.96	rs17599989	ENSG00000259728.4	LINC00933	7.7	3.23e-14	9.12e-12	0.3	0.23	Schizophrenia;	chr15:84742305	chr15:84570649~84580175:+
BRCA	cis	rs950880	0.71	rs11683700	ENSG00000234389.1	AC007278.3	-7.7	3.23e-14	9.13e-12	-0.24	-0.23	Serum protein levels (sST2);	chr2:102380345	chr2:102438713~102440475:+
BRCA	cis	rs801193	0.935	rs3800820	ENSG00000237310.1	GS1-124K5.4	-7.7	3.24e-14	9.13e-12	-0.24	-0.23	Aortic root size;	chr7:66682191	chr7:66493706~66495474:+
BRCA	cis	rs904251	0.6	rs11756241	ENSG00000204110.6	RP1-153P14.8	-7.7	3.24e-14	9.14e-12	-0.26	-0.23	Cognitive performance;	chr6:37477325	chr6:37507348~37535616:+
BRCA	cis	rs7520050	0.667	rs11211176	ENSG00000280836.1	AL355480.1	7.7	3.24e-14	9.14e-12	0.27	0.23	Reticulocyte count;Red blood cell count;	chr1:45757414	chr1:45581219~45581321:-
BRCA	cis	rs2303759	0.874	rs10411630	ENSG00000268686.1	AC010524.2	-7.7	3.24e-14	9.15e-12	-0.36	-0.23	Multiple sclerosis;	chr19:49388057	chr19:49368705~49388081:-
BRCA	cis	rs875971	0.825	rs4587224	ENSG00000232559.3	GS1-124K5.12	-7.7	3.24e-14	9.15e-12	-0.28	-0.23	Aortic root size;	chr7:66271195	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.792	rs6971752	ENSG00000232559.3	GS1-124K5.12	-7.7	3.24e-14	9.15e-12	-0.28	-0.23	Aortic root size;	chr7:66272999	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.862	rs10950033	ENSG00000232559.3	GS1-124K5.12	-7.7	3.24e-14	9.15e-12	-0.28	-0.23	Aortic root size;	chr7:66274686	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.862	rs11760844	ENSG00000232559.3	GS1-124K5.12	-7.7	3.24e-14	9.15e-12	-0.28	-0.23	Aortic root size;	chr7:66274896	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.83	rs12673450	ENSG00000232559.3	GS1-124K5.12	7.7	3.24e-14	9.16e-12	0.29	0.23	Aortic root size;	chr7:66544233	chr7:66554588~66576923:-
BRCA	cis	rs4927850	1	rs10881564	ENSG00000242086.7	LINC00969	7.7	3.25e-14	9.16e-12	0.26	0.23	Pancreatic cancer;	chr3:196023455	chr3:195658062~195739964:+
BRCA	cis	rs875971	0.66	rs801193	ENSG00000224316.1	RP11-479O9.2	-7.7	3.25e-14	9.17e-12	-0.23	-0.23	Aortic root size;	chr7:66565625	chr7:65773620~65802067:+
BRCA	cis	rs13068223	0.819	rs8792	ENSG00000243926.1	TIPARP-AS1	-7.7	3.25e-14	9.17e-12	-0.23	-0.23	Age-related hearing impairment (SNP x SNP interaction);	chr3:156747639	chr3:156671862~156674378:-
BRCA	cis	rs875971	0.545	rs17138149	ENSG00000224316.1	RP11-479O9.2	7.7	3.26e-14	9.2e-12	0.26	0.23	Aortic root size;	chr7:66228193	chr7:65773620~65802067:+
BRCA	cis	rs113835537	0.529	rs3816492	ENSG00000255517.5	CTD-3074O7.5	-7.7	3.27e-14	9.22e-12	-0.32	-0.23	Airway imaging phenotypes;	chr11:66529892	chr11:66473490~66480233:-
BRCA	cis	rs77204473	1	rs12292614	ENSG00000254851.1	RP11-109L13.1	7.69	3.27e-14	9.24e-12	0.53	0.23	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116877799	chr11:117135528~117138582:+
BRCA	cis	rs2033711	0.783	rs8113810	ENSG00000269473.1	CTD-2619J13.19	7.69	3.28e-14	9.25e-12	0.28	0.23	Uric acid clearance;	chr19:58420739	chr19:58440448~58445849:+
BRCA	cis	rs4835473	0.932	rs1839449	ENSG00000251600.4	RP11-673E1.1	7.69	3.29e-14	9.28e-12	0.28	0.23	Immature fraction of reticulocytes;	chr4:143730222	chr4:143912331~143982454:+
BRCA	cis	rs6570726	0.791	rs448939	ENSG00000235652.6	RP11-545I5.3	7.69	3.29e-14	9.28e-12	0.22	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145487184	chr6:145799409~145886585:+
BRCA	cis	rs875971	0.862	rs10276077	ENSG00000232559.3	GS1-124K5.12	-7.69	3.3e-14	9.3e-12	-0.28	-0.23	Aortic root size;	chr7:66263424	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.638	rs6460305	ENSG00000224316.1	RP11-479O9.2	-7.69	3.3e-14	9.3e-12	-0.23	-0.23	Aortic root size;	chr7:66595421	chr7:65773620~65802067:+
BRCA	cis	rs7927771	0.832	rs4992357	ENSG00000280615.1	Y_RNA	-7.69	3.3e-14	9.31e-12	-0.28	-0.23	Subjective well-being;	chr11:47372087	chr11:47614898~47614994:-
BRCA	cis	rs2179367	0.543	rs9498328	ENSG00000231760.4	RP11-350J20.5	7.69	3.32e-14	9.35e-12	0.34	0.23	Dupuytren's disease;	chr6:149348715	chr6:149796151~149826294:-
BRCA	cis	rs10463554	0.892	rs2195272	ENSG00000175749.11	EIF3KP1	7.69	3.32e-14	9.37e-12	0.32	0.23	Parkinson's disease;	chr5:102959800	chr5:103032376~103033031:+
BRCA	cis	rs6860806	0.507	rs272872	ENSG00000233006.5	AC034220.3	-7.69	3.33e-14	9.39e-12	-0.18	-0.23	Breast cancer;	chr5:132340171	chr5:132311285~132369916:-
BRCA	cis	rs7615952	0.599	rs16834938	ENSG00000250012.1	RP11-124N2.1	-7.69	3.33e-14	9.39e-12	-0.3	-0.23	Blood pressure (smoking interaction);	chr3:125987203	chr3:126084220~126095349:+
BRCA	cis	rs2060793	0.552	rs939968	ENSG00000251991.1	RNU7-49P	7.69	3.33e-14	9.4e-12	0.24	0.23	Vitamin D levels;	chr11:14608134	chr11:14478892~14478953:+
BRCA	cis	rs11098499	0.955	rs1511018	ENSG00000248280.1	RP11-33B1.2	7.69	3.34e-14	9.42e-12	0.24	0.23	Corneal astigmatism;	chr4:119240425	chr4:119440561~119450157:-
BRCA	cis	rs896854	0.738	rs527234	ENSG00000253528.2	RP11-347C18.4	-7.69	3.35e-14	9.45e-12	-0.25	-0.23	Type 2 diabetes;	chr8:94951570	chr8:94974573~94974853:-
BRCA	cis	rs950880	0.71	rs2287035	ENSG00000234389.1	AC007278.3	-7.69	3.35e-14	9.46e-12	-0.24	-0.23	Serum protein levels (sST2);	chr2:102394070	chr2:102438713~102440475:+
BRCA	cis	rs4835473	0.932	rs13129993	ENSG00000251600.4	RP11-673E1.1	-7.69	3.36e-14	9.46e-12	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143763076	chr4:143912331~143982454:+
BRCA	cis	rs7811142	1	rs1073	ENSG00000242294.5	STAG3L5P	7.69	3.36e-14	9.46e-12	0.23	0.23	Platelet count;	chr7:100433989	chr7:100336079~100351900:+
BRCA	cis	rs2115630	1	rs56074163	ENSG00000225151.9	GOLGA2P7	7.69	3.37e-14	9.5e-12	0.25	0.23	P wave terminal force;	chr15:84808101	chr15:84199311~84230136:-
BRCA	cis	rs10129255	0.518	rs2006284	ENSG00000211970.3	IGHV4-61	-7.69	3.37e-14	9.51e-12	-0.15	-0.23	Kawasaki disease;	chr14:106676185	chr14:106639119~106639657:-
BRCA	cis	rs2274273	0.624	rs10141396	ENSG00000258413.1	RP11-665C16.6	-7.69	3.38e-14	9.52e-12	-0.31	-0.23	Protein biomarker;	chr14:55350207	chr14:55262767~55272075:-
BRCA	cis	rs2439831	0.85	rs28413704	ENSG00000205771.5	CATSPER2P1	-7.69	3.38e-14	9.54e-12	-0.4	-0.23	Lung cancer in ever smokers;	chr15:43856229	chr15:43726918~43747094:-
BRCA	cis	rs4927850	1	rs7625570	ENSG00000242086.7	LINC00969	7.69	3.39e-14	9.57e-12	0.26	0.23	Pancreatic cancer;	chr3:196020527	chr3:195658062~195739964:+
BRCA	cis	rs896854	0.738	rs2515226	ENSG00000253528.2	RP11-347C18.4	-7.69	3.4e-14	9.57e-12	-0.26	-0.23	Type 2 diabetes;	chr8:94953515	chr8:94974573~94974853:-
BRCA	cis	rs875971	0.522	rs1968127	ENSG00000224316.1	RP11-479O9.2	-7.69	3.4e-14	9.57e-12	-0.23	-0.23	Aortic root size;	chr7:66591816	chr7:65773620~65802067:+
BRCA	cis	rs3762637	1	rs28497203	ENSG00000272758.4	RP11-299J3.8	-7.69	3.4e-14	9.58e-12	-0.35	-0.23	LDL cholesterol levels;	chr3:122512972	chr3:122416207~122443180:+
BRCA	cis	rs712022	0.537	rs4420266	ENSG00000246225.5	RP11-17A1.3	-7.69	3.4e-14	9.58e-12	-0.28	-0.23	Dialysis-related mortality;	chr11:22852637	chr11:22829380~22945393:+
BRCA	cis	rs3758911	0.894	rs10789620	ENSG00000255353.1	RP11-382M14.1	-7.69	3.4e-14	9.59e-12	-0.31	-0.23	Coronary artery disease;	chr11:107334700	chr11:107176286~107177530:+
BRCA	cis	rs875971	0.862	rs6959268	ENSG00000232559.3	GS1-124K5.12	-7.69	3.41e-14	9.61e-12	-0.28	-0.23	Aortic root size;	chr7:66347979	chr7:66554588~66576923:-
BRCA	cis	rs2274273	0.624	rs7154796	ENSG00000258413.1	RP11-665C16.6	-7.69	3.42e-14	9.64e-12	-0.31	-0.23	Protein biomarker;	chr14:55304740	chr14:55262767~55272075:-
BRCA	cis	rs11098499	1	rs3749591	ENSG00000248280.1	RP11-33B1.2	7.69	3.43e-14	9.65e-12	0.25	0.23	Corneal astigmatism;	chr4:119292875	chr4:119440561~119450157:-
BRCA	cis	rs7811142	0.945	rs6955362	ENSG00000242294.5	STAG3L5P	7.69	3.43e-14	9.65e-12	0.23	0.23	Platelet count;	chr7:100458543	chr7:100336079~100351900:+
BRCA	cis	rs7811142	1	rs6975514	ENSG00000242294.5	STAG3L5P	7.69	3.43e-14	9.65e-12	0.23	0.23	Platelet count;	chr7:100458597	chr7:100336079~100351900:+
BRCA	cis	rs4835473	0.808	rs6836630	ENSG00000251600.4	RP11-673E1.1	-7.69	3.43e-14	9.66e-12	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143801068	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs13101541	ENSG00000251600.4	RP11-673E1.1	-7.69	3.43e-14	9.66e-12	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143806590	chr4:143912331~143982454:+
BRCA	cis	rs10463554	0.963	rs257294	ENSG00000175749.11	EIF3KP1	7.69	3.43e-14	9.66e-12	0.32	0.23	Parkinson's disease;	chr5:103131563	chr5:103032376~103033031:+
BRCA	cis	rs526231	0.578	rs1898672	ENSG00000175749.11	EIF3KP1	-7.69	3.43e-14	9.66e-12	-0.32	-0.23	Primary biliary cholangitis;	chr5:102958149	chr5:103032376~103033031:+
BRCA	cis	rs6822297	0.504	rs12152700	ENSG00000240005.4	RP11-293A21.1	7.69	3.43e-14	9.66e-12	0.28	0.23	Obesity-related traits;	chr4:27005029	chr4:26859806~26860599:-
BRCA	cis	rs10050311	0.79	rs72667716	ENSG00000251411.1	RP11-397E7.4	-7.69	3.43e-14	9.67e-12	-0.34	-0.23	Insulin-related traits;	chr4:86912775	chr4:86913266~86914817:-
BRCA	cis	rs7811142	1	rs67471932	ENSG00000242294.5	STAG3L5P	7.69	3.44e-14	9.68e-12	0.23	0.23	Platelet count;	chr7:100412362	chr7:100336079~100351900:+
BRCA	cis	rs250518	0.926	rs7720803	ENSG00000272081.1	CTD-2376I4.2	7.69	3.45e-14	9.72e-12	0.3	0.23	Mean corpuscular hemoglobin concentration;	chr5:72762870	chr5:72955206~72955699:-
BRCA	cis	rs4835473	0.864	rs1597446	ENSG00000251600.4	RP11-673E1.1	7.69	3.46e-14	9.73e-12	0.28	0.23	Immature fraction of reticulocytes;	chr4:143708338	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.835	rs1450247	ENSG00000251600.4	RP11-673E1.1	7.69	3.46e-14	9.73e-12	0.28	0.23	Immature fraction of reticulocytes;	chr4:143708529	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.897	rs7681914	ENSG00000251600.4	RP11-673E1.1	7.69	3.46e-14	9.73e-12	0.28	0.23	Immature fraction of reticulocytes;	chr4:143708838	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.864	rs7682096	ENSG00000251600.4	RP11-673E1.1	7.69	3.46e-14	9.73e-12	0.28	0.23	Immature fraction of reticulocytes;	chr4:143708892	chr4:143912331~143982454:+
BRCA	cis	rs2179367	0.632	rs9498325	ENSG00000231760.4	RP11-350J20.5	7.69	3.46e-14	9.74e-12	0.33	0.23	Dupuytren's disease;	chr6:149345993	chr6:149796151~149826294:-
BRCA	cis	rs2179367	0.632	rs9498326	ENSG00000231760.4	RP11-350J20.5	7.69	3.46e-14	9.74e-12	0.33	0.23	Dupuytren's disease;	chr6:149346112	chr6:149796151~149826294:-
BRCA	cis	rs4934494	0.768	rs34663515	ENSG00000240996.1	RP11-80H5.7	-7.69	3.46e-14	9.75e-12	-0.29	-0.23	Red blood cell count;	chr10:89632786	chr10:89694295~89697928:-
BRCA	cis	rs10129255	0.913	rs28861466	ENSG00000223648.3	IGHV3-64	7.69	3.47e-14	9.75e-12	0.21	0.23	Kawasaki disease;	chr14:106718572	chr14:106643132~106658258:-
BRCA	cis	rs875971	0.767	rs12668005	ENSG00000232559.3	GS1-124K5.12	7.69	3.47e-14	9.77e-12	0.28	0.23	Aortic root size;	chr7:66444034	chr7:66554588~66576923:-
BRCA	cis	rs11098499	0.71	rs4145952	ENSG00000245958.5	RP11-33B1.1	-7.69	3.47e-14	9.77e-12	-0.22	-0.23	Corneal astigmatism;	chr4:119234651	chr4:119454791~119552025:+
BRCA	cis	rs2880765	0.805	rs11858817	ENSG00000259295.5	CSPG4P12	7.69	3.49e-14	9.83e-12	0.28	0.23	Coronary artery disease;	chr15:85488029	chr15:85191438~85213905:+
BRCA	cis	rs2880765	0.835	rs28874135	ENSG00000259295.5	CSPG4P12	7.69	3.49e-14	9.83e-12	0.28	0.23	Coronary artery disease;	chr15:85488272	chr15:85191438~85213905:+
BRCA	cis	rs2880765	0.835	rs11633604	ENSG00000259295.5	CSPG4P12	7.69	3.49e-14	9.83e-12	0.28	0.23	Coronary artery disease;	chr15:85488348	chr15:85191438~85213905:+
BRCA	cis	rs801193	0.569	rs881285	ENSG00000232559.3	GS1-124K5.12	-7.69	3.5e-14	9.84e-12	-0.28	-0.23	Aortic root size;	chr7:66654433	chr7:66554588~66576923:-
BRCA	cis	rs9880211	1	rs17364492	ENSG00000239213.4	NCK1-AS1	-7.69	3.51e-14	9.87e-12	-0.29	-0.23	Height;Body mass index;	chr3:136485595	chr3:136841726~136862054:-
BRCA	cis	rs7927771	0.832	rs7940536	ENSG00000280615.1	Y_RNA	7.69	3.51e-14	9.88e-12	0.28	0.23	Subjective well-being;	chr11:47373689	chr11:47614898~47614994:-
BRCA	cis	rs875971	0.83	rs4718358	ENSG00000232559.3	GS1-124K5.12	7.68	3.54e-14	9.96e-12	0.28	0.23	Aortic root size;	chr7:66508681	chr7:66554588~66576923:-
BRCA	cis	rs7809950	1	rs2520264	ENSG00000238832.1	snoU109	-7.68	3.54e-14	9.97e-12	-0.3	-0.23	Coronary artery disease;	chr7:107538899	chr7:107603363~107603507:+
BRCA	cis	rs293748	0.571	rs16903531	ENSG00000250155.1	CTD-2353F22.1	-7.68	3.55e-14	9.98e-12	-0.31	-0.23	Obesity-related traits;	chr5:37197058	chr5:36666214~36725195:-
BRCA	cis	rs6840258	0.547	rs72667721	ENSG00000251411.1	RP11-397E7.4	-7.68	3.55e-14	9.98e-12	-0.35	-0.23	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86919644	chr4:86913266~86914817:-
BRCA	cis	rs375066	0.935	rs396973	ENSG00000267058.1	RP11-15A1.3	7.68	3.56e-14	1e-11	0.26	0.23	Breast cancer;	chr19:43895154	chr19:43891804~43901805:-
BRCA	cis	rs10129255	1	rs10134517	ENSG00000223648.3	IGHV3-64	7.68	3.56e-14	1e-11	0.2	0.23	Kawasaki disease;	chr14:106718498	chr14:106643132~106658258:-
BRCA	cis	rs9876781	0.933	rs6442124	ENSG00000244380.1	RP11-24C3.2	7.68	3.57e-14	1e-11	0.27	0.23	Longevity;	chr3:48463903	chr3:48440352~48446656:-
BRCA	cis	rs293748	0.571	rs13184464	ENSG00000250155.1	CTD-2353F22.1	-7.68	3.57e-14	1e-11	-0.31	-0.23	Obesity-related traits;	chr5:37191983	chr5:36666214~36725195:-
BRCA	cis	rs875971	0.862	rs1875057	ENSG00000232559.3	GS1-124K5.12	-7.68	3.57e-14	1e-11	-0.28	-0.23	Aortic root size;	chr7:66266868	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.862	rs6960446	ENSG00000232559.3	GS1-124K5.12	-7.68	3.57e-14	1e-11	-0.28	-0.23	Aortic root size;	chr7:66268272	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.789	rs10260426	ENSG00000232559.3	GS1-124K5.12	-7.68	3.57e-14	1e-11	-0.28	-0.23	Aortic root size;	chr7:66271055	chr7:66554588~66576923:-
BRCA	cis	rs6539288	0.899	rs2053206	ENSG00000260329.1	RP11-412D9.4	-7.68	3.57e-14	1e-11	-0.27	-0.23	Total body bone mineral density;	chr12:106912401	chr12:106954029~106955497:-
BRCA	cis	rs12701220	0.655	rs9638973	ENSG00000229043.2	AC091729.9	-7.68	3.58e-14	1.01e-11	-0.34	-0.23	Bronchopulmonary dysplasia;	chr7:1094042	chr7:1160374~1165267:+
BRCA	cis	rs4845875	0.514	rs198406	ENSG00000242349.4	NPPA-AS1	-7.68	3.59e-14	1.01e-11	-0.25	-0.23	Midregional pro atrial natriuretic peptide levels;	chr1:11837535	chr1:11841017~11848079:+
BRCA	cis	rs9880211	0.8	rs35100027	ENSG00000239213.4	NCK1-AS1	7.68	3.59e-14	1.01e-11	0.31	0.23	Height;Body mass index;	chr3:136748719	chr3:136841726~136862054:-
BRCA	cis	rs8031584	0.678	rs3122	ENSG00000260382.1	RP11-540B6.2	-7.68	3.6e-14	1.01e-11	-0.27	-0.23	Huntington's disease progression;	chr15:30878087	chr15:30882267~30883231:-
BRCA	cis	rs61270009	0.955	rs780399	ENSG00000247828.6	TMEM161B-AS1	-7.68	3.61e-14	1.01e-11	-0.29	-0.23	Depressive symptoms;	chr5:88237160	chr5:88268895~88436685:+
BRCA	cis	rs61270009	0.913	rs380670	ENSG00000247828.6	TMEM161B-AS1	-7.68	3.61e-14	1.01e-11	-0.29	-0.23	Depressive symptoms;	chr5:88243132	chr5:88268895~88436685:+
BRCA	cis	rs61270009	0.955	rs379430	ENSG00000247828.6	TMEM161B-AS1	-7.68	3.61e-14	1.01e-11	-0.29	-0.23	Depressive symptoms;	chr5:88243275	chr5:88268895~88436685:+
BRCA	cis	rs875971	0.651	rs313829	ENSG00000224316.1	RP11-479O9.2	-7.68	3.61e-14	1.02e-11	-0.25	-0.23	Aortic root size;	chr7:66087510	chr7:65773620~65802067:+
BRCA	cis	rs11098499	0.604	rs12642411	ENSG00000245958.5	RP11-33B1.1	-7.68	3.62e-14	1.02e-11	-0.24	-0.23	Corneal astigmatism;	chr4:119659370	chr4:119454791~119552025:+
BRCA	cis	rs2243480	0.803	rs423187	ENSG00000273142.1	RP11-458F8.4	-7.68	3.62e-14	1.02e-11	-0.33	-0.23	Diabetic kidney disease;	chr7:66044512	chr7:66902857~66906297:+
BRCA	cis	rs6822297	0.504	rs7681802	ENSG00000240005.4	RP11-293A21.1	7.68	3.63e-14	1.02e-11	0.28	0.23	Obesity-related traits;	chr4:26989777	chr4:26859806~26860599:-
BRCA	cis	rs3823536	0.5	rs4728144	ENSG00000275106.1	RP11-309L24.10	-7.68	3.64e-14	1.02e-11	-0.29	-0.23	Sjögren's syndrome;	chr7:129000280	chr7:128952527~128953316:-
BRCA	cis	rs6142102	0.517	rs8119076	ENSG00000275784.1	RP5-1125A11.6	-7.68	3.65e-14	1.02e-11	-0.27	-0.23	Skin pigmentation;	chr20:33937909	chr20:33989480~33991818:-
BRCA	cis	rs950776	0.714	rs514743	ENSG00000261762.1	RP11-650L12.2	-7.68	3.65e-14	1.03e-11	-0.26	-0.23	Sudden cardiac arrest;	chr15:78591885	chr15:78589123~78591276:-
BRCA	cis	rs2060793	0.519	rs1403247	ENSG00000251991.1	RNU7-49P	-7.68	3.65e-14	1.03e-11	-0.25	-0.23	Vitamin D levels;	chr11:14611024	chr11:14478892~14478953:+
BRCA	cis	rs3762637	1	rs9833415	ENSG00000272758.4	RP11-299J3.8	-7.68	3.66e-14	1.03e-11	-0.33	-0.23	LDL cholesterol levels;	chr3:122440993	chr3:122416207~122443180:+
BRCA	cis	rs801193	1	rs7782320	ENSG00000237310.1	GS1-124K5.4	7.68	3.67e-14	1.03e-11	0.24	0.23	Aortic root size;	chr7:66712111	chr7:66493706~66495474:+
BRCA	cis	rs62388641	0.539	rs56304710	ENSG00000272279.1	RP11-157J24.2	7.68	3.67e-14	1.03e-11	0.28	0.23	Daytime sleep phenotypes;	chr6:1542341	chr6:1528364~1528911:-
BRCA	cis	rs7811142	1	rs66632384	ENSG00000242294.5	STAG3L5P	7.68	3.68e-14	1.03e-11	0.23	0.23	Platelet count;	chr7:100421281	chr7:100336079~100351900:+
BRCA	cis	rs7811142	0.943	rs73403312	ENSG00000242294.5	STAG3L5P	7.68	3.68e-14	1.03e-11	0.23	0.23	Platelet count;	chr7:100426530	chr7:100336079~100351900:+
BRCA	cis	rs7615952	0.576	rs66671308	ENSG00000250012.1	RP11-124N2.1	-7.68	3.68e-14	1.03e-11	-0.32	-0.23	Blood pressure (smoking interaction);	chr3:126074683	chr3:126084220~126095349:+
BRCA	cis	rs11098499	1	rs6837898	ENSG00000248280.1	RP11-33B1.2	7.68	3.69e-14	1.04e-11	0.24	0.23	Corneal astigmatism;	chr4:119257999	chr4:119440561~119450157:-
BRCA	cis	rs8005677	1	rs1043209	ENSG00000279656.1	RP11-298I3.6	-7.68	3.7e-14	1.04e-11	-0.27	-0.23	Cognitive ability (multi-trait analysis);	chr14:22904777	chr14:23023083~23024217:-
BRCA	cis	rs875971	0.862	rs11765791	ENSG00000232559.3	GS1-124K5.12	7.68	3.7e-14	1.04e-11	0.28	0.23	Aortic root size;	chr7:66471587	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.862	rs949930	ENSG00000232559.3	GS1-124K5.12	-7.68	3.7e-14	1.04e-11	-0.28	-0.23	Aortic root size;	chr7:66301835	chr7:66554588~66576923:-
BRCA	cis	rs801193	0.636	rs10233806	ENSG00000232559.3	GS1-124K5.12	-7.68	3.7e-14	1.04e-11	-0.28	-0.23	Aortic root size;	chr7:66653261	chr7:66554588~66576923:-
BRCA	cis	rs6545883	0.894	rs2167566	ENSG00000271889.1	RP11-493E12.1	7.68	3.71e-14	1.04e-11	0.29	0.23	Tuberculosis;	chr2:61292273	chr2:61151433~61162105:-
BRCA	cis	rs801193	0.569	rs3846973	ENSG00000232559.3	GS1-124K5.12	-7.68	3.71e-14	1.04e-11	-0.28	-0.23	Aortic root size;	chr7:66655048	chr7:66554588~66576923:-
BRCA	cis	rs7927771	1	rs4752873	ENSG00000280615.1	Y_RNA	-7.68	3.72e-14	1.04e-11	-0.29	-0.23	Subjective well-being;	chr11:47835968	chr11:47614898~47614994:-
BRCA	cis	rs875971	0.862	rs801195	ENSG00000232559.3	GS1-124K5.12	-7.68	3.72e-14	1.04e-11	-0.28	-0.23	Aortic root size;	chr7:66561128	chr7:66554588~66576923:-
BRCA	cis	rs4927850	0.881	rs7624638	ENSG00000242086.7	LINC00969	7.68	3.73e-14	1.05e-11	0.26	0.23	Pancreatic cancer;	chr3:196021858	chr3:195658062~195739964:+
BRCA	cis	rs7927771	0.864	rs3781626	ENSG00000280615.1	Y_RNA	-7.68	3.73e-14	1.05e-11	-0.27	-0.23	Subjective well-being;	chr11:47421342	chr11:47614898~47614994:-
BRCA	cis	rs3814244	0.868	rs10878726	ENSG00000236946.2	HNRNPA1P70	-7.68	3.73e-14	1.05e-11	-0.19	-0.23	Itch intensity from mosquito bite adjusted by bite size;	chr12:68022865	chr12:68035767~68036853:+
BRCA	cis	rs858239	0.6	rs10256359	ENSG00000230042.1	AK3P3	-7.68	3.74e-14	1.05e-11	-0.27	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23084258	chr7:23129178~23129841:+
BRCA	cis	rs875971	0.571	rs160641	ENSG00000224316.1	RP11-479O9.2	-7.68	3.74e-14	1.05e-11	-0.26	-0.23	Aortic root size;	chr7:66112359	chr7:65773620~65802067:+
BRCA	cis	rs6545883	0.772	rs1186709	ENSG00000271889.1	RP11-493E12.1	7.68	3.74e-14	1.05e-11	0.31	0.23	Tuberculosis;	chr2:61462245	chr2:61151433~61162105:-
BRCA	cis	rs875971	0.642	rs35526611	ENSG00000237310.1	GS1-124K5.4	-7.68	3.74e-14	1.05e-11	-0.24	-0.23	Aortic root size;	chr7:66629021	chr7:66493706~66495474:+
BRCA	cis	rs62355901	0.545	rs2113084	ENSG00000271828.1	CTD-2310F14.1	7.68	3.74e-14	1.05e-11	0.4	0.23	Breast cancer;	chr5:56737844	chr5:56927874~56929573:+
BRCA	cis	rs287982	1	rs287982	ENSG00000269973.1	RP11-95D17.1	7.68	3.74e-14	1.05e-11	0.28	0.23	Nonsyndromic cleft lip with cleft palate;	chr2:9832313	chr2:9936360~9939590:+
BRCA	cis	rs6545883	0.895	rs6545871	ENSG00000271889.1	RP11-493E12.1	7.68	3.75e-14	1.05e-11	0.31	0.23	Tuberculosis;	chr2:61465068	chr2:61151433~61162105:-
BRCA	cis	rs7809950	1	rs4727681	ENSG00000238832.1	snoU109	-7.68	3.75e-14	1.05e-11	-0.3	-0.23	Coronary artery disease;	chr7:107455699	chr7:107603363~107603507:+
BRCA	cis	rs875971	0.545	rs316305	ENSG00000224316.1	RP11-479O9.2	-7.68	3.75e-14	1.05e-11	-0.26	-0.23	Aortic root size;	chr7:66152984	chr7:65773620~65802067:+
BRCA	cis	rs66887589	0.807	rs13134517	ENSG00000248280.1	RP11-33B1.2	7.68	3.76e-14	1.05e-11	0.22	0.23	Diastolic blood pressure;	chr4:119484107	chr4:119440561~119450157:-
BRCA	cis	rs66887589	0.837	rs6534135	ENSG00000248280.1	RP11-33B1.2	7.68	3.76e-14	1.05e-11	0.22	0.23	Diastolic blood pressure;	chr4:119485147	chr4:119440561~119450157:-
BRCA	cis	rs7927771	1	rs11039426	ENSG00000280615.1	Y_RNA	-7.68	3.76e-14	1.05e-11	-0.29	-0.23	Subjective well-being;	chr11:47841567	chr11:47614898~47614994:-
BRCA	cis	rs4835473	0.932	rs34917094	ENSG00000251600.4	RP11-673E1.1	-7.68	3.76e-14	1.05e-11	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143832003	chr4:143912331~143982454:+
BRCA	cis	rs10510102	0.872	rs3862129	ENSG00000276742.1	RP11-500G22.4	7.68	3.76e-14	1.06e-11	0.38	0.23	Breast cancer;	chr10:121824460	chr10:121956782~121957098:+
BRCA	cis	rs7811142	1	rs73161759	ENSG00000242294.5	STAG3L5P	7.68	3.77e-14	1.06e-11	0.23	0.23	Platelet count;	chr7:100412371	chr7:100336079~100351900:+
BRCA	cis	rs801193	0.967	rs2707841	ENSG00000237310.1	GS1-124K5.4	7.68	3.79e-14	1.06e-11	0.24	0.23	Aortic root size;	chr7:66692033	chr7:66493706~66495474:+
BRCA	cis	rs801193	1	rs4717310	ENSG00000237310.1	GS1-124K5.4	7.68	3.79e-14	1.06e-11	0.24	0.23	Aortic root size;	chr7:66696020	chr7:66493706~66495474:+
BRCA	cis	rs950880	0.71	rs3771172	ENSG00000234389.1	AC007278.3	-7.68	3.79e-14	1.06e-11	-0.24	-0.23	Serum protein levels (sST2);	chr2:102369352	chr2:102438713~102440475:+
BRCA	cis	rs9368481	0.729	rs9379948	ENSG00000241549.7	GUSBP2	7.68	3.79e-14	1.06e-11	0.27	0.23	Autism spectrum disorder or schizophrenia;	chr6:26977004	chr6:26871484~26956554:-
BRCA	cis	rs4753788	0.534	rs10789590	ENSG00000255353.1	RP11-382M14.1	-7.68	3.79e-14	1.06e-11	-0.28	-0.23	Coronary artery disease;	chr11:107266877	chr11:107176286~107177530:+
BRCA	cis	rs4753788	0.511	rs1388168	ENSG00000255353.1	RP11-382M14.1	-7.68	3.79e-14	1.06e-11	-0.28	-0.23	Coronary artery disease;	chr11:107267191	chr11:107176286~107177530:+
BRCA	cis	rs10463554	0.927	rs55641526	ENSG00000175749.11	EIF3KP1	7.68	3.79e-14	1.06e-11	0.32	0.23	Parkinson's disease;	chr5:102915301	chr5:103032376~103033031:+
BRCA	cis	rs10463554	0.856	rs26522	ENSG00000175749.11	EIF3KP1	-7.67	3.79e-14	1.06e-11	-0.3	-0.23	Parkinson's disease;	chr5:103148695	chr5:103032376~103033031:+
BRCA	cis	rs10129255	1	rs61997605	ENSG00000211972.2	IGHV3-66	7.67	3.8e-14	1.06e-11	0.18	0.23	Kawasaki disease;	chr14:106678368	chr14:106675017~106675544:-
BRCA	cis	rs8062405	0.823	rs7202948	ENSG00000251417.2	RP11-1348G14.4	-7.67	3.8e-14	1.06e-11	-0.26	-0.23	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28546968	chr16:28802743~28817828:+
BRCA	cis	rs3762637	0.943	rs10222564	ENSG00000272758.4	RP11-299J3.8	-7.67	3.8e-14	1.07e-11	-0.34	-0.23	LDL cholesterol levels;	chr3:122547489	chr3:122416207~122443180:+
BRCA	cis	rs4835473	0.897	rs7682128	ENSG00000251600.4	RP11-673E1.1	7.67	3.8e-14	1.07e-11	0.28	0.23	Immature fraction of reticulocytes;	chr4:143708950	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.897	rs7687317	ENSG00000251600.4	RP11-673E1.1	7.67	3.8e-14	1.07e-11	0.28	0.23	Immature fraction of reticulocytes;	chr4:143709010	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.9	rs3856989	ENSG00000251600.4	RP11-673E1.1	7.67	3.81e-14	1.07e-11	0.29	0.23	Immature fraction of reticulocytes;	chr4:143921752	chr4:143912331~143982454:+
BRCA	cis	rs7927771	1	rs11039412	ENSG00000280615.1	Y_RNA	-7.67	3.83e-14	1.07e-11	-0.29	-0.23	Subjective well-being;	chr11:47820029	chr11:47614898~47614994:-
BRCA	cis	rs7927771	0.965	rs11039416	ENSG00000280615.1	Y_RNA	-7.67	3.83e-14	1.07e-11	-0.29	-0.23	Subjective well-being;	chr11:47825159	chr11:47614898~47614994:-
BRCA	cis	rs7927771	0.965	rs35985502	ENSG00000280615.1	Y_RNA	-7.67	3.83e-14	1.07e-11	-0.29	-0.23	Subjective well-being;	chr11:47825876	chr11:47614898~47614994:-
BRCA	cis	rs4927850	0.752	rs7624460	ENSG00000242086.7	LINC00969	7.67	3.83e-14	1.07e-11	0.25	0.23	Pancreatic cancer;	chr3:196021659	chr3:195658062~195739964:+
BRCA	cis	rs2742234	1	rs1864399	ENSG00000273008.1	RP11-351D16.3	-7.67	3.84e-14	1.08e-11	-0.27	-0.23	Hirschsprung disease;	chr10:43115007	chr10:43136824~43138334:-
BRCA	cis	rs4835473	0.932	rs13107719	ENSG00000251600.4	RP11-673E1.1	-7.67	3.84e-14	1.08e-11	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143752034	chr4:143912331~143982454:+
BRCA	cis	rs6142102	0.659	rs6057945	ENSG00000276073.1	RP5-1125A11.7	-7.67	3.85e-14	1.08e-11	-0.28	-0.23	Skin pigmentation;	chr20:33929374	chr20:33985617~33988989:-
BRCA	cis	rs4845875	0.535	rs198408	ENSG00000242349.4	NPPA-AS1	-7.67	3.85e-14	1.08e-11	-0.25	-0.23	Midregional pro atrial natriuretic peptide levels;	chr1:11838073	chr1:11841017~11848079:+
BRCA	cis	rs875971	0.862	rs10274883	ENSG00000232559.3	GS1-124K5.12	-7.67	3.86e-14	1.08e-11	-0.28	-0.23	Aortic root size;	chr7:66651104	chr7:66554588~66576923:-
BRCA	cis	rs7615952	0.599	rs6803160	ENSG00000250012.1	RP11-124N2.1	-7.67	3.86e-14	1.08e-11	-0.31	-0.23	Blood pressure (smoking interaction);	chr3:125990711	chr3:126084220~126095349:+
BRCA	cis	rs2179367	0.632	rs12197598	ENSG00000231760.4	RP11-350J20.5	7.67	3.86e-14	1.08e-11	0.34	0.23	Dupuytren's disease;	chr6:149385418	chr6:149796151~149826294:-
BRCA	cis	rs77204473	1	rs12278117	ENSG00000254851.1	RP11-109L13.1	7.67	3.87e-14	1.08e-11	0.52	0.23	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116877453	chr11:117135528~117138582:+
BRCA	cis	rs896854	0.714	rs572547	ENSG00000253528.2	RP11-347C18.4	-7.67	3.87e-14	1.08e-11	-0.26	-0.23	Type 2 diabetes;	chr8:94954058	chr8:94974573~94974853:-
BRCA	cis	rs62388641	0.547	rs2745610	ENSG00000272279.1	RP11-157J24.2	-7.67	3.88e-14	1.09e-11	-0.31	-0.23	Daytime sleep phenotypes;	chr6:1553741	chr6:1528364~1528911:-
BRCA	cis	rs3762637	1	rs9968189	ENSG00000272758.4	RP11-299J3.8	-7.67	3.88e-14	1.09e-11	-0.34	-0.23	LDL cholesterol levels;	chr3:122456289	chr3:122416207~122443180:+
BRCA	cis	rs3762637	0.941	rs60222267	ENSG00000272758.4	RP11-299J3.8	-7.67	3.88e-14	1.09e-11	-0.34	-0.23	LDL cholesterol levels;	chr3:122460785	chr3:122416207~122443180:+
BRCA	cis	rs3762637	0.882	rs56074178	ENSG00000272758.4	RP11-299J3.8	-7.67	3.88e-14	1.09e-11	-0.34	-0.23	LDL cholesterol levels;	chr3:122461164	chr3:122416207~122443180:+
BRCA	cis	rs3762637	1	rs72958458	ENSG00000272758.4	RP11-299J3.8	-7.67	3.88e-14	1.09e-11	-0.34	-0.23	LDL cholesterol levels;	chr3:122466702	chr3:122416207~122443180:+
BRCA	cis	rs3762637	1	rs7642869	ENSG00000272758.4	RP11-299J3.8	-7.67	3.88e-14	1.09e-11	-0.34	-0.23	LDL cholesterol levels;	chr3:122471939	chr3:122416207~122443180:+
BRCA	cis	rs3762637	1	rs7617042	ENSG00000272758.4	RP11-299J3.8	-7.67	3.88e-14	1.09e-11	-0.34	-0.23	LDL cholesterol levels;	chr3:122472138	chr3:122416207~122443180:+
BRCA	cis	rs3762637	1	rs6790051	ENSG00000272758.4	RP11-299J3.8	-7.67	3.88e-14	1.09e-11	-0.34	-0.23	LDL cholesterol levels;	chr3:122473999	chr3:122416207~122443180:+
BRCA	cis	rs3762637	1	rs9878699	ENSG00000272758.4	RP11-299J3.8	-7.67	3.88e-14	1.09e-11	-0.34	-0.23	LDL cholesterol levels;	chr3:122475384	chr3:122416207~122443180:+
BRCA	cis	rs3762637	1	rs12638866	ENSG00000272758.4	RP11-299J3.8	-7.67	3.88e-14	1.09e-11	-0.34	-0.23	LDL cholesterol levels;	chr3:122475535	chr3:122416207~122443180:+
BRCA	cis	rs4835473	0.932	rs1813908	ENSG00000251600.4	RP11-673E1.1	7.67	3.88e-14	1.09e-11	0.28	0.23	Immature fraction of reticulocytes;	chr4:143728174	chr4:143912331~143982454:+
BRCA	cis	rs516805	0.961	rs573709	ENSG00000279114.1	RP3-425C14.5	7.67	3.88e-14	1.09e-11	0.24	0.23	Lymphocyte counts;	chr6:122457673	chr6:122471923~122484161:+
BRCA	cis	rs3758911	0.796	rs10890720	ENSG00000255353.1	RP11-382M14.1	7.67	3.89e-14	1.09e-11	0.31	0.23	Coronary artery disease;	chr11:107335292	chr11:107176286~107177530:+
BRCA	cis	rs11143230	1	rs11143230	ENSG00000225434.2	LINC01504	7.67	3.89e-14	1.09e-11	0.26	0.23	Suicidal ideation;	chr9:72272787	chr9:72305430~72343210:+
BRCA	cis	rs6700559	0.81	rs2808248	ENSG00000260088.1	RP11-92G12.3	7.67	3.89e-14	1.09e-11	0.29	0.23	Coronary artery disease;	chr1:200623147	chr1:200669507~200694250:+
BRCA	cis	rs712022	0.534	rs4494299	ENSG00000246225.5	RP11-17A1.3	-7.67	3.9e-14	1.09e-11	-0.27	-0.23	Dialysis-related mortality;	chr11:22850686	chr11:22829380~22945393:+
BRCA	cis	rs919433	1	rs2889363	ENSG00000231621.1	AC013264.2	7.67	3.9e-14	1.09e-11	0.21	0.23	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197298975	chr2:197197991~197199273:+
BRCA	cis	rs875971	0.862	rs709609	ENSG00000232559.3	GS1-124K5.12	-7.67	3.9e-14	1.09e-11	-0.28	-0.23	Aortic root size;	chr7:66095574	chr7:66554588~66576923:-
BRCA	cis	rs712022	0.534	rs4550218	ENSG00000246225.5	RP11-17A1.3	-7.67	3.91e-14	1.09e-11	-0.27	-0.23	Dialysis-related mortality;	chr11:22842112	chr11:22829380~22945393:+
BRCA	cis	rs10463554	0.892	rs62362519	ENSG00000175749.11	EIF3KP1	7.67	3.92e-14	1.1e-11	0.32	0.23	Parkinson's disease;	chr5:102965759	chr5:103032376~103033031:+
BRCA	cis	rs10463554	0.853	rs2241565	ENSG00000175749.11	EIF3KP1	7.67	3.92e-14	1.1e-11	0.32	0.23	Parkinson's disease;	chr5:102966233	chr5:103032376~103033031:+
BRCA	cis	rs7520050	0.778	rs3014238	ENSG00000280836.1	AL355480.1	7.67	3.92e-14	1.1e-11	0.27	0.23	Reticulocyte count;Red blood cell count;	chr1:45624542	chr1:45581219~45581321:-
BRCA	cis	rs34779708	0.677	rs112355105	ENSG00000271335.4	RP11-324I22.4	7.67	3.92e-14	1.1e-11	0.24	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35261366	chr10:35314552~35336401:-
BRCA	cis	rs250518	0.926	rs35132569	ENSG00000272081.1	CTD-2376I4.2	7.67	3.93e-14	1.1e-11	0.29	0.23	Mean corpuscular hemoglobin concentration;	chr5:72763914	chr5:72955206~72955699:-
BRCA	cis	rs1499614	1	rs1267818	ENSG00000273142.1	RP11-458F8.4	-7.67	3.93e-14	1.1e-11	-0.32	-0.23	Gout;	chr7:66642037	chr7:66902857~66906297:+
BRCA	cis	rs10510102	0.872	rs10887003	ENSG00000276742.1	RP11-500G22.4	7.67	3.94e-14	1.1e-11	0.38	0.23	Breast cancer;	chr10:121864660	chr10:121956782~121957098:+
BRCA	cis	rs10129255	0.957	rs1024349	ENSG00000211972.2	IGHV3-66	7.67	3.94e-14	1.1e-11	0.18	0.23	Kawasaki disease;	chr14:106689997	chr14:106675017~106675544:-
BRCA	cis	rs875971	0.928	rs2036263	ENSG00000232559.3	GS1-124K5.12	-7.67	3.95e-14	1.1e-11	-0.28	-0.23	Aortic root size;	chr7:66335210	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.862	rs10240949	ENSG00000232559.3	GS1-124K5.12	-7.67	3.95e-14	1.1e-11	-0.28	-0.23	Aortic root size;	chr7:66339430	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.862	rs7782704	ENSG00000232559.3	GS1-124K5.12	-7.67	3.95e-14	1.1e-11	-0.28	-0.23	Aortic root size;	chr7:66340379	chr7:66554588~66576923:-
BRCA	cis	rs801193	1	rs62466794	ENSG00000237310.1	GS1-124K5.4	7.67	3.95e-14	1.11e-11	0.24	0.23	Aortic root size;	chr7:66726592	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.66	rs1860470	ENSG00000237310.1	GS1-124K5.4	-7.67	3.96e-14	1.11e-11	-0.24	-0.23	Aortic root size;	chr7:66638707	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.79	rs10257911	ENSG00000232559.3	GS1-124K5.12	-7.67	3.96e-14	1.11e-11	-0.28	-0.23	Aortic root size;	chr7:66278783	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.638	rs35986979	ENSG00000237310.1	GS1-124K5.4	-7.67	3.96e-14	1.11e-11	-0.24	-0.23	Aortic root size;	chr7:66624003	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.66	rs3764903	ENSG00000237310.1	GS1-124K5.4	-7.67	3.96e-14	1.11e-11	-0.24	-0.23	Aortic root size;	chr7:66633495	chr7:66493706~66495474:+
BRCA	cis	rs7772486	0.902	rs1331643	ENSG00000235652.6	RP11-545I5.3	7.67	3.96e-14	1.11e-11	0.23	0.23	Lobe attachment (rater-scored or self-reported);	chr6:146077737	chr6:145799409~145886585:+
BRCA	cis	rs2439831	0.85	rs28564774	ENSG00000275601.1	AC011330.13	-7.67	3.97e-14	1.11e-11	-0.37	-0.23	Lung cancer in ever smokers;	chr15:43833277	chr15:43642389~43643023:-
BRCA	cis	rs875971	0.862	rs6978028	ENSG00000232559.3	GS1-124K5.12	7.67	3.97e-14	1.11e-11	0.28	0.23	Aortic root size;	chr7:66421313	chr7:66554588~66576923:-
BRCA	cis	rs287982	1	rs112307255	ENSG00000269973.1	RP11-95D17.1	-7.67	3.97e-14	1.11e-11	-0.29	-0.23	Nonsyndromic cleft lip with cleft palate;	chr2:9842137	chr2:9936360~9939590:+
BRCA	cis	rs6921919	0.583	rs6922169	ENSG00000204709.4	LINC01556	7.67	3.97e-14	1.11e-11	0.31	0.23	Autism spectrum disorder or schizophrenia;	chr6:28415155	chr6:28943877~28944537:+
BRCA	cis	rs6921919	0.559	rs13210866	ENSG00000204709.4	LINC01556	7.67	3.97e-14	1.11e-11	0.31	0.23	Autism spectrum disorder or schizophrenia;	chr6:28416065	chr6:28943877~28944537:+
BRCA	cis	rs17772222	0.917	rs12587200	ENSG00000258983.2	RP11-507K2.2	7.67	3.98e-14	1.11e-11	0.26	0.23	Coronary artery calcification;	chr14:88632060	chr14:88499334~88515502:+
BRCA	cis	rs812925	0.826	rs2694633	ENSG00000271889.1	RP11-493E12.1	-7.67	3.98e-14	1.11e-11	-0.31	-0.23	Immature fraction of reticulocytes;	chr2:61313507	chr2:61151433~61162105:-
BRCA	cis	rs2033711	0.728	rs4801586	ENSG00000269473.1	CTD-2619J13.19	7.67	4.01e-14	1.12e-11	0.28	0.23	Uric acid clearance;	chr19:58423161	chr19:58440448~58445849:+
BRCA	cis	rs904251	0.523	rs914348	ENSG00000204110.6	RP1-153P14.8	-7.67	4.01e-14	1.12e-11	-0.25	-0.23	Cognitive performance;	chr6:37516953	chr6:37507348~37535616:+
BRCA	cis	rs2179367	0.537	rs6911411	ENSG00000231760.4	RP11-350J20.5	7.67	4.04e-14	1.13e-11	0.36	0.23	Dupuytren's disease;	chr6:149366954	chr6:149796151~149826294:-
BRCA	cis	rs10129255	0.536	rs6576201	ENSG00000280411.1	IGHV1-69-2	7.67	4.04e-14	1.13e-11	0.15	0.23	Kawasaki disease;	chr14:106683696	chr14:106762092~106762588:-
BRCA	cis	rs858239	0.6	rs9691762	ENSG00000230042.1	AK3P3	-7.67	4.05e-14	1.13e-11	-0.26	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23086303	chr7:23129178~23129841:+
BRCA	cis	rs3762637	0.943	rs9841897	ENSG00000272758.4	RP11-299J3.8	-7.67	4.07e-14	1.14e-11	-0.34	-0.23	LDL cholesterol levels;	chr3:122563722	chr3:122416207~122443180:+
BRCA	cis	rs10510102	0.935	rs11200183	ENSG00000276742.1	RP11-500G22.4	7.67	4.07e-14	1.14e-11	0.4	0.23	Breast cancer;	chr10:121829908	chr10:121956782~121957098:+
BRCA	cis	rs7085104	0.632	rs3781287	ENSG00000236937.2	PTGES3P4	7.67	4.07e-14	1.14e-11	0.29	0.23	Immature fraction of reticulocytes;Schizophrenia;	chr10:102835663	chr10:102845595~102845950:+
BRCA	cis	rs9368481	0.672	rs3931463	ENSG00000241549.7	GUSBP2	7.66	4.09e-14	1.14e-11	0.27	0.23	Autism spectrum disorder or schizophrenia;	chr6:26972018	chr6:26871484~26956554:-
BRCA	cis	rs2179367	0.959	rs540538	ENSG00000231760.4	RP11-350J20.5	7.66	4.1e-14	1.15e-11	0.3	0.23	Dupuytren's disease;	chr6:149326808	chr6:149796151~149826294:-
BRCA	cis	rs3758911	0.861	rs11212163	ENSG00000255353.1	RP11-382M14.1	-7.66	4.1e-14	1.15e-11	-0.31	-0.23	Coronary artery disease;	chr11:107328005	chr11:107176286~107177530:+
BRCA	cis	rs875971	0.66	rs10272357	ENSG00000224316.1	RP11-479O9.2	-7.66	4.11e-14	1.15e-11	-0.23	-0.23	Aortic root size;	chr7:66598087	chr7:65773620~65802067:+
BRCA	cis	rs6921919	0.583	rs4254981	ENSG00000204709.4	LINC01556	7.66	4.11e-14	1.15e-11	0.31	0.23	Autism spectrum disorder or schizophrenia;	chr6:28403625	chr6:28943877~28944537:+
BRCA	cis	rs9880211	0.898	rs34031772	ENSG00000273486.1	RP11-731C17.2	7.66	4.11e-14	1.15e-11	0.3	0.23	Height;Body mass index;	chr3:136299299	chr3:136837338~136839021:-
BRCA	cis	rs17711722	0.653	rs2460421	ENSG00000222364.1	RNU6-96P	7.66	4.12e-14	1.15e-11	0.27	0.23	Calcium levels;	chr7:66026136	chr7:66395191~66395286:+
BRCA	cis	rs4835473	0.932	rs17695782	ENSG00000251600.4	RP11-673E1.1	-7.66	4.12e-14	1.15e-11	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143830311	chr4:143912331~143982454:+
BRCA	cis	rs10740039	0.883	rs1561850	ENSG00000254271.1	RP11-131N11.4	7.66	4.12e-14	1.15e-11	0.3	0.23	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60631583	chr10:60734342~60741828:+
BRCA	cis	rs780096	0.526	rs7602534	ENSG00000234072.1	AC074117.10	-7.66	4.13e-14	1.15e-11	-0.22	-0.23	Total body bone mineral density;	chr2:27369556	chr2:27356246~27367622:+
BRCA	cis	rs10740039	0.804	rs894384	ENSG00000254271.1	RP11-131N11.4	7.66	4.14e-14	1.16e-11	0.3	0.23	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60692535	chr10:60734342~60741828:+
BRCA	cis	rs10200159	1	rs3748955	ENSG00000272606.1	RP11-554J4.1	7.66	4.15e-14	1.16e-11	0.44	0.23	Vitiligo;	chr2:55626335	chr2:55617909~55618373:+
BRCA	cis	rs7811142	1	rs60257855	ENSG00000242294.5	STAG3L5P	7.66	4.17e-14	1.17e-11	0.23	0.23	Platelet count;	chr7:100429157	chr7:100336079~100351900:+
BRCA	cis	rs10463554	0.892	rs1898673	ENSG00000175749.11	EIF3KP1	7.66	4.17e-14	1.17e-11	0.32	0.23	Parkinson's disease;	chr5:102957676	chr5:103032376~103033031:+
BRCA	cis	rs875971	0.545	rs316328	ENSG00000224316.1	RP11-479O9.2	-7.66	4.19e-14	1.17e-11	-0.25	-0.23	Aortic root size;	chr7:66143851	chr7:65773620~65802067:+
BRCA	cis	rs526231	0.578	rs6860588	ENSG00000175749.11	EIF3KP1	-7.66	4.19e-14	1.17e-11	-0.33	-0.23	Primary biliary cholangitis;	chr5:102944598	chr5:103032376~103033031:+
BRCA	cis	rs1075265	0.54	rs2542587	ENSG00000233266.1	HMGB1P31	7.66	4.2e-14	1.17e-11	0.28	0.23	Chronotype;Morning vs. evening chronotype;	chr2:53788839	chr2:54051334~54051760:+
BRCA	cis	rs1075265	0.563	rs2692537	ENSG00000233266.1	HMGB1P31	7.66	4.2e-14	1.17e-11	0.28	0.23	Chronotype;Morning vs. evening chronotype;	chr2:53788840	chr2:54051334~54051760:+
BRCA	cis	rs10129255	0.744	rs28517388	ENSG00000223648.3	IGHV3-64	7.66	4.2e-14	1.17e-11	0.22	0.23	Kawasaki disease;	chr14:106704323	chr14:106643132~106658258:-
BRCA	cis	rs3762637	0.943	rs9289198	ENSG00000272758.4	RP11-299J3.8	-7.66	4.21e-14	1.17e-11	-0.34	-0.23	LDL cholesterol levels;	chr3:122558313	chr3:122416207~122443180:+
BRCA	cis	rs3762637	0.943	rs9289199	ENSG00000272758.4	RP11-299J3.8	-7.66	4.21e-14	1.17e-11	-0.34	-0.23	LDL cholesterol levels;	chr3:122558325	chr3:122416207~122443180:+
BRCA	cis	rs10200159	1	rs10172506	ENSG00000272606.1	RP11-554J4.1	7.66	4.21e-14	1.17e-11	0.44	0.23	Vitiligo;	chr2:55638334	chr2:55617909~55618373:+
BRCA	cis	rs10200159	1	rs7558127	ENSG00000272606.1	RP11-554J4.1	7.66	4.21e-14	1.17e-11	0.44	0.23	Vitiligo;	chr2:55639470	chr2:55617909~55618373:+
BRCA	cis	rs9880211	1	rs28641809	ENSG00000273486.1	RP11-731C17.2	7.66	4.21e-14	1.17e-11	0.3	0.23	Height;Body mass index;	chr3:136571647	chr3:136837338~136839021:-
BRCA	cis	rs2179367	0.632	rs55836833	ENSG00000231760.4	RP11-350J20.5	7.66	4.21e-14	1.18e-11	0.34	0.23	Dupuytren's disease;	chr6:149403736	chr6:149796151~149826294:-
BRCA	cis	rs6569038	0.557	rs9374777	ENSG00000253194.1	RP11-351A11.1	-7.66	4.22e-14	1.18e-11	-0.29	-0.23	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr6:119056334	chr6:118934785~119031541:+
BRCA	cis	rs3814244	0.528	rs7952790	ENSG00000236946.2	HNRNPA1P70	-7.66	4.22e-14	1.18e-11	-0.19	-0.23	Itch intensity from mosquito bite adjusted by bite size;	chr12:68012672	chr12:68035767~68036853:+
BRCA	cis	rs7809950	1	rs7786801	ENSG00000238832.1	snoU109	-7.66	4.22e-14	1.18e-11	-0.3	-0.23	Coronary artery disease;	chr7:107445444	chr7:107603363~107603507:+
BRCA	cis	rs2880765	0.835	rs56406982	ENSG00000259295.5	CSPG4P12	7.66	4.23e-14	1.18e-11	0.28	0.23	Coronary artery disease;	chr15:85493148	chr15:85191438~85213905:+
BRCA	cis	rs807029	0.577	rs701835	ENSG00000272572.1	RP11-179B2.2	-7.66	4.23e-14	1.18e-11	-0.29	-0.23	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:101002370	chr10:100911103~100912739:-
BRCA	cis	rs526231	0.543	rs62362521	ENSG00000175749.11	EIF3KP1	7.66	4.24e-14	1.18e-11	0.34	0.23	Primary biliary cholangitis;	chr5:102970357	chr5:103032376~103033031:+
BRCA	cis	rs526231	0.575	rs12652973	ENSG00000175749.11	EIF3KP1	7.66	4.24e-14	1.18e-11	0.34	0.23	Primary biliary cholangitis;	chr5:102970618	chr5:103032376~103033031:+
BRCA	cis	rs526231	0.575	rs66730942	ENSG00000175749.11	EIF3KP1	7.66	4.24e-14	1.18e-11	0.34	0.23	Primary biliary cholangitis;	chr5:102971075	chr5:103032376~103033031:+
BRCA	cis	rs17772222	0.917	rs61984737	ENSG00000258983.2	RP11-507K2.2	7.66	4.24e-14	1.18e-11	0.26	0.23	Coronary artery calcification;	chr14:88637028	chr14:88499334~88515502:+
BRCA	cis	rs62355901	0.599	rs12655060	ENSG00000271828.1	CTD-2310F14.1	7.66	4.28e-14	1.19e-11	0.4	0.23	Breast cancer;	chr5:56720808	chr5:56927874~56929573:+
BRCA	cis	rs875971	0.83	rs778711	ENSG00000232559.3	GS1-124K5.12	7.66	4.29e-14	1.2e-11	0.28	0.23	Aortic root size;	chr7:66386670	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.862	rs1083554	ENSG00000232559.3	GS1-124K5.12	7.66	4.29e-14	1.2e-11	0.28	0.23	Aortic root size;	chr7:66387354	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.862	rs778707	ENSG00000232559.3	GS1-124K5.12	7.66	4.29e-14	1.2e-11	0.28	0.23	Aortic root size;	chr7:66392040	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.862	rs778705	ENSG00000232559.3	GS1-124K5.12	7.66	4.29e-14	1.2e-11	0.28	0.23	Aortic root size;	chr7:66396128	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.862	rs778697	ENSG00000232559.3	GS1-124K5.12	7.66	4.29e-14	1.2e-11	0.28	0.23	Aortic root size;	chr7:66405439	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.798	rs7789615	ENSG00000232559.3	GS1-124K5.12	7.66	4.29e-14	1.2e-11	0.28	0.23	Aortic root size;	chr7:66413674	chr7:66554588~66576923:-
BRCA	cis	rs11098499	0.863	rs10004484	ENSG00000248280.1	RP11-33B1.2	7.66	4.29e-14	1.2e-11	0.23	0.23	Corneal astigmatism;	chr4:119521273	chr4:119440561~119450157:-
BRCA	cis	rs1023500	0.505	rs134874	ENSG00000205702.9	CYP2D7	7.66	4.29e-14	1.2e-11	0.19	0.23	Schizophrenia;	chr22:42265138	chr22:42140203~42144577:-
BRCA	cis	rs950776	0.593	rs621849	ENSG00000261762.1	RP11-650L12.2	-7.66	4.3e-14	1.2e-11	-0.25	-0.23	Sudden cardiac arrest;	chr15:78580519	chr15:78589123~78591276:-
BRCA	cis	rs7727544	0.684	rs274546	ENSG00000233006.5	AC034220.3	7.66	4.3e-14	1.2e-11	0.17	0.23	Blood metabolite levels;	chr5:132364175	chr5:132311285~132369916:-
BRCA	cis	rs4927850	1	rs10881563	ENSG00000242086.7	LINC00969	7.66	4.3e-14	1.2e-11	0.26	0.23	Pancreatic cancer;	chr3:196023354	chr3:195658062~195739964:+
BRCA	cis	rs2028299	0.92	rs12594774	ENSG00000259677.1	RP11-493E3.1	7.66	4.3e-14	1.2e-11	0.32	0.23	Type 2 diabetes;	chr15:89863652	chr15:89876540~89877285:+
BRCA	cis	rs2880765	0.835	rs6497206	ENSG00000259295.5	CSPG4P12	7.66	4.31e-14	1.2e-11	0.28	0.23	Coronary artery disease;	chr15:85485994	chr15:85191438~85213905:+
BRCA	cis	rs496547	0.719	rs476246	ENSG00000278376.1	RP11-158I9.8	7.66	4.32e-14	1.2e-11	0.22	0.23	Hip minimal joint space width;	chr11:118747211	chr11:118791254~118793137:+
BRCA	cis	rs7615952	0.599	rs7652883	ENSG00000250012.1	RP11-124N2.1	-7.66	4.32e-14	1.2e-11	-0.31	-0.23	Blood pressure (smoking interaction);	chr3:125989134	chr3:126084220~126095349:+
BRCA	cis	rs2179367	0.632	rs10872636	ENSG00000231760.4	RP11-350J20.5	7.66	4.33e-14	1.21e-11	0.33	0.23	Dupuytren's disease;	chr6:149353678	chr6:149796151~149826294:-
BRCA	cis	rs77204473	1	rs75294699	ENSG00000254851.1	RP11-109L13.1	7.66	4.35e-14	1.21e-11	0.54	0.23	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116878356	chr11:117135528~117138582:+
BRCA	cis	rs919433	0.929	rs10931779	ENSG00000231621.1	AC013264.2	7.66	4.36e-14	1.21e-11	0.21	0.23	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197302101	chr2:197197991~197199273:+
BRCA	cis	rs12237653	1	rs12237653	ENSG00000236404.7	VLDLR-AS1	7.66	4.36e-14	1.22e-11	0.35	0.23	Gambling;	chr9:2551654	chr9:2422702~2643359:-
BRCA	cis	rs6504622	0.755	rs7219544	ENSG00000262879.4	RP11-156P1.3	-7.66	4.37e-14	1.22e-11	-0.24	-0.23	Orofacial clefts;	chr17:47089562	chr17:46984045~47100323:-
BRCA	cis	rs34779708	0.766	rs7913451	ENSG00000271335.4	RP11-324I22.4	7.66	4.37e-14	1.22e-11	0.24	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35262597	chr10:35314552~35336401:-
BRCA	cis	rs4835473	0.868	rs5025156	ENSG00000251600.4	RP11-673E1.1	-7.66	4.37e-14	1.22e-11	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143738025	chr4:143912331~143982454:+
BRCA	cis	rs12188164	0.543	rs2672722	ENSG00000225138.6	CTD-2228K2.7	-7.66	4.37e-14	1.22e-11	-0.25	-0.23	Cystic fibrosis severity;	chr5:453452	chr5:473236~480884:+
BRCA	cis	rs875971	0.638	rs7793569	ENSG00000237310.1	GS1-124K5.4	-7.66	4.38e-14	1.22e-11	-0.24	-0.23	Aortic root size;	chr7:66651646	chr7:66493706~66495474:+
BRCA	cis	rs801193	1	rs3857688	ENSG00000237310.1	GS1-124K5.4	-7.66	4.38e-14	1.22e-11	-0.24	-0.23	Aortic root size;	chr7:66662819	chr7:66493706~66495474:+
BRCA	cis	rs801193	1	rs2286684	ENSG00000237310.1	GS1-124K5.4	-7.66	4.38e-14	1.22e-11	-0.24	-0.23	Aortic root size;	chr7:66664843	chr7:66493706~66495474:+
BRCA	cis	rs801193	0.935	rs2286683	ENSG00000237310.1	GS1-124K5.4	-7.66	4.38e-14	1.22e-11	-0.24	-0.23	Aortic root size;	chr7:66664856	chr7:66493706~66495474:+
BRCA	cis	rs801193	1	rs10274773	ENSG00000237310.1	GS1-124K5.4	-7.66	4.38e-14	1.22e-11	-0.24	-0.23	Aortic root size;	chr7:66668591	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.862	rs6460302	ENSG00000232559.3	GS1-124K5.12	7.66	4.39e-14	1.22e-11	0.28	0.23	Aortic root size;	chr7:66495270	chr7:66554588~66576923:-
BRCA	cis	rs10050311	0.79	rs4693154	ENSG00000251411.1	RP11-397E7.4	-7.66	4.39e-14	1.22e-11	-0.35	-0.23	Insulin-related traits;	chr4:86922109	chr4:86913266~86914817:-
BRCA	cis	rs7085104	0.7	rs3740397	ENSG00000236937.2	PTGES3P4	7.65	4.4e-14	1.22e-11	0.3	0.23	Immature fraction of reticulocytes;Schizophrenia;	chr10:102832918	chr10:102845595~102845950:+
BRCA	cis	rs6921919	0.609	rs36018474	ENSG00000204709.4	LINC01556	7.65	4.41e-14	1.23e-11	0.31	0.23	Autism spectrum disorder or schizophrenia;	chr6:28417752	chr6:28943877~28944537:+
BRCA	cis	rs6921919	0.583	rs13201726	ENSG00000204709.4	LINC01556	7.65	4.41e-14	1.23e-11	0.31	0.23	Autism spectrum disorder or schizophrenia;	chr6:28417774	chr6:28943877~28944537:+
BRCA	cis	rs3733309	0.648	rs10016631	ENSG00000269949.1	RP11-738E22.3	7.65	4.41e-14	1.23e-11	0.35	0.23	Height;	chr4:57019797	chr4:56960927~56961373:-
BRCA	cis	rs17264034	0.861	rs11749803	ENSG00000250786.1	SNHG18	7.65	4.42e-14	1.23e-11	0.32	0.23	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9553456	chr5:9546200~9550609:+
BRCA	cis	rs375066	0.901	rs1978723	ENSG00000267058.1	RP11-15A1.3	7.65	4.42e-14	1.23e-11	0.26	0.23	Breast cancer;	chr19:43879648	chr19:43891804~43901805:-
BRCA	cis	rs2243480	1	rs13310597	ENSG00000273142.1	RP11-458F8.4	-7.65	4.43e-14	1.23e-11	-0.32	-0.23	Diabetic kidney disease;	chr7:66133553	chr7:66902857~66906297:+
BRCA	cis	rs853679	1	rs2799079	ENSG00000220721.1	OR1F12	7.65	4.44e-14	1.24e-11	0.35	0.23	Depression;	chr6:28267398	chr6:28073316~28074233:+
BRCA	cis	rs875971	0.862	rs4718319	ENSG00000232559.3	GS1-124K5.12	-7.65	4.47e-14	1.24e-11	-0.28	-0.23	Aortic root size;	chr7:66187797	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.723	rs28391294	ENSG00000232559.3	GS1-124K5.12	-7.65	4.47e-14	1.24e-11	-0.28	-0.23	Aortic root size;	chr7:66189328	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.83	rs6967708	ENSG00000232559.3	GS1-124K5.12	-7.65	4.47e-14	1.24e-11	-0.28	-0.23	Aortic root size;	chr7:66192326	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.895	rs7782806	ENSG00000232559.3	GS1-124K5.12	-7.65	4.47e-14	1.24e-11	-0.28	-0.23	Aortic root size;	chr7:66192910	chr7:66554588~66576923:-
BRCA	cis	rs801193	0.613	rs2659900	ENSG00000232559.3	GS1-124K5.12	7.65	4.48e-14	1.25e-11	0.28	0.23	Aortic root size;	chr7:66719456	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.862	rs880166	ENSG00000232559.3	GS1-124K5.12	-7.65	4.48e-14	1.25e-11	-0.28	-0.23	Aortic root size;	chr7:66205775	chr7:66554588~66576923:-
BRCA	cis	rs2742234	0.541	rs2742235	ENSG00000273008.1	RP11-351D16.3	-7.65	4.49e-14	1.25e-11	-0.3	-0.23	Hirschsprung disease;	chr10:43120877	chr10:43136824~43138334:-
BRCA	cis	rs62103177	0.564	rs2115996	ENSG00000261126.6	RP11-795F19.1	7.65	4.5e-14	1.25e-11	0.35	0.23	Opioid sensitivity;	chr18:79941007	chr18:80046900~80095482:+
BRCA	cis	rs250518	0.926	rs34669	ENSG00000272081.1	CTD-2376I4.2	-7.65	4.5e-14	1.25e-11	-0.29	-0.23	Mean corpuscular hemoglobin concentration;	chr5:72866437	chr5:72955206~72955699:-
BRCA	cis	rs66887589	0.776	rs10518337	ENSG00000248280.1	RP11-33B1.2	-7.65	4.5e-14	1.25e-11	-0.22	-0.23	Diastolic blood pressure;	chr4:119653719	chr4:119440561~119450157:-
BRCA	cis	rs287982	1	rs287981	ENSG00000269973.1	RP11-95D17.1	7.65	4.51e-14	1.25e-11	0.28	0.23	Nonsyndromic cleft lip with cleft palate;	chr2:9831433	chr2:9936360~9939590:+
BRCA	cis	rs113835537	0.597	rs7116921	ENSG00000255517.5	CTD-3074O7.5	-7.65	4.51e-14	1.25e-11	-0.3	-0.23	Airway imaging phenotypes;	chr11:66536383	chr11:66473490~66480233:-
BRCA	cis	rs526231	0.543	rs6880911	ENSG00000175749.11	EIF3KP1	7.65	4.52e-14	1.26e-11	0.34	0.23	Primary biliary cholangitis;	chr5:102971767	chr5:103032376~103033031:+
BRCA	cis	rs7615952	0.599	rs6766327	ENSG00000250012.1	RP11-124N2.1	-7.65	4.52e-14	1.26e-11	-0.32	-0.23	Blood pressure (smoking interaction);	chr3:126004834	chr3:126084220~126095349:+
BRCA	cis	rs17772222	0.876	rs12586348	ENSG00000258983.2	RP11-507K2.2	7.65	4.53e-14	1.26e-11	0.26	0.23	Coronary artery calcification;	chr14:88643523	chr14:88499334~88515502:+
BRCA	cis	rs8031584	0.697	rs8036176	ENSG00000260382.1	RP11-540B6.2	7.65	4.54e-14	1.26e-11	0.28	0.23	Huntington's disease progression;	chr15:30883066	chr15:30882267~30883231:-
BRCA	cis	rs17772222	1	rs17772288	ENSG00000258983.2	RP11-507K2.2	7.65	4.55e-14	1.27e-11	0.25	0.23	Coronary artery calcification;	chr14:88361022	chr14:88499334~88515502:+
BRCA	cis	rs2033711	0.837	rs3764535	ENSG00000269473.1	CTD-2619J13.19	7.65	4.56e-14	1.27e-11	0.27	0.23	Uric acid clearance;	chr19:58417685	chr19:58440448~58445849:+
BRCA	cis	rs875971	0.862	rs35378740	ENSG00000232559.3	GS1-124K5.12	7.65	4.57e-14	1.27e-11	0.28	0.23	Aortic root size;	chr7:66522725	chr7:66554588~66576923:-
BRCA	cis	rs10463554	0.856	rs26260	ENSG00000175749.11	EIF3KP1	7.65	4.58e-14	1.27e-11	0.31	0.23	Parkinson's disease;	chr5:103211493	chr5:103032376~103033031:+
BRCA	cis	rs904251	0.523	rs9369005	ENSG00000204110.6	RP1-153P14.8	-7.65	4.59e-14	1.28e-11	-0.25	-0.23	Cognitive performance;	chr6:37515333	chr6:37507348~37535616:+
BRCA	cis	rs2742234	0.578	rs2742241	ENSG00000273008.1	RP11-351D16.3	-7.65	4.59e-14	1.28e-11	-0.29	-0.23	Hirschsprung disease;	chr10:43129775	chr10:43136824~43138334:-
BRCA	cis	rs2842992	0.915	rs2842958	ENSG00000237927.1	RP3-393E18.2	-7.65	4.6e-14	1.28e-11	-0.33	-0.23	Age-related macular degeneration (geographic atrophy);	chr6:159687393	chr6:159586955~159589169:-
BRCA	cis	rs7267979	0.789	rs6083841	ENSG00000274973.1	RP13-401N8.7	7.65	4.6e-14	1.28e-11	0.27	0.23	Liver enzyme levels (alkaline phosphatase);	chr20:25403928	chr20:25845497~25845862:+
BRCA	cis	rs6545883	0.794	rs12053388	ENSG00000271889.1	RP11-493E12.1	-7.65	4.61e-14	1.28e-11	-0.3	-0.23	Tuberculosis;	chr2:61305185	chr2:61151433~61162105:-
BRCA	cis	rs4842666	0.915	rs6538195	ENSG00000258302.2	RP11-981P6.1	7.65	4.62e-14	1.29e-11	0.28	0.23	Blood pressure;	chr12:89668599	chr12:89561129~89594878:+
BRCA	cis	rs2911132	1	rs2911131	ENSG00000248734.2	CTD-2260A17.1	-7.65	4.63e-14	1.29e-11	-0.27	-0.23	Urate levels (BMI interaction);	chr5:96850246	chr5:96784777~96785999:+
BRCA	cis	rs10510102	0.935	rs12255859	ENSG00000276742.1	RP11-500G22.4	7.65	4.63e-14	1.29e-11	0.4	0.23	Breast cancer;	chr10:121831661	chr10:121956782~121957098:+
BRCA	cis	rs704795	0.867	rs7566052	ENSG00000234072.1	AC074117.10	-7.65	4.65e-14	1.29e-11	-0.22	-0.23	Menopause (age at onset);	chr2:27405768	chr2:27356246~27367622:+
BRCA	cis	rs2243480	0.522	rs431168	ENSG00000226824.5	RP4-756H11.3	-7.65	4.67e-14	1.3e-11	-0.55	-0.23	Diabetic kidney disease;	chr7:66046617	chr7:66654538~66669855:+
BRCA	cis	rs8062405	0.72	rs9926245	ENSG00000251417.2	RP11-1348G14.4	-7.65	4.69e-14	1.3e-11	-0.26	-0.23	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28544385	chr16:28802743~28817828:+
BRCA	cis	rs7727544	0.684	rs272869	ENSG00000233006.5	AC034220.3	7.65	4.7e-14	1.3e-11	0.17	0.23	Blood metabolite levels;	chr5:132342304	chr5:132311285~132369916:-
BRCA	cis	rs10463554	0.892	rs6872442	ENSG00000175749.11	EIF3KP1	7.65	4.7e-14	1.3e-11	0.32	0.23	Parkinson's disease;	chr5:102930818	chr5:103032376~103033031:+
BRCA	cis	rs950776	0.593	rs601079	ENSG00000261762.1	RP11-650L12.2	-7.65	4.7e-14	1.31e-11	-0.25	-0.23	Sudden cardiac arrest;	chr15:78577237	chr15:78589123~78591276:-
BRCA	cis	rs950776	0.593	rs680244	ENSG00000261762.1	RP11-650L12.2	-7.65	4.7e-14	1.31e-11	-0.25	-0.23	Sudden cardiac arrest;	chr15:78578946	chr15:78589123~78591276:-
BRCA	cis	rs10510102	1	rs10886994	ENSG00000276742.1	RP11-500G22.4	7.65	4.7e-14	1.31e-11	0.4	0.23	Breast cancer;	chr10:121841075	chr10:121956782~121957098:+
BRCA	cis	rs2439831	0.85	rs28513374	ENSG00000275601.1	AC011330.13	-7.65	4.7e-14	1.31e-11	-0.37	-0.23	Lung cancer in ever smokers;	chr15:43833297	chr15:43642389~43643023:-
BRCA	cis	rs11976180	1	rs11976037	ENSG00000170356.8	OR2A20P	-7.65	4.7e-14	1.31e-11	-0.33	-0.23	Obesity-related traits;	chr7:144043931	chr7:144250045~144252957:-
BRCA	cis	rs7811142	0.83	rs75636500	ENSG00000242294.5	STAG3L5P	7.65	4.72e-14	1.31e-11	0.25	0.23	Platelet count;	chr7:100350034	chr7:100336079~100351900:+
BRCA	cis	rs2014572	0.904	rs10412465	ENSG00000268379.1	CTC-360J11.4	7.65	4.72e-14	1.31e-11	0.28	0.23	Hyperactive-impulsive symptoms;	chr19:57242563	chr19:57175233~57177921:+
BRCA	cis	rs875971	0.862	rs2420174	ENSG00000232559.3	GS1-124K5.12	-7.65	4.73e-14	1.31e-11	-0.28	-0.23	Aortic root size;	chr7:66180374	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.862	rs2420173	ENSG00000232559.3	GS1-124K5.12	-7.65	4.73e-14	1.31e-11	-0.28	-0.23	Aortic root size;	chr7:66180412	chr7:66554588~66576923:-
BRCA	cis	rs867371	0.717	rs3858954	ENSG00000259429.4	UBE2Q2P2	-7.65	4.73e-14	1.31e-11	-0.24	-0.23	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82265693	chr15:82355142~82420075:+
BRCA	cis	rs17023223	0.537	rs12081585	ENSG00000231365.4	RP11-418J17.1	-7.65	4.73e-14	1.31e-11	-0.31	-0.23	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119073333	chr1:119140396~119275973:+
BRCA	cis	rs2742234	0.541	rs4648313	ENSG00000273008.1	RP11-351D16.3	7.64	4.74e-14	1.32e-11	0.3	0.23	Hirschsprung disease;	chr10:43221291	chr10:43136824~43138334:-
BRCA	cis	rs2742234	0.541	rs10793424	ENSG00000273008.1	RP11-351D16.3	7.64	4.74e-14	1.32e-11	0.3	0.23	Hirschsprung disease;	chr10:43221668	chr10:43136824~43138334:-
BRCA	cis	rs2742234	0.541	rs11238481	ENSG00000273008.1	RP11-351D16.3	7.64	4.74e-14	1.32e-11	0.3	0.23	Hirschsprung disease;	chr10:43223838	chr10:43136824~43138334:-
BRCA	cis	rs2742234	0.541	rs61268333	ENSG00000273008.1	RP11-351D16.3	7.64	4.74e-14	1.32e-11	0.3	0.23	Hirschsprung disease;	chr10:43225922	chr10:43136824~43138334:-
BRCA	cis	rs2742234	0.541	rs60845448	ENSG00000273008.1	RP11-351D16.3	7.64	4.74e-14	1.32e-11	0.3	0.23	Hirschsprung disease;	chr10:43226014	chr10:43136824~43138334:-
BRCA	cis	rs17772222	0.917	rs17188228	ENSG00000258983.2	RP11-507K2.2	7.64	4.74e-14	1.32e-11	0.27	0.23	Coronary artery calcification;	chr14:88738921	chr14:88499334~88515502:+
BRCA	cis	rs7809950	1	rs3801954	ENSG00000238832.1	snoU109	-7.64	4.75e-14	1.32e-11	-0.3	-0.23	Coronary artery disease;	chr7:107476603	chr7:107603363~107603507:+
BRCA	cis	rs2179367	0.632	rs9498348	ENSG00000231760.4	RP11-350J20.5	7.64	4.75e-14	1.32e-11	0.34	0.23	Dupuytren's disease;	chr6:149418352	chr6:149796151~149826294:-
BRCA	cis	rs2179367	0.613	rs62426122	ENSG00000231760.4	RP11-350J20.5	7.64	4.76e-14	1.32e-11	0.33	0.23	Dupuytren's disease;	chr6:149427449	chr6:149796151~149826294:-
BRCA	cis	rs516805	0.847	rs520867	ENSG00000279114.1	RP3-425C14.5	-7.64	4.76e-14	1.32e-11	-0.24	-0.23	Lymphocyte counts;	chr6:122465501	chr6:122471923~122484161:+
BRCA	cis	rs516805	0.961	rs693669	ENSG00000279114.1	RP3-425C14.5	-7.64	4.76e-14	1.32e-11	-0.24	-0.23	Lymphocyte counts;	chr6:122465690	chr6:122471923~122484161:+
BRCA	cis	rs4934494	0.768	rs17126269	ENSG00000240996.1	RP11-80H5.7	-7.64	4.77e-14	1.32e-11	-0.29	-0.23	Red blood cell count;	chr10:89694974	chr10:89694295~89697928:-
BRCA	cis	rs4934494	0.768	rs768805	ENSG00000240996.1	RP11-80H5.7	-7.64	4.77e-14	1.32e-11	-0.29	-0.23	Red blood cell count;	chr10:89695448	chr10:89694295~89697928:-
BRCA	cis	rs4934494	0.768	rs12571268	ENSG00000240996.1	RP11-80H5.7	-7.64	4.77e-14	1.32e-11	-0.29	-0.23	Red blood cell count;	chr10:89698830	chr10:89694295~89697928:-
BRCA	cis	rs5760092	0.572	rs738806	ENSG00000231271.1	AP000350.8	7.64	4.78e-14	1.33e-11	0.32	0.23	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23891985	chr22:23949918~23954042:+
BRCA	cis	rs7811142	0.943	rs10241492	ENSG00000242294.5	STAG3L5P	7.64	4.78e-14	1.33e-11	0.23	0.23	Platelet count;	chr7:100397190	chr7:100336079~100351900:+
BRCA	cis	rs79040073	0.53	rs17476940	ENSG00000259531.2	RP11-295H24.3	-7.64	4.79e-14	1.33e-11	-0.36	-0.23	Lung cancer in ever smokers;	chr15:49332587	chr15:49365124~49366685:-
BRCA	cis	rs10463554	0.856	rs2432169	ENSG00000175749.11	EIF3KP1	7.64	4.79e-14	1.33e-11	0.3	0.23	Parkinson's disease;	chr5:103179056	chr5:103032376~103033031:+
BRCA	cis	rs875971	0.862	rs13232191	ENSG00000232559.3	GS1-124K5.12	7.64	4.81e-14	1.33e-11	0.28	0.23	Aortic root size;	chr7:66521661	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.862	rs10950043	ENSG00000232559.3	GS1-124K5.12	7.64	4.81e-14	1.33e-11	0.28	0.23	Aortic root size;	chr7:66523623	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.862	rs17747530	ENSG00000232559.3	GS1-124K5.12	7.64	4.81e-14	1.33e-11	0.28	0.23	Aortic root size;	chr7:66529742	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.862	rs13536	ENSG00000232559.3	GS1-124K5.12	-7.64	4.81e-14	1.33e-11	-0.28	-0.23	Aortic root size;	chr7:66554203	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.862	rs801209	ENSG00000232559.3	GS1-124K5.12	-7.64	4.81e-14	1.33e-11	-0.28	-0.23	Aortic root size;	chr7:66554403	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.862	rs801206	ENSG00000232559.3	GS1-124K5.12	-7.64	4.81e-14	1.33e-11	-0.28	-0.23	Aortic root size;	chr7:66556979	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.862	rs801204	ENSG00000232559.3	GS1-124K5.12	-7.64	4.81e-14	1.33e-11	-0.28	-0.23	Aortic root size;	chr7:66557934	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.862	rs801203	ENSG00000232559.3	GS1-124K5.12	-7.64	4.81e-14	1.33e-11	-0.28	-0.23	Aortic root size;	chr7:66558025	chr7:66554588~66576923:-
BRCA	cis	rs2842992	0.872	rs2758330	ENSG00000237927.1	RP3-393E18.2	-7.64	4.82e-14	1.34e-11	-0.33	-0.23	Age-related macular degeneration (geographic atrophy);	chr6:159683812	chr6:159586955~159589169:-
BRCA	cis	rs4842666	0.85	rs11105328	ENSG00000258302.2	RP11-981P6.1	7.64	4.82e-14	1.34e-11	0.28	0.23	Blood pressure;	chr12:89548613	chr12:89561129~89594878:+
BRCA	cis	rs4266144	0.544	rs7340627	ENSG00000244515.1	KRT18P34	-7.64	4.84e-14	1.34e-11	-0.27	-0.23	Coronary artery disease;	chr3:157114604	chr3:157162663~157163932:-
BRCA	cis	rs11295209	1	rs11295209	ENSG00000248280.1	RP11-33B1.2	-7.64	4.85e-14	1.35e-11	-0.21	-0.23	Plateletcrit;	chr4:119559079	chr4:119440561~119450157:-
BRCA	cis	rs875971	0.862	rs6460306	ENSG00000232559.3	GS1-124K5.12	-7.64	4.87e-14	1.35e-11	-0.28	-0.23	Aortic root size;	chr7:66595806	chr7:66554588~66576923:-
BRCA	cis	rs2880765	0.835	rs900573	ENSG00000259295.5	CSPG4P12	-7.64	4.87e-14	1.35e-11	-0.28	-0.23	Coronary artery disease;	chr15:85494762	chr15:85191438~85213905:+
BRCA	cis	rs42648	0.935	rs42629	ENSG00000225498.1	AC002064.5	7.64	4.87e-14	1.35e-11	0.22	0.23	Homocysteine levels;	chr7:90334010	chr7:90312496~90322592:+
BRCA	cis	rs8031584	0.706	rs798084	ENSG00000260382.1	RP11-540B6.2	7.64	4.87e-14	1.35e-11	0.29	0.23	Huntington's disease progression;	chr15:30834732	chr15:30882267~30883231:-
BRCA	cis	rs8072100	0.967	rs4794058	ENSG00000228782.6	CTD-2026D20.3	-7.64	4.9e-14	1.36e-11	-0.25	-0.23	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47519732	chr17:47450568~47492492:-
BRCA	cis	rs9880211	1	rs6774964	ENSG00000273486.1	RP11-731C17.2	7.64	4.9e-14	1.36e-11	0.3	0.23	Height;Body mass index;	chr3:136556740	chr3:136837338~136839021:-
BRCA	cis	rs9880211	1	rs6775314	ENSG00000273486.1	RP11-731C17.2	7.64	4.9e-14	1.36e-11	0.3	0.23	Height;Body mass index;	chr3:136557106	chr3:136837338~136839021:-
BRCA	cis	rs287982	0.932	rs58521916	ENSG00000269973.1	RP11-95D17.1	-7.64	4.9e-14	1.36e-11	-0.29	-0.23	Nonsyndromic cleft lip with cleft palate;	chr2:9826341	chr2:9936360~9939590:+
BRCA	cis	rs10510102	0.872	rs56108883	ENSG00000276742.1	RP11-500G22.4	7.64	4.92e-14	1.36e-11	0.4	0.23	Breast cancer;	chr10:121825567	chr10:121956782~121957098:+
BRCA	cis	rs71520386	0.53	rs10256628	ENSG00000228649.7	AC005682.5	-7.64	4.93e-14	1.37e-11	-0.22	-0.23	Fibrinogen levels;	chr7:22843640	chr7:22854178~22861579:+
BRCA	cis	rs875971	0.862	rs2024192	ENSG00000232559.3	GS1-124K5.12	-7.64	4.94e-14	1.37e-11	-0.28	-0.23	Aortic root size;	chr7:66576460	chr7:66554588~66576923:-
BRCA	cis	rs253959	0.672	rs4920903	ENSG00000271918.1	CTD-2287O16.5	7.64	4.94e-14	1.37e-11	0.19	0.23	Bipolar disorder and schizophrenia;	chr5:116085892	chr5:116083807~116085416:-
BRCA	cis	rs875971	0.862	rs2901152	ENSG00000232559.3	GS1-124K5.12	-7.64	4.96e-14	1.37e-11	-0.28	-0.23	Aortic root size;	chr7:66300017	chr7:66554588~66576923:-
BRCA	cis	rs10129255	0.957	rs11847726	ENSG00000211972.2	IGHV3-66	7.64	4.96e-14	1.37e-11	0.18	0.23	Kawasaki disease;	chr14:106779116	chr14:106675017~106675544:-
BRCA	cis	rs867371	0.964	rs7169961	ENSG00000259429.4	UBE2Q2P2	-7.64	4.97e-14	1.38e-11	-0.23	-0.23	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82186588	chr15:82355142~82420075:+
BRCA	cis	rs10510102	0.935	rs11200187	ENSG00000276742.1	RP11-500G22.4	7.64	4.97e-14	1.38e-11	0.4	0.23	Breast cancer;	chr10:121843050	chr10:121956782~121957098:+
BRCA	cis	rs875971	0.767	rs61348003	ENSG00000232559.3	GS1-124K5.12	7.64	4.99e-14	1.38e-11	0.28	0.23	Aortic root size;	chr7:66540947	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.825	rs801202	ENSG00000232559.3	GS1-124K5.12	-7.64	4.99e-14	1.38e-11	-0.28	-0.23	Aortic root size;	chr7:66558942	chr7:66554588~66576923:-
BRCA	cis	rs7567389	0.51	rs1473623	ENSG00000236682.1	AC068282.3	7.64	5e-14	1.39e-11	0.31	0.23	Self-rated health;	chr2:127438644	chr2:127389130~127400580:+
BRCA	cis	rs4934494	0.689	rs17127588	ENSG00000240996.1	RP11-80H5.7	-7.64	5.01e-14	1.39e-11	-0.28	-0.23	Red blood cell count;	chr10:89815887	chr10:89694295~89697928:-
BRCA	cis	rs12468226	1	rs7597156	ENSG00000273456.1	RP11-686O6.2	7.64	5.04e-14	1.39e-11	0.31	0.23	Urate levels;	chr2:202329339	chr2:202374932~202375604:-
BRCA	cis	rs10759883	0.525	rs1556026	ENSG00000175611.10	LINC00476	7.64	5.05e-14	1.4e-11	0.26	0.23	Nicotine dependence;	chr9:96046454	chr9:95759231~95875977:-
BRCA	cis	rs6860806	0.507	rs2631362	ENSG00000233006.5	AC034220.3	-7.64	5.05e-14	1.4e-11	-0.19	-0.23	Breast cancer;	chr5:132371601	chr5:132311285~132369916:-
BRCA	cis	rs2712431	0.554	rs9864772	ENSG00000242551.2	POU5F1P6	-7.64	5.05e-14	1.4e-11	-0.28	-0.23	Monocyte chemoattractant protein-1 levels;	chr3:128598096	chr3:128674735~128677005:-
BRCA	cis	rs2274273	0.529	rs10131562	ENSG00000258413.1	RP11-665C16.6	-7.64	5.06e-14	1.4e-11	-0.3	-0.23	Protein biomarker;	chr14:55380297	chr14:55262767~55272075:-
BRCA	cis	rs6558530	0.692	rs7818406	ENSG00000253982.1	CTD-2336O2.1	7.64	5.06e-14	1.4e-11	0.29	0.23	Systolic blood pressure;	chr8:1753084	chr8:1761990~1764502:-
BRCA	cis	rs6558530	0.692	rs10105317	ENSG00000253982.1	CTD-2336O2.1	7.64	5.06e-14	1.4e-11	0.29	0.23	Systolic blood pressure;	chr8:1753266	chr8:1761990~1764502:-
BRCA	cis	rs9876781	1	rs9876781	ENSG00000244380.1	RP11-24C3.2	7.64	5.07e-14	1.4e-11	0.26	0.23	Longevity;	chr3:48445934	chr3:48440352~48446656:-
BRCA	cis	rs2179367	0.568	rs62426092	ENSG00000231760.4	RP11-350J20.5	7.64	5.08e-14	1.41e-11	0.33	0.23	Dupuytren's disease;	chr6:149352720	chr6:149796151~149826294:-
BRCA	cis	rs2115630	1	rs2115630	ENSG00000225151.9	GOLGA2P7	7.64	5.09e-14	1.41e-11	0.25	0.23	P wave terminal force;	chr15:84821285	chr15:84199311~84230136:-
BRCA	cis	rs77204473	1	rs11216174	ENSG00000254851.1	RP11-109L13.1	7.64	5.09e-14	1.41e-11	0.54	0.23	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116886532	chr11:117135528~117138582:+
BRCA	cis	rs77204473	1	rs11216175	ENSG00000254851.1	RP11-109L13.1	7.64	5.09e-14	1.41e-11	0.54	0.23	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116886682	chr11:117135528~117138582:+
BRCA	cis	rs7246657	0.943	rs10415358	ENSG00000276846.1	CTD-3220F14.3	7.63	5.1e-14	1.41e-11	0.32	0.23	Coronary artery calcification;	chr19:37317961	chr19:37314868~37315620:-
BRCA	cis	rs6921919	0.525	rs6929825	ENSG00000204709.4	LINC01556	7.63	5.11e-14	1.41e-11	0.31	0.23	Autism spectrum disorder or schizophrenia;	chr6:28411182	chr6:28943877~28944537:+
BRCA	cis	rs6921919	0.583	rs35599905	ENSG00000204709.4	LINC01556	7.63	5.11e-14	1.41e-11	0.31	0.23	Autism spectrum disorder or schizophrenia;	chr6:28411886	chr6:28943877~28944537:+
BRCA	cis	rs6921919	0.583	rs1124131	ENSG00000204709.4	LINC01556	7.63	5.11e-14	1.41e-11	0.31	0.23	Autism spectrum disorder or schizophrenia;	chr6:28412471	chr6:28943877~28944537:+
BRCA	cis	rs6921919	0.583	rs6899389	ENSG00000204709.4	LINC01556	7.63	5.11e-14	1.41e-11	0.31	0.23	Autism spectrum disorder or schizophrenia;	chr6:28413363	chr6:28943877~28944537:+
BRCA	cis	rs6921919	0.583	rs6922374	ENSG00000204709.4	LINC01556	7.63	5.11e-14	1.41e-11	0.31	0.23	Autism spectrum disorder or schizophrenia;	chr6:28413495	chr6:28943877~28944537:+
BRCA	cis	rs6921919	0.583	rs6899603	ENSG00000204709.4	LINC01556	7.63	5.11e-14	1.41e-11	0.31	0.23	Autism spectrum disorder or schizophrenia;	chr6:28413528	chr6:28943877~28944537:+
BRCA	cis	rs6921919	0.583	rs6922429	ENSG00000204709.4	LINC01556	7.63	5.11e-14	1.41e-11	0.31	0.23	Autism spectrum disorder or schizophrenia;	chr6:28413568	chr6:28943877~28944537:+
BRCA	cis	rs875971	0.862	rs13226170	ENSG00000232559.3	GS1-124K5.12	7.63	5.11e-14	1.42e-11	0.28	0.23	Aortic root size;	chr7:66534311	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.862	rs2420611	ENSG00000232559.3	GS1-124K5.12	7.63	5.11e-14	1.42e-11	0.28	0.23	Aortic root size;	chr7:66534333	chr7:66554588~66576923:-
BRCA	cis	rs7115242	1	rs7115242	ENSG00000280143.1	AP000892.6	-7.63	5.11e-14	1.42e-11	-0.35	-0.23	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117037567	chr11:117204967~117210292:+
BRCA	cis	rs4835473	0.897	rs28825455	ENSG00000251600.4	RP11-673E1.1	7.63	5.12e-14	1.42e-11	0.28	0.23	Immature fraction of reticulocytes;	chr4:143707593	chr4:143912331~143982454:+
BRCA	cis	rs2243480	1	rs313802	ENSG00000273142.1	RP11-458F8.4	-7.63	5.12e-14	1.42e-11	-0.33	-0.23	Diabetic kidney disease;	chr7:66051386	chr7:66902857~66906297:+
BRCA	cis	rs2243480	0.803	rs403089	ENSG00000273142.1	RP11-458F8.4	-7.63	5.12e-14	1.42e-11	-0.33	-0.23	Diabetic kidney disease;	chr7:66052736	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs458291	ENSG00000273142.1	RP11-458F8.4	-7.63	5.12e-14	1.42e-11	-0.33	-0.23	Diabetic kidney disease;	chr7:66055492	chr7:66902857~66906297:+
BRCA	cis	rs875971	0.545	rs1547529	ENSG00000224316.1	RP11-479O9.2	7.63	5.13e-14	1.42e-11	0.26	0.23	Aortic root size;	chr7:66258859	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.862	rs801194	ENSG00000232559.3	GS1-124K5.12	-7.63	5.13e-14	1.42e-11	-0.28	-0.23	Aortic root size;	chr7:66563508	chr7:66554588~66576923:-
BRCA	cis	rs77204473	1	rs12416987	ENSG00000254851.1	RP11-109L13.1	7.63	5.14e-14	1.42e-11	0.54	0.23	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116883549	chr11:117135528~117138582:+
BRCA	cis	rs6545883	0.929	rs1838978	ENSG00000271889.1	RP11-493E12.1	-7.63	5.15e-14	1.42e-11	-0.3	-0.23	Tuberculosis;	chr2:61313788	chr2:61151433~61162105:-
BRCA	cis	rs1552244	0.882	rs13084194	ENSG00000180385.7	EMC3-AS1	7.63	5.17e-14	1.43e-11	0.31	0.23	Alzheimer's disease;	chr3:9989808	chr3:9986893~10006990:+
BRCA	cis	rs1552244	0.882	rs13099507	ENSG00000180385.7	EMC3-AS1	7.63	5.17e-14	1.43e-11	0.31	0.23	Alzheimer's disease;	chr3:9989919	chr3:9986893~10006990:+
BRCA	cis	rs2243480	1	rs410128	ENSG00000273142.1	RP11-458F8.4	-7.63	5.17e-14	1.43e-11	-0.33	-0.23	Diabetic kidney disease;	chr7:66138186	chr7:66902857~66906297:+
BRCA	cis	rs3762637	1	rs10049131	ENSG00000272758.4	RP11-299J3.8	-7.63	5.17e-14	1.43e-11	-0.33	-0.23	LDL cholesterol levels;	chr3:122483255	chr3:122416207~122443180:+
BRCA	cis	rs875971	1	rs11971949	ENSG00000232559.3	GS1-124K5.12	-7.63	5.17e-14	1.43e-11	-0.27	-0.23	Aortic root size;	chr7:66161027	chr7:66554588~66576923:-
BRCA	cis	rs6142102	0.812	rs6059558	ENSG00000276073.1	RP5-1125A11.7	-7.63	5.19e-14	1.44e-11	-0.28	-0.23	Skin pigmentation;	chr20:33929024	chr20:33985617~33988989:-
BRCA	cis	rs9880211	0.948	rs1604793	ENSG00000273486.1	RP11-731C17.2	7.63	5.2e-14	1.44e-11	0.31	0.23	Height;Body mass index;	chr3:136462228	chr3:136837338~136839021:-
BRCA	cis	rs17711722	0.522	rs4642526	ENSG00000273024.4	INTS4P2	-7.63	5.21e-14	1.44e-11	-0.26	-0.23	Calcium levels;	chr7:65751755	chr7:65647864~65715661:+
BRCA	cis	rs7927771	0.832	rs896816	ENSG00000280615.1	Y_RNA	7.63	5.22e-14	1.44e-11	0.28	0.23	Subjective well-being;	chr11:47372787	chr11:47614898~47614994:-
BRCA	cis	rs6921919	0.525	rs11760133	ENSG00000204709.4	LINC01556	7.63	5.23e-14	1.44e-11	0.31	0.23	Autism spectrum disorder or schizophrenia;	chr6:28418962	chr6:28943877~28944537:+
BRCA	cis	rs287982	0.932	rs9973654	ENSG00000269973.1	RP11-95D17.1	-7.63	5.24e-14	1.45e-11	-0.29	-0.23	Nonsyndromic cleft lip with cleft palate;	chr2:9822439	chr2:9936360~9939590:+
BRCA	cis	rs875971	0.862	rs778736	ENSG00000232559.3	GS1-124K5.12	7.63	5.25e-14	1.45e-11	0.28	0.23	Aortic root size;	chr7:66348861	chr7:66554588~66576923:-
BRCA	cis	rs1075265	0.597	rs10490471	ENSG00000233266.1	HMGB1P31	7.63	5.26e-14	1.45e-11	0.28	0.23	Chronotype;Morning vs. evening chronotype;	chr2:53769446	chr2:54051334~54051760:+
BRCA	cis	rs4835473	0.897	rs1450249	ENSG00000251600.4	RP11-673E1.1	7.63	5.26e-14	1.45e-11	0.28	0.23	Immature fraction of reticulocytes;	chr4:143724425	chr4:143912331~143982454:+
BRCA	cis	rs10463554	1	rs56372231	ENSG00000175749.11	EIF3KP1	7.63	5.26e-14	1.45e-11	0.32	0.23	Parkinson's disease;	chr5:102986201	chr5:103032376~103033031:+
BRCA	cis	rs6860806	0.507	rs272883	ENSG00000233006.5	AC034220.3	7.63	5.28e-14	1.46e-11	0.19	0.23	Breast cancer;	chr5:132333005	chr5:132311285~132369916:-
BRCA	cis	rs6860806	0.507	rs272882	ENSG00000233006.5	AC034220.3	7.63	5.28e-14	1.46e-11	0.19	0.23	Breast cancer;	chr5:132333468	chr5:132311285~132369916:-
BRCA	cis	rs2243480	1	rs422164	ENSG00000273142.1	RP11-458F8.4	-7.63	5.28e-14	1.46e-11	-0.32	-0.23	Diabetic kidney disease;	chr7:66121618	chr7:66902857~66906297:+
BRCA	cis	rs6539288	0.77	rs1468908	ENSG00000260329.1	RP11-412D9.4	-7.63	5.28e-14	1.46e-11	-0.26	-0.23	Total body bone mineral density;	chr12:106904539	chr12:106954029~106955497:-
BRCA	cis	rs6539288	0.933	rs1470380	ENSG00000260329.1	RP11-412D9.4	-7.63	5.28e-14	1.46e-11	-0.26	-0.23	Total body bone mineral density;	chr12:106904961	chr12:106954029~106955497:-
BRCA	cis	rs801193	1	rs2003301	ENSG00000237310.1	GS1-124K5.4	-7.63	5.29e-14	1.46e-11	-0.24	-0.23	Aortic root size;	chr7:66682669	chr7:66493706~66495474:+
BRCA	cis	rs12188164	0.525	rs1114665	ENSG00000225138.6	CTD-2228K2.7	-7.63	5.29e-14	1.46e-11	-0.25	-0.23	Cystic fibrosis severity;	chr5:452132	chr5:473236~480884:+
BRCA	cis	rs516805	0.961	rs483933	ENSG00000279114.1	RP3-425C14.5	-7.63	5.29e-14	1.46e-11	-0.24	-0.23	Lymphocyte counts;	chr6:122460377	chr6:122471923~122484161:+
BRCA	cis	rs4835473	0.714	rs10013005	ENSG00000251600.4	RP11-673E1.1	7.63	5.29e-14	1.46e-11	0.28	0.23	Immature fraction of reticulocytes;	chr4:143711351	chr4:143912331~143982454:+
BRCA	cis	rs853679	0.567	rs3799499	ENSG00000204709.4	LINC01556	7.63	5.3e-14	1.46e-11	0.34	0.23	Depression;	chr6:28386473	chr6:28943877~28944537:+
BRCA	cis	rs853679	0.567	rs2232427	ENSG00000204709.4	LINC01556	7.63	5.3e-14	1.46e-11	0.34	0.23	Depression;	chr6:28391932	chr6:28943877~28944537:+
BRCA	cis	rs526231	0.578	rs3776870	ENSG00000175749.11	EIF3KP1	7.63	5.31e-14	1.47e-11	0.33	0.23	Primary biliary cholangitis;	chr5:102959366	chr5:103032376~103033031:+
BRCA	cis	rs4835473	0.932	rs1849113	ENSG00000251600.4	RP11-673E1.1	-7.63	5.31e-14	1.47e-11	-0.28	-0.23	Immature fraction of reticulocytes;	chr4:143962512	chr4:143912331~143982454:+
BRCA	cis	rs7811142	0.943	rs66958101	ENSG00000242294.5	STAG3L5P	7.63	5.33e-14	1.47e-11	0.22	0.23	Platelet count;	chr7:100476397	chr7:100336079~100351900:+
BRCA	cis	rs516805	0.961	rs1267942	ENSG00000279114.1	RP3-425C14.5	-7.63	5.33e-14	1.47e-11	-0.24	-0.23	Lymphocyte counts;	chr6:122472375	chr6:122471923~122484161:+
BRCA	cis	rs2179367	0.632	rs11155649	ENSG00000231760.4	RP11-350J20.5	7.63	5.34e-14	1.48e-11	0.33	0.23	Dupuytren's disease;	chr6:149405830	chr6:149796151~149826294:-
BRCA	cis	rs2279440	0.759	rs7642020	ENSG00000206573.7	THUMPD3-AS1	7.63	5.34e-14	1.48e-11	0.26	0.23	Glucose homeostasis traits;	chr3:9480796	chr3:9349689~9398579:-
BRCA	cis	rs2439831	0.85	rs12442297	ENSG00000275601.1	AC011330.13	-7.63	5.35e-14	1.48e-11	-0.38	-0.23	Lung cancer in ever smokers;	chr15:43876272	chr15:43642389~43643023:-
BRCA	cis	rs881375	0.678	rs2416804	ENSG00000226752.6	PSMD5-AS1	7.63	5.35e-14	1.48e-11	0.28	0.23	Rheumatoid arthritis;	chr9:120914118	chr9:120824828~120854385:+
BRCA	cis	rs11098499	0.657	rs10434028	ENSG00000248280.1	RP11-33B1.2	7.63	5.36e-14	1.48e-11	0.23	0.23	Corneal astigmatism;	chr4:119373309	chr4:119440561~119450157:-
BRCA	cis	rs293748	0.771	rs158410	ENSG00000250155.1	CTD-2353F22.1	-7.63	5.36e-14	1.48e-11	-0.33	-0.23	Obesity-related traits;	chr5:36858559	chr5:36666214~36725195:-
BRCA	cis	rs4835473	0.897	rs7695328	ENSG00000251600.4	RP11-673E1.1	7.63	5.37e-14	1.48e-11	0.27	0.23	Immature fraction of reticulocytes;	chr4:143703768	chr4:143912331~143982454:+
BRCA	cis	rs875971	0.756	rs2901210	ENSG00000232559.3	GS1-124K5.12	-7.63	5.37e-14	1.48e-11	-0.28	-0.23	Aortic root size;	chr7:66552518	chr7:66554588~66576923:-
BRCA	cis	rs42648	0.935	rs42644	ENSG00000225498.1	AC002064.5	7.63	5.37e-14	1.48e-11	0.22	0.23	Homocysteine levels;	chr7:90345550	chr7:90312496~90322592:+
BRCA	cis	rs4835473	0.897	rs1817027	ENSG00000251600.4	RP11-673E1.1	-7.63	5.37e-14	1.48e-11	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143713336	chr4:143912331~143982454:+
BRCA	cis	rs897984	0.542	rs11865038	ENSG00000260911.2	RP11-196G11.2	7.63	5.38e-14	1.48e-11	0.21	0.23	Dementia with Lewy bodies;	chr16:31083850	chr16:31043150~31049868:+
BRCA	cis	rs897984	0.542	rs11864806	ENSG00000260911.2	RP11-196G11.2	7.63	5.38e-14	1.48e-11	0.21	0.23	Dementia with Lewy bodies;	chr16:31083883	chr16:31043150~31049868:+
BRCA	cis	rs897984	0.542	rs7199949	ENSG00000260911.2	RP11-196G11.2	7.63	5.38e-14	1.48e-11	0.21	0.23	Dementia with Lewy bodies;	chr16:31084843	chr16:31043150~31049868:+
BRCA	cis	rs904251	0.523	rs12202055	ENSG00000204110.6	RP1-153P14.8	-7.63	5.38e-14	1.48e-11	-0.26	-0.23	Cognitive performance;	chr6:37518304	chr6:37507348~37535616:+
BRCA	cis	rs6142102	0.961	rs2284387	ENSG00000276073.1	RP5-1125A11.7	-7.63	5.39e-14	1.49e-11	-0.28	-0.23	Skin pigmentation;	chr20:34056782	chr20:33985617~33988989:-
BRCA	cis	rs2243480	1	rs316313	ENSG00000273142.1	RP11-458F8.4	-7.63	5.39e-14	1.49e-11	-0.32	-0.23	Diabetic kidney disease;	chr7:66128561	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs316312	ENSG00000273142.1	RP11-458F8.4	-7.63	5.39e-14	1.49e-11	-0.32	-0.23	Diabetic kidney disease;	chr7:66131504	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs419603	ENSG00000273142.1	RP11-458F8.4	-7.63	5.39e-14	1.49e-11	-0.32	-0.23	Diabetic kidney disease;	chr7:66132354	chr7:66902857~66906297:+
BRCA	cis	rs293748	0.54	rs12652735	ENSG00000250155.1	CTD-2353F22.1	-7.63	5.41e-14	1.49e-11	-0.31	-0.23	Obesity-related traits;	chr5:37230629	chr5:36666214~36725195:-
BRCA	cis	rs2179367	0.632	rs11155650	ENSG00000231760.4	RP11-350J20.5	7.63	5.41e-14	1.49e-11	0.33	0.23	Dupuytren's disease;	chr6:149407613	chr6:149796151~149826294:-
BRCA	cis	rs2179367	0.632	rs11155651	ENSG00000231760.4	RP11-350J20.5	7.63	5.41e-14	1.49e-11	0.33	0.23	Dupuytren's disease;	chr6:149408146	chr6:149796151~149826294:-
BRCA	cis	rs2179367	0.632	rs7896	ENSG00000231760.4	RP11-350J20.5	7.63	5.41e-14	1.49e-11	0.33	0.23	Dupuytren's disease;	chr6:149410340	chr6:149796151~149826294:-
BRCA	cis	rs62388641	0.539	rs56016631	ENSG00000272279.1	RP11-157J24.2	7.63	5.41e-14	1.49e-11	0.28	0.23	Daytime sleep phenotypes;	chr6:1542340	chr6:1528364~1528911:-
BRCA	cis	rs4835473	0.932	rs7697916	ENSG00000251600.4	RP11-673E1.1	-7.63	5.43e-14	1.5e-11	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143765628	chr4:143912331~143982454:+
BRCA	cis	rs807029	0.577	rs701834	ENSG00000272572.1	RP11-179B2.2	-7.63	5.45e-14	1.5e-11	-0.3	-0.23	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:101002044	chr10:100911103~100912739:-
BRCA	cis	rs113835537	0.627	rs11227534	ENSG00000255517.5	CTD-3074O7.5	-7.63	5.46e-14	1.51e-11	-0.3	-0.23	Airway imaging phenotypes;	chr11:66568700	chr11:66473490~66480233:-
BRCA	cis	rs7131987	0.585	rs2059362	ENSG00000257176.2	RP11-996F15.2	7.63	5.47e-14	1.51e-11	0.27	0.23	QT interval;	chr12:29243072	chr12:29280418~29317848:-
BRCA	cis	rs301901	0.895	rs292172	ENSG00000250155.1	CTD-2353F22.1	-7.63	5.48e-14	1.51e-11	-0.25	-0.23	Height;	chr5:36817237	chr5:36666214~36725195:-
BRCA	cis	rs10129255	0.518	rs10136903	ENSG00000211970.3	IGHV4-61	-7.62	5.49e-14	1.52e-11	-0.15	-0.23	Kawasaki disease;	chr14:106778866	chr14:106639119~106639657:-
BRCA	cis	rs2179367	0.959	rs536203	ENSG00000231760.4	RP11-350J20.5	7.62	5.5e-14	1.52e-11	0.3	0.23	Dupuytren's disease;	chr6:149330128	chr6:149796151~149826294:-
BRCA	cis	rs2179367	0.632	rs12196750	ENSG00000231760.4	RP11-350J20.5	7.62	5.5e-14	1.52e-11	0.33	0.23	Dupuytren's disease;	chr6:149413335	chr6:149796151~149826294:-
BRCA	cis	rs7520050	0.807	rs6656279	ENSG00000280836.1	AL355480.1	-7.62	5.5e-14	1.52e-11	-0.27	-0.23	Reticulocyte count;Red blood cell count;	chr1:45658416	chr1:45581219~45581321:-
BRCA	cis	rs7520050	0.807	rs6671802	ENSG00000280836.1	AL355480.1	-7.62	5.5e-14	1.52e-11	-0.27	-0.23	Reticulocyte count;Red blood cell count;	chr1:45658991	chr1:45581219~45581321:-
BRCA	cis	rs2179367	0.919	rs577001	ENSG00000231760.4	RP11-350J20.5	7.62	5.51e-14	1.52e-11	0.3	0.23	Dupuytren's disease;	chr6:149325172	chr6:149796151~149826294:-
BRCA	cis	rs77204473	1	rs10892040	ENSG00000254851.1	RP11-109L13.1	7.62	5.51e-14	1.52e-11	0.54	0.23	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116886270	chr11:117135528~117138582:+
BRCA	cis	rs2115630	0.791	rs2008262	ENSG00000225151.9	GOLGA2P7	7.62	5.52e-14	1.52e-11	0.26	0.23	P wave terminal force;	chr15:84762039	chr15:84199311~84230136:-
BRCA	cis	rs7474896	0.583	rs10827818	ENSG00000226578.1	RP11-258F22.1	-7.62	5.55e-14	1.53e-11	-0.3	-0.23	Obesity (extreme);	chr10:37711928	chr10:37775371~37784131:-
BRCA	cis	rs250518	0.926	rs10942402	ENSG00000272081.1	CTD-2376I4.2	-7.62	5.55e-14	1.53e-11	-0.29	-0.23	Mean corpuscular hemoglobin concentration;	chr5:72760272	chr5:72955206~72955699:-
BRCA	cis	rs3758911	1	rs3758911	ENSG00000255353.1	RP11-382M14.1	-7.62	5.56e-14	1.53e-11	-0.3	-0.23	Coronary artery disease;	chr11:107326914	chr11:107176286~107177530:+
BRCA	cis	rs3758911	1	rs11212159	ENSG00000255353.1	RP11-382M14.1	-7.62	5.57e-14	1.54e-11	-0.3	-0.23	Coronary artery disease;	chr11:107326003	chr11:107176286~107177530:+
BRCA	cis	rs3758911	1	rs11212160	ENSG00000255353.1	RP11-382M14.1	-7.62	5.57e-14	1.54e-11	-0.3	-0.23	Coronary artery disease;	chr11:107326192	chr11:107176286~107177530:+
BRCA	cis	rs6539288	0.933	rs1037011	ENSG00000260329.1	RP11-412D9.4	-7.62	5.6e-14	1.54e-11	-0.26	-0.23	Total body bone mineral density;	chr12:106909000	chr12:106954029~106955497:-
BRCA	cis	rs904251	0.504	rs9380677	ENSG00000204110.6	RP1-153P14.8	-7.62	5.6e-14	1.54e-11	-0.26	-0.23	Cognitive performance;	chr6:37512590	chr6:37507348~37535616:+
BRCA	cis	rs30380	1	rs27529	ENSG00000272109.1	CTD-2260A17.3	-7.62	5.61e-14	1.55e-11	-0.29	-0.23	Cerebrospinal fluid biomarker levels;	chr5:96790605	chr5:96804353~96806105:+
BRCA	cis	rs858239	0.6	rs7799422	ENSG00000230042.1	AK3P3	-7.62	5.63e-14	1.55e-11	-0.26	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23088794	chr7:23129178~23129841:+
BRCA	cis	rs11098499	0.722	rs1814814	ENSG00000248280.1	RP11-33B1.2	7.62	5.64e-14	1.55e-11	0.22	0.23	Corneal astigmatism;	chr4:119336969	chr4:119440561~119450157:-
BRCA	cis	rs1113500	0.787	rs10881502	ENSG00000226822.1	RP11-356N1.2	-7.62	5.64e-14	1.55e-11	-0.29	-0.23	Growth-regulated protein alpha levels;	chr1:108099197	chr1:108071482~108074519:+
BRCA	cis	rs8072100	0.79	rs11079783	ENSG00000228782.6	CTD-2026D20.3	-7.62	5.65e-14	1.56e-11	-0.25	-0.23	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47608650	chr17:47450568~47492492:-
BRCA	cis	rs3781264	0.595	rs11187881	ENSG00000273450.1	RP11-76P2.4	7.62	5.66e-14	1.56e-11	0.3	0.23	Esophageal cancer and gastric cancer;	chr10:94335697	chr10:94314907~94315327:-
BRCA	cis	rs1609391	0.543	rs9881139	ENSG00000273486.1	RP11-731C17.2	7.62	5.66e-14	1.56e-11	0.25	0.23	Neuroticism;	chr3:136915198	chr3:136837338~136839021:-
BRCA	cis	rs2297363	1	rs3777411	ENSG00000213073.4	RP11-288H12.3	-7.62	5.67e-14	1.56e-11	-0.26	-0.23	Total cholesterol levels;Blood protein levels;	chr6:160055913	chr6:160093082~160096212:+
BRCA	cis	rs875971	0.66	rs7807944	ENSG00000224316.1	RP11-479O9.2	-7.62	5.68e-14	1.56e-11	-0.23	-0.23	Aortic root size;	chr7:66622208	chr7:65773620~65802067:+
BRCA	cis	rs957448	0.698	rs116348949	ENSG00000253704.1	RP11-267M23.4	7.62	5.71e-14	1.57e-11	0.25	0.23	Nonsyndromic cleft lip with cleft palate;	chr8:94557488	chr8:94553722~94569745:+
BRCA	cis	rs6539288	0.933	rs6539289	ENSG00000260329.1	RP11-412D9.4	7.62	5.72e-14	1.58e-11	0.26	0.23	Total body bone mineral density;	chr12:106915538	chr12:106954029~106955497:-
BRCA	cis	rs3762637	0.943	rs28372690	ENSG00000272758.4	RP11-299J3.8	-7.62	5.72e-14	1.58e-11	-0.34	-0.23	LDL cholesterol levels;	chr3:122564248	chr3:122416207~122443180:+
BRCA	cis	rs13068223	0.819	rs11917436	ENSG00000243926.1	TIPARP-AS1	7.62	5.72e-14	1.58e-11	0.23	0.23	Age-related hearing impairment (SNP x SNP interaction);	chr3:156747839	chr3:156671862~156674378:-
BRCA	cis	rs516805	0.847	rs520046	ENSG00000279114.1	RP3-425C14.5	-7.62	5.73e-14	1.58e-11	-0.23	-0.23	Lymphocyte counts;	chr6:122446048	chr6:122471923~122484161:+
BRCA	cis	rs113835537	0.66	rs7116940	ENSG00000255517.5	CTD-3074O7.5	-7.62	5.73e-14	1.58e-11	-0.3	-0.23	Airway imaging phenotypes;	chr11:66536424	chr11:66473490~66480233:-
BRCA	cis	rs2348418	0.733	rs7137557	ENSG00000247934.4	RP11-967K21.1	7.62	5.74e-14	1.58e-11	0.26	0.23	Lung function (FEV1);Lung function (FVC);	chr12:28221259	chr12:28163298~28190738:-
BRCA	cis	rs897984	0.513	rs17839568	ENSG00000260911.2	RP11-196G11.2	7.62	5.74e-14	1.58e-11	0.21	0.23	Dementia with Lewy bodies;	chr16:31088462	chr16:31043150~31049868:+
BRCA	cis	rs858239	0.899	rs7794684	ENSG00000230042.1	AK3P3	-7.62	5.74e-14	1.58e-11	-0.27	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23271186	chr7:23129178~23129841:+
BRCA	cis	rs2179367	0.632	rs66672129	ENSG00000231760.4	RP11-350J20.5	7.62	5.75e-14	1.58e-11	0.33	0.23	Dupuytren's disease;	chr6:149334387	chr6:149796151~149826294:-
BRCA	cis	rs2179367	0.632	rs9498322	ENSG00000231760.4	RP11-350J20.5	7.62	5.75e-14	1.58e-11	0.33	0.23	Dupuytren's disease;	chr6:149335950	chr6:149796151~149826294:-
BRCA	cis	rs2179367	0.632	rs9498323	ENSG00000231760.4	RP11-350J20.5	7.62	5.75e-14	1.58e-11	0.33	0.23	Dupuytren's disease;	chr6:149336077	chr6:149796151~149826294:-
BRCA	cis	rs2179367	0.632	rs12204793	ENSG00000231760.4	RP11-350J20.5	7.62	5.75e-14	1.58e-11	0.33	0.23	Dupuytren's disease;	chr6:149340102	chr6:149796151~149826294:-
BRCA	cis	rs7169304	0.531	rs59356430	ENSG00000259531.2	RP11-295H24.3	7.62	5.76e-14	1.58e-11	0.34	0.23	Lung cancer;Lung cancer in ever smokers;Lung adenocarcinoma;	chr15:49324835	chr15:49365124~49366685:-
BRCA	cis	rs2243480	1	rs387676	ENSG00000273142.1	RP11-458F8.4	-7.62	5.78e-14	1.59e-11	-0.32	-0.23	Diabetic kidney disease;	chr7:66133233	chr7:66902857~66906297:+
BRCA	cis	rs780096	0.546	rs7563162	ENSG00000234072.1	AC074117.10	-7.62	5.78e-14	1.59e-11	-0.22	-0.23	Total body bone mineral density;	chr2:27408324	chr2:27356246~27367622:+
BRCA	cis	rs274567	0.55	rs272885	ENSG00000233006.5	AC034220.3	7.62	5.79e-14	1.59e-11	0.19	0.23	Blood metabolite levels;	chr5:132332043	chr5:132311285~132369916:-
BRCA	cis	rs875971	0.66	rs7807944	ENSG00000237310.1	GS1-124K5.4	-7.62	5.8e-14	1.59e-11	-0.24	-0.23	Aortic root size;	chr7:66622208	chr7:66493706~66495474:+
BRCA	cis	rs62103177	0.608	rs59300126	ENSG00000261126.6	RP11-795F19.1	7.62	5.83e-14	1.6e-11	0.33	0.23	Opioid sensitivity;	chr18:79934439	chr18:80046900~80095482:+
BRCA	cis	rs891378	0.785	rs1896956	ENSG00000274245.1	RP11-357P18.2	-7.62	5.83e-14	1.6e-11	-0.29	-0.23	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207236302	chr1:207372559~207373252:+
BRCA	cis	rs6921919	0.583	rs35560946	ENSG00000204709.4	LINC01556	7.62	5.84e-14	1.61e-11	0.31	0.23	Autism spectrum disorder or schizophrenia;	chr6:28427660	chr6:28943877~28944537:+
BRCA	cis	rs875971	1	rs709597	ENSG00000232559.3	GS1-124K5.12	-7.62	5.84e-14	1.61e-11	-0.27	-0.23	Aortic root size;	chr7:66360996	chr7:66554588~66576923:-
BRCA	cis	rs9649213	0.574	rs34817002	ENSG00000272950.1	RP11-307C18.1	7.62	5.85e-14	1.61e-11	0.3	0.23	Prostate cancer (SNP x SNP interaction);	chr7:98257739	chr7:98322853~98323430:+
BRCA	cis	rs950027	0.538	rs635205	ENSG00000259520.4	CTD-2651B20.3	-7.62	5.85e-14	1.61e-11	-0.28	-0.23	Response to fenofibrate (adiponectin levels);	chr15:45656186	chr15:45251580~45279251:-
BRCA	cis	rs6570726	0.935	rs585292	ENSG00000235652.6	RP11-545I5.3	7.62	5.85e-14	1.61e-11	0.22	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145541092	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.837	rs419991	ENSG00000235652.6	RP11-545I5.3	7.62	5.85e-14	1.61e-11	0.22	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145543076	chr6:145799409~145886585:+
BRCA	cis	rs7927771	1	rs34910028	ENSG00000280615.1	Y_RNA	-7.62	5.86e-14	1.61e-11	-0.29	-0.23	Subjective well-being;	chr11:47736897	chr11:47614898~47614994:-
BRCA	cis	rs11602339	1	rs11602339	ENSG00000280615.1	Y_RNA	-7.62	5.86e-14	1.61e-11	-0.29	-0.23	Body mass index;	chr11:47739919	chr11:47614898~47614994:-
BRCA	cis	rs7927771	1	rs12421210	ENSG00000280615.1	Y_RNA	-7.62	5.86e-14	1.61e-11	-0.29	-0.23	Subjective well-being;	chr11:47758034	chr11:47614898~47614994:-
BRCA	cis	rs7927771	1	rs7927771	ENSG00000280615.1	Y_RNA	-7.62	5.86e-14	1.61e-11	-0.29	-0.23	Subjective well-being;	chr11:47759754	chr11:47614898~47614994:-
BRCA	cis	rs7927771	1	rs12361031	ENSG00000280615.1	Y_RNA	-7.62	5.86e-14	1.61e-11	-0.29	-0.23	Subjective well-being;	chr11:47761524	chr11:47614898~47614994:-
BRCA	cis	rs7927771	1	rs7947730	ENSG00000280615.1	Y_RNA	-7.62	5.86e-14	1.61e-11	-0.29	-0.23	Subjective well-being;	chr11:47764632	chr11:47614898~47614994:-
BRCA	cis	rs7927771	1	rs35902101	ENSG00000280615.1	Y_RNA	-7.62	5.86e-14	1.61e-11	-0.29	-0.23	Subjective well-being;	chr11:47773617	chr11:47614898~47614994:-
BRCA	cis	rs7927771	1	rs11039390	ENSG00000280615.1	Y_RNA	-7.62	5.86e-14	1.61e-11	-0.29	-0.23	Subjective well-being;	chr11:47774743	chr11:47614898~47614994:-
BRCA	cis	rs875971	0.545	rs316324	ENSG00000224316.1	RP11-479O9.2	-7.62	5.86e-14	1.61e-11	-0.26	-0.23	Aortic root size;	chr7:66145627	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.545	rs316323	ENSG00000224316.1	RP11-479O9.2	-7.62	5.86e-14	1.61e-11	-0.26	-0.23	Aortic root size;	chr7:66146002	chr7:65773620~65802067:+
BRCA	cis	rs9880211	1	rs9812579	ENSG00000273486.1	RP11-731C17.2	7.62	5.86e-14	1.61e-11	0.31	0.23	Height;Body mass index;	chr3:136432408	chr3:136837338~136839021:-
BRCA	cis	rs1552244	0.882	rs55962400	ENSG00000180385.7	EMC3-AS1	7.62	5.86e-14	1.61e-11	0.31	0.23	Alzheimer's disease;	chr3:10002773	chr3:9986893~10006990:+
BRCA	cis	rs3758911	0.894	rs10890717	ENSG00000255353.1	RP11-382M14.1	-7.62	5.86e-14	1.61e-11	-0.31	-0.23	Coronary artery disease;	chr11:107324666	chr11:107176286~107177530:+
BRCA	cis	rs2033711	0.87	rs7409473	ENSG00000269473.1	CTD-2619J13.19	7.62	5.86e-14	1.61e-11	0.27	0.23	Uric acid clearance;	chr19:58427798	chr19:58440448~58445849:+
BRCA	cis	rs2033711	0.87	rs7408188	ENSG00000269473.1	CTD-2619J13.19	7.62	5.86e-14	1.61e-11	0.27	0.23	Uric acid clearance;	chr19:58428022	chr19:58440448~58445849:+
BRCA	cis	rs875971	0.862	rs12537823	ENSG00000232559.3	GS1-124K5.12	7.62	5.87e-14	1.61e-11	0.28	0.23	Aortic root size;	chr7:66255897	chr7:66554588~66576923:-
BRCA	cis	rs9880211	0.8	rs9813376	ENSG00000273486.1	RP11-731C17.2	7.62	5.87e-14	1.62e-11	0.31	0.23	Height;Body mass index;	chr3:136756584	chr3:136837338~136839021:-
BRCA	cis	rs6921919	0.789	rs17301128	ENSG00000204709.4	LINC01556	7.62	5.88e-14	1.62e-11	0.34	0.23	Autism spectrum disorder or schizophrenia;	chr6:28340257	chr6:28943877~28944537:+
BRCA	cis	rs2243480	1	rs316307	ENSG00000273142.1	RP11-458F8.4	-7.62	5.88e-14	1.62e-11	-0.32	-0.23	Diabetic kidney disease;	chr7:66105184	chr7:66902857~66906297:+
BRCA	cis	rs801193	1	rs6975195	ENSG00000237310.1	GS1-124K5.4	-7.61	5.94e-14	1.63e-11	-0.24	-0.23	Aortic root size;	chr7:66659787	chr7:66493706~66495474:+
BRCA	cis	rs904251	0.523	rs2776874	ENSG00000204110.6	RP1-153P14.8	-7.61	5.95e-14	1.63e-11	-0.25	-0.23	Cognitive performance;	chr6:37515421	chr6:37507348~37535616:+
BRCA	cis	rs2880765	0.835	rs6496027	ENSG00000259295.5	CSPG4P12	7.61	5.95e-14	1.64e-11	0.28	0.23	Coronary artery disease;	chr15:85506757	chr15:85191438~85213905:+
BRCA	cis	rs875971	0.66	rs7807930	ENSG00000224316.1	RP11-479O9.2	-7.61	5.96e-14	1.64e-11	-0.23	-0.23	Aortic root size;	chr7:66622178	chr7:65773620~65802067:+
BRCA	cis	rs2179367	0.632	rs9498324	ENSG00000231760.4	RP11-350J20.5	7.61	5.97e-14	1.64e-11	0.33	0.23	Dupuytren's disease;	chr6:149338973	chr6:149796151~149826294:-
BRCA	cis	rs2179367	0.632	rs55826712	ENSG00000231760.4	RP11-350J20.5	7.61	5.97e-14	1.64e-11	0.33	0.23	Dupuytren's disease;	chr6:149344716	chr6:149796151~149826294:-
BRCA	cis	rs801193	0.569	rs13242290	ENSG00000232559.3	GS1-124K5.12	-7.61	5.97e-14	1.64e-11	-0.28	-0.23	Aortic root size;	chr7:66656898	chr7:66554588~66576923:-
BRCA	cis	rs293748	0.571	rs13171061	ENSG00000250155.1	CTD-2353F22.1	-7.61	5.98e-14	1.64e-11	-0.31	-0.23	Obesity-related traits;	chr5:37154591	chr5:36666214~36725195:-
BRCA	cis	rs712022	0.534	rs4567455	ENSG00000246225.5	RP11-17A1.3	-7.61	5.99e-14	1.64e-11	-0.27	-0.23	Dialysis-related mortality;	chr11:22841980	chr11:22829380~22945393:+
BRCA	cis	rs4835473	0.897	rs55945293	ENSG00000251600.4	RP11-673E1.1	-7.61	5.99e-14	1.65e-11	-0.28	-0.23	Immature fraction of reticulocytes;	chr4:143704766	chr4:143912331~143982454:+
BRCA	cis	rs867371	0.892	rs4344697	ENSG00000259429.4	UBE2Q2P2	-7.61	6e-14	1.65e-11	-0.23	-0.23	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82252873	chr15:82355142~82420075:+
BRCA	cis	rs9527	0.571	rs4917985	ENSG00000213061.2	PFN1P11	7.61	6.01e-14	1.65e-11	0.3	0.23	Arsenic metabolism;	chr10:102864315	chr10:102838011~102845473:-
BRCA	cis	rs6545883	0.929	rs2600663	ENSG00000271889.1	RP11-493E12.1	-7.61	6.02e-14	1.65e-11	-0.29	-0.23	Tuberculosis;	chr2:61313552	chr2:61151433~61162105:-
BRCA	cis	rs524281	0.692	rs10791845	ENSG00000255320.1	RP11-755F10.1	-7.61	6.03e-14	1.66e-11	-0.33	-0.23	Electroencephalogram traits;	chr11:66066869	chr11:66244840~66246239:-
BRCA	cis	rs526231	0.543	rs6881225	ENSG00000175749.11	EIF3KP1	7.61	6.04e-14	1.66e-11	0.34	0.23	Primary biliary cholangitis;	chr5:102971888	chr5:103032376~103033031:+
BRCA	cis	rs858239	0.899	rs2268745	ENSG00000230042.1	AK3P3	-7.61	6.06e-14	1.66e-11	-0.27	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23277981	chr7:23129178~23129841:+
BRCA	cis	rs17818399	0.62	rs6544906	ENSG00000279254.1	RP11-536C12.1	-7.61	6.06e-14	1.66e-11	-0.27	-0.23	Height;	chr2:46636733	chr2:46668870~46670778:+
BRCA	cis	rs2243480	1	rs402418	ENSG00000273142.1	RP11-458F8.4	-7.61	6.09e-14	1.67e-11	-0.32	-0.23	Diabetic kidney disease;	chr7:66044482	chr7:66902857~66906297:+
BRCA	cis	rs6504622	0.702	rs11079747	ENSG00000262879.4	RP11-156P1.3	-7.61	6.09e-14	1.67e-11	-0.24	-0.23	Orofacial clefts;	chr17:47001484	chr17:46984045~47100323:-
BRCA	cis	rs3781264	0.6	rs10882416	ENSG00000273450.1	RP11-76P2.4	-7.61	6.11e-14	1.68e-11	-0.3	-0.23	Esophageal cancer and gastric cancer;	chr10:94285297	chr10:94314907~94315327:-
BRCA	cis	rs4835473	0.864	rs57137521	ENSG00000251600.4	RP11-673E1.1	-7.61	6.12e-14	1.68e-11	-0.27	-0.23	Immature fraction of reticulocytes;	chr4:143704045	chr4:143912331~143982454:+
BRCA	cis	rs801193	1	rs2659912	ENSG00000237310.1	GS1-124K5.4	7.61	6.15e-14	1.69e-11	0.24	0.23	Aortic root size;	chr7:66693012	chr7:66493706~66495474:+
BRCA	cis	rs6844153	1	rs7655686	ENSG00000240005.4	RP11-293A21.1	-7.61	6.17e-14	1.69e-11	-0.35	-0.23	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26897955	chr4:26859806~26860599:-
BRCA	cis	rs12655019	0.92	rs6882657	ENSG00000271828.1	CTD-2310F14.1	7.61	6.18e-14	1.69e-11	0.41	0.23	Breast cancer (early onset);	chr5:56926912	chr5:56927874~56929573:+
BRCA	cis	rs875971	0.706	rs1643374	ENSG00000224316.1	RP11-479O9.2	7.61	6.2e-14	1.7e-11	0.23	0.23	Aortic root size;	chr7:66407695	chr7:65773620~65802067:+
BRCA	cis	rs6569038	0.669	rs17513308	ENSG00000253194.1	RP11-351A11.1	7.61	6.2e-14	1.7e-11	0.29	0.23	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr6:119061186	chr6:118934785~119031541:+
BRCA	cis	rs4964805	1	rs4964806	ENSG00000257681.1	RP11-341G23.4	7.61	6.21e-14	1.7e-11	0.28	0.23	Attention deficit hyperactivity disorder;	chr12:103798982	chr12:103746315~103768858:-
BRCA	cis	rs875971	0.862	rs3893216	ENSG00000232559.3	GS1-124K5.12	-7.61	6.21e-14	1.7e-11	-0.28	-0.23	Aortic root size;	chr7:66325720	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.862	rs6958294	ENSG00000232559.3	GS1-124K5.12	-7.61	6.21e-14	1.7e-11	-0.28	-0.23	Aortic root size;	chr7:66329809	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.862	rs2088655	ENSG00000232559.3	GS1-124K5.12	-7.61	6.21e-14	1.7e-11	-0.28	-0.23	Aortic root size;	chr7:66330724	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.895	rs10447522	ENSG00000232559.3	GS1-124K5.12	-7.61	6.21e-14	1.7e-11	-0.28	-0.23	Aortic root size;	chr7:66331087	chr7:66554588~66576923:-
BRCA	cis	rs10463554	0.853	rs257309	ENSG00000175749.11	EIF3KP1	7.61	6.22e-14	1.71e-11	0.3	0.23	Parkinson's disease;	chr5:103082900	chr5:103032376~103033031:+
BRCA	cis	rs4845875	0.6	rs4846040	ENSG00000242349.4	NPPA-AS1	7.61	6.24e-14	1.71e-11	0.27	0.23	Midregional pro atrial natriuretic peptide levels;	chr1:11776991	chr1:11841017~11848079:+
BRCA	cis	rs4845875	0.6	rs4846041	ENSG00000242349.4	NPPA-AS1	7.61	6.24e-14	1.71e-11	0.27	0.23	Midregional pro atrial natriuretic peptide levels;	chr1:11776994	chr1:11841017~11848079:+
BRCA	cis	rs925255	0.901	rs906805	ENSG00000270210.1	RP11-373D23.3	7.61	6.25e-14	1.71e-11	0.29	0.23	Inflammatory bowel disease;Crohn's disease;	chr2:28382012	chr2:28425945~28426719:+
BRCA	cis	rs875971	0.66	rs801192	ENSG00000224316.1	RP11-479O9.2	-7.61	6.25e-14	1.71e-11	-0.23	-0.23	Aortic root size;	chr7:66566965	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.66	rs801190	ENSG00000224316.1	RP11-479O9.2	-7.61	6.25e-14	1.71e-11	-0.23	-0.23	Aortic root size;	chr7:66568046	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.66	rs3857686	ENSG00000224316.1	RP11-479O9.2	-7.61	6.25e-14	1.71e-11	-0.23	-0.23	Aortic root size;	chr7:66571204	chr7:65773620~65802067:+
BRCA	cis	rs293748	0.882	rs245588	ENSG00000250155.1	CTD-2353F22.1	-7.61	6.25e-14	1.71e-11	-0.33	-0.23	Obesity-related traits;	chr5:36923108	chr5:36666214~36725195:-
BRCA	cis	rs9527	0.637	rs11191424	ENSG00000213061.2	PFN1P11	7.61	6.26e-14	1.72e-11	0.3	0.23	Arsenic metabolism;	chr10:102866129	chr10:102838011~102845473:-
BRCA	cis	rs2742234	0.541	rs10899778	ENSG00000273008.1	RP11-351D16.3	7.61	6.28e-14	1.72e-11	0.29	0.23	Hirschsprung disease;	chr10:43223061	chr10:43136824~43138334:-
BRCA	cis	rs10463554	0.892	rs32842	ENSG00000175749.11	EIF3KP1	7.61	6.29e-14	1.72e-11	0.32	0.23	Parkinson's disease;	chr5:103142298	chr5:103032376~103033031:+
BRCA	cis	rs801193	0.591	rs9986881	ENSG00000224316.1	RP11-479O9.2	7.61	6.29e-14	1.73e-11	0.24	0.23	Aortic root size;	chr7:66708053	chr7:65773620~65802067:+
BRCA	cis	rs11098499	0.604	rs12642411	ENSG00000248280.1	RP11-33B1.2	7.61	6.3e-14	1.73e-11	0.25	0.23	Corneal astigmatism;	chr4:119659370	chr4:119440561~119450157:-
BRCA	cis	rs1113500	0.787	rs10881501	ENSG00000226822.1	RP11-356N1.2	7.61	6.3e-14	1.73e-11	0.29	0.23	Growth-regulated protein alpha levels;	chr1:108099123	chr1:108071482~108074519:+
BRCA	cis	rs2028299	0.879	rs4932263	ENSG00000259677.1	RP11-493E3.1	7.61	6.3e-14	1.73e-11	0.32	0.23	Type 2 diabetes;	chr15:89896395	chr15:89876540~89877285:+
BRCA	cis	rs853679	0.567	rs1005126	ENSG00000204709.4	LINC01556	7.61	6.31e-14	1.73e-11	0.34	0.23	Depression;	chr6:28399846	chr6:28943877~28944537:+
BRCA	cis	rs2348418	0.733	rs1904386	ENSG00000247934.4	RP11-967K21.1	-7.61	6.31e-14	1.73e-11	-0.26	-0.23	Lung function (FEV1);Lung function (FVC);	chr12:28202321	chr12:28163298~28190738:-
BRCA	cis	rs301901	1	rs158796	ENSG00000250155.1	CTD-2353F22.1	-7.6	6.36e-14	1.74e-11	-0.25	-0.23	Height;	chr5:36878678	chr5:36666214~36725195:-
BRCA	cis	rs8062405	0.755	rs55792032	ENSG00000251417.2	RP11-1348G14.4	-7.6	6.36e-14	1.74e-11	-0.27	-0.23	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28588090	chr16:28802743~28817828:+
BRCA	cis	rs875971	0.545	rs1909508	ENSG00000224316.1	RP11-479O9.2	7.6	6.36e-14	1.74e-11	0.26	0.23	Aortic root size;	chr7:66301366	chr7:65773620~65802067:+
BRCA	cis	rs10463554	0.963	rs10463555	ENSG00000175749.11	EIF3KP1	7.6	6.37e-14	1.74e-11	0.32	0.23	Parkinson's disease;	chr5:102983333	chr5:103032376~103033031:+
BRCA	cis	rs4266144	0.558	rs34696078	ENSG00000244515.1	KRT18P34	-7.6	6.37e-14	1.75e-11	-0.27	-0.23	Coronary artery disease;	chr3:157114875	chr3:157162663~157163932:-
BRCA	cis	rs11098499	0.615	rs59867181	ENSG00000248280.1	RP11-33B1.2	-7.6	6.39e-14	1.75e-11	-0.22	-0.23	Corneal astigmatism;	chr4:119635312	chr4:119440561~119450157:-
BRCA	cis	rs4835473	0.868	rs1822841	ENSG00000251600.4	RP11-673E1.1	7.6	6.41e-14	1.76e-11	0.29	0.23	Immature fraction of reticulocytes;	chr4:143921485	chr4:143912331~143982454:+
BRCA	cis	rs4072705	0.967	rs4838200	ENSG00000224020.1	MIR181A2HG	7.6	6.42e-14	1.76e-11	0.26	0.23	Menarche (age at onset);	chr9:124688778	chr9:124658467~124698631:+
BRCA	cis	rs1061377	0.76	rs7678457	ENSG00000249685.1	RP11-360F5.3	7.6	6.43e-14	1.76e-11	0.28	0.23	Uric acid levels;	chr4:39136041	chr4:39133913~39135608:+
BRCA	cis	rs867371	0.896	rs6495647	ENSG00000255769.6	GOLGA2P10	-7.6	6.43e-14	1.76e-11	-0.26	-0.23	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82244708	chr15:82472993~82513950:-
BRCA	cis	rs11089937	0.626	rs4820337	ENSG00000211639.2	IGLV4-60	-7.6	6.43e-14	1.76e-11	-0.23	-0.23	Periodontitis (PAL4Q3);	chr22:22164374	chr22:22162199~22162681:+
BRCA	cis	rs6570726	0.935	rs110289	ENSG00000235652.6	RP11-545I5.3	7.6	6.45e-14	1.77e-11	0.22	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145544040	chr6:145799409~145886585:+
BRCA	cis	rs11159086	1	rs4899514	ENSG00000259005.1	RP3-449M8.6	-7.6	6.46e-14	1.77e-11	-0.37	-0.23	Advanced glycation end-product levels;	chr14:74473467	chr14:74474007~74474864:-
BRCA	cis	rs780096	0.546	rs1104	ENSG00000234072.1	AC074117.10	-7.6	6.46e-14	1.77e-11	-0.22	-0.23	Total body bone mineral density;	chr2:27377008	chr2:27356246~27367622:+
BRCA	cis	rs9876781	1	rs725310	ENSG00000244380.1	RP11-24C3.2	-7.6	6.46e-14	1.77e-11	-0.26	-0.23	Longevity;	chr3:48377081	chr3:48440352~48446656:-
BRCA	cis	rs9640161	0.83	rs17173682	ENSG00000261305.1	RP4-584D14.7	7.6	6.47e-14	1.77e-11	0.35	0.23	Blood protein levels;Circulating chemerin levels;	chr7:150362513	chr7:150341771~150342607:+
BRCA	cis	rs6504622	0.702	rs3851792	ENSG00000262879.4	RP11-156P1.3	7.6	6.47e-14	1.77e-11	0.23	0.23	Orofacial clefts;	chr17:46982458	chr17:46984045~47100323:-
BRCA	cis	rs2243480	0.803	rs160649	ENSG00000273142.1	RP11-458F8.4	-7.6	6.47e-14	1.77e-11	-0.32	-0.23	Diabetic kidney disease;	chr7:66078212	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs160648	ENSG00000273142.1	RP11-458F8.4	-7.6	6.47e-14	1.77e-11	-0.32	-0.23	Diabetic kidney disease;	chr7:66078397	chr7:66902857~66906297:+
BRCA	cis	rs10206020	0.885	rs6720797	ENSG00000231482.2	AC141930.2	-7.6	6.47e-14	1.77e-11	-0.29	-0.23	IgG glycosylation;	chr2:1570568	chr2:1572554~1580311:-
BRCA	cis	rs875971	0.638	rs3898855	ENSG00000224316.1	RP11-479O9.2	-7.6	6.49e-14	1.78e-11	-0.23	-0.23	Aortic root size;	chr7:66571411	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.638	rs10278816	ENSG00000224316.1	RP11-479O9.2	-7.6	6.49e-14	1.78e-11	-0.23	-0.23	Aortic root size;	chr7:66572000	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.66	rs10281080	ENSG00000224316.1	RP11-479O9.2	-7.6	6.49e-14	1.78e-11	-0.23	-0.23	Aortic root size;	chr7:66577454	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.66	rs10950044	ENSG00000224316.1	RP11-479O9.2	-7.6	6.49e-14	1.78e-11	-0.23	-0.23	Aortic root size;	chr7:66577989	chr7:65773620~65802067:+
BRCA	cis	rs10050311	0.79	rs55831707	ENSG00000251411.1	RP11-397E7.4	-7.6	6.49e-14	1.78e-11	-0.35	-0.23	Insulin-related traits;	chr4:86918376	chr4:86913266~86914817:-
BRCA	cis	rs74233809	1	rs77787671	ENSG00000213277.3	MARCKSL1P1	7.6	6.5e-14	1.78e-11	0.43	0.23	Birth weight;	chr10:103016448	chr10:103175554~103176094:+
BRCA	cis	rs7674212	0.507	rs223361	ENSG00000251288.2	RP11-10L12.2	-7.6	6.51e-14	1.78e-11	-0.28	-0.23	Type 2 diabetes;	chr4:102848147	chr4:102751401~102752641:+
BRCA	cis	rs7927771	1	rs7105282	ENSG00000280615.1	Y_RNA	-7.6	6.51e-14	1.78e-11	-0.29	-0.23	Subjective well-being;	chr11:47784062	chr11:47614898~47614994:-
BRCA	cis	rs10129255	1	rs8012033	ENSG00000211972.2	IGHV3-66	7.6	6.52e-14	1.78e-11	0.18	0.23	Kawasaki disease;	chr14:106678854	chr14:106675017~106675544:-
BRCA	cis	rs801193	1	rs7788576	ENSG00000237310.1	GS1-124K5.4	-7.6	6.53e-14	1.79e-11	-0.24	-0.23	Aortic root size;	chr7:66683315	chr7:66493706~66495474:+
BRCA	cis	rs9309711	0.698	rs9750503	ENSG00000225234.1	TRAPPC12-AS1	7.6	6.53e-14	1.79e-11	0.27	0.23	Neurofibrillary tangles;	chr2:3488001	chr2:3481242~3482409:-
BRCA	cis	rs10206020	0.885	rs6720923	ENSG00000231482.2	AC141930.2	-7.6	6.54e-14	1.79e-11	-0.29	-0.23	IgG glycosylation;	chr2:1570425	chr2:1572554~1580311:-
BRCA	cis	rs2243480	1	rs313803	ENSG00000273142.1	RP11-458F8.4	-7.6	6.54e-14	1.79e-11	-0.32	-0.23	Diabetic kidney disease;	chr7:66049744	chr7:66902857~66906297:+
BRCA	cis	rs867371	1	rs6495643	ENSG00000259429.4	UBE2Q2P2	-7.6	6.55e-14	1.79e-11	-0.23	-0.23	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82186913	chr15:82355142~82420075:+
BRCA	cis	rs66887589	0.774	rs9307477	ENSG00000248280.1	RP11-33B1.2	7.6	6.56e-14	1.8e-11	0.21	0.23	Diastolic blood pressure;	chr4:119500654	chr4:119440561~119450157:-
BRCA	cis	rs6570726	0.875	rs12524077	ENSG00000235652.6	RP11-545I5.3	7.6	6.6e-14	1.8e-11	0.22	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145545197	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.875	rs416243	ENSG00000235652.6	RP11-545I5.3	7.6	6.6e-14	1.8e-11	0.22	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145546945	chr6:145799409~145886585:+
BRCA	cis	rs113835537	0.597	rs3737525	ENSG00000255517.5	CTD-3074O7.5	-7.6	6.6e-14	1.81e-11	-0.32	-0.23	Airway imaging phenotypes;	chr11:66538884	chr11:66473490~66480233:-
BRCA	cis	rs1061377	1	rs56119980	ENSG00000249685.1	RP11-360F5.3	7.6	6.6e-14	1.81e-11	0.28	0.23	Uric acid levels;	chr4:39139390	chr4:39133913~39135608:+
BRCA	cis	rs7927771	0.864	rs10838724	ENSG00000280615.1	Y_RNA	-7.6	6.6e-14	1.81e-11	-0.28	-0.23	Subjective well-being;	chr11:47505500	chr11:47614898~47614994:-
BRCA	cis	rs61270009	0.955	rs383385	ENSG00000247828.6	TMEM161B-AS1	-7.6	6.61e-14	1.81e-11	-0.28	-0.23	Depressive symptoms;	chr5:88246065	chr5:88268895~88436685:+
BRCA	cis	rs61270009	0.955	rs396702	ENSG00000247828.6	TMEM161B-AS1	-7.6	6.61e-14	1.81e-11	-0.28	-0.23	Depressive symptoms;	chr5:88247486	chr5:88268895~88436685:+
BRCA	cis	rs801193	1	rs2659889	ENSG00000237310.1	GS1-124K5.4	7.6	6.62e-14	1.81e-11	0.24	0.23	Aortic root size;	chr7:66752125	chr7:66493706~66495474:+
BRCA	cis	rs74233809	1	rs11191531	ENSG00000213277.3	MARCKSL1P1	7.6	6.63e-14	1.81e-11	0.42	0.23	Birth weight;	chr10:103047141	chr10:103175554~103176094:+
BRCA	cis	rs10129255	0.912	rs8011090	ENSG00000211972.2	IGHV3-66	7.6	6.63e-14	1.81e-11	0.18	0.23	Kawasaki disease;	chr14:106678896	chr14:106675017~106675544:-
BRCA	cis	rs6496044	0.507	rs62022863	ENSG00000202081.1	RNU6-1280P	-7.6	6.63e-14	1.81e-11	-0.27	-0.23	Interstitial lung disease;	chr15:85618822	chr15:85651522~85651628:-
BRCA	cis	rs2033711	0.87	rs4801583	ENSG00000269473.1	CTD-2619J13.19	7.6	6.63e-14	1.81e-11	0.27	0.23	Uric acid clearance;	chr19:58407038	chr19:58440448~58445849:+
BRCA	cis	rs3758911	0.894	rs11212166	ENSG00000255353.1	RP11-382M14.1	-7.6	6.63e-14	1.81e-11	-0.31	-0.23	Coronary artery disease;	chr11:107331878	chr11:107176286~107177530:+
BRCA	cis	rs3758911	0.894	rs7358308	ENSG00000255353.1	RP11-382M14.1	-7.6	6.63e-14	1.81e-11	-0.31	-0.23	Coronary artery disease;	chr11:107333178	chr11:107176286~107177530:+
BRCA	cis	rs17772222	0.876	rs12436982	ENSG00000258983.2	RP11-507K2.2	7.6	6.66e-14	1.82e-11	0.26	0.23	Coronary artery calcification;	chr14:88689862	chr14:88499334~88515502:+
BRCA	cis	rs6539288	0.933	rs6539291	ENSG00000260329.1	RP11-412D9.4	-7.6	6.67e-14	1.82e-11	-0.26	-0.23	Total body bone mineral density;	chr12:106916033	chr12:106954029~106955497:-
BRCA	cis	rs1862618	0.853	rs252922	ENSG00000271828.1	CTD-2310F14.1	7.6	6.67e-14	1.82e-11	0.31	0.23	Initial pursuit acceleration;	chr5:56840516	chr5:56927874~56929573:+
BRCA	cis	rs10463554	0.895	rs12656561	ENSG00000175749.11	EIF3KP1	7.6	6.69e-14	1.83e-11	0.3	0.23	Parkinson's disease;	chr5:102989988	chr5:103032376~103033031:+
BRCA	cis	rs3814244	0.528	rs10878723	ENSG00000236946.2	HNRNPA1P70	-7.6	6.71e-14	1.83e-11	-0.19	-0.23	Itch intensity from mosquito bite adjusted by bite size;	chr12:68005493	chr12:68035767~68036853:+
BRCA	cis	rs4835473	0.897	rs6832722	ENSG00000251600.4	RP11-673E1.1	7.6	6.72e-14	1.84e-11	0.28	0.23	Immature fraction of reticulocytes;	chr4:143709430	chr4:143912331~143982454:+
BRCA	cis	rs293748	0.571	rs13181187	ENSG00000250155.1	CTD-2353F22.1	-7.6	6.75e-14	1.85e-11	-0.31	-0.23	Obesity-related traits;	chr5:37239275	chr5:36666214~36725195:-
BRCA	cis	rs7085104	0.591	rs4919683	ENSG00000213061.2	PFN1P11	7.6	6.78e-14	1.85e-11	0.29	0.23	Immature fraction of reticulocytes;Schizophrenia;	chr10:102825368	chr10:102838011~102845473:-
BRCA	cis	rs2274273	0.624	rs10143136	ENSG00000258413.1	RP11-665C16.6	-7.6	6.8e-14	1.86e-11	-0.31	-0.23	Protein biomarker;	chr14:55276810	chr14:55262767~55272075:-
BRCA	cis	rs12999373	0.523	rs9678953	ENSG00000272342.1	RP13-539J13.1	-7.6	6.8e-14	1.86e-11	-0.3	-0.23	Response to fenofibrate (adiponectin levels);Uric acid levels;	chr2:694759	chr2:739588~740164:-
BRCA	cis	rs3762637	1	rs10934602	ENSG00000272758.4	RP11-299J3.8	7.6	6.81e-14	1.86e-11	0.33	0.23	LDL cholesterol levels;	chr3:122504335	chr3:122416207~122443180:+
BRCA	cis	rs7927771	0.832	rs7105851	ENSG00000280615.1	Y_RNA	7.6	6.82e-14	1.86e-11	0.27	0.23	Subjective well-being;	chr11:47361724	chr11:47614898~47614994:-
BRCA	cis	rs10463554	0.892	rs3776874	ENSG00000175749.11	EIF3KP1	7.6	6.82e-14	1.86e-11	0.31	0.23	Parkinson's disease;	chr5:102946613	chr5:103032376~103033031:+
BRCA	cis	rs9649213	0.574	rs34830366	ENSG00000272950.1	RP11-307C18.1	7.6	6.82e-14	1.86e-11	0.3	0.23	Prostate cancer (SNP x SNP interaction);	chr7:98270223	chr7:98322853~98323430:+
BRCA	cis	rs9649213	0.593	rs34776142	ENSG00000272950.1	RP11-307C18.1	7.6	6.82e-14	1.86e-11	0.3	0.23	Prostate cancer (SNP x SNP interaction);	chr7:98270561	chr7:98322853~98323430:+
BRCA	cis	rs7772486	0.875	rs2777482	ENSG00000235652.6	RP11-545I5.3	7.6	6.83e-14	1.86e-11	0.23	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145999205	chr6:145799409~145886585:+
BRCA	cis	rs4820294	0.669	rs732857	ENSG00000233360.4	Z83844.1	7.6	6.83e-14	1.86e-11	0.25	0.23	Fat distribution (HIV);	chr22:37664843	chr22:37641832~37658377:-
BRCA	cis	rs4845875	0.529	rs6680385	ENSG00000242349.4	NPPA-AS1	7.59	6.85e-14	1.87e-11	0.27	0.23	Midregional pro atrial natriuretic peptide levels;	chr1:11771699	chr1:11841017~11848079:+
BRCA	cis	rs10129255	0.5	rs8014529	ENSG00000211970.3	IGHV4-61	-7.59	6.85e-14	1.87e-11	-0.15	-0.23	Kawasaki disease;	chr14:106784065	chr14:106639119~106639657:-
BRCA	cis	rs763567	0.605	rs619456	ENSG00000271811.1	RP1-79C4.4	-7.59	6.85e-14	1.87e-11	-0.25	-0.23	Tonsillectomy;	chr1:170616691	chr1:170667381~170669425:+
BRCA	cis	rs801193	0.761	rs2659888	ENSG00000237310.1	GS1-124K5.4	7.59	6.85e-14	1.87e-11	0.24	0.23	Aortic root size;	chr7:66765184	chr7:66493706~66495474:+
BRCA	cis	rs67981189	0.579	rs2240533	ENSG00000269927.1	RP6-91H8.3	7.59	6.86e-14	1.87e-11	0.29	0.23	Schizophrenia;	chr14:71074309	chr14:71141125~71143253:-
BRCA	cis	rs3762637	0.943	rs78429050	ENSG00000272758.4	RP11-299J3.8	-7.59	6.89e-14	1.88e-11	-0.34	-0.23	LDL cholesterol levels;	chr3:122533581	chr3:122416207~122443180:+
BRCA	cis	rs2742234	0.915	rs2742233	ENSG00000273008.1	RP11-351D16.3	-7.59	6.89e-14	1.88e-11	-0.26	-0.23	Hirschsprung disease;	chr10:43115110	chr10:43136824~43138334:-
BRCA	cis	rs13113518	0.729	rs13120134	ENSG00000249700.7	SRD5A3-AS1	7.59	6.91e-14	1.89e-11	0.32	0.23	Height;	chr4:55415153	chr4:55363971~55395847:-
BRCA	cis	rs11098499	0.863	rs1155576	ENSG00000248280.1	RP11-33B1.2	7.59	6.92e-14	1.89e-11	0.23	0.23	Corneal astigmatism;	chr4:119529004	chr4:119440561~119450157:-
BRCA	cis	rs3762637	1	rs9867429	ENSG00000272758.4	RP11-299J3.8	-7.59	6.93e-14	1.89e-11	-0.33	-0.23	LDL cholesterol levels;	chr3:122513821	chr3:122416207~122443180:+
BRCA	cis	rs801193	1	rs6958520	ENSG00000237310.1	GS1-124K5.4	7.59	6.94e-14	1.89e-11	0.24	0.23	Aortic root size;	chr7:66686466	chr7:66493706~66495474:+
BRCA	cis	rs919433	0.963	rs1366837	ENSG00000231621.1	AC013264.2	7.59	6.94e-14	1.9e-11	0.21	0.23	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197295777	chr2:197197991~197199273:+
BRCA	cis	rs3758911	0.894	rs1490947	ENSG00000255353.1	RP11-382M14.1	-7.59	6.94e-14	1.9e-11	-0.31	-0.23	Coronary artery disease;	chr11:107325294	chr11:107176286~107177530:+
BRCA	cis	rs10129255	0.912	rs67410411	ENSG00000211972.2	IGHV3-66	7.59	6.97e-14	1.9e-11	0.18	0.23	Kawasaki disease;	chr14:106680324	chr14:106675017~106675544:-
BRCA	cis	rs7474896	0.583	rs7071147	ENSG00000226578.1	RP11-258F22.1	-7.59	7e-14	1.91e-11	-0.3	-0.23	Obesity (extreme);	chr10:37714448	chr10:37775371~37784131:-
BRCA	cis	rs7927771	0.697	rs11039307	ENSG00000280615.1	Y_RNA	-7.59	7e-14	1.91e-11	-0.27	-0.23	Subjective well-being;	chr11:47589600	chr11:47614898~47614994:-
BRCA	cis	rs293748	0.571	rs12652882	ENSG00000250155.1	CTD-2353F22.1	-7.59	7.01e-14	1.91e-11	-0.3	-0.23	Obesity-related traits;	chr5:37188340	chr5:36666214~36725195:-
BRCA	cis	rs66887589	0.56	rs9684327	ENSG00000248280.1	RP11-33B1.2	7.59	7.03e-14	1.92e-11	0.21	0.23	Diastolic blood pressure;	chr4:119444286	chr4:119440561~119450157:-
BRCA	cis	rs2880765	0.835	rs4843063	ENSG00000259295.5	CSPG4P12	7.59	7.03e-14	1.92e-11	0.28	0.23	Coronary artery disease;	chr15:85505517	chr15:85191438~85213905:+
BRCA	cis	rs7615952	0.688	rs12485622	ENSG00000250012.1	RP11-124N2.1	-7.59	7.03e-14	1.92e-11	-0.31	-0.23	Blood pressure (smoking interaction);	chr3:125991896	chr3:126084220~126095349:+
BRCA	cis	rs9816784	0.901	rs12490036	ENSG00000231464.1	AC024937.4	-7.59	7.07e-14	1.93e-11	-0.28	-0.23	Mean corpuscular hemoglobin;	chr3:196089324	chr3:195996738~195998233:+
BRCA	cis	rs2243480	1	rs160633	ENSG00000273142.1	RP11-458F8.4	-7.59	7.07e-14	1.93e-11	-0.33	-0.23	Diabetic kidney disease;	chr7:66063241	chr7:66902857~66906297:+
BRCA	cis	rs58873874	0.579	rs79615135	ENSG00000251405.2	CTB-109A12.1	7.59	7.07e-14	1.93e-11	0.52	0.23	Bipolar disorder (body mass index interaction);	chr5:157275758	chr5:157362615~157460078:-
BRCA	cis	rs4835473	0.897	rs2219912	ENSG00000251600.4	RP11-673E1.1	7.59	7.07e-14	1.93e-11	0.28	0.23	Immature fraction of reticulocytes;	chr4:143707909	chr4:143912331~143982454:+
BRCA	cis	rs10510102	0.935	rs75339296	ENSG00000276742.1	RP11-500G22.4	7.59	7.07e-14	1.93e-11	0.38	0.23	Breast cancer;	chr10:121859895	chr10:121956782~121957098:+
BRCA	cis	rs1075265	0.563	rs2542588	ENSG00000233266.1	HMGB1P31	-7.59	7.09e-14	1.93e-11	-0.28	-0.23	Chronotype;Morning vs. evening chronotype;	chr2:53791787	chr2:54051334~54051760:+
BRCA	cis	rs10463554	0.857	rs3776871	ENSG00000175749.11	EIF3KP1	7.59	7.09e-14	1.93e-11	0.32	0.23	Parkinson's disease;	chr5:102956507	chr5:103032376~103033031:+
BRCA	cis	rs17772222	0.917	rs17260415	ENSG00000258983.2	RP11-507K2.2	7.59	7.11e-14	1.94e-11	0.26	0.23	Coronary artery calcification;	chr14:88745629	chr14:88499334~88515502:+
BRCA	cis	rs2179367	0.632	rs11155640	ENSG00000231760.4	RP11-350J20.5	7.59	7.11e-14	1.94e-11	0.34	0.23	Dupuytren's disease;	chr6:149323648	chr6:149796151~149826294:-
BRCA	cis	rs7927771	1	rs9909	ENSG00000280615.1	Y_RNA	-7.59	7.11e-14	1.94e-11	-0.28	-0.23	Subjective well-being;	chr11:47778223	chr11:47614898~47614994:-
BRCA	cis	rs66887589	0.807	rs9799664	ENSG00000248280.1	RP11-33B1.2	7.59	7.12e-14	1.94e-11	0.21	0.23	Diastolic blood pressure;	chr4:119405523	chr4:119440561~119450157:-
BRCA	cis	rs17711722	0.523	rs365896	ENSG00000273024.4	INTS4P2	7.59	7.12e-14	1.94e-11	0.26	0.23	Calcium levels;	chr7:66045710	chr7:65647864~65715661:+
BRCA	cis	rs2243480	1	rs464895	ENSG00000273142.1	RP11-458F8.4	-7.59	7.13e-14	1.94e-11	-0.33	-0.23	Diabetic kidney disease;	chr7:66062119	chr7:66902857~66906297:+
BRCA	cis	rs2179367	0.586	rs62426088	ENSG00000231760.4	RP11-350J20.5	7.59	7.13e-14	1.94e-11	0.33	0.23	Dupuytren's disease;	chr6:149339301	chr6:149796151~149826294:-
BRCA	cis	rs9880211	1	rs9823373	ENSG00000273486.1	RP11-731C17.2	7.59	7.14e-14	1.95e-11	0.31	0.23	Height;Body mass index;	chr3:136448185	chr3:136837338~136839021:-
BRCA	cis	rs2439831	0.85	rs12441984	ENSG00000205771.5	CATSPER2P1	-7.59	7.14e-14	1.95e-11	-0.4	-0.23	Lung cancer in ever smokers;	chr15:43834087	chr15:43726918~43747094:-
BRCA	cis	rs4835473	0.897	rs6832749	ENSG00000251600.4	RP11-673E1.1	7.59	7.14e-14	1.95e-11	0.28	0.23	Immature fraction of reticulocytes;	chr4:143709473	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.897	rs6831477	ENSG00000251600.4	RP11-673E1.1	7.59	7.14e-14	1.95e-11	0.28	0.23	Immature fraction of reticulocytes;	chr4:143709487	chr4:143912331~143982454:+
BRCA	cis	rs801193	0.967	rs2707849	ENSG00000237310.1	GS1-124K5.4	7.59	7.15e-14	1.95e-11	0.24	0.23	Aortic root size;	chr7:66687725	chr7:66493706~66495474:+
BRCA	cis	rs526231	0.578	rs2112886	ENSG00000175749.11	EIF3KP1	-7.59	7.15e-14	1.95e-11	-0.33	-0.23	Primary biliary cholangitis;	chr5:102915678	chr5:103032376~103033031:+
BRCA	cis	rs17772222	0.917	rs58984912	ENSG00000258983.2	RP11-507K2.2	7.59	7.16e-14	1.95e-11	0.26	0.23	Coronary artery calcification;	chr14:88698172	chr14:88499334~88515502:+
BRCA	cis	rs896854	0.738	rs509594	ENSG00000253528.2	RP11-347C18.4	-7.59	7.17e-14	1.96e-11	-0.26	-0.23	Type 2 diabetes;	chr8:94954928	chr8:94974573~94974853:-
BRCA	cis	rs4845875	0.514	rs198392	ENSG00000242349.4	NPPA-AS1	-7.59	7.17e-14	1.96e-11	-0.24	-0.23	Midregional pro atrial natriuretic peptide levels;	chr1:11819105	chr1:11841017~11848079:+
BRCA	cis	rs6472827	0.762	rs2936687	ENSG00000253983.2	RP1-16A9.1	7.59	7.17e-14	1.96e-11	0.37	0.23	Uterine fibroids;	chr8:74205136	chr8:74199396~74208441:+
BRCA	cis	rs6472827	0.762	rs77058572	ENSG00000253983.2	RP1-16A9.1	7.59	7.17e-14	1.96e-11	0.37	0.23	Uterine fibroids;	chr8:74205137	chr8:74199396~74208441:+
BRCA	cis	rs712022	0.534	rs10833839	ENSG00000246225.5	RP11-17A1.3	-7.59	7.18e-14	1.96e-11	-0.27	-0.23	Dialysis-related mortality;	chr11:22846282	chr11:22829380~22945393:+
BRCA	cis	rs6496044	0.507	rs1471455	ENSG00000202081.1	RNU6-1280P	-7.59	7.18e-14	1.96e-11	-0.26	-0.23	Interstitial lung disease;	chr15:85611496	chr15:85651522~85651628:-
BRCA	cis	rs875971	0.577	rs35072105	ENSG00000236529.1	RP13-254B10.1	-7.59	7.19e-14	1.96e-11	-0.25	-0.23	Aortic root size;	chr7:66144830	chr7:65840212~65840596:+
BRCA	cis	rs62355901	0.599	rs12656399	ENSG00000271828.1	CTD-2310F14.1	7.59	7.19e-14	1.96e-11	0.4	0.23	Breast cancer;	chr5:56731016	chr5:56927874~56929573:+
BRCA	cis	rs17711722	0.565	rs73372653	ENSG00000273024.4	INTS4P2	-7.59	7.19e-14	1.96e-11	-0.26	-0.23	Calcium levels;	chr7:65977808	chr7:65647864~65715661:+
BRCA	cis	rs293748	0.54	rs13166829	ENSG00000250155.1	CTD-2353F22.1	-7.59	7.2e-14	1.96e-11	-0.31	-0.23	Obesity-related traits;	chr5:37222124	chr5:36666214~36725195:-
BRCA	cis	rs250518	1	rs250518	ENSG00000272081.1	CTD-2376I4.2	-7.59	7.2e-14	1.96e-11	-0.29	-0.23	Mean corpuscular hemoglobin concentration;	chr5:72905231	chr5:72955206~72955699:-
BRCA	cis	rs9880211	0.948	rs34282798	ENSG00000273486.1	RP11-731C17.2	7.59	7.23e-14	1.97e-11	0.3	0.23	Height;Body mass index;	chr3:136424515	chr3:136837338~136839021:-
BRCA	cis	rs293748	0.771	rs292186	ENSG00000250155.1	CTD-2353F22.1	-7.59	7.23e-14	1.97e-11	-0.32	-0.23	Obesity-related traits;	chr5:36967320	chr5:36666214~36725195:-
BRCA	cis	rs516805	0.961	rs527978	ENSG00000279114.1	RP3-425C14.5	-7.59	7.24e-14	1.97e-11	-0.24	-0.23	Lymphocyte counts;	chr6:122475225	chr6:122471923~122484161:+
BRCA	cis	rs7927771	0.832	rs10769258	ENSG00000280615.1	Y_RNA	7.59	7.24e-14	1.97e-11	0.27	0.23	Subjective well-being;	chr11:47369488	chr11:47614898~47614994:-
BRCA	cis	rs293748	0.571	rs13171414	ENSG00000250155.1	CTD-2353F22.1	-7.59	7.25e-14	1.97e-11	-0.31	-0.23	Obesity-related traits;	chr5:37231977	chr5:36666214~36725195:-
BRCA	cis	rs875971	0.862	rs6947339	ENSG00000232559.3	GS1-124K5.12	7.59	7.29e-14	1.98e-11	0.28	0.23	Aortic root size;	chr7:66423483	chr7:66554588~66576923:-
BRCA	cis	rs74233809	1	rs10509759	ENSG00000213277.3	MARCKSL1P1	7.59	7.3e-14	1.99e-11	0.43	0.23	Birth weight;	chr10:102929908	chr10:103175554~103176094:+
BRCA	cis	rs74233809	1	rs10883806	ENSG00000213277.3	MARCKSL1P1	7.59	7.3e-14	1.99e-11	0.43	0.23	Birth weight;	chr10:102953319	chr10:103175554~103176094:+
BRCA	cis	rs74233809	1	rs78260931	ENSG00000213277.3	MARCKSL1P1	7.59	7.3e-14	1.99e-11	0.43	0.23	Birth weight;	chr10:102962205	chr10:103175554~103176094:+
BRCA	cis	rs5760092	0.572	rs738806	ENSG00000250470.1	AP000351.3	7.59	7.33e-14	2e-11	0.3	0.23	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23891985	chr22:23976904~23977585:-
BRCA	cis	rs2243480	1	rs431076	ENSG00000273142.1	RP11-458F8.4	-7.59	7.33e-14	2e-11	-0.32	-0.23	Diabetic kidney disease;	chr7:66135333	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs2460422	ENSG00000273142.1	RP11-458F8.4	-7.59	7.33e-14	2e-11	-0.32	-0.23	Diabetic kidney disease;	chr7:66136518	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs316334	ENSG00000273142.1	RP11-458F8.4	-7.59	7.33e-14	2e-11	-0.32	-0.23	Diabetic kidney disease;	chr7:66137139	chr7:66902857~66906297:+
BRCA	cis	rs1075265	0.587	rs2949812	ENSG00000233266.1	HMGB1P31	7.58	7.36e-14	2e-11	0.27	0.23	Chronotype;Morning vs. evening chronotype;	chr2:53797190	chr2:54051334~54051760:+
BRCA	cis	rs11976180	1	rs1919950	ENSG00000170356.8	OR2A20P	-7.58	7.36e-14	2e-11	-0.33	-0.23	Obesity-related traits;	chr7:144070805	chr7:144250045~144252957:-
BRCA	cis	rs9880211	0.752	rs13062352	ENSG00000239213.4	NCK1-AS1	7.58	7.36e-14	2.01e-11	0.31	0.23	Height;Body mass index;	chr3:136745920	chr3:136841726~136862054:-
BRCA	cis	rs6657613	0.628	rs761423	ENSG00000186715.9	MST1L	7.58	7.37e-14	2.01e-11	0.21	0.23	Hip circumference adjusted for BMI;	chr1:16975177	chr1:16754910~16770237:-
BRCA	cis	rs801193	0.967	rs2707853	ENSG00000237310.1	GS1-124K5.4	7.58	7.37e-14	2.01e-11	0.24	0.23	Aortic root size;	chr7:66749023	chr7:66493706~66495474:+
BRCA	cis	rs7246657	0.943	rs10403613	ENSG00000276846.1	CTD-3220F14.3	7.58	7.37e-14	2.01e-11	0.32	0.23	Coronary artery calcification;	chr19:37353404	chr19:37314868~37315620:-
BRCA	cis	rs4835473	0.932	rs1450250	ENSG00000251600.4	RP11-673E1.1	7.58	7.37e-14	2.01e-11	0.28	0.23	Immature fraction of reticulocytes;	chr4:143731873	chr4:143912331~143982454:+
BRCA	cis	rs6840258	0.547	rs17012170	ENSG00000251411.1	RP11-397E7.4	-7.58	7.38e-14	2.01e-11	-0.35	-0.23	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86939692	chr4:86913266~86914817:-
BRCA	cis	rs10129255	0.518	rs8009594	ENSG00000211970.3	IGHV4-61	-7.58	7.39e-14	2.01e-11	-0.15	-0.23	Kawasaki disease;	chr14:106777494	chr14:106639119~106639657:-
BRCA	cis	rs7474896	0.583	rs4934898	ENSG00000226578.1	RP11-258F22.1	-7.58	7.43e-14	2.02e-11	-0.3	-0.23	Obesity (extreme);	chr10:37701467	chr10:37775371~37784131:-
BRCA	cis	rs7727544	0.684	rs272849	ENSG00000233006.5	AC034220.3	7.58	7.43e-14	2.02e-11	0.17	0.23	Blood metabolite levels;	chr5:132354548	chr5:132311285~132369916:-
BRCA	cis	rs4308124	1	rs4308124	ENSG00000227992.1	AC108463.2	-7.58	7.43e-14	2.02e-11	-0.26	-0.23	Vitiligo;	chr2:111252909	chr2:111203964~111206215:-
BRCA	cis	rs8059260	0.932	rs7186166	ENSG00000274038.1	RP11-66H6.4	-7.58	7.44e-14	2.02e-11	-0.29	-0.23	Alcohol consumption over the past year;	chr16:11011577	chr16:11056556~11057034:+
BRCA	cis	rs293748	0.771	rs35701604	ENSG00000250155.1	CTD-2353F22.1	-7.58	7.44e-14	2.02e-11	-0.32	-0.23	Obesity-related traits;	chr5:37021831	chr5:36666214~36725195:-
BRCA	cis	rs4845875	0.6	rs6696752	ENSG00000242349.4	NPPA-AS1	7.58	7.44e-14	2.03e-11	0.27	0.23	Midregional pro atrial natriuretic peptide levels;	chr1:11775878	chr1:11841017~11848079:+
BRCA	cis	rs2283792	0.764	rs2298432	ENSG00000224086.5	LL22NC03-86G7.1	-7.58	7.49e-14	2.04e-11	-0.26	-0.23	Multiple sclerosis;	chr22:21768900	chr22:21938293~21977632:+
BRCA	cis	rs14027	0.961	rs7017279	ENSG00000279347.1	RP11-85I17.2	7.58	7.51e-14	2.04e-11	0.23	0.23	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119847580	chr8:119838736~119840385:-
BRCA	cis	rs2179367	0.632	rs9322179	ENSG00000231760.4	RP11-350J20.5	7.58	7.51e-14	2.04e-11	0.33	0.23	Dupuytren's disease;	chr6:149418664	chr6:149796151~149826294:-
BRCA	cis	rs10129255	0.5	rs59939897	ENSG00000211970.3	IGHV4-61	-7.58	7.52e-14	2.05e-11	-0.15	-0.23	Kawasaki disease;	chr14:106783414	chr14:106639119~106639657:-
BRCA	cis	rs4835473	0.897	rs6537172	ENSG00000251600.4	RP11-673E1.1	7.58	7.54e-14	2.05e-11	0.28	0.23	Immature fraction of reticulocytes;	chr4:143710612	chr4:143912331~143982454:+
BRCA	cis	rs891378	0.727	rs7513914	ENSG00000274245.1	RP11-357P18.2	-7.58	7.54e-14	2.05e-11	-0.29	-0.23	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207236087	chr1:207372559~207373252:+
BRCA	cis	rs7487637	0.566	rs875023	ENSG00000276691.1	RP5-1057I20.5	-7.58	7.56e-14	2.06e-11	-0.3	-0.23	Mononucleosis;	chr12:47800652	chr12:47788426~47788971:+
BRCA	cis	rs2033711	0.84	rs3764533	ENSG00000269473.1	CTD-2619J13.19	7.58	7.56e-14	2.06e-11	0.27	0.23	Uric acid clearance;	chr19:58417827	chr19:58440448~58445849:+
BRCA	cis	rs8062405	0.755	rs4788073	ENSG00000251417.2	RP11-1348G14.4	-7.58	7.57e-14	2.06e-11	-0.27	-0.23	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28583228	chr16:28802743~28817828:+
BRCA	cis	rs9527	0.501	rs12244388	ENSG00000213061.2	PFN1P11	7.58	7.6e-14	2.07e-11	0.3	0.23	Arsenic metabolism;	chr10:102880295	chr10:102838011~102845473:-
BRCA	cis	rs74233809	1	rs11191514	ENSG00000213277.3	MARCKSL1P1	7.58	7.6e-14	2.07e-11	0.42	0.23	Birth weight;	chr10:103013607	chr10:103175554~103176094:+
BRCA	cis	rs2281558	0.583	rs7260957	ENSG00000125804.12	FAM182A	-7.58	7.63e-14	2.08e-11	-0.39	-0.23	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25741826	chr20:26054655~26086917:+
BRCA	cis	rs2933343	0.553	rs35979399	ENSG00000231305.3	RP11-723O4.2	7.58	7.64e-14	2.08e-11	0.26	0.23	IgG glycosylation;	chr3:128978470	chr3:128861313~128871540:-
BRCA	cis	rs10463554	0.895	rs3756583	ENSG00000175749.11	EIF3KP1	7.58	7.64e-14	2.08e-11	0.3	0.23	Parkinson's disease;	chr5:102998340	chr5:103032376~103033031:+
BRCA	cis	rs17772222	0.917	rs12588535	ENSG00000258983.2	RP11-507K2.2	7.58	7.64e-14	2.08e-11	0.27	0.23	Coronary artery calcification;	chr14:88781900	chr14:88499334~88515502:+
BRCA	cis	rs801193	1	rs11773829	ENSG00000237310.1	GS1-124K5.4	-7.58	7.68e-14	2.09e-11	-0.24	-0.23	Aortic root size;	chr7:66676087	chr7:66493706~66495474:+
BRCA	cis	rs2179367	0.632	rs59820585	ENSG00000231760.4	RP11-350J20.5	7.58	7.68e-14	2.09e-11	0.33	0.23	Dupuytren's disease;	chr6:149350249	chr6:149796151~149826294:-
BRCA	cis	rs2179367	0.632	rs56924465	ENSG00000231760.4	RP11-350J20.5	7.58	7.68e-14	2.09e-11	0.33	0.23	Dupuytren's disease;	chr6:149350270	chr6:149796151~149826294:-
BRCA	cis	rs7772486	0.902	rs1125462	ENSG00000235652.6	RP11-545I5.3	7.58	7.68e-14	2.09e-11	0.23	0.23	Lobe attachment (rater-scored or self-reported);	chr6:146096696	chr6:145799409~145886585:+
BRCA	cis	rs7927771	0.832	rs935914	ENSG00000280615.1	Y_RNA	7.58	7.7e-14	2.09e-11	0.27	0.23	Subjective well-being;	chr11:47366048	chr11:47614898~47614994:-
BRCA	cis	rs919433	1	rs2195510	ENSG00000231621.1	AC013264.2	7.58	7.73e-14	2.1e-11	0.21	0.23	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197296471	chr2:197197991~197199273:+
BRCA	cis	rs8072100	0.656	rs2610367	ENSG00000228782.6	CTD-2026D20.3	7.58	7.74e-14	2.1e-11	0.25	0.23	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47492449	chr17:47450568~47492492:-
BRCA	cis	rs801193	1	rs4717319	ENSG00000237310.1	GS1-124K5.4	7.58	7.75e-14	2.11e-11	0.24	0.23	Aortic root size;	chr7:66777606	chr7:66493706~66495474:+
BRCA	cis	rs6740322	0.748	rs6544636	ENSG00000234936.1	AC010883.5	7.58	7.76e-14	2.11e-11	0.26	0.23	Coronary artery disease;	chr2:43260347	chr2:43229573~43233394:+
BRCA	cis	rs11971779	0.638	rs77668044	ENSG00000273391.1	RP11-634H22.1	7.58	7.76e-14	2.11e-11	0.26	0.23	Diisocyanate-induced asthma;	chr7:139426339	chr7:139359032~139359566:-
BRCA	cis	rs2880765	0.835	rs730372	ENSG00000259295.5	CSPG4P12	-7.58	7.77e-14	2.11e-11	-0.28	-0.23	Coronary artery disease;	chr15:85494962	chr15:85191438~85213905:+
BRCA	cis	rs11976180	1	rs1533267	ENSG00000170356.8	OR2A20P	-7.58	7.77e-14	2.11e-11	-0.32	-0.23	Obesity-related traits;	chr7:144069347	chr7:144250045~144252957:-
BRCA	cis	rs904251	0.6	rs1874736	ENSG00000204110.6	RP1-153P14.8	-7.58	7.77e-14	2.11e-11	-0.26	-0.23	Cognitive performance;	chr6:37480218	chr6:37507348~37535616:+
BRCA	cis	rs801193	0.904	rs4718403	ENSG00000237310.1	GS1-124K5.4	7.58	7.78e-14	2.11e-11	0.24	0.23	Aortic root size;	chr7:66777742	chr7:66493706~66495474:+
BRCA	cis	rs780094	0.585	rs7586601	ENSG00000234072.1	AC074117.10	-7.58	7.8e-14	2.12e-11	-0.22	-0.23	Urate levels in overweight individuals;C-reactive protein;Metabolic syndrome;Red blood cell count;Renal underexcretion gout;Nonalcoholic fatty liver disease;Age-related diseases, mortality and associated endophenotypes;Crohn's disease;Calcium levels;Fasting plasma glucose;Metabolic traits;Fasting blood glucose;Fasting blood insulin;Urate levels in obese individuals;Alcohol consumption (drinks per week);Height;Urate levels;Gondoic acid (20:1n-9) levels;Uric acid levels;Age-related disease endophenotypes;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Homeostasis model assessment of insulin resistance;Alcohol consumption;Fasting blood insulin (BMI interaction);Triglycerides;Fasting blood glucose (BMI interaction);Hypertriglyceridemia;LDL cholesterol;Type 2 diabetes;Triglyceride levels;	chr2:27361799	chr2:27356246~27367622:+
BRCA	cis	rs1075265	0.587	rs2949811	ENSG00000233266.1	HMGB1P31	7.58	7.8e-14	2.12e-11	0.27	0.23	Chronotype;Morning vs. evening chronotype;	chr2:53797028	chr2:54051334~54051760:+
BRCA	cis	rs9513627	0.915	rs7327204	ENSG00000280710.1	RP11-214F16.8	-7.58	7.81e-14	2.12e-11	-0.37	-0.23	Obesity-related traits;	chr13:99474698	chr13:99498524~99501315:+
BRCA	cis	rs875971	0.545	rs4441996	ENSG00000224316.1	RP11-479O9.2	-7.58	7.82e-14	2.12e-11	-0.25	-0.23	Aortic root size;	chr7:66123233	chr7:65773620~65802067:+
BRCA	cis	rs9880211	1	rs12695649	ENSG00000273486.1	RP11-731C17.2	7.58	7.85e-14	2.13e-11	0.3	0.23	Height;Body mass index;	chr3:136553074	chr3:136837338~136839021:-
BRCA	cis	rs9880211	0.948	rs34913797	ENSG00000273486.1	RP11-731C17.2	7.58	7.85e-14	2.13e-11	0.31	0.23	Height;Body mass index;	chr3:136408728	chr3:136837338~136839021:-
BRCA	cis	rs7927771	1	rs12787330	ENSG00000280615.1	Y_RNA	-7.58	7.86e-14	2.13e-11	-0.28	-0.23	Subjective well-being;	chr11:47790759	chr11:47614898~47614994:-
BRCA	cis	rs2117029	0.782	rs7969091	ENSG00000258017.1	RP11-386G11.10	-7.58	7.88e-14	2.14e-11	-0.31	-0.23	Intelligence (multi-trait analysis);	chr12:49070666	chr12:49127782~49147869:+
BRCA	cis	rs10459221	1	rs10459221	ENSG00000258017.1	RP11-386G11.10	-7.58	7.88e-14	2.14e-11	-0.31	-0.23	Bipolar disorder;	chr12:49073211	chr12:49127782~49147869:+
BRCA	cis	rs875971	0.66	rs79009421	ENSG00000237310.1	GS1-124K5.4	-7.57	7.91e-14	2.15e-11	-0.24	-0.23	Aortic root size;	chr7:66603522	chr7:66493706~66495474:+
BRCA	cis	rs293748	0.771	rs292181	ENSG00000250155.1	CTD-2353F22.1	-7.57	7.91e-14	2.15e-11	-0.32	-0.23	Obesity-related traits;	chr5:36952474	chr5:36666214~36725195:-
BRCA	cis	rs4934494	0.689	rs17127596	ENSG00000240996.1	RP11-80H5.7	7.57	7.92e-14	2.15e-11	0.27	0.23	Red blood cell count;	chr10:89816128	chr10:89694295~89697928:-
BRCA	cis	rs10129255	0.913	rs10140943	ENSG00000211972.2	IGHV3-66	7.57	7.95e-14	2.16e-11	0.18	0.23	Kawasaki disease;	chr14:106767441	chr14:106675017~106675544:-
BRCA	cis	rs9876781	1	rs6442123	ENSG00000244380.1	RP11-24C3.2	7.57	7.95e-14	2.16e-11	0.26	0.23	Longevity;	chr3:48458887	chr3:48440352~48446656:-
BRCA	cis	rs875971	0.66	rs6460308	ENSG00000237310.1	GS1-124K5.4	-7.57	7.96e-14	2.16e-11	-0.24	-0.23	Aortic root size;	chr7:66619753	chr7:66493706~66495474:+
BRCA	cis	rs2842992	0.915	rs2758335	ENSG00000237927.1	RP3-393E18.2	-7.57	7.96e-14	2.16e-11	-0.33	-0.23	Age-related macular degeneration (geographic atrophy);	chr6:159689979	chr6:159586955~159589169:-
BRCA	cis	rs10861661	0.963	rs10444533	ENSG00000260329.1	RP11-412D9.4	7.57	7.97e-14	2.16e-11	0.3	0.23	Triglyceride levels;	chr12:106835927	chr12:106954029~106955497:-
BRCA	cis	rs10754283	0.935	rs1934046	ENSG00000231613.1	RP5-943J3.1	-7.57	7.99e-14	2.17e-11	-0.26	-0.23	Amyotrophic lateral sclerosis (sporadic);	chr1:89653731	chr1:89788914~89790492:+
BRCA	cis	rs10510102	0.935	rs12240893	ENSG00000276742.1	RP11-500G22.4	7.57	7.99e-14	2.17e-11	0.39	0.23	Breast cancer;	chr10:121870572	chr10:121956782~121957098:+
BRCA	cis	rs1113500	0.805	rs11185248	ENSG00000226822.1	RP11-356N1.2	-7.57	8e-14	2.17e-11	-0.29	-0.23	Growth-regulated protein alpha levels;	chr1:108068379	chr1:108071482~108074519:+
BRCA	cis	rs6472827	0.904	rs11996617	ENSG00000253983.2	RP1-16A9.1	-7.57	8.01e-14	2.17e-11	-0.36	-0.23	Uterine fibroids;	chr8:74208452	chr8:74199396~74208441:+
BRCA	cis	rs3758911	1	rs1046095	ENSG00000255353.1	RP11-382M14.1	-7.57	8.03e-14	2.18e-11	-0.3	-0.23	Coronary artery disease;	chr11:107326509	chr11:107176286~107177530:+
BRCA	cis	rs812925	0.892	rs4672440	ENSG00000271889.1	RP11-493E12.1	-7.57	8.03e-14	2.18e-11	-0.3	-0.23	Immature fraction of reticulocytes;	chr2:61389518	chr2:61151433~61162105:-
BRCA	cis	rs4845875	0.6	rs4846039	ENSG00000242349.4	NPPA-AS1	7.57	8.04e-14	2.18e-11	0.27	0.23	Midregional pro atrial natriuretic peptide levels;	chr1:11776811	chr1:11841017~11848079:+
BRCA	cis	rs4845875	0.6	rs10779765	ENSG00000242349.4	NPPA-AS1	7.57	8.04e-14	2.18e-11	0.27	0.23	Midregional pro atrial natriuretic peptide levels;	chr1:11777954	chr1:11841017~11848079:+
BRCA	cis	rs4845875	0.563	rs10864540	ENSG00000242349.4	NPPA-AS1	7.57	8.04e-14	2.18e-11	0.27	0.23	Midregional pro atrial natriuretic peptide levels;	chr1:11778042	chr1:11841017~11848079:+
BRCA	cis	rs801193	1	rs2659906	ENSG00000237310.1	GS1-124K5.4	7.57	8.05e-14	2.18e-11	0.24	0.23	Aortic root size;	chr7:66700323	chr7:66493706~66495474:+
BRCA	cis	rs2439831	0.85	rs8032649	ENSG00000205771.5	CATSPER2P1	7.57	8.06e-14	2.19e-11	0.4	0.23	Lung cancer in ever smokers;	chr15:43842724	chr15:43726918~43747094:-
BRCA	cis	rs3733829	1	rs3733829	ENSG00000268529.1	CYP2T3P	-7.57	8.06e-14	2.19e-11	-0.29	-0.23	Smoking behavior;	chr19:40804666	chr19:41134722~41137308:+
BRCA	cis	rs2179367	0.632	rs2341774	ENSG00000231760.4	RP11-350J20.5	7.57	8.07e-14	2.19e-11	0.34	0.23	Dupuytren's disease;	chr6:149425014	chr6:149796151~149826294:-
BRCA	cis	rs13113518	0.729	rs11133377	ENSG00000273257.1	RP11-177J6.1	7.57	8.07e-14	2.19e-11	0.33	0.23	Height;	chr4:55413708	chr4:55387949~55388271:+
BRCA	cis	rs12188164	0.561	rs2721010	ENSG00000225138.6	CTD-2228K2.7	-7.57	8.08e-14	2.19e-11	-0.24	-0.23	Cystic fibrosis severity;	chr5:456800	chr5:473236~480884:+
BRCA	cis	rs7520050	0.807	rs4660312	ENSG00000280836.1	AL355480.1	-7.57	8.09e-14	2.19e-11	-0.26	-0.23	Reticulocyte count;Red blood cell count;	chr1:45644900	chr1:45581219~45581321:-
BRCA	cis	rs7520050	0.778	rs2991985	ENSG00000280836.1	AL355480.1	7.57	8.1e-14	2.2e-11	0.26	0.23	Reticulocyte count;Red blood cell count;	chr1:45614858	chr1:45581219~45581321:-
BRCA	cis	rs9880211	0.752	rs9838884	ENSG00000239213.4	NCK1-AS1	7.57	8.1e-14	2.2e-11	0.31	0.23	Height;Body mass index;	chr3:136736862	chr3:136841726~136862054:-
BRCA	cis	rs7927771	0.801	rs12798028	ENSG00000280615.1	Y_RNA	-7.57	8.13e-14	2.21e-11	-0.26	-0.23	Subjective well-being;	chr11:47583087	chr11:47614898~47614994:-
BRCA	cis	rs293748	0.771	rs292196	ENSG00000250155.1	CTD-2353F22.1	7.57	8.15e-14	2.21e-11	0.32	0.23	Obesity-related traits;	chr5:36914077	chr5:36666214~36725195:-
BRCA	cis	rs13113518	0.729	rs11133377	ENSG00000249700.7	SRD5A3-AS1	7.57	8.16e-14	2.21e-11	0.32	0.23	Height;	chr4:55413708	chr4:55363971~55395847:-
BRCA	cis	rs9649213	0.593	rs6465672	ENSG00000272950.1	RP11-307C18.1	-7.57	8.19e-14	2.22e-11	-0.28	-0.23	Prostate cancer (SNP x SNP interaction);	chr7:98334405	chr7:98322853~98323430:+
BRCA	cis	rs875971	0.66	rs6460308	ENSG00000224316.1	RP11-479O9.2	-7.57	8.2e-14	2.22e-11	-0.23	-0.23	Aortic root size;	chr7:66619753	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.619	rs10278371	ENSG00000237310.1	GS1-124K5.4	-7.57	8.21e-14	2.23e-11	-0.24	-0.23	Aortic root size;	chr7:66586553	chr7:66493706~66495474:+
BRCA	cis	rs1861628	1	rs1861628	ENSG00000237930.1	AC007563.4	7.57	8.21e-14	2.23e-11	0.27	0.23	Serum thyroid-stimulating hormone levels;Hypothyroidism;	chr2:216763707	chr2:216785774~216786144:-
BRCA	cis	rs853679	0.567	rs7774981	ENSG00000204709.4	LINC01556	7.57	8.24e-14	2.23e-11	0.34	0.23	Depression;	chr6:28379133	chr6:28943877~28944537:+
BRCA	cis	rs853679	0.567	rs7754960	ENSG00000204709.4	LINC01556	7.57	8.24e-14	2.23e-11	0.34	0.23	Depression;	chr6:28379168	chr6:28943877~28944537:+
BRCA	cis	rs2439831	0.85	rs28413704	ENSG00000275601.1	AC011330.13	-7.57	8.27e-14	2.24e-11	-0.37	-0.23	Lung cancer in ever smokers;	chr15:43856229	chr15:43642389~43643023:-
BRCA	cis	rs11098499	0.562	rs2389879	ENSG00000248280.1	RP11-33B1.2	-7.57	8.27e-14	2.24e-11	-0.22	-0.23	Corneal astigmatism;	chr4:119636529	chr4:119440561~119450157:-
BRCA	cis	rs875971	0.638	rs35986979	ENSG00000224316.1	RP11-479O9.2	-7.57	8.28e-14	2.24e-11	-0.23	-0.23	Aortic root size;	chr7:66624003	chr7:65773620~65802067:+
BRCA	cis	rs801193	1	rs13239306	ENSG00000224316.1	RP11-479O9.2	-7.57	8.28e-14	2.24e-11	-0.23	-0.23	Aortic root size;	chr7:66671030	chr7:65773620~65802067:+
BRCA	cis	rs2842992	0.915	rs2758350	ENSG00000237927.1	RP3-393E18.2	-7.57	8.28e-14	2.24e-11	-0.33	-0.23	Age-related macular degeneration (geographic atrophy);	chr6:159697024	chr6:159586955~159589169:-
BRCA	cis	rs1862618	0.853	rs252916	ENSG00000271828.1	CTD-2310F14.1	7.57	8.28e-14	2.25e-11	0.31	0.23	Initial pursuit acceleration;	chr5:56825961	chr5:56927874~56929573:+
BRCA	cis	rs9880211	0.706	rs9289513	ENSG00000239213.4	NCK1-AS1	7.57	8.29e-14	2.25e-11	0.3	0.23	Height;Body mass index;	chr3:136732904	chr3:136841726~136862054:-
BRCA	cis	rs1113500	0.814	rs12039712	ENSG00000226822.1	RP11-356N1.2	7.57	8.29e-14	2.25e-11	0.29	0.23	Growth-regulated protein alpha levels;	chr1:108098577	chr1:108071482~108074519:+
BRCA	cis	rs11976180	1	rs1919949	ENSG00000170356.8	OR2A20P	-7.57	8.31e-14	2.25e-11	-0.32	-0.23	Obesity-related traits;	chr7:144070630	chr7:144250045~144252957:-
BRCA	cis	rs4237845	0.844	rs7306124	ENSG00000257159.1	RP11-58A17.3	7.57	8.31e-14	2.25e-11	0.26	0.23	Intelligence (multi-trait analysis);	chr12:57909566	chr12:57967058~57968399:+
BRCA	cis	rs801193	0.935	rs11772264	ENSG00000237310.1	GS1-124K5.4	7.57	8.32e-14	2.25e-11	0.24	0.23	Aortic root size;	chr7:66711400	chr7:66493706~66495474:+
BRCA	cis	rs2274273	0.624	rs7155954	ENSG00000258413.1	RP11-665C16.6	-7.57	8.32e-14	2.25e-11	-0.31	-0.23	Protein biomarker;	chr14:55284225	chr14:55262767~55272075:-
BRCA	cis	rs7927771	0.839	rs7124681	ENSG00000280615.1	Y_RNA	-7.57	8.32e-14	2.25e-11	-0.26	-0.23	Subjective well-being;	chr11:47508395	chr11:47614898~47614994:-
BRCA	cis	rs2274273	0.553	rs56166765	ENSG00000258413.1	RP11-665C16.6	-7.57	8.33e-14	2.26e-11	-0.31	-0.23	Protein biomarker;	chr14:55271300	chr14:55262767~55272075:-
BRCA	cis	rs801193	0.935	rs2659899	ENSG00000237310.1	GS1-124K5.4	7.57	8.34e-14	2.26e-11	0.24	0.23	Aortic root size;	chr7:66721734	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.825	rs6951503	ENSG00000232559.3	GS1-124K5.12	-7.57	8.35e-14	2.26e-11	-0.28	-0.23	Aortic root size;	chr7:66253949	chr7:66554588~66576923:-
BRCA	cis	rs4934494	0.768	rs17125834	ENSG00000240996.1	RP11-80H5.7	-7.57	8.35e-14	2.26e-11	-0.29	-0.23	Red blood cell count;	chr10:89673405	chr10:89694295~89697928:-
BRCA	cis	rs4934494	0.768	rs12571918	ENSG00000240996.1	RP11-80H5.7	-7.57	8.35e-14	2.26e-11	-0.29	-0.23	Red blood cell count;	chr10:89674920	chr10:89694295~89697928:-
BRCA	cis	rs4934494	0.768	rs12776306	ENSG00000240996.1	RP11-80H5.7	-7.57	8.35e-14	2.26e-11	-0.29	-0.23	Red blood cell count;	chr10:89676300	chr10:89694295~89697928:-
BRCA	cis	rs4934494	0.768	rs7078321	ENSG00000240996.1	RP11-80H5.7	-7.57	8.35e-14	2.26e-11	-0.29	-0.23	Red blood cell count;	chr10:89678341	chr10:89694295~89697928:-
BRCA	cis	rs4934494	0.768	rs34379399	ENSG00000240996.1	RP11-80H5.7	-7.57	8.35e-14	2.26e-11	-0.29	-0.23	Red blood cell count;	chr10:89683526	chr10:89694295~89697928:-
BRCA	cis	rs11976180	1	rs2961132	ENSG00000170356.8	OR2A20P	-7.57	8.38e-14	2.27e-11	-0.33	-0.23	Obesity-related traits;	chr7:144071035	chr7:144250045~144252957:-
BRCA	cis	rs801193	0.844	rs2244022	ENSG00000236529.1	RP13-254B10.1	7.57	8.4e-14	2.28e-11	0.25	0.23	Aortic root size;	chr7:66737443	chr7:65840212~65840596:+
BRCA	cis	rs7927771	0.839	rs11039308	ENSG00000280615.1	Y_RNA	-7.57	8.42e-14	2.28e-11	-0.26	-0.23	Subjective well-being;	chr11:47600860	chr11:47614898~47614994:-
BRCA	cis	rs8012947	0.916	rs11627199	ENSG00000279636.2	LINC00216	7.57	8.42e-14	2.28e-11	0.27	0.23	Alcohol consumption in current drinkers;	chr14:58386288	chr14:58288033~58289158:+
BRCA	cis	rs875971	0.862	rs2909688	ENSG00000232559.3	GS1-124K5.12	7.57	8.42e-14	2.28e-11	0.28	0.23	Aortic root size;	chr7:66376625	chr7:66554588~66576923:-
BRCA	cis	rs4266144	0.558	rs7623382	ENSG00000244515.1	KRT18P34	-7.57	8.43e-14	2.28e-11	-0.27	-0.23	Coronary artery disease;	chr3:157115105	chr3:157162663~157163932:-
BRCA	cis	rs801193	1	rs11773829	ENSG00000224316.1	RP11-479O9.2	-7.57	8.44e-14	2.29e-11	-0.23	-0.23	Aortic root size;	chr7:66676087	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.66	rs79009421	ENSG00000224316.1	RP11-479O9.2	-7.57	8.48e-14	2.3e-11	-0.23	-0.23	Aortic root size;	chr7:66603522	chr7:65773620~65802067:+
BRCA	cis	rs56046484	0.703	rs116893322	ENSG00000259295.5	CSPG4P12	7.57	8.49e-14	2.3e-11	0.43	0.23	Testicular germ cell tumor;	chr15:84981397	chr15:85191438~85213905:+
BRCA	cis	rs4835473	0.637	rs1825040	ENSG00000251600.4	RP11-673E1.1	-7.57	8.5e-14	2.3e-11	-0.25	-0.23	Immature fraction of reticulocytes;	chr4:143794417	chr4:143912331~143982454:+
BRCA	cis	rs10510102	0.935	rs11200263	ENSG00000276742.1	RP11-500G22.4	7.56	8.52e-14	2.31e-11	0.39	0.23	Breast cancer;	chr10:121922836	chr10:121956782~121957098:+
BRCA	cis	rs704795	0.836	rs1083865	ENSG00000234072.1	AC074117.10	-7.56	8.53e-14	2.31e-11	-0.22	-0.23	Menopause (age at onset);	chr2:27397960	chr2:27356246~27367622:+
BRCA	cis	rs4845875	0.6	rs6699881	ENSG00000242349.4	NPPA-AS1	7.56	8.53e-14	2.31e-11	0.27	0.23	Midregional pro atrial natriuretic peptide levels;	chr1:11776571	chr1:11841017~11848079:+
BRCA	cis	rs875971	0.895	rs12531677	ENSG00000232559.3	GS1-124K5.12	-7.56	8.54e-14	2.31e-11	-0.28	-0.23	Aortic root size;	chr7:66304099	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.862	rs7798630	ENSG00000232559.3	GS1-124K5.12	-7.56	8.54e-14	2.31e-11	-0.28	-0.23	Aortic root size;	chr7:66306492	chr7:66554588~66576923:-
BRCA	cis	rs801193	1	rs2707836	ENSG00000237310.1	GS1-124K5.4	7.56	8.54e-14	2.31e-11	0.24	0.23	Aortic root size;	chr7:66695448	chr7:66493706~66495474:+
BRCA	cis	rs801193	0.844	rs7779971	ENSG00000237310.1	GS1-124K5.4	7.56	8.54e-14	2.31e-11	0.24	0.23	Aortic root size;	chr7:66696803	chr7:66493706~66495474:+
BRCA	cis	rs2243480	1	rs431318	ENSG00000273142.1	RP11-458F8.4	-7.56	8.55e-14	2.31e-11	-0.32	-0.23	Diabetic kidney disease;	chr7:66046610	chr7:66902857~66906297:+
BRCA	cis	rs4835473	0.897	rs924234	ENSG00000251600.4	RP11-673E1.1	7.56	8.58e-14	2.32e-11	0.27	0.23	Immature fraction of reticulocytes;	chr4:143706799	chr4:143912331~143982454:+
BRCA	cis	rs2880765	0.835	rs7168860	ENSG00000259295.5	CSPG4P12	7.56	8.59e-14	2.32e-11	0.28	0.23	Coronary artery disease;	chr15:85493799	chr15:85191438~85213905:+
BRCA	cis	rs4845875	0.6	rs1889293	ENSG00000242349.4	NPPA-AS1	7.56	8.59e-14	2.32e-11	0.27	0.23	Midregional pro atrial natriuretic peptide levels;	chr1:11780805	chr1:11841017~11848079:+
BRCA	cis	rs4835473	0.897	rs6537171	ENSG00000251600.4	RP11-673E1.1	7.56	8.62e-14	2.33e-11	0.28	0.23	Immature fraction of reticulocytes;	chr4:143709222	chr4:143912331~143982454:+
BRCA	cis	rs7809950	1	rs2712201	ENSG00000238832.1	snoU109	-7.56	8.62e-14	2.33e-11	-0.3	-0.23	Coronary artery disease;	chr7:107505119	chr7:107603363~107603507:+
BRCA	cis	rs8062405	0.824	rs4788083	ENSG00000251417.2	RP11-1348G14.4	-7.56	8.62e-14	2.33e-11	-0.26	-0.23	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28534128	chr16:28802743~28817828:+
BRCA	cis	rs2179367	0.632	rs2143075	ENSG00000231760.4	RP11-350J20.5	7.56	8.63e-14	2.33e-11	0.33	0.23	Dupuytren's disease;	chr6:149425507	chr6:149796151~149826294:-
BRCA	cis	rs11723261	0.582	rs6599293	ENSG00000211553.1	AC253576.2	-7.56	8.64e-14	2.34e-11	-0.33	-0.23	Immune response to smallpox vaccine (IL-6);	chr4:139246	chr4:136461~136568:+
BRCA	cis	rs61270009	0.955	rs13189889	ENSG00000247828.6	TMEM161B-AS1	7.56	8.66e-14	2.34e-11	0.3	0.23	Depressive symptoms;	chr5:88365589	chr5:88268895~88436685:+
BRCA	cis	rs4803480	0.578	rs7252454	ENSG00000270164.1	LINC01480	-7.56	8.66e-14	2.34e-11	-0.27	-0.23	Schizophrenia;	chr19:41527343	chr19:41535183~41536904:+
BRCA	cis	rs7615952	0.576	rs2276727	ENSG00000250012.1	RP11-124N2.1	-7.56	8.66e-14	2.34e-11	-0.31	-0.23	Blood pressure (smoking interaction);	chr3:126107400	chr3:126084220~126095349:+
BRCA	cis	rs875971	0.545	rs316316	ENSG00000224316.1	RP11-479O9.2	-7.56	8.68e-14	2.35e-11	-0.26	-0.23	Aortic root size;	chr7:66149270	chr7:65773620~65802067:+
BRCA	cis	rs7246657	1	rs7246657	ENSG00000276846.1	CTD-3220F14.3	-7.56	8.68e-14	2.35e-11	-0.31	-0.23	Coronary artery calcification;	chr19:37256206	chr19:37314868~37315620:-
BRCA	cis	rs10129255	0.5	rs12101190	ENSG00000211970.3	IGHV4-61	-7.56	8.69e-14	2.35e-11	-0.15	-0.23	Kawasaki disease;	chr14:106784149	chr14:106639119~106639657:-
BRCA	cis	rs10129255	0.518	rs8004895	ENSG00000211970.3	IGHV4-61	-7.56	8.69e-14	2.35e-11	-0.15	-0.23	Kawasaki disease;	chr14:106785139	chr14:106639119~106639657:-
BRCA	cis	rs42648	0.617	rs11563435	ENSG00000225498.1	AC002064.5	7.56	8.7e-14	2.35e-11	0.22	0.23	Homocysteine levels;	chr7:90270893	chr7:90312496~90322592:+
BRCA	cis	rs875971	0.66	rs801211	ENSG00000224316.1	RP11-479O9.2	-7.56	8.71e-14	2.35e-11	-0.23	-0.23	Aortic root size;	chr7:66550702	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.638	rs801205	ENSG00000224316.1	RP11-479O9.2	-7.56	8.71e-14	2.35e-11	-0.23	-0.23	Aortic root size;	chr7:66557157	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.617	rs810400	ENSG00000224316.1	RP11-479O9.2	-7.56	8.71e-14	2.35e-11	-0.23	-0.23	Aortic root size;	chr7:66557902	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.66	rs28698552	ENSG00000224316.1	RP11-479O9.2	7.56	8.71e-14	2.36e-11	0.23	0.23	Aortic root size;	chr7:66540031	chr7:65773620~65802067:+
BRCA	cis	rs2980436	1	rs2980436	ENSG00000253981.4	ALG1L13P	-7.56	8.72e-14	2.36e-11	-0.27	-0.23	Schizophrenia;	chr8:8234503	chr8:8236003~8244667:-
BRCA	cis	rs1609391	0.543	rs2117009	ENSG00000273486.1	RP11-731C17.2	-7.56	8.75e-14	2.36e-11	-0.25	-0.23	Neuroticism;	chr3:136914729	chr3:136837338~136839021:-
BRCA	cis	rs42490	0.873	rs218903	ENSG00000251136.7	RP11-37B2.1	-7.56	8.76e-14	2.37e-11	-0.23	-0.23	Leprosy;	chr8:89721458	chr8:89609409~89757727:-
BRCA	cis	rs2742234	0.504	rs7093409	ENSG00000273008.1	RP11-351D16.3	7.56	8.77e-14	2.37e-11	0.28	0.23	Hirschsprung disease;	chr10:43244619	chr10:43136824~43138334:-
BRCA	cis	rs2243480	1	rs160655	ENSG00000273142.1	RP11-458F8.4	-7.56	8.78e-14	2.37e-11	-0.32	-0.23	Diabetic kidney disease;	chr7:66068227	chr7:66902857~66906297:+
BRCA	cis	rs801193	1	rs7788576	ENSG00000224316.1	RP11-479O9.2	-7.56	8.78e-14	2.37e-11	-0.23	-0.23	Aortic root size;	chr7:66683315	chr7:65773620~65802067:+
BRCA	cis	rs732716	0.853	rs1127888	ENSG00000267769.1	CTB-50L17.9	-7.56	8.78e-14	2.37e-11	-0.27	-0.23	Mean corpuscular volume;	chr19:4454086	chr19:4454014~4455286:+
BRCA	cis	rs301901	1	rs158623	ENSG00000250155.1	CTD-2353F22.1	-7.56	8.79e-14	2.38e-11	-0.25	-0.23	Height;	chr5:36882917	chr5:36666214~36725195:-
BRCA	cis	rs9649213	0.593	rs2394854	ENSG00000272950.1	RP11-307C18.1	7.56	8.8e-14	2.38e-11	0.29	0.23	Prostate cancer (SNP x SNP interaction);	chr7:98397994	chr7:98322853~98323430:+
BRCA	cis	rs9880211	0.8	rs9873536	ENSG00000239213.4	NCK1-AS1	7.56	8.8e-14	2.38e-11	0.31	0.23	Height;Body mass index;	chr3:136755425	chr3:136841726~136862054:-
BRCA	cis	rs2439831	0.85	rs7169322	ENSG00000275601.1	AC011330.13	-7.56	8.81e-14	2.38e-11	-0.37	-0.23	Lung cancer in ever smokers;	chr15:43838816	chr15:43642389~43643023:-
BRCA	cis	rs2439831	0.85	rs28707214	ENSG00000275601.1	AC011330.13	-7.56	8.81e-14	2.38e-11	-0.37	-0.23	Lung cancer in ever smokers;	chr15:43839425	chr15:43642389~43643023:-
BRCA	cis	rs10129255	0.5	rs34326748	ENSG00000211970.3	IGHV4-61	-7.56	8.83e-14	2.39e-11	-0.15	-0.23	Kawasaki disease;	chr14:106782523	chr14:106639119~106639657:-
BRCA	cis	rs10129255	0.5	rs10143385	ENSG00000211970.3	IGHV4-61	-7.56	8.83e-14	2.39e-11	-0.15	-0.23	Kawasaki disease;	chr14:106782559	chr14:106639119~106639657:-
BRCA	cis	rs4934494	0.768	rs2094214	ENSG00000240996.1	RP11-80H5.7	-7.56	8.83e-14	2.39e-11	-0.29	-0.23	Red blood cell count;	chr10:89649624	chr10:89694295~89697928:-
BRCA	cis	rs732716	0.853	rs12459922	ENSG00000267769.1	CTB-50L17.9	-7.56	8.83e-14	2.39e-11	-0.27	-0.23	Mean corpuscular volume;	chr19:4455865	chr19:4454014~4455286:+
BRCA	cis	rs10129255	0.536	rs10142951	ENSG00000211970.3	IGHV4-61	-7.56	8.84e-14	2.39e-11	-0.15	-0.23	Kawasaki disease;	chr14:106782337	chr14:106639119~106639657:-
BRCA	cis	rs10510102	0.935	rs11200203	ENSG00000276742.1	RP11-500G22.4	7.56	8.84e-14	2.39e-11	0.39	0.23	Breast cancer;	chr10:121874014	chr10:121956782~121957098:+
BRCA	cis	rs875971	0.619	rs12533585	ENSG00000224316.1	RP11-479O9.2	7.56	8.84e-14	2.39e-11	0.23	0.23	Aortic root size;	chr7:66519618	chr7:65773620~65802067:+
BRCA	cis	rs526231	0.575	rs10463990	ENSG00000175749.11	EIF3KP1	7.56	8.84e-14	2.39e-11	0.34	0.23	Primary biliary cholangitis;	chr5:102981714	chr5:103032376~103033031:+
BRCA	cis	rs6570726	0.935	rs407721	ENSG00000235652.6	RP11-545I5.3	7.56	8.85e-14	2.39e-11	0.22	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145550218	chr6:145799409~145886585:+
BRCA	cis	rs6142102	0.886	rs6142098	ENSG00000275784.1	RP5-1125A11.6	-7.56	8.85e-14	2.39e-11	-0.26	-0.23	Skin pigmentation;	chr20:34100488	chr20:33989480~33991818:-
BRCA	cis	rs34779708	0.733	rs12254018	ENSG00000271335.4	RP11-324I22.4	7.56	8.86e-14	2.39e-11	0.23	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35261713	chr10:35314552~35336401:-
BRCA	cis	rs6570726	0.935	rs408768	ENSG00000235652.6	RP11-545I5.3	7.56	8.88e-14	2.4e-11	0.22	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145550599	chr6:145799409~145886585:+
BRCA	cis	rs801193	1	rs62466793	ENSG00000237310.1	GS1-124K5.4	7.56	8.89e-14	2.4e-11	0.24	0.23	Aortic root size;	chr7:66726530	chr7:66493706~66495474:+
BRCA	cis	rs9309473	1	rs10190219	ENSG00000163016.8	ALMS1P	7.56	8.91e-14	2.41e-11	0.29	0.23	Metabolite levels;	chr2:73431203	chr2:73644919~73685576:+
BRCA	cis	rs875971	0.66	rs62465434	ENSG00000224316.1	RP11-479O9.2	7.56	8.92e-14	2.41e-11	0.23	0.23	Aortic root size;	chr7:66540165	chr7:65773620~65802067:+
BRCA	cis	rs74233809	1	rs1060240	ENSG00000213277.3	MARCKSL1P1	7.56	8.94e-14	2.41e-11	0.43	0.23	Birth weight;	chr10:103123580	chr10:103175554~103176094:+
BRCA	cis	rs74233809	1	rs10883835	ENSG00000213277.3	MARCKSL1P1	7.56	8.94e-14	2.41e-11	0.43	0.23	Birth weight;	chr10:103124451	chr10:103175554~103176094:+
BRCA	cis	rs9876781	0.967	rs9876891	ENSG00000244380.1	RP11-24C3.2	7.56	8.94e-14	2.42e-11	0.27	0.23	Longevity;	chr3:48440024	chr3:48440352~48446656:-
BRCA	cis	rs4934494	0.635	rs12572869	ENSG00000240996.1	RP11-80H5.7	-7.56	8.95e-14	2.42e-11	-0.29	-0.23	Red blood cell count;	chr10:89653611	chr10:89694295~89697928:-
BRCA	cis	rs301901	1	rs300064	ENSG00000250155.1	CTD-2353F22.1	7.56	8.95e-14	2.42e-11	0.25	0.23	Height;	chr5:37025769	chr5:36666214~36725195:-
BRCA	cis	rs875971	0.66	rs801217	ENSG00000224316.1	RP11-479O9.2	-7.56	8.96e-14	2.42e-11	-0.23	-0.23	Aortic root size;	chr7:66545590	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.638	rs801216	ENSG00000224316.1	RP11-479O9.2	-7.56	8.96e-14	2.42e-11	-0.23	-0.23	Aortic root size;	chr7:66546680	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.66	rs13224319	ENSG00000224316.1	RP11-479O9.2	7.56	8.96e-14	2.42e-11	0.23	0.23	Aortic root size;	chr7:66542376	chr7:65773620~65802067:+
BRCA	cis	rs293748	0.771	rs158792	ENSG00000250155.1	CTD-2353F22.1	-7.56	8.96e-14	2.42e-11	-0.32	-0.23	Obesity-related traits;	chr5:36889068	chr5:36666214~36725195:-
BRCA	cis	rs4865169	0.791	rs11731868	ENSG00000269949.1	RP11-738E22.3	-7.56	8.97e-14	2.42e-11	-0.27	-0.23	Breast cancer;	chr4:57029048	chr4:56960927~56961373:-
BRCA	cis	rs904251	0.523	rs10807184	ENSG00000204110.6	RP1-153P14.8	-7.56	8.97e-14	2.42e-11	-0.25	-0.23	Cognitive performance;	chr6:37515937	chr6:37507348~37535616:+
BRCA	cis	rs4964805	1	rs4964805	ENSG00000257681.1	RP11-341G23.4	7.56	8.98e-14	2.42e-11	0.28	0.23	Attention deficit hyperactivity disorder;	chr12:103799046	chr12:103746315~103768858:-
BRCA	cis	rs17772222	0.917	rs61986670	ENSG00000258983.2	RP11-507K2.2	7.56	8.98e-14	2.42e-11	0.26	0.23	Coronary artery calcification;	chr14:88730875	chr14:88499334~88515502:+
BRCA	cis	rs7811142	0.887	rs35111986	ENSG00000242294.5	STAG3L5P	7.56	9.02e-14	2.43e-11	0.24	0.23	Platelet count;	chr7:100402651	chr7:100336079~100351900:+
BRCA	cis	rs66887589	0.934	rs2389873	ENSG00000248280.1	RP11-33B1.2	-7.56	9.07e-14	2.45e-11	-0.21	-0.23	Diastolic blood pressure;	chr4:119633559	chr4:119440561~119450157:-
BRCA	cis	rs66887589	0.934	rs4834792	ENSG00000248280.1	RP11-33B1.2	-7.56	9.07e-14	2.45e-11	-0.21	-0.23	Diastolic blood pressure;	chr4:119634541	chr4:119440561~119450157:-
BRCA	cis	rs3096299	0.679	rs3096322	ENSG00000274627.1	RP11-104N10.2	-7.56	9.1e-14	2.46e-11	-0.24	-0.23	Multiple myeloma (IgH translocation);	chr16:89374715	chr16:89516797~89522217:+
BRCA	cis	rs61270009	0.955	rs2305104	ENSG00000247828.6	TMEM161B-AS1	-7.56	9.1e-14	2.46e-11	-0.29	-0.23	Depressive symptoms;	chr5:88324853	chr5:88268895~88436685:+
BRCA	cis	rs875971	0.638	rs3898855	ENSG00000237310.1	GS1-124K5.4	-7.56	9.1e-14	2.46e-11	-0.24	-0.23	Aortic root size;	chr7:66571411	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.638	rs10278816	ENSG00000237310.1	GS1-124K5.4	-7.56	9.1e-14	2.46e-11	-0.24	-0.23	Aortic root size;	chr7:66572000	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.66	rs10281080	ENSG00000237310.1	GS1-124K5.4	-7.56	9.1e-14	2.46e-11	-0.24	-0.23	Aortic root size;	chr7:66577454	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.66	rs10950044	ENSG00000237310.1	GS1-124K5.4	-7.56	9.1e-14	2.46e-11	-0.24	-0.23	Aortic root size;	chr7:66577989	chr7:66493706~66495474:+
BRCA	cis	rs9880211	1	rs34757183	ENSG00000273486.1	RP11-731C17.2	7.56	9.11e-14	2.46e-11	0.3	0.23	Height;Body mass index;	chr3:136424826	chr3:136837338~136839021:-
BRCA	cis	rs2034650	0.544	rs8034416	ENSG00000223313.1	RNU6-516P	7.55	9.15e-14	2.47e-11	0.28	0.23	Interstitial lung disease;	chr15:40411140	chr15:40529570~40529673:+
BRCA	cis	rs875971	0.861	rs801215	ENSG00000232559.3	GS1-124K5.12	-7.55	9.15e-14	2.47e-11	-0.28	-0.23	Aortic root size;	chr7:66546951	chr7:66554588~66576923:-
BRCA	cis	rs9527	0.637	rs12219247	ENSG00000236937.2	PTGES3P4	7.55	9.17e-14	2.47e-11	0.3	0.23	Arsenic metabolism;	chr10:102853604	chr10:102845595~102845950:+
BRCA	cis	rs875971	0.66	rs12698534	ENSG00000224316.1	RP11-479O9.2	7.55	9.18e-14	2.48e-11	0.23	0.23	Aortic root size;	chr7:66521858	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.66	rs1860468	ENSG00000237310.1	GS1-124K5.4	-7.55	9.2e-14	2.48e-11	-0.24	-0.23	Aortic root size;	chr7:66642265	chr7:66493706~66495474:+
BRCA	cis	rs867371	0.762	rs1846910	ENSG00000259429.4	UBE2Q2P2	-7.55	9.2e-14	2.48e-11	-0.23	-0.23	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82279439	chr15:82355142~82420075:+
BRCA	cis	rs4835473	0.897	rs12505617	ENSG00000251600.4	RP11-673E1.1	7.55	9.22e-14	2.49e-11	0.28	0.23	Immature fraction of reticulocytes;	chr4:143723522	chr4:143912331~143982454:+
BRCA	cis	rs2179367	0.632	rs9285520	ENSG00000231760.4	RP11-350J20.5	-7.55	9.22e-14	2.49e-11	-0.32	-0.23	Dupuytren's disease;	chr6:149372001	chr6:149796151~149826294:-
BRCA	cis	rs10492201	0.529	rs10878724	ENSG00000255733.4	IFNG-AS1	-7.55	9.25e-14	2.49e-11	-0.21	-0.23	Itch intensity from mosquito bite adjusted by bite size;	chr12:68006091	chr12:67989445~68234686:+
BRCA	cis	rs74233809	1	rs9633712	ENSG00000213277.3	MARCKSL1P1	7.55	9.25e-14	2.49e-11	0.42	0.23	Birth weight;	chr10:103114004	chr10:103175554~103176094:+
BRCA	cis	rs74233809	0.786	rs11191564	ENSG00000213277.3	MARCKSL1P1	7.55	9.25e-14	2.49e-11	0.42	0.23	Birth weight;	chr10:103118786	chr10:103175554~103176094:+
BRCA	cis	rs7927771	0.965	rs4752881	ENSG00000280615.1	Y_RNA	-7.55	9.26e-14	2.5e-11	-0.28	-0.23	Subjective well-being;	chr11:47876983	chr11:47614898~47614994:-
BRCA	cis	rs904251	0.561	rs1757189	ENSG00000204110.6	RP1-153P14.8	-7.55	9.33e-14	2.52e-11	-0.25	-0.23	Cognitive performance;	chr6:37515951	chr6:37507348~37535616:+
BRCA	cis	rs2179367	0.552	rs11155652	ENSG00000231760.4	RP11-350J20.5	7.55	9.34e-14	2.52e-11	0.33	0.23	Dupuytren's disease;	chr6:149417849	chr6:149796151~149826294:-
BRCA	cis	rs2179367	0.632	rs12209364	ENSG00000231760.4	RP11-350J20.5	7.55	9.34e-14	2.52e-11	0.33	0.23	Dupuytren's disease;	chr6:149418062	chr6:149796151~149826294:-
BRCA	cis	rs293748	0.571	rs9632396	ENSG00000250155.1	CTD-2353F22.1	-7.55	9.36e-14	2.52e-11	-0.3	-0.23	Obesity-related traits;	chr5:37140229	chr5:36666214~36725195:-
BRCA	cis	rs293748	0.571	rs10512664	ENSG00000250155.1	CTD-2353F22.1	-7.55	9.36e-14	2.52e-11	-0.3	-0.23	Obesity-related traits;	chr5:37158021	chr5:36666214~36725195:-
BRCA	cis	rs74233809	1	rs75970938	ENSG00000213277.3	MARCKSL1P1	7.55	9.36e-14	2.52e-11	0.44	0.23	Birth weight;	chr10:103033891	chr10:103175554~103176094:+
BRCA	cis	rs9649213	0.593	rs6970990	ENSG00000272950.1	RP11-307C18.1	7.55	9.37e-14	2.52e-11	0.29	0.23	Prostate cancer (SNP x SNP interaction);	chr7:98296070	chr7:98322853~98323430:+
BRCA	cis	rs9649213	0.555	rs34695842	ENSG00000272950.1	RP11-307C18.1	7.55	9.37e-14	2.52e-11	0.29	0.23	Prostate cancer (SNP x SNP interaction);	chr7:98301750	chr7:98322853~98323430:+
BRCA	cis	rs2348418	0.669	rs7959641	ENSG00000247934.4	RP11-967K21.1	7.55	9.4e-14	2.53e-11	0.26	0.23	Lung function (FEV1);Lung function (FVC);	chr12:28237267	chr12:28163298~28190738:-
BRCA	cis	rs4934494	0.689	rs11185895	ENSG00000240996.1	RP11-80H5.7	7.55	9.41e-14	2.53e-11	0.27	0.23	Red blood cell count;	chr10:89817482	chr10:89694295~89697928:-
BRCA	cis	rs74233809	1	rs11191575	ENSG00000213277.3	MARCKSL1P1	7.55	9.41e-14	2.53e-11	0.42	0.23	Birth weight;	chr10:103138580	chr10:103175554~103176094:+
BRCA	cis	rs6921919	0.609	rs67211468	ENSG00000204709.4	LINC01556	7.55	9.42e-14	2.54e-11	0.31	0.23	Autism spectrum disorder or schizophrenia;	chr6:28424210	chr6:28943877~28944537:+
BRCA	cis	rs858239	0.6	rs13438179	ENSG00000230042.1	AK3P3	-7.55	9.42e-14	2.54e-11	-0.26	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23104232	chr7:23129178~23129841:+
BRCA	cis	rs2243480	0.764	rs2460423	ENSG00000273142.1	RP11-458F8.4	-7.55	9.43e-14	2.54e-11	-0.32	-0.23	Diabetic kidney disease;	chr7:66136229	chr7:66902857~66906297:+
BRCA	cis	rs2028299	0.879	rs4932262	ENSG00000259677.1	RP11-493E3.1	7.55	9.46e-14	2.55e-11	0.32	0.23	Type 2 diabetes;	chr15:89896365	chr15:89876540~89877285:+
BRCA	cis	rs12188164	0.561	rs2251843	ENSG00000225138.6	CTD-2228K2.7	7.55	9.47e-14	2.55e-11	0.24	0.23	Cystic fibrosis severity;	chr5:457840	chr5:473236~480884:+
BRCA	cis	rs875971	0.522	rs1968127	ENSG00000237310.1	GS1-124K5.4	-7.55	9.49e-14	2.56e-11	-0.24	-0.23	Aortic root size;	chr7:66591816	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.862	rs28470208	ENSG00000232559.3	GS1-124K5.12	-7.55	9.49e-14	2.56e-11	-0.28	-0.23	Aortic root size;	chr7:66119713	chr7:66554588~66576923:-
BRCA	cis	rs27524	0.734	rs27037	ENSG00000248734.2	CTD-2260A17.1	7.55	9.5e-14	2.56e-11	0.25	0.23	Hodgkin's lymphoma;Psoriasis;	chr5:96758990	chr5:96784777~96785999:+
BRCA	cis	rs2243480	1	rs1499614	ENSG00000273142.1	RP11-458F8.4	-7.55	9.52e-14	2.56e-11	-0.31	-0.23	Diabetic kidney disease;	chr7:66265811	chr7:66902857~66906297:+
BRCA	cis	rs2098713	0.512	rs13166974	ENSG00000250155.1	CTD-2353F22.1	-7.55	9.54e-14	2.57e-11	-0.3	-0.23	Telomere length;	chr5:37171263	chr5:36666214~36725195:-
BRCA	cis	rs7927771	1	rs10838747	ENSG00000280615.1	Y_RNA	-7.55	9.56e-14	2.57e-11	-0.28	-0.23	Subjective well-being;	chr11:47694772	chr11:47614898~47614994:-
BRCA	cis	rs4713118	0.669	rs200997	ENSG00000220721.1	OR1F12	7.55	9.57e-14	2.58e-11	0.27	0.23	Parkinson's disease;	chr6:27844037	chr6:28073316~28074233:+
BRCA	cis	rs875971	1	rs1981798	ENSG00000232559.3	GS1-124K5.12	7.55	9.57e-14	2.58e-11	0.27	0.23	Aortic root size;	chr7:66489916	chr7:66554588~66576923:-
BRCA	cis	rs9880211	0.8	rs9813376	ENSG00000239213.4	NCK1-AS1	7.55	9.57e-14	2.58e-11	0.31	0.23	Height;Body mass index;	chr3:136756584	chr3:136841726~136862054:-
BRCA	cis	rs11191419	1	rs11191419	ENSG00000236937.2	PTGES3P4	7.55	9.59e-14	2.58e-11	0.3	0.23	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr10:102852578	chr10:102845595~102845950:+
BRCA	cis	rs2028299	0.92	rs1866476	ENSG00000259677.1	RP11-493E3.1	7.55	9.6e-14	2.59e-11	0.3	0.23	Type 2 diabetes;	chr15:89885311	chr15:89876540~89877285:+
BRCA	cis	rs10754283	0.934	rs6661282	ENSG00000231613.1	RP5-943J3.1	7.55	9.6e-14	2.59e-11	0.26	0.23	Amyotrophic lateral sclerosis (sporadic);	chr1:89654433	chr1:89788914~89790492:+
BRCA	cis	rs875971	0.628	rs6974355	ENSG00000224316.1	RP11-479O9.2	7.55	9.61e-14	2.59e-11	0.23	0.23	Aortic root size;	chr7:66376994	chr7:65773620~65802067:+
BRCA	cis	rs2742234	0.541	rs7096500	ENSG00000273008.1	RP11-351D16.3	7.55	9.62e-14	2.59e-11	0.29	0.23	Hirschsprung disease;	chr10:43216647	chr10:43136824~43138334:-
BRCA	cis	rs801193	0.967	rs2707849	ENSG00000224316.1	RP11-479O9.2	7.55	9.62e-14	2.59e-11	0.23	0.23	Aortic root size;	chr7:66687725	chr7:65773620~65802067:+
BRCA	cis	rs2842992	0.872	rs1570318	ENSG00000237927.1	RP3-393E18.2	-7.55	9.62e-14	2.59e-11	-0.32	-0.23	Age-related macular degeneration (geographic atrophy);	chr6:159690441	chr6:159586955~159589169:-
BRCA	cis	rs7520050	0.771	rs4660882	ENSG00000280836.1	AL355480.1	-7.55	9.63e-14	2.59e-11	-0.26	-0.23	Reticulocyte count;Red blood cell count;	chr1:45650620	chr1:45581219~45581321:-
BRCA	cis	rs2898290	0.5	rs11998678	ENSG00000255046.1	RP11-297N6.4	7.55	9.63e-14	2.59e-11	0.27	0.23	Systolic blood pressure;	chr8:11972641	chr8:11797928~11802568:-
BRCA	cis	rs58873874	0.579	rs10040318	ENSG00000251405.2	CTB-109A12.1	7.55	9.65e-14	2.6e-11	0.46	0.23	Bipolar disorder (body mass index interaction);	chr5:157283016	chr5:157362615~157460078:-
BRCA	cis	rs6921919	0.583	rs3800328	ENSG00000204709.4	LINC01556	7.55	9.68e-14	2.61e-11	0.31	0.23	Autism spectrum disorder or schizophrenia;	chr6:28423066	chr6:28943877~28944537:+
BRCA	cis	rs1609391	0.543	rs1347209	ENSG00000273486.1	RP11-731C17.2	7.55	9.69e-14	2.61e-11	0.25	0.23	Neuroticism;	chr3:136907855	chr3:136837338~136839021:-
BRCA	cis	rs891378	0.675	rs6700746	ENSG00000274245.1	RP11-357P18.2	-7.55	9.7e-14	2.61e-11	-0.29	-0.23	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207228666	chr1:207372559~207373252:+
BRCA	cis	rs3781264	0.761	rs11187869	ENSG00000273450.1	RP11-76P2.4	7.55	9.7e-14	2.61e-11	0.32	0.23	Esophageal cancer and gastric cancer;	chr10:94327740	chr10:94314907~94315327:-
BRCA	cis	rs34779708	0.733	rs3853672	ENSG00000271335.4	RP11-324I22.4	7.55	9.7e-14	2.61e-11	0.23	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35260678	chr10:35314552~35336401:-
BRCA	cis	rs11159086	1	rs11626856	ENSG00000259005.1	RP3-449M8.6	7.55	9.73e-14	2.62e-11	0.38	0.23	Advanced glycation end-product levels;	chr14:74469665	chr14:74474007~74474864:-
BRCA	cis	rs712022	0.534	rs7395098	ENSG00000246225.5	RP11-17A1.3	-7.55	9.74e-14	2.62e-11	-0.27	-0.23	Dialysis-related mortality;	chr11:22856901	chr11:22829380~22945393:+
BRCA	cis	rs7520050	0.778	rs3013597	ENSG00000280836.1	AL355480.1	-7.55	9.74e-14	2.62e-11	-0.26	-0.23	Reticulocyte count;Red blood cell count;	chr1:45662684	chr1:45581219~45581321:-
BRCA	cis	rs74233809	1	rs732998	ENSG00000213277.3	MARCKSL1P1	-7.55	9.79e-14	2.63e-11	-0.41	-0.23	Birth weight;	chr10:103138144	chr10:103175554~103176094:+
BRCA	cis	rs17772222	0.837	rs57118463	ENSG00000258983.2	RP11-507K2.2	7.55	9.79e-14	2.64e-11	0.26	0.23	Coronary artery calcification;	chr14:88665822	chr14:88499334~88515502:+
BRCA	cis	rs4934494	0.768	rs67111731	ENSG00000240996.1	RP11-80H5.7	-7.55	9.81e-14	2.64e-11	-0.29	-0.23	Red blood cell count;	chr10:89659528	chr10:89694295~89697928:-
BRCA	cis	rs801193	1	rs10252765	ENSG00000224316.1	RP11-479O9.2	7.55	9.82e-14	2.64e-11	0.23	0.23	Aortic root size;	chr7:66763745	chr7:65773620~65802067:+
BRCA	cis	rs17772222	0.917	rs12431548	ENSG00000258983.2	RP11-507K2.2	7.55	9.83e-14	2.64e-11	0.26	0.23	Coronary artery calcification;	chr14:88635826	chr14:88499334~88515502:+
BRCA	cis	rs11098499	0.588	rs6534149	ENSG00000248280.1	RP11-33B1.2	-7.54	9.85e-14	2.65e-11	-0.22	-0.23	Corneal astigmatism;	chr4:119638137	chr4:119440561~119450157:-
BRCA	cis	rs2274273	0.624	rs10146637	ENSG00000258413.1	RP11-665C16.6	-7.54	9.86e-14	2.65e-11	-0.3	-0.23	Protein biomarker;	chr14:55278092	chr14:55262767~55272075:-
BRCA	cis	rs987724	0.592	rs1430410	ENSG00000240875.4	LINC00886	-7.54	9.86e-14	2.65e-11	-0.26	-0.23	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156807773	chr3:156747346~156817062:-
BRCA	cis	rs17711722	0.523	rs313812	ENSG00000273024.4	INTS4P2	7.54	9.88e-14	2.66e-11	0.26	0.23	Calcium levels;	chr7:66040056	chr7:65647864~65715661:+
BRCA	cis	rs8177876	0.749	rs10459871	ENSG00000261838.4	RP11-303E16.6	7.54	9.9e-14	2.66e-11	0.47	0.23	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81059462	chr16:81069854~81076598:+
BRCA	cis	rs287982	1	rs72780999	ENSG00000269973.1	RP11-95D17.1	-7.54	9.91e-14	2.66e-11	-0.29	-0.23	Nonsyndromic cleft lip with cleft palate;	chr2:9841841	chr2:9936360~9939590:+
BRCA	cis	rs2880765	0.835	rs6497202	ENSG00000259295.5	CSPG4P12	7.54	9.92e-14	2.67e-11	0.28	0.23	Coronary artery disease;	chr15:85478144	chr15:85191438~85213905:+
BRCA	cis	rs1552244	0.882	rs28366039	ENSG00000180385.7	EMC3-AS1	7.54	9.93e-14	2.67e-11	0.3	0.23	Alzheimer's disease;	chr3:9987304	chr3:9986893~10006990:+
BRCA	cis	rs293748	0.771	rs158797	ENSG00000250155.1	CTD-2353F22.1	-7.54	9.95e-14	2.67e-11	-0.32	-0.23	Obesity-related traits;	chr5:36870318	chr5:36666214~36725195:-
BRCA	cis	rs2274273	0.563	rs79163357	ENSG00000258413.1	RP11-665C16.6	-7.54	9.96e-14	2.68e-11	-0.31	-0.23	Protein biomarker;	chr14:55271731	chr14:55262767~55272075:-
BRCA	cis	rs526231	0.578	rs17154821	ENSG00000175749.11	EIF3KP1	7.54	1e-13	2.69e-11	0.32	0.23	Primary biliary cholangitis;	chr5:102905637	chr5:103032376~103033031:+
BRCA	cis	rs875971	1	rs6979382	ENSG00000232559.3	GS1-124K5.12	7.54	1e-13	2.69e-11	0.27	0.23	Aortic root size;	chr7:66421388	chr7:66554588~66576923:-
BRCA	cis	rs875971	1	rs6961990	ENSG00000232559.3	GS1-124K5.12	7.54	1e-13	2.69e-11	0.27	0.23	Aortic root size;	chr7:66423583	chr7:66554588~66576923:-
BRCA	cis	rs3794924	0.925	rs35427815	ENSG00000266521.1	RP11-650P15.1	7.54	1e-13	2.69e-11	0.41	0.23	Survival in colon cancer;	chr18:31466438	chr18:31496645~31497195:-
BRCA	cis	rs7809950	0.862	rs58391518	ENSG00000238832.1	snoU109	-7.54	1e-13	2.7e-11	-0.3	-0.23	Coronary artery disease;	chr7:107390342	chr7:107603363~107603507:+
BRCA	cis	rs6921919	0.583	rs2027361	ENSG00000204709.4	LINC01556	7.54	1e-13	2.7e-11	0.31	0.23	Autism spectrum disorder or schizophrenia;	chr6:28420531	chr6:28943877~28944537:+
BRCA	cis	rs73186030	0.546	rs6791616	ENSG00000272758.4	RP11-299J3.8	7.54	1e-13	2.7e-11	0.3	0.23	Serum parathyroid hormone levels;	chr3:122388388	chr3:122416207~122443180:+
BRCA	cis	rs17772222	0.917	rs61986671	ENSG00000258983.2	RP11-507K2.2	7.54	1.01e-13	2.7e-11	0.26	0.23	Coronary artery calcification;	chr14:88732917	chr14:88499334~88515502:+
BRCA	cis	rs875971	0.619	rs2302918	ENSG00000224316.1	RP11-479O9.2	7.54	1.01e-13	2.71e-11	0.23	0.23	Aortic root size;	chr7:66535945	chr7:65773620~65802067:+
BRCA	cis	rs2348418	0.733	rs1824769	ENSG00000247934.4	RP11-967K21.1	-7.54	1.01e-13	2.71e-11	-0.26	-0.23	Lung function (FEV1);Lung function (FVC);	chr12:28202322	chr12:28163298~28190738:-
BRCA	cis	rs2348418	0.671	rs2169753	ENSG00000247934.4	RP11-967K21.1	-7.54	1.01e-13	2.71e-11	-0.26	-0.23	Lung function (FEV1);Lung function (FVC);	chr12:28203481	chr12:28163298~28190738:-
BRCA	cis	rs274567	0.602	rs272853	ENSG00000233006.5	AC034220.3	7.54	1.01e-13	2.71e-11	0.17	0.23	Blood metabolite levels;	chr5:132352868	chr5:132311285~132369916:-
BRCA	cis	rs853679	0.882	rs9380069	ENSG00000220721.1	OR1F12	7.54	1.01e-13	2.71e-11	0.38	0.23	Depression;	chr6:28235522	chr6:28073316~28074233:+
BRCA	cis	rs13113518	0.729	rs13120134	ENSG00000273257.1	RP11-177J6.1	7.54	1.01e-13	2.71e-11	0.32	0.23	Height;	chr4:55415153	chr4:55387949~55388271:+
BRCA	cis	rs293748	0.54	rs13163937	ENSG00000250155.1	CTD-2353F22.1	-7.54	1.01e-13	2.72e-11	-0.31	-0.23	Obesity-related traits;	chr5:37253547	chr5:36666214~36725195:-
BRCA	cis	rs1552244	0.882	rs3755783	ENSG00000180385.7	EMC3-AS1	7.54	1.01e-13	2.72e-11	0.3	0.23	Alzheimer's disease;	chr3:9987605	chr3:9986893~10006990:+
BRCA	cis	rs4927850	0.958	rs1975582	ENSG00000242086.7	LINC00969	7.54	1.01e-13	2.72e-11	0.25	0.23	Pancreatic cancer;	chr3:196024568	chr3:195658062~195739964:+
BRCA	cis	rs875971	0.862	rs778720	ENSG00000232559.3	GS1-124K5.12	-7.54	1.02e-13	2.73e-11	-0.28	-0.23	Aortic root size;	chr7:66381288	chr7:66554588~66576923:-
BRCA	cis	rs12701220	0.503	rs12702024	ENSG00000229043.2	AC091729.9	-7.54	1.02e-13	2.73e-11	-0.37	-0.23	Bronchopulmonary dysplasia;	chr7:1090184	chr7:1160374~1165267:+
BRCA	cis	rs2933343	0.533	rs13086121	ENSG00000231305.3	RP11-723O4.2	7.54	1.02e-13	2.74e-11	0.26	0.23	IgG glycosylation;	chr3:128985447	chr3:128861313~128871540:-
BRCA	cis	rs7246657	0.943	rs10422967	ENSG00000276846.1	CTD-3220F14.3	7.54	1.02e-13	2.74e-11	0.32	0.23	Coronary artery calcification;	chr19:37359235	chr19:37314868~37315620:-
BRCA	cis	rs801193	1	rs3778909	ENSG00000237310.1	GS1-124K5.4	7.54	1.02e-13	2.75e-11	0.24	0.23	Aortic root size;	chr7:66790659	chr7:66493706~66495474:+
BRCA	cis	rs301901	0.828	rs151944	ENSG00000250155.1	CTD-2353F22.1	-7.54	1.02e-13	2.75e-11	-0.24	-0.23	Height;	chr5:36904297	chr5:36666214~36725195:-
BRCA	cis	rs301901	1	rs301859	ENSG00000250155.1	CTD-2353F22.1	-7.54	1.02e-13	2.75e-11	-0.25	-0.23	Height;	chr5:37045739	chr5:36666214~36725195:-
BRCA	cis	rs780094	0.606	rs6729709	ENSG00000234072.1	AC074117.10	-7.54	1.02e-13	2.75e-11	-0.22	-0.23	Urate levels in overweight individuals;C-reactive protein;Metabolic syndrome;Red blood cell count;Renal underexcretion gout;Nonalcoholic fatty liver disease;Age-related diseases, mortality and associated endophenotypes;Crohn's disease;Calcium levels;Fasting plasma glucose;Metabolic traits;Fasting blood glucose;Fasting blood insulin;Urate levels in obese individuals;Alcohol consumption (drinks per week);Height;Urate levels;Gondoic acid (20:1n-9) levels;Uric acid levels;Age-related disease endophenotypes;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Homeostasis model assessment of insulin resistance;Alcohol consumption;Fasting blood insulin (BMI interaction);Triglycerides;Fasting blood glucose (BMI interaction);Hypertriglyceridemia;LDL cholesterol;Type 2 diabetes;Triglyceride levels;	chr2:27360289	chr2:27356246~27367622:+
BRCA	cis	rs10510102	0.935	rs7923634	ENSG00000276742.1	RP11-500G22.4	7.54	1.03e-13	2.75e-11	0.39	0.23	Breast cancer;	chr10:121832800	chr10:121956782~121957098:+
BRCA	cis	rs8072100	0.79	rs6505048	ENSG00000228782.6	CTD-2026D20.3	-7.54	1.03e-13	2.76e-11	-0.25	-0.23	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47597632	chr17:47450568~47492492:-
BRCA	cis	rs3758911	0.894	rs12286915	ENSG00000255353.1	RP11-382M14.1	-7.54	1.03e-13	2.77e-11	-0.31	-0.23	Coronary artery disease;	chr11:107340608	chr11:107176286~107177530:+
BRCA	cis	rs7520050	0.807	rs4468203	ENSG00000280836.1	AL355480.1	-7.54	1.03e-13	2.78e-11	-0.26	-0.23	Reticulocyte count;Red blood cell count;	chr1:45647600	chr1:45581219~45581321:-
BRCA	cis	rs9649213	0.593	rs7795176	ENSG00000272950.1	RP11-307C18.1	7.54	1.03e-13	2.78e-11	0.29	0.23	Prostate cancer (SNP x SNP interaction);	chr7:98348975	chr7:98322853~98323430:+
BRCA	cis	rs9649213	0.593	rs62478200	ENSG00000272950.1	RP11-307C18.1	7.54	1.03e-13	2.78e-11	0.29	0.23	Prostate cancer (SNP x SNP interaction);	chr7:98350733	chr7:98322853~98323430:+
BRCA	cis	rs11976180	0.569	rs12703565	ENSG00000273234.1	OR2A13P	-7.54	1.04e-13	2.78e-11	-0.4	-0.23	Obesity-related traits;	chr7:144057308	chr7:144142009~144142938:+
BRCA	cis	rs919433	0.89	rs979020	ENSG00000231621.1	AC013264.2	7.54	1.04e-13	2.79e-11	0.21	0.23	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197305025	chr2:197197991~197199273:+
BRCA	cis	rs2243480	1	rs437889	ENSG00000273142.1	RP11-458F8.4	-7.54	1.04e-13	2.79e-11	-0.32	-0.23	Diabetic kidney disease;	chr7:66044247	chr7:66902857~66906297:+
BRCA	cis	rs4835473	0.897	rs1450246	ENSG00000251600.4	RP11-673E1.1	7.54	1.04e-13	2.79e-11	0.27	0.23	Immature fraction of reticulocytes;	chr4:143702954	chr4:143912331~143982454:+
BRCA	cis	rs2933343	0.533	rs11915889	ENSG00000231305.3	RP11-723O4.2	7.54	1.04e-13	2.79e-11	0.26	0.23	IgG glycosylation;	chr3:128982023	chr3:128861313~128871540:-
BRCA	cis	rs875971	0.638	rs6960778	ENSG00000237310.1	GS1-124K5.4	-7.54	1.04e-13	2.79e-11	-0.24	-0.23	Aortic root size;	chr7:66606610	chr7:66493706~66495474:+
BRCA	cis	rs9649213	0.555	rs6956686	ENSG00000272950.1	RP11-307C18.1	7.54	1.05e-13	2.81e-11	0.29	0.23	Prostate cancer (SNP x SNP interaction);	chr7:98368633	chr7:98322853~98323430:+
BRCA	cis	rs74233809	1	rs79668541	ENSG00000213277.3	MARCKSL1P1	7.54	1.05e-13	2.81e-11	0.44	0.23	Birth weight;	chr10:103034147	chr10:103175554~103176094:+
BRCA	cis	rs375066	0.935	rs407731	ENSG00000267058.1	RP11-15A1.3	7.54	1.05e-13	2.81e-11	0.26	0.23	Breast cancer;	chr19:43913925	chr19:43891804~43901805:-
BRCA	cis	rs748404	1	rs12909095	ENSG00000249839.1	AC011330.5	-7.54	1.05e-13	2.81e-11	-0.32	-0.23	Lung cancer;	chr15:43265944	chr15:43663654~43684339:-
BRCA	cis	rs801193	0.935	rs2659916	ENSG00000237310.1	GS1-124K5.4	7.54	1.05e-13	2.81e-11	0.24	0.23	Aortic root size;	chr7:66686365	chr7:66493706~66495474:+
BRCA	cis	rs10200159	1	rs13428382	ENSG00000272606.1	RP11-554J4.1	7.54	1.05e-13	2.82e-11	0.43	0.23	Vitiligo;	chr2:55636929	chr2:55617909~55618373:+
BRCA	cis	rs2378497	1	rs12137305	ENSG00000232679.1	RP11-400N13.3	7.54	1.05e-13	2.83e-11	0.3	0.23	Serum thyroid-stimulating hormone levels;	chr1:222047359	chr1:222041705~222064763:-
BRCA	cis	rs9315786	0.924	rs7323436	ENSG00000176268.5	CYCSP34	-7.54	1.06e-13	2.83e-11	-0.25	-0.23	Neutrophil percentage of granulocytes;	chr13:40776843	chr13:40863599~40863902:-
BRCA	cis	rs2439831	0.85	rs11856795	ENSG00000275601.1	AC011330.13	-7.54	1.06e-13	2.83e-11	-0.37	-0.23	Lung cancer in ever smokers;	chr15:43868384	chr15:43642389~43643023:-
BRCA	cis	rs62103177	0.564	rs11874805	ENSG00000261126.6	RP11-795F19.1	7.53	1.06e-13	2.84e-11	0.33	0.23	Opioid sensitivity;	chr18:79937110	chr18:80046900~80095482:+
BRCA	cis	rs875971	0.862	rs11984115	ENSG00000232559.3	GS1-124K5.12	-7.53	1.06e-13	2.84e-11	-0.28	-0.23	Aortic root size;	chr7:66308872	chr7:66554588~66576923:-
BRCA	cis	rs6570726	0.967	rs7772286	ENSG00000235652.6	RP11-545I5.3	-7.53	1.06e-13	2.85e-11	-0.22	-0.23	Lobe attachment (rater-scored or self-reported);	chr6:145609287	chr6:145799409~145886585:+
BRCA	cis	rs11976180	0.953	rs2951355	ENSG00000170356.8	OR2A20P	-7.53	1.06e-13	2.85e-11	-0.32	-0.23	Obesity-related traits;	chr7:144063469	chr7:144250045~144252957:-
BRCA	cis	rs11976180	1	rs2951354	ENSG00000170356.8	OR2A20P	-7.53	1.06e-13	2.85e-11	-0.32	-0.23	Obesity-related traits;	chr7:144063908	chr7:144250045~144252957:-
BRCA	cis	rs11976180	1	rs2961125	ENSG00000170356.8	OR2A20P	-7.53	1.06e-13	2.85e-11	-0.32	-0.23	Obesity-related traits;	chr7:144064677	chr7:144250045~144252957:-
BRCA	cis	rs11976180	1	rs2961126	ENSG00000170356.8	OR2A20P	-7.53	1.06e-13	2.85e-11	-0.32	-0.23	Obesity-related traits;	chr7:144065643	chr7:144250045~144252957:-
BRCA	cis	rs11976180	0.953	rs2961127	ENSG00000170356.8	OR2A20P	-7.53	1.06e-13	2.85e-11	-0.32	-0.23	Obesity-related traits;	chr7:144065644	chr7:144250045~144252957:-
BRCA	cis	rs11976180	1	rs1919948	ENSG00000170356.8	OR2A20P	-7.53	1.06e-13	2.85e-11	-0.32	-0.23	Obesity-related traits;	chr7:144065750	chr7:144250045~144252957:-
BRCA	cis	rs11976180	1	rs2961128	ENSG00000170356.8	OR2A20P	-7.53	1.06e-13	2.85e-11	-0.32	-0.23	Obesity-related traits;	chr7:144066390	chr7:144250045~144252957:-
BRCA	cis	rs11976180	1	rs2371248	ENSG00000170356.8	OR2A20P	-7.53	1.06e-13	2.85e-11	-0.32	-0.23	Obesity-related traits;	chr7:144067096	chr7:144250045~144252957:-
BRCA	cis	rs11143230	1	rs62564005	ENSG00000225434.2	LINC01504	-7.53	1.06e-13	2.85e-11	-0.26	-0.23	Suicidal ideation;	chr9:72273467	chr9:72305430~72343210:+
BRCA	cis	rs78456975	0.574	rs13412980	ENSG00000231482.2	AC141930.2	-7.53	1.06e-13	2.85e-11	-0.33	-0.23	Placebo response in major depressive disorder (% change in symptom score);	chr2:1541459	chr2:1572554~1580311:-
BRCA	cis	rs2742234	0.59	rs2565201	ENSG00000273008.1	RP11-351D16.3	-7.53	1.07e-13	2.85e-11	-0.29	-0.23	Hirschsprung disease;	chr10:43123036	chr10:43136824~43138334:-
BRCA	cis	rs6844153	0.887	rs3792685	ENSG00000240005.4	RP11-293A21.1	-7.53	1.07e-13	2.86e-11	-0.33	-0.23	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26957585	chr4:26859806~26860599:-
BRCA	cis	rs526231	0.511	rs10515341	ENSG00000175749.11	EIF3KP1	7.53	1.07e-13	2.86e-11	0.33	0.23	Primary biliary cholangitis;	chr5:102981413	chr5:103032376~103033031:+
BRCA	cis	rs2348418	0.765	rs4931734	ENSG00000247934.4	RP11-967K21.1	-7.53	1.07e-13	2.86e-11	-0.26	-0.23	Lung function (FEV1);Lung function (FVC);	chr12:28196661	chr12:28163298~28190738:-
BRCA	cis	rs2179367	0.6	rs1001305	ENSG00000231760.4	RP11-350J20.5	7.53	1.07e-13	2.86e-11	0.34	0.23	Dupuytren's disease;	chr6:149436808	chr6:149796151~149826294:-
BRCA	cis	rs74233809	1	rs79993475	ENSG00000213277.3	MARCKSL1P1	7.53	1.07e-13	2.86e-11	0.43	0.23	Birth weight;	chr10:103141274	chr10:103175554~103176094:+
BRCA	cis	rs7567389	0.6	rs72845979	ENSG00000236682.1	AC068282.3	-7.53	1.07e-13	2.86e-11	-0.33	-0.23	Self-rated health;	chr2:127338178	chr2:127389130~127400580:+
BRCA	cis	rs7567389	0.534	rs72845982	ENSG00000236682.1	AC068282.3	-7.53	1.07e-13	2.86e-11	-0.33	-0.23	Self-rated health;	chr2:127340994	chr2:127389130~127400580:+
BRCA	cis	rs9876781	1	rs6794875	ENSG00000244380.1	RP11-24C3.2	7.53	1.07e-13	2.88e-11	0.26	0.23	Longevity;	chr3:48414217	chr3:48440352~48446656:-
BRCA	cis	rs7809950	1	rs28714607	ENSG00000238832.1	snoU109	-7.53	1.07e-13	2.88e-11	-0.3	-0.23	Coronary artery disease;	chr7:107465808	chr7:107603363~107603507:+
BRCA	cis	rs2179367	0.959	rs514839	ENSG00000231760.4	RP11-350J20.5	7.53	1.08e-13	2.88e-11	0.29	0.23	Dupuytren's disease;	chr6:149327304	chr6:149796151~149826294:-
BRCA	cis	rs293748	0.882	rs293774	ENSG00000250155.1	CTD-2353F22.1	-7.53	1.08e-13	2.88e-11	-0.33	-0.23	Obesity-related traits;	chr5:36943166	chr5:36666214~36725195:-
BRCA	cis	rs2274273	0.624	rs66464079	ENSG00000258413.1	RP11-665C16.6	-7.53	1.08e-13	2.89e-11	-0.3	-0.23	Protein biomarker;	chr14:55299446	chr14:55262767~55272075:-
BRCA	cis	rs4835473	0.932	rs34570929	ENSG00000251600.4	RP11-673E1.1	-7.53	1.09e-13	2.91e-11	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143730766	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.9	rs17750172	ENSG00000251600.4	RP11-673E1.1	-7.53	1.09e-13	2.91e-11	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143731094	chr4:143912331~143982454:+
BRCA	cis	rs891378	0.755	rs6703809	ENSG00000274245.1	RP11-357P18.2	-7.53	1.09e-13	2.91e-11	-0.29	-0.23	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207228650	chr1:207372559~207373252:+
BRCA	cis	rs8062405	0.69	rs62034351	ENSG00000251417.2	RP11-1348G14.4	-7.53	1.09e-13	2.92e-11	-0.29	-0.23	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554168	chr16:28802743~28817828:+
BRCA	cis	rs2274273	0.624	rs8014477	ENSG00000258413.1	RP11-665C16.6	7.53	1.09e-13	2.93e-11	0.3	0.23	Protein biomarker;	chr14:55374759	chr14:55262767~55272075:-
BRCA	cis	rs11976180	1	rs2961120	ENSG00000170356.8	OR2A20P	-7.53	1.09e-13	2.93e-11	-0.32	-0.23	Obesity-related traits;	chr7:144059492	chr7:144250045~144252957:-
BRCA	cis	rs6543140	0.964	rs6748390	ENSG00000234389.1	AC007278.3	7.53	1.09e-13	2.93e-11	0.23	0.23	Blood protein levels;	chr2:102445715	chr2:102438713~102440475:+
BRCA	cis	rs74233809	1	rs12413409	ENSG00000213277.3	MARCKSL1P1	7.53	1.09e-13	2.93e-11	0.42	0.23	Birth weight;	chr10:102959339	chr10:103175554~103176094:+
BRCA	cis	rs7246657	0.943	rs10404602	ENSG00000276846.1	CTD-3220F14.3	7.53	1.09e-13	2.93e-11	0.32	0.23	Coronary artery calcification;	chr19:37334731	chr19:37314868~37315620:-
BRCA	cis	rs10771431	0.967	rs7137443	ENSG00000111788.10	RP11-22B23.1	7.53	1.1e-13	2.93e-11	0.21	0.23	Breast size;	chr12:9219433	chr12:9277235~9313241:+
BRCA	cis	rs858239	0.6	rs1468592	ENSG00000230042.1	AK3P3	7.53	1.1e-13	2.94e-11	0.25	0.23	Cerebrospinal fluid biomarker levels;	chr7:23101028	chr7:23129178~23129841:+
BRCA	cis	rs1862618	0.853	rs33325	ENSG00000271828.1	CTD-2310F14.1	7.53	1.1e-13	2.94e-11	0.31	0.23	Initial pursuit acceleration;	chr5:56846720	chr5:56927874~56929573:+
BRCA	cis	rs1862618	0.802	rs42769	ENSG00000271828.1	CTD-2310F14.1	7.53	1.1e-13	2.94e-11	0.31	0.23	Initial pursuit acceleration;	chr5:56848325	chr5:56927874~56929573:+
BRCA	cis	rs17818399	0.62	rs1080871	ENSG00000279254.1	RP11-536C12.1	-7.53	1.1e-13	2.94e-11	-0.28	-0.23	Height;	chr2:46627569	chr2:46668870~46670778:+
BRCA	cis	rs4842666	0.915	rs111478946	ENSG00000258302.2	RP11-981P6.1	7.53	1.1e-13	2.94e-11	0.28	0.23	Blood pressure;	chr12:89665065	chr12:89561129~89594878:+
BRCA	cis	rs4845875	0.563	rs11121829	ENSG00000242349.4	NPPA-AS1	7.53	1.1e-13	2.94e-11	0.27	0.23	Midregional pro atrial natriuretic peptide levels;	chr1:11774708	chr1:11841017~11848079:+
BRCA	cis	rs812925	0.784	rs7588041	ENSG00000271889.1	RP11-493E12.1	-7.53	1.1e-13	2.95e-11	-0.28	-0.23	Immature fraction of reticulocytes;	chr2:61234277	chr2:61151433~61162105:-
BRCA	cis	rs875971	0.66	rs7807930	ENSG00000237310.1	GS1-124K5.4	-7.53	1.1e-13	2.95e-11	-0.24	-0.23	Aortic root size;	chr7:66622178	chr7:66493706~66495474:+
BRCA	cis	rs66887589	0.627	rs3872807	ENSG00000248280.1	RP11-33B1.2	7.53	1.11e-13	2.96e-11	0.21	0.23	Diastolic blood pressure;	chr4:119439096	chr4:119440561~119450157:-
BRCA	cis	rs301901	1	rs150380	ENSG00000250155.1	CTD-2353F22.1	-7.53	1.11e-13	2.96e-11	-0.25	-0.23	Height;	chr5:36880769	chr5:36666214~36725195:-
BRCA	cis	rs42648	0.806	rs6951894	ENSG00000225498.1	AC002064.5	7.53	1.11e-13	2.96e-11	0.22	0.23	Homocysteine levels;	chr7:90264631	chr7:90312496~90322592:+
BRCA	cis	rs1609391	0.543	rs6800690	ENSG00000273486.1	RP11-731C17.2	7.53	1.11e-13	2.97e-11	0.25	0.23	Neuroticism;	chr3:136904184	chr3:136837338~136839021:-
BRCA	cis	rs1609391	0.543	rs7651085	ENSG00000273486.1	RP11-731C17.2	7.53	1.11e-13	2.97e-11	0.25	0.23	Neuroticism;	chr3:136906497	chr3:136837338~136839021:-
BRCA	cis	rs1609391	0.543	rs6761993	ENSG00000273486.1	RP11-731C17.2	7.53	1.11e-13	2.97e-11	0.25	0.23	Neuroticism;	chr3:136907060	chr3:136837338~136839021:-
BRCA	cis	rs11723261	0.582	rs7679573	ENSG00000211553.1	AC253576.2	-7.53	1.11e-13	2.97e-11	-0.33	-0.23	Immune response to smallpox vaccine (IL-6);	chr4:157810	chr4:136461~136568:+
BRCA	cis	rs2033711	0.87	rs1051500	ENSG00000269473.1	CTD-2619J13.19	7.53	1.11e-13	2.97e-11	0.27	0.23	Uric acid clearance;	chr19:58433035	chr19:58440448~58445849:+
BRCA	cis	rs6921919	0.583	rs740622	ENSG00000204709.4	LINC01556	7.53	1.11e-13	2.97e-11	0.31	0.23	Autism spectrum disorder or schizophrenia;	chr6:28430514	chr6:28943877~28944537:+
BRCA	cis	rs10463554	1	rs6596529	ENSG00000175749.11	EIF3KP1	7.53	1.11e-13	2.98e-11	0.31	0.23	Parkinson's disease;	chr5:102981338	chr5:103032376~103033031:+
BRCA	cis	rs301901	1	rs300058	ENSG00000250155.1	CTD-2353F22.1	-7.53	1.11e-13	2.98e-11	-0.25	-0.23	Height;	chr5:37053874	chr5:36666214~36725195:-
BRCA	cis	rs9880211	0.948	rs13321721	ENSG00000273486.1	RP11-731C17.2	7.53	1.11e-13	2.98e-11	0.3	0.23	Height;Body mass index;	chr3:136490708	chr3:136837338~136839021:-
BRCA	cis	rs12468226	0.689	rs17656903	ENSG00000273456.1	RP11-686O6.2	-7.53	1.12e-13	2.98e-11	-0.35	-0.23	Urate levels;	chr2:202106312	chr2:202374932~202375604:-
BRCA	cis	rs7617773	0.817	rs9311421	ENSG00000228638.1	FCF1P2	-7.53	1.12e-13	2.99e-11	-0.24	-0.23	Coronary artery disease;	chr3:48251588	chr3:48290793~48291375:-
BRCA	cis	rs66887589	0.87	rs59590064	ENSG00000248280.1	RP11-33B1.2	-7.53	1.12e-13	2.99e-11	-0.21	-0.23	Diastolic blood pressure;	chr4:119618598	chr4:119440561~119450157:-
BRCA	cis	rs2280018	1	rs2280018	ENSG00000260735.1	RP11-72I8.1	-7.53	1.12e-13	2.99e-11	-0.25	-0.23	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15056976	chr16:15094411~15109197:+
BRCA	cis	rs10129255	0.556	rs8010005	ENSG00000211970.3	IGHV4-61	-7.53	1.12e-13	2.99e-11	-0.15	-0.23	Kawasaki disease;	chr14:106777987	chr14:106639119~106639657:-
BRCA	cis	rs10129255	0.556	rs6576224	ENSG00000211970.3	IGHV4-61	-7.53	1.12e-13	2.99e-11	-0.15	-0.23	Kawasaki disease;	chr14:106777997	chr14:106639119~106639657:-
BRCA	cis	rs10129255	0.518	rs8010020	ENSG00000211970.3	IGHV4-61	-7.53	1.12e-13	2.99e-11	-0.15	-0.23	Kawasaki disease;	chr14:106778016	chr14:106639119~106639657:-
BRCA	cis	rs56046484	0.703	rs12439802	ENSG00000259295.5	CSPG4P12	7.53	1.12e-13	2.99e-11	0.41	0.23	Testicular germ cell tumor;	chr15:84977098	chr15:85191438~85213905:+
BRCA	cis	rs10463554	0.818	rs2241564	ENSG00000175749.11	EIF3KP1	7.53	1.12e-13	2.99e-11	0.32	0.23	Parkinson's disease;	chr5:102966547	chr5:103032376~103033031:+
BRCA	cis	rs3758911	0.894	rs10890723	ENSG00000255353.1	RP11-382M14.1	-7.53	1.12e-13	2.99e-11	-0.31	-0.23	Coronary artery disease;	chr11:107342510	chr11:107176286~107177530:+
BRCA	cis	rs3758911	0.894	rs7350479	ENSG00000255353.1	RP11-382M14.1	-7.53	1.12e-13	2.99e-11	-0.31	-0.23	Coronary artery disease;	chr11:107342553	chr11:107176286~107177530:+
BRCA	cis	rs3758911	0.894	rs56393657	ENSG00000255353.1	RP11-382M14.1	-7.53	1.12e-13	2.99e-11	-0.31	-0.23	Coronary artery disease;	chr11:107342902	chr11:107176286~107177530:+
BRCA	cis	rs7811142	1	rs74460138	ENSG00000242294.5	STAG3L5P	7.53	1.12e-13	2.99e-11	0.22	0.23	Platelet count;	chr7:100429716	chr7:100336079~100351900:+
BRCA	cis	rs7811142	1	rs4989959	ENSG00000242294.5	STAG3L5P	7.53	1.12e-13	2.99e-11	0.22	0.23	Platelet count;	chr7:100434665	chr7:100336079~100351900:+
BRCA	cis	rs11976180	1	rs11976180	ENSG00000170356.8	OR2A20P	-7.53	1.12e-13	3e-11	-0.33	-0.23	Obesity-related traits;	chr7:144044487	chr7:144250045~144252957:-
BRCA	cis	rs1862618	0.853	rs832578	ENSG00000271828.1	CTD-2310F14.1	7.53	1.12e-13	3e-11	0.31	0.23	Initial pursuit acceleration;	chr5:56868396	chr5:56927874~56929573:+
BRCA	cis	rs1061377	0.674	rs34506243	ENSG00000249685.1	RP11-360F5.3	7.53	1.12e-13	3e-11	0.27	0.23	Uric acid levels;	chr4:39082702	chr4:39133913~39135608:+
BRCA	cis	rs66887589	0.777	rs4643791	ENSG00000248280.1	RP11-33B1.2	-7.53	1.12e-13	3e-11	-0.21	-0.23	Diastolic blood pressure;	chr4:119344464	chr4:119440561~119450157:-
BRCA	cis	rs801193	0.935	rs2659916	ENSG00000224316.1	RP11-479O9.2	7.53	1.13e-13	3.01e-11	0.23	0.23	Aortic root size;	chr7:66686365	chr7:65773620~65802067:+
BRCA	cis	rs293748	0.571	rs13169211	ENSG00000250155.1	CTD-2353F22.1	-7.53	1.13e-13	3.01e-11	-0.3	-0.23	Obesity-related traits;	chr5:37131567	chr5:36666214~36725195:-
BRCA	cis	rs34779708	0.649	rs34421369	ENSG00000271335.4	RP11-324I22.4	7.53	1.13e-13	3.01e-11	0.23	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35261347	chr10:35314552~35336401:-
BRCA	cis	rs10463554	1	rs6879788	ENSG00000175749.11	EIF3KP1	7.53	1.13e-13	3.01e-11	0.31	0.23	Parkinson's disease;	chr5:102978353	chr5:103032376~103033031:+
BRCA	cis	rs6921919	0.583	rs4642462	ENSG00000204709.4	LINC01556	7.53	1.13e-13	3.01e-11	0.31	0.23	Autism spectrum disorder or schizophrenia;	chr6:28421474	chr6:28943877~28944537:+
BRCA	cis	rs4835473	0.932	rs17750042	ENSG00000251600.4	RP11-673E1.1	-7.53	1.13e-13	3.02e-11	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143726691	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.932	rs1375989	ENSG00000251600.4	RP11-673E1.1	-7.53	1.13e-13	3.02e-11	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143726893	chr4:143912331~143982454:+
BRCA	cis	rs9649213	0.537	rs6971825	ENSG00000272950.1	RP11-307C18.1	7.53	1.13e-13	3.02e-11	0.29	0.23	Prostate cancer (SNP x SNP interaction);	chr7:98350236	chr7:98322853~98323430:+
BRCA	cis	rs867371	1	rs13380317	ENSG00000259429.4	UBE2Q2P2	7.53	1.13e-13	3.03e-11	0.22	0.23	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82214449	chr15:82355142~82420075:+
BRCA	cis	rs66887589	0.934	rs7672519	ENSG00000248280.1	RP11-33B1.2	-7.53	1.14e-13	3.03e-11	-0.21	-0.23	Diastolic blood pressure;	chr4:119622957	chr4:119440561~119450157:-
BRCA	cis	rs801193	0.591	rs9986881	ENSG00000237310.1	GS1-124K5.4	7.53	1.14e-13	3.04e-11	0.24	0.23	Aortic root size;	chr7:66708053	chr7:66493706~66495474:+
BRCA	cis	rs2348418	0.733	rs12425200	ENSG00000247934.4	RP11-967K21.1	7.53	1.14e-13	3.04e-11	0.26	0.23	Lung function (FEV1);Lung function (FVC);	chr12:28237896	chr12:28163298~28190738:-
BRCA	cis	rs8062405	0.755	rs17640009	ENSG00000251417.2	RP11-1348G14.4	-7.53	1.14e-13	3.04e-11	-0.27	-0.23	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28584379	chr16:28802743~28817828:+
BRCA	cis	rs6061231	0.624	rs8668	ENSG00000273619.1	RP5-908M14.9	7.53	1.14e-13	3.04e-11	0.19	0.23	Colorectal cancer;	chr20:62389008	chr20:62386303~62386970:-
BRCA	cis	rs875971	0.862	rs2088653	ENSG00000232559.3	GS1-124K5.12	-7.52	1.14e-13	3.04e-11	-0.28	-0.23	Aortic root size;	chr7:66343621	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.862	rs6460293	ENSG00000232559.3	GS1-124K5.12	-7.52	1.14e-13	3.04e-11	-0.28	-0.23	Aortic root size;	chr7:66345205	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.895	rs6460278	ENSG00000232559.3	GS1-124K5.12	-7.52	1.14e-13	3.04e-11	-0.28	-0.23	Aortic root size;	chr7:66197749	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.862	rs6460279	ENSG00000232559.3	GS1-124K5.12	-7.52	1.14e-13	3.04e-11	-0.28	-0.23	Aortic root size;	chr7:66197774	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.862	rs28491091	ENSG00000232559.3	GS1-124K5.12	-7.52	1.14e-13	3.04e-11	-0.28	-0.23	Aortic root size;	chr7:66204077	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.789	rs28815324	ENSG00000224316.1	RP11-479O9.2	-7.52	1.14e-13	3.06e-11	-0.26	-0.23	Aortic root size;	chr7:66100789	chr7:65773620~65802067:+
BRCA	cis	rs66887589	0.934	rs6817317	ENSG00000248280.1	RP11-33B1.2	-7.52	1.14e-13	3.06e-11	-0.21	-0.23	Diastolic blood pressure;	chr4:119621672	chr4:119440561~119450157:-
BRCA	cis	rs9880211	0.8	rs9845862	ENSG00000239213.4	NCK1-AS1	7.52	1.15e-13	3.06e-11	0.31	0.23	Height;Body mass index;	chr3:136753731	chr3:136841726~136862054:-
BRCA	cis	rs17711722	0.653	rs2460421	ENSG00000164669.11	INTS4P1	7.52	1.15e-13	3.07e-11	0.28	0.23	Calcium levels;	chr7:66026136	chr7:65141225~65234216:+
BRCA	cis	rs4835473	0.932	rs35598827	ENSG00000251600.4	RP11-673E1.1	-7.52	1.15e-13	3.07e-11	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143729605	chr4:143912331~143982454:+
BRCA	cis	rs6142102	1	rs6059681	ENSG00000276073.1	RP5-1125A11.7	-7.52	1.15e-13	3.07e-11	-0.28	-0.23	Skin pigmentation;	chr20:34135535	chr20:33985617~33988989:-
BRCA	cis	rs875971	0.545	rs73376394	ENSG00000222364.1	RNU6-96P	-7.52	1.15e-13	3.08e-11	-0.29	-0.23	Aortic root size;	chr7:66172694	chr7:66395191~66395286:+
BRCA	cis	rs11976180	1	rs1533268	ENSG00000170356.8	OR2A20P	-7.52	1.15e-13	3.08e-11	-0.32	-0.23	Obesity-related traits;	chr7:144069265	chr7:144250045~144252957:-
BRCA	cis	rs3758911	0.861	rs10789593	ENSG00000255353.1	RP11-382M14.1	-7.52	1.15e-13	3.08e-11	-0.31	-0.23	Coronary artery disease;	chr11:107286154	chr11:107176286~107177530:+
BRCA	cis	rs13068223	0.84	rs1469536	ENSG00000243926.1	TIPARP-AS1	7.52	1.15e-13	3.08e-11	0.23	0.23	Age-related hearing impairment (SNP x SNP interaction);	chr3:156710038	chr3:156671862~156674378:-
BRCA	cis	rs526231	0.575	rs62362523	ENSG00000175749.11	EIF3KP1	7.52	1.15e-13	3.08e-11	0.33	0.23	Primary biliary cholangitis;	chr5:102977979	chr5:103032376~103033031:+
BRCA	cis	rs526231	0.575	rs62362524	ENSG00000175749.11	EIF3KP1	7.52	1.15e-13	3.08e-11	0.33	0.23	Primary biliary cholangitis;	chr5:102978523	chr5:103032376~103033031:+
BRCA	cis	rs7567389	0.6	rs11691088	ENSG00000236682.1	AC068282.3	-7.52	1.16e-13	3.09e-11	-0.33	-0.23	Self-rated health;	chr2:127374277	chr2:127389130~127400580:+
BRCA	cis	rs4835473	0.897	rs13144504	ENSG00000251600.4	RP11-673E1.1	-7.52	1.16e-13	3.09e-11	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143707402	chr4:143912331~143982454:+
BRCA	cis	rs7617773	0.817	rs11928691	ENSG00000228638.1	FCF1P2	-7.52	1.16e-13	3.09e-11	-0.24	-0.23	Coronary artery disease;	chr3:48245275	chr3:48290793~48291375:-
BRCA	cis	rs2179367	0.632	rs9498321	ENSG00000231760.4	RP11-350J20.5	7.52	1.16e-13	3.1e-11	0.33	0.23	Dupuytren's disease;	chr6:149322573	chr6:149796151~149826294:-
BRCA	cis	rs74233809	1	rs3781285	ENSG00000213277.3	MARCKSL1P1	7.52	1.17e-13	3.11e-11	0.44	0.23	Birth weight;	chr10:103065908	chr10:103175554~103176094:+
BRCA	cis	rs2117029	0.782	rs10459232	ENSG00000258017.1	RP11-386G11.10	-7.52	1.17e-13	3.11e-11	-0.29	-0.23	Intelligence (multi-trait analysis);	chr12:49073293	chr12:49127782~49147869:+
BRCA	cis	rs780096	0.505	rs12475426	ENSG00000234072.1	AC074117.10	-7.52	1.17e-13	3.11e-11	-0.22	-0.23	Total body bone mineral density;	chr2:27376265	chr2:27356246~27367622:+
BRCA	cis	rs4934494	0.768	rs12570813	ENSG00000240996.1	RP11-80H5.7	-7.52	1.17e-13	3.11e-11	-0.29	-0.23	Red blood cell count;	chr10:89630974	chr10:89694295~89697928:-
BRCA	cis	rs2742234	0.541	rs10899779	ENSG00000273008.1	RP11-351D16.3	7.52	1.18e-13	3.14e-11	0.29	0.23	Hirschsprung disease;	chr10:43228528	chr10:43136824~43138334:-
BRCA	cis	rs4835473	0.897	rs1553070	ENSG00000251600.4	RP11-673E1.1	7.52	1.18e-13	3.14e-11	0.27	0.23	Immature fraction of reticulocytes;	chr4:143715981	chr4:143912331~143982454:+
BRCA	cis	rs1757171	0.542	rs1757186	ENSG00000204110.6	RP1-153P14.8	-7.52	1.18e-13	3.14e-11	-0.25	-0.23	Cognitive performance;	chr6:37516335	chr6:37507348~37535616:+
BRCA	cis	rs875971	0.755	rs10228885	ENSG00000232559.3	GS1-124K5.12	-7.52	1.18e-13	3.15e-11	-0.28	-0.23	Aortic root size;	chr7:66315542	chr7:66554588~66576923:-
BRCA	cis	rs9649213	0.593	rs6944262	ENSG00000272950.1	RP11-307C18.1	7.52	1.18e-13	3.16e-11	0.29	0.23	Prostate cancer (SNP x SNP interaction);	chr7:98356103	chr7:98322853~98323430:+
BRCA	cis	rs1510272	0.515	rs2089735	ENSG00000243926.1	TIPARP-AS1	-7.52	1.18e-13	3.16e-11	-0.29	-0.23	Testicular germ cell tumor;	chr3:156624763	chr3:156671862~156674378:-
BRCA	cis	rs293748	0.771	rs35263618	ENSG00000250155.1	CTD-2353F22.1	-7.52	1.19e-13	3.17e-11	-0.32	-0.23	Obesity-related traits;	chr5:36795112	chr5:36666214~36725195:-
BRCA	cis	rs8062405	0.755	rs4788076	ENSG00000251417.2	RP11-1348G14.4	-7.52	1.19e-13	3.17e-11	-0.27	-0.23	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28558684	chr16:28802743~28817828:+
BRCA	cis	rs62034325	0.697	rs710410	ENSG00000251417.2	RP11-1348G14.4	-7.52	1.19e-13	3.17e-11	-0.28	-0.23	Body mass index;	chr16:28592021	chr16:28802743~28817828:+
BRCA	cis	rs7809950	1	rs2712191	ENSG00000238832.1	snoU109	-7.52	1.19e-13	3.17e-11	-0.3	-0.23	Coronary artery disease;	chr7:107542279	chr7:107603363~107603507:+
BRCA	cis	rs875971	0.66	rs12698534	ENSG00000237310.1	GS1-124K5.4	7.52	1.19e-13	3.18e-11	0.24	0.23	Aortic root size;	chr7:66521858	chr7:66493706~66495474:+
BRCA	cis	rs4835473	0.897	rs7678190	ENSG00000251600.4	RP11-673E1.1	7.52	1.19e-13	3.18e-11	0.28	0.23	Immature fraction of reticulocytes;	chr4:143722421	chr4:143912331~143982454:+
BRCA	cis	rs925255	0.776	rs2279990	ENSG00000270210.1	RP11-373D23.3	7.52	1.19e-13	3.19e-11	0.28	0.23	Inflammatory bowel disease;Crohn's disease;	chr2:28413873	chr2:28425945~28426719:+
BRCA	cis	rs7474896	0.609	rs11011336	ENSG00000226578.1	RP11-258F22.1	-7.52	1.2e-13	3.19e-11	-0.29	-0.23	Obesity (extreme);	chr10:37696388	chr10:37775371~37784131:-
BRCA	cis	rs875971	0.638	rs6960778	ENSG00000224316.1	RP11-479O9.2	-7.52	1.2e-13	3.2e-11	-0.23	-0.23	Aortic root size;	chr7:66606610	chr7:65773620~65802067:+
BRCA	cis	rs34779708	0.766	rs35308730	ENSG00000271335.4	RP11-324I22.4	7.52	1.2e-13	3.2e-11	0.23	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35260868	chr10:35314552~35336401:-
BRCA	cis	rs34779708	0.736	rs34195979	ENSG00000271335.4	RP11-324I22.4	7.52	1.2e-13	3.2e-11	0.23	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35260889	chr10:35314552~35336401:-
BRCA	cis	rs11098499	0.955	rs13113112	ENSG00000248280.1	RP11-33B1.2	7.52	1.2e-13	3.2e-11	0.24	0.23	Corneal astigmatism;	chr4:119234885	chr4:119440561~119450157:-
BRCA	cis	rs875971	0.66	rs62465434	ENSG00000237310.1	GS1-124K5.4	7.52	1.2e-13	3.2e-11	0.24	0.23	Aortic root size;	chr7:66540165	chr7:66493706~66495474:+
BRCA	cis	rs61270009	0.955	rs2115884	ENSG00000247828.6	TMEM161B-AS1	7.52	1.2e-13	3.21e-11	0.31	0.23	Depressive symptoms;	chr5:88358839	chr5:88268895~88436685:+
BRCA	cis	rs293748	0.771	rs34092841	ENSG00000250155.1	CTD-2353F22.1	-7.52	1.2e-13	3.21e-11	-0.32	-0.23	Obesity-related traits;	chr5:36803462	chr5:36666214~36725195:-
BRCA	cis	rs293748	0.771	rs35660956	ENSG00000250155.1	CTD-2353F22.1	-7.52	1.2e-13	3.21e-11	-0.32	-0.23	Obesity-related traits;	chr5:36803648	chr5:36666214~36725195:-
BRCA	cis	rs293748	0.771	rs292163	ENSG00000250155.1	CTD-2353F22.1	-7.52	1.2e-13	3.21e-11	-0.32	-0.23	Obesity-related traits;	chr5:36803847	chr5:36666214~36725195:-
BRCA	cis	rs293748	0.771	rs172384	ENSG00000250155.1	CTD-2353F22.1	-7.52	1.2e-13	3.21e-11	-0.32	-0.23	Obesity-related traits;	chr5:36804123	chr5:36666214~36725195:-
BRCA	cis	rs293748	0.771	rs292164	ENSG00000250155.1	CTD-2353F22.1	-7.52	1.2e-13	3.21e-11	-0.32	-0.23	Obesity-related traits;	chr5:36804643	chr5:36666214~36725195:-
BRCA	cis	rs858239	0.632	rs1985769	ENSG00000230042.1	AK3P3	-7.52	1.21e-13	3.22e-11	-0.26	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23082887	chr7:23129178~23129841:+
BRCA	cis	rs858239	0.6	rs28499396	ENSG00000230042.1	AK3P3	-7.52	1.21e-13	3.22e-11	-0.26	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23084479	chr7:23129178~23129841:+
BRCA	cis	rs858239	0.6	rs7789237	ENSG00000230042.1	AK3P3	-7.52	1.21e-13	3.22e-11	-0.26	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23085094	chr7:23129178~23129841:+
BRCA	cis	rs8005677	1	rs8006409	ENSG00000279656.1	RP11-298I3.6	7.52	1.21e-13	3.22e-11	0.27	0.23	Cognitive ability (multi-trait analysis);	chr14:22927302	chr14:23023083~23024217:-
BRCA	cis	rs17772222	0.917	rs17188046	ENSG00000258983.2	RP11-507K2.2	7.52	1.22e-13	3.24e-11	0.26	0.23	Coronary artery calcification;	chr14:88624417	chr14:88499334~88515502:+
BRCA	cis	rs11098499	0.955	rs11944880	ENSG00000248280.1	RP11-33B1.2	-7.52	1.22e-13	3.24e-11	-0.23	-0.23	Corneal astigmatism;	chr4:119238179	chr4:119440561~119450157:-
BRCA	cis	rs10129255	1	rs9324091	ENSG00000211972.2	IGHV3-66	7.52	1.22e-13	3.24e-11	0.18	0.23	Kawasaki disease;	chr14:106676625	chr14:106675017~106675544:-
BRCA	cis	rs4763555	1	rs4763555	ENSG00000256667.5	KLRAP1	7.52	1.22e-13	3.25e-11	0.23	0.23	Cognitive function;	chr12:10568857	chr12:10588063~10599669:-
BRCA	cis	rs10129255	0.5	rs8006888	ENSG00000211970.3	IGHV4-61	-7.51	1.22e-13	3.26e-11	-0.15	-0.23	Kawasaki disease;	chr14:106782219	chr14:106639119~106639657:-
BRCA	cis	rs875971	0.66	rs13224319	ENSG00000237310.1	GS1-124K5.4	7.51	1.22e-13	3.26e-11	0.24	0.23	Aortic root size;	chr7:66542376	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.66	rs801217	ENSG00000237310.1	GS1-124K5.4	-7.51	1.22e-13	3.26e-11	-0.24	-0.23	Aortic root size;	chr7:66545590	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.638	rs801216	ENSG00000237310.1	GS1-124K5.4	-7.51	1.22e-13	3.26e-11	-0.24	-0.23	Aortic root size;	chr7:66546680	chr7:66493706~66495474:+
BRCA	cis	rs896854	0.516	rs12679044	ENSG00000253528.2	RP11-347C18.4	7.51	1.23e-13	3.26e-11	0.24	0.23	Type 2 diabetes;	chr8:94879128	chr8:94974573~94974853:-
BRCA	cis	rs17711722	0.528	rs73138179	ENSG00000213640.3	EEF1DP4	-7.51	1.23e-13	3.26e-11	-0.3	-0.23	Calcium levels;	chr7:65829495	chr7:64862999~64864370:+
BRCA	cis	rs10129255	1	rs10141557	ENSG00000211972.2	IGHV3-66	7.51	1.23e-13	3.28e-11	0.18	0.23	Kawasaki disease;	chr14:106767990	chr14:106675017~106675544:-
BRCA	cis	rs712022	0.505	rs11026816	ENSG00000246225.5	RP11-17A1.3	-7.51	1.23e-13	3.29e-11	-0.27	-0.23	Dialysis-related mortality;	chr11:22855277	chr11:22829380~22945393:+
BRCA	cis	rs891378	0.785	rs10864144	ENSG00000274245.1	RP11-357P18.2	-7.51	1.24e-13	3.29e-11	-0.29	-0.23	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207229508	chr1:207372559~207373252:+
BRCA	cis	rs891378	0.785	rs60673767	ENSG00000274245.1	RP11-357P18.2	-7.51	1.24e-13	3.29e-11	-0.29	-0.23	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207230859	chr1:207372559~207373252:+
BRCA	cis	rs891378	0.655	rs1019829	ENSG00000274245.1	RP11-357P18.2	-7.51	1.24e-13	3.29e-11	-0.29	-0.23	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207231786	chr1:207372559~207373252:+
BRCA	cis	rs9649213	0.593	rs6465675	ENSG00000272950.1	RP11-307C18.1	-7.51	1.24e-13	3.29e-11	-0.29	-0.23	Prostate cancer (SNP x SNP interaction);	chr7:98352791	chr7:98322853~98323430:+
BRCA	cis	rs875971	0.66	rs801211	ENSG00000237310.1	GS1-124K5.4	-7.51	1.24e-13	3.3e-11	-0.24	-0.23	Aortic root size;	chr7:66550702	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.638	rs801205	ENSG00000237310.1	GS1-124K5.4	-7.51	1.24e-13	3.3e-11	-0.24	-0.23	Aortic root size;	chr7:66557157	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.617	rs810400	ENSG00000237310.1	GS1-124K5.4	-7.51	1.24e-13	3.3e-11	-0.24	-0.23	Aortic root size;	chr7:66557902	chr7:66493706~66495474:+
BRCA	cis	rs801193	0.935	rs11772264	ENSG00000224316.1	RP11-479O9.2	7.51	1.24e-13	3.31e-11	0.22	0.23	Aortic root size;	chr7:66711400	chr7:65773620~65802067:+
BRCA	cis	rs9880211	0.8	rs35100027	ENSG00000273486.1	RP11-731C17.2	7.51	1.24e-13	3.31e-11	0.31	0.23	Height;Body mass index;	chr3:136748719	chr3:136837338~136839021:-
BRCA	cis	rs61270009	0.955	rs12514004	ENSG00000247828.6	TMEM161B-AS1	7.51	1.24e-13	3.31e-11	0.29	0.23	Depressive symptoms;	chr5:88269979	chr5:88268895~88436685:+
BRCA	cis	rs11976180	1	rs2951353	ENSG00000170356.8	OR2A20P	-7.51	1.24e-13	3.31e-11	-0.32	-0.23	Obesity-related traits;	chr7:144064023	chr7:144250045~144252957:-
BRCA	cis	rs8062405	0.755	rs12447461	ENSG00000251417.2	RP11-1348G14.4	-7.51	1.24e-13	3.31e-11	-0.27	-0.23	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28571620	chr16:28802743~28817828:+
BRCA	cis	rs8062405	0.755	rs111693583	ENSG00000251417.2	RP11-1348G14.4	-7.51	1.24e-13	3.31e-11	-0.27	-0.23	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28572289	chr16:28802743~28817828:+
BRCA	cis	rs9649213	0.593	rs7776638	ENSG00000272950.1	RP11-307C18.1	7.51	1.24e-13	3.31e-11	0.29	0.23	Prostate cancer (SNP x SNP interaction);	chr7:98364194	chr7:98322853~98323430:+
BRCA	cis	rs875971	0.862	rs7786892	ENSG00000232559.3	GS1-124K5.12	-7.51	1.24e-13	3.31e-11	-0.27	-0.23	Aortic root size;	chr7:66163889	chr7:66554588~66576923:-
BRCA	cis	rs9649213	0.593	rs1859482	ENSG00000272950.1	RP11-307C18.1	7.51	1.24e-13	3.31e-11	0.29	0.23	Prostate cancer (SNP x SNP interaction);	chr7:98354462	chr7:98322853~98323430:+
BRCA	cis	rs9649213	0.593	rs13246868	ENSG00000272950.1	RP11-307C18.1	7.51	1.24e-13	3.31e-11	0.29	0.23	Prostate cancer (SNP x SNP interaction);	chr7:98357141	chr7:98322853~98323430:+
BRCA	cis	rs9649213	0.593	rs12672092	ENSG00000272950.1	RP11-307C18.1	7.51	1.24e-13	3.31e-11	0.29	0.23	Prostate cancer (SNP x SNP interaction);	chr7:98357245	chr7:98322853~98323430:+
BRCA	cis	rs11976180	1	rs6464574	ENSG00000204959.4	ARHGEF34P	7.51	1.25e-13	3.31e-11	0.3	0.23	Obesity-related traits;	chr7:144051164	chr7:144272445~144286966:-
BRCA	cis	rs891378	0.785	rs11120485	ENSG00000274245.1	RP11-357P18.2	-7.51	1.25e-13	3.32e-11	-0.29	-0.23	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207232482	chr1:207372559~207373252:+
BRCA	cis	rs1510272	0.515	rs6762762	ENSG00000243926.1	TIPARP-AS1	-7.51	1.25e-13	3.32e-11	-0.3	-0.23	Testicular germ cell tumor;	chr3:156625194	chr3:156671862~156674378:-
BRCA	cis	rs6472827	0.953	rs4604419	ENSG00000253983.2	RP1-16A9.1	7.51	1.25e-13	3.32e-11	0.35	0.23	Uterine fibroids;	chr8:74209330	chr8:74199396~74208441:+
BRCA	cis	rs6539288	0.899	rs6539290	ENSG00000260329.1	RP11-412D9.4	-7.51	1.25e-13	3.32e-11	-0.26	-0.23	Total body bone mineral density;	chr12:106915871	chr12:106954029~106955497:-
BRCA	cis	rs1862618	0.802	rs832560	ENSG00000271828.1	CTD-2310F14.1	7.51	1.25e-13	3.33e-11	0.31	0.23	Initial pursuit acceleration;	chr5:56828596	chr5:56927874~56929573:+
BRCA	cis	rs7580658	0.55	rs62160290	ENSG00000236682.1	AC068282.3	-7.51	1.26e-13	3.36e-11	-0.31	-0.23	Protein C levels;	chr2:127443119	chr2:127389130~127400580:+
BRCA	cis	rs6496044	0.507	rs7175731	ENSG00000202081.1	RNU6-1280P	-7.51	1.26e-13	3.36e-11	-0.26	-0.23	Interstitial lung disease;	chr15:85611115	chr15:85651522~85651628:-
BRCA	cis	rs780096	0.587	rs6743819	ENSG00000234072.1	AC074117.10	-7.51	1.26e-13	3.36e-11	-0.22	-0.23	Total body bone mineral density;	chr2:27344540	chr2:27356246~27367622:+
BRCA	cis	rs6860806	0.531	rs272887	ENSG00000233006.5	AC034220.3	7.51	1.27e-13	3.37e-11	0.18	0.23	Breast cancer;	chr5:132330020	chr5:132311285~132369916:-
BRCA	cis	rs6545883	0.859	rs2600661	ENSG00000271889.1	RP11-493E12.1	-7.51	1.27e-13	3.37e-11	-0.29	-0.23	Tuberculosis;	chr2:61315946	chr2:61151433~61162105:-
BRCA	cis	rs904251	0.522	rs882322	ENSG00000204110.6	RP1-153P14.8	-7.51	1.27e-13	3.37e-11	-0.25	-0.23	Cognitive performance;	chr6:37516327	chr6:37507348~37535616:+
BRCA	cis	rs4835473	0.897	rs11735341	ENSG00000251600.4	RP11-673E1.1	-7.51	1.27e-13	3.38e-11	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143716030	chr4:143912331~143982454:+
BRCA	cis	rs74233809	1	rs11191519	ENSG00000213277.3	MARCKSL1P1	7.51	1.28e-13	3.39e-11	0.42	0.23	Birth weight;	chr10:103025161	chr10:103175554~103176094:+
BRCA	cis	rs801193	1	rs6958520	ENSG00000224316.1	RP11-479O9.2	7.51	1.28e-13	3.4e-11	0.22	0.23	Aortic root size;	chr7:66686466	chr7:65773620~65802067:+
BRCA	cis	rs17772222	0.917	rs11159868	ENSG00000258983.2	RP11-507K2.2	7.51	1.28e-13	3.4e-11	0.26	0.23	Coronary artery calcification;	chr14:88760528	chr14:88499334~88515502:+
BRCA	cis	rs3745672	1	rs10413462	ENSG00000219665.7	CTD-2006C1.2	-7.51	1.28e-13	3.4e-11	-0.57	-0.23	Multiple sclerosis;	chr19:11943821	chr19:11987617~12046275:+
BRCA	cis	rs9649213	0.574	rs36099592	ENSG00000272950.1	RP11-307C18.1	7.51	1.28e-13	3.41e-11	0.29	0.23	Prostate cancer (SNP x SNP interaction);	chr7:98373019	chr7:98322853~98323430:+
BRCA	cis	rs4835473	0.932	rs4092718	ENSG00000251600.4	RP11-673E1.1	-7.51	1.28e-13	3.41e-11	-0.28	-0.23	Immature fraction of reticulocytes;	chr4:143799637	chr4:143912331~143982454:+
BRCA	cis	rs801193	0.761	rs2659888	ENSG00000224316.1	RP11-479O9.2	7.51	1.29e-13	3.42e-11	0.23	0.23	Aortic root size;	chr7:66765184	chr7:65773620~65802067:+
BRCA	cis	rs7567389	0.6	rs3732209	ENSG00000236682.1	AC068282.3	-7.51	1.29e-13	3.42e-11	-0.33	-0.23	Self-rated health;	chr2:127322230	chr2:127389130~127400580:+
BRCA	cis	rs6543140	0.929	rs11465700	ENSG00000234389.1	AC007278.3	7.51	1.29e-13	3.43e-11	0.23	0.23	Blood protein levels;	chr2:102441208	chr2:102438713~102440475:+
BRCA	cis	rs755249	0.958	rs2068663	ENSG00000228060.1	RP11-69E11.8	-7.51	1.3e-13	3.44e-11	-0.27	-0.23	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39572899	chr1:39565160~39573203:+
BRCA	cis	rs6860806	0.507	rs2631369	ENSG00000233006.5	AC034220.3	-7.51	1.3e-13	3.44e-11	-0.18	-0.23	Breast cancer;	chr5:132369574	chr5:132311285~132369916:-
BRCA	cis	rs274567	0.501	rs2631368	ENSG00000233006.5	AC034220.3	-7.51	1.3e-13	3.44e-11	-0.18	-0.23	Blood metabolite levels;	chr5:132369605	chr5:132311285~132369916:-
BRCA	cis	rs11098499	0.955	rs35197422	ENSG00000248280.1	RP11-33B1.2	7.51	1.3e-13	3.45e-11	0.23	0.23	Corneal astigmatism;	chr4:119248159	chr4:119440561~119450157:-
BRCA	cis	rs801193	1	rs3800812	ENSG00000237310.1	GS1-124K5.4	7.51	1.3e-13	3.46e-11	0.23	0.23	Aortic root size;	chr7:66758474	chr7:66493706~66495474:+
BRCA	cis	rs801193	1	rs4279493	ENSG00000237310.1	GS1-124K5.4	7.51	1.3e-13	3.46e-11	0.23	0.23	Aortic root size;	chr7:66761633	chr7:66493706~66495474:+
BRCA	cis	rs11098499	0.863	rs6858592	ENSG00000248280.1	RP11-33B1.2	7.51	1.3e-13	3.46e-11	0.23	0.23	Corneal astigmatism;	chr4:119537537	chr4:119440561~119450157:-
BRCA	cis	rs7246657	0.943	rs8106839	ENSG00000276846.1	CTD-3220F14.3	7.51	1.3e-13	3.47e-11	0.31	0.23	Coronary artery calcification;	chr19:37467573	chr19:37314868~37315620:-
BRCA	cis	rs11098499	0.562	rs58583086	ENSG00000245958.5	RP11-33B1.1	7.51	1.31e-13	3.47e-11	0.21	0.23	Corneal astigmatism;	chr4:119635207	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.863	rs3736115	ENSG00000248280.1	RP11-33B1.2	-7.51	1.31e-13	3.47e-11	-0.23	-0.23	Corneal astigmatism;	chr4:119567548	chr4:119440561~119450157:-
BRCA	cis	rs7474896	0.559	rs10740949	ENSG00000226578.1	RP11-258F22.1	-7.51	1.31e-13	3.47e-11	-0.29	-0.23	Obesity (extreme);	chr10:37689507	chr10:37775371~37784131:-
BRCA	cis	rs2179367	0.632	rs62426068	ENSG00000231760.4	RP11-350J20.5	7.51	1.31e-13	3.48e-11	0.33	0.23	Dupuytren's disease;	chr6:149325795	chr6:149796151~149826294:-
BRCA	cis	rs2179367	0.632	rs62426069	ENSG00000231760.4	RP11-350J20.5	7.51	1.31e-13	3.48e-11	0.33	0.23	Dupuytren's disease;	chr6:149325804	chr6:149796151~149826294:-
BRCA	cis	rs858239	0.6	rs7341483	ENSG00000230042.1	AK3P3	7.51	1.31e-13	3.48e-11	0.26	0.23	Cerebrospinal fluid biomarker levels;	chr7:23088038	chr7:23129178~23129841:+
BRCA	cis	rs7586673	1	rs16845584	ENSG00000235724.7	AC009299.2	7.5	1.32e-13	3.5e-11	0.27	0.23	Intelligence (multi-trait analysis);	chr2:161067319	chr2:161222785~161308303:-
BRCA	cis	rs11976180	1	rs2951308	ENSG00000170356.8	OR2A20P	7.5	1.32e-13	3.51e-11	0.32	0.23	Obesity-related traits;	chr7:144070056	chr7:144250045~144252957:-
BRCA	cis	rs2439831	0.85	rs61390361	ENSG00000275601.1	AC011330.13	-7.5	1.32e-13	3.51e-11	-0.36	-0.23	Lung cancer in ever smokers;	chr15:43867644	chr15:43642389~43643023:-
BRCA	cis	rs801193	1	rs2659906	ENSG00000224316.1	RP11-479O9.2	7.5	1.33e-13	3.53e-11	0.22	0.23	Aortic root size;	chr7:66700323	chr7:65773620~65802067:+
BRCA	cis	rs6539288	0.834	rs1545097	ENSG00000260329.1	RP11-412D9.4	-7.5	1.33e-13	3.54e-11	-0.26	-0.23	Total body bone mineral density;	chr12:106919918	chr12:106954029~106955497:-
BRCA	cis	rs6539288	0.899	rs6539292	ENSG00000260329.1	RP11-412D9.4	-7.5	1.33e-13	3.54e-11	-0.26	-0.23	Total body bone mineral density;	chr12:106919935	chr12:106954029~106955497:-
BRCA	cis	rs875971	0.545	rs7783889	ENSG00000224316.1	RP11-479O9.2	7.5	1.33e-13	3.54e-11	0.26	0.23	Aortic root size;	chr7:66283366	chr7:65773620~65802067:+
BRCA	cis	rs7811142	0.943	rs3900792	ENSG00000242294.5	STAG3L5P	7.5	1.33e-13	3.54e-11	0.22	0.23	Platelet count;	chr7:100406954	chr7:100336079~100351900:+
BRCA	cis	rs17772222	0.917	rs7157149	ENSG00000258983.2	RP11-507K2.2	7.5	1.34e-13	3.55e-11	0.27	0.23	Coronary artery calcification;	chr14:88765501	chr14:88499334~88515502:+
BRCA	cis	rs526231	0.578	rs59323174	ENSG00000175749.11	EIF3KP1	7.5	1.34e-13	3.55e-11	0.32	0.23	Primary biliary cholangitis;	chr5:102932165	chr5:103032376~103033031:+
BRCA	cis	rs4723738	1	rs2159501	ENSG00000227191.5	TRGC2	-7.5	1.34e-13	3.56e-11	-0.2	-0.23	Treatment response for severe sepsis;	chr7:38199675	chr7:38239580~38368091:-
BRCA	cis	rs4723738	0.934	rs1860522	ENSG00000227191.5	TRGC2	-7.5	1.34e-13	3.56e-11	-0.2	-0.23	Treatment response for severe sepsis;	chr7:38200439	chr7:38239580~38368091:-
BRCA	cis	rs780096	0.526	rs4582	ENSG00000234072.1	AC074117.10	-7.5	1.34e-13	3.56e-11	-0.22	-0.23	Total body bone mineral density;	chr2:27381412	chr2:27356246~27367622:+
BRCA	cis	rs875971	0.66	rs801192	ENSG00000237310.1	GS1-124K5.4	-7.5	1.34e-13	3.56e-11	-0.23	-0.23	Aortic root size;	chr7:66566965	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.66	rs801190	ENSG00000237310.1	GS1-124K5.4	-7.5	1.34e-13	3.56e-11	-0.23	-0.23	Aortic root size;	chr7:66568046	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.66	rs3857686	ENSG00000237310.1	GS1-124K5.4	-7.5	1.34e-13	3.56e-11	-0.23	-0.23	Aortic root size;	chr7:66571204	chr7:66493706~66495474:+
BRCA	cis	rs10463554	0.856	rs257293	ENSG00000175749.11	EIF3KP1	7.5	1.35e-13	3.57e-11	0.3	0.23	Parkinson's disease;	chr5:103159824	chr5:103032376~103033031:+
BRCA	cis	rs293748	0.724	rs55668350	ENSG00000250155.1	CTD-2353F22.1	-7.5	1.35e-13	3.57e-11	-0.31	-0.23	Obesity-related traits;	chr5:36801181	chr5:36666214~36725195:-
BRCA	cis	rs6921919	1	rs6922111	ENSG00000204709.4	LINC01556	7.5	1.35e-13	3.57e-11	0.34	0.23	Autism spectrum disorder or schizophrenia;	chr6:28357531	chr6:28943877~28944537:+
BRCA	cis	rs10129255	0.5	rs7161740	ENSG00000211970.3	IGHV4-61	-7.5	1.35e-13	3.59e-11	-0.15	-0.23	Kawasaki disease;	chr14:106776119	chr14:106639119~106639657:-
BRCA	cis	rs11023332	0.617	rs1451678	ENSG00000251991.1	RNU7-49P	7.5	1.35e-13	3.59e-11	0.24	0.23	Vitamin D levels;Adiponectin levels;	chr11:14760075	chr11:14478892~14478953:+
BRCA	cis	rs2274273	0.588	rs2880103	ENSG00000258413.1	RP11-665C16.6	-7.5	1.35e-13	3.59e-11	-0.3	-0.23	Protein biomarker;	chr14:55271114	chr14:55262767~55272075:-
BRCA	cis	rs919433	0.929	rs4850788	ENSG00000231621.1	AC013264.2	7.5	1.35e-13	3.59e-11	0.21	0.23	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197318216	chr2:197197991~197199273:+
BRCA	cis	rs12200782	0.53	rs9379892	ENSG00000241549.7	GUSBP2	7.5	1.36e-13	3.6e-11	0.3	0.23	Small cell lung carcinoma;	chr6:26582186	chr6:26871484~26956554:-
BRCA	cis	rs780096	0.587	rs10205219	ENSG00000234072.1	AC074117.10	-7.5	1.36e-13	3.6e-11	-0.22	-0.23	Total body bone mineral density;	chr2:27345698	chr2:27356246~27367622:+
BRCA	cis	rs4835473	0.932	rs7670010	ENSG00000251600.4	RP11-673E1.1	7.5	1.36e-13	3.6e-11	0.28	0.23	Immature fraction of reticulocytes;	chr4:143821679	chr4:143912331~143982454:+
BRCA	cis	rs2742234	0.955	rs2075913	ENSG00000273008.1	RP11-351D16.3	-7.5	1.36e-13	3.61e-11	-0.26	-0.23	Hirschsprung disease;	chr10:43126920	chr10:43136824~43138334:-
BRCA	cis	rs8072100	0.967	rs4289035	ENSG00000228782.6	CTD-2026D20.3	7.5	1.36e-13	3.61e-11	0.24	0.23	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47629845	chr17:47450568~47492492:-
BRCA	cis	rs5751614	0.537	rs7288846	ENSG00000230701.2	FBXW4P1	-7.5	1.37e-13	3.62e-11	-0.29	-0.23	Height;	chr22:23281097	chr22:23262767~23265005:+
BRCA	cis	rs853679	0.567	rs13196606	ENSG00000204709.4	LINC01556	7.5	1.37e-13	3.63e-11	0.33	0.23	Depression;	chr6:28402301	chr6:28943877~28944537:+
BRCA	cis	rs2117029	0.638	rs7296288	ENSG00000258017.1	RP11-386G11.10	-7.5	1.37e-13	3.63e-11	-0.28	-0.23	Intelligence (multi-trait analysis);	chr12:49086185	chr12:49127782~49147869:+
BRCA	cis	rs2243480	1	rs2462569	ENSG00000273142.1	RP11-458F8.4	7.5	1.37e-13	3.63e-11	0.3	0.23	Diabetic kidney disease;	chr7:66009859	chr7:66902857~66906297:+
BRCA	cis	rs6921919	0.583	rs740621	ENSG00000204709.4	LINC01556	7.5	1.37e-13	3.64e-11	0.31	0.23	Autism spectrum disorder or schizophrenia;	chr6:28430010	chr6:28943877~28944537:+
BRCA	cis	rs4784934	1	rs4784934	ENSG00000260186.4	RP11-481J2.2	7.5	1.38e-13	3.65e-11	0.29	0.23	QT interval;	chr16:58426022	chr16:58421326~58462470:+
BRCA	cis	rs2348418	0.67	rs4035202	ENSG00000247934.4	RP11-967K21.1	-7.5	1.38e-13	3.65e-11	-0.26	-0.23	Lung function (FEV1);Lung function (FVC);	chr12:28118015	chr12:28163298~28190738:-
BRCA	cis	rs6142102	0.812	rs6059578	ENSG00000276073.1	RP5-1125A11.7	-7.5	1.38e-13	3.66e-11	-0.28	-0.23	Skin pigmentation;	chr20:33939900	chr20:33985617~33988989:-
BRCA	cis	rs10129255	0.5	rs8022547	ENSG00000211970.3	IGHV4-61	-7.5	1.38e-13	3.66e-11	-0.14	-0.23	Kawasaki disease;	chr14:106781985	chr14:106639119~106639657:-
BRCA	cis	rs875971	0.862	rs908915	ENSG00000232559.3	GS1-124K5.12	-7.5	1.38e-13	3.67e-11	-0.27	-0.23	Aortic root size;	chr7:66149664	chr7:66554588~66576923:-
BRCA	cis	rs6142102	1	rs6059672	ENSG00000276073.1	RP5-1125A11.7	-7.5	1.38e-13	3.67e-11	-0.28	-0.23	Skin pigmentation;	chr20:34117662	chr20:33985617~33988989:-
BRCA	cis	rs875971	0.66	rs10272357	ENSG00000237310.1	GS1-124K5.4	-7.5	1.39e-13	3.67e-11	-0.24	-0.23	Aortic root size;	chr7:66598087	chr7:66493706~66495474:+
BRCA	cis	rs1864400	0.645	rs2249005	ENSG00000273008.1	RP11-351D16.3	-7.5	1.39e-13	3.68e-11	-0.29	-0.23	Hirschsprung disease;	chr10:43131832	chr10:43136824~43138334:-
BRCA	cis	rs11976180	1	rs2371247	ENSG00000170356.8	OR2A20P	-7.5	1.39e-13	3.68e-11	-0.32	-0.23	Obesity-related traits;	chr7:144067086	chr7:144250045~144252957:-
BRCA	cis	rs6545883	0.868	rs6748003	ENSG00000271889.1	RP11-493E12.1	7.5	1.39e-13	3.68e-11	0.29	0.23	Tuberculosis;	chr2:61579565	chr2:61151433~61162105:-
BRCA	cis	rs801193	1	rs3800812	ENSG00000224316.1	RP11-479O9.2	7.5	1.39e-13	3.69e-11	0.22	0.23	Aortic root size;	chr7:66758474	chr7:65773620~65802067:+
BRCA	cis	rs801193	1	rs4279493	ENSG00000224316.1	RP11-479O9.2	7.5	1.39e-13	3.69e-11	0.22	0.23	Aortic root size;	chr7:66761633	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.638	rs6460305	ENSG00000237310.1	GS1-124K5.4	-7.5	1.4e-13	3.7e-11	-0.23	-0.23	Aortic root size;	chr7:66595421	chr7:66493706~66495474:+
BRCA	cis	rs9880211	0.8	rs9873536	ENSG00000273486.1	RP11-731C17.2	7.5	1.4e-13	3.71e-11	0.31	0.23	Height;Body mass index;	chr3:136755425	chr3:136837338~136839021:-
BRCA	cis	rs2028299	0.92	rs2043880	ENSG00000259677.1	RP11-493E3.1	7.5	1.4e-13	3.71e-11	0.32	0.23	Type 2 diabetes;	chr15:89889294	chr15:89876540~89877285:+
BRCA	cis	rs2014572	0.51	rs8111661	ENSG00000268379.1	CTC-360J11.4	-7.5	1.4e-13	3.71e-11	-0.28	-0.23	Hyperactive-impulsive symptoms;	chr19:57240958	chr19:57175233~57177921:+
BRCA	cis	rs74233809	1	rs11191454	ENSG00000213277.3	MARCKSL1P1	7.5	1.4e-13	3.71e-11	0.43	0.23	Birth weight;	chr10:102900247	chr10:103175554~103176094:+
BRCA	cis	rs10463554	0.892	rs72783889	ENSG00000175749.11	EIF3KP1	7.5	1.4e-13	3.71e-11	0.31	0.23	Parkinson's disease;	chr5:102938835	chr5:103032376~103033031:+
BRCA	cis	rs10463554	0.892	rs72783890	ENSG00000175749.11	EIF3KP1	7.5	1.4e-13	3.71e-11	0.31	0.23	Parkinson's disease;	chr5:102938836	chr5:103032376~103033031:+
BRCA	cis	rs2034650	0.544	rs2289330	ENSG00000223313.1	RNU6-516P	7.5	1.4e-13	3.72e-11	0.28	0.23	Interstitial lung disease;	chr15:40412906	chr15:40529570~40529673:+
BRCA	cis	rs9649213	0.593	rs13246843	ENSG00000272950.1	RP11-307C18.1	7.5	1.4e-13	3.72e-11	0.29	0.23	Prostate cancer (SNP x SNP interaction);	chr7:98373349	chr7:98322853~98323430:+
BRCA	cis	rs2348418	0.733	rs2169752	ENSG00000247934.4	RP11-967K21.1	-7.5	1.41e-13	3.72e-11	-0.26	-0.23	Lung function (FEV1);Lung function (FVC);	chr12:28239279	chr12:28163298~28190738:-
BRCA	cis	rs10463554	0.963	rs26254	ENSG00000175749.11	EIF3KP1	7.5	1.41e-13	3.73e-11	0.31	0.23	Parkinson's disease;	chr5:103221158	chr5:103032376~103033031:+
BRCA	cis	rs2906856	0.848	rs3015001	ENSG00000236946.2	HNRNPA1P70	7.5	1.41e-13	3.74e-11	0.18	0.23	Mosquito bite size;	chr12:68003593	chr12:68035767~68036853:+
BRCA	cis	rs9880211	1	rs9826454	ENSG00000273486.1	RP11-731C17.2	7.5	1.41e-13	3.74e-11	0.3	0.23	Height;Body mass index;	chr3:136234378	chr3:136837338~136839021:-
BRCA	cis	rs193541	0.53	rs9327272	ENSG00000263432.2	RN7SL689P	7.49	1.41e-13	3.74e-11	0.3	0.23	Glucose homeostasis traits;	chr5:122737853	chr5:123022487~123022783:-
BRCA	cis	rs13113518	0.812	rs12648271	ENSG00000249700.7	SRD5A3-AS1	7.49	1.41e-13	3.74e-11	0.32	0.23	Height;	chr4:55501955	chr4:55363971~55395847:-
BRCA	cis	rs801193	0.66	rs2659914	ENSG00000232559.3	GS1-124K5.12	7.49	1.41e-13	3.74e-11	0.27	0.23	Aortic root size;	chr7:66691927	chr7:66554588~66576923:-
BRCA	cis	rs801193	0.591	rs2707839	ENSG00000232559.3	GS1-124K5.12	7.49	1.41e-13	3.74e-11	0.27	0.23	Aortic root size;	chr7:66728097	chr7:66554588~66576923:-
BRCA	cis	rs1552244	0.882	rs17050672	ENSG00000180385.7	EMC3-AS1	7.49	1.42e-13	3.75e-11	0.3	0.23	Alzheimer's disease;	chr3:9983779	chr3:9986893~10006990:+
BRCA	cis	rs293748	0.771	rs16903490	ENSG00000250155.1	CTD-2353F22.1	-7.49	1.42e-13	3.76e-11	-0.31	-0.23	Obesity-related traits;	chr5:37067944	chr5:36666214~36725195:-
BRCA	cis	rs3814244	0.528	rs61923060	ENSG00000236946.2	HNRNPA1P70	-7.49	1.42e-13	3.77e-11	-0.19	-0.23	Itch intensity from mosquito bite adjusted by bite size;	chr12:67997341	chr12:68035767~68036853:+
BRCA	cis	rs17772222	0.917	rs61983300	ENSG00000258983.2	RP11-507K2.2	7.49	1.43e-13	3.77e-11	0.26	0.23	Coronary artery calcification;	chr14:88754047	chr14:88499334~88515502:+
BRCA	cis	rs8062405	0.755	rs1074631	ENSG00000251417.2	RP11-1348G14.4	7.49	1.43e-13	3.78e-11	0.27	0.23	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28542787	chr16:28802743~28817828:+
BRCA	cis	rs7615952	0.641	rs61048217	ENSG00000250012.1	RP11-124N2.1	-7.49	1.44e-13	3.8e-11	-0.31	-0.23	Blood pressure (smoking interaction);	chr3:126089062	chr3:126084220~126095349:+
BRCA	cis	rs7615952	0.641	rs60839048	ENSG00000250012.1	RP11-124N2.1	-7.49	1.44e-13	3.8e-11	-0.31	-0.23	Blood pressure (smoking interaction);	chr3:126089095	chr3:126084220~126095349:+
BRCA	cis	rs7615952	0.641	rs7640158	ENSG00000250012.1	RP11-124N2.1	-7.49	1.44e-13	3.8e-11	-0.31	-0.23	Blood pressure (smoking interaction);	chr3:126089168	chr3:126084220~126095349:+
BRCA	cis	rs7615952	0.641	rs2365019	ENSG00000250012.1	RP11-124N2.1	-7.49	1.44e-13	3.8e-11	-0.31	-0.23	Blood pressure (smoking interaction);	chr3:126089292	chr3:126084220~126095349:+
BRCA	cis	rs2439831	0.85	rs7169322	ENSG00000205771.5	CATSPER2P1	-7.49	1.44e-13	3.8e-11	-0.4	-0.23	Lung cancer in ever smokers;	chr15:43838816	chr15:43726918~43747094:-
BRCA	cis	rs2439831	0.85	rs28707214	ENSG00000205771.5	CATSPER2P1	-7.49	1.44e-13	3.8e-11	-0.4	-0.23	Lung cancer in ever smokers;	chr15:43839425	chr15:43726918~43747094:-
BRCA	cis	rs17772222	0.917	rs8006652	ENSG00000258983.2	RP11-507K2.2	7.49	1.44e-13	3.81e-11	0.26	0.23	Coronary artery calcification;	chr14:88631290	chr14:88499334~88515502:+
BRCA	cis	rs875971	0.862	rs10263690	ENSG00000232559.3	GS1-124K5.12	-7.49	1.44e-13	3.81e-11	-0.27	-0.23	Aortic root size;	chr7:66301466	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.862	rs10250544	ENSG00000232559.3	GS1-124K5.12	-7.49	1.44e-13	3.81e-11	-0.27	-0.23	Aortic root size;	chr7:66301574	chr7:66554588~66576923:-
BRCA	cis	rs9880211	0.948	rs9872178	ENSG00000273486.1	RP11-731C17.2	7.49	1.44e-13	3.81e-11	0.3	0.23	Height;Body mass index;	chr3:136267596	chr3:136837338~136839021:-
BRCA	cis	rs4723738	0.967	rs10480164	ENSG00000227191.5	TRGC2	-7.49	1.44e-13	3.82e-11	-0.2	-0.23	Treatment response for severe sepsis;	chr7:38206281	chr7:38239580~38368091:-
BRCA	cis	rs4308124	1	rs62160391	ENSG00000227992.1	AC108463.2	-7.49	1.45e-13	3.82e-11	-0.26	-0.23	Vitiligo;	chr2:111251258	chr2:111203964~111206215:-
BRCA	cis	rs10771431	0.935	rs1117735	ENSG00000111788.10	RP11-22B23.1	7.49	1.45e-13	3.83e-11	0.2	0.23	Breast size;	chr12:9220132	chr12:9277235~9313241:+
BRCA	cis	rs301901	1	rs301901	ENSG00000250155.1	CTD-2353F22.1	-7.49	1.45e-13	3.83e-11	-0.25	-0.23	Height;	chr5:37046524	chr5:36666214~36725195:-
BRCA	cis	rs10463554	1	rs17154893	ENSG00000175749.11	EIF3KP1	7.49	1.46e-13	3.85e-11	0.31	0.23	Parkinson's disease;	chr5:102980902	chr5:103032376~103033031:+
BRCA	cis	rs11098499	0.604	rs2389886	ENSG00000245958.5	RP11-33B1.1	-7.49	1.46e-13	3.86e-11	-0.23	-0.23	Corneal astigmatism;	chr4:119649267	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.913	rs11098496	ENSG00000248280.1	RP11-33B1.2	7.49	1.46e-13	3.86e-11	0.23	0.23	Corneal astigmatism;	chr4:119246311	chr4:119440561~119450157:-
BRCA	cis	rs61270009	0.955	rs415302	ENSG00000247828.6	TMEM161B-AS1	-7.49	1.46e-13	3.87e-11	-0.28	-0.23	Depressive symptoms;	chr5:88231628	chr5:88268895~88436685:+
BRCA	cis	rs61270009	0.955	rs780398	ENSG00000247828.6	TMEM161B-AS1	-7.49	1.46e-13	3.87e-11	-0.28	-0.23	Depressive symptoms;	chr5:88234112	chr5:88268895~88436685:+
BRCA	cis	rs2933343	0.553	rs35076317	ENSG00000231305.3	RP11-723O4.2	7.49	1.46e-13	3.87e-11	0.26	0.23	IgG glycosylation;	chr3:128996692	chr3:128861313~128871540:-
BRCA	cis	rs301901	1	rs168662	ENSG00000250155.1	CTD-2353F22.1	-7.49	1.47e-13	3.88e-11	-0.24	-0.23	Height;	chr5:36925633	chr5:36666214~36725195:-
BRCA	cis	rs7809950	0.954	rs2520242	ENSG00000238832.1	snoU109	7.49	1.47e-13	3.88e-11	0.3	0.23	Coronary artery disease;	chr7:107495875	chr7:107603363~107603507:+
BRCA	cis	rs9880211	0.752	rs9838884	ENSG00000273486.1	RP11-731C17.2	7.49	1.47e-13	3.88e-11	0.31	0.23	Height;Body mass index;	chr3:136736862	chr3:136837338~136839021:-
BRCA	cis	rs301901	1	rs388098	ENSG00000250155.1	CTD-2353F22.1	-7.49	1.47e-13	3.89e-11	-0.25	-0.23	Height;	chr5:37068442	chr5:36666214~36725195:-
BRCA	cis	rs867371	0.896	rs6495647	ENSG00000259429.4	UBE2Q2P2	-7.49	1.47e-13	3.89e-11	-0.23	-0.23	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82244708	chr15:82355142~82420075:+
BRCA	cis	rs293748	0.771	rs158799	ENSG00000250155.1	CTD-2353F22.1	-7.49	1.47e-13	3.89e-11	-0.31	-0.23	Obesity-related traits;	chr5:36869149	chr5:36666214~36725195:-
BRCA	cis	rs2034650	0.563	rs2412523	ENSG00000223313.1	RNU6-516P	7.49	1.48e-13	3.9e-11	0.27	0.23	Interstitial lung disease;	chr15:40417487	chr15:40529570~40529673:+
BRCA	cis	rs2274273	0.624	rs3783651	ENSG00000258413.1	RP11-665C16.6	-7.49	1.48e-13	3.9e-11	-0.3	-0.23	Protein biomarker;	chr14:55384255	chr14:55262767~55272075:-
BRCA	cis	rs17772222	0.917	rs12434935	ENSG00000258983.2	RP11-507K2.2	7.49	1.48e-13	3.9e-11	0.26	0.23	Coronary artery calcification;	chr14:88645449	chr14:88499334~88515502:+
BRCA	cis	rs10129255	0.5	rs2027902	ENSG00000280411.1	IGHV1-69-2	-7.49	1.48e-13	3.9e-11	-0.15	-0.23	Kawasaki disease;	chr14:106807157	chr14:106762092~106762588:-
BRCA	cis	rs801193	1	rs10234018	ENSG00000224316.1	RP11-479O9.2	-7.49	1.48e-13	3.92e-11	-0.23	-0.23	Aortic root size;	chr7:66681297	chr7:65773620~65802067:+
BRCA	cis	rs11976180	1	rs11975942	ENSG00000170356.8	OR2A20P	-7.49	1.49e-13	3.93e-11	-0.33	-0.23	Obesity-related traits;	chr7:144043487	chr7:144250045~144252957:-
BRCA	cis	rs801193	1	rs1553609	ENSG00000237310.1	GS1-124K5.4	7.49	1.49e-13	3.93e-11	0.23	0.23	Aortic root size;	chr7:66732152	chr7:66493706~66495474:+
BRCA	cis	rs10771431	0.935	rs1988852	ENSG00000111788.10	RP11-22B23.1	7.49	1.49e-13	3.94e-11	0.2	0.23	Breast size;	chr12:9220266	chr12:9277235~9313241:+
BRCA	cis	rs12701220	0.553	rs34062359	ENSG00000229043.2	AC091729.9	-7.49	1.5e-13	3.95e-11	-0.37	-0.23	Bronchopulmonary dysplasia;	chr7:1099440	chr7:1160374~1165267:+
BRCA	cis	rs9880211	1	rs9837158	ENSG00000273486.1	RP11-731C17.2	7.49	1.5e-13	3.97e-11	0.3	0.23	Height;Body mass index;	chr3:136354321	chr3:136837338~136839021:-
BRCA	cis	rs301901	1	rs188541	ENSG00000250155.1	CTD-2353F22.1	-7.49	1.51e-13	3.98e-11	-0.25	-0.23	Height;	chr5:37061159	chr5:36666214~36725195:-
BRCA	cis	rs2348418	0.67	rs1824919	ENSG00000247934.4	RP11-967K21.1	-7.49	1.51e-13	3.99e-11	-0.26	-0.23	Lung function (FEV1);Lung function (FVC);	chr12:28118449	chr12:28163298~28190738:-
BRCA	cis	rs10129255	0.5	rs6576231	ENSG00000211970.3	IGHV4-61	-7.49	1.51e-13	3.99e-11	-0.15	-0.23	Kawasaki disease;	chr14:106783693	chr14:106639119~106639657:-
BRCA	cis	rs858239	0.899	rs28635122	ENSG00000230042.1	AK3P3	-7.49	1.51e-13	3.99e-11	-0.27	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23270562	chr7:23129178~23129841:+
BRCA	cis	rs4835473	0.897	rs62337587	ENSG00000251600.4	RP11-673E1.1	-7.49	1.51e-13	3.99e-11	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143725839	chr4:143912331~143982454:+
BRCA	cis	rs780096	0.526	rs780117	ENSG00000234072.1	AC074117.10	-7.49	1.51e-13	4e-11	-0.22	-0.23	Total body bone mineral density;	chr2:27475476	chr2:27356246~27367622:+
BRCA	cis	rs11159086	0.941	rs12434836	ENSG00000259005.1	RP3-449M8.6	7.49	1.52e-13	4e-11	0.38	0.23	Advanced glycation end-product levels;	chr14:74468887	chr14:74474007~74474864:-
BRCA	cis	rs7246657	0.943	rs8111782	ENSG00000276846.1	CTD-3220F14.3	7.49	1.52e-13	4.01e-11	0.32	0.23	Coronary artery calcification;	chr19:37377002	chr19:37314868~37315620:-
BRCA	cis	rs9649213	0.593	rs7807555	ENSG00000272950.1	RP11-307C18.1	7.49	1.52e-13	4.01e-11	0.29	0.23	Prostate cancer (SNP x SNP interaction);	chr7:98328205	chr7:98322853~98323430:+
BRCA	cis	rs9649213	0.593	rs6465667	ENSG00000272950.1	RP11-307C18.1	7.49	1.52e-13	4.01e-11	0.29	0.23	Prostate cancer (SNP x SNP interaction);	chr7:98328573	chr7:98322853~98323430:+
BRCA	cis	rs9649213	0.593	rs6949214	ENSG00000272950.1	RP11-307C18.1	7.49	1.52e-13	4.01e-11	0.29	0.23	Prostate cancer (SNP x SNP interaction);	chr7:98330921	chr7:98322853~98323430:+
BRCA	cis	rs10463554	1	rs10463554	ENSG00000175749.11	EIF3KP1	7.48	1.52e-13	4.01e-11	0.32	0.23	Parkinson's disease;	chr5:102983270	chr5:103032376~103033031:+
BRCA	cis	rs12188164	0.543	rs2672757	ENSG00000225138.6	CTD-2228K2.7	-7.48	1.52e-13	4.01e-11	-0.24	-0.23	Cystic fibrosis severity;	chr5:454617	chr5:473236~480884:+
BRCA	cis	rs875971	0.638	rs10249404	ENSG00000224316.1	RP11-479O9.2	-7.48	1.53e-13	4.03e-11	-0.23	-0.23	Aortic root size;	chr7:66581737	chr7:65773620~65802067:+
BRCA	cis	rs7267979	0.668	rs4815398	ENSG00000274973.1	RP13-401N8.7	7.48	1.53e-13	4.04e-11	0.27	0.23	Liver enzyme levels (alkaline phosphatase);	chr20:25256702	chr20:25845497~25845862:+
BRCA	cis	rs1757171	0.542	rs3818985	ENSG00000204110.6	RP1-153P14.8	-7.48	1.53e-13	4.04e-11	-0.25	-0.23	Cognitive performance;	chr6:37516438	chr6:37507348~37535616:+
BRCA	cis	rs8005677	1	rs4982709	ENSG00000279656.1	RP11-298I3.6	7.48	1.54e-13	4.06e-11	0.27	0.23	Cognitive ability (multi-trait analysis);	chr14:22925490	chr14:23023083~23024217:-
BRCA	cis	rs4835473	0.801	rs999049	ENSG00000251600.4	RP11-673E1.1	-7.48	1.54e-13	4.06e-11	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143715440	chr4:143912331~143982454:+
BRCA	cis	rs42648	0.748	rs10226014	ENSG00000225498.1	AC002064.5	-7.48	1.55e-13	4.08e-11	-0.22	-0.23	Homocysteine levels;	chr7:90273219	chr7:90312496~90322592:+
BRCA	cis	rs8062405	0.698	rs7188071	ENSG00000278665.1	RP11-666O2.4	-7.48	1.55e-13	4.08e-11	-0.25	-0.23	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28906323	chr16:28599241~28601881:-
BRCA	cis	rs2243480	1	rs73142162	ENSG00000273142.1	RP11-458F8.4	-7.48	1.55e-13	4.09e-11	-0.31	-0.23	Diabetic kidney disease;	chr7:65909309	chr7:66902857~66906297:+
BRCA	cis	rs3781264	0.595	rs7096037	ENSG00000273450.1	RP11-76P2.4	7.48	1.55e-13	4.09e-11	0.3	0.23	Esophageal cancer and gastric cancer;	chr10:94329950	chr10:94314907~94315327:-
BRCA	cis	rs1861628	0.927	rs6724363	ENSG00000237930.1	AC007563.4	7.48	1.55e-13	4.1e-11	0.27	0.23	Serum thyroid-stimulating hormone levels;Hypothyroidism;	chr2:216761868	chr2:216785774~216786144:-
BRCA	cis	rs1075265	0.563	rs2692536	ENSG00000233266.1	HMGB1P31	7.48	1.56e-13	4.11e-11	0.28	0.23	Chronotype;Morning vs. evening chronotype;	chr2:53788266	chr2:54051334~54051760:+
BRCA	cis	rs858239	0.932	rs858272	ENSG00000230042.1	AK3P3	-7.48	1.56e-13	4.11e-11	-0.27	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23237166	chr7:23129178~23129841:+
BRCA	cis	rs66887589	0.616	rs6843509	ENSG00000248280.1	RP11-33B1.2	7.48	1.56e-13	4.12e-11	0.21	0.23	Diastolic blood pressure;	chr4:119299041	chr4:119440561~119450157:-
BRCA	cis	rs143626010	1	rs143626010	ENSG00000251417.2	RP11-1348G14.4	-7.48	1.56e-13	4.12e-11	-0.27	-0.23	Mosquito bite size;	chr16:28528081	chr16:28802743~28817828:+
BRCA	cis	rs9649213	0.593	rs6949718	ENSG00000272950.1	RP11-307C18.1	7.48	1.56e-13	4.12e-11	0.29	0.23	Prostate cancer (SNP x SNP interaction);	chr7:98295171	chr7:98322853~98323430:+
BRCA	cis	rs2179367	0.632	rs997682	ENSG00000231760.4	RP11-350J20.5	-7.48	1.56e-13	4.12e-11	-0.33	-0.23	Dupuytren's disease;	chr6:149345484	chr6:149796151~149826294:-
BRCA	cis	rs9649213	0.531	rs35216698	ENSG00000272950.1	RP11-307C18.1	7.48	1.56e-13	4.12e-11	0.29	0.23	Prostate cancer (SNP x SNP interaction);	chr7:98266863	chr7:98322853~98323430:+
BRCA	cis	rs7587476	0.501	rs11888027	ENSG00000229267.2	AC072062.1	7.48	1.57e-13	4.13e-11	0.26	0.23	Neuroblastoma;	chr2:214774888	chr2:214810229~214963274:+
BRCA	cis	rs73186030	0.546	rs67931976	ENSG00000272758.4	RP11-299J3.8	7.48	1.57e-13	4.13e-11	0.31	0.23	Serum parathyroid hormone levels;	chr3:122386868	chr3:122416207~122443180:+
BRCA	cis	rs4660214	0.671	rs16826012	ENSG00000237624.1	OXCT2P1	-7.48	1.57e-13	4.14e-11	-0.36	-0.23	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39253847	chr1:39514956~39516490:+
BRCA	cis	rs812925	0.859	rs778138	ENSG00000271889.1	RP11-493E12.1	7.48	1.57e-13	4.14e-11	0.29	0.23	Immature fraction of reticulocytes;	chr2:61460079	chr2:61151433~61162105:-
BRCA	cis	rs1609391	0.543	rs9828009	ENSG00000273486.1	RP11-731C17.2	7.48	1.57e-13	4.14e-11	0.25	0.23	Neuroticism;	chr3:136912433	chr3:136837338~136839021:-
BRCA	cis	rs42648	0.667	rs2157793	ENSG00000225498.1	AC002064.5	7.48	1.57e-13	4.14e-11	0.22	0.23	Homocysteine levels;	chr7:90251040	chr7:90312496~90322592:+
BRCA	cis	rs858239	0.806	rs10268610	ENSG00000230042.1	AK3P3	-7.48	1.57e-13	4.14e-11	-0.26	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23235145	chr7:23129178~23129841:+
BRCA	cis	rs10129255	1	rs8010605	ENSG00000211972.2	IGHV3-66	7.48	1.57e-13	4.14e-11	0.18	0.23	Kawasaki disease;	chr14:106678742	chr14:106675017~106675544:-
BRCA	cis	rs74233809	1	rs74444347	ENSG00000213277.3	MARCKSL1P1	7.48	1.57e-13	4.15e-11	0.42	0.23	Birth weight;	chr10:103009518	chr10:103175554~103176094:+
BRCA	cis	rs74233809	1	rs12221335	ENSG00000213277.3	MARCKSL1P1	7.48	1.57e-13	4.15e-11	0.42	0.23	Birth weight;	chr10:103009635	chr10:103175554~103176094:+
BRCA	cis	rs11023332	0.641	rs4281505	ENSG00000251991.1	RNU7-49P	7.48	1.57e-13	4.15e-11	0.24	0.23	Vitamin D levels;Adiponectin levels;	chr11:14779114	chr11:14478892~14478953:+
BRCA	cis	rs11023332	0.65	rs2122942	ENSG00000251991.1	RNU7-49P	7.48	1.57e-13	4.15e-11	0.24	0.23	Vitamin D levels;Adiponectin levels;	chr11:14785829	chr11:14478892~14478953:+
BRCA	cis	rs875971	0.862	rs7783779	ENSG00000232559.3	GS1-124K5.12	-7.48	1.58e-13	4.15e-11	-0.27	-0.23	Aortic root size;	chr7:66331639	chr7:66554588~66576923:-
BRCA	cis	rs2439831	0.85	rs12441984	ENSG00000275601.1	AC011330.13	-7.48	1.58e-13	4.15e-11	-0.37	-0.23	Lung cancer in ever smokers;	chr15:43834087	chr15:43642389~43643023:-
BRCA	cis	rs7246657	0.943	rs10404920	ENSG00000276846.1	CTD-3220F14.3	7.48	1.58e-13	4.16e-11	0.31	0.23	Coronary artery calcification;	chr19:37390654	chr19:37314868~37315620:-
BRCA	cis	rs3814244	0.868	rs11177007	ENSG00000236946.2	HNRNPA1P70	-7.48	1.58e-13	4.16e-11	-0.19	-0.23	Itch intensity from mosquito bite adjusted by bite size;	chr12:68020964	chr12:68035767~68036853:+
BRCA	cis	rs6860806	0.507	rs270601	ENSG00000233006.5	AC034220.3	7.48	1.58e-13	4.17e-11	0.18	0.23	Breast cancer;	chr5:132321304	chr5:132311285~132369916:-
BRCA	cis	rs7567389	0.6	rs7590030	ENSG00000236682.1	AC068282.3	7.48	1.58e-13	4.17e-11	0.33	0.23	Self-rated health;	chr2:127298391	chr2:127389130~127400580:+
BRCA	cis	rs17772222	0.917	rs17260380	ENSG00000258983.2	RP11-507K2.2	7.48	1.58e-13	4.17e-11	0.26	0.23	Coronary artery calcification;	chr14:88682142	chr14:88499334~88515502:+
BRCA	cis	rs6840258	0.547	rs2053771	ENSG00000251411.1	RP11-397E7.4	-7.48	1.58e-13	4.17e-11	-0.34	-0.23	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86937396	chr4:86913266~86914817:-
BRCA	cis	rs6504622	0.755	rs12938690	ENSG00000262879.4	RP11-156P1.3	-7.48	1.59e-13	4.18e-11	-0.24	-0.23	Orofacial clefts;	chr17:46997999	chr17:46984045~47100323:-
BRCA	cis	rs11098499	0.913	rs10010696	ENSG00000248280.1	RP11-33B1.2	7.48	1.59e-13	4.19e-11	0.23	0.23	Corneal astigmatism;	chr4:119243148	chr4:119440561~119450157:-
BRCA	cis	rs1874124	0.577	rs2807880	ENSG00000272823.1	RP11-295M18.6	7.48	1.59e-13	4.2e-11	0.33	0.23	Cholesterol, total;	chr1:220869661	chr1:220828676~220829211:-
BRCA	cis	rs526231	0.543	rs42431	ENSG00000175749.11	EIF3KP1	-7.48	1.6e-13	4.2e-11	-0.33	-0.23	Primary biliary cholangitis;	chr5:103064359	chr5:103032376~103033031:+
BRCA	cis	rs9880211	1	rs9818056	ENSG00000273486.1	RP11-731C17.2	7.48	1.6e-13	4.22e-11	0.29	0.23	Height;Body mass index;	chr3:136491232	chr3:136837338~136839021:-
BRCA	cis	rs3781264	0.6	rs12263737	ENSG00000273450.1	RP11-76P2.4	7.48	1.6e-13	4.22e-11	0.29	0.23	Esophageal cancer and gastric cancer;	chr10:94285156	chr10:94314907~94315327:-
BRCA	cis	rs875971	0.545	rs2420456	ENSG00000224316.1	RP11-479O9.2	7.48	1.61e-13	4.23e-11	0.26	0.23	Aortic root size;	chr7:66280619	chr7:65773620~65802067:+
BRCA	cis	rs6545883	0.929	rs12713436	ENSG00000271889.1	RP11-493E12.1	7.48	1.61e-13	4.24e-11	0.29	0.23	Tuberculosis;	chr2:61464125	chr2:61151433~61162105:-
BRCA	cis	rs17772222	0.917	rs8018755	ENSG00000258983.2	RP11-507K2.2	7.48	1.61e-13	4.24e-11	0.26	0.23	Coronary artery calcification;	chr14:88714249	chr14:88499334~88515502:+
BRCA	cis	rs17772222	0.917	rs8018630	ENSG00000258983.2	RP11-507K2.2	7.48	1.61e-13	4.24e-11	0.26	0.23	Coronary artery calcification;	chr14:88714250	chr14:88499334~88515502:+
BRCA	cis	rs2348418	0.67	rs899504	ENSG00000247934.4	RP11-967K21.1	-7.48	1.62e-13	4.25e-11	-0.26	-0.23	Lung function (FEV1);Lung function (FVC);	chr12:28118723	chr12:28163298~28190738:-
BRCA	cis	rs875971	0.895	rs7788984	ENSG00000232559.3	GS1-124K5.12	7.48	1.62e-13	4.25e-11	0.27	0.23	Aortic root size;	chr7:66450629	chr7:66554588~66576923:-
BRCA	cis	rs293748	0.771	rs158798	ENSG00000250155.1	CTD-2353F22.1	-7.48	1.62e-13	4.25e-11	-0.31	-0.23	Obesity-related traits;	chr5:36869157	chr5:36666214~36725195:-
BRCA	cis	rs4835473	0.838	rs10024263	ENSG00000251600.4	RP11-673E1.1	7.48	1.62e-13	4.26e-11	0.28	0.23	Immature fraction of reticulocytes;	chr4:144038174	chr4:143912331~143982454:+
BRCA	cis	rs4713118	0.588	rs200994	ENSG00000220721.1	OR1F12	-7.48	1.62e-13	4.26e-11	-0.29	-0.23	Parkinson's disease;	chr6:27846035	chr6:28073316~28074233:+
BRCA	cis	rs712022	0.507	rs11026815	ENSG00000246225.5	RP11-17A1.3	-7.48	1.62e-13	4.27e-11	-0.27	-0.23	Dialysis-related mortality;	chr11:22854432	chr11:22829380~22945393:+
BRCA	cis	rs11976180	1	rs2951360	ENSG00000170356.8	OR2A20P	-7.48	1.62e-13	4.27e-11	-0.32	-0.23	Obesity-related traits;	chr7:144060256	chr7:144250045~144252957:-
BRCA	cis	rs113835537	0.597	rs11227523	ENSG00000255517.5	CTD-3074O7.5	-7.48	1.63e-13	4.28e-11	-0.29	-0.23	Airway imaging phenotypes;	chr11:66538467	chr11:66473490~66480233:-
BRCA	cis	rs2243480	1	rs2257790	ENSG00000273142.1	RP11-458F8.4	-7.48	1.63e-13	4.28e-11	-0.31	-0.23	Diabetic kidney disease;	chr7:66135463	chr7:66902857~66906297:+
BRCA	cis	rs293377	0.961	rs293370	ENSG00000260123.1	RP11-326A19.4	-7.48	1.63e-13	4.29e-11	-0.26	-0.23	Gut microbiota (beta diversity);	chr15:89087245	chr15:89041223~89082819:+
BRCA	cis	rs7267979	0.789	rs62213729	ENSG00000274973.1	RP13-401N8.7	7.47	1.64e-13	4.32e-11	0.26	0.23	Liver enzyme levels (alkaline phosphatase);	chr20:25382790	chr20:25845497~25845862:+
BRCA	cis	rs10510102	0.935	rs10510101	ENSG00000276742.1	RP11-500G22.4	7.47	1.64e-13	4.32e-11	0.37	0.23	Breast cancer;	chr10:121898614	chr10:121956782~121957098:+
BRCA	cis	rs1874124	0.577	rs2807872	ENSG00000272823.1	RP11-295M18.6	-7.47	1.64e-13	4.32e-11	-0.31	-0.23	Cholesterol, total;	chr1:220866908	chr1:220828676~220829211:-
BRCA	cis	rs66887589	0.967	rs1155577	ENSG00000248280.1	RP11-33B1.2	-7.47	1.65e-13	4.34e-11	-0.21	-0.23	Diastolic blood pressure;	chr4:119528655	chr4:119440561~119450157:-
BRCA	cis	rs3781264	0.595	rs11187876	ENSG00000273450.1	RP11-76P2.4	7.47	1.65e-13	4.34e-11	0.3	0.23	Esophageal cancer and gastric cancer;	chr10:94330382	chr10:94314907~94315327:-
BRCA	cis	rs2378497	0.887	rs12122410	ENSG00000232679.1	RP11-400N13.3	7.47	1.65e-13	4.35e-11	0.32	0.23	Serum thyroid-stimulating hormone levels;	chr1:222038169	chr1:222041705~222064763:-
BRCA	cis	rs4835473	0.897	rs4835333	ENSG00000251600.4	RP11-673E1.1	-7.47	1.65e-13	4.35e-11	-0.27	-0.23	Immature fraction of reticulocytes;	chr4:143703174	chr4:143912331~143982454:+
BRCA	cis	rs8062405	0.755	rs2077031	ENSG00000251417.2	RP11-1348G14.4	-7.47	1.66e-13	4.35e-11	-0.27	-0.23	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28591847	chr16:28802743~28817828:+
BRCA	cis	rs293748	0.771	rs294695	ENSG00000250155.1	CTD-2353F22.1	-7.47	1.66e-13	4.36e-11	-0.32	-0.23	Obesity-related traits;	chr5:36986586	chr5:36666214~36725195:-
BRCA	cis	rs293748	0.54	rs10461978	ENSG00000250155.1	CTD-2353F22.1	-7.47	1.66e-13	4.37e-11	-0.31	-0.23	Obesity-related traits;	chr5:37274810	chr5:36666214~36725195:-
BRCA	cis	rs6539288	0.901	rs1444580	ENSG00000260329.1	RP11-412D9.4	-7.47	1.66e-13	4.37e-11	-0.26	-0.23	Total body bone mineral density;	chr12:106920780	chr12:106954029~106955497:-
BRCA	cis	rs42648	0.748	rs10227385	ENSG00000225498.1	AC002064.5	7.47	1.66e-13	4.37e-11	0.22	0.23	Homocysteine levels;	chr7:90261054	chr7:90312496~90322592:+
BRCA	cis	rs2243480	1	rs313814	ENSG00000273142.1	RP11-458F8.4	-7.47	1.66e-13	4.37e-11	-0.32	-0.23	Diabetic kidney disease;	chr7:66038306	chr7:66902857~66906297:+
BRCA	cis	rs6921919	0.583	rs7740351	ENSG00000204709.4	LINC01556	7.47	1.67e-13	4.38e-11	0.31	0.23	Autism spectrum disorder or schizophrenia;	chr6:28431635	chr6:28943877~28944537:+
BRCA	cis	rs2179367	0.6	rs9498355	ENSG00000231760.4	RP11-350J20.5	-7.47	1.67e-13	4.38e-11	-0.34	-0.23	Dupuytren's disease;	chr6:149442274	chr6:149796151~149826294:-
BRCA	cis	rs3762637	0.882	rs72958418	ENSG00000272758.4	RP11-299J3.8	-7.47	1.67e-13	4.39e-11	-0.32	-0.23	LDL cholesterol levels;	chr3:122441526	chr3:122416207~122443180:+
BRCA	cis	rs2742234	0.541	rs11238483	ENSG00000273008.1	RP11-351D16.3	7.47	1.67e-13	4.39e-11	0.29	0.23	Hirschsprung disease;	chr10:43233332	chr10:43136824~43138334:-
BRCA	cis	rs6543140	0.964	rs4851010	ENSG00000234389.1	AC007278.3	-7.47	1.67e-13	4.4e-11	-0.23	-0.23	Blood protein levels;	chr2:102439667	chr2:102438713~102440475:+
BRCA	cis	rs7085104	0.552	rs11191414	ENSG00000236937.2	PTGES3P4	7.47	1.68e-13	4.4e-11	0.29	0.23	Immature fraction of reticulocytes;Schizophrenia;	chr10:102841808	chr10:102845595~102845950:+
BRCA	cis	rs3781264	0.595	rs10882430	ENSG00000273450.1	RP11-76P2.4	7.47	1.68e-13	4.41e-11	0.29	0.23	Esophageal cancer and gastric cancer;	chr10:94330915	chr10:94314907~94315327:-
BRCA	cis	rs6545883	0.868	rs2518933	ENSG00000271889.1	RP11-493E12.1	7.47	1.68e-13	4.42e-11	0.29	0.23	Tuberculosis;	chr2:61569895	chr2:61151433~61162105:-
BRCA	cis	rs17772222	0.876	rs61983303	ENSG00000258983.2	RP11-507K2.2	7.47	1.69e-13	4.44e-11	0.26	0.23	Coronary artery calcification;	chr14:88764459	chr14:88499334~88515502:+
BRCA	cis	rs11098499	1	rs58601355	ENSG00000248280.1	RP11-33B1.2	7.47	1.69e-13	4.44e-11	0.24	0.23	Corneal astigmatism;	chr4:119265212	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.604	rs2389882	ENSG00000248280.1	RP11-33B1.2	7.47	1.69e-13	4.44e-11	0.24	0.23	Corneal astigmatism;	chr4:119645578	chr4:119440561~119450157:-
BRCA	cis	rs6545883	0.783	rs7579651	ENSG00000271889.1	RP11-493E12.1	7.47	1.7e-13	4.46e-11	0.29	0.23	Tuberculosis;	chr2:61573144	chr2:61151433~61162105:-
BRCA	cis	rs6472827	0.953	rs7827128	ENSG00000253983.2	RP1-16A9.1	7.47	1.71e-13	4.48e-11	0.34	0.23	Uterine fibroids;	chr8:74209641	chr8:74199396~74208441:+
BRCA	cis	rs1075265	0.62	rs2542584	ENSG00000233266.1	HMGB1P31	7.47	1.71e-13	4.48e-11	0.27	0.23	Chronotype;Morning vs. evening chronotype;	chr2:53782707	chr2:54051334~54051760:+
BRCA	cis	rs2243480	1	rs34193460	ENSG00000273142.1	RP11-458F8.4	-7.47	1.71e-13	4.48e-11	-0.31	-0.23	Diabetic kidney disease;	chr7:65928123	chr7:66902857~66906297:+
BRCA	cis	rs10463554	0.784	rs187424	ENSG00000175749.11	EIF3KP1	7.47	1.71e-13	4.5e-11	0.31	0.23	Parkinson's disease;	chr5:103251882	chr5:103032376~103033031:+
BRCA	cis	rs3781264	0.724	rs11558740	ENSG00000273450.1	RP11-76P2.4	7.47	1.72e-13	4.51e-11	0.32	0.23	Esophageal cancer and gastric cancer;	chr10:94333618	chr10:94314907~94315327:-
BRCA	cis	rs293748	0.66	rs61748200	ENSG00000250155.1	CTD-2353F22.1	-7.47	1.72e-13	4.51e-11	-0.33	-0.23	Obesity-related traits;	chr5:37036390	chr5:36666214~36725195:-
BRCA	cis	rs9649213	0.593	rs6945554	ENSG00000272950.1	RP11-307C18.1	7.47	1.72e-13	4.51e-11	0.29	0.23	Prostate cancer (SNP x SNP interaction);	chr7:98343634	chr7:98322853~98323430:+
BRCA	cis	rs8005677	0.962	rs10130756	ENSG00000279656.1	RP11-298I3.6	7.47	1.72e-13	4.52e-11	0.27	0.23	Cognitive ability (multi-trait analysis);	chr14:22927391	chr14:23023083~23024217:-
BRCA	cis	rs9649213	0.502	rs6465680	ENSG00000272950.1	RP11-307C18.1	7.47	1.72e-13	4.52e-11	0.28	0.23	Prostate cancer (SNP x SNP interaction);	chr7:98376466	chr7:98322853~98323430:+
BRCA	cis	rs853679	0.713	rs200991	ENSG00000220721.1	OR1F12	-7.47	1.72e-13	4.52e-11	-0.34	-0.23	Depression;	chr6:27847716	chr6:28073316~28074233:+
BRCA	cis	rs2243480	1	rs1723269	ENSG00000273142.1	RP11-458F8.4	-7.47	1.73e-13	4.54e-11	-0.31	-0.23	Diabetic kidney disease;	chr7:66007799	chr7:66902857~66906297:+
BRCA	cis	rs9880211	0.8	rs66509730	ENSG00000239213.4	NCK1-AS1	7.47	1.73e-13	4.55e-11	0.29	0.23	Height;Body mass index;	chr3:136785416	chr3:136841726~136862054:-
BRCA	cis	rs14027	0.921	rs3812463	ENSG00000279347.1	RP11-85I17.2	-7.47	1.74e-13	4.56e-11	-0.24	-0.23	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119839860	chr8:119838736~119840385:-
BRCA	cis	rs7267979	0.789	rs6083820	ENSG00000274973.1	RP13-401N8.7	7.47	1.74e-13	4.56e-11	0.26	0.23	Liver enzyme levels (alkaline phosphatase);	chr20:25373542	chr20:25845497~25845862:+
BRCA	cis	rs875971	0.54	rs35510581	ENSG00000236529.1	RP13-254B10.1	-7.47	1.74e-13	4.56e-11	-0.25	-0.23	Aortic root size;	chr7:66113790	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.66	rs28698552	ENSG00000237310.1	GS1-124K5.4	7.47	1.74e-13	4.57e-11	0.23	0.23	Aortic root size;	chr7:66540031	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.619	rs12533585	ENSG00000237310.1	GS1-124K5.4	7.47	1.74e-13	4.57e-11	0.23	0.23	Aortic root size;	chr7:66519618	chr7:66493706~66495474:+
BRCA	cis	rs66887589	0.967	rs59516282	ENSG00000248280.1	RP11-33B1.2	-7.47	1.75e-13	4.58e-11	-0.21	-0.23	Diastolic blood pressure;	chr4:119580861	chr4:119440561~119450157:-
BRCA	cis	rs2243480	1	rs57057549	ENSG00000273142.1	RP11-458F8.4	-7.47	1.75e-13	4.59e-11	-0.31	-0.23	Diabetic kidney disease;	chr7:65940751	chr7:66902857~66906297:+
BRCA	cis	rs2179367	0.632	rs9485384	ENSG00000231760.4	RP11-350J20.5	7.47	1.75e-13	4.6e-11	0.33	0.23	Dupuytren's disease;	chr6:149328808	chr6:149796151~149826294:-
BRCA	cis	rs2243480	1	rs73142166	ENSG00000273142.1	RP11-458F8.4	-7.47	1.75e-13	4.6e-11	-0.31	-0.23	Diabetic kidney disease;	chr7:65910845	chr7:66902857~66906297:+
BRCA	cis	rs7085104	0.632	rs7097872	ENSG00000236937.2	PTGES3P4	7.46	1.76e-13	4.61e-11	0.29	0.23	Immature fraction of reticulocytes;Schizophrenia;	chr10:102846879	chr10:102845595~102845950:+
BRCA	cis	rs77204473	1	rs12279433	ENSG00000254851.1	RP11-109L13.1	7.46	1.76e-13	4.61e-11	0.5	0.23	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116877505	chr11:117135528~117138582:+
BRCA	cis	rs74233809	1	rs11191472	ENSG00000213277.3	MARCKSL1P1	7.46	1.76e-13	4.61e-11	0.44	0.23	Birth weight;	chr10:102947259	chr10:103175554~103176094:+
BRCA	cis	rs4927850	0.957	rs4927851	ENSG00000242086.7	LINC00969	7.46	1.76e-13	4.63e-11	0.25	0.23	Pancreatic cancer;	chr3:196024982	chr3:195658062~195739964:+
BRCA	cis	rs2179367	0.6	rs9498352	ENSG00000231760.4	RP11-350J20.5	7.46	1.77e-13	4.63e-11	0.34	0.23	Dupuytren's disease;	chr6:149439108	chr6:149796151~149826294:-
BRCA	cis	rs6570726	0.935	rs368848	ENSG00000235652.6	RP11-545I5.3	7.46	1.77e-13	4.63e-11	0.22	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145534145	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.935	rs374000	ENSG00000235652.6	RP11-545I5.3	7.46	1.77e-13	4.63e-11	0.22	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145534154	chr6:145799409~145886585:+
BRCA	cis	rs6558530	0.587	rs6986102	ENSG00000253982.1	CTD-2336O2.1	7.46	1.77e-13	4.64e-11	0.28	0.23	Systolic blood pressure;	chr8:1752474	chr8:1761990~1764502:-
BRCA	cis	rs904251	0.6	rs12211110	ENSG00000204110.6	RP1-153P14.8	-7.46	1.77e-13	4.64e-11	-0.25	-0.23	Cognitive performance;	chr6:37498456	chr6:37507348~37535616:+
BRCA	cis	rs1862618	0.802	rs7733041	ENSG00000271828.1	CTD-2310F14.1	7.46	1.77e-13	4.65e-11	0.29	0.23	Initial pursuit acceleration;	chr5:56811550	chr5:56927874~56929573:+
BRCA	cis	rs17772222	0.876	rs78068036	ENSG00000258983.2	RP11-507K2.2	7.46	1.77e-13	4.65e-11	0.26	0.23	Coronary artery calcification;	chr14:88754817	chr14:88499334~88515502:+
BRCA	cis	rs11976180	1	rs1533266	ENSG00000170356.8	OR2A20P	-7.46	1.78e-13	4.65e-11	-0.32	-0.23	Obesity-related traits;	chr7:144069621	chr7:144250045~144252957:-
BRCA	cis	rs74233809	1	rs11191502	ENSG00000213277.3	MARCKSL1P1	7.46	1.78e-13	4.66e-11	0.42	0.23	Birth weight;	chr10:103005737	chr10:103175554~103176094:+
BRCA	cis	rs7520050	0.807	rs72688483	ENSG00000280836.1	AL355480.1	-7.46	1.78e-13	4.67e-11	-0.26	-0.23	Reticulocyte count;Red blood cell count;	chr1:45683537	chr1:45581219~45581321:-
BRCA	cis	rs9876781	1	rs4858793	ENSG00000244380.1	RP11-24C3.2	-7.46	1.79e-13	4.69e-11	-0.26	-0.23	Longevity;	chr3:48373517	chr3:48440352~48446656:-
BRCA	cis	rs2439831	0.85	rs28684672	ENSG00000275601.1	AC011330.13	-7.46	1.8e-13	4.7e-11	-0.37	-0.23	Lung cancer in ever smokers;	chr15:43815464	chr15:43642389~43643023:-
BRCA	cis	rs7246657	0.943	rs10426666	ENSG00000276846.1	CTD-3220F14.3	7.46	1.8e-13	4.72e-11	0.31	0.23	Coronary artery calcification;	chr19:37337612	chr19:37314868~37315620:-
BRCA	cis	rs7246657	0.943	rs28402338	ENSG00000276846.1	CTD-3220F14.3	7.46	1.8e-13	4.72e-11	0.31	0.23	Coronary artery calcification;	chr19:37343021	chr19:37314868~37315620:-
BRCA	cis	rs7246657	0.943	rs10417503	ENSG00000276846.1	CTD-3220F14.3	7.46	1.8e-13	4.72e-11	0.31	0.23	Coronary artery calcification;	chr19:37351833	chr19:37314868~37315620:-
BRCA	cis	rs7246657	0.943	rs9304566	ENSG00000276846.1	CTD-3220F14.3	7.46	1.8e-13	4.72e-11	0.31	0.23	Coronary artery calcification;	chr19:37354602	chr19:37314868~37315620:-
BRCA	cis	rs7246657	0.943	rs4417644	ENSG00000276846.1	CTD-3220F14.3	7.46	1.8e-13	4.72e-11	0.31	0.23	Coronary artery calcification;	chr19:37361570	chr19:37314868~37315620:-
BRCA	cis	rs7246657	0.943	rs10405064	ENSG00000276846.1	CTD-3220F14.3	7.46	1.8e-13	4.72e-11	0.31	0.23	Coronary artery calcification;	chr19:37370959	chr19:37314868~37315620:-
BRCA	cis	rs875971	0.545	rs73376394	ENSG00000224316.1	RP11-479O9.2	7.46	1.8e-13	4.72e-11	0.25	0.23	Aortic root size;	chr7:66172694	chr7:65773620~65802067:+
BRCA	cis	rs6142102	1	rs6059673	ENSG00000276073.1	RP5-1125A11.7	-7.46	1.8e-13	4.72e-11	-0.28	-0.23	Skin pigmentation;	chr20:34117755	chr20:33985617~33988989:-
BRCA	cis	rs34779708	0.733	rs16935948	ENSG00000271335.4	RP11-324I22.4	7.46	1.81e-13	4.74e-11	0.23	0.23	Inflammatory bowel disease;Crohn's disease;	chr10:35260820	chr10:35314552~35336401:-
BRCA	cis	rs2117029	0.782	rs6580699	ENSG00000258017.1	RP11-386G11.10	7.46	1.81e-13	4.74e-11	0.28	0.23	Intelligence (multi-trait analysis);	chr12:49085029	chr12:49127782~49147869:+
BRCA	cis	rs7727544	0.645	rs272857	ENSG00000233006.5	AC034220.3	7.46	1.81e-13	4.75e-11	0.17	0.23	Blood metabolite levels;	chr5:132349604	chr5:132311285~132369916:-
BRCA	cis	rs10463554	0.856	rs257292	ENSG00000175749.11	EIF3KP1	7.46	1.81e-13	4.75e-11	0.3	0.23	Parkinson's disease;	chr5:103159047	chr5:103032376~103033031:+
BRCA	cis	rs3758911	0.894	rs12285491	ENSG00000255353.1	RP11-382M14.1	-7.46	1.82e-13	4.76e-11	-0.3	-0.23	Coronary artery disease;	chr11:107340319	chr11:107176286~107177530:+
BRCA	cis	rs301901	1	rs6875748	ENSG00000250155.1	CTD-2353F22.1	7.46	1.82e-13	4.77e-11	0.25	0.23	Height;	chr5:37041491	chr5:36666214~36725195:-
BRCA	cis	rs74233809	1	rs11191580	ENSG00000213277.3	MARCKSL1P1	-7.46	1.82e-13	4.77e-11	-0.43	-0.23	Birth weight;	chr10:103146454	chr10:103175554~103176094:+
BRCA	cis	rs919433	0.963	rs1429417	ENSG00000231621.1	AC013264.2	7.46	1.83e-13	4.8e-11	0.21	0.23	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197293447	chr2:197197991~197199273:+
BRCA	cis	rs10129255	0.556	rs6576222	ENSG00000211970.3	IGHV4-61	-7.46	1.84e-13	4.81e-11	-0.15	-0.23	Kawasaki disease;	chr14:106776442	chr14:106639119~106639657:-
BRCA	cis	rs10129255	0.5	rs988134	ENSG00000211970.3	IGHV4-61	-7.46	1.84e-13	4.82e-11	-0.14	-0.23	Kawasaki disease;	chr14:106776698	chr14:106639119~106639657:-
BRCA	cis	rs10129255	0.5	rs988133	ENSG00000211970.3	IGHV4-61	-7.46	1.84e-13	4.82e-11	-0.14	-0.23	Kawasaki disease;	chr14:106776724	chr14:106639119~106639657:-
BRCA	cis	rs780096	0.587	rs1049817	ENSG00000234072.1	AC074117.10	-7.46	1.84e-13	4.82e-11	-0.22	-0.23	Total body bone mineral density;	chr2:27328100	chr2:27356246~27367622:+
BRCA	cis	rs10129255	0.5	rs8004923	ENSG00000211970.3	IGHV4-61	-7.46	1.84e-13	4.83e-11	-0.14	-0.23	Kawasaki disease;	chr14:106785926	chr14:106639119~106639657:-
BRCA	cis	rs3781264	0.761	rs12781451	ENSG00000273450.1	RP11-76P2.4	7.46	1.85e-13	4.83e-11	0.31	0.23	Esophageal cancer and gastric cancer;	chr10:94324163	chr10:94314907~94315327:-
BRCA	cis	rs10129255	0.536	rs6576223	ENSG00000211970.3	IGHV4-61	-7.46	1.85e-13	4.84e-11	-0.15	-0.23	Kawasaki disease;	chr14:106776448	chr14:106639119~106639657:-
BRCA	cis	rs3762637	0.823	rs9849013	ENSG00000272758.4	RP11-299J3.8	-7.46	1.85e-13	4.84e-11	-0.32	-0.23	LDL cholesterol levels;	chr3:122531758	chr3:122416207~122443180:+
BRCA	cis	rs875971	0.638	rs7793569	ENSG00000224316.1	RP11-479O9.2	-7.46	1.85e-13	4.85e-11	-0.22	-0.23	Aortic root size;	chr7:66651646	chr7:65773620~65802067:+
BRCA	cis	rs801193	1	rs3857688	ENSG00000224316.1	RP11-479O9.2	-7.46	1.85e-13	4.85e-11	-0.22	-0.23	Aortic root size;	chr7:66662819	chr7:65773620~65802067:+
BRCA	cis	rs801193	1	rs2286684	ENSG00000224316.1	RP11-479O9.2	-7.46	1.85e-13	4.85e-11	-0.22	-0.23	Aortic root size;	chr7:66664843	chr7:65773620~65802067:+
BRCA	cis	rs801193	0.935	rs2286683	ENSG00000224316.1	RP11-479O9.2	-7.46	1.85e-13	4.85e-11	-0.22	-0.23	Aortic root size;	chr7:66664856	chr7:65773620~65802067:+
BRCA	cis	rs801193	1	rs10274773	ENSG00000224316.1	RP11-479O9.2	-7.46	1.85e-13	4.85e-11	-0.22	-0.23	Aortic root size;	chr7:66668591	chr7:65773620~65802067:+
BRCA	cis	rs7267979	0.789	rs6083810	ENSG00000274973.1	RP13-401N8.7	7.46	1.85e-13	4.85e-11	0.26	0.23	Liver enzyme levels (alkaline phosphatase);	chr20:25349123	chr20:25845497~25845862:+
BRCA	cis	rs6142102	1	rs4911412	ENSG00000276073.1	RP5-1125A11.7	-7.46	1.86e-13	4.86e-11	-0.28	-0.23	Skin pigmentation;	chr20:34128629	chr20:33985617~33988989:-
BRCA	cis	rs17772222	0.917	rs8020072	ENSG00000258983.2	RP11-507K2.2	7.46	1.86e-13	4.87e-11	0.26	0.23	Coronary artery calcification;	chr14:88714332	chr14:88499334~88515502:+
BRCA	cis	rs17772222	0.917	rs12589982	ENSG00000258983.2	RP11-507K2.2	7.46	1.86e-13	4.87e-11	0.26	0.23	Coronary artery calcification;	chr14:88716861	chr14:88499334~88515502:+
BRCA	cis	rs780096	0.546	rs1647284	ENSG00000234072.1	AC074117.10	-7.46	1.86e-13	4.87e-11	-0.22	-0.23	Total body bone mineral density;	chr2:27385248	chr2:27356246~27367622:+
BRCA	cis	rs780096	0.526	rs7594812	ENSG00000234072.1	AC074117.10	-7.46	1.86e-13	4.87e-11	-0.22	-0.23	Total body bone mineral density;	chr2:27388602	chr2:27356246~27367622:+
BRCA	cis	rs704795	0.805	rs1728926	ENSG00000234072.1	AC074117.10	-7.46	1.86e-13	4.87e-11	-0.22	-0.23	Menopause (age at onset);	chr2:27390070	chr2:27356246~27367622:+
BRCA	cis	rs704795	0.836	rs1647281	ENSG00000234072.1	AC074117.10	-7.46	1.86e-13	4.87e-11	-0.22	-0.23	Menopause (age at onset);	chr2:27390071	chr2:27356246~27367622:+
BRCA	cis	rs780096	0.526	rs809058	ENSG00000234072.1	AC074117.10	-7.46	1.86e-13	4.87e-11	-0.22	-0.23	Total body bone mineral density;	chr2:27393923	chr2:27356246~27367622:+
BRCA	cis	rs17772222	1	rs17698817	ENSG00000258983.2	RP11-507K2.2	7.46	1.87e-13	4.88e-11	0.25	0.23	Coronary artery calcification;	chr14:88356632	chr14:88499334~88515502:+
BRCA	cis	rs1862618	0.756	rs9292125	ENSG00000271828.1	CTD-2310F14.1	7.46	1.87e-13	4.88e-11	0.31	0.23	Initial pursuit acceleration;	chr5:56811373	chr5:56927874~56929573:+
BRCA	cis	rs7085104	0.632	rs6162	ENSG00000236937.2	PTGES3P4	7.46	1.87e-13	4.88e-11	0.28	0.23	Immature fraction of reticulocytes;Schizophrenia;	chr10:102837224	chr10:102845595~102845950:+
BRCA	cis	rs301901	0.965	rs3104057	ENSG00000250155.1	CTD-2353F22.1	-7.46	1.87e-13	4.89e-11	-0.25	-0.23	Height;	chr5:36982949	chr5:36666214~36725195:-
BRCA	cis	rs7674212	0.581	rs11946020	ENSG00000251288.2	RP11-10L12.2	-7.46	1.87e-13	4.9e-11	-0.27	-0.23	Type 2 diabetes;	chr4:103023585	chr4:102751401~102752641:+
BRCA	cis	rs780096	0.587	rs6760828	ENSG00000234072.1	AC074117.10	-7.46	1.87e-13	4.9e-11	-0.22	-0.23	Total body bone mineral density;	chr2:27356364	chr2:27356246~27367622:+
BRCA	cis	rs6061231	1	rs11696991	ENSG00000273619.1	RP5-908M14.9	-7.46	1.88e-13	4.91e-11	-0.19	-0.23	Colorectal cancer;	chr20:62384638	chr20:62386303~62386970:-
BRCA	cis	rs61270009	0.955	rs12163987	ENSG00000247828.6	TMEM161B-AS1	7.46	1.88e-13	4.91e-11	0.31	0.23	Depressive symptoms;	chr5:88276209	chr5:88268895~88436685:+
BRCA	cis	rs61160187	0.61	rs4700399	ENSG00000215032.2	GNL3LP1	7.46	1.88e-13	4.92e-11	0.28	0.23	Educational attainment (years of education);Educational attainment (college completion);	chr5:60840627	chr5:60891935~60893577:-
BRCA	cis	rs875971	0.893	rs62465470	ENSG00000232559.3	GS1-124K5.12	-7.46	1.88e-13	4.92e-11	-0.27	-0.23	Aortic root size;	chr7:66136231	chr7:66554588~66576923:-
BRCA	cis	rs10510102	0.935	rs10466217	ENSG00000276742.1	RP11-500G22.4	7.45	1.89e-13	4.94e-11	0.39	0.23	Breast cancer;	chr10:121860362	chr10:121956782~121957098:+
BRCA	cis	rs7246657	0.943	rs4969487	ENSG00000276846.1	CTD-3220F14.3	7.45	1.89e-13	4.94e-11	0.31	0.23	Coronary artery calcification;	chr19:37340137	chr19:37314868~37315620:-
BRCA	cis	rs2880765	0.835	rs7169632	ENSG00000259295.5	CSPG4P12	7.45	1.89e-13	4.95e-11	0.27	0.23	Coronary artery disease;	chr15:85501436	chr15:85191438~85213905:+
BRCA	cis	rs287982	1	rs287976	ENSG00000269973.1	RP11-95D17.1	7.45	1.9e-13	4.95e-11	0.27	0.23	Nonsyndromic cleft lip with cleft palate;	chr2:9829559	chr2:9936360~9939590:+
BRCA	cis	rs6472827	0.645	rs2956060	ENSG00000253983.2	RP1-16A9.1	-7.45	1.9e-13	4.96e-11	-0.31	-0.23	Uterine fibroids;	chr8:74197550	chr8:74199396~74208441:+
BRCA	cis	rs10129255	0.5	rs6576230	ENSG00000211970.3	IGHV4-61	-7.45	1.9e-13	4.96e-11	-0.14	-0.22	Kawasaki disease;	chr14:106778539	chr14:106639119~106639657:-
BRCA	cis	rs7615952	0.576	rs6780025	ENSG00000250012.1	RP11-124N2.1	-7.45	1.9e-13	4.97e-11	-0.31	-0.22	Blood pressure (smoking interaction);	chr3:126096781	chr3:126084220~126095349:+
BRCA	cis	rs7615952	0.576	rs6804482	ENSG00000250012.1	RP11-124N2.1	-7.45	1.9e-13	4.97e-11	-0.31	-0.22	Blood pressure (smoking interaction);	chr3:126096919	chr3:126084220~126095349:+
BRCA	cis	rs3781264	0.595	rs10882424	ENSG00000273450.1	RP11-76P2.4	7.45	1.9e-13	4.98e-11	0.29	0.22	Esophageal cancer and gastric cancer;	chr10:94326321	chr10:94314907~94315327:-
BRCA	cis	rs301901	1	rs300061	ENSG00000250155.1	CTD-2353F22.1	-7.45	1.91e-13	4.99e-11	-0.25	-0.22	Height;	chr5:37022673	chr5:36666214~36725195:-
BRCA	cis	rs6840258	0.547	rs72667727	ENSG00000251411.1	RP11-397E7.4	-7.45	1.92e-13	5e-11	-0.34	-0.22	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86936370	chr4:86913266~86914817:-
BRCA	cis	rs2179367	0.959	rs521845	ENSG00000231760.4	RP11-350J20.5	-7.45	1.92e-13	5.01e-11	-0.28	-0.22	Dupuytren's disease;	chr6:149350562	chr6:149796151~149826294:-
BRCA	cis	rs801193	1	rs7785213	ENSG00000224316.1	RP11-479O9.2	-7.45	1.92e-13	5.01e-11	-0.22	-0.22	Aortic root size;	chr7:66673991	chr7:65773620~65802067:+
BRCA	cis	rs17711722	0.522	rs6957759	ENSG00000273024.4	INTS4P2	-7.45	1.92e-13	5.02e-11	-0.25	-0.22	Calcium levels;	chr7:65806798	chr7:65647864~65715661:+
BRCA	cis	rs801193	1	rs2707836	ENSG00000224316.1	RP11-479O9.2	7.45	1.92e-13	5.03e-11	0.22	0.22	Aortic root size;	chr7:66695448	chr7:65773620~65802067:+
BRCA	cis	rs801193	0.844	rs7779971	ENSG00000224316.1	RP11-479O9.2	7.45	1.92e-13	5.03e-11	0.22	0.22	Aortic root size;	chr7:66696803	chr7:65773620~65802067:+
BRCA	cis	rs4266144	0.544	rs13080798	ENSG00000244515.1	KRT18P34	-7.45	1.93e-13	5.04e-11	-0.27	-0.22	Coronary artery disease;	chr3:157114612	chr3:157162663~157163932:-
BRCA	cis	rs875971	0.66	rs10215132	ENSG00000237310.1	GS1-124K5.4	-7.45	1.93e-13	5.05e-11	-0.24	-0.22	Aortic root size;	chr7:66589419	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.638	rs10249404	ENSG00000237310.1	GS1-124K5.4	-7.45	1.94e-13	5.07e-11	-0.23	-0.22	Aortic root size;	chr7:66581737	chr7:66493706~66495474:+
BRCA	cis	rs301901	0.965	rs158803	ENSG00000250155.1	CTD-2353F22.1	-7.45	1.94e-13	5.08e-11	-0.25	-0.22	Height;	chr5:36911514	chr5:36666214~36725195:-
BRCA	cis	rs16978956	0.592	rs16990329	ENSG00000236474.1	GCNT1P1	7.45	1.94e-13	5.08e-11	0.33	0.22	Body mass index;	chr20:18345414	chr20:18420160~18421454:-
BRCA	cis	rs7246657	0.943	rs9917081	ENSG00000276846.1	CTD-3220F14.3	7.45	1.94e-13	5.08e-11	0.31	0.22	Coronary artery calcification;	chr19:37385714	chr19:37314868~37315620:-
BRCA	cis	rs2726040	0.902	rs33957528	ENSG00000259982.1	CDC37P1	-7.45	1.94e-13	5.08e-11	-0.27	-0.22	Hip circumference;	chr16:28296619	chr16:28700294~28701540:-
BRCA	cis	rs11098499	0.954	rs6820115	ENSG00000248280.1	RP11-33B1.2	7.45	1.95e-13	5.08e-11	0.22	0.22	Corneal astigmatism;	chr4:119477027	chr4:119440561~119450157:-
BRCA	cis	rs11098499	1	rs28374891	ENSG00000248280.1	RP11-33B1.2	7.45	1.95e-13	5.1e-11	0.23	0.22	Corneal astigmatism;	chr4:119262395	chr4:119440561~119450157:-
BRCA	cis	rs2243480	1	rs35820085	ENSG00000273142.1	RP11-458F8.4	-7.45	1.96e-13	5.11e-11	-0.31	-0.22	Diabetic kidney disease;	chr7:65977771	chr7:66902857~66906297:+
BRCA	cis	rs1862618	0.853	rs252921	ENSG00000271828.1	CTD-2310F14.1	7.45	1.96e-13	5.11e-11	0.31	0.22	Initial pursuit acceleration;	chr5:56841960	chr5:56927874~56929573:+
BRCA	cis	rs875971	0.862	rs4368860	ENSG00000232559.3	GS1-124K5.12	-7.45	1.96e-13	5.12e-11	-0.27	-0.22	Aortic root size;	chr7:66143495	chr7:66554588~66576923:-
BRCA	cis	rs3758911	0.796	rs59525924	ENSG00000255353.1	RP11-382M14.1	-7.45	1.96e-13	5.12e-11	-0.31	-0.22	Coronary artery disease;	chr11:107339286	chr11:107176286~107177530:+
BRCA	cis	rs2243480	0.803	rs36127118	ENSG00000273142.1	RP11-458F8.4	-7.45	1.96e-13	5.12e-11	-0.31	-0.22	Diabetic kidney disease;	chr7:66100518	chr7:66902857~66906297:+
BRCA	cis	rs10754283	0.967	rs4658307	ENSG00000231613.1	RP5-943J3.1	7.45	1.97e-13	5.14e-11	0.25	0.22	Amyotrophic lateral sclerosis (sporadic);	chr1:89652027	chr1:89788914~89790492:+
BRCA	cis	rs6921919	0.583	rs16894108	ENSG00000204709.4	LINC01556	7.45	1.97e-13	5.14e-11	0.31	0.22	Autism spectrum disorder or schizophrenia;	chr6:28434013	chr6:28943877~28944537:+
BRCA	cis	rs17711722	0.522	rs62469933	ENSG00000273024.4	INTS4P2	-7.45	1.97e-13	5.14e-11	-0.25	-0.22	Calcium levels;	chr7:65800652	chr7:65647864~65715661:+
BRCA	cis	rs2243480	1	rs781157	ENSG00000273142.1	RP11-458F8.4	-7.45	1.97e-13	5.15e-11	-0.3	-0.22	Diabetic kidney disease;	chr7:66013324	chr7:66902857~66906297:+
BRCA	cis	rs9640161	0.83	rs76741564	ENSG00000261305.1	RP4-584D14.7	7.45	1.97e-13	5.15e-11	0.34	0.22	Blood protein levels;Circulating chemerin levels;	chr7:150362440	chr7:150341771~150342607:+
BRCA	cis	rs801193	1	rs2707856	ENSG00000224316.1	RP11-479O9.2	7.45	1.97e-13	5.15e-11	0.22	0.22	Aortic root size;	chr7:66746023	chr7:65773620~65802067:+
BRCA	cis	rs7727544	0.684	rs272893	ENSG00000233006.5	AC034220.3	7.45	1.98e-13	5.16e-11	0.17	0.22	Blood metabolite levels;	chr5:132327369	chr5:132311285~132369916:-
BRCA	cis	rs17772222	0.917	rs61982733	ENSG00000258983.2	RP11-507K2.2	7.45	1.98e-13	5.17e-11	0.26	0.22	Coronary artery calcification;	chr14:88776244	chr14:88499334~88515502:+
BRCA	cis	rs17772222	0.917	rs2145120	ENSG00000258983.2	RP11-507K2.2	7.45	1.98e-13	5.17e-11	0.26	0.22	Coronary artery calcification;	chr14:88777699	chr14:88499334~88515502:+
BRCA	cis	rs17772222	0.917	rs61986664	ENSG00000258983.2	RP11-507K2.2	7.45	1.98e-13	5.17e-11	0.26	0.22	Coronary artery calcification;	chr14:88711251	chr14:88499334~88515502:+
BRCA	cis	rs9880211	0.898	rs13434116	ENSG00000273486.1	RP11-731C17.2	7.45	1.98e-13	5.18e-11	0.3	0.22	Height;Body mass index;	chr3:136634232	chr3:136837338~136839021:-
BRCA	cis	rs6921919	0.583	rs2071965	ENSG00000204709.4	LINC01556	7.45	1.99e-13	5.19e-11	0.3	0.22	Autism spectrum disorder or schizophrenia;	chr6:28435448	chr6:28943877~28944537:+
BRCA	cis	rs9880211	1	rs6771002	ENSG00000273486.1	RP11-731C17.2	7.45	1.99e-13	5.2e-11	0.29	0.22	Height;Body mass index;	chr3:136522186	chr3:136837338~136839021:-
BRCA	cis	rs7246657	0.943	rs10424574	ENSG00000276846.1	CTD-3220F14.3	7.45	1.99e-13	5.2e-11	0.31	0.22	Coronary artery calcification;	chr19:37347491	chr19:37314868~37315620:-
BRCA	cis	rs763512	0.504	rs6607279	ENSG00000276054.1	RP11-378E13.3	7.45	2e-13	5.21e-11	0.33	0.22	3-hydroxypropylmercapturic acid levels in smokers;	chr17:37564796	chr17:37386886~37387926:+
BRCA	cis	rs6504622	0.667	rs11653589	ENSG00000262879.4	RP11-156P1.3	-7.45	2e-13	5.21e-11	-0.23	-0.22	Orofacial clefts;	chr17:46990299	chr17:46984045~47100323:-
BRCA	cis	rs6844153	0.887	rs62302532	ENSG00000240005.4	RP11-293A21.1	-7.45	2e-13	5.22e-11	-0.33	-0.22	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26947150	chr4:26859806~26860599:-
BRCA	cis	rs6844153	0.887	rs6448488	ENSG00000240005.4	RP11-293A21.1	-7.45	2e-13	5.22e-11	-0.33	-0.22	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26949365	chr4:26859806~26860599:-
BRCA	cis	rs2179367	0.613	rs12207047	ENSG00000231760.4	RP11-350J20.5	7.45	2e-13	5.22e-11	0.33	0.22	Dupuytren's disease;	chr6:149423496	chr6:149796151~149826294:-
BRCA	cis	rs17264034	0.821	rs60322708	ENSG00000250786.1	SNHG18	7.45	2e-13	5.23e-11	0.3	0.22	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9555837	chr5:9546200~9550609:+
BRCA	cis	rs17772222	0.876	rs58655091	ENSG00000258983.2	RP11-507K2.2	7.45	2e-13	5.23e-11	0.26	0.22	Coronary artery calcification;	chr14:88748567	chr14:88499334~88515502:+
BRCA	cis	rs7617773	0.779	rs11718329	ENSG00000228638.1	FCF1P2	-7.45	2.01e-13	5.24e-11	-0.24	-0.22	Coronary artery disease;	chr3:48268338	chr3:48290793~48291375:-
BRCA	cis	rs4934494	0.768	rs1409357	ENSG00000240996.1	RP11-80H5.7	-7.45	2.01e-13	5.24e-11	-0.29	-0.22	Red blood cell count;	chr10:89669719	chr10:89694295~89697928:-
BRCA	cis	rs2274273	0.624	rs72717738	ENSG00000258413.1	RP11-665C16.6	-7.45	2.02e-13	5.27e-11	-0.3	-0.22	Protein biomarker;	chr14:55376043	chr14:55262767~55272075:-
BRCA	cis	rs2060793	0.519	rs10832285	ENSG00000251991.1	RNU7-49P	7.45	2.02e-13	5.27e-11	0.24	0.22	Vitamin D levels;	chr11:14628031	chr11:14478892~14478953:+
BRCA	cis	rs2742234	0.504	rs10899780	ENSG00000273008.1	RP11-351D16.3	7.45	2.02e-13	5.28e-11	0.29	0.22	Hirschsprung disease;	chr10:43230348	chr10:43136824~43138334:-
BRCA	cis	rs42648	0.693	rs3747800	ENSG00000225498.1	AC002064.5	7.45	2.03e-13	5.28e-11	0.21	0.22	Homocysteine levels;	chr7:90270174	chr7:90312496~90322592:+
BRCA	cis	rs875971	0.862	rs7809814	ENSG00000232559.3	GS1-124K5.12	-7.44	2.03e-13	5.29e-11	-0.27	-0.22	Aortic root size;	chr7:66150410	chr7:66554588~66576923:-
BRCA	cis	rs7615952	0.512	rs1077621	ENSG00000250012.1	RP11-124N2.1	-7.44	2.03e-13	5.3e-11	-0.31	-0.22	Blood pressure (smoking interaction);	chr3:126100956	chr3:126084220~126095349:+
BRCA	cis	rs780096	0.506	rs2950834	ENSG00000234072.1	AC074117.10	-7.44	2.03e-13	5.3e-11	-0.22	-0.22	Total body bone mineral density;	chr2:27404499	chr2:27356246~27367622:+
BRCA	cis	rs9876781	1	rs2242150	ENSG00000244380.1	RP11-24C3.2	-7.44	2.03e-13	5.3e-11	-0.25	-0.22	Longevity;	chr3:48464565	chr3:48440352~48446656:-
BRCA	cis	rs2243480	1	rs2243480	ENSG00000273142.1	RP11-458F8.4	-7.44	2.04e-13	5.31e-11	-0.32	-0.22	Diabetic kidney disease;	chr7:66134209	chr7:66902857~66906297:+
BRCA	cis	rs11098499	0.644	rs10012252	ENSG00000245958.5	RP11-33B1.1	-7.44	2.04e-13	5.31e-11	-0.21	-0.22	Corneal astigmatism;	chr4:119637984	chr4:119454791~119552025:+
BRCA	cis	rs858239	1	rs156407	ENSG00000230042.1	AK3P3	-7.44	2.04e-13	5.31e-11	-0.26	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23276020	chr7:23129178~23129841:+
BRCA	cis	rs3814244	0.528	rs2860609	ENSG00000236946.2	HNRNPA1P70	7.44	2.04e-13	5.32e-11	0.19	0.22	Itch intensity from mosquito bite adjusted by bite size;	chr12:67997215	chr12:68035767~68036853:+
BRCA	cis	rs9880211	0.752	rs13062352	ENSG00000273486.1	RP11-731C17.2	7.44	2.04e-13	5.33e-11	0.31	0.22	Height;Body mass index;	chr3:136745920	chr3:136837338~136839021:-
BRCA	cis	rs10740039	0.883	rs1442540	ENSG00000254271.1	RP11-131N11.4	-7.44	2.04e-13	5.33e-11	-0.3	-0.22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60653548	chr10:60734342~60741828:+
BRCA	cis	rs9649213	0.593	rs6973775	ENSG00000272950.1	RP11-307C18.1	7.44	2.05e-13	5.33e-11	0.29	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98375373	chr7:98322853~98323430:+
BRCA	cis	rs2034650	0.544	rs600791	ENSG00000223313.1	RNU6-516P	7.44	2.06e-13	5.37e-11	0.28	0.22	Interstitial lung disease;	chr15:40428868	chr15:40529570~40529673:+
BRCA	cis	rs9880211	0.718	rs28631273	ENSG00000273486.1	RP11-731C17.2	7.44	2.06e-13	5.37e-11	0.28	0.22	Height;Body mass index;	chr3:136215869	chr3:136837338~136839021:-
BRCA	cis	rs9649213	0.593	rs1468340	ENSG00000272950.1	RP11-307C18.1	7.44	2.07e-13	5.38e-11	0.29	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98358364	chr7:98322853~98323430:+
BRCA	cis	rs9649213	0.593	rs6969234	ENSG00000272950.1	RP11-307C18.1	7.44	2.07e-13	5.38e-11	0.29	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98358674	chr7:98322853~98323430:+
BRCA	cis	rs9649213	0.593	rs3801256	ENSG00000272950.1	RP11-307C18.1	7.44	2.07e-13	5.38e-11	0.29	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98362783	chr7:98322853~98323430:+
BRCA	cis	rs6762	0.748	rs5030780	ENSG00000279672.1	CMB9-55F22.1	7.44	2.07e-13	5.38e-11	0.25	0.22	Mean platelet volume;	chr11:838110	chr11:779617~780755:+
BRCA	cis	rs9649213	0.593	rs2240349	ENSG00000272950.1	RP11-307C18.1	7.44	2.07e-13	5.38e-11	0.29	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98355351	chr7:98322853~98323430:+
BRCA	cis	rs9649213	0.593	rs13307593	ENSG00000272950.1	RP11-307C18.1	7.44	2.07e-13	5.38e-11	0.29	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98356834	chr7:98322853~98323430:+
BRCA	cis	rs9880211	1	rs6768743	ENSG00000273486.1	RP11-731C17.2	-7.44	2.07e-13	5.4e-11	-0.29	-0.22	Height;Body mass index;	chr3:136486165	chr3:136837338~136839021:-
BRCA	cis	rs4842666	0.831	rs11105378	ENSG00000258302.2	RP11-981P6.1	7.44	2.07e-13	5.4e-11	0.28	0.22	Blood pressure;	chr12:89696964	chr12:89561129~89594878:+
BRCA	cis	rs801193	1	rs6975195	ENSG00000224316.1	RP11-479O9.2	-7.44	2.07e-13	5.4e-11	-0.22	-0.22	Aortic root size;	chr7:66659787	chr7:65773620~65802067:+
BRCA	cis	rs66887589	0.775	rs6843229	ENSG00000248280.1	RP11-33B1.2	7.44	2.08e-13	5.4e-11	0.21	0.22	Diastolic blood pressure;	chr4:119502932	chr4:119440561~119450157:-
BRCA	cis	rs10740039	0.804	rs4948424	ENSG00000254271.1	RP11-131N11.4	7.44	2.08e-13	5.43e-11	0.3	0.22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60681812	chr10:60734342~60741828:+
BRCA	cis	rs6142102	0.961	rs6087557	ENSG00000275784.1	RP5-1125A11.6	-7.44	2.09e-13	5.45e-11	-0.26	-0.22	Skin pigmentation;	chr20:34110469	chr20:33989480~33991818:-
BRCA	cis	rs2933343	0.553	rs35979399	ENSG00000261159.1	RP11-723O4.9	7.44	2.09e-13	5.45e-11	0.25	0.22	IgG glycosylation;	chr3:128978470	chr3:128859716~128860526:-
BRCA	cis	rs6545883	0.931	rs12713438	ENSG00000271889.1	RP11-493E12.1	7.44	2.09e-13	5.45e-11	0.29	0.22	Tuberculosis;	chr2:61498366	chr2:61151433~61162105:-
BRCA	cis	rs301901	1	rs210540	ENSG00000250155.1	CTD-2353F22.1	-7.44	2.1e-13	5.46e-11	-0.24	-0.22	Height;	chr5:36804263	chr5:36666214~36725195:-
BRCA	cis	rs9309473	1	rs6755241	ENSG00000163016.8	ALMS1P	7.44	2.1e-13	5.47e-11	0.29	0.22	Metabolite levels;	chr2:73414236	chr2:73644919~73685576:+
BRCA	cis	rs9660180	0.62	rs3817856	ENSG00000231050.1	RP1-140A9.1	-7.44	2.1e-13	5.47e-11	-0.27	-0.22	Body mass index;	chr1:1732392	chr1:1891471~1892658:+
BRCA	cis	rs11098499	0.955	rs1511015	ENSG00000248280.1	RP11-33B1.2	7.44	2.1e-13	5.48e-11	0.23	0.22	Corneal astigmatism;	chr4:119249318	chr4:119440561~119450157:-
BRCA	cis	rs7829975	0.577	rs940030	ENSG00000253893.2	FAM85B	7.44	2.11e-13	5.49e-11	0.29	0.22	Mood instability;	chr8:8689418	chr8:8167819~8226614:-
BRCA	cis	rs7429990	0.727	rs319695	ENSG00000229759.1	MRPS18AP1	-7.44	2.11e-13	5.49e-11	-0.26	-0.22	Educational attainment (years of education);	chr3:47842749	chr3:48256350~48256938:-
BRCA	cis	rs891378	0.651	rs7546693	ENSG00000274245.1	RP11-357P18.2	-7.44	2.11e-13	5.5e-11	-0.29	-0.22	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207192864	chr1:207372559~207373252:+
BRCA	cis	rs17772222	0.917	rs1956406	ENSG00000258983.2	RP11-507K2.2	7.44	2.12e-13	5.5e-11	0.26	0.22	Coronary artery calcification;	chr14:88749711	chr14:88499334~88515502:+
BRCA	cis	rs2380205	0.546	rs635532	ENSG00000232807.2	RP11-536K7.3	-7.44	2.12e-13	5.52e-11	-0.23	-0.22	Breast cancer;	chr10:5928365	chr10:5934270~5945900:-
BRCA	cis	rs7809950	0.954	rs62482543	ENSG00000238832.1	snoU109	-7.44	2.13e-13	5.54e-11	-0.3	-0.22	Coronary artery disease;	chr7:107440211	chr7:107603363~107603507:+
BRCA	cis	rs9649213	0.593	rs3801255	ENSG00000272950.1	RP11-307C18.1	7.44	2.13e-13	5.54e-11	0.29	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98371617	chr7:98322853~98323430:+
BRCA	cis	rs10129255	0.957	rs12590735	ENSG00000211972.2	IGHV3-66	7.44	2.13e-13	5.54e-11	0.17	0.22	Kawasaki disease;	chr14:106779660	chr14:106675017~106675544:-
BRCA	cis	rs4723738	1	rs4723738	ENSG00000227191.5	TRGC2	-7.44	2.13e-13	5.55e-11	-0.2	-0.22	Treatment response for severe sepsis;	chr7:38201307	chr7:38239580~38368091:-
BRCA	cis	rs4266144	0.581	rs1806867	ENSG00000244515.1	KRT18P34	-7.44	2.14e-13	5.56e-11	-0.27	-0.22	Coronary artery disease;	chr3:157110513	chr3:157162663~157163932:-
BRCA	cis	rs1862618	0.756	rs13356762	ENSG00000271828.1	CTD-2310F14.1	7.44	2.14e-13	5.57e-11	0.31	0.22	Initial pursuit acceleration;	chr5:56815165	chr5:56927874~56929573:+
BRCA	cis	rs287982	1	rs287975	ENSG00000269973.1	RP11-95D17.1	-7.44	2.14e-13	5.58e-11	-0.28	-0.22	Nonsyndromic cleft lip with cleft palate;	chr2:9829346	chr2:9936360~9939590:+
BRCA	cis	rs9880211	0.898	rs35304385	ENSG00000273486.1	RP11-731C17.2	7.44	2.15e-13	5.58e-11	0.3	0.22	Height;Body mass index;	chr3:136667411	chr3:136837338~136839021:-
BRCA	cis	rs4927850	0.918	rs4361313	ENSG00000242086.7	LINC00969	7.44	2.15e-13	5.6e-11	0.25	0.22	Pancreatic cancer;	chr3:196025389	chr3:195658062~195739964:+
BRCA	cis	rs3781264	0.848	rs3781265	ENSG00000273450.1	RP11-76P2.4	7.44	2.15e-13	5.6e-11	0.29	0.22	Esophageal cancer and gastric cancer;	chr10:94303522	chr10:94314907~94315327:-
BRCA	cis	rs8072100	0.805	rs67919208	ENSG00000228782.6	CTD-2026D20.3	7.44	2.16e-13	5.62e-11	0.24	0.22	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47694507	chr17:47450568~47492492:-
BRCA	cis	rs755249	0.756	rs72637908	ENSG00000228060.1	RP11-69E11.8	-7.44	2.16e-13	5.62e-11	-0.24	-0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39557375	chr1:39565160~39573203:+
BRCA	cis	rs9880211	1	rs4038586	ENSG00000273486.1	RP11-731C17.2	7.44	2.16e-13	5.62e-11	0.3	0.22	Height;Body mass index;	chr3:136644449	chr3:136837338~136839021:-
BRCA	cis	rs9880211	1	rs6767889	ENSG00000273486.1	RP11-731C17.2	7.44	2.16e-13	5.62e-11	0.3	0.22	Height;Body mass index;	chr3:136646613	chr3:136837338~136839021:-
BRCA	cis	rs6142102	0.812	rs761236	ENSG00000276073.1	RP5-1125A11.7	-7.44	2.16e-13	5.63e-11	-0.28	-0.22	Skin pigmentation;	chr20:33932245	chr20:33985617~33988989:-
BRCA	cis	rs801193	0.636	rs2659895	ENSG00000232559.3	GS1-124K5.12	7.44	2.16e-13	5.63e-11	0.27	0.22	Aortic root size;	chr7:66731484	chr7:66554588~66576923:-
BRCA	cis	rs9876781	1	rs6770470	ENSG00000244380.1	RP11-24C3.2	7.44	2.17e-13	5.63e-11	0.26	0.22	Longevity;	chr3:48393659	chr3:48440352~48446656:-
BRCA	cis	rs7811142	1	rs7803454	ENSG00000242294.5	STAG3L5P	7.44	2.17e-13	5.63e-11	0.24	0.22	Platelet count;	chr7:100393925	chr7:100336079~100351900:+
BRCA	cis	rs7811142	0.943	rs11769886	ENSG00000242294.5	STAG3L5P	7.44	2.17e-13	5.63e-11	0.24	0.22	Platelet count;	chr7:100400984	chr7:100336079~100351900:+
BRCA	cis	rs11098499	0.863	rs3775858	ENSG00000248280.1	RP11-33B1.2	7.44	2.17e-13	5.64e-11	0.23	0.22	Corneal astigmatism;	chr4:119564873	chr4:119440561~119450157:-
BRCA	cis	rs9876781	1	rs6810060	ENSG00000244380.1	RP11-24C3.2	7.44	2.17e-13	5.64e-11	0.26	0.22	Longevity;	chr3:48393284	chr3:48440352~48446656:-
BRCA	cis	rs10463554	0.889	rs246912	ENSG00000175749.11	EIF3KP1	7.44	2.17e-13	5.64e-11	0.32	0.22	Parkinson's disease;	chr5:103225140	chr5:103032376~103033031:+
BRCA	cis	rs780096	0.506	rs1647285	ENSG00000234072.1	AC074117.10	-7.44	2.18e-13	5.66e-11	-0.22	-0.22	Total body bone mineral density;	chr2:27491644	chr2:27356246~27367622:+
BRCA	cis	rs780096	0.506	rs1647286	ENSG00000234072.1	AC074117.10	-7.44	2.18e-13	5.66e-11	-0.22	-0.22	Total body bone mineral density;	chr2:27491650	chr2:27356246~27367622:+
BRCA	cis	rs13113518	0.595	rs13120635	ENSG00000273257.1	RP11-177J6.1	7.43	2.18e-13	5.67e-11	0.33	0.22	Height;	chr4:55361200	chr4:55387949~55388271:+
BRCA	cis	rs858239	0.6	rs7456915	ENSG00000230042.1	AK3P3	-7.43	2.19e-13	5.68e-11	-0.25	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23103430	chr7:23129178~23129841:+
BRCA	cis	rs7727544	0.684	rs270602	ENSG00000233006.5	AC034220.3	7.43	2.19e-13	5.69e-11	0.17	0.22	Blood metabolite levels;	chr5:132321007	chr5:132311285~132369916:-
BRCA	cis	rs61270009	0.955	rs34241164	ENSG00000247828.6	TMEM161B-AS1	7.43	2.19e-13	5.7e-11	0.3	0.22	Depressive symptoms;	chr5:88293189	chr5:88268895~88436685:+
BRCA	cis	rs801193	1	rs7782320	ENSG00000224316.1	RP11-479O9.2	7.43	2.19e-13	5.7e-11	0.22	0.22	Aortic root size;	chr7:66712111	chr7:65773620~65802067:+
BRCA	cis	rs62355901	0.8	rs7709971	ENSG00000271828.1	CTD-2310F14.1	7.43	2.2e-13	5.71e-11	0.31	0.22	Breast cancer;	chr5:56711512	chr5:56927874~56929573:+
BRCA	cis	rs6142102	0.961	rs6088361	ENSG00000276073.1	RP5-1125A11.7	-7.43	2.2e-13	5.71e-11	-0.27	-0.22	Skin pigmentation;	chr20:33969520	chr20:33985617~33988989:-
BRCA	cis	rs3758911	0.894	rs11212156	ENSG00000255353.1	RP11-382M14.1	-7.43	2.2e-13	5.71e-11	-0.29	-0.22	Coronary artery disease;	chr11:107323381	chr11:107176286~107177530:+
BRCA	cis	rs7208859	0.623	rs11657662	ENSG00000266490.1	CTD-2349P21.9	-7.43	2.21e-13	5.73e-11	-0.34	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30749329	chr17:30792372~30792833:+
BRCA	cis	rs875971	0.66	rs10215132	ENSG00000224316.1	RP11-479O9.2	-7.43	2.21e-13	5.73e-11	-0.23	-0.22	Aortic root size;	chr7:66589419	chr7:65773620~65802067:+
BRCA	cis	rs2439831	0.85	rs3816792	ENSG00000205771.5	CATSPER2P1	7.43	2.21e-13	5.74e-11	0.38	0.22	Lung cancer in ever smokers;	chr15:43824788	chr15:43726918~43747094:-
BRCA	cis	rs911555	0.662	rs4906322	ENSG00000244691.1	RPL10AP1	7.43	2.21e-13	5.75e-11	0.29	0.22	Intelligence (multi-trait analysis);	chr14:103412695	chr14:103412119~103412761:-
BRCA	cis	rs2742234	0.59	rs2742237	ENSG00000273008.1	RP11-351D16.3	-7.43	2.22e-13	5.77e-11	-0.29	-0.22	Hirschsprung disease;	chr10:43125875	chr10:43136824~43138334:-
BRCA	cis	rs9880211	0.8	rs13314357	ENSG00000239213.4	NCK1-AS1	7.43	2.23e-13	5.78e-11	0.3	0.22	Height;Body mass index;	chr3:136768717	chr3:136841726~136862054:-
BRCA	cis	rs875971	0.862	rs1612452	ENSG00000232559.3	GS1-124K5.12	-7.43	2.23e-13	5.79e-11	-0.27	-0.22	Aortic root size;	chr7:66108909	chr7:66554588~66576923:-
BRCA	cis	rs7927771	0.965	rs12364432	ENSG00000280615.1	Y_RNA	-7.43	2.23e-13	5.8e-11	-0.28	-0.22	Subjective well-being;	chr11:47881331	chr11:47614898~47614994:-
BRCA	cis	rs270601	0.913	rs273916	ENSG00000233006.5	AC034220.3	7.43	2.24e-13	5.81e-11	0.18	0.22	Acylcarnitine levels;	chr5:132324137	chr5:132311285~132369916:-
BRCA	cis	rs9880211	1	rs28634226	ENSG00000273486.1	RP11-731C17.2	7.43	2.24e-13	5.81e-11	0.3	0.22	Height;Body mass index;	chr3:136411040	chr3:136837338~136839021:-
BRCA	cis	rs2221433	0.889	rs1394564	ENSG00000260310.1	RP11-27M24.2	7.43	2.24e-13	5.82e-11	0.27	0.22	Eating disorders;	chr16:10583324	chr16:10576499~10578183:-
BRCA	cis	rs17772222	0.917	rs2224333	ENSG00000258983.2	RP11-507K2.2	7.43	2.24e-13	5.82e-11	0.26	0.22	Coronary artery calcification;	chr14:88768748	chr14:88499334~88515502:+
BRCA	cis	rs17772222	0.917	rs12590826	ENSG00000258983.2	RP11-507K2.2	7.43	2.24e-13	5.82e-11	0.26	0.22	Coronary artery calcification;	chr14:88769357	chr14:88499334~88515502:+
BRCA	cis	rs13178541	0.748	rs4976306	ENSG00000250378.1	RP11-119J18.1	7.43	2.24e-13	5.82e-11	0.31	0.22	IgG glycosylation;	chr5:135728489	chr5:135812667~135826582:+
BRCA	cis	rs7927771	0.793	rs3740686	ENSG00000280615.1	Y_RNA	7.43	2.24e-13	5.82e-11	0.27	0.22	Subjective well-being;	chr11:47354812	chr11:47614898~47614994:-
BRCA	cis	rs7809950	1	rs2712214	ENSG00000238832.1	snoU109	-7.43	2.24e-13	5.83e-11	-0.29	-0.22	Coronary artery disease;	chr7:107547586	chr7:107603363~107603507:+
BRCA	cis	rs7809950	1	rs2712215	ENSG00000238832.1	snoU109	-7.43	2.24e-13	5.83e-11	-0.29	-0.22	Coronary artery disease;	chr7:107547762	chr7:107603363~107603507:+
BRCA	cis	rs2288884	0.559	rs61287503	ENSG00000275055.1	CTC-471J1.11	-7.43	2.25e-13	5.83e-11	-0.26	-0.22	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52017939	chr19:52049007~52049754:+
BRCA	cis	rs858239	0.539	rs870476	ENSG00000230042.1	AK3P3	-7.43	2.25e-13	5.83e-11	-0.26	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23153652	chr7:23129178~23129841:+
BRCA	cis	rs2880765	0.835	rs7169429	ENSG00000259295.5	CSPG4P12	7.43	2.25e-13	5.84e-11	0.27	0.22	Coronary artery disease;	chr15:85493417	chr15:85191438~85213905:+
BRCA	cis	rs801193	1	rs2659915	ENSG00000224316.1	RP11-479O9.2	7.43	2.25e-13	5.85e-11	0.22	0.22	Aortic root size;	chr7:66688114	chr7:65773620~65802067:+
BRCA	cis	rs2439831	0.702	rs9989313	ENSG00000275601.1	AC011330.13	-7.43	2.25e-13	5.85e-11	-0.36	-0.22	Lung cancer in ever smokers;	chr15:43860619	chr15:43642389~43643023:-
BRCA	cis	rs7520050	0.743	rs61789988	ENSG00000280836.1	AL355480.1	7.43	2.26e-13	5.85e-11	0.26	0.22	Reticulocyte count;Red blood cell count;	chr1:45619570	chr1:45581219~45581321:-
BRCA	cis	rs7811142	1	rs7794485	ENSG00000242294.5	STAG3L5P	7.43	2.26e-13	5.87e-11	0.23	0.22	Platelet count;	chr7:100471313	chr7:100336079~100351900:+
BRCA	cis	rs1015362	0.869	rs6088411	ENSG00000275784.1	RP5-1125A11.6	7.43	2.26e-13	5.88e-11	0.27	0.22	Freckles;Red vs. non-red hair color;Skin sensitivity to sun;Burning and freckling;	chr20:34152101	chr20:33989480~33991818:-
BRCA	cis	rs9309711	0.772	rs9309714	ENSG00000225234.1	TRAPPC12-AS1	-7.43	2.27e-13	5.9e-11	-0.27	-0.22	Neurofibrillary tangles;	chr2:3488059	chr2:3481242~3482409:-
BRCA	cis	rs12664251	0.706	rs2797356	ENSG00000253194.1	RP11-351A11.1	-7.43	2.27e-13	5.9e-11	-0.27	-0.22	Schizophrenia;	chr6:119014786	chr6:118934785~119031541:+
BRCA	cis	rs1609391	0.543	rs9859810	ENSG00000273486.1	RP11-731C17.2	7.43	2.27e-13	5.9e-11	0.24	0.22	Neuroticism;	chr3:136911144	chr3:136837338~136839021:-
BRCA	cis	rs6545883	0.899	rs12473030	ENSG00000271889.1	RP11-493E12.1	7.43	2.28e-13	5.91e-11	0.29	0.22	Tuberculosis;	chr2:61493362	chr2:61151433~61162105:-
BRCA	cis	rs2243480	1	rs427044	ENSG00000273142.1	RP11-458F8.4	-7.43	2.28e-13	5.92e-11	-0.32	-0.22	Diabetic kidney disease;	chr7:66043558	chr7:66902857~66906297:+
BRCA	cis	rs453301	0.686	rs6601280	ENSG00000253893.2	FAM85B	-7.43	2.28e-13	5.93e-11	-0.29	-0.22	Joint mobility (Beighton score);	chr8:9051726	chr8:8167819~8226614:-
BRCA	cis	rs10050311	0.585	rs113536481	ENSG00000251411.1	RP11-397E7.4	-7.43	2.29e-13	5.95e-11	-0.33	-0.22	Insulin-related traits;	chr4:86943979	chr4:86913266~86914817:-
BRCA	cis	rs801193	0.548	rs2659904	ENSG00000232559.3	GS1-124K5.12	7.43	2.3e-13	5.96e-11	0.27	0.22	Aortic root size;	chr7:66713615	chr7:66554588~66576923:-
BRCA	cis	rs780096	0.526	rs4803	ENSG00000234072.1	AC074117.10	-7.43	2.3e-13	5.96e-11	-0.22	-0.22	Total body bone mineral density;	chr2:27444430	chr2:27356246~27367622:+
BRCA	cis	rs9649213	0.593	rs7807455	ENSG00000272950.1	RP11-307C18.1	7.43	2.3e-13	5.96e-11	0.28	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98328310	chr7:98322853~98323430:+
BRCA	cis	rs293748	0.771	rs35011787	ENSG00000250155.1	CTD-2353F22.1	-7.43	2.3e-13	5.97e-11	-0.32	-0.22	Obesity-related traits;	chr5:37010302	chr5:36666214~36725195:-
BRCA	cis	rs74233809	1	rs77860422	ENSG00000213277.3	MARCKSL1P1	7.43	2.3e-13	5.97e-11	0.42	0.22	Birth weight;	chr10:102988252	chr10:103175554~103176094:+
BRCA	cis	rs3794924	1	rs34350106	ENSG00000266521.1	RP11-650P15.1	7.43	2.3e-13	5.97e-11	0.41	0.22	Survival in colon cancer;	chr18:31462496	chr18:31496645~31497195:-
BRCA	cis	rs7615952	0.609	rs13088451	ENSG00000171084.14	FAM86JP	7.43	2.3e-13	5.98e-11	0.36	0.22	Blood pressure (smoking interaction);	chr3:125834656	chr3:125916620~125930024:+
BRCA	cis	rs11098499	0.955	rs1397608	ENSG00000248280.1	RP11-33B1.2	7.43	2.31e-13	5.98e-11	0.23	0.22	Corneal astigmatism;	chr4:119240589	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.955	rs7685268	ENSG00000248280.1	RP11-33B1.2	7.43	2.31e-13	5.98e-11	0.23	0.22	Corneal astigmatism;	chr4:119241033	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.955	rs7684942	ENSG00000248280.1	RP11-33B1.2	7.43	2.31e-13	5.98e-11	0.23	0.22	Corneal astigmatism;	chr4:119241046	chr4:119440561~119450157:-
BRCA	cis	rs13113518	0.812	rs12500686	ENSG00000249700.7	SRD5A3-AS1	7.43	2.31e-13	5.99e-11	0.31	0.22	Height;	chr4:55457922	chr4:55363971~55395847:-
BRCA	cis	rs293748	0.882	rs158802	ENSG00000250155.1	CTD-2353F22.1	-7.43	2.31e-13	6e-11	-0.32	-0.22	Obesity-related traits;	chr5:36941446	chr5:36666214~36725195:-
BRCA	cis	rs10206020	0.842	rs7609325	ENSG00000231482.2	AC141930.2	-7.43	2.32e-13	6e-11	-0.29	-0.22	IgG glycosylation;	chr2:1570946	chr2:1572554~1580311:-
BRCA	cis	rs1061377	0.748	rs12642261	ENSG00000249685.1	RP11-360F5.3	7.43	2.32e-13	6.01e-11	0.27	0.22	Uric acid levels;	chr4:39096278	chr4:39133913~39135608:+
BRCA	cis	rs2243480	1	rs1723270	ENSG00000273142.1	RP11-458F8.4	-7.43	2.32e-13	6.01e-11	-0.31	-0.22	Diabetic kidney disease;	chr7:66004843	chr7:66902857~66906297:+
BRCA	cis	rs10206020	0.885	rs11886082	ENSG00000231482.2	AC141930.2	-7.43	2.32e-13	6.02e-11	-0.29	-0.22	IgG glycosylation;	chr2:1572911	chr2:1572554~1580311:-
BRCA	cis	rs7809950	1	rs10251808	ENSG00000238832.1	snoU109	-7.43	2.33e-13	6.05e-11	-0.3	-0.22	Coronary artery disease;	chr7:107480008	chr7:107603363~107603507:+
BRCA	cis	rs4835473	0.897	rs34425128	ENSG00000251600.4	RP11-673E1.1	-7.43	2.34e-13	6.05e-11	-0.29	-0.22	Immature fraction of reticulocytes;	chr4:143725191	chr4:143912331~143982454:+
BRCA	cis	rs7274963	1	rs7274963	ENSG00000236474.1	GCNT1P1	7.43	2.34e-13	6.06e-11	0.29	0.22	Body mass index;	chr20:18310335	chr20:18420160~18421454:-
BRCA	cis	rs950776	0.648	rs57945453	ENSG00000261762.1	RP11-650L12.2	7.43	2.34e-13	6.06e-11	0.26	0.22	Sudden cardiac arrest;	chr15:78570503	chr15:78589123~78591276:-
BRCA	cis	rs9649213	0.537	rs35997266	ENSG00000272950.1	RP11-307C18.1	7.42	2.35e-13	6.08e-11	0.29	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98336254	chr7:98322853~98323430:+
BRCA	cis	rs8062405	0.755	rs56209193	ENSG00000251417.2	RP11-1348G14.4	-7.42	2.35e-13	6.08e-11	-0.27	-0.22	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28574315	chr16:28802743~28817828:+
BRCA	cis	rs2439831	0.85	rs12440573	ENSG00000275601.1	AC011330.13	-7.42	2.35e-13	6.1e-11	-0.37	-0.22	Lung cancer in ever smokers;	chr15:43816799	chr15:43642389~43643023:-
BRCA	cis	rs1113500	0.787	rs11185266	ENSG00000226822.1	RP11-356N1.2	7.42	2.35e-13	6.1e-11	0.29	0.22	Growth-regulated protein alpha levels;	chr1:108100042	chr1:108071482~108074519:+
BRCA	cis	rs11098499	0.604	rs17051352	ENSG00000245958.5	RP11-33B1.1	-7.42	2.35e-13	6.1e-11	-0.23	-0.22	Corneal astigmatism;	chr4:119660272	chr4:119454791~119552025:+
BRCA	cis	rs7246657	1	rs6508710	ENSG00000276846.1	CTD-3220F14.3	7.42	2.36e-13	6.1e-11	0.31	0.22	Coronary artery calcification;	chr19:37258984	chr19:37314868~37315620:-
BRCA	cis	rs7615952	0.576	rs12497295	ENSG00000250012.1	RP11-124N2.1	-7.42	2.37e-13	6.13e-11	-0.31	-0.22	Blood pressure (smoking interaction);	chr3:126099807	chr3:126084220~126095349:+
BRCA	cis	rs7615952	0.512	rs4646765	ENSG00000250012.1	RP11-124N2.1	-7.42	2.37e-13	6.13e-11	-0.31	-0.22	Blood pressure (smoking interaction);	chr3:126101864	chr3:126084220~126095349:+
BRCA	cis	rs7615952	0.576	rs4646763	ENSG00000250012.1	RP11-124N2.1	-7.42	2.37e-13	6.13e-11	-0.31	-0.22	Blood pressure (smoking interaction);	chr3:126103286	chr3:126084220~126095349:+
BRCA	cis	rs7615952	0.576	rs4646759	ENSG00000250012.1	RP11-124N2.1	-7.42	2.37e-13	6.13e-11	-0.31	-0.22	Blood pressure (smoking interaction);	chr3:126104103	chr3:126084220~126095349:+
BRCA	cis	rs7178375	1	rs7169064	ENSG00000215302.7	CTD-3092A11.1	-7.42	2.37e-13	6.14e-11	-0.35	-0.22	Hypertriglyceridemia;	chr15:30918659	chr15:30470779~30507623:+
BRCA	cis	rs7474896	0.583	rs1735621	ENSG00000226578.1	RP11-258F22.1	7.42	2.37e-13	6.15e-11	0.29	0.22	Obesity (extreme);	chr10:37878795	chr10:37775371~37784131:-
BRCA	cis	rs34779708	0.706	rs36027395	ENSG00000271335.4	RP11-324I22.4	7.42	2.38e-13	6.15e-11	0.23	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35261395	chr10:35314552~35336401:-
BRCA	cis	rs7927771	0.931	rs4752801	ENSG00000280615.1	Y_RNA	-7.42	2.38e-13	6.17e-11	-0.27	-0.22	Subjective well-being;	chr11:47886089	chr11:47614898~47614994:-
BRCA	cis	rs6472827	0.953	rs2936686	ENSG00000253983.2	RP1-16A9.1	7.42	2.38e-13	6.18e-11	0.36	0.22	Uterine fibroids;	chr8:74203974	chr8:74199396~74208441:+
BRCA	cis	rs891378	0.727	rs11120492	ENSG00000274245.1	RP11-357P18.2	-7.42	2.39e-13	6.18e-11	-0.29	-0.22	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207234553	chr1:207372559~207373252:+
BRCA	cis	rs8062405	0.755	rs7186573	ENSG00000251417.2	RP11-1348G14.4	-7.42	2.39e-13	6.19e-11	-0.26	-0.22	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576068	chr16:28802743~28817828:+
BRCA	cis	rs11723261	0.582	rs4634177	ENSG00000211553.1	AC253576.2	-7.42	2.39e-13	6.2e-11	-0.32	-0.22	Immune response to smallpox vaccine (IL-6);	chr4:143055	chr4:136461~136568:+
BRCA	cis	rs1861628	1	rs13020935	ENSG00000237930.1	AC007563.4	7.42	2.4e-13	6.2e-11	0.27	0.22	Serum thyroid-stimulating hormone levels;Hypothyroidism;	chr2:216760956	chr2:216785774~216786144:-
BRCA	cis	rs9880211	0.752	rs67145204	ENSG00000239213.4	NCK1-AS1	7.42	2.4e-13	6.21e-11	0.29	0.22	Height;Body mass index;	chr3:136609823	chr3:136841726~136862054:-
BRCA	cis	rs9880211	0.752	rs9847427	ENSG00000239213.4	NCK1-AS1	7.42	2.4e-13	6.22e-11	0.3	0.22	Height;Body mass index;	chr3:136632708	chr3:136841726~136862054:-
BRCA	cis	rs66887589	0.592	rs2175383	ENSG00000248280.1	RP11-33B1.2	7.42	2.4e-13	6.22e-11	0.21	0.22	Diastolic blood pressure;	chr4:119294681	chr4:119440561~119450157:-
BRCA	cis	rs1861628	1	rs13015993	ENSG00000237930.1	AC007563.4	-7.42	2.41e-13	6.23e-11	-0.27	-0.22	Serum thyroid-stimulating hormone levels;Hypothyroidism;	chr2:216760800	chr2:216785774~216786144:-
BRCA	cis	rs801193	1	rs2003301	ENSG00000224316.1	RP11-479O9.2	-7.42	2.41e-13	6.23e-11	-0.22	-0.22	Aortic root size;	chr7:66682669	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.862	rs1167390	ENSG00000232559.3	GS1-124K5.12	-7.42	2.41e-13	6.24e-11	-0.27	-0.22	Aortic root size;	chr7:66110906	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.862	rs35034167	ENSG00000232559.3	GS1-124K5.12	-7.42	2.41e-13	6.24e-11	-0.27	-0.22	Aortic root size;	chr7:66115179	chr7:66554588~66576923:-
BRCA	cis	rs6860806	0.507	rs272880	ENSG00000233006.5	AC034220.3	7.42	2.41e-13	6.24e-11	0.18	0.22	Breast cancer;	chr5:132334485	chr5:132311285~132369916:-
BRCA	cis	rs763567	0.565	rs546258	ENSG00000271811.1	RP1-79C4.4	-7.42	2.41e-13	6.24e-11	-0.24	-0.22	Tonsillectomy;	chr1:170610453	chr1:170667381~170669425:+
BRCA	cis	rs1510272	0.515	rs6807235	ENSG00000243926.1	TIPARP-AS1	-7.42	2.42e-13	6.27e-11	-0.3	-0.22	Testicular germ cell tumor;	chr3:156623812	chr3:156671862~156674378:-
BRCA	cis	rs9876781	1	rs9883759	ENSG00000244380.1	RP11-24C3.2	7.42	2.43e-13	6.28e-11	0.26	0.22	Longevity;	chr3:48422209	chr3:48440352~48446656:-
BRCA	cis	rs9876781	1	rs6442120	ENSG00000244380.1	RP11-24C3.2	7.42	2.43e-13	6.28e-11	0.26	0.22	Longevity;	chr3:48423094	chr3:48440352~48446656:-
BRCA	cis	rs9649213	0.593	rs6967457	ENSG00000272950.1	RP11-307C18.1	7.42	2.43e-13	6.28e-11	0.28	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98282909	chr7:98322853~98323430:+
BRCA	cis	rs919433	0.963	rs10199410	ENSG00000231621.1	AC013264.2	7.42	2.43e-13	6.29e-11	0.21	0.22	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197291052	chr2:197197991~197199273:+
BRCA	cis	rs253959	0.672	rs4921056	ENSG00000271918.1	CTD-2287O16.5	7.42	2.43e-13	6.29e-11	0.18	0.22	Bipolar disorder and schizophrenia;	chr5:116087237	chr5:116083807~116085416:-
BRCA	cis	rs30380	1	rs27710	ENSG00000272109.1	CTD-2260A17.3	7.42	2.43e-13	6.29e-11	0.28	0.22	Cerebrospinal fluid biomarker levels;	chr5:96790494	chr5:96804353~96806105:+
BRCA	cis	rs6570726	0.846	rs397311	ENSG00000235652.6	RP11-545I5.3	-7.42	2.44e-13	6.3e-11	-0.22	-0.22	Lobe attachment (rater-scored or self-reported);	chr6:145485565	chr6:145799409~145886585:+
BRCA	cis	rs732716	0.74	rs62129356	ENSG00000267980.1	AC007292.6	-7.42	2.44e-13	6.3e-11	-0.3	-0.22	Mean corpuscular volume;	chr19:4400317	chr19:4363789~4364640:+
BRCA	cis	rs6545883	0.965	rs6718887	ENSG00000271889.1	RP11-493E12.1	7.42	2.45e-13	6.33e-11	0.29	0.22	Tuberculosis;	chr2:61500080	chr2:61151433~61162105:-
BRCA	cis	rs875971	0.545	rs4718325	ENSG00000224316.1	RP11-479O9.2	7.42	2.45e-13	6.33e-11	0.26	0.22	Aortic root size;	chr7:66215323	chr7:65773620~65802067:+
BRCA	cis	rs2117029	0.782	rs11168850	ENSG00000258017.1	RP11-386G11.10	-7.42	2.45e-13	6.34e-11	-0.29	-0.22	Intelligence (multi-trait analysis);	chr12:49079182	chr12:49127782~49147869:+
BRCA	cis	rs10129255	0.872	rs8015406	ENSG00000211972.2	IGHV3-66	7.42	2.45e-13	6.34e-11	0.18	0.22	Kawasaki disease;	chr14:106670611	chr14:106675017~106675544:-
BRCA	cis	rs2060793	0.526	rs10766194	ENSG00000251991.1	RNU7-49P	7.42	2.46e-13	6.37e-11	0.24	0.22	Vitamin D levels;	chr11:14842668	chr11:14478892~14478953:+
BRCA	cis	rs61270009	0.955	rs11748798	ENSG00000247828.6	TMEM161B-AS1	7.42	2.47e-13	6.38e-11	0.3	0.22	Depressive symptoms;	chr5:88354925	chr5:88268895~88436685:+
BRCA	cis	rs61270009	0.955	rs11740836	ENSG00000247828.6	TMEM161B-AS1	7.42	2.47e-13	6.38e-11	0.3	0.22	Depressive symptoms;	chr5:88356311	chr5:88268895~88436685:+
BRCA	cis	rs61270009	0.913	rs13154590	ENSG00000247828.6	TMEM161B-AS1	7.42	2.47e-13	6.38e-11	0.3	0.22	Depressive symptoms;	chr5:88357208	chr5:88268895~88436685:+
BRCA	cis	rs17772222	1	rs12587386	ENSG00000258983.2	RP11-507K2.2	7.42	2.47e-13	6.38e-11	0.25	0.22	Coronary artery calcification;	chr14:88361420	chr14:88499334~88515502:+
BRCA	cis	rs9640161	0.789	rs34311995	ENSG00000261305.1	RP4-584D14.7	7.42	2.47e-13	6.38e-11	0.34	0.22	Blood protein levels;Circulating chemerin levels;	chr7:150362166	chr7:150341771~150342607:+
BRCA	cis	rs801193	0.569	rs10950050	ENSG00000232559.3	GS1-124K5.12	7.42	2.47e-13	6.39e-11	0.27	0.22	Aortic root size;	chr7:66774601	chr7:66554588~66576923:-
BRCA	cis	rs17772222	0.876	rs61986665	ENSG00000258983.2	RP11-507K2.2	7.42	2.47e-13	6.39e-11	0.26	0.22	Coronary artery calcification;	chr14:88711354	chr14:88499334~88515502:+
BRCA	cis	rs10754283	0.84	rs6428560	ENSG00000231613.1	RP5-943J3.1	7.42	2.49e-13	6.43e-11	0.25	0.22	Amyotrophic lateral sclerosis (sporadic);	chr1:89636903	chr1:89788914~89790492:+
BRCA	cis	rs10129255	0.536	rs8004835	ENSG00000211970.3	IGHV4-61	-7.42	2.49e-13	6.44e-11	-0.14	-0.22	Kawasaki disease;	chr14:106686361	chr14:106639119~106639657:-
BRCA	cis	rs138087875	1	rs138087875	ENSG00000264247.1	LINC00909	-7.42	2.5e-13	6.45e-11	-0.45	-0.22	Brain volume in infants (grey matter);	chr18:74593493	chr18:74591774~74598508:-
BRCA	cis	rs950776	0.714	rs615470	ENSG00000261762.1	RP11-650L12.2	-7.42	2.5e-13	6.47e-11	-0.25	-0.22	Sudden cardiac arrest;	chr15:78593646	chr15:78589123~78591276:-
BRCA	cis	rs755249	0.958	rs2068663	ENSG00000237624.1	OXCT2P1	7.42	2.51e-13	6.48e-11	0.32	0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39572899	chr1:39514956~39516490:+
BRCA	cis	rs6740322	0.748	rs6732337	ENSG00000234936.1	AC010883.5	-7.42	2.51e-13	6.48e-11	-0.25	-0.22	Coronary artery disease;	chr2:43235683	chr2:43229573~43233394:+
BRCA	cis	rs858239	0.899	rs2268747	ENSG00000230042.1	AK3P3	-7.42	2.51e-13	6.49e-11	-0.26	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23273843	chr7:23129178~23129841:+
BRCA	cis	rs74233809	1	rs17115213	ENSG00000213277.3	MARCKSL1P1	7.42	2.51e-13	6.49e-11	0.43	0.22	Birth weight;	chr10:102921386	chr10:103175554~103176094:+
BRCA	cis	rs9649213	0.593	rs36017146	ENSG00000272950.1	RP11-307C18.1	7.42	2.51e-13	6.49e-11	0.29	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98345305	chr7:98322853~98323430:+
BRCA	cis	rs13315649	0.639	rs7612926	ENSG00000242551.2	POU5F1P6	-7.42	2.51e-13	6.49e-11	-0.32	-0.22	Sum eosinophil basophil counts;	chr3:128689221	chr3:128674735~128677005:-
BRCA	cis	rs293748	0.771	rs293746	ENSG00000250155.1	CTD-2353F22.1	-7.41	2.52e-13	6.5e-11	-0.32	-0.22	Obesity-related traits;	chr5:36895168	chr5:36666214~36725195:-
BRCA	cis	rs293748	0.771	rs292160	ENSG00000250155.1	CTD-2353F22.1	-7.41	2.52e-13	6.5e-11	-0.32	-0.22	Obesity-related traits;	chr5:36895971	chr5:36666214~36725195:-
BRCA	cis	rs2274273	0.624	rs8015211	ENSG00000258413.1	RP11-665C16.6	-7.41	2.52e-13	6.5e-11	-0.3	-0.22	Protein biomarker;	chr14:55374729	chr14:55262767~55272075:-
BRCA	cis	rs6496044	0.507	rs8034676	ENSG00000202081.1	RNU6-1280P	7.41	2.52e-13	6.5e-11	0.26	0.22	Interstitial lung disease;	chr15:85616031	chr15:85651522~85651628:-
BRCA	cis	rs2179367	0.632	rs12211357	ENSG00000231760.4	RP11-350J20.5	7.41	2.52e-13	6.52e-11	0.33	0.22	Dupuytren's disease;	chr6:149331148	chr6:149796151~149826294:-
BRCA	cis	rs1275468	1	rs1275468	ENSG00000257497.2	RP11-585P4.5	-7.41	2.53e-13	6.53e-11	-0.31	-0.22	Polycystic ovary syndrome;	chr12:75541377	chr12:75483454~75489820:-
BRCA	cis	rs11098499	0.863	rs10018280	ENSG00000248280.1	RP11-33B1.2	7.41	2.53e-13	6.53e-11	0.23	0.22	Corneal astigmatism;	chr4:119556984	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.863	rs6534141	ENSG00000248280.1	RP11-33B1.2	7.41	2.53e-13	6.53e-11	0.23	0.22	Corneal astigmatism;	chr4:119564068	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.863	rs2127823	ENSG00000248280.1	RP11-33B1.2	7.41	2.53e-13	6.53e-11	0.23	0.22	Corneal astigmatism;	chr4:119564515	chr4:119440561~119450157:-
BRCA	cis	rs3762637	0.943	rs6762156	ENSG00000272758.4	RP11-299J3.8	-7.41	2.53e-13	6.54e-11	-0.31	-0.22	LDL cholesterol levels;	chr3:122517178	chr3:122416207~122443180:+
BRCA	cis	rs3762637	0.943	rs9872708	ENSG00000272758.4	RP11-299J3.8	-7.41	2.53e-13	6.54e-11	-0.31	-0.22	LDL cholesterol levels;	chr3:122523960	chr3:122416207~122443180:+
BRCA	cis	rs858239	0.6	rs7785842	ENSG00000230042.1	AK3P3	-7.41	2.55e-13	6.58e-11	-0.25	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23102087	chr7:23129178~23129841:+
BRCA	cis	rs875971	0.642	rs35526611	ENSG00000224316.1	RP11-479O9.2	-7.41	2.56e-13	6.6e-11	-0.22	-0.22	Aortic root size;	chr7:66629021	chr7:65773620~65802067:+
BRCA	cis	rs42648	0.869	rs42617	ENSG00000225498.1	AC002064.5	7.41	2.56e-13	6.6e-11	0.22	0.22	Homocysteine levels;	chr7:90322732	chr7:90312496~90322592:+
BRCA	cis	rs74233809	1	rs11191582	ENSG00000213277.3	MARCKSL1P1	7.41	2.56e-13	6.62e-11	0.46	0.22	Birth weight;	chr10:103153896	chr10:103175554~103176094:+
BRCA	cis	rs919433	1	rs919433	ENSG00000231621.1	AC013264.2	7.41	2.56e-13	6.62e-11	0.21	0.22	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197301841	chr2:197197991~197199273:+
BRCA	cis	rs7617773	0.78	rs13090538	ENSG00000228638.1	FCF1P2	-7.41	2.57e-13	6.64e-11	-0.25	-0.22	Coronary artery disease;	chr3:48329279	chr3:48290793~48291375:-
BRCA	cis	rs7809950	1	rs12667527	ENSG00000238832.1	snoU109	-7.41	2.58e-13	6.65e-11	-0.3	-0.22	Coronary artery disease;	chr7:107446524	chr7:107603363~107603507:+
BRCA	cis	rs9309711	0.961	rs35067331	ENSG00000225234.1	TRAPPC12-AS1	-7.41	2.58e-13	6.65e-11	-0.27	-0.22	Neurofibrillary tangles;	chr2:3470314	chr2:3481242~3482409:-
BRCA	cis	rs10206020	0.921	rs72778009	ENSG00000231482.2	AC141930.2	-7.41	2.58e-13	6.66e-11	-0.29	-0.22	IgG glycosylation;	chr2:1569550	chr2:1572554~1580311:-
BRCA	cis	rs11098499	1	rs10029750	ENSG00000248280.1	RP11-33B1.2	7.41	2.6e-13	6.72e-11	0.23	0.22	Corneal astigmatism;	chr4:119251388	chr4:119440561~119450157:-
BRCA	cis	rs61270009	0.955	rs10942528	ENSG00000247828.6	TMEM161B-AS1	7.41	2.61e-13	6.73e-11	0.3	0.22	Depressive symptoms;	chr5:88314098	chr5:88268895~88436685:+
BRCA	cis	rs1862618	0.853	rs863840	ENSG00000271828.1	CTD-2310F14.1	7.41	2.61e-13	6.73e-11	0.32	0.22	Initial pursuit acceleration;	chr5:56833172	chr5:56927874~56929573:+
BRCA	cis	rs875971	0.545	rs10261710	ENSG00000224316.1	RP11-479O9.2	7.41	2.61e-13	6.73e-11	0.26	0.22	Aortic root size;	chr7:66249202	chr7:65773620~65802067:+
BRCA	cis	rs673078	0.607	rs7967900	ENSG00000275409.1	RP11-131L12.4	7.41	2.61e-13	6.74e-11	0.33	0.22	Glucose homeostasis traits;	chr12:118381902	chr12:118430147~118430699:+
BRCA	cis	rs7246657	0.714	rs12972195	ENSG00000276846.1	CTD-3220F14.3	7.41	2.61e-13	6.75e-11	0.31	0.22	Coronary artery calcification;	chr19:37261603	chr19:37314868~37315620:-
BRCA	cis	rs8062405	0.723	rs35175818	ENSG00000251417.2	RP11-1348G14.4	-7.41	2.62e-13	6.75e-11	-0.27	-0.22	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28597425	chr16:28802743~28817828:+
BRCA	cis	rs8100891	0.734	rs8104048	ENSG00000267213.4	AC007773.2	-7.41	2.62e-13	6.75e-11	-0.26	-0.22	Neuroticism;	chr19:32338400	chr19:32390050~32405560:-
BRCA	cis	rs6570726	0.875	rs373313	ENSG00000235652.6	RP11-545I5.3	7.41	2.62e-13	6.76e-11	0.22	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145536655	chr6:145799409~145886585:+
BRCA	cis	rs6907340	0.517	rs6939160	ENSG00000228412.5	RP4-625H18.2	7.41	2.62e-13	6.76e-11	0.3	0.22	Endometriosis;	chr6:19802086	chr6:19802164~19804752:-
BRCA	cis	rs6860806	0.507	rs273915	ENSG00000233006.5	AC034220.3	7.41	2.62e-13	6.76e-11	0.18	0.22	Breast cancer;	chr5:132324426	chr5:132311285~132369916:-
BRCA	cis	rs780096	0.526	rs780112	ENSG00000234072.1	AC074117.10	-7.41	2.62e-13	6.76e-11	-0.22	-0.22	Total body bone mineral density;	chr2:27442494	chr2:27356246~27367622:+
BRCA	cis	rs6545883	0.965	rs12713439	ENSG00000271889.1	RP11-493E12.1	7.41	2.62e-13	6.77e-11	0.29	0.22	Tuberculosis;	chr2:61525019	chr2:61151433~61162105:-
BRCA	cis	rs10206020	0.885	rs13411553	ENSG00000231482.2	AC141930.2	-7.41	2.63e-13	6.77e-11	-0.28	-0.22	IgG glycosylation;	chr2:1570246	chr2:1572554~1580311:-
BRCA	cis	rs9880211	0.752	rs9820717	ENSG00000239213.4	NCK1-AS1	7.41	2.63e-13	6.78e-11	0.29	0.22	Height;Body mass index;	chr3:136627771	chr3:136841726~136862054:-
BRCA	cis	rs4927850	1	rs7630875	ENSG00000242086.7	LINC00969	7.41	2.63e-13	6.79e-11	0.25	0.22	Pancreatic cancer;	chr3:196026895	chr3:195658062~195739964:+
BRCA	cis	rs11098499	0.955	rs6815725	ENSG00000248280.1	RP11-33B1.2	7.41	2.63e-13	6.79e-11	0.23	0.22	Corneal astigmatism;	chr4:119237255	chr4:119440561~119450157:-
BRCA	cis	rs763567	0.585	rs476810	ENSG00000271811.1	RP1-79C4.4	-7.41	2.64e-13	6.8e-11	-0.24	-0.22	Tonsillectomy;	chr1:170604673	chr1:170667381~170669425:+
BRCA	cis	rs732716	0.853	rs72990643	ENSG00000267769.1	CTB-50L17.9	-7.41	2.64e-13	6.8e-11	-0.27	-0.22	Mean corpuscular volume;	chr19:4454739	chr19:4454014~4455286:+
BRCA	cis	rs9876781	1	rs3774808	ENSG00000244380.1	RP11-24C3.2	7.41	2.64e-13	6.8e-11	0.26	0.22	Longevity;	chr3:48440237	chr3:48440352~48446656:-
BRCA	cis	rs62025270	0.547	rs338520	ENSG00000202081.1	RNU6-1280P	7.41	2.64e-13	6.8e-11	0.27	0.22	Idiopathic pulmonary fibrosis;	chr15:85671567	chr15:85651522~85651628:-
BRCA	cis	rs875971	1	rs7792762	ENSG00000232559.3	GS1-124K5.12	7.41	2.64e-13	6.81e-11	0.27	0.22	Aortic root size;	chr7:66539151	chr7:66554588~66576923:-
BRCA	cis	rs1862618	0.853	rs860580	ENSG00000271828.1	CTD-2310F14.1	-7.41	2.64e-13	6.81e-11	-0.31	-0.22	Initial pursuit acceleration;	chr5:56853602	chr5:56927874~56929573:+
BRCA	cis	rs3758911	0.765	rs609821	ENSG00000255353.1	RP11-382M14.1	7.41	2.64e-13	6.81e-11	0.3	0.22	Coronary artery disease;	chr11:107468429	chr11:107176286~107177530:+
BRCA	cis	rs8100891	0.734	rs4804990	ENSG00000267213.4	AC007773.2	-7.41	2.65e-13	6.82e-11	-0.27	-0.22	Neuroticism;	chr19:32346523	chr19:32390050~32405560:-
BRCA	cis	rs6545883	0.965	rs6734830	ENSG00000271889.1	RP11-493E12.1	7.41	2.65e-13	6.83e-11	0.29	0.22	Tuberculosis;	chr2:61503977	chr2:61151433~61162105:-
BRCA	cis	rs9309473	1	rs7598396	ENSG00000163016.8	ALMS1P	7.41	2.65e-13	6.84e-11	0.29	0.22	Metabolite levels;	chr2:73425500	chr2:73644919~73685576:+
BRCA	cis	rs763567	0.585	rs1234233	ENSG00000271811.1	RP1-79C4.4	-7.41	2.66e-13	6.85e-11	-0.24	-0.22	Tonsillectomy;	chr1:170605787	chr1:170667381~170669425:+
BRCA	cis	rs763567	0.546	rs566850	ENSG00000271811.1	RP1-79C4.4	-7.41	2.66e-13	6.85e-11	-0.24	-0.22	Tonsillectomy;	chr1:170607597	chr1:170667381~170669425:+
BRCA	cis	rs526231	0.578	rs35100629	ENSG00000175749.11	EIF3KP1	7.41	2.66e-13	6.85e-11	0.32	0.22	Primary biliary cholangitis;	chr5:102910381	chr5:103032376~103033031:+
BRCA	cis	rs10740039	0.883	rs7068934	ENSG00000254271.1	RP11-131N11.4	7.41	2.66e-13	6.86e-11	0.3	0.22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60636490	chr10:60734342~60741828:+
BRCA	cis	rs6545883	0.965	rs7421663	ENSG00000271889.1	RP11-493E12.1	7.41	2.66e-13	6.86e-11	0.29	0.22	Tuberculosis;	chr2:61526651	chr2:61151433~61162105:-
BRCA	cis	rs875971	0.545	rs221986	ENSG00000224316.1	RP11-479O9.2	-7.41	2.66e-13	6.86e-11	-0.26	-0.22	Aortic root size;	chr7:66105323	chr7:65773620~65802067:+
BRCA	cis	rs2243480	0.901	rs313808	ENSG00000273142.1	RP11-458F8.4	-7.41	2.67e-13	6.88e-11	-0.3	-0.22	Diabetic kidney disease;	chr7:66034886	chr7:66902857~66906297:+
BRCA	cis	rs11098499	0.644	rs3806808	ENSG00000245958.5	RP11-33B1.1	-7.41	2.68e-13	6.89e-11	-0.21	-0.22	Corneal astigmatism;	chr4:119629930	chr4:119454791~119552025:+
BRCA	cis	rs2243480	1	rs56016656	ENSG00000273142.1	RP11-458F8.4	-7.41	2.68e-13	6.89e-11	-0.31	-0.22	Diabetic kidney disease;	chr7:65918494	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs56291018	ENSG00000273142.1	RP11-458F8.4	-7.41	2.68e-13	6.89e-11	-0.31	-0.22	Diabetic kidney disease;	chr7:65925352	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs36033484	ENSG00000273142.1	RP11-458F8.4	-7.41	2.68e-13	6.89e-11	-0.31	-0.22	Diabetic kidney disease;	chr7:65925571	chr7:66902857~66906297:+
BRCA	cis	rs858239	1	rs858240	ENSG00000230042.1	AK3P3	-7.41	2.68e-13	6.91e-11	-0.26	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23244618	chr7:23129178~23129841:+
BRCA	cis	rs9876781	0.9	rs1037773	ENSG00000244380.1	RP11-24C3.2	7.41	2.69e-13	6.92e-11	0.26	0.22	Longevity;	chr3:48426493	chr3:48440352~48446656:-
BRCA	cis	rs9876781	1	rs2279077	ENSG00000244380.1	RP11-24C3.2	7.41	2.69e-13	6.92e-11	0.26	0.22	Longevity;	chr3:48432839	chr3:48440352~48446656:-
BRCA	cis	rs4845875	0.534	rs6541003	ENSG00000242349.4	NPPA-AS1	7.41	2.69e-13	6.92e-11	0.24	0.22	Midregional pro atrial natriuretic peptide levels;	chr1:11795810	chr1:11841017~11848079:+
BRCA	cis	rs6570726	0.935	rs369214	ENSG00000235652.6	RP11-545I5.3	7.41	2.69e-13	6.94e-11	0.22	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145535573	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.935	rs390252	ENSG00000235652.6	RP11-545I5.3	7.41	2.69e-13	6.94e-11	0.22	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145535760	chr6:145799409~145886585:+
BRCA	cis	rs2179367	0.613	rs12207261	ENSG00000231760.4	RP11-350J20.5	7.41	2.7e-13	6.94e-11	0.32	0.22	Dupuytren's disease;	chr6:149423722	chr6:149796151~149826294:-
BRCA	cis	rs9880211	1	rs13092193	ENSG00000273486.1	RP11-731C17.2	7.4	2.71e-13	6.97e-11	0.29	0.22	Height;Body mass index;	chr3:136521524	chr3:136837338~136839021:-
BRCA	cis	rs6545883	0.929	rs2463100	ENSG00000271889.1	RP11-493E12.1	7.4	2.71e-13	6.97e-11	0.31	0.22	Tuberculosis;	chr2:61432064	chr2:61151433~61162105:-
BRCA	cis	rs13113518	0.595	rs13120635	ENSG00000249700.7	SRD5A3-AS1	7.4	2.72e-13	6.99e-11	0.32	0.22	Height;	chr4:55361200	chr4:55363971~55395847:-
BRCA	cis	rs10206020	0.879	rs72778007	ENSG00000231482.2	AC141930.2	-7.4	2.72e-13	7e-11	-0.29	-0.22	IgG glycosylation;	chr2:1569406	chr2:1572554~1580311:-
BRCA	cis	rs10206020	0.797	rs72778008	ENSG00000231482.2	AC141930.2	-7.4	2.72e-13	7e-11	-0.29	-0.22	IgG glycosylation;	chr2:1569410	chr2:1572554~1580311:-
BRCA	cis	rs2880765	0.835	rs4536419	ENSG00000259295.5	CSPG4P12	7.4	2.72e-13	7e-11	0.27	0.22	Coronary artery disease;	chr15:85496240	chr15:85191438~85213905:+
BRCA	cis	rs11143230	1	rs17628494	ENSG00000225434.2	LINC01504	-7.4	2.72e-13	7.01e-11	-0.26	-0.22	Suicidal ideation;	chr9:72274251	chr9:72305430~72343210:+
BRCA	cis	rs66887589	0.616	rs1052633	ENSG00000248280.1	RP11-33B1.2	7.4	2.73e-13	7.03e-11	0.21	0.22	Diastolic blood pressure;	chr4:119294159	chr4:119440561~119450157:-
BRCA	cis	rs1075265	0.587	rs2542585	ENSG00000233266.1	HMGB1P31	7.4	2.73e-13	7.04e-11	0.27	0.22	Chronotype;Morning vs. evening chronotype;	chr2:53786407	chr2:54051334~54051760:+
BRCA	cis	rs2243480	1	rs34560516	ENSG00000273142.1	RP11-458F8.4	-7.4	2.74e-13	7.05e-11	-0.31	-0.22	Diabetic kidney disease;	chr7:65939105	chr7:66902857~66906297:+
BRCA	cis	rs780096	0.526	rs704791	ENSG00000234072.1	AC074117.10	-7.4	2.74e-13	7.05e-11	-0.22	-0.22	Total body bone mineral density;	chr2:27434300	chr2:27356246~27367622:+
BRCA	cis	rs780096	0.526	rs1260341	ENSG00000234072.1	AC074117.10	-7.4	2.74e-13	7.05e-11	-0.22	-0.22	Total body bone mineral density;	chr2:27440348	chr2:27356246~27367622:+
BRCA	cis	rs780096	0.526	rs1260342	ENSG00000234072.1	AC074117.10	-7.4	2.74e-13	7.05e-11	-0.22	-0.22	Total body bone mineral density;	chr2:27440549	chr2:27356246~27367622:+
BRCA	cis	rs780096	0.565	rs780104	ENSG00000234072.1	AC074117.10	-7.4	2.74e-13	7.05e-11	-0.22	-0.22	Total body bone mineral density;	chr2:27454824	chr2:27356246~27367622:+
BRCA	cis	rs780096	0.526	rs780106	ENSG00000234072.1	AC074117.10	-7.4	2.74e-13	7.05e-11	-0.22	-0.22	Total body bone mineral density;	chr2:27458731	chr2:27356246~27367622:+
BRCA	cis	rs780096	0.526	rs780107	ENSG00000234072.1	AC074117.10	-7.4	2.74e-13	7.05e-11	-0.22	-0.22	Total body bone mineral density;	chr2:27461867	chr2:27356246~27367622:+
BRCA	cis	rs780096	0.526	rs1647276	ENSG00000234072.1	AC074117.10	-7.4	2.74e-13	7.05e-11	-0.22	-0.22	Total body bone mineral density;	chr2:27465734	chr2:27356246~27367622:+
BRCA	cis	rs780096	0.526	rs1406295	ENSG00000234072.1	AC074117.10	-7.4	2.74e-13	7.05e-11	-0.22	-0.22	Total body bone mineral density;	chr2:27466833	chr2:27356246~27367622:+
BRCA	cis	rs780096	0.506	rs1647265	ENSG00000234072.1	AC074117.10	-7.4	2.74e-13	7.05e-11	-0.22	-0.22	Total body bone mineral density;	chr2:27469394	chr2:27356246~27367622:+
BRCA	cis	rs780096	0.526	rs1647266	ENSG00000234072.1	AC074117.10	-7.4	2.74e-13	7.05e-11	-0.22	-0.22	Total body bone mineral density;	chr2:27470618	chr2:27356246~27367622:+
BRCA	cis	rs801193	1	rs1553610	ENSG00000224316.1	RP11-479O9.2	7.4	2.74e-13	7.06e-11	0.22	0.22	Aortic root size;	chr7:66732246	chr7:65773620~65802067:+
BRCA	cis	rs801193	1	rs2707845	ENSG00000224316.1	RP11-479O9.2	7.4	2.74e-13	7.06e-11	0.22	0.22	Aortic root size;	chr7:66733811	chr7:65773620~65802067:+
BRCA	cis	rs801193	1	rs2707850	ENSG00000224316.1	RP11-479O9.2	7.4	2.74e-13	7.06e-11	0.22	0.22	Aortic root size;	chr7:66738883	chr7:65773620~65802067:+
BRCA	cis	rs801193	0.967	rs1110414	ENSG00000224316.1	RP11-479O9.2	7.4	2.74e-13	7.06e-11	0.22	0.22	Aortic root size;	chr7:66740595	chr7:65773620~65802067:+
BRCA	cis	rs801193	1	rs7783924	ENSG00000224316.1	RP11-479O9.2	7.4	2.74e-13	7.06e-11	0.22	0.22	Aortic root size;	chr7:66744070	chr7:65773620~65802067:+
BRCA	cis	rs801193	1	rs7789184	ENSG00000224316.1	RP11-479O9.2	7.4	2.74e-13	7.06e-11	0.22	0.22	Aortic root size;	chr7:66745208	chr7:65773620~65802067:+
BRCA	cis	rs801193	1	rs2707854	ENSG00000224316.1	RP11-479O9.2	7.4	2.74e-13	7.06e-11	0.22	0.22	Aortic root size;	chr7:66747610	chr7:65773620~65802067:+
BRCA	cis	rs473651	0.935	rs1103770	ENSG00000229915.1	AC016999.2	-7.4	2.74e-13	7.06e-11	-0.31	-0.22	Multiple system atrophy;	chr2:238430640	chr2:238427077~238427729:-
BRCA	cis	rs473651	0.935	rs10170056	ENSG00000229915.1	AC016999.2	-7.4	2.74e-13	7.06e-11	-0.31	-0.22	Multiple system atrophy;	chr2:238430650	chr2:238427077~238427729:-
BRCA	cis	rs473651	0.935	rs559579	ENSG00000229915.1	AC016999.2	-7.4	2.74e-13	7.06e-11	-0.31	-0.22	Multiple system atrophy;	chr2:238430860	chr2:238427077~238427729:-
BRCA	cis	rs10050311	0.79	rs17751557	ENSG00000251411.1	RP11-397E7.4	-7.4	2.75e-13	7.07e-11	-0.31	-0.22	Insulin-related traits;	chr4:86913454	chr4:86913266~86914817:-
BRCA	cis	rs2243480	0.901	rs73148097	ENSG00000273142.1	RP11-458F8.4	-7.4	2.75e-13	7.08e-11	-0.31	-0.22	Diabetic kidney disease;	chr7:65966800	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs906134	ENSG00000273142.1	RP11-458F8.4	-7.4	2.75e-13	7.08e-11	-0.31	-0.22	Diabetic kidney disease;	chr7:65979301	chr7:66902857~66906297:+
BRCA	cis	rs293748	0.771	rs159141	ENSG00000250155.1	CTD-2353F22.1	-7.4	2.76e-13	7.09e-11	-0.32	-0.22	Obesity-related traits;	chr5:36925544	chr5:36666214~36725195:-
BRCA	cis	rs17772222	0.917	rs57889459	ENSG00000258983.2	RP11-507K2.2	7.4	2.76e-13	7.1e-11	0.26	0.22	Coronary artery calcification;	chr14:88770820	chr14:88499334~88515502:+
BRCA	cis	rs526231	0.578	rs6867392	ENSG00000175749.11	EIF3KP1	7.4	2.77e-13	7.13e-11	0.32	0.22	Primary biliary cholangitis;	chr5:102946183	chr5:103032376~103033031:+
BRCA	cis	rs1862618	0.853	rs2432195	ENSG00000271828.1	CTD-2310F14.1	7.4	2.78e-13	7.15e-11	0.31	0.22	Initial pursuit acceleration;	chr5:56824586	chr5:56927874~56929573:+
BRCA	cis	rs1075265	0.553	rs2692532	ENSG00000233266.1	HMGB1P31	7.4	2.78e-13	7.15e-11	0.27	0.22	Chronotype;Morning vs. evening chronotype;	chr2:53778962	chr2:54051334~54051760:+
BRCA	cis	rs42648	0.693	rs2106274	ENSG00000225498.1	AC002064.5	7.4	2.78e-13	7.16e-11	0.21	0.22	Homocysteine levels;	chr7:90251234	chr7:90312496~90322592:+
BRCA	cis	rs2348418	0.639	rs10459087	ENSG00000247934.4	RP11-967K21.1	7.4	2.78e-13	7.16e-11	0.26	0.22	Lung function (FEV1);Lung function (FVC);	chr12:28115904	chr12:28163298~28190738:-
BRCA	cis	rs10740039	0.883	rs10740038	ENSG00000254271.1	RP11-131N11.4	7.4	2.79e-13	7.16e-11	0.3	0.22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60643479	chr10:60734342~60741828:+
BRCA	cis	rs7712401	0.58	rs4288111	ENSG00000263432.2	RN7SL689P	-7.4	2.8e-13	7.19e-11	-0.27	-0.22	Mean platelet volume;	chr5:123052487	chr5:123022487~123022783:-
BRCA	cis	rs9649213	0.593	rs3823740	ENSG00000272950.1	RP11-307C18.1	7.4	2.8e-13	7.2e-11	0.28	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98327792	chr7:98322853~98323430:+
BRCA	cis	rs2243480	1	rs313809	ENSG00000273142.1	RP11-458F8.4	-7.4	2.8e-13	7.21e-11	-0.31	-0.22	Diabetic kidney disease;	chr7:66034996	chr7:66902857~66906297:+
BRCA	cis	rs9880211	0.699	rs34804893	ENSG00000239213.4	NCK1-AS1	7.4	2.81e-13	7.22e-11	0.3	0.22	Height;Body mass index;	chr3:136621128	chr3:136841726~136862054:-
BRCA	cis	rs34779708	0.801	rs12255409	ENSG00000271335.4	RP11-324I22.4	7.4	2.81e-13	7.22e-11	0.23	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35246497	chr10:35314552~35336401:-
BRCA	cis	rs9637599	0.967	rs7661312	ENSG00000246375.2	RP11-10L7.1	7.4	2.81e-13	7.22e-11	0.29	0.22	Metabolite levels (small molecules and protein measures);	chr4:88279855	chr4:88284942~88331421:+
BRCA	cis	rs1555322	0.53	rs6058224	ENSG00000261582.1	RP4-614O4.11	-7.4	2.82e-13	7.25e-11	-0.24	-0.22	Attention deficit hyperactivity disorder;	chr20:35293971	chr20:35267885~35280043:-
BRCA	cis	rs10510102	0.872	rs12264046	ENSG00000276742.1	RP11-500G22.4	7.4	2.82e-13	7.25e-11	0.38	0.22	Breast cancer;	chr10:121894996	chr10:121956782~121957098:+
BRCA	cis	rs3781264	0.816	rs7084339	ENSG00000273450.1	RP11-76P2.4	-7.4	2.83e-13	7.26e-11	-0.28	-0.22	Esophageal cancer and gastric cancer;	chr10:94283975	chr10:94314907~94315327:-
BRCA	cis	rs12548874	0.607	rs12543492	ENSG00000253528.2	RP11-347C18.4	7.4	2.83e-13	7.26e-11	0.24	0.22	Hemoglobin concentration;	chr8:94879615	chr8:94974573~94974853:-
BRCA	cis	rs34779708	0.733	rs7070778	ENSG00000271335.4	RP11-324I22.4	7.4	2.83e-13	7.27e-11	0.23	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35252760	chr10:35314552~35336401:-
BRCA	cis	rs2243480	1	rs2961102	ENSG00000273142.1	RP11-458F8.4	-7.4	2.83e-13	7.27e-11	-0.31	-0.22	Diabetic kidney disease;	chr7:65959671	chr7:66902857~66906297:+
BRCA	cis	rs10510102	1	rs6585764	ENSG00000276742.1	RP11-500G22.4	7.4	2.83e-13	7.27e-11	0.36	0.22	Breast cancer;	chr10:121837308	chr10:121956782~121957098:+
BRCA	cis	rs6860806	0.507	rs272892	ENSG00000233006.5	AC034220.3	7.4	2.83e-13	7.28e-11	0.18	0.22	Breast cancer;	chr5:132328656	chr5:132311285~132369916:-
BRCA	cis	rs12664251	0.706	rs1775620	ENSG00000253194.1	RP11-351A11.1	-7.4	2.84e-13	7.29e-11	-0.27	-0.22	Schizophrenia;	chr6:119012273	chr6:118934785~119031541:+
BRCA	cis	rs9880211	1	rs28750366	ENSG00000273486.1	RP11-731C17.2	7.4	2.84e-13	7.3e-11	0.29	0.22	Height;Body mass index;	chr3:136642213	chr3:136837338~136839021:-
BRCA	cis	rs1862618	0.853	rs832554	ENSG00000271828.1	CTD-2310F14.1	7.4	2.85e-13	7.32e-11	0.31	0.22	Initial pursuit acceleration;	chr5:56819209	chr5:56927874~56929573:+
BRCA	cis	rs875971	1	rs6963646	ENSG00000232559.3	GS1-124K5.12	-7.4	2.86e-13	7.33e-11	-0.26	-0.22	Aortic root size;	chr7:66220780	chr7:66554588~66576923:-
BRCA	cis	rs301901	1	rs6899155	ENSG00000250155.1	CTD-2353F22.1	-7.4	2.87e-13	7.36e-11	-0.24	-0.22	Height;	chr5:36786357	chr5:36666214~36725195:-
BRCA	cis	rs12444979	0.517	rs720173	ENSG00000261195.1	CTD-2380F24.1	-7.4	2.87e-13	7.37e-11	-0.35	-0.22	Body mass index;	chr16:19710484	chr16:19761172~19766099:-
BRCA	cis	rs780096	0.526	rs1647267	ENSG00000234072.1	AC074117.10	-7.4	2.87e-13	7.38e-11	-0.22	-0.22	Total body bone mineral density;	chr2:27428187	chr2:27356246~27367622:+
BRCA	cis	rs780096	0.526	rs10182937	ENSG00000234072.1	AC074117.10	-7.4	2.87e-13	7.38e-11	-0.22	-0.22	Total body bone mineral density;	chr2:27428826	chr2:27356246~27367622:+
BRCA	cis	rs338389	0.591	rs8037902	ENSG00000260657.2	RP11-315D16.4	7.4	2.88e-13	7.4e-11	0.26	0.22	Survival in rectal cancer;	chr15:67988365	chr15:68267792~68277994:-
BRCA	cis	rs7487637	0.529	rs11168244	ENSG00000276691.1	RP5-1057I20.5	7.4	2.88e-13	7.4e-11	0.29	0.22	Mononucleosis;	chr12:47809158	chr12:47788426~47788971:+
BRCA	cis	rs897984	0.683	rs729482	ENSG00000260911.2	RP11-196G11.2	7.4	2.88e-13	7.4e-11	0.21	0.22	Dementia with Lewy bodies;	chr16:31005649	chr16:31043150~31049868:+
BRCA	cis	rs2243480	1	rs781150	ENSG00000273142.1	RP11-458F8.4	-7.4	2.89e-13	7.4e-11	-0.31	-0.22	Diabetic kidney disease;	chr7:66015986	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs313798	ENSG00000273142.1	RP11-458F8.4	-7.4	2.89e-13	7.4e-11	-0.31	-0.22	Diabetic kidney disease;	chr7:66028044	chr7:66902857~66906297:+
BRCA	cis	rs8062405	0.755	rs62034325	ENSG00000251417.2	RP11-1348G14.4	-7.4	2.89e-13	7.41e-11	-0.27	-0.22	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28527319	chr16:28802743~28817828:+
BRCA	cis	rs293748	0.771	rs13174506	ENSG00000250155.1	CTD-2353F22.1	-7.4	2.89e-13	7.42e-11	-0.31	-0.22	Obesity-related traits;	chr5:36801678	chr5:36666214~36725195:-
BRCA	cis	rs293748	0.771	rs12654600	ENSG00000250155.1	CTD-2353F22.1	-7.4	2.89e-13	7.42e-11	-0.31	-0.22	Obesity-related traits;	chr5:36802066	chr5:36666214~36725195:-
BRCA	cis	rs293748	0.771	rs34139494	ENSG00000250155.1	CTD-2353F22.1	-7.4	2.89e-13	7.42e-11	-0.31	-0.22	Obesity-related traits;	chr5:36802466	chr5:36666214~36725195:-
BRCA	cis	rs9880211	0.898	rs6770476	ENSG00000239213.4	NCK1-AS1	7.4	2.9e-13	7.43e-11	0.26	0.22	Height;Body mass index;	chr3:136355078	chr3:136841726~136862054:-
BRCA	cis	rs34779708	0.733	rs12249814	ENSG00000271335.4	RP11-324I22.4	7.39	2.9e-13	7.45e-11	0.23	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35253829	chr10:35314552~35336401:-
BRCA	cis	rs7246657	0.943	rs10409204	ENSG00000276846.1	CTD-3220F14.3	7.39	2.91e-13	7.47e-11	0.31	0.22	Coronary artery calcification;	chr19:37426790	chr19:37314868~37315620:-
BRCA	cis	rs875971	0.54	rs781152	ENSG00000222364.1	RNU6-96P	-7.39	2.91e-13	7.47e-11	-0.26	-0.22	Aortic root size;	chr7:66014585	chr7:66395191~66395286:+
BRCA	cis	rs17711722	0.727	rs781151	ENSG00000222364.1	RNU6-96P	-7.39	2.91e-13	7.47e-11	-0.26	-0.22	Calcium levels;	chr7:66014891	chr7:66395191~66395286:+
BRCA	cis	rs732716	0.785	rs62130978	ENSG00000267980.1	AC007292.6	-7.39	2.91e-13	7.48e-11	-0.3	-0.22	Mean corpuscular volume;	chr19:4429010	chr19:4363789~4364640:+
BRCA	cis	rs2243480	1	rs7794661	ENSG00000273142.1	RP11-458F8.4	-7.39	2.92e-13	7.48e-11	-0.3	-0.22	Diabetic kidney disease;	chr7:65924743	chr7:66902857~66906297:+
BRCA	cis	rs2933343	0.533	rs11915889	ENSG00000261159.1	RP11-723O4.9	7.39	2.94e-13	7.53e-11	0.25	0.22	IgG glycosylation;	chr3:128982023	chr3:128859716~128860526:-
BRCA	cis	rs763567	0.626	rs1234230	ENSG00000271811.1	RP1-79C4.4	-7.39	2.96e-13	7.58e-11	-0.24	-0.22	Tonsillectomy;	chr1:170602702	chr1:170667381~170669425:+
BRCA	cis	rs801193	0.569	rs2659908	ENSG00000232559.3	GS1-124K5.12	7.39	2.96e-13	7.58e-11	0.27	0.22	Aortic root size;	chr7:66695835	chr7:66554588~66576923:-
BRCA	cis	rs801193	1	rs2707856	ENSG00000237310.1	GS1-124K5.4	7.39	2.96e-13	7.58e-11	0.23	0.22	Aortic root size;	chr7:66746023	chr7:66493706~66495474:+
BRCA	cis	rs10206020	0.921	rs9678719	ENSG00000231482.2	AC141930.2	-7.39	2.96e-13	7.59e-11	-0.3	-0.22	IgG glycosylation;	chr2:1545856	chr2:1572554~1580311:-
BRCA	cis	rs78456975	0.506	rs6756310	ENSG00000231482.2	AC141930.2	-7.39	2.96e-13	7.59e-11	-0.3	-0.22	Placebo response in major depressive disorder (% change in symptom score);	chr2:1546037	chr2:1572554~1580311:-
BRCA	cis	rs301901	1	rs159913	ENSG00000250155.1	CTD-2353F22.1	-7.39	2.96e-13	7.59e-11	-0.25	-0.22	Height;	chr5:37053881	chr5:36666214~36725195:-
BRCA	cis	rs293748	0.771	rs34701667	ENSG00000250155.1	CTD-2353F22.1	-7.39	2.97e-13	7.61e-11	-0.31	-0.22	Obesity-related traits;	chr5:36799375	chr5:36666214~36725195:-
BRCA	cis	rs9880211	0.948	rs6806123	ENSG00000273486.1	RP11-731C17.2	7.39	2.98e-13	7.63e-11	0.3	0.22	Height;Body mass index;	chr3:136586634	chr3:136837338~136839021:-
BRCA	cis	rs11098499	0.604	rs10022185	ENSG00000245958.5	RP11-33B1.1	-7.39	2.98e-13	7.63e-11	-0.23	-0.22	Corneal astigmatism;	chr4:119650610	chr4:119454791~119552025:+
BRCA	cis	rs6142102	0.961	rs2235596	ENSG00000275784.1	RP5-1125A11.6	7.39	2.98e-13	7.64e-11	0.25	0.22	Skin pigmentation;	chr20:34096503	chr20:33989480~33991818:-
BRCA	cis	rs10510102	1	rs7923678	ENSG00000276742.1	RP11-500G22.4	7.39	2.99e-13	7.65e-11	0.36	0.22	Breast cancer;	chr10:121832546	chr10:121956782~121957098:+
BRCA	cis	rs2015599	0.549	rs7311081	ENSG00000257176.2	RP11-996F15.2	7.39	2.99e-13	7.66e-11	0.26	0.22	Platelet count;Mean platelet volume;	chr12:29278235	chr12:29280418~29317848:-
BRCA	cis	rs4835473	0.897	rs7657088	ENSG00000251600.4	RP11-673E1.1	-7.39	3e-13	7.68e-11	-0.27	-0.22	Immature fraction of reticulocytes;	chr4:143701877	chr4:143912331~143982454:+
BRCA	cis	rs10129255	0.536	rs10139058	ENSG00000211970.3	IGHV4-61	-7.39	3e-13	7.68e-11	-0.14	-0.22	Kawasaki disease;	chr14:106685899	chr14:106639119~106639657:-
BRCA	cis	rs7160336	0.641	rs4899503	ENSG00000259065.1	RP5-1021I20.1	7.39	3e-13	7.69e-11	0.26	0.22	Blood protein levels;	chr14:74217234	chr14:73787360~73803270:+
BRCA	cis	rs2439831	0.618	rs8023508	ENSG00000205771.5	CATSPER2P1	7.39	3e-13	7.69e-11	0.34	0.22	Lung cancer in ever smokers;	chr15:43883905	chr15:43726918~43747094:-
BRCA	cis	rs6142102	0.961	rs4911405	ENSG00000275784.1	RP5-1125A11.6	-7.39	3e-13	7.7e-11	-0.28	-0.22	Skin pigmentation;	chr20:34087161	chr20:33989480~33991818:-
BRCA	cis	rs3762637	0.941	rs7653592	ENSG00000272758.4	RP11-299J3.8	-7.39	3.01e-13	7.7e-11	-0.32	-0.22	LDL cholesterol levels;	chr3:122499524	chr3:122416207~122443180:+
BRCA	cis	rs10754283	0.967	rs10801757	ENSG00000231613.1	RP5-943J3.1	7.39	3.01e-13	7.7e-11	0.25	0.22	Amyotrophic lateral sclerosis (sporadic);	chr1:89637521	chr1:89788914~89790492:+
BRCA	cis	rs3781264	0.848	rs7099485	ENSG00000273450.1	RP11-76P2.4	7.39	3.02e-13	7.73e-11	0.28	0.22	Esophageal cancer and gastric cancer;	chr10:94305937	chr10:94314907~94315327:-
BRCA	cis	rs9880211	1	rs9869630	ENSG00000273486.1	RP11-731C17.2	7.39	3.02e-13	7.73e-11	0.29	0.22	Height;Body mass index;	chr3:136529177	chr3:136837338~136839021:-
BRCA	cis	rs4660456	0.913	rs545218	ENSG00000237899.1	RP4-739H11.3	7.39	3.02e-13	7.74e-11	0.34	0.22	Platelet count;	chr1:40675313	chr1:40669089~40687588:-
BRCA	cis	rs34779708	0.702	rs7087150	ENSG00000271335.4	RP11-324I22.4	7.39	3.02e-13	7.74e-11	0.23	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35253210	chr10:35314552~35336401:-
BRCA	cis	rs56046484	0.956	rs16974820	ENSG00000259295.5	CSPG4P12	7.39	3.02e-13	7.74e-11	0.33	0.22	Testicular germ cell tumor;	chr15:85084075	chr15:85191438~85213905:+
BRCA	cis	rs6570726	0.935	rs406343	ENSG00000235652.6	RP11-545I5.3	7.39	3.03e-13	7.77e-11	0.22	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145553252	chr6:145799409~145886585:+
BRCA	cis	rs10050311	0.79	rs61651372	ENSG00000251411.1	RP11-397E7.4	-7.39	3.04e-13	7.78e-11	-0.32	-0.22	Insulin-related traits;	chr4:86912903	chr4:86913266~86914817:-
BRCA	cis	rs7927771	0.931	rs12361256	ENSG00000280615.1	Y_RNA	-7.39	3.04e-13	7.79e-11	-0.26	-0.22	Subjective well-being;	chr11:47889271	chr11:47614898~47614994:-
BRCA	cis	rs9649213	0.574	rs7791321	ENSG00000272950.1	RP11-307C18.1	7.39	3.04e-13	7.79e-11	0.28	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98314813	chr7:98322853~98323430:+
BRCA	cis	rs61270009	0.908	rs780405	ENSG00000247828.6	TMEM161B-AS1	-7.39	3.05e-13	7.81e-11	-0.29	-0.22	Depressive symptoms;	chr5:88260522	chr5:88268895~88436685:+
BRCA	cis	rs1862618	0.511	rs2591952	ENSG00000271828.1	CTD-2310F14.1	7.39	3.05e-13	7.81e-11	0.31	0.22	Initial pursuit acceleration;	chr5:56824942	chr5:56927874~56929573:+
BRCA	cis	rs3762637	1	rs7609972	ENSG00000272758.4	RP11-299J3.8	-7.39	3.05e-13	7.81e-11	-0.31	-0.22	LDL cholesterol levels;	chr3:122480579	chr3:122416207~122443180:+
BRCA	cis	rs2243480	1	rs1964692	ENSG00000273142.1	RP11-458F8.4	-7.39	3.05e-13	7.81e-11	-0.31	-0.22	Diabetic kidney disease;	chr7:65989196	chr7:66902857~66906297:+
BRCA	cis	rs42648	0.633	rs11563909	ENSG00000225498.1	AC002064.5	7.39	3.05e-13	7.81e-11	0.21	0.22	Homocysteine levels;	chr7:90306390	chr7:90312496~90322592:+
BRCA	cis	rs6844153	0.887	rs60890366	ENSG00000240005.4	RP11-293A21.1	-7.39	3.05e-13	7.82e-11	-0.32	-0.22	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26938615	chr4:26859806~26860599:-
BRCA	cis	rs11098499	1	rs12506395	ENSG00000248280.1	RP11-33B1.2	7.39	3.06e-13	7.84e-11	0.23	0.22	Corneal astigmatism;	chr4:119263939	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.954	rs12505469	ENSG00000249244.1	RP11-548H18.2	7.39	3.06e-13	7.84e-11	0.27	0.22	Corneal astigmatism;	chr4:119328430	chr4:119391831~119395335:-
BRCA	cis	rs301901	0.581	rs292174	ENSG00000250155.1	CTD-2353F22.1	-7.39	3.07e-13	7.84e-11	-0.25	-0.22	Height;	chr5:36832039	chr5:36666214~36725195:-
BRCA	cis	rs812925	0.964	rs11125883	ENSG00000271889.1	RP11-493E12.1	7.39	3.07e-13	7.85e-11	0.29	0.22	Immature fraction of reticulocytes;	chr2:61483438	chr2:61151433~61162105:-
BRCA	cis	rs2179367	0.6	rs9498353	ENSG00000231760.4	RP11-350J20.5	7.39	3.07e-13	7.85e-11	0.33	0.22	Dupuytren's disease;	chr6:149439860	chr6:149796151~149826294:-
BRCA	cis	rs6504622	0.702	rs3851799	ENSG00000262879.4	RP11-156P1.3	-7.39	3.07e-13	7.86e-11	-0.23	-0.22	Orofacial clefts;	chr17:46989122	chr17:46984045~47100323:-
BRCA	cis	rs801193	0.527	rs2707837	ENSG00000232559.3	GS1-124K5.12	7.39	3.07e-13	7.87e-11	0.27	0.22	Aortic root size;	chr7:66716086	chr7:66554588~66576923:-
BRCA	cis	rs9649213	0.574	rs7789440	ENSG00000272950.1	RP11-307C18.1	7.39	3.07e-13	7.87e-11	0.29	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98259486	chr7:98322853~98323430:+
BRCA	cis	rs801193	0.569	rs4717315	ENSG00000232559.3	GS1-124K5.12	7.39	3.08e-13	7.88e-11	0.27	0.22	Aortic root size;	chr7:66713338	chr7:66554588~66576923:-
BRCA	cis	rs7567389	0.51	rs6755028	ENSG00000236682.1	AC068282.3	7.39	3.08e-13	7.88e-11	0.31	0.22	Self-rated health;	chr2:127437866	chr2:127389130~127400580:+
BRCA	cis	rs9649213	0.593	rs6961438	ENSG00000272950.1	RP11-307C18.1	7.39	3.09e-13	7.9e-11	0.28	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98376537	chr7:98322853~98323430:+
BRCA	cis	rs10510102	0.935	rs10887014	ENSG00000276742.1	RP11-500G22.4	7.39	3.1e-13	7.93e-11	0.38	0.22	Breast cancer;	chr10:121892322	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.872	rs11818735	ENSG00000276742.1	RP11-500G22.4	7.39	3.1e-13	7.93e-11	0.38	0.22	Breast cancer;	chr10:121892472	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.81	rs12259902	ENSG00000276742.1	RP11-500G22.4	7.39	3.1e-13	7.93e-11	0.38	0.22	Breast cancer;	chr10:121893017	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.935	rs11200228	ENSG00000276742.1	RP11-500G22.4	7.39	3.1e-13	7.93e-11	0.38	0.22	Breast cancer;	chr10:121893358	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.935	rs11200229	ENSG00000276742.1	RP11-500G22.4	7.39	3.1e-13	7.93e-11	0.38	0.22	Breast cancer;	chr10:121893519	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.935	rs10887016	ENSG00000276742.1	RP11-500G22.4	7.39	3.1e-13	7.93e-11	0.38	0.22	Breast cancer;	chr10:121893830	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.935	rs10887018	ENSG00000276742.1	RP11-500G22.4	7.39	3.1e-13	7.93e-11	0.38	0.22	Breast cancer;	chr10:121894457	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.935	rs11200230	ENSG00000276742.1	RP11-500G22.4	7.39	3.1e-13	7.93e-11	0.38	0.22	Breast cancer;	chr10:121895117	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.935	rs11200234	ENSG00000276742.1	RP11-500G22.4	7.39	3.1e-13	7.93e-11	0.38	0.22	Breast cancer;	chr10:121895851	chr10:121956782~121957098:+
BRCA	cis	rs2243480	0.808	rs12698508	ENSG00000273142.1	RP11-458F8.4	-7.39	3.1e-13	7.93e-11	-0.31	-0.22	Diabetic kidney disease;	chr7:65946971	chr7:66902857~66906297:+
BRCA	cis	rs801193	0.569	rs2707824	ENSG00000232559.3	GS1-124K5.12	7.39	3.11e-13	7.95e-11	0.27	0.22	Aortic root size;	chr7:66724256	chr7:66554588~66576923:-
BRCA	cis	rs4934494	0.813	rs12775783	ENSG00000240996.1	RP11-80H5.7	-7.39	3.11e-13	7.95e-11	-0.28	-0.22	Red blood cell count;	chr10:89646494	chr10:89694295~89697928:-
BRCA	cis	rs11098499	0.863	rs9997631	ENSG00000248280.1	RP11-33B1.2	7.39	3.11e-13	7.96e-11	0.23	0.22	Corneal astigmatism;	chr4:119548840	chr4:119440561~119450157:-
BRCA	cis	rs7674212	0.531	rs4698876	ENSG00000251288.2	RP11-10L12.2	-7.38	3.12e-13	7.97e-11	-0.27	-0.22	Type 2 diabetes;	chr4:103012410	chr4:102751401~102752641:+
BRCA	cis	rs3020264	0.579	rs2454517	ENSG00000271743.1	CTD-2541M15.3	-7.38	3.12e-13	7.99e-11	-0.32	-0.22	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 24 weeks);	chr8:6616237	chr8:6615604~6617198:-
BRCA	cis	rs2243480	1	rs1723267	ENSG00000273142.1	RP11-458F8.4	-7.38	3.12e-13	7.99e-11	-0.3	-0.22	Diabetic kidney disease;	chr7:66008327	chr7:66902857~66906297:+
BRCA	cis	rs4761702	1	rs4761702	ENSG00000257252.4	RP11-486A14.2	-7.38	3.13e-13	8e-11	-0.31	-0.22	Immature fraction of reticulocytes;	chr12:93316116	chr12:93317135~93377736:-
BRCA	cis	rs9880211	0.706	rs9289513	ENSG00000273486.1	RP11-731C17.2	7.38	3.13e-13	8.01e-11	0.3	0.22	Height;Body mass index;	chr3:136732904	chr3:136837338~136839021:-
BRCA	cis	rs858239	0.539	rs6945510	ENSG00000230042.1	AK3P3	-7.38	3.13e-13	8.01e-11	-0.26	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23152621	chr7:23129178~23129841:+
BRCA	cis	rs9649213	0.593	rs7458551	ENSG00000272950.1	RP11-307C18.1	7.38	3.14e-13	8.02e-11	0.28	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98322855	chr7:98322853~98323430:+
BRCA	cis	rs9876781	1	rs13314659	ENSG00000244380.1	RP11-24C3.2	-7.38	3.14e-13	8.02e-11	-0.26	-0.22	Longevity;	chr3:48407742	chr3:48440352~48446656:-
BRCA	cis	rs17772222	1	rs17772064	ENSG00000258983.2	RP11-507K2.2	7.38	3.15e-13	8.04e-11	0.25	0.22	Coronary artery calcification;	chr14:88356527	chr14:88499334~88515502:+
BRCA	cis	rs10510102	0.935	rs12264495	ENSG00000276742.1	RP11-500G22.4	7.38	3.15e-13	8.05e-11	0.37	0.22	Breast cancer;	chr10:121919967	chr10:121956782~121957098:+
BRCA	cis	rs42648	0.693	rs194533	ENSG00000225498.1	AC002064.5	7.38	3.15e-13	8.05e-11	0.21	0.22	Homocysteine levels;	chr7:90241463	chr7:90312496~90322592:+
BRCA	cis	rs17772222	1	rs7145588	ENSG00000258983.2	RP11-507K2.2	7.38	3.17e-13	8.09e-11	0.25	0.22	Coronary artery calcification;	chr14:88360452	chr14:88499334~88515502:+
BRCA	cis	rs858239	0.614	rs10229956	ENSG00000226816.2	AC005082.12	-7.38	3.17e-13	8.09e-11	-0.25	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23363317	chr7:23206013~23208045:+
BRCA	cis	rs17711722	0.522	rs62469933	ENSG00000228409.4	CCT6P1	-7.38	3.17e-13	8.1e-11	-0.2	-0.22	Calcium levels;	chr7:65800652	chr7:65751142~65763354:+
BRCA	cis	rs780096	0.506	rs780100	ENSG00000234072.1	AC074117.10	-7.38	3.18e-13	8.11e-11	-0.21	-0.22	Total body bone mineral density;	chr2:27429286	chr2:27356246~27367622:+
BRCA	cis	rs4927850	0.752	rs7618864	ENSG00000207650.1	MIR570	7.38	3.19e-13	8.15e-11	0.27	0.22	Pancreatic cancer;	chr3:196022690	chr3:195699401~195699497:+
BRCA	cis	rs2015599	0.517	rs7295212	ENSG00000257176.2	RP11-996F15.2	7.38	3.19e-13	8.15e-11	0.26	0.22	Platelet count;Mean platelet volume;	chr12:29278432	chr12:29280418~29317848:-
BRCA	cis	rs62355901	0.8	rs10461612	ENSG00000271828.1	CTD-2310F14.1	7.38	3.19e-13	8.15e-11	0.31	0.22	Breast cancer;	chr5:56708004	chr5:56927874~56929573:+
BRCA	cis	rs10129255	1	rs11627342	ENSG00000211972.2	IGHV3-66	7.38	3.19e-13	8.16e-11	0.18	0.22	Kawasaki disease;	chr14:106675823	chr14:106675017~106675544:-
BRCA	cis	rs7474896	0.583	rs10764144	ENSG00000226578.1	RP11-258F22.1	-7.38	3.19e-13	8.16e-11	-0.29	-0.22	Obesity (extreme);	chr10:37686804	chr10:37775371~37784131:-
BRCA	cis	rs6142102	0.812	rs6059574	ENSG00000276073.1	RP5-1125A11.7	7.38	3.2e-13	8.17e-11	0.26	0.22	Skin pigmentation;	chr20:33935366	chr20:33985617~33988989:-
BRCA	cis	rs57677839	1	rs57677839	ENSG00000184669.7	OR7E14P	-7.38	3.2e-13	8.17e-11	-0.3	-0.22	Coronary artery disease;	chr11:17006642	chr11:17013998~17053024:+
BRCA	cis	rs801193	1	rs62466793	ENSG00000224316.1	RP11-479O9.2	7.38	3.2e-13	8.18e-11	0.22	0.22	Aortic root size;	chr7:66726530	chr7:65773620~65802067:+
BRCA	cis	rs7976269	0.559	rs10843304	ENSG00000257176.2	RP11-996F15.2	-7.38	3.21e-13	8.19e-11	-0.26	-0.22	Male-pattern baldness;	chr12:29071226	chr12:29280418~29317848:-
BRCA	cis	rs11098499	0.604	rs2389887	ENSG00000245958.5	RP11-33B1.1	-7.38	3.22e-13	8.22e-11	-0.23	-0.22	Corneal astigmatism;	chr4:119649489	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.604	rs34278750	ENSG00000245958.5	RP11-33B1.1	-7.38	3.22e-13	8.22e-11	-0.23	-0.22	Corneal astigmatism;	chr4:119649981	chr4:119454791~119552025:+
BRCA	cis	rs10129255	0.957	rs8005468	ENSG00000211972.2	IGHV3-66	7.38	3.23e-13	8.24e-11	0.17	0.22	Kawasaki disease;	chr14:106686431	chr14:106675017~106675544:-
BRCA	cis	rs301901	1	rs159751	ENSG00000250155.1	CTD-2353F22.1	-7.38	3.23e-13	8.26e-11	-0.24	-0.22	Height;	chr5:36999896	chr5:36666214~36725195:-
BRCA	cis	rs4964805	0.632	rs11111782	ENSG00000257681.1	RP11-341G23.4	-7.38	3.24e-13	8.28e-11	-0.25	-0.22	Attention deficit hyperactivity disorder;	chr12:103794698	chr12:103746315~103768858:-
BRCA	cis	rs801193	1	rs1553610	ENSG00000237310.1	GS1-124K5.4	7.38	3.25e-13	8.29e-11	0.23	0.22	Aortic root size;	chr7:66732246	chr7:66493706~66495474:+
BRCA	cis	rs801193	1	rs2707845	ENSG00000237310.1	GS1-124K5.4	7.38	3.25e-13	8.29e-11	0.23	0.22	Aortic root size;	chr7:66733811	chr7:66493706~66495474:+
BRCA	cis	rs801193	1	rs2707850	ENSG00000237310.1	GS1-124K5.4	7.38	3.25e-13	8.29e-11	0.23	0.22	Aortic root size;	chr7:66738883	chr7:66493706~66495474:+
BRCA	cis	rs801193	0.967	rs1110414	ENSG00000237310.1	GS1-124K5.4	7.38	3.25e-13	8.29e-11	0.23	0.22	Aortic root size;	chr7:66740595	chr7:66493706~66495474:+
BRCA	cis	rs801193	1	rs7783924	ENSG00000237310.1	GS1-124K5.4	7.38	3.25e-13	8.29e-11	0.23	0.22	Aortic root size;	chr7:66744070	chr7:66493706~66495474:+
BRCA	cis	rs801193	1	rs7789184	ENSG00000237310.1	GS1-124K5.4	7.38	3.25e-13	8.29e-11	0.23	0.22	Aortic root size;	chr7:66745208	chr7:66493706~66495474:+
BRCA	cis	rs801193	1	rs2707854	ENSG00000237310.1	GS1-124K5.4	7.38	3.25e-13	8.29e-11	0.23	0.22	Aortic root size;	chr7:66747610	chr7:66493706~66495474:+
BRCA	cis	rs7520050	0.807	rs3013595	ENSG00000280836.1	AL355480.1	-7.38	3.25e-13	8.3e-11	-0.26	-0.22	Reticulocyte count;Red blood cell count;	chr1:45687531	chr1:45581219~45581321:-
BRCA	cis	rs9880211	1	rs28718456	ENSG00000273486.1	RP11-731C17.2	7.38	3.26e-13	8.31e-11	0.29	0.22	Height;Body mass index;	chr3:136485164	chr3:136837338~136839021:-
BRCA	cis	rs2274273	0.624	rs8014540	ENSG00000258413.1	RP11-665C16.6	-7.38	3.26e-13	8.32e-11	-0.3	-0.22	Protein biomarker;	chr14:55374970	chr14:55262767~55272075:-
BRCA	cis	rs72772090	0.71	rs17479052	ENSG00000248734.2	CTD-2260A17.1	-7.38	3.27e-13	8.34e-11	-0.36	-0.22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96729932	chr5:96784777~96785999:+
BRCA	cis	rs6504622	0.702	rs3851796	ENSG00000262879.4	RP11-156P1.3	-7.38	3.28e-13	8.35e-11	-0.23	-0.22	Orofacial clefts;	chr17:46983809	chr17:46984045~47100323:-
BRCA	cis	rs10510102	1	rs11200181	ENSG00000276742.1	RP11-500G22.4	7.38	3.28e-13	8.36e-11	0.36	0.22	Breast cancer;	chr10:121828528	chr10:121956782~121957098:+
BRCA	cis	rs6504622	0.634	rs8068715	ENSG00000262879.4	RP11-156P1.3	-7.38	3.28e-13	8.37e-11	-0.23	-0.22	Orofacial clefts;	chr17:46991022	chr17:46984045~47100323:-
BRCA	cis	rs1864400	0.696	rs2742239	ENSG00000273008.1	RP11-351D16.3	-7.38	3.28e-13	8.37e-11	-0.28	-0.22	Hirschsprung disease;	chr10:43126264	chr10:43136824~43138334:-
BRCA	cis	rs2742234	0.59	rs2075912	ENSG00000273008.1	RP11-351D16.3	-7.38	3.28e-13	8.37e-11	-0.28	-0.22	Hirschsprung disease;	chr10:43126769	chr10:43136824~43138334:-
BRCA	cis	rs7927771	0.756	rs2856661	ENSG00000280615.1	Y_RNA	7.38	3.29e-13	8.38e-11	0.28	0.22	Subjective well-being;	chr11:47353447	chr11:47614898~47614994:-
BRCA	cis	rs6570726	0.935	rs384519	ENSG00000235652.6	RP11-545I5.3	7.38	3.29e-13	8.38e-11	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145524881	chr6:145799409~145886585:+
BRCA	cis	rs9880211	0.848	rs71336069	ENSG00000273486.1	RP11-731C17.2	7.38	3.29e-13	8.38e-11	0.29	0.22	Height;Body mass index;	chr3:136633024	chr3:136837338~136839021:-
BRCA	cis	rs526231	0.578	rs17154825	ENSG00000175749.11	EIF3KP1	7.38	3.29e-13	8.38e-11	0.32	0.22	Primary biliary cholangitis;	chr5:102910365	chr5:103032376~103033031:+
BRCA	cis	rs301901	1	rs300055	ENSG00000250155.1	CTD-2353F22.1	-7.38	3.29e-13	8.39e-11	-0.24	-0.22	Height;	chr5:37072722	chr5:36666214~36725195:-
BRCA	cis	rs6504622	0.514	rs60611133	ENSG00000262879.4	RP11-156P1.3	-7.38	3.3e-13	8.41e-11	-0.23	-0.22	Orofacial clefts;	chr17:46993027	chr17:46984045~47100323:-
BRCA	cis	rs9527	0.525	rs12770034	ENSG00000213061.2	PFN1P11	7.38	3.3e-13	8.42e-11	0.29	0.22	Arsenic metabolism;	chr10:102875838	chr10:102838011~102845473:-
BRCA	cis	rs875971	0.66	rs1860470	ENSG00000224316.1	RP11-479O9.2	-7.38	3.3e-13	8.42e-11	-0.22	-0.22	Aortic root size;	chr7:66638707	chr7:65773620~65802067:+
BRCA	cis	rs9876781	1	rs1109227	ENSG00000244380.1	RP11-24C3.2	7.38	3.3e-13	8.42e-11	0.26	0.22	Longevity;	chr3:48437797	chr3:48440352~48446656:-
BRCA	cis	rs7617773	0.817	rs9847953	ENSG00000228638.1	FCF1P2	-7.38	3.31e-13	8.43e-11	-0.24	-0.22	Coronary artery disease;	chr3:48241205	chr3:48290793~48291375:-
BRCA	cis	rs875971	0.545	rs73136346	ENSG00000224316.1	RP11-479O9.2	-7.38	3.31e-13	8.44e-11	-0.26	-0.22	Aortic root size;	chr7:66101095	chr7:65773620~65802067:+
BRCA	cis	rs301901	1	rs158622	ENSG00000250155.1	CTD-2353F22.1	7.38	3.32e-13	8.47e-11	0.24	0.22	Height;	chr5:36887793	chr5:36666214~36725195:-
BRCA	cis	rs10129255	0.912	rs61997792	ENSG00000224373.3	IGHV4-59	7.38	3.33e-13	8.48e-11	0.15	0.22	Kawasaki disease;	chr14:106799304	chr14:106627249~106627825:-
BRCA	cis	rs67311347	0.544	rs2278927	ENSG00000223797.4	ENTPD3-AS1	7.38	3.33e-13	8.48e-11	0.24	0.22	Renal cell carcinoma;	chr3:40308956	chr3:40313802~40453329:-
BRCA	cis	rs34779708	0.733	rs11010146	ENSG00000271335.4	RP11-324I22.4	7.38	3.33e-13	8.5e-11	0.23	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35252633	chr10:35314552~35336401:-
BRCA	cis	rs11098499	0.575	rs9996586	ENSG00000248280.1	RP11-33B1.2	7.38	3.35e-13	8.52e-11	0.21	0.22	Corneal astigmatism;	chr4:119405787	chr4:119440561~119450157:-
BRCA	cis	rs1707322	0.827	rs6683274	ENSG00000281133.1	AL355480.3	-7.37	3.35e-13	8.53e-11	-0.29	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45775966	chr1:45580892~45580996:-
BRCA	cis	rs858239	0.571	rs2390755	ENSG00000230042.1	AK3P3	-7.37	3.35e-13	8.54e-11	-0.26	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23151097	chr7:23129178~23129841:+
BRCA	cis	rs2060793	0.519	rs7931291	ENSG00000251991.1	RNU7-49P	-7.37	3.35e-13	8.54e-11	-0.24	-0.22	Vitamin D levels;	chr11:14622880	chr11:14478892~14478953:+
BRCA	cis	rs10129255	0.5	rs6576232	ENSG00000211970.3	IGHV4-61	-7.37	3.36e-13	8.55e-11	-0.14	-0.22	Kawasaki disease;	chr14:106787090	chr14:106639119~106639657:-
BRCA	cis	rs12291225	0.753	rs1431374	ENSG00000251991.1	RNU7-49P	7.37	3.36e-13	8.55e-11	0.26	0.22	Sense of smell;	chr11:14282429	chr11:14478892~14478953:+
BRCA	cis	rs13177755	1	rs13177755	ENSG00000247828.6	TMEM161B-AS1	7.37	3.36e-13	8.56e-11	0.3	0.22	Depressive symptoms (multi-trait analysis);	chr5:88296420	chr5:88268895~88436685:+
BRCA	cis	rs61270009	0.955	rs13159835	ENSG00000247828.6	TMEM161B-AS1	7.37	3.36e-13	8.56e-11	0.3	0.22	Depressive symptoms;	chr5:88305576	chr5:88268895~88436685:+
BRCA	cis	rs12291225	0.679	rs7934671	ENSG00000251991.1	RNU7-49P	7.37	3.37e-13	8.57e-11	0.26	0.22	Sense of smell;	chr11:14283555	chr11:14478892~14478953:+
BRCA	cis	rs10985070	0.507	rs12551347	ENSG00000226752.6	PSMD5-AS1	-7.37	3.37e-13	8.58e-11	-0.26	-0.22	Rheumatoid arthritis;	chr9:121174316	chr9:120824828~120854385:+
BRCA	cis	rs9649213	0.593	rs6465666	ENSG00000272950.1	RP11-307C18.1	-7.37	3.37e-13	8.59e-11	-0.28	-0.22	Prostate cancer (SNP x SNP interaction);	chr7:98307946	chr7:98322853~98323430:+
BRCA	cis	rs780096	0.526	rs13391837	ENSG00000234072.1	AC074117.10	-7.37	3.37e-13	8.59e-11	-0.22	-0.22	Total body bone mineral density;	chr2:27426508	chr2:27356246~27367622:+
BRCA	cis	rs7809950	1	rs2520265	ENSG00000238832.1	snoU109	-7.37	3.37e-13	8.59e-11	-0.29	-0.22	Coronary artery disease;	chr7:107540786	chr7:107603363~107603507:+
BRCA	cis	rs4845875	0.626	rs12734761	ENSG00000242349.4	NPPA-AS1	7.37	3.37e-13	8.59e-11	0.24	0.22	Midregional pro atrial natriuretic peptide levels;	chr1:11774125	chr1:11841017~11848079:+
BRCA	cis	rs9880211	0.8	rs9845862	ENSG00000273486.1	RP11-731C17.2	7.37	3.39e-13	8.63e-11	0.3	0.22	Height;Body mass index;	chr3:136753731	chr3:136837338~136839021:-
BRCA	cis	rs875971	0.66	rs3764903	ENSG00000224316.1	RP11-479O9.2	-7.37	3.4e-13	8.64e-11	-0.22	-0.22	Aortic root size;	chr7:66633495	chr7:65773620~65802067:+
BRCA	cis	rs9876781	1	rs9881491	ENSG00000244380.1	RP11-24C3.2	7.37	3.4e-13	8.65e-11	0.26	0.22	Longevity;	chr3:48446507	chr3:48440352~48446656:-
BRCA	cis	rs6860806	0.531	rs272888	ENSG00000233006.5	AC034220.3	7.37	3.4e-13	8.66e-11	0.18	0.22	Breast cancer;	chr5:132329730	chr5:132311285~132369916:-
BRCA	cis	rs4835473	0.897	rs1545437	ENSG00000251600.4	RP11-673E1.1	-7.37	3.41e-13	8.68e-11	-0.27	-0.22	Immature fraction of reticulocytes;	chr4:143696689	chr4:143912331~143982454:+
BRCA	cis	rs10510102	0.935	rs12244951	ENSG00000276742.1	RP11-500G22.4	7.37	3.41e-13	8.68e-11	0.38	0.22	Breast cancer;	chr10:121896879	chr10:121956782~121957098:+
BRCA	cis	rs801193	0.967	rs2707841	ENSG00000224316.1	RP11-479O9.2	7.37	3.41e-13	8.68e-11	0.22	0.22	Aortic root size;	chr7:66692033	chr7:65773620~65802067:+
BRCA	cis	rs801193	1	rs4717310	ENSG00000224316.1	RP11-479O9.2	7.37	3.41e-13	8.68e-11	0.22	0.22	Aortic root size;	chr7:66696020	chr7:65773620~65802067:+
BRCA	cis	rs867371	0.722	rs8033050	ENSG00000259429.4	UBE2Q2P2	-7.37	3.41e-13	8.68e-11	-0.23	-0.22	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82269648	chr15:82355142~82420075:+
BRCA	cis	rs2243480	1	rs313807	ENSG00000273142.1	RP11-458F8.4	-7.37	3.41e-13	8.69e-11	-0.3	-0.22	Diabetic kidney disease;	chr7:66034494	chr7:66902857~66906297:+
BRCA	cis	rs801193	0.569	rs7782587	ENSG00000232559.3	GS1-124K5.12	7.37	3.42e-13	8.71e-11	0.27	0.22	Aortic root size;	chr7:66701485	chr7:66554588~66576923:-
BRCA	cis	rs801193	0.66	rs974239	ENSG00000232559.3	GS1-124K5.12	7.37	3.42e-13	8.72e-11	0.27	0.22	Aortic root size;	chr7:66748504	chr7:66554588~66576923:-
BRCA	cis	rs4845875	0.6	rs11805138	ENSG00000242349.4	NPPA-AS1	7.37	3.43e-13	8.73e-11	0.26	0.22	Midregional pro atrial natriuretic peptide levels;	chr1:11773102	chr1:11841017~11848079:+
BRCA	cis	rs2243480	1	rs781149	ENSG00000273142.1	RP11-458F8.4	-7.37	3.44e-13	8.76e-11	-0.3	-0.22	Diabetic kidney disease;	chr7:66016297	chr7:66902857~66906297:+
BRCA	cis	rs2243480	0.901	rs58207111	ENSG00000273142.1	RP11-458F8.4	-7.37	3.44e-13	8.76e-11	-0.3	-0.22	Diabetic kidney disease;	chr7:66021736	chr7:66902857~66906297:+
BRCA	cis	rs74233809	1	rs5011520	ENSG00000213277.3	MARCKSL1P1	7.37	3.45e-13	8.79e-11	0.41	0.22	Birth weight;	chr10:102937759	chr10:103175554~103176094:+
BRCA	cis	rs74233809	1	rs10883808	ENSG00000213277.3	MARCKSL1P1	7.37	3.45e-13	8.79e-11	0.41	0.22	Birth weight;	chr10:102961369	chr10:103175554~103176094:+
BRCA	cis	rs74233809	1	rs11191479	ENSG00000213277.3	MARCKSL1P1	7.37	3.45e-13	8.79e-11	0.41	0.22	Birth weight;	chr10:102963863	chr10:103175554~103176094:+
BRCA	cis	rs875971	0.862	rs778724	ENSG00000232559.3	GS1-124K5.12	7.37	3.47e-13	8.83e-11	0.27	0.22	Aortic root size;	chr7:66364304	chr7:66554588~66576923:-
BRCA	cis	rs6504622	0.677	rs12949446	ENSG00000262879.4	RP11-156P1.3	-7.37	3.48e-13	8.86e-11	-0.23	-0.22	Orofacial clefts;	chr17:46994311	chr17:46984045~47100323:-
BRCA	cis	rs7246657	1	rs1529957	ENSG00000276846.1	CTD-3220F14.3	7.37	3.48e-13	8.86e-11	0.31	0.22	Coronary artery calcification;	chr19:37248899	chr19:37314868~37315620:-
BRCA	cis	rs79040073	0.637	rs61259878	ENSG00000259531.2	RP11-295H24.3	7.37	3.49e-13	8.87e-11	0.37	0.22	Lung cancer in ever smokers;	chr15:49432564	chr15:49365124~49366685:-
BRCA	cis	rs7267979	0.789	rs6076347	ENSG00000274973.1	RP13-401N8.7	7.37	3.49e-13	8.88e-11	0.26	0.22	Liver enzyme levels (alkaline phosphatase);	chr20:25418154	chr20:25845497~25845862:+
BRCA	cis	rs801193	0.935	rs3800820	ENSG00000224316.1	RP11-479O9.2	-7.37	3.5e-13	8.91e-11	-0.22	-0.22	Aortic root size;	chr7:66682191	chr7:65773620~65802067:+
BRCA	cis	rs10129255	0.872	rs1858683	ENSG00000211972.2	IGHV3-66	7.37	3.51e-13	8.93e-11	0.18	0.22	Kawasaki disease;	chr14:106670217	chr14:106675017~106675544:-
BRCA	cis	rs2243480	1	rs1167613	ENSG00000273142.1	RP11-458F8.4	-7.37	3.52e-13	8.95e-11	-0.3	-0.22	Diabetic kidney disease;	chr7:66022452	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs313799	ENSG00000273142.1	RP11-458F8.4	-7.37	3.52e-13	8.95e-11	-0.3	-0.22	Diabetic kidney disease;	chr7:66029343	chr7:66902857~66906297:+
BRCA	cis	rs293748	0.771	rs159140	ENSG00000250155.1	CTD-2353F22.1	-7.37	3.52e-13	8.96e-11	-0.32	-0.22	Obesity-related traits;	chr5:36925903	chr5:36666214~36725195:-
BRCA	cis	rs801193	0.967	rs3800823	ENSG00000237310.1	GS1-124K5.4	-7.37	3.53e-13	8.97e-11	-0.23	-0.22	Aortic root size;	chr7:66682123	chr7:66493706~66495474:+
BRCA	cis	rs4761702	1	rs4761701	ENSG00000257252.4	RP11-486A14.2	-7.37	3.53e-13	8.97e-11	-0.3	-0.22	Immature fraction of reticulocytes;	chr12:93315956	chr12:93317135~93377736:-
BRCA	cis	rs61270009	0.955	rs768705	ENSG00000247828.6	TMEM161B-AS1	7.37	3.53e-13	8.98e-11	0.28	0.22	Depressive symptoms;	chr5:88272893	chr5:88268895~88436685:+
BRCA	cis	rs10129255	0.5	rs10131875	ENSG00000211970.3	IGHV4-61	-7.37	3.53e-13	8.99e-11	-0.14	-0.22	Kawasaki disease;	chr14:106792798	chr14:106639119~106639657:-
BRCA	cis	rs11098499	0.908	rs2017057	ENSG00000249244.1	RP11-548H18.2	7.37	3.54e-13	9.01e-11	0.27	0.22	Corneal astigmatism;	chr4:119336556	chr4:119391831~119395335:-
BRCA	cis	rs2248020	0.501	rs2263368	ENSG00000279684.1	RP11-755E23.2	-7.37	3.55e-13	9.04e-11	-0.27	-0.22	Insulin levels in response to oral glucose tolerance test (30 minutes);	chr11:93531514	chr11:93286629~93288903:-
BRCA	cis	rs780096	0.545	rs11695549	ENSG00000234072.1	AC074117.10	-7.37	3.56e-13	9.05e-11	-0.22	-0.22	Total body bone mineral density;	chr2:27363288	chr2:27356246~27367622:+
BRCA	cis	rs3781264	0.56	rs3765524	ENSG00000273450.1	RP11-76P2.4	7.37	3.57e-13	9.07e-11	0.29	0.22	Esophageal cancer and gastric cancer;	chr10:94298541	chr10:94314907~94315327:-
BRCA	cis	rs9527	0.571	rs12765337	ENSG00000213061.2	PFN1P11	7.37	3.57e-13	9.07e-11	0.29	0.22	Arsenic metabolism;	chr10:102875587	chr10:102838011~102845473:-
BRCA	cis	rs10129255	0.5	rs11628999	ENSG00000211970.3	IGHV4-61	-7.37	3.58e-13	9.09e-11	-0.14	-0.22	Kawasaki disease;	chr14:106800208	chr14:106639119~106639657:-
BRCA	cis	rs9649213	0.613	rs7777415	ENSG00000272950.1	RP11-307C18.1	7.37	3.58e-13	9.1e-11	0.28	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98329902	chr7:98322853~98323430:+
BRCA	cis	rs9880211	0.846	rs73230043	ENSG00000273486.1	RP11-731C17.2	7.37	3.58e-13	9.1e-11	0.29	0.22	Height;Body mass index;	chr3:136688317	chr3:136837338~136839021:-
BRCA	cis	rs301901	1	rs13176880	ENSG00000250155.1	CTD-2353F22.1	-7.37	3.58e-13	9.11e-11	-0.24	-0.22	Height;	chr5:37081780	chr5:36666214~36725195:-
BRCA	cis	rs875971	0.965	rs28682868	ENSG00000232559.3	GS1-124K5.12	-7.37	3.58e-13	9.11e-11	-0.26	-0.22	Aortic root size;	chr7:66224822	chr7:66554588~66576923:-
BRCA	cis	rs9876781	1	rs4858817	ENSG00000244380.1	RP11-24C3.2	-7.37	3.59e-13	9.13e-11	-0.25	-0.22	Longevity;	chr3:48375266	chr3:48440352~48446656:-
BRCA	cis	rs2280018	0.963	rs4985147	ENSG00000260735.1	RP11-72I8.1	-7.37	3.59e-13	9.13e-11	-0.25	-0.22	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15074903	chr16:15094411~15109197:+
BRCA	cis	rs2277027	0.541	rs56168343	ENSG00000248544.2	CTB-47B11.3	7.36	3.6e-13	9.14e-11	0.38	0.22	Pulmonary function;Pulmonary function (smoking interaction);	chr5:157501000	chr5:157375741~157384950:-
BRCA	cis	rs12701220	0.504	rs12702092	ENSG00000229043.2	AC091729.9	-7.36	3.6e-13	9.15e-11	-0.34	-0.22	Bronchopulmonary dysplasia;	chr7:1106232	chr7:1160374~1165267:+
BRCA	cis	rs875971	0.545	rs73142233	ENSG00000224316.1	RP11-479O9.2	7.36	3.61e-13	9.17e-11	0.26	0.22	Aortic root size;	chr7:66221293	chr7:65773620~65802067:+
BRCA	cis	rs2028299	0.92	rs2118847	ENSG00000259677.1	RP11-493E3.1	7.36	3.61e-13	9.18e-11	0.3	0.22	Type 2 diabetes;	chr15:89865615	chr15:89876540~89877285:+
BRCA	cis	rs2880765	0.835	rs7163958	ENSG00000259295.5	CSPG4P12	7.36	3.62e-13	9.2e-11	0.27	0.22	Coronary artery disease;	chr15:85501984	chr15:85191438~85213905:+
BRCA	cis	rs7927771	0.832	rs1542321	ENSG00000280615.1	Y_RNA	7.36	3.62e-13	9.2e-11	0.27	0.22	Subjective well-being;	chr11:47358064	chr11:47614898~47614994:-
BRCA	cis	rs4723738	1	rs4723734	ENSG00000227191.5	TRGC2	-7.36	3.64e-13	9.24e-11	-0.2	-0.22	Treatment response for severe sepsis;	chr7:38192459	chr7:38239580~38368091:-
BRCA	cis	rs4723738	1	rs10282407	ENSG00000227191.5	TRGC2	-7.36	3.64e-13	9.24e-11	-0.2	-0.22	Treatment response for severe sepsis;	chr7:38193791	chr7:38239580~38368091:-
BRCA	cis	rs6496044	0.547	rs1564719	ENSG00000259295.5	CSPG4P12	7.36	3.65e-13	9.27e-11	0.27	0.22	Interstitial lung disease;	chr15:85511035	chr15:85191438~85213905:+
BRCA	cis	rs293748	0.771	rs167146	ENSG00000250155.1	CTD-2353F22.1	-7.36	3.65e-13	9.27e-11	-0.32	-0.22	Obesity-related traits;	chr5:36922204	chr5:36666214~36725195:-
BRCA	cis	rs7809950	1	rs4730245	ENSG00000238832.1	snoU109	-7.36	3.65e-13	9.28e-11	-0.3	-0.22	Coronary artery disease;	chr7:107446849	chr7:107603363~107603507:+
BRCA	cis	rs6840258	0.547	rs4693795	ENSG00000251411.1	RP11-397E7.4	-7.36	3.66e-13	9.28e-11	-0.32	-0.22	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86946904	chr4:86913266~86914817:-
BRCA	cis	rs1275468	1	rs1795379	ENSG00000257497.2	RP11-585P4.5	-7.36	3.66e-13	9.28e-11	-0.31	-0.22	Polycystic ovary syndrome;	chr12:75547262	chr12:75483454~75489820:-
BRCA	cis	rs10463554	0.892	rs17154859	ENSG00000175749.11	EIF3KP1	-7.36	3.67e-13	9.31e-11	-0.3	-0.22	Parkinson's disease;	chr5:102955208	chr5:103032376~103033031:+
BRCA	cis	rs801193	0.935	rs2659899	ENSG00000224316.1	RP11-479O9.2	7.36	3.67e-13	9.32e-11	0.22	0.22	Aortic root size;	chr7:66721734	chr7:65773620~65802067:+
BRCA	cis	rs17772222	1	rs61977049	ENSG00000258983.2	RP11-507K2.2	7.36	3.67e-13	9.32e-11	0.25	0.22	Coronary artery calcification;	chr14:88360656	chr14:88499334~88515502:+
BRCA	cis	rs8062405	0.755	rs4787457	ENSG00000251417.2	RP11-1348G14.4	-7.36	3.67e-13	9.32e-11	-0.27	-0.22	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28544079	chr16:28802743~28817828:+
BRCA	cis	rs6545883	0.931	rs12713437	ENSG00000271889.1	RP11-493E12.1	7.36	3.67e-13	9.33e-11	0.29	0.22	Tuberculosis;	chr2:61495769	chr2:61151433~61162105:-
BRCA	cis	rs4845875	0.626	rs2004445	ENSG00000242349.4	NPPA-AS1	7.36	3.68e-13	9.33e-11	0.24	0.22	Midregional pro atrial natriuretic peptide levels;	chr1:11781309	chr1:11841017~11848079:+
BRCA	cis	rs2933343	0.553	rs789212	ENSG00000231305.3	RP11-723O4.2	7.36	3.69e-13	9.36e-11	0.25	0.22	IgG glycosylation;	chr3:128968069	chr3:128861313~128871540:-
BRCA	cis	rs858239	0.899	rs1881203	ENSG00000230042.1	AK3P3	-7.36	3.7e-13	9.38e-11	-0.26	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23253189	chr7:23129178~23129841:+
BRCA	cis	rs2599510	0.811	rs2754523	ENSG00000276334.1	AL133243.1	7.36	3.7e-13	9.4e-11	0.27	0.22	Interleukin-18 levels;	chr2:32612043	chr2:32521927~32523547:+
BRCA	cis	rs10754283	0.871	rs72712569	ENSG00000231613.1	RP5-943J3.1	-7.36	3.71e-13	9.43e-11	-0.26	-0.22	Amyotrophic lateral sclerosis (sporadic);	chr1:89660098	chr1:89788914~89790492:+
BRCA	cis	rs2742234	0.541	rs11528481	ENSG00000273008.1	RP11-351D16.3	7.36	3.72e-13	9.44e-11	0.28	0.22	Hirschsprung disease;	chr10:43242319	chr10:43136824~43138334:-
BRCA	cis	rs8062405	0.755	rs62034358	ENSG00000251417.2	RP11-1348G14.4	-7.36	3.72e-13	9.44e-11	-0.26	-0.22	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576276	chr16:28802743~28817828:+
BRCA	cis	rs8062405	0.755	rs12445823	ENSG00000251417.2	RP11-1348G14.4	-7.36	3.72e-13	9.44e-11	-0.26	-0.22	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576728	chr16:28802743~28817828:+
BRCA	cis	rs8062405	0.723	rs12445744	ENSG00000251417.2	RP11-1348G14.4	-7.36	3.72e-13	9.44e-11	-0.26	-0.22	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28577074	chr16:28802743~28817828:+
BRCA	cis	rs8062405	0.755	rs4787455	ENSG00000251417.2	RP11-1348G14.4	-7.36	3.72e-13	9.44e-11	-0.26	-0.22	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28578134	chr16:28802743~28817828:+
BRCA	cis	rs6539288	0.933	rs1822736	ENSG00000260329.1	RP11-412D9.4	7.36	3.72e-13	9.44e-11	0.25	0.22	Total body bone mineral density;	chr12:106915481	chr12:106954029~106955497:-
BRCA	cis	rs8062405	0.755	rs7193402	ENSG00000251417.2	RP11-1348G14.4	-7.36	3.72e-13	9.45e-11	-0.26	-0.22	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28574806	chr16:28802743~28817828:+
BRCA	cis	rs950169	0.58	rs2271431	ENSG00000259728.4	LINC00933	7.36	3.72e-13	9.45e-11	0.29	0.22	Schizophrenia;	chr15:84646233	chr15:84570649~84580175:+
BRCA	cis	rs4934494	0.768	rs12771413	ENSG00000240996.1	RP11-80H5.7	7.36	3.73e-13	9.47e-11	0.27	0.22	Red blood cell count;	chr10:89633010	chr10:89694295~89697928:-
BRCA	cis	rs1499614	0.522	rs13247442	ENSG00000226824.5	RP4-756H11.3	-7.36	3.74e-13	9.49e-11	-0.55	-0.22	Gout;	chr7:66723871	chr7:66654538~66669855:+
BRCA	cis	rs10510102	0.935	rs74362676	ENSG00000276742.1	RP11-500G22.4	7.36	3.74e-13	9.49e-11	0.37	0.22	Breast cancer;	chr10:121898216	chr10:121956782~121957098:+
BRCA	cis	rs950776	0.684	rs61012457	ENSG00000261762.1	RP11-650L12.2	7.36	3.75e-13	9.5e-11	0.26	0.22	Sudden cardiac arrest;	chr15:78573352	chr15:78589123~78591276:-
BRCA	cis	rs9309473	1	rs7607014	ENSG00000163016.8	ALMS1P	-7.36	3.75e-13	9.5e-11	-0.28	-0.22	Metabolite levels;	chr2:73503047	chr2:73644919~73685576:+
BRCA	cis	rs2034650	0.525	rs11790	ENSG00000223313.1	RNU6-516P	7.36	3.75e-13	9.52e-11	0.27	0.22	Interstitial lung disease;	chr15:40420538	chr15:40529570~40529673:+
BRCA	cis	rs10510102	0.872	rs78369301	ENSG00000276742.1	RP11-500G22.4	7.36	3.76e-13	9.53e-11	0.38	0.22	Breast cancer;	chr10:121858527	chr10:121956782~121957098:+
BRCA	cis	rs801193	0.967	rs2707853	ENSG00000224316.1	RP11-479O9.2	7.36	3.76e-13	9.54e-11	0.22	0.22	Aortic root size;	chr7:66749023	chr7:65773620~65802067:+
BRCA	cis	rs6558530	0.666	rs7005699	ENSG00000253982.1	CTD-2336O2.1	7.36	3.77e-13	9.56e-11	0.28	0.22	Systolic blood pressure;	chr8:1752454	chr8:1761990~1764502:-
BRCA	cis	rs42648	0.642	rs11771963	ENSG00000225498.1	AC002064.5	7.36	3.78e-13	9.59e-11	0.21	0.22	Homocysteine levels;	chr7:90258273	chr7:90312496~90322592:+
BRCA	cis	rs7674212	0.531	rs7665026	ENSG00000251288.2	RP11-10L12.2	-7.36	3.79e-13	9.61e-11	-0.27	-0.22	Type 2 diabetes;	chr4:103015491	chr4:102751401~102752641:+
BRCA	cis	rs34779708	0.733	rs12240638	ENSG00000271335.4	RP11-324I22.4	7.36	3.79e-13	9.61e-11	0.23	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35253682	chr10:35314552~35336401:-
BRCA	cis	rs7674212	0.531	rs10006474	ENSG00000251288.2	RP11-10L12.2	-7.36	3.8e-13	9.63e-11	-0.27	-0.22	Type 2 diabetes;	chr4:103006890	chr4:102751401~102752641:+
BRCA	cis	rs10206020	0.842	rs7590900	ENSG00000231482.2	AC141930.2	-7.36	3.81e-13	9.65e-11	-0.28	-0.22	IgG glycosylation;	chr2:1571130	chr2:1572554~1580311:-
BRCA	cis	rs875971	0.577	rs34888281	ENSG00000236529.1	RP13-254B10.1	-7.36	3.81e-13	9.67e-11	-0.25	-0.22	Aortic root size;	chr7:66120784	chr7:65840212~65840596:+
BRCA	cis	rs9649213	0.593	rs10953257	ENSG00000272950.1	RP11-307C18.1	-7.36	3.82e-13	9.67e-11	-0.28	-0.22	Prostate cancer (SNP x SNP interaction);	chr7:98331352	chr7:98322853~98323430:+
BRCA	cis	rs6504622	0.693	rs12952596	ENSG00000262879.4	RP11-156P1.3	-7.36	3.82e-13	9.68e-11	-0.23	-0.22	Orofacial clefts;	chr17:46994319	chr17:46984045~47100323:-
BRCA	cis	rs11976180	1	rs1320893	ENSG00000204959.4	ARHGEF34P	7.36	3.83e-13	9.7e-11	0.27	0.22	Obesity-related traits;	chr7:144055019	chr7:144272445~144286966:-
BRCA	cis	rs56046484	0.711	rs71397835	ENSG00000259295.5	CSPG4P12	7.36	3.83e-13	9.71e-11	0.42	0.22	Testicular germ cell tumor;	chr15:84987540	chr15:85191438~85213905:+
BRCA	cis	rs7085104	0.66	rs7902804	ENSG00000236937.2	PTGES3P4	7.36	3.83e-13	9.71e-11	0.29	0.22	Immature fraction of reticulocytes;Schizophrenia;	chr10:102825648	chr10:102845595~102845950:+
BRCA	cis	rs875971	0.558	rs4433015	ENSG00000236529.1	RP13-254B10.1	-7.36	3.85e-13	9.76e-11	-0.24	-0.22	Aortic root size;	chr7:66174736	chr7:65840212~65840596:+
BRCA	cis	rs801193	0.569	rs13226966	ENSG00000232559.3	GS1-124K5.12	7.36	3.85e-13	9.76e-11	0.27	0.22	Aortic root size;	chr7:66768636	chr7:66554588~66576923:-
BRCA	cis	rs9880211	0.8	rs1872239	ENSG00000239213.4	NCK1-AS1	7.36	3.85e-13	9.76e-11	0.29	0.22	Height;Body mass index;	chr3:136785069	chr3:136841726~136862054:-
BRCA	cis	rs10129255	0.518	rs8009612	ENSG00000211970.3	IGHV4-61	-7.36	3.86e-13	9.77e-11	-0.14	-0.22	Kawasaki disease;	chr14:106777510	chr14:106639119~106639657:-
BRCA	cis	rs17495987	0.871	rs73061231	ENSG00000219545.8	UMAD1	7.36	3.86e-13	9.77e-11	0.29	0.22	Tonsillectomy;	chr7:7864765	chr7:7640711~8004059:+
BRCA	cis	rs8062405	0.755	rs4149398	ENSG00000251417.2	RP11-1348G14.4	-7.36	3.86e-13	9.77e-11	-0.27	-0.22	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28597617	chr16:28802743~28817828:+
BRCA	cis	rs2243480	1	rs316331	ENSG00000273142.1	RP11-458F8.4	7.35	3.86e-13	9.78e-11	0.3	0.22	Diabetic kidney disease;	chr7:66139635	chr7:66902857~66906297:+
BRCA	cis	rs6570726	0.935	rs397418	ENSG00000235652.6	RP11-545I5.3	7.35	3.88e-13	9.82e-11	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145521226	chr6:145799409~145886585:+
BRCA	cis	rs11098499	0.913	rs67073020	ENSG00000248280.1	RP11-33B1.2	7.35	3.88e-13	9.82e-11	0.24	0.22	Corneal astigmatism;	chr4:119231402	chr4:119440561~119450157:-
BRCA	cis	rs42648	0.935	rs42627	ENSG00000225498.1	AC002064.5	7.35	3.88e-13	9.83e-11	0.22	0.22	Homocysteine levels;	chr7:90332562	chr7:90312496~90322592:+
BRCA	cis	rs2179367	0.6	rs11155654	ENSG00000231760.4	RP11-350J20.5	7.35	3.9e-13	9.87e-11	0.33	0.22	Dupuytren's disease;	chr6:149442001	chr6:149796151~149826294:-
BRCA	cis	rs4723738	1	rs6462817	ENSG00000227191.5	TRGC2	-7.35	3.9e-13	9.88e-11	-0.2	-0.22	Treatment response for severe sepsis;	chr7:38211264	chr7:38239580~38368091:-
BRCA	cis	rs301901	0.548	rs2366176	ENSG00000250155.1	CTD-2353F22.1	7.35	3.9e-13	9.88e-11	0.25	0.22	Height;	chr5:37439326	chr5:36666214~36725195:-
BRCA	cis	rs897984	0.542	rs11864839	ENSG00000260911.2	RP11-196G11.2	7.35	3.9e-13	9.88e-11	0.2	0.22	Dementia with Lewy bodies;	chr16:31083930	chr16:31043150~31049868:+
BRCA	cis	rs7976269	0.559	rs10771477	ENSG00000257176.2	RP11-996F15.2	-7.35	3.91e-13	9.91e-11	-0.26	-0.22	Male-pattern baldness;	chr12:29074137	chr12:29280418~29317848:-
BRCA	cis	rs7976269	0.559	rs10843307	ENSG00000257176.2	RP11-996F15.2	-7.35	3.91e-13	9.91e-11	-0.26	-0.22	Male-pattern baldness;	chr12:29074710	chr12:29280418~29317848:-
BRCA	cis	rs10129255	0.957	rs28887506	ENSG00000211972.2	IGHV3-66	7.35	3.94e-13	9.96e-11	0.17	0.22	Kawasaki disease;	chr14:106785589	chr14:106675017~106675544:-
BRCA	cis	rs9880211	0.706	rs67382287	ENSG00000239213.4	NCK1-AS1	7.35	3.94e-13	9.96e-11	0.3	0.22	Height;Body mass index;	chr3:136661617	chr3:136841726~136862054:-
BRCA	cis	rs2028299	0.92	rs11638138	ENSG00000259677.1	RP11-493E3.1	-7.35	3.94e-13	9.97e-11	-0.29	-0.22	Type 2 diabetes;	chr15:89885523	chr15:89876540~89877285:+
BRCA	cis	rs7189233	0.955	rs16952242	ENSG00000279344.1	RP11-44F14.7	7.35	3.95e-13	9.98e-11	0.24	0.22	Intelligence (multi-trait analysis);	chr16:53440338	chr16:53478957~53481550:-
BRCA	cis	rs9880211	0.752	rs9881831	ENSG00000239213.4	NCK1-AS1	7.35	3.95e-13	9.99e-11	0.3	0.22	Height;Body mass index;	chr3:136670876	chr3:136841726~136862054:-
BRCA	cis	rs10129255	0.828	rs10140989	ENSG00000211972.2	IGHV3-66	7.35	3.95e-13	1e-10	0.18	0.22	Kawasaki disease;	chr14:106668657	chr14:106675017~106675544:-
BRCA	cis	rs293748	0.771	rs292179	ENSG00000250155.1	CTD-2353F22.1	-7.35	3.96e-13	1e-10	-0.31	-0.22	Obesity-related traits;	chr5:36947511	chr5:36666214~36725195:-
BRCA	cis	rs2243480	1	rs35058610	ENSG00000273142.1	RP11-458F8.4	-7.35	3.96e-13	1e-10	-0.3	-0.22	Diabetic kidney disease;	chr7:65925938	chr7:66902857~66906297:+
BRCA	cis	rs74233809	0.901	rs12416331	ENSG00000213277.3	MARCKSL1P1	7.35	3.96e-13	1e-10	0.43	0.22	Birth weight;	chr10:103169157	chr10:103175554~103176094:+
BRCA	cis	rs8062405	0.723	rs62031562	ENSG00000251417.2	RP11-1348G14.4	-7.35	3.97e-13	1e-10	-0.27	-0.22	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28598008	chr16:28802743~28817828:+
BRCA	cis	rs1862618	0.802	rs986049	ENSG00000271828.1	CTD-2310F14.1	7.35	3.98e-13	1.01e-10	0.31	0.22	Initial pursuit acceleration;	chr5:56814406	chr5:56927874~56929573:+
BRCA	cis	rs34779708	0.733	rs60553075	ENSG00000271335.4	RP11-324I22.4	7.35	3.99e-13	1.01e-10	0.23	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35253534	chr10:35314552~35336401:-
BRCA	cis	rs3762637	0.943	rs72960447	ENSG00000272758.4	RP11-299J3.8	-7.35	4e-13	1.01e-10	-0.31	-0.22	LDL cholesterol levels;	chr3:122516258	chr3:122416207~122443180:+
BRCA	cis	rs950173	1	rs6716901	ENSG00000228389.1	AC068039.4	7.35	4e-13	1.01e-10	0.43	0.22	Hippocampal volume;	chr2:171816943	chr2:171773482~171775844:+
BRCA	cis	rs61270009	0.913	rs13190179	ENSG00000247828.6	TMEM161B-AS1	7.35	4.01e-13	1.01e-10	0.3	0.22	Depressive symptoms;	chr5:88314755	chr5:88268895~88436685:+
BRCA	cis	rs61270009	0.955	rs11738675	ENSG00000247828.6	TMEM161B-AS1	7.35	4.01e-13	1.01e-10	0.3	0.22	Depressive symptoms;	chr5:88315360	chr5:88268895~88436685:+
BRCA	cis	rs61270009	0.955	rs60331678	ENSG00000247828.6	TMEM161B-AS1	7.35	4.01e-13	1.01e-10	0.3	0.22	Depressive symptoms;	chr5:88315547	chr5:88268895~88436685:+
BRCA	cis	rs61270009	0.955	rs10462333	ENSG00000247828.6	TMEM161B-AS1	7.35	4.01e-13	1.01e-10	0.3	0.22	Depressive symptoms;	chr5:88315871	chr5:88268895~88436685:+
BRCA	cis	rs61270009	0.955	rs6872897	ENSG00000247828.6	TMEM161B-AS1	7.35	4.01e-13	1.01e-10	0.3	0.22	Depressive symptoms;	chr5:88322248	chr5:88268895~88436685:+
BRCA	cis	rs61270009	0.908	rs16903077	ENSG00000247828.6	TMEM161B-AS1	7.35	4.01e-13	1.01e-10	0.3	0.22	Depressive symptoms;	chr5:88323008	chr5:88268895~88436685:+
BRCA	cis	rs9649213	0.593	rs12728	ENSG00000272950.1	RP11-307C18.1	7.35	4.01e-13	1.01e-10	0.28	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98293539	chr7:98322853~98323430:+
BRCA	cis	rs9649213	0.593	rs6948540	ENSG00000272950.1	RP11-307C18.1	7.35	4.02e-13	1.02e-10	0.28	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98330754	chr7:98322853~98323430:+
BRCA	cis	rs9649213	0.555	rs6955259	ENSG00000272950.1	RP11-307C18.1	7.35	4.03e-13	1.02e-10	0.29	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98263044	chr7:98322853~98323430:+
BRCA	cis	rs2348418	0.767	rs1478332	ENSG00000247934.4	RP11-967K21.1	-7.35	4.05e-13	1.02e-10	-0.25	-0.22	Lung function (FEV1);Lung function (FVC);	chr12:28255432	chr12:28163298~28190738:-
BRCA	cis	rs6545883	0.931	rs9807965	ENSG00000271889.1	RP11-493E12.1	7.35	4.07e-13	1.03e-10	0.28	0.22	Tuberculosis;	chr2:61505024	chr2:61151433~61162105:-
BRCA	cis	rs2243480	1	rs35432774	ENSG00000273142.1	RP11-458F8.4	-7.35	4.08e-13	1.03e-10	-0.3	-0.22	Diabetic kidney disease;	chr7:65928032	chr7:66902857~66906297:+
BRCA	cis	rs473651	0.935	rs558924	ENSG00000229915.1	AC016999.2	-7.35	4.08e-13	1.03e-10	-0.31	-0.22	Multiple system atrophy;	chr2:238430870	chr2:238427077~238427729:-
BRCA	cis	rs638893	0.578	rs582200	ENSG00000278376.1	RP11-158I9.8	7.35	4.08e-13	1.03e-10	0.32	0.22	Vitiligo;	chr11:118798199	chr11:118791254~118793137:+
BRCA	cis	rs3758911	0.894	rs11212162	ENSG00000255353.1	RP11-382M14.1	-7.35	4.09e-13	1.03e-10	-0.29	-0.22	Coronary artery disease;	chr11:107327884	chr11:107176286~107177530:+
BRCA	cis	rs6762	0.748	rs1130663	ENSG00000279672.1	CMB9-55F22.1	7.35	4.09e-13	1.03e-10	0.25	0.22	Mean platelet volume;	chr11:837582	chr11:779617~780755:+
BRCA	cis	rs6543140	0.89	rs61122764	ENSG00000234389.1	AC007278.3	7.35	4.09e-13	1.03e-10	0.22	0.22	Blood protein levels;	chr2:102383060	chr2:102438713~102440475:+
BRCA	cis	rs9649213	0.593	rs35535338	ENSG00000272950.1	RP11-307C18.1	7.35	4.09e-13	1.03e-10	0.28	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98333007	chr7:98322853~98323430:+
BRCA	cis	rs780094	0.564	rs4665978	ENSG00000234072.1	AC074117.10	-7.35	4.1e-13	1.04e-10	-0.22	-0.22	Urate levels in overweight individuals;C-reactive protein;Metabolic syndrome;Red blood cell count;Renal underexcretion gout;Nonalcoholic fatty liver disease;Age-related diseases, mortality and associated endophenotypes;Crohn's disease;Calcium levels;Fasting plasma glucose;Metabolic traits;Fasting blood glucose;Fasting blood insulin;Urate levels in obese individuals;Alcohol consumption (drinks per week);Height;Urate levels;Gondoic acid (20:1n-9) levels;Uric acid levels;Age-related disease endophenotypes;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Homeostasis model assessment of insulin resistance;Alcohol consumption;Fasting blood insulin (BMI interaction);Triglycerides;Fasting blood glucose (BMI interaction);Hypertriglyceridemia;LDL cholesterol;Type 2 diabetes;Triglyceride levels;	chr2:27425859	chr2:27356246~27367622:+
BRCA	cis	rs42648	0.902	rs17874789	ENSG00000225498.1	AC002064.5	-7.35	4.12e-13	1.04e-10	-0.21	-0.22	Homocysteine levels;	chr7:90371846	chr7:90312496~90322592:+
BRCA	cis	rs801193	0.967	rs2420827	ENSG00000237310.1	GS1-124K5.4	-7.35	4.12e-13	1.04e-10	-0.23	-0.22	Aortic root size;	chr7:66682114	chr7:66493706~66495474:+
BRCA	cis	rs11976180	1	rs2961144	ENSG00000204959.4	ARHGEF34P	-7.35	4.13e-13	1.04e-10	-0.27	-0.22	Obesity-related traits;	chr7:144050777	chr7:144272445~144286966:-
BRCA	cis	rs7085104	0.632	rs7096475	ENSG00000236937.2	PTGES3P4	7.35	4.14e-13	1.04e-10	0.28	0.22	Immature fraction of reticulocytes;Schizophrenia;	chr10:102849919	chr10:102845595~102845950:+
BRCA	cis	rs3758911	0.796	rs56753250	ENSG00000255353.1	RP11-382M14.1	-7.34	4.15e-13	1.05e-10	-0.3	-0.22	Coronary artery disease;	chr11:107338499	chr11:107176286~107177530:+
BRCA	cis	rs11098499	0.955	rs11931312	ENSG00000248280.1	RP11-33B1.2	7.34	4.16e-13	1.05e-10	0.23	0.22	Corneal astigmatism;	chr4:119237868	chr4:119440561~119450157:-
BRCA	cis	rs801193	1	rs2659889	ENSG00000224316.1	RP11-479O9.2	7.34	4.17e-13	1.05e-10	0.22	0.22	Aortic root size;	chr7:66752125	chr7:65773620~65802067:+
BRCA	cis	rs11098499	1	rs6849889	ENSG00000248280.1	RP11-33B1.2	7.34	4.17e-13	1.05e-10	0.23	0.22	Corneal astigmatism;	chr4:119265193	chr4:119440561~119450157:-
BRCA	cis	rs4845875	0.602	rs2001584	ENSG00000242349.4	NPPA-AS1	7.34	4.18e-13	1.06e-10	0.24	0.22	Midregional pro atrial natriuretic peptide levels;	chr1:11781294	chr1:11841017~11848079:+
BRCA	cis	rs875971	0.965	rs7794930	ENSG00000232559.3	GS1-124K5.12	-7.34	4.19e-13	1.06e-10	-0.26	-0.22	Aortic root size;	chr7:66313559	chr7:66554588~66576923:-
BRCA	cis	rs2239557	1	rs7157566	ENSG00000259065.1	RP5-1021I20.1	7.34	4.19e-13	1.06e-10	0.25	0.22	Common traits (Other);	chr14:74182426	chr14:73787360~73803270:+
BRCA	cis	rs6570726	0.902	rs373321	ENSG00000235652.6	RP11-545I5.3	7.34	4.19e-13	1.06e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145533014	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.967	rs374728	ENSG00000235652.6	RP11-545I5.3	7.34	4.19e-13	1.06e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145533462	chr6:145799409~145886585:+
BRCA	cis	rs34779708	0.702	rs35969476	ENSG00000271335.4	RP11-324I22.4	7.34	4.19e-13	1.06e-10	0.23	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35255390	chr10:35314552~35336401:-
BRCA	cis	rs74233809	1	rs12220743	ENSG00000213277.3	MARCKSL1P1	7.34	4.2e-13	1.06e-10	0.41	0.22	Birth weight;	chr10:103092155	chr10:103175554~103176094:+
BRCA	cis	rs2243480	1	rs12698509	ENSG00000273142.1	RP11-458F8.4	-7.34	4.2e-13	1.06e-10	-0.29	-0.22	Diabetic kidney disease;	chr7:65953889	chr7:66902857~66906297:+
BRCA	cis	rs10510102	0.935	rs7907871	ENSG00000276742.1	RP11-500G22.4	7.34	4.2e-13	1.06e-10	0.37	0.22	Breast cancer;	chr10:121878185	chr10:121956782~121957098:+
BRCA	cis	rs72772090	0.71	rs11739280	ENSG00000248734.2	CTD-2260A17.1	7.34	4.21e-13	1.06e-10	0.35	0.22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96738443	chr5:96784777~96785999:+
BRCA	cis	rs34779708	0.733	rs7083266	ENSG00000271335.4	RP11-324I22.4	7.34	4.21e-13	1.06e-10	0.23	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35252704	chr10:35314552~35336401:-
BRCA	cis	rs875971	0.543	rs801191	ENSG00000236529.1	RP13-254B10.1	-7.34	4.21e-13	1.06e-10	-0.24	-0.22	Aortic root size;	chr7:66567968	chr7:65840212~65840596:+
BRCA	cis	rs9876781	1	rs13091785	ENSG00000244380.1	RP11-24C3.2	7.34	4.21e-13	1.06e-10	0.26	0.22	Longevity;	chr3:48452692	chr3:48440352~48446656:-
BRCA	cis	rs2243480	0.831	rs7806717	ENSG00000273142.1	RP11-458F8.4	7.34	4.21e-13	1.06e-10	0.3	0.22	Diabetic kidney disease;	chr7:65928187	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs34933526	ENSG00000273142.1	RP11-458F8.4	-7.34	4.21e-13	1.06e-10	-0.3	-0.22	Diabetic kidney disease;	chr7:65918212	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs6949812	ENSG00000273142.1	RP11-458F8.4	-7.34	4.21e-13	1.06e-10	-0.3	-0.22	Diabetic kidney disease;	chr7:65922114	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs6970243	ENSG00000273142.1	RP11-458F8.4	-7.34	4.21e-13	1.06e-10	-0.3	-0.22	Diabetic kidney disease;	chr7:65923503	chr7:66902857~66906297:+
BRCA	cis	rs2243480	0.708	rs35310401	ENSG00000273142.1	RP11-458F8.4	-7.34	4.21e-13	1.06e-10	-0.3	-0.22	Diabetic kidney disease;	chr7:65925372	chr7:66902857~66906297:+
BRCA	cis	rs1555322	0.505	rs639763	ENSG00000261582.1	RP4-614O4.11	-7.34	4.23e-13	1.07e-10	-0.26	-0.22	Attention deficit hyperactivity disorder;	chr20:35274101	chr20:35267885~35280043:-
BRCA	cis	rs17711722	0.522	rs6957759	ENSG00000228409.4	CCT6P1	-7.34	4.23e-13	1.07e-10	-0.2	-0.22	Calcium levels;	chr7:65806798	chr7:65751142~65763354:+
BRCA	cis	rs12291225	0.679	rs10832240	ENSG00000251991.1	RNU7-49P	7.34	4.23e-13	1.07e-10	0.26	0.22	Sense of smell;	chr11:14283198	chr11:14478892~14478953:+
BRCA	cis	rs13068223	0.967	rs344035	ENSG00000243926.1	TIPARP-AS1	-7.34	4.24e-13	1.07e-10	-0.23	-0.22	Age-related hearing impairment (SNP x SNP interaction);	chr3:156743490	chr3:156671862~156674378:-
BRCA	cis	rs6543140	0.964	rs6736135	ENSG00000234389.1	AC007278.3	7.34	4.24e-13	1.07e-10	0.22	0.22	Blood protein levels;	chr2:102448464	chr2:102438713~102440475:+
BRCA	cis	rs6570726	0.905	rs430248	ENSG00000235652.6	RP11-545I5.3	7.34	4.24e-13	1.07e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145552968	chr6:145799409~145886585:+
BRCA	cis	rs9880211	1	rs12695645	ENSG00000273486.1	RP11-731C17.2	7.34	4.25e-13	1.07e-10	0.29	0.22	Height;Body mass index;	chr3:136272039	chr3:136837338~136839021:-
BRCA	cis	rs6545883	0.868	rs2441381	ENSG00000271889.1	RP11-493E12.1	7.34	4.25e-13	1.07e-10	0.29	0.22	Tuberculosis;	chr2:61571694	chr2:61151433~61162105:-
BRCA	cis	rs801193	0.569	rs11761542	ENSG00000232559.3	GS1-124K5.12	7.34	4.27e-13	1.08e-10	0.27	0.22	Aortic root size;	chr7:66753209	chr7:66554588~66576923:-
BRCA	cis	rs755249	0.958	rs61781370	ENSG00000228060.1	RP11-69E11.8	-7.34	4.27e-13	1.08e-10	-0.27	-0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39579628	chr1:39565160~39573203:+
BRCA	cis	rs11159086	1	rs17100451	ENSG00000259005.1	RP3-449M8.6	7.34	4.27e-13	1.08e-10	0.36	0.22	Advanced glycation end-product levels;	chr14:74476210	chr14:74474007~74474864:-
BRCA	cis	rs812925	0.855	rs6545851	ENSG00000271889.1	RP11-493E12.1	-7.34	4.27e-13	1.08e-10	-0.29	-0.22	Immature fraction of reticulocytes;	chr2:61271222	chr2:61151433~61162105:-
BRCA	cis	rs301901	0.965	rs159749	ENSG00000250155.1	CTD-2353F22.1	-7.34	4.27e-13	1.08e-10	-0.24	-0.22	Height;	chr5:36968438	chr5:36666214~36725195:-
BRCA	cis	rs73173548	0.502	rs13165428	ENSG00000247828.6	TMEM161B-AS1	-7.34	4.28e-13	1.08e-10	-0.29	-0.22	Macular telangiectasia type 2;	chr5:88443945	chr5:88268895~88436685:+
BRCA	cis	rs875971	0.862	rs709596	ENSG00000232559.3	GS1-124K5.12	7.34	4.28e-13	1.08e-10	0.27	0.22	Aortic root size;	chr7:66360926	chr7:66554588~66576923:-
BRCA	cis	rs2243480	1	rs34970380	ENSG00000273142.1	RP11-458F8.4	-7.34	4.28e-13	1.08e-10	-0.3	-0.22	Diabetic kidney disease;	chr7:65966506	chr7:66902857~66906297:+
BRCA	cis	rs10463554	0.824	rs60588319	ENSG00000175749.11	EIF3KP1	7.34	4.3e-13	1.08e-10	0.32	0.22	Parkinson's disease;	chr5:102988656	chr5:103032376~103033031:+
BRCA	cis	rs2243480	0.901	rs35087093	ENSG00000273142.1	RP11-458F8.4	-7.34	4.31e-13	1.09e-10	-0.3	-0.22	Diabetic kidney disease;	chr7:65940221	chr7:66902857~66906297:+
BRCA	cis	rs780094	0.544	rs2303370	ENSG00000234072.1	AC074117.10	-7.34	4.31e-13	1.09e-10	-0.22	-0.22	Urate levels in overweight individuals;C-reactive protein;Metabolic syndrome;Red blood cell count;Renal underexcretion gout;Nonalcoholic fatty liver disease;Age-related diseases, mortality and associated endophenotypes;Crohn's disease;Calcium levels;Fasting plasma glucose;Metabolic traits;Fasting blood glucose;Fasting blood insulin;Urate levels in obese individuals;Alcohol consumption (drinks per week);Height;Urate levels;Gondoic acid (20:1n-9) levels;Uric acid levels;Age-related disease endophenotypes;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Homeostasis model assessment of insulin resistance;Alcohol consumption;Fasting blood insulin (BMI interaction);Triglycerides;Fasting blood glucose (BMI interaction);Hypertriglyceridemia;LDL cholesterol;Type 2 diabetes;Triglyceride levels;	chr2:27428508	chr2:27356246~27367622:+
BRCA	cis	rs61270009	0.955	rs10462472	ENSG00000247828.6	TMEM161B-AS1	7.34	4.32e-13	1.09e-10	0.3	0.22	Depressive symptoms;	chr5:88346652	chr5:88268895~88436685:+
BRCA	cis	rs34779708	0.733	rs59287215	ENSG00000271335.4	RP11-324I22.4	7.34	4.34e-13	1.09e-10	0.23	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35255066	chr10:35314552~35336401:-
BRCA	cis	rs8062405	0.755	rs4788080	ENSG00000251417.2	RP11-1348G14.4	-7.34	4.35e-13	1.1e-10	-0.27	-0.22	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28546760	chr16:28802743~28817828:+
BRCA	cis	rs8062405	0.755	rs4787456	ENSG00000251417.2	RP11-1348G14.4	-7.34	4.35e-13	1.1e-10	-0.27	-0.22	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548252	chr16:28802743~28817828:+
BRCA	cis	rs8062405	0.755	rs4788078	ENSG00000251417.2	RP11-1348G14.4	-7.34	4.35e-13	1.1e-10	-0.27	-0.22	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548660	chr16:28802743~28817828:+
BRCA	cis	rs8062405	0.723	rs762633	ENSG00000251417.2	RP11-1348G14.4	-7.34	4.38e-13	1.1e-10	-0.27	-0.22	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28597020	chr16:28802743~28817828:+
BRCA	cis	rs6472827	0.953	rs6472828	ENSG00000253983.2	RP1-16A9.1	-7.34	4.39e-13	1.1e-10	-0.34	-0.22	Uterine fibroids;	chr8:74210961	chr8:74199396~74208441:+
BRCA	cis	rs17818399	0.708	rs13000706	ENSG00000279254.1	RP11-536C12.1	-7.34	4.39e-13	1.1e-10	-0.26	-0.22	Height;	chr2:46611108	chr2:46668870~46670778:+
BRCA	cis	rs9880211	0.948	rs13316214	ENSG00000273486.1	RP11-731C17.2	7.34	4.39e-13	1.11e-10	0.29	0.22	Height;Body mass index;	chr3:136439379	chr3:136837338~136839021:-
BRCA	cis	rs1555322	0.53	rs6060341	ENSG00000279253.1	RP4-614O4.13	7.34	4.4e-13	1.11e-10	0.29	0.22	Attention deficit hyperactivity disorder;	chr20:35275830	chr20:35262727~35264187:-
BRCA	cis	rs6750795	0.502	rs11685196	ENSG00000223198.1	RNU2-22P	-7.34	4.41e-13	1.11e-10	-0.26	-0.22	Height;	chr2:231516587	chr2:231501990~231502201:-
BRCA	cis	rs10510102	0.872	rs11200261	ENSG00000276742.1	RP11-500G22.4	7.34	4.41e-13	1.11e-10	0.37	0.22	Breast cancer;	chr10:121921133	chr10:121956782~121957098:+
BRCA	cis	rs7927771	0.832	rs10838699	ENSG00000280615.1	Y_RNA	7.34	4.42e-13	1.11e-10	0.26	0.22	Subjective well-being;	chr11:47364522	chr11:47614898~47614994:-
BRCA	cis	rs10740039	0.883	rs10994446	ENSG00000254271.1	RP11-131N11.4	7.34	4.42e-13	1.11e-10	0.29	0.22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60639433	chr10:60734342~60741828:+
BRCA	cis	rs2179367	0.632	rs9485389	ENSG00000231760.4	RP11-350J20.5	-7.34	4.43e-13	1.11e-10	-0.32	-0.22	Dupuytren's disease;	chr6:149420078	chr6:149796151~149826294:-
BRCA	cis	rs1322639	1	rs1322639	ENSG00000261039.2	RP11-417E7.2	7.34	4.43e-13	1.12e-10	0.23	0.22	Pulse pressure;	chr6:169187008	chr6:169175304~169182740:-
BRCA	cis	rs911555	0.723	rs56227024	ENSG00000244691.1	RPL10AP1	7.34	4.43e-13	1.12e-10	0.28	0.22	Intelligence (multi-trait analysis);	chr14:103395369	chr14:103412119~103412761:-
BRCA	cis	rs3781264	0.595	rs12220125	ENSG00000273450.1	RP11-76P2.4	7.34	4.44e-13	1.12e-10	0.3	0.22	Esophageal cancer and gastric cancer;	chr10:94315182	chr10:94314907~94315327:-
BRCA	cis	rs42648	0.837	rs4728879	ENSG00000225498.1	AC002064.5	7.34	4.45e-13	1.12e-10	0.21	0.22	Homocysteine levels;	chr7:90294923	chr7:90312496~90322592:+
BRCA	cis	rs875971	0.52	rs160645	ENSG00000224316.1	RP11-479O9.2	-7.33	4.45e-13	1.12e-10	-0.26	-0.22	Aortic root size;	chr7:66091320	chr7:65773620~65802067:+
BRCA	cis	rs9649213	0.574	rs3801251	ENSG00000272950.1	RP11-307C18.1	7.33	4.47e-13	1.12e-10	0.28	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98398306	chr7:98322853~98323430:+
BRCA	cis	rs9649213	0.593	rs3779193	ENSG00000272950.1	RP11-307C18.1	7.33	4.47e-13	1.12e-10	0.28	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98399154	chr7:98322853~98323430:+
BRCA	cis	rs9649213	0.593	rs12704989	ENSG00000272950.1	RP11-307C18.1	7.33	4.47e-13	1.12e-10	0.28	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98400126	chr7:98322853~98323430:+
BRCA	cis	rs11098499	0.913	rs35271032	ENSG00000248280.1	RP11-33B1.2	7.33	4.47e-13	1.12e-10	0.23	0.22	Corneal astigmatism;	chr4:119235504	chr4:119440561~119450157:-
BRCA	cis	rs10027350	0.765	rs6838393	ENSG00000281501.1	SEPSECS-AS1	7.33	4.48e-13	1.13e-10	0.27	0.22	Childhood ear infection;	chr4:25172629	chr4:25160641~25201440:+
BRCA	cis	rs2439831	0.85	rs8032649	ENSG00000275601.1	AC011330.13	7.33	4.48e-13	1.13e-10	0.36	0.22	Lung cancer in ever smokers;	chr15:43842724	chr15:43642389~43643023:-
BRCA	cis	rs858239	1	rs858239	ENSG00000230042.1	AK3P3	-7.33	4.48e-13	1.13e-10	-0.26	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23246696	chr7:23129178~23129841:+
BRCA	cis	rs72772090	0.71	rs17400741	ENSG00000248734.2	CTD-2260A17.1	-7.33	4.48e-13	1.13e-10	-0.36	-0.22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96730872	chr5:96784777~96785999:+
BRCA	cis	rs875971	0.545	rs1638735	ENSG00000222364.1	RNU6-96P	-7.33	4.49e-13	1.13e-10	-0.29	-0.22	Aortic root size;	chr7:66630751	chr7:66395191~66395286:+
BRCA	cis	rs12291225	0.679	rs11023178	ENSG00000251991.1	RNU7-49P	7.33	4.49e-13	1.13e-10	0.26	0.22	Sense of smell;	chr11:14288736	chr11:14478892~14478953:+
BRCA	cis	rs8100891	0.734	rs741445	ENSG00000267213.4	AC007773.2	-7.33	4.5e-13	1.13e-10	-0.26	-0.22	Neuroticism;	chr19:32345686	chr19:32390050~32405560:-
BRCA	cis	rs56046484	0.956	rs34345801	ENSG00000259295.5	CSPG4P12	7.33	4.51e-13	1.13e-10	0.33	0.22	Testicular germ cell tumor;	chr15:85101842	chr15:85191438~85213905:+
BRCA	cis	rs6558530	0.653	rs6984632	ENSG00000253982.1	CTD-2336O2.1	7.33	4.52e-13	1.14e-10	0.28	0.22	Systolic blood pressure;	chr8:1752268	chr8:1761990~1764502:-
BRCA	cis	rs801193	0.66	rs1016265	ENSG00000232559.3	GS1-124K5.12	7.33	4.52e-13	1.14e-10	0.26	0.22	Aortic root size;	chr7:66749580	chr7:66554588~66576923:-
BRCA	cis	rs801193	0.66	rs4610622	ENSG00000232559.3	GS1-124K5.12	7.33	4.52e-13	1.14e-10	0.26	0.22	Aortic root size;	chr7:66759510	chr7:66554588~66576923:-
BRCA	cis	rs2243480	1	rs35396113	ENSG00000273142.1	RP11-458F8.4	-7.33	4.52e-13	1.14e-10	-0.3	-0.22	Diabetic kidney disease;	chr7:66030474	chr7:66902857~66906297:+
BRCA	cis	rs301901	1	rs300060	ENSG00000250155.1	CTD-2353F22.1	-7.33	4.54e-13	1.14e-10	-0.24	-0.22	Height;	chr5:37019252	chr5:36666214~36725195:-
BRCA	cis	rs516805	0.961	rs544099	ENSG00000279114.1	RP3-425C14.5	7.33	4.54e-13	1.14e-10	0.23	0.22	Lymphocyte counts;	chr6:122479837	chr6:122471923~122484161:+
BRCA	cis	rs6570726	0.935	rs380433	ENSG00000235652.6	RP11-545I5.3	7.33	4.56e-13	1.15e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145538465	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.935	rs367643	ENSG00000235652.6	RP11-545I5.3	7.33	4.56e-13	1.15e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145538466	chr6:145799409~145886585:+
BRCA	cis	rs875971	0.964	rs697969	ENSG00000232559.3	GS1-124K5.12	-7.33	4.56e-13	1.15e-10	-0.27	-0.22	Aortic root size;	chr7:66093491	chr7:66554588~66576923:-
BRCA	cis	rs875971	1	rs1182882	ENSG00000232559.3	GS1-124K5.12	-7.33	4.56e-13	1.15e-10	-0.27	-0.22	Aortic root size;	chr7:66097076	chr7:66554588~66576923:-
BRCA	cis	rs1555322	0.53	rs6060341	ENSG00000261582.1	RP4-614O4.11	7.33	4.57e-13	1.15e-10	0.24	0.22	Attention deficit hyperactivity disorder;	chr20:35275830	chr20:35267885~35280043:-
BRCA	cis	rs7809950	0.954	rs2520241	ENSG00000238832.1	snoU109	-7.33	4.58e-13	1.15e-10	-0.29	-0.22	Coronary artery disease;	chr7:107494998	chr7:107603363~107603507:+
BRCA	cis	rs10129255	0.5	rs6576225	ENSG00000211970.3	IGHV4-61	-7.33	4.59e-13	1.15e-10	-0.14	-0.22	Kawasaki disease;	chr14:106778120	chr14:106639119~106639657:-
BRCA	cis	rs10129255	0.5	rs6576226	ENSG00000211970.3	IGHV4-61	-7.33	4.59e-13	1.15e-10	-0.14	-0.22	Kawasaki disease;	chr14:106778135	chr14:106639119~106639657:-
BRCA	cis	rs13315649	0.614	rs7609765	ENSG00000242551.2	POU5F1P6	-7.33	4.6e-13	1.15e-10	-0.31	-0.22	Sum eosinophil basophil counts;	chr3:128688295	chr3:128674735~128677005:-
BRCA	cis	rs10463554	0.892	rs10463988	ENSG00000175749.11	EIF3KP1	7.33	4.6e-13	1.15e-10	0.31	0.22	Parkinson's disease;	chr5:102913595	chr5:103032376~103033031:+
BRCA	cis	rs301901	1	rs296962	ENSG00000250155.1	CTD-2353F22.1	-7.33	4.62e-13	1.16e-10	-0.24	-0.22	Height;	chr5:36990381	chr5:36666214~36725195:-
BRCA	cis	rs9649213	0.593	rs62478177	ENSG00000272950.1	RP11-307C18.1	7.33	4.66e-13	1.17e-10	0.28	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98335299	chr7:98322853~98323430:+
BRCA	cis	rs9309473	1	rs7564890	ENSG00000163016.8	ALMS1P	7.33	4.66e-13	1.17e-10	0.28	0.22	Metabolite levels;	chr2:73414725	chr2:73644919~73685576:+
BRCA	cis	rs34779708	0.733	rs7086715	ENSG00000271335.4	RP11-324I22.4	7.33	4.67e-13	1.17e-10	0.23	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35252912	chr10:35314552~35336401:-
BRCA	cis	rs2880765	0.835	rs7162502	ENSG00000259295.5	CSPG4P12	7.33	4.68e-13	1.17e-10	0.27	0.22	Coronary artery disease;	chr15:85501242	chr15:85191438~85213905:+
BRCA	cis	rs2880765	0.835	rs12910373	ENSG00000259295.5	CSPG4P12	7.33	4.68e-13	1.17e-10	0.27	0.22	Coronary artery disease;	chr15:85503571	chr15:85191438~85213905:+
BRCA	cis	rs10740039	0.883	rs7902632	ENSG00000254271.1	RP11-131N11.4	7.33	4.68e-13	1.18e-10	0.29	0.22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60643811	chr10:60734342~60741828:+
BRCA	cis	rs10463554	0.889	rs246911	ENSG00000175749.11	EIF3KP1	7.33	4.69e-13	1.18e-10	0.31	0.22	Parkinson's disease;	chr5:103227502	chr5:103032376~103033031:+
BRCA	cis	rs34779708	0.733	rs16935945	ENSG00000271335.4	RP11-324I22.4	7.33	4.69e-13	1.18e-10	0.23	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35251392	chr10:35314552~35336401:-
BRCA	cis	rs34779708	0.733	rs12777960	ENSG00000271335.4	RP11-324I22.4	7.33	4.69e-13	1.18e-10	0.23	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35252098	chr10:35314552~35336401:-
BRCA	cis	rs9601248	0.841	rs9545146	ENSG00000227676.3	LINC01068	-7.33	4.7e-13	1.18e-10	-0.26	-0.22	Major depressive disorder;	chr13:79601471	chr13:79566727~79571436:+
BRCA	cis	rs10129255	0.518	rs11847766	ENSG00000211970.3	IGHV4-61	-7.33	4.71e-13	1.18e-10	-0.14	-0.22	Kawasaki disease;	chr14:106779186	chr14:106639119~106639657:-
BRCA	cis	rs755249	1	rs2293476	ENSG00000237624.1	OXCT2P1	-7.33	4.71e-13	1.18e-10	-0.32	-0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39571175	chr1:39514956~39516490:+
BRCA	cis	rs6723162	0.757	rs4852724	ENSG00000237751.2	LINC01143	-7.33	4.76e-13	1.19e-10	-0.26	-0.22	Neurocognitive impairment in HIV-1 infection (dichotomous);	chr2:70889967	chr2:70887871~70889959:+
BRCA	cis	rs2742234	0.955	rs1800861	ENSG00000273008.1	RP11-351D16.3	-7.32	4.78e-13	1.2e-10	-0.26	-0.22	Hirschsprung disease;	chr10:43118395	chr10:43136824~43138334:-
BRCA	cis	rs2742234	0.955	rs2075910	ENSG00000273008.1	RP11-351D16.3	-7.32	4.78e-13	1.2e-10	-0.26	-0.22	Hirschsprung disease;	chr10:43118782	chr10:43136824~43138334:-
BRCA	cis	rs875971	0.545	rs313828	ENSG00000224316.1	RP11-479O9.2	-7.32	4.8e-13	1.2e-10	-0.26	-0.22	Aortic root size;	chr7:66087627	chr7:65773620~65802067:+
BRCA	cis	rs1555322	0.505	rs639763	ENSG00000279253.1	RP4-614O4.13	-7.32	4.81e-13	1.21e-10	-0.3	-0.22	Attention deficit hyperactivity disorder;	chr20:35274101	chr20:35262727~35264187:-
BRCA	cis	rs2880765	0.835	rs4280192	ENSG00000259295.5	CSPG4P12	7.32	4.81e-13	1.21e-10	0.27	0.22	Coronary artery disease;	chr15:85499789	chr15:85191438~85213905:+
BRCA	cis	rs4934494	0.768	rs58163515	ENSG00000240996.1	RP11-80H5.7	-7.32	4.82e-13	1.21e-10	-0.28	-0.22	Red blood cell count;	chr10:89637807	chr10:89694295~89697928:-
BRCA	cis	rs9649213	0.593	rs13246942	ENSG00000272950.1	RP11-307C18.1	7.32	4.82e-13	1.21e-10	0.28	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98285709	chr7:98322853~98323430:+
BRCA	cis	rs9649213	0.593	rs6968144	ENSG00000272950.1	RP11-307C18.1	7.32	4.82e-13	1.21e-10	0.28	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98286385	chr7:98322853~98323430:+
BRCA	cis	rs9649213	0.574	rs62479853	ENSG00000272950.1	RP11-307C18.1	7.32	4.82e-13	1.21e-10	0.28	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98287846	chr7:98322853~98323430:+
BRCA	cis	rs9876781	1	rs9838618	ENSG00000244380.1	RP11-24C3.2	7.32	4.82e-13	1.21e-10	0.26	0.22	Longevity;	chr3:48445949	chr3:48440352~48446656:-
BRCA	cis	rs858239	0.899	rs28458177	ENSG00000230042.1	AK3P3	-7.32	4.84e-13	1.21e-10	-0.26	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23255253	chr7:23129178~23129841:+
BRCA	cis	rs7809950	0.954	rs2520245	ENSG00000238832.1	snoU109	-7.32	4.85e-13	1.22e-10	-0.29	-0.22	Coronary artery disease;	chr7:107496983	chr7:107603363~107603507:+
BRCA	cis	rs78456975	0.527	rs7590743	ENSG00000231482.2	AC141930.2	-7.32	4.86e-13	1.22e-10	-0.28	-0.22	Placebo response in major depressive disorder (% change in symptom score);	chr2:1571276	chr2:1572554~1580311:-
BRCA	cis	rs78456975	0.527	rs7590742	ENSG00000231482.2	AC141930.2	-7.32	4.86e-13	1.22e-10	-0.28	-0.22	Placebo response in major depressive disorder (% change in symptom score);	chr2:1571277	chr2:1572554~1580311:-
BRCA	cis	rs801193	1	rs2659912	ENSG00000224316.1	RP11-479O9.2	7.32	4.86e-13	1.22e-10	0.22	0.22	Aortic root size;	chr7:66693012	chr7:65773620~65802067:+
BRCA	cis	rs801193	1	rs1553609	ENSG00000224316.1	RP11-479O9.2	7.32	4.86e-13	1.22e-10	0.22	0.22	Aortic root size;	chr7:66732152	chr7:65773620~65802067:+
BRCA	cis	rs3794924	1	rs35585743	ENSG00000266521.1	RP11-650P15.1	7.32	4.87e-13	1.22e-10	0.41	0.22	Survival in colon cancer;	chr18:31470398	chr18:31496645~31497195:-
BRCA	cis	rs10740039	0.883	rs34168977	ENSG00000254271.1	RP11-131N11.4	7.32	4.88e-13	1.22e-10	0.29	0.22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60632916	chr10:60734342~60741828:+
BRCA	cis	rs17711722	0.565	rs4717276	ENSG00000273024.4	INTS4P2	-7.32	4.9e-13	1.23e-10	-0.25	-0.22	Calcium levels;	chr7:65829754	chr7:65647864~65715661:+
BRCA	cis	rs61160187	0.577	rs34741733	ENSG00000215032.2	GNL3LP1	7.32	4.91e-13	1.23e-10	0.28	0.22	Educational attainment (years of education);Educational attainment (college completion);	chr5:60843721	chr5:60891935~60893577:-
BRCA	cis	rs4723738	0.967	rs12531618	ENSG00000227191.5	TRGC2	-7.32	4.91e-13	1.23e-10	-0.2	-0.22	Treatment response for severe sepsis;	chr7:38213263	chr7:38239580~38368091:-
BRCA	cis	rs6142102	0.812	rs725478	ENSG00000276073.1	RP5-1125A11.7	7.32	4.92e-13	1.23e-10	0.28	0.22	Skin pigmentation;	chr20:33930548	chr20:33985617~33988989:-
BRCA	cis	rs732716	0.889	rs11666856	ENSG00000267769.1	CTB-50L17.9	-7.32	4.92e-13	1.23e-10	-0.27	-0.22	Mean corpuscular volume;	chr19:4437453	chr19:4454014~4455286:+
BRCA	cis	rs526231	0.547	rs72783895	ENSG00000175749.11	EIF3KP1	7.32	4.96e-13	1.24e-10	0.33	0.22	Primary biliary cholangitis;	chr5:102951792	chr5:103032376~103033031:+
BRCA	cis	rs875971	0.545	rs313830	ENSG00000224316.1	RP11-479O9.2	-7.32	4.96e-13	1.24e-10	-0.26	-0.22	Aortic root size;	chr7:66086944	chr7:65773620~65802067:+
BRCA	cis	rs11159086	1	rs58384818	ENSG00000259005.1	RP3-449M8.6	7.32	4.96e-13	1.24e-10	0.36	0.22	Advanced glycation end-product levels;	chr14:74487045	chr14:74474007~74474864:-
BRCA	cis	rs11159086	1	rs17100588	ENSG00000259005.1	RP3-449M8.6	7.32	4.96e-13	1.24e-10	0.36	0.22	Advanced glycation end-product levels;	chr14:74487624	chr14:74474007~74474864:-
BRCA	cis	rs10129255	0.518	rs10150460	ENSG00000211970.3	IGHV4-61	7.32	4.97e-13	1.24e-10	0.14	0.22	Kawasaki disease;	chr14:106677179	chr14:106639119~106639657:-
BRCA	cis	rs7829975	0.539	rs940031	ENSG00000253893.2	FAM85B	7.32	4.97e-13	1.24e-10	0.28	0.22	Mood instability;	chr8:8689338	chr8:8167819~8226614:-
BRCA	cis	rs12439619	1	rs35152457	ENSG00000255769.6	GOLGA2P10	-7.32	4.97e-13	1.24e-10	-0.27	-0.22	Intelligence (multi-trait analysis);	chr15:82254207	chr15:82472993~82513950:-
BRCA	cis	rs2742234	0.541	rs1317214	ENSG00000273008.1	RP11-351D16.3	7.32	4.98e-13	1.25e-10	0.28	0.22	Hirschsprung disease;	chr10:43238083	chr10:43136824~43138334:-
BRCA	cis	rs6545883	0.929	rs3732170	ENSG00000271889.1	RP11-493E12.1	7.32	4.98e-13	1.25e-10	0.28	0.22	Tuberculosis;	chr2:61522581	chr2:61151433~61162105:-
BRCA	cis	rs6822297	0.522	rs7700108	ENSG00000240005.4	RP11-293A21.1	7.32	4.98e-13	1.25e-10	0.26	0.22	Obesity-related traits;	chr4:26967785	chr4:26859806~26860599:-
BRCA	cis	rs6570726	0.935	rs421268	ENSG00000235652.6	RP11-545I5.3	7.32	4.99e-13	1.25e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145524422	chr6:145799409~145886585:+
BRCA	cis	rs10206020	0.885	rs11887527	ENSG00000231482.2	AC141930.2	-7.32	5.01e-13	1.25e-10	-0.29	-0.22	IgG glycosylation;	chr2:1574308	chr2:1572554~1580311:-
BRCA	cis	rs10206020	0.885	rs11885392	ENSG00000231482.2	AC141930.2	-7.32	5.01e-13	1.25e-10	-0.29	-0.22	IgG glycosylation;	chr2:1574410	chr2:1572554~1580311:-
BRCA	cis	rs8062405	0.722	rs3785354	ENSG00000251417.2	RP11-1348G14.4	-7.32	5.04e-13	1.26e-10	-0.26	-0.22	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28539346	chr16:28802743~28817828:+
BRCA	cis	rs72772090	0.71	rs17400685	ENSG00000248734.2	CTD-2260A17.1	7.32	5.04e-13	1.26e-10	0.35	0.22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96730662	chr5:96784777~96785999:+
BRCA	cis	rs9649213	0.593	rs7781916	ENSG00000272950.1	RP11-307C18.1	7.32	5.04e-13	1.26e-10	0.28	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98300426	chr7:98322853~98323430:+
BRCA	cis	rs9649213	0.593	rs736753	ENSG00000272950.1	RP11-307C18.1	7.32	5.04e-13	1.26e-10	0.28	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98302177	chr7:98322853~98323430:+
BRCA	cis	rs9649213	0.593	rs736754	ENSG00000272950.1	RP11-307C18.1	7.32	5.04e-13	1.26e-10	0.28	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98302247	chr7:98322853~98323430:+
BRCA	cis	rs2880765	0.805	rs34598679	ENSG00000259295.5	CSPG4P12	7.32	5.06e-13	1.27e-10	0.27	0.22	Coronary artery disease;	chr15:85498974	chr15:85191438~85213905:+
BRCA	cis	rs2880765	0.835	rs4344688	ENSG00000259295.5	CSPG4P12	7.32	5.06e-13	1.27e-10	0.27	0.22	Coronary artery disease;	chr15:85499776	chr15:85191438~85213905:+
BRCA	cis	rs780096	0.525	rs13388159	ENSG00000234072.1	AC074117.10	-7.32	5.06e-13	1.27e-10	-0.21	-0.22	Total body bone mineral density;	chr2:27425417	chr2:27356246~27367622:+
BRCA	cis	rs875971	0.571	rs160647	ENSG00000224316.1	RP11-479O9.2	-7.32	5.08e-13	1.27e-10	-0.25	-0.22	Aortic root size;	chr7:66089365	chr7:65773620~65802067:+
BRCA	cis	rs12291225	0.679	rs34238445	ENSG00000251991.1	RNU7-49P	7.32	5.09e-13	1.27e-10	0.26	0.22	Sense of smell;	chr11:14294369	chr11:14478892~14478953:+
BRCA	cis	rs858239	0.539	rs10279194	ENSG00000230042.1	AK3P3	-7.32	5.09e-13	1.27e-10	-0.25	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23151464	chr7:23129178~23129841:+
BRCA	cis	rs858239	0.539	rs3950345	ENSG00000230042.1	AK3P3	-7.32	5.09e-13	1.27e-10	-0.25	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23151495	chr7:23129178~23129841:+
BRCA	cis	rs858239	0.539	rs2178139	ENSG00000230042.1	AK3P3	-7.32	5.09e-13	1.27e-10	-0.25	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23152017	chr7:23129178~23129841:+
BRCA	cis	rs858239	0.539	rs2141306	ENSG00000230042.1	AK3P3	-7.32	5.09e-13	1.27e-10	-0.25	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23152045	chr7:23129178~23129841:+
BRCA	cis	rs6570726	0.935	rs419854	ENSG00000235652.6	RP11-545I5.3	7.32	5.09e-13	1.27e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145522949	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.935	rs365658	ENSG00000235652.6	RP11-545I5.3	7.32	5.09e-13	1.27e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145523452	chr6:145799409~145886585:+
BRCA	cis	rs875971	0.545	rs73142245	ENSG00000224316.1	RP11-479O9.2	7.32	5.1e-13	1.27e-10	0.26	0.22	Aortic root size;	chr7:66226662	chr7:65773620~65802067:+
BRCA	cis	rs6545883	0.929	rs7606167	ENSG00000271889.1	RP11-493E12.1	7.32	5.11e-13	1.28e-10	0.28	0.22	Tuberculosis;	chr2:61515519	chr2:61151433~61162105:-
BRCA	cis	rs2880765	0.835	rs4360874	ENSG00000259295.5	CSPG4P12	7.32	5.11e-13	1.28e-10	0.27	0.22	Coronary artery disease;	chr15:85497589	chr15:85191438~85213905:+
BRCA	cis	rs875971	0.66	rs1860468	ENSG00000224316.1	RP11-479O9.2	-7.32	5.12e-13	1.28e-10	-0.22	-0.22	Aortic root size;	chr7:66642265	chr7:65773620~65802067:+
BRCA	cis	rs75422866	0.867	rs7303895	ENSG00000274902.1	RP1-197B17.4	7.31	5.14e-13	1.29e-10	0.51	0.22	Pneumonia;	chr12:47683290	chr12:47731908~47732351:+
BRCA	cis	rs1555322	0.53	rs2425042	ENSG00000279253.1	RP4-614O4.13	-7.31	5.16e-13	1.29e-10	-0.3	-0.22	Attention deficit hyperactivity disorder;	chr20:35278092	chr20:35262727~35264187:-
BRCA	cis	rs858239	0.899	rs5850	ENSG00000230042.1	AK3P3	-7.31	5.17e-13	1.29e-10	-0.26	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23274928	chr7:23129178~23129841:+
BRCA	cis	rs4845875	0.626	rs10864542	ENSG00000242349.4	NPPA-AS1	7.31	5.17e-13	1.29e-10	0.24	0.22	Midregional pro atrial natriuretic peptide levels;	chr1:11782087	chr1:11841017~11848079:+
BRCA	cis	rs61270009	0.955	rs10514299	ENSG00000247828.6	TMEM161B-AS1	7.31	5.18e-13	1.29e-10	0.29	0.22	Depressive symptoms;	chr5:88367793	chr5:88268895~88436685:+
BRCA	cis	rs9527	0.551	rs28606370	ENSG00000213061.2	PFN1P11	7.31	5.18e-13	1.29e-10	0.3	0.22	Arsenic metabolism;	chr10:102911075	chr10:102838011~102845473:-
BRCA	cis	rs9309711	0.772	rs9309715	ENSG00000225234.1	TRAPPC12-AS1	7.31	5.19e-13	1.3e-10	0.26	0.22	Neurofibrillary tangles;	chr2:3488547	chr2:3481242~3482409:-
BRCA	cis	rs875971	0.825	rs1000464	ENSG00000232559.3	GS1-124K5.12	-7.31	5.2e-13	1.3e-10	-0.27	-0.22	Aortic root size;	chr7:66312922	chr7:66554588~66576923:-
BRCA	cis	rs2842992	0.915	rs2758321	ENSG00000237927.1	RP3-393E18.2	-7.31	5.21e-13	1.3e-10	-0.31	-0.22	Age-related macular degeneration (geographic atrophy);	chr6:159650579	chr6:159586955~159589169:-
BRCA	cis	rs801193	0.844	rs732465	ENSG00000236529.1	RP13-254B10.1	7.31	5.22e-13	1.3e-10	0.24	0.22	Aortic root size;	chr7:66533463	chr7:65840212~65840596:+
BRCA	cis	rs801193	0.967	rs3800823	ENSG00000224316.1	RP11-479O9.2	-7.31	5.23e-13	1.31e-10	-0.22	-0.22	Aortic root size;	chr7:66682123	chr7:65773620~65802067:+
BRCA	cis	rs301901	0.965	rs292195	ENSG00000250155.1	CTD-2353F22.1	-7.31	5.23e-13	1.31e-10	-0.24	-0.22	Height;	chr5:36941456	chr5:36666214~36725195:-
BRCA	cis	rs11976180	1	rs1540894	ENSG00000170356.8	OR2A20P	-7.31	5.24e-13	1.31e-10	-0.32	-0.22	Obesity-related traits;	chr7:144070583	chr7:144250045~144252957:-
BRCA	cis	rs9880211	0.8	rs35880395	ENSG00000239213.4	NCK1-AS1	7.31	5.24e-13	1.31e-10	0.3	0.22	Height;Body mass index;	chr3:136788248	chr3:136841726~136862054:-
BRCA	cis	rs17711722	0.51	rs11767457	ENSG00000213640.3	EEF1DP4	-7.31	5.25e-13	1.31e-10	-0.29	-0.22	Calcium levels;	chr7:65825628	chr7:64862999~64864370:+
BRCA	cis	rs301901	0.965	rs13170811	ENSG00000250155.1	CTD-2353F22.1	-7.31	5.25e-13	1.31e-10	-0.24	-0.22	Height;	chr5:36795628	chr5:36666214~36725195:-
BRCA	cis	rs9649213	0.574	rs3801257	ENSG00000272950.1	RP11-307C18.1	7.31	5.26e-13	1.31e-10	0.28	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98362480	chr7:98322853~98323430:+
BRCA	cis	rs9649213	0.593	rs7803372	ENSG00000272950.1	RP11-307C18.1	7.31	5.26e-13	1.31e-10	0.28	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98362945	chr7:98322853~98323430:+
BRCA	cis	rs8005677	1	rs2295685	ENSG00000279656.1	RP11-298I3.6	7.31	5.29e-13	1.32e-10	0.27	0.22	Cognitive ability (multi-trait analysis);	chr14:22928944	chr14:23023083~23024217:-
BRCA	cis	rs801193	0.569	rs2659907	ENSG00000232559.3	GS1-124K5.12	7.31	5.31e-13	1.32e-10	0.27	0.22	Aortic root size;	chr7:66699045	chr7:66554588~66576923:-
BRCA	cis	rs1555322	0.53	rs2297789	ENSG00000279253.1	RP4-614O4.13	-7.31	5.32e-13	1.33e-10	-0.29	-0.22	Attention deficit hyperactivity disorder;	chr20:35279445	chr20:35262727~35264187:-
BRCA	cis	rs74233809	1	rs11191453	ENSG00000213277.3	MARCKSL1P1	7.31	5.32e-13	1.33e-10	0.41	0.22	Birth weight;	chr10:102900095	chr10:103175554~103176094:+
BRCA	cis	rs875971	0.508	rs10242423	ENSG00000224316.1	RP11-479O9.2	-7.31	5.32e-13	1.33e-10	-0.22	-0.22	Aortic root size;	chr7:66594188	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.508	rs10253883	ENSG00000224316.1	RP11-479O9.2	-7.31	5.32e-13	1.33e-10	-0.22	-0.22	Aortic root size;	chr7:66596151	chr7:65773620~65802067:+
BRCA	cis	rs6723162	0.965	rs11126307	ENSG00000237751.2	LINC01143	-7.31	5.32e-13	1.33e-10	-0.26	-0.22	Neurocognitive impairment in HIV-1 infection (dichotomous);	chr2:70884060	chr2:70887871~70889959:+
BRCA	cis	rs7267979	0.844	rs6050477	ENSG00000274973.1	RP13-401N8.7	7.31	5.32e-13	1.33e-10	0.26	0.22	Liver enzyme levels (alkaline phosphatase);	chr20:25240911	chr20:25845497~25845862:+
BRCA	cis	rs9649213	0.593	rs6970801	ENSG00000272950.1	RP11-307C18.1	7.31	5.33e-13	1.33e-10	0.28	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98295928	chr7:98322853~98323430:+
BRCA	cis	rs9649213	0.593	rs12704982	ENSG00000272950.1	RP11-307C18.1	7.31	5.33e-13	1.33e-10	0.28	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98296741	chr7:98322853~98323430:+
BRCA	cis	rs9649213	0.593	rs34129434	ENSG00000272950.1	RP11-307C18.1	7.31	5.33e-13	1.33e-10	0.28	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98297152	chr7:98322853~98323430:+
BRCA	cis	rs11098499	0.955	rs13114751	ENSG00000248280.1	RP11-33B1.2	7.31	5.33e-13	1.33e-10	0.23	0.22	Corneal astigmatism;	chr4:119235462	chr4:119440561~119450157:-
BRCA	cis	rs42648	0.935	rs42664	ENSG00000225498.1	AC002064.5	7.31	5.34e-13	1.33e-10	0.21	0.22	Homocysteine levels;	chr7:90355095	chr7:90312496~90322592:+
BRCA	cis	rs6496044	0.507	rs410522	ENSG00000202081.1	RNU6-1280P	-7.31	5.35e-13	1.33e-10	-0.26	-0.22	Interstitial lung disease;	chr15:85663813	chr15:85651522~85651628:-
BRCA	cis	rs858239	0.539	rs4365988	ENSG00000230042.1	AK3P3	-7.31	5.35e-13	1.33e-10	-0.25	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23151252	chr7:23129178~23129841:+
BRCA	cis	rs2028299	0.879	rs7163629	ENSG00000259677.1	RP11-493E3.1	7.31	5.35e-13	1.33e-10	0.3	0.22	Type 2 diabetes;	chr15:89873508	chr15:89876540~89877285:+
BRCA	cis	rs42648	0.935	rs42660	ENSG00000225498.1	AC002064.5	7.31	5.35e-13	1.33e-10	0.21	0.22	Homocysteine levels;	chr7:90353208	chr7:90312496~90322592:+
BRCA	cis	rs6142102	0.527	rs1015362	ENSG00000275784.1	RP5-1125A11.6	7.31	5.35e-13	1.33e-10	0.27	0.22	Skin pigmentation;	chr20:34150806	chr20:33989480~33991818:-
BRCA	cis	rs10515750	0.588	rs73815868	ENSG00000251405.2	CTB-109A12.1	7.31	5.36e-13	1.34e-10	0.34	0.22	Lung function (FEV1/FVC);	chr5:157363429	chr5:157362615~157460078:-
BRCA	cis	rs6545883	0.965	rs6545872	ENSG00000271889.1	RP11-493E12.1	7.31	5.36e-13	1.34e-10	0.29	0.22	Tuberculosis;	chr2:61497433	chr2:61151433~61162105:-
BRCA	cis	rs987724	0.592	rs1430411	ENSG00000240875.4	LINC00886	-7.31	5.36e-13	1.34e-10	-0.26	-0.22	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156807607	chr3:156747346~156817062:-
BRCA	cis	rs3814244	0.528	rs1468487	ENSG00000236946.2	HNRNPA1P70	7.31	5.37e-13	1.34e-10	0.18	0.22	Itch intensity from mosquito bite adjusted by bite size;	chr12:67996602	chr12:68035767~68036853:+
BRCA	cis	rs7809950	1	rs10273733	ENSG00000238832.1	snoU109	7.31	5.38e-13	1.34e-10	0.3	0.22	Coronary artery disease;	chr7:107617676	chr7:107603363~107603507:+
BRCA	cis	rs1862618	0.853	rs832553	ENSG00000271828.1	CTD-2310F14.1	7.31	5.38e-13	1.34e-10	0.31	0.22	Initial pursuit acceleration;	chr5:56818959	chr5:56927874~56929573:+
BRCA	cis	rs801193	0.967	rs34356500	ENSG00000237310.1	GS1-124K5.4	7.31	5.38e-13	1.34e-10	0.23	0.22	Aortic root size;	chr7:66771620	chr7:66493706~66495474:+
BRCA	cis	rs780096	0.526	rs780102	ENSG00000234072.1	AC074117.10	-7.31	5.38e-13	1.34e-10	-0.21	-0.22	Total body bone mineral density;	chr2:27436624	chr2:27356246~27367622:+
BRCA	cis	rs1823913	0.637	rs2356354	ENSG00000280083.1	RP11-317J9.1	7.31	5.39e-13	1.34e-10	0.26	0.22	Obesity-related traits;	chr2:191270970	chr2:191154118~191156070:-
BRCA	cis	rs301901	1	rs292194	ENSG00000250155.1	CTD-2353F22.1	7.31	5.4e-13	1.34e-10	0.24	0.22	Height;	chr5:36941665	chr5:36666214~36725195:-
BRCA	cis	rs8062405	0.69	rs7187604	ENSG00000251417.2	RP11-1348G14.4	-7.31	5.4e-13	1.35e-10	-0.26	-0.22	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554632	chr16:28802743~28817828:+
BRCA	cis	rs1861628	0.927	rs737308	ENSG00000237930.1	AC007563.4	7.31	5.4e-13	1.35e-10	0.26	0.22	Serum thyroid-stimulating hormone levels;Hypothyroidism;	chr2:216758526	chr2:216785774~216786144:-
BRCA	cis	rs6740322	0.748	rs6720087	ENSG00000234936.1	AC010883.5	-7.31	5.41e-13	1.35e-10	-0.25	-0.22	Coronary artery disease;	chr2:43241606	chr2:43229573~43233394:+
BRCA	cis	rs34779708	0.733	rs7087099	ENSG00000271335.4	RP11-324I22.4	7.31	5.41e-13	1.35e-10	0.23	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35253054	chr10:35314552~35336401:-
BRCA	cis	rs1023500	0.505	rs134887	ENSG00000205702.9	CYP2D7	7.31	5.42e-13	1.35e-10	0.18	0.22	Schizophrenia;	chr22:42278233	chr22:42140203~42144577:-
BRCA	cis	rs7688540	0.723	rs7687112	ENSG00000275426.1	CH17-262A2.1	7.31	5.43e-13	1.35e-10	0.32	0.22	Facial morphology (factor 6, height of vermillion lower lip);	chr4:249767	chr4:149738~150317:+
BRCA	cis	rs1609391	0.561	rs9817967	ENSG00000273486.1	RP11-731C17.2	7.31	5.44e-13	1.36e-10	0.24	0.22	Neuroticism;	chr3:136910648	chr3:136837338~136839021:-
BRCA	cis	rs780096	0.506	rs8395	ENSG00000234072.1	AC074117.10	-7.31	5.47e-13	1.36e-10	-0.21	-0.22	Total body bone mineral density;	chr2:27492340	chr2:27356246~27367622:+
BRCA	cis	rs7727544	0.684	rs2631363	ENSG00000233006.5	AC034220.3	-7.31	5.47e-13	1.36e-10	-0.16	-0.22	Blood metabolite levels;	chr5:132371403	chr5:132311285~132369916:-
BRCA	cis	rs10466239	0.73	rs2243492	ENSG00000230555.2	RP11-517P14.2	7.31	5.47e-13	1.36e-10	0.31	0.22	Telomere length;	chr10:43353910	chr10:43420738~43422100:+
BRCA	cis	rs2243480	1	rs34136756	ENSG00000273142.1	RP11-458F8.4	-7.31	5.5e-13	1.37e-10	-0.3	-0.22	Diabetic kidney disease;	chr7:65916269	chr7:66902857~66906297:+
BRCA	cis	rs755249	0.517	rs66880209	ENSG00000237624.1	OXCT2P1	7.3	5.5e-13	1.37e-10	0.36	0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39254140	chr1:39514956~39516490:+
BRCA	cis	rs9876781	0.559	rs1841178	ENSG00000229759.1	MRPS18AP1	7.3	5.52e-13	1.37e-10	0.25	0.22	Longevity;	chr3:48355556	chr3:48256350~48256938:-
BRCA	cis	rs1861628	1	rs737310	ENSG00000237930.1	AC007563.4	7.3	5.52e-13	1.38e-10	0.26	0.22	Serum thyroid-stimulating hormone levels;Hypothyroidism;	chr2:216758503	chr2:216785774~216786144:-
BRCA	cis	rs9649213	0.593	rs3801264	ENSG00000272950.1	RP11-307C18.1	7.3	5.53e-13	1.38e-10	0.28	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98321308	chr7:98322853~98323430:+
BRCA	cis	rs9649213	0.593	rs1468338	ENSG00000272950.1	RP11-307C18.1	7.3	5.53e-13	1.38e-10	0.28	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98321806	chr7:98322853~98323430:+
BRCA	cis	rs9649213	0.593	rs2158553	ENSG00000272950.1	RP11-307C18.1	7.3	5.53e-13	1.38e-10	0.28	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98321819	chr7:98322853~98323430:+
BRCA	cis	rs9649213	0.613	rs10953256	ENSG00000272950.1	RP11-307C18.1	7.3	5.53e-13	1.38e-10	0.28	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98322574	chr7:98322853~98323430:+
BRCA	cis	rs9649213	0.613	rs2286074	ENSG00000272950.1	RP11-307C18.1	7.3	5.53e-13	1.38e-10	0.28	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98322699	chr7:98322853~98323430:+
BRCA	cis	rs875971	0.628	rs6974355	ENSG00000237310.1	GS1-124K5.4	7.3	5.54e-13	1.38e-10	0.23	0.22	Aortic root size;	chr7:66376994	chr7:66493706~66495474:+
BRCA	cis	rs8012947	0.917	rs2145600	ENSG00000279636.2	LINC00216	7.3	5.55e-13	1.38e-10	0.26	0.22	Alcohol consumption in current drinkers;	chr14:58284184	chr14:58288033~58289158:+
BRCA	cis	rs2439831	0.85	rs7179388	ENSG00000205771.5	CATSPER2P1	-7.3	5.55e-13	1.38e-10	-0.4	-0.22	Lung cancer in ever smokers;	chr15:43831747	chr15:43726918~43747094:-
BRCA	cis	rs9649213	0.593	rs7789380	ENSG00000272950.1	RP11-307C18.1	7.3	5.55e-13	1.38e-10	0.28	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98326868	chr7:98322853~98323430:+
BRCA	cis	rs6907340	0.517	rs9465531	ENSG00000228412.5	RP4-625H18.2	7.3	5.56e-13	1.38e-10	0.29	0.22	Endometriosis;	chr6:19798418	chr6:19802164~19804752:-
BRCA	cis	rs6907340	0.517	rs9465533	ENSG00000228412.5	RP4-625H18.2	7.3	5.56e-13	1.38e-10	0.29	0.22	Endometriosis;	chr6:19801477	chr6:19802164~19804752:-
BRCA	cis	rs10129255	0.5	rs8004923	ENSG00000280411.1	IGHV1-69-2	-7.3	5.58e-13	1.39e-10	-0.14	-0.22	Kawasaki disease;	chr14:106785926	chr14:106762092~106762588:-
BRCA	cis	rs34779708	0.733	rs61449529	ENSG00000271335.4	RP11-324I22.4	7.3	5.59e-13	1.39e-10	0.23	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35254986	chr10:35314552~35336401:-
BRCA	cis	rs301901	0.581	rs158409	ENSG00000250155.1	CTD-2353F22.1	-7.3	5.59e-13	1.39e-10	-0.24	-0.22	Height;	chr5:36848456	chr5:36666214~36725195:-
BRCA	cis	rs30380	1	rs469758	ENSG00000272109.1	CTD-2260A17.3	-7.3	5.59e-13	1.39e-10	-0.28	-0.22	Cerebrospinal fluid biomarker levels;	chr5:96786011	chr5:96804353~96806105:+
BRCA	cis	rs7520050	0.807	rs28378621	ENSG00000280836.1	AL355480.1	-7.3	5.6e-13	1.39e-10	-0.26	-0.22	Reticulocyte count;Red blood cell count;	chr1:45723882	chr1:45581219~45581321:-
BRCA	cis	rs9649213	0.593	rs62478233	ENSG00000272950.1	RP11-307C18.1	7.3	5.61e-13	1.4e-10	0.28	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98393780	chr7:98322853~98323430:+
BRCA	cis	rs13113518	0.812	rs12500686	ENSG00000273257.1	RP11-177J6.1	7.3	5.61e-13	1.4e-10	0.31	0.22	Height;	chr4:55457922	chr4:55387949~55388271:+
BRCA	cis	rs858239	0.539	rs2178140	ENSG00000230042.1	AK3P3	-7.3	5.61e-13	1.4e-10	-0.25	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23152006	chr7:23129178~23129841:+
BRCA	cis	rs58873874	0.579	rs35536103	ENSG00000248544.2	CTB-47B11.3	7.3	5.61e-13	1.4e-10	0.46	0.22	Bipolar disorder (body mass index interaction);	chr5:157308391	chr5:157375741~157384950:-
BRCA	cis	rs780096	0.565	rs813592	ENSG00000234072.1	AC074117.10	-7.3	5.62e-13	1.4e-10	-0.21	-0.22	Total body bone mineral density;	chr2:27499104	chr2:27356246~27367622:+
BRCA	cis	rs801193	0.773	rs801207	ENSG00000236529.1	RP13-254B10.1	-7.3	5.62e-13	1.4e-10	-0.24	-0.22	Aortic root size;	chr7:66555603	chr7:65840212~65840596:+
BRCA	cis	rs301901	1	rs159753	ENSG00000250155.1	CTD-2353F22.1	-7.3	5.64e-13	1.4e-10	-0.24	-0.22	Height;	chr5:37007527	chr5:36666214~36725195:-
BRCA	cis	rs4835473	0.797	rs34585546	ENSG00000251600.4	RP11-673E1.1	-7.3	5.64e-13	1.4e-10	-0.29	-0.22	Immature fraction of reticulocytes;	chr4:143680693	chr4:143912331~143982454:+
BRCA	cis	rs801193	1	rs62466794	ENSG00000224316.1	RP11-479O9.2	7.3	5.65e-13	1.4e-10	0.22	0.22	Aortic root size;	chr7:66726592	chr7:65773620~65802067:+
BRCA	cis	rs7617773	0.817	rs6801801	ENSG00000228638.1	FCF1P2	-7.3	5.69e-13	1.41e-10	-0.24	-0.22	Coronary artery disease;	chr3:48284943	chr3:48290793~48291375:-
BRCA	cis	rs7617773	0.743	rs6804986	ENSG00000228638.1	FCF1P2	-7.3	5.69e-13	1.42e-10	-0.24	-0.22	Coronary artery disease;	chr3:48322105	chr3:48290793~48291375:-
BRCA	cis	rs2243480	1	rs709607	ENSG00000273142.1	RP11-458F8.4	7.3	5.69e-13	1.42e-10	0.29	0.22	Diabetic kidney disease;	chr7:65984554	chr7:66902857~66906297:+
BRCA	cis	rs61270009	0.955	rs16903057	ENSG00000247828.6	TMEM161B-AS1	7.3	5.71e-13	1.42e-10	0.3	0.22	Depressive symptoms;	chr5:88292603	chr5:88268895~88436685:+
BRCA	cis	rs8062405	0.688	rs3924376	ENSG00000278665.1	RP11-666O2.4	-7.3	5.71e-13	1.42e-10	-0.26	-0.22	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28914657	chr16:28599241~28601881:-
BRCA	cis	rs4787484	0.964	rs7498372	ENSG00000214725.6	CDIPT-AS1	-7.3	5.73e-13	1.42e-10	-0.28	-0.22	Response to taxane treatment (placlitaxel);	chr16:29899404	chr16:29863593~29868053:+
BRCA	cis	rs7927771	0.698	rs34467936	ENSG00000280615.1	Y_RNA	-7.3	5.73e-13	1.42e-10	-0.27	-0.22	Subjective well-being;	chr11:47893747	chr11:47614898~47614994:-
BRCA	cis	rs293748	0.54	rs6879284	ENSG00000250155.1	CTD-2353F22.1	-7.3	5.74e-13	1.43e-10	-0.28	-0.22	Obesity-related traits;	chr5:37230185	chr5:36666214~36725195:-
BRCA	cis	rs9876781	0.559	rs11130167	ENSG00000229759.1	MRPS18AP1	7.3	5.74e-13	1.43e-10	0.26	0.22	Longevity;	chr3:48358570	chr3:48256350~48256938:-
BRCA	cis	rs301901	1	rs184182	ENSG00000250155.1	CTD-2353F22.1	-7.3	5.75e-13	1.43e-10	-0.24	-0.22	Height;	chr5:37005003	chr5:36666214~36725195:-
BRCA	cis	rs11976180	1	rs13243677	ENSG00000204959.4	ARHGEF34P	7.3	5.75e-13	1.43e-10	0.27	0.22	Obesity-related traits;	chr7:144049479	chr7:144272445~144286966:-
BRCA	cis	rs9649213	0.574	rs6979373	ENSG00000272950.1	RP11-307C18.1	7.3	5.75e-13	1.43e-10	0.28	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98332532	chr7:98322853~98323430:+
BRCA	cis	rs9649213	0.574	rs34717219	ENSG00000272950.1	RP11-307C18.1	7.3	5.75e-13	1.43e-10	0.28	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98332959	chr7:98322853~98323430:+
BRCA	cis	rs10206020	0.921	rs72776302	ENSG00000231482.2	AC141930.2	-7.3	5.76e-13	1.43e-10	-0.29	-0.22	IgG glycosylation;	chr2:1567611	chr2:1572554~1580311:-
BRCA	cis	rs8012947	0.607	rs1051858	ENSG00000279636.2	LINC00216	7.3	5.77e-13	1.43e-10	0.23	0.22	Alcohol consumption in current drinkers;	chr14:58364424	chr14:58288033~58289158:+
BRCA	cis	rs1862618	0.853	rs252904	ENSG00000271828.1	CTD-2310F14.1	7.3	5.77e-13	1.43e-10	0.31	0.22	Initial pursuit acceleration;	chr5:56822906	chr5:56927874~56929573:+
BRCA	cis	rs2742234	0.541	rs871763	ENSG00000273008.1	RP11-351D16.3	7.3	5.78e-13	1.44e-10	0.28	0.22	Hirschsprung disease;	chr10:43238740	chr10:43136824~43138334:-
BRCA	cis	rs79040073	0.637	rs11635005	ENSG00000259531.2	RP11-295H24.3	7.3	5.78e-13	1.44e-10	0.36	0.22	Lung cancer in ever smokers;	chr15:49309228	chr15:49365124~49366685:-
BRCA	cis	rs30380	1	rs30378	ENSG00000272109.1	CTD-2260A17.3	-7.3	5.78e-13	1.44e-10	-0.28	-0.22	Cerebrospinal fluid biomarker levels;	chr5:96786290	chr5:96804353~96806105:+
BRCA	cis	rs11098499	1	rs13435802	ENSG00000248280.1	RP11-33B1.2	-7.3	5.79e-13	1.44e-10	-0.23	-0.22	Corneal astigmatism;	chr4:119256805	chr4:119440561~119450157:-
BRCA	cis	rs9649213	0.593	rs3801263	ENSG00000272950.1	RP11-307C18.1	7.3	5.8e-13	1.44e-10	0.28	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98335704	chr7:98322853~98323430:+
BRCA	cis	rs10206020	0.885	rs11899557	ENSG00000231482.2	AC141930.2	-7.3	5.83e-13	1.45e-10	-0.28	-0.22	IgG glycosylation;	chr2:1572351	chr2:1572554~1580311:-
BRCA	cis	rs10206020	0.759	rs11903889	ENSG00000231482.2	AC141930.2	-7.3	5.83e-13	1.45e-10	-0.28	-0.22	IgG glycosylation;	chr2:1572829	chr2:1572554~1580311:-
BRCA	cis	rs10206020	0.885	rs6746052	ENSG00000231482.2	AC141930.2	-7.3	5.83e-13	1.45e-10	-0.28	-0.22	IgG glycosylation;	chr2:1573039	chr2:1572554~1580311:-
BRCA	cis	rs858239	0.539	rs1358442	ENSG00000230042.1	AK3P3	-7.3	5.83e-13	1.45e-10	-0.25	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23150120	chr7:23129178~23129841:+
BRCA	cis	rs7617773	0.851	rs6775179	ENSG00000228638.1	FCF1P2	-7.3	5.83e-13	1.45e-10	-0.23	-0.22	Coronary artery disease;	chr3:48271928	chr3:48290793~48291375:-
BRCA	cis	rs9649213	0.593	rs6975156	ENSG00000272950.1	RP11-307C18.1	7.3	5.85e-13	1.45e-10	0.28	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98296222	chr7:98322853~98323430:+
BRCA	cis	rs875971	0.545	rs10950029	ENSG00000236529.1	RP13-254B10.1	7.3	5.86e-13	1.46e-10	0.27	0.22	Aortic root size;	chr7:66169334	chr7:65840212~65840596:+
BRCA	cis	rs847577	0.609	rs11763970	ENSG00000272950.1	RP11-307C18.1	7.3	5.87e-13	1.46e-10	0.29	0.22	Breast cancer;	chr7:98188009	chr7:98322853~98323430:+
BRCA	cis	rs875971	0.867	rs1002053	ENSG00000232559.3	GS1-124K5.12	-7.3	5.87e-13	1.46e-10	-0.26	-0.22	Aortic root size;	chr7:66333558	chr7:66554588~66576923:-
BRCA	cis	rs2033711	0.87	rs11084545	ENSG00000269473.1	CTD-2619J13.19	7.3	5.87e-13	1.46e-10	0.26	0.22	Uric acid clearance;	chr19:58440326	chr19:58440448~58445849:+
BRCA	cis	rs6504622	0.702	rs2316758	ENSG00000262879.4	RP11-156P1.3	-7.3	5.89e-13	1.46e-10	-0.23	-0.22	Orofacial clefts;	chr17:46988999	chr17:46984045~47100323:-
BRCA	cis	rs75422866	0.867	rs7304743	ENSG00000274902.1	RP1-197B17.4	-7.3	5.89e-13	1.46e-10	-0.5	-0.22	Pneumonia;	chr12:47683658	chr12:47731908~47732351:+
BRCA	cis	rs7976269	0.537	rs10843303	ENSG00000257176.2	RP11-996F15.2	-7.29	5.92e-13	1.47e-10	-0.26	-0.22	Male-pattern baldness;	chr12:29069435	chr12:29280418~29317848:-
BRCA	cis	rs10206020	0.885	rs13388254	ENSG00000231482.2	AC141930.2	-7.29	5.92e-13	1.47e-10	-0.28	-0.22	IgG glycosylation;	chr2:1573437	chr2:1572554~1580311:-
BRCA	cis	rs13178541	0.748	rs9327727	ENSG00000250378.1	RP11-119J18.1	-7.29	5.93e-13	1.47e-10	-0.3	-0.22	IgG glycosylation;	chr5:135725997	chr5:135812667~135826582:+
BRCA	cis	rs7809950	0.862	rs62482502	ENSG00000238832.1	snoU109	-7.29	5.93e-13	1.47e-10	-0.29	-0.22	Coronary artery disease;	chr7:107347365	chr7:107603363~107603507:+
BRCA	cis	rs7208859	0.623	rs73269923	ENSG00000263603.1	CTD-2349P21.5	-7.29	5.98e-13	1.48e-10	-0.4	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775553	chr17:30729469~30731202:+
BRCA	cis	rs875971	0.862	rs6460290	ENSG00000232559.3	GS1-124K5.12	-7.29	6.01e-13	1.49e-10	-0.26	-0.22	Aortic root size;	chr7:66344119	chr7:66554588~66576923:-
BRCA	cis	rs13315649	0.525	rs62270822	ENSG00000242551.2	POU5F1P6	-7.29	6.01e-13	1.49e-10	-0.31	-0.22	Sum eosinophil basophil counts;	chr3:128683677	chr3:128674735~128677005:-
BRCA	cis	rs10740039	0.883	rs7476720	ENSG00000254271.1	RP11-131N11.4	7.29	6.02e-13	1.49e-10	0.29	0.22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60650610	chr10:60734342~60741828:+
BRCA	cis	rs13113518	0.812	rs12648271	ENSG00000273257.1	RP11-177J6.1	7.29	6.03e-13	1.5e-10	0.32	0.22	Height;	chr4:55501955	chr4:55387949~55388271:+
BRCA	cis	rs6860806	0.507	rs200837	ENSG00000233006.5	AC034220.3	7.29	6.03e-13	1.5e-10	0.18	0.22	Breast cancer;	chr5:132364266	chr5:132311285~132369916:-
BRCA	cis	rs7637701	0.818	rs11717133	ENSG00000240875.4	LINC00886	-7.29	6.06e-13	1.5e-10	-0.26	-0.22	Breast cancer;	chr3:156816792	chr3:156747346~156817062:-
BRCA	cis	rs7927771	0.832	rs10838698	ENSG00000280615.1	Y_RNA	7.29	6.06e-13	1.5e-10	0.26	0.22	Subjective well-being;	chr11:47364372	chr11:47614898~47614994:-
BRCA	cis	rs9649213	0.555	rs12667634	ENSG00000272950.1	RP11-307C18.1	7.29	6.06e-13	1.5e-10	0.28	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98336130	chr7:98322853~98323430:+
BRCA	cis	rs6545883	0.868	rs7608483	ENSG00000271889.1	RP11-493E12.1	7.29	6.06e-13	1.5e-10	0.29	0.22	Tuberculosis;	chr2:61609100	chr2:61151433~61162105:-
BRCA	cis	rs11976180	1	rs1919951	ENSG00000204959.4	ARHGEF34P	7.29	6.07e-13	1.5e-10	0.28	0.22	Obesity-related traits;	chr7:144071798	chr7:144272445~144286966:-
BRCA	cis	rs2439831	0.85	rs3736180	ENSG00000275601.1	AC011330.13	-7.29	6.07e-13	1.51e-10	-0.36	-0.22	Lung cancer in ever smokers;	chr15:43814426	chr15:43642389~43643023:-
BRCA	cis	rs7586673	0.964	rs34444368	ENSG00000235724.7	AC009299.2	-7.29	6.08e-13	1.51e-10	-0.26	-0.22	Intelligence (multi-trait analysis);	chr2:161097706	chr2:161222785~161308303:-
BRCA	cis	rs6570726	0.935	rs366308	ENSG00000235652.6	RP11-545I5.3	7.29	6.08e-13	1.51e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145493396	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.935	rs384806	ENSG00000235652.6	RP11-545I5.3	7.29	6.08e-13	1.51e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145493753	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.935	rs385185	ENSG00000235652.6	RP11-545I5.3	7.29	6.08e-13	1.51e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145493856	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.935	rs384453	ENSG00000235652.6	RP11-545I5.3	7.29	6.08e-13	1.51e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145494009	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.935	rs372378	ENSG00000235652.6	RP11-545I5.3	7.29	6.08e-13	1.51e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145495091	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.905	rs388728	ENSG00000235652.6	RP11-545I5.3	7.29	6.08e-13	1.51e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145495283	chr6:145799409~145886585:+
BRCA	cis	rs17772222	0.874	rs78077739	ENSG00000258983.2	RP11-507K2.2	7.29	6.08e-13	1.51e-10	0.25	0.22	Coronary artery calcification;	chr14:88741176	chr14:88499334~88515502:+
BRCA	cis	rs7674212	0.507	rs223331	ENSG00000251288.2	RP11-10L12.2	-7.29	6.09e-13	1.51e-10	-0.27	-0.22	Type 2 diabetes;	chr4:102872408	chr4:102751401~102752641:+
BRCA	cis	rs66887589	0.616	rs11732621	ENSG00000248280.1	RP11-33B1.2	7.29	6.09e-13	1.51e-10	0.21	0.22	Diastolic blood pressure;	chr4:119291728	chr4:119440561~119450157:-
BRCA	cis	rs301901	1	rs300063	ENSG00000250155.1	CTD-2353F22.1	-7.29	6.1e-13	1.51e-10	-0.24	-0.22	Height;	chr5:37023796	chr5:36666214~36725195:-
BRCA	cis	rs780096	0.506	rs2303369	ENSG00000234072.1	AC074117.10	-7.29	6.1e-13	1.51e-10	-0.21	-0.22	Total body bone mineral density;	chr2:27492549	chr2:27356246~27367622:+
BRCA	cis	rs2880765	0.835	rs12708553	ENSG00000259295.5	CSPG4P12	-7.29	6.11e-13	1.51e-10	-0.27	-0.22	Coronary artery disease;	chr15:85503602	chr15:85191438~85213905:+
BRCA	cis	rs34779708	0.733	rs7081597	ENSG00000271335.4	RP11-324I22.4	7.29	6.11e-13	1.52e-10	0.23	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35257403	chr10:35314552~35336401:-
BRCA	cis	rs6545883	0.868	rs2427885	ENSG00000271889.1	RP11-493E12.1	7.29	6.13e-13	1.52e-10	0.28	0.22	Tuberculosis;	chr2:61589642	chr2:61151433~61162105:-
BRCA	cis	rs10740039	0.883	rs2119912	ENSG00000254271.1	RP11-131N11.4	7.29	6.13e-13	1.52e-10	0.29	0.22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60639754	chr10:60734342~60741828:+
BRCA	cis	rs7617773	0.817	rs9837228	ENSG00000228638.1	FCF1P2	7.29	6.14e-13	1.52e-10	0.23	0.22	Coronary artery disease;	chr3:48282976	chr3:48290793~48291375:-
BRCA	cis	rs4723738	1	rs10951552	ENSG00000227191.5	TRGC2	-7.29	6.14e-13	1.52e-10	-0.2	-0.22	Treatment response for severe sepsis;	chr7:38190180	chr7:38239580~38368091:-
BRCA	cis	rs526231	0.578	rs10463553	ENSG00000175749.11	EIF3KP1	7.29	6.14e-13	1.52e-10	0.31	0.22	Primary biliary cholangitis;	chr5:102913503	chr5:103032376~103033031:+
BRCA	cis	rs526231	0.578	rs6876278	ENSG00000175749.11	EIF3KP1	7.29	6.14e-13	1.52e-10	0.31	0.22	Primary biliary cholangitis;	chr5:102913842	chr5:103032376~103033031:+
BRCA	cis	rs9527	0.571	rs7904113	ENSG00000213061.2	PFN1P11	7.29	6.15e-13	1.52e-10	0.29	0.22	Arsenic metabolism;	chr10:102873357	chr10:102838011~102845473:-
BRCA	cis	rs2243480	1	rs937108	ENSG00000273142.1	RP11-458F8.4	-7.29	6.18e-13	1.53e-10	-0.3	-0.22	Diabetic kidney disease;	chr7:65963465	chr7:66902857~66906297:+
BRCA	cis	rs2288884	0.559	rs8111873	ENSG00000275055.1	CTC-471J1.11	-7.29	6.2e-13	1.53e-10	-0.26	-0.22	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52014267	chr19:52049007~52049754:+
BRCA	cis	rs9649213	0.555	rs7785612	ENSG00000272950.1	RP11-307C18.1	7.29	6.2e-13	1.54e-10	0.28	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98304555	chr7:98322853~98323430:+
BRCA	cis	rs7976269	0.537	rs2117992	ENSG00000257176.2	RP11-996F15.2	-7.29	6.2e-13	1.54e-10	-0.26	-0.22	Male-pattern baldness;	chr12:29070611	chr12:29280418~29317848:-
BRCA	cis	rs1972460	0.506	rs62012050	ENSG00000255769.6	GOLGA2P10	-7.29	6.22e-13	1.54e-10	-0.27	-0.22	Intelligence (multi-trait analysis);	chr15:82239933	chr15:82472993~82513950:-
BRCA	cis	rs5850	0.557	rs10270788	ENSG00000230042.1	AK3P3	-7.29	6.23e-13	1.54e-10	-0.25	-0.22	Blood protein levels;	chr7:23149381	chr7:23129178~23129841:+
BRCA	cis	rs858239	0.539	rs28716381	ENSG00000230042.1	AK3P3	-7.29	6.23e-13	1.54e-10	-0.25	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23149396	chr7:23129178~23129841:+
BRCA	cis	rs2348418	0.639	rs2881788	ENSG00000247934.4	RP11-967K21.1	-7.29	6.24e-13	1.54e-10	-0.26	-0.22	Lung function (FEV1);Lung function (FVC);	chr12:28119641	chr12:28163298~28190738:-
BRCA	cis	rs4723738	0.935	rs10233340	ENSG00000227191.5	TRGC2	-7.29	6.24e-13	1.55e-10	-0.2	-0.22	Treatment response for severe sepsis;	chr7:38183679	chr7:38239580~38368091:-
BRCA	cis	rs73173548	0.502	rs13165211	ENSG00000247828.6	TMEM161B-AS1	7.29	6.26e-13	1.55e-10	0.29	0.22	Macular telangiectasia type 2;	chr5:88443772	chr5:88268895~88436685:+
BRCA	cis	rs73173548	0.528	rs68019847	ENSG00000247828.6	TMEM161B-AS1	7.29	6.26e-13	1.55e-10	0.29	0.22	Macular telangiectasia type 2;	chr5:88446795	chr5:88268895~88436685:+
BRCA	cis	rs4727443	0.866	rs13238380	ENSG00000235713.1	RP4-604G5.3	-7.29	6.26e-13	1.55e-10	-0.25	-0.22	Interstitial lung disease;	chr7:100031438	chr7:99992397~99993050:+
BRCA	cis	rs3794924	0.925	rs35293326	ENSG00000266521.1	RP11-650P15.1	7.29	6.26e-13	1.55e-10	0.4	0.22	Survival in colon cancer;	chr18:31466467	chr18:31496645~31497195:-
BRCA	cis	rs780096	0.527	rs59644396	ENSG00000234072.1	AC074117.10	-7.29	6.26e-13	1.55e-10	-0.21	-0.22	Total body bone mineral density;	chr2:27423216	chr2:27356246~27367622:+
BRCA	cis	rs10754283	0.967	rs2390763	ENSG00000231613.1	RP5-943J3.1	7.29	6.26e-13	1.55e-10	0.25	0.22	Amyotrophic lateral sclerosis (sporadic);	chr1:89640129	chr1:89788914~89790492:+
BRCA	cis	rs1320333	0.685	rs6710875	ENSG00000233296.1	AC092159.2	-7.29	6.26e-13	1.55e-10	-0.38	-0.22	Obesity-related traits;	chr2:699976	chr2:677186~697371:+
BRCA	cis	rs11159086	1	rs4899516	ENSG00000259005.1	RP3-449M8.6	7.29	6.27e-13	1.55e-10	0.36	0.22	Advanced glycation end-product levels;	chr14:74492825	chr14:74474007~74474864:-
BRCA	cis	rs6723162	0.868	rs2192403	ENSG00000237751.2	LINC01143	-7.29	6.28e-13	1.55e-10	-0.26	-0.22	Neurocognitive impairment in HIV-1 infection (dichotomous);	chr2:70886008	chr2:70887871~70889959:+
BRCA	cis	rs7665090	0.87	rs228616	ENSG00000246560.2	RP11-10L12.4	-7.29	6.28e-13	1.55e-10	-0.23	-0.22	Primary biliary cholangitis;	chr4:102658534	chr4:102828055~102844075:+
BRCA	cis	rs875971	0.508	rs10242423	ENSG00000236529.1	RP13-254B10.1	-7.29	6.29e-13	1.56e-10	-0.24	-0.22	Aortic root size;	chr7:66594188	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.508	rs10253883	ENSG00000236529.1	RP13-254B10.1	-7.29	6.29e-13	1.56e-10	-0.24	-0.22	Aortic root size;	chr7:66596151	chr7:65840212~65840596:+
BRCA	cis	rs801193	0.66	rs10950049	ENSG00000232559.3	GS1-124K5.12	7.29	6.29e-13	1.56e-10	0.26	0.22	Aortic root size;	chr7:66765873	chr7:66554588~66576923:-
BRCA	cis	rs4835473	0.9	rs10027246	ENSG00000251600.4	RP11-673E1.1	-7.29	6.29e-13	1.56e-10	-0.28	-0.22	Immature fraction of reticulocytes;	chr4:143935069	chr4:143912331~143982454:+
BRCA	cis	rs7809950	1	rs10267907	ENSG00000238832.1	snoU109	-7.29	6.3e-13	1.56e-10	-0.29	-0.22	Coronary artery disease;	chr7:107544021	chr7:107603363~107603507:+
BRCA	cis	rs1667284	1	rs1667284	ENSG00000266521.1	RP11-650P15.1	-7.29	6.31e-13	1.56e-10	-0.27	-0.22	Problematic alcohol use in trauma-exposed individuals;	chr18:31646245	chr18:31496645~31497195:-
BRCA	cis	rs1555322	0.53	rs7004	ENSG00000279253.1	RP4-614O4.13	-7.29	6.31e-13	1.56e-10	-0.3	-0.22	Attention deficit hyperactivity disorder;	chr20:35278950	chr20:35262727~35264187:-
BRCA	cis	rs77204473	1	rs12292278	ENSG00000254851.1	RP11-109L13.1	-7.29	6.32e-13	1.56e-10	-0.5	-0.22	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116887977	chr11:117135528~117138582:+
BRCA	cis	rs3762637	1	rs72960431	ENSG00000272758.4	RP11-299J3.8	-7.28	6.34e-13	1.57e-10	-0.31	-0.22	LDL cholesterol levels;	chr3:122509814	chr3:122416207~122443180:+
BRCA	cis	rs3762637	1	rs28434553	ENSG00000272758.4	RP11-299J3.8	-7.28	6.34e-13	1.57e-10	-0.31	-0.22	LDL cholesterol levels;	chr3:122510668	chr3:122416207~122443180:+
BRCA	cis	rs3762637	0.941	rs9837149	ENSG00000272758.4	RP11-299J3.8	-7.28	6.34e-13	1.57e-10	-0.31	-0.22	LDL cholesterol levels;	chr3:122511998	chr3:122416207~122443180:+
BRCA	cis	rs950169	0.58	rs11634320	ENSG00000259728.4	LINC00933	-7.28	6.36e-13	1.57e-10	-0.28	-0.22	Schizophrenia;	chr15:84628952	chr15:84570649~84580175:+
BRCA	cis	rs2243480	1	rs73150014	ENSG00000273142.1	RP11-458F8.4	-7.28	6.38e-13	1.58e-10	-0.3	-0.22	Diabetic kidney disease;	chr7:65985932	chr7:66902857~66906297:+
BRCA	cis	rs73173548	0.502	rs34743961	ENSG00000247828.6	TMEM161B-AS1	7.28	6.38e-13	1.58e-10	0.29	0.22	Macular telangiectasia type 2;	chr5:88435952	chr5:88268895~88436685:+
BRCA	cis	rs10740039	0.883	rs7089287	ENSG00000254271.1	RP11-131N11.4	7.28	6.38e-13	1.58e-10	0.29	0.22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60634006	chr10:60734342~60741828:+
BRCA	cis	rs10740039	0.883	rs7093573	ENSG00000254271.1	RP11-131N11.4	7.28	6.38e-13	1.58e-10	0.29	0.22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60634611	chr10:60734342~60741828:+
BRCA	cis	rs10740039	0.883	rs7097818	ENSG00000254271.1	RP11-131N11.4	7.28	6.38e-13	1.58e-10	0.29	0.22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60635106	chr10:60734342~60741828:+
BRCA	cis	rs10740039	0.842	rs2119913	ENSG00000254271.1	RP11-131N11.4	7.28	6.38e-13	1.58e-10	0.29	0.22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60635631	chr10:60734342~60741828:+
BRCA	cis	rs8062405	0.723	rs4788079	ENSG00000251417.2	RP11-1348G14.4	-7.28	6.39e-13	1.58e-10	-0.26	-0.22	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548042	chr16:28802743~28817828:+
BRCA	cis	rs9649213	0.593	rs6969731	ENSG00000272950.1	RP11-307C18.1	7.28	6.41e-13	1.58e-10	0.28	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98295259	chr7:98322853~98323430:+
BRCA	cis	rs10463554	0.853	rs246907	ENSG00000175749.11	EIF3KP1	7.28	6.41e-13	1.58e-10	0.31	0.22	Parkinson's disease;	chr5:103230577	chr5:103032376~103033031:+
BRCA	cis	rs6545883	0.899	rs1562309	ENSG00000271889.1	RP11-493E12.1	7.28	6.41e-13	1.58e-10	0.29	0.22	Tuberculosis;	chr2:61542991	chr2:61151433~61162105:-
BRCA	cis	rs9527	0.571	rs3740400	ENSG00000213061.2	PFN1P11	7.28	6.42e-13	1.59e-10	0.29	0.22	Arsenic metabolism;	chr10:102869708	chr10:102838011~102845473:-
BRCA	cis	rs9880211	0.904	rs9857833	ENSG00000273486.1	RP11-731C17.2	7.28	6.42e-13	1.59e-10	0.29	0.22	Height;Body mass index;	chr3:136685625	chr3:136837338~136839021:-
BRCA	cis	rs7927771	0.929	rs12787646	ENSG00000280615.1	Y_RNA	-7.28	6.43e-13	1.59e-10	-0.27	-0.22	Subjective well-being;	chr11:47648113	chr11:47614898~47614994:-
BRCA	cis	rs10754283	0.967	rs1317864	ENSG00000231613.1	RP5-943J3.1	7.28	6.43e-13	1.59e-10	0.25	0.22	Amyotrophic lateral sclerosis (sporadic);	chr1:89639889	chr1:89788914~89790492:+
BRCA	cis	rs1113500	0.547	rs12076264	ENSG00000226822.1	RP11-356N1.2	-7.28	6.43e-13	1.59e-10	-0.28	-0.22	Growth-regulated protein alpha levels;	chr1:108014486	chr1:108071482~108074519:+
BRCA	cis	rs6545883	0.868	rs2518932	ENSG00000271889.1	RP11-493E12.1	7.28	6.43e-13	1.59e-10	0.28	0.22	Tuberculosis;	chr2:61574142	chr2:61151433~61162105:-
BRCA	cis	rs56046484	0.75	rs12900078	ENSG00000259295.5	CSPG4P12	7.28	6.44e-13	1.59e-10	0.42	0.22	Testicular germ cell tumor;	chr15:84980738	chr15:85191438~85213905:+
BRCA	cis	rs30380	1	rs26510	ENSG00000272109.1	CTD-2260A17.3	-7.28	6.46e-13	1.6e-10	-0.27	-0.22	Cerebrospinal fluid biomarker levels;	chr5:96790207	chr5:96804353~96806105:+
BRCA	cis	rs4723738	1	rs10240479	ENSG00000227191.5	TRGC2	-7.28	6.46e-13	1.6e-10	-0.2	-0.22	Treatment response for severe sepsis;	chr7:38181654	chr7:38239580~38368091:-
BRCA	cis	rs7208859	0.573	rs11654035	ENSG00000266490.1	CTD-2349P21.9	7.28	6.47e-13	1.6e-10	0.33	0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809408	chr17:30792372~30792833:+
BRCA	cis	rs2243480	1	rs781156	ENSG00000273142.1	RP11-458F8.4	-7.28	6.47e-13	1.6e-10	-0.3	-0.22	Diabetic kidney disease;	chr7:66014154	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs451396	ENSG00000273142.1	RP11-458F8.4	-7.28	6.47e-13	1.6e-10	-0.3	-0.22	Diabetic kidney disease;	chr7:66019087	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs1715235	ENSG00000273142.1	RP11-458F8.4	-7.28	6.47e-13	1.6e-10	-0.3	-0.22	Diabetic kidney disease;	chr7:66023407	chr7:66902857~66906297:+
BRCA	cis	rs858239	0.72	rs10227559	ENSG00000230042.1	AK3P3	-7.28	6.48e-13	1.6e-10	-0.26	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23232525	chr7:23129178~23129841:+
BRCA	cis	rs858239	0.601	rs764534	ENSG00000230042.1	AK3P3	-7.28	6.48e-13	1.6e-10	-0.25	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23114316	chr7:23129178~23129841:+
BRCA	cis	rs858239	0.601	rs2068459	ENSG00000230042.1	AK3P3	-7.28	6.48e-13	1.6e-10	-0.25	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23114694	chr7:23129178~23129841:+
BRCA	cis	rs253959	0.672	rs1133186	ENSG00000271918.1	CTD-2287O16.5	7.28	6.48e-13	1.6e-10	0.18	0.22	Bipolar disorder and schizophrenia;	chr5:116084718	chr5:116083807~116085416:-
BRCA	cis	rs801193	0.742	rs9969300	ENSG00000222364.1	RNU6-96P	7.28	6.5e-13	1.6e-10	0.25	0.22	Aortic root size;	chr7:66316659	chr7:66395191~66395286:+
BRCA	cis	rs465969	1	rs465969	ENSG00000255389.1	C6orf3	-7.28	6.5e-13	1.6e-10	-0.35	-0.22	Psoriasis;	chr6:111334327	chr6:111599875~111602295:+
BRCA	cis	rs42648	0.869	rs6973816	ENSG00000225498.1	AC002064.5	7.28	6.5e-13	1.61e-10	0.21	0.22	Homocysteine levels;	chr7:90291758	chr7:90312496~90322592:+
BRCA	cis	rs7586673	0.725	rs6715870	ENSG00000227403.1	AC009299.3	-7.28	6.51e-13	1.61e-10	-0.3	-0.22	Intelligence (multi-trait analysis);	chr2:161038275	chr2:161244739~161249050:+
BRCA	cis	rs2742234	0.541	rs7098236	ENSG00000273008.1	RP11-351D16.3	7.28	6.52e-13	1.61e-10	0.28	0.22	Hirschsprung disease;	chr10:43245060	chr10:43136824~43138334:-
BRCA	cis	rs1864400	0.69	rs7098237	ENSG00000273008.1	RP11-351D16.3	7.28	6.52e-13	1.61e-10	0.28	0.22	Hirschsprung disease;	chr10:43245065	chr10:43136824~43138334:-
BRCA	cis	rs17428076	0.556	rs12692976	ENSG00000228389.1	AC068039.4	7.28	6.53e-13	1.61e-10	0.27	0.22	Myopia;	chr2:171827893	chr2:171773482~171775844:+
BRCA	cis	rs9876781	0.559	rs7630053	ENSG00000229759.1	MRPS18AP1	7.28	6.55e-13	1.62e-10	0.26	0.22	Longevity;	chr3:48357096	chr3:48256350~48256938:-
BRCA	cis	rs9649213	0.593	rs11760930	ENSG00000272950.1	RP11-307C18.1	7.28	6.56e-13	1.62e-10	0.28	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98286477	chr7:98322853~98323430:+
BRCA	cis	rs911555	0.755	rs12436729	ENSG00000244691.1	RPL10AP1	7.28	6.57e-13	1.62e-10	0.28	0.22	Intelligence (multi-trait analysis);	chr14:103463552	chr14:103412119~103412761:-
BRCA	cis	rs42648	0.87	rs7783199	ENSG00000225498.1	AC002064.5	-7.28	6.57e-13	1.62e-10	-0.21	-0.22	Homocysteine levels;	chr7:90369991	chr7:90312496~90322592:+
BRCA	cis	rs12446554	0.509	rs56100071	ENSG00000261195.1	CTD-2380F24.1	-7.28	6.57e-13	1.62e-10	-0.34	-0.22	Obesity;	chr16:19698429	chr16:19761172~19766099:-
BRCA	cis	rs11096990	0.855	rs2566172	ENSG00000249207.1	RP11-360F5.1	7.28	6.58e-13	1.62e-10	0.26	0.22	Cognitive function;	chr4:39150943	chr4:39112677~39126818:-
BRCA	cis	rs9880211	0.8	rs35422852	ENSG00000239213.4	NCK1-AS1	7.28	6.59e-13	1.63e-10	0.29	0.22	Height;Body mass index;	chr3:136787073	chr3:136841726~136862054:-
BRCA	cis	rs801193	0.569	rs2659893	ENSG00000232559.3	GS1-124K5.12	7.28	6.59e-13	1.63e-10	0.27	0.22	Aortic root size;	chr7:66735006	chr7:66554588~66576923:-
BRCA	cis	rs801193	0.569	rs2659892	ENSG00000232559.3	GS1-124K5.12	7.28	6.59e-13	1.63e-10	0.27	0.22	Aortic root size;	chr7:66735318	chr7:66554588~66576923:-
BRCA	cis	rs801193	0.569	rs2707847	ENSG00000232559.3	GS1-124K5.12	7.28	6.59e-13	1.63e-10	0.27	0.22	Aortic root size;	chr7:66737884	chr7:66554588~66576923:-
BRCA	cis	rs8059260	0.696	rs2110354	ENSG00000274038.1	RP11-66H6.4	-7.28	6.61e-13	1.63e-10	-0.27	-0.22	Alcohol consumption over the past year;	chr16:11013635	chr16:11056556~11057034:+
BRCA	cis	rs6545883	0.965	rs1992765	ENSG00000271889.1	RP11-493E12.1	7.28	6.62e-13	1.63e-10	0.28	0.22	Tuberculosis;	chr2:61524198	chr2:61151433~61162105:-
BRCA	cis	rs2742234	0.541	rs10899782	ENSG00000273008.1	RP11-351D16.3	7.28	6.62e-13	1.63e-10	0.28	0.22	Hirschsprung disease;	chr10:43240913	chr10:43136824~43138334:-
BRCA	cis	rs2274273	0.624	rs67412516	ENSG00000258413.1	RP11-665C16.6	-7.28	6.65e-13	1.64e-10	-0.3	-0.22	Protein biomarker;	chr14:55386519	chr14:55262767~55272075:-
BRCA	cis	rs6570726	0.846	rs7773939	ENSG00000270638.1	RP3-466P17.1	-7.28	6.65e-13	1.64e-10	-0.26	-0.22	Lobe attachment (rater-scored or self-reported);	chr6:145606248	chr6:145735570~145737218:+
BRCA	cis	rs10510102	0.935	rs11818001	ENSG00000276742.1	RP11-500G22.4	-7.28	6.65e-13	1.64e-10	-0.37	-0.22	Breast cancer;	chr10:121884830	chr10:121956782~121957098:+
BRCA	cis	rs301901	0.965	rs2886201	ENSG00000250155.1	CTD-2353F22.1	-7.28	6.66e-13	1.64e-10	-0.23	-0.22	Height;	chr5:36796728	chr5:36666214~36725195:-
BRCA	cis	rs2288884	0.636	rs11669439	ENSG00000275055.1	CTC-471J1.11	-7.28	6.66e-13	1.64e-10	-0.26	-0.22	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52069047	chr19:52049007~52049754:+
BRCA	cis	rs875971	0.558	rs4433015	ENSG00000237310.1	GS1-124K5.4	-7.28	6.67e-13	1.65e-10	-0.23	-0.22	Aortic root size;	chr7:66174736	chr7:66493706~66495474:+
BRCA	cis	rs6545883	0.931	rs778768	ENSG00000271889.1	RP11-493E12.1	7.28	6.68e-13	1.65e-10	0.29	0.22	Tuberculosis;	chr2:61563154	chr2:61151433~61162105:-
BRCA	cis	rs77204473	1	rs12294191	ENSG00000254851.1	RP11-109L13.1	7.28	6.7e-13	1.65e-10	0.47	0.22	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116889108	chr11:117135528~117138582:+
BRCA	cis	rs4727443	0.866	rs2897075	ENSG00000235713.1	RP4-604G5.3	-7.28	6.71e-13	1.66e-10	-0.25	-0.22	Interstitial lung disease;	chr7:100032719	chr7:99992397~99993050:+
BRCA	cis	rs2599510	0.811	rs2583713	ENSG00000276334.1	AL133243.1	7.28	6.72e-13	1.66e-10	0.28	0.22	Interleukin-18 levels;	chr2:32597662	chr2:32521927~32523547:+
BRCA	cis	rs2288884	0.581	rs9636144	ENSG00000275055.1	CTC-471J1.11	-7.28	6.72e-13	1.66e-10	-0.26	-0.22	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52057881	chr19:52049007~52049754:+
BRCA	cis	rs11976180	1	rs2961115	ENSG00000204959.4	ARHGEF34P	7.28	6.73e-13	1.66e-10	0.27	0.22	Obesity-related traits;	chr7:144056278	chr7:144272445~144286966:-
BRCA	cis	rs875971	1	rs6945843	ENSG00000232559.3	GS1-124K5.12	-7.28	6.74e-13	1.66e-10	-0.26	-0.22	Aortic root size;	chr7:66269796	chr7:66554588~66576923:-
BRCA	cis	rs2288884	0.636	rs8105801	ENSG00000275055.1	CTC-471J1.11	-7.28	6.74e-13	1.66e-10	-0.26	-0.22	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52074095	chr19:52049007~52049754:+
BRCA	cis	rs10463554	0.889	rs246899	ENSG00000175749.11	EIF3KP1	7.28	6.75e-13	1.66e-10	0.31	0.22	Parkinson's disease;	chr5:103241438	chr5:103032376~103033031:+
BRCA	cis	rs4723738	1	rs35997004	ENSG00000227191.5	TRGC2	-7.28	6.76e-13	1.67e-10	-0.2	-0.22	Treatment response for severe sepsis;	chr7:38186081	chr7:38239580~38368091:-
BRCA	cis	rs4723738	1	rs11766312	ENSG00000227191.5	TRGC2	-7.28	6.76e-13	1.67e-10	-0.2	-0.22	Treatment response for severe sepsis;	chr7:38187990	chr7:38239580~38368091:-
BRCA	cis	rs4727443	0.866	rs12531809	ENSG00000235713.1	RP4-604G5.3	-7.28	6.76e-13	1.67e-10	-0.25	-0.22	Interstitial lung disease;	chr7:100022850	chr7:99992397~99993050:+
BRCA	cis	rs11098499	0.955	rs1551	ENSG00000248280.1	RP11-33B1.2	7.28	6.77e-13	1.67e-10	0.23	0.22	Corneal astigmatism;	chr4:119237345	chr4:119440561~119450157:-
BRCA	cis	rs6545883	1	rs778758	ENSG00000271889.1	RP11-493E12.1	7.28	6.78e-13	1.67e-10	0.29	0.22	Tuberculosis;	chr2:61555026	chr2:61151433~61162105:-
BRCA	cis	rs9649213	0.593	rs6465673	ENSG00000272950.1	RP11-307C18.1	7.28	6.79e-13	1.67e-10	0.28	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98339575	chr7:98322853~98323430:+
BRCA	cis	rs858239	0.67	rs6967526	ENSG00000230042.1	AK3P3	-7.28	6.8e-13	1.67e-10	-0.25	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23119622	chr7:23129178~23129841:+
BRCA	cis	rs8062405	0.723	rs113208333	ENSG00000251417.2	RP11-1348G14.4	-7.28	6.8e-13	1.68e-10	-0.26	-0.22	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28594839	chr16:28802743~28817828:+
BRCA	cis	rs10754283	0.967	rs7513928	ENSG00000231613.1	RP5-943J3.1	7.28	6.8e-13	1.68e-10	0.25	0.22	Amyotrophic lateral sclerosis (sporadic);	chr1:89639275	chr1:89788914~89790492:+
BRCA	cis	rs801193	0.844	rs732465	ENSG00000224316.1	RP11-479O9.2	7.27	6.81e-13	1.68e-10	0.22	0.22	Aortic root size;	chr7:66533463	chr7:65773620~65802067:+
BRCA	cis	rs4835473	0.897	rs36083752	ENSG00000251600.4	RP11-673E1.1	-7.27	6.82e-13	1.68e-10	-0.26	-0.22	Immature fraction of reticulocytes;	chr4:143693377	chr4:143912331~143982454:+
BRCA	cis	rs4835473	0.897	rs35162238	ENSG00000251600.4	RP11-673E1.1	-7.27	6.82e-13	1.68e-10	-0.26	-0.22	Immature fraction of reticulocytes;	chr4:143693518	chr4:143912331~143982454:+
BRCA	cis	rs2274273	0.624	rs10132453	ENSG00000258413.1	RP11-665C16.6	-7.27	6.82e-13	1.68e-10	-0.3	-0.22	Protein biomarker;	chr14:55374133	chr14:55262767~55272075:-
BRCA	cis	rs78456975	0.506	rs10167704	ENSG00000231482.2	AC141930.2	-7.27	6.82e-13	1.68e-10	-0.29	-0.22	Placebo response in major depressive disorder (% change in symptom score);	chr2:1567265	chr2:1572554~1580311:-
BRCA	cis	rs78456975	0.527	rs10184112	ENSG00000231482.2	AC141930.2	-7.27	6.82e-13	1.68e-10	-0.29	-0.22	Placebo response in major depressive disorder (% change in symptom score);	chr2:1567340	chr2:1572554~1580311:-
BRCA	cis	rs10206020	0.921	rs72776300	ENSG00000231482.2	AC141930.2	-7.27	6.82e-13	1.68e-10	-0.29	-0.22	IgG glycosylation;	chr2:1567380	chr2:1572554~1580311:-
BRCA	cis	rs34375054	1	rs3751178	ENSG00000279233.1	RP11-158L12.4	-7.27	6.83e-13	1.68e-10	-0.26	-0.22	Post bronchodilator FEV1/FVC ratio;	chr12:125179811	chr12:125138245~125141711:+
BRCA	cis	rs950776	0.647	rs495956	ENSG00000261762.1	RP11-650L12.2	-7.27	6.84e-13	1.68e-10	-0.24	-0.22	Sudden cardiac arrest;	chr15:78577588	chr15:78589123~78591276:-
BRCA	cis	rs801193	0.548	rs2659891	ENSG00000232559.3	GS1-124K5.12	7.27	6.84e-13	1.69e-10	0.27	0.22	Aortic root size;	chr7:66736127	chr7:66554588~66576923:-
BRCA	cis	rs801193	0.548	rs7805152	ENSG00000232559.3	GS1-124K5.12	7.27	6.84e-13	1.69e-10	0.27	0.22	Aortic root size;	chr7:66744266	chr7:66554588~66576923:-
BRCA	cis	rs780096	0.546	rs12473776	ENSG00000234072.1	AC074117.10	-7.27	6.85e-13	1.69e-10	-0.21	-0.22	Total body bone mineral density;	chr2:27413607	chr2:27356246~27367622:+
BRCA	cis	rs780096	0.506	rs1728922	ENSG00000234072.1	AC074117.10	-7.27	6.85e-13	1.69e-10	-0.21	-0.22	Total body bone mineral density;	chr2:27421597	chr2:27356246~27367622:+
BRCA	cis	rs987724	0.571	rs7641929	ENSG00000240875.4	LINC00886	-7.27	6.87e-13	1.69e-10	-0.25	-0.22	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156811605	chr3:156747346~156817062:-
BRCA	cis	rs987724	0.531	rs12492804	ENSG00000240875.4	LINC00886	-7.27	6.87e-13	1.69e-10	-0.25	-0.22	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156814356	chr3:156747346~156817062:-
BRCA	cis	rs987724	0.592	rs12497539	ENSG00000240875.4	LINC00886	-7.27	6.87e-13	1.69e-10	-0.25	-0.22	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156816148	chr3:156747346~156817062:-
BRCA	cis	rs987724	0.571	rs59717073	ENSG00000240875.4	LINC00886	-7.27	6.87e-13	1.69e-10	-0.25	-0.22	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156816456	chr3:156747346~156817062:-
BRCA	cis	rs10129255	0.556	rs9324093	ENSG00000211970.3	IGHV4-61	-7.27	6.88e-13	1.69e-10	-0.14	-0.22	Kawasaki disease;	chr14:106683893	chr14:106639119~106639657:-
BRCA	cis	rs11976180	1	rs13226728	ENSG00000204959.4	ARHGEF34P	7.27	6.88e-13	1.69e-10	0.27	0.22	Obesity-related traits;	chr7:144049485	chr7:144272445~144286966:-
BRCA	cis	rs1322639	1	rs9689079	ENSG00000261039.2	RP11-417E7.2	7.27	6.89e-13	1.7e-10	0.23	0.22	Pulse pressure;	chr6:169187053	chr6:169175304~169182740:-
BRCA	cis	rs7208859	0.623	rs9895785	ENSG00000263603.1	CTD-2349P21.5	7.27	6.9e-13	1.7e-10	0.38	0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780690	chr17:30729469~30731202:+
BRCA	cis	rs6570726	0.935	rs454370	ENSG00000235652.6	RP11-545I5.3	7.27	6.92e-13	1.7e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145525593	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.935	rs416987	ENSG00000235652.6	RP11-545I5.3	7.27	6.92e-13	1.7e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145525869	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.905	rs452770	ENSG00000235652.6	RP11-545I5.3	7.27	6.92e-13	1.7e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145526026	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.935	rs442254	ENSG00000235652.6	RP11-545I5.3	7.27	6.92e-13	1.7e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145527982	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.846	rs441575	ENSG00000235652.6	RP11-545I5.3	7.27	6.92e-13	1.7e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145528069	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.935	rs436212	ENSG00000235652.6	RP11-545I5.3	7.27	6.92e-13	1.7e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145528264	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.935	rs414222	ENSG00000235652.6	RP11-545I5.3	7.27	6.92e-13	1.7e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145529346	chr6:145799409~145886585:+
BRCA	cis	rs7208859	0.623	rs122898	ENSG00000263603.1	CTD-2349P21.5	7.27	6.95e-13	1.71e-10	0.39	0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30578236	chr17:30729469~30731202:+
BRCA	cis	rs780096	0.526	rs3845687	ENSG00000234072.1	AC074117.10	-7.27	6.95e-13	1.71e-10	-0.21	-0.22	Total body bone mineral density;	chr2:27467032	chr2:27356246~27367622:+
BRCA	cis	rs6570726	0.935	rs411641	ENSG00000235652.6	RP11-545I5.3	7.27	6.95e-13	1.71e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145506396	chr6:145799409~145886585:+
BRCA	cis	rs7688540	0.723	rs9684973	ENSG00000211553.1	AC253576.2	-7.27	6.95e-13	1.71e-10	-0.31	-0.22	Facial morphology (factor 6, height of vermillion lower lip);	chr4:245032	chr4:136461~136568:+
BRCA	cis	rs6762	0.719	rs28655651	ENSG00000279672.1	CMB9-55F22.1	7.27	6.96e-13	1.71e-10	0.25	0.22	Mean platelet volume;	chr11:837121	chr11:779617~780755:+
BRCA	cis	rs10861661	1	rs10861661	ENSG00000260329.1	RP11-412D9.4	-7.27	6.96e-13	1.71e-10	-0.28	-0.22	Triglyceride levels;	chr12:106780868	chr12:106954029~106955497:-
BRCA	cis	rs875971	0.545	rs11767262	ENSG00000224316.1	RP11-479O9.2	7.27	6.97e-13	1.71e-10	0.25	0.22	Aortic root size;	chr7:66302237	chr7:65773620~65802067:+
BRCA	cis	rs7617773	0.815	rs9825637	ENSG00000228638.1	FCF1P2	-7.27	6.98e-13	1.72e-10	-0.24	-0.22	Coronary artery disease;	chr3:48330792	chr3:48290793~48291375:-
BRCA	cis	rs10515750	0.588	rs10077326	ENSG00000248544.2	CTB-47B11.3	7.27	6.99e-13	1.72e-10	0.32	0.22	Lung function (FEV1/FVC);	chr5:157343761	chr5:157375741~157384950:-
BRCA	cis	rs10515750	0.588	rs10077470	ENSG00000248544.2	CTB-47B11.3	7.27	6.99e-13	1.72e-10	0.32	0.22	Lung function (FEV1/FVC);	chr5:157343975	chr5:157375741~157384950:-
BRCA	cis	rs9649213	0.593	rs6465678	ENSG00000272950.1	RP11-307C18.1	7.27	7e-13	1.72e-10	0.28	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98374745	chr7:98322853~98323430:+
BRCA	cis	rs12291225	0.679	rs11605531	ENSG00000251991.1	RNU7-49P	7.27	7e-13	1.72e-10	0.26	0.22	Sense of smell;	chr11:14270048	chr11:14478892~14478953:+
BRCA	cis	rs11976180	1	rs6464573	ENSG00000204959.4	ARHGEF34P	-7.27	7.01e-13	1.72e-10	-0.27	-0.22	Obesity-related traits;	chr7:144051005	chr7:144272445~144286966:-
BRCA	cis	rs950776	0.616	rs495090	ENSG00000261762.1	RP11-650L12.2	-7.27	7.01e-13	1.72e-10	-0.24	-0.22	Sudden cardiac arrest;	chr15:78577661	chr15:78589123~78591276:-
BRCA	cis	rs950776	0.722	rs471889	ENSG00000261762.1	RP11-650L12.2	-7.27	7.01e-13	1.72e-10	-0.24	-0.22	Sudden cardiac arrest;	chr15:78577893	chr15:78589123~78591276:-
BRCA	cis	rs858239	0.867	rs10250602	ENSG00000230042.1	AK3P3	-7.27	7.02e-13	1.73e-10	-0.26	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23264082	chr7:23129178~23129841:+
BRCA	cis	rs74233809	1	rs11191499	ENSG00000213277.3	MARCKSL1P1	7.27	7.02e-13	1.73e-10	0.39	0.22	Birth weight;	chr10:103004514	chr10:103175554~103176094:+
BRCA	cis	rs2060793	0.55	rs1037378	ENSG00000251991.1	RNU7-49P	7.27	7.05e-13	1.73e-10	0.24	0.22	Vitamin D levels;	chr11:14830944	chr11:14478892~14478953:+
BRCA	cis	rs1499614	1	rs2141924	ENSG00000232546.1	RP11-458F8.1	-7.27	7.06e-13	1.74e-10	-0.3	-0.22	Gout;	chr7:66721259	chr7:66848496~66858136:+
BRCA	cis	rs66887589	0.967	rs2892869	ENSG00000248280.1	RP11-33B1.2	-7.27	7.06e-13	1.74e-10	-0.2	-0.22	Diastolic blood pressure;	chr4:119600142	chr4:119440561~119450157:-
BRCA	cis	rs2880765	0.835	rs11856869	ENSG00000259295.5	CSPG4P12	7.27	7.06e-13	1.74e-10	0.27	0.22	Coronary artery disease;	chr15:85485866	chr15:85191438~85213905:+
BRCA	cis	rs7615952	0.599	rs12485717	ENSG00000250012.1	RP11-124N2.1	7.27	7.06e-13	1.74e-10	0.3	0.22	Blood pressure (smoking interaction);	chr3:125988232	chr3:126084220~126095349:+
BRCA	cis	rs6545883	0.965	rs9989775	ENSG00000271889.1	RP11-493E12.1	7.27	7.07e-13	1.74e-10	0.28	0.22	Tuberculosis;	chr2:61534639	chr2:61151433~61162105:-
BRCA	cis	rs950776	0.752	rs7182583	ENSG00000261762.1	RP11-650L12.2	7.27	7.07e-13	1.74e-10	0.25	0.22	Sudden cardiac arrest;	chr15:78606868	chr15:78589123~78591276:-
BRCA	cis	rs10510102	0.935	rs12262776	ENSG00000276742.1	RP11-500G22.4	7.27	7.07e-13	1.74e-10	0.37	0.22	Breast cancer;	chr10:121884532	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.935	rs12244866	ENSG00000276742.1	RP11-500G22.4	7.27	7.07e-13	1.74e-10	0.37	0.22	Breast cancer;	chr10:121886013	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.935	rs12266597	ENSG00000276742.1	RP11-500G22.4	7.27	7.07e-13	1.74e-10	0.37	0.22	Breast cancer;	chr10:121886062	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.935	rs12245018	ENSG00000276742.1	RP11-500G22.4	7.27	7.07e-13	1.74e-10	0.37	0.22	Breast cancer;	chr10:121886195	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.935	rs11200217	ENSG00000276742.1	RP11-500G22.4	7.27	7.07e-13	1.74e-10	0.37	0.22	Breast cancer;	chr10:121886372	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.935	rs11200218	ENSG00000276742.1	RP11-500G22.4	7.27	7.07e-13	1.74e-10	0.37	0.22	Breast cancer;	chr10:121886410	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.935	rs10887008	ENSG00000276742.1	RP11-500G22.4	7.27	7.07e-13	1.74e-10	0.37	0.22	Breast cancer;	chr10:121886714	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.935	rs12268872	ENSG00000276742.1	RP11-500G22.4	7.27	7.07e-13	1.74e-10	0.37	0.22	Breast cancer;	chr10:121887426	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.935	rs9630107	ENSG00000276742.1	RP11-500G22.4	7.27	7.07e-13	1.74e-10	0.37	0.22	Breast cancer;	chr10:121887713	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.935	rs10887010	ENSG00000276742.1	RP11-500G22.4	7.27	7.07e-13	1.74e-10	0.37	0.22	Breast cancer;	chr10:121888542	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.935	rs12251175	ENSG00000276742.1	RP11-500G22.4	7.27	7.07e-13	1.74e-10	0.37	0.22	Breast cancer;	chr10:121889015	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.872	rs11200220	ENSG00000276742.1	RP11-500G22.4	7.27	7.07e-13	1.74e-10	0.37	0.22	Breast cancer;	chr10:121889949	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.935	rs11200221	ENSG00000276742.1	RP11-500G22.4	7.27	7.07e-13	1.74e-10	0.37	0.22	Breast cancer;	chr10:121890134	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.935	rs10887011	ENSG00000276742.1	RP11-500G22.4	7.27	7.07e-13	1.74e-10	0.37	0.22	Breast cancer;	chr10:121890203	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.935	rs10887012	ENSG00000276742.1	RP11-500G22.4	7.27	7.07e-13	1.74e-10	0.37	0.22	Breast cancer;	chr10:121890454	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.872	rs11200222	ENSG00000276742.1	RP11-500G22.4	7.27	7.07e-13	1.74e-10	0.37	0.22	Breast cancer;	chr10:121891177	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.935	rs11200223	ENSG00000276742.1	RP11-500G22.4	7.27	7.07e-13	1.74e-10	0.37	0.22	Breast cancer;	chr10:121891416	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.935	rs10887013	ENSG00000276742.1	RP11-500G22.4	7.27	7.07e-13	1.74e-10	0.37	0.22	Breast cancer;	chr10:121891546	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.872	rs11200225	ENSG00000276742.1	RP11-500G22.4	7.27	7.07e-13	1.74e-10	0.37	0.22	Breast cancer;	chr10:121891948	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.935	rs11200226	ENSG00000276742.1	RP11-500G22.4	7.27	7.07e-13	1.74e-10	0.37	0.22	Breast cancer;	chr10:121891988	chr10:121956782~121957098:+
BRCA	cis	rs12237653	0.929	rs4741732	ENSG00000236404.7	VLDLR-AS1	7.27	7.07e-13	1.74e-10	0.34	0.22	Gambling;	chr9:2548026	chr9:2422702~2643359:-
BRCA	cis	rs11098499	0.532	rs4833624	ENSG00000245958.5	RP11-33B1.1	-7.27	7.1e-13	1.74e-10	-0.21	-0.22	Corneal astigmatism;	chr4:119664342	chr4:119454791~119552025:+
BRCA	cis	rs293748	0.54	rs12655320	ENSG00000250155.1	CTD-2353F22.1	-7.27	7.1e-13	1.75e-10	-0.3	-0.22	Obesity-related traits;	chr5:37104756	chr5:36666214~36725195:-
BRCA	cis	rs4835473	0.863	rs7696828	ENSG00000251600.4	RP11-673E1.1	7.27	7.13e-13	1.75e-10	0.26	0.22	Immature fraction of reticulocytes;	chr4:143700846	chr4:143912331~143982454:+
BRCA	cis	rs6545883	0.929	rs55806663	ENSG00000271889.1	RP11-493E12.1	7.27	7.13e-13	1.75e-10	0.28	0.22	Tuberculosis;	chr2:61513352	chr2:61151433~61162105:-
BRCA	cis	rs2880765	0.835	rs4514633	ENSG00000259295.5	CSPG4P12	7.27	7.14e-13	1.75e-10	0.27	0.22	Coronary artery disease;	chr15:85497786	chr15:85191438~85213905:+
BRCA	cis	rs2742234	0.955	rs2503849	ENSG00000273008.1	RP11-351D16.3	-7.27	7.15e-13	1.76e-10	-0.26	-0.22	Hirschsprung disease;	chr10:43177328	chr10:43136824~43138334:-
BRCA	cis	rs2742234	0.955	rs2435384	ENSG00000273008.1	RP11-351D16.3	-7.27	7.15e-13	1.76e-10	-0.26	-0.22	Hirschsprung disease;	chr10:43178283	chr10:43136824~43138334:-
BRCA	cis	rs2243480	0.901	rs57126451	ENSG00000273142.1	RP11-458F8.4	-7.27	7.16e-13	1.76e-10	-0.3	-0.22	Diabetic kidney disease;	chr7:65951319	chr7:66902857~66906297:+
BRCA	cis	rs11098499	0.566	rs7664440	ENSG00000245958.5	RP11-33B1.1	-7.27	7.17e-13	1.76e-10	-0.22	-0.22	Corneal astigmatism;	chr4:119657385	chr4:119454791~119552025:+
BRCA	cis	rs9880211	0.898	rs6770476	ENSG00000273486.1	RP11-731C17.2	7.27	7.19e-13	1.77e-10	0.26	0.22	Height;Body mass index;	chr3:136355078	chr3:136837338~136839021:-
BRCA	cis	rs2688608	0.592	rs7923045	ENSG00000271816.1	BMS1P4	7.27	7.2e-13	1.77e-10	0.21	0.22	Inflammatory bowel disease;	chr10:73727740	chr10:73699151~73730487:-
BRCA	cis	rs7208859	0.573	rs11654035	ENSG00000263603.1	CTD-2349P21.5	-7.27	7.21e-13	1.77e-10	-0.39	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809408	chr17:30729469~30731202:+
BRCA	cis	rs867371	0.717	rs3858954	ENSG00000255769.6	GOLGA2P10	-7.27	7.21e-13	1.77e-10	-0.26	-0.22	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82265693	chr15:82472993~82513950:-
BRCA	cis	rs9880211	0.8	rs9865995	ENSG00000239213.4	NCK1-AS1	7.27	7.23e-13	1.77e-10	0.29	0.22	Height;Body mass index;	chr3:136794508	chr3:136841726~136862054:-
BRCA	cis	rs9880211	0.8	rs9871184	ENSG00000239213.4	NCK1-AS1	7.27	7.23e-13	1.77e-10	0.29	0.22	Height;Body mass index;	chr3:136795468	chr3:136841726~136862054:-
BRCA	cis	rs6570726	0.935	rs385134	ENSG00000235652.6	RP11-545I5.3	7.27	7.24e-13	1.78e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145529869	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.935	rs415590	ENSG00000235652.6	RP11-545I5.3	7.27	7.24e-13	1.78e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145530108	chr6:145799409~145886585:+
BRCA	cis	rs780096	0.546	rs2911712	ENSG00000234072.1	AC074117.10	-7.27	7.24e-13	1.78e-10	-0.21	-0.22	Total body bone mineral density;	chr2:27404078	chr2:27356246~27367622:+
BRCA	cis	rs6545883	0.931	rs11125885	ENSG00000271889.1	RP11-493E12.1	7.27	7.24e-13	1.78e-10	0.28	0.22	Tuberculosis;	chr2:61528593	chr2:61151433~61162105:-
BRCA	cis	rs7927771	1	rs10838757	ENSG00000280615.1	Y_RNA	-7.27	7.28e-13	1.79e-10	-0.27	-0.22	Subjective well-being;	chr11:47741464	chr11:47614898~47614994:-
BRCA	cis	rs875971	0.508	rs10950045	ENSG00000236529.1	RP13-254B10.1	-7.27	7.29e-13	1.79e-10	-0.24	-0.22	Aortic root size;	chr7:66601386	chr7:65840212~65840596:+
BRCA	cis	rs801193	0.839	rs6968619	ENSG00000236529.1	RP13-254B10.1	-7.27	7.29e-13	1.79e-10	-0.24	-0.22	Aortic root size;	chr7:66603880	chr7:65840212~65840596:+
BRCA	cis	rs801193	0.805	rs12532355	ENSG00000236529.1	RP13-254B10.1	-7.27	7.29e-13	1.79e-10	-0.24	-0.22	Aortic root size;	chr7:66605597	chr7:65840212~65840596:+
BRCA	cis	rs11976180	1	rs2951368	ENSG00000204959.4	ARHGEF34P	7.26	7.3e-13	1.79e-10	0.27	0.22	Obesity-related traits;	chr7:144055728	chr7:144272445~144286966:-
BRCA	cis	rs801193	0.569	rs11772819	ENSG00000232559.3	GS1-124K5.12	7.26	7.32e-13	1.8e-10	0.26	0.22	Aortic root size;	chr7:66752983	chr7:66554588~66576923:-
BRCA	cis	rs801193	0.569	rs7800620	ENSG00000232559.3	GS1-124K5.12	7.26	7.32e-13	1.8e-10	0.26	0.22	Aortic root size;	chr7:66758701	chr7:66554588~66576923:-
BRCA	cis	rs7809950	0.953	rs2520263	ENSG00000238832.1	snoU109	-7.26	7.32e-13	1.8e-10	-0.29	-0.22	Coronary artery disease;	chr7:107538674	chr7:107603363~107603507:+
BRCA	cis	rs6545883	1	rs778763	ENSG00000271889.1	RP11-493E12.1	7.26	7.33e-13	1.8e-10	0.28	0.22	Tuberculosis;	chr2:61558504	chr2:61151433~61162105:-
BRCA	cis	rs3814244	0.515	rs2906856	ENSG00000236946.2	HNRNPA1P70	7.26	7.33e-13	1.8e-10	0.18	0.22	Itch intensity from mosquito bite adjusted by bite size;	chr12:67996421	chr12:68035767~68036853:+
BRCA	cis	rs74233809	1	rs76752100	ENSG00000213277.3	MARCKSL1P1	7.26	7.35e-13	1.8e-10	0.4	0.22	Birth weight;	chr10:103034329	chr10:103175554~103176094:+
BRCA	cis	rs875971	0.929	rs4122249	ENSG00000232559.3	GS1-124K5.12	7.26	7.36e-13	1.81e-10	0.26	0.22	Aortic root size;	chr7:66455949	chr7:66554588~66576923:-
BRCA	cis	rs42648	0.869	rs10234301	ENSG00000225498.1	AC002064.5	7.26	7.39e-13	1.81e-10	0.21	0.22	Homocysteine levels;	chr7:90288964	chr7:90312496~90322592:+
BRCA	cis	rs66887589	0.967	rs7678973	ENSG00000248280.1	RP11-33B1.2	-7.26	7.39e-13	1.81e-10	-0.2	-0.22	Diastolic blood pressure;	chr4:119590662	chr4:119440561~119450157:-
BRCA	cis	rs891378	0.755	rs7411168	ENSG00000274245.1	RP11-357P18.2	-7.26	7.39e-13	1.81e-10	-0.28	-0.22	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207201970	chr1:207372559~207373252:+
BRCA	cis	rs2243480	1	rs35046236	ENSG00000273142.1	RP11-458F8.4	-7.26	7.41e-13	1.82e-10	-0.3	-0.22	Diabetic kidney disease;	chr7:65943626	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs36068983	ENSG00000273142.1	RP11-458F8.4	-7.26	7.41e-13	1.82e-10	-0.3	-0.22	Diabetic kidney disease;	chr7:65944004	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs68189316	ENSG00000273142.1	RP11-458F8.4	-7.26	7.41e-13	1.82e-10	-0.3	-0.22	Diabetic kidney disease;	chr7:65944182	chr7:66902857~66906297:+
BRCA	cis	rs73173548	0.502	rs34969608	ENSG00000247828.6	TMEM161B-AS1	7.26	7.41e-13	1.82e-10	0.29	0.22	Macular telangiectasia type 2;	chr5:88448606	chr5:88268895~88436685:+
BRCA	cis	rs73173548	0.502	rs6885165	ENSG00000247828.6	TMEM161B-AS1	7.26	7.41e-13	1.82e-10	0.29	0.22	Macular telangiectasia type 2;	chr5:88449705	chr5:88268895~88436685:+
BRCA	cis	rs4835473	0.868	rs4350958	ENSG00000251600.4	RP11-673E1.1	7.26	7.42e-13	1.82e-10	0.28	0.22	Immature fraction of reticulocytes;	chr4:143744656	chr4:143912331~143982454:+
BRCA	cis	rs2337406	0.538	rs10141701	ENSG00000274576.2	IGHV2-70	-7.26	7.42e-13	1.82e-10	-0.22	-0.22	Alzheimer's disease (late onset);	chr14:106633467	chr14:106770577~106771020:-
BRCA	cis	rs897984	0.542	rs750952	ENSG00000260911.2	RP11-196G11.2	7.26	7.43e-13	1.82e-10	0.2	0.22	Dementia with Lewy bodies;	chr16:31082633	chr16:31043150~31049868:+
BRCA	cis	rs875971	0.545	rs12670811	ENSG00000224316.1	RP11-479O9.2	7.26	7.44e-13	1.82e-10	0.25	0.22	Aortic root size;	chr7:66358032	chr7:65773620~65802067:+
BRCA	cis	rs10740039	1	rs10740039	ENSG00000254271.1	RP11-131N11.4	7.26	7.44e-13	1.83e-10	0.28	0.22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60654924	chr10:60734342~60741828:+
BRCA	cis	rs74233809	1	rs35125602	ENSG00000213277.3	MARCKSL1P1	7.26	7.44e-13	1.83e-10	0.41	0.22	Birth weight;	chr10:102896282	chr10:103175554~103176094:+
BRCA	cis	rs17772222	0.682	rs2401751	ENSG00000258983.2	RP11-507K2.2	-7.26	7.46e-13	1.83e-10	-0.23	-0.22	Coronary artery calcification;	chr14:88480278	chr14:88499334~88515502:+
BRCA	cis	rs875971	0.545	rs2707851	ENSG00000224316.1	RP11-479O9.2	-7.26	7.47e-13	1.83e-10	-0.25	-0.22	Aortic root size;	chr7:66624178	chr7:65773620~65802067:+
BRCA	cis	rs42648	0.837	rs12375075	ENSG00000225498.1	AC002064.5	7.26	7.5e-13	1.84e-10	0.21	0.22	Homocysteine levels;	chr7:90311017	chr7:90312496~90322592:+
BRCA	cis	rs7246657	0.882	rs10412043	ENSG00000276846.1	CTD-3220F14.3	7.26	7.5e-13	1.84e-10	0.29	0.22	Coronary artery calcification;	chr19:37335724	chr19:37314868~37315620:-
BRCA	cis	rs6545883	0.831	rs9309336	ENSG00000271889.1	RP11-493E12.1	7.26	7.51e-13	1.84e-10	0.28	0.22	Tuberculosis;	chr2:61536030	chr2:61151433~61162105:-
BRCA	cis	rs14027	0.921	rs16893077	ENSG00000279347.1	RP11-85I17.2	-7.26	7.53e-13	1.84e-10	-0.23	-0.22	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119740332	chr8:119838736~119840385:-
BRCA	cis	rs9532669	0.89	rs4941999	ENSG00000239827.7	SUGT1P3	-7.26	7.54e-13	1.85e-10	-0.26	-0.22	Cervical cancer;	chr13:40859926	chr13:40908159~40921774:-
BRCA	cis	rs9649213	0.593	rs6465677	ENSG00000272950.1	RP11-307C18.1	7.26	7.55e-13	1.85e-10	0.28	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98374240	chr7:98322853~98323430:+
BRCA	cis	rs9649213	0.593	rs7796611	ENSG00000272950.1	RP11-307C18.1	7.26	7.55e-13	1.85e-10	0.28	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98278911	chr7:98322853~98323430:+
BRCA	cis	rs9649213	0.574	rs13238610	ENSG00000272950.1	RP11-307C18.1	7.26	7.55e-13	1.85e-10	0.28	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98279965	chr7:98322853~98323430:+
BRCA	cis	rs875971	0.964	rs55748098	ENSG00000232559.3	GS1-124K5.12	-7.26	7.57e-13	1.85e-10	-0.26	-0.22	Aortic root size;	chr7:66298631	chr7:66554588~66576923:-
BRCA	cis	rs2933343	0.553	rs35076317	ENSG00000261159.1	RP11-723O4.9	7.26	7.57e-13	1.85e-10	0.24	0.22	IgG glycosylation;	chr3:128996692	chr3:128859716~128860526:-
BRCA	cis	rs7246657	0.943	rs10417844	ENSG00000276846.1	CTD-3220F14.3	7.26	7.58e-13	1.86e-10	0.29	0.22	Coronary artery calcification;	chr19:37346685	chr19:37314868~37315620:-
BRCA	cis	rs42648	0.72	rs9655741	ENSG00000225498.1	AC002064.5	7.26	7.63e-13	1.87e-10	0.21	0.22	Homocysteine levels;	chr7:90304560	chr7:90312496~90322592:+
BRCA	cis	rs9649213	0.593	rs10953255	ENSG00000272950.1	RP11-307C18.1	7.26	7.64e-13	1.87e-10	0.28	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98293886	chr7:98322853~98323430:+
BRCA	cis	rs7617773	0.784	rs9850672	ENSG00000228638.1	FCF1P2	-7.26	7.66e-13	1.87e-10	-0.23	-0.22	Coronary artery disease;	chr3:48259682	chr3:48290793~48291375:-
BRCA	cis	rs9880211	1	rs9880211	ENSG00000273486.1	RP11-731C17.2	7.26	7.66e-13	1.88e-10	0.29	0.22	Height;Body mass index;	chr3:136388707	chr3:136837338~136839021:-
BRCA	cis	rs7131987	0.621	rs6487805	ENSG00000257176.2	RP11-996F15.2	7.26	7.67e-13	1.88e-10	0.27	0.22	QT interval;	chr12:29304617	chr12:29280418~29317848:-
BRCA	cis	rs875971	1	rs2220626	ENSG00000232559.3	GS1-124K5.12	-7.26	7.67e-13	1.88e-10	-0.26	-0.22	Aortic root size;	chr7:66081075	chr7:66554588~66576923:-
BRCA	cis	rs9880211	0.8	rs115050567	ENSG00000239213.4	NCK1-AS1	7.26	7.67e-13	1.88e-10	0.29	0.22	Height;Body mass index;	chr3:136796817	chr3:136841726~136862054:-
BRCA	cis	rs9880211	0.8	rs9858560	ENSG00000239213.4	NCK1-AS1	7.26	7.67e-13	1.88e-10	0.29	0.22	Height;Body mass index;	chr3:136798312	chr3:136841726~136862054:-
BRCA	cis	rs30380	1	rs30187	ENSG00000272109.1	CTD-2260A17.3	-7.26	7.68e-13	1.88e-10	-0.27	-0.22	Cerebrospinal fluid biomarker levels;	chr5:96788627	chr5:96804353~96806105:+
BRCA	cis	rs61160187	0.582	rs11740632	ENSG00000215032.2	GNL3LP1	7.26	7.7e-13	1.88e-10	0.27	0.22	Educational attainment (years of education);Educational attainment (college completion);	chr5:60845418	chr5:60891935~60893577:-
BRCA	cis	rs7246657	0.943	rs10420754	ENSG00000276846.1	CTD-3220F14.3	7.26	7.73e-13	1.89e-10	0.29	0.22	Coronary artery calcification;	chr19:37468470	chr19:37314868~37315620:-
BRCA	cis	rs7727544	0.684	rs274560	ENSG00000233006.5	AC034220.3	-7.26	7.74e-13	1.89e-10	-0.16	-0.22	Blood metabolite levels;	chr5:132383758	chr5:132311285~132369916:-
BRCA	cis	rs6740322	0.748	rs6544634	ENSG00000234936.1	AC010883.5	7.26	7.74e-13	1.89e-10	0.24	0.22	Coronary artery disease;	chr2:43244389	chr2:43229573~43233394:+
BRCA	cis	rs10129255	0.5	rs7157975	ENSG00000211970.3	IGHV4-61	-7.26	7.76e-13	1.9e-10	-0.14	-0.22	Kawasaki disease;	chr14:106804049	chr14:106639119~106639657:-
BRCA	cis	rs8005677	1	rs7145494	ENSG00000279656.1	RP11-298I3.6	7.26	7.76e-13	1.9e-10	0.26	0.22	Cognitive ability (multi-trait analysis);	chr14:22930581	chr14:23023083~23024217:-
BRCA	cis	rs8005677	1	rs7155857	ENSG00000279656.1	RP11-298I3.6	7.26	7.76e-13	1.9e-10	0.26	0.22	Cognitive ability (multi-trait analysis);	chr14:22930850	chr14:23023083~23024217:-
BRCA	cis	rs14027	0.921	rs16893113	ENSG00000279347.1	RP11-85I17.2	-7.26	7.77e-13	1.9e-10	-0.23	-0.22	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119756447	chr8:119838736~119840385:-
BRCA	cis	rs14027	0.921	rs2326377	ENSG00000279347.1	RP11-85I17.2	-7.26	7.77e-13	1.9e-10	-0.23	-0.22	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119756696	chr8:119838736~119840385:-
BRCA	cis	rs14027	0.921	rs13257002	ENSG00000279347.1	RP11-85I17.2	-7.26	7.77e-13	1.9e-10	-0.23	-0.22	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119757489	chr8:119838736~119840385:-
BRCA	cis	rs14027	0.921	rs62526565	ENSG00000279347.1	RP11-85I17.2	-7.26	7.77e-13	1.9e-10	-0.23	-0.22	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119759301	chr8:119838736~119840385:-
BRCA	cis	rs61270009	0.955	rs454693	ENSG00000247828.6	TMEM161B-AS1	7.26	7.77e-13	1.9e-10	0.27	0.22	Depressive symptoms;	chr5:88248396	chr5:88268895~88436685:+
BRCA	cis	rs2033711	0.87	rs7259841	ENSG00000269473.1	CTD-2619J13.19	7.26	7.77e-13	1.9e-10	0.26	0.22	Uric acid clearance;	chr19:58439756	chr19:58440448~58445849:+
BRCA	cis	rs4845875	0.626	rs1889292	ENSG00000242349.4	NPPA-AS1	7.26	7.78e-13	1.9e-10	0.24	0.22	Midregional pro atrial natriuretic peptide levels;	chr1:11780886	chr1:11841017~11848079:+
BRCA	cis	rs1555322	0.505	rs591590	ENSG00000279253.1	RP4-614O4.13	7.26	7.79e-13	1.9e-10	0.29	0.22	Attention deficit hyperactivity disorder;	chr20:35278225	chr20:35262727~35264187:-
BRCA	cis	rs73173548	0.502	rs4129236	ENSG00000247828.6	TMEM161B-AS1	7.26	7.8e-13	1.91e-10	0.29	0.22	Macular telangiectasia type 2;	chr5:88441542	chr5:88268895~88436685:+
BRCA	cis	rs73173548	0.502	rs36077166	ENSG00000247828.6	TMEM161B-AS1	7.26	7.8e-13	1.91e-10	0.29	0.22	Macular telangiectasia type 2;	chr5:88441770	chr5:88268895~88436685:+
BRCA	cis	rs2288884	0.636	rs8101936	ENSG00000275055.1	CTC-471J1.11	-7.26	7.8e-13	1.91e-10	-0.26	-0.22	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52073226	chr19:52049007~52049754:+
BRCA	cis	rs9880211	0.8	rs28390205	ENSG00000239213.4	NCK1-AS1	7.26	7.81e-13	1.91e-10	0.29	0.22	Height;Body mass index;	chr3:136646008	chr3:136841726~136862054:-
BRCA	cis	rs61270009	0.955	rs12653830	ENSG00000247828.6	TMEM161B-AS1	7.26	7.81e-13	1.91e-10	0.27	0.22	Depressive symptoms;	chr5:88353712	chr5:88268895~88436685:+
BRCA	cis	rs6142102	1	rs2378078	ENSG00000276073.1	RP5-1125A11.7	-7.26	7.82e-13	1.91e-10	-0.27	-0.22	Skin pigmentation;	chr20:34126922	chr20:33985617~33988989:-
BRCA	cis	rs2115630	0.875	rs8039472	ENSG00000229212.6	RP11-561C5.4	7.26	7.82e-13	1.91e-10	0.25	0.22	P wave terminal force;	chr15:84818413	chr15:85205440~85234795:-
BRCA	cis	rs1862618	0.853	rs10461617	ENSG00000271828.1	CTD-2310F14.1	7.26	7.83e-13	1.91e-10	0.3	0.22	Initial pursuit acceleration;	chr5:56808481	chr5:56927874~56929573:+
BRCA	cis	rs10510102	0.935	rs11200260	ENSG00000276742.1	RP11-500G22.4	7.25	7.84e-13	1.92e-10	0.37	0.22	Breast cancer;	chr10:121920169	chr10:121956782~121957098:+
BRCA	cis	rs755249	0.727	rs12028034	ENSG00000237624.1	OXCT2P1	-7.25	7.84e-13	1.92e-10	-0.27	-0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39574035	chr1:39514956~39516490:+
BRCA	cis	rs10740039	0.883	rs10761542	ENSG00000254271.1	RP11-131N11.4	7.25	7.86e-13	1.92e-10	0.29	0.22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60655465	chr10:60734342~60741828:+
BRCA	cis	rs34779708	0.733	rs4007271	ENSG00000271335.4	RP11-324I22.4	7.25	7.87e-13	1.92e-10	0.22	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35257683	chr10:35314552~35336401:-
BRCA	cis	rs34779708	0.702	rs4007272	ENSG00000271335.4	RP11-324I22.4	7.25	7.87e-13	1.92e-10	0.22	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35257931	chr10:35314552~35336401:-
BRCA	cis	rs34779708	0.733	rs4934740	ENSG00000271335.4	RP11-324I22.4	7.25	7.87e-13	1.92e-10	0.22	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35258213	chr10:35314552~35336401:-
BRCA	cis	rs34779708	0.702	rs4244995	ENSG00000271335.4	RP11-324I22.4	7.25	7.87e-13	1.92e-10	0.22	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35258247	chr10:35314552~35336401:-
BRCA	cis	rs34779708	0.733	rs4244997	ENSG00000271335.4	RP11-324I22.4	7.25	7.87e-13	1.92e-10	0.22	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35258326	chr10:35314552~35336401:-
BRCA	cis	rs34779708	0.733	rs4298846	ENSG00000271335.4	RP11-324I22.4	7.25	7.87e-13	1.92e-10	0.22	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35258452	chr10:35314552~35336401:-
BRCA	cis	rs34779708	0.733	rs4391768	ENSG00000271335.4	RP11-324I22.4	7.25	7.87e-13	1.92e-10	0.22	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35258667	chr10:35314552~35336401:-
BRCA	cis	rs34779708	0.733	rs7914468	ENSG00000271335.4	RP11-324I22.4	7.25	7.87e-13	1.92e-10	0.22	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35259143	chr10:35314552~35336401:-
BRCA	cis	rs34779708	0.733	rs7914560	ENSG00000271335.4	RP11-324I22.4	7.25	7.87e-13	1.92e-10	0.22	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35259171	chr10:35314552~35336401:-
BRCA	cis	rs34779708	0.733	rs4444023	ENSG00000271335.4	RP11-324I22.4	7.25	7.87e-13	1.92e-10	0.22	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35259426	chr10:35314552~35336401:-
BRCA	cis	rs34779708	0.733	rs12243593	ENSG00000271335.4	RP11-324I22.4	7.25	7.87e-13	1.92e-10	0.22	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35260117	chr10:35314552~35336401:-
BRCA	cis	rs34779708	0.733	rs3936502	ENSG00000271335.4	RP11-324I22.4	7.25	7.87e-13	1.92e-10	0.22	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35260290	chr10:35314552~35336401:-
BRCA	cis	rs42490	1	rs43134	ENSG00000251136.7	RP11-37B2.1	7.25	7.87e-13	1.92e-10	0.22	0.22	Leprosy;	chr8:89775732	chr8:89609409~89757727:-
BRCA	cis	rs875971	0.577	rs35072105	ENSG00000237310.1	GS1-124K5.4	-7.25	7.88e-13	1.92e-10	-0.23	-0.22	Aortic root size;	chr7:66144830	chr7:66493706~66495474:+
BRCA	cis	rs7927771	0.839	rs3817334	ENSG00000280615.1	Y_RNA	-7.25	7.88e-13	1.93e-10	-0.25	-0.22	Subjective well-being;	chr11:47629441	chr11:47614898~47614994:-
BRCA	cis	rs2980436	1	rs2980436	ENSG00000254153.1	CTA-398F10.2	-7.25	7.88e-13	1.93e-10	-0.28	-0.22	Schizophrenia;	chr8:8234503	chr8:8456909~8461337:-
BRCA	cis	rs66887589	0.934	rs7681980	ENSG00000248280.1	RP11-33B1.2	-7.25	7.89e-13	1.93e-10	-0.2	-0.22	Diastolic blood pressure;	chr4:119612068	chr4:119440561~119450157:-
BRCA	cis	rs4845875	0.535	rs4846045	ENSG00000242349.4	NPPA-AS1	7.25	7.89e-13	1.93e-10	0.24	0.22	Midregional pro atrial natriuretic peptide levels;	chr1:11780323	chr1:11841017~11848079:+
BRCA	cis	rs6545883	0.965	rs1562308	ENSG00000271889.1	RP11-493E12.1	7.25	7.89e-13	1.93e-10	0.28	0.22	Tuberculosis;	chr2:61541286	chr2:61151433~61162105:-
BRCA	cis	rs1900504	0.509	rs11197779	ENSG00000266200.5	PNLIPRP2	7.25	7.89e-13	1.93e-10	0.36	0.22	Tonsillectomy;	chr10:116644721	chr10:116620953~116645143:+
BRCA	cis	rs10510102	0.872	rs12244199	ENSG00000276742.1	RP11-500G22.4	7.25	7.9e-13	1.93e-10	0.38	0.22	Breast cancer;	chr10:121965117	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.935	rs78525391	ENSG00000276742.1	RP11-500G22.4	7.25	7.91e-13	1.93e-10	0.37	0.22	Breast cancer;	chr10:121901102	chr10:121956782~121957098:+
BRCA	cis	rs9291683	0.609	rs3796836	ENSG00000250413.1	RP11-448G15.1	-7.25	7.91e-13	1.93e-10	-0.29	-0.22	Bone mineral density;	chr4:10009721	chr4:10006482~10009725:+
BRCA	cis	rs875971	1	rs10257427	ENSG00000232559.3	GS1-124K5.12	-7.25	7.93e-13	1.94e-10	-0.26	-0.22	Aortic root size;	chr7:66278221	chr7:66554588~66576923:-
BRCA	cis	rs6860806	0.507	rs272868	ENSG00000233006.5	AC034220.3	7.25	7.93e-13	1.94e-10	0.18	0.22	Breast cancer;	chr5:132345058	chr5:132311285~132369916:-
BRCA	cis	rs2288884	0.636	rs1560690	ENSG00000275055.1	CTC-471J1.11	-7.25	7.93e-13	1.94e-10	-0.26	-0.22	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52075094	chr19:52049007~52049754:+
BRCA	cis	rs875971	0.508	rs6947808	ENSG00000236529.1	RP13-254B10.1	-7.25	7.95e-13	1.94e-10	-0.24	-0.22	Aortic root size;	chr7:66580095	chr7:65840212~65840596:+
BRCA	cis	rs3126085	0.935	rs11204934	ENSG00000237975.5	FLG-AS1	7.25	7.96e-13	1.94e-10	0.31	0.22	Atopic dermatitis;	chr1:152204372	chr1:152168125~152445456:+
BRCA	cis	rs3781264	0.595	rs7084988	ENSG00000273450.1	RP11-76P2.4	7.25	8e-13	1.95e-10	0.29	0.22	Esophageal cancer and gastric cancer;	chr10:94349085	chr10:94314907~94315327:-
BRCA	cis	rs9309473	1	rs6705489	ENSG00000163016.8	ALMS1P	7.25	8.01e-13	1.96e-10	0.28	0.22	Metabolite levels;	chr2:73421683	chr2:73644919~73685576:+
BRCA	cis	rs9649213	0.593	rs10808107	ENSG00000272950.1	RP11-307C18.1	7.25	8.03e-13	1.96e-10	0.27	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98322359	chr7:98322853~98323430:+
BRCA	cis	rs10754283	0.967	rs2002883	ENSG00000231613.1	RP5-943J3.1	7.25	8.04e-13	1.96e-10	0.25	0.22	Amyotrophic lateral sclerosis (sporadic);	chr1:89640279	chr1:89788914~89790492:+
BRCA	cis	rs10754283	0.934	rs1934043	ENSG00000231613.1	RP5-943J3.1	7.25	8.04e-13	1.96e-10	0.25	0.22	Amyotrophic lateral sclerosis (sporadic);	chr1:89641086	chr1:89788914~89790492:+
BRCA	cis	rs10754283	0.967	rs2185195	ENSG00000231613.1	RP5-943J3.1	7.25	8.04e-13	1.96e-10	0.25	0.22	Amyotrophic lateral sclerosis (sporadic);	chr1:89641138	chr1:89788914~89790492:+
BRCA	cis	rs10754283	0.967	rs6657988	ENSG00000231613.1	RP5-943J3.1	7.25	8.04e-13	1.96e-10	0.25	0.22	Amyotrophic lateral sclerosis (sporadic);	chr1:89641186	chr1:89788914~89790492:+
BRCA	cis	rs10754283	0.967	rs6698273	ENSG00000231613.1	RP5-943J3.1	7.25	8.04e-13	1.96e-10	0.25	0.22	Amyotrophic lateral sclerosis (sporadic);	chr1:89641232	chr1:89788914~89790492:+
BRCA	cis	rs4853012	0.539	rs9789534	ENSG00000257800.1	FNBP1P1	7.25	8.06e-13	1.97e-10	0.22	0.22	Gestational age at birth (maternal effect);	chr2:74135863	chr2:74120680~74123218:+
BRCA	cis	rs10740039	0.586	rs7068462	ENSG00000254271.1	RP11-131N11.4	7.25	8.06e-13	1.97e-10	0.29	0.22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60636240	chr10:60734342~60741828:+
BRCA	cis	rs10740039	0.883	rs7069814	ENSG00000254271.1	RP11-131N11.4	7.25	8.06e-13	1.97e-10	0.29	0.22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60637001	chr10:60734342~60741828:+
BRCA	cis	rs10740039	0.883	rs10740037	ENSG00000254271.1	RP11-131N11.4	7.25	8.06e-13	1.97e-10	0.29	0.22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60637747	chr10:60734342~60741828:+
BRCA	cis	rs10740039	0.804	rs10761531	ENSG00000254271.1	RP11-131N11.4	7.25	8.06e-13	1.97e-10	0.29	0.22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60638177	chr10:60734342~60741828:+
BRCA	cis	rs10740039	0.846	rs2165690	ENSG00000254271.1	RP11-131N11.4	7.25	8.06e-13	1.97e-10	0.29	0.22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60639609	chr10:60734342~60741828:+
BRCA	cis	rs10740039	0.883	rs2119911	ENSG00000254271.1	RP11-131N11.4	7.25	8.06e-13	1.97e-10	0.29	0.22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60639808	chr10:60734342~60741828:+
BRCA	cis	rs10740039	0.804	rs2028563	ENSG00000254271.1	RP11-131N11.4	-7.25	8.08e-13	1.97e-10	-0.28	-0.22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60677139	chr10:60734342~60741828:+
BRCA	cis	rs10740039	0.883	rs1837945	ENSG00000254271.1	RP11-131N11.4	7.25	8.09e-13	1.97e-10	0.29	0.22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60633757	chr10:60734342~60741828:+
BRCA	cis	rs1555322	0.53	rs2425042	ENSG00000261582.1	RP4-614O4.11	-7.25	8.1e-13	1.98e-10	-0.25	-0.22	Attention deficit hyperactivity disorder;	chr20:35278092	chr20:35267885~35280043:-
BRCA	cis	rs4835473	0.863	rs13146607	ENSG00000251600.4	RP11-673E1.1	-7.25	8.1e-13	1.98e-10	-0.28	-0.22	Immature fraction of reticulocytes;	chr4:143687283	chr4:143912331~143982454:+
BRCA	cis	rs10740039	0.883	rs10994455	ENSG00000254271.1	RP11-131N11.4	7.25	8.11e-13	1.98e-10	0.29	0.22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60645589	chr10:60734342~60741828:+
BRCA	cis	rs7404843	0.789	rs222907	ENSG00000263335.1	AF001548.5	7.25	8.13e-13	1.98e-10	0.38	0.22	Testicular germ cell tumor;	chr16:15404950	chr16:15726674~15732993:+
BRCA	cis	rs473651	0.901	rs563282	ENSG00000229915.1	AC016999.2	-7.25	8.13e-13	1.98e-10	-0.28	-0.22	Multiple system atrophy;	chr2:238421095	chr2:238427077~238427729:-
BRCA	cis	rs2274273	0.6	rs10131730	ENSG00000258413.1	RP11-665C16.6	-7.25	8.14e-13	1.99e-10	-0.29	-0.22	Protein biomarker;	chr14:55373374	chr14:55262767~55272075:-
BRCA	cis	rs2274273	0.624	rs12050123	ENSG00000258413.1	RP11-665C16.6	-7.25	8.14e-13	1.99e-10	-0.29	-0.22	Protein biomarker;	chr14:55373668	chr14:55262767~55272075:-
BRCA	cis	rs10754283	0.967	rs1320563	ENSG00000231613.1	RP5-943J3.1	7.25	8.14e-13	1.99e-10	0.25	0.22	Amyotrophic lateral sclerosis (sporadic);	chr1:89655473	chr1:89788914~89790492:+
BRCA	cis	rs72772090	0.71	rs11750400	ENSG00000248734.2	CTD-2260A17.1	-7.25	8.15e-13	1.99e-10	-0.35	-0.22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96742264	chr5:96784777~96785999:+
BRCA	cis	rs72772090	0.71	rs10515244	ENSG00000248734.2	CTD-2260A17.1	-7.25	8.15e-13	1.99e-10	-0.35	-0.22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96742633	chr5:96784777~96785999:+
BRCA	cis	rs72772090	0.71	rs1559085	ENSG00000248734.2	CTD-2260A17.1	-7.25	8.15e-13	1.99e-10	-0.35	-0.22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96742998	chr5:96784777~96785999:+
BRCA	cis	rs8062405	0.691	rs743590	ENSG00000251417.2	RP11-1348G14.4	-7.25	8.17e-13	1.99e-10	-0.26	-0.22	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28596909	chr16:28802743~28817828:+
BRCA	cis	rs1853665	1	rs9383993	ENSG00000231760.4	RP11-350J20.5	-7.25	8.17e-13	1.99e-10	-0.33	-0.22	Radiation response;	chr6:149978163	chr6:149796151~149826294:-
BRCA	cis	rs3794924	1	rs35242229	ENSG00000266521.1	RP11-650P15.1	7.25	8.18e-13	2e-10	0.4	0.22	Survival in colon cancer;	chr18:31472920	chr18:31496645~31497195:-
BRCA	cis	rs3794924	1	rs71372018	ENSG00000266521.1	RP11-650P15.1	7.25	8.18e-13	2e-10	0.4	0.22	Survival in colon cancer;	chr18:31473571	chr18:31496645~31497195:-
BRCA	cis	rs9402682	0.596	rs9494149	ENSG00000232876.1	CTA-212D2.2	7.25	8.18e-13	2e-10	0.31	0.22	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr6:135128177	chr6:135055033~135060550:+
BRCA	cis	rs7208859	0.623	rs11658022	ENSG00000266490.1	CTD-2349P21.9	7.25	8.18e-13	2e-10	0.34	0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30758341	chr17:30792372~30792833:+
BRCA	cis	rs6822297	0.504	rs9291487	ENSG00000240005.4	RP11-293A21.1	7.25	8.2e-13	2e-10	0.26	0.22	Obesity-related traits;	chr4:26965862	chr4:26859806~26860599:-
BRCA	cis	rs6543140	0.964	rs6761350	ENSG00000234389.1	AC007278.3	7.25	8.21e-13	2e-10	0.22	0.22	Blood protein levels;	chr2:102414316	chr2:102438713~102440475:+
BRCA	cis	rs6543140	0.929	rs7602207	ENSG00000234389.1	AC007278.3	7.25	8.21e-13	2e-10	0.22	0.22	Blood protein levels;	chr2:102415906	chr2:102438713~102440475:+
BRCA	cis	rs6543140	0.964	rs2160200	ENSG00000234389.1	AC007278.3	7.25	8.21e-13	2e-10	0.22	0.22	Blood protein levels;	chr2:102417503	chr2:102438713~102440475:+
BRCA	cis	rs1823913	0.503	rs6706578	ENSG00000227542.1	AC092614.2	7.25	8.22e-13	2.01e-10	0.27	0.22	Obesity-related traits;	chr2:191346992	chr2:191229165~191246172:-
BRCA	cis	rs17818399	0.574	rs6544907	ENSG00000279254.1	RP11-536C12.1	-7.25	8.22e-13	2.01e-10	-0.26	-0.22	Height;	chr2:46641180	chr2:46668870~46670778:+
BRCA	cis	rs9649213	0.593	rs3779194	ENSG00000272950.1	RP11-307C18.1	7.25	8.22e-13	2.01e-10	0.28	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98380965	chr7:98322853~98323430:+
BRCA	cis	rs507080	0.501	rs494459	ENSG00000278376.1	RP11-158I9.8	7.25	8.23e-13	2.01e-10	0.2	0.22	Serum metabolite levels;	chr11:118703966	chr11:118791254~118793137:+
BRCA	cis	rs9649213	0.593	rs1468341	ENSG00000272950.1	RP11-307C18.1	7.25	8.24e-13	2.01e-10	0.28	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98358384	chr7:98322853~98323430:+
BRCA	cis	rs10740039	0.842	rs10761537	ENSG00000254271.1	RP11-131N11.4	7.25	8.29e-13	2.02e-10	0.29	0.22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60649263	chr10:60734342~60741828:+
BRCA	cis	rs7567389	0.6	rs11679414	ENSG00000236682.1	AC068282.3	-7.25	8.29e-13	2.02e-10	-0.33	-0.22	Self-rated health;	chr2:127393427	chr2:127389130~127400580:+
BRCA	cis	rs858239	0.539	rs10280815	ENSG00000230042.1	AK3P3	-7.25	8.29e-13	2.02e-10	-0.25	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23148751	chr7:23129178~23129841:+
BRCA	cis	rs858239	0.539	rs10225608	ENSG00000230042.1	AK3P3	-7.25	8.29e-13	2.02e-10	-0.25	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23149289	chr7:23129178~23129841:+
BRCA	cis	rs66887589	0.592	rs11731571	ENSG00000248280.1	RP11-33B1.2	7.25	8.32e-13	2.03e-10	0.21	0.22	Diastolic blood pressure;	chr4:119300030	chr4:119440561~119450157:-
BRCA	cis	rs780096	0.526	rs2010087	ENSG00000234072.1	AC074117.10	-7.25	8.33e-13	2.03e-10	-0.21	-0.22	Total body bone mineral density;	chr2:27414368	chr2:27356246~27367622:+
BRCA	cis	rs9876781	0.559	rs7611415	ENSG00000229759.1	MRPS18AP1	7.25	8.33e-13	2.03e-10	0.26	0.22	Longevity;	chr3:48363659	chr3:48256350~48256938:-
BRCA	cis	rs4072705	0.967	rs4838209	ENSG00000224020.1	MIR181A2HG	-7.25	8.33e-13	2.03e-10	-0.25	-0.22	Menarche (age at onset);	chr9:124766563	chr9:124658467~124698631:+
BRCA	cis	rs7809950	1	rs2066735	ENSG00000238832.1	snoU109	-7.25	8.33e-13	2.03e-10	-0.29	-0.22	Coronary artery disease;	chr7:107548274	chr7:107603363~107603507:+
BRCA	cis	rs755249	0.958	rs61781370	ENSG00000237624.1	OXCT2P1	7.25	8.33e-13	2.03e-10	0.32	0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39579628	chr1:39514956~39516490:+
BRCA	cis	rs875971	0.543	rs801191	ENSG00000224316.1	RP11-479O9.2	-7.25	8.34e-13	2.03e-10	-0.22	-0.22	Aortic root size;	chr7:66567968	chr7:65773620~65802067:+
BRCA	cis	rs301901	0.965	rs13180309	ENSG00000250155.1	CTD-2353F22.1	-7.25	8.35e-13	2.03e-10	-0.23	-0.22	Height;	chr5:36789899	chr5:36666214~36725195:-
BRCA	cis	rs10463554	0.889	rs246908	ENSG00000175749.11	EIF3KP1	7.25	8.37e-13	2.04e-10	0.31	0.22	Parkinson's disease;	chr5:103228476	chr5:103032376~103033031:+
BRCA	cis	rs2742234	0.541	rs7073849	ENSG00000273008.1	RP11-351D16.3	7.25	8.37e-13	2.04e-10	0.28	0.22	Hirschsprung disease;	chr10:43245026	chr10:43136824~43138334:-
BRCA	cis	rs9876781	0.874	rs56298324	ENSG00000229759.1	MRPS18AP1	-7.25	8.38e-13	2.04e-10	-0.25	-0.22	Longevity;	chr3:48393626	chr3:48256350~48256938:-
BRCA	cis	rs7811142	1	rs2406255	ENSG00000242294.5	STAG3L5P	7.25	8.38e-13	2.04e-10	0.23	0.22	Platelet count;	chr7:100456067	chr7:100336079~100351900:+
BRCA	cis	rs11098499	0.644	rs2389880	ENSG00000245958.5	RP11-33B1.1	-7.25	8.39e-13	2.04e-10	-0.21	-0.22	Corneal astigmatism;	chr4:119638715	chr4:119454791~119552025:+
BRCA	cis	rs2117029	0.782	rs6580698	ENSG00000258017.1	RP11-386G11.10	-7.24	8.41e-13	2.05e-10	-0.28	-0.22	Intelligence (multi-trait analysis);	chr12:49084875	chr12:49127782~49147869:+
BRCA	cis	rs1823913	0.503	rs6434464	ENSG00000227542.1	AC092614.2	-7.24	8.41e-13	2.05e-10	-0.26	-0.22	Obesity-related traits;	chr2:191341120	chr2:191229165~191246172:-
BRCA	cis	rs2276314	0.553	rs4799842	ENSG00000278986.1	RP11-723J4.3	-7.24	8.43e-13	2.05e-10	-0.25	-0.22	Endometriosis;Drug-induced torsades de pointes;	chr18:36048005	chr18:35972151~35973916:+
BRCA	cis	rs10740039	0.804	rs7902456	ENSG00000254271.1	RP11-131N11.4	7.24	8.43e-13	2.05e-10	0.29	0.22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60643937	chr10:60734342~60741828:+
BRCA	cis	rs10740039	0.96	rs10761536	ENSG00000254271.1	RP11-131N11.4	7.24	8.43e-13	2.05e-10	0.29	0.22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60644657	chr10:60734342~60741828:+
BRCA	cis	rs66887589	0.616	rs11098497	ENSG00000248280.1	RP11-33B1.2	7.24	8.43e-13	2.05e-10	0.21	0.22	Diastolic blood pressure;	chr4:119265913	chr4:119440561~119450157:-
BRCA	cis	rs4727443	0.866	rs13243708	ENSG00000235713.1	RP4-604G5.3	-7.24	8.46e-13	2.06e-10	-0.25	-0.22	Interstitial lung disease;	chr7:100018668	chr7:99992397~99993050:+
BRCA	cis	rs6840360	0.642	rs2724567	ENSG00000270265.1	RP11-731D1.4	7.24	8.46e-13	2.06e-10	0.24	0.22	Intelligence (multi-trait analysis);	chr4:151430008	chr4:151333775~151353224:-
BRCA	cis	rs801193	1	rs17566701	ENSG00000237310.1	GS1-124K5.4	7.24	8.47e-13	2.06e-10	0.23	0.22	Aortic root size;	chr7:66728196	chr7:66493706~66495474:+
BRCA	cis	rs9649213	0.593	rs6947208	ENSG00000272950.1	RP11-307C18.1	7.24	8.5e-13	2.07e-10	0.27	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98282892	chr7:98322853~98323430:+
BRCA	cis	rs848490	0.674	rs62460676	ENSG00000214293.7	APTR	7.24	8.5e-13	2.07e-10	0.26	0.22	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77680405	chr7:77657660~77696265:-
BRCA	cis	rs6543140	0.964	rs4851578	ENSG00000234389.1	AC007278.3	7.24	8.5e-13	2.07e-10	0.22	0.22	Blood protein levels;	chr2:102412491	chr2:102438713~102440475:+
BRCA	cis	rs2348418	0.639	rs10459086	ENSG00000247934.4	RP11-967K21.1	-7.24	8.51e-13	2.07e-10	-0.25	-0.22	Lung function (FEV1);Lung function (FVC);	chr12:28115511	chr12:28163298~28190738:-
BRCA	cis	rs6545883	0.929	rs13413337	ENSG00000271889.1	RP11-493E12.1	7.24	8.53e-13	2.07e-10	0.28	0.22	Tuberculosis;	chr2:61519988	chr2:61151433~61162105:-
BRCA	cis	rs10463554	0.746	rs6876072	ENSG00000175749.11	EIF3KP1	7.24	8.54e-13	2.08e-10	0.3	0.22	Parkinson's disease;	chr5:103251872	chr5:103032376~103033031:+
BRCA	cis	rs10510102	0.935	rs12243529	ENSG00000276742.1	RP11-500G22.4	7.24	8.57e-13	2.09e-10	0.37	0.22	Breast cancer;	chr10:121880321	chr10:121956782~121957098:+
BRCA	cis	rs9527	0.545	rs35756290	ENSG00000213061.2	PFN1P11	7.24	8.59e-13	2.09e-10	0.33	0.22	Arsenic metabolism;	chr10:102825815	chr10:102838011~102845473:-
BRCA	cis	rs6840258	0.66	rs55851914	ENSG00000251411.1	RP11-397E7.4	-7.24	8.6e-13	2.09e-10	-0.33	-0.22	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86955903	chr4:86913266~86914817:-
BRCA	cis	rs875971	1	rs10215948	ENSG00000232559.3	GS1-124K5.12	-7.24	8.62e-13	2.1e-10	-0.26	-0.22	Aortic root size;	chr7:66282799	chr7:66554588~66576923:-
BRCA	cis	rs4927850	1	rs4927850	ENSG00000242086.7	LINC00969	-7.24	8.68e-13	2.11e-10	-0.24	-0.22	Pancreatic cancer;	chr3:196024759	chr3:195658062~195739964:+
BRCA	cis	rs13315649	0.724	rs28787069	ENSG00000242551.2	POU5F1P6	-7.24	8.68e-13	2.11e-10	-0.31	-0.22	Sum eosinophil basophil counts;	chr3:128695613	chr3:128674735~128677005:-
BRCA	cis	rs6740322	0.948	rs6722694	ENSG00000234936.1	AC010883.5	7.24	8.68e-13	2.11e-10	0.24	0.22	Coronary artery disease;	chr2:43342659	chr2:43229573~43233394:+
BRCA	cis	rs9649213	0.574	rs7802541	ENSG00000272950.1	RP11-307C18.1	7.24	8.69e-13	2.11e-10	0.28	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98304543	chr7:98322853~98323430:+
BRCA	cis	rs1499614	1	rs1638731	ENSG00000232546.1	RP11-458F8.1	-7.24	8.7e-13	2.12e-10	-0.3	-0.22	Gout;	chr7:66679692	chr7:66848496~66858136:+
BRCA	cis	rs1499614	1	rs1882655	ENSG00000232546.1	RP11-458F8.1	7.24	8.7e-13	2.12e-10	0.3	0.22	Gout;	chr7:66682070	chr7:66848496~66858136:+
BRCA	cis	rs1499614	0.831	rs3800822	ENSG00000232546.1	RP11-458F8.1	7.24	8.7e-13	2.12e-10	0.3	0.22	Gout;	chr7:66682162	chr7:66848496~66858136:+
BRCA	cis	rs10754283	0.967	rs10737706	ENSG00000231613.1	RP5-943J3.1	7.24	8.72e-13	2.12e-10	0.24	0.22	Amyotrophic lateral sclerosis (sporadic);	chr1:89647020	chr1:89788914~89790492:+
BRCA	cis	rs61160187	0.61	rs4700397	ENSG00000215032.2	GNL3LP1	-7.24	8.72e-13	2.12e-10	-0.27	-0.22	Educational attainment (years of education);Educational attainment (college completion);	chr5:60840135	chr5:60891935~60893577:-
BRCA	cis	rs2072438	0.505	rs7034074	ENSG00000226752.6	PSMD5-AS1	-7.24	8.73e-13	2.12e-10	-0.26	-0.22	Rheumatoid arthritis;	chr9:121160751	chr9:120824828~120854385:+
BRCA	cis	rs10129255	0.5	rs11627315	ENSG00000211970.3	IGHV4-61	-7.24	8.75e-13	2.13e-10	-0.14	-0.22	Kawasaki disease;	chr14:106802182	chr14:106639119~106639657:-
BRCA	cis	rs66887589	0.934	rs56843000	ENSG00000248280.1	RP11-33B1.2	-7.24	8.75e-13	2.13e-10	-0.2	-0.22	Diastolic blood pressure;	chr4:119595442	chr4:119440561~119450157:-
BRCA	cis	rs875971	1	rs1540651	ENSG00000224316.1	RP11-479O9.2	-7.24	8.76e-13	2.13e-10	-0.22	-0.22	Aortic root size;	chr7:66185134	chr7:65773620~65802067:+
BRCA	cis	rs1320333	0.772	rs2867136	ENSG00000233296.1	AC092159.2	-7.24	8.78e-13	2.13e-10	-0.37	-0.22	Obesity-related traits;	chr2:701455	chr2:677186~697371:+
BRCA	cis	rs9880211	0.752	rs35428413	ENSG00000239213.4	NCK1-AS1	7.24	8.78e-13	2.13e-10	0.29	0.22	Height;Body mass index;	chr3:136661856	chr3:136841726~136862054:-
BRCA	cis	rs780096	0.506	rs2288155	ENSG00000234072.1	AC074117.10	-7.24	8.79e-13	2.14e-10	-0.21	-0.22	Total body bone mineral density;	chr2:27491659	chr2:27356246~27367622:+
BRCA	cis	rs858239	0.539	rs2141305	ENSG00000230042.1	AK3P3	-7.24	8.79e-13	2.14e-10	-0.25	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23152280	chr7:23129178~23129841:+
BRCA	cis	rs4072705	1	rs10760372	ENSG00000224020.1	MIR181A2HG	-7.24	8.79e-13	2.14e-10	-0.25	-0.22	Menarche (age at onset);	chr9:124706537	chr9:124658467~124698631:+
BRCA	cis	rs755249	0.567	rs41270807	ENSG00000228060.1	RP11-69E11.8	-7.24	8.81e-13	2.14e-10	-0.27	-0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39336143	chr1:39565160~39573203:+
BRCA	cis	rs755249	0.53	rs16826087	ENSG00000228060.1	RP11-69E11.8	-7.24	8.81e-13	2.14e-10	-0.27	-0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39346846	chr1:39565160~39573203:+
BRCA	cis	rs755249	0.567	rs41270811	ENSG00000228060.1	RP11-69E11.8	-7.24	8.81e-13	2.14e-10	-0.27	-0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39349672	chr1:39565160~39573203:+
BRCA	cis	rs755249	0.567	rs61779274	ENSG00000228060.1	RP11-69E11.8	-7.24	8.81e-13	2.14e-10	-0.27	-0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39351269	chr1:39565160~39573203:+
BRCA	cis	rs6723162	0.965	rs7594319	ENSG00000237751.2	LINC01143	-7.24	8.81e-13	2.14e-10	-0.25	-0.22	Neurocognitive impairment in HIV-1 infection (dichotomous);	chr2:70891627	chr2:70887871~70889959:+
BRCA	cis	rs7772486	0.743	rs1292339	ENSG00000235652.6	RP11-545I5.3	-7.24	8.81e-13	2.14e-10	-0.21	-0.22	Lobe attachment (rater-scored or self-reported);	chr6:145645950	chr6:145799409~145886585:+
BRCA	cis	rs6860806	0.507	rs156322	ENSG00000233006.5	AC034220.3	7.24	8.82e-13	2.14e-10	0.18	0.22	Breast cancer;	chr5:132318232	chr5:132311285~132369916:-
BRCA	cis	rs10740039	0.883	rs7089720	ENSG00000254271.1	RP11-131N11.4	7.24	8.82e-13	2.14e-10	0.29	0.22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60634063	chr10:60734342~60741828:+
BRCA	cis	rs10740039	0.804	rs7093882	ENSG00000254271.1	RP11-131N11.4	7.24	8.82e-13	2.14e-10	0.29	0.22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60634863	chr10:60734342~60741828:+
BRCA	cis	rs7927771	0.689	rs10734557	ENSG00000280615.1	Y_RNA	7.24	8.82e-13	2.14e-10	0.27	0.22	Subjective well-being;	chr11:47358510	chr11:47614898~47614994:-
BRCA	cis	rs30380	1	rs151964	ENSG00000272109.1	CTD-2260A17.3	-7.24	8.84e-13	2.15e-10	-0.27	-0.22	Cerebrospinal fluid biomarker levels;	chr5:96787963	chr5:96804353~96806105:+
BRCA	cis	rs9649213	0.574	rs12873	ENSG00000272950.1	RP11-307C18.1	7.24	8.86e-13	2.15e-10	0.27	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98293461	chr7:98322853~98323430:+
BRCA	cis	rs11089937	0.616	rs12484496	ENSG00000211639.2	IGLV4-60	-7.24	8.88e-13	2.16e-10	-0.21	-0.22	Periodontitis (PAL4Q3);	chr22:22180296	chr22:22162199~22162681:+
BRCA	cis	rs11098499	0.644	rs10009566	ENSG00000245958.5	RP11-33B1.1	-7.24	8.89e-13	2.16e-10	-0.21	-0.22	Corneal astigmatism;	chr4:119637453	chr4:119454791~119552025:+
BRCA	cis	rs780096	0.546	rs715326	ENSG00000234072.1	AC074117.10	7.24	8.89e-13	2.16e-10	0.21	0.22	Total body bone mineral density;	chr2:27502894	chr2:27356246~27367622:+
BRCA	cis	rs11098499	0.955	rs4145951	ENSG00000248280.1	RP11-33B1.2	7.24	8.9e-13	2.16e-10	0.23	0.22	Corneal astigmatism;	chr4:119234662	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.955	rs35916640	ENSG00000248280.1	RP11-33B1.2	7.24	8.9e-13	2.16e-10	0.23	0.22	Corneal astigmatism;	chr4:119234697	chr4:119440561~119450157:-
BRCA	cis	rs7474896	0.559	rs1735641	ENSG00000226578.1	RP11-258F22.1	7.24	8.9e-13	2.16e-10	0.29	0.22	Obesity (extreme);	chr10:37895924	chr10:37775371~37784131:-
BRCA	cis	rs9880211	1	rs9841529	ENSG00000273486.1	RP11-731C17.2	7.24	8.94e-13	2.17e-10	0.29	0.22	Height;Body mass index;	chr3:136418441	chr3:136837338~136839021:-
BRCA	cis	rs66887589	0.616	rs7659403	ENSG00000248280.1	RP11-33B1.2	7.24	8.95e-13	2.17e-10	0.21	0.22	Diastolic blood pressure;	chr4:119286099	chr4:119440561~119450157:-
BRCA	cis	rs6142102	0.961	rs6120519	ENSG00000275784.1	RP5-1125A11.6	-7.24	8.95e-13	2.17e-10	-0.25	-0.22	Skin pigmentation;	chr20:34100307	chr20:33989480~33991818:-
BRCA	cis	rs1499614	0.901	rs2178742	ENSG00000232546.1	RP11-458F8.1	-7.24	8.96e-13	2.18e-10	-0.3	-0.22	Gout;	chr7:66732812	chr7:66848496~66858136:+
BRCA	cis	rs2599510	0.811	rs176410	ENSG00000276334.1	AL133243.1	-7.24	8.96e-13	2.18e-10	-0.26	-0.22	Interleukin-18 levels;	chr2:32418369	chr2:32521927~32523547:+
BRCA	cis	rs74233809	1	rs10883815	ENSG00000213277.3	MARCKSL1P1	7.24	8.97e-13	2.18e-10	0.41	0.22	Birth weight;	chr10:102979422	chr10:103175554~103176094:+
BRCA	cis	rs74233809	1	rs112390216	ENSG00000213277.3	MARCKSL1P1	7.24	8.97e-13	2.18e-10	0.41	0.22	Birth weight;	chr10:102981274	chr10:103175554~103176094:+
BRCA	cis	rs7246657	0.941	rs67293224	ENSG00000276846.1	CTD-3220F14.3	7.24	8.99e-13	2.18e-10	0.31	0.22	Coronary artery calcification;	chr19:37312346	chr19:37314868~37315620:-
BRCA	cis	rs10510102	0.935	rs11200237	ENSG00000276742.1	RP11-500G22.4	7.24	9e-13	2.18e-10	0.37	0.22	Breast cancer;	chr10:121900715	chr10:121956782~121957098:+
BRCA	cis	rs12291225	0.639	rs61883858	ENSG00000251991.1	RNU7-49P	7.23	9.01e-13	2.19e-10	0.26	0.22	Sense of smell;	chr11:14273162	chr11:14478892~14478953:+
BRCA	cis	rs2281636	0.723	rs11190255	ENSG00000233690.1	EBAG9P1	7.23	9.01e-13	2.19e-10	0.26	0.22	Obesity-related traits;	chr10:99714742	chr10:99697407~99697949:-
BRCA	cis	rs1555322	0.53	rs7004	ENSG00000261582.1	RP4-614O4.11	-7.23	9.04e-13	2.19e-10	-0.25	-0.22	Attention deficit hyperactivity disorder;	chr20:35278950	chr20:35267885~35280043:-
BRCA	cis	rs858239	0.539	rs6965833	ENSG00000230042.1	AK3P3	-7.23	9.04e-13	2.19e-10	-0.25	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23152747	chr7:23129178~23129841:+
BRCA	cis	rs858239	0.539	rs6949363	ENSG00000230042.1	AK3P3	-7.23	9.04e-13	2.19e-10	-0.25	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23152775	chr7:23129178~23129841:+
BRCA	cis	rs4835473	0.932	rs11724752	ENSG00000251600.4	RP11-673E1.1	-7.23	9.04e-13	2.19e-10	-0.27	-0.22	Immature fraction of reticulocytes;	chr4:143769473	chr4:143912331~143982454:+
BRCA	cis	rs74233809	0.892	rs11191447	ENSG00000213277.3	MARCKSL1P1	7.23	9.05e-13	2.2e-10	0.41	0.22	Birth weight;	chr10:102892566	chr10:103175554~103176094:+
BRCA	cis	rs74233809	1	rs74233296	ENSG00000213277.3	MARCKSL1P1	7.23	9.05e-13	2.2e-10	0.41	0.22	Birth weight;	chr10:102895593	chr10:103175554~103176094:+
BRCA	cis	rs9649213	0.593	rs7812180	ENSG00000272950.1	RP11-307C18.1	-7.23	9.06e-13	2.2e-10	-0.3	-0.22	Prostate cancer (SNP x SNP interaction);	chr7:98339828	chr7:98322853~98323430:+
BRCA	cis	rs17818399	0.735	rs11894342	ENSG00000279254.1	RP11-536C12.1	-7.23	9.06e-13	2.2e-10	-0.26	-0.22	Height;	chr2:46609300	chr2:46668870~46670778:+
BRCA	cis	rs301901	1	rs300051	ENSG00000250155.1	CTD-2353F22.1	-7.23	9.07e-13	2.2e-10	-0.24	-0.22	Height;	chr5:37088525	chr5:36666214~36725195:-
BRCA	cis	rs7567389	0.564	rs10209483	ENSG00000236682.1	AC068282.3	7.23	9.1e-13	2.21e-10	0.32	0.22	Self-rated health;	chr2:127401061	chr2:127389130~127400580:+
BRCA	cis	rs875971	1	rs6460292	ENSG00000232559.3	GS1-124K5.12	-7.23	9.1e-13	2.21e-10	-0.26	-0.22	Aortic root size;	chr7:66345088	chr7:66554588~66576923:-
BRCA	cis	rs74233809	1	rs12219027	ENSG00000213277.3	MARCKSL1P1	7.23	9.11e-13	2.21e-10	0.4	0.22	Birth weight;	chr10:103051446	chr10:103175554~103176094:+
BRCA	cis	rs2348418	0.733	rs2019011	ENSG00000247934.4	RP11-967K21.1	7.23	9.11e-13	2.21e-10	0.25	0.22	Lung function (FEV1);Lung function (FVC);	chr12:28228144	chr12:28163298~28190738:-
BRCA	cis	rs3814244	0.528	rs7962511	ENSG00000236946.2	HNRNPA1P70	-7.23	9.14e-13	2.22e-10	-0.19	-0.22	Itch intensity from mosquito bite adjusted by bite size;	chr12:68002854	chr12:68035767~68036853:+
BRCA	cis	rs875971	0.666	rs13242072	ENSG00000237310.1	GS1-124K5.4	-7.23	9.14e-13	2.22e-10	-0.23	-0.22	Aortic root size;	chr7:66301001	chr7:66493706~66495474:+
BRCA	cis	rs10754283	0.967	rs4658302	ENSG00000231613.1	RP5-943J3.1	7.23	9.19e-13	2.23e-10	0.24	0.22	Amyotrophic lateral sclerosis (sporadic);	chr1:89637777	chr1:89788914~89790492:+
BRCA	cis	rs867371	0.929	rs1045508	ENSG00000259429.4	UBE2Q2P2	7.23	9.2e-13	2.23e-10	0.21	0.22	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82157565	chr15:82355142~82420075:+
BRCA	cis	rs6570726	0.935	rs379164	ENSG00000235652.6	RP11-545I5.3	7.23	9.22e-13	2.24e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145507957	chr6:145799409~145886585:+
BRCA	cis	rs9649213	0.593	rs56286037	ENSG00000272950.1	RP11-307C18.1	7.23	9.23e-13	2.24e-10	0.28	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98390210	chr7:98322853~98323430:+
BRCA	cis	rs301901	1	rs300065	ENSG00000250155.1	CTD-2353F22.1	-7.23	9.23e-13	2.24e-10	-0.24	-0.22	Height;	chr5:36997725	chr5:36666214~36725195:-
BRCA	cis	rs875971	0.545	rs73142265	ENSG00000224316.1	RP11-479O9.2	7.23	9.23e-13	2.24e-10	0.25	0.22	Aortic root size;	chr7:66234510	chr7:65773620~65802067:+
BRCA	cis	rs9649213	0.593	rs6465662	ENSG00000272950.1	RP11-307C18.1	7.23	9.28e-13	2.25e-10	0.27	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98288489	chr7:98322853~98323430:+
BRCA	cis	rs9649213	0.593	rs34534766	ENSG00000272950.1	RP11-307C18.1	7.23	9.28e-13	2.25e-10	0.27	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98291559	chr7:98322853~98323430:+
BRCA	cis	rs2836950	0.772	rs62222988	ENSG00000255568.3	BRWD1-AS2	-7.23	9.29e-13	2.25e-10	-0.22	-0.22	Menarche (age at onset);	chr21:39197582	chr21:39313935~39314962:+
BRCA	cis	rs6545883	0.929	rs7563678	ENSG00000271889.1	RP11-493E12.1	-7.23	9.32e-13	2.26e-10	-0.28	-0.22	Tuberculosis;	chr2:61514676	chr2:61151433~61162105:-
BRCA	cis	rs858239	0.537	rs2286272	ENSG00000230042.1	AK3P3	-7.23	9.33e-13	2.26e-10	-0.25	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23184748	chr7:23129178~23129841:+
BRCA	cis	rs6570726	0.935	rs12663211	ENSG00000235652.6	RP11-545I5.3	7.23	9.34e-13	2.26e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145497291	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.934	rs430003	ENSG00000235652.6	RP11-545I5.3	7.23	9.34e-13	2.26e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145498370	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.935	rs395948	ENSG00000235652.6	RP11-545I5.3	7.23	9.34e-13	2.26e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145499049	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.935	rs452552	ENSG00000235652.6	RP11-545I5.3	7.23	9.34e-13	2.26e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145499645	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.935	rs451349	ENSG00000235652.6	RP11-545I5.3	7.23	9.34e-13	2.26e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145499758	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.905	rs406799	ENSG00000235652.6	RP11-545I5.3	7.23	9.34e-13	2.26e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145500701	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.935	rs1883406	ENSG00000235652.6	RP11-545I5.3	7.23	9.34e-13	2.26e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145502069	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.87	rs370653	ENSG00000235652.6	RP11-545I5.3	7.23	9.34e-13	2.26e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145502506	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.935	rs391524	ENSG00000235652.6	RP11-545I5.3	7.23	9.34e-13	2.26e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145502708	chr6:145799409~145886585:+
BRCA	cis	rs10510102	0.935	rs7098562	ENSG00000276742.1	RP11-500G22.4	7.23	9.35e-13	2.27e-10	0.37	0.22	Breast cancer;	chr10:121902148	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.935	rs7098822	ENSG00000276742.1	RP11-500G22.4	7.23	9.35e-13	2.27e-10	0.37	0.22	Breast cancer;	chr10:121902157	chr10:121956782~121957098:+
BRCA	cis	rs17711722	0.503	rs453835	ENSG00000228409.4	CCT6P1	7.23	9.36e-13	2.27e-10	0.2	0.22	Calcium levels;	chr7:66046172	chr7:65751142~65763354:+
BRCA	cis	rs904251	0.6	rs4714068	ENSG00000204110.6	RP1-153P14.8	-7.23	9.36e-13	2.27e-10	-0.24	-0.22	Cognitive performance;	chr6:37487866	chr6:37507348~37535616:+
BRCA	cis	rs10050311	0.858	rs55698195	ENSG00000251411.1	RP11-397E7.4	-7.23	9.37e-13	2.27e-10	-0.33	-0.22	Insulin-related traits;	chr4:86872297	chr4:86913266~86914817:-
BRCA	cis	rs2243480	1	rs4718317	ENSG00000230295.1	RP11-458F8.2	7.23	9.38e-13	2.27e-10	0.28	0.22	Diabetic kidney disease;	chr7:66183914	chr7:66880708~66882981:+
BRCA	cis	rs10510102	0.935	rs4627017	ENSG00000276742.1	RP11-500G22.4	7.23	9.38e-13	2.27e-10	0.37	0.22	Breast cancer;	chr10:121901878	chr10:121956782~121957098:+
BRCA	cis	rs7674212	0.507	rs6843738	ENSG00000251288.2	RP11-10L12.2	-7.23	9.38e-13	2.27e-10	-0.27	-0.22	Type 2 diabetes;	chr4:103014844	chr4:102751401~102752641:+
BRCA	cis	rs780094	0.585	rs3739095	ENSG00000234072.1	AC074117.10	-7.23	9.39e-13	2.27e-10	-0.21	-0.22	Urate levels in overweight individuals;C-reactive protein;Metabolic syndrome;Red blood cell count;Renal underexcretion gout;Nonalcoholic fatty liver disease;Age-related diseases, mortality and associated endophenotypes;Crohn's disease;Calcium levels;Fasting plasma glucose;Metabolic traits;Fasting blood glucose;Fasting blood insulin;Urate levels in obese individuals;Alcohol consumption (drinks per week);Height;Urate levels;Gondoic acid (20:1n-9) levels;Uric acid levels;Age-related disease endophenotypes;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Homeostasis model assessment of insulin resistance;Alcohol consumption;Fasting blood insulin (BMI interaction);Triglycerides;Fasting blood glucose (BMI interaction);Hypertriglyceridemia;LDL cholesterol;Type 2 diabetes;Triglyceride levels;	chr2:27333854	chr2:27356246~27367622:+
BRCA	cis	rs66887589	0.87	rs2389875	ENSG00000248280.1	RP11-33B1.2	-7.23	9.39e-13	2.27e-10	-0.21	-0.22	Diastolic blood pressure;	chr4:119635859	chr4:119440561~119450157:-
BRCA	cis	rs891378	0.785	rs7516468	ENSG00000274245.1	RP11-357P18.2	-7.23	9.4e-13	2.28e-10	-0.27	-0.22	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207235943	chr1:207372559~207373252:+
BRCA	cis	rs10754283	0.935	rs10801756	ENSG00000231613.1	RP5-943J3.1	7.23	9.42e-13	2.28e-10	0.24	0.22	Amyotrophic lateral sclerosis (sporadic);	chr1:89636273	chr1:89788914~89790492:+
BRCA	cis	rs10754283	0.934	rs6684676	ENSG00000231613.1	RP5-943J3.1	7.23	9.42e-13	2.28e-10	0.24	0.22	Amyotrophic lateral sclerosis (sporadic);	chr1:89636614	chr1:89788914~89790492:+
BRCA	cis	rs10754283	0.967	rs6428561	ENSG00000231613.1	RP5-943J3.1	7.23	9.42e-13	2.28e-10	0.24	0.22	Amyotrophic lateral sclerosis (sporadic);	chr1:89637060	chr1:89788914~89790492:+
BRCA	cis	rs10754283	0.967	rs6428562	ENSG00000231613.1	RP5-943J3.1	7.23	9.42e-13	2.28e-10	0.24	0.22	Amyotrophic lateral sclerosis (sporadic);	chr1:89637106	chr1:89788914~89790492:+
BRCA	cis	rs10050311	0.79	rs17751427	ENSG00000251411.1	RP11-397E7.4	-7.23	9.42e-13	2.28e-10	-0.32	-0.22	Insulin-related traits;	chr4:86909939	chr4:86913266~86914817:-
BRCA	cis	rs6545883	0.929	rs6545877	ENSG00000271889.1	RP11-493E12.1	7.23	9.44e-13	2.29e-10	0.28	0.22	Tuberculosis;	chr2:61514812	chr2:61151433~61162105:-
BRCA	cis	rs6952407	1	rs6952407	ENSG00000237310.1	GS1-124K5.4	-7.23	9.46e-13	2.29e-10	-0.23	-0.22	Cotinine glucuronidation;	chr7:66580525	chr7:66493706~66495474:+
BRCA	cis	rs699371	0.507	rs10149538	ENSG00000270000.1	RP3-449M8.9	7.23	9.48e-13	2.29e-10	0.27	0.22	Height;	chr14:74458694	chr14:74471930~74472360:-
BRCA	cis	rs2243480	0.908	rs55876148	ENSG00000273142.1	RP11-458F8.4	-7.23	9.48e-13	2.29e-10	-0.3	-0.22	Diabetic kidney disease;	chr7:65914813	chr7:66902857~66906297:+
BRCA	cis	rs8005677	1	rs4982710	ENSG00000279656.1	RP11-298I3.6	7.23	9.49e-13	2.3e-10	0.26	0.22	Cognitive ability (multi-trait analysis);	chr14:22929693	chr14:23023083~23024217:-
BRCA	cis	rs2933343	0.533	rs13086121	ENSG00000261159.1	RP11-723O4.9	7.23	9.5e-13	2.3e-10	0.24	0.22	IgG glycosylation;	chr3:128985447	chr3:128859716~128860526:-
BRCA	cis	rs875971	1	rs6956179	ENSG00000232559.3	GS1-124K5.12	-7.23	9.5e-13	2.3e-10	-0.26	-0.22	Aortic root size;	chr7:66341672	chr7:66554588~66576923:-
BRCA	cis	rs9649213	0.593	rs12704983	ENSG00000272950.1	RP11-307C18.1	7.23	9.53e-13	2.31e-10	0.28	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98297733	chr7:98322853~98323430:+
BRCA	cis	rs9880211	1	rs9809988	ENSG00000273486.1	RP11-731C17.2	7.23	9.54e-13	2.31e-10	0.29	0.22	Height;Body mass index;	chr3:136803379	chr3:136837338~136839021:-
BRCA	cis	rs10129255	0.5	rs6576232	ENSG00000280411.1	IGHV1-69-2	-7.23	9.55e-13	2.31e-10	-0.14	-0.22	Kawasaki disease;	chr14:106787090	chr14:106762092~106762588:-
BRCA	cis	rs9880211	0.8	rs9819856	ENSG00000239213.4	NCK1-AS1	7.23	9.55e-13	2.31e-10	0.29	0.22	Height;Body mass index;	chr3:136773307	chr3:136841726~136862054:-
BRCA	cis	rs9880211	0.8	rs36109616	ENSG00000239213.4	NCK1-AS1	7.23	9.55e-13	2.31e-10	0.29	0.22	Height;Body mass index;	chr3:136773561	chr3:136841726~136862054:-
BRCA	cis	rs9880211	0.8	rs35198484	ENSG00000239213.4	NCK1-AS1	7.23	9.55e-13	2.31e-10	0.29	0.22	Height;Body mass index;	chr3:136773795	chr3:136841726~136862054:-
BRCA	cis	rs9880211	0.66	rs9289514	ENSG00000239213.4	NCK1-AS1	7.23	9.55e-13	2.31e-10	0.29	0.22	Height;Body mass index;	chr3:136774361	chr3:136841726~136862054:-
BRCA	cis	rs9880211	0.8	rs79876804	ENSG00000239213.4	NCK1-AS1	7.23	9.55e-13	2.31e-10	0.29	0.22	Height;Body mass index;	chr3:136775308	chr3:136841726~136862054:-
BRCA	cis	rs9880211	0.706	rs35716521	ENSG00000239213.4	NCK1-AS1	7.23	9.55e-13	2.31e-10	0.29	0.22	Height;Body mass index;	chr3:136775828	chr3:136841726~136862054:-
BRCA	cis	rs9880211	0.8	rs35210994	ENSG00000239213.4	NCK1-AS1	7.23	9.55e-13	2.31e-10	0.29	0.22	Height;Body mass index;	chr3:136777294	chr3:136841726~136862054:-
BRCA	cis	rs9880211	0.8	rs17365792	ENSG00000239213.4	NCK1-AS1	7.23	9.55e-13	2.31e-10	0.29	0.22	Height;Body mass index;	chr3:136778550	chr3:136841726~136862054:-
BRCA	cis	rs6570726	0.818	rs398812	ENSG00000235652.6	RP11-545I5.3	7.23	9.56e-13	2.31e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145496135	chr6:145799409~145886585:+
BRCA	cis	rs11976180	1	rs2951364	ENSG00000204959.4	ARHGEF34P	7.23	9.58e-13	2.32e-10	0.27	0.22	Obesity-related traits;	chr7:144057390	chr7:144272445~144286966:-
BRCA	cis	rs7617773	0.817	rs11710861	ENSG00000228638.1	FCF1P2	-7.23	9.58e-13	2.32e-10	-0.23	-0.22	Coronary artery disease;	chr3:48256070	chr3:48290793~48291375:-
BRCA	cis	rs875971	0.965	rs10267430	ENSG00000232559.3	GS1-124K5.12	-7.23	9.58e-13	2.32e-10	-0.26	-0.22	Aortic root size;	chr7:66278036	chr7:66554588~66576923:-
BRCA	cis	rs2880765	0.835	rs4526974	ENSG00000259295.5	CSPG4P12	7.23	9.6e-13	2.32e-10	0.27	0.22	Coronary artery disease;	chr15:85481053	chr15:85191438~85213905:+
BRCA	cis	rs74233809	1	rs11191551	ENSG00000213277.3	MARCKSL1P1	7.23	9.61e-13	2.32e-10	0.41	0.22	Birth weight;	chr10:103091078	chr10:103175554~103176094:+
BRCA	cis	rs74233809	1	rs17094683	ENSG00000213277.3	MARCKSL1P1	7.23	9.61e-13	2.32e-10	0.41	0.22	Birth weight;	chr10:103091544	chr10:103175554~103176094:+
BRCA	cis	rs910316	1	rs8003506	ENSG00000279594.1	RP11-950C14.10	-7.23	9.62e-13	2.33e-10	-0.25	-0.22	Height;	chr14:75119585	chr14:75011269~75012851:-
BRCA	cis	rs14027	0.921	rs13270831	ENSG00000279347.1	RP11-85I17.2	-7.23	9.62e-13	2.33e-10	-0.23	-0.22	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119755071	chr8:119838736~119840385:-
BRCA	cis	rs2337406	0.925	rs2011167	ENSG00000254174.1	IGHV1-12	7.23	9.62e-13	2.33e-10	0.24	0.22	Alzheimer's disease (late onset);	chr14:106680831	chr14:106122420~106122709:-
BRCA	cis	rs9527	0.662	rs743575	ENSG00000213061.2	PFN1P11	7.23	9.62e-13	2.33e-10	0.31	0.22	Arsenic metabolism;	chr10:102835149	chr10:102838011~102845473:-
BRCA	cis	rs9309473	1	rs13421462	ENSG00000163016.8	ALMS1P	7.23	9.63e-13	2.33e-10	0.28	0.22	Metabolite levels;	chr2:73492748	chr2:73644919~73685576:+
BRCA	cis	rs6570726	0.935	rs429306	ENSG00000235652.6	RP11-545I5.3	7.23	9.63e-13	2.33e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145505880	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.935	rs428659	ENSG00000235652.6	RP11-545I5.3	7.23	9.63e-13	2.33e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145505903	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.935	rs376991	ENSG00000235652.6	RP11-545I5.3	7.23	9.63e-13	2.33e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145506937	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.935	rs401888	ENSG00000235652.6	RP11-545I5.3	7.23	9.63e-13	2.33e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145510399	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.935	rs414646	ENSG00000235652.6	RP11-545I5.3	7.23	9.63e-13	2.33e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145510549	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.935	rs454614	ENSG00000235652.6	RP11-545I5.3	7.23	9.63e-13	2.33e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145511497	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.846	rs411468	ENSG00000235652.6	RP11-545I5.3	7.23	9.63e-13	2.33e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145511656	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.935	rs425731	ENSG00000235652.6	RP11-545I5.3	7.23	9.63e-13	2.33e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145513015	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.935	rs421690	ENSG00000235652.6	RP11-545I5.3	7.23	9.63e-13	2.33e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145513458	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.935	rs399169	ENSG00000235652.6	RP11-545I5.3	7.23	9.63e-13	2.33e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145515217	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.935	rs377130	ENSG00000235652.6	RP11-545I5.3	7.23	9.63e-13	2.33e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145515496	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.935	rs422540	ENSG00000235652.6	RP11-545I5.3	7.23	9.63e-13	2.33e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145516679	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.935	rs425717	ENSG00000235652.6	RP11-545I5.3	7.23	9.63e-13	2.33e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145517484	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.935	rs409121	ENSG00000235652.6	RP11-545I5.3	7.23	9.63e-13	2.33e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145518657	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.935	rs424263	ENSG00000235652.6	RP11-545I5.3	7.23	9.63e-13	2.33e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145518937	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.905	rs419575	ENSG00000235652.6	RP11-545I5.3	7.23	9.63e-13	2.33e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145519038	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.935	rs409725	ENSG00000235652.6	RP11-545I5.3	7.23	9.63e-13	2.33e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145519204	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.935	rs386823	ENSG00000235652.6	RP11-545I5.3	7.23	9.63e-13	2.33e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145520229	chr6:145799409~145886585:+
BRCA	cis	rs270601	0.837	rs367805	ENSG00000233006.5	AC034220.3	7.23	9.65e-13	2.33e-10	0.18	0.22	Acylcarnitine levels;	chr5:132365587	chr5:132311285~132369916:-
BRCA	cis	rs4723738	1	rs17171307	ENSG00000227191.5	TRGC2	-7.23	9.65e-13	2.33e-10	-0.2	-0.22	Treatment response for severe sepsis;	chr7:38188976	chr7:38239580~38368091:-
BRCA	cis	rs7809950	1	rs6976607	ENSG00000238832.1	snoU109	7.23	9.66e-13	2.34e-10	0.3	0.22	Coronary artery disease;	chr7:107582956	chr7:107603363~107603507:+
BRCA	cis	rs13178541	0.81	rs4976465	ENSG00000250378.1	RP11-119J18.1	-7.22	9.69e-13	2.34e-10	-0.3	-0.22	IgG glycosylation;	chr5:135815226	chr5:135812667~135826582:+
BRCA	cis	rs79040073	0.637	rs73398276	ENSG00000259531.2	RP11-295H24.3	7.22	9.69e-13	2.34e-10	0.36	0.22	Lung cancer in ever smokers;	chr15:49418782	chr15:49365124~49366685:-
BRCA	cis	rs11018904	0.906	rs10501713	ENSG00000280385.1	AP000648.5	-7.22	9.7e-13	2.34e-10	-0.33	-0.22	Intelligence (multi-trait analysis);	chr11:90219845	chr11:90193614~90198120:+
BRCA	cis	rs56046484	1	rs56046484	ENSG00000259295.5	CSPG4P12	7.22	9.71e-13	2.35e-10	0.33	0.22	Testicular germ cell tumor;	chr15:85062196	chr15:85191438~85213905:+
BRCA	cis	rs293748	0.571	rs10042473	ENSG00000250155.1	CTD-2353F22.1	-7.22	9.72e-13	2.35e-10	-0.28	-0.22	Obesity-related traits;	chr5:37243651	chr5:36666214~36725195:-
BRCA	cis	rs58873874	0.579	rs80253028	ENSG00000248544.2	CTB-47B11.3	7.22	9.75e-13	2.36e-10	0.45	0.22	Bipolar disorder (body mass index interaction);	chr5:157340020	chr5:157375741~157384950:-
BRCA	cis	rs9880211	0.679	rs9818740	ENSG00000273486.1	RP11-731C17.2	7.22	9.76e-13	2.36e-10	0.29	0.22	Height;Body mass index;	chr3:136220744	chr3:136837338~136839021:-
BRCA	cis	rs2288884	0.636	rs73066154	ENSG00000275055.1	CTC-471J1.11	-7.22	9.77e-13	2.36e-10	-0.26	-0.22	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52060240	chr19:52049007~52049754:+
BRCA	cis	rs6570726	0.935	rs408723	ENSG00000235652.6	RP11-545I5.3	7.22	9.78e-13	2.36e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145517399	chr6:145799409~145886585:+
BRCA	cis	rs7246657	0.943	rs10405325	ENSG00000276846.1	CTD-3220F14.3	7.22	9.8e-13	2.37e-10	0.31	0.22	Coronary artery calcification;	chr19:37392575	chr19:37314868~37315620:-
BRCA	cis	rs9880211	0.8	rs75901823	ENSG00000239213.4	NCK1-AS1	7.22	9.8e-13	2.37e-10	0.29	0.22	Height;Body mass index;	chr3:136775309	chr3:136841726~136862054:-
BRCA	cis	rs6570726	0.935	rs432086	ENSG00000235652.6	RP11-545I5.3	-7.22	9.81e-13	2.37e-10	-0.21	-0.22	Lobe attachment (rater-scored or self-reported);	chr6:145520457	chr6:145799409~145886585:+
BRCA	cis	rs10050311	0.746	rs969734	ENSG00000251411.1	RP11-397E7.4	-7.22	9.81e-13	2.37e-10	-0.32	-0.22	Insulin-related traits;	chr4:86744231	chr4:86913266~86914817:-
BRCA	cis	rs1552244	0.882	rs34706481	ENSG00000180385.7	EMC3-AS1	7.22	9.81e-13	2.37e-10	0.29	0.22	Alzheimer's disease;	chr3:9962439	chr3:9986893~10006990:+
BRCA	cis	rs61160187	0.582	rs976631	ENSG00000215032.2	GNL3LP1	7.22	9.86e-13	2.38e-10	0.27	0.22	Educational attainment (years of education);Educational attainment (college completion);	chr5:60920216	chr5:60891935~60893577:-
BRCA	cis	rs8005677	0.962	rs8003934	ENSG00000279656.1	RP11-298I3.6	7.22	9.86e-13	2.38e-10	0.26	0.22	Cognitive ability (multi-trait analysis);	chr14:22931933	chr14:23023083~23024217:-
BRCA	cis	rs11098499	0.954	rs878373	ENSG00000249244.1	RP11-548H18.2	7.22	9.87e-13	2.38e-10	0.26	0.22	Corneal astigmatism;	chr4:119316329	chr4:119391831~119395335:-
BRCA	cis	rs4835473	0.897	rs11100802	ENSG00000251600.4	RP11-673E1.1	-7.22	9.88e-13	2.39e-10	-0.26	-0.22	Immature fraction of reticulocytes;	chr4:143700046	chr4:143912331~143982454:+
BRCA	cis	rs867371	0.762	rs12905578	ENSG00000255769.6	GOLGA2P10	7.22	9.89e-13	2.39e-10	0.26	0.22	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82288923	chr15:82472993~82513950:-
BRCA	cis	rs7474896	0.559	rs1208779	ENSG00000226578.1	RP11-258F22.1	-7.22	9.92e-13	2.4e-10	-0.29	-0.22	Obesity (extreme);	chr10:37788801	chr10:37775371~37784131:-
BRCA	cis	rs6570726	0.935	rs413916	ENSG00000235652.6	RP11-545I5.3	7.22	9.94e-13	2.4e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145510264	chr6:145799409~145886585:+
BRCA	cis	rs6543140	0.964	rs62154972	ENSG00000234389.1	AC007278.3	7.22	9.94e-13	2.4e-10	0.22	0.22	Blood protein levels;	chr2:102432278	chr2:102438713~102440475:+
BRCA	cis	rs9880211	0.699	rs13433688	ENSG00000239213.4	NCK1-AS1	7.22	9.94e-13	2.4e-10	0.29	0.22	Height;Body mass index;	chr3:136690329	chr3:136841726~136862054:-
BRCA	cis	rs7809950	1	rs4727684	ENSG00000238832.1	snoU109	-7.22	9.94e-13	2.4e-10	-0.3	-0.22	Coronary artery disease;	chr7:107586025	chr7:107603363~107603507:+
BRCA	cis	rs2033711	0.902	rs4801589	ENSG00000269473.1	CTD-2619J13.19	7.22	9.99e-13	2.41e-10	0.26	0.22	Uric acid clearance;	chr19:58442031	chr19:58440448~58445849:+
BRCA	cis	rs61270009	0.955	rs13171573	ENSG00000247828.6	TMEM161B-AS1	7.22	1e-12	2.41e-10	0.29	0.22	Depressive symptoms;	chr5:88383625	chr5:88268895~88436685:+
BRCA	cis	rs7246657	0.943	rs1382357	ENSG00000276846.1	CTD-3220F14.3	7.22	1e-12	2.41e-10	0.29	0.22	Coronary artery calcification;	chr19:37486707	chr19:37314868~37315620:-
BRCA	cis	rs875971	0.502	rs2465121	ENSG00000224316.1	RP11-479O9.2	-7.22	1e-12	2.42e-10	-0.25	-0.22	Aortic root size;	chr7:66156017	chr7:65773620~65802067:+
BRCA	cis	rs10515750	0.588	rs11743536	ENSG00000251405.2	CTB-109A12.1	-7.22	1e-12	2.42e-10	-0.33	-0.22	Lung function (FEV1/FVC);	chr5:157347044	chr5:157362615~157460078:-
BRCA	cis	rs9649213	0.593	rs6955647	ENSG00000272950.1	RP11-307C18.1	7.22	1e-12	2.42e-10	0.28	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98375250	chr7:98322853~98323430:+
BRCA	cis	rs9649213	0.593	rs13232181	ENSG00000272950.1	RP11-307C18.1	7.22	1e-12	2.42e-10	0.27	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98306359	chr7:98322853~98323430:+
BRCA	cis	rs858239	0.537	rs6955115	ENSG00000230042.1	AK3P3	-7.22	1.01e-12	2.43e-10	-0.25	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23187525	chr7:23129178~23129841:+
BRCA	cis	rs3781264	0.687	rs11187900	ENSG00000273450.1	RP11-76P2.4	7.22	1.01e-12	2.43e-10	0.3	0.22	Esophageal cancer and gastric cancer;	chr10:94348607	chr10:94314907~94315327:-
BRCA	cis	rs11098499	0.955	rs56386062	ENSG00000248280.1	RP11-33B1.2	7.22	1.01e-12	2.44e-10	0.23	0.22	Corneal astigmatism;	chr4:119233980	chr4:119440561~119450157:-
BRCA	cis	rs10771431	1	rs10771431	ENSG00000111788.10	RP11-22B23.1	7.22	1.01e-12	2.44e-10	0.2	0.22	Breast size;	chr12:9228263	chr12:9277235~9313241:+
BRCA	cis	rs10129255	0.5	rs10131875	ENSG00000280411.1	IGHV1-69-2	-7.22	1.02e-12	2.45e-10	-0.14	-0.22	Kawasaki disease;	chr14:106792798	chr14:106762092~106762588:-
BRCA	cis	rs732716	0.813	rs760369	ENSG00000267769.1	CTB-50L17.9	7.22	1.02e-12	2.45e-10	0.25	0.22	Mean corpuscular volume;	chr19:4449290	chr19:4454014~4455286:+
BRCA	cis	rs66887589	0.967	rs13104219	ENSG00000248280.1	RP11-33B1.2	7.22	1.02e-12	2.46e-10	0.2	0.22	Diastolic blood pressure;	chr4:119517019	chr4:119440561~119450157:-
BRCA	cis	rs2274273	0.967	rs8013027	ENSG00000258413.1	RP11-665C16.6	-7.22	1.02e-12	2.46e-10	-0.27	-0.22	Protein biomarker;	chr14:55144222	chr14:55262767~55272075:-
BRCA	cis	rs10129255	0.5	rs11628999	ENSG00000280411.1	IGHV1-69-2	-7.22	1.02e-12	2.46e-10	-0.14	-0.22	Kawasaki disease;	chr14:106800208	chr14:106762092~106762588:-
BRCA	cis	rs2742234	0.955	rs2435385	ENSG00000273008.1	RP11-351D16.3	-7.22	1.02e-12	2.46e-10	-0.25	-0.22	Hirschsprung disease;	chr10:43170302	chr10:43136824~43138334:-
BRCA	cis	rs9880211	1	rs13071220	ENSG00000273486.1	RP11-731C17.2	7.22	1.02e-12	2.47e-10	0.29	0.22	Height;Body mass index;	chr3:136595277	chr3:136837338~136839021:-
BRCA	cis	rs801193	0.839	rs12534943	ENSG00000236529.1	RP13-254B10.1	-7.22	1.02e-12	2.47e-10	-0.24	-0.22	Aortic root size;	chr7:66605533	chr7:65840212~65840596:+
BRCA	cis	rs6545883	0.965	rs3771258	ENSG00000271889.1	RP11-493E12.1	7.22	1.02e-12	2.47e-10	0.28	0.22	Tuberculosis;	chr2:61537005	chr2:61151433~61162105:-
BRCA	cis	rs11098499	0.863	rs17050695	ENSG00000248280.1	RP11-33B1.2	7.22	1.03e-12	2.47e-10	0.22	0.22	Corneal astigmatism;	chr4:119568372	chr4:119440561~119450157:-
BRCA	cis	rs10740039	0.883	rs7905018	ENSG00000254271.1	RP11-131N11.4	7.22	1.03e-12	2.49e-10	0.29	0.22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60647585	chr10:60734342~60741828:+
BRCA	cis	rs755249	1	rs4660293	ENSG00000237624.1	OXCT2P1	-7.22	1.03e-12	2.49e-10	-0.31	-0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39562508	chr1:39514956~39516490:+
BRCA	cis	rs858239	0.539	rs57864591	ENSG00000230042.1	AK3P3	-7.22	1.03e-12	2.49e-10	-0.25	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23144805	chr7:23129178~23129841:+
BRCA	cis	rs11976180	1	rs2951363	ENSG00000204959.4	ARHGEF34P	7.22	1.04e-12	2.5e-10	0.27	0.22	Obesity-related traits;	chr7:144057631	chr7:144272445~144286966:-
BRCA	cis	rs9880211	0.563	rs9848926	ENSG00000273486.1	RP11-731C17.2	7.22	1.04e-12	2.5e-10	0.28	0.22	Height;Body mass index;	chr3:136097460	chr3:136837338~136839021:-
BRCA	cis	rs7208859	0.524	rs73988172	ENSG00000263603.1	CTD-2349P21.5	-7.21	1.04e-12	2.5e-10	-0.37	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759314	chr17:30729469~30731202:+
BRCA	cis	rs2243480	1	rs781142	ENSG00000273142.1	RP11-458F8.4	-7.21	1.04e-12	2.5e-10	-0.29	-0.22	Diabetic kidney disease;	chr7:65973791	chr7:66902857~66906297:+
BRCA	cis	rs10740039	0.883	rs1470237	ENSG00000254271.1	RP11-131N11.4	7.21	1.04e-12	2.5e-10	0.29	0.22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60653381	chr10:60734342~60741828:+
BRCA	cis	rs202072	0.652	rs453695	ENSG00000272379.1	RP1-257A7.5	-7.21	1.04e-12	2.51e-10	-0.35	-0.22	HIV-1 viral setpoint;	chr6:13262274	chr6:13290018~13290490:-
BRCA	cis	rs7617773	0.78	rs13084616	ENSG00000228638.1	FCF1P2	7.21	1.04e-12	2.51e-10	0.25	0.22	Coronary artery disease;	chr3:48298209	chr3:48290793~48291375:-
BRCA	cis	rs494459	0.929	rs627391	ENSG00000278376.1	RP11-158I9.8	-7.21	1.04e-12	2.51e-10	-0.2	-0.22	Height;	chr11:118703207	chr11:118791254~118793137:+
BRCA	cis	rs10129255	0.957	rs10136560	ENSG00000224373.3	IGHV4-59	7.21	1.04e-12	2.52e-10	0.14	0.22	Kawasaki disease;	chr14:106787630	chr14:106627249~106627825:-
BRCA	cis	rs875971	0.965	rs9969301	ENSG00000232559.3	GS1-124K5.12	-7.21	1.05e-12	2.52e-10	-0.26	-0.22	Aortic root size;	chr7:66316668	chr7:66554588~66576923:-
BRCA	cis	rs801193	0.967	rs34356500	ENSG00000224316.1	RP11-479O9.2	7.21	1.05e-12	2.52e-10	0.21	0.22	Aortic root size;	chr7:66771620	chr7:65773620~65802067:+
BRCA	cis	rs10740039	0.883	rs7898504	ENSG00000254271.1	RP11-131N11.4	7.21	1.05e-12	2.52e-10	0.29	0.22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60658233	chr10:60734342~60741828:+
BRCA	cis	rs780096	0.526	rs3845686	ENSG00000234072.1	AC074117.10	-7.21	1.05e-12	2.53e-10	-0.21	-0.22	Total body bone mineral density;	chr2:27432580	chr2:27356246~27367622:+
BRCA	cis	rs4835473	0.864	rs61427459	ENSG00000251600.4	RP11-673E1.1	-7.21	1.05e-12	2.53e-10	-0.26	-0.22	Immature fraction of reticulocytes;	chr4:143699605	chr4:143912331~143982454:+
BRCA	cis	rs9880211	0.8	rs13314357	ENSG00000273486.1	RP11-731C17.2	7.21	1.06e-12	2.54e-10	0.29	0.22	Height;Body mass index;	chr3:136768717	chr3:136837338~136839021:-
BRCA	cis	rs7246657	0.943	rs12981532	ENSG00000276846.1	CTD-3220F14.3	7.21	1.06e-12	2.55e-10	0.31	0.22	Coronary artery calcification;	chr19:37398378	chr19:37314868~37315620:-
BRCA	cis	rs7246657	0.943	rs7246993	ENSG00000276846.1	CTD-3220F14.3	7.21	1.06e-12	2.55e-10	0.31	0.22	Coronary artery calcification;	chr19:37399252	chr19:37314868~37315620:-
BRCA	cis	rs7246657	0.943	rs10413602	ENSG00000276846.1	CTD-3220F14.3	7.21	1.06e-12	2.55e-10	0.31	0.22	Coronary artery calcification;	chr19:37400590	chr19:37314868~37315620:-
BRCA	cis	rs34779708	0.741	rs34397613	ENSG00000271335.4	RP11-324I22.4	7.21	1.06e-12	2.55e-10	0.23	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35261385	chr10:35314552~35336401:-
BRCA	cis	rs2274273	0.588	rs9323285	ENSG00000258413.1	RP11-665C16.6	7.21	1.06e-12	2.55e-10	0.29	0.22	Protein biomarker;	chr14:55397111	chr14:55262767~55272075:-
BRCA	cis	rs4723738	1	rs7788819	ENSG00000227191.5	TRGC2	-7.21	1.06e-12	2.55e-10	-0.2	-0.22	Treatment response for severe sepsis;	chr7:38187056	chr7:38239580~38368091:-
BRCA	cis	rs10740039	0.842	rs10761539	ENSG00000254271.1	RP11-131N11.4	7.21	1.06e-12	2.55e-10	0.29	0.22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60649733	chr10:60734342~60741828:+
BRCA	cis	rs10754283	0.967	rs10922679	ENSG00000231613.1	RP5-943J3.1	7.21	1.06e-12	2.55e-10	0.24	0.22	Amyotrophic lateral sclerosis (sporadic);	chr1:89635366	chr1:89788914~89790492:+
BRCA	cis	rs12291225	0.679	rs4756786	ENSG00000251991.1	RNU7-49P	7.21	1.06e-12	2.56e-10	0.25	0.22	Sense of smell;	chr11:14264354	chr11:14478892~14478953:+
BRCA	cis	rs7247513	1	rs2042947	ENSG00000230310.1	CTD-2192J16.11	-7.21	1.06e-12	2.56e-10	-0.27	-0.22	Bipolar disorder;	chr19:12582289	chr19:12552597~12553644:+
BRCA	cis	rs858239	0.601	rs10224327	ENSG00000230042.1	AK3P3	-7.21	1.06e-12	2.56e-10	-0.25	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23122201	chr7:23129178~23129841:+
BRCA	cis	rs858239	0.899	rs10262243	ENSG00000230042.1	AK3P3	-7.21	1.07e-12	2.56e-10	-0.25	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23251368	chr7:23129178~23129841:+
BRCA	cis	rs11976180	1	rs1320894	ENSG00000204959.4	ARHGEF34P	7.21	1.07e-12	2.57e-10	0.27	0.22	Obesity-related traits;	chr7:144054709	chr7:144272445~144286966:-
BRCA	cis	rs11976180	1	rs2951369	ENSG00000204959.4	ARHGEF34P	7.21	1.07e-12	2.57e-10	0.27	0.22	Obesity-related traits;	chr7:144055545	chr7:144272445~144286966:-
BRCA	cis	rs3020264	1	rs3020264	ENSG00000271743.1	CTD-2541M15.3	7.21	1.07e-12	2.57e-10	0.31	0.22	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 24 weeks);	chr8:6631056	chr8:6615604~6617198:-
BRCA	cis	rs7246657	0.943	rs4802766	ENSG00000276846.1	CTD-3220F14.3	7.21	1.07e-12	2.58e-10	0.3	0.22	Coronary artery calcification;	chr19:37491031	chr19:37314868~37315620:-
BRCA	cis	rs9649213	0.593	rs6963210	ENSG00000272950.1	RP11-307C18.1	7.21	1.07e-12	2.59e-10	0.27	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98315674	chr7:98322853~98323430:+
BRCA	cis	rs2014572	0.933	rs8107516	ENSG00000268379.1	CTC-360J11.4	7.21	1.08e-12	2.59e-10	0.27	0.22	Hyperactive-impulsive symptoms;	chr19:57247077	chr19:57175233~57177921:+
BRCA	cis	rs61160187	0.582	rs1460961	ENSG00000215032.2	GNL3LP1	7.21	1.08e-12	2.59e-10	0.27	0.22	Educational attainment (years of education);Educational attainment (college completion);	chr5:61116005	chr5:60891935~60893577:-
BRCA	cis	rs7674212	0.531	rs6816370	ENSG00000251288.2	RP11-10L12.2	-7.21	1.08e-12	2.6e-10	-0.27	-0.22	Type 2 diabetes;	chr4:103018276	chr4:102751401~102752641:+
BRCA	cis	rs2243480	0.711	rs1626926	ENSG00000273142.1	RP11-458F8.4	-7.21	1.08e-12	2.6e-10	-0.29	-0.22	Diabetic kidney disease;	chr7:65970805	chr7:66902857~66906297:+
BRCA	cis	rs732716	0.74	rs78869060	ENSG00000267769.1	CTB-50L17.9	-7.21	1.08e-12	2.6e-10	-0.26	-0.22	Mean corpuscular volume;	chr19:4444745	chr19:4454014~4455286:+
BRCA	cis	rs12237653	0.929	rs10966858	ENSG00000236404.7	VLDLR-AS1	7.21	1.08e-12	2.6e-10	0.35	0.22	Gambling;	chr9:2541910	chr9:2422702~2643359:-
BRCA	cis	rs3781264	1	rs11187851	ENSG00000273450.1	RP11-76P2.4	7.21	1.08e-12	2.6e-10	0.3	0.22	Esophageal cancer and gastric cancer;	chr10:94310118	chr10:94314907~94315327:-
BRCA	cis	rs2274273	0.648	rs58553156	ENSG00000258413.1	RP11-665C16.6	-7.21	1.08e-12	2.6e-10	-0.28	-0.22	Protein biomarker;	chr14:55115976	chr14:55262767~55272075:-
BRCA	cis	rs6740322	0.901	rs2163228	ENSG00000234936.1	AC010883.5	7.21	1.08e-12	2.61e-10	0.26	0.22	Coronary artery disease;	chr2:43322107	chr2:43229573~43233394:+
BRCA	cis	rs801193	0.773	rs801207	ENSG00000224316.1	RP11-479O9.2	-7.21	1.08e-12	2.61e-10	-0.22	-0.22	Aortic root size;	chr7:66555603	chr7:65773620~65802067:+
BRCA	cis	rs1075232	1	rs72722829	ENSG00000215302.7	CTD-3092A11.1	-7.21	1.09e-12	2.63e-10	-0.54	-0.22	Survival in colorectal cancer (non-distant metastatic);	chr15:31346911	chr15:30470779~30507623:+
BRCA	cis	rs4845875	0.557	rs6659541	ENSG00000242349.4	NPPA-AS1	7.21	1.09e-12	2.63e-10	0.24	0.22	Midregional pro atrial natriuretic peptide levels;	chr1:11776385	chr1:11841017~11848079:+
BRCA	cis	rs9527	0.662	rs4919687	ENSG00000213061.2	PFN1P11	7.21	1.09e-12	2.63e-10	0.31	0.22	Arsenic metabolism;	chr10:102835491	chr10:102838011~102845473:-
BRCA	cis	rs4072705	0.967	rs4838208	ENSG00000224020.1	MIR181A2HG	-7.21	1.1e-12	2.64e-10	-0.25	-0.22	Menarche (age at onset);	chr9:124765756	chr9:124658467~124698631:+
BRCA	cis	rs4934494	0.768	rs12572608	ENSG00000240996.1	RP11-80H5.7	7.21	1.1e-12	2.65e-10	0.28	0.22	Red blood cell count;	chr10:89647170	chr10:89694295~89697928:-
BRCA	cis	rs875971	0.619	rs2302918	ENSG00000236529.1	RP13-254B10.1	7.21	1.1e-12	2.65e-10	0.24	0.22	Aortic root size;	chr7:66535945	chr7:65840212~65840596:+
BRCA	cis	rs9876781	1	rs2885510	ENSG00000244380.1	RP11-24C3.2	-7.21	1.1e-12	2.65e-10	-0.25	-0.22	Longevity;	chr3:48376736	chr3:48440352~48446656:-
BRCA	cis	rs9876781	1	rs725309	ENSG00000244380.1	RP11-24C3.2	-7.21	1.1e-12	2.65e-10	-0.25	-0.22	Longevity;	chr3:48377218	chr3:48440352~48446656:-
BRCA	cis	rs7246657	0.943	rs34603719	ENSG00000276846.1	CTD-3220F14.3	7.21	1.1e-12	2.65e-10	0.31	0.22	Coronary artery calcification;	chr19:37303626	chr19:37314868~37315620:-
BRCA	cis	rs7621025	0.664	rs6439657	ENSG00000239213.4	NCK1-AS1	-7.21	1.1e-12	2.66e-10	-0.27	-0.22	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136775797	chr3:136841726~136862054:-
BRCA	cis	rs2243480	0.901	rs2949697	ENSG00000273142.1	RP11-458F8.4	-7.21	1.11e-12	2.66e-10	-0.3	-0.22	Diabetic kidney disease;	chr7:65999249	chr7:66902857~66906297:+
BRCA	cis	rs3762637	1	rs7645862	ENSG00000272758.4	RP11-299J3.8	-7.21	1.11e-12	2.66e-10	-0.32	-0.22	LDL cholesterol levels;	chr3:122502292	chr3:122416207~122443180:+
BRCA	cis	rs9876781	0.559	rs13073692	ENSG00000229759.1	MRPS18AP1	7.21	1.11e-12	2.66e-10	0.25	0.22	Longevity;	chr3:48361812	chr3:48256350~48256938:-
BRCA	cis	rs6496044	0.507	rs2467096	ENSG00000202081.1	RNU6-1280P	-7.21	1.11e-12	2.66e-10	-0.25	-0.22	Interstitial lung disease;	chr15:85667447	chr15:85651522~85651628:-
BRCA	cis	rs9527	0.637	rs7085104	ENSG00000236937.2	PTGES3P4	7.21	1.11e-12	2.66e-10	0.29	0.22	Arsenic metabolism;	chr10:102869116	chr10:102845595~102845950:+
BRCA	cis	rs9880211	1	rs9828976	ENSG00000273486.1	RP11-731C17.2	7.21	1.11e-12	2.67e-10	0.29	0.22	Height;Body mass index;	chr3:136817993	chr3:136837338~136839021:-
BRCA	cis	rs10740039	0.883	rs7088404	ENSG00000254271.1	RP11-131N11.4	7.21	1.11e-12	2.67e-10	0.29	0.22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60633320	chr10:60734342~60741828:+
BRCA	cis	rs7474896	0.537	rs2505255	ENSG00000226578.1	RP11-258F22.1	-7.2	1.11e-12	2.68e-10	-0.28	-0.22	Obesity (extreme);	chr10:38070714	chr10:37775371~37784131:-
BRCA	cis	rs4723738	1	rs1019180	ENSG00000227191.5	TRGC2	-7.2	1.11e-12	2.68e-10	-0.19	-0.22	Treatment response for severe sepsis;	chr7:38179410	chr7:38239580~38368091:-
BRCA	cis	rs3781264	0.595	rs7085378	ENSG00000273450.1	RP11-76P2.4	7.2	1.11e-12	2.68e-10	0.28	0.22	Esophageal cancer and gastric cancer;	chr10:94349568	chr10:94314907~94315327:-
BRCA	cis	rs875971	1	rs55962648	ENSG00000232559.3	GS1-124K5.12	-7.2	1.11e-12	2.68e-10	-0.26	-0.22	Aortic root size;	chr7:66160764	chr7:66554588~66576923:-
BRCA	cis	rs858239	0.6	rs10235786	ENSG00000230042.1	AK3P3	-7.2	1.12e-12	2.68e-10	-0.25	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23100321	chr7:23129178~23129841:+
BRCA	cis	rs10740039	0.96	rs10443928	ENSG00000254271.1	RP11-131N11.4	7.2	1.12e-12	2.69e-10	0.29	0.22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60645718	chr10:60734342~60741828:+
BRCA	cis	rs10740039	0.883	rs10443929	ENSG00000254271.1	RP11-131N11.4	7.2	1.12e-12	2.69e-10	0.29	0.22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60645852	chr10:60734342~60741828:+
BRCA	cis	rs10740039	0.883	rs1837946	ENSG00000254271.1	RP11-131N11.4	7.2	1.12e-12	2.69e-10	0.29	0.22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60633676	chr10:60734342~60741828:+
BRCA	cis	rs9640161	0.83	rs17173681	ENSG00000261305.1	RP4-584D14.7	-7.2	1.12e-12	2.69e-10	-0.33	-0.22	Blood protein levels;Circulating chemerin levels;	chr7:150362325	chr7:150341771~150342607:+
BRCA	cis	rs2060793	0.506	rs10741658	ENSG00000251991.1	RNU7-49P	7.2	1.12e-12	2.69e-10	0.23	0.22	Vitamin D levels;	chr11:14903190	chr11:14478892~14478953:+
BRCA	cis	rs1322639	0.806	rs1322640	ENSG00000261039.2	RP11-417E7.2	7.2	1.12e-12	2.7e-10	0.23	0.22	Pulse pressure;	chr6:169186792	chr6:169175304~169182740:-
BRCA	cis	rs9880211	0.8	rs75901823	ENSG00000273486.1	RP11-731C17.2	7.2	1.12e-12	2.7e-10	0.29	0.22	Height;Body mass index;	chr3:136775309	chr3:136837338~136839021:-
BRCA	cis	rs780096	0.526	rs11126999	ENSG00000234072.1	AC074117.10	-7.2	1.12e-12	2.7e-10	-0.21	-0.22	Total body bone mineral density;	chr2:27447440	chr2:27356246~27367622:+
BRCA	cis	rs780096	0.506	rs56076827	ENSG00000234072.1	AC074117.10	-7.2	1.12e-12	2.7e-10	-0.21	-0.22	Total body bone mineral density;	chr2:27453420	chr2:27356246~27367622:+
BRCA	cis	rs780096	0.526	rs72819536	ENSG00000234072.1	AC074117.10	-7.2	1.12e-12	2.7e-10	-0.21	-0.22	Total body bone mineral density;	chr2:27459983	chr2:27356246~27367622:+
BRCA	cis	rs780096	0.526	rs11127013	ENSG00000234072.1	AC074117.10	-7.2	1.12e-12	2.7e-10	-0.21	-0.22	Total body bone mineral density;	chr2:27470106	chr2:27356246~27367622:+
BRCA	cis	rs7246657	0.943	rs4452075	ENSG00000276846.1	CTD-3220F14.3	7.2	1.13e-12	2.71e-10	0.29	0.22	Coronary artery calcification;	chr19:37388687	chr19:37314868~37315620:-
BRCA	cis	rs2599510	0.744	rs4952212	ENSG00000276334.1	AL133243.1	-7.2	1.13e-12	2.71e-10	-0.27	-0.22	Interleukin-18 levels;	chr2:32393425	chr2:32521927~32523547:+
BRCA	cis	rs10129255	0.957	rs10138532	ENSG00000224373.3	IGHV4-59	7.2	1.13e-12	2.71e-10	0.15	0.22	Kawasaki disease;	chr14:106803901	chr14:106627249~106627825:-
BRCA	cis	rs7246657	0.943	rs1373991	ENSG00000276846.1	CTD-3220F14.3	7.2	1.13e-12	2.71e-10	0.29	0.22	Coronary artery calcification;	chr19:37348009	chr19:37314868~37315620:-
BRCA	cis	rs7246657	0.943	rs10405407	ENSG00000276846.1	CTD-3220F14.3	7.2	1.13e-12	2.71e-10	0.29	0.22	Coronary artery calcification;	chr19:37348262	chr19:37314868~37315620:-
BRCA	cis	rs7246657	0.943	rs12709813	ENSG00000276846.1	CTD-3220F14.3	7.2	1.13e-12	2.71e-10	0.29	0.22	Coronary artery calcification;	chr19:37354081	chr19:37314868~37315620:-
BRCA	cis	rs7246657	0.943	rs13345116	ENSG00000276846.1	CTD-3220F14.3	7.2	1.13e-12	2.71e-10	0.29	0.22	Coronary artery calcification;	chr19:37356196	chr19:37314868~37315620:-
BRCA	cis	rs7246657	0.765	rs7247259	ENSG00000276846.1	CTD-3220F14.3	7.2	1.13e-12	2.71e-10	0.29	0.22	Coronary artery calcification;	chr19:37360188	chr19:37314868~37315620:-
BRCA	cis	rs7246657	0.943	rs3745765	ENSG00000276846.1	CTD-3220F14.3	7.2	1.13e-12	2.71e-10	0.29	0.22	Coronary artery calcification;	chr19:37363333	chr19:37314868~37315620:-
BRCA	cis	rs2906856	0.921	rs1019076	ENSG00000236946.2	HNRNPA1P70	7.2	1.13e-12	2.72e-10	0.18	0.22	Mosquito bite size;	chr12:68004338	chr12:68035767~68036853:+
BRCA	cis	rs10861661	0.963	rs11113118	ENSG00000260329.1	RP11-412D9.4	-7.2	1.13e-12	2.72e-10	-0.27	-0.22	Triglyceride levels;	chr12:106805364	chr12:106954029~106955497:-
BRCA	cis	rs301901	0.965	rs1466862	ENSG00000250155.1	CTD-2353F22.1	-7.2	1.13e-12	2.73e-10	-0.23	-0.22	Height;	chr5:36791710	chr5:36666214~36725195:-
BRCA	cis	rs67311347	1	rs11129876	ENSG00000280739.1	EIF1B-AS1	-7.2	1.13e-12	2.73e-10	-0.24	-0.22	Renal cell carcinoma;	chr3:40360145	chr3:40173145~40309698:-
BRCA	cis	rs61160187	0.582	rs1021005	ENSG00000215032.2	GNL3LP1	7.2	1.14e-12	2.73e-10	0.27	0.22	Educational attainment (years of education);Educational attainment (college completion);	chr5:60895633	chr5:60891935~60893577:-
BRCA	cis	rs6570726	0.935	rs387965	ENSG00000235652.6	RP11-545I5.3	7.2	1.14e-12	2.73e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145548230	chr6:145799409~145886585:+
BRCA	cis	rs6840258	0.66	rs72667736	ENSG00000251411.1	RP11-397E7.4	-7.2	1.14e-12	2.74e-10	-0.33	-0.22	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86954803	chr4:86913266~86914817:-
BRCA	cis	rs526231	0.543	rs246913	ENSG00000175749.11	EIF3KP1	7.2	1.14e-12	2.75e-10	0.33	0.22	Primary biliary cholangitis;	chr5:103224669	chr5:103032376~103033031:+
BRCA	cis	rs10740039	0.883	rs1442546	ENSG00000254271.1	RP11-131N11.4	7.2	1.14e-12	2.75e-10	0.29	0.22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60650240	chr10:60734342~60741828:+
BRCA	cis	rs875971	1	rs2420168	ENSG00000232559.3	GS1-124K5.12	-7.2	1.15e-12	2.75e-10	-0.26	-0.22	Aortic root size;	chr7:66165644	chr7:66554588~66576923:-
BRCA	cis	rs9527	0.637	rs11191424	ENSG00000236937.2	PTGES3P4	7.2	1.15e-12	2.75e-10	0.28	0.22	Arsenic metabolism;	chr10:102866129	chr10:102845595~102845950:+
BRCA	cis	rs6570726	0.935	rs419847	ENSG00000235652.6	RP11-545I5.3	7.2	1.15e-12	2.75e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145506142	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.935	rs419850	ENSG00000235652.6	RP11-545I5.3	7.2	1.15e-12	2.75e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145506145	chr6:145799409~145886585:+
BRCA	cis	rs9649213	0.555	rs6968193	ENSG00000272950.1	RP11-307C18.1	7.2	1.15e-12	2.75e-10	0.27	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98286590	chr7:98322853~98323430:+
BRCA	cis	rs7937890	0.505	rs1403248	ENSG00000251991.1	RNU7-49P	7.2	1.15e-12	2.75e-10	0.24	0.22	Mitochondrial DNA levels;	chr11:14657471	chr11:14478892~14478953:+
BRCA	cis	rs2303759	0.676	rs7248378	ENSG00000268686.1	AC010524.2	-7.2	1.15e-12	2.76e-10	-0.33	-0.22	Multiple sclerosis;	chr19:49404887	chr19:49368705~49388081:-
BRCA	cis	rs9649213	0.593	rs2107716	ENSG00000272950.1	RP11-307C18.1	7.2	1.15e-12	2.76e-10	0.27	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98315432	chr7:98322853~98323430:+
BRCA	cis	rs7520050	0.751	rs592214	ENSG00000280836.1	AL355480.1	7.2	1.15e-12	2.76e-10	0.26	0.22	Reticulocyte count;Red blood cell count;	chr1:45558833	chr1:45581219~45581321:-
BRCA	cis	rs78456975	0.657	rs116217838	ENSG00000231482.2	AC141930.2	-7.2	1.15e-12	2.77e-10	-0.28	-0.22	Placebo response in major depressive disorder (% change in symptom score);	chr2:1565401	chr2:1572554~1580311:-
BRCA	cis	rs10740039	0.883	rs10821809	ENSG00000254271.1	RP11-131N11.4	7.2	1.15e-12	2.77e-10	0.29	0.22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60637612	chr10:60734342~60741828:+
BRCA	cis	rs10740039	0.883	rs10761533	ENSG00000254271.1	RP11-131N11.4	7.2	1.15e-12	2.77e-10	0.29	0.22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60638573	chr10:60734342~60741828:+
BRCA	cis	rs1075232	1	rs16956707	ENSG00000215302.7	CTD-3092A11.1	-7.2	1.15e-12	2.77e-10	-0.54	-0.22	Survival in colorectal cancer (non-distant metastatic);	chr15:31349430	chr15:30470779~30507623:+
BRCA	cis	rs2348418	0.966	rs7316797	ENSG00000247934.4	RP11-967K21.1	7.2	1.15e-12	2.77e-10	0.25	0.22	Lung function (FEV1);Lung function (FVC);	chr12:28529776	chr12:28163298~28190738:-
BRCA	cis	rs66887589	0.967	rs56173225	ENSG00000248280.1	RP11-33B1.2	-7.2	1.16e-12	2.78e-10	-0.2	-0.22	Diastolic blood pressure;	chr4:119588817	chr4:119440561~119450157:-
BRCA	cis	rs875971	0.508	rs6947808	ENSG00000224316.1	RP11-479O9.2	-7.2	1.16e-12	2.78e-10	-0.22	-0.22	Aortic root size;	chr7:66580095	chr7:65773620~65802067:+
BRCA	cis	rs7208859	0.673	rs2433	ENSG00000263603.1	CTD-2349P21.5	-7.2	1.16e-12	2.78e-10	-0.4	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30899210	chr17:30729469~30731202:+
BRCA	cis	rs7246657	0.882	rs8112610	ENSG00000276846.1	CTD-3220F14.3	7.2	1.16e-12	2.78e-10	0.29	0.22	Coronary artery calcification;	chr19:37437828	chr19:37314868~37315620:-
BRCA	cis	rs911555	0.723	rs12894652	ENSG00000244691.1	RPL10AP1	7.2	1.16e-12	2.78e-10	0.28	0.22	Intelligence (multi-trait analysis);	chr14:103459687	chr14:103412119~103412761:-
BRCA	cis	rs4927850	1	rs7614767	ENSG00000242086.7	LINC00969	7.2	1.16e-12	2.79e-10	0.24	0.22	Pancreatic cancer;	chr3:196026580	chr3:195658062~195739964:+
BRCA	cis	rs875971	0.545	rs6970498	ENSG00000224316.1	RP11-479O9.2	7.2	1.16e-12	2.79e-10	0.25	0.22	Aortic root size;	chr7:66275908	chr7:65773620~65802067:+
BRCA	cis	rs17301013	0.606	rs6676161	ENSG00000227373.4	RP11-160H22.5	7.2	1.16e-12	2.79e-10	0.31	0.22	Systemic lupus erythematosus;	chr1:174138555	chr1:174115300~174160004:-
BRCA	cis	rs13108904	0.65	rs3796618	ENSG00000254094.1	AC078852.1	-7.2	1.16e-12	2.79e-10	-0.24	-0.22	Obesity-related traits;	chr4:1355814	chr4:1356581~1358075:+
BRCA	cis	rs494459	0.964	rs576283	ENSG00000278376.1	RP11-158I9.8	-7.2	1.16e-12	2.79e-10	-0.2	-0.22	Height;	chr11:118703185	chr11:118791254~118793137:+
BRCA	cis	rs507080	0.524	rs524409	ENSG00000278376.1	RP11-158I9.8	-7.2	1.16e-12	2.79e-10	-0.2	-0.22	Serum metabolite levels;	chr11:118703602	chr11:118791254~118793137:+
BRCA	cis	rs10754283	0.967	rs10754285	ENSG00000231613.1	RP5-943J3.1	7.2	1.17e-12	2.8e-10	0.24	0.22	Amyotrophic lateral sclerosis (sporadic);	chr1:89651028	chr1:89788914~89790492:+
BRCA	cis	rs10740039	0.883	rs7918897	ENSG00000254271.1	RP11-131N11.4	7.2	1.17e-12	2.8e-10	0.29	0.22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60643754	chr10:60734342~60741828:+
BRCA	cis	rs7927771	1	rs10838748	ENSG00000280615.1	Y_RNA	-7.2	1.17e-12	2.8e-10	-0.27	-0.22	Subjective well-being;	chr11:47694829	chr11:47614898~47614994:-
BRCA	cis	rs2348418	0.798	rs7310297	ENSG00000247934.4	RP11-967K21.1	7.2	1.17e-12	2.81e-10	0.25	0.22	Lung function (FEV1);Lung function (FVC);	chr12:28313638	chr12:28163298~28190738:-
BRCA	cis	rs12237653	0.929	rs4740696	ENSG00000236404.7	VLDLR-AS1	7.2	1.17e-12	2.81e-10	0.34	0.22	Gambling;	chr9:2548106	chr9:2422702~2643359:-
BRCA	cis	rs56046484	0.957	rs35127646	ENSG00000259295.5	CSPG4P12	7.2	1.17e-12	2.82e-10	0.33	0.22	Testicular germ cell tumor;	chr15:85058640	chr15:85191438~85213905:+
BRCA	cis	rs74233809	1	rs12221064	ENSG00000213277.3	MARCKSL1P1	7.2	1.17e-12	2.82e-10	0.41	0.22	Birth weight;	chr10:102917369	chr10:103175554~103176094:+
BRCA	cis	rs74233809	1	rs77602510	ENSG00000213277.3	MARCKSL1P1	7.2	1.17e-12	2.82e-10	0.41	0.22	Birth weight;	chr10:102922845	chr10:103175554~103176094:+
BRCA	cis	rs74233809	1	rs78821730	ENSG00000213277.3	MARCKSL1P1	7.2	1.17e-12	2.82e-10	0.41	0.22	Birth weight;	chr10:102924787	chr10:103175554~103176094:+
BRCA	cis	rs10754283	0.967	rs6663363	ENSG00000231613.1	RP5-943J3.1	7.2	1.18e-12	2.82e-10	0.24	0.22	Amyotrophic lateral sclerosis (sporadic);	chr1:89651295	chr1:89788914~89790492:+
BRCA	cis	rs4723738	1	rs4723733	ENSG00000227191.5	TRGC2	7.2	1.18e-12	2.82e-10	0.19	0.22	Treatment response for severe sepsis;	chr7:38184011	chr7:38239580~38368091:-
BRCA	cis	rs2280018	0.963	rs11075255	ENSG00000260735.1	RP11-72I8.1	-7.2	1.18e-12	2.82e-10	-0.24	-0.22	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15072375	chr16:15094411~15109197:+
BRCA	cis	rs2836950	0.805	rs2836961	ENSG00000255568.3	BRWD1-AS2	-7.2	1.18e-12	2.82e-10	-0.21	-0.22	Menarche (age at onset);	chr21:39255094	chr21:39313935~39314962:+
BRCA	cis	rs780096	0.546	rs1260320	ENSG00000234072.1	AC074117.10	7.2	1.18e-12	2.83e-10	0.21	0.22	Total body bone mineral density;	chr2:27499549	chr2:27356246~27367622:+
BRCA	cis	rs301901	1	rs292184	ENSG00000250155.1	CTD-2353F22.1	-7.2	1.18e-12	2.83e-10	-0.24	-0.22	Height;	chr5:36963703	chr5:36666214~36725195:-
BRCA	cis	rs7809950	0.911	rs1015411	ENSG00000238832.1	snoU109	-7.2	1.18e-12	2.83e-10	-0.29	-0.22	Coronary artery disease;	chr7:107495167	chr7:107603363~107603507:+
BRCA	cis	rs12237653	0.799	rs12684409	ENSG00000236404.7	VLDLR-AS1	-7.2	1.18e-12	2.83e-10	-0.32	-0.22	Gambling;	chr9:2546716	chr9:2422702~2643359:-
BRCA	cis	rs79040073	0.607	rs17400706	ENSG00000259531.2	RP11-295H24.3	7.2	1.18e-12	2.84e-10	0.36	0.22	Lung cancer in ever smokers;	chr15:49455148	chr15:49365124~49366685:-
BRCA	cis	rs2348418	0.765	rs12368743	ENSG00000247934.4	RP11-967K21.1	-7.2	1.19e-12	2.84e-10	-0.25	-0.22	Lung function (FEV1);Lung function (FVC);	chr12:28192409	chr12:28163298~28190738:-
BRCA	cis	rs2288884	0.559	rs8104890	ENSG00000275055.1	CTC-471J1.11	-7.2	1.19e-12	2.84e-10	-0.26	-0.22	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52016355	chr19:52049007~52049754:+
BRCA	cis	rs780096	0.778	rs780094	ENSG00000234072.1	AC074117.10	7.2	1.19e-12	2.84e-10	0.2	0.22	Total body bone mineral density;	chr2:27518370	chr2:27356246~27367622:+
BRCA	cis	rs911555	0.755	rs2756132	ENSG00000244691.1	RPL10AP1	7.2	1.19e-12	2.85e-10	0.28	0.22	Intelligence (multi-trait analysis);	chr14:103501483	chr14:103412119~103412761:-
BRCA	cis	rs3760982	0.967	rs3760984	ENSG00000267058.1	RP11-15A1.3	-7.2	1.19e-12	2.85e-10	-0.24	-0.22	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43782610	chr19:43891804~43901805:-
BRCA	cis	rs950776	0.752	rs2869546	ENSG00000261762.1	RP11-650L12.2	-7.2	1.19e-12	2.85e-10	-0.25	-0.22	Sudden cardiac arrest;	chr15:78615003	chr15:78589123~78591276:-
BRCA	cis	rs7246657	0.943	rs13343502	ENSG00000276846.1	CTD-3220F14.3	7.19	1.19e-12	2.86e-10	0.3	0.22	Coronary artery calcification;	chr19:37471390	chr19:37314868~37315620:-
BRCA	cis	rs4072705	1	rs6478680	ENSG00000224020.1	MIR181A2HG	-7.19	1.19e-12	2.86e-10	-0.25	-0.22	Menarche (age at onset);	chr9:124696189	chr9:124658467~124698631:+
BRCA	cis	rs6840360	0.607	rs2724565	ENSG00000270265.1	RP11-731D1.4	-7.19	1.19e-12	2.86e-10	-0.24	-0.22	Intelligence (multi-trait analysis);	chr4:151429153	chr4:151333775~151353224:-
BRCA	cis	rs30380	1	rs30379	ENSG00000272109.1	CTD-2260A17.3	-7.19	1.2e-12	2.87e-10	-0.27	-0.22	Cerebrospinal fluid biomarker levels;	chr5:96786556	chr5:96804353~96806105:+
BRCA	cis	rs30380	1	rs30380	ENSG00000272109.1	CTD-2260A17.3	-7.19	1.2e-12	2.87e-10	-0.27	-0.22	Cerebrospinal fluid biomarker levels;	chr5:96786577	chr5:96804353~96806105:+
BRCA	cis	rs780096	0.526	rs12476704	ENSG00000234072.1	AC074117.10	-7.19	1.2e-12	2.87e-10	-0.21	-0.22	Total body bone mineral density;	chr2:27390164	chr2:27356246~27367622:+
BRCA	cis	rs6860806	0.507	rs270606	ENSG00000233006.5	AC034220.3	7.19	1.2e-12	2.88e-10	0.18	0.22	Breast cancer;	chr5:132315174	chr5:132311285~132369916:-
BRCA	cis	rs944990	0.557	rs10761237	ENSG00000227603.1	RP11-165J3.6	7.19	1.2e-12	2.88e-10	0.22	0.22	Body mass index;	chr9:93578535	chr9:93435332~93437121:-
BRCA	cis	rs7246657	0.943	rs10406177	ENSG00000276846.1	CTD-3220F14.3	7.19	1.21e-12	2.9e-10	0.29	0.22	Coronary artery calcification;	chr19:37417045	chr19:37314868~37315620:-
BRCA	cis	rs7246657	0.882	rs28623164	ENSG00000276846.1	CTD-3220F14.3	7.19	1.21e-12	2.9e-10	0.29	0.22	Coronary artery calcification;	chr19:37422551	chr19:37314868~37315620:-
BRCA	cis	rs7246657	0.943	rs7252346	ENSG00000276846.1	CTD-3220F14.3	7.19	1.21e-12	2.9e-10	0.29	0.22	Coronary artery calcification;	chr19:37423780	chr19:37314868~37315620:-
BRCA	cis	rs7246657	0.943	rs2891699	ENSG00000276846.1	CTD-3220F14.3	7.19	1.21e-12	2.9e-10	0.29	0.22	Coronary artery calcification;	chr19:37429335	chr19:37314868~37315620:-
BRCA	cis	rs7246657	0.943	rs9676967	ENSG00000276846.1	CTD-3220F14.3	7.19	1.21e-12	2.9e-10	0.29	0.22	Coronary artery calcification;	chr19:37437187	chr19:37314868~37315620:-
BRCA	cis	rs7246657	0.943	rs8109632	ENSG00000276846.1	CTD-3220F14.3	7.19	1.21e-12	2.9e-10	0.29	0.22	Coronary artery calcification;	chr19:37440223	chr19:37314868~37315620:-
BRCA	cis	rs7246657	0.943	rs7255407	ENSG00000276846.1	CTD-3220F14.3	7.19	1.21e-12	2.9e-10	0.29	0.22	Coronary artery calcification;	chr19:37443034	chr19:37314868~37315620:-
BRCA	cis	rs9876781	1	rs6442119	ENSG00000244380.1	RP11-24C3.2	7.19	1.21e-12	2.9e-10	0.25	0.22	Longevity;	chr3:48398713	chr3:48440352~48446656:-
BRCA	cis	rs11098499	0.562	rs58583086	ENSG00000248280.1	RP11-33B1.2	-7.19	1.21e-12	2.91e-10	-0.21	-0.22	Corneal astigmatism;	chr4:119635207	chr4:119440561~119450157:-
BRCA	cis	rs4835473	0.897	rs6537170	ENSG00000251600.4	RP11-673E1.1	7.19	1.23e-12	2.93e-10	0.26	0.22	Immature fraction of reticulocytes;	chr4:143691747	chr4:143912331~143982454:+
BRCA	cis	rs61160187	0.582	rs62372134	ENSG00000215032.2	GNL3LP1	7.19	1.23e-12	2.93e-10	0.27	0.22	Educational attainment (years of education);Educational attainment (college completion);	chr5:60906420	chr5:60891935~60893577:-
BRCA	cis	rs11089937	0.616	rs713644	ENSG00000211639.2	IGLV4-60	7.19	1.23e-12	2.93e-10	0.21	0.22	Periodontitis (PAL4Q3);	chr22:22180747	chr22:22162199~22162681:+
BRCA	cis	rs11089937	0.616	rs713624	ENSG00000211639.2	IGLV4-60	7.19	1.23e-12	2.93e-10	0.21	0.22	Periodontitis (PAL4Q3);	chr22:22180754	chr22:22162199~22162681:+
BRCA	cis	rs7665090	0.806	rs413967	ENSG00000246560.2	RP11-10L12.4	-7.19	1.23e-12	2.94e-10	-0.23	-0.22	Primary biliary cholangitis;	chr4:102662039	chr4:102828055~102844075:+
BRCA	cis	rs7665090	0.806	rs404574	ENSG00000246560.2	RP11-10L12.4	-7.19	1.23e-12	2.94e-10	-0.23	-0.22	Primary biliary cholangitis;	chr4:102662051	chr4:102828055~102844075:+
BRCA	cis	rs8054556	0.692	rs7201384	ENSG00000273724.1	RP11-347C12.12	-7.19	1.23e-12	2.94e-10	-0.24	-0.22	Autism spectrum disorder or schizophrenia;	chr16:29913584	chr16:30336400~30343336:+
BRCA	cis	rs78456975	0.506	rs13402886	ENSG00000231482.2	AC141930.2	-7.19	1.23e-12	2.94e-10	-0.28	-0.22	Placebo response in major depressive disorder (% change in symptom score);	chr2:1571576	chr2:1572554~1580311:-
BRCA	cis	rs10510102	0.872	rs3750837	ENSG00000276742.1	RP11-500G22.4	7.19	1.23e-12	2.95e-10	0.36	0.22	Breast cancer;	chr10:121899080	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.872	rs3750836	ENSG00000276742.1	RP11-500G22.4	7.19	1.23e-12	2.95e-10	0.36	0.22	Breast cancer;	chr10:121899087	chr10:121956782~121957098:+
BRCA	cis	rs2919009	0.544	rs7920943	ENSG00000271670.1	RP11-95I16.4	7.19	1.23e-12	2.95e-10	0.27	0.22	Obesity-related traits;	chr10:120923456	chr10:120879256~120880667:-
BRCA	cis	rs875971	0.577	rs34888281	ENSG00000237310.1	GS1-124K5.4	-7.19	1.24e-12	2.96e-10	-0.23	-0.22	Aortic root size;	chr7:66120784	chr7:66493706~66495474:+
BRCA	cis	rs7520050	0.751	rs2991975	ENSG00000280836.1	AL355480.1	7.19	1.24e-12	2.96e-10	0.25	0.22	Reticulocyte count;Red blood cell count;	chr1:45558854	chr1:45581219~45581321:-
BRCA	cis	rs61160187	0.582	rs67555188	ENSG00000215032.2	GNL3LP1	7.19	1.24e-12	2.96e-10	0.27	0.22	Educational attainment (years of education);Educational attainment (college completion);	chr5:60847401	chr5:60891935~60893577:-
BRCA	cis	rs61160187	0.582	rs67858932	ENSG00000215032.2	GNL3LP1	7.19	1.24e-12	2.96e-10	0.27	0.22	Educational attainment (years of education);Educational attainment (college completion);	chr5:60847424	chr5:60891935~60893577:-
BRCA	cis	rs6570726	0.935	rs906774	ENSG00000235652.6	RP11-545I5.3	7.19	1.24e-12	2.97e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145492634	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.837	rs636894	ENSG00000235652.6	RP11-545I5.3	7.19	1.24e-12	2.97e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145542986	chr6:145799409~145886585:+
BRCA	cis	rs74233809	1	rs11191543	ENSG00000213277.3	MARCKSL1P1	7.19	1.24e-12	2.98e-10	0.4	0.22	Birth weight;	chr10:103064630	chr10:103175554~103176094:+
BRCA	cis	rs6740322	0.895	rs11684601	ENSG00000234936.1	AC010883.5	7.19	1.25e-12	2.98e-10	0.24	0.22	Coronary artery disease;	chr2:43347103	chr2:43229573~43233394:+
BRCA	cis	rs4723738	1	rs6975531	ENSG00000227191.5	TRGC2	-7.19	1.25e-12	2.98e-10	-0.2	-0.22	Treatment response for severe sepsis;	chr7:38179748	chr7:38239580~38368091:-
BRCA	cis	rs17253792	0.822	rs17746106	ENSG00000186615.9	KTN1-AS1	-7.19	1.25e-12	2.99e-10	-0.37	-0.22	Putamen volume;	chr14:55602450	chr14:55499278~55580110:-
BRCA	cis	rs7617773	0.817	rs9818937	ENSG00000228638.1	FCF1P2	-7.19	1.26e-12	3e-10	-0.23	-0.22	Coronary artery disease;	chr3:48283791	chr3:48290793~48291375:-
BRCA	cis	rs6840258	0.66	rs72667737	ENSG00000251411.1	RP11-397E7.4	-7.19	1.26e-12	3.01e-10	-0.31	-0.22	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86955264	chr4:86913266~86914817:-
BRCA	cis	rs6840258	0.66	rs72667739	ENSG00000251411.1	RP11-397E7.4	-7.19	1.26e-12	3.01e-10	-0.31	-0.22	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86956347	chr4:86913266~86914817:-
BRCA	cis	rs875971	0.508	rs10258739	ENSG00000236529.1	RP13-254B10.1	-7.19	1.26e-12	3.02e-10	-0.23	-0.22	Aortic root size;	chr7:66597948	chr7:65840212~65840596:+
BRCA	cis	rs7474896	0.583	rs1208770	ENSG00000226578.1	RP11-258F22.1	-7.19	1.26e-12	3.02e-10	-0.29	-0.22	Obesity (extreme);	chr10:37755755	chr10:37775371~37784131:-
BRCA	cis	rs7474896	0.526	rs1742235	ENSG00000226578.1	RP11-258F22.1	-7.19	1.26e-12	3.02e-10	-0.29	-0.22	Obesity (extreme);	chr10:37763328	chr10:37775371~37784131:-
BRCA	cis	rs4072705	1	rs4836991	ENSG00000224020.1	MIR181A2HG	7.19	1.26e-12	3.02e-10	0.25	0.22	Menarche (age at onset);	chr9:124749761	chr9:124658467~124698631:+
BRCA	cis	rs704795	0.902	rs11887784	ENSG00000234072.1	AC074117.10	-7.19	1.27e-12	3.03e-10	-0.21	-0.22	Menopause (age at onset);	chr2:27457052	chr2:27356246~27367622:+
BRCA	cis	rs9291683	0.552	rs11736410	ENSG00000250413.1	RP11-448G15.1	-7.19	1.27e-12	3.03e-10	-0.28	-0.22	Bone mineral density;	chr4:10015617	chr4:10006482~10009725:+
BRCA	cis	rs7520050	0.778	rs2088102	ENSG00000280836.1	AL355480.1	7.19	1.27e-12	3.03e-10	0.25	0.22	Reticulocyte count;Red blood cell count;	chr1:45567302	chr1:45581219~45581321:-
BRCA	cis	rs2348418	0.832	rs12303069	ENSG00000247934.4	RP11-967K21.1	7.19	1.27e-12	3.03e-10	0.24	0.22	Lung function (FEV1);Lung function (FVC);	chr12:28294319	chr12:28163298~28190738:-
BRCA	cis	rs301901	1	rs159755	ENSG00000250155.1	CTD-2353F22.1	-7.19	1.27e-12	3.03e-10	-0.24	-0.22	Height;	chr5:36995103	chr5:36666214~36725195:-
BRCA	cis	rs7246657	0.943	rs4803229	ENSG00000276846.1	CTD-3220F14.3	7.19	1.27e-12	3.03e-10	0.29	0.22	Coronary artery calcification;	chr19:37373780	chr19:37314868~37315620:-
BRCA	cis	rs7809950	1	rs2520269	ENSG00000238832.1	snoU109	-7.19	1.27e-12	3.04e-10	-0.29	-0.22	Coronary artery disease;	chr7:107550882	chr7:107603363~107603507:+
BRCA	cis	rs526231	0.543	rs152137	ENSG00000175749.11	EIF3KP1	7.19	1.27e-12	3.04e-10	0.33	0.22	Primary biliary cholangitis;	chr5:103224362	chr5:103032376~103033031:+
BRCA	cis	rs858239	0.6	rs13438188	ENSG00000230042.1	AK3P3	7.19	1.27e-12	3.04e-10	0.25	0.22	Cerebrospinal fluid biomarker levels;	chr7:23104578	chr7:23129178~23129841:+
BRCA	cis	rs2286503	1	rs17724311	ENSG00000228649.7	AC005682.5	7.19	1.28e-12	3.05e-10	0.19	0.22	Fibrinogen;	chr7:22837174	chr7:22854178~22861579:+
BRCA	cis	rs10740039	0.842	rs10821819	ENSG00000254271.1	RP11-131N11.4	7.19	1.28e-12	3.05e-10	0.29	0.22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60658857	chr10:60734342~60741828:+
BRCA	cis	rs9309711	0.922	rs7561600	ENSG00000225234.1	TRAPPC12-AS1	-7.18	1.28e-12	3.06e-10	-0.25	-0.22	Neurofibrillary tangles;	chr2:3482322	chr2:3481242~3482409:-
BRCA	cis	rs858239	0.539	rs7791200	ENSG00000230042.1	AK3P3	-7.18	1.28e-12	3.06e-10	-0.25	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23142502	chr7:23129178~23129841:+
BRCA	cis	rs2074409	0.53	rs7224979	ENSG00000276054.1	RP11-378E13.3	-7.18	1.28e-12	3.06e-10	-0.3	-0.22	Response to angiotensin II receptor blocker therapy;	chr17:37593525	chr17:37386886~37387926:+
BRCA	cis	rs7617773	0.78	rs6442111	ENSG00000228638.1	FCF1P2	-7.18	1.28e-12	3.07e-10	-0.23	-0.22	Coronary artery disease;	chr3:48270570	chr3:48290793~48291375:-
BRCA	cis	rs3762637	0.943	rs28403550	ENSG00000272758.4	RP11-299J3.8	-7.18	1.28e-12	3.07e-10	-0.3	-0.22	LDL cholesterol levels;	chr3:122532991	chr3:122416207~122443180:+
BRCA	cis	rs9880211	0.8	rs34324561	ENSG00000273486.1	RP11-731C17.2	7.18	1.28e-12	3.07e-10	0.29	0.22	Height;Body mass index;	chr3:136382400	chr3:136837338~136839021:-
BRCA	cis	rs7208859	0.623	rs73269923	ENSG00000266490.1	CTD-2349P21.9	7.18	1.29e-12	3.07e-10	0.34	0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775553	chr17:30792372~30792833:+
BRCA	cis	rs7617773	0.817	rs3937	ENSG00000228638.1	FCF1P2	-7.18	1.29e-12	3.07e-10	-0.23	-0.22	Coronary artery disease;	chr3:48270912	chr3:48290793~48291375:-
BRCA	cis	rs10515750	0.588	rs62390102	ENSG00000251405.2	CTB-109A12.1	7.18	1.29e-12	3.08e-10	0.33	0.22	Lung function (FEV1/FVC);	chr5:157354934	chr5:157362615~157460078:-
BRCA	cis	rs72772090	0.71	rs11750399	ENSG00000248734.2	CTD-2260A17.1	-7.18	1.29e-12	3.08e-10	-0.35	-0.22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96742236	chr5:96784777~96785999:+
BRCA	cis	rs7586673	1	rs7586673	ENSG00000235724.7	AC009299.2	-7.18	1.29e-12	3.08e-10	-0.26	-0.22	Intelligence (multi-trait analysis);	chr2:161067009	chr2:161222785~161308303:-
BRCA	cis	rs8005677	1	rs11157930	ENSG00000279656.1	RP11-298I3.6	7.18	1.29e-12	3.09e-10	0.26	0.22	Cognitive ability (multi-trait analysis);	chr14:22933962	chr14:23023083~23024217:-
BRCA	cis	rs919433	0.963	rs1896857	ENSG00000231621.1	AC013264.2	7.18	1.29e-12	3.09e-10	0.2	0.22	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197299806	chr2:197197991~197199273:+
BRCA	cis	rs2348418	0.8	rs6487667	ENSG00000247934.4	RP11-967K21.1	-7.18	1.3e-12	3.1e-10	-0.25	-0.22	Lung function (FEV1);Lung function (FVC);	chr12:28195643	chr12:28163298~28190738:-
BRCA	cis	rs2348418	0.733	rs4931078	ENSG00000247934.4	RP11-967K21.1	-7.18	1.3e-12	3.1e-10	-0.25	-0.22	Lung function (FEV1);Lung function (FVC);	chr12:28215067	chr12:28163298~28190738:-
BRCA	cis	rs10740039	0.842	rs7069157	ENSG00000254271.1	RP11-131N11.4	7.18	1.3e-12	3.1e-10	0.29	0.22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60629475	chr10:60734342~60741828:+
BRCA	cis	rs8072100	0.837	rs8070463	ENSG00000228782.6	CTD-2026D20.3	7.18	1.3e-12	3.1e-10	0.23	0.22	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47691470	chr17:47450568~47492492:-
BRCA	cis	rs7131987	0.565	rs10743652	ENSG00000275476.1	RP11-996F15.4	7.18	1.3e-12	3.11e-10	0.25	0.22	QT interval;	chr12:29255074	chr12:29277397~29277882:-
BRCA	cis	rs73173548	0.502	rs12189501	ENSG00000247828.6	TMEM161B-AS1	-7.18	1.3e-12	3.11e-10	-0.29	-0.22	Macular telangiectasia type 2;	chr5:88462208	chr5:88268895~88436685:+
BRCA	cis	rs9649213	0.555	rs6948346	ENSG00000272950.1	RP11-307C18.1	7.18	1.31e-12	3.11e-10	0.27	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98330644	chr7:98322853~98323430:+
BRCA	cis	rs11098499	0.954	rs10006877	ENSG00000249244.1	RP11-548H18.2	7.18	1.31e-12	3.12e-10	0.26	0.22	Corneal astigmatism;	chr4:119321638	chr4:119391831~119395335:-
BRCA	cis	rs7617773	0.817	rs745116	ENSG00000228638.1	FCF1P2	-7.18	1.31e-12	3.13e-10	-0.23	-0.22	Coronary artery disease;	chr3:48231046	chr3:48290793~48291375:-
BRCA	cis	rs897984	0.645	rs9938550	ENSG00000260911.2	RP11-196G11.2	-7.18	1.31e-12	3.13e-10	-0.2	-0.22	Dementia with Lewy bodies;	chr16:30987821	chr16:31043150~31049868:+
BRCA	cis	rs7674212	0.507	rs223317	ENSG00000251288.2	RP11-10L12.2	-7.18	1.32e-12	3.14e-10	-0.27	-0.22	Type 2 diabetes;	chr4:102881667	chr4:102751401~102752641:+
BRCA	cis	rs12291225	0.637	rs8570	ENSG00000251991.1	RNU7-49P	7.18	1.32e-12	3.14e-10	0.25	0.22	Sense of smell;	chr11:14279213	chr11:14478892~14478953:+
BRCA	cis	rs61270009	0.955	rs390856	ENSG00000247828.6	TMEM161B-AS1	7.18	1.32e-12	3.15e-10	0.28	0.22	Depressive symptoms;	chr5:88251742	chr5:88268895~88436685:+
BRCA	cis	rs7246657	0.943	rs1559229	ENSG00000276846.1	CTD-3220F14.3	7.18	1.32e-12	3.15e-10	0.29	0.22	Coronary artery calcification;	chr19:37385295	chr19:37314868~37315620:-
BRCA	cis	rs7246657	0.882	rs6508719	ENSG00000276846.1	CTD-3220F14.3	7.18	1.32e-12	3.15e-10	0.29	0.22	Coronary artery calcification;	chr19:37386517	chr19:37314868~37315620:-
BRCA	cis	rs812925	1	rs4672441	ENSG00000271889.1	RP11-493E12.1	-7.18	1.32e-12	3.15e-10	-0.28	-0.22	Immature fraction of reticulocytes;	chr2:61411817	chr2:61151433~61162105:-
BRCA	cis	rs2348418	0.701	rs6487670	ENSG00000247934.4	RP11-967K21.1	-7.18	1.32e-12	3.15e-10	-0.25	-0.22	Lung function (FEV1);Lung function (FVC);	chr12:28210856	chr12:28163298~28190738:-
BRCA	cis	rs77972916	0.517	rs17406126	ENSG00000234936.1	AC010883.5	7.18	1.33e-12	3.16e-10	0.32	0.22	Granulocyte percentage of myeloid white cells;	chr2:43319493	chr2:43229573~43233394:+
BRCA	cis	rs30380	0.922	rs246453	ENSG00000272109.1	CTD-2260A17.3	-7.18	1.33e-12	3.16e-10	-0.27	-0.22	Cerebrospinal fluid biomarker levels;	chr5:96787633	chr5:96804353~96806105:+
BRCA	cis	rs3794924	1	rs3810005	ENSG00000266521.1	RP11-650P15.1	7.18	1.33e-12	3.17e-10	0.4	0.22	Survival in colon cancer;	chr18:31473913	chr18:31496645~31497195:-
BRCA	cis	rs66887589	0.967	rs3775842	ENSG00000248280.1	RP11-33B1.2	7.18	1.33e-12	3.17e-10	0.2	0.22	Diastolic blood pressure;	chr4:119506577	chr4:119440561~119450157:-
BRCA	cis	rs2303759	1	rs2303759	ENSG00000268686.1	AC010524.2	-7.18	1.33e-12	3.18e-10	-0.33	-0.22	Multiple sclerosis;	chr19:49365794	chr19:49368705~49388081:-
BRCA	cis	rs7520050	0.778	rs3014218	ENSG00000280836.1	AL355480.1	7.18	1.33e-12	3.18e-10	0.25	0.22	Reticulocyte count;Red blood cell count;	chr1:45560656	chr1:45581219~45581321:-
BRCA	cis	rs7520050	0.807	rs28647556	ENSG00000280836.1	AL355480.1	-7.18	1.33e-12	3.18e-10	-0.25	-0.22	Reticulocyte count;Red blood cell count;	chr1:45740727	chr1:45581219~45581321:-
BRCA	cis	rs7520050	0.807	rs4274104	ENSG00000280836.1	AL355480.1	-7.18	1.33e-12	3.18e-10	-0.25	-0.22	Reticulocyte count;Red blood cell count;	chr1:45752269	chr1:45581219~45581321:-
BRCA	cis	rs875971	0.508	rs10950045	ENSG00000224316.1	RP11-479O9.2	-7.18	1.34e-12	3.19e-10	-0.22	-0.22	Aortic root size;	chr7:66601386	chr7:65773620~65802067:+
BRCA	cis	rs801193	0.839	rs6968619	ENSG00000224316.1	RP11-479O9.2	-7.18	1.34e-12	3.19e-10	-0.22	-0.22	Aortic root size;	chr7:66603880	chr7:65773620~65802067:+
BRCA	cis	rs801193	0.805	rs12532355	ENSG00000224316.1	RP11-479O9.2	-7.18	1.34e-12	3.19e-10	-0.22	-0.22	Aortic root size;	chr7:66605597	chr7:65773620~65802067:+
BRCA	cis	rs4845875	0.626	rs12735869	ENSG00000242349.4	NPPA-AS1	7.18	1.34e-12	3.2e-10	0.24	0.22	Midregional pro atrial natriuretic peptide levels;	chr1:11774106	chr1:11841017~11848079:+
BRCA	cis	rs11976180	0.517	rs6949375	ENSG00000273234.1	OR2A13P	-7.18	1.35e-12	3.21e-10	-0.39	-0.22	Obesity-related traits;	chr7:144076758	chr7:144142009~144142938:+
BRCA	cis	rs4723738	1	rs7795499	ENSG00000227191.5	TRGC2	-7.18	1.35e-12	3.21e-10	-0.19	-0.22	Treatment response for severe sepsis;	chr7:38228794	chr7:38239580~38368091:-
BRCA	cis	rs9649213	0.593	rs7787858	ENSG00000272950.1	RP11-307C18.1	7.18	1.35e-12	3.21e-10	0.28	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98380602	chr7:98322853~98323430:+
BRCA	cis	rs9649213	0.593	rs3801254	ENSG00000272950.1	RP11-307C18.1	7.18	1.35e-12	3.21e-10	0.28	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98381499	chr7:98322853~98323430:+
BRCA	cis	rs7246657	0.943	rs2303131	ENSG00000276846.1	CTD-3220F14.3	7.18	1.35e-12	3.21e-10	0.3	0.22	Coronary artery calcification;	chr19:37445123	chr19:37314868~37315620:-
BRCA	cis	rs9649213	0.593	rs13246725	ENSG00000272950.1	RP11-307C18.1	7.18	1.35e-12	3.22e-10	0.27	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98285586	chr7:98322853~98323430:+
BRCA	cis	rs9649213	0.593	rs11766808	ENSG00000272950.1	RP11-307C18.1	7.18	1.35e-12	3.22e-10	0.27	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98286064	chr7:98322853~98323430:+
BRCA	cis	rs9649213	0.593	rs35941058	ENSG00000272950.1	RP11-307C18.1	7.18	1.35e-12	3.22e-10	0.27	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98288847	chr7:98322853~98323430:+
BRCA	cis	rs9649213	0.593	rs7778015	ENSG00000272950.1	RP11-307C18.1	7.18	1.35e-12	3.22e-10	0.27	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98290958	chr7:98322853~98323430:+
BRCA	cis	rs9649213	0.593	rs6465664	ENSG00000272950.1	RP11-307C18.1	7.18	1.35e-12	3.22e-10	0.27	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98292522	chr7:98322853~98323430:+
BRCA	cis	rs7569084	0.687	rs963539	ENSG00000204929.10	AC074391.1	-7.18	1.36e-12	3.24e-10	-0.28	-0.22	Sum eosinophil basophil counts;	chr2:65421413	chr2:65436711~66084639:+
BRCA	cis	rs2288884	0.636	rs6509620	ENSG00000275055.1	CTC-471J1.11	-7.18	1.36e-12	3.24e-10	-0.26	-0.22	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52077543	chr19:52049007~52049754:+
BRCA	cis	rs301901	0.772	rs7735138	ENSG00000250155.1	CTD-2353F22.1	-7.18	1.36e-12	3.24e-10	-0.23	-0.22	Height;	chr5:37239138	chr5:36666214~36725195:-
BRCA	cis	rs7811142	1	rs11761725	ENSG00000242294.5	STAG3L5P	7.18	1.36e-12	3.25e-10	0.23	0.22	Platelet count;	chr7:100442192	chr7:100336079~100351900:+
BRCA	cis	rs42648	0.935	rs42668	ENSG00000225498.1	AC002064.5	7.18	1.37e-12	3.25e-10	0.21	0.22	Homocysteine levels;	chr7:90357211	chr7:90312496~90322592:+
BRCA	cis	rs74233809	1	rs3740390	ENSG00000213277.3	MARCKSL1P1	7.18	1.37e-12	3.26e-10	0.39	0.22	Birth weight;	chr10:102878723	chr10:103175554~103176094:+
BRCA	cis	rs10515750	0.656	rs112839393	ENSG00000248544.2	CTB-47B11.3	7.18	1.37e-12	3.26e-10	0.45	0.22	Lung function (FEV1/FVC);	chr5:157282304	chr5:157375741~157384950:-
BRCA	cis	rs2742234	0.541	rs10899786	ENSG00000273008.1	RP11-351D16.3	7.17	1.37e-12	3.27e-10	0.28	0.22	Hirschsprung disease;	chr10:43249135	chr10:43136824~43138334:-
BRCA	cis	rs9880211	0.8	rs9819856	ENSG00000273486.1	RP11-731C17.2	7.17	1.38e-12	3.27e-10	0.29	0.22	Height;Body mass index;	chr3:136773307	chr3:136837338~136839021:-
BRCA	cis	rs9880211	0.8	rs36109616	ENSG00000273486.1	RP11-731C17.2	7.17	1.38e-12	3.27e-10	0.29	0.22	Height;Body mass index;	chr3:136773561	chr3:136837338~136839021:-
BRCA	cis	rs9880211	0.8	rs35198484	ENSG00000273486.1	RP11-731C17.2	7.17	1.38e-12	3.27e-10	0.29	0.22	Height;Body mass index;	chr3:136773795	chr3:136837338~136839021:-
BRCA	cis	rs9880211	0.66	rs9289514	ENSG00000273486.1	RP11-731C17.2	7.17	1.38e-12	3.27e-10	0.29	0.22	Height;Body mass index;	chr3:136774361	chr3:136837338~136839021:-
BRCA	cis	rs9880211	0.8	rs79876804	ENSG00000273486.1	RP11-731C17.2	7.17	1.38e-12	3.27e-10	0.29	0.22	Height;Body mass index;	chr3:136775308	chr3:136837338~136839021:-
BRCA	cis	rs9880211	0.706	rs35716521	ENSG00000273486.1	RP11-731C17.2	7.17	1.38e-12	3.27e-10	0.29	0.22	Height;Body mass index;	chr3:136775828	chr3:136837338~136839021:-
BRCA	cis	rs9880211	0.8	rs35210994	ENSG00000273486.1	RP11-731C17.2	7.17	1.38e-12	3.27e-10	0.29	0.22	Height;Body mass index;	chr3:136777294	chr3:136837338~136839021:-
BRCA	cis	rs9880211	0.8	rs17365792	ENSG00000273486.1	RP11-731C17.2	7.17	1.38e-12	3.27e-10	0.29	0.22	Height;Body mass index;	chr3:136778550	chr3:136837338~136839021:-
BRCA	cis	rs11098499	0.71	rs4145952	ENSG00000248280.1	RP11-33B1.2	7.17	1.38e-12	3.28e-10	0.21	0.22	Corneal astigmatism;	chr4:119234651	chr4:119440561~119450157:-
BRCA	cis	rs812925	1	rs812925	ENSG00000271889.1	RP11-493E12.1	-7.17	1.38e-12	3.28e-10	-0.28	-0.22	Immature fraction of reticulocytes;	chr2:61453858	chr2:61151433~61162105:-
BRCA	cis	rs875971	0.628	rs6974355	ENSG00000236529.1	RP13-254B10.1	7.17	1.38e-12	3.29e-10	0.24	0.22	Aortic root size;	chr7:66376994	chr7:65840212~65840596:+
BRCA	cis	rs66887589	0.934	rs2715016	ENSG00000248280.1	RP11-33B1.2	-7.17	1.38e-12	3.29e-10	-0.21	-0.22	Diastolic blood pressure;	chr4:119531201	chr4:119440561~119450157:-
BRCA	cis	rs2348418	0.832	rs11611406	ENSG00000247934.4	RP11-967K21.1	7.17	1.39e-12	3.29e-10	0.24	0.22	Lung function (FEV1);Lung function (FVC);	chr12:28310910	chr12:28163298~28190738:-
BRCA	cis	rs2348418	0.832	rs11611382	ENSG00000247934.4	RP11-967K21.1	7.17	1.39e-12	3.29e-10	0.24	0.22	Lung function (FEV1);Lung function (FVC);	chr12:28310959	chr12:28163298~28190738:-
BRCA	cis	rs3761847	0.593	rs1468673	ENSG00000226752.6	PSMD5-AS1	-7.17	1.39e-12	3.3e-10	-0.26	-0.22	Rheumatoid arthritis;	chr9:121047612	chr9:120824828~120854385:+
BRCA	cis	rs13178541	0.683	rs4036630	ENSG00000250378.1	RP11-119J18.1	-7.17	1.39e-12	3.3e-10	-0.3	-0.22	IgG glycosylation;	chr5:135752980	chr5:135812667~135826582:+
BRCA	cis	rs13178541	0.748	rs7379672	ENSG00000250378.1	RP11-119J18.1	-7.17	1.39e-12	3.3e-10	-0.3	-0.22	IgG glycosylation;	chr5:135754136	chr5:135812667~135826582:+
BRCA	cis	rs13178541	0.81	rs11950793	ENSG00000250378.1	RP11-119J18.1	-7.17	1.39e-12	3.3e-10	-0.3	-0.22	IgG glycosylation;	chr5:135754394	chr5:135812667~135826582:+
BRCA	cis	rs897984	0.721	rs28360557	ENSG00000260911.2	RP11-196G11.2	-7.17	1.39e-12	3.31e-10	-0.2	-0.22	Dementia with Lewy bodies;	chr16:30971939	chr16:31043150~31049868:+
BRCA	cis	rs72634501	0.54	rs16826036	ENSG00000228060.1	RP11-69E11.8	-7.17	1.39e-12	3.31e-10	-0.27	-0.22	HDL cholesterol;	chr1:39292127	chr1:39565160~39573203:+
BRCA	cis	rs755249	0.567	rs16826038	ENSG00000228060.1	RP11-69E11.8	-7.17	1.39e-12	3.31e-10	-0.27	-0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39292962	chr1:39565160~39573203:+
BRCA	cis	rs755249	0.567	rs61782157	ENSG00000228060.1	RP11-69E11.8	-7.17	1.39e-12	3.31e-10	-0.27	-0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39297217	chr1:39565160~39573203:+
BRCA	cis	rs755249	0.567	rs41270803	ENSG00000228060.1	RP11-69E11.8	-7.17	1.39e-12	3.31e-10	-0.27	-0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39300369	chr1:39565160~39573203:+
BRCA	cis	rs10740039	1	rs10761543	ENSG00000254271.1	RP11-131N11.4	7.17	1.39e-12	3.31e-10	0.29	0.22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60655633	chr10:60734342~60741828:+
BRCA	cis	rs10740039	0.883	rs10761544	ENSG00000254271.1	RP11-131N11.4	7.17	1.39e-12	3.31e-10	0.29	0.22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60655647	chr10:60734342~60741828:+
BRCA	cis	rs10740039	0.804	rs7900848	ENSG00000254271.1	RP11-131N11.4	7.17	1.39e-12	3.31e-10	0.29	0.22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60655893	chr10:60734342~60741828:+
BRCA	cis	rs10510102	0.935	rs7921873	ENSG00000276742.1	RP11-500G22.4	7.17	1.39e-12	3.31e-10	0.36	0.22	Breast cancer;	chr10:121881736	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.935	rs12258426	ENSG00000276742.1	RP11-500G22.4	7.17	1.39e-12	3.31e-10	0.36	0.22	Breast cancer;	chr10:121882189	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.935	rs12266380	ENSG00000276742.1	RP11-500G22.4	7.17	1.39e-12	3.31e-10	0.36	0.22	Breast cancer;	chr10:121882559	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.935	rs11200212	ENSG00000276742.1	RP11-500G22.4	7.17	1.39e-12	3.31e-10	0.36	0.22	Breast cancer;	chr10:121883145	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.935	rs11200213	ENSG00000276742.1	RP11-500G22.4	7.17	1.39e-12	3.31e-10	0.36	0.22	Breast cancer;	chr10:121883228	chr10:121956782~121957098:+
BRCA	cis	rs2599510	0.755	rs67257914	ENSG00000276334.1	AL133243.1	7.17	1.39e-12	3.31e-10	0.28	0.22	Interleukin-18 levels;	chr2:32578951	chr2:32521927~32523547:+
BRCA	cis	rs61160187	0.517	rs6884966	ENSG00000215032.2	GNL3LP1	7.17	1.39e-12	3.31e-10	0.27	0.22	Educational attainment (years of education);Educational attainment (college completion);	chr5:60897512	chr5:60891935~60893577:-
BRCA	cis	rs7665090	0.806	rs434644	ENSG00000246560.2	RP11-10L12.4	-7.17	1.4e-12	3.32e-10	-0.23	-0.22	Primary biliary cholangitis;	chr4:102662032	chr4:102828055~102844075:+
BRCA	cis	rs10510102	0.935	rs12247749	ENSG00000276742.1	RP11-500G22.4	7.17	1.4e-12	3.32e-10	0.36	0.22	Breast cancer;	chr10:121884196	chr10:121956782~121957098:+
BRCA	cis	rs6545883	0.965	rs2305156	ENSG00000271889.1	RP11-493E12.1	7.17	1.4e-12	3.32e-10	0.28	0.22	Tuberculosis;	chr2:61502133	chr2:61151433~61162105:-
BRCA	cis	rs10181042	0.565	rs2564117	ENSG00000271889.1	RP11-493E12.1	7.17	1.4e-12	3.33e-10	0.27	0.22	Crohn's disease;	chr2:61005887	chr2:61151433~61162105:-
BRCA	cis	rs7246657	0.943	rs10415024	ENSG00000276846.1	CTD-3220F14.3	7.17	1.4e-12	3.33e-10	0.3	0.22	Coronary artery calcification;	chr19:37323822	chr19:37314868~37315620:-
BRCA	cis	rs7927771	0.756	rs10742803	ENSG00000280615.1	Y_RNA	7.17	1.41e-12	3.34e-10	0.25	0.22	Subjective well-being;	chr11:47418387	chr11:47614898~47614994:-
BRCA	cis	rs4835473	0.808	rs11725413	ENSG00000251600.4	RP11-673E1.1	-7.17	1.41e-12	3.34e-10	-0.27	-0.22	Immature fraction of reticulocytes;	chr4:143943366	chr4:143912331~143982454:+
BRCA	cis	rs858239	0.568	rs6970694	ENSG00000230042.1	AK3P3	-7.17	1.41e-12	3.34e-10	-0.25	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23211209	chr7:23129178~23129841:+
BRCA	cis	rs875971	1	rs11974219	ENSG00000232559.3	GS1-124K5.12	-7.17	1.41e-12	3.34e-10	-0.26	-0.22	Aortic root size;	chr7:66182423	chr7:66554588~66576923:-
BRCA	cis	rs801193	0.66	rs2659897	ENSG00000232559.3	GS1-124K5.12	-7.17	1.41e-12	3.34e-10	-0.26	-0.22	Aortic root size;	chr7:66722728	chr7:66554588~66576923:-
BRCA	cis	rs896854	0.715	rs12548874	ENSG00000253528.2	RP11-347C18.4	-7.17	1.41e-12	3.35e-10	-0.23	-0.22	Type 2 diabetes;	chr8:94922936	chr8:94974573~94974853:-
BRCA	cis	rs9649213	0.593	rs6465683	ENSG00000272950.1	RP11-307C18.1	7.17	1.41e-12	3.36e-10	0.28	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98396780	chr7:98322853~98323430:+
BRCA	cis	rs61160187	0.582	rs4647132	ENSG00000215032.2	GNL3LP1	7.17	1.41e-12	3.36e-10	0.27	0.22	Educational attainment (years of education);Educational attainment (college completion);	chr5:60886893	chr5:60891935~60893577:-
BRCA	cis	rs875971	1	rs1167612	ENSG00000232559.3	GS1-124K5.12	-7.17	1.42e-12	3.36e-10	-0.26	-0.22	Aortic root size;	chr7:66102989	chr7:66554588~66576923:-
BRCA	cis	rs6142102	1	rs2143230	ENSG00000275784.1	RP5-1125A11.6	-7.17	1.42e-12	3.37e-10	-0.26	-0.22	Skin pigmentation;	chr20:34136539	chr20:33989480~33991818:-
BRCA	cis	rs911555	0.755	rs975892	ENSG00000244691.1	RPL10AP1	-7.17	1.42e-12	3.37e-10	-0.27	-0.22	Intelligence (multi-trait analysis);	chr14:103417012	chr14:103412119~103412761:-
BRCA	cis	rs301901	0.965	rs13158310	ENSG00000250155.1	CTD-2353F22.1	7.17	1.42e-12	3.37e-10	0.23	0.22	Height;	chr5:36789552	chr5:36666214~36725195:-
BRCA	cis	rs897984	0.762	rs897986	ENSG00000260911.2	RP11-196G11.2	-7.17	1.42e-12	3.37e-10	-0.2	-0.22	Dementia with Lewy bodies;	chr16:30969581	chr16:31043150~31049868:+
BRCA	cis	rs11976180	1	rs2951372	ENSG00000204959.4	ARHGEF34P	7.17	1.43e-12	3.39e-10	0.27	0.22	Obesity-related traits;	chr7:144052410	chr7:144272445~144286966:-
BRCA	cis	rs858239	0.539	rs28624974	ENSG00000230042.1	AK3P3	-7.17	1.43e-12	3.39e-10	-0.25	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23149317	chr7:23129178~23129841:+
BRCA	cis	rs7945705	0.818	rs4929916	ENSG00000254860.4	TMEM9B-AS1	-7.17	1.43e-12	3.4e-10	-0.2	-0.22	Hemoglobin concentration;	chr11:8803449	chr11:8964675~8977527:+
BRCA	cis	rs3760982	1	rs3760982	ENSG00000267058.1	RP11-15A1.3	-7.17	1.44e-12	3.41e-10	-0.24	-0.22	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43782361	chr19:43891804~43901805:-
BRCA	cis	rs858239	0.601	rs73272053	ENSG00000230042.1	AK3P3	-7.17	1.44e-12	3.41e-10	-0.25	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23115906	chr7:23129178~23129841:+
BRCA	cis	rs847577	0.715	rs12665986	ENSG00000272950.1	RP11-307C18.1	-7.17	1.44e-12	3.41e-10	-0.28	-0.22	Breast cancer;	chr7:98090364	chr7:98322853~98323430:+
BRCA	cis	rs4787491	0.658	rs11647753	ENSG00000273724.1	RP11-347C12.12	7.17	1.44e-12	3.42e-10	0.24	0.22	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:29916794	chr16:30336400~30343336:+
BRCA	cis	rs875971	0.545	rs1267814	ENSG00000224316.1	RP11-479O9.2	-7.17	1.44e-12	3.42e-10	-0.25	-0.22	Aortic root size;	chr7:66579422	chr7:65773620~65802067:+
BRCA	cis	rs9649213	0.593	rs1132971	ENSG00000272950.1	RP11-307C18.1	7.17	1.45e-12	3.44e-10	0.27	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98292221	chr7:98322853~98323430:+
BRCA	cis	rs13178541	0.81	rs2304074	ENSG00000250378.1	RP11-119J18.1	7.17	1.45e-12	3.44e-10	0.29	0.22	IgG glycosylation;	chr5:135824368	chr5:135812667~135826582:+
BRCA	cis	rs74233809	1	rs77420391	ENSG00000213277.3	MARCKSL1P1	7.17	1.45e-12	3.45e-10	0.43	0.22	Birth weight;	chr10:103186066	chr10:103175554~103176094:+
BRCA	cis	rs7246657	0.943	rs10415937	ENSG00000276846.1	CTD-3220F14.3	7.17	1.46e-12	3.46e-10	0.29	0.22	Coronary artery calcification;	chr19:37339162	chr19:37314868~37315620:-
BRCA	cis	rs7246657	0.943	rs10414904	ENSG00000276846.1	CTD-3220F14.3	7.17	1.46e-12	3.46e-10	0.29	0.22	Coronary artery calcification;	chr19:37339186	chr19:37314868~37315620:-
BRCA	cis	rs9876781	0.967	rs2885509	ENSG00000244380.1	RP11-24C3.2	-7.17	1.46e-12	3.46e-10	-0.25	-0.22	Longevity;	chr3:48376729	chr3:48440352~48446656:-
BRCA	cis	rs7246657	0.943	rs2112923	ENSG00000276846.1	CTD-3220F14.3	7.17	1.46e-12	3.46e-10	0.29	0.22	Coronary artery calcification;	chr19:37449425	chr19:37314868~37315620:-
BRCA	cis	rs7246657	0.943	rs3760825	ENSG00000276846.1	CTD-3220F14.3	7.17	1.46e-12	3.46e-10	0.29	0.22	Coronary artery calcification;	chr19:37454699	chr19:37314868~37315620:-
BRCA	cis	rs10740039	0.883	rs1975442	ENSG00000254271.1	RP11-131N11.4	7.17	1.46e-12	3.47e-10	0.29	0.22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60651161	chr10:60734342~60741828:+
BRCA	cis	rs10740039	0.804	rs7094818	ENSG00000254271.1	RP11-131N11.4	7.17	1.46e-12	3.47e-10	0.29	0.22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60652213	chr10:60734342~60741828:+
BRCA	cis	rs7665090	1	rs3733202	ENSG00000246560.2	RP11-10L12.4	7.17	1.46e-12	3.47e-10	0.23	0.22	Primary biliary cholangitis;	chr4:102635704	chr4:102828055~102844075:+
BRCA	cis	rs9309473	1	rs7594511	ENSG00000163016.8	ALMS1P	7.17	1.47e-12	3.48e-10	0.28	0.22	Metabolite levels;	chr2:73454512	chr2:73644919~73685576:+
BRCA	cis	rs875971	0.789	rs28815324	ENSG00000236529.1	RP13-254B10.1	-7.17	1.47e-12	3.48e-10	-0.27	-0.22	Aortic root size;	chr7:66100789	chr7:65840212~65840596:+
BRCA	cis	rs2599510	0.811	rs2710615	ENSG00000276334.1	AL133243.1	7.17	1.47e-12	3.48e-10	0.27	0.22	Interleukin-18 levels;	chr2:32566155	chr2:32521927~32523547:+
BRCA	cis	rs7246657	0.943	rs10422074	ENSG00000276846.1	CTD-3220F14.3	7.16	1.47e-12	3.49e-10	0.3	0.22	Coronary artery calcification;	chr19:37403334	chr19:37314868~37315620:-
BRCA	cis	rs9876781	1	rs6776700	ENSG00000244380.1	RP11-24C3.2	7.16	1.47e-12	3.49e-10	0.25	0.22	Longevity;	chr3:48455358	chr3:48440352~48446656:-
BRCA	cis	rs9649213	0.593	rs7797943	ENSG00000272950.1	RP11-307C18.1	7.16	1.47e-12	3.49e-10	0.27	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98317590	chr7:98322853~98323430:+
BRCA	cis	rs42648	0.748	rs12673914	ENSG00000225498.1	AC002064.5	7.16	1.48e-12	3.5e-10	0.21	0.22	Homocysteine levels;	chr7:90314075	chr7:90312496~90322592:+
BRCA	cis	rs66887589	0.616	rs11731675	ENSG00000248280.1	RP11-33B1.2	7.16	1.48e-12	3.5e-10	0.2	0.22	Diastolic blood pressure;	chr4:119291359	chr4:119440561~119450157:-
BRCA	cis	rs10740039	0.883	rs10761538	ENSG00000254271.1	RP11-131N11.4	7.16	1.48e-12	3.51e-10	0.29	0.22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60649463	chr10:60734342~60741828:+
BRCA	cis	rs8005677	0.962	rs11157931	ENSG00000279656.1	RP11-298I3.6	7.16	1.48e-12	3.51e-10	0.26	0.22	Cognitive ability (multi-trait analysis);	chr14:22933984	chr14:23023083~23024217:-
BRCA	cis	rs5758511	0.689	rs55906806	ENSG00000205702.9	CYP2D7	7.16	1.48e-12	3.52e-10	0.27	0.22	Birth weight;	chr22:42248465	chr22:42140203~42144577:-
BRCA	cis	rs875971	0.862	rs11773628	ENSG00000232559.3	GS1-124K5.12	-7.16	1.49e-12	3.52e-10	-0.26	-0.22	Aortic root size;	chr7:66517644	chr7:66554588~66576923:-
BRCA	cis	rs6545883	0.965	rs11887205	ENSG00000271889.1	RP11-493E12.1	7.16	1.49e-12	3.53e-10	0.28	0.22	Tuberculosis;	chr2:61547338	chr2:61151433~61162105:-
BRCA	cis	rs7811142	1	rs7783159	ENSG00000242294.5	STAG3L5P	7.16	1.49e-12	3.54e-10	0.22	0.22	Platelet count;	chr7:100419831	chr7:100336079~100351900:+
BRCA	cis	rs2599510	0.811	rs176413	ENSG00000276334.1	AL133243.1	-7.16	1.5e-12	3.55e-10	-0.26	-0.22	Interleukin-18 levels;	chr2:32421779	chr2:32521927~32523547:+
BRCA	cis	rs875971	0.54	rs35510581	ENSG00000237310.1	GS1-124K5.4	-7.16	1.5e-12	3.55e-10	-0.23	-0.22	Aortic root size;	chr7:66113790	chr7:66493706~66495474:+
BRCA	cis	rs9649213	0.593	rs6947340	ENSG00000272950.1	RP11-307C18.1	-7.16	1.5e-12	3.55e-10	-0.26	-0.22	Prostate cancer (SNP x SNP interaction);	chr7:98282929	chr7:98322853~98323430:+
BRCA	cis	rs9649213	0.537	rs6465663	ENSG00000272950.1	RP11-307C18.1	7.16	1.5e-12	3.55e-10	0.27	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98289571	chr7:98322853~98323430:+
BRCA	cis	rs11098499	0.532	rs4504231	ENSG00000245958.5	RP11-33B1.1	-7.16	1.5e-12	3.56e-10	-0.21	-0.22	Corneal astigmatism;	chr4:119665736	chr4:119454791~119552025:+
BRCA	cis	rs1499614	1	rs2659903	ENSG00000232546.1	RP11-458F8.1	-7.16	1.5e-12	3.56e-10	-0.29	-0.22	Gout;	chr7:66715944	chr7:66848496~66858136:+
BRCA	cis	rs8012947	0.651	rs74055634	ENSG00000279636.2	LINC00216	7.16	1.5e-12	3.56e-10	0.23	0.22	Alcohol consumption in current drinkers;	chr14:58361359	chr14:58288033~58289158:+
BRCA	cis	rs9649213	0.574	rs62478236	ENSG00000272950.1	RP11-307C18.1	7.16	1.51e-12	3.57e-10	0.28	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98401065	chr7:98322853~98323430:+
BRCA	cis	rs858239	0.899	rs10085838	ENSG00000230042.1	AK3P3	-7.16	1.51e-12	3.57e-10	-0.26	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23258796	chr7:23129178~23129841:+
BRCA	cis	rs10740039	0.842	rs7090892	ENSG00000254271.1	RP11-131N11.4	7.16	1.51e-12	3.58e-10	0.29	0.22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60652093	chr10:60734342~60741828:+
BRCA	cis	rs10463554	0.963	rs6889592	ENSG00000175749.11	EIF3KP1	7.16	1.51e-12	3.58e-10	0.3	0.22	Parkinson's disease;	chr5:102978235	chr5:103032376~103033031:+
BRCA	cis	rs10446497	0.585	rs13074050	ENSG00000272359.1	U4	7.16	1.51e-12	3.59e-10	0.3	0.22	Schizophrenia;	chr3:196816270	chr3:196747192~196747324:-
BRCA	cis	rs4842666	0.915	rs73437338	ENSG00000258302.2	RP11-981P6.1	7.16	1.52e-12	3.59e-10	0.28	0.22	Blood pressure;	chr12:89660842	chr12:89561129~89594878:+
BRCA	cis	rs2303759	0.83	rs7257053	ENSG00000268686.1	AC010524.2	-7.16	1.52e-12	3.59e-10	-0.34	-0.22	Multiple sclerosis;	chr19:49391199	chr19:49368705~49388081:-
BRCA	cis	rs6840360	0.642	rs7678823	ENSG00000270265.1	RP11-731D1.4	-7.16	1.52e-12	3.61e-10	-0.24	-0.22	Intelligence (multi-trait analysis);	chr4:151435967	chr4:151333775~151353224:-
BRCA	cis	rs11098499	0.954	rs6857105	ENSG00000249244.1	RP11-548H18.2	7.16	1.52e-12	3.61e-10	0.26	0.22	Corneal astigmatism;	chr4:119301143	chr4:119391831~119395335:-
BRCA	cis	rs6570726	0.935	rs382910	ENSG00000235652.6	RP11-545I5.3	7.16	1.52e-12	3.61e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145544805	chr6:145799409~145886585:+
BRCA	cis	rs7727544	0.66	rs2631361	ENSG00000233006.5	AC034220.3	-7.16	1.53e-12	3.61e-10	-0.16	-0.22	Blood metabolite levels;	chr5:132371688	chr5:132311285~132369916:-
BRCA	cis	rs10740039	0.883	rs2393676	ENSG00000254271.1	RP11-131N11.4	7.16	1.53e-12	3.62e-10	0.29	0.22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60630500	chr10:60734342~60741828:+
BRCA	cis	rs1499614	1	rs2707840	ENSG00000232546.1	RP11-458F8.1	-7.16	1.53e-12	3.62e-10	-0.29	-0.22	Gout;	chr7:66693028	chr7:66848496~66858136:+
BRCA	cis	rs6142102	0.961	rs6120487	ENSG00000275784.1	RP5-1125A11.6	-7.16	1.53e-12	3.62e-10	-0.25	-0.22	Skin pigmentation;	chr20:34034802	chr20:33989480~33991818:-
BRCA	cis	rs7976269	0.559	rs4930848	ENSG00000257176.2	RP11-996F15.2	-7.16	1.53e-12	3.62e-10	-0.26	-0.22	Male-pattern baldness;	chr12:29068441	chr12:29280418~29317848:-
BRCA	cis	rs7131987	0.565	rs10843372	ENSG00000257176.2	RP11-996F15.2	7.16	1.53e-12	3.62e-10	0.25	0.22	QT interval;	chr12:29262863	chr12:29280418~29317848:-
BRCA	cis	rs858239	0.537	rs10279691	ENSG00000230042.1	AK3P3	-7.16	1.53e-12	3.62e-10	-0.25	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23188768	chr7:23129178~23129841:+
BRCA	cis	rs6860806	0.507	rs273917	ENSG00000233006.5	AC034220.3	7.16	1.53e-12	3.62e-10	0.18	0.22	Breast cancer;	chr5:132323925	chr5:132311285~132369916:-
BRCA	cis	rs858239	0.539	rs4504540	ENSG00000230042.1	AK3P3	-7.16	1.53e-12	3.62e-10	-0.25	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23146579	chr7:23129178~23129841:+
BRCA	cis	rs10740039	0.883	rs1442545	ENSG00000254271.1	RP11-131N11.4	7.16	1.53e-12	3.63e-10	0.29	0.22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60650268	chr10:60734342~60741828:+
BRCA	cis	rs673078	0.607	rs7309484	ENSG00000275409.1	RP11-131L12.4	-7.16	1.53e-12	3.63e-10	-0.32	-0.22	Glucose homeostasis traits;	chr12:118400833	chr12:118430147~118430699:+
BRCA	cis	rs10740039	0.883	rs1867081	ENSG00000254271.1	RP11-131N11.4	7.16	1.54e-12	3.64e-10	0.28	0.22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60626569	chr10:60734342~60741828:+
BRCA	cis	rs7131987	0.565	rs7976227	ENSG00000257176.2	RP11-996F15.2	7.16	1.54e-12	3.64e-10	0.25	0.22	QT interval;	chr12:29264843	chr12:29280418~29317848:-
BRCA	cis	rs2212361	0.558	rs11020812	ENSG00000255893.1	RP11-685N10.1	7.16	1.54e-12	3.65e-10	0.26	0.22	Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction);	chr11:94533951	chr11:94472908~94473570:-
BRCA	cis	rs6840360	0.642	rs7684462	ENSG00000270265.1	RP11-731D1.4	-7.16	1.54e-12	3.65e-10	-0.24	-0.22	Intelligence (multi-trait analysis);	chr4:151427270	chr4:151333775~151353224:-
BRCA	cis	rs9649213	0.574	rs9648908	ENSG00000272950.1	RP11-307C18.1	7.16	1.55e-12	3.66e-10	0.27	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98315924	chr7:98322853~98323430:+
BRCA	cis	rs34779708	0.733	rs4102764	ENSG00000271335.4	RP11-324I22.4	7.16	1.55e-12	3.66e-10	0.22	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35256464	chr10:35314552~35336401:-
BRCA	cis	rs9595908	0.9	rs1324414	ENSG00000212293.1	SNORA16	7.16	1.55e-12	3.66e-10	0.24	0.22	Body mass index;	chr13:32600088	chr13:32420390~32420516:-
BRCA	cis	rs8062405	0.755	rs62034350	ENSG00000251417.2	RP11-1348G14.4	-7.16	1.55e-12	3.67e-10	-0.26	-0.22	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28550935	chr16:28802743~28817828:+
BRCA	cis	rs1499614	1	rs2659913	ENSG00000232546.1	RP11-458F8.1	-7.16	1.55e-12	3.68e-10	-0.29	-0.22	Gout;	chr7:66692349	chr7:66848496~66858136:+
BRCA	cis	rs1499614	1	rs2659911	ENSG00000232546.1	RP11-458F8.1	-7.16	1.55e-12	3.68e-10	-0.29	-0.22	Gout;	chr7:66693433	chr7:66848496~66858136:+
BRCA	cis	rs1499614	1	rs2707838	ENSG00000232546.1	RP11-458F8.1	-7.16	1.55e-12	3.68e-10	-0.29	-0.22	Gout;	chr7:66694214	chr7:66848496~66858136:+
BRCA	cis	rs1499614	1	rs60326618	ENSG00000232546.1	RP11-458F8.1	-7.16	1.55e-12	3.68e-10	-0.29	-0.22	Gout;	chr7:66701371	chr7:66848496~66858136:+
BRCA	cis	rs1499614	1	rs2707830	ENSG00000232546.1	RP11-458F8.1	-7.16	1.55e-12	3.68e-10	-0.29	-0.22	Gout;	chr7:66702658	chr7:66848496~66858136:+
BRCA	cis	rs1499614	1	rs2707828	ENSG00000232546.1	RP11-458F8.1	-7.16	1.55e-12	3.68e-10	-0.29	-0.22	Gout;	chr7:66706390	chr7:66848496~66858136:+
BRCA	cis	rs1499614	0.803	rs1922723	ENSG00000232546.1	RP11-458F8.1	-7.16	1.55e-12	3.68e-10	-0.29	-0.22	Gout;	chr7:66710076	chr7:66848496~66858136:+
BRCA	cis	rs12237653	0.929	rs13284385	ENSG00000236404.7	VLDLR-AS1	7.16	1.55e-12	3.68e-10	0.34	0.22	Gambling;	chr9:2544001	chr9:2422702~2643359:-
BRCA	cis	rs6921919	0.583	rs6908137	ENSG00000204709.4	LINC01556	7.16	1.56e-12	3.68e-10	0.29	0.22	Autism spectrum disorder or schizophrenia;	chr6:28402616	chr6:28943877~28944537:+
BRCA	cis	rs8005677	1	rs4982712	ENSG00000279656.1	RP11-298I3.6	7.16	1.56e-12	3.68e-10	0.26	0.22	Cognitive ability (multi-trait analysis);	chr14:22934519	chr14:23023083~23024217:-
BRCA	cis	rs858239	0.539	rs4294098	ENSG00000230042.1	AK3P3	-7.16	1.56e-12	3.68e-10	-0.25	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23146376	chr7:23129178~23129841:+
BRCA	cis	rs2303759	0.918	rs2288480	ENSG00000268686.1	AC010524.2	-7.16	1.56e-12	3.69e-10	-0.33	-0.22	Multiple sclerosis;	chr19:49363759	chr19:49368705~49388081:-
BRCA	cis	rs801193	0.839	rs12534943	ENSG00000224316.1	RP11-479O9.2	-7.16	1.56e-12	3.7e-10	-0.22	-0.22	Aortic root size;	chr7:66605533	chr7:65773620~65802067:+
BRCA	cis	rs755249	0.567	rs3754346	ENSG00000228060.1	RP11-69E11.8	-7.16	1.57e-12	3.71e-10	-0.27	-0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39349288	chr1:39565160~39573203:+
BRCA	cis	rs755249	0.567	rs16826093	ENSG00000228060.1	RP11-69E11.8	-7.16	1.57e-12	3.71e-10	-0.27	-0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39349471	chr1:39565160~39573203:+
BRCA	cis	rs755249	0.567	rs17264671	ENSG00000228060.1	RP11-69E11.8	-7.16	1.57e-12	3.71e-10	-0.27	-0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39352380	chr1:39565160~39573203:+
BRCA	cis	rs755249	0.567	rs4660690	ENSG00000228060.1	RP11-69E11.8	-7.16	1.57e-12	3.71e-10	-0.27	-0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39353831	chr1:39565160~39573203:+
BRCA	cis	rs12237653	0.929	rs4741731	ENSG00000236404.7	VLDLR-AS1	7.16	1.57e-12	3.72e-10	0.35	0.22	Gambling;	chr9:2547959	chr9:2422702~2643359:-
BRCA	cis	rs858239	0.509	rs6975524	ENSG00000230042.1	AK3P3	-7.15	1.58e-12	3.73e-10	-0.25	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23146833	chr7:23129178~23129841:+
BRCA	cis	rs858239	0.539	rs6955726	ENSG00000230042.1	AK3P3	-7.15	1.58e-12	3.73e-10	-0.25	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23147072	chr7:23129178~23129841:+
BRCA	cis	rs858239	0.539	rs6956828	ENSG00000230042.1	AK3P3	-7.15	1.58e-12	3.73e-10	-0.25	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23147728	chr7:23129178~23129841:+
BRCA	cis	rs237743	1	rs238217	ENSG00000222365.1	SNORD12B	-7.15	1.58e-12	3.74e-10	-0.28	-0.22	Height;	chr20:49254902	chr20:49280319~49280409:+
BRCA	cis	rs9527	0.662	rs10786714	ENSG00000213061.2	PFN1P11	7.15	1.59e-12	3.76e-10	0.31	0.22	Arsenic metabolism;	chr10:102838849	chr10:102838011~102845473:-
BRCA	cis	rs2243480	1	rs316327	ENSG00000273142.1	RP11-458F8.4	7.15	1.6e-12	3.77e-10	0.29	0.22	Diabetic kidney disease;	chr7:66144214	chr7:66902857~66906297:+
BRCA	cis	rs950169	0.519	rs7237	ENSG00000259728.4	LINC00933	7.15	1.6e-12	3.78e-10	0.29	0.22	Schizophrenia;	chr15:84643346	chr15:84570649~84580175:+
BRCA	cis	rs7246657	0.882	rs10422667	ENSG00000276846.1	CTD-3220F14.3	7.15	1.6e-12	3.78e-10	0.3	0.22	Coronary artery calcification;	chr19:37446974	chr19:37314868~37315620:-
BRCA	cis	rs7246657	0.943	rs1015848	ENSG00000276846.1	CTD-3220F14.3	7.15	1.6e-12	3.78e-10	0.3	0.22	Coronary artery calcification;	chr19:37454372	chr19:37314868~37315620:-
BRCA	cis	rs7246657	0.943	rs4801759	ENSG00000276846.1	CTD-3220F14.3	7.15	1.6e-12	3.78e-10	0.3	0.22	Coronary artery calcification;	chr19:37464083	chr19:37314868~37315620:-
BRCA	cis	rs7246657	0.943	rs3803895	ENSG00000276846.1	CTD-3220F14.3	7.15	1.6e-12	3.79e-10	0.29	0.22	Coronary artery calcification;	chr19:37407767	chr19:37314868~37315620:-
BRCA	cis	rs6840360	0.642	rs4235219	ENSG00000270265.1	RP11-731D1.4	-7.15	1.61e-12	3.79e-10	-0.24	-0.22	Intelligence (multi-trait analysis);	chr4:151424951	chr4:151333775~151353224:-
BRCA	cis	rs6840360	0.642	rs6851814	ENSG00000270265.1	RP11-731D1.4	-7.15	1.61e-12	3.79e-10	-0.24	-0.22	Intelligence (multi-trait analysis);	chr4:151425285	chr4:151333775~151353224:-
BRCA	cis	rs6840360	0.606	rs10028035	ENSG00000270265.1	RP11-731D1.4	-7.15	1.61e-12	3.79e-10	-0.24	-0.22	Intelligence (multi-trait analysis);	chr4:151426673	chr4:151333775~151353224:-
BRCA	cis	rs6840360	0.667	rs4266275	ENSG00000270265.1	RP11-731D1.4	-7.15	1.61e-12	3.79e-10	-0.24	-0.22	Intelligence (multi-trait analysis);	chr4:151426912	chr4:151333775~151353224:-
BRCA	cis	rs891378	0.755	rs1019830	ENSG00000274245.1	RP11-357P18.2	-7.15	1.61e-12	3.79e-10	-0.28	-0.22	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207236817	chr1:207372559~207373252:+
BRCA	cis	rs858239	0.738	rs7807879	ENSG00000230042.1	AK3P3	-7.15	1.61e-12	3.8e-10	-0.25	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23220969	chr7:23129178~23129841:+
BRCA	cis	rs7809950	0.911	rs7778250	ENSG00000238832.1	snoU109	7.15	1.61e-12	3.81e-10	0.3	0.22	Coronary artery disease;	chr7:107584120	chr7:107603363~107603507:+
BRCA	cis	rs9880211	0.613	rs28535121	ENSG00000273486.1	RP11-731C17.2	7.15	1.62e-12	3.82e-10	0.28	0.22	Height;Body mass index;	chr3:136173956	chr3:136837338~136839021:-
BRCA	cis	rs10510102	0.872	rs12264952	ENSG00000276742.1	RP11-500G22.4	7.15	1.62e-12	3.82e-10	0.36	0.22	Breast cancer;	chr10:121885673	chr10:121956782~121957098:+
BRCA	cis	rs9880211	0.718	rs35320690	ENSG00000273486.1	RP11-731C17.2	-7.15	1.62e-12	3.82e-10	-0.27	-0.22	Height;Body mass index;	chr3:136213652	chr3:136837338~136839021:-
BRCA	cis	rs858267	1	rs858267	ENSG00000226816.2	AC005082.12	7.15	1.62e-12	3.82e-10	0.54	0.22	Blood protein levels;	chr7:23170510	chr7:23206013~23208045:+
BRCA	cis	rs4845875	0.602	rs4846043	ENSG00000242349.4	NPPA-AS1	7.15	1.62e-12	3.83e-10	0.24	0.22	Midregional pro atrial natriuretic peptide levels;	chr1:11779909	chr1:11841017~11848079:+
BRCA	cis	rs7208859	0.623	rs9898084	ENSG00000263603.1	CTD-2349P21.5	-7.15	1.62e-12	3.83e-10	-0.37	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30755316	chr17:30729469~30731202:+
BRCA	cis	rs4072705	1	rs10760370	ENSG00000224020.1	MIR181A2HG	-7.15	1.62e-12	3.83e-10	-0.24	-0.22	Menarche (age at onset);	chr9:124655724	chr9:124658467~124698631:+
BRCA	cis	rs7474896	0.515	rs675628	ENSG00000226578.1	RP11-258F22.1	7.15	1.62e-12	3.83e-10	0.28	0.22	Obesity (extreme);	chr10:38016403	chr10:37775371~37784131:-
BRCA	cis	rs911555	0.755	rs35233301	ENSG00000244691.1	RPL10AP1	7.15	1.63e-12	3.84e-10	0.28	0.22	Intelligence (multi-trait analysis);	chr14:103418954	chr14:103412119~103412761:-
BRCA	cis	rs6570726	0.935	rs447818	ENSG00000235652.6	RP11-545I5.3	7.15	1.63e-12	3.85e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145547860	chr6:145799409~145886585:+
BRCA	cis	rs17711722	0.522	rs4642526	ENSG00000228409.4	CCT6P1	-7.15	1.64e-12	3.87e-10	-0.19	-0.22	Calcium levels;	chr7:65751755	chr7:65751142~65763354:+
BRCA	cis	rs6570726	0.935	rs12663204	ENSG00000235652.6	RP11-545I5.3	7.15	1.64e-12	3.88e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145497237	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.935	rs12663205	ENSG00000235652.6	RP11-545I5.3	7.15	1.64e-12	3.88e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145497242	chr6:145799409~145886585:+
BRCA	cis	rs71520386	0.632	rs28526185	ENSG00000228649.7	AC005682.5	-7.15	1.64e-12	3.88e-10	-0.21	-0.22	Fibrinogen levels;	chr7:22831699	chr7:22854178~22861579:+
BRCA	cis	rs704795	0.775	rs4665975	ENSG00000234072.1	AC074117.10	-7.15	1.64e-12	3.88e-10	-0.21	-0.22	Menopause (age at onset);	chr2:27403150	chr2:27356246~27367622:+
BRCA	cis	rs9876781	1	rs13071337	ENSG00000244380.1	RP11-24C3.2	7.15	1.65e-12	3.89e-10	0.25	0.22	Longevity;	chr3:48396724	chr3:48440352~48446656:-
BRCA	cis	rs74233809	1	rs12219901	ENSG00000213277.3	MARCKSL1P1	7.15	1.65e-12	3.89e-10	0.4	0.22	Birth weight;	chr10:103081210	chr10:103175554~103176094:+
BRCA	cis	rs74233809	1	rs10458729	ENSG00000213277.3	MARCKSL1P1	7.15	1.65e-12	3.89e-10	0.4	0.22	Birth weight;	chr10:103081722	chr10:103175554~103176094:+
BRCA	cis	rs74233809	1	rs12221193	ENSG00000213277.3	MARCKSL1P1	7.15	1.65e-12	3.9e-10	0.41	0.22	Birth weight;	chr10:102905510	chr10:103175554~103176094:+
BRCA	cis	rs74233809	1	rs77180047	ENSG00000213277.3	MARCKSL1P1	7.15	1.65e-12	3.9e-10	0.41	0.22	Birth weight;	chr10:102907000	chr10:103175554~103176094:+
BRCA	cis	rs7474896	0.515	rs594594	ENSG00000226578.1	RP11-258F22.1	7.15	1.66e-12	3.92e-10	0.28	0.22	Obesity (extreme);	chr10:38018795	chr10:37775371~37784131:-
BRCA	cis	rs2439831	0.702	rs16977724	ENSG00000205771.5	CATSPER2P1	-7.15	1.66e-12	3.92e-10	-0.4	-0.22	Lung cancer in ever smokers;	chr15:43859101	chr15:43726918~43747094:-
BRCA	cis	rs9494145	0.68	rs9402686	ENSG00000232876.1	CTA-212D2.2	-7.15	1.67e-12	3.93e-10	-0.32	-0.22	Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count;	chr6:135106679	chr6:135055033~135060550:+
BRCA	cis	rs526231	0.543	rs171558	ENSG00000175749.11	EIF3KP1	7.15	1.67e-12	3.93e-10	0.33	0.22	Primary biliary cholangitis;	chr5:103242193	chr5:103032376~103033031:+
BRCA	cis	rs2638953	0.924	rs11049415	ENSG00000278733.1	RP11-425D17.1	-7.15	1.68e-12	3.96e-10	-0.27	-0.22	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28190188	chr12:28185625~28186190:-
BRCA	cis	rs2348418	0.765	rs10843117	ENSG00000247934.4	RP11-967K21.1	-7.15	1.68e-12	3.96e-10	-0.25	-0.22	Lung function (FEV1);Lung function (FVC);	chr12:28162457	chr12:28163298~28190738:-
BRCA	cis	rs875971	0.825	rs1129531	ENSG00000232559.3	GS1-124K5.12	-7.15	1.68e-12	3.96e-10	-0.26	-0.22	Aortic root size;	chr7:66154117	chr7:66554588~66576923:-
BRCA	cis	rs911555	0.755	rs12432803	ENSG00000244691.1	RPL10AP1	7.15	1.68e-12	3.96e-10	0.28	0.22	Intelligence (multi-trait analysis);	chr14:103463695	chr14:103412119~103412761:-
BRCA	cis	rs2243480	1	rs6958420	ENSG00000232546.1	RP11-458F8.1	7.15	1.68e-12	3.96e-10	0.29	0.22	Diabetic kidney disease;	chr7:66286184	chr7:66848496~66858136:+
BRCA	cis	rs2243480	1	rs1392104	ENSG00000232546.1	RP11-458F8.1	7.15	1.68e-12	3.96e-10	0.29	0.22	Diabetic kidney disease;	chr7:66294120	chr7:66848496~66858136:+
BRCA	cis	rs858239	0.539	rs6976957	ENSG00000230042.1	AK3P3	-7.14	1.69e-12	3.98e-10	-0.25	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23147714	chr7:23129178~23129841:+
BRCA	cis	rs600231	0.683	rs588298	ENSG00000245532.5	NEAT1	7.14	1.69e-12	3.99e-10	0.2	0.22	Bone mineral density;	chr11:65486103	chr11:65422774~65445540:+
BRCA	cis	rs17495987	1	rs17495987	ENSG00000219545.8	UMAD1	7.14	1.7e-12	3.99e-10	0.28	0.22	Tonsillectomy;	chr7:7860334	chr7:7640711~8004059:+
BRCA	cis	rs2348418	0.765	rs10843118	ENSG00000247934.4	RP11-967K21.1	-7.14	1.7e-12	4e-10	-0.25	-0.22	Lung function (FEV1);Lung function (FVC);	chr12:28164396	chr12:28163298~28190738:-
BRCA	cis	rs6504622	0.702	rs3851798	ENSG00000262879.4	RP11-156P1.3	7.14	1.7e-12	4e-10	0.22	0.22	Orofacial clefts;	chr17:46988901	chr17:46984045~47100323:-
BRCA	cis	rs858239	0.539	rs6955969	ENSG00000230042.1	AK3P3	-7.14	1.7e-12	4e-10	-0.25	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23147080	chr7:23129178~23129841:+
BRCA	cis	rs7927771	0.864	rs2293580	ENSG00000280615.1	Y_RNA	7.14	1.7e-12	4.01e-10	0.25	0.22	Subjective well-being;	chr11:47418732	chr11:47614898~47614994:-
BRCA	cis	rs9876781	1	rs6442117	ENSG00000244380.1	RP11-24C3.2	-7.14	1.7e-12	4.01e-10	-0.24	-0.22	Longevity;	chr3:48378407	chr3:48440352~48446656:-
BRCA	cis	rs780096	0.565	rs10169261	ENSG00000234072.1	AC074117.10	-7.14	1.71e-12	4.02e-10	-0.21	-0.22	Total body bone mineral density;	chr2:27504447	chr2:27356246~27367622:+
BRCA	cis	rs1823913	0.538	rs11892998	ENSG00000227542.1	AC092614.2	7.14	1.71e-12	4.03e-10	0.26	0.22	Obesity-related traits;	chr2:191340159	chr2:191229165~191246172:-
BRCA	cis	rs1823913	0.538	rs13432697	ENSG00000227542.1	AC092614.2	7.14	1.71e-12	4.04e-10	0.26	0.22	Obesity-related traits;	chr2:191345944	chr2:191229165~191246172:-
BRCA	cis	rs780096	0.526	rs75855890	ENSG00000234072.1	AC074117.10	-7.14	1.72e-12	4.04e-10	-0.21	-0.22	Total body bone mineral density;	chr2:27402138	chr2:27356246~27367622:+
BRCA	cis	rs9876781	0.967	rs1870444	ENSG00000244380.1	RP11-24C3.2	7.14	1.72e-12	4.05e-10	0.25	0.22	Longevity;	chr3:48445369	chr3:48440352~48446656:-
BRCA	cis	rs66887589	0.967	rs6844263	ENSG00000248280.1	RP11-33B1.2	7.14	1.72e-12	4.05e-10	0.2	0.22	Diastolic blood pressure;	chr4:119512652	chr4:119440561~119450157:-
BRCA	cis	rs6860806	0.507	rs273901	ENSG00000233006.5	AC034220.3	7.14	1.72e-12	4.05e-10	0.18	0.22	Breast cancer;	chr5:132358667	chr5:132311285~132369916:-
BRCA	cis	rs270601	0.913	rs273899	ENSG00000233006.5	AC034220.3	7.14	1.72e-12	4.05e-10	0.18	0.22	Acylcarnitine levels;	chr5:132359485	chr5:132311285~132369916:-
BRCA	cis	rs10050311	0.858	rs76283582	ENSG00000251411.1	RP11-397E7.4	-7.14	1.72e-12	4.05e-10	-0.31	-0.22	Insulin-related traits;	chr4:86878202	chr4:86913266~86914817:-
BRCA	cis	rs11159086	0.941	rs11846588	ENSG00000259005.1	RP3-449M8.6	7.14	1.72e-12	4.05e-10	0.33	0.22	Advanced glycation end-product levels;	chr14:74505398	chr14:74474007~74474864:-
BRCA	cis	rs6840360	0.642	rs2709825	ENSG00000270265.1	RP11-731D1.4	-7.14	1.72e-12	4.06e-10	-0.24	-0.22	Intelligence (multi-trait analysis);	chr4:151444411	chr4:151333775~151353224:-
BRCA	cis	rs6840360	0.607	rs2724547	ENSG00000270265.1	RP11-731D1.4	-7.14	1.72e-12	4.06e-10	-0.24	-0.22	Intelligence (multi-trait analysis);	chr4:151444424	chr4:151333775~151353224:-
BRCA	cis	rs780096	0.526	rs2911713	ENSG00000234072.1	AC074117.10	-7.14	1.72e-12	4.06e-10	-0.21	-0.22	Total body bone mineral density;	chr2:27418113	chr2:27356246~27367622:+
BRCA	cis	rs8062405	0.755	rs4788074	ENSG00000251417.2	RP11-1348G14.4	7.14	1.73e-12	4.06e-10	0.25	0.22	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28582276	chr16:28802743~28817828:+
BRCA	cis	rs7727544	0.684	rs274561	ENSG00000233006.5	AC034220.3	7.14	1.74e-12	4.1e-10	0.16	0.22	Blood metabolite levels;	chr5:132383536	chr5:132311285~132369916:-
BRCA	cis	rs897984	0.762	rs2054213	ENSG00000260911.2	RP11-196G11.2	-7.14	1.74e-12	4.1e-10	-0.2	-0.22	Dementia with Lewy bodies;	chr16:30960489	chr16:31043150~31049868:+
BRCA	cis	rs2243480	1	rs4718317	ENSG00000232546.1	RP11-458F8.1	7.14	1.74e-12	4.11e-10	0.28	0.22	Diabetic kidney disease;	chr7:66183914	chr7:66848496~66858136:+
BRCA	cis	rs7246657	0.943	rs4803460	ENSG00000276846.1	CTD-3220F14.3	7.14	1.74e-12	4.11e-10	0.29	0.22	Coronary artery calcification;	chr19:37394326	chr19:37314868~37315620:-
BRCA	cis	rs10129255	0.957	rs6576233	ENSG00000223648.3	IGHV3-64	7.14	1.75e-12	4.11e-10	0.18	0.22	Kawasaki disease;	chr14:106787239	chr14:106643132~106658258:-
BRCA	cis	rs2243480	1	rs10807702	ENSG00000232546.1	RP11-458F8.1	-7.14	1.75e-12	4.12e-10	-0.29	-0.22	Diabetic kidney disease;	chr7:66302856	chr7:66848496~66858136:+
BRCA	cis	rs526231	0.578	rs10515337	ENSG00000175749.11	EIF3KP1	-7.14	1.75e-12	4.12e-10	-0.3	-0.22	Primary biliary cholangitis;	chr5:102965664	chr5:103032376~103033031:+
BRCA	cis	rs9649213	0.555	rs67132564	ENSG00000272950.1	RP11-307C18.1	7.14	1.75e-12	4.12e-10	0.27	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98385588	chr7:98322853~98323430:+
BRCA	cis	rs3760982	1	rs60184524	ENSG00000267058.1	RP11-15A1.3	-7.14	1.75e-12	4.12e-10	-0.24	-0.22	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43790063	chr19:43891804~43901805:-
BRCA	cis	rs2303759	0.918	rs1054770	ENSG00000268686.1	AC010524.2	-7.14	1.75e-12	4.13e-10	-0.33	-0.22	Multiple sclerosis;	chr19:49374858	chr19:49368705~49388081:-
BRCA	cis	rs6840360	0.617	rs2724563	ENSG00000270265.1	RP11-731D1.4	-7.14	1.76e-12	4.13e-10	-0.24	-0.22	Intelligence (multi-trait analysis);	chr4:151428807	chr4:151333775~151353224:-
BRCA	cis	rs6840360	0.617	rs2724564	ENSG00000270265.1	RP11-731D1.4	-7.14	1.76e-12	4.13e-10	-0.24	-0.22	Intelligence (multi-trait analysis);	chr4:151428810	chr4:151333775~151353224:-
BRCA	cis	rs2243480	0.901	rs778730	ENSG00000230295.1	RP11-458F8.2	-7.14	1.76e-12	4.13e-10	-0.29	-0.22	Diabetic kidney disease;	chr7:66358338	chr7:66880708~66882981:+
BRCA	cis	rs987724	0.512	rs9842198	ENSG00000240875.4	LINC00886	-7.14	1.77e-12	4.17e-10	-0.25	-0.22	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156821415	chr3:156747346~156817062:-
BRCA	cis	rs875971	1	rs11974264	ENSG00000224316.1	RP11-479O9.2	-7.14	1.78e-12	4.18e-10	-0.22	-0.22	Aortic root size;	chr7:66182595	chr7:65773620~65802067:+
BRCA	cis	rs780096	0.546	rs6547626	ENSG00000234072.1	AC074117.10	-7.14	1.78e-12	4.19e-10	-0.21	-0.22	Total body bone mineral density;	chr2:27423903	chr2:27356246~27367622:+
BRCA	cis	rs237743	1	rs238174	ENSG00000222365.1	SNORD12B	-7.14	1.78e-12	4.19e-10	-0.28	-0.22	Height;	chr20:49262572	chr20:49280319~49280409:+
BRCA	cis	rs875971	1	rs1565531	ENSG00000232559.3	GS1-124K5.12	-7.14	1.79e-12	4.2e-10	-0.26	-0.22	Aortic root size;	chr7:66198126	chr7:66554588~66576923:-
BRCA	cis	rs6545883	0.929	rs12617911	ENSG00000271889.1	RP11-493E12.1	7.14	1.79e-12	4.22e-10	0.27	0.22	Tuberculosis;	chr2:61513690	chr2:61151433~61162105:-
BRCA	cis	rs6545883	1	rs778762	ENSG00000271889.1	RP11-493E12.1	7.14	1.8e-12	4.22e-10	0.28	0.22	Tuberculosis;	chr2:61555786	chr2:61151433~61162105:-
BRCA	cis	rs9880211	0.706	rs67382287	ENSG00000273486.1	RP11-731C17.2	7.14	1.8e-12	4.23e-10	0.29	0.22	Height;Body mass index;	chr3:136661617	chr3:136837338~136839021:-
BRCA	cis	rs10492201	0.529	rs7313068	ENSG00000255733.4	IFNG-AS1	-7.14	1.8e-12	4.23e-10	-0.21	-0.22	Itch intensity from mosquito bite adjusted by bite size;	chr12:68011805	chr12:67989445~68234686:+
BRCA	cis	rs1499614	1	rs2141924	ENSG00000230295.1	RP11-458F8.2	-7.14	1.8e-12	4.24e-10	-0.29	-0.22	Gout;	chr7:66721259	chr7:66880708~66882981:+
BRCA	cis	rs6921919	0.806	rs213230	ENSG00000204709.4	LINC01556	7.14	1.8e-12	4.24e-10	0.31	0.22	Autism spectrum disorder or schizophrenia;	chr6:28362487	chr6:28943877~28944537:+
BRCA	cis	rs7131987	0.65	rs16934135	ENSG00000257176.2	RP11-996F15.2	-7.14	1.81e-12	4.24e-10	-0.27	-0.22	QT interval;	chr12:29331030	chr12:29280418~29317848:-
BRCA	cis	rs1707322	0.789	rs7540578	ENSG00000281133.1	AL355480.3	-7.14	1.81e-12	4.25e-10	-0.27	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45786472	chr1:45580892~45580996:-
BRCA	cis	rs7617773	0.744	rs2125482	ENSG00000228638.1	FCF1P2	-7.14	1.81e-12	4.25e-10	-0.23	-0.22	Coronary artery disease;	chr3:48281643	chr3:48290793~48291375:-
BRCA	cis	rs12291225	0.679	rs11023170	ENSG00000251991.1	RNU7-49P	7.13	1.81e-12	4.25e-10	0.25	0.22	Sense of smell;	chr11:14273363	chr11:14478892~14478953:+
BRCA	cis	rs9880211	0.8	rs1872239	ENSG00000273486.1	RP11-731C17.2	7.13	1.81e-12	4.26e-10	0.29	0.22	Height;Body mass index;	chr3:136785069	chr3:136837338~136839021:-
BRCA	cis	rs7178375	1	rs12907055	ENSG00000215302.7	CTD-3092A11.1	-7.13	1.81e-12	4.26e-10	-0.33	-0.22	Hypertriglyceridemia;	chr15:30912091	chr15:30470779~30507623:+
BRCA	cis	rs9494145	0.68	rs9389269	ENSG00000232876.1	CTA-212D2.2	-7.13	1.81e-12	4.26e-10	-0.32	-0.22	Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count;	chr6:135106021	chr6:135055033~135060550:+
BRCA	cis	rs6142102	1	rs12480839	ENSG00000275784.1	RP5-1125A11.6	-7.13	1.82e-12	4.26e-10	-0.26	-0.22	Skin pigmentation;	chr20:34139624	chr20:33989480~33991818:-
BRCA	cis	rs875971	0.898	rs6977501	ENSG00000224316.1	RP11-479O9.2	-7.13	1.82e-12	4.28e-10	-0.22	-0.22	Aortic root size;	chr7:66228355	chr7:65773620~65802067:+
BRCA	cis	rs2880765	0.835	rs4843062	ENSG00000259295.5	CSPG4P12	7.13	1.82e-12	4.28e-10	0.26	0.22	Coronary artery disease;	chr15:85496906	chr15:85191438~85213905:+
BRCA	cis	rs2014572	0.967	rs10411941	ENSG00000268379.1	CTC-360J11.4	7.13	1.83e-12	4.29e-10	0.26	0.22	Hyperactive-impulsive symptoms;	chr19:57251518	chr19:57175233~57177921:+
BRCA	cis	rs2014572	0.967	rs11667407	ENSG00000268379.1	CTC-360J11.4	7.13	1.83e-12	4.29e-10	0.26	0.22	Hyperactive-impulsive symptoms;	chr19:57251754	chr19:57175233~57177921:+
BRCA	cis	rs2599510	0.807	rs176416	ENSG00000276334.1	AL133243.1	-7.13	1.83e-12	4.29e-10	-0.26	-0.22	Interleukin-18 levels;	chr2:32427155	chr2:32521927~32523547:+
BRCA	cis	rs3760982	1	rs3760983	ENSG00000267058.1	RP11-15A1.3	7.13	1.83e-12	4.29e-10	0.24	0.22	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43782508	chr19:43891804~43901805:-
BRCA	cis	rs11159086	1	rs12433848	ENSG00000259005.1	RP3-449M8.6	7.13	1.83e-12	4.3e-10	0.35	0.22	Advanced glycation end-product levels;	chr14:74497570	chr14:74474007~74474864:-
BRCA	cis	rs6545883	0.929	rs7561229	ENSG00000271889.1	RP11-493E12.1	7.13	1.83e-12	4.3e-10	0.27	0.22	Tuberculosis;	chr2:61510855	chr2:61151433~61162105:-
BRCA	cis	rs2288884	0.559	rs73052102	ENSG00000275055.1	CTC-471J1.11	-7.13	1.83e-12	4.3e-10	-0.26	-0.22	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52021748	chr19:52049007~52049754:+
BRCA	cis	rs875971	0.545	rs66594357	ENSG00000224316.1	RP11-479O9.2	7.13	1.83e-12	4.3e-10	0.24	0.22	Aortic root size;	chr7:66327797	chr7:65773620~65802067:+
BRCA	cis	rs6545883	0.929	rs6707830	ENSG00000271889.1	RP11-493E12.1	7.13	1.84e-12	4.31e-10	0.28	0.22	Tuberculosis;	chr2:61522337	chr2:61151433~61162105:-
BRCA	cis	rs13178541	0.683	rs7378856	ENSG00000250378.1	RP11-119J18.1	-7.13	1.84e-12	4.31e-10	-0.3	-0.22	IgG glycosylation;	chr5:135751404	chr5:135812667~135826582:+
BRCA	cis	rs6723162	0.965	rs7564690	ENSG00000237751.2	LINC01143	-7.13	1.84e-12	4.31e-10	-0.26	-0.22	Neurocognitive impairment in HIV-1 infection (dichotomous);	chr2:70885113	chr2:70887871~70889959:+
BRCA	cis	rs6840360	0.642	rs2724578	ENSG00000270265.1	RP11-731D1.4	-7.13	1.84e-12	4.32e-10	-0.24	-0.22	Intelligence (multi-trait analysis);	chr4:151446152	chr4:151333775~151353224:-
BRCA	cis	rs6840360	0.574	rs2709844	ENSG00000270265.1	RP11-731D1.4	-7.13	1.84e-12	4.32e-10	-0.24	-0.22	Intelligence (multi-trait analysis);	chr4:151447060	chr4:151333775~151353224:-
BRCA	cis	rs2836950	0.805	rs62223042	ENSG00000255568.3	BRWD1-AS2	-7.13	1.84e-12	4.33e-10	-0.22	-0.22	Menarche (age at onset);	chr21:39311814	chr21:39313935~39314962:+
BRCA	cis	rs10740039	0.883	rs7920170	ENSG00000254271.1	RP11-131N11.4	7.13	1.85e-12	4.33e-10	0.29	0.22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60647766	chr10:60734342~60741828:+
BRCA	cis	rs7617773	0.817	rs11720622	ENSG00000228638.1	FCF1P2	-7.13	1.85e-12	4.34e-10	-0.21	-0.22	Coronary artery disease;	chr3:48205189	chr3:48290793~48291375:-
BRCA	cis	rs9880211	1	rs17364492	ENSG00000273486.1	RP11-731C17.2	-7.13	1.85e-12	4.35e-10	-0.28	-0.22	Height;Body mass index;	chr3:136485595	chr3:136837338~136839021:-
BRCA	cis	rs875971	1	rs11971949	ENSG00000224316.1	RP11-479O9.2	-7.13	1.85e-12	4.35e-10	-0.22	-0.22	Aortic root size;	chr7:66161027	chr7:65773620~65802067:+
BRCA	cis	rs4835473	0.897	rs13135627	ENSG00000251600.4	RP11-673E1.1	-7.13	1.85e-12	4.35e-10	-0.28	-0.22	Immature fraction of reticulocytes;	chr4:143691099	chr4:143912331~143982454:+
BRCA	cis	rs875971	0.66	rs10263935	ENSG00000224316.1	RP11-479O9.2	7.13	1.85e-12	4.35e-10	0.21	0.22	Aortic root size;	chr7:66631041	chr7:65773620~65802067:+
BRCA	cis	rs3760982	1	rs10421887	ENSG00000267058.1	RP11-15A1.3	7.13	1.86e-12	4.36e-10	0.24	0.22	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43790697	chr19:43891804~43901805:-
BRCA	cis	rs891378	0.785	rs10158940	ENSG00000274245.1	RP11-357P18.2	-7.13	1.86e-12	4.36e-10	-0.28	-0.22	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207191575	chr1:207372559~207373252:+
BRCA	cis	rs2274273	0.624	rs7150763	ENSG00000258413.1	RP11-665C16.6	-7.13	1.86e-12	4.36e-10	-0.29	-0.22	Protein biomarker;	chr14:55373083	chr14:55262767~55272075:-
BRCA	cis	rs6860806	0.507	rs273912	ENSG00000233006.5	AC034220.3	-7.13	1.86e-12	4.37e-10	-0.18	-0.22	Breast cancer;	chr5:132325656	chr5:132311285~132369916:-
BRCA	cis	rs2014572	0.967	rs8111977	ENSG00000268379.1	CTC-360J11.4	7.13	1.86e-12	4.37e-10	0.26	0.22	Hyperactive-impulsive symptoms;	chr19:57247790	chr19:57175233~57177921:+
BRCA	cis	rs7208859	0.623	rs11658022	ENSG00000263603.1	CTD-2349P21.5	-7.13	1.87e-12	4.38e-10	-0.4	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30758341	chr17:30729469~30731202:+
BRCA	cis	rs10129255	0.536	rs3944157	ENSG00000211970.3	IGHV4-61	-7.13	1.87e-12	4.38e-10	-0.14	-0.22	Kawasaki disease;	chr14:106682286	chr14:106639119~106639657:-
BRCA	cis	rs2243480	1	rs2465120	ENSG00000232546.1	RP11-458F8.1	-7.13	1.87e-12	4.39e-10	-0.29	-0.22	Diabetic kidney disease;	chr7:66155987	chr7:66848496~66858136:+
BRCA	cis	rs2243480	0.908	rs2460431	ENSG00000232546.1	RP11-458F8.1	7.13	1.87e-12	4.39e-10	0.29	0.22	Diabetic kidney disease;	chr7:66157859	chr7:66848496~66858136:+
BRCA	cis	rs2243480	1	rs4718309	ENSG00000232546.1	RP11-458F8.1	7.13	1.87e-12	4.39e-10	0.29	0.22	Diabetic kidney disease;	chr7:66162777	chr7:66848496~66858136:+
BRCA	cis	rs2243480	1	rs6460274	ENSG00000232546.1	RP11-458F8.1	7.13	1.87e-12	4.39e-10	0.29	0.22	Diabetic kidney disease;	chr7:66163497	chr7:66848496~66858136:+
BRCA	cis	rs2243480	1	rs7787230	ENSG00000232546.1	RP11-458F8.1	7.13	1.87e-12	4.39e-10	0.29	0.22	Diabetic kidney disease;	chr7:66164112	chr7:66848496~66858136:+
BRCA	cis	rs4835473	0.864	rs7681559	ENSG00000251600.4	RP11-673E1.1	-7.13	1.87e-12	4.39e-10	-0.28	-0.22	Immature fraction of reticulocytes;	chr4:143695248	chr4:143912331~143982454:+
BRCA	cis	rs9876781	1	rs7651407	ENSG00000244380.1	RP11-24C3.2	7.13	1.88e-12	4.4e-10	0.25	0.22	Longevity;	chr3:48402409	chr3:48440352~48446656:-
BRCA	cis	rs7246657	0.882	rs4803539	ENSG00000276846.1	CTD-3220F14.3	7.13	1.88e-12	4.41e-10	0.29	0.22	Coronary artery calcification;	chr19:37406620	chr19:37314868~37315620:-
BRCA	cis	rs911555	0.755	rs8018400	ENSG00000244691.1	RPL10AP1	7.13	1.89e-12	4.42e-10	0.27	0.22	Intelligence (multi-trait analysis);	chr14:103434748	chr14:103412119~103412761:-
BRCA	cis	rs6840258	0.66	rs72667741	ENSG00000251411.1	RP11-397E7.4	-7.13	1.89e-12	4.42e-10	-0.31	-0.22	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86970923	chr4:86913266~86914817:-
BRCA	cis	rs2348418	0.765	rs11049381	ENSG00000247934.4	RP11-967K21.1	-7.13	1.89e-12	4.43e-10	-0.25	-0.22	Lung function (FEV1);Lung function (FVC);	chr12:28162107	chr12:28163298~28190738:-
BRCA	cis	rs875971	0.666	rs13242072	ENSG00000236529.1	RP13-254B10.1	-7.13	1.89e-12	4.43e-10	-0.24	-0.22	Aortic root size;	chr7:66301001	chr7:65840212~65840596:+
BRCA	cis	rs755249	0.567	rs1126313	ENSG00000228060.1	RP11-69E11.8	7.13	1.89e-12	4.44e-10	0.27	0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39174072	chr1:39565160~39573203:+
BRCA	cis	rs712022	0.534	rs3213706	ENSG00000246225.5	RP11-17A1.3	-7.13	1.9e-12	4.44e-10	-0.26	-0.22	Dialysis-related mortality;	chr11:22859456	chr11:22829380~22945393:+
BRCA	cis	rs9880211	0.8	rs66509730	ENSG00000273486.1	RP11-731C17.2	7.13	1.9e-12	4.45e-10	0.29	0.22	Height;Body mass index;	chr3:136785416	chr3:136837338~136839021:-
BRCA	cis	rs6142102	0.961	rs2284389	ENSG00000275784.1	RP5-1125A11.6	-7.13	1.9e-12	4.45e-10	-0.25	-0.22	Skin pigmentation;	chr20:34069035	chr20:33989480~33991818:-
BRCA	cis	rs10754283	0.967	rs10922680	ENSG00000231613.1	RP5-943J3.1	-7.13	1.9e-12	4.45e-10	-0.24	-0.22	Amyotrophic lateral sclerosis (sporadic);	chr1:89635767	chr1:89788914~89790492:+
BRCA	cis	rs957448	0.561	rs4735302	ENSG00000253704.1	RP11-267M23.4	-7.13	1.9e-12	4.46e-10	-0.23	-0.22	Nonsyndromic cleft lip with cleft palate;	chr8:94604752	chr8:94553722~94569745:+
BRCA	cis	rs3794924	1	rs3794924	ENSG00000266521.1	RP11-650P15.1	-7.13	1.91e-12	4.47e-10	-0.38	-0.22	Survival in colon cancer;	chr18:31461771	chr18:31496645~31497195:-
BRCA	cis	rs2348418	0.765	rs7954851	ENSG00000247934.4	RP11-967K21.1	-7.13	1.91e-12	4.47e-10	-0.25	-0.22	Lung function (FEV1);Lung function (FVC);	chr12:28162909	chr12:28163298~28190738:-
BRCA	cis	rs4835473	0.864	rs57648439	ENSG00000251600.4	RP11-673E1.1	-7.13	1.91e-12	4.48e-10	-0.26	-0.22	Immature fraction of reticulocytes;	chr4:143691519	chr4:143912331~143982454:+
BRCA	cis	rs2281636	0.798	rs3184991	ENSG00000233690.1	EBAG9P1	-7.13	1.92e-12	4.49e-10	-0.25	-0.22	Obesity-related traits;	chr10:99755559	chr10:99697407~99697949:-
BRCA	cis	rs875971	1	rs875971	ENSG00000232559.3	GS1-124K5.12	-7.13	1.92e-12	4.49e-10	-0.25	-0.22	Aortic root size;	chr7:66152608	chr7:66554588~66576923:-
BRCA	cis	rs10510102	0.935	rs12250677	ENSG00000276742.1	RP11-500G22.4	7.13	1.92e-12	4.5e-10	0.36	0.22	Breast cancer;	chr10:121880575	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.872	rs12243874	ENSG00000276742.1	RP11-500G22.4	7.13	1.92e-12	4.5e-10	0.36	0.22	Breast cancer;	chr10:121880788	chr10:121956782~121957098:+
BRCA	cis	rs4927850	0.752	rs7624460	ENSG00000207650.1	MIR570	7.13	1.92e-12	4.5e-10	0.26	0.22	Pancreatic cancer;	chr3:196021659	chr3:195699401~195699497:+
BRCA	cis	rs6969780	0.915	rs2107063	ENSG00000233429.8	HOTAIRM1	-7.13	1.92e-12	4.5e-10	-0.25	-0.22	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27127727	chr7:27095647~27100265:+
BRCA	cis	rs6570726	0.935	rs446242	ENSG00000235652.6	RP11-545I5.3	7.13	1.92e-12	4.5e-10	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145522730	chr6:145799409~145886585:+
BRCA	cis	rs10510102	0.935	rs11200243	ENSG00000276742.1	RP11-500G22.4	7.13	1.92e-12	4.51e-10	0.36	0.22	Breast cancer;	chr10:121906888	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.935	rs11200244	ENSG00000276742.1	RP11-500G22.4	7.13	1.92e-12	4.51e-10	0.36	0.22	Breast cancer;	chr10:121906944	chr10:121956782~121957098:+
BRCA	cis	rs6472827	0.645	rs2956059	ENSG00000253983.2	RP1-16A9.1	7.13	1.93e-12	4.51e-10	0.3	0.22	Uterine fibroids;	chr8:74197795	chr8:74199396~74208441:+
BRCA	cis	rs10510102	0.935	rs11200258	ENSG00000276742.1	RP11-500G22.4	7.13	1.93e-12	4.51e-10	0.36	0.22	Breast cancer;	chr10:121918392	chr10:121956782~121957098:+
BRCA	cis	rs113835537	0.529	rs57724777	ENSG00000255517.5	CTD-3074O7.5	-7.12	1.94e-12	4.54e-10	-0.3	-0.22	Airway imaging phenotypes;	chr11:66468960	chr11:66473490~66480233:-
BRCA	cis	rs897984	0.684	rs6950	ENSG00000260911.2	RP11-196G11.2	-7.12	1.95e-12	4.56e-10	-0.2	-0.22	Dementia with Lewy bodies;	chr16:30984348	chr16:31043150~31049868:+
BRCA	cis	rs4845875	0.626	rs7538516	ENSG00000242349.4	NPPA-AS1	7.12	1.95e-12	4.56e-10	0.24	0.22	Midregional pro atrial natriuretic peptide levels;	chr1:11776625	chr1:11841017~11848079:+
BRCA	cis	rs4845875	0.626	rs6697244	ENSG00000242349.4	NPPA-AS1	7.12	1.95e-12	4.56e-10	0.24	0.22	Midregional pro atrial natriuretic peptide levels;	chr1:11778791	chr1:11841017~11848079:+
BRCA	cis	rs4835473	0.897	rs11723113	ENSG00000251600.4	RP11-673E1.1	7.12	1.95e-12	4.56e-10	0.26	0.22	Immature fraction of reticulocytes;	chr4:143707283	chr4:143912331~143982454:+
BRCA	cis	rs10754283	0.934	rs10493829	ENSG00000231613.1	RP5-943J3.1	7.12	1.96e-12	4.58e-10	0.24	0.22	Amyotrophic lateral sclerosis (sporadic);	chr1:89652274	chr1:89788914~89790492:+
BRCA	cis	rs237743	0.928	rs237714	ENSG00000222365.1	SNORD12B	-7.12	1.96e-12	4.59e-10	-0.27	-0.22	Height;	chr20:49306363	chr20:49280319~49280409:+
BRCA	cis	rs7178375	1	rs9806159	ENSG00000215302.7	CTD-3092A11.1	-7.12	1.96e-12	4.59e-10	-0.32	-0.22	Hypertriglyceridemia;	chr15:30917451	chr15:30470779~30507623:+
BRCA	cis	rs12237653	0.929	rs13298979	ENSG00000236404.7	VLDLR-AS1	7.12	1.96e-12	4.6e-10	0.34	0.22	Gambling;	chr9:2543199	chr9:2422702~2643359:-
BRCA	cis	rs9649213	0.593	rs55825602	ENSG00000272950.1	RP11-307C18.1	7.12	1.97e-12	4.6e-10	0.27	0.22	Prostate cancer (SNP x SNP interaction);	chr7:98383727	chr7:98322853~98323430:+
BRCA	cis	rs4927850	0.723	rs7630825	ENSG00000242086.7	LINC00969	7.12	1.97e-12	4.6e-10	0.24	0.22	Pancreatic cancer;	chr3:196026869	chr3:195658062~195739964:+
BRCA	cis	rs848490	0.651	rs11489586	ENSG00000214293.7	APTR	7.12	1.97e-12	4.61e-10	0.25	0.22	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77685900	chr7:77657660~77696265:-
BRCA	cis	rs6545883	0.965	rs778752	ENSG00000271889.1	RP11-493E12.1	7.12	1.97e-12	4.62e-10	0.28	0.22	Tuberculosis;	chr2:61549767	chr2:61151433~61162105:-
BRCA	cis	rs74233809	1	rs79237883	ENSG00000213277.3	MARCKSL1P1	7.12	1.97e-12	4.62e-10	0.41	0.22	Birth weight;	chr10:103181189	chr10:103175554~103176094:+
BRCA	cis	rs7617773	0.817	rs6800492	ENSG00000228638.1	FCF1P2	-7.12	1.98e-12	4.62e-10	-0.23	-0.22	Coronary artery disease;	chr3:48282400	chr3:48290793~48291375:-
BRCA	cis	rs7178375	1	rs35162264	ENSG00000215302.7	CTD-3092A11.1	-7.12	1.98e-12	4.62e-10	-0.33	-0.22	Hypertriglyceridemia;	chr15:30908480	chr15:30470779~30507623:+
BRCA	cis	rs7674212	0.531	rs4698875	ENSG00000251288.2	RP11-10L12.2	-7.12	1.98e-12	4.63e-10	-0.26	-0.22	Type 2 diabetes;	chr4:103012211	chr4:102751401~102752641:+
BRCA	cis	rs6496044	0.526	rs4291869	ENSG00000259295.5	CSPG4P12	7.12	1.98e-12	4.64e-10	0.26	0.22	Interstitial lung disease;	chr15:85511292	chr15:85191438~85213905:+
BRCA	cis	rs10740039	0.671	rs7913549	ENSG00000254271.1	RP11-131N11.4	7.12	1.98e-12	4.64e-10	0.28	0.22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60658474	chr10:60734342~60741828:+
BRCA	cis	rs858239	0.601	rs7805206	ENSG00000230042.1	AK3P3	-7.12	1.99e-12	4.66e-10	-0.24	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23120591	chr7:23129178~23129841:+
BRCA	cis	rs875971	0.597	rs11763224	ENSG00000224316.1	RP11-479O9.2	7.12	2e-12	4.67e-10	0.25	0.22	Aortic root size;	chr7:66518628	chr7:65773620~65802067:+
BRCA	cis	rs3930017	1	rs7783809	ENSG00000242435.1	UPK3BP1	7.12	2e-12	4.68e-10	0.25	0.22	Body mass index;	chr7:77090234	chr7:77004662~77005774:+
BRCA	cis	rs7246657	0.943	rs10405325	ENSG00000226686.6	LINC01535	-7.12	2e-12	4.68e-10	-0.33	-0.22	Coronary artery calcification;	chr19:37392575	chr19:37251912~37265535:+
BRCA	cis	rs7520050	0.807	rs28844317	ENSG00000280836.1	AL355480.1	-7.12	2.01e-12	4.69e-10	-0.25	-0.22	Reticulocyte count;Red blood cell count;	chr1:45743535	chr1:45581219~45581321:-
BRCA	cis	rs7520050	0.807	rs6429576	ENSG00000280836.1	AL355480.1	-7.12	2.01e-12	4.69e-10	-0.25	-0.22	Reticulocyte count;Red blood cell count;	chr1:45750903	chr1:45581219~45581321:-
BRCA	cis	rs10129255	1	rs11621409	ENSG00000211972.2	IGHV3-66	7.12	2.01e-12	4.69e-10	0.18	0.22	Kawasaki disease;	chr14:106695603	chr14:106675017~106675544:-
BRCA	cis	rs1823913	0.637	rs4853569	ENSG00000280083.1	RP11-317J9.1	7.12	2.01e-12	4.69e-10	0.24	0.22	Obesity-related traits;	chr2:191266970	chr2:191154118~191156070:-
BRCA	cis	rs6844153	1	rs74356465	ENSG00000240005.4	RP11-293A21.1	-7.12	2.01e-12	4.69e-10	-0.32	-0.22	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26902405	chr4:26859806~26860599:-
BRCA	cis	rs897984	0.762	rs2305880	ENSG00000260911.2	RP11-196G11.2	-7.12	2.01e-12	4.69e-10	-0.2	-0.22	Dementia with Lewy bodies;	chr16:30988141	chr16:31043150~31049868:+
BRCA	cis	rs8072100	0.79	rs3760371	ENSG00000228782.6	CTD-2026D20.3	-7.12	2.01e-12	4.69e-10	-0.24	-0.22	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47618548	chr17:47450568~47492492:-
BRCA	cis	rs875971	0.545	rs67397473	ENSG00000236529.1	RP13-254B10.1	7.12	2.01e-12	4.7e-10	0.26	0.22	Aortic root size;	chr7:66168318	chr7:65840212~65840596:+
BRCA	cis	rs8031584	0.781	rs4779498	ENSG00000260382.1	RP11-540B6.2	7.12	2.02e-12	4.71e-10	0.26	0.22	Huntington's disease progression;	chr15:30885273	chr15:30882267~30883231:-
BRCA	cis	rs6142102	1	rs6142102	ENSG00000275784.1	RP5-1125A11.6	-7.12	2.02e-12	4.71e-10	-0.25	-0.22	Skin pigmentation;	chr20:34116821	chr20:33989480~33991818:-
BRCA	cis	rs526231	0.543	rs246906	ENSG00000175749.11	EIF3KP1	7.12	2.02e-12	4.72e-10	0.32	0.22	Primary biliary cholangitis;	chr5:103230770	chr5:103032376~103033031:+
BRCA	cis	rs10129255	0.5	rs7157975	ENSG00000280411.1	IGHV1-69-2	-7.12	2.02e-12	4.72e-10	-0.14	-0.22	Kawasaki disease;	chr14:106804049	chr14:106762092~106762588:-
BRCA	cis	rs10510102	0.81	rs11200240	ENSG00000276742.1	RP11-500G22.4	7.12	2.02e-12	4.72e-10	0.36	0.22	Breast cancer;	chr10:121903265	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.935	rs74914751	ENSG00000276742.1	RP11-500G22.4	7.12	2.02e-12	4.72e-10	0.36	0.22	Breast cancer;	chr10:121904496	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.935	rs11200242	ENSG00000276742.1	RP11-500G22.4	7.12	2.02e-12	4.72e-10	0.36	0.22	Breast cancer;	chr10:121905378	chr10:121956782~121957098:+
BRCA	cis	rs6840360	0.642	rs2709828	ENSG00000270265.1	RP11-731D1.4	-7.12	2.02e-12	4.72e-10	-0.24	-0.22	Intelligence (multi-trait analysis);	chr4:151434116	chr4:151333775~151353224:-
BRCA	cis	rs6840360	0.642	rs2724551	ENSG00000270265.1	RP11-731D1.4	-7.12	2.02e-12	4.72e-10	-0.24	-0.22	Intelligence (multi-trait analysis);	chr4:151434231	chr4:151333775~151353224:-
BRCA	cis	rs6840360	0.667	rs2709829	ENSG00000270265.1	RP11-731D1.4	-7.12	2.02e-12	4.72e-10	-0.24	-0.22	Intelligence (multi-trait analysis);	chr4:151434238	chr4:151333775~151353224:-
BRCA	cis	rs6840360	0.606	rs2709813	ENSG00000270265.1	RP11-731D1.4	-7.12	2.02e-12	4.72e-10	-0.24	-0.22	Intelligence (multi-trait analysis);	chr4:151436292	chr4:151333775~151353224:-
BRCA	cis	rs6840360	0.606	rs2724550	ENSG00000270265.1	RP11-731D1.4	-7.12	2.02e-12	4.72e-10	-0.24	-0.22	Intelligence (multi-trait analysis);	chr4:151437834	chr4:151333775~151353224:-
BRCA	cis	rs6840360	0.642	rs2709815	ENSG00000270265.1	RP11-731D1.4	-7.12	2.02e-12	4.72e-10	-0.24	-0.22	Intelligence (multi-trait analysis);	chr4:151442620	chr4:151333775~151353224:-
BRCA	cis	rs4927850	1	rs7627706	ENSG00000242086.7	LINC00969	7.12	2.02e-12	4.73e-10	0.24	0.22	Pancreatic cancer;	chr3:196026482	chr3:195658062~195739964:+
BRCA	cis	rs4927850	0.881	rs7630489	ENSG00000242086.7	LINC00969	7.12	2.02e-12	4.73e-10	0.24	0.22	Pancreatic cancer;	chr3:196026530	chr3:195658062~195739964:+
BRCA	cis	rs4927850	1	rs7627868	ENSG00000242086.7	LINC00969	7.12	2.02e-12	4.73e-10	0.24	0.22	Pancreatic cancer;	chr3:196026602	chr3:195658062~195739964:+
BRCA	cis	rs11096990	0.855	rs2566170	ENSG00000249207.1	RP11-360F5.1	7.12	2.03e-12	4.73e-10	0.26	0.22	Cognitive function;	chr4:39150757	chr4:39112677~39126818:-
BRCA	cis	rs17301013	0.606	rs7547766	ENSG00000227373.4	RP11-160H22.5	7.12	2.03e-12	4.73e-10	0.31	0.22	Systemic lupus erythematosus;	chr1:174180977	chr1:174115300~174160004:-
BRCA	cis	rs6840360	0.642	rs7657670	ENSG00000270265.1	RP11-731D1.4	-7.12	2.03e-12	4.74e-10	-0.24	-0.22	Intelligence (multi-trait analysis);	chr4:151432223	chr4:151333775~151353224:-
BRCA	cis	rs9309473	1	rs62151652	ENSG00000163016.8	ALMS1P	7.12	2.03e-12	4.74e-10	0.28	0.22	Metabolite levels;	chr2:73473004	chr2:73644919~73685576:+
BRCA	cis	rs56804039	0.524	rs11783173	ENSG00000253893.2	FAM85B	7.12	2.03e-12	4.74e-10	0.33	0.22	Cervical cancer;	chr8:8505200	chr8:8167819~8226614:-
BRCA	cis	rs4835473	0.897	rs7676614	ENSG00000251600.4	RP11-673E1.1	-7.12	2.03e-12	4.75e-10	-0.28	-0.22	Immature fraction of reticulocytes;	chr4:143695213	chr4:143912331~143982454:+
BRCA	cis	rs61160187	0.518	rs62372133	ENSG00000215032.2	GNL3LP1	7.12	2.04e-12	4.76e-10	0.27	0.22	Educational attainment (years of education);Educational attainment (college completion);	chr5:60906350	chr5:60891935~60893577:-
BRCA	cis	rs673078	0.607	rs17440893	ENSG00000275409.1	RP11-131L12.4	-7.12	2.04e-12	4.76e-10	-0.32	-0.22	Glucose homeostasis traits;	chr12:118362532	chr12:118430147~118430699:+
BRCA	cis	rs10483853	0.806	rs12586996	ENSG00000258408.1	NT5CP2	7.12	2.04e-12	4.76e-10	0.29	0.22	Coronary artery calcification;	chr14:73342516	chr14:73539221~73539781:-
BRCA	cis	rs780096	0.546	rs4665976	ENSG00000234072.1	AC074117.10	-7.12	2.04e-12	4.77e-10	-0.21	-0.22	Total body bone mineral density;	chr2:27417458	chr2:27356246~27367622:+
BRCA	cis	rs78456975	0.527	rs11886696	ENSG00000231482.2	AC141930.2	-7.12	2.05e-12	4.78e-10	-0.29	-0.22	Placebo response in major depressive disorder (% change in symptom score);	chr2:1564069	chr2:1572554~1580311:-
BRCA	cis	rs858239	0.665	rs6964665	ENSG00000230042.1	AK3P3	-7.12	2.05e-12	4.78e-10	-0.25	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23171733	chr7:23129178~23129841:+
BRCA	cis	rs2835345	0.563	rs12482140	ENSG00000230479.1	AP000695.6	7.12	2.05e-12	4.78e-10	0.21	0.22	Pulmonary function;	chr21:36451735	chr21:36430360~36481070:+
BRCA	cis	rs2835345	0.528	rs73204243	ENSG00000230479.1	AP000695.6	7.12	2.05e-12	4.78e-10	0.21	0.22	Pulmonary function;	chr21:36451776	chr21:36430360~36481070:+
BRCA	cis	rs2835345	0.595	rs78237434	ENSG00000230479.1	AP000695.6	7.12	2.05e-12	4.78e-10	0.21	0.22	Pulmonary function;	chr21:36451826	chr21:36430360~36481070:+
BRCA	cis	rs2243480	1	rs6958289	ENSG00000232546.1	RP11-458F8.1	7.12	2.05e-12	4.79e-10	0.29	0.22	Diabetic kidney disease;	chr7:66192124	chr7:66848496~66858136:+
BRCA	cis	rs801193	1	rs17566701	ENSG00000224316.1	RP11-479O9.2	7.12	2.05e-12	4.79e-10	0.22	0.22	Aortic root size;	chr7:66728196	chr7:65773620~65802067:+
BRCA	cis	rs34779708	0.643	rs4275563	ENSG00000271335.4	RP11-324I22.4	7.12	2.05e-12	4.79e-10	0.22	0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35256358	chr10:35314552~35336401:-
BRCA	cis	rs34779708	0.733	rs3936503	ENSG00000271335.4	RP11-324I22.4	-7.12	2.05e-12	4.8e-10	-0.22	-0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35260329	chr10:35314552~35336401:-
BRCA	cis	rs8030379	1	rs11633301	ENSG00000230373.7	GOLGA6L5P	7.12	2.06e-12	4.8e-10	0.23	0.22	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83916286	chr15:84507885~84516814:-
BRCA	cis	rs875971	1	rs709595	ENSG00000232559.3	GS1-124K5.12	7.12	2.06e-12	4.81e-10	0.25	0.22	Aortic root size;	chr7:66352346	chr7:66554588~66576923:-
BRCA	cis	rs875971	1	rs811880	ENSG00000232559.3	GS1-124K5.12	7.12	2.06e-12	4.81e-10	0.25	0.22	Aortic root size;	chr7:66353659	chr7:66554588~66576923:-
BRCA	cis	rs4722166	0.532	rs1404008	ENSG00000179428.2	AC073072.5	-7.12	2.06e-12	4.81e-10	-0.22	-0.22	Lung cancer;	chr7:22716381	chr7:22725395~22727620:-
BRCA	cis	rs919433	0.963	rs7582736	ENSG00000231621.1	AC013264.2	7.12	2.06e-12	4.81e-10	0.21	0.22	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197305618	chr2:197197991~197199273:+
BRCA	cis	rs919433	0.963	rs12618612	ENSG00000231621.1	AC013264.2	7.12	2.06e-12	4.81e-10	0.21	0.22	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197306334	chr2:197197991~197199273:+
BRCA	cis	rs875971	0.66	rs801193	ENSG00000236529.1	RP13-254B10.1	-7.12	2.06e-12	4.81e-10	-0.23	-0.22	Aortic root size;	chr7:66565625	chr7:65840212~65840596:+
BRCA	cis	rs7811142	1	rs73161762	ENSG00000242294.5	STAG3L5P	7.12	2.06e-12	4.82e-10	0.23	0.22	Platelet count;	chr7:100417223	chr7:100336079~100351900:+
BRCA	cis	rs17253792	0.822	rs77197405	ENSG00000186615.9	KTN1-AS1	-7.12	2.06e-12	4.82e-10	-0.44	-0.22	Putamen volume;	chr14:55692944	chr14:55499278~55580110:-
BRCA	cis	rs12439619	1	rs12439619	ENSG00000255769.6	GOLGA2P10	-7.12	2.07e-12	4.83e-10	-0.26	-0.22	Intelligence (multi-trait analysis);	chr15:82254605	chr15:82472993~82513950:-
BRCA	cis	rs7208859	0.673	rs61348930	ENSG00000263603.1	CTD-2349P21.5	-7.12	2.07e-12	4.83e-10	-0.39	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30894745	chr17:30729469~30731202:+
BRCA	cis	rs7208859	0.614	rs28758251	ENSG00000263603.1	CTD-2349P21.5	-7.12	2.07e-12	4.83e-10	-0.39	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30896294	chr17:30729469~30731202:+
BRCA	cis	rs7208859	0.673	rs9899943	ENSG00000263603.1	CTD-2349P21.5	-7.12	2.07e-12	4.83e-10	-0.39	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30896907	chr17:30729469~30731202:+
BRCA	cis	rs7208859	0.673	rs11080138	ENSG00000263603.1	CTD-2349P21.5	-7.12	2.07e-12	4.83e-10	-0.39	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30897524	chr17:30729469~30731202:+
BRCA	cis	rs7208859	0.673	rs73265612	ENSG00000263603.1	CTD-2349P21.5	-7.12	2.07e-12	4.83e-10	-0.39	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30898965	chr17:30729469~30731202:+
BRCA	cis	rs7208859	0.673	rs11658435	ENSG00000263603.1	CTD-2349P21.5	-7.12	2.07e-12	4.83e-10	-0.39	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30901543	chr17:30729469~30731202:+
BRCA	cis	rs7208859	0.673	rs73265624	ENSG00000263603.1	CTD-2349P21.5	-7.12	2.07e-12	4.83e-10	-0.39	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30905048	chr17:30729469~30731202:+
BRCA	cis	rs66887589	1	rs66887589	ENSG00000248280.1	RP11-33B1.2	-7.12	2.07e-12	4.84e-10	-0.2	-0.22	Diastolic blood pressure;	chr4:119588124	chr4:119440561~119450157:-
BRCA	cis	rs7927771	0.864	rs7937331	ENSG00000280615.1	Y_RNA	7.12	2.07e-12	4.84e-10	0.25	0.22	Subjective well-being;	chr11:47408907	chr11:47614898~47614994:-
BRCA	cis	rs10510102	0.935	rs12246704	ENSG00000276742.1	RP11-500G22.4	7.12	2.07e-12	4.84e-10	0.36	0.22	Breast cancer;	chr10:121906165	chr10:121956782~121957098:+
BRCA	cis	rs2015599	0.549	rs7311081	ENSG00000275476.1	RP11-996F15.4	7.12	2.08e-12	4.85e-10	0.24	0.22	Platelet count;Mean platelet volume;	chr12:29278235	chr12:29277397~29277882:-
BRCA	cis	rs58873874	0.737	rs12654973	ENSG00000248544.2	CTB-47B11.3	7.11	2.08e-12	4.85e-10	0.45	0.22	Bipolar disorder (body mass index interaction);	chr5:157280938	chr5:157375741~157384950:-
BRCA	cis	rs58873874	0.579	rs74804793	ENSG00000248544.2	CTB-47B11.3	7.11	2.08e-12	4.85e-10	0.45	0.22	Bipolar disorder (body mass index interaction);	chr5:157281515	chr5:157375741~157384950:-
BRCA	cis	rs42648	0.869	rs42614	ENSG00000225498.1	AC002064.5	7.11	2.08e-12	4.86e-10	0.2	0.22	Homocysteine levels;	chr7:90321049	chr7:90312496~90322592:+
BRCA	cis	rs2835345	0.563	rs58602880	ENSG00000230479.1	AP000695.6	7.11	2.08e-12	4.86e-10	0.22	0.22	Pulmonary function;	chr21:36454610	chr21:36430360~36481070:+
BRCA	cis	rs7615952	0.576	rs4646748	ENSG00000250012.1	RP11-124N2.1	-7.11	2.08e-12	4.86e-10	-0.3	-0.22	Blood pressure (smoking interaction);	chr3:126107486	chr3:126084220~126095349:+
BRCA	cis	rs1552244	0.744	rs6763366	ENSG00000180385.7	EMC3-AS1	7.11	2.08e-12	4.86e-10	0.26	0.22	Alzheimer's disease;	chr3:9991860	chr3:9986893~10006990:+
BRCA	cis	rs2060793	0.684	rs1597689	ENSG00000251991.1	RNU7-49P	7.11	2.09e-12	4.86e-10	0.24	0.22	Vitamin D levels;	chr11:14824638	chr11:14478892~14478953:+
BRCA	cis	rs7727544	0.684	rs272889	ENSG00000233006.5	AC034220.3	7.11	2.09e-12	4.87e-10	0.16	0.22	Blood metabolite levels;	chr5:132329685	chr5:132311285~132369916:-
BRCA	cis	rs9876781	0.967	rs1459249	ENSG00000244380.1	RP11-24C3.2	7.11	2.09e-12	4.87e-10	0.24	0.22	Longevity;	chr3:48438208	chr3:48440352~48446656:-
BRCA	cis	rs71520386	0.634	rs13240023	ENSG00000228649.7	AC005682.5	-7.11	2.09e-12	4.88e-10	-0.21	-0.22	Fibrinogen levels;	chr7:22827874	chr7:22854178~22861579:+
BRCA	cis	rs875971	0.545	rs73376401	ENSG00000236529.1	RP13-254B10.1	7.11	2.09e-12	4.88e-10	0.26	0.22	Aortic root size;	chr7:66174841	chr7:65840212~65840596:+
BRCA	cis	rs7044106	0.664	rs7861679	ENSG00000238181.2	AHCYP2	7.11	2.1e-12	4.9e-10	0.28	0.22	Hip circumference adjusted for BMI;	chr9:120613311	chr9:120720673~120721972:+
BRCA	cis	rs9880211	0.563	rs1393787	ENSG00000273486.1	RP11-731C17.2	7.11	2.11e-12	4.9e-10	0.28	0.22	Height;Body mass index;	chr3:136135359	chr3:136837338~136839021:-
BRCA	cis	rs1799810	0.64	rs55998444	ENSG00000236682.1	AC068282.3	-7.11	2.11e-12	4.91e-10	-0.3	-0.22	Self-rated health;	chr2:127362270	chr2:127389130~127400580:+
BRCA	cis	rs875971	0.545	rs17138156	ENSG00000236529.1	RP13-254B10.1	7.11	2.11e-12	4.92e-10	0.26	0.22	Aortic root size;	chr7:66249708	chr7:65840212~65840596:+
BRCA	cis	rs2243480	0.803	rs55700941	ENSG00000273142.1	RP11-458F8.4	-7.11	2.11e-12	4.92e-10	-0.3	-0.22	Diabetic kidney disease;	chr7:65924813	chr7:66902857~66906297:+
BRCA	cis	rs7178375	0.941	rs4779796	ENSG00000215302.7	CTD-3092A11.1	-7.11	2.12e-12	4.93e-10	-0.33	-0.22	Hypertriglyceridemia;	chr15:30915847	chr15:30470779~30507623:+
BRCA	cis	rs420259	0.51	rs12921516	ENSG00000260136.4	CTD-2270L9.4	-7.11	2.12e-12	4.93e-10	-0.22	-0.22	Bipolar disorder;	chr16:23510082	chr16:23452758~23457606:+
BRCA	cis	rs7246657	0.943	rs7252325	ENSG00000276846.1	CTD-3220F14.3	7.11	2.12e-12	4.94e-10	0.29	0.22	Coronary artery calcification;	chr19:37439743	chr19:37314868~37315620:-
BRCA	cis	rs2243480	1	rs1618893	ENSG00000273142.1	RP11-458F8.4	-7.11	2.13e-12	4.95e-10	-0.28	-0.22	Diabetic kidney disease;	chr7:66631132	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs1546059	ENSG00000230295.1	RP11-458F8.2	7.11	2.13e-12	4.95e-10	0.29	0.22	Diabetic kidney disease;	chr7:66189722	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs2420170	ENSG00000230295.1	RP11-458F8.2	7.11	2.13e-12	4.95e-10	0.29	0.22	Diabetic kidney disease;	chr7:66191066	chr7:66880708~66882981:+
BRCA	cis	rs270601	0.955	rs273911	ENSG00000233006.5	AC034220.3	7.11	2.13e-12	4.95e-10	0.18	0.22	Acylcarnitine levels;	chr5:132325833	chr5:132311285~132369916:-
BRCA	cis	rs17253792	0.822	rs17685102	ENSG00000186615.9	KTN1-AS1	-7.11	2.13e-12	4.95e-10	-0.45	-0.22	Putamen volume;	chr14:55662496	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs77033617	ENSG00000186615.9	KTN1-AS1	-7.11	2.13e-12	4.95e-10	-0.45	-0.22	Putamen volume;	chr14:55663028	chr14:55499278~55580110:-
BRCA	cis	rs61270009	0.687	rs10942530	ENSG00000247828.6	TMEM161B-AS1	7.11	2.13e-12	4.95e-10	0.29	0.22	Depressive symptoms;	chr5:88414221	chr5:88268895~88436685:+
BRCA	cis	rs73173548	0.502	rs10942531	ENSG00000247828.6	TMEM161B-AS1	7.11	2.13e-12	4.95e-10	0.29	0.22	Macular telangiectasia type 2;	chr5:88414280	chr5:88268895~88436685:+
BRCA	cis	rs875971	0.83	rs587360	ENSG00000232559.3	GS1-124K5.12	7.11	2.13e-12	4.95e-10	0.26	0.22	Aortic root size;	chr7:66057711	chr7:66554588~66576923:-
BRCA	cis	rs9291683	0.552	rs10939655	ENSG00000250413.1	RP11-448G15.1	-7.11	2.13e-12	4.96e-10	-0.28	-0.22	Bone mineral density;	chr4:10013018	chr4:10006482~10009725:+
BRCA	cis	rs9309711	0.961	rs11675119	ENSG00000225234.1	TRAPPC12-AS1	-7.11	2.13e-12	4.97e-10	-0.25	-0.22	Neurofibrillary tangles;	chr2:3472651	chr2:3481242~3482409:-
BRCA	cis	rs10754283	0.967	rs10737707	ENSG00000231613.1	RP5-943J3.1	7.11	2.14e-12	4.98e-10	0.24	0.22	Amyotrophic lateral sclerosis (sporadic);	chr1:89653745	chr1:89788914~89790492:+
BRCA	cis	rs7617773	0.817	rs9819094	ENSG00000228638.1	FCF1P2	-7.11	2.14e-12	4.98e-10	-0.23	-0.22	Coronary artery disease;	chr3:48278068	chr3:48290793~48291375:-
BRCA	cis	rs10515750	0.588	rs11749220	ENSG00000251405.2	CTB-109A12.1	7.11	2.15e-12	4.99e-10	0.33	0.22	Lung function (FEV1/FVC);	chr5:157362486	chr5:157362615~157460078:-
BRCA	cis	rs6860806	0.507	rs272891	ENSG00000233006.5	AC034220.3	7.11	2.16e-12	5.02e-10	0.18	0.22	Breast cancer;	chr5:132328701	chr5:132311285~132369916:-
BRCA	cis	rs73173548	0.528	rs34182576	ENSG00000247828.6	TMEM161B-AS1	7.11	2.16e-12	5.02e-10	0.29	0.22	Macular telangiectasia type 2;	chr5:88438321	chr5:88268895~88436685:+
BRCA	cis	rs2014572	0.967	rs8112572	ENSG00000268379.1	CTC-360J11.4	7.11	2.16e-12	5.03e-10	0.26	0.22	Hyperactive-impulsive symptoms;	chr19:57248244	chr19:57175233~57177921:+
BRCA	cis	rs3760982	0.845	rs62116962	ENSG00000267058.1	RP11-15A1.3	7.11	2.16e-12	5.03e-10	0.24	0.22	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43783082	chr19:43891804~43901805:-
BRCA	cis	rs11671005	0.571	rs56243535	ENSG00000252334.1	RNU6-1337P	7.11	2.16e-12	5.03e-10	0.36	0.22	Mean platelet volume;	chr19:58494783	chr19:58483749~58483843:-
BRCA	cis	rs1009647	0.656	rs10147254	ENSG00000258413.1	RP11-665C16.6	-7.11	2.17e-12	5.04e-10	-0.29	-0.22	Testicular germ cell tumor;	chr14:55383597	chr14:55262767~55272075:-
BRCA	cis	rs1823913	0.599	rs13035132	ENSG00000280083.1	RP11-317J9.1	-7.11	2.17e-12	5.05e-10	-0.24	-0.22	Obesity-related traits;	chr2:191265275	chr2:191154118~191156070:-
BRCA	cis	rs9527	0.662	rs4919686	ENSG00000213061.2	PFN1P11	7.11	2.17e-12	5.06e-10	0.32	0.22	Arsenic metabolism;	chr10:102832492	chr10:102838011~102845473:-
BRCA	cis	rs4835473	0.832	rs55935372	ENSG00000251600.4	RP11-673E1.1	-7.11	2.18e-12	5.06e-10	-0.28	-0.22	Immature fraction of reticulocytes;	chr4:143700626	chr4:143912331~143982454:+
BRCA	cis	rs2243480	1	rs958550	ENSG00000232546.1	RP11-458F8.1	7.11	2.18e-12	5.06e-10	0.28	0.22	Diabetic kidney disease;	chr7:66170692	chr7:66848496~66858136:+
BRCA	cis	rs7809950	1	rs2237677	ENSG00000238832.1	snoU109	-7.11	2.18e-12	5.06e-10	-0.28	-0.22	Coronary artery disease;	chr7:107562057	chr7:107603363~107603507:+
BRCA	cis	rs7617773	0.779	rs9833309	ENSG00000228638.1	FCF1P2	-7.11	2.18e-12	5.07e-10	-0.23	-0.22	Coronary artery disease;	chr3:48285960	chr3:48290793~48291375:-
BRCA	cis	rs7617773	0.817	rs9853804	ENSG00000228638.1	FCF1P2	-7.11	2.18e-12	5.07e-10	-0.23	-0.22	Coronary artery disease;	chr3:48286239	chr3:48290793~48291375:-
BRCA	cis	rs7617773	0.817	rs9834095	ENSG00000228638.1	FCF1P2	-7.11	2.18e-12	5.07e-10	-0.23	-0.22	Coronary artery disease;	chr3:48286261	chr3:48290793~48291375:-
BRCA	cis	rs780096	0.526	rs13472	ENSG00000234072.1	AC074117.10	-7.11	2.19e-12	5.08e-10	-0.21	-0.22	Total body bone mineral density;	chr2:27377372	chr2:27356246~27367622:+
BRCA	cis	rs2976388	0.609	rs2376491	ENSG00000253741.1	CTD-2292P10.4	-7.11	2.19e-12	5.09e-10	-0.24	-0.22	Urinary tract infection frequency;	chr8:142709516	chr8:142702252~142726973:-
BRCA	cis	rs17253792	0.822	rs17253730	ENSG00000186615.9	KTN1-AS1	-7.11	2.19e-12	5.1e-10	-0.44	-0.22	Putamen volume;	chr14:55691193	chr14:55499278~55580110:-
BRCA	cis	rs2015599	0.517	rs7295212	ENSG00000275476.1	RP11-996F15.4	7.11	2.19e-12	5.1e-10	0.24	0.22	Platelet count;Mean platelet volume;	chr12:29278432	chr12:29277397~29277882:-
BRCA	cis	rs61160187	0.556	rs10939881	ENSG00000215032.2	GNL3LP1	7.11	2.2e-12	5.1e-10	0.26	0.22	Educational attainment (years of education);Educational attainment (college completion);	chr5:61087146	chr5:60891935~60893577:-
BRCA	cis	rs801193	1	rs2055682	ENSG00000237310.1	GS1-124K5.4	7.11	2.2e-12	5.11e-10	0.22	0.22	Aortic root size;	chr7:66795302	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.508	rs10258739	ENSG00000224316.1	RP11-479O9.2	-7.11	2.2e-12	5.11e-10	-0.21	-0.22	Aortic root size;	chr7:66597948	chr7:65773620~65802067:+
BRCA	cis	rs2243480	1	rs1039664	ENSG00000273142.1	RP11-458F8.4	-7.11	2.2e-12	5.11e-10	-0.29	-0.22	Diabetic kidney disease;	chr7:65984729	chr7:66902857~66906297:+
BRCA	cis	rs7927771	0.864	rs755553	ENSG00000280615.1	Y_RNA	7.11	2.2e-12	5.12e-10	0.25	0.22	Subjective well-being;	chr11:47410752	chr11:47614898~47614994:-
BRCA	cis	rs7665090	0.846	rs4496586	ENSG00000246560.2	RP11-10L12.4	7.11	2.21e-12	5.13e-10	0.23	0.21	Primary biliary cholangitis;	chr4:102636154	chr4:102828055~102844075:+
BRCA	cis	rs79040073	0.637	rs11633981	ENSG00000259531.2	RP11-295H24.3	7.11	2.21e-12	5.13e-10	0.36	0.21	Lung cancer in ever smokers;	chr15:49360903	chr15:49365124~49366685:-
BRCA	cis	rs79040073	0.637	rs11633282	ENSG00000259531.2	RP11-295H24.3	7.11	2.21e-12	5.13e-10	0.36	0.21	Lung cancer in ever smokers;	chr15:49372472	chr15:49365124~49366685:-
BRCA	cis	rs79040073	0.637	rs11638606	ENSG00000259531.2	RP11-295H24.3	7.11	2.21e-12	5.13e-10	0.36	0.21	Lung cancer in ever smokers;	chr15:49372564	chr15:49365124~49366685:-
BRCA	cis	rs7809950	0.906	rs2395907	ENSG00000238832.1	snoU109	7.11	2.21e-12	5.14e-10	0.29	0.21	Coronary artery disease;	chr7:107612859	chr7:107603363~107603507:+
BRCA	cis	rs2599510	0.783	rs2038534	ENSG00000276334.1	AL133243.1	7.11	2.21e-12	5.14e-10	0.27	0.21	Interleukin-18 levels;	chr2:32434421	chr2:32521927~32523547:+
BRCA	cis	rs875971	0.502	rs2946580	ENSG00000224316.1	RP11-479O9.2	-7.11	2.22e-12	5.15e-10	-0.25	-0.21	Aortic root size;	chr7:66066855	chr7:65773620~65802067:+
BRCA	cis	rs9291683	0.595	rs35501905	ENSG00000250413.1	RP11-448G15.1	-7.11	2.22e-12	5.16e-10	-0.29	-0.21	Bone mineral density;	chr4:10051807	chr4:10006482~10009725:+
BRCA	cis	rs2060793	1	rs2060793	ENSG00000251991.1	RNU7-49P	7.11	2.22e-12	5.16e-10	0.24	0.21	Vitamin D levels;	chr11:14893764	chr11:14478892~14478953:+
BRCA	cis	rs6570726	0.935	rs434298	ENSG00000235652.6	RP11-545I5.3	7.11	2.22e-12	5.16e-10	0.21	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145525737	chr6:145799409~145886585:+
BRCA	cis	rs7520050	0.778	rs3014216	ENSG00000280836.1	AL355480.1	-7.11	2.23e-12	5.17e-10	-0.25	-0.21	Reticulocyte count;Red blood cell count;	chr1:45570088	chr1:45581219~45581321:-
BRCA	cis	rs6545883	0.931	rs7557230	ENSG00000271889.1	RP11-493E12.1	7.11	2.23e-12	5.17e-10	0.28	0.21	Tuberculosis;	chr2:61509517	chr2:61151433~61162105:-
BRCA	cis	rs2348418	0.832	rs11049512	ENSG00000247934.4	RP11-967K21.1	7.1	2.23e-12	5.18e-10	0.24	0.21	Lung function (FEV1);Lung function (FVC);	chr12:28295880	chr12:28163298~28190738:-
BRCA	cis	rs9880211	0.563	rs6792630	ENSG00000273486.1	RP11-731C17.2	7.1	2.23e-12	5.18e-10	0.28	0.21	Height;Body mass index;	chr3:136106059	chr3:136837338~136839021:-
BRCA	cis	rs1555322	0.53	rs2425053	ENSG00000261582.1	RP4-614O4.11	-7.1	2.23e-12	5.18e-10	-0.24	-0.21	Attention deficit hyperactivity disorder;	chr20:35294017	chr20:35267885~35280043:-
BRCA	cis	rs9291683	0.551	rs2240720	ENSG00000250413.1	RP11-448G15.1	-7.1	2.23e-12	5.19e-10	-0.28	-0.21	Bone mineral density;	chr4:10018856	chr4:10006482~10009725:+
BRCA	cis	rs1552244	0.882	rs13099136	ENSG00000180385.7	EMC3-AS1	7.1	2.23e-12	5.19e-10	0.26	0.21	Alzheimer's disease;	chr3:9989747	chr3:9986893~10006990:+
BRCA	cis	rs875971	0.545	rs73152714	ENSG00000224316.1	RP11-479O9.2	7.1	2.23e-12	5.19e-10	0.24	0.21	Aortic root size;	chr7:66534641	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.545	rs4718364	ENSG00000224316.1	RP11-479O9.2	7.1	2.23e-12	5.19e-10	0.24	0.21	Aortic root size;	chr7:66536353	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.545	rs801199	ENSG00000224316.1	RP11-479O9.2	-7.1	2.23e-12	5.19e-10	-0.24	-0.21	Aortic root size;	chr7:66560286	chr7:65773620~65802067:+
BRCA	cis	rs9309473	1	rs6710438	ENSG00000163016.8	ALMS1P	-7.1	2.23e-12	5.19e-10	-0.28	-0.21	Metabolite levels;	chr2:73592981	chr2:73644919~73685576:+
BRCA	cis	rs4845875	0.626	rs11121828	ENSG00000242349.4	NPPA-AS1	7.1	2.24e-12	5.19e-10	0.23	0.21	Midregional pro atrial natriuretic peptide levels;	chr1:11774397	chr1:11841017~11848079:+
BRCA	cis	rs9649213	0.574	rs6961790	ENSG00000272950.1	RP11-307C18.1	7.1	2.24e-12	5.19e-10	0.27	0.21	Prostate cancer (SNP x SNP interaction);	chr7:98378681	chr7:98322853~98323430:+
BRCA	cis	rs66887589	0.934	rs12648182	ENSG00000248280.1	RP11-33B1.2	-7.1	2.24e-12	5.19e-10	-0.2	-0.21	Diastolic blood pressure;	chr4:119582736	chr4:119440561~119450157:-
BRCA	cis	rs875971	0.545	rs1909508	ENSG00000236529.1	RP13-254B10.1	7.1	2.24e-12	5.2e-10	0.26	0.21	Aortic root size;	chr7:66301366	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.545	rs73148639	ENSG00000224316.1	RP11-479O9.2	7.1	2.24e-12	5.2e-10	0.24	0.21	Aortic root size;	chr7:66390342	chr7:65773620~65802067:+
BRCA	cis	rs17253792	0.822	rs78988988	ENSG00000186615.9	KTN1-AS1	-7.1	2.24e-12	5.2e-10	-0.44	-0.21	Putamen volume;	chr14:55685686	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs17253716	ENSG00000186615.9	KTN1-AS1	-7.1	2.24e-12	5.2e-10	-0.44	-0.21	Putamen volume;	chr14:55686943	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs17253723	ENSG00000186615.9	KTN1-AS1	-7.1	2.24e-12	5.2e-10	-0.44	-0.21	Putamen volume;	chr14:55687297	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs77415412	ENSG00000186615.9	KTN1-AS1	-7.1	2.24e-12	5.2e-10	-0.44	-0.21	Putamen volume;	chr14:55687428	chr14:55499278~55580110:-
BRCA	cis	rs6570726	0.935	rs366621	ENSG00000235652.6	RP11-545I5.3	7.1	2.25e-12	5.22e-10	0.21	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145540139	chr6:145799409~145886585:+
BRCA	cis	rs7809950	1	rs986994	ENSG00000238832.1	snoU109	-7.1	2.25e-12	5.23e-10	-0.29	-0.21	Coronary artery disease;	chr7:107463670	chr7:107603363~107603507:+
BRCA	cis	rs3733585	0.773	rs13107466	ENSG00000250413.1	RP11-448G15.1	-7.1	2.26e-12	5.24e-10	-0.28	-0.21	Cleft plate (environmental tobacco smoke interaction);	chr4:10017766	chr4:10006482~10009725:+
BRCA	cis	rs9291683	0.588	rs13133766	ENSG00000250413.1	RP11-448G15.1	-7.1	2.26e-12	5.24e-10	-0.28	-0.21	Bone mineral density;	chr4:10018108	chr4:10006482~10009725:+
BRCA	cis	rs61160187	0.582	rs1382917	ENSG00000215032.2	GNL3LP1	7.1	2.26e-12	5.24e-10	0.27	0.21	Educational attainment (years of education);Educational attainment (college completion);	chr5:60956668	chr5:60891935~60893577:-
BRCA	cis	rs7131987	0.65	rs11050187	ENSG00000257176.2	RP11-996F15.2	-7.1	2.26e-12	5.25e-10	-0.27	-0.21	QT interval;	chr12:29319943	chr12:29280418~29317848:-
BRCA	cis	rs9291683	0.588	rs3756238	ENSG00000250413.1	RP11-448G15.1	-7.1	2.27e-12	5.25e-10	-0.28	-0.21	Bone mineral density;	chr4:10011578	chr4:10006482~10009725:+
BRCA	cis	rs9291683	0.588	rs3756237	ENSG00000250413.1	RP11-448G15.1	-7.1	2.27e-12	5.25e-10	-0.28	-0.21	Bone mineral density;	chr4:10011754	chr4:10006482~10009725:+
BRCA	cis	rs9291683	0.588	rs3756236	ENSG00000250413.1	RP11-448G15.1	-7.1	2.27e-12	5.25e-10	-0.28	-0.21	Bone mineral density;	chr4:10011839	chr4:10006482~10009725:+
BRCA	cis	rs7829975	0.564	rs2976855	ENSG00000254153.1	CTA-398F10.2	7.1	2.27e-12	5.26e-10	0.26	0.21	Mood instability;	chr8:8444284	chr8:8456909~8461337:-
BRCA	cis	rs7809950	0.954	rs11977187	ENSG00000238832.1	snoU109	7.1	2.27e-12	5.27e-10	0.29	0.21	Coronary artery disease;	chr7:107569938	chr7:107603363~107603507:+
BRCA	cis	rs7665090	0.87	rs228615	ENSG00000246560.2	RP11-10L12.4	-7.1	2.27e-12	5.27e-10	-0.23	-0.21	Primary biliary cholangitis;	chr4:102658303	chr4:102828055~102844075:+
BRCA	cis	rs9807989	0.839	rs1362348	ENSG00000234389.1	AC007278.3	7.1	2.28e-12	5.28e-10	0.2	0.21	Asthma;	chr2:102368164	chr2:102438713~102440475:+
BRCA	cis	rs17301013	0.606	rs4650950	ENSG00000227373.4	RP11-160H22.5	7.1	2.28e-12	5.28e-10	0.31	0.21	Systemic lupus erythematosus;	chr1:174134264	chr1:174115300~174160004:-
BRCA	cis	rs6142102	0.847	rs4911413	ENSG00000275784.1	RP5-1125A11.6	-7.1	2.28e-12	5.28e-10	-0.25	-0.21	Skin pigmentation;	chr20:34133969	chr20:33989480~33991818:-
BRCA	cis	rs10861661	0.963	rs7977765	ENSG00000260329.1	RP11-412D9.4	-7.1	2.28e-12	5.29e-10	-0.28	-0.21	Triglyceride levels;	chr12:106811612	chr12:106954029~106955497:-
BRCA	cis	rs11976180	0.569	rs12703565	ENSG00000244479.5	OR2A1-AS1	7.1	2.28e-12	5.29e-10	0.38	0.21	Obesity-related traits;	chr7:144057308	chr7:144251264~144356181:-
BRCA	cis	rs9291683	0.517	rs11736479	ENSG00000250413.1	RP11-448G15.1	-7.1	2.28e-12	5.29e-10	-0.28	-0.21	Bone mineral density;	chr4:10015763	chr4:10006482~10009725:+
BRCA	cis	rs9291683	0.588	rs13113730	ENSG00000250413.1	RP11-448G15.1	-7.1	2.28e-12	5.29e-10	-0.28	-0.21	Bone mineral density;	chr4:10016004	chr4:10006482~10009725:+
BRCA	cis	rs9291683	0.588	rs6857693	ENSG00000250413.1	RP11-448G15.1	-7.1	2.28e-12	5.29e-10	-0.28	-0.21	Bone mineral density;	chr4:10016811	chr4:10006482~10009725:+
BRCA	cis	rs9291683	0.588	rs6844329	ENSG00000250413.1	RP11-448G15.1	-7.1	2.28e-12	5.29e-10	-0.28	-0.21	Bone mineral density;	chr4:10016920	chr4:10006482~10009725:+
BRCA	cis	rs9291683	0.588	rs3796829	ENSG00000250413.1	RP11-448G15.1	-7.1	2.28e-12	5.29e-10	-0.28	-0.21	Bone mineral density;	chr4:10017514	chr4:10006482~10009725:+
BRCA	cis	rs62103177	0.608	rs4442895	ENSG00000261126.6	RP11-795F19.1	-7.1	2.29e-12	5.3e-10	-0.26	-0.21	Opioid sensitivity;	chr18:80066399	chr18:80046900~80095482:+
BRCA	cis	rs10129255	0.833	rs61997797	ENSG00000211972.2	IGHV3-66	7.1	2.29e-12	5.31e-10	0.17	0.21	Kawasaki disease;	chr14:106815190	chr14:106675017~106675544:-
BRCA	cis	rs10129255	0.833	rs7156689	ENSG00000211972.2	IGHV3-66	7.1	2.29e-12	5.31e-10	0.17	0.21	Kawasaki disease;	chr14:106816039	chr14:106675017~106675544:-
BRCA	cis	rs61160187	0.582	rs12654306	ENSG00000215032.2	GNL3LP1	7.1	2.29e-12	5.32e-10	0.27	0.21	Educational attainment (years of education);Educational attainment (college completion);	chr5:60889029	chr5:60891935~60893577:-
BRCA	cis	rs681343	1	rs679574	ENSG00000232871.7	SEC1P	7.1	2.29e-12	5.32e-10	0.24	0.21	Primary sclerosing cholangitis;Childhood ear infection;Lung adenocarcinoma;	chr19:48702851	chr19:48638071~48682245:+
BRCA	cis	rs4072705	0.967	rs7020358	ENSG00000224020.1	MIR181A2HG	-7.1	2.3e-12	5.32e-10	-0.24	-0.21	Menarche (age at onset);	chr9:124720192	chr9:124658467~124698631:+
BRCA	cis	rs755249	0.567	rs61783376	ENSG00000228060.1	RP11-69E11.8	-7.1	2.3e-12	5.33e-10	-0.27	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39303328	chr1:39565160~39573203:+
BRCA	cis	rs755249	0.567	rs4660636	ENSG00000228060.1	RP11-69E11.8	-7.1	2.3e-12	5.33e-10	-0.27	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39304555	chr1:39565160~39573203:+
BRCA	cis	rs875971	0.545	rs10950036	ENSG00000224316.1	RP11-479O9.2	7.1	2.3e-12	5.33e-10	0.24	0.21	Aortic root size;	chr7:66353241	chr7:65773620~65802067:+
BRCA	cis	rs2243480	1	rs2533288	ENSG00000232546.1	RP11-458F8.1	-7.1	2.3e-12	5.34e-10	-0.29	-0.21	Diabetic kidney disease;	chr7:66591724	chr7:66848496~66858136:+
BRCA	cis	rs17826219	0.568	rs11658027	ENSG00000266490.1	CTD-2349P21.9	-7.1	2.3e-12	5.34e-10	-0.31	-0.21	Body mass index;	chr17:30767864	chr17:30792372~30792833:+
BRCA	cis	rs10861661	0.963	rs3782707	ENSG00000260329.1	RP11-412D9.4	-7.1	2.31e-12	5.35e-10	-0.28	-0.21	Triglyceride levels;	chr12:106791409	chr12:106954029~106955497:-
BRCA	cis	rs17711722	0.528	rs73138179	ENSG00000228409.4	CCT6P1	-7.1	2.31e-12	5.35e-10	-0.2	-0.21	Calcium levels;	chr7:65829495	chr7:65751142~65763354:+
BRCA	cis	rs6921919	0.609	rs9461455	ENSG00000204709.4	LINC01556	7.1	2.31e-12	5.35e-10	0.3	0.21	Autism spectrum disorder or schizophrenia;	chr6:28361954	chr6:28943877~28944537:+
BRCA	cis	rs10740039	0.842	rs1442541	ENSG00000254271.1	RP11-131N11.4	7.1	2.32e-12	5.36e-10	0.28	0.21	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60626285	chr10:60734342~60741828:+
BRCA	cis	rs73173548	0.502	rs71639110	ENSG00000247828.6	TMEM161B-AS1	7.1	2.32e-12	5.37e-10	0.29	0.21	Macular telangiectasia type 2;	chr5:88422222	chr5:88268895~88436685:+
BRCA	cis	rs79040073	0.563	rs17478618	ENSG00000259531.2	RP11-295H24.3	-7.1	2.32e-12	5.37e-10	-0.35	-0.21	Lung cancer in ever smokers;	chr15:49444621	chr15:49365124~49366685:-
BRCA	cis	rs17818399	0.597	rs12104572	ENSG00000279254.1	RP11-536C12.1	-7.1	2.32e-12	5.38e-10	-0.26	-0.21	Height;	chr2:46635327	chr2:46668870~46670778:+
BRCA	cis	rs6545883	0.965	rs766447	ENSG00000271889.1	RP11-493E12.1	7.1	2.32e-12	5.38e-10	0.27	0.21	Tuberculosis;	chr2:61508434	chr2:61151433~61162105:-
BRCA	cis	rs673078	0.66	rs11068917	ENSG00000275409.1	RP11-131L12.4	-7.1	2.33e-12	5.39e-10	-0.27	-0.21	Glucose homeostasis traits;	chr12:118353315	chr12:118430147~118430699:+
BRCA	cis	rs2524005	1	rs2524005	ENSG00000176998.4	HCG4	-7.1	2.33e-12	5.39e-10	-0.33	-0.21	Bipolar disorder and schizophrenia;	chr6:29931900	chr6:29791753~29792750:-
BRCA	cis	rs10510102	0.688	rs56094144	ENSG00000276742.1	RP11-500G22.4	7.1	2.33e-12	5.39e-10	0.36	0.21	Breast cancer;	chr10:121903941	chr10:121956782~121957098:+
BRCA	cis	rs860818	1	rs858291	ENSG00000226816.2	AC005082.12	7.1	2.33e-12	5.4e-10	0.5	0.21	Initial pursuit acceleration;	chr7:23207742	chr7:23206013~23208045:+
BRCA	cis	rs113835537	0.529	rs3179961	ENSG00000255517.5	CTD-3074O7.5	-7.1	2.34e-12	5.41e-10	-0.28	-0.21	Airway imaging phenotypes;	chr11:66476983	chr11:66473490~66480233:-
BRCA	cis	rs681343	1	rs516246	ENSG00000232871.7	SEC1P	7.1	2.34e-12	5.41e-10	0.24	0.21	Primary sclerosing cholangitis;Childhood ear infection;Lung adenocarcinoma;	chr19:48702915	chr19:48638071~48682245:+
BRCA	cis	rs74233809	1	rs12411886	ENSG00000213277.3	MARCKSL1P1	7.1	2.34e-12	5.42e-10	0.43	0.21	Birth weight;	chr10:102925542	chr10:103175554~103176094:+
BRCA	cis	rs17253792	0.822	rs75936910	ENSG00000186615.9	KTN1-AS1	-7.1	2.34e-12	5.42e-10	-0.44	-0.21	Putamen volume;	chr14:55682633	chr14:55499278~55580110:-
BRCA	cis	rs7615952	0.599	rs2333408	ENSG00000250012.1	RP11-124N2.1	-7.1	2.34e-12	5.42e-10	-0.28	-0.21	Blood pressure (smoking interaction);	chr3:126013255	chr3:126084220~126095349:+
BRCA	cis	rs9291683	0.609	rs12507050	ENSG00000250413.1	RP11-448G15.1	-7.1	2.34e-12	5.42e-10	-0.28	-0.21	Bone mineral density;	chr4:10005681	chr4:10006482~10009725:+
BRCA	cis	rs301901	1	rs292182	ENSG00000250155.1	CTD-2353F22.1	-7.1	2.35e-12	5.43e-10	-0.23	-0.21	Height;	chr5:36954710	chr5:36666214~36725195:-
BRCA	cis	rs10740039	1	rs10761541	ENSG00000254271.1	RP11-131N11.4	7.1	2.36e-12	5.46e-10	0.27	0.21	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60655383	chr10:60734342~60741828:+
BRCA	cis	rs442309	0.532	rs10995276	ENSG00000238280.1	RP11-436D10.3	7.1	2.36e-12	5.47e-10	0.3	0.21	Vogt-Koyanagi-Harada syndrome;	chr10:62694301	chr10:62793562~62805887:-
BRCA	cis	rs681343	1	rs681343	ENSG00000232871.7	SEC1P	7.1	2.36e-12	5.47e-10	0.24	0.21	Primary sclerosing cholangitis;Childhood ear infection;Lung adenocarcinoma;	chr19:48703205	chr19:48638071~48682245:+
BRCA	cis	rs858239	0.601	rs10239760	ENSG00000230042.1	AK3P3	-7.1	2.37e-12	5.48e-10	-0.25	-0.21	Cerebrospinal fluid biomarker levels;	chr7:23110331	chr7:23129178~23129841:+
BRCA	cis	rs10754283	0.967	rs12058749	ENSG00000231613.1	RP5-943J3.1	7.1	2.37e-12	5.49e-10	0.25	0.21	Amyotrophic lateral sclerosis (sporadic);	chr1:89640045	chr1:89788914~89790492:+
BRCA	cis	rs867371	0.762	rs1846910	ENSG00000255769.6	GOLGA2P10	-7.1	2.38e-12	5.5e-10	-0.25	-0.21	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82279439	chr15:82472993~82513950:-
BRCA	cis	rs7246657	0.943	rs10407084	ENSG00000276846.1	CTD-3220F14.3	7.1	2.38e-12	5.5e-10	0.3	0.21	Coronary artery calcification;	chr19:37416890	chr19:37314868~37315620:-
BRCA	cis	rs7246657	0.943	rs7252099	ENSG00000276846.1	CTD-3220F14.3	7.1	2.38e-12	5.5e-10	0.3	0.21	Coronary artery calcification;	chr19:37442878	chr19:37314868~37315620:-
BRCA	cis	rs7246657	0.943	rs7255972	ENSG00000276846.1	CTD-3220F14.3	7.1	2.38e-12	5.5e-10	0.3	0.21	Coronary artery calcification;	chr19:37442939	chr19:37314868~37315620:-
BRCA	cis	rs6840258	0.66	rs17012200	ENSG00000251411.1	RP11-397E7.4	7.1	2.38e-12	5.51e-10	0.31	0.21	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86963494	chr4:86913266~86914817:-
BRCA	cis	rs875971	0.545	rs6961853	ENSG00000224316.1	RP11-479O9.2	7.1	2.38e-12	5.51e-10	0.24	0.21	Aortic root size;	chr7:66537035	chr7:65773620~65802067:+
BRCA	cis	rs13068223	1	rs13068223	ENSG00000243926.1	TIPARP-AS1	7.1	2.38e-12	5.51e-10	0.22	0.21	Age-related hearing impairment (SNP x SNP interaction);	chr3:156753166	chr3:156671862~156674378:-
BRCA	cis	rs853679	1	rs10456362	ENSG00000220721.1	OR1F12	-7.1	2.39e-12	5.52e-10	-0.32	-0.21	Depression;	chr6:28254038	chr6:28073316~28074233:+
BRCA	cis	rs10754283	0.967	rs10922685	ENSG00000231613.1	RP5-943J3.1	7.09	2.39e-12	5.53e-10	0.24	0.21	Amyotrophic lateral sclerosis (sporadic);	chr1:89652761	chr1:89788914~89790492:+
BRCA	cis	rs113835537	0.529	rs75685325	ENSG00000255517.5	CTD-3074O7.5	-7.09	2.39e-12	5.53e-10	-0.3	-0.21	Airway imaging phenotypes;	chr11:66467771	chr11:66473490~66480233:-
BRCA	cis	rs237743	1	rs238200	ENSG00000222365.1	SNORD12B	-7.09	2.4e-12	5.55e-10	-0.27	-0.21	Height;	chr20:49283115	chr20:49280319~49280409:+
BRCA	cis	rs79040073	0.637	rs35692325	ENSG00000259531.2	RP11-295H24.3	7.09	2.41e-12	5.57e-10	0.36	0.21	Lung cancer in ever smokers;	chr15:49316062	chr15:49365124~49366685:-
BRCA	cis	rs2179367	0.553	rs7762222	ENSG00000231760.4	RP11-350J20.5	7.09	2.41e-12	5.58e-10	0.32	0.21	Dupuytren's disease;	chr6:149444846	chr6:149796151~149826294:-
BRCA	cis	rs7474896	0.526	rs1208633	ENSG00000226578.1	RP11-258F22.1	7.09	2.42e-12	5.58e-10	0.28	0.21	Obesity (extreme);	chr10:37867945	chr10:37775371~37784131:-
BRCA	cis	rs7474896	0.559	rs1779075	ENSG00000226578.1	RP11-258F22.1	7.09	2.42e-12	5.58e-10	0.28	0.21	Obesity (extreme);	chr10:37878602	chr10:37775371~37784131:-
BRCA	cis	rs875971	0.706	rs1643374	ENSG00000237310.1	GS1-124K5.4	7.09	2.42e-12	5.59e-10	0.22	0.21	Aortic root size;	chr7:66407695	chr7:66493706~66495474:+
BRCA	cis	rs2034650	0.506	rs1984793	ENSG00000223313.1	RNU6-516P	7.09	2.42e-12	5.6e-10	0.25	0.21	Interstitial lung disease;	chr15:40407172	chr15:40529570~40529673:+
BRCA	cis	rs74233809	1	rs12219304	ENSG00000213277.3	MARCKSL1P1	7.09	2.43e-12	5.61e-10	0.41	0.21	Birth weight;	chr10:103171827	chr10:103175554~103176094:+
BRCA	cis	rs6844153	0.938	rs12646473	ENSG00000240005.4	RP11-293A21.1	-7.09	2.43e-12	5.61e-10	-0.33	-0.21	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26873833	chr4:26859806~26860599:-
BRCA	cis	rs7474896	0.559	rs2753880	ENSG00000226578.1	RP11-258F22.1	7.09	2.43e-12	5.62e-10	0.28	0.21	Obesity (extreme);	chr10:37884410	chr10:37775371~37784131:-
BRCA	cis	rs812925	0.893	rs1186705	ENSG00000271889.1	RP11-493E12.1	7.09	2.43e-12	5.62e-10	0.27	0.21	Immature fraction of reticulocytes;	chr2:61446143	chr2:61151433~61162105:-
BRCA	cis	rs1020064	0.636	rs2679876	ENSG00000235319.1	AC012360.4	-7.09	2.43e-12	5.62e-10	-0.28	-0.21	AIDS;	chr2:105321650	chr2:105324210~105330529:+
BRCA	cis	rs6570726	0.846	rs973856	ENSG00000235652.6	RP11-545I5.3	-7.09	2.44e-12	5.63e-10	-0.21	-0.21	Lobe attachment (rater-scored or self-reported);	chr6:145460780	chr6:145799409~145886585:+
BRCA	cis	rs17253792	0.822	rs78143160	ENSG00000186615.9	KTN1-AS1	-7.09	2.44e-12	5.64e-10	-0.44	-0.21	Putamen volume;	chr14:55683379	chr14:55499278~55580110:-
BRCA	cis	rs6545883	0.868	rs6545887	ENSG00000271889.1	RP11-493E12.1	7.09	2.44e-12	5.64e-10	0.27	0.21	Tuberculosis;	chr2:61601683	chr2:61151433~61162105:-
BRCA	cis	rs71520386	0.607	rs4308627	ENSG00000228649.7	AC005682.5	-7.09	2.44e-12	5.64e-10	-0.21	-0.21	Fibrinogen levels;	chr7:22840285	chr7:22854178~22861579:+
BRCA	cis	rs875971	0.545	rs35459055	ENSG00000224316.1	RP11-479O9.2	7.09	2.44e-12	5.64e-10	0.24	0.21	Aortic root size;	chr7:66479399	chr7:65773620~65802067:+
BRCA	cis	rs6545883	0.931	rs778765	ENSG00000271889.1	RP11-493E12.1	7.09	2.44e-12	5.64e-10	0.28	0.21	Tuberculosis;	chr2:61559250	chr2:61151433~61162105:-
BRCA	cis	rs2836950	0.762	rs8134638	ENSG00000255568.3	BRWD1-AS2	-7.09	2.44e-12	5.65e-10	-0.21	-0.21	Menarche (age at onset);	chr21:39272244	chr21:39313935~39314962:+
BRCA	cis	rs2243480	1	rs78803505	ENSG00000273142.1	RP11-458F8.4	-7.09	2.44e-12	5.65e-10	-0.29	-0.21	Diabetic kidney disease;	chr7:65917585	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs34577383	ENSG00000273142.1	RP11-458F8.4	-7.09	2.44e-12	5.65e-10	-0.29	-0.21	Diabetic kidney disease;	chr7:65920739	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs55895244	ENSG00000273142.1	RP11-458F8.4	-7.09	2.44e-12	5.65e-10	-0.29	-0.21	Diabetic kidney disease;	chr7:65922691	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs7795242	ENSG00000273142.1	RP11-458F8.4	-7.09	2.44e-12	5.65e-10	-0.29	-0.21	Diabetic kidney disease;	chr7:65925107	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs2177703	ENSG00000273142.1	RP11-458F8.4	-7.09	2.44e-12	5.65e-10	-0.29	-0.21	Diabetic kidney disease;	chr7:65926730	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs56985706	ENSG00000273142.1	RP11-458F8.4	-7.09	2.44e-12	5.65e-10	-0.29	-0.21	Diabetic kidney disease;	chr7:65929575	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs60683927	ENSG00000273142.1	RP11-458F8.4	-7.09	2.44e-12	5.65e-10	-0.29	-0.21	Diabetic kidney disease;	chr7:65929781	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs58062456	ENSG00000273142.1	RP11-458F8.4	-7.09	2.44e-12	5.65e-10	-0.29	-0.21	Diabetic kidney disease;	chr7:65929865	chr7:66902857~66906297:+
BRCA	cis	rs4835473	0.863	rs11735239	ENSG00000251600.4	RP11-673E1.1	-7.09	2.45e-12	5.65e-10	-0.28	-0.21	Immature fraction of reticulocytes;	chr4:143689372	chr4:143912331~143982454:+
BRCA	cis	rs2243480	1	rs34529418	ENSG00000273142.1	RP11-458F8.4	-7.09	2.45e-12	5.65e-10	-0.29	-0.21	Diabetic kidney disease;	chr7:65938222	chr7:66902857~66906297:+
BRCA	cis	rs601338	1	rs601338	ENSG00000232871.7	SEC1P	7.09	2.45e-12	5.65e-10	0.24	0.21	Blood metabolite ratios;Number of common colds;Blood metabolite levels;	chr19:48703417	chr19:48638071~48682245:+
BRCA	cis	rs712022	0.534	rs4281481	ENSG00000246225.5	RP11-17A1.3	-7.09	2.45e-12	5.66e-10	-0.26	-0.21	Dialysis-related mortality;	chr11:22859013	chr11:22829380~22945393:+
BRCA	cis	rs919433	1	rs1429414	ENSG00000231621.1	AC013264.2	7.09	2.45e-12	5.66e-10	0.2	0.21	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197297706	chr2:197197991~197199273:+
BRCA	cis	rs1862618	0.853	rs252898	ENSG00000271828.1	CTD-2310F14.1	7.09	2.45e-12	5.66e-10	0.3	0.21	Initial pursuit acceleration;	chr5:56893104	chr5:56927874~56929573:+
BRCA	cis	rs1862618	0.802	rs194058	ENSG00000271828.1	CTD-2310F14.1	7.09	2.45e-12	5.66e-10	0.3	0.21	Initial pursuit acceleration;	chr5:56893150	chr5:56927874~56929573:+
BRCA	cis	rs10754283	0.901	rs10922683	ENSG00000231613.1	RP5-943J3.1	7.09	2.45e-12	5.67e-10	0.24	0.21	Amyotrophic lateral sclerosis (sporadic);	chr1:89650509	chr1:89788914~89790492:+
BRCA	cis	rs780096	0.546	rs2293572	ENSG00000234072.1	AC074117.10	7.09	2.46e-12	5.67e-10	0.21	0.21	Total body bone mineral density;	chr2:27505910	chr2:27356246~27367622:+
BRCA	cis	rs2976388	0.647	rs2585154	ENSG00000253741.1	CTD-2292P10.4	-7.09	2.46e-12	5.68e-10	-0.24	-0.21	Urinary tract infection frequency;	chr8:142702067	chr8:142702252~142726973:-
BRCA	cis	rs17264034	0.95	rs17328863	ENSG00000250786.1	SNHG18	-7.09	2.46e-12	5.69e-10	-0.34	-0.21	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9542919	chr5:9546200~9550609:+
BRCA	cis	rs957448	1	rs1992370	ENSG00000253175.1	RP11-267M23.6	7.09	2.46e-12	5.69e-10	0.28	0.21	Nonsyndromic cleft lip with cleft palate;	chr8:94546466	chr8:94565036~94565715:+
BRCA	cis	rs12025262	0.546	rs10754539	ENSG00000227671.4	RP11-488L18.4	-7.09	2.46e-12	5.69e-10	-0.15	-0.21	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr1:247202128	chr1:247189851~247210856:-
BRCA	cis	rs113835537	0.529	rs116867234	ENSG00000255517.5	CTD-3074O7.5	-7.09	2.47e-12	5.7e-10	-0.3	-0.21	Airway imaging phenotypes;	chr11:66441553	chr11:66473490~66480233:-
BRCA	cis	rs30380	1	rs246454	ENSG00000272109.1	CTD-2260A17.3	-7.09	2.47e-12	5.7e-10	-0.27	-0.21	Cerebrospinal fluid biomarker levels;	chr5:96787561	chr5:96804353~96806105:+
BRCA	cis	rs875971	0.545	rs67775320	ENSG00000236529.1	RP13-254B10.1	7.09	2.47e-12	5.71e-10	0.26	0.21	Aortic root size;	chr7:66193792	chr7:65840212~65840596:+
BRCA	cis	rs6142102	0.961	rs2268089	ENSG00000275784.1	RP5-1125A11.6	-7.09	2.47e-12	5.71e-10	-0.25	-0.21	Skin pigmentation;	chr20:34079492	chr20:33989480~33991818:-
BRCA	cis	rs7615952	0.641	rs6438951	ENSG00000250012.1	RP11-124N2.1	-7.09	2.48e-12	5.72e-10	-0.29	-0.21	Blood pressure (smoking interaction);	chr3:125978156	chr3:126084220~126095349:+
BRCA	cis	rs7474896	0.559	rs1208645	ENSG00000226578.1	RP11-258F22.1	7.09	2.48e-12	5.72e-10	0.28	0.21	Obesity (extreme);	chr10:37843159	chr10:37775371~37784131:-
BRCA	cis	rs4660261	0.526	rs2485997	ENSG00000237950.1	RP11-7O11.3	7.09	2.49e-12	5.74e-10	0.25	0.21	Intelligence (multi-trait analysis);	chr1:43880169	chr1:43944370~43946551:-
BRCA	cis	rs73186030	0.591	rs28630628	ENSG00000272758.4	RP11-299J3.8	7.09	2.49e-12	5.75e-10	0.28	0.21	Serum parathyroid hormone levels;	chr3:122386769	chr3:122416207~122443180:+
BRCA	cis	rs732716	0.819	rs12459919	ENSG00000267980.1	AC007292.6	-7.09	2.49e-12	5.75e-10	-0.29	-0.21	Mean corpuscular volume;	chr19:4434506	chr19:4363789~4364640:+
BRCA	cis	rs858239	0.738	rs13225593	ENSG00000230042.1	AK3P3	-7.09	2.49e-12	5.75e-10	-0.25	-0.21	Cerebrospinal fluid biomarker levels;	chr7:23220688	chr7:23129178~23129841:+
BRCA	cis	rs12291225	0.645	rs3763950	ENSG00000251991.1	RNU7-49P	7.09	2.5e-12	5.76e-10	0.25	0.21	Sense of smell;	chr11:14256503	chr11:14478892~14478953:+
BRCA	cis	rs1707322	0.721	rs6699418	ENSG00000281133.1	AL355480.3	-7.09	2.5e-12	5.76e-10	-0.27	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634509	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.721	rs4431884	ENSG00000281133.1	AL355480.3	-7.09	2.5e-12	5.76e-10	-0.27	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45635651	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.65	rs4660879	ENSG00000281133.1	AL355480.3	-7.09	2.5e-12	5.76e-10	-0.27	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45639729	chr1:45580892~45580996:-
BRCA	cis	rs7617773	0.817	rs6787500	ENSG00000228638.1	FCF1P2	-7.09	2.5e-12	5.77e-10	-0.21	-0.21	Coronary artery disease;	chr3:48257949	chr3:48290793~48291375:-
BRCA	cis	rs1020064	0.636	rs2679883	ENSG00000235319.1	AC012360.4	-7.09	2.5e-12	5.77e-10	-0.29	-0.21	AIDS;	chr2:105333211	chr2:105324210~105330529:+
BRCA	cis	rs858239	0.6	rs4409314	ENSG00000230042.1	AK3P3	-7.09	2.5e-12	5.77e-10	-0.24	-0.21	Cerebrospinal fluid biomarker levels;	chr7:23088333	chr7:23129178~23129841:+
BRCA	cis	rs17253792	0.822	rs77182097	ENSG00000186615.9	KTN1-AS1	-7.09	2.5e-12	5.78e-10	-0.44	-0.21	Putamen volume;	chr14:55669977	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs45501402	ENSG00000186615.9	KTN1-AS1	-7.09	2.5e-12	5.78e-10	-0.44	-0.21	Putamen volume;	chr14:55673397	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs76164147	ENSG00000186615.9	KTN1-AS1	-7.09	2.5e-12	5.78e-10	-0.44	-0.21	Putamen volume;	chr14:55673651	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs74935793	ENSG00000186615.9	KTN1-AS1	-7.09	2.5e-12	5.78e-10	-0.44	-0.21	Putamen volume;	chr14:55676559	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.749	rs45458197	ENSG00000186615.9	KTN1-AS1	-7.09	2.5e-12	5.78e-10	-0.44	-0.21	Putamen volume;	chr14:55678300	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs10483650	ENSG00000186615.9	KTN1-AS1	-7.09	2.5e-12	5.78e-10	-0.44	-0.21	Putamen volume;	chr14:55678594	chr14:55499278~55580110:-
BRCA	cis	rs9876781	1	rs1563736	ENSG00000244380.1	RP11-24C3.2	7.09	2.5e-12	5.78e-10	0.25	0.21	Longevity;	chr3:48395329	chr3:48440352~48446656:-
BRCA	cis	rs9307551	0.817	rs13127970	ENSG00000250334.4	LINC00989	-7.09	2.51e-12	5.78e-10	-0.3	-0.21	Refractive error;	chr4:79581236	chr4:79492416~79576460:+
BRCA	cis	rs9880211	0.563	rs6769762	ENSG00000273486.1	RP11-731C17.2	7.09	2.51e-12	5.78e-10	0.28	0.21	Height;Body mass index;	chr3:136189336	chr3:136837338~136839021:-
BRCA	cis	rs8062405	0.655	rs7184597	ENSG00000278665.1	RP11-666O2.4	-7.09	2.51e-12	5.79e-10	-0.25	-0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28910488	chr16:28599241~28601881:-
BRCA	cis	rs10029851	0.627	rs72893189	ENSG00000234492.4	RPL34-AS1	7.09	2.52e-12	5.81e-10	0.34	0.21	Amyotrophic lateral sclerosis (sporadic);	chr4:108635577	chr4:108538190~108620460:-
BRCA	cis	rs526231	0.543	rs62362884	ENSG00000175749.11	EIF3KP1	7.09	2.52e-12	5.81e-10	0.32	0.21	Primary biliary cholangitis;	chr5:103231754	chr5:103032376~103033031:+
BRCA	cis	rs2014572	1	rs3746231	ENSG00000268379.1	CTC-360J11.4	7.09	2.53e-12	5.84e-10	0.26	0.21	Hyperactive-impulsive symptoms;	chr19:57248689	chr19:57175233~57177921:+
BRCA	cis	rs10740039	0.842	rs7915540	ENSG00000254271.1	RP11-131N11.4	7.09	2.53e-12	5.84e-10	0.28	0.21	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60646538	chr10:60734342~60741828:+
BRCA	cis	rs516805	0.961	rs544099	ENSG00000279453.1	RP3-425C14.4	7.09	2.53e-12	5.84e-10	0.25	0.21	Lymphocyte counts;	chr6:122479837	chr6:122436789~122439223:-
BRCA	cis	rs9649213	0.593	rs6465682	ENSG00000272950.1	RP11-307C18.1	7.09	2.53e-12	5.85e-10	0.27	0.21	Prostate cancer (SNP x SNP interaction);	chr7:98387105	chr7:98322853~98323430:+
BRCA	cis	rs858239	0.601	rs28673077	ENSG00000230042.1	AK3P3	-7.09	2.54e-12	5.85e-10	-0.25	-0.21	Cerebrospinal fluid biomarker levels;	chr7:23211235	chr7:23129178~23129841:+
BRCA	cis	rs1020064	0.636	rs1529974	ENSG00000235319.1	AC012360.4	-7.09	2.54e-12	5.86e-10	-0.28	-0.21	AIDS;	chr2:105311539	chr2:105324210~105330529:+
BRCA	cis	rs8072100	0.79	rs7222225	ENSG00000228782.6	CTD-2026D20.3	-7.09	2.55e-12	5.87e-10	-0.24	-0.21	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47616131	chr17:47450568~47492492:-
BRCA	cis	rs237743	1	rs237711	ENSG00000222365.1	SNORD12B	-7.09	2.55e-12	5.87e-10	-0.27	-0.21	Height;	chr20:49310319	chr20:49280319~49280409:+
BRCA	cis	rs875971	0.706	rs1643374	ENSG00000236529.1	RP13-254B10.1	7.09	2.55e-12	5.88e-10	0.23	0.21	Aortic root size;	chr7:66407695	chr7:65840212~65840596:+
BRCA	cis	rs2880765	0.743	rs7168345	ENSG00000259295.5	CSPG4P12	-7.09	2.55e-12	5.88e-10	-0.26	-0.21	Coronary artery disease;	chr15:85470370	chr15:85191438~85213905:+
BRCA	cis	rs61160187	0.556	rs4647052	ENSG00000215032.2	GNL3LP1	7.09	2.55e-12	5.89e-10	0.27	0.21	Educational attainment (years of education);Educational attainment (college completion);	chr5:60939656	chr5:60891935~60893577:-
BRCA	cis	rs6740322	1	rs6756736	ENSG00000234936.1	AC010883.5	7.09	2.56e-12	5.89e-10	0.24	0.21	Coronary artery disease;	chr2:43331604	chr2:43229573~43233394:+
BRCA	cis	rs875971	1	rs9986696	ENSG00000232559.3	GS1-124K5.12	-7.08	2.56e-12	5.91e-10	-0.26	-0.21	Aortic root size;	chr7:66239589	chr7:66554588~66576923:-
BRCA	cis	rs9309711	0.961	rs11678655	ENSG00000225234.1	TRAPPC12-AS1	-7.08	2.57e-12	5.92e-10	-0.25	-0.21	Neurofibrillary tangles;	chr2:3472463	chr2:3481242~3482409:-
BRCA	cis	rs875971	0.545	rs10950027	ENSG00000236529.1	RP13-254B10.1	7.08	2.57e-12	5.92e-10	0.26	0.21	Aortic root size;	chr7:66169164	chr7:65840212~65840596:+
BRCA	cis	rs7617773	0.78	rs71323395	ENSG00000228638.1	FCF1P2	-7.08	2.57e-12	5.92e-10	-0.25	-0.21	Coronary artery disease;	chr3:48332587	chr3:48290793~48291375:-
BRCA	cis	rs7617773	0.743	rs71323397	ENSG00000228638.1	FCF1P2	-7.08	2.57e-12	5.92e-10	-0.25	-0.21	Coronary artery disease;	chr3:48333384	chr3:48290793~48291375:-
BRCA	cis	rs13068223	0.84	rs11709829	ENSG00000243926.1	TIPARP-AS1	7.08	2.57e-12	5.92e-10	0.22	0.21	Age-related hearing impairment (SNP x SNP interaction);	chr3:156716300	chr3:156671862~156674378:-
BRCA	cis	rs1555322	0.53	rs2275275	ENSG00000279253.1	RP4-614O4.13	-7.08	2.57e-12	5.93e-10	-0.28	-0.21	Attention deficit hyperactivity disorder;	chr20:35284508	chr20:35262727~35264187:-
BRCA	cis	rs6723162	1	rs6723162	ENSG00000237751.2	LINC01143	-7.08	2.58e-12	5.95e-10	-0.24	-0.21	Neurocognitive impairment in HIV-1 infection (dichotomous);	chr2:70875156	chr2:70887871~70889959:+
BRCA	cis	rs2243480	1	rs1546059	ENSG00000232546.1	RP11-458F8.1	7.08	2.58e-12	5.95e-10	0.28	0.21	Diabetic kidney disease;	chr7:66189722	chr7:66848496~66858136:+
BRCA	cis	rs2243480	1	rs2420170	ENSG00000232546.1	RP11-458F8.1	7.08	2.58e-12	5.95e-10	0.28	0.21	Diabetic kidney disease;	chr7:66191066	chr7:66848496~66858136:+
BRCA	cis	rs875971	0.545	rs313830	ENSG00000236529.1	RP13-254B10.1	-7.08	2.58e-12	5.95e-10	-0.27	-0.21	Aortic root size;	chr7:66086944	chr7:65840212~65840596:+
BRCA	cis	rs838147	0.537	rs632111	ENSG00000232871.7	SEC1P	7.08	2.58e-12	5.96e-10	0.23	0.21	Dietary macronutrient intake;	chr19:48705721	chr19:48638071~48682245:+
BRCA	cis	rs7586673	0.725	rs6757645	ENSG00000227403.1	AC009299.3	-7.08	2.59e-12	5.97e-10	-0.29	-0.21	Intelligence (multi-trait analysis);	chr2:161034871	chr2:161244739~161249050:+
BRCA	cis	rs4072705	1	rs10760371	ENSG00000224020.1	MIR181A2HG	-7.08	2.59e-12	5.97e-10	-0.23	-0.21	Menarche (age at onset);	chr9:124690698	chr9:124658467~124698631:+
BRCA	cis	rs3930017	1	rs3930017	ENSG00000242435.1	UPK3BP1	7.08	2.59e-12	5.98e-10	0.25	0.21	Body mass index;	chr7:77091265	chr7:77004662~77005774:+
BRCA	cis	rs9876781	1	rs11712561	ENSG00000244380.1	RP11-24C3.2	7.08	2.59e-12	5.98e-10	0.25	0.21	Longevity;	chr3:48393807	chr3:48440352~48446656:-
BRCA	cis	rs9876781	1	rs11130170	ENSG00000244380.1	RP11-24C3.2	7.08	2.59e-12	5.98e-10	0.25	0.21	Longevity;	chr3:48408490	chr3:48440352~48446656:-
BRCA	cis	rs11907546	1	rs11907546	ENSG00000275784.1	RP5-1125A11.6	-7.08	2.6e-12	6e-10	-0.25	-0.21	Cancer (pleiotropy);Cancer;	chr20:34131991	chr20:33989480~33991818:-
BRCA	cis	rs7247513	1	rs2042947	ENSG00000213290.4	PGK1P2	-7.08	2.6e-12	6e-10	-0.28	-0.21	Bipolar disorder;	chr19:12582289	chr19:12559571~12561105:+
BRCA	cis	rs17301013	0.606	rs727912	ENSG00000227373.4	RP11-160H22.5	7.08	2.61e-12	6e-10	0.31	0.21	Systemic lupus erythematosus;	chr1:174132729	chr1:174115300~174160004:-
BRCA	cis	rs6840360	0.642	rs7677131	ENSG00000270265.1	RP11-731D1.4	-7.08	2.61e-12	6.01e-10	-0.24	-0.21	Intelligence (multi-trait analysis);	chr4:151431863	chr4:151333775~151353224:-
BRCA	cis	rs61160187	0.582	rs34619	ENSG00000215032.2	GNL3LP1	7.08	2.61e-12	6.01e-10	0.27	0.21	Educational attainment (years of education);Educational attainment (college completion);	chr5:61169538	chr5:60891935~60893577:-
BRCA	cis	rs12291225	0.679	rs11023172	ENSG00000251991.1	RNU7-49P	7.08	2.61e-12	6.02e-10	0.25	0.21	Sense of smell;	chr11:14273821	chr11:14478892~14478953:+
BRCA	cis	rs12291225	0.679	rs4757245	ENSG00000251991.1	RNU7-49P	7.08	2.61e-12	6.02e-10	0.25	0.21	Sense of smell;	chr11:14276326	chr11:14478892~14478953:+
BRCA	cis	rs11096990	0.819	rs2711992	ENSG00000249207.1	RP11-360F5.1	7.08	2.61e-12	6.02e-10	0.25	0.21	Cognitive function;	chr4:39148651	chr4:39112677~39126818:-
BRCA	cis	rs17301013	0.606	rs4650951	ENSG00000227373.4	RP11-160H22.5	7.08	2.62e-12	6.03e-10	0.31	0.21	Systemic lupus erythematosus;	chr1:174134368	chr1:174115300~174160004:-
BRCA	cis	rs17301013	0.606	rs4652191	ENSG00000227373.4	RP11-160H22.5	7.08	2.62e-12	6.03e-10	0.31	0.21	Systemic lupus erythematosus;	chr1:174135473	chr1:174115300~174160004:-
BRCA	cis	rs11098499	0.954	rs6848389	ENSG00000249244.1	RP11-548H18.2	7.08	2.62e-12	6.03e-10	0.25	0.21	Corneal astigmatism;	chr4:119481467	chr4:119391831~119395335:-
BRCA	cis	rs1440410	0.835	rs7684481	ENSG00000250326.1	RP11-284M14.1	-7.08	2.62e-12	6.04e-10	-0.24	-0.21	Ischemic stroke;	chr4:143133252	chr4:142933195~143184861:-
BRCA	cis	rs1499614	1	rs1638731	ENSG00000230295.1	RP11-458F8.2	-7.08	2.62e-12	6.04e-10	-0.29	-0.21	Gout;	chr7:66679692	chr7:66880708~66882981:+
BRCA	cis	rs1499614	1	rs1882655	ENSG00000230295.1	RP11-458F8.2	7.08	2.62e-12	6.04e-10	0.29	0.21	Gout;	chr7:66682070	chr7:66880708~66882981:+
BRCA	cis	rs1499614	0.831	rs3800822	ENSG00000230295.1	RP11-458F8.2	7.08	2.62e-12	6.04e-10	0.29	0.21	Gout;	chr7:66682162	chr7:66880708~66882981:+
BRCA	cis	rs911555	0.755	rs1116095	ENSG00000244691.1	RPL10AP1	7.08	2.63e-12	6.05e-10	0.27	0.21	Intelligence (multi-trait analysis);	chr14:103465542	chr14:103412119~103412761:-
BRCA	cis	rs911555	0.755	rs8010247	ENSG00000244691.1	RPL10AP1	7.08	2.63e-12	6.05e-10	0.27	0.21	Intelligence (multi-trait analysis);	chr14:103467219	chr14:103412119~103412761:-
BRCA	cis	rs6545883	0.831	rs2592356	ENSG00000271889.1	RP11-493E12.1	7.08	2.63e-12	6.06e-10	0.28	0.21	Tuberculosis;	chr2:61583293	chr2:61151433~61162105:-
BRCA	cis	rs71520386	0.632	rs9691076	ENSG00000228649.7	AC005682.5	-7.08	2.63e-12	6.07e-10	-0.21	-0.21	Fibrinogen levels;	chr7:22829742	chr7:22854178~22861579:+
BRCA	cis	rs2243480	0.901	rs778730	ENSG00000232546.1	RP11-458F8.1	-7.08	2.63e-12	6.07e-10	-0.29	-0.21	Diabetic kidney disease;	chr7:66358338	chr7:66848496~66858136:+
BRCA	cis	rs61160187	0.582	rs12655603	ENSG00000215032.2	GNL3LP1	7.08	2.64e-12	6.07e-10	0.27	0.21	Educational attainment (years of education);Educational attainment (college completion);	chr5:60908769	chr5:60891935~60893577:-
BRCA	cis	rs79040073	0.637	rs73398272	ENSG00000259531.2	RP11-295H24.3	7.08	2.64e-12	6.08e-10	0.35	0.21	Lung cancer in ever smokers;	chr15:49416426	chr15:49365124~49366685:-
BRCA	cis	rs79040073	0.637	rs73396235	ENSG00000259531.2	RP11-295H24.3	7.08	2.65e-12	6.1e-10	0.36	0.21	Lung cancer in ever smokers;	chr15:49346956	chr15:49365124~49366685:-
BRCA	cis	rs6570726	0.935	rs380883	ENSG00000235652.6	RP11-545I5.3	7.08	2.65e-12	6.11e-10	0.21	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145501856	chr6:145799409~145886585:+
BRCA	cis	rs1075265	0.62	rs10192626	ENSG00000233266.1	HMGB1P31	7.08	2.66e-12	6.11e-10	0.26	0.21	Chronotype;Morning vs. evening chronotype;	chr2:53760885	chr2:54051334~54051760:+
BRCA	cis	rs9880211	0.613	rs1393786	ENSG00000273486.1	RP11-731C17.2	7.08	2.66e-12	6.12e-10	0.27	0.21	Height;Body mass index;	chr3:136135193	chr3:136837338~136839021:-
BRCA	cis	rs673078	0.607	rs17512644	ENSG00000275409.1	RP11-131L12.4	-7.08	2.66e-12	6.12e-10	-0.32	-0.21	Glucose homeostasis traits;	chr12:118359963	chr12:118430147~118430699:+
BRCA	cis	rs673078	0.607	rs17512652	ENSG00000275409.1	RP11-131L12.4	-7.08	2.66e-12	6.12e-10	-0.32	-0.21	Glucose homeostasis traits;	chr12:118361278	chr12:118430147~118430699:+
BRCA	cis	rs7617773	0.78	rs13082158	ENSG00000228638.1	FCF1P2	-7.08	2.67e-12	6.14e-10	-0.25	-0.21	Coronary artery disease;	chr3:48330980	chr3:48290793~48291375:-
BRCA	cis	rs7617773	0.78	rs11710257	ENSG00000228638.1	FCF1P2	-7.08	2.67e-12	6.14e-10	-0.25	-0.21	Coronary artery disease;	chr3:48331724	chr3:48290793~48291375:-
BRCA	cis	rs74233809	0.901	rs11191425	ENSG00000213277.3	MARCKSL1P1	7.08	2.67e-12	6.14e-10	0.39	0.21	Birth weight;	chr10:102866213	chr10:103175554~103176094:+
BRCA	cis	rs10754283	0.967	rs10737708	ENSG00000231613.1	RP5-943J3.1	7.08	2.67e-12	6.14e-10	0.24	0.21	Amyotrophic lateral sclerosis (sporadic);	chr1:89654245	chr1:89788914~89790492:+
BRCA	cis	rs7474896	0.583	rs10740950	ENSG00000226578.1	RP11-258F22.1	-7.08	2.67e-12	6.15e-10	-0.28	-0.21	Obesity (extreme);	chr10:37714568	chr10:37775371~37784131:-
BRCA	cis	rs237743	1	rs6648	ENSG00000222365.1	SNORD12B	-7.08	2.67e-12	6.15e-10	-0.27	-0.21	Height;	chr20:49278705	chr20:49280319~49280409:+
BRCA	cis	rs780096	0.526	rs704795	ENSG00000234072.1	AC074117.10	-7.08	2.67e-12	6.15e-10	-0.21	-0.21	Total body bone mineral density;	chr2:27493627	chr2:27356246~27367622:+
BRCA	cis	rs35851103	0.507	rs6601649	ENSG00000255046.1	RP11-297N6.4	7.08	2.68e-12	6.16e-10	0.26	0.21	Neuroticism;	chr8:11999808	chr8:11797928~11802568:-
BRCA	cis	rs858239	0.67	rs3807452	ENSG00000230042.1	AK3P3	7.08	2.68e-12	6.16e-10	0.25	0.21	Cerebrospinal fluid biomarker levels;	chr7:23122462	chr7:23129178~23129841:+
BRCA	cis	rs7727544	0.66	rs274563	ENSG00000233006.5	AC034220.3	-7.08	2.68e-12	6.17e-10	-0.16	-0.21	Blood metabolite levels;	chr5:132382167	chr5:132311285~132369916:-
BRCA	cis	rs7079041	1	rs7079041	ENSG00000273038.2	RP11-479G22.8	-7.08	2.68e-12	6.18e-10	-0.25	-0.21	Suicide in bipolar disorder;	chr10:32704340	chr10:32887255~32889311:-
BRCA	cis	rs3781264	0.595	rs11187853	ENSG00000273450.1	RP11-76P2.4	7.08	2.69e-12	6.2e-10	0.28	0.21	Esophageal cancer and gastric cancer;	chr10:94312471	chr10:94314907~94315327:-
BRCA	cis	rs858239	0.6	rs6461691	ENSG00000230042.1	AK3P3	-7.08	2.7e-12	6.2e-10	-0.24	-0.21	Cerebrospinal fluid biomarker levels;	chr7:23099726	chr7:23129178~23129841:+
BRCA	cis	rs875971	0.545	rs1547529	ENSG00000236529.1	RP13-254B10.1	7.08	2.7e-12	6.21e-10	0.26	0.21	Aortic root size;	chr7:66258859	chr7:65840212~65840596:+
BRCA	cis	rs73173548	0.502	rs71639111	ENSG00000247828.6	TMEM161B-AS1	7.08	2.7e-12	6.22e-10	0.29	0.21	Macular telangiectasia type 2;	chr5:88428788	chr5:88268895~88436685:+
BRCA	cis	rs1862618	0.754	rs252899	ENSG00000271828.1	CTD-2310F14.1	7.08	2.7e-12	6.22e-10	0.3	0.21	Initial pursuit acceleration;	chr5:56892742	chr5:56927874~56929573:+
BRCA	cis	rs8177876	0.822	rs10514514	ENSG00000261838.4	RP11-303E16.6	7.08	2.7e-12	6.22e-10	0.42	0.21	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081668	chr16:81069854~81076598:+
BRCA	cis	rs6840360	0.642	rs2709838	ENSG00000270265.1	RP11-731D1.4	-7.08	2.7e-12	6.22e-10	-0.24	-0.21	Intelligence (multi-trait analysis);	chr4:151450212	chr4:151333775~151353224:-
BRCA	cis	rs237743	1	rs237741	ENSG00000222365.1	SNORD12B	-7.08	2.71e-12	6.22e-10	-0.27	-0.21	Height;	chr20:49287143	chr20:49280319~49280409:+
BRCA	cis	rs237743	1	rs13038621	ENSG00000222365.1	SNORD12B	-7.08	2.71e-12	6.22e-10	-0.27	-0.21	Height;	chr20:49291523	chr20:49280319~49280409:+
BRCA	cis	rs9527	0.662	rs10883783	ENSG00000213061.2	PFN1P11	7.08	2.71e-12	6.24e-10	0.31	0.21	Arsenic metabolism;	chr10:102831395	chr10:102838011~102845473:-
BRCA	cis	rs2243480	1	rs6958289	ENSG00000230295.1	RP11-458F8.2	7.08	2.71e-12	6.24e-10	0.28	0.21	Diabetic kidney disease;	chr7:66192124	chr7:66880708~66882981:+
BRCA	cis	rs7927771	0.864	rs2293577	ENSG00000280615.1	Y_RNA	7.08	2.71e-12	6.24e-10	0.25	0.21	Subjective well-being;	chr11:47415651	chr11:47614898~47614994:-
BRCA	cis	rs61270009	0.955	rs780401	ENSG00000247828.6	TMEM161B-AS1	-7.08	2.72e-12	6.25e-10	-0.27	-0.21	Depressive symptoms;	chr5:88244393	chr5:88268895~88436685:+
BRCA	cis	rs3781264	0.595	rs11187901	ENSG00000273450.1	RP11-76P2.4	7.08	2.72e-12	6.25e-10	0.28	0.21	Esophageal cancer and gastric cancer;	chr10:94355251	chr10:94314907~94315327:-
BRCA	cis	rs9876781	1	rs2362450	ENSG00000244380.1	RP11-24C3.2	7.08	2.72e-12	6.26e-10	0.24	0.21	Longevity;	chr3:48419904	chr3:48440352~48446656:-
BRCA	cis	rs904251	1	rs12212090	ENSG00000204110.6	RP1-153P14.8	-7.08	2.73e-12	6.28e-10	-0.24	-0.21	Cognitive performance;	chr6:37464032	chr6:37507348~37535616:+
BRCA	cis	rs10483853	0.525	rs7158272	ENSG00000258695.2	RP3-414A15.2	7.08	2.73e-12	6.29e-10	0.34	0.21	Coronary artery calcification;	chr14:73476486	chr14:73522878~73530610:+
BRCA	cis	rs2976388	0.647	rs2164307	ENSG00000253741.1	CTD-2292P10.4	-7.08	2.73e-12	6.29e-10	-0.24	-0.21	Urinary tract infection frequency;	chr8:142707413	chr8:142702252~142726973:-
BRCA	cis	rs2976388	0.573	rs1529865	ENSG00000253741.1	CTD-2292P10.4	-7.08	2.73e-12	6.29e-10	-0.24	-0.21	Urinary tract infection frequency;	chr8:142707753	chr8:142702252~142726973:-
BRCA	cis	rs2976388	0.609	rs1560986	ENSG00000253741.1	CTD-2292P10.4	-7.08	2.73e-12	6.29e-10	-0.24	-0.21	Urinary tract infection frequency;	chr8:142708357	chr8:142702252~142726973:-
BRCA	cis	rs2439831	1	rs9920763	ENSG00000249839.1	AC011330.5	-7.08	2.74e-12	6.29e-10	-0.39	-0.21	Lung cancer in ever smokers;	chr15:43468310	chr15:43663654~43684339:-
BRCA	cis	rs7131987	0.65	rs3782509	ENSG00000257176.2	RP11-996F15.2	-7.07	2.75e-12	6.32e-10	-0.26	-0.21	QT interval;	chr12:29300845	chr12:29280418~29317848:-
BRCA	cis	rs6840360	0.642	rs2724574	ENSG00000270265.1	RP11-731D1.4	7.07	2.75e-12	6.32e-10	0.24	0.21	Intelligence (multi-trait analysis);	chr4:151460648	chr4:151333775~151353224:-
BRCA	cis	rs61160187	0.549	rs56031340	ENSG00000215032.2	GNL3LP1	7.07	2.75e-12	6.32e-10	0.27	0.21	Educational attainment (years of education);Educational attainment (college completion);	chr5:60958043	chr5:60891935~60893577:-
BRCA	cis	rs160451	0.933	rs2088198	ENSG00000251136.7	RP11-37B2.1	7.07	2.75e-12	6.33e-10	0.21	0.21	Leprosy;	chr8:89678693	chr8:89609409~89757727:-
BRCA	cis	rs10181042	0.528	rs2564118	ENSG00000271889.1	RP11-493E12.1	7.07	2.75e-12	6.33e-10	0.27	0.21	Crohn's disease;	chr2:61006154	chr2:61151433~61162105:-
BRCA	cis	rs3760982	1	rs11665924	ENSG00000267058.1	RP11-15A1.3	-7.07	2.76e-12	6.34e-10	-0.24	-0.21	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43782830	chr19:43891804~43901805:-
BRCA	cis	rs7246657	0.943	rs10420430	ENSG00000276846.1	CTD-3220F14.3	7.07	2.76e-12	6.34e-10	0.3	0.21	Coronary artery calcification;	chr19:37403292	chr19:37314868~37315620:-
BRCA	cis	rs237743	1	rs238198	ENSG00000222365.1	SNORD12B	-7.07	2.76e-12	6.35e-10	-0.27	-0.21	Height;	chr20:49282523	chr20:49280319~49280409:+
BRCA	cis	rs237743	1	rs3021	ENSG00000222365.1	SNORD12B	-7.07	2.77e-12	6.36e-10	-0.28	-0.21	Height;	chr20:49257468	chr20:49280319~49280409:+
BRCA	cis	rs3781264	0.761	rs11187894	ENSG00000273450.1	RP11-76P2.4	7.07	2.77e-12	6.37e-10	0.3	0.21	Esophageal cancer and gastric cancer;	chr10:94346268	chr10:94314907~94315327:-
BRCA	cis	rs9880211	0.898	rs1052620	ENSG00000273486.1	RP11-731C17.2	7.07	2.77e-12	6.37e-10	0.3	0.21	Height;Body mass index;	chr3:136855679	chr3:136837338~136839021:-
BRCA	cis	rs875971	0.545	rs6950988	ENSG00000224316.1	RP11-479O9.2	7.07	2.77e-12	6.37e-10	0.24	0.21	Aortic root size;	chr7:66511428	chr7:65773620~65802067:+
BRCA	cis	rs9287719	0.674	rs10929690	ENSG00000234818.1	AC092687.5	-7.07	2.78e-12	6.38e-10	-0.25	-0.21	Prostate cancer;	chr2:10665848	chr2:10589166~10604830:+
BRCA	cis	rs9880211	0.563	rs9881400	ENSG00000273486.1	RP11-731C17.2	7.07	2.78e-12	6.39e-10	0.28	0.21	Height;Body mass index;	chr3:136142824	chr3:136837338~136839021:-
BRCA	cis	rs34779708	0.931	rs7079498	ENSG00000271335.4	RP11-324I22.4	7.07	2.78e-12	6.39e-10	0.22	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35086416	chr10:35314552~35336401:-
BRCA	cis	rs61160187	0.582	rs7713481	ENSG00000215032.2	GNL3LP1	7.07	2.78e-12	6.39e-10	0.26	0.21	Educational attainment (years of education);Educational attainment (college completion);	chr5:61093038	chr5:60891935~60893577:-
BRCA	cis	rs2412819	0.571	rs28410121	ENSG00000205771.5	CATSPER2P1	7.07	2.79e-12	6.4e-10	0.3	0.21	Lung cancer;	chr15:43777831	chr15:43726918~43747094:-
BRCA	cis	rs867371	0.722	rs8033050	ENSG00000255769.6	GOLGA2P10	-7.07	2.8e-12	6.42e-10	-0.25	-0.21	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82269648	chr15:82472993~82513950:-
BRCA	cis	rs10510102	0.935	rs11200252	ENSG00000276742.1	RP11-500G22.4	7.07	2.81e-12	6.45e-10	0.36	0.21	Breast cancer;	chr10:121914728	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.935	rs12254184	ENSG00000276742.1	RP11-500G22.4	7.07	2.81e-12	6.45e-10	0.36	0.21	Breast cancer;	chr10:121914971	chr10:121956782~121957098:+
BRCA	cis	rs919433	0.963	rs4850428	ENSG00000231621.1	AC013264.2	7.07	2.81e-12	6.45e-10	0.21	0.21	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197305048	chr2:197197991~197199273:+
BRCA	cis	rs7617773	0.78	rs71323396	ENSG00000228638.1	FCF1P2	-7.07	2.81e-12	6.46e-10	-0.24	-0.21	Coronary artery disease;	chr3:48333244	chr3:48290793~48291375:-
BRCA	cis	rs61160187	0.582	rs62372103	ENSG00000215032.2	GNL3LP1	7.07	2.81e-12	6.46e-10	0.27	0.21	Educational attainment (years of education);Educational attainment (college completion);	chr5:60849621	chr5:60891935~60893577:-
BRCA	cis	rs7617773	0.743	rs4632568	ENSG00000228638.1	FCF1P2	-7.07	2.81e-12	6.46e-10	-0.24	-0.21	Coronary artery disease;	chr3:48326329	chr3:48290793~48291375:-
BRCA	cis	rs7246657	0.943	rs1015849	ENSG00000276846.1	CTD-3220F14.3	7.07	2.82e-12	6.47e-10	0.3	0.21	Coronary artery calcification;	chr19:37455278	chr19:37314868~37315620:-
BRCA	cis	rs3794924	1	rs35777565	ENSG00000266521.1	RP11-650P15.1	7.07	2.82e-12	6.48e-10	0.4	0.21	Survival in colon cancer;	chr18:31469409	chr18:31496645~31497195:-
BRCA	cis	rs17214007	0.735	rs8045778	ENSG00000263335.1	AF001548.5	7.07	2.83e-12	6.49e-10	0.3	0.21	Cognitive function;	chr16:15784395	chr16:15726674~15732993:+
BRCA	cis	rs9880211	0.752	rs9881831	ENSG00000273486.1	RP11-731C17.2	7.07	2.83e-12	6.49e-10	0.29	0.21	Height;Body mass index;	chr3:136670876	chr3:136837338~136839021:-
BRCA	cis	rs11098499	0.566	rs17051356	ENSG00000245958.5	RP11-33B1.1	-7.07	2.83e-12	6.49e-10	-0.22	-0.21	Corneal astigmatism;	chr4:119664153	chr4:119454791~119552025:+
BRCA	cis	rs61160187	0.582	rs4647150	ENSG00000215032.2	GNL3LP1	7.07	2.83e-12	6.5e-10	0.27	0.21	Educational attainment (years of education);Educational attainment (college completion);	chr5:60874778	chr5:60891935~60893577:-
BRCA	cis	rs875971	0.528	rs801213	ENSG00000224316.1	RP11-479O9.2	-7.07	2.84e-12	6.51e-10	-0.24	-0.21	Aortic root size;	chr7:66549931	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.545	rs801212	ENSG00000224316.1	RP11-479O9.2	-7.07	2.84e-12	6.51e-10	-0.24	-0.21	Aortic root size;	chr7:66550643	chr7:65773620~65802067:+
BRCA	cis	rs4835473	0.897	rs11728121	ENSG00000251600.4	RP11-673E1.1	7.07	2.84e-12	6.52e-10	0.27	0.21	Immature fraction of reticulocytes;	chr4:143707079	chr4:143912331~143982454:+
BRCA	cis	rs858239	0.601	rs6461702	ENSG00000230042.1	AK3P3	-7.07	2.84e-12	6.52e-10	-0.25	-0.21	Cerebrospinal fluid biomarker levels;	chr7:23209654	chr7:23129178~23129841:+
BRCA	cis	rs6840360	0.642	rs2724580	ENSG00000270265.1	RP11-731D1.4	-7.07	2.86e-12	6.57e-10	-0.24	-0.21	Intelligence (multi-trait analysis);	chr4:151451353	chr4:151333775~151353224:-
BRCA	cis	rs13126694	0.71	rs4574459	ENSG00000248429.4	RP11-597D13.9	7.07	2.87e-12	6.58e-10	0.19	0.21	Blood osmolality (transformed sodium);	chr4:157991482	chr4:158170752~158202877:+
BRCA	cis	rs7474896	0.559	rs1735629	ENSG00000226578.1	RP11-258F22.1	7.07	2.87e-12	6.58e-10	0.29	0.21	Obesity (extreme);	chr10:37889381	chr10:37775371~37784131:-
BRCA	cis	rs10740039	0.842	rs7080024	ENSG00000254271.1	RP11-131N11.4	-7.07	2.87e-12	6.58e-10	-0.28	-0.21	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60632033	chr10:60734342~60741828:+
BRCA	cis	rs73173548	0.502	rs10505857	ENSG00000247828.6	TMEM161B-AS1	7.07	2.87e-12	6.59e-10	0.29	0.21	Macular telangiectasia type 2;	chr5:88420376	chr5:88268895~88436685:+
BRCA	cis	rs801193	0.967	rs2420827	ENSG00000224316.1	RP11-479O9.2	-7.07	2.88e-12	6.61e-10	-0.21	-0.21	Aortic root size;	chr7:66682114	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.545	rs6460276	ENSG00000236529.1	RP13-254B10.1	7.07	2.89e-12	6.62e-10	0.26	0.21	Aortic root size;	chr7:66182290	chr7:65840212~65840596:+
BRCA	cis	rs10129255	0.509	rs756583	ENSG00000211970.3	IGHV4-61	-7.07	2.89e-12	6.63e-10	-0.14	-0.21	Kawasaki disease;	chr14:106680002	chr14:106639119~106639657:-
BRCA	cis	rs875971	0.66	rs2013222	ENSG00000224316.1	RP11-479O9.2	-7.07	2.89e-12	6.64e-10	-0.21	-0.21	Aortic root size;	chr7:66570949	chr7:65773620~65802067:+
BRCA	cis	rs7520050	0.751	rs2230657	ENSG00000280836.1	AL355480.1	7.07	2.9e-12	6.65e-10	0.25	0.21	Reticulocyte count;Red blood cell count;	chr1:45607817	chr1:45581219~45581321:-
BRCA	cis	rs911555	0.755	rs34411783	ENSG00000244691.1	RPL10AP1	7.07	2.9e-12	6.66e-10	0.27	0.21	Intelligence (multi-trait analysis);	chr14:103434302	chr14:103412119~103412761:-
BRCA	cis	rs7746199	0.673	rs35501037	ENSG00000220721.1	OR1F12	7.07	2.91e-12	6.66e-10	0.48	0.21	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27771787	chr6:28073316~28074233:+
BRCA	cis	rs7131987	0.565	rs766445	ENSG00000257176.2	RP11-996F15.2	7.07	2.91e-12	6.66e-10	0.25	0.21	QT interval;	chr12:29260560	chr12:29280418~29317848:-
BRCA	cis	rs7617773	0.778	rs11707997	ENSG00000228638.1	FCF1P2	-7.07	2.91e-12	6.67e-10	-0.25	-0.21	Coronary artery disease;	chr3:48336385	chr3:48290793~48291375:-
BRCA	cis	rs919433	0.963	rs10153881	ENSG00000231621.1	AC013264.2	7.07	2.92e-12	6.68e-10	0.21	0.21	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197306374	chr2:197197991~197199273:+
BRCA	cis	rs7617773	0.707	rs13061269	ENSG00000228638.1	FCF1P2	-7.07	2.92e-12	6.7e-10	-0.25	-0.21	Coronary artery disease;	chr3:48331853	chr3:48290793~48291375:-
BRCA	cis	rs2742234	0.911	rs3004214	ENSG00000273008.1	RP11-351D16.3	-7.07	2.92e-12	6.7e-10	-0.27	-0.21	Hirschsprung disease;	chr10:43136250	chr10:43136824~43138334:-
BRCA	cis	rs274567	0.501	rs272856	ENSG00000233006.5	AC034220.3	7.06	2.94e-12	6.73e-10	0.18	0.21	Blood metabolite levels;	chr5:132351388	chr5:132311285~132369916:-
BRCA	cis	rs6569038	0.631	rs2357030	ENSG00000253194.1	RP11-351A11.1	7.06	2.94e-12	6.73e-10	0.27	0.21	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr6:119065138	chr6:118934785~119031541:+
BRCA	cis	rs12291225	0.679	rs11369	ENSG00000251991.1	RNU7-49P	7.06	2.94e-12	6.74e-10	0.25	0.21	Sense of smell;	chr11:14266550	chr11:14478892~14478953:+
BRCA	cis	rs10740039	0.81	rs4440977	ENSG00000254271.1	RP11-131N11.4	7.06	2.95e-12	6.75e-10	0.29	0.21	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60618163	chr10:60734342~60741828:+
BRCA	cis	rs6921919	0.551	rs13201753	ENSG00000204709.4	LINC01556	7.06	2.95e-12	6.76e-10	0.3	0.21	Autism spectrum disorder or schizophrenia;	chr6:28363351	chr6:28943877~28944537:+
BRCA	cis	rs526231	0.543	rs246909	ENSG00000175749.11	EIF3KP1	7.06	2.95e-12	6.76e-10	0.32	0.21	Primary biliary cholangitis;	chr5:103227976	chr5:103032376~103033031:+
BRCA	cis	rs6479891	0.908	rs11817901	ENSG00000232075.1	MRPL35P2	7.06	2.96e-12	6.77e-10	0.41	0.21	Arthritis (juvenile idiopathic);	chr10:63580123	chr10:63634317~63634827:-
BRCA	cis	rs2236231	0.55	rs4902496	ENSG00000259502.1	RP11-643G16.3	-7.06	2.96e-12	6.78e-10	-0.3	-0.21	Plasma kynurenine levels in major depressive disorder;	chr14:67588896	chr14:67610986~67613864:+
BRCA	cis	rs4218	1	rs4218	ENSG00000277144.1	RP11-59H7.4	-7.06	2.96e-12	6.78e-10	-0.26	-0.21	Social communication problems;	chr15:59136459	chr15:59115547~59116089:-
BRCA	cis	rs79040073	0.637	rs75612464	ENSG00000259531.2	RP11-295H24.3	7.06	2.96e-12	6.78e-10	0.36	0.21	Lung cancer in ever smokers;	chr15:49270727	chr15:49365124~49366685:-
BRCA	cis	rs7085104	0.513	rs192569	ENSG00000236937.2	PTGES3P4	-7.06	2.97e-12	6.79e-10	-0.27	-0.21	Immature fraction of reticulocytes;Schizophrenia;	chr10:102818158	chr10:102845595~102845950:+
BRCA	cis	rs6840360	0.693	rs28622593	ENSG00000270265.1	RP11-731D1.4	-7.06	2.97e-12	6.79e-10	-0.24	-0.21	Intelligence (multi-trait analysis);	chr4:151452928	chr4:151333775~151353224:-
BRCA	cis	rs732716	0.785	rs55660045	ENSG00000267980.1	AC007292.6	-7.06	2.97e-12	6.81e-10	-0.28	-0.21	Mean corpuscular volume;	chr19:4425308	chr19:4363789~4364640:+
BRCA	cis	rs58873874	0.579	rs75099611	ENSG00000248544.2	CTB-47B11.3	7.06	2.97e-12	6.81e-10	0.44	0.21	Bipolar disorder (body mass index interaction);	chr5:157312920	chr5:157375741~157384950:-
BRCA	cis	rs10129255	0.784	rs7147210	ENSG00000211972.2	IGHV3-66	7.06	2.98e-12	6.82e-10	0.17	0.21	Kawasaki disease;	chr14:106705271	chr14:106675017~106675544:-
BRCA	cis	rs7617773	0.817	rs3731555	ENSG00000228638.1	FCF1P2	-7.06	2.98e-12	6.83e-10	-0.24	-0.21	Coronary artery disease;	chr3:48164612	chr3:48290793~48291375:-
BRCA	cis	rs1862618	0.853	rs252915	ENSG00000271828.1	CTD-2310F14.1	-7.06	2.98e-12	6.83e-10	-0.3	-0.21	Initial pursuit acceleration;	chr5:56825927	chr5:56927874~56929573:+
BRCA	cis	rs507080	0.501	rs626645	ENSG00000278376.1	RP11-158I9.8	-7.06	3e-12	6.86e-10	-0.2	-0.21	Serum metabolite levels;	chr11:118704471	chr11:118791254~118793137:+
BRCA	cis	rs9368481	0.569	rs6907403	ENSG00000241549.7	GUSBP2	7.06	3e-12	6.87e-10	0.24	0.21	Autism spectrum disorder or schizophrenia;	chr6:26909518	chr6:26871484~26956554:-
BRCA	cis	rs9368481	0.502	rs3933232	ENSG00000241549.7	GUSBP2	7.06	3e-12	6.87e-10	0.24	0.21	Autism spectrum disorder or schizophrenia;	chr6:26909667	chr6:26871484~26956554:-
BRCA	cis	rs7727544	0.684	rs2516788	ENSG00000233006.5	AC034220.3	-7.06	3.01e-12	6.89e-10	-0.16	-0.21	Blood metabolite levels;	chr5:132379873	chr5:132311285~132369916:-
BRCA	cis	rs250585	0.736	rs727238	ENSG00000260136.4	CTD-2270L9.4	-7.06	3.01e-12	6.89e-10	-0.22	-0.21	Egg allergy;	chr16:23509745	chr16:23452758~23457606:+
BRCA	cis	rs9876781	1	rs2045554	ENSG00000244380.1	RP11-24C3.2	-7.06	3.01e-12	6.89e-10	-0.24	-0.21	Longevity;	chr3:48453142	chr3:48440352~48446656:-
BRCA	cis	rs10206020	0.921	rs11884956	ENSG00000231482.2	AC141930.2	-7.06	3.01e-12	6.9e-10	-0.28	-0.21	IgG glycosylation;	chr2:1562654	chr2:1572554~1580311:-
BRCA	cis	rs9880211	0.8	rs115050567	ENSG00000273486.1	RP11-731C17.2	7.06	3.01e-12	6.9e-10	0.29	0.21	Height;Body mass index;	chr3:136796817	chr3:136837338~136839021:-
BRCA	cis	rs9880211	0.8	rs9858560	ENSG00000273486.1	RP11-731C17.2	7.06	3.01e-12	6.9e-10	0.29	0.21	Height;Body mass index;	chr3:136798312	chr3:136837338~136839021:-
BRCA	cis	rs7617773	0.778	rs11715776	ENSG00000228638.1	FCF1P2	-7.06	3.02e-12	6.91e-10	-0.25	-0.21	Coronary artery disease;	chr3:48336121	chr3:48290793~48291375:-
BRCA	cis	rs10510102	0.935	rs12245528	ENSG00000276742.1	RP11-500G22.4	-7.06	3.02e-12	6.91e-10	-0.36	-0.21	Breast cancer;	chr10:121881006	chr10:121956782~121957098:+
BRCA	cis	rs2274273	0.588	rs17675223	ENSG00000258413.1	RP11-665C16.6	-7.06	3.02e-12	6.92e-10	-0.29	-0.21	Protein biomarker;	chr14:55395518	chr14:55262767~55272075:-
BRCA	cis	rs1555322	0.505	rs591590	ENSG00000261582.1	RP4-614O4.11	7.06	3.03e-12	6.92e-10	0.24	0.21	Attention deficit hyperactivity disorder;	chr20:35278225	chr20:35267885~35280043:-
BRCA	cis	rs7246657	0.823	rs4802236	ENSG00000276846.1	CTD-3220F14.3	7.06	3.03e-12	6.93e-10	0.3	0.21	Coronary artery calcification;	chr19:37428344	chr19:37314868~37315620:-
BRCA	cis	rs6921919	0.583	rs11755942	ENSG00000204709.4	LINC01556	7.06	3.03e-12	6.93e-10	0.29	0.21	Autism spectrum disorder or schizophrenia;	chr6:28401760	chr6:28943877~28944537:+
BRCA	cis	rs875971	0.545	rs7787063	ENSG00000236529.1	RP13-254B10.1	7.06	3.03e-12	6.94e-10	0.26	0.21	Aortic root size;	chr7:66164012	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.545	rs12673308	ENSG00000236529.1	RP13-254B10.1	7.06	3.03e-12	6.94e-10	0.26	0.21	Aortic root size;	chr7:66166374	chr7:65840212~65840596:+
BRCA	cis	rs113835537	0.529	rs17580784	ENSG00000255517.5	CTD-3074O7.5	-7.06	3.03e-12	6.94e-10	-0.3	-0.21	Airway imaging phenotypes;	chr11:66447388	chr11:66473490~66480233:-
BRCA	cis	rs17301013	0.606	rs6694208	ENSG00000227373.4	RP11-160H22.5	7.06	3.04e-12	6.96e-10	0.31	0.21	Systemic lupus erythematosus;	chr1:174127631	chr1:174115300~174160004:-
BRCA	cis	rs12664251	0.666	rs1889561	ENSG00000253194.1	RP11-351A11.1	-7.06	3.04e-12	6.96e-10	-0.26	-0.21	Schizophrenia;	chr6:119014700	chr6:118934785~119031541:+
BRCA	cis	rs1864400	0.69	rs2565200	ENSG00000273008.1	RP11-351D16.3	-7.06	3.05e-12	6.97e-10	-0.27	-0.21	Hirschsprung disease;	chr10:43127485	chr10:43136824~43138334:-
BRCA	cis	rs875971	0.545	rs73136346	ENSG00000236529.1	RP13-254B10.1	-7.06	3.05e-12	6.98e-10	-0.27	-0.21	Aortic root size;	chr7:66101095	chr7:65840212~65840596:+
BRCA	cis	rs897984	0.806	rs8050588	ENSG00000260911.2	RP11-196G11.2	7.06	3.05e-12	6.98e-10	0.2	0.21	Dementia with Lewy bodies;	chr16:30926478	chr16:31043150~31049868:+
BRCA	cis	rs7617773	0.78	rs7645425	ENSG00000228638.1	FCF1P2	-7.06	3.06e-12	7e-10	-0.24	-0.21	Coronary artery disease;	chr3:48320879	chr3:48290793~48291375:-
BRCA	cis	rs7617773	0.743	rs11716371	ENSG00000228638.1	FCF1P2	-7.06	3.06e-12	7e-10	-0.24	-0.21	Coronary artery disease;	chr3:48321260	chr3:48290793~48291375:-
BRCA	cis	rs7617773	0.78	rs6793223	ENSG00000228638.1	FCF1P2	-7.06	3.06e-12	7e-10	-0.24	-0.21	Coronary artery disease;	chr3:48322611	chr3:48290793~48291375:-
BRCA	cis	rs7617773	0.78	rs11714944	ENSG00000228638.1	FCF1P2	-7.06	3.06e-12	7e-10	-0.24	-0.21	Coronary artery disease;	chr3:48325481	chr3:48290793~48291375:-
BRCA	cis	rs7617773	0.78	rs7653336	ENSG00000228638.1	FCF1P2	-7.06	3.06e-12	7e-10	-0.24	-0.21	Coronary artery disease;	chr3:48327974	chr3:48290793~48291375:-
BRCA	cis	rs7569084	0.663	rs6546150	ENSG00000204929.10	AC074391.1	-7.06	3.07e-12	7.03e-10	-0.28	-0.21	Sum eosinophil basophil counts;	chr2:65415066	chr2:65436711~66084639:+
BRCA	cis	rs17711722	0.523	rs313812	ENSG00000228409.4	CCT6P1	7.06	3.08e-12	7.04e-10	0.19	0.21	Calcium levels;	chr7:66040056	chr7:65751142~65763354:+
BRCA	cis	rs2638953	0.85	rs11049402	ENSG00000278733.1	RP11-425D17.1	-7.06	3.09e-12	7.06e-10	-0.27	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28175974	chr12:28185625~28186190:-
BRCA	cis	rs9549367	0.826	rs2302755	ENSG00000269125.1	RP11-98F14.11	-7.06	3.09e-12	7.06e-10	-0.28	-0.21	Platelet distribution width;	chr13:113244104	chr13:113165002~113165183:-
BRCA	cis	rs10050311	0.858	rs1985944	ENSG00000251411.1	RP11-397E7.4	-7.06	3.09e-12	7.06e-10	-0.31	-0.21	Insulin-related traits;	chr4:86898130	chr4:86913266~86914817:-
BRCA	cis	rs755249	0.567	rs66531516	ENSG00000228060.1	RP11-69E11.8	-7.06	3.1e-12	7.08e-10	-0.26	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39163390	chr1:39565160~39573203:+
BRCA	cis	rs7309	0.622	rs4664396	ENSG00000235724.7	AC009299.2	7.06	3.1e-12	7.08e-10	0.25	0.21	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161045139	chr2:161222785~161308303:-
BRCA	cis	rs801193	1	rs3778909	ENSG00000236529.1	RP13-254B10.1	7.06	3.1e-12	7.08e-10	0.23	0.21	Aortic root size;	chr7:66790659	chr7:65840212~65840596:+
BRCA	cis	rs237743	1	rs237743	ENSG00000222365.1	SNORD12B	7.06	3.1e-12	7.09e-10	0.27	0.21	Height;	chr20:49286482	chr20:49280319~49280409:+
BRCA	cis	rs858239	0.601	rs12539331	ENSG00000230042.1	AK3P3	-7.06	3.1e-12	7.09e-10	-0.25	-0.21	Cerebrospinal fluid biomarker levels;	chr7:23111711	chr7:23129178~23129841:+
BRCA	cis	rs6840360	0.642	rs7698816	ENSG00000270265.1	RP11-731D1.4	-7.06	3.1e-12	7.1e-10	-0.24	-0.21	Intelligence (multi-trait analysis);	chr4:151431820	chr4:151333775~151353224:-
BRCA	cis	rs911555	0.723	rs12436956	ENSG00000244691.1	RPL10AP1	7.06	3.11e-12	7.1e-10	0.28	0.21	Intelligence (multi-trait analysis);	chr14:103386270	chr14:103412119~103412761:-
BRCA	cis	rs3781264	0.848	rs11187850	ENSG00000273450.1	RP11-76P2.4	7.06	3.12e-12	7.12e-10	0.28	0.21	Esophageal cancer and gastric cancer;	chr10:94308723	chr10:94314907~94315327:-
BRCA	cis	rs66887589	0.616	rs11098498	ENSG00000248280.1	RP11-33B1.2	7.06	3.12e-12	7.13e-10	0.2	0.21	Diastolic blood pressure;	chr4:119265964	chr4:119440561~119450157:-
BRCA	cis	rs7727544	0.684	rs611084	ENSG00000233006.5	AC034220.3	-7.06	3.12e-12	7.14e-10	-0.16	-0.21	Blood metabolite levels;	chr5:132374047	chr5:132311285~132369916:-
BRCA	cis	rs10754283	0.934	rs10754284	ENSG00000231613.1	RP5-943J3.1	7.06	3.13e-12	7.14e-10	0.24	0.21	Amyotrophic lateral sclerosis (sporadic);	chr1:89648143	chr1:89788914~89790492:+
BRCA	cis	rs10754283	0.967	rs10801759	ENSG00000231613.1	RP5-943J3.1	7.06	3.13e-12	7.14e-10	0.24	0.21	Amyotrophic lateral sclerosis (sporadic);	chr1:89648186	chr1:89788914~89790492:+
BRCA	cis	rs10754283	0.967	rs10801760	ENSG00000231613.1	RP5-943J3.1	7.06	3.13e-12	7.14e-10	0.24	0.21	Amyotrophic lateral sclerosis (sporadic);	chr1:89648265	chr1:89788914~89790492:+
BRCA	cis	rs2243480	0.901	rs2456483	ENSG00000273142.1	RP11-458F8.4	-7.06	3.13e-12	7.15e-10	-0.29	-0.21	Diabetic kidney disease;	chr7:65996588	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs1701750	ENSG00000273142.1	RP11-458F8.4	-7.06	3.13e-12	7.15e-10	-0.29	-0.21	Diabetic kidney disease;	chr7:66002158	chr7:66902857~66906297:+
BRCA	cis	rs7617773	0.747	rs34076262	ENSG00000228638.1	FCF1P2	-7.06	3.14e-12	7.17e-10	-0.24	-0.21	Coronary artery disease;	chr3:48328926	chr3:48290793~48291375:-
BRCA	cis	rs681343	1	rs492602	ENSG00000232871.7	SEC1P	7.05	3.14e-12	7.18e-10	0.24	0.21	Primary sclerosing cholangitis;Childhood ear infection;Lung adenocarcinoma;	chr19:48703160	chr19:48638071~48682245:+
BRCA	cis	rs10754283	0.901	rs10922684	ENSG00000231613.1	RP5-943J3.1	7.05	3.15e-12	7.19e-10	0.24	0.21	Amyotrophic lateral sclerosis (sporadic);	chr1:89652375	chr1:89788914~89790492:+
BRCA	cis	rs875971	0.545	rs1796217	ENSG00000224316.1	RP11-479O9.2	-7.05	3.15e-12	7.19e-10	-0.24	-0.21	Aortic root size;	chr7:66620931	chr7:65773620~65802067:+
BRCA	cis	rs1552244	0.51	rs13075308	ENSG00000180385.7	EMC3-AS1	7.05	3.15e-12	7.2e-10	0.26	0.21	Alzheimer's disease;	chr3:9993241	chr3:9986893~10006990:+
BRCA	cis	rs1552244	0.626	rs2886396	ENSG00000180385.7	EMC3-AS1	7.05	3.15e-12	7.2e-10	0.26	0.21	Alzheimer's disease;	chr3:9995986	chr3:9986893~10006990:+
BRCA	cis	rs1552244	0.882	rs13088350	ENSG00000180385.7	EMC3-AS1	7.05	3.15e-12	7.2e-10	0.26	0.21	Alzheimer's disease;	chr3:10002942	chr3:9986893~10006990:+
BRCA	cis	rs2115630	0.645	rs1107179	ENSG00000229212.6	RP11-561C5.4	-7.05	3.17e-12	7.24e-10	-0.24	-0.21	P wave terminal force;	chr15:84655131	chr15:85205440~85234795:-
BRCA	cis	rs7617773	0.78	rs4541431	ENSG00000228638.1	FCF1P2	-7.05	3.18e-12	7.25e-10	-0.24	-0.21	Coronary artery disease;	chr3:48323728	chr3:48290793~48291375:-
BRCA	cis	rs7617773	0.743	rs13071960	ENSG00000228638.1	FCF1P2	-7.05	3.18e-12	7.25e-10	-0.24	-0.21	Coronary artery disease;	chr3:48326047	chr3:48290793~48291375:-
BRCA	cis	rs7617773	0.78	rs11130164	ENSG00000228638.1	FCF1P2	-7.05	3.18e-12	7.25e-10	-0.24	-0.21	Coronary artery disease;	chr3:48327544	chr3:48290793~48291375:-
BRCA	cis	rs442309	0.553	rs7088592	ENSG00000238280.1	RP11-436D10.3	-7.05	3.18e-12	7.25e-10	-0.3	-0.21	Vogt-Koyanagi-Harada syndrome;	chr10:62721530	chr10:62793562~62805887:-
BRCA	cis	rs10206020	0.921	rs10177509	ENSG00000231482.2	AC141930.2	-7.05	3.18e-12	7.25e-10	-0.28	-0.21	IgG glycosylation;	chr2:1564764	chr2:1572554~1580311:-
BRCA	cis	rs7674212	0.531	rs4699048	ENSG00000251288.2	RP11-10L12.2	-7.05	3.19e-12	7.27e-10	-0.26	-0.21	Type 2 diabetes;	chr4:103005570	chr4:102751401~102752641:+
BRCA	cis	rs2742234	0.91	rs2505511	ENSG00000273008.1	RP11-351D16.3	-7.05	3.19e-12	7.27e-10	-0.25	-0.21	Hirschsprung disease;	chr10:43145581	chr10:43136824~43138334:-
BRCA	cis	rs10740039	0.734	rs10821815	ENSG00000254271.1	RP11-131N11.4	7.05	3.19e-12	7.28e-10	0.28	0.21	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60644843	chr10:60734342~60741828:+
BRCA	cis	rs9880211	0.8	rs9865995	ENSG00000273486.1	RP11-731C17.2	7.05	3.19e-12	7.28e-10	0.29	0.21	Height;Body mass index;	chr3:136794508	chr3:136837338~136839021:-
BRCA	cis	rs9880211	0.8	rs9871184	ENSG00000273486.1	RP11-731C17.2	7.05	3.19e-12	7.28e-10	0.29	0.21	Height;Body mass index;	chr3:136795468	chr3:136837338~136839021:-
BRCA	cis	rs6940638	0.513	rs4424065	ENSG00000241549.7	GUSBP2	-7.05	3.2e-12	7.3e-10	-0.23	-0.21	Intelligence (multi-trait analysis);	chr6:27068677	chr6:26871484~26956554:-
BRCA	cis	rs7428	0.545	rs2366404	ENSG00000246575.2	AC093162.5	7.05	3.2e-12	7.31e-10	0.22	0.21	Ear protrusion;	chr2:85324656	chr2:85315041~85316529:+
BRCA	cis	rs6921919	0.583	rs9461459	ENSG00000204709.4	LINC01556	7.05	3.21e-12	7.32e-10	0.29	0.21	Autism spectrum disorder or schizophrenia;	chr6:28394139	chr6:28943877~28944537:+
BRCA	cis	rs6921919	0.583	rs28360638	ENSG00000204709.4	LINC01556	7.05	3.21e-12	7.32e-10	0.29	0.21	Autism spectrum disorder or schizophrenia;	chr6:28394552	chr6:28943877~28944537:+
BRCA	cis	rs6921919	0.583	rs9468368	ENSG00000204709.4	LINC01556	7.05	3.21e-12	7.32e-10	0.29	0.21	Autism spectrum disorder or schizophrenia;	chr6:28397172	chr6:28943877~28944537:+
BRCA	cis	rs911555	0.723	rs4906324	ENSG00000244691.1	RPL10AP1	7.05	3.22e-12	7.34e-10	0.27	0.21	Intelligence (multi-trait analysis);	chr14:103456762	chr14:103412119~103412761:-
BRCA	cis	rs911555	0.723	rs2273701	ENSG00000244691.1	RPL10AP1	7.05	3.22e-12	7.34e-10	0.27	0.21	Intelligence (multi-trait analysis);	chr14:103456888	chr14:103412119~103412761:-
BRCA	cis	rs73173548	0.502	rs13180798	ENSG00000247828.6	TMEM161B-AS1	7.05	3.23e-12	7.36e-10	0.29	0.21	Macular telangiectasia type 2;	chr5:88425633	chr5:88268895~88436685:+
BRCA	cis	rs17772222	0.876	rs12587598	ENSG00000258983.2	RP11-507K2.2	7.05	3.23e-12	7.36e-10	0.23	0.21	Coronary artery calcification;	chr14:88729474	chr14:88499334~88515502:+
BRCA	cis	rs11098499	0.954	rs1546505	ENSG00000249244.1	RP11-548H18.2	7.05	3.25e-12	7.4e-10	0.25	0.21	Corneal astigmatism;	chr4:119320069	chr4:119391831~119395335:-
BRCA	cis	rs875971	0.862	rs1983372	ENSG00000232559.3	GS1-124K5.12	-7.05	3.25e-12	7.4e-10	-0.25	-0.21	Aortic root size;	chr7:66146364	chr7:66554588~66576923:-
BRCA	cis	rs11098499	0.954	rs6822679	ENSG00000249244.1	RP11-548H18.2	7.05	3.25e-12	7.41e-10	0.25	0.21	Corneal astigmatism;	chr4:119481547	chr4:119391831~119395335:-
BRCA	cis	rs7617773	0.817	rs6791930	ENSG00000228638.1	FCF1P2	-7.05	3.26e-12	7.43e-10	-0.23	-0.21	Coronary artery disease;	chr3:48288410	chr3:48290793~48291375:-
BRCA	cis	rs7617773	0.817	rs6794644	ENSG00000228638.1	FCF1P2	-7.05	3.26e-12	7.43e-10	-0.23	-0.21	Coronary artery disease;	chr3:48288547	chr3:48290793~48291375:-
BRCA	cis	rs11098499	0.954	rs12508504	ENSG00000249244.1	RP11-548H18.2	7.05	3.27e-12	7.44e-10	0.26	0.21	Corneal astigmatism;	chr4:119489452	chr4:119391831~119395335:-
BRCA	cis	rs2033711	0.783	rs11671113	ENSG00000269473.1	CTD-2619J13.19	7.05	3.27e-12	7.44e-10	0.26	0.21	Uric acid clearance;	chr19:58446720	chr19:58440448~58445849:+
BRCA	cis	rs10466239	0.73	rs2460535	ENSG00000230555.2	RP11-517P14.2	7.05	3.27e-12	7.46e-10	0.32	0.21	Telomere length;	chr10:43325932	chr10:43420738~43422100:+
BRCA	cis	rs875971	0.964	rs778721	ENSG00000232559.3	GS1-124K5.12	7.05	3.29e-12	7.5e-10	0.25	0.21	Aortic root size;	chr7:66380410	chr7:66554588~66576923:-
BRCA	cis	rs73173548	0.502	rs13163266	ENSG00000247828.6	TMEM161B-AS1	7.05	3.29e-12	7.5e-10	0.29	0.21	Macular telangiectasia type 2;	chr5:88425703	chr5:88268895~88436685:+
BRCA	cis	rs17711722	0.727	rs1880555	ENSG00000237310.1	GS1-124K5.4	7.05	3.3e-12	7.52e-10	0.22	0.21	Calcium levels;	chr7:65967580	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.571	rs160647	ENSG00000236529.1	RP13-254B10.1	-7.05	3.31e-12	7.54e-10	-0.27	-0.21	Aortic root size;	chr7:66089365	chr7:65840212~65840596:+
BRCA	cis	rs11098499	0.865	rs28753180	ENSG00000249244.1	RP11-548H18.2	7.05	3.32e-12	7.55e-10	0.26	0.21	Corneal astigmatism;	chr4:119484212	chr4:119391831~119395335:-
BRCA	cis	rs2243480	1	rs7804223	ENSG00000232546.1	RP11-458F8.1	7.05	3.32e-12	7.55e-10	0.28	0.21	Diabetic kidney disease;	chr7:66199572	chr7:66848496~66858136:+
BRCA	cis	rs9907295	0.901	rs4796120	ENSG00000270977.1	AC015849.16	7.05	3.32e-12	7.56e-10	0.37	0.21	Fibroblast growth factor basic levels;	chr17:35873887	chr17:35893707~35911023:-
BRCA	cis	rs11098499	0.863	rs6534139	ENSG00000249244.1	RP11-548H18.2	-7.05	3.32e-12	7.57e-10	-0.27	-0.21	Corneal astigmatism;	chr4:119528301	chr4:119391831~119395335:-
BRCA	cis	rs699371	0.507	rs10149787	ENSG00000270000.1	RP3-449M8.9	-7.05	3.32e-12	7.57e-10	-0.26	-0.21	Height;	chr14:74458749	chr14:74471930~74472360:-
BRCA	cis	rs10492201	0.529	rs12422954	ENSG00000255733.4	IFNG-AS1	7.05	3.33e-12	7.57e-10	0.21	0.21	Itch intensity from mosquito bite adjusted by bite size;	chr12:68007611	chr12:67989445~68234686:+
BRCA	cis	rs7246657	1	rs1823061	ENSG00000276846.1	CTD-3220F14.3	7.05	3.34e-12	7.6e-10	0.3	0.21	Coronary artery calcification;	chr19:37309724	chr19:37314868~37315620:-
BRCA	cis	rs5758511	0.689	rs17478227	ENSG00000205702.9	CYP2D7	-7.05	3.34e-12	7.6e-10	-0.26	-0.21	Birth weight;	chr22:42258321	chr22:42140203~42144577:-
BRCA	cis	rs875971	1	rs2420168	ENSG00000224316.1	RP11-479O9.2	-7.05	3.34e-12	7.6e-10	-0.21	-0.21	Aortic root size;	chr7:66165644	chr7:65773620~65802067:+
BRCA	cis	rs7727544	0.684	rs274567	ENSG00000233006.5	AC034220.3	-7.05	3.34e-12	7.61e-10	-0.16	-0.21	Blood metabolite levels;	chr5:132378717	chr5:132311285~132369916:-
BRCA	cis	rs4723738	1	rs2159499	ENSG00000227191.5	TRGC2	-7.05	3.34e-12	7.61e-10	-0.19	-0.21	Treatment response for severe sepsis;	chr7:38189300	chr7:38239580~38368091:-
BRCA	cis	rs17711722	0.565	rs4717276	ENSG00000228409.4	CCT6P1	-7.05	3.34e-12	7.61e-10	-0.19	-0.21	Calcium levels;	chr7:65829754	chr7:65751142~65763354:+
BRCA	cis	rs7617773	0.78	rs35297486	ENSG00000228638.1	FCF1P2	-7.05	3.35e-12	7.62e-10	-0.25	-0.21	Coronary artery disease;	chr3:48336657	chr3:48290793~48291375:-
BRCA	cis	rs7617773	0.694	rs13099560	ENSG00000228638.1	FCF1P2	7.05	3.35e-12	7.62e-10	0.21	0.21	Coronary artery disease;	chr3:48163278	chr3:48290793~48291375:-
BRCA	cis	rs17711722	0.565	rs4275112	ENSG00000228409.4	CCT6P1	7.05	3.35e-12	7.63e-10	0.19	0.21	Calcium levels;	chr7:65733651	chr7:65751142~65763354:+
BRCA	cis	rs7615952	0.515	rs7637246	ENSG00000171084.14	FAM86JP	7.05	3.36e-12	7.64e-10	0.33	0.21	Blood pressure (smoking interaction);	chr3:125959863	chr3:125916620~125930024:+
BRCA	cis	rs58873874	0.579	rs11551374	ENSG00000248544.2	CTB-47B11.3	7.05	3.36e-12	7.64e-10	0.43	0.21	Bipolar disorder (body mass index interaction);	chr5:157326249	chr5:157375741~157384950:-
BRCA	cis	rs9291683	0.588	rs2240721	ENSG00000250413.1	RP11-448G15.1	-7.05	3.36e-12	7.65e-10	-0.28	-0.21	Bone mineral density;	chr4:10018940	chr4:10006482~10009725:+
BRCA	cis	rs7617773	0.743	rs11715876	ENSG00000228638.1	FCF1P2	-7.04	3.37e-12	7.67e-10	-0.25	-0.21	Coronary artery disease;	chr3:48336432	chr3:48290793~48291375:-
BRCA	cis	rs17772222	0.74	rs11845147	ENSG00000258983.2	RP11-507K2.2	7.04	3.37e-12	7.67e-10	0.23	0.21	Coronary artery calcification;	chr14:88502804	chr14:88499334~88515502:+
BRCA	cis	rs79040073	0.637	rs57252806	ENSG00000259531.2	RP11-295H24.3	7.04	3.37e-12	7.68e-10	0.36	0.21	Lung cancer in ever smokers;	chr15:49352188	chr15:49365124~49366685:-
BRCA	cis	rs4266144	0.569	rs729257	ENSG00000244515.1	KRT18P34	-7.04	3.37e-12	7.68e-10	-0.25	-0.21	Coronary artery disease;	chr3:157111034	chr3:157162663~157163932:-
BRCA	cis	rs673078	0.607	rs61943400	ENSG00000275409.1	RP11-131L12.4	-7.04	3.38e-12	7.69e-10	-0.32	-0.21	Glucose homeostasis traits;	chr12:118398236	chr12:118430147~118430699:+
BRCA	cis	rs673078	0.607	rs61943401	ENSG00000275409.1	RP11-131L12.4	-7.04	3.38e-12	7.69e-10	-0.32	-0.21	Glucose homeostasis traits;	chr12:118398527	chr12:118430147~118430699:+
BRCA	cis	rs673078	0.607	rs61943402	ENSG00000275409.1	RP11-131L12.4	-7.04	3.38e-12	7.69e-10	-0.32	-0.21	Glucose homeostasis traits;	chr12:118398808	chr12:118430147~118430699:+
BRCA	cis	rs801193	1	rs62466793	ENSG00000236529.1	RP13-254B10.1	7.04	3.39e-12	7.7e-10	0.23	0.21	Aortic root size;	chr7:66726530	chr7:65840212~65840596:+
BRCA	cis	rs42648	0.935	rs7793743	ENSG00000225498.1	AC002064.5	-7.04	3.39e-12	7.71e-10	-0.2	-0.21	Homocysteine levels;	chr7:90402305	chr7:90312496~90322592:+
BRCA	cis	rs9291683	0.588	rs11732054	ENSG00000250413.1	RP11-448G15.1	-7.04	3.39e-12	7.72e-10	-0.28	-0.21	Bone mineral density;	chr4:9998253	chr4:10006482~10009725:+
BRCA	cis	rs270601	0.909	rs2569265	ENSG00000233006.5	AC034220.3	-7.04	3.41e-12	7.76e-10	-0.17	-0.21	Acylcarnitine levels;	chr5:132368827	chr5:132311285~132369916:-
BRCA	cis	rs77204473	0.744	rs12420200	ENSG00000280143.1	AP000892.6	7.04	3.41e-12	7.77e-10	0.32	0.21	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117127590	chr11:117204967~117210292:+
BRCA	cis	rs2243480	1	rs1701758	ENSG00000273142.1	RP11-458F8.4	-7.04	3.41e-12	7.77e-10	-0.29	-0.21	Diabetic kidney disease;	chr7:66005214	chr7:66902857~66906297:+
BRCA	cis	rs2348418	0.765	rs7954877	ENSG00000247934.4	RP11-967K21.1	-7.04	3.42e-12	7.78e-10	-0.24	-0.21	Lung function (FEV1);Lung function (FVC);	chr12:28163008	chr12:28163298~28190738:-
BRCA	cis	rs11098499	0.866	rs7665125	ENSG00000248280.1	RP11-33B1.2	7.04	3.42e-12	7.78e-10	0.21	0.21	Corneal astigmatism;	chr4:119480924	chr4:119440561~119450157:-
BRCA	cis	rs6125961	0.629	rs6125971	ENSG00000224397.4	LINC01272	7.04	3.43e-12	7.8e-10	0.24	0.21	Granulocyte percentage of myeloid white cells;Monocyte count;	chr20:50299229	chr20:50267486~50279795:+
BRCA	cis	rs875971	0.545	rs10950025	ENSG00000236529.1	RP13-254B10.1	7.04	3.46e-12	7.86e-10	0.26	0.21	Aortic root size;	chr7:66158946	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.52	rs12666485	ENSG00000236529.1	RP13-254B10.1	7.04	3.46e-12	7.86e-10	0.26	0.21	Aortic root size;	chr7:66160135	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.545	rs67688847	ENSG00000236529.1	RP13-254B10.1	7.04	3.46e-12	7.86e-10	0.26	0.21	Aortic root size;	chr7:66161064	chr7:65840212~65840596:+
BRCA	cis	rs3814244	0.515	rs2906862	ENSG00000236946.2	HNRNPA1P70	7.04	3.46e-12	7.86e-10	0.17	0.21	Itch intensity from mosquito bite adjusted by bite size;	chr12:68005371	chr12:68035767~68036853:+
BRCA	cis	rs73173548	0.502	rs13180932	ENSG00000247828.6	TMEM161B-AS1	7.04	3.46e-12	7.86e-10	0.29	0.21	Macular telangiectasia type 2;	chr5:88425720	chr5:88268895~88436685:+
BRCA	cis	rs875971	0.964	rs1643388	ENSG00000232559.3	GS1-124K5.12	7.04	3.46e-12	7.87e-10	0.25	0.21	Aortic root size;	chr7:66379575	chr7:66554588~66576923:-
BRCA	cis	rs875971	1	rs778722	ENSG00000232559.3	GS1-124K5.12	7.04	3.46e-12	7.87e-10	0.25	0.21	Aortic root size;	chr7:66379841	chr7:66554588~66576923:-
BRCA	cis	rs7662987	0.793	rs7669660	ENSG00000272777.1	RP11-571L19.8	7.04	3.46e-12	7.87e-10	0.3	0.21	Smoking initiation;	chr4:99071451	chr4:99067256~99068125:-
BRCA	cis	rs875971	0.965	rs6971509	ENSG00000224316.1	RP11-479O9.2	-7.04	3.47e-12	7.88e-10	-0.21	-0.21	Aortic root size;	chr7:66249983	chr7:65773620~65802067:+
BRCA	cis	rs1823913	0.637	rs6741454	ENSG00000280083.1	RP11-317J9.1	7.04	3.47e-12	7.88e-10	0.24	0.21	Obesity-related traits;	chr2:191269520	chr2:191154118~191156070:-
BRCA	cis	rs61160187	0.667	rs7722373	ENSG00000215032.2	GNL3LP1	7.04	3.47e-12	7.88e-10	0.26	0.21	Educational attainment (years of education);Educational attainment (college completion);	chr5:60951988	chr5:60891935~60893577:-
BRCA	cis	rs9309473	1	rs7572722	ENSG00000163016.8	ALMS1P	7.04	3.48e-12	7.92e-10	0.28	0.21	Metabolite levels;	chr2:73497548	chr2:73644919~73685576:+
BRCA	cis	rs7617773	0.78	rs11720026	ENSG00000228638.1	FCF1P2	-7.04	3.5e-12	7.94e-10	-0.25	-0.21	Coronary artery disease;	chr3:48336431	chr3:48290793~48291375:-
BRCA	cis	rs9876781	0.967	rs7618883	ENSG00000244380.1	RP11-24C3.2	7.04	3.5e-12	7.96e-10	0.25	0.21	Longevity;	chr3:48457056	chr3:48440352~48446656:-
BRCA	cis	rs801193	1	rs2659909	ENSG00000237310.1	GS1-124K5.4	7.04	3.51e-12	7.97e-10	0.22	0.21	Aortic root size;	chr7:66695292	chr7:66493706~66495474:+
BRCA	cis	rs473651	0.503	rs515342	ENSG00000229915.1	AC016999.2	7.04	3.52e-12	7.99e-10	0.32	0.21	Multiple system atrophy;	chr2:238458655	chr2:238427077~238427729:-
BRCA	cis	rs7809950	1	rs2253146	ENSG00000238832.1	snoU109	-7.04	3.53e-12	8.02e-10	-0.28	-0.21	Coronary artery disease;	chr7:107559874	chr7:107603363~107603507:+
BRCA	cis	rs237743	1	rs238164	ENSG00000222365.1	SNORD12B	-7.04	3.53e-12	8.02e-10	-0.28	-0.21	Height;	chr20:49227804	chr20:49280319~49280409:+
BRCA	cis	rs2835345	0.563	rs12483690	ENSG00000230479.1	AP000695.6	7.04	3.54e-12	8.03e-10	0.21	0.21	Pulmonary function;	chr21:36451265	chr21:36430360~36481070:+
BRCA	cis	rs2835345	0.596	rs12482097	ENSG00000230479.1	AP000695.6	7.04	3.54e-12	8.03e-10	0.21	0.21	Pulmonary function;	chr21:36451592	chr21:36430360~36481070:+
BRCA	cis	rs2835345	0.596	rs12482138	ENSG00000230479.1	AP000695.6	7.04	3.54e-12	8.03e-10	0.21	0.21	Pulmonary function;	chr21:36451608	chr21:36430360~36481070:+
BRCA	cis	rs2835345	0.563	rs12482257	ENSG00000230479.1	AP000695.6	7.04	3.54e-12	8.03e-10	0.21	0.21	Pulmonary function;	chr21:36451660	chr21:36430360~36481070:+
BRCA	cis	rs7617773	0.817	rs11130163	ENSG00000228638.1	FCF1P2	-7.04	3.54e-12	8.04e-10	-0.21	-0.21	Coronary artery disease;	chr3:48271168	chr3:48290793~48291375:-
BRCA	cis	rs12802244	1	rs12802244	ENSG00000280615.1	Y_RNA	-7.04	3.54e-12	8.04e-10	-0.27	-0.21	Neuroticism;	chr11:47911114	chr11:47614898~47614994:-
BRCA	cis	rs4835473	0.897	rs1391189	ENSG00000251600.4	RP11-673E1.1	-7.04	3.55e-12	8.07e-10	-0.26	-0.21	Immature fraction of reticulocytes;	chr4:143690951	chr4:143912331~143982454:+
BRCA	cis	rs11098499	0.909	rs1546502	ENSG00000249244.1	RP11-548H18.2	7.04	3.56e-12	8.07e-10	0.25	0.21	Corneal astigmatism;	chr4:119314743	chr4:119391831~119395335:-
BRCA	cis	rs2742234	0.868	rs2505512	ENSG00000273008.1	RP11-351D16.3	-7.04	3.56e-12	8.07e-10	-0.25	-0.21	Hirschsprung disease;	chr10:43138148	chr10:43136824~43138334:-
BRCA	cis	rs2835345	0.563	rs12627167	ENSG00000230479.1	AP000695.6	7.04	3.56e-12	8.09e-10	0.21	0.21	Pulmonary function;	chr21:36449855	chr21:36430360~36481070:+
BRCA	cis	rs875971	0.545	rs221986	ENSG00000236529.1	RP13-254B10.1	-7.04	3.57e-12	8.11e-10	-0.27	-0.21	Aortic root size;	chr7:66105323	chr7:65840212~65840596:+
BRCA	cis	rs6142102	0.961	rs6119447	ENSG00000275784.1	RP5-1125A11.6	-7.04	3.57e-12	8.11e-10	-0.25	-0.21	Skin pigmentation;	chr20:34080770	chr20:33989480~33991818:-
BRCA	cis	rs79040073	0.636	rs74339964	ENSG00000259531.2	RP11-295H24.3	7.04	3.58e-12	8.13e-10	0.37	0.21	Lung cancer in ever smokers;	chr15:49329916	chr15:49365124~49366685:-
BRCA	cis	rs9527	0.641	rs4919684	ENSG00000213061.2	PFN1P11	7.04	3.59e-12	8.14e-10	0.31	0.21	Arsenic metabolism;	chr10:102827267	chr10:102838011~102845473:-
BRCA	cis	rs11098499	0.954	rs4577559	ENSG00000249244.1	RP11-548H18.2	7.04	3.59e-12	8.14e-10	0.25	0.21	Corneal astigmatism;	chr4:119482888	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.954	rs7656252	ENSG00000249244.1	RP11-548H18.2	7.04	3.59e-12	8.14e-10	0.25	0.21	Corneal astigmatism;	chr4:119483113	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.865	rs28845498	ENSG00000249244.1	RP11-548H18.2	7.04	3.59e-12	8.14e-10	0.25	0.21	Corneal astigmatism;	chr4:119484031	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.954	rs56270433	ENSG00000249244.1	RP11-548H18.2	7.04	3.59e-12	8.14e-10	0.25	0.21	Corneal astigmatism;	chr4:119484875	chr4:119391831~119395335:-
BRCA	cis	rs7617773	0.817	rs4131361	ENSG00000228638.1	FCF1P2	-7.04	3.59e-12	8.14e-10	-0.23	-0.21	Coronary artery disease;	chr3:48287322	chr3:48290793~48291375:-
BRCA	cis	rs4072705	0.967	rs4076333	ENSG00000224020.1	MIR181A2HG	-7.04	3.6e-12	8.16e-10	-0.25	-0.21	Menarche (age at onset);	chr9:124623330	chr9:124658467~124698631:+
BRCA	cis	rs34779708	0.801	rs12098720	ENSG00000271335.4	RP11-324I22.4	7.04	3.6e-12	8.16e-10	0.22	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35249755	chr10:35314552~35336401:-
BRCA	cis	rs34779708	0.801	rs34592588	ENSG00000271335.4	RP11-324I22.4	7.04	3.6e-12	8.16e-10	0.22	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35251206	chr10:35314552~35336401:-
BRCA	cis	rs7845219	0.539	rs713113	ENSG00000253528.2	RP11-347C18.4	-7.04	3.6e-12	8.17e-10	-0.22	-0.21	Type 2 diabetes;	chr8:94865559	chr8:94974573~94974853:-
BRCA	cis	rs2243480	0.711	rs2460426	ENSG00000232546.1	RP11-458F8.1	7.03	3.61e-12	8.18e-10	0.28	0.21	Diabetic kidney disease;	chr7:66158142	chr7:66848496~66858136:+
BRCA	cis	rs1823913	0.614	rs6755243	ENSG00000280083.1	RP11-317J9.1	7.03	3.61e-12	8.2e-10	0.24	0.21	Obesity-related traits;	chr2:191269810	chr2:191154118~191156070:-
BRCA	cis	rs891378	0.755	rs10157327	ENSG00000274245.1	RP11-357P18.2	-7.03	3.62e-12	8.2e-10	-0.27	-0.21	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207191756	chr1:207372559~207373252:+
BRCA	cis	rs7208859	0.623	rs11657662	ENSG00000263603.1	CTD-2349P21.5	7.03	3.62e-12	8.2e-10	0.38	0.21	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30749329	chr17:30729469~30731202:+
BRCA	cis	rs6142102	0.961	rs4911408	ENSG00000275784.1	RP5-1125A11.6	-7.03	3.62e-12	8.22e-10	-0.26	-0.21	Skin pigmentation;	chr20:34112760	chr20:33989480~33991818:-
BRCA	cis	rs13217239	0.646	rs7747454	ENSG00000241549.7	GUSBP2	-7.03	3.62e-12	8.22e-10	-0.23	-0.21	Schizophrenia;	chr6:27066474	chr6:26871484~26956554:-
BRCA	cis	rs10754283	0.967	rs10801761	ENSG00000231613.1	RP5-943J3.1	7.03	3.62e-12	8.22e-10	0.24	0.21	Amyotrophic lateral sclerosis (sporadic);	chr1:89649710	chr1:89788914~89790492:+
BRCA	cis	rs2014572	1	rs2014572	ENSG00000268379.1	CTC-360J11.4	7.03	3.63e-12	8.22e-10	0.26	0.21	Hyperactive-impulsive symptoms;	chr19:57248650	chr19:57175233~57177921:+
BRCA	cis	rs11098499	0.588	rs2389874	ENSG00000245958.5	RP11-33B1.1	7.03	3.64e-12	8.26e-10	0.2	0.21	Corneal astigmatism;	chr4:119633836	chr4:119454791~119552025:+
BRCA	cis	rs9402682	0.629	rs2223385	ENSG00000232876.1	CTA-212D2.2	-7.03	3.64e-12	8.27e-10	-0.29	-0.21	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr6:135114033	chr6:135055033~135060550:+
BRCA	cis	rs9287719	0.674	rs1387566	ENSG00000234818.1	AC092687.5	-7.03	3.64e-12	8.27e-10	-0.25	-0.21	Prostate cancer;	chr2:10688524	chr2:10589166~10604830:+
BRCA	cis	rs77972916	0.561	rs17406174	ENSG00000234936.1	AC010883.5	7.03	3.65e-12	8.27e-10	0.32	0.21	Granulocyte percentage of myeloid white cells;	chr2:43330345	chr2:43229573~43233394:+
BRCA	cis	rs77972916	0.518	rs55877805	ENSG00000234936.1	AC010883.5	7.03	3.65e-12	8.27e-10	0.32	0.21	Granulocyte percentage of myeloid white cells;	chr2:43330458	chr2:43229573~43233394:+
BRCA	cis	rs61160187	0.582	rs67490467	ENSG00000215032.2	GNL3LP1	7.03	3.65e-12	8.28e-10	0.27	0.21	Educational attainment (years of education);Educational attainment (college completion);	chr5:60967991	chr5:60891935~60893577:-
BRCA	cis	rs2303759	0.676	rs10426452	ENSG00000268686.1	AC010524.2	-7.03	3.65e-12	8.28e-10	-0.31	-0.21	Multiple sclerosis;	chr19:49404433	chr19:49368705~49388081:-
BRCA	cis	rs801193	0.904	rs4718403	ENSG00000236529.1	RP13-254B10.1	7.03	3.66e-12	8.3e-10	0.23	0.21	Aortic root size;	chr7:66777742	chr7:65840212~65840596:+
BRCA	cis	rs79040073	0.637	rs73396238	ENSG00000259531.2	RP11-295H24.3	7.03	3.66e-12	8.31e-10	0.36	0.21	Lung cancer in ever smokers;	chr15:49347146	chr15:49365124~49366685:-
BRCA	cis	rs4722166	0.598	rs7804146	ENSG00000179428.2	AC073072.5	-7.03	3.67e-12	8.33e-10	-0.22	-0.21	Lung cancer;	chr7:22761310	chr7:22725395~22727620:-
BRCA	cis	rs7927771	0.757	rs1057233	ENSG00000280615.1	Y_RNA	7.03	3.67e-12	8.33e-10	0.26	0.21	Subjective well-being;	chr11:47354897	chr11:47614898~47614994:-
BRCA	cis	rs11096990	0.855	rs2711935	ENSG00000249207.1	RP11-360F5.1	7.03	3.68e-12	8.35e-10	0.25	0.21	Cognitive function;	chr4:39160837	chr4:39112677~39126818:-
BRCA	cis	rs293748	0.771	rs35135658	ENSG00000250155.1	CTD-2353F22.1	-7.03	3.69e-12	8.35e-10	-0.29	-0.21	Obesity-related traits;	chr5:36786777	chr5:36666214~36725195:-
BRCA	cis	rs6142102	0.961	rs8119937	ENSG00000275784.1	RP5-1125A11.6	-7.03	3.69e-12	8.36e-10	-0.24	-0.21	Skin pigmentation;	chr20:34057745	chr20:33989480~33991818:-
BRCA	cis	rs10510102	0.935	rs7906667	ENSG00000276742.1	RP11-500G22.4	7.03	3.69e-12	8.37e-10	0.36	0.21	Breast cancer;	chr10:121909142	chr10:121956782~121957098:+
BRCA	cis	rs9649213	0.593	rs35983874	ENSG00000272950.1	RP11-307C18.1	7.03	3.69e-12	8.37e-10	0.27	0.21	Prostate cancer (SNP x SNP interaction);	chr7:98287149	chr7:98322853~98323430:+
BRCA	cis	rs62025270	0.547	rs416916	ENSG00000202081.1	RNU6-1280P	-7.03	3.7e-12	8.39e-10	-0.26	-0.21	Idiopathic pulmonary fibrosis;	chr15:85649185	chr15:85651522~85651628:-
BRCA	cis	rs3781264	1	rs3781264	ENSG00000273450.1	RP11-76P2.4	7.03	3.7e-12	8.4e-10	0.29	0.21	Esophageal cancer and gastric cancer;	chr10:94310618	chr10:94314907~94315327:-
BRCA	cis	rs11098499	0.954	rs12502423	ENSG00000249244.1	RP11-548H18.2	7.03	3.71e-12	8.4e-10	0.26	0.21	Corneal astigmatism;	chr4:119503017	chr4:119391831~119395335:-
BRCA	cis	rs2060793	0.519	rs1357332	ENSG00000251991.1	RNU7-49P	7.03	3.71e-12	8.41e-10	0.23	0.21	Vitamin D levels;	chr11:14618570	chr11:14478892~14478953:+
BRCA	cis	rs780096	0.546	rs35073769	ENSG00000234072.1	AC074117.10	-7.03	3.71e-12	8.41e-10	-0.21	-0.21	Total body bone mineral density;	chr2:27508509	chr2:27356246~27367622:+
BRCA	cis	rs73173548	0.502	rs34394411	ENSG00000247828.6	TMEM161B-AS1	7.03	3.71e-12	8.41e-10	0.29	0.21	Macular telangiectasia type 2;	chr5:88436903	chr5:88268895~88436685:+
BRCA	cis	rs7085104	0.591	rs4919683	ENSG00000236937.2	PTGES3P4	7.03	3.71e-12	8.41e-10	0.27	0.21	Immature fraction of reticulocytes;Schizophrenia;	chr10:102825368	chr10:102845595~102845950:+
BRCA	cis	rs801193	1	rs10234018	ENSG00000236529.1	RP13-254B10.1	-7.03	3.71e-12	8.41e-10	-0.23	-0.21	Aortic root size;	chr7:66681297	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.571	rs160641	ENSG00000236529.1	RP13-254B10.1	-7.03	3.71e-12	8.41e-10	-0.26	-0.21	Aortic root size;	chr7:66112359	chr7:65840212~65840596:+
BRCA	cis	rs7809950	0.953	rs1468336	ENSG00000238832.1	snoU109	7.03	3.72e-12	8.43e-10	0.29	0.21	Coronary artery disease;	chr7:107567805	chr7:107603363~107603507:+
BRCA	cis	rs11098499	0.908	rs11098527	ENSG00000249244.1	RP11-548H18.2	7.03	3.72e-12	8.43e-10	0.26	0.21	Corneal astigmatism;	chr4:119478751	chr4:119391831~119395335:-
BRCA	cis	rs9309711	0.961	rs11692184	ENSG00000225234.1	TRAPPC12-AS1	-7.03	3.73e-12	8.44e-10	-0.24	-0.21	Neurofibrillary tangles;	chr2:3476939	chr2:3481242~3482409:-
BRCA	cis	rs7474896	0.609	rs1830612	ENSG00000226578.1	RP11-258F22.1	-7.03	3.73e-12	8.45e-10	-0.28	-0.21	Obesity (extreme);	chr10:37710955	chr10:37775371~37784131:-
BRCA	cis	rs9516	0.966	rs2887135	ENSG00000254974.1	RP11-702H23.2	7.03	3.73e-12	8.46e-10	0.25	0.21	Facial morphology (factor 15, philtrum width);	chr11:74452810	chr11:74485580~74486051:-
BRCA	cis	rs10510102	0.935	rs11200253	ENSG00000276742.1	RP11-500G22.4	7.03	3.74e-12	8.47e-10	0.36	0.21	Breast cancer;	chr10:121915114	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.935	rs11200254	ENSG00000276742.1	RP11-500G22.4	7.03	3.74e-12	8.47e-10	0.36	0.21	Breast cancer;	chr10:121915241	chr10:121956782~121957098:+
BRCA	cis	rs7617773	0.676	rs13060020	ENSG00000228638.1	FCF1P2	-7.03	3.74e-12	8.47e-10	-0.24	-0.21	Coronary artery disease;	chr3:48331156	chr3:48290793~48291375:-
BRCA	cis	rs375066	0.736	rs62114649	ENSG00000267058.1	RP11-15A1.3	7.03	3.74e-12	8.47e-10	0.25	0.21	Breast cancer;	chr19:43912415	chr19:43891804~43901805:-
BRCA	cis	rs7246657	0.943	rs10420430	ENSG00000226686.6	LINC01535	-7.03	3.74e-12	8.48e-10	-0.33	-0.21	Coronary artery calcification;	chr19:37403292	chr19:37251912~37265535:+
BRCA	cis	rs10050311	0.858	rs1010902	ENSG00000251411.1	RP11-397E7.4	-7.03	3.75e-12	8.5e-10	-0.31	-0.21	Insulin-related traits;	chr4:86898002	chr4:86913266~86914817:-
BRCA	cis	rs3930017	1	rs3930016	ENSG00000242435.1	UPK3BP1	7.03	3.75e-12	8.5e-10	0.25	0.21	Body mass index;	chr7:77091132	chr7:77004662~77005774:+
BRCA	cis	rs875971	0.83	rs427575	ENSG00000232559.3	GS1-124K5.12	7.03	3.75e-12	8.5e-10	0.26	0.21	Aortic root size;	chr7:66054232	chr7:66554588~66576923:-
BRCA	cis	rs9880211	0.613	rs12330335	ENSG00000273486.1	RP11-731C17.2	7.03	3.75e-12	8.5e-10	0.27	0.21	Height;Body mass index;	chr3:136134690	chr3:136837338~136839021:-
BRCA	cis	rs71520386	0.632	rs10254365	ENSG00000228649.7	AC005682.5	-7.03	3.75e-12	8.5e-10	-0.21	-0.21	Fibrinogen levels;	chr7:22825135	chr7:22854178~22861579:+
BRCA	cis	rs9291683	0.588	rs35438220	ENSG00000250413.1	RP11-448G15.1	-7.03	3.76e-12	8.51e-10	-0.28	-0.21	Bone mineral density;	chr4:9997774	chr4:10006482~10009725:+
BRCA	cis	rs6543140	0.964	rs2080288	ENSG00000234389.1	AC007278.3	7.03	3.76e-12	8.52e-10	0.21	0.21	Blood protein levels;	chr2:102405706	chr2:102438713~102440475:+
BRCA	cis	rs2835345	0.528	rs12483650	ENSG00000230479.1	AP000695.6	7.03	3.76e-12	8.52e-10	0.21	0.21	Pulmonary function;	chr21:36450778	chr21:36430360~36481070:+
BRCA	cis	rs2835345	0.563	rs12483621	ENSG00000230479.1	AP000695.6	7.03	3.76e-12	8.52e-10	0.21	0.21	Pulmonary function;	chr21:36450798	chr21:36430360~36481070:+
BRCA	cis	rs897984	0.806	rs1458202	ENSG00000260911.2	RP11-196G11.2	7.03	3.76e-12	8.53e-10	0.19	0.21	Dementia with Lewy bodies;	chr16:30941881	chr16:31043150~31049868:+
BRCA	cis	rs6142102	1	rs4911410	ENSG00000275784.1	RP5-1125A11.6	-7.03	3.77e-12	8.53e-10	-0.25	-0.21	Skin pigmentation;	chr20:34123168	chr20:33989480~33991818:-
BRCA	cis	rs9876781	1	rs9864371	ENSG00000244380.1	RP11-24C3.2	7.03	3.77e-12	8.53e-10	0.25	0.21	Longevity;	chr3:48385276	chr3:48440352~48446656:-
BRCA	cis	rs6921919	0.583	rs7764722	ENSG00000204709.4	LINC01556	7.03	3.77e-12	8.54e-10	0.29	0.21	Autism spectrum disorder or schizophrenia;	chr6:28386756	chr6:28943877~28944537:+
BRCA	cis	rs7246657	0.943	rs10420722	ENSG00000276846.1	CTD-3220F14.3	7.03	3.77e-12	8.54e-10	0.3	0.21	Coronary artery calcification;	chr19:37482872	chr19:37314868~37315620:-
BRCA	cis	rs6504622	0.818	rs11079742	ENSG00000262879.4	RP11-156P1.3	-7.03	3.78e-12	8.55e-10	-0.21	-0.21	Orofacial clefts;	chr17:46942762	chr17:46984045~47100323:-
BRCA	cis	rs6723162	0.965	rs11126308	ENSG00000237751.2	LINC01143	-7.03	3.78e-12	8.56e-10	-0.25	-0.21	Neurocognitive impairment in HIV-1 infection (dichotomous);	chr2:70887591	chr2:70887871~70889959:+
BRCA	cis	rs9876781	1	rs7634377	ENSG00000244380.1	RP11-24C3.2	7.03	3.79e-12	8.57e-10	0.24	0.21	Longevity;	chr3:48379768	chr3:48440352~48446656:-
BRCA	cis	rs6840258	0.66	rs17012216	ENSG00000251411.1	RP11-397E7.4	-7.03	3.79e-12	8.58e-10	-0.3	-0.21	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86968285	chr4:86913266~86914817:-
BRCA	cis	rs6539288	0.933	rs1444581	ENSG00000260329.1	RP11-412D9.4	-7.03	3.79e-12	8.58e-10	-0.24	-0.21	Total body bone mineral density;	chr12:106920473	chr12:106954029~106955497:-
BRCA	cis	rs801193	1	rs62466794	ENSG00000236529.1	RP13-254B10.1	7.03	3.79e-12	8.59e-10	0.23	0.21	Aortic root size;	chr7:66726592	chr7:65840212~65840596:+
BRCA	cis	rs858239	0.537	rs6942981	ENSG00000230042.1	AK3P3	-7.03	3.81e-12	8.62e-10	-0.25	-0.21	Cerebrospinal fluid biomarker levels;	chr7:23191929	chr7:23129178~23129841:+
BRCA	cis	rs17301013	0.606	rs12079689	ENSG00000227373.4	RP11-160H22.5	7.03	3.81e-12	8.62e-10	0.3	0.21	Systemic lupus erythematosus;	chr1:174240514	chr1:174115300~174160004:-
BRCA	cis	rs4722166	0.598	rs4722178	ENSG00000179428.2	AC073072.5	-7.03	3.81e-12	8.63e-10	-0.22	-0.21	Lung cancer;	chr7:22759031	chr7:22725395~22727620:-
BRCA	cis	rs7809950	0.906	rs2253269	ENSG00000238832.1	snoU109	-7.03	3.82e-12	8.65e-10	-0.28	-0.21	Coronary artery disease;	chr7:107560669	chr7:107603363~107603507:+
BRCA	cis	rs8072100	0.79	rs34200664	ENSG00000228782.6	CTD-2026D20.3	-7.03	3.82e-12	8.65e-10	-0.24	-0.21	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47667286	chr17:47450568~47492492:-
BRCA	cis	rs10129255	0.826	rs7150693	ENSG00000211972.2	IGHV3-66	7.03	3.83e-12	8.66e-10	0.17	0.21	Kawasaki disease;	chr14:106705382	chr14:106675017~106675544:-
BRCA	cis	rs10129255	0.869	rs7150549	ENSG00000211972.2	IGHV3-66	7.03	3.83e-12	8.66e-10	0.17	0.21	Kawasaki disease;	chr14:106705441	chr14:106675017~106675544:-
BRCA	cis	rs2243480	1	rs11538349	ENSG00000273142.1	RP11-458F8.4	-7.03	3.83e-12	8.67e-10	-0.28	-0.21	Diabetic kidney disease;	chr7:65956884	chr7:66902857~66906297:+
BRCA	cis	rs7809950	1	rs10258385	ENSG00000238832.1	snoU109	7.03	3.83e-12	8.67e-10	0.29	0.21	Coronary artery disease;	chr7:107602905	chr7:107603363~107603507:+
BRCA	cis	rs6860806	0.531	rs270607	ENSG00000233006.5	AC034220.3	7.03	3.84e-12	8.69e-10	0.17	0.21	Breast cancer;	chr5:132313493	chr5:132311285~132369916:-
BRCA	cis	rs17301013	0.606	rs6692437	ENSG00000227373.4	RP11-160H22.5	7.03	3.84e-12	8.7e-10	0.3	0.21	Systemic lupus erythematosus;	chr1:174213771	chr1:174115300~174160004:-
BRCA	cis	rs9880211	0.562	rs13068210	ENSG00000273486.1	RP11-731C17.2	7.03	3.85e-12	8.71e-10	0.27	0.21	Height;Body mass index;	chr3:136186704	chr3:136837338~136839021:-
BRCA	cis	rs6570726	0.902	rs396681	ENSG00000235652.6	RP11-545I5.3	7.03	3.86e-12	8.72e-10	0.21	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145532467	chr6:145799409~145886585:+
BRCA	cis	rs17301013	0.606	rs12082461	ENSG00000227373.4	RP11-160H22.5	7.03	3.86e-12	8.72e-10	0.31	0.21	Systemic lupus erythematosus;	chr1:174169876	chr1:174115300~174160004:-
BRCA	cis	rs6479891	0.908	rs16918638	ENSG00000232075.1	MRPL35P2	7.03	3.86e-12	8.73e-10	0.4	0.21	Arthritis (juvenile idiopathic);	chr10:63583371	chr10:63634317~63634827:-
BRCA	cis	rs2243480	0.901	rs1701759	ENSG00000273142.1	RP11-458F8.4	-7.02	3.86e-12	8.73e-10	-0.29	-0.21	Diabetic kidney disease;	chr7:66005945	chr7:66902857~66906297:+
BRCA	cis	rs9368481	0.594	rs7768643	ENSG00000241549.7	GUSBP2	7.02	3.87e-12	8.74e-10	0.24	0.21	Autism spectrum disorder or schizophrenia;	chr6:26924140	chr6:26871484~26956554:-
BRCA	cis	rs9368481	0.594	rs7768814	ENSG00000241549.7	GUSBP2	7.02	3.87e-12	8.74e-10	0.24	0.21	Autism spectrum disorder or schizophrenia;	chr6:26924257	chr6:26871484~26956554:-
BRCA	cis	rs911555	0.755	rs4906329	ENSG00000244691.1	RPL10AP1	7.02	3.87e-12	8.75e-10	0.27	0.21	Intelligence (multi-trait analysis);	chr14:103476332	chr14:103412119~103412761:-
BRCA	cis	rs11955398	0.62	rs6449512	ENSG00000215032.2	GNL3LP1	7.02	3.88e-12	8.77e-10	0.26	0.21	Intelligence (multi-trait analysis);	chr5:60938415	chr5:60891935~60893577:-
BRCA	cis	rs6723162	0.965	rs7567290	ENSG00000237751.2	LINC01143	-7.02	3.89e-12	8.81e-10	-0.25	-0.21	Neurocognitive impairment in HIV-1 infection (dichotomous);	chr2:70887870	chr2:70887871~70889959:+
BRCA	cis	rs7662987	0.793	rs12106	ENSG00000272777.1	RP11-571L19.8	7.02	3.9e-12	8.82e-10	0.3	0.21	Smoking initiation;	chr4:99072199	chr4:99067256~99068125:-
BRCA	cis	rs17301013	0.606	rs7535987	ENSG00000227373.4	RP11-160H22.5	7.02	3.91e-12	8.83e-10	0.3	0.21	Systemic lupus erythematosus;	chr1:174240840	chr1:174115300~174160004:-
BRCA	cis	rs2492286	0.597	rs2712372	ENSG00000242551.2	POU5F1P6	-7.02	3.91e-12	8.83e-10	-0.32	-0.21	Eosinophil counts;	chr3:128604994	chr3:128674735~128677005:-
BRCA	cis	rs875971	1	rs778726	ENSG00000232559.3	GS1-124K5.12	7.02	3.91e-12	8.84e-10	0.25	0.21	Aortic root size;	chr7:66363744	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.767	rs1695815	ENSG00000232559.3	GS1-124K5.12	7.02	3.91e-12	8.84e-10	0.25	0.21	Aortic root size;	chr7:66366357	chr7:66554588~66576923:-
BRCA	cis	rs875971	1	rs778685	ENSG00000232559.3	GS1-124K5.12	7.02	3.91e-12	8.84e-10	0.25	0.21	Aortic root size;	chr7:66371189	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.929	rs778682	ENSG00000232559.3	GS1-124K5.12	7.02	3.91e-12	8.84e-10	0.25	0.21	Aortic root size;	chr7:66372947	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.964	rs11765965	ENSG00000232559.3	GS1-124K5.12	7.02	3.91e-12	8.84e-10	0.25	0.21	Aortic root size;	chr7:66377234	chr7:66554588~66576923:-
BRCA	cis	rs6543140	0.964	rs1035126	ENSG00000234389.1	AC007278.3	7.02	3.91e-12	8.84e-10	0.21	0.21	Blood protein levels;	chr2:102403521	chr2:102438713~102440475:+
BRCA	cis	rs2348418	0.832	rs1552760	ENSG00000247934.4	RP11-967K21.1	7.02	3.91e-12	8.84e-10	0.24	0.21	Lung function (FEV1);Lung function (FVC);	chr12:28383884	chr12:28163298~28190738:-
BRCA	cis	rs755249	0.567	rs4660603	ENSG00000228060.1	RP11-69E11.8	7.02	3.92e-12	8.86e-10	0.26	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39270662	chr1:39565160~39573203:+
BRCA	cis	rs79040073	0.637	rs73394324	ENSG00000259531.2	RP11-295H24.3	7.02	3.92e-12	8.86e-10	0.36	0.21	Lung cancer in ever smokers;	chr15:49274894	chr15:49365124~49366685:-
BRCA	cis	rs6921919	0.525	rs16894095	ENSG00000204709.4	LINC01556	7.02	3.93e-12	8.88e-10	0.29	0.21	Autism spectrum disorder or schizophrenia;	chr6:28422453	chr6:28943877~28944537:+
BRCA	cis	rs2145598	0.874	rs58231973	ENSG00000279636.2	LINC00216	-7.02	3.93e-12	8.88e-10	-0.21	-0.21	Coronary artery disease;	chr14:58330929	chr14:58288033~58289158:+
BRCA	cis	rs2243480	0.803	rs13224048	ENSG00000232546.1	RP11-458F8.1	-7.02	3.93e-12	8.89e-10	-0.28	-0.21	Diabetic kidney disease;	chr7:66528779	chr7:66848496~66858136:+
BRCA	cis	rs911555	0.692	rs7146215	ENSG00000244691.1	RPL10AP1	7.02	3.94e-12	8.89e-10	0.27	0.21	Intelligence (multi-trait analysis);	chr14:103449571	chr14:103412119~103412761:-
BRCA	cis	rs4722166	0.532	rs4719713	ENSG00000179428.2	AC073072.5	-7.02	3.94e-12	8.9e-10	-0.22	-0.21	Lung cancer;	chr7:22719192	chr7:22725395~22727620:-
BRCA	cis	rs4372836	0.93	rs7607844	ENSG00000226833.4	AC097724.3	7.02	3.94e-12	8.91e-10	0.26	0.21	Body mass index;	chr2:28748872	chr2:28708953~28736205:-
BRCA	cis	rs9287719	0.674	rs11691060	ENSG00000234818.1	AC092687.5	-7.02	3.95e-12	8.93e-10	-0.25	-0.21	Prostate cancer;	chr2:10686935	chr2:10589166~10604830:+
BRCA	cis	rs9287719	0.674	rs11684157	ENSG00000234818.1	AC092687.5	-7.02	3.95e-12	8.93e-10	-0.25	-0.21	Prostate cancer;	chr2:10687031	chr2:10589166~10604830:+
BRCA	cis	rs13217239	0.646	rs9379956	ENSG00000241549.7	GUSBP2	-7.02	3.96e-12	8.96e-10	-0.23	-0.21	Schizophrenia;	chr6:27065956	chr6:26871484~26956554:-
BRCA	cis	rs7474896	0.583	rs11011341	ENSG00000226578.1	RP11-258F22.1	-7.02	3.97e-12	8.97e-10	-0.28	-0.21	Obesity (extreme);	chr10:37709572	chr10:37775371~37784131:-
BRCA	cis	rs9287719	0.674	rs759399	ENSG00000234818.1	AC092687.5	-7.02	3.97e-12	8.97e-10	-0.25	-0.21	Prostate cancer;	chr2:10656757	chr2:10589166~10604830:+
BRCA	cis	rs6095360	0.517	rs237700	ENSG00000222365.1	SNORD12B	-7.02	3.97e-12	8.97e-10	-0.27	-0.21	Intelligence (multi-trait analysis);	chr20:49293285	chr20:49280319~49280409:+
BRCA	cis	rs2243480	1	rs10807702	ENSG00000230295.1	RP11-458F8.2	-7.02	3.97e-12	8.97e-10	-0.28	-0.21	Diabetic kidney disease;	chr7:66302856	chr7:66880708~66882981:+
BRCA	cis	rs6570726	0.935	rs453609	ENSG00000235652.6	RP11-545I5.3	7.02	3.99e-12	9.01e-10	0.2	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145491196	chr6:145799409~145886585:+
BRCA	cis	rs7246657	0.941	rs12982333	ENSG00000276846.1	CTD-3220F14.3	7.02	3.99e-12	9.02e-10	0.29	0.21	Coronary artery calcification;	chr19:37303822	chr19:37314868~37315620:-
BRCA	cis	rs71520386	0.607	rs11767419	ENSG00000228649.7	AC005682.5	-7.02	4.01e-12	9.05e-10	-0.21	-0.21	Fibrinogen levels;	chr7:22839364	chr7:22854178~22861579:+
BRCA	cis	rs79040073	0.637	rs17396119	ENSG00000259531.2	RP11-295H24.3	7.02	4.02e-12	9.07e-10	0.37	0.21	Lung cancer in ever smokers;	chr15:49242167	chr15:49365124~49366685:-
BRCA	cis	rs9309711	0.961	rs11890651	ENSG00000225234.1	TRAPPC12-AS1	-7.02	4.02e-12	9.07e-10	-0.24	-0.21	Neurofibrillary tangles;	chr2:3479025	chr2:3481242~3482409:-
BRCA	cis	rs1020064	0.636	rs2576726	ENSG00000235319.1	AC012360.4	-7.02	4.02e-12	9.07e-10	-0.28	-0.21	AIDS;	chr2:105319955	chr2:105324210~105330529:+
BRCA	cis	rs1862618	0.853	rs2113079	ENSG00000271828.1	CTD-2310F14.1	7.02	4.02e-12	9.08e-10	0.3	0.21	Initial pursuit acceleration;	chr5:56862124	chr5:56927874~56929573:+
BRCA	cis	rs4722166	0.598	rs35658589	ENSG00000179428.2	AC073072.5	-7.02	4.02e-12	9.08e-10	-0.22	-0.21	Lung cancer;	chr7:22760816	chr7:22725395~22727620:-
BRCA	cis	rs858267	1	rs858267	ENSG00000230658.1	KLHL7-AS1	-7.02	4.02e-12	9.09e-10	-0.6	-0.21	Blood protein levels;	chr7:23170510	chr7:23101228~23105703:-
BRCA	cis	rs11098499	0.954	rs10518328	ENSG00000249244.1	RP11-548H18.2	7.02	4.02e-12	9.09e-10	0.25	0.21	Corneal astigmatism;	chr4:119480624	chr4:119391831~119395335:-
BRCA	cis	rs875971	0.545	rs17138149	ENSG00000236529.1	RP13-254B10.1	7.02	4.03e-12	9.09e-10	0.26	0.21	Aortic root size;	chr7:66228193	chr7:65840212~65840596:+
BRCA	cis	rs875971	1	rs6957199	ENSG00000232559.3	GS1-124K5.12	7.02	4.03e-12	9.1e-10	0.25	0.21	Aortic root size;	chr7:66513532	chr7:66554588~66576923:-
BRCA	cis	rs673078	0.607	rs7968011	ENSG00000275409.1	RP11-131L12.4	-7.02	4.05e-12	9.14e-10	-0.32	-0.21	Glucose homeostasis traits;	chr12:118382001	chr12:118430147~118430699:+
BRCA	cis	rs7131987	0.565	rs10843365	ENSG00000257176.2	RP11-996F15.2	7.02	4.05e-12	9.15e-10	0.25	0.21	QT interval;	chr12:29252691	chr12:29280418~29317848:-
BRCA	cis	rs4713118	0.568	rs9468213	ENSG00000216901.1	AL022393.7	7.02	4.06e-12	9.16e-10	0.27	0.21	Parkinson's disease;	chr6:27738401	chr6:28176188~28176674:+
BRCA	cis	rs10463554	0.853	rs246902	ENSG00000175749.11	EIF3KP1	7.02	4.06e-12	9.16e-10	0.28	0.21	Parkinson's disease;	chr5:103253553	chr5:103032376~103033031:+
BRCA	cis	rs10754283	0.905	rs7519969	ENSG00000231613.1	RP5-943J3.1	7.02	4.06e-12	9.16e-10	0.24	0.21	Amyotrophic lateral sclerosis (sporadic);	chr1:89643162	chr1:89788914~89790492:+
BRCA	cis	rs10754283	0.967	rs7519971	ENSG00000231613.1	RP5-943J3.1	7.02	4.06e-12	9.16e-10	0.24	0.21	Amyotrophic lateral sclerosis (sporadic);	chr1:89643184	chr1:89788914~89790492:+
BRCA	cis	rs10754283	0.967	rs7546410	ENSG00000231613.1	RP5-943J3.1	7.02	4.06e-12	9.16e-10	0.24	0.21	Amyotrophic lateral sclerosis (sporadic);	chr1:89644256	chr1:89788914~89790492:+
BRCA	cis	rs10754283	0.967	rs7515375	ENSG00000231613.1	RP5-943J3.1	7.02	4.06e-12	9.16e-10	0.24	0.21	Amyotrophic lateral sclerosis (sporadic);	chr1:89644295	chr1:89788914~89790492:+
BRCA	cis	rs10754283	0.901	rs6663526	ENSG00000231613.1	RP5-943J3.1	7.02	4.06e-12	9.16e-10	0.24	0.21	Amyotrophic lateral sclerosis (sporadic);	chr1:89645303	chr1:89788914~89790492:+
BRCA	cis	rs10754283	0.934	rs7529653	ENSG00000231613.1	RP5-943J3.1	7.02	4.06e-12	9.16e-10	0.24	0.21	Amyotrophic lateral sclerosis (sporadic);	chr1:89646292	chr1:89788914~89790492:+
BRCA	cis	rs10754283	0.87	rs2390764	ENSG00000231613.1	RP5-943J3.1	7.02	4.06e-12	9.16e-10	0.24	0.21	Amyotrophic lateral sclerosis (sporadic);	chr1:89647268	chr1:89788914~89790492:+
BRCA	cis	rs10754283	0.901	rs4520403	ENSG00000231613.1	RP5-943J3.1	7.02	4.06e-12	9.16e-10	0.24	0.21	Amyotrophic lateral sclerosis (sporadic);	chr1:89647281	chr1:89788914~89790492:+
BRCA	cis	rs10754283	0.967	rs4658130	ENSG00000231613.1	RP5-943J3.1	7.02	4.06e-12	9.16e-10	0.24	0.21	Amyotrophic lateral sclerosis (sporadic);	chr1:89647888	chr1:89788914~89790492:+
BRCA	cis	rs10754283	0.967	rs7528433	ENSG00000231613.1	RP5-943J3.1	7.02	4.06e-12	9.16e-10	0.24	0.21	Amyotrophic lateral sclerosis (sporadic);	chr1:89648512	chr1:89788914~89790492:+
BRCA	cis	rs10754283	0.967	rs7552896	ENSG00000231613.1	RP5-943J3.1	7.02	4.07e-12	9.17e-10	0.24	0.21	Amyotrophic lateral sclerosis (sporadic);	chr1:89637635	chr1:89788914~89790492:+
BRCA	cis	rs7617773	0.78	rs13066044	ENSG00000228638.1	FCF1P2	-7.02	4.07e-12	9.2e-10	-0.24	-0.21	Coronary artery disease;	chr3:48335786	chr3:48290793~48291375:-
BRCA	cis	rs79040073	0.637	rs73398250	ENSG00000259531.2	RP11-295H24.3	7.02	4.08e-12	9.22e-10	0.35	0.21	Lung cancer in ever smokers;	chr15:49404829	chr15:49365124~49366685:-
BRCA	cis	rs8031584	0.723	rs11632229	ENSG00000260382.1	RP11-540B6.2	-7.02	4.08e-12	9.22e-10	-0.25	-0.21	Huntington's disease progression;	chr15:30887331	chr15:30882267~30883231:-
BRCA	cis	rs9527	0.571	rs7096249	ENSG00000236937.2	PTGES3P4	7.02	4.09e-12	9.24e-10	0.27	0.21	Arsenic metabolism;	chr10:102858767	chr10:102845595~102845950:+
BRCA	cis	rs10861661	0.963	rs10778511	ENSG00000260329.1	RP11-412D9.4	-7.02	4.1e-12	9.24e-10	-0.26	-0.21	Triglyceride levels;	chr12:106831553	chr12:106954029~106955497:-
BRCA	cis	rs11024102	0.83	rs11024110	ENSG00000184669.7	OR7E14P	-7.02	4.1e-12	9.25e-10	-0.32	-0.21	Glaucoma (primary angle closure);	chr11:17006843	chr11:17013998~17053024:+
BRCA	cis	rs6840258	0.66	rs74784659	ENSG00000251411.1	RP11-397E7.4	-7.02	4.1e-12	9.26e-10	-0.3	-0.21	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86967777	chr4:86913266~86914817:-
BRCA	cis	rs6840258	0.66	rs17012213	ENSG00000251411.1	RP11-397E7.4	-7.02	4.1e-12	9.26e-10	-0.3	-0.21	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86968015	chr4:86913266~86914817:-
BRCA	cis	rs10050311	0.858	rs72667703	ENSG00000251411.1	RP11-397E7.4	-7.02	4.1e-12	9.26e-10	-0.32	-0.21	Insulin-related traits;	chr4:86891825	chr4:86913266~86914817:-
BRCA	cis	rs1501911	0.611	rs1875529	ENSG00000248489.1	CTD-2007H13.3	-7.02	4.11e-12	9.27e-10	-0.27	-0.21	Lung function (FEV1/FVC);	chr5:99033350	chr5:98929171~98995013:+
BRCA	cis	rs1499614	0.901	rs2178742	ENSG00000230295.1	RP11-458F8.2	-7.02	4.11e-12	9.28e-10	-0.29	-0.21	Gout;	chr7:66732812	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs2707844	ENSG00000232546.1	RP11-458F8.1	-7.02	4.11e-12	9.28e-10	-0.28	-0.21	Diabetic kidney disease;	chr7:66594522	chr7:66848496~66858136:+
BRCA	cis	rs2243480	1	rs1796220	ENSG00000232546.1	RP11-458F8.1	-7.02	4.11e-12	9.28e-10	-0.28	-0.21	Diabetic kidney disease;	chr7:66597113	chr7:66848496~66858136:+
BRCA	cis	rs2243480	1	rs2707831	ENSG00000232546.1	RP11-458F8.1	-7.02	4.11e-12	9.28e-10	-0.28	-0.21	Diabetic kidney disease;	chr7:66597524	chr7:66848496~66858136:+
BRCA	cis	rs10899021	1	rs11236190	ENSG00000279353.1	RP11-864N7.4	7.02	4.11e-12	9.28e-10	0.48	0.21	Response to metformin (IC50);	chr11:74655710	chr11:74698231~74699658:-
BRCA	cis	rs763567	0.585	rs577827	ENSG00000271811.1	RP1-79C4.4	7.02	4.11e-12	9.28e-10	0.23	0.21	Tonsillectomy;	chr1:170593942	chr1:170667381~170669425:+
BRCA	cis	rs2835345	0.563	rs78113480	ENSG00000230479.1	AP000695.6	7.02	4.13e-12	9.32e-10	0.21	0.21	Pulmonary function;	chr21:36452022	chr21:36430360~36481070:+
BRCA	cis	rs2835345	0.563	rs4378885	ENSG00000230479.1	AP000695.6	7.02	4.13e-12	9.32e-10	0.21	0.21	Pulmonary function;	chr21:36452613	chr21:36430360~36481070:+
BRCA	cis	rs2835345	0.563	rs4481073	ENSG00000230479.1	AP000695.6	7.02	4.13e-12	9.32e-10	0.21	0.21	Pulmonary function;	chr21:36452657	chr21:36430360~36481070:+
BRCA	cis	rs2835345	0.563	rs2835361	ENSG00000230479.1	AP000695.6	7.02	4.13e-12	9.32e-10	0.21	0.21	Pulmonary function;	chr21:36452699	chr21:36430360~36481070:+
BRCA	cis	rs875971	1	rs4718307	ENSG00000232559.3	GS1-124K5.12	-7.01	4.14e-12	9.33e-10	-0.25	-0.21	Aortic root size;	chr7:66146001	chr7:66554588~66576923:-
BRCA	cis	rs875971	1	rs7801282	ENSG00000232559.3	GS1-124K5.12	-7.01	4.14e-12	9.33e-10	-0.25	-0.21	Aortic root size;	chr7:66148700	chr7:66554588~66576923:-
BRCA	cis	rs6142102	0.961	rs4911407	ENSG00000275784.1	RP5-1125A11.6	-7.01	4.14e-12	9.33e-10	-0.25	-0.21	Skin pigmentation;	chr20:34095759	chr20:33989480~33991818:-
BRCA	cis	rs2842992	0.83	rs2758352	ENSG00000237927.1	RP3-393E18.2	-7.01	4.14e-12	9.33e-10	-0.3	-0.21	Age-related macular degeneration (geographic atrophy);	chr6:159701889	chr6:159586955~159589169:-
BRCA	cis	rs875971	0.545	rs316306	ENSG00000236529.1	RP13-254B10.1	-7.01	4.14e-12	9.33e-10	-0.26	-0.21	Aortic root size;	chr7:66153687	chr7:65840212~65840596:+
BRCA	cis	rs2243480	0.831	rs57294491	ENSG00000230295.1	RP11-458F8.2	7.01	4.14e-12	9.34e-10	0.29	0.21	Diabetic kidney disease;	chr7:66219914	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs2533288	ENSG00000230295.1	RP11-458F8.2	-7.01	4.15e-12	9.35e-10	-0.28	-0.21	Diabetic kidney disease;	chr7:66591724	chr7:66880708~66882981:+
BRCA	cis	rs957448	1	rs1055800	ENSG00000253175.1	RP11-267M23.6	-7.01	4.15e-12	9.36e-10	-0.26	-0.21	Nonsyndromic cleft lip with cleft palate;	chr8:94510810	chr8:94565036~94565715:+
BRCA	cis	rs838147	0.537	rs504963	ENSG00000232871.7	SEC1P	7.01	4.16e-12	9.37e-10	0.23	0.21	Dietary macronutrient intake;	chr19:48705608	chr19:48638071~48682245:+
BRCA	cis	rs2835345	0.563	rs73204246	ENSG00000230479.1	AP000695.6	7.01	4.19e-12	9.45e-10	0.21	0.21	Pulmonary function;	chr21:36452402	chr21:36430360~36481070:+
BRCA	cis	rs2835345	0.563	rs73204248	ENSG00000230479.1	AP000695.6	7.01	4.19e-12	9.45e-10	0.21	0.21	Pulmonary function;	chr21:36452411	chr21:36430360~36481070:+
BRCA	cis	rs2243480	0.803	rs34804747	ENSG00000273142.1	RP11-458F8.4	-7.01	4.19e-12	9.45e-10	-0.28	-0.21	Diabetic kidney disease;	chr7:65947955	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs59794892	ENSG00000273142.1	RP11-458F8.4	-7.01	4.19e-12	9.45e-10	-0.28	-0.21	Diabetic kidney disease;	chr7:65950886	chr7:66902857~66906297:+
BRCA	cis	rs2243480	0.803	rs36004293	ENSG00000273142.1	RP11-458F8.4	-7.01	4.19e-12	9.45e-10	-0.28	-0.21	Diabetic kidney disease;	chr7:65951525	chr7:66902857~66906297:+
BRCA	cis	rs2243480	0.803	rs35268390	ENSG00000273142.1	RP11-458F8.4	-7.01	4.19e-12	9.45e-10	-0.28	-0.21	Diabetic kidney disease;	chr7:65951549	chr7:66902857~66906297:+
BRCA	cis	rs875971	0.52	rs160645	ENSG00000236529.1	RP13-254B10.1	-7.01	4.19e-12	9.46e-10	-0.27	-0.21	Aortic root size;	chr7:66091320	chr7:65840212~65840596:+
BRCA	cis	rs673078	0.562	rs4767672	ENSG00000275409.1	RP11-131L12.4	-7.01	4.2e-12	9.46e-10	-0.32	-0.21	Glucose homeostasis traits;	chr12:118397048	chr12:118430147~118430699:+
BRCA	cis	rs673078	0.607	rs73205594	ENSG00000275409.1	RP11-131L12.4	-7.01	4.2e-12	9.46e-10	-0.32	-0.21	Glucose homeostasis traits;	chr12:118397168	chr12:118430147~118430699:+
BRCA	cis	rs9652601	0.919	rs12924729	ENSG00000274038.1	RP11-66H6.4	-7.01	4.2e-12	9.46e-10	-0.24	-0.21	Systemic lupus erythematosus;	chr16:11093926	chr16:11056556~11057034:+
BRCA	cis	rs6840360	0.642	rs2709834	ENSG00000270265.1	RP11-731D1.4	-7.01	4.2e-12	9.48e-10	-0.24	-0.21	Intelligence (multi-trait analysis);	chr4:151454272	chr4:151333775~151353224:-
BRCA	cis	rs2880765	0.835	rs4360875	ENSG00000259295.5	CSPG4P12	7.01	4.21e-12	9.49e-10	0.26	0.21	Coronary artery disease;	chr15:85497163	chr15:85191438~85213905:+
BRCA	cis	rs801193	0.967	rs2420827	ENSG00000236529.1	RP13-254B10.1	-7.01	4.21e-12	9.49e-10	-0.23	-0.21	Aortic root size;	chr7:66682114	chr7:65840212~65840596:+
BRCA	cis	rs10029851	0.627	rs2880787	ENSG00000234492.4	RPL34-AS1	7.01	4.21e-12	9.5e-10	0.33	0.21	Amyotrophic lateral sclerosis (sporadic);	chr4:108632175	chr4:108538190~108620460:-
BRCA	cis	rs8030379	1	rs2401173	ENSG00000230373.7	GOLGA6L5P	-7.01	4.21e-12	9.5e-10	-0.23	-0.21	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83908218	chr15:84507885~84516814:-
BRCA	cis	rs8003054	0.572	rs11626277	ENSG00000258515.1	RP11-203M5.7	7.01	4.22e-12	9.5e-10	0.19	0.21	Facial morphology (factor 1, breadth of lateral portion of upper face);	chr14:20445990	chr14:20451305~20451918:+
BRCA	cis	rs801193	1	rs13239306	ENSG00000236529.1	RP13-254B10.1	-7.01	4.22e-12	9.51e-10	-0.24	-0.21	Aortic root size;	chr7:66671030	chr7:65840212~65840596:+
BRCA	cis	rs7617773	0.78	rs11716848	ENSG00000228638.1	FCF1P2	-7.01	4.23e-12	9.53e-10	-0.24	-0.21	Coronary artery disease;	chr3:48337010	chr3:48290793~48291375:-
BRCA	cis	rs7246657	0.943	rs12981532	ENSG00000226686.6	LINC01535	-7.01	4.23e-12	9.53e-10	-0.33	-0.21	Coronary artery calcification;	chr19:37398378	chr19:37251912~37265535:+
BRCA	cis	rs7246657	0.943	rs7246993	ENSG00000226686.6	LINC01535	-7.01	4.23e-12	9.53e-10	-0.33	-0.21	Coronary artery calcification;	chr19:37399252	chr19:37251912~37265535:+
BRCA	cis	rs7246657	0.943	rs10413602	ENSG00000226686.6	LINC01535	-7.01	4.23e-12	9.53e-10	-0.33	-0.21	Coronary artery calcification;	chr19:37400590	chr19:37251912~37265535:+
BRCA	cis	rs2236231	0.55	rs12897715	ENSG00000259502.1	RP11-643G16.3	-7.01	4.24e-12	9.56e-10	-0.29	-0.21	Plasma kynurenine levels in major depressive disorder;	chr14:67593117	chr14:67610986~67613864:+
BRCA	cis	rs755249	1	rs61779359	ENSG00000237624.1	OXCT2P1	7.01	4.25e-12	9.58e-10	0.3	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39544563	chr1:39514956~39516490:+
BRCA	cis	rs755249	0.959	rs61781363	ENSG00000237624.1	OXCT2P1	7.01	4.25e-12	9.58e-10	0.3	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39546761	chr1:39514956~39516490:+
BRCA	cis	rs755249	1	rs4660808	ENSG00000237624.1	OXCT2P1	7.01	4.25e-12	9.58e-10	0.3	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39552837	chr1:39514956~39516490:+
BRCA	cis	rs755249	1	rs61781364	ENSG00000237624.1	OXCT2P1	7.01	4.25e-12	9.58e-10	0.3	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39553919	chr1:39514956~39516490:+
BRCA	cis	rs10754283	0.967	rs6428559	ENSG00000231613.1	RP5-943J3.1	7.01	4.26e-12	9.59e-10	0.24	0.21	Amyotrophic lateral sclerosis (sporadic);	chr1:89633477	chr1:89788914~89790492:+
BRCA	cis	rs3781264	0.848	rs10882422	ENSG00000273450.1	RP11-76P2.4	-7.01	4.26e-12	9.59e-10	-0.27	-0.21	Esophageal cancer and gastric cancer;	chr10:94313806	chr10:94314907~94315327:-
BRCA	cis	rs7208859	0.623	rs609063	ENSG00000266490.1	CTD-2349P21.9	7.01	4.26e-12	9.59e-10	0.33	0.21	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30624495	chr17:30792372~30792833:+
BRCA	cis	rs875971	0.8	rs427557	ENSG00000232559.3	GS1-124K5.12	7.01	4.26e-12	9.6e-10	0.26	0.21	Aortic root size;	chr7:66054263	chr7:66554588~66576923:-
BRCA	cis	rs11098499	0.908	rs7696649	ENSG00000249244.1	RP11-548H18.2	7.01	4.27e-12	9.61e-10	0.25	0.21	Corneal astigmatism;	chr4:119401022	chr4:119391831~119395335:-
BRCA	cis	rs8003054	0.537	rs11160711	ENSG00000258515.1	RP11-203M5.7	-7.01	4.27e-12	9.61e-10	-0.19	-0.21	Facial morphology (factor 1, breadth of lateral portion of upper face);	chr14:20445837	chr14:20451305~20451918:+
BRCA	cis	rs2842992	0.747	rs733319	ENSG00000237927.1	RP3-393E18.2	-7.01	4.28e-12	9.64e-10	-0.31	-0.21	Age-related macular degeneration (geographic atrophy);	chr6:159800443	chr6:159586955~159589169:-
BRCA	cis	rs293748	0.771	rs58952013	ENSG00000250155.1	CTD-2353F22.1	-7.01	4.28e-12	9.64e-10	-0.29	-0.21	Obesity-related traits;	chr5:36787362	chr5:36666214~36725195:-
BRCA	cis	rs881375	0.967	rs1548783	ENSG00000226752.6	PSMD5-AS1	-7.01	4.28e-12	9.65e-10	-0.26	-0.21	Rheumatoid arthritis;	chr9:120896361	chr9:120824828~120854385:+
BRCA	cis	rs79040073	0.637	rs11634636	ENSG00000259531.2	RP11-295H24.3	7.01	4.29e-12	9.65e-10	0.37	0.21	Lung cancer in ever smokers;	chr15:49315407	chr15:49365124~49366685:-
BRCA	cis	rs1555322	0.53	rs932562	ENSG00000279253.1	RP4-614O4.13	-7.01	4.29e-12	9.66e-10	-0.28	-0.21	Attention deficit hyperactivity disorder;	chr20:35283507	chr20:35262727~35264187:-
BRCA	cis	rs875971	0.564	rs313804	ENSG00000232559.3	GS1-124K5.12	7.01	4.3e-12	9.68e-10	0.25	0.21	Aortic root size;	chr7:66049635	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.662	rs448725	ENSG00000232559.3	GS1-124K5.12	7.01	4.3e-12	9.68e-10	0.25	0.21	Aortic root size;	chr7:66049641	chr7:66554588~66576923:-
BRCA	cis	rs7976269	0.515	rs11049999	ENSG00000257176.2	RP11-996F15.2	-7.01	4.3e-12	9.69e-10	-0.25	-0.21	Male-pattern baldness;	chr12:29042854	chr12:29280418~29317848:-
BRCA	cis	rs61270009	0.955	rs415449	ENSG00000247828.6	TMEM161B-AS1	-7.01	4.3e-12	9.69e-10	-0.27	-0.21	Depressive symptoms;	chr5:88231533	chr5:88268895~88436685:+
BRCA	cis	rs780094	0.544	rs780110	ENSG00000234072.1	AC074117.10	-7.01	4.31e-12	9.7e-10	-0.21	-0.21	Urate levels in overweight individuals;C-reactive protein;Metabolic syndrome;Red blood cell count;Renal underexcretion gout;Nonalcoholic fatty liver disease;Age-related diseases, mortality and associated endophenotypes;Crohn's disease;Calcium levels;Fasting plasma glucose;Metabolic traits;Fasting blood glucose;Fasting blood insulin;Urate levels in obese individuals;Alcohol consumption (drinks per week);Height;Urate levels;Gondoic acid (20:1n-9) levels;Uric acid levels;Age-related disease endophenotypes;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Homeostasis model assessment of insulin resistance;Alcohol consumption;Fasting blood insulin (BMI interaction);Triglycerides;Fasting blood glucose (BMI interaction);Hypertriglyceridemia;LDL cholesterol;Type 2 diabetes;Triglyceride levels;	chr2:27462521	chr2:27356246~27367622:+
BRCA	cis	rs12200782	0.505	rs9295696	ENSG00000241549.7	GUSBP2	7.01	4.32e-12	9.73e-10	0.27	0.21	Small cell lung carcinoma;	chr6:26550060	chr6:26871484~26956554:-
BRCA	cis	rs2348418	0.832	rs1032391	ENSG00000247934.4	RP11-967K21.1	7.01	4.33e-12	9.75e-10	0.24	0.21	Lung function (FEV1);Lung function (FVC);	chr12:28383775	chr12:28163298~28190738:-
BRCA	cis	rs12237653	0.929	rs10966874	ENSG00000236404.7	VLDLR-AS1	7.01	4.34e-12	9.77e-10	0.33	0.21	Gambling;	chr9:2545581	chr9:2422702~2643359:-
BRCA	cis	rs9907295	0.818	rs9303692	ENSG00000270977.1	AC015849.16	7.01	4.34e-12	9.77e-10	0.3	0.21	Fibroblast growth factor basic levels;	chr17:35861492	chr17:35893707~35911023:-
BRCA	cis	rs11098499	0.863	rs1552095	ENSG00000249244.1	RP11-548H18.2	7.01	4.34e-12	9.78e-10	0.26	0.21	Corneal astigmatism;	chr4:119539151	chr4:119391831~119395335:-
BRCA	cis	rs748404	0.666	rs514438	ENSG00000249839.1	AC011330.5	-7.01	4.35e-12	9.78e-10	-0.3	-0.21	Lung cancer;	chr15:43328245	chr15:43663654~43684339:-
BRCA	cis	rs755249	0.567	rs2036463	ENSG00000228060.1	RP11-69E11.8	-7.01	4.35e-12	9.78e-10	-0.26	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39222403	chr1:39565160~39573203:+
BRCA	cis	rs755249	0.567	rs2036464	ENSG00000228060.1	RP11-69E11.8	-7.01	4.35e-12	9.78e-10	-0.26	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39222570	chr1:39565160~39573203:+
BRCA	cis	rs755249	0.567	rs905381	ENSG00000228060.1	RP11-69E11.8	-7.01	4.35e-12	9.78e-10	-0.26	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39222880	chr1:39565160~39573203:+
BRCA	cis	rs9309473	1	rs56154726	ENSG00000163016.8	ALMS1P	7.01	4.35e-12	9.79e-10	0.28	0.21	Metabolite levels;	chr2:73494640	chr2:73644919~73685576:+
BRCA	cis	rs1823913	0.637	rs11688994	ENSG00000280083.1	RP11-317J9.1	-7.01	4.36e-12	9.82e-10	-0.24	-0.21	Obesity-related traits;	chr2:191266242	chr2:191154118~191156070:-
BRCA	cis	rs673078	0.607	rs17441172	ENSG00000275409.1	RP11-131L12.4	7.01	4.37e-12	9.83e-10	0.31	0.21	Glucose homeostasis traits;	chr12:118430456	chr12:118430147~118430699:+
BRCA	cis	rs13113518	0.513	rs13147861	ENSG00000249700.7	SRD5A3-AS1	7.01	4.37e-12	9.84e-10	0.27	0.21	Height;	chr4:55611014	chr4:55363971~55395847:-
BRCA	cis	rs58873874	0.579	rs77042939	ENSG00000248544.2	CTB-47B11.3	7.01	4.38e-12	9.86e-10	0.46	0.21	Bipolar disorder (body mass index interaction);	chr5:157303027	chr5:157375741~157384950:-
BRCA	cis	rs526231	0.543	rs246905	ENSG00000175749.11	EIF3KP1	7.01	4.39e-12	9.87e-10	0.3	0.21	Primary biliary cholangitis;	chr5:103255242	chr5:103032376~103033031:+
BRCA	cis	rs2492286	0.597	rs2712407	ENSG00000242551.2	POU5F1P6	-7.01	4.39e-12	9.88e-10	-0.32	-0.21	Eosinophil counts;	chr3:128607964	chr3:128674735~128677005:-
BRCA	cis	rs780094	0.544	rs780108	ENSG00000234072.1	AC074117.10	-7.01	4.4e-12	9.89e-10	-0.21	-0.21	Urate levels in overweight individuals;C-reactive protein;Metabolic syndrome;Red blood cell count;Renal underexcretion gout;Nonalcoholic fatty liver disease;Age-related diseases, mortality and associated endophenotypes;Crohn's disease;Calcium levels;Fasting plasma glucose;Metabolic traits;Fasting blood glucose;Fasting blood insulin;Urate levels in obese individuals;Alcohol consumption (drinks per week);Height;Urate levels;Gondoic acid (20:1n-9) levels;Uric acid levels;Age-related disease endophenotypes;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Homeostasis model assessment of insulin resistance;Alcohol consumption;Fasting blood insulin (BMI interaction);Triglycerides;Fasting blood glucose (BMI interaction);Hypertriglyceridemia;LDL cholesterol;Type 2 diabetes;Triglyceride levels;	chr2:27462090	chr2:27356246~27367622:+
BRCA	cis	rs4835473	0.932	rs4835455	ENSG00000251600.4	RP11-673E1.1	7.01	4.41e-12	9.91e-10	0.25	0.21	Immature fraction of reticulocytes;	chr4:143962290	chr4:143912331~143982454:+
BRCA	cis	rs2348418	0.801	rs7298379	ENSG00000247934.4	RP11-967K21.1	7.01	4.42e-12	9.93e-10	0.24	0.21	Lung function (FEV1);Lung function (FVC);	chr12:28270541	chr12:28163298~28190738:-
BRCA	cis	rs17301013	0.531	rs6678286	ENSG00000227373.4	RP11-160H22.5	7.01	4.42e-12	9.93e-10	0.3	0.21	Systemic lupus erythematosus;	chr1:174200481	chr1:174115300~174160004:-
BRCA	cis	rs6723162	0.868	rs2215826	ENSG00000237751.2	LINC01143	-7	4.43e-12	9.95e-10	-0.25	-0.21	Neurocognitive impairment in HIV-1 infection (dichotomous);	chr2:70886266	chr2:70887871~70889959:+
BRCA	cis	rs9309473	1	rs13398956	ENSG00000163016.8	ALMS1P	7	4.43e-12	9.97e-10	0.28	0.21	Metabolite levels;	chr2:73493131	chr2:73644919~73685576:+
BRCA	cis	rs7809950	0.954	rs3779494	ENSG00000238832.1	snoU109	7	4.44e-12	9.98e-10	0.29	0.21	Coronary artery disease;	chr7:107609910	chr7:107603363~107603507:+
BRCA	cis	rs2243480	0.708	rs35825036	ENSG00000232546.1	RP11-458F8.1	-7	4.44e-12	9.98e-10	-0.28	-0.21	Diabetic kidney disease;	chr7:66521515	chr7:66848496~66858136:+
BRCA	cis	rs2243480	1	rs13237037	ENSG00000232546.1	RP11-458F8.1	-7	4.44e-12	9.98e-10	-0.28	-0.21	Diabetic kidney disease;	chr7:66532895	chr7:66848496~66858136:+
BRCA	cis	rs2243480	1	rs1796228	ENSG00000232546.1	RP11-458F8.1	-7	4.44e-12	9.98e-10	-0.28	-0.21	Diabetic kidney disease;	chr7:66568097	chr7:66848496~66858136:+
BRCA	cis	rs77972916	0.561	rs72788900	ENSG00000234936.1	AC010883.5	7	4.44e-12	9.99e-10	0.31	0.21	Granulocyte percentage of myeloid white cells;	chr2:43331948	chr2:43229573~43233394:+
BRCA	cis	rs9880211	0.8	rs35880395	ENSG00000273486.1	RP11-731C17.2	7	4.45e-12	9.99e-10	0.29	0.21	Height;Body mass index;	chr3:136788248	chr3:136837338~136839021:-
BRCA	cis	rs9287719	0.674	rs6432130	ENSG00000234818.1	AC092687.5	-7	4.45e-12	1e-09	-0.25	-0.21	Prostate cancer;	chr2:10681431	chr2:10589166~10604830:+
BRCA	cis	rs4727443	0.866	rs35228488	ENSG00000235713.1	RP4-604G5.3	-7	4.45e-12	1e-09	-0.24	-0.21	Interstitial lung disease;	chr7:100020229	chr7:99992397~99993050:+
BRCA	cis	rs9880211	0.752	rs9847427	ENSG00000273486.1	RP11-731C17.2	7	4.45e-12	1e-09	0.29	0.21	Height;Body mass index;	chr3:136632708	chr3:136837338~136839021:-
BRCA	cis	rs919433	0.963	rs1896854	ENSG00000231621.1	AC013264.2	7	4.46e-12	1e-09	0.19	0.21	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197283052	chr2:197197991~197199273:+
BRCA	cis	rs61160187	0.582	rs72757187	ENSG00000215032.2	GNL3LP1	7	4.46e-12	1e-09	0.27	0.21	Educational attainment (years of education);Educational attainment (college completion);	chr5:60967939	chr5:60891935~60893577:-
BRCA	cis	rs7586673	0.93	rs6432667	ENSG00000235724.7	AC009299.2	-7	4.46e-12	1e-09	-0.25	-0.21	Intelligence (multi-trait analysis);	chr2:161048490	chr2:161222785~161308303:-
BRCA	cis	rs9527	0.615	rs4919685	ENSG00000213061.2	PFN1P11	7	4.46e-12	1e-09	0.31	0.21	Arsenic metabolism;	chr10:102827605	chr10:102838011~102845473:-
BRCA	cis	rs293748	0.771	rs12656269	ENSG00000250155.1	CTD-2353F22.1	7	4.46e-12	1e-09	0.29	0.21	Obesity-related traits;	chr5:36787776	chr5:36666214~36725195:-
BRCA	cis	rs9527	1	rs4919690	ENSG00000213061.2	PFN1P11	-7	4.47e-12	1e-09	-0.32	-0.21	Arsenic metabolism;	chr10:102856743	chr10:102838011~102845473:-
BRCA	cis	rs2243480	1	rs958550	ENSG00000230295.1	RP11-458F8.2	7	4.47e-12	1e-09	0.27	0.21	Diabetic kidney disease;	chr7:66170692	chr7:66880708~66882981:+
BRCA	cis	rs1322639	0.697	rs12661910	ENSG00000261039.2	RP11-417E7.2	-7	4.49e-12	1.01e-09	-0.26	-0.21	Pulse pressure;	chr6:169184293	chr6:169175304~169182740:-
BRCA	cis	rs2243480	1	rs1267820	ENSG00000232546.1	RP11-458F8.1	-7	4.49e-12	1.01e-09	-0.29	-0.21	Diabetic kidney disease;	chr7:66585308	chr7:66848496~66858136:+
BRCA	cis	rs9876781	1	rs2362452	ENSG00000244380.1	RP11-24C3.2	-7	4.49e-12	1.01e-09	-0.24	-0.21	Longevity;	chr3:48376724	chr3:48440352~48446656:-
BRCA	cis	rs61270009	0.955	rs430943	ENSG00000247828.6	TMEM161B-AS1	-7	4.49e-12	1.01e-09	-0.28	-0.21	Depressive symptoms;	chr5:88251306	chr5:88268895~88436685:+
BRCA	cis	rs61270009	0.913	rs373845	ENSG00000247828.6	TMEM161B-AS1	-7	4.49e-12	1.01e-09	-0.28	-0.21	Depressive symptoms;	chr5:88253893	chr5:88268895~88436685:+
BRCA	cis	rs1823913	0.637	rs11686185	ENSG00000280083.1	RP11-317J9.1	7	4.49e-12	1.01e-09	0.24	0.21	Obesity-related traits;	chr2:191289282	chr2:191154118~191156070:-
BRCA	cis	rs4865169	0.595	rs9998008	ENSG00000269949.1	RP11-738E22.3	7	4.5e-12	1.01e-09	0.25	0.21	Breast cancer;	chr4:56899886	chr4:56960927~56961373:-
BRCA	cis	rs2243480	0.831	rs57294491	ENSG00000232546.1	RP11-458F8.1	7	4.5e-12	1.01e-09	0.29	0.21	Diabetic kidney disease;	chr7:66219914	chr7:66848496~66858136:+
BRCA	cis	rs8054556	0.692	rs4424923	ENSG00000273724.1	RP11-347C12.12	-7	4.5e-12	1.01e-09	-0.23	-0.21	Autism spectrum disorder or schizophrenia;	chr16:29927972	chr16:30336400~30343336:+
BRCA	cis	rs875971	1	rs2087647	ENSG00000232559.3	GS1-124K5.12	-7	4.5e-12	1.01e-09	-0.25	-0.21	Aortic root size;	chr7:66128201	chr7:66554588~66576923:-
BRCA	cis	rs9840812	0.623	rs4678433	ENSG00000239213.4	NCK1-AS1	7	4.51e-12	1.01e-09	0.25	0.21	Fibrinogen levels;	chr3:136546840	chr3:136841726~136862054:-
BRCA	cis	rs875971	0.964	rs778723	ENSG00000232559.3	GS1-124K5.12	7	4.51e-12	1.01e-09	0.25	0.21	Aortic root size;	chr7:66364510	chr7:66554588~66576923:-
BRCA	cis	rs61160187	0.582	rs62367903	ENSG00000215032.2	GNL3LP1	7	4.52e-12	1.01e-09	0.26	0.21	Educational attainment (years of education);Educational attainment (college completion);	chr5:61023146	chr5:60891935~60893577:-
BRCA	cis	rs17301013	0.581	rs7551605	ENSG00000227373.4	RP11-160H22.5	7	4.52e-12	1.02e-09	0.3	0.21	Systemic lupus erythematosus;	chr1:174245718	chr1:174115300~174160004:-
BRCA	cis	rs10754283	0.967	rs10801763	ENSG00000231613.1	RP5-943J3.1	7	4.52e-12	1.02e-09	0.24	0.21	Amyotrophic lateral sclerosis (sporadic);	chr1:89655263	chr1:89788914~89790492:+
BRCA	cis	rs11098499	0.909	rs1546504	ENSG00000249244.1	RP11-548H18.2	7	4.53e-12	1.02e-09	0.25	0.21	Corneal astigmatism;	chr4:119320024	chr4:119391831~119395335:-
BRCA	cis	rs780096	0.546	rs715325	ENSG00000234072.1	AC074117.10	-7	4.53e-12	1.02e-09	-0.21	-0.21	Total body bone mineral density;	chr2:27502705	chr2:27356246~27367622:+
BRCA	cis	rs2243480	1	rs6958420	ENSG00000230295.1	RP11-458F8.2	7	4.54e-12	1.02e-09	0.28	0.21	Diabetic kidney disease;	chr7:66286184	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs1392104	ENSG00000230295.1	RP11-458F8.2	7	4.54e-12	1.02e-09	0.28	0.21	Diabetic kidney disease;	chr7:66294120	chr7:66880708~66882981:+
BRCA	cis	rs17253792	0.822	rs76819679	ENSG00000186615.9	KTN1-AS1	-7	4.54e-12	1.02e-09	-0.44	-0.21	Putamen volume;	chr14:55667954	chr14:55499278~55580110:-
BRCA	cis	rs17772222	0.682	rs28711639	ENSG00000258983.2	RP11-507K2.2	7	4.55e-12	1.02e-09	0.22	0.21	Coronary artery calcification;	chr14:88482277	chr14:88499334~88515502:+
BRCA	cis	rs10463554	0.655	rs152138	ENSG00000175749.11	EIF3KP1	7	4.56e-12	1.02e-09	0.3	0.21	Parkinson's disease;	chr5:103223727	chr5:103032376~103033031:+
BRCA	cis	rs957448	1	rs2381882	ENSG00000253175.1	RP11-267M23.6	7	4.56e-12	1.02e-09	0.27	0.21	Nonsyndromic cleft lip with cleft palate;	chr8:94535496	chr8:94565036~94565715:+
BRCA	cis	rs3781264	0.724	rs10882435	ENSG00000273450.1	RP11-76P2.4	7	4.56e-12	1.02e-09	0.29	0.21	Esophageal cancer and gastric cancer;	chr10:94348110	chr10:94314907~94315327:-
BRCA	cis	rs3781264	0.761	rs11187899	ENSG00000273450.1	RP11-76P2.4	7	4.56e-12	1.02e-09	0.29	0.21	Esophageal cancer and gastric cancer;	chr10:94348345	chr10:94314907~94315327:-
BRCA	cis	rs3781264	0.687	rs10882436	ENSG00000273450.1	RP11-76P2.4	7	4.56e-12	1.02e-09	0.29	0.21	Esophageal cancer and gastric cancer;	chr10:94349043	chr10:94314907~94315327:-
BRCA	cis	rs875971	1	rs1565531	ENSG00000224316.1	RP11-479O9.2	-7	4.58e-12	1.03e-09	-0.21	-0.21	Aortic root size;	chr7:66198126	chr7:65773620~65802067:+
BRCA	cis	rs875971	1	rs6958484	ENSG00000232559.3	GS1-124K5.12	-7	4.58e-12	1.03e-09	-0.25	-0.21	Aortic root size;	chr7:66134459	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.658	rs432667	ENSG00000232559.3	GS1-124K5.12	7	4.59e-12	1.03e-09	0.25	0.21	Aortic root size;	chr7:66049646	chr7:66554588~66576923:-
BRCA	cis	rs17301013	0.606	rs11802158	ENSG00000227373.4	RP11-160H22.5	7	4.59e-12	1.03e-09	0.3	0.21	Systemic lupus erythematosus;	chr1:174223973	chr1:174115300~174160004:-
BRCA	cis	rs17301013	0.581	rs12081445	ENSG00000227373.4	RP11-160H22.5	7	4.59e-12	1.03e-09	0.3	0.21	Systemic lupus erythematosus;	chr1:174226923	chr1:174115300~174160004:-
BRCA	cis	rs7945705	0.791	rs7944560	ENSG00000254860.4	TMEM9B-AS1	-7	4.59e-12	1.03e-09	-0.2	-0.21	Hemoglobin concentration;	chr11:8795729	chr11:8964675~8977527:+
BRCA	cis	rs1864400	0.605	rs12360493	ENSG00000273008.1	RP11-351D16.3	7	4.6e-12	1.03e-09	0.25	0.21	Hirschsprung disease;	chr10:43223165	chr10:43136824~43138334:-
BRCA	cis	rs61270009	0.955	rs75214722	ENSG00000247828.6	TMEM161B-AS1	7	4.6e-12	1.03e-09	0.28	0.21	Depressive symptoms;	chr5:88269908	chr5:88268895~88436685:+
BRCA	cis	rs875971	0.545	rs6979636	ENSG00000224316.1	RP11-479O9.2	7	4.6e-12	1.03e-09	0.24	0.21	Aortic root size;	chr7:66276638	chr7:65773620~65802067:+
BRCA	cis	rs2145598	1	rs2145598	ENSG00000279636.2	LINC00216	-7	4.61e-12	1.03e-09	-0.21	-0.21	Coronary artery disease;	chr14:58327283	chr14:58288033~58289158:+
BRCA	cis	rs11098499	0.954	rs9998585	ENSG00000249244.1	RP11-548H18.2	7	4.61e-12	1.04e-09	0.25	0.21	Corneal astigmatism;	chr4:119475647	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.909	rs6842762	ENSG00000249244.1	RP11-548H18.2	7	4.61e-12	1.04e-09	0.25	0.21	Corneal astigmatism;	chr4:119477081	chr4:119391831~119395335:-
BRCA	cis	rs875971	0.619	rs10278371	ENSG00000236529.1	RP13-254B10.1	-7	4.62e-12	1.04e-09	-0.23	-0.21	Aortic root size;	chr7:66586553	chr7:65840212~65840596:+
BRCA	cis	rs2060793	0.741	rs4757268	ENSG00000251991.1	RNU7-49P	7	4.62e-12	1.04e-09	0.23	0.21	Vitamin D levels;	chr11:14789216	chr11:14478892~14478953:+
BRCA	cis	rs1862618	0.802	rs2591949	ENSG00000271828.1	CTD-2310F14.1	7	4.63e-12	1.04e-09	0.3	0.21	Initial pursuit acceleration;	chr5:56836800	chr5:56927874~56929573:+
BRCA	cis	rs1862618	0.853	rs2548664	ENSG00000271828.1	CTD-2310F14.1	7	4.63e-12	1.04e-09	0.3	0.21	Initial pursuit acceleration;	chr5:56837728	chr5:56927874~56929573:+
BRCA	cis	rs237743	1	rs238150	ENSG00000222365.1	SNORD12B	-7	4.64e-12	1.04e-09	-0.27	-0.21	Height;	chr20:49235382	chr20:49280319~49280409:+
BRCA	cis	rs2348418	0.864	rs1949978	ENSG00000247934.4	RP11-967K21.1	7	4.64e-12	1.04e-09	0.24	0.21	Lung function (FEV1);Lung function (FVC);	chr12:28443951	chr12:28163298~28190738:-
BRCA	cis	rs673078	0.607	rs2036314	ENSG00000275409.1	RP11-131L12.4	-7	4.64e-12	1.04e-09	-0.27	-0.21	Glucose homeostasis traits;	chr12:118367132	chr12:118430147~118430699:+
BRCA	cis	rs673078	0.607	rs61943369	ENSG00000275409.1	RP11-131L12.4	-7	4.64e-12	1.04e-09	-0.27	-0.21	Glucose homeostasis traits;	chr12:118368145	chr12:118430147~118430699:+
BRCA	cis	rs2303759	0.543	rs7255778	ENSG00000268686.1	AC010524.2	-7	4.66e-12	1.05e-09	-0.32	-0.21	Multiple sclerosis;	chr19:49403351	chr19:49368705~49388081:-
BRCA	cis	rs6539288	0.803	rs10778517	ENSG00000260329.1	RP11-412D9.4	7	4.67e-12	1.05e-09	0.24	0.21	Total body bone mineral density;	chr12:106947886	chr12:106954029~106955497:-
BRCA	cis	rs801193	1	rs4717319	ENSG00000236529.1	RP13-254B10.1	7	4.68e-12	1.05e-09	0.23	0.21	Aortic root size;	chr7:66777606	chr7:65840212~65840596:+
BRCA	cis	rs2243480	1	rs316321	ENSG00000232546.1	RP11-458F8.1	-7	4.69e-12	1.05e-09	-0.28	-0.21	Diabetic kidney disease;	chr7:66146626	chr7:66848496~66858136:+
BRCA	cis	rs2243480	1	rs316318	ENSG00000232546.1	RP11-458F8.1	-7	4.69e-12	1.05e-09	-0.28	-0.21	Diabetic kidney disease;	chr7:66147917	chr7:66848496~66858136:+
BRCA	cis	rs2243480	1	rs316317	ENSG00000232546.1	RP11-458F8.1	-7	4.69e-12	1.05e-09	-0.28	-0.21	Diabetic kidney disease;	chr7:66148650	chr7:66848496~66858136:+
BRCA	cis	rs2243480	1	rs316304	ENSG00000232546.1	RP11-458F8.1	-7	4.69e-12	1.05e-09	-0.28	-0.21	Diabetic kidney disease;	chr7:66151907	chr7:66848496~66858136:+
BRCA	cis	rs6921919	0.583	rs7759191	ENSG00000204709.4	LINC01556	7	4.69e-12	1.05e-09	0.29	0.21	Autism spectrum disorder or schizophrenia;	chr6:28385657	chr6:28943877~28944537:+
BRCA	cis	rs6921919	0.583	rs7764737	ENSG00000204709.4	LINC01556	7	4.69e-12	1.05e-09	0.29	0.21	Autism spectrum disorder or schizophrenia;	chr6:28386838	chr6:28943877~28944537:+
BRCA	cis	rs6921919	0.583	rs9461458	ENSG00000204709.4	LINC01556	7	4.69e-12	1.05e-09	0.29	0.21	Autism spectrum disorder or schizophrenia;	chr6:28388098	chr6:28943877~28944537:+
BRCA	cis	rs6921919	0.609	rs9468365	ENSG00000204709.4	LINC01556	7	4.69e-12	1.05e-09	0.29	0.21	Autism spectrum disorder or schizophrenia;	chr6:28390189	chr6:28943877~28944537:+
BRCA	cis	rs6921919	0.583	rs1361385	ENSG00000204709.4	LINC01556	7	4.69e-12	1.05e-09	0.29	0.21	Autism spectrum disorder or schizophrenia;	chr6:28390543	chr6:28943877~28944537:+
BRCA	cis	rs6921919	0.583	rs1416918	ENSG00000204709.4	LINC01556	7	4.69e-12	1.05e-09	0.29	0.21	Autism spectrum disorder or schizophrenia;	chr6:28390558	chr6:28943877~28944537:+
BRCA	cis	rs6921919	0.583	rs9468367	ENSG00000204709.4	LINC01556	7	4.69e-12	1.05e-09	0.29	0.21	Autism spectrum disorder or schizophrenia;	chr6:28392469	chr6:28943877~28944537:+
BRCA	cis	rs2060793	0.712	rs11023310	ENSG00000251991.1	RNU7-49P	7	4.69e-12	1.05e-09	0.23	0.21	Vitamin D levels;	chr11:14703717	chr11:14478892~14478953:+
BRCA	cis	rs17253792	0.822	rs74940664	ENSG00000186615.9	KTN1-AS1	-7	4.7e-12	1.05e-09	-0.44	-0.21	Putamen volume;	chr14:55668347	chr14:55499278~55580110:-
BRCA	cis	rs591584	0.73	rs11020847	ENSG00000255893.1	RP11-685N10.1	7	4.7e-12	1.05e-09	0.25	0.21	Macrophage Migration Inhibitory Factor levels;	chr11:94590746	chr11:94472908~94473570:-
BRCA	cis	rs801193	0.967	rs2707849	ENSG00000236529.1	RP13-254B10.1	7	4.7e-12	1.05e-09	0.23	0.21	Aortic root size;	chr7:66687725	chr7:65840212~65840596:+
BRCA	cis	rs2742234	0.541	rs1879310	ENSG00000273008.1	RP11-351D16.3	7	4.71e-12	1.05e-09	0.26	0.21	Hirschsprung disease;	chr10:43239327	chr10:43136824~43138334:-
BRCA	cis	rs8031584	0.958	rs35256769	ENSG00000260382.1	RP11-540B6.2	7	4.71e-12	1.06e-09	0.25	0.21	Huntington's disease progression;	chr15:30945573	chr15:30882267~30883231:-
BRCA	cis	rs8031584	0.958	rs11629793	ENSG00000260382.1	RP11-540B6.2	7	4.71e-12	1.06e-09	0.25	0.21	Huntington's disease progression;	chr15:30946220	chr15:30882267~30883231:-
BRCA	cis	rs17301013	0.606	rs1853321	ENSG00000227373.4	RP11-160H22.5	7	4.72e-12	1.06e-09	0.3	0.21	Systemic lupus erythematosus;	chr1:174125295	chr1:174115300~174160004:-
BRCA	cis	rs79040073	0.637	rs73392277	ENSG00000259531.2	RP11-295H24.3	7	4.72e-12	1.06e-09	0.36	0.21	Lung cancer in ever smokers;	chr15:49243772	chr15:49365124~49366685:-
BRCA	cis	rs7246657	1	rs10426297	ENSG00000276846.1	CTD-3220F14.3	7	4.74e-12	1.06e-09	0.29	0.21	Coronary artery calcification;	chr19:37307471	chr19:37314868~37315620:-
BRCA	cis	rs6840360	0.642	rs2709822	ENSG00000270265.1	RP11-731D1.4	-7	4.74e-12	1.06e-09	-0.24	-0.21	Intelligence (multi-trait analysis);	chr4:151430348	chr4:151333775~151353224:-
BRCA	cis	rs61160187	0.582	rs1471488	ENSG00000215032.2	GNL3LP1	6.99	4.75e-12	1.06e-09	0.26	0.21	Educational attainment (years of education);Educational attainment (college completion);	chr5:60990270	chr5:60891935~60893577:-
BRCA	cis	rs2835345	0.63	rs55681268	ENSG00000230479.1	AP000695.6	6.99	4.75e-12	1.06e-09	0.21	0.21	Pulmonary function;	chr21:36449419	chr21:36430360~36481070:+
BRCA	cis	rs801193	1	rs2420824	ENSG00000237310.1	GS1-124K5.4	-6.99	4.76e-12	1.07e-09	-0.22	-0.21	Aortic root size;	chr7:66666129	chr7:66493706~66495474:+
BRCA	cis	rs9309473	1	rs9309473	ENSG00000163016.8	ALMS1P	6.99	4.76e-12	1.07e-09	0.27	0.21	Metabolite levels;	chr2:73516855	chr2:73644919~73685576:+
BRCA	cis	rs673078	0.607	rs17512763	ENSG00000275409.1	RP11-131L12.4	-6.99	4.77e-12	1.07e-09	-0.31	-0.21	Glucose homeostasis traits;	chr12:118400974	chr12:118430147~118430699:+
BRCA	cis	rs6921919	0.609	rs1005127	ENSG00000204709.4	LINC01556	6.99	4.77e-12	1.07e-09	0.29	0.21	Autism spectrum disorder or schizophrenia;	chr6:28399881	chr6:28943877~28944537:+
BRCA	cis	rs853679	0.515	rs4580862	ENSG00000204709.4	LINC01556	6.99	4.77e-12	1.07e-09	0.29	0.21	Depression;	chr6:28399886	chr6:28943877~28944537:+
BRCA	cis	rs6921919	0.583	rs4357130	ENSG00000204709.4	LINC01556	6.99	4.77e-12	1.07e-09	0.29	0.21	Autism spectrum disorder or schizophrenia;	chr6:28399906	chr6:28943877~28944537:+
BRCA	cis	rs9876781	1	rs7630741	ENSG00000244380.1	RP11-24C3.2	6.99	4.77e-12	1.07e-09	0.25	0.21	Longevity;	chr3:48378233	chr3:48440352~48446656:-
BRCA	cis	rs459482	1	rs459498	ENSG00000228318.3	AP001610.5	-6.99	4.77e-12	1.07e-09	-0.25	-0.21	IgG glycosylation;	chr21:41423100	chr21:41441056~41445708:-
BRCA	cis	rs2599510	0.703	rs58852184	ENSG00000276334.1	AL133243.1	6.99	4.77e-12	1.07e-09	0.26	0.21	Interleukin-18 levels;	chr2:32504696	chr2:32521927~32523547:+
BRCA	cis	rs58873874	0.579	rs10037386	ENSG00000248544.2	CTB-47B11.3	6.99	4.78e-12	1.07e-09	0.41	0.21	Bipolar disorder (body mass index interaction);	chr5:157342641	chr5:157375741~157384950:-
BRCA	cis	rs7119038	0.509	rs10892256	ENSG00000255239.1	AP002954.6	-6.99	4.79e-12	1.07e-09	-0.3	-0.21	Sjögren's syndrome;	chr11:118707996	chr11:118688039~118690600:-
BRCA	cis	rs7119038	0.509	rs10892257	ENSG00000255239.1	AP002954.6	-6.99	4.79e-12	1.07e-09	-0.3	-0.21	Sjögren's syndrome;	chr11:118708618	chr11:118688039~118690600:-
BRCA	cis	rs61270009	0.955	rs895295	ENSG00000247828.6	TMEM161B-AS1	6.99	4.79e-12	1.07e-09	0.28	0.21	Depressive symptoms;	chr5:88271529	chr5:88268895~88436685:+
BRCA	cis	rs61270009	0.913	rs16903040	ENSG00000247828.6	TMEM161B-AS1	6.99	4.79e-12	1.07e-09	0.28	0.21	Depressive symptoms;	chr5:88273220	chr5:88268895~88436685:+
BRCA	cis	rs10029851	0.627	rs6821411	ENSG00000234492.4	RPL34-AS1	6.99	4.79e-12	1.07e-09	0.33	0.21	Amyotrophic lateral sclerosis (sporadic);	chr4:108618352	chr4:108538190~108620460:-
BRCA	cis	rs67981189	0.858	rs2526862	ENSG00000269927.1	RP6-91H8.3	-6.99	4.79e-12	1.07e-09	-0.26	-0.21	Schizophrenia;	chr14:70942897	chr14:71141125~71143253:-
BRCA	cis	rs67981189	0.788	rs2526860	ENSG00000269927.1	RP6-91H8.3	-6.99	4.79e-12	1.07e-09	-0.26	-0.21	Schizophrenia;	chr14:70945161	chr14:71141125~71143253:-
BRCA	cis	rs6570726	0.935	rs369458	ENSG00000235652.6	RP11-545I5.3	6.99	4.8e-12	1.07e-09	0.2	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145491673	chr6:145799409~145886585:+
BRCA	cis	rs838147	0.508	rs507766	ENSG00000232871.7	SEC1P	6.99	4.8e-12	1.08e-09	0.23	0.21	Dietary macronutrient intake;	chr19:48705286	chr19:48638071~48682245:+
BRCA	cis	rs904251	1	rs10947673	ENSG00000204110.6	RP1-153P14.8	-6.99	4.81e-12	1.08e-09	-0.24	-0.21	Cognitive performance;	chr6:37477303	chr6:37507348~37535616:+
BRCA	cis	rs7567389	0.505	rs56273408	ENSG00000236682.1	AC068282.3	-6.99	4.81e-12	1.08e-09	-0.29	-0.21	Self-rated health;	chr2:127338012	chr2:127389130~127400580:+
BRCA	cis	rs151227923	1	rs151227923	ENSG00000273117.1	AC144652.1	6.99	4.81e-12	1.08e-09	0.23	0.21	Stem cell growth factor beta levels;	chr7:155314854	chr7:155295918~155297541:-
BRCA	cis	rs140365914	1	rs140365914	ENSG00000273117.1	AC144652.1	6.99	4.81e-12	1.08e-09	0.23	0.21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr7:155314860	chr7:155295918~155297541:-
BRCA	cis	rs77204473	1	rs2044426	ENSG00000254851.1	RP11-109L13.1	6.99	4.81e-12	1.08e-09	0.42	0.21	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116885467	chr11:117135528~117138582:+
BRCA	cis	rs4727443	0.866	rs6963345	ENSG00000235713.1	RP4-604G5.3	-6.99	4.82e-12	1.08e-09	-0.24	-0.21	Interstitial lung disease;	chr7:100020983	chr7:99992397~99993050:+
BRCA	cis	rs801193	1	rs10252765	ENSG00000236529.1	RP13-254B10.1	6.99	4.82e-12	1.08e-09	0.23	0.21	Aortic root size;	chr7:66763745	chr7:65840212~65840596:+
BRCA	cis	rs1113500	0.575	rs1781070	ENSG00000226822.1	RP11-356N1.2	-6.99	4.82e-12	1.08e-09	-0.27	-0.21	Growth-regulated protein alpha levels;	chr1:108027076	chr1:108071482~108074519:+
BRCA	cis	rs2034650	0.544	rs2289331	ENSG00000223313.1	RNU6-516P	6.99	4.82e-12	1.08e-09	0.26	0.21	Interstitial lung disease;	chr15:40407739	chr15:40529570~40529673:+
BRCA	cis	rs1862618	0.853	rs252902	ENSG00000271828.1	CTD-2310F14.1	6.99	4.83e-12	1.08e-09	0.3	0.21	Initial pursuit acceleration;	chr5:56820258	chr5:56927874~56929573:+
BRCA	cis	rs12908161	0.959	rs17598603	ENSG00000259728.4	LINC00933	-6.99	4.83e-12	1.08e-09	-0.28	-0.21	Schizophrenia;	chr15:84656980	chr15:84570649~84580175:+
BRCA	cis	rs950880	0.553	rs3755272	ENSG00000234389.1	AC007278.3	-6.99	4.83e-12	1.08e-09	-0.24	-0.21	Serum protein levels (sST2);	chr2:102417365	chr2:102438713~102440475:+
BRCA	cis	rs10200159	0.793	rs6545512	ENSG00000272606.1	RP11-554J4.1	6.99	4.84e-12	1.08e-09	0.39	0.21	Vitiligo;	chr2:55656896	chr2:55617909~55618373:+
BRCA	cis	rs7829975	0.688	rs6601703	ENSG00000254153.1	CTA-398F10.2	6.99	4.85e-12	1.09e-09	0.25	0.21	Mood instability;	chr8:8522714	chr8:8456909~8461337:-
BRCA	cis	rs7809950	0.834	rs2712199	ENSG00000238832.1	snoU109	-6.99	4.85e-12	1.09e-09	-0.28	-0.21	Coronary artery disease;	chr7:107499794	chr7:107603363~107603507:+
BRCA	cis	rs301901	0.686	rs158795	ENSG00000250155.1	CTD-2353F22.1	-6.99	4.85e-12	1.09e-09	-0.25	-0.21	Height;	chr5:36882886	chr5:36666214~36725195:-
BRCA	cis	rs853679	0.769	rs17720293	ENSG00000220721.1	OR1F12	6.99	4.86e-12	1.09e-09	0.43	0.21	Depression;	chr6:28246920	chr6:28073316~28074233:+
BRCA	cis	rs6570726	0.935	rs447247	ENSG00000235652.6	RP11-545I5.3	6.99	4.86e-12	1.09e-09	0.2	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145491542	chr6:145799409~145886585:+
BRCA	cis	rs860818	1	rs858302	ENSG00000226816.2	AC005082.12	6.99	4.86e-12	1.09e-09	0.5	0.21	Initial pursuit acceleration;	chr7:23204624	chr7:23206013~23208045:+
BRCA	cis	rs860818	1	rs858301	ENSG00000226816.2	AC005082.12	6.99	4.86e-12	1.09e-09	0.5	0.21	Initial pursuit acceleration;	chr7:23204704	chr7:23206013~23208045:+
BRCA	cis	rs860818	1	rs858297	ENSG00000226816.2	AC005082.12	6.99	4.86e-12	1.09e-09	0.5	0.21	Initial pursuit acceleration;	chr7:23205342	chr7:23206013~23208045:+
BRCA	cis	rs860818	1	rs858296	ENSG00000226816.2	AC005082.12	6.99	4.86e-12	1.09e-09	0.5	0.21	Initial pursuit acceleration;	chr7:23205929	chr7:23206013~23208045:+
BRCA	cis	rs2239557	1	rs7153160	ENSG00000259065.1	RP5-1021I20.1	-6.99	4.86e-12	1.09e-09	-0.25	-0.21	Common traits (Other);	chr14:74042674	chr14:73787360~73803270:+
BRCA	cis	rs2033711	0.84	rs4801590	ENSG00000269473.1	CTD-2619J13.19	6.99	4.87e-12	1.09e-09	0.25	0.21	Uric acid clearance;	chr19:58450446	chr19:58440448~58445849:+
BRCA	cis	rs875971	0.545	rs3735147	ENSG00000224316.1	RP11-479O9.2	6.99	4.87e-12	1.09e-09	0.24	0.21	Aortic root size;	chr7:66505541	chr7:65773620~65802067:+
BRCA	cis	rs6840360	0.642	rs1470280	ENSG00000270265.1	RP11-731D1.4	-6.99	4.88e-12	1.09e-09	-0.24	-0.21	Intelligence (multi-trait analysis);	chr4:151510618	chr4:151333775~151353224:-
BRCA	cis	rs858239	0.896	rs1637193	ENSG00000230042.1	AK3P3	-6.99	4.88e-12	1.09e-09	-0.25	-0.21	Cerebrospinal fluid biomarker levels;	chr7:23220632	chr7:23129178~23129841:+
BRCA	cis	rs7267979	0.789	rs6050472	ENSG00000274973.1	RP13-401N8.7	-6.99	4.89e-12	1.09e-09	-0.25	-0.21	Liver enzyme levels (alkaline phosphatase);	chr20:25239216	chr20:25845497~25845862:+
BRCA	cis	rs2060793	0.774	rs1403249	ENSG00000251991.1	RNU7-49P	6.99	4.89e-12	1.09e-09	0.23	0.21	Vitamin D levels;	chr11:14651438	chr11:14478892~14478953:+
BRCA	cis	rs875971	0.502	rs11769702	ENSG00000224316.1	RP11-479O9.2	6.99	4.89e-12	1.09e-09	0.25	0.21	Aortic root size;	chr7:66255529	chr7:65773620~65802067:+
BRCA	cis	rs10515750	0.5	rs10463005	ENSG00000251405.2	CTB-109A12.1	-6.99	4.9e-12	1.1e-09	-0.33	-0.21	Lung function (FEV1/FVC);	chr5:157278870	chr5:157362615~157460078:-
BRCA	cis	rs875971	1	rs6961717	ENSG00000232559.3	GS1-124K5.12	-6.99	4.9e-12	1.1e-09	-0.25	-0.21	Aortic root size;	chr7:66122550	chr7:66554588~66576923:-
BRCA	cis	rs2243480	1	rs4718315	ENSG00000232546.1	RP11-458F8.1	6.99	4.91e-12	1.1e-09	0.28	0.21	Diabetic kidney disease;	chr7:66183554	chr7:66848496~66858136:+
BRCA	cis	rs2243480	1	rs4718316	ENSG00000232546.1	RP11-458F8.1	6.99	4.91e-12	1.1e-09	0.28	0.21	Diabetic kidney disease;	chr7:66183744	chr7:66848496~66858136:+
BRCA	cis	rs7662987	0.793	rs28730632	ENSG00000272777.1	RP11-571L19.8	6.99	4.91e-12	1.1e-09	0.3	0.21	Smoking initiation;	chr4:99074552	chr4:99067256~99068125:-
BRCA	cis	rs6163	0.727	rs284854	ENSG00000236937.2	PTGES3P4	-6.99	4.92e-12	1.1e-09	-0.27	-0.21	Waist circumference;Hip circumference;	chr10:102814805	chr10:102845595~102845950:+
BRCA	cis	rs875971	0.522	rs2949690	ENSG00000237310.1	GS1-124K5.4	-6.99	4.92e-12	1.1e-09	-0.22	-0.21	Aortic root size;	chr7:66018255	chr7:66493706~66495474:+
BRCA	cis	rs12446554	0.511	rs72769544	ENSG00000261195.1	CTD-2380F24.1	-6.99	4.94e-12	1.1e-09	-0.33	-0.21	Obesity;	chr16:19765915	chr16:19761172~19766099:-
BRCA	cis	rs9807989	0.839	rs3771166	ENSG00000234389.1	AC007278.3	6.99	4.94e-12	1.1e-09	0.2	0.21	Asthma;	chr2:102369762	chr2:102438713~102440475:+
BRCA	cis	rs11096990	0.855	rs75746161	ENSG00000249207.1	RP11-360F5.1	6.99	4.95e-12	1.11e-09	0.25	0.21	Cognitive function;	chr4:39167481	chr4:39112677~39126818:-
BRCA	cis	rs11671005	0.696	rs73066211	ENSG00000252334.1	RNU6-1337P	6.99	4.96e-12	1.11e-09	0.34	0.21	Mean platelet volume;	chr19:58485712	chr19:58483749~58483843:-
BRCA	cis	rs12999373	1	rs12999373	ENSG00000272342.1	RP13-539J13.1	6.99	4.96e-12	1.11e-09	0.28	0.21	Response to fenofibrate (adiponectin levels);Uric acid levels;	chr2:663483	chr2:739588~740164:-
BRCA	cis	rs73173548	0.502	rs13185071	ENSG00000247828.6	TMEM161B-AS1	6.99	4.97e-12	1.11e-09	0.29	0.21	Macular telangiectasia type 2;	chr5:88429895	chr5:88268895~88436685:+
BRCA	cis	rs73173548	0.502	rs34634636	ENSG00000247828.6	TMEM161B-AS1	6.99	4.97e-12	1.11e-09	0.29	0.21	Macular telangiectasia type 2;	chr5:88435989	chr5:88268895~88436685:+
BRCA	cis	rs293748	0.571	rs13177573	ENSG00000250155.1	CTD-2353F22.1	6.99	4.97e-12	1.11e-09	0.28	0.21	Obesity-related traits;	chr5:37233335	chr5:36666214~36725195:-
BRCA	cis	rs755249	0.567	rs4660546	ENSG00000228060.1	RP11-69E11.8	-6.99	4.98e-12	1.11e-09	-0.26	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39213730	chr1:39565160~39573203:+
BRCA	cis	rs2337406	1	rs3858878	ENSG00000211974.3	IGHV2-70	-6.99	4.99e-12	1.11e-09	-0.26	-0.21	Alzheimer's disease (late onset);	chr14:106688061	chr14:106723574~106724093:-
BRCA	cis	rs2835345	0.563	rs12627161	ENSG00000230479.1	AP000695.6	6.99	4.99e-12	1.11e-09	0.21	0.21	Pulmonary function;	chr21:36449649	chr21:36430360~36481070:+
BRCA	cis	rs2835345	0.563	rs12627241	ENSG00000230479.1	AP000695.6	6.99	4.99e-12	1.11e-09	0.21	0.21	Pulmonary function;	chr21:36449689	chr21:36430360~36481070:+
BRCA	cis	rs2835345	0.563	rs12627173	ENSG00000230479.1	AP000695.6	6.99	4.99e-12	1.11e-09	0.21	0.21	Pulmonary function;	chr21:36449715	chr21:36430360~36481070:+
BRCA	cis	rs2742234	0.614	rs3026750	ENSG00000273008.1	RP11-351D16.3	-6.99	5e-12	1.12e-09	-0.24	-0.21	Hirschsprung disease;	chr10:43112308	chr10:43136824~43138334:-
BRCA	cis	rs17301013	0.581	rs12080977	ENSG00000227373.4	RP11-160H22.5	6.99	5.01e-12	1.12e-09	0.3	0.21	Systemic lupus erythematosus;	chr1:174247026	chr1:174115300~174160004:-
BRCA	cis	rs875971	1	rs55962648	ENSG00000224316.1	RP11-479O9.2	-6.99	5.02e-12	1.12e-09	-0.21	-0.21	Aortic root size;	chr7:66160764	chr7:65773620~65802067:+
BRCA	cis	rs801193	1	rs2659909	ENSG00000224316.1	RP11-479O9.2	6.99	5.03e-12	1.12e-09	0.21	0.21	Aortic root size;	chr7:66695292	chr7:65773620~65802067:+
BRCA	cis	rs847577	0.832	rs1799068	ENSG00000272950.1	RP11-307C18.1	-6.99	5.04e-12	1.13e-09	-0.27	-0.21	Breast cancer;	chr7:98077757	chr7:98322853~98323430:+
BRCA	cis	rs4237845	0.715	rs4760340	ENSG00000257159.1	RP11-58A17.3	6.99	5.05e-12	1.13e-09	0.24	0.21	Intelligence (multi-trait analysis);	chr12:57881393	chr12:57967058~57968399:+
BRCA	cis	rs9341808	0.556	rs10455370	ENSG00000272129.1	RP11-250B2.6	-6.99	5.05e-12	1.13e-09	-0.26	-0.21	Sitting height ratio;	chr6:80331150	chr6:80355424~80356859:+
BRCA	cis	rs61160187	0.582	rs12652878	ENSG00000215032.2	GNL3LP1	6.99	5.06e-12	1.13e-09	0.26	0.21	Educational attainment (years of education);Educational attainment (college completion);	chr5:60868949	chr5:60891935~60893577:-
BRCA	cis	rs61160187	0.548	rs17392014	ENSG00000215032.2	GNL3LP1	6.99	5.06e-12	1.13e-09	0.26	0.21	Educational attainment (years of education);Educational attainment (college completion);	chr5:60869373	chr5:60891935~60893577:-
BRCA	cis	rs2060793	0.712	rs10741654	ENSG00000251991.1	RNU7-49P	6.99	5.06e-12	1.13e-09	0.23	0.21	Vitamin D levels;	chr11:14726506	chr11:14478892~14478953:+
BRCA	cis	rs13178541	0.745	rs4976326	ENSG00000250378.1	RP11-119J18.1	6.98	5.07e-12	1.13e-09	0.29	0.21	IgG glycosylation;	chr5:135728800	chr5:135812667~135826582:+
BRCA	cis	rs224090	0.54	rs11592442	ENSG00000238280.1	RP11-436D10.3	-6.98	5.08e-12	1.13e-09	-0.3	-0.21	Crohn's disease;	chr10:62774144	chr10:62793562~62805887:-
BRCA	cis	rs9807989	0.839	rs1974675	ENSG00000234389.1	AC007278.3	6.98	5.09e-12	1.14e-09	0.2	0.21	Asthma;	chr2:102369915	chr2:102438713~102440475:+
BRCA	cis	rs638893	0.617	rs7933007	ENSG00000278376.1	RP11-158I9.8	6.98	5.09e-12	1.14e-09	0.23	0.21	Vitiligo;	chr11:118859960	chr11:118791254~118793137:+
BRCA	cis	rs11098499	0.874	rs13139045	ENSG00000248280.1	RP11-33B1.2	6.98	5.1e-12	1.14e-09	0.21	0.21	Corneal astigmatism;	chr4:119247433	chr4:119440561~119450157:-
BRCA	cis	rs2243480	1	rs7804223	ENSG00000230295.1	RP11-458F8.2	6.98	5.1e-12	1.14e-09	0.28	0.21	Diabetic kidney disease;	chr7:66199572	chr7:66880708~66882981:+
BRCA	cis	rs6142102	1	rs4911414	ENSG00000275784.1	RP5-1125A11.6	-6.98	5.1e-12	1.14e-09	-0.26	-0.21	Skin pigmentation;	chr20:34141638	chr20:33989480~33991818:-
BRCA	cis	rs858239	0.699	rs955187	ENSG00000230042.1	AK3P3	6.98	5.11e-12	1.14e-09	0.24	0.21	Cerebrospinal fluid biomarker levels;	chr7:23154986	chr7:23129178~23129841:+
BRCA	cis	rs10129255	0.536	rs6576201	ENSG00000211970.3	IGHV4-61	6.98	5.11e-12	1.14e-09	0.14	0.21	Kawasaki disease;	chr14:106683696	chr14:106639119~106639657:-
BRCA	cis	rs375066	0.762	rs10424336	ENSG00000267058.1	RP11-15A1.3	-6.98	5.12e-12	1.14e-09	-0.25	-0.21	Breast cancer;	chr19:43887948	chr19:43891804~43901805:-
BRCA	cis	rs7976269	0.609	rs4931137	ENSG00000257176.2	RP11-996F15.2	-6.98	5.12e-12	1.14e-09	-0.25	-0.21	Male-pattern baldness;	chr12:29049701	chr12:29280418~29317848:-
BRCA	cis	rs2880765	0.835	rs2170735	ENSG00000259295.5	CSPG4P12	6.98	5.12e-12	1.14e-09	0.26	0.21	Coronary artery disease;	chr15:85500254	chr15:85191438~85213905:+
BRCA	cis	rs8031584	0.958	rs7168641	ENSG00000260382.1	RP11-540B6.2	6.98	5.15e-12	1.15e-09	0.25	0.21	Huntington's disease progression;	chr15:30943249	chr15:30882267~30883231:-
BRCA	cis	rs73173548	0.502	rs34933255	ENSG00000247828.6	TMEM161B-AS1	6.98	5.15e-12	1.15e-09	0.29	0.21	Macular telangiectasia type 2;	chr5:88446492	chr5:88268895~88436685:+
BRCA	cis	rs73173548	0.502	rs12188494	ENSG00000247828.6	TMEM161B-AS1	6.98	5.15e-12	1.15e-09	0.29	0.21	Macular telangiectasia type 2;	chr5:88447747	chr5:88268895~88436685:+
BRCA	cis	rs2281636	0.723	rs1128642	ENSG00000233690.1	EBAG9P1	6.98	5.15e-12	1.15e-09	0.25	0.21	Obesity-related traits;	chr10:99711938	chr10:99697407~99697949:-
BRCA	cis	rs66887589	0.934	rs41464847	ENSG00000248280.1	RP11-33B1.2	-6.98	5.15e-12	1.15e-09	-0.2	-0.21	Diastolic blood pressure;	chr4:119611246	chr4:119440561~119450157:-
BRCA	cis	rs950880	0.553	rs2293225	ENSG00000234389.1	AC007278.3	-6.98	5.16e-12	1.15e-09	-0.24	-0.21	Serum protein levels (sST2);	chr2:102419429	chr2:102438713~102440475:+
BRCA	cis	rs11098499	0.532	rs12512646	ENSG00000245958.5	RP11-33B1.1	-6.98	5.16e-12	1.15e-09	-0.2	-0.21	Corneal astigmatism;	chr4:119664578	chr4:119454791~119552025:+
BRCA	cis	rs847577	0.715	rs4729402	ENSG00000272950.1	RP11-307C18.1	6.98	5.16e-12	1.15e-09	0.27	0.21	Breast cancer;	chr7:98078419	chr7:98322853~98323430:+
BRCA	cis	rs17301013	0.581	rs12083540	ENSG00000227373.4	RP11-160H22.5	6.98	5.18e-12	1.16e-09	0.3	0.21	Systemic lupus erythematosus;	chr1:174254096	chr1:174115300~174160004:-
BRCA	cis	rs17301013	0.606	rs12085311	ENSG00000227373.4	RP11-160H22.5	6.98	5.18e-12	1.16e-09	0.3	0.21	Systemic lupus erythematosus;	chr1:174256097	chr1:174115300~174160004:-
BRCA	cis	rs7208859	0.573	rs56031503	ENSG00000263603.1	CTD-2349P21.5	-6.98	5.2e-12	1.16e-09	-0.36	-0.21	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748647	chr17:30729469~30731202:+
BRCA	cis	rs3760982	0.626	rs12463370	ENSG00000267058.1	RP11-15A1.3	-6.98	5.22e-12	1.16e-09	-0.24	-0.21	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43788014	chr19:43891804~43901805:-
BRCA	cis	rs875971	0.545	rs316305	ENSG00000236529.1	RP13-254B10.1	-6.98	5.22e-12	1.16e-09	-0.26	-0.21	Aortic root size;	chr7:66152984	chr7:65840212~65840596:+
BRCA	cis	rs11098499	0.954	rs11098526	ENSG00000249244.1	RP11-548H18.2	6.98	5.22e-12	1.16e-09	0.25	0.21	Corneal astigmatism;	chr4:119469204	chr4:119391831~119395335:-
BRCA	cis	rs9649213	0.574	rs7790229	ENSG00000272950.1	RP11-307C18.1	6.98	5.23e-12	1.17e-09	0.27	0.21	Prostate cancer (SNP x SNP interaction);	chr7:98290026	chr7:98322853~98323430:+
BRCA	cis	rs7945705	0.875	rs4929914	ENSG00000254860.4	TMEM9B-AS1	6.98	5.23e-12	1.17e-09	0.2	0.21	Hemoglobin concentration;	chr11:8802841	chr11:8964675~8977527:+
BRCA	cis	rs17301013	0.606	rs10912737	ENSG00000227373.4	RP11-160H22.5	6.98	5.25e-12	1.17e-09	0.3	0.21	Systemic lupus erythematosus;	chr1:174172999	chr1:174115300~174160004:-
BRCA	cis	rs17301013	0.531	rs12079687	ENSG00000227373.4	RP11-160H22.5	6.98	5.25e-12	1.17e-09	0.3	0.21	Systemic lupus erythematosus;	chr1:174175545	chr1:174115300~174160004:-
BRCA	cis	rs10483853	0.525	rs10138789	ENSG00000258408.1	NT5CP2	-6.98	5.25e-12	1.17e-09	-0.29	-0.21	Coronary artery calcification;	chr14:73497574	chr14:73539221~73539781:-
BRCA	cis	rs7119038	0.509	rs11216960	ENSG00000255239.1	AP002954.6	-6.98	5.25e-12	1.17e-09	-0.3	-0.21	Sjögren's syndrome;	chr11:118707164	chr11:118688039~118690600:-
BRCA	cis	rs253959	0.629	rs10054121	ENSG00000271918.1	CTD-2287O16.5	6.98	5.26e-12	1.17e-09	0.17	0.21	Bipolar disorder and schizophrenia;	chr5:116084271	chr5:116083807~116085416:-
BRCA	cis	rs73173548	0.502	rs6867204	ENSG00000247828.6	TMEM161B-AS1	6.98	5.26e-12	1.17e-09	0.29	0.21	Macular telangiectasia type 2;	chr5:88446423	chr5:88268895~88436685:+
BRCA	cis	rs2179367	0.6	rs9498356	ENSG00000231760.4	RP11-350J20.5	6.98	5.26e-12	1.17e-09	0.32	0.21	Dupuytren's disease;	chr6:149443337	chr6:149796151~149826294:-
BRCA	cis	rs17711722	0.51	rs11767457	ENSG00000228409.4	CCT6P1	-6.98	5.28e-12	1.18e-09	-0.2	-0.21	Calcium levels;	chr7:65825628	chr7:65751142~65763354:+
BRCA	cis	rs10515750	0.588	rs11739823	ENSG00000248544.2	CTB-47B11.3	6.98	5.29e-12	1.18e-09	0.3	0.21	Lung function (FEV1/FVC);	chr5:157342000	chr5:157375741~157384950:-
BRCA	cis	rs10899021	1	rs11236201	ENSG00000279353.1	RP11-864N7.4	6.98	5.29e-12	1.18e-09	0.49	0.21	Response to metformin (IC50);	chr11:74664588	chr11:74698231~74699658:-
BRCA	cis	rs10899021	1	rs11236202	ENSG00000279353.1	RP11-864N7.4	6.98	5.29e-12	1.18e-09	0.49	0.21	Response to metformin (IC50);	chr11:74665647	chr11:74698231~74699658:-
BRCA	cis	rs9291683	0.567	rs12499857	ENSG00000250413.1	RP11-448G15.1	-6.98	5.3e-12	1.18e-09	-0.28	-0.21	Bone mineral density;	chr4:9993752	chr4:10006482~10009725:+
BRCA	cis	rs875971	0.545	rs75577046	ENSG00000224316.1	RP11-479O9.2	6.98	5.31e-12	1.18e-09	0.24	0.21	Aortic root size;	chr7:66493729	chr7:65773620~65802067:+
BRCA	cis	rs911555	0.574	rs34251103	ENSG00000244691.1	RPL10AP1	6.98	5.31e-12	1.18e-09	0.27	0.21	Intelligence (multi-trait analysis);	chr14:103393726	chr14:103412119~103412761:-
BRCA	cis	rs7918232	0.574	rs10458708	ENSG00000262412.1	RP11-85G18.6	6.98	5.31e-12	1.18e-09	0.27	0.21	Breast cancer;	chr10:27166676	chr10:27243130~27250804:+
BRCA	cis	rs9309711	0.77	rs13409323	ENSG00000225234.1	TRAPPC12-AS1	-6.98	5.31e-12	1.18e-09	-0.25	-0.21	Neurofibrillary tangles;	chr2:3484413	chr2:3481242~3482409:-
BRCA	cis	rs1862618	0.853	rs2548665	ENSG00000271828.1	CTD-2310F14.1	6.98	5.32e-12	1.18e-09	0.3	0.21	Initial pursuit acceleration;	chr5:56835978	chr5:56927874~56929573:+
BRCA	cis	rs7617773	0.817	rs13094727	ENSG00000228638.1	FCF1P2	-6.98	5.32e-12	1.18e-09	-0.24	-0.21	Coronary artery disease;	chr3:48281999	chr3:48290793~48291375:-
BRCA	cis	rs911555	0.617	rs7156036	ENSG00000244691.1	RPL10AP1	6.98	5.33e-12	1.19e-09	0.27	0.21	Intelligence (multi-trait analysis);	chr14:103441805	chr14:103412119~103412761:-
BRCA	cis	rs911555	0.723	rs6575991	ENSG00000244691.1	RPL10AP1	6.98	5.33e-12	1.19e-09	0.27	0.21	Intelligence (multi-trait analysis);	chr14:103442096	chr14:103412119~103412761:-
BRCA	cis	rs79040073	0.637	rs17396747	ENSG00000259531.2	RP11-295H24.3	6.98	5.33e-12	1.19e-09	0.35	0.21	Lung cancer in ever smokers;	chr15:49269330	chr15:49365124~49366685:-
BRCA	cis	rs2243480	1	rs6974723	ENSG00000232546.1	RP11-458F8.1	6.98	5.34e-12	1.19e-09	0.28	0.21	Diabetic kidney disease;	chr7:66172952	chr7:66848496~66858136:+
BRCA	cis	rs2243480	1	rs9769882	ENSG00000232546.1	RP11-458F8.1	6.98	5.34e-12	1.19e-09	0.28	0.21	Diabetic kidney disease;	chr7:66177938	chr7:66848496~66858136:+
BRCA	cis	rs2243480	1	rs6966322	ENSG00000232546.1	RP11-458F8.1	6.98	5.34e-12	1.19e-09	0.28	0.21	Diabetic kidney disease;	chr7:66181767	chr7:66848496~66858136:+
BRCA	cis	rs2243480	1	rs4145008	ENSG00000232546.1	RP11-458F8.1	6.98	5.34e-12	1.19e-09	0.28	0.21	Diabetic kidney disease;	chr7:66182524	chr7:66848496~66858136:+
BRCA	cis	rs77972916	0.519	rs13411327	ENSG00000234936.1	AC010883.5	6.98	5.35e-12	1.19e-09	0.3	0.21	Granulocyte percentage of myeloid white cells;	chr2:43288344	chr2:43229573~43233394:+
BRCA	cis	rs160451	0.966	rs183363	ENSG00000251136.7	RP11-37B2.1	6.98	5.37e-12	1.2e-09	0.21	0.21	Leprosy;	chr8:89665951	chr8:89609409~89757727:-
BRCA	cis	rs6545883	0.929	rs6545873	ENSG00000271889.1	RP11-493E12.1	6.98	5.37e-12	1.2e-09	0.27	0.21	Tuberculosis;	chr2:61505877	chr2:61151433~61162105:-
BRCA	cis	rs13217239	0.646	rs10946888	ENSG00000241549.7	GUSBP2	6.98	5.38e-12	1.2e-09	0.23	0.21	Schizophrenia;	chr6:26983899	chr6:26871484~26956554:-
BRCA	cis	rs2243480	1	rs1267820	ENSG00000230295.1	RP11-458F8.2	-6.98	5.39e-12	1.2e-09	-0.28	-0.21	Diabetic kidney disease;	chr7:66585308	chr7:66880708~66882981:+
BRCA	cis	rs3760982	1	rs4803658	ENSG00000267058.1	RP11-15A1.3	-6.98	5.39e-12	1.2e-09	-0.24	-0.21	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43785861	chr19:43891804~43901805:-
BRCA	cis	rs12237653	0.929	rs4740695	ENSG00000236404.7	VLDLR-AS1	6.98	5.4e-12	1.2e-09	0.34	0.21	Gambling;	chr9:2547987	chr9:2422702~2643359:-
BRCA	cis	rs11098499	0.954	rs1022145	ENSG00000249244.1	RP11-548H18.2	6.98	5.4e-12	1.2e-09	0.25	0.21	Corneal astigmatism;	chr4:119309824	chr4:119391831~119395335:-
BRCA	cis	rs8062405	0.691	rs11646653	ENSG00000278665.1	RP11-666O2.4	-6.98	5.4e-12	1.2e-09	-0.23	-0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28910828	chr16:28599241~28601881:-
BRCA	cis	rs10129255	0.5	rs8011115	ENSG00000211970.3	IGHV4-61	-6.98	5.41e-12	1.2e-09	-0.13	-0.21	Kawasaki disease;	chr14:106786292	chr14:106639119~106639657:-
BRCA	cis	rs2337406	1	rs11845269	ENSG00000211974.3	IGHV2-70	-6.98	5.41e-12	1.2e-09	-0.26	-0.21	Alzheimer's disease (late onset);	chr14:106683851	chr14:106723574~106724093:-
BRCA	cis	rs11098499	0.697	rs28655325	ENSG00000249244.1	RP11-548H18.2	6.98	5.41e-12	1.2e-09	0.25	0.21	Corneal astigmatism;	chr4:119451844	chr4:119391831~119395335:-
BRCA	cis	rs9876781	1	rs9812647	ENSG00000244380.1	RP11-24C3.2	-6.98	5.42e-12	1.21e-09	-0.25	-0.21	Longevity;	chr3:48407507	chr3:48440352~48446656:-
BRCA	cis	rs4722166	0.532	rs4719712	ENSG00000179428.2	AC073072.5	-6.98	5.42e-12	1.21e-09	-0.22	-0.21	Lung cancer;	chr7:22716188	chr7:22725395~22727620:-
BRCA	cis	rs17301013	0.606	rs72713503	ENSG00000227373.4	RP11-160H22.5	6.98	5.42e-12	1.21e-09	0.3	0.21	Systemic lupus erythematosus;	chr1:174247553	chr1:174115300~174160004:-
BRCA	cis	rs17301013	0.606	rs16846816	ENSG00000227373.4	RP11-160H22.5	6.98	5.42e-12	1.21e-09	0.3	0.21	Systemic lupus erythematosus;	chr1:174251602	chr1:174115300~174160004:-
BRCA	cis	rs3760982	1	rs11669175	ENSG00000267058.1	RP11-15A1.3	-6.98	5.43e-12	1.21e-09	-0.24	-0.21	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43785672	chr19:43891804~43901805:-
BRCA	cis	rs2033711	0.87	rs6510152	ENSG00000269473.1	CTD-2619J13.19	6.97	5.44e-12	1.21e-09	0.25	0.21	Uric acid clearance;	chr19:58441952	chr19:58440448~58445849:+
BRCA	cis	rs3761847	0.622	rs10435888	ENSG00000226752.6	PSMD5-AS1	-6.97	5.44e-12	1.21e-09	-0.25	-0.21	Rheumatoid arthritis;	chr9:121057325	chr9:120824828~120854385:+
BRCA	cis	rs801193	0.761	rs2659888	ENSG00000236529.1	RP13-254B10.1	6.97	5.45e-12	1.21e-09	0.23	0.21	Aortic root size;	chr7:66765184	chr7:65840212~65840596:+
BRCA	cis	rs10740039	1	rs10994460	ENSG00000254271.1	RP11-131N11.4	6.97	5.45e-12	1.21e-09	0.27	0.21	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60659033	chr10:60734342~60741828:+
BRCA	cis	rs760794	0.577	rs17483277	ENSG00000228412.5	RP4-625H18.2	6.97	5.45e-12	1.21e-09	0.26	0.21	Endometriosis;	chr6:19790340	chr6:19802164~19804752:-
BRCA	cis	rs10740039	0.961	rs2083696	ENSG00000254271.1	RP11-131N11.4	6.97	5.46e-12	1.21e-09	0.27	0.21	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60656430	chr10:60734342~60741828:+
BRCA	cis	rs10740039	1	rs10821818	ENSG00000254271.1	RP11-131N11.4	6.97	5.46e-12	1.21e-09	0.27	0.21	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60657178	chr10:60734342~60741828:+
BRCA	cis	rs10740039	1	rs10761545	ENSG00000254271.1	RP11-131N11.4	6.97	5.46e-12	1.21e-09	0.27	0.21	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60658811	chr10:60734342~60741828:+
BRCA	cis	rs61160187	0.582	rs7737276	ENSG00000215032.2	GNL3LP1	6.97	5.46e-12	1.21e-09	0.26	0.21	Educational attainment (years of education);Educational attainment (college completion);	chr5:61102467	chr5:60891935~60893577:-
BRCA	cis	rs10181042	0.565	rs1177234	ENSG00000271889.1	RP11-493E12.1	6.97	5.46e-12	1.21e-09	0.26	0.21	Crohn's disease;	chr2:61032928	chr2:61151433~61162105:-
BRCA	cis	rs12701220	0.52	rs7803208	ENSG00000229043.2	AC091729.9	-6.97	5.46e-12	1.22e-09	-0.28	-0.21	Bronchopulmonary dysplasia;	chr7:1122448	chr7:1160374~1165267:+
BRCA	cis	rs801193	1	rs1553610	ENSG00000236529.1	RP13-254B10.1	6.97	5.48e-12	1.22e-09	0.23	0.21	Aortic root size;	chr7:66732246	chr7:65840212~65840596:+
BRCA	cis	rs801193	1	rs2707845	ENSG00000236529.1	RP13-254B10.1	6.97	5.48e-12	1.22e-09	0.23	0.21	Aortic root size;	chr7:66733811	chr7:65840212~65840596:+
BRCA	cis	rs801193	1	rs2707850	ENSG00000236529.1	RP13-254B10.1	6.97	5.48e-12	1.22e-09	0.23	0.21	Aortic root size;	chr7:66738883	chr7:65840212~65840596:+
BRCA	cis	rs801193	0.967	rs1110414	ENSG00000236529.1	RP13-254B10.1	6.97	5.48e-12	1.22e-09	0.23	0.21	Aortic root size;	chr7:66740595	chr7:65840212~65840596:+
BRCA	cis	rs801193	1	rs7783924	ENSG00000236529.1	RP13-254B10.1	6.97	5.48e-12	1.22e-09	0.23	0.21	Aortic root size;	chr7:66744070	chr7:65840212~65840596:+
BRCA	cis	rs801193	1	rs7789184	ENSG00000236529.1	RP13-254B10.1	6.97	5.48e-12	1.22e-09	0.23	0.21	Aortic root size;	chr7:66745208	chr7:65840212~65840596:+
BRCA	cis	rs801193	1	rs2707854	ENSG00000236529.1	RP13-254B10.1	6.97	5.48e-12	1.22e-09	0.23	0.21	Aortic root size;	chr7:66747610	chr7:65840212~65840596:+
BRCA	cis	rs62355901	0.545	rs16886260	ENSG00000271828.1	CTD-2310F14.1	-6.97	5.49e-12	1.22e-09	-0.35	-0.21	Breast cancer;	chr5:56769629	chr5:56927874~56929573:+
BRCA	cis	rs2014572	0.967	rs4801452	ENSG00000268379.1	CTC-360J11.4	6.97	5.5e-12	1.22e-09	0.26	0.21	Hyperactive-impulsive symptoms;	chr19:57256698	chr19:57175233~57177921:+
BRCA	cis	rs9527	0.571	rs10786715	ENSG00000236937.2	PTGES3P4	6.97	5.5e-12	1.22e-09	0.27	0.21	Arsenic metabolism;	chr10:102860978	chr10:102845595~102845950:+
BRCA	cis	rs875971	0.545	rs75840613	ENSG00000224316.1	RP11-479O9.2	6.97	5.51e-12	1.22e-09	0.24	0.21	Aortic root size;	chr7:66376399	chr7:65773620~65802067:+
BRCA	cis	rs911555	0.755	rs8016676	ENSG00000244691.1	RPL10AP1	6.97	5.51e-12	1.23e-09	0.27	0.21	Intelligence (multi-trait analysis);	chr14:103438505	chr14:103412119~103412761:-
BRCA	cis	rs10754283	0.901	rs10047070	ENSG00000231613.1	RP5-943J3.1	6.97	5.53e-12	1.23e-09	0.24	0.21	Amyotrophic lateral sclerosis (sporadic);	chr1:89633156	chr1:89788914~89790492:+
BRCA	cis	rs1707322	0.685	rs56177313	ENSG00000281133.1	AL355480.3	-6.97	5.55e-12	1.23e-09	-0.27	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45760134	chr1:45580892~45580996:-
BRCA	cis	rs801193	1	rs2659915	ENSG00000236529.1	RP13-254B10.1	6.97	5.55e-12	1.23e-09	0.23	0.21	Aortic root size;	chr7:66688114	chr7:65840212~65840596:+
BRCA	cis	rs13315649	0.642	rs9811914	ENSG00000242551.2	POU5F1P6	-6.97	5.55e-12	1.23e-09	-0.3	-0.21	Sum eosinophil basophil counts;	chr3:128676517	chr3:128674735~128677005:-
BRCA	cis	rs911555	0.755	rs8014013	ENSG00000244691.1	RPL10AP1	6.97	5.57e-12	1.24e-09	0.27	0.21	Intelligence (multi-trait analysis);	chr14:103471035	chr14:103412119~103412761:-
BRCA	cis	rs42490	1	rs454441	ENSG00000251136.7	RP11-37B2.1	-6.97	5.58e-12	1.24e-09	-0.21	-0.21	Leprosy;	chr8:89750842	chr8:89609409~89757727:-
BRCA	cis	rs67981189	0.789	rs2810073	ENSG00000269927.1	RP6-91H8.3	-6.97	5.58e-12	1.24e-09	-0.27	-0.21	Schizophrenia;	chr14:70917131	chr14:71141125~71143253:-
BRCA	cis	rs812925	0.762	rs3213951	ENSG00000271889.1	RP11-493E12.1	6.97	5.59e-12	1.24e-09	0.28	0.21	Immature fraction of reticulocytes;	chr2:61395116	chr2:61151433~61162105:-
BRCA	cis	rs9876781	1	rs28824259	ENSG00000244380.1	RP11-24C3.2	6.97	5.6e-12	1.24e-09	0.24	0.21	Longevity;	chr3:48384185	chr3:48440352~48446656:-
BRCA	cis	rs9876781	1	rs12487542	ENSG00000244380.1	RP11-24C3.2	6.97	5.6e-12	1.24e-09	0.24	0.21	Longevity;	chr3:48384586	chr3:48440352~48446656:-
BRCA	cis	rs9876781	1	rs73074358	ENSG00000244380.1	RP11-24C3.2	6.97	5.6e-12	1.24e-09	0.24	0.21	Longevity;	chr3:48385757	chr3:48440352~48446656:-
BRCA	cis	rs9876781	0.967	rs34761139	ENSG00000244380.1	RP11-24C3.2	6.97	5.6e-12	1.24e-09	0.24	0.21	Longevity;	chr3:48386489	chr3:48440352~48446656:-
BRCA	cis	rs9876781	0.868	rs9875280	ENSG00000244380.1	RP11-24C3.2	6.97	5.6e-12	1.24e-09	0.24	0.21	Longevity;	chr3:48387420	chr3:48440352~48446656:-
BRCA	cis	rs9876781	1	rs6796491	ENSG00000244380.1	RP11-24C3.2	6.97	5.6e-12	1.24e-09	0.24	0.21	Longevity;	chr3:48388977	chr3:48440352~48446656:-
BRCA	cis	rs755249	0.529	rs4660732	ENSG00000228060.1	RP11-69E11.8	-6.97	5.6e-12	1.24e-09	-0.26	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39397543	chr1:39565160~39573203:+
BRCA	cis	rs4845875	0.626	rs11121827	ENSG00000242349.4	NPPA-AS1	6.97	5.6e-12	1.24e-09	0.23	0.21	Midregional pro atrial natriuretic peptide levels;	chr1:11772043	chr1:11841017~11848079:+
BRCA	cis	rs838147	0.508	rs507711	ENSG00000232871.7	SEC1P	6.97	5.62e-12	1.25e-09	0.23	0.21	Dietary macronutrient intake;	chr19:48705307	chr19:48638071~48682245:+
BRCA	cis	rs7617773	0.817	rs11130162	ENSG00000228638.1	FCF1P2	-6.97	5.63e-12	1.25e-09	-0.21	-0.21	Coronary artery disease;	chr3:48256121	chr3:48290793~48291375:-
BRCA	cis	rs875971	0.545	rs7783889	ENSG00000236529.1	RP13-254B10.1	6.97	5.63e-12	1.25e-09	0.26	0.21	Aortic root size;	chr7:66283366	chr7:65840212~65840596:+
BRCA	cis	rs71520386	0.607	rs28660425	ENSG00000228649.7	AC005682.5	-6.97	5.63e-12	1.25e-09	-0.2	-0.21	Fibrinogen levels;	chr7:22818532	chr7:22854178~22861579:+
BRCA	cis	rs1707322	0.721	rs11211178	ENSG00000281133.1	AL355480.3	-6.97	5.65e-12	1.26e-09	-0.27	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45761894	chr1:45580892~45580996:-
BRCA	cis	rs10754283	0.934	rs6428563	ENSG00000231613.1	RP5-943J3.1	6.97	5.65e-12	1.26e-09	0.24	0.21	Amyotrophic lateral sclerosis (sporadic);	chr1:89646024	chr1:89788914~89790492:+
BRCA	cis	rs6603134	0.502	rs6603131	ENSG00000267939.1	CTD-2325M2.1	-6.97	5.66e-12	1.26e-09	-0.25	-0.21	Blood protein levels;	chr19:8037873	chr19:8008729~8016025:+
BRCA	cis	rs7617773	0.817	rs6806112	ENSG00000228638.1	FCF1P2	-6.97	5.66e-12	1.26e-09	-0.21	-0.21	Coronary artery disease;	chr3:48234587	chr3:48290793~48291375:-
BRCA	cis	rs61160187	0.582	rs4642318	ENSG00000215032.2	GNL3LP1	6.97	5.67e-12	1.26e-09	0.26	0.21	Educational attainment (years of education);Educational attainment (college completion);	chr5:60996931	chr5:60891935~60893577:-
BRCA	cis	rs9876781	1	rs9826195	ENSG00000244380.1	RP11-24C3.2	6.97	5.67e-12	1.26e-09	0.24	0.21	Longevity;	chr3:48392157	chr3:48440352~48446656:-
BRCA	cis	rs9876781	0.967	rs9864815	ENSG00000244380.1	RP11-24C3.2	6.97	5.67e-12	1.26e-09	0.24	0.21	Longevity;	chr3:48392588	chr3:48440352~48446656:-
BRCA	cis	rs9876781	1	rs9809843	ENSG00000244380.1	RP11-24C3.2	6.97	5.67e-12	1.26e-09	0.24	0.21	Longevity;	chr3:48392923	chr3:48440352~48446656:-
BRCA	cis	rs6840360	0.642	rs11099815	ENSG00000270265.1	RP11-731D1.4	-6.97	5.68e-12	1.26e-09	-0.24	-0.21	Intelligence (multi-trait analysis);	chr4:151422736	chr4:151333775~151353224:-
BRCA	cis	rs160451	0.899	rs218918	ENSG00000251136.7	RP11-37B2.1	-6.97	5.69e-12	1.26e-09	-0.21	-0.21	Leprosy;	chr8:89690153	chr8:89609409~89757727:-
BRCA	cis	rs755249	0.567	rs41270799	ENSG00000228060.1	RP11-69E11.8	-6.97	5.7e-12	1.27e-09	-0.26	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39282990	chr1:39565160~39573203:+
BRCA	cis	rs1320333	0.772	rs17786111	ENSG00000233296.1	AC092159.2	6.97	5.7e-12	1.27e-09	0.39	0.21	Obesity-related traits;	chr2:700562	chr2:677186~697371:+
BRCA	cis	rs1862618	0.853	rs6450408	ENSG00000271828.1	CTD-2310F14.1	6.97	5.71e-12	1.27e-09	0.3	0.21	Initial pursuit acceleration;	chr5:56802319	chr5:56927874~56929573:+
BRCA	cis	rs6840360	0.642	rs2724568	ENSG00000270265.1	RP11-731D1.4	-6.97	5.71e-12	1.27e-09	-0.24	-0.21	Intelligence (multi-trait analysis);	chr4:151431071	chr4:151333775~151353224:-
BRCA	cis	rs2919009	0.58	rs4281410	ENSG00000271670.1	RP11-95I16.4	6.97	5.72e-12	1.27e-09	0.26	0.21	Obesity-related traits;	chr10:120871075	chr10:120879256~120880667:-
BRCA	cis	rs35851103	0.507	rs6601649	ENSG00000254866.2	DEFB109P3	6.97	5.72e-12	1.27e-09	0.28	0.21	Neuroticism;	chr8:11999808	chr8:12150895~12151134:-
BRCA	cis	rs911555	0.692	rs7140647	ENSG00000244691.1	RPL10AP1	6.97	5.74e-12	1.27e-09	0.27	0.21	Intelligence (multi-trait analysis);	chr14:103427128	chr14:103412119~103412761:-
BRCA	cis	rs9840812	0.592	rs12489577	ENSG00000239213.4	NCK1-AS1	6.97	5.75e-12	1.28e-09	0.25	0.21	Fibrinogen levels;	chr3:136494303	chr3:136841726~136862054:-
BRCA	cis	rs7674212	0.507	rs223322	ENSG00000251288.2	RP11-10L12.2	-6.97	5.76e-12	1.28e-09	-0.26	-0.21	Type 2 diabetes;	chr4:102879037	chr4:102751401~102752641:+
BRCA	cis	rs10129255	0.956	rs10137268	ENSG00000211972.2	IGHV3-66	6.97	5.78e-12	1.28e-09	0.17	0.21	Kawasaki disease;	chr14:106697402	chr14:106675017~106675544:-
BRCA	cis	rs875971	0.545	rs313828	ENSG00000236529.1	RP13-254B10.1	-6.97	5.79e-12	1.28e-09	-0.26	-0.21	Aortic root size;	chr7:66087627	chr7:65840212~65840596:+
BRCA	cis	rs801193	1	rs2659889	ENSG00000236529.1	RP13-254B10.1	6.97	5.8e-12	1.29e-09	0.23	0.21	Aortic root size;	chr7:66752125	chr7:65840212~65840596:+
BRCA	cis	rs9876781	1	rs922075	ENSG00000244380.1	RP11-24C3.2	-6.97	5.81e-12	1.29e-09	-0.24	-0.21	Longevity;	chr3:48447994	chr3:48440352~48446656:-
BRCA	cis	rs7208859	0.623	rs7503335	ENSG00000263603.1	CTD-2349P21.5	-6.96	5.81e-12	1.29e-09	-0.36	-0.21	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30746944	chr17:30729469~30731202:+
BRCA	cis	rs7520050	0.807	rs12025621	ENSG00000280836.1	AL355480.1	6.96	5.81e-12	1.29e-09	0.25	0.21	Reticulocyte count;Red blood cell count;	chr1:45762719	chr1:45581219~45581321:-
BRCA	cis	rs9876781	1	rs10470686	ENSG00000244380.1	RP11-24C3.2	6.96	5.81e-12	1.29e-09	0.24	0.21	Longevity;	chr3:48408549	chr3:48440352~48446656:-
BRCA	cis	rs7976269	0.559	rs10771471	ENSG00000257176.2	RP11-996F15.2	-6.96	5.81e-12	1.29e-09	-0.25	-0.21	Male-pattern baldness;	chr12:29050894	chr12:29280418~29317848:-
BRCA	cis	rs10740039	0.768	rs10994432	ENSG00000254271.1	RP11-131N11.4	6.96	5.82e-12	1.29e-09	0.28	0.21	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60623831	chr10:60734342~60741828:+
BRCA	cis	rs7927771	0.864	rs755554	ENSG00000280615.1	Y_RNA	6.96	5.83e-12	1.29e-09	0.25	0.21	Subjective well-being;	chr11:47410483	chr11:47614898~47614994:-
BRCA	cis	rs6723226	0.961	rs13010404	ENSG00000276334.1	AL133243.1	-6.96	5.83e-12	1.29e-09	-0.27	-0.21	Intelligence (multi-trait analysis);	chr2:32623787	chr2:32521927~32523547:+
BRCA	cis	rs7246657	0.943	rs10404920	ENSG00000226686.6	LINC01535	-6.96	5.85e-12	1.3e-09	-0.32	-0.21	Coronary artery calcification;	chr19:37390654	chr19:37251912~37265535:+
BRCA	cis	rs8054556	0.74	rs4609871	ENSG00000273724.1	RP11-347C12.12	6.96	5.86e-12	1.3e-09	0.23	0.21	Autism spectrum disorder or schizophrenia;	chr16:29920743	chr16:30336400~30343336:+
BRCA	cis	rs875971	0.545	rs2460427	ENSG00000236529.1	RP13-254B10.1	-6.96	5.87e-12	1.3e-09	-0.26	-0.21	Aortic root size;	chr7:66154218	chr7:65840212~65840596:+
BRCA	cis	rs7520050	0.778	rs12404197	ENSG00000280836.1	AL355480.1	6.96	5.88e-12	1.3e-09	0.25	0.21	Reticulocyte count;Red blood cell count;	chr1:45766748	chr1:45581219~45581321:-
BRCA	cis	rs7520050	0.801	rs6703960	ENSG00000280836.1	AL355480.1	6.96	5.88e-12	1.3e-09	0.25	0.21	Reticulocyte count;Red blood cell count;	chr1:45767051	chr1:45581219~45581321:-
BRCA	cis	rs7937890	0.505	rs9971395	ENSG00000251991.1	RNU7-49P	6.96	5.88e-12	1.3e-09	0.23	0.21	Mitochondrial DNA levels;	chr11:14745580	chr11:14478892~14478953:+
BRCA	cis	rs11098499	0.954	rs2306455	ENSG00000249244.1	RP11-548H18.2	6.96	5.89e-12	1.31e-09	0.25	0.21	Corneal astigmatism;	chr4:119500814	chr4:119391831~119395335:-
BRCA	cis	rs4845875	0.626	rs10779764	ENSG00000242349.4	NPPA-AS1	6.96	5.9e-12	1.31e-09	0.23	0.21	Midregional pro atrial natriuretic peptide levels;	chr1:11772254	chr1:11841017~11848079:+
BRCA	cis	rs9880211	0.752	rs67145204	ENSG00000273486.1	RP11-731C17.2	6.96	5.91e-12	1.31e-09	0.28	0.21	Height;Body mass index;	chr3:136609823	chr3:136837338~136839021:-
BRCA	cis	rs4072705	1	rs4836985	ENSG00000224020.1	MIR181A2HG	-6.96	5.92e-12	1.31e-09	-0.23	-0.21	Menarche (age at onset);	chr9:124645615	chr9:124658467~124698631:+
BRCA	cis	rs10463554	0.853	rs246903	ENSG00000175749.11	EIF3KP1	6.96	5.92e-12	1.31e-09	0.28	0.21	Parkinson's disease;	chr5:103253753	chr5:103032376~103033031:+
BRCA	cis	rs911555	0.755	rs55742283	ENSG00000244691.1	RPL10AP1	6.96	5.92e-12	1.31e-09	0.27	0.21	Intelligence (multi-trait analysis);	chr14:103476628	chr14:103412119~103412761:-
BRCA	cis	rs801193	1	rs3800812	ENSG00000236529.1	RP13-254B10.1	6.96	5.93e-12	1.31e-09	0.23	0.21	Aortic root size;	chr7:66758474	chr7:65840212~65840596:+
BRCA	cis	rs801193	1	rs4279493	ENSG00000236529.1	RP13-254B10.1	6.96	5.93e-12	1.31e-09	0.23	0.21	Aortic root size;	chr7:66761633	chr7:65840212~65840596:+
BRCA	cis	rs7131987	0.585	rs2059362	ENSG00000275476.1	RP11-996F15.4	6.96	5.93e-12	1.31e-09	0.24	0.21	QT interval;	chr12:29243072	chr12:29277397~29277882:-
BRCA	cis	rs6142102	0.651	rs1015361	ENSG00000276073.1	RP5-1125A11.7	6.96	5.94e-12	1.32e-09	0.25	0.21	Skin pigmentation;	chr20:34150880	chr20:33985617~33988989:-
BRCA	cis	rs11098499	0.955	rs13129661	ENSG00000248280.1	RP11-33B1.2	6.96	5.95e-12	1.32e-09	0.22	0.21	Corneal astigmatism;	chr4:119231754	chr4:119440561~119450157:-
BRCA	cis	rs6840360	0.642	rs7658169	ENSG00000270265.1	RP11-731D1.4	-6.96	5.95e-12	1.32e-09	-0.24	-0.21	Intelligence (multi-trait analysis);	chr4:151432262	chr4:151333775~151353224:-
BRCA	cis	rs2060793	0.741	rs4344519	ENSG00000251991.1	RNU7-49P	6.96	5.97e-12	1.32e-09	0.23	0.21	Vitamin D levels;	chr11:14701347	chr11:14478892~14478953:+
BRCA	cis	rs13217239	0.646	rs6456767	ENSG00000241549.7	GUSBP2	-6.96	5.97e-12	1.32e-09	-0.23	-0.21	Schizophrenia;	chr6:27102764	chr6:26871484~26956554:-
BRCA	cis	rs507080	0.501	rs625735	ENSG00000278376.1	RP11-158I9.8	-6.96	5.99e-12	1.33e-09	-0.2	-0.21	Serum metabolite levels;	chr11:118704710	chr11:118791254~118793137:+
BRCA	cis	rs293748	0.771	rs12659981	ENSG00000250155.1	CTD-2353F22.1	-6.96	6.01e-12	1.33e-09	-0.29	-0.21	Obesity-related traits;	chr5:36787996	chr5:36666214~36725195:-
BRCA	cis	rs293748	0.771	rs12659983	ENSG00000250155.1	CTD-2353F22.1	-6.96	6.01e-12	1.33e-09	-0.29	-0.21	Obesity-related traits;	chr5:36788002	chr5:36666214~36725195:-
BRCA	cis	rs42648	0.755	rs1557650	ENSG00000225498.1	AC002064.5	6.96	6.01e-12	1.33e-09	0.21	0.21	Homocysteine levels;	chr7:90342242	chr7:90312496~90322592:+
BRCA	cis	rs7567389	0.505	rs1518760	ENSG00000236682.1	AC068282.3	-6.96	6.01e-12	1.33e-09	-0.29	-0.21	Self-rated health;	chr2:127382924	chr2:127389130~127400580:+
BRCA	cis	rs9660180	0.62	rs34298494	ENSG00000231050.1	RP1-140A9.1	-6.96	6.01e-12	1.33e-09	-0.25	-0.21	Body mass index;	chr1:1731963	chr1:1891471~1892658:+
BRCA	cis	rs4723738	1	rs11766341	ENSG00000227191.5	TRGC2	-6.96	6.01e-12	1.33e-09	-0.19	-0.21	Treatment response for severe sepsis;	chr7:38188147	chr7:38239580~38368091:-
BRCA	cis	rs2933343	0.553	rs789212	ENSG00000261159.1	RP11-723O4.9	6.96	6.02e-12	1.33e-09	0.23	0.21	IgG glycosylation;	chr3:128968069	chr3:128859716~128860526:-
BRCA	cis	rs7085104	0.572	rs284858	ENSG00000236937.2	PTGES3P4	-6.96	6.03e-12	1.33e-09	-0.27	-0.21	Immature fraction of reticulocytes;Schizophrenia;	chr10:102814179	chr10:102845595~102845950:+
BRCA	cis	rs71520386	0.632	rs2286509	ENSG00000228649.7	AC005682.5	-6.96	6.03e-12	1.34e-09	-0.21	-0.21	Fibrinogen levels;	chr7:22814832	chr7:22854178~22861579:+
BRCA	cis	rs2243480	1	rs35542501	ENSG00000273142.1	RP11-458F8.4	-6.96	6.04e-12	1.34e-09	-0.28	-0.21	Diabetic kidney disease;	chr7:65966228	chr7:66902857~66906297:+
BRCA	cis	rs2243480	0.708	rs781141	ENSG00000273142.1	RP11-458F8.4	-6.96	6.04e-12	1.34e-09	-0.28	-0.21	Diabetic kidney disease;	chr7:65973566	chr7:66902857~66906297:+
BRCA	cis	rs13068223	1	rs36126086	ENSG00000243926.1	TIPARP-AS1	6.96	6.04e-12	1.34e-09	0.22	0.21	Age-related hearing impairment (SNP x SNP interaction);	chr3:156749028	chr3:156671862~156674378:-
BRCA	cis	rs2014572	0.967	rs8100154	ENSG00000268379.1	CTC-360J11.4	6.96	6.05e-12	1.34e-09	0.26	0.21	Hyperactive-impulsive symptoms;	chr19:57254064	chr19:57175233~57177921:+
BRCA	cis	rs442309	0.553	rs10995281	ENSG00000238280.1	RP11-436D10.3	-6.96	6.05e-12	1.34e-09	-0.3	-0.21	Vogt-Koyanagi-Harada syndrome;	chr10:62707416	chr10:62793562~62805887:-
BRCA	cis	rs3781264	1	rs7096678	ENSG00000273450.1	RP11-76P2.4	6.96	6.05e-12	1.34e-09	0.29	0.21	Esophageal cancer and gastric cancer;	chr10:94309451	chr10:94314907~94315327:-
BRCA	cis	rs6840360	0.642	rs2709831	ENSG00000270265.1	RP11-731D1.4	-6.96	6.07e-12	1.34e-09	-0.23	-0.21	Intelligence (multi-trait analysis);	chr4:151458499	chr4:151333775~151353224:-
BRCA	cis	rs7131987	0.65	rs10843382	ENSG00000257176.2	RP11-996F15.2	-6.96	6.07e-12	1.34e-09	-0.26	-0.21	QT interval;	chr12:29298788	chr12:29280418~29317848:-
BRCA	cis	rs2145598	1	rs10137475	ENSG00000279636.2	LINC00216	-6.96	6.08e-12	1.35e-09	-0.21	-0.21	Coronary artery disease;	chr14:58331235	chr14:58288033~58289158:+
BRCA	cis	rs67311347	1	rs11914297	ENSG00000280739.1	EIF1B-AS1	6.96	6.08e-12	1.35e-09	0.24	0.21	Renal cell carcinoma;	chr3:40368579	chr3:40173145~40309698:-
BRCA	cis	rs3781264	0.761	rs11187893	ENSG00000273450.1	RP11-76P2.4	-6.96	6.09e-12	1.35e-09	-0.29	-0.21	Esophageal cancer and gastric cancer;	chr10:94346222	chr10:94314907~94315327:-
BRCA	cis	rs1707322	0.721	rs10789468	ENSG00000281133.1	AL355480.3	-6.96	6.1e-12	1.35e-09	-0.26	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45658886	chr1:45580892~45580996:-
BRCA	cis	rs3781264	0.848	rs6583935	ENSG00000273450.1	RP11-76P2.4	6.96	6.1e-12	1.35e-09	0.27	0.21	Esophageal cancer and gastric cancer;	chr10:94313568	chr10:94314907~94315327:-
BRCA	cis	rs72627509	0.629	rs1277313	ENSG00000269949.1	RP11-738E22.3	-6.96	6.12e-12	1.35e-09	-0.29	-0.21	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:57037782	chr4:56960927~56961373:-
BRCA	cis	rs73173548	0.502	rs6865869	ENSG00000247828.6	TMEM161B-AS1	6.96	6.13e-12	1.36e-09	0.29	0.21	Macular telangiectasia type 2;	chr5:88449645	chr5:88268895~88436685:+
BRCA	cis	rs61270009	0.738	rs12659772	ENSG00000247828.6	TMEM161B-AS1	6.96	6.13e-12	1.36e-09	0.29	0.21	Depressive symptoms;	chr5:88451917	chr5:88268895~88436685:+
BRCA	cis	rs919433	0.963	rs12693815	ENSG00000231621.1	AC013264.2	6.96	6.14e-12	1.36e-09	0.21	0.21	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197303679	chr2:197197991~197199273:+
BRCA	cis	rs801193	1	rs1553609	ENSG00000236529.1	RP13-254B10.1	6.96	6.16e-12	1.36e-09	0.23	0.21	Aortic root size;	chr7:66732152	chr7:65840212~65840596:+
BRCA	cis	rs293748	0.771	rs12659960	ENSG00000250155.1	CTD-2353F22.1	-6.96	6.16e-12	1.36e-09	-0.29	-0.21	Obesity-related traits;	chr5:36787913	chr5:36666214~36725195:-
BRCA	cis	rs1555322	0.53	rs2425047	ENSG00000279253.1	RP4-614O4.13	6.96	6.16e-12	1.36e-09	0.27	0.21	Attention deficit hyperactivity disorder;	chr20:35283872	chr20:35262727~35264187:-
BRCA	cis	rs9601248	1	rs9601248	ENSG00000227676.3	LINC01068	-6.96	6.18e-12	1.37e-09	-0.24	-0.21	Major depressive disorder;	chr13:79594869	chr13:79566727~79571436:+
BRCA	cis	rs301901	0.581	rs292175	ENSG00000250155.1	CTD-2353F22.1	-6.96	6.18e-12	1.37e-09	-0.23	-0.21	Height;	chr5:36832512	chr5:36666214~36725195:-
BRCA	cis	rs7976269	0.559	rs1344853	ENSG00000257176.2	RP11-996F15.2	-6.96	6.19e-12	1.37e-09	-0.25	-0.21	Male-pattern baldness;	chr12:29058623	chr12:29280418~29317848:-
BRCA	cis	rs34779708	0.931	rs10508815	ENSG00000271335.4	RP11-324I22.4	6.96	6.21e-12	1.37e-09	0.21	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35043693	chr10:35314552~35336401:-
BRCA	cis	rs516805	0.961	rs471620	ENSG00000279453.1	RP3-425C14.4	-6.95	6.22e-12	1.38e-09	-0.24	-0.21	Lymphocyte counts;	chr6:122473532	chr6:122436789~122439223:-
BRCA	cis	rs801193	1	rs17566701	ENSG00000236529.1	RP13-254B10.1	6.95	6.23e-12	1.38e-09	0.23	0.21	Aortic root size;	chr7:66728196	chr7:65840212~65840596:+
BRCA	cis	rs73173548	0.528	rs34857793	ENSG00000247828.6	TMEM161B-AS1	6.95	6.24e-12	1.38e-09	0.29	0.21	Macular telangiectasia type 2;	chr5:88467749	chr5:88268895~88436685:+
BRCA	cis	rs919433	0.963	rs12469546	ENSG00000231621.1	AC013264.2	6.95	6.24e-12	1.38e-09	0.21	0.21	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197314102	chr2:197197991~197199273:+
BRCA	cis	rs801193	0.569	rs35070132	ENSG00000232559.3	GS1-124K5.12	6.95	6.24e-12	1.38e-09	0.26	0.21	Aortic root size;	chr7:66773096	chr7:66554588~66576923:-
BRCA	cis	rs73173548	0.502	rs10505855	ENSG00000247828.6	TMEM161B-AS1	6.95	6.25e-12	1.38e-09	0.29	0.21	Macular telangiectasia type 2;	chr5:88440962	chr5:88268895~88436685:+
BRCA	cis	rs73173548	0.502	rs4129235	ENSG00000247828.6	TMEM161B-AS1	6.95	6.25e-12	1.38e-09	0.29	0.21	Macular telangiectasia type 2;	chr5:88441465	chr5:88268895~88436685:+
BRCA	cis	rs2060793	0.712	rs10832290	ENSG00000251991.1	RNU7-49P	6.95	6.25e-12	1.38e-09	0.23	0.21	Vitamin D levels;	chr11:14650684	chr11:14478892~14478953:+
BRCA	cis	rs9291683	0.588	rs3733586	ENSG00000250413.1	RP11-448G15.1	-6.95	6.26e-12	1.38e-09	-0.27	-0.21	Bone mineral density;	chr4:9995910	chr4:10006482~10009725:+
BRCA	cis	rs34375054	0.573	rs12811438	ENSG00000279233.1	RP11-158L12.4	6.95	6.27e-12	1.39e-09	0.31	0.21	Post bronchodilator FEV1/FVC ratio;	chr12:125168944	chr12:125138245~125141711:+
BRCA	cis	rs10276381	1	rs10276381	ENSG00000234336.5	JAZF1-AS1	6.95	6.27e-12	1.39e-09	0.35	0.21	Crohn's disease;	chr7:28150502	chr7:28180322~28243917:+
BRCA	cis	rs79040073	0.637	rs79311354	ENSG00000259531.2	RP11-295H24.3	6.95	6.27e-12	1.39e-09	0.35	0.21	Lung cancer in ever smokers;	chr15:49255987	chr15:49365124~49366685:-
BRCA	cis	rs10740039	0.846	rs10761529	ENSG00000254271.1	RP11-131N11.4	6.95	6.27e-12	1.39e-09	0.28	0.21	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60627052	chr10:60734342~60741828:+
BRCA	cis	rs11096990	0.855	rs1820939	ENSG00000249207.1	RP11-360F5.1	6.95	6.28e-12	1.39e-09	0.25	0.21	Cognitive function;	chr4:39170115	chr4:39112677~39126818:-
BRCA	cis	rs2243480	0.803	rs13224048	ENSG00000230295.1	RP11-458F8.2	-6.95	6.29e-12	1.39e-09	-0.28	-0.21	Diabetic kidney disease;	chr7:66528779	chr7:66880708~66882981:+
BRCA	cis	rs875971	0.564	rs313804	ENSG00000224316.1	RP11-479O9.2	6.95	6.3e-12	1.39e-09	0.21	0.21	Aortic root size;	chr7:66049635	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.662	rs448725	ENSG00000224316.1	RP11-479O9.2	6.95	6.3e-12	1.39e-09	0.21	0.21	Aortic root size;	chr7:66049641	chr7:65773620~65802067:+
BRCA	cis	rs783540	0.609	rs803686	ENSG00000278603.1	RP13-608F4.5	-6.95	6.31e-12	1.39e-09	-0.31	-0.21	Schizophrenia;	chr15:82550590	chr15:82472203~82472426:+
BRCA	cis	rs12468579	0.77	rs13395505	ENSG00000235852.1	AC005540.3	-6.95	6.31e-12	1.39e-09	-0.22	-0.21	JT interval (sulfonylurea treatment interaction);	chr2:190973788	chr2:190880797~190882059:-
BRCA	cis	rs2412819	0.545	rs17795279	ENSG00000205771.5	CATSPER2P1	6.95	6.32e-12	1.4e-09	0.32	0.21	Lung cancer;	chr15:43637180	chr15:43726918~43747094:-
BRCA	cis	rs9291683	0.588	rs17247314	ENSG00000250413.1	RP11-448G15.1	-6.95	6.34e-12	1.4e-09	-0.28	-0.21	Bone mineral density;	chr4:10003119	chr4:10006482~10009725:+
BRCA	cis	rs61160187	0.582	rs62367872	ENSG00000215032.2	GNL3LP1	6.95	6.35e-12	1.4e-09	0.26	0.21	Educational attainment (years of education);Educational attainment (college completion);	chr5:60976943	chr5:60891935~60893577:-
BRCA	cis	rs61160187	0.556	rs55738840	ENSG00000215032.2	GNL3LP1	6.95	6.35e-12	1.4e-09	0.26	0.21	Educational attainment (years of education);Educational attainment (college completion);	chr5:60977587	chr5:60891935~60893577:-
BRCA	cis	rs61160187	0.582	rs58646987	ENSG00000215032.2	GNL3LP1	6.95	6.35e-12	1.4e-09	0.26	0.21	Educational attainment (years of education);Educational attainment (college completion);	chr5:60979867	chr5:60891935~60893577:-
BRCA	cis	rs61160187	0.582	rs11739952	ENSG00000215032.2	GNL3LP1	6.95	6.35e-12	1.4e-09	0.26	0.21	Educational attainment (years of education);Educational attainment (college completion);	chr5:60980150	chr5:60891935~60893577:-
BRCA	cis	rs6442522	0.733	rs4143273	ENSG00000249786.6	EAF1-AS1	-6.95	6.35e-12	1.4e-09	-0.22	-0.21	Uric acid levels;	chr3:15460301	chr3:15436171~15455940:-
BRCA	cis	rs9368481	0.569	rs10946868	ENSG00000241549.7	GUSBP2	6.95	6.35e-12	1.4e-09	0.24	0.21	Autism spectrum disorder or schizophrenia;	chr6:26920151	chr6:26871484~26956554:-
BRCA	cis	rs2976388	0.609	rs2585148	ENSG00000253741.1	CTD-2292P10.4	-6.95	6.36e-12	1.4e-09	-0.24	-0.21	Urinary tract infection frequency;	chr8:142714775	chr8:142702252~142726973:-
BRCA	cis	rs755249	0.567	rs6668369	ENSG00000228060.1	RP11-69E11.8	-6.95	6.36e-12	1.4e-09	-0.26	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39382675	chr1:39565160~39573203:+
BRCA	cis	rs1707322	0.721	rs6429574	ENSG00000281133.1	AL355480.3	-6.95	6.37e-12	1.41e-09	-0.26	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45668382	chr1:45580892~45580996:-
BRCA	cis	rs71520386	0.632	rs10279864	ENSG00000228649.7	AC005682.5	-6.95	6.37e-12	1.41e-09	-0.2	-0.21	Fibrinogen levels;	chr7:22824205	chr7:22854178~22861579:+
BRCA	cis	rs2243480	0.901	rs778687	ENSG00000232546.1	RP11-458F8.1	-6.95	6.39e-12	1.41e-09	-0.28	-0.21	Diabetic kidney disease;	chr7:66370832	chr7:66848496~66858136:+
BRCA	cis	rs2243480	1	rs778704	ENSG00000232546.1	RP11-458F8.1	-6.95	6.39e-12	1.41e-09	-0.28	-0.21	Diabetic kidney disease;	chr7:66398480	chr7:66848496~66858136:+
BRCA	cis	rs2243480	0.901	rs778693	ENSG00000232546.1	RP11-458F8.1	-6.95	6.39e-12	1.41e-09	-0.28	-0.21	Diabetic kidney disease;	chr7:66407358	chr7:66848496~66858136:+
BRCA	cis	rs2243480	1	rs778691	ENSG00000232546.1	RP11-458F8.1	-6.95	6.39e-12	1.41e-09	-0.28	-0.21	Diabetic kidney disease;	chr7:66408105	chr7:66848496~66858136:+
BRCA	cis	rs2243480	1	rs13235972	ENSG00000232546.1	RP11-458F8.1	-6.95	6.39e-12	1.41e-09	-0.28	-0.21	Diabetic kidney disease;	chr7:66418618	chr7:66848496~66858136:+
BRCA	cis	rs2243480	1	rs34192067	ENSG00000232546.1	RP11-458F8.1	-6.95	6.39e-12	1.41e-09	-0.28	-0.21	Diabetic kidney disease;	chr7:66422670	chr7:66848496~66858136:+
BRCA	cis	rs7246657	0.943	rs35540940	ENSG00000267422.1	CTD-2554C21.1	-6.95	6.39e-12	1.41e-09	-0.31	-0.21	Coronary artery calcification;	chr19:37517333	chr19:37779686~37792865:+
BRCA	cis	rs11098499	0.866	rs10518329	ENSG00000248280.1	RP11-33B1.2	6.95	6.4e-12	1.41e-09	0.21	0.21	Corneal astigmatism;	chr4:119480680	chr4:119440561~119450157:-
BRCA	cis	rs10515750	0.53	rs13358909	ENSG00000251405.2	CTB-109A12.1	6.95	6.4e-12	1.41e-09	0.46	0.21	Lung function (FEV1/FVC);	chr5:157288824	chr5:157362615~157460078:-
BRCA	cis	rs11723261	0.621	rs7440274	ENSG00000211553.1	AC253576.2	6.95	6.41e-12	1.42e-09	0.31	0.21	Immune response to smallpox vaccine (IL-6);	chr4:161923	chr4:136461~136568:+
BRCA	cis	rs2933343	0.951	rs9871612	ENSG00000261159.1	RP11-723O4.9	6.95	6.42e-12	1.42e-09	0.25	0.21	IgG glycosylation;	chr3:128851559	chr3:128859716~128860526:-
BRCA	cis	rs600231	0.708	rs602838	ENSG00000245532.5	NEAT1	6.95	6.43e-12	1.42e-09	0.19	0.21	Bone mineral density;	chr11:65485776	chr11:65422774~65445540:+
BRCA	cis	rs7772486	0.686	rs9376961	ENSG00000270638.1	RP3-466P17.1	6.95	6.44e-12	1.42e-09	0.24	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145727601	chr6:145735570~145737218:+
BRCA	cis	rs8177876	0.642	rs4454990	ENSG00000261838.4	RP11-303E16.6	-6.95	6.44e-12	1.42e-09	-0.4	-0.21	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81106550	chr16:81069854~81076598:+
BRCA	cis	rs11098499	0.954	rs10006706	ENSG00000249244.1	RP11-548H18.2	6.95	6.44e-12	1.42e-09	0.25	0.21	Corneal astigmatism;	chr4:119487997	chr4:119391831~119395335:-
BRCA	cis	rs875971	0.895	rs4145009	ENSG00000232559.3	GS1-124K5.12	-6.95	6.45e-12	1.42e-09	-0.25	-0.21	Aortic root size;	chr7:66261628	chr7:66554588~66576923:-
BRCA	cis	rs6840360	0.642	rs6845648	ENSG00000270265.1	RP11-731D1.4	-6.95	6.46e-12	1.43e-09	-0.23	-0.21	Intelligence (multi-trait analysis);	chr4:151454898	chr4:151333775~151353224:-
BRCA	cis	rs6840360	0.642	rs2724571	ENSG00000270265.1	RP11-731D1.4	-6.95	6.46e-12	1.43e-09	-0.23	-0.21	Intelligence (multi-trait analysis);	chr4:151455643	chr4:151333775~151353224:-
BRCA	cis	rs6840360	0.642	rs2709833	ENSG00000270265.1	RP11-731D1.4	-6.95	6.46e-12	1.43e-09	-0.23	-0.21	Intelligence (multi-trait analysis);	chr4:151456470	chr4:151333775~151353224:-
BRCA	cis	rs1499614	1	rs2707840	ENSG00000230295.1	RP11-458F8.2	-6.95	6.46e-12	1.43e-09	-0.28	-0.21	Gout;	chr7:66693028	chr7:66880708~66882981:+
BRCA	cis	rs755249	0.567	rs72661961	ENSG00000228060.1	RP11-69E11.8	-6.95	6.47e-12	1.43e-09	-0.26	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39366096	chr1:39565160~39573203:+
BRCA	cis	rs755249	0.532	rs61779277	ENSG00000228060.1	RP11-69E11.8	-6.95	6.47e-12	1.43e-09	-0.26	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39367863	chr1:39565160~39573203:+
BRCA	cis	rs755249	0.532	rs61779278	ENSG00000228060.1	RP11-69E11.8	-6.95	6.47e-12	1.43e-09	-0.26	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39368945	chr1:39565160~39573203:+
BRCA	cis	rs755249	0.567	rs2296172	ENSG00000228060.1	RP11-69E11.8	-6.95	6.47e-12	1.43e-09	-0.26	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39370145	chr1:39565160~39573203:+
BRCA	cis	rs755249	0.567	rs61779279	ENSG00000228060.1	RP11-69E11.8	-6.95	6.47e-12	1.43e-09	-0.26	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39371430	chr1:39565160~39573203:+
BRCA	cis	rs79040073	0.637	rs73392288	ENSG00000259531.2	RP11-295H24.3	6.95	6.48e-12	1.43e-09	0.35	0.21	Lung cancer in ever smokers;	chr15:49250842	chr15:49365124~49366685:-
BRCA	cis	rs42648	0.935	rs42659	ENSG00000225498.1	AC002064.5	6.95	6.49e-12	1.43e-09	0.2	0.21	Homocysteine levels;	chr7:90352644	chr7:90312496~90322592:+
BRCA	cis	rs7809950	0.954	rs2894466	ENSG00000238832.1	snoU109	6.95	6.49e-12	1.43e-09	0.29	0.21	Coronary artery disease;	chr7:107602464	chr7:107603363~107603507:+
BRCA	cis	rs7809950	0.834	rs3801946	ENSG00000238832.1	snoU109	6.95	6.49e-12	1.43e-09	0.29	0.21	Coronary artery disease;	chr7:107602550	chr7:107603363~107603507:+
BRCA	cis	rs113835537	0.529	rs60358007	ENSG00000255517.5	CTD-3074O7.5	-6.95	6.49e-12	1.43e-09	-0.29	-0.21	Airway imaging phenotypes;	chr11:66454882	chr11:66473490~66480233:-
BRCA	cis	rs801193	0.935	rs2659899	ENSG00000236529.1	RP13-254B10.1	6.95	6.5e-12	1.43e-09	0.23	0.21	Aortic root size;	chr7:66721734	chr7:65840212~65840596:+
BRCA	cis	rs2880765	0.743	rs6416598	ENSG00000259295.5	CSPG4P12	6.95	6.5e-12	1.43e-09	0.26	0.21	Coronary artery disease;	chr15:85468617	chr15:85191438~85213905:+
BRCA	cis	rs6723226	1	rs6723226	ENSG00000276334.1	AL133243.1	6.95	6.5e-12	1.43e-09	0.26	0.21	Intelligence (multi-trait analysis);	chr2:32624140	chr2:32521927~32523547:+
BRCA	cis	rs6921919	0.583	rs16894060	ENSG00000204709.4	LINC01556	6.95	6.51e-12	1.44e-09	0.29	0.21	Autism spectrum disorder or schizophrenia;	chr6:28394694	chr6:28943877~28944537:+
BRCA	cis	rs9291683	0.609	rs4622999	ENSG00000250413.1	RP11-448G15.1	-6.95	6.52e-12	1.44e-09	-0.27	-0.21	Bone mineral density;	chr4:10001771	chr4:10006482~10009725:+
BRCA	cis	rs755249	0.567	rs3818806	ENSG00000228060.1	RP11-69E11.8	-6.95	6.56e-12	1.45e-09	-0.26	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39282599	chr1:39565160~39573203:+
BRCA	cis	rs61160187	0.582	rs12652830	ENSG00000215032.2	GNL3LP1	6.95	6.56e-12	1.45e-09	0.26	0.21	Educational attainment (years of education);Educational attainment (college completion);	chr5:60956655	chr5:60891935~60893577:-
BRCA	cis	rs7044106	0.762	rs1158554	ENSG00000238181.2	AHCYP2	-6.95	6.56e-12	1.45e-09	-0.27	-0.21	Hip circumference adjusted for BMI;	chr9:120638620	chr9:120720673~120721972:+
BRCA	cis	rs10740039	1	rs10740040	ENSG00000254271.1	RP11-131N11.4	6.95	6.56e-12	1.45e-09	0.27	0.21	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60654985	chr10:60734342~60741828:+
BRCA	cis	rs2014572	0.967	rs10413671	ENSG00000268379.1	CTC-360J11.4	6.95	6.58e-12	1.45e-09	0.26	0.21	Hyperactive-impulsive symptoms;	chr19:57252121	chr19:57175233~57177921:+
BRCA	cis	rs6142102	0.651	rs6059692	ENSG00000276073.1	RP5-1125A11.7	6.95	6.59e-12	1.45e-09	0.26	0.21	Skin pigmentation;	chr20:34158397	chr20:33985617~33988989:-
BRCA	cis	rs9880211	0.8	rs35422852	ENSG00000273486.1	RP11-731C17.2	6.95	6.59e-12	1.45e-09	0.29	0.21	Height;Body mass index;	chr3:136787073	chr3:136837338~136839021:-
BRCA	cis	rs6840360	0.606	rs2709814	ENSG00000270265.1	RP11-731D1.4	-6.95	6.6e-12	1.45e-09	-0.24	-0.21	Intelligence (multi-trait analysis);	chr4:151439718	chr4:151333775~151353224:-
BRCA	cis	rs2638953	0.924	rs1551987	ENSG00000278733.1	RP11-425D17.1	-6.95	6.6e-12	1.46e-09	-0.26	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28178761	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.924	rs1551986	ENSG00000278733.1	RP11-425D17.1	-6.95	6.6e-12	1.46e-09	-0.26	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28178778	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.924	rs2078017	ENSG00000278733.1	RP11-425D17.1	-6.95	6.6e-12	1.46e-09	-0.26	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28180175	chr12:28185625~28186190:-
BRCA	cis	rs78456975	0.527	rs72778003	ENSG00000231482.2	AC141930.2	-6.95	6.61e-12	1.46e-09	-0.28	-0.21	Placebo response in major depressive disorder (% change in symptom score);	chr2:1567715	chr2:1572554~1580311:-
BRCA	cis	rs66887589	0.616	rs6822808	ENSG00000248280.1	RP11-33B1.2	6.95	6.61e-12	1.46e-09	0.2	0.21	Diastolic blood pressure;	chr4:119296210	chr4:119440561~119450157:-
BRCA	cis	rs7674212	0.865	rs13149311	ENSG00000246560.2	RP11-10L12.4	6.95	6.61e-12	1.46e-09	0.23	0.21	Type 2 diabetes;	chr4:103056543	chr4:102828055~102844075:+
BRCA	cis	rs6142102	0.923	rs4911379	ENSG00000275784.1	RP5-1125A11.6	-6.95	6.61e-12	1.46e-09	-0.25	-0.21	Skin pigmentation;	chr20:33947499	chr20:33989480~33991818:-
BRCA	cis	rs7131987	0.65	rs7973786	ENSG00000257176.2	RP11-996F15.2	-6.95	6.63e-12	1.46e-09	-0.26	-0.21	QT interval;	chr12:29309811	chr12:29280418~29317848:-
BRCA	cis	rs875971	0.929	rs6970860	ENSG00000232559.3	GS1-124K5.12	6.95	6.64e-12	1.46e-09	0.25	0.21	Aortic root size;	chr7:66511647	chr7:66554588~66576923:-
BRCA	cis	rs2638953	0.924	rs11049415	ENSG00000247934.4	RP11-967K21.1	-6.95	6.64e-12	1.46e-09	-0.27	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28190188	chr12:28163298~28190738:-
BRCA	cis	rs6545883	0.965	rs7591345	ENSG00000271889.1	RP11-493E12.1	6.95	6.64e-12	1.46e-09	0.27	0.21	Tuberculosis;	chr2:61502506	chr2:61151433~61162105:-
BRCA	cis	rs801193	1	rs2003301	ENSG00000236529.1	RP13-254B10.1	-6.95	6.65e-12	1.46e-09	-0.23	-0.21	Aortic root size;	chr7:66682669	chr7:65840212~65840596:+
BRCA	cis	rs6921919	0.583	rs1054372	ENSG00000204709.4	LINC01556	6.94	6.66e-12	1.47e-09	0.29	0.21	Autism spectrum disorder or schizophrenia;	chr6:28368965	chr6:28943877~28944537:+
BRCA	cis	rs6921919	0.583	rs9468354	ENSG00000204709.4	LINC01556	6.94	6.66e-12	1.47e-09	0.29	0.21	Autism spectrum disorder or schizophrenia;	chr6:28370024	chr6:28943877~28944537:+
BRCA	cis	rs6921919	0.583	rs7773051	ENSG00000204709.4	LINC01556	6.94	6.66e-12	1.47e-09	0.29	0.21	Autism spectrum disorder or schizophrenia;	chr6:28372539	chr6:28943877~28944537:+
BRCA	cis	rs6921919	0.583	rs12697938	ENSG00000204709.4	LINC01556	6.94	6.66e-12	1.47e-09	0.29	0.21	Autism spectrum disorder or schizophrenia;	chr6:28373322	chr6:28943877~28944537:+
BRCA	cis	rs6921919	0.583	rs13437294	ENSG00000204709.4	LINC01556	6.94	6.66e-12	1.47e-09	0.29	0.21	Autism spectrum disorder or schizophrenia;	chr6:28373758	chr6:28943877~28944537:+
BRCA	cis	rs6921919	0.609	rs9468357	ENSG00000204709.4	LINC01556	6.94	6.66e-12	1.47e-09	0.29	0.21	Autism spectrum disorder or schizophrenia;	chr6:28374276	chr6:28943877~28944537:+
BRCA	cis	rs6921919	0.583	rs34513104	ENSG00000204709.4	LINC01556	6.94	6.66e-12	1.47e-09	0.29	0.21	Autism spectrum disorder or schizophrenia;	chr6:28375566	chr6:28943877~28944537:+
BRCA	cis	rs6921919	0.583	rs9461456	ENSG00000204709.4	LINC01556	6.94	6.66e-12	1.47e-09	0.29	0.21	Autism spectrum disorder or schizophrenia;	chr6:28376039	chr6:28943877~28944537:+
BRCA	cis	rs6921919	0.525	rs9468360	ENSG00000204709.4	LINC01556	6.94	6.66e-12	1.47e-09	0.29	0.21	Autism spectrum disorder or schizophrenia;	chr6:28376661	chr6:28943877~28944537:+
BRCA	cis	rs6921919	0.583	rs16894021	ENSG00000204709.4	LINC01556	6.94	6.66e-12	1.47e-09	0.29	0.21	Autism spectrum disorder or schizophrenia;	chr6:28377249	chr6:28943877~28944537:+
BRCA	cis	rs6921919	0.583	rs11751693	ENSG00000204709.4	LINC01556	6.94	6.66e-12	1.47e-09	0.29	0.21	Autism spectrum disorder or schizophrenia;	chr6:28377306	chr6:28943877~28944537:+
BRCA	cis	rs6921919	0.583	rs7749736	ENSG00000204709.4	LINC01556	6.94	6.66e-12	1.47e-09	0.29	0.21	Autism spectrum disorder or schizophrenia;	chr6:28378254	chr6:28943877~28944537:+
BRCA	cis	rs6921919	0.525	rs9468361	ENSG00000204709.4	LINC01556	6.94	6.66e-12	1.47e-09	0.29	0.21	Autism spectrum disorder or schizophrenia;	chr6:28378541	chr6:28943877~28944537:+
BRCA	cis	rs6921919	0.583	rs7775132	ENSG00000204709.4	LINC01556	6.94	6.66e-12	1.47e-09	0.29	0.21	Autism spectrum disorder or schizophrenia;	chr6:28379236	chr6:28943877~28944537:+
BRCA	cis	rs6921919	0.583	rs3734563	ENSG00000204709.4	LINC01556	6.94	6.66e-12	1.47e-09	0.29	0.21	Autism spectrum disorder or schizophrenia;	chr6:28381948	chr6:28943877~28944537:+
BRCA	cis	rs6921919	0.583	rs1591913	ENSG00000204709.4	LINC01556	6.94	6.66e-12	1.47e-09	0.29	0.21	Autism spectrum disorder or schizophrenia;	chr6:28383951	chr6:28943877~28944537:+
BRCA	cis	rs11098499	0.78	rs7692994	ENSG00000248280.1	RP11-33B1.2	6.94	6.66e-12	1.47e-09	0.21	0.21	Corneal astigmatism;	chr4:119506334	chr4:119440561~119450157:-
BRCA	cis	rs2014572	0.967	rs10412975	ENSG00000268379.1	CTC-360J11.4	6.94	6.67e-12	1.47e-09	0.26	0.21	Hyperactive-impulsive symptoms;	chr19:57259186	chr19:57175233~57177921:+
BRCA	cis	rs801193	1	rs2055682	ENSG00000236529.1	RP13-254B10.1	6.94	6.67e-12	1.47e-09	0.23	0.21	Aortic root size;	chr7:66795302	chr7:65840212~65840596:+
BRCA	cis	rs1275468	0.518	rs1552040	ENSG00000257497.2	RP11-585P4.5	-6.94	6.67e-12	1.47e-09	-0.3	-0.21	Polycystic ovary syndrome;	chr12:75528437	chr12:75483454~75489820:-
BRCA	cis	rs6545883	0.868	rs7574631	ENSG00000271889.1	RP11-493E12.1	6.94	6.68e-12	1.47e-09	0.27	0.21	Tuberculosis;	chr2:61598007	chr2:61151433~61162105:-
BRCA	cis	rs67311347	1	rs9860162	ENSG00000280739.1	EIF1B-AS1	6.94	6.69e-12	1.47e-09	0.24	0.21	Renal cell carcinoma;	chr3:40362384	chr3:40173145~40309698:-
BRCA	cis	rs9813712	0.571	rs9824426	ENSG00000228252.7	COL6A4P2	-6.94	6.69e-12	1.47e-09	-0.24	-0.21	Response to amphetamines;	chr3:130226115	chr3:130212823~130273806:+
BRCA	cis	rs11148252	0.74	rs9536052	ENSG00000278238.1	RP11-245D16.4	6.94	6.7e-12	1.48e-09	0.23	0.21	Lewy body disease;	chr13:52386574	chr13:52454775~52455331:-
BRCA	cis	rs8062405	0.54	rs480400	ENSG00000251417.2	RP11-1348G14.4	-6.94	6.71e-12	1.48e-09	-0.23	-0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28563294	chr16:28802743~28817828:+
BRCA	cis	rs17301013	0.606	rs56338048	ENSG00000227373.4	RP11-160H22.5	6.94	6.71e-12	1.48e-09	0.3	0.21	Systemic lupus erythematosus;	chr1:174220266	chr1:174115300~174160004:-
BRCA	cis	rs13113518	0.812	rs6830409	ENSG00000249700.7	SRD5A3-AS1	6.94	6.72e-12	1.48e-09	0.27	0.21	Height;	chr4:55522229	chr4:55363971~55395847:-
BRCA	cis	rs801193	1	rs2659912	ENSG00000236529.1	RP13-254B10.1	6.94	6.72e-12	1.48e-09	0.23	0.21	Aortic root size;	chr7:66693012	chr7:65840212~65840596:+
BRCA	cis	rs71520386	0.632	rs9654968	ENSG00000228649.7	AC005682.5	-6.94	6.72e-12	1.48e-09	-0.21	-0.21	Fibrinogen levels;	chr7:22836697	chr7:22854178~22861579:+
BRCA	cis	rs11098499	0.954	rs71629403	ENSG00000249244.1	RP11-548H18.2	6.94	6.72e-12	1.48e-09	0.25	0.21	Corneal astigmatism;	chr4:119451412	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.909	rs28571712	ENSG00000249244.1	RP11-548H18.2	6.94	6.72e-12	1.48e-09	0.25	0.21	Corneal astigmatism;	chr4:119454825	chr4:119391831~119395335:-
BRCA	cis	rs1707322	0.785	rs10890348	ENSG00000281133.1	AL355480.3	-6.94	6.73e-12	1.48e-09	-0.27	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45776751	chr1:45580892~45580996:-
BRCA	cis	rs875971	1	rs12698523	ENSG00000232559.3	GS1-124K5.12	6.94	6.73e-12	1.48e-09	0.25	0.21	Aortic root size;	chr7:66503126	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.545	rs6460281	ENSG00000236529.1	RP13-254B10.1	6.94	6.74e-12	1.48e-09	0.26	0.21	Aortic root size;	chr7:66216128	chr7:65840212~65840596:+
BRCA	cis	rs8062405	0.691	rs11646653	ENSG00000251417.2	RP11-1348G14.4	6.94	6.74e-12	1.49e-09	0.25	0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28910828	chr16:28802743~28817828:+
BRCA	cis	rs7131987	0.65	rs10843377	ENSG00000257176.2	RP11-996F15.2	6.94	6.75e-12	1.49e-09	0.26	0.21	QT interval;	chr12:29284120	chr12:29280418~29317848:-
BRCA	cis	rs2337406	1	rs17113257	ENSG00000254174.1	IGHV1-12	6.94	6.76e-12	1.49e-09	0.22	0.21	Alzheimer's disease (late onset);	chr14:106679574	chr14:106122420~106122709:-
BRCA	cis	rs9307551	0.857	rs2165387	ENSG00000250334.4	LINC00989	-6.94	6.76e-12	1.49e-09	-0.28	-0.21	Refractive error;	chr4:79570666	chr4:79492416~79576460:+
BRCA	cis	rs375066	0.762	rs239939	ENSG00000267058.1	RP11-15A1.3	-6.94	6.76e-12	1.49e-09	-0.24	-0.21	Breast cancer;	chr19:43883815	chr19:43891804~43901805:-
BRCA	cis	rs375066	0.762	rs239938	ENSG00000267058.1	RP11-15A1.3	-6.94	6.76e-12	1.49e-09	-0.24	-0.21	Breast cancer;	chr19:43886153	chr19:43891804~43901805:-
BRCA	cis	rs2243480	1	rs1873494	ENSG00000230295.1	RP11-458F8.2	6.94	6.76e-12	1.49e-09	0.28	0.21	Diabetic kidney disease;	chr7:66184912	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs6959002	ENSG00000230295.1	RP11-458F8.2	6.94	6.76e-12	1.49e-09	0.28	0.21	Diabetic kidney disease;	chr7:66185509	chr7:66880708~66882981:+
BRCA	cis	rs62025270	0.522	rs338519	ENSG00000202081.1	RNU6-1280P	-6.94	6.76e-12	1.49e-09	-0.26	-0.21	Idiopathic pulmonary fibrosis;	chr15:85671648	chr15:85651522~85651628:-
BRCA	cis	rs2599510	0.811	rs2710628	ENSG00000276334.1	AL133243.1	6.94	6.78e-12	1.49e-09	0.25	0.21	Interleukin-18 levels;	chr2:32533286	chr2:32521927~32523547:+
BRCA	cis	rs2835345	0.563	rs60727080	ENSG00000230479.1	AP000695.6	6.94	6.79e-12	1.49e-09	0.21	0.21	Pulmonary function;	chr21:36454876	chr21:36430360~36481070:+
BRCA	cis	rs11096990	0.855	rs2566177	ENSG00000249207.1	RP11-360F5.1	6.94	6.79e-12	1.49e-09	0.25	0.21	Cognitive function;	chr4:39154558	chr4:39112677~39126818:-
BRCA	cis	rs11096990	0.855	rs2711934	ENSG00000249207.1	RP11-360F5.1	6.94	6.79e-12	1.49e-09	0.25	0.21	Cognitive function;	chr4:39156254	chr4:39112677~39126818:-
BRCA	cis	rs7246657	0.943	rs2291004	ENSG00000276846.1	CTD-3220F14.3	6.94	6.8e-12	1.5e-09	0.29	0.21	Coronary artery calcification;	chr19:37507050	chr19:37314868~37315620:-
BRCA	cis	rs10200159	0.744	rs6545513	ENSG00000272606.1	RP11-554J4.1	6.94	6.8e-12	1.5e-09	0.38	0.21	Vitiligo;	chr2:55657729	chr2:55617909~55618373:+
BRCA	cis	rs34779708	0.931	rs2001893	ENSG00000271335.4	RP11-324I22.4	6.94	6.8e-12	1.5e-09	0.21	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35011695	chr10:35314552~35336401:-
BRCA	cis	rs11098499	0.954	rs12499324	ENSG00000249244.1	RP11-548H18.2	6.94	6.83e-12	1.5e-09	0.25	0.21	Corneal astigmatism;	chr4:119472631	chr4:119391831~119395335:-
BRCA	cis	rs9880211	0.752	rs9820717	ENSG00000273486.1	RP11-731C17.2	6.94	6.83e-12	1.5e-09	0.28	0.21	Height;Body mass index;	chr3:136627771	chr3:136837338~136839021:-
BRCA	cis	rs13113518	0.812	rs2035691	ENSG00000249700.7	SRD5A3-AS1	6.94	6.83e-12	1.5e-09	0.27	0.21	Height;	chr4:55529786	chr4:55363971~55395847:-
BRCA	cis	rs13113518	0.756	rs11939652	ENSG00000249700.7	SRD5A3-AS1	6.94	6.83e-12	1.5e-09	0.27	0.21	Height;	chr4:55532542	chr4:55363971~55395847:-
BRCA	cis	rs9880211	0.699	rs34804893	ENSG00000273486.1	RP11-731C17.2	6.94	6.84e-12	1.51e-09	0.28	0.21	Height;Body mass index;	chr3:136621128	chr3:136837338~136839021:-
BRCA	cis	rs2638953	0.924	rs10492368	ENSG00000278733.1	RP11-425D17.1	-6.94	6.85e-12	1.51e-09	-0.26	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28173941	chr12:28185625~28186190:-
BRCA	cis	rs875971	0.862	rs10256544	ENSG00000232559.3	GS1-124K5.12	6.94	6.86e-12	1.51e-09	0.25	0.21	Aortic root size;	chr7:66210141	chr7:66554588~66576923:-
BRCA	cis	rs9291683	0.588	rs2240722	ENSG00000250413.1	RP11-448G15.1	-6.94	6.86e-12	1.51e-09	-0.27	-0.21	Bone mineral density;	chr4:10019133	chr4:10006482~10009725:+
BRCA	cis	rs301901	1	rs158791	ENSG00000250155.1	CTD-2353F22.1	6.94	6.87e-12	1.51e-09	0.23	0.21	Height;	chr5:36948260	chr5:36666214~36725195:-
BRCA	cis	rs42490	1	rs40246	ENSG00000251136.7	RP11-37B2.1	-6.94	6.87e-12	1.51e-09	-0.21	-0.21	Leprosy;	chr8:89752944	chr8:89609409~89757727:-
BRCA	cis	rs2243480	1	rs2707844	ENSG00000230295.1	RP11-458F8.2	-6.94	6.87e-12	1.51e-09	-0.28	-0.21	Diabetic kidney disease;	chr7:66594522	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs1796220	ENSG00000230295.1	RP11-458F8.2	-6.94	6.87e-12	1.51e-09	-0.28	-0.21	Diabetic kidney disease;	chr7:66597113	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs2707831	ENSG00000230295.1	RP11-458F8.2	-6.94	6.87e-12	1.51e-09	-0.28	-0.21	Diabetic kidney disease;	chr7:66597524	chr7:66880708~66882981:+
BRCA	cis	rs875971	0.545	rs1638724	ENSG00000224316.1	RP11-479O9.2	-6.94	6.91e-12	1.52e-09	-0.24	-0.21	Aortic root size;	chr7:66575494	chr7:65773620~65802067:+
BRCA	cis	rs1823913	0.637	rs897197	ENSG00000280083.1	RP11-317J9.1	6.94	6.93e-12	1.52e-09	0.24	0.21	Obesity-related traits;	chr2:191281456	chr2:191154118~191156070:-
BRCA	cis	rs801193	0.844	rs2244022	ENSG00000224316.1	RP11-479O9.2	6.94	6.95e-12	1.53e-09	0.21	0.21	Aortic root size;	chr7:66737443	chr7:65773620~65802067:+
BRCA	cis	rs73173548	0.502	rs4601863	ENSG00000247828.6	TMEM161B-AS1	6.94	6.97e-12	1.53e-09	0.29	0.21	Macular telangiectasia type 2;	chr5:88433804	chr5:88268895~88436685:+
BRCA	cis	rs9291683	0.588	rs35866697	ENSG00000250413.1	RP11-448G15.1	-6.94	6.98e-12	1.53e-09	-0.27	-0.21	Bone mineral density;	chr4:10016980	chr4:10006482~10009725:+
BRCA	cis	rs919433	1	rs7422899	ENSG00000231621.1	AC013264.2	6.94	6.98e-12	1.54e-09	0.21	0.21	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197298803	chr2:197197991~197199273:+
BRCA	cis	rs9291683	0.588	rs35099040	ENSG00000250413.1	RP11-448G15.1	-6.94	7.02e-12	1.54e-09	-0.27	-0.21	Bone mineral density;	chr4:10017215	chr4:10006482~10009725:+
BRCA	cis	rs9807989	0.708	rs6543124	ENSG00000234389.1	AC007278.3	6.94	7.02e-12	1.54e-09	0.2	0.21	Asthma;	chr2:102370999	chr2:102438713~102440475:+
BRCA	cis	rs9368481	0.524	rs9393768	ENSG00000241549.7	GUSBP2	6.94	7.03e-12	1.55e-09	0.24	0.21	Autism spectrum disorder or schizophrenia;	chr6:26917840	chr6:26871484~26956554:-
BRCA	cis	rs61160187	0.582	rs7723901	ENSG00000215032.2	GNL3LP1	6.94	7.03e-12	1.55e-09	0.26	0.21	Educational attainment (years of education);Educational attainment (college completion);	chr5:60977163	chr5:60891935~60893577:-
BRCA	cis	rs17301013	0.581	rs6685499	ENSG00000227373.4	RP11-160H22.5	6.94	7.05e-12	1.55e-09	0.3	0.21	Systemic lupus erythematosus;	chr1:174144237	chr1:174115300~174160004:-
BRCA	cis	rs801193	1	rs2420824	ENSG00000224316.1	RP11-479O9.2	-6.94	7.06e-12	1.55e-09	-0.21	-0.21	Aortic root size;	chr7:66666129	chr7:65773620~65802067:+
BRCA	cis	rs10129255	0.5	rs8011115	ENSG00000274576.2	IGHV2-70	-6.94	7.07e-12	1.55e-09	-0.17	-0.21	Kawasaki disease;	chr14:106786292	chr14:106770577~106771020:-
BRCA	cis	rs17826219	0.568	rs11658027	ENSG00000263603.1	CTD-2349P21.5	6.94	7.07e-12	1.55e-09	0.35	0.21	Body mass index;	chr17:30767864	chr17:30729469~30731202:+
BRCA	cis	rs755249	0.532	rs2296173	ENSG00000228060.1	RP11-69E11.8	-6.94	7.07e-12	1.55e-09	-0.26	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39447679	chr1:39565160~39573203:+
BRCA	cis	rs755249	0.567	rs3118014	ENSG00000228060.1	RP11-69E11.8	-6.94	7.07e-12	1.55e-09	-0.26	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39448418	chr1:39565160~39573203:+
BRCA	cis	rs17301013	0.606	rs724888	ENSG00000227373.4	RP11-160H22.5	6.94	7.07e-12	1.55e-09	0.3	0.21	Systemic lupus erythematosus;	chr1:174180403	chr1:174115300~174160004:-
BRCA	cis	rs2014572	0.875	rs10405008	ENSG00000268379.1	CTC-360J11.4	-6.94	7.09e-12	1.56e-09	-0.26	-0.21	Hyperactive-impulsive symptoms;	chr19:57242275	chr19:57175233~57177921:+
BRCA	cis	rs875971	0.522	rs1701760	ENSG00000237310.1	GS1-124K5.4	6.94	7.09e-12	1.56e-09	0.22	0.21	Aortic root size;	chr7:66008701	chr7:66493706~66495474:+
BRCA	cis	rs755249	0.567	rs76111861	ENSG00000228060.1	RP11-69E11.8	-6.94	7.1e-12	1.56e-09	-0.26	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39377018	chr1:39565160~39573203:+
BRCA	cis	rs755249	0.567	rs72661965	ENSG00000228060.1	RP11-69E11.8	-6.94	7.1e-12	1.56e-09	-0.26	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39380918	chr1:39565160~39573203:+
BRCA	cis	rs9649213	0.593	rs6465665	ENSG00000272950.1	RP11-307C18.1	6.94	7.1e-12	1.56e-09	0.26	0.21	Prostate cancer (SNP x SNP interaction);	chr7:98304838	chr7:98322853~98323430:+
BRCA	cis	rs5758659	0.652	rs4822084	ENSG00000273366.1	CTA-989H11.1	6.94	7.11e-12	1.56e-09	0.26	0.21	Cognitive function;	chr22:42039864	chr22:42278188~42278846:+
BRCA	cis	rs61160187	0.582	rs55814394	ENSG00000215032.2	GNL3LP1	6.94	7.11e-12	1.56e-09	0.26	0.21	Educational attainment (years of education);Educational attainment (college completion);	chr5:61014107	chr5:60891935~60893577:-
BRCA	cis	rs11098499	0.954	rs10518331	ENSG00000249244.1	RP11-548H18.2	6.94	7.12e-12	1.56e-09	0.25	0.21	Corneal astigmatism;	chr4:119402440	chr4:119391831~119395335:-
BRCA	cis	rs1499614	1	rs2659903	ENSG00000230295.1	RP11-458F8.2	-6.94	7.12e-12	1.56e-09	-0.28	-0.21	Gout;	chr7:66715944	chr7:66880708~66882981:+
BRCA	cis	rs11098499	0.865	rs9994730	ENSG00000249244.1	RP11-548H18.2	6.93	7.12e-12	1.56e-09	0.25	0.21	Corneal astigmatism;	chr4:119460409	chr4:119391831~119395335:-
BRCA	cis	rs17301013	0.507	rs10912762	ENSG00000227373.4	RP11-160H22.5	6.93	7.13e-12	1.57e-09	0.3	0.21	Systemic lupus erythematosus;	chr1:174312477	chr1:174115300~174160004:-
BRCA	cis	rs17301013	0.507	rs12097252	ENSG00000227373.4	RP11-160H22.5	6.93	7.13e-12	1.57e-09	0.3	0.21	Systemic lupus erythematosus;	chr1:174318374	chr1:174115300~174160004:-
BRCA	cis	rs919433	0.927	rs1429412	ENSG00000231621.1	AC013264.2	6.93	7.13e-12	1.57e-09	0.2	0.21	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197326170	chr2:197197991~197199273:+
BRCA	cis	rs3794924	1	rs8091481	ENSG00000266521.1	RP11-650P15.1	6.93	7.13e-12	1.57e-09	0.37	0.21	Survival in colon cancer;	chr18:31471714	chr18:31496645~31497195:-
BRCA	cis	rs848490	0.651	rs7810273	ENSG00000214293.7	APTR	6.93	7.13e-12	1.57e-09	0.24	0.21	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77685327	chr7:77657660~77696265:-
BRCA	cis	rs13113518	0.812	rs13116035	ENSG00000249700.7	SRD5A3-AS1	6.93	7.15e-12	1.57e-09	0.27	0.21	Height;	chr4:55561218	chr4:55363971~55395847:-
BRCA	cis	rs11098499	0.954	rs3890049	ENSG00000249244.1	RP11-548H18.2	6.93	7.15e-12	1.57e-09	0.25	0.21	Corneal astigmatism;	chr4:119405128	chr4:119391831~119395335:-
BRCA	cis	rs71520386	0.632	rs9692432	ENSG00000228649.7	AC005682.5	-6.93	7.17e-12	1.57e-09	-0.2	-0.21	Fibrinogen levels;	chr7:22829244	chr7:22854178~22861579:+
BRCA	cis	rs71520386	0.632	rs71520387	ENSG00000228649.7	AC005682.5	-6.93	7.17e-12	1.57e-09	-0.2	-0.21	Fibrinogen levels;	chr7:22830057	chr7:22854178~22861579:+
BRCA	cis	rs71520386	0.632	rs10224244	ENSG00000228649.7	AC005682.5	-6.93	7.17e-12	1.57e-09	-0.2	-0.21	Fibrinogen levels;	chr7:22830455	chr7:22854178~22861579:+
BRCA	cis	rs2243480	1	rs1979823	ENSG00000232546.1	RP11-458F8.1	6.93	7.17e-12	1.57e-09	0.28	0.21	Diabetic kidney disease;	chr7:66239626	chr7:66848496~66858136:+
BRCA	cis	rs1862618	0.802	rs4389648	ENSG00000271828.1	CTD-2310F14.1	6.93	7.17e-12	1.58e-09	0.3	0.21	Initial pursuit acceleration;	chr5:56807775	chr5:56927874~56929573:+
BRCA	cis	rs11098499	0.954	rs2389802	ENSG00000249244.1	RP11-548H18.2	6.93	7.18e-12	1.58e-09	0.25	0.21	Corneal astigmatism;	chr4:119404577	chr4:119391831~119395335:-
BRCA	cis	rs1707322	0.686	rs2991977	ENSG00000281133.1	AL355480.3	6.93	7.18e-12	1.58e-09	0.27	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45588011	chr1:45580892~45580996:-
BRCA	cis	rs7617773	0.817	rs4131362	ENSG00000228638.1	FCF1P2	-6.93	7.21e-12	1.58e-09	-0.23	-0.21	Coronary artery disease;	chr3:48287546	chr3:48290793~48291375:-
BRCA	cis	rs301901	0.772	rs6451313	ENSG00000250155.1	CTD-2353F22.1	-6.93	7.22e-12	1.59e-09	-0.23	-0.21	Height;	chr5:37182208	chr5:36666214~36725195:-
BRCA	cis	rs2337406	1	rs17095456	ENSG00000211974.3	IGHV2-70	-6.93	7.22e-12	1.59e-09	-0.27	-0.21	Alzheimer's disease (late onset);	chr14:106676559	chr14:106723574~106724093:-
BRCA	cis	rs1707322	0.721	rs4660883	ENSG00000281133.1	AL355480.3	-6.93	7.22e-12	1.59e-09	-0.27	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45770426	chr1:45580892~45580996:-
BRCA	cis	rs2599510	0.783	rs62136349	ENSG00000276334.1	AL133243.1	6.93	7.24e-12	1.59e-09	0.27	0.21	Interleukin-18 levels;	chr2:32602437	chr2:32521927~32523547:+
BRCA	cis	rs11096990	0.892	rs11937540	ENSG00000249207.1	RP11-360F5.1	6.93	7.24e-12	1.59e-09	0.25	0.21	Cognitive function;	chr4:39179897	chr4:39112677~39126818:-
BRCA	cis	rs1862618	0.853	rs252910	ENSG00000271828.1	CTD-2310F14.1	6.93	7.25e-12	1.59e-09	0.3	0.21	Initial pursuit acceleration;	chr5:56897156	chr5:56927874~56929573:+
BRCA	cis	rs919433	0.963	rs2043016	ENSG00000231621.1	AC013264.2	6.93	7.25e-12	1.59e-09	0.19	0.21	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197281657	chr2:197197991~197199273:+
BRCA	cis	rs755249	0.567	rs61779284	ENSG00000228060.1	RP11-69E11.8	-6.93	7.26e-12	1.59e-09	-0.26	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39389505	chr1:39565160~39573203:+
BRCA	cis	rs2060793	0.741	rs2060794	ENSG00000251991.1	RNU7-49P	6.93	7.29e-12	1.6e-09	0.23	0.21	Vitamin D levels;	chr11:14791437	chr11:14478892~14478953:+
BRCA	cis	rs2060793	0.741	rs3740823	ENSG00000251991.1	RNU7-49P	6.93	7.29e-12	1.6e-09	0.23	0.21	Vitamin D levels;	chr11:14804158	chr11:14478892~14478953:+
BRCA	cis	rs17301013	0.606	rs2103640	ENSG00000227373.4	RP11-160H22.5	6.93	7.3e-12	1.6e-09	0.3	0.21	Systemic lupus erythematosus;	chr1:174219147	chr1:174115300~174160004:-
BRCA	cis	rs12460587	0.587	rs10415150	ENSG00000275055.1	CTC-471J1.11	-6.93	7.31e-12	1.6e-09	-0.24	-0.21	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52101372	chr19:52049007~52049754:+
BRCA	cis	rs7182621	0.639	rs1561048	ENSG00000182397.13	DNM1P46	6.93	7.31e-12	1.6e-09	0.25	0.21	Colonoscopy-negative controls vs population controls;	chr15:99875369	chr15:99790156~99806927:-
BRCA	cis	rs16846053	0.551	rs12692640	ENSG00000227403.1	AC009299.3	-6.93	7.32e-12	1.61e-09	-0.35	-0.21	Blood osmolality (transformed sodium);	chr2:161669405	chr2:161244739~161249050:+
BRCA	cis	rs17301013	0.606	rs10912750	ENSG00000227373.4	RP11-160H22.5	6.93	7.32e-12	1.61e-09	0.3	0.21	Systemic lupus erythematosus;	chr1:174253637	chr1:174115300~174160004:-
BRCA	cis	rs237743	1	rs6012617	ENSG00000222365.1	SNORD12B	6.93	7.33e-12	1.61e-09	0.27	0.21	Height;	chr20:49220589	chr20:49280319~49280409:+
BRCA	cis	rs2919009	0.544	rs28829929	ENSG00000271670.1	RP11-95I16.4	6.93	7.33e-12	1.61e-09	0.26	0.21	Obesity-related traits;	chr10:120881969	chr10:120879256~120880667:-
BRCA	cis	rs7119038	0.509	rs11216961	ENSG00000255239.1	AP002954.6	-6.93	7.33e-12	1.61e-09	-0.29	-0.21	Sjögren's syndrome;	chr11:118709629	chr11:118688039~118690600:-
BRCA	cis	rs2348418	0.831	rs10843173	ENSG00000247934.4	RP11-967K21.1	6.93	7.34e-12	1.61e-09	0.24	0.21	Lung function (FEV1);Lung function (FVC);	chr12:28453092	chr12:28163298~28190738:-
BRCA	cis	rs2348418	0.864	rs10843174	ENSG00000247934.4	RP11-967K21.1	6.93	7.34e-12	1.61e-09	0.24	0.21	Lung function (FEV1);Lung function (FVC);	chr12:28453135	chr12:28163298~28190738:-
BRCA	cis	rs7086627	0.515	rs4933390	ENSG00000226659.1	RP11-137H2.4	-6.93	7.34e-12	1.61e-09	-0.27	-0.21	Post bronchodilator FEV1;	chr10:80453325	chr10:80529597~80535942:-
BRCA	cis	rs8114671	0.967	rs6088747	ENSG00000269202.1	RP4-614O4.12	-6.93	7.35e-12	1.61e-09	-0.22	-0.21	Height;	chr20:35166801	chr20:35201747~35203288:-
BRCA	cis	rs7208859	0.673	rs2269915	ENSG00000263603.1	CTD-2349P21.5	-6.93	7.35e-12	1.61e-09	-0.38	-0.21	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30906326	chr17:30729469~30731202:+
BRCA	cis	rs7208859	0.673	rs2269916	ENSG00000263603.1	CTD-2349P21.5	-6.93	7.35e-12	1.61e-09	-0.38	-0.21	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30906745	chr17:30729469~30731202:+
BRCA	cis	rs7208859	0.673	rs11649765	ENSG00000263603.1	CTD-2349P21.5	-6.93	7.35e-12	1.61e-09	-0.38	-0.21	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30906870	chr17:30729469~30731202:+
BRCA	cis	rs801193	0.967	rs2707853	ENSG00000236529.1	RP13-254B10.1	6.93	7.35e-12	1.61e-09	0.23	0.21	Aortic root size;	chr7:66749023	chr7:65840212~65840596:+
BRCA	cis	rs2348418	0.639	rs2347595	ENSG00000247934.4	RP11-967K21.1	-6.93	7.35e-12	1.61e-09	-0.24	-0.21	Lung function (FEV1);Lung function (FVC);	chr12:28109947	chr12:28163298~28190738:-
BRCA	cis	rs12501370	0.921	rs7674811	ENSG00000201736.1	RNA5SP160	6.93	7.35e-12	1.61e-09	0.25	0.21	Iris color (L* coordinate);	chr4:41037718	chr4:40990154~40990273:+
BRCA	cis	rs17301013	0.606	rs4233169	ENSG00000227373.4	RP11-160H22.5	6.93	7.36e-12	1.61e-09	0.3	0.21	Systemic lupus erythematosus;	chr1:174118986	chr1:174115300~174160004:-
BRCA	cis	rs17301013	0.632	rs12079214	ENSG00000227373.4	RP11-160H22.5	6.93	7.37e-12	1.62e-09	0.3	0.21	Systemic lupus erythematosus;	chr1:174149572	chr1:174115300~174160004:-
BRCA	cis	rs17301013	0.606	rs12065785	ENSG00000227373.4	RP11-160H22.5	6.93	7.37e-12	1.62e-09	0.3	0.21	Systemic lupus erythematosus;	chr1:174151296	chr1:174115300~174160004:-
BRCA	cis	rs9307551	0.779	rs12501981	ENSG00000250334.4	LINC00989	-6.93	7.38e-12	1.62e-09	-0.28	-0.21	Refractive error;	chr4:79591850	chr4:79492416~79576460:+
BRCA	cis	rs595244	0.764	rs6493333	ENSG00000259705.1	RP11-227D13.1	-6.93	7.38e-12	1.62e-09	-0.3	-0.21	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48646849	chr15:48645951~48652016:+
BRCA	cis	rs10078	0.898	rs2241598	ENSG00000221990.4	EXOC3-AS1	-6.93	7.38e-12	1.62e-09	-0.24	-0.21	Fat distribution (HIV);	chr5:438449	chr5:441498~443160:-
BRCA	cis	rs9880211	0.613	rs28519617	ENSG00000273486.1	RP11-731C17.2	6.93	7.38e-12	1.62e-09	0.27	0.21	Height;Body mass index;	chr3:136156088	chr3:136837338~136839021:-
BRCA	cis	rs9880211	0.613	rs28669017	ENSG00000273486.1	RP11-731C17.2	6.93	7.38e-12	1.62e-09	0.27	0.21	Height;Body mass index;	chr3:136156090	chr3:136837338~136839021:-
BRCA	cis	rs8062405	0.558	rs231976	ENSG00000251417.2	RP11-1348G14.4	-6.93	7.39e-12	1.62e-09	-0.22	-0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28534266	chr16:28802743~28817828:+
BRCA	cis	rs71520386	0.632	rs12532938	ENSG00000228649.7	AC005682.5	-6.93	7.4e-12	1.62e-09	-0.2	-0.21	Fibrinogen levels;	chr7:22820876	chr7:22854178~22861579:+
BRCA	cis	rs897984	0.574	rs11647284	ENSG00000260911.2	RP11-196G11.2	6.93	7.41e-12	1.62e-09	0.2	0.21	Dementia with Lewy bodies;	chr16:31066014	chr16:31043150~31049868:+
BRCA	cis	rs911555	0.692	rs60235428	ENSG00000244691.1	RPL10AP1	6.93	7.42e-12	1.63e-09	0.27	0.21	Intelligence (multi-trait analysis);	chr14:103438013	chr14:103412119~103412761:-
BRCA	cis	rs7246657	0.943	rs10426666	ENSG00000226686.6	LINC01535	-6.93	7.42e-12	1.63e-09	-0.32	-0.21	Coronary artery calcification;	chr19:37337612	chr19:37251912~37265535:+
BRCA	cis	rs7246657	0.943	rs28402338	ENSG00000226686.6	LINC01535	-6.93	7.42e-12	1.63e-09	-0.32	-0.21	Coronary artery calcification;	chr19:37343021	chr19:37251912~37265535:+
BRCA	cis	rs7246657	0.943	rs10417503	ENSG00000226686.6	LINC01535	-6.93	7.42e-12	1.63e-09	-0.32	-0.21	Coronary artery calcification;	chr19:37351833	chr19:37251912~37265535:+
BRCA	cis	rs7246657	0.943	rs9304566	ENSG00000226686.6	LINC01535	-6.93	7.42e-12	1.63e-09	-0.32	-0.21	Coronary artery calcification;	chr19:37354602	chr19:37251912~37265535:+
BRCA	cis	rs7246657	0.943	rs4417644	ENSG00000226686.6	LINC01535	-6.93	7.42e-12	1.63e-09	-0.32	-0.21	Coronary artery calcification;	chr19:37361570	chr19:37251912~37265535:+
BRCA	cis	rs7246657	0.943	rs10405064	ENSG00000226686.6	LINC01535	-6.93	7.42e-12	1.63e-09	-0.32	-0.21	Coronary artery calcification;	chr19:37370959	chr19:37251912~37265535:+
BRCA	cis	rs1499614	1	rs2659913	ENSG00000230295.1	RP11-458F8.2	-6.93	7.42e-12	1.63e-09	-0.28	-0.21	Gout;	chr7:66692349	chr7:66880708~66882981:+
BRCA	cis	rs1499614	1	rs2659911	ENSG00000230295.1	RP11-458F8.2	-6.93	7.42e-12	1.63e-09	-0.28	-0.21	Gout;	chr7:66693433	chr7:66880708~66882981:+
BRCA	cis	rs1499614	1	rs2707838	ENSG00000230295.1	RP11-458F8.2	-6.93	7.42e-12	1.63e-09	-0.28	-0.21	Gout;	chr7:66694214	chr7:66880708~66882981:+
BRCA	cis	rs1499614	1	rs60326618	ENSG00000230295.1	RP11-458F8.2	-6.93	7.42e-12	1.63e-09	-0.28	-0.21	Gout;	chr7:66701371	chr7:66880708~66882981:+
BRCA	cis	rs1499614	1	rs2707830	ENSG00000230295.1	RP11-458F8.2	-6.93	7.42e-12	1.63e-09	-0.28	-0.21	Gout;	chr7:66702658	chr7:66880708~66882981:+
BRCA	cis	rs1499614	1	rs2707828	ENSG00000230295.1	RP11-458F8.2	-6.93	7.42e-12	1.63e-09	-0.28	-0.21	Gout;	chr7:66706390	chr7:66880708~66882981:+
BRCA	cis	rs1499614	0.803	rs1922723	ENSG00000230295.1	RP11-458F8.2	-6.93	7.42e-12	1.63e-09	-0.28	-0.21	Gout;	chr7:66710076	chr7:66880708~66882981:+
BRCA	cis	rs7586673	0.857	rs16845580	ENSG00000235724.7	AC009299.2	-6.93	7.43e-12	1.63e-09	-0.25	-0.21	Intelligence (multi-trait analysis);	chr2:161064373	chr2:161222785~161308303:-
BRCA	cis	rs7131987	0.65	rs7301398	ENSG00000257176.2	RP11-996F15.2	-6.93	7.43e-12	1.63e-09	-0.26	-0.21	QT interval;	chr12:29302457	chr12:29280418~29317848:-
BRCA	cis	rs7131987	0.65	rs7301188	ENSG00000257176.2	RP11-996F15.2	-6.93	7.43e-12	1.63e-09	-0.26	-0.21	QT interval;	chr12:29302458	chr12:29280418~29317848:-
BRCA	cis	rs801193	1	rs6958520	ENSG00000236529.1	RP13-254B10.1	6.93	7.43e-12	1.63e-09	0.23	0.21	Aortic root size;	chr7:66686466	chr7:65840212~65840596:+
BRCA	cis	rs13287066	0.692	rs2184255	ENSG00000227603.1	RP11-165J3.6	-6.93	7.44e-12	1.63e-09	-0.22	-0.21	Intelligence (multi-trait analysis);	chr9:93413921	chr9:93435332~93437121:-
BRCA	cis	rs1862618	0.853	rs832565	ENSG00000271828.1	CTD-2310F14.1	6.93	7.44e-12	1.63e-09	0.3	0.21	Initial pursuit acceleration;	chr5:56854976	chr5:56927874~56929573:+
BRCA	cis	rs860818	1	rs858237	ENSG00000226816.2	AC005082.12	6.93	7.45e-12	1.63e-09	0.49	0.21	Initial pursuit acceleration;	chr7:23199604	chr7:23206013~23208045:+
BRCA	cis	rs801193	1	rs7785213	ENSG00000236529.1	RP13-254B10.1	-6.93	7.45e-12	1.63e-09	-0.23	-0.21	Aortic root size;	chr7:66673991	chr7:65840212~65840596:+
BRCA	cis	rs2348418	0.864	rs7299039	ENSG00000247934.4	RP11-967K21.1	6.93	7.46e-12	1.63e-09	0.24	0.21	Lung function (FEV1);Lung function (FVC);	chr12:28454083	chr12:28163298~28190738:-
BRCA	cis	rs7662987	0.793	rs7684735	ENSG00000272777.1	RP11-571L19.8	6.93	7.46e-12	1.63e-09	0.29	0.21	Smoking initiation;	chr4:99070355	chr4:99067256~99068125:-
BRCA	cis	rs801193	0.935	rs11772264	ENSG00000236529.1	RP13-254B10.1	6.93	7.47e-12	1.64e-09	0.23	0.21	Aortic root size;	chr7:66711400	chr7:65840212~65840596:+
BRCA	cis	rs72627509	0.629	rs1718824	ENSG00000269949.1	RP11-738E22.3	-6.93	7.47e-12	1.64e-09	-0.29	-0.21	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:57037581	chr4:56960927~56961373:-
BRCA	cis	rs473651	0.777	rs550890	ENSG00000229915.1	AC016999.2	-6.93	7.47e-12	1.64e-09	-0.28	-0.21	Multiple system atrophy;	chr2:238423914	chr2:238427077~238427729:-
BRCA	cis	rs13113518	0.812	rs11939580	ENSG00000249700.7	SRD5A3-AS1	6.93	7.48e-12	1.64e-09	0.27	0.21	Height;	chr4:55517185	chr4:55363971~55395847:-
BRCA	cis	rs74233809	0.901	rs17115100	ENSG00000213277.3	MARCKSL1P1	6.93	7.49e-12	1.64e-09	0.37	0.21	Birth weight;	chr10:102831636	chr10:103175554~103176094:+
BRCA	cis	rs2976388	0.647	rs2244163	ENSG00000253741.1	CTD-2292P10.4	-6.93	7.5e-12	1.64e-09	-0.24	-0.21	Urinary tract infection frequency;	chr8:142703082	chr8:142702252~142726973:-
BRCA	cis	rs10129255	0.957	rs10136817	ENSG00000224373.3	IGHV4-59	6.93	7.5e-12	1.64e-09	0.14	0.21	Kawasaki disease;	chr14:106787730	chr14:106627249~106627825:-
BRCA	cis	rs2842992	0.789	rs4709376	ENSG00000237927.1	RP3-393E18.2	-6.93	7.51e-12	1.64e-09	-0.31	-0.21	Age-related macular degeneration (geographic atrophy);	chr6:159805305	chr6:159586955~159589169:-
BRCA	cis	rs11971779	0.7	rs11763942	ENSG00000273391.1	RP11-634H22.1	6.93	7.52e-12	1.65e-09	0.25	0.21	Diisocyanate-induced asthma;	chr7:139321049	chr7:139359032~139359566:-
BRCA	cis	rs875971	1	rs6963646	ENSG00000224316.1	RP11-479O9.2	-6.93	7.53e-12	1.65e-09	-0.21	-0.21	Aortic root size;	chr7:66220780	chr7:65773620~65802067:+
BRCA	cis	rs673078	0.607	rs7299040	ENSG00000275409.1	RP11-131L12.4	-6.93	7.53e-12	1.65e-09	-0.32	-0.21	Glucose homeostasis traits;	chr12:118380660	chr12:118430147~118430699:+
BRCA	cis	rs9307551	0.817	rs1348086	ENSG00000250334.4	LINC00989	-6.93	7.54e-12	1.65e-09	-0.28	-0.21	Refractive error;	chr4:79605078	chr4:79492416~79576460:+
BRCA	cis	rs42648	0.935	rs7803012	ENSG00000225498.1	AC002064.5	-6.93	7.55e-12	1.65e-09	-0.2	-0.21	Homocysteine levels;	chr7:90396852	chr7:90312496~90322592:+
BRCA	cis	rs8177876	0.642	rs10514513	ENSG00000261838.4	RP11-303E16.6	6.93	7.55e-12	1.65e-09	0.4	0.21	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81080578	chr16:81069854~81076598:+
BRCA	cis	rs875971	0.545	rs6460298	ENSG00000224316.1	RP11-479O9.2	6.93	7.57e-12	1.66e-09	0.24	0.21	Aortic root size;	chr7:66442783	chr7:65773620~65802067:+
BRCA	cis	rs801193	1	rs2707836	ENSG00000236529.1	RP13-254B10.1	6.93	7.58e-12	1.66e-09	0.23	0.21	Aortic root size;	chr7:66695448	chr7:65840212~65840596:+
BRCA	cis	rs801193	0.844	rs7779971	ENSG00000236529.1	RP13-254B10.1	6.93	7.58e-12	1.66e-09	0.23	0.21	Aortic root size;	chr7:66696803	chr7:65840212~65840596:+
BRCA	cis	rs11976180	1	rs11976037	ENSG00000204959.4	ARHGEF34P	6.93	7.61e-12	1.67e-09	0.27	0.21	Obesity-related traits;	chr7:144043931	chr7:144272445~144286966:-
BRCA	cis	rs9859260	0.614	rs493661	ENSG00000231464.1	AC024937.4	-6.92	7.62e-12	1.67e-09	-0.27	-0.21	Mean corpuscular volume;	chr3:196059618	chr3:195996738~195998233:+
BRCA	cis	rs875971	0.66	rs2013222	ENSG00000237310.1	GS1-124K5.4	-6.92	7.63e-12	1.67e-09	-0.21	-0.21	Aortic root size;	chr7:66570949	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.929	rs10950041	ENSG00000232559.3	GS1-124K5.12	6.92	7.63e-12	1.67e-09	0.25	0.21	Aortic root size;	chr7:66508888	chr7:66554588~66576923:-
BRCA	cis	rs8114671	0.967	rs2093058	ENSG00000269202.1	RP4-614O4.12	6.92	7.63e-12	1.67e-09	0.22	0.21	Height;	chr20:35203478	chr20:35201747~35203288:-
BRCA	cis	rs9527	0.571	rs12219246	ENSG00000236937.2	PTGES3P4	6.92	7.64e-12	1.67e-09	0.27	0.21	Arsenic metabolism;	chr10:102853598	chr10:102845595~102845950:+
BRCA	cis	rs9807989	0.839	rs7603730	ENSG00000234389.1	AC007278.3	6.92	7.65e-12	1.67e-09	0.2	0.21	Asthma;	chr2:102357911	chr2:102438713~102440475:+
BRCA	cis	rs801193	0.901	rs4273746	ENSG00000237310.1	GS1-124K5.4	-6.92	7.66e-12	1.68e-09	-0.22	-0.21	Aortic root size;	chr7:66836124	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.545	rs13311962	ENSG00000224316.1	RP11-479O9.2	-6.92	7.66e-12	1.68e-09	-0.24	-0.21	Aortic root size;	chr7:66603142	chr7:65773620~65802067:+
BRCA	cis	rs11098499	0.954	rs28685688	ENSG00000249244.1	RP11-548H18.2	6.92	7.66e-12	1.68e-09	0.25	0.21	Corneal astigmatism;	chr4:119499179	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.954	rs7687843	ENSG00000249244.1	RP11-548H18.2	6.92	7.66e-12	1.68e-09	0.25	0.21	Corneal astigmatism;	chr4:119500056	chr4:119391831~119395335:-
BRCA	cis	rs10515750	0.588	rs1900157	ENSG00000248544.2	CTB-47B11.3	6.92	7.67e-12	1.68e-09	0.31	0.21	Lung function (FEV1/FVC);	chr5:157333834	chr5:157375741~157384950:-
BRCA	cis	rs9880211	0.613	rs34864445	ENSG00000273486.1	RP11-731C17.2	6.92	7.68e-12	1.68e-09	0.27	0.21	Height;Body mass index;	chr3:136104082	chr3:136837338~136839021:-
BRCA	cis	rs9876781	1	rs7653691	ENSG00000244380.1	RP11-24C3.2	-6.92	7.69e-12	1.68e-09	-0.24	-0.21	Longevity;	chr3:48378199	chr3:48440352~48446656:-
BRCA	cis	rs7246657	0.823	rs4802236	ENSG00000226686.6	LINC01535	-6.92	7.73e-12	1.69e-09	-0.32	-0.21	Coronary artery calcification;	chr19:37428344	chr19:37251912~37265535:+
BRCA	cis	rs2337406	1	rs1961901	ENSG00000254174.1	IGHV1-12	6.92	7.73e-12	1.69e-09	0.22	0.21	Alzheimer's disease (late onset);	chr14:106680856	chr14:106122420~106122709:-
BRCA	cis	rs3761847	0.593	rs10985140	ENSG00000226752.6	PSMD5-AS1	-6.92	7.74e-12	1.69e-09	-0.25	-0.21	Rheumatoid arthritis;	chr9:121060559	chr9:120824828~120854385:+
BRCA	cis	rs858239	0.965	rs156429	ENSG00000230042.1	AK3P3	-6.92	7.75e-12	1.69e-09	-0.25	-0.21	Cerebrospinal fluid biomarker levels;	chr7:23266401	chr7:23129178~23129841:+
BRCA	cis	rs7617773	0.78	rs3731550	ENSG00000228638.1	FCF1P2	-6.92	7.76e-12	1.7e-09	-0.24	-0.21	Coronary artery disease;	chr3:48165093	chr3:48290793~48291375:-
BRCA	cis	rs7617773	0.817	rs3731534	ENSG00000228638.1	FCF1P2	-6.92	7.76e-12	1.7e-09	-0.24	-0.21	Coronary artery disease;	chr3:48170287	chr3:48290793~48291375:-
BRCA	cis	rs17301013	0.606	rs12087808	ENSG00000227373.4	RP11-160H22.5	6.92	7.76e-12	1.7e-09	0.3	0.21	Systemic lupus erythematosus;	chr1:174178848	chr1:174115300~174160004:-
BRCA	cis	rs10740039	0.883	rs6479722	ENSG00000254271.1	RP11-131N11.4	6.92	7.78e-12	1.7e-09	0.27	0.21	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60657923	chr10:60734342~60741828:+
BRCA	cis	rs10740039	1	rs6479723	ENSG00000254271.1	RP11-131N11.4	6.92	7.78e-12	1.7e-09	0.27	0.21	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60658127	chr10:60734342~60741828:+
BRCA	cis	rs6543140	0.964	rs1523206	ENSG00000234389.1	AC007278.3	6.92	7.79e-12	1.7e-09	0.21	0.21	Blood protein levels;	chr2:102453715	chr2:102438713~102440475:+
BRCA	cis	rs6543140	0.964	rs1523205	ENSG00000234389.1	AC007278.3	6.92	7.79e-12	1.7e-09	0.21	0.21	Blood protein levels;	chr2:102453716	chr2:102438713~102440475:+
BRCA	cis	rs6543140	0.964	rs10169192	ENSG00000234389.1	AC007278.3	6.92	7.79e-12	1.7e-09	0.21	0.21	Blood protein levels;	chr2:102455751	chr2:102438713~102440475:+
BRCA	cis	rs6543140	0.964	rs11886793	ENSG00000234389.1	AC007278.3	6.92	7.79e-12	1.7e-09	0.21	0.21	Blood protein levels;	chr2:102455760	chr2:102438713~102440475:+
BRCA	cis	rs6543140	0.964	rs2310301	ENSG00000234389.1	AC007278.3	6.92	7.79e-12	1.7e-09	0.21	0.21	Blood protein levels;	chr2:102456475	chr2:102438713~102440475:+
BRCA	cis	rs6543140	1	rs6543140	ENSG00000234389.1	AC007278.3	6.92	7.79e-12	1.7e-09	0.21	0.21	Blood protein levels;	chr2:102457814	chr2:102438713~102440475:+
BRCA	cis	rs6543140	0.964	rs13390895	ENSG00000234389.1	AC007278.3	6.92	7.79e-12	1.7e-09	0.21	0.21	Blood protein levels;	chr2:102459039	chr2:102438713~102440475:+
BRCA	cis	rs11742741	0.652	rs66527927	ENSG00000248874.4	C5orf17	-6.92	7.79e-12	1.7e-09	-0.27	-0.21	Educational attainment;	chr5:24226579	chr5:23951348~24178263:+
BRCA	cis	rs801193	1	rs2659909	ENSG00000236529.1	RP13-254B10.1	6.92	7.81e-12	1.71e-09	0.22	0.21	Aortic root size;	chr7:66695292	chr7:65840212~65840596:+
BRCA	cis	rs780096	0.565	rs13022659	ENSG00000234072.1	AC074117.10	-6.92	7.81e-12	1.71e-09	-0.2	-0.21	Total body bone mineral density;	chr2:27520763	chr2:27356246~27367622:+
BRCA	cis	rs7131987	0.622	rs7294598	ENSG00000257176.2	RP11-996F15.2	6.92	7.82e-12	1.71e-09	0.26	0.21	QT interval;	chr12:29379056	chr12:29280418~29317848:-
BRCA	cis	rs904251	0.737	rs914347	ENSG00000204110.6	RP1-153P14.8	-6.92	7.84e-12	1.71e-09	-0.23	-0.21	Cognitive performance;	chr6:37517194	chr6:37507348~37535616:+
BRCA	cis	rs113835537	0.597	rs4576	ENSG00000255517.5	CTD-3074O7.5	-6.92	7.84e-12	1.71e-09	-0.27	-0.21	Airway imaging phenotypes;	chr11:66563529	chr11:66473490~66480233:-
BRCA	cis	rs1707322	0.752	rs4660313	ENSG00000281133.1	AL355480.3	6.92	7.84e-12	1.71e-09	0.27	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45645169	chr1:45580892~45580996:-
BRCA	cis	rs13287066	0.692	rs10992723	ENSG00000227603.1	RP11-165J3.6	6.92	7.86e-12	1.72e-09	0.22	0.21	Intelligence (multi-trait analysis);	chr9:93407016	chr9:93435332~93437121:-
BRCA	cis	rs79040073	0.637	rs73392256	ENSG00000259531.2	RP11-295H24.3	6.92	7.86e-12	1.72e-09	0.35	0.21	Lung cancer in ever smokers;	chr15:49228379	chr15:49365124~49366685:-
BRCA	cis	rs875971	1	rs7789554	ENSG00000232559.3	GS1-124K5.12	6.92	7.87e-12	1.72e-09	0.25	0.21	Aortic root size;	chr7:66481051	chr7:66554588~66576923:-
BRCA	cis	rs875971	1	rs4717300	ENSG00000232559.3	GS1-124K5.12	6.92	7.87e-12	1.72e-09	0.25	0.21	Aortic root size;	chr7:66482393	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.895	rs1974769	ENSG00000232559.3	GS1-124K5.12	6.92	7.87e-12	1.72e-09	0.25	0.21	Aortic root size;	chr7:66485627	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.895	rs6460300	ENSG00000232559.3	GS1-124K5.12	6.92	7.87e-12	1.72e-09	0.25	0.21	Aortic root size;	chr7:66487937	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.862	rs7803416	ENSG00000232559.3	GS1-124K5.12	6.92	7.87e-12	1.72e-09	0.25	0.21	Aortic root size;	chr7:66489212	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.964	rs2277911	ENSG00000232559.3	GS1-124K5.12	6.92	7.87e-12	1.72e-09	0.25	0.21	Aortic root size;	chr7:66493638	chr7:66554588~66576923:-
BRCA	cis	rs858239	0.6	rs10266123	ENSG00000230042.1	AK3P3	-6.92	7.87e-12	1.72e-09	-0.24	-0.21	Cerebrospinal fluid biomarker levels;	chr7:23096868	chr7:23129178~23129841:+
BRCA	cis	rs919433	0.927	rs7592748	ENSG00000231621.1	AC013264.2	6.92	7.89e-12	1.72e-09	0.21	0.21	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197305964	chr2:197197991~197199273:+
BRCA	cis	rs3781264	0.687	rs12217597	ENSG00000273450.1	RP11-76P2.4	-6.92	7.91e-12	1.73e-09	-0.29	-0.21	Esophageal cancer and gastric cancer;	chr10:94351055	chr10:94314907~94315327:-
BRCA	cis	rs2243480	0.711	rs2420172	ENSG00000232546.1	RP11-458F8.1	6.92	7.91e-12	1.73e-09	0.28	0.21	Diabetic kidney disease;	chr7:66170354	chr7:66848496~66858136:+
BRCA	cis	rs79040073	0.637	rs11632303	ENSG00000259531.2	RP11-295H24.3	6.92	7.92e-12	1.73e-09	0.35	0.21	Lung cancer in ever smokers;	chr15:49238124	chr15:49365124~49366685:-
BRCA	cis	rs7085104	0.572	rs284856	ENSG00000236937.2	PTGES3P4	-6.92	7.92e-12	1.73e-09	-0.26	-0.21	Immature fraction of reticulocytes;Schizophrenia;	chr10:102814572	chr10:102845595~102845950:+
BRCA	cis	rs11098499	0.954	rs10031483	ENSG00000249244.1	RP11-548H18.2	6.92	7.94e-12	1.73e-09	0.25	0.21	Corneal astigmatism;	chr4:119501481	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.954	rs10031665	ENSG00000249244.1	RP11-548H18.2	6.92	7.94e-12	1.73e-09	0.25	0.21	Corneal astigmatism;	chr4:119501697	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.954	rs3733523	ENSG00000249244.1	RP11-548H18.2	6.92	7.94e-12	1.73e-09	0.25	0.21	Corneal astigmatism;	chr4:119502564	chr4:119391831~119395335:-
BRCA	cis	rs780096	0.506	rs1262430	ENSG00000234072.1	AC074117.10	-6.92	7.95e-12	1.74e-09	-0.2	-0.21	Total body bone mineral density;	chr2:27450931	chr2:27356246~27367622:+
BRCA	cis	rs875971	0.895	rs778700	ENSG00000232559.3	GS1-124K5.12	6.92	7.97e-12	1.74e-09	0.25	0.21	Aortic root size;	chr7:66401463	chr7:66554588~66576923:-
BRCA	cis	rs875971	1	rs778699	ENSG00000232559.3	GS1-124K5.12	6.92	7.97e-12	1.74e-09	0.25	0.21	Aortic root size;	chr7:66403303	chr7:66554588~66576923:-
BRCA	cis	rs3761847	0.651	rs1323472	ENSG00000226752.6	PSMD5-AS1	-6.92	7.98e-12	1.74e-09	-0.25	-0.21	Rheumatoid arthritis;	chr9:121064057	chr9:120824828~120854385:+
BRCA	cis	rs7613051	1	rs7613051	ENSG00000223899.1	SEC13P1	6.92	7.98e-12	1.74e-09	0.27	0.21	Atopic dermatitis;	chr3:33023847	chr3:33033863~33034810:+
BRCA	cis	rs2060793	0.741	rs10741656	ENSG00000251991.1	RNU7-49P	6.92	7.98e-12	1.74e-09	0.23	0.21	Vitamin D levels;	chr11:14803699	chr11:14478892~14478953:+
BRCA	cis	rs10740039	0.81	rs10159646	ENSG00000254271.1	RP11-131N11.4	6.92	7.99e-12	1.75e-09	0.28	0.21	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60620366	chr10:60734342~60741828:+
BRCA	cis	rs875971	0.929	rs12535036	ENSG00000232559.3	GS1-124K5.12	6.92	8e-12	1.75e-09	0.25	0.21	Aortic root size;	chr7:66499076	chr7:66554588~66576923:-
BRCA	cis	rs875971	1	rs6970030	ENSG00000232559.3	GS1-124K5.12	6.92	8e-12	1.75e-09	0.25	0.21	Aortic root size;	chr7:66503692	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.928	rs6970357	ENSG00000232559.3	GS1-124K5.12	6.92	8e-12	1.75e-09	0.25	0.21	Aortic root size;	chr7:66503891	chr7:66554588~66576923:-
BRCA	cis	rs13113518	0.812	rs12500601	ENSG00000249700.7	SRD5A3-AS1	6.92	8.01e-12	1.75e-09	0.27	0.21	Height;	chr4:55451489	chr4:55363971~55395847:-
BRCA	cis	rs919433	0.963	rs4850786	ENSG00000231621.1	AC013264.2	-6.92	8.02e-12	1.75e-09	-0.21	-0.21	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197313884	chr2:197197991~197199273:+
BRCA	cis	rs2880765	0.835	rs4340287	ENSG00000259295.5	CSPG4P12	6.92	8.03e-12	1.75e-09	0.26	0.21	Coronary artery disease;	chr15:85500506	chr15:85191438~85213905:+
BRCA	cis	rs17301013	0.606	rs72711487	ENSG00000227373.4	RP11-160H22.5	6.92	8.03e-12	1.75e-09	0.3	0.21	Systemic lupus erythematosus;	chr1:174189002	chr1:174115300~174160004:-
BRCA	cis	rs17253792	0.822	rs79873916	ENSG00000186615.9	KTN1-AS1	-6.92	8.04e-12	1.75e-09	-0.43	-0.21	Putamen volume;	chr14:55705913	chr14:55499278~55580110:-
BRCA	cis	rs2348418	0.832	rs2126894	ENSG00000247934.4	RP11-967K21.1	6.92	8.04e-12	1.75e-09	0.24	0.21	Lung function (FEV1);Lung function (FVC);	chr12:28323914	chr12:28163298~28190738:-
BRCA	cis	rs911555	0.755	rs8014800	ENSG00000244691.1	RPL10AP1	6.92	8.04e-12	1.76e-09	0.26	0.21	Intelligence (multi-trait analysis);	chr14:103479965	chr14:103412119~103412761:-
BRCA	cis	rs2880765	0.835	rs2170736	ENSG00000259295.5	CSPG4P12	6.92	8.05e-12	1.76e-09	0.26	0.21	Coronary artery disease;	chr15:85500167	chr15:85191438~85213905:+
BRCA	cis	rs10129255	0.957	rs10140904	ENSG00000211972.2	IGHV3-66	6.92	8.05e-12	1.76e-09	0.16	0.21	Kawasaki disease;	chr14:106776558	chr14:106675017~106675544:-
BRCA	cis	rs2014572	0.967	rs7248000	ENSG00000268379.1	CTC-360J11.4	6.92	8.06e-12	1.76e-09	0.26	0.21	Hyperactive-impulsive symptoms;	chr19:57250771	chr19:57175233~57177921:+
BRCA	cis	rs7246657	0.943	rs10403613	ENSG00000226686.6	LINC01535	-6.92	8.07e-12	1.76e-09	-0.32	-0.21	Coronary artery calcification;	chr19:37353404	chr19:37251912~37265535:+
BRCA	cis	rs1862618	0.853	rs832568	ENSG00000271828.1	CTD-2310F14.1	6.92	8.09e-12	1.76e-09	0.29	0.21	Initial pursuit acceleration;	chr5:56857949	chr5:56927874~56929573:+
BRCA	cis	rs1862618	0.853	rs832569	ENSG00000271828.1	CTD-2310F14.1	6.92	8.09e-12	1.76e-09	0.29	0.21	Initial pursuit acceleration;	chr5:56858757	chr5:56927874~56929573:+
BRCA	cis	rs875971	1	rs12532998	ENSG00000232559.3	GS1-124K5.12	6.92	8.09e-12	1.77e-09	0.25	0.21	Aortic root size;	chr7:66502472	chr7:66554588~66576923:-
BRCA	cis	rs8072100	0.967	rs11079784	ENSG00000228782.6	CTD-2026D20.3	-6.92	8.1e-12	1.77e-09	-0.23	-0.21	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47624914	chr17:47450568~47492492:-
BRCA	cis	rs919433	0.927	rs1429418	ENSG00000231621.1	AC013264.2	6.92	8.1e-12	1.77e-09	0.21	0.21	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197293427	chr2:197197991~197199273:+
BRCA	cis	rs9876781	1	rs6442123	ENSG00000229759.1	MRPS18AP1	6.92	8.11e-12	1.77e-09	0.23	0.21	Longevity;	chr3:48458887	chr3:48256350~48256938:-
BRCA	cis	rs9876781	1	rs9311423	ENSG00000244380.1	RP11-24C3.2	6.92	8.11e-12	1.77e-09	0.24	0.21	Longevity;	chr3:48378818	chr3:48440352~48446656:-
BRCA	cis	rs875971	0.964	rs6978429	ENSG00000232559.3	GS1-124K5.12	6.92	8.12e-12	1.77e-09	0.25	0.21	Aortic root size;	chr7:66494889	chr7:66554588~66576923:-
BRCA	cis	rs875971	1	rs4718357	ENSG00000232559.3	GS1-124K5.12	6.92	8.12e-12	1.77e-09	0.25	0.21	Aortic root size;	chr7:66495891	chr7:66554588~66576923:-
BRCA	cis	rs6142102	0.961	rs1055857	ENSG00000275784.1	RP5-1125A11.6	-6.92	8.13e-12	1.77e-09	-0.24	-0.21	Skin pigmentation;	chr20:34026067	chr20:33989480~33991818:-
BRCA	cis	rs919433	0.963	rs13033821	ENSG00000231621.1	AC013264.2	6.92	8.13e-12	1.77e-09	0.21	0.21	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197308812	chr2:197197991~197199273:+
BRCA	cis	rs681343	1	rs516316	ENSG00000232871.7	SEC1P	6.92	8.14e-12	1.78e-09	0.23	0.21	Primary sclerosing cholangitis;Childhood ear infection;Lung adenocarcinoma;	chr19:48702888	chr19:48638071~48682245:+
BRCA	cis	rs6921919	0.583	rs6907950	ENSG00000204709.4	LINC01556	6.91	8.16e-12	1.78e-09	0.28	0.21	Autism spectrum disorder or schizophrenia;	chr6:28402469	chr6:28943877~28944537:+
BRCA	cis	rs2348418	0.832	rs4931080	ENSG00000247934.4	RP11-967K21.1	6.91	8.16e-12	1.78e-09	0.24	0.21	Lung function (FEV1);Lung function (FVC);	chr12:28433843	chr12:28163298~28190738:-
BRCA	cis	rs10129255	0.957	rs10136817	ENSG00000211972.2	IGHV3-66	6.91	8.18e-12	1.78e-09	0.17	0.21	Kawasaki disease;	chr14:106787730	chr14:106675017~106675544:-
BRCA	cis	rs7615952	0.599	rs6438955	ENSG00000250012.1	RP11-124N2.1	-6.91	8.18e-12	1.78e-09	-0.27	-0.21	Blood pressure (smoking interaction);	chr3:126011490	chr3:126084220~126095349:+
BRCA	cis	rs875971	1	rs6958271	ENSG00000232559.3	GS1-124K5.12	6.91	8.18e-12	1.78e-09	0.25	0.21	Aortic root size;	chr7:66514344	chr7:66554588~66576923:-
BRCA	cis	rs875971	1	rs6958277	ENSG00000232559.3	GS1-124K5.12	6.91	8.18e-12	1.78e-09	0.25	0.21	Aortic root size;	chr7:66514362	chr7:66554588~66576923:-
BRCA	cis	rs6545883	0.929	rs3732171	ENSG00000271889.1	RP11-493E12.1	6.91	8.18e-12	1.78e-09	0.27	0.21	Tuberculosis;	chr2:61522555	chr2:61151433~61162105:-
BRCA	cis	rs7131987	0.617	rs3764953	ENSG00000257176.2	RP11-996F15.2	-6.91	8.19e-12	1.79e-09	-0.26	-0.21	QT interval;	chr12:29349303	chr12:29280418~29317848:-
BRCA	cis	rs11096990	0.855	rs2566183	ENSG00000249207.1	RP11-360F5.1	6.91	8.19e-12	1.79e-09	0.25	0.21	Cognitive function;	chr4:39162288	chr4:39112677~39126818:-
BRCA	cis	rs875971	0.522	rs9530	ENSG00000237310.1	GS1-124K5.4	6.91	8.2e-12	1.79e-09	0.22	0.21	Aortic root size;	chr7:65960907	chr7:66493706~66495474:+
BRCA	cis	rs11098499	0.909	rs2127821	ENSG00000249244.1	RP11-548H18.2	6.91	8.2e-12	1.79e-09	0.25	0.21	Corneal astigmatism;	chr4:119473380	chr4:119391831~119395335:-
BRCA	cis	rs6840360	0.642	rs2709820	ENSG00000270265.1	RP11-731D1.4	-6.91	8.21e-12	1.79e-09	-0.23	-0.21	Intelligence (multi-trait analysis);	chr4:151462887	chr4:151333775~151353224:-
BRCA	cis	rs10129255	0.957	rs4387509	ENSG00000211972.2	IGHV3-66	6.91	8.21e-12	1.79e-09	0.17	0.21	Kawasaki disease;	chr14:106704386	chr14:106675017~106675544:-
BRCA	cis	rs7246657	0.722	rs958305	ENSG00000267422.1	CTD-2554C21.1	6.91	8.22e-12	1.79e-09	0.31	0.21	Coronary artery calcification;	chr19:37698539	chr19:37779686~37792865:+
BRCA	cis	rs17301013	0.606	rs3086	ENSG00000227373.4	RP11-160H22.5	6.91	8.23e-12	1.79e-09	0.3	0.21	Systemic lupus erythematosus;	chr1:174167236	chr1:174115300~174160004:-
BRCA	cis	rs2072438	0.503	rs2146838	ENSG00000226752.6	PSMD5-AS1	6.91	8.23e-12	1.79e-09	0.25	0.21	Rheumatoid arthritis;	chr9:121114027	chr9:120824828~120854385:+
BRCA	cis	rs11098499	0.562	rs13101722	ENSG00000245958.5	RP11-33B1.1	6.91	8.25e-12	1.8e-09	0.19	0.21	Corneal astigmatism;	chr4:119634820	chr4:119454791~119552025:+
BRCA	cis	rs2880765	0.743	rs6497194	ENSG00000259295.5	CSPG4P12	6.91	8.27e-12	1.8e-09	0.26	0.21	Coronary artery disease;	chr15:85470885	chr15:85191438~85213905:+
BRCA	cis	rs9788721	0.592	rs28564957	ENSG00000261762.1	RP11-650L12.2	-6.91	8.3e-12	1.81e-09	-0.23	-0.21	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78613765	chr15:78589123~78591276:-
BRCA	cis	rs9307551	0.817	rs13142610	ENSG00000250334.4	LINC00989	-6.91	8.3e-12	1.81e-09	-0.28	-0.21	Refractive error;	chr4:79602297	chr4:79492416~79576460:+
BRCA	cis	rs9307551	0.817	rs17003985	ENSG00000250334.4	LINC00989	-6.91	8.3e-12	1.81e-09	-0.28	-0.21	Refractive error;	chr4:79602561	chr4:79492416~79576460:+
BRCA	cis	rs9307551	0.817	rs35487709	ENSG00000250334.4	LINC00989	-6.91	8.3e-12	1.81e-09	-0.28	-0.21	Refractive error;	chr4:79603180	chr4:79492416~79576460:+
BRCA	cis	rs9307551	0.817	rs35631270	ENSG00000250334.4	LINC00989	-6.91	8.3e-12	1.81e-09	-0.28	-0.21	Refractive error;	chr4:79603194	chr4:79492416~79576460:+
BRCA	cis	rs2243480	1	rs67728539	ENSG00000273142.1	RP11-458F8.4	-6.91	8.31e-12	1.81e-09	-0.28	-0.21	Diabetic kidney disease;	chr7:65913137	chr7:66902857~66906297:+
BRCA	cis	rs7662987	0.793	rs4699700	ENSG00000272777.1	RP11-571L19.8	6.91	8.31e-12	1.81e-09	0.3	0.21	Smoking initiation;	chr4:99077184	chr4:99067256~99068125:-
BRCA	cis	rs61160187	0.582	rs12516995	ENSG00000215032.2	GNL3LP1	6.91	8.32e-12	1.81e-09	0.26	0.21	Educational attainment (years of education);Educational attainment (college completion);	chr5:61012447	chr5:60891935~60893577:-
BRCA	cis	rs71520386	0.632	rs10269414	ENSG00000228649.7	AC005682.5	-6.91	8.32e-12	1.81e-09	-0.2	-0.21	Fibrinogen levels;	chr7:22816674	chr7:22854178~22861579:+
BRCA	cis	rs71520386	0.632	rs2286500	ENSG00000228649.7	AC005682.5	-6.91	8.32e-12	1.81e-09	-0.2	-0.21	Fibrinogen levels;	chr7:22817185	chr7:22854178~22861579:+
BRCA	cis	rs651907	0.513	rs34963630	ENSG00000244119.1	PDCL3P4	6.91	8.33e-12	1.81e-09	0.17	0.21	Colorectal cancer;	chr3:101785973	chr3:101712472~101713191:+
BRCA	cis	rs2599510	0.783	rs2710630	ENSG00000276334.1	AL133243.1	-6.91	8.33e-12	1.82e-09	-0.26	-0.21	Interleukin-18 levels;	chr2:32540930	chr2:32521927~32523547:+
BRCA	cis	rs2243480	0.901	rs13237344	ENSG00000232546.1	RP11-458F8.1	-6.91	8.34e-12	1.82e-09	-0.28	-0.21	Diabetic kidney disease;	chr7:66557269	chr7:66848496~66858136:+
BRCA	cis	rs3761847	0.622	rs1323471	ENSG00000226752.6	PSMD5-AS1	-6.91	8.34e-12	1.82e-09	-0.25	-0.21	Rheumatoid arthritis;	chr9:121064037	chr9:120824828~120854385:+
BRCA	cis	rs4713118	0.869	rs4713121	ENSG00000220721.1	OR1F12	6.91	8.34e-12	1.82e-09	0.26	0.21	Parkinson's disease;	chr6:27754285	chr6:28073316~28074233:+
BRCA	cis	rs67311347	1	rs6801859	ENSG00000280739.1	EIF1B-AS1	-6.91	8.35e-12	1.82e-09	-0.23	-0.21	Renal cell carcinoma;	chr3:40451727	chr3:40173145~40309698:-
BRCA	cis	rs2243480	1	rs1873494	ENSG00000232546.1	RP11-458F8.1	6.91	8.35e-12	1.82e-09	0.28	0.21	Diabetic kidney disease;	chr7:66184912	chr7:66848496~66858136:+
BRCA	cis	rs2243480	1	rs6959002	ENSG00000232546.1	RP11-458F8.1	6.91	8.35e-12	1.82e-09	0.28	0.21	Diabetic kidney disease;	chr7:66185509	chr7:66848496~66858136:+
BRCA	cis	rs801193	0.901	rs4273746	ENSG00000236529.1	RP13-254B10.1	-6.91	8.35e-12	1.82e-09	-0.23	-0.21	Aortic root size;	chr7:66836124	chr7:65840212~65840596:+
BRCA	cis	rs2014572	0.967	rs10418480	ENSG00000268379.1	CTC-360J11.4	6.91	8.36e-12	1.82e-09	0.25	0.21	Hyperactive-impulsive symptoms;	chr19:57243687	chr19:57175233~57177921:+
BRCA	cis	rs801193	1	rs7782320	ENSG00000236529.1	RP13-254B10.1	6.91	8.37e-12	1.82e-09	0.23	0.21	Aortic root size;	chr7:66712111	chr7:65840212~65840596:+
BRCA	cis	rs7131987	0.621	rs57803026	ENSG00000257176.2	RP11-996F15.2	-6.91	8.38e-12	1.82e-09	-0.26	-0.21	QT interval;	chr12:29344573	chr12:29280418~29317848:-
BRCA	cis	rs6570726	0.935	rs388394	ENSG00000235652.6	RP11-545I5.3	6.91	8.4e-12	1.83e-09	0.2	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145531553	chr6:145799409~145886585:+
BRCA	cis	rs11096990	1	rs11096990	ENSG00000249207.1	RP11-360F5.1	-6.91	8.4e-12	1.83e-09	-0.24	-0.21	Cognitive function;	chr4:39285329	chr4:39112677~39126818:-
BRCA	cis	rs202072	0.652	rs202064	ENSG00000272379.1	RP1-257A7.5	-6.91	8.45e-12	1.84e-09	-0.35	-0.21	HIV-1 viral setpoint;	chr6:13263794	chr6:13290018~13290490:-
BRCA	cis	rs6545883	0.929	rs12612982	ENSG00000271889.1	RP11-493E12.1	6.91	8.46e-12	1.84e-09	0.27	0.21	Tuberculosis;	chr2:61520220	chr2:61151433~61162105:-
BRCA	cis	rs904251	0.965	rs62406516	ENSG00000204110.6	RP1-153P14.8	-6.91	8.46e-12	1.84e-09	-0.24	-0.21	Cognitive performance;	chr6:37471588	chr6:37507348~37535616:+
BRCA	cis	rs875971	1	rs778706	ENSG00000232559.3	GS1-124K5.12	6.91	8.46e-12	1.84e-09	0.25	0.21	Aortic root size;	chr7:66395437	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.658	rs432667	ENSG00000224316.1	RP11-479O9.2	6.91	8.46e-12	1.84e-09	0.21	0.21	Aortic root size;	chr7:66049646	chr7:65773620~65802067:+
BRCA	cis	rs9876781	1	rs1459242	ENSG00000244380.1	RP11-24C3.2	-6.91	8.48e-12	1.85e-09	-0.24	-0.21	Longevity;	chr3:48372047	chr3:48440352~48446656:-
BRCA	cis	rs875971	1	rs6961717	ENSG00000224316.1	RP11-479O9.2	-6.91	8.5e-12	1.85e-09	-0.21	-0.21	Aortic root size;	chr7:66122550	chr7:65773620~65802067:+
BRCA	cis	rs9807989	0.729	rs10170583	ENSG00000234389.1	AC007278.3	6.91	8.5e-12	1.85e-09	0.2	0.21	Asthma;	chr2:102358304	chr2:102438713~102440475:+
BRCA	cis	rs7131987	0.718	rs7976961	ENSG00000257176.2	RP11-996F15.2	-6.91	8.51e-12	1.85e-09	-0.26	-0.21	QT interval;	chr12:29310155	chr12:29280418~29317848:-
BRCA	cis	rs11096990	0.855	rs2566168	ENSG00000249207.1	RP11-360F5.1	6.91	8.51e-12	1.85e-09	0.25	0.21	Cognitive function;	chr4:39150053	chr4:39112677~39126818:-
BRCA	cis	rs9291683	0.595	rs13150928	ENSG00000250413.1	RP11-448G15.1	-6.91	8.51e-12	1.85e-09	-0.28	-0.21	Bone mineral density;	chr4:10051337	chr4:10006482~10009725:+
BRCA	cis	rs2243480	0.708	rs35825036	ENSG00000230295.1	RP11-458F8.2	-6.91	8.52e-12	1.85e-09	-0.28	-0.21	Diabetic kidney disease;	chr7:66521515	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs13237037	ENSG00000230295.1	RP11-458F8.2	-6.91	8.52e-12	1.85e-09	-0.28	-0.21	Diabetic kidney disease;	chr7:66532895	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs1796228	ENSG00000230295.1	RP11-458F8.2	-6.91	8.52e-12	1.85e-09	-0.28	-0.21	Diabetic kidney disease;	chr7:66568097	chr7:66880708~66882981:+
BRCA	cis	rs801193	0.967	rs2707841	ENSG00000236529.1	RP13-254B10.1	6.91	8.52e-12	1.85e-09	0.23	0.21	Aortic root size;	chr7:66692033	chr7:65840212~65840596:+
BRCA	cis	rs801193	1	rs4717310	ENSG00000236529.1	RP13-254B10.1	6.91	8.52e-12	1.85e-09	0.23	0.21	Aortic root size;	chr7:66696020	chr7:65840212~65840596:+
BRCA	cis	rs6543140	0.964	rs7561351	ENSG00000234389.1	AC007278.3	6.91	8.55e-12	1.86e-09	0.21	0.21	Blood protein levels;	chr2:102461320	chr2:102438713~102440475:+
BRCA	cis	rs2060793	0.741	rs7119073	ENSG00000251991.1	RNU7-49P	6.91	8.57e-12	1.86e-09	0.23	0.21	Vitamin D levels;	chr11:14669416	chr11:14478892~14478953:+
BRCA	cis	rs10510102	0.935	rs11200257	ENSG00000276742.1	RP11-500G22.4	6.91	8.57e-12	1.86e-09	0.34	0.21	Breast cancer;	chr10:121917232	chr10:121956782~121957098:+
BRCA	cis	rs11098499	0.909	rs11723839	ENSG00000249244.1	RP11-548H18.2	6.91	8.58e-12	1.86e-09	0.25	0.21	Corneal astigmatism;	chr4:119378518	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.779	rs7699346	ENSG00000249244.1	RP11-548H18.2	6.91	8.58e-12	1.86e-09	0.25	0.21	Corneal astigmatism;	chr4:119389387	chr4:119391831~119395335:-
BRCA	cis	rs7208859	0.623	rs3794796	ENSG00000263603.1	CTD-2349P21.5	-6.91	8.59e-12	1.87e-09	-0.37	-0.21	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30803862	chr17:30729469~30731202:+
BRCA	cis	rs919433	0.963	rs4850787	ENSG00000231621.1	AC013264.2	6.91	8.59e-12	1.87e-09	0.2	0.21	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197317026	chr2:197197991~197199273:+
BRCA	cis	rs13217239	0.572	rs9379958	ENSG00000241549.7	GUSBP2	-6.91	8.6e-12	1.87e-09	-0.23	-0.21	Schizophrenia;	chr6:27098384	chr6:26871484~26956554:-
BRCA	cis	rs2337406	1	rs17095456	ENSG00000254174.1	IGHV1-12	6.91	8.61e-12	1.87e-09	0.23	0.21	Alzheimer's disease (late onset);	chr14:106676559	chr14:106122420~106122709:-
BRCA	cis	rs6840360	0.642	rs2709819	ENSG00000270265.1	RP11-731D1.4	-6.91	8.63e-12	1.88e-09	-0.23	-0.21	Intelligence (multi-trait analysis);	chr4:151462680	chr4:151333775~151353224:-
BRCA	cis	rs780096	0.527	rs12471703	ENSG00000234072.1	AC074117.10	-6.91	8.63e-12	1.88e-09	-0.2	-0.21	Total body bone mineral density;	chr2:27515987	chr2:27356246~27367622:+
BRCA	cis	rs13217239	0.646	rs9393789	ENSG00000241549.7	GUSBP2	-6.91	8.64e-12	1.88e-09	-0.23	-0.21	Schizophrenia;	chr6:27099249	chr6:26871484~26956554:-
BRCA	cis	rs13315649	0.562	rs6439137	ENSG00000242551.2	POU5F1P6	-6.91	8.64e-12	1.88e-09	-0.29	-0.21	Sum eosinophil basophil counts;	chr3:128668107	chr3:128674735~128677005:-
BRCA	cis	rs17253792	0.822	rs77315200	ENSG00000186615.9	KTN1-AS1	-6.91	8.64e-12	1.88e-09	-0.4	-0.21	Putamen volume;	chr14:55605925	chr14:55499278~55580110:-
BRCA	cis	rs17301013	0.606	rs4652193	ENSG00000227373.4	RP11-160H22.5	6.91	8.65e-12	1.88e-09	0.3	0.21	Systemic lupus erythematosus;	chr1:174144554	chr1:174115300~174160004:-
BRCA	cis	rs17301013	0.606	rs16846717	ENSG00000227373.4	RP11-160H22.5	6.91	8.65e-12	1.88e-09	0.3	0.21	Systemic lupus erythematosus;	chr1:174152180	chr1:174115300~174160004:-
BRCA	cis	rs17301013	0.606	rs16846718	ENSG00000227373.4	RP11-160H22.5	6.91	8.65e-12	1.88e-09	0.3	0.21	Systemic lupus erythematosus;	chr1:174152782	chr1:174115300~174160004:-
BRCA	cis	rs17301013	0.606	rs10912735	ENSG00000227373.4	RP11-160H22.5	6.91	8.65e-12	1.88e-09	0.3	0.21	Systemic lupus erythematosus;	chr1:174159002	chr1:174115300~174160004:-
BRCA	cis	rs17301013	0.606	rs12354141	ENSG00000227373.4	RP11-160H22.5	6.91	8.65e-12	1.88e-09	0.3	0.21	Systemic lupus erythematosus;	chr1:174166078	chr1:174115300~174160004:-
BRCA	cis	rs847577	0.677	rs4729403	ENSG00000272950.1	RP11-307C18.1	-6.91	8.68e-12	1.88e-09	-0.27	-0.21	Breast cancer;	chr7:98078529	chr7:98322853~98323430:+
BRCA	cis	rs1862618	0.853	rs252919	ENSG00000271828.1	CTD-2310F14.1	6.91	8.68e-12	1.89e-09	0.29	0.21	Initial pursuit acceleration;	chr5:56828284	chr5:56927874~56929573:+
BRCA	cis	rs375066	0.762	rs62114648	ENSG00000267058.1	RP11-15A1.3	6.91	8.69e-12	1.89e-09	0.24	0.21	Breast cancer;	chr19:43910664	chr19:43891804~43901805:-
BRCA	cis	rs6840360	0.642	rs2709817	ENSG00000270265.1	RP11-731D1.4	-6.91	8.7e-12	1.89e-09	-0.23	-0.21	Intelligence (multi-trait analysis);	chr4:151460898	chr4:151333775~151353224:-
BRCA	cis	rs6840360	0.642	rs2709818	ENSG00000270265.1	RP11-731D1.4	-6.91	8.7e-12	1.89e-09	-0.23	-0.21	Intelligence (multi-trait analysis);	chr4:151461482	chr4:151333775~151353224:-
BRCA	cis	rs74233809	1	rs11191587	ENSG00000213277.3	MARCKSL1P1	6.91	8.7e-12	1.89e-09	0.39	0.21	Birth weight;	chr10:103169959	chr10:103175554~103176094:+
BRCA	cis	rs11096990	0.855	rs6855008	ENSG00000249207.1	RP11-360F5.1	6.91	8.7e-12	1.89e-09	0.25	0.21	Cognitive function;	chr4:39172006	chr4:39112677~39126818:-
BRCA	cis	rs516805	0.961	rs573709	ENSG00000279453.1	RP3-425C14.4	6.91	8.71e-12	1.89e-09	0.24	0.21	Lymphocyte counts;	chr6:122457673	chr6:122436789~122439223:-
BRCA	cis	rs6479891	0.908	rs61853655	ENSG00000232075.1	MRPL35P2	6.91	8.71e-12	1.89e-09	0.4	0.21	Arthritis (juvenile idiopathic);	chr10:63570645	chr10:63634317~63634827:-
BRCA	cis	rs6504622	0.818	rs9303532	ENSG00000262879.4	RP11-156P1.3	-6.9	8.76e-12	1.9e-09	-0.21	-0.21	Orofacial clefts;	chr17:46956636	chr17:46984045~47100323:-
BRCA	cis	rs7829975	0.688	rs7827182	ENSG00000254153.1	CTA-398F10.2	6.9	8.77e-12	1.9e-09	0.25	0.21	Mood instability;	chr8:8522961	chr8:8456909~8461337:-
BRCA	cis	rs801193	0.935	rs3800820	ENSG00000236529.1	RP13-254B10.1	-6.9	8.77e-12	1.91e-09	-0.23	-0.21	Aortic root size;	chr7:66682191	chr7:65840212~65840596:+
BRCA	cis	rs3781264	0.557	rs10882437	ENSG00000273450.1	RP11-76P2.4	6.9	8.78e-12	1.91e-09	0.27	0.21	Esophageal cancer and gastric cancer;	chr10:94362073	chr10:94314907~94315327:-
BRCA	cis	rs6142102	0.961	rs8123521	ENSG00000275784.1	RP5-1125A11.6	-6.9	8.79e-12	1.91e-09	-0.25	-0.21	Skin pigmentation;	chr20:34081079	chr20:33989480~33991818:-
BRCA	cis	rs7131987	0.65	rs4331146	ENSG00000257176.2	RP11-996F15.2	-6.9	8.79e-12	1.91e-09	-0.26	-0.21	QT interval;	chr12:29287150	chr12:29280418~29317848:-
BRCA	cis	rs1555322	0.53	rs8122819	ENSG00000261582.1	RP4-614O4.11	-6.9	8.8e-12	1.91e-09	-0.23	-0.21	Attention deficit hyperactivity disorder;	chr20:35293783	chr20:35267885~35280043:-
BRCA	cis	rs932287	0.536	rs10840160	ENSG00000254860.4	TMEM9B-AS1	6.9	8.81e-12	1.91e-09	0.21	0.21	Colonoscopy-negative controls vs population controls;	chr11:9031989	chr11:8964675~8977527:+
BRCA	cis	rs17301013	0.606	rs10912746	ENSG00000227373.4	RP11-160H22.5	6.9	8.81e-12	1.91e-09	0.3	0.21	Systemic lupus erythematosus;	chr1:174210205	chr1:174115300~174160004:-
BRCA	cis	rs7246657	0.943	rs8111782	ENSG00000226686.6	LINC01535	-6.9	8.81e-12	1.91e-09	-0.32	-0.21	Coronary artery calcification;	chr19:37377002	chr19:37251912~37265535:+
BRCA	cis	rs875971	0.8	rs427557	ENSG00000224316.1	RP11-479O9.2	6.9	8.82e-12	1.91e-09	0.21	0.21	Aortic root size;	chr7:66054263	chr7:65773620~65802067:+
BRCA	cis	rs1707322	0.721	rs10890333	ENSG00000281133.1	AL355480.3	-6.9	8.82e-12	1.92e-09	-0.27	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634650	chr1:45580892~45580996:-
BRCA	cis	rs172166	0.637	rs1071893	ENSG00000216901.1	AL022393.7	6.9	8.83e-12	1.92e-09	0.27	0.21	Cardiac Troponin-T levels;	chr6:28199857	chr6:28176188~28176674:+
BRCA	cis	rs875971	0.862	rs1981799	ENSG00000232559.3	GS1-124K5.12	6.9	8.84e-12	1.92e-09	0.25	0.21	Aortic root size;	chr7:66490572	chr7:66554588~66576923:-
BRCA	cis	rs875971	1	rs2087647	ENSG00000224316.1	RP11-479O9.2	-6.9	8.85e-12	1.92e-09	-0.21	-0.21	Aortic root size;	chr7:66128201	chr7:65773620~65802067:+
BRCA	cis	rs9880211	0.613	rs6767060	ENSG00000273486.1	RP11-731C17.2	6.9	8.85e-12	1.92e-09	0.26	0.21	Height;Body mass index;	chr3:136148248	chr3:136837338~136839021:-
BRCA	cis	rs13113518	0.783	rs12510400	ENSG00000249700.7	SRD5A3-AS1	6.9	8.87e-12	1.93e-09	0.27	0.21	Height;	chr4:55577294	chr4:55363971~55395847:-
BRCA	cis	rs8003054	0.589	rs4465523	ENSG00000258515.1	RP11-203M5.7	6.9	8.87e-12	1.93e-09	0.18	0.21	Facial morphology (factor 1, breadth of lateral portion of upper face);	chr14:20445364	chr14:20451305~20451918:+
BRCA	cis	rs11098499	0.909	rs73842633	ENSG00000249244.1	RP11-548H18.2	6.9	8.87e-12	1.93e-09	0.25	0.21	Corneal astigmatism;	chr4:119454309	chr4:119391831~119395335:-
BRCA	cis	rs375066	0.762	rs12610287	ENSG00000267058.1	RP11-15A1.3	6.9	8.88e-12	1.93e-09	0.24	0.21	Breast cancer;	chr19:43896511	chr19:43891804~43901805:-
BRCA	cis	rs7432375	0.641	rs835649	ENSG00000239213.4	NCK1-AS1	6.9	8.89e-12	1.93e-09	0.22	0.21	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136953048	chr3:136841726~136862054:-
BRCA	cis	rs780096	0.814	rs780093	ENSG00000234072.1	AC074117.10	-6.9	8.89e-12	1.93e-09	-0.2	-0.21	Total body bone mineral density;	chr2:27519736	chr2:27356246~27367622:+
BRCA	cis	rs11512640	1	rs11220120	ENSG00000254671.2	STT3A-AS1	6.9	8.9e-12	1.93e-09	0.48	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr11:125529894	chr11:125570284~125592568:-
BRCA	cis	rs10515750	0.588	rs56656884	ENSG00000251405.2	CTB-109A12.1	6.9	8.92e-12	1.94e-09	0.32	0.21	Lung function (FEV1/FVC);	chr5:157361963	chr5:157362615~157460078:-
BRCA	cis	rs1823913	0.637	rs12624271	ENSG00000280083.1	RP11-317J9.1	6.9	8.93e-12	1.94e-09	0.24	0.21	Obesity-related traits;	chr2:191288586	chr2:191154118~191156070:-
BRCA	cis	rs10515750	0.588	rs11134720	ENSG00000251405.2	CTB-109A12.1	6.9	8.94e-12	1.94e-09	0.32	0.21	Lung function (FEV1/FVC);	chr5:157358662	chr5:157362615~157460078:-
BRCA	cis	rs1707322	0.656	rs2991981	ENSG00000281133.1	AL355480.3	6.9	8.95e-12	1.94e-09	0.27	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45591472	chr1:45580892~45580996:-
BRCA	cis	rs7131987	0.65	rs67146951	ENSG00000257176.2	RP11-996F15.2	-6.9	8.96e-12	1.94e-09	-0.26	-0.21	QT interval;	chr12:29297620	chr12:29280418~29317848:-
BRCA	cis	rs875971	0.929	rs778692	ENSG00000232559.3	GS1-124K5.12	6.9	8.97e-12	1.95e-09	0.25	0.21	Aortic root size;	chr7:66407462	chr7:66554588~66576923:-
BRCA	cis	rs875971	1	rs4718343	ENSG00000232559.3	GS1-124K5.12	6.9	8.97e-12	1.95e-09	0.25	0.21	Aortic root size;	chr7:66409301	chr7:66554588~66576923:-
BRCA	cis	rs875971	1	rs1968225	ENSG00000232559.3	GS1-124K5.12	6.9	8.97e-12	1.95e-09	0.25	0.21	Aortic root size;	chr7:66409786	chr7:66554588~66576923:-
BRCA	cis	rs875971	1	rs6460295	ENSG00000232559.3	GS1-124K5.12	6.9	8.97e-12	1.95e-09	0.25	0.21	Aortic root size;	chr7:66417741	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.964	rs6978721	ENSG00000232559.3	GS1-124K5.12	6.9	8.97e-12	1.95e-09	0.25	0.21	Aortic root size;	chr7:66418217	chr7:66554588~66576923:-
BRCA	cis	rs9291683	0.588	rs17246745	ENSG00000250413.1	RP11-448G15.1	-6.9	8.99e-12	1.95e-09	-0.27	-0.21	Bone mineral density;	chr4:9992959	chr4:10006482~10009725:+
BRCA	cis	rs7246657	0.943	rs10422074	ENSG00000226686.6	LINC01535	-6.9	9e-12	1.95e-09	-0.32	-0.21	Coronary artery calcification;	chr19:37403334	chr19:37251912~37265535:+
BRCA	cis	rs10510102	0.935	rs79360006	ENSG00000276742.1	RP11-500G22.4	6.9	9.02e-12	1.96e-09	0.35	0.21	Breast cancer;	chr10:121912856	chr10:121956782~121957098:+
BRCA	cis	rs4072705	1	rs10818983	ENSG00000224020.1	MIR181A2HG	-6.9	9.03e-12	1.96e-09	-0.23	-0.21	Menarche (age at onset);	chr9:124649298	chr9:124658467~124698631:+
BRCA	cis	rs67981189	0.865	rs2810115	ENSG00000269927.1	RP6-91H8.3	-6.9	9.03e-12	1.96e-09	-0.26	-0.21	Schizophrenia;	chr14:70928070	chr14:71141125~71143253:-
BRCA	cis	rs67981189	0.896	rs917065	ENSG00000269927.1	RP6-91H8.3	-6.9	9.03e-12	1.96e-09	-0.26	-0.21	Schizophrenia;	chr14:70931129	chr14:71141125~71143253:-
BRCA	cis	rs67981189	0.896	rs1018977	ENSG00000269927.1	RP6-91H8.3	-6.9	9.03e-12	1.96e-09	-0.26	-0.21	Schizophrenia;	chr14:70933936	chr14:71141125~71143253:-
BRCA	cis	rs67981189	0.752	rs2332477	ENSG00000269927.1	RP6-91H8.3	-6.9	9.03e-12	1.96e-09	-0.26	-0.21	Schizophrenia;	chr14:70936594	chr14:71141125~71143253:-
BRCA	cis	rs7613051	0.945	rs7629880	ENSG00000223899.1	SEC13P1	-6.9	9.04e-12	1.96e-09	-0.27	-0.21	Atopic dermatitis;	chr3:33017319	chr3:33033863~33034810:+
BRCA	cis	rs13113518	0.513	rs13132085	ENSG00000249700.7	SRD5A3-AS1	-6.9	9.05e-12	1.96e-09	-0.27	-0.21	Height;	chr4:55593918	chr4:55363971~55395847:-
BRCA	cis	rs1707322	0.685	rs11211177	ENSG00000281133.1	AL355480.3	-6.9	9.08e-12	1.97e-09	-0.27	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45760677	chr1:45580892~45580996:-
BRCA	cis	rs375066	0.762	rs1073654	ENSG00000267058.1	RP11-15A1.3	6.9	9.09e-12	1.97e-09	0.24	0.21	Breast cancer;	chr19:43907268	chr19:43891804~43901805:-
BRCA	cis	rs375066	0.762	rs1073653	ENSG00000267058.1	RP11-15A1.3	6.9	9.09e-12	1.97e-09	0.24	0.21	Breast cancer;	chr19:43907391	chr19:43891804~43901805:-
BRCA	cis	rs6142102	0.961	rs4911389	ENSG00000275784.1	RP5-1125A11.6	-6.9	9.1e-12	1.97e-09	-0.25	-0.21	Skin pigmentation;	chr20:33977235	chr20:33989480~33991818:-
BRCA	cis	rs2880765	0.714	rs6497187	ENSG00000259295.5	CSPG4P12	6.9	9.11e-12	1.97e-09	0.26	0.21	Coronary artery disease;	chr15:85468119	chr15:85191438~85213905:+
BRCA	cis	rs11096990	0.855	rs57488936	ENSG00000249207.1	RP11-360F5.1	6.9	9.12e-12	1.98e-09	0.24	0.21	Cognitive function;	chr4:39220626	chr4:39112677~39126818:-
BRCA	cis	rs7871764	0.881	rs35017035	ENSG00000260947.1	RP11-384P7.7	6.9	9.13e-12	1.98e-09	0.27	0.21	Height;	chr9:34072896	chr9:33697459~33700986:+
BRCA	cis	rs875971	0.964	rs778708	ENSG00000232559.3	GS1-124K5.12	6.9	9.13e-12	1.98e-09	0.25	0.21	Aortic root size;	chr7:66391332	chr7:66554588~66576923:-
BRCA	cis	rs78456975	0.739	rs13405352	ENSG00000231482.2	AC141930.2	-6.9	9.14e-12	1.98e-09	-0.29	-0.21	Placebo response in major depressive disorder (% change in symptom score);	chr2:1514954	chr2:1572554~1580311:-
BRCA	cis	rs17214007	0.877	rs11075281	ENSG00000263335.1	AF001548.5	-6.9	9.15e-12	1.98e-09	-0.31	-0.21	Cognitive function;	chr16:15780585	chr16:15726674~15732993:+
BRCA	cis	rs919433	0.963	rs12617117	ENSG00000231621.1	AC013264.2	6.9	9.15e-12	1.98e-09	0.21	0.21	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197290446	chr2:197197991~197199273:+
BRCA	cis	rs13217239	0.646	rs7451149	ENSG00000241549.7	GUSBP2	-6.9	9.15e-12	1.98e-09	-0.23	-0.21	Schizophrenia;	chr6:27089739	chr6:26871484~26956554:-
BRCA	cis	rs17301013	0.507	rs10912757	ENSG00000227373.4	RP11-160H22.5	6.9	9.15e-12	1.98e-09	0.3	0.21	Systemic lupus erythematosus;	chr1:174299064	chr1:174115300~174160004:-
BRCA	cis	rs2599510	0.811	rs2710625	ENSG00000276334.1	AL133243.1	6.9	9.17e-12	1.99e-09	0.26	0.21	Interleukin-18 levels;	chr2:32597890	chr2:32521927~32523547:+
BRCA	cis	rs10463554	0.853	rs458598	ENSG00000175749.11	EIF3KP1	6.9	9.17e-12	1.99e-09	0.29	0.21	Parkinson's disease;	chr5:103233677	chr5:103032376~103033031:+
BRCA	cis	rs13113518	0.812	rs11945371	ENSG00000249700.7	SRD5A3-AS1	6.9	9.17e-12	1.99e-09	0.26	0.21	Height;	chr4:55409063	chr4:55363971~55395847:-
BRCA	cis	rs875971	1	rs12533997	ENSG00000232559.3	GS1-124K5.12	6.9	9.2e-12	1.99e-09	0.25	0.21	Aortic root size;	chr7:66500390	chr7:66554588~66576923:-
BRCA	cis	rs801193	1	rs7788576	ENSG00000236529.1	RP13-254B10.1	-6.9	9.23e-12	2e-09	-0.23	-0.21	Aortic root size;	chr7:66683315	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.545	rs1796226	ENSG00000224316.1	RP11-479O9.2	6.9	9.23e-12	2e-09	0.23	0.21	Aortic root size;	chr7:66622723	chr7:65773620~65802067:+
BRCA	cis	rs79040073	0.593	rs11632038	ENSG00000259531.2	RP11-295H24.3	6.9	9.24e-12	2e-09	0.37	0.21	Lung cancer in ever smokers;	chr15:49314101	chr15:49365124~49366685:-
BRCA	cis	rs7617773	0.817	rs13072018	ENSG00000228638.1	FCF1P2	-6.9	9.26e-12	2e-09	-0.24	-0.21	Coronary artery disease;	chr3:48278842	chr3:48290793~48291375:-
BRCA	cis	rs6603134	0.502	rs10411185	ENSG00000267939.1	CTD-2325M2.1	-6.9	9.26e-12	2e-09	-0.24	-0.21	Blood protein levels;	chr19:8038997	chr19:8008729~8016025:+
BRCA	cis	rs7976269	0.609	rs2082943	ENSG00000257176.2	RP11-996F15.2	-6.9	9.27e-12	2.01e-09	-0.25	-0.21	Male-pattern baldness;	chr12:29050251	chr12:29280418~29317848:-
BRCA	cis	rs9876781	1	rs9815103	ENSG00000244380.1	RP11-24C3.2	6.9	9.28e-12	2.01e-09	0.24	0.21	Longevity;	chr3:48372725	chr3:48440352~48446656:-
BRCA	cis	rs6740322	0.843	rs6727237	ENSG00000234936.1	AC010883.5	6.9	9.28e-12	2.01e-09	0.23	0.21	Coronary artery disease;	chr2:43334861	chr2:43229573~43233394:+
BRCA	cis	rs17301013	0.507	rs10912753	ENSG00000227373.4	RP11-160H22.5	6.9	9.28e-12	2.01e-09	0.3	0.21	Systemic lupus erythematosus;	chr1:174265226	chr1:174115300~174160004:-
BRCA	cis	rs875971	1	rs6958484	ENSG00000224316.1	RP11-479O9.2	-6.9	9.32e-12	2.02e-09	-0.21	-0.21	Aortic root size;	chr7:66134459	chr7:65773620~65802067:+
BRCA	cis	rs2070074	0.591	rs3739882	ENSG00000230074.1	RP11-195F19.9	6.89	9.34e-12	2.02e-09	0.48	0.21	CTACK levels;	chr9:34653112	chr9:34665665~34681298:+
BRCA	cis	rs11671005	0.779	rs55875034	ENSG00000252334.1	RNU6-1337P	6.89	9.35e-12	2.02e-09	0.33	0.21	Mean platelet volume;	chr19:58472191	chr19:58483749~58483843:-
BRCA	cis	rs7809950	1	rs7809950	ENSG00000238832.1	snoU109	6.89	9.36e-12	2.02e-09	0.29	0.21	Coronary artery disease;	chr7:107597362	chr7:107603363~107603507:+
BRCA	cis	rs6545883	0.868	rs7594191	ENSG00000271889.1	RP11-493E12.1	-6.89	9.39e-12	2.03e-09	-0.26	-0.21	Tuberculosis;	chr2:61612883	chr2:61151433~61162105:-
BRCA	cis	rs10754283	0.967	rs1934045	ENSG00000231613.1	RP5-943J3.1	-6.89	9.39e-12	2.03e-09	-0.23	-0.21	Amyotrophic lateral sclerosis (sporadic);	chr1:89642240	chr1:89788914~89790492:+
BRCA	cis	rs7246657	0.943	rs10407084	ENSG00000226686.6	LINC01535	-6.89	9.4e-12	2.03e-09	-0.32	-0.21	Coronary artery calcification;	chr19:37416890	chr19:37251912~37265535:+
BRCA	cis	rs7246657	0.943	rs7252099	ENSG00000226686.6	LINC01535	-6.89	9.4e-12	2.03e-09	-0.32	-0.21	Coronary artery calcification;	chr19:37442878	chr19:37251912~37265535:+
BRCA	cis	rs7246657	0.943	rs7255972	ENSG00000226686.6	LINC01535	-6.89	9.4e-12	2.03e-09	-0.32	-0.21	Coronary artery calcification;	chr19:37442939	chr19:37251912~37265535:+
BRCA	cis	rs875971	0.545	rs316324	ENSG00000236529.1	RP13-254B10.1	-6.89	9.41e-12	2.04e-09	-0.26	-0.21	Aortic root size;	chr7:66145627	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.545	rs316323	ENSG00000236529.1	RP13-254B10.1	-6.89	9.41e-12	2.04e-09	-0.26	-0.21	Aortic root size;	chr7:66146002	chr7:65840212~65840596:+
BRCA	cis	rs7772486	0.521	rs9485017	ENSG00000235652.6	RP11-545I5.3	6.89	9.42e-12	2.04e-09	0.21	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145702190	chr6:145799409~145886585:+
BRCA	cis	rs801193	1	rs2659906	ENSG00000236529.1	RP13-254B10.1	6.89	9.42e-12	2.04e-09	0.22	0.21	Aortic root size;	chr7:66700323	chr7:65840212~65840596:+
BRCA	cis	rs9880211	0.699	rs13433688	ENSG00000273486.1	RP11-731C17.2	6.89	9.44e-12	2.04e-09	0.28	0.21	Height;Body mass index;	chr3:136690329	chr3:136837338~136839021:-
BRCA	cis	rs867371	0.929	rs7173852	ENSG00000259429.4	UBE2Q2P2	-6.89	9.46e-12	2.05e-09	-0.2	-0.21	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82169512	chr15:82355142~82420075:+
BRCA	cis	rs17301013	0.606	rs6670425	ENSG00000227373.4	RP11-160H22.5	6.89	9.46e-12	2.05e-09	0.3	0.21	Systemic lupus erythematosus;	chr1:174144204	chr1:174115300~174160004:-
BRCA	cis	rs10936632	0.565	rs6794467	ENSG00000242578.1	RP11-469J4.3	-6.89	9.47e-12	2.05e-09	-0.24	-0.21	Prostate cancer;	chr3:170430203	chr3:170410512~170418615:+
BRCA	cis	rs34779708	0.931	rs2384275	ENSG00000271335.4	RP11-324I22.4	6.89	9.5e-12	2.05e-09	0.21	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35008214	chr10:35314552~35336401:-
BRCA	cis	rs673078	0.607	rs7137055	ENSG00000275409.1	RP11-131L12.4	-6.89	9.5e-12	2.05e-09	-0.31	-0.21	Glucose homeostasis traits;	chr12:118395030	chr12:118430147~118430699:+
BRCA	cis	rs673078	0.607	rs7137184	ENSG00000275409.1	RP11-131L12.4	-6.89	9.5e-12	2.05e-09	-0.31	-0.21	Glucose homeostasis traits;	chr12:118395163	chr12:118430147~118430699:+
BRCA	cis	rs4072705	0.967	rs2148787	ENSG00000224020.1	MIR181A2HG	-6.89	9.51e-12	2.06e-09	-0.23	-0.21	Menarche (age at onset);	chr9:124705925	chr9:124658467~124698631:+
BRCA	cis	rs801193	0.967	rs3800823	ENSG00000236529.1	RP13-254B10.1	-6.89	9.53e-12	2.06e-09	-0.23	-0.21	Aortic root size;	chr7:66682123	chr7:65840212~65840596:+
BRCA	cis	rs71520386	0.632	rs10224419	ENSG00000228649.7	AC005682.5	6.89	9.54e-12	2.06e-09	0.2	0.21	Fibrinogen levels;	chr7:22830397	chr7:22854178~22861579:+
BRCA	cis	rs10861661	1	rs4964491	ENSG00000260329.1	RP11-412D9.4	-6.89	9.55e-12	2.06e-09	-0.26	-0.21	Triglyceride levels;	chr12:106828737	chr12:106954029~106955497:-
BRCA	cis	rs2348418	0.67	rs10843098	ENSG00000247934.4	RP11-967K21.1	-6.89	9.55e-12	2.07e-09	-0.24	-0.21	Lung function (FEV1);Lung function (FVC);	chr12:28116709	chr12:28163298~28190738:-
BRCA	cis	rs7428	0.545	rs4832163	ENSG00000246575.2	AC093162.5	6.89	9.56e-12	2.07e-09	0.22	0.21	Ear protrusion;	chr2:85313960	chr2:85315041~85316529:+
BRCA	cis	rs875971	0.638	rs7793569	ENSG00000236529.1	RP13-254B10.1	-6.89	9.56e-12	2.07e-09	-0.23	-0.21	Aortic root size;	chr7:66651646	chr7:65840212~65840596:+
BRCA	cis	rs801193	1	rs3857688	ENSG00000236529.1	RP13-254B10.1	-6.89	9.56e-12	2.07e-09	-0.23	-0.21	Aortic root size;	chr7:66662819	chr7:65840212~65840596:+
BRCA	cis	rs801193	1	rs2286684	ENSG00000236529.1	RP13-254B10.1	-6.89	9.56e-12	2.07e-09	-0.23	-0.21	Aortic root size;	chr7:66664843	chr7:65840212~65840596:+
BRCA	cis	rs801193	0.935	rs2286683	ENSG00000236529.1	RP13-254B10.1	-6.89	9.56e-12	2.07e-09	-0.23	-0.21	Aortic root size;	chr7:66664856	chr7:65840212~65840596:+
BRCA	cis	rs801193	1	rs10274773	ENSG00000236529.1	RP13-254B10.1	-6.89	9.56e-12	2.07e-09	-0.23	-0.21	Aortic root size;	chr7:66668591	chr7:65840212~65840596:+
BRCA	cis	rs6142102	0.923	rs6057961	ENSG00000275784.1	RP5-1125A11.6	-6.89	9.56e-12	2.07e-09	-0.25	-0.21	Skin pigmentation;	chr20:33986005	chr20:33989480~33991818:-
BRCA	cis	rs1707322	0.721	rs12043945	ENSG00000281133.1	AL355480.3	-6.89	9.57e-12	2.07e-09	-0.27	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45641250	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.721	rs12091503	ENSG00000281133.1	AL355480.3	-6.89	9.57e-12	2.07e-09	-0.27	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45642196	chr1:45580892~45580996:-
BRCA	cis	rs301901	0.714	rs301869	ENSG00000250155.1	CTD-2353F22.1	-6.89	9.57e-12	2.07e-09	-0.23	-0.21	Height;	chr5:37140495	chr5:36666214~36725195:-
BRCA	cis	rs2880765	0.743	rs16940052	ENSG00000259295.5	CSPG4P12	6.89	9.58e-12	2.07e-09	0.26	0.21	Coronary artery disease;	chr15:85463443	chr15:85191438~85213905:+
BRCA	cis	rs61160187	0.582	rs4700402	ENSG00000215032.2	GNL3LP1	6.89	9.58e-12	2.07e-09	0.26	0.21	Educational attainment (years of education);Educational attainment (college completion);	chr5:60966220	chr5:60891935~60893577:-
BRCA	cis	rs2836950	0.84	rs12482317	ENSG00000255568.3	BRWD1-AS2	-6.89	9.6e-12	2.08e-09	-0.21	-0.21	Menarche (age at onset);	chr21:39216315	chr21:39313935~39314962:+
BRCA	cis	rs274567	0.501	rs272855	ENSG00000233006.5	AC034220.3	6.89	9.63e-12	2.08e-09	0.17	0.21	Blood metabolite levels;	chr5:132351482	chr5:132311285~132369916:-
BRCA	cis	rs7246657	0.943	rs10422967	ENSG00000226686.6	LINC01535	-6.89	9.64e-12	2.08e-09	-0.32	-0.21	Coronary artery calcification;	chr19:37359235	chr19:37251912~37265535:+
BRCA	cis	rs6840360	0.642	rs7682770	ENSG00000270265.1	RP11-731D1.4	-6.89	9.67e-12	2.09e-09	-0.23	-0.21	Intelligence (multi-trait analysis);	chr4:151469261	chr4:151333775~151353224:-
BRCA	cis	rs6840360	0.667	rs9994482	ENSG00000270265.1	RP11-731D1.4	-6.89	9.67e-12	2.09e-09	-0.23	-0.21	Intelligence (multi-trait analysis);	chr4:151470078	chr4:151333775~151353224:-
BRCA	cis	rs6840360	0.642	rs11729923	ENSG00000270265.1	RP11-731D1.4	-6.89	9.67e-12	2.09e-09	-0.23	-0.21	Intelligence (multi-trait analysis);	chr4:151470884	chr4:151333775~151353224:-
BRCA	cis	rs6840360	0.642	rs7676059	ENSG00000270265.1	RP11-731D1.4	-6.89	9.67e-12	2.09e-09	-0.23	-0.21	Intelligence (multi-trait analysis);	chr4:151472115	chr4:151333775~151353224:-
BRCA	cis	rs6840360	0.642	rs7657747	ENSG00000270265.1	RP11-731D1.4	-6.89	9.67e-12	2.09e-09	-0.23	-0.21	Intelligence (multi-trait analysis);	chr4:151473102	chr4:151333775~151353224:-
BRCA	cis	rs6569038	0.508	rs4946388	ENSG00000253194.1	RP11-351A11.1	6.89	9.67e-12	2.09e-09	0.26	0.21	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr6:119032352	chr6:118934785~119031541:+
BRCA	cis	rs3781264	0.595	rs10786161	ENSG00000273450.1	RP11-76P2.4	6.89	9.69e-12	2.09e-09	0.27	0.21	Esophageal cancer and gastric cancer;	chr10:94347914	chr10:94314907~94315327:-
BRCA	cis	rs11096990	0.855	rs11730771	ENSG00000249207.1	RP11-360F5.1	6.89	9.71e-12	2.1e-09	0.24	0.21	Cognitive function;	chr4:39220787	chr4:39112677~39126818:-
BRCA	cis	rs801193	1	rs2420824	ENSG00000236529.1	RP13-254B10.1	-6.89	9.71e-12	2.1e-09	-0.22	-0.21	Aortic root size;	chr7:66666129	chr7:65840212~65840596:+
BRCA	cis	rs7976269	0.609	rs10771470	ENSG00000257176.2	RP11-996F15.2	-6.89	9.72e-12	2.1e-09	-0.25	-0.21	Male-pattern baldness;	chr12:29050620	chr12:29280418~29317848:-
BRCA	cis	rs7976269	0.609	rs10743641	ENSG00000257176.2	RP11-996F15.2	-6.89	9.72e-12	2.1e-09	-0.25	-0.21	Male-pattern baldness;	chr12:29050819	chr12:29280418~29317848:-
BRCA	cis	rs7976269	0.609	rs4930846	ENSG00000257176.2	RP11-996F15.2	-6.89	9.72e-12	2.1e-09	-0.25	-0.21	Male-pattern baldness;	chr12:29051306	chr12:29280418~29317848:-
BRCA	cis	rs11098499	0.909	rs79026312	ENSG00000249244.1	RP11-548H18.2	6.89	9.73e-12	2.1e-09	0.25	0.21	Corneal astigmatism;	chr4:119519522	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.909	rs35111518	ENSG00000249244.1	RP11-548H18.2	6.89	9.73e-12	2.1e-09	0.25	0.21	Corneal astigmatism;	chr4:119519527	chr4:119391831~119395335:-
BRCA	cis	rs6479891	0.908	rs16918603	ENSG00000232075.1	MRPL35P2	6.89	9.73e-12	2.1e-09	0.4	0.21	Arthritis (juvenile idiopathic);	chr10:63561712	chr10:63634317~63634827:-
BRCA	cis	rs11098499	0.954	rs6838814	ENSG00000249244.1	RP11-548H18.2	6.89	9.75e-12	2.1e-09	0.25	0.21	Corneal astigmatism;	chr4:119471288	chr4:119391831~119395335:-
BRCA	cis	rs17495987	0.913	rs73059192	ENSG00000219545.8	UMAD1	6.89	9.75e-12	2.11e-09	0.27	0.21	Tonsillectomy;	chr7:7860495	chr7:7640711~8004059:+
BRCA	cis	rs11096990	0.819	rs2381225	ENSG00000249207.1	RP11-360F5.1	6.89	9.76e-12	2.11e-09	0.25	0.21	Cognitive function;	chr4:39158915	chr4:39112677~39126818:-
BRCA	cis	rs6142102	0.651	rs6119463	ENSG00000276073.1	RP5-1125A11.7	6.89	9.77e-12	2.11e-09	0.25	0.21	Skin pigmentation;	chr20:34149412	chr20:33985617~33988989:-
BRCA	cis	rs7937890	0.506	rs10741655	ENSG00000251991.1	RNU7-49P	6.89	9.78e-12	2.11e-09	0.23	0.21	Mitochondrial DNA levels;	chr11:14746838	chr11:14478892~14478953:+
BRCA	cis	rs11096990	0.821	rs2711991	ENSG00000249207.1	RP11-360F5.1	6.89	9.79e-12	2.11e-09	0.25	0.21	Cognitive function;	chr4:39149733	chr4:39112677~39126818:-
BRCA	cis	rs7937	0.693	rs12973666	ENSG00000268529.1	CYP2T3P	-6.89	9.79e-12	2.11e-09	-0.25	-0.21	Chronic obstructive pulmonary disease;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;	chr19:40783492	chr19:41134722~41137308:+
BRCA	cis	rs4787484	1	rs11344	ENSG00000214725.6	CDIPT-AS1	-6.89	9.79e-12	2.11e-09	-0.26	-0.21	Response to taxane treatment (placlitaxel);	chr16:29899197	chr16:29863593~29868053:+
BRCA	cis	rs755249	0.567	rs2018212	ENSG00000228060.1	RP11-69E11.8	-6.89	9.81e-12	2.12e-09	-0.26	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39439916	chr1:39565160~39573203:+
BRCA	cis	rs755249	0.567	rs4660751	ENSG00000228060.1	RP11-69E11.8	-6.89	9.81e-12	2.12e-09	-0.26	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39440201	chr1:39565160~39573203:+
BRCA	cis	rs67311347	1	rs9849992	ENSG00000280739.1	EIF1B-AS1	6.89	9.82e-12	2.12e-09	0.24	0.21	Renal cell carcinoma;	chr3:40360649	chr3:40173145~40309698:-
BRCA	cis	rs1552244	0.882	rs2030564	ENSG00000180385.7	EMC3-AS1	6.89	9.83e-12	2.12e-09	0.26	0.21	Alzheimer's disease;	chr3:9997360	chr3:9986893~10006990:+
BRCA	cis	rs755249	0.642	rs28788506	ENSG00000237624.1	OXCT2P1	6.89	9.85e-12	2.12e-09	0.27	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39611108	chr1:39514956~39516490:+
BRCA	cis	rs875971	0.964	rs60193905	ENSG00000232559.3	GS1-124K5.12	6.89	9.85e-12	2.12e-09	0.25	0.21	Aortic root size;	chr7:66506273	chr7:66554588~66576923:-
BRCA	cis	rs7247513	1	rs7247513	ENSG00000230310.1	CTD-2192J16.11	-6.89	9.87e-12	2.13e-09	-0.26	-0.21	Bipolar disorder;	chr19:12580371	chr19:12552597~12553644:+
BRCA	cis	rs10754283	0.967	rs7546518	ENSG00000231613.1	RP5-943J3.1	6.89	9.88e-12	2.13e-09	0.24	0.21	Amyotrophic lateral sclerosis (sporadic);	chr1:89644397	chr1:89788914~89790492:+
BRCA	cis	rs2153535	0.585	rs980083	ENSG00000230939.1	RP11-314C16.1	6.89	9.89e-12	2.13e-09	0.24	0.21	Motion sickness;	chr6:8589683	chr6:8784178~8785445:+
BRCA	cis	rs11098499	0.954	rs10006525	ENSG00000249244.1	RP11-548H18.2	6.89	9.91e-12	2.14e-09	0.25	0.21	Corneal astigmatism;	chr4:119487776	chr4:119391831~119395335:-
BRCA	cis	rs16846053	0.515	rs4664047	ENSG00000227403.1	AC009299.3	-6.89	9.92e-12	2.14e-09	-0.35	-0.21	Blood osmolality (transformed sodium);	chr2:161649360	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.515	rs6432699	ENSG00000227403.1	AC009299.3	-6.89	9.92e-12	2.14e-09	-0.35	-0.21	Blood osmolality (transformed sodium);	chr2:161652729	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.515	rs6758760	ENSG00000227403.1	AC009299.3	-6.89	9.92e-12	2.14e-09	-0.35	-0.21	Blood osmolality (transformed sodium);	chr2:161654331	chr2:161244739~161249050:+
BRCA	cis	rs7246657	0.943	rs10415024	ENSG00000267422.1	CTD-2554C21.1	-6.89	9.93e-12	2.14e-09	-0.31	-0.21	Coronary artery calcification;	chr19:37323822	chr19:37779686~37792865:+
BRCA	cis	rs1823913	0.599	rs6736071	ENSG00000280083.1	RP11-317J9.1	6.89	9.95e-12	2.14e-09	0.23	0.21	Obesity-related traits;	chr2:191287265	chr2:191154118~191156070:-
BRCA	cis	rs7688540	0.771	rs10027325	ENSG00000211553.1	AC253576.2	-6.89	9.95e-12	2.15e-09	-0.29	-0.21	Facial morphology (factor 6, height of vermillion lower lip);	chr4:288819	chr4:136461~136568:+
BRCA	cis	rs7688540	0.771	rs1986557	ENSG00000211553.1	AC253576.2	-6.89	9.95e-12	2.15e-09	-0.29	-0.21	Facial morphology (factor 6, height of vermillion lower lip);	chr4:289329	chr4:136461~136568:+
BRCA	cis	rs9291683	0.53	rs4235346	ENSG00000250413.1	RP11-448G15.1	6.89	9.97e-12	2.15e-09	0.27	0.21	Bone mineral density;	chr4:9943672	chr4:10006482~10009725:+
BRCA	cis	rs2348418	0.832	rs11049560	ENSG00000247934.4	RP11-967K21.1	6.88	9.98e-12	2.15e-09	0.23	0.21	Lung function (FEV1);Lung function (FVC);	chr12:28372504	chr12:28163298~28190738:-
BRCA	cis	rs838147	0.507	rs692854	ENSG00000232871.7	SEC1P	6.88	9.99e-12	2.15e-09	0.23	0.21	Dietary macronutrient intake;	chr19:48706207	chr19:48638071~48682245:+
BRCA	cis	rs2810114	0.834	rs36559	ENSG00000269927.1	RP6-91H8.3	6.88	1e-11	2.16e-09	0.27	0.21	Alcohol dependence;	chr14:70888232	chr14:71141125~71143253:-
BRCA	cis	rs9880211	0.613	rs10222451	ENSG00000273486.1	RP11-731C17.2	6.88	1e-11	2.16e-09	0.27	0.21	Height;Body mass index;	chr3:136158571	chr3:136837338~136839021:-
BRCA	cis	rs2638953	0.924	rs11049409	ENSG00000278733.1	RP11-425D17.1	-6.88	1e-11	2.16e-09	-0.26	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28182686	chr12:28185625~28186190:-
BRCA	cis	rs56046484	1	rs2304415	ENSG00000259295.5	CSPG4P12	6.88	1e-11	2.16e-09	0.31	0.21	Testicular germ cell tumor;	chr15:85075610	chr15:85191438~85213905:+
BRCA	cis	rs6740322	1	rs4128209	ENSG00000234936.1	AC010883.5	6.88	1e-11	2.16e-09	0.23	0.21	Coronary artery disease;	chr2:43327590	chr2:43229573~43233394:+
BRCA	cis	rs2337406	1	rs4774172	ENSG00000254174.1	IGHV1-12	6.88	1e-11	2.16e-09	0.22	0.21	Alzheimer's disease (late onset);	chr14:106681320	chr14:106122420~106122709:-
BRCA	cis	rs58873874	0.579	rs3815829	ENSG00000248544.2	CTB-47B11.3	6.88	1.01e-11	2.17e-09	0.43	0.21	Bipolar disorder (body mass index interaction);	chr5:157300684	chr5:157375741~157384950:-
BRCA	cis	rs673078	0.66	rs17619932	ENSG00000275409.1	RP11-131L12.4	-6.88	1.01e-11	2.17e-09	-0.27	-0.21	Glucose homeostasis traits;	chr12:118352228	chr12:118430147~118430699:+
BRCA	cis	rs8114671	0.933	rs2103971	ENSG00000269202.1	RP4-614O4.12	6.88	1.01e-11	2.17e-09	0.21	0.21	Height;	chr20:35198453	chr20:35201747~35203288:-
BRCA	cis	rs13068223	1	rs34111024	ENSG00000243926.1	TIPARP-AS1	6.88	1.01e-11	2.17e-09	0.21	0.21	Age-related hearing impairment (SNP x SNP interaction);	chr3:156748947	chr3:156671862~156674378:-
BRCA	cis	rs755249	0.567	rs3768301	ENSG00000228060.1	RP11-69E11.8	-6.88	1.01e-11	2.17e-09	-0.26	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39405121	chr1:39565160~39573203:+
BRCA	cis	rs7613051	0.947	rs13093698	ENSG00000223899.1	SEC13P1	6.88	1.01e-11	2.17e-09	0.29	0.21	Atopic dermatitis;	chr3:33021558	chr3:33033863~33034810:+
BRCA	cis	rs6543140	0.964	rs918000	ENSG00000234389.1	AC007278.3	6.88	1.01e-11	2.18e-09	0.21	0.21	Blood protein levels;	chr2:102451402	chr2:102438713~102440475:+
BRCA	cis	rs6543140	0.927	rs917999	ENSG00000234389.1	AC007278.3	6.88	1.01e-11	2.18e-09	0.21	0.21	Blood protein levels;	chr2:102451409	chr2:102438713~102440475:+
BRCA	cis	rs17301013	0.507	rs6693198	ENSG00000227373.4	RP11-160H22.5	6.88	1.01e-11	2.18e-09	0.3	0.21	Systemic lupus erythematosus;	chr1:174304301	chr1:174115300~174160004:-
BRCA	cis	rs17213965	0.561	rs11866891	ENSG00000207425.1	Y_RNA	-6.88	1.01e-11	2.18e-09	-0.3	-0.21	Waist-hip ratio;	chr16:15781561	chr16:14915457~14915556:-
BRCA	cis	rs11976180	1	rs2961117	ENSG00000170356.8	OR2A20P	-6.88	1.01e-11	2.18e-09	-0.3	-0.21	Obesity-related traits;	chr7:144058160	chr7:144250045~144252957:-
BRCA	cis	rs17711722	0.701	rs781145	ENSG00000237310.1	GS1-124K5.4	6.88	1.01e-11	2.19e-09	0.22	0.21	Calcium levels;	chr7:65975383	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.862	rs6460282	ENSG00000224316.1	RP11-479O9.2	-6.88	1.01e-11	2.19e-09	-0.21	-0.21	Aortic root size;	chr7:66226259	chr7:65773620~65802067:+
BRCA	cis	rs2014572	0.967	rs8106734	ENSG00000268379.1	CTC-360J11.4	6.88	1.02e-11	2.19e-09	0.25	0.21	Hyperactive-impulsive symptoms;	chr19:57252178	chr19:57175233~57177921:+
BRCA	cis	rs6740322	0.895	rs10166994	ENSG00000234936.1	AC010883.5	6.88	1.02e-11	2.19e-09	0.23	0.21	Coronary artery disease;	chr2:43330838	chr2:43229573~43233394:+
BRCA	cis	rs1322639	0.614	rs7751131	ENSG00000261039.2	RP11-417E7.2	-6.88	1.02e-11	2.19e-09	-0.27	-0.21	Pulse pressure;	chr6:169178615	chr6:169175304~169182740:-
BRCA	cis	rs1322639	0.574	rs9364360	ENSG00000261039.2	RP11-417E7.2	-6.88	1.02e-11	2.19e-09	-0.27	-0.21	Pulse pressure;	chr6:169180079	chr6:169175304~169182740:-
BRCA	cis	rs755249	0.567	rs61779285	ENSG00000228060.1	RP11-69E11.8	-6.88	1.02e-11	2.19e-09	-0.26	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39401383	chr1:39565160~39573203:+
BRCA	cis	rs6969780	0.915	rs4722659	ENSG00000233429.8	HOTAIRM1	-6.88	1.02e-11	2.2e-09	-0.24	-0.21	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27127131	chr7:27095647~27100265:+
BRCA	cis	rs7428	0.545	rs9248	ENSG00000246575.2	AC093162.5	6.88	1.02e-11	2.2e-09	0.22	0.21	Ear protrusion;	chr2:85310189	chr2:85315041~85316529:+
BRCA	cis	rs9880211	0.821	rs9832813	ENSG00000239213.4	NCK1-AS1	6.88	1.02e-11	2.2e-09	0.25	0.21	Height;Body mass index;	chr3:136346723	chr3:136841726~136862054:-
BRCA	cis	rs56046484	1	rs28718705	ENSG00000259295.5	CSPG4P12	6.88	1.02e-11	2.2e-09	0.31	0.21	Testicular germ cell tumor;	chr15:85074579	chr15:85191438~85213905:+
BRCA	cis	rs34779708	0.801	rs12246600	ENSG00000271335.4	RP11-324I22.4	6.88	1.02e-11	2.2e-09	0.22	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35249193	chr10:35314552~35336401:-
BRCA	cis	rs957448	1	rs16916874	ENSG00000253175.1	RP11-267M23.6	6.88	1.02e-11	2.2e-09	0.27	0.21	Nonsyndromic cleft lip with cleft palate;	chr8:94537749	chr8:94565036~94565715:+
BRCA	cis	rs7976269	0.609	rs2117993	ENSG00000257176.2	RP11-996F15.2	-6.88	1.02e-11	2.2e-09	-0.25	-0.21	Male-pattern baldness;	chr12:29060041	chr12:29280418~29317848:-
BRCA	cis	rs780096	0.565	rs11681351	ENSG00000234072.1	AC074117.10	-6.88	1.03e-11	2.21e-09	-0.2	-0.21	Total body bone mineral density;	chr2:27520556	chr2:27356246~27367622:+
BRCA	cis	rs16978956	0.901	rs2424179	ENSG00000236474.1	GCNT1P1	-6.88	1.03e-11	2.21e-09	-0.25	-0.21	Body mass index;	chr20:18362464	chr20:18420160~18421454:-
BRCA	cis	rs2348418	0.832	rs11049559	ENSG00000247934.4	RP11-967K21.1	6.88	1.03e-11	2.21e-09	0.23	0.21	Lung function (FEV1);Lung function (FVC);	chr12:28372264	chr12:28163298~28190738:-
BRCA	cis	rs875971	1	rs778710	ENSG00000232559.3	GS1-124K5.12	6.88	1.03e-11	2.21e-09	0.25	0.21	Aortic root size;	chr7:66389847	chr7:66554588~66576923:-
BRCA	cis	rs858239	0.699	rs858260	ENSG00000230042.1	AK3P3	-6.88	1.03e-11	2.21e-09	-0.24	-0.21	Cerebrospinal fluid biomarker levels;	chr7:23173315	chr7:23129178~23129841:+
BRCA	cis	rs875971	1	rs3735148	ENSG00000232559.3	GS1-124K5.12	6.88	1.03e-11	2.22e-09	0.25	0.21	Aortic root size;	chr7:66506022	chr7:66554588~66576923:-
BRCA	cis	rs7587476	0.784	rs34112702	ENSG00000229267.2	AC072062.1	-6.88	1.03e-11	2.22e-09	-0.28	-0.21	Neuroblastoma;	chr2:214831278	chr2:214810229~214963274:+
BRCA	cis	rs6545883	0.929	rs10173974	ENSG00000271889.1	RP11-493E12.1	6.88	1.03e-11	2.22e-09	0.27	0.21	Tuberculosis;	chr2:61521765	chr2:61151433~61162105:-
BRCA	cis	rs755249	0.567	rs3768302	ENSG00000228060.1	RP11-69E11.8	-6.88	1.03e-11	2.22e-09	-0.26	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39414647	chr1:39565160~39573203:+
BRCA	cis	rs7568498	0.564	rs10490563	ENSG00000235724.7	AC009299.2	6.88	1.03e-11	2.22e-09	0.26	0.21	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);	chr2:161057657	chr2:161222785~161308303:-
BRCA	cis	rs9876781	1	rs6784322	ENSG00000244380.1	RP11-24C3.2	6.88	1.03e-11	2.22e-09	0.24	0.21	Longevity;	chr3:48380745	chr3:48440352~48446656:-
BRCA	cis	rs875971	1	rs778696	ENSG00000232559.3	GS1-124K5.12	6.88	1.03e-11	2.22e-09	0.25	0.21	Aortic root size;	chr7:66405826	chr7:66554588~66576923:-
BRCA	cis	rs875971	1	rs778694	ENSG00000232559.3	GS1-124K5.12	6.88	1.03e-11	2.22e-09	0.25	0.21	Aortic root size;	chr7:66406571	chr7:66554588~66576923:-
BRCA	cis	rs875971	1	rs4718344	ENSG00000232559.3	GS1-124K5.12	6.88	1.03e-11	2.22e-09	0.25	0.21	Aortic root size;	chr7:66409394	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.737	rs7803424	ENSG00000232559.3	GS1-124K5.12	6.88	1.03e-11	2.22e-09	0.25	0.21	Aortic root size;	chr7:66415618	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.83	rs7799834	ENSG00000232559.3	GS1-124K5.12	6.88	1.03e-11	2.22e-09	0.25	0.21	Aortic root size;	chr7:66415707	chr7:66554588~66576923:-
BRCA	cis	rs67981189	0.865	rs2810117	ENSG00000269927.1	RP6-91H8.3	-6.88	1.03e-11	2.23e-09	-0.26	-0.21	Schizophrenia;	chr14:70924308	chr14:71141125~71143253:-
BRCA	cis	rs7809950	0.953	rs2253271	ENSG00000238832.1	snoU109	-6.88	1.04e-11	2.23e-09	-0.27	-0.21	Coronary artery disease;	chr7:107560807	chr7:107603363~107603507:+
BRCA	cis	rs6142102	0.961	rs1883524	ENSG00000275784.1	RP5-1125A11.6	-6.88	1.04e-11	2.24e-09	-0.24	-0.21	Skin pigmentation;	chr20:34038301	chr20:33989480~33991818:-
BRCA	cis	rs7246657	0.943	rs1015849	ENSG00000226686.6	LINC01535	-6.88	1.04e-11	2.24e-09	-0.32	-0.21	Coronary artery calcification;	chr19:37455278	chr19:37251912~37265535:+
BRCA	cis	rs2645424	1	rs7009302	ENSG00000255046.1	RP11-297N6.4	6.88	1.04e-11	2.24e-09	0.25	0.21	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);	chr8:11828472	chr8:11797928~11802568:-
BRCA	cis	rs13113518	0.783	rs1586555	ENSG00000249700.7	SRD5A3-AS1	6.88	1.04e-11	2.24e-09	0.27	0.21	Height;	chr4:55587104	chr4:55363971~55395847:-
BRCA	cis	rs67981189	0.835	rs2526855	ENSG00000269927.1	RP6-91H8.3	-6.88	1.05e-11	2.26e-09	-0.26	-0.21	Schizophrenia;	chr14:70946629	chr14:71141125~71143253:-
BRCA	cis	rs67981189	0.766	rs2526852	ENSG00000269927.1	RP6-91H8.3	-6.88	1.05e-11	2.26e-09	-0.26	-0.21	Schizophrenia;	chr14:70949450	chr14:71141125~71143253:-
BRCA	cis	rs9876781	1	rs898225	ENSG00000244380.1	RP11-24C3.2	-6.88	1.05e-11	2.26e-09	-0.24	-0.21	Longevity;	chr3:48371689	chr3:48440352~48446656:-
BRCA	cis	rs2337406	1	rs4774173	ENSG00000254174.1	IGHV1-12	6.88	1.05e-11	2.26e-09	0.21	0.21	Alzheimer's disease (late onset);	chr14:106682029	chr14:106122420~106122709:-
BRCA	cis	rs6142102	0.961	rs4911390	ENSG00000275784.1	RP5-1125A11.6	-6.88	1.05e-11	2.26e-09	-0.25	-0.21	Skin pigmentation;	chr20:33977401	chr20:33989480~33991818:-
BRCA	cis	rs2072438	0.503	rs4837810	ENSG00000226752.6	PSMD5-AS1	-6.88	1.05e-11	2.26e-09	-0.25	-0.21	Rheumatoid arthritis;	chr9:121118921	chr9:120824828~120854385:+
BRCA	cis	rs7976269	0.609	rs4931142	ENSG00000257176.2	RP11-996F15.2	-6.88	1.05e-11	2.26e-09	-0.25	-0.21	Male-pattern baldness;	chr12:29057877	chr12:29280418~29317848:-
BRCA	cis	rs2408955	0.542	rs7975632	ENSG00000240399.1	RP1-228P16.1	6.88	1.05e-11	2.26e-09	0.25	0.21	Glycated hemoglobin levels;	chr12:48049265	chr12:48054813~48055591:-
BRCA	cis	rs9500256	0.711	rs6588685	ENSG00000215190.7	LINC00680	-6.88	1.05e-11	2.26e-09	-0.25	-0.21	Eosinophilic esophagitis (pediatric);	chr6:57993375	chr6:57946074~57961501:-
BRCA	cis	rs7246657	0.943	rs4969487	ENSG00000226686.6	LINC01535	-6.88	1.05e-11	2.26e-09	-0.32	-0.21	Coronary artery calcification;	chr19:37340137	chr19:37251912~37265535:+
BRCA	cis	rs1707322	0.656	rs3014210	ENSG00000281133.1	AL355480.3	6.88	1.05e-11	2.27e-09	0.26	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45600936	chr1:45580892~45580996:-
BRCA	cis	rs1862618	0.853	rs43184	ENSG00000271828.1	CTD-2310F14.1	6.88	1.06e-11	2.27e-09	0.29	0.21	Initial pursuit acceleration;	chr5:56845950	chr5:56927874~56929573:+
BRCA	cis	rs12922040	0.651	rs35288467	ENSG00000263065.1	AF001548.6	-6.88	1.06e-11	2.27e-09	-0.25	-0.21	Serum uric acid levels in response to allopurinol in gout;	chr16:15773097	chr16:15741151~15741791:+
BRCA	cis	rs1499614	1	rs1267817	ENSG00000232546.1	RP11-458F8.1	-6.88	1.06e-11	2.27e-09	-0.28	-0.21	Gout;	chr7:66645053	chr7:66848496~66858136:+
BRCA	cis	rs61160187	0.549	rs61017995	ENSG00000215032.2	GNL3LP1	6.88	1.06e-11	2.28e-09	0.26	0.21	Educational attainment (years of education);Educational attainment (college completion);	chr5:60968176	chr5:60891935~60893577:-
BRCA	cis	rs10181042	0.565	rs1177233	ENSG00000271889.1	RP11-493E12.1	-6.88	1.06e-11	2.28e-09	-0.26	-0.21	Crohn's disease;	chr2:61034999	chr2:61151433~61162105:-
BRCA	cis	rs1707322	0.827	rs6694302	ENSG00000281133.1	AL355480.3	-6.88	1.06e-11	2.28e-09	-0.27	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45779973	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.827	rs12125508	ENSG00000281133.1	AL355480.3	-6.88	1.06e-11	2.28e-09	-0.27	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45780338	chr1:45580892~45580996:-
BRCA	cis	rs250585	1	rs6497670	ENSG00000260136.4	CTD-2270L9.4	-6.88	1.06e-11	2.28e-09	-0.23	-0.21	Egg allergy;	chr16:23525045	chr16:23452758~23457606:+
BRCA	cis	rs9876781	1	rs3214041	ENSG00000244380.1	RP11-24C3.2	6.88	1.06e-11	2.28e-09	0.24	0.21	Longevity;	chr3:48413059	chr3:48440352~48446656:-
BRCA	cis	rs7085104	0.572	rs284860	ENSG00000236937.2	PTGES3P4	-6.88	1.06e-11	2.29e-09	-0.26	-0.21	Immature fraction of reticulocytes;Schizophrenia;	chr10:102813206	chr10:102845595~102845950:+
BRCA	cis	rs13113518	0.812	rs13140590	ENSG00000249700.7	SRD5A3-AS1	6.88	1.06e-11	2.29e-09	0.27	0.21	Height;	chr4:55548666	chr4:55363971~55395847:-
BRCA	cis	rs944990	0.576	rs10821126	ENSG00000227603.1	RP11-165J3.6	6.88	1.06e-11	2.29e-09	0.21	0.21	Body mass index;	chr9:93436451	chr9:93435332~93437121:-
BRCA	cis	rs10740039	0.81	rs6479720	ENSG00000254271.1	RP11-131N11.4	6.88	1.06e-11	2.29e-09	0.28	0.21	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60610935	chr10:60734342~60741828:+
BRCA	cis	rs8030379	1	rs4842838	ENSG00000230373.7	GOLGA6L5P	6.88	1.07e-11	2.29e-09	0.22	0.21	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83913372	chr15:84507885~84516814:-
BRCA	cis	rs2835345	0.563	rs12482423	ENSG00000230479.1	AP000695.6	6.87	1.07e-11	2.3e-09	0.2	0.21	Pulmonary function;	chr21:36448662	chr21:36430360~36481070:+
BRCA	cis	rs7246657	0.943	rs2126977	ENSG00000276846.1	CTD-3220F14.3	-6.87	1.07e-11	2.3e-09	-0.28	-0.21	Coronary artery calcification;	chr19:37504845	chr19:37314868~37315620:-
BRCA	cis	rs1862618	0.853	rs3099459	ENSG00000271828.1	CTD-2310F14.1	6.87	1.08e-11	2.31e-09	0.29	0.21	Initial pursuit acceleration;	chr5:56841343	chr5:56927874~56929573:+
BRCA	cis	rs61160187	0.549	rs62367879	ENSG00000215032.2	GNL3LP1	6.87	1.08e-11	2.31e-09	0.26	0.21	Educational attainment (years of education);Educational attainment (college completion);	chr5:60996384	chr5:60891935~60893577:-
BRCA	cis	rs875971	0.54	rs1723268	ENSG00000237310.1	GS1-124K5.4	6.87	1.08e-11	2.31e-09	0.22	0.21	Aortic root size;	chr7:66008093	chr7:66493706~66495474:+
BRCA	cis	rs301901	0.897	rs12657771	ENSG00000250155.1	CTD-2353F22.1	-6.87	1.08e-11	2.31e-09	-0.22	-0.21	Height;	chr5:36787860	chr5:36666214~36725195:-
BRCA	cis	rs2835345	0.563	rs73204244	ENSG00000230479.1	AP000695.6	6.87	1.08e-11	2.32e-09	0.2	0.21	Pulmonary function;	chr21:36452373	chr21:36430360~36481070:+
BRCA	cis	rs8030379	1	rs1480823	ENSG00000230373.7	GOLGA6L5P	-6.87	1.08e-11	2.32e-09	-0.22	-0.21	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83916994	chr15:84507885~84516814:-
BRCA	cis	rs9368481	0.546	rs12664610	ENSG00000241549.7	GUSBP2	6.87	1.08e-11	2.32e-09	0.24	0.21	Autism spectrum disorder or schizophrenia;	chr6:26917252	chr6:26871484~26956554:-
BRCA	cis	rs1552244	0.808	rs7615088	ENSG00000180385.7	EMC3-AS1	6.87	1.08e-11	2.33e-09	0.26	0.21	Alzheimer's disease;	chr3:9994212	chr3:9986893~10006990:+
BRCA	cis	rs1552244	0.882	rs61429272	ENSG00000180385.7	EMC3-AS1	6.87	1.08e-11	2.33e-09	0.26	0.21	Alzheimer's disease;	chr3:9995636	chr3:9986893~10006990:+
BRCA	cis	rs1552244	0.882	rs9757159	ENSG00000180385.7	EMC3-AS1	6.87	1.08e-11	2.33e-09	0.26	0.21	Alzheimer's disease;	chr3:9997482	chr3:9986893~10006990:+
BRCA	cis	rs1552244	0.816	rs17050701	ENSG00000180385.7	EMC3-AS1	6.87	1.08e-11	2.33e-09	0.26	0.21	Alzheimer's disease;	chr3:9999870	chr3:9986893~10006990:+
BRCA	cis	rs1552244	0.882	rs55840655	ENSG00000180385.7	EMC3-AS1	6.87	1.08e-11	2.33e-09	0.26	0.21	Alzheimer's disease;	chr3:10001006	chr3:9986893~10006990:+
BRCA	cis	rs1552244	0.816	rs56387520	ENSG00000180385.7	EMC3-AS1	6.87	1.08e-11	2.33e-09	0.26	0.21	Alzheimer's disease;	chr3:10001098	chr3:9986893~10006990:+
BRCA	cis	rs1552244	0.882	rs56224841	ENSG00000180385.7	EMC3-AS1	6.87	1.08e-11	2.33e-09	0.26	0.21	Alzheimer's disease;	chr3:10002330	chr3:9986893~10006990:+
BRCA	cis	rs116139393	0.54	rs12539942	ENSG00000187953.9	PMS2CL	-6.87	1.08e-11	2.33e-09	-0.28	-0.21	Alzheimer's disease (APOE e4 interaction);	chr7:6736954	chr7:6710128~6753862:+
BRCA	cis	rs6969780	0.915	rs3801320	ENSG00000233429.8	HOTAIRM1	6.87	1.08e-11	2.33e-09	0.24	0.21	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27124745	chr7:27095647~27100265:+
BRCA	cis	rs1707322	0.963	rs12145287	ENSG00000281133.1	AL355480.3	-6.87	1.08e-11	2.33e-09	-0.27	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45859330	chr1:45580892~45580996:-
BRCA	cis	rs6844153	1	rs80197589	ENSG00000240005.4	RP11-293A21.1	-6.87	1.08e-11	2.33e-09	-0.31	-0.21	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26887030	chr4:26859806~26860599:-
BRCA	cis	rs875971	0.545	rs6979636	ENSG00000273024.4	INTS4P2	-6.87	1.09e-11	2.33e-09	-0.26	-0.21	Aortic root size;	chr7:66276638	chr7:65647864~65715661:+
BRCA	cis	rs42490	1	rs13279023	ENSG00000251136.7	RP11-37B2.1	-6.87	1.09e-11	2.33e-09	-0.2	-0.21	Leprosy;	chr8:89748816	chr8:89609409~89757727:-
BRCA	cis	rs12291225	0.679	rs11238	ENSG00000251991.1	RNU7-49P	-6.87	1.09e-11	2.34e-09	-0.24	-0.21	Sense of smell;	chr11:14266582	chr11:14478892~14478953:+
BRCA	cis	rs9307551	0.817	rs2903640	ENSG00000250334.4	LINC00989	-6.87	1.09e-11	2.34e-09	-0.28	-0.21	Refractive error;	chr4:79610171	chr4:79492416~79576460:+
BRCA	cis	rs2919009	0.537	rs11199650	ENSG00000271670.1	RP11-95I16.4	6.87	1.09e-11	2.34e-09	0.25	0.21	Obesity-related traits;	chr10:120923297	chr10:120879256~120880667:-
BRCA	cis	rs1707322	0.721	rs10890343	ENSG00000281133.1	AL355480.3	-6.87	1.09e-11	2.34e-09	-0.27	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692250	chr1:45580892~45580996:-
BRCA	cis	rs875971	0.505	rs2462573	ENSG00000237310.1	GS1-124K5.4	-6.87	1.09e-11	2.35e-09	-0.22	-0.21	Aortic root size;	chr7:66042405	chr7:66493706~66495474:+
BRCA	cis	rs1707322	0.964	rs7512395	ENSG00000281133.1	AL355480.3	-6.87	1.1e-11	2.35e-09	-0.27	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45895505	chr1:45580892~45580996:-
BRCA	cis	rs1823913	0.637	rs2883912	ENSG00000280083.1	RP11-317J9.1	6.87	1.1e-11	2.36e-09	0.23	0.21	Obesity-related traits;	chr2:191284290	chr2:191154118~191156070:-
BRCA	cis	rs6163	0.727	rs284862	ENSG00000236937.2	PTGES3P4	-6.87	1.1e-11	2.36e-09	-0.27	-0.21	Waist circumference;Hip circumference;	chr10:102812324	chr10:102845595~102845950:+
BRCA	cis	rs7617773	0.817	rs13068265	ENSG00000228638.1	FCF1P2	-6.87	1.1e-11	2.36e-09	-0.23	-0.21	Coronary artery disease;	chr3:48260124	chr3:48290793~48291375:-
BRCA	cis	rs801193	1	rs2707856	ENSG00000236529.1	RP13-254B10.1	6.87	1.1e-11	2.36e-09	0.22	0.21	Aortic root size;	chr7:66746023	chr7:65840212~65840596:+
BRCA	cis	rs9649213	0.593	rs1076272	ENSG00000272950.1	RP11-307C18.1	6.87	1.1e-11	2.37e-09	0.27	0.21	Prostate cancer (SNP x SNP interaction);	chr7:98401693	chr7:98322853~98323430:+
BRCA	cis	rs67981189	0.896	rs2526882	ENSG00000269927.1	RP6-91H8.3	-6.87	1.1e-11	2.37e-09	-0.26	-0.21	Schizophrenia;	chr14:70907985	chr14:71141125~71143253:-
BRCA	cis	rs7617773	0.817	rs3731513	ENSG00000228638.1	FCF1P2	-6.87	1.1e-11	2.37e-09	-0.24	-0.21	Coronary artery disease;	chr3:48178047	chr3:48290793~48291375:-
BRCA	cis	rs67981189	0.865	rs2189806	ENSG00000269927.1	RP6-91H8.3	-6.87	1.11e-11	2.37e-09	-0.26	-0.21	Schizophrenia;	chr14:70921681	chr14:71141125~71143253:-
BRCA	cis	rs2243480	1	rs4718315	ENSG00000230295.1	RP11-458F8.2	6.87	1.11e-11	2.37e-09	0.28	0.21	Diabetic kidney disease;	chr7:66183554	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs4718316	ENSG00000230295.1	RP11-458F8.2	6.87	1.11e-11	2.37e-09	0.28	0.21	Diabetic kidney disease;	chr7:66183744	chr7:66880708~66882981:+
BRCA	cis	rs911555	0.723	rs6575982	ENSG00000244691.1	RPL10AP1	6.87	1.11e-11	2.37e-09	0.26	0.21	Intelligence (multi-trait analysis);	chr14:103396344	chr14:103412119~103412761:-
BRCA	cis	rs4713118	0.866	rs9468217	ENSG00000220721.1	OR1F12	6.87	1.11e-11	2.38e-09	0.27	0.21	Parkinson's disease;	chr6:27758688	chr6:28073316~28074233:+
BRCA	cis	rs4713118	0.911	rs9295746	ENSG00000220721.1	OR1F12	6.87	1.11e-11	2.38e-09	0.27	0.21	Parkinson's disease;	chr6:27762285	chr6:28073316~28074233:+
BRCA	cis	rs2243480	0.908	rs2460431	ENSG00000230295.1	RP11-458F8.2	6.87	1.11e-11	2.38e-09	0.28	0.21	Diabetic kidney disease;	chr7:66157859	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs4718309	ENSG00000230295.1	RP11-458F8.2	6.87	1.11e-11	2.38e-09	0.28	0.21	Diabetic kidney disease;	chr7:66162777	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs6460274	ENSG00000230295.1	RP11-458F8.2	6.87	1.11e-11	2.38e-09	0.28	0.21	Diabetic kidney disease;	chr7:66163497	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs7787230	ENSG00000230295.1	RP11-458F8.2	6.87	1.11e-11	2.38e-09	0.28	0.21	Diabetic kidney disease;	chr7:66164112	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs2465120	ENSG00000230295.1	RP11-458F8.2	-6.87	1.11e-11	2.38e-09	-0.28	-0.21	Diabetic kidney disease;	chr7:66155987	chr7:66880708~66882981:+
BRCA	cis	rs6142102	0.961	rs909884	ENSG00000275784.1	RP5-1125A11.6	-6.87	1.11e-11	2.38e-09	-0.25	-0.21	Skin pigmentation;	chr20:34058257	chr20:33989480~33991818:-
BRCA	cis	rs17301013	0.507	rs10912763	ENSG00000227373.4	RP11-160H22.5	6.87	1.11e-11	2.38e-09	0.3	0.21	Systemic lupus erythematosus;	chr1:174316083	chr1:174115300~174160004:-
BRCA	cis	rs17301013	0.507	rs10912764	ENSG00000227373.4	RP11-160H22.5	6.87	1.11e-11	2.38e-09	0.3	0.21	Systemic lupus erythematosus;	chr1:174316085	chr1:174115300~174160004:-
BRCA	cis	rs17301013	0.507	rs10912765	ENSG00000227373.4	RP11-160H22.5	6.87	1.11e-11	2.38e-09	0.3	0.21	Systemic lupus erythematosus;	chr1:174322812	chr1:174115300~174160004:-
BRCA	cis	rs2998286	0.862	rs2807732	ENSG00000254635.4	WAC-AS1	-6.87	1.12e-11	2.39e-09	-0.28	-0.21	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28520318	chr10:28522652~28532743:-
BRCA	cis	rs755249	0.762	rs1775654	ENSG00000228060.1	RP11-69E11.8	-6.87	1.12e-11	2.4e-09	-0.23	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39484408	chr1:39565160~39573203:+
BRCA	cis	rs6840360	0.642	rs2709842	ENSG00000270265.1	RP11-731D1.4	6.87	1.12e-11	2.41e-09	0.23	0.21	Intelligence (multi-trait analysis);	chr4:151449485	chr4:151333775~151353224:-
BRCA	cis	rs9549367	0.789	rs8001506	ENSG00000269125.1	RP11-98F14.11	-6.87	1.12e-11	2.41e-09	-0.27	-0.21	Platelet distribution width;	chr13:113212839	chr13:113165002~113165183:-
BRCA	cis	rs4072705	1	rs10986391	ENSG00000224020.1	MIR181A2HG	-6.87	1.12e-11	2.41e-09	-0.22	-0.21	Menarche (age at onset);	chr9:124665956	chr9:124658467~124698631:+
BRCA	cis	rs919433	0.963	rs4850429	ENSG00000231621.1	AC013264.2	-6.87	1.13e-11	2.41e-09	-0.21	-0.21	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197313685	chr2:197197991~197199273:+
BRCA	cis	rs9291683	0.588	rs12507330	ENSG00000250413.1	RP11-448G15.1	-6.87	1.13e-11	2.42e-09	-0.27	-0.21	Bone mineral density;	chr4:10000571	chr4:10006482~10009725:+
BRCA	cis	rs858239	0.932	rs1728313	ENSG00000230042.1	AK3P3	-6.87	1.13e-11	2.42e-09	-0.24	-0.21	Cerebrospinal fluid biomarker levels;	chr7:23231412	chr7:23129178~23129841:+
BRCA	cis	rs2976388	0.647	rs2082801	ENSG00000253741.1	CTD-2292P10.4	-6.87	1.13e-11	2.42e-09	-0.23	-0.21	Urinary tract infection frequency;	chr8:142705043	chr8:142702252~142726973:-
BRCA	cis	rs2842992	0.789	rs4235925	ENSG00000237927.1	RP3-393E18.2	-6.87	1.13e-11	2.42e-09	-0.3	-0.21	Age-related macular degeneration (geographic atrophy);	chr6:159781828	chr6:159586955~159589169:-
BRCA	cis	rs1322639	0.657	rs9355135	ENSG00000261039.2	RP11-417E7.2	-6.87	1.13e-11	2.43e-09	-0.28	-0.21	Pulse pressure;	chr6:169172911	chr6:169175304~169182740:-
BRCA	cis	rs42490	1	rs13252013	ENSG00000251136.7	RP11-37B2.1	-6.87	1.13e-11	2.43e-09	-0.2	-0.21	Leprosy;	chr8:89746881	chr8:89609409~89757727:-
BRCA	cis	rs9880211	0.718	rs56398805	ENSG00000273486.1	RP11-731C17.2	6.87	1.14e-11	2.44e-09	0.26	0.21	Height;Body mass index;	chr3:136213558	chr3:136837338~136839021:-
BRCA	cis	rs61270009	0.955	rs454830	ENSG00000247828.6	TMEM161B-AS1	-6.87	1.14e-11	2.44e-09	-0.28	-0.21	Depressive symptoms;	chr5:88254678	chr5:88268895~88436685:+
BRCA	cis	rs10515750	0.588	rs10077326	ENSG00000251405.2	CTB-109A12.1	6.87	1.14e-11	2.44e-09	0.32	0.21	Lung function (FEV1/FVC);	chr5:157343761	chr5:157362615~157460078:-
BRCA	cis	rs10515750	0.588	rs10077470	ENSG00000251405.2	CTB-109A12.1	6.87	1.14e-11	2.44e-09	0.32	0.21	Lung function (FEV1/FVC);	chr5:157343975	chr5:157362615~157460078:-
BRCA	cis	rs8114671	0.967	rs6142320	ENSG00000269202.1	RP4-614O4.12	6.87	1.14e-11	2.44e-09	0.22	0.21	Height;	chr20:35200390	chr20:35201747~35203288:-
BRCA	cis	rs8114671	0.967	rs6142321	ENSG00000269202.1	RP4-614O4.12	6.87	1.14e-11	2.44e-09	0.22	0.21	Height;	chr20:35200671	chr20:35201747~35203288:-
BRCA	cis	rs9867325	0.778	rs9877089	ENSG00000239213.4	NCK1-AS1	6.86	1.14e-11	2.45e-09	0.31	0.21	Body mass index;	chr3:136937751	chr3:136841726~136862054:-
BRCA	cis	rs3814244	0.528	rs2906854	ENSG00000236946.2	HNRNPA1P70	6.86	1.14e-11	2.45e-09	0.17	0.21	Itch intensity from mosquito bite adjusted by bite size;	chr12:67993566	chr12:68035767~68036853:+
BRCA	cis	rs588177	0.613	rs3782101	ENSG00000236935.1	AP003774.1	-6.86	1.14e-11	2.45e-09	-0.2	-0.21	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;	chr11:64363808	chr11:64325050~64329504:-
BRCA	cis	rs1823913	0.637	rs921737	ENSG00000280083.1	RP11-317J9.1	6.86	1.15e-11	2.46e-09	0.23	0.21	Obesity-related traits;	chr2:191286097	chr2:191154118~191156070:-
BRCA	cis	rs2014572	0.967	rs10413037	ENSG00000268379.1	CTC-360J11.4	6.86	1.15e-11	2.46e-09	0.25	0.21	Hyperactive-impulsive symptoms;	chr19:57260515	chr19:57175233~57177921:+
BRCA	cis	rs755249	0.669	rs4660311	ENSG00000237624.1	OXCT2P1	6.86	1.15e-11	2.47e-09	0.27	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39613442	chr1:39514956~39516490:+
BRCA	cis	rs2243480	1	rs6964245	ENSG00000232546.1	RP11-458F8.1	6.86	1.15e-11	2.47e-09	0.27	0.21	Diabetic kidney disease;	chr7:66253730	chr7:66848496~66858136:+
BRCA	cis	rs755249	0.567	rs16825939	ENSG00000228060.1	RP11-69E11.8	-6.86	1.15e-11	2.47e-09	-0.25	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39196836	chr1:39565160~39573203:+
BRCA	cis	rs755249	0.567	rs16825942	ENSG00000228060.1	RP11-69E11.8	-6.86	1.15e-11	2.47e-09	-0.25	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39196946	chr1:39565160~39573203:+
BRCA	cis	rs755249	0.567	rs67020650	ENSG00000228060.1	RP11-69E11.8	-6.86	1.15e-11	2.47e-09	-0.25	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39202343	chr1:39565160~39573203:+
BRCA	cis	rs755249	0.567	rs72661925	ENSG00000228060.1	RP11-69E11.8	-6.86	1.15e-11	2.47e-09	-0.25	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39203865	chr1:39565160~39573203:+
BRCA	cis	rs755249	0.567	rs72661927	ENSG00000228060.1	RP11-69E11.8	-6.86	1.15e-11	2.47e-09	-0.25	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39209650	chr1:39565160~39573203:+
BRCA	cis	rs67981189	0.892	rs221899	ENSG00000269927.1	RP6-91H8.3	6.86	1.15e-11	2.47e-09	0.26	0.21	Schizophrenia;	chr14:71138551	chr14:71141125~71143253:-
BRCA	cis	rs12935418	0.83	rs12928638	ENSG00000261061.1	RP11-303E16.2	-6.86	1.16e-11	2.47e-09	-0.23	-0.21	Mean corpuscular volume;	chr16:81016195	chr16:81030770~81031485:+
BRCA	cis	rs8030379	1	rs4842924	ENSG00000230373.7	GOLGA6L5P	6.86	1.16e-11	2.48e-09	0.22	0.21	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83918855	chr15:84507885~84516814:-
BRCA	cis	rs9880211	0.8	rs28390205	ENSG00000273486.1	RP11-731C17.2	6.86	1.16e-11	2.48e-09	0.28	0.21	Height;Body mass index;	chr3:136646008	chr3:136837338~136839021:-
BRCA	cis	rs11157436	0.56	rs11623957	ENSG00000211812.1	TRAV26-2	-6.86	1.16e-11	2.48e-09	-0.17	-0.21	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22224735	chr14:22202583~22203368:+
BRCA	cis	rs655720	1	rs655720	ENSG00000239213.4	NCK1-AS1	6.86	1.16e-11	2.48e-09	0.24	0.21	Coronary artery disease;	chr3:136384425	chr3:136841726~136862054:-
BRCA	cis	rs9291683	0.588	rs34501273	ENSG00000250413.1	RP11-448G15.1	-6.86	1.16e-11	2.48e-09	-0.26	-0.21	Bone mineral density;	chr4:9995372	chr4:10006482~10009725:+
BRCA	cis	rs7568498	0.564	rs9287807	ENSG00000235724.7	AC009299.2	6.86	1.16e-11	2.48e-09	0.26	0.21	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);	chr2:161058850	chr2:161222785~161308303:-
BRCA	cis	rs61160187	0.556	rs62367862	ENSG00000215032.2	GNL3LP1	6.86	1.16e-11	2.48e-09	0.26	0.21	Educational attainment (years of education);Educational attainment (college completion);	chr5:60973134	chr5:60891935~60893577:-
BRCA	cis	rs7246657	0.943	rs2303131	ENSG00000226686.6	LINC01535	-6.86	1.16e-11	2.48e-09	-0.32	-0.21	Coronary artery calcification;	chr19:37445123	chr19:37251912~37265535:+
BRCA	cis	rs4713118	0.955	rs9468206	ENSG00000220721.1	OR1F12	6.86	1.16e-11	2.48e-09	0.26	0.21	Parkinson's disease;	chr6:27722674	chr6:28073316~28074233:+
BRCA	cis	rs74233809	0.901	rs11191416	ENSG00000213277.3	MARCKSL1P1	-6.86	1.16e-11	2.49e-09	-0.37	-0.21	Birth weight;	chr10:102845159	chr10:103175554~103176094:+
BRCA	cis	rs1862618	0.853	rs190414	ENSG00000271828.1	CTD-2310F14.1	6.86	1.16e-11	2.49e-09	0.29	0.21	Initial pursuit acceleration;	chr5:56820945	chr5:56927874~56929573:+
BRCA	cis	rs2880765	0.743	rs4551990	ENSG00000259295.5	CSPG4P12	6.86	1.16e-11	2.49e-09	0.26	0.21	Coronary artery disease;	chr15:85472056	chr15:85191438~85213905:+
BRCA	cis	rs858239	0.602	rs6953996	ENSG00000230042.1	AK3P3	-6.86	1.16e-11	2.49e-09	-0.24	-0.21	Cerebrospinal fluid biomarker levels;	chr7:23136327	chr7:23129178~23129841:+
BRCA	cis	rs7246657	0.882	rs59224125	ENSG00000276846.1	CTD-3220F14.3	6.86	1.16e-11	2.49e-09	0.27	0.21	Coronary artery calcification;	chr19:37472303	chr19:37314868~37315620:-
BRCA	cis	rs73173548	0.502	rs12659818	ENSG00000247828.6	TMEM161B-AS1	6.86	1.16e-11	2.49e-09	0.29	0.21	Macular telangiectasia type 2;	chr5:88451964	chr5:88268895~88436685:+
BRCA	cis	rs2599510	0.934	rs2710634	ENSG00000276334.1	AL133243.1	6.86	1.17e-11	2.5e-09	0.26	0.21	Interleukin-18 levels;	chr2:32583737	chr2:32521927~32523547:+
BRCA	cis	rs875971	0.505	rs1167385	ENSG00000237310.1	GS1-124K5.4	-6.86	1.17e-11	2.5e-09	-0.22	-0.21	Aortic root size;	chr7:66048321	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.545	rs316316	ENSG00000236529.1	RP13-254B10.1	-6.86	1.17e-11	2.5e-09	-0.25	-0.21	Aortic root size;	chr7:66149270	chr7:65840212~65840596:+
BRCA	cis	rs9402682	0.629	rs6924609	ENSG00000232876.1	CTA-212D2.2	6.86	1.17e-11	2.5e-09	0.28	0.21	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr6:135119519	chr6:135055033~135060550:+
BRCA	cis	rs8072100	0.79	rs1962307	ENSG00000228782.6	CTD-2026D20.3	6.86	1.18e-11	2.51e-09	0.23	0.21	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47630505	chr17:47450568~47492492:-
BRCA	cis	rs9368481	0.547	rs2093303	ENSG00000241549.7	GUSBP2	6.86	1.18e-11	2.52e-09	0.23	0.21	Autism spectrum disorder or schizophrenia;	chr6:26896627	chr6:26871484~26956554:-
BRCA	cis	rs860818	1	rs1728327	ENSG00000226816.2	AC005082.12	6.86	1.18e-11	2.52e-09	0.49	0.21	Initial pursuit acceleration;	chr7:23195864	chr7:23206013~23208045:+
BRCA	cis	rs860818	1	rs1637214	ENSG00000226816.2	AC005082.12	6.86	1.18e-11	2.52e-09	0.49	0.21	Initial pursuit acceleration;	chr7:23197223	chr7:23206013~23208045:+
BRCA	cis	rs2243480	1	rs6974723	ENSG00000230295.1	RP11-458F8.2	6.86	1.18e-11	2.52e-09	0.27	0.21	Diabetic kidney disease;	chr7:66172952	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs9769882	ENSG00000230295.1	RP11-458F8.2	6.86	1.18e-11	2.52e-09	0.27	0.21	Diabetic kidney disease;	chr7:66177938	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs6966322	ENSG00000230295.1	RP11-458F8.2	6.86	1.18e-11	2.52e-09	0.27	0.21	Diabetic kidney disease;	chr7:66181767	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs4145008	ENSG00000230295.1	RP11-458F8.2	6.86	1.18e-11	2.52e-09	0.27	0.21	Diabetic kidney disease;	chr7:66182524	chr7:66880708~66882981:+
BRCA	cis	rs1020064	0.636	rs1529975	ENSG00000235319.1	AC012360.4	-6.86	1.18e-11	2.52e-09	-0.27	-0.21	AIDS;	chr2:105313444	chr2:105324210~105330529:+
BRCA	cis	rs875971	0.862	rs6952182	ENSG00000224316.1	RP11-479O9.2	-6.86	1.18e-11	2.53e-09	-0.21	-0.21	Aortic root size;	chr7:66218330	chr7:65773620~65802067:+
BRCA	cis	rs10029851	0.627	rs17512211	ENSG00000234492.4	RPL34-AS1	6.86	1.19e-11	2.54e-09	0.33	0.21	Amyotrophic lateral sclerosis (sporadic);	chr4:108607724	chr4:108538190~108620460:-
BRCA	cis	rs875971	0.545	rs73378304	ENSG00000236529.1	RP13-254B10.1	6.86	1.19e-11	2.54e-09	0.25	0.21	Aortic root size;	chr7:66175760	chr7:65840212~65840596:+
BRCA	cis	rs73173548	0.502	rs10942532	ENSG00000247828.6	TMEM161B-AS1	6.86	1.19e-11	2.55e-09	0.29	0.21	Macular telangiectasia type 2;	chr5:88462015	chr5:88268895~88436685:+
BRCA	cis	rs7976269	0.609	rs7310276	ENSG00000257176.2	RP11-996F15.2	6.86	1.19e-11	2.55e-09	0.25	0.21	Male-pattern baldness;	chr12:29054128	chr12:29280418~29317848:-
BRCA	cis	rs9291683	0.588	rs2240724	ENSG00000250413.1	RP11-448G15.1	-6.86	1.2e-11	2.55e-09	-0.27	-0.21	Bone mineral density;	chr4:10019666	chr4:10006482~10009725:+
BRCA	cis	rs2014572	0.967	rs10421632	ENSG00000268379.1	CTC-360J11.4	6.86	1.2e-11	2.55e-09	0.25	0.21	Hyperactive-impulsive symptoms;	chr19:57253402	chr19:57175233~57177921:+
BRCA	cis	rs7246657	0.943	rs9917081	ENSG00000226686.6	LINC01535	-6.86	1.2e-11	2.56e-09	-0.32	-0.21	Coronary artery calcification;	chr19:37385714	chr19:37251912~37265535:+
BRCA	cis	rs11096990	0.855	rs2711988	ENSG00000249207.1	RP11-360F5.1	6.86	1.2e-11	2.56e-09	0.24	0.21	Cognitive function;	chr4:39151128	chr4:39112677~39126818:-
BRCA	cis	rs4845875	0.626	rs6540999	ENSG00000242349.4	NPPA-AS1	6.86	1.2e-11	2.56e-09	0.23	0.21	Midregional pro atrial natriuretic peptide levels;	chr1:11773309	chr1:11841017~11848079:+
BRCA	cis	rs919433	0.854	rs13013049	ENSG00000231621.1	AC013264.2	6.86	1.2e-11	2.56e-09	0.21	0.21	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197343940	chr2:197197991~197199273:+
BRCA	cis	rs6603134	0.502	rs6603133	ENSG00000267939.1	CTD-2325M2.1	-6.86	1.2e-11	2.56e-09	-0.25	-0.21	Blood protein levels;	chr19:8038352	chr19:8008729~8016025:+
BRCA	cis	rs11098499	0.954	rs10017371	ENSG00000249244.1	RP11-548H18.2	6.86	1.2e-11	2.56e-09	0.25	0.21	Corneal astigmatism;	chr4:119372621	chr4:119391831~119395335:-
BRCA	cis	rs875971	0.929	rs778712	ENSG00000232559.3	GS1-124K5.12	6.86	1.2e-11	2.56e-09	0.25	0.21	Aortic root size;	chr7:66384991	chr7:66554588~66576923:-
BRCA	cis	rs7911264	0.507	rs2901597	ENSG00000236493.2	EIF2S2P3	6.86	1.2e-11	2.56e-09	0.28	0.21	Inflammatory bowel disease;	chr10:92582906	chr10:92668745~92669743:-
BRCA	cis	rs12655019	0.92	rs7725377	ENSG00000271828.1	CTD-2310F14.1	-6.86	1.2e-11	2.57e-09	-0.34	-0.21	Breast cancer (early onset);	chr5:56960769	chr5:56927874~56929573:+
BRCA	cis	rs804292	0.695	rs804279	ENSG00000255046.1	RP11-297N6.4	6.86	1.2e-11	2.57e-09	0.26	0.21	Nicotine use;Alcohol dependence;	chr8:11766380	chr8:11797928~11802568:-
BRCA	cis	rs2599510	0.783	rs2710626	ENSG00000276334.1	AL133243.1	6.86	1.2e-11	2.57e-09	0.25	0.21	Interleukin-18 levels;	chr2:32533687	chr2:32521927~32523547:+
BRCA	cis	rs2412819	0.571	rs7174260	ENSG00000205771.5	CATSPER2P1	-6.86	1.2e-11	2.57e-09	-0.33	-0.21	Lung cancer;	chr15:43751988	chr15:43726918~43747094:-
BRCA	cis	rs6840360	0.642	rs2709816	ENSG00000270265.1	RP11-731D1.4	-6.86	1.21e-11	2.58e-09	-0.23	-0.21	Intelligence (multi-trait analysis);	chr4:151459117	chr4:151333775~151353224:-
BRCA	cis	rs6142102	0.924	rs6059662	ENSG00000275784.1	RP5-1125A11.6	6.86	1.21e-11	2.59e-09	0.26	0.21	Skin pigmentation;	chr20:34087921	chr20:33989480~33991818:-
BRCA	cis	rs7976269	0.609	rs4402335	ENSG00000257176.2	RP11-996F15.2	-6.86	1.21e-11	2.59e-09	-0.25	-0.21	Male-pattern baldness;	chr12:29052836	chr12:29280418~29317848:-
BRCA	cis	rs7085104	0.572	rs284860	ENSG00000213061.2	PFN1P11	-6.86	1.22e-11	2.59e-09	-0.27	-0.21	Immature fraction of reticulocytes;Schizophrenia;	chr10:102813206	chr10:102838011~102845473:-
BRCA	cis	rs2060793	0.539	rs962025	ENSG00000251991.1	RNU7-49P	6.86	1.22e-11	2.59e-09	0.22	0.21	Vitamin D levels;	chr11:14618744	chr11:14478892~14478953:+
BRCA	cis	rs375066	0.762	rs171238	ENSG00000267058.1	RP11-15A1.3	-6.86	1.22e-11	2.6e-09	-0.24	-0.21	Breast cancer;	chr19:43875402	chr19:43891804~43901805:-
BRCA	cis	rs13113518	0.812	rs4865003	ENSG00000249700.7	SRD5A3-AS1	6.86	1.22e-11	2.6e-09	0.26	0.21	Height;	chr4:55514802	chr4:55363971~55395847:-
BRCA	cis	rs13113518	0.756	rs12510275	ENSG00000249700.7	SRD5A3-AS1	6.86	1.22e-11	2.6e-09	0.26	0.21	Height;	chr4:55516548	chr4:55363971~55395847:-
BRCA	cis	rs13113518	0.812	rs12510327	ENSG00000249700.7	SRD5A3-AS1	6.86	1.22e-11	2.6e-09	0.26	0.21	Height;	chr4:55516744	chr4:55363971~55395847:-
BRCA	cis	rs2998286	0.666	rs2491251	ENSG00000254635.4	WAC-AS1	-6.86	1.22e-11	2.6e-09	-0.28	-0.21	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28525363	chr10:28522652~28532743:-
BRCA	cis	rs6844153	1	rs57663175	ENSG00000240005.4	RP11-293A21.1	-6.86	1.22e-11	2.6e-09	-0.31	-0.21	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26917770	chr4:26859806~26860599:-
BRCA	cis	rs2599510	0.783	rs13399071	ENSG00000276334.1	AL133243.1	6.85	1.22e-11	2.6e-09	0.26	0.21	Interleukin-18 levels;	chr2:32568716	chr2:32521927~32523547:+
BRCA	cis	rs7976269	0.609	rs4931141	ENSG00000257176.2	RP11-996F15.2	-6.85	1.22e-11	2.61e-09	-0.24	-0.21	Male-pattern baldness;	chr12:29057763	chr12:29280418~29317848:-
BRCA	cis	rs66887589	0.616	rs10032299	ENSG00000248280.1	RP11-33B1.2	6.85	1.22e-11	2.61e-09	0.2	0.21	Diastolic blood pressure;	chr4:119285264	chr4:119440561~119450157:-
BRCA	cis	rs67311347	1	rs11715214	ENSG00000280739.1	EIF1B-AS1	6.85	1.22e-11	2.61e-09	0.23	0.21	Renal cell carcinoma;	chr3:40361513	chr3:40173145~40309698:-
BRCA	cis	rs13217239	0.646	rs7768407	ENSG00000241549.7	GUSBP2	6.85	1.22e-11	2.61e-09	0.23	0.21	Schizophrenia;	chr6:27049016	chr6:26871484~26956554:-
BRCA	cis	rs875971	0.505	rs1167386	ENSG00000237310.1	GS1-124K5.4	-6.85	1.22e-11	2.61e-09	-0.22	-0.21	Aortic root size;	chr7:66048109	chr7:66493706~66495474:+
BRCA	cis	rs2243480	0.711	rs2460426	ENSG00000230295.1	RP11-458F8.2	6.85	1.22e-11	2.61e-09	0.28	0.21	Diabetic kidney disease;	chr7:66158142	chr7:66880708~66882981:+
BRCA	cis	rs9309473	1	rs6711033	ENSG00000163016.8	ALMS1P	6.85	1.23e-11	2.62e-09	0.26	0.21	Metabolite levels;	chr2:73519516	chr2:73644919~73685576:+
BRCA	cis	rs8062405	0.54	rs151226	ENSG00000251417.2	RP11-1348G14.4	-6.85	1.23e-11	2.62e-09	-0.23	-0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28538502	chr16:28802743~28817828:+
BRCA	cis	rs7176527	0.784	rs62021162	ENSG00000229212.6	RP11-561C5.4	6.85	1.23e-11	2.62e-09	0.3	0.21	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84565602	chr15:85205440~85234795:-
BRCA	cis	rs8062405	0.755	rs17707300	ENSG00000251417.2	RP11-1348G14.4	-6.85	1.23e-11	2.63e-09	-0.24	-0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28582026	chr16:28802743~28817828:+
BRCA	cis	rs67981189	0.865	rs2810071	ENSG00000269927.1	RP6-91H8.3	-6.85	1.23e-11	2.63e-09	-0.26	-0.21	Schizophrenia;	chr14:70920931	chr14:71141125~71143253:-
BRCA	cis	rs16978956	1	rs2284897	ENSG00000236474.1	GCNT1P1	6.85	1.23e-11	2.63e-09	0.24	0.21	Body mass index;	chr20:18309354	chr20:18420160~18421454:-
BRCA	cis	rs7246657	0.943	rs10424574	ENSG00000226686.6	LINC01535	-6.85	1.23e-11	2.63e-09	-0.32	-0.21	Coronary artery calcification;	chr19:37347491	chr19:37251912~37265535:+
BRCA	cis	rs74233809	1	rs34747231	ENSG00000213277.3	MARCKSL1P1	6.85	1.24e-11	2.63e-09	0.41	0.21	Birth weight;	chr10:103182487	chr10:103175554~103176094:+
BRCA	cis	rs6545883	0.965	rs2305155	ENSG00000271889.1	RP11-493E12.1	6.85	1.24e-11	2.64e-09	0.26	0.21	Tuberculosis;	chr2:61502123	chr2:61151433~61162105:-
BRCA	cis	rs7131987	0.65	rs10843384	ENSG00000257176.2	RP11-996F15.2	-6.85	1.24e-11	2.64e-09	-0.25	-0.21	QT interval;	chr12:29319476	chr12:29280418~29317848:-
BRCA	cis	rs7131987	0.65	rs11050188	ENSG00000257176.2	RP11-996F15.2	-6.85	1.24e-11	2.64e-09	-0.25	-0.21	QT interval;	chr12:29320175	chr12:29280418~29317848:-
BRCA	cis	rs7131987	0.683	rs12366505	ENSG00000257176.2	RP11-996F15.2	-6.85	1.24e-11	2.64e-09	-0.25	-0.21	QT interval;	chr12:29321177	chr12:29280418~29317848:-
BRCA	cis	rs7131987	0.65	rs12366527	ENSG00000257176.2	RP11-996F15.2	-6.85	1.24e-11	2.64e-09	-0.25	-0.21	QT interval;	chr12:29321323	chr12:29280418~29317848:-
BRCA	cis	rs7131987	0.65	rs7311912	ENSG00000257176.2	RP11-996F15.2	-6.85	1.24e-11	2.64e-09	-0.25	-0.21	QT interval;	chr12:29322770	chr12:29280418~29317848:-
BRCA	cis	rs804280	0.565	rs1466785	ENSG00000255046.1	RP11-297N6.4	-6.85	1.24e-11	2.65e-09	-0.24	-0.21	Myopia (pathological);	chr8:11765947	chr8:11797928~11802568:-
BRCA	cis	rs2014572	0.933	rs8109882	ENSG00000268379.1	CTC-360J11.4	6.85	1.25e-11	2.66e-09	0.25	0.21	Hyperactive-impulsive symptoms;	chr19:57244250	chr19:57175233~57177921:+
BRCA	cis	rs2014572	0.901	rs35658377	ENSG00000268379.1	CTC-360J11.4	6.85	1.25e-11	2.66e-09	0.25	0.21	Hyperactive-impulsive symptoms;	chr19:57244259	chr19:57175233~57177921:+
BRCA	cis	rs1555322	0.53	rs2297789	ENSG00000261582.1	RP4-614O4.11	-6.85	1.26e-11	2.68e-09	-0.23	-0.21	Attention deficit hyperactivity disorder;	chr20:35279445	chr20:35267885~35280043:-
BRCA	cis	rs9638182	0.72	rs13235543	ENSG00000274080.1	CTA-315H11.2	6.85	1.26e-11	2.68e-09	0.42	0.21	Triglycerides;	chr7:73599571	chr7:73609262~73611502:-
BRCA	cis	rs875971	0.895	rs10755833	ENSG00000232559.3	GS1-124K5.12	6.85	1.26e-11	2.68e-09	0.25	0.21	Aortic root size;	chr7:66448930	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.895	rs1833495	ENSG00000232559.3	GS1-124K5.12	6.85	1.26e-11	2.68e-09	0.25	0.21	Aortic root size;	chr7:66456608	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.964	rs6945032	ENSG00000232559.3	GS1-124K5.12	6.85	1.26e-11	2.68e-09	0.25	0.21	Aortic root size;	chr7:66457499	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.929	rs12673810	ENSG00000232559.3	GS1-124K5.12	6.85	1.26e-11	2.68e-09	0.25	0.21	Aortic root size;	chr7:66458866	chr7:66554588~66576923:-
BRCA	cis	rs875971	1	rs6961155	ENSG00000232559.3	GS1-124K5.12	6.85	1.26e-11	2.68e-09	0.25	0.21	Aortic root size;	chr7:66468308	chr7:66554588~66576923:-
BRCA	cis	rs875971	1	rs7789768	ENSG00000232559.3	GS1-124K5.12	6.85	1.26e-11	2.68e-09	0.25	0.21	Aortic root size;	chr7:66473993	chr7:66554588~66576923:-
BRCA	cis	rs875971	1	rs1363055	ENSG00000232559.3	GS1-124K5.12	6.85	1.26e-11	2.68e-09	0.25	0.21	Aortic root size;	chr7:66478288	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.964	rs9691480	ENSG00000232559.3	GS1-124K5.12	6.85	1.26e-11	2.68e-09	0.25	0.21	Aortic root size;	chr7:66479319	chr7:66554588~66576923:-
BRCA	cis	rs11976180	1	rs2961134	ENSG00000204959.4	ARHGEF34P	6.85	1.26e-11	2.68e-09	0.26	0.21	Obesity-related traits;	chr7:144073969	chr7:144272445~144286966:-
BRCA	cis	rs11976180	1	rs2961134	ENSG00000170356.8	OR2A20P	-6.85	1.26e-11	2.68e-09	-0.29	-0.21	Obesity-related traits;	chr7:144073969	chr7:144250045~144252957:-
BRCA	cis	rs516805	0.52	rs197678	ENSG00000279114.1	RP3-425C14.5	-6.85	1.27e-11	2.69e-09	-0.2	-0.21	Lymphocyte counts;	chr6:122534039	chr6:122471923~122484161:+
BRCA	cis	rs237743	0.896	rs2063710	ENSG00000222365.1	SNORD12B	6.85	1.27e-11	2.7e-09	0.27	0.21	Height;	chr20:49215517	chr20:49280319~49280409:+
BRCA	cis	rs801193	0.935	rs2659916	ENSG00000236529.1	RP13-254B10.1	6.85	1.27e-11	2.7e-09	0.23	0.21	Aortic root size;	chr7:66686365	chr7:65840212~65840596:+
BRCA	cis	rs17818399	0.888	rs2346419	ENSG00000279254.1	RP11-536C12.1	-6.85	1.27e-11	2.7e-09	-0.26	-0.21	Height;	chr2:46617930	chr2:46668870~46670778:+
BRCA	cis	rs875971	0.965	rs28682868	ENSG00000224316.1	RP11-479O9.2	-6.85	1.27e-11	2.7e-09	-0.21	-0.21	Aortic root size;	chr7:66224822	chr7:65773620~65802067:+
BRCA	cis	rs1823913	0.637	rs1349938	ENSG00000280083.1	RP11-317J9.1	6.85	1.27e-11	2.71e-09	0.23	0.21	Obesity-related traits;	chr2:191299970	chr2:191154118~191156070:-
BRCA	cis	rs1823913	0.592	rs1349939	ENSG00000280083.1	RP11-317J9.1	6.85	1.27e-11	2.71e-09	0.23	0.21	Obesity-related traits;	chr2:191300079	chr2:191154118~191156070:-
BRCA	cis	rs1823913	0.614	rs6434459	ENSG00000280083.1	RP11-317J9.1	6.85	1.27e-11	2.71e-09	0.23	0.21	Obesity-related traits;	chr2:191300886	chr2:191154118~191156070:-
BRCA	cis	rs1823913	0.592	rs7588555	ENSG00000280083.1	RP11-317J9.1	6.85	1.27e-11	2.71e-09	0.23	0.21	Obesity-related traits;	chr2:191300912	chr2:191154118~191156070:-
BRCA	cis	rs1823913	0.637	rs4853581	ENSG00000280083.1	RP11-317J9.1	6.85	1.27e-11	2.71e-09	0.23	0.21	Obesity-related traits;	chr2:191301533	chr2:191154118~191156070:-
BRCA	cis	rs1823913	0.614	rs7565987	ENSG00000280083.1	RP11-317J9.1	6.85	1.27e-11	2.71e-09	0.23	0.21	Obesity-related traits;	chr2:191301815	chr2:191154118~191156070:-
BRCA	cis	rs1823913	0.614	rs1973067	ENSG00000280083.1	RP11-317J9.1	6.85	1.27e-11	2.71e-09	0.23	0.21	Obesity-related traits;	chr2:191302021	chr2:191154118~191156070:-
BRCA	cis	rs1823913	0.637	rs1973068	ENSG00000280083.1	RP11-317J9.1	6.85	1.27e-11	2.71e-09	0.23	0.21	Obesity-related traits;	chr2:191302227	chr2:191154118~191156070:-
BRCA	cis	rs1823913	0.637	rs7569231	ENSG00000280083.1	RP11-317J9.1	6.85	1.27e-11	2.71e-09	0.23	0.21	Obesity-related traits;	chr2:191302373	chr2:191154118~191156070:-
BRCA	cis	rs1823913	0.637	rs6434461	ENSG00000280083.1	RP11-317J9.1	6.85	1.27e-11	2.71e-09	0.23	0.21	Obesity-related traits;	chr2:191302661	chr2:191154118~191156070:-
BRCA	cis	rs1823913	0.614	rs6434462	ENSG00000280083.1	RP11-317J9.1	6.85	1.27e-11	2.71e-09	0.23	0.21	Obesity-related traits;	chr2:191302705	chr2:191154118~191156070:-
BRCA	cis	rs7617773	0.817	rs17786132	ENSG00000228638.1	FCF1P2	-6.85	1.27e-11	2.71e-09	-0.23	-0.21	Coronary artery disease;	chr3:48207930	chr3:48290793~48291375:-
BRCA	cis	rs7617773	0.817	rs35456569	ENSG00000228638.1	FCF1P2	-6.85	1.27e-11	2.71e-09	-0.23	-0.21	Coronary artery disease;	chr3:48209409	chr3:48290793~48291375:-
BRCA	cis	rs61160187	0.582	rs10939879	ENSG00000215032.2	GNL3LP1	6.85	1.28e-11	2.72e-09	0.26	0.21	Educational attainment (years of education);Educational attainment (college completion);	chr5:61019996	chr5:60891935~60893577:-
BRCA	cis	rs11096990	0.855	rs2566173	ENSG00000249207.1	RP11-360F5.1	6.85	1.28e-11	2.72e-09	0.24	0.21	Cognitive function;	chr4:39151111	chr4:39112677~39126818:-
BRCA	cis	rs11096990	0.855	rs2043102	ENSG00000249207.1	RP11-360F5.1	6.85	1.28e-11	2.72e-09	0.24	0.21	Cognitive function;	chr4:39151292	chr4:39112677~39126818:-
BRCA	cis	rs11096990	0.855	rs2711986	ENSG00000249207.1	RP11-360F5.1	6.85	1.28e-11	2.72e-09	0.24	0.21	Cognitive function;	chr4:39152258	chr4:39112677~39126818:-
BRCA	cis	rs11096990	0.75	rs2465242	ENSG00000249207.1	RP11-360F5.1	6.85	1.28e-11	2.72e-09	0.24	0.21	Cognitive function;	chr4:39153796	chr4:39112677~39126818:-
BRCA	cis	rs11096990	0.855	rs2465243	ENSG00000249207.1	RP11-360F5.1	6.85	1.28e-11	2.72e-09	0.24	0.21	Cognitive function;	chr4:39154036	chr4:39112677~39126818:-
BRCA	cis	rs11096990	0.855	rs2566176	ENSG00000249207.1	RP11-360F5.1	6.85	1.28e-11	2.72e-09	0.24	0.21	Cognitive function;	chr4:39154373	chr4:39112677~39126818:-
BRCA	cis	rs11096990	0.855	rs2566178	ENSG00000249207.1	RP11-360F5.1	6.85	1.28e-11	2.72e-09	0.24	0.21	Cognitive function;	chr4:39155194	chr4:39112677~39126818:-
BRCA	cis	rs11096990	0.819	rs2435528	ENSG00000249207.1	RP11-360F5.1	6.85	1.28e-11	2.72e-09	0.24	0.21	Cognitive function;	chr4:39155916	chr4:39112677~39126818:-
BRCA	cis	rs11096990	0.855	rs2711933	ENSG00000249207.1	RP11-360F5.1	6.85	1.28e-11	2.72e-09	0.24	0.21	Cognitive function;	chr4:39156090	chr4:39112677~39126818:-
BRCA	cis	rs11096990	0.855	rs2566179	ENSG00000249207.1	RP11-360F5.1	6.85	1.28e-11	2.72e-09	0.24	0.21	Cognitive function;	chr4:39156413	chr4:39112677~39126818:-
BRCA	cis	rs11096990	0.855	rs2566180	ENSG00000249207.1	RP11-360F5.1	6.85	1.28e-11	2.72e-09	0.24	0.21	Cognitive function;	chr4:39157381	chr4:39112677~39126818:-
BRCA	cis	rs2060793	1	rs1993116	ENSG00000251991.1	RNU7-49P	6.85	1.28e-11	2.72e-09	0.23	0.21	Vitamin D levels;	chr11:14888688	chr11:14478892~14478953:+
BRCA	cis	rs755249	0.567	rs4660543	ENSG00000237624.1	OXCT2P1	6.85	1.28e-11	2.72e-09	0.3	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39213318	chr1:39514956~39516490:+
BRCA	cis	rs16846053	0.515	rs6750756	ENSG00000227403.1	AC009299.3	-6.85	1.28e-11	2.72e-09	-0.34	-0.21	Blood osmolality (transformed sodium);	chr2:161659798	chr2:161244739~161249050:+
BRCA	cis	rs11976180	1	rs2961120	ENSG00000204959.4	ARHGEF34P	6.85	1.28e-11	2.73e-09	0.26	0.21	Obesity-related traits;	chr7:144059492	chr7:144272445~144286966:-
BRCA	cis	rs9880211	0.752	rs35428413	ENSG00000273486.1	RP11-731C17.2	6.85	1.28e-11	2.73e-09	0.28	0.21	Height;Body mass index;	chr3:136661856	chr3:136837338~136839021:-
BRCA	cis	rs7246657	0.882	rs10422667	ENSG00000226686.6	LINC01535	-6.85	1.28e-11	2.73e-09	-0.32	-0.21	Coronary artery calcification;	chr19:37446974	chr19:37251912~37265535:+
BRCA	cis	rs7246657	0.943	rs1015848	ENSG00000226686.6	LINC01535	-6.85	1.28e-11	2.73e-09	-0.32	-0.21	Coronary artery calcification;	chr19:37454372	chr19:37251912~37265535:+
BRCA	cis	rs7246657	0.943	rs4801759	ENSG00000226686.6	LINC01535	-6.85	1.28e-11	2.73e-09	-0.32	-0.21	Coronary artery calcification;	chr19:37464083	chr19:37251912~37265535:+
BRCA	cis	rs11976180	1	rs1919951	ENSG00000170356.8	OR2A20P	-6.85	1.28e-11	2.73e-09	-0.3	-0.21	Obesity-related traits;	chr7:144071798	chr7:144250045~144252957:-
BRCA	cis	rs7474896	0.583	rs12776092	ENSG00000226578.1	RP11-258F22.1	-6.85	1.28e-11	2.73e-09	-0.27	-0.21	Obesity (extreme);	chr10:37726867	chr10:37775371~37784131:-
BRCA	cis	rs780096	0.546	rs8179225	ENSG00000234072.1	AC074117.10	-6.85	1.29e-11	2.73e-09	-0.2	-0.21	Total body bone mineral density;	chr2:27514314	chr2:27356246~27367622:+
BRCA	cis	rs2243480	1	rs466983	ENSG00000229886.1	RP5-1132H15.3	6.85	1.29e-11	2.74e-09	0.38	0.21	Diabetic kidney disease;	chr7:66055509	chr7:66025126~66031544:-
BRCA	cis	rs957448	1	rs72674861	ENSG00000253175.1	RP11-267M23.6	6.85	1.29e-11	2.74e-09	0.27	0.21	Nonsyndromic cleft lip with cleft palate;	chr8:94550051	chr8:94565036~94565715:+
BRCA	cis	rs2638953	0.924	rs11049398	ENSG00000278733.1	RP11-425D17.1	-6.85	1.29e-11	2.74e-09	-0.26	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28172371	chr12:28185625~28186190:-
BRCA	cis	rs897984	0.762	rs8062719	ENSG00000260911.2	RP11-196G11.2	-6.85	1.29e-11	2.75e-09	-0.19	-0.21	Dementia with Lewy bodies;	chr16:30991343	chr16:31043150~31049868:+
BRCA	cis	rs755249	0.567	rs113214136	ENSG00000228060.1	RP11-69E11.8	-6.85	1.29e-11	2.75e-09	-0.26	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39408867	chr1:39565160~39573203:+
BRCA	cis	rs755249	0.567	rs61779300	ENSG00000228060.1	RP11-69E11.8	-6.85	1.29e-11	2.75e-09	-0.26	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39420091	chr1:39565160~39573203:+
BRCA	cis	rs2638953	0.924	rs11049399	ENSG00000278733.1	RP11-425D17.1	-6.85	1.29e-11	2.75e-09	-0.26	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28174213	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.924	rs61920227	ENSG00000278733.1	RP11-425D17.1	-6.85	1.29e-11	2.75e-09	-0.26	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28174584	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.924	rs11049400	ENSG00000278733.1	RP11-425D17.1	-6.85	1.29e-11	2.75e-09	-0.26	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28175051	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.924	rs11049401	ENSG00000278733.1	RP11-425D17.1	-6.85	1.29e-11	2.75e-09	-0.26	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28175218	chr12:28185625~28186190:-
BRCA	cis	rs6840360	0.667	rs2709832	ENSG00000270265.1	RP11-731D1.4	-6.85	1.3e-11	2.76e-09	-0.23	-0.21	Intelligence (multi-trait analysis);	chr4:151458242	chr4:151333775~151353224:-
BRCA	cis	rs7978895	0.669	rs1399374	ENSG00000258331.1	RP11-118A3.1	-6.85	1.3e-11	2.76e-09	-0.21	-0.21	Type 2 diabetes;	chr12:43150804	chr12:43155315~43163110:+
BRCA	cis	rs2380205	0.546	rs633928	ENSG00000232807.2	RP11-536K7.3	-6.85	1.3e-11	2.76e-09	-0.21	-0.21	Breast cancer;	chr10:5902547	chr10:5934270~5945900:-
BRCA	cis	rs34526934	0.566	rs34028621	ENSG00000226363.3	HAGLROS	6.85	1.3e-11	2.76e-09	0.31	0.21	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:176178051	chr2:176177717~176179008:+
BRCA	cis	rs7208859	0.673	rs11657270	ENSG00000263603.1	CTD-2349P21.5	-6.85	1.3e-11	2.76e-09	-0.37	-0.21	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887369	chr17:30729469~30731202:+
BRCA	cis	rs875971	1	rs11974219	ENSG00000224316.1	RP11-479O9.2	-6.85	1.3e-11	2.77e-09	-0.21	-0.21	Aortic root size;	chr7:66182423	chr7:65773620~65802067:+
BRCA	cis	rs11098499	0.821	rs10032151	ENSG00000249244.1	RP11-548H18.2	6.85	1.3e-11	2.77e-09	0.25	0.21	Corneal astigmatism;	chr4:119470473	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.865	rs10032158	ENSG00000249244.1	RP11-548H18.2	6.85	1.3e-11	2.77e-09	0.25	0.21	Corneal astigmatism;	chr4:119470477	chr4:119391831~119395335:-
BRCA	cis	rs6543140	0.964	rs6543138	ENSG00000234389.1	AC007278.3	6.85	1.3e-11	2.77e-09	0.21	0.21	Blood protein levels;	chr2:102449672	chr2:102438713~102440475:+
BRCA	cis	rs11096990	0.855	rs2566181	ENSG00000249207.1	RP11-360F5.1	6.85	1.3e-11	2.77e-09	0.24	0.21	Cognitive function;	chr4:39157987	chr4:39112677~39126818:-
BRCA	cis	rs11096990	0.819	rs1367297	ENSG00000249207.1	RP11-360F5.1	6.85	1.3e-11	2.77e-09	0.24	0.21	Cognitive function;	chr4:39159614	chr4:39112677~39126818:-
BRCA	cis	rs2060793	0.741	rs10741653	ENSG00000251991.1	RNU7-49P	6.84	1.31e-11	2.78e-09	0.22	0.21	Vitamin D levels;	chr11:14683294	chr11:14478892~14478953:+
BRCA	cis	rs11098499	0.954	rs10008459	ENSG00000249244.1	RP11-548H18.2	6.84	1.31e-11	2.78e-09	0.25	0.21	Corneal astigmatism;	chr4:119473076	chr4:119391831~119395335:-
BRCA	cis	rs2243480	1	rs2420171	ENSG00000232546.1	RP11-458F8.1	6.84	1.31e-11	2.78e-09	0.28	0.21	Diabetic kidney disease;	chr7:66172773	chr7:66848496~66858136:+
BRCA	cis	rs7976269	0.609	rs10843300	ENSG00000257176.2	RP11-996F15.2	-6.84	1.32e-11	2.8e-09	-0.25	-0.21	Male-pattern baldness;	chr12:29060934	chr12:29280418~29317848:-
BRCA	cis	rs4787484	1	rs7189750	ENSG00000214725.6	CDIPT-AS1	-6.84	1.32e-11	2.8e-09	-0.26	-0.21	Response to taxane treatment (placlitaxel);	chr16:29900095	chr16:29863593~29868053:+
BRCA	cis	rs13217239	0.646	rs11756275	ENSG00000241549.7	GUSBP2	-6.84	1.32e-11	2.8e-09	-0.23	-0.21	Schizophrenia;	chr6:27039334	chr6:26871484~26956554:-
BRCA	cis	rs875971	0.545	rs4441996	ENSG00000236529.1	RP13-254B10.1	-6.84	1.32e-11	2.81e-09	-0.25	-0.21	Aortic root size;	chr7:66123233	chr7:65840212~65840596:+
BRCA	cis	rs2348418	0.966	rs11049698	ENSG00000247934.4	RP11-967K21.1	6.84	1.32e-11	2.81e-09	0.23	0.21	Lung function (FEV1);Lung function (FVC);	chr12:28535354	chr12:28163298~28190738:-
BRCA	cis	rs2243480	1	rs316321	ENSG00000230295.1	RP11-458F8.2	-6.84	1.33e-11	2.81e-09	-0.28	-0.21	Diabetic kidney disease;	chr7:66146626	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs316318	ENSG00000230295.1	RP11-458F8.2	-6.84	1.33e-11	2.81e-09	-0.28	-0.21	Diabetic kidney disease;	chr7:66147917	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs316317	ENSG00000230295.1	RP11-458F8.2	-6.84	1.33e-11	2.81e-09	-0.28	-0.21	Diabetic kidney disease;	chr7:66148650	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs316304	ENSG00000230295.1	RP11-458F8.2	-6.84	1.33e-11	2.81e-09	-0.28	-0.21	Diabetic kidney disease;	chr7:66151907	chr7:66880708~66882981:+
BRCA	cis	rs6840360	0.582	rs2709812	ENSG00000270265.1	RP11-731D1.4	6.84	1.33e-11	2.82e-09	0.23	0.21	Intelligence (multi-trait analysis);	chr4:151414597	chr4:151333775~151353224:-
BRCA	cis	rs600231	0.708	rs1784100	ENSG00000245532.5	NEAT1	6.84	1.33e-11	2.82e-09	0.19	0.21	Bone mineral density;	chr11:65481756	chr11:65422774~65445540:+
BRCA	cis	rs2638953	0.924	rs11049405	ENSG00000278733.1	RP11-425D17.1	-6.84	1.33e-11	2.82e-09	-0.26	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28181003	chr12:28185625~28186190:-
BRCA	cis	rs858239	0.6	rs10233039	ENSG00000230042.1	AK3P3	-6.84	1.33e-11	2.82e-09	-0.23	-0.21	Cerebrospinal fluid biomarker levels;	chr7:23103494	chr7:23129178~23129841:+
BRCA	cis	rs17711722	0.503	rs453835	ENSG00000237310.1	GS1-124K5.4	-6.84	1.33e-11	2.82e-09	-0.23	-0.21	Calcium levels;	chr7:66046172	chr7:66493706~66495474:+
BRCA	cis	rs9506514	0.509	rs9509279	ENSG00000238286.1	SLC35E1P1	6.84	1.33e-11	2.82e-09	0.22	0.21	Coronary artery calcification;	chr13:20559580	chr13:20607268~20608131:+
BRCA	cis	rs12817211	0.502	rs17124432	ENSG00000272368.2	RP4-605O3.4	6.84	1.33e-11	2.82e-09	0.21	0.21	Colorectal or endometrial cancer;	chr12:50116994	chr12:50112197~50165618:+
BRCA	cis	rs71520386	0.607	rs28617621	ENSG00000228649.7	AC005682.5	-6.84	1.33e-11	2.83e-09	-0.2	-0.21	Fibrinogen levels;	chr7:22818063	chr7:22854178~22861579:+
BRCA	cis	rs9549328	0.731	rs7983602	ENSG00000267868.1	RP11-120K24.3	6.84	1.33e-11	2.83e-09	0.27	0.21	Systolic blood pressure;	chr13:112966168	chr13:112964835~112966131:-
BRCA	cis	rs875971	0.638	rs35986979	ENSG00000236529.1	RP13-254B10.1	-6.84	1.33e-11	2.83e-09	-0.23	-0.21	Aortic root size;	chr7:66624003	chr7:65840212~65840596:+
BRCA	cis	rs442309	0.553	rs7073430	ENSG00000238280.1	RP11-436D10.3	-6.84	1.34e-11	2.84e-09	-0.29	-0.21	Vogt-Koyanagi-Harada syndrome;	chr10:62695121	chr10:62793562~62805887:-
BRCA	cis	rs2408955	0.561	rs9971924	ENSG00000240399.1	RP1-228P16.1	-6.84	1.34e-11	2.84e-09	-0.24	-0.21	Glycated hemoglobin levels;	chr12:48086049	chr12:48054813~48055591:-
BRCA	cis	rs755249	0.567	rs41270821	ENSG00000228060.1	RP11-69E11.8	-6.84	1.34e-11	2.84e-09	-0.26	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39458060	chr1:39565160~39573203:+
BRCA	cis	rs755249	0.567	rs2296175	ENSG00000228060.1	RP11-69E11.8	-6.84	1.34e-11	2.84e-09	-0.26	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39458726	chr1:39565160~39573203:+
BRCA	cis	rs860818	1	rs858304	ENSG00000226816.2	AC005082.12	-6.84	1.34e-11	2.84e-09	-0.49	-0.21	Initial pursuit acceleration;	chr7:23203534	chr7:23206013~23208045:+
BRCA	cis	rs7615952	0.932	rs11922218	ENSG00000171084.14	FAM86JP	6.84	1.34e-11	2.85e-09	0.34	0.21	Blood pressure (smoking interaction);	chr3:125912446	chr3:125916620~125930024:+
BRCA	cis	rs7615952	0.866	rs11922276	ENSG00000171084.14	FAM86JP	6.84	1.34e-11	2.85e-09	0.34	0.21	Blood pressure (smoking interaction);	chr3:125912483	chr3:125916620~125930024:+
BRCA	cis	rs600231	0.719	rs7114809	ENSG00000245532.5	NEAT1	6.84	1.34e-11	2.85e-09	0.19	0.21	Bone mineral density;	chr11:65483973	chr11:65422774~65445540:+
BRCA	cis	rs13113518	0.812	rs13107810	ENSG00000249700.7	SRD5A3-AS1	6.84	1.34e-11	2.85e-09	0.26	0.21	Height;	chr4:55542243	chr4:55363971~55395847:-
BRCA	cis	rs919433	0.927	rs6759834	ENSG00000231621.1	AC013264.2	6.84	1.34e-11	2.85e-09	0.21	0.21	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197340136	chr2:197197991~197199273:+
BRCA	cis	rs755249	0.567	rs61779306	ENSG00000228060.1	RP11-69E11.8	-6.84	1.35e-11	2.85e-09	-0.26	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39456754	chr1:39565160~39573203:+
BRCA	cis	rs7246657	0.943	rs10404602	ENSG00000226686.6	LINC01535	-6.84	1.35e-11	2.86e-09	-0.32	-0.21	Coronary artery calcification;	chr19:37334731	chr19:37251912~37265535:+
BRCA	cis	rs2243480	0.901	rs13237344	ENSG00000230295.1	RP11-458F8.2	-6.84	1.35e-11	2.86e-09	-0.28	-0.21	Diabetic kidney disease;	chr7:66557269	chr7:66880708~66882981:+
BRCA	cis	rs2880765	0.835	rs12324277	ENSG00000259295.5	CSPG4P12	6.84	1.35e-11	2.86e-09	0.25	0.21	Coronary artery disease;	chr15:85498504	chr15:85191438~85213905:+
BRCA	cis	rs6545883	0.718	rs3771260	ENSG00000271889.1	RP11-493E12.1	6.84	1.35e-11	2.87e-09	0.27	0.21	Tuberculosis;	chr2:61535249	chr2:61151433~61162105:-
BRCA	cis	rs17301013	0.606	rs10912740	ENSG00000227373.4	RP11-160H22.5	6.84	1.35e-11	2.87e-09	0.3	0.21	Systemic lupus erythematosus;	chr1:174180224	chr1:174115300~174160004:-
BRCA	cis	rs11098499	0.954	rs6834796	ENSG00000249244.1	RP11-548H18.2	6.84	1.36e-11	2.89e-09	0.25	0.21	Corneal astigmatism;	chr4:119493538	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.954	rs11734241	ENSG00000249244.1	RP11-548H18.2	6.84	1.36e-11	2.89e-09	0.25	0.21	Corneal astigmatism;	chr4:119495717	chr4:119391831~119395335:-
BRCA	cis	rs3758785	0.512	rs7950328	ENSG00000255893.1	RP11-685N10.1	-6.84	1.36e-11	2.89e-09	-0.25	-0.21	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);	chr11:94366449	chr11:94472908~94473570:-
BRCA	cis	rs42648	0.596	rs194524	ENSG00000225498.1	AC002064.5	6.84	1.36e-11	2.89e-09	0.2	0.21	Homocysteine levels;	chr7:90232518	chr7:90312496~90322592:+
BRCA	cis	rs7246657	0.943	rs10415358	ENSG00000226686.6	LINC01535	-6.84	1.36e-11	2.89e-09	-0.32	-0.21	Coronary artery calcification;	chr19:37317961	chr19:37251912~37265535:+
BRCA	cis	rs9307551	0.711	rs11098774	ENSG00000250334.4	LINC00989	6.84	1.36e-11	2.89e-09	0.29	0.21	Refractive error;	chr4:79615697	chr4:79492416~79576460:+
BRCA	cis	rs16846053	0.515	rs3849355	ENSG00000227403.1	AC009299.3	-6.84	1.37e-11	2.89e-09	-0.34	-0.21	Blood osmolality (transformed sodium);	chr2:161531204	chr2:161244739~161249050:+
BRCA	cis	rs904251	0.797	rs1776460	ENSG00000204110.6	RP1-153P14.8	-6.84	1.37e-11	2.9e-09	-0.23	-0.21	Cognitive performance;	chr6:37517708	chr6:37507348~37535616:+
BRCA	cis	rs7474896	0.583	rs11011347	ENSG00000226578.1	RP11-258F22.1	-6.84	1.37e-11	2.9e-09	-0.27	-0.21	Obesity (extreme);	chr10:37730336	chr10:37775371~37784131:-
BRCA	cis	rs10129255	0.5	rs11627315	ENSG00000280411.1	IGHV1-69-2	-6.84	1.37e-11	2.91e-09	-0.14	-0.21	Kawasaki disease;	chr14:106802182	chr14:106762092~106762588:-
BRCA	cis	rs10129255	0.913	rs28861466	ENSG00000211972.2	IGHV3-66	6.84	1.37e-11	2.91e-09	0.17	0.21	Kawasaki disease;	chr14:106718572	chr14:106675017~106675544:-
BRCA	cis	rs9500256	1	rs9500256	ENSG00000215190.7	LINC00680	-6.84	1.37e-11	2.91e-09	-0.23	-0.21	Eosinophilic esophagitis (pediatric);	chr6:57982677	chr6:57946074~57961501:-
BRCA	cis	rs6545883	0.965	rs3771261	ENSG00000271889.1	RP11-493E12.1	6.84	1.37e-11	2.91e-09	0.27	0.21	Tuberculosis;	chr2:61535026	chr2:61151433~61162105:-
BRCA	cis	rs2243480	0.908	rs1532573	ENSG00000230295.1	RP11-458F8.2	6.84	1.38e-11	2.92e-09	0.28	0.21	Diabetic kidney disease;	chr7:66333815	chr7:66880708~66882981:+
BRCA	cis	rs17253792	0.822	rs10083431	ENSG00000186615.9	KTN1-AS1	-6.84	1.38e-11	2.92e-09	-0.4	-0.21	Putamen volume;	chr14:55601630	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs10083303	ENSG00000186615.9	KTN1-AS1	-6.84	1.38e-11	2.92e-09	-0.4	-0.21	Putamen volume;	chr14:55601803	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs78820104	ENSG00000186615.9	KTN1-AS1	-6.84	1.38e-11	2.92e-09	-0.4	-0.21	Putamen volume;	chr14:55602136	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs76055105	ENSG00000186615.9	KTN1-AS1	-6.84	1.38e-11	2.92e-09	-0.4	-0.21	Putamen volume;	chr14:55602409	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs78386830	ENSG00000186615.9	KTN1-AS1	-6.84	1.38e-11	2.92e-09	-0.4	-0.21	Putamen volume;	chr14:55602506	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs75115817	ENSG00000186615.9	KTN1-AS1	-6.84	1.38e-11	2.92e-09	-0.4	-0.21	Putamen volume;	chr14:55602819	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs77990307	ENSG00000186615.9	KTN1-AS1	-6.84	1.38e-11	2.92e-09	-0.4	-0.21	Putamen volume;	chr14:55603331	chr14:55499278~55580110:-
BRCA	cis	rs12188164	0.543	rs2434695	ENSG00000225138.6	CTD-2228K2.7	-6.84	1.38e-11	2.92e-09	-0.23	-0.21	Cystic fibrosis severity;	chr5:464062	chr5:473236~480884:+
BRCA	cis	rs4356203	0.543	rs214093	ENSG00000272034.1	SNORD14A	-6.84	1.38e-11	2.92e-09	-0.22	-0.21	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17273241	chr11:17074654~17074744:-
BRCA	cis	rs11098499	0.954	rs10017543	ENSG00000249244.1	RP11-548H18.2	6.84	1.38e-11	2.92e-09	0.25	0.21	Corneal astigmatism;	chr4:119400265	chr4:119391831~119395335:-
BRCA	cis	rs6840360	0.642	rs4696089	ENSG00000270265.1	RP11-731D1.4	-6.84	1.38e-11	2.92e-09	-0.23	-0.21	Intelligence (multi-trait analysis);	chr4:151474581	chr4:151333775~151353224:-
BRCA	cis	rs6840360	0.642	rs11932398	ENSG00000270265.1	RP11-731D1.4	-6.84	1.38e-11	2.92e-09	-0.23	-0.21	Intelligence (multi-trait analysis);	chr4:151476402	chr4:151333775~151353224:-
BRCA	cis	rs6840360	0.642	rs4263379	ENSG00000270265.1	RP11-731D1.4	-6.84	1.38e-11	2.92e-09	-0.23	-0.21	Intelligence (multi-trait analysis);	chr4:151477979	chr4:151333775~151353224:-
BRCA	cis	rs2919009	0.602	rs7906342	ENSG00000271670.1	RP11-95I16.4	6.84	1.38e-11	2.93e-09	0.25	0.21	Obesity-related traits;	chr10:120923654	chr10:120879256~120880667:-
BRCA	cis	rs7085104	0.513	rs619824	ENSG00000236937.2	PTGES3P4	6.84	1.38e-11	2.93e-09	0.26	0.21	Immature fraction of reticulocytes;Schizophrenia;	chr10:102821531	chr10:102845595~102845950:+
BRCA	cis	rs74233809	1	rs11191593	ENSG00000213277.3	MARCKSL1P1	6.84	1.38e-11	2.93e-09	0.39	0.21	Birth weight;	chr10:103179458	chr10:103175554~103176094:+
BRCA	cis	rs17301013	0.507	rs10912758	ENSG00000227373.4	RP11-160H22.5	6.84	1.39e-11	2.94e-09	0.3	0.21	Systemic lupus erythematosus;	chr1:174300822	chr1:174115300~174160004:-
BRCA	cis	rs875971	0.505	rs1723275	ENSG00000237310.1	GS1-124K5.4	-6.84	1.39e-11	2.94e-09	-0.22	-0.21	Aortic root size;	chr7:66039646	chr7:66493706~66495474:+
BRCA	cis	rs1862618	0.853	rs33326	ENSG00000271828.1	CTD-2310F14.1	6.84	1.39e-11	2.94e-09	0.29	0.21	Initial pursuit acceleration;	chr5:56846774	chr5:56927874~56929573:+
BRCA	cis	rs1862618	0.802	rs33327	ENSG00000271828.1	CTD-2310F14.1	6.84	1.39e-11	2.94e-09	0.29	0.21	Initial pursuit acceleration;	chr5:56846866	chr5:56927874~56929573:+
BRCA	cis	rs1823913	0.637	rs6750360	ENSG00000280083.1	RP11-317J9.1	6.84	1.39e-11	2.94e-09	0.23	0.21	Obesity-related traits;	chr2:191303089	chr2:191154118~191156070:-
BRCA	cis	rs1823913	0.637	rs11677694	ENSG00000280083.1	RP11-317J9.1	6.84	1.39e-11	2.94e-09	0.23	0.21	Obesity-related traits;	chr2:191303203	chr2:191154118~191156070:-
BRCA	cis	rs1823913	0.571	rs6737307	ENSG00000280083.1	RP11-317J9.1	6.84	1.39e-11	2.94e-09	0.23	0.21	Obesity-related traits;	chr2:191303247	chr2:191154118~191156070:-
BRCA	cis	rs1823913	0.637	rs4853582	ENSG00000280083.1	RP11-317J9.1	6.84	1.39e-11	2.94e-09	0.23	0.21	Obesity-related traits;	chr2:191303483	chr2:191154118~191156070:-
BRCA	cis	rs1823913	0.637	rs35200176	ENSG00000280083.1	RP11-317J9.1	6.84	1.39e-11	2.94e-09	0.23	0.21	Obesity-related traits;	chr2:191303534	chr2:191154118~191156070:-
BRCA	cis	rs1823913	0.637	rs17348013	ENSG00000280083.1	RP11-317J9.1	6.84	1.39e-11	2.94e-09	0.23	0.21	Obesity-related traits;	chr2:191303726	chr2:191154118~191156070:-
BRCA	cis	rs875971	0.545	rs11767262	ENSG00000236529.1	RP13-254B10.1	6.84	1.39e-11	2.95e-09	0.26	0.21	Aortic root size;	chr7:66302237	chr7:65840212~65840596:+
BRCA	cis	rs2337406	0.925	rs11851094	ENSG00000254174.1	IGHV1-12	6.84	1.39e-11	2.95e-09	0.22	0.21	Alzheimer's disease (late onset);	chr14:106688967	chr14:106122420~106122709:-
BRCA	cis	rs2243480	0.908	rs1532573	ENSG00000232546.1	RP11-458F8.1	6.84	1.39e-11	2.95e-09	0.28	0.21	Diabetic kidney disease;	chr7:66333815	chr7:66848496~66858136:+
BRCA	cis	rs4948102	0.642	rs6593297	ENSG00000226278.1	PSPHP1	6.84	1.39e-11	2.95e-09	0.22	0.21	Plasma homocysteine levels (post-methionine load test);	chr7:56054365	chr7:55764797~55773288:+
BRCA	cis	rs2243480	1	rs313820	ENSG00000232546.1	RP11-458F8.1	-6.83	1.39e-11	2.95e-09	-0.28	-0.21	Diabetic kidney disease;	chr7:66109479	chr7:66848496~66858136:+
BRCA	cis	rs2834288	0.5	rs766425	ENSG00000273102.1	AP000569.9	6.83	1.4e-11	2.96e-09	0.22	0.21	Gut microbiota (bacterial taxa);	chr21:33962264	chr21:33967101~33968573:-
BRCA	cis	rs1476670	0.545	rs11210947	ENSG00000230615.5	RP5-1198O20.4	-6.83	1.4e-11	2.96e-09	-0.28	-0.21	Eotaxin levels;	chr1:44054398	chr1:44030443~44115913:+
BRCA	cis	rs2638953	0.814	rs11049413	ENSG00000278733.1	RP11-425D17.1	-6.83	1.4e-11	2.97e-09	-0.26	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28186322	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.85	rs11049414	ENSG00000278733.1	RP11-425D17.1	-6.83	1.4e-11	2.97e-09	-0.26	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28186325	chr12:28185625~28186190:-
BRCA	cis	rs875971	0.545	rs4718348	ENSG00000224316.1	RP11-479O9.2	6.83	1.4e-11	2.97e-09	0.24	0.21	Aortic root size;	chr7:66441589	chr7:65773620~65802067:+
BRCA	cis	rs9368481	0.524	rs12530345	ENSG00000241549.7	GUSBP2	6.83	1.4e-11	2.97e-09	0.23	0.21	Autism spectrum disorder or schizophrenia;	chr6:26916464	chr6:26871484~26956554:-
BRCA	cis	rs11098499	0.954	rs17006190	ENSG00000249244.1	RP11-548H18.2	6.83	1.41e-11	2.98e-09	0.25	0.21	Corneal astigmatism;	chr4:119497683	chr4:119391831~119395335:-
BRCA	cis	rs7674212	0.556	rs34475639	ENSG00000251288.2	RP11-10L12.2	-6.83	1.41e-11	2.98e-09	-0.25	-0.21	Type 2 diabetes;	chr4:103033694	chr4:102751401~102752641:+
BRCA	cis	rs875971	1	rs4717292	ENSG00000232559.3	GS1-124K5.12	6.83	1.41e-11	2.98e-09	0.25	0.21	Aortic root size;	chr7:66430611	chr7:66554588~66576923:-
BRCA	cis	rs875971	1	rs35149210	ENSG00000232559.3	GS1-124K5.12	6.83	1.41e-11	2.98e-09	0.25	0.21	Aortic root size;	chr7:66464938	chr7:66554588~66576923:-
BRCA	cis	rs2243480	0.901	rs12530490	ENSG00000232546.1	RP11-458F8.1	6.83	1.41e-11	2.99e-09	0.28	0.21	Diabetic kidney disease;	chr7:66226660	chr7:66848496~66858136:+
BRCA	cis	rs2243480	1	rs7778911	ENSG00000232546.1	RP11-458F8.1	6.83	1.41e-11	2.99e-09	0.28	0.21	Diabetic kidney disease;	chr7:66229519	chr7:66848496~66858136:+
BRCA	cis	rs11098499	0.863	rs34868248	ENSG00000249244.1	RP11-548H18.2	6.83	1.42e-11	3e-09	0.25	0.21	Corneal astigmatism;	chr4:119521275	chr4:119391831~119395335:-
BRCA	cis	rs2638953	0.925	rs11049412	ENSG00000278733.1	RP11-425D17.1	-6.83	1.42e-11	3e-09	-0.26	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28186199	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.924	rs12366932	ENSG00000278733.1	RP11-425D17.1	-6.83	1.42e-11	3e-09	-0.26	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28188953	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.924	rs1478336	ENSG00000278733.1	RP11-425D17.1	-6.83	1.42e-11	3e-09	-0.26	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28189186	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.924	rs1478335	ENSG00000278733.1	RP11-425D17.1	-6.83	1.42e-11	3e-09	-0.26	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28189244	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.924	rs1478334	ENSG00000278733.1	RP11-425D17.1	-6.83	1.42e-11	3e-09	-0.26	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28189425	chr12:28185625~28186190:-
BRCA	cis	rs2348418	0.798	rs11049546	ENSG00000247934.4	RP11-967K21.1	6.83	1.42e-11	3e-09	0.23	0.21	Lung function (FEV1);Lung function (FVC);	chr12:28346942	chr12:28163298~28190738:-
BRCA	cis	rs13068223	1	rs9868587	ENSG00000243926.1	TIPARP-AS1	6.83	1.42e-11	3.01e-09	0.21	0.21	Age-related hearing impairment (SNP x SNP interaction);	chr3:156743800	chr3:156671862~156674378:-
BRCA	cis	rs2638953	0.924	rs61920228	ENSG00000278733.1	RP11-425D17.1	-6.83	1.42e-11	3.01e-09	-0.26	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28183780	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.924	rs7306838	ENSG00000278733.1	RP11-425D17.1	-6.83	1.42e-11	3.01e-09	-0.26	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28184449	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.924	rs7138173	ENSG00000278733.1	RP11-425D17.1	-6.83	1.42e-11	3.01e-09	-0.26	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28184970	chr12:28185625~28186190:-
BRCA	cis	rs801193	1	rs6975195	ENSG00000236529.1	RP13-254B10.1	-6.83	1.42e-11	3.01e-09	-0.22	-0.21	Aortic root size;	chr7:66659787	chr7:65840212~65840596:+
BRCA	cis	rs13113518	0.783	rs13111128	ENSG00000249700.7	SRD5A3-AS1	6.83	1.42e-11	3.01e-09	0.27	0.21	Height;	chr4:55578154	chr4:55363971~55395847:-
BRCA	cis	rs62246343	0.564	rs2279440	ENSG00000206573.7	THUMPD3-AS1	-6.83	1.42e-11	3.01e-09	-0.25	-0.21	Fibrinogen levels;	chr3:9476827	chr3:9349689~9398579:-
BRCA	cis	rs2243480	1	rs313814	ENSG00000229886.1	RP5-1132H15.3	6.83	1.42e-11	3.01e-09	0.37	0.21	Diabetic kidney disease;	chr7:66038306	chr7:66025126~66031544:-
BRCA	cis	rs6603134	0.502	rs6603132	ENSG00000267939.1	CTD-2325M2.1	-6.83	1.42e-11	3.01e-09	-0.25	-0.21	Blood protein levels;	chr19:8037908	chr19:8008729~8016025:+
BRCA	cis	rs11098499	0.863	rs3733525	ENSG00000249244.1	RP11-548H18.2	6.83	1.43e-11	3.02e-09	0.25	0.21	Corneal astigmatism;	chr4:119525893	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.863	rs3775847	ENSG00000249244.1	RP11-548H18.2	6.83	1.43e-11	3.02e-09	0.25	0.21	Corneal astigmatism;	chr4:119526487	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.863	rs3775848	ENSG00000249244.1	RP11-548H18.2	6.83	1.43e-11	3.02e-09	0.25	0.21	Corneal astigmatism;	chr4:119526569	chr4:119391831~119395335:-
BRCA	cis	rs42648	0.792	rs4236517	ENSG00000225498.1	AC002064.5	6.83	1.43e-11	3.02e-09	0.2	0.21	Homocysteine levels;	chr7:90334151	chr7:90312496~90322592:+
BRCA	cis	rs2243480	0.901	rs778687	ENSG00000230295.1	RP11-458F8.2	-6.83	1.43e-11	3.03e-09	-0.28	-0.21	Diabetic kidney disease;	chr7:66370832	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs778704	ENSG00000230295.1	RP11-458F8.2	-6.83	1.43e-11	3.03e-09	-0.28	-0.21	Diabetic kidney disease;	chr7:66398480	chr7:66880708~66882981:+
BRCA	cis	rs2243480	0.901	rs778693	ENSG00000230295.1	RP11-458F8.2	-6.83	1.43e-11	3.03e-09	-0.28	-0.21	Diabetic kidney disease;	chr7:66407358	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs778691	ENSG00000230295.1	RP11-458F8.2	-6.83	1.43e-11	3.03e-09	-0.28	-0.21	Diabetic kidney disease;	chr7:66408105	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs13235972	ENSG00000230295.1	RP11-458F8.2	-6.83	1.43e-11	3.03e-09	-0.28	-0.21	Diabetic kidney disease;	chr7:66418618	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs34192067	ENSG00000230295.1	RP11-458F8.2	-6.83	1.43e-11	3.03e-09	-0.28	-0.21	Diabetic kidney disease;	chr7:66422670	chr7:66880708~66882981:+
BRCA	cis	rs7976269	0.609	rs7135891	ENSG00000257176.2	RP11-996F15.2	-6.83	1.43e-11	3.03e-09	-0.25	-0.21	Male-pattern baldness;	chr12:29053944	chr12:29280418~29317848:-
BRCA	cis	rs301901	0.772	rs6887958	ENSG00000250155.1	CTD-2353F22.1	-6.83	1.43e-11	3.03e-09	-0.23	-0.21	Height;	chr5:37189717	chr5:36666214~36725195:-
BRCA	cis	rs875971	0.964	rs12668936	ENSG00000232559.3	GS1-124K5.12	6.83	1.43e-11	3.03e-09	0.25	0.21	Aortic root size;	chr7:66449417	chr7:66554588~66576923:-
BRCA	cis	rs2880765	0.743	rs6497191	ENSG00000259295.5	CSPG4P12	6.83	1.44e-11	3.03e-09	0.26	0.21	Coronary artery disease;	chr15:85468270	chr15:85191438~85213905:+
BRCA	cis	rs875971	1	rs7781698	ENSG00000232559.3	GS1-124K5.12	6.83	1.44e-11	3.04e-09	0.25	0.21	Aortic root size;	chr7:66431325	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.862	rs6964437	ENSG00000224316.1	RP11-479O9.2	-6.83	1.44e-11	3.04e-09	-0.21	-0.21	Aortic root size;	chr7:66221457	chr7:65773620~65802067:+
BRCA	cis	rs10129255	0.5	rs2027902	ENSG00000274576.2	IGHV2-70	-6.83	1.44e-11	3.04e-09	-0.17	-0.21	Kawasaki disease;	chr14:106807157	chr14:106770577~106771020:-
BRCA	cis	rs875971	0.895	rs4718349	ENSG00000232559.3	GS1-124K5.12	6.83	1.44e-11	3.04e-09	0.24	0.21	Aortic root size;	chr7:66444024	chr7:66554588~66576923:-
BRCA	cis	rs875971	1	rs2042133	ENSG00000232559.3	GS1-124K5.12	6.83	1.44e-11	3.04e-09	0.24	0.21	Aortic root size;	chr7:66466935	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.964	rs2161065	ENSG00000232559.3	GS1-124K5.12	6.83	1.44e-11	3.04e-09	0.24	0.21	Aortic root size;	chr7:66467918	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.862	rs12698521	ENSG00000232559.3	GS1-124K5.12	6.83	1.44e-11	3.04e-09	0.24	0.21	Aortic root size;	chr7:66474502	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.83	rs427575	ENSG00000224316.1	RP11-479O9.2	6.83	1.44e-11	3.04e-09	0.21	0.21	Aortic root size;	chr7:66054232	chr7:65773620~65802067:+
BRCA	cis	rs6921919	0.583	rs2041230	ENSG00000204709.4	LINC01556	6.83	1.44e-11	3.05e-09	0.28	0.21	Autism spectrum disorder or schizophrenia;	chr6:28397738	chr6:28943877~28944537:+
BRCA	cis	rs919433	0.927	rs3843857	ENSG00000231621.1	AC013264.2	6.83	1.44e-11	3.05e-09	0.2	0.21	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197331241	chr2:197197991~197199273:+
BRCA	cis	rs2243480	1	rs1267820	ENSG00000229886.1	RP5-1132H15.3	6.83	1.44e-11	3.05e-09	0.37	0.21	Diabetic kidney disease;	chr7:66585308	chr7:66025126~66031544:-
BRCA	cis	rs11098499	0.954	rs3733519	ENSG00000249244.1	RP11-548H18.2	6.83	1.44e-11	3.05e-09	0.25	0.21	Corneal astigmatism;	chr4:119502293	chr4:119391831~119395335:-
BRCA	cis	rs61160187	0.582	rs1479645	ENSG00000215032.2	GNL3LP1	6.83	1.45e-11	3.05e-09	0.26	0.21	Educational attainment (years of education);Educational attainment (college completion);	chr5:61023904	chr5:60891935~60893577:-
BRCA	cis	rs11098499	0.738	rs34965784	ENSG00000249244.1	RP11-548H18.2	6.83	1.45e-11	3.06e-09	0.24	0.21	Corneal astigmatism;	chr4:119440431	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.779	rs28495013	ENSG00000249244.1	RP11-548H18.2	6.83	1.45e-11	3.06e-09	0.24	0.21	Corneal astigmatism;	chr4:119454676	chr4:119391831~119395335:-
BRCA	cis	rs2243480	1	rs10807701	ENSG00000232546.1	RP11-458F8.1	6.83	1.45e-11	3.06e-09	0.27	0.21	Diabetic kidney disease;	chr7:66259699	chr7:66848496~66858136:+
BRCA	cis	rs9807989	0.839	rs10182710	ENSG00000234389.1	AC007278.3	6.83	1.45e-11	3.06e-09	0.19	0.21	Asthma;	chr2:102364846	chr2:102438713~102440475:+
BRCA	cis	rs9807989	0.839	rs13392100	ENSG00000234389.1	AC007278.3	6.83	1.45e-11	3.06e-09	0.19	0.21	Asthma;	chr2:102365634	chr2:102438713~102440475:+
BRCA	cis	rs3126085	0.877	rs4456098	ENSG00000237975.5	FLG-AS1	-6.83	1.45e-11	3.06e-09	-0.27	-0.21	Atopic dermatitis;	chr1:152203558	chr1:152168125~152445456:+
BRCA	cis	rs9807989	0.801	rs11123925	ENSG00000234389.1	AC007278.3	6.83	1.45e-11	3.06e-09	0.19	0.21	Asthma;	chr2:102361051	chr2:102438713~102440475:+
BRCA	cis	rs9807989	0.839	rs10204837	ENSG00000234389.1	AC007278.3	6.83	1.45e-11	3.06e-09	0.19	0.21	Asthma;	chr2:102361270	chr2:102438713~102440475:+
BRCA	cis	rs9807989	0.839	rs3755276	ENSG00000234389.1	AC007278.3	6.83	1.45e-11	3.06e-09	0.19	0.21	Asthma;	chr2:102361999	chr2:102438713~102440475:+
BRCA	cis	rs9807989	0.839	rs9308857	ENSG00000234389.1	AC007278.3	6.83	1.45e-11	3.06e-09	0.19	0.21	Asthma;	chr2:102363164	chr2:102438713~102440475:+
BRCA	cis	rs9807989	0.839	rs1420099	ENSG00000234389.1	AC007278.3	6.83	1.45e-11	3.06e-09	0.19	0.21	Asthma;	chr2:102364083	chr2:102438713~102440475:+
BRCA	cis	rs9880211	0.718	rs28631273	ENSG00000239213.4	NCK1-AS1	6.83	1.45e-11	3.07e-09	0.26	0.21	Height;Body mass index;	chr3:136215869	chr3:136841726~136862054:-
BRCA	cis	rs62025270	0.547	rs386346	ENSG00000202081.1	RNU6-1280P	-6.83	1.45e-11	3.07e-09	-0.25	-0.21	Idiopathic pulmonary fibrosis;	chr15:85651328	chr15:85651522~85651628:-
BRCA	cis	rs7829975	0.623	rs10087493	ENSG00000254153.1	CTA-398F10.2	-6.83	1.45e-11	3.07e-09	-0.25	-0.21	Mood instability;	chr8:8516047	chr8:8456909~8461337:-
BRCA	cis	rs11098499	0.954	rs7681544	ENSG00000249244.1	RP11-548H18.2	6.83	1.46e-11	3.08e-09	0.25	0.21	Corneal astigmatism;	chr4:119490100	chr4:119391831~119395335:-
BRCA	cis	rs17253792	0.822	rs78429067	ENSG00000186615.9	KTN1-AS1	-6.83	1.46e-11	3.09e-09	-0.43	-0.21	Putamen volume;	chr14:55625833	chr14:55499278~55580110:-
BRCA	cis	rs12468226	1	rs13426118	ENSG00000273456.1	RP11-686O6.2	6.83	1.46e-11	3.09e-09	0.26	0.21	Urate levels;	chr2:202390762	chr2:202374932~202375604:-
BRCA	cis	rs13113518	0.678	rs7663650	ENSG00000273257.1	RP11-177J6.1	-6.83	1.46e-11	3.09e-09	-0.26	-0.21	Height;	chr4:55364952	chr4:55387949~55388271:+
BRCA	cis	rs17253792	0.822	rs10139905	ENSG00000186615.9	KTN1-AS1	-6.83	1.46e-11	3.09e-09	-0.37	-0.21	Putamen volume;	chr14:55703313	chr14:55499278~55580110:-
BRCA	cis	rs2243480	0.901	rs12530490	ENSG00000230295.1	RP11-458F8.2	6.83	1.47e-11	3.1e-09	0.28	0.21	Diabetic kidney disease;	chr7:66226660	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs7778911	ENSG00000230295.1	RP11-458F8.2	6.83	1.47e-11	3.1e-09	0.28	0.21	Diabetic kidney disease;	chr7:66229519	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs160639	ENSG00000230295.1	RP11-458F8.2	-6.83	1.47e-11	3.11e-09	-0.28	-0.21	Diabetic kidney disease;	chr7:66115000	chr7:66880708~66882981:+
BRCA	cis	rs858239	0.6	rs10241208	ENSG00000230042.1	AK3P3	-6.83	1.47e-11	3.11e-09	-0.24	-0.21	Cerebrospinal fluid biomarker levels;	chr7:23105295	chr7:23129178~23129841:+
BRCA	cis	rs10515750	0.5	rs7728460	ENSG00000248544.2	CTB-47B11.3	6.83	1.48e-11	3.11e-09	0.3	0.21	Lung function (FEV1/FVC);	chr5:157286607	chr5:157375741~157384950:-
BRCA	cis	rs11098499	0.954	rs13133522	ENSG00000249244.1	RP11-548H18.2	6.83	1.48e-11	3.11e-09	0.24	0.21	Corneal astigmatism;	chr4:119403269	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.954	rs35091806	ENSG00000249244.1	RP11-548H18.2	6.83	1.48e-11	3.11e-09	0.24	0.21	Corneal astigmatism;	chr4:119404374	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.909	rs35165976	ENSG00000249244.1	RP11-548H18.2	6.83	1.48e-11	3.11e-09	0.24	0.21	Corneal astigmatism;	chr4:119404475	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.954	rs6846442	ENSG00000249244.1	RP11-548H18.2	6.83	1.48e-11	3.11e-09	0.24	0.21	Corneal astigmatism;	chr4:119405168	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.954	rs71614438	ENSG00000249244.1	RP11-548H18.2	6.83	1.48e-11	3.11e-09	0.24	0.21	Corneal astigmatism;	chr4:119450097	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.954	rs66506550	ENSG00000249244.1	RP11-548H18.2	6.83	1.48e-11	3.11e-09	0.24	0.21	Corneal astigmatism;	chr4:119450290	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.909	rs7659501	ENSG00000249244.1	RP11-548H18.2	6.83	1.48e-11	3.11e-09	0.24	0.21	Corneal astigmatism;	chr4:119450397	chr4:119391831~119395335:-
BRCA	cis	rs875971	0.642	rs35526611	ENSG00000236529.1	RP13-254B10.1	-6.83	1.48e-11	3.12e-09	-0.23	-0.21	Aortic root size;	chr7:66629021	chr7:65840212~65840596:+
BRCA	cis	rs9807989	0.801	rs10173193	ENSG00000234389.1	AC007278.3	6.83	1.48e-11	3.12e-09	0.19	0.21	Asthma;	chr2:102358590	chr2:102438713~102440475:+
BRCA	cis	rs9807989	0.801	rs10176664	ENSG00000234389.1	AC007278.3	6.83	1.48e-11	3.12e-09	0.19	0.21	Asthma;	chr2:102359712	chr2:102438713~102440475:+
BRCA	cis	rs9807989	0.839	rs6543123	ENSG00000234389.1	AC007278.3	6.83	1.48e-11	3.12e-09	0.19	0.21	Asthma;	chr2:102360736	chr2:102438713~102440475:+
BRCA	cis	rs3781264	0.595	rs3818432	ENSG00000273450.1	RP11-76P2.4	6.83	1.48e-11	3.12e-09	0.28	0.21	Esophageal cancer and gastric cancer;	chr10:94304411	chr10:94314907~94315327:-
BRCA	cis	rs2243480	0.901	rs13237344	ENSG00000229886.1	RP5-1132H15.3	6.83	1.48e-11	3.12e-09	0.37	0.21	Diabetic kidney disease;	chr7:66557269	chr7:66025126~66031544:-
BRCA	cis	rs780096	0.546	rs2293571	ENSG00000234072.1	AC074117.10	-6.83	1.48e-11	3.12e-09	-0.2	-0.21	Total body bone mineral density;	chr2:27506613	chr2:27356246~27367622:+
BRCA	cis	rs172166	0.637	rs1071893	ENSG00000204709.4	LINC01556	6.83	1.48e-11	3.12e-09	0.27	0.21	Cardiac Troponin-T levels;	chr6:28199857	chr6:28943877~28944537:+
BRCA	cis	rs1552244	0.882	rs66559400	ENSG00000180385.7	EMC3-AS1	6.83	1.48e-11	3.13e-09	0.25	0.21	Alzheimer's disease;	chr3:9970867	chr3:9986893~10006990:+
BRCA	cis	rs17767294	0.612	rs12332927	ENSG00000220721.1	OR1F12	6.83	1.49e-11	3.14e-09	0.34	0.21	Parkinson's disease;	chr6:27987337	chr6:28073316~28074233:+
BRCA	cis	rs9880211	0.563	rs67589653	ENSG00000273486.1	RP11-731C17.2	6.83	1.49e-11	3.14e-09	0.27	0.21	Height;Body mass index;	chr3:136092732	chr3:136837338~136839021:-
BRCA	cis	rs9880211	0.563	rs10512990	ENSG00000273486.1	RP11-731C17.2	6.83	1.49e-11	3.14e-09	0.27	0.21	Height;Body mass index;	chr3:136095785	chr3:136837338~136839021:-
BRCA	cis	rs7674212	0.556	rs6533039	ENSG00000251288.2	RP11-10L12.2	-6.82	1.49e-11	3.15e-09	-0.25	-0.21	Type 2 diabetes;	chr4:102938381	chr4:102751401~102752641:+
BRCA	cis	rs11098499	0.954	rs7436506	ENSG00000249244.1	RP11-548H18.2	6.82	1.5e-11	3.15e-09	0.25	0.21	Corneal astigmatism;	chr4:119472614	chr4:119391831~119395335:-
BRCA	cis	rs516805	0.961	rs527978	ENSG00000279453.1	RP3-425C14.4	-6.82	1.5e-11	3.16e-09	-0.24	-0.21	Lymphocyte counts;	chr6:122475225	chr6:122436789~122439223:-
BRCA	cis	rs2337406	0.925	rs76288499	ENSG00000211974.3	IGHV2-70	-6.82	1.5e-11	3.16e-09	-0.27	-0.21	Alzheimer's disease (late onset);	chr14:106686309	chr14:106723574~106724093:-
BRCA	cis	rs1823913	0.637	rs4853465	ENSG00000280083.1	RP11-317J9.1	6.82	1.5e-11	3.16e-09	0.23	0.21	Obesity-related traits;	chr2:191294768	chr2:191154118~191156070:-
BRCA	cis	rs9309473	1	rs6753344	ENSG00000163016.8	ALMS1P	-6.82	1.5e-11	3.16e-09	-0.26	-0.21	Metabolite levels;	chr2:73426010	chr2:73644919~73685576:+
BRCA	cis	rs4237845	0.837	rs7954957	ENSG00000257159.1	RP11-58A17.3	6.82	1.5e-11	3.16e-09	0.23	0.21	Intelligence (multi-trait analysis);	chr12:57905467	chr12:57967058~57968399:+
BRCA	cis	rs11098499	0.615	rs59867181	ENSG00000245958.5	RP11-33B1.1	6.82	1.51e-11	3.17e-09	0.19	0.21	Corneal astigmatism;	chr4:119635312	chr4:119454791~119552025:+
BRCA	cis	rs1823913	0.637	rs4853575	ENSG00000280083.1	RP11-317J9.1	6.82	1.51e-11	3.17e-09	0.23	0.21	Obesity-related traits;	chr2:191296149	chr2:191154118~191156070:-
BRCA	cis	rs11096990	0.892	rs2381349	ENSG00000249207.1	RP11-360F5.1	6.82	1.51e-11	3.18e-09	0.24	0.21	Cognitive function;	chr4:39210390	chr4:39112677~39126818:-
BRCA	cis	rs875971	0.895	rs3857684	ENSG00000232559.3	GS1-124K5.12	6.82	1.51e-11	3.18e-09	0.24	0.21	Aortic root size;	chr7:66473171	chr7:66554588~66576923:-
BRCA	cis	rs801193	1	rs11773829	ENSG00000236529.1	RP13-254B10.1	-6.82	1.51e-11	3.18e-09	-0.22	-0.21	Aortic root size;	chr7:66676087	chr7:65840212~65840596:+
BRCA	cis	rs11976180	1	rs2961118	ENSG00000204959.4	ARHGEF34P	6.82	1.51e-11	3.18e-09	0.26	0.21	Obesity-related traits;	chr7:144058350	chr7:144272445~144286966:-
BRCA	cis	rs1029738	0.659	rs1608553	ENSG00000226329.2	AC005682.6	6.82	1.51e-11	3.18e-09	0.2	0.21	Fibrinogen levels;	chr7:22856612	chr7:22863874~22881350:-
BRCA	cis	rs78456975	0.527	rs4073862	ENSG00000231482.2	AC141930.2	-6.82	1.51e-11	3.18e-09	-0.27	-0.21	Placebo response in major depressive disorder (% change in symptom score);	chr2:1559661	chr2:1572554~1580311:-
BRCA	cis	rs2599510	0.703	rs762023	ENSG00000276334.1	AL133243.1	6.82	1.51e-11	3.19e-09	0.25	0.21	Interleukin-18 levels;	chr2:32488103	chr2:32521927~32523547:+
BRCA	cis	rs67981189	0.865	rs34488204	ENSG00000269927.1	RP6-91H8.3	6.82	1.51e-11	3.19e-09	0.26	0.21	Schizophrenia;	chr14:71028571	chr14:71141125~71143253:-
BRCA	cis	rs904251	0.58	rs62408367	ENSG00000204110.6	RP1-153P14.8	-6.82	1.52e-11	3.19e-09	-0.23	-0.21	Cognitive performance;	chr6:37477037	chr6:37507348~37535616:+
BRCA	cis	rs7674212	0.833	rs61075040	ENSG00000246560.2	RP11-10L12.4	6.82	1.52e-11	3.2e-09	0.22	0.21	Type 2 diabetes;	chr4:103052804	chr4:102828055~102844075:+
BRCA	cis	rs6543140	0.855	rs4851591	ENSG00000234389.1	AC007278.3	6.82	1.52e-11	3.2e-09	0.2	0.21	Blood protein levels;	chr2:102460963	chr2:102438713~102440475:+
BRCA	cis	rs875971	0.66	rs7807944	ENSG00000236529.1	RP13-254B10.1	-6.82	1.52e-11	3.2e-09	-0.23	-0.21	Aortic root size;	chr7:66622208	chr7:65840212~65840596:+
BRCA	cis	rs17711722	0.74	rs7809991	ENSG00000237310.1	GS1-124K5.4	6.82	1.52e-11	3.2e-09	0.21	0.21	Calcium levels;	chr7:65941231	chr7:66493706~66495474:+
BRCA	cis	rs600231	0.665	rs1784859	ENSG00000245532.5	NEAT1	-6.82	1.52e-11	3.21e-09	-0.19	-0.21	Bone mineral density;	chr11:65453278	chr11:65422774~65445540:+
BRCA	cis	rs7665090	0.87	rs227361	ENSG00000246560.2	RP11-10L12.4	6.82	1.52e-11	3.21e-09	0.21	0.21	Primary biliary cholangitis;	chr4:102665820	chr4:102828055~102844075:+
BRCA	cis	rs11976180	1	rs2961119	ENSG00000204959.4	ARHGEF34P	6.82	1.52e-11	3.21e-09	0.26	0.21	Obesity-related traits;	chr7:144058759	chr7:144272445~144286966:-
BRCA	cis	rs6686842	0.689	rs2885697	ENSG00000235358.1	RP11-399E6.1	-6.82	1.52e-11	3.21e-09	-0.27	-0.21	Height;	chr1:41078607	chr1:41242373~41284861:+
BRCA	cis	rs1555322	0.53	rs6060347	ENSG00000261582.1	RP4-614O4.11	-6.82	1.52e-11	3.21e-09	-0.23	-0.21	Attention deficit hyperactivity disorder;	chr20:35286348	chr20:35267885~35280043:-
BRCA	cis	rs8114671	0.967	rs6142323	ENSG00000269202.1	RP4-614O4.12	6.82	1.52e-11	3.21e-09	0.21	0.21	Height;	chr20:35201180	chr20:35201747~35203288:-
BRCA	cis	rs10515750	0.588	rs2289851	ENSG00000251405.2	CTB-109A12.1	6.82	1.53e-11	3.21e-09	0.32	0.21	Lung function (FEV1/FVC);	chr5:157359160	chr5:157362615~157460078:-
BRCA	cis	rs875971	0.66	rs10263935	ENSG00000236529.1	RP13-254B10.1	6.82	1.53e-11	3.21e-09	0.22	0.21	Aortic root size;	chr7:66631041	chr7:65840212~65840596:+
BRCA	cis	rs2688608	0.53	rs71507081	ENSG00000271816.1	BMS1P4	6.82	1.53e-11	3.22e-09	0.2	0.21	Inflammatory bowel disease;	chr10:73733378	chr10:73699151~73730487:-
BRCA	cis	rs875971	0.522	rs10807697	ENSG00000237310.1	GS1-124K5.4	6.82	1.53e-11	3.22e-09	0.21	0.21	Aortic root size;	chr7:65951183	chr7:66493706~66495474:+
BRCA	cis	rs9291683	0.609	rs13149985	ENSG00000250413.1	RP11-448G15.1	-6.82	1.53e-11	3.22e-09	-0.27	-0.21	Bone mineral density;	chr4:10026766	chr4:10006482~10009725:+
BRCA	cis	rs2675662	0.525	rs12264025	ENSG00000271816.1	BMS1P4	6.82	1.53e-11	3.22e-09	0.2	0.21	Psoriasis vulgaris;Psoriasis;	chr10:73734692	chr10:73699151~73730487:-
BRCA	cis	rs6840360	0.582	rs2724555	ENSG00000270265.1	RP11-731D1.4	-6.82	1.53e-11	3.23e-09	-0.23	-0.21	Intelligence (multi-trait analysis);	chr4:151420726	chr4:151333775~151353224:-
BRCA	cis	rs4237845	0.837	rs7954591	ENSG00000257159.1	RP11-58A17.3	6.82	1.53e-11	3.23e-09	0.23	0.21	Intelligence (multi-trait analysis);	chr12:57905254	chr12:57967058~57968399:+
BRCA	cis	rs2688608	0.592	rs11814282	ENSG00000271816.1	BMS1P4	6.82	1.53e-11	3.23e-09	0.2	0.21	Inflammatory bowel disease;	chr10:73730459	chr10:73699151~73730487:-
BRCA	cis	rs11098499	0.954	rs11729521	ENSG00000249244.1	RP11-548H18.2	6.82	1.53e-11	3.23e-09	0.25	0.21	Corneal astigmatism;	chr4:119495633	chr4:119391831~119395335:-
BRCA	cis	rs9859260	0.744	rs406271	ENSG00000231464.1	AC024937.4	-6.82	1.53e-11	3.23e-09	-0.26	-0.21	Mean corpuscular volume;	chr3:196050105	chr3:195996738~195998233:+
BRCA	cis	rs2599510	0.729	rs1135484	ENSG00000276334.1	AL133243.1	6.82	1.53e-11	3.23e-09	0.25	0.21	Interleukin-18 levels;	chr2:32523993	chr2:32521927~32523547:+
BRCA	cis	rs11976180	1	rs1540894	ENSG00000204959.4	ARHGEF34P	6.82	1.54e-11	3.24e-09	0.26	0.21	Obesity-related traits;	chr7:144070583	chr7:144272445~144286966:-
BRCA	cis	rs420259	0.516	rs2239951	ENSG00000260136.4	CTD-2270L9.4	-6.82	1.54e-11	3.24e-09	-0.21	-0.21	Bipolar disorder;	chr16:23493672	chr16:23452758~23457606:+
BRCA	cis	rs9291683	0.679	rs13137795	ENSG00000250413.1	RP11-448G15.1	-6.82	1.54e-11	3.25e-09	-0.28	-0.21	Bone mineral density;	chr4:10049882	chr4:10006482~10009725:+
BRCA	cis	rs7809950	0.723	rs62483634	ENSG00000238832.1	snoU109	-6.82	1.55e-11	3.26e-09	-0.29	-0.21	Coronary artery disease;	chr7:107238071	chr7:107603363~107603507:+
BRCA	cis	rs11096990	0.892	rs11730558	ENSG00000249207.1	RP11-360F5.1	-6.82	1.55e-11	3.27e-09	-0.25	-0.21	Cognitive function;	chr4:39228151	chr4:39112677~39126818:-
BRCA	cis	rs11098499	0.657	rs71614442	ENSG00000249244.1	RP11-548H18.2	6.82	1.55e-11	3.27e-09	0.24	0.21	Corneal astigmatism;	chr4:119458191	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.954	rs2892848	ENSG00000249244.1	RP11-548H18.2	6.82	1.55e-11	3.27e-09	0.24	0.21	Corneal astigmatism;	chr4:119460186	chr4:119391831~119395335:-
BRCA	cis	rs7617773	0.817	rs11707606	ENSG00000228638.1	FCF1P2	-6.82	1.56e-11	3.28e-09	-0.23	-0.21	Coronary artery disease;	chr3:48195597	chr3:48290793~48291375:-
BRCA	cis	rs780096	0.546	rs4425043	ENSG00000234072.1	AC074117.10	-6.82	1.56e-11	3.28e-09	-0.2	-0.21	Total body bone mineral density;	chr2:27510585	chr2:27356246~27367622:+
BRCA	cis	rs10446497	0.61	rs12497046	ENSG00000272359.1	U4	6.82	1.56e-11	3.29e-09	0.27	0.21	Schizophrenia;	chr3:196816775	chr3:196747192~196747324:-
BRCA	cis	rs2638953	0.924	rs7307078	ENSG00000278733.1	RP11-425D17.1	-6.82	1.56e-11	3.29e-09	-0.26	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28184645	chr12:28185625~28186190:-
BRCA	cis	rs10129255	0.5	rs2027902	ENSG00000211970.3	IGHV4-61	-6.82	1.56e-11	3.29e-09	-0.13	-0.21	Kawasaki disease;	chr14:106807157	chr14:106639119~106639657:-
BRCA	cis	rs4072705	0.967	rs4838210	ENSG00000224020.1	MIR181A2HG	6.82	1.57e-11	3.29e-09	0.22	0.21	Menarche (age at onset);	chr9:124783904	chr9:124658467~124698631:+
BRCA	cis	rs6683071	0.557	rs2378605	ENSG00000272750.1	RP11-378J18.8	-6.82	1.57e-11	3.29e-09	-0.4	-0.21	Cognitive performance;	chr1:222732211	chr1:222658867~222661512:-
BRCA	cis	rs4072705	1	rs2416949	ENSG00000224020.1	MIR181A2HG	-6.82	1.57e-11	3.3e-09	-0.23	-0.21	Menarche (age at onset);	chr9:124712832	chr9:124658467~124698631:+
BRCA	cis	rs2034650	0.544	rs8034217	ENSG00000223313.1	RNU6-516P	-6.82	1.57e-11	3.3e-09	-0.27	-0.21	Interstitial lung disease;	chr15:40429501	chr15:40529570~40529673:+
BRCA	cis	rs875971	0.545	rs1796219	ENSG00000224316.1	RP11-479O9.2	-6.82	1.57e-11	3.3e-09	-0.24	-0.21	Aortic root size;	chr7:66645977	chr7:65773620~65802067:+
BRCA	cis	rs10181042	0.535	rs2441465	ENSG00000271889.1	RP11-493E12.1	6.82	1.57e-11	3.3e-09	0.25	0.21	Crohn's disease;	chr2:61084052	chr2:61151433~61162105:-
BRCA	cis	rs7044106	0.791	rs4617229	ENSG00000238181.2	AHCYP2	-6.82	1.57e-11	3.3e-09	-0.27	-0.21	Hip circumference adjusted for BMI;	chr9:120718418	chr9:120720673~120721972:+
BRCA	cis	rs375066	0.762	rs239943	ENSG00000267058.1	RP11-15A1.3	-6.82	1.57e-11	3.3e-09	-0.24	-0.21	Breast cancer;	chr19:43870564	chr19:43891804~43901805:-
BRCA	cis	rs755249	0.567	rs16826009	ENSG00000228060.1	RP11-69E11.8	-6.82	1.57e-11	3.3e-09	-0.25	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39251230	chr1:39565160~39573203:+
BRCA	cis	rs67981189	0.896	rs1859468	ENSG00000269927.1	RP6-91H8.3	-6.82	1.57e-11	3.3e-09	-0.26	-0.21	Schizophrenia;	chr14:70935573	chr14:71141125~71143253:-
BRCA	cis	rs812925	0.892	rs1186699	ENSG00000271889.1	RP11-493E12.1	6.82	1.57e-11	3.3e-09	0.26	0.21	Immature fraction of reticulocytes;	chr2:61435420	chr2:61151433~61162105:-
BRCA	cis	rs7845219	0.597	rs7002058	ENSG00000253528.2	RP11-347C18.4	6.82	1.57e-11	3.31e-09	0.21	0.21	Type 2 diabetes;	chr8:94861765	chr8:94974573~94974853:-
BRCA	cis	rs7247513	0.964	rs8105902	ENSG00000230310.1	CTD-2192J16.11	-6.82	1.57e-11	3.31e-09	-0.27	-0.21	Bipolar disorder;	chr19:12607537	chr19:12552597~12553644:+
BRCA	cis	rs9309473	0.948	rs11884776	ENSG00000163016.8	ALMS1P	6.82	1.58e-11	3.31e-09	0.26	0.21	Metabolite levels;	chr2:73519796	chr2:73644919~73685576:+
BRCA	cis	rs7976269	0.609	rs2117994	ENSG00000257176.2	RP11-996F15.2	-6.82	1.58e-11	3.32e-09	-0.25	-0.21	Male-pattern baldness;	chr12:29054666	chr12:29280418~29317848:-
BRCA	cis	rs7976269	0.583	rs6487753	ENSG00000257176.2	RP11-996F15.2	-6.82	1.58e-11	3.32e-09	-0.25	-0.21	Male-pattern baldness;	chr12:29056103	chr12:29280418~29317848:-
BRCA	cis	rs7976269	0.583	rs6487754	ENSG00000257176.2	RP11-996F15.2	-6.82	1.58e-11	3.32e-09	-0.25	-0.21	Male-pattern baldness;	chr12:29056104	chr12:29280418~29317848:-
BRCA	cis	rs7976269	0.609	rs6487755	ENSG00000257176.2	RP11-996F15.2	-6.82	1.58e-11	3.32e-09	-0.25	-0.21	Male-pattern baldness;	chr12:29056156	chr12:29280418~29317848:-
BRCA	cis	rs2834288	0.5	rs2834304	ENSG00000273102.1	AP000569.9	6.82	1.58e-11	3.32e-09	0.22	0.21	Gut microbiota (bacterial taxa);	chr21:33949550	chr21:33967101~33968573:-
BRCA	cis	rs4683346	0.549	rs6442067	ENSG00000173811.9	CCDC13-AS1	6.82	1.58e-11	3.32e-09	0.26	0.21	Granulocyte percentage of myeloid white cells;	chr3:42783623	chr3:42732575~42746768:+
BRCA	cis	rs12817211	0.502	rs1554844	ENSG00000272368.2	RP4-605O3.4	-6.82	1.58e-11	3.32e-09	-0.21	-0.21	Colorectal or endometrial cancer;	chr12:50120582	chr12:50112197~50165618:+
BRCA	cis	rs4372836	0.928	rs55836936	ENSG00000226833.4	AC097724.3	-6.82	1.58e-11	3.32e-09	-0.26	-0.21	Body mass index;	chr2:28699967	chr2:28708953~28736205:-
BRCA	cis	rs2348418	0.579	rs2126896	ENSG00000247934.4	RP11-967K21.1	-6.82	1.58e-11	3.33e-09	-0.23	-0.21	Lung function (FEV1);Lung function (FVC);	chr12:28239701	chr12:28163298~28190738:-
BRCA	cis	rs7809950	1	rs2520271	ENSG00000238832.1	snoU109	-6.82	1.59e-11	3.33e-09	-0.27	-0.21	Coronary artery disease;	chr7:107554504	chr7:107603363~107603507:+
BRCA	cis	rs7809950	1	rs2237676	ENSG00000238832.1	snoU109	-6.82	1.59e-11	3.33e-09	-0.27	-0.21	Coronary artery disease;	chr7:107557634	chr7:107603363~107603507:+
BRCA	cis	rs11098499	0.58	rs12509234	ENSG00000249244.1	RP11-548H18.2	6.82	1.59e-11	3.33e-09	0.25	0.21	Corneal astigmatism;	chr4:119398279	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.909	rs10014719	ENSG00000249244.1	RP11-548H18.2	6.82	1.59e-11	3.33e-09	0.25	0.21	Corneal astigmatism;	chr4:119399560	chr4:119391831~119395335:-
BRCA	cis	rs911555	0.755	rs12435516	ENSG00000244691.1	RPL10AP1	6.82	1.59e-11	3.33e-09	0.26	0.21	Intelligence (multi-trait analysis);	chr14:103488067	chr14:103412119~103412761:-
BRCA	cis	rs911555	0.755	rs2756135	ENSG00000244691.1	RPL10AP1	6.82	1.59e-11	3.33e-09	0.26	0.21	Intelligence (multi-trait analysis);	chr14:103496242	chr14:103412119~103412761:-
BRCA	cis	rs17253792	0.822	rs10137340	ENSG00000186615.9	KTN1-AS1	-6.82	1.59e-11	3.34e-09	-0.37	-0.21	Putamen volume;	chr14:55584271	chr14:55499278~55580110:-
BRCA	cis	rs944990	0.576	rs10992731	ENSG00000227603.1	RP11-165J3.6	6.82	1.59e-11	3.34e-09	0.21	0.21	Body mass index;	chr9:93436816	chr9:93435332~93437121:-
BRCA	cis	rs7474896	0.515	rs2505233	ENSG00000226578.1	RP11-258F22.1	-6.82	1.59e-11	3.34e-09	-0.26	-0.21	Obesity (extreme);	chr10:38051337	chr10:37775371~37784131:-
BRCA	cis	rs7246657	0.943	rs8109038	ENSG00000267422.1	CTD-2554C21.1	6.82	1.59e-11	3.34e-09	0.31	0.21	Coronary artery calcification;	chr19:37524807	chr19:37779686~37792865:+
BRCA	cis	rs919433	0.68	rs787983	ENSG00000231621.1	AC013264.2	-6.82	1.59e-11	3.34e-09	-0.19	-0.21	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197481073	chr2:197197991~197199273:+
BRCA	cis	rs9309711	0.922	rs13399524	ENSG00000225234.1	TRAPPC12-AS1	-6.82	1.59e-11	3.34e-09	-0.23	-0.21	Neurofibrillary tangles;	chr2:3476435	chr2:3481242~3482409:-
BRCA	cis	rs1707322	0.721	rs28501477	ENSG00000281133.1	AL355480.3	-6.81	1.59e-11	3.35e-09	-0.27	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45733412	chr1:45580892~45580996:-
BRCA	cis	rs875971	0.862	rs880166	ENSG00000224316.1	RP11-479O9.2	-6.81	1.6e-11	3.35e-09	-0.21	-0.21	Aortic root size;	chr7:66205775	chr7:65773620~65802067:+
BRCA	cis	rs2243480	0.901	rs778732	ENSG00000232546.1	RP11-458F8.1	-6.81	1.6e-11	3.36e-09	-0.28	-0.21	Diabetic kidney disease;	chr7:66357373	chr7:66848496~66858136:+
BRCA	cis	rs2243480	1	rs10247526	ENSG00000230295.1	RP11-458F8.2	6.81	1.6e-11	3.36e-09	0.28	0.21	Diabetic kidney disease;	chr7:66315709	chr7:66880708~66882981:+
BRCA	cis	rs4072705	1	rs722477	ENSG00000224020.1	MIR181A2HG	-6.81	1.6e-11	3.37e-09	-0.23	-0.21	Menarche (age at onset);	chr9:124712315	chr9:124658467~124698631:+
BRCA	cis	rs6969780	0.915	rs4722657	ENSG00000233429.8	HOTAIRM1	-6.81	1.61e-11	3.38e-09	-0.24	-0.21	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27118137	chr7:27095647~27100265:+
BRCA	cis	rs9291683	0.588	rs3796842	ENSG00000250413.1	RP11-448G15.1	-6.81	1.61e-11	3.38e-09	-0.26	-0.21	Bone mineral density;	chr4:9994227	chr4:10006482~10009725:+
BRCA	cis	rs904251	1	rs904251	ENSG00000204110.6	RP1-153P14.8	-6.81	1.61e-11	3.38e-09	-0.23	-0.21	Cognitive performance;	chr6:37483920	chr6:37507348~37535616:+
BRCA	cis	rs875971	1	rs2077593	ENSG00000232559.3	GS1-124K5.12	6.81	1.61e-11	3.38e-09	0.25	0.21	Aortic root size;	chr7:66427543	chr7:66554588~66576923:-
BRCA	cis	rs1823913	0.637	rs4853573	ENSG00000280083.1	RP11-317J9.1	6.81	1.61e-11	3.38e-09	0.23	0.21	Obesity-related traits;	chr2:191295866	chr2:191154118~191156070:-
BRCA	cis	rs875971	1	rs2420591	ENSG00000232559.3	GS1-124K5.12	6.81	1.61e-11	3.39e-09	0.25	0.21	Aortic root size;	chr7:66447394	chr7:66554588~66576923:-
BRCA	cis	rs11098499	0.954	rs11098525	ENSG00000249244.1	RP11-548H18.2	6.81	1.62e-11	3.39e-09	0.24	0.21	Corneal astigmatism;	chr4:119468997	chr4:119391831~119395335:-
BRCA	cis	rs7829975	0.688	rs7826654	ENSG00000254153.1	CTA-398F10.2	6.81	1.62e-11	3.39e-09	0.25	0.21	Mood instability;	chr8:8521596	chr8:8456909~8461337:-
BRCA	cis	rs7829975	0.688	rs7826660	ENSG00000254153.1	CTA-398F10.2	6.81	1.62e-11	3.39e-09	0.25	0.21	Mood instability;	chr8:8521597	chr8:8456909~8461337:-
BRCA	cis	rs875971	1	rs6460296	ENSG00000232559.3	GS1-124K5.12	6.81	1.62e-11	3.39e-09	0.24	0.21	Aortic root size;	chr7:66430152	chr7:66554588~66576923:-
BRCA	cis	rs67981189	0.821	rs61990419	ENSG00000269927.1	RP6-91H8.3	6.81	1.62e-11	3.4e-09	0.26	0.21	Schizophrenia;	chr14:71069570	chr14:71141125~71143253:-
BRCA	cis	rs79040073	0.637	rs57749497	ENSG00000259531.2	RP11-295H24.3	6.81	1.62e-11	3.4e-09	0.33	0.21	Lung cancer in ever smokers;	chr15:49297661	chr15:49365124~49366685:-
BRCA	cis	rs2348418	0.966	rs11049695	ENSG00000247934.4	RP11-967K21.1	6.81	1.62e-11	3.4e-09	0.23	0.21	Lung function (FEV1);Lung function (FVC);	chr12:28527934	chr12:28163298~28190738:-
BRCA	cis	rs875971	0.83	rs587360	ENSG00000224316.1	RP11-479O9.2	6.81	1.62e-11	3.4e-09	0.21	0.21	Aortic root size;	chr7:66057711	chr7:65773620~65802067:+
BRCA	cis	rs899997	0.773	rs12595461	ENSG00000261143.1	ADAMTS7P3	-6.81	1.62e-11	3.41e-09	-0.32	-0.21	Coronary artery disease or large artery stroke;	chr15:78676830	chr15:77976042~77993057:+
BRCA	cis	rs13113518	0.783	rs6843722	ENSG00000249700.7	SRD5A3-AS1	6.81	1.63e-11	3.41e-09	0.26	0.21	Height;	chr4:55465165	chr4:55363971~55395847:-
BRCA	cis	rs4722166	0.532	rs6461662	ENSG00000179428.2	AC073072.5	-6.81	1.63e-11	3.41e-09	-0.22	-0.21	Lung cancer;	chr7:22717470	chr7:22725395~22727620:-
BRCA	cis	rs9876781	1	rs7635522	ENSG00000244380.1	RP11-24C3.2	6.81	1.63e-11	3.42e-09	0.24	0.21	Longevity;	chr3:48382166	chr3:48440352~48446656:-
BRCA	cis	rs710913	0.531	rs1180331	ENSG00000237624.1	OXCT2P1	-6.81	1.63e-11	3.42e-09	-0.24	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39546512	chr1:39514956~39516490:+
BRCA	cis	rs9876781	1	rs2242150	ENSG00000229759.1	MRPS18AP1	-6.81	1.63e-11	3.42e-09	-0.23	-0.21	Longevity;	chr3:48464565	chr3:48256350~48256938:-
BRCA	cis	rs10515750	0.588	rs11739823	ENSG00000251405.2	CTB-109A12.1	6.81	1.63e-11	3.42e-09	0.31	0.21	Lung function (FEV1/FVC);	chr5:157342000	chr5:157362615~157460078:-
BRCA	cis	rs2688608	0.592	rs11000760	ENSG00000271816.1	BMS1P4	6.81	1.63e-11	3.43e-09	0.2	0.21	Inflammatory bowel disease;	chr10:73733976	chr10:73699151~73730487:-
BRCA	cis	rs34779708	0.931	rs4934524	ENSG00000271335.4	RP11-324I22.4	6.81	1.64e-11	3.43e-09	0.22	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:34981993	chr10:35314552~35336401:-
BRCA	cis	rs34779708	0.931	rs4934693	ENSG00000271335.4	RP11-324I22.4	6.81	1.64e-11	3.43e-09	0.22	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:34982916	chr10:35314552~35336401:-
BRCA	cis	rs13217239	0.608	rs6930508	ENSG00000241549.7	GUSBP2	-6.81	1.64e-11	3.44e-09	-0.23	-0.21	Schizophrenia;	chr6:27085363	chr6:26871484~26956554:-
BRCA	cis	rs13217239	0.646	rs2142685	ENSG00000241549.7	GUSBP2	-6.81	1.64e-11	3.44e-09	-0.23	-0.21	Schizophrenia;	chr6:27086718	chr6:26871484~26956554:-
BRCA	cis	rs10754283	0.967	rs7523046	ENSG00000231613.1	RP5-943J3.1	6.81	1.65e-11	3.46e-09	0.23	0.21	Amyotrophic lateral sclerosis (sporadic);	chr1:89643940	chr1:89788914~89790492:+
BRCA	cis	rs10754283	0.967	rs7523518	ENSG00000231613.1	RP5-943J3.1	6.81	1.65e-11	3.46e-09	0.23	0.21	Amyotrophic lateral sclerosis (sporadic);	chr1:89644451	chr1:89788914~89790492:+
BRCA	cis	rs600231	0.623	rs587080	ENSG00000245532.5	NEAT1	6.81	1.65e-11	3.46e-09	0.19	0.21	Bone mineral density;	chr11:65486329	chr11:65422774~65445540:+
BRCA	cis	rs420259	0.516	rs7190131	ENSG00000260136.4	CTD-2270L9.4	-6.81	1.65e-11	3.46e-09	-0.21	-0.21	Bipolar disorder;	chr16:23490828	chr16:23452758~23457606:+
BRCA	cis	rs875971	1	rs4718307	ENSG00000224316.1	RP11-479O9.2	-6.81	1.65e-11	3.47e-09	-0.2	-0.21	Aortic root size;	chr7:66146001	chr7:65773620~65802067:+
BRCA	cis	rs875971	1	rs7801282	ENSG00000224316.1	RP11-479O9.2	-6.81	1.65e-11	3.47e-09	-0.2	-0.21	Aortic root size;	chr7:66148700	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.522	rs2008188	ENSG00000237310.1	GS1-124K5.4	6.81	1.65e-11	3.47e-09	0.21	0.21	Aortic root size;	chr7:65964026	chr7:66493706~66495474:+
BRCA	cis	rs67311347	1	rs9865348	ENSG00000280739.1	EIF1B-AS1	6.81	1.65e-11	3.47e-09	0.23	0.21	Renal cell carcinoma;	chr3:40356167	chr3:40173145~40309698:-
BRCA	cis	rs2239547	0.603	rs6805298	ENSG00000242142.1	SERBP1P3	-6.81	1.66e-11	3.47e-09	-0.25	-0.21	Schizophrenia;	chr3:53062536	chr3:53064283~53065091:-
BRCA	cis	rs875971	1	rs6946143	ENSG00000232559.3	GS1-124K5.12	6.81	1.66e-11	3.48e-09	0.25	0.21	Aortic root size;	chr7:66114735	chr7:66554588~66576923:-
BRCA	cis	rs1823913	0.614	rs4853466	ENSG00000280083.1	RP11-317J9.1	6.81	1.66e-11	3.48e-09	0.23	0.21	Obesity-related traits;	chr2:191295943	chr2:191154118~191156070:-
BRCA	cis	rs1499614	1	rs1267817	ENSG00000230295.1	RP11-458F8.2	-6.81	1.66e-11	3.49e-09	-0.28	-0.21	Gout;	chr7:66645053	chr7:66880708~66882981:+
BRCA	cis	rs5015933	0.902	rs1969045	ENSG00000232630.1	PRPS1P2	-6.81	1.66e-11	3.49e-09	-0.19	-0.21	Body mass index;	chr9:125368261	chr9:125150653~125151589:+
BRCA	cis	rs1555322	0.53	rs2425044	ENSG00000279253.1	RP4-614O4.13	-6.81	1.67e-11	3.5e-09	-0.28	-0.21	Attention deficit hyperactivity disorder;	chr20:35281932	chr20:35262727~35264187:-
BRCA	cis	rs2842992	0.789	rs7765490	ENSG00000237927.1	RP3-393E18.2	-6.81	1.67e-11	3.5e-09	-0.29	-0.21	Age-related macular degeneration (geographic atrophy);	chr6:159783294	chr6:159586955~159589169:-
BRCA	cis	rs6142102	0.923	rs3787230	ENSG00000275784.1	RP5-1125A11.6	-6.81	1.67e-11	3.51e-09	-0.24	-0.21	Skin pigmentation;	chr20:34052466	chr20:33989480~33991818:-
BRCA	cis	rs2243480	1	rs313824	ENSG00000232546.1	RP11-458F8.1	-6.81	1.68e-11	3.51e-09	-0.28	-0.21	Diabetic kidney disease;	chr7:66116220	chr7:66848496~66858136:+
BRCA	cis	rs2243480	1	rs186378	ENSG00000232546.1	RP11-458F8.1	-6.81	1.68e-11	3.51e-09	-0.28	-0.21	Diabetic kidney disease;	chr7:66117071	chr7:66848496~66858136:+
BRCA	cis	rs2243480	1	rs160637	ENSG00000232546.1	RP11-458F8.1	-6.81	1.68e-11	3.51e-09	-0.28	-0.21	Diabetic kidney disease;	chr7:66119331	chr7:66848496~66858136:+
BRCA	cis	rs2638953	0.924	rs12368652	ENSG00000278733.1	RP11-425D17.1	-6.81	1.68e-11	3.51e-09	-0.26	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28170046	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.924	rs11049392	ENSG00000278733.1	RP11-425D17.1	-6.81	1.68e-11	3.51e-09	-0.26	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28170256	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.924	rs11049394	ENSG00000278733.1	RP11-425D17.1	-6.81	1.68e-11	3.51e-09	-0.26	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28170947	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.886	rs11049395	ENSG00000278733.1	RP11-425D17.1	-6.81	1.68e-11	3.51e-09	-0.26	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28171087	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.886	rs11049397	ENSG00000278733.1	RP11-425D17.1	-6.81	1.68e-11	3.51e-09	-0.26	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28171909	chr12:28185625~28186190:-
BRCA	cis	rs7131987	0.65	rs7954871	ENSG00000257176.2	RP11-996F15.2	-6.81	1.68e-11	3.52e-09	-0.25	-0.21	QT interval;	chr12:29306799	chr12:29280418~29317848:-
BRCA	cis	rs8062405	0.558	rs151228	ENSG00000251417.2	RP11-1348G14.4	-6.81	1.68e-11	3.53e-09	-0.22	-0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28551705	chr16:28802743~28817828:+
BRCA	cis	rs17253792	0.822	rs10136155	ENSG00000186615.9	KTN1-AS1	-6.81	1.68e-11	3.53e-09	-0.4	-0.21	Putamen volume;	chr14:55582411	chr14:55499278~55580110:-
BRCA	cis	rs73186030	0.764	rs66508963	ENSG00000272758.4	RP11-299J3.8	6.81	1.69e-11	3.54e-09	0.29	0.21	Serum parathyroid hormone levels;	chr3:122365682	chr3:122416207~122443180:+
BRCA	cis	rs7085104	0.514	rs284855	ENSG00000236937.2	PTGES3P4	-6.81	1.69e-11	3.54e-09	-0.26	-0.21	Immature fraction of reticulocytes;Schizophrenia;	chr10:102814665	chr10:102845595~102845950:+
BRCA	cis	rs4356203	0.519	rs214092	ENSG00000272034.1	SNORD14A	-6.81	1.69e-11	3.54e-09	-0.22	-0.21	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17273499	chr11:17074654~17074744:-
BRCA	cis	rs9307551	0.817	rs1031004	ENSG00000250334.4	LINC00989	-6.81	1.69e-11	3.54e-09	-0.28	-0.21	Refractive error;	chr4:79595695	chr4:79492416~79576460:+
BRCA	cis	rs2033711	0.87	rs11669741	ENSG00000269473.1	CTD-2619J13.19	-6.81	1.69e-11	3.55e-09	-0.24	-0.21	Uric acid clearance;	chr19:58449114	chr19:58440448~58445849:+
BRCA	cis	rs755249	0.532	rs17343193	ENSG00000228060.1	RP11-69E11.8	-6.81	1.69e-11	3.55e-09	-0.26	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39415796	chr1:39565160~39573203:+
BRCA	cis	rs2749097	0.825	rs11208265	ENSG00000244256.3	RN7SL130P	-6.81	1.7e-11	3.56e-09	-0.26	-0.21	Alcohol consumption (transferrin glycosylation);	chr1:63659563	chr1:63655743~63656047:+
BRCA	cis	rs9291683	0.588	rs12647117	ENSG00000250413.1	RP11-448G15.1	-6.81	1.7e-11	3.56e-09	-0.27	-0.21	Bone mineral density;	chr4:10020435	chr4:10006482~10009725:+
BRCA	cis	rs9291683	0.551	rs2276961	ENSG00000250413.1	RP11-448G15.1	-6.81	1.7e-11	3.56e-09	-0.27	-0.21	Bone mineral density;	chr4:10021357	chr4:10006482~10009725:+
BRCA	cis	rs7176527	1	rs3762169	ENSG00000229212.6	RP11-561C5.4	6.81	1.7e-11	3.56e-09	0.3	0.21	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84598728	chr15:85205440~85234795:-
BRCA	cis	rs11098499	0.863	rs12508173	ENSG00000249244.1	RP11-548H18.2	6.8	1.7e-11	3.57e-09	0.25	0.21	Corneal astigmatism;	chr4:119397371	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.908	rs12504149	ENSG00000249244.1	RP11-548H18.2	6.8	1.7e-11	3.57e-09	0.25	0.21	Corneal astigmatism;	chr4:119397422	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.82	rs13128602	ENSG00000249244.1	RP11-548H18.2	-6.8	1.7e-11	3.57e-09	-0.25	-0.21	Corneal astigmatism;	chr4:119538211	chr4:119391831~119395335:-
BRCA	cis	rs17253792	0.822	rs11546	ENSG00000186615.9	KTN1-AS1	-6.8	1.71e-11	3.57e-09	-0.4	-0.21	Putamen volume;	chr14:55679639	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs10148122	ENSG00000186615.9	KTN1-AS1	-6.8	1.71e-11	3.57e-09	-0.4	-0.21	Putamen volume;	chr14:55679976	chr14:55499278~55580110:-
BRCA	cis	rs6543140	0.964	rs13393175	ENSG00000234389.1	AC007278.3	6.8	1.71e-11	3.57e-09	0.2	0.21	Blood protein levels;	chr2:102462389	chr2:102438713~102440475:+
BRCA	cis	rs9840812	0.623	rs1394092	ENSG00000239213.4	NCK1-AS1	6.8	1.71e-11	3.57e-09	0.24	0.21	Fibrinogen levels;	chr3:136477229	chr3:136841726~136862054:-
BRCA	cis	rs2842992	0.789	rs6908680	ENSG00000237927.1	RP3-393E18.2	-6.8	1.71e-11	3.58e-09	-0.3	-0.21	Age-related macular degeneration (geographic atrophy);	chr6:159797177	chr6:159586955~159589169:-
BRCA	cis	rs2842992	0.672	rs4708845	ENSG00000237927.1	RP3-393E18.2	-6.8	1.71e-11	3.58e-09	-0.3	-0.21	Age-related macular degeneration (geographic atrophy);	chr6:159798569	chr6:159586955~159589169:-
BRCA	cis	rs2842992	0.789	rs2342446	ENSG00000237927.1	RP3-393E18.2	-6.8	1.71e-11	3.58e-09	-0.3	-0.21	Age-related macular degeneration (geographic atrophy);	chr6:159799655	chr6:159586955~159589169:-
BRCA	cis	rs516805	0.961	rs1267942	ENSG00000279453.1	RP3-425C14.4	-6.8	1.71e-11	3.58e-09	-0.24	-0.21	Lymphocyte counts;	chr6:122472375	chr6:122436789~122439223:-
BRCA	cis	rs71520386	0.632	rs1474349	ENSG00000228649.7	AC005682.5	-6.8	1.72e-11	3.6e-09	-0.2	-0.21	Fibrinogen levels;	chr7:22814146	chr7:22854178~22861579:+
BRCA	cis	rs367615	0.68	rs77013	ENSG00000249476.1	CTD-2587M2.1	6.8	1.72e-11	3.61e-09	0.25	0.21	Colorectal cancer (SNP x SNP interaction);	chr5:109627385	chr5:109237120~109326369:-
BRCA	cis	rs2842992	0.789	rs2146163	ENSG00000237927.1	RP3-393E18.2	-6.8	1.72e-11	3.61e-09	-0.3	-0.21	Age-related macular degeneration (geographic atrophy);	chr6:159803314	chr6:159586955~159589169:-
BRCA	cis	rs2842992	0.789	rs9364536	ENSG00000237927.1	RP3-393E18.2	-6.8	1.72e-11	3.61e-09	-0.3	-0.21	Age-related macular degeneration (geographic atrophy);	chr6:159804527	chr6:159586955~159589169:-
BRCA	cis	rs4803480	0.678	rs3745936	ENSG00000270164.1	LINC01480	-6.8	1.73e-11	3.62e-09	-0.24	-0.21	Schizophrenia;	chr19:41586462	chr19:41535183~41536904:+
BRCA	cis	rs4691139	1	rs13134489	ENSG00000248632.1	RP11-366M4.11	6.8	1.73e-11	3.62e-09	0.21	0.21	Ovarian cancer in BRCA1 mutation carriers;	chr4:164968285	chr4:164968587~164970002:-
BRCA	cis	rs17301013	0.581	rs1591944	ENSG00000227373.4	RP11-160H22.5	6.8	1.74e-11	3.63e-09	0.3	0.21	Systemic lupus erythematosus;	chr1:174204917	chr1:174115300~174160004:-
BRCA	cis	rs13287066	0.692	rs72743489	ENSG00000227603.1	RP11-165J3.6	6.8	1.74e-11	3.63e-09	0.21	0.21	Intelligence (multi-trait analysis);	chr9:93406201	chr9:93435332~93437121:-
BRCA	cis	rs1440410	0.835	rs11722027	ENSG00000250326.1	RP11-284M14.1	-6.8	1.74e-11	3.64e-09	-0.23	-0.21	Ischemic stroke;	chr4:143128864	chr4:142933195~143184861:-
BRCA	cis	rs67311347	1	rs17078511	ENSG00000280739.1	EIF1B-AS1	6.8	1.74e-11	3.64e-09	0.23	0.21	Renal cell carcinoma;	chr3:40354763	chr3:40173145~40309698:-
BRCA	cis	rs4722166	0.532	rs1546763	ENSG00000179428.2	AC073072.5	-6.8	1.74e-11	3.64e-09	-0.22	-0.21	Lung cancer;	chr7:22718224	chr7:22725395~22727620:-
BRCA	cis	rs4266144	0.563	rs61124401	ENSG00000244515.1	KRT18P34	-6.8	1.74e-11	3.64e-09	-0.28	-0.21	Coronary artery disease;	chr3:157123130	chr3:157162663~157163932:-
BRCA	cis	rs7914558	0.752	rs7896519	ENSG00000213061.2	PFN1P11	6.8	1.74e-11	3.64e-09	0.28	0.21	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103107106	chr10:102838011~102845473:-
BRCA	cis	rs78456975	0.699	rs17091772	ENSG00000231482.2	AC141930.2	-6.8	1.74e-11	3.64e-09	-0.29	-0.21	Placebo response in major depressive disorder (% change in symptom score);	chr2:1515907	chr2:1572554~1580311:-
BRCA	cis	rs6603134	0.502	rs10406511	ENSG00000267939.1	CTD-2325M2.1	-6.8	1.74e-11	3.65e-09	-0.24	-0.21	Blood protein levels;	chr19:8039061	chr19:8008729~8016025:+
BRCA	cis	rs11018904	0.906	rs55685917	ENSG00000280385.1	AP000648.5	-6.8	1.75e-11	3.65e-09	-0.3	-0.21	Intelligence (multi-trait analysis);	chr11:90231197	chr11:90193614~90198120:+
BRCA	cis	rs11018904	0.906	rs35286339	ENSG00000280385.1	AP000648.5	-6.8	1.75e-11	3.65e-09	-0.3	-0.21	Intelligence (multi-trait analysis);	chr11:90232511	chr11:90193614~90198120:+
BRCA	cis	rs2243480	0.908	rs55876148	ENSG00000228409.4	CCT6P1	6.8	1.75e-11	3.66e-09	0.29	0.21	Diabetic kidney disease;	chr7:65914813	chr7:65751142~65763354:+
BRCA	cis	rs1800795	0.599	rs1546762	ENSG00000179428.2	AC073072.5	-6.8	1.75e-11	3.66e-09	-0.22	-0.21	Cerebrospinal fluid clusterin levels in APOEe4- carriers;	chr7:22717884	chr7:22725395~22727620:-
BRCA	cis	rs11098499	0.874	rs28452522	ENSG00000248280.1	RP11-33B1.2	6.8	1.75e-11	3.66e-09	0.23	0.21	Corneal astigmatism;	chr4:119189629	chr4:119440561~119450157:-
BRCA	cis	rs42648	0.596	rs194518	ENSG00000225498.1	AC002064.5	6.8	1.75e-11	3.66e-09	0.2	0.21	Homocysteine levels;	chr7:90223835	chr7:90312496~90322592:+
BRCA	cis	rs13113518	0.812	rs13107810	ENSG00000223305.1	RN7SKP30	6.8	1.75e-11	3.66e-09	0.26	0.21	Height;	chr4:55542243	chr4:55540502~55540835:-
BRCA	cis	rs2880765	0.743	rs8039049	ENSG00000259295.5	CSPG4P12	6.8	1.76e-11	3.68e-09	0.26	0.21	Coronary artery disease;	chr15:85464398	chr15:85191438~85213905:+
BRCA	cis	rs2880765	0.743	rs8039631	ENSG00000259295.5	CSPG4P12	6.8	1.76e-11	3.68e-09	0.26	0.21	Coronary artery disease;	chr15:85464700	chr15:85191438~85213905:+
BRCA	cis	rs2880765	0.743	rs12906308	ENSG00000259295.5	CSPG4P12	-6.8	1.76e-11	3.68e-09	-0.26	-0.21	Coronary artery disease;	chr15:85464828	chr15:85191438~85213905:+
BRCA	cis	rs17253792	0.822	rs10083499	ENSG00000186615.9	KTN1-AS1	-6.8	1.76e-11	3.68e-09	-0.4	-0.21	Putamen volume;	chr14:55599872	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs75437558	ENSG00000186615.9	KTN1-AS1	-6.8	1.76e-11	3.68e-09	-0.4	-0.21	Putamen volume;	chr14:55600080	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs76267907	ENSG00000186615.9	KTN1-AS1	-6.8	1.76e-11	3.68e-09	-0.4	-0.21	Putamen volume;	chr14:55600251	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs75232282	ENSG00000186615.9	KTN1-AS1	-6.8	1.76e-11	3.68e-09	-0.4	-0.21	Putamen volume;	chr14:55600572	chr14:55499278~55580110:-
BRCA	cis	rs301901	0.861	rs217797	ENSG00000250155.1	CTD-2353F22.1	-6.8	1.76e-11	3.68e-09	-0.23	-0.21	Height;	chr5:37318193	chr5:36666214~36725195:-
BRCA	cis	rs2835345	0.596	rs62229441	ENSG00000230479.1	AP000695.6	6.8	1.76e-11	3.68e-09	0.21	0.21	Pulmonary function;	chr21:36447559	chr21:36430360~36481070:+
BRCA	cis	rs2060793	1	rs10741657	ENSG00000251991.1	RNU7-49P	6.8	1.77e-11	3.69e-09	0.23	0.21	Vitamin D levels;	chr11:14893332	chr11:14478892~14478953:+
BRCA	cis	rs61160187	0.582	rs2898309	ENSG00000215032.2	GNL3LP1	6.8	1.77e-11	3.69e-09	0.26	0.21	Educational attainment (years of education);Educational attainment (college completion);	chr5:60981546	chr5:60891935~60893577:-
BRCA	cis	rs34779708	0.931	rs67976880	ENSG00000271335.4	RP11-324I22.4	6.8	1.77e-11	3.69e-09	0.22	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35083333	chr10:35314552~35336401:-
BRCA	cis	rs34779708	0.931	rs72789687	ENSG00000271335.4	RP11-324I22.4	6.8	1.77e-11	3.69e-09	0.22	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35083561	chr10:35314552~35336401:-
BRCA	cis	rs34779708	0.931	rs35997236	ENSG00000271335.4	RP11-324I22.4	6.8	1.77e-11	3.69e-09	0.22	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35087762	chr10:35314552~35336401:-
BRCA	cis	rs34779708	0.931	rs4934719	ENSG00000271335.4	RP11-324I22.4	6.8	1.77e-11	3.69e-09	0.22	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35087841	chr10:35314552~35336401:-
BRCA	cis	rs34779708	0.931	rs4934720	ENSG00000271335.4	RP11-324I22.4	6.8	1.77e-11	3.69e-09	0.22	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35087872	chr10:35314552~35336401:-
BRCA	cis	rs2842992	0.789	rs10945635	ENSG00000237927.1	RP3-393E18.2	-6.8	1.77e-11	3.7e-09	-0.3	-0.21	Age-related macular degeneration (geographic atrophy);	chr6:159793455	chr6:159586955~159589169:-
BRCA	cis	rs2976388	0.647	rs2572906	ENSG00000253741.1	CTD-2292P10.4	-6.8	1.77e-11	3.7e-09	-0.23	-0.21	Urinary tract infection frequency;	chr8:142716851	chr8:142702252~142726973:-
BRCA	cis	rs6740322	0.948	rs6715072	ENSG00000234936.1	AC010883.5	6.8	1.78e-11	3.71e-09	0.23	0.21	Coronary artery disease;	chr2:43335091	chr2:43229573~43233394:+
BRCA	cis	rs12817211	0.502	rs7961065	ENSG00000272368.2	RP4-605O3.4	-6.8	1.78e-11	3.71e-09	-0.21	-0.21	Colorectal or endometrial cancer;	chr12:50119904	chr12:50112197~50165618:+
BRCA	cis	rs13113518	0.812	rs11133385	ENSG00000249700.7	SRD5A3-AS1	6.8	1.78e-11	3.72e-09	0.26	0.21	Height;	chr4:55460485	chr4:55363971~55395847:-
BRCA	cis	rs7131987	0.65	rs7957339	ENSG00000257176.2	RP11-996F15.2	-6.8	1.78e-11	3.72e-09	-0.25	-0.21	QT interval;	chr12:29303562	chr12:29280418~29317848:-
BRCA	cis	rs77972916	0.609	rs72790907	ENSG00000234936.1	AC010883.5	6.8	1.78e-11	3.72e-09	0.31	0.21	Granulocyte percentage of myeloid white cells;	chr2:43348056	chr2:43229573~43233394:+
BRCA	cis	rs10129255	0.957	rs8009464	ENSG00000211972.2	IGHV3-66	6.8	1.78e-11	3.72e-09	0.15	0.21	Kawasaki disease;	chr14:106777611	chr14:106675017~106675544:-
BRCA	cis	rs79040073	0.637	rs73394355	ENSG00000259531.2	RP11-295H24.3	6.8	1.79e-11	3.73e-09	0.33	0.21	Lung cancer in ever smokers;	chr15:49299893	chr15:49365124~49366685:-
BRCA	cis	rs9549367	0.789	rs12584813	ENSG00000269125.1	RP11-98F14.11	-6.8	1.79e-11	3.74e-09	-0.27	-0.21	Platelet distribution width;	chr13:113241129	chr13:113165002~113165183:-
BRCA	cis	rs2337406	0.925	rs2011167	ENSG00000211974.3	IGHV2-70	-6.8	1.79e-11	3.74e-09	-0.27	-0.21	Alzheimer's disease (late onset);	chr14:106680831	chr14:106723574~106724093:-
BRCA	cis	rs2408955	0.522	rs4760679	ENSG00000240399.1	RP1-228P16.1	-6.8	1.79e-11	3.74e-09	-0.24	-0.21	Glycated hemoglobin levels;	chr12:48067852	chr12:48054813~48055591:-
BRCA	cis	rs11098499	0.954	rs11940028	ENSG00000249244.1	RP11-548H18.2	6.8	1.79e-11	3.75e-09	0.25	0.21	Corneal astigmatism;	chr4:119490752	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.954	rs11935596	ENSG00000249244.1	RP11-548H18.2	6.8	1.79e-11	3.75e-09	0.25	0.21	Corneal astigmatism;	chr4:119491302	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.954	rs12507964	ENSG00000249244.1	RP11-548H18.2	6.8	1.79e-11	3.75e-09	0.25	0.21	Corneal astigmatism;	chr4:119491906	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.909	rs11098530	ENSG00000249244.1	RP11-548H18.2	6.8	1.79e-11	3.75e-09	0.25	0.21	Corneal astigmatism;	chr4:119491999	chr4:119391831~119395335:-
BRCA	cis	rs2243480	1	rs410128	ENSG00000232546.1	RP11-458F8.1	-6.8	1.8e-11	3.75e-09	-0.29	-0.21	Diabetic kidney disease;	chr7:66138186	chr7:66848496~66858136:+
BRCA	cis	rs7945705	0.774	rs6486060	ENSG00000254860.4	TMEM9B-AS1	-6.8	1.8e-11	3.75e-09	-0.2	-0.21	Hemoglobin concentration;	chr11:9003083	chr11:8964675~8977527:+
BRCA	cis	rs2348418	0.832	rs4930823	ENSG00000247934.4	RP11-967K21.1	6.8	1.8e-11	3.75e-09	0.23	0.21	Lung function (FEV1);Lung function (FVC);	chr12:28421892	chr12:28163298~28190738:-
BRCA	cis	rs4713118	0.591	rs2056924	ENSG00000216901.1	AL022393.7	6.8	1.8e-11	3.75e-09	0.26	0.21	Parkinson's disease;	chr6:27722395	chr6:28176188~28176674:+
BRCA	cis	rs9840812	0.592	rs1711161	ENSG00000239213.4	NCK1-AS1	6.8	1.8e-11	3.75e-09	0.24	0.21	Fibrinogen levels;	chr3:136361695	chr3:136841726~136862054:-
BRCA	cis	rs875971	0.895	rs6460278	ENSG00000224316.1	RP11-479O9.2	-6.8	1.8e-11	3.76e-09	-0.21	-0.21	Aortic root size;	chr7:66197749	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.862	rs6460279	ENSG00000224316.1	RP11-479O9.2	-6.8	1.8e-11	3.76e-09	-0.21	-0.21	Aortic root size;	chr7:66197774	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.862	rs28491091	ENSG00000224316.1	RP11-479O9.2	-6.8	1.8e-11	3.76e-09	-0.21	-0.21	Aortic root size;	chr7:66204077	chr7:65773620~65802067:+
BRCA	cis	rs301901	0.772	rs301873	ENSG00000250155.1	CTD-2353F22.1	-6.8	1.8e-11	3.76e-09	-0.22	-0.21	Height;	chr5:37136896	chr5:36666214~36725195:-
BRCA	cis	rs13217239	0.574	rs9366680	ENSG00000241549.7	GUSBP2	6.8	1.8e-11	3.76e-09	0.23	0.21	Schizophrenia;	chr6:27038344	chr6:26871484~26956554:-
BRCA	cis	rs2976388	0.565	rs2572905	ENSG00000253741.1	CTD-2292P10.4	-6.8	1.8e-11	3.76e-09	-0.23	-0.21	Urinary tract infection frequency;	chr8:142715686	chr8:142702252~142726973:-
BRCA	cis	rs2235642	0.671	rs2235641	ENSG00000280231.1	LA16c-380F5.3	-6.8	1.81e-11	3.77e-09	-0.27	-0.21	Coronary artery disease;	chr16:1558176	chr16:1553655~1554130:-
BRCA	cis	rs516805	0.52	rs9375150	ENSG00000279453.1	RP3-425C14.4	6.8	1.81e-11	3.77e-09	0.22	0.21	Lymphocyte counts;	chr6:122566410	chr6:122436789~122439223:-
BRCA	cis	rs1075232	0.826	rs16956738	ENSG00000215302.7	CTD-3092A11.1	6.8	1.81e-11	3.78e-09	0.47	0.21	Survival in colorectal cancer (non-distant metastatic);	chr15:31444028	chr15:30470779~30507623:+
BRCA	cis	rs442309	0.553	rs10761660	ENSG00000238280.1	RP11-436D10.3	-6.8	1.81e-11	3.78e-09	-0.29	-0.21	Vogt-Koyanagi-Harada syndrome;	chr10:62756546	chr10:62793562~62805887:-
BRCA	cis	rs8114671	0.935	rs35193912	ENSG00000269202.1	RP4-614O4.12	6.8	1.81e-11	3.78e-09	0.21	0.21	Height;	chr20:35197247	chr20:35201747~35203288:-
BRCA	cis	rs8114671	0.967	rs34515766	ENSG00000269202.1	RP4-614O4.12	6.8	1.81e-11	3.78e-09	0.21	0.21	Height;	chr20:35197418	chr20:35201747~35203288:-
BRCA	cis	rs2380205	0.58	rs980230	ENSG00000232807.2	RP11-536K7.3	6.8	1.81e-11	3.78e-09	0.22	0.21	Breast cancer;	chr10:5863268	chr10:5934270~5945900:-
BRCA	cis	rs11098499	0.954	rs12506546	ENSG00000249244.1	RP11-548H18.2	6.8	1.81e-11	3.78e-09	0.25	0.21	Corneal astigmatism;	chr4:119380463	chr4:119391831~119395335:-
BRCA	cis	rs6142102	0.961	rs4911392	ENSG00000275784.1	RP5-1125A11.6	-6.8	1.82e-11	3.79e-09	-0.24	-0.21	Skin pigmentation;	chr20:33982712	chr20:33989480~33991818:-
BRCA	cis	rs6142102	0.961	rs4911393	ENSG00000275784.1	RP5-1125A11.6	-6.8	1.82e-11	3.79e-09	-0.24	-0.21	Skin pigmentation;	chr20:33983120	chr20:33989480~33991818:-
BRCA	cis	rs2281636	0.723	rs11190245	ENSG00000233690.1	EBAG9P1	6.8	1.82e-11	3.79e-09	0.24	0.21	Obesity-related traits;	chr10:99691502	chr10:99697407~99697949:-
BRCA	cis	rs9291683	0.552	rs10939656	ENSG00000250413.1	RP11-448G15.1	-6.79	1.82e-11	3.8e-09	-0.27	-0.21	Bone mineral density;	chr4:10013022	chr4:10006482~10009725:+
BRCA	cis	rs301901	0.698	rs62360226	ENSG00000250155.1	CTD-2353F22.1	6.79	1.82e-11	3.8e-09	0.23	0.21	Height;	chr5:37428489	chr5:36666214~36725195:-
BRCA	cis	rs13113518	0.812	rs7667741	ENSG00000249700.7	SRD5A3-AS1	6.79	1.82e-11	3.8e-09	0.26	0.21	Height;	chr4:55544621	chr4:55363971~55395847:-
BRCA	cis	rs13113518	0.812	rs7667741	ENSG00000223305.1	RN7SKP30	6.79	1.82e-11	3.8e-09	0.26	0.21	Height;	chr4:55544621	chr4:55540502~55540835:-
BRCA	cis	rs11671005	0.779	rs11670125	ENSG00000252334.1	RNU6-1337P	6.79	1.82e-11	3.8e-09	0.33	0.21	Mean platelet volume;	chr19:58476023	chr19:58483749~58483843:-
BRCA	cis	rs6547705	0.702	rs4832049	ENSG00000231259.4	AC125232.1	6.79	1.82e-11	3.8e-09	0.29	0.21	Progressive supranuclear palsy;	chr2:86826596	chr2:87031815~87053069:-
BRCA	cis	rs17711722	0.565	rs4275112	ENSG00000213640.3	EEF1DP4	6.79	1.83e-11	3.81e-09	0.26	0.21	Calcium levels;	chr7:65733651	chr7:64862999~64864370:+
BRCA	cis	rs17772222	0.682	rs10132554	ENSG00000258983.2	RP11-507K2.2	6.79	1.83e-11	3.81e-09	0.22	0.21	Coronary artery calcification;	chr14:88473090	chr14:88499334~88515502:+
BRCA	cis	rs10129255	0.957	rs8009948	ENSG00000224373.3	IGHV4-59	6.79	1.83e-11	3.82e-09	0.14	0.21	Kawasaki disease;	chr14:106805607	chr14:106627249~106627825:-
BRCA	cis	rs8031584	0.958	rs61997079	ENSG00000260382.1	RP11-540B6.2	6.79	1.83e-11	3.82e-09	0.25	0.21	Huntington's disease progression;	chr15:30946068	chr15:30882267~30883231:-
BRCA	cis	rs8031584	0.958	rs11637469	ENSG00000260382.1	RP11-540B6.2	6.79	1.83e-11	3.82e-09	0.25	0.21	Huntington's disease progression;	chr15:30946580	chr15:30882267~30883231:-
BRCA	cis	rs11096990	0.929	rs56037933	ENSG00000249207.1	RP11-360F5.1	6.79	1.83e-11	3.83e-09	0.24	0.21	Cognitive function;	chr4:39225653	chr4:39112677~39126818:-
BRCA	cis	rs13113518	0.783	rs34534635	ENSG00000249700.7	SRD5A3-AS1	6.79	1.84e-11	3.83e-09	0.26	0.21	Height;	chr4:55573424	chr4:55363971~55395847:-
BRCA	cis	rs13113518	0.783	rs7690837	ENSG00000249700.7	SRD5A3-AS1	6.79	1.84e-11	3.83e-09	0.26	0.21	Height;	chr4:55575856	chr4:55363971~55395847:-
BRCA	cis	rs2408955	0.522	rs7139330	ENSG00000240399.1	RP1-228P16.1	-6.79	1.84e-11	3.83e-09	-0.24	-0.21	Glycated hemoglobin levels;	chr12:48089701	chr12:48054813~48055591:-
BRCA	cis	rs875971	0.545	rs2707851	ENSG00000236529.1	RP13-254B10.1	-6.79	1.84e-11	3.83e-09	-0.26	-0.21	Aortic root size;	chr7:66624178	chr7:65840212~65840596:+
BRCA	cis	rs2243480	0.803	rs423187	ENSG00000229886.1	RP5-1132H15.3	6.79	1.84e-11	3.83e-09	0.37	0.21	Diabetic kidney disease;	chr7:66044512	chr7:66025126~66031544:-
BRCA	cis	rs755249	0.567	rs4660208	ENSG00000228060.1	RP11-69E11.8	-6.79	1.84e-11	3.84e-09	-0.25	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39256542	chr1:39565160~39573203:+
BRCA	cis	rs3126085	0.935	rs4845736	ENSG00000237975.5	FLG-AS1	-6.79	1.84e-11	3.84e-09	-0.27	-0.21	Atopic dermatitis;	chr1:152203075	chr1:152168125~152445456:+
BRCA	cis	rs987724	0.592	rs9858861	ENSG00000240875.4	LINC00886	-6.79	1.84e-11	3.85e-09	-0.24	-0.21	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156824848	chr3:156747346~156817062:-
BRCA	cis	rs13068223	0.905	rs344027	ENSG00000243926.1	TIPARP-AS1	-6.79	1.85e-11	3.85e-09	-0.22	-0.21	Age-related hearing impairment (SNP x SNP interaction);	chr3:156750604	chr3:156671862~156674378:-
BRCA	cis	rs7617773	0.817	rs13059037	ENSG00000228638.1	FCF1P2	-6.79	1.85e-11	3.85e-09	-0.23	-0.21	Coronary artery disease;	chr3:48246389	chr3:48290793~48291375:-
BRCA	cis	rs7976269	0.609	rs2196482	ENSG00000257176.2	RP11-996F15.2	-6.79	1.85e-11	3.86e-09	-0.25	-0.21	Male-pattern baldness;	chr12:29052559	chr12:29280418~29317848:-
BRCA	cis	rs7976269	0.609	rs2217906	ENSG00000257176.2	RP11-996F15.2	-6.79	1.85e-11	3.86e-09	-0.25	-0.21	Male-pattern baldness;	chr12:29052626	chr12:29280418~29317848:-
BRCA	cis	rs957448	0.561	rs71532325	ENSG00000253704.1	RP11-267M23.4	6.79	1.85e-11	3.86e-09	0.23	0.21	Nonsyndromic cleft lip with cleft palate;	chr8:94615738	chr8:94553722~94569745:+
BRCA	cis	rs6570726	0.905	rs442435	ENSG00000235652.6	RP11-545I5.3	6.79	1.85e-11	3.86e-09	0.2	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145494423	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.905	rs396492	ENSG00000235652.6	RP11-545I5.3	6.79	1.85e-11	3.86e-09	0.2	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145495044	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.935	rs7757387	ENSG00000235652.6	RP11-545I5.3	6.79	1.85e-11	3.86e-09	0.2	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145495590	chr6:145799409~145886585:+
BRCA	cis	rs7246657	0.943	rs2081096	ENSG00000276846.1	CTD-3220F14.3	6.79	1.85e-11	3.86e-09	0.27	0.21	Coronary artery calcification;	chr19:37473798	chr19:37314868~37315620:-
BRCA	cis	rs1707322	0.716	rs6694889	ENSG00000281133.1	AL355480.3	-6.79	1.86e-11	3.87e-09	-0.26	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45636134	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.682	rs12041197	ENSG00000281133.1	AL355480.3	-6.79	1.86e-11	3.87e-09	-0.26	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45638792	chr1:45580892~45580996:-
BRCA	cis	rs7487075	0.78	rs12307969	ENSG00000257261.4	RP11-96H19.1	6.79	1.86e-11	3.88e-09	0.23	0.21	Itch intensity from mosquito bite;	chr12:46365274	chr12:46383679~46876159:+
BRCA	cis	rs1823913	0.614	rs4853463	ENSG00000280083.1	RP11-317J9.1	6.79	1.86e-11	3.88e-09	0.23	0.21	Obesity-related traits;	chr2:191278699	chr2:191154118~191156070:-
BRCA	cis	rs6543140	0.865	rs6760275	ENSG00000234389.1	AC007278.3	6.79	1.86e-11	3.88e-09	0.2	0.21	Blood protein levels;	chr2:102463147	chr2:102438713~102440475:+
BRCA	cis	rs6543140	0.964	rs6734203	ENSG00000234389.1	AC007278.3	6.79	1.86e-11	3.88e-09	0.2	0.21	Blood protein levels;	chr2:102463606	chr2:102438713~102440475:+
BRCA	cis	rs6543140	0.964	rs6543142	ENSG00000234389.1	AC007278.3	6.79	1.86e-11	3.88e-09	0.2	0.21	Blood protein levels;	chr2:102465546	chr2:102438713~102440475:+
BRCA	cis	rs6543140	0.929	rs6742530	ENSG00000234389.1	AC007278.3	6.79	1.86e-11	3.88e-09	0.2	0.21	Blood protein levels;	chr2:102465820	chr2:102438713~102440475:+
BRCA	cis	rs2348418	0.864	rs11049580	ENSG00000247934.4	RP11-967K21.1	6.79	1.87e-11	3.89e-09	0.23	0.21	Lung function (FEV1);Lung function (FVC);	chr12:28414696	chr12:28163298~28190738:-
BRCA	cis	rs79040073	0.607	rs17479205	ENSG00000259531.2	RP11-295H24.3	6.79	1.87e-11	3.89e-09	0.32	0.21	Lung cancer in ever smokers;	chr15:49456065	chr15:49365124~49366685:-
BRCA	cis	rs6683071	0.557	rs4240934	ENSG00000272750.1	RP11-378J18.8	6.79	1.87e-11	3.9e-09	0.39	0.21	Cognitive performance;	chr1:222730956	chr1:222658867~222661512:-
BRCA	cis	rs2834288	0.5	rs7280837	ENSG00000273102.1	AP000569.9	6.79	1.87e-11	3.9e-09	0.22	0.21	Gut microbiota (bacterial taxa);	chr21:33951533	chr21:33967101~33968573:-
BRCA	cis	rs2834288	0.5	rs4817602	ENSG00000273102.1	AP000569.9	6.79	1.87e-11	3.9e-09	0.22	0.21	Gut microbiota (bacterial taxa);	chr21:33952354	chr21:33967101~33968573:-
BRCA	cis	rs459482	1	rs464783	ENSG00000228318.3	AP001610.5	6.79	1.88e-11	3.91e-09	0.24	0.21	IgG glycosylation;	chr21:41424553	chr21:41441056~41445708:-
BRCA	cis	rs11098499	0.908	rs7695996	ENSG00000249244.1	RP11-548H18.2	6.79	1.88e-11	3.91e-09	0.24	0.21	Corneal astigmatism;	chr4:119400878	chr4:119391831~119395335:-
BRCA	cis	rs9876781	1	rs6442118	ENSG00000244380.1	RP11-24C3.2	6.79	1.88e-11	3.92e-09	0.24	0.21	Longevity;	chr3:48398582	chr3:48440352~48446656:-
BRCA	cis	rs5758659	0.504	rs133367	ENSG00000205702.9	CYP2D7	-6.79	1.88e-11	3.92e-09	-0.17	-0.21	Cognitive function;	chr22:42067362	chr22:42140203~42144577:-
BRCA	cis	rs875971	0.964	rs6945019	ENSG00000232559.3	GS1-124K5.12	6.79	1.89e-11	3.93e-09	0.25	0.21	Aortic root size;	chr7:66457471	chr7:66554588~66576923:-
BRCA	cis	rs1707322	0.721	rs10430124	ENSG00000281133.1	AL355480.3	-6.79	1.89e-11	3.93e-09	-0.27	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755945	chr1:45580892~45580996:-
BRCA	cis	rs2599510	0.84	rs466146	ENSG00000276334.1	AL133243.1	6.79	1.89e-11	3.93e-09	0.24	0.21	Interleukin-18 levels;	chr2:32314167	chr2:32521927~32523547:+
BRCA	cis	rs12691307	1	rs12691307	ENSG00000273724.1	RP11-347C12.12	-6.79	1.89e-11	3.94e-09	-0.23	-0.21	Schizophrenia;	chr16:29928556	chr16:30336400~30343336:+
BRCA	cis	rs875971	0.756	rs4718328	ENSG00000224316.1	RP11-479O9.2	-6.79	1.89e-11	3.94e-09	-0.21	-0.21	Aortic root size;	chr7:66228350	chr7:65773620~65802067:+
BRCA	cis	rs2638953	0.924	rs2061758	ENSG00000278733.1	RP11-425D17.1	-6.79	1.89e-11	3.94e-09	-0.26	-0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28186575	chr12:28185625~28186190:-
BRCA	cis	rs875971	0.862	rs4718330	ENSG00000224316.1	RP11-479O9.2	-6.79	1.9e-11	3.95e-09	-0.21	-0.21	Aortic root size;	chr7:66250256	chr7:65773620~65802067:+
BRCA	cis	rs2243480	0.901	rs778732	ENSG00000230295.1	RP11-458F8.2	-6.79	1.9e-11	3.96e-09	-0.28	-0.21	Diabetic kidney disease;	chr7:66357373	chr7:66880708~66882981:+
BRCA	cis	rs875971	0.545	rs6979636	ENSG00000236529.1	RP13-254B10.1	6.79	1.91e-11	3.97e-09	0.25	0.21	Aortic root size;	chr7:66276638	chr7:65840212~65840596:+
BRCA	cis	rs6921919	0.583	rs9468370	ENSG00000204709.4	LINC01556	6.79	1.91e-11	3.97e-09	0.28	0.21	Autism spectrum disorder or schizophrenia;	chr6:28401163	chr6:28943877~28944537:+
BRCA	cis	rs9291683	0.588	rs4280729	ENSG00000250413.1	RP11-448G15.1	-6.79	1.91e-11	3.98e-09	-0.27	-0.21	Bone mineral density;	chr4:10012237	chr4:10006482~10009725:+
BRCA	cis	rs919433	0.926	rs12618567	ENSG00000231621.1	AC013264.2	6.79	1.92e-11	3.99e-09	0.19	0.21	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197283467	chr2:197197991~197199273:+
BRCA	cis	rs7085104	0.572	rs284856	ENSG00000213061.2	PFN1P11	-6.79	1.92e-11	3.99e-09	-0.26	-0.21	Immature fraction of reticulocytes;Schizophrenia;	chr10:102814572	chr10:102838011~102845473:-
BRCA	cis	rs7923609	0.812	rs10822184	ENSG00000232075.1	MRPL35P2	6.79	1.92e-11	3.99e-09	0.26	0.21	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63577393	chr10:63634317~63634827:-
BRCA	cis	rs6142102	0.961	rs4911401	ENSG00000275784.1	RP5-1125A11.6	-6.79	1.92e-11	4e-09	-0.25	-0.21	Skin pigmentation;	chr20:34066756	chr20:33989480~33991818:-
BRCA	cis	rs2835345	0.561	rs5026478	ENSG00000230479.1	AP000695.6	6.79	1.92e-11	4e-09	0.2	0.21	Pulmonary function;	chr21:36453531	chr21:36430360~36481070:+
BRCA	cis	rs1823913	0.637	rs4853583	ENSG00000280083.1	RP11-317J9.1	6.79	1.92e-11	4e-09	0.23	0.21	Obesity-related traits;	chr2:191304648	chr2:191154118~191156070:-
BRCA	cis	rs7617773	0.779	rs77957078	ENSG00000228638.1	FCF1P2	-6.79	1.92e-11	4e-09	-0.23	-0.21	Coronary artery disease;	chr3:48289796	chr3:48290793~48291375:-
BRCA	cis	rs67981189	0.758	rs221921	ENSG00000269927.1	RP6-91H8.3	-6.79	1.93e-11	4.01e-09	-0.26	-0.21	Schizophrenia;	chr14:71119411	chr14:71141125~71143253:-
BRCA	cis	rs11976180	1	rs2951360	ENSG00000204959.4	ARHGEF34P	6.79	1.93e-11	4.01e-09	0.26	0.21	Obesity-related traits;	chr7:144060256	chr7:144272445~144286966:-
BRCA	cis	rs875971	1	rs875971	ENSG00000224316.1	RP11-479O9.2	-6.79	1.93e-11	4.01e-09	-0.2	-0.21	Aortic root size;	chr7:66152608	chr7:65773620~65802067:+
BRCA	cis	rs7976269	0.559	rs10771473	ENSG00000257176.2	RP11-996F15.2	-6.79	1.94e-11	4.03e-09	-0.24	-0.21	Male-pattern baldness;	chr12:29068729	chr12:29280418~29317848:-
BRCA	cis	rs13113518	0.812	rs12649507	ENSG00000249700.7	SRD5A3-AS1	-6.79	1.94e-11	4.03e-09	-0.26	-0.21	Height;	chr4:55514317	chr4:55363971~55395847:-
BRCA	cis	rs11723261	0.582	rs11732336	ENSG00000211553.1	AC253576.2	-6.78	1.94e-11	4.04e-09	-0.29	-0.21	Immune response to smallpox vaccine (IL-6);	chr4:146728	chr4:136461~136568:+
BRCA	cis	rs2072438	0.503	rs10739590	ENSG00000226752.6	PSMD5-AS1	-6.78	1.94e-11	4.05e-09	-0.24	-0.21	Rheumatoid arthritis;	chr9:121109203	chr9:120824828~120854385:+
BRCA	cis	rs780096	0.527	rs11127044	ENSG00000234072.1	AC074117.10	-6.78	1.95e-11	4.05e-09	-0.2	-0.21	Total body bone mineral density;	chr2:27517537	chr2:27356246~27367622:+
BRCA	cis	rs9450351	0.744	rs9359674	ENSG00000203875.9	SNHG5	6.78	1.95e-11	4.05e-09	0.39	0.21	Interferon gamma-induced protein 10 levels;	chr6:85996191	chr6:85660950~85678736:-
BRCA	cis	rs7665090	1	rs11727546	ENSG00000246560.2	RP11-10L12.4	6.78	1.96e-11	4.07e-09	0.22	0.21	Primary biliary cholangitis;	chr4:102636507	chr4:102828055~102844075:+
BRCA	cis	rs7945705	0.875	rs10769957	ENSG00000254860.4	TMEM9B-AS1	6.78	1.96e-11	4.08e-09	0.2	0.21	Hemoglobin concentration;	chr11:8787469	chr11:8964675~8977527:+
BRCA	cis	rs7826238	0.72	rs12546760	ENSG00000254153.1	CTA-398F10.2	-6.78	1.96e-11	4.08e-09	-0.24	-0.21	Systolic blood pressure;	chr8:8517326	chr8:8456909~8461337:-
BRCA	cis	rs61160187	0.582	rs56025209	ENSG00000215032.2	GNL3LP1	6.78	1.96e-11	4.08e-09	0.25	0.21	Educational attainment (years of education);Educational attainment (college completion);	chr5:61053793	chr5:60891935~60893577:-
BRCA	cis	rs71520386	0.632	rs12532922	ENSG00000228649.7	AC005682.5	-6.78	1.96e-11	4.08e-09	-0.2	-0.21	Fibrinogen levels;	chr7:22820796	chr7:22854178~22861579:+
BRCA	cis	rs8114671	0.967	rs3746427	ENSG00000269202.1	RP4-614O4.12	-6.78	1.96e-11	4.08e-09	-0.21	-0.21	Height;	chr20:35142661	chr20:35201747~35203288:-
BRCA	cis	rs10129255	0.957	rs8009948	ENSG00000211972.2	IGHV3-66	6.78	1.96e-11	4.08e-09	0.17	0.21	Kawasaki disease;	chr14:106805607	chr14:106675017~106675544:-
BRCA	cis	rs11096990	0.855	rs56275407	ENSG00000249207.1	RP11-360F5.1	6.78	1.97e-11	4.09e-09	0.24	0.21	Cognitive function;	chr4:39177224	chr4:39112677~39126818:-
BRCA	cis	rs12200782	0.505	rs1535275	ENSG00000241549.7	GUSBP2	6.78	1.97e-11	4.09e-09	0.27	0.21	Small cell lung carcinoma;	chr6:26520539	chr6:26871484~26956554:-
BRCA	cis	rs875971	0.545	rs73146609	ENSG00000224316.1	RP11-479O9.2	6.78	1.97e-11	4.09e-09	0.24	0.21	Aortic root size;	chr7:66302477	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.545	rs2173571	ENSG00000224316.1	RP11-479O9.2	6.78	1.97e-11	4.09e-09	0.24	0.21	Aortic root size;	chr7:66305392	chr7:65773620~65802067:+
BRCA	cis	rs6142102	0.961	rs2284379	ENSG00000275784.1	RP5-1125A11.6	-6.78	1.97e-11	4.09e-09	-0.25	-0.21	Skin pigmentation;	chr20:34006836	chr20:33989480~33991818:-
BRCA	cis	rs11671005	0.779	rs3794971	ENSG00000252334.1	RNU6-1337P	6.78	1.97e-11	4.09e-09	0.32	0.21	Mean platelet volume;	chr19:58474499	chr19:58483749~58483843:-
BRCA	cis	rs7246657	0.551	rs10404069	ENSG00000276846.1	CTD-3220F14.3	6.78	1.97e-11	4.1e-09	0.31	0.21	Coronary artery calcification;	chr19:37147502	chr19:37314868~37315620:-
BRCA	cis	rs4072705	1	rs10760374	ENSG00000224020.1	MIR181A2HG	-6.78	1.97e-11	4.1e-09	-0.23	-0.21	Menarche (age at onset);	chr9:124733229	chr9:124658467~124698631:+
BRCA	cis	rs2599510	0.811	rs2754520	ENSG00000276334.1	AL133243.1	6.78	1.98e-11	4.11e-09	0.26	0.21	Interleukin-18 levels;	chr2:32585226	chr2:32521927~32523547:+
BRCA	cis	rs2348418	0.966	rs11049694	ENSG00000247934.4	RP11-967K21.1	6.78	1.98e-11	4.11e-09	0.23	0.21	Lung function (FEV1);Lung function (FVC);	chr12:28527925	chr12:28163298~28190738:-
BRCA	cis	rs34929064	0.781	rs2905324	ENSG00000179428.2	AC073072.5	-6.78	1.98e-11	4.11e-09	-0.22	-0.21	Major depression and alcohol dependence;	chr7:22669384	chr7:22725395~22727620:-
BRCA	cis	rs1387259	0.69	rs1601985	ENSG00000273765.1	RP11-370I10.11	6.78	1.99e-11	4.13e-09	0.25	0.21	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48368131	chr12:48360920~48361377:+
BRCA	cis	rs34779708	0.931	rs11593858	ENSG00000271335.4	RP11-324I22.4	6.78	1.99e-11	4.13e-09	0.22	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35092445	chr10:35314552~35336401:-
BRCA	cis	rs8072100	0.713	rs2292346	ENSG00000228782.6	CTD-2026D20.3	6.78	1.99e-11	4.14e-09	0.23	0.21	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47378107	chr17:47450568~47492492:-
BRCA	cis	rs8072100	0.666	rs9913014	ENSG00000228782.6	CTD-2026D20.3	6.78	1.99e-11	4.14e-09	0.23	0.21	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47382823	chr17:47450568~47492492:-
BRCA	cis	rs7085104	0.514	rs284855	ENSG00000213061.2	PFN1P11	-6.78	1.99e-11	4.14e-09	-0.26	-0.21	Immature fraction of reticulocytes;Schizophrenia;	chr10:102814665	chr10:102838011~102845473:-
BRCA	cis	rs1707322	1	rs10789479	ENSG00000281133.1	AL355480.3	-6.78	2e-11	4.15e-09	-0.27	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45886828	chr1:45580892~45580996:-
BRCA	cis	rs6088813	0.961	rs6060373	ENSG00000126005.14	MMP24-AS1	6.78	2e-11	4.15e-09	0.24	0.21	Height;	chr20:35326405	chr20:35216462~35278131:-
BRCA	cis	rs9876781	1	rs6804774	ENSG00000244380.1	RP11-24C3.2	6.78	2e-11	4.15e-09	0.24	0.21	Longevity;	chr3:48389129	chr3:48440352~48446656:-
BRCA	cis	rs7809950	0.678	rs2395869	ENSG00000238832.1	snoU109	-6.78	2e-11	4.16e-09	-0.29	-0.21	Coronary artery disease;	chr7:107299653	chr7:107603363~107603507:+
BRCA	cis	rs7829975	0.688	rs13270194	ENSG00000254153.1	CTA-398F10.2	6.78	2e-11	4.16e-09	0.25	0.21	Mood instability;	chr8:8520592	chr8:8456909~8461337:-
BRCA	cis	rs7474896	0.559	rs1212108	ENSG00000226578.1	RP11-258F22.1	-6.78	2.01e-11	4.17e-09	-0.28	-0.21	Obesity (extreme);	chr10:37805394	chr10:37775371~37784131:-
BRCA	cis	rs172166	0.694	rs536704	ENSG00000216901.1	AL022393.7	6.78	2.01e-11	4.17e-09	0.27	0.21	Cardiac Troponin-T levels;	chr6:28124825	chr6:28176188~28176674:+
BRCA	cis	rs11157436	0.602	rs11157435	ENSG00000211812.1	TRAV26-2	-6.78	2.01e-11	4.17e-09	-0.18	-0.21	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22168888	chr14:22202583~22203368:+
BRCA	cis	rs61160187	0.582	rs2049579	ENSG00000215032.2	GNL3LP1	6.78	2.01e-11	4.18e-09	0.25	0.21	Educational attainment (years of education);Educational attainment (college completion);	chr5:61054838	chr5:60891935~60893577:-
BRCA	cis	rs61160187	0.549	rs12518404	ENSG00000215032.2	GNL3LP1	6.78	2.02e-11	4.19e-09	0.25	0.21	Educational attainment (years of education);Educational attainment (college completion);	chr5:61046169	chr5:60891935~60893577:-
BRCA	cis	rs7487075	0.754	rs10880962	ENSG00000257261.4	RP11-96H19.1	6.78	2.02e-11	4.19e-09	0.22	0.21	Itch intensity from mosquito bite;	chr12:46379661	chr12:46383679~46876159:+
BRCA	cis	rs9788721	0.63	rs77681598	ENSG00000261762.1	RP11-650L12.2	-6.78	2.02e-11	4.19e-09	-0.22	-0.21	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78613761	chr15:78589123~78591276:-
BRCA	cis	rs899997	0.773	rs62010525	ENSG00000261143.1	ADAMTS7P3	-6.78	2.02e-11	4.19e-09	-0.32	-0.21	Coronary artery disease or large artery stroke;	chr15:78675968	chr15:77976042~77993057:+
BRCA	cis	rs8054556	0.73	rs4788190	ENSG00000273724.1	RP11-347C12.12	-6.78	2.03e-11	4.21e-09	-0.23	-0.21	Autism spectrum disorder or schizophrenia;	chr16:29937080	chr16:30336400~30343336:+
BRCA	cis	rs957448	1	rs72674852	ENSG00000253175.1	RP11-267M23.6	6.78	2.03e-11	4.21e-09	0.26	0.21	Nonsyndromic cleft lip with cleft palate;	chr8:94536523	chr8:94565036~94565715:+
BRCA	cis	rs13178541	0.689	rs12521005	ENSG00000250378.1	RP11-119J18.1	-6.78	2.03e-11	4.21e-09	-0.28	-0.21	IgG glycosylation;	chr5:135823313	chr5:135812667~135826582:+
BRCA	cis	rs1707322	0.682	rs10890334	ENSG00000281133.1	AL355480.3	-6.78	2.03e-11	4.21e-09	-0.26	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634706	chr1:45580892~45580996:-
BRCA	cis	rs12478296	1	rs12478296	ENSG00000261186.2	RP11-341N2.1	6.78	2.03e-11	4.21e-09	0.32	0.21	Obesity-related traits;	chr2:242106609	chr2:242087351~242088457:-
BRCA	cis	rs61160187	0.576	rs10805374	ENSG00000215032.2	GNL3LP1	6.78	2.03e-11	4.22e-09	0.25	0.21	Educational attainment (years of education);Educational attainment (college completion);	chr5:61004078	chr5:60891935~60893577:-
BRCA	cis	rs3781264	0.724	rs12780491	ENSG00000273450.1	RP11-76P2.4	6.78	2.03e-11	4.22e-09	0.29	0.21	Esophageal cancer and gastric cancer;	chr10:94361265	chr10:94314907~94315327:-
BRCA	cis	rs7428	0.502	rs3184781	ENSG00000246575.2	AC093162.5	6.78	2.04e-11	4.23e-09	0.21	0.21	Ear protrusion;	chr2:85322404	chr2:85315041~85316529:+
BRCA	cis	rs7428	0.527	rs3184780	ENSG00000246575.2	AC093162.5	6.78	2.04e-11	4.23e-09	0.21	0.21	Ear protrusion;	chr2:85322424	chr2:85315041~85316529:+
BRCA	cis	rs4072705	1	rs10760373	ENSG00000224020.1	MIR181A2HG	-6.78	2.04e-11	4.23e-09	-0.22	-0.21	Menarche (age at onset);	chr9:124723166	chr9:124658467~124698631:+
BRCA	cis	rs8031584	0.958	rs1043742	ENSG00000260382.1	RP11-540B6.2	6.78	2.04e-11	4.23e-09	0.24	0.21	Huntington's disease progression;	chr15:30940378	chr15:30882267~30883231:-
BRCA	cis	rs3096299	0.606	rs8052103	ENSG00000274627.1	RP11-104N10.2	-6.78	2.04e-11	4.23e-09	-0.24	-0.21	Multiple myeloma (IgH translocation);	chr16:89474835	chr16:89516797~89522217:+
BRCA	cis	rs11098499	0.863	rs7699064	ENSG00000249244.1	RP11-548H18.2	-6.78	2.04e-11	4.23e-09	-0.25	-0.21	Corneal astigmatism;	chr4:119507154	chr4:119391831~119395335:-
BRCA	cis	rs12701220	0.895	rs12534778	ENSG00000229043.2	AC091729.9	6.78	2.04e-11	4.24e-09	0.32	0.21	Bronchopulmonary dysplasia;	chr7:1026225	chr7:1160374~1165267:+
BRCA	cis	rs11976180	1	rs2961132	ENSG00000204959.4	ARHGEF34P	6.78	2.04e-11	4.24e-09	0.26	0.21	Obesity-related traits;	chr7:144071035	chr7:144272445~144286966:-
BRCA	cis	rs11089937	0.616	rs7291684	ENSG00000211639.2	IGLV4-60	6.78	2.04e-11	4.24e-09	0.2	0.21	Periodontitis (PAL4Q3);	chr22:22183834	chr22:22162199~22162681:+
BRCA	cis	rs11089937	0.616	rs6001219	ENSG00000211639.2	IGLV4-60	6.78	2.04e-11	4.24e-09	0.2	0.21	Periodontitis (PAL4Q3);	chr22:22184348	chr22:22162199~22162681:+
BRCA	cis	rs11096990	0.855	rs1597722	ENSG00000249207.1	RP11-360F5.1	-6.78	2.04e-11	4.24e-09	-0.24	-0.21	Cognitive function;	chr4:39173255	chr4:39112677~39126818:-
BRCA	cis	rs13113518	0.812	rs2048564	ENSG00000249700.7	SRD5A3-AS1	6.78	2.05e-11	4.24e-09	0.26	0.21	Height;	chr4:55407965	chr4:55363971~55395847:-
BRCA	cis	rs11098499	0.954	rs11722872	ENSG00000249244.1	RP11-548H18.2	6.78	2.05e-11	4.25e-09	0.25	0.21	Corneal astigmatism;	chr4:119311875	chr4:119391831~119395335:-
BRCA	cis	rs2834288	0.5	rs2834305	ENSG00000273102.1	AP000569.9	6.78	2.05e-11	4.26e-09	0.22	0.21	Gut microbiota (bacterial taxa);	chr21:33955321	chr21:33967101~33968573:-
BRCA	cis	rs2348418	0.83	rs4930821	ENSG00000247934.4	RP11-967K21.1	6.78	2.05e-11	4.26e-09	0.23	0.21	Lung function (FEV1);Lung function (FVC);	chr12:28410948	chr12:28163298~28190738:-
BRCA	cis	rs4927850	0.723	rs7630825	ENSG00000207650.1	MIR570	6.78	2.05e-11	4.26e-09	0.24	0.21	Pancreatic cancer;	chr3:196026869	chr3:195699401~195699497:+
BRCA	cis	rs8031584	0.958	rs8034856	ENSG00000260382.1	RP11-540B6.2	6.78	2.06e-11	4.27e-09	0.25	0.21	Huntington's disease progression;	chr15:30948754	chr15:30882267~30883231:-
BRCA	cis	rs875971	0.545	rs73376394	ENSG00000236529.1	RP13-254B10.1	6.78	2.06e-11	4.27e-09	0.25	0.21	Aortic root size;	chr7:66172694	chr7:65840212~65840596:+
BRCA	cis	rs11098499	0.779	rs80242894	ENSG00000249244.1	RP11-548H18.2	6.78	2.06e-11	4.28e-09	0.24	0.21	Corneal astigmatism;	chr4:119454597	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.863	rs10013305	ENSG00000249244.1	RP11-548H18.2	6.78	2.06e-11	4.28e-09	0.25	0.21	Corneal astigmatism;	chr4:119529269	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.863	rs3775849	ENSG00000249244.1	RP11-548H18.2	6.78	2.06e-11	4.28e-09	0.25	0.21	Corneal astigmatism;	chr4:119529753	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.818	rs7688802	ENSG00000249244.1	RP11-548H18.2	6.78	2.06e-11	4.28e-09	0.25	0.21	Corneal astigmatism;	chr4:119530513	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.863	rs7695620	ENSG00000249244.1	RP11-548H18.2	6.78	2.06e-11	4.28e-09	0.25	0.21	Corneal astigmatism;	chr4:119531621	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.863	rs12502389	ENSG00000249244.1	RP11-548H18.2	6.78	2.06e-11	4.28e-09	0.25	0.21	Corneal astigmatism;	chr4:119533036	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.821	rs3775852	ENSG00000249244.1	RP11-548H18.2	6.78	2.06e-11	4.28e-09	0.25	0.21	Corneal astigmatism;	chr4:119533401	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.82	rs6534140	ENSG00000249244.1	RP11-548H18.2	6.78	2.06e-11	4.28e-09	0.25	0.21	Corneal astigmatism;	chr4:119534156	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.863	rs7657849	ENSG00000249244.1	RP11-548H18.2	6.78	2.06e-11	4.28e-09	0.25	0.21	Corneal astigmatism;	chr4:119534339	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.863	rs10034450	ENSG00000249244.1	RP11-548H18.2	6.78	2.06e-11	4.28e-09	0.25	0.21	Corneal astigmatism;	chr4:119534494	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.863	rs1480939	ENSG00000249244.1	RP11-548H18.2	6.78	2.06e-11	4.28e-09	0.25	0.21	Corneal astigmatism;	chr4:119535772	chr4:119391831~119395335:-
BRCA	cis	rs11168351	0.833	rs6580652	ENSG00000240399.1	RP1-228P16.1	-6.78	2.07e-11	4.28e-09	-0.23	-0.21	Bipolar disorder and schizophrenia;	chr12:48053322	chr12:48054813~48055591:-
BRCA	cis	rs11098499	0.738	rs34566984	ENSG00000249244.1	RP11-548H18.2	6.78	2.07e-11	4.29e-09	0.24	0.21	Corneal astigmatism;	chr4:119440115	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.954	rs9685777	ENSG00000249244.1	RP11-548H18.2	6.78	2.07e-11	4.29e-09	0.24	0.21	Corneal astigmatism;	chr4:119444810	chr4:119391831~119395335:-
BRCA	cis	rs875971	0.545	rs2420456	ENSG00000236529.1	RP13-254B10.1	6.78	2.07e-11	4.29e-09	0.25	0.21	Aortic root size;	chr7:66280619	chr7:65840212~65840596:+
BRCA	cis	rs228614	0.509	rs223482	ENSG00000251288.2	RP11-10L12.2	-6.78	2.07e-11	4.29e-09	-0.24	-0.21	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102766051	chr4:102751401~102752641:+
BRCA	cis	rs1707322	0.717	rs1972410	ENSG00000281133.1	AL355480.3	-6.78	2.07e-11	4.29e-09	-0.26	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45615275	chr1:45580892~45580996:-
BRCA	cis	rs4713118	0.911	rs9461406	ENSG00000220721.1	OR1F12	-6.78	2.07e-11	4.29e-09	-0.26	-0.21	Parkinson's disease;	chr6:27751985	chr6:28073316~28074233:+
BRCA	cis	rs74233809	0.901	rs3824754	ENSG00000213277.3	MARCKSL1P1	6.78	2.07e-11	4.3e-09	0.38	0.21	Birth weight;	chr10:102854593	chr10:103175554~103176094:+
BRCA	cis	rs12460587	0.622	rs7247612	ENSG00000275055.1	CTC-471J1.11	-6.77	2.08e-11	4.31e-09	-0.24	-0.21	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52082336	chr19:52049007~52049754:+
BRCA	cis	rs6543140	0.964	rs6543136	ENSG00000234389.1	AC007278.3	6.77	2.08e-11	4.32e-09	0.21	0.21	Blood protein levels;	chr2:102449087	chr2:102438713~102440475:+
BRCA	cis	rs3198697	0.663	rs12928099	ENSG00000263335.1	AF001548.5	-6.77	2.09e-11	4.33e-09	-0.29	-0.21	Triglycerides;	chr16:15056648	chr16:15726674~15732993:+
BRCA	cis	rs875971	0.522	rs709604	ENSG00000237310.1	GS1-124K5.4	-6.77	2.09e-11	4.33e-09	-0.21	-0.21	Aortic root size;	chr7:66032447	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.522	rs1968127	ENSG00000236529.1	RP13-254B10.1	-6.77	2.09e-11	4.33e-09	-0.22	-0.21	Aortic root size;	chr7:66591816	chr7:65840212~65840596:+
BRCA	cis	rs12501370	1	rs17588627	ENSG00000201736.1	RNA5SP160	-6.77	2.09e-11	4.33e-09	-0.25	-0.21	Iris color (L* coordinate);	chr4:41016277	chr4:40990154~40990273:+
BRCA	cis	rs7246657	0.941	rs10418729	ENSG00000276846.1	CTD-3220F14.3	6.77	2.09e-11	4.34e-09	0.29	0.21	Coronary artery calcification;	chr19:37246163	chr19:37314868~37315620:-
BRCA	cis	rs6860806	0.507	rs272854	ENSG00000233006.5	AC034220.3	6.77	2.1e-11	4.34e-09	0.17	0.21	Breast cancer;	chr5:132352324	chr5:132311285~132369916:-
BRCA	cis	rs2243480	0.711	rs2420172	ENSG00000230295.1	RP11-458F8.2	6.77	2.1e-11	4.35e-09	0.27	0.21	Diabetic kidney disease;	chr7:66170354	chr7:66880708~66882981:+
BRCA	cis	rs838147	0.537	rs503279	ENSG00000232871.7	SEC1P	-6.77	2.1e-11	4.35e-09	-0.22	-0.21	Dietary macronutrient intake;	chr19:48705753	chr19:48638071~48682245:+
BRCA	cis	rs7208859	0.573	rs216443	ENSG00000266490.1	CTD-2349P21.9	6.77	2.1e-11	4.35e-09	0.33	0.21	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30604853	chr17:30792372~30792833:+
BRCA	cis	rs6603134	0.502	rs10406540	ENSG00000267939.1	CTD-2325M2.1	-6.77	2.1e-11	4.36e-09	-0.24	-0.21	Blood protein levels;	chr19:8039113	chr19:8008729~8016025:+
BRCA	cis	rs9549367	0.789	rs57747440	ENSG00000269125.1	RP11-98F14.11	-6.77	2.11e-11	4.36e-09	-0.27	-0.21	Platelet distribution width;	chr13:113240436	chr13:113165002~113165183:-
BRCA	cis	rs9549367	0.789	rs71446679	ENSG00000269125.1	RP11-98F14.11	-6.77	2.11e-11	4.36e-09	-0.27	-0.21	Platelet distribution width;	chr13:113240507	chr13:113165002~113165183:-
BRCA	cis	rs7247513	1	rs7247513	ENSG00000213290.4	PGK1P2	-6.77	2.11e-11	4.37e-09	-0.27	-0.21	Bipolar disorder;	chr19:12580371	chr19:12559571~12561105:+
BRCA	cis	rs9549367	0.789	rs9577218	ENSG00000269125.1	RP11-98F14.11	-6.77	2.11e-11	4.38e-09	-0.27	-0.21	Platelet distribution width;	chr13:113240597	chr13:113165002~113165183:-
BRCA	cis	rs875971	0.66	rs1860468	ENSG00000236529.1	RP13-254B10.1	-6.77	2.11e-11	4.38e-09	-0.22	-0.21	Aortic root size;	chr7:66642265	chr7:65840212~65840596:+
BRCA	cis	rs6543140	0.964	rs10193485	ENSG00000234389.1	AC007278.3	6.77	2.11e-11	4.38e-09	0.21	0.21	Blood protein levels;	chr2:102473114	chr2:102438713~102440475:+
BRCA	cis	rs6543140	0.964	rs10196334	ENSG00000234389.1	AC007278.3	6.77	2.11e-11	4.38e-09	0.21	0.21	Blood protein levels;	chr2:102473582	chr2:102438713~102440475:+
BRCA	cis	rs6740322	0.895	rs9309098	ENSG00000234936.1	AC010883.5	-6.77	2.11e-11	4.38e-09	-0.23	-0.21	Coronary artery disease;	chr2:43327833	chr2:43229573~43233394:+
BRCA	cis	rs875971	0.502	rs2946580	ENSG00000236529.1	RP13-254B10.1	-6.77	2.12e-11	4.38e-09	-0.26	-0.21	Aortic root size;	chr7:66066855	chr7:65840212~65840596:+
BRCA	cis	rs2243480	1	rs1979823	ENSG00000230295.1	RP11-458F8.2	6.77	2.12e-11	4.39e-09	0.27	0.21	Diabetic kidney disease;	chr7:66239626	chr7:66880708~66882981:+
BRCA	cis	rs7246657	0.941	rs10418729	ENSG00000226686.6	LINC01535	-6.77	2.12e-11	4.39e-09	-0.31	-0.21	Coronary artery calcification;	chr19:37246163	chr19:37251912~37265535:+
BRCA	cis	rs7665090	1	rs735403	ENSG00000246560.2	RP11-10L12.4	-6.77	2.12e-11	4.39e-09	-0.21	-0.21	Primary biliary cholangitis;	chr4:102632386	chr4:102828055~102844075:+
BRCA	cis	rs11098499	0.954	rs17009122	ENSG00000249244.1	RP11-548H18.2	6.77	2.12e-11	4.39e-09	0.24	0.21	Corneal astigmatism;	chr4:119441248	chr4:119391831~119395335:-
BRCA	cis	rs2348418	0.832	rs1907692	ENSG00000247934.4	RP11-967K21.1	6.77	2.12e-11	4.39e-09	0.23	0.21	Lung function (FEV1);Lung function (FVC);	chr12:28385178	chr12:28163298~28190738:-
BRCA	cis	rs9876781	1	rs6810060	ENSG00000229759.1	MRPS18AP1	6.77	2.12e-11	4.39e-09	0.23	0.21	Longevity;	chr3:48393284	chr3:48256350~48256938:-
BRCA	cis	rs9859260	0.71	rs419068	ENSG00000231464.1	AC024937.4	-6.77	2.13e-11	4.41e-09	-0.26	-0.21	Mean corpuscular volume;	chr3:196055305	chr3:195996738~195998233:+
BRCA	cis	rs9859260	0.71	rs366268	ENSG00000231464.1	AC024937.4	-6.77	2.13e-11	4.41e-09	-0.26	-0.21	Mean corpuscular volume;	chr3:196055306	chr3:195996738~195998233:+
BRCA	cis	rs9859260	0.744	rs419059	ENSG00000231464.1	AC024937.4	-6.77	2.13e-11	4.41e-09	-0.26	-0.21	Mean corpuscular volume;	chr3:196055313	chr3:195996738~195998233:+
BRCA	cis	rs2243480	1	rs410128	ENSG00000230295.1	RP11-458F8.2	-6.77	2.13e-11	4.41e-09	-0.29	-0.21	Diabetic kidney disease;	chr7:66138186	chr7:66880708~66882981:+
BRCA	cis	rs7809950	1	rs2712189	ENSG00000238832.1	snoU109	-6.77	2.13e-11	4.41e-09	-0.27	-0.21	Coronary artery disease;	chr7:107555302	chr7:107603363~107603507:+
BRCA	cis	rs6504622	0.818	rs9910899	ENSG00000262879.4	RP11-156P1.3	6.77	2.13e-11	4.41e-09	0.21	0.21	Orofacial clefts;	chr17:46956976	chr17:46984045~47100323:-
BRCA	cis	rs11148252	0.74	rs3803264	ENSG00000278238.1	RP11-245D16.4	6.77	2.13e-11	4.41e-09	0.22	0.21	Lewy body disease;	chr13:52397758	chr13:52454775~52455331:-
BRCA	cis	rs875971	0.54	rs781152	ENSG00000234585.5	CCT6P3	6.77	2.13e-11	4.42e-09	0.2	0.21	Aortic root size;	chr7:66014585	chr7:65038354~65074713:+
BRCA	cis	rs17711722	0.727	rs781151	ENSG00000234585.5	CCT6P3	6.77	2.13e-11	4.42e-09	0.2	0.21	Calcium levels;	chr7:66014891	chr7:65038354~65074713:+
BRCA	cis	rs2998286	0.862	rs2807728	ENSG00000254635.4	WAC-AS1	6.77	2.13e-11	4.42e-09	0.28	0.21	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28526504	chr10:28522652~28532743:-
BRCA	cis	rs160451	0.966	rs160447	ENSG00000251136.7	RP11-37B2.1	6.77	2.14e-11	4.42e-09	0.2	0.21	Leprosy;	chr8:89647432	chr8:89609409~89757727:-
BRCA	cis	rs17767294	0.612	rs9461425	ENSG00000220721.1	OR1F12	6.77	2.14e-11	4.43e-09	0.35	0.21	Parkinson's disease;	chr6:27951910	chr6:28073316~28074233:+
BRCA	cis	rs237743	1	rs8117111	ENSG00000222365.1	SNORD12B	-6.77	2.14e-11	4.43e-09	-0.27	-0.21	Height;	chr20:49267648	chr20:49280319~49280409:+
BRCA	cis	rs13631	0.965	rs9411307	ENSG00000268996.3	MAN1B1-AS1	6.77	2.14e-11	4.43e-09	0.2	0.21	Cerebrospinal fluid biomarker levels;	chr9:137100495	chr9:137084946~137086817:-
BRCA	cis	rs7617773	0.71	rs36064160	ENSG00000228638.1	FCF1P2	-6.77	2.15e-11	4.44e-09	-0.23	-0.21	Coronary artery disease;	chr3:48201611	chr3:48290793~48291375:-
BRCA	cis	rs875971	1	rs10215948	ENSG00000224316.1	RP11-479O9.2	-6.77	2.15e-11	4.44e-09	-0.2	-0.21	Aortic root size;	chr7:66282799	chr7:65773620~65802067:+
BRCA	cis	rs9494145	0.68	rs4895441	ENSG00000232876.1	CTA-212D2.2	6.77	2.15e-11	4.44e-09	0.3	0.21	Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count;	chr6:135105435	chr6:135055033~135060550:+
BRCA	cis	rs6969780	0.915	rs11983200	ENSG00000233429.8	HOTAIRM1	6.77	2.15e-11	4.44e-09	0.27	0.21	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27146977	chr7:27095647~27100265:+
BRCA	cis	rs1862618	0.853	rs2113078	ENSG00000271828.1	CTD-2310F14.1	6.77	2.15e-11	4.45e-09	0.29	0.21	Initial pursuit acceleration;	chr5:56791363	chr5:56927874~56929573:+
BRCA	cis	rs919433	0.963	rs10166569	ENSG00000231621.1	AC013264.2	6.77	2.15e-11	4.45e-09	0.2	0.21	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197318715	chr2:197197991~197199273:+
BRCA	cis	rs7487075	0.78	rs10785624	ENSG00000257261.4	RP11-96H19.1	6.77	2.15e-11	4.45e-09	0.23	0.21	Itch intensity from mosquito bite;	chr12:46373004	chr12:46383679~46876159:+
BRCA	cis	rs7487075	0.78	rs2279559	ENSG00000257261.4	RP11-96H19.1	6.77	2.15e-11	4.45e-09	0.23	0.21	Itch intensity from mosquito bite;	chr12:46373392	chr12:46383679~46876159:+
BRCA	cis	rs2348418	0.832	rs7294553	ENSG00000247934.4	RP11-967K21.1	6.77	2.15e-11	4.45e-09	0.23	0.21	Lung function (FEV1);Lung function (FVC);	chr12:28334832	chr12:28163298~28190738:-
BRCA	cis	rs7246657	0.941	rs67293224	ENSG00000226686.6	LINC01535	-6.77	2.15e-11	4.45e-09	-0.32	-0.21	Coronary artery calcification;	chr19:37312346	chr19:37251912~37265535:+
BRCA	cis	rs7587476	0.784	rs13008641	ENSG00000229267.2	AC072062.1	-6.77	2.15e-11	4.46e-09	-0.28	-0.21	Neuroblastoma;	chr2:214833309	chr2:214810229~214963274:+
BRCA	cis	rs10985070	0.504	rs2296077	ENSG00000226752.6	PSMD5-AS1	-6.77	2.15e-11	4.46e-09	-0.24	-0.21	Rheumatoid arthritis;	chr9:121182665	chr9:120824828~120854385:+
BRCA	cis	rs7208859	0.573	rs55661352	ENSG00000263603.1	CTD-2349P21.5	-6.77	2.16e-11	4.47e-09	-0.38	-0.21	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30718610	chr17:30729469~30731202:+
BRCA	cis	rs10510102	0.935	rs12253283	ENSG00000276742.1	RP11-500G22.4	-6.77	2.16e-11	4.47e-09	-0.34	-0.21	Breast cancer;	chr10:121909740	chr10:121956782~121957098:+
BRCA	cis	rs13113518	0.783	rs6843997	ENSG00000249700.7	SRD5A3-AS1	6.77	2.16e-11	4.48e-09	0.26	0.21	Height;	chr4:55508982	chr4:55363971~55395847:-
BRCA	cis	rs2243480	1	rs4718334	ENSG00000232546.1	RP11-458F8.1	6.77	2.17e-11	4.48e-09	0.27	0.21	Diabetic kidney disease;	chr7:66324467	chr7:66848496~66858136:+
BRCA	cis	rs9876781	1	rs6770470	ENSG00000229759.1	MRPS18AP1	6.77	2.17e-11	4.49e-09	0.23	0.21	Longevity;	chr3:48393659	chr3:48256350~48256938:-
BRCA	cis	rs1707322	0.721	rs10890336	ENSG00000281133.1	AL355480.3	-6.77	2.17e-11	4.49e-09	-0.26	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45645384	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.721	rs11211151	ENSG00000281133.1	AL355480.3	-6.77	2.17e-11	4.49e-09	-0.26	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45647080	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.721	rs12045096	ENSG00000281133.1	AL355480.3	-6.77	2.17e-11	4.49e-09	-0.26	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45648756	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.721	rs4609469	ENSG00000281133.1	AL355480.3	-6.77	2.17e-11	4.49e-09	-0.26	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45651513	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.721	rs12049027	ENSG00000281133.1	AL355480.3	-6.77	2.17e-11	4.49e-09	-0.26	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45652512	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.752	rs10789467	ENSG00000281133.1	AL355480.3	-6.77	2.17e-11	4.49e-09	-0.26	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45653073	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.721	rs10890337	ENSG00000281133.1	AL355480.3	-6.77	2.17e-11	4.49e-09	-0.26	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45658855	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.752	rs3811435	ENSG00000281133.1	AL355480.3	-6.77	2.17e-11	4.49e-09	-0.26	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45660118	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.721	rs9793568	ENSG00000281133.1	AL355480.3	-6.77	2.17e-11	4.49e-09	-0.26	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45664701	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.685	rs6690926	ENSG00000281133.1	AL355480.3	-6.77	2.17e-11	4.49e-09	-0.26	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45669306	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.752	rs8179402	ENSG00000281133.1	AL355480.3	-6.77	2.17e-11	4.49e-09	-0.26	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45676794	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.752	rs8179296	ENSG00000281133.1	AL355480.3	-6.77	2.17e-11	4.49e-09	-0.26	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45678119	chr1:45580892~45580996:-
BRCA	cis	rs79040073	0.563	rs17479003	ENSG00000259531.2	RP11-295H24.3	6.77	2.17e-11	4.49e-09	0.32	0.21	Lung cancer in ever smokers;	chr15:49453223	chr15:49365124~49366685:-
BRCA	cis	rs17253792	0.822	rs76918910	ENSG00000186615.9	KTN1-AS1	-6.77	2.17e-11	4.49e-09	-0.4	-0.21	Putamen volume;	chr14:55592044	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs77599953	ENSG00000186615.9	KTN1-AS1	-6.77	2.17e-11	4.49e-09	-0.4	-0.21	Putamen volume;	chr14:55592187	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs10137364	ENSG00000186615.9	KTN1-AS1	-6.77	2.17e-11	4.49e-09	-0.4	-0.21	Putamen volume;	chr14:55593269	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs17683728	ENSG00000186615.9	KTN1-AS1	-6.77	2.17e-11	4.49e-09	-0.4	-0.21	Putamen volume;	chr14:55593671	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs76264681	ENSG00000186615.9	KTN1-AS1	-6.77	2.17e-11	4.49e-09	-0.4	-0.21	Putamen volume;	chr14:55593729	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs17746033	ENSG00000186615.9	KTN1-AS1	-6.77	2.17e-11	4.49e-09	-0.4	-0.21	Putamen volume;	chr14:55595119	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs8009608	ENSG00000186615.9	KTN1-AS1	-6.77	2.17e-11	4.49e-09	-0.4	-0.21	Putamen volume;	chr14:55595872	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs76201070	ENSG00000186615.9	KTN1-AS1	-6.77	2.17e-11	4.49e-09	-0.4	-0.21	Putamen volume;	chr14:55596886	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs10150498	ENSG00000186615.9	KTN1-AS1	-6.77	2.17e-11	4.49e-09	-0.4	-0.21	Putamen volume;	chr14:55597406	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs10133962	ENSG00000186615.9	KTN1-AS1	-6.77	2.17e-11	4.49e-09	-0.4	-0.21	Putamen volume;	chr14:55599370	chr14:55499278~55580110:-
BRCA	cis	rs1552244	1	rs35993975	ENSG00000180385.7	EMC3-AS1	6.77	2.17e-11	4.5e-09	0.28	0.21	Alzheimer's disease;	chr3:10026110	chr3:9986893~10006990:+
BRCA	cis	rs7617773	0.746	rs7619865	ENSG00000228638.1	FCF1P2	-6.77	2.17e-11	4.5e-09	-0.21	-0.21	Coronary artery disease;	chr3:48329090	chr3:48290793~48291375:-
BRCA	cis	rs1823913	0.637	rs1947456	ENSG00000280083.1	RP11-317J9.1	6.77	2.18e-11	4.5e-09	0.23	0.21	Obesity-related traits;	chr2:191298759	chr2:191154118~191156070:-
BRCA	cis	rs11009175	0.725	rs11009195	ENSG00000273038.2	RP11-479G22.8	-6.77	2.18e-11	4.5e-09	-0.34	-0.21	Depression (quantitative trait);	chr10:33045345	chr10:32887255~32889311:-
BRCA	cis	rs6543140	0.964	rs10200081	ENSG00000234389.1	AC007278.3	6.77	2.18e-11	4.5e-09	0.21	0.21	Blood protein levels;	chr2:102475097	chr2:102438713~102440475:+
BRCA	cis	rs7085104	0.572	rs284858	ENSG00000213061.2	PFN1P11	-6.77	2.18e-11	4.51e-09	-0.26	-0.21	Immature fraction of reticulocytes;Schizophrenia;	chr10:102814179	chr10:102838011~102845473:-
BRCA	cis	rs6545883	0.868	rs6752938	ENSG00000271889.1	RP11-493E12.1	6.77	2.18e-11	4.51e-09	0.26	0.21	Tuberculosis;	chr2:61614453	chr2:61151433~61162105:-
BRCA	cis	rs1707322	0.826	rs10890349	ENSG00000281133.1	AL355480.3	-6.77	2.18e-11	4.52e-09	-0.27	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45784283	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.758	rs10789474	ENSG00000281133.1	AL355480.3	-6.77	2.18e-11	4.52e-09	-0.27	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45784368	chr1:45580892~45580996:-
BRCA	cis	rs2243480	1	rs427044	ENSG00000229886.1	RP5-1132H15.3	6.77	2.19e-11	4.52e-09	0.37	0.21	Diabetic kidney disease;	chr7:66043558	chr7:66025126~66031544:-
BRCA	cis	rs875971	0.638	rs3898855	ENSG00000236529.1	RP13-254B10.1	-6.77	2.19e-11	4.53e-09	-0.22	-0.21	Aortic root size;	chr7:66571411	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.638	rs10278816	ENSG00000236529.1	RP13-254B10.1	-6.77	2.19e-11	4.53e-09	-0.22	-0.21	Aortic root size;	chr7:66572000	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.66	rs10281080	ENSG00000236529.1	RP13-254B10.1	-6.77	2.19e-11	4.53e-09	-0.22	-0.21	Aortic root size;	chr7:66577454	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.66	rs10950044	ENSG00000236529.1	RP13-254B10.1	-6.77	2.19e-11	4.53e-09	-0.22	-0.21	Aortic root size;	chr7:66577989	chr7:65840212~65840596:+
BRCA	cis	rs301901	0.734	rs10941321	ENSG00000250155.1	CTD-2353F22.1	-6.77	2.19e-11	4.53e-09	-0.23	-0.21	Height;	chr5:37213248	chr5:36666214~36725195:-
BRCA	cis	rs6603134	0.502	rs10405582	ENSG00000267939.1	CTD-2325M2.1	-6.77	2.19e-11	4.53e-09	-0.24	-0.21	Blood protein levels;	chr19:8038654	chr19:8008729~8016025:+
BRCA	cis	rs6860806	0.507	rs2631371	ENSG00000233006.5	AC034220.3	-6.77	2.2e-11	4.54e-09	-0.17	-0.21	Breast cancer;	chr5:132367999	chr5:132311285~132369916:-
BRCA	cis	rs7587476	0.784	rs13032278	ENSG00000229267.2	AC072062.1	-6.77	2.2e-11	4.54e-09	-0.28	-0.21	Neuroblastoma;	chr2:214833310	chr2:214810229~214963274:+
BRCA	cis	rs71520386	0.632	rs10224533	ENSG00000228649.7	AC005682.5	-6.77	2.2e-11	4.54e-09	-0.2	-0.21	Fibrinogen levels;	chr7:22821522	chr7:22854178~22861579:+
BRCA	cis	rs11671005	0.61	rs8103813	ENSG00000252334.1	RNU6-1337P	6.77	2.2e-11	4.56e-09	0.32	0.21	Mean platelet volume;	chr19:58561317	chr19:58483749~58483843:-
BRCA	cis	rs11098499	0.562	rs2389879	ENSG00000245958.5	RP11-33B1.1	6.77	2.21e-11	4.56e-09	0.19	0.21	Corneal astigmatism;	chr4:119636529	chr4:119454791~119552025:+
BRCA	cis	rs6603134	0.502	rs10405588	ENSG00000267939.1	CTD-2325M2.1	-6.77	2.21e-11	4.56e-09	-0.24	-0.21	Blood protein levels;	chr19:8038663	chr19:8008729~8016025:+
BRCA	cis	rs1275468	0.554	rs1147994	ENSG00000257497.2	RP11-585P4.5	-6.77	2.21e-11	4.56e-09	-0.3	-0.21	Polycystic ovary syndrome;	chr12:75566186	chr12:75483454~75489820:-
BRCA	cis	rs4356203	0.519	rs214097	ENSG00000272034.1	SNORD14A	-6.77	2.21e-11	4.57e-09	-0.22	-0.21	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17269952	chr11:17074654~17074744:-
BRCA	cis	rs7069191	0.668	rs10994491	ENSG00000254271.1	RP11-131N11.4	6.77	2.21e-11	4.57e-09	0.35	0.21	Pediatric bone mineral density (spine);	chr10:60744463	chr10:60734342~60741828:+
BRCA	cis	rs673078	0.607	rs11068919	ENSG00000275409.1	RP11-131L12.4	-6.77	2.21e-11	4.57e-09	-0.27	-0.21	Glucose homeostasis traits;	chr12:118354925	chr12:118430147~118430699:+
BRCA	cis	rs7829975	0.688	rs7837587	ENSG00000254153.1	CTA-398F10.2	6.77	2.21e-11	4.57e-09	0.25	0.21	Mood instability;	chr8:8521482	chr8:8456909~8461337:-
BRCA	cis	rs17301013	0.507	rs1121537	ENSG00000227373.4	RP11-160H22.5	6.77	2.21e-11	4.58e-09	0.29	0.21	Systemic lupus erythematosus;	chr1:174307568	chr1:174115300~174160004:-
BRCA	cis	rs34779708	0.931	rs7923217	ENSG00000271335.4	RP11-324I22.4	6.77	2.22e-11	4.58e-09	0.21	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35020661	chr10:35314552~35336401:-
BRCA	cis	rs3126085	0.935	rs12408581	ENSG00000237975.5	FLG-AS1	6.77	2.22e-11	4.58e-09	0.32	0.21	Atopic dermatitis;	chr1:152202735	chr1:152168125~152445456:+
BRCA	cis	rs6504622	0.818	rs9912794	ENSG00000262879.4	RP11-156P1.3	6.76	2.22e-11	4.59e-09	0.21	0.21	Orofacial clefts;	chr17:46957075	chr17:46984045~47100323:-
BRCA	cis	rs2243480	1	rs2420171	ENSG00000230295.1	RP11-458F8.2	6.76	2.22e-11	4.59e-09	0.27	0.21	Diabetic kidney disease;	chr7:66172773	chr7:66880708~66882981:+
BRCA	cis	rs8054556	0.74	rs3924855	ENSG00000273724.1	RP11-347C12.12	-6.76	2.22e-11	4.59e-09	-0.23	-0.21	Autism spectrum disorder or schizophrenia;	chr16:29943634	chr16:30336400~30343336:+
BRCA	cis	rs4266144	0.592	rs1545854	ENSG00000244515.1	KRT18P34	6.76	2.23e-11	4.61e-09	0.28	0.21	Coronary artery disease;	chr3:157122349	chr3:157162663~157163932:-
BRCA	cis	rs10050311	0.858	rs1010903	ENSG00000251411.1	RP11-397E7.4	-6.76	2.23e-11	4.61e-09	-0.3	-0.21	Insulin-related traits;	chr4:86898040	chr4:86913266~86914817:-
BRCA	cis	rs67981189	0.896	rs7153237	ENSG00000269927.1	RP6-91H8.3	6.76	2.23e-11	4.61e-09	0.25	0.21	Schizophrenia;	chr14:71021937	chr14:71141125~71143253:-
BRCA	cis	rs13113518	0.812	rs4865001	ENSG00000249700.7	SRD5A3-AS1	6.76	2.23e-11	4.61e-09	0.26	0.21	Height;	chr4:55490176	chr4:55363971~55395847:-
BRCA	cis	rs13113518	0.756	rs7658446	ENSG00000249700.7	SRD5A3-AS1	6.76	2.23e-11	4.61e-09	0.26	0.21	Height;	chr4:55495262	chr4:55363971~55395847:-
BRCA	cis	rs7428	0.545	rs1053561	ENSG00000246575.2	AC093162.5	6.76	2.24e-11	4.62e-09	0.21	0.21	Ear protrusion;	chr2:85318929	chr2:85315041~85316529:+
BRCA	cis	rs2243480	1	rs57057549	ENSG00000228409.4	CCT6P1	6.76	2.24e-11	4.62e-09	0.28	0.21	Diabetic kidney disease;	chr7:65940751	chr7:65751142~65763354:+
BRCA	cis	rs11098499	0.908	rs1002152	ENSG00000249244.1	RP11-548H18.2	6.76	2.24e-11	4.63e-09	0.24	0.21	Corneal astigmatism;	chr4:119352232	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.954	rs67265404	ENSG00000249244.1	RP11-548H18.2	6.76	2.24e-11	4.63e-09	0.25	0.21	Corneal astigmatism;	chr4:119438115	chr4:119391831~119395335:-
BRCA	cis	rs9880211	0.679	rs9818740	ENSG00000239213.4	NCK1-AS1	6.76	2.24e-11	4.63e-09	0.26	0.21	Height;Body mass index;	chr3:136220744	chr3:136841726~136862054:-
BRCA	cis	rs11098499	0.874	rs7661020	ENSG00000248280.1	RP11-33B1.2	6.76	2.25e-11	4.64e-09	0.22	0.21	Corneal astigmatism;	chr4:119185827	chr4:119440561~119450157:-
BRCA	cis	rs17711722	0.565	rs73372653	ENSG00000228409.4	CCT6P1	-6.76	2.25e-11	4.64e-09	-0.19	-0.21	Calcium levels;	chr7:65977808	chr7:65751142~65763354:+
BRCA	cis	rs7520050	0.645	rs1768809	ENSG00000280836.1	AL355480.1	6.76	2.25e-11	4.65e-09	0.24	0.21	Reticulocyte count;Red blood cell count;	chr1:46037164	chr1:45581219~45581321:-
BRCA	cis	rs673078	0.607	rs61943399	ENSG00000275409.1	RP11-131L12.4	-6.76	2.26e-11	4.66e-09	-0.31	-0.21	Glucose homeostasis traits;	chr12:118393628	chr12:118430147~118430699:+
BRCA	cis	rs875971	0.638	rs10249404	ENSG00000236529.1	RP13-254B10.1	-6.76	2.26e-11	4.66e-09	-0.22	-0.21	Aortic root size;	chr7:66581737	chr7:65840212~65840596:+
BRCA	cis	rs2348418	0.832	rs4930822	ENSG00000247934.4	RP11-967K21.1	6.76	2.26e-11	4.66e-09	0.23	0.21	Lung function (FEV1);Lung function (FVC);	chr12:28421789	chr12:28163298~28190738:-
BRCA	cis	rs7829975	0.606	rs7819827	ENSG00000233609.3	RP11-62H7.2	-6.76	2.26e-11	4.66e-09	-0.19	-0.21	Mood instability;	chr8:8939545	chr8:8961200~8979025:+
BRCA	cis	rs7829975	0.573	rs7842359	ENSG00000233609.3	RP11-62H7.2	-6.76	2.26e-11	4.66e-09	-0.19	-0.21	Mood instability;	chr8:8939568	chr8:8961200~8979025:+
BRCA	cis	rs2274273	0.638	rs3825614	ENSG00000258413.1	RP11-665C16.6	-6.76	2.26e-11	4.67e-09	-0.28	-0.21	Protein biomarker;	chr14:55262669	chr14:55262767~55272075:-
BRCA	cis	rs7617773	0.817	rs35414021	ENSG00000228638.1	FCF1P2	-6.76	2.26e-11	4.67e-09	-0.23	-0.21	Coronary artery disease;	chr3:48252034	chr3:48290793~48291375:-
BRCA	cis	rs1707322	0.721	rs11211157	ENSG00000281133.1	AL355480.3	-6.76	2.26e-11	4.67e-09	-0.26	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45667172	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.721	rs11211158	ENSG00000281133.1	AL355480.3	-6.76	2.26e-11	4.67e-09	-0.26	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45667178	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.721	rs6429575	ENSG00000281133.1	AL355480.3	-6.76	2.26e-11	4.67e-09	-0.26	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45668544	chr1:45580892~45580996:-
BRCA	cis	rs11976180	0.953	rs2951355	ENSG00000204959.4	ARHGEF34P	6.76	2.26e-11	4.67e-09	0.26	0.21	Obesity-related traits;	chr7:144063469	chr7:144272445~144286966:-
BRCA	cis	rs11976180	1	rs2951354	ENSG00000204959.4	ARHGEF34P	6.76	2.26e-11	4.67e-09	0.26	0.21	Obesity-related traits;	chr7:144063908	chr7:144272445~144286966:-
BRCA	cis	rs11976180	1	rs2961125	ENSG00000204959.4	ARHGEF34P	6.76	2.26e-11	4.67e-09	0.26	0.21	Obesity-related traits;	chr7:144064677	chr7:144272445~144286966:-
BRCA	cis	rs11976180	1	rs2961126	ENSG00000204959.4	ARHGEF34P	6.76	2.26e-11	4.67e-09	0.26	0.21	Obesity-related traits;	chr7:144065643	chr7:144272445~144286966:-
BRCA	cis	rs11976180	0.953	rs2961127	ENSG00000204959.4	ARHGEF34P	6.76	2.26e-11	4.67e-09	0.26	0.21	Obesity-related traits;	chr7:144065644	chr7:144272445~144286966:-
BRCA	cis	rs11976180	1	rs1919948	ENSG00000204959.4	ARHGEF34P	6.76	2.26e-11	4.67e-09	0.26	0.21	Obesity-related traits;	chr7:144065750	chr7:144272445~144286966:-
BRCA	cis	rs11976180	1	rs2961128	ENSG00000204959.4	ARHGEF34P	6.76	2.26e-11	4.67e-09	0.26	0.21	Obesity-related traits;	chr7:144066390	chr7:144272445~144286966:-
BRCA	cis	rs11976180	1	rs2371248	ENSG00000204959.4	ARHGEF34P	6.76	2.26e-11	4.67e-09	0.26	0.21	Obesity-related traits;	chr7:144067096	chr7:144272445~144286966:-
BRCA	cis	rs9291683	0.655	rs35750364	ENSG00000250413.1	RP11-448G15.1	-6.76	2.26e-11	4.67e-09	-0.27	-0.21	Bone mineral density;	chr4:10047425	chr4:10006482~10009725:+
BRCA	cis	rs3126085	0.56	rs11204985	ENSG00000237975.5	FLG-AS1	-6.76	2.27e-11	4.68e-09	-0.28	-0.21	Atopic dermatitis;	chr1:152361121	chr1:152168125~152445456:+
BRCA	cis	rs957448	0.561	rs58663902	ENSG00000253704.1	RP11-267M23.4	6.76	2.27e-11	4.68e-09	0.22	0.21	Nonsyndromic cleft lip with cleft palate;	chr8:94610177	chr8:94553722~94569745:+
BRCA	cis	rs6952407	1	rs6952407	ENSG00000236529.1	RP13-254B10.1	-6.76	2.27e-11	4.69e-09	-0.22	-0.21	Cotinine glucuronidation;	chr7:66580525	chr7:65840212~65840596:+
BRCA	cis	rs5015933	0.815	rs13294021	ENSG00000232630.1	PRPS1P2	-6.76	2.27e-11	4.69e-09	-0.19	-0.21	Body mass index;	chr9:125306109	chr9:125150653~125151589:+
BRCA	cis	rs7978895	0.669	rs1399377	ENSG00000258331.1	RP11-118A3.1	-6.76	2.27e-11	4.69e-09	-0.21	-0.21	Type 2 diabetes;	chr12:43154835	chr12:43155315~43163110:+
BRCA	cis	rs301901	0.772	rs6860727	ENSG00000250155.1	CTD-2353F22.1	-6.76	2.28e-11	4.71e-09	-0.22	-0.2	Height;	chr5:37179239	chr5:36666214~36725195:-
BRCA	cis	rs7246657	0.943	rs10420722	ENSG00000226686.6	LINC01535	-6.76	2.28e-11	4.71e-09	-0.31	-0.2	Coronary artery calcification;	chr19:37482872	chr19:37251912~37265535:+
BRCA	cis	rs2842992	0.789	rs2277072	ENSG00000237927.1	RP3-393E18.2	-6.76	2.28e-11	4.71e-09	-0.29	-0.2	Age-related macular degeneration (geographic atrophy);	chr6:159761813	chr6:159586955~159589169:-
BRCA	cis	rs10027350	0.757	rs4459977	ENSG00000281501.1	SEPSECS-AS1	6.76	2.28e-11	4.71e-09	0.25	0.2	Childhood ear infection;	chr4:25183937	chr4:25160641~25201440:+
BRCA	cis	rs7976269	0.609	rs6487744	ENSG00000257176.2	RP11-996F15.2	-6.76	2.29e-11	4.72e-09	-0.25	-0.2	Male-pattern baldness;	chr12:29030756	chr12:29280418~29317848:-
BRCA	cis	rs1707322	0.647	rs6686944	ENSG00000281133.1	AL355480.3	-6.76	2.29e-11	4.72e-09	-0.27	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45690636	chr1:45580892~45580996:-
BRCA	cis	rs875971	0.502	rs11769702	ENSG00000273024.4	INTS4P2	-6.76	2.29e-11	4.73e-09	-0.26	-0.2	Aortic root size;	chr7:66255529	chr7:65647864~65715661:+
BRCA	cis	rs6840360	0.642	rs4696092	ENSG00000270265.1	RP11-731D1.4	-6.76	2.29e-11	4.73e-09	-0.23	-0.2	Intelligence (multi-trait analysis);	chr4:151491451	chr4:151333775~151353224:-
BRCA	cis	rs848490	0.651	rs12113119	ENSG00000214293.7	APTR	6.76	2.29e-11	4.73e-09	0.24	0.2	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77685501	chr7:77657660~77696265:-
BRCA	cis	rs7809950	1	rs2520268	ENSG00000238832.1	snoU109	-6.76	2.3e-11	4.75e-09	-0.28	-0.2	Coronary artery disease;	chr7:107550716	chr7:107603363~107603507:+
BRCA	cis	rs3747113	1	rs3747113	ENSG00000128262.7	POM121L9P	6.76	2.3e-11	4.75e-09	0.24	0.2	Gut microbiome composition (summer);	chr22:24321550	chr22:24251828~24265525:+
BRCA	cis	rs7246657	0.943	rs7253091	ENSG00000276846.1	CTD-3220F14.3	6.76	2.31e-11	4.76e-09	0.27	0.2	Coronary artery calcification;	chr19:37476312	chr19:37314868~37315620:-
BRCA	cis	rs6142102	0.886	rs4911147	ENSG00000275784.1	RP5-1125A11.6	-6.76	2.31e-11	4.76e-09	-0.25	-0.2	Skin pigmentation;	chr20:34079801	chr20:33989480~33991818:-
BRCA	cis	rs1707322	0.721	rs6697821	ENSG00000281133.1	AL355480.3	-6.76	2.31e-11	4.77e-09	-0.27	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45751050	chr1:45580892~45580996:-
BRCA	cis	rs7044106	0.762	rs1324473	ENSG00000238181.2	AHCYP2	6.76	2.31e-11	4.77e-09	0.27	0.2	Hip circumference adjusted for BMI;	chr9:120642332	chr9:120720673~120721972:+
BRCA	cis	rs6142102	0.961	rs2268088	ENSG00000275784.1	RP5-1125A11.6	-6.76	2.32e-11	4.78e-09	-0.25	-0.2	Skin pigmentation;	chr20:34061258	chr20:33989480~33991818:-
BRCA	cis	rs6142102	0.961	rs2284388	ENSG00000275784.1	RP5-1125A11.6	-6.76	2.32e-11	4.78e-09	-0.25	-0.2	Skin pigmentation;	chr20:34067935	chr20:33989480~33991818:-
BRCA	cis	rs860818	1	rs858245	ENSG00000226816.2	AC005082.12	6.76	2.32e-11	4.78e-09	0.49	0.2	Initial pursuit acceleration;	chr7:23183108	chr7:23206013~23208045:+
BRCA	cis	rs9990333	0.622	rs57783901	ENSG00000231464.1	AC024937.4	6.76	2.32e-11	4.78e-09	0.26	0.2	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196089486	chr3:195996738~195998233:+
BRCA	cis	rs11098499	0.954	rs1480931	ENSG00000249244.1	RP11-548H18.2	6.76	2.32e-11	4.78e-09	0.24	0.2	Corneal astigmatism;	chr4:119474654	chr4:119391831~119395335:-
BRCA	cis	rs7474896	0.583	rs10827817	ENSG00000226578.1	RP11-258F22.1	-6.76	2.32e-11	4.78e-09	-0.27	-0.2	Obesity (extreme);	chr10:37709046	chr10:37775371~37784131:-
BRCA	cis	rs42648	0.596	rs194520	ENSG00000225498.1	AC002064.5	6.76	2.32e-11	4.79e-09	0.2	0.2	Homocysteine levels;	chr7:90225132	chr7:90312496~90322592:+
BRCA	cis	rs2243480	1	rs6964530	ENSG00000232546.1	RP11-458F8.1	6.76	2.34e-11	4.82e-09	0.27	0.2	Diabetic kidney disease;	chr7:66253864	chr7:66848496~66858136:+
BRCA	cis	rs79040073	0.637	rs73394359	ENSG00000259531.2	RP11-295H24.3	6.76	2.34e-11	4.82e-09	0.33	0.2	Lung cancer in ever smokers;	chr15:49300941	chr15:49365124~49366685:-
BRCA	cis	rs9880211	0.613	rs6786582	ENSG00000273486.1	RP11-731C17.2	-6.76	2.34e-11	4.82e-09	-0.27	-0.2	Height;Body mass index;	chr3:136180142	chr3:136837338~136839021:-
BRCA	cis	rs34929064	0.881	rs2961311	ENSG00000179428.2	AC073072.5	6.76	2.34e-11	4.83e-09	0.23	0.2	Major depression and alcohol dependence;	chr7:22687919	chr7:22725395~22727620:-
BRCA	cis	rs2243480	1	rs4718334	ENSG00000230295.1	RP11-458F8.2	6.76	2.35e-11	4.83e-09	0.27	0.2	Diabetic kidney disease;	chr7:66324467	chr7:66880708~66882981:+
BRCA	cis	rs2243480	0.808	rs12698508	ENSG00000228409.4	CCT6P1	6.76	2.35e-11	4.83e-09	0.28	0.2	Diabetic kidney disease;	chr7:65946971	chr7:65751142~65763354:+
BRCA	cis	rs301901	0.698	rs11948801	ENSG00000250155.1	CTD-2353F22.1	6.76	2.35e-11	4.84e-09	0.22	0.2	Height;	chr5:37430113	chr5:36666214~36725195:-
BRCA	cis	rs6142102	0.961	rs4911411	ENSG00000275784.1	RP5-1125A11.6	-6.76	2.35e-11	4.84e-09	-0.24	-0.2	Skin pigmentation;	chr20:34128036	chr20:33989480~33991818:-
BRCA	cis	rs7246657	0.943	rs4803460	ENSG00000226686.6	LINC01535	-6.76	2.35e-11	4.84e-09	-0.3	-0.2	Coronary artery calcification;	chr19:37394326	chr19:37251912~37265535:+
BRCA	cis	rs7978895	0.669	rs1399373	ENSG00000258331.1	RP11-118A3.1	-6.76	2.35e-11	4.85e-09	-0.21	-0.2	Type 2 diabetes;	chr12:43150938	chr12:43155315~43163110:+
BRCA	cis	rs7978895	0.669	rs1399372	ENSG00000258331.1	RP11-118A3.1	-6.76	2.35e-11	4.85e-09	-0.21	-0.2	Type 2 diabetes;	chr12:43150972	chr12:43155315~43163110:+
BRCA	cis	rs875971	0.66	rs6460308	ENSG00000236529.1	RP13-254B10.1	-6.76	2.36e-11	4.85e-09	-0.22	-0.2	Aortic root size;	chr7:66619753	chr7:65840212~65840596:+
BRCA	cis	rs1707322	0.721	rs4660314	ENSG00000281133.1	AL355480.3	-6.76	2.36e-11	4.86e-09	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45764213	chr1:45580892~45580996:-
BRCA	cis	rs801193	0.742	rs9969300	ENSG00000224316.1	RP11-479O9.2	-6.76	2.36e-11	4.86e-09	-0.2	-0.2	Aortic root size;	chr7:66316659	chr7:65773620~65802067:+
BRCA	cis	rs2835345	0.563	rs12482435	ENSG00000230479.1	AP000695.6	6.76	2.36e-11	4.86e-09	0.2	0.2	Pulmonary function;	chr21:36448658	chr21:36430360~36481070:+
BRCA	cis	rs1823874	0.72	rs1993296	ENSG00000182397.13	DNM1P46	-6.76	2.36e-11	4.87e-09	-0.22	-0.2	IgG glycosylation;	chr15:99823383	chr15:99790156~99806927:-
BRCA	cis	rs2998286	0.862	rs2185293	ENSG00000254635.4	WAC-AS1	-6.76	2.36e-11	4.87e-09	-0.28	-0.2	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28519170	chr10:28522652~28532743:-
BRCA	cis	rs919433	0.963	rs4850430	ENSG00000231621.1	AC013264.2	6.76	2.37e-11	4.88e-09	0.2	0.2	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197318072	chr2:197197991~197199273:+
BRCA	cis	rs7617773	0.746	rs6796343	ENSG00000228638.1	FCF1P2	-6.75	2.37e-11	4.89e-09	-0.23	-0.2	Coronary artery disease;	chr3:48240531	chr3:48290793~48291375:-
BRCA	cis	rs2880765	0.525	rs35899940	ENSG00000259295.5	CSPG4P12	6.75	2.38e-11	4.9e-09	0.27	0.2	Coronary artery disease;	chr15:85510466	chr15:85191438~85213905:+
BRCA	cis	rs1061377	0.748	rs6816202	ENSG00000249685.1	RP11-360F5.3	6.75	2.38e-11	4.9e-09	0.25	0.2	Uric acid levels;	chr4:39106868	chr4:39133913~39135608:+
BRCA	cis	rs1061377	0.748	rs6842561	ENSG00000249685.1	RP11-360F5.3	6.75	2.38e-11	4.9e-09	0.25	0.2	Uric acid levels;	chr4:39106873	chr4:39133913~39135608:+
BRCA	cis	rs17253792	0.731	rs74829671	ENSG00000186615.9	KTN1-AS1	-6.75	2.38e-11	4.91e-09	-0.4	-0.2	Putamen volume;	chr14:55646041	chr14:55499278~55580110:-
BRCA	cis	rs1707322	0.686	rs11211179	ENSG00000281133.1	AL355480.3	-6.75	2.39e-11	4.91e-09	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45762410	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.721	rs10157795	ENSG00000281133.1	AL355480.3	-6.75	2.39e-11	4.91e-09	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45762520	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.963	rs10890373	ENSG00000281133.1	AL355480.3	-6.75	2.39e-11	4.91e-09	-0.27	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45928083	chr1:45580892~45580996:-
BRCA	cis	rs11976180	1	rs11975942	ENSG00000204959.4	ARHGEF34P	6.75	2.39e-11	4.92e-09	0.26	0.2	Obesity-related traits;	chr7:144043487	chr7:144272445~144286966:-
BRCA	cis	rs237743	1	rs35506374	ENSG00000222365.1	SNORD12B	-6.75	2.39e-11	4.92e-09	-0.27	-0.2	Height;	chr20:49311346	chr20:49280319~49280409:+
BRCA	cis	rs67981189	0.858	rs17108877	ENSG00000269927.1	RP6-91H8.3	6.75	2.39e-11	4.92e-09	0.25	0.2	Schizophrenia;	chr14:71007092	chr14:71141125~71143253:-
BRCA	cis	rs875971	0.66	rs79009421	ENSG00000236529.1	RP13-254B10.1	-6.75	2.39e-11	4.92e-09	-0.22	-0.2	Aortic root size;	chr7:66603522	chr7:65840212~65840596:+
BRCA	cis	rs301901	0.772	rs2098713	ENSG00000250155.1	CTD-2353F22.1	-6.75	2.39e-11	4.93e-09	-0.22	-0.2	Height;	chr5:37144472	chr5:36666214~36725195:-
BRCA	cis	rs2412819	0.597	rs514311	ENSG00000205771.5	CATSPER2P1	-6.75	2.4e-11	4.94e-09	-0.3	-0.2	Lung cancer;	chr15:43869376	chr15:43726918~43747094:-
BRCA	cis	rs957448	1	rs957447	ENSG00000253175.1	RP11-267M23.6	6.75	2.4e-11	4.94e-09	0.26	0.2	Nonsyndromic cleft lip with cleft palate;	chr8:94528995	chr8:94565036~94565715:+
BRCA	cis	rs2337406	0.925	rs11851094	ENSG00000211974.3	IGHV2-70	-6.75	2.4e-11	4.94e-09	-0.26	-0.2	Alzheimer's disease (late onset);	chr14:106688967	chr14:106723574~106724093:-
BRCA	cis	rs919433	0.684	rs55775495	ENSG00000231621.1	AC013264.2	-6.75	2.41e-11	4.95e-09	-0.19	-0.2	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197381241	chr2:197197991~197199273:+
BRCA	cis	rs875971	0.66	rs2013222	ENSG00000236529.1	RP13-254B10.1	-6.75	2.41e-11	4.96e-09	-0.22	-0.2	Aortic root size;	chr7:66570949	chr7:65840212~65840596:+
BRCA	cis	rs10740039	0.81	rs1372709	ENSG00000254271.1	RP11-131N11.4	6.75	2.41e-11	4.96e-09	0.28	0.2	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60621666	chr10:60734342~60741828:+
BRCA	cis	rs2842992	0.747	rs1547093	ENSG00000237927.1	RP3-393E18.2	-6.75	2.41e-11	4.96e-09	-0.29	-0.2	Age-related macular degeneration (geographic atrophy);	chr6:159784959	chr6:159586955~159589169:-
BRCA	cis	rs7976269	0.609	rs2349574	ENSG00000257176.2	RP11-996F15.2	-6.75	2.41e-11	4.96e-09	-0.24	-0.2	Male-pattern baldness;	chr12:29053805	chr12:29280418~29317848:-
BRCA	cis	rs228614	0.536	rs223478	ENSG00000251288.2	RP11-10L12.2	-6.75	2.41e-11	4.97e-09	-0.24	-0.2	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102768648	chr4:102751401~102752641:+
BRCA	cis	rs228614	0.536	rs150898	ENSG00000251288.2	RP11-10L12.2	-6.75	2.41e-11	4.97e-09	-0.24	-0.2	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102769234	chr4:102751401~102752641:+
BRCA	cis	rs1862618	0.853	rs6885541	ENSG00000271828.1	CTD-2310F14.1	6.75	2.42e-11	4.97e-09	0.29	0.2	Initial pursuit acceleration;	chr5:56815030	chr5:56927874~56929573:+
BRCA	cis	rs1862618	0.853	rs11739344	ENSG00000271828.1	CTD-2310F14.1	6.75	2.42e-11	4.97e-09	0.29	0.2	Initial pursuit acceleration;	chr5:56815260	chr5:56927874~56929573:+
BRCA	cis	rs17214007	0.877	rs4482303	ENSG00000263335.1	AF001548.5	-6.75	2.42e-11	4.98e-09	-0.3	-0.2	Cognitive function;	chr16:15777020	chr16:15726674~15732993:+
BRCA	cis	rs11976180	1	rs1919950	ENSG00000204959.4	ARHGEF34P	6.75	2.42e-11	4.98e-09	0.26	0.2	Obesity-related traits;	chr7:144070805	chr7:144272445~144286966:-
BRCA	cis	rs944990	0.597	rs11789176	ENSG00000227603.1	RP11-165J3.6	6.75	2.42e-11	4.99e-09	0.21	0.2	Body mass index;	chr9:93433884	chr9:93435332~93437121:-
BRCA	cis	rs2243480	1	rs34193460	ENSG00000228409.4	CCT6P1	6.75	2.43e-11	4.99e-09	0.28	0.2	Diabetic kidney disease;	chr7:65928123	chr7:65751142~65763354:+
BRCA	cis	rs4713118	0.786	rs200503	ENSG00000220721.1	OR1F12	6.75	2.43e-11	4.99e-09	0.26	0.2	Parkinson's disease;	chr6:27818104	chr6:28073316~28074233:+
BRCA	cis	rs4713118	0.786	rs200502	ENSG00000220721.1	OR1F12	6.75	2.43e-11	4.99e-09	0.26	0.2	Parkinson's disease;	chr6:27820284	chr6:28073316~28074233:+
BRCA	cis	rs13178541	0.683	rs9800300	ENSG00000250378.1	RP11-119J18.1	-6.75	2.43e-11	5e-09	-0.29	-0.2	IgG glycosylation;	chr5:135760622	chr5:135812667~135826582:+
BRCA	cis	rs11096990	0.855	rs2566184	ENSG00000249207.1	RP11-360F5.1	6.75	2.44e-11	5.01e-09	0.24	0.2	Cognitive function;	chr4:39162700	chr4:39112677~39126818:-
BRCA	cis	rs9291683	0.609	rs55959894	ENSG00000250413.1	RP11-448G15.1	-6.75	2.44e-11	5.01e-09	-0.27	-0.2	Bone mineral density;	chr4:10024956	chr4:10006482~10009725:+
BRCA	cis	rs11098499	0.863	rs7678400	ENSG00000249244.1	RP11-548H18.2	6.75	2.44e-11	5.01e-09	0.25	0.2	Corneal astigmatism;	chr4:119540802	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.863	rs1480936	ENSG00000249244.1	RP11-548H18.2	6.75	2.44e-11	5.01e-09	0.25	0.2	Corneal astigmatism;	chr4:119541706	chr4:119391831~119395335:-
BRCA	cis	rs2688608	0.592	rs11000757	ENSG00000271816.1	BMS1P4	6.75	2.44e-11	5.01e-09	0.2	0.2	Inflammatory bowel disease;	chr10:73727057	chr10:73699151~73730487:-
BRCA	cis	rs17711722	0.565	rs4717276	ENSG00000213640.3	EEF1DP4	-6.75	2.44e-11	5.02e-09	-0.26	-0.2	Calcium levels;	chr7:65829754	chr7:64862999~64864370:+
BRCA	cis	rs79040073	0.637	rs73392249	ENSG00000259531.2	RP11-295H24.3	6.75	2.44e-11	5.02e-09	0.33	0.2	Lung cancer in ever smokers;	chr15:49224264	chr15:49365124~49366685:-
BRCA	cis	rs9291683	0.588	rs12506364	ENSG00000250413.1	RP11-448G15.1	-6.75	2.45e-11	5.03e-09	-0.27	-0.2	Bone mineral density;	chr4:10021824	chr4:10006482~10009725:+
BRCA	cis	rs10129255	0.833	rs7156689	ENSG00000224373.3	IGHV4-59	6.75	2.45e-11	5.04e-09	0.13	0.2	Kawasaki disease;	chr14:106816039	chr14:106627249~106627825:-
BRCA	cis	rs11098499	0.697	rs11941899	ENSG00000249244.1	RP11-548H18.2	6.75	2.46e-11	5.05e-09	0.24	0.2	Corneal astigmatism;	chr4:119461603	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.909	rs7681978	ENSG00000249244.1	RP11-548H18.2	6.75	2.46e-11	5.05e-09	0.24	0.2	Corneal astigmatism;	chr4:119462620	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.821	rs28665282	ENSG00000249244.1	RP11-548H18.2	6.75	2.46e-11	5.05e-09	0.24	0.2	Corneal astigmatism;	chr4:119463031	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.738	rs10026493	ENSG00000249244.1	RP11-548H18.2	6.75	2.46e-11	5.05e-09	0.24	0.2	Corneal astigmatism;	chr4:119463039	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.909	rs7681214	ENSG00000249244.1	RP11-548H18.2	6.75	2.46e-11	5.05e-09	0.24	0.2	Corneal astigmatism;	chr4:119464165	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.909	rs28632018	ENSG00000249244.1	RP11-548H18.2	6.75	2.46e-11	5.05e-09	0.24	0.2	Corneal astigmatism;	chr4:119465575	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.908	rs71614449	ENSG00000249244.1	RP11-548H18.2	6.75	2.46e-11	5.05e-09	0.24	0.2	Corneal astigmatism;	chr4:119465900	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.954	rs35063680	ENSG00000249244.1	RP11-548H18.2	6.75	2.46e-11	5.05e-09	0.24	0.2	Corneal astigmatism;	chr4:119465947	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.954	rs34858317	ENSG00000249244.1	RP11-548H18.2	6.75	2.46e-11	5.05e-09	0.24	0.2	Corneal astigmatism;	chr4:119465955	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.954	rs17046116	ENSG00000249244.1	RP11-548H18.2	6.75	2.46e-11	5.05e-09	0.24	0.2	Corneal astigmatism;	chr4:119466104	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.909	rs17046118	ENSG00000249244.1	RP11-548H18.2	6.75	2.46e-11	5.05e-09	0.24	0.2	Corneal astigmatism;	chr4:119466341	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.954	rs7654587	ENSG00000249244.1	RP11-548H18.2	6.75	2.46e-11	5.05e-09	0.24	0.2	Corneal astigmatism;	chr4:119467251	chr4:119391831~119395335:-
BRCA	cis	rs2380205	0.546	rs626344	ENSG00000232807.2	RP11-536K7.3	-6.75	2.46e-11	5.05e-09	-0.21	-0.2	Breast cancer;	chr10:5908272	chr10:5934270~5945900:-
BRCA	cis	rs858239	0.932	rs199355	ENSG00000230042.1	AK3P3	-6.75	2.46e-11	5.05e-09	-0.23	-0.2	Cerebrospinal fluid biomarker levels;	chr7:23256914	chr7:23129178~23129841:+
BRCA	cis	rs34779708	0.931	rs11592404	ENSG00000271335.4	RP11-324I22.4	6.75	2.46e-11	5.06e-09	0.22	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:34984548	chr10:35314552~35336401:-
BRCA	cis	rs17772222	0.682	rs28482235	ENSG00000258983.2	RP11-507K2.2	6.75	2.46e-11	5.06e-09	0.21	0.2	Coronary artery calcification;	chr14:88472857	chr14:88499334~88515502:+
BRCA	cis	rs9652601	0.959	rs12927355	ENSG00000274038.1	RP11-66H6.4	-6.75	2.46e-11	5.07e-09	-0.24	-0.2	Systemic lupus erythematosus;	chr16:11100914	chr16:11056556~11057034:+
BRCA	cis	rs34779708	0.931	rs79749947	ENSG00000271335.4	RP11-324I22.4	6.75	2.47e-11	5.07e-09	0.22	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:34988153	chr10:35314552~35336401:-
BRCA	cis	rs875971	1	rs3981131	ENSG00000232559.3	GS1-124K5.12	6.75	2.47e-11	5.07e-09	0.24	0.2	Aortic root size;	chr7:66486690	chr7:66554588~66576923:-
BRCA	cis	rs7978895	0.669	rs10880428	ENSG00000258331.1	RP11-118A3.1	-6.75	2.47e-11	5.07e-09	-0.21	-0.2	Type 2 diabetes;	chr12:43165435	chr12:43155315~43163110:+
BRCA	cis	rs7978895	0.669	rs7953134	ENSG00000258331.1	RP11-118A3.1	-6.75	2.47e-11	5.07e-09	-0.21	-0.2	Type 2 diabetes;	chr12:43165884	chr12:43155315~43163110:+
BRCA	cis	rs7978895	0.669	rs7309190	ENSG00000258331.1	RP11-118A3.1	-6.75	2.47e-11	5.07e-09	-0.21	-0.2	Type 2 diabetes;	chr12:43167000	chr12:43155315~43163110:+
BRCA	cis	rs9876781	1	rs7636782	ENSG00000244380.1	RP11-24C3.2	6.75	2.47e-11	5.07e-09	0.23	0.2	Longevity;	chr3:48379897	chr3:48440352~48446656:-
BRCA	cis	rs9880211	0.613	rs13079205	ENSG00000273486.1	RP11-731C17.2	6.75	2.47e-11	5.08e-09	0.27	0.2	Height;Body mass index;	chr3:136081851	chr3:136837338~136839021:-
BRCA	cis	rs3761847	0.622	rs4837807	ENSG00000226752.6	PSMD5-AS1	-6.75	2.47e-11	5.08e-09	-0.24	-0.2	Rheumatoid arthritis;	chr9:121029727	chr9:120824828~120854385:+
BRCA	cis	rs10129255	0.833	rs61997797	ENSG00000224373.3	IGHV4-59	6.75	2.47e-11	5.09e-09	0.13	0.2	Kawasaki disease;	chr14:106815190	chr14:106627249~106627825:-
BRCA	cis	rs2599510	0.783	rs2568464	ENSG00000276334.1	AL133243.1	-6.75	2.47e-11	5.09e-09	-0.25	-0.2	Interleukin-18 levels;	chr2:32623591	chr2:32521927~32523547:+
BRCA	cis	rs2834288	0.5	rs881231	ENSG00000273102.1	AP000569.9	6.75	2.48e-11	5.09e-09	0.22	0.2	Gut microbiota (bacterial taxa);	chr21:33950526	chr21:33967101~33968573:-
BRCA	cis	rs2243480	1	rs313802	ENSG00000229886.1	RP5-1132H15.3	6.75	2.49e-11	5.11e-09	0.37	0.2	Diabetic kidney disease;	chr7:66051386	chr7:66025126~66031544:-
BRCA	cis	rs2243480	0.803	rs403089	ENSG00000229886.1	RP5-1132H15.3	6.75	2.49e-11	5.11e-09	0.37	0.2	Diabetic kidney disease;	chr7:66052736	chr7:66025126~66031544:-
BRCA	cis	rs2243480	1	rs458291	ENSG00000229886.1	RP5-1132H15.3	6.75	2.49e-11	5.11e-09	0.37	0.2	Diabetic kidney disease;	chr7:66055492	chr7:66025126~66031544:-
BRCA	cis	rs875971	0.66	rs1860470	ENSG00000236529.1	RP13-254B10.1	-6.75	2.49e-11	5.12e-09	-0.22	-0.2	Aortic root size;	chr7:66638707	chr7:65840212~65840596:+
BRCA	cis	rs6840360	0.642	rs7680013	ENSG00000270265.1	RP11-731D1.4	-6.75	2.49e-11	5.12e-09	-0.23	-0.2	Intelligence (multi-trait analysis);	chr4:151488325	chr4:151333775~151353224:-
BRCA	cis	rs6840360	0.642	rs7680236	ENSG00000270265.1	RP11-731D1.4	-6.75	2.49e-11	5.12e-09	-0.23	-0.2	Intelligence (multi-trait analysis);	chr4:151488449	chr4:151333775~151353224:-
BRCA	cis	rs2243480	1	rs6964245	ENSG00000230295.1	RP11-458F8.2	6.75	2.49e-11	5.12e-09	0.27	0.2	Diabetic kidney disease;	chr7:66253730	chr7:66880708~66882981:+
BRCA	cis	rs1823913	0.637	rs4853579	ENSG00000280083.1	RP11-317J9.1	6.75	2.49e-11	5.12e-09	0.23	0.2	Obesity-related traits;	chr2:191297413	chr2:191154118~191156070:-
BRCA	cis	rs1707322	0.682	rs28490344	ENSG00000281133.1	AL355480.3	-6.75	2.5e-11	5.14e-09	-0.27	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45732276	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.721	rs28641748	ENSG00000281133.1	AL355480.3	-6.75	2.5e-11	5.14e-09	-0.27	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45747164	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.721	rs4330955	ENSG00000281133.1	AL355480.3	-6.75	2.5e-11	5.14e-09	-0.27	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45751813	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.691	rs12031182	ENSG00000281133.1	AL355480.3	-6.75	2.5e-11	5.14e-09	-0.27	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755327	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.721	rs10430123	ENSG00000281133.1	AL355480.3	-6.75	2.5e-11	5.14e-09	-0.27	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755768	chr1:45580892~45580996:-
BRCA	cis	rs8114671	1	rs8114671	ENSG00000269202.1	RP4-614O4.12	6.75	2.5e-11	5.14e-09	0.21	0.2	Height;	chr20:35201339	chr20:35201747~35203288:-
BRCA	cis	rs1862618	0.853	rs832583	ENSG00000271828.1	CTD-2310F14.1	6.75	2.5e-11	5.14e-09	0.29	0.2	Initial pursuit acceleration;	chr5:56882390	chr5:56927874~56929573:+
BRCA	cis	rs7978895	0.669	rs1514675	ENSG00000258331.1	RP11-118A3.1	6.75	2.51e-11	5.15e-09	0.21	0.2	Type 2 diabetes;	chr12:43169324	chr12:43155315~43163110:+
BRCA	cis	rs11976180	1	rs2951353	ENSG00000204959.4	ARHGEF34P	6.75	2.51e-11	5.15e-09	0.26	0.2	Obesity-related traits;	chr7:144064023	chr7:144272445~144286966:-
BRCA	cis	rs7246657	0.943	rs13343502	ENSG00000226686.6	LINC01535	-6.75	2.51e-11	5.15e-09	-0.31	-0.2	Coronary artery calcification;	chr19:37471390	chr19:37251912~37265535:+
BRCA	cis	rs2688608	0.592	rs12253429	ENSG00000271816.1	BMS1P4	6.75	2.51e-11	5.15e-09	0.2	0.2	Inflammatory bowel disease;	chr10:73736403	chr10:73699151~73730487:-
BRCA	cis	rs13113518	0.783	rs11943206	ENSG00000249700.7	SRD5A3-AS1	6.75	2.51e-11	5.16e-09	0.26	0.2	Height;	chr4:55570843	chr4:55363971~55395847:-
BRCA	cis	rs6142102	1	rs6059681	ENSG00000275784.1	RP5-1125A11.6	-6.75	2.51e-11	5.16e-09	-0.25	-0.2	Skin pigmentation;	chr20:34135535	chr20:33989480~33991818:-
BRCA	cis	rs2688608	0.592	rs11000758	ENSG00000271816.1	BMS1P4	6.75	2.51e-11	5.16e-09	0.2	0.2	Inflammatory bowel disease;	chr10:73733852	chr10:73699151~73730487:-
BRCA	cis	rs1823913	0.599	rs1823912	ENSG00000280083.1	RP11-317J9.1	-6.75	2.51e-11	5.16e-09	-0.23	-0.2	Obesity-related traits;	chr2:191266388	chr2:191154118~191156070:-
BRCA	cis	rs950880	0.553	rs2241116	ENSG00000234389.1	AC007278.3	-6.75	2.52e-11	5.17e-09	-0.23	-0.2	Serum protein levels (sST2);	chr2:102386805	chr2:102438713~102440475:+
BRCA	cis	rs1322639	0.618	rs9505942	ENSG00000261039.2	RP11-417E7.2	-6.75	2.52e-11	5.17e-09	-0.26	-0.2	Pulse pressure;	chr6:169191698	chr6:169175304~169182740:-
BRCA	cis	rs3761847	0.622	rs10818498	ENSG00000226752.6	PSMD5-AS1	-6.75	2.52e-11	5.18e-09	-0.24	-0.2	Rheumatoid arthritis;	chr9:121025288	chr9:120824828~120854385:+
BRCA	cis	rs875971	0.66	rs3764903	ENSG00000236529.1	RP13-254B10.1	-6.75	2.52e-11	5.18e-09	-0.22	-0.2	Aortic root size;	chr7:66633495	chr7:65840212~65840596:+
BRCA	cis	rs62025270	0.547	rs338536	ENSG00000202081.1	RNU6-1280P	-6.75	2.52e-11	5.18e-09	-0.25	-0.2	Idiopathic pulmonary fibrosis;	chr15:85654009	chr15:85651522~85651628:-
BRCA	cis	rs42648	0.596	rs194511	ENSG00000225498.1	AC002064.5	6.75	2.53e-11	5.19e-09	0.2	0.2	Homocysteine levels;	chr7:90217413	chr7:90312496~90322592:+
BRCA	cis	rs1387259	0.929	rs11168484	ENSG00000273765.1	RP11-370I10.11	6.74	2.53e-11	5.2e-09	0.25	0.2	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48239806	chr12:48360920~48361377:+
BRCA	cis	rs12501370	1	rs4398555	ENSG00000201736.1	RNA5SP160	6.74	2.54e-11	5.22e-09	0.26	0.2	Iris color (L* coordinate);	chr4:41026846	chr4:40990154~40990273:+
BRCA	cis	rs7246657	0.943	rs2291004	ENSG00000267422.1	CTD-2554C21.1	-6.74	2.55e-11	5.22e-09	-0.31	-0.2	Coronary artery calcification;	chr19:37507050	chr19:37779686~37792865:+
BRCA	cis	rs801193	0.904	rs4718405	ENSG00000237310.1	GS1-124K5.4	6.74	2.55e-11	5.23e-09	0.21	0.2	Aortic root size;	chr7:66789659	chr7:66493706~66495474:+
BRCA	cis	rs34929064	0.846	rs2905342	ENSG00000179428.2	AC073072.5	6.74	2.55e-11	5.24e-09	0.23	0.2	Major depression and alcohol dependence;	chr7:22691425	chr7:22725395~22727620:-
BRCA	cis	rs9549367	0.789	rs71446682	ENSG00000269125.1	RP11-98F14.11	-6.74	2.55e-11	5.24e-09	-0.27	-0.2	Platelet distribution width;	chr13:113240594	chr13:113165002~113165183:-
BRCA	cis	rs11098499	0.865	rs28634456	ENSG00000249244.1	RP11-548H18.2	6.74	2.56e-11	5.24e-09	0.24	0.2	Corneal astigmatism;	chr4:119454623	chr4:119391831~119395335:-
BRCA	cis	rs2337406	1	rs10459466	ENSG00000254174.1	IGHV1-12	6.74	2.56e-11	5.25e-09	0.23	0.2	Alzheimer's disease (late onset);	chr14:106689255	chr14:106122420~106122709:-
BRCA	cis	rs1707322	0.682	rs10890335	ENSG00000281133.1	AL355480.3	-6.74	2.57e-11	5.27e-09	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634722	chr1:45580892~45580996:-
BRCA	cis	rs712039	0.958	rs1016679	ENSG00000276054.1	RP11-378E13.3	-6.74	2.57e-11	5.28e-09	-0.27	-0.2	Tuberculosis;	chr17:37514228	chr17:37386886~37387926:+
BRCA	cis	rs2281636	0.63	rs12355655	ENSG00000233690.1	EBAG9P1	6.74	2.57e-11	5.28e-09	0.24	0.2	Obesity-related traits;	chr10:99616982	chr10:99697407~99697949:-
BRCA	cis	rs4372836	1	rs7562170	ENSG00000226833.4	AC097724.3	-6.74	2.57e-11	5.28e-09	-0.25	-0.2	Body mass index;	chr2:28720650	chr2:28708953~28736205:-
BRCA	cis	rs1707322	0.789	rs10789473	ENSG00000281133.1	AL355480.3	-6.74	2.58e-11	5.29e-09	-0.27	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45782459	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.717	rs1135812	ENSG00000281133.1	AL355480.3	-6.74	2.58e-11	5.29e-09	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45629600	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.752	rs6703748	ENSG00000281133.1	AL355480.3	-6.74	2.58e-11	5.29e-09	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45630304	chr1:45580892~45580996:-
BRCA	cis	rs2337406	0.925	rs76288499	ENSG00000254174.1	IGHV1-12	6.74	2.58e-11	5.3e-09	0.22	0.2	Alzheimer's disease (late onset);	chr14:106686309	chr14:106122420~106122709:-
BRCA	cis	rs237743	1	rs36016605	ENSG00000222365.1	SNORD12B	-6.74	2.58e-11	5.3e-09	-0.27	-0.2	Height;	chr20:49279608	chr20:49280319~49280409:+
BRCA	cis	rs673078	0.607	rs61943443	ENSG00000275409.1	RP11-131L12.4	-6.74	2.59e-11	5.3e-09	-0.31	-0.2	Glucose homeostasis traits;	chr12:118416602	chr12:118430147~118430699:+
BRCA	cis	rs7978895	0.647	rs8181625	ENSG00000258331.1	RP11-118A3.1	-6.74	2.59e-11	5.3e-09	-0.21	-0.2	Type 2 diabetes;	chr12:43162246	chr12:43155315~43163110:+
BRCA	cis	rs13315649	0.562	rs6797317	ENSG00000242551.2	POU5F1P6	-6.74	2.59e-11	5.32e-09	-0.28	-0.2	Sum eosinophil basophil counts;	chr3:128684381	chr3:128674735~128677005:-
BRCA	cis	rs8114671	0.967	rs4911478	ENSG00000269202.1	RP4-614O4.12	6.74	2.59e-11	5.32e-09	0.21	0.2	Height;	chr20:35194822	chr20:35201747~35203288:-
BRCA	cis	rs6840360	0.642	rs1470281	ENSG00000270265.1	RP11-731D1.4	-6.74	2.6e-11	5.32e-09	-0.23	-0.2	Intelligence (multi-trait analysis);	chr4:151510400	chr4:151333775~151353224:-
BRCA	cis	rs2732480	0.5	rs2450989	ENSG00000273765.1	RP11-370I10.11	-6.74	2.6e-11	5.32e-09	-0.24	-0.2	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48259625	chr12:48360920~48361377:+
BRCA	cis	rs237743	0.963	rs35772539	ENSG00000222365.1	SNORD12B	-6.74	2.6e-11	5.33e-09	-0.27	-0.2	Height;	chr20:49282748	chr20:49280319~49280409:+
BRCA	cis	rs237743	1	rs35387764	ENSG00000222365.1	SNORD12B	-6.74	2.6e-11	5.33e-09	-0.27	-0.2	Height;	chr20:49286304	chr20:49280319~49280409:+
BRCA	cis	rs10515750	0.588	rs1900157	ENSG00000251405.2	CTB-109A12.1	6.74	2.6e-11	5.33e-09	0.32	0.2	Lung function (FEV1/FVC);	chr5:157333834	chr5:157362615~157460078:-
BRCA	cis	rs801193	1	rs10234018	ENSG00000237310.1	GS1-124K5.4	-6.74	2.61e-11	5.35e-09	-0.21	-0.2	Aortic root size;	chr7:66681297	chr7:66493706~66495474:+
BRCA	cis	rs911555	0.692	rs7145753	ENSG00000244691.1	RPL10AP1	6.74	2.61e-11	5.35e-09	0.26	0.2	Intelligence (multi-trait analysis);	chr14:103399763	chr14:103412119~103412761:-
BRCA	cis	rs7208859	0.673	rs73263776	ENSG00000263603.1	CTD-2349P21.5	-6.74	2.61e-11	5.36e-09	-0.37	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30884313	chr17:30729469~30731202:+
BRCA	cis	rs7208859	0.623	rs11650271	ENSG00000263603.1	CTD-2349P21.5	-6.74	2.61e-11	5.36e-09	-0.37	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30886925	chr17:30729469~30731202:+
BRCA	cis	rs1823913	0.66	rs1454752	ENSG00000280083.1	RP11-317J9.1	6.74	2.61e-11	5.36e-09	0.23	0.2	Obesity-related traits;	chr2:191298668	chr2:191154118~191156070:-
BRCA	cis	rs237743	1	rs8123912	ENSG00000222365.1	SNORD12B	-6.74	2.62e-11	5.37e-09	-0.27	-0.2	Height;	chr20:49246745	chr20:49280319~49280409:+
BRCA	cis	rs875971	0.895	rs12698520	ENSG00000232559.3	GS1-124K5.12	6.74	2.62e-11	5.38e-09	0.24	0.2	Aortic root size;	chr7:66453720	chr7:66554588~66576923:-
BRCA	cis	rs1707322	0.717	rs12023439	ENSG00000281133.1	AL355480.3	-6.74	2.62e-11	5.38e-09	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45638964	chr1:45580892~45580996:-
BRCA	cis	rs2235642	0.533	rs9922661	ENSG00000280231.1	LA16c-380F5.3	-6.74	2.63e-11	5.38e-09	-0.29	-0.2	Coronary artery disease;	chr16:1555162	chr16:1553655~1554130:-
BRCA	cis	rs73173548	0.502	rs4423262	ENSG00000247828.6	TMEM161B-AS1	6.74	2.63e-11	5.39e-09	0.28	0.2	Macular telangiectasia type 2;	chr5:88438609	chr5:88268895~88436685:+
BRCA	cis	rs467650	0.963	rs154197	ENSG00000248489.1	CTD-2007H13.3	6.74	2.63e-11	5.39e-09	0.23	0.2	Venous thromboembolism (SNP x SNP interaction);	chr5:98642639	chr5:98929171~98995013:+
BRCA	cis	rs4691139	0.873	rs12509081	ENSG00000248632.1	RP11-366M4.11	6.74	2.63e-11	5.39e-09	0.21	0.2	Ovarian cancer in BRCA1 mutation carriers;	chr4:164971812	chr4:164968587~164970002:-
BRCA	cis	rs35542019	1	rs35542019	ENSG00000273102.1	AP000569.9	6.74	2.63e-11	5.39e-09	0.22	0.2	Hemoglobin concentration;Hematocrit;Red blood cell count;	chr21:33974555	chr21:33967101~33968573:-
BRCA	cis	rs6840258	0.66	rs55816619	ENSG00000251411.1	RP11-397E7.4	-6.74	2.64e-11	5.4e-09	-0.31	-0.2	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87038653	chr4:86913266~86914817:-
BRCA	cis	rs8054556	0.656	rs4420550	ENSG00000273724.1	RP11-347C12.12	-6.74	2.64e-11	5.4e-09	-0.22	-0.2	Autism spectrum disorder or schizophrenia;	chr16:29927499	chr16:30336400~30343336:+
BRCA	cis	rs13113518	0.812	rs13140590	ENSG00000223305.1	RN7SKP30	6.74	2.64e-11	5.42e-09	0.25	0.2	Height;	chr4:55548666	chr4:55540502~55540835:-
BRCA	cis	rs7474896	0.526	rs1208716	ENSG00000226578.1	RP11-258F22.1	-6.74	2.64e-11	5.42e-09	-0.28	-0.2	Obesity (extreme);	chr10:37800345	chr10:37775371~37784131:-
BRCA	cis	rs2842992	0.83	rs2273819	ENSG00000237927.1	RP3-393E18.2	-6.74	2.65e-11	5.42e-09	-0.29	-0.2	Age-related macular degeneration (geographic atrophy);	chr6:159762293	chr6:159586955~159589169:-
BRCA	cis	rs875971	0.638	rs6460305	ENSG00000236529.1	RP13-254B10.1	-6.74	2.65e-11	5.43e-09	-0.22	-0.2	Aortic root size;	chr7:66595421	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.66	rs10272357	ENSG00000236529.1	RP13-254B10.1	-6.74	2.65e-11	5.43e-09	-0.22	-0.2	Aortic root size;	chr7:66598087	chr7:65840212~65840596:+
BRCA	cis	rs7119038	0.509	rs10790261	ENSG00000255239.1	AP002954.6	6.74	2.65e-11	5.43e-09	0.29	0.2	Sjögren's syndrome;	chr11:118709038	chr11:118688039~118690600:-
BRCA	cis	rs1707322	0.721	rs11211165	ENSG00000281133.1	AL355480.3	-6.74	2.66e-11	5.44e-09	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692234	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.721	rs11211166	ENSG00000281133.1	AL355480.3	-6.74	2.66e-11	5.44e-09	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692270	chr1:45580892~45580996:-
BRCA	cis	rs74233809	0.748	rs10786736	ENSG00000213277.3	MARCKSL1P1	6.74	2.66e-11	5.44e-09	0.36	0.2	Birth weight;	chr10:103089359	chr10:103175554~103176094:+
BRCA	cis	rs2380205	0.601	rs4293039	ENSG00000232807.2	RP11-536K7.3	6.74	2.66e-11	5.45e-09	0.21	0.2	Breast cancer;	chr10:5856261	chr10:5934270~5945900:-
BRCA	cis	rs853679	0.546	rs200952	ENSG00000220721.1	OR1F12	6.74	2.66e-11	5.45e-09	0.37	0.2	Depression;	chr6:27869198	chr6:28073316~28074233:+
BRCA	cis	rs11976180	1	rs2371247	ENSG00000204959.4	ARHGEF34P	6.74	2.67e-11	5.46e-09	0.26	0.2	Obesity-related traits;	chr7:144067086	chr7:144272445~144286966:-
BRCA	cis	rs2243480	1	rs10247526	ENSG00000232546.1	RP11-458F8.1	6.74	2.67e-11	5.47e-09	0.28	0.2	Diabetic kidney disease;	chr7:66315709	chr7:66848496~66858136:+
BRCA	cis	rs6142102	0.962	rs2206448	ENSG00000275784.1	RP5-1125A11.6	-6.74	2.68e-11	5.48e-09	-0.24	-0.2	Skin pigmentation;	chr20:34121719	chr20:33989480~33991818:-
BRCA	cis	rs875971	0.862	rs7786892	ENSG00000224316.1	RP11-479O9.2	-6.74	2.68e-11	5.48e-09	-0.21	-0.2	Aortic root size;	chr7:66163889	chr7:65773620~65802067:+
BRCA	cis	rs72759215	1	rs72759215	ENSG00000215032.2	GNL3LP1	6.74	2.68e-11	5.48e-09	0.25	0.2	Intelligence (multi-trait analysis);	chr5:61056756	chr5:60891935~60893577:-
BRCA	cis	rs2243480	1	rs2961102	ENSG00000228409.4	CCT6P1	6.74	2.68e-11	5.49e-09	0.28	0.2	Diabetic kidney disease;	chr7:65959671	chr7:65751142~65763354:+
BRCA	cis	rs11671005	0.572	rs11669127	ENSG00000252334.1	RNU6-1337P	-6.74	2.68e-11	5.49e-09	-0.33	-0.2	Mean platelet volume;	chr19:58492463	chr19:58483749~58483843:-
BRCA	cis	rs1552244	0.816	rs13059144	ENSG00000180385.7	EMC3-AS1	6.74	2.69e-11	5.5e-09	0.25	0.2	Alzheimer's disease;	chr3:9968513	chr3:9986893~10006990:+
BRCA	cis	rs11098499	0.505	rs75122014	ENSG00000249244.1	RP11-548H18.2	6.74	2.69e-11	5.51e-09	0.24	0.2	Corneal astigmatism;	chr4:119441271	chr4:119391831~119395335:-
BRCA	cis	rs42648	0.623	rs194505	ENSG00000225498.1	AC002064.5	6.74	2.69e-11	5.51e-09	0.2	0.2	Homocysteine levels;	chr7:90211993	chr7:90312496~90322592:+
BRCA	cis	rs875971	0.545	rs12671152	ENSG00000224316.1	RP11-479O9.2	6.74	2.69e-11	5.51e-09	0.24	0.2	Aortic root size;	chr7:66311140	chr7:65773620~65802067:+
BRCA	cis	rs11148252	0.74	rs9526914	ENSG00000278238.1	RP11-245D16.4	-6.74	2.7e-11	5.52e-09	-0.22	-0.2	Lewy body disease;	chr13:52402165	chr13:52454775~52455331:-
BRCA	cis	rs13113518	0.776	rs13124436	ENSG00000249700.7	SRD5A3-AS1	6.74	2.7e-11	5.52e-09	0.26	0.2	Height;	chr4:55502504	chr4:55363971~55395847:-
BRCA	cis	rs17301013	0.507	rs6697959	ENSG00000227373.4	RP11-160H22.5	6.74	2.7e-11	5.53e-09	0.3	0.2	Systemic lupus erythematosus;	chr1:174285450	chr1:174115300~174160004:-
BRCA	cis	rs1387259	0.79	rs2732445	ENSG00000273765.1	RP11-370I10.11	6.74	2.7e-11	5.53e-09	0.25	0.2	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48251750	chr12:48360920~48361377:+
BRCA	cis	rs1823913	0.637	rs12622194	ENSG00000280083.1	RP11-317J9.1	6.74	2.7e-11	5.53e-09	0.23	0.2	Obesity-related traits;	chr2:191298680	chr2:191154118~191156070:-
BRCA	cis	rs1823913	0.637	rs13019567	ENSG00000280083.1	RP11-317J9.1	6.74	2.7e-11	5.53e-09	0.23	0.2	Obesity-related traits;	chr2:191298736	chr2:191154118~191156070:-
BRCA	cis	rs2243480	0.901	rs34807232	ENSG00000232546.1	RP11-458F8.1	-6.74	2.7e-11	5.53e-09	-0.27	-0.2	Diabetic kidney disease;	chr7:66500146	chr7:66848496~66858136:+
BRCA	cis	rs2243480	0.901	rs35823062	ENSG00000232546.1	RP11-458F8.1	-6.74	2.7e-11	5.53e-09	-0.27	-0.2	Diabetic kidney disease;	chr7:66500834	chr7:66848496~66858136:+
BRCA	cis	rs9311474	1	rs6445358	ENSG00000243224.1	RP5-1157M23.2	-6.74	2.7e-11	5.53e-09	-0.23	-0.2	Electroencephalogram traits;	chr3:52274829	chr3:52239258~52241097:+
BRCA	cis	rs9880211	0.821	rs9832813	ENSG00000273486.1	RP11-731C17.2	6.73	2.71e-11	5.54e-09	0.24	0.2	Height;Body mass index;	chr3:136346723	chr3:136837338~136839021:-
BRCA	cis	rs9876781	1	rs4858793	ENSG00000229759.1	MRPS18AP1	-6.73	2.71e-11	5.54e-09	-0.23	-0.2	Longevity;	chr3:48373517	chr3:48256350~48256938:-
BRCA	cis	rs6570726	0.967	rs403584	ENSG00000235652.6	RP11-545I5.3	6.73	2.71e-11	5.54e-09	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145485874	chr6:145799409~145886585:+
BRCA	cis	rs10050311	0.858	rs72667705	ENSG00000251411.1	RP11-397E7.4	-6.73	2.71e-11	5.55e-09	-0.3	-0.2	Insulin-related traits;	chr4:86892986	chr4:86913266~86914817:-
BRCA	cis	rs8002861	0.664	rs9525873	ENSG00000274001.1	RP11-5G9.5	6.73	2.71e-11	5.55e-09	0.24	0.2	Leprosy;	chr13:43908068	chr13:43877715~43878163:-
BRCA	cis	rs2243480	1	rs2707844	ENSG00000229886.1	RP5-1132H15.3	6.73	2.71e-11	5.55e-09	0.36	0.2	Diabetic kidney disease;	chr7:66594522	chr7:66025126~66031544:-
BRCA	cis	rs2243480	1	rs1796220	ENSG00000229886.1	RP5-1132H15.3	6.73	2.71e-11	5.55e-09	0.36	0.2	Diabetic kidney disease;	chr7:66597113	chr7:66025126~66031544:-
BRCA	cis	rs2243480	1	rs2707831	ENSG00000229886.1	RP5-1132H15.3	6.73	2.71e-11	5.55e-09	0.36	0.2	Diabetic kidney disease;	chr7:66597524	chr7:66025126~66031544:-
BRCA	cis	rs858239	0.601	rs2141307	ENSG00000230042.1	AK3P3	-6.73	2.72e-11	5.56e-09	-0.23	-0.2	Cerebrospinal fluid biomarker levels;	chr7:23151805	chr7:23129178~23129841:+
BRCA	cis	rs1862618	0.713	rs832549	ENSG00000271828.1	CTD-2310F14.1	6.73	2.72e-11	5.56e-09	0.29	0.2	Initial pursuit acceleration;	chr5:56887715	chr5:56927874~56929573:+
BRCA	cis	rs875971	0.545	rs12671152	ENSG00000236529.1	RP13-254B10.1	6.73	2.72e-11	5.56e-09	0.26	0.2	Aortic root size;	chr7:66311140	chr7:65840212~65840596:+
BRCA	cis	rs2243480	1	rs316329	ENSG00000229886.1	RP5-1132H15.3	6.73	2.72e-11	5.56e-09	0.35	0.2	Diabetic kidney disease;	chr7:66143429	chr7:66025126~66031544:-
BRCA	cis	rs73186030	0.764	rs4491840	ENSG00000272758.4	RP11-299J3.8	6.73	2.73e-11	5.58e-09	0.29	0.2	Serum parathyroid hormone levels;	chr3:122361900	chr3:122416207~122443180:+
BRCA	cis	rs2732480	0.5	rs1387257	ENSG00000273765.1	RP11-370I10.11	6.73	2.73e-11	5.58e-09	0.25	0.2	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48242883	chr12:48360920~48361377:+
BRCA	cis	rs1707322	0.685	rs28617418	ENSG00000281133.1	AL355480.3	-6.73	2.73e-11	5.58e-09	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45723854	chr1:45580892~45580996:-
BRCA	cis	rs7829975	0.593	rs2921061	ENSG00000254153.1	CTA-398F10.2	6.73	2.73e-11	5.59e-09	0.25	0.2	Mood instability;	chr8:8460105	chr8:8456909~8461337:-
BRCA	cis	rs1667284	0.935	rs1791171	ENSG00000266521.1	RP11-650P15.1	6.73	2.73e-11	5.59e-09	0.25	0.2	Problematic alcohol use in trauma-exposed individuals;	chr18:31636194	chr18:31496645~31497195:-
BRCA	cis	rs853679	0.546	rs200954	ENSG00000220721.1	OR1F12	6.73	2.73e-11	5.59e-09	0.37	0.2	Depression;	chr6:27870986	chr6:28073316~28074233:+
BRCA	cis	rs1862618	0.853	rs252887	ENSG00000271828.1	CTD-2310F14.1	6.73	2.74e-11	5.6e-09	0.29	0.2	Initial pursuit acceleration;	chr5:56870361	chr5:56927874~56929573:+
BRCA	cis	rs7608910	0.578	rs2564114	ENSG00000271889.1	RP11-493E12.1	6.73	2.74e-11	5.6e-09	0.26	0.2	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;	chr2:61003512	chr2:61151433~61162105:-
BRCA	cis	rs11098499	0.863	rs10030660	ENSG00000249244.1	RP11-548H18.2	6.73	2.74e-11	5.6e-09	0.25	0.2	Corneal astigmatism;	chr4:119515549	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.863	rs13149407	ENSG00000249244.1	RP11-548H18.2	6.73	2.74e-11	5.6e-09	0.25	0.2	Corneal astigmatism;	chr4:119516670	chr4:119391831~119395335:-
BRCA	cis	rs67981189	0.896	rs2810100	ENSG00000269927.1	RP6-91H8.3	-6.73	2.74e-11	5.61e-09	-0.25	-0.2	Schizophrenia;	chr14:70965455	chr14:71141125~71143253:-
BRCA	cis	rs875971	0.862	rs4718319	ENSG00000224316.1	RP11-479O9.2	-6.73	2.74e-11	5.61e-09	-0.21	-0.2	Aortic root size;	chr7:66187797	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.723	rs28391294	ENSG00000224316.1	RP11-479O9.2	-6.73	2.74e-11	5.61e-09	-0.21	-0.2	Aortic root size;	chr7:66189328	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.83	rs6967708	ENSG00000224316.1	RP11-479O9.2	-6.73	2.74e-11	5.61e-09	-0.21	-0.2	Aortic root size;	chr7:66192326	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.895	rs7782806	ENSG00000224316.1	RP11-479O9.2	-6.73	2.74e-11	5.61e-09	-0.21	-0.2	Aortic root size;	chr7:66192910	chr7:65773620~65802067:+
BRCA	cis	rs9291683	0.53	rs6449196	ENSG00000250413.1	RP11-448G15.1	6.73	2.75e-11	5.61e-09	0.26	0.2	Bone mineral density;	chr4:9972036	chr4:10006482~10009725:+
BRCA	cis	rs4671400	0.571	rs68020555	ENSG00000271889.1	RP11-493E12.1	-6.73	2.75e-11	5.62e-09	-0.26	-0.2	3-hydroxypropylmercapturic acid levels in smokers;	chr2:61258647	chr2:61151433~61162105:-
BRCA	cis	rs1862618	0.853	rs252909	ENSG00000271828.1	CTD-2310F14.1	6.73	2.75e-11	5.63e-09	0.29	0.2	Initial pursuit acceleration;	chr5:56825304	chr5:56927874~56929573:+
BRCA	cis	rs13178541	0.745	rs7380109	ENSG00000250378.1	RP11-119J18.1	-6.73	2.76e-11	5.64e-09	-0.27	-0.2	IgG glycosylation;	chr5:135751385	chr5:135812667~135826582:+
BRCA	cis	rs3126085	0.935	rs7533529	ENSG00000237975.5	FLG-AS1	-6.73	2.76e-11	5.64e-09	-0.27	-0.2	Atopic dermatitis;	chr1:152204395	chr1:152168125~152445456:+
BRCA	cis	rs3781264	0.761	rs12219063	ENSG00000273450.1	RP11-76P2.4	6.73	2.76e-11	5.64e-09	0.28	0.2	Esophageal cancer and gastric cancer;	chr10:94366173	chr10:94314907~94315327:-
BRCA	cis	rs2408955	0.522	rs2051851	ENSG00000240399.1	RP1-228P16.1	-6.73	2.76e-11	5.64e-09	-0.23	-0.2	Glycated hemoglobin levels;	chr12:48092157	chr12:48054813~48055591:-
BRCA	cis	rs9291683	0.552	rs17187075	ENSG00000250413.1	RP11-448G15.1	-6.73	2.76e-11	5.65e-09	-0.27	-0.2	Bone mineral density;	chr4:9988704	chr4:10006482~10009725:+
BRCA	cis	rs34779708	0.931	rs6481935	ENSG00000271335.4	RP11-324I22.4	6.73	2.77e-11	5.65e-09	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35054031	chr10:35314552~35336401:-
BRCA	cis	rs34779708	0.931	rs12242882	ENSG00000271335.4	RP11-324I22.4	6.73	2.77e-11	5.65e-09	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35058932	chr10:35314552~35336401:-
BRCA	cis	rs875971	0.66	rs801192	ENSG00000236529.1	RP13-254B10.1	-6.73	2.77e-11	5.66e-09	-0.22	-0.2	Aortic root size;	chr7:66566965	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.66	rs801190	ENSG00000236529.1	RP13-254B10.1	-6.73	2.77e-11	5.66e-09	-0.22	-0.2	Aortic root size;	chr7:66568046	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.66	rs3857686	ENSG00000236529.1	RP13-254B10.1	-6.73	2.77e-11	5.66e-09	-0.22	-0.2	Aortic root size;	chr7:66571204	chr7:65840212~65840596:+
BRCA	cis	rs34779708	0.897	rs34481177	ENSG00000271335.4	RP11-324I22.4	6.73	2.77e-11	5.66e-09	0.22	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35091985	chr10:35314552~35336401:-
BRCA	cis	rs34779708	0.931	rs4934723	ENSG00000271335.4	RP11-324I22.4	6.73	2.77e-11	5.66e-09	0.22	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35092835	chr10:35314552~35336401:-
BRCA	cis	rs34779708	0.931	rs72789690	ENSG00000271335.4	RP11-324I22.4	6.73	2.77e-11	5.66e-09	0.22	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35093889	chr10:35314552~35336401:-
BRCA	cis	rs7617773	0.817	rs936427	ENSG00000228638.1	FCF1P2	6.73	2.77e-11	5.67e-09	0.23	0.2	Coronary artery disease;	chr3:48259584	chr3:48290793~48291375:-
BRCA	cis	rs6142102	0.961	rs973409	ENSG00000275784.1	RP5-1125A11.6	-6.73	2.77e-11	5.67e-09	-0.25	-0.2	Skin pigmentation;	chr20:33948558	chr20:33989480~33991818:-
BRCA	cis	rs2749097	0.825	rs11208264	ENSG00000244256.3	RN7SL130P	-6.73	2.78e-11	5.67e-09	-0.26	-0.2	Alcohol consumption (transferrin glycosylation);	chr1:63659401	chr1:63655743~63656047:+
BRCA	cis	rs6095360	0.69	rs35649484	ENSG00000222365.1	SNORD12B	-6.73	2.78e-11	5.67e-09	-0.27	-0.2	Intelligence (multi-trait analysis);	chr20:49138625	chr20:49280319~49280409:+
BRCA	cis	rs853679	0.607	rs13199906	ENSG00000220721.1	OR1F12	6.73	2.78e-11	5.68e-09	0.49	0.2	Depression;	chr6:27866361	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.546	rs36116761	ENSG00000220721.1	OR1F12	6.73	2.78e-11	5.68e-09	0.49	0.2	Depression;	chr6:27850704	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.546	rs34194357	ENSG00000220721.1	OR1F12	6.73	2.78e-11	5.68e-09	0.49	0.2	Depression;	chr6:27850757	chr6:28073316~28074233:+
BRCA	cis	rs13217239	0.646	rs35691005	ENSG00000241549.7	GUSBP2	6.73	2.78e-11	5.68e-09	0.22	0.2	Schizophrenia;	chr6:27004291	chr6:26871484~26956554:-
BRCA	cis	rs13217239	0.646	rs10946891	ENSG00000241549.7	GUSBP2	6.73	2.78e-11	5.68e-09	0.22	0.2	Schizophrenia;	chr6:27005436	chr6:26871484~26956554:-
BRCA	cis	rs13217239	0.646	rs12201393	ENSG00000241549.7	GUSBP2	6.73	2.78e-11	5.68e-09	0.22	0.2	Schizophrenia;	chr6:27007911	chr6:26871484~26956554:-
BRCA	cis	rs2732480	0.5	rs11168464	ENSG00000273765.1	RP11-370I10.11	6.73	2.79e-11	5.69e-09	0.25	0.2	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48208332	chr12:48360920~48361377:+
BRCA	cis	rs4763879	0.502	rs11052552	ENSG00000256673.1	RP11-599J14.2	-6.73	2.79e-11	5.7e-09	-0.22	-0.2	Type 1 diabetes;	chr12:9703362	chr12:9398355~9414851:-
BRCA	cis	rs9859260	0.744	rs539816	ENSG00000231464.1	AC024937.4	-6.73	2.79e-11	5.71e-09	-0.26	-0.2	Mean corpuscular volume;	chr3:196057205	chr3:195996738~195998233:+
BRCA	cis	rs9859260	0.744	rs492349	ENSG00000231464.1	AC024937.4	-6.73	2.79e-11	5.71e-09	-0.26	-0.2	Mean corpuscular volume;	chr3:196057321	chr3:195996738~195998233:+
BRCA	cis	rs9859260	0.744	rs492288	ENSG00000231464.1	AC024937.4	-6.73	2.79e-11	5.71e-09	-0.26	-0.2	Mean corpuscular volume;	chr3:196057339	chr3:195996738~195998233:+
BRCA	cis	rs7246657	0.943	rs7255952	ENSG00000276846.1	CTD-3220F14.3	6.73	2.8e-11	5.71e-09	0.28	0.2	Coronary artery calcification;	chr19:37497895	chr19:37314868~37315620:-
BRCA	cis	rs61160187	0.517	rs7709522	ENSG00000215032.2	GNL3LP1	6.73	2.8e-11	5.71e-09	0.25	0.2	Educational attainment (years of education);Educational attainment (college completion);	chr5:61022188	chr5:60891935~60893577:-
BRCA	cis	rs56046484	1	rs2304416	ENSG00000259295.5	CSPG4P12	-6.73	2.81e-11	5.73e-09	-0.3	-0.2	Testicular germ cell tumor;	chr15:85075651	chr15:85191438~85213905:+
BRCA	cis	rs11098499	0.909	rs9759478	ENSG00000249244.1	RP11-548H18.2	6.73	2.81e-11	5.73e-09	0.25	0.2	Corneal astigmatism;	chr4:119446843	chr4:119391831~119395335:-
BRCA	cis	rs2286503	0.78	rs1304431	ENSG00000228649.7	AC005682.5	6.73	2.81e-11	5.73e-09	0.18	0.2	Fibrinogen;	chr7:22825793	chr7:22854178~22861579:+
BRCA	cis	rs1707322	0.638	rs9429095	ENSG00000280836.1	AL355480.1	6.73	2.81e-11	5.73e-09	0.25	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46137676	chr1:45581219~45581321:-
BRCA	cis	rs7246657	0.943	rs4801803	ENSG00000276846.1	CTD-3220F14.3	-6.73	2.81e-11	5.74e-09	-0.28	-0.2	Coronary artery calcification;	chr19:37476021	chr19:37314868~37315620:-
BRCA	cis	rs7829975	0.567	rs6601273	ENSG00000233609.3	RP11-62H7.2	-6.73	2.82e-11	5.75e-09	-0.19	-0.2	Mood instability;	chr8:8939009	chr8:8961200~8979025:+
BRCA	cis	rs875971	1	rs9986696	ENSG00000224316.1	RP11-479O9.2	-6.73	2.82e-11	5.76e-09	-0.2	-0.2	Aortic root size;	chr7:66239589	chr7:65773620~65802067:+
BRCA	cis	rs2243480	1	rs313803	ENSG00000229886.1	RP5-1132H15.3	6.73	2.82e-11	5.76e-09	0.37	0.2	Diabetic kidney disease;	chr7:66049744	chr7:66025126~66031544:-
BRCA	cis	rs2276314	0.6	rs28729782	ENSG00000278986.1	RP11-723J4.3	-6.73	2.82e-11	5.76e-09	-0.24	-0.2	Endometriosis;Drug-induced torsades de pointes;	chr18:36010566	chr18:35972151~35973916:+
BRCA	cis	rs875971	0.838	rs2173570	ENSG00000224316.1	RP11-479O9.2	-6.73	2.83e-11	5.76e-09	-0.2	-0.2	Aortic root size;	chr7:66297976	chr7:65773620~65802067:+
BRCA	cis	rs3814244	0.515	rs3015002	ENSG00000236946.2	HNRNPA1P70	6.73	2.83e-11	5.77e-09	0.16	0.2	Itch intensity from mosquito bite adjusted by bite size;	chr12:68010853	chr12:68035767~68036853:+
BRCA	cis	rs13068223	0.904	rs13322900	ENSG00000243926.1	TIPARP-AS1	6.73	2.83e-11	5.77e-09	0.21	0.2	Age-related hearing impairment (SNP x SNP interaction);	chr3:156732229	chr3:156671862~156674378:-
BRCA	cis	rs4713118	0.869	rs6914924	ENSG00000220721.1	OR1F12	6.73	2.83e-11	5.77e-09	0.25	0.2	Parkinson's disease;	chr6:27743751	chr6:28073316~28074233:+
BRCA	cis	rs1707322	0.721	rs11211163	ENSG00000281133.1	AL355480.3	-6.73	2.83e-11	5.77e-09	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45687876	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.721	rs12037803	ENSG00000281133.1	AL355480.3	-6.73	2.83e-11	5.77e-09	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45690820	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.721	rs61784796	ENSG00000281133.1	AL355480.3	-6.73	2.83e-11	5.77e-09	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45697584	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.721	rs10749856	ENSG00000281133.1	AL355480.3	-6.73	2.83e-11	5.77e-09	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45699174	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.721	rs10890344	ENSG00000281133.1	AL355480.3	-6.73	2.83e-11	5.77e-09	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45700418	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.721	rs4564187	ENSG00000281133.1	AL355480.3	-6.73	2.83e-11	5.77e-09	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45701189	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.752	rs28438704	ENSG00000281133.1	AL355480.3	-6.73	2.83e-11	5.77e-09	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45704872	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.721	rs28442079	ENSG00000281133.1	AL355480.3	-6.73	2.83e-11	5.77e-09	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45706329	chr1:45580892~45580996:-
BRCA	cis	rs10925040	0.666	rs10737808	ENSG00000227135.1	GCSAML-AS1	-6.73	2.83e-11	5.77e-09	-0.24	-0.2	Tumor necrosis factor beta levels;	chr1:247459638	chr1:247524679~247526752:-
BRCA	cis	rs2243480	1	rs10807701	ENSG00000230295.1	RP11-458F8.2	6.73	2.83e-11	5.78e-09	0.27	0.2	Diabetic kidney disease;	chr7:66259699	chr7:66880708~66882981:+
BRCA	cis	rs13113518	0.678	rs7663650	ENSG00000249700.7	SRD5A3-AS1	-6.73	2.83e-11	5.78e-09	-0.25	-0.2	Height;	chr4:55364952	chr4:55363971~55395847:-
BRCA	cis	rs4728142	1	rs4728142	ENSG00000275106.1	RP11-309L24.10	-6.73	2.84e-11	5.79e-09	-0.26	-0.2	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128933913	chr7:128952527~128953316:-
BRCA	cis	rs9527	0.59	rs1475642	ENSG00000236937.2	PTGES3P4	-6.73	2.84e-11	5.79e-09	-0.29	-0.2	Arsenic metabolism;	chr10:102786426	chr10:102845595~102845950:+
BRCA	cis	rs1707322	0.721	rs11211181	ENSG00000281133.1	AL355480.3	-6.73	2.84e-11	5.8e-09	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45771128	chr1:45580892~45580996:-
BRCA	cis	rs442309	0.553	rs10995278	ENSG00000238280.1	RP11-436D10.3	-6.73	2.84e-11	5.8e-09	-0.29	-0.2	Vogt-Koyanagi-Harada syndrome;	chr10:62694737	chr10:62793562~62805887:-
BRCA	cis	rs17253792	0.822	rs75509578	ENSG00000186615.9	KTN1-AS1	-6.73	2.84e-11	5.8e-09	-0.4	-0.2	Putamen volume;	chr14:55666775	chr14:55499278~55580110:-
BRCA	cis	rs12594515	0.967	rs11857628	ENSG00000259200.1	RP11-718O11.1	-6.73	2.84e-11	5.8e-09	-0.23	-0.2	Weight;Waist circumference;	chr15:45706008	chr15:45705078~45931069:+
BRCA	cis	rs780096	0.506	rs72819512	ENSG00000234072.1	AC074117.10	-6.73	2.84e-11	5.8e-09	-0.2	-0.2	Total body bone mineral density;	chr2:27391582	chr2:27356246~27367622:+
BRCA	cis	rs7246657	0.943	rs10415024	ENSG00000226686.6	LINC01535	-6.73	2.85e-11	5.81e-09	-0.31	-0.2	Coronary artery calcification;	chr19:37323822	chr19:37251912~37265535:+
BRCA	cis	rs1499614	1	rs2707840	ENSG00000229886.1	RP5-1132H15.3	6.73	2.85e-11	5.82e-09	0.36	0.2	Gout;	chr7:66693028	chr7:66025126~66031544:-
BRCA	cis	rs2115630	0.691	rs2292462	ENSG00000229212.6	RP11-561C5.4	6.73	2.86e-11	5.82e-09	0.23	0.2	P wave terminal force;	chr15:84657523	chr15:85205440~85234795:-
BRCA	cis	rs1499614	1	rs2659903	ENSG00000229886.1	RP5-1132H15.3	6.73	2.86e-11	5.83e-09	0.37	0.2	Gout;	chr7:66715944	chr7:66025126~66031544:-
BRCA	cis	rs2034650	0.563	rs11070270	ENSG00000223313.1	RNU6-516P	-6.73	2.86e-11	5.84e-09	-0.25	-0.2	Interstitial lung disease;	chr15:40416223	chr15:40529570~40529673:+
BRCA	cis	rs77204473	1	rs17120119	ENSG00000254851.1	RP11-109L13.1	6.73	2.87e-11	5.84e-09	0.42	0.2	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116876566	chr11:117135528~117138582:+
BRCA	cis	rs875971	0.66	rs801211	ENSG00000236529.1	RP13-254B10.1	-6.73	2.87e-11	5.84e-09	-0.22	-0.2	Aortic root size;	chr7:66550702	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.638	rs801205	ENSG00000236529.1	RP13-254B10.1	-6.73	2.87e-11	5.84e-09	-0.22	-0.2	Aortic root size;	chr7:66557157	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.617	rs810400	ENSG00000236529.1	RP13-254B10.1	-6.73	2.87e-11	5.84e-09	-0.22	-0.2	Aortic root size;	chr7:66557902	chr7:65840212~65840596:+
BRCA	cis	rs11098499	0.874	rs13123591	ENSG00000248280.1	RP11-33B1.2	6.73	2.87e-11	5.85e-09	0.22	0.2	Corneal astigmatism;	chr4:119184835	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.909	rs78332141	ENSG00000249244.1	RP11-548H18.2	6.73	2.87e-11	5.85e-09	0.24	0.2	Corneal astigmatism;	chr4:119454627	chr4:119391831~119395335:-
BRCA	cis	rs875971	0.66	rs62465434	ENSG00000236529.1	RP13-254B10.1	6.73	2.87e-11	5.86e-09	0.22	0.2	Aortic root size;	chr7:66540165	chr7:65840212~65840596:+
BRCA	cis	rs11018904	0.906	rs17227345	ENSG00000280385.1	AP000648.5	6.73	2.88e-11	5.87e-09	0.3	0.2	Intelligence (multi-trait analysis);	chr11:90221517	chr11:90193614~90198120:+
BRCA	cis	rs6969780	0.915	rs12666919	ENSG00000233429.8	HOTAIRM1	-6.73	2.88e-11	5.87e-09	-0.25	-0.2	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27149879	chr7:27095647~27100265:+
BRCA	cis	rs875971	0.66	rs801217	ENSG00000236529.1	RP13-254B10.1	-6.73	2.88e-11	5.88e-09	-0.22	-0.2	Aortic root size;	chr7:66545590	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.638	rs801216	ENSG00000236529.1	RP13-254B10.1	-6.73	2.88e-11	5.88e-09	-0.22	-0.2	Aortic root size;	chr7:66546680	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.66	rs13224319	ENSG00000236529.1	RP13-254B10.1	6.73	2.88e-11	5.88e-09	0.22	0.2	Aortic root size;	chr7:66542376	chr7:65840212~65840596:+
BRCA	cis	rs237743	1	rs34580798	ENSG00000222365.1	SNORD12B	-6.73	2.88e-11	5.88e-09	-0.27	-0.2	Height;	chr20:49283420	chr20:49280319~49280409:+
BRCA	cis	rs73173548	0.502	rs76393802	ENSG00000247828.6	TMEM161B-AS1	6.72	2.89e-11	5.89e-09	0.28	0.2	Macular telangiectasia type 2;	chr5:88455311	chr5:88268895~88436685:+
BRCA	cis	rs919433	0.889	rs10931782	ENSG00000231621.1	AC013264.2	6.72	2.89e-11	5.89e-09	0.19	0.2	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197346855	chr2:197197991~197199273:+
BRCA	cis	rs11096990	0.855	rs2711989	ENSG00000249207.1	RP11-360F5.1	6.72	2.89e-11	5.89e-09	0.24	0.2	Cognitive function;	chr4:39150416	chr4:39112677~39126818:-
BRCA	cis	rs11096990	0.855	rs2566169	ENSG00000249207.1	RP11-360F5.1	6.72	2.89e-11	5.89e-09	0.24	0.2	Cognitive function;	chr4:39150420	chr4:39112677~39126818:-
BRCA	cis	rs420259	0.516	rs9927961	ENSG00000260136.4	CTD-2270L9.4	-6.72	2.89e-11	5.89e-09	-0.21	-0.2	Bipolar disorder;	chr16:23503204	chr16:23452758~23457606:+
BRCA	cis	rs6142102	0.961	rs1555075	ENSG00000275784.1	RP5-1125A11.6	-6.72	2.89e-11	5.9e-09	-0.25	-0.2	Skin pigmentation;	chr20:34022595	chr20:33989480~33991818:-
BRCA	cis	rs67981189	0.896	rs2526890	ENSG00000269927.1	RP6-91H8.3	-6.72	2.9e-11	5.9e-09	-0.25	-0.2	Schizophrenia;	chr14:70963410	chr14:71141125~71143253:-
BRCA	cis	rs957448	1	rs60655325	ENSG00000253175.1	RP11-267M23.6	6.72	2.9e-11	5.91e-09	0.26	0.2	Nonsyndromic cleft lip with cleft palate;	chr8:94552606	chr8:94565036~94565715:+
BRCA	cis	rs34929064	0.836	rs2961301	ENSG00000179428.2	AC073072.5	6.72	2.9e-11	5.91e-09	0.23	0.2	Major depression and alcohol dependence;	chr7:22669410	chr7:22725395~22727620:-
BRCA	cis	rs853679	0.607	rs13199772	ENSG00000220721.1	OR1F12	6.72	2.9e-11	5.91e-09	0.49	0.2	Depression;	chr6:27866307	chr6:28073316~28074233:+
BRCA	cis	rs875971	0.66	rs12698534	ENSG00000236529.1	RP13-254B10.1	6.72	2.91e-11	5.92e-09	0.22	0.2	Aortic root size;	chr7:66521858	chr7:65840212~65840596:+
BRCA	cis	rs34779708	0.931	rs35388511	ENSG00000271335.4	RP11-324I22.4	6.72	2.91e-11	5.92e-09	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35007688	chr10:35314552~35336401:-
BRCA	cis	rs34779708	0.931	rs34815241	ENSG00000271335.4	RP11-324I22.4	6.72	2.91e-11	5.92e-09	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35007748	chr10:35314552~35336401:-
BRCA	cis	rs10861661	0.856	rs4964190	ENSG00000260329.1	RP11-412D9.4	-6.72	2.91e-11	5.93e-09	-0.24	-0.2	Triglyceride levels;	chr12:106822581	chr12:106954029~106955497:-
BRCA	cis	rs7617773	0.78	rs3731489	ENSG00000228638.1	FCF1P2	-6.72	2.91e-11	5.94e-09	-0.23	-0.2	Coronary artery disease;	chr3:48187416	chr3:48290793~48291375:-
BRCA	cis	rs61270009	0.731	rs13189022	ENSG00000247828.6	TMEM161B-AS1	6.72	2.92e-11	5.95e-09	0.28	0.2	Depressive symptoms;	chr5:88445017	chr5:88268895~88436685:+
BRCA	cis	rs9309711	0.737	rs9284795	ENSG00000225234.1	TRAPPC12-AS1	-6.72	2.92e-11	5.95e-09	-0.24	-0.2	Neurofibrillary tangles;	chr2:3488294	chr2:3481242~3482409:-
BRCA	cis	rs2243480	1	rs1553174	ENSG00000232546.1	RP11-458F8.1	6.72	2.93e-11	5.96e-09	0.27	0.2	Diabetic kidney disease;	chr7:66266207	chr7:66848496~66858136:+
BRCA	cis	rs2243480	1	rs10950032	ENSG00000232546.1	RP11-458F8.1	6.72	2.93e-11	5.96e-09	0.27	0.2	Diabetic kidney disease;	chr7:66273604	chr7:66848496~66858136:+
BRCA	cis	rs9291683	0.632	rs10939669	ENSG00000250413.1	RP11-448G15.1	-6.72	2.93e-11	5.97e-09	-0.27	-0.2	Bone mineral density;	chr4:10044203	chr4:10006482~10009725:+
BRCA	cis	rs9291683	0.632	rs11734375	ENSG00000250413.1	RP11-448G15.1	-6.72	2.93e-11	5.97e-09	-0.27	-0.2	Bone mineral density;	chr4:10044674	chr4:10006482~10009725:+
BRCA	cis	rs12501370	1	rs13109452	ENSG00000201736.1	RNA5SP160	6.72	2.93e-11	5.97e-09	0.26	0.2	Iris color (L* coordinate);	chr4:41042751	chr4:40990154~40990273:+
BRCA	cis	rs2243480	0.901	rs34807232	ENSG00000229886.1	RP5-1132H15.3	6.72	2.94e-11	5.98e-09	0.36	0.2	Diabetic kidney disease;	chr7:66500146	chr7:66025126~66031544:-
BRCA	cis	rs2243480	0.901	rs35823062	ENSG00000229886.1	RP5-1132H15.3	6.72	2.94e-11	5.98e-09	0.36	0.2	Diabetic kidney disease;	chr7:66500834	chr7:66025126~66031544:-
BRCA	cis	rs2688608	0.62	rs12253408	ENSG00000271816.1	BMS1P4	6.72	2.94e-11	5.98e-09	0.2	0.2	Inflammatory bowel disease;	chr10:73736198	chr10:73699151~73730487:-
BRCA	cis	rs754466	0.651	rs11813532	ENSG00000204049.1	RP11-126H7.4	6.72	2.94e-11	5.99e-09	0.24	0.2	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77878233	chr10:77866875~77869610:+
BRCA	cis	rs7665090	1	rs909349	ENSG00000246560.2	RP11-10L12.4	-6.72	2.94e-11	5.99e-09	-0.21	-0.2	Primary biliary cholangitis;	chr4:102635159	chr4:102828055~102844075:+
BRCA	cis	rs1707322	0.721	rs10789470	ENSG00000281133.1	AL355480.3	-6.72	2.94e-11	6e-09	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692659	chr1:45580892~45580996:-
BRCA	cis	rs301901	0.581	rs292170	ENSG00000250155.1	CTD-2353F22.1	-6.72	2.95e-11	6e-09	-0.24	-0.2	Height;	chr5:36816559	chr5:36666214~36725195:-
BRCA	cis	rs9992667	0.91	rs10019144	ENSG00000231160.8	KLF3-AS1	6.72	2.95e-11	6.01e-09	0.25	0.2	Eosinophil percentage of granulocytes;	chr4:38684784	chr4:38612701~38664883:-
BRCA	cis	rs7246657	0.943	rs35540940	ENSG00000276846.1	CTD-3220F14.3	6.72	2.95e-11	6.01e-09	0.28	0.2	Coronary artery calcification;	chr19:37517333	chr19:37314868~37315620:-
BRCA	cis	rs73173548	0.502	rs12653074	ENSG00000247828.6	TMEM161B-AS1	6.72	2.96e-11	6.02e-09	0.28	0.2	Macular telangiectasia type 2;	chr5:88452920	chr5:88268895~88436685:+
BRCA	cis	rs2842992	0.747	rs9365095	ENSG00000237927.1	RP3-393E18.2	-6.72	2.96e-11	6.02e-09	-0.29	-0.2	Age-related macular degeneration (geographic atrophy);	chr6:159771896	chr6:159586955~159589169:-
BRCA	cis	rs2842992	0.789	rs9355748	ENSG00000237927.1	RP3-393E18.2	-6.72	2.96e-11	6.02e-09	-0.29	-0.2	Age-related macular degeneration (geographic atrophy);	chr6:159773850	chr6:159586955~159589169:-
BRCA	cis	rs1823913	0.599	rs1378155	ENSG00000280083.1	RP11-317J9.1	-6.72	2.96e-11	6.03e-09	-0.23	-0.2	Obesity-related traits;	chr2:191266610	chr2:191154118~191156070:-
BRCA	cis	rs2834288	0.5	rs881230	ENSG00000273102.1	AP000569.9	6.72	2.97e-11	6.04e-09	0.22	0.2	Gut microbiota (bacterial taxa);	chr21:33950521	chr21:33967101~33968573:-
BRCA	cis	rs7246657	0.943	rs7255785	ENSG00000276846.1	CTD-3220F14.3	6.72	2.97e-11	6.04e-09	0.27	0.2	Coronary artery calcification;	chr19:37480781	chr19:37314868~37315620:-
BRCA	cis	rs7246657	0.943	rs7255996	ENSG00000276846.1	CTD-3220F14.3	6.72	2.97e-11	6.04e-09	0.27	0.2	Coronary artery calcification;	chr19:37480797	chr19:37314868~37315620:-
BRCA	cis	rs13113518	0.783	rs12508367	ENSG00000249700.7	SRD5A3-AS1	6.72	2.97e-11	6.04e-09	0.26	0.2	Height;	chr4:55509442	chr4:55363971~55395847:-
BRCA	cis	rs13113518	0.812	rs2272073	ENSG00000249700.7	SRD5A3-AS1	6.72	2.97e-11	6.04e-09	0.26	0.2	Height;	chr4:55510177	chr4:55363971~55395847:-
BRCA	cis	rs755249	0.567	rs4660214	ENSG00000228060.1	RP11-69E11.8	-6.72	2.97e-11	6.05e-09	-0.25	-0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39265878	chr1:39565160~39573203:+
BRCA	cis	rs853679	0.607	rs17763089	ENSG00000220721.1	OR1F12	6.72	2.97e-11	6.05e-09	0.49	0.2	Depression;	chr6:27867440	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.546	rs17695758	ENSG00000220721.1	OR1F12	6.72	2.97e-11	6.05e-09	0.49	0.2	Depression;	chr6:27869405	chr6:28073316~28074233:+
BRCA	cis	rs2243480	0.901	rs73148097	ENSG00000228409.4	CCT6P1	6.72	2.97e-11	6.05e-09	0.28	0.2	Diabetic kidney disease;	chr7:65966800	chr7:65751142~65763354:+
BRCA	cis	rs2243480	1	rs906134	ENSG00000228409.4	CCT6P1	6.72	2.97e-11	6.05e-09	0.28	0.2	Diabetic kidney disease;	chr7:65979301	chr7:65751142~65763354:+
BRCA	cis	rs2243480	0.901	rs34807232	ENSG00000230295.1	RP11-458F8.2	-6.72	2.97e-11	6.05e-09	-0.27	-0.2	Diabetic kidney disease;	chr7:66500146	chr7:66880708~66882981:+
BRCA	cis	rs2243480	0.901	rs35823062	ENSG00000230295.1	RP11-458F8.2	-6.72	2.97e-11	6.05e-09	-0.27	-0.2	Diabetic kidney disease;	chr7:66500834	chr7:66880708~66882981:+
BRCA	cis	rs3781264	0.761	rs7081265	ENSG00000273450.1	RP11-76P2.4	-6.72	2.98e-11	6.06e-09	-0.28	-0.2	Esophageal cancer and gastric cancer;	chr10:94365892	chr10:94314907~94315327:-
BRCA	cis	rs2014572	0.967	rs10426174	ENSG00000268379.1	CTC-360J11.4	6.72	2.98e-11	6.06e-09	0.24	0.2	Hyperactive-impulsive symptoms;	chr19:57244687	chr19:57175233~57177921:+
BRCA	cis	rs2014572	0.87	rs10426580	ENSG00000268379.1	CTC-360J11.4	6.72	2.98e-11	6.06e-09	0.24	0.2	Hyperactive-impulsive symptoms;	chr19:57244853	chr19:57175233~57177921:+
BRCA	cis	rs67981189	0.865	rs2526876	ENSG00000269927.1	RP6-91H8.3	-6.72	2.98e-11	6.07e-09	-0.25	-0.2	Schizophrenia;	chr14:70911471	chr14:71141125~71143253:-
BRCA	cis	rs6740322	0.895	rs6760797	ENSG00000234936.1	AC010883.5	6.72	2.98e-11	6.07e-09	0.23	0.2	Coronary artery disease;	chr2:43332473	chr2:43229573~43233394:+
BRCA	cis	rs6095360	0.727	rs34385643	ENSG00000222365.1	SNORD12B	-6.72	2.98e-11	6.07e-09	-0.26	-0.2	Intelligence (multi-trait analysis);	chr20:48956879	chr20:49280319~49280409:+
BRCA	cis	rs600231	0.708	rs682845	ENSG00000245532.5	NEAT1	6.72	2.98e-11	6.07e-09	0.19	0.2	Bone mineral density;	chr11:65486730	chr11:65422774~65445540:+
BRCA	cis	rs2014572	0.967	rs10427146	ENSG00000268379.1	CTC-360J11.4	6.72	2.98e-11	6.07e-09	0.24	0.2	Hyperactive-impulsive symptoms;	chr19:57244630	chr19:57175233~57177921:+
BRCA	cis	rs2014572	0.967	rs11084492	ENSG00000268379.1	CTC-360J11.4	6.72	2.98e-11	6.07e-09	0.24	0.2	Hyperactive-impulsive symptoms;	chr19:57244658	chr19:57175233~57177921:+
BRCA	cis	rs6860806	0.507	rs2631372	ENSG00000233006.5	AC034220.3	6.72	2.99e-11	6.07e-09	0.17	0.2	Breast cancer;	chr5:132367886	chr5:132311285~132369916:-
BRCA	cis	rs9291683	0.595	rs35250962	ENSG00000250413.1	RP11-448G15.1	-6.72	2.99e-11	6.07e-09	-0.27	-0.2	Bone mineral density;	chr4:10046647	chr4:10006482~10009725:+
BRCA	cis	rs34779708	0.658	rs4934715	ENSG00000271335.4	RP11-324I22.4	6.72	2.99e-11	6.08e-09	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35076064	chr10:35314552~35336401:-
BRCA	cis	rs6969780	0.915	rs3807597	ENSG00000233429.8	HOTAIRM1	-6.72	2.99e-11	6.09e-09	-0.25	-0.2	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27149576	chr7:27095647~27100265:+
BRCA	cis	rs6969780	0.915	rs12666926	ENSG00000233429.8	HOTAIRM1	-6.72	2.99e-11	6.09e-09	-0.25	-0.2	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27149942	chr7:27095647~27100265:+
BRCA	cis	rs34779708	0.931	rs12240347	ENSG00000271335.4	RP11-324I22.4	6.72	2.99e-11	6.09e-09	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35070547	chr10:35314552~35336401:-
BRCA	cis	rs67517081	1	rs67517081	ENSG00000260911.2	RP11-196G11.2	-6.72	2.99e-11	6.09e-09	-0.19	-0.2	Mean corpuscular hemoglobin;	chr16:30976060	chr16:31043150~31049868:+
BRCA	cis	rs2243480	1	rs160639	ENSG00000232546.1	RP11-458F8.1	-6.72	3e-11	6.09e-09	-0.27	-0.2	Diabetic kidney disease;	chr7:66115000	chr7:66848496~66858136:+
BRCA	cis	rs71520386	0.632	rs1029738	ENSG00000228649.7	AC005682.5	-6.72	3e-11	6.1e-09	-0.2	-0.2	Fibrinogen levels;	chr7:22834428	chr7:22854178~22861579:+
BRCA	cis	rs17711722	0.727	rs2658585	ENSG00000237310.1	GS1-124K5.4	6.72	3e-11	6.1e-09	0.21	0.2	Calcium levels;	chr7:65996954	chr7:66493706~66495474:+
BRCA	cis	rs2286503	0.809	rs4719716	ENSG00000228649.7	AC005682.5	6.72	3e-11	6.11e-09	0.18	0.2	Fibrinogen;	chr7:22821750	chr7:22854178~22861579:+
BRCA	cis	rs2286503	0.839	rs2270108	ENSG00000228649.7	AC005682.5	6.72	3e-11	6.11e-09	0.18	0.2	Fibrinogen;	chr7:22822512	chr7:22854178~22861579:+
BRCA	cis	rs2286503	0.839	rs2270107	ENSG00000228649.7	AC005682.5	6.72	3e-11	6.11e-09	0.18	0.2	Fibrinogen;	chr7:22822564	chr7:22854178~22861579:+
BRCA	cis	rs2286503	0.839	rs2270105	ENSG00000228649.7	AC005682.5	6.72	3e-11	6.11e-09	0.18	0.2	Fibrinogen;	chr7:22822848	chr7:22854178~22861579:+
BRCA	cis	rs2286503	0.839	rs2270103	ENSG00000228649.7	AC005682.5	6.72	3e-11	6.11e-09	0.18	0.2	Fibrinogen;	chr7:22823103	chr7:22854178~22861579:+
BRCA	cis	rs2286503	0.839	rs10276099	ENSG00000228649.7	AC005682.5	6.72	3e-11	6.11e-09	0.18	0.2	Fibrinogen;	chr7:22823331	chr7:22854178~22861579:+
BRCA	cis	rs875971	0.545	rs1638735	ENSG00000224316.1	RP11-479O9.2	6.72	3.01e-11	6.11e-09	0.23	0.2	Aortic root size;	chr7:66630751	chr7:65773620~65802067:+
BRCA	cis	rs2976388	0.609	rs2572907	ENSG00000253741.1	CTD-2292P10.4	-6.72	3.01e-11	6.11e-09	-0.23	-0.2	Urinary tract infection frequency;	chr8:142720520	chr8:142702252~142726973:-
BRCA	cis	rs2976388	0.609	rs2572908	ENSG00000253741.1	CTD-2292P10.4	-6.72	3.01e-11	6.11e-09	-0.23	-0.2	Urinary tract infection frequency;	chr8:142721218	chr8:142702252~142726973:-
BRCA	cis	rs9307551	0.817	rs11098762	ENSG00000250334.4	LINC00989	-6.72	3.01e-11	6.11e-09	-0.27	-0.2	Refractive error;	chr4:79575097	chr4:79492416~79576460:+
BRCA	cis	rs957448	0.948	rs1470153	ENSG00000253175.1	RP11-267M23.6	6.72	3.01e-11	6.12e-09	0.26	0.2	Nonsyndromic cleft lip with cleft palate;	chr8:94514587	chr8:94565036~94565715:+
BRCA	cis	rs4845875	0.603	rs10864539	ENSG00000242349.4	NPPA-AS1	6.72	3.01e-11	6.12e-09	0.22	0.2	Midregional pro atrial natriuretic peptide levels;	chr1:11773853	chr1:11841017~11848079:+
BRCA	cis	rs1667284	0.967	rs895888	ENSG00000266521.1	RP11-650P15.1	6.72	3.01e-11	6.12e-09	0.25	0.2	Problematic alcohol use in trauma-exposed individuals;	chr18:31648224	chr18:31496645~31497195:-
BRCA	cis	rs62025270	0.547	rs338540	ENSG00000202081.1	RNU6-1280P	6.72	3.01e-11	6.12e-09	0.25	0.2	Idiopathic pulmonary fibrosis;	chr15:85652500	chr15:85651522~85651628:-
BRCA	cis	rs6543140	0.693	rs7579737	ENSG00000234389.1	AC007278.3	6.72	3.01e-11	6.12e-09	0.2	0.2	Blood protein levels;	chr2:102370901	chr2:102438713~102440475:+
BRCA	cis	rs4072705	0.967	rs10217141	ENSG00000224020.1	MIR181A2HG	-6.72	3.01e-11	6.13e-09	-0.22	-0.2	Menarche (age at onset);	chr9:124641656	chr9:124658467~124698631:+
BRCA	cis	rs6504622	1	rs6504622	ENSG00000262879.4	RP11-156P1.3	6.72	3.03e-11	6.16e-09	0.2	0.2	Orofacial clefts;	chr17:46942365	chr17:46984045~47100323:-
BRCA	cis	rs957448	0.507	rs1984711	ENSG00000253704.1	RP11-267M23.4	6.72	3.03e-11	6.16e-09	0.22	0.2	Nonsyndromic cleft lip with cleft palate;	chr8:94600276	chr8:94553722~94569745:+
BRCA	cis	rs1707322	0.821	rs11211182	ENSG00000281133.1	AL355480.3	-6.72	3.03e-11	6.16e-09	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45774498	chr1:45580892~45580996:-
BRCA	cis	rs6969780	0.915	rs886339	ENSG00000233429.8	HOTAIRM1	-6.72	3.03e-11	6.17e-09	-0.24	-0.2	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27151051	chr7:27095647~27100265:+
BRCA	cis	rs860818	1	rs1637224	ENSG00000226816.2	AC005082.12	6.72	3.03e-11	6.17e-09	0.49	0.2	Initial pursuit acceleration;	chr7:23188781	chr7:23206013~23208045:+
BRCA	cis	rs17301013	0.507	rs12066504	ENSG00000227373.4	RP11-160H22.5	6.72	3.04e-11	6.17e-09	0.3	0.2	Systemic lupus erythematosus;	chr1:174288695	chr1:174115300~174160004:-
BRCA	cis	rs71520386	0.632	rs35353454	ENSG00000228649.7	AC005682.5	-6.72	3.04e-11	6.18e-09	-0.2	-0.2	Fibrinogen levels;	chr7:22822120	chr7:22854178~22861579:+
BRCA	cis	rs73186030	0.687	rs55636509	ENSG00000272758.4	RP11-299J3.8	6.72	3.05e-11	6.19e-09	0.3	0.2	Serum parathyroid hormone levels;	chr3:122351816	chr3:122416207~122443180:+
BRCA	cis	rs6969780	1	rs6976129	ENSG00000233429.8	HOTAIRM1	6.72	3.05e-11	6.19e-09	0.26	0.2	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27138127	chr7:27095647~27100265:+
BRCA	cis	rs6545883	1	rs6742276	ENSG00000271889.1	RP11-493E12.1	6.72	3.05e-11	6.19e-09	0.26	0.2	Tuberculosis;	chr2:61541610	chr2:61151433~61162105:-
BRCA	cis	rs1667284	0.967	rs1667281	ENSG00000266521.1	RP11-650P15.1	6.72	3.06e-11	6.21e-09	0.24	0.2	Problematic alcohol use in trauma-exposed individuals;	chr18:31640793	chr18:31496645~31497195:-
BRCA	cis	rs1667284	1	rs1612691	ENSG00000266521.1	RP11-650P15.1	6.72	3.06e-11	6.21e-09	0.24	0.2	Problematic alcohol use in trauma-exposed individuals;	chr18:31640955	chr18:31496645~31497195:-
BRCA	cis	rs17253792	0.545	rs12893610	ENSG00000186615.9	KTN1-AS1	-6.72	3.06e-11	6.21e-09	-0.4	-0.2	Putamen volume;	chr14:55549629	chr14:55499278~55580110:-
BRCA	cis	rs1707322	0.752	rs11211146	ENSG00000281133.1	AL355480.3	-6.72	3.06e-11	6.21e-09	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45644122	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.752	rs11211147	ENSG00000281133.1	AL355480.3	-6.72	3.06e-11	6.21e-09	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45644422	chr1:45580892~45580996:-
BRCA	cis	rs13113518	0.812	rs4864543	ENSG00000249700.7	SRD5A3-AS1	6.72	3.06e-11	6.22e-09	0.26	0.2	Height;	chr4:55490228	chr4:55363971~55395847:-
BRCA	cis	rs13113518	0.812	rs6825774	ENSG00000249700.7	SRD5A3-AS1	6.72	3.06e-11	6.22e-09	0.26	0.2	Height;	chr4:55491150	chr4:55363971~55395847:-
BRCA	cis	rs13113518	0.812	rs3805153	ENSG00000249700.7	SRD5A3-AS1	6.72	3.06e-11	6.22e-09	0.26	0.2	Height;	chr4:55493557	chr4:55363971~55395847:-
BRCA	cis	rs2348418	0.733	rs11049508	ENSG00000247934.4	RP11-967K21.1	6.72	3.07e-11	6.23e-09	0.23	0.2	Lung function (FEV1);Lung function (FVC);	chr12:28289633	chr12:28163298~28190738:-
BRCA	cis	rs4372836	1	rs55835850	ENSG00000226833.4	AC097724.3	-6.72	3.07e-11	6.23e-09	-0.25	-0.2	Body mass index;	chr2:28726430	chr2:28708953~28736205:-
BRCA	cis	rs6088580	0.524	rs6088575	ENSG00000269202.1	RP4-614O4.12	-6.72	3.07e-11	6.24e-09	-0.22	-0.2	Glomerular filtration rate (creatinine);	chr20:34685599	chr20:35201747~35203288:-
BRCA	cis	rs6740322	0.748	rs6727631	ENSG00000234936.1	AC010883.5	6.72	3.08e-11	6.25e-09	0.23	0.2	Coronary artery disease;	chr2:43243269	chr2:43229573~43233394:+
BRCA	cis	rs875971	0.545	rs66594357	ENSG00000236529.1	RP13-254B10.1	6.72	3.08e-11	6.26e-09	0.25	0.2	Aortic root size;	chr7:66327797	chr7:65840212~65840596:+
BRCA	cis	rs760794	0.577	rs7752808	ENSG00000228412.5	RP4-625H18.2	6.72	3.08e-11	6.26e-09	0.26	0.2	Endometriosis;	chr6:19792665	chr6:19802164~19804752:-
BRCA	cis	rs2243480	1	rs437889	ENSG00000229886.1	RP5-1132H15.3	6.71	3.09e-11	6.27e-09	0.37	0.2	Diabetic kidney disease;	chr7:66044247	chr7:66025126~66031544:-
BRCA	cis	rs875971	0.638	rs6960778	ENSG00000236529.1	RP13-254B10.1	-6.71	3.09e-11	6.27e-09	-0.22	-0.2	Aortic root size;	chr7:66606610	chr7:65840212~65840596:+
BRCA	cis	rs34779708	0.897	rs4934529	ENSG00000271335.4	RP11-324I22.4	6.71	3.09e-11	6.28e-09	0.22	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35013448	chr10:35314552~35336401:-
BRCA	cis	rs34779708	0.897	rs12830	ENSG00000271335.4	RP11-324I22.4	6.71	3.09e-11	6.28e-09	0.22	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35013777	chr10:35314552~35336401:-
BRCA	cis	rs34779708	0.931	rs7920095	ENSG00000271335.4	RP11-324I22.4	6.71	3.09e-11	6.28e-09	0.22	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35014406	chr10:35314552~35336401:-
BRCA	cis	rs11742741	0.714	rs11744373	ENSG00000248874.4	C5orf17	-6.71	3.1e-11	6.29e-09	-0.26	-0.2	Educational attainment;	chr5:24156562	chr5:23951348~24178263:+
BRCA	cis	rs67981189	0.896	rs2526878	ENSG00000269927.1	RP6-91H8.3	-6.71	3.1e-11	6.29e-09	-0.25	-0.2	Schizophrenia;	chr14:70910578	chr14:71141125~71143253:-
BRCA	cis	rs904251	0.797	rs1757181	ENSG00000204110.6	RP1-153P14.8	6.71	3.1e-11	6.3e-09	0.22	0.2	Cognitive performance;	chr6:37517952	chr6:37507348~37535616:+
BRCA	cis	rs875971	0.545	rs1796217	ENSG00000236529.1	RP13-254B10.1	-6.71	3.11e-11	6.32e-09	-0.25	-0.2	Aortic root size;	chr7:66620931	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.522	rs4502988	ENSG00000237310.1	GS1-124K5.4	6.71	3.11e-11	6.32e-09	0.21	0.2	Aortic root size;	chr7:65832759	chr7:66493706~66495474:+
BRCA	cis	rs6569038	0.522	rs1334922	ENSG00000253194.1	RP11-351A11.1	6.71	3.12e-11	6.33e-09	0.26	0.2	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr6:119052007	chr6:118934785~119031541:+
BRCA	cis	rs9307551	0.817	rs6852514	ENSG00000250334.4	LINC00989	-6.71	3.12e-11	6.33e-09	-0.27	-0.2	Refractive error;	chr4:79580759	chr4:79492416~79576460:+
BRCA	cis	rs34779708	0.75	rs35032841	ENSG00000271335.4	RP11-324I22.4	6.71	3.12e-11	6.33e-09	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35023759	chr10:35314552~35336401:-
BRCA	cis	rs34779708	0.742	rs35912711	ENSG00000271335.4	RP11-324I22.4	6.71	3.12e-11	6.33e-09	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35024068	chr10:35314552~35336401:-
BRCA	cis	rs6570726	0.902	rs973855	ENSG00000235652.6	RP11-545I5.3	-6.71	3.12e-11	6.34e-09	-0.2	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:145460714	chr6:145799409~145886585:+
BRCA	cis	rs367615	0.591	rs4530812	ENSG00000249476.1	CTD-2587M2.1	-6.71	3.12e-11	6.34e-09	-0.23	-0.2	Colorectal cancer (SNP x SNP interaction);	chr5:109522886	chr5:109237120~109326369:-
BRCA	cis	rs858239	0.539	rs10254544	ENSG00000230042.1	AK3P3	-6.71	3.13e-11	6.34e-09	-0.24	-0.2	Cerebrospinal fluid biomarker levels;	chr7:23180616	chr7:23129178~23129841:+
BRCA	cis	rs7208859	0.673	rs9911989	ENSG00000263603.1	CTD-2349P21.5	6.71	3.13e-11	6.35e-09	0.37	0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30910684	chr17:30729469~30731202:+
BRCA	cis	rs17301013	0.507	rs2860909	ENSG00000227373.4	RP11-160H22.5	6.71	3.14e-11	6.37e-09	0.29	0.2	Systemic lupus erythematosus;	chr1:174305211	chr1:174115300~174160004:-
BRCA	cis	rs1020064	0.636	rs2576750	ENSG00000235319.1	AC012360.4	-6.71	3.15e-11	6.38e-09	-0.27	-0.2	AIDS;	chr2:105300178	chr2:105324210~105330529:+
BRCA	cis	rs375066	0.762	rs17656688	ENSG00000267058.1	RP11-15A1.3	6.71	3.15e-11	6.39e-09	0.24	0.2	Breast cancer;	chr19:43920925	chr19:43891804~43901805:-
BRCA	cis	rs228614	0.509	rs223476	ENSG00000251288.2	RP11-10L12.2	-6.71	3.15e-11	6.39e-09	-0.24	-0.2	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102771000	chr4:102751401~102752641:+
BRCA	cis	rs228614	0.509	rs150896	ENSG00000251288.2	RP11-10L12.2	-6.71	3.15e-11	6.39e-09	-0.24	-0.2	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102771186	chr4:102751401~102752641:+
BRCA	cis	rs17253792	0.822	rs10142757	ENSG00000186615.9	KTN1-AS1	-6.71	3.15e-11	6.39e-09	-0.39	-0.2	Putamen volume;	chr14:55607493	chr14:55499278~55580110:-
BRCA	cis	rs17711722	0.701	rs781143	ENSG00000237310.1	GS1-124K5.4	6.71	3.15e-11	6.39e-09	0.21	0.2	Calcium levels;	chr7:65974892	chr7:66493706~66495474:+
BRCA	cis	rs9307551	0.779	rs1440854	ENSG00000250334.4	LINC00989	-6.71	3.16e-11	6.4e-09	-0.28	-0.2	Refractive error;	chr4:79585580	chr4:79492416~79576460:+
BRCA	cis	rs11089937	0.616	rs928895	ENSG00000211639.2	IGLV4-60	6.71	3.16e-11	6.41e-09	0.2	0.2	Periodontitis (PAL4Q3);	chr22:22185915	chr22:22162199~22162681:+
BRCA	cis	rs17772222	0.636	rs10484010	ENSG00000258983.2	RP11-507K2.2	6.71	3.16e-11	6.41e-09	0.24	0.2	Coronary artery calcification;	chr14:88831944	chr14:88499334~88515502:+
BRCA	cis	rs7131987	0.65	rs6487808	ENSG00000257176.2	RP11-996F15.2	6.71	3.16e-11	6.41e-09	0.25	0.2	QT interval;	chr12:29310426	chr12:29280418~29317848:-
BRCA	cis	rs755249	0.567	rs16826000	ENSG00000228060.1	RP11-69E11.8	-6.71	3.17e-11	6.42e-09	-0.25	-0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39248188	chr1:39565160~39573203:+
BRCA	cis	rs6840258	0.941	rs55913164	ENSG00000251411.1	RP11-397E7.4	-6.71	3.17e-11	6.42e-09	-0.3	-0.2	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86977778	chr4:86913266~86914817:-
BRCA	cis	rs8072100	0.544	rs7214993	ENSG00000228782.6	CTD-2026D20.3	6.71	3.17e-11	6.42e-09	0.22	0.2	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47309431	chr17:47450568~47492492:-
BRCA	cis	rs7246657	0.943	rs10409204	ENSG00000226686.6	LINC01535	-6.71	3.17e-11	6.43e-09	-0.31	-0.2	Coronary artery calcification;	chr19:37426790	chr19:37251912~37265535:+
BRCA	cis	rs12922040	0.701	rs12149912	ENSG00000263065.1	AF001548.6	-6.71	3.17e-11	6.44e-09	-0.24	-0.2	Serum uric acid levels in response to allopurinol in gout;	chr16:15774798	chr16:15741151~15741791:+
BRCA	cis	rs6504622	1	rs1047779	ENSG00000262879.4	RP11-156P1.3	-6.71	3.17e-11	6.44e-09	-0.2	-0.2	Orofacial clefts;	chr17:46941877	chr17:46984045~47100323:-
BRCA	cis	rs1499614	1	rs2659913	ENSG00000229886.1	RP5-1132H15.3	6.71	3.19e-11	6.47e-09	0.36	0.2	Gout;	chr7:66692349	chr7:66025126~66031544:-
BRCA	cis	rs1499614	1	rs2659911	ENSG00000229886.1	RP5-1132H15.3	6.71	3.19e-11	6.47e-09	0.36	0.2	Gout;	chr7:66693433	chr7:66025126~66031544:-
BRCA	cis	rs1499614	1	rs2707838	ENSG00000229886.1	RP5-1132H15.3	6.71	3.19e-11	6.47e-09	0.36	0.2	Gout;	chr7:66694214	chr7:66025126~66031544:-
BRCA	cis	rs1499614	1	rs60326618	ENSG00000229886.1	RP5-1132H15.3	6.71	3.19e-11	6.47e-09	0.36	0.2	Gout;	chr7:66701371	chr7:66025126~66031544:-
BRCA	cis	rs1499614	1	rs2707830	ENSG00000229886.1	RP5-1132H15.3	6.71	3.19e-11	6.47e-09	0.36	0.2	Gout;	chr7:66702658	chr7:66025126~66031544:-
BRCA	cis	rs1499614	1	rs2707828	ENSG00000229886.1	RP5-1132H15.3	6.71	3.19e-11	6.47e-09	0.36	0.2	Gout;	chr7:66706390	chr7:66025126~66031544:-
BRCA	cis	rs1499614	0.803	rs1922723	ENSG00000229886.1	RP5-1132H15.3	6.71	3.19e-11	6.47e-09	0.36	0.2	Gout;	chr7:66710076	chr7:66025126~66031544:-
BRCA	cis	rs2348418	0.798	rs11049486	ENSG00000247934.4	RP11-967K21.1	-6.71	3.19e-11	6.47e-09	-0.23	-0.2	Lung function (FEV1);Lung function (FVC);	chr12:28253224	chr12:28163298~28190738:-
BRCA	cis	rs1707322	1	rs4074225	ENSG00000281133.1	AL355480.3	-6.71	3.2e-11	6.48e-09	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45926692	chr1:45580892~45580996:-
BRCA	cis	rs11089937	0.616	rs6001224	ENSG00000211639.2	IGLV4-60	6.71	3.2e-11	6.48e-09	0.2	0.2	Periodontitis (PAL4Q3);	chr22:22186042	chr22:22162199~22162681:+
BRCA	cis	rs1823913	0.614	rs11693878	ENSG00000280083.1	RP11-317J9.1	6.71	3.2e-11	6.48e-09	0.23	0.2	Obesity-related traits;	chr2:191299399	chr2:191154118~191156070:-
BRCA	cis	rs1823913	0.637	rs10931494	ENSG00000280083.1	RP11-317J9.1	6.71	3.2e-11	6.48e-09	0.23	0.2	Obesity-related traits;	chr2:191299442	chr2:191154118~191156070:-
BRCA	cis	rs1823913	0.637	rs10931495	ENSG00000280083.1	RP11-317J9.1	6.71	3.2e-11	6.48e-09	0.23	0.2	Obesity-related traits;	chr2:191299447	chr2:191154118~191156070:-
BRCA	cis	rs1823913	0.637	rs12623156	ENSG00000280083.1	RP11-317J9.1	6.71	3.2e-11	6.48e-09	0.23	0.2	Obesity-related traits;	chr2:191299661	chr2:191154118~191156070:-
BRCA	cis	rs11976180	1	rs7777389	ENSG00000204959.4	ARHGEF34P	6.71	3.2e-11	6.49e-09	0.26	0.2	Obesity-related traits;	chr7:144047709	chr7:144272445~144286966:-
BRCA	cis	rs11976180	1	rs67239267	ENSG00000204959.4	ARHGEF34P	6.71	3.2e-11	6.49e-09	0.26	0.2	Obesity-related traits;	chr7:144048023	chr7:144272445~144286966:-
BRCA	cis	rs1707322	0.686	rs61784833	ENSG00000281133.1	AL355480.3	-6.71	3.21e-11	6.49e-09	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45768100	chr1:45580892~45580996:-
BRCA	cis	rs9307551	1	rs9307551	ENSG00000250334.4	LINC00989	-6.71	3.22e-11	6.51e-09	-0.3	-0.2	Refractive error;	chr4:79609517	chr4:79492416~79576460:+
BRCA	cis	rs2018683	0.624	rs2286219	ENSG00000228421.2	AC005013.5	6.71	3.22e-11	6.52e-09	0.25	0.2	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28959047	chr7:28957667~28959345:+
BRCA	cis	rs2599510	0.811	rs62136345	ENSG00000276334.1	AL133243.1	6.71	3.22e-11	6.52e-09	0.25	0.2	Interleukin-18 levels;	chr2:32582156	chr2:32521927~32523547:+
BRCA	cis	rs13631	0.928	rs9411308	ENSG00000268996.3	MAN1B1-AS1	6.71	3.22e-11	6.52e-09	0.2	0.2	Cerebrospinal fluid biomarker levels;	chr9:137105663	chr9:137084946~137086817:-
BRCA	cis	rs1075265	0.508	rs12621225	ENSG00000233266.1	HMGB1P31	6.71	3.22e-11	6.53e-09	0.25	0.2	Chronotype;Morning vs. evening chronotype;	chr2:53710040	chr2:54051334~54051760:+
BRCA	cis	rs6740322	0.895	rs6711966	ENSG00000234936.1	AC010883.5	6.71	3.23e-11	6.53e-09	0.22	0.2	Coronary artery disease;	chr2:43334850	chr2:43229573~43233394:+
BRCA	cis	rs875971	0.862	rs1875057	ENSG00000224316.1	RP11-479O9.2	-6.71	3.23e-11	6.54e-09	-0.21	-0.2	Aortic root size;	chr7:66266868	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.862	rs6960446	ENSG00000224316.1	RP11-479O9.2	-6.71	3.23e-11	6.54e-09	-0.21	-0.2	Aortic root size;	chr7:66268272	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.789	rs10260426	ENSG00000224316.1	RP11-479O9.2	-6.71	3.23e-11	6.54e-09	-0.21	-0.2	Aortic root size;	chr7:66271055	chr7:65773620~65802067:+
BRCA	cis	rs6142102	0.961	rs2300204	ENSG00000275784.1	RP5-1125A11.6	-6.71	3.24e-11	6.55e-09	-0.24	-0.2	Skin pigmentation;	chr20:34000967	chr20:33989480~33991818:-
BRCA	cis	rs2946505	0.871	rs2466244	ENSG00000251468.2	RP11-369K16.1	6.71	3.24e-11	6.56e-09	0.28	0.2	Migraine;	chr8:12964370	chr8:12958387~12962200:+
BRCA	cis	rs6142102	0.961	rs761235	ENSG00000275784.1	RP5-1125A11.6	-6.71	3.25e-11	6.57e-09	-0.25	-0.2	Skin pigmentation;	chr20:33946602	chr20:33989480~33991818:-
BRCA	cis	rs61160187	0.582	rs12655209	ENSG00000215032.2	GNL3LP1	-6.71	3.25e-11	6.58e-09	-0.25	-0.2	Educational attainment (years of education);Educational attainment (college completion);	chr5:61010225	chr5:60891935~60893577:-
BRCA	cis	rs4713118	0.869	rs9283883	ENSG00000220721.1	OR1F12	6.71	3.25e-11	6.58e-09	0.25	0.2	Parkinson's disease;	chr6:27747691	chr6:28073316~28074233:+
BRCA	cis	rs8103033	0.824	rs35457488	ENSG00000226025.8	LGALS17A	-6.71	3.26e-11	6.59e-09	-0.22	-0.2	Obesity-related traits;	chr19:39646532	chr19:39679374~39686373:+
BRCA	cis	rs875971	0.545	rs73142265	ENSG00000273024.4	INTS4P2	-6.71	3.26e-11	6.6e-09	-0.26	-0.2	Aortic root size;	chr7:66234510	chr7:65647864~65715661:+
BRCA	cis	rs6142102	1	rs4911409	ENSG00000275784.1	RP5-1125A11.6	-6.71	3.27e-11	6.62e-09	-0.24	-0.2	Skin pigmentation;	chr20:34122904	chr20:33989480~33991818:-
BRCA	cis	rs12468579	0.74	rs11894425	ENSG00000235852.1	AC005540.3	6.71	3.27e-11	6.62e-09	0.21	0.2	JT interval (sulfonylurea treatment interaction);	chr2:190973115	chr2:190880797~190882059:-
BRCA	cis	rs6969780	0.908	rs6461987	ENSG00000233429.8	HOTAIRM1	6.71	3.27e-11	6.63e-09	0.26	0.2	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27127337	chr7:27095647~27100265:+
BRCA	cis	rs875971	0.545	rs1638735	ENSG00000236529.1	RP13-254B10.1	6.71	3.29e-11	6.66e-09	0.25	0.2	Aortic root size;	chr7:66630751	chr7:65840212~65840596:+
BRCA	cis	rs9652601	0.959	rs12928537	ENSG00000274038.1	RP11-66H6.4	-6.71	3.29e-11	6.66e-09	-0.23	-0.2	Systemic lupus erythematosus;	chr16:11097543	chr16:11056556~11057034:+
BRCA	cis	rs6840360	0.642	rs1899550	ENSG00000270265.1	RP11-731D1.4	-6.7	3.3e-11	6.67e-09	-0.23	-0.2	Intelligence (multi-trait analysis);	chr4:151486084	chr4:151333775~151353224:-
BRCA	cis	rs16846053	0.515	rs7588198	ENSG00000227403.1	AC009299.3	-6.7	3.3e-11	6.67e-09	-0.34	-0.2	Blood osmolality (transformed sodium);	chr2:161508691	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.515	rs10202267	ENSG00000227403.1	AC009299.3	-6.7	3.3e-11	6.67e-09	-0.34	-0.2	Blood osmolality (transformed sodium);	chr2:161509616	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.515	rs7595197	ENSG00000227403.1	AC009299.3	-6.7	3.3e-11	6.67e-09	-0.34	-0.2	Blood osmolality (transformed sodium);	chr2:161510325	chr2:161244739~161249050:+
BRCA	cis	rs11098499	0.954	rs17005535	ENSG00000249244.1	RP11-548H18.2	6.7	3.3e-11	6.68e-09	0.24	0.2	Corneal astigmatism;	chr4:119490407	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.909	rs71614422	ENSG00000249244.1	RP11-548H18.2	6.7	3.31e-11	6.7e-09	0.24	0.2	Corneal astigmatism;	chr4:119438185	chr4:119391831~119395335:-
BRCA	cis	rs3733585	0.781	rs4292328	ENSG00000250413.1	RP11-448G15.1	6.7	3.32e-11	6.71e-09	0.26	0.2	Cleft plate (environmental tobacco smoke interaction);	chr4:9969338	chr4:10006482~10009725:+
BRCA	cis	rs17253792	0.822	rs10143002	ENSG00000186615.9	KTN1-AS1	-6.7	3.32e-11	6.71e-09	-0.39	-0.2	Putamen volume;	chr14:55607560	chr14:55499278~55580110:-
BRCA	cis	rs3126085	0.935	rs12063165	ENSG00000237975.5	FLG-AS1	-6.7	3.32e-11	6.72e-09	-0.27	-0.2	Atopic dermatitis;	chr1:152203881	chr1:152168125~152445456:+
BRCA	cis	rs74233809	0.901	rs17878846	ENSG00000213277.3	MARCKSL1P1	6.7	3.32e-11	6.72e-09	0.39	0.2	Birth weight;	chr10:102870655	chr10:103175554~103176094:+
BRCA	cis	rs1499614	1	rs2707832	ENSG00000229886.1	RP5-1132H15.3	6.7	3.33e-11	6.73e-09	0.35	0.2	Gout;	chr7:66671562	chr7:66025126~66031544:-
BRCA	cis	rs1707322	0.721	rs12069121	ENSG00000281133.1	AL355480.3	-6.7	3.34e-11	6.75e-09	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45766312	chr1:45580892~45580996:-
BRCA	cis	rs8054556	0.692	rs12716972	ENSG00000273724.1	RP11-347C12.12	-6.7	3.34e-11	6.75e-09	-0.22	-0.2	Autism spectrum disorder or schizophrenia;	chr16:29925333	chr16:30336400~30343336:+
BRCA	cis	rs4722166	0.598	rs4722179	ENSG00000179428.2	AC073072.5	-6.7	3.34e-11	6.75e-09	-0.21	-0.2	Lung cancer;	chr7:22764242	chr7:22725395~22727620:-
BRCA	cis	rs13113518	0.812	rs4864996	ENSG00000249700.7	SRD5A3-AS1	6.7	3.34e-11	6.76e-09	0.26	0.2	Height;	chr4:55452921	chr4:55363971~55395847:-
BRCA	cis	rs11098499	0.863	rs58452170	ENSG00000249244.1	RP11-548H18.2	6.7	3.34e-11	6.76e-09	0.25	0.2	Corneal astigmatism;	chr4:119538519	chr4:119391831~119395335:-
BRCA	cis	rs516805	0.961	rs483933	ENSG00000279453.1	RP3-425C14.4	-6.7	3.34e-11	6.76e-09	-0.23	-0.2	Lymphocyte counts;	chr6:122460377	chr6:122436789~122439223:-
BRCA	cis	rs6860806	0.507	rs270608	ENSG00000233006.5	AC034220.3	6.7	3.35e-11	6.77e-09	0.17	0.2	Breast cancer;	chr5:132312713	chr5:132311285~132369916:-
BRCA	cis	rs26528	0.584	rs153103	ENSG00000259982.1	CDC37P1	-6.7	3.35e-11	6.78e-09	-0.25	-0.2	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr16:28517302	chr16:28700294~28701540:-
BRCA	cis	rs2243480	1	rs2533288	ENSG00000229886.1	RP5-1132H15.3	6.7	3.36e-11	6.79e-09	0.36	0.2	Diabetic kidney disease;	chr7:66591724	chr7:66025126~66031544:-
BRCA	cis	rs1707322	1	rs11211232	ENSG00000281133.1	AL355480.3	-6.7	3.36e-11	6.8e-09	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45945474	chr1:45580892~45580996:-
BRCA	cis	rs9307551	0.817	rs12507160	ENSG00000250334.4	LINC00989	-6.7	3.37e-11	6.82e-09	-0.27	-0.2	Refractive error;	chr4:79573647	chr4:79492416~79576460:+
BRCA	cis	rs172166	0.694	rs203884	ENSG00000204709.4	LINC01556	6.7	3.37e-11	6.82e-09	0.27	0.2	Cardiac Troponin-T levels;	chr6:28109596	chr6:28943877~28944537:+
BRCA	cis	rs1499614	1	rs1267818	ENSG00000229886.1	RP5-1132H15.3	6.7	3.38e-11	6.82e-09	0.36	0.2	Gout;	chr7:66642037	chr7:66025126~66031544:-
BRCA	cis	rs34779708	0.897	rs9787566	ENSG00000271335.4	RP11-324I22.4	6.7	3.38e-11	6.83e-09	0.22	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:34990527	chr10:35314552~35336401:-
BRCA	cis	rs9291683	0.609	rs7678012	ENSG00000250413.1	RP11-448G15.1	-6.7	3.39e-11	6.85e-09	-0.26	-0.2	Bone mineral density;	chr4:9992148	chr4:10006482~10009725:+
BRCA	cis	rs375066	0.762	rs17713001	ENSG00000267058.1	RP11-15A1.3	6.7	3.39e-11	6.86e-09	0.24	0.2	Breast cancer;	chr19:43917073	chr19:43891804~43901805:-
BRCA	cis	rs375066	0.762	rs2284245	ENSG00000267058.1	RP11-15A1.3	6.7	3.39e-11	6.86e-09	0.24	0.2	Breast cancer;	chr19:43918437	chr19:43891804~43901805:-
BRCA	cis	rs8114671	0.967	rs1577924	ENSG00000269202.1	RP4-614O4.12	6.7	3.4e-11	6.87e-09	0.21	0.2	Height;	chr20:35196485	chr20:35201747~35203288:-
BRCA	cis	rs6860806	0.507	rs2631364	ENSG00000233006.5	AC034220.3	-6.7	3.4e-11	6.87e-09	-0.17	-0.2	Breast cancer;	chr5:132371222	chr5:132311285~132369916:-
BRCA	cis	rs1387259	0.899	rs7307566	ENSG00000273765.1	RP11-370I10.11	6.7	3.4e-11	6.87e-09	0.25	0.2	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48210899	chr12:48360920~48361377:+
BRCA	cis	rs600231	0.665	rs2105608	ENSG00000245532.5	NEAT1	6.7	3.4e-11	6.87e-09	0.19	0.2	Bone mineral density;	chr11:65461147	chr11:65422774~65445540:+
BRCA	cis	rs1499614	0.901	rs3936	ENSG00000229886.1	RP5-1132H15.3	6.7	3.41e-11	6.89e-09	0.36	0.2	Gout;	chr7:66661502	chr7:66025126~66031544:-
BRCA	cis	rs2243480	1	rs313824	ENSG00000230295.1	RP11-458F8.2	-6.7	3.41e-11	6.9e-09	-0.27	-0.2	Diabetic kidney disease;	chr7:66116220	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs186378	ENSG00000230295.1	RP11-458F8.2	-6.7	3.41e-11	6.9e-09	-0.27	-0.2	Diabetic kidney disease;	chr7:66117071	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs160637	ENSG00000230295.1	RP11-458F8.2	-6.7	3.41e-11	6.9e-09	-0.27	-0.2	Diabetic kidney disease;	chr7:66119331	chr7:66880708~66882981:+
BRCA	cis	rs10129255	0.912	rs61997792	ENSG00000211972.2	IGHV3-66	6.7	3.41e-11	6.9e-09	0.16	0.2	Kawasaki disease;	chr14:106799304	chr14:106675017~106675544:-
BRCA	cis	rs875971	0.66	rs7807930	ENSG00000236529.1	RP13-254B10.1	-6.7	3.42e-11	6.9e-09	-0.22	-0.2	Aortic root size;	chr7:66622178	chr7:65840212~65840596:+
BRCA	cis	rs2286503	0.78	rs981792	ENSG00000228649.7	AC005682.5	6.7	3.42e-11	6.92e-09	0.18	0.2	Fibrinogen;	chr7:22822020	chr7:22854178~22861579:+
BRCA	cis	rs600231	0.651	rs2846862	ENSG00000245532.5	NEAT1	6.7	3.43e-11	6.92e-09	0.19	0.2	Bone mineral density;	chr11:65452319	chr11:65422774~65445540:+
BRCA	cis	rs17711722	0.522	rs4642526	ENSG00000213640.3	EEF1DP4	-6.7	3.43e-11	6.93e-09	-0.26	-0.2	Calcium levels;	chr7:65751755	chr7:64862999~64864370:+
BRCA	cis	rs1707322	0.929	rs785513	ENSG00000281133.1	AL355480.3	6.7	3.44e-11	6.95e-09	0.26	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46072648	chr1:45580892~45580996:-
BRCA	cis	rs957448	1	rs28817653	ENSG00000253175.1	RP11-267M23.6	6.7	3.45e-11	6.96e-09	0.26	0.2	Nonsyndromic cleft lip with cleft palate;	chr8:94557822	chr8:94565036~94565715:+
BRCA	cis	rs7617773	0.817	rs34728236	ENSG00000228638.1	FCF1P2	-6.7	3.45e-11	6.96e-09	-0.23	-0.2	Coronary artery disease;	chr3:48217618	chr3:48290793~48291375:-
BRCA	cis	rs7617773	0.817	rs79310258	ENSG00000228638.1	FCF1P2	-6.7	3.45e-11	6.96e-09	-0.23	-0.2	Coronary artery disease;	chr3:48218177	chr3:48290793~48291375:-
BRCA	cis	rs78456975	0.941	rs11886649	ENSG00000231482.2	AC141930.2	-6.7	3.45e-11	6.96e-09	-0.29	-0.2	Placebo response in major depressive disorder (% change in symptom score);	chr2:1563985	chr2:1572554~1580311:-
BRCA	cis	rs227275	0.554	rs223485	ENSG00000251288.2	RP11-10L12.2	-6.7	3.45e-11	6.97e-09	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102764018	chr4:102751401~102752641:+
BRCA	cis	rs2836950	0.52	rs2836966	ENSG00000255568.3	BRWD1-AS2	-6.7	3.45e-11	6.97e-09	-0.19	-0.2	Menarche (age at onset);	chr21:39265595	chr21:39313935~39314962:+
BRCA	cis	rs11098499	0.954	rs10008392	ENSG00000249244.1	RP11-548H18.2	6.7	3.45e-11	6.97e-09	0.24	0.2	Corneal astigmatism;	chr4:119397684	chr4:119391831~119395335:-
BRCA	cis	rs897984	0.762	rs1870293	ENSG00000260911.2	RP11-196G11.2	-6.7	3.46e-11	6.98e-09	-0.19	-0.2	Dementia with Lewy bodies;	chr16:30959620	chr16:31043150~31049868:+
BRCA	cis	rs67981189	0.821	rs34257131	ENSG00000269927.1	RP6-91H8.3	6.7	3.46e-11	6.99e-09	0.26	0.2	Schizophrenia;	chr14:71053723	chr14:71141125~71143253:-
BRCA	cis	rs67981189	0.821	rs12896370	ENSG00000269927.1	RP6-91H8.3	6.7	3.46e-11	6.99e-09	0.26	0.2	Schizophrenia;	chr14:71054623	chr14:71141125~71143253:-
BRCA	cis	rs67981189	0.821	rs2286310	ENSG00000269927.1	RP6-91H8.3	6.7	3.46e-11	6.99e-09	0.26	0.2	Schizophrenia;	chr14:71056888	chr14:71141125~71143253:-
BRCA	cis	rs34779708	0.931	rs4934533	ENSG00000271335.4	RP11-324I22.4	6.7	3.46e-11	6.99e-09	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35070691	chr10:35314552~35336401:-
BRCA	cis	rs13178541	0.81	rs62365677	ENSG00000250378.1	RP11-119J18.1	-6.7	3.46e-11	6.99e-09	-0.27	-0.2	IgG glycosylation;	chr5:135752861	chr5:135812667~135826582:+
BRCA	cis	rs13178541	0.81	rs7380576	ENSG00000250378.1	RP11-119J18.1	-6.7	3.46e-11	6.99e-09	-0.27	-0.2	IgG glycosylation;	chr5:135752903	chr5:135812667~135826582:+
BRCA	cis	rs13178541	0.81	rs7380618	ENSG00000250378.1	RP11-119J18.1	-6.7	3.46e-11	6.99e-09	-0.27	-0.2	IgG glycosylation;	chr5:135753120	chr5:135812667~135826582:+
BRCA	cis	rs1823913	0.599	rs4146103	ENSG00000280083.1	RP11-317J9.1	-6.7	3.46e-11	6.99e-09	-0.23	-0.2	Obesity-related traits;	chr2:191272000	chr2:191154118~191156070:-
BRCA	cis	rs755249	0.567	rs61779309	ENSG00000228060.1	RP11-69E11.8	-6.7	3.46e-11	6.99e-09	-0.26	-0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39474827	chr1:39565160~39573203:+
BRCA	cis	rs172166	0.694	rs203876	ENSG00000204709.4	LINC01556	6.7	3.46e-11	6.99e-09	0.27	0.2	Cardiac Troponin-T levels;	chr6:28078895	chr6:28943877~28944537:+
BRCA	cis	rs12817211	0.502	rs12369049	ENSG00000272368.2	RP4-605O3.4	-6.7	3.47e-11	7e-09	-0.2	-0.2	Colorectal or endometrial cancer;	chr12:50116679	chr12:50112197~50165618:+
BRCA	cis	rs1707322	0.691	rs61784803	ENSG00000281133.1	AL355480.3	6.7	3.47e-11	7.01e-09	0.26	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45713599	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.663	rs3935296	ENSG00000281133.1	AL355480.3	6.7	3.47e-11	7.01e-09	0.26	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45714798	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.721	rs28817701	ENSG00000281133.1	AL355480.3	-6.7	3.47e-11	7.01e-09	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45720378	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.691	rs28495425	ENSG00000281133.1	AL355480.3	-6.7	3.47e-11	7.01e-09	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45721648	chr1:45580892~45580996:-
BRCA	cis	rs8054556	0.647	rs8048433	ENSG00000273724.1	RP11-347C12.12	-6.7	3.47e-11	7.01e-09	-0.23	-0.2	Autism spectrum disorder or schizophrenia;	chr16:29920272	chr16:30336400~30343336:+
BRCA	cis	rs1707322	0.963	rs10789478	ENSG00000281133.1	AL355480.3	-6.7	3.48e-11	7.02e-09	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45884834	chr1:45580892~45580996:-
BRCA	cis	rs11089937	0.929	rs5750624	ENSG00000211638.2	IGLV8-61	-6.7	3.48e-11	7.02e-09	-0.18	-0.2	Periodontitis (PAL4Q3);	chr22:22165354	chr22:22098700~22099212:+
BRCA	cis	rs8114671	0.967	rs6142322	ENSG00000269202.1	RP4-614O4.12	6.7	3.48e-11	7.03e-09	0.21	0.2	Height;	chr20:35200735	chr20:35201747~35203288:-
BRCA	cis	rs7131987	0.526	rs7954375	ENSG00000257176.2	RP11-996F15.2	6.7	3.49e-11	7.04e-09	0.23	0.2	QT interval;	chr12:29241487	chr12:29280418~29317848:-
BRCA	cis	rs3126085	1	rs72696952	ENSG00000237975.5	FLG-AS1	6.7	3.5e-11	7.05e-09	0.31	0.2	Atopic dermatitis;	chr1:152200218	chr1:152168125~152445456:+
BRCA	cis	rs6969780	0.915	rs10085570	ENSG00000233429.8	HOTAIRM1	-6.7	3.5e-11	7.05e-09	-0.23	-0.2	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27111569	chr7:27095647~27100265:+
BRCA	cis	rs61160187	0.582	rs56284222	ENSG00000215032.2	GNL3LP1	6.7	3.5e-11	7.06e-09	0.25	0.2	Educational attainment (years of education);Educational attainment (college completion);	chr5:61065723	chr5:60891935~60893577:-
BRCA	cis	rs9813712	0.571	rs6795143	ENSG00000228252.7	COL6A4P2	-6.7	3.51e-11	7.07e-09	-0.24	-0.2	Response to amphetamines;	chr3:130224355	chr3:130212823~130273806:+
BRCA	cis	rs9813712	0.571	rs9289366	ENSG00000228252.7	COL6A4P2	-6.7	3.51e-11	7.07e-09	-0.24	-0.2	Response to amphetamines;	chr3:130225267	chr3:130212823~130273806:+
BRCA	cis	rs9813712	0.571	rs9289367	ENSG00000228252.7	COL6A4P2	-6.7	3.51e-11	7.07e-09	-0.24	-0.2	Response to amphetamines;	chr3:130225286	chr3:130212823~130273806:+
BRCA	cis	rs9813712	0.571	rs9289368	ENSG00000228252.7	COL6A4P2	-6.7	3.51e-11	7.07e-09	-0.24	-0.2	Response to amphetamines;	chr3:130225562	chr3:130212823~130273806:+
BRCA	cis	rs9813712	0.571	rs6774141	ENSG00000228252.7	COL6A4P2	-6.7	3.51e-11	7.07e-09	-0.24	-0.2	Response to amphetamines;	chr3:130225599	chr3:130212823~130273806:+
BRCA	cis	rs1707322	0.691	rs11211174	ENSG00000281133.1	AL355480.3	-6.7	3.51e-11	7.08e-09	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755144	chr1:45580892~45580996:-
BRCA	cis	rs755249	0.567	rs1537817	ENSG00000228060.1	RP11-69E11.8	6.7	3.51e-11	7.08e-09	0.24	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39173981	chr1:39565160~39573203:+
BRCA	cis	rs6740322	0.643	rs13390381	ENSG00000234936.1	AC010883.5	6.7	3.51e-11	7.08e-09	0.24	0.2	Coronary artery disease;	chr2:43307275	chr2:43229573~43233394:+
BRCA	cis	rs34779708	0.931	rs9663401	ENSG00000271335.4	RP11-324I22.4	6.7	3.51e-11	7.08e-09	0.22	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:34989921	chr10:35314552~35336401:-
BRCA	cis	rs8114671	0.967	rs6142324	ENSG00000269202.1	RP4-614O4.12	6.7	3.51e-11	7.08e-09	0.21	0.2	Height;	chr20:35201240	chr20:35201747~35203288:-
BRCA	cis	rs911555	0.723	rs7149767	ENSG00000244691.1	RPL10AP1	6.7	3.51e-11	7.08e-09	0.26	0.2	Intelligence (multi-trait analysis);	chr14:103397208	chr14:103412119~103412761:-
BRCA	cis	rs11089937	0.616	rs5995615	ENSG00000211639.2	IGLV4-60	6.7	3.52e-11	7.09e-09	0.2	0.2	Periodontitis (PAL4Q3);	chr22:22185250	chr22:22162199~22162681:+
BRCA	cis	rs11089937	0.616	rs6001223	ENSG00000211639.2	IGLV4-60	6.7	3.52e-11	7.09e-09	0.2	0.2	Periodontitis (PAL4Q3);	chr22:22185359	chr22:22162199~22162681:+
BRCA	cis	rs1707322	1	rs4606257	ENSG00000281133.1	AL355480.3	-6.7	3.52e-11	7.09e-09	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45841596	chr1:45580892~45580996:-
BRCA	cis	rs2732480	0.5	rs12829841	ENSG00000273765.1	RP11-370I10.11	6.7	3.52e-11	7.09e-09	0.25	0.2	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48234956	chr12:48360920~48361377:+
BRCA	cis	rs2732480	0.523	rs34286639	ENSG00000273765.1	RP11-370I10.11	6.7	3.52e-11	7.09e-09	0.25	0.2	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48235261	chr12:48360920~48361377:+
BRCA	cis	rs2060793	0.659	rs1839834	ENSG00000251991.1	RNU7-49P	6.69	3.52e-11	7.1e-09	0.22	0.2	Vitamin D levels;	chr11:14807914	chr11:14478892~14478953:+
BRCA	cis	rs10936632	0.565	rs9865021	ENSG00000242578.1	RP11-469J4.3	-6.69	3.52e-11	7.1e-09	-0.24	-0.2	Prostate cancer;	chr3:170429093	chr3:170410512~170418615:+
BRCA	cis	rs2243480	1	rs402418	ENSG00000229886.1	RP5-1132H15.3	6.69	3.52e-11	7.1e-09	0.37	0.2	Diabetic kidney disease;	chr7:66044482	chr7:66025126~66031544:-
BRCA	cis	rs17655730	0.52	rs2178798	ENSG00000277290.1	RP11-326C3.16	-6.69	3.52e-11	7.1e-09	-0.2	-0.2	Mean platelet volume;	chr11:254869	chr11:243099~243483:-
BRCA	cis	rs11336847	1	rs11336847	ENSG00000234072.1	AC074117.10	-6.69	3.52e-11	7.11e-09	-0.2	-0.2	Granulocyte percentage of myeloid white cells;Monocyte percentage of white cells;	chr2:27526126	chr2:27356246~27367622:+
BRCA	cis	rs6163	0.727	rs284862	ENSG00000213061.2	PFN1P11	-6.69	3.52e-11	7.11e-09	-0.27	-0.2	Waist circumference;Hip circumference;	chr10:102812324	chr10:102838011~102845473:-
BRCA	cis	rs1707322	0.721	rs10890346	ENSG00000281133.1	AL355480.3	6.69	3.53e-11	7.12e-09	0.26	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45758220	chr1:45580892~45580996:-
BRCA	cis	rs2348418	0.864	rs11049578	ENSG00000247934.4	RP11-967K21.1	6.69	3.53e-11	7.12e-09	0.23	0.2	Lung function (FEV1);Lung function (FVC);	chr12:28414520	chr12:28163298~28190738:-
BRCA	cis	rs957448	1	rs72674843	ENSG00000253175.1	RP11-267M23.6	6.69	3.54e-11	7.13e-09	0.26	0.2	Nonsyndromic cleft lip with cleft palate;	chr8:94520772	chr8:94565036~94565715:+
BRCA	cis	rs6740322	0.895	rs6744746	ENSG00000234936.1	AC010883.5	-6.69	3.54e-11	7.13e-09	-0.23	-0.2	Coronary artery disease;	chr2:43328666	chr2:43229573~43233394:+
BRCA	cis	rs7221109	0.71	rs1048572	ENSG00000278834.1	RP11-458J1.1	-6.69	3.54e-11	7.14e-09	-0.22	-0.2	Type 1 diabetes;	chr17:40640990	chr17:40648300~40649718:+
BRCA	cis	rs673078	0.607	rs73207504	ENSG00000275409.1	RP11-131L12.4	-6.69	3.55e-11	7.16e-09	-0.31	-0.2	Glucose homeostasis traits;	chr12:118427914	chr12:118430147~118430699:+
BRCA	cis	rs4835473	0.6	rs9997101	ENSG00000251600.4	RP11-673E1.1	6.69	3.55e-11	7.16e-09	0.23	0.2	Immature fraction of reticulocytes;	chr4:143777892	chr4:143912331~143982454:+
BRCA	cis	rs1552244	0.882	rs56332224	ENSG00000180385.7	EMC3-AS1	6.69	3.56e-11	7.17e-09	0.25	0.2	Alzheimer's disease;	chr3:9995637	chr3:9986893~10006990:+
BRCA	cis	rs6504622	0.875	rs3851786	ENSG00000262879.4	RP11-156P1.3	6.69	3.56e-11	7.18e-09	0.21	0.2	Orofacial clefts;	chr17:46969566	chr17:46984045~47100323:-
BRCA	cis	rs7567389	0.677	rs6757492	ENSG00000236682.1	AC068282.3	6.69	3.57e-11	7.19e-09	0.3	0.2	Self-rated health;	chr2:127237756	chr2:127389130~127400580:+
BRCA	cis	rs66887589	0.616	rs13113885	ENSG00000248280.1	RP11-33B1.2	6.69	3.57e-11	7.19e-09	0.2	0.2	Diastolic blood pressure;	chr4:119300021	chr4:119440561~119450157:-
BRCA	cis	rs11671005	0.779	rs731259	ENSG00000252334.1	RNU6-1337P	6.69	3.57e-11	7.2e-09	0.33	0.2	Mean platelet volume;	chr19:58478057	chr19:58483749~58483843:-
BRCA	cis	rs9291683	0.588	rs13121211	ENSG00000250413.1	RP11-448G15.1	-6.69	3.57e-11	7.2e-09	-0.26	-0.2	Bone mineral density;	chr4:9997915	chr4:10006482~10009725:+
BRCA	cis	rs7617773	0.784	rs11715799	ENSG00000228638.1	FCF1P2	-6.69	3.58e-11	7.21e-09	-0.23	-0.2	Coronary artery disease;	chr3:48213730	chr3:48290793~48291375:-
BRCA	cis	rs34779708	0.931	rs2490663	ENSG00000271335.4	RP11-324I22.4	-6.69	3.58e-11	7.21e-09	-0.2	-0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35040807	chr10:35314552~35336401:-
BRCA	cis	rs6740322	0.895	rs13384080	ENSG00000234936.1	AC010883.5	6.69	3.59e-11	7.23e-09	0.23	0.2	Coronary artery disease;	chr2:43330224	chr2:43229573~43233394:+
BRCA	cis	rs13126694	0.778	rs10000610	ENSG00000251429.1	RP11-597D13.7	6.69	3.6e-11	7.24e-09	0.19	0.2	Blood osmolality (transformed sodium);	chr4:158112023	chr4:158270378~158278676:+
BRCA	cis	rs6496932	0.563	rs2344083	ENSG00000259630.2	CTD-2262B20.1	-6.69	3.6e-11	7.24e-09	-0.26	-0.2	Central corneal thickness;Corneal structure;	chr15:85354201	chr15:85415228~85415633:+
BRCA	cis	rs34779708	0.966	rs4934737	ENSG00000271335.4	RP11-324I22.4	6.69	3.6e-11	7.25e-09	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35223871	chr10:35314552~35336401:-
BRCA	cis	rs4372836	1	rs7598876	ENSG00000226833.4	AC097724.3	6.69	3.6e-11	7.25e-09	0.25	0.2	Body mass index;	chr2:28751600	chr2:28708953~28736205:-
BRCA	cis	rs12501370	1	rs4323143	ENSG00000201736.1	RNA5SP160	6.69	3.6e-11	7.25e-09	0.25	0.2	Iris color (L* coordinate);	chr4:41026876	chr4:40990154~40990273:+
BRCA	cis	rs848490	0.894	rs17233275	ENSG00000214293.7	APTR	6.69	3.6e-11	7.25e-09	0.24	0.2	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77680725	chr7:77657660~77696265:-
BRCA	cis	rs2243480	1	rs34560516	ENSG00000228409.4	CCT6P1	6.69	3.6e-11	7.26e-09	0.28	0.2	Diabetic kidney disease;	chr7:65939105	chr7:65751142~65763354:+
BRCA	cis	rs7945705	0.806	rs12224436	ENSG00000254860.4	TMEM9B-AS1	-6.69	3.6e-11	7.26e-09	-0.19	-0.2	Hemoglobin concentration;	chr11:8794278	chr11:8964675~8977527:+
BRCA	cis	rs34779708	0.931	rs4351760	ENSG00000271335.4	RP11-324I22.4	6.69	3.6e-11	7.26e-09	0.22	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:34991326	chr10:35314552~35336401:-
BRCA	cis	rs34779708	0.898	rs4934695	ENSG00000271335.4	RP11-324I22.4	6.69	3.6e-11	7.26e-09	0.22	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:34991677	chr10:35314552~35336401:-
BRCA	cis	rs7246657	0.943	rs34603719	ENSG00000226686.6	LINC01535	-6.69	3.61e-11	7.26e-09	-0.32	-0.2	Coronary artery calcification;	chr19:37303626	chr19:37251912~37265535:+
BRCA	cis	rs2243480	1	rs316329	ENSG00000232546.1	RP11-458F8.1	-6.69	3.61e-11	7.28e-09	-0.26	-0.2	Diabetic kidney disease;	chr7:66143429	chr7:66848496~66858136:+
BRCA	cis	rs875971	0.66	rs28698552	ENSG00000236529.1	RP13-254B10.1	6.69	3.61e-11	7.28e-09	0.22	0.2	Aortic root size;	chr7:66540031	chr7:65840212~65840596:+
BRCA	cis	rs853679	0.599	rs149949	ENSG00000220721.1	OR1F12	6.69	3.61e-11	7.28e-09	0.36	0.2	Depression;	chr6:28043738	chr6:28073316~28074233:+
BRCA	cis	rs6570726	0.935	rs449377	ENSG00000235652.6	RP11-545I5.3	6.69	3.61e-11	7.28e-09	0.19	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145531301	chr6:145799409~145886585:+
BRCA	cis	rs9549367	0.789	rs34568744	ENSG00000269125.1	RP11-98F14.11	-6.69	3.62e-11	7.28e-09	-0.27	-0.2	Platelet distribution width;	chr13:113240250	chr13:113165002~113165183:-
BRCA	cis	rs6840360	0.642	rs12647555	ENSG00000270265.1	RP11-731D1.4	-6.69	3.62e-11	7.28e-09	-0.23	-0.2	Intelligence (multi-trait analysis);	chr4:151479946	chr4:151333775~151353224:-
BRCA	cis	rs34779708	0.931	rs59418206	ENSG00000271335.4	RP11-324I22.4	6.69	3.62e-11	7.29e-09	0.22	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35042696	chr10:35314552~35336401:-
BRCA	cis	rs11976180	1	rs1533268	ENSG00000204959.4	ARHGEF34P	6.69	3.62e-11	7.3e-09	0.25	0.2	Obesity-related traits;	chr7:144069265	chr7:144272445~144286966:-
BRCA	cis	rs11098499	0.874	rs12502503	ENSG00000248280.1	RP11-33B1.2	6.69	3.62e-11	7.3e-09	0.22	0.2	Corneal astigmatism;	chr4:119195100	chr4:119440561~119450157:-
BRCA	cis	rs34779708	0.931	rs4934700	ENSG00000271335.4	RP11-324I22.4	6.69	3.62e-11	7.3e-09	0.22	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35021914	chr10:35314552~35336401:-
BRCA	cis	rs74233809	1	rs11191607	ENSG00000213277.3	MARCKSL1P1	6.69	3.63e-11	7.3e-09	0.38	0.2	Birth weight;	chr10:103199431	chr10:103175554~103176094:+
BRCA	cis	rs1499614	0.803	rs1796229	ENSG00000229886.1	RP5-1132H15.3	6.69	3.63e-11	7.31e-09	0.36	0.2	Gout;	chr7:66654674	chr7:66025126~66031544:-
BRCA	cis	rs853679	0.599	rs202906	ENSG00000220721.1	OR1F12	-6.69	3.63e-11	7.31e-09	-0.35	-0.2	Depression;	chr6:28043874	chr6:28073316~28074233:+
BRCA	cis	rs11671005	0.779	rs3794970	ENSG00000252334.1	RNU6-1337P	-6.69	3.63e-11	7.32e-09	-0.32	-0.2	Mean platelet volume;	chr19:58474893	chr19:58483749~58483843:-
BRCA	cis	rs4683346	0.616	rs6779561	ENSG00000173811.9	CCDC13-AS1	6.69	3.63e-11	7.32e-09	0.26	0.2	Granulocyte percentage of myeloid white cells;	chr3:42808326	chr3:42732575~42746768:+
BRCA	cis	rs6951245	0.554	rs76243429	ENSG00000229043.2	AC091729.9	-6.69	3.64e-11	7.32e-09	-0.31	-0.2	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1112907	chr7:1160374~1165267:+
BRCA	cis	rs2286503	0.839	rs4722189	ENSG00000228649.7	AC005682.5	6.69	3.64e-11	7.33e-09	0.18	0.2	Fibrinogen;	chr7:22820855	chr7:22854178~22861579:+
BRCA	cis	rs6840360	0.642	rs6843639	ENSG00000270265.1	RP11-731D1.4	-6.69	3.64e-11	7.33e-09	-0.23	-0.2	Intelligence (multi-trait analysis);	chr4:151494863	chr4:151333775~151353224:-
BRCA	cis	rs10129255	0.5	rs2027902	ENSG00000224373.3	IGHV4-59	6.69	3.65e-11	7.35e-09	0.11	0.2	Kawasaki disease;	chr14:106807157	chr14:106627249~106627825:-
BRCA	cis	rs2303759	0.874	rs8108669	ENSG00000268686.1	AC010524.2	-6.69	3.65e-11	7.36e-09	-0.31	-0.2	Multiple sclerosis;	chr19:49342638	chr19:49368705~49388081:-
BRCA	cis	rs6570726	0.811	rs375873	ENSG00000235652.6	RP11-545I5.3	6.69	3.65e-11	7.36e-09	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145491235	chr6:145799409~145886585:+
BRCA	cis	rs7246657	0.943	rs6508733	ENSG00000276846.1	CTD-3220F14.3	6.69	3.65e-11	7.36e-09	0.27	0.2	Coronary artery calcification;	chr19:37509646	chr19:37314868~37315620:-
BRCA	cis	rs7662987	0.793	rs12697	ENSG00000272777.1	RP11-571L19.8	-6.69	3.66e-11	7.37e-09	-0.28	-0.2	Smoking initiation;	chr4:99072225	chr4:99067256~99068125:-
BRCA	cis	rs9880211	0.613	rs6439629	ENSG00000273486.1	RP11-731C17.2	6.69	3.66e-11	7.37e-09	0.26	0.2	Height;Body mass index;	chr3:136182428	chr3:136837338~136839021:-
BRCA	cis	rs875971	0.619	rs12533585	ENSG00000236529.1	RP13-254B10.1	6.69	3.66e-11	7.37e-09	0.22	0.2	Aortic root size;	chr7:66519618	chr7:65840212~65840596:+
BRCA	cis	rs17301013	0.507	rs2142864	ENSG00000227373.4	RP11-160H22.5	6.69	3.67e-11	7.39e-09	0.29	0.2	Systemic lupus erythematosus;	chr1:174304924	chr1:174115300~174160004:-
BRCA	cis	rs10029851	0.627	rs17584324	ENSG00000234492.4	RPL34-AS1	6.69	3.67e-11	7.39e-09	0.32	0.2	Amyotrophic lateral sclerosis (sporadic);	chr4:108608230	chr4:108538190~108620460:-
BRCA	cis	rs6740322	1	rs11693666	ENSG00000234936.1	AC010883.5	-6.69	3.68e-11	7.4e-09	-0.22	-0.2	Coronary artery disease;	chr2:43335340	chr2:43229573~43233394:+
BRCA	cis	rs7474896	0.537	rs2749589	ENSG00000226578.1	RP11-258F22.1	6.69	3.68e-11	7.41e-09	0.26	0.2	Obesity (extreme);	chr10:37977942	chr10:37775371~37784131:-
BRCA	cis	rs9527	0.59	rs1475642	ENSG00000213061.2	PFN1P11	-6.69	3.69e-11	7.42e-09	-0.3	-0.2	Arsenic metabolism;	chr10:102786426	chr10:102838011~102845473:-
BRCA	cis	rs13113518	0.812	rs6849474	ENSG00000249700.7	SRD5A3-AS1	6.69	3.69e-11	7.42e-09	0.26	0.2	Height;	chr4:55452295	chr4:55363971~55395847:-
BRCA	cis	rs17301013	0.606	rs10912751	ENSG00000227373.4	RP11-160H22.5	6.69	3.69e-11	7.43e-09	0.29	0.2	Systemic lupus erythematosus;	chr1:174262992	chr1:174115300~174160004:-
BRCA	cis	rs34779708	0.931	rs12248333	ENSG00000271335.4	RP11-324I22.4	6.69	3.69e-11	7.43e-09	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35074049	chr10:35314552~35336401:-
BRCA	cis	rs875971	0.66	rs10215132	ENSG00000236529.1	RP13-254B10.1	-6.69	3.69e-11	7.43e-09	-0.22	-0.2	Aortic root size;	chr7:66589419	chr7:65840212~65840596:+
BRCA	cis	rs11098499	0.863	rs1383532	ENSG00000249244.1	RP11-548H18.2	-6.69	3.7e-11	7.44e-09	-0.24	-0.2	Corneal astigmatism;	chr4:119513249	chr4:119391831~119395335:-
BRCA	cis	rs9307551	0.779	rs13124357	ENSG00000250334.4	LINC00989	-6.69	3.7e-11	7.45e-09	-0.27	-0.2	Refractive error;	chr4:79591148	chr4:79492416~79576460:+
BRCA	cis	rs7746199	0.736	rs34064842	ENSG00000220721.1	OR1F12	6.69	3.71e-11	7.46e-09	0.47	0.2	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27720846	chr6:28073316~28074233:+
BRCA	cis	rs6840360	0.642	rs7676493	ENSG00000270265.1	RP11-731D1.4	-6.69	3.71e-11	7.46e-09	-0.23	-0.2	Intelligence (multi-trait analysis);	chr4:151505613	chr4:151333775~151353224:-
BRCA	cis	rs6840360	0.642	rs11735957	ENSG00000270265.1	RP11-731D1.4	-6.69	3.71e-11	7.46e-09	-0.23	-0.2	Intelligence (multi-trait analysis);	chr4:151506354	chr4:151333775~151353224:-
BRCA	cis	rs6840360	0.642	rs2053566	ENSG00000270265.1	RP11-731D1.4	-6.69	3.71e-11	7.46e-09	-0.23	-0.2	Intelligence (multi-trait analysis);	chr4:151524679	chr4:151333775~151353224:-
BRCA	cis	rs6840360	0.607	rs1561918	ENSG00000270265.1	RP11-731D1.4	-6.69	3.71e-11	7.46e-09	-0.23	-0.2	Intelligence (multi-trait analysis);	chr4:151525680	chr4:151333775~151353224:-
BRCA	cis	rs1823913	0.576	rs13011608	ENSG00000280083.1	RP11-317J9.1	-6.69	3.71e-11	7.46e-09	-0.23	-0.2	Obesity-related traits;	chr2:191267097	chr2:191154118~191156070:-
BRCA	cis	rs3733585	0.783	rs13148371	ENSG00000250413.1	RP11-448G15.1	-6.69	3.71e-11	7.47e-09	-0.26	-0.2	Cleft plate (environmental tobacco smoke interaction);	chr4:10030937	chr4:10006482~10009725:+
BRCA	cis	rs6142102	0.961	rs2235597	ENSG00000275784.1	RP5-1125A11.6	-6.69	3.72e-11	7.48e-09	-0.24	-0.2	Skin pigmentation;	chr20:34077808	chr20:33989480~33991818:-
BRCA	cis	rs10492201	0.554	rs2870962	ENSG00000255733.4	IFNG-AS1	-6.69	3.72e-11	7.48e-09	-0.2	-0.2	Itch intensity from mosquito bite adjusted by bite size;	chr12:68008143	chr12:67989445~68234686:+
BRCA	cis	rs7569084	0.663	rs10190233	ENSG00000204929.10	AC074391.1	-6.69	3.72e-11	7.49e-09	-0.26	-0.2	Sum eosinophil basophil counts;	chr2:65413095	chr2:65436711~66084639:+
BRCA	cis	rs7665090	1	rs7664828	ENSG00000246560.2	RP11-10L12.4	6.69	3.73e-11	7.5e-09	0.21	0.2	Primary biliary cholangitis;	chr4:102630219	chr4:102828055~102844075:+
BRCA	cis	rs7665090	0.967	rs7690123	ENSG00000246560.2	RP11-10L12.4	6.69	3.73e-11	7.5e-09	0.21	0.2	Primary biliary cholangitis;	chr4:102630602	chr4:102828055~102844075:+
BRCA	cis	rs7665090	1	rs7665659	ENSG00000246560.2	RP11-10L12.4	6.69	3.73e-11	7.5e-09	0.21	0.2	Primary biliary cholangitis;	chr4:102630661	chr4:102828055~102844075:+
BRCA	cis	rs7665090	1	rs7665854	ENSG00000246560.2	RP11-10L12.4	6.69	3.73e-11	7.5e-09	0.21	0.2	Primary biliary cholangitis;	chr4:102630752	chr4:102828055~102844075:+
BRCA	cis	rs7665090	0.846	rs7690700	ENSG00000246560.2	RP11-10L12.4	6.69	3.73e-11	7.5e-09	0.21	0.2	Primary biliary cholangitis;	chr4:102630911	chr4:102828055~102844075:+
BRCA	cis	rs7665090	1	rs12644381	ENSG00000246560.2	RP11-10L12.4	6.69	3.73e-11	7.5e-09	0.21	0.2	Primary biliary cholangitis;	chr4:102631273	chr4:102828055~102844075:+
BRCA	cis	rs7665090	1	rs1054037	ENSG00000246560.2	RP11-10L12.4	6.69	3.73e-11	7.5e-09	0.21	0.2	Primary biliary cholangitis;	chr4:102631552	chr4:102828055~102844075:+
BRCA	cis	rs755249	0.529	rs3768299	ENSG00000237624.1	OXCT2P1	6.69	3.74e-11	7.51e-09	0.29	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39391520	chr1:39514956~39516490:+
BRCA	cis	rs4763879	0.634	rs12424826	ENSG00000214776.8	RP11-726G1.1	-6.69	3.74e-11	7.51e-09	-0.22	-0.2	Type 1 diabetes;	chr12:9701981	chr12:9467552~9576275:+
BRCA	cis	rs2842992	0.789	rs3818300	ENSG00000237927.1	RP3-393E18.2	-6.69	3.74e-11	7.51e-09	-0.29	-0.2	Age-related macular degeneration (geographic atrophy);	chr6:159780645	chr6:159586955~159589169:-
BRCA	cis	rs2243480	1	rs431318	ENSG00000229886.1	RP5-1132H15.3	6.69	3.75e-11	7.53e-09	0.36	0.2	Diabetic kidney disease;	chr7:66046610	chr7:66025126~66031544:-
BRCA	cis	rs875971	0.545	rs73142245	ENSG00000236529.1	RP13-254B10.1	6.69	3.75e-11	7.55e-09	0.26	0.2	Aortic root size;	chr7:66226662	chr7:65840212~65840596:+
BRCA	cis	rs1707322	0.638	rs1416706	ENSG00000280836.1	AL355480.1	6.69	3.76e-11	7.55e-09	0.27	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46137172	chr1:45581219~45581321:-
BRCA	cis	rs6840360	0.642	rs11099819	ENSG00000270265.1	RP11-731D1.4	-6.68	3.76e-11	7.55e-09	-0.23	-0.2	Intelligence (multi-trait analysis);	chr4:151509026	chr4:151333775~151353224:-
BRCA	cis	rs6840360	0.607	rs6815320	ENSG00000270265.1	RP11-731D1.4	-6.68	3.76e-11	7.55e-09	-0.23	-0.2	Intelligence (multi-trait analysis);	chr4:151511348	chr4:151333775~151353224:-
BRCA	cis	rs6840360	0.642	rs11726254	ENSG00000270265.1	RP11-731D1.4	-6.68	3.76e-11	7.55e-09	-0.23	-0.2	Intelligence (multi-trait analysis);	chr4:151517698	chr4:151333775~151353224:-
BRCA	cis	rs875971	0.54	rs4717275	ENSG00000237310.1	GS1-124K5.4	-6.68	3.76e-11	7.56e-09	-0.21	-0.2	Aortic root size;	chr7:65800193	chr7:66493706~66495474:+
BRCA	cis	rs2880765	0.743	rs8028240	ENSG00000259295.5	CSPG4P12	6.68	3.76e-11	7.56e-09	0.25	0.2	Coronary artery disease;	chr15:85470017	chr15:85191438~85213905:+
BRCA	cis	rs375066	0.71	rs11881193	ENSG00000267058.1	RP11-15A1.3	6.68	3.77e-11	7.57e-09	0.24	0.2	Breast cancer;	chr19:43917364	chr19:43891804~43901805:-
BRCA	cis	rs1014246	0.807	rs10886003	ENSG00000232767.1	RP11-498B4.5	-6.68	3.77e-11	7.57e-09	-0.24	-0.2	Age at smoking initiation in chronic obstructive pulmonary disease;	chr10:116701715	chr10:116670103~116672739:+
BRCA	cis	rs34779708	0.966	rs10827487	ENSG00000271335.4	RP11-324I22.4	6.68	3.78e-11	7.59e-09	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35117950	chr10:35314552~35336401:-
BRCA	cis	rs11098499	0.588	rs6534149	ENSG00000245958.5	RP11-33B1.1	6.68	3.78e-11	7.6e-09	0.19	0.2	Corneal astigmatism;	chr4:119638137	chr4:119454791~119552025:+
BRCA	cis	rs1862618	0.853	rs832551	ENSG00000271828.1	CTD-2310F14.1	6.68	3.78e-11	7.6e-09	0.28	0.2	Initial pursuit acceleration;	chr5:56884285	chr5:56927874~56929573:+
BRCA	cis	rs1862618	0.713	rs832550	ENSG00000271828.1	CTD-2310F14.1	6.68	3.78e-11	7.6e-09	0.28	0.2	Initial pursuit acceleration;	chr5:56886762	chr5:56927874~56929573:+
BRCA	cis	rs1862618	0.756	rs832548	ENSG00000271828.1	CTD-2310F14.1	6.68	3.78e-11	7.6e-09	0.28	0.2	Initial pursuit acceleration;	chr5:56887810	chr5:56927874~56929573:+
BRCA	cis	rs1862618	0.802	rs832547	ENSG00000271828.1	CTD-2310F14.1	6.68	3.78e-11	7.6e-09	0.28	0.2	Initial pursuit acceleration;	chr5:56888114	chr5:56927874~56929573:+
BRCA	cis	rs10492201	0.529	rs740420	ENSG00000255733.4	IFNG-AS1	-6.68	3.78e-11	7.6e-09	-0.2	-0.2	Itch intensity from mosquito bite adjusted by bite size;	chr12:68007862	chr12:67989445~68234686:+
BRCA	cis	rs34779708	0.931	rs11597483	ENSG00000271335.4	RP11-324I22.4	6.68	3.79e-11	7.61e-09	0.22	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:34996189	chr10:35314552~35336401:-
BRCA	cis	rs34779708	0.931	rs35317849	ENSG00000271335.4	RP11-324I22.4	6.68	3.79e-11	7.61e-09	0.22	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:34996793	chr10:35314552~35336401:-
BRCA	cis	rs853679	0.607	rs34950484	ENSG00000220721.1	OR1F12	6.68	3.8e-11	7.62e-09	0.47	0.2	Depression;	chr6:28310911	chr6:28073316~28074233:+
BRCA	cis	rs2880765	0.743	rs11630410	ENSG00000259295.5	CSPG4P12	6.68	3.8e-11	7.62e-09	0.25	0.2	Coronary artery disease;	chr15:85461510	chr15:85191438~85213905:+
BRCA	cis	rs2880765	0.71	rs11630457	ENSG00000259295.5	CSPG4P12	6.68	3.8e-11	7.62e-09	0.25	0.2	Coronary artery disease;	chr15:85461570	chr15:85191438~85213905:+
BRCA	cis	rs73186030	0.764	rs55744726	ENSG00000272758.4	RP11-299J3.8	6.68	3.8e-11	7.64e-09	0.29	0.2	Serum parathyroid hormone levels;	chr3:122368907	chr3:122416207~122443180:+
BRCA	cis	rs73186030	0.764	rs73186095	ENSG00000272758.4	RP11-299J3.8	6.68	3.8e-11	7.64e-09	0.29	0.2	Serum parathyroid hormone levels;	chr3:122372769	chr3:122416207~122443180:+
BRCA	cis	rs73186030	0.764	rs67446552	ENSG00000272758.4	RP11-299J3.8	6.68	3.8e-11	7.64e-09	0.29	0.2	Serum parathyroid hormone levels;	chr3:122377448	chr3:122416207~122443180:+
BRCA	cis	rs73186030	0.764	rs67706840	ENSG00000272758.4	RP11-299J3.8	6.68	3.8e-11	7.64e-09	0.29	0.2	Serum parathyroid hormone levels;	chr3:122377717	chr3:122416207~122443180:+
BRCA	cis	rs73186030	0.764	rs16833078	ENSG00000272758.4	RP11-299J3.8	6.68	3.8e-11	7.64e-09	0.29	0.2	Serum parathyroid hormone levels;	chr3:122380747	chr3:122416207~122443180:+
BRCA	cis	rs34526934	0.566	rs1374325	ENSG00000226363.3	HAGLROS	6.68	3.81e-11	7.65e-09	0.3	0.2	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:176179243	chr2:176177717~176179008:+
BRCA	cis	rs1552244	0.882	rs13063098	ENSG00000180385.7	EMC3-AS1	6.68	3.81e-11	7.66e-09	0.25	0.2	Alzheimer's disease;	chr3:9968235	chr3:9986893~10006990:+
BRCA	cis	rs2243480	1	rs67536397	ENSG00000229886.1	RP5-1132H15.3	6.68	3.81e-11	7.66e-09	0.36	0.2	Diabetic kidney disease;	chr7:66482930	chr7:66025126~66031544:-
BRCA	cis	rs2243480	1	rs58669269	ENSG00000229886.1	RP5-1132H15.3	6.68	3.81e-11	7.66e-09	0.36	0.2	Diabetic kidney disease;	chr7:66486966	chr7:66025126~66031544:-
BRCA	cis	rs11096990	0.892	rs28639548	ENSG00000249207.1	RP11-360F5.1	6.68	3.81e-11	7.66e-09	0.24	0.2	Cognitive function;	chr4:39185530	chr4:39112677~39126818:-
BRCA	cis	rs2348418	0.966	rs4144964	ENSG00000247934.4	RP11-967K21.1	6.68	3.82e-11	7.66e-09	0.23	0.2	Lung function (FEV1);Lung function (FVC);	chr12:28531249	chr12:28163298~28190738:-
BRCA	cis	rs875971	0.545	rs4718325	ENSG00000236529.1	RP13-254B10.1	6.68	3.82e-11	7.66e-09	0.26	0.2	Aortic root size;	chr7:66215323	chr7:65840212~65840596:+
BRCA	cis	rs2243480	0.708	rs35825036	ENSG00000229886.1	RP5-1132H15.3	6.68	3.82e-11	7.67e-09	0.36	0.2	Diabetic kidney disease;	chr7:66521515	chr7:66025126~66031544:-
BRCA	cis	rs2243480	1	rs13237037	ENSG00000229886.1	RP5-1132H15.3	6.68	3.82e-11	7.67e-09	0.36	0.2	Diabetic kidney disease;	chr7:66532895	chr7:66025126~66031544:-
BRCA	cis	rs2243480	1	rs1796228	ENSG00000229886.1	RP5-1132H15.3	6.68	3.82e-11	7.67e-09	0.36	0.2	Diabetic kidney disease;	chr7:66568097	chr7:66025126~66031544:-
BRCA	cis	rs67981189	0.896	rs3814869	ENSG00000269927.1	RP6-91H8.3	6.68	3.82e-11	7.68e-09	0.25	0.2	Schizophrenia;	chr14:71028982	chr14:71141125~71143253:-
BRCA	cis	rs7246657	0.55	rs10411176	ENSG00000276846.1	CTD-3220F14.3	6.68	3.83e-11	7.69e-09	0.32	0.2	Coronary artery calcification;	chr19:37196051	chr19:37314868~37315620:-
BRCA	cis	rs13113518	0.783	rs11133389	ENSG00000249700.7	SRD5A3-AS1	6.68	3.83e-11	7.7e-09	0.26	0.2	Height;	chr4:55486718	chr4:55363971~55395847:-
BRCA	cis	rs7520050	0.898	rs4660885	ENSG00000280836.1	AL355480.1	6.68	3.83e-11	7.7e-09	0.24	0.2	Reticulocyte count;Red blood cell count;	chr1:45778084	chr1:45581219~45581321:-
BRCA	cis	rs2688608	0.592	rs10762560	ENSG00000271816.1	BMS1P4	6.68	3.84e-11	7.71e-09	0.2	0.2	Inflammatory bowel disease;	chr10:73735647	chr10:73699151~73730487:-
BRCA	cis	rs9291683	0.618	rs13137343	ENSG00000250413.1	RP11-448G15.1	-6.68	3.84e-11	7.71e-09	-0.27	-0.2	Bone mineral density;	chr4:10041404	chr4:10006482~10009725:+
BRCA	cis	rs6840360	0.642	rs28666858	ENSG00000270265.1	RP11-731D1.4	-6.68	3.84e-11	7.71e-09	-0.23	-0.2	Intelligence (multi-trait analysis);	chr4:151495230	chr4:151333775~151353224:-
BRCA	cis	rs1387259	0.723	rs2732488	ENSG00000273765.1	RP11-370I10.11	6.68	3.85e-11	7.73e-09	0.25	0.2	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48377661	chr12:48360920~48361377:+
BRCA	cis	rs1387259	0.758	rs2634670	ENSG00000273765.1	RP11-370I10.11	6.68	3.85e-11	7.73e-09	0.25	0.2	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48378094	chr12:48360920~48361377:+
BRCA	cis	rs73173548	0.528	rs6872276	ENSG00000247828.6	TMEM161B-AS1	6.68	3.85e-11	7.73e-09	0.28	0.2	Macular telangiectasia type 2;	chr5:88473903	chr5:88268895~88436685:+
BRCA	cis	rs2492301	0.54	rs10796907	ENSG00000233621.1	LINC01137	-6.68	3.85e-11	7.73e-09	-0.21	-0.2	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr1:37434572	chr1:37454879~37474411:-
BRCA	cis	rs9307551	0.817	rs11098764	ENSG00000250334.4	LINC00989	-6.68	3.85e-11	7.73e-09	-0.27	-0.2	Refractive error;	chr4:79578860	chr4:79492416~79576460:+
BRCA	cis	rs804292	1	rs804292	ENSG00000255046.1	RP11-297N6.4	-6.68	3.86e-11	7.75e-09	-0.28	-0.2	Nicotine use;Alcohol dependence;	chr8:11786406	chr8:11797928~11802568:-
BRCA	cis	rs11089937	0.616	rs928896	ENSG00000211639.2	IGLV4-60	6.68	3.87e-11	7.76e-09	0.2	0.2	Periodontitis (PAL4Q3);	chr22:22185929	chr22:22162199~22162681:+
BRCA	cis	rs34779708	0.897	rs7897827	ENSG00000271335.4	RP11-324I22.4	6.68	3.87e-11	7.76e-09	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35097309	chr10:35314552~35336401:-
BRCA	cis	rs6740322	0.895	rs9309097	ENSG00000234936.1	AC010883.5	6.68	3.87e-11	7.76e-09	0.23	0.2	Coronary artery disease;	chr2:43327258	chr2:43229573~43233394:+
BRCA	cis	rs1387259	0.929	rs11168460	ENSG00000273765.1	RP11-370I10.11	6.68	3.87e-11	7.77e-09	0.24	0.2	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48203582	chr12:48360920~48361377:+
BRCA	cis	rs1707322	0.721	rs56255771	ENSG00000281133.1	AL355480.3	-6.68	3.87e-11	7.77e-09	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45758647	chr1:45580892~45580996:-
BRCA	cis	rs853679	0.546	rs200948	ENSG00000220721.1	OR1F12	6.68	3.88e-11	7.78e-09	0.37	0.2	Depression;	chr6:27867494	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.546	rs200950	ENSG00000220721.1	OR1F12	6.68	3.88e-11	7.78e-09	0.37	0.2	Depression;	chr6:27867994	chr6:28073316~28074233:+
BRCA	cis	rs4927850	0.501	rs9881504	ENSG00000231464.1	AC024937.4	6.68	3.88e-11	7.79e-09	0.27	0.2	Pancreatic cancer;	chr3:195929743	chr3:195996738~195998233:+
BRCA	cis	rs9500256	0.655	rs12210275	ENSG00000215190.7	LINC00680	-6.68	3.88e-11	7.79e-09	-0.25	-0.2	Eosinophilic esophagitis (pediatric);	chr6:58005481	chr6:57946074~57961501:-
BRCA	cis	rs1707322	0.721	rs7519900	ENSG00000281133.1	AL355480.3	-6.68	3.89e-11	7.8e-09	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45769275	chr1:45580892~45580996:-
BRCA	cis	rs2348418	0.966	rs7136139	ENSG00000247934.4	RP11-967K21.1	6.68	3.89e-11	7.8e-09	0.23	0.2	Lung function (FEV1);Lung function (FVC);	chr12:28531087	chr12:28163298~28190738:-
BRCA	cis	rs875971	0.545	rs73142233	ENSG00000236529.1	RP13-254B10.1	6.68	3.89e-11	7.81e-09	0.25	0.2	Aortic root size;	chr7:66221293	chr7:65840212~65840596:+
BRCA	cis	rs9291683	0.525	rs12506455	ENSG00000250413.1	RP11-448G15.1	-6.68	3.9e-11	7.81e-09	-0.26	-0.2	Bone mineral density;	chr4:10029945	chr4:10006482~10009725:+
BRCA	cis	rs9307551	0.817	rs1440852	ENSG00000250334.4	LINC00989	-6.68	3.9e-11	7.82e-09	-0.27	-0.2	Refractive error;	chr4:79585435	chr4:79492416~79576460:+
BRCA	cis	rs13113518	0.812	rs2412648	ENSG00000249700.7	SRD5A3-AS1	6.68	3.9e-11	7.82e-09	0.26	0.2	Height;	chr4:55454900	chr4:55363971~55395847:-
BRCA	cis	rs13113518	0.812	rs12512737	ENSG00000249700.7	SRD5A3-AS1	6.68	3.9e-11	7.82e-09	0.26	0.2	Height;	chr4:55454938	chr4:55363971~55395847:-
BRCA	cis	rs13113518	0.812	rs13125984	ENSG00000249700.7	SRD5A3-AS1	6.68	3.9e-11	7.82e-09	0.26	0.2	Height;	chr4:55455102	chr4:55363971~55395847:-
BRCA	cis	rs2014572	0.967	rs7259978	ENSG00000268379.1	CTC-360J11.4	6.68	3.91e-11	7.83e-09	0.24	0.2	Hyperactive-impulsive symptoms;	chr19:57244761	chr19:57175233~57177921:+
BRCA	cis	rs7976269	0.583	rs7955393	ENSG00000257176.2	RP11-996F15.2	-6.68	3.91e-11	7.83e-09	-0.24	-0.2	Male-pattern baldness;	chr12:29065773	chr12:29280418~29317848:-
BRCA	cis	rs1707322	0.964	rs12067716	ENSG00000281133.1	AL355480.3	-6.68	3.91e-11	7.84e-09	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45968756	chr1:45580892~45580996:-
BRCA	cis	rs2243480	1	rs56016656	ENSG00000228409.4	CCT6P1	6.68	3.91e-11	7.84e-09	0.28	0.2	Diabetic kidney disease;	chr7:65918494	chr7:65751142~65763354:+
BRCA	cis	rs2243480	1	rs56291018	ENSG00000228409.4	CCT6P1	6.68	3.91e-11	7.84e-09	0.28	0.2	Diabetic kidney disease;	chr7:65925352	chr7:65751142~65763354:+
BRCA	cis	rs2243480	1	rs36033484	ENSG00000228409.4	CCT6P1	6.68	3.91e-11	7.84e-09	0.28	0.2	Diabetic kidney disease;	chr7:65925571	chr7:65751142~65763354:+
BRCA	cis	rs11976180	1	rs11976180	ENSG00000204959.4	ARHGEF34P	6.68	3.92e-11	7.85e-09	0.26	0.2	Obesity-related traits;	chr7:144044487	chr7:144272445~144286966:-
BRCA	cis	rs7617773	0.779	rs3731487	ENSG00000228638.1	FCF1P2	-6.68	3.92e-11	7.86e-09	-0.23	-0.2	Coronary artery disease;	chr3:48188134	chr3:48290793~48291375:-
BRCA	cis	rs2060793	0.741	rs1542291	ENSG00000251991.1	RNU7-49P	6.68	3.95e-11	7.92e-09	0.22	0.2	Vitamin D levels;	chr11:14784720	chr11:14478892~14478953:+
BRCA	cis	rs1707322	1	rs6677777	ENSG00000281133.1	AL355480.3	-6.68	3.95e-11	7.93e-09	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46010164	chr1:45580892~45580996:-
BRCA	cis	rs6142102	0.961	rs6088360	ENSG00000275784.1	RP5-1125A11.6	-6.68	3.96e-11	7.94e-09	-0.25	-0.2	Skin pigmentation;	chr20:33969383	chr20:33989480~33991818:-
BRCA	cis	rs4072705	1	rs4838206	ENSG00000224020.1	MIR181A2HG	-6.68	3.97e-11	7.95e-09	-0.22	-0.2	Menarche (age at onset);	chr9:124749645	chr9:124658467~124698631:+
BRCA	cis	rs3126085	0.935	rs56013982	ENSG00000237975.5	FLG-AS1	6.68	3.97e-11	7.95e-09	0.32	0.2	Atopic dermatitis;	chr1:152204027	chr1:152168125~152445456:+
BRCA	cis	rs11976180	1	rs1919949	ENSG00000204959.4	ARHGEF34P	6.68	3.97e-11	7.96e-09	0.25	0.2	Obesity-related traits;	chr7:144070630	chr7:144272445~144286966:-
BRCA	cis	rs4908760	0.811	rs301802	ENSG00000232912.4	RP5-1115A15.1	6.68	3.97e-11	7.96e-09	0.19	0.2	Vitiligo;	chr1:8437247	chr1:8424645~8434838:+
BRCA	cis	rs919433	0.889	rs6711624	ENSG00000231621.1	AC013264.2	6.68	3.98e-11	7.97e-09	0.19	0.2	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197342883	chr2:197197991~197199273:+
BRCA	cis	rs1555322	0.53	rs6058224	ENSG00000279253.1	RP4-614O4.13	-6.68	3.99e-11	7.99e-09	-0.26	-0.2	Attention deficit hyperactivity disorder;	chr20:35293971	chr20:35262727~35264187:-
BRCA	cis	rs875971	0.545	rs10261710	ENSG00000236529.1	RP13-254B10.1	6.68	4e-11	8e-09	0.26	0.2	Aortic root size;	chr7:66249202	chr7:65840212~65840596:+
BRCA	cis	rs2842992	0.673	rs6930904	ENSG00000237927.1	RP3-393E18.2	-6.68	4e-11	8.01e-09	-0.29	-0.2	Age-related macular degeneration (geographic atrophy);	chr6:159796401	chr6:159586955~159589169:-
BRCA	cis	rs1707322	0.964	rs1768802	ENSG00000281133.1	AL355480.3	6.67	4.01e-11	8.03e-09	0.25	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46082196	chr1:45580892~45580996:-
BRCA	cis	rs1707322	1	rs1588663	ENSG00000281133.1	AL355480.3	6.67	4.01e-11	8.03e-09	0.25	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46083153	chr1:45580892~45580996:-
BRCA	cis	rs1707322	1	rs1768801	ENSG00000281133.1	AL355480.3	6.67	4.01e-11	8.03e-09	0.25	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46083465	chr1:45580892~45580996:-
BRCA	cis	rs1707322	1	rs1768800	ENSG00000281133.1	AL355480.3	6.67	4.01e-11	8.03e-09	0.25	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46083516	chr1:45580892~45580996:-
BRCA	cis	rs13113518	0.812	rs12500686	ENSG00000223305.1	RN7SKP30	6.67	4.01e-11	8.03e-09	0.27	0.2	Height;	chr4:55457922	chr4:55540502~55540835:-
BRCA	cis	rs2732480	0.5	rs7315820	ENSG00000273765.1	RP11-370I10.11	6.67	4.02e-11	8.04e-09	0.24	0.2	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48205155	chr12:48360920~48361377:+
BRCA	cis	rs3781264	0.761	rs7077192	ENSG00000273450.1	RP11-76P2.4	6.67	4.02e-11	8.05e-09	0.28	0.2	Esophageal cancer and gastric cancer;	chr10:94365407	chr10:94314907~94315327:-
BRCA	cis	rs172166	0.694	rs203877	ENSG00000204709.4	LINC01556	6.67	4.03e-11	8.07e-09	0.27	0.2	Cardiac Troponin-T levels;	chr6:28080846	chr6:28943877~28944537:+
BRCA	cis	rs17711722	0.653	rs2460421	ENSG00000273024.4	INTS4P2	6.67	4.04e-11	8.09e-09	0.22	0.2	Calcium levels;	chr7:66026136	chr7:65647864~65715661:+
BRCA	cis	rs172166	0.694	rs2791332	ENSG00000216901.1	AL022393.7	6.67	4.04e-11	8.09e-09	0.27	0.2	Cardiac Troponin-T levels;	chr6:28141010	chr6:28176188~28176674:+
BRCA	cis	rs7976269	0.609	rs1344854	ENSG00000257176.2	RP11-996F15.2	6.67	4.05e-11	8.11e-09	0.24	0.2	Male-pattern baldness;	chr12:29065440	chr12:29280418~29317848:-
BRCA	cis	rs2288884	0.537	rs4145658	ENSG00000275055.1	CTC-471J1.11	-6.67	4.06e-11	8.12e-09	-0.23	-0.2	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52085465	chr19:52049007~52049754:+
BRCA	cis	rs7688540	0.771	rs7674560	ENSG00000211553.1	AC253576.2	-6.67	4.06e-11	8.12e-09	-0.3	-0.2	Facial morphology (factor 6, height of vermillion lower lip);	chr4:269530	chr4:136461~136568:+
BRCA	cis	rs9307551	0.817	rs12507375	ENSG00000250334.4	LINC00989	-6.67	4.06e-11	8.12e-09	-0.27	-0.2	Refractive error;	chr4:79575206	chr4:79492416~79576460:+
BRCA	cis	rs6840360	0.558	rs2709821	ENSG00000270265.1	RP11-731D1.4	-6.67	4.06e-11	8.13e-09	-0.23	-0.2	Intelligence (multi-trait analysis);	chr4:151421038	chr4:151333775~151353224:-
BRCA	cis	rs6142102	0.961	rs2377957	ENSG00000275784.1	RP5-1125A11.6	-6.67	4.06e-11	8.13e-09	-0.23	-0.2	Skin pigmentation;	chr20:33966667	chr20:33989480~33991818:-
BRCA	cis	rs7674212	0.531	rs2866416	ENSG00000251288.2	RP11-10L12.2	-6.67	4.07e-11	8.15e-09	-0.25	-0.2	Type 2 diabetes;	chr4:102959554	chr4:102751401~102752641:+
BRCA	cis	rs2880765	0.743	rs8032488	ENSG00000259295.5	CSPG4P12	6.67	4.08e-11	8.15e-09	0.25	0.2	Coronary artery disease;	chr15:85469537	chr15:85191438~85213905:+
BRCA	cis	rs516805	0.847	rs520867	ENSG00000279453.1	RP3-425C14.4	-6.67	4.08e-11	8.16e-09	-0.23	-0.2	Lymphocyte counts;	chr6:122465501	chr6:122436789~122439223:-
BRCA	cis	rs516805	0.961	rs693669	ENSG00000279453.1	RP3-425C14.4	-6.67	4.08e-11	8.16e-09	-0.23	-0.2	Lymphocyte counts;	chr6:122465690	chr6:122436789~122439223:-
BRCA	cis	rs7246657	0.943	rs1035479	ENSG00000276846.1	CTD-3220F14.3	-6.67	4.08e-11	8.16e-09	-0.27	-0.2	Coronary artery calcification;	chr19:37402398	chr19:37314868~37315620:-
BRCA	cis	rs2243480	1	rs4149468	ENSG00000232546.1	RP11-458F8.1	-6.67	4.08e-11	8.17e-09	-0.27	-0.2	Diabetic kidney disease;	chr7:66360703	chr7:66848496~66858136:+
BRCA	cis	rs875971	0.545	rs73142265	ENSG00000236529.1	RP13-254B10.1	6.67	4.09e-11	8.18e-09	0.25	0.2	Aortic root size;	chr7:66234510	chr7:65840212~65840596:+
BRCA	cis	rs7587476	0.954	rs3768708	ENSG00000229267.2	AC072062.1	6.67	4.09e-11	8.19e-09	0.26	0.2	Neuroblastoma;	chr2:214780322	chr2:214810229~214963274:+
BRCA	cis	rs7945705	0.846	rs4929911	ENSG00000254860.4	TMEM9B-AS1	-6.67	4.09e-11	8.19e-09	-0.19	-0.2	Hemoglobin concentration;	chr11:8794948	chr11:8964675~8977527:+
BRCA	cis	rs2834288	0.5	rs7277248	ENSG00000273102.1	AP000569.9	6.67	4.09e-11	8.19e-09	0.22	0.2	Gut microbiota (bacterial taxa);	chr21:33957948	chr21:33967101~33968573:-
BRCA	cis	rs11098499	0.874	rs6832670	ENSG00000248280.1	RP11-33B1.2	6.67	4.1e-11	8.2e-09	0.22	0.2	Corneal astigmatism;	chr4:119197637	chr4:119440561~119450157:-
BRCA	cis	rs6142102	0.961	rs4911146	ENSG00000275784.1	RP5-1125A11.6	-6.67	4.1e-11	8.21e-09	-0.24	-0.2	Skin pigmentation;	chr20:34052241	chr20:33989480~33991818:-
BRCA	cis	rs2072438	0.503	rs1323474	ENSG00000226752.6	PSMD5-AS1	-6.67	4.11e-11	8.21e-09	-0.24	-0.2	Rheumatoid arthritis;	chr9:121090581	chr9:120824828~120854385:+
BRCA	cis	rs17253792	0.822	rs17683656	ENSG00000186615.9	KTN1-AS1	6.67	4.12e-11	8.23e-09	0.39	0.2	Putamen volume;	chr14:55586643	chr14:55499278~55580110:-
BRCA	cis	rs172166	0.694	rs2791332	ENSG00000204709.4	LINC01556	6.67	4.12e-11	8.23e-09	0.28	0.2	Cardiac Troponin-T levels;	chr6:28141010	chr6:28943877~28944537:+
BRCA	cis	rs58873874	0.579	rs11738062	ENSG00000248544.2	CTB-47B11.3	6.67	4.12e-11	8.24e-09	0.38	0.2	Bipolar disorder (body mass index interaction);	chr5:157358059	chr5:157375741~157384950:-
BRCA	cis	rs34779708	0.931	rs2384283	ENSG00000271335.4	RP11-324I22.4	6.67	4.13e-11	8.27e-09	0.22	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35037861	chr10:35314552~35336401:-
BRCA	cis	rs755249	0.567	rs72637906	ENSG00000228060.1	RP11-69E11.8	-6.67	4.14e-11	8.27e-09	-0.25	-0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39242630	chr1:39565160~39573203:+
BRCA	cis	rs755249	0.567	rs67886352	ENSG00000228060.1	RP11-69E11.8	-6.67	4.14e-11	8.27e-09	-0.25	-0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39243031	chr1:39565160~39573203:+
BRCA	cis	rs755249	0.567	rs60323161	ENSG00000228060.1	RP11-69E11.8	-6.67	4.14e-11	8.27e-09	-0.25	-0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39244787	chr1:39565160~39573203:+
BRCA	cis	rs755249	0.567	rs66727439	ENSG00000228060.1	RP11-69E11.8	-6.67	4.14e-11	8.27e-09	-0.25	-0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39246258	chr1:39565160~39573203:+
BRCA	cis	rs9291683	0.595	rs10939665	ENSG00000250413.1	RP11-448G15.1	-6.67	4.14e-11	8.28e-09	-0.27	-0.2	Bone mineral density;	chr4:10036004	chr4:10006482~10009725:+
BRCA	cis	rs2842992	0.789	rs4709370	ENSG00000237927.1	RP3-393E18.2	-6.67	4.14e-11	8.28e-09	-0.29	-0.2	Age-related macular degeneration (geographic atrophy);	chr6:159789029	chr6:159586955~159589169:-
BRCA	cis	rs7923837	0.656	rs6583826	ENSG00000236493.2	EIF2S2P3	6.67	4.15e-11	8.29e-09	0.26	0.2	Multiple sclerosis;Body mass index;	chr10:92588073	chr10:92668745~92669743:-
BRCA	cis	rs34779708	0.931	rs2505631	ENSG00000271335.4	RP11-324I22.4	-6.67	4.15e-11	8.29e-09	-0.2	-0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35079457	chr10:35314552~35336401:-
BRCA	cis	rs2243480	0.615	rs34363376	ENSG00000229886.1	RP5-1132H15.3	6.67	4.15e-11	8.3e-09	0.36	0.2	Diabetic kidney disease;	chr7:66474549	chr7:66025126~66031544:-
BRCA	cis	rs61160187	0.582	rs888799	ENSG00000215032.2	GNL3LP1	6.67	4.16e-11	8.31e-09	0.25	0.2	Educational attainment (years of education);Educational attainment (college completion);	chr5:61049363	chr5:60891935~60893577:-
BRCA	cis	rs2243480	1	rs35820085	ENSG00000228409.4	CCT6P1	6.67	4.16e-11	8.31e-09	0.28	0.2	Diabetic kidney disease;	chr7:65977771	chr7:65751142~65763354:+
BRCA	cis	rs4713118	0.591	rs2056924	ENSG00000220721.1	OR1F12	6.67	4.16e-11	8.32e-09	0.24	0.2	Parkinson's disease;	chr6:27722395	chr6:28073316~28074233:+
BRCA	cis	rs11512640	1	rs12363935	ENSG00000254671.2	STT3A-AS1	6.67	4.16e-11	8.32e-09	0.47	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr11:125558406	chr11:125570284~125592568:-
BRCA	cis	rs2836950	0.501	rs2056844	ENSG00000255568.3	BRWD1-AS2	-6.67	4.16e-11	8.32e-09	-0.19	-0.2	Menarche (age at onset);	chr21:39298534	chr21:39313935~39314962:+
BRCA	cis	rs875971	1	rs10257427	ENSG00000224316.1	RP11-479O9.2	-6.67	4.16e-11	8.32e-09	-0.2	-0.2	Aortic root size;	chr7:66278221	chr7:65773620~65802067:+
BRCA	cis	rs4218	0.859	rs1486878	ENSG00000277144.1	RP11-59H7.4	-6.67	4.16e-11	8.32e-09	-0.25	-0.2	Social communication problems;	chr15:59123268	chr15:59115547~59116089:-
BRCA	cis	rs875971	0.964	rs55748098	ENSG00000224316.1	RP11-479O9.2	-6.67	4.16e-11	8.32e-09	-0.2	-0.2	Aortic root size;	chr7:66298631	chr7:65773620~65802067:+
BRCA	cis	rs2998286	0.862	rs2993989	ENSG00000254635.4	WAC-AS1	-6.67	4.17e-11	8.33e-09	-0.27	-0.2	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28512986	chr10:28522652~28532743:-
BRCA	cis	rs1707322	0.752	rs11211152	ENSG00000281133.1	AL355480.3	-6.67	4.17e-11	8.33e-09	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45648485	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.752	rs4607935	ENSG00000281133.1	AL355480.3	-6.67	4.17e-11	8.33e-09	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45651489	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.681	rs12048866	ENSG00000281133.1	AL355480.3	-6.67	4.17e-11	8.33e-09	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45651820	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.752	rs3811436	ENSG00000281133.1	AL355480.3	-6.67	4.17e-11	8.33e-09	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45660208	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.752	rs12024590	ENSG00000281133.1	AL355480.3	-6.67	4.17e-11	8.33e-09	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45661824	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.752	rs12027622	ENSG00000281133.1	AL355480.3	-6.67	4.17e-11	8.33e-09	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45664580	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.752	rs7529699	ENSG00000281133.1	AL355480.3	-6.67	4.17e-11	8.33e-09	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45668962	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.716	rs6699444	ENSG00000281133.1	AL355480.3	-6.67	4.17e-11	8.33e-09	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45669448	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.752	rs10430105	ENSG00000281133.1	AL355480.3	-6.67	4.17e-11	8.33e-09	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45673204	chr1:45580892~45580996:-
BRCA	cis	rs3761847	0.622	rs10818500	ENSG00000226752.6	PSMD5-AS1	6.67	4.18e-11	8.34e-09	0.24	0.2	Rheumatoid arthritis;	chr9:121048605	chr9:120824828~120854385:+
BRCA	cis	rs17772222	0.74	rs7160647	ENSG00000258983.2	RP11-507K2.2	6.67	4.19e-11	8.37e-09	0.21	0.2	Coronary artery calcification;	chr14:88507340	chr14:88499334~88515502:+
BRCA	cis	rs2880765	0.677	rs7181410	ENSG00000259295.5	CSPG4P12	-6.67	4.19e-11	8.38e-09	-0.25	-0.2	Coronary artery disease;	chr15:85463104	chr15:85191438~85213905:+
BRCA	cis	rs72772090	1	rs72772090	ENSG00000248734.2	CTD-2260A17.1	-6.67	4.2e-11	8.38e-09	-0.32	-0.2	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96700607	chr5:96784777~96785999:+
BRCA	cis	rs61160187	0.548	rs1983484	ENSG00000215032.2	GNL3LP1	6.67	4.2e-11	8.39e-09	0.25	0.2	Educational attainment (years of education);Educational attainment (college completion);	chr5:61050998	chr5:60891935~60893577:-
BRCA	cis	rs4237845	0.773	rs6650217	ENSG00000257159.1	RP11-58A17.3	6.67	4.21e-11	8.4e-09	0.23	0.2	Intelligence (multi-trait analysis);	chr12:57895289	chr12:57967058~57968399:+
BRCA	cis	rs4237845	0.773	rs6650218	ENSG00000257159.1	RP11-58A17.3	6.67	4.21e-11	8.4e-09	0.23	0.2	Intelligence (multi-trait analysis);	chr12:57895295	chr12:57967058~57968399:+
BRCA	cis	rs7688540	0.74	rs28784663	ENSG00000275426.1	CH17-262A2.1	6.67	4.21e-11	8.41e-09	0.27	0.2	Facial morphology (factor 6, height of vermillion lower lip);	chr4:293257	chr4:149738~150317:+
BRCA	cis	rs73173548	0.502	rs74429030	ENSG00000247828.6	TMEM161B-AS1	6.67	4.21e-11	8.41e-09	0.28	0.2	Macular telangiectasia type 2;	chr5:88474689	chr5:88268895~88436685:+
BRCA	cis	rs9638182	0.778	rs35332062	ENSG00000274080.1	CTA-315H11.2	6.67	4.21e-11	8.41e-09	0.41	0.2	Triglycerides;	chr7:73597712	chr7:73609262~73611502:-
BRCA	cis	rs9638182	0.614	rs79624003	ENSG00000274080.1	CTA-315H11.2	6.67	4.21e-11	8.41e-09	0.41	0.2	Triglycerides;	chr7:73598455	chr7:73609262~73611502:-
BRCA	cis	rs7487075	0.78	rs1873793	ENSG00000257261.4	RP11-96H19.1	-6.67	4.23e-11	8.44e-09	-0.21	-0.2	Itch intensity from mosquito bite;	chr12:46367541	chr12:46383679~46876159:+
BRCA	cis	rs2243480	1	rs313820	ENSG00000230295.1	RP11-458F8.2	-6.67	4.23e-11	8.44e-09	-0.27	-0.2	Diabetic kidney disease;	chr7:66109479	chr7:66880708~66882981:+
BRCA	cis	rs957448	1	rs12678305	ENSG00000253175.1	RP11-267M23.6	6.67	4.23e-11	8.44e-09	0.26	0.2	Nonsyndromic cleft lip with cleft palate;	chr8:94508911	chr8:94565036~94565715:+
BRCA	cis	rs4763879	0.634	rs917913	ENSG00000214776.8	RP11-726G1.1	-6.67	4.23e-11	8.44e-09	-0.22	-0.2	Type 1 diabetes;	chr12:9707040	chr12:9467552~9576275:+
BRCA	cis	rs2243480	1	rs160652	ENSG00000229886.1	RP5-1132H15.3	6.67	4.23e-11	8.45e-09	0.38	0.2	Diabetic kidney disease;	chr7:66073444	chr7:66025126~66031544:-
BRCA	cis	rs10899021	0.92	rs76121309	ENSG00000279353.1	RP11-864N7.4	6.67	4.24e-11	8.46e-09	0.46	0.2	Response to metformin (IC50);	chr11:74632876	chr11:74698231~74699658:-
BRCA	cis	rs7976269	0.609	rs11050010	ENSG00000257176.2	RP11-996F15.2	-6.67	4.24e-11	8.47e-09	-0.24	-0.2	Male-pattern baldness;	chr12:29061952	chr12:29280418~29317848:-
BRCA	cis	rs7976269	0.609	rs2196480	ENSG00000257176.2	RP11-996F15.2	-6.67	4.24e-11	8.47e-09	-0.24	-0.2	Male-pattern baldness;	chr12:29062850	chr12:29280418~29317848:-
BRCA	cis	rs7976269	0.537	rs10743642	ENSG00000257176.2	RP11-996F15.2	-6.67	4.24e-11	8.47e-09	-0.24	-0.2	Male-pattern baldness;	chr12:29063557	chr12:29280418~29317848:-
BRCA	cis	rs7976269	0.609	rs10771472	ENSG00000257176.2	RP11-996F15.2	-6.67	4.24e-11	8.47e-09	-0.24	-0.2	Male-pattern baldness;	chr12:29063930	chr12:29280418~29317848:-
BRCA	cis	rs13113518	0.812	rs12500601	ENSG00000223305.1	RN7SKP30	6.67	4.25e-11	8.47e-09	0.25	0.2	Height;	chr4:55451489	chr4:55540502~55540835:-
BRCA	cis	rs4372836	1	rs11688129	ENSG00000226833.4	AC097724.3	-6.67	4.25e-11	8.49e-09	-0.25	-0.2	Body mass index;	chr2:28729715	chr2:28708953~28736205:-
BRCA	cis	rs516805	0.52	rs9375150	ENSG00000279114.1	RP3-425C14.5	6.67	4.27e-11	8.52e-09	0.19	0.2	Lymphocyte counts;	chr6:122566410	chr6:122471923~122484161:+
BRCA	cis	rs1707322	1	rs12124847	ENSG00000281133.1	AL355480.3	-6.67	4.28e-11	8.53e-09	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45915178	chr1:45580892~45580996:-
BRCA	cis	rs7945705	0.875	rs11042059	ENSG00000254860.4	TMEM9B-AS1	-6.67	4.28e-11	8.53e-09	-0.2	-0.2	Hemoglobin concentration;	chr11:8773533	chr11:8964675~8977527:+
BRCA	cis	rs1707322	1	rs1612419	ENSG00000281133.1	AL355480.3	6.67	4.28e-11	8.53e-09	0.26	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46081273	chr1:45580892~45580996:-
BRCA	cis	rs17711722	0.701	rs55773927	ENSG00000237310.1	GS1-124K5.4	6.66	4.29e-11	8.56e-09	0.21	0.2	Calcium levels;	chr7:65872915	chr7:66493706~66495474:+
BRCA	cis	rs853679	0.517	rs9393884	ENSG00000219392.1	RP1-265C24.5	-6.66	4.29e-11	8.56e-09	-0.3	-0.2	Depression;	chr6:28079011	chr6:28115628~28116551:+
BRCA	cis	rs67981189	0.896	rs7146932	ENSG00000269927.1	RP6-91H8.3	6.66	4.29e-11	8.56e-09	0.25	0.2	Schizophrenia;	chr14:71010328	chr14:71141125~71143253:-
BRCA	cis	rs16846053	0.515	rs4001644	ENSG00000227403.1	AC009299.3	-6.66	4.3e-11	8.58e-09	-0.33	-0.2	Blood osmolality (transformed sodium);	chr2:161542357	chr2:161244739~161249050:+
BRCA	cis	rs853679	0.517	rs12174753	ENSG00000219392.1	RP1-265C24.5	-6.66	4.3e-11	8.58e-09	-0.3	-0.2	Depression;	chr6:28074687	chr6:28115628~28116551:+
BRCA	cis	rs7665090	1	rs13112557	ENSG00000246560.2	RP11-10L12.4	6.66	4.3e-11	8.59e-09	0.21	0.2	Primary biliary cholangitis;	chr4:102631096	chr4:102828055~102844075:+
BRCA	cis	rs6840360	0.681	rs9968292	ENSG00000270265.1	RP11-731D1.4	-6.66	4.3e-11	8.59e-09	-0.23	-0.2	Intelligence (multi-trait analysis);	chr4:151376216	chr4:151333775~151353224:-
BRCA	cis	rs7923609	0.841	rs10761786	ENSG00000232075.1	MRPL35P2	-6.66	4.31e-11	8.6e-09	-0.25	-0.2	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63576447	chr10:63634317~63634827:-
BRCA	cis	rs6840360	0.642	rs10857260	ENSG00000270265.1	RP11-731D1.4	-6.66	4.32e-11	8.61e-09	-0.23	-0.2	Intelligence (multi-trait analysis);	chr4:151502904	chr4:151333775~151353224:-
BRCA	cis	rs7131987	0.621	rs11050181	ENSG00000257176.2	RP11-996F15.2	-6.66	4.33e-11	8.63e-09	-0.25	-0.2	QT interval;	chr12:29314736	chr12:29280418~29317848:-
BRCA	cis	rs172166	0.694	rs203893	ENSG00000216901.1	AL022393.7	6.66	4.33e-11	8.63e-09	0.26	0.2	Cardiac Troponin-T levels;	chr6:28094288	chr6:28176188~28176674:+
BRCA	cis	rs853679	0.607	rs67998226	ENSG00000220721.1	OR1F12	6.66	4.33e-11	8.64e-09	0.46	0.2	Depression;	chr6:28270281	chr6:28073316~28074233:+
BRCA	cis	rs911555	0.723	rs7144010	ENSG00000244691.1	RPL10AP1	6.66	4.34e-11	8.65e-09	0.26	0.2	Intelligence (multi-trait analysis);	chr14:103403532	chr14:103412119~103412761:-
BRCA	cis	rs17253792	0.822	rs10142497	ENSG00000186615.9	KTN1-AS1	6.66	4.34e-11	8.65e-09	0.38	0.2	Putamen volume;	chr14:55581230	chr14:55499278~55580110:-
BRCA	cis	rs2281636	0.691	rs11190218	ENSG00000233690.1	EBAG9P1	6.66	4.35e-11	8.67e-09	0.24	0.2	Obesity-related traits;	chr10:99650305	chr10:99697407~99697949:-
BRCA	cis	rs2235642	0.507	rs2235645	ENSG00000280231.1	LA16c-380F5.3	-6.66	4.35e-11	8.67e-09	-0.29	-0.2	Coronary artery disease;	chr16:1547923	chr16:1553655~1554130:-
BRCA	cis	rs1707322	0.721	rs4415615	ENSG00000281133.1	AL355480.3	-6.66	4.35e-11	8.67e-09	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45666437	chr1:45580892~45580996:-
BRCA	cis	rs7176527	1	rs7176527	ENSG00000229212.6	RP11-561C5.4	6.66	4.35e-11	8.68e-09	0.31	0.2	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84597563	chr15:85205440~85234795:-
BRCA	cis	rs4722166	0.532	rs1880242	ENSG00000179428.2	AC073072.5	6.66	4.37e-11	8.7e-09	0.21	0.2	Lung cancer;	chr7:22719988	chr7:22725395~22727620:-
BRCA	cis	rs1440410	0.835	rs10011709	ENSG00000250326.1	RP11-284M14.1	-6.66	4.38e-11	8.73e-09	-0.22	-0.2	Ischemic stroke;	chr4:143159347	chr4:142933195~143184861:-
BRCA	cis	rs17253792	0.822	rs80328469	ENSG00000186615.9	KTN1-AS1	-6.66	4.38e-11	8.73e-09	-0.41	-0.2	Putamen volume;	chr14:55600983	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs77420254	ENSG00000186615.9	KTN1-AS1	-6.66	4.38e-11	8.73e-09	-0.41	-0.2	Putamen volume;	chr14:55602928	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs78395034	ENSG00000186615.9	KTN1-AS1	-6.66	4.38e-11	8.73e-09	-0.41	-0.2	Putamen volume;	chr14:55603065	chr14:55499278~55580110:-
BRCA	cis	rs67981189	0.896	rs17108925	ENSG00000269927.1	RP6-91H8.3	6.66	4.39e-11	8.75e-09	0.25	0.2	Schizophrenia;	chr14:71033010	chr14:71141125~71143253:-
BRCA	cis	rs67981189	0.896	rs28374308	ENSG00000269927.1	RP6-91H8.3	6.66	4.39e-11	8.75e-09	0.25	0.2	Schizophrenia;	chr14:71035040	chr14:71141125~71143253:-
BRCA	cis	rs67981189	0.896	rs8016506	ENSG00000269927.1	RP6-91H8.3	6.66	4.39e-11	8.75e-09	0.25	0.2	Schizophrenia;	chr14:71039600	chr14:71141125~71143253:-
BRCA	cis	rs67981189	0.858	rs35631530	ENSG00000269927.1	RP6-91H8.3	6.66	4.39e-11	8.75e-09	0.25	0.2	Schizophrenia;	chr14:71041312	chr14:71141125~71143253:-
BRCA	cis	rs957448	1	rs16916881	ENSG00000253175.1	RP11-267M23.6	6.66	4.4e-11	8.76e-09	0.26	0.2	Nonsyndromic cleft lip with cleft palate;	chr8:94554042	chr8:94565036~94565715:+
BRCA	cis	rs1707322	0.963	rs6429581	ENSG00000281133.1	AL355480.3	-6.66	4.4e-11	8.76e-09	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45853424	chr1:45580892~45580996:-
BRCA	cis	rs875971	0.929	rs34406470	ENSG00000232559.3	GS1-124K5.12	6.66	4.4e-11	8.76e-09	0.24	0.2	Aortic root size;	chr7:66464969	chr7:66554588~66576923:-
BRCA	cis	rs11671005	0.61	rs3794966	ENSG00000252334.1	RNU6-1337P	6.66	4.4e-11	8.77e-09	0.32	0.2	Mean platelet volume;	chr19:58557629	chr19:58483749~58483843:-
BRCA	cis	rs7587476	0.822	rs6726763	ENSG00000229267.2	AC072062.1	-6.66	4.4e-11	8.77e-09	-0.27	-0.2	Neuroblastoma;	chr2:214816856	chr2:214810229~214963274:+
BRCA	cis	rs67340775	0.748	rs13212651	ENSG00000220721.1	OR1F12	6.66	4.41e-11	8.79e-09	0.47	0.2	Lung cancer in ever smokers;	chr6:27839207	chr6:28073316~28074233:+
BRCA	cis	rs172166	0.611	rs203882	ENSG00000204709.4	LINC01556	6.66	4.41e-11	8.8e-09	0.27	0.2	Cardiac Troponin-T levels;	chr6:28110724	chr6:28943877~28944537:+
BRCA	cis	rs9307551	0.817	rs12500146	ENSG00000250334.4	LINC00989	-6.66	4.42e-11	8.8e-09	-0.27	-0.2	Refractive error;	chr4:79580002	chr4:79492416~79576460:+
BRCA	cis	rs2688608	0.592	rs7909802	ENSG00000271816.1	BMS1P4	6.66	4.43e-11	8.82e-09	0.2	0.2	Inflammatory bowel disease;	chr10:73724428	chr10:73699151~73730487:-
BRCA	cis	rs4713118	0.523	rs2179096	ENSG00000216901.1	AL022393.7	6.66	4.44e-11	8.84e-09	0.25	0.2	Parkinson's disease;	chr6:27698141	chr6:28176188~28176674:+
BRCA	cis	rs7665090	0.936	rs2866412	ENSG00000246560.2	RP11-10L12.4	6.66	4.44e-11	8.84e-09	0.21	0.2	Primary biliary cholangitis;	chr4:102633193	chr4:102828055~102844075:+
BRCA	cis	rs11098499	0.874	rs17839089	ENSG00000248280.1	RP11-33B1.2	6.66	4.44e-11	8.84e-09	0.22	0.2	Corneal astigmatism;	chr4:119189914	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.874	rs6826823	ENSG00000248280.1	RP11-33B1.2	6.66	4.44e-11	8.84e-09	0.22	0.2	Corneal astigmatism;	chr4:119190943	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.874	rs12509054	ENSG00000248280.1	RP11-33B1.2	6.66	4.44e-11	8.84e-09	0.22	0.2	Corneal astigmatism;	chr4:119193920	chr4:119440561~119450157:-
BRCA	cis	rs11009175	0.725	rs11009183	ENSG00000273038.2	RP11-479G22.8	-6.66	4.44e-11	8.84e-09	-0.33	-0.2	Depression (quantitative trait);	chr10:33017381	chr10:32887255~32889311:-
BRCA	cis	rs875971	0.545	rs73142245	ENSG00000273024.4	INTS4P2	-6.66	4.44e-11	8.85e-09	-0.26	-0.2	Aortic root size;	chr7:66226662	chr7:65647864~65715661:+
BRCA	cis	rs2732480	0.5	rs11168468	ENSG00000273765.1	RP11-370I10.11	6.66	4.45e-11	8.86e-09	0.24	0.2	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48218682	chr12:48360920~48361377:+
BRCA	cis	rs227275	0.554	rs223334	ENSG00000251288.2	RP11-10L12.2	6.66	4.46e-11	8.88e-09	0.24	0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102867054	chr4:102751401~102752641:+
BRCA	cis	rs7246657	0.943	rs13343471	ENSG00000276846.1	CTD-3220F14.3	6.66	4.46e-11	8.88e-09	0.29	0.2	Coronary artery calcification;	chr19:37441228	chr19:37314868~37315620:-
BRCA	cis	rs34929064	0.881	rs7802442	ENSG00000179428.2	AC073072.5	-6.66	4.47e-11	8.9e-09	-0.22	-0.2	Major depression and alcohol dependence;	chr7:22696827	chr7:22725395~22727620:-
BRCA	cis	rs67981189	0.896	rs2526846	ENSG00000269927.1	RP6-91H8.3	-6.66	4.47e-11	8.91e-09	-0.25	-0.2	Schizophrenia;	chr14:70957538	chr14:71141125~71143253:-
BRCA	cis	rs2688608	0.587	rs2894040	ENSG00000271816.1	BMS1P4	6.66	4.48e-11	8.91e-09	0.2	0.2	Inflammatory bowel disease;	chr10:73718401	chr10:73699151~73730487:-
BRCA	cis	rs2688608	0.592	rs3849967	ENSG00000271816.1	BMS1P4	6.66	4.48e-11	8.91e-09	0.2	0.2	Inflammatory bowel disease;	chr10:73723608	chr10:73699151~73730487:-
BRCA	cis	rs7069191	0.73	rs10994493	ENSG00000254271.1	RP11-131N11.4	6.66	4.48e-11	8.91e-09	0.36	0.2	Pediatric bone mineral density (spine);	chr10:60749542	chr10:60734342~60741828:+
BRCA	cis	rs516805	0.961	rs510283	ENSG00000279453.1	RP3-425C14.4	-6.66	4.48e-11	8.92e-09	-0.23	-0.2	Lymphocyte counts;	chr6:122451547	chr6:122436789~122439223:-
BRCA	cis	rs2836950	0.565	rs8131132	ENSG00000255568.3	BRWD1-AS2	-6.66	4.48e-11	8.93e-09	-0.19	-0.2	Menarche (age at onset);	chr21:39166330	chr21:39313935~39314962:+
BRCA	cis	rs9291683	0.609	rs12500810	ENSG00000250413.1	RP11-448G15.1	-6.66	4.49e-11	8.93e-09	-0.26	-0.2	Bone mineral density;	chr4:10029444	chr4:10006482~10009725:+
BRCA	cis	rs875971	0.893	rs62465470	ENSG00000224316.1	RP11-479O9.2	-6.66	4.49e-11	8.94e-09	-0.2	-0.2	Aortic root size;	chr7:66136231	chr7:65773620~65802067:+
BRCA	cis	rs10510102	0.872	rs7906462	ENSG00000276742.1	RP11-500G22.4	6.66	4.49e-11	8.95e-09	0.33	0.2	Breast cancer;	chr10:121948098	chr10:121956782~121957098:+
BRCA	cis	rs6840258	1	rs17752307	ENSG00000251411.1	RP11-397E7.4	-6.66	4.5e-11	8.95e-09	-0.29	-0.2	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86978133	chr4:86913266~86914817:-
BRCA	cis	rs4372836	1	rs4549034	ENSG00000226833.4	AC097724.3	6.66	4.5e-11	8.96e-09	0.25	0.2	Body mass index;	chr2:28749713	chr2:28708953~28736205:-
BRCA	cis	rs67981189	0.896	rs7157250	ENSG00000269927.1	RP6-91H8.3	6.66	4.5e-11	8.97e-09	0.25	0.2	Schizophrenia;	chr14:70991112	chr14:71141125~71143253:-
BRCA	cis	rs8005677	1	rs8006396	ENSG00000257285.4	RP11-298I3.1	6.66	4.52e-11	8.99e-09	0.22	0.2	Cognitive ability (multi-trait analysis);	chr14:22911641	chr14:22929609~22955562:+
BRCA	cis	rs8005677	1	rs4982706	ENSG00000257285.4	RP11-298I3.1	6.66	4.52e-11	8.99e-09	0.22	0.2	Cognitive ability (multi-trait analysis);	chr14:22912488	chr14:22929609~22955562:+
BRCA	cis	rs13315649	0.724	rs7624610	ENSG00000242551.2	POU5F1P6	-6.66	4.52e-11	8.99e-09	-0.29	-0.2	Sum eosinophil basophil counts;	chr3:128698450	chr3:128674735~128677005:-
BRCA	cis	rs1823913	0.599	rs17412094	ENSG00000280083.1	RP11-317J9.1	-6.66	4.52e-11	9e-09	-0.23	-0.2	Obesity-related traits;	chr2:191284202	chr2:191154118~191156070:-
BRCA	cis	rs2243480	0.803	rs13224048	ENSG00000229886.1	RP5-1132H15.3	6.66	4.53e-11	9e-09	0.36	0.2	Diabetic kidney disease;	chr7:66528779	chr7:66025126~66031544:-
BRCA	cis	rs2842992	0.83	rs2025190	ENSG00000237927.1	RP3-393E18.2	-6.66	4.53e-11	9.02e-09	-0.29	-0.2	Age-related macular degeneration (geographic atrophy);	chr6:159717209	chr6:159586955~159589169:-
BRCA	cis	rs11024102	1	rs10766368	ENSG00000184669.7	OR7E14P	-6.66	4.53e-11	9.02e-09	-0.32	-0.2	Glaucoma (primary angle closure);	chr11:16993335	chr11:17013998~17053024:+
BRCA	cis	rs1322639	0.657	rs12203887	ENSG00000261039.2	RP11-417E7.2	-6.66	4.54e-11	9.02e-09	-0.27	-0.2	Pulse pressure;	chr6:169172157	chr6:169175304~169182740:-
BRCA	cis	rs1440410	0.798	rs7663553	ENSG00000250326.1	RP11-284M14.1	-6.66	4.54e-11	9.03e-09	-0.22	-0.2	Ischemic stroke;	chr4:143127883	chr4:142933195~143184861:-
BRCA	cis	rs1440410	0.835	rs7663762	ENSG00000250326.1	RP11-284M14.1	-6.66	4.54e-11	9.03e-09	-0.22	-0.2	Ischemic stroke;	chr4:143128019	chr4:142933195~143184861:-
BRCA	cis	rs1440410	0.835	rs7670624	ENSG00000250326.1	RP11-284M14.1	-6.66	4.54e-11	9.03e-09	-0.22	-0.2	Ischemic stroke;	chr4:143129092	chr4:142933195~143184861:-
BRCA	cis	rs1440410	0.835	rs7665674	ENSG00000250326.1	RP11-284M14.1	-6.66	4.54e-11	9.03e-09	-0.22	-0.2	Ischemic stroke;	chr4:143129181	chr4:142933195~143184861:-
BRCA	cis	rs17253792	0.822	rs8013714	ENSG00000186615.9	KTN1-AS1	-6.66	4.54e-11	9.03e-09	-0.36	-0.2	Putamen volume;	chr14:55705568	chr14:55499278~55580110:-
BRCA	cis	rs853679	0.517	rs7755442	ENSG00000219392.1	RP1-265C24.5	-6.66	4.54e-11	9.03e-09	-0.3	-0.2	Depression;	chr6:28071237	chr6:28115628~28116551:+
BRCA	cis	rs853679	0.517	rs55747925	ENSG00000219392.1	RP1-265C24.5	-6.66	4.54e-11	9.03e-09	-0.3	-0.2	Depression;	chr6:28076559	chr6:28115628~28116551:+
BRCA	cis	rs853679	0.517	rs34716816	ENSG00000219392.1	RP1-265C24.5	-6.66	4.54e-11	9.03e-09	-0.3	-0.2	Depression;	chr6:28078391	chr6:28115628~28116551:+
BRCA	cis	rs853679	0.517	rs9380049	ENSG00000219392.1	RP1-265C24.5	-6.66	4.54e-11	9.03e-09	-0.3	-0.2	Depression;	chr6:28080757	chr6:28115628~28116551:+
BRCA	cis	rs853679	0.517	rs9380050	ENSG00000219392.1	RP1-265C24.5	-6.66	4.54e-11	9.03e-09	-0.3	-0.2	Depression;	chr6:28080760	chr6:28115628~28116551:+
BRCA	cis	rs875971	0.54	rs781152	ENSG00000237310.1	GS1-124K5.4	6.66	4.54e-11	9.04e-09	0.21	0.2	Aortic root size;	chr7:66014585	chr7:66493706~66495474:+
BRCA	cis	rs17711722	0.727	rs781151	ENSG00000237310.1	GS1-124K5.4	6.66	4.54e-11	9.04e-09	0.21	0.2	Calcium levels;	chr7:66014891	chr7:66493706~66495474:+
BRCA	cis	rs2243480	1	rs1499613	ENSG00000232546.1	RP11-458F8.1	6.66	4.55e-11	9.04e-09	0.27	0.2	Diabetic kidney disease;	chr7:66265873	chr7:66848496~66858136:+
BRCA	cis	rs2842992	0.83	rs1535475	ENSG00000237927.1	RP3-393E18.2	-6.66	4.55e-11	9.04e-09	-0.29	-0.2	Age-related macular degeneration (geographic atrophy);	chr6:159727903	chr6:159586955~159589169:-
BRCA	cis	rs5015933	0.815	rs13291655	ENSG00000232630.1	PRPS1P2	-6.66	4.55e-11	9.05e-09	-0.19	-0.2	Body mass index;	chr9:125348274	chr9:125150653~125151589:+
BRCA	cis	rs875971	0.502	rs6460311	ENSG00000224316.1	RP11-479O9.2	-6.66	4.55e-11	9.05e-09	-0.23	-0.2	Aortic root size;	chr7:66646886	chr7:65773620~65802067:+
BRCA	cis	rs1707322	1	rs4134387	ENSG00000281133.1	AL355480.3	-6.66	4.56e-11	9.06e-09	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45929486	chr1:45580892~45580996:-
BRCA	cis	rs6142102	0.812	rs6120440	ENSG00000275784.1	RP5-1125A11.6	6.66	4.56e-11	9.07e-09	0.25	0.2	Skin pigmentation;	chr20:33929779	chr20:33989480~33991818:-
BRCA	cis	rs8114671	0.967	rs4911476	ENSG00000269202.1	RP4-614O4.12	6.66	4.56e-11	9.07e-09	0.21	0.2	Height;	chr20:35192965	chr20:35201747~35203288:-
BRCA	cis	rs5758511	0.689	rs56906457	ENSG00000205702.9	CYP2D7	6.66	4.56e-11	9.08e-09	0.24	0.2	Birth weight;	chr22:42232329	chr22:42140203~42144577:-
BRCA	cis	rs1020064	0.583	rs2576775	ENSG00000235319.1	AC012360.4	-6.66	4.57e-11	9.08e-09	-0.27	-0.2	AIDS;	chr2:105356755	chr2:105324210~105330529:+
BRCA	cis	rs67981189	0.896	rs2526874	ENSG00000269927.1	RP6-91H8.3	-6.65	4.58e-11	9.1e-09	-0.25	-0.2	Schizophrenia;	chr14:70914502	chr14:71141125~71143253:-
BRCA	cis	rs10740039	0.81	rs10761528	ENSG00000254271.1	RP11-131N11.4	6.65	4.58e-11	9.1e-09	0.27	0.2	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60607902	chr10:60734342~60741828:+
BRCA	cis	rs7617773	0.78	rs34523942	ENSG00000228638.1	FCF1P2	-6.65	4.59e-11	9.12e-09	-0.22	-0.2	Coronary artery disease;	chr3:48301179	chr3:48290793~48291375:-
BRCA	cis	rs34779708	0.931	rs66887762	ENSG00000271335.4	RP11-324I22.4	6.65	4.59e-11	9.12e-09	0.22	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35041649	chr10:35314552~35336401:-
BRCA	cis	rs172166	0.694	rs203876	ENSG00000216901.1	AL022393.7	6.65	4.59e-11	9.12e-09	0.26	0.2	Cardiac Troponin-T levels;	chr6:28078895	chr6:28176188~28176674:+
BRCA	cis	rs79040073	0.607	rs10519227	ENSG00000259531.2	RP11-295H24.3	6.65	4.59e-11	9.12e-09	0.3	0.2	Lung cancer in ever smokers;	chr15:49454167	chr15:49365124~49366685:-
BRCA	cis	rs67981189	0.784	rs58984901	ENSG00000269927.1	RP6-91H8.3	6.65	4.6e-11	9.14e-09	0.25	0.2	Schizophrenia;	chr14:71085271	chr14:71141125~71143253:-
BRCA	cis	rs11976180	1	rs2951308	ENSG00000204959.4	ARHGEF34P	-6.65	4.6e-11	9.14e-09	-0.25	-0.2	Obesity-related traits;	chr7:144070056	chr7:144272445~144286966:-
BRCA	cis	rs8114671	0.935	rs6058198	ENSG00000269202.1	RP4-614O4.12	-6.65	4.6e-11	9.15e-09	-0.21	-0.2	Height;	chr20:35160450	chr20:35201747~35203288:-
BRCA	cis	rs67340775	0.541	rs200979	ENSG00000220721.1	OR1F12	6.65	4.61e-11	9.15e-09	0.3	0.2	Lung cancer in ever smokers;	chr6:27884579	chr6:28073316~28074233:+
BRCA	cis	rs897984	0.542	rs35713203	ENSG00000260911.2	RP11-196G11.2	6.65	4.61e-11	9.16e-09	0.19	0.2	Dementia with Lewy bodies;	chr16:31079086	chr16:31043150~31049868:+
BRCA	cis	rs2243480	1	rs316330	ENSG00000229886.1	RP5-1132H15.3	6.65	4.61e-11	9.16e-09	0.36	0.2	Diabetic kidney disease;	chr7:66140385	chr7:66025126~66031544:-
BRCA	cis	rs11742741	0.676	rs62347896	ENSG00000248874.4	C5orf17	-6.65	4.62e-11	9.18e-09	-0.25	-0.2	Educational attainment;	chr5:24204990	chr5:23951348~24178263:+
BRCA	cis	rs2243480	0.908	rs313822	ENSG00000232546.1	RP11-458F8.1	-6.65	4.63e-11	9.19e-09	-0.27	-0.2	Diabetic kidney disease;	chr7:66108952	chr7:66848496~66858136:+
BRCA	cis	rs11159086	1	rs72730186	ENSG00000259005.1	RP3-449M8.6	6.65	4.63e-11	9.19e-09	0.39	0.2	Advanced glycation end-product levels;	chr14:74475610	chr14:74474007~74474864:-
BRCA	cis	rs13068223	1	rs13095806	ENSG00000243926.1	TIPARP-AS1	-6.65	4.63e-11	9.2e-09	-0.21	-0.2	Age-related hearing impairment (SNP x SNP interaction);	chr3:156738271	chr3:156671862~156674378:-
BRCA	cis	rs8086028	1	rs8086028	ENSG00000264714.1	RP11-21G15.1	6.65	4.63e-11	9.21e-09	0.23	0.2	Venous thromboembolism (SNP x SNP interaction);	chr18:10737781	chr18:10724619~10728539:+
BRCA	cis	rs13113518	0.812	rs13116035	ENSG00000223305.1	RN7SKP30	6.65	4.64e-11	9.21e-09	0.25	0.2	Height;	chr4:55561218	chr4:55540502~55540835:-
BRCA	cis	rs1862618	0.853	rs33322	ENSG00000271828.1	CTD-2310F14.1	6.65	4.65e-11	9.23e-09	0.28	0.2	Initial pursuit acceleration;	chr5:56879399	chr5:56927874~56929573:+
BRCA	cis	rs6142102	0.961	rs6088355	ENSG00000275784.1	RP5-1125A11.6	-6.65	4.65e-11	9.25e-09	-0.25	-0.2	Skin pigmentation;	chr20:33958081	chr20:33989480~33991818:-
BRCA	cis	rs2836950	0.565	rs4816617	ENSG00000255568.3	BRWD1-AS2	-6.65	4.66e-11	9.26e-09	-0.19	-0.2	Menarche (age at onset);	chr21:39168764	chr21:39313935~39314962:+
BRCA	cis	rs2412819	0.571	rs2729494	ENSG00000205771.5	CATSPER2P1	6.65	4.68e-11	9.29e-09	0.29	0.2	Lung cancer;	chr15:43837395	chr15:43726918~43747094:-
BRCA	cis	rs8031584	0.872	rs11634761	ENSG00000260382.1	RP11-540B6.2	6.65	4.68e-11	9.29e-09	0.25	0.2	Huntington's disease progression;	chr15:30950970	chr15:30882267~30883231:-
BRCA	cis	rs2638953	0.924	rs1551987	ENSG00000247934.4	RP11-967K21.1	-6.65	4.69e-11	9.32e-09	-0.26	-0.2	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28178761	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.924	rs1551986	ENSG00000247934.4	RP11-967K21.1	-6.65	4.69e-11	9.32e-09	-0.26	-0.2	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28178778	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.924	rs2078017	ENSG00000247934.4	RP11-967K21.1	-6.65	4.69e-11	9.32e-09	-0.26	-0.2	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28180175	chr12:28163298~28190738:-
BRCA	cis	rs13217239	0.646	rs12209886	ENSG00000241549.7	GUSBP2	6.65	4.7e-11	9.32e-09	0.22	0.2	Schizophrenia;	chr6:27016978	chr6:26871484~26956554:-
BRCA	cis	rs6940638	0.531	rs12211984	ENSG00000241549.7	GUSBP2	6.65	4.7e-11	9.32e-09	0.22	0.2	Intelligence (multi-trait analysis);	chr6:27018275	chr6:26871484~26956554:-
BRCA	cis	rs17214007	0.877	rs4541094	ENSG00000263335.1	AF001548.5	-6.65	4.7e-11	9.33e-09	-0.3	-0.2	Cognitive function;	chr16:15776878	chr16:15726674~15732993:+
BRCA	cis	rs2976388	0.609	rs2717605	ENSG00000253741.1	CTD-2292P10.4	-6.65	4.7e-11	9.33e-09	-0.23	-0.2	Urinary tract infection frequency;	chr8:142719597	chr8:142702252~142726973:-
BRCA	cis	rs11168351	0.864	rs10875743	ENSG00000240399.1	RP1-228P16.1	-6.65	4.7e-11	9.33e-09	-0.23	-0.2	Bipolar disorder and schizophrenia;	chr12:48104630	chr12:48054813~48055591:-
BRCA	cis	rs11098499	0.863	rs2291185	ENSG00000249244.1	RP11-548H18.2	6.65	4.71e-11	9.35e-09	0.24	0.2	Corneal astigmatism;	chr4:119513678	chr4:119391831~119395335:-
BRCA	cis	rs10129255	0.957	rs6576233	ENSG00000224373.3	IGHV4-59	6.65	4.71e-11	9.36e-09	0.12	0.2	Kawasaki disease;	chr14:106787239	chr14:106627249~106627825:-
BRCA	cis	rs6840360	0.582	rs2709823	ENSG00000270265.1	RP11-731D1.4	-6.65	4.72e-11	9.36e-09	-0.23	-0.2	Intelligence (multi-trait analysis);	chr4:151419294	chr4:151333775~151353224:-
BRCA	cis	rs1552244	0.882	rs13066757	ENSG00000180385.7	EMC3-AS1	6.65	4.72e-11	9.36e-09	0.25	0.2	Alzheimer's disease;	chr3:10003346	chr3:9986893~10006990:+
BRCA	cis	rs853679	0.607	rs67101035	ENSG00000220721.1	OR1F12	6.65	4.72e-11	9.37e-09	0.47	0.2	Depression;	chr6:27831109	chr6:28073316~28074233:+
BRCA	cis	rs4763879	0.634	rs7974396	ENSG00000214776.8	RP11-726G1.1	-6.65	4.72e-11	9.37e-09	-0.22	-0.2	Type 1 diabetes;	chr12:9708101	chr12:9467552~9576275:+
BRCA	cis	rs228614	0.51	rs223438	ENSG00000251288.2	RP11-10L12.2	6.65	4.72e-11	9.37e-09	0.24	0.2	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102798584	chr4:102751401~102752641:+
BRCA	cis	rs10129255	0.789	rs61997796	ENSG00000224373.3	IGHV4-59	6.65	4.73e-11	9.38e-09	0.13	0.2	Kawasaki disease;	chr14:106813798	chr14:106627249~106627825:-
BRCA	cis	rs2348418	0.966	rs11049699	ENSG00000247934.4	RP11-967K21.1	6.65	4.74e-11	9.4e-09	0.23	0.2	Lung function (FEV1);Lung function (FVC);	chr12:28535487	chr12:28163298~28190738:-
BRCA	cis	rs13178541	0.745	rs3963615	ENSG00000250378.1	RP11-119J18.1	-6.65	4.74e-11	9.41e-09	-0.27	-0.2	IgG glycosylation;	chr5:135750292	chr5:135812667~135826582:+
BRCA	cis	rs4722166	0.532	rs4719711	ENSG00000179428.2	AC073072.5	6.65	4.74e-11	9.41e-09	0.21	0.2	Lung cancer;	chr7:22716069	chr7:22725395~22727620:-
BRCA	cis	rs34779708	0.931	rs3740083	ENSG00000271335.4	RP11-324I22.4	6.65	4.75e-11	9.43e-09	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35031455	chr10:35314552~35336401:-
BRCA	cis	rs11976180	1	rs2371244	ENSG00000204959.4	ARHGEF34P	6.65	4.75e-11	9.43e-09	0.25	0.2	Obesity-related traits;	chr7:144060518	chr7:144272445~144286966:-
BRCA	cis	rs58873874	1	rs11740562	ENSG00000251405.2	CTB-109A12.1	-6.65	4.76e-11	9.44e-09	-0.45	-0.2	Bipolar disorder (body mass index interaction);	chr5:157515277	chr5:157362615~157460078:-
BRCA	cis	rs7615952	0.599	rs66532274	ENSG00000250012.1	RP11-124N2.1	-6.65	4.76e-11	9.44e-09	-0.26	-0.2	Blood pressure (smoking interaction);	chr3:126013002	chr3:126084220~126095349:+
BRCA	cis	rs16846053	0.515	rs1567981	ENSG00000227403.1	AC009299.3	-6.65	4.77e-11	9.46e-09	-0.35	-0.2	Blood osmolality (transformed sodium);	chr2:161692589	chr2:161244739~161249050:+
BRCA	cis	rs875971	0.862	rs1983372	ENSG00000224316.1	RP11-479O9.2	-6.65	4.77e-11	9.47e-09	-0.2	-0.2	Aortic root size;	chr7:66146364	chr7:65773620~65802067:+
BRCA	cis	rs8005677	1	rs4981446	ENSG00000257285.4	RP11-298I3.1	6.65	4.78e-11	9.48e-09	0.22	0.2	Cognitive ability (multi-trait analysis);	chr14:22912204	chr14:22929609~22955562:+
BRCA	cis	rs17253792	0.822	rs13379343	ENSG00000186615.9	KTN1-AS1	-6.65	4.78e-11	9.49e-09	-0.38	-0.2	Putamen volume;	chr14:55583487	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs13379340	ENSG00000186615.9	KTN1-AS1	-6.65	4.78e-11	9.49e-09	-0.38	-0.2	Putamen volume;	chr14:55583628	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs13379342	ENSG00000186615.9	KTN1-AS1	-6.65	4.78e-11	9.49e-09	-0.38	-0.2	Putamen volume;	chr14:55583734	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs13379353	ENSG00000186615.9	KTN1-AS1	-6.65	4.78e-11	9.49e-09	-0.38	-0.2	Putamen volume;	chr14:55583760	chr14:55499278~55580110:-
BRCA	cis	rs2243480	1	rs34970380	ENSG00000228409.4	CCT6P1	6.65	4.78e-11	9.49e-09	0.28	0.2	Diabetic kidney disease;	chr7:65966506	chr7:65751142~65763354:+
BRCA	cis	rs11098499	0.874	rs10022508	ENSG00000248280.1	RP11-33B1.2	6.65	4.79e-11	9.5e-09	0.22	0.2	Corneal astigmatism;	chr4:119194073	chr4:119440561~119450157:-
BRCA	cis	rs875971	0.965	rs10267430	ENSG00000224316.1	RP11-479O9.2	-6.65	4.79e-11	9.5e-09	-0.2	-0.2	Aortic root size;	chr7:66278036	chr7:65773620~65802067:+
BRCA	cis	rs6142102	0.961	rs6059587	ENSG00000275784.1	RP5-1125A11.6	-6.65	4.79e-11	9.51e-09	-0.25	-0.2	Skin pigmentation;	chr20:33955120	chr20:33989480~33991818:-
BRCA	cis	rs34779708	0.931	rs7923172	ENSG00000271335.4	RP11-324I22.4	6.65	4.81e-11	9.54e-09	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35020439	chr10:35314552~35336401:-
BRCA	cis	rs4835473	0.637	rs11932061	ENSG00000251600.4	RP11-673E1.1	6.65	4.81e-11	9.54e-09	0.23	0.2	Immature fraction of reticulocytes;	chr4:143768124	chr4:143912331~143982454:+
BRCA	cis	rs11098499	0.913	rs10006304	ENSG00000248280.1	RP11-33B1.2	6.65	4.82e-11	9.56e-09	0.22	0.2	Corneal astigmatism;	chr4:119203150	chr4:119440561~119450157:-
BRCA	cis	rs375066	0.623	rs10415344	ENSG00000267058.1	RP11-15A1.3	6.65	4.83e-11	9.57e-09	0.23	0.2	Breast cancer;	chr19:43846566	chr19:43891804~43901805:-
BRCA	cis	rs1823913	0.637	rs12992372	ENSG00000280083.1	RP11-317J9.1	-6.65	4.83e-11	9.57e-09	-0.23	-0.2	Obesity-related traits;	chr2:191289251	chr2:191154118~191156070:-
BRCA	cis	rs1707322	0.721	rs10890341	ENSG00000281133.1	AL355480.3	-6.65	4.83e-11	9.58e-09	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45681568	chr1:45580892~45580996:-
BRCA	cis	rs7617773	0.817	rs11709691	ENSG00000228638.1	FCF1P2	-6.65	4.83e-11	9.58e-09	-0.23	-0.2	Coronary artery disease;	chr3:48262179	chr3:48290793~48291375:-
BRCA	cis	rs853679	0.517	rs56310871	ENSG00000219392.1	RP1-265C24.5	-6.65	4.83e-11	9.58e-09	-0.3	-0.2	Depression;	chr6:28076704	chr6:28115628~28116551:+
BRCA	cis	rs875971	0.522	rs6960048	ENSG00000237310.1	GS1-124K5.4	6.65	4.83e-11	9.59e-09	0.21	0.2	Aortic root size;	chr7:65943052	chr7:66493706~66495474:+
BRCA	cis	rs891378	1	rs2802217	ENSG00000274245.1	RP11-357P18.2	-6.65	4.84e-11	9.59e-09	-0.29	-0.2	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207309625	chr1:207372559~207373252:+
BRCA	cis	rs7247513	0.866	rs2861405	ENSG00000230310.1	CTD-2192J16.11	-6.65	4.84e-11	9.59e-09	-0.26	-0.2	Bipolar disorder;	chr19:12611518	chr19:12552597~12553644:+
BRCA	cis	rs7976269	0.609	rs7979788	ENSG00000257176.2	RP11-996F15.2	-6.65	4.84e-11	9.6e-09	-0.24	-0.2	Male-pattern baldness;	chr12:29064827	chr12:29280418~29317848:-
BRCA	cis	rs755249	0.753	rs72663529	ENSG00000237624.1	OXCT2P1	6.65	4.85e-11	9.61e-09	0.24	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39557684	chr1:39514956~39516490:+
BRCA	cis	rs34779708	0.931	rs4934697	ENSG00000271335.4	RP11-324I22.4	6.65	4.85e-11	9.61e-09	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:34998264	chr10:35314552~35336401:-
BRCA	cis	rs7131987	0.565	rs7976227	ENSG00000275476.1	RP11-996F15.4	6.65	4.85e-11	9.62e-09	0.22	0.2	QT interval;	chr12:29264843	chr12:29277397~29277882:-
BRCA	cis	rs9291683	0.632	rs13137074	ENSG00000250413.1	RP11-448G15.1	-6.65	4.86e-11	9.63e-09	-0.27	-0.2	Bone mineral density;	chr4:10041218	chr4:10006482~10009725:+
BRCA	cis	rs9291683	0.632	rs13101785	ENSG00000250413.1	RP11-448G15.1	-6.65	4.86e-11	9.63e-09	-0.27	-0.2	Bone mineral density;	chr4:10041291	chr4:10006482~10009725:+
BRCA	cis	rs78456975	0.739	rs28913003	ENSG00000231482.2	AC141930.2	-6.65	4.86e-11	9.63e-09	-0.28	-0.2	Placebo response in major depressive disorder (% change in symptom score);	chr2:1515848	chr2:1572554~1580311:-
BRCA	cis	rs7665090	0.905	rs2866410	ENSG00000246560.2	RP11-10L12.4	6.65	4.86e-11	9.63e-09	0.21	0.2	Primary biliary cholangitis;	chr4:102633178	chr4:102828055~102844075:+
BRCA	cis	rs858239	0.508	rs10242104	ENSG00000230042.1	AK3P3	-6.65	4.86e-11	9.64e-09	-0.24	-0.2	Cerebrospinal fluid biomarker levels;	chr7:23180831	chr7:23129178~23129841:+
BRCA	cis	rs4713118	0.869	rs7773070	ENSG00000220721.1	OR1F12	6.65	4.86e-11	9.64e-09	0.25	0.2	Parkinson's disease;	chr6:27761048	chr6:28073316~28074233:+
BRCA	cis	rs3758911	0.788	rs10890680	ENSG00000255353.1	RP11-382M14.1	-6.65	4.86e-11	9.64e-09	-0.28	-0.2	Coronary artery disease;	chr11:107255139	chr11:107176286~107177530:+
BRCA	cis	rs911555	0.723	rs4906320	ENSG00000244691.1	RPL10AP1	6.65	4.87e-11	9.64e-09	0.26	0.2	Intelligence (multi-trait analysis);	chr14:103410588	chr14:103412119~103412761:-
BRCA	cis	rs13217239	0.646	rs12527111	ENSG00000241549.7	GUSBP2	6.65	4.87e-11	9.65e-09	0.22	0.2	Schizophrenia;	chr6:27038696	chr6:26871484~26956554:-
BRCA	cis	rs7131987	0.565	rs10843372	ENSG00000275476.1	RP11-996F15.4	6.65	4.87e-11	9.65e-09	0.22	0.2	QT interval;	chr12:29262863	chr12:29277397~29277882:-
BRCA	cis	rs9859260	0.71	rs41298097	ENSG00000231464.1	AC024937.4	-6.65	4.87e-11	9.66e-09	-0.26	-0.2	Mean corpuscular volume;	chr3:196052284	chr3:195996738~195998233:+
BRCA	cis	rs9859260	0.71	rs34906439	ENSG00000231464.1	AC024937.4	-6.65	4.87e-11	9.66e-09	-0.26	-0.2	Mean corpuscular volume;	chr3:196052835	chr3:195996738~195998233:+
BRCA	cis	rs9500256	0.683	rs10458024	ENSG00000215190.7	LINC00680	-6.65	4.87e-11	9.66e-09	-0.25	-0.2	Eosinophilic esophagitis (pediatric);	chr6:57997811	chr6:57946074~57961501:-
BRCA	cis	rs13217239	0.646	rs10456351	ENSG00000241549.7	GUSBP2	6.65	4.88e-11	9.66e-09	0.22	0.2	Schizophrenia;	chr6:27019013	chr6:26871484~26956554:-
BRCA	cis	rs9652601	0.879	rs8062322	ENSG00000274038.1	RP11-66H6.4	-6.64	4.88e-11	9.68e-09	-0.23	-0.2	Systemic lupus erythematosus;	chr16:10998462	chr16:11056556~11057034:+
BRCA	cis	rs2243480	1	rs1638734	ENSG00000229886.1	RP5-1132H15.3	6.64	4.89e-11	9.68e-09	0.36	0.2	Diabetic kidney disease;	chr7:66632552	chr7:66025126~66031544:-
BRCA	cis	rs1555322	0.53	rs2425044	ENSG00000261582.1	RP4-614O4.11	-6.64	4.9e-11	9.7e-09	-0.23	-0.2	Attention deficit hyperactivity disorder;	chr20:35281932	chr20:35267885~35280043:-
BRCA	cis	rs2732480	0.5	rs7966829	ENSG00000273765.1	RP11-370I10.11	6.64	4.9e-11	9.71e-09	0.24	0.2	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48221820	chr12:48360920~48361377:+
BRCA	cis	rs8002861	0.664	rs2184882	ENSG00000274001.1	RP11-5G9.5	6.64	4.9e-11	9.71e-09	0.23	0.2	Leprosy;	chr13:43876210	chr13:43877715~43878163:-
BRCA	cis	rs7665090	1	rs7677509	ENSG00000246560.2	RP11-10L12.4	6.64	4.91e-11	9.72e-09	0.21	0.2	Primary biliary cholangitis;	chr4:102628849	chr4:102828055~102844075:+
BRCA	cis	rs7665090	0.967	rs7699231	ENSG00000246560.2	RP11-10L12.4	6.64	4.91e-11	9.72e-09	0.21	0.2	Primary biliary cholangitis;	chr4:102628918	chr4:102828055~102844075:+
BRCA	cis	rs7665090	1	rs7699678	ENSG00000246560.2	RP11-10L12.4	6.64	4.91e-11	9.72e-09	0.21	0.2	Primary biliary cholangitis;	chr4:102628939	chr4:102828055~102844075:+
BRCA	cis	rs7665090	1	rs11724614	ENSG00000246560.2	RP11-10L12.4	6.64	4.91e-11	9.72e-09	0.21	0.2	Primary biliary cholangitis;	chr4:102629091	chr4:102828055~102844075:+
BRCA	cis	rs10129255	0.789	rs61997796	ENSG00000211972.2	IGHV3-66	6.64	4.91e-11	9.72e-09	0.16	0.2	Kawasaki disease;	chr14:106813798	chr14:106675017~106675544:-
BRCA	cis	rs34779708	0.897	rs4934527	ENSG00000271335.4	RP11-324I22.4	6.64	4.91e-11	9.73e-09	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:34992190	chr10:35314552~35336401:-
BRCA	cis	rs1499614	1	rs2707832	ENSG00000232546.1	RP11-458F8.1	-6.64	4.92e-11	9.74e-09	-0.26	-0.2	Gout;	chr7:66671562	chr7:66848496~66858136:+
BRCA	cis	rs7665090	1	rs6810869	ENSG00000246560.2	RP11-10L12.4	6.64	4.92e-11	9.75e-09	0.21	0.2	Primary biliary cholangitis;	chr4:102637357	chr4:102828055~102844075:+
BRCA	cis	rs1823913	0.637	rs4853574	ENSG00000280083.1	RP11-317J9.1	6.64	4.93e-11	9.76e-09	0.23	0.2	Obesity-related traits;	chr2:191296113	chr2:191154118~191156070:-
BRCA	cis	rs78456975	0.739	rs11891867	ENSG00000231482.2	AC141930.2	-6.64	4.93e-11	9.77e-09	-0.28	-0.2	Placebo response in major depressive disorder (% change in symptom score);	chr2:1514122	chr2:1572554~1580311:-
BRCA	cis	rs2842992	0.789	rs7758895	ENSG00000237927.1	RP3-393E18.2	-6.64	4.93e-11	9.77e-09	-0.29	-0.2	Age-related macular degeneration (geographic atrophy);	chr6:159772433	chr6:159586955~159589169:-
BRCA	cis	rs2842992	0.789	rs4276525	ENSG00000237927.1	RP3-393E18.2	-6.64	4.93e-11	9.77e-09	-0.29	-0.2	Age-related macular degeneration (geographic atrophy);	chr6:159772580	chr6:159586955~159589169:-
BRCA	cis	rs172166	0.694	rs203892	ENSG00000216901.1	AL022393.7	6.64	4.93e-11	9.77e-09	0.26	0.2	Cardiac Troponin-T levels;	chr6:28099418	chr6:28176188~28176674:+
BRCA	cis	rs172166	0.694	rs188105	ENSG00000216901.1	AL022393.7	6.64	4.93e-11	9.77e-09	0.26	0.2	Cardiac Troponin-T levels;	chr6:28103615	chr6:28176188~28176674:+
BRCA	cis	rs2835345	0.563	rs60511692	ENSG00000230479.1	AP000695.6	6.64	4.93e-11	9.77e-09	0.2	0.2	Pulmonary function;	chr21:36454091	chr21:36430360~36481070:+
BRCA	cis	rs7665090	1	rs735404	ENSG00000246560.2	RP11-10L12.4	6.64	4.93e-11	9.77e-09	0.21	0.2	Primary biliary cholangitis;	chr4:102632508	chr4:102828055~102844075:+
BRCA	cis	rs1552244	1	rs17032299	ENSG00000180385.7	EMC3-AS1	6.64	4.93e-11	9.77e-09	0.26	0.2	Alzheimer's disease;	chr3:10045954	chr3:9986893~10006990:+
BRCA	cis	rs78456975	1	rs6730391	ENSG00000231482.2	AC141930.2	-6.64	4.94e-11	9.77e-09	-0.29	-0.2	Placebo response in major depressive disorder (% change in symptom score);	chr2:1563066	chr2:1572554~1580311:-
BRCA	cis	rs6142102	0.961	rs6059596	ENSG00000275784.1	RP5-1125A11.6	-6.64	4.94e-11	9.78e-09	-0.25	-0.2	Skin pigmentation;	chr20:33969313	chr20:33989480~33991818:-
BRCA	cis	rs11098499	0.874	rs6822498	ENSG00000248280.1	RP11-33B1.2	6.64	4.94e-11	9.79e-09	0.22	0.2	Corneal astigmatism;	chr4:119199028	chr4:119440561~119450157:-
BRCA	cis	rs2243480	0.708	rs13242216	ENSG00000229886.1	RP5-1132H15.3	6.64	4.95e-11	9.8e-09	0.36	0.2	Diabetic kidney disease;	chr7:66433290	chr7:66025126~66031544:-
BRCA	cis	rs919433	0.783	rs805497	ENSG00000231621.1	AC013264.2	-6.64	4.95e-11	9.8e-09	-0.2	-0.2	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197357824	chr2:197197991~197199273:+
BRCA	cis	rs8005677	1	rs1956881	ENSG00000257285.4	RP11-298I3.1	6.64	4.95e-11	9.81e-09	0.22	0.2	Cognitive ability (multi-trait analysis);	chr14:22924860	chr14:22929609~22955562:+
BRCA	cis	rs853679	0.517	rs17711344	ENSG00000280107.1	AL022393.9	6.64	4.96e-11	9.82e-09	0.3	0.2	Depression;	chr6:28109824	chr6:28170845~28172521:+
BRCA	cis	rs875971	0.545	rs11770063	ENSG00000224316.1	RP11-479O9.2	6.64	4.96e-11	9.82e-09	0.23	0.2	Aortic root size;	chr7:66318029	chr7:65773620~65802067:+
BRCA	cis	rs6543140	0.964	rs4851592	ENSG00000234389.1	AC007278.3	6.64	4.96e-11	9.83e-09	0.2	0.2	Blood protein levels;	chr2:102471181	chr2:102438713~102440475:+
BRCA	cis	rs17253792	0.822	rs8013831	ENSG00000186615.9	KTN1-AS1	-6.64	4.97e-11	9.85e-09	-0.36	-0.2	Putamen volume;	chr14:55706180	chr14:55499278~55580110:-
BRCA	cis	rs7845219	0.539	rs10441538	ENSG00000253528.2	RP11-347C18.4	6.64	4.97e-11	9.85e-09	0.21	0.2	Type 2 diabetes;	chr8:94856380	chr8:94974573~94974853:-
BRCA	cis	rs875971	0.54	rs4717275	ENSG00000234585.5	CCT6P3	-6.64	4.98e-11	9.86e-09	-0.19	-0.2	Aortic root size;	chr7:65800193	chr7:65038354~65074713:+
BRCA	cis	rs11976180	1	rs4726669	ENSG00000204959.4	ARHGEF34P	6.64	4.98e-11	9.87e-09	0.25	0.2	Obesity-related traits;	chr7:144061098	chr7:144272445~144286966:-
BRCA	cis	rs6723226	0.882	rs13035097	ENSG00000276334.1	AL133243.1	-6.64	4.99e-11	9.88e-09	-0.26	-0.2	Intelligence (multi-trait analysis);	chr2:32611295	chr2:32521927~32523547:+
BRCA	cis	rs2243480	1	rs67536397	ENSG00000232546.1	RP11-458F8.1	-6.64	5.01e-11	9.91e-09	-0.27	-0.2	Diabetic kidney disease;	chr7:66482930	chr7:66848496~66858136:+
BRCA	cis	rs2243480	1	rs58669269	ENSG00000232546.1	RP11-458F8.1	-6.64	5.01e-11	9.91e-09	-0.27	-0.2	Diabetic kidney disease;	chr7:66486966	chr7:66848496~66858136:+
BRCA	cis	rs9307551	0.817	rs13146986	ENSG00000250334.4	LINC00989	-6.64	5.01e-11	9.92e-09	-0.27	-0.2	Refractive error;	chr4:79591074	chr4:79492416~79576460:+
BRCA	cis	rs12439619	1	rs12439619	ENSG00000259429.4	UBE2Q2P2	-6.64	5.02e-11	9.93e-09	-0.21	-0.2	Intelligence (multi-trait analysis);	chr15:82254605	chr15:82355142~82420075:+
BRCA	cis	rs7665090	1	rs2866413	ENSG00000246560.2	RP11-10L12.4	6.64	5.02e-11	9.94e-09	0.21	0.2	Primary biliary cholangitis;	chr4:102635920	chr4:102828055~102844075:+
BRCA	cis	rs7665090	1	rs4547797	ENSG00000246560.2	RP11-10L12.4	6.64	5.02e-11	9.94e-09	0.21	0.2	Primary biliary cholangitis;	chr4:102636035	chr4:102828055~102844075:+
BRCA	cis	rs7665090	1	rs2866414	ENSG00000246560.2	RP11-10L12.4	6.64	5.02e-11	9.94e-09	0.21	0.2	Primary biliary cholangitis;	chr4:102636062	chr4:102828055~102844075:+
BRCA	cis	rs7665090	1	rs2903283	ENSG00000246560.2	RP11-10L12.4	6.64	5.02e-11	9.94e-09	0.21	0.2	Primary biliary cholangitis;	chr4:102636596	chr4:102828055~102844075:+
BRCA	cis	rs7665090	1	rs4579121	ENSG00000246560.2	RP11-10L12.4	6.64	5.02e-11	9.94e-09	0.21	0.2	Primary biliary cholangitis;	chr4:102637012	chr4:102828055~102844075:+
BRCA	cis	rs7665090	0.934	rs6533020	ENSG00000246560.2	RP11-10L12.4	6.64	5.02e-11	9.94e-09	0.21	0.2	Primary biliary cholangitis;	chr4:102637648	chr4:102828055~102844075:+
BRCA	cis	rs7665090	0.934	rs6533021	ENSG00000246560.2	RP11-10L12.4	6.64	5.02e-11	9.94e-09	0.21	0.2	Primary biliary cholangitis;	chr4:102637696	chr4:102828055~102844075:+
BRCA	cis	rs74233809	0.901	rs7098825	ENSG00000213277.3	MARCKSL1P1	6.64	5.03e-11	9.96e-09	0.37	0.2	Birth weight;	chr10:102868477	chr10:103175554~103176094:+
BRCA	cis	rs12594515	0.967	rs11854477	ENSG00000259200.1	RP11-718O11.1	-6.64	5.03e-11	9.96e-09	-0.22	-0.2	Weight;Waist circumference;	chr15:45706147	chr15:45705078~45931069:+
BRCA	cis	rs17807185	0.676	rs4273781	ENSG00000214293.7	APTR	6.64	5.04e-11	9.96e-09	0.23	0.2	Height;	chr7:77671806	chr7:77657660~77696265:-
BRCA	cis	rs3781264	0.848	rs7897678	ENSG00000273450.1	RP11-76P2.4	6.64	5.04e-11	9.97e-09	0.26	0.2	Esophageal cancer and gastric cancer;	chr10:94300853	chr10:94314907~94315327:-
BRCA	cis	rs3781264	0.804	rs7914672	ENSG00000273450.1	RP11-76P2.4	6.64	5.04e-11	9.97e-09	0.26	0.2	Esophageal cancer and gastric cancer;	chr10:94301090	chr10:94314907~94315327:-
BRCA	cis	rs600231	0.708	rs661403	ENSG00000245532.5	NEAT1	6.64	5.04e-11	9.97e-09	0.19	0.2	Bone mineral density;	chr11:65475007	chr11:65422774~65445540:+
BRCA	cis	rs2554380	0.55	rs4572348	ENSG00000230373.7	GOLGA6L5P	-6.64	5.04e-11	9.97e-09	-0.25	-0.2	Height;	chr15:83871411	chr15:84507885~84516814:-
BRCA	cis	rs9907295	0.901	rs4796120	ENSG00000271013.1	AC015849.15	6.64	5.04e-11	9.98e-09	0.31	0.2	Fibroblast growth factor basic levels;	chr17:35873887	chr17:35912635~35918010:-
BRCA	cis	rs9840812	0.567	rs2655008	ENSG00000239213.4	NCK1-AS1	6.64	5.05e-11	9.98e-09	0.24	0.2	Fibrinogen levels;	chr3:136404933	chr3:136841726~136862054:-
BRCA	cis	rs6597981	0.675	rs4963120	ENSG00000255284.1	AP006621.5	-6.64	5.05e-11	9.98e-09	-0.18	-0.2	Breast cancer;	chr11:825777	chr11:777578~784297:+
BRCA	cis	rs9291683	0.609	rs13141233	ENSG00000250413.1	RP11-448G15.1	-6.64	5.05e-11	9.98e-09	-0.26	-0.2	Bone mineral density;	chr4:10027105	chr4:10006482~10009725:+
BRCA	cis	rs9291683	0.609	rs34709913	ENSG00000250413.1	RP11-448G15.1	-6.64	5.05e-11	9.98e-09	-0.26	-0.2	Bone mineral density;	chr4:10027331	chr4:10006482~10009725:+
BRCA	cis	rs9859260	0.744	rs557527	ENSG00000231464.1	AC024937.4	-6.64	5.05e-11	9.99e-09	-0.26	-0.2	Mean corpuscular volume;	chr3:196053838	chr3:195996738~195998233:+
BRCA	cis	rs67981189	0.806	rs2810107	ENSG00000269927.1	RP6-91H8.3	-6.64	5.05e-11	9.99e-09	-0.25	-0.2	Schizophrenia;	chr14:70954340	chr14:71141125~71143253:-
BRCA	cis	rs7665090	1	rs9996834	ENSG00000246560.2	RP11-10L12.4	6.64	5.06e-11	1e-08	0.21	0.2	Primary biliary cholangitis;	chr4:102636372	chr4:102828055~102844075:+
BRCA	cis	rs9876781	0.874	rs56298324	ENSG00000244380.1	RP11-24C3.2	-6.64	5.06e-11	1e-08	-0.23	-0.2	Longevity;	chr3:48393626	chr3:48440352~48446656:-
BRCA	cis	rs7976269	0.559	rs10843313	ENSG00000257176.2	RP11-996F15.2	-6.64	5.06e-11	1e-08	-0.25	-0.2	Male-pattern baldness;	chr12:29078317	chr12:29280418~29317848:-
BRCA	cis	rs4356203	0.543	rs214088	ENSG00000272034.1	SNORD14A	-6.64	5.07e-11	1e-08	-0.22	-0.2	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17276578	chr11:17074654~17074744:-
BRCA	cis	rs1555322	0.53	rs2275275	ENSG00000261582.1	RP4-614O4.11	-6.64	5.08e-11	1e-08	-0.22	-0.2	Attention deficit hyperactivity disorder;	chr20:35284508	chr20:35267885~35280043:-
BRCA	cis	rs9291683	0.609	rs36084205	ENSG00000250413.1	RP11-448G15.1	-6.64	5.08e-11	1e-08	-0.26	-0.2	Bone mineral density;	chr4:10027054	chr4:10006482~10009725:+
BRCA	cis	rs62355901	0.505	rs17661089	ENSG00000271828.1	CTD-2310F14.1	6.64	5.1e-11	1.01e-08	0.41	0.2	Breast cancer;	chr5:56810169	chr5:56927874~56929573:+
BRCA	cis	rs11159086	1	rs11159087	ENSG00000259005.1	RP3-449M8.6	6.64	5.1e-11	1.01e-08	0.32	0.2	Advanced glycation end-product levels;	chr14:74504671	chr14:74474007~74474864:-
BRCA	cis	rs4713118	0.513	rs149972	ENSG00000204709.4	LINC01556	6.64	5.11e-11	1.01e-08	0.27	0.2	Parkinson's disease;	chr6:28015449	chr6:28943877~28944537:+
BRCA	cis	rs4713118	0.513	rs149975	ENSG00000204709.4	LINC01556	6.64	5.11e-11	1.01e-08	0.27	0.2	Parkinson's disease;	chr6:28018562	chr6:28943877~28944537:+
BRCA	cis	rs2243480	1	rs4718333	ENSG00000230295.1	RP11-458F8.2	6.64	5.13e-11	1.01e-08	0.27	0.2	Diabetic kidney disease;	chr7:66307771	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs7792391	ENSG00000230295.1	RP11-458F8.2	6.64	5.13e-11	1.01e-08	0.27	0.2	Diabetic kidney disease;	chr7:66308442	chr7:66880708~66882981:+
BRCA	cis	rs78456975	0.943	rs7602369	ENSG00000231482.2	AC141930.2	-6.64	5.13e-11	1.01e-08	-0.29	-0.2	Placebo response in major depressive disorder (% change in symptom score);	chr2:1570982	chr2:1572554~1580311:-
BRCA	cis	rs17772222	0.682	rs8017689	ENSG00000258983.2	RP11-507K2.2	6.64	5.13e-11	1.01e-08	0.21	0.2	Coronary artery calcification;	chr14:88483442	chr14:88499334~88515502:+
BRCA	cis	rs875971	0.545	rs1796222	ENSG00000224316.1	RP11-479O9.2	-6.64	5.14e-11	1.02e-08	-0.23	-0.2	Aortic root size;	chr7:66592167	chr7:65773620~65802067:+
BRCA	cis	rs78456975	1	rs10189336	ENSG00000231482.2	AC141930.2	-6.64	5.15e-11	1.02e-08	-0.29	-0.2	Placebo response in major depressive disorder (% change in symptom score);	chr2:1554243	chr2:1572554~1580311:-
BRCA	cis	rs6543140	0.964	rs4851593	ENSG00000234389.1	AC007278.3	-6.64	5.15e-11	1.02e-08	-0.2	-0.2	Blood protein levels;	chr2:102472767	chr2:102438713~102440475:+
BRCA	cis	rs7615952	0.641	rs12491577	ENSG00000171084.14	FAM86JP	6.64	5.15e-11	1.02e-08	0.31	0.2	Blood pressure (smoking interaction);	chr3:126012288	chr3:125916620~125930024:+
BRCA	cis	rs7246657	0.943	rs10415937	ENSG00000226686.6	LINC01535	-6.64	5.15e-11	1.02e-08	-0.29	-0.2	Coronary artery calcification;	chr19:37339162	chr19:37251912~37265535:+
BRCA	cis	rs7246657	0.943	rs10414904	ENSG00000226686.6	LINC01535	-6.64	5.15e-11	1.02e-08	-0.29	-0.2	Coronary artery calcification;	chr19:37339186	chr19:37251912~37265535:+
BRCA	cis	rs13287066	0.692	rs7031032	ENSG00000227603.1	RP11-165J3.6	6.64	5.15e-11	1.02e-08	0.21	0.2	Intelligence (multi-trait analysis);	chr9:93412186	chr9:93435332~93437121:-
BRCA	cis	rs2243480	1	rs316332	ENSG00000229886.1	RP5-1132H15.3	6.64	5.16e-11	1.02e-08	0.35	0.2	Diabetic kidney disease;	chr7:66139312	chr7:66025126~66031544:-
BRCA	cis	rs919433	0.889	rs12472355	ENSG00000231621.1	AC013264.2	6.64	5.16e-11	1.02e-08	0.19	0.2	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197341116	chr2:197197991~197199273:+
BRCA	cis	rs11976180	1	rs1533267	ENSG00000204959.4	ARHGEF34P	6.64	5.16e-11	1.02e-08	0.25	0.2	Obesity-related traits;	chr7:144069347	chr7:144272445~144286966:-
BRCA	cis	rs875971	0.825	rs4587224	ENSG00000224316.1	RP11-479O9.2	-6.64	5.17e-11	1.02e-08	-0.2	-0.2	Aortic root size;	chr7:66271195	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.792	rs6971752	ENSG00000224316.1	RP11-479O9.2	-6.64	5.17e-11	1.02e-08	-0.2	-0.2	Aortic root size;	chr7:66272999	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.862	rs10950033	ENSG00000224316.1	RP11-479O9.2	-6.64	5.17e-11	1.02e-08	-0.2	-0.2	Aortic root size;	chr7:66274686	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.862	rs11760844	ENSG00000224316.1	RP11-479O9.2	-6.64	5.17e-11	1.02e-08	-0.2	-0.2	Aortic root size;	chr7:66274896	chr7:65773620~65802067:+
BRCA	cis	rs9291683	0.53	rs11723591	ENSG00000250413.1	RP11-448G15.1	-6.64	5.17e-11	1.02e-08	-0.26	-0.2	Bone mineral density;	chr4:9983774	chr4:10006482~10009725:+
BRCA	cis	rs8114671	0.967	rs6088734	ENSG00000269202.1	RP4-614O4.12	-6.64	5.17e-11	1.02e-08	-0.21	-0.2	Height;	chr20:35157243	chr20:35201747~35203288:-
BRCA	cis	rs11098499	0.818	rs55825515	ENSG00000249244.1	RP11-548H18.2	6.64	5.18e-11	1.02e-08	0.25	0.2	Corneal astigmatism;	chr4:119565247	chr4:119391831~119395335:-
BRCA	cis	rs2836950	0.501	rs35994303	ENSG00000255568.3	BRWD1-AS2	-6.64	5.18e-11	1.02e-08	-0.19	-0.2	Menarche (age at onset);	chr21:39314094	chr21:39313935~39314962:+
BRCA	cis	rs12594515	1	rs8039622	ENSG00000259200.1	RP11-718O11.1	-6.64	5.19e-11	1.02e-08	-0.22	-0.2	Weight;Waist circumference;	chr15:45694233	chr15:45705078~45931069:+
BRCA	cis	rs7246657	0.943	rs6508733	ENSG00000226686.6	LINC01535	-6.64	5.19e-11	1.02e-08	-0.29	-0.2	Coronary artery calcification;	chr19:37509646	chr19:37251912~37265535:+
BRCA	cis	rs896854	0.552	rs2515236	ENSG00000253528.2	RP11-347C18.4	-6.64	5.19e-11	1.03e-08	-0.23	-0.2	Type 2 diabetes;	chr8:94922679	chr8:94974573~94974853:-
BRCA	cis	rs875971	0.79	rs10257911	ENSG00000224316.1	RP11-479O9.2	-6.64	5.2e-11	1.03e-08	-0.21	-0.2	Aortic root size;	chr7:66278783	chr7:65773620~65802067:+
BRCA	cis	rs11098499	0.913	rs68128210	ENSG00000248280.1	RP11-33B1.2	6.64	5.2e-11	1.03e-08	0.22	0.2	Corneal astigmatism;	chr4:119216664	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.913	rs13126596	ENSG00000248280.1	RP11-33B1.2	6.64	5.2e-11	1.03e-08	0.22	0.2	Corneal astigmatism;	chr4:119219574	chr4:119440561~119450157:-
BRCA	cis	rs61160187	0.582	rs12653132	ENSG00000215032.2	GNL3LP1	6.64	5.21e-11	1.03e-08	0.25	0.2	Educational attainment (years of education);Educational attainment (college completion);	chr5:61062881	chr5:60891935~60893577:-
BRCA	cis	rs7178375	1	rs7178375	ENSG00000215302.7	CTD-3092A11.1	-6.63	5.21e-11	1.03e-08	-0.31	-0.2	Hypertriglyceridemia;	chr15:30923732	chr15:30470779~30507623:+
BRCA	cis	rs10181042	0.565	rs62150982	ENSG00000271889.1	RP11-493E12.1	-6.63	5.21e-11	1.03e-08	-0.24	-0.2	Crohn's disease;	chr2:61053540	chr2:61151433~61162105:-
BRCA	cis	rs73186030	0.764	rs2332179	ENSG00000272758.4	RP11-299J3.8	6.63	5.21e-11	1.03e-08	0.28	0.2	Serum parathyroid hormone levels;	chr3:122360583	chr3:122416207~122443180:+
BRCA	cis	rs78456975	0.527	rs11885279	ENSG00000231482.2	AC141930.2	-6.63	5.22e-11	1.03e-08	-0.27	-0.2	Placebo response in major depressive disorder (% change in symptom score);	chr2:1556861	chr2:1572554~1580311:-
BRCA	cis	rs172166	0.652	rs476167	ENSG00000204709.4	LINC01556	6.63	5.22e-11	1.03e-08	0.27	0.2	Cardiac Troponin-T levels;	chr6:28098110	chr6:28943877~28944537:+
BRCA	cis	rs12501370	1	rs2341573	ENSG00000201736.1	RNA5SP160	6.63	5.23e-11	1.03e-08	0.25	0.2	Iris color (L* coordinate);	chr4:40997603	chr4:40990154~40990273:+
BRCA	cis	rs2348418	0.868	rs12302861	ENSG00000247934.4	RP11-967K21.1	6.63	5.23e-11	1.03e-08	0.23	0.2	Lung function (FEV1);Lung function (FVC);	chr12:28516269	chr12:28163298~28190738:-
BRCA	cis	rs2060793	0.741	rs10734227	ENSG00000251991.1	RNU7-49P	6.63	5.23e-11	1.03e-08	0.22	0.2	Vitamin D levels;	chr11:14767471	chr11:14478892~14478953:+
BRCA	cis	rs11098499	0.863	rs2306456	ENSG00000249244.1	RP11-548H18.2	6.63	5.25e-11	1.04e-08	0.24	0.2	Corneal astigmatism;	chr4:119551267	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.863	rs11947234	ENSG00000249244.1	RP11-548H18.2	6.63	5.25e-11	1.04e-08	0.24	0.2	Corneal astigmatism;	chr4:119553704	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.863	rs11933966	ENSG00000249244.1	RP11-548H18.2	6.63	5.25e-11	1.04e-08	0.24	0.2	Corneal astigmatism;	chr4:119555560	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.863	rs36040693	ENSG00000249244.1	RP11-548H18.2	6.63	5.25e-11	1.04e-08	0.24	0.2	Corneal astigmatism;	chr4:119556461	chr4:119391831~119395335:-
BRCA	cis	rs34779708	0.931	rs4934721	ENSG00000271335.4	RP11-324I22.4	6.63	5.25e-11	1.04e-08	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35088787	chr10:35314552~35336401:-
BRCA	cis	rs1862618	0.853	rs866222	ENSG00000271828.1	CTD-2310F14.1	6.63	5.26e-11	1.04e-08	0.28	0.2	Initial pursuit acceleration;	chr5:56888617	chr5:56927874~56929573:+
BRCA	cis	rs1862618	0.853	rs861283	ENSG00000271828.1	CTD-2310F14.1	6.63	5.26e-11	1.04e-08	0.28	0.2	Initial pursuit acceleration;	chr5:56888783	chr5:56927874~56929573:+
BRCA	cis	rs1862618	0.802	rs252900	ENSG00000271828.1	CTD-2310F14.1	6.63	5.26e-11	1.04e-08	0.28	0.2	Initial pursuit acceleration;	chr5:56889454	chr5:56927874~56929573:+
BRCA	cis	rs2243480	0.908	rs313822	ENSG00000230295.1	RP11-458F8.2	-6.63	5.27e-11	1.04e-08	-0.27	-0.2	Diabetic kidney disease;	chr7:66108952	chr7:66880708~66882981:+
BRCA	cis	rs13126694	0.778	rs4691454	ENSG00000251429.1	RP11-597D13.7	6.63	5.27e-11	1.04e-08	0.19	0.2	Blood osmolality (transformed sodium);	chr4:158117101	chr4:158270378~158278676:+
BRCA	cis	rs7246657	0.943	rs1373991	ENSG00000226686.6	LINC01535	-6.63	5.27e-11	1.04e-08	-0.29	-0.2	Coronary artery calcification;	chr19:37348009	chr19:37251912~37265535:+
BRCA	cis	rs7246657	0.943	rs10405407	ENSG00000226686.6	LINC01535	-6.63	5.27e-11	1.04e-08	-0.29	-0.2	Coronary artery calcification;	chr19:37348262	chr19:37251912~37265535:+
BRCA	cis	rs7246657	0.943	rs12709813	ENSG00000226686.6	LINC01535	-6.63	5.27e-11	1.04e-08	-0.29	-0.2	Coronary artery calcification;	chr19:37354081	chr19:37251912~37265535:+
BRCA	cis	rs7246657	0.943	rs13345116	ENSG00000226686.6	LINC01535	-6.63	5.27e-11	1.04e-08	-0.29	-0.2	Coronary artery calcification;	chr19:37356196	chr19:37251912~37265535:+
BRCA	cis	rs7246657	0.765	rs7247259	ENSG00000226686.6	LINC01535	-6.63	5.27e-11	1.04e-08	-0.29	-0.2	Coronary artery calcification;	chr19:37360188	chr19:37251912~37265535:+
BRCA	cis	rs7246657	0.943	rs3745765	ENSG00000226686.6	LINC01535	-6.63	5.27e-11	1.04e-08	-0.29	-0.2	Coronary artery calcification;	chr19:37363333	chr19:37251912~37265535:+
BRCA	cis	rs7520050	0.902	rs7514192	ENSG00000280836.1	AL355480.1	6.63	5.28e-11	1.04e-08	0.24	0.2	Reticulocyte count;Red blood cell count;	chr1:45783305	chr1:45581219~45581321:-
BRCA	cis	rs7617773	0.851	rs7647817	ENSG00000228638.1	FCF1P2	-6.63	5.29e-11	1.04e-08	-0.23	-0.2	Coronary artery disease;	chr3:48195017	chr3:48290793~48291375:-
BRCA	cis	rs17214007	0.877	rs10852376	ENSG00000263335.1	AF001548.5	6.63	5.29e-11	1.04e-08	0.29	0.2	Cognitive function;	chr16:15778216	chr16:15726674~15732993:+
BRCA	cis	rs7976269	0.609	rs10771475	ENSG00000257176.2	RP11-996F15.2	-6.63	5.29e-11	1.04e-08	-0.24	-0.2	Male-pattern baldness;	chr12:29071077	chr12:29280418~29317848:-
BRCA	cis	rs17253792	0.822	rs8006705	ENSG00000186615.9	KTN1-AS1	-6.63	5.29e-11	1.04e-08	-0.36	-0.2	Putamen volume;	chr14:55704565	chr14:55499278~55580110:-
BRCA	cis	rs11009175	0.725	rs10827173	ENSG00000273038.2	RP11-479G22.8	-6.63	5.29e-11	1.04e-08	-0.33	-0.2	Depression (quantitative trait);	chr10:33039851	chr10:32887255~32889311:-
BRCA	cis	rs8031584	1	rs1474380	ENSG00000260382.1	RP11-540B6.2	6.63	5.3e-11	1.04e-08	0.24	0.2	Huntington's disease progression;	chr15:30977032	chr15:30882267~30883231:-
BRCA	cis	rs1707322	1	rs12097761	ENSG00000281133.1	AL355480.3	-6.63	5.3e-11	1.04e-08	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45825490	chr1:45580892~45580996:-
BRCA	cis	rs2408955	0.522	rs973398	ENSG00000240399.1	RP1-228P16.1	-6.63	5.3e-11	1.04e-08	-0.23	-0.2	Glycated hemoglobin levels;	chr12:48097265	chr12:48054813~48055591:-
BRCA	cis	rs7945705	0.776	rs11042069	ENSG00000254860.4	TMEM9B-AS1	-6.63	5.31e-11	1.05e-08	-0.2	-0.2	Hemoglobin concentration;	chr11:8795768	chr11:8964675~8977527:+
BRCA	cis	rs17253792	0.822	rs74051609	ENSG00000186615.9	KTN1-AS1	-6.63	5.32e-11	1.05e-08	-0.36	-0.2	Putamen volume;	chr14:55704414	chr14:55499278~55580110:-
BRCA	cis	rs673078	0.607	rs4767671	ENSG00000275409.1	RP11-131L12.4	-6.63	5.32e-11	1.05e-08	-0.31	-0.2	Glucose homeostasis traits;	chr12:118396038	chr12:118430147~118430699:+
BRCA	cis	rs9876781	0.933	rs6442124	ENSG00000229759.1	MRPS18AP1	6.63	5.33e-11	1.05e-08	0.23	0.2	Longevity;	chr3:48463903	chr3:48256350~48256938:-
BRCA	cis	rs1823913	0.637	rs4853577	ENSG00000280083.1	RP11-317J9.1	6.63	5.34e-11	1.05e-08	0.23	0.2	Obesity-related traits;	chr2:191297118	chr2:191154118~191156070:-
BRCA	cis	rs847577	0.609	rs6465658	ENSG00000272950.1	RP11-307C18.1	6.63	5.35e-11	1.05e-08	0.26	0.2	Breast cancer;	chr7:98187326	chr7:98322853~98323430:+
BRCA	cis	rs957448	0.561	rs4734282	ENSG00000253704.1	RP11-267M23.4	6.63	5.36e-11	1.06e-08	0.22	0.2	Nonsyndromic cleft lip with cleft palate;	chr8:94603827	chr8:94553722~94569745:+
BRCA	cis	rs227275	0.555	rs223403	ENSG00000251288.2	RP11-10L12.2	-6.63	5.36e-11	1.06e-08	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102817086	chr4:102751401~102752641:+
BRCA	cis	rs227275	0.555	rs223402	ENSG00000251288.2	RP11-10L12.2	-6.63	5.36e-11	1.06e-08	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102817198	chr4:102751401~102752641:+
BRCA	cis	rs853679	0.517	rs16893666	ENSG00000219392.1	RP1-265C24.5	6.63	5.36e-11	1.06e-08	0.3	0.2	Depression;	chr6:28086929	chr6:28115628~28116551:+
BRCA	cis	rs875971	0.545	rs6970498	ENSG00000273024.4	INTS4P2	-6.63	5.37e-11	1.06e-08	-0.26	-0.2	Aortic root size;	chr7:66275908	chr7:65647864~65715661:+
BRCA	cis	rs10515750	0.5	rs7728460	ENSG00000251405.2	CTB-109A12.1	6.63	5.37e-11	1.06e-08	0.31	0.2	Lung function (FEV1/FVC);	chr5:157286607	chr5:157362615~157460078:-
BRCA	cis	rs875971	0.502	rs1796227	ENSG00000224316.1	RP11-479O9.2	-6.63	5.38e-11	1.06e-08	-0.23	-0.2	Aortic root size;	chr7:66622032	chr7:65773620~65802067:+
BRCA	cis	rs4722166	0.598	rs4722180	ENSG00000179428.2	AC073072.5	-6.63	5.38e-11	1.06e-08	-0.21	-0.2	Lung cancer;	chr7:22765453	chr7:22725395~22727620:-
BRCA	cis	rs1555322	0.53	rs932562	ENSG00000261582.1	RP4-614O4.11	-6.63	5.38e-11	1.06e-08	-0.22	-0.2	Attention deficit hyperactivity disorder;	chr20:35283507	chr20:35267885~35280043:-
BRCA	cis	rs11089937	0.616	rs6001227	ENSG00000211639.2	IGLV4-60	6.63	5.39e-11	1.06e-08	0.2	0.2	Periodontitis (PAL4Q3);	chr22:22187099	chr22:22162199~22162681:+
BRCA	cis	rs78456975	1	rs13416881	ENSG00000231482.2	AC141930.2	-6.63	5.39e-11	1.06e-08	-0.3	-0.2	Placebo response in major depressive disorder (% change in symptom score);	chr2:1551036	chr2:1572554~1580311:-
BRCA	cis	rs7247513	0.964	rs8100964	ENSG00000230310.1	CTD-2192J16.11	-6.63	5.4e-11	1.06e-08	-0.26	-0.2	Bipolar disorder;	chr19:12609817	chr19:12552597~12553644:+
BRCA	cis	rs2243480	1	rs4149468	ENSG00000230295.1	RP11-458F8.2	-6.63	5.41e-11	1.07e-08	-0.27	-0.2	Diabetic kidney disease;	chr7:66360703	chr7:66880708~66882981:+
BRCA	cis	rs3781264	0.677	rs7100870	ENSG00000273450.1	RP11-76P2.4	6.63	5.41e-11	1.07e-08	0.28	0.2	Esophageal cancer and gastric cancer;	chr10:94363069	chr10:94314907~94315327:-
BRCA	cis	rs7520050	0.902	rs4626927	ENSG00000280836.1	AL355480.1	6.63	5.42e-11	1.07e-08	0.24	0.2	Reticulocyte count;Red blood cell count;	chr1:45782973	chr1:45581219~45581321:-
BRCA	cis	rs67981189	0.896	rs2526877	ENSG00000269927.1	RP6-91H8.3	-6.63	5.44e-11	1.07e-08	-0.25	-0.2	Schizophrenia;	chr14:70966605	chr14:71141125~71143253:-
BRCA	cis	rs7428	0.545	rs17026212	ENSG00000246575.2	AC093162.5	6.63	5.44e-11	1.07e-08	0.21	0.2	Ear protrusion;	chr2:85324573	chr2:85315041~85316529:+
BRCA	cis	rs8016982	0.674	rs6574631	ENSG00000258999.1	RP11-114N19.3	6.63	5.44e-11	1.07e-08	0.25	0.2	Schizophrenia;	chr14:81209428	chr14:81107033~81170414:-
BRCA	cis	rs9311474	0.967	rs11717383	ENSG00000243224.1	RP5-1157M23.2	-6.63	5.45e-11	1.07e-08	-0.22	-0.2	Electroencephalogram traits;	chr3:52253452	chr3:52239258~52241097:+
BRCA	cis	rs801193	0.548	rs6975044	ENSG00000232559.3	GS1-124K5.12	6.63	5.45e-11	1.07e-08	0.24	0.2	Aortic root size;	chr7:66762495	chr7:66554588~66576923:-
BRCA	cis	rs1508798	0.539	rs3798092	ENSG00000250786.1	SNHG18	-6.63	5.45e-11	1.07e-08	-0.24	-0.2	Coronary artery disease;	chr5:9541581	chr5:9546200~9550609:+
BRCA	cis	rs944990	0.597	rs4607675	ENSG00000227603.1	RP11-165J3.6	6.63	5.46e-11	1.08e-08	0.2	0.2	Body mass index;	chr9:93454127	chr9:93435332~93437121:-
BRCA	cis	rs9876781	1	rs6794875	ENSG00000229759.1	MRPS18AP1	6.63	5.47e-11	1.08e-08	0.22	0.2	Longevity;	chr3:48414217	chr3:48256350~48256938:-
BRCA	cis	rs11168351	0.864	rs12228750	ENSG00000240399.1	RP1-228P16.1	-6.63	5.47e-11	1.08e-08	-0.23	-0.2	Bipolar disorder and schizophrenia;	chr12:48103214	chr12:48054813~48055591:-
BRCA	cis	rs9992667	0.955	rs9998440	ENSG00000231160.8	KLF3-AS1	-6.63	5.48e-11	1.08e-08	-0.24	-0.2	Eosinophil percentage of granulocytes;	chr4:38606180	chr4:38612701~38664883:-
BRCA	cis	rs17213965	0.925	rs62030569	ENSG00000260872.1	RP11-680G24.5	-6.63	5.48e-11	1.08e-08	-0.28	-0.2	Waist-hip ratio;	chr16:15786892	chr16:15018106~15020488:-
BRCA	cis	rs3747113	1	rs9624447	ENSG00000128262.7	POM121L9P	-6.63	5.49e-11	1.08e-08	-0.25	-0.2	Gut microbiome composition (summer);	chr22:24285587	chr22:24251828~24265525:+
BRCA	cis	rs9876781	1	rs2362452	ENSG00000229759.1	MRPS18AP1	-6.63	5.5e-11	1.08e-08	-0.22	-0.2	Longevity;	chr3:48376724	chr3:48256350~48256938:-
BRCA	cis	rs7911264	0.967	rs2497318	ENSG00000236493.2	EIF2S2P3	-6.63	5.5e-11	1.08e-08	-0.27	-0.2	Inflammatory bowel disease;	chr10:92672243	chr10:92668745~92669743:-
BRCA	cis	rs867371	0.929	rs1501371	ENSG00000259429.4	UBE2Q2P2	-6.63	5.51e-11	1.08e-08	-0.2	-0.2	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82168099	chr15:82355142~82420075:+
BRCA	cis	rs17253792	0.822	rs78323463	ENSG00000186615.9	KTN1-AS1	-6.63	5.51e-11	1.08e-08	-0.41	-0.2	Putamen volume;	chr14:55578733	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs111467375	ENSG00000186615.9	KTN1-AS1	-6.63	5.51e-11	1.08e-08	-0.41	-0.2	Putamen volume;	chr14:55579441	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.731	rs79483151	ENSG00000186615.9	KTN1-AS1	-6.63	5.51e-11	1.08e-08	-0.41	-0.2	Putamen volume;	chr14:55582133	chr14:55499278~55580110:-
BRCA	cis	rs7665090	0.87	rs228614	ENSG00000246560.2	RP11-10L12.4	-6.63	5.51e-11	1.09e-08	-0.21	-0.2	Primary biliary cholangitis;	chr4:102657480	chr4:102828055~102844075:+
BRCA	cis	rs8114671	0.935	rs6060282	ENSG00000269202.1	RP4-614O4.12	-6.63	5.52e-11	1.09e-08	-0.21	-0.2	Height;	chr20:35179263	chr20:35201747~35203288:-
BRCA	cis	rs8114671	0.967	rs2065978	ENSG00000269202.1	RP4-614O4.12	-6.63	5.52e-11	1.09e-08	-0.21	-0.2	Height;	chr20:35179488	chr20:35201747~35203288:-
BRCA	cis	rs8114671	0.967	rs2065979	ENSG00000269202.1	RP4-614O4.12	-6.63	5.52e-11	1.09e-08	-0.21	-0.2	Height;	chr20:35179887	chr20:35201747~35203288:-
BRCA	cis	rs944990	0.618	rs7023577	ENSG00000227603.1	RP11-165J3.6	6.63	5.52e-11	1.09e-08	0.21	0.2	Body mass index;	chr9:93574711	chr9:93435332~93437121:-
BRCA	cis	rs1707322	1	rs10890382	ENSG00000281133.1	AL355480.3	-6.63	5.52e-11	1.09e-08	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46004002	chr1:45580892~45580996:-
BRCA	cis	rs34779708	0.931	rs4007289	ENSG00000271335.4	RP11-324I22.4	6.63	5.53e-11	1.09e-08	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:34980862	chr10:35314552~35336401:-
BRCA	cis	rs467650	0.782	rs56264044	ENSG00000248489.1	CTD-2007H13.3	6.63	5.55e-11	1.09e-08	0.24	0.2	Venous thromboembolism (SNP x SNP interaction);	chr5:98724439	chr5:98929171~98995013:+
BRCA	cis	rs681343	0.746	rs633372	ENSG00000232871.7	SEC1P	6.63	5.55e-11	1.09e-08	0.22	0.2	Primary sclerosing cholangitis;Childhood ear infection;Lung adenocarcinoma;	chr19:48705969	chr19:48638071~48682245:+
BRCA	cis	rs875971	0.862	rs2420174	ENSG00000224316.1	RP11-479O9.2	-6.63	5.55e-11	1.09e-08	-0.2	-0.2	Aortic root size;	chr7:66180374	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.862	rs2420173	ENSG00000224316.1	RP11-479O9.2	-6.63	5.55e-11	1.09e-08	-0.2	-0.2	Aortic root size;	chr7:66180412	chr7:65773620~65802067:+
BRCA	cis	rs17214007	0.877	rs11644832	ENSG00000263335.1	AF001548.5	-6.63	5.56e-11	1.09e-08	-0.29	-0.2	Cognitive function;	chr16:15778891	chr16:15726674~15732993:+
BRCA	cis	rs17214007	0.877	rs11645883	ENSG00000263335.1	AF001548.5	-6.63	5.56e-11	1.09e-08	-0.29	-0.2	Cognitive function;	chr16:15778950	chr16:15726674~15732993:+
BRCA	cis	rs149313	1	rs149313	ENSG00000248734.2	CTD-2260A17.1	-6.62	5.56e-11	1.09e-08	-0.2	-0.2	Blood protein levels;	chr5:96734501	chr5:96784777~96785999:+
BRCA	cis	rs237743	1	rs67375757	ENSG00000222365.1	SNORD12B	-6.62	5.57e-11	1.1e-08	-0.27	-0.2	Height;	chr20:49299758	chr20:49280319~49280409:+
BRCA	cis	rs237743	1	rs68014903	ENSG00000222365.1	SNORD12B	-6.62	5.57e-11	1.1e-08	-0.27	-0.2	Height;	chr20:49295502	chr20:49280319~49280409:+
BRCA	cis	rs1707322	0.686	rs3014251	ENSG00000281133.1	AL355480.3	6.62	5.58e-11	1.1e-08	0.26	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45611756	chr1:45580892~45580996:-
BRCA	cis	rs13113518	0.812	rs11945371	ENSG00000223305.1	RN7SKP30	6.62	5.58e-11	1.1e-08	0.25	0.2	Height;	chr4:55409063	chr4:55540502~55540835:-
BRCA	cis	rs957448	1	rs12680965	ENSG00000253175.1	RP11-267M23.6	6.62	5.59e-11	1.1e-08	0.26	0.2	Nonsyndromic cleft lip with cleft palate;	chr8:94554069	chr8:94565036~94565715:+
BRCA	cis	rs113835537	0.597	rs2075792	ENSG00000255517.5	CTD-3074O7.5	-6.62	5.59e-11	1.1e-08	-0.26	-0.2	Airway imaging phenotypes;	chr11:66567085	chr11:66473490~66480233:-
BRCA	cis	rs34779708	0.931	rs10466072	ENSG00000271335.4	RP11-324I22.4	6.62	5.6e-11	1.1e-08	0.2	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35113828	chr10:35314552~35336401:-
BRCA	cis	rs7809950	0.678	rs62482499	ENSG00000238832.1	snoU109	-6.62	5.6e-11	1.1e-08	-0.28	-0.2	Coronary artery disease;	chr7:107334614	chr7:107603363~107603507:+
BRCA	cis	rs2243480	1	rs1638734	ENSG00000232559.3	GS1-124K5.12	6.62	5.61e-11	1.1e-08	0.38	0.2	Diabetic kidney disease;	chr7:66632552	chr7:66554588~66576923:-
BRCA	cis	rs11098499	0.874	rs6851169	ENSG00000248280.1	RP11-33B1.2	6.62	5.62e-11	1.1e-08	0.22	0.2	Corneal astigmatism;	chr4:119196355	chr4:119440561~119450157:-
BRCA	cis	rs6860806	0.507	rs635620	ENSG00000233006.5	AC034220.3	-6.62	5.62e-11	1.1e-08	-0.17	-0.2	Breast cancer;	chr5:132384571	chr5:132311285~132369916:-
BRCA	cis	rs6860806	0.507	rs635619	ENSG00000233006.5	AC034220.3	-6.62	5.62e-11	1.1e-08	-0.17	-0.2	Breast cancer;	chr5:132384573	chr5:132311285~132369916:-
BRCA	cis	rs6840258	0.607	rs56023922	ENSG00000251411.1	RP11-397E7.4	-6.62	5.62e-11	1.1e-08	-0.3	-0.2	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86994934	chr4:86913266~86914817:-
BRCA	cis	rs420259	0.516	rs11643602	ENSG00000260136.4	CTD-2270L9.4	-6.62	5.62e-11	1.1e-08	-0.2	-0.2	Bipolar disorder;	chr16:23545588	chr16:23452758~23457606:+
BRCA	cis	rs420259	0.516	rs4968019	ENSG00000260136.4	CTD-2270L9.4	-6.62	5.62e-11	1.1e-08	-0.2	-0.2	Bipolar disorder;	chr16:23546469	chr16:23452758~23457606:+
BRCA	cis	rs9494145	0.68	rs9376092	ENSG00000232876.1	CTA-212D2.2	6.62	5.62e-11	1.11e-08	0.28	0.2	Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count;	chr6:135106006	chr6:135055033~135060550:+
BRCA	cis	rs2836950	0.565	rs2836926	ENSG00000255568.3	BRWD1-AS2	-6.62	5.62e-11	1.11e-08	-0.19	-0.2	Menarche (age at onset);	chr21:39164864	chr21:39313935~39314962:+
BRCA	cis	rs6840360	0.642	rs1596290	ENSG00000270265.1	RP11-731D1.4	-6.62	5.63e-11	1.11e-08	-0.23	-0.2	Intelligence (multi-trait analysis);	chr4:151489388	chr4:151333775~151353224:-
BRCA	cis	rs9652601	0.959	rs741172	ENSG00000274038.1	RP11-66H6.4	-6.62	5.63e-11	1.11e-08	-0.24	-0.2	Systemic lupus erythematosus;	chr16:11106941	chr16:11056556~11057034:+
BRCA	cis	rs2243480	1	rs316331	ENSG00000232559.3	GS1-124K5.12	-6.62	5.64e-11	1.11e-08	-0.38	-0.2	Diabetic kidney disease;	chr7:66139635	chr7:66554588~66576923:-
BRCA	cis	rs228614	0.509	rs223486	ENSG00000251288.2	RP11-10L12.2	-6.62	5.65e-11	1.11e-08	-0.23	-0.2	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102763796	chr4:102751401~102752641:+
BRCA	cis	rs34779708	0.931	rs12268745	ENSG00000271335.4	RP11-324I22.4	6.62	5.66e-11	1.11e-08	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35017061	chr10:35314552~35336401:-
BRCA	cis	rs1823913	0.599	rs35892286	ENSG00000280083.1	RP11-317J9.1	-6.62	5.66e-11	1.11e-08	-0.23	-0.2	Obesity-related traits;	chr2:191269010	chr2:191154118~191156070:-
BRCA	cis	rs9291683	0.595	rs13145442	ENSG00000250413.1	RP11-448G15.1	-6.62	5.66e-11	1.11e-08	-0.26	-0.2	Bone mineral density;	chr4:10035637	chr4:10006482~10009725:+
BRCA	cis	rs9291683	0.595	rs11731110	ENSG00000250413.1	RP11-448G15.1	-6.62	5.66e-11	1.11e-08	-0.26	-0.2	Bone mineral density;	chr4:10035722	chr4:10006482~10009725:+
BRCA	cis	rs17253792	0.822	rs79398217	ENSG00000186615.9	KTN1-AS1	-6.62	5.66e-11	1.11e-08	-0.41	-0.2	Putamen volume;	chr14:55600632	chr14:55499278~55580110:-
BRCA	cis	rs748404	0.736	rs542036	ENSG00000249839.1	AC011330.5	6.62	5.67e-11	1.11e-08	0.25	0.2	Lung cancer;	chr15:43248941	chr15:43663654~43684339:-
BRCA	cis	rs172166	0.694	rs203877	ENSG00000216901.1	AL022393.7	6.62	5.68e-11	1.12e-08	0.26	0.2	Cardiac Troponin-T levels;	chr6:28080846	chr6:28176188~28176674:+
BRCA	cis	rs27524	0.734	rs27037	ENSG00000272109.1	CTD-2260A17.3	-6.62	5.68e-11	1.12e-08	-0.26	-0.2	Hodgkin's lymphoma;Psoriasis;	chr5:96758990	chr5:96804353~96806105:+
BRCA	cis	rs9876781	0.563	rs4858821	ENSG00000244380.1	RP11-24C3.2	-6.62	5.69e-11	1.12e-08	-0.26	-0.2	Longevity;	chr3:48512515	chr3:48440352~48446656:-
BRCA	cis	rs2489715	0.723	rs2801942	ENSG00000185904.10	LINC00839	-6.62	5.69e-11	1.12e-08	-0.28	-0.2	Helix rolling;	chr10:42443920	chr10:42475543~42495336:+
BRCA	cis	rs7727544	0.904	rs58835386	ENSG00000233006.5	AC034220.3	6.62	5.69e-11	1.12e-08	0.15	0.2	Blood metabolite levels;	chr5:132264866	chr5:132311285~132369916:-
BRCA	cis	rs2412819	0.571	rs495880	ENSG00000205771.5	CATSPER2P1	6.62	5.7e-11	1.12e-08	0.29	0.2	Lung cancer;	chr15:43855067	chr15:43726918~43747094:-
BRCA	cis	rs4372836	1	rs34409160	ENSG00000226833.4	AC097724.3	-6.62	5.7e-11	1.12e-08	-0.25	-0.2	Body mass index;	chr2:28720999	chr2:28708953~28736205:-
BRCA	cis	rs78456975	0.739	rs11896906	ENSG00000231482.2	AC141930.2	-6.62	5.71e-11	1.12e-08	-0.28	-0.2	Placebo response in major depressive disorder (% change in symptom score);	chr2:1515778	chr2:1572554~1580311:-
BRCA	cis	rs3126085	0.935	rs12409762	ENSG00000237975.5	FLG-AS1	6.62	5.71e-11	1.12e-08	0.28	0.2	Atopic dermatitis;	chr1:152202922	chr1:152168125~152445456:+
BRCA	cis	rs4660456	0.572	rs7519348	ENSG00000237899.1	RP4-739H11.3	-6.62	5.72e-11	1.12e-08	-0.25	-0.2	Platelet count;	chr1:40694532	chr1:40669089~40687588:-
BRCA	cis	rs7665090	1	rs4013	ENSG00000246560.2	RP11-10L12.4	6.62	5.72e-11	1.12e-08	0.21	0.2	Primary biliary cholangitis;	chr4:102631656	chr4:102828055~102844075:+
BRCA	cis	rs7665090	0.967	rs4019	ENSG00000246560.2	RP11-10L12.4	6.62	5.72e-11	1.12e-08	0.21	0.2	Primary biliary cholangitis;	chr4:102631673	chr4:102828055~102844075:+
BRCA	cis	rs2243480	1	rs316332	ENSG00000230295.1	RP11-458F8.2	-6.62	5.73e-11	1.13e-08	-0.26	-0.2	Diabetic kidney disease;	chr7:66139312	chr7:66880708~66882981:+
BRCA	cis	rs13113518	0.738	rs6849883	ENSG00000249700.7	SRD5A3-AS1	6.62	5.73e-11	1.13e-08	0.26	0.2	Height;	chr4:55387515	chr4:55363971~55395847:-
BRCA	cis	rs2732480	0.538	rs1387260	ENSG00000273765.1	RP11-370I10.11	6.62	5.73e-11	1.13e-08	0.25	0.2	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48309308	chr12:48360920~48361377:+
BRCA	cis	rs1440410	0.835	rs7685075	ENSG00000250326.1	RP11-284M14.1	-6.62	5.74e-11	1.13e-08	-0.22	-0.2	Ischemic stroke;	chr4:143133546	chr4:142933195~143184861:-
BRCA	cis	rs1440410	0.835	rs10155324	ENSG00000250326.1	RP11-284M14.1	-6.62	5.74e-11	1.13e-08	-0.22	-0.2	Ischemic stroke;	chr4:143135820	chr4:142933195~143184861:-
BRCA	cis	rs1440410	0.835	rs6537150	ENSG00000250326.1	RP11-284M14.1	-6.62	5.74e-11	1.13e-08	-0.22	-0.2	Ischemic stroke;	chr4:143146716	chr4:142933195~143184861:-
BRCA	cis	rs1440410	0.835	rs4337690	ENSG00000250326.1	RP11-284M14.1	-6.62	5.74e-11	1.13e-08	-0.22	-0.2	Ischemic stroke;	chr4:143148408	chr4:142933195~143184861:-
BRCA	cis	rs1440410	0.835	rs7670439	ENSG00000250326.1	RP11-284M14.1	-6.62	5.74e-11	1.13e-08	-0.22	-0.2	Ischemic stroke;	chr4:143159114	chr4:142933195~143184861:-
BRCA	cis	rs1440410	0.835	rs10015190	ENSG00000250326.1	RP11-284M14.1	-6.62	5.74e-11	1.13e-08	-0.22	-0.2	Ischemic stroke;	chr4:143160595	chr4:142933195~143184861:-
BRCA	cis	rs516805	0.52	rs9388099	ENSG00000279114.1	RP3-425C14.5	6.62	5.75e-11	1.13e-08	0.19	0.2	Lymphocyte counts;	chr6:122566904	chr6:122471923~122484161:+
BRCA	cis	rs875971	0.862	rs7796162	ENSG00000224316.1	RP11-479O9.2	-6.62	5.75e-11	1.13e-08	-0.2	-0.2	Aortic root size;	chr7:66280771	chr7:65773620~65802067:+
BRCA	cis	rs9311474	1	rs7614727	ENSG00000243224.1	RP5-1157M23.2	-6.62	5.77e-11	1.13e-08	-0.22	-0.2	Electroencephalogram traits;	chr3:52261879	chr3:52239258~52241097:+
BRCA	cis	rs11098499	0.908	rs28559989	ENSG00000249244.1	RP11-548H18.2	6.62	5.78e-11	1.13e-08	0.24	0.2	Corneal astigmatism;	chr4:119465472	chr4:119391831~119395335:-
BRCA	cis	rs2836950	0.565	rs3171465	ENSG00000255568.3	BRWD1-AS2	-6.62	5.78e-11	1.13e-08	-0.19	-0.2	Menarche (age at onset);	chr21:39180381	chr21:39313935~39314962:+
BRCA	cis	rs2638953	0.924	rs10492368	ENSG00000247934.4	RP11-967K21.1	-6.62	5.78e-11	1.13e-08	-0.26	-0.2	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28173941	chr12:28163298~28190738:-
BRCA	cis	rs78456975	0.527	rs11884165	ENSG00000231482.2	AC141930.2	-6.62	5.78e-11	1.14e-08	-0.27	-0.2	Placebo response in major depressive disorder (% change in symptom score);	chr2:1557280	chr2:1572554~1580311:-
BRCA	cis	rs12594515	1	rs7172161	ENSG00000259200.1	RP11-718O11.1	-6.62	5.79e-11	1.14e-08	-0.22	-0.2	Weight;Waist circumference;	chr15:45698582	chr15:45705078~45931069:+
BRCA	cis	rs2842992	0.789	rs2295901	ENSG00000237927.1	RP3-393E18.2	-6.62	5.79e-11	1.14e-08	-0.28	-0.2	Age-related macular degeneration (geographic atrophy);	chr6:159780263	chr6:159586955~159589169:-
BRCA	cis	rs2732480	0.5	rs7297824	ENSG00000273765.1	RP11-370I10.11	6.62	5.79e-11	1.14e-08	0.24	0.2	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48204867	chr12:48360920~48361377:+
BRCA	cis	rs12468226	0.938	rs10166594	ENSG00000273456.1	RP11-686O6.2	6.62	5.79e-11	1.14e-08	0.26	0.2	Urate levels;	chr2:202250262	chr2:202374932~202375604:-
BRCA	cis	rs780096	0.565	rs8179252	ENSG00000234072.1	AC074117.10	-6.62	5.79e-11	1.14e-08	-0.19	-0.2	Total body bone mineral density;	chr2:27523965	chr2:27356246~27367622:+
BRCA	cis	rs9652601	0.959	rs9746695	ENSG00000274038.1	RP11-66H6.4	6.62	5.8e-11	1.14e-08	0.23	0.2	Systemic lupus erythematosus;	chr16:11114037	chr16:11056556~11057034:+
BRCA	cis	rs9500256	0.515	rs12207710	ENSG00000215190.7	LINC00680	-6.62	5.81e-11	1.14e-08	-0.25	-0.2	Eosinophilic esophagitis (pediatric);	chr6:57943175	chr6:57946074~57961501:-
BRCA	cis	rs8114671	0.967	rs1415773	ENSG00000269202.1	RP4-614O4.12	-6.62	5.81e-11	1.14e-08	-0.21	-0.2	Height;	chr20:35177782	chr20:35201747~35203288:-
BRCA	cis	rs172166	0.694	rs203892	ENSG00000204709.4	LINC01556	6.62	5.83e-11	1.14e-08	0.27	0.2	Cardiac Troponin-T levels;	chr6:28099418	chr6:28943877~28944537:+
BRCA	cis	rs172166	0.694	rs188105	ENSG00000204709.4	LINC01556	6.62	5.83e-11	1.14e-08	0.27	0.2	Cardiac Troponin-T levels;	chr6:28103615	chr6:28943877~28944537:+
BRCA	cis	rs12594515	1	rs8027000	ENSG00000259200.1	RP11-718O11.1	-6.62	5.83e-11	1.14e-08	-0.22	-0.2	Weight;Waist circumference;	chr15:45695597	chr15:45705078~45931069:+
BRCA	cis	rs77972916	0.561	rs4372955	ENSG00000234936.1	AC010883.5	6.62	5.84e-11	1.15e-08	0.26	0.2	Granulocyte percentage of myeloid white cells;	chr2:43339007	chr2:43229573~43233394:+
BRCA	cis	rs1707322	1	rs10890376	ENSG00000281133.1	AL355480.3	-6.62	5.85e-11	1.15e-08	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45940910	chr1:45580892~45580996:-
BRCA	cis	rs11976180	1	rs11976180	ENSG00000273234.1	OR2A13P	-6.62	5.85e-11	1.15e-08	-0.28	-0.2	Obesity-related traits;	chr7:144044487	chr7:144142009~144142938:+
BRCA	cis	rs2153535	0.764	rs12190361	ENSG00000230939.1	RP11-314C16.1	6.62	5.85e-11	1.15e-08	0.23	0.2	Motion sickness;	chr6:8377079	chr6:8784178~8785445:+
BRCA	cis	rs1707322	1	rs10789485	ENSG00000281133.1	AL355480.3	-6.62	5.85e-11	1.15e-08	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45941636	chr1:45580892~45580996:-
BRCA	cis	rs17772222	0.74	rs7143642	ENSG00000258983.2	RP11-507K2.2	6.62	5.86e-11	1.15e-08	0.21	0.2	Coronary artery calcification;	chr14:88507616	chr14:88499334~88515502:+
BRCA	cis	rs228614	0.51	rs223443	ENSG00000251288.2	RP11-10L12.2	-6.62	5.86e-11	1.15e-08	-0.24	-0.2	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102793629	chr4:102751401~102752641:+
BRCA	cis	rs2836950	0.509	rs11088466	ENSG00000255568.3	BRWD1-AS2	-6.62	5.87e-11	1.15e-08	-0.19	-0.2	Menarche (age at onset);	chr21:39208091	chr21:39313935~39314962:+
BRCA	cis	rs34779708	0.966	rs11010129	ENSG00000271335.4	RP11-324I22.4	6.62	5.88e-11	1.15e-08	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35221894	chr10:35314552~35336401:-
BRCA	cis	rs2348418	0.639	rs41505151	ENSG00000247934.4	RP11-967K21.1	6.62	5.88e-11	1.15e-08	0.23	0.2	Lung function (FEV1);Lung function (FVC);	chr12:28112651	chr12:28163298~28190738:-
BRCA	cis	rs17818399	0.62	rs3087822	ENSG00000279254.1	RP11-536C12.1	6.62	5.88e-11	1.15e-08	0.24	0.2	Height;	chr2:46624894	chr2:46668870~46670778:+
BRCA	cis	rs442309	0.553	rs10995299	ENSG00000238280.1	RP11-436D10.3	-6.62	5.89e-11	1.16e-08	-0.28	-0.2	Vogt-Koyanagi-Harada syndrome;	chr10:62744443	chr10:62793562~62805887:-
BRCA	cis	rs875971	0.545	rs2279757	ENSG00000224316.1	RP11-479O9.2	6.62	5.9e-11	1.16e-08	0.23	0.2	Aortic root size;	chr7:66363676	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.545	rs11766183	ENSG00000224316.1	RP11-479O9.2	6.62	5.9e-11	1.16e-08	0.23	0.2	Aortic root size;	chr7:66374173	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.545	rs1065265	ENSG00000224316.1	RP11-479O9.2	6.62	5.9e-11	1.16e-08	0.23	0.2	Aortic root size;	chr7:66376216	chr7:65773620~65802067:+
BRCA	cis	rs6142102	1	rs4911412	ENSG00000275784.1	RP5-1125A11.6	-6.62	5.9e-11	1.16e-08	-0.25	-0.2	Skin pigmentation;	chr20:34128629	chr20:33989480~33991818:-
BRCA	cis	rs2836950	0.52	rs11911087	ENSG00000255568.3	BRWD1-AS2	-6.62	5.9e-11	1.16e-08	-0.19	-0.2	Menarche (age at onset);	chr21:39293266	chr21:39313935~39314962:+
BRCA	cis	rs6543140	0.964	rs13383602	ENSG00000234389.1	AC007278.3	6.62	5.9e-11	1.16e-08	0.2	0.2	Blood protein levels;	chr2:102469502	chr2:102438713~102440475:+
BRCA	cis	rs2337406	1	rs17113276	ENSG00000254174.1	IGHV1-12	-6.62	5.91e-11	1.16e-08	-0.21	-0.2	Alzheimer's disease (late onset);	chr14:106683485	chr14:106122420~106122709:-
BRCA	cis	rs10463554	0.853	rs2432177	ENSG00000175749.11	EIF3KP1	6.62	5.92e-11	1.16e-08	0.29	0.2	Parkinson's disease;	chr5:103236172	chr5:103032376~103033031:+
BRCA	cis	rs875971	1	rs937495	ENSG00000224316.1	RP11-479O9.2	-6.62	5.92e-11	1.16e-08	-0.2	-0.2	Aortic root size;	chr7:66314811	chr7:65773620~65802067:+
BRCA	cis	rs875971	1	rs2036264	ENSG00000224316.1	RP11-479O9.2	-6.62	5.92e-11	1.16e-08	-0.2	-0.2	Aortic root size;	chr7:66334917	chr7:65773620~65802067:+
BRCA	cis	rs875971	1	rs7783613	ENSG00000224316.1	RP11-479O9.2	-6.62	5.92e-11	1.16e-08	-0.2	-0.2	Aortic root size;	chr7:66340274	chr7:65773620~65802067:+
BRCA	cis	rs172166	0.611	rs203883	ENSG00000204709.4	LINC01556	6.62	5.92e-11	1.16e-08	0.27	0.2	Cardiac Troponin-T levels;	chr6:28110578	chr6:28943877~28944537:+
BRCA	cis	rs11742741	0.676	rs34323137	ENSG00000248874.4	C5orf17	-6.61	5.93e-11	1.16e-08	-0.25	-0.2	Educational attainment;	chr5:24196120	chr5:23951348~24178263:+
BRCA	cis	rs11742741	0.676	rs34415514	ENSG00000248874.4	C5orf17	-6.61	5.93e-11	1.16e-08	-0.25	-0.2	Educational attainment;	chr5:24196173	chr5:23951348~24178263:+
BRCA	cis	rs1167827	0.68	rs1167796	ENSG00000165178.9	NCF1C	-6.61	5.93e-11	1.16e-08	-0.16	-0.2	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75543861	chr7:75156639~75172044:-
BRCA	cis	rs4356203	0.519	rs214084	ENSG00000272034.1	SNORD14A	-6.61	5.94e-11	1.16e-08	-0.22	-0.2	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17277267	chr11:17074654~17074744:-
BRCA	cis	rs4356203	0.519	rs214083	ENSG00000272034.1	SNORD14A	-6.61	5.94e-11	1.16e-08	-0.22	-0.2	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17277312	chr11:17074654~17074744:-
BRCA	cis	rs4356203	0.519	rs214082	ENSG00000272034.1	SNORD14A	-6.61	5.94e-11	1.16e-08	-0.22	-0.2	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17277843	chr11:17074654~17074744:-
BRCA	cis	rs1499614	0.803	rs1796229	ENSG00000230295.1	RP11-458F8.2	-6.61	5.94e-11	1.16e-08	-0.27	-0.2	Gout;	chr7:66654674	chr7:66880708~66882981:+
BRCA	cis	rs2348418	0.966	rs16932891	ENSG00000247934.4	RP11-967K21.1	6.61	5.95e-11	1.17e-08	0.23	0.2	Lung function (FEV1);Lung function (FVC);	chr12:28537055	chr12:28163298~28190738:-
BRCA	cis	rs3781264	0.557	rs7100430	ENSG00000273450.1	RP11-76P2.4	6.61	5.95e-11	1.17e-08	0.27	0.2	Esophageal cancer and gastric cancer;	chr10:94362786	chr10:94314907~94315327:-
BRCA	cis	rs12594515	1	rs8038058	ENSG00000259200.1	RP11-718O11.1	-6.61	5.96e-11	1.17e-08	-0.22	-0.2	Weight;Waist circumference;	chr15:45698074	chr15:45705078~45931069:+
BRCA	cis	rs944990	0.597	rs61707921	ENSG00000227603.1	RP11-165J3.6	6.61	5.97e-11	1.17e-08	0.2	0.2	Body mass index;	chr9:93475813	chr9:93435332~93437121:-
BRCA	cis	rs11098499	0.863	rs3775845	ENSG00000249244.1	RP11-548H18.2	6.61	5.97e-11	1.17e-08	0.24	0.2	Corneal astigmatism;	chr4:119511292	chr4:119391831~119395335:-
BRCA	cis	rs11024102	0.962	rs12575487	ENSG00000184669.7	OR7E14P	-6.61	5.99e-11	1.17e-08	-0.31	-0.2	Glaucoma (primary angle closure);	chr11:16997770	chr11:17013998~17053024:+
BRCA	cis	rs3794924	1	rs7236589	ENSG00000266521.1	RP11-650P15.1	6.61	6e-11	1.18e-08	0.36	0.2	Survival in colon cancer;	chr18:31475207	chr18:31496645~31497195:-
BRCA	cis	rs7246657	0.765	rs10402455	ENSG00000276846.1	CTD-3220F14.3	6.61	6e-11	1.18e-08	0.31	0.2	Coronary artery calcification;	chr19:37237805	chr19:37314868~37315620:-
BRCA	cis	rs2842992	0.789	rs2475566	ENSG00000237927.1	RP3-393E18.2	-6.61	6.01e-11	1.18e-08	-0.29	-0.2	Age-related macular degeneration (geographic atrophy);	chr6:159727709	chr6:159586955~159589169:-
BRCA	cis	rs12594515	1	rs7173144	ENSG00000259200.1	RP11-718O11.1	-6.61	6.02e-11	1.18e-08	-0.22	-0.2	Weight;Waist circumference;	chr15:45698998	chr15:45705078~45931069:+
BRCA	cis	rs919433	0.963	rs6738836	ENSG00000231621.1	AC013264.2	6.61	6.02e-11	1.18e-08	0.2	0.2	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197317708	chr2:197197991~197199273:+
BRCA	cis	rs2243480	1	rs2243480	ENSG00000230295.1	RP11-458F8.2	-6.61	6.02e-11	1.18e-08	-0.27	-0.2	Diabetic kidney disease;	chr7:66134209	chr7:66880708~66882981:+
BRCA	cis	rs5015933	0.815	rs13291322	ENSG00000232630.1	PRPS1P2	-6.61	6.03e-11	1.18e-08	-0.18	-0.2	Body mass index;	chr9:125348076	chr9:125150653~125151589:+
BRCA	cis	rs172166	0.652	rs476167	ENSG00000216901.1	AL022393.7	6.61	6.04e-11	1.18e-08	0.26	0.2	Cardiac Troponin-T levels;	chr6:28098110	chr6:28176188~28176674:+
BRCA	cis	rs848490	0.674	rs4727461	ENSG00000214293.7	APTR	6.61	6.05e-11	1.18e-08	0.23	0.2	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77691071	chr7:77657660~77696265:-
BRCA	cis	rs17772222	0.682	rs28371093	ENSG00000258983.2	RP11-507K2.2	6.61	6.05e-11	1.19e-08	0.21	0.2	Coronary artery calcification;	chr14:88486112	chr14:88499334~88515502:+
BRCA	cis	rs754466	0.651	rs10762767	ENSG00000204049.1	RP11-126H7.4	6.61	6.07e-11	1.19e-08	0.24	0.2	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77885312	chr10:77866875~77869610:+
BRCA	cis	rs2732480	0.557	rs2409004	ENSG00000273765.1	RP11-370I10.11	6.61	6.07e-11	1.19e-08	0.24	0.2	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48327668	chr12:48360920~48361377:+
BRCA	cis	rs6860806	0.507	rs169256	ENSG00000233006.5	AC034220.3	6.61	6.07e-11	1.19e-08	0.17	0.2	Breast cancer;	chr5:132352840	chr5:132311285~132369916:-
BRCA	cis	rs9876781	1	rs13076076	ENSG00000229759.1	MRPS18AP1	6.61	6.07e-11	1.19e-08	0.22	0.2	Longevity;	chr3:48437629	chr3:48256350~48256938:-
BRCA	cis	rs8114671	0.967	rs9574	ENSG00000269202.1	RP4-614O4.12	-6.61	6.08e-11	1.19e-08	-0.21	-0.2	Height;	chr20:35176829	chr20:35201747~35203288:-
BRCA	cis	rs7178375	1	rs1474382	ENSG00000215302.7	CTD-3092A11.1	-6.61	6.08e-11	1.19e-08	-0.31	-0.2	Hypertriglyceridemia;	chr15:30922446	chr15:30470779~30507623:+
BRCA	cis	rs875971	0.545	rs7811204	ENSG00000224316.1	RP11-479O9.2	6.61	6.09e-11	1.19e-08	0.23	0.2	Aortic root size;	chr7:66387213	chr7:65773620~65802067:+
BRCA	cis	rs2060793	0.87	rs1868997	ENSG00000251991.1	RNU7-49P	6.61	6.1e-11	1.19e-08	0.22	0.2	Vitamin D levels;	chr11:14872674	chr11:14478892~14478953:+
BRCA	cis	rs944990	0.538	rs10992789	ENSG00000227603.1	RP11-165J3.6	6.61	6.1e-11	1.19e-08	0.21	0.2	Body mass index;	chr9:93578914	chr9:93435332~93437121:-
BRCA	cis	rs9291683	0.632	rs12508991	ENSG00000250413.1	RP11-448G15.1	-6.61	6.1e-11	1.19e-08	-0.26	-0.2	Bone mineral density;	chr4:10039480	chr4:10006482~10009725:+
BRCA	cis	rs9291683	0.632	rs7679916	ENSG00000250413.1	RP11-448G15.1	-6.61	6.1e-11	1.19e-08	-0.26	-0.2	Bone mineral density;	chr4:10040536	chr4:10006482~10009725:+
BRCA	cis	rs61160187	0.582	rs726824	ENSG00000215032.2	GNL3LP1	6.61	6.11e-11	1.2e-08	0.25	0.2	Educational attainment (years of education);Educational attainment (college completion);	chr5:61036989	chr5:60891935~60893577:-
BRCA	cis	rs11098499	0.874	rs9995277	ENSG00000248280.1	RP11-33B1.2	6.61	6.12e-11	1.2e-08	0.22	0.2	Corneal astigmatism;	chr4:119187448	chr4:119440561~119450157:-
BRCA	cis	rs1862618	0.853	rs832582	ENSG00000271828.1	CTD-2310F14.1	6.61	6.13e-11	1.2e-08	0.28	0.2	Initial pursuit acceleration;	chr5:56881916	chr5:56927874~56929573:+
BRCA	cis	rs17772222	0.74	rs7160471	ENSG00000258983.2	RP11-507K2.2	6.61	6.13e-11	1.2e-08	0.21	0.2	Coronary artery calcification;	chr14:88507241	chr14:88499334~88515502:+
BRCA	cis	rs17772222	0.74	rs9323830	ENSG00000258983.2	RP11-507K2.2	6.61	6.13e-11	1.2e-08	0.21	0.2	Coronary artery calcification;	chr14:88507260	chr14:88499334~88515502:+
BRCA	cis	rs17772222	0.74	rs10143744	ENSG00000258983.2	RP11-507K2.2	6.61	6.13e-11	1.2e-08	0.21	0.2	Coronary artery calcification;	chr14:88508073	chr14:88499334~88515502:+
BRCA	cis	rs17772222	0.74	rs1999177	ENSG00000258983.2	RP11-507K2.2	6.61	6.13e-11	1.2e-08	0.21	0.2	Coronary artery calcification;	chr14:88508298	chr14:88499334~88515502:+
BRCA	cis	rs17772222	0.74	rs1999176	ENSG00000258983.2	RP11-507K2.2	6.61	6.13e-11	1.2e-08	0.21	0.2	Coronary artery calcification;	chr14:88508371	chr14:88499334~88515502:+
BRCA	cis	rs17772222	0.74	rs1864746	ENSG00000258983.2	RP11-507K2.2	6.61	6.13e-11	1.2e-08	0.21	0.2	Coronary artery calcification;	chr14:88508455	chr14:88499334~88515502:+
BRCA	cis	rs17772222	0.74	rs1864747	ENSG00000258983.2	RP11-507K2.2	6.61	6.13e-11	1.2e-08	0.21	0.2	Coronary artery calcification;	chr14:88508523	chr14:88499334~88515502:+
BRCA	cis	rs1014246	0.848	rs10787714	ENSG00000232767.1	RP11-498B4.5	-6.61	6.14e-11	1.2e-08	-0.23	-0.2	Age at smoking initiation in chronic obstructive pulmonary disease;	chr10:116699873	chr10:116670103~116672739:+
BRCA	cis	rs1014246	0.848	rs10787715	ENSG00000232767.1	RP11-498B4.5	-6.61	6.14e-11	1.2e-08	-0.23	-0.2	Age at smoking initiation in chronic obstructive pulmonary disease;	chr10:116700060	chr10:116670103~116672739:+
BRCA	cis	rs875971	0.965	rs9969301	ENSG00000224316.1	RP11-479O9.2	-6.61	6.15e-11	1.2e-08	-0.2	-0.2	Aortic root size;	chr7:66316668	chr7:65773620~65802067:+
BRCA	cis	rs1499614	0.901	rs3936	ENSG00000230295.1	RP11-458F8.2	-6.61	6.16e-11	1.21e-08	-0.27	-0.2	Gout;	chr7:66661502	chr7:66880708~66882981:+
BRCA	cis	rs17253792	0.822	rs10137885	ENSG00000186615.9	KTN1-AS1	-6.61	6.17e-11	1.21e-08	-0.36	-0.2	Putamen volume;	chr14:55706872	chr14:55499278~55580110:-
BRCA	cis	rs2732480	0.557	rs923397	ENSG00000273765.1	RP11-370I10.11	6.61	6.17e-11	1.21e-08	0.24	0.2	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48326609	chr12:48360920~48361377:+
BRCA	cis	rs4722166	0.532	rs6963866	ENSG00000179428.2	AC073072.5	-6.61	6.17e-11	1.21e-08	-0.21	-0.2	Lung cancer;	chr7:22717722	chr7:22725395~22727620:-
BRCA	cis	rs13113518	0.812	rs2048564	ENSG00000223305.1	RN7SKP30	6.61	6.18e-11	1.21e-08	0.25	0.2	Height;	chr4:55407965	chr4:55540502~55540835:-
BRCA	cis	rs7746199	0.736	rs13193542	ENSG00000220721.1	OR1F12	6.61	6.18e-11	1.21e-08	0.48	0.2	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27734646	chr6:28073316~28074233:+
BRCA	cis	rs7746199	0.736	rs13193480	ENSG00000220721.1	OR1F12	6.61	6.18e-11	1.21e-08	0.48	0.2	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27734782	chr6:28073316~28074233:+
BRCA	cis	rs3814244	0.528	rs2906859	ENSG00000236946.2	HNRNPA1P70	-6.61	6.18e-11	1.21e-08	-0.16	-0.2	Itch intensity from mosquito bite adjusted by bite size;	chr12:68002355	chr12:68035767~68036853:+
BRCA	cis	rs4664293	0.737	rs1549579	ENSG00000226266.5	AC009961.3	-6.61	6.18e-11	1.21e-08	-0.24	-0.2	Monocyte percentage of white cells;	chr2:159812150	chr2:159670708~159712435:-
BRCA	cis	rs2638953	0.924	rs11049409	ENSG00000247934.4	RP11-967K21.1	-6.61	6.18e-11	1.21e-08	-0.26	-0.2	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28182686	chr12:28163298~28190738:-
BRCA	cis	rs78456975	1	rs10192959	ENSG00000231482.2	AC141930.2	-6.61	6.19e-11	1.21e-08	-0.3	-0.2	Placebo response in major depressive disorder (% change in symptom score);	chr2:1549621	chr2:1572554~1580311:-
BRCA	cis	rs875971	0.522	rs7784623	ENSG00000237310.1	GS1-124K5.4	6.61	6.19e-11	1.21e-08	0.21	0.2	Aortic root size;	chr7:65930047	chr7:66493706~66495474:+
BRCA	cis	rs4356203	0.543	rs214081	ENSG00000272034.1	SNORD14A	-6.61	6.2e-11	1.21e-08	-0.22	-0.2	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17278107	chr11:17074654~17074744:-
BRCA	cis	rs3758911	0.788	rs10890676	ENSG00000255353.1	RP11-382M14.1	-6.61	6.2e-11	1.21e-08	-0.27	-0.2	Coronary artery disease;	chr11:107254631	chr11:107176286~107177530:+
BRCA	cis	rs34779708	0.931	rs11010130	ENSG00000271335.4	RP11-324I22.4	6.61	6.2e-11	1.21e-08	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35224379	chr10:35314552~35336401:-
BRCA	cis	rs34779708	0.897	rs11010131	ENSG00000271335.4	RP11-324I22.4	6.61	6.2e-11	1.21e-08	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35224388	chr10:35314552~35336401:-
BRCA	cis	rs755249	0.567	rs4660543	ENSG00000228060.1	RP11-69E11.8	-6.61	6.21e-11	1.21e-08	-0.24	-0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39213318	chr1:39565160~39573203:+
BRCA	cis	rs2842992	0.715	rs2277073	ENSG00000237927.1	RP3-393E18.2	-6.61	6.21e-11	1.22e-08	-0.29	-0.2	Age-related macular degeneration (geographic atrophy);	chr6:159761717	chr6:159586955~159589169:-
BRCA	cis	rs13113518	0.812	rs4864996	ENSG00000223305.1	RN7SKP30	6.61	6.22e-11	1.22e-08	0.25	0.2	Height;	chr4:55452921	chr4:55540502~55540835:-
BRCA	cis	rs13217239	0.646	rs10456352	ENSG00000241549.7	GUSBP2	6.61	6.22e-11	1.22e-08	0.22	0.2	Schizophrenia;	chr6:27022579	chr6:26871484~26956554:-
BRCA	cis	rs13217239	0.646	rs4583981	ENSG00000241549.7	GUSBP2	6.61	6.22e-11	1.22e-08	0.22	0.2	Schizophrenia;	chr6:27024244	chr6:26871484~26956554:-
BRCA	cis	rs2281636	0.723	rs2150916	ENSG00000233690.1	EBAG9P1	6.61	6.22e-11	1.22e-08	0.23	0.2	Obesity-related traits;	chr10:99692737	chr10:99697407~99697949:-
BRCA	cis	rs6142102	0.961	rs6057957	ENSG00000275784.1	RP5-1125A11.6	-6.61	6.22e-11	1.22e-08	-0.24	-0.2	Skin pigmentation;	chr20:33962052	chr20:33989480~33991818:-
BRCA	cis	rs957448	0.904	rs56302978	ENSG00000253175.1	RP11-267M23.6	6.61	6.22e-11	1.22e-08	0.26	0.2	Nonsyndromic cleft lip with cleft palate;	chr8:94505883	chr8:94565036~94565715:+
BRCA	cis	rs2998286	0.862	rs1339704	ENSG00000254635.4	WAC-AS1	-6.61	6.22e-11	1.22e-08	-0.27	-0.2	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28527400	chr10:28522652~28532743:-
BRCA	cis	rs12594515	0.967	rs67854274	ENSG00000259200.1	RP11-718O11.1	-6.61	6.23e-11	1.22e-08	-0.22	-0.2	Weight;Waist circumference;	chr15:45698320	chr15:45705078~45931069:+
BRCA	cis	rs2492286	0.597	rs2712384	ENSG00000242551.2	POU5F1P6	-6.61	6.25e-11	1.22e-08	-0.29	-0.2	Eosinophil counts;	chr3:128615429	chr3:128674735~128677005:-
BRCA	cis	rs875971	0.545	rs3936065	ENSG00000224316.1	RP11-479O9.2	6.61	6.26e-11	1.22e-08	0.23	0.2	Aortic root size;	chr7:66325577	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.545	rs4718335	ENSG00000224316.1	RP11-479O9.2	6.61	6.26e-11	1.22e-08	0.23	0.2	Aortic root size;	chr7:66339619	chr7:65773620~65802067:+
BRCA	cis	rs12594515	1	rs6493176	ENSG00000259200.1	RP11-718O11.1	-6.61	6.26e-11	1.22e-08	-0.22	-0.2	Weight;Waist circumference;	chr15:45697828	chr15:45705078~45931069:+
BRCA	cis	rs12594515	0.967	rs8039088	ENSG00000259200.1	RP11-718O11.1	-6.61	6.26e-11	1.22e-08	-0.22	-0.2	Weight;Waist circumference;	chr15:45697980	chr15:45705078~45931069:+
BRCA	cis	rs12594515	1	rs8038320	ENSG00000259200.1	RP11-718O11.1	-6.61	6.26e-11	1.22e-08	-0.22	-0.2	Weight;Waist circumference;	chr15:45698069	chr15:45705078~45931069:+
BRCA	cis	rs9500256	0.655	rs12191043	ENSG00000215190.7	LINC00680	-6.61	6.27e-11	1.22e-08	-0.24	-0.2	Eosinophilic esophagitis (pediatric);	chr6:58020205	chr6:57946074~57961501:-
BRCA	cis	rs1823913	0.599	rs10497713	ENSG00000280083.1	RP11-317J9.1	-6.61	6.27e-11	1.23e-08	-0.23	-0.2	Obesity-related traits;	chr2:191279312	chr2:191154118~191156070:-
BRCA	cis	rs919433	0.889	rs12693816	ENSG00000231621.1	AC013264.2	6.61	6.28e-11	1.23e-08	0.19	0.2	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197343696	chr2:197197991~197199273:+
BRCA	cis	rs7665090	1	rs2866409	ENSG00000246560.2	RP11-10L12.4	6.61	6.29e-11	1.23e-08	0.21	0.2	Primary biliary cholangitis;	chr4:102633104	chr4:102828055~102844075:+
BRCA	cis	rs8005677	1	rs10148215	ENSG00000257285.4	RP11-298I3.1	6.61	6.29e-11	1.23e-08	0.22	0.2	Cognitive ability (multi-trait analysis);	chr14:22913136	chr14:22929609~22955562:+
BRCA	cis	rs7665090	1	rs2866406	ENSG00000246560.2	RP11-10L12.4	6.61	6.29e-11	1.23e-08	0.21	0.2	Primary biliary cholangitis;	chr4:102632862	chr4:102828055~102844075:+
BRCA	cis	rs6543140	0.964	rs11903551	ENSG00000234389.1	AC007278.3	6.61	6.31e-11	1.23e-08	0.2	0.2	Blood protein levels;	chr2:102467721	chr2:102438713~102440475:+
BRCA	cis	rs6543140	0.964	rs6543143	ENSG00000234389.1	AC007278.3	6.61	6.31e-11	1.23e-08	0.2	0.2	Blood protein levels;	chr2:102468960	chr2:102438713~102440475:+
BRCA	cis	rs2732480	0.577	rs2450994	ENSG00000273765.1	RP11-370I10.11	6.61	6.31e-11	1.23e-08	0.24	0.2	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48328049	chr12:48360920~48361377:+
BRCA	cis	rs1707322	1	rs10890381	ENSG00000281133.1	AL355480.3	-6.61	6.31e-11	1.23e-08	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45986099	chr1:45580892~45580996:-
BRCA	cis	rs1552244	0.882	rs2130813	ENSG00000180385.7	EMC3-AS1	6.61	6.32e-11	1.23e-08	0.25	0.2	Alzheimer's disease;	chr3:9997022	chr3:9986893~10006990:+
BRCA	cis	rs1552244	0.882	rs17081288	ENSG00000180385.7	EMC3-AS1	6.61	6.32e-11	1.23e-08	0.25	0.2	Alzheimer's disease;	chr3:10000429	chr3:9986893~10006990:+
BRCA	cis	rs1552244	0.816	rs56271597	ENSG00000180385.7	EMC3-AS1	6.61	6.32e-11	1.23e-08	0.25	0.2	Alzheimer's disease;	chr3:10001106	chr3:9986893~10006990:+
BRCA	cis	rs237743	1	rs381262	ENSG00000222365.1	SNORD12B	-6.61	6.32e-11	1.24e-08	-0.24	-0.2	Height;	chr20:49316942	chr20:49280319~49280409:+
BRCA	cis	rs1499614	0.803	rs1796229	ENSG00000232546.1	RP11-458F8.1	-6.61	6.32e-11	1.24e-08	-0.27	-0.2	Gout;	chr7:66654674	chr7:66848496~66858136:+
BRCA	cis	rs5015933	0.815	rs10986716	ENSG00000232630.1	PRPS1P2	-6.6	6.33e-11	1.24e-08	-0.18	-0.2	Body mass index;	chr9:125345606	chr9:125150653~125151589:+
BRCA	cis	rs2060793	0.769	rs7125781	ENSG00000251991.1	RNU7-49P	6.6	6.33e-11	1.24e-08	0.22	0.2	Vitamin D levels;	chr11:14856401	chr11:14478892~14478953:+
BRCA	cis	rs2060793	0.87	rs6486205	ENSG00000251991.1	RNU7-49P	6.6	6.33e-11	1.24e-08	0.22	0.2	Vitamin D levels;	chr11:14859710	chr11:14478892~14478953:+
BRCA	cis	rs2060793	0.87	rs7116978	ENSG00000251991.1	RNU7-49P	6.6	6.33e-11	1.24e-08	0.22	0.2	Vitamin D levels;	chr11:14860225	chr11:14478892~14478953:+
BRCA	cis	rs3743162	0.553	rs12900463	ENSG00000225151.9	GOLGA2P7	-6.6	6.33e-11	1.24e-08	-0.28	-0.2	Alzheimer's disease (age of onset);	chr15:84872155	chr15:84199311~84230136:-
BRCA	cis	rs944990	0.576	rs7040832	ENSG00000227603.1	RP11-165J3.6	6.6	6.34e-11	1.24e-08	0.21	0.2	Body mass index;	chr9:93436508	chr9:93435332~93437121:-
BRCA	cis	rs1440410	0.835	rs13139558	ENSG00000250326.1	RP11-284M14.1	-6.6	6.34e-11	1.24e-08	-0.22	-0.2	Ischemic stroke;	chr4:143149410	chr4:142933195~143184861:-
BRCA	cis	rs1124769	0.748	rs1318765	ENSG00000259378.1	DCAF13P3	6.6	6.36e-11	1.24e-08	0.29	0.2	Cognitive performance;	chr15:51029750	chr15:50944663~50945996:+
BRCA	cis	rs4237845	0.742	rs3751330	ENSG00000257159.1	RP11-58A17.3	6.6	6.36e-11	1.24e-08	0.22	0.2	Intelligence (multi-trait analysis);	chr12:57896443	chr12:57967058~57968399:+
BRCA	cis	rs6583826	0.758	rs7076966	ENSG00000236493.2	EIF2S2P3	6.6	6.36e-11	1.24e-08	0.26	0.2	Type 2 diabetes;	chr10:92565754	chr10:92668745~92669743:-
BRCA	cis	rs4538475	1	rs4273468	ENSG00000214846.4	RP11-115L11.1	-6.6	6.36e-11	1.24e-08	-0.3	-0.2	Parkinson's disease;	chr4:15736240	chr4:15730962~15731627:-
BRCA	cis	rs17508449	0.821	rs1419231	ENSG00000232450.1	RP4-730K3.3	-6.6	6.38e-11	1.25e-08	-0.37	-0.2	Leprosy;	chr1:113583596	chr1:113698884~113699631:-
BRCA	cis	rs10181042	0.565	rs3108630	ENSG00000271889.1	RP11-493E12.1	-6.6	6.38e-11	1.25e-08	-0.24	-0.2	Crohn's disease;	chr2:61041025	chr2:61151433~61162105:-
BRCA	cis	rs66887589	0.967	rs1480933	ENSG00000248280.1	RP11-33B1.2	6.6	6.4e-11	1.25e-08	0.19	0.2	Diastolic blood pressure;	chr4:119512093	chr4:119440561~119450157:-
BRCA	cis	rs1707322	0.686	rs2230659	ENSG00000281133.1	AL355480.3	6.6	6.4e-11	1.25e-08	0.26	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613212	chr1:45580892~45580996:-
BRCA	cis	rs7945705	0.791	rs6484484	ENSG00000254860.4	TMEM9B-AS1	-6.6	6.4e-11	1.25e-08	-0.18	-0.2	Hemoglobin concentration;	chr11:8795659	chr11:8964675~8977527:+
BRCA	cis	rs875971	0.522	rs1917563	ENSG00000237310.1	GS1-124K5.4	-6.6	6.4e-11	1.25e-08	-0.21	-0.2	Aortic root size;	chr7:65950660	chr7:66493706~66495474:+
BRCA	cis	rs10022260	1	rs10022260	ENSG00000251022.5	THAP9-AS1	-6.6	6.4e-11	1.25e-08	-0.26	-0.2	Adult asthma;	chr4:82872768	chr4:82893009~82900960:-
BRCA	cis	rs7567389	0.638	rs12105051	ENSG00000236682.1	AC068282.3	6.6	6.42e-11	1.25e-08	0.3	0.2	Self-rated health;	chr2:127232601	chr2:127389130~127400580:+
BRCA	cis	rs875971	1	rs709595	ENSG00000224316.1	RP11-479O9.2	6.6	6.42e-11	1.25e-08	0.2	0.2	Aortic root size;	chr7:66352346	chr7:65773620~65802067:+
BRCA	cis	rs875971	1	rs811880	ENSG00000224316.1	RP11-479O9.2	6.6	6.42e-11	1.25e-08	0.2	0.2	Aortic root size;	chr7:66353659	chr7:65773620~65802067:+
BRCA	cis	rs2243480	1	rs160633	ENSG00000229886.1	RP5-1132H15.3	6.6	6.42e-11	1.25e-08	0.37	0.2	Diabetic kidney disease;	chr7:66063241	chr7:66025126~66031544:-
BRCA	cis	rs944990	0.538	rs10992788	ENSG00000227603.1	RP11-165J3.6	6.6	6.42e-11	1.25e-08	0.21	0.2	Body mass index;	chr9:93571377	chr9:93435332~93437121:-
BRCA	cis	rs875971	0.862	rs7809814	ENSG00000224316.1	RP11-479O9.2	-6.6	6.43e-11	1.25e-08	-0.2	-0.2	Aortic root size;	chr7:66150410	chr7:65773620~65802067:+
BRCA	cis	rs12594515	1	rs58368732	ENSG00000259200.1	RP11-718O11.1	-6.6	6.43e-11	1.26e-08	-0.22	-0.2	Weight;Waist circumference;	chr15:45698333	chr15:45705078~45931069:+
BRCA	cis	rs34779708	0.931	rs11010077	ENSG00000271335.4	RP11-324I22.4	-6.6	6.44e-11	1.26e-08	-0.2	-0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35039160	chr10:35314552~35336401:-
BRCA	cis	rs2274273	0.638	rs9919921	ENSG00000258413.1	RP11-665C16.6	-6.6	6.45e-11	1.26e-08	-0.28	-0.2	Protein biomarker;	chr14:55228787	chr14:55262767~55272075:-
BRCA	cis	rs13129838	1	rs13129838	ENSG00000250334.4	LINC00989	-6.6	6.46e-11	1.26e-08	-0.27	-0.2	Myopia;	chr4:79587634	chr4:79492416~79576460:+
BRCA	cis	rs9307551	0.817	rs12643976	ENSG00000250334.4	LINC00989	-6.6	6.46e-11	1.26e-08	-0.27	-0.2	Refractive error;	chr4:79589616	chr4:79492416~79576460:+
BRCA	cis	rs7587476	0.682	rs13009646	ENSG00000229267.2	AC072062.1	-6.6	6.46e-11	1.26e-08	-0.27	-0.2	Neuroblastoma;	chr2:214826535	chr2:214810229~214963274:+
BRCA	cis	rs11742741	0.702	rs3924719	ENSG00000248874.4	C5orf17	-6.6	6.46e-11	1.26e-08	-0.25	-0.2	Educational attainment;	chr5:24206968	chr5:23951348~24178263:+
BRCA	cis	rs17253792	0.822	rs10083493	ENSG00000186615.9	KTN1-AS1	-6.6	6.46e-11	1.26e-08	-0.38	-0.2	Putamen volume;	chr14:55578693	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.732	rs10146604	ENSG00000186615.9	KTN1-AS1	-6.6	6.46e-11	1.26e-08	-0.38	-0.2	Putamen volume;	chr14:55579052	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs10149408	ENSG00000186615.9	KTN1-AS1	-6.6	6.46e-11	1.26e-08	-0.38	-0.2	Putamen volume;	chr14:55579357	chr14:55499278~55580110:-
BRCA	cis	rs2337406	1	rs17113276	ENSG00000211972.2	IGHV3-66	-6.6	6.46e-11	1.26e-08	-0.18	-0.2	Alzheimer's disease (late onset);	chr14:106683485	chr14:106675017~106675544:-
BRCA	cis	rs34779708	0.966	rs998658	ENSG00000271335.4	RP11-324I22.4	6.6	6.46e-11	1.26e-08	0.2	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35119726	chr10:35314552~35336401:-
BRCA	cis	rs12594515	1	rs6493175	ENSG00000259200.1	RP11-718O11.1	-6.6	6.47e-11	1.26e-08	-0.22	-0.2	Weight;Waist circumference;	chr15:45697700	chr15:45705078~45931069:+
BRCA	cis	rs875971	0.502	rs11769702	ENSG00000236529.1	RP13-254B10.1	6.6	6.47e-11	1.26e-08	0.25	0.2	Aortic root size;	chr7:66255529	chr7:65840212~65840596:+
BRCA	cis	rs8005677	0.926	rs34344888	ENSG00000257285.4	RP11-298I3.1	6.6	6.47e-11	1.26e-08	0.22	0.2	Cognitive ability (multi-trait analysis);	chr14:22918376	chr14:22929609~22955562:+
BRCA	cis	rs8005677	0.962	rs34917191	ENSG00000257285.4	RP11-298I3.1	6.6	6.47e-11	1.26e-08	0.22	0.2	Cognitive ability (multi-trait analysis);	chr14:22918419	chr14:22929609~22955562:+
BRCA	cis	rs8005677	1	rs1951119	ENSG00000257285.4	RP11-298I3.1	6.6	6.47e-11	1.26e-08	0.22	0.2	Cognitive ability (multi-trait analysis);	chr14:22919117	chr14:22929609~22955562:+
BRCA	cis	rs8005677	1	rs2295683	ENSG00000257285.4	RP11-298I3.1	6.6	6.47e-11	1.26e-08	0.22	0.2	Cognitive ability (multi-trait analysis);	chr14:22919173	chr14:22929609~22955562:+
BRCA	cis	rs8005677	1	rs4981449	ENSG00000257285.4	RP11-298I3.1	6.6	6.47e-11	1.26e-08	0.22	0.2	Cognitive ability (multi-trait analysis);	chr14:22919662	chr14:22929609~22955562:+
BRCA	cis	rs237743	1	rs11905214	ENSG00000222365.1	SNORD12B	-6.6	6.47e-11	1.26e-08	-0.27	-0.2	Height;	chr20:49272073	chr20:49280319~49280409:+
BRCA	cis	rs13217239	0.621	rs12527231	ENSG00000241549.7	GUSBP2	6.6	6.48e-11	1.26e-08	0.22	0.2	Schizophrenia;	chr6:27033509	chr6:26871484~26956554:-
BRCA	cis	rs13217239	0.646	rs12523820	ENSG00000241549.7	GUSBP2	6.6	6.48e-11	1.26e-08	0.22	0.2	Schizophrenia;	chr6:27033723	chr6:26871484~26956554:-
BRCA	cis	rs34779708	0.931	rs4934702	ENSG00000271335.4	RP11-324I22.4	6.6	6.48e-11	1.26e-08	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35034146	chr10:35314552~35336401:-
BRCA	cis	rs9880211	0.644	rs6799320	ENSG00000273486.1	RP11-731C17.2	6.6	6.49e-11	1.27e-08	0.26	0.2	Height;Body mass index;	chr3:136083597	chr3:136837338~136839021:-
BRCA	cis	rs9880211	0.613	rs9653930	ENSG00000273486.1	RP11-731C17.2	6.6	6.49e-11	1.27e-08	0.26	0.2	Height;Body mass index;	chr3:136091472	chr3:136837338~136839021:-
BRCA	cis	rs17772222	0.74	rs7151164	ENSG00000258983.2	RP11-507K2.2	6.6	6.5e-11	1.27e-08	0.21	0.2	Coronary artery calcification;	chr14:88509329	chr14:88499334~88515502:+
BRCA	cis	rs17772222	0.74	rs12433026	ENSG00000258983.2	RP11-507K2.2	6.6	6.5e-11	1.27e-08	0.21	0.2	Coronary artery calcification;	chr14:88509495	chr14:88499334~88515502:+
BRCA	cis	rs17772222	0.74	rs10138139	ENSG00000258983.2	RP11-507K2.2	6.6	6.5e-11	1.27e-08	0.21	0.2	Coronary artery calcification;	chr14:88510027	chr14:88499334~88515502:+
BRCA	cis	rs1499614	0.901	rs3936	ENSG00000232546.1	RP11-458F8.1	-6.6	6.5e-11	1.27e-08	-0.27	-0.2	Gout;	chr7:66661502	chr7:66848496~66858136:+
BRCA	cis	rs13113518	0.812	rs2412648	ENSG00000223305.1	RN7SKP30	6.6	6.5e-11	1.27e-08	0.25	0.2	Height;	chr4:55454900	chr4:55540502~55540835:-
BRCA	cis	rs13113518	0.812	rs12512737	ENSG00000223305.1	RN7SKP30	6.6	6.5e-11	1.27e-08	0.25	0.2	Height;	chr4:55454938	chr4:55540502~55540835:-
BRCA	cis	rs13113518	0.812	rs13125984	ENSG00000223305.1	RN7SKP30	6.6	6.5e-11	1.27e-08	0.25	0.2	Height;	chr4:55455102	chr4:55540502~55540835:-
BRCA	cis	rs600231	0.665	rs1626021	ENSG00000245532.5	NEAT1	6.6	6.5e-11	1.27e-08	0.19	0.2	Bone mineral density;	chr11:65458716	chr11:65422774~65445540:+
BRCA	cis	rs13217239	0.646	rs6937880	ENSG00000241549.7	GUSBP2	6.6	6.51e-11	1.27e-08	0.22	0.2	Schizophrenia;	chr6:27032457	chr6:26871484~26956554:-
BRCA	cis	rs7809950	0.731	rs2712196	ENSG00000238832.1	snoU109	-6.6	6.51e-11	1.27e-08	-0.29	-0.2	Coronary artery disease;	chr7:107488352	chr7:107603363~107603507:+
BRCA	cis	rs4372836	1	rs4666118	ENSG00000226833.4	AC097724.3	6.6	6.52e-11	1.27e-08	0.24	0.2	Body mass index;	chr2:28728832	chr2:28708953~28736205:-
BRCA	cis	rs4713118	0.955	rs9380010	ENSG00000220721.1	OR1F12	6.6	6.54e-11	1.27e-08	0.25	0.2	Parkinson's disease;	chr6:27715793	chr6:28073316~28074233:+
BRCA	cis	rs5015933	0.815	rs10124754	ENSG00000232630.1	PRPS1P2	-6.6	6.54e-11	1.28e-08	-0.18	-0.2	Body mass index;	chr9:125327479	chr9:125150653~125151589:+
BRCA	cis	rs957448	0.948	rs11992893	ENSG00000253175.1	RP11-267M23.6	6.6	6.54e-11	1.28e-08	0.26	0.2	Nonsyndromic cleft lip with cleft palate;	chr8:94508473	chr8:94565036~94565715:+
BRCA	cis	rs957448	1	rs1048029	ENSG00000253175.1	RP11-267M23.6	6.6	6.54e-11	1.28e-08	0.26	0.2	Nonsyndromic cleft lip with cleft palate;	chr8:94510149	chr8:94565036~94565715:+
BRCA	cis	rs875971	0.545	rs4718325	ENSG00000273024.4	INTS4P2	-6.6	6.55e-11	1.28e-08	-0.25	-0.2	Aortic root size;	chr7:66215323	chr7:65647864~65715661:+
BRCA	cis	rs172166	0.694	rs536704	ENSG00000204709.4	LINC01556	6.6	6.56e-11	1.28e-08	0.27	0.2	Cardiac Troponin-T levels;	chr6:28124825	chr6:28943877~28944537:+
BRCA	cis	rs1707322	1	rs4660332	ENSG00000281133.1	AL355480.3	-6.6	6.57e-11	1.28e-08	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45995746	chr1:45580892~45580996:-
BRCA	cis	rs673078	0.607	rs61943447	ENSG00000275409.1	RP11-131L12.4	-6.6	6.58e-11	1.28e-08	-0.3	-0.2	Glucose homeostasis traits;	chr12:118430598	chr12:118430147~118430699:+
BRCA	cis	rs754466	0.724	rs11002318	ENSG00000204049.1	RP11-126H7.4	6.6	6.58e-11	1.28e-08	0.24	0.2	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77874049	chr10:77866875~77869610:+
BRCA	cis	rs860818	1	rs858232	ENSG00000226816.2	AC005082.12	6.6	6.58e-11	1.28e-08	0.49	0.2	Initial pursuit acceleration;	chr7:23202100	chr7:23206013~23208045:+
BRCA	cis	rs1823913	0.599	rs67342262	ENSG00000280083.1	RP11-317J9.1	-6.6	6.58e-11	1.28e-08	-0.23	-0.2	Obesity-related traits;	chr2:191295612	chr2:191154118~191156070:-
BRCA	cis	rs420259	0.516	rs2097662	ENSG00000260136.4	CTD-2270L9.4	-6.6	6.58e-11	1.28e-08	-0.2	-0.2	Bipolar disorder;	chr16:23512024	chr16:23452758~23457606:+
BRCA	cis	rs1707322	0.686	rs2230658	ENSG00000281133.1	AL355480.3	6.6	6.58e-11	1.28e-08	0.26	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613182	chr1:45580892~45580996:-
BRCA	cis	rs420259	0.516	rs1135045	ENSG00000260136.4	CTD-2270L9.4	-6.6	6.58e-11	1.28e-08	-0.2	-0.2	Bipolar disorder;	chr16:23478390	chr16:23452758~23457606:+
BRCA	cis	rs875971	0.545	rs73142233	ENSG00000273024.4	INTS4P2	-6.6	6.59e-11	1.28e-08	-0.25	-0.2	Aortic root size;	chr7:66221293	chr7:65647864~65715661:+
BRCA	cis	rs7665090	1	rs2866407	ENSG00000246560.2	RP11-10L12.4	6.6	6.6e-11	1.29e-08	0.21	0.2	Primary biliary cholangitis;	chr4:102632951	chr4:102828055~102844075:+
BRCA	cis	rs7665090	1	rs2866408	ENSG00000246560.2	RP11-10L12.4	6.6	6.6e-11	1.29e-08	0.21	0.2	Primary biliary cholangitis;	chr4:102632956	chr4:102828055~102844075:+
BRCA	cis	rs17711722	0.522	rs62469933	ENSG00000213640.3	EEF1DP4	-6.6	6.61e-11	1.29e-08	-0.25	-0.2	Calcium levels;	chr7:65800652	chr7:64862999~64864370:+
BRCA	cis	rs1707322	0.964	rs785508	ENSG00000281133.1	AL355480.3	6.6	6.62e-11	1.29e-08	0.25	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46061487	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.964	rs785509	ENSG00000281133.1	AL355480.3	6.6	6.62e-11	1.29e-08	0.25	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46061628	chr1:45580892~45580996:-
BRCA	cis	rs867371	0.896	rs8033831	ENSG00000259429.4	UBE2Q2P2	-6.6	6.63e-11	1.29e-08	-0.2	-0.2	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82220953	chr15:82355142~82420075:+
BRCA	cis	rs7665090	0.936	rs2866411	ENSG00000246560.2	RP11-10L12.4	6.6	6.64e-11	1.29e-08	0.21	0.2	Primary biliary cholangitis;	chr4:102633183	chr4:102828055~102844075:+
BRCA	cis	rs4218	0.543	rs11852461	ENSG00000277144.1	RP11-59H7.4	-6.6	6.64e-11	1.29e-08	-0.24	-0.2	Social communication problems;	chr15:59021728	chr15:59115547~59116089:-
BRCA	cis	rs2348418	0.966	rs1527578	ENSG00000247934.4	RP11-967K21.1	6.6	6.66e-11	1.3e-08	0.23	0.2	Lung function (FEV1);Lung function (FVC);	chr12:28536903	chr12:28163298~28190738:-
BRCA	cis	rs875971	0.862	rs28470208	ENSG00000224316.1	RP11-479O9.2	-6.6	6.67e-11	1.3e-08	-0.2	-0.2	Aortic root size;	chr7:66119713	chr7:65773620~65802067:+
BRCA	cis	rs227275	0.554	rs223467	ENSG00000251288.2	RP11-10L12.2	-6.6	6.68e-11	1.3e-08	-0.23	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102779721	chr4:102751401~102752641:+
BRCA	cis	rs7246657	0.943	rs2291004	ENSG00000226686.6	LINC01535	-6.6	6.69e-11	1.3e-08	-0.3	-0.2	Coronary artery calcification;	chr19:37507050	chr19:37251912~37265535:+
BRCA	cis	rs6840360	0.642	rs1443089	ENSG00000270265.1	RP11-731D1.4	-6.6	6.71e-11	1.31e-08	-0.22	-0.2	Intelligence (multi-trait analysis);	chr4:151529148	chr4:151333775~151353224:-
BRCA	cis	rs875971	0.545	rs3936065	ENSG00000273024.4	INTS4P2	-6.6	6.71e-11	1.31e-08	-0.25	-0.2	Aortic root size;	chr7:66325577	chr7:65647864~65715661:+
BRCA	cis	rs875971	0.545	rs4718335	ENSG00000273024.4	INTS4P2	-6.6	6.71e-11	1.31e-08	-0.25	-0.2	Aortic root size;	chr7:66339619	chr7:65647864~65715661:+
BRCA	cis	rs17711722	0.523	rs365896	ENSG00000228409.4	CCT6P1	6.6	6.71e-11	1.31e-08	0.18	0.2	Calcium levels;	chr7:66045710	chr7:65751142~65763354:+
BRCA	cis	rs10740039	0.768	rs10821801	ENSG00000254271.1	RP11-131N11.4	6.6	6.71e-11	1.31e-08	0.27	0.2	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60612017	chr10:60734342~60741828:+
BRCA	cis	rs2243480	1	rs313813	ENSG00000232546.1	RP11-458F8.1	-6.6	6.72e-11	1.31e-08	-0.27	-0.2	Diabetic kidney disease;	chr7:66038513	chr7:66848496~66858136:+
BRCA	cis	rs7976269	0.609	rs10843306	ENSG00000257176.2	RP11-996F15.2	-6.6	6.73e-11	1.31e-08	-0.24	-0.2	Male-pattern baldness;	chr12:29073417	chr12:29280418~29317848:-
BRCA	cis	rs16863064	0.866	rs9855318	ENSG00000279891.1	FLJ42393	6.6	6.74e-11	1.31e-08	0.28	0.2	Schizophrenia;	chr3:188169593	chr3:188178543~188180812:+
BRCA	cis	rs838147	0.505	rs1688264	ENSG00000232871.7	SEC1P	6.6	6.75e-11	1.31e-08	0.22	0.2	Dietary macronutrient intake;	chr19:48706303	chr19:48638071~48682245:+
BRCA	cis	rs838147	0.507	rs1704773	ENSG00000232871.7	SEC1P	6.6	6.75e-11	1.31e-08	0.22	0.2	Dietary macronutrient intake;	chr19:48706309	chr19:48638071~48682245:+
BRCA	cis	rs2998286	0.822	rs2095901	ENSG00000254635.4	WAC-AS1	-6.59	6.75e-11	1.31e-08	-0.28	-0.2	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28514790	chr10:28522652~28532743:-
BRCA	cis	rs2998286	0.862	rs2993990	ENSG00000254635.4	WAC-AS1	-6.59	6.75e-11	1.31e-08	-0.28	-0.2	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28518041	chr10:28522652~28532743:-
BRCA	cis	rs2638953	0.85	rs11049402	ENSG00000247934.4	RP11-967K21.1	-6.59	6.76e-11	1.32e-08	-0.25	-0.2	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28175974	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.924	rs11049405	ENSG00000247934.4	RP11-967K21.1	-6.59	6.76e-11	1.32e-08	-0.26	-0.2	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28181003	chr12:28163298~28190738:-
BRCA	cis	rs11098499	0.908	rs9995234	ENSG00000249244.1	RP11-548H18.2	6.59	6.77e-11	1.32e-08	0.25	0.2	Corneal astigmatism;	chr4:119400672	chr4:119391831~119395335:-
BRCA	cis	rs2060793	0.87	rs10732460	ENSG00000251991.1	RNU7-49P	6.59	6.77e-11	1.32e-08	0.22	0.2	Vitamin D levels;	chr11:14854025	chr11:14478892~14478953:+
BRCA	cis	rs1499614	1	rs1267817	ENSG00000229886.1	RP5-1132H15.3	6.59	6.79e-11	1.32e-08	0.36	0.2	Gout;	chr7:66645053	chr7:66025126~66031544:-
BRCA	cis	rs17772222	0.655	rs10150594	ENSG00000258983.2	RP11-507K2.2	6.59	6.79e-11	1.32e-08	0.21	0.2	Coronary artery calcification;	chr14:88489613	chr14:88499334~88515502:+
BRCA	cis	rs2235642	0.891	rs2281231	ENSG00000280231.1	LA16c-380F5.3	-6.59	6.79e-11	1.32e-08	-0.26	-0.2	Coronary artery disease;	chr16:1551878	chr16:1553655~1554130:-
BRCA	cis	rs6570726	1	rs1935617	ENSG00000235652.6	RP11-545I5.3	6.59	6.8e-11	1.32e-08	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145622190	chr6:145799409~145886585:+
BRCA	cis	rs7246657	0.882	rs4803539	ENSG00000226686.6	LINC01535	-6.59	6.8e-11	1.32e-08	-0.29	-0.2	Coronary artery calcification;	chr19:37406620	chr19:37251912~37265535:+
BRCA	cis	rs9816784	0.901	rs56253832	ENSG00000231464.1	AC024937.4	6.59	6.8e-11	1.32e-08	0.25	0.2	Mean corpuscular hemoglobin;	chr3:196090304	chr3:195996738~195998233:+
BRCA	cis	rs9807989	0.839	rs4988957	ENSG00000234389.1	AC007278.3	-6.59	6.8e-11	1.32e-08	-0.19	-0.2	Asthma;	chr2:102351615	chr2:102438713~102440475:+
BRCA	cis	rs2243480	1	rs2243480	ENSG00000232546.1	RP11-458F8.1	-6.59	6.81e-11	1.32e-08	-0.27	-0.2	Diabetic kidney disease;	chr7:66134209	chr7:66848496~66858136:+
BRCA	cis	rs5015933	0.815	rs4991998	ENSG00000232630.1	PRPS1P2	-6.59	6.81e-11	1.32e-08	-0.18	-0.2	Body mass index;	chr9:125314702	chr9:125150653~125151589:+
BRCA	cis	rs6142102	0.651	rs6088412	ENSG00000276073.1	RP5-1125A11.7	6.59	6.83e-11	1.33e-08	0.27	0.2	Skin pigmentation;	chr20:34154262	chr20:33985617~33988989:-
BRCA	cis	rs875971	0.862	rs4368860	ENSG00000224316.1	RP11-479O9.2	-6.59	6.83e-11	1.33e-08	-0.2	-0.2	Aortic root size;	chr7:66143495	chr7:65773620~65802067:+
BRCA	cis	rs11742741	0.64	rs62347897	ENSG00000248874.4	C5orf17	-6.59	6.83e-11	1.33e-08	-0.25	-0.2	Educational attainment;	chr5:24214756	chr5:23951348~24178263:+
BRCA	cis	rs2243480	1	rs778679	ENSG00000229886.1	RP5-1132H15.3	6.59	6.83e-11	1.33e-08	0.36	0.2	Diabetic kidney disease;	chr7:66375924	chr7:66025126~66031544:-
BRCA	cis	rs5015933	0.815	rs937482	ENSG00000232630.1	PRPS1P2	-6.59	6.83e-11	1.33e-08	-0.18	-0.2	Body mass index;	chr9:125354538	chr9:125150653~125151589:+
BRCA	cis	rs11742741	0.714	rs1428203	ENSG00000248874.4	C5orf17	-6.59	6.84e-11	1.33e-08	-0.25	-0.2	Educational attainment;	chr5:24164504	chr5:23951348~24178263:+
BRCA	cis	rs11098499	0.954	rs12510138	ENSG00000249244.1	RP11-548H18.2	6.59	6.84e-11	1.33e-08	0.24	0.2	Corneal astigmatism;	chr4:119502780	chr4:119391831~119395335:-
BRCA	cis	rs7976269	0.609	rs10771474	ENSG00000257176.2	RP11-996F15.2	6.59	6.84e-11	1.33e-08	0.24	0.2	Male-pattern baldness;	chr12:29068776	chr12:29280418~29317848:-
BRCA	cis	rs9876781	1	rs2290822	ENSG00000229759.1	MRPS18AP1	6.59	6.85e-11	1.33e-08	0.22	0.2	Longevity;	chr3:48431794	chr3:48256350~48256938:-
BRCA	cis	rs1707322	1	rs785507	ENSG00000281133.1	AL355480.3	6.59	6.86e-11	1.33e-08	0.26	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46075886	chr1:45580892~45580996:-
BRCA	cis	rs754466	0.651	rs11818687	ENSG00000204049.1	RP11-126H7.4	6.59	6.87e-11	1.34e-08	0.24	0.2	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77877951	chr10:77866875~77869610:+
BRCA	cis	rs1707322	0.691	rs11211175	ENSG00000281133.1	AL355480.3	-6.59	6.87e-11	1.34e-08	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755212	chr1:45580892~45580996:-
BRCA	cis	rs66887589	0.66	rs4833613	ENSG00000245958.5	RP11-33B1.1	6.59	6.87e-11	1.34e-08	0.18	0.2	Diastolic blood pressure;	chr4:119229001	chr4:119454791~119552025:+
BRCA	cis	rs2243480	1	rs67536397	ENSG00000230295.1	RP11-458F8.2	-6.59	6.88e-11	1.34e-08	-0.27	-0.2	Diabetic kidney disease;	chr7:66482930	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs58669269	ENSG00000230295.1	RP11-458F8.2	-6.59	6.88e-11	1.34e-08	-0.27	-0.2	Diabetic kidney disease;	chr7:66486966	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs316326	ENSG00000232546.1	RP11-458F8.1	-6.59	6.88e-11	1.34e-08	-0.26	-0.2	Diabetic kidney disease;	chr7:66144466	chr7:66848496~66858136:+
BRCA	cis	rs2243480	1	rs316325	ENSG00000232546.1	RP11-458F8.1	-6.59	6.88e-11	1.34e-08	-0.26	-0.2	Diabetic kidney disease;	chr7:66144531	chr7:66848496~66858136:+
BRCA	cis	rs2599510	0.811	rs2243844	ENSG00000276334.1	AL133243.1	6.59	6.89e-11	1.34e-08	0.24	0.2	Interleukin-18 levels;	chr2:32550917	chr2:32521927~32523547:+
BRCA	cis	rs7772486	0.774	rs6930181	ENSG00000235652.6	RP11-545I5.3	-6.59	6.89e-11	1.34e-08	-0.19	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:145859838	chr6:145799409~145886585:+
BRCA	cis	rs1729407	0.774	rs2849167	ENSG00000280143.1	AP000892.6	-6.59	6.89e-11	1.34e-08	-0.2	-0.2	Apolipoprotein A-IV levels;	chr11:116814028	chr11:117204967~117210292:+
BRCA	cis	rs17711722	0.727	rs35850374	ENSG00000237310.1	GS1-124K5.4	6.59	6.9e-11	1.34e-08	0.21	0.2	Calcium levels;	chr7:65892789	chr7:66493706~66495474:+
BRCA	cis	rs1823913	0.599	rs58106487	ENSG00000280083.1	RP11-317J9.1	-6.59	6.91e-11	1.34e-08	-0.23	-0.2	Obesity-related traits;	chr2:191292404	chr2:191154118~191156070:-
BRCA	cis	rs17253792	0.822	rs112238223	ENSG00000186615.9	KTN1-AS1	-6.59	6.91e-11	1.34e-08	-0.42	-0.2	Putamen volume;	chr14:55589426	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs80174205	ENSG00000186615.9	KTN1-AS1	-6.59	6.91e-11	1.34e-08	-0.42	-0.2	Putamen volume;	chr14:55591976	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs78261053	ENSG00000186615.9	KTN1-AS1	-6.59	6.91e-11	1.34e-08	-0.42	-0.2	Putamen volume;	chr14:55595066	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.731	rs8008528	ENSG00000186615.9	KTN1-AS1	-6.59	6.91e-11	1.34e-08	-0.42	-0.2	Putamen volume;	chr14:55595334	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs8009239	ENSG00000186615.9	KTN1-AS1	-6.59	6.91e-11	1.34e-08	-0.42	-0.2	Putamen volume;	chr14:55595772	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs79291233	ENSG00000186615.9	KTN1-AS1	-6.59	6.91e-11	1.34e-08	-0.42	-0.2	Putamen volume;	chr14:55598584	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.818	rs78393484	ENSG00000186615.9	KTN1-AS1	-6.59	6.91e-11	1.34e-08	-0.42	-0.2	Putamen volume;	chr14:55599084	chr14:55499278~55580110:-
BRCA	cis	rs853679	0.556	rs34706883	ENSG00000220721.1	OR1F12	6.59	6.91e-11	1.34e-08	0.47	0.2	Depression;	chr6:27837477	chr6:28073316~28074233:+
BRCA	cis	rs847577	0.588	rs6946915	ENSG00000272950.1	RP11-307C18.1	6.59	6.91e-11	1.34e-08	0.26	0.2	Breast cancer;	chr7:98082028	chr7:98322853~98323430:+
BRCA	cis	rs12594515	1	rs11070464	ENSG00000259200.1	RP11-718O11.1	-6.59	6.91e-11	1.34e-08	-0.22	-0.2	Weight;Waist circumference;	chr15:45692578	chr15:45705078~45931069:+
BRCA	cis	rs7617773	0.817	rs3731497	ENSG00000228638.1	FCF1P2	-6.59	6.92e-11	1.34e-08	-0.22	-0.2	Coronary artery disease;	chr3:48185063	chr3:48290793~48291375:-
BRCA	cis	rs2337406	1	rs17113257	ENSG00000211974.3	IGHV2-70	-6.59	6.92e-11	1.34e-08	-0.25	-0.2	Alzheimer's disease (late onset);	chr14:106679574	chr14:106723574~106724093:-
BRCA	cis	rs2243480	0.803	rs55700941	ENSG00000228409.4	CCT6P1	6.59	6.93e-11	1.35e-08	0.28	0.2	Diabetic kidney disease;	chr7:65924813	chr7:65751142~65763354:+
BRCA	cis	rs9307551	0.744	rs968176	ENSG00000250334.4	LINC00989	-6.59	6.93e-11	1.35e-08	-0.27	-0.2	Refractive error;	chr4:79585080	chr4:79492416~79576460:+
BRCA	cis	rs4713118	0.955	rs9468201	ENSG00000220721.1	OR1F12	6.59	6.93e-11	1.35e-08	0.25	0.2	Parkinson's disease;	chr6:27719256	chr6:28073316~28074233:+
BRCA	cis	rs4366055	1	rs4366055	ENSG00000253175.1	RP11-267M23.6	6.59	6.94e-11	1.35e-08	0.24	0.2	Body mass index;	chr8:94495100	chr8:94565036~94565715:+
BRCA	cis	rs17253792	0.822	rs78826571	ENSG00000186615.9	KTN1-AS1	-6.59	6.94e-11	1.35e-08	-0.41	-0.2	Putamen volume;	chr14:55582188	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.731	rs74823888	ENSG00000186615.9	KTN1-AS1	-6.59	6.94e-11	1.35e-08	-0.41	-0.2	Putamen volume;	chr14:55583082	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs75016910	ENSG00000186615.9	KTN1-AS1	-6.59	6.94e-11	1.35e-08	-0.41	-0.2	Putamen volume;	chr14:55583748	chr14:55499278~55580110:-
BRCA	cis	rs17214007	0.877	rs2075514	ENSG00000263335.1	AF001548.5	-6.59	6.94e-11	1.35e-08	-0.29	-0.2	Cognitive function;	chr16:15778752	chr16:15726674~15732993:+
BRCA	cis	rs875971	0.964	rs778735	ENSG00000224316.1	RP11-479O9.2	6.59	6.95e-11	1.35e-08	0.2	0.2	Aortic root size;	chr7:66349822	chr7:65773620~65802067:+
BRCA	cis	rs7432375	0.609	rs835637	ENSG00000239213.4	NCK1-AS1	6.59	6.96e-11	1.35e-08	0.21	0.2	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136954315	chr3:136841726~136862054:-
BRCA	cis	rs1275468	0.68	rs1697753	ENSG00000257497.2	RP11-585P4.5	-6.59	6.96e-11	1.35e-08	-0.3	-0.2	Polycystic ovary syndrome;	chr12:75562074	chr12:75483454~75489820:-
BRCA	cis	rs2274273	1	rs7160110	ENSG00000258413.1	RP11-665C16.6	-6.59	6.97e-11	1.35e-08	-0.26	-0.2	Protein biomarker;	chr14:55127917	chr14:55262767~55272075:-
BRCA	cis	rs10740039	0.729	rs6479721	ENSG00000254271.1	RP11-131N11.4	6.59	6.97e-11	1.35e-08	0.27	0.2	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60613364	chr10:60734342~60741828:+
BRCA	cis	rs2638953	0.814	rs11049413	ENSG00000247934.4	RP11-967K21.1	-6.59	6.97e-11	1.36e-08	-0.26	-0.2	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28186322	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.85	rs11049414	ENSG00000247934.4	RP11-967K21.1	-6.59	6.97e-11	1.36e-08	-0.26	-0.2	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28186325	chr12:28163298~28190738:-
BRCA	cis	rs2286503	0.78	rs2286506	ENSG00000228649.7	AC005682.5	6.59	6.98e-11	1.36e-08	0.18	0.2	Fibrinogen;	chr7:22815196	chr7:22854178~22861579:+
BRCA	cis	rs13113518	0.841	rs7699867	ENSG00000249700.7	SRD5A3-AS1	6.59	6.98e-11	1.36e-08	0.26	0.2	Height;	chr4:55483718	chr4:55363971~55395847:-
BRCA	cis	rs1275468	0.731	rs1795380	ENSG00000257497.2	RP11-585P4.5	-6.59	6.98e-11	1.36e-08	-0.3	-0.2	Polycystic ovary syndrome;	chr12:75559432	chr12:75483454~75489820:-
BRCA	cis	rs9307551	0.857	rs2218213	ENSG00000250334.4	LINC00989	-6.59	6.99e-11	1.36e-08	-0.27	-0.2	Refractive error;	chr4:79614890	chr4:79492416~79576460:+
BRCA	cis	rs6844153	0.938	rs16878655	ENSG00000240005.4	RP11-293A21.1	6.59	7e-11	1.36e-08	0.3	0.2	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26964655	chr4:26859806~26860599:-
BRCA	cis	rs7772486	0.743	rs111332144	ENSG00000235652.6	RP11-545I5.3	-6.59	7.01e-11	1.36e-08	-0.2	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:145735545	chr6:145799409~145886585:+
BRCA	cis	rs7246657	0.943	rs3803895	ENSG00000226686.6	LINC01535	-6.59	7.02e-11	1.36e-08	-0.29	-0.2	Coronary artery calcification;	chr19:37407767	chr19:37251912~37265535:+
BRCA	cis	rs2243480	1	rs316332	ENSG00000232546.1	RP11-458F8.1	-6.59	7.03e-11	1.37e-08	-0.26	-0.2	Diabetic kidney disease;	chr7:66139312	chr7:66848496~66858136:+
BRCA	cis	rs9638182	0.725	rs17145738	ENSG00000274080.1	CTA-315H11.2	6.59	7.04e-11	1.37e-08	0.39	0.2	Triglycerides;	chr7:73568544	chr7:73609262~73611502:-
BRCA	cis	rs7665090	1	rs1054029	ENSG00000246560.2	RP11-10L12.4	6.59	7.04e-11	1.37e-08	0.21	0.2	Primary biliary cholangitis;	chr4:102631896	chr4:102828055~102844075:+
BRCA	cis	rs7665090	1	rs3194585	ENSG00000246560.2	RP11-10L12.4	6.59	7.04e-11	1.37e-08	0.21	0.2	Primary biliary cholangitis;	chr4:102631933	chr4:102828055~102844075:+
BRCA	cis	rs2243480	1	rs1553174	ENSG00000230295.1	RP11-458F8.2	6.59	7.05e-11	1.37e-08	0.26	0.2	Diabetic kidney disease;	chr7:66266207	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs10950032	ENSG00000230295.1	RP11-458F8.2	6.59	7.05e-11	1.37e-08	0.26	0.2	Diabetic kidney disease;	chr7:66273604	chr7:66880708~66882981:+
BRCA	cis	rs858239	1	rs199357	ENSG00000230042.1	AK3P3	6.59	7.05e-11	1.37e-08	0.23	0.2	Cerebrospinal fluid biomarker levels;	chr7:23248690	chr7:23129178~23129841:+
BRCA	cis	rs250585	0.92	rs11074563	ENSG00000260136.4	CTD-2270L9.4	-6.59	7.05e-11	1.37e-08	-0.23	-0.2	Egg allergy;	chr16:23511972	chr16:23452758~23457606:+
BRCA	cis	rs250585	1	rs9940058	ENSG00000260136.4	CTD-2270L9.4	-6.59	7.05e-11	1.37e-08	-0.23	-0.2	Egg allergy;	chr16:23515741	chr16:23452758~23457606:+
BRCA	cis	rs250585	0.915	rs2369011	ENSG00000260136.4	CTD-2270L9.4	-6.59	7.05e-11	1.37e-08	-0.23	-0.2	Egg allergy;	chr16:23518485	chr16:23452758~23457606:+
BRCA	cis	rs250585	1	rs2040572	ENSG00000260136.4	CTD-2270L9.4	-6.59	7.05e-11	1.37e-08	-0.23	-0.2	Egg allergy;	chr16:23518565	chr16:23452758~23457606:+
BRCA	cis	rs4664293	0.565	rs10165197	ENSG00000226266.5	AC009961.3	6.59	7.06e-11	1.37e-08	0.24	0.2	Monocyte percentage of white cells;	chr2:159537137	chr2:159670708~159712435:-
BRCA	cis	rs860818	1	rs858247	ENSG00000226816.2	AC005082.12	6.59	7.06e-11	1.37e-08	0.48	0.2	Initial pursuit acceleration;	chr7:23181664	chr7:23206013~23208045:+
BRCA	cis	rs875971	0.545	rs6970498	ENSG00000236529.1	RP13-254B10.1	6.59	7.07e-11	1.37e-08	0.25	0.2	Aortic root size;	chr7:66275908	chr7:65840212~65840596:+
BRCA	cis	rs858239	0.6	rs10488077	ENSG00000230042.1	AK3P3	-6.59	7.07e-11	1.37e-08	-0.23	-0.2	Cerebrospinal fluid biomarker levels;	chr7:23104563	chr7:23129178~23129841:+
BRCA	cis	rs16846053	0.515	rs1510084	ENSG00000227403.1	AC009299.3	-6.59	7.08e-11	1.37e-08	-0.33	-0.2	Blood osmolality (transformed sodium);	chr2:161647233	chr2:161244739~161249050:+
BRCA	cis	rs7829975	0.572	rs7005000	ENSG00000233609.3	RP11-62H7.2	-6.59	7.08e-11	1.37e-08	-0.18	-0.2	Mood instability;	chr8:8939092	chr8:8961200~8979025:+
BRCA	cis	rs6142102	0.961	rs6059649	ENSG00000275784.1	RP5-1125A11.6	-6.59	7.09e-11	1.38e-08	-0.24	-0.2	Skin pigmentation;	chr20:34056071	chr20:33989480~33991818:-
BRCA	cis	rs7178375	1	rs10163148	ENSG00000215302.7	CTD-3092A11.1	-6.59	7.09e-11	1.38e-08	-0.3	-0.2	Hypertriglyceridemia;	chr15:30920481	chr15:30470779~30507623:+
BRCA	cis	rs34779708	0.931	rs10437420	ENSG00000271335.4	RP11-324I22.4	-6.59	7.09e-11	1.38e-08	-0.2	-0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35046116	chr10:35314552~35336401:-
BRCA	cis	rs11976180	1	rs2961117	ENSG00000204959.4	ARHGEF34P	6.59	7.1e-11	1.38e-08	0.25	0.2	Obesity-related traits;	chr7:144058160	chr7:144272445~144286966:-
BRCA	cis	rs62355901	0.505	rs3733951	ENSG00000271828.1	CTD-2310F14.1	-6.59	7.1e-11	1.38e-08	-0.35	-0.2	Breast cancer;	chr5:56833976	chr5:56927874~56929573:+
BRCA	cis	rs8030379	1	rs10906982	ENSG00000230373.7	GOLGA6L5P	-6.59	7.11e-11	1.38e-08	-0.21	-0.2	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83899406	chr15:84507885~84516814:-
BRCA	cis	rs9307551	0.857	rs2218212	ENSG00000250334.4	LINC00989	-6.59	7.11e-11	1.38e-08	-0.27	-0.2	Refractive error;	chr4:79614887	chr4:79492416~79576460:+
BRCA	cis	rs4934494	0.768	rs3740034	ENSG00000240996.1	RP11-80H5.7	-6.59	7.12e-11	1.38e-08	-0.24	-0.2	Red blood cell count;	chr10:89634902	chr10:89694295~89697928:-
BRCA	cis	rs853679	0.517	rs6932109	ENSG00000219392.1	RP1-265C24.5	6.59	7.12e-11	1.38e-08	0.3	0.2	Depression;	chr6:28110525	chr6:28115628~28116551:+
BRCA	cis	rs875971	0.545	rs6969224	ENSG00000224316.1	RP11-479O9.2	6.59	7.12e-11	1.38e-08	0.23	0.2	Aortic root size;	chr7:66370011	chr7:65773620~65802067:+
BRCA	cis	rs853679	0.517	rs9380047	ENSG00000219392.1	RP1-265C24.5	-6.59	7.12e-11	1.38e-08	-0.3	-0.2	Depression;	chr6:28070115	chr6:28115628~28116551:+
BRCA	cis	rs3781264	0.816	rs2274223	ENSG00000273450.1	RP11-76P2.4	6.59	7.13e-11	1.38e-08	0.26	0.2	Esophageal cancer and gastric cancer;	chr10:94306584	chr10:94314907~94315327:-
BRCA	cis	rs669446	0.533	rs4660261	ENSG00000237950.1	RP11-7O11.3	6.59	7.14e-11	1.38e-08	0.23	0.2	Amyotrophic lateral sclerosis (age of onset);	chr1:43763926	chr1:43944370~43946551:-
BRCA	cis	rs67981189	0.789	rs12101246	ENSG00000269927.1	RP6-91H8.3	6.59	7.14e-11	1.38e-08	0.25	0.2	Schizophrenia;	chr14:71084618	chr14:71141125~71143253:-
BRCA	cis	rs919433	0.926	rs787997	ENSG00000231621.1	AC013264.2	-6.59	7.14e-11	1.39e-08	-0.19	-0.2	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197351547	chr2:197197991~197199273:+
BRCA	cis	rs11098499	0.863	rs3775841	ENSG00000249244.1	RP11-548H18.2	6.59	7.14e-11	1.39e-08	0.24	0.2	Corneal astigmatism;	chr4:119504622	chr4:119391831~119395335:-
BRCA	cis	rs172166	0.694	rs1631552	ENSG00000204709.4	LINC01556	6.59	7.14e-11	1.39e-08	0.27	0.2	Cardiac Troponin-T levels;	chr6:28121921	chr6:28943877~28944537:+
BRCA	cis	rs516805	0.847	rs520046	ENSG00000279453.1	RP3-425C14.4	-6.59	7.15e-11	1.39e-08	-0.23	-0.2	Lymphocyte counts;	chr6:122446048	chr6:122436789~122439223:-
BRCA	cis	rs17772222	0.74	rs10150311	ENSG00000258983.2	RP11-507K2.2	6.59	7.15e-11	1.39e-08	0.21	0.2	Coronary artery calcification;	chr14:88510128	chr14:88499334~88515502:+
BRCA	cis	rs11096990	0.964	rs6835064	ENSG00000249207.1	RP11-360F5.1	6.59	7.16e-11	1.39e-08	0.23	0.2	Cognitive function;	chr4:39264346	chr4:39112677~39126818:-
BRCA	cis	rs11089937	0.555	rs6001226	ENSG00000211639.2	IGLV4-60	6.59	7.16e-11	1.39e-08	0.2	0.2	Periodontitis (PAL4Q3);	chr22:22186888	chr22:22162199~22162681:+
BRCA	cis	rs2153535	0.518	rs9392227	ENSG00000230939.1	RP11-314C16.1	-6.59	7.16e-11	1.39e-08	-0.24	-0.2	Motion sickness;	chr6:8581553	chr6:8784178~8785445:+
BRCA	cis	rs11098499	0.863	rs1383533	ENSG00000249244.1	RP11-548H18.2	6.59	7.17e-11	1.39e-08	0.24	0.2	Corneal astigmatism;	chr4:119513421	chr4:119391831~119395335:-
BRCA	cis	rs853679	0.517	rs4713135	ENSG00000219392.1	RP1-265C24.5	-6.59	7.17e-11	1.39e-08	-0.3	-0.2	Depression;	chr6:28071808	chr6:28115628~28116551:+
BRCA	cis	rs172166	0.694	rs1631552	ENSG00000216901.1	AL022393.7	6.59	7.18e-11	1.39e-08	0.26	0.2	Cardiac Troponin-T levels;	chr6:28121921	chr6:28176188~28176674:+
BRCA	cis	rs4372836	0.93	rs4233727	ENSG00000226833.4	AC097724.3	6.59	7.19e-11	1.39e-08	0.24	0.2	Body mass index;	chr2:28754378	chr2:28708953~28736205:-
BRCA	cis	rs4845875	0.542	rs7537955	ENSG00000242349.4	NPPA-AS1	6.59	7.19e-11	1.4e-08	0.24	0.2	Midregional pro atrial natriuretic peptide levels;	chr1:11797353	chr1:11841017~11848079:+
BRCA	cis	rs9307551	0.817	rs1975399	ENSG00000250334.4	LINC00989	-6.59	7.19e-11	1.4e-08	-0.27	-0.2	Refractive error;	chr4:79582612	chr4:79492416~79576460:+
BRCA	cis	rs9500256	0.655	rs12208465	ENSG00000215190.7	LINC00680	-6.59	7.2e-11	1.4e-08	-0.24	-0.2	Eosinophilic esophagitis (pediatric);	chr6:58004603	chr6:57946074~57961501:-
BRCA	cis	rs2842992	0.872	rs2758315	ENSG00000237927.1	RP3-393E18.2	-6.58	7.22e-11	1.4e-08	-0.28	-0.2	Age-related macular degeneration (geographic atrophy);	chr6:159737608	chr6:159586955~159589169:-
BRCA	cis	rs875971	0.545	rs10950036	ENSG00000236529.1	RP13-254B10.1	6.58	7.22e-11	1.4e-08	0.25	0.2	Aortic root size;	chr7:66353241	chr7:65840212~65840596:+
BRCA	cis	rs7131987	0.565	rs7300032	ENSG00000257176.2	RP11-996F15.2	6.58	7.24e-11	1.4e-08	0.23	0.2	QT interval;	chr12:29256859	chr12:29280418~29317848:-
BRCA	cis	rs7131987	0.547	rs4370971	ENSG00000257176.2	RP11-996F15.2	6.58	7.24e-11	1.4e-08	0.23	0.2	QT interval;	chr12:29257066	chr12:29280418~29317848:-
BRCA	cis	rs2638953	0.925	rs11049412	ENSG00000247934.4	RP11-967K21.1	-6.58	7.25e-11	1.41e-08	-0.26	-0.2	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28186199	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.924	rs12366932	ENSG00000247934.4	RP11-967K21.1	-6.58	7.25e-11	1.41e-08	-0.26	-0.2	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28188953	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.924	rs1478336	ENSG00000247934.4	RP11-967K21.1	-6.58	7.25e-11	1.41e-08	-0.26	-0.2	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28189186	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.924	rs1478335	ENSG00000247934.4	RP11-967K21.1	-6.58	7.25e-11	1.41e-08	-0.26	-0.2	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28189244	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.924	rs1478334	ENSG00000247934.4	RP11-967K21.1	-6.58	7.25e-11	1.41e-08	-0.26	-0.2	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28189425	chr12:28163298~28190738:-
BRCA	cis	rs5760092	0.572	rs738806	ENSG00000099984.9	GSTT2	-6.58	7.26e-11	1.41e-08	-0.26	-0.2	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23891985	chr22:23980123~23983911:+
BRCA	cis	rs4886920	0.692	rs4625694	ENSG00000260776.4	RP11-114H24.2	6.58	7.28e-11	1.41e-08	0.27	0.2	Neuroticism;	chr15:77826137	chr15:77914217~77926846:-
BRCA	cis	rs4886920	0.692	rs4625695	ENSG00000260776.4	RP11-114H24.2	6.58	7.28e-11	1.41e-08	0.27	0.2	Neuroticism;	chr15:77826153	chr15:77914217~77926846:-
BRCA	cis	rs4886920	0.723	rs11633959	ENSG00000260776.4	RP11-114H24.2	6.58	7.28e-11	1.41e-08	0.27	0.2	Neuroticism;	chr15:77826362	chr15:77914217~77926846:-
BRCA	cis	rs7665090	1	rs735405	ENSG00000246560.2	RP11-10L12.4	6.58	7.29e-11	1.41e-08	0.21	0.2	Primary biliary cholangitis;	chr4:102632759	chr4:102828055~102844075:+
BRCA	cis	rs7665090	1	rs1077358	ENSG00000246560.2	RP11-10L12.4	6.58	7.29e-11	1.41e-08	0.21	0.2	Primary biliary cholangitis;	chr4:102632769	chr4:102828055~102844075:+
BRCA	cis	rs669446	0.533	rs7543520	ENSG00000237950.1	RP11-7O11.3	6.58	7.3e-11	1.41e-08	0.23	0.2	Amyotrophic lateral sclerosis (age of onset);	chr1:43778195	chr1:43944370~43946551:-
BRCA	cis	rs34779708	0.931	rs12776390	ENSG00000271335.4	RP11-324I22.4	6.58	7.3e-11	1.42e-08	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35102607	chr10:35314552~35336401:-
BRCA	cis	rs13113518	0.783	rs6843722	ENSG00000223305.1	RN7SKP30	6.58	7.32e-11	1.42e-08	0.25	0.2	Height;	chr4:55465165	chr4:55540502~55540835:-
BRCA	cis	rs7809950	0.817	rs2712195	ENSG00000238832.1	snoU109	-6.58	7.33e-11	1.42e-08	-0.29	-0.2	Coronary artery disease;	chr7:107487051	chr7:107603363~107603507:+
BRCA	cis	rs13113518	0.812	rs6849474	ENSG00000223305.1	RN7SKP30	6.58	7.33e-11	1.42e-08	0.25	0.2	Height;	chr4:55452295	chr4:55540502~55540835:-
BRCA	cis	rs2243480	1	rs778729	ENSG00000229886.1	RP5-1132H15.3	6.58	7.34e-11	1.42e-08	0.36	0.2	Diabetic kidney disease;	chr7:66359432	chr7:66025126~66031544:-
BRCA	cis	rs1707322	1	rs2458400	ENSG00000281133.1	AL355480.3	6.58	7.34e-11	1.42e-08	0.25	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46065126	chr1:45580892~45580996:-
BRCA	cis	rs1555322	0.53	rs2425043	ENSG00000261582.1	RP4-614O4.11	-6.58	7.35e-11	1.42e-08	-0.22	-0.2	Attention deficit hyperactivity disorder;	chr20:35280899	chr20:35267885~35280043:-
BRCA	cis	rs79040073	0.637	rs11630318	ENSG00000259531.2	RP11-295H24.3	-6.58	7.35e-11	1.42e-08	-0.31	-0.2	Lung cancer in ever smokers;	chr15:49312606	chr15:49365124~49366685:-
BRCA	cis	rs2243480	1	rs13310597	ENSG00000232546.1	RP11-458F8.1	-6.58	7.37e-11	1.43e-08	-0.27	-0.2	Diabetic kidney disease;	chr7:66133553	chr7:66848496~66858136:+
BRCA	cis	rs7945705	0.776	rs2316865	ENSG00000254860.4	TMEM9B-AS1	-6.58	7.39e-11	1.43e-08	-0.2	-0.2	Hemoglobin concentration;	chr11:8793923	chr11:8964675~8977527:+
BRCA	cis	rs7246657	0.943	rs713256	ENSG00000226686.6	LINC01535	-6.58	7.39e-11	1.43e-08	-0.31	-0.2	Coronary artery calcification;	chr19:37374463	chr19:37251912~37265535:+
BRCA	cis	rs34779708	0.931	rs68039650	ENSG00000271335.4	RP11-324I22.4	6.58	7.4e-11	1.43e-08	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35096571	chr10:35314552~35336401:-
BRCA	cis	rs34779708	0.931	rs35136660	ENSG00000271335.4	RP11-324I22.4	6.58	7.4e-11	1.43e-08	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35097045	chr10:35314552~35336401:-
BRCA	cis	rs34779708	0.897	rs12764820	ENSG00000271335.4	RP11-324I22.4	6.58	7.4e-11	1.43e-08	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35097393	chr10:35314552~35336401:-
BRCA	cis	rs34779708	0.931	rs67261877	ENSG00000271335.4	RP11-324I22.4	6.58	7.4e-11	1.43e-08	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35097412	chr10:35314552~35336401:-
BRCA	cis	rs34779708	0.931	rs12768019	ENSG00000271335.4	RP11-324I22.4	6.58	7.4e-11	1.43e-08	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35100915	chr10:35314552~35336401:-
BRCA	cis	rs6740322	0.857	rs11690012	ENSG00000234936.1	AC010883.5	6.58	7.4e-11	1.43e-08	0.22	0.2	Coronary artery disease;	chr2:43315341	chr2:43229573~43233394:+
BRCA	cis	rs853679	0.599	rs188015	ENSG00000220721.1	OR1F12	6.58	7.41e-11	1.43e-08	0.37	0.2	Depression;	chr6:27909668	chr6:28073316~28074233:+
BRCA	cis	rs7617773	0.78	rs7653152	ENSG00000228638.1	FCF1P2	-6.58	7.42e-11	1.44e-08	-0.23	-0.2	Coronary artery disease;	chr3:48320607	chr3:48290793~48291375:-
BRCA	cis	rs1707322	1	rs9429186	ENSG00000281133.1	AL355480.3	6.58	7.43e-11	1.44e-08	0.25	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46074015	chr1:45580892~45580996:-
BRCA	cis	rs301901	0.698	rs2886593	ENSG00000250155.1	CTD-2353F22.1	6.58	7.44e-11	1.44e-08	0.22	0.2	Height;	chr5:37427041	chr5:36666214~36725195:-
BRCA	cis	rs6583826	0.758	rs10882083	ENSG00000236493.2	EIF2S2P3	6.58	7.44e-11	1.44e-08	0.26	0.2	Type 2 diabetes;	chr10:92562216	chr10:92668745~92669743:-
BRCA	cis	rs467650	0.817	rs17730306	ENSG00000248489.1	CTD-2007H13.3	6.58	7.44e-11	1.44e-08	0.24	0.2	Venous thromboembolism (SNP x SNP interaction);	chr5:98721327	chr5:98929171~98995013:+
BRCA	cis	rs9291683	0.595	rs11722930	ENSG00000250413.1	RP11-448G15.1	-6.58	7.45e-11	1.44e-08	-0.26	-0.2	Bone mineral density;	chr4:10033830	chr4:10006482~10009725:+
BRCA	cis	rs9291683	0.595	rs3733585	ENSG00000250413.1	RP11-448G15.1	-6.58	7.45e-11	1.44e-08	-0.26	-0.2	Bone mineral density;	chr4:10034715	chr4:10006482~10009725:+
BRCA	cis	rs9291683	0.561	rs3733584	ENSG00000250413.1	RP11-448G15.1	-6.58	7.45e-11	1.44e-08	-0.26	-0.2	Bone mineral density;	chr4:10034882	chr4:10006482~10009725:+
BRCA	cis	rs13113518	0.812	rs11133385	ENSG00000223305.1	RN7SKP30	6.58	7.47e-11	1.45e-08	0.25	0.2	Height;	chr4:55460485	chr4:55540502~55540835:-
BRCA	cis	rs11089937	0.616	rs7286793	ENSG00000211639.2	IGLV4-60	6.58	7.47e-11	1.45e-08	0.19	0.2	Periodontitis (PAL4Q3);	chr22:22182951	chr22:22162199~22162681:+
BRCA	cis	rs67981189	0.821	rs56021283	ENSG00000269927.1	RP6-91H8.3	6.58	7.47e-11	1.45e-08	0.25	0.2	Schizophrenia;	chr14:70996042	chr14:71141125~71143253:-
BRCA	cis	rs5015933	0.815	rs16928051	ENSG00000232630.1	PRPS1P2	-6.58	7.47e-11	1.45e-08	-0.18	-0.2	Body mass index;	chr9:125308738	chr9:125150653~125151589:+
BRCA	cis	rs237743	1	rs67652499	ENSG00000222365.1	SNORD12B	-6.58	7.48e-11	1.45e-08	-0.26	-0.2	Height;	chr20:49310154	chr20:49280319~49280409:+
BRCA	cis	rs11098499	0.863	rs1480940	ENSG00000249244.1	RP11-548H18.2	6.58	7.49e-11	1.45e-08	0.24	0.2	Corneal astigmatism;	chr4:119536527	chr4:119391831~119395335:-
BRCA	cis	rs853679	0.546	rs200989	ENSG00000220721.1	OR1F12	6.58	7.49e-11	1.45e-08	0.36	0.2	Depression;	chr6:27848664	chr6:28073316~28074233:+
BRCA	cis	rs1707322	1	rs785469	ENSG00000281133.1	AL355480.3	6.58	7.5e-11	1.45e-08	0.25	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46055419	chr1:45580892~45580996:-
BRCA	cis	rs1707322	1	rs785468	ENSG00000281133.1	AL355480.3	6.58	7.5e-11	1.45e-08	0.25	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46055845	chr1:45580892~45580996:-
BRCA	cis	rs6860806	0.507	rs183898	ENSG00000233006.5	AC034220.3	-6.58	7.5e-11	1.45e-08	-0.16	-0.2	Breast cancer;	chr5:132381210	chr5:132311285~132369916:-
BRCA	cis	rs172166	0.694	rs1770131	ENSG00000204709.4	LINC01556	6.58	7.51e-11	1.45e-08	0.27	0.2	Cardiac Troponin-T levels;	chr6:28118635	chr6:28943877~28944537:+
BRCA	cis	rs9880211	0.613	rs9834966	ENSG00000273486.1	RP11-731C17.2	6.58	7.53e-11	1.46e-08	0.26	0.2	Height;Body mass index;	chr3:136089778	chr3:136837338~136839021:-
BRCA	cis	rs853679	0.517	rs9393885	ENSG00000219392.1	RP1-265C24.5	-6.58	7.54e-11	1.46e-08	-0.3	-0.2	Depression;	chr6:28082231	chr6:28115628~28116551:+
BRCA	cis	rs853679	0.517	rs9393886	ENSG00000219392.1	RP1-265C24.5	-6.58	7.54e-11	1.46e-08	-0.3	-0.2	Depression;	chr6:28082261	chr6:28115628~28116551:+
BRCA	cis	rs4713118	0.515	rs9368549	ENSG00000219392.1	RP1-265C24.5	-6.58	7.54e-11	1.46e-08	-0.3	-0.2	Parkinson's disease;	chr6:28082269	chr6:28115628~28116551:+
BRCA	cis	rs4372836	1	rs4372836	ENSG00000226833.4	AC097724.3	6.58	7.54e-11	1.46e-08	0.24	0.2	Body mass index;	chr2:28751017	chr2:28708953~28736205:-
BRCA	cis	rs8114671	0.935	rs945960	ENSG00000269202.1	RP4-614O4.12	-6.58	7.55e-11	1.46e-08	-0.21	-0.2	Height;	chr20:35175051	chr20:35201747~35203288:-
BRCA	cis	rs8114671	0.967	rs2069952	ENSG00000269202.1	RP4-614O4.12	-6.58	7.55e-11	1.46e-08	-0.21	-0.2	Height;	chr20:35176148	chr20:35201747~35203288:-
BRCA	cis	rs2288884	0.537	rs16983434	ENSG00000275055.1	CTC-471J1.11	-6.58	7.55e-11	1.46e-08	-0.23	-0.2	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52088180	chr19:52049007~52049754:+
BRCA	cis	rs1667284	0.967	rs1791221	ENSG00000266521.1	RP11-650P15.1	6.58	7.55e-11	1.46e-08	0.24	0.2	Problematic alcohol use in trauma-exposed individuals;	chr18:31639928	chr18:31496645~31497195:-
BRCA	cis	rs6860806	0.531	rs274556	ENSG00000233006.5	AC034220.3	-6.58	7.55e-11	1.46e-08	-0.16	-0.2	Breast cancer;	chr5:132386383	chr5:132311285~132369916:-
BRCA	cis	rs1707322	1	rs785510	ENSG00000281133.1	AL355480.3	6.58	7.56e-11	1.46e-08	0.26	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46062946	chr1:45580892~45580996:-
BRCA	cis	rs11098499	0.863	rs11098531	ENSG00000249244.1	RP11-548H18.2	6.58	7.56e-11	1.46e-08	0.24	0.2	Corneal astigmatism;	chr4:119543846	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.863	rs28718422	ENSG00000249244.1	RP11-548H18.2	6.58	7.56e-11	1.46e-08	0.24	0.2	Corneal astigmatism;	chr4:119545149	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.818	rs12498599	ENSG00000249244.1	RP11-548H18.2	6.58	7.56e-11	1.46e-08	0.24	0.2	Corneal astigmatism;	chr4:119547348	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.863	rs10009626	ENSG00000249244.1	RP11-548H18.2	6.58	7.56e-11	1.46e-08	0.24	0.2	Corneal astigmatism;	chr4:119548850	chr4:119391831~119395335:-
BRCA	cis	rs4713118	0.868	rs2893928	ENSG00000220721.1	OR1F12	6.58	7.57e-11	1.46e-08	0.27	0.2	Parkinson's disease;	chr6:27770651	chr6:28073316~28074233:+
BRCA	cis	rs2842992	0.83	rs2758312	ENSG00000237927.1	RP3-393E18.2	-6.58	7.57e-11	1.46e-08	-0.28	-0.2	Age-related macular degeneration (geographic atrophy);	chr6:159732420	chr6:159586955~159589169:-
BRCA	cis	rs7615952	0.611	rs35321002	ENSG00000171084.14	FAM86JP	6.58	7.58e-11	1.47e-08	0.37	0.2	Blood pressure (smoking interaction);	chr3:125893222	chr3:125916620~125930024:+
BRCA	cis	rs11098499	0.909	rs10026736	ENSG00000249244.1	RP11-548H18.2	6.58	7.59e-11	1.47e-08	0.24	0.2	Corneal astigmatism;	chr4:119463167	chr4:119391831~119395335:-
BRCA	cis	rs897984	0.542	rs73530203	ENSG00000260911.2	RP11-196G11.2	6.58	7.59e-11	1.47e-08	0.19	0.2	Dementia with Lewy bodies;	chr16:31088538	chr16:31043150~31049868:+
BRCA	cis	rs2842992	0.789	rs9365093	ENSG00000237927.1	RP3-393E18.2	-6.58	7.6e-11	1.47e-08	-0.28	-0.2	Age-related macular degeneration (geographic atrophy);	chr6:159754787	chr6:159586955~159589169:-
BRCA	cis	rs2243480	1	rs1723270	ENSG00000228409.4	CCT6P1	6.58	7.61e-11	1.47e-08	0.28	0.2	Diabetic kidney disease;	chr7:66004843	chr7:65751142~65763354:+
BRCA	cis	rs1499614	1	rs1267818	ENSG00000232559.3	GS1-124K5.12	6.58	7.62e-11	1.47e-08	0.38	0.2	Gout;	chr7:66642037	chr7:66554588~66576923:-
BRCA	cis	rs4787484	1	rs7189550	ENSG00000214725.6	CDIPT-AS1	6.58	7.64e-11	1.48e-08	0.25	0.2	Response to taxane treatment (placlitaxel);	chr16:29899939	chr16:29863593~29868053:+
BRCA	cis	rs67311347	0.544	rs7644643	ENSG00000223797.4	ENTPD3-AS1	-6.58	7.65e-11	1.48e-08	-0.21	-0.2	Renal cell carcinoma;	chr3:40308718	chr3:40313802~40453329:-
BRCA	cis	rs4713118	0.955	rs9368528	ENSG00000220721.1	OR1F12	6.58	7.66e-11	1.48e-08	0.25	0.2	Parkinson's disease;	chr6:27716019	chr6:28073316~28074233:+
BRCA	cis	rs4713118	0.955	rs9380011	ENSG00000220721.1	OR1F12	6.58	7.66e-11	1.48e-08	0.25	0.2	Parkinson's disease;	chr6:27716145	chr6:28073316~28074233:+
BRCA	cis	rs4713118	0.955	rs9380012	ENSG00000220721.1	OR1F12	6.58	7.66e-11	1.48e-08	0.25	0.2	Parkinson's disease;	chr6:27716875	chr6:28073316~28074233:+
BRCA	cis	rs2243480	1	rs4718333	ENSG00000232546.1	RP11-458F8.1	6.58	7.67e-11	1.48e-08	0.27	0.2	Diabetic kidney disease;	chr7:66307771	chr7:66848496~66858136:+
BRCA	cis	rs2243480	1	rs7792391	ENSG00000232546.1	RP11-458F8.1	6.58	7.67e-11	1.48e-08	0.27	0.2	Diabetic kidney disease;	chr7:66308442	chr7:66848496~66858136:+
BRCA	cis	rs34779708	0.966	rs12765038	ENSG00000271335.4	RP11-324I22.4	6.58	7.67e-11	1.48e-08	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35127585	chr10:35314552~35336401:-
BRCA	cis	rs34779708	0.966	rs11010095	ENSG00000271335.4	RP11-324I22.4	6.58	7.68e-11	1.48e-08	0.2	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35107020	chr10:35314552~35336401:-
BRCA	cis	rs7617773	0.817	rs3729577	ENSG00000228638.1	FCF1P2	-6.57	7.68e-11	1.49e-08	-0.23	-0.2	Coronary artery disease;	chr3:48187504	chr3:48290793~48291375:-
BRCA	cis	rs6543140	0.964	rs2141781	ENSG00000234389.1	AC007278.3	6.57	7.68e-11	1.49e-08	0.2	0.2	Blood protein levels;	chr2:102466446	chr2:102438713~102440475:+
BRCA	cis	rs600231	0.665	rs1784858	ENSG00000245532.5	NEAT1	6.57	7.69e-11	1.49e-08	0.18	0.2	Bone mineral density;	chr11:65455481	chr11:65422774~65445540:+
BRCA	cis	rs4950322	0.57	rs80270233	ENSG00000278811.3	LINC00624	6.57	7.69e-11	1.49e-08	0.27	0.2	Protein quantitative trait loci;	chr1:147263320	chr1:147258885~147517875:-
BRCA	cis	rs2732480	0.5	rs1552550	ENSG00000273765.1	RP11-370I10.11	6.57	7.69e-11	1.49e-08	0.24	0.2	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48249568	chr12:48360920~48361377:+
BRCA	cis	rs2732480	0.5	rs2450991	ENSG00000273765.1	RP11-370I10.11	6.57	7.69e-11	1.49e-08	0.24	0.2	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48257838	chr12:48360920~48361377:+
BRCA	cis	rs1707322	0.721	rs4559551	ENSG00000281133.1	AL355480.3	-6.57	7.69e-11	1.49e-08	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45701861	chr1:45580892~45580996:-
BRCA	cis	rs7829975	0.509	rs7838674	ENSG00000233609.3	RP11-62H7.2	-6.57	7.69e-11	1.49e-08	-0.19	-0.2	Mood instability;	chr8:8939563	chr8:8961200~8979025:+
BRCA	cis	rs6570726	0.902	rs9390326	ENSG00000235652.6	RP11-545I5.3	-6.57	7.71e-11	1.49e-08	-0.19	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:145470086	chr6:145799409~145886585:+
BRCA	cis	rs17818399	0.51	rs1451153	ENSG00000279254.1	RP11-536C12.1	-6.57	7.72e-11	1.49e-08	-0.24	-0.2	Height;	chr2:46572713	chr2:46668870~46670778:+
BRCA	cis	rs12501370	0.959	rs12501316	ENSG00000201736.1	RNA5SP160	6.57	7.72e-11	1.49e-08	0.25	0.2	Iris color (L* coordinate);	chr4:41036503	chr4:40990154~40990273:+
BRCA	cis	rs853679	0.517	rs9393887	ENSG00000219392.1	RP1-265C24.5	-6.57	7.74e-11	1.49e-08	-0.3	-0.2	Depression;	chr6:28091242	chr6:28115628~28116551:+
BRCA	cis	rs7246657	0.653	rs10425441	ENSG00000276846.1	CTD-3220F14.3	6.57	7.74e-11	1.5e-08	0.31	0.2	Coronary artery calcification;	chr19:37179746	chr19:37314868~37315620:-
BRCA	cis	rs875971	0.545	rs4441996	ENSG00000273024.4	INTS4P2	6.57	7.75e-11	1.5e-08	0.24	0.2	Aortic root size;	chr7:66123233	chr7:65647864~65715661:+
BRCA	cis	rs2286503	0.752	rs2286504	ENSG00000228649.7	AC005682.5	6.57	7.76e-11	1.5e-08	0.18	0.2	Fibrinogen;	chr7:22815228	chr7:22854178~22861579:+
BRCA	cis	rs1440410	0.798	rs34664017	ENSG00000250326.1	RP11-284M14.1	-6.57	7.76e-11	1.5e-08	-0.22	-0.2	Ischemic stroke;	chr4:143173191	chr4:142933195~143184861:-
BRCA	cis	rs11089937	0.616	rs4145537	ENSG00000211639.2	IGLV4-60	-6.57	7.77e-11	1.5e-08	-0.2	-0.2	Periodontitis (PAL4Q3);	chr22:22182550	chr22:22162199~22162681:+
BRCA	cis	rs6088813	1	rs1570004	ENSG00000126005.14	MMP24-AS1	6.57	7.77e-11	1.5e-08	0.23	0.2	Height;	chr20:35370450	chr20:35216462~35278131:-
BRCA	cis	rs237743	1	rs34804433	ENSG00000222365.1	SNORD12B	-6.57	7.79e-11	1.51e-08	-0.26	-0.2	Height;	chr20:49279650	chr20:49280319~49280409:+
BRCA	cis	rs237743	1	rs67214274	ENSG00000222365.1	SNORD12B	-6.57	7.79e-11	1.51e-08	-0.26	-0.2	Height;	chr20:49282024	chr20:49280319~49280409:+
BRCA	cis	rs957448	1	rs10956915	ENSG00000253175.1	RP11-267M23.6	6.57	7.79e-11	1.51e-08	0.26	0.2	Nonsyndromic cleft lip with cleft palate;	chr8:94502362	chr8:94565036~94565715:+
BRCA	cis	rs2243480	1	rs1723269	ENSG00000228409.4	CCT6P1	6.57	7.8e-11	1.51e-08	0.28	0.2	Diabetic kidney disease;	chr7:66007799	chr7:65751142~65763354:+
BRCA	cis	rs853679	0.607	rs13194781	ENSG00000220721.1	OR1F12	6.57	7.8e-11	1.51e-08	0.48	0.2	Depression;	chr6:27847861	chr6:28073316~28074233:+
BRCA	cis	rs3764021	1	rs3764021	ENSG00000214776.8	RP11-726G1.1	6.57	7.82e-11	1.51e-08	0.22	0.2	Type 1 diabetes;	chr12:9681032	chr12:9467552~9576275:+
BRCA	cis	rs4072705	1	rs4836988	ENSG00000224020.1	MIR181A2HG	-6.57	7.82e-11	1.51e-08	-0.22	-0.2	Menarche (age at onset);	chr9:124735294	chr9:124658467~124698631:+
BRCA	cis	rs2018683	0.584	rs4722880	ENSG00000228421.2	AC005013.5	6.57	7.82e-11	1.51e-08	0.25	0.2	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28959581	chr7:28957667~28959345:+
BRCA	cis	rs10936632	0.728	rs10804840	ENSG00000242578.1	RP11-469J4.3	-6.57	7.83e-11	1.51e-08	-0.24	-0.2	Prostate cancer;	chr3:170354019	chr3:170410512~170418615:+
BRCA	cis	rs17301013	0.606	rs724889	ENSG00000227373.4	RP11-160H22.5	-6.57	7.84e-11	1.51e-08	-0.29	-0.2	Systemic lupus erythematosus;	chr1:174180326	chr1:174115300~174160004:-
BRCA	cis	rs7976269	0.609	rs10843305	ENSG00000257176.2	RP11-996F15.2	-6.57	7.85e-11	1.52e-08	-0.24	-0.2	Male-pattern baldness;	chr12:29073147	chr12:29280418~29317848:-
BRCA	cis	rs2732480	0.5	rs12828309	ENSG00000273765.1	RP11-370I10.11	6.57	7.85e-11	1.52e-08	0.24	0.2	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48247377	chr12:48360920~48361377:+
BRCA	cis	rs957448	0.539	rs9643346	ENSG00000253704.1	RP11-267M23.4	6.57	7.85e-11	1.52e-08	0.22	0.2	Nonsyndromic cleft lip with cleft palate;	chr8:94601587	chr8:94553722~94569745:+
BRCA	cis	rs8114671	0.935	rs6142313	ENSG00000269202.1	RP4-614O4.12	6.57	7.86e-11	1.52e-08	0.2	0.2	Height;	chr20:35192624	chr20:35201747~35203288:-
BRCA	cis	rs10129255	0.957	rs10138532	ENSG00000211972.2	IGHV3-66	6.57	7.86e-11	1.52e-08	0.16	0.2	Kawasaki disease;	chr14:106803901	chr14:106675017~106675544:-
BRCA	cis	rs11096990	0.892	rs6531696	ENSG00000249207.1	RP11-360F5.1	6.57	7.86e-11	1.52e-08	0.23	0.2	Cognitive function;	chr4:39190134	chr4:39112677~39126818:-
BRCA	cis	rs2842992	0.83	rs2842974	ENSG00000237927.1	RP3-393E18.2	-6.57	7.86e-11	1.52e-08	-0.29	-0.2	Age-related macular degeneration (geographic atrophy);	chr6:159738002	chr6:159586955~159589169:-
BRCA	cis	rs2439831	0.557	rs13329084	ENSG00000205771.5	CATSPER2P1	6.57	7.87e-11	1.52e-08	0.39	0.2	Lung cancer in ever smokers;	chr15:43858865	chr15:43726918~43747094:-
BRCA	cis	rs10050311	0.698	rs67867077	ENSG00000251411.1	RP11-397E7.4	-6.57	7.87e-11	1.52e-08	-0.29	-0.2	Insulin-related traits;	chr4:86722593	chr4:86913266~86914817:-
BRCA	cis	rs193541	0.632	rs246279	ENSG00000263432.2	RN7SL689P	-6.57	7.87e-11	1.52e-08	-0.34	-0.2	Glucose homeostasis traits;	chr5:122905568	chr5:123022487~123022783:-
BRCA	cis	rs12468579	0.74	rs12693588	ENSG00000235852.1	AC005540.3	6.57	7.88e-11	1.52e-08	0.21	0.2	JT interval (sulfonylurea treatment interaction);	chr2:190967766	chr2:190880797~190882059:-
BRCA	cis	rs673078	0.66	rs17512574	ENSG00000275409.1	RP11-131L12.4	-6.57	7.89e-11	1.52e-08	-0.28	-0.2	Glucose homeostasis traits;	chr12:118350198	chr12:118430147~118430699:+
BRCA	cis	rs12594515	1	rs6493170	ENSG00000259200.1	RP11-718O11.1	-6.57	7.9e-11	1.52e-08	-0.22	-0.2	Weight;Waist circumference;	chr15:45694821	chr15:45705078~45931069:+
BRCA	cis	rs13178541	0.748	rs4317317	ENSG00000250378.1	RP11-119J18.1	-6.57	7.9e-11	1.53e-08	-0.27	-0.2	IgG glycosylation;	chr5:135740765	chr5:135812667~135826582:+
BRCA	cis	rs6740322	0.841	rs10210507	ENSG00000234936.1	AC010883.5	6.57	7.9e-11	1.53e-08	0.23	0.2	Coronary artery disease;	chr2:43329497	chr2:43229573~43233394:+
BRCA	cis	rs11096990	0.855	rs2711990	ENSG00000249207.1	RP11-360F5.1	6.57	7.91e-11	1.53e-08	0.23	0.2	Cognitive function;	chr4:39150116	chr4:39112677~39126818:-
BRCA	cis	rs7246657	0.943	rs4452075	ENSG00000226686.6	LINC01535	-6.57	7.91e-11	1.53e-08	-0.29	-0.2	Coronary artery calcification;	chr19:37388687	chr19:37251912~37265535:+
BRCA	cis	rs420259	0.516	rs10153059	ENSG00000260136.4	CTD-2270L9.4	-6.57	7.92e-11	1.53e-08	-0.2	-0.2	Bipolar disorder;	chr16:23501062	chr16:23452758~23457606:+
BRCA	cis	rs6095360	0.7	rs2295026	ENSG00000222365.1	SNORD12B	-6.57	7.92e-11	1.53e-08	-0.25	-0.2	Intelligence (multi-trait analysis);	chr20:48966248	chr20:49280319~49280409:+
BRCA	cis	rs2243480	1	rs2462569	ENSG00000229886.1	RP5-1132H15.3	-6.57	7.93e-11	1.53e-08	-0.33	-0.2	Diabetic kidney disease;	chr7:66009859	chr7:66025126~66031544:-
BRCA	cis	rs17818399	0.51	rs12105801	ENSG00000279254.1	RP11-536C12.1	-6.57	7.93e-11	1.53e-08	-0.24	-0.2	Height;	chr2:46572204	chr2:46668870~46670778:+
BRCA	cis	rs301901	0.828	rs4304095	ENSG00000250155.1	CTD-2353F22.1	6.57	7.93e-11	1.53e-08	0.22	0.2	Height;	chr5:37454360	chr5:36666214~36725195:-
BRCA	cis	rs6142102	1	rs6059672	ENSG00000275784.1	RP5-1125A11.6	-6.57	7.94e-11	1.53e-08	-0.24	-0.2	Skin pigmentation;	chr20:34117662	chr20:33989480~33991818:-
BRCA	cis	rs34779708	0.931	rs12767414	ENSG00000271335.4	RP11-324I22.4	6.57	7.95e-11	1.53e-08	0.2	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35101265	chr10:35314552~35336401:-
BRCA	cis	rs2239547	0.603	rs4687698	ENSG00000242142.1	SERBP1P3	6.57	7.96e-11	1.54e-08	0.25	0.2	Schizophrenia;	chr3:53063092	chr3:53064283~53065091:-
BRCA	cis	rs875971	0.545	rs73148639	ENSG00000236529.1	RP13-254B10.1	6.57	7.96e-11	1.54e-08	0.25	0.2	Aortic root size;	chr7:66390342	chr7:65840212~65840596:+
BRCA	cis	rs13118159	0.55	rs11941200	ENSG00000254094.1	AC078852.1	-6.57	7.96e-11	1.54e-08	-0.25	-0.2	Longevity;	chr4:1375305	chr4:1356581~1358075:+
BRCA	cis	rs13118159	0.55	rs11946956	ENSG00000254094.1	AC078852.1	-6.57	7.96e-11	1.54e-08	-0.25	-0.2	Longevity;	chr4:1375306	chr4:1356581~1358075:+
BRCA	cis	rs6570726	0.875	rs368744	ENSG00000235652.6	RP11-545I5.3	6.57	7.96e-11	1.54e-08	0.19	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145491486	chr6:145799409~145886585:+
BRCA	cis	rs13126694	0.744	rs4077776	ENSG00000248429.4	RP11-597D13.9	6.57	7.97e-11	1.54e-08	0.18	0.2	Blood osmolality (transformed sodium);	chr4:158008446	chr4:158170752~158202877:+
BRCA	cis	rs1823913	0.599	rs1378156	ENSG00000280083.1	RP11-317J9.1	6.57	7.97e-11	1.54e-08	0.23	0.2	Obesity-related traits;	chr2:191272466	chr2:191154118~191156070:-
BRCA	cis	rs8114671	0.869	rs2038503	ENSG00000269202.1	RP4-614O4.12	6.57	7.98e-11	1.54e-08	0.2	0.2	Height;	chr20:35088097	chr20:35201747~35203288:-
BRCA	cis	rs875971	0.522	rs4718286	ENSG00000237310.1	GS1-124K5.4	6.57	8e-11	1.54e-08	0.21	0.2	Aortic root size;	chr7:65827777	chr7:66493706~66495474:+
BRCA	cis	rs17711722	0.585	rs6942660	ENSG00000237310.1	GS1-124K5.4	6.57	8e-11	1.54e-08	0.21	0.2	Calcium levels;	chr7:65837419	chr7:66493706~66495474:+
BRCA	cis	rs17711722	0.727	rs1880555	ENSG00000234585.5	CCT6P3	6.57	8.01e-11	1.55e-08	0.19	0.2	Calcium levels;	chr7:65967580	chr7:65038354~65074713:+
BRCA	cis	rs638893	0.617	rs7933007	ENSG00000255239.1	AP002954.6	-6.57	8.01e-11	1.55e-08	-0.26	-0.2	Vitiligo;	chr11:118859960	chr11:118688039~118690600:-
BRCA	cis	rs6570726	0.526	rs9403699	ENSG00000235652.6	RP11-545I5.3	6.57	8.01e-11	1.55e-08	0.19	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145409549	chr6:145799409~145886585:+
BRCA	cis	rs7246657	0.943	rs10417844	ENSG00000226686.6	LINC01535	-6.57	8.02e-11	1.55e-08	-0.29	-0.2	Coronary artery calcification;	chr19:37346685	chr19:37251912~37265535:+
BRCA	cis	rs7773456	1	rs7773456	ENSG00000228412.5	RP4-625H18.2	6.57	8.02e-11	1.55e-08	0.25	0.2	Lupus nephritis in systemic lupus erythematosus;	chr6:19823007	chr6:19802164~19804752:-
BRCA	cis	rs2638953	0.924	rs61920228	ENSG00000247934.4	RP11-967K21.1	-6.57	8.02e-11	1.55e-08	-0.25	-0.2	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28183780	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.924	rs7306838	ENSG00000247934.4	RP11-967K21.1	-6.57	8.02e-11	1.55e-08	-0.25	-0.2	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28184449	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.924	rs7138173	ENSG00000247934.4	RP11-967K21.1	-6.57	8.02e-11	1.55e-08	-0.25	-0.2	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28184970	chr12:28163298~28190738:-
BRCA	cis	rs4372836	0.964	rs4665432	ENSG00000226833.4	AC097724.3	-6.57	8.02e-11	1.55e-08	-0.24	-0.2	Body mass index;	chr2:28729160	chr2:28708953~28736205:-
BRCA	cis	rs78456975	1	rs6708604	ENSG00000231482.2	AC141930.2	-6.57	8.02e-11	1.55e-08	-0.29	-0.2	Placebo response in major depressive disorder (% change in symptom score);	chr2:1553115	chr2:1572554~1580311:-
BRCA	cis	rs2976388	0.669	rs2976391	ENSG00000253741.1	CTD-2292P10.4	-6.57	8.03e-11	1.55e-08	-0.22	-0.2	Urinary tract infection frequency;	chr8:142681306	chr8:142702252~142726973:-
BRCA	cis	rs58873874	1	rs11740562	ENSG00000248544.2	CTB-47B11.3	-6.57	8.03e-11	1.55e-08	-0.42	-0.2	Bipolar disorder (body mass index interaction);	chr5:157515277	chr5:157375741~157384950:-
BRCA	cis	rs34779708	0.931	rs7084196	ENSG00000271335.4	RP11-324I22.4	6.57	8.04e-11	1.55e-08	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35078233	chr10:35314552~35336401:-
BRCA	cis	rs61160187	0.582	rs28436304	ENSG00000215032.2	GNL3LP1	6.57	8.05e-11	1.55e-08	0.24	0.2	Educational attainment (years of education);Educational attainment (college completion);	chr5:61038584	chr5:60891935~60893577:-
BRCA	cis	rs858239	0.539	rs2103281	ENSG00000230042.1	AK3P3	-6.57	8.05e-11	1.55e-08	-0.23	-0.2	Cerebrospinal fluid biomarker levels;	chr7:23154612	chr7:23129178~23129841:+
BRCA	cis	rs34779708	0.931	rs12773169	ENSG00000271335.4	RP11-324I22.4	6.57	8.06e-11	1.55e-08	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35077534	chr10:35314552~35336401:-
BRCA	cis	rs8005677	1	rs1956880	ENSG00000257285.4	RP11-298I3.1	6.57	8.06e-11	1.55e-08	0.22	0.2	Cognitive ability (multi-trait analysis);	chr14:22924798	chr14:22929609~22955562:+
BRCA	cis	rs227932	0.764	rs6461725	ENSG00000234286.1	AC006026.13	-6.57	8.06e-11	1.55e-08	-0.34	-0.2	Schizophrenia;	chr7:23690555	chr7:23680195~23680786:-
BRCA	cis	rs17214007	0.877	rs11075280	ENSG00000263335.1	AF001548.5	-6.57	8.06e-11	1.56e-08	-0.29	-0.2	Cognitive function;	chr16:15776630	chr16:15726674~15732993:+
BRCA	cis	rs2348418	0.639	rs61301264	ENSG00000247934.4	RP11-967K21.1	-6.57	8.07e-11	1.56e-08	-0.23	-0.2	Lung function (FEV1);Lung function (FVC);	chr12:28112922	chr12:28163298~28190738:-
BRCA	cis	rs172166	0.694	rs9295760	ENSG00000216901.1	AL022393.7	6.57	8.07e-11	1.56e-08	0.26	0.2	Cardiac Troponin-T levels;	chr6:28179607	chr6:28176188~28176674:+
BRCA	cis	rs1823913	0.614	rs4853576	ENSG00000280083.1	RP11-317J9.1	6.57	8.08e-11	1.56e-08	0.23	0.2	Obesity-related traits;	chr2:191296618	chr2:191154118~191156070:-
BRCA	cis	rs1707322	0.717	rs3014249	ENSG00000281133.1	AL355480.3	6.57	8.09e-11	1.56e-08	0.26	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613821	chr1:45580892~45580996:-
BRCA	cis	rs77972916	0.609	rs72790903	ENSG00000234936.1	AC010883.5	6.57	8.09e-11	1.56e-08	0.3	0.2	Granulocyte percentage of myeloid white cells;	chr2:43334846	chr2:43229573~43233394:+
BRCA	cis	rs539096	0.692	rs6686238	ENSG00000237950.1	RP11-7O11.3	6.57	8.09e-11	1.56e-08	0.23	0.2	Intelligence (multi-trait analysis);	chr1:43744582	chr1:43944370~43946551:-
BRCA	cis	rs11096990	0.892	rs1473364	ENSG00000249207.1	RP11-360F5.1	-6.57	8.11e-11	1.56e-08	-0.23	-0.2	Cognitive function;	chr4:39211259	chr4:39112677~39126818:-
BRCA	cis	rs7246657	0.653	rs10401525	ENSG00000276846.1	CTD-3220F14.3	6.57	8.12e-11	1.56e-08	0.31	0.2	Coronary artery calcification;	chr19:37168077	chr19:37314868~37315620:-
BRCA	cis	rs8177876	0.822	rs16954582	ENSG00000261838.4	RP11-303E16.6	6.57	8.12e-11	1.57e-08	0.36	0.2	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81080552	chr16:81069854~81076598:+
BRCA	cis	rs78456975	1	rs13429866	ENSG00000231482.2	AC141930.2	-6.57	8.13e-11	1.57e-08	-0.29	-0.2	Placebo response in major depressive disorder (% change in symptom score);	chr2:1551439	chr2:1572554~1580311:-
BRCA	cis	rs1124769	0.778	rs12902649	ENSG00000259378.1	DCAF13P3	6.57	8.14e-11	1.57e-08	0.28	0.2	Cognitive performance;	chr15:51039413	chr15:50944663~50945996:+
BRCA	cis	rs2412819	0.571	rs528764	ENSG00000205771.5	CATSPER2P1	6.57	8.15e-11	1.57e-08	0.29	0.2	Lung cancer;	chr15:43838650	chr15:43726918~43747094:-
BRCA	cis	rs7474896	0.583	rs34185758	ENSG00000226578.1	RP11-258F22.1	-6.57	8.16e-11	1.57e-08	-0.27	-0.2	Obesity (extreme);	chr10:37701926	chr10:37775371~37784131:-
BRCA	cis	rs7208859	0.623	rs9914242	ENSG00000263603.1	CTD-2349P21.5	-6.57	8.18e-11	1.58e-08	-0.34	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30889227	chr17:30729469~30731202:+
BRCA	cis	rs853679	0.517	rs2273564	ENSG00000219392.1	RP1-265C24.5	-6.57	8.18e-11	1.58e-08	-0.3	-0.2	Depression;	chr6:28089816	chr6:28115628~28116551:+
BRCA	cis	rs853679	0.517	rs1853097	ENSG00000219392.1	RP1-265C24.5	-6.57	8.18e-11	1.58e-08	-0.3	-0.2	Depression;	chr6:28090857	chr6:28115628~28116551:+
BRCA	cis	rs853679	0.517	rs9393888	ENSG00000219392.1	RP1-265C24.5	-6.57	8.18e-11	1.58e-08	-0.3	-0.2	Depression;	chr6:28091439	chr6:28115628~28116551:+
BRCA	cis	rs853679	0.517	rs3734573	ENSG00000219392.1	RP1-265C24.5	-6.57	8.18e-11	1.58e-08	-0.3	-0.2	Depression;	chr6:28091659	chr6:28115628~28116551:+
BRCA	cis	rs853679	0.517	rs3823180	ENSG00000219392.1	RP1-265C24.5	-6.57	8.18e-11	1.58e-08	-0.3	-0.2	Depression;	chr6:28093966	chr6:28115628~28116551:+
BRCA	cis	rs853679	0.517	rs9368551	ENSG00000219392.1	RP1-265C24.5	-6.57	8.18e-11	1.58e-08	-0.3	-0.2	Depression;	chr6:28094014	chr6:28115628~28116551:+
BRCA	cis	rs2243480	1	rs1964692	ENSG00000228409.4	CCT6P1	6.56	8.2e-11	1.58e-08	0.28	0.2	Diabetic kidney disease;	chr7:65989196	chr7:65751142~65763354:+
BRCA	cis	rs4713118	0.512	rs2622319	ENSG00000216901.1	AL022393.7	6.56	8.21e-11	1.58e-08	0.26	0.2	Parkinson's disease;	chr6:28152623	chr6:28176188~28176674:+
BRCA	cis	rs172166	0.694	rs1150666	ENSG00000216901.1	AL022393.7	6.56	8.21e-11	1.58e-08	0.26	0.2	Cardiac Troponin-T levels;	chr6:28156150	chr6:28176188~28176674:+
BRCA	cis	rs7246657	0.943	rs4803229	ENSG00000226686.6	LINC01535	-6.56	8.21e-11	1.58e-08	-0.29	-0.2	Coronary artery calcification;	chr19:37373780	chr19:37251912~37265535:+
BRCA	cis	rs7587476	0.822	rs13018304	ENSG00000229267.2	AC072062.1	-6.56	8.22e-11	1.58e-08	-0.27	-0.2	Neuroblastoma;	chr2:214817494	chr2:214810229~214963274:+
BRCA	cis	rs13068223	0.935	rs1560414	ENSG00000243926.1	TIPARP-AS1	6.56	8.23e-11	1.59e-08	0.2	0.2	Age-related hearing impairment (SNP x SNP interaction);	chr3:156723960	chr3:156671862~156674378:-
BRCA	cis	rs8114671	0.967	rs6060285	ENSG00000269202.1	RP4-614O4.12	-6.56	8.25e-11	1.59e-08	-0.21	-0.2	Height;	chr20:35182684	chr20:35201747~35203288:-
BRCA	cis	rs8114671	0.967	rs2378337	ENSG00000269202.1	RP4-614O4.12	-6.56	8.25e-11	1.59e-08	-0.21	-0.2	Height;	chr20:35183632	chr20:35201747~35203288:-
BRCA	cis	rs11098499	0.863	rs1552092	ENSG00000249244.1	RP11-548H18.2	6.56	8.25e-11	1.59e-08	0.24	0.2	Corneal astigmatism;	chr4:119567341	chr4:119391831~119395335:-
BRCA	cis	rs12594515	1	rs8039974	ENSG00000259200.1	RP11-718O11.1	-6.56	8.26e-11	1.59e-08	-0.22	-0.2	Weight;Waist circumference;	chr15:45694467	chr15:45705078~45931069:+
BRCA	cis	rs9859260	0.744	rs3933	ENSG00000231464.1	AC024937.4	-6.56	8.26e-11	1.59e-08	-0.25	-0.2	Mean corpuscular volume;	chr3:196058126	chr3:195996738~195998233:+
BRCA	cis	rs4763879	0.739	rs12582584	ENSG00000256673.1	RP11-599J14.2	6.56	8.27e-11	1.59e-08	0.23	0.2	Type 1 diabetes;	chr12:9671542	chr12:9398355~9414851:-
BRCA	cis	rs12594515	1	rs6493167	ENSG00000259200.1	RP11-718O11.1	-6.56	8.27e-11	1.59e-08	-0.22	-0.2	Weight;Waist circumference;	chr15:45694611	chr15:45705078~45931069:+
BRCA	cis	rs12594515	1	rs6493168	ENSG00000259200.1	RP11-718O11.1	-6.56	8.27e-11	1.59e-08	-0.22	-0.2	Weight;Waist circumference;	chr15:45694613	chr15:45705078~45931069:+
BRCA	cis	rs4763879	0.865	rs4763840	ENSG00000214776.8	RP11-726G1.1	-6.56	8.28e-11	1.59e-08	-0.22	-0.2	Type 1 diabetes;	chr12:9731814	chr12:9467552~9576275:+
BRCA	cis	rs2243480	1	rs73150014	ENSG00000228409.4	CCT6P1	6.56	8.28e-11	1.59e-08	0.28	0.2	Diabetic kidney disease;	chr7:65985932	chr7:65751142~65763354:+
BRCA	cis	rs172166	0.694	rs1225716	ENSG00000216901.1	AL022393.7	6.56	8.28e-11	1.6e-08	0.26	0.2	Cardiac Troponin-T levels;	chr6:28145968	chr6:28176188~28176674:+
BRCA	cis	rs11009175	0.725	rs1832926	ENSG00000273038.2	RP11-479G22.8	-6.56	8.29e-11	1.6e-08	-0.32	-0.2	Depression (quantitative trait);	chr10:33014676	chr10:32887255~32889311:-
BRCA	cis	rs12594515	0.967	rs11070466	ENSG00000259200.1	RP11-718O11.1	-6.56	8.3e-11	1.6e-08	-0.22	-0.2	Weight;Waist circumference;	chr15:45692757	chr15:45705078~45931069:+
BRCA	cis	rs7727544	1	rs7727038	ENSG00000233006.5	AC034220.3	6.56	8.3e-11	1.6e-08	0.14	0.2	Blood metabolite levels;	chr5:132254564	chr5:132311285~132369916:-
BRCA	cis	rs991427	0.643	rs67078592	ENSG00000258100.1	RP11-121E16.1	-6.56	8.3e-11	1.6e-08	-0.33	-0.2	Systolic blood pressure (alcohol consumption interaction);	chr12:91063754	chr12:91362196~91368606:+
BRCA	cis	rs7727544	1	rs7727544	ENSG00000233006.5	AC034220.3	6.56	8.31e-11	1.6e-08	0.14	0.2	Blood metabolite levels;	chr5:132254841	chr5:132311285~132369916:-
BRCA	cis	rs1476670	0.545	rs2158822	ENSG00000230615.5	RP5-1198O20.4	6.56	8.32e-11	1.6e-08	0.27	0.2	Eotaxin levels;	chr1:44053775	chr1:44030443~44115913:+
BRCA	cis	rs7662987	0.793	rs28730602	ENSG00000272777.1	RP11-571L19.8	6.56	8.34e-11	1.6e-08	0.28	0.2	Smoking initiation;	chr4:99080531	chr4:99067256~99068125:-
BRCA	cis	rs7246657	0.943	rs10420430	ENSG00000267422.1	CTD-2554C21.1	-6.56	8.35e-11	1.61e-08	-0.3	-0.2	Coronary artery calcification;	chr19:37403292	chr19:37779686~37792865:+
BRCA	cis	rs6088580	0.524	rs6088565	ENSG00000269202.1	RP4-614O4.12	6.56	8.35e-11	1.61e-08	0.22	0.2	Glomerular filtration rate (creatinine);	chr20:34667182	chr20:35201747~35203288:-
BRCA	cis	rs3743162	0.553	rs12915656	ENSG00000225151.9	GOLGA2P7	-6.56	8.36e-11	1.61e-08	-0.28	-0.2	Alzheimer's disease (age of onset);	chr15:84872349	chr15:84199311~84230136:-
BRCA	cis	rs7617773	0.817	rs13100815	ENSG00000228638.1	FCF1P2	-6.56	8.37e-11	1.61e-08	-0.23	-0.2	Coronary artery disease;	chr3:48245959	chr3:48290793~48291375:-
BRCA	cis	rs4072705	1	rs4072705	ENSG00000224020.1	MIR181A2HG	-6.56	8.38e-11	1.61e-08	-0.22	-0.2	Menarche (age at onset);	chr9:124611184	chr9:124658467~124698631:+
BRCA	cis	rs957448	0.529	rs9642928	ENSG00000253704.1	RP11-267M23.4	6.56	8.4e-11	1.62e-08	0.22	0.2	Nonsyndromic cleft lip with cleft palate;	chr8:94601698	chr8:94553722~94569745:+
BRCA	cis	rs17711722	1	rs17711722	ENSG00000237310.1	GS1-124K5.4	-6.56	8.41e-11	1.62e-08	-0.21	-0.2	Calcium levels;	chr7:65806210	chr7:66493706~66495474:+
BRCA	cis	rs1124769	0.748	rs57324163	ENSG00000259378.1	DCAF13P3	6.56	8.41e-11	1.62e-08	0.28	0.2	Cognitive performance;	chr15:51069551	chr15:50944663~50945996:+
BRCA	cis	rs17301013	0.507	rs4651008	ENSG00000227373.4	RP11-160H22.5	6.56	8.41e-11	1.62e-08	0.28	0.2	Systemic lupus erythematosus;	chr1:174342681	chr1:174115300~174160004:-
BRCA	cis	rs7246657	0.943	rs35540940	ENSG00000226686.6	LINC01535	-6.56	8.42e-11	1.62e-08	-0.3	-0.2	Coronary artery calcification;	chr19:37517333	chr19:37251912~37265535:+
BRCA	cis	rs13126694	0.778	rs10013448	ENSG00000251429.1	RP11-597D13.7	6.56	8.43e-11	1.62e-08	0.19	0.2	Blood osmolality (transformed sodium);	chr4:158116101	chr4:158270378~158278676:+
BRCA	cis	rs875971	0.545	rs11770063	ENSG00000273024.4	INTS4P2	-6.56	8.43e-11	1.62e-08	-0.25	-0.2	Aortic root size;	chr7:66318029	chr7:65647864~65715661:+
BRCA	cis	rs17711722	0.522	rs6957759	ENSG00000213640.3	EEF1DP4	-6.56	8.44e-11	1.62e-08	-0.25	-0.2	Calcium levels;	chr7:65806798	chr7:64862999~64864370:+
BRCA	cis	rs1707322	0.752	rs28550303	ENSG00000281133.1	AL355480.3	-6.56	8.45e-11	1.63e-08	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45723242	chr1:45580892~45580996:-
BRCA	cis	rs9876781	1	rs9817615	ENSG00000229759.1	MRPS18AP1	6.56	8.47e-11	1.63e-08	0.22	0.2	Longevity;	chr3:48429347	chr3:48256350~48256938:-
BRCA	cis	rs860818	1	rs858298	ENSG00000226816.2	AC005082.12	6.56	8.49e-11	1.63e-08	0.49	0.2	Initial pursuit acceleration;	chr7:23205301	chr7:23206013~23208045:+
BRCA	cis	rs7617773	0.78	rs13067450	ENSG00000228638.1	FCF1P2	-6.56	8.49e-11	1.63e-08	-0.23	-0.2	Coronary artery disease;	chr3:48295716	chr3:48290793~48291375:-
BRCA	cis	rs7617773	0.78	rs4479622	ENSG00000228638.1	FCF1P2	-6.56	8.49e-11	1.63e-08	-0.23	-0.2	Coronary artery disease;	chr3:48296683	chr3:48290793~48291375:-
BRCA	cis	rs7617773	0.78	rs34946886	ENSG00000228638.1	FCF1P2	-6.56	8.49e-11	1.63e-08	-0.23	-0.2	Coronary artery disease;	chr3:48296997	chr3:48290793~48291375:-
BRCA	cis	rs7617773	0.78	rs34589064	ENSG00000228638.1	FCF1P2	-6.56	8.49e-11	1.63e-08	-0.23	-0.2	Coronary artery disease;	chr3:48298059	chr3:48290793~48291375:-
BRCA	cis	rs7617773	0.78	rs2541	ENSG00000228638.1	FCF1P2	-6.56	8.49e-11	1.63e-08	-0.23	-0.2	Coronary artery disease;	chr3:48298128	chr3:48290793~48291375:-
BRCA	cis	rs7617773	0.78	rs13085251	ENSG00000228638.1	FCF1P2	-6.56	8.49e-11	1.63e-08	-0.23	-0.2	Coronary artery disease;	chr3:48298555	chr3:48290793~48291375:-
BRCA	cis	rs858239	0.669	rs12539467	ENSG00000230042.1	AK3P3	-6.56	8.5e-11	1.63e-08	-0.23	-0.2	Cerebrospinal fluid biomarker levels;	chr7:23076240	chr7:23129178~23129841:+
BRCA	cis	rs4372836	0.93	rs7589860	ENSG00000226833.4	AC097724.3	6.56	8.5e-11	1.63e-08	0.24	0.2	Body mass index;	chr2:28744782	chr2:28708953~28736205:-
BRCA	cis	rs13113518	0.812	rs2035691	ENSG00000223305.1	RN7SKP30	6.56	8.5e-11	1.64e-08	0.25	0.2	Height;	chr4:55529786	chr4:55540502~55540835:-
BRCA	cis	rs13113518	0.756	rs11939652	ENSG00000223305.1	RN7SKP30	6.56	8.5e-11	1.64e-08	0.25	0.2	Height;	chr4:55532542	chr4:55540502~55540835:-
BRCA	cis	rs9807989	0.839	rs10192036	ENSG00000234389.1	AC007278.3	6.56	8.5e-11	1.64e-08	0.19	0.2	Asthma;	chr2:102351751	chr2:102438713~102440475:+
BRCA	cis	rs9807989	0.839	rs10204137	ENSG00000234389.1	AC007278.3	6.56	8.5e-11	1.64e-08	0.19	0.2	Asthma;	chr2:102351752	chr2:102438713~102440475:+
BRCA	cis	rs1275468	0.678	rs2620687	ENSG00000257497.2	RP11-585P4.5	-6.56	8.51e-11	1.64e-08	-0.3	-0.2	Polycystic ovary syndrome;	chr12:75560395	chr12:75483454~75489820:-
BRCA	cis	rs875971	0.862	rs6944374	ENSG00000224316.1	RP11-479O9.2	-6.56	8.51e-11	1.64e-08	-0.21	-0.2	Aortic root size;	chr7:66221942	chr7:65773620~65802067:+
BRCA	cis	rs2749097	0.825	rs6671606	ENSG00000244256.3	RN7SL130P	-6.56	8.52e-11	1.64e-08	-0.25	-0.2	Alcohol consumption (transferrin glycosylation);	chr1:63658197	chr1:63655743~63656047:+
BRCA	cis	rs34792	0.554	rs12933773	ENSG00000207425.1	Y_RNA	-6.56	8.54e-11	1.64e-08	-0.24	-0.2	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15529325	chr16:14915457~14915556:-
BRCA	cis	rs1275468	0.724	rs1611928	ENSG00000257497.2	RP11-585P4.5	-6.56	8.55e-11	1.64e-08	-0.29	-0.2	Polycystic ovary syndrome;	chr12:75561705	chr12:75483454~75489820:-
BRCA	cis	rs9291683	0.538	rs11727199	ENSG00000250413.1	RP11-448G15.1	-6.56	8.57e-11	1.65e-08	-0.26	-0.2	Bone mineral density;	chr4:10034566	chr4:10006482~10009725:+
BRCA	cis	rs9494145	0.648	rs7758845	ENSG00000232876.1	CTA-212D2.2	-6.56	8.57e-11	1.65e-08	-0.27	-0.2	Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count;	chr6:135107399	chr6:135055033~135060550:+
BRCA	cis	rs12501370	1	rs1022018	ENSG00000201736.1	RNA5SP160	6.56	8.57e-11	1.65e-08	0.25	0.2	Iris color (L* coordinate);	chr4:41008954	chr4:40990154~40990273:+
BRCA	cis	rs12501370	1	rs12642733	ENSG00000201736.1	RNA5SP160	6.56	8.57e-11	1.65e-08	0.25	0.2	Iris color (L* coordinate);	chr4:41009117	chr4:40990154~40990273:+
BRCA	cis	rs34779708	0.931	rs2384287	ENSG00000271335.4	RP11-324I22.4	6.56	8.58e-11	1.65e-08	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35051631	chr10:35314552~35336401:-
BRCA	cis	rs1707322	0.721	rs7520123	ENSG00000281133.1	AL355480.3	-6.56	8.59e-11	1.65e-08	-0.25	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45769547	chr1:45580892~45580996:-
BRCA	cis	rs34779708	0.931	rs11010101	ENSG00000271335.4	RP11-324I22.4	6.56	8.6e-11	1.65e-08	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35122117	chr10:35314552~35336401:-
BRCA	cis	rs34779708	0.966	rs11010102	ENSG00000271335.4	RP11-324I22.4	6.56	8.6e-11	1.65e-08	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35122138	chr10:35314552~35336401:-
BRCA	cis	rs467650	0.817	rs61637015	ENSG00000248489.1	CTD-2007H13.3	6.56	8.62e-11	1.66e-08	0.24	0.2	Venous thromboembolism (SNP x SNP interaction);	chr5:98716535	chr5:98929171~98995013:+
BRCA	cis	rs1707322	1	rs7539800	ENSG00000281133.1	AL355480.3	6.56	8.63e-11	1.66e-08	0.26	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45796457	chr1:45580892~45580996:-
BRCA	cis	rs78456975	0.943	rs6721243	ENSG00000231482.2	AC141930.2	-6.56	8.63e-11	1.66e-08	-0.27	-0.2	Placebo response in major depressive disorder (% change in symptom score);	chr2:1576478	chr2:1572554~1580311:-
BRCA	cis	rs13113518	0.812	rs12501746	ENSG00000249700.7	SRD5A3-AS1	6.56	8.63e-11	1.66e-08	0.25	0.2	Height;	chr4:55437438	chr4:55363971~55395847:-
BRCA	cis	rs67311347	0.866	rs2371183	ENSG00000280739.1	EIF1B-AS1	-6.56	8.63e-11	1.66e-08	-0.21	-0.2	Renal cell carcinoma;	chr3:40292756	chr3:40173145~40309698:-
BRCA	cis	rs1707322	1	rs785467	ENSG00000281133.1	AL355480.3	6.56	8.63e-11	1.66e-08	0.25	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46055887	chr1:45580892~45580996:-
BRCA	cis	rs301901	0.796	rs62361483	ENSG00000250155.1	CTD-2353F22.1	6.56	8.64e-11	1.66e-08	0.22	0.2	Height;	chr5:37468413	chr5:36666214~36725195:-
BRCA	cis	rs11976180	1	rs1533266	ENSG00000204959.4	ARHGEF34P	6.56	8.64e-11	1.66e-08	0.25	0.2	Obesity-related traits;	chr7:144069621	chr7:144272445~144286966:-
BRCA	cis	rs6740322	0.895	rs10196095	ENSG00000234936.1	AC010883.5	6.56	8.64e-11	1.66e-08	0.23	0.2	Coronary artery disease;	chr2:43344746	chr2:43229573~43233394:+
BRCA	cis	rs1823913	0.637	rs10931493	ENSG00000280083.1	RP11-317J9.1	-6.56	8.65e-11	1.66e-08	-0.22	-0.2	Obesity-related traits;	chr2:191288142	chr2:191154118~191156070:-
BRCA	cis	rs4950322	0.57	rs72691090	ENSG00000278811.3	LINC00624	6.56	8.66e-11	1.66e-08	0.27	0.2	Protein quantitative trait loci;	chr1:147297884	chr1:147258885~147517875:-
BRCA	cis	rs9840812	0.592	rs1711161	ENSG00000273486.1	RP11-731C17.2	6.56	8.67e-11	1.67e-08	0.24	0.2	Fibrinogen levels;	chr3:136361695	chr3:136837338~136839021:-
BRCA	cis	rs8072100	0.713	rs9807106	ENSG00000228782.6	CTD-2026D20.3	6.56	8.69e-11	1.67e-08	0.22	0.2	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47379736	chr17:47450568~47492492:-
BRCA	cis	rs6543140	0.964	rs6543144	ENSG00000234389.1	AC007278.3	6.56	8.7e-11	1.67e-08	0.2	0.2	Blood protein levels;	chr2:102476116	chr2:102438713~102440475:+
BRCA	cis	rs1707322	0.682	rs28508523	ENSG00000281133.1	AL355480.3	-6.56	8.71e-11	1.67e-08	-0.25	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45723953	chr1:45580892~45580996:-
BRCA	cis	rs420259	0.516	rs7405145	ENSG00000260136.4	CTD-2270L9.4	-6.56	8.72e-11	1.67e-08	-0.2	-0.2	Bipolar disorder;	chr16:23526451	chr16:23452758~23457606:+
BRCA	cis	rs250585	1	rs1468138	ENSG00000260136.4	CTD-2270L9.4	-6.56	8.72e-11	1.68e-08	-0.22	-0.2	Egg allergy;	chr16:23524359	chr16:23452758~23457606:+
BRCA	cis	rs250585	1	rs6497671	ENSG00000260136.4	CTD-2270L9.4	-6.56	8.72e-11	1.68e-08	-0.22	-0.2	Egg allergy;	chr16:23525363	chr16:23452758~23457606:+
BRCA	cis	rs4713118	0.955	rs9368529	ENSG00000220721.1	OR1F12	6.55	8.74e-11	1.68e-08	0.25	0.2	Parkinson's disease;	chr6:27716852	chr6:28073316~28074233:+
BRCA	cis	rs2408955	0.541	rs11168428	ENSG00000240399.1	RP1-228P16.1	-6.55	8.74e-11	1.68e-08	-0.23	-0.2	Glycated hemoglobin levels;	chr12:48153345	chr12:48054813~48055591:-
BRCA	cis	rs4218	0.543	rs8027536	ENSG00000277144.1	RP11-59H7.4	-6.55	8.76e-11	1.68e-08	-0.24	-0.2	Social communication problems;	chr15:59022364	chr15:59115547~59116089:-
BRCA	cis	rs2243480	1	rs464895	ENSG00000229886.1	RP5-1132H15.3	6.55	8.76e-11	1.68e-08	0.37	0.2	Diabetic kidney disease;	chr7:66062119	chr7:66025126~66031544:-
BRCA	cis	rs1707322	0.963	rs1768815	ENSG00000281133.1	AL355480.3	6.55	8.77e-11	1.68e-08	0.25	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46062931	chr1:45580892~45580996:-
BRCA	cis	rs7727544	0.904	rs7736102	ENSG00000233006.5	AC034220.3	6.55	8.77e-11	1.68e-08	0.15	0.2	Blood metabolite levels;	chr5:132268564	chr5:132311285~132369916:-
BRCA	cis	rs7727544	0.904	rs6897575	ENSG00000233006.5	AC034220.3	6.55	8.77e-11	1.68e-08	0.15	0.2	Blood metabolite levels;	chr5:132268842	chr5:132311285~132369916:-
BRCA	cis	rs7927771	0.839	rs59360790	ENSG00000280615.1	Y_RNA	-6.55	8.78e-11	1.69e-08	-0.23	-0.2	Subjective well-being;	chr11:47647623	chr11:47614898~47614994:-
BRCA	cis	rs7085104	0.572	rs284857	ENSG00000213061.2	PFN1P11	-6.55	8.78e-11	1.69e-08	-0.25	-0.2	Immature fraction of reticulocytes;Schizophrenia;	chr10:102814306	chr10:102838011~102845473:-
BRCA	cis	rs7246657	0.882	rs10412043	ENSG00000226686.6	LINC01535	-6.55	8.78e-11	1.69e-08	-0.29	-0.2	Coronary artery calcification;	chr19:37335724	chr19:37251912~37265535:+
BRCA	cis	rs7131987	0.565	rs7971296	ENSG00000257176.2	RP11-996F15.2	6.55	8.8e-11	1.69e-08	0.23	0.2	QT interval;	chr12:29263297	chr12:29280418~29317848:-
BRCA	cis	rs7131987	0.605	rs1120528	ENSG00000257176.2	RP11-996F15.2	6.55	8.8e-11	1.69e-08	0.23	0.2	QT interval;	chr12:29264237	chr12:29280418~29317848:-
BRCA	cis	rs7131987	0.585	rs6487795	ENSG00000257176.2	RP11-996F15.2	6.55	8.8e-11	1.69e-08	0.23	0.2	QT interval;	chr12:29266228	chr12:29280418~29317848:-
BRCA	cis	rs420259	0.516	rs2072062	ENSG00000260136.4	CTD-2270L9.4	-6.55	8.8e-11	1.69e-08	-0.2	-0.2	Bipolar disorder;	chr16:23529477	chr16:23452758~23457606:+
BRCA	cis	rs78456975	0.622	rs11896517	ENSG00000231482.2	AC141930.2	-6.55	8.8e-11	1.69e-08	-0.27	-0.2	Placebo response in major depressive disorder (% change in symptom score);	chr2:1514340	chr2:1572554~1580311:-
BRCA	cis	rs4072705	0.934	rs4838194	ENSG00000224020.1	MIR181A2HG	-6.55	8.81e-11	1.69e-08	-0.22	-0.2	Menarche (age at onset);	chr9:124580536	chr9:124658467~124698631:+
BRCA	cis	rs3126085	0.935	rs11588174	ENSG00000237975.5	FLG-AS1	6.55	8.81e-11	1.69e-08	0.27	0.2	Atopic dermatitis;	chr1:152203494	chr1:152168125~152445456:+
BRCA	cis	rs10492201	0.529	rs4913269	ENSG00000255733.4	IFNG-AS1	-6.55	8.82e-11	1.69e-08	-0.19	-0.2	Itch intensity from mosquito bite adjusted by bite size;	chr12:68014065	chr12:67989445~68234686:+
BRCA	cis	rs1707322	1	rs4660335	ENSG00000281133.1	AL355480.3	-6.55	8.82e-11	1.69e-08	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46009046	chr1:45580892~45580996:-
BRCA	cis	rs2749097	0.825	rs11208261	ENSG00000244256.3	RN7SL130P	-6.55	8.82e-11	1.69e-08	-0.25	-0.2	Alcohol consumption (transferrin glycosylation);	chr1:63658331	chr1:63655743~63656047:+
BRCA	cis	rs7587476	0.862	rs13001462	ENSG00000229267.2	AC072062.1	-6.55	8.83e-11	1.7e-08	-0.27	-0.2	Neuroblastoma;	chr2:214813622	chr2:214810229~214963274:+
BRCA	cis	rs67981189	0.778	rs989501	ENSG00000269927.1	RP6-91H8.3	-6.55	8.84e-11	1.7e-08	-0.25	-0.2	Schizophrenia;	chr14:70894697	chr14:71141125~71143253:-
BRCA	cis	rs1667284	1	rs1667275	ENSG00000266521.1	RP11-650P15.1	6.55	8.84e-11	1.7e-08	0.24	0.2	Problematic alcohol use in trauma-exposed individuals;	chr18:31633302	chr18:31496645~31497195:-
BRCA	cis	rs16846053	0.515	rs7557876	ENSG00000227403.1	AC009299.3	-6.55	8.84e-11	1.7e-08	-0.33	-0.2	Blood osmolality (transformed sodium);	chr2:161633024	chr2:161244739~161249050:+
BRCA	cis	rs6142102	0.961	rs4911385	ENSG00000275784.1	RP5-1125A11.6	-6.55	8.84e-11	1.7e-08	-0.24	-0.2	Skin pigmentation;	chr20:33970787	chr20:33989480~33991818:-
BRCA	cis	rs11146838	1	rs11146838	ENSG00000263064.2	RP11-291L22.7	6.55	8.84e-11	1.7e-08	0.24	0.2	Breast cancer;	chr10:38856846	chr10:38448689~38448949:+
BRCA	cis	rs3781264	1	rs10509671	ENSG00000273450.1	RP11-76P2.4	6.55	8.85e-11	1.7e-08	0.27	0.2	Esophageal cancer and gastric cancer;	chr10:94309297	chr10:94314907~94315327:-
BRCA	cis	rs6840360	0.642	rs7682837	ENSG00000270265.1	RP11-731D1.4	-6.55	8.85e-11	1.7e-08	-0.22	-0.2	Intelligence (multi-trait analysis);	chr4:151506534	chr4:151333775~151353224:-
BRCA	cis	rs4842666	0.528	rs7302816	ENSG00000258302.2	RP11-981P6.1	-6.55	8.85e-11	1.7e-08	-0.22	-0.2	Blood pressure;	chr12:89556543	chr12:89561129~89594878:+
BRCA	cis	rs2153535	0.585	rs58117210	ENSG00000230939.1	RP11-314C16.1	-6.55	8.85e-11	1.7e-08	-0.23	-0.2	Motion sickness;	chr6:8603881	chr6:8784178~8785445:+
BRCA	cis	rs67981189	0.896	rs221922	ENSG00000269927.1	RP6-91H8.3	-6.55	8.9e-11	1.71e-08	-0.25	-0.2	Schizophrenia;	chr14:71118396	chr14:71141125~71143253:-
BRCA	cis	rs7914558	0.966	rs10748835	ENSG00000213061.2	PFN1P11	6.55	8.9e-11	1.71e-08	0.26	0.2	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102900499	chr10:102838011~102845473:-
BRCA	cis	rs17214007	0.877	rs1569300	ENSG00000263335.1	AF001548.5	-6.55	8.9e-11	1.71e-08	-0.29	-0.2	Cognitive function;	chr16:15776891	chr16:15726674~15732993:+
BRCA	cis	rs2243480	0.901	rs1701759	ENSG00000228409.4	CCT6P1	6.55	8.9e-11	1.71e-08	0.27	0.2	Diabetic kidney disease;	chr7:66005945	chr7:65751142~65763354:+
BRCA	cis	rs12594515	1	rs8026221	ENSG00000259200.1	RP11-718O11.1	-6.55	8.91e-11	1.71e-08	-0.22	-0.2	Weight;Waist circumference;	chr15:45695712	chr15:45705078~45931069:+
BRCA	cis	rs7665090	0.934	rs35112949	ENSG00000246560.2	RP11-10L12.4	6.55	8.91e-11	1.71e-08	0.21	0.2	Primary biliary cholangitis;	chr4:102638473	chr4:102828055~102844075:+
BRCA	cis	rs7665090	0.87	rs34349956	ENSG00000246560.2	RP11-10L12.4	6.55	8.91e-11	1.71e-08	0.21	0.2	Primary biliary cholangitis;	chr4:102638476	chr4:102828055~102844075:+
BRCA	cis	rs838147	0.534	rs2638280	ENSG00000232871.7	SEC1P	6.55	8.91e-11	1.71e-08	0.22	0.2	Dietary macronutrient intake;	chr19:48706061	chr19:48638071~48682245:+
BRCA	cis	rs9309711	0.736	rs9678647	ENSG00000225234.1	TRAPPC12-AS1	6.55	8.92e-11	1.71e-08	0.23	0.2	Neurofibrillary tangles;	chr2:3493265	chr2:3481242~3482409:-
BRCA	cis	rs8114671	0.967	rs4911472	ENSG00000269202.1	RP4-614O4.12	-6.55	8.92e-11	1.71e-08	-0.21	-0.2	Height;	chr20:35187574	chr20:35201747~35203288:-
BRCA	cis	rs2243480	0.901	rs2949697	ENSG00000229886.1	RP5-1132H15.3	6.55	8.94e-11	1.72e-08	0.35	0.2	Diabetic kidney disease;	chr7:65999249	chr7:66025126~66031544:-
BRCA	cis	rs4372836	1	rs6710959	ENSG00000226833.4	AC097724.3	6.55	8.95e-11	1.72e-08	0.24	0.2	Body mass index;	chr2:28735737	chr2:28708953~28736205:-
BRCA	cis	rs1823913	0.637	rs4853578	ENSG00000280083.1	RP11-317J9.1	-6.55	8.96e-11	1.72e-08	-0.22	-0.2	Obesity-related traits;	chr2:191297215	chr2:191154118~191156070:-
BRCA	cis	rs1707322	1	rs785506	ENSG00000281133.1	AL355480.3	6.55	8.97e-11	1.72e-08	0.25	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46074980	chr1:45580892~45580996:-
BRCA	cis	rs4072705	1	rs721862	ENSG00000224020.1	MIR181A2HG	-6.55	8.97e-11	1.72e-08	-0.22	-0.2	Menarche (age at onset);	chr9:124773713	chr9:124658467~124698631:+
BRCA	cis	rs1823874	0.72	rs2003037	ENSG00000182397.13	DNM1P46	-6.55	8.97e-11	1.72e-08	-0.21	-0.2	IgG glycosylation;	chr15:99821757	chr15:99790156~99806927:-
BRCA	cis	rs853679	0.556	rs45509595	ENSG00000220721.1	OR1F12	6.55	8.99e-11	1.72e-08	0.49	0.2	Depression;	chr6:27873148	chr6:28073316~28074233:+
BRCA	cis	rs2243480	1	rs160643	ENSG00000273142.1	RP11-458F8.4	-6.55	8.99e-11	1.73e-08	-0.26	-0.2	Diabetic kidney disease;	chr7:66093235	chr7:66902857~66906297:+
BRCA	cis	rs8114671	0.901	rs6119581	ENSG00000269202.1	RP4-614O4.12	-6.55	9e-11	1.73e-08	-0.21	-0.2	Height;	chr20:35185886	chr20:35201747~35203288:-
BRCA	cis	rs8114671	0.933	rs6087683	ENSG00000269202.1	RP4-614O4.12	-6.55	9e-11	1.73e-08	-0.21	-0.2	Height;	chr20:35186641	chr20:35201747~35203288:-
BRCA	cis	rs9307551	0.817	rs1440864	ENSG00000250334.4	LINC00989	-6.55	9.03e-11	1.73e-08	-0.27	-0.2	Refractive error;	chr4:79571830	chr4:79492416~79576460:+
BRCA	cis	rs12468226	0.938	rs76658848	ENSG00000226261.1	AC064836.3	6.55	9.03e-11	1.73e-08	0.34	0.2	Urate levels;	chr2:202275548	chr2:202336024~202336727:-
BRCA	cis	rs2243480	1	rs316313	ENSG00000232546.1	RP11-458F8.1	-6.55	9.03e-11	1.73e-08	-0.26	-0.2	Diabetic kidney disease;	chr7:66128561	chr7:66848496~66858136:+
BRCA	cis	rs2243480	1	rs316312	ENSG00000232546.1	RP11-458F8.1	-6.55	9.03e-11	1.73e-08	-0.26	-0.2	Diabetic kidney disease;	chr7:66131504	chr7:66848496~66858136:+
BRCA	cis	rs2243480	1	rs419603	ENSG00000232546.1	RP11-458F8.1	-6.55	9.03e-11	1.73e-08	-0.26	-0.2	Diabetic kidney disease;	chr7:66132354	chr7:66848496~66858136:+
BRCA	cis	rs673078	0.607	rs7312555	ENSG00000275409.1	RP11-131L12.4	-6.55	9.04e-11	1.73e-08	-0.31	-0.2	Glucose homeostasis traits;	chr12:118414120	chr12:118430147~118430699:+
BRCA	cis	rs10208649	0.908	rs11887593	ENSG00000233266.1	HMGB1P31	6.55	9.04e-11	1.73e-08	0.48	0.2	Body mass index;	chr2:54040638	chr2:54051334~54051760:+
BRCA	cis	rs12501370	1	rs2063173	ENSG00000201736.1	RNA5SP160	6.55	9.05e-11	1.74e-08	0.25	0.2	Iris color (L* coordinate);	chr4:41015610	chr4:40990154~40990273:+
BRCA	cis	rs12501370	1	rs17627002	ENSG00000201736.1	RNA5SP160	6.55	9.05e-11	1.74e-08	0.25	0.2	Iris color (L* coordinate);	chr4:41017871	chr4:40990154~40990273:+
BRCA	cis	rs9959145	0.543	rs11664013	ENSG00000267108.1	RP11-861E21.1	-6.55	9.06e-11	1.74e-08	-0.26	-0.2	Immune response to smallpox vaccine (IL-6);	chr18:12582789	chr18:12432897~12437635:+
BRCA	cis	rs4713118	0.869	rs10214440	ENSG00000220721.1	OR1F12	6.55	9.06e-11	1.74e-08	0.25	0.2	Parkinson's disease;	chr6:27734661	chr6:28073316~28074233:+
BRCA	cis	rs7246657	0.653	rs10414983	ENSG00000276846.1	CTD-3220F14.3	6.55	9.06e-11	1.74e-08	0.31	0.2	Coronary artery calcification;	chr19:37174830	chr19:37314868~37315620:-
BRCA	cis	rs7246657	0.598	rs10405372	ENSG00000276846.1	CTD-3220F14.3	6.55	9.06e-11	1.74e-08	0.31	0.2	Coronary artery calcification;	chr19:37177873	chr19:37314868~37315620:-
BRCA	cis	rs7246657	0.653	rs4805207	ENSG00000276846.1	CTD-3220F14.3	6.55	9.06e-11	1.74e-08	0.31	0.2	Coronary artery calcification;	chr19:37182831	chr19:37314868~37315620:-
BRCA	cis	rs6570726	0.935	rs392014	ENSG00000235652.6	RP11-545I5.3	6.55	9.07e-11	1.74e-08	0.19	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145522555	chr6:145799409~145886585:+
BRCA	cis	rs911555	0.755	rs17841064	ENSG00000244691.1	RPL10AP1	-6.55	9.07e-11	1.74e-08	-0.25	-0.2	Intelligence (multi-trait analysis);	chr14:103434272	chr14:103412119~103412761:-
BRCA	cis	rs7131987	0.546	rs7299648	ENSG00000257176.2	RP11-996F15.2	6.55	9.07e-11	1.74e-08	0.23	0.2	QT interval;	chr12:29256797	chr12:29280418~29317848:-
BRCA	cis	rs7131987	0.565	rs7316026	ENSG00000257176.2	RP11-996F15.2	6.55	9.07e-11	1.74e-08	0.23	0.2	QT interval;	chr12:29258881	chr12:29280418~29317848:-
BRCA	cis	rs7131987	0.565	rs6487792	ENSG00000257176.2	RP11-996F15.2	6.55	9.07e-11	1.74e-08	0.23	0.2	QT interval;	chr12:29259743	chr12:29280418~29317848:-
BRCA	cis	rs7131987	0.585	rs2194517	ENSG00000257176.2	RP11-996F15.2	6.55	9.07e-11	1.74e-08	0.23	0.2	QT interval;	chr12:29260002	chr12:29280418~29317848:-
BRCA	cis	rs6570726	0.967	rs1396648	ENSG00000235652.6	RP11-545I5.3	-6.55	9.08e-11	1.74e-08	-0.19	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:145464112	chr6:145799409~145886585:+
BRCA	cis	rs10492201	0.529	rs11177004	ENSG00000255733.4	IFNG-AS1	-6.55	9.08e-11	1.74e-08	-0.19	-0.2	Itch intensity from mosquito bite adjusted by bite size;	chr12:68015229	chr12:67989445~68234686:+
BRCA	cis	rs1499614	1	rs2141924	ENSG00000229886.1	RP5-1132H15.3	6.55	9.09e-11	1.74e-08	0.36	0.2	Gout;	chr7:66721259	chr7:66025126~66031544:-
BRCA	cis	rs2842992	0.83	rs2025189	ENSG00000237927.1	RP3-393E18.2	-6.55	9.11e-11	1.75e-08	-0.28	-0.2	Age-related macular degeneration (geographic atrophy);	chr6:159716486	chr6:159586955~159589169:-
BRCA	cis	rs2842992	0.83	rs2495279	ENSG00000237927.1	RP3-393E18.2	-6.55	9.11e-11	1.75e-08	-0.28	-0.2	Age-related macular degeneration (geographic atrophy);	chr6:159717764	chr6:159586955~159589169:-
BRCA	cis	rs13113518	0.812	rs11932712	ENSG00000249700.7	SRD5A3-AS1	6.55	9.11e-11	1.75e-08	0.25	0.2	Height;	chr4:55436423	chr4:55363971~55395847:-
BRCA	cis	rs1707322	0.752	rs28719889	ENSG00000281133.1	AL355480.3	-6.55	9.12e-11	1.75e-08	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45736611	chr1:45580892~45580996:-
BRCA	cis	rs2842992	0.709	rs1853257	ENSG00000237927.1	RP3-393E18.2	-6.55	9.12e-11	1.75e-08	-0.28	-0.2	Age-related macular degeneration (geographic atrophy);	chr6:159791678	chr6:159586955~159589169:-
BRCA	cis	rs4934494	0.834	rs3740033	ENSG00000240996.1	RP11-80H5.7	6.55	9.14e-11	1.75e-08	0.22	0.2	Red blood cell count;	chr10:89634639	chr10:89694295~89697928:-
BRCA	cis	rs17711722	0.675	rs6947132	ENSG00000237310.1	GS1-124K5.4	-6.55	9.14e-11	1.75e-08	-0.21	-0.2	Calcium levels;	chr7:65808508	chr7:66493706~66495474:+
BRCA	cis	rs757081	0.506	rs11529609	ENSG00000184669.7	OR7E14P	-6.55	9.14e-11	1.75e-08	-0.3	-0.2	Systolic blood pressure;	chr11:17042243	chr11:17013998~17053024:+
BRCA	cis	rs1993293	1	rs1993293	ENSG00000259363.4	CTD-2054N24.2	6.55	9.14e-11	1.75e-08	0.22	0.2	Coronary artery calcification;	chr15:99757458	chr15:99807023~99877148:+
BRCA	cis	rs2243480	1	rs1638734	ENSG00000232546.1	RP11-458F8.1	-6.55	9.15e-11	1.75e-08	-0.27	-0.2	Diabetic kidney disease;	chr7:66632552	chr7:66848496~66858136:+
BRCA	cis	rs11096990	0.892	rs4974924	ENSG00000249207.1	RP11-360F5.1	6.55	9.15e-11	1.75e-08	0.23	0.2	Cognitive function;	chr4:39196091	chr4:39112677~39126818:-
BRCA	cis	rs2638953	0.924	rs11049475	ENSG00000278733.1	RP11-425D17.1	-6.55	9.16e-11	1.76e-08	-0.25	-0.2	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28239731	chr12:28185625~28186190:-
BRCA	cis	rs11096990	0.892	rs7680520	ENSG00000249207.1	RP11-360F5.1	6.55	9.18e-11	1.76e-08	0.23	0.2	Cognitive function;	chr4:39219013	chr4:39112677~39126818:-
BRCA	cis	rs73173548	0.528	rs12189274	ENSG00000247828.6	TMEM161B-AS1	-6.55	9.18e-11	1.76e-08	-0.27	-0.2	Macular telangiectasia type 2;	chr5:88468669	chr5:88268895~88436685:+
BRCA	cis	rs4372836	0.828	rs6728459	ENSG00000226833.4	AC097724.3	6.55	9.19e-11	1.76e-08	0.25	0.2	Body mass index;	chr2:28776470	chr2:28708953~28736205:-
BRCA	cis	rs1707322	0.721	rs11211149	ENSG00000281133.1	AL355480.3	-6.55	9.19e-11	1.76e-08	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45646546	chr1:45580892~45580996:-
BRCA	cis	rs6840258	0.66	rs6531941	ENSG00000251411.1	RP11-397E7.4	6.55	9.19e-11	1.76e-08	0.26	0.2	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86974808	chr4:86913266~86914817:-
BRCA	cis	rs60843830	0.508	rs300750	ENSG00000272342.1	RP13-539J13.1	6.55	9.21e-11	1.76e-08	0.23	0.2	Spherical equivalent (joint analysis main effects and education interaction);	chr2:208794	chr2:739588~740164:-
BRCA	cis	rs34779708	0.966	rs2045917	ENSG00000271335.4	RP11-324I22.4	6.55	9.23e-11	1.77e-08	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35129598	chr10:35314552~35336401:-
BRCA	cis	rs7246657	0.943	rs1382357	ENSG00000226686.6	LINC01535	-6.55	9.23e-11	1.77e-08	-0.29	-0.2	Coronary artery calcification;	chr19:37486707	chr19:37251912~37265535:+
BRCA	cis	rs2919009	0.607	rs2919007	ENSG00000271670.1	RP11-95I16.4	6.55	9.23e-11	1.77e-08	0.26	0.2	Obesity-related traits;	chr10:120842499	chr10:120879256~120880667:-
BRCA	cis	rs1707322	0.716	rs28375469	ENSG00000281133.1	AL355480.3	-6.55	9.23e-11	1.77e-08	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45729703	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.752	rs28545085	ENSG00000281133.1	AL355480.3	-6.55	9.23e-11	1.77e-08	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45736278	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.752	rs28812624	ENSG00000281133.1	AL355480.3	-6.55	9.23e-11	1.77e-08	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45738064	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.752	rs28507722	ENSG00000281133.1	AL355480.3	-6.55	9.23e-11	1.77e-08	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45740868	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.752	rs28568986	ENSG00000281133.1	AL355480.3	-6.55	9.23e-11	1.77e-08	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45742071	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.717	rs28396194	ENSG00000281133.1	AL355480.3	-6.55	9.23e-11	1.77e-08	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45747555	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.717	rs28752166	ENSG00000281133.1	AL355480.3	-6.55	9.23e-11	1.77e-08	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45747637	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.717	rs10890345	ENSG00000281133.1	AL355480.3	-6.55	9.23e-11	1.77e-08	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45748255	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.721	rs10789471	ENSG00000281133.1	AL355480.3	-6.55	9.23e-11	1.77e-08	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45749947	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.752	rs11211173	ENSG00000281133.1	AL355480.3	-6.55	9.23e-11	1.77e-08	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45753704	chr1:45580892~45580996:-
BRCA	cis	rs710913	0.717	rs2068473	ENSG00000237624.1	OXCT2P1	-6.55	9.25e-11	1.77e-08	-0.23	-0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39572925	chr1:39514956~39516490:+
BRCA	cis	rs2243480	1	rs160634	ENSG00000273142.1	RP11-458F8.4	6.55	9.25e-11	1.77e-08	0.26	0.2	Diabetic kidney disease;	chr7:66063677	chr7:66902857~66906297:+
BRCA	cis	rs7246657	0.882	rs10422667	ENSG00000267422.1	CTD-2554C21.1	-6.55	9.26e-11	1.77e-08	-0.3	-0.2	Coronary artery calcification;	chr19:37446974	chr19:37779686~37792865:+
BRCA	cis	rs7246657	0.943	rs1015848	ENSG00000267422.1	CTD-2554C21.1	-6.55	9.26e-11	1.77e-08	-0.3	-0.2	Coronary artery calcification;	chr19:37454372	chr19:37779686~37792865:+
BRCA	cis	rs7246657	0.943	rs4801759	ENSG00000267422.1	CTD-2554C21.1	-6.55	9.26e-11	1.77e-08	-0.3	-0.2	Coronary artery calcification;	chr19:37464083	chr19:37779686~37792865:+
BRCA	cis	rs853679	0.517	rs2281588	ENSG00000219392.1	RP1-265C24.5	-6.55	9.26e-11	1.77e-08	-0.3	-0.2	Depression;	chr6:28104824	chr6:28115628~28116551:+
BRCA	cis	rs6840360	0.642	rs6855845	ENSG00000270265.1	RP11-731D1.4	-6.55	9.26e-11	1.77e-08	-0.22	-0.2	Intelligence (multi-trait analysis);	chr4:151496228	chr4:151333775~151353224:-
BRCA	cis	rs34779708	0.931	rs11010082	ENSG00000271335.4	RP11-324I22.4	6.55	9.26e-11	1.77e-08	0.2	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35062227	chr10:35314552~35336401:-
BRCA	cis	rs13217239	0.646	rs10946897	ENSG00000241549.7	GUSBP2	6.55	9.27e-11	1.77e-08	0.22	0.2	Schizophrenia;	chr6:27027472	chr6:26871484~26956554:-
BRCA	cis	rs17772222	0.74	rs10150986	ENSG00000258983.2	RP11-507K2.2	6.55	9.27e-11	1.77e-08	0.21	0.2	Coronary artery calcification;	chr14:88517326	chr14:88499334~88515502:+
BRCA	cis	rs875971	0.862	rs4149461	ENSG00000224316.1	RP11-479O9.2	-6.55	9.27e-11	1.77e-08	-0.2	-0.2	Aortic root size;	chr7:66279745	chr7:65773620~65802067:+
BRCA	cis	rs5015933	0.815	rs12338077	ENSG00000232630.1	PRPS1P2	-6.55	9.27e-11	1.78e-08	-0.18	-0.2	Body mass index;	chr9:125345427	chr9:125150653~125151589:+
BRCA	cis	rs2638953	0.861	rs11049685	ENSG00000278733.1	RP11-425D17.1	-6.55	9.28e-11	1.78e-08	-0.24	-0.2	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28512775	chr12:28185625~28186190:-
BRCA	cis	rs8114671	0.967	rs6058202	ENSG00000269202.1	RP4-614O4.12	-6.55	9.29e-11	1.78e-08	-0.21	-0.2	Height;	chr20:35190180	chr20:35201747~35203288:-
BRCA	cis	rs944990	0.597	rs4744245	ENSG00000227603.1	RP11-165J3.6	6.55	9.3e-11	1.78e-08	0.2	0.2	Body mass index;	chr9:93480372	chr9:93435332~93437121:-
BRCA	cis	rs2348418	0.864	rs6487688	ENSG00000247934.4	RP11-967K21.1	-6.55	9.31e-11	1.78e-08	-0.22	-0.2	Lung function (FEV1);Lung function (FVC);	chr12:28558278	chr12:28163298~28190738:-
BRCA	cis	rs2998286	0.723	rs332161	ENSG00000254635.4	WAC-AS1	6.54	9.32e-11	1.78e-08	0.29	0.2	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28599911	chr10:28522652~28532743:-
BRCA	cis	rs7937890	1	rs2970334	ENSG00000251991.1	RNU7-49P	-6.54	9.32e-11	1.78e-08	-0.21	-0.2	Mitochondrial DNA levels;	chr11:14307809	chr11:14478892~14478953:+
BRCA	cis	rs10129255	1	rs4612959	ENSG00000211972.2	IGHV3-66	6.54	9.33e-11	1.79e-08	0.15	0.2	Kawasaki disease;	chr14:106767055	chr14:106675017~106675544:-
BRCA	cis	rs8002861	0.664	rs4941474	ENSG00000274001.1	RP11-5G9.5	6.54	9.33e-11	1.79e-08	0.23	0.2	Leprosy;	chr13:43876153	chr13:43877715~43878163:-
BRCA	cis	rs7246657	0.943	rs8109038	ENSG00000276846.1	CTD-3220F14.3	-6.54	9.33e-11	1.79e-08	-0.27	-0.2	Coronary artery calcification;	chr19:37524807	chr19:37314868~37315620:-
BRCA	cis	rs11096990	0.928	rs2008681	ENSG00000249207.1	RP11-360F5.1	6.54	9.33e-11	1.79e-08	0.23	0.2	Cognitive function;	chr4:39266396	chr4:39112677~39126818:-
BRCA	cis	rs67981189	0.896	rs4132849	ENSG00000269927.1	RP6-91H8.3	6.54	9.34e-11	1.79e-08	0.25	0.2	Schizophrenia;	chr14:70992806	chr14:71141125~71143253:-
BRCA	cis	rs42648	0.819	rs10953006	ENSG00000225498.1	AC002064.5	6.54	9.34e-11	1.79e-08	0.19	0.2	Homocysteine levels;	chr7:90400839	chr7:90312496~90322592:+
BRCA	cis	rs875971	0.862	rs10276077	ENSG00000224316.1	RP11-479O9.2	-6.54	9.34e-11	1.79e-08	-0.2	-0.2	Aortic root size;	chr7:66263424	chr7:65773620~65802067:+
BRCA	cis	rs2243480	0.901	rs1701759	ENSG00000229886.1	RP5-1132H15.3	6.54	9.35e-11	1.79e-08	0.35	0.2	Diabetic kidney disease;	chr7:66005945	chr7:66025126~66031544:-
BRCA	cis	rs4845875	0.504	rs198396	ENSG00000242349.4	NPPA-AS1	-6.54	9.35e-11	1.79e-08	-0.24	-0.2	Midregional pro atrial natriuretic peptide levels;	chr1:11821263	chr1:11841017~11848079:+
BRCA	cis	rs74233809	0.901	rs4409766	ENSG00000213277.3	MARCKSL1P1	6.54	9.36e-11	1.79e-08	0.33	0.2	Birth weight;	chr10:102856906	chr10:103175554~103176094:+
BRCA	cis	rs529866	0.5	rs918739	ENSG00000262636.1	CTD-3088G3.4	-6.54	9.37e-11	1.79e-08	-0.27	-0.2	Inflammatory bowel disease;Crohn's disease;	chr16:11345876	chr16:11380859~11381118:-
BRCA	cis	rs957448	1	rs1023767	ENSG00000253175.1	RP11-267M23.6	6.54	9.4e-11	1.8e-08	0.24	0.2	Nonsyndromic cleft lip with cleft palate;	chr8:94518741	chr8:94565036~94565715:+
BRCA	cis	rs2842992	0.83	rs752779	ENSG00000237927.1	RP3-393E18.2	-6.54	9.4e-11	1.8e-08	-0.28	-0.2	Age-related macular degeneration (geographic atrophy);	chr6:159712925	chr6:159586955~159589169:-
BRCA	cis	rs17772222	0.653	rs1346996	ENSG00000258983.2	RP11-507K2.2	6.54	9.41e-11	1.8e-08	0.21	0.2	Coronary artery calcification;	chr14:88507174	chr14:88499334~88515502:+
BRCA	cis	rs2732480	0.538	rs1387259	ENSG00000273765.1	RP11-370I10.11	-6.54	9.41e-11	1.8e-08	-0.25	-0.2	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48309739	chr12:48360920~48361377:+
BRCA	cis	rs2348418	0.864	rs7295120	ENSG00000247934.4	RP11-967K21.1	6.54	9.41e-11	1.8e-08	0.22	0.2	Lung function (FEV1);Lung function (FVC);	chr12:28565175	chr12:28163298~28190738:-
BRCA	cis	rs9907295	0.688	rs2526327	ENSG00000271013.1	AC015849.15	6.54	9.41e-11	1.8e-08	0.24	0.2	Fibroblast growth factor basic levels;	chr17:35929902	chr17:35912635~35918010:-
BRCA	cis	rs875971	0.545	rs313830	ENSG00000273024.4	INTS4P2	6.54	9.41e-11	1.8e-08	0.25	0.2	Aortic root size;	chr7:66086944	chr7:65647864~65715661:+
BRCA	cis	rs1124769	0.748	rs12912106	ENSG00000259378.1	DCAF13P3	6.54	9.41e-11	1.8e-08	0.28	0.2	Cognitive performance;	chr15:51067255	chr15:50944663~50945996:+
BRCA	cis	rs11098499	0.863	rs7664986	ENSG00000249244.1	RP11-548H18.2	6.54	9.42e-11	1.8e-08	0.24	0.2	Corneal astigmatism;	chr4:119508797	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.818	rs10008791	ENSG00000249244.1	RP11-548H18.2	6.54	9.42e-11	1.8e-08	0.24	0.2	Corneal astigmatism;	chr4:119510314	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.863	rs11736416	ENSG00000249244.1	RP11-548H18.2	6.54	9.42e-11	1.8e-08	0.24	0.2	Corneal astigmatism;	chr4:119510506	chr4:119391831~119395335:-
BRCA	cis	rs34779708	0.931	rs11010067	ENSG00000271335.4	RP11-324I22.4	-6.54	9.43e-11	1.8e-08	-0.2	-0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35006503	chr10:35314552~35336401:-
BRCA	cis	rs957448	0.561	rs1808488	ENSG00000253704.1	RP11-267M23.4	6.54	9.44e-11	1.8e-08	0.22	0.2	Nonsyndromic cleft lip with cleft palate;	chr8:94602636	chr8:94553722~94569745:+
BRCA	cis	rs957448	0.583	rs754275	ENSG00000253704.1	RP11-267M23.4	6.54	9.44e-11	1.8e-08	0.22	0.2	Nonsyndromic cleft lip with cleft palate;	chr8:94602741	chr8:94553722~94569745:+
BRCA	cis	rs957448	0.561	rs1426172	ENSG00000253704.1	RP11-267M23.4	6.54	9.44e-11	1.8e-08	0.22	0.2	Nonsyndromic cleft lip with cleft palate;	chr8:94602988	chr8:94553722~94569745:+
BRCA	cis	rs1275468	0.731	rs1630753	ENSG00000257497.2	RP11-585P4.5	-6.54	9.45e-11	1.81e-08	-0.29	-0.2	Polycystic ovary syndrome;	chr12:75569518	chr12:75483454~75489820:-
BRCA	cis	rs957448	1	rs2381885	ENSG00000253175.1	RP11-267M23.6	6.54	9.45e-11	1.81e-08	0.25	0.2	Nonsyndromic cleft lip with cleft palate;	chr8:94499974	chr8:94565036~94565715:+
BRCA	cis	rs1124769	0.748	rs35372376	ENSG00000259378.1	DCAF13P3	6.54	9.45e-11	1.81e-08	0.28	0.2	Cognitive performance;	chr15:51016774	chr15:50944663~50945996:+
BRCA	cis	rs4691139	1	rs7692919	ENSG00000248632.1	RP11-366M4.11	6.54	9.46e-11	1.81e-08	0.2	0.2	Ovarian cancer in BRCA1 mutation carriers;	chr4:164981629	chr4:164968587~164970002:-
BRCA	cis	rs2243480	0.803	rs160649	ENSG00000229886.1	RP5-1132H15.3	6.54	9.47e-11	1.81e-08	0.36	0.2	Diabetic kidney disease;	chr7:66078212	chr7:66025126~66031544:-
BRCA	cis	rs2243480	1	rs160648	ENSG00000229886.1	RP5-1132H15.3	6.54	9.47e-11	1.81e-08	0.36	0.2	Diabetic kidney disease;	chr7:66078397	chr7:66025126~66031544:-
BRCA	cis	rs6583826	0.758	rs12220493	ENSG00000236493.2	EIF2S2P3	6.54	9.47e-11	1.81e-08	0.26	0.2	Type 2 diabetes;	chr10:92551152	chr10:92668745~92669743:-
BRCA	cis	rs2337406	0.925	rs11851094	ENSG00000211972.2	IGHV3-66	6.54	9.47e-11	1.81e-08	0.19	0.2	Alzheimer's disease (late onset);	chr14:106688967	chr14:106675017~106675544:-
BRCA	cis	rs2243480	1	rs709607	ENSG00000230295.1	RP11-458F8.2	6.54	9.47e-11	1.81e-08	0.26	0.2	Diabetic kidney disease;	chr7:65984554	chr7:66880708~66882981:+
BRCA	cis	rs2492286	0.518	rs2811506	ENSG00000242551.2	POU5F1P6	-6.54	9.48e-11	1.81e-08	-0.29	-0.2	Eosinophil counts;	chr3:128610801	chr3:128674735~128677005:-
BRCA	cis	rs11098499	0.863	rs6835635	ENSG00000249244.1	RP11-548H18.2	6.54	9.48e-11	1.81e-08	0.25	0.2	Corneal astigmatism;	chr4:119537712	chr4:119391831~119395335:-
BRCA	cis	rs2243480	1	rs313813	ENSG00000230295.1	RP11-458F8.2	-6.54	9.48e-11	1.81e-08	-0.27	-0.2	Diabetic kidney disease;	chr7:66038513	chr7:66880708~66882981:+
BRCA	cis	rs8114671	0.933	rs6142327	ENSG00000269202.1	RP4-614O4.12	6.54	9.49e-11	1.81e-08	0.2	0.2	Height;	chr20:35205344	chr20:35201747~35203288:-
BRCA	cis	rs467650	0.782	rs719246	ENSG00000248489.1	CTD-2007H13.3	-6.54	9.5e-11	1.82e-08	-0.23	-0.2	Venous thromboembolism (SNP x SNP interaction);	chr5:98722220	chr5:98929171~98995013:+
BRCA	cis	rs2243480	1	rs1701758	ENSG00000228409.4	CCT6P1	6.54	9.5e-11	1.82e-08	0.27	0.2	Diabetic kidney disease;	chr7:66005214	chr7:65751142~65763354:+
BRCA	cis	rs6142102	0.923	rs4911394	ENSG00000275784.1	RP5-1125A11.6	-6.54	9.5e-11	1.82e-08	-0.24	-0.2	Skin pigmentation;	chr20:33989521	chr20:33989480~33991818:-
BRCA	cis	rs944990	0.538	rs966789	ENSG00000227603.1	RP11-165J3.6	6.54	9.51e-11	1.82e-08	0.21	0.2	Body mass index;	chr9:93556861	chr9:93435332~93437121:-
BRCA	cis	rs7587476	0.784	rs62202001	ENSG00000229267.2	AC072062.1	-6.54	9.51e-11	1.82e-08	-0.27	-0.2	Neuroblastoma;	chr2:214825635	chr2:214810229~214963274:+
BRCA	cis	rs7587476	0.736	rs62202002	ENSG00000229267.2	AC072062.1	-6.54	9.51e-11	1.82e-08	-0.27	-0.2	Neuroblastoma;	chr2:214825876	chr2:214810229~214963274:+
BRCA	cis	rs2153535	0.518	rs9502728	ENSG00000230939.1	RP11-314C16.1	-6.54	9.52e-11	1.82e-08	-0.24	-0.2	Motion sickness;	chr6:8602710	chr6:8784178~8785445:+
BRCA	cis	rs60843830	0.55	rs300751	ENSG00000272342.1	RP13-539J13.1	6.54	9.52e-11	1.82e-08	0.23	0.2	Spherical equivalent (joint analysis main effects and education interaction);	chr2:209063	chr2:739588~740164:-
BRCA	cis	rs12594515	1	rs8025258	ENSG00000259200.1	RP11-718O11.1	-6.54	9.53e-11	1.82e-08	-0.22	-0.2	Weight;Waist circumference;	chr15:45695356	chr15:45705078~45931069:+
BRCA	cis	rs4691139	1	rs1914859	ENSG00000248632.1	RP11-366M4.11	6.54	9.54e-11	1.82e-08	0.2	0.2	Ovarian cancer in BRCA1 mutation carriers;	chr4:164984989	chr4:164968587~164970002:-
BRCA	cis	rs3760982	0.813	rs8111664	ENSG00000267058.1	RP11-15A1.3	6.54	9.55e-11	1.82e-08	0.23	0.2	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43790940	chr19:43891804~43901805:-
BRCA	cis	rs67981189	0.896	rs4048474	ENSG00000269927.1	RP6-91H8.3	6.54	9.55e-11	1.82e-08	0.25	0.2	Schizophrenia;	chr14:71060982	chr14:71141125~71143253:-
BRCA	cis	rs875971	0.862	rs1167390	ENSG00000224316.1	RP11-479O9.2	-6.54	9.56e-11	1.83e-08	-0.2	-0.2	Aortic root size;	chr7:66110906	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.862	rs35034167	ENSG00000224316.1	RP11-479O9.2	-6.54	9.56e-11	1.83e-08	-0.2	-0.2	Aortic root size;	chr7:66115179	chr7:65773620~65802067:+
BRCA	cis	rs2836950	0.565	rs2836934	ENSG00000255568.3	BRWD1-AS2	-6.54	9.56e-11	1.83e-08	-0.19	-0.2	Menarche (age at onset);	chr21:39192959	chr21:39313935~39314962:+
BRCA	cis	rs13113518	0.812	rs1522114	ENSG00000249700.7	SRD5A3-AS1	6.54	9.56e-11	1.83e-08	0.25	0.2	Height;	chr4:55489895	chr4:55363971~55395847:-
BRCA	cis	rs34779708	0.931	rs2384289	ENSG00000271335.4	RP11-324I22.4	6.54	9.56e-11	1.83e-08	0.2	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35054597	chr10:35314552~35336401:-
BRCA	cis	rs9992667	0.955	rs28418927	ENSG00000231160.8	KLF3-AS1	6.54	9.59e-11	1.83e-08	0.24	0.2	Eosinophil percentage of granulocytes;	chr4:38624509	chr4:38612701~38664883:-
BRCA	cis	rs301901	0.828	rs4308503	ENSG00000250155.1	CTD-2353F22.1	6.54	9.59e-11	1.83e-08	0.22	0.2	Height;	chr5:37454091	chr5:36666214~36725195:-
BRCA	cis	rs6142102	0.923	rs4911383	ENSG00000275784.1	RP5-1125A11.6	-6.54	9.59e-11	1.83e-08	-0.24	-0.2	Skin pigmentation;	chr20:33967973	chr20:33989480~33991818:-
BRCA	cis	rs16846053	0.515	rs1510094	ENSG00000227403.1	AC009299.3	6.54	9.59e-11	1.83e-08	0.33	0.2	Blood osmolality (transformed sodium);	chr2:161632681	chr2:161244739~161249050:+
BRCA	cis	rs4713118	0.869	rs9468214	ENSG00000220721.1	OR1F12	6.54	9.6e-11	1.83e-08	0.25	0.2	Parkinson's disease;	chr6:27745520	chr6:28073316~28074233:+
BRCA	cis	rs9840812	0.592	rs900048	ENSG00000239213.4	NCK1-AS1	6.54	9.62e-11	1.84e-08	0.23	0.2	Fibrinogen levels;	chr3:136500088	chr3:136841726~136862054:-
BRCA	cis	rs875971	0.862	rs1612452	ENSG00000224316.1	RP11-479O9.2	-6.54	9.62e-11	1.84e-08	-0.2	-0.2	Aortic root size;	chr7:66108909	chr7:65773620~65802067:+
BRCA	cis	rs7617773	0.643	rs78159520	ENSG00000228638.1	FCF1P2	-6.54	9.63e-11	1.84e-08	-0.23	-0.2	Coronary artery disease;	chr3:48307533	chr3:48290793~48291375:-
BRCA	cis	rs7617773	0.78	rs3197223	ENSG00000228638.1	FCF1P2	-6.54	9.65e-11	1.84e-08	-0.23	-0.2	Coronary artery disease;	chr3:48294367	chr3:48290793~48291375:-
BRCA	cis	rs853679	0.517	rs9357063	ENSG00000219392.1	RP1-265C24.5	-6.54	9.65e-11	1.84e-08	-0.3	-0.2	Depression;	chr6:28092227	chr6:28115628~28116551:+
BRCA	cis	rs2243480	1	rs316327	ENSG00000229886.1	RP5-1132H15.3	-6.54	9.67e-11	1.85e-08	-0.34	-0.2	Diabetic kidney disease;	chr7:66144214	chr7:66025126~66031544:-
BRCA	cis	rs6142102	0.961	rs4911144	ENSG00000275784.1	RP5-1125A11.6	-6.54	9.69e-11	1.85e-08	-0.24	-0.2	Skin pigmentation;	chr20:34026565	chr20:33989480~33991818:-
BRCA	cis	rs4835473	0.637	rs13110964	ENSG00000251600.4	RP11-673E1.1	6.54	9.69e-11	1.85e-08	0.23	0.2	Immature fraction of reticulocytes;	chr4:143765119	chr4:143912331~143982454:+
BRCA	cis	rs7635879	0.693	rs4687496	ENSG00000230102.6	RP11-407B7.1	6.54	9.7e-11	1.85e-08	0.24	0.2	Breastfeeding duration;	chr3:194011436	chr3:194005259~194070970:-
BRCA	cis	rs1387259	0.929	rs2634666	ENSG00000273765.1	RP11-370I10.11	6.54	9.7e-11	1.85e-08	0.24	0.2	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48269887	chr12:48360920~48361377:+
BRCA	cis	rs2732480	0.538	rs2732462	ENSG00000273765.1	RP11-370I10.11	6.54	9.71e-11	1.85e-08	0.24	0.2	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48302601	chr12:48360920~48361377:+
BRCA	cis	rs4072705	1	rs13283284	ENSG00000224020.1	MIR181A2HG	-6.54	9.71e-11	1.85e-08	-0.22	-0.2	Menarche (age at onset);	chr9:124753898	chr9:124658467~124698631:+
BRCA	cis	rs1707322	0.721	rs6665808	ENSG00000281133.1	AL355480.3	-6.54	9.72e-11	1.85e-08	-0.25	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45696611	chr1:45580892~45580996:-
BRCA	cis	rs858239	0.539	rs6461695	ENSG00000230042.1	AK3P3	-6.54	9.72e-11	1.85e-08	-0.23	-0.2	Cerebrospinal fluid biomarker levels;	chr7:23158165	chr7:23129178~23129841:+
BRCA	cis	rs2243480	1	rs387676	ENSG00000232546.1	RP11-458F8.1	-6.54	9.73e-11	1.86e-08	-0.26	-0.2	Diabetic kidney disease;	chr7:66133233	chr7:66848496~66858136:+
BRCA	cis	rs2239547	0.603	rs9870898	ENSG00000242142.1	SERBP1P3	6.54	9.73e-11	1.86e-08	0.25	0.2	Schizophrenia;	chr3:53058359	chr3:53064283~53065091:-
BRCA	cis	rs228614	0.51	rs223415	ENSG00000251288.2	RP11-10L12.2	-6.54	9.76e-11	1.86e-08	-0.24	-0.2	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102811016	chr4:102751401~102752641:+
BRCA	cis	rs6095360	0.727	rs13037813	ENSG00000222365.1	SNORD12B	-6.54	9.76e-11	1.86e-08	-0.26	-0.2	Intelligence (multi-trait analysis);	chr20:49134051	chr20:49280319~49280409:+
BRCA	cis	rs6583826	0.758	rs7073833	ENSG00000236493.2	EIF2S2P3	6.54	9.77e-11	1.86e-08	0.26	0.2	Type 2 diabetes;	chr10:92526663	chr10:92668745~92669743:-
BRCA	cis	rs12468226	0.938	rs57571703	ENSG00000226261.1	AC064836.3	6.54	9.77e-11	1.86e-08	0.34	0.2	Urate levels;	chr2:202281997	chr2:202336024~202336727:-
BRCA	cis	rs12468226	0.938	rs77062060	ENSG00000226261.1	AC064836.3	6.54	9.77e-11	1.86e-08	0.34	0.2	Urate levels;	chr2:202285639	chr2:202336024~202336727:-
BRCA	cis	rs250585	0.646	rs66569010	ENSG00000260136.4	CTD-2270L9.4	-6.54	9.77e-11	1.86e-08	-0.2	-0.2	Egg allergy;	chr16:23475631	chr16:23452758~23457606:+
BRCA	cis	rs1211375	0.607	rs1203978	ENSG00000268836.1	LA16c-OS12.2	-6.54	9.78e-11	1.87e-08	-0.2	-0.2	Mean corpuscular volume;Hematology traits;Mean corpuscular hemoglobin;	chr16:207212	chr16:185748~186294:-
BRCA	cis	rs8031584	0.958	rs34294266	ENSG00000260382.1	RP11-540B6.2	6.54	9.78e-11	1.87e-08	0.24	0.2	Huntington's disease progression;	chr15:30954637	chr15:30882267~30883231:-
BRCA	cis	rs2243480	0.764	rs2460423	ENSG00000232546.1	RP11-458F8.1	-6.54	9.79e-11	1.87e-08	-0.26	-0.2	Diabetic kidney disease;	chr7:66136229	chr7:66848496~66858136:+
BRCA	cis	rs9402682	0.592	rs9385717	ENSG00000232876.1	CTA-212D2.2	-6.54	9.79e-11	1.87e-08	-0.28	-0.2	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr6:135137285	chr6:135055033~135060550:+
BRCA	cis	rs7665090	1	rs7665090	ENSG00000246560.2	RP11-10L12.4	-6.54	9.82e-11	1.87e-08	-0.21	-0.2	Primary biliary cholangitis;	chr4:102630446	chr4:102828055~102844075:+
BRCA	cis	rs2286503	0.839	rs4722188	ENSG00000228649.7	AC005682.5	6.54	9.82e-11	1.87e-08	0.17	0.2	Fibrinogen;	chr7:22820592	chr7:22854178~22861579:+
BRCA	cis	rs2243480	1	rs313813	ENSG00000229886.1	RP5-1132H15.3	6.54	9.82e-11	1.87e-08	0.36	0.2	Diabetic kidney disease;	chr7:66038513	chr7:66025126~66031544:-
BRCA	cis	rs7665090	1	rs5026473	ENSG00000246560.2	RP11-10L12.4	6.54	9.82e-11	1.87e-08	0.21	0.2	Primary biliary cholangitis;	chr4:102633636	chr4:102828055~102844075:+
BRCA	cis	rs17253792	0.822	rs28409547	ENSG00000186615.9	KTN1-AS1	-6.54	9.84e-11	1.88e-08	-0.37	-0.2	Putamen volume;	chr14:55581108	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs28478195	ENSG00000186615.9	KTN1-AS1	-6.54	9.84e-11	1.88e-08	-0.37	-0.2	Putamen volume;	chr14:55581133	chr14:55499278~55580110:-
BRCA	cis	rs2408955	0.568	rs12099462	ENSG00000240399.1	RP1-228P16.1	-6.54	9.84e-11	1.88e-08	-0.23	-0.2	Glycated hemoglobin levels;	chr12:48109321	chr12:48054813~48055591:-
BRCA	cis	rs11098499	0.863	rs13134665	ENSG00000249244.1	RP11-548H18.2	6.54	9.84e-11	1.88e-08	0.24	0.2	Corneal astigmatism;	chr4:119505275	chr4:119391831~119395335:-
BRCA	cis	rs2243480	1	rs6964530	ENSG00000230295.1	RP11-458F8.2	6.54	9.85e-11	1.88e-08	0.26	0.2	Diabetic kidney disease;	chr7:66253864	chr7:66880708~66882981:+
BRCA	cis	rs7246657	0.653	rs4805208	ENSG00000276846.1	CTD-3220F14.3	6.54	9.87e-11	1.88e-08	0.31	0.2	Coronary artery calcification;	chr19:37183357	chr19:37314868~37315620:-
BRCA	cis	rs2018683	0.624	rs2286220	ENSG00000228421.2	AC005013.5	6.54	9.87e-11	1.88e-08	0.25	0.2	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28959083	chr7:28957667~28959345:+
BRCA	cis	rs2243480	1	rs781150	ENSG00000229886.1	RP5-1132H15.3	6.54	9.88e-11	1.88e-08	0.35	0.2	Diabetic kidney disease;	chr7:66015986	chr7:66025126~66031544:-
BRCA	cis	rs2243480	1	rs313798	ENSG00000229886.1	RP5-1132H15.3	6.54	9.88e-11	1.88e-08	0.35	0.2	Diabetic kidney disease;	chr7:66028044	chr7:66025126~66031544:-
BRCA	cis	rs7474896	0.515	rs662928	ENSG00000226578.1	RP11-258F22.1	6.54	9.92e-11	1.89e-08	0.25	0.2	Obesity (extreme);	chr10:38027288	chr10:37775371~37784131:-
BRCA	cis	rs7246657	0.598	rs28660259	ENSG00000276846.1	CTD-3220F14.3	6.53	9.94e-11	1.9e-08	0.31	0.2	Coronary artery calcification;	chr19:37167779	chr19:37314868~37315620:-
BRCA	cis	rs2243480	1	rs1701758	ENSG00000229886.1	RP5-1132H15.3	6.53	9.95e-11	1.9e-08	0.35	0.2	Diabetic kidney disease;	chr7:66005214	chr7:66025126~66031544:-
BRCA	cis	rs7246657	0.943	rs7258692	ENSG00000267422.1	CTD-2554C21.1	-6.53	9.95e-11	1.9e-08	-0.3	-0.2	Coronary artery calcification;	chr19:37327927	chr19:37779686~37792865:+
BRCA	cis	rs6570726	0.967	rs9403706	ENSG00000235652.6	RP11-545I5.3	-6.53	9.95e-11	1.9e-08	-0.19	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:145474051	chr6:145799409~145886585:+
BRCA	cis	rs1440410	0.835	rs7693583	ENSG00000250326.1	RP11-284M14.1	-6.53	9.96e-11	1.9e-08	-0.22	-0.2	Ischemic stroke;	chr4:143130189	chr4:142933195~143184861:-
BRCA	cis	rs2274273	0.638	rs58269011	ENSG00000258413.1	RP11-665C16.6	-6.53	9.97e-11	1.9e-08	-0.27	-0.2	Protein biomarker;	chr14:55217670	chr14:55262767~55272075:-
BRCA	cis	rs16846053	0.515	rs3843853	ENSG00000227403.1	AC009299.3	-6.53	9.97e-11	1.9e-08	-0.33	-0.2	Blood osmolality (transformed sodium);	chr2:161645081	chr2:161244739~161249050:+
BRCA	cis	rs853679	0.607	rs34661125	ENSG00000220721.1	OR1F12	6.53	9.97e-11	1.9e-08	0.46	0.2	Depression;	chr6:28314117	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.607	rs13190888	ENSG00000220721.1	OR1F12	6.53	9.97e-11	1.9e-08	0.46	0.2	Depression;	chr6:28318208	chr6:28073316~28074233:+
BRCA	cis	rs12594515	1	rs6493172	ENSG00000259200.1	RP11-718O11.1	-6.53	9.98e-11	1.9e-08	-0.22	-0.2	Weight;Waist circumference;	chr15:45695015	chr15:45705078~45931069:+
BRCA	cis	rs875971	0.505	rs6955582	ENSG00000237310.1	GS1-124K5.4	6.53	9.99e-11	1.9e-08	0.21	0.2	Aortic root size;	chr7:65966699	chr7:66493706~66495474:+
BRCA	cis	rs9638182	0.725	rs80189144	ENSG00000274080.1	CTA-315H11.2	6.53	1e-10	1.91e-08	0.39	0.2	Triglycerides;	chr7:73525609	chr7:73609262~73611502:-
BRCA	cis	rs4072705	0.933	rs10760376	ENSG00000224020.1	MIR181A2HG	6.53	1e-10	1.91e-08	0.22	0.2	Menarche (age at onset);	chr9:124791791	chr9:124658467~124698631:+
BRCA	cis	rs1555322	0.53	rs2250205	ENSG00000279253.1	RP4-614O4.13	-6.53	1e-10	1.91e-08	-0.26	-0.2	Attention deficit hyperactivity disorder;	chr20:35280121	chr20:35262727~35264187:-
BRCA	cis	rs73411413	0.661	rs11599981	ENSG00000233930.3	KRTAP5-AS1	-6.53	1e-10	1.91e-08	-0.3	-0.2	Myringotomy;	chr11:1498833	chr11:1571353~1599184:+
BRCA	cis	rs55726902	0.761	rs2544029	ENSG00000276691.1	RP5-1057I20.5	6.53	1e-10	1.91e-08	0.23	0.2	Allergic disease (asthma, hay fever or eczema);	chr12:47801174	chr12:47788426~47788971:+
BRCA	cis	rs669446	0.533	rs2158956	ENSG00000237950.1	RP11-7O11.3	6.53	1e-10	1.91e-08	0.23	0.2	Amyotrophic lateral sclerosis (age of onset);	chr1:43746026	chr1:43944370~43946551:-
BRCA	cis	rs237743	1	rs67733885	ENSG00000222365.1	SNORD12B	-6.53	1e-10	1.91e-08	-0.26	-0.2	Height;	chr20:49280020	chr20:49280319~49280409:+
BRCA	cis	rs12594515	0.967	rs11856523	ENSG00000259200.1	RP11-718O11.1	-6.53	1e-10	1.91e-08	-0.22	-0.2	Weight;Waist circumference;	chr15:45697297	chr15:45705078~45931069:+
BRCA	cis	rs2880765	0.706	rs7172006	ENSG00000259295.5	CSPG4P12	6.53	1e-10	1.91e-08	0.26	0.2	Coronary artery disease;	chr15:85510128	chr15:85191438~85213905:+
BRCA	cis	rs8072100	0.713	rs2136750	ENSG00000228782.6	CTD-2026D20.3	6.53	1e-10	1.91e-08	0.22	0.2	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47378734	chr17:47450568~47492492:-
BRCA	cis	rs113835537	0.597	rs10896129	ENSG00000255517.5	CTD-3074O7.5	-6.53	1.01e-10	1.92e-08	-0.26	-0.2	Airway imaging phenotypes;	chr11:66570829	chr11:66473490~66480233:-
BRCA	cis	rs113835537	0.559	rs57045447	ENSG00000255517.5	CTD-3074O7.5	-6.53	1.01e-10	1.92e-08	-0.26	-0.2	Airway imaging phenotypes;	chr11:66572212	chr11:66473490~66480233:-
BRCA	cis	rs8114671	0.967	rs12481169	ENSG00000269202.1	RP4-614O4.12	6.53	1.01e-10	1.92e-08	0.21	0.2	Height;	chr20:35206707	chr20:35201747~35203288:-
BRCA	cis	rs853679	0.607	rs34878803	ENSG00000220721.1	OR1F12	6.53	1.01e-10	1.92e-08	0.45	0.2	Depression;	chr6:28282402	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.607	rs34396849	ENSG00000220721.1	OR1F12	6.53	1.01e-10	1.92e-08	0.45	0.2	Depression;	chr6:28283178	chr6:28073316~28074233:+
BRCA	cis	rs17572109	0.666	rs11696005	ENSG00000261338.2	RP11-378A13.1	-6.53	1.01e-10	1.92e-08	-0.25	-0.2	Platelet count;Platelet distribution width;Mean platelet volume;	chr2:218364918	chr2:218255319~218257366:+
BRCA	cis	rs7246657	0.653	rs28701616	ENSG00000276846.1	CTD-3220F14.3	6.53	1.01e-10	1.92e-08	0.31	0.2	Coronary artery calcification;	chr19:37190196	chr19:37314868~37315620:-
BRCA	cis	rs67981189	1	rs67981189	ENSG00000269927.1	RP6-91H8.3	6.53	1.01e-10	1.92e-08	0.24	0.2	Schizophrenia;	chr14:71005509	chr14:71141125~71143253:-
BRCA	cis	rs67981189	0.896	rs7145484	ENSG00000269927.1	RP6-91H8.3	6.53	1.01e-10	1.92e-08	0.24	0.2	Schizophrenia;	chr14:71006820	chr14:71141125~71143253:-
BRCA	cis	rs853679	0.517	rs56364346	ENSG00000219392.1	RP1-265C24.5	-6.53	1.01e-10	1.92e-08	-0.3	-0.2	Depression;	chr6:28082984	chr6:28115628~28116551:+
BRCA	cis	rs853679	0.517	rs9357061	ENSG00000219392.1	RP1-265C24.5	-6.53	1.01e-10	1.92e-08	-0.3	-0.2	Depression;	chr6:28083994	chr6:28115628~28116551:+
BRCA	cis	rs853679	0.517	rs9368550	ENSG00000219392.1	RP1-265C24.5	-6.53	1.01e-10	1.92e-08	-0.3	-0.2	Depression;	chr6:28084025	chr6:28115628~28116551:+
BRCA	cis	rs853679	0.542	rs2295594	ENSG00000219392.1	RP1-265C24.5	-6.53	1.01e-10	1.92e-08	-0.3	-0.2	Depression;	chr6:28085319	chr6:28115628~28116551:+
BRCA	cis	rs4372836	1	rs2169751	ENSG00000226833.4	AC097724.3	6.53	1.01e-10	1.92e-08	0.24	0.2	Body mass index;	chr2:28743892	chr2:28708953~28736205:-
BRCA	cis	rs9876781	1	rs13314659	ENSG00000229759.1	MRPS18AP1	-6.53	1.01e-10	1.92e-08	-0.22	-0.2	Longevity;	chr3:48407742	chr3:48256350~48256938:-
BRCA	cis	rs2836950	0.565	rs7278297	ENSG00000238141.2	BRWD1-AS1	-6.53	1.01e-10	1.93e-08	-0.22	-0.2	Menarche (age at onset);	chr21:39253826	chr21:39315707~39323218:+
BRCA	cis	rs270601	0.77	rs10463891	ENSG00000233006.5	AC034220.3	-6.53	1.01e-10	1.93e-08	-0.15	-0.2	Acylcarnitine levels;	chr5:132261699	chr5:132311285~132369916:-
BRCA	cis	rs2732480	0.557	rs2732454	ENSG00000273765.1	RP11-370I10.11	6.53	1.02e-10	1.93e-08	0.24	0.2	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48325894	chr12:48360920~48361377:+
BRCA	cis	rs11098499	0.954	rs2389803	ENSG00000249244.1	RP11-548H18.2	-6.53	1.02e-10	1.93e-08	-0.24	-0.2	Corneal astigmatism;	chr4:119472356	chr4:119391831~119395335:-
BRCA	cis	rs10740039	0.81	rs1442543	ENSG00000254271.1	RP11-131N11.4	6.53	1.02e-10	1.94e-08	0.27	0.2	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60613704	chr10:60734342~60741828:+
BRCA	cis	rs7131987	0.565	rs10743651	ENSG00000257176.2	RP11-996F15.2	6.53	1.02e-10	1.94e-08	0.23	0.2	QT interval;	chr12:29255006	chr12:29280418~29317848:-
BRCA	cis	rs12594515	1	rs8031128	ENSG00000259200.1	RP11-718O11.1	-6.53	1.02e-10	1.94e-08	-0.22	-0.2	Weight;Waist circumference;	chr15:45696330	chr15:45705078~45931069:+
BRCA	cis	rs12594515	0.967	rs71405295	ENSG00000259200.1	RP11-718O11.1	-6.53	1.02e-10	1.94e-08	-0.22	-0.2	Weight;Waist circumference;	chr15:45696723	chr15:45705078~45931069:+
BRCA	cis	rs875971	0.545	rs1267814	ENSG00000236529.1	RP13-254B10.1	-6.53	1.02e-10	1.94e-08	-0.25	-0.2	Aortic root size;	chr7:66579422	chr7:65840212~65840596:+
BRCA	cis	rs2243480	1	rs1553174	ENSG00000229886.1	RP5-1132H15.3	-6.53	1.02e-10	1.95e-08	-0.35	-0.2	Diabetic kidney disease;	chr7:66266207	chr7:66025126~66031544:-
BRCA	cis	rs2243480	1	rs10950032	ENSG00000229886.1	RP5-1132H15.3	-6.53	1.02e-10	1.95e-08	-0.35	-0.2	Diabetic kidney disease;	chr7:66273604	chr7:66025126~66031544:-
BRCA	cis	rs875971	0.545	rs73146609	ENSG00000273024.4	INTS4P2	-6.53	1.02e-10	1.95e-08	-0.25	-0.2	Aortic root size;	chr7:66302477	chr7:65647864~65715661:+
BRCA	cis	rs875971	0.545	rs2173571	ENSG00000273024.4	INTS4P2	-6.53	1.02e-10	1.95e-08	-0.25	-0.2	Aortic root size;	chr7:66305392	chr7:65647864~65715661:+
BRCA	cis	rs16949788	1	rs11071894	ENSG00000261351.2	CTD-3185P2.1	6.53	1.02e-10	1.95e-08	0.38	0.2	Spherical equivalent (joint analysis main effects and education interaction);	chr15:66481395	chr15:66488658~66492109:-
BRCA	cis	rs4907240	0.731	rs11900310	ENSG00000237510.6	AC008268.2	6.53	1.02e-10	1.95e-08	0.26	0.2	Event-related brain oscillations;	chr2:96476093	chr2:95789654~95800166:+
BRCA	cis	rs7267979	0.789	rs6083841	ENSG00000204556.4	CTD-2514C3.1	6.53	1.02e-10	1.95e-08	0.27	0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25403928	chr20:26018832~26020684:+
BRCA	cis	rs7684253	1	rs7684253	ENSG00000269949.1	RP11-738E22.3	6.53	1.02e-10	1.95e-08	0.23	0.2	Migraine;	chr4:56861145	chr4:56960927~56961373:-
BRCA	cis	rs8072100	0.713	rs57427906	ENSG00000228782.6	CTD-2026D20.3	6.53	1.02e-10	1.95e-08	0.22	0.2	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47416648	chr17:47450568~47492492:-
BRCA	cis	rs2243480	1	rs316326	ENSG00000229886.1	RP5-1132H15.3	6.53	1.02e-10	1.95e-08	0.35	0.2	Diabetic kidney disease;	chr7:66144466	chr7:66025126~66031544:-
BRCA	cis	rs2243480	1	rs316325	ENSG00000229886.1	RP5-1132H15.3	6.53	1.02e-10	1.95e-08	0.35	0.2	Diabetic kidney disease;	chr7:66144531	chr7:66025126~66031544:-
BRCA	cis	rs6472827	1	rs6472827	ENSG00000253983.2	RP1-16A9.1	-6.53	1.02e-10	1.95e-08	-0.34	-0.2	Uterine fibroids;	chr8:74207107	chr8:74199396~74208441:+
BRCA	cis	rs467650	0.817	rs977028	ENSG00000248489.1	CTD-2007H13.3	6.53	1.03e-10	1.95e-08	0.24	0.2	Venous thromboembolism (SNP x SNP interaction);	chr5:98720804	chr5:98929171~98995013:+
BRCA	cis	rs875971	0.545	rs1796226	ENSG00000236529.1	RP13-254B10.1	6.53	1.03e-10	1.96e-08	0.24	0.2	Aortic root size;	chr7:66622723	chr7:65840212~65840596:+
BRCA	cis	rs8030379	1	rs11259936	ENSG00000230373.7	GOLGA6L5P	6.53	1.03e-10	1.96e-08	0.21	0.2	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83911830	chr15:84507885~84516814:-
BRCA	cis	rs1061377	0.748	rs6812316	ENSG00000249685.1	RP11-360F5.3	6.53	1.03e-10	1.96e-08	0.24	0.2	Uric acid levels;	chr4:39106617	chr4:39133913~39135608:+
BRCA	cis	rs11096990	0.892	rs11930865	ENSG00000249207.1	RP11-360F5.1	6.53	1.03e-10	1.96e-08	0.23	0.2	Cognitive function;	chr4:39218711	chr4:39112677~39126818:-
BRCA	cis	rs755249	0.501	rs2455648	ENSG00000228060.1	RP11-69E11.8	-6.53	1.03e-10	1.96e-08	-0.21	-0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39178040	chr1:39565160~39573203:+
BRCA	cis	rs227275	0.524	rs223337	ENSG00000251288.2	RP11-10L12.2	-6.53	1.03e-10	1.96e-08	-0.23	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102865214	chr4:102751401~102752641:+
BRCA	cis	rs172166	0.694	rs203893	ENSG00000204709.4	LINC01556	6.53	1.03e-10	1.97e-08	0.27	0.2	Cardiac Troponin-T levels;	chr6:28094288	chr6:28943877~28944537:+
BRCA	cis	rs2243480	1	rs316322	ENSG00000229886.1	RP5-1132H15.3	6.53	1.03e-10	1.97e-08	0.35	0.2	Diabetic kidney disease;	chr7:66146246	chr7:66025126~66031544:-
BRCA	cis	rs7474896	0.583	rs11011346	ENSG00000226578.1	RP11-258F22.1	-6.53	1.03e-10	1.97e-08	-0.26	-0.2	Obesity (extreme);	chr10:37720555	chr10:37775371~37784131:-
BRCA	cis	rs9840812	0.623	rs1145106	ENSG00000239213.4	NCK1-AS1	6.53	1.03e-10	1.97e-08	0.23	0.2	Fibrinogen levels;	chr3:136393075	chr3:136841726~136862054:-
BRCA	cis	rs2348418	0.832	rs4244844	ENSG00000247934.4	RP11-967K21.1	6.53	1.03e-10	1.97e-08	0.22	0.2	Lung function (FEV1);Lung function (FVC);	chr12:28434062	chr12:28163298~28190738:-
BRCA	cis	rs8031584	0.958	rs11293	ENSG00000260382.1	RP11-540B6.2	6.53	1.04e-10	1.97e-08	0.24	0.2	Huntington's disease progression;	chr15:30942778	chr15:30882267~30883231:-
BRCA	cis	rs6142102	0.961	rs2056990	ENSG00000275784.1	RP5-1125A11.6	-6.53	1.04e-10	1.98e-08	-0.24	-0.2	Skin pigmentation;	chr20:34035658	chr20:33989480~33991818:-
BRCA	cis	rs2976388	0.507	rs2572874	ENSG00000253741.1	CTD-2292P10.4	-6.53	1.04e-10	1.98e-08	-0.23	-0.2	Urinary tract infection frequency;	chr8:142755801	chr8:142702252~142726973:-
BRCA	cis	rs11742741	0.714	rs61442687	ENSG00000248874.4	C5orf17	-6.53	1.04e-10	1.98e-08	-0.25	-0.2	Educational attainment;	chr5:24189306	chr5:23951348~24178263:+
BRCA	cis	rs2243480	1	rs1499613	ENSG00000229886.1	RP5-1132H15.3	-6.53	1.04e-10	1.98e-08	-0.35	-0.2	Diabetic kidney disease;	chr7:66265873	chr7:66025126~66031544:-
BRCA	cis	rs1861628	0.512	rs10932677	ENSG00000237930.1	AC007563.4	-6.53	1.04e-10	1.98e-08	-0.3	-0.2	Serum thyroid-stimulating hormone levels;Hypothyroidism;	chr2:216762427	chr2:216785774~216786144:-
BRCA	cis	rs3764021	0.527	rs2114870	ENSG00000214776.8	RP11-726G1.1	6.53	1.04e-10	1.98e-08	0.24	0.2	Type 1 diabetes;	chr12:9670544	chr12:9467552~9576275:+
BRCA	cis	rs4763879	0.502	rs11052552	ENSG00000214776.8	RP11-726G1.1	6.53	1.04e-10	1.98e-08	0.21	0.2	Type 1 diabetes;	chr12:9703362	chr12:9467552~9576275:+
BRCA	cis	rs73173548	0.557	rs71580759	ENSG00000247828.6	TMEM161B-AS1	6.53	1.04e-10	1.98e-08	0.27	0.2	Macular telangiectasia type 2;	chr5:88474306	chr5:88268895~88436685:+
BRCA	cis	rs8031584	0.918	rs34095794	ENSG00000260382.1	RP11-540B6.2	6.53	1.04e-10	1.98e-08	0.23	0.2	Huntington's disease progression;	chr15:30977488	chr15:30882267~30883231:-
BRCA	cis	rs9527	0.551	rs28606370	ENSG00000236937.2	PTGES3P4	6.53	1.04e-10	1.98e-08	0.26	0.2	Arsenic metabolism;	chr10:102911075	chr10:102845595~102845950:+
BRCA	cis	rs7665090	0.967	rs5026469	ENSG00000246560.2	RP11-10L12.4	6.53	1.04e-10	1.98e-08	0.21	0.2	Primary biliary cholangitis;	chr4:102633556	chr4:102828055~102844075:+
BRCA	cis	rs7665090	0.967	rs5026470	ENSG00000246560.2	RP11-10L12.4	6.53	1.04e-10	1.98e-08	0.21	0.2	Primary biliary cholangitis;	chr4:102633565	chr4:102828055~102844075:+
BRCA	cis	rs7665090	0.967	rs5026471	ENSG00000246560.2	RP11-10L12.4	6.53	1.04e-10	1.98e-08	0.21	0.2	Primary biliary cholangitis;	chr4:102633576	chr4:102828055~102844075:+
BRCA	cis	rs2337406	1	rs3858878	ENSG00000254174.1	IGHV1-12	6.53	1.04e-10	1.99e-08	0.2	0.2	Alzheimer's disease (late onset);	chr14:106688061	chr14:106122420~106122709:-
BRCA	cis	rs1707322	0.716	rs10890342	ENSG00000281133.1	AL355480.3	-6.53	1.04e-10	1.99e-08	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45691415	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.752	rs6658700	ENSG00000281133.1	AL355480.3	-6.53	1.04e-10	1.99e-08	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45694588	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.752	rs12047629	ENSG00000281133.1	AL355480.3	-6.53	1.04e-10	1.99e-08	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45697130	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.752	rs11211171	ENSG00000281133.1	AL355480.3	-6.53	1.04e-10	1.99e-08	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45702970	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.752	rs28623463	ENSG00000281133.1	AL355480.3	-6.53	1.04e-10	1.99e-08	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45705086	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.716	rs28370457	ENSG00000281133.1	AL355480.3	-6.53	1.04e-10	1.99e-08	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45706390	chr1:45580892~45580996:-
BRCA	cis	rs6570726	0.905	rs1355146	ENSG00000235652.6	RP11-545I5.3	-6.53	1.05e-10	1.99e-08	-0.19	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:145460605	chr6:145799409~145886585:+
BRCA	cis	rs2243480	1	rs6460260	ENSG00000228409.4	CCT6P1	-6.53	1.05e-10	1.99e-08	-0.27	-0.2	Diabetic kidney disease;	chr7:65750468	chr7:65751142~65763354:+
BRCA	cis	rs2243480	1	rs6460261	ENSG00000228409.4	CCT6P1	-6.53	1.05e-10	1.99e-08	-0.27	-0.2	Diabetic kidney disease;	chr7:65750593	chr7:65751142~65763354:+
BRCA	cis	rs2836950	0.545	rs2297256	ENSG00000255568.3	BRWD1-AS2	-6.53	1.05e-10	1.99e-08	-0.19	-0.2	Menarche (age at onset);	chr21:39186495	chr21:39313935~39314962:+
BRCA	cis	rs957448	0.561	rs34471170	ENSG00000253704.1	RP11-267M23.4	6.53	1.05e-10	1.99e-08	0.21	0.2	Nonsyndromic cleft lip with cleft palate;	chr8:94601135	chr8:94553722~94569745:+
BRCA	cis	rs957448	0.561	rs9642927	ENSG00000253704.1	RP11-267M23.4	6.53	1.05e-10	1.99e-08	0.21	0.2	Nonsyndromic cleft lip with cleft palate;	chr8:94601414	chr8:94553722~94569745:+
BRCA	cis	rs2842992	0.83	rs2758313	ENSG00000237927.1	RP3-393E18.2	-6.53	1.05e-10	2e-08	-0.28	-0.2	Age-related macular degeneration (geographic atrophy);	chr6:159733067	chr6:159586955~159589169:-
BRCA	cis	rs4761702	0.857	rs1135400	ENSG00000257252.4	RP11-486A14.2	6.53	1.05e-10	2e-08	0.26	0.2	Immature fraction of reticulocytes;	chr12:93315763	chr12:93317135~93377736:-
BRCA	cis	rs7665090	0.936	rs5026474	ENSG00000246560.2	RP11-10L12.4	6.53	1.05e-10	2e-08	0.21	0.2	Primary biliary cholangitis;	chr4:102633653	chr4:102828055~102844075:+
BRCA	cis	rs34779708	0.931	rs2244100	ENSG00000271335.4	RP11-324I22.4	-6.53	1.05e-10	2e-08	-0.2	-0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35034708	chr10:35314552~35336401:-
BRCA	cis	rs600231	0.665	rs2846861	ENSG00000245532.5	NEAT1	6.53	1.05e-10	2e-08	0.18	0.2	Bone mineral density;	chr11:65454834	chr11:65422774~65445540:+
BRCA	cis	rs9876781	1	rs9849509	ENSG00000229759.1	MRPS18AP1	6.53	1.05e-10	2e-08	0.22	0.2	Longevity;	chr3:48442021	chr3:48256350~48256938:-
BRCA	cis	rs9876781	1	rs60512868	ENSG00000229759.1	MRPS18AP1	6.53	1.05e-10	2e-08	0.22	0.2	Longevity;	chr3:48442035	chr3:48256350~48256938:-
BRCA	cis	rs957448	1	rs1055797	ENSG00000253175.1	RP11-267M23.6	6.53	1.05e-10	2e-08	0.25	0.2	Nonsyndromic cleft lip with cleft palate;	chr8:94511005	chr8:94565036~94565715:+
BRCA	cis	rs6969780	1	rs929249	ENSG00000233429.8	HOTAIRM1	6.53	1.05e-10	2.01e-08	0.26	0.2	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27127918	chr7:27095647~27100265:+
BRCA	cis	rs853679	0.585	rs201004	ENSG00000220721.1	OR1F12	6.53	1.06e-10	2.01e-08	0.29	0.2	Depression;	chr6:27837156	chr6:28073316~28074233:+
BRCA	cis	rs67981189	0.896	rs34049963	ENSG00000269927.1	RP6-91H8.3	6.53	1.06e-10	2.01e-08	0.24	0.2	Schizophrenia;	chr14:70974029	chr14:71141125~71143253:-
BRCA	cis	rs34779708	0.931	rs72789609	ENSG00000271335.4	RP11-324I22.4	6.53	1.06e-10	2.01e-08	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35017278	chr10:35314552~35336401:-
BRCA	cis	rs2243480	1	rs464895	ENSG00000230295.1	RP11-458F8.2	-6.53	1.06e-10	2.01e-08	-0.28	-0.2	Diabetic kidney disease;	chr7:66062119	chr7:66880708~66882981:+
BRCA	cis	rs1707322	0.506	rs2991983	ENSG00000281133.1	AL355480.3	6.52	1.06e-10	2.02e-08	0.26	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613719	chr1:45580892~45580996:-
BRCA	cis	rs7665090	0.967	rs6812747	ENSG00000246560.2	RP11-10L12.4	6.52	1.06e-10	2.02e-08	0.21	0.2	Primary biliary cholangitis;	chr4:102634260	chr4:102828055~102844075:+
BRCA	cis	rs7665090	1	rs6839064	ENSG00000246560.2	RP11-10L12.4	6.52	1.06e-10	2.02e-08	0.21	0.2	Primary biliary cholangitis;	chr4:102634519	chr4:102828055~102844075:+
BRCA	cis	rs7665090	1	rs2272695	ENSG00000246560.2	RP11-10L12.4	6.52	1.06e-10	2.02e-08	0.21	0.2	Primary biliary cholangitis;	chr4:102634646	chr4:102828055~102844075:+
BRCA	cis	rs7665090	1	rs2272696	ENSG00000246560.2	RP11-10L12.4	6.52	1.06e-10	2.02e-08	0.21	0.2	Primary biliary cholangitis;	chr4:102634664	chr4:102828055~102844075:+
BRCA	cis	rs10029851	0.54	rs7682499	ENSG00000234492.4	RPL34-AS1	6.52	1.06e-10	2.02e-08	0.31	0.2	Amyotrophic lateral sclerosis (sporadic);	chr4:108596565	chr4:108538190~108620460:-
BRCA	cis	rs7665090	1	rs5026476	ENSG00000246560.2	RP11-10L12.4	6.52	1.06e-10	2.02e-08	0.21	0.2	Primary biliary cholangitis;	chr4:102633753	chr4:102828055~102844075:+
BRCA	cis	rs7665090	1	rs2272697	ENSG00000246560.2	RP11-10L12.4	6.52	1.06e-10	2.02e-08	0.21	0.2	Primary biliary cholangitis;	chr4:102634835	chr4:102828055~102844075:+
BRCA	cis	rs2243480	1	rs431076	ENSG00000232546.1	RP11-458F8.1	-6.52	1.06e-10	2.02e-08	-0.26	-0.2	Diabetic kidney disease;	chr7:66135333	chr7:66848496~66858136:+
BRCA	cis	rs2243480	1	rs2460422	ENSG00000232546.1	RP11-458F8.1	-6.52	1.06e-10	2.02e-08	-0.26	-0.2	Diabetic kidney disease;	chr7:66136518	chr7:66848496~66858136:+
BRCA	cis	rs2243480	1	rs316334	ENSG00000232546.1	RP11-458F8.1	-6.52	1.06e-10	2.02e-08	-0.26	-0.2	Diabetic kidney disease;	chr7:66137139	chr7:66848496~66858136:+
BRCA	cis	rs2348418	1	rs2348418	ENSG00000247934.4	RP11-967K21.1	6.52	1.06e-10	2.02e-08	0.22	0.2	Lung function (FEV1);Lung function (FVC);	chr12:28536581	chr12:28163298~28190738:-
BRCA	cis	rs8072100	0.607	rs9894594	ENSG00000228782.6	CTD-2026D20.3	6.52	1.07e-10	2.02e-08	0.22	0.2	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47384017	chr17:47450568~47492492:-
BRCA	cis	rs2243480	1	rs6460260	ENSG00000229886.1	RP5-1132H15.3	-6.52	1.07e-10	2.03e-08	-0.35	-0.2	Diabetic kidney disease;	chr7:65750468	chr7:66025126~66031544:-
BRCA	cis	rs2243480	1	rs6460261	ENSG00000229886.1	RP5-1132H15.3	-6.52	1.07e-10	2.03e-08	-0.35	-0.2	Diabetic kidney disease;	chr7:65750593	chr7:66025126~66031544:-
BRCA	cis	rs2732480	0.5	rs2732461	ENSG00000273765.1	RP11-370I10.11	6.52	1.07e-10	2.03e-08	0.24	0.2	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48299019	chr12:48360920~48361377:+
BRCA	cis	rs858239	0.6	rs4628176	ENSG00000230042.1	AK3P3	-6.52	1.07e-10	2.03e-08	-0.23	-0.2	Cerebrospinal fluid biomarker levels;	chr7:23102947	chr7:23129178~23129841:+
BRCA	cis	rs4713118	0.513	rs149955	ENSG00000204709.4	LINC01556	6.52	1.07e-10	2.03e-08	0.27	0.2	Parkinson's disease;	chr6:28068447	chr6:28943877~28944537:+
BRCA	cis	rs1707322	0.752	rs12062535	ENSG00000281133.1	AL355480.3	-6.52	1.07e-10	2.03e-08	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45757208	chr1:45580892~45580996:-
BRCA	cis	rs6688613	1	rs12130629	ENSG00000225171.2	DUTP6	-6.52	1.07e-10	2.03e-08	-0.24	-0.2	Refractive astigmatism;	chr1:166984047	chr1:166868748~166869209:+
BRCA	cis	rs875971	0.545	rs7810213	ENSG00000224316.1	RP11-479O9.2	6.52	1.07e-10	2.03e-08	0.23	0.2	Aortic root size;	chr7:66481592	chr7:65773620~65802067:+
BRCA	cis	rs2348418	0.798	rs7309905	ENSG00000247934.4	RP11-967K21.1	6.52	1.07e-10	2.03e-08	0.22	0.2	Lung function (FEV1);Lung function (FVC);	chr12:28373473	chr12:28163298~28190738:-
BRCA	cis	rs67981189	0.896	rs58133478	ENSG00000269927.1	RP6-91H8.3	6.52	1.07e-10	2.03e-08	0.25	0.2	Schizophrenia;	chr14:71058370	chr14:71141125~71143253:-
BRCA	cis	rs8031584	0.918	rs34331396	ENSG00000260382.1	RP11-540B6.2	6.52	1.07e-10	2.04e-08	0.24	0.2	Huntington's disease progression;	chr15:30956533	chr15:30882267~30883231:-
BRCA	cis	rs301901	0.796	rs62359002	ENSG00000250155.1	CTD-2353F22.1	6.52	1.07e-10	2.04e-08	0.22	0.2	Height;	chr5:37499677	chr5:36666214~36725195:-
BRCA	cis	rs2243480	1	rs35820085	ENSG00000229886.1	RP5-1132H15.3	6.52	1.07e-10	2.04e-08	0.35	0.2	Diabetic kidney disease;	chr7:65977771	chr7:66025126~66031544:-
BRCA	cis	rs17301013	0.507	rs2146564	ENSG00000227373.4	RP11-160H22.5	6.52	1.07e-10	2.04e-08	0.3	0.2	Systemic lupus erythematosus;	chr1:174716214	chr1:174115300~174160004:-
BRCA	cis	rs8114671	0.967	rs2069948	ENSG00000269202.1	RP4-614O4.12	-6.52	1.07e-10	2.04e-08	-0.21	-0.2	Height;	chr20:35174686	chr20:35201747~35203288:-
BRCA	cis	rs2060793	0.867	rs2122941	ENSG00000251991.1	RNU7-49P	6.52	1.07e-10	2.04e-08	0.22	0.2	Vitamin D levels;	chr11:14834821	chr11:14478892~14478953:+
BRCA	cis	rs17772222	0.682	rs3783889	ENSG00000258983.2	RP11-507K2.2	6.52	1.07e-10	2.04e-08	0.21	0.2	Coronary artery calcification;	chr14:88475637	chr14:88499334~88515502:+
BRCA	cis	rs4372836	1	rs11690423	ENSG00000226833.4	AC097724.3	-6.52	1.07e-10	2.04e-08	-0.24	-0.2	Body mass index;	chr2:28728671	chr2:28708953~28736205:-
BRCA	cis	rs9992667	0.955	rs11096953	ENSG00000231160.8	KLF3-AS1	-6.52	1.07e-10	2.04e-08	-0.24	-0.2	Eosinophil percentage of granulocytes;	chr4:38642171	chr4:38612701~38664883:-
BRCA	cis	rs875971	1	rs6460292	ENSG00000224316.1	RP11-479O9.2	-6.52	1.08e-10	2.04e-08	-0.2	-0.2	Aortic root size;	chr7:66345088	chr7:65773620~65802067:+
BRCA	cis	rs4713118	0.869	rs6902689	ENSG00000220721.1	OR1F12	6.52	1.08e-10	2.05e-08	0.25	0.2	Parkinson's disease;	chr6:27741662	chr6:28073316~28074233:+
BRCA	cis	rs35146811	0.586	rs1076237	ENSG00000235713.1	RP4-604G5.3	6.52	1.08e-10	2.05e-08	0.24	0.2	Coronary artery disease;	chr7:99987818	chr7:99992397~99993050:+
BRCA	cis	rs11096990	0.964	rs16995206	ENSG00000249207.1	RP11-360F5.1	6.52	1.08e-10	2.05e-08	0.23	0.2	Cognitive function;	chr4:39262887	chr4:39112677~39126818:-
BRCA	cis	rs2243480	1	rs778679	ENSG00000232546.1	RP11-458F8.1	-6.52	1.08e-10	2.05e-08	-0.27	-0.2	Diabetic kidney disease;	chr7:66375924	chr7:66848496~66858136:+
BRCA	cis	rs875971	0.577	rs34888281	ENSG00000164669.11	INTS4P1	6.52	1.08e-10	2.05e-08	0.25	0.2	Aortic root size;	chr7:66120784	chr7:65141225~65234216:+
BRCA	cis	rs7665090	1	rs5026472	ENSG00000246560.2	RP11-10L12.4	6.52	1.08e-10	2.05e-08	0.21	0.2	Primary biliary cholangitis;	chr4:102633616	chr4:102828055~102844075:+
BRCA	cis	rs1707322	0.964	rs785483	ENSG00000281133.1	AL355480.3	6.52	1.08e-10	2.05e-08	0.25	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46093499	chr1:45580892~45580996:-
BRCA	cis	rs9309711	0.736	rs13409102	ENSG00000225234.1	TRAPPC12-AS1	-6.52	1.08e-10	2.06e-08	-0.24	-0.2	Neurofibrillary tangles;	chr2:3492550	chr2:3481242~3482409:-
BRCA	cis	rs42490	0.966	rs39499	ENSG00000251136.7	RP11-37B2.1	-6.52	1.09e-10	2.06e-08	-0.19	-0.2	Leprosy;	chr8:89758381	chr8:89609409~89757727:-
BRCA	cis	rs2243480	0.901	rs2456483	ENSG00000228409.4	CCT6P1	6.52	1.09e-10	2.06e-08	0.27	0.2	Diabetic kidney disease;	chr7:65996588	chr7:65751142~65763354:+
BRCA	cis	rs2243480	1	rs1701750	ENSG00000228409.4	CCT6P1	6.52	1.09e-10	2.06e-08	0.27	0.2	Diabetic kidney disease;	chr7:66002158	chr7:65751142~65763354:+
BRCA	cis	rs891378	1	rs971317	ENSG00000274245.1	RP11-357P18.2	-6.52	1.09e-10	2.06e-08	-0.28	-0.2	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207302695	chr1:207372559~207373252:+
BRCA	cis	rs16846053	0.515	rs2892770	ENSG00000227403.1	AC009299.3	-6.52	1.09e-10	2.06e-08	-0.33	-0.2	Blood osmolality (transformed sodium);	chr2:161638321	chr2:161244739~161249050:+
BRCA	cis	rs7617773	0.78	rs9846818	ENSG00000228638.1	FCF1P2	-6.52	1.09e-10	2.06e-08	-0.2	-0.2	Coronary artery disease;	chr3:48334195	chr3:48290793~48291375:-
BRCA	cis	rs7937890	1	rs2970335	ENSG00000251991.1	RNU7-49P	6.52	1.09e-10	2.06e-08	0.21	0.2	Mitochondrial DNA levels;	chr11:14303855	chr11:14478892~14478953:+
BRCA	cis	rs919433	0.854	rs787994	ENSG00000231621.1	AC013264.2	-6.52	1.09e-10	2.07e-08	-0.19	-0.2	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197358397	chr2:197197991~197199273:+
BRCA	cis	rs7617773	0.78	rs13079728	ENSG00000228638.1	FCF1P2	-6.52	1.09e-10	2.07e-08	-0.23	-0.2	Coronary artery disease;	chr3:48297870	chr3:48290793~48291375:-
BRCA	cis	rs7746199	0.736	rs13202291	ENSG00000220721.1	OR1F12	6.52	1.09e-10	2.07e-08	0.47	0.2	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27731078	chr6:28073316~28074233:+
BRCA	cis	rs7746199	0.736	rs17750424	ENSG00000220721.1	OR1F12	6.52	1.09e-10	2.07e-08	0.47	0.2	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27733343	chr6:28073316~28074233:+
BRCA	cis	rs1823913	0.599	rs17412635	ENSG00000280083.1	RP11-317J9.1	6.52	1.09e-10	2.07e-08	0.23	0.2	Obesity-related traits;	chr2:191294834	chr2:191154118~191156070:-
BRCA	cis	rs7246657	0.943	rs2303131	ENSG00000267422.1	CTD-2554C21.1	-6.52	1.09e-10	2.07e-08	-0.3	-0.2	Coronary artery calcification;	chr19:37445123	chr19:37779686~37792865:+
BRCA	cis	rs71520386	0.632	rs10253651	ENSG00000228649.7	AC005682.5	-6.52	1.09e-10	2.07e-08	-0.19	-0.2	Fibrinogen levels;	chr7:22830564	chr7:22854178~22861579:+
BRCA	cis	rs1499614	1	rs2707832	ENSG00000230295.1	RP11-458F8.2	-6.52	1.09e-10	2.07e-08	-0.26	-0.2	Gout;	chr7:66671562	chr7:66880708~66882981:+
BRCA	cis	rs957448	0.561	rs7459558	ENSG00000253704.1	RP11-267M23.4	6.52	1.09e-10	2.08e-08	0.21	0.2	Nonsyndromic cleft lip with cleft palate;	chr8:94598618	chr8:94553722~94569745:+
BRCA	cis	rs12468226	0.938	rs16841867	ENSG00000226261.1	AC064836.3	6.52	1.09e-10	2.08e-08	0.33	0.2	Urate levels;	chr2:202303512	chr2:202336024~202336727:-
BRCA	cis	rs12468226	0.938	rs16839065	ENSG00000226261.1	AC064836.3	6.52	1.09e-10	2.08e-08	0.33	0.2	Urate levels;	chr2:202308774	chr2:202336024~202336727:-
BRCA	cis	rs6088580	0.524	rs4911437	ENSG00000269202.1	RP4-614O4.12	6.52	1.09e-10	2.08e-08	0.22	0.2	Glomerular filtration rate (creatinine);	chr20:34678345	chr20:35201747~35203288:-
BRCA	cis	rs2638953	0.924	rs2061758	ENSG00000247934.4	RP11-967K21.1	-6.52	1.1e-10	2.08e-08	-0.25	-0.2	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28186575	chr12:28163298~28190738:-
BRCA	cis	rs2348418	0.932	rs10843190	ENSG00000247934.4	RP11-967K21.1	6.52	1.1e-10	2.08e-08	0.22	0.2	Lung function (FEV1);Lung function (FVC);	chr12:28507412	chr12:28163298~28190738:-
BRCA	cis	rs1707322	0.752	rs6678444	ENSG00000281133.1	AL355480.3	-6.52	1.1e-10	2.08e-08	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45764175	chr1:45580892~45580996:-
BRCA	cis	rs17772222	0.637	rs879932	ENSG00000258983.2	RP11-507K2.2	6.52	1.1e-10	2.08e-08	0.21	0.2	Coronary artery calcification;	chr14:88479247	chr14:88499334~88515502:+
BRCA	cis	rs13108904	0.901	rs2293634	ENSG00000254094.1	AC078852.1	-6.52	1.1e-10	2.08e-08	-0.21	-0.2	Obesity-related traits;	chr4:1297923	chr4:1356581~1358075:+
BRCA	cis	rs3781264	0.848	rs6583934	ENSG00000273450.1	RP11-76P2.4	6.52	1.1e-10	2.09e-08	0.26	0.2	Esophageal cancer and gastric cancer;	chr10:94309648	chr10:94314907~94315327:-
BRCA	cis	rs4713118	0.513	rs149989	ENSG00000204709.4	LINC01556	6.52	1.1e-10	2.09e-08	0.27	0.2	Parkinson's disease;	chr6:28030406	chr6:28943877~28944537:+
BRCA	cis	rs6142102	0.886	rs6059583	ENSG00000275784.1	RP5-1125A11.6	-6.52	1.1e-10	2.09e-08	-0.25	-0.2	Skin pigmentation;	chr20:33944308	chr20:33989480~33991818:-
BRCA	cis	rs875971	0.516	rs6945322	ENSG00000237310.1	GS1-124K5.4	6.52	1.1e-10	2.09e-08	0.21	0.2	Aortic root size;	chr7:65871069	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.545	rs73150604	ENSG00000224316.1	RP11-479O9.2	6.52	1.1e-10	2.09e-08	0.23	0.2	Aortic root size;	chr7:66480545	chr7:65773620~65802067:+
BRCA	cis	rs6095360	0.69	rs35888516	ENSG00000222365.1	SNORD12B	-6.52	1.11e-10	2.1e-08	-0.26	-0.2	Intelligence (multi-trait analysis);	chr20:49147738	chr20:49280319~49280409:+
BRCA	cis	rs2243480	0.901	rs2456483	ENSG00000229886.1	RP5-1132H15.3	6.52	1.11e-10	2.1e-08	0.35	0.2	Diabetic kidney disease;	chr7:65996588	chr7:66025126~66031544:-
BRCA	cis	rs2243480	1	rs1701750	ENSG00000229886.1	RP5-1132H15.3	6.52	1.11e-10	2.1e-08	0.35	0.2	Diabetic kidney disease;	chr7:66002158	chr7:66025126~66031544:-
BRCA	cis	rs17680741	0.802	rs7088704	ENSG00000226659.1	RP11-137H2.4	-6.52	1.11e-10	2.1e-08	-0.26	-0.2	Coronary artery disease;	chr10:80482174	chr10:80529597~80535942:-
BRCA	cis	rs919433	0.889	rs788004	ENSG00000231621.1	AC013264.2	-6.52	1.11e-10	2.1e-08	-0.18	-0.2	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197354308	chr2:197197991~197199273:+
BRCA	cis	rs1387259	0.931	rs1107654	ENSG00000273765.1	RP11-370I10.11	6.52	1.11e-10	2.11e-08	0.24	0.2	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48287314	chr12:48360920~48361377:+
BRCA	cis	rs13178541	0.638	rs6861738	ENSG00000250378.1	RP11-119J18.1	-6.52	1.12e-10	2.11e-08	-0.25	-0.2	IgG glycosylation;	chr5:135714486	chr5:135812667~135826582:+
BRCA	cis	rs11096990	0.855	rs3796524	ENSG00000249207.1	RP11-360F5.1	6.52	1.12e-10	2.11e-08	0.23	0.2	Cognitive function;	chr4:39194367	chr4:39112677~39126818:-
BRCA	cis	rs6570726	0.967	rs413880	ENSG00000235652.6	RP11-545I5.3	6.52	1.12e-10	2.12e-08	0.19	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145483686	chr6:145799409~145886585:+
BRCA	cis	rs754466	0.651	rs11815015	ENSG00000204049.1	RP11-126H7.4	6.52	1.12e-10	2.12e-08	0.24	0.2	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77865724	chr10:77866875~77869610:+
BRCA	cis	rs754466	0.651	rs56138814	ENSG00000204049.1	RP11-126H7.4	6.52	1.12e-10	2.12e-08	0.24	0.2	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77866037	chr10:77866875~77869610:+
BRCA	cis	rs754466	0.651	rs10824584	ENSG00000204049.1	RP11-126H7.4	6.52	1.12e-10	2.12e-08	0.24	0.2	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77866189	chr10:77866875~77869610:+
BRCA	cis	rs10483853	0.525	rs7158272	ENSG00000258408.1	NT5CP2	6.52	1.12e-10	2.12e-08	0.28	0.2	Coronary artery calcification;	chr14:73476486	chr14:73539221~73539781:-
BRCA	cis	rs875971	0.862	rs908915	ENSG00000224316.1	RP11-479O9.2	-6.52	1.12e-10	2.12e-08	-0.2	-0.2	Aortic root size;	chr7:66149664	chr7:65773620~65802067:+
BRCA	cis	rs4950322	0.57	rs17160051	ENSG00000278811.3	LINC00624	6.52	1.12e-10	2.12e-08	0.26	0.2	Protein quantitative trait loci;	chr1:147255733	chr1:147258885~147517875:-
BRCA	cis	rs2842992	0.789	rs2842969	ENSG00000237927.1	RP3-393E18.2	-6.52	1.12e-10	2.12e-08	-0.28	-0.2	Age-related macular degeneration (geographic atrophy);	chr6:159724332	chr6:159586955~159589169:-
BRCA	cis	rs2842992	0.83	rs1853259	ENSG00000237927.1	RP3-393E18.2	6.52	1.12e-10	2.12e-08	0.28	0.2	Age-related macular degeneration (geographic atrophy);	chr6:159726409	chr6:159586955~159589169:-
BRCA	cis	rs17301013	0.507	rs16847335	ENSG00000227373.4	RP11-160H22.5	6.52	1.12e-10	2.13e-08	0.3	0.2	Systemic lupus erythematosus;	chr1:174682746	chr1:174115300~174160004:-
BRCA	cis	rs12468226	0.938	rs79117531	ENSG00000226261.1	AC064836.3	6.52	1.12e-10	2.13e-08	0.33	0.2	Urate levels;	chr2:202307690	chr2:202336024~202336727:-
BRCA	cis	rs78456975	1	rs11891809	ENSG00000231482.2	AC141930.2	-6.52	1.12e-10	2.13e-08	-0.28	-0.2	Placebo response in major depressive disorder (% change in symptom score);	chr2:1562229	chr2:1572554~1580311:-
BRCA	cis	rs6723226	0.572	rs176404	ENSG00000276334.1	AL133243.1	-6.52	1.13e-10	2.13e-08	-0.24	-0.2	Intelligence (multi-trait analysis);	chr2:32413778	chr2:32521927~32523547:+
BRCA	cis	rs6570726	0.935	rs371744	ENSG00000235652.6	RP11-545I5.3	6.52	1.13e-10	2.13e-08	0.19	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145519888	chr6:145799409~145886585:+
BRCA	cis	rs237743	1	rs35759030	ENSG00000222365.1	SNORD12B	-6.52	1.13e-10	2.13e-08	-0.26	-0.2	Height;	chr20:49241753	chr20:49280319~49280409:+
BRCA	cis	rs34779708	0.966	rs7077242	ENSG00000271335.4	RP11-324I22.4	-6.52	1.13e-10	2.13e-08	-0.21	-0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35193037	chr10:35314552~35336401:-
BRCA	cis	rs78456975	0.527	rs11901028	ENSG00000231482.2	AC141930.2	-6.52	1.13e-10	2.13e-08	-0.26	-0.2	Placebo response in major depressive disorder (% change in symptom score);	chr2:1554200	chr2:1572554~1580311:-
BRCA	cis	rs78456975	0.527	rs10203194	ENSG00000231482.2	AC141930.2	-6.52	1.13e-10	2.13e-08	-0.26	-0.2	Placebo response in major depressive disorder (% change in symptom score);	chr2:1554249	chr2:1572554~1580311:-
BRCA	cis	rs17508449	0.819	rs4839329	ENSG00000232450.1	RP4-730K3.3	-6.52	1.13e-10	2.13e-08	-0.36	-0.2	Leprosy;	chr1:113593083	chr1:113698884~113699631:-
BRCA	cis	rs6142102	1	rs2378078	ENSG00000275784.1	RP5-1125A11.6	-6.52	1.13e-10	2.13e-08	-0.24	-0.2	Skin pigmentation;	chr20:34126922	chr20:33989480~33991818:-
BRCA	cis	rs875971	0.545	rs10261710	ENSG00000273024.4	INTS4P2	-6.52	1.13e-10	2.13e-08	-0.25	-0.2	Aortic root size;	chr7:66249202	chr7:65647864~65715661:+
BRCA	cis	rs755249	0.567	rs16825939	ENSG00000237624.1	OXCT2P1	6.52	1.13e-10	2.13e-08	0.28	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39196836	chr1:39514956~39516490:+
BRCA	cis	rs755249	0.567	rs16825942	ENSG00000237624.1	OXCT2P1	6.52	1.13e-10	2.13e-08	0.28	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39196946	chr1:39514956~39516490:+
BRCA	cis	rs755249	0.567	rs67020650	ENSG00000237624.1	OXCT2P1	6.52	1.13e-10	2.13e-08	0.28	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39202343	chr1:39514956~39516490:+
BRCA	cis	rs755249	0.567	rs72661925	ENSG00000237624.1	OXCT2P1	6.52	1.13e-10	2.13e-08	0.28	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39203865	chr1:39514956~39516490:+
BRCA	cis	rs755249	0.567	rs72661927	ENSG00000237624.1	OXCT2P1	6.52	1.13e-10	2.13e-08	0.28	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39209650	chr1:39514956~39516490:+
BRCA	cis	rs7246657	0.943	rs4801803	ENSG00000226686.6	LINC01535	6.52	1.13e-10	2.13e-08	0.3	0.2	Coronary artery calcification;	chr19:37476021	chr19:37251912~37265535:+
BRCA	cis	rs34779708	0.966	rs34296409	ENSG00000271335.4	RP11-324I22.4	6.52	1.13e-10	2.14e-08	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35115685	chr10:35314552~35336401:-
BRCA	cis	rs2302464	1	rs2302464	ENSG00000214846.4	RP11-115L11.1	-6.52	1.13e-10	2.14e-08	-0.53	-0.2	Cerebrospinal fluid biomarker levels;	chr4:15707629	chr4:15730962~15731627:-
BRCA	cis	rs4372836	1	rs72782294	ENSG00000226833.4	AC097724.3	-6.51	1.13e-10	2.14e-08	-0.24	-0.2	Body mass index;	chr2:28730524	chr2:28708953~28736205:-
BRCA	cis	rs2243480	0.901	rs2900904	ENSG00000228409.4	CCT6P1	6.51	1.13e-10	2.14e-08	0.27	0.2	Diabetic kidney disease;	chr7:65739282	chr7:65751142~65763354:+
BRCA	cis	rs13113518	0.683	rs9761521	ENSG00000249700.7	SRD5A3-AS1	6.51	1.13e-10	2.14e-08	0.26	0.2	Height;	chr4:55363436	chr4:55363971~55395847:-
BRCA	cis	rs4713118	0.868	rs760587	ENSG00000220721.1	OR1F12	6.51	1.13e-10	2.15e-08	0.26	0.2	Parkinson's disease;	chr6:27772521	chr6:28073316~28074233:+
BRCA	cis	rs7246657	0.943	rs10406177	ENSG00000226686.6	LINC01535	-6.51	1.13e-10	2.15e-08	-0.29	-0.2	Coronary artery calcification;	chr19:37417045	chr19:37251912~37265535:+
BRCA	cis	rs7246657	0.882	rs28623164	ENSG00000226686.6	LINC01535	-6.51	1.13e-10	2.15e-08	-0.29	-0.2	Coronary artery calcification;	chr19:37422551	chr19:37251912~37265535:+
BRCA	cis	rs7246657	0.943	rs7252346	ENSG00000226686.6	LINC01535	-6.51	1.13e-10	2.15e-08	-0.29	-0.2	Coronary artery calcification;	chr19:37423780	chr19:37251912~37265535:+
BRCA	cis	rs7246657	0.943	rs2891699	ENSG00000226686.6	LINC01535	-6.51	1.13e-10	2.15e-08	-0.29	-0.2	Coronary artery calcification;	chr19:37429335	chr19:37251912~37265535:+
BRCA	cis	rs7246657	0.943	rs9676967	ENSG00000226686.6	LINC01535	-6.51	1.13e-10	2.15e-08	-0.29	-0.2	Coronary artery calcification;	chr19:37437187	chr19:37251912~37265535:+
BRCA	cis	rs7246657	0.943	rs8109632	ENSG00000226686.6	LINC01535	-6.51	1.13e-10	2.15e-08	-0.29	-0.2	Coronary artery calcification;	chr19:37440223	chr19:37251912~37265535:+
BRCA	cis	rs7246657	0.943	rs7255407	ENSG00000226686.6	LINC01535	-6.51	1.13e-10	2.15e-08	-0.29	-0.2	Coronary artery calcification;	chr19:37443034	chr19:37251912~37265535:+
BRCA	cis	rs12501370	0.959	rs4472173	ENSG00000201736.1	RNA5SP160	6.51	1.14e-10	2.15e-08	0.25	0.2	Iris color (L* coordinate);	chr4:40998807	chr4:40990154~40990273:+
BRCA	cis	rs17253792	0.822	rs78522049	ENSG00000186615.9	KTN1-AS1	-6.51	1.14e-10	2.15e-08	-0.37	-0.2	Putamen volume;	chr14:55604485	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs79022053	ENSG00000186615.9	KTN1-AS1	-6.51	1.14e-10	2.15e-08	-0.37	-0.2	Putamen volume;	chr14:55605003	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs76555508	ENSG00000186615.9	KTN1-AS1	-6.51	1.14e-10	2.15e-08	-0.37	-0.2	Putamen volume;	chr14:55605150	chr14:55499278~55580110:-
BRCA	cis	rs17027633	0.5	rs1764808	ENSG00000260948.1	RP11-552M11.8	-6.51	1.14e-10	2.15e-08	-0.3	-0.2	Cerebrospinal fluid t-tau:AB1-42 ratio;	chr1:111413696	chr1:111431046~111433068:-
BRCA	cis	rs9876781	1	rs11130171	ENSG00000229759.1	MRPS18AP1	6.51	1.14e-10	2.15e-08	0.22	0.2	Longevity;	chr3:48421052	chr3:48256350~48256938:-
BRCA	cis	rs9876781	1	rs9883927	ENSG00000229759.1	MRPS18AP1	6.51	1.14e-10	2.15e-08	0.22	0.2	Longevity;	chr3:48422302	chr3:48256350~48256938:-
BRCA	cis	rs1707322	0.686	rs3014242	ENSG00000281133.1	AL355480.3	6.51	1.14e-10	2.16e-08	0.26	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45621905	chr1:45580892~45580996:-
BRCA	cis	rs6840360	0.901	rs1443094	ENSG00000270265.1	RP11-731D1.4	-6.51	1.14e-10	2.16e-08	-0.22	-0.2	Intelligence (multi-trait analysis);	chr4:151535572	chr4:151333775~151353224:-
BRCA	cis	rs11976180	1	rs6464574	ENSG00000273234.1	OR2A13P	-6.51	1.14e-10	2.16e-08	-0.28	-0.2	Obesity-related traits;	chr7:144051164	chr7:144142009~144142938:+
BRCA	cis	rs4664293	0.541	rs1863218	ENSG00000226266.5	AC009961.3	6.51	1.14e-10	2.16e-08	0.23	0.2	Monocyte percentage of white cells;	chr2:159512276	chr2:159670708~159712435:-
BRCA	cis	rs673078	0.607	rs61943403	ENSG00000275409.1	RP11-131L12.4	-6.51	1.14e-10	2.16e-08	-0.28	-0.2	Glucose homeostasis traits;	chr12:118399887	chr12:118430147~118430699:+
BRCA	cis	rs2348418	0.864	rs7136843	ENSG00000247934.4	RP11-967K21.1	6.51	1.14e-10	2.16e-08	0.22	0.2	Lung function (FEV1);Lung function (FVC);	chr12:28564875	chr12:28163298~28190738:-
BRCA	cis	rs2348418	0.832	rs1552761	ENSG00000247934.4	RP11-967K21.1	6.51	1.15e-10	2.17e-08	0.22	0.2	Lung function (FEV1);Lung function (FVC);	chr12:28383406	chr12:28163298~28190738:-
BRCA	cis	rs10740039	0.81	rs1006956	ENSG00000254271.1	RP11-131N11.4	-6.51	1.15e-10	2.17e-08	-0.26	-0.2	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60608218	chr10:60734342~60741828:+
BRCA	cis	rs2274273	0.624	rs8003279	ENSG00000258413.1	RP11-665C16.6	-6.51	1.15e-10	2.17e-08	-0.27	-0.2	Protein biomarker;	chr14:55397412	chr14:55262767~55272075:-
BRCA	cis	rs4072705	0.967	rs12339980	ENSG00000224020.1	MIR181A2HG	-6.51	1.15e-10	2.17e-08	-0.22	-0.2	Menarche (age at onset);	chr9:124556424	chr9:124658467~124698631:+
BRCA	cis	rs669446	0.533	rs3791042	ENSG00000237950.1	RP11-7O11.3	6.51	1.15e-10	2.17e-08	0.23	0.2	Amyotrophic lateral sclerosis (age of onset);	chr1:43753604	chr1:43944370~43946551:-
BRCA	cis	rs17253792	0.822	rs12323476	ENSG00000186615.9	KTN1-AS1	6.51	1.15e-10	2.18e-08	0.33	0.2	Putamen volume;	chr14:55706004	chr14:55499278~55580110:-
BRCA	cis	rs9876781	1	rs7636044	ENSG00000229759.1	MRPS18AP1	6.51	1.15e-10	2.18e-08	0.22	0.2	Longevity;	chr3:48443151	chr3:48256350~48256938:-
BRCA	cis	rs9876781	1	rs4490383	ENSG00000229759.1	MRPS18AP1	6.51	1.15e-10	2.18e-08	0.22	0.2	Longevity;	chr3:48443275	chr3:48256350~48256938:-
BRCA	cis	rs67981189	0.788	rs34093157	ENSG00000269927.1	RP6-91H8.3	6.51	1.15e-10	2.18e-08	0.25	0.2	Schizophrenia;	chr14:71101966	chr14:71141125~71143253:-
BRCA	cis	rs875971	0.545	rs73150604	ENSG00000273024.4	INTS4P2	-6.51	1.15e-10	2.18e-08	-0.25	-0.2	Aortic root size;	chr7:66480545	chr7:65647864~65715661:+
BRCA	cis	rs9500256	0.967	rs1012500	ENSG00000215190.7	LINC00680	-6.51	1.16e-10	2.18e-08	-0.22	-0.2	Eosinophilic esophagitis (pediatric);	chr6:57978391	chr6:57946074~57961501:-
BRCA	cis	rs10050311	0.586	rs2054592	ENSG00000251411.1	RP11-397E7.4	-6.51	1.16e-10	2.18e-08	-0.29	-0.2	Insulin-related traits;	chr4:86752292	chr4:86913266~86914817:-
BRCA	cis	rs10050311	0.746	rs17454662	ENSG00000251411.1	RP11-397E7.4	-6.51	1.16e-10	2.18e-08	-0.29	-0.2	Insulin-related traits;	chr4:86752611	chr4:86913266~86914817:-
BRCA	cis	rs10050311	0.746	rs72665791	ENSG00000251411.1	RP11-397E7.4	-6.51	1.16e-10	2.18e-08	-0.29	-0.2	Insulin-related traits;	chr4:86757634	chr4:86913266~86914817:-
BRCA	cis	rs4950322	0.57	rs72691054	ENSG00000278811.3	LINC00624	6.51	1.16e-10	2.18e-08	0.27	0.2	Protein quantitative trait loci;	chr1:147277942	chr1:147258885~147517875:-
BRCA	cis	rs1667284	1	rs1667283	ENSG00000266521.1	RP11-650P15.1	6.51	1.16e-10	2.19e-08	0.24	0.2	Problematic alcohol use in trauma-exposed individuals;	chr18:31643658	chr18:31496645~31497195:-
BRCA	cis	rs10129255	0.5	rs7157975	ENSG00000274576.2	IGHV2-70	-6.51	1.16e-10	2.19e-08	-0.16	-0.2	Kawasaki disease;	chr14:106804049	chr14:106770577~106771020:-
BRCA	cis	rs7665090	0.967	rs13106304	ENSG00000246560.2	RP11-10L12.4	6.51	1.16e-10	2.19e-08	0.21	0.2	Primary biliary cholangitis;	chr4:102633818	chr4:102828055~102844075:+
BRCA	cis	rs7665090	0.967	rs13106325	ENSG00000246560.2	RP11-10L12.4	6.51	1.16e-10	2.19e-08	0.21	0.2	Primary biliary cholangitis;	chr4:102633835	chr4:102828055~102844075:+
BRCA	cis	rs1318937	1	rs11713836	ENSG00000224660.1	SH3BP5-AS1	6.51	1.16e-10	2.19e-08	0.24	0.2	Alcohol dependence;Alcohol and nicotine co-dependence;	chr3:15253304	chr3:15254184~15264493:+
BRCA	cis	rs7246657	0.943	rs2081096	ENSG00000226686.6	LINC01535	-6.51	1.16e-10	2.19e-08	-0.29	-0.2	Coronary artery calcification;	chr19:37473798	chr19:37251912~37265535:+
BRCA	cis	rs673078	0.607	rs882927	ENSG00000275409.1	RP11-131L12.4	-6.51	1.16e-10	2.19e-08	-0.28	-0.2	Glucose homeostasis traits;	chr12:118406737	chr12:118430147~118430699:+
BRCA	cis	rs2243480	1	rs313809	ENSG00000229886.1	RP5-1132H15.3	6.51	1.16e-10	2.19e-08	0.35	0.2	Diabetic kidney disease;	chr7:66034996	chr7:66025126~66031544:-
BRCA	cis	rs61160187	0.582	rs4700404	ENSG00000215032.2	GNL3LP1	6.51	1.16e-10	2.19e-08	0.24	0.2	Educational attainment (years of education);Educational attainment (college completion);	chr5:61028769	chr5:60891935~60893577:-
BRCA	cis	rs2732480	0.5	rs2450986	ENSG00000273765.1	RP11-370I10.11	6.51	1.16e-10	2.2e-08	0.24	0.2	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48267905	chr12:48360920~48361377:+
BRCA	cis	rs9876781	1	rs6784322	ENSG00000229759.1	MRPS18AP1	6.51	1.16e-10	2.2e-08	0.23	0.2	Longevity;	chr3:48380745	chr3:48256350~48256938:-
BRCA	cis	rs13217239	0.646	rs4403259	ENSG00000241549.7	GUSBP2	6.51	1.16e-10	2.2e-08	0.22	0.2	Schizophrenia;	chr6:27029838	chr6:26871484~26956554:-
BRCA	cis	rs4948102	0.667	rs7811270	ENSG00000226278.1	PSPHP1	-6.51	1.16e-10	2.2e-08	-0.22	-0.2	Plasma homocysteine levels (post-methionine load test);	chr7:56072297	chr7:55764797~55773288:+
BRCA	cis	rs1707322	0.686	rs2991986	ENSG00000281133.1	AL355480.3	6.51	1.16e-10	2.2e-08	0.26	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45615610	chr1:45580892~45580996:-
BRCA	cis	rs13113518	0.812	rs11945371	ENSG00000273257.1	RP11-177J6.1	6.51	1.17e-10	2.2e-08	0.26	0.2	Height;	chr4:55409063	chr4:55387949~55388271:+
BRCA	cis	rs11098499	0.954	rs9993199	ENSG00000249244.1	RP11-548H18.2	-6.51	1.17e-10	2.2e-08	-0.23	-0.2	Corneal astigmatism;	chr4:119471718	chr4:119391831~119395335:-
BRCA	cis	rs172166	0.694	rs1225716	ENSG00000204709.4	LINC01556	6.51	1.17e-10	2.21e-08	0.27	0.2	Cardiac Troponin-T levels;	chr6:28145968	chr6:28943877~28944537:+
BRCA	cis	rs1707322	0.827	rs10890347	ENSG00000281133.1	AL355480.3	6.51	1.17e-10	2.21e-08	0.26	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45776660	chr1:45580892~45580996:-
BRCA	cis	rs11009175	0.725	rs4934646	ENSG00000273038.2	RP11-479G22.8	-6.51	1.17e-10	2.21e-08	-0.29	-0.2	Depression (quantitative trait);	chr10:33007681	chr10:32887255~32889311:-
BRCA	cis	rs7665090	0.875	rs6813322	ENSG00000246560.2	RP11-10L12.4	6.51	1.17e-10	2.21e-08	0.21	0.2	Primary biliary cholangitis;	chr4:102634462	chr4:102828055~102844075:+
BRCA	cis	rs4713118	0.869	rs7776351	ENSG00000220721.1	OR1F12	-6.51	1.17e-10	2.21e-08	-0.25	-0.2	Parkinson's disease;	chr6:27758952	chr6:28073316~28074233:+
BRCA	cis	rs6840258	0.6	rs1447994	ENSG00000251411.1	RP11-397E7.4	6.51	1.17e-10	2.21e-08	0.26	0.2	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86966902	chr4:86913266~86914817:-
BRCA	cis	rs6840258	0.66	rs10015639	ENSG00000251411.1	RP11-397E7.4	6.51	1.17e-10	2.21e-08	0.26	0.2	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86970413	chr4:86913266~86914817:-
BRCA	cis	rs4950322	0.57	rs17356184	ENSG00000278811.3	LINC00624	6.51	1.17e-10	2.21e-08	0.27	0.2	Protein quantitative trait loci;	chr1:147262943	chr1:147258885~147517875:-
BRCA	cis	rs4950322	0.57	rs4950392	ENSG00000278811.3	LINC00624	6.51	1.17e-10	2.21e-08	0.27	0.2	Protein quantitative trait loci;	chr1:147264889	chr1:147258885~147517875:-
BRCA	cis	rs7746199	0.736	rs13212318	ENSG00000220721.1	OR1F12	6.51	1.17e-10	2.21e-08	0.47	0.2	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27721062	chr6:28073316~28074233:+
BRCA	cis	rs875971	1	rs2220626	ENSG00000224316.1	RP11-479O9.2	-6.51	1.17e-10	2.21e-08	-0.2	-0.2	Aortic root size;	chr7:66081075	chr7:65773620~65802067:+
BRCA	cis	rs1387259	0.929	rs2956703	ENSG00000273765.1	RP11-370I10.11	6.51	1.17e-10	2.21e-08	0.24	0.2	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48276511	chr12:48360920~48361377:+
BRCA	cis	rs6163	0.727	rs284854	ENSG00000213061.2	PFN1P11	-6.51	1.17e-10	2.21e-08	-0.26	-0.2	Waist circumference;Hip circumference;	chr10:102814805	chr10:102838011~102845473:-
BRCA	cis	rs2243480	1	rs316329	ENSG00000232559.3	GS1-124K5.12	6.51	1.17e-10	2.21e-08	0.36	0.2	Diabetic kidney disease;	chr7:66143429	chr7:66554588~66576923:-
BRCA	cis	rs7246657	0.943	rs7408563	ENSG00000267422.1	CTD-2554C21.1	-6.51	1.17e-10	2.21e-08	-0.3	-0.2	Coronary artery calcification;	chr19:37317683	chr19:37779686~37792865:+
BRCA	cis	rs853679	0.55	rs34477097	ENSG00000204709.4	LINC01556	6.51	1.17e-10	2.21e-08	0.28	0.2	Depression;	chr6:28229408	chr6:28943877~28944537:+
BRCA	cis	rs2243480	0.901	rs2900904	ENSG00000229886.1	RP5-1132H15.3	6.51	1.17e-10	2.21e-08	0.34	0.2	Diabetic kidney disease;	chr7:65739282	chr7:66025126~66031544:-
BRCA	cis	rs919433	0.756	rs7575389	ENSG00000231621.1	AC013264.2	6.51	1.17e-10	2.22e-08	0.19	0.2	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197333765	chr2:197197991~197199273:+
BRCA	cis	rs1707322	1	rs785498	ENSG00000281133.1	AL355480.3	6.51	1.17e-10	2.22e-08	0.25	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46126742	chr1:45580892~45580996:-
BRCA	cis	rs228614	0.509	rs223481	ENSG00000251288.2	RP11-10L12.2	-6.51	1.17e-10	2.22e-08	-0.23	-0.2	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102766860	chr4:102751401~102752641:+
BRCA	cis	rs2243480	1	rs1723269	ENSG00000229886.1	RP5-1132H15.3	6.51	1.17e-10	2.22e-08	0.35	0.2	Diabetic kidney disease;	chr7:66007799	chr7:66025126~66031544:-
BRCA	cis	rs1707322	1	rs785465	ENSG00000281133.1	AL355480.3	-6.51	1.18e-10	2.22e-08	-0.25	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46056905	chr1:45580892~45580996:-
BRCA	cis	rs1862618	0.715	rs6866779	ENSG00000271828.1	CTD-2310F14.1	6.51	1.18e-10	2.22e-08	0.29	0.2	Initial pursuit acceleration;	chr5:56794173	chr5:56927874~56929573:+
BRCA	cis	rs875971	0.545	rs1547529	ENSG00000273024.4	INTS4P2	-6.51	1.18e-10	2.22e-08	-0.25	-0.2	Aortic root size;	chr7:66258859	chr7:65647864~65715661:+
BRCA	cis	rs7246657	0.943	rs10422967	ENSG00000267422.1	CTD-2554C21.1	-6.51	1.18e-10	2.22e-08	-0.3	-0.2	Coronary artery calcification;	chr19:37359235	chr19:37779686~37792865:+
BRCA	cis	rs8177876	0.822	rs8177959	ENSG00000261838.4	RP11-303E16.6	6.51	1.18e-10	2.23e-08	0.37	0.2	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81082082	chr16:81069854~81076598:+
BRCA	cis	rs9307551	0.744	rs10004226	ENSG00000250334.4	LINC00989	-6.51	1.18e-10	2.23e-08	-0.27	-0.2	Refractive error;	chr4:79569654	chr4:79492416~79576460:+
BRCA	cis	rs4763879	0.634	rs2012643	ENSG00000214776.8	RP11-726G1.1	-6.51	1.18e-10	2.23e-08	-0.21	-0.2	Type 1 diabetes;	chr12:9707128	chr12:9467552~9576275:+
BRCA	cis	rs2638953	0.924	rs11049416	ENSG00000278733.1	RP11-425D17.1	6.51	1.18e-10	2.23e-08	0.27	0.2	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28190305	chr12:28185625~28186190:-
BRCA	cis	rs853679	0.517	rs1904841	ENSG00000280107.1	AL022393.9	-6.51	1.18e-10	2.23e-08	-0.3	-0.2	Depression;	chr6:28140307	chr6:28170845~28172521:+
BRCA	cis	rs35146811	0.622	rs6946204	ENSG00000235713.1	RP4-604G5.3	6.51	1.18e-10	2.23e-08	0.24	0.2	Coronary artery disease;	chr7:99991502	chr7:99992397~99993050:+
BRCA	cis	rs35146811	0.586	rs6964754	ENSG00000235713.1	RP4-604G5.3	6.51	1.18e-10	2.23e-08	0.24	0.2	Coronary artery disease;	chr7:99991781	chr7:99992397~99993050:+
BRCA	cis	rs2638953	0.888	rs11049407	ENSG00000278733.1	RP11-425D17.1	-6.51	1.18e-10	2.23e-08	-0.25	-0.2	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28181431	chr12:28185625~28186190:-
BRCA	cis	rs11096990	0.964	rs4974999	ENSG00000249207.1	RP11-360F5.1	-6.51	1.18e-10	2.23e-08	-0.23	-0.2	Cognitive function;	chr4:39262294	chr4:39112677~39126818:-
BRCA	cis	rs991427	0.643	rs2701155	ENSG00000258100.1	RP11-121E16.1	-6.51	1.18e-10	2.24e-08	-0.33	-0.2	Systolic blood pressure (alcohol consumption interaction);	chr12:91061769	chr12:91362196~91368606:+
BRCA	cis	rs991427	0.643	rs73197018	ENSG00000258100.1	RP11-121E16.1	-6.51	1.18e-10	2.24e-08	-0.33	-0.2	Systolic blood pressure (alcohol consumption interaction);	chr12:91063690	chr12:91362196~91368606:+
BRCA	cis	rs7665090	0.967	rs6533022	ENSG00000246560.2	RP11-10L12.4	6.51	1.18e-10	2.24e-08	0.21	0.2	Primary biliary cholangitis;	chr4:102637794	chr4:102828055~102844075:+
BRCA	cis	rs7246657	0.653	rs10406612	ENSG00000276846.1	CTD-3220F14.3	6.51	1.19e-10	2.24e-08	0.31	0.2	Coronary artery calcification;	chr19:37225709	chr19:37314868~37315620:-
BRCA	cis	rs2243480	0.708	rs13242216	ENSG00000232546.1	RP11-458F8.1	-6.51	1.19e-10	2.24e-08	-0.27	-0.2	Diabetic kidney disease;	chr7:66433290	chr7:66848496~66858136:+
BRCA	cis	rs875971	0.545	rs316328	ENSG00000236529.1	RP13-254B10.1	-6.51	1.19e-10	2.24e-08	-0.23	-0.2	Aortic root size;	chr7:66143851	chr7:65840212~65840596:+
BRCA	cis	rs34779708	0.966	rs17591163	ENSG00000271335.4	RP11-324I22.4	6.51	1.19e-10	2.24e-08	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35176351	chr10:35314552~35336401:-
BRCA	cis	rs17772222	0.682	rs1864744	ENSG00000258983.2	RP11-507K2.2	-6.51	1.19e-10	2.24e-08	-0.2	-0.2	Coronary artery calcification;	chr14:88484662	chr14:88499334~88515502:+
BRCA	cis	rs77972916	0.505	rs6736400	ENSG00000234936.1	AC010883.5	6.51	1.19e-10	2.25e-08	0.24	0.2	Granulocyte percentage of myeloid white cells;	chr2:43273665	chr2:43229573~43233394:+
BRCA	cis	rs7274963	0.704	rs3918466	ENSG00000236474.1	GCNT1P1	6.51	1.19e-10	2.25e-08	0.22	0.2	Body mass index;	chr20:18312174	chr20:18420160~18421454:-
BRCA	cis	rs897984	0.542	rs7294	ENSG00000260911.2	RP11-196G11.2	-6.51	1.19e-10	2.25e-08	-0.18	-0.2	Dementia with Lewy bodies;	chr16:31091000	chr16:31043150~31049868:+
BRCA	cis	rs2836950	0.501	rs2056844	ENSG00000238141.2	BRWD1-AS1	-6.51	1.2e-10	2.26e-08	-0.22	-0.2	Menarche (age at onset);	chr21:39298534	chr21:39315707~39323218:+
BRCA	cis	rs2243480	1	rs2257790	ENSG00000230295.1	RP11-458F8.2	-6.51	1.2e-10	2.26e-08	-0.26	-0.2	Diabetic kidney disease;	chr7:66135463	chr7:66880708~66882981:+
BRCA	cis	rs3736858	0.825	rs2120061	ENSG00000261105.4	LMO7-AS1	-6.51	1.2e-10	2.26e-08	-0.32	-0.2	Interleukin-9 levels;	chr13:75813370	chr13:75604700~75635994:-
BRCA	cis	rs58873874	0.579	rs79615135	ENSG00000248544.2	CTB-47B11.3	6.51	1.2e-10	2.26e-08	0.42	0.2	Bipolar disorder (body mass index interaction);	chr5:157275758	chr5:157375741~157384950:-
BRCA	cis	rs12468226	0.938	rs116601501	ENSG00000226261.1	AC064836.3	6.51	1.2e-10	2.26e-08	0.34	0.2	Urate levels;	chr2:202274567	chr2:202336024~202336727:-
BRCA	cis	rs12468226	0.938	rs78928733	ENSG00000226261.1	AC064836.3	6.51	1.2e-10	2.26e-08	0.34	0.2	Urate levels;	chr2:202283787	chr2:202336024~202336727:-
BRCA	cis	rs801193	0.66	rs1962050	ENSG00000232559.3	GS1-124K5.12	-6.51	1.2e-10	2.26e-08	-0.23	-0.2	Aortic root size;	chr7:66775021	chr7:66554588~66576923:-
BRCA	cis	rs919433	0.783	rs788011	ENSG00000231621.1	AC013264.2	-6.51	1.2e-10	2.26e-08	-0.19	-0.2	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197366047	chr2:197197991~197199273:+
BRCA	cis	rs875971	0.545	rs6460281	ENSG00000273024.4	INTS4P2	-6.51	1.2e-10	2.26e-08	-0.25	-0.2	Aortic root size;	chr7:66216128	chr7:65647864~65715661:+
BRCA	cis	rs228614	0.51	rs223472	ENSG00000251288.2	RP11-10L12.2	-6.51	1.2e-10	2.26e-08	-0.23	-0.2	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102774327	chr4:102751401~102752641:+
BRCA	cis	rs1707322	0.65	rs4553239	ENSG00000281133.1	AL355480.3	-6.51	1.2e-10	2.26e-08	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45684814	chr1:45580892~45580996:-
BRCA	cis	rs875971	0.522	rs34973832	ENSG00000237310.1	GS1-124K5.4	6.51	1.2e-10	2.26e-08	0.21	0.2	Aortic root size;	chr7:65931217	chr7:66493706~66495474:+
BRCA	cis	rs4950322	0.57	rs17356219	ENSG00000278811.3	LINC00624	6.51	1.2e-10	2.27e-08	0.27	0.2	Protein quantitative trait loci;	chr1:147265684	chr1:147258885~147517875:-
BRCA	cis	rs4950322	0.57	rs17356233	ENSG00000278811.3	LINC00624	6.51	1.2e-10	2.27e-08	0.27	0.2	Protein quantitative trait loci;	chr1:147268843	chr1:147258885~147517875:-
BRCA	cis	rs8002861	0.619	rs1337203	ENSG00000274001.1	RP11-5G9.5	6.51	1.2e-10	2.27e-08	0.23	0.2	Leprosy;	chr13:43849485	chr13:43877715~43878163:-
BRCA	cis	rs2243480	1	rs160655	ENSG00000229886.1	RP5-1132H15.3	6.51	1.2e-10	2.27e-08	0.36	0.2	Diabetic kidney disease;	chr7:66068227	chr7:66025126~66031544:-
BRCA	cis	rs10740039	0.81	rs10821800	ENSG00000254271.1	RP11-131N11.4	6.5	1.21e-10	2.27e-08	0.27	0.2	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60607812	chr10:60734342~60741828:+
BRCA	cis	rs67981189	0.896	rs3814871	ENSG00000269927.1	RP6-91H8.3	6.5	1.21e-10	2.27e-08	0.24	0.2	Schizophrenia;	chr14:70978071	chr14:71141125~71143253:-
BRCA	cis	rs7178375	1	rs7178533	ENSG00000215302.7	CTD-3092A11.1	-6.5	1.21e-10	2.27e-08	-0.31	-0.2	Hypertriglyceridemia;	chr15:30923773	chr15:30470779~30507623:+
BRCA	cis	rs2243480	1	rs73142166	ENSG00000228409.4	CCT6P1	6.5	1.21e-10	2.28e-08	0.28	0.2	Diabetic kidney disease;	chr7:65910845	chr7:65751142~65763354:+
BRCA	cis	rs875971	0.545	rs6969224	ENSG00000273024.4	INTS4P2	-6.5	1.21e-10	2.28e-08	-0.25	-0.2	Aortic root size;	chr7:66370011	chr7:65647864~65715661:+
BRCA	cis	rs7162943	0.887	rs11858077	ENSG00000260123.1	RP11-326A19.4	-6.5	1.21e-10	2.28e-08	-0.23	-0.2	Mean platelet volume;	chr15:89068326	chr15:89041223~89082819:+
BRCA	cis	rs7246657	0.598	rs10417545	ENSG00000276846.1	CTD-3220F14.3	6.5	1.21e-10	2.28e-08	0.31	0.2	Coronary artery calcification;	chr19:37163361	chr19:37314868~37315620:-
BRCA	cis	rs9311474	1	rs7629072	ENSG00000243224.1	RP5-1157M23.2	-6.5	1.21e-10	2.28e-08	-0.21	-0.2	Electroencephalogram traits;	chr3:52271617	chr3:52239258~52241097:+
BRCA	cis	rs301901	0.796	rs11742177	ENSG00000250155.1	CTD-2353F22.1	6.5	1.21e-10	2.28e-08	0.22	0.2	Height;	chr5:37504063	chr5:36666214~36725195:-
BRCA	cis	rs875971	0.502	rs2465121	ENSG00000236529.1	RP13-254B10.1	-6.5	1.21e-10	2.28e-08	-0.25	-0.2	Aortic root size;	chr7:66156017	chr7:65840212~65840596:+
BRCA	cis	rs10129255	1	rs10129319	ENSG00000211972.2	IGHV3-66	6.5	1.21e-10	2.28e-08	0.15	0.2	Kawasaki disease;	chr14:106767996	chr14:106675017~106675544:-
BRCA	cis	rs78456975	0.943	rs13421238	ENSG00000231482.2	AC141930.2	-6.5	1.21e-10	2.28e-08	-0.28	-0.2	Placebo response in major depressive disorder (% change in symptom score);	chr2:1573107	chr2:1572554~1580311:-
BRCA	cis	rs2348418	0.966	rs2881910	ENSG00000247934.4	RP11-967K21.1	6.5	1.21e-10	2.29e-08	0.22	0.2	Lung function (FEV1);Lung function (FVC);	chr12:28544459	chr12:28163298~28190738:-
BRCA	cis	rs301901	0.729	rs217781	ENSG00000250155.1	CTD-2353F22.1	-6.5	1.22e-10	2.29e-08	-0.22	-0.2	Height;	chr5:37344444	chr5:36666214~36725195:-
BRCA	cis	rs1552244	0.882	rs67762674	ENSG00000180385.7	EMC3-AS1	6.5	1.22e-10	2.29e-08	0.24	0.2	Alzheimer's disease;	chr3:9972801	chr3:9986893~10006990:+
BRCA	cis	rs1707322	0.821	rs10749857	ENSG00000281133.1	AL355480.3	-6.5	1.22e-10	2.29e-08	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45782471	chr1:45580892~45580996:-
BRCA	cis	rs4950322	0.57	rs7554833	ENSG00000278811.3	LINC00624	-6.5	1.22e-10	2.29e-08	-0.28	-0.2	Protein quantitative trait loci;	chr1:147289362	chr1:147258885~147517875:-
BRCA	cis	rs10461617	0.617	rs79742142	ENSG00000271828.1	CTD-2310F14.1	6.5	1.22e-10	2.29e-08	0.28	0.2	Type 2 diabetes;	chr5:56808550	chr5:56927874~56929573:+
BRCA	cis	rs754466	0.58	rs1866437	ENSG00000204049.1	RP11-126H7.4	6.5	1.22e-10	2.29e-08	0.24	0.2	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77767008	chr10:77866875~77869610:+
BRCA	cis	rs7586673	0.866	rs747003	ENSG00000235724.7	AC009299.2	6.5	1.22e-10	2.29e-08	0.23	0.2	Intelligence (multi-trait analysis);	chr2:161059898	chr2:161222785~161308303:-
BRCA	cis	rs2732480	0.5	rs2932093	ENSG00000273765.1	RP11-370I10.11	6.5	1.22e-10	2.3e-08	0.24	0.2	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48254488	chr12:48360920~48361377:+
BRCA	cis	rs301901	0.796	rs1829292	ENSG00000250155.1	CTD-2353F22.1	6.5	1.22e-10	2.3e-08	0.22	0.2	Height;	chr5:37505544	chr5:36666214~36725195:-
BRCA	cis	rs10833905	0.697	rs10766983	ENSG00000246225.5	RP11-17A1.3	-6.5	1.22e-10	2.3e-08	-0.29	-0.2	Sudden cardiac arrest;	chr11:22924603	chr11:22829380~22945393:+
BRCA	cis	rs669446	0.533	rs28833034	ENSG00000237950.1	RP11-7O11.3	6.5	1.22e-10	2.3e-08	0.23	0.2	Amyotrophic lateral sclerosis (age of onset);	chr1:43747271	chr1:43944370~43946551:-
BRCA	cis	rs4691139	1	rs7693977	ENSG00000248632.1	RP11-366M4.11	6.5	1.22e-10	2.3e-08	0.2	0.2	Ovarian cancer in BRCA1 mutation carriers;	chr4:164981898	chr4:164968587~164970002:-
BRCA	cis	rs875971	0.571	rs78668714	ENSG00000224316.1	RP11-479O9.2	6.5	1.22e-10	2.3e-08	0.23	0.2	Aortic root size;	chr7:66474464	chr7:65773620~65802067:+
BRCA	cis	rs539096	0.692	rs7549094	ENSG00000237950.1	RP11-7O11.3	6.5	1.22e-10	2.3e-08	0.23	0.2	Intelligence (multi-trait analysis);	chr1:43747507	chr1:43944370~43946551:-
BRCA	cis	rs2303759	0.914	rs2288481	ENSG00000268686.1	AC010524.2	-6.5	1.22e-10	2.31e-08	-0.33	-0.2	Multiple sclerosis;	chr19:49374939	chr19:49368705~49388081:-
BRCA	cis	rs7246657	0.943	rs10404602	ENSG00000267422.1	CTD-2554C21.1	-6.5	1.23e-10	2.31e-08	-0.3	-0.2	Coronary artery calcification;	chr19:37334731	chr19:37779686~37792865:+
BRCA	cis	rs858239	1	rs199348	ENSG00000230042.1	AK3P3	-6.5	1.23e-10	2.31e-08	-0.23	-0.2	Cerebrospinal fluid biomarker levels;	chr7:23253479	chr7:23129178~23129841:+
BRCA	cis	rs1440410	0.835	rs11100770	ENSG00000250326.1	RP11-284M14.1	-6.5	1.23e-10	2.31e-08	-0.22	-0.2	Ischemic stroke;	chr4:143132629	chr4:142933195~143184861:-
BRCA	cis	rs755249	0.567	rs4660546	ENSG00000237624.1	OXCT2P1	6.5	1.23e-10	2.31e-08	0.28	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39213730	chr1:39514956~39516490:+
BRCA	cis	rs3126085	0.515	rs6668764	ENSG00000237975.5	FLG-AS1	-6.5	1.23e-10	2.31e-08	-0.25	-0.2	Atopic dermatitis;	chr1:152376602	chr1:152168125~152445456:+
BRCA	cis	rs875971	0.545	rs12670811	ENSG00000236529.1	RP13-254B10.1	6.5	1.23e-10	2.32e-08	0.25	0.2	Aortic root size;	chr7:66358032	chr7:65840212~65840596:+
BRCA	cis	rs6504622	0.905	rs736603	ENSG00000262879.4	RP11-156P1.3	6.5	1.23e-10	2.32e-08	0.2	0.2	Orofacial clefts;	chr17:46947379	chr17:46984045~47100323:-
BRCA	cis	rs2274273	0.662	rs4040064	ENSG00000258413.1	RP11-665C16.6	-6.5	1.23e-10	2.32e-08	-0.27	-0.2	Protein biomarker;	chr14:55211370	chr14:55262767~55272075:-
BRCA	cis	rs4372836	1	rs4640348	ENSG00000226833.4	AC097724.3	6.5	1.23e-10	2.32e-08	0.24	0.2	Body mass index;	chr2:28742613	chr2:28708953~28736205:-
BRCA	cis	rs11098499	0.82	rs28394116	ENSG00000249244.1	RP11-548H18.2	6.5	1.24e-10	2.33e-08	0.24	0.2	Corneal astigmatism;	chr4:119603128	chr4:119391831~119395335:-
BRCA	cis	rs875971	1	rs6946143	ENSG00000224316.1	RP11-479O9.2	6.5	1.24e-10	2.33e-08	0.2	0.2	Aortic root size;	chr7:66114735	chr7:65773620~65802067:+
BRCA	cis	rs1555322	0.53	rs2425043	ENSG00000279253.1	RP4-614O4.13	-6.5	1.24e-10	2.33e-08	-0.26	-0.2	Attention deficit hyperactivity disorder;	chr20:35280899	chr20:35262727~35264187:-
BRCA	cis	rs2836950	0.545	rs11701805	ENSG00000255568.3	BRWD1-AS2	-6.5	1.24e-10	2.33e-08	-0.19	-0.2	Menarche (age at onset);	chr21:39246757	chr21:39313935~39314962:+
BRCA	cis	rs2153535	0.518	rs913571	ENSG00000230939.1	RP11-314C16.1	-6.5	1.24e-10	2.34e-08	-0.24	-0.2	Motion sickness;	chr6:8591095	chr6:8784178~8785445:+
BRCA	cis	rs2998286	0.862	rs2790448	ENSG00000254635.4	WAC-AS1	-6.5	1.24e-10	2.34e-08	-0.28	-0.2	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28512828	chr10:28522652~28532743:-
BRCA	cis	rs2998286	0.822	rs2807734	ENSG00000254635.4	WAC-AS1	-6.5	1.24e-10	2.34e-08	-0.28	-0.2	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28513036	chr10:28522652~28532743:-
BRCA	cis	rs2243480	1	rs34193460	ENSG00000229886.1	RP5-1132H15.3	6.5	1.25e-10	2.35e-08	0.35	0.2	Diabetic kidney disease;	chr7:65928123	chr7:66025126~66031544:-
BRCA	cis	rs2243480	1	rs781149	ENSG00000229886.1	RP5-1132H15.3	6.5	1.25e-10	2.35e-08	0.34	0.2	Diabetic kidney disease;	chr7:66016297	chr7:66025126~66031544:-
BRCA	cis	rs2243480	0.901	rs58207111	ENSG00000229886.1	RP5-1132H15.3	6.5	1.25e-10	2.35e-08	0.34	0.2	Diabetic kidney disease;	chr7:66021736	chr7:66025126~66031544:-
BRCA	cis	rs11976180	1	rs2961134	ENSG00000273234.1	OR2A13P	-6.5	1.25e-10	2.35e-08	-0.26	-0.2	Obesity-related traits;	chr7:144073969	chr7:144142009~144142938:+
BRCA	cis	rs2404602	0.536	rs17364330	ENSG00000259422.1	RP11-593F23.1	6.5	1.25e-10	2.35e-08	0.25	0.2	Blood metabolite levels;	chr15:76473044	chr15:76174891~76181486:-
BRCA	cis	rs9807989	0.765	rs13424006	ENSG00000234389.1	AC007278.3	6.5	1.25e-10	2.35e-08	0.18	0.2	Asthma;	chr2:102350776	chr2:102438713~102440475:+
BRCA	cis	rs2243480	1	rs4149468	ENSG00000229886.1	RP5-1132H15.3	6.5	1.25e-10	2.35e-08	0.35	0.2	Diabetic kidney disease;	chr7:66360703	chr7:66025126~66031544:-
BRCA	cis	rs7474896	0.537	rs1208683	ENSG00000226578.1	RP11-258F22.1	6.5	1.25e-10	2.35e-08	0.26	0.2	Obesity (extreme);	chr10:37804795	chr10:37775371~37784131:-
BRCA	cis	rs1707322	0.865	rs785501	ENSG00000281133.1	AL355480.3	6.5	1.25e-10	2.35e-08	0.25	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46113939	chr1:45580892~45580996:-
BRCA	cis	rs9876781	0.53	rs11708617	ENSG00000229759.1	MRPS18AP1	6.5	1.25e-10	2.36e-08	0.23	0.2	Longevity;	chr3:48354819	chr3:48256350~48256938:-
BRCA	cis	rs8002861	0.664	rs1808097	ENSG00000274001.1	RP11-5G9.5	6.5	1.25e-10	2.36e-08	0.23	0.2	Leprosy;	chr13:43850630	chr13:43877715~43878163:-
BRCA	cis	rs8002861	0.664	rs2218497	ENSG00000274001.1	RP11-5G9.5	6.5	1.25e-10	2.36e-08	0.23	0.2	Leprosy;	chr13:43854657	chr13:43877715~43878163:-
BRCA	cis	rs860818	1	rs858292	ENSG00000226816.2	AC005082.12	6.5	1.25e-10	2.36e-08	0.49	0.2	Initial pursuit acceleration;	chr7:23207114	chr7:23206013~23208045:+
BRCA	cis	rs860818	1	rs858285	ENSG00000226816.2	AC005082.12	6.5	1.25e-10	2.36e-08	0.49	0.2	Initial pursuit acceleration;	chr7:23209899	chr7:23206013~23208045:+
BRCA	cis	rs17253792	0.822	rs75763956	ENSG00000186615.9	KTN1-AS1	-6.5	1.26e-10	2.36e-08	-0.37	-0.2	Putamen volume;	chr14:55604458	chr14:55499278~55580110:-
BRCA	cis	rs7208859	0.623	rs73269923	ENSG00000265443.1	CTD-2349P21.6	-6.5	1.26e-10	2.36e-08	-0.34	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775553	chr17:30726305~30727564:-
BRCA	cis	rs2243480	1	rs778729	ENSG00000232546.1	RP11-458F8.1	-6.5	1.26e-10	2.36e-08	-0.26	-0.2	Diabetic kidney disease;	chr7:66359432	chr7:66848496~66858136:+
BRCA	cis	rs1322639	0.614	rs9455889	ENSG00000261039.2	RP11-417E7.2	-6.5	1.26e-10	2.36e-08	-0.25	-0.2	Pulse pressure;	chr6:169165992	chr6:169175304~169182740:-
BRCA	cis	rs1499614	0.901	rs2178742	ENSG00000229886.1	RP5-1132H15.3	6.5	1.26e-10	2.36e-08	0.36	0.2	Gout;	chr7:66732812	chr7:66025126~66031544:-
BRCA	cis	rs45509595	0.556	rs34409918	ENSG00000220721.1	OR1F12	6.5	1.26e-10	2.37e-08	0.47	0.2	Breast cancer;	chr6:27717569	chr6:28073316~28074233:+
BRCA	cis	rs9876781	0.967	rs1459249	ENSG00000229759.1	MRPS18AP1	6.5	1.26e-10	2.37e-08	0.22	0.2	Longevity;	chr3:48438208	chr3:48256350~48256938:-
BRCA	cis	rs7246657	0.943	rs2112923	ENSG00000226686.6	LINC01535	-6.5	1.26e-10	2.37e-08	-0.29	-0.2	Coronary artery calcification;	chr19:37449425	chr19:37251912~37265535:+
BRCA	cis	rs7246657	0.943	rs3760825	ENSG00000226686.6	LINC01535	-6.5	1.26e-10	2.37e-08	-0.29	-0.2	Coronary artery calcification;	chr19:37454699	chr19:37251912~37265535:+
BRCA	cis	rs875971	1	rs1167612	ENSG00000224316.1	RP11-479O9.2	-6.5	1.26e-10	2.37e-08	-0.2	-0.2	Aortic root size;	chr7:66102989	chr7:65773620~65802067:+
BRCA	cis	rs2638953	0.962	rs7303747	ENSG00000278733.1	RP11-425D17.1	-6.5	1.26e-10	2.37e-08	-0.27	-0.2	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28241969	chr12:28185625~28186190:-
BRCA	cis	rs9311474	1	rs1060330	ENSG00000243224.1	RP5-1157M23.2	-6.5	1.26e-10	2.37e-08	-0.21	-0.2	Electroencephalogram traits;	chr3:52254929	chr3:52239258~52241097:+
BRCA	cis	rs7085104	0.513	rs192569	ENSG00000213061.2	PFN1P11	-6.5	1.26e-10	2.37e-08	-0.26	-0.2	Immature fraction of reticulocytes;Schizophrenia;	chr10:102818158	chr10:102838011~102845473:-
BRCA	cis	rs16978956	0.901	rs2424168	ENSG00000236474.1	GCNT1P1	-6.5	1.26e-10	2.37e-08	-0.24	-0.2	Body mass index;	chr20:18345356	chr20:18420160~18421454:-
BRCA	cis	rs4691139	0.967	rs4588418	ENSG00000248632.1	RP11-366M4.11	6.5	1.26e-10	2.37e-08	0.2	0.2	Ovarian cancer in BRCA1 mutation carriers;	chr4:164981136	chr4:164968587~164970002:-
BRCA	cis	rs420259	0.516	rs9933261	ENSG00000260136.4	CTD-2270L9.4	-6.5	1.27e-10	2.38e-08	-0.2	-0.2	Bipolar disorder;	chr16:23504631	chr16:23452758~23457606:+
BRCA	cis	rs2412819	0.571	rs10163069	ENSG00000205771.5	CATSPER2P1	6.5	1.27e-10	2.38e-08	0.28	0.2	Lung cancer;	chr15:43755372	chr15:43726918~43747094:-
BRCA	cis	rs11098499	0.863	rs3775843	ENSG00000249244.1	RP11-548H18.2	6.5	1.27e-10	2.38e-08	0.24	0.2	Corneal astigmatism;	chr4:119506689	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.863	rs3775844	ENSG00000249244.1	RP11-548H18.2	6.5	1.27e-10	2.38e-08	0.24	0.2	Corneal astigmatism;	chr4:119506878	chr4:119391831~119395335:-
BRCA	cis	rs6669008	1	rs1891969	ENSG00000232450.1	RP4-730K3.3	-6.5	1.27e-10	2.38e-08	-0.24	-0.2	Bacteremia;	chr1:113643233	chr1:113698884~113699631:-
BRCA	cis	rs1707322	0.686	rs3014236	ENSG00000281133.1	AL355480.3	6.5	1.27e-10	2.38e-08	0.25	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45625633	chr1:45580892~45580996:-
BRCA	cis	rs34779708	0.931	rs34087268	ENSG00000271335.4	RP11-324I22.4	6.5	1.27e-10	2.39e-08	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35057796	chr10:35314552~35336401:-
BRCA	cis	rs34779708	0.931	rs58159560	ENSG00000271335.4	RP11-324I22.4	6.5	1.27e-10	2.39e-08	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35062321	chr10:35314552~35336401:-
BRCA	cis	rs2933343	0.951	rs9871612	ENSG00000231305.3	RP11-723O4.2	6.5	1.27e-10	2.39e-08	0.25	0.2	IgG glycosylation;	chr3:128851559	chr3:128861313~128871540:-
BRCA	cis	rs1707322	0.896	rs785512	ENSG00000281133.1	AL355480.3	6.5	1.27e-10	2.39e-08	0.25	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46068871	chr1:45580892~45580996:-
BRCA	cis	rs172166	0.694	rs9295760	ENSG00000204709.4	LINC01556	6.5	1.27e-10	2.39e-08	0.27	0.2	Cardiac Troponin-T levels;	chr6:28179607	chr6:28943877~28944537:+
BRCA	cis	rs875971	0.964	rs778723	ENSG00000224316.1	RP11-479O9.2	6.5	1.27e-10	2.39e-08	0.2	0.2	Aortic root size;	chr7:66364510	chr7:65773620~65802067:+
BRCA	cis	rs673078	0.607	rs6490177	ENSG00000275409.1	RP11-131L12.4	-6.5	1.27e-10	2.39e-08	-0.25	-0.2	Glucose homeostasis traits;	chr12:118358280	chr12:118430147~118430699:+
BRCA	cis	rs1707322	0.752	rs61784793	ENSG00000281133.1	AL355480.3	-6.5	1.28e-10	2.4e-08	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45683613	chr1:45580892~45580996:-
BRCA	cis	rs7927771	0.524	rs7118747	ENSG00000280615.1	Y_RNA	-6.5	1.28e-10	2.4e-08	-0.22	-0.2	Subjective well-being;	chr11:47867993	chr11:47614898~47614994:-
BRCA	cis	rs1707322	0.752	rs28890893	ENSG00000281133.1	AL355480.3	-6.5	1.28e-10	2.4e-08	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45720904	chr1:45580892~45580996:-
BRCA	cis	rs2836950	0.502	rs12627205	ENSG00000255568.3	BRWD1-AS2	-6.5	1.28e-10	2.4e-08	-0.19	-0.2	Menarche (age at onset);	chr21:39258101	chr21:39313935~39314962:+
BRCA	cis	rs2243480	1	rs160633	ENSG00000230295.1	RP11-458F8.2	-6.5	1.28e-10	2.4e-08	-0.27	-0.2	Diabetic kidney disease;	chr7:66063241	chr7:66880708~66882981:+
BRCA	cis	rs4713118	0.513	rs149941	ENSG00000204709.4	LINC01556	6.5	1.28e-10	2.4e-08	0.27	0.2	Parkinson's disease;	chr6:28033255	chr6:28943877~28944537:+
BRCA	cis	rs9527	0.571	rs3740400	ENSG00000236937.2	PTGES3P4	6.5	1.28e-10	2.4e-08	0.25	0.2	Arsenic metabolism;	chr10:102869708	chr10:102845595~102845950:+
BRCA	cis	rs34779708	0.897	rs16935880	ENSG00000271335.4	RP11-324I22.4	6.5	1.28e-10	2.4e-08	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35126540	chr10:35314552~35336401:-
BRCA	cis	rs34779708	0.966	rs4934730	ENSG00000271335.4	RP11-324I22.4	6.5	1.28e-10	2.4e-08	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35126627	chr10:35314552~35336401:-
BRCA	cis	rs7124681	0.584	rs11039448	ENSG00000280615.1	Y_RNA	-6.5	1.28e-10	2.41e-08	-0.23	-0.2	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:47896864	chr11:47614898~47614994:-
BRCA	cis	rs1707322	0.752	rs11488313	ENSG00000281133.1	AL355480.3	-6.5	1.28e-10	2.41e-08	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45759108	chr1:45580892~45580996:-
BRCA	cis	rs4072705	1	rs6478671	ENSG00000224020.1	MIR181A2HG	-6.5	1.28e-10	2.41e-08	-0.22	-0.2	Menarche (age at onset);	chr9:124611716	chr9:124658467~124698631:+
BRCA	cis	rs228614	0.536	rs223484	ENSG00000251288.2	RP11-10L12.2	-6.5	1.28e-10	2.41e-08	-0.23	-0.2	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102764314	chr4:102751401~102752641:+
BRCA	cis	rs7246657	0.882	rs8112610	ENSG00000226686.6	LINC01535	-6.5	1.28e-10	2.41e-08	-0.29	-0.2	Coronary artery calcification;	chr19:37437828	chr19:37251912~37265535:+
BRCA	cis	rs7119038	0.629	rs10892272	ENSG00000255239.1	AP002954.6	-6.5	1.28e-10	2.41e-08	-0.25	-0.2	Sjögren's syndrome;	chr11:118731998	chr11:118688039~118690600:-
BRCA	cis	rs6570726	0.935	rs386344	ENSG00000235652.6	RP11-545I5.3	6.5	1.28e-10	2.41e-08	0.19	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145534486	chr6:145799409~145886585:+
BRCA	cis	rs919433	0.889	rs787995	ENSG00000231621.1	AC013264.2	-6.49	1.28e-10	2.41e-08	-0.18	-0.2	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197352129	chr2:197197991~197199273:+
BRCA	cis	rs73193808	0.901	rs73354869	ENSG00000215533.7	LINC00189	-6.49	1.29e-10	2.41e-08	-0.28	-0.2	Coronary artery disease;	chr21:29194964	chr21:29193480~29288205:+
BRCA	cis	rs6840258	0.941	rs7665282	ENSG00000251411.1	RP11-397E7.4	-6.49	1.29e-10	2.41e-08	-0.27	-0.2	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86979698	chr4:86913266~86914817:-
BRCA	cis	rs10506328	0.509	rs1920046	ENSG00000257534.1	RP11-834C11.10	6.49	1.29e-10	2.42e-08	0.21	0.2	Mean platelet volume;	chr12:54276271	chr12:54162065~54164452:-
BRCA	cis	rs2836950	0.545	rs2836922	ENSG00000255568.3	BRWD1-AS2	-6.49	1.29e-10	2.42e-08	-0.19	-0.2	Menarche (age at onset);	chr21:39144382	chr21:39313935~39314962:+
BRCA	cis	rs2348418	0.966	rs7315631	ENSG00000247934.4	RP11-967K21.1	6.49	1.29e-10	2.42e-08	0.22	0.2	Lung function (FEV1);Lung function (FVC);	chr12:28545311	chr12:28163298~28190738:-
BRCA	cis	rs2288884	0.559	rs12611043	ENSG00000275055.1	CTC-471J1.11	-6.49	1.29e-10	2.42e-08	-0.23	-0.2	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52084372	chr19:52049007~52049754:+
BRCA	cis	rs6570726	0.967	rs373527	ENSG00000235652.6	RP11-545I5.3	6.49	1.29e-10	2.42e-08	0.19	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145480725	chr6:145799409~145886585:+
BRCA	cis	rs797680	0.576	rs55838267	ENSG00000229635.1	RP4-713B5.2	6.49	1.29e-10	2.42e-08	0.35	0.2	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93338159	chr1:93384487~93384998:-
BRCA	cis	rs10129255	0.957	rs10142859	ENSG00000211972.2	IGHV3-66	6.49	1.29e-10	2.42e-08	0.15	0.2	Kawasaki disease;	chr14:106782238	chr14:106675017~106675544:-
BRCA	cis	rs10129255	0.744	rs28517388	ENSG00000211972.2	IGHV3-66	6.49	1.29e-10	2.42e-08	0.17	0.2	Kawasaki disease;	chr14:106704323	chr14:106675017~106675544:-
BRCA	cis	rs67981189	0.896	rs17108822	ENSG00000269927.1	RP6-91H8.3	6.49	1.29e-10	2.43e-08	0.24	0.2	Schizophrenia;	chr14:70979189	chr14:71141125~71143253:-
BRCA	cis	rs67981189	0.896	rs8012728	ENSG00000269927.1	RP6-91H8.3	6.49	1.29e-10	2.43e-08	0.24	0.2	Schizophrenia;	chr14:70981231	chr14:71141125~71143253:-
BRCA	cis	rs67981189	0.896	rs34731365	ENSG00000269927.1	RP6-91H8.3	6.49	1.29e-10	2.43e-08	0.24	0.2	Schizophrenia;	chr14:70982877	chr14:71141125~71143253:-
BRCA	cis	rs11098499	0.913	rs56122576	ENSG00000248280.1	RP11-33B1.2	6.49	1.3e-10	2.43e-08	0.21	0.2	Corneal astigmatism;	chr4:119208181	chr4:119440561~119450157:-
BRCA	cis	rs2998286	0.768	rs332137	ENSG00000254635.4	WAC-AS1	-6.49	1.3e-10	2.43e-08	-0.28	-0.2	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28570050	chr10:28522652~28532743:-
BRCA	cis	rs9638182	0.623	rs13246490	ENSG00000274080.1	CTA-315H11.2	6.49	1.3e-10	2.43e-08	0.39	0.2	Triglycerides;	chr7:73578020	chr7:73609262~73611502:-
BRCA	cis	rs4218	0.531	rs10431791	ENSG00000277144.1	RP11-59H7.4	-6.49	1.3e-10	2.44e-08	-0.24	-0.2	Social communication problems;	chr15:59055159	chr15:59115547~59116089:-
BRCA	cis	rs957448	1	rs957448	ENSG00000253175.1	RP11-267M23.6	6.49	1.3e-10	2.44e-08	0.24	0.2	Nonsyndromic cleft lip with cleft palate;	chr8:94529074	chr8:94565036~94565715:+
BRCA	cis	rs4713118	0.513	rs149942	ENSG00000204709.4	LINC01556	6.49	1.3e-10	2.44e-08	0.27	0.2	Parkinson's disease;	chr6:28033832	chr6:28943877~28944537:+
BRCA	cis	rs4713118	0.513	rs149944	ENSG00000204709.4	LINC01556	6.49	1.3e-10	2.44e-08	0.27	0.2	Parkinson's disease;	chr6:28035040	chr6:28943877~28944537:+
BRCA	cis	rs4713118	0.513	rs149945	ENSG00000204709.4	LINC01556	6.49	1.3e-10	2.44e-08	0.27	0.2	Parkinson's disease;	chr6:28035075	chr6:28943877~28944537:+
BRCA	cis	rs42648	0.748	rs10225744	ENSG00000225498.1	AC002064.5	6.49	1.3e-10	2.44e-08	0.19	0.2	Homocysteine levels;	chr7:90316689	chr7:90312496~90322592:+
BRCA	cis	rs12594515	1	rs11070467	ENSG00000259200.1	RP11-718O11.1	6.49	1.3e-10	2.44e-08	0.22	0.2	Weight;Waist circumference;	chr15:45692803	chr15:45705078~45931069:+
BRCA	cis	rs7246657	0.943	rs7255785	ENSG00000226686.6	LINC01535	-6.49	1.3e-10	2.44e-08	-0.29	-0.2	Coronary artery calcification;	chr19:37480781	chr19:37251912~37265535:+
BRCA	cis	rs7246657	0.943	rs7255996	ENSG00000226686.6	LINC01535	-6.49	1.3e-10	2.44e-08	-0.29	-0.2	Coronary artery calcification;	chr19:37480797	chr19:37251912~37265535:+
BRCA	cis	rs1124769	0.748	rs10851493	ENSG00000259378.1	DCAF13P3	6.49	1.3e-10	2.45e-08	0.28	0.2	Cognitive performance;	chr15:51056489	chr15:50944663~50945996:+
BRCA	cis	rs7246657	0.943	rs13343502	ENSG00000267422.1	CTD-2554C21.1	-6.49	1.3e-10	2.45e-08	-0.3	-0.2	Coronary artery calcification;	chr19:37471390	chr19:37779686~37792865:+
BRCA	cis	rs8177876	0.749	rs11537	ENSG00000261838.4	RP11-303E16.6	6.49	1.3e-10	2.45e-08	0.4	0.2	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81046894	chr16:81069854~81076598:+
BRCA	cis	rs9876781	1	rs4858817	ENSG00000229759.1	MRPS18AP1	-6.49	1.3e-10	2.45e-08	-0.22	-0.2	Longevity;	chr3:48375266	chr3:48256350~48256938:-
BRCA	cis	rs6142102	1	rs6059673	ENSG00000275784.1	RP5-1125A11.6	-6.49	1.31e-10	2.45e-08	-0.24	-0.2	Skin pigmentation;	chr20:34117755	chr20:33989480~33991818:-
BRCA	cis	rs8002861	0.664	rs9533662	ENSG00000274001.1	RP11-5G9.5	6.49	1.31e-10	2.45e-08	0.23	0.2	Leprosy;	chr13:43861852	chr13:43877715~43878163:-
BRCA	cis	rs8002861	0.619	rs9567289	ENSG00000274001.1	RP11-5G9.5	6.49	1.31e-10	2.45e-08	0.23	0.2	Leprosy;	chr13:43862968	chr13:43877715~43878163:-
BRCA	cis	rs7746199	0.736	rs34105070	ENSG00000220721.1	OR1F12	6.49	1.31e-10	2.45e-08	0.47	0.2	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27593026	chr6:28073316~28074233:+
BRCA	cis	rs12501370	1	rs35089980	ENSG00000201736.1	RNA5SP160	6.49	1.31e-10	2.46e-08	0.25	0.2	Iris color (L* coordinate);	chr4:40999201	chr4:40990154~40990273:+
BRCA	cis	rs6740322	0.748	rs13432574	ENSG00000234936.1	AC010883.5	6.49	1.31e-10	2.46e-08	0.22	0.2	Coronary artery disease;	chr2:43317189	chr2:43229573~43233394:+
BRCA	cis	rs7927771	0.524	rs4752798	ENSG00000280615.1	Y_RNA	-6.49	1.31e-10	2.47e-08	-0.22	-0.2	Subjective well-being;	chr11:47864812	chr11:47614898~47614994:-
BRCA	cis	rs67981189	0.896	rs12883437	ENSG00000269927.1	RP6-91H8.3	6.49	1.32e-10	2.47e-08	0.24	0.2	Schizophrenia;	chr14:70998064	chr14:71141125~71143253:-
BRCA	cis	rs2288884	0.559	rs11084130	ENSG00000275055.1	CTC-471J1.11	-6.49	1.32e-10	2.47e-08	-0.24	-0.2	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52009443	chr19:52049007~52049754:+
BRCA	cis	rs6095360	0.7	rs79941596	ENSG00000222365.1	SNORD12B	-6.49	1.32e-10	2.47e-08	-0.26	-0.2	Intelligence (multi-trait analysis);	chr20:49177259	chr20:49280319~49280409:+
BRCA	cis	rs12468226	0.938	rs116109808	ENSG00000226261.1	AC064836.3	6.49	1.32e-10	2.47e-08	0.34	0.2	Urate levels;	chr2:202287356	chr2:202336024~202336727:-
BRCA	cis	rs12468226	0.873	rs78175596	ENSG00000226261.1	AC064836.3	6.49	1.32e-10	2.47e-08	0.34	0.2	Urate levels;	chr2:202287993	chr2:202336024~202336727:-
BRCA	cis	rs12468226	0.938	rs74454549	ENSG00000226261.1	AC064836.3	6.49	1.32e-10	2.47e-08	0.34	0.2	Urate levels;	chr2:202288044	chr2:202336024~202336727:-
BRCA	cis	rs2348418	0.966	rs7316351	ENSG00000247934.4	RP11-967K21.1	6.49	1.32e-10	2.48e-08	0.22	0.2	Lung function (FEV1);Lung function (FVC);	chr12:28545595	chr12:28163298~28190738:-
BRCA	cis	rs7131987	0.565	rs766445	ENSG00000275476.1	RP11-996F15.4	6.49	1.32e-10	2.48e-08	0.22	0.2	QT interval;	chr12:29260560	chr12:29277397~29277882:-
BRCA	cis	rs1823913	0.599	rs13399251	ENSG00000280083.1	RP11-317J9.1	-6.49	1.32e-10	2.48e-08	-0.22	-0.2	Obesity-related traits;	chr2:191268758	chr2:191154118~191156070:-
BRCA	cis	rs919433	0.927	rs13032495	ENSG00000231621.1	AC013264.2	6.49	1.32e-10	2.48e-08	0.19	0.2	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197324622	chr2:197197991~197199273:+
BRCA	cis	rs7587476	0.784	rs36086595	ENSG00000229267.2	AC072062.1	-6.49	1.32e-10	2.48e-08	-0.26	-0.2	Neuroblastoma;	chr2:214815569	chr2:214810229~214963274:+
BRCA	cis	rs2929278	0.617	rs3986209	ENSG00000205771.5	CATSPER2P1	6.49	1.32e-10	2.48e-08	0.28	0.2	Schizophrenia;	chr15:43758675	chr15:43726918~43747094:-
BRCA	cis	rs2274273	0.662	rs67958555	ENSG00000258413.1	RP11-665C16.6	-6.49	1.33e-10	2.49e-08	-0.27	-0.2	Protein biomarker;	chr14:55204148	chr14:55262767~55272075:-
BRCA	cis	rs2274273	0.662	rs67092614	ENSG00000258413.1	RP11-665C16.6	-6.49	1.33e-10	2.49e-08	-0.27	-0.2	Protein biomarker;	chr14:55205337	chr14:55262767~55272075:-
BRCA	cis	rs2274273	0.615	rs17672058	ENSG00000258413.1	RP11-665C16.6	-6.49	1.33e-10	2.49e-08	-0.27	-0.2	Protein biomarker;	chr14:55206676	chr14:55262767~55272075:-
BRCA	cis	rs2274273	0.662	rs67215571	ENSG00000258413.1	RP11-665C16.6	-6.49	1.33e-10	2.49e-08	-0.27	-0.2	Protein biomarker;	chr14:55207005	chr14:55262767~55272075:-
BRCA	cis	rs7246657	0.943	rs1015849	ENSG00000267422.1	CTD-2554C21.1	-6.49	1.33e-10	2.49e-08	-0.3	-0.2	Coronary artery calcification;	chr19:37455278	chr19:37779686~37792865:+
BRCA	cis	rs8031584	0.958	rs7176569	ENSG00000260382.1	RP11-540B6.2	-6.49	1.33e-10	2.49e-08	-0.24	-0.2	Huntington's disease progression;	chr15:30952292	chr15:30882267~30883231:-
BRCA	cis	rs17711722	0.64	rs13237956	ENSG00000237310.1	GS1-124K5.4	6.49	1.33e-10	2.49e-08	0.2	0.2	Calcium levels;	chr7:65853042	chr7:66493706~66495474:+
BRCA	cis	rs7246657	0.943	rs4802766	ENSG00000267422.1	CTD-2554C21.1	-6.49	1.33e-10	2.49e-08	-0.3	-0.2	Coronary artery calcification;	chr19:37491031	chr19:37779686~37792865:+
BRCA	cis	rs7665090	1	rs12498722	ENSG00000246560.2	RP11-10L12.4	6.49	1.33e-10	2.49e-08	0.21	0.2	Primary biliary cholangitis;	chr4:102633365	chr4:102828055~102844075:+
BRCA	cis	rs7746199	0.736	rs34965299	ENSG00000220721.1	OR1F12	6.49	1.33e-10	2.5e-08	0.45	0.2	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27554077	chr6:28073316~28074233:+
BRCA	cis	rs6570726	0.905	rs421032	ENSG00000235652.6	RP11-545I5.3	6.49	1.33e-10	2.5e-08	0.19	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145506635	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.935	rs9390329	ENSG00000235652.6	RP11-545I5.3	6.49	1.33e-10	2.5e-08	0.19	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145506890	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.902	rs406979	ENSG00000235652.6	RP11-545I5.3	6.49	1.33e-10	2.5e-08	0.19	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145517847	chr6:145799409~145886585:+
BRCA	cis	rs2348418	0.798	rs10843161	ENSG00000247934.4	RP11-967K21.1	6.49	1.33e-10	2.5e-08	0.22	0.2	Lung function (FEV1);Lung function (FVC);	chr12:28367688	chr12:28163298~28190738:-
BRCA	cis	rs9291683	0.53	rs13115193	ENSG00000250413.1	RP11-448G15.1	-6.49	1.33e-10	2.5e-08	-0.26	-0.2	Bone mineral density;	chr4:9980567	chr4:10006482~10009725:+
BRCA	cis	rs9807989	0.839	rs4988958	ENSG00000234389.1	AC007278.3	6.49	1.33e-10	2.5e-08	0.18	0.2	Asthma;	chr2:102351825	chr2:102438713~102440475:+
BRCA	cis	rs9807989	0.839	rs10192157	ENSG00000234389.1	AC007278.3	6.49	1.33e-10	2.5e-08	0.18	0.2	Asthma;	chr2:102351896	chr2:102438713~102440475:+
BRCA	cis	rs9807989	0.839	rs10206753	ENSG00000234389.1	AC007278.3	6.49	1.33e-10	2.5e-08	0.18	0.2	Asthma;	chr2:102351902	chr2:102438713~102440475:+
BRCA	cis	rs873549	0.959	rs10779467	ENSG00000232679.1	RP11-400N13.3	-6.49	1.33e-10	2.5e-08	-0.23	-0.2	Keloid;	chr1:222092288	chr1:222041705~222064763:-
BRCA	cis	rs11098499	0.82	rs28535956	ENSG00000249244.1	RP11-548H18.2	-6.49	1.34e-10	2.5e-08	-0.24	-0.2	Corneal astigmatism;	chr4:119615703	chr4:119391831~119395335:-
BRCA	cis	rs228614	0.51	rs223405	ENSG00000251288.2	RP11-10L12.2	-6.49	1.34e-10	2.5e-08	-0.23	-0.2	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102815894	chr4:102751401~102752641:+
BRCA	cis	rs2836950	0.502	rs12627205	ENSG00000238141.2	BRWD1-AS1	-6.49	1.34e-10	2.5e-08	-0.22	-0.2	Menarche (age at onset);	chr21:39258101	chr21:39315707~39323218:+
BRCA	cis	rs2688608	0.592	rs7909544	ENSG00000271816.1	BMS1P4	6.49	1.34e-10	2.5e-08	0.19	0.2	Inflammatory bowel disease;	chr10:73724246	chr10:73699151~73730487:-
BRCA	cis	rs1823913	0.599	rs67781530	ENSG00000280083.1	RP11-317J9.1	-6.49	1.34e-10	2.51e-08	-0.23	-0.2	Obesity-related traits;	chr2:191295608	chr2:191154118~191156070:-
BRCA	cis	rs11024102	1	rs4141194	ENSG00000184669.7	OR7E14P	6.49	1.34e-10	2.51e-08	0.31	0.2	Glaucoma (primary angle closure);	chr11:16989629	chr11:17013998~17053024:+
BRCA	cis	rs2243480	1	rs313832	ENSG00000229886.1	RP5-1132H15.3	6.49	1.34e-10	2.51e-08	0.36	0.2	Diabetic kidney disease;	chr7:66085904	chr7:66025126~66031544:-
BRCA	cis	rs73186030	0.764	rs6438725	ENSG00000272758.4	RP11-299J3.8	6.49	1.34e-10	2.51e-08	0.27	0.2	Serum parathyroid hormone levels;	chr3:122369259	chr3:122416207~122443180:+
BRCA	cis	rs73186030	0.764	rs9881201	ENSG00000272758.4	RP11-299J3.8	6.49	1.34e-10	2.51e-08	0.27	0.2	Serum parathyroid hormone levels;	chr3:122375838	chr3:122416207~122443180:+
BRCA	cis	rs875971	0.545	rs2279757	ENSG00000273024.4	INTS4P2	-6.49	1.34e-10	2.52e-08	-0.25	-0.2	Aortic root size;	chr7:66363676	chr7:65647864~65715661:+
BRCA	cis	rs875971	0.545	rs11766183	ENSG00000273024.4	INTS4P2	-6.49	1.34e-10	2.52e-08	-0.25	-0.2	Aortic root size;	chr7:66374173	chr7:65647864~65715661:+
BRCA	cis	rs875971	0.545	rs1065265	ENSG00000273024.4	INTS4P2	-6.49	1.34e-10	2.52e-08	-0.25	-0.2	Aortic root size;	chr7:66376216	chr7:65647864~65715661:+
BRCA	cis	rs7246657	0.882	rs59224125	ENSG00000226686.6	LINC01535	-6.49	1.34e-10	2.52e-08	-0.28	-0.2	Coronary artery calcification;	chr19:37472303	chr19:37251912~37265535:+
BRCA	cis	rs2179367	0.509	rs9485390	ENSG00000216906.2	RP11-350J20.9	6.49	1.34e-10	2.52e-08	0.28	0.2	Dupuytren's disease;	chr6:149421004	chr6:149904243~149906418:+
BRCA	cis	rs1275468	0.731	rs1627431	ENSG00000257497.2	RP11-585P4.5	-6.49	1.34e-10	2.52e-08	-0.29	-0.2	Polycystic ovary syndrome;	chr12:75569132	chr12:75483454~75489820:-
BRCA	cis	rs2732480	0.577	rs2732481	ENSG00000257763.1	OR5BK1P	6.49	1.35e-10	2.52e-08	0.22	0.2	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48343202	chr12:48355792~48356614:-
BRCA	cis	rs2732480	0.557	rs2732484	ENSG00000257763.1	OR5BK1P	6.49	1.35e-10	2.52e-08	0.22	0.2	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48343462	chr12:48355792~48356614:-
BRCA	cis	rs2732480	0.577	rs2732486	ENSG00000257763.1	OR5BK1P	6.49	1.35e-10	2.52e-08	0.22	0.2	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344051	chr12:48355792~48356614:-
BRCA	cis	rs2732480	0.517	rs2634676	ENSG00000257763.1	OR5BK1P	6.49	1.35e-10	2.52e-08	0.22	0.2	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344453	chr12:48355792~48356614:-
BRCA	cis	rs1862618	0.853	rs832584	ENSG00000271828.1	CTD-2310F14.1	-6.49	1.35e-10	2.52e-08	-0.28	-0.2	Initial pursuit acceleration;	chr5:56883385	chr5:56927874~56929573:+
BRCA	cis	rs228614	0.536	rs223437	ENSG00000251288.2	RP11-10L12.2	-6.49	1.35e-10	2.52e-08	-0.23	-0.2	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102798736	chr4:102751401~102752641:+
BRCA	cis	rs228614	0.51	rs223435	ENSG00000251288.2	RP11-10L12.2	-6.49	1.35e-10	2.52e-08	-0.23	-0.2	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102799826	chr4:102751401~102752641:+
BRCA	cis	rs250585	1	rs2073951	ENSG00000260136.4	CTD-2270L9.4	-6.49	1.35e-10	2.52e-08	-0.22	-0.2	Egg allergy;	chr16:23535240	chr16:23452758~23457606:+
BRCA	cis	rs1707322	0.721	rs61784800	ENSG00000281133.1	AL355480.3	6.49	1.35e-10	2.53e-08	0.25	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45712440	chr1:45580892~45580996:-
BRCA	cis	rs6095360	0.689	rs35667796	ENSG00000222365.1	SNORD12B	-6.49	1.35e-10	2.53e-08	-0.26	-0.2	Intelligence (multi-trait analysis);	chr20:49186764	chr20:49280319~49280409:+
BRCA	cis	rs2243480	1	rs57057549	ENSG00000229886.1	RP5-1132H15.3	6.49	1.35e-10	2.53e-08	0.34	0.2	Diabetic kidney disease;	chr7:65940751	chr7:66025126~66031544:-
BRCA	cis	rs9527	0.571	rs7904113	ENSG00000236937.2	PTGES3P4	6.49	1.35e-10	2.53e-08	0.25	0.2	Arsenic metabolism;	chr10:102873357	chr10:102845595~102845950:+
BRCA	cis	rs8031584	0.918	rs61997139	ENSG00000260382.1	RP11-540B6.2	6.49	1.36e-10	2.54e-08	0.23	0.2	Huntington's disease progression;	chr15:30981399	chr15:30882267~30883231:-
BRCA	cis	rs7621025	0.63	rs1681816	ENSG00000239213.4	NCK1-AS1	-6.49	1.36e-10	2.54e-08	-0.24	-0.2	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136755920	chr3:136841726~136862054:-
BRCA	cis	rs1440410	0.835	rs4626148	ENSG00000250326.1	RP11-284M14.1	-6.49	1.36e-10	2.54e-08	-0.22	-0.2	Ischemic stroke;	chr4:143131307	chr4:142933195~143184861:-
BRCA	cis	rs1440410	0.835	rs10034769	ENSG00000250326.1	RP11-284M14.1	-6.49	1.36e-10	2.54e-08	-0.22	-0.2	Ischemic stroke;	chr4:143131740	chr4:142933195~143184861:-
BRCA	cis	rs1440410	0.835	rs6829621	ENSG00000250326.1	RP11-284M14.1	-6.49	1.36e-10	2.54e-08	-0.22	-0.2	Ischemic stroke;	chr4:143131818	chr4:142933195~143184861:-
BRCA	cis	rs1020064	0.636	rs12476328	ENSG00000235319.1	AC012360.4	-6.49	1.36e-10	2.54e-08	-0.27	-0.2	AIDS;	chr2:105359887	chr2:105324210~105330529:+
BRCA	cis	rs673078	0.607	rs55929628	ENSG00000275409.1	RP11-131L12.4	-6.49	1.36e-10	2.54e-08	-0.31	-0.2	Glucose homeostasis traits;	chr12:118371332	chr12:118430147~118430699:+
BRCA	cis	rs34779708	0.966	rs2045915	ENSG00000271335.4	RP11-324I22.4	6.49	1.36e-10	2.54e-08	0.2	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35129688	chr10:35314552~35336401:-
BRCA	cis	rs67766926	0.587	rs72809443	ENSG00000271889.1	RP11-493E12.1	6.49	1.36e-10	2.55e-08	0.3	0.2	Inflammatory skin disease;	chr2:61028918	chr2:61151433~61162105:-
BRCA	cis	rs9291683	0.509	rs6849717	ENSG00000250413.1	RP11-448G15.1	6.49	1.36e-10	2.55e-08	0.25	0.2	Bone mineral density;	chr4:9957095	chr4:10006482~10009725:+
BRCA	cis	rs2726040	0.902	rs33957528	ENSG00000278665.1	RP11-666O2.4	-6.49	1.36e-10	2.55e-08	-0.21	-0.2	Hip circumference;	chr16:28296619	chr16:28599241~28601881:-
BRCA	cis	rs17508449	0.865	rs76112502	ENSG00000232450.1	RP4-730K3.3	-6.49	1.36e-10	2.55e-08	-0.36	-0.2	Leprosy;	chr1:113607074	chr1:113698884~113699631:-
BRCA	cis	rs3760982	1	rs12460161	ENSG00000267058.1	RP11-15A1.3	-6.49	1.36e-10	2.55e-08	-0.22	-0.2	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43789834	chr19:43891804~43901805:-
BRCA	cis	rs4713118	0.955	rs9468204	ENSG00000220721.1	OR1F12	6.49	1.36e-10	2.55e-08	0.25	0.2	Parkinson's disease;	chr6:27721030	chr6:28073316~28074233:+
BRCA	cis	rs1061377	0.748	rs6810770	ENSG00000249685.1	RP11-360F5.3	6.49	1.36e-10	2.55e-08	0.24	0.2	Uric acid levels;	chr4:39106545	chr4:39133913~39135608:+
BRCA	cis	rs11098499	0.863	rs1010740	ENSG00000249244.1	RP11-548H18.2	-6.49	1.36e-10	2.55e-08	-0.24	-0.2	Corneal astigmatism;	chr4:119542254	chr4:119391831~119395335:-
BRCA	cis	rs2998286	0.723	rs332154	ENSG00000254635.4	WAC-AS1	-6.48	1.37e-10	2.56e-08	-0.29	-0.2	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28591465	chr10:28522652~28532743:-
BRCA	cis	rs2998286	0.723	rs332156	ENSG00000254635.4	WAC-AS1	-6.48	1.37e-10	2.56e-08	-0.29	-0.2	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28593152	chr10:28522652~28532743:-
BRCA	cis	rs2243480	1	rs316322	ENSG00000232546.1	RP11-458F8.1	-6.48	1.37e-10	2.56e-08	-0.26	-0.2	Diabetic kidney disease;	chr7:66146246	chr7:66848496~66858136:+
BRCA	cis	rs228614	0.51	rs223445	ENSG00000251288.2	RP11-10L12.2	-6.48	1.37e-10	2.57e-08	-0.23	-0.2	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102793337	chr4:102751401~102752641:+
BRCA	cis	rs17772222	0.74	rs73317739	ENSG00000258983.2	RP11-507K2.2	6.48	1.37e-10	2.57e-08	0.21	0.2	Coronary artery calcification;	chr14:88511400	chr14:88499334~88515502:+
BRCA	cis	rs12468226	0.938	rs114177656	ENSG00000226261.1	AC064836.3	6.48	1.37e-10	2.57e-08	0.33	0.2	Urate levels;	chr2:202291596	chr2:202336024~202336727:-
BRCA	cis	rs2337406	1	rs4774173	ENSG00000211974.3	IGHV2-70	-6.48	1.37e-10	2.57e-08	-0.24	-0.2	Alzheimer's disease (late onset);	chr14:106682029	chr14:106723574~106724093:-
BRCA	cis	rs875971	1	rs778726	ENSG00000224316.1	RP11-479O9.2	6.48	1.37e-10	2.57e-08	0.2	0.2	Aortic root size;	chr7:66363744	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.767	rs1695815	ENSG00000224316.1	RP11-479O9.2	6.48	1.37e-10	2.57e-08	0.2	0.2	Aortic root size;	chr7:66366357	chr7:65773620~65802067:+
BRCA	cis	rs875971	1	rs778685	ENSG00000224316.1	RP11-479O9.2	6.48	1.37e-10	2.57e-08	0.2	0.2	Aortic root size;	chr7:66371189	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.929	rs778682	ENSG00000224316.1	RP11-479O9.2	6.48	1.37e-10	2.57e-08	0.2	0.2	Aortic root size;	chr7:66372947	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.964	rs11765965	ENSG00000224316.1	RP11-479O9.2	6.48	1.37e-10	2.57e-08	0.2	0.2	Aortic root size;	chr7:66377234	chr7:65773620~65802067:+
BRCA	cis	rs2243480	0.808	rs12698508	ENSG00000229886.1	RP5-1132H15.3	6.48	1.37e-10	2.57e-08	0.34	0.2	Diabetic kidney disease;	chr7:65946971	chr7:66025126~66031544:-
BRCA	cis	rs7208859	0.573	rs11654035	ENSG00000265443.1	CTD-2349P21.6	-6.48	1.38e-10	2.57e-08	-0.33	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809408	chr17:30726305~30727564:-
BRCA	cis	rs2243480	1	rs313802	ENSG00000232546.1	RP11-458F8.1	-6.48	1.38e-10	2.57e-08	-0.27	-0.2	Diabetic kidney disease;	chr7:66051386	chr7:66848496~66858136:+
BRCA	cis	rs2243480	0.803	rs403089	ENSG00000232546.1	RP11-458F8.1	-6.48	1.38e-10	2.57e-08	-0.27	-0.2	Diabetic kidney disease;	chr7:66052736	chr7:66848496~66858136:+
BRCA	cis	rs2243480	1	rs458291	ENSG00000232546.1	RP11-458F8.1	-6.48	1.38e-10	2.57e-08	-0.27	-0.2	Diabetic kidney disease;	chr7:66055492	chr7:66848496~66858136:+
BRCA	cis	rs1707322	0.686	rs1250	ENSG00000281133.1	AL355480.3	-6.48	1.38e-10	2.58e-08	-0.25	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45628355	chr1:45580892~45580996:-
BRCA	cis	rs867371	1	rs7180584	ENSG00000276710.3	CSPG4P8	-6.48	1.38e-10	2.58e-08	-0.21	-0.2	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82163493	chr15:82459472~82477258:+
BRCA	cis	rs991427	0.643	rs17018636	ENSG00000258100.1	RP11-121E16.1	-6.48	1.38e-10	2.58e-08	-0.33	-0.2	Systolic blood pressure (alcohol consumption interaction);	chr12:91061469	chr12:91362196~91368606:+
BRCA	cis	rs34779708	0.931	rs11597392	ENSG00000271335.4	RP11-324I22.4	6.48	1.38e-10	2.58e-08	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:34999647	chr10:35314552~35336401:-
BRCA	cis	rs9880211	0.8	rs13433683	ENSG00000239213.4	NCK1-AS1	-6.48	1.38e-10	2.58e-08	-0.26	-0.2	Height;Body mass index;	chr3:136799828	chr3:136841726~136862054:-
BRCA	cis	rs4664293	0.585	rs35081473	ENSG00000226266.5	AC009961.3	6.48	1.38e-10	2.58e-08	0.24	0.2	Monocyte percentage of white cells;	chr2:159679970	chr2:159670708~159712435:-
BRCA	cis	rs4664293	0.605	rs7556888	ENSG00000226266.5	AC009961.3	6.48	1.38e-10	2.58e-08	0.24	0.2	Monocyte percentage of white cells;	chr2:159683750	chr2:159670708~159712435:-
BRCA	cis	rs539096	0.692	rs6669157	ENSG00000237950.1	RP11-7O11.3	6.48	1.38e-10	2.58e-08	0.23	0.2	Intelligence (multi-trait analysis);	chr1:43751205	chr1:43944370~43946551:-
BRCA	cis	rs4950322	0.515	rs72691016	ENSG00000278811.3	LINC00624	6.48	1.38e-10	2.58e-08	0.25	0.2	Protein quantitative trait loci;	chr1:147245375	chr1:147258885~147517875:-
BRCA	cis	rs11098499	0.863	rs11098532	ENSG00000249244.1	RP11-548H18.2	6.48	1.38e-10	2.58e-08	0.24	0.2	Corneal astigmatism;	chr4:119569571	chr4:119391831~119395335:-
BRCA	cis	rs875971	0.545	rs4718348	ENSG00000236529.1	RP13-254B10.1	6.48	1.38e-10	2.59e-08	0.25	0.2	Aortic root size;	chr7:66441589	chr7:65840212~65840596:+
BRCA	cis	rs66887589	0.616	rs10032299	ENSG00000245958.5	RP11-33B1.1	-6.48	1.38e-10	2.59e-08	-0.18	-0.2	Diastolic blood pressure;	chr4:119285264	chr4:119454791~119552025:+
BRCA	cis	rs202072	0.585	rs536208	ENSG00000272379.1	RP1-257A7.5	6.48	1.39e-10	2.59e-08	0.31	0.2	HIV-1 viral setpoint;	chr6:13256715	chr6:13290018~13290490:-
BRCA	cis	rs17213965	0.852	rs4781692	ENSG00000260872.1	RP11-680G24.5	6.48	1.39e-10	2.59e-08	0.29	0.2	Waist-hip ratio;	chr16:15784296	chr16:15018106~15020488:-
BRCA	cis	rs8114671	0.805	rs6060168	ENSG00000269202.1	RP4-614O4.12	-6.48	1.39e-10	2.59e-08	-0.2	-0.2	Height;	chr20:35033214	chr20:35201747~35203288:-
BRCA	cis	rs860818	1	rs858282	ENSG00000226816.2	AC005082.12	6.48	1.39e-10	2.59e-08	0.46	0.2	Initial pursuit acceleration;	chr7:23210416	chr7:23206013~23208045:+
BRCA	cis	rs7246657	0.943	rs4802766	ENSG00000226686.6	LINC01535	-6.48	1.39e-10	2.59e-08	-0.3	-0.2	Coronary artery calcification;	chr19:37491031	chr19:37251912~37265535:+
BRCA	cis	rs7182621	0.639	rs1561047	ENSG00000182397.13	DNM1P46	6.48	1.39e-10	2.6e-08	0.25	0.2	Colonoscopy-negative controls vs population controls;	chr15:99874606	chr15:99790156~99806927:-
BRCA	cis	rs673078	0.607	rs10082823	ENSG00000275409.1	RP11-131L12.4	-6.48	1.39e-10	2.6e-08	-0.24	-0.2	Glucose homeostasis traits;	chr12:118365386	chr12:118430147~118430699:+
BRCA	cis	rs4950322	0.57	rs2354428	ENSG00000278811.3	LINC00624	6.48	1.39e-10	2.6e-08	0.27	0.2	Protein quantitative trait loci;	chr1:147277512	chr1:147258885~147517875:-
BRCA	cis	rs12439619	1	rs35152457	ENSG00000259429.4	UBE2Q2P2	-6.48	1.4e-10	2.61e-08	-0.21	-0.2	Intelligence (multi-trait analysis);	chr15:82254207	chr15:82355142~82420075:+
BRCA	cis	rs73193808	1	rs8127464	ENSG00000215533.7	LINC00189	-6.48	1.4e-10	2.61e-08	-0.28	-0.2	Coronary artery disease;	chr21:29187381	chr21:29193480~29288205:+
BRCA	cis	rs2337406	1	rs10459466	ENSG00000211974.3	IGHV2-70	-6.48	1.4e-10	2.61e-08	-0.27	-0.2	Alzheimer's disease (late onset);	chr14:106689255	chr14:106723574~106724093:-
BRCA	cis	rs420259	0.516	rs7199108	ENSG00000260136.4	CTD-2270L9.4	-6.48	1.4e-10	2.61e-08	-0.2	-0.2	Bipolar disorder;	chr16:23537480	chr16:23452758~23457606:+
BRCA	cis	rs12594515	1	rs8032361	ENSG00000259200.1	RP11-718O11.1	-6.48	1.4e-10	2.61e-08	-0.22	-0.2	Weight;Waist circumference;	chr15:45696355	chr15:45705078~45931069:+
BRCA	cis	rs4713118	0.513	rs149950	ENSG00000204709.4	LINC01556	6.48	1.4e-10	2.61e-08	0.27	0.2	Parkinson's disease;	chr6:28065261	chr6:28943877~28944537:+
BRCA	cis	rs4713118	0.513	rs149951	ENSG00000204709.4	LINC01556	6.48	1.4e-10	2.61e-08	0.27	0.2	Parkinson's disease;	chr6:28065309	chr6:28943877~28944537:+
BRCA	cis	rs2243480	1	rs1499613	ENSG00000230295.1	RP11-458F8.2	6.48	1.4e-10	2.61e-08	0.26	0.2	Diabetic kidney disease;	chr7:66265873	chr7:66880708~66882981:+
BRCA	cis	rs420259	0.516	rs2106456	ENSG00000260136.4	CTD-2270L9.4	-6.48	1.4e-10	2.61e-08	-0.2	-0.2	Bipolar disorder;	chr16:23539610	chr16:23452758~23457606:+
BRCA	cis	rs4950322	0.634	rs7542951	ENSG00000278811.3	LINC00624	6.48	1.4e-10	2.62e-08	0.27	0.2	Protein quantitative trait loci;	chr1:147340308	chr1:147258885~147517875:-
BRCA	cis	rs11976180	1	rs11975942	ENSG00000273234.1	OR2A13P	-6.48	1.4e-10	2.62e-08	-0.27	-0.2	Obesity-related traits;	chr7:144043487	chr7:144142009~144142938:+
BRCA	cis	rs172166	0.694	rs1770131	ENSG00000216901.1	AL022393.7	6.48	1.4e-10	2.62e-08	0.26	0.2	Cardiac Troponin-T levels;	chr6:28118635	chr6:28176188~28176674:+
BRCA	cis	rs1124769	0.748	rs17703518	ENSG00000259378.1	DCAF13P3	6.48	1.4e-10	2.62e-08	0.28	0.2	Cognitive performance;	chr15:51063746	chr15:50944663~50945996:+
BRCA	cis	rs6583826	0.758	rs11187072	ENSG00000236493.2	EIF2S2P3	6.48	1.4e-10	2.62e-08	0.26	0.2	Type 2 diabetes;	chr10:92564652	chr10:92668745~92669743:-
BRCA	cis	rs9527	0.614	rs4919691	ENSG00000213061.2	PFN1P11	6.48	1.4e-10	2.62e-08	0.26	0.2	Arsenic metabolism;	chr10:102864718	chr10:102838011~102845473:-
BRCA	cis	rs2439831	0.85	rs7179388	ENSG00000275601.1	AC011330.13	-6.48	1.41e-10	2.63e-08	-0.33	-0.2	Lung cancer in ever smokers;	chr15:43831747	chr15:43642389~43643023:-
BRCA	cis	rs42648	0.596	rs194513	ENSG00000225498.1	AC002064.5	6.48	1.41e-10	2.63e-08	0.18	0.2	Homocysteine levels;	chr7:90220856	chr7:90312496~90322592:+
BRCA	cis	rs4713118	0.911	rs2394000	ENSG00000220721.1	OR1F12	6.48	1.41e-10	2.63e-08	0.25	0.2	Parkinson's disease;	chr6:27719212	chr6:28073316~28074233:+
BRCA	cis	rs4713118	0.955	rs9393847	ENSG00000220721.1	OR1F12	6.48	1.41e-10	2.63e-08	0.25	0.2	Parkinson's disease;	chr6:27720194	chr6:28073316~28074233:+
BRCA	cis	rs17301013	0.606	rs28831202	ENSG00000227373.4	RP11-160H22.5	6.48	1.41e-10	2.63e-08	0.29	0.2	Systemic lupus erythematosus;	chr1:174099231	chr1:174115300~174160004:-
BRCA	cis	rs12594515	1	rs12906442	ENSG00000259200.1	RP11-718O11.1	-6.48	1.41e-10	2.63e-08	-0.22	-0.2	Weight;Waist circumference;	chr15:45693056	chr15:45705078~45931069:+
BRCA	cis	rs2243480	1	rs781150	ENSG00000228409.4	CCT6P1	6.48	1.41e-10	2.64e-08	0.27	0.2	Diabetic kidney disease;	chr7:66015986	chr7:65751142~65763354:+
BRCA	cis	rs2243480	1	rs313798	ENSG00000228409.4	CCT6P1	6.48	1.41e-10	2.64e-08	0.27	0.2	Diabetic kidney disease;	chr7:66028044	chr7:65751142~65763354:+
BRCA	cis	rs1061377	0.71	rs12503506	ENSG00000249685.1	RP11-360F5.3	6.48	1.41e-10	2.64e-08	0.24	0.2	Uric acid levels;	chr4:39082553	chr4:39133913~39135608:+
BRCA	cis	rs6740322	0.895	rs6710656	ENSG00000234936.1	AC010883.5	6.48	1.41e-10	2.64e-08	0.22	0.2	Coronary artery disease;	chr2:43339802	chr2:43229573~43233394:+
BRCA	cis	rs228614	0.51	rs223451	ENSG00000251288.2	RP11-10L12.2	-6.48	1.41e-10	2.64e-08	-0.23	-0.2	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102791032	chr4:102751401~102752641:+
BRCA	cis	rs228614	0.51	rs223450	ENSG00000251288.2	RP11-10L12.2	-6.48	1.41e-10	2.64e-08	-0.23	-0.2	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102791052	chr4:102751401~102752641:+
BRCA	cis	rs16846053	0.515	rs1399650	ENSG00000227403.1	AC009299.3	-6.48	1.41e-10	2.64e-08	-0.34	-0.2	Blood osmolality (transformed sodium);	chr2:161695208	chr2:161244739~161249050:+
BRCA	cis	rs73173548	0.528	rs80083342	ENSG00000247828.6	TMEM161B-AS1	6.48	1.42e-10	2.64e-08	0.27	0.2	Macular telangiectasia type 2;	chr5:88476921	chr5:88268895~88436685:+
BRCA	cis	rs10515750	0.5	rs2288069	ENSG00000251405.2	CTB-109A12.1	6.48	1.42e-10	2.65e-08	0.3	0.2	Lung function (FEV1/FVC);	chr5:157285187	chr5:157362615~157460078:-
BRCA	cis	rs10129255	0.957	rs10141009	ENSG00000211972.2	IGHV3-66	6.48	1.42e-10	2.65e-08	0.15	0.2	Kawasaki disease;	chr14:106776695	chr14:106675017~106675544:-
BRCA	cis	rs13287066	0.692	rs4563950	ENSG00000227603.1	RP11-165J3.6	6.48	1.42e-10	2.65e-08	0.21	0.2	Intelligence (multi-trait analysis);	chr9:93405359	chr9:93435332~93437121:-
BRCA	cis	rs9807989	0.839	rs4988956	ENSG00000234389.1	AC007278.3	6.48	1.42e-10	2.65e-08	0.18	0.2	Asthma;	chr2:102351547	chr2:102438713~102440475:+
BRCA	cis	rs2337406	1	rs1961901	ENSG00000211974.3	IGHV2-70	-6.48	1.42e-10	2.65e-08	-0.24	-0.2	Alzheimer's disease (late onset);	chr14:106680856	chr14:106723574~106724093:-
BRCA	cis	rs62025270	0.547	rs8035496	ENSG00000202081.1	RNU6-1280P	-6.48	1.42e-10	2.65e-08	-0.25	-0.2	Idiopathic pulmonary fibrosis;	chr15:85591101	chr15:85651522~85651628:-
BRCA	cis	rs2179367	0.568	rs6932778	ENSG00000231760.4	RP11-350J20.5	6.48	1.42e-10	2.66e-08	0.3	0.2	Dupuytren's disease;	chr6:149328293	chr6:149796151~149826294:-
BRCA	cis	rs2836950	0.527	rs2836958	ENSG00000238141.2	BRWD1-AS1	-6.48	1.42e-10	2.66e-08	-0.22	-0.2	Menarche (age at onset);	chr21:39251600	chr21:39315707~39323218:+
BRCA	cis	rs12594515	1	rs7162201	ENSG00000259200.1	RP11-718O11.1	-6.48	1.42e-10	2.66e-08	-0.22	-0.2	Weight;Waist circumference;	chr15:45700460	chr15:45705078~45931069:+
BRCA	cis	rs858239	0.932	rs858275	ENSG00000230042.1	AK3P3	-6.48	1.42e-10	2.66e-08	-0.22	-0.2	Cerebrospinal fluid biomarker levels;	chr7:23254525	chr7:23129178~23129841:+
BRCA	cis	rs9291683	0.632	rs11734786	ENSG00000250413.1	RP11-448G15.1	-6.48	1.43e-10	2.66e-08	-0.26	-0.2	Bone mineral density;	chr4:10039875	chr4:10006482~10009725:+
BRCA	cis	rs10740039	0.732	rs10160182	ENSG00000254271.1	RP11-131N11.4	6.48	1.43e-10	2.66e-08	0.27	0.2	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60602693	chr10:60734342~60741828:+
BRCA	cis	rs10740039	0.768	rs10159993	ENSG00000254271.1	RP11-131N11.4	6.48	1.43e-10	2.66e-08	0.27	0.2	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60602788	chr10:60734342~60741828:+
BRCA	cis	rs7520050	0.966	rs785471	ENSG00000280836.1	AL355480.1	6.48	1.43e-10	2.66e-08	0.23	0.2	Reticulocyte count;Red blood cell count;	chr1:46053005	chr1:45581219~45581321:-
BRCA	cis	rs7746199	0.673	rs72845046	ENSG00000220721.1	OR1F12	6.48	1.43e-10	2.67e-08	0.47	0.2	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27607489	chr6:28073316~28074233:+
BRCA	cis	rs7131987	0.683	rs3782511	ENSG00000257176.2	RP11-996F15.2	-6.48	1.43e-10	2.67e-08	-0.25	-0.2	QT interval;	chr12:29343291	chr12:29280418~29317848:-
BRCA	cis	rs34779708	0.931	rs4934709	ENSG00000271335.4	RP11-324I22.4	-6.48	1.43e-10	2.67e-08	-0.2	-0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35050396	chr10:35314552~35336401:-
BRCA	cis	rs6860806	0.507	rs582490	ENSG00000233006.5	AC034220.3	-6.48	1.43e-10	2.67e-08	-0.16	-0.2	Breast cancer;	chr5:132374403	chr5:132311285~132369916:-
BRCA	cis	rs2243480	1	rs1723267	ENSG00000228409.4	CCT6P1	6.48	1.43e-10	2.67e-08	0.27	0.2	Diabetic kidney disease;	chr7:66008327	chr7:65751142~65763354:+
BRCA	cis	rs2243480	0.615	rs34363376	ENSG00000232546.1	RP11-458F8.1	-6.48	1.43e-10	2.68e-08	-0.27	-0.2	Diabetic kidney disease;	chr7:66474549	chr7:66848496~66858136:+
BRCA	cis	rs11671005	0.737	rs11673101	ENSG00000252334.1	RNU6-1337P	6.48	1.43e-10	2.68e-08	0.33	0.2	Mean platelet volume;	chr19:58483686	chr19:58483749~58483843:-
BRCA	cis	rs9992667	0.826	rs7656708	ENSG00000231160.8	KLF3-AS1	6.48	1.44e-10	2.68e-08	0.25	0.2	Eosinophil percentage of granulocytes;	chr4:38640041	chr4:38612701~38664883:-
BRCA	cis	rs9992667	0.744	rs7657152	ENSG00000231160.8	KLF3-AS1	6.48	1.44e-10	2.68e-08	0.25	0.2	Eosinophil percentage of granulocytes;	chr4:38640315	chr4:38612701~38664883:-
BRCA	cis	rs1440410	0.835	rs9790822	ENSG00000250326.1	RP11-284M14.1	-6.48	1.44e-10	2.68e-08	-0.22	-0.2	Ischemic stroke;	chr4:143130748	chr4:142933195~143184861:-
BRCA	cis	rs1440410	0.835	rs4323054	ENSG00000250326.1	RP11-284M14.1	-6.48	1.44e-10	2.68e-08	-0.22	-0.2	Ischemic stroke;	chr4:143130970	chr4:142933195~143184861:-
BRCA	cis	rs7246657	0.943	rs10422074	ENSG00000267422.1	CTD-2554C21.1	-6.48	1.44e-10	2.68e-08	-0.3	-0.2	Coronary artery calcification;	chr19:37403334	chr19:37779686~37792865:+
BRCA	cis	rs11722228	0.522	rs62286604	ENSG00000261490.1	RP11-448G15.3	6.48	1.44e-10	2.68e-08	0.22	0.2	Urate levels;Serum uric acid levels;Gout;	chr4:10129537	chr4:10068089~10073019:-
BRCA	cis	rs6142102	0.961	rs6059651	ENSG00000275784.1	RP5-1125A11.6	-6.48	1.44e-10	2.68e-08	-0.24	-0.2	Skin pigmentation;	chr20:34057246	chr20:33989480~33991818:-
BRCA	cis	rs227275	0.556	rs223426	ENSG00000251288.2	RP11-10L12.2	-6.48	1.44e-10	2.69e-08	-0.23	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102801330	chr4:102751401~102752641:+
BRCA	cis	rs227275	0.554	rs223425	ENSG00000251288.2	RP11-10L12.2	-6.48	1.44e-10	2.69e-08	-0.23	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102802836	chr4:102751401~102752641:+
BRCA	cis	rs2834288	0.535	rs13049489	ENSG00000273102.1	AP000569.9	6.48	1.44e-10	2.69e-08	0.22	0.2	Gut microbiota (bacterial taxa);	chr21:33961054	chr21:33967101~33968573:-
BRCA	cis	rs7914558	0.966	rs4532960	ENSG00000213061.2	PFN1P11	6.48	1.44e-10	2.69e-08	0.26	0.2	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102907649	chr10:102838011~102845473:-
BRCA	cis	rs7914558	0.966	rs10786724	ENSG00000213061.2	PFN1P11	6.48	1.44e-10	2.69e-08	0.26	0.2	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102909185	chr10:102838011~102845473:-
BRCA	cis	rs8114671	0.935	rs633198	ENSG00000269202.1	RP4-614O4.12	6.48	1.44e-10	2.69e-08	0.2	0.2	Height;	chr20:35190631	chr20:35201747~35203288:-
BRCA	cis	rs301901	0.796	rs4869527	ENSG00000250155.1	CTD-2353F22.1	6.48	1.44e-10	2.7e-08	0.22	0.2	Height;	chr5:37533964	chr5:36666214~36725195:-
BRCA	cis	rs2015599	0.549	rs7134187	ENSG00000257176.2	RP11-996F15.2	-6.48	1.45e-10	2.7e-08	-0.23	-0.2	Platelet count;Mean platelet volume;	chr12:29294113	chr12:29280418~29317848:-
BRCA	cis	rs34779708	0.966	rs11599606	ENSG00000271335.4	RP11-324I22.4	6.48	1.45e-10	2.7e-08	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35117698	chr10:35314552~35336401:-
BRCA	cis	rs6504622	0.875	rs4968250	ENSG00000262879.4	RP11-156P1.3	6.48	1.45e-10	2.7e-08	0.2	0.2	Orofacial clefts;	chr17:46967985	chr17:46984045~47100323:-
BRCA	cis	rs442309	0.583	rs10995307	ENSG00000238280.1	RP11-436D10.3	6.48	1.45e-10	2.7e-08	0.25	0.2	Vogt-Koyanagi-Harada syndrome;	chr10:62792482	chr10:62793562~62805887:-
BRCA	cis	rs67981189	0.896	rs34763296	ENSG00000269927.1	RP6-91H8.3	6.48	1.45e-10	2.7e-08	0.24	0.2	Schizophrenia;	chr14:71083458	chr14:71141125~71143253:-
BRCA	cis	rs67340775	0.541	rs200965	ENSG00000220721.1	OR1F12	6.48	1.45e-10	2.7e-08	0.3	0.2	Lung cancer in ever smokers;	chr6:27898606	chr6:28073316~28074233:+
BRCA	cis	rs301901	0.828	rs56007618	ENSG00000250155.1	CTD-2353F22.1	6.48	1.45e-10	2.71e-08	0.22	0.2	Height;	chr5:37475788	chr5:36666214~36725195:-
BRCA	cis	rs10129255	0.912	rs6576227	ENSG00000211972.2	IGHV3-66	6.48	1.45e-10	2.71e-08	0.15	0.2	Kawasaki disease;	chr14:106778202	chr14:106675017~106675544:-
BRCA	cis	rs10129255	0.957	rs6576228	ENSG00000211972.2	IGHV3-66	6.48	1.45e-10	2.71e-08	0.15	0.2	Kawasaki disease;	chr14:106778401	chr14:106675017~106675544:-
BRCA	cis	rs4948102	0.599	rs2230197	ENSG00000226278.1	PSPHP1	-6.48	1.45e-10	2.71e-08	-0.22	-0.2	Plasma homocysteine levels (post-methionine load test);	chr7:56058667	chr7:55764797~55773288:+
BRCA	cis	rs2880765	0.525	rs2062234	ENSG00000259295.5	CSPG4P12	6.48	1.45e-10	2.71e-08	0.26	0.2	Coronary artery disease;	chr15:85511259	chr15:85191438~85213905:+
BRCA	cis	rs13178541	0.81	rs11951836	ENSG00000250378.1	RP11-119J18.1	-6.48	1.45e-10	2.71e-08	-0.27	-0.2	IgG glycosylation;	chr5:135816068	chr5:135812667~135826582:+
BRCA	cis	rs1707322	0.752	rs4660880	ENSG00000281133.1	AL355480.3	-6.48	1.46e-10	2.72e-08	-0.25	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45645368	chr1:45580892~45580996:-
BRCA	cis	rs2243480	1	rs466983	ENSG00000232546.1	RP11-458F8.1	-6.48	1.46e-10	2.72e-08	-0.27	-0.2	Diabetic kidney disease;	chr7:66055509	chr7:66848496~66858136:+
BRCA	cis	rs4639966	0.836	rs10892282	ENSG00000255239.1	AP002954.6	6.47	1.46e-10	2.72e-08	0.26	0.2	Systemic lupus erythematosus;	chr11:118757069	chr11:118688039~118690600:-
BRCA	cis	rs67340775	0.541	rs200968	ENSG00000220721.1	OR1F12	6.47	1.46e-10	2.73e-08	0.29	0.2	Lung cancer in ever smokers;	chr6:27891790	chr6:28073316~28074233:+
BRCA	cis	rs12908161	0.515	rs12907646	ENSG00000225151.9	GOLGA2P7	-6.47	1.46e-10	2.73e-08	-0.28	-0.2	Schizophrenia;	chr15:84860265	chr15:84199311~84230136:-
BRCA	cis	rs4237845	0.742	rs6650219	ENSG00000257159.1	RP11-58A17.3	6.47	1.47e-10	2.73e-08	0.22	0.2	Intelligence (multi-trait analysis);	chr12:57895317	chr12:57967058~57968399:+
BRCA	cis	rs34779708	0.931	rs7908573	ENSG00000271335.4	RP11-324I22.4	6.47	1.47e-10	2.73e-08	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35020585	chr10:35314552~35336401:-
BRCA	cis	rs34779708	0.931	rs17583009	ENSG00000271335.4	RP11-324I22.4	6.47	1.47e-10	2.73e-08	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35031987	chr10:35314552~35336401:-
BRCA	cis	rs34779708	0.898	rs11595898	ENSG00000271335.4	RP11-324I22.4	6.47	1.47e-10	2.73e-08	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35037335	chr10:35314552~35336401:-
BRCA	cis	rs34779708	0.931	rs35886556	ENSG00000271335.4	RP11-324I22.4	6.47	1.47e-10	2.73e-08	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35046057	chr10:35314552~35336401:-
BRCA	cis	rs2834288	0.5	rs2051189	ENSG00000273102.1	AP000569.9	6.47	1.47e-10	2.74e-08	0.21	0.2	Gut microbiota (bacterial taxa);	chr21:33949712	chr21:33967101~33968573:-
BRCA	cis	rs4713118	0.621	rs9295755	ENSG00000219392.1	RP1-265C24.5	6.47	1.47e-10	2.74e-08	0.3	0.2	Parkinson's disease;	chr6:28065396	chr6:28115628~28116551:+
BRCA	cis	rs7937890	0.967	rs963212	ENSG00000251991.1	RNU7-49P	-6.47	1.47e-10	2.74e-08	-0.21	-0.2	Mitochondrial DNA levels;	chr11:14303186	chr11:14478892~14478953:+
BRCA	cis	rs1707322	0.686	rs2991987	ENSG00000281133.1	AL355480.3	6.47	1.47e-10	2.74e-08	0.25	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45615750	chr1:45580892~45580996:-
BRCA	cis	rs10129255	0.957	rs10142918	ENSG00000211972.2	IGHV3-66	6.47	1.47e-10	2.74e-08	0.15	0.2	Kawasaki disease;	chr14:106782206	chr14:106675017~106675544:-
BRCA	cis	rs904251	0.828	rs1757178	ENSG00000204110.6	RP1-153P14.8	6.47	1.47e-10	2.74e-08	0.21	0.2	Cognitive performance;	chr6:37518534	chr6:37507348~37535616:+
BRCA	cis	rs875971	0.545	rs7811204	ENSG00000273024.4	INTS4P2	-6.47	1.47e-10	2.74e-08	-0.25	-0.2	Aortic root size;	chr7:66387213	chr7:65647864~65715661:+
BRCA	cis	rs6723226	0.75	rs762019	ENSG00000276334.1	AL133243.1	6.47	1.47e-10	2.74e-08	0.23	0.2	Intelligence (multi-trait analysis);	chr2:32463533	chr2:32521927~32523547:+
BRCA	cis	rs1707322	0.752	rs7541962	ENSG00000281133.1	AL355480.3	-6.47	1.47e-10	2.74e-08	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45769445	chr1:45580892~45580996:-
BRCA	cis	rs7746199	0.736	rs67652222	ENSG00000220721.1	OR1F12	6.47	1.47e-10	2.75e-08	0.47	0.2	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27618441	chr6:28073316~28074233:+
BRCA	cis	rs12594515	1	rs8029209	ENSG00000259200.1	RP11-718O11.1	-6.47	1.47e-10	2.75e-08	-0.22	-0.2	Weight;Waist circumference;	chr15:45701291	chr15:45705078~45931069:+
BRCA	cis	rs2243480	0.901	rs73142137	ENSG00000232546.1	RP11-458F8.1	-6.47	1.47e-10	2.75e-08	-0.26	-0.2	Diabetic kidney disease;	chr7:65878455	chr7:66848496~66858136:+
BRCA	cis	rs2243480	1	rs13247184	ENSG00000232546.1	RP11-458F8.1	-6.47	1.47e-10	2.75e-08	-0.26	-0.2	Diabetic kidney disease;	chr7:65893941	chr7:66848496~66858136:+
BRCA	cis	rs2243480	1	rs35283677	ENSG00000232546.1	RP11-458F8.1	-6.47	1.47e-10	2.75e-08	-0.26	-0.2	Diabetic kidney disease;	chr7:65894246	chr7:66848496~66858136:+
BRCA	cis	rs2243480	1	rs35421653	ENSG00000232546.1	RP11-458F8.1	-6.47	1.47e-10	2.75e-08	-0.26	-0.2	Diabetic kidney disease;	chr7:65898442	chr7:66848496~66858136:+
BRCA	cis	rs67311347	0.544	rs2887965	ENSG00000223797.4	ENTPD3-AS1	-6.47	1.48e-10	2.75e-08	-0.21	-0.2	Renal cell carcinoma;	chr3:40292663	chr3:40313802~40453329:-
BRCA	cis	rs875971	0.571	rs78668714	ENSG00000273024.4	INTS4P2	-6.47	1.48e-10	2.75e-08	-0.25	-0.2	Aortic root size;	chr7:66474464	chr7:65647864~65715661:+
BRCA	cis	rs228614	0.536	rs223475	ENSG00000251288.2	RP11-10L12.2	-6.47	1.48e-10	2.75e-08	-0.23	-0.2	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102771986	chr4:102751401~102752641:+
BRCA	cis	rs228614	0.536	rs223474	ENSG00000251288.2	RP11-10L12.2	-6.47	1.48e-10	2.75e-08	-0.23	-0.2	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102772007	chr4:102751401~102752641:+
BRCA	cis	rs237743	1	rs6512577	ENSG00000222365.1	SNORD12B	-6.47	1.48e-10	2.75e-08	-0.26	-0.2	Height;	chr20:49249247	chr20:49280319~49280409:+
BRCA	cis	rs11742741	0.676	rs13155915	ENSG00000248874.4	C5orf17	-6.47	1.48e-10	2.75e-08	-0.25	-0.2	Educational attainment;	chr5:24191881	chr5:23951348~24178263:+
BRCA	cis	rs11742741	0.702	rs13154927	ENSG00000248874.4	C5orf17	-6.47	1.48e-10	2.75e-08	-0.25	-0.2	Educational attainment;	chr5:24191972	chr5:23951348~24178263:+
BRCA	cis	rs7246657	0.943	rs1559229	ENSG00000226686.6	LINC01535	-6.47	1.48e-10	2.76e-08	-0.29	-0.2	Coronary artery calcification;	chr19:37385295	chr19:37251912~37265535:+
BRCA	cis	rs7246657	0.882	rs6508719	ENSG00000226686.6	LINC01535	-6.47	1.48e-10	2.76e-08	-0.29	-0.2	Coronary artery calcification;	chr19:37386517	chr19:37251912~37265535:+
BRCA	cis	rs875971	1	rs6979382	ENSG00000224316.1	RP11-479O9.2	6.47	1.48e-10	2.76e-08	0.2	0.2	Aortic root size;	chr7:66421388	chr7:65773620~65802067:+
BRCA	cis	rs875971	1	rs6961990	ENSG00000224316.1	RP11-479O9.2	6.47	1.48e-10	2.76e-08	0.2	0.2	Aortic root size;	chr7:66423583	chr7:65773620~65802067:+
BRCA	cis	rs7617773	0.817	rs6796490	ENSG00000228638.1	FCF1P2	-6.47	1.48e-10	2.76e-08	-0.2	-0.2	Coronary artery disease;	chr3:48195614	chr3:48290793~48291375:-
BRCA	cis	rs9880211	0.718	rs35320690	ENSG00000239213.4	NCK1-AS1	-6.47	1.48e-10	2.76e-08	-0.24	-0.2	Height;Body mass index;	chr3:136213652	chr3:136841726~136862054:-
BRCA	cis	rs1823913	0.622	rs55787447	ENSG00000280083.1	RP11-317J9.1	-6.47	1.48e-10	2.76e-08	-0.22	-0.2	Obesity-related traits;	chr2:191288596	chr2:191154118~191156070:-
BRCA	cis	rs17253792	0.822	rs80085988	ENSG00000186615.9	KTN1-AS1	-6.47	1.48e-10	2.76e-08	-0.38	-0.2	Putamen volume;	chr14:55629455	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs77676035	ENSG00000186615.9	KTN1-AS1	-6.47	1.48e-10	2.76e-08	-0.38	-0.2	Putamen volume;	chr14:55629511	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs75555677	ENSG00000186615.9	KTN1-AS1	-6.47	1.48e-10	2.76e-08	-0.38	-0.2	Putamen volume;	chr14:55629711	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs2274075	ENSG00000186615.9	KTN1-AS1	-6.47	1.48e-10	2.76e-08	-0.38	-0.2	Putamen volume;	chr14:55630013	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.731	rs28587929	ENSG00000186615.9	KTN1-AS1	-6.47	1.48e-10	2.76e-08	-0.38	-0.2	Putamen volume;	chr14:55630774	chr14:55499278~55580110:-
BRCA	cis	rs113835537	0.597	rs7939759	ENSG00000255517.5	CTD-3074O7.5	-6.47	1.48e-10	2.76e-08	-0.25	-0.2	Airway imaging phenotypes;	chr11:66570493	chr11:66473490~66480233:-
BRCA	cis	rs12468226	0.938	rs56684065	ENSG00000226261.1	AC064836.3	6.47	1.48e-10	2.76e-08	0.33	0.2	Urate levels;	chr2:202289528	chr2:202336024~202336727:-
BRCA	cis	rs12468226	0.938	rs1474001	ENSG00000226261.1	AC064836.3	6.47	1.48e-10	2.76e-08	0.33	0.2	Urate levels;	chr2:202290230	chr2:202336024~202336727:-
BRCA	cis	rs12468226	0.938	rs76664732	ENSG00000226261.1	AC064836.3	6.47	1.48e-10	2.76e-08	0.33	0.2	Urate levels;	chr2:202296298	chr2:202336024~202336727:-
BRCA	cis	rs1499614	1	rs1638731	ENSG00000229886.1	RP5-1132H15.3	6.47	1.49e-10	2.77e-08	0.35	0.2	Gout;	chr7:66679692	chr7:66025126~66031544:-
BRCA	cis	rs1499614	1	rs1882655	ENSG00000229886.1	RP5-1132H15.3	-6.47	1.49e-10	2.77e-08	-0.35	-0.2	Gout;	chr7:66682070	chr7:66025126~66031544:-
BRCA	cis	rs1499614	0.831	rs3800822	ENSG00000229886.1	RP5-1132H15.3	-6.47	1.49e-10	2.77e-08	-0.35	-0.2	Gout;	chr7:66682162	chr7:66025126~66031544:-
BRCA	cis	rs237743	1	rs9753608	ENSG00000222365.1	SNORD12B	-6.47	1.49e-10	2.77e-08	-0.26	-0.2	Height;	chr20:49220669	chr20:49280319~49280409:+
BRCA	cis	rs710913	0.745	rs1180334	ENSG00000237624.1	OXCT2P1	-6.47	1.49e-10	2.77e-08	-0.23	-0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39555972	chr1:39514956~39516490:+
BRCA	cis	rs12468226	0.938	rs115418918	ENSG00000226261.1	AC064836.3	6.47	1.49e-10	2.77e-08	0.33	0.2	Urate levels;	chr2:202315145	chr2:202336024~202336727:-
BRCA	cis	rs42648	0.596	rs6465251	ENSG00000225498.1	AC002064.5	6.47	1.49e-10	2.77e-08	0.18	0.2	Homocysteine levels;	chr7:90218567	chr7:90312496~90322592:+
BRCA	cis	rs919433	0.783	rs55725278	ENSG00000231621.1	AC013264.2	-6.47	1.49e-10	2.78e-08	-0.19	-0.2	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197373499	chr2:197197991~197199273:+
BRCA	cis	rs919433	0.783	rs787980	ENSG00000231621.1	AC013264.2	-6.47	1.49e-10	2.78e-08	-0.19	-0.2	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197374501	chr2:197197991~197199273:+
BRCA	cis	rs301901	0.634	rs4869429	ENSG00000250155.1	CTD-2353F22.1	6.47	1.49e-10	2.78e-08	0.22	0.2	Height;	chr5:37407777	chr5:36666214~36725195:-
BRCA	cis	rs13113518	0.812	rs4865001	ENSG00000223305.1	RN7SKP30	6.47	1.49e-10	2.78e-08	0.24	0.2	Height;	chr4:55490176	chr4:55540502~55540835:-
BRCA	cis	rs13113518	0.756	rs7658446	ENSG00000223305.1	RN7SKP30	6.47	1.49e-10	2.78e-08	0.24	0.2	Height;	chr4:55495262	chr4:55540502~55540835:-
BRCA	cis	rs4713118	0.513	rs149954	ENSG00000204709.4	LINC01556	6.47	1.49e-10	2.78e-08	0.27	0.2	Parkinson's disease;	chr6:28067468	chr6:28943877~28944537:+
BRCA	cis	rs7665090	1	rs4586937	ENSG00000246560.2	RP11-10L12.4	-6.47	1.49e-10	2.78e-08	-0.21	-0.2	Primary biliary cholangitis;	chr4:102635305	chr4:102828055~102844075:+
BRCA	cis	rs17772222	0.682	rs61542857	ENSG00000258983.2	RP11-507K2.2	6.47	1.5e-10	2.78e-08	0.2	0.2	Coronary artery calcification;	chr14:88470358	chr14:88499334~88515502:+
BRCA	cis	rs17772222	0.637	rs7161660	ENSG00000258983.2	RP11-507K2.2	6.47	1.5e-10	2.78e-08	0.2	0.2	Coronary artery calcification;	chr14:88471832	chr14:88499334~88515502:+
BRCA	cis	rs6840360	0.642	rs7666571	ENSG00000270265.1	RP11-731D1.4	-6.47	1.5e-10	2.79e-08	-0.22	-0.2	Intelligence (multi-trait analysis);	chr4:151522121	chr4:151333775~151353224:-
BRCA	cis	rs875971	0.545	rs2420456	ENSG00000273024.4	INTS4P2	-6.47	1.5e-10	2.79e-08	-0.25	-0.2	Aortic root size;	chr7:66280619	chr7:65647864~65715661:+
BRCA	cis	rs7937890	1	rs7937890	ENSG00000251991.1	RNU7-49P	6.47	1.5e-10	2.79e-08	0.21	0.2	Mitochondrial DNA levels;	chr11:14374939	chr11:14478892~14478953:+
BRCA	cis	rs467650	1	rs467650	ENSG00000248489.1	CTD-2007H13.3	6.47	1.5e-10	2.79e-08	0.22	0.2	Venous thromboembolism (SNP x SNP interaction);	chr5:98633749	chr5:98929171~98995013:+
BRCA	cis	rs17253792	0.822	rs76472022	ENSG00000186615.9	KTN1-AS1	-6.47	1.51e-10	2.8e-08	-0.4	-0.2	Putamen volume;	chr14:55586942	chr14:55499278~55580110:-
BRCA	cis	rs9291683	0.551	rs62295971	ENSG00000250413.1	RP11-448G15.1	-6.47	1.51e-10	2.8e-08	-0.25	-0.2	Bone mineral density;	chr4:9976518	chr4:10006482~10009725:+
BRCA	cis	rs1707322	1	rs785504	ENSG00000281133.1	AL355480.3	6.47	1.51e-10	2.8e-08	0.25	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46130024	chr1:45580892~45580996:-
BRCA	cis	rs2688608	0.592	rs3933085	ENSG00000271816.1	BMS1P4	6.47	1.51e-10	2.8e-08	0.19	0.2	Inflammatory bowel disease;	chr10:73723573	chr10:73699151~73730487:-
BRCA	cis	rs6142102	0.651	rs6059692	ENSG00000275784.1	RP5-1125A11.6	6.47	1.51e-10	2.81e-08	0.24	0.2	Skin pigmentation;	chr20:34158397	chr20:33989480~33991818:-
BRCA	cis	rs7809950	0.678	rs17153981	ENSG00000238832.1	snoU109	-6.47	1.51e-10	2.81e-08	-0.29	-0.2	Coronary artery disease;	chr7:107281661	chr7:107603363~107603507:+
BRCA	cis	rs2243480	1	rs781156	ENSG00000229886.1	RP5-1132H15.3	6.47	1.51e-10	2.81e-08	0.34	0.2	Diabetic kidney disease;	chr7:66014154	chr7:66025126~66031544:-
BRCA	cis	rs2243480	1	rs451396	ENSG00000229886.1	RP5-1132H15.3	6.47	1.51e-10	2.81e-08	0.34	0.2	Diabetic kidney disease;	chr7:66019087	chr7:66025126~66031544:-
BRCA	cis	rs2243480	1	rs1715235	ENSG00000229886.1	RP5-1132H15.3	6.47	1.51e-10	2.81e-08	0.34	0.2	Diabetic kidney disease;	chr7:66023407	chr7:66025126~66031544:-
BRCA	cis	rs875971	1	rs697970	ENSG00000224316.1	RP11-479O9.2	-6.47	1.51e-10	2.81e-08	-0.2	-0.2	Aortic root size;	chr7:66095065	chr7:65773620~65802067:+
BRCA	cis	rs7674212	0.581	rs13150953	ENSG00000251288.2	RP11-10L12.2	-6.47	1.51e-10	2.82e-08	-0.24	-0.2	Type 2 diabetes;	chr4:103021341	chr4:102751401~102752641:+
BRCA	cis	rs7674212	0.556	rs13151569	ENSG00000251288.2	RP11-10L12.2	-6.47	1.51e-10	2.82e-08	-0.24	-0.2	Type 2 diabetes;	chr4:103021633	chr4:102751401~102752641:+
BRCA	cis	rs34779708	0.931	rs4934704	ENSG00000271335.4	RP11-324I22.4	6.47	1.51e-10	2.82e-08	0.2	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35043236	chr10:35314552~35336401:-
BRCA	cis	rs858239	1	rs156421	ENSG00000230042.1	AK3P3	-6.47	1.51e-10	2.82e-08	-0.22	-0.2	Cerebrospinal fluid biomarker levels;	chr7:23272868	chr7:23129178~23129841:+
BRCA	cis	rs78456975	0.527	rs10206020	ENSG00000231482.2	AC141930.2	-6.47	1.52e-10	2.82e-08	-0.26	-0.2	Placebo response in major depressive disorder (% change in symptom score);	chr2:1554155	chr2:1572554~1580311:-
BRCA	cis	rs1707322	0.896	rs809774	ENSG00000281133.1	AL355480.3	6.47	1.52e-10	2.82e-08	0.25	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46094572	chr1:45580892~45580996:-
BRCA	cis	rs8005677	1	rs4982709	ENSG00000257285.4	RP11-298I3.1	6.47	1.52e-10	2.82e-08	0.22	0.2	Cognitive ability (multi-trait analysis);	chr14:22925490	chr14:22929609~22955562:+
BRCA	cis	rs11722779	0.815	rs223347	ENSG00000251288.2	RP11-10L12.2	-6.47	1.52e-10	2.83e-08	-0.23	-0.2	Schizophrenia;	chr4:102858815	chr4:102751401~102752641:+
BRCA	cis	rs7746199	0.673	rs72847313	ENSG00000220721.1	OR1F12	6.47	1.52e-10	2.83e-08	0.47	0.2	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27762303	chr6:28073316~28074233:+
BRCA	cis	rs7746199	0.611	rs17750747	ENSG00000220721.1	OR1F12	6.47	1.52e-10	2.83e-08	0.47	0.2	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27762555	chr6:28073316~28074233:+
BRCA	cis	rs5015933	0.801	rs4837016	ENSG00000232630.1	PRPS1P2	6.47	1.52e-10	2.83e-08	0.19	0.2	Body mass index;	chr9:125379530	chr9:125150653~125151589:+
BRCA	cis	rs45509595	0.841	rs17751184	ENSG00000220721.1	OR1F12	6.47	1.52e-10	2.83e-08	0.46	0.2	Breast cancer;	chr6:27807250	chr6:28073316~28074233:+
BRCA	cis	rs2243480	1	rs10807701	ENSG00000229886.1	RP5-1132H15.3	-6.47	1.52e-10	2.83e-08	-0.34	-0.2	Diabetic kidney disease;	chr7:66259699	chr7:66025126~66031544:-
BRCA	cis	rs669446	0.533	rs3791041	ENSG00000237950.1	RP11-7O11.3	6.47	1.52e-10	2.83e-08	0.23	0.2	Amyotrophic lateral sclerosis (age of onset);	chr1:43737320	chr1:43944370~43946551:-
BRCA	cis	rs9876781	1	rs7636782	ENSG00000229759.1	MRPS18AP1	6.47	1.52e-10	2.83e-08	0.22	0.2	Longevity;	chr3:48379897	chr3:48256350~48256938:-
BRCA	cis	rs2348418	0.932	rs11049623	ENSG00000247934.4	RP11-967K21.1	6.47	1.52e-10	2.83e-08	0.22	0.2	Lung function (FEV1);Lung function (FVC);	chr12:28458374	chr12:28163298~28190738:-
BRCA	cis	rs2243480	1	rs2961102	ENSG00000229886.1	RP5-1132H15.3	6.47	1.52e-10	2.84e-08	0.34	0.2	Diabetic kidney disease;	chr7:65959671	chr7:66025126~66031544:-
BRCA	cis	rs1499614	1	rs2707832	ENSG00000232559.3	GS1-124K5.12	6.47	1.52e-10	2.84e-08	0.37	0.2	Gout;	chr7:66671562	chr7:66554588~66576923:-
BRCA	cis	rs71520386	0.579	rs4394299	ENSG00000228649.7	AC005682.5	-6.47	1.52e-10	2.84e-08	-0.19	-0.2	Fibrinogen levels;	chr7:22825763	chr7:22854178~22861579:+
BRCA	cis	rs11742741	0.572	rs4701425	ENSG00000248874.4	C5orf17	-6.47	1.53e-10	2.84e-08	-0.25	-0.2	Educational attainment;	chr5:24172342	chr5:23951348~24178263:+
BRCA	cis	rs34779708	0.966	rs2045918	ENSG00000271335.4	RP11-324I22.4	6.47	1.53e-10	2.84e-08	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35129589	chr10:35314552~35336401:-
BRCA	cis	rs34779708	0.966	rs4294520	ENSG00000271335.4	RP11-324I22.4	6.47	1.53e-10	2.84e-08	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35133578	chr10:35314552~35336401:-
BRCA	cis	rs301901	0.698	rs217837	ENSG00000250155.1	CTD-2353F22.1	6.47	1.53e-10	2.84e-08	0.22	0.2	Height;	chr5:37376570	chr5:36666214~36725195:-
BRCA	cis	rs1979679	0.842	rs35098487	ENSG00000278733.1	RP11-425D17.1	6.47	1.53e-10	2.84e-08	0.24	0.2	Ossification of the posterior longitudinal ligament of the spine;	chr12:28191043	chr12:28185625~28186190:-
BRCA	cis	rs7474896	0.515	rs624359	ENSG00000226578.1	RP11-258F22.1	6.47	1.53e-10	2.84e-08	0.25	0.2	Obesity (extreme);	chr10:38010204	chr10:37775371~37784131:-
BRCA	cis	rs7474896	0.537	rs598857	ENSG00000226578.1	RP11-258F22.1	6.47	1.53e-10	2.84e-08	0.25	0.2	Obesity (extreme);	chr10:38013998	chr10:37775371~37784131:-
BRCA	cis	rs7474896	0.515	rs2738208	ENSG00000226578.1	RP11-258F22.1	6.47	1.53e-10	2.84e-08	0.25	0.2	Obesity (extreme);	chr10:38017200	chr10:37775371~37784131:-
BRCA	cis	rs228614	0.51	rs223459	ENSG00000251288.2	RP11-10L12.2	-6.47	1.53e-10	2.84e-08	-0.23	-0.2	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102788229	chr4:102751401~102752641:+
BRCA	cis	rs11096990	0.855	rs4974986	ENSG00000249207.1	RP11-360F5.1	6.47	1.53e-10	2.84e-08	0.23	0.2	Cognitive function;	chr4:39165308	chr4:39112677~39126818:-
BRCA	cis	rs4722166	0.532	rs6963591	ENSG00000179428.2	AC073072.5	6.47	1.53e-10	2.85e-08	0.2	0.2	Lung cancer;	chr7:22717651	chr7:22725395~22727620:-
BRCA	cis	rs875971	0.522	rs1917563	ENSG00000234585.5	CCT6P3	-6.47	1.53e-10	2.85e-08	-0.19	-0.2	Aortic root size;	chr7:65950660	chr7:65038354~65074713:+
BRCA	cis	rs2836950	0.52	rs2836966	ENSG00000238141.2	BRWD1-AS1	-6.47	1.53e-10	2.85e-08	-0.22	-0.2	Menarche (age at onset);	chr21:39265595	chr21:39315707~39323218:+
BRCA	cis	rs1707322	0.717	rs11211161	ENSG00000281133.1	AL355480.3	-6.47	1.53e-10	2.85e-08	-0.25	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45682466	chr1:45580892~45580996:-
BRCA	cis	rs1322639	0.614	rs6937001	ENSG00000261039.2	RP11-417E7.2	6.47	1.53e-10	2.85e-08	0.25	0.2	Pulse pressure;	chr6:169164991	chr6:169175304~169182740:-
BRCA	cis	rs7124681	0.584	rs1471712	ENSG00000280615.1	Y_RNA	-6.47	1.53e-10	2.85e-08	-0.22	-0.2	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:47890598	chr11:47614898~47614994:-
BRCA	cis	rs2348418	0.864	rs11049716	ENSG00000247934.4	RP11-967K21.1	6.47	1.53e-10	2.85e-08	0.22	0.2	Lung function (FEV1);Lung function (FVC);	chr12:28564713	chr12:28163298~28190738:-
BRCA	cis	rs12237653	0.929	rs12685652	ENSG00000236404.7	VLDLR-AS1	6.47	1.54e-10	2.86e-08	0.3	0.2	Gambling;	chr9:2546525	chr9:2422702~2643359:-
BRCA	cis	rs228614	0.536	rs223418	ENSG00000251288.2	RP11-10L12.2	-6.47	1.54e-10	2.86e-08	-0.23	-0.2	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102809336	chr4:102751401~102752641:+
BRCA	cis	rs8114671	0.904	rs6060197	ENSG00000269202.1	RP4-614O4.12	6.47	1.54e-10	2.86e-08	0.2	0.2	Height;	chr20:35066512	chr20:35201747~35203288:-
BRCA	cis	rs8114671	0.839	rs6142290	ENSG00000269202.1	RP4-614O4.12	6.47	1.54e-10	2.86e-08	0.2	0.2	Height;	chr20:35066869	chr20:35201747~35203288:-
BRCA	cis	rs8114671	0.869	rs6060199	ENSG00000269202.1	RP4-614O4.12	6.47	1.54e-10	2.86e-08	0.2	0.2	Height;	chr20:35066970	chr20:35201747~35203288:-
BRCA	cis	rs3733585	0.806	rs11723382	ENSG00000250413.1	RP11-448G15.1	6.47	1.54e-10	2.86e-08	0.25	0.2	Cleft plate (environmental tobacco smoke interaction);	chr4:9953036	chr4:10006482~10009725:+
BRCA	cis	rs4713118	0.621	rs9368548	ENSG00000219392.1	RP1-265C24.5	-6.47	1.54e-10	2.86e-08	-0.3	-0.2	Parkinson's disease;	chr6:28066959	chr6:28115628~28116551:+
BRCA	cis	rs10129255	1	rs10129407	ENSG00000211972.2	IGHV3-66	6.47	1.54e-10	2.87e-08	0.15	0.2	Kawasaki disease;	chr14:106767956	chr14:106675017~106675544:-
BRCA	cis	rs17772222	0.74	rs3783885	ENSG00000258983.2	RP11-507K2.2	6.47	1.54e-10	2.87e-08	0.21	0.2	Coronary artery calcification;	chr14:88510714	chr14:88499334~88515502:+
BRCA	cis	rs17772222	0.74	rs11159857	ENSG00000258983.2	RP11-507K2.2	6.47	1.54e-10	2.87e-08	0.21	0.2	Coronary artery calcification;	chr14:88510796	chr14:88499334~88515502:+
BRCA	cis	rs17772222	0.74	rs4594187	ENSG00000258983.2	RP11-507K2.2	6.47	1.54e-10	2.87e-08	0.21	0.2	Coronary artery calcification;	chr14:88511071	chr14:88499334~88515502:+
BRCA	cis	rs17772222	0.74	rs4514599	ENSG00000258983.2	RP11-507K2.2	6.47	1.54e-10	2.87e-08	0.21	0.2	Coronary artery calcification;	chr14:88511083	chr14:88499334~88515502:+
BRCA	cis	rs17772222	0.74	rs61975276	ENSG00000258983.2	RP11-507K2.2	6.47	1.54e-10	2.87e-08	0.21	0.2	Coronary artery calcification;	chr14:88511193	chr14:88499334~88515502:+
BRCA	cis	rs17772222	0.74	rs61975277	ENSG00000258983.2	RP11-507K2.2	6.47	1.54e-10	2.87e-08	0.21	0.2	Coronary artery calcification;	chr14:88511202	chr14:88499334~88515502:+
BRCA	cis	rs4713118	0.868	rs35069907	ENSG00000220721.1	OR1F12	6.47	1.55e-10	2.87e-08	0.26	0.2	Parkinson's disease;	chr6:27778913	chr6:28073316~28074233:+
BRCA	cis	rs4713118	0.868	rs10484401	ENSG00000220721.1	OR1F12	-6.47	1.55e-10	2.87e-08	-0.26	-0.2	Parkinson's disease;	chr6:27778811	chr6:28073316~28074233:+
BRCA	cis	rs7162943	0.887	rs12438271	ENSG00000260123.1	RP11-326A19.4	-6.47	1.55e-10	2.87e-08	-0.23	-0.2	Mean platelet volume;	chr15:89069996	chr15:89041223~89082819:+
BRCA	cis	rs875971	0.522	rs4718285	ENSG00000237310.1	GS1-124K5.4	6.47	1.55e-10	2.88e-08	0.2	0.2	Aortic root size;	chr7:65827018	chr7:66493706~66495474:+
BRCA	cis	rs2412819	0.571	rs12443084	ENSG00000205771.5	CATSPER2P1	6.47	1.55e-10	2.88e-08	0.28	0.2	Lung cancer;	chr15:43748767	chr15:43726918~43747094:-
BRCA	cis	rs2348418	0.864	rs7978086	ENSG00000247934.4	RP11-967K21.1	6.47	1.55e-10	2.88e-08	0.22	0.2	Lung function (FEV1);Lung function (FVC);	chr12:28562761	chr12:28163298~28190738:-
BRCA	cis	rs7746199	0.736	rs13202295	ENSG00000220721.1	OR1F12	6.47	1.55e-10	2.88e-08	0.47	0.2	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27731058	chr6:28073316~28074233:+
BRCA	cis	rs2835345	0.511	rs57583267	ENSG00000230479.1	AP000695.6	6.47	1.55e-10	2.88e-08	0.2	0.2	Pulmonary function;	chr21:36445230	chr21:36430360~36481070:+
BRCA	cis	rs875971	0.862	rs10263690	ENSG00000224316.1	RP11-479O9.2	-6.46	1.55e-10	2.89e-08	-0.2	-0.2	Aortic root size;	chr7:66301466	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.862	rs10250544	ENSG00000224316.1	RP11-479O9.2	-6.46	1.55e-10	2.89e-08	-0.2	-0.2	Aortic root size;	chr7:66301574	chr7:65773620~65802067:+
BRCA	cis	rs1113500	0.575	rs1781067	ENSG00000226822.1	RP11-356N1.2	6.46	1.55e-10	2.89e-08	0.25	0.2	Growth-regulated protein alpha levels;	chr1:108025389	chr1:108071482~108074519:+
BRCA	cis	rs274567	0.501	rs274571	ENSG00000233006.5	AC034220.3	-6.46	1.56e-10	2.89e-08	-0.16	-0.2	Blood metabolite levels;	chr5:132376433	chr5:132311285~132369916:-
BRCA	cis	rs2243480	1	rs781157	ENSG00000229886.1	RP5-1132H15.3	6.46	1.56e-10	2.89e-08	0.34	0.2	Diabetic kidney disease;	chr7:66013324	chr7:66025126~66031544:-
BRCA	cis	rs1707322	0.752	rs11211169	ENSG00000281133.1	AL355480.3	-6.46	1.56e-10	2.89e-08	-0.25	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45701037	chr1:45580892~45580996:-
BRCA	cis	rs34779708	0.966	rs4934725	ENSG00000271335.4	RP11-324I22.4	6.46	1.56e-10	2.89e-08	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35109308	chr10:35314552~35336401:-
BRCA	cis	rs34779708	0.966	rs12774834	ENSG00000271335.4	RP11-324I22.4	6.46	1.56e-10	2.89e-08	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35111142	chr10:35314552~35336401:-
BRCA	cis	rs34779708	0.966	rs12775759	ENSG00000271335.4	RP11-324I22.4	6.46	1.56e-10	2.89e-08	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35111255	chr10:35314552~35336401:-
BRCA	cis	rs34779708	0.966	rs35777088	ENSG00000271335.4	RP11-324I22.4	6.46	1.56e-10	2.89e-08	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35120120	chr10:35314552~35336401:-
BRCA	cis	rs34779708	0.966	rs11592567	ENSG00000271335.4	RP11-324I22.4	6.46	1.56e-10	2.89e-08	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35120441	chr10:35314552~35336401:-
BRCA	cis	rs875971	0.965	rs7794930	ENSG00000224316.1	RP11-479O9.2	-6.46	1.56e-10	2.89e-08	-0.2	-0.2	Aortic root size;	chr7:66313559	chr7:65773620~65802067:+
BRCA	cis	rs5015933	0.966	rs1965342	ENSG00000232630.1	PRPS1P2	-6.46	1.56e-10	2.9e-08	-0.19	-0.2	Body mass index;	chr9:125371382	chr9:125150653~125151589:+
BRCA	cis	rs919433	0.926	rs787996	ENSG00000231621.1	AC013264.2	-6.46	1.56e-10	2.9e-08	-0.18	-0.2	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197352081	chr2:197197991~197199273:+
BRCA	cis	rs7176527	0.579	rs366717	ENSG00000230373.7	GOLGA6L5P	6.46	1.56e-10	2.9e-08	0.26	0.2	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84544848	chr15:84507885~84516814:-
BRCA	cis	rs10515750	0.5	rs6890694	ENSG00000248544.2	CTB-47B11.3	6.46	1.56e-10	2.9e-08	0.29	0.2	Lung function (FEV1/FVC);	chr5:157283735	chr5:157375741~157384950:-
BRCA	cis	rs9652601	0.879	rs9926367	ENSG00000274038.1	RP11-66H6.4	-6.46	1.56e-10	2.9e-08	-0.23	-0.2	Systemic lupus erythematosus;	chr16:10999322	chr16:11056556~11057034:+
BRCA	cis	rs7923609	0.756	rs12768534	ENSG00000232075.1	MRPL35P2	-6.46	1.56e-10	2.91e-08	-0.25	-0.2	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63581137	chr10:63634317~63634827:-
BRCA	cis	rs1707322	0.682	rs12037459	ENSG00000281133.1	AL355480.3	-6.46	1.56e-10	2.91e-08	-0.25	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45629287	chr1:45580892~45580996:-
BRCA	cis	rs7246657	0.943	rs10407084	ENSG00000267422.1	CTD-2554C21.1	-6.46	1.57e-10	2.91e-08	-0.3	-0.2	Coronary artery calcification;	chr19:37416890	chr19:37779686~37792865:+
BRCA	cis	rs7246657	0.943	rs7252099	ENSG00000267422.1	CTD-2554C21.1	-6.46	1.57e-10	2.91e-08	-0.3	-0.2	Coronary artery calcification;	chr19:37442878	chr19:37779686~37792865:+
BRCA	cis	rs7246657	0.943	rs7255972	ENSG00000267422.1	CTD-2554C21.1	-6.46	1.57e-10	2.91e-08	-0.3	-0.2	Coronary artery calcification;	chr19:37442939	chr19:37779686~37792865:+
BRCA	cis	rs2492286	0.597	rs6802078	ENSG00000242551.2	POU5F1P6	-6.46	1.57e-10	2.91e-08	-0.29	-0.2	Eosinophil counts;	chr3:128639910	chr3:128674735~128677005:-
BRCA	cis	rs7569084	1	rs13385171	ENSG00000204929.10	AC074391.1	-6.46	1.57e-10	2.91e-08	-0.24	-0.2	Sum eosinophil basophil counts;	chr2:65434709	chr2:65436711~66084639:+
BRCA	cis	rs2348418	0.932	rs16932850	ENSG00000247934.4	RP11-967K21.1	6.46	1.57e-10	2.91e-08	0.22	0.2	Lung function (FEV1);Lung function (FVC);	chr12:28457941	chr12:28163298~28190738:-
BRCA	cis	rs2179367	0.6	rs9498354	ENSG00000231760.4	RP11-350J20.5	-6.46	1.57e-10	2.91e-08	-0.29	-0.2	Dupuytren's disease;	chr6:149441715	chr6:149796151~149826294:-
BRCA	cis	rs875971	0.545	rs13311962	ENSG00000236529.1	RP13-254B10.1	-6.46	1.57e-10	2.91e-08	-0.24	-0.2	Aortic root size;	chr7:66603142	chr7:65840212~65840596:+
BRCA	cis	rs10515750	0.588	rs11743536	ENSG00000248544.2	CTB-47B11.3	-6.46	1.57e-10	2.92e-08	-0.28	-0.2	Lung function (FEV1/FVC);	chr5:157347044	chr5:157375741~157384950:-
BRCA	cis	rs4763879	0.778	rs1056151	ENSG00000214776.8	RP11-726G1.1	-6.46	1.57e-10	2.92e-08	-0.22	-0.2	Type 1 diabetes;	chr12:9698427	chr12:9467552~9576275:+
BRCA	cis	rs13178541	0.81	rs4457070	ENSG00000250378.1	RP11-119J18.1	6.46	1.57e-10	2.92e-08	0.27	0.2	IgG glycosylation;	chr5:135814396	chr5:135812667~135826582:+
BRCA	cis	rs2243480	1	rs313803	ENSG00000232546.1	RP11-458F8.1	-6.46	1.57e-10	2.92e-08	-0.27	-0.2	Diabetic kidney disease;	chr7:66049744	chr7:66848496~66858136:+
BRCA	cis	rs4780355	0.619	rs918737	ENSG00000262636.1	CTD-3088G3.4	-6.46	1.57e-10	2.92e-08	-0.27	-0.2	Crohn's disease and psoriasis;	chr16:11345782	chr16:11380859~11381118:-
BRCA	cis	rs4984778	0.75	rs7198064	ENSG00000260182.1	RP11-616M22.5	6.46	1.58e-10	2.92e-08	0.22	0.2	Blood protein levels;	chr16:1222472	chr16:1257339~1258074:+
BRCA	cis	rs2836950	0.545	rs2836956	ENSG00000238141.2	BRWD1-AS1	6.46	1.58e-10	2.93e-08	0.22	0.2	Menarche (age at onset);	chr21:39251092	chr21:39315707~39323218:+
BRCA	cis	rs2115630	0.967	rs11073731	ENSG00000229212.6	RP11-561C5.4	6.46	1.58e-10	2.93e-08	0.22	0.2	P wave terminal force;	chr15:84811882	chr15:85205440~85234795:-
BRCA	cis	rs34779708	0.966	rs34605125	ENSG00000271335.4	RP11-324I22.4	6.46	1.58e-10	2.93e-08	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35122318	chr10:35314552~35336401:-
BRCA	cis	rs73193808	0.901	rs67137684	ENSG00000215533.7	LINC00189	-6.46	1.58e-10	2.93e-08	-0.28	-0.2	Coronary artery disease;	chr21:29195373	chr21:29193480~29288205:+
BRCA	cis	rs875971	0.502	rs2465121	ENSG00000273024.4	INTS4P2	6.46	1.58e-10	2.93e-08	0.25	0.2	Aortic root size;	chr7:66156017	chr7:65647864~65715661:+
BRCA	cis	rs9291683	0.526	rs7695555	ENSG00000250413.1	RP11-448G15.1	-6.46	1.58e-10	2.94e-08	-0.25	-0.2	Bone mineral density;	chr4:10000032	chr4:10006482~10009725:+
BRCA	cis	rs67340775	0.541	rs200975	ENSG00000220721.1	OR1F12	6.46	1.58e-10	2.94e-08	0.29	0.2	Lung cancer in ever smokers;	chr6:27887847	chr6:28073316~28074233:+
BRCA	cis	rs67340775	0.541	rs200974	ENSG00000220721.1	OR1F12	6.46	1.58e-10	2.94e-08	0.29	0.2	Lung cancer in ever smokers;	chr6:27888067	chr6:28073316~28074233:+
BRCA	cis	rs34779708	0.931	rs4934731	ENSG00000271335.4	RP11-324I22.4	6.46	1.59e-10	2.94e-08	0.2	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35142708	chr10:35314552~35336401:-
BRCA	cis	rs6860806	0.531	rs2631359	ENSG00000233006.5	AC034220.3	-6.46	1.59e-10	2.94e-08	-0.16	-0.2	Breast cancer;	chr5:132372200	chr5:132311285~132369916:-
BRCA	cis	rs4763879	0.634	rs2012643	ENSG00000256673.1	RP11-599J14.2	6.46	1.59e-10	2.95e-08	0.22	0.2	Type 1 diabetes;	chr12:9707128	chr12:9398355~9414851:-
BRCA	cis	rs904251	0.797	rs1757177	ENSG00000204110.6	RP1-153P14.8	-6.46	1.59e-10	2.96e-08	-0.21	-0.2	Cognitive performance;	chr6:37518594	chr6:37507348~37535616:+
BRCA	cis	rs13113518	0.738	rs6849883	ENSG00000273257.1	RP11-177J6.1	6.46	1.59e-10	2.96e-08	0.26	0.2	Height;	chr4:55387515	chr4:55387949~55388271:+
BRCA	cis	rs2243480	1	rs1167613	ENSG00000229886.1	RP5-1132H15.3	6.46	1.59e-10	2.96e-08	0.34	0.2	Diabetic kidney disease;	chr7:66022452	chr7:66025126~66031544:-
BRCA	cis	rs2243480	1	rs313799	ENSG00000229886.1	RP5-1132H15.3	6.46	1.59e-10	2.96e-08	0.34	0.2	Diabetic kidney disease;	chr7:66029343	chr7:66025126~66031544:-
BRCA	cis	rs7772486	0.774	rs2247571	ENSG00000235652.6	RP11-545I5.3	6.46	1.59e-10	2.96e-08	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145898397	chr6:145799409~145886585:+
BRCA	cis	rs2243480	0.711	rs2420172	ENSG00000229886.1	RP5-1132H15.3	-6.46	1.6e-10	2.96e-08	-0.34	-0.2	Diabetic kidney disease;	chr7:66170354	chr7:66025126~66031544:-
BRCA	cis	rs172166	0.611	rs203883	ENSG00000216901.1	AL022393.7	6.46	1.6e-10	2.96e-08	0.26	0.2	Cardiac Troponin-T levels;	chr6:28110578	chr6:28176188~28176674:+
BRCA	cis	rs17772222	0.682	rs2297129	ENSG00000258983.2	RP11-507K2.2	6.46	1.6e-10	2.97e-08	0.2	0.2	Coronary artery calcification;	chr14:88469581	chr14:88499334~88515502:+
BRCA	cis	rs17772222	0.682	rs7141363	ENSG00000258983.2	RP11-507K2.2	6.46	1.6e-10	2.97e-08	0.2	0.2	Coronary artery calcification;	chr14:88471879	chr14:88499334~88515502:+
BRCA	cis	rs17301013	0.606	rs72711443	ENSG00000227373.4	RP11-160H22.5	6.46	1.6e-10	2.97e-08	0.29	0.2	Systemic lupus erythematosus;	chr1:174090876	chr1:174115300~174160004:-
BRCA	cis	rs1275468	0.731	rs1679384	ENSG00000257497.2	RP11-585P4.5	-6.46	1.6e-10	2.97e-08	-0.29	-0.2	Polycystic ovary syndrome;	chr12:75567552	chr12:75483454~75489820:-
BRCA	cis	rs8002861	0.664	rs9567292	ENSG00000274001.1	RP11-5G9.5	6.46	1.6e-10	2.98e-08	0.23	0.2	Leprosy;	chr13:43870680	chr13:43877715~43878163:-
BRCA	cis	rs2599510	0.748	rs6718214	ENSG00000276334.1	AL133243.1	-6.46	1.61e-10	2.98e-08	-0.24	-0.2	Interleukin-18 levels;	chr2:32325416	chr2:32521927~32523547:+
BRCA	cis	rs6740322	0.841	rs10211126	ENSG00000234936.1	AC010883.5	6.46	1.61e-10	2.98e-08	0.22	0.2	Coronary artery disease;	chr2:43324277	chr2:43229573~43233394:+
BRCA	cis	rs875971	0.862	rs10282433	ENSG00000224316.1	RP11-479O9.2	-6.46	1.61e-10	2.98e-08	-0.2	-0.2	Aortic root size;	chr7:66256452	chr7:65773620~65802067:+
BRCA	cis	rs2337406	1	rs4774172	ENSG00000211974.3	IGHV2-70	-6.46	1.61e-10	2.98e-08	-0.24	-0.2	Alzheimer's disease (late onset);	chr14:106681320	chr14:106723574~106724093:-
BRCA	cis	rs11722779	0.873	rs223346	ENSG00000251288.2	RP11-10L12.2	-6.46	1.61e-10	2.99e-08	-0.23	-0.2	Schizophrenia;	chr4:102859339	chr4:102751401~102752641:+
BRCA	cis	rs4780355	0.776	rs9936459	ENSG00000262636.1	CTD-3088G3.4	-6.46	1.61e-10	2.99e-08	-0.27	-0.2	Crohn's disease and psoriasis;	chr16:11343922	chr16:11380859~11381118:-
BRCA	cis	rs12468226	0.935	rs113188021	ENSG00000226261.1	AC064836.3	6.46	1.62e-10	3e-08	0.33	0.2	Urate levels;	chr2:202336237	chr2:202336024~202336727:-
BRCA	cis	rs12468226	1	rs6731027	ENSG00000226261.1	AC064836.3	6.46	1.62e-10	3e-08	0.33	0.2	Urate levels;	chr2:202337443	chr2:202336024~202336727:-
BRCA	cis	rs6740322	0.895	rs6738717	ENSG00000234936.1	AC010883.5	6.46	1.62e-10	3e-08	0.22	0.2	Coronary artery disease;	chr2:43346531	chr2:43229573~43233394:+
BRCA	cis	rs7914558	0.966	rs1591915	ENSG00000213061.2	PFN1P11	6.46	1.62e-10	3e-08	0.26	0.2	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102887092	chr10:102838011~102845473:-
BRCA	cis	rs7914558	0.966	rs56946876	ENSG00000213061.2	PFN1P11	6.46	1.62e-10	3e-08	0.26	0.2	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102893788	chr10:102838011~102845473:-
BRCA	cis	rs7914558	0.933	rs12763665	ENSG00000213061.2	PFN1P11	6.46	1.62e-10	3e-08	0.26	0.2	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102893960	chr10:102838011~102845473:-
BRCA	cis	rs7914558	0.966	rs10786721	ENSG00000213061.2	PFN1P11	6.46	1.62e-10	3e-08	0.26	0.2	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102894626	chr10:102838011~102845473:-
BRCA	cis	rs1555322	0.53	rs2425047	ENSG00000261582.1	RP4-614O4.11	6.46	1.62e-10	3e-08	0.21	0.2	Attention deficit hyperactivity disorder;	chr20:35283872	chr20:35267885~35280043:-
BRCA	cis	rs11018904	0.575	rs12797899	ENSG00000280385.1	AP000648.5	-6.46	1.62e-10	3.01e-08	-0.26	-0.2	Intelligence (multi-trait analysis);	chr11:90242309	chr11:90193614~90198120:+
BRCA	cis	rs12594515	0.967	rs11070465	ENSG00000259200.1	RP11-718O11.1	-6.46	1.62e-10	3.01e-08	-0.22	-0.2	Weight;Waist circumference;	chr15:45692701	chr15:45705078~45931069:+
BRCA	cis	rs61270009	0.955	rs780402	ENSG00000247828.6	TMEM161B-AS1	-6.46	1.62e-10	3.01e-08	-0.26	-0.2	Depressive symptoms;	chr5:88244890	chr5:88268895~88436685:+
BRCA	cis	rs1552244	0.882	rs17050660	ENSG00000180385.7	EMC3-AS1	-6.46	1.63e-10	3.01e-08	-0.24	-0.2	Alzheimer's disease;	chr3:9960088	chr3:9986893~10006990:+
BRCA	cis	rs8002861	0.713	rs7339417	ENSG00000274001.1	RP11-5G9.5	6.46	1.63e-10	3.02e-08	0.23	0.2	Leprosy;	chr13:43839360	chr13:43877715~43878163:-
BRCA	cis	rs944990	0.64	rs10821131	ENSG00000227603.1	RP11-165J3.6	6.46	1.63e-10	3.02e-08	0.2	0.2	Body mass index;	chr9:93466540	chr9:93435332~93437121:-
BRCA	cis	rs2274273	0.686	rs17253695	ENSG00000258413.1	RP11-665C16.6	6.46	1.63e-10	3.02e-08	0.26	0.2	Protein biomarker;	chr14:55107892	chr14:55262767~55272075:-
BRCA	cis	rs61160187	0.582	rs17419290	ENSG00000215032.2	GNL3LP1	-6.46	1.63e-10	3.02e-08	-0.25	-0.2	Educational attainment (years of education);Educational attainment (college completion);	chr5:61012077	chr5:60891935~60893577:-
BRCA	cis	rs7246657	0.943	rs10424574	ENSG00000267422.1	CTD-2554C21.1	-6.46	1.63e-10	3.02e-08	-0.3	-0.2	Coronary artery calcification;	chr19:37347491	chr19:37779686~37792865:+
BRCA	cis	rs516805	0.52	rs197678	ENSG00000279453.1	RP3-425C14.4	-6.46	1.63e-10	3.02e-08	-0.21	-0.2	Lymphocyte counts;	chr6:122534039	chr6:122436789~122439223:-
BRCA	cis	rs2243480	1	rs313809	ENSG00000228409.4	CCT6P1	6.46	1.63e-10	3.03e-08	0.27	0.2	Diabetic kidney disease;	chr7:66034996	chr7:65751142~65763354:+
BRCA	cis	rs17301013	0.606	rs4652168	ENSG00000227373.4	RP11-160H22.5	6.46	1.63e-10	3.03e-08	0.29	0.2	Systemic lupus erythematosus;	chr1:174095077	chr1:174115300~174160004:-
BRCA	cis	rs6969780	1	rs1548497	ENSG00000233429.8	HOTAIRM1	-6.46	1.63e-10	3.03e-08	-0.25	-0.2	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27134697	chr7:27095647~27100265:+
BRCA	cis	rs9291683	0.53	rs35908990	ENSG00000250413.1	RP11-448G15.1	-6.46	1.63e-10	3.03e-08	-0.25	-0.2	Bone mineral density;	chr4:9974481	chr4:10006482~10009725:+
BRCA	cis	rs2688608	0.592	rs10762559	ENSG00000271816.1	BMS1P4	6.46	1.64e-10	3.03e-08	0.19	0.2	Inflammatory bowel disease;	chr10:73726695	chr10:73699151~73730487:-
BRCA	cis	rs1387259	0.859	rs2054905	ENSG00000273765.1	RP11-370I10.11	6.46	1.64e-10	3.03e-08	0.24	0.2	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48294168	chr12:48360920~48361377:+
BRCA	cis	rs17253792	0.822	rs74412558	ENSG00000186615.9	KTN1-AS1	-6.46	1.64e-10	3.03e-08	-0.4	-0.2	Putamen volume;	chr14:55587593	chr14:55499278~55580110:-
BRCA	cis	rs7267979	0.789	rs6083810	ENSG00000204556.4	CTD-2514C3.1	6.46	1.64e-10	3.03e-08	0.27	0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25349123	chr20:26018832~26020684:+
BRCA	cis	rs2018683	0.6	rs6948880	ENSG00000228421.2	AC005013.5	6.46	1.64e-10	3.04e-08	0.24	0.2	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28963862	chr7:28957667~28959345:+
BRCA	cis	rs71520386	0.632	rs12535331	ENSG00000228649.7	AC005682.5	6.46	1.64e-10	3.04e-08	0.19	0.2	Fibrinogen levels;	chr7:22838485	chr7:22854178~22861579:+
BRCA	cis	rs4908768	0.52	rs7520025	ENSG00000270282.1	RP5-1115A15.2	6.46	1.64e-10	3.04e-08	0.21	0.2	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8638218	chr1:8512653~8513021:+
BRCA	cis	rs6142102	0.651	rs6119463	ENSG00000275784.1	RP5-1125A11.6	6.46	1.64e-10	3.04e-08	0.24	0.2	Skin pigmentation;	chr20:34149412	chr20:33989480~33991818:-
BRCA	cis	rs875971	0.545	rs7810213	ENSG00000273024.4	INTS4P2	-6.46	1.64e-10	3.04e-08	-0.25	-0.2	Aortic root size;	chr7:66481592	chr7:65647864~65715661:+
BRCA	cis	rs853679	0.607	rs67340775	ENSG00000220721.1	OR1F12	6.46	1.64e-10	3.04e-08	0.45	0.2	Depression;	chr6:28336607	chr6:28073316~28074233:+
BRCA	cis	rs301901	0.734	rs216385	ENSG00000250155.1	CTD-2353F22.1	-6.46	1.64e-10	3.04e-08	-0.22	-0.2	Height;	chr5:37275173	chr5:36666214~36725195:-
BRCA	cis	rs847577	0.63	rs6967926	ENSG00000272950.1	RP11-307C18.1	6.46	1.64e-10	3.04e-08	0.25	0.2	Breast cancer;	chr7:98085776	chr7:98322853~98323430:+
BRCA	cis	rs17508449	0.865	rs75419513	ENSG00000232450.1	RP4-730K3.3	-6.46	1.64e-10	3.04e-08	-0.36	-0.2	Leprosy;	chr1:113590174	chr1:113698884~113699631:-
BRCA	cis	rs2274273	0.638	rs67416413	ENSG00000258413.1	RP11-665C16.6	-6.46	1.65e-10	3.05e-08	-0.27	-0.2	Protein biomarker;	chr14:55235545	chr14:55262767~55272075:-
BRCA	cis	rs2274273	0.615	rs67008693	ENSG00000258413.1	RP11-665C16.6	-6.46	1.65e-10	3.05e-08	-0.27	-0.2	Protein biomarker;	chr14:55235975	chr14:55262767~55272075:-
BRCA	cis	rs301901	0.531	rs292171	ENSG00000250155.1	CTD-2353F22.1	-6.46	1.65e-10	3.05e-08	-0.21	-0.2	Height;	chr5:36816591	chr5:36666214~36725195:-
BRCA	cis	rs7746199	0.736	rs13212093	ENSG00000220721.1	OR1F12	6.46	1.65e-10	3.06e-08	0.46	0.2	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27638937	chr6:28073316~28074233:+
BRCA	cis	rs7746199	0.736	rs34038546	ENSG00000220721.1	OR1F12	6.46	1.65e-10	3.06e-08	0.46	0.2	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27639881	chr6:28073316~28074233:+
BRCA	cis	rs141342723	1	rs141342723	ENSG00000220721.1	OR1F12	6.46	1.65e-10	3.06e-08	0.46	0.2	Autism spectrum disorder or schizophrenia;	chr6:27654305	chr6:28073316~28074233:+
BRCA	cis	rs7746199	0.736	rs34543938	ENSG00000220721.1	OR1F12	6.46	1.65e-10	3.06e-08	0.46	0.2	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27656861	chr6:28073316~28074233:+
BRCA	cis	rs7746199	0.736	rs56405707	ENSG00000220721.1	OR1F12	6.46	1.65e-10	3.06e-08	0.46	0.2	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27672467	chr6:28073316~28074233:+
BRCA	cis	rs66887589	0.592	rs62320740	ENSG00000245958.5	RP11-33B1.1	-6.46	1.65e-10	3.07e-08	-0.18	-0.2	Diastolic blood pressure;	chr4:119358331	chr4:119454791~119552025:+
BRCA	cis	rs5015933	0.705	rs13288223	ENSG00000232630.1	PRPS1P2	-6.45	1.66e-10	3.07e-08	-0.18	-0.2	Body mass index;	chr9:125335388	chr9:125150653~125151589:+
BRCA	cis	rs17301013	0.507	rs72715204	ENSG00000227373.4	RP11-160H22.5	6.45	1.66e-10	3.07e-08	0.3	0.2	Systemic lupus erythematosus;	chr1:174492787	chr1:174115300~174160004:-
BRCA	cis	rs9450351	0.744	rs9353348	ENSG00000203875.9	SNHG5	-6.45	1.66e-10	3.07e-08	-0.36	-0.2	Interferon gamma-induced protein 10 levels;	chr6:85981635	chr6:85660950~85678736:-
BRCA	cis	rs853679	0.517	rs9393884	ENSG00000280107.1	AL022393.9	-6.45	1.66e-10	3.07e-08	-0.29	-0.2	Depression;	chr6:28079011	chr6:28170845~28172521:+
BRCA	cis	rs13113518	0.812	rs12501746	ENSG00000223305.1	RN7SKP30	6.45	1.66e-10	3.07e-08	0.24	0.2	Height;	chr4:55437438	chr4:55540502~55540835:-
BRCA	cis	rs721917	0.506	rs2819102	ENSG00000244733.5	RP11-506M13.3	-6.45	1.66e-10	3.08e-08	-0.24	-0.2	Chronic obstructive pulmonary disease;	chr10:79928914	chr10:79660891~79677996:+
BRCA	cis	rs2562456	0.876	rs7252585	ENSG00000268081.1	RP11-678G14.2	-6.45	1.66e-10	3.08e-08	-0.28	-0.2	Pain;	chr19:21475141	chr19:21554640~21569237:-
BRCA	cis	rs853679	0.55	rs1233704	ENSG00000204709.4	LINC01556	-6.45	1.66e-10	3.08e-08	-0.28	-0.2	Depression;	chr6:28199145	chr6:28943877~28944537:+
BRCA	cis	rs2243480	1	rs13310597	ENSG00000229886.1	RP5-1132H15.3	6.45	1.66e-10	3.08e-08	0.35	0.2	Diabetic kidney disease;	chr7:66133553	chr7:66025126~66031544:-
BRCA	cis	rs2834288	0.535	rs7278341	ENSG00000273102.1	AP000569.9	6.45	1.66e-10	3.08e-08	0.22	0.2	Gut microbiota (bacterial taxa);	chr21:33961692	chr21:33967101~33968573:-
BRCA	cis	rs2834288	0.535	rs7279183	ENSG00000273102.1	AP000569.9	6.45	1.66e-10	3.08e-08	0.22	0.2	Gut microbiota (bacterial taxa);	chr21:33961701	chr21:33967101~33968573:-
BRCA	cis	rs10506328	0.509	rs4759075	ENSG00000257534.1	RP11-834C11.10	6.45	1.66e-10	3.08e-08	0.21	0.2	Mean platelet volume;	chr12:54273501	chr12:54162065~54164452:-
BRCA	cis	rs17711722	0.701	rs4467826	ENSG00000237310.1	GS1-124K5.4	6.45	1.66e-10	3.08e-08	0.2	0.2	Calcium levels;	chr7:65903721	chr7:66493706~66495474:+
BRCA	cis	rs875971	0.545	rs2420612	ENSG00000224316.1	RP11-479O9.2	6.45	1.66e-10	3.08e-08	0.23	0.2	Aortic root size;	chr7:66536825	chr7:65773620~65802067:+
BRCA	cis	rs721917	0.506	rs2758556	ENSG00000244733.5	RP11-506M13.3	6.45	1.67e-10	3.09e-08	0.24	0.2	Chronic obstructive pulmonary disease;	chr10:79931229	chr10:79660891~79677996:+
BRCA	cis	rs2243480	1	rs4718270	ENSG00000228409.4	CCT6P1	6.45	1.67e-10	3.09e-08	0.27	0.2	Diabetic kidney disease;	chr7:65737415	chr7:65751142~65763354:+
BRCA	cis	rs7086627	0.515	rs4934189	ENSG00000226659.1	RP11-137H2.4	-6.45	1.67e-10	3.09e-08	-0.25	-0.2	Post bronchodilator FEV1;	chr10:80455036	chr10:80529597~80535942:-
BRCA	cis	rs228614	0.51	rs223447	ENSG00000251288.2	RP11-10L12.2	-6.45	1.67e-10	3.09e-08	-0.23	-0.2	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102792202	chr4:102751401~102752641:+
BRCA	cis	rs2348418	0.932	rs7968515	ENSG00000247934.4	RP11-967K21.1	6.45	1.67e-10	3.09e-08	0.22	0.2	Lung function (FEV1);Lung function (FVC);	chr12:28542914	chr12:28163298~28190738:-
BRCA	cis	rs34779708	0.931	rs34876468	ENSG00000271335.4	RP11-324I22.4	6.45	1.67e-10	3.1e-08	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35135522	chr10:35314552~35336401:-
BRCA	cis	rs6840360	0.582	rs2709826	ENSG00000270265.1	RP11-731D1.4	-6.45	1.67e-10	3.1e-08	-0.22	-0.2	Intelligence (multi-trait analysis);	chr4:151410968	chr4:151333775~151353224:-
BRCA	cis	rs11976180	1	rs11976037	ENSG00000273234.1	OR2A13P	-6.45	1.68e-10	3.1e-08	-0.27	-0.2	Obesity-related traits;	chr7:144043931	chr7:144142009~144142938:+
BRCA	cis	rs2018683	0.624	rs6462119	ENSG00000228421.2	AC005013.5	6.45	1.68e-10	3.1e-08	0.24	0.2	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28964109	chr7:28957667~28959345:+
BRCA	cis	rs6583826	0.681	rs2421943	ENSG00000236493.2	EIF2S2P3	6.45	1.68e-10	3.1e-08	0.26	0.2	Type 2 diabetes;	chr10:92552058	chr10:92668745~92669743:-
BRCA	cis	rs9638182	0.725	rs13232120	ENSG00000274080.1	CTA-315H11.2	6.45	1.68e-10	3.1e-08	0.39	0.2	Triglycerides;	chr7:73568980	chr7:73609262~73611502:-
BRCA	cis	rs1124769	0.748	rs12593778	ENSG00000259378.1	DCAF13P3	6.45	1.68e-10	3.1e-08	0.28	0.2	Cognitive performance;	chr15:51005929	chr15:50944663~50945996:+
BRCA	cis	rs11722228	0.539	rs62287552	ENSG00000261490.1	RP11-448G15.3	6.45	1.68e-10	3.11e-08	0.23	0.2	Urate levels;Serum uric acid levels;Gout;	chr4:10151573	chr4:10068089~10073019:-
BRCA	cis	rs2348418	0.832	rs1405811	ENSG00000247934.4	RP11-967K21.1	6.45	1.68e-10	3.11e-08	0.22	0.2	Lung function (FEV1);Lung function (FVC);	chr12:28428169	chr12:28163298~28190738:-
BRCA	cis	rs891378	1	rs7543250	ENSG00000274245.1	RP11-357P18.2	6.45	1.68e-10	3.11e-08	0.26	0.2	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207251698	chr1:207372559~207373252:+
BRCA	cis	rs875971	0.862	rs10261398	ENSG00000224316.1	RP11-479O9.2	-6.45	1.68e-10	3.11e-08	-0.2	-0.2	Aortic root size;	chr7:66285177	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.862	rs10224872	ENSG00000224316.1	RP11-479O9.2	-6.45	1.68e-10	3.11e-08	-0.2	-0.2	Aortic root size;	chr7:66294786	chr7:65773620~65802067:+
BRCA	cis	rs2243480	0.901	rs73148097	ENSG00000229886.1	RP5-1132H15.3	6.45	1.68e-10	3.11e-08	0.34	0.2	Diabetic kidney disease;	chr7:65966800	chr7:66025126~66031544:-
BRCA	cis	rs2243480	1	rs906134	ENSG00000229886.1	RP5-1132H15.3	6.45	1.68e-10	3.11e-08	0.34	0.2	Diabetic kidney disease;	chr7:65979301	chr7:66025126~66031544:-
BRCA	cis	rs2998286	0.862	rs2153300	ENSG00000254635.4	WAC-AS1	-6.45	1.69e-10	3.12e-08	-0.28	-0.2	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28519041	chr10:28522652~28532743:-
BRCA	cis	rs1499614	0.901	rs3936	ENSG00000232559.3	GS1-124K5.12	6.45	1.69e-10	3.12e-08	0.38	0.2	Gout;	chr7:66661502	chr7:66554588~66576923:-
BRCA	cis	rs2638953	0.85	rs11049428	ENSG00000278733.1	RP11-425D17.1	-6.45	1.69e-10	3.12e-08	-0.25	-0.2	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28194267	chr12:28185625~28186190:-
BRCA	cis	rs6740322	0.895	rs10210125	ENSG00000234936.1	AC010883.5	6.45	1.69e-10	3.13e-08	0.22	0.2	Coronary artery disease;	chr2:43329294	chr2:43229573~43233394:+
BRCA	cis	rs172166	0.611	rs203882	ENSG00000216901.1	AL022393.7	6.45	1.69e-10	3.13e-08	0.25	0.2	Cardiac Troponin-T levels;	chr6:28110724	chr6:28176188~28176674:+
BRCA	cis	rs1707322	1	rs785486	ENSG00000281133.1	AL355480.3	6.45	1.69e-10	3.13e-08	0.25	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46109476	chr1:45580892~45580996:-
BRCA	cis	rs17772222	0.74	rs61975278	ENSG00000258983.2	RP11-507K2.2	6.45	1.69e-10	3.13e-08	0.21	0.2	Coronary artery calcification;	chr14:88511223	chr14:88499334~88515502:+
BRCA	cis	rs2348418	0.832	rs12301674	ENSG00000247934.4	RP11-967K21.1	6.45	1.69e-10	3.13e-08	0.22	0.2	Lung function (FEV1);Lung function (FVC);	chr12:28357543	chr12:28163298~28190738:-
BRCA	cis	rs875971	1	rs778710	ENSG00000224316.1	RP11-479O9.2	6.45	1.69e-10	3.13e-08	0.19	0.2	Aortic root size;	chr7:66389847	chr7:65773620~65802067:+
BRCA	cis	rs11672691	0.756	rs8107333	ENSG00000270164.1	LINC01480	-6.45	1.7e-10	3.14e-08	-0.23	-0.2	Prostate cancer;	chr19:41481965	chr19:41535183~41536904:+
BRCA	cis	rs2337406	1	rs17113257	ENSG00000211972.2	IGHV3-66	6.45	1.7e-10	3.14e-08	0.18	0.2	Alzheimer's disease (late onset);	chr14:106679574	chr14:106675017~106675544:-
BRCA	cis	rs1440410	0.798	rs1039763	ENSG00000250326.1	RP11-284M14.1	-6.45	1.7e-10	3.14e-08	-0.22	-0.2	Ischemic stroke;	chr4:143246860	chr4:142933195~143184861:-
BRCA	cis	rs1440410	0.763	rs1039762	ENSG00000250326.1	RP11-284M14.1	-6.45	1.7e-10	3.14e-08	-0.22	-0.2	Ischemic stroke;	chr4:143246893	chr4:142933195~143184861:-
BRCA	cis	rs34779708	0.771	rs12098283	ENSG00000271335.4	RP11-324I22.4	6.45	1.7e-10	3.14e-08	0.2	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35189187	chr10:35314552~35336401:-
BRCA	cis	rs7246657	0.943	rs12981532	ENSG00000267422.1	CTD-2554C21.1	-6.45	1.7e-10	3.14e-08	-0.3	-0.2	Coronary artery calcification;	chr19:37398378	chr19:37779686~37792865:+
BRCA	cis	rs7246657	0.943	rs7246993	ENSG00000267422.1	CTD-2554C21.1	-6.45	1.7e-10	3.14e-08	-0.3	-0.2	Coronary artery calcification;	chr19:37399252	chr19:37779686~37792865:+
BRCA	cis	rs7246657	0.943	rs10413602	ENSG00000267422.1	CTD-2554C21.1	-6.45	1.7e-10	3.14e-08	-0.3	-0.2	Coronary artery calcification;	chr19:37400590	chr19:37779686~37792865:+
BRCA	cis	rs16846053	0.515	rs6432688	ENSG00000227403.1	AC009299.3	-6.45	1.7e-10	3.14e-08	-0.33	-0.2	Blood osmolality (transformed sodium);	chr2:161522146	chr2:161244739~161249050:+
BRCA	cis	rs10129255	0.957	rs10141052	ENSG00000211972.2	IGHV3-66	6.45	1.7e-10	3.14e-08	0.14	0.2	Kawasaki disease;	chr14:106776528	chr14:106675017~106675544:-
BRCA	cis	rs875971	0.862	rs4236208	ENSG00000224316.1	RP11-479O9.2	-6.45	1.7e-10	3.14e-08	-0.2	-0.2	Aortic root size;	chr7:66284091	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.502	rs2946580	ENSG00000273024.4	INTS4P2	6.45	1.7e-10	3.15e-08	0.25	0.2	Aortic root size;	chr7:66066855	chr7:65647864~65715661:+
BRCA	cis	rs1440410	0.798	rs1605581	ENSG00000250326.1	RP11-284M14.1	-6.45	1.7e-10	3.15e-08	-0.22	-0.2	Ischemic stroke;	chr4:143245634	chr4:142933195~143184861:-
BRCA	cis	rs17572109	0.666	rs4674297	ENSG00000261338.2	RP11-378A13.1	6.45	1.7e-10	3.15e-08	0.25	0.2	Platelet count;Platelet distribution width;Mean platelet volume;	chr2:218364424	chr2:218255319~218257366:+
BRCA	cis	rs875971	0.522	rs2008188	ENSG00000234585.5	CCT6P3	6.45	1.71e-10	3.15e-08	0.19	0.2	Aortic root size;	chr7:65964026	chr7:65038354~65074713:+
BRCA	cis	rs228614	0.51	rs223434	ENSG00000251288.2	RP11-10L12.2	-6.45	1.71e-10	3.16e-08	-0.23	-0.2	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102799902	chr4:102751401~102752641:+
BRCA	cis	rs853679	0.546	rs34295134	ENSG00000220721.1	OR1F12	6.45	1.71e-10	3.16e-08	0.36	0.2	Depression;	chr6:27860373	chr6:28073316~28074233:+
BRCA	cis	rs12594515	0.506	rs74199860	ENSG00000259200.1	RP11-718O11.1	-6.45	1.71e-10	3.16e-08	-0.22	-0.2	Weight;Waist circumference;	chr15:45696992	chr15:45705078~45931069:+
BRCA	cis	rs9527	0.545	rs35756290	ENSG00000236937.2	PTGES3P4	6.45	1.71e-10	3.16e-08	0.29	0.2	Arsenic metabolism;	chr10:102825815	chr10:102845595~102845950:+
BRCA	cis	rs755249	0.567	rs2036463	ENSG00000237624.1	OXCT2P1	6.45	1.71e-10	3.16e-08	0.28	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39222403	chr1:39514956~39516490:+
BRCA	cis	rs755249	0.567	rs2036464	ENSG00000237624.1	OXCT2P1	6.45	1.71e-10	3.16e-08	0.28	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39222570	chr1:39514956~39516490:+
BRCA	cis	rs755249	0.567	rs905381	ENSG00000237624.1	OXCT2P1	6.45	1.71e-10	3.16e-08	0.28	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39222880	chr1:39514956~39516490:+
BRCA	cis	rs42648	0.738	rs13247172	ENSG00000225498.1	AC002064.5	6.45	1.71e-10	3.16e-08	0.21	0.2	Homocysteine levels;	chr7:90259890	chr7:90312496~90322592:+
BRCA	cis	rs2153535	0.585	rs9379226	ENSG00000230939.1	RP11-314C16.1	-6.45	1.71e-10	3.16e-08	-0.23	-0.2	Motion sickness;	chr6:8584232	chr6:8784178~8785445:+
BRCA	cis	rs867371	0.826	rs2047678	ENSG00000259429.4	UBE2Q2P2	-6.45	1.71e-10	3.16e-08	-0.2	-0.2	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82205857	chr15:82355142~82420075:+
BRCA	cis	rs301901	0.663	rs217847	ENSG00000250155.1	CTD-2353F22.1	6.45	1.71e-10	3.17e-08	0.22	0.2	Height;	chr5:37367135	chr5:36666214~36725195:-
BRCA	cis	rs11098499	0.909	rs10017335	ENSG00000249244.1	RP11-548H18.2	-6.45	1.71e-10	3.17e-08	-0.24	-0.2	Corneal astigmatism;	chr4:119460368	chr4:119391831~119395335:-
BRCA	cis	rs7927771	0.524	rs1563820	ENSG00000280615.1	Y_RNA	-6.45	1.71e-10	3.17e-08	-0.22	-0.2	Subjective well-being;	chr11:47811846	chr11:47614898~47614994:-
BRCA	cis	rs7927771	0.524	rs4752796	ENSG00000280615.1	Y_RNA	-6.45	1.71e-10	3.17e-08	-0.22	-0.2	Subjective well-being;	chr11:47820310	chr11:47614898~47614994:-
BRCA	cis	rs7432375	0.58	rs4678441	ENSG00000239213.4	NCK1-AS1	6.45	1.71e-10	3.17e-08	0.2	0.2	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136813986	chr3:136841726~136862054:-
BRCA	cis	rs7432375	0.58	rs4678442	ENSG00000239213.4	NCK1-AS1	6.45	1.71e-10	3.17e-08	0.2	0.2	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136814129	chr3:136841726~136862054:-
BRCA	cis	rs73186030	0.764	rs56236741	ENSG00000272758.4	RP11-299J3.8	6.45	1.72e-10	3.17e-08	0.27	0.2	Serum parathyroid hormone levels;	chr3:122379136	chr3:122416207~122443180:+
BRCA	cis	rs944990	0.576	rs3933795	ENSG00000227603.1	RP11-165J3.6	6.45	1.72e-10	3.17e-08	0.2	0.2	Body mass index;	chr9:93423391	chr9:93435332~93437121:-
BRCA	cis	rs237743	1	rs56335217	ENSG00000222365.1	SNORD12B	-6.45	1.72e-10	3.17e-08	-0.26	-0.2	Height;	chr20:49254660	chr20:49280319~49280409:+
BRCA	cis	rs1707322	0.964	rs796773	ENSG00000281133.1	AL355480.3	6.45	1.72e-10	3.18e-08	0.25	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46098803	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.896	rs785518	ENSG00000281133.1	AL355480.3	6.45	1.72e-10	3.18e-08	0.25	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46102750	chr1:45580892~45580996:-
BRCA	cis	rs1707322	1	rs785519	ENSG00000281133.1	AL355480.3	6.45	1.72e-10	3.18e-08	0.25	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46102890	chr1:45580892~45580996:-
BRCA	cis	rs17214007	0.877	rs2075515	ENSG00000263335.1	AF001548.5	-6.45	1.72e-10	3.18e-08	-0.29	-0.2	Cognitive function;	chr16:15778462	chr16:15726674~15732993:+
BRCA	cis	rs10515750	0.5	rs2288069	ENSG00000248544.2	CTB-47B11.3	6.45	1.72e-10	3.18e-08	0.28	0.2	Lung function (FEV1/FVC);	chr5:157285187	chr5:157375741~157384950:-
BRCA	cis	rs1476670	0.545	rs11210948	ENSG00000230615.5	RP5-1198O20.4	-6.45	1.73e-10	3.19e-08	-0.26	-0.2	Eotaxin levels;	chr1:44054441	chr1:44030443~44115913:+
BRCA	cis	rs78456975	1	rs13422995	ENSG00000231482.2	AC141930.2	-6.45	1.73e-10	3.19e-08	-0.28	-0.2	Placebo response in major depressive disorder (% change in symptom score);	chr2:1549782	chr2:1572554~1580311:-
BRCA	cis	rs78456975	1	rs13413096	ENSG00000231482.2	AC141930.2	-6.45	1.73e-10	3.19e-08	-0.28	-0.2	Placebo response in major depressive disorder (% change in symptom score);	chr2:1549816	chr2:1572554~1580311:-
BRCA	cis	rs2243480	1	rs160646	ENSG00000229886.1	RP5-1132H15.3	6.45	1.73e-10	3.2e-08	0.35	0.2	Diabetic kidney disease;	chr7:66091293	chr7:66025126~66031544:-
BRCA	cis	rs6095360	0.727	rs17378391	ENSG00000222365.1	SNORD12B	-6.45	1.73e-10	3.2e-08	-0.26	-0.2	Intelligence (multi-trait analysis);	chr20:49156064	chr20:49280319~49280409:+
BRCA	cis	rs11763147	1	rs11763147	ENSG00000237310.1	GS1-124K5.4	-6.45	1.73e-10	3.2e-08	-0.2	-0.2	Corneal structure;	chr7:65861834	chr7:66493706~66495474:+
BRCA	cis	rs1499614	1	rs1267817	ENSG00000232559.3	GS1-124K5.12	6.45	1.73e-10	3.2e-08	0.38	0.2	Gout;	chr7:66645053	chr7:66554588~66576923:-
BRCA	cis	rs2243480	1	rs1873494	ENSG00000229886.1	RP5-1132H15.3	-6.45	1.73e-10	3.2e-08	-0.34	-0.2	Diabetic kidney disease;	chr7:66184912	chr7:66025126~66031544:-
BRCA	cis	rs2243480	1	rs6959002	ENSG00000229886.1	RP5-1132H15.3	-6.45	1.73e-10	3.2e-08	-0.34	-0.2	Diabetic kidney disease;	chr7:66185509	chr7:66025126~66031544:-
BRCA	cis	rs2243480	1	rs316313	ENSG00000229886.1	RP5-1132H15.3	6.45	1.74e-10	3.21e-08	0.35	0.2	Diabetic kidney disease;	chr7:66128561	chr7:66025126~66031544:-
BRCA	cis	rs2243480	1	rs316312	ENSG00000229886.1	RP5-1132H15.3	6.45	1.74e-10	3.21e-08	0.35	0.2	Diabetic kidney disease;	chr7:66131504	chr7:66025126~66031544:-
BRCA	cis	rs2243480	1	rs419603	ENSG00000229886.1	RP5-1132H15.3	6.45	1.74e-10	3.21e-08	0.35	0.2	Diabetic kidney disease;	chr7:66132354	chr7:66025126~66031544:-
BRCA	cis	rs301901	0.734	rs216387	ENSG00000250155.1	CTD-2353F22.1	-6.45	1.74e-10	3.21e-08	-0.22	-0.2	Height;	chr5:37276657	chr5:36666214~36725195:-
BRCA	cis	rs13160562	0.623	rs26509	ENSG00000272109.1	CTD-2260A17.3	6.45	1.74e-10	3.21e-08	0.25	0.2	Alcohol dependence;	chr5:96746976	chr5:96804353~96806105:+
BRCA	cis	rs9992667	0.955	rs28491682	ENSG00000231160.8	KLF3-AS1	6.45	1.74e-10	3.21e-08	0.24	0.2	Eosinophil percentage of granulocytes;	chr4:38639268	chr4:38612701~38664883:-
BRCA	cis	rs2243480	0.908	rs4718273	ENSG00000228409.4	CCT6P1	-6.45	1.74e-10	3.21e-08	-0.27	-0.2	Diabetic kidney disease;	chr7:65751112	chr7:65751142~65763354:+
BRCA	cis	rs2348418	0.767	rs7972954	ENSG00000247934.4	RP11-967K21.1	6.45	1.74e-10	3.21e-08	0.22	0.2	Lung function (FEV1);Lung function (FVC);	chr12:28260273	chr12:28163298~28190738:-
BRCA	cis	rs67981189	0.778	rs2189807	ENSG00000269927.1	RP6-91H8.3	6.45	1.74e-10	3.21e-08	0.24	0.2	Schizophrenia;	chr14:70896314	chr14:71141125~71143253:-
BRCA	cis	rs2337406	1	rs3858878	ENSG00000211972.2	IGHV3-66	6.45	1.74e-10	3.22e-08	0.18	0.2	Alzheimer's disease (late onset);	chr14:106688061	chr14:106675017~106675544:-
BRCA	cis	rs4713118	0.621	rs10484403	ENSG00000219392.1	RP1-265C24.5	-6.45	1.74e-10	3.22e-08	-0.3	-0.2	Parkinson's disease;	chr6:28065745	chr6:28115628~28116551:+
BRCA	cis	rs4713118	0.826	rs2893929	ENSG00000220721.1	OR1F12	6.45	1.75e-10	3.22e-08	0.26	0.2	Parkinson's disease;	chr6:27770953	chr6:28073316~28074233:+
BRCA	cis	rs4713118	0.666	rs4140646	ENSG00000220721.1	OR1F12	6.45	1.75e-10	3.22e-08	0.26	0.2	Parkinson's disease;	chr6:27771022	chr6:28073316~28074233:+
BRCA	cis	rs4713118	0.666	rs2893930	ENSG00000220721.1	OR1F12	6.45	1.75e-10	3.22e-08	0.26	0.2	Parkinson's disease;	chr6:27771027	chr6:28073316~28074233:+
BRCA	cis	rs3760982	0.935	rs10422990	ENSG00000267058.1	RP11-15A1.3	-6.45	1.75e-10	3.23e-08	-0.22	-0.2	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43791121	chr19:43891804~43901805:-
BRCA	cis	rs7809950	0.817	rs2253833	ENSG00000238832.1	snoU109	6.45	1.75e-10	3.23e-08	0.29	0.2	Coronary artery disease;	chr7:107565224	chr7:107603363~107603507:+
BRCA	cis	rs17253792	0.822	rs75897560	ENSG00000186615.9	KTN1-AS1	-6.45	1.75e-10	3.23e-08	-0.38	-0.2	Putamen volume;	chr14:55624247	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs28549152	ENSG00000186615.9	KTN1-AS1	-6.45	1.75e-10	3.23e-08	-0.38	-0.2	Putamen volume;	chr14:55624521	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs10147431	ENSG00000186615.9	KTN1-AS1	-6.45	1.75e-10	3.23e-08	-0.38	-0.2	Putamen volume;	chr14:55625123	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs75663029	ENSG00000186615.9	KTN1-AS1	-6.45	1.75e-10	3.23e-08	-0.38	-0.2	Putamen volume;	chr14:55625667	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs75991559	ENSG00000186615.9	KTN1-AS1	-6.45	1.75e-10	3.23e-08	-0.38	-0.2	Putamen volume;	chr14:55625701	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs79262019	ENSG00000186615.9	KTN1-AS1	-6.45	1.75e-10	3.23e-08	-0.38	-0.2	Putamen volume;	chr14:55625986	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs79024594	ENSG00000186615.9	KTN1-AS1	-6.45	1.75e-10	3.23e-08	-0.38	-0.2	Putamen volume;	chr14:55626279	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs28392709	ENSG00000186615.9	KTN1-AS1	-6.45	1.75e-10	3.23e-08	-0.38	-0.2	Putamen volume;	chr14:55626967	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs79618862	ENSG00000186615.9	KTN1-AS1	-6.45	1.75e-10	3.23e-08	-0.38	-0.2	Putamen volume;	chr14:55627253	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs28513551	ENSG00000186615.9	KTN1-AS1	-6.45	1.75e-10	3.23e-08	-0.38	-0.2	Putamen volume;	chr14:55628275	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs74824071	ENSG00000186615.9	KTN1-AS1	-6.45	1.75e-10	3.23e-08	-0.38	-0.2	Putamen volume;	chr14:55628424	chr14:55499278~55580110:-
BRCA	cis	rs919433	0.783	rs787979	ENSG00000231621.1	AC013264.2	-6.45	1.76e-10	3.24e-08	-0.18	-0.2	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197378144	chr2:197197991~197199273:+
BRCA	cis	rs11096990	0.855	rs11737290	ENSG00000249207.1	RP11-360F5.1	6.45	1.76e-10	3.24e-08	0.23	0.2	Cognitive function;	chr4:39192318	chr4:39112677~39126818:-
BRCA	cis	rs2348418	0.83	rs7977418	ENSG00000247934.4	RP11-967K21.1	6.45	1.76e-10	3.24e-08	0.22	0.2	Lung function (FEV1);Lung function (FVC);	chr12:28435309	chr12:28163298~28190738:-
BRCA	cis	rs13287066	0.692	rs10761225	ENSG00000227603.1	RP11-165J3.6	6.45	1.76e-10	3.24e-08	0.2	0.2	Intelligence (multi-trait analysis);	chr9:93404358	chr9:93435332~93437121:-
BRCA	cis	rs9307551	0.817	rs11098766	ENSG00000250334.4	LINC00989	-6.45	1.76e-10	3.24e-08	-0.26	-0.2	Refractive error;	chr4:79579266	chr4:79492416~79576460:+
BRCA	cis	rs710913	0.691	rs1180351	ENSG00000237624.1	OXCT2P1	-6.45	1.76e-10	3.24e-08	-0.23	-0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39541605	chr1:39514956~39516490:+
BRCA	cis	rs11098499	0.82	rs13122709	ENSG00000249244.1	RP11-548H18.2	6.45	1.76e-10	3.24e-08	0.24	0.2	Corneal astigmatism;	chr4:119634201	chr4:119391831~119395335:-
BRCA	cis	rs7976269	0.537	rs10843308	ENSG00000257176.2	RP11-996F15.2	-6.45	1.76e-10	3.24e-08	-0.24	-0.2	Male-pattern baldness;	chr12:29075172	chr12:29280418~29317848:-
BRCA	cis	rs7246657	0.943	rs10420754	ENSG00000226686.6	LINC01535	-6.45	1.76e-10	3.25e-08	-0.28	-0.2	Coronary artery calcification;	chr19:37468470	chr19:37251912~37265535:+
BRCA	cis	rs13217239	0.646	rs10946898	ENSG00000241549.7	GUSBP2	6.45	1.76e-10	3.25e-08	0.21	0.2	Schizophrenia;	chr6:27036105	chr6:26871484~26956554:-
BRCA	cis	rs1440410	0.798	rs10002867	ENSG00000250326.1	RP11-284M14.1	-6.44	1.76e-10	3.26e-08	-0.22	-0.2	Ischemic stroke;	chr4:143248497	chr4:142933195~143184861:-
BRCA	cis	rs853679	0.585	rs201001	ENSG00000220721.1	OR1F12	6.44	1.77e-10	3.26e-08	0.28	0.2	Depression;	chr6:27841121	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.585	rs201000	ENSG00000220721.1	OR1F12	6.44	1.77e-10	3.26e-08	0.28	0.2	Depression;	chr6:27841381	chr6:28073316~28074233:+
BRCA	cis	rs721917	0.586	rs2758550	ENSG00000244733.5	RP11-506M13.3	-6.44	1.77e-10	3.26e-08	-0.24	-0.2	Chronic obstructive pulmonary disease;	chr10:79932606	chr10:79660891~79677996:+
BRCA	cis	rs7246657	0.943	rs7253091	ENSG00000226686.6	LINC01535	-6.44	1.77e-10	3.26e-08	-0.28	-0.2	Coronary artery calcification;	chr19:37476312	chr19:37251912~37265535:+
BRCA	cis	rs9638182	0.725	rs35173225	ENSG00000274080.1	CTA-315H11.2	6.44	1.77e-10	3.26e-08	0.4	0.2	Triglycerides;	chr7:73586691	chr7:73609262~73611502:-
BRCA	cis	rs2243480	1	rs35396113	ENSG00000229886.1	RP5-1132H15.3	6.44	1.77e-10	3.26e-08	0.34	0.2	Diabetic kidney disease;	chr7:66030474	chr7:66025126~66031544:-
BRCA	cis	rs4713118	0.621	rs4713132	ENSG00000219392.1	RP1-265C24.5	-6.44	1.77e-10	3.26e-08	-0.3	-0.2	Parkinson's disease;	chr6:28066257	chr6:28115628~28116551:+
BRCA	cis	rs4713118	0.621	rs4713133	ENSG00000219392.1	RP1-265C24.5	-6.44	1.77e-10	3.26e-08	-0.3	-0.2	Parkinson's disease;	chr6:28066263	chr6:28115628~28116551:+
BRCA	cis	rs4713118	0.621	rs4713134	ENSG00000219392.1	RP1-265C24.5	-6.44	1.77e-10	3.26e-08	-0.3	-0.2	Parkinson's disease;	chr6:28066343	chr6:28115628~28116551:+
BRCA	cis	rs2638953	0.924	rs11049398	ENSG00000247934.4	RP11-967K21.1	-6.44	1.77e-10	3.26e-08	-0.25	-0.2	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28172371	chr12:28163298~28190738:-
BRCA	cis	rs1707322	1	rs6672115	ENSG00000281133.1	AL355480.3	-6.44	1.77e-10	3.26e-08	-0.25	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45807207	chr1:45580892~45580996:-
BRCA	cis	rs7927771	0.524	rs10838769	ENSG00000280615.1	Y_RNA	-6.44	1.77e-10	3.27e-08	-0.22	-0.2	Subjective well-being;	chr11:47803781	chr11:47614898~47614994:-
BRCA	cis	rs2243480	1	rs387676	ENSG00000229886.1	RP5-1132H15.3	6.44	1.77e-10	3.27e-08	0.35	0.2	Diabetic kidney disease;	chr7:66133233	chr7:66025126~66031544:-
BRCA	cis	rs2243480	0.615	rs34363376	ENSG00000230295.1	RP11-458F8.2	-6.44	1.77e-10	3.27e-08	-0.26	-0.2	Diabetic kidney disease;	chr7:66474549	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs73142162	ENSG00000228409.4	CCT6P1	6.44	1.77e-10	3.27e-08	0.27	0.2	Diabetic kidney disease;	chr7:65909309	chr7:65751142~65763354:+
BRCA	cis	rs2243480	0.711	rs1626926	ENSG00000228409.4	CCT6P1	6.44	1.77e-10	3.27e-08	0.27	0.2	Diabetic kidney disease;	chr7:65970805	chr7:65751142~65763354:+
BRCA	cis	rs2243480	0.908	rs4718273	ENSG00000229886.1	RP5-1132H15.3	-6.44	1.77e-10	3.27e-08	-0.34	-0.2	Diabetic kidney disease;	chr7:65751112	chr7:66025126~66031544:-
BRCA	cis	rs6969780	0.841	rs2301720	ENSG00000233429.8	HOTAIRM1	-6.44	1.78e-10	3.27e-08	-0.22	-0.2	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27156450	chr7:27095647~27100265:+
BRCA	cis	rs919433	0.75	rs788012	ENSG00000231621.1	AC013264.2	-6.44	1.78e-10	3.28e-08	-0.19	-0.2	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197365132	chr2:197197991~197199273:+
BRCA	cis	rs2243480	1	rs6964245	ENSG00000229886.1	RP5-1132H15.3	-6.44	1.78e-10	3.28e-08	-0.34	-0.2	Diabetic kidney disease;	chr7:66253730	chr7:66025126~66031544:-
BRCA	cis	rs7587476	0.784	rs17424051	ENSG00000229267.2	AC072062.1	-6.44	1.78e-10	3.28e-08	-0.26	-0.2	Neuroblastoma;	chr2:214824268	chr2:214810229~214963274:+
BRCA	cis	rs67981189	0.896	rs4391999	ENSG00000269927.1	RP6-91H8.3	6.44	1.78e-10	3.28e-08	0.24	0.2	Schizophrenia;	chr14:70978696	chr14:71141125~71143253:-
BRCA	cis	rs11089937	0.616	rs5995616	ENSG00000211639.2	IGLV4-60	-6.44	1.78e-10	3.28e-08	-0.19	-0.2	Periodontitis (PAL4Q3);	chr22:22186667	chr22:22162199~22162681:+
BRCA	cis	rs7474896	0.583	rs12783272	ENSG00000226578.1	RP11-258F22.1	-6.44	1.78e-10	3.28e-08	-0.27	-0.2	Obesity (extreme);	chr10:37735957	chr10:37775371~37784131:-
BRCA	cis	rs2243480	1	rs781142	ENSG00000228409.4	CCT6P1	6.44	1.78e-10	3.29e-08	0.27	0.2	Diabetic kidney disease;	chr7:65973791	chr7:65751142~65763354:+
BRCA	cis	rs2836950	0.561	rs34705151	ENSG00000255568.3	BRWD1-AS2	-6.44	1.79e-10	3.29e-08	-0.19	-0.2	Menarche (age at onset);	chr21:39181418	chr21:39313935~39314962:+
BRCA	cis	rs67766926	0.587	rs12713431	ENSG00000271889.1	RP11-493E12.1	-6.44	1.79e-10	3.29e-08	-0.29	-0.2	Inflammatory skin disease;	chr2:61022541	chr2:61151433~61162105:-
BRCA	cis	rs11098499	0.954	rs13145352	ENSG00000248280.1	RP11-33B1.2	-6.44	1.79e-10	3.3e-08	-0.2	-0.2	Corneal astigmatism;	chr4:119488808	chr4:119440561~119450157:-
BRCA	cis	rs2243480	1	rs316326	ENSG00000230295.1	RP11-458F8.2	-6.44	1.79e-10	3.3e-08	-0.26	-0.2	Diabetic kidney disease;	chr7:66144466	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs316325	ENSG00000230295.1	RP11-458F8.2	-6.44	1.79e-10	3.3e-08	-0.26	-0.2	Diabetic kidney disease;	chr7:66144531	chr7:66880708~66882981:+
BRCA	cis	rs3760982	0.813	rs8104447	ENSG00000267058.1	RP11-15A1.3	6.44	1.79e-10	3.3e-08	0.23	0.2	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43789126	chr19:43891804~43901805:-
BRCA	cis	rs7267979	0.789	rs2260197	ENSG00000204556.4	CTD-2514C3.1	-6.44	1.79e-10	3.31e-08	-0.27	-0.2	Liver enzyme levels (alkaline phosphatase);	chr20:25303707	chr20:26018832~26020684:+
BRCA	cis	rs10129255	0.957	rs8014696	ENSG00000211972.2	IGHV3-66	-6.44	1.8e-10	3.31e-08	-0.15	-0.2	Kawasaki disease;	chr14:106769752	chr14:106675017~106675544:-
BRCA	cis	rs2911132	0.511	rs13160562	ENSG00000248734.2	CTD-2260A17.1	6.44	1.8e-10	3.32e-08	0.24	0.2	Urate levels (BMI interaction);	chr5:96775667	chr5:96784777~96785999:+
BRCA	cis	rs3126085	0.867	rs12748016	ENSG00000237975.5	FLG-AS1	6.44	1.81e-10	3.33e-08	0.26	0.2	Atopic dermatitis;	chr1:152224759	chr1:152168125~152445456:+
BRCA	cis	rs274567	0.501	rs581968	ENSG00000233006.5	AC034220.3	-6.44	1.81e-10	3.33e-08	-0.16	-0.2	Blood metabolite levels;	chr5:132374510	chr5:132311285~132369916:-
BRCA	cis	rs6860806	0.507	rs274572	ENSG00000233006.5	AC034220.3	-6.44	1.81e-10	3.33e-08	-0.16	-0.2	Breast cancer;	chr5:132375225	chr5:132311285~132369916:-
BRCA	cis	rs2836950	0.545	rs2836952	ENSG00000255568.3	BRWD1-AS2	-6.44	1.81e-10	3.33e-08	-0.19	-0.2	Menarche (age at onset);	chr21:39244725	chr21:39313935~39314962:+
BRCA	cis	rs1499614	0.803	rs1796229	ENSG00000232559.3	GS1-124K5.12	6.44	1.81e-10	3.33e-08	0.37	0.2	Gout;	chr7:66654674	chr7:66554588~66576923:-
BRCA	cis	rs2836950	0.52	rs11911087	ENSG00000238141.2	BRWD1-AS1	-6.44	1.81e-10	3.33e-08	-0.22	-0.2	Menarche (age at onset);	chr21:39293266	chr21:39315707~39323218:+
BRCA	cis	rs1124769	0.748	rs11070832	ENSG00000259378.1	DCAF13P3	6.44	1.81e-10	3.33e-08	0.28	0.2	Cognitive performance;	chr15:51070642	chr15:50944663~50945996:+
BRCA	cis	rs12655019	0.92	rs16886496	ENSG00000271828.1	CTD-2310F14.1	-6.44	1.81e-10	3.33e-08	-0.36	-0.2	Breast cancer (early onset);	chr5:56921702	chr5:56927874~56929573:+
BRCA	cis	rs13113518	0.783	rs6843997	ENSG00000223305.1	RN7SKP30	6.44	1.81e-10	3.33e-08	0.24	0.2	Height;	chr4:55508982	chr4:55540502~55540835:-
BRCA	cis	rs2243480	1	rs160646	ENSG00000230295.1	RP11-458F8.2	-6.44	1.81e-10	3.33e-08	-0.26	-0.2	Diabetic kidney disease;	chr7:66091293	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs2257790	ENSG00000232546.1	RP11-458F8.1	-6.44	1.81e-10	3.33e-08	-0.26	-0.2	Diabetic kidney disease;	chr7:66135463	chr7:66848496~66858136:+
BRCA	cis	rs957448	1	rs72674855	ENSG00000253175.1	RP11-267M23.6	6.44	1.81e-10	3.33e-08	0.24	0.2	Nonsyndromic cleft lip with cleft palate;	chr8:94536706	chr8:94565036~94565715:+
BRCA	cis	rs1124769	0.748	rs2289304	ENSG00000259378.1	DCAF13P3	6.44	1.81e-10	3.34e-08	0.27	0.2	Cognitive performance;	chr15:50997198	chr15:50944663~50945996:+
BRCA	cis	rs793571	0.505	rs16940587	ENSG00000259250.1	RP11-50C13.1	-6.44	1.82e-10	3.35e-08	-0.33	-0.2	Schizophrenia;	chr15:58606464	chr15:58587507~58591676:+
BRCA	cis	rs6504622	0.905	rs9889741	ENSG00000262879.4	RP11-156P1.3	6.44	1.82e-10	3.35e-08	0.2	0.2	Orofacial clefts;	chr17:46948967	chr17:46984045~47100323:-
BRCA	cis	rs42648	0.738	rs10248104	ENSG00000225498.1	AC002064.5	6.44	1.82e-10	3.35e-08	0.21	0.2	Homocysteine levels;	chr7:90265948	chr7:90312496~90322592:+
BRCA	cis	rs2638953	0.924	rs7961407	ENSG00000278733.1	RP11-425D17.1	-6.44	1.82e-10	3.35e-08	-0.25	-0.2	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28195482	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.924	rs7974904	ENSG00000278733.1	RP11-425D17.1	-6.44	1.82e-10	3.35e-08	-0.25	-0.2	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28195491	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.924	rs7974979	ENSG00000278733.1	RP11-425D17.1	-6.44	1.82e-10	3.35e-08	-0.25	-0.2	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28195496	chr12:28185625~28186190:-
BRCA	cis	rs853679	0.517	rs9283884	ENSG00000219392.1	RP1-265C24.5	6.44	1.82e-10	3.35e-08	0.29	0.2	Depression;	chr6:28167882	chr6:28115628~28116551:+
BRCA	cis	rs4950322	0.57	rs17356240	ENSG00000278811.3	LINC00624	6.44	1.82e-10	3.35e-08	0.26	0.2	Protein quantitative trait loci;	chr1:147269877	chr1:147258885~147517875:-
BRCA	cis	rs4950322	0.57	rs1999820	ENSG00000278811.3	LINC00624	6.44	1.82e-10	3.35e-08	0.26	0.2	Protein quantitative trait loci;	chr1:147270329	chr1:147258885~147517875:-
BRCA	cis	rs4950322	0.57	rs4950316	ENSG00000278811.3	LINC00624	6.44	1.82e-10	3.35e-08	0.26	0.2	Protein quantitative trait loci;	chr1:147273712	chr1:147258885~147517875:-
BRCA	cis	rs6840258	1	rs72667750	ENSG00000251411.1	RP11-397E7.4	-6.44	1.82e-10	3.36e-08	-0.28	-0.2	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87009273	chr4:86913266~86914817:-
BRCA	cis	rs7246657	0.943	rs4801803	ENSG00000267422.1	CTD-2554C21.1	6.44	1.83e-10	3.36e-08	0.29	0.2	Coronary artery calcification;	chr19:37476021	chr19:37779686~37792865:+
BRCA	cis	rs3733585	0.66	rs13122290	ENSG00000250413.1	RP11-448G15.1	6.44	1.83e-10	3.36e-08	0.26	0.2	Cleft plate (environmental tobacco smoke interaction);	chr4:9932208	chr4:10006482~10009725:+
BRCA	cis	rs4950322	0.57	rs72691095	ENSG00000278811.3	LINC00624	6.44	1.83e-10	3.37e-08	0.27	0.2	Protein quantitative trait loci;	chr1:147298305	chr1:147258885~147517875:-
BRCA	cis	rs2243480	1	rs1499614	ENSG00000230295.1	RP11-458F8.2	-6.44	1.83e-10	3.37e-08	-0.26	-0.2	Diabetic kidney disease;	chr7:66265811	chr7:66880708~66882981:+
BRCA	cis	rs875971	0.545	rs17138156	ENSG00000273024.4	INTS4P2	-6.44	1.83e-10	3.37e-08	-0.24	-0.2	Aortic root size;	chr7:66249708	chr7:65647864~65715661:+
BRCA	cis	rs13113518	0.783	rs11133389	ENSG00000223305.1	RN7SKP30	6.44	1.83e-10	3.37e-08	0.24	0.2	Height;	chr4:55486718	chr4:55540502~55540835:-
BRCA	cis	rs2243480	1	rs316307	ENSG00000232546.1	RP11-458F8.1	-6.44	1.83e-10	3.37e-08	-0.26	-0.2	Diabetic kidney disease;	chr7:66105184	chr7:66848496~66858136:+
BRCA	cis	rs4072705	0.967	rs4287038	ENSG00000224020.1	MIR181A2HG	6.44	1.83e-10	3.38e-08	0.23	0.2	Menarche (age at onset);	chr9:124607400	chr9:124658467~124698631:+
BRCA	cis	rs957448	0.561	rs12679785	ENSG00000253704.1	RP11-267M23.4	6.44	1.83e-10	3.38e-08	0.21	0.2	Nonsyndromic cleft lip with cleft palate;	chr8:94593349	chr8:94553722~94569745:+
BRCA	cis	rs12444979	0.517	rs720176	ENSG00000261195.1	CTD-2380F24.1	-6.44	1.84e-10	3.38e-08	-0.29	-0.2	Body mass index;	chr16:19710193	chr16:19761172~19766099:-
BRCA	cis	rs4950322	0.57	rs72691041	ENSG00000278811.3	LINC00624	6.44	1.84e-10	3.38e-08	0.26	0.2	Protein quantitative trait loci;	chr1:147267084	chr1:147258885~147517875:-
BRCA	cis	rs17253792	0.822	rs76557162	ENSG00000186615.9	KTN1-AS1	-6.44	1.84e-10	3.38e-08	-0.37	-0.2	Putamen volume;	chr14:55597983	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.908	rs74354306	ENSG00000186615.9	KTN1-AS1	-6.44	1.84e-10	3.38e-08	-0.37	-0.2	Putamen volume;	chr14:55599060	chr14:55499278~55580110:-
BRCA	cis	rs2243480	1	rs465359	ENSG00000232546.1	RP11-458F8.1	-6.44	1.84e-10	3.38e-08	-0.26	-0.2	Diabetic kidney disease;	chr7:66093177	chr7:66848496~66858136:+
BRCA	cis	rs2243480	1	rs462853	ENSG00000232546.1	RP11-458F8.1	-6.44	1.84e-10	3.38e-08	-0.26	-0.2	Diabetic kidney disease;	chr7:66093180	chr7:66848496~66858136:+
BRCA	cis	rs2243480	1	rs160644	ENSG00000232546.1	RP11-458F8.1	-6.44	1.84e-10	3.38e-08	-0.26	-0.2	Diabetic kidney disease;	chr7:66093199	chr7:66848496~66858136:+
BRCA	cis	rs2243480	1	rs160642	ENSG00000232546.1	RP11-458F8.1	-6.44	1.84e-10	3.38e-08	-0.26	-0.2	Diabetic kidney disease;	chr7:66093386	chr7:66848496~66858136:+
BRCA	cis	rs2243480	0.614	rs34032527	ENSG00000232546.1	RP11-458F8.1	-6.44	1.84e-10	3.38e-08	-0.26	-0.2	Diabetic kidney disease;	chr7:66100154	chr7:66848496~66858136:+
BRCA	cis	rs875971	1	rs6945843	ENSG00000224316.1	RP11-479O9.2	-6.44	1.84e-10	3.38e-08	-0.19	-0.2	Aortic root size;	chr7:66269796	chr7:65773620~65802067:+
BRCA	cis	rs755249	0.567	rs16826009	ENSG00000237624.1	OXCT2P1	6.44	1.84e-10	3.39e-08	0.29	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39251230	chr1:39514956~39516490:+
BRCA	cis	rs10492201	0.529	rs4913390	ENSG00000255733.4	IFNG-AS1	-6.44	1.84e-10	3.39e-08	-0.2	-0.2	Itch intensity from mosquito bite adjusted by bite size;	chr12:67993696	chr12:67989445~68234686:+
BRCA	cis	rs10492201	0.529	rs11176998	ENSG00000255733.4	IFNG-AS1	-6.44	1.84e-10	3.39e-08	-0.2	-0.2	Itch intensity from mosquito bite adjusted by bite size;	chr12:67993774	chr12:67989445~68234686:+
BRCA	cis	rs7615952	0.576	rs17523380	ENSG00000171084.14	FAM86JP	6.44	1.84e-10	3.39e-08	0.28	0.2	Blood pressure (smoking interaction);	chr3:126084031	chr3:125916620~125930024:+
BRCA	cis	rs1440410	0.835	rs4690771	ENSG00000250326.1	RP11-284M14.1	-6.44	1.84e-10	3.39e-08	-0.22	-0.2	Ischemic stroke;	chr4:143129944	chr4:142933195~143184861:-
BRCA	cis	rs34779708	1	rs34779708	ENSG00000271335.4	RP11-324I22.4	6.44	1.84e-10	3.39e-08	0.2	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35177257	chr10:35314552~35336401:-
BRCA	cis	rs67981189	0.896	rs8003227	ENSG00000269927.1	RP6-91H8.3	6.44	1.84e-10	3.39e-08	0.24	0.2	Schizophrenia;	chr14:71093635	chr14:71141125~71143253:-
BRCA	cis	rs7978895	0.647	rs7299983	ENSG00000258331.1	RP11-118A3.1	-6.44	1.85e-10	3.4e-08	-0.2	-0.2	Type 2 diabetes;	chr12:43172570	chr12:43155315~43163110:+
BRCA	cis	rs2998286	0.862	rs2993981	ENSG00000254635.4	WAC-AS1	-6.44	1.85e-10	3.4e-08	-0.26	-0.2	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28506552	chr10:28522652~28532743:-
BRCA	cis	rs2998286	0.862	rs2993982	ENSG00000254635.4	WAC-AS1	-6.44	1.85e-10	3.4e-08	-0.26	-0.2	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28506559	chr10:28522652~28532743:-
BRCA	cis	rs367615	0.68	rs385728	ENSG00000249476.1	CTD-2587M2.1	-6.44	1.85e-10	3.4e-08	-0.24	-0.2	Colorectal cancer (SNP x SNP interaction);	chr5:109630308	chr5:109237120~109326369:-
BRCA	cis	rs2243480	1	rs2243480	ENSG00000232559.3	GS1-124K5.12	6.44	1.85e-10	3.4e-08	0.38	0.2	Diabetic kidney disease;	chr7:66134209	chr7:66554588~66576923:-
BRCA	cis	rs1440410	0.835	rs7682068	ENSG00000250326.1	RP11-284M14.1	-6.44	1.85e-10	3.4e-08	-0.21	-0.2	Ischemic stroke;	chr4:143129226	chr4:142933195~143184861:-
BRCA	cis	rs4950322	0.57	rs72691097	ENSG00000278811.3	LINC00624	6.44	1.85e-10	3.4e-08	0.26	0.2	Protein quantitative trait loci;	chr1:147299711	chr1:147258885~147517875:-
BRCA	cis	rs4950322	0.57	rs72691098	ENSG00000278811.3	LINC00624	6.44	1.85e-10	3.4e-08	0.26	0.2	Protein quantitative trait loci;	chr1:147300142	chr1:147258885~147517875:-
BRCA	cis	rs3781264	0.848	rs10509670	ENSG00000273450.1	RP11-76P2.4	-6.44	1.85e-10	3.4e-08	-0.25	-0.2	Esophageal cancer and gastric cancer;	chr10:94308190	chr10:94314907~94315327:-
BRCA	cis	rs2834288	0.536	rs762357	ENSG00000273102.1	AP000569.9	6.44	1.85e-10	3.4e-08	0.22	0.2	Gut microbiota (bacterial taxa);	chr21:33964695	chr21:33967101~33968573:-
BRCA	cis	rs10936632	0.755	rs10804839	ENSG00000242578.1	RP11-469J4.3	-6.44	1.85e-10	3.4e-08	-0.24	-0.2	Prostate cancer;	chr3:170353995	chr3:170410512~170418615:+
BRCA	cis	rs1707322	0.752	rs4586014	ENSG00000281133.1	AL355480.3	-6.44	1.85e-10	3.41e-08	-0.25	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45684771	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.648	rs4439382	ENSG00000281133.1	AL355480.3	-6.44	1.85e-10	3.41e-08	-0.25	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45685133	chr1:45580892~45580996:-
BRCA	cis	rs34779708	0.931	rs4934724	ENSG00000271335.4	RP11-324I22.4	6.44	1.85e-10	3.41e-08	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35104741	chr10:35314552~35336401:-
BRCA	cis	rs11992162	0.967	rs10108320	ENSG00000255046.1	RP11-297N6.4	6.44	1.85e-10	3.41e-08	0.23	0.2	Monocyte count;	chr8:11974754	chr8:11797928~11802568:-
BRCA	cis	rs6570726	1	rs386678	ENSG00000235652.6	RP11-545I5.3	6.44	1.86e-10	3.41e-08	0.19	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145547874	chr6:145799409~145886585:+
BRCA	cis	rs301901	0.828	rs62361485	ENSG00000250155.1	CTD-2353F22.1	6.44	1.86e-10	3.41e-08	0.22	0.2	Height;	chr5:37474739	chr5:36666214~36725195:-
BRCA	cis	rs17767294	0.612	rs9461424	ENSG00000220721.1	OR1F12	6.44	1.86e-10	3.41e-08	0.34	0.2	Parkinson's disease;	chr6:27951623	chr6:28073316~28074233:+
BRCA	cis	rs9876781	1	rs1563736	ENSG00000229759.1	MRPS18AP1	6.44	1.86e-10	3.42e-08	0.22	0.2	Longevity;	chr3:48395329	chr3:48256350~48256938:-
BRCA	cis	rs710913	0.738	rs755247	ENSG00000182109.6	RP11-69E11.4	-6.44	1.86e-10	3.42e-08	-0.22	-0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39528873	chr1:39522280~39546187:-
BRCA	cis	rs6142102	0.961	rs6088361	ENSG00000275784.1	RP5-1125A11.6	-6.44	1.86e-10	3.42e-08	-0.23	-0.2	Skin pigmentation;	chr20:33969520	chr20:33989480~33991818:-
BRCA	cis	rs2243480	1	rs313807	ENSG00000229886.1	RP5-1132H15.3	6.44	1.86e-10	3.42e-08	0.34	0.2	Diabetic kidney disease;	chr7:66034494	chr7:66025126~66031544:-
BRCA	cis	rs2836950	0.545	rs11701805	ENSG00000238141.2	BRWD1-AS1	-6.44	1.86e-10	3.43e-08	-0.22	-0.2	Menarche (age at onset);	chr21:39246757	chr21:39315707~39323218:+
BRCA	cis	rs7760535	0.656	rs7766190	ENSG00000255389.1	C6orf3	-6.44	1.87e-10	3.43e-08	-0.19	-0.2	Metabolic traits;	chr6:111583863	chr6:111599875~111602295:+
BRCA	cis	rs8005677	1	rs8014936	ENSG00000257285.4	RP11-298I3.1	6.44	1.87e-10	3.43e-08	0.21	0.2	Cognitive ability (multi-trait analysis);	chr14:22905936	chr14:22929609~22955562:+
BRCA	cis	rs8005677	1	rs8016061	ENSG00000257285.4	RP11-298I3.1	6.44	1.87e-10	3.43e-08	0.21	0.2	Cognitive ability (multi-trait analysis);	chr14:22906600	chr14:22929609~22955562:+
BRCA	cis	rs227275	0.554	rs223390	ENSG00000251288.2	RP11-10L12.2	-6.44	1.87e-10	3.43e-08	-0.23	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102827640	chr4:102751401~102752641:+
BRCA	cis	rs12468226	0.873	rs60722019	ENSG00000226261.1	AC064836.3	6.44	1.87e-10	3.43e-08	0.33	0.2	Urate levels;	chr2:202282060	chr2:202336024~202336727:-
BRCA	cis	rs860818	1	rs858278	ENSG00000226816.2	AC005082.12	6.44	1.87e-10	3.43e-08	0.49	0.2	Initial pursuit acceleration;	chr7:23212583	chr7:23206013~23208045:+
BRCA	cis	rs17772222	0.74	rs4390529	ENSG00000258983.2	RP11-507K2.2	6.44	1.87e-10	3.44e-08	0.21	0.2	Coronary artery calcification;	chr14:88510853	chr14:88499334~88515502:+
BRCA	cis	rs17772222	0.771	rs4516145	ENSG00000258983.2	RP11-507K2.2	6.44	1.87e-10	3.44e-08	0.21	0.2	Coronary artery calcification;	chr14:88510953	chr14:88499334~88515502:+
BRCA	cis	rs1823913	0.599	rs7598639	ENSG00000280083.1	RP11-317J9.1	-6.44	1.87e-10	3.44e-08	-0.22	-0.2	Obesity-related traits;	chr2:191267958	chr2:191154118~191156070:-
BRCA	cis	rs7246657	0.943	rs10426666	ENSG00000267422.1	CTD-2554C21.1	-6.44	1.87e-10	3.44e-08	-0.3	-0.2	Coronary artery calcification;	chr19:37337612	chr19:37779686~37792865:+
BRCA	cis	rs7246657	0.943	rs28402338	ENSG00000267422.1	CTD-2554C21.1	-6.44	1.87e-10	3.44e-08	-0.3	-0.2	Coronary artery calcification;	chr19:37343021	chr19:37779686~37792865:+
BRCA	cis	rs7246657	0.943	rs10417503	ENSG00000267422.1	CTD-2554C21.1	-6.44	1.87e-10	3.44e-08	-0.3	-0.2	Coronary artery calcification;	chr19:37351833	chr19:37779686~37792865:+
BRCA	cis	rs7246657	0.943	rs9304566	ENSG00000267422.1	CTD-2554C21.1	-6.44	1.87e-10	3.44e-08	-0.3	-0.2	Coronary artery calcification;	chr19:37354602	chr19:37779686~37792865:+
BRCA	cis	rs7246657	0.943	rs4417644	ENSG00000267422.1	CTD-2554C21.1	-6.44	1.87e-10	3.44e-08	-0.3	-0.2	Coronary artery calcification;	chr19:37361570	chr19:37779686~37792865:+
BRCA	cis	rs7246657	0.943	rs10405064	ENSG00000267422.1	CTD-2554C21.1	-6.44	1.87e-10	3.44e-08	-0.3	-0.2	Coronary artery calcification;	chr19:37370959	chr19:37779686~37792865:+
BRCA	cis	rs2243480	1	rs6974723	ENSG00000229886.1	RP5-1132H15.3	-6.44	1.88e-10	3.45e-08	-0.34	-0.2	Diabetic kidney disease;	chr7:66172952	chr7:66025126~66031544:-
BRCA	cis	rs2243480	1	rs9769882	ENSG00000229886.1	RP5-1132H15.3	-6.44	1.88e-10	3.45e-08	-0.34	-0.2	Diabetic kidney disease;	chr7:66177938	chr7:66025126~66031544:-
BRCA	cis	rs2243480	1	rs6966322	ENSG00000229886.1	RP5-1132H15.3	-6.44	1.88e-10	3.45e-08	-0.34	-0.2	Diabetic kidney disease;	chr7:66181767	chr7:66025126~66031544:-
BRCA	cis	rs2243480	1	rs4145008	ENSG00000229886.1	RP5-1132H15.3	-6.44	1.88e-10	3.45e-08	-0.34	-0.2	Diabetic kidney disease;	chr7:66182524	chr7:66025126~66031544:-
BRCA	cis	rs1440410	0.798	rs11100773	ENSG00000250326.1	RP11-284M14.1	-6.44	1.88e-10	3.45e-08	-0.21	-0.2	Ischemic stroke;	chr4:143133075	chr4:142933195~143184861:-
BRCA	cis	rs875971	0.789	rs28815324	ENSG00000273024.4	INTS4P2	6.43	1.88e-10	3.46e-08	0.25	0.2	Aortic root size;	chr7:66100789	chr7:65647864~65715661:+
BRCA	cis	rs78456975	1	rs78456975	ENSG00000231482.2	AC141930.2	-6.43	1.88e-10	3.46e-08	-0.29	-0.2	Placebo response in major depressive disorder (% change in symptom score);	chr2:1550418	chr2:1572554~1580311:-
BRCA	cis	rs78456975	1	rs111935361	ENSG00000231482.2	AC141930.2	-6.43	1.88e-10	3.46e-08	-0.29	-0.2	Placebo response in major depressive disorder (% change in symptom score);	chr2:1550420	chr2:1572554~1580311:-
BRCA	cis	rs2243480	1	rs313831	ENSG00000229886.1	RP5-1132H15.3	6.43	1.88e-10	3.46e-08	0.36	0.2	Diabetic kidney disease;	chr7:66086239	chr7:66025126~66031544:-
BRCA	cis	rs67766926	0.543	rs68180594	ENSG00000271889.1	RP11-493E12.1	6.43	1.88e-10	3.46e-08	0.3	0.2	Inflammatory skin disease;	chr2:61042787	chr2:61151433~61162105:-
BRCA	cis	rs1061377	0.748	rs11096977	ENSG00000249685.1	RP11-360F5.3	6.43	1.88e-10	3.46e-08	0.24	0.2	Uric acid levels;	chr4:39106186	chr4:39133913~39135608:+
BRCA	cis	rs9992667	0.955	rs7654470	ENSG00000231160.8	KLF3-AS1	6.43	1.89e-10	3.46e-08	0.24	0.2	Eosinophil percentage of granulocytes;	chr4:38634608	chr4:38612701~38664883:-
BRCA	cis	rs4713118	0.513	rs9368547	ENSG00000204709.4	LINC01556	6.43	1.89e-10	3.47e-08	0.26	0.2	Parkinson's disease;	chr6:28060289	chr6:28943877~28944537:+
BRCA	cis	rs4713118	0.513	rs183244	ENSG00000204709.4	LINC01556	6.43	1.89e-10	3.47e-08	0.26	0.2	Parkinson's disease;	chr6:28064060	chr6:28943877~28944537:+
BRCA	cis	rs1823913	0.614	rs12616167	ENSG00000280083.1	RP11-317J9.1	6.43	1.89e-10	3.47e-08	0.22	0.2	Obesity-related traits;	chr2:191311274	chr2:191154118~191156070:-
BRCA	cis	rs6142102	0.961	rs1007090	ENSG00000275784.1	RP5-1125A11.6	-6.43	1.89e-10	3.47e-08	-0.24	-0.2	Skin pigmentation;	chr20:33995065	chr20:33989480~33991818:-
BRCA	cis	rs6142102	0.923	rs2284377	ENSG00000275784.1	RP5-1125A11.6	-6.43	1.89e-10	3.47e-08	-0.24	-0.2	Skin pigmentation;	chr20:33998876	chr20:33989480~33991818:-
BRCA	cis	rs6142102	0.961	rs2284378	ENSG00000275784.1	RP5-1125A11.6	-6.43	1.89e-10	3.47e-08	-0.24	-0.2	Skin pigmentation;	chr20:34000289	chr20:33989480~33991818:-
BRCA	cis	rs6142102	0.961	rs2268080	ENSG00000275784.1	RP5-1125A11.6	-6.43	1.89e-10	3.47e-08	-0.24	-0.2	Skin pigmentation;	chr20:34009910	chr20:33989480~33991818:-
BRCA	cis	rs6728642	1	rs116171118	ENSG00000230606.9	AC159540.1	6.43	1.89e-10	3.48e-08	0.42	0.2	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:97029299	chr2:97416165~97433527:-
BRCA	cis	rs6840360	0.642	rs10454251	ENSG00000270265.1	RP11-731D1.4	-6.43	1.89e-10	3.48e-08	-0.22	-0.2	Intelligence (multi-trait analysis);	chr4:151462810	chr4:151333775~151353224:-
BRCA	cis	rs6545883	0.965	rs10186325	ENSG00000271889.1	RP11-493E12.1	6.43	1.89e-10	3.48e-08	0.25	0.2	Tuberculosis;	chr2:61530586	chr2:61151433~61162105:-
BRCA	cis	rs9307551	0.948	rs13109727	ENSG00000250334.4	LINC00989	-6.43	1.9e-10	3.48e-08	-0.29	-0.2	Refractive error;	chr4:79609563	chr4:79492416~79576460:+
BRCA	cis	rs9876781	1	rs9876781	ENSG00000229759.1	MRPS18AP1	6.43	1.9e-10	3.48e-08	0.22	0.2	Longevity;	chr3:48445934	chr3:48256350~48256938:-
BRCA	cis	rs2239547	0.523	rs6803486	ENSG00000242142.1	SERBP1P3	6.43	1.9e-10	3.48e-08	0.24	0.2	Schizophrenia;	chr3:53064193	chr3:53064283~53065091:-
BRCA	cis	rs1440410	0.835	rs7684847	ENSG00000250326.1	RP11-284M14.1	-6.43	1.9e-10	3.48e-08	-0.22	-0.2	Ischemic stroke;	chr4:143133414	chr4:142933195~143184861:-
BRCA	cis	rs7182621	0.639	rs34701806	ENSG00000182397.13	DNM1P46	6.43	1.9e-10	3.49e-08	0.24	0.2	Colonoscopy-negative controls vs population controls;	chr15:99872953	chr15:99790156~99806927:-
BRCA	cis	rs755249	0.567	rs61779308	ENSG00000228060.1	RP11-69E11.8	-6.43	1.9e-10	3.49e-08	-0.25	-0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39472585	chr1:39565160~39573203:+
BRCA	cis	rs4237845	0.804	rs11172372	ENSG00000257159.1	RP11-58A17.3	6.43	1.9e-10	3.5e-08	0.22	0.2	Intelligence (multi-trait analysis);	chr12:57892490	chr12:57967058~57968399:+
BRCA	cis	rs2644899	0.593	rs3733828	ENSG00000268529.1	CYP2T3P	6.43	1.91e-10	3.5e-08	0.25	0.2	Post bronchodilator FEV1/FVC ratio;	chr19:40804704	chr19:41134722~41137308:+
BRCA	cis	rs2281636	0.723	rs11190246	ENSG00000233690.1	EBAG9P1	6.43	1.91e-10	3.5e-08	0.23	0.2	Obesity-related traits;	chr10:99691854	chr10:99697407~99697949:-
BRCA	cis	rs875971	0.825	rs6951503	ENSG00000224316.1	RP11-479O9.2	-6.43	1.91e-10	3.5e-08	-0.2	-0.2	Aortic root size;	chr7:66253949	chr7:65773620~65802067:+
BRCA	cis	rs875971	1	rs778696	ENSG00000224316.1	RP11-479O9.2	6.43	1.91e-10	3.51e-08	0.19	0.2	Aortic root size;	chr7:66405826	chr7:65773620~65802067:+
BRCA	cis	rs875971	1	rs778694	ENSG00000224316.1	RP11-479O9.2	6.43	1.91e-10	3.51e-08	0.19	0.2	Aortic root size;	chr7:66406571	chr7:65773620~65802067:+
BRCA	cis	rs875971	1	rs4718344	ENSG00000224316.1	RP11-479O9.2	6.43	1.91e-10	3.51e-08	0.19	0.2	Aortic root size;	chr7:66409394	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.737	rs7803424	ENSG00000224316.1	RP11-479O9.2	6.43	1.91e-10	3.51e-08	0.19	0.2	Aortic root size;	chr7:66415618	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.83	rs7799834	ENSG00000224316.1	RP11-479O9.2	6.43	1.91e-10	3.51e-08	0.19	0.2	Aortic root size;	chr7:66415707	chr7:65773620~65802067:+
BRCA	cis	rs3764021	0.527	rs10844380	ENSG00000214776.8	RP11-726G1.1	6.43	1.91e-10	3.51e-08	0.24	0.2	Type 1 diabetes;	chr12:9670678	chr12:9467552~9576275:+
BRCA	cis	rs67766926	0.587	rs6727926	ENSG00000271889.1	RP11-493E12.1	6.43	1.91e-10	3.51e-08	0.3	0.2	Inflammatory skin disease;	chr2:61013401	chr2:61151433~61162105:-
BRCA	cis	rs2439831	0.702	rs16977724	ENSG00000275601.1	AC011330.13	-6.43	1.91e-10	3.51e-08	-0.33	-0.2	Lung cancer in ever smokers;	chr15:43859101	chr15:43642389~43643023:-
BRCA	cis	rs7586673	0.866	rs7579662	ENSG00000235724.7	AC009299.2	-6.43	1.91e-10	3.51e-08	-0.23	-0.2	Intelligence (multi-trait analysis);	chr2:161059299	chr2:161222785~161308303:-
BRCA	cis	rs2243480	0.708	rs13242216	ENSG00000230295.1	RP11-458F8.2	-6.43	1.92e-10	3.52e-08	-0.26	-0.2	Diabetic kidney disease;	chr7:66433290	chr7:66880708~66882981:+
BRCA	cis	rs8098244	0.597	rs1154246	ENSG00000264745.1	TTC39C-AS1	6.43	1.92e-10	3.52e-08	0.3	0.2	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23984242	chr18:23994213~24015339:-
BRCA	cis	rs1552244	0.832	rs3732968	ENSG00000180385.7	EMC3-AS1	6.43	1.92e-10	3.52e-08	0.24	0.2	Alzheimer's disease;	chr3:9971589	chr3:9986893~10006990:+
BRCA	cis	rs10740039	0.768	rs1372710	ENSG00000254271.1	RP11-131N11.4	6.43	1.92e-10	3.52e-08	0.27	0.2	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60603200	chr10:60734342~60741828:+
BRCA	cis	rs11098499	0.82	rs28578366	ENSG00000249244.1	RP11-548H18.2	-6.43	1.92e-10	3.52e-08	-0.23	-0.2	Corneal astigmatism;	chr4:119615750	chr4:119391831~119395335:-
BRCA	cis	rs875971	0.964	rs1643388	ENSG00000224316.1	RP11-479O9.2	6.43	1.92e-10	3.52e-08	0.19	0.2	Aortic root size;	chr7:66379575	chr7:65773620~65802067:+
BRCA	cis	rs875971	1	rs778722	ENSG00000224316.1	RP11-479O9.2	6.43	1.92e-10	3.52e-08	0.19	0.2	Aortic root size;	chr7:66379841	chr7:65773620~65802067:+
BRCA	cis	rs17772222	0.74	rs10138309	ENSG00000258983.2	RP11-507K2.2	6.43	1.92e-10	3.53e-08	0.21	0.2	Coronary artery calcification;	chr14:88510352	chr14:88499334~88515502:+
BRCA	cis	rs2348418	0.932	rs6487685	ENSG00000247934.4	RP11-967K21.1	6.43	1.92e-10	3.53e-08	0.22	0.2	Lung function (FEV1);Lung function (FVC);	chr12:28505417	chr12:28163298~28190738:-
BRCA	cis	rs2243480	1	rs313814	ENSG00000232546.1	RP11-458F8.1	-6.43	1.92e-10	3.53e-08	-0.26	-0.2	Diabetic kidney disease;	chr7:66038306	chr7:66848496~66858136:+
BRCA	cis	rs875971	0.929	rs778712	ENSG00000224316.1	RP11-479O9.2	6.43	1.92e-10	3.53e-08	0.19	0.2	Aortic root size;	chr7:66384991	chr7:65773620~65802067:+
BRCA	cis	rs8016982	0.674	rs1951614	ENSG00000258999.1	RP11-114N19.3	-6.43	1.92e-10	3.53e-08	-0.24	-0.2	Schizophrenia;	chr14:81205762	chr14:81107033~81170414:-
BRCA	cis	rs6840360	0.681	rs4519779	ENSG00000270265.1	RP11-731D1.4	-6.43	1.92e-10	3.53e-08	-0.22	-0.2	Intelligence (multi-trait analysis);	chr4:151380033	chr4:151333775~151353224:-
BRCA	cis	rs17301013	0.606	rs10912728	ENSG00000227373.4	RP11-160H22.5	6.43	1.93e-10	3.53e-08	0.29	0.2	Systemic lupus erythematosus;	chr1:174093234	chr1:174115300~174160004:-
BRCA	cis	rs875971	0.964	rs778721	ENSG00000224316.1	RP11-479O9.2	6.43	1.93e-10	3.53e-08	0.19	0.2	Aortic root size;	chr7:66380410	chr7:65773620~65802067:+
BRCA	cis	rs651907	0.557	rs2288272	ENSG00000244119.1	PDCL3P4	6.43	1.93e-10	3.54e-08	0.16	0.2	Colorectal cancer;	chr3:101659632	chr3:101712472~101713191:+
BRCA	cis	rs1150668	0.83	rs2531831	ENSG00000220721.1	OR1F12	6.43	1.93e-10	3.54e-08	0.22	0.2	Pubertal anthropometrics;	chr6:28420988	chr6:28073316~28074233:+
BRCA	cis	rs11976180	1	rs2951360	ENSG00000273234.1	OR2A13P	-6.43	1.93e-10	3.54e-08	-0.27	-0.2	Obesity-related traits;	chr7:144060256	chr7:144142009~144142938:+
BRCA	cis	rs17711722	0.74	rs7809991	ENSG00000234585.5	CCT6P3	6.43	1.93e-10	3.54e-08	0.19	0.2	Calcium levels;	chr7:65941231	chr7:65038354~65074713:+
BRCA	cis	rs17301013	0.507	rs11807229	ENSG00000227373.4	RP11-160H22.5	6.43	1.93e-10	3.55e-08	0.3	0.2	Systemic lupus erythematosus;	chr1:174519456	chr1:174115300~174160004:-
BRCA	cis	rs496547	0.719	rs476246	ENSG00000255422.1	AP002954.4	6.43	1.93e-10	3.55e-08	0.23	0.2	Hip minimal joint space width;	chr11:118747211	chr11:118704607~118750263:+
BRCA	cis	rs8005677	1	rs8005677	ENSG00000257285.4	RP11-298I3.1	6.43	1.94e-10	3.55e-08	0.21	0.2	Cognitive ability (multi-trait analysis);	chr14:22907469	chr14:22929609~22955562:+
BRCA	cis	rs2732480	0.577	rs2634680	ENSG00000257763.1	OR5BK1P	6.43	1.94e-10	3.55e-08	0.21	0.2	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48340781	chr12:48355792~48356614:-
BRCA	cis	rs2732480	0.577	rs2634678	ENSG00000257763.1	OR5BK1P	6.43	1.94e-10	3.55e-08	0.21	0.2	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48341755	chr12:48355792~48356614:-
BRCA	cis	rs2732480	0.577	rs1489109	ENSG00000257763.1	OR5BK1P	6.43	1.94e-10	3.55e-08	0.21	0.2	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344997	chr12:48355792~48356614:-
BRCA	cis	rs2732480	0.577	rs1489108	ENSG00000257763.1	OR5BK1P	6.43	1.94e-10	3.55e-08	0.21	0.2	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344998	chr12:48355792~48356614:-
BRCA	cis	rs4664293	0.51	rs1968343	ENSG00000226266.5	AC009961.3	6.43	1.94e-10	3.55e-08	0.24	0.2	Monocyte percentage of white cells;	chr2:159712247	chr2:159670708~159712435:-
BRCA	cis	rs2732480	0.577	rs2732479	ENSG00000257763.1	OR5BK1P	6.43	1.94e-10	3.55e-08	0.21	0.2	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48342477	chr12:48355792~48356614:-
BRCA	cis	rs2732480	0.537	rs1061986	ENSG00000257763.1	OR5BK1P	6.43	1.94e-10	3.55e-08	0.21	0.2	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48342656	chr12:48355792~48356614:-
BRCA	cis	rs8031584	0.958	rs3512	ENSG00000260382.1	RP11-540B6.2	6.43	1.94e-10	3.56e-08	0.24	0.2	Huntington's disease progression;	chr15:30942802	chr15:30882267~30883231:-
BRCA	cis	rs4713118	0.512	rs2622319	ENSG00000204709.4	LINC01556	6.43	1.94e-10	3.56e-08	0.27	0.2	Parkinson's disease;	chr6:28152623	chr6:28943877~28944537:+
BRCA	cis	rs172166	0.694	rs1150666	ENSG00000204709.4	LINC01556	6.43	1.94e-10	3.56e-08	0.27	0.2	Cardiac Troponin-T levels;	chr6:28156150	chr6:28943877~28944537:+
BRCA	cis	rs780096	0.967	rs1260334	ENSG00000234072.1	AC074117.10	-6.43	1.94e-10	3.56e-08	-0.18	-0.2	Total body bone mineral density;	chr2:27525730	chr2:27356246~27367622:+
BRCA	cis	rs6142102	0.961	rs2284387	ENSG00000275784.1	RP5-1125A11.6	-6.43	1.94e-10	3.56e-08	-0.24	-0.2	Skin pigmentation;	chr20:34056782	chr20:33989480~33991818:-
BRCA	cis	rs7131987	0.565	rs10843365	ENSG00000275476.1	RP11-996F15.4	6.43	1.94e-10	3.57e-08	0.22	0.2	QT interval;	chr12:29252691	chr12:29277397~29277882:-
BRCA	cis	rs78456975	1	rs10205916	ENSG00000231482.2	AC141930.2	6.43	1.95e-10	3.57e-08	0.29	0.2	Placebo response in major depressive disorder (% change in symptom score);	chr2:1554679	chr2:1572554~1580311:-
BRCA	cis	rs13113518	0.812	rs1522114	ENSG00000223305.1	RN7SKP30	6.43	1.95e-10	3.57e-08	0.24	0.2	Height;	chr4:55489895	chr4:55540502~55540835:-
BRCA	cis	rs916888	0.773	rs9896243	ENSG00000232300.1	FAM215B	6.43	1.95e-10	3.57e-08	0.31	0.2	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:46558830~46562795:-
BRCA	cis	rs9549328	0.8	rs9549326	ENSG00000267868.1	RP11-120K24.3	6.43	1.95e-10	3.57e-08	0.27	0.2	Systolic blood pressure;	chr13:112976139	chr13:112964835~112966131:-
BRCA	cis	rs9291683	0.53	rs10939620	ENSG00000250413.1	RP11-448G15.1	6.43	1.95e-10	3.58e-08	0.25	0.2	Bone mineral density;	chr4:9944508	chr4:10006482~10009725:+
BRCA	cis	rs4908760	0.792	rs6577515	ENSG00000270282.1	RP5-1115A15.2	6.43	1.95e-10	3.58e-08	0.21	0.2	Vitiligo;	chr1:8654143	chr1:8512653~8513021:+
BRCA	cis	rs7567389	0.677	rs11680949	ENSG00000236682.1	AC068282.3	-6.43	1.95e-10	3.58e-08	-0.29	-0.2	Self-rated health;	chr2:127365986	chr2:127389130~127400580:+
BRCA	cis	rs710913	0.618	rs6587	ENSG00000237624.1	OXCT2P1	6.43	1.95e-10	3.58e-08	0.23	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39624273	chr1:39514956~39516490:+
BRCA	cis	rs12594515	1	rs12592190	ENSG00000259200.1	RP11-718O11.1	-6.43	1.95e-10	3.58e-08	-0.22	-0.2	Weight;Waist circumference;	chr15:45701830	chr15:45705078~45931069:+
BRCA	cis	rs12594515	1	rs11854554	ENSG00000259200.1	RP11-718O11.1	-6.43	1.95e-10	3.58e-08	-0.22	-0.2	Weight;Waist circumference;	chr15:45702348	chr15:45705078~45931069:+
BRCA	cis	rs12594515	1	rs35182335	ENSG00000259200.1	RP11-718O11.1	-6.43	1.95e-10	3.58e-08	-0.22	-0.2	Weight;Waist circumference;	chr15:45702986	chr15:45705078~45931069:+
BRCA	cis	rs12594515	1	rs11855509	ENSG00000259200.1	RP11-718O11.1	-6.43	1.95e-10	3.58e-08	-0.22	-0.2	Weight;Waist circumference;	chr15:45703276	chr15:45705078~45931069:+
BRCA	cis	rs12594515	1	rs11855562	ENSG00000259200.1	RP11-718O11.1	-6.43	1.95e-10	3.58e-08	-0.22	-0.2	Weight;Waist circumference;	chr15:45703461	chr15:45705078~45931069:+
BRCA	cis	rs34779708	0.931	rs35848945	ENSG00000271335.4	RP11-324I22.4	6.43	1.95e-10	3.58e-08	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:34998633	chr10:35314552~35336401:-
BRCA	cis	rs6688613	1	rs6688613	ENSG00000225171.2	DUTP6	6.43	1.96e-10	3.59e-08	0.23	0.2	Refractive astigmatism;	chr1:166982632	chr1:166868748~166869209:+
BRCA	cis	rs9876781	1	rs13071337	ENSG00000229759.1	MRPS18AP1	6.43	1.96e-10	3.59e-08	0.22	0.2	Longevity;	chr3:48396724	chr3:48256350~48256938:-
BRCA	cis	rs9907295	1	rs11655533	ENSG00000270977.1	AC015849.16	-6.43	1.96e-10	3.6e-08	-0.33	-0.2	Fibroblast growth factor basic levels;	chr17:35908002	chr17:35893707~35911023:-
BRCA	cis	rs2243480	1	rs1964692	ENSG00000229886.1	RP5-1132H15.3	6.43	1.96e-10	3.6e-08	0.34	0.2	Diabetic kidney disease;	chr7:65989196	chr7:66025126~66031544:-
BRCA	cis	rs11098499	0.954	rs6849561	ENSG00000249244.1	RP11-548H18.2	-6.43	1.96e-10	3.6e-08	-0.24	-0.2	Corneal astigmatism;	chr4:119488539	chr4:119391831~119395335:-
BRCA	cis	rs6479891	0.908	rs4746201	ENSG00000232075.1	MRPL35P2	6.43	1.96e-10	3.6e-08	0.36	0.2	Arthritis (juvenile idiopathic);	chr10:63562621	chr10:63634317~63634827:-
BRCA	cis	rs1823913	0.599	rs56328712	ENSG00000280083.1	RP11-317J9.1	-6.43	1.97e-10	3.6e-08	-0.22	-0.2	Obesity-related traits;	chr2:191273807	chr2:191154118~191156070:-
BRCA	cis	rs1823913	0.599	rs55862924	ENSG00000280083.1	RP11-317J9.1	-6.43	1.97e-10	3.6e-08	-0.22	-0.2	Obesity-related traits;	chr2:191273809	chr2:191154118~191156070:-
BRCA	cis	rs34779708	0.966	rs6481941	ENSG00000271335.4	RP11-324I22.4	6.43	1.97e-10	3.6e-08	0.2	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35151213	chr10:35314552~35336401:-
BRCA	cis	rs932287	1	rs932287	ENSG00000254860.4	TMEM9B-AS1	6.43	1.97e-10	3.61e-08	0.18	0.2	Colonoscopy-negative controls vs population controls;	chr11:9023220	chr11:8964675~8977527:+
BRCA	cis	rs2243480	1	rs4718315	ENSG00000229886.1	RP5-1132H15.3	-6.43	1.97e-10	3.61e-08	-0.34	-0.2	Diabetic kidney disease;	chr7:66183554	chr7:66025126~66031544:-
BRCA	cis	rs2243480	1	rs4718316	ENSG00000229886.1	RP5-1132H15.3	-6.43	1.97e-10	3.61e-08	-0.34	-0.2	Diabetic kidney disease;	chr7:66183744	chr7:66025126~66031544:-
BRCA	cis	rs2638953	0.924	rs11049399	ENSG00000247934.4	RP11-967K21.1	-6.43	1.97e-10	3.61e-08	-0.25	-0.2	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28174213	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.924	rs61920227	ENSG00000247934.4	RP11-967K21.1	-6.43	1.97e-10	3.61e-08	-0.25	-0.2	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28174584	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.924	rs11049400	ENSG00000247934.4	RP11-967K21.1	-6.43	1.97e-10	3.61e-08	-0.25	-0.2	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28175051	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.924	rs11049401	ENSG00000247934.4	RP11-967K21.1	-6.43	1.97e-10	3.61e-08	-0.25	-0.2	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28175218	chr12:28163298~28190738:-
BRCA	cis	rs867371	1	rs6495642	ENSG00000276710.3	CSPG4P8	-6.43	1.97e-10	3.61e-08	-0.21	-0.2	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82165156	chr15:82459472~82477258:+
BRCA	cis	rs7131987	0.565	rs4412790	ENSG00000257176.2	RP11-996F15.2	6.43	1.97e-10	3.61e-08	0.22	0.2	QT interval;	chr12:29253828	chr12:29280418~29317848:-
BRCA	cis	rs7246657	0.943	rs10403613	ENSG00000267422.1	CTD-2554C21.1	-6.43	1.97e-10	3.61e-08	-0.3	-0.2	Coronary artery calcification;	chr19:37353404	chr19:37779686~37792865:+
BRCA	cis	rs7674212	0.581	rs10516496	ENSG00000251288.2	RP11-10L12.2	-6.43	1.98e-10	3.62e-08	-0.24	-0.2	Type 2 diabetes;	chr4:103021008	chr4:102751401~102752641:+
BRCA	cis	rs8031584	0.541	rs2955797	ENSG00000270015.1	RP11-540B6.6	6.43	1.98e-10	3.63e-08	0.2	0.2	Huntington's disease progression;	chr15:30918778	chr15:30926514~30928407:+
BRCA	cis	rs2898290	0.5	rs11998678	ENSG00000254866.2	DEFB109P3	6.43	1.98e-10	3.63e-08	0.26	0.2	Systolic blood pressure;	chr8:11972641	chr8:12150895~12151134:-
BRCA	cis	rs7246657	0.943	rs10415358	ENSG00000267422.1	CTD-2554C21.1	-6.43	1.98e-10	3.63e-08	-0.3	-0.2	Coronary artery calcification;	chr19:37317961	chr19:37779686~37792865:+
BRCA	cis	rs875971	0.545	rs35459055	ENSG00000236529.1	RP13-254B10.1	6.43	1.98e-10	3.63e-08	0.24	0.2	Aortic root size;	chr7:66479399	chr7:65840212~65840596:+
BRCA	cis	rs2153535	0.585	rs1983603	ENSG00000230939.1	RP11-314C16.1	-6.43	1.99e-10	3.64e-08	-0.22	-0.2	Motion sickness;	chr6:8580747	chr6:8784178~8785445:+
BRCA	cis	rs6504622	1	rs2003539	ENSG00000262879.4	RP11-156P1.3	-6.43	1.99e-10	3.64e-08	-0.2	-0.2	Orofacial clefts;	chr17:46947953	chr17:46984045~47100323:-
BRCA	cis	rs1707322	0.963	rs4630155	ENSG00000281133.1	AL355480.3	-6.43	1.99e-10	3.64e-08	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45791438	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.963	rs12076580	ENSG00000281133.1	AL355480.3	-6.43	1.99e-10	3.64e-08	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45792487	chr1:45580892~45580996:-
BRCA	cis	rs2836950	0.585	rs1029004	ENSG00000255568.3	BRWD1-AS2	-6.43	1.99e-10	3.65e-08	-0.19	-0.2	Menarche (age at onset);	chr21:39243417	chr21:39313935~39314962:+
BRCA	cis	rs5015933	1	rs10760395	ENSG00000232630.1	PRPS1P2	-6.43	1.99e-10	3.65e-08	-0.18	-0.2	Body mass index;	chr9:125369582	chr9:125150653~125151589:+
BRCA	cis	rs67981189	0.752	rs221902	ENSG00000269927.1	RP6-91H8.3	-6.43	1.99e-10	3.65e-08	-0.24	-0.2	Schizophrenia;	chr14:71134362	chr14:71141125~71143253:-
BRCA	cis	rs34779708	1	rs12769189	ENSG00000271335.4	RP11-324I22.4	6.43	1.99e-10	3.65e-08	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35110740	chr10:35314552~35336401:-
BRCA	cis	rs13108904	0.71	rs11937232	ENSG00000254094.1	AC078852.1	-6.43	1.99e-10	3.65e-08	-0.21	-0.2	Obesity-related traits;	chr4:1213809	chr4:1356581~1358075:+
BRCA	cis	rs7914558	0.966	rs10786725	ENSG00000213061.2	PFN1P11	6.43	2e-10	3.66e-08	0.26	0.2	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102922600	chr10:102838011~102845473:-
BRCA	cis	rs7809950	0.817	rs34325395	ENSG00000238832.1	snoU109	-6.43	2e-10	3.66e-08	-0.29	-0.2	Coronary artery disease;	chr7:107473363	chr7:107603363~107603507:+
BRCA	cis	rs2274273	0.638	rs17672364	ENSG00000258413.1	RP11-665C16.6	-6.43	2e-10	3.67e-08	-0.27	-0.2	Protein biomarker;	chr14:55239186	chr14:55262767~55272075:-
BRCA	cis	rs867371	1	rs7181655	ENSG00000276710.3	CSPG4P8	-6.43	2e-10	3.67e-08	-0.21	-0.2	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82163275	chr15:82459472~82477258:+
BRCA	cis	rs34779708	0.931	rs7897457	ENSG00000271335.4	RP11-324I22.4	6.42	2e-10	3.67e-08	0.2	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35097112	chr10:35314552~35336401:-
BRCA	cis	rs919433	0.889	rs788001	ENSG00000231621.1	AC013264.2	-6.42	2.01e-10	3.67e-08	-0.18	-0.2	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197348996	chr2:197197991~197199273:+
BRCA	cis	rs17253792	0.908	rs9972177	ENSG00000186615.9	KTN1-AS1	-6.42	2.01e-10	3.67e-08	-0.37	-0.2	Putamen volume;	chr14:55606488	chr14:55499278~55580110:-
BRCA	cis	rs3733585	0.674	rs7375643	ENSG00000250413.1	RP11-448G15.1	6.42	2.01e-10	3.68e-08	0.25	0.2	Cleft plate (environmental tobacco smoke interaction);	chr4:9953615	chr4:10006482~10009725:+
BRCA	cis	rs72772090	1	rs72772092	ENSG00000248734.2	CTD-2260A17.1	-6.42	2.01e-10	3.68e-08	-0.3	-0.2	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96711208	chr5:96784777~96785999:+
BRCA	cis	rs875971	0.545	rs221986	ENSG00000273024.4	INTS4P2	6.42	2.01e-10	3.69e-08	0.25	0.2	Aortic root size;	chr7:66105323	chr7:65647864~65715661:+
BRCA	cis	rs904251	0.861	rs1776456	ENSG00000204110.6	RP1-153P14.8	-6.42	2.01e-10	3.69e-08	-0.22	-0.2	Cognitive performance;	chr6:37516922	chr6:37507348~37535616:+
BRCA	cis	rs2243480	1	rs422164	ENSG00000232546.1	RP11-458F8.1	-6.42	2.01e-10	3.69e-08	-0.26	-0.2	Diabetic kidney disease;	chr7:66121618	chr7:66848496~66858136:+
BRCA	cis	rs16978956	0.901	rs2424167	ENSG00000236474.1	GCNT1P1	-6.42	2.01e-10	3.69e-08	-0.23	-0.2	Body mass index;	chr20:18344711	chr20:18420160~18421454:-
BRCA	cis	rs11098499	0.865	rs11722183	ENSG00000249244.1	RP11-548H18.2	6.42	2.01e-10	3.69e-08	0.23	0.2	Corneal astigmatism;	chr4:119359442	chr4:119391831~119395335:-
BRCA	cis	rs1552244	0.882	rs13063929	ENSG00000180385.7	EMC3-AS1	6.42	2.02e-10	3.69e-08	0.24	0.2	Alzheimer's disease;	chr3:9968624	chr3:9986893~10006990:+
BRCA	cis	rs9992667	0.955	rs28664852	ENSG00000231160.8	KLF3-AS1	6.42	2.02e-10	3.69e-08	0.24	0.2	Eosinophil percentage of granulocytes;	chr4:38644479	chr4:38612701~38664883:-
BRCA	cis	rs42648	0.569	rs110360	ENSG00000225498.1	AC002064.5	6.42	2.02e-10	3.69e-08	0.18	0.2	Homocysteine levels;	chr7:90227294	chr7:90312496~90322592:+
BRCA	cis	rs5015933	1	rs11998746	ENSG00000232630.1	PRPS1P2	-6.42	2.02e-10	3.7e-08	-0.18	-0.2	Body mass index;	chr9:125373083	chr9:125150653~125151589:+
BRCA	cis	rs42648	0.935	rs42651	ENSG00000225498.1	AC002064.5	6.42	2.03e-10	3.71e-08	0.19	0.2	Homocysteine levels;	chr7:90349276	chr7:90312496~90322592:+
BRCA	cis	rs11096990	0.964	rs3733280	ENSG00000249207.1	RP11-360F5.1	6.42	2.03e-10	3.71e-08	0.22	0.2	Cognitive function;	chr4:39269921	chr4:39112677~39126818:-
BRCA	cis	rs5015933	1	rs4289914	ENSG00000232630.1	PRPS1P2	-6.42	2.03e-10	3.71e-08	-0.18	-0.2	Body mass index;	chr9:125373526	chr9:125150653~125151589:+
BRCA	cis	rs1124769	0.748	rs3825798	ENSG00000259378.1	DCAF13P3	6.42	2.03e-10	3.71e-08	0.28	0.2	Cognitive performance;	chr15:51002635	chr15:50944663~50945996:+
BRCA	cis	rs11098499	0.863	rs13140391	ENSG00000249244.1	RP11-548H18.2	6.42	2.03e-10	3.71e-08	0.24	0.2	Corneal astigmatism;	chr4:119582282	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.863	rs13140409	ENSG00000249244.1	RP11-548H18.2	6.42	2.03e-10	3.71e-08	0.24	0.2	Corneal astigmatism;	chr4:119582305	chr4:119391831~119395335:-
BRCA	cis	rs9880211	0.563	rs9848926	ENSG00000239213.4	NCK1-AS1	6.42	2.03e-10	3.71e-08	0.25	0.2	Height;Body mass index;	chr3:136097460	chr3:136841726~136862054:-
BRCA	cis	rs9341808	0.739	rs4706831	ENSG00000272129.1	RP11-250B2.6	6.42	2.03e-10	3.71e-08	0.24	0.2	Sitting height ratio;	chr6:80297982	chr6:80355424~80356859:+
BRCA	cis	rs42648	0.596	rs194523	ENSG00000225498.1	AC002064.5	6.42	2.03e-10	3.72e-08	0.18	0.2	Homocysteine levels;	chr7:90231260	chr7:90312496~90322592:+
BRCA	cis	rs2638953	0.924	rs7307078	ENSG00000247934.4	RP11-967K21.1	-6.42	2.03e-10	3.72e-08	-0.25	-0.2	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28184645	chr12:28163298~28190738:-
BRCA	cis	rs2243480	1	rs7794661	ENSG00000228409.4	CCT6P1	6.42	2.03e-10	3.72e-08	0.27	0.2	Diabetic kidney disease;	chr7:65924743	chr7:65751142~65763354:+
BRCA	cis	rs301901	0.828	rs55731764	ENSG00000250155.1	CTD-2353F22.1	6.42	2.03e-10	3.72e-08	0.22	0.2	Height;	chr5:37475789	chr5:36666214~36725195:-
BRCA	cis	rs875971	0.867	rs1002053	ENSG00000224316.1	RP11-479O9.2	-6.42	2.03e-10	3.72e-08	-0.19	-0.2	Aortic root size;	chr7:66333558	chr7:65773620~65802067:+
BRCA	cis	rs227275	0.588	rs223458	ENSG00000251288.2	RP11-10L12.2	-6.42	2.03e-10	3.72e-08	-0.23	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102788414	chr4:102751401~102752641:+
BRCA	cis	rs11096990	0.929	rs55976583	ENSG00000249207.1	RP11-360F5.1	6.42	2.03e-10	3.72e-08	0.23	0.2	Cognitive function;	chr4:39222871	chr4:39112677~39126818:-
BRCA	cis	rs2732480	0.5	rs2450989	ENSG00000257763.1	OR5BK1P	-6.42	2.03e-10	3.72e-08	-0.21	-0.2	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48259625	chr12:48355792~48356614:-
BRCA	cis	rs7665090	0.875	rs6813687	ENSG00000246560.2	RP11-10L12.4	6.42	2.03e-10	3.72e-08	0.21	0.2	Primary biliary cholangitis;	chr4:102634455	chr4:102828055~102844075:+
BRCA	cis	rs2348418	0.798	rs10771423	ENSG00000247934.4	RP11-967K21.1	6.42	2.04e-10	3.73e-08	0.22	0.2	Lung function (FEV1);Lung function (FVC);	chr12:28396205	chr12:28163298~28190738:-
BRCA	cis	rs2919009	0.882	rs2919008	ENSG00000271670.1	RP11-95I16.4	6.42	2.04e-10	3.73e-08	0.25	0.2	Obesity-related traits;	chr10:120838163	chr10:120879256~120880667:-
BRCA	cis	rs6570726	0.967	rs373704	ENSG00000235652.6	RP11-545I5.3	6.42	2.04e-10	3.73e-08	0.19	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145539482	chr6:145799409~145886585:+
BRCA	cis	rs7432375	0.61	rs28458819	ENSG00000239213.4	NCK1-AS1	6.42	2.04e-10	3.73e-08	0.2	0.2	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136803472	chr3:136841726~136862054:-
BRCA	cis	rs2492286	0.597	rs2811487	ENSG00000242551.2	POU5F1P6	-6.42	2.04e-10	3.73e-08	-0.28	-0.2	Eosinophil counts;	chr3:128613036	chr3:128674735~128677005:-
BRCA	cis	rs9527	1	rs9527	ENSG00000213061.2	PFN1P11	6.42	2.04e-10	3.74e-08	0.3	0.2	Arsenic metabolism;	chr10:102863821	chr10:102838011~102845473:-
BRCA	cis	rs10129255	0.5	rs8011115	ENSG00000224373.3	IGHV4-59	6.42	2.04e-10	3.74e-08	0.11	0.2	Kawasaki disease;	chr14:106786292	chr14:106627249~106627825:-
BRCA	cis	rs11096990	0.964	rs56284364	ENSG00000249207.1	RP11-360F5.1	6.42	2.04e-10	3.74e-08	0.23	0.2	Cognitive function;	chr4:39255028	chr4:39112677~39126818:-
BRCA	cis	rs12594515	1	rs12594515	ENSG00000259200.1	RP11-718O11.1	6.42	2.04e-10	3.74e-08	0.22	0.2	Weight;Waist circumference;	chr15:45692873	chr15:45705078~45931069:+
BRCA	cis	rs4713118	0.955	rs34752872	ENSG00000220721.1	OR1F12	6.42	2.04e-10	3.74e-08	0.25	0.2	Parkinson's disease;	chr6:27715465	chr6:28073316~28074233:+
BRCA	cis	rs2243480	1	rs1723267	ENSG00000229886.1	RP5-1132H15.3	6.42	2.05e-10	3.74e-08	0.34	0.2	Diabetic kidney disease;	chr7:66008327	chr7:66025126~66031544:-
BRCA	cis	rs72681920	0.881	rs12512053	ENSG00000246090.5	RP11-696N14.1	-6.42	2.05e-10	3.74e-08	-0.31	-0.2	Alcohol dependence;	chr4:99281999	chr4:99088857~99301356:+
BRCA	cis	rs72681920	0.881	rs12508502	ENSG00000246090.5	RP11-696N14.1	-6.42	2.05e-10	3.74e-08	-0.31	-0.2	Alcohol dependence;	chr4:99282019	chr4:99088857~99301356:+
BRCA	cis	rs72681920	0.881	rs2276332	ENSG00000246090.5	RP11-696N14.1	-6.42	2.05e-10	3.74e-08	-0.31	-0.2	Alcohol dependence;	chr4:99282290	chr4:99088857~99301356:+
BRCA	cis	rs7927771	0.524	rs7116346	ENSG00000280615.1	Y_RNA	-6.42	2.05e-10	3.75e-08	-0.22	-0.2	Subjective well-being;	chr11:47862328	chr11:47614898~47614994:-
BRCA	cis	rs7914558	0.966	rs2297786	ENSG00000213061.2	PFN1P11	6.42	2.05e-10	3.75e-08	0.26	0.2	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102920221	chr10:102838011~102845473:-
BRCA	cis	rs853679	0.55	rs1150689	ENSG00000204709.4	LINC01556	6.42	2.05e-10	3.75e-08	0.27	0.2	Depression;	chr6:28197321	chr6:28943877~28944537:+
BRCA	cis	rs853679	0.55	rs1225599	ENSG00000204709.4	LINC01556	6.42	2.05e-10	3.75e-08	0.27	0.2	Depression;	chr6:28197412	chr6:28943877~28944537:+
BRCA	cis	rs853679	0.574	rs1233705	ENSG00000204709.4	LINC01556	6.42	2.05e-10	3.75e-08	0.27	0.2	Depression;	chr6:28198669	chr6:28943877~28944537:+
BRCA	cis	rs5758511	0.773	rs10154700	ENSG00000205702.9	CYP2D7	6.42	2.05e-10	3.75e-08	0.2	0.2	Birth weight;	chr22:41969069	chr22:42140203~42144577:-
BRCA	cis	rs7246657	0.943	rs34603719	ENSG00000267422.1	CTD-2554C21.1	-6.42	2.05e-10	3.76e-08	-0.3	-0.2	Coronary artery calcification;	chr19:37303626	chr19:37779686~37792865:+
BRCA	cis	rs6840360	0.87	rs1372978	ENSG00000270265.1	RP11-731D1.4	-6.42	2.05e-10	3.76e-08	-0.22	-0.2	Intelligence (multi-trait analysis);	chr4:151535028	chr4:151333775~151353224:-
BRCA	cis	rs13113518	0.812	rs4864543	ENSG00000223305.1	RN7SKP30	6.42	2.05e-10	3.76e-08	0.24	0.2	Height;	chr4:55490228	chr4:55540502~55540835:-
BRCA	cis	rs13113518	0.812	rs6825774	ENSG00000223305.1	RN7SKP30	6.42	2.05e-10	3.76e-08	0.24	0.2	Height;	chr4:55491150	chr4:55540502~55540835:-
BRCA	cis	rs13113518	0.812	rs3805153	ENSG00000223305.1	RN7SKP30	6.42	2.05e-10	3.76e-08	0.24	0.2	Height;	chr4:55493557	chr4:55540502~55540835:-
BRCA	cis	rs9527	0.501	rs12244388	ENSG00000236937.2	PTGES3P4	6.42	2.06e-10	3.76e-08	0.25	0.2	Arsenic metabolism;	chr10:102880295	chr10:102845595~102845950:+
BRCA	cis	rs4372836	0.964	rs4408686	ENSG00000226833.4	AC097724.3	-6.42	2.06e-10	3.76e-08	-0.24	-0.2	Body mass index;	chr2:28717660	chr2:28708953~28736205:-
BRCA	cis	rs875971	0.929	rs778692	ENSG00000224316.1	RP11-479O9.2	6.42	2.06e-10	3.76e-08	0.19	0.2	Aortic root size;	chr7:66407462	chr7:65773620~65802067:+
BRCA	cis	rs875971	1	rs4718343	ENSG00000224316.1	RP11-479O9.2	6.42	2.06e-10	3.76e-08	0.19	0.2	Aortic root size;	chr7:66409301	chr7:65773620~65802067:+
BRCA	cis	rs875971	1	rs1968225	ENSG00000224316.1	RP11-479O9.2	6.42	2.06e-10	3.76e-08	0.19	0.2	Aortic root size;	chr7:66409786	chr7:65773620~65802067:+
BRCA	cis	rs875971	1	rs6460295	ENSG00000224316.1	RP11-479O9.2	6.42	2.06e-10	3.76e-08	0.19	0.2	Aortic root size;	chr7:66417741	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.964	rs6978721	ENSG00000224316.1	RP11-479O9.2	6.42	2.06e-10	3.76e-08	0.19	0.2	Aortic root size;	chr7:66418217	chr7:65773620~65802067:+
BRCA	cis	rs72772090	0.908	rs76539796	ENSG00000248734.2	CTD-2260A17.1	-6.42	2.06e-10	3.76e-08	-0.31	-0.2	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96702971	chr5:96784777~96785999:+
BRCA	cis	rs2732480	0.577	rs2732481	ENSG00000273765.1	RP11-370I10.11	6.42	2.06e-10	3.76e-08	0.24	0.2	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48343202	chr12:48360920~48361377:+
BRCA	cis	rs2732480	0.557	rs2732484	ENSG00000273765.1	RP11-370I10.11	6.42	2.06e-10	3.76e-08	0.24	0.2	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48343462	chr12:48360920~48361377:+
BRCA	cis	rs2732480	0.577	rs2732486	ENSG00000273765.1	RP11-370I10.11	6.42	2.06e-10	3.76e-08	0.24	0.2	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344051	chr12:48360920~48361377:+
BRCA	cis	rs2732480	0.517	rs2634676	ENSG00000273765.1	RP11-370I10.11	6.42	2.06e-10	3.76e-08	0.24	0.2	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344453	chr12:48360920~48361377:+
BRCA	cis	rs10129255	0.912	rs8009135	ENSG00000211972.2	IGHV3-66	6.42	2.06e-10	3.76e-08	0.15	0.2	Kawasaki disease;	chr14:106777528	chr14:106675017~106675544:-
BRCA	cis	rs4664293	0.541	rs1425047	ENSG00000226266.5	AC009961.3	6.42	2.06e-10	3.77e-08	0.23	0.2	Monocyte percentage of white cells;	chr2:159517946	chr2:159670708~159712435:-
BRCA	cis	rs7246657	0.823	rs4802236	ENSG00000267422.1	CTD-2554C21.1	-6.42	2.06e-10	3.77e-08	-0.3	-0.2	Coronary artery calcification;	chr19:37428344	chr19:37779686~37792865:+
BRCA	cis	rs2243480	1	rs1638734	ENSG00000230295.1	RP11-458F8.2	-6.42	2.06e-10	3.77e-08	-0.26	-0.2	Diabetic kidney disease;	chr7:66632552	chr7:66880708~66882981:+
BRCA	cis	rs1979679	0.842	rs10459091	ENSG00000278733.1	RP11-425D17.1	6.42	2.06e-10	3.77e-08	0.24	0.2	Ossification of the posterior longitudinal ligament of the spine;	chr12:28188383	chr12:28185625~28186190:-
BRCA	cis	rs2179367	0.632	rs9498336	ENSG00000216906.2	RP11-350J20.9	6.42	2.06e-10	3.77e-08	0.28	0.2	Dupuytren's disease;	chr6:149374208	chr6:149904243~149906418:+
BRCA	cis	rs2179367	0.632	rs1980774	ENSG00000216906.2	RP11-350J20.9	6.42	2.06e-10	3.77e-08	0.28	0.2	Dupuytren's disease;	chr6:149375030	chr6:149904243~149906418:+
BRCA	cis	rs2179367	0.632	rs9498337	ENSG00000216906.2	RP11-350J20.9	6.42	2.06e-10	3.77e-08	0.28	0.2	Dupuytren's disease;	chr6:149375970	chr6:149904243~149906418:+
BRCA	cis	rs1014246	0.813	rs11197797	ENSG00000232767.1	RP11-498B4.5	-6.42	2.06e-10	3.77e-08	-0.23	-0.2	Age at smoking initiation in chronic obstructive pulmonary disease;	chr10:116694988	chr10:116670103~116672739:+
BRCA	cis	rs9876781	0.967	rs7618883	ENSG00000229759.1	MRPS18AP1	6.42	2.06e-10	3.77e-08	0.22	0.2	Longevity;	chr3:48457056	chr3:48256350~48256938:-
BRCA	cis	rs1440410	0.798	rs11100772	ENSG00000250326.1	RP11-284M14.1	-6.42	2.06e-10	3.77e-08	-0.21	-0.2	Ischemic stroke;	chr4:143132935	chr4:142933195~143184861:-
BRCA	cis	rs5015933	0.815	rs10114168	ENSG00000232630.1	PRPS1P2	-6.42	2.06e-10	3.77e-08	-0.18	-0.2	Body mass index;	chr9:125273170	chr9:125150653~125151589:+
BRCA	cis	rs7617773	0.78	rs35411187	ENSG00000228638.1	FCF1P2	-6.42	2.06e-10	3.77e-08	-0.22	-0.2	Coronary artery disease;	chr3:48318527	chr3:48290793~48291375:-
BRCA	cis	rs7617773	0.78	rs11714176	ENSG00000228638.1	FCF1P2	-6.42	2.06e-10	3.77e-08	-0.22	-0.2	Coronary artery disease;	chr3:48319372	chr3:48290793~48291375:-
BRCA	cis	rs2243480	0.764	rs2460423	ENSG00000229886.1	RP5-1132H15.3	6.42	2.07e-10	3.78e-08	0.35	0.2	Diabetic kidney disease;	chr7:66136229	chr7:66025126~66031544:-
BRCA	cis	rs4713118	0.955	rs9468200	ENSG00000220721.1	OR1F12	6.42	2.07e-10	3.78e-08	0.25	0.2	Parkinson's disease;	chr6:27715284	chr6:28073316~28074233:+
BRCA	cis	rs2243480	1	rs73142166	ENSG00000229886.1	RP5-1132H15.3	6.42	2.07e-10	3.78e-08	0.34	0.2	Diabetic kidney disease;	chr7:65910845	chr7:66025126~66031544:-
BRCA	cis	rs2243480	1	rs1723270	ENSG00000229886.1	RP5-1132H15.3	6.42	2.07e-10	3.78e-08	0.34	0.2	Diabetic kidney disease;	chr7:66004843	chr7:66025126~66031544:-
BRCA	cis	rs17253792	0.822	rs9972178	ENSG00000186615.9	KTN1-AS1	-6.42	2.07e-10	3.78e-08	-0.37	-0.2	Putamen volume;	chr14:55606762	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs9972180	ENSG00000186615.9	KTN1-AS1	-6.42	2.07e-10	3.78e-08	-0.37	-0.2	Putamen volume;	chr14:55607014	chr14:55499278~55580110:-
BRCA	cis	rs2348418	0.864	rs6487690	ENSG00000247934.4	RP11-967K21.1	6.42	2.07e-10	3.79e-08	0.22	0.2	Lung function (FEV1);Lung function (FVC);	chr12:28560407	chr12:28163298~28190738:-
BRCA	cis	rs9527	0.525	rs12770034	ENSG00000236937.2	PTGES3P4	6.42	2.07e-10	3.79e-08	0.25	0.2	Arsenic metabolism;	chr10:102875838	chr10:102845595~102845950:+
BRCA	cis	rs7829975	0.582	rs6982832	ENSG00000233609.3	RP11-62H7.2	-6.42	2.08e-10	3.79e-08	-0.18	-0.2	Mood instability;	chr8:8934707	chr8:8961200~8979025:+
BRCA	cis	rs7976269	0.609	rs10771478	ENSG00000257176.2	RP11-996F15.2	6.42	2.08e-10	3.79e-08	0.23	0.2	Male-pattern baldness;	chr12:29075351	chr12:29280418~29317848:-
BRCA	cis	rs860818	1	rs858303	ENSG00000226816.2	AC005082.12	6.42	2.08e-10	3.79e-08	0.44	0.2	Initial pursuit acceleration;	chr7:23203879	chr7:23206013~23208045:+
BRCA	cis	rs6840258	1	rs6819155	ENSG00000251411.1	RP11-397E7.4	-6.42	2.08e-10	3.8e-08	-0.26	-0.2	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87055026	chr4:86913266~86914817:-
BRCA	cis	rs228614	0.51	rs3774987	ENSG00000251288.2	RP11-10L12.2	-6.42	2.08e-10	3.8e-08	-0.23	-0.2	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102799709	chr4:102751401~102752641:+
BRCA	cis	rs600231	0.708	rs2957268	ENSG00000245532.5	NEAT1	6.42	2.08e-10	3.8e-08	0.18	0.2	Bone mineral density;	chr11:65478345	chr11:65422774~65445540:+
BRCA	cis	rs155076	1	rs155076	ENSG00000235438.6	ESRRAP2	6.42	2.08e-10	3.8e-08	0.28	0.2	White matter hyperintensity burden;	chr13:21295975	chr13:21260015~21295003:+
BRCA	cis	rs2337406	1	rs1961901	ENSG00000211972.2	IGHV3-66	6.42	2.08e-10	3.8e-08	0.18	0.2	Alzheimer's disease (late onset);	chr14:106680856	chr14:106675017~106675544:-
BRCA	cis	rs2562456	0.917	rs2650825	ENSG00000268081.1	RP11-678G14.2	6.42	2.08e-10	3.8e-08	0.31	0.2	Pain;	chr19:21516423	chr19:21554640~21569237:-
BRCA	cis	rs6504622	0.875	rs28553405	ENSG00000262879.4	RP11-156P1.3	6.42	2.08e-10	3.81e-08	0.2	0.2	Orofacial clefts;	chr17:46968529	chr17:46984045~47100323:-
BRCA	cis	rs891378	1	rs2802238	ENSG00000274245.1	RP11-357P18.2	-6.42	2.08e-10	3.81e-08	-0.28	-0.2	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207302796	chr1:207372559~207373252:+
BRCA	cis	rs2179367	0.632	rs9498338	ENSG00000216906.2	RP11-350J20.9	6.42	2.08e-10	3.81e-08	0.28	0.2	Dupuytren's disease;	chr6:149376428	chr6:149904243~149906418:+
BRCA	cis	rs9907295	0.591	rs3760327	ENSG00000270977.1	AC015849.16	-6.42	2.09e-10	3.81e-08	-0.25	-0.2	Fibroblast growth factor basic levels;	chr17:35836383	chr17:35893707~35911023:-
BRCA	cis	rs7162943	0.887	rs11858280	ENSG00000260123.1	RP11-326A19.4	-6.42	2.09e-10	3.81e-08	-0.23	-0.2	Mean platelet volume;	chr15:89069059	chr15:89041223~89082819:+
BRCA	cis	rs2243480	1	rs781156	ENSG00000228409.4	CCT6P1	6.42	2.09e-10	3.81e-08	0.27	0.2	Diabetic kidney disease;	chr7:66014154	chr7:65751142~65763354:+
BRCA	cis	rs2243480	1	rs451396	ENSG00000228409.4	CCT6P1	6.42	2.09e-10	3.81e-08	0.27	0.2	Diabetic kidney disease;	chr7:66019087	chr7:65751142~65763354:+
BRCA	cis	rs2243480	1	rs1715235	ENSG00000228409.4	CCT6P1	6.42	2.09e-10	3.81e-08	0.27	0.2	Diabetic kidney disease;	chr7:66023407	chr7:65751142~65763354:+
BRCA	cis	rs755249	0.567	rs16826000	ENSG00000237624.1	OXCT2P1	6.42	2.09e-10	3.81e-08	0.28	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39248188	chr1:39514956~39516490:+
BRCA	cis	rs2243480	1	rs316330	ENSG00000232546.1	RP11-458F8.1	-6.42	2.09e-10	3.82e-08	-0.26	-0.2	Diabetic kidney disease;	chr7:66140385	chr7:66848496~66858136:+
BRCA	cis	rs2919009	0.664	rs55848502	ENSG00000271670.1	RP11-95I16.4	6.42	2.09e-10	3.82e-08	0.25	0.2	Obesity-related traits;	chr10:120925258	chr10:120879256~120880667:-
BRCA	cis	rs2239547	0.562	rs6794389	ENSG00000242142.1	SERBP1P3	6.42	2.09e-10	3.82e-08	0.24	0.2	Schizophrenia;	chr3:53062378	chr3:53064283~53065091:-
BRCA	cis	rs7246657	0.943	rs4969487	ENSG00000267422.1	CTD-2554C21.1	-6.42	2.1e-10	3.83e-08	-0.3	-0.2	Coronary artery calcification;	chr19:37340137	chr19:37779686~37792865:+
BRCA	cis	rs2276314	0.553	rs12964535	ENSG00000278986.1	RP11-723J4.3	6.42	2.1e-10	3.83e-08	0.22	0.19	Endometriosis;Drug-induced torsades de pointes;	chr18:36031728	chr18:35972151~35973916:+
BRCA	cis	rs2243480	1	rs10807702	ENSG00000229886.1	RP5-1132H15.3	6.42	2.1e-10	3.83e-08	0.34	0.19	Diabetic kidney disease;	chr7:66302856	chr7:66025126~66031544:-
BRCA	cis	rs9527	0.571	rs12765337	ENSG00000236937.2	PTGES3P4	6.42	2.1e-10	3.83e-08	0.25	0.19	Arsenic metabolism;	chr10:102875587	chr10:102845595~102845950:+
BRCA	cis	rs3858145	0.588	rs731063	ENSG00000233590.1	RP11-153K11.3	6.42	2.11e-10	3.85e-08	0.26	0.19	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68283433	chr10:68233251~68242379:-
BRCA	cis	rs853679	0.546	rs35819751	ENSG00000220721.1	OR1F12	6.42	2.11e-10	3.85e-08	0.47	0.19	Depression;	chr6:27842791	chr6:28073316~28074233:+
BRCA	cis	rs1552244	1	rs9849434	ENSG00000180385.7	EMC3-AS1	-6.42	2.11e-10	3.85e-08	-0.24	-0.19	Alzheimer's disease;	chr3:10092026	chr3:9986893~10006990:+
BRCA	cis	rs67981189	0.858	rs2526862	ENSG00000258571.1	PTTG4P	6.42	2.11e-10	3.85e-08	0.22	0.19	Schizophrenia;	chr14:70942897	chr14:71085482~71085833:-
BRCA	cis	rs67981189	0.788	rs2526860	ENSG00000258571.1	PTTG4P	6.42	2.11e-10	3.85e-08	0.22	0.19	Schizophrenia;	chr14:70945161	chr14:71085482~71085833:-
BRCA	cis	rs10129255	0.5	rs10131875	ENSG00000274576.2	IGHV2-70	-6.42	2.11e-10	3.85e-08	-0.16	-0.19	Kawasaki disease;	chr14:106792798	chr14:106770577~106771020:-
BRCA	cis	rs34779708	0.966	rs57081218	ENSG00000271335.4	RP11-324I22.4	6.42	2.11e-10	3.85e-08	0.2	0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35145680	chr10:35314552~35336401:-
BRCA	cis	rs2243480	1	rs778729	ENSG00000230295.1	RP11-458F8.2	-6.42	2.11e-10	3.85e-08	-0.26	-0.19	Diabetic kidney disease;	chr7:66359432	chr7:66880708~66882981:+
BRCA	cis	rs2380205	0.58	rs907687	ENSG00000232807.2	RP11-536K7.3	-6.42	2.11e-10	3.86e-08	-0.2	-0.19	Breast cancer;	chr10:5858799	chr10:5934270~5945900:-
BRCA	cis	rs2337406	0.539	rs2583292	ENSG00000254174.1	IGHV1-12	6.42	2.12e-10	3.86e-08	0.2	0.19	Alzheimer's disease (late onset);	chr14:106649040	chr14:106122420~106122709:-
BRCA	cis	rs12594515	1	rs56220882	ENSG00000259200.1	RP11-718O11.1	-6.42	2.12e-10	3.86e-08	-0.22	-0.19	Weight;Waist circumference;	chr15:45704877	chr15:45705078~45931069:+
BRCA	cis	rs1124769	0.748	rs17703435	ENSG00000259378.1	DCAF13P3	6.42	2.12e-10	3.86e-08	0.28	0.19	Cognitive performance;	chr15:51011007	chr15:50944663~50945996:+
BRCA	cis	rs1707322	0.686	rs3014239	ENSG00000281133.1	AL355480.3	6.42	2.12e-10	3.86e-08	0.25	0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45624129	chr1:45580892~45580996:-
BRCA	cis	rs6142102	0.961	rs2284386	ENSG00000275784.1	RP5-1125A11.6	-6.42	2.12e-10	3.87e-08	-0.23	-0.19	Skin pigmentation;	chr20:34056590	chr20:33989480~33991818:-
BRCA	cis	rs7474896	0.515	rs688608	ENSG00000226578.1	RP11-258F22.1	6.42	2.12e-10	3.88e-08	0.27	0.19	Obesity (extreme);	chr10:38042696	chr10:37775371~37784131:-
BRCA	cis	rs11098499	0.954	rs59394118	ENSG00000249244.1	RP11-548H18.2	6.42	2.13e-10	3.88e-08	0.23	0.19	Corneal astigmatism;	chr4:119374396	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.865	rs9996417	ENSG00000249244.1	RP11-548H18.2	6.42	2.13e-10	3.88e-08	0.23	0.19	Corneal astigmatism;	chr4:119374707	chr4:119391831~119395335:-
BRCA	cis	rs11976180	1	rs2961120	ENSG00000273234.1	OR2A13P	-6.42	2.13e-10	3.89e-08	-0.27	-0.19	Obesity-related traits;	chr7:144059492	chr7:144142009~144142938:+
BRCA	cis	rs2243480	1	rs316330	ENSG00000232559.3	GS1-124K5.12	6.41	2.13e-10	3.89e-08	0.37	0.19	Diabetic kidney disease;	chr7:66140385	chr7:66554588~66576923:-
BRCA	cis	rs459482	0.576	rs461448	ENSG00000228318.3	AP001610.5	-6.41	2.14e-10	3.9e-08	-0.23	-0.19	IgG glycosylation;	chr21:41428996	chr21:41441056~41445708:-
BRCA	cis	rs1979679	0.842	rs10459090	ENSG00000278733.1	RP11-425D17.1	6.41	2.14e-10	3.9e-08	0.25	0.19	Ossification of the posterior longitudinal ligament of the spine;	chr12:28188207	chr12:28185625~28186190:-
BRCA	cis	rs13113518	0.812	rs11939580	ENSG00000223305.1	RN7SKP30	6.41	2.14e-10	3.9e-08	0.24	0.19	Height;	chr4:55517185	chr4:55540502~55540835:-
BRCA	cis	rs10129255	0.5	rs11628999	ENSG00000274576.2	IGHV2-70	-6.41	2.14e-10	3.91e-08	-0.16	-0.19	Kawasaki disease;	chr14:106800208	chr14:106770577~106771020:-
BRCA	cis	rs2243480	1	rs4718270	ENSG00000229886.1	RP5-1132H15.3	6.41	2.14e-10	3.91e-08	0.34	0.19	Diabetic kidney disease;	chr7:65737415	chr7:66025126~66031544:-
BRCA	cis	rs6740322	0.895	rs28456986	ENSG00000234936.1	AC010883.5	6.41	2.14e-10	3.91e-08	0.22	0.19	Coronary artery disease;	chr2:43326182	chr2:43229573~43233394:+
BRCA	cis	rs9992667	0.955	rs66709517	ENSG00000231160.8	KLF3-AS1	6.41	2.15e-10	3.92e-08	0.24	0.19	Eosinophil percentage of granulocytes;	chr4:38647772	chr4:38612701~38664883:-
BRCA	cis	rs875971	0.545	rs73136346	ENSG00000273024.4	INTS4P2	6.41	2.15e-10	3.92e-08	0.25	0.19	Aortic root size;	chr7:66101095	chr7:65647864~65715661:+
BRCA	cis	rs7246657	0.943	rs10405325	ENSG00000267422.1	CTD-2554C21.1	-6.41	2.15e-10	3.92e-08	-0.3	-0.19	Coronary artery calcification;	chr19:37392575	chr19:37779686~37792865:+
BRCA	cis	rs875971	1	rs7792762	ENSG00000224316.1	RP11-479O9.2	6.41	2.15e-10	3.93e-08	0.2	0.19	Aortic root size;	chr7:66539151	chr7:65773620~65802067:+
BRCA	cis	rs12468226	1	rs16839090	ENSG00000226261.1	AC064836.3	6.41	2.15e-10	3.93e-08	0.33	0.19	Urate levels;	chr2:202348338	chr2:202336024~202336727:-
BRCA	cis	rs1124769	0.719	rs1009882	ENSG00000259378.1	DCAF13P3	6.41	2.15e-10	3.93e-08	0.28	0.19	Cognitive performance;	chr15:51099519	chr15:50944663~50945996:+
BRCA	cis	rs801193	0.967	rs34356500	ENSG00000236529.1	RP13-254B10.1	6.41	2.15e-10	3.93e-08	0.21	0.19	Aortic root size;	chr7:66771620	chr7:65840212~65840596:+
BRCA	cis	rs3760982	1	rs4802200	ENSG00000267058.1	RP11-15A1.3	-6.41	2.15e-10	3.93e-08	-0.22	-0.19	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43785366	chr19:43891804~43901805:-
BRCA	cis	rs66887589	0.592	rs28580295	ENSG00000245958.5	RP11-33B1.1	-6.41	2.16e-10	3.94e-08	-0.17	-0.19	Diastolic blood pressure;	chr4:119357718	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.863	rs3822192	ENSG00000249244.1	RP11-548H18.2	6.41	2.16e-10	3.94e-08	0.24	0.19	Corneal astigmatism;	chr4:119524565	chr4:119391831~119395335:-
BRCA	cis	rs7617773	0.78	rs34630841	ENSG00000228638.1	FCF1P2	-6.41	2.16e-10	3.95e-08	-0.22	-0.19	Coronary artery disease;	chr3:48301771	chr3:48290793~48291375:-
BRCA	cis	rs10129255	0.5	rs7157975	ENSG00000224373.3	IGHV4-59	6.41	2.17e-10	3.95e-08	0.11	0.19	Kawasaki disease;	chr14:106804049	chr14:106627249~106627825:-
BRCA	cis	rs4865169	0.595	rs4865165	ENSG00000269949.1	RP11-738E22.3	-6.41	2.17e-10	3.95e-08	-0.23	-0.19	Breast cancer;	chr4:56899380	chr4:56960927~56961373:-
BRCA	cis	rs34779708	0.931	rs11010125	ENSG00000271335.4	RP11-324I22.4	6.41	2.17e-10	3.96e-08	0.2	0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35214025	chr10:35314552~35336401:-
BRCA	cis	rs2243480	1	rs422164	ENSG00000229886.1	RP5-1132H15.3	6.41	2.17e-10	3.96e-08	0.34	0.19	Diabetic kidney disease;	chr7:66121618	chr7:66025126~66031544:-
BRCA	cis	rs7567389	0.677	rs72845976	ENSG00000236682.1	AC068282.3	-6.41	2.18e-10	3.97e-08	-0.3	-0.19	Self-rated health;	chr2:127328864	chr2:127389130~127400580:+
BRCA	cis	rs58873874	0.522	rs111370613	ENSG00000248544.2	CTB-47B11.3	6.41	2.18e-10	3.97e-08	0.41	0.19	Bipolar disorder (body mass index interaction);	chr5:157271128	chr5:157375741~157384950:-
BRCA	cis	rs2742234	0.955	rs1272142	ENSG00000273008.1	RP11-351D16.3	-6.41	2.18e-10	3.97e-08	-0.23	-0.19	Hirschsprung disease;	chr10:43200036	chr10:43136824~43138334:-
BRCA	cis	rs1823913	0.599	rs2124095	ENSG00000280083.1	RP11-317J9.1	-6.41	2.18e-10	3.97e-08	-0.22	-0.19	Obesity-related traits;	chr2:191301728	chr2:191154118~191156070:-
BRCA	cis	rs10771431	0.782	rs10771415	ENSG00000111788.10	RP11-22B23.1	6.41	2.18e-10	3.97e-08	0.17	0.19	Breast size;	chr12:9205627	chr12:9277235~9313241:+
BRCA	cis	rs2243480	1	rs778679	ENSG00000230295.1	RP11-458F8.2	-6.41	2.18e-10	3.97e-08	-0.26	-0.19	Diabetic kidney disease;	chr7:66375924	chr7:66880708~66882981:+
BRCA	cis	rs2179367	0.586	rs9498341	ENSG00000216906.2	RP11-350J20.9	6.41	2.18e-10	3.97e-08	0.28	0.19	Dupuytren's disease;	chr6:149379737	chr6:149904243~149906418:+
BRCA	cis	rs2179367	0.632	rs9498342	ENSG00000216906.2	RP11-350J20.9	6.41	2.18e-10	3.97e-08	0.28	0.19	Dupuytren's disease;	chr6:149379806	chr6:149904243~149906418:+
BRCA	cis	rs2179367	0.632	rs12191079	ENSG00000216906.2	RP11-350J20.9	6.41	2.18e-10	3.97e-08	0.28	0.19	Dupuytren's disease;	chr6:149380333	chr6:149904243~149906418:+
BRCA	cis	rs2179367	0.632	rs12204461	ENSG00000216906.2	RP11-350J20.9	6.41	2.18e-10	3.97e-08	0.28	0.19	Dupuytren's disease;	chr6:149380399	chr6:149904243~149906418:+
BRCA	cis	rs11742741	0.69	rs35311965	ENSG00000248874.4	C5orf17	-6.41	2.18e-10	3.98e-08	-0.24	-0.19	Educational attainment;	chr5:24176027	chr5:23951348~24178263:+
BRCA	cis	rs2243480	0.901	rs313808	ENSG00000229886.1	RP5-1132H15.3	6.41	2.18e-10	3.98e-08	0.34	0.19	Diabetic kidney disease;	chr7:66034886	chr7:66025126~66031544:-
BRCA	cis	rs853679	0.517	rs868987	ENSG00000219392.1	RP1-265C24.5	6.41	2.18e-10	3.98e-08	0.3	0.19	Depression;	chr6:28142370	chr6:28115628~28116551:+
BRCA	cis	rs4950322	0.57	rs3737855	ENSG00000278811.3	LINC00624	6.41	2.19e-10	3.98e-08	0.26	0.19	Protein quantitative trait loci;	chr1:147271257	chr1:147258885~147517875:-
BRCA	cis	rs7829975	0.617	rs4841071	ENSG00000233609.3	RP11-62H7.2	6.41	2.19e-10	3.99e-08	0.18	0.19	Mood instability;	chr8:8933634	chr8:8961200~8979025:+
BRCA	cis	rs11098499	0.618	rs28491261	ENSG00000249244.1	RP11-548H18.2	6.41	2.19e-10	3.99e-08	0.23	0.19	Corneal astigmatism;	chr4:119373745	chr4:119391831~119395335:-
BRCA	cis	rs13113518	0.812	rs6830409	ENSG00000223305.1	RN7SKP30	6.41	2.19e-10	3.99e-08	0.24	0.19	Height;	chr4:55522229	chr4:55540502~55540835:-
BRCA	cis	rs1823913	0.526	rs36028476	ENSG00000280083.1	RP11-317J9.1	-6.41	2.19e-10	3.99e-08	-0.22	-0.19	Obesity-related traits;	chr2:191300595	chr2:191154118~191156070:-
BRCA	cis	rs2243480	1	rs1039664	ENSG00000229886.1	RP5-1132H15.3	6.41	2.19e-10	3.99e-08	0.34	0.19	Diabetic kidney disease;	chr7:65984729	chr7:66025126~66031544:-
BRCA	cis	rs3764021	0.527	rs11052423	ENSG00000214776.8	RP11-726G1.1	-6.41	2.19e-10	3.99e-08	-0.24	-0.19	Type 1 diabetes;	chr12:9687442	chr12:9467552~9576275:+
BRCA	cis	rs6969780	1	rs6973182	ENSG00000233429.8	HOTAIRM1	6.41	2.19e-10	4e-08	0.25	0.19	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27132702	chr7:27095647~27100265:+
BRCA	cis	rs9876781	1	rs9826195	ENSG00000229759.1	MRPS18AP1	6.41	2.19e-10	4e-08	0.22	0.19	Longevity;	chr3:48392157	chr3:48256350~48256938:-
BRCA	cis	rs9876781	0.967	rs9864815	ENSG00000229759.1	MRPS18AP1	6.41	2.19e-10	4e-08	0.22	0.19	Longevity;	chr3:48392588	chr3:48256350~48256938:-
BRCA	cis	rs9876781	1	rs9809843	ENSG00000229759.1	MRPS18AP1	6.41	2.19e-10	4e-08	0.22	0.19	Longevity;	chr3:48392923	chr3:48256350~48256938:-
BRCA	cis	rs9307551	1	rs1031005	ENSG00000250334.4	LINC00989	-6.41	2.19e-10	4e-08	-0.28	-0.19	Refractive error;	chr4:79595750	chr4:79492416~79576460:+
BRCA	cis	rs4763879	0.634	rs917913	ENSG00000256673.1	RP11-599J14.2	6.41	2.19e-10	4e-08	0.21	0.19	Type 1 diabetes;	chr12:9707040	chr12:9398355~9414851:-
BRCA	cis	rs1440410	0.835	rs11100780	ENSG00000250326.1	RP11-284M14.1	-6.41	2.2e-10	4e-08	-0.21	-0.19	Ischemic stroke;	chr4:143183753	chr4:142933195~143184861:-
BRCA	cis	rs710913	0.717	rs1180349	ENSG00000237624.1	OXCT2P1	-6.41	2.2e-10	4e-08	-0.22	-0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39540380	chr1:39514956~39516490:+
BRCA	cis	rs73186030	0.764	rs9834317	ENSG00000272758.4	RP11-299J3.8	6.41	2.2e-10	4e-08	0.27	0.19	Serum parathyroid hormone levels;	chr3:122370512	chr3:122416207~122443180:+
BRCA	cis	rs2243480	1	rs13310597	ENSG00000230295.1	RP11-458F8.2	-6.41	2.2e-10	4.01e-08	-0.26	-0.19	Diabetic kidney disease;	chr7:66133553	chr7:66880708~66882981:+
BRCA	cis	rs755249	0.567	rs72637906	ENSG00000237624.1	OXCT2P1	6.41	2.2e-10	4.01e-08	0.29	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39242630	chr1:39514956~39516490:+
BRCA	cis	rs755249	0.567	rs67886352	ENSG00000237624.1	OXCT2P1	6.41	2.2e-10	4.01e-08	0.29	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39243031	chr1:39514956~39516490:+
BRCA	cis	rs755249	0.567	rs60323161	ENSG00000237624.1	OXCT2P1	6.41	2.2e-10	4.01e-08	0.29	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39244787	chr1:39514956~39516490:+
BRCA	cis	rs755249	0.567	rs66727439	ENSG00000237624.1	OXCT2P1	6.41	2.2e-10	4.01e-08	0.29	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39246258	chr1:39514956~39516490:+
BRCA	cis	rs227932	0.541	rs78177212	ENSG00000234286.1	AC006026.13	-6.41	2.2e-10	4.01e-08	-0.33	-0.19	Schizophrenia;	chr7:23770500	chr7:23680195~23680786:-
BRCA	cis	rs1124769	0.654	rs12914185	ENSG00000259378.1	DCAF13P3	6.41	2.21e-10	4.02e-08	0.28	0.19	Cognitive performance;	chr15:51071687	chr15:50944663~50945996:+
BRCA	cis	rs875971	0.522	rs10807697	ENSG00000234585.5	CCT6P3	6.41	2.21e-10	4.02e-08	0.19	0.19	Aortic root size;	chr7:65951183	chr7:65038354~65074713:+
BRCA	cis	rs2281558	0.837	rs56238023	ENSG00000125804.12	FAM182A	-6.41	2.21e-10	4.02e-08	-0.29	-0.19	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25536311	chr20:26054655~26086917:+
BRCA	cis	rs4763879	0.778	rs7977940	ENSG00000256673.1	RP11-599J14.2	6.41	2.21e-10	4.02e-08	0.22	0.19	Type 1 diabetes;	chr12:9686320	chr12:9398355~9414851:-
BRCA	cis	rs17508449	0.865	rs76308249	ENSG00000232450.1	RP4-730K3.3	-6.41	2.21e-10	4.02e-08	-0.36	-0.19	Leprosy;	chr1:113605059	chr1:113698884~113699631:-
BRCA	cis	rs17508449	0.779	rs78703286	ENSG00000232450.1	RP4-730K3.3	-6.41	2.21e-10	4.02e-08	-0.36	-0.19	Leprosy;	chr1:113605493	chr1:113698884~113699631:-
BRCA	cis	rs8072100	0.57	rs9905073	ENSG00000228782.6	CTD-2026D20.3	6.41	2.21e-10	4.02e-08	0.22	0.19	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47390930	chr17:47450568~47492492:-
BRCA	cis	rs12468226	1	rs7597469	ENSG00000226261.1	AC064836.3	6.41	2.21e-10	4.03e-08	0.33	0.19	Urate levels;	chr2:202329547	chr2:202336024~202336727:-
BRCA	cis	rs2243480	1	rs56016656	ENSG00000229886.1	RP5-1132H15.3	6.41	2.21e-10	4.03e-08	0.34	0.19	Diabetic kidney disease;	chr7:65918494	chr7:66025126~66031544:-
BRCA	cis	rs2243480	1	rs56291018	ENSG00000229886.1	RP5-1132H15.3	6.41	2.21e-10	4.03e-08	0.34	0.19	Diabetic kidney disease;	chr7:65925352	chr7:66025126~66031544:-
BRCA	cis	rs2243480	1	rs36033484	ENSG00000229886.1	RP5-1132H15.3	6.41	2.21e-10	4.03e-08	0.34	0.19	Diabetic kidney disease;	chr7:65925571	chr7:66025126~66031544:-
BRCA	cis	rs2638953	0.893	rs1464011	ENSG00000278733.1	RP11-425D17.1	-6.41	2.21e-10	4.03e-08	-0.24	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28516871	chr12:28185625~28186190:-
BRCA	cis	rs1499614	1	rs1267818	ENSG00000232546.1	RP11-458F8.1	-6.41	2.21e-10	4.03e-08	-0.26	-0.19	Gout;	chr7:66642037	chr7:66848496~66858136:+
BRCA	cis	rs2243480	1	rs35396113	ENSG00000228409.4	CCT6P1	6.41	2.22e-10	4.04e-08	0.27	0.19	Diabetic kidney disease;	chr7:66030474	chr7:65751142~65763354:+
BRCA	cis	rs2243480	1	rs73142162	ENSG00000232546.1	RP11-458F8.1	-6.41	2.22e-10	4.04e-08	-0.26	-0.19	Diabetic kidney disease;	chr7:65909309	chr7:66848496~66858136:+
BRCA	cis	rs1823913	0.599	rs12989203	ENSG00000280083.1	RP11-317J9.1	-6.41	2.22e-10	4.04e-08	-0.22	-0.19	Obesity-related traits;	chr2:191276617	chr2:191154118~191156070:-
BRCA	cis	rs409045	0.525	rs452688	ENSG00000271874.1	CTD-2024P10.2	-6.41	2.22e-10	4.04e-08	-0.24	-0.19	Left ventricular mass;	chr5:34628325	chr5:34651457~34651888:-
BRCA	cis	rs7945705	0.846	rs4929912	ENSG00000254860.4	TMEM9B-AS1	6.41	2.22e-10	4.04e-08	0.19	0.19	Hemoglobin concentration;	chr11:8795148	chr11:8964675~8977527:+
BRCA	cis	rs67981189	0.821	rs8007026	ENSG00000269927.1	RP6-91H8.3	6.41	2.22e-10	4.04e-08	0.24	0.19	Schizophrenia;	chr14:70997667	chr14:71141125~71143253:-
BRCA	cis	rs78456975	1	rs13413356	ENSG00000231482.2	AC141930.2	-6.41	2.22e-10	4.04e-08	-0.28	-0.19	Placebo response in major depressive disorder (% change in symptom score);	chr2:1550077	chr2:1572554~1580311:-
BRCA	cis	rs9880211	0.613	rs1393786	ENSG00000239213.4	NCK1-AS1	6.41	2.22e-10	4.05e-08	0.25	0.19	Height;Body mass index;	chr3:136135193	chr3:136841726~136862054:-
BRCA	cis	rs7520050	0.966	rs1707340	ENSG00000280836.1	AL355480.1	6.41	2.22e-10	4.05e-08	0.23	0.19	Reticulocyte count;Red blood cell count;	chr1:46049270	chr1:45581219~45581321:-
BRCA	cis	rs7520050	1	rs785473	ENSG00000280836.1	AL355480.1	6.41	2.22e-10	4.05e-08	0.23	0.19	Reticulocyte count;Red blood cell count;	chr1:46051191	chr1:45581219~45581321:-
BRCA	cis	rs7520050	0.931	rs785472	ENSG00000280836.1	AL355480.1	6.41	2.22e-10	4.05e-08	0.23	0.19	Reticulocyte count;Red blood cell count;	chr1:46052616	chr1:45581219~45581321:-
BRCA	cis	rs12594515	1	rs6493169	ENSG00000259200.1	RP11-718O11.1	6.41	2.22e-10	4.05e-08	0.22	0.19	Weight;Waist circumference;	chr15:45694796	chr15:45705078~45931069:+
BRCA	cis	rs4950322	0.57	rs72691102	ENSG00000278811.3	LINC00624	6.41	2.22e-10	4.05e-08	0.26	0.19	Protein quantitative trait loci;	chr1:147301189	chr1:147258885~147517875:-
BRCA	cis	rs4950322	0.57	rs72692904	ENSG00000278811.3	LINC00624	6.41	2.22e-10	4.05e-08	0.26	0.19	Protein quantitative trait loci;	chr1:147301437	chr1:147258885~147517875:-
BRCA	cis	rs4950322	0.57	rs72692905	ENSG00000278811.3	LINC00624	6.41	2.22e-10	4.05e-08	0.26	0.19	Protein quantitative trait loci;	chr1:147301560	chr1:147258885~147517875:-
BRCA	cis	rs4763879	0.778	rs1044771	ENSG00000256673.1	RP11-599J14.2	6.41	2.22e-10	4.05e-08	0.22	0.19	Type 1 diabetes;	chr12:9699333	chr12:9398355~9414851:-
BRCA	cis	rs2998286	0.723	rs332168	ENSG00000254635.4	WAC-AS1	-6.41	2.22e-10	4.05e-08	-0.28	-0.19	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28607488	chr10:28522652~28532743:-
BRCA	cis	rs721917	0.506	rs1923540	ENSG00000244733.5	RP11-506M13.3	-6.41	2.23e-10	4.05e-08	-0.24	-0.19	Chronic obstructive pulmonary disease;	chr10:79930616	chr10:79660891~79677996:+
BRCA	cis	rs2412819	0.571	rs11070411	ENSG00000205771.5	CATSPER2P1	6.41	2.23e-10	4.06e-08	0.29	0.19	Lung cancer;	chr15:43766436	chr15:43726918~43747094:-
BRCA	cis	rs6095360	0.727	rs7264419	ENSG00000222365.1	SNORD12B	-6.41	2.23e-10	4.06e-08	-0.24	-0.19	Intelligence (multi-trait analysis);	chr20:49084772	chr20:49280319~49280409:+
BRCA	cis	rs944990	0.576	rs4744243	ENSG00000227603.1	RP11-165J3.6	-6.41	2.24e-10	4.07e-08	-0.2	-0.19	Body mass index;	chr9:93477942	chr9:93435332~93437121:-
BRCA	cis	rs2281558	0.837	rs67676850	ENSG00000125804.12	FAM182A	-6.41	2.24e-10	4.07e-08	-0.29	-0.19	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25388781	chr20:26054655~26086917:+
BRCA	cis	rs73186030	0.687	rs16833080	ENSG00000272758.4	RP11-299J3.8	-6.41	2.24e-10	4.07e-08	-0.27	-0.19	Serum parathyroid hormone levels;	chr3:122382060	chr3:122416207~122443180:+
BRCA	cis	rs853679	0.517	rs1904841	ENSG00000219392.1	RP1-265C24.5	-6.41	2.24e-10	4.07e-08	-0.3	-0.19	Depression;	chr6:28140307	chr6:28115628~28116551:+
BRCA	cis	rs9876781	1	rs2362450	ENSG00000229759.1	MRPS18AP1	6.41	2.24e-10	4.07e-08	0.22	0.19	Longevity;	chr3:48419904	chr3:48256350~48256938:-
BRCA	cis	rs17301013	0.507	rs12067852	ENSG00000227373.4	RP11-160H22.5	-6.41	2.24e-10	4.08e-08	-0.29	-0.19	Systemic lupus erythematosus;	chr1:174302481	chr1:174115300~174160004:-
BRCA	cis	rs8114671	0.805	rs4616	ENSG00000269202.1	RP4-614O4.12	6.41	2.24e-10	4.08e-08	0.2	0.19	Height;	chr20:35002555	chr20:35201747~35203288:-
BRCA	cis	rs875971	0.522	rs4502988	ENSG00000234585.5	CCT6P3	6.41	2.25e-10	4.09e-08	0.19	0.19	Aortic root size;	chr7:65832759	chr7:65038354~65074713:+
BRCA	cis	rs1555322	0.53	rs6060347	ENSG00000279253.1	RP4-614O4.13	-6.41	2.25e-10	4.09e-08	-0.26	-0.19	Attention deficit hyperactivity disorder;	chr20:35286348	chr20:35262727~35264187:-
BRCA	cis	rs7976269	0.583	rs4931131	ENSG00000257176.2	RP11-996F15.2	-6.41	2.25e-10	4.09e-08	-0.24	-0.19	Male-pattern baldness;	chr12:29015898	chr12:29280418~29317848:-
BRCA	cis	rs1707322	0.963	rs4508055	ENSG00000281133.1	AL355480.3	-6.41	2.25e-10	4.1e-08	-0.26	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45792059	chr1:45580892~45580996:-
BRCA	cis	rs11096990	0.964	rs6828598	ENSG00000249207.1	RP11-360F5.1	6.41	2.25e-10	4.1e-08	0.23	0.19	Cognitive function;	chr4:39259850	chr4:39112677~39126818:-
BRCA	cis	rs4372836	0.964	rs11683296	ENSG00000226833.4	AC097724.3	-6.41	2.25e-10	4.1e-08	-0.24	-0.19	Body mass index;	chr2:28702538	chr2:28708953~28736205:-
BRCA	cis	rs67311347	1	rs9874499	ENSG00000280739.1	EIF1B-AS1	6.41	2.26e-10	4.1e-08	0.22	0.19	Renal cell carcinoma;	chr3:40400417	chr3:40173145~40309698:-
BRCA	cis	rs6669008	1	rs55912359	ENSG00000232450.1	RP4-730K3.3	-6.41	2.26e-10	4.11e-08	-0.24	-0.19	Bacteremia;	chr1:113624477	chr1:113698884~113699631:-
BRCA	cis	rs3764021	0.506	rs11052372	ENSG00000214776.8	RP11-726G1.1	6.41	2.26e-10	4.12e-08	0.24	0.19	Type 1 diabetes;	chr12:9679363	chr12:9467552~9576275:+
BRCA	cis	rs944990	0.576	rs3901421	ENSG00000227603.1	RP11-165J3.6	6.41	2.27e-10	4.12e-08	0.2	0.19	Body mass index;	chr9:93442256	chr9:93435332~93437121:-
BRCA	cis	rs6504622	0.905	rs736604	ENSG00000262879.4	RP11-156P1.3	6.41	2.27e-10	4.12e-08	0.2	0.19	Orofacial clefts;	chr17:46947443	chr17:46984045~47100323:-
BRCA	cis	rs35146811	0.586	rs10267231	ENSG00000235713.1	RP4-604G5.3	6.41	2.27e-10	4.12e-08	0.24	0.19	Coronary artery disease;	chr7:99997857	chr7:99992397~99993050:+
BRCA	cis	rs7914558	0.899	rs7913682	ENSG00000213061.2	PFN1P11	6.41	2.27e-10	4.12e-08	0.26	0.19	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102924635	chr10:102838011~102845473:-
BRCA	cis	rs755249	0.565	rs7539261	ENSG00000228060.1	RP11-69E11.8	6.41	2.27e-10	4.13e-08	0.19	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39584831	chr1:39565160~39573203:+
BRCA	cis	rs224090	0.601	rs10761661	ENSG00000238280.1	RP11-436D10.3	-6.41	2.27e-10	4.13e-08	-0.26	-0.19	Crohn's disease;	chr10:62765375	chr10:62793562~62805887:-
BRCA	cis	rs919433	0.783	rs788014	ENSG00000231621.1	AC013264.2	-6.4	2.27e-10	4.13e-08	-0.18	-0.19	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197364273	chr2:197197991~197199273:+
BRCA	cis	rs853679	0.55	rs1233704	ENSG00000219392.1	RP1-265C24.5	6.4	2.27e-10	4.13e-08	0.28	0.19	Depression;	chr6:28199145	chr6:28115628~28116551:+
BRCA	cis	rs2638953	0.886	rs10492369	ENSG00000278733.1	RP11-425D17.1	6.4	2.27e-10	4.13e-08	0.26	0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28172185	chr12:28185625~28186190:-
BRCA	cis	rs5015933	0.902	rs2270746	ENSG00000232630.1	PRPS1P2	6.4	2.28e-10	4.14e-08	0.18	0.19	Body mass index;	chr9:125359313	chr9:125150653~125151589:+
BRCA	cis	rs957448	0.561	rs13258635	ENSG00000253704.1	RP11-267M23.4	6.4	2.28e-10	4.14e-08	0.21	0.19	Nonsyndromic cleft lip with cleft palate;	chr8:94595629	chr8:94553722~94569745:+
BRCA	cis	rs12594515	1	rs12911309	ENSG00000259200.1	RP11-718O11.1	-6.4	2.28e-10	4.14e-08	-0.22	-0.19	Weight;Waist circumference;	chr15:45693521	chr15:45705078~45931069:+
BRCA	cis	rs7182621	0.639	rs12906050	ENSG00000182397.13	DNM1P46	6.4	2.28e-10	4.14e-08	0.24	0.19	Colonoscopy-negative controls vs population controls;	chr15:99873384	chr15:99790156~99806927:-
BRCA	cis	rs10050311	0.8	rs17420966	ENSG00000251411.1	RP11-397E7.4	-6.4	2.28e-10	4.14e-08	-0.31	-0.19	Insulin-related traits;	chr4:86770976	chr4:86913266~86914817:-
BRCA	cis	rs9840812	0.535	rs695983	ENSG00000239213.4	NCK1-AS1	6.4	2.28e-10	4.15e-08	0.22	0.19	Fibrinogen levels;	chr3:136345705	chr3:136841726~136862054:-
BRCA	cis	rs904251	0.861	rs914349	ENSG00000204110.6	RP1-153P14.8	-6.4	2.28e-10	4.15e-08	-0.21	-0.19	Cognitive performance;	chr6:37516939	chr6:37507348~37535616:+
BRCA	cis	rs2115630	1	rs2115630	ENSG00000229212.6	RP11-561C5.4	6.4	2.28e-10	4.15e-08	0.21	0.19	P wave terminal force;	chr15:84821285	chr15:85205440~85234795:-
BRCA	cis	rs2998286	0.723	rs332172	ENSG00000254635.4	WAC-AS1	-6.4	2.28e-10	4.15e-08	-0.28	-0.19	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28610394	chr10:28522652~28532743:-
BRCA	cis	rs7246657	0.653	rs10402050	ENSG00000276846.1	CTD-3220F14.3	6.4	2.28e-10	4.15e-08	0.3	0.19	Coronary artery calcification;	chr19:37198056	chr19:37314868~37315620:-
BRCA	cis	rs7587476	0.784	rs13026390	ENSG00000229267.2	AC072062.1	6.4	2.29e-10	4.15e-08	0.26	0.19	Neuroblastoma;	chr2:214822351	chr2:214810229~214963274:+
BRCA	cis	rs12468226	0.938	rs76501067	ENSG00000226261.1	AC064836.3	6.4	2.29e-10	4.16e-08	0.33	0.19	Urate levels;	chr2:202318042	chr2:202336024~202336727:-
BRCA	cis	rs17711722	0.51	rs11767457	ENSG00000237310.1	GS1-124K5.4	6.4	2.29e-10	4.16e-08	0.21	0.19	Calcium levels;	chr7:65825628	chr7:66493706~66495474:+
BRCA	cis	rs6840258	1	rs56406125	ENSG00000251411.1	RP11-397E7.4	-6.4	2.29e-10	4.16e-08	-0.28	-0.19	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87019053	chr4:86913266~86914817:-
BRCA	cis	rs4950322	0.57	rs4950409	ENSG00000278811.3	LINC00624	6.4	2.29e-10	4.16e-08	0.27	0.19	Protein quantitative trait loci;	chr1:147335879	chr1:147258885~147517875:-
BRCA	cis	rs4950322	0.57	rs72692980	ENSG00000278811.3	LINC00624	6.4	2.29e-10	4.16e-08	0.27	0.19	Protein quantitative trait loci;	chr1:147337830	chr1:147258885~147517875:-
BRCA	cis	rs853679	0.55	rs1225598	ENSG00000204709.4	LINC01556	6.4	2.29e-10	4.16e-08	0.27	0.19	Depression;	chr6:28193021	chr6:28943877~28944537:+
BRCA	cis	rs7474896	0.515	rs2749582	ENSG00000226578.1	RP11-258F22.1	6.4	2.29e-10	4.17e-08	0.25	0.19	Obesity (extreme);	chr10:37986356	chr10:37775371~37784131:-
BRCA	cis	rs78773383	0.505	rs10033019	ENSG00000249207.1	RP11-360F5.1	6.4	2.3e-10	4.17e-08	0.21	0.19	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr4:39390320	chr4:39112677~39126818:-
BRCA	cis	rs6969780	0.915	rs17471520	ENSG00000233429.8	HOTAIRM1	6.4	2.3e-10	4.18e-08	0.24	0.19	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27139171	chr7:27095647~27100265:+
BRCA	cis	rs13217239	0.646	rs62401067	ENSG00000241549.7	GUSBP2	6.4	2.31e-10	4.19e-08	0.22	0.19	Schizophrenia;	chr6:27050322	chr6:26871484~26956554:-
BRCA	cis	rs2337406	1	rs4774172	ENSG00000211972.2	IGHV3-66	6.4	2.31e-10	4.19e-08	0.18	0.19	Alzheimer's disease (late onset);	chr14:106681320	chr14:106675017~106675544:-
BRCA	cis	rs17253792	0.822	rs28831725	ENSG00000186615.9	KTN1-AS1	-6.4	2.31e-10	4.2e-08	-0.38	-0.19	Putamen volume;	chr14:55620851	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.732	rs28380739	ENSG00000186615.9	KTN1-AS1	-6.4	2.31e-10	4.2e-08	-0.38	-0.19	Putamen volume;	chr14:55621684	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs28681420	ENSG00000186615.9	KTN1-AS1	-6.4	2.31e-10	4.2e-08	-0.38	-0.19	Putamen volume;	chr14:55621685	chr14:55499278~55580110:-
BRCA	cis	rs2832191	0.716	rs1888439	ENSG00000176054.6	RPL23P2	6.4	2.31e-10	4.2e-08	0.21	0.19	Dental caries;	chr21:29082136	chr21:28997613~28998033:-
BRCA	cis	rs7665090	1	rs6821119	ENSG00000246560.2	RP11-10L12.4	6.4	2.32e-10	4.21e-08	0.21	0.19	Primary biliary cholangitis;	chr4:102634076	chr4:102828055~102844075:+
BRCA	cis	rs7665090	0.934	rs6844332	ENSG00000246560.2	RP11-10L12.4	6.4	2.32e-10	4.21e-08	0.21	0.19	Primary biliary cholangitis;	chr4:102634095	chr4:102828055~102844075:+
BRCA	cis	rs7665090	0.967	rs6821133	ENSG00000246560.2	RP11-10L12.4	6.4	2.32e-10	4.21e-08	0.21	0.19	Primary biliary cholangitis;	chr4:102634096	chr4:102828055~102844075:+
BRCA	cis	rs853679	0.517	rs16893666	ENSG00000280107.1	AL022393.9	6.4	2.32e-10	4.21e-08	0.29	0.19	Depression;	chr6:28086929	chr6:28170845~28172521:+
BRCA	cis	rs34779708	0.931	rs2148482	ENSG00000271335.4	RP11-324I22.4	6.4	2.32e-10	4.21e-08	0.2	0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35059982	chr10:35314552~35336401:-
BRCA	cis	rs301901	0.766	rs12521993	ENSG00000250155.1	CTD-2353F22.1	6.4	2.32e-10	4.21e-08	0.22	0.19	Height;	chr5:37488095	chr5:36666214~36725195:-
BRCA	cis	rs6723226	0.557	rs62136260	ENSG00000276334.1	AL133243.1	-6.4	2.32e-10	4.21e-08	-0.24	-0.19	Intelligence (multi-trait analysis);	chr2:32350379	chr2:32521927~32523547:+
BRCA	cis	rs919433	0.783	rs788007	ENSG00000231621.1	AC013264.2	-6.4	2.32e-10	4.22e-08	-0.18	-0.19	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197368952	chr2:197197991~197199273:+
BRCA	cis	rs1707322	0.662	rs11211160	ENSG00000281133.1	AL355480.3	-6.4	2.32e-10	4.22e-08	-0.25	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45680557	chr1:45580892~45580996:-
BRCA	cis	rs4950322	0.57	rs72691093	ENSG00000278811.3	LINC00624	6.4	2.32e-10	4.22e-08	0.26	0.19	Protein quantitative trait loci;	chr1:147297977	chr1:147258885~147517875:-
BRCA	cis	rs4950322	0.57	rs76236344	ENSG00000278811.3	LINC00624	6.4	2.32e-10	4.22e-08	0.26	0.19	Protein quantitative trait loci;	chr1:147297989	chr1:147258885~147517875:-
BRCA	cis	rs1322639	0.614	rs6925188	ENSG00000261039.2	RP11-417E7.2	-6.4	2.32e-10	4.22e-08	-0.25	-0.19	Pulse pressure;	chr6:169163242	chr6:169175304~169182740:-
BRCA	cis	rs875971	1	rs709597	ENSG00000224316.1	RP11-479O9.2	-6.4	2.32e-10	4.22e-08	-0.2	-0.19	Aortic root size;	chr7:66360996	chr7:65773620~65802067:+
BRCA	cis	rs783540	0.681	rs1259178	ENSG00000278603.1	RP13-608F4.5	-6.4	2.32e-10	4.22e-08	-0.28	-0.19	Schizophrenia;	chr15:82603127	chr15:82472203~82472426:+
BRCA	cis	rs673078	0.607	rs4766900	ENSG00000275409.1	RP11-131L12.4	-6.4	2.32e-10	4.22e-08	-0.27	-0.19	Glucose homeostasis traits;	chr12:118375139	chr12:118430147~118430699:+
BRCA	cis	rs721917	0.506	rs1923538	ENSG00000244733.5	RP11-506M13.3	-6.4	2.33e-10	4.22e-08	-0.24	-0.19	Chronic obstructive pulmonary disease;	chr10:79935276	chr10:79660891~79677996:+
BRCA	cis	rs11098499	0.865	rs11098513	ENSG00000249244.1	RP11-548H18.2	6.4	2.33e-10	4.22e-08	0.23	0.19	Corneal astigmatism;	chr4:119394920	chr4:119391831~119395335:-
BRCA	cis	rs6570726	0.967	rs365515	ENSG00000235652.6	RP11-545I5.3	-6.4	2.33e-10	4.22e-08	-0.19	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145481697	chr6:145799409~145886585:+
BRCA	cis	rs2998286	0.541	rs332180	ENSG00000254635.4	WAC-AS1	-6.4	2.33e-10	4.23e-08	-0.32	-0.19	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28621166	chr10:28522652~28532743:-
BRCA	cis	rs7567389	0.677	rs72845975	ENSG00000236682.1	AC068282.3	-6.4	2.33e-10	4.23e-08	-0.29	-0.19	Self-rated health;	chr2:127328698	chr2:127389130~127400580:+
BRCA	cis	rs2243480	0.803	rs160649	ENSG00000228409.4	CCT6P1	6.4	2.33e-10	4.23e-08	0.28	0.19	Diabetic kidney disease;	chr7:66078212	chr7:65751142~65763354:+
BRCA	cis	rs2243480	1	rs160648	ENSG00000228409.4	CCT6P1	6.4	2.33e-10	4.23e-08	0.28	0.19	Diabetic kidney disease;	chr7:66078397	chr7:65751142~65763354:+
BRCA	cis	rs73193808	0.901	rs67463471	ENSG00000215533.7	LINC00189	-6.4	2.33e-10	4.24e-08	-0.28	-0.19	Coronary artery disease;	chr21:29195488	chr21:29193480~29288205:+
BRCA	cis	rs2638953	0.924	rs10843124	ENSG00000278733.1	RP11-425D17.1	-6.4	2.33e-10	4.24e-08	-0.25	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28198189	chr12:28185625~28186190:-
BRCA	cis	rs6840360	0.582	rs6535796	ENSG00000270265.1	RP11-731D1.4	-6.4	2.33e-10	4.24e-08	-0.22	-0.19	Intelligence (multi-trait analysis);	chr4:151383576	chr4:151333775~151353224:-
BRCA	cis	rs11024102	1	rs11024102	ENSG00000184669.7	OR7E14P	-6.4	2.33e-10	4.24e-08	-0.3	-0.19	Glaucoma (primary angle closure);	chr11:16987058	chr11:17013998~17053024:+
BRCA	cis	rs1707322	0.691	rs61784799	ENSG00000281133.1	AL355480.3	6.4	2.33e-10	4.24e-08	0.25	0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45712076	chr1:45580892~45580996:-
BRCA	cis	rs35491132	1	rs35491132	ENSG00000220721.1	OR1F12	6.4	2.34e-10	4.24e-08	0.45	0.19	Urinary tract infection frequency;	chr6:27559449	chr6:28073316~28074233:+
BRCA	cis	rs67981189	0.896	rs12100737	ENSG00000269927.1	RP6-91H8.3	-6.4	2.34e-10	4.25e-08	-0.24	-0.19	Schizophrenia;	chr14:71004383	chr14:71141125~71143253:-
BRCA	cis	rs11992162	0.636	rs11250182	ENSG00000255046.1	RP11-297N6.4	6.4	2.34e-10	4.25e-08	0.22	0.19	Monocyte count;	chr8:11950067	chr8:11797928~11802568:-
BRCA	cis	rs34779708	0.966	rs35814343	ENSG00000271335.4	RP11-324I22.4	6.4	2.35e-10	4.26e-08	0.21	0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35138786	chr10:35314552~35336401:-
BRCA	cis	rs875971	0.862	rs2901152	ENSG00000224316.1	RP11-479O9.2	-6.4	2.35e-10	4.26e-08	-0.2	-0.19	Aortic root size;	chr7:66300017	chr7:65773620~65802067:+
BRCA	cis	rs34779708	0.966	rs12762493	ENSG00000271335.4	RP11-324I22.4	6.4	2.35e-10	4.26e-08	0.2	0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35182945	chr10:35314552~35336401:-
BRCA	cis	rs12468226	1	rs111252524	ENSG00000226261.1	AC064836.3	6.4	2.35e-10	4.26e-08	0.33	0.19	Urate levels;	chr2:202334465	chr2:202336024~202336727:-
BRCA	cis	rs12468226	1	rs112753638	ENSG00000226261.1	AC064836.3	6.4	2.35e-10	4.26e-08	0.33	0.19	Urate levels;	chr2:202334496	chr2:202336024~202336727:-
BRCA	cis	rs2732480	0.577	rs2634680	ENSG00000273765.1	RP11-370I10.11	6.4	2.35e-10	4.27e-08	0.24	0.19	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48340781	chr12:48360920~48361377:+
BRCA	cis	rs2732480	0.577	rs2634678	ENSG00000273765.1	RP11-370I10.11	6.4	2.35e-10	4.27e-08	0.24	0.19	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48341755	chr12:48360920~48361377:+
BRCA	cis	rs1707322	0.686	rs1084086	ENSG00000281133.1	AL355480.3	6.4	2.35e-10	4.27e-08	0.25	0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45575428	chr1:45580892~45580996:-
BRCA	cis	rs35146811	0.66	rs6465760	ENSG00000235713.1	RP4-604G5.3	-6.4	2.35e-10	4.27e-08	-0.23	-0.19	Coronary artery disease;	chr7:99993795	chr7:99992397~99993050:+
BRCA	cis	rs34779708	0.966	rs17591781	ENSG00000271335.4	RP11-324I22.4	6.4	2.35e-10	4.27e-08	0.2	0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35209610	chr10:35314552~35336401:-
BRCA	cis	rs875971	0.964	rs778708	ENSG00000224316.1	RP11-479O9.2	6.4	2.36e-10	4.28e-08	0.19	0.19	Aortic root size;	chr7:66391332	chr7:65773620~65802067:+
BRCA	cis	rs7555523	0.779	rs6662839	ENSG00000224358.1	RP11-466F5.8	-6.4	2.36e-10	4.28e-08	-0.35	-0.19	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165753409	chr1:165768929~165775176:+
BRCA	cis	rs8114671	0.967	rs6088753	ENSG00000269202.1	RP4-614O4.12	-6.4	2.36e-10	4.28e-08	-0.2	-0.19	Height;	chr20:35180449	chr20:35201747~35203288:-
BRCA	cis	rs2243480	0.901	rs2949697	ENSG00000228409.4	CCT6P1	6.4	2.36e-10	4.28e-08	0.27	0.19	Diabetic kidney disease;	chr7:65999249	chr7:65751142~65763354:+
BRCA	cis	rs11742741	0.579	rs17444609	ENSG00000248874.4	C5orf17	6.4	2.36e-10	4.29e-08	0.25	0.19	Educational attainment;	chr5:24110244	chr5:23951348~24178263:+
BRCA	cis	rs11098499	0.78	rs7680914	ENSG00000249244.1	RP11-548H18.2	6.4	2.36e-10	4.29e-08	0.24	0.19	Corneal astigmatism;	chr4:119641898	chr4:119391831~119395335:-
BRCA	cis	rs67981189	0.896	rs17108804	ENSG00000269927.1	RP6-91H8.3	-6.4	2.37e-10	4.3e-08	-0.24	-0.19	Schizophrenia;	chr14:70974807	chr14:71141125~71143253:-
BRCA	cis	rs2030746	1	rs2030746	ENSG00000237614.1	AC073257.2	6.4	2.37e-10	4.3e-08	0.24	0.19	LDL cholesterol;Total cholesterol levels;LDL cholesterol levels;	chr2:120551912	chr2:120542909~120544326:-
BRCA	cis	rs919433	0.783	rs2565158	ENSG00000231621.1	AC013264.2	-6.4	2.37e-10	4.3e-08	-0.18	-0.19	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197371379	chr2:197197991~197199273:+
BRCA	cis	rs919433	0.783	rs2565155	ENSG00000231621.1	AC013264.2	-6.4	2.37e-10	4.3e-08	-0.18	-0.19	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197371701	chr2:197197991~197199273:+
BRCA	cis	rs919433	0.783	rs3097383	ENSG00000231621.1	AC013264.2	-6.4	2.37e-10	4.3e-08	-0.18	-0.19	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197372163	chr2:197197991~197199273:+
BRCA	cis	rs919433	0.662	rs2043018	ENSG00000231621.1	AC013264.2	-6.4	2.37e-10	4.3e-08	-0.18	-0.19	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197372234	chr2:197197991~197199273:+
BRCA	cis	rs2638953	0.744	rs11049426	ENSG00000278733.1	RP11-425D17.1	-6.4	2.37e-10	4.3e-08	-0.25	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28193573	chr12:28185625~28186190:-
BRCA	cis	rs1707322	0.717	rs1135850	ENSG00000281133.1	AL355480.3	-6.4	2.37e-10	4.31e-08	-0.25	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45628020	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.686	rs3014235	ENSG00000281133.1	AL355480.3	6.4	2.37e-10	4.31e-08	0.25	0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45625840	chr1:45580892~45580996:-
BRCA	cis	rs6504622	0.875	rs11652318	ENSG00000262879.4	RP11-156P1.3	6.4	2.37e-10	4.31e-08	0.2	0.19	Orofacial clefts;	chr17:46963728	chr17:46984045~47100323:-
BRCA	cis	rs12594515	1	rs12595137	ENSG00000259200.1	RP11-718O11.1	-6.4	2.37e-10	4.31e-08	-0.22	-0.19	Weight;Waist circumference;	chr15:45693907	chr15:45705078~45931069:+
BRCA	cis	rs12594515	0.967	rs12595138	ENSG00000259200.1	RP11-718O11.1	-6.4	2.37e-10	4.31e-08	-0.22	-0.19	Weight;Waist circumference;	chr15:45693910	chr15:45705078~45931069:+
BRCA	cis	rs858239	0.636	rs7808488	ENSG00000230042.1	AK3P3	-6.4	2.37e-10	4.31e-08	-0.22	-0.19	Cerebrospinal fluid biomarker levels;	chr7:23182251	chr7:23129178~23129841:+
BRCA	cis	rs919433	1	rs1560277	ENSG00000231621.1	AC013264.2	-6.4	2.38e-10	4.31e-08	-0.19	-0.19	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197323179	chr2:197197991~197199273:+
BRCA	cis	rs17301013	0.507	rs72715237	ENSG00000227373.4	RP11-160H22.5	6.4	2.38e-10	4.31e-08	0.3	0.19	Systemic lupus erythematosus;	chr1:174550527	chr1:174115300~174160004:-
BRCA	cis	rs1823913	0.637	rs10931497	ENSG00000280083.1	RP11-317J9.1	6.4	2.38e-10	4.31e-08	0.22	0.19	Obesity-related traits;	chr2:191306254	chr2:191154118~191156070:-
BRCA	cis	rs10740039	0.81	rs9415605	ENSG00000254271.1	RP11-131N11.4	-6.4	2.38e-10	4.31e-08	-0.29	-0.19	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60616809	chr10:60734342~60741828:+
BRCA	cis	rs6504622	0.875	rs2316330	ENSG00000262879.4	RP11-156P1.3	6.4	2.38e-10	4.31e-08	0.2	0.19	Orofacial clefts;	chr17:46962666	chr17:46984045~47100323:-
BRCA	cis	rs6504622	0.905	rs3851785	ENSG00000262879.4	RP11-156P1.3	6.4	2.38e-10	4.31e-08	0.2	0.19	Orofacial clefts;	chr17:46962781	chr17:46984045~47100323:-
BRCA	cis	rs4713118	0.739	rs2893931	ENSG00000220721.1	OR1F12	6.4	2.38e-10	4.31e-08	0.24	0.19	Parkinson's disease;	chr6:27780231	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.517	rs1904840	ENSG00000280107.1	AL022393.9	-6.4	2.38e-10	4.31e-08	-0.29	-0.19	Depression;	chr6:28140454	chr6:28170845~28172521:+
BRCA	cis	rs2243480	0.764	rs2460423	ENSG00000230295.1	RP11-458F8.2	-6.4	2.38e-10	4.31e-08	-0.26	-0.19	Diabetic kidney disease;	chr7:66136229	chr7:66880708~66882981:+
BRCA	cis	rs13113518	0.776	rs13124436	ENSG00000223305.1	RN7SKP30	6.4	2.38e-10	4.31e-08	0.24	0.19	Height;	chr4:55502504	chr4:55540502~55540835:-
BRCA	cis	rs2836950	0.545	rs2836940	ENSG00000255568.3	BRWD1-AS2	-6.4	2.38e-10	4.32e-08	-0.18	-0.19	Menarche (age at onset);	chr21:39216770	chr21:39313935~39314962:+
BRCA	cis	rs801193	0.636	rs10233806	ENSG00000224316.1	RP11-479O9.2	-6.4	2.38e-10	4.32e-08	-0.2	-0.19	Aortic root size;	chr7:66653261	chr7:65773620~65802067:+
BRCA	cis	rs55702914	0.837	rs2195507	ENSG00000231621.1	AC013264.2	6.4	2.38e-10	4.32e-08	0.19	0.19	Major depression and alcohol dependence;	chr2:197307612	chr2:197197991~197199273:+
BRCA	cis	rs10208649	1	rs72906711	ENSG00000233266.1	HMGB1P31	6.4	2.39e-10	4.33e-08	0.47	0.19	Body mass index;	chr2:54036465	chr2:54051334~54051760:+
BRCA	cis	rs10208649	0.908	rs13387890	ENSG00000233266.1	HMGB1P31	6.4	2.39e-10	4.33e-08	0.47	0.19	Body mass index;	chr2:54039249	chr2:54051334~54051760:+
BRCA	cis	rs2348418	0.932	rs7136429	ENSG00000247934.4	RP11-967K21.1	6.4	2.39e-10	4.33e-08	0.22	0.19	Lung function (FEV1);Lung function (FVC);	chr12:28460306	chr12:28163298~28190738:-
BRCA	cis	rs2749097	0.609	rs2360159	ENSG00000244256.3	RN7SL130P	-6.4	2.39e-10	4.33e-08	-0.26	-0.19	Alcohol consumption (transferrin glycosylation);	chr1:63653130	chr1:63655743~63656047:+
BRCA	cis	rs11096990	0.964	rs11096986	ENSG00000249207.1	RP11-360F5.1	6.4	2.39e-10	4.33e-08	0.22	0.19	Cognitive function;	chr4:39257122	chr4:39112677~39126818:-
BRCA	cis	rs2243480	1	rs34560516	ENSG00000229886.1	RP5-1132H15.3	6.4	2.39e-10	4.34e-08	0.34	0.19	Diabetic kidney disease;	chr7:65939105	chr7:66025126~66031544:-
BRCA	cis	rs2492301	0.506	rs11264049	ENSG00000233621.1	LINC01137	6.4	2.39e-10	4.34e-08	0.2	0.19	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr1:37436534	chr1:37454879~37474411:-
BRCA	cis	rs2836950	0.565	rs8130320	ENSG00000255568.3	BRWD1-AS2	-6.4	2.39e-10	4.34e-08	-0.19	-0.19	Menarche (age at onset);	chr21:39208332	chr21:39313935~39314962:+
BRCA	cis	rs1167827	1	rs1167827	ENSG00000165178.9	NCF1C	6.4	2.39e-10	4.34e-08	0.16	0.19	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75533848	chr7:75156639~75172044:-
BRCA	cis	rs7555523	0.943	rs4537525	ENSG00000224358.1	RP11-466F5.8	-6.4	2.39e-10	4.34e-08	-0.35	-0.19	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165741852	chr1:165768929~165775176:+
BRCA	cis	rs7555523	0.887	rs4269750	ENSG00000224358.1	RP11-466F5.8	-6.4	2.39e-10	4.34e-08	-0.35	-0.19	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165742273	chr1:165768929~165775176:+
BRCA	cis	rs7555523	0.887	rs10918274	ENSG00000224358.1	RP11-466F5.8	-6.4	2.39e-10	4.34e-08	-0.35	-0.19	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165745179	chr1:165768929~165775176:+
BRCA	cis	rs2243480	1	rs402418	ENSG00000232546.1	RP11-458F8.1	-6.4	2.4e-10	4.34e-08	-0.26	-0.19	Diabetic kidney disease;	chr7:66044482	chr7:66848496~66858136:+
BRCA	cis	rs2243480	1	rs937108	ENSG00000228409.4	CCT6P1	6.4	2.4e-10	4.35e-08	0.26	0.19	Diabetic kidney disease;	chr7:65963465	chr7:65751142~65763354:+
BRCA	cis	rs6928977	0.5	rs6925161	ENSG00000231028.7	LINC00271	-6.4	2.4e-10	4.35e-08	-0.2	-0.19	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135615496	chr6:135497801~135716055:+
BRCA	cis	rs7931462	0.655	rs6483208	ENSG00000279696.1	RP11-178H8.7	-6.4	2.4e-10	4.35e-08	-0.3	-0.19	DNA methylation (parent-of-origin);	chr11:92972678	chr11:93726654~93729805:-
BRCA	cis	rs7615952	0.641	rs7618515	ENSG00000171084.14	FAM86JP	6.4	2.4e-10	4.36e-08	0.3	0.19	Blood pressure (smoking interaction);	chr3:126071735	chr3:125916620~125930024:+
BRCA	cis	rs6142102	0.778	rs6059581	ENSG00000275784.1	RP5-1125A11.6	-6.4	2.4e-10	4.36e-08	-0.24	-0.19	Skin pigmentation;	chr20:33940582	chr20:33989480~33991818:-
BRCA	cis	rs2732480	0.577	rs2732479	ENSG00000273765.1	RP11-370I10.11	6.4	2.4e-10	4.36e-08	0.24	0.19	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48342477	chr12:48360920~48361377:+
BRCA	cis	rs2732480	0.537	rs1061986	ENSG00000273765.1	RP11-370I10.11	6.4	2.4e-10	4.36e-08	0.24	0.19	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48342656	chr12:48360920~48361377:+
BRCA	cis	rs673078	0.66	rs73205531	ENSG00000275409.1	RP11-131L12.4	-6.4	2.41e-10	4.36e-08	-0.31	-0.19	Glucose homeostasis traits;	chr12:118282063	chr12:118430147~118430699:+
BRCA	cis	rs17253792	0.822	rs28481586	ENSG00000186615.9	KTN1-AS1	-6.4	2.41e-10	4.37e-08	-0.36	-0.19	Putamen volume;	chr14:55587145	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs10147380	ENSG00000186615.9	KTN1-AS1	-6.4	2.41e-10	4.37e-08	-0.36	-0.19	Putamen volume;	chr14:55587636	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs10147688	ENSG00000186615.9	KTN1-AS1	-6.4	2.41e-10	4.37e-08	-0.36	-0.19	Putamen volume;	chr14:55587924	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.822	rs10135426	ENSG00000186615.9	KTN1-AS1	-6.4	2.41e-10	4.37e-08	-0.36	-0.19	Putamen volume;	chr14:55587926	chr14:55499278~55580110:-
BRCA	cis	rs1707322	0.752	rs11211168	ENSG00000281133.1	AL355480.3	-6.4	2.41e-10	4.37e-08	-0.25	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45697975	chr1:45580892~45580996:-
BRCA	cis	rs6951245	0.554	rs10270249	ENSG00000229043.2	AC091729.9	-6.4	2.42e-10	4.38e-08	-0.29	-0.19	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1112250	chr7:1160374~1165267:+
BRCA	cis	rs875971	0.545	rs75840613	ENSG00000236529.1	RP13-254B10.1	6.4	2.42e-10	4.38e-08	0.24	0.19	Aortic root size;	chr7:66376399	chr7:65840212~65840596:+
BRCA	cis	rs34779708	0.966	rs4934536	ENSG00000271335.4	RP11-324I22.4	6.4	2.42e-10	4.38e-08	0.21	0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35152241	chr10:35314552~35336401:-
BRCA	cis	rs755249	0.567	rs4660208	ENSG00000237624.1	OXCT2P1	6.4	2.42e-10	4.38e-08	0.28	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39256542	chr1:39514956~39516490:+
BRCA	cis	rs67981189	0.865	rs2189806	ENSG00000258571.1	PTTG4P	6.4	2.42e-10	4.38e-08	0.21	0.19	Schizophrenia;	chr14:70921681	chr14:71085482~71085833:-
BRCA	cis	rs8072100	0.713	rs8074451	ENSG00000228782.6	CTD-2026D20.3	6.4	2.42e-10	4.38e-08	0.22	0.19	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47400207	chr17:47450568~47492492:-
BRCA	cis	rs2348418	0.832	rs10506031	ENSG00000247934.4	RP11-967K21.1	-6.39	2.42e-10	4.39e-08	-0.22	-0.19	Lung function (FEV1);Lung function (FVC);	chr12:28379061	chr12:28163298~28190738:-
BRCA	cis	rs12594515	1	rs12185095	ENSG00000259200.1	RP11-718O11.1	-6.39	2.42e-10	4.39e-08	-0.22	-0.19	Weight;Waist circumference;	chr15:45702437	chr15:45705078~45931069:+
BRCA	cis	rs875971	0.825	rs1000464	ENSG00000224316.1	RP11-479O9.2	-6.39	2.42e-10	4.39e-08	-0.2	-0.19	Aortic root size;	chr7:66312922	chr7:65773620~65802067:+
BRCA	cis	rs1707322	0.627	rs3014213	ENSG00000281133.1	AL355480.3	6.39	2.43e-10	4.39e-08	0.25	0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45579850	chr1:45580892~45580996:-
BRCA	cis	rs228614	0.536	rs223477	ENSG00000251288.2	RP11-10L12.2	-6.39	2.43e-10	4.41e-08	-0.23	-0.19	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102769099	chr4:102751401~102752641:+
BRCA	cis	rs600231	0.708	rs2957269	ENSG00000245532.5	NEAT1	6.39	2.43e-10	4.41e-08	0.18	0.19	Bone mineral density;	chr11:65475536	chr11:65422774~65445540:+
BRCA	cis	rs2638953	0.886	rs11049429	ENSG00000278733.1	RP11-425D17.1	-6.39	2.44e-10	4.42e-08	-0.24	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28194332	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.779	rs11049432	ENSG00000278733.1	RP11-425D17.1	-6.39	2.44e-10	4.42e-08	-0.24	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28194454	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.85	rs4284426	ENSG00000278733.1	RP11-425D17.1	-6.39	2.44e-10	4.42e-08	-0.24	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28194543	chr12:28185625~28186190:-
BRCA	cis	rs6543140	0.964	rs4851589	ENSG00000234389.1	AC007278.3	6.39	2.44e-10	4.42e-08	0.19	0.19	Blood protein levels;	chr2:102460685	chr2:102438713~102440475:+
BRCA	cis	rs919433	0.75	rs788010	ENSG00000231621.1	AC013264.2	-6.39	2.44e-10	4.43e-08	-0.18	-0.19	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197366225	chr2:197197991~197199273:+
BRCA	cis	rs7246657	0.943	rs10420722	ENSG00000267422.1	CTD-2554C21.1	-6.39	2.45e-10	4.43e-08	-0.29	-0.19	Coronary artery calcification;	chr19:37482872	chr19:37779686~37792865:+
BRCA	cis	rs9992667	0.955	rs6858772	ENSG00000231160.8	KLF3-AS1	6.39	2.45e-10	4.44e-08	0.24	0.19	Eosinophil percentage of granulocytes;	chr4:38649382	chr4:38612701~38664883:-
BRCA	cis	rs10050311	0.746	rs17420607	ENSG00000251411.1	RP11-397E7.4	-6.39	2.45e-10	4.44e-08	-0.29	-0.19	Insulin-related traits;	chr4:86749048	chr4:86913266~86914817:-
BRCA	cis	rs10515750	0.5	rs10463005	ENSG00000248544.2	CTB-47B11.3	-6.39	2.45e-10	4.44e-08	-0.28	-0.19	Lung function (FEV1/FVC);	chr5:157278870	chr5:157375741~157384950:-
BRCA	cis	rs2243480	0.803	rs36127118	ENSG00000232559.3	GS1-124K5.12	6.39	2.45e-10	4.44e-08	0.37	0.19	Diabetic kidney disease;	chr7:66100518	chr7:66554588~66576923:-
BRCA	cis	rs853679	0.55	rs1233707	ENSG00000204709.4	LINC01556	6.39	2.46e-10	4.45e-08	0.27	0.19	Depression;	chr6:28205175	chr6:28943877~28944537:+
BRCA	cis	rs1014246	0.848	rs58568639	ENSG00000232767.1	RP11-498B4.5	-6.39	2.46e-10	4.45e-08	-0.23	-0.19	Age at smoking initiation in chronic obstructive pulmonary disease;	chr10:116697375	chr10:116670103~116672739:+
BRCA	cis	rs17807185	0.653	rs9641271	ENSG00000214293.7	APTR	6.39	2.46e-10	4.45e-08	0.22	0.19	Height;	chr7:77668098	chr7:77657660~77696265:-
BRCA	cis	rs301901	0.734	rs216386	ENSG00000250155.1	CTD-2353F22.1	-6.39	2.46e-10	4.45e-08	-0.21	-0.19	Height;	chr5:37276224	chr5:36666214~36725195:-
BRCA	cis	rs2554380	0.55	rs62025831	ENSG00000230373.7	GOLGA6L5P	6.39	2.46e-10	4.46e-08	0.25	0.19	Height;	chr15:83876933	chr15:84507885~84516814:-
BRCA	cis	rs11154801	0.696	rs4432992	ENSG00000231028.7	LINC00271	-6.39	2.46e-10	4.46e-08	-0.21	-0.19	Multiple sclerosis;	chr6:135612356	chr6:135497801~135716055:+
BRCA	cis	rs9601248	0.627	rs2146593	ENSG00000227354.5	RBM26-AS1	6.39	2.46e-10	4.46e-08	0.23	0.19	Major depressive disorder;	chr13:79605977	chr13:79406309~79424328:+
BRCA	cis	rs1440410	0.835	rs9790396	ENSG00000250326.1	RP11-284M14.1	-6.39	2.47e-10	4.47e-08	-0.21	-0.19	Ischemic stroke;	chr4:143130366	chr4:142933195~143184861:-
BRCA	cis	rs1440410	0.798	rs7693817	ENSG00000250326.1	RP11-284M14.1	-6.39	2.47e-10	4.47e-08	-0.21	-0.19	Ischemic stroke;	chr4:143130372	chr4:142933195~143184861:-
BRCA	cis	rs10740039	0.81	rs7098097	ENSG00000254271.1	RP11-131N11.4	6.39	2.47e-10	4.47e-08	0.26	0.19	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60605233	chr10:60734342~60741828:+
BRCA	cis	rs10740039	0.81	rs10740036	ENSG00000254271.1	RP11-131N11.4	6.39	2.47e-10	4.47e-08	0.26	0.19	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60606216	chr10:60734342~60741828:+
BRCA	cis	rs11105298	0.891	rs10858890	ENSG00000270344.2	RP11-734K2.4	6.39	2.47e-10	4.47e-08	0.23	0.19	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89513389	chr12:89525654~89548005:+
BRCA	cis	rs875971	0.862	rs6460290	ENSG00000224316.1	RP11-479O9.2	-6.39	2.47e-10	4.47e-08	-0.19	-0.19	Aortic root size;	chr7:66344119	chr7:65773620~65802067:+
BRCA	cis	rs4683346	0.616	rs7641046	ENSG00000173811.9	CCDC13-AS1	-6.39	2.47e-10	4.47e-08	-0.26	-0.19	Granulocyte percentage of myeloid white cells;	chr3:42789838	chr3:42732575~42746768:+
BRCA	cis	rs4683346	0.585	rs11129975	ENSG00000173811.9	CCDC13-AS1	-6.39	2.47e-10	4.47e-08	-0.26	-0.19	Granulocyte percentage of myeloid white cells;	chr3:42794493	chr3:42732575~42746768:+
BRCA	cis	rs4683346	0.616	rs13096498	ENSG00000173811.9	CCDC13-AS1	-6.39	2.47e-10	4.47e-08	-0.26	-0.19	Granulocyte percentage of myeloid white cells;	chr3:42795494	chr3:42732575~42746768:+
BRCA	cis	rs17772222	0.682	rs2274736	ENSG00000258983.2	RP11-507K2.2	6.39	2.47e-10	4.48e-08	0.2	0.19	Coronary artery calcification;	chr14:88472308	chr14:88499334~88515502:+
BRCA	cis	rs1320333	0.772	rs17786120	ENSG00000233296.1	AC092159.2	6.39	2.48e-10	4.49e-08	0.36	0.19	Obesity-related traits;	chr2:700580	chr2:677186~697371:+
BRCA	cis	rs10129255	0.5	rs11627315	ENSG00000274576.2	IGHV2-70	-6.39	2.48e-10	4.49e-08	-0.16	-0.19	Kawasaki disease;	chr14:106802182	chr14:106770577~106771020:-
BRCA	cis	rs9907295	0.681	rs9912284	ENSG00000270977.1	AC015849.16	-6.39	2.48e-10	4.49e-08	-0.33	-0.19	Fibroblast growth factor basic levels;	chr17:35906638	chr17:35893707~35911023:-
BRCA	cis	rs7267979	0.789	rs62213729	ENSG00000204556.4	CTD-2514C3.1	6.39	2.48e-10	4.49e-08	0.27	0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25382790	chr20:26018832~26020684:+
BRCA	cis	rs301901	0.675	rs2366274	ENSG00000250155.1	CTD-2353F22.1	-6.39	2.48e-10	4.5e-08	-0.22	-0.19	Height;	chr5:37266341	chr5:36666214~36725195:-
BRCA	cis	rs13113518	0.783	rs12508367	ENSG00000223305.1	RN7SKP30	6.39	2.49e-10	4.5e-08	0.24	0.19	Height;	chr4:55509442	chr4:55540502~55540835:-
BRCA	cis	rs13113518	0.812	rs2272073	ENSG00000223305.1	RN7SKP30	6.39	2.49e-10	4.5e-08	0.24	0.19	Height;	chr4:55510177	chr4:55540502~55540835:-
BRCA	cis	rs7746199	0.736	rs35848276	ENSG00000220721.1	OR1F12	6.39	2.49e-10	4.5e-08	0.46	0.19	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27553317	chr6:28073316~28074233:+
BRCA	cis	rs35146811	0.586	rs6946168	ENSG00000235713.1	RP4-604G5.3	6.39	2.49e-10	4.5e-08	0.24	0.19	Coronary artery disease;	chr7:100000663	chr7:99992397~99993050:+
BRCA	cis	rs853679	0.517	rs9393887	ENSG00000280107.1	AL022393.9	-6.39	2.49e-10	4.51e-08	-0.29	-0.19	Depression;	chr6:28091242	chr6:28170845~28172521:+
BRCA	cis	rs2412819	0.571	rs2930531	ENSG00000205771.5	CATSPER2P1	6.39	2.49e-10	4.51e-08	0.28	0.19	Lung cancer;	chr15:43829372	chr15:43726918~43747094:-
BRCA	cis	rs4713118	0.869	rs9348775	ENSG00000220721.1	OR1F12	6.39	2.49e-10	4.51e-08	0.24	0.19	Parkinson's disease;	chr6:27727550	chr6:28073316~28074233:+
BRCA	cis	rs4908760	0.864	rs1463052	ENSG00000270282.1	RP5-1115A15.2	6.39	2.49e-10	4.51e-08	0.21	0.19	Vitiligo;	chr1:8641172	chr1:8512653~8513021:+
BRCA	cis	rs9880211	0.613	rs12695644	ENSG00000273486.1	RP11-731C17.2	6.39	2.49e-10	4.51e-08	0.24	0.19	Height;Body mass index;	chr3:136126096	chr3:136837338~136839021:-
BRCA	cis	rs6504622	0.905	rs197926	ENSG00000262879.4	RP11-156P1.3	6.39	2.49e-10	4.51e-08	0.2	0.19	Orofacial clefts;	chr17:46934721	chr17:46984045~47100323:-
BRCA	cis	rs7615952	0.641	rs7632497	ENSG00000171084.14	FAM86JP	6.39	2.49e-10	4.51e-08	0.3	0.19	Blood pressure (smoking interaction);	chr3:126064243	chr3:125916620~125930024:+
BRCA	cis	rs7615952	0.641	rs12487875	ENSG00000171084.14	FAM86JP	6.39	2.49e-10	4.51e-08	0.3	0.19	Blood pressure (smoking interaction);	chr3:126068381	chr3:125916620~125930024:+
BRCA	cis	rs13631	0.894	rs7856589	ENSG00000268996.3	MAN1B1-AS1	-6.39	2.49e-10	4.51e-08	-0.18	-0.19	Cerebrospinal fluid biomarker levels;	chr9:137109469	chr9:137084946~137086817:-
BRCA	cis	rs2408955	0.521	rs7301003	ENSG00000240399.1	RP1-228P16.1	6.39	2.51e-10	4.53e-08	0.22	0.19	Glycated hemoglobin levels;	chr12:48156444	chr12:48054813~48055591:-
BRCA	cis	rs4713118	0.824	rs9468225	ENSG00000220721.1	OR1F12	6.39	2.51e-10	4.53e-08	0.24	0.19	Parkinson's disease;	chr6:27777940	chr6:28073316~28074233:+
BRCA	cis	rs754466	0.606	rs11002315	ENSG00000204049.1	RP11-126H7.4	6.39	2.51e-10	4.54e-08	0.23	0.19	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77857627	chr10:77866875~77869610:+
BRCA	cis	rs754466	0.651	rs11002317	ENSG00000204049.1	RP11-126H7.4	6.39	2.51e-10	4.54e-08	0.23	0.19	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77857890	chr10:77866875~77869610:+
BRCA	cis	rs1707322	0.964	rs785516	ENSG00000281133.1	AL355480.3	6.39	2.51e-10	4.54e-08	0.25	0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46099086	chr1:45580892~45580996:-
BRCA	cis	rs1707322	1	rs785517	ENSG00000281133.1	AL355480.3	6.39	2.51e-10	4.54e-08	0.25	0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46101863	chr1:45580892~45580996:-
BRCA	cis	rs1707322	1	rs785484	ENSG00000281133.1	AL355480.3	6.39	2.51e-10	4.54e-08	0.25	0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46108343	chr1:45580892~45580996:-
BRCA	cis	rs875971	0.545	rs73146609	ENSG00000236529.1	RP13-254B10.1	6.39	2.51e-10	4.54e-08	0.25	0.19	Aortic root size;	chr7:66302477	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.545	rs2173571	ENSG00000236529.1	RP13-254B10.1	6.39	2.51e-10	4.54e-08	0.25	0.19	Aortic root size;	chr7:66305392	chr7:65840212~65840596:+
BRCA	cis	rs5015933	0.801	rs4240490	ENSG00000232630.1	PRPS1P2	-6.39	2.51e-10	4.54e-08	-0.18	-0.19	Body mass index;	chr9:125377728	chr9:125150653~125151589:+
BRCA	cis	rs2243480	1	rs4718333	ENSG00000229886.1	RP5-1132H15.3	-6.39	2.51e-10	4.54e-08	-0.35	-0.19	Diabetic kidney disease;	chr7:66307771	chr7:66025126~66031544:-
BRCA	cis	rs2243480	1	rs7792391	ENSG00000229886.1	RP5-1132H15.3	-6.39	2.51e-10	4.54e-08	-0.35	-0.19	Diabetic kidney disease;	chr7:66308442	chr7:66025126~66031544:-
BRCA	cis	rs853679	0.517	rs868987	ENSG00000280107.1	AL022393.9	6.39	2.51e-10	4.54e-08	0.29	0.19	Depression;	chr6:28142370	chr6:28170845~28172521:+
BRCA	cis	rs2898681	0.58	rs41279517	ENSG00000248375.1	RP11-177B4.1	-6.39	2.51e-10	4.55e-08	-0.38	-0.19	Optic nerve measurement (cup area);	chr4:52863604	chr4:52720081~52720831:-
BRCA	cis	rs2898681	0.567	rs77657787	ENSG00000248375.1	RP11-177B4.1	-6.39	2.51e-10	4.55e-08	-0.38	-0.19	Optic nerve measurement (cup area);	chr4:52863814	chr4:52720081~52720831:-
BRCA	cis	rs755249	0.567	rs61779309	ENSG00000237624.1	OXCT2P1	6.39	2.51e-10	4.55e-08	0.29	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39474827	chr1:39514956~39516490:+
BRCA	cis	rs2179367	0.632	rs9498348	ENSG00000216906.2	RP11-350J20.9	6.39	2.51e-10	4.55e-08	0.28	0.19	Dupuytren's disease;	chr6:149418352	chr6:149904243~149906418:+
BRCA	cis	rs10029851	0.58	rs6854331	ENSG00000234492.4	RPL34-AS1	6.39	2.51e-10	4.55e-08	0.29	0.19	Amyotrophic lateral sclerosis (sporadic);	chr4:108589529	chr4:108538190~108620460:-
BRCA	cis	rs7085104	0.513	rs619824	ENSG00000213061.2	PFN1P11	6.39	2.52e-10	4.55e-08	0.25	0.19	Immature fraction of reticulocytes;Schizophrenia;	chr10:102821531	chr10:102838011~102845473:-
BRCA	cis	rs67766926	0.587	rs17539290	ENSG00000271889.1	RP11-493E12.1	6.39	2.52e-10	4.55e-08	0.29	0.19	Inflammatory skin disease;	chr2:61020375	chr2:61151433~61162105:-
BRCA	cis	rs10515750	0.5	rs6890694	ENSG00000251405.2	CTB-109A12.1	6.39	2.52e-10	4.56e-08	0.3	0.19	Lung function (FEV1/FVC);	chr5:157283735	chr5:157362615~157460078:-
BRCA	cis	rs12501370	1	rs13105816	ENSG00000201736.1	RNA5SP160	6.39	2.52e-10	4.56e-08	0.25	0.19	Iris color (L* coordinate);	chr4:40986763	chr4:40990154~40990273:+
BRCA	cis	rs7555523	0.887	rs6696454	ENSG00000224358.1	RP11-466F5.8	-6.39	2.53e-10	4.57e-08	-0.35	-0.19	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165738686	chr1:165768929~165775176:+
BRCA	cis	rs12468226	0.938	rs114922024	ENSG00000226261.1	AC064836.3	6.39	2.53e-10	4.58e-08	0.33	0.19	Urate levels;	chr2:202315958	chr2:202336024~202336727:-
BRCA	cis	rs12468226	0.938	rs77261109	ENSG00000226261.1	AC064836.3	6.39	2.53e-10	4.58e-08	0.33	0.19	Urate levels;	chr2:202316233	chr2:202336024~202336727:-
BRCA	cis	rs12468226	0.938	rs12466003	ENSG00000226261.1	AC064836.3	6.39	2.53e-10	4.58e-08	0.33	0.19	Urate levels;	chr2:202317317	chr2:202336024~202336727:-
BRCA	cis	rs17253792	0.822	rs75995456	ENSG00000186615.9	KTN1-AS1	-6.39	2.53e-10	4.58e-08	-0.4	-0.19	Putamen volume;	chr14:55606476	chr14:55499278~55580110:-
BRCA	cis	rs2998286	0.723	rs332139	ENSG00000254635.4	WAC-AS1	-6.39	2.53e-10	4.58e-08	-0.28	-0.19	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28570150	chr10:28522652~28532743:-
BRCA	cis	rs853679	0.607	rs13211507	ENSG00000220721.1	OR1F12	6.39	2.54e-10	4.58e-08	0.44	0.19	Depression;	chr6:28289600	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.607	rs34691223	ENSG00000220721.1	OR1F12	6.39	2.54e-10	4.58e-08	0.44	0.19	Depression;	chr6:28290431	chr6:28073316~28074233:+
BRCA	cis	rs67981189	0.858	rs221927	ENSG00000269927.1	RP6-91H8.3	-6.39	2.54e-10	4.59e-08	-0.24	-0.19	Schizophrenia;	chr14:71112024	chr14:71141125~71143253:-
BRCA	cis	rs6728642	0.708	rs115507803	ENSG00000230606.9	AC159540.1	6.39	2.54e-10	4.59e-08	0.41	0.19	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:97086317	chr2:97416165~97433527:-
BRCA	cis	rs2243480	0.803	rs423187	ENSG00000232546.1	RP11-458F8.1	-6.39	2.55e-10	4.6e-08	-0.26	-0.19	Diabetic kidney disease;	chr7:66044512	chr7:66848496~66858136:+
BRCA	cis	rs8031584	0.918	rs34693097	ENSG00000260382.1	RP11-540B6.2	6.39	2.55e-10	4.6e-08	0.23	0.19	Huntington's disease progression;	chr15:30961781	chr15:30882267~30883231:-
BRCA	cis	rs34779708	0.931	rs34304999	ENSG00000271335.4	RP11-324I22.4	6.39	2.55e-10	4.61e-08	0.21	0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35076777	chr10:35314552~35336401:-
BRCA	cis	rs2562456	0.917	rs2681389	ENSG00000268081.1	RP11-678G14.2	-6.39	2.55e-10	4.61e-08	-0.3	-0.19	Pain;	chr19:21509773	chr19:21554640~21569237:-
BRCA	cis	rs2303759	0.881	rs10412811	ENSG00000268686.1	AC010524.2	-6.39	2.55e-10	4.61e-08	-0.31	-0.19	Multiple sclerosis;	chr19:49381238	chr19:49368705~49388081:-
BRCA	cis	rs35146811	0.586	rs10267212	ENSG00000235713.1	RP4-604G5.3	6.39	2.55e-10	4.61e-08	0.23	0.19	Coronary artery disease;	chr7:99997799	chr7:99992397~99993050:+
BRCA	cis	rs957448	1	rs7829886	ENSG00000253175.1	RP11-267M23.6	6.39	2.55e-10	4.61e-08	0.23	0.19	Nonsyndromic cleft lip with cleft palate;	chr8:94485160	chr8:94565036~94565715:+
BRCA	cis	rs4713118	0.868	rs9468220	ENSG00000220721.1	OR1F12	-6.39	2.55e-10	4.61e-08	-0.25	-0.19	Parkinson's disease;	chr6:27765197	chr6:28073316~28074233:+
BRCA	cis	rs34779708	0.931	rs7099036	ENSG00000271335.4	RP11-324I22.4	6.39	2.56e-10	4.62e-08	0.2	0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35060646	chr10:35314552~35336401:-
BRCA	cis	rs4691139	1	rs6855591	ENSG00000248632.1	RP11-366M4.11	6.39	2.56e-10	4.62e-08	0.2	0.19	Ovarian cancer in BRCA1 mutation carriers;	chr4:164985571	chr4:164968587~164970002:-
BRCA	cis	rs6570726	0.967	rs450973	ENSG00000235652.6	RP11-545I5.3	6.39	2.56e-10	4.62e-08	0.19	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145541929	chr6:145799409~145886585:+
BRCA	cis	rs7246657	0.943	rs13343471	ENSG00000267422.1	CTD-2554C21.1	-6.39	2.56e-10	4.63e-08	-0.31	-0.19	Coronary artery calcification;	chr19:37441228	chr19:37779686~37792865:+
BRCA	cis	rs6142102	0.812	rs2377955	ENSG00000275784.1	RP5-1125A11.6	-6.39	2.56e-10	4.63e-08	-0.24	-0.19	Skin pigmentation;	chr20:33937564	chr20:33989480~33991818:-
BRCA	cis	rs7615952	0.599	rs6438953	ENSG00000250012.1	RP11-124N2.1	-6.39	2.56e-10	4.63e-08	-0.25	-0.19	Blood pressure (smoking interaction);	chr3:126006108	chr3:126084220~126095349:+
BRCA	cis	rs7615952	0.599	rs1044215	ENSG00000250012.1	RP11-124N2.1	-6.39	2.56e-10	4.63e-08	-0.25	-0.19	Blood pressure (smoking interaction);	chr3:126006716	chr3:126084220~126095349:+
BRCA	cis	rs34779708	0.931	rs4934535	ENSG00000271335.4	RP11-324I22.4	6.39	2.56e-10	4.63e-08	0.21	0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35143793	chr10:35314552~35336401:-
BRCA	cis	rs34779708	0.966	rs4934734	ENSG00000271335.4	RP11-324I22.4	6.39	2.56e-10	4.63e-08	0.21	0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35145445	chr10:35314552~35336401:-
BRCA	cis	rs34779708	0.966	rs12769575	ENSG00000271335.4	RP11-324I22.4	6.39	2.56e-10	4.63e-08	0.21	0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35146999	chr10:35314552~35336401:-
BRCA	cis	rs12680842	0.842	rs34691145	ENSG00000253704.1	RP11-267M23.4	6.39	2.56e-10	4.63e-08	0.21	0.19	Body mass index;	chr8:94597715	chr8:94553722~94569745:+
BRCA	cis	rs4713118	0.868	rs742047	ENSG00000220721.1	OR1F12	6.39	2.57e-10	4.64e-08	0.25	0.19	Parkinson's disease;	chr6:27771601	chr6:28073316~28074233:+
BRCA	cis	rs7617773	0.674	rs13069029	ENSG00000228638.1	FCF1P2	-6.39	2.57e-10	4.64e-08	-0.22	-0.19	Coronary artery disease;	chr3:48313534	chr3:48290793~48291375:-
BRCA	cis	rs7914558	1	rs11191541	ENSG00000213061.2	PFN1P11	6.39	2.57e-10	4.64e-08	0.25	0.19	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103064442	chr10:102838011~102845473:-
BRCA	cis	rs2842992	0.83	rs1998365	ENSG00000237927.1	RP3-393E18.2	-6.39	2.57e-10	4.65e-08	-0.28	-0.19	Age-related macular degeneration (geographic atrophy);	chr6:159758503	chr6:159586955~159589169:-
BRCA	cis	rs9907295	1	rs9913488	ENSG00000270977.1	AC015849.16	-6.39	2.58e-10	4.65e-08	-0.33	-0.19	Fibroblast growth factor basic levels;	chr17:35906447	chr17:35893707~35911023:-
BRCA	cis	rs9907295	1	rs9912571	ENSG00000270977.1	AC015849.16	-6.39	2.58e-10	4.65e-08	-0.33	-0.19	Fibroblast growth factor basic levels;	chr17:35906782	chr17:35893707~35911023:-
BRCA	cis	rs9907295	1	rs9912793	ENSG00000270977.1	AC015849.16	-6.39	2.58e-10	4.65e-08	-0.33	-0.19	Fibroblast growth factor basic levels;	chr17:35906867	chr17:35893707~35911023:-
BRCA	cis	rs2179367	0.632	rs12196656	ENSG00000216906.2	RP11-350J20.9	6.38	2.58e-10	4.66e-08	0.28	0.19	Dupuytren's disease;	chr6:149383104	chr6:149904243~149906418:+
BRCA	cis	rs2179367	0.632	rs12211570	ENSG00000216906.2	RP11-350J20.9	6.38	2.58e-10	4.66e-08	0.28	0.19	Dupuytren's disease;	chr6:149383616	chr6:149904243~149906418:+
BRCA	cis	rs2179367	0.568	rs11155647	ENSG00000216906.2	RP11-350J20.9	6.38	2.58e-10	4.66e-08	0.28	0.19	Dupuytren's disease;	chr6:149384499	chr6:149904243~149906418:+
BRCA	cis	rs2749097	0.609	rs2269233	ENSG00000244256.3	RN7SL130P	-6.38	2.58e-10	4.66e-08	-0.26	-0.19	Alcohol consumption (transferrin glycosylation);	chr1:63653675	chr1:63655743~63656047:+
BRCA	cis	rs7247513	0.964	rs4804202	ENSG00000230310.1	CTD-2192J16.11	-6.38	2.59e-10	4.67e-08	-0.24	-0.19	Bipolar disorder;	chr19:12607805	chr19:12552597~12553644:+
BRCA	cis	rs4713118	0.621	rs9295756	ENSG00000219392.1	RP1-265C24.5	-6.38	2.59e-10	4.68e-08	-0.29	-0.19	Parkinson's disease;	chr6:28065618	chr6:28115628~28116551:+
BRCA	cis	rs2179367	0.632	rs997682	ENSG00000216906.2	RP11-350J20.9	-6.38	2.59e-10	4.68e-08	-0.27	-0.19	Dupuytren's disease;	chr6:149345484	chr6:149904243~149906418:+
BRCA	cis	rs875971	1	rs2077593	ENSG00000224316.1	RP11-479O9.2	6.38	2.6e-10	4.69e-08	0.19	0.19	Aortic root size;	chr7:66427543	chr7:65773620~65802067:+
BRCA	cis	rs4713118	0.869	rs9461405	ENSG00000220721.1	OR1F12	6.38	2.6e-10	4.69e-08	0.24	0.19	Parkinson's disease;	chr6:27751596	chr6:28073316~28074233:+
BRCA	cis	rs2243480	1	rs13310597	ENSG00000232559.3	GS1-124K5.12	6.38	2.6e-10	4.69e-08	0.37	0.19	Diabetic kidney disease;	chr7:66133553	chr7:66554588~66576923:-
BRCA	cis	rs6840360	0.642	rs2034061	ENSG00000270265.1	RP11-731D1.4	-6.38	2.61e-10	4.7e-08	-0.22	-0.19	Intelligence (multi-trait analysis);	chr4:151499604	chr4:151333775~151353224:-
BRCA	cis	rs8031584	0.918	rs35784593	ENSG00000260382.1	RP11-540B6.2	6.38	2.61e-10	4.71e-08	0.23	0.19	Huntington's disease progression;	chr15:30962385	chr15:30882267~30883231:-
BRCA	cis	rs1440410	0.798	rs7684430	ENSG00000250326.1	RP11-284M14.1	-6.38	2.61e-10	4.71e-08	-0.21	-0.19	Ischemic stroke;	chr4:143133191	chr4:142933195~143184861:-
BRCA	cis	rs6740322	0.748	rs6544635	ENSG00000234936.1	AC010883.5	6.38	2.61e-10	4.72e-08	0.22	0.19	Coronary artery disease;	chr2:43259565	chr2:43229573~43233394:+
BRCA	cis	rs7617773	0.78	rs4511916	ENSG00000228638.1	FCF1P2	-6.38	2.61e-10	4.72e-08	-0.22	-0.19	Coronary artery disease;	chr3:48308876	chr3:48290793~48291375:-
BRCA	cis	rs7617773	0.815	rs6793150	ENSG00000228638.1	FCF1P2	-6.38	2.61e-10	4.72e-08	-0.22	-0.19	Coronary artery disease;	chr3:48310070	chr3:48290793~48291375:-
BRCA	cis	rs7617773	0.78	rs6793239	ENSG00000228638.1	FCF1P2	-6.38	2.61e-10	4.72e-08	-0.22	-0.19	Coronary artery disease;	chr3:48310128	chr3:48290793~48291375:-
BRCA	cis	rs7617773	0.78	rs6782166	ENSG00000228638.1	FCF1P2	-6.38	2.61e-10	4.72e-08	-0.22	-0.19	Coronary artery disease;	chr3:48310193	chr3:48290793~48291375:-
BRCA	cis	rs7617773	0.78	rs4130522	ENSG00000228638.1	FCF1P2	-6.38	2.61e-10	4.72e-08	-0.22	-0.19	Coronary artery disease;	chr3:48310823	chr3:48290793~48291375:-
BRCA	cis	rs7617773	0.78	rs13081169	ENSG00000228638.1	FCF1P2	-6.38	2.61e-10	4.72e-08	-0.22	-0.19	Coronary artery disease;	chr3:48315307	chr3:48290793~48291375:-
BRCA	cis	rs3820443	0.83	rs57294801	ENSG00000234020.1	CHIAP3	-6.38	2.62e-10	4.72e-08	-0.23	-0.19	Late-onset Alzheimer's disease;	chr1:111353909	chr1:111353275~111367409:-
BRCA	cis	rs2919009	0.544	rs2901280	ENSG00000271670.1	RP11-95I16.4	-6.38	2.62e-10	4.73e-08	-0.24	-0.19	Obesity-related traits;	chr10:120895865	chr10:120879256~120880667:-
BRCA	cis	rs8114671	0.836	rs6060140	ENSG00000269202.1	RP4-614O4.12	-6.38	2.62e-10	4.73e-08	-0.2	-0.19	Height;	chr20:34978704	chr20:35201747~35203288:-
BRCA	cis	rs875971	0.545	rs316324	ENSG00000273024.4	INTS4P2	6.38	2.63e-10	4.75e-08	0.24	0.19	Aortic root size;	chr7:66145627	chr7:65647864~65715661:+
BRCA	cis	rs875971	0.545	rs316323	ENSG00000273024.4	INTS4P2	6.38	2.63e-10	4.75e-08	0.24	0.19	Aortic root size;	chr7:66146002	chr7:65647864~65715661:+
BRCA	cis	rs853679	0.517	rs9393890	ENSG00000219392.1	RP1-265C24.5	-6.38	2.63e-10	4.75e-08	-0.29	-0.19	Depression;	chr6:28096077	chr6:28115628~28116551:+
BRCA	cis	rs853679	0.517	rs9366715	ENSG00000219392.1	RP1-265C24.5	-6.38	2.63e-10	4.75e-08	-0.29	-0.19	Depression;	chr6:28096855	chr6:28115628~28116551:+
BRCA	cis	rs149313	0.901	rs697976	ENSG00000248734.2	CTD-2260A17.1	6.38	2.63e-10	4.75e-08	0.2	0.19	Blood protein levels;	chr5:96733063	chr5:96784777~96785999:+
BRCA	cis	rs2998286	0.723	rs332146	ENSG00000254635.4	WAC-AS1	-6.38	2.63e-10	4.75e-08	-0.28	-0.19	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28580255	chr10:28522652~28532743:-
BRCA	cis	rs227275	0.556	rs223449	ENSG00000251288.2	RP11-10L12.2	-6.38	2.64e-10	4.76e-08	-0.23	-0.19	Allergic disease (asthma, hay fever or eczema);	chr4:102791180	chr4:102751401~102752641:+
BRCA	cis	rs228614	0.51	rs223446	ENSG00000251288.2	RP11-10L12.2	-6.38	2.64e-10	4.76e-08	-0.23	-0.19	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102793025	chr4:102751401~102752641:+
BRCA	cis	rs13631	0.965	rs7853589	ENSG00000268996.3	MAN1B1-AS1	-6.38	2.64e-10	4.76e-08	-0.18	-0.19	Cerebrospinal fluid biomarker levels;	chr9:137109392	chr9:137084946~137086817:-
BRCA	cis	rs2243480	1	rs316330	ENSG00000230295.1	RP11-458F8.2	-6.38	2.64e-10	4.76e-08	-0.26	-0.19	Diabetic kidney disease;	chr7:66140385	chr7:66880708~66882981:+
BRCA	cis	rs853679	0.517	rs35193936	ENSG00000219392.1	RP1-265C24.5	-6.38	2.64e-10	4.76e-08	-0.29	-0.19	Depression;	chr6:28108492	chr6:28115628~28116551:+
BRCA	cis	rs34779708	0.966	rs10827492	ENSG00000271335.4	RP11-324I22.4	-6.38	2.65e-10	4.77e-08	-0.2	-0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35140897	chr10:35314552~35336401:-
BRCA	cis	rs9876781	1	rs898225	ENSG00000229759.1	MRPS18AP1	-6.38	2.65e-10	4.78e-08	-0.22	-0.19	Longevity;	chr3:48371689	chr3:48256350~48256938:-
BRCA	cis	rs1823913	0.599	rs34100174	ENSG00000280083.1	RP11-317J9.1	-6.38	2.65e-10	4.78e-08	-0.22	-0.19	Obesity-related traits;	chr2:191283579	chr2:191154118~191156070:-
BRCA	cis	rs2836950	0.565	rs7279497	ENSG00000255568.3	BRWD1-AS2	6.38	2.65e-10	4.78e-08	0.18	0.19	Menarche (age at onset);	chr21:39159380	chr21:39313935~39314962:+
BRCA	cis	rs853679	0.55	rs1150689	ENSG00000219392.1	RP1-265C24.5	-6.38	2.65e-10	4.78e-08	-0.28	-0.19	Depression;	chr6:28197321	chr6:28115628~28116551:+
BRCA	cis	rs853679	0.55	rs1225599	ENSG00000219392.1	RP1-265C24.5	-6.38	2.65e-10	4.78e-08	-0.28	-0.19	Depression;	chr6:28197412	chr6:28115628~28116551:+
BRCA	cis	rs853679	0.574	rs1233705	ENSG00000219392.1	RP1-265C24.5	-6.38	2.65e-10	4.78e-08	-0.28	-0.19	Depression;	chr6:28198669	chr6:28115628~28116551:+
BRCA	cis	rs13113518	0.812	rs11932712	ENSG00000223305.1	RN7SKP30	6.38	2.65e-10	4.78e-08	0.24	0.19	Height;	chr4:55436423	chr4:55540502~55540835:-
BRCA	cis	rs9992667	0.955	rs12331049	ENSG00000231160.8	KLF3-AS1	6.38	2.66e-10	4.79e-08	0.24	0.19	Eosinophil percentage of granulocytes;	chr4:38654151	chr4:38612701~38664883:-
BRCA	cis	rs7927771	0.524	rs7122182	ENSG00000280615.1	Y_RNA	-6.38	2.66e-10	4.79e-08	-0.22	-0.19	Subjective well-being;	chr11:47821581	chr11:47614898~47614994:-
BRCA	cis	rs13113518	0.513	rs13132085	ENSG00000273257.1	RP11-177J6.1	-6.38	2.66e-10	4.79e-08	-0.26	-0.19	Height;	chr4:55593918	chr4:55387949~55388271:+
BRCA	cis	rs4713118	0.513	rs149897	ENSG00000204709.4	LINC01556	6.38	2.66e-10	4.8e-08	0.26	0.19	Parkinson's disease;	chr6:28038872	chr6:28943877~28944537:+
BRCA	cis	rs4713118	0.513	rs156734	ENSG00000204709.4	LINC01556	6.38	2.66e-10	4.8e-08	0.26	0.19	Parkinson's disease;	chr6:28039579	chr6:28943877~28944537:+
BRCA	cis	rs1823913	0.637	rs4853584	ENSG00000280083.1	RP11-317J9.1	6.38	2.67e-10	4.81e-08	0.22	0.19	Obesity-related traits;	chr2:191310596	chr2:191154118~191156070:-
BRCA	cis	rs2492286	0.569	rs2712383	ENSG00000242551.2	POU5F1P6	-6.38	2.67e-10	4.81e-08	-0.28	-0.19	Eosinophil counts;	chr3:128629033	chr3:128674735~128677005:-
BRCA	cis	rs6840258	1	rs55787557	ENSG00000251411.1	RP11-397E7.4	-6.38	2.67e-10	4.82e-08	-0.26	-0.19	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87029673	chr4:86913266~86914817:-
BRCA	cis	rs8072100	0.713	rs11651643	ENSG00000228782.6	CTD-2026D20.3	6.38	2.67e-10	4.82e-08	0.21	0.19	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47405863	chr17:47450568~47492492:-
BRCA	cis	rs793571	0.505	rs12901989	ENSG00000259250.1	RP11-50C13.1	-6.38	2.68e-10	4.83e-08	-0.35	-0.19	Schizophrenia;	chr15:58603861	chr15:58587507~58591676:+
BRCA	cis	rs2665103	0.589	rs2134046	ENSG00000255769.6	GOLGA2P10	-6.38	2.68e-10	4.84e-08	-0.22	-0.19	Intelligence (multi-trait analysis);	chr15:82232203	chr15:82472993~82513950:-
BRCA	cis	rs12594515	1	rs8043291	ENSG00000259200.1	RP11-718O11.1	-6.38	2.68e-10	4.84e-08	-0.22	-0.19	Weight;Waist circumference;	chr15:45704049	chr15:45705078~45931069:+
BRCA	cis	rs12594515	1	rs56412446	ENSG00000259200.1	RP11-718O11.1	-6.38	2.68e-10	4.84e-08	-0.22	-0.19	Weight;Waist circumference;	chr15:45704226	chr15:45705078~45931069:+
BRCA	cis	rs12594515	1	rs57299255	ENSG00000259200.1	RP11-718O11.1	-6.38	2.68e-10	4.84e-08	-0.22	-0.19	Weight;Waist circumference;	chr15:45704334	chr15:45705078~45931069:+
BRCA	cis	rs853679	0.517	rs9380058	ENSG00000280107.1	AL022393.9	-6.38	2.68e-10	4.84e-08	-0.29	-0.19	Depression;	chr6:28159666	chr6:28170845~28172521:+
BRCA	cis	rs853679	0.517	rs9393898	ENSG00000280107.1	AL022393.9	-6.38	2.68e-10	4.84e-08	-0.29	-0.19	Depression;	chr6:28162598	chr6:28170845~28172521:+
BRCA	cis	rs8002861	0.641	rs4942252	ENSG00000274001.1	RP11-5G9.5	6.38	2.68e-10	4.84e-08	0.23	0.19	Leprosy;	chr13:43868903	chr13:43877715~43878163:-
BRCA	cis	rs7246657	0.943	rs10409204	ENSG00000267422.1	CTD-2554C21.1	-6.38	2.69e-10	4.84e-08	-0.3	-0.19	Coronary artery calcification;	chr19:37426790	chr19:37779686~37792865:+
BRCA	cis	rs5015933	0.815	rs10819044	ENSG00000232630.1	PRPS1P2	-6.38	2.69e-10	4.84e-08	-0.18	-0.19	Body mass index;	chr9:125278750	chr9:125150653~125151589:+
BRCA	cis	rs853679	0.517	rs9368555	ENSG00000280107.1	AL022393.9	-6.38	2.69e-10	4.84e-08	-0.29	-0.19	Depression;	chr6:28141189	chr6:28170845~28172521:+
BRCA	cis	rs853679	0.517	rs9393893	ENSG00000280107.1	AL022393.9	-6.38	2.69e-10	4.84e-08	-0.29	-0.19	Depression;	chr6:28141484	chr6:28170845~28172521:+
BRCA	cis	rs1707322	0.686	rs2152078	ENSG00000281133.1	AL355480.3	6.38	2.69e-10	4.85e-08	0.25	0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45589928	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.686	rs2991979	ENSG00000281133.1	AL355480.3	6.38	2.69e-10	4.85e-08	0.25	0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45590186	chr1:45580892~45580996:-
BRCA	cis	rs228614	0.51	rs223455	ENSG00000251288.2	RP11-10L12.2	-6.38	2.69e-10	4.85e-08	-0.23	-0.19	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102789026	chr4:102751401~102752641:+
BRCA	cis	rs4713118	0.868	rs7756968	ENSG00000220721.1	OR1F12	6.38	2.69e-10	4.85e-08	0.25	0.19	Parkinson's disease;	chr6:27767175	chr6:28073316~28074233:+
BRCA	cis	rs6723226	0.75	rs1033751	ENSG00000276334.1	AL133243.1	6.38	2.69e-10	4.85e-08	0.23	0.19	Intelligence (multi-trait analysis);	chr2:32470691	chr2:32521927~32523547:+
BRCA	cis	rs8114671	0.869	rs1407202	ENSG00000269202.1	RP4-614O4.12	6.38	2.69e-10	4.85e-08	0.2	0.19	Height;	chr20:35064164	chr20:35201747~35203288:-
BRCA	cis	rs2243480	1	rs2257790	ENSG00000229886.1	RP5-1132H15.3	6.38	2.69e-10	4.85e-08	0.34	0.19	Diabetic kidney disease;	chr7:66135463	chr7:66025126~66031544:-
BRCA	cis	rs11096990	0.892	rs11932351	ENSG00000249207.1	RP11-360F5.1	6.38	2.69e-10	4.86e-08	0.22	0.19	Cognitive function;	chr4:39229837	chr4:39112677~39126818:-
BRCA	cis	rs1667284	0.935	rs1791161	ENSG00000266521.1	RP11-650P15.1	6.38	2.7e-10	4.86e-08	0.23	0.19	Problematic alcohol use in trauma-exposed individuals;	chr18:31624247	chr18:31496645~31497195:-
BRCA	cis	rs5015933	1	rs10760397	ENSG00000232630.1	PRPS1P2	-6.38	2.7e-10	4.86e-08	-0.18	-0.19	Body mass index;	chr9:125370928	chr9:125150653~125151589:+
BRCA	cis	rs7474896	0.537	rs2749586	ENSG00000226578.1	RP11-258F22.1	6.38	2.7e-10	4.87e-08	0.25	0.19	Obesity (extreme);	chr10:37981286	chr10:37775371~37784131:-
BRCA	cis	rs2243480	1	rs431076	ENSG00000230295.1	RP11-458F8.2	-6.38	2.7e-10	4.87e-08	-0.26	-0.19	Diabetic kidney disease;	chr7:66135333	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs2460422	ENSG00000230295.1	RP11-458F8.2	-6.38	2.7e-10	4.87e-08	-0.26	-0.19	Diabetic kidney disease;	chr7:66136518	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs316334	ENSG00000230295.1	RP11-458F8.2	-6.38	2.7e-10	4.87e-08	-0.26	-0.19	Diabetic kidney disease;	chr7:66137139	chr7:66880708~66882981:+
BRCA	cis	rs2911132	0.564	rs1057569	ENSG00000248734.2	CTD-2260A17.1	6.38	2.7e-10	4.87e-08	0.24	0.19	Urate levels (BMI interaction);	chr5:96773906	chr5:96784777~96785999:+
BRCA	cis	rs58873874	0.522	rs77458926	ENSG00000248544.2	CTB-47B11.3	6.38	2.71e-10	4.87e-08	0.41	0.19	Bipolar disorder (body mass index interaction);	chr5:157271198	chr5:157375741~157384950:-
BRCA	cis	rs9527	0.615	rs11191401	ENSG00000213061.2	PFN1P11	6.38	2.71e-10	4.88e-08	0.28	0.19	Arsenic metabolism;	chr10:102813646	chr10:102838011~102845473:-
BRCA	cis	rs2638953	0.924	rs12368652	ENSG00000247934.4	RP11-967K21.1	-6.38	2.71e-10	4.89e-08	-0.25	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28170046	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.924	rs11049392	ENSG00000247934.4	RP11-967K21.1	-6.38	2.71e-10	4.89e-08	-0.25	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28170256	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.924	rs11049394	ENSG00000247934.4	RP11-967K21.1	-6.38	2.71e-10	4.89e-08	-0.25	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28170947	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.886	rs11049395	ENSG00000247934.4	RP11-967K21.1	-6.38	2.71e-10	4.89e-08	-0.25	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28171087	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.886	rs11049397	ENSG00000247934.4	RP11-967K21.1	-6.38	2.71e-10	4.89e-08	-0.25	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28171909	chr12:28163298~28190738:-
BRCA	cis	rs78487399	0.908	rs57066469	ENSG00000234936.1	AC010883.5	6.38	2.72e-10	4.89e-08	0.26	0.19	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43616674	chr2:43229573~43233394:+
BRCA	cis	rs1707322	1	rs1613296	ENSG00000281133.1	AL355480.3	6.38	2.72e-10	4.9e-08	0.24	0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46081180	chr1:45580892~45580996:-
BRCA	cis	rs13178541	0.81	rs10070559	ENSG00000250378.1	RP11-119J18.1	-6.38	2.72e-10	4.9e-08	-0.27	-0.19	IgG glycosylation;	chr5:135822430	chr5:135812667~135826582:+
BRCA	cis	rs919433	0.783	rs2565165	ENSG00000231621.1	AC013264.2	-6.38	2.72e-10	4.91e-08	-0.18	-0.19	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197368851	chr2:197197991~197199273:+
BRCA	cis	rs2179367	0.632	rs2341774	ENSG00000216906.2	RP11-350J20.9	6.38	2.73e-10	4.91e-08	0.28	0.19	Dupuytren's disease;	chr6:149425014	chr6:149904243~149906418:+
BRCA	cis	rs9880211	0.583	rs9870122	ENSG00000273486.1	RP11-731C17.2	6.38	2.74e-10	4.93e-08	0.24	0.19	Height;Body mass index;	chr3:136101423	chr3:136837338~136839021:-
BRCA	cis	rs6504622	0.905	rs3809854	ENSG00000262879.4	RP11-156P1.3	6.38	2.74e-10	4.94e-08	0.2	0.19	Orofacial clefts;	chr17:46951928	chr17:46984045~47100323:-
BRCA	cis	rs10754283	0.967	rs1934044	ENSG00000231613.1	RP5-943J3.1	-6.38	2.74e-10	4.94e-08	-0.22	-0.19	Amyotrophic lateral sclerosis (sporadic);	chr1:89641942	chr1:89788914~89790492:+
BRCA	cis	rs2243480	1	rs316322	ENSG00000230295.1	RP11-458F8.2	-6.38	2.74e-10	4.94e-08	-0.26	-0.19	Diabetic kidney disease;	chr7:66146246	chr7:66880708~66882981:+
BRCA	cis	rs9287719	0.601	rs13427815	ENSG00000243819.4	RN7SL832P	6.37	2.75e-10	4.96e-08	0.2	0.19	Prostate cancer;	chr2:10567859	chr2:10690344~10692099:+
BRCA	cis	rs2243480	1	rs387676	ENSG00000232559.3	GS1-124K5.12	6.37	2.75e-10	4.96e-08	0.37	0.19	Diabetic kidney disease;	chr7:66133233	chr7:66554588~66576923:-
BRCA	cis	rs10510102	0.516	rs12256693	ENSG00000276742.1	RP11-500G22.4	6.37	2.76e-10	4.96e-08	0.36	0.19	Breast cancer;	chr10:121976839	chr10:121956782~121957098:+
BRCA	cis	rs853679	0.517	rs1904840	ENSG00000219392.1	RP1-265C24.5	-6.37	2.76e-10	4.97e-08	-0.3	-0.19	Depression;	chr6:28140454	chr6:28115628~28116551:+
BRCA	cis	rs301901	0.662	rs7726960	ENSG00000250155.1	CTD-2353F22.1	6.37	2.76e-10	4.97e-08	0.22	0.19	Height;	chr5:37490184	chr5:36666214~36725195:-
BRCA	cis	rs853679	0.517	rs36078605	ENSG00000219392.1	RP1-265C24.5	-6.37	2.76e-10	4.97e-08	-0.29	-0.19	Depression;	chr6:28110254	chr6:28115628~28116551:+
BRCA	cis	rs9500256	0.966	rs1322446	ENSG00000215190.7	LINC00680	-6.37	2.76e-10	4.98e-08	-0.22	-0.19	Eosinophilic esophagitis (pediatric);	chr6:57985672	chr6:57946074~57961501:-
BRCA	cis	rs853679	0.598	rs9380054	ENSG00000219392.1	RP1-265C24.5	-6.37	2.77e-10	4.98e-08	-0.29	-0.19	Depression;	chr6:28099759	chr6:28115628~28116551:+
BRCA	cis	rs4713118	0.547	rs2116981	ENSG00000219392.1	RP1-265C24.5	-6.37	2.77e-10	4.98e-08	-0.29	-0.19	Parkinson's disease;	chr6:28100173	chr6:28115628~28116551:+
BRCA	cis	rs853679	0.517	rs9368552	ENSG00000219392.1	RP1-265C24.5	-6.37	2.77e-10	4.98e-08	-0.29	-0.19	Depression;	chr6:28100648	chr6:28115628~28116551:+
BRCA	cis	rs853679	0.542	rs34131763	ENSG00000219392.1	RP1-265C24.5	-6.37	2.77e-10	4.98e-08	-0.29	-0.19	Depression;	chr6:28107222	chr6:28115628~28116551:+
BRCA	cis	rs9880211	0.635	rs6775778	ENSG00000273486.1	RP11-731C17.2	-6.37	2.77e-10	4.98e-08	-0.26	-0.19	Height;Body mass index;	chr3:136007837	chr3:136837338~136839021:-
BRCA	cis	rs2998286	0.768	rs332140	ENSG00000254635.4	WAC-AS1	-6.37	2.77e-10	4.98e-08	-0.28	-0.19	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28570431	chr10:28522652~28532743:-
BRCA	cis	rs2911132	0.511	rs7063	ENSG00000248734.2	CTD-2260A17.1	6.37	2.77e-10	4.99e-08	0.24	0.19	Urate levels (BMI interaction);	chr5:96774507	chr5:96784777~96785999:+
BRCA	cis	rs7621025	0.664	rs6439657	ENSG00000273486.1	RP11-731C17.2	-6.37	2.77e-10	4.99e-08	-0.24	-0.19	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136775797	chr3:136837338~136839021:-
BRCA	cis	rs2492286	0.569	rs9848287	ENSG00000242551.2	POU5F1P6	-6.37	2.78e-10	4.99e-08	-0.28	-0.19	Eosinophil counts;	chr3:128628799	chr3:128674735~128677005:-
BRCA	cis	rs875971	1	rs10244498	ENSG00000224316.1	RP11-479O9.2	6.37	2.78e-10	4.99e-08	0.2	0.19	Aortic root size;	chr7:66651069	chr7:65773620~65802067:+
BRCA	cis	rs2153535	0.526	rs9505487	ENSG00000230939.1	RP11-314C16.1	-6.37	2.78e-10	5e-08	-0.23	-0.19	Motion sickness;	chr6:8593521	chr6:8784178~8785445:+
BRCA	cis	rs7772486	0.712	rs6570726	ENSG00000235652.6	RP11-545I5.3	6.37	2.78e-10	5e-08	0.19	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145838324	chr6:145799409~145886585:+
BRCA	cis	rs3126085	0.56	rs2525	ENSG00000237975.5	FLG-AS1	6.37	2.78e-10	5e-08	0.26	0.19	Atopic dermatitis;	chr1:152366588	chr1:152168125~152445456:+
BRCA	cis	rs3126085	0.56	rs941935	ENSG00000237975.5	FLG-AS1	6.37	2.78e-10	5e-08	0.26	0.19	Atopic dermatitis;	chr1:152367012	chr1:152168125~152445456:+
BRCA	cis	rs2492286	0.597	rs1126828	ENSG00000242551.2	POU5F1P6	-6.37	2.78e-10	5e-08	-0.27	-0.19	Eosinophil counts;	chr3:128625943	chr3:128674735~128677005:-
BRCA	cis	rs2919009	0.664	rs11815788	ENSG00000271670.1	RP11-95I16.4	6.37	2.78e-10	5.01e-08	0.25	0.19	Obesity-related traits;	chr10:120924582	chr10:120879256~120880667:-
BRCA	cis	rs7208859	0.573	rs216443	ENSG00000263603.1	CTD-2349P21.5	-6.37	2.79e-10	5.02e-08	-0.36	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30604853	chr17:30729469~30731202:+
BRCA	cis	rs11105298	0.891	rs11105314	ENSG00000270344.2	RP11-734K2.4	6.37	2.79e-10	5.02e-08	0.22	0.19	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89530782	chr12:89525654~89548005:+
BRCA	cis	rs875971	0.545	rs6950988	ENSG00000236529.1	RP13-254B10.1	6.37	2.79e-10	5.02e-08	0.24	0.19	Aortic root size;	chr7:66511428	chr7:65840212~65840596:+
BRCA	cis	rs7829975	0.606	rs891570	ENSG00000233609.3	RP11-62H7.2	-6.37	2.8e-10	5.03e-08	-0.18	-0.19	Mood instability;	chr8:8936944	chr8:8961200~8979025:+
BRCA	cis	rs7246657	0.943	rs2126977	ENSG00000226686.6	LINC01535	6.37	2.8e-10	5.04e-08	0.29	0.19	Coronary artery calcification;	chr19:37504845	chr19:37251912~37265535:+
BRCA	cis	rs78456975	1	rs6712176	ENSG00000231482.2	AC141930.2	-6.37	2.8e-10	5.04e-08	-0.28	-0.19	Placebo response in major depressive disorder (% change in symptom score);	chr2:1552621	chr2:1572554~1580311:-
BRCA	cis	rs853679	0.517	rs6932109	ENSG00000280107.1	AL022393.9	6.37	2.8e-10	5.04e-08	0.28	0.19	Depression;	chr6:28110525	chr6:28170845~28172521:+
BRCA	cis	rs73193808	1	rs66716206	ENSG00000215533.7	LINC00189	-6.37	2.81e-10	5.04e-08	-0.28	-0.19	Coronary artery disease;	chr21:29183333	chr21:29193480~29288205:+
BRCA	cis	rs2243480	1	rs316313	ENSG00000230295.1	RP11-458F8.2	-6.37	2.81e-10	5.05e-08	-0.26	-0.19	Diabetic kidney disease;	chr7:66128561	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs316312	ENSG00000230295.1	RP11-458F8.2	-6.37	2.81e-10	5.05e-08	-0.26	-0.19	Diabetic kidney disease;	chr7:66131504	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs419603	ENSG00000230295.1	RP11-458F8.2	-6.37	2.81e-10	5.05e-08	-0.26	-0.19	Diabetic kidney disease;	chr7:66132354	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs10247526	ENSG00000229886.1	RP5-1132H15.3	-6.37	2.81e-10	5.05e-08	-0.35	-0.19	Diabetic kidney disease;	chr7:66315709	chr7:66025126~66031544:-
BRCA	cis	rs2243480	1	rs160652	ENSG00000230295.1	RP11-458F8.2	-6.37	2.81e-10	5.05e-08	-0.27	-0.19	Diabetic kidney disease;	chr7:66073444	chr7:66880708~66882981:+
BRCA	cis	rs10129255	0.536	rs17113249	ENSG00000274576.2	IGHV2-70	-6.37	2.81e-10	5.05e-08	-0.16	-0.19	Kawasaki disease;	chr14:106678273	chr14:106770577~106771020:-
BRCA	cis	rs6088813	0.961	rs3795159	ENSG00000126005.14	MMP24-AS1	-6.37	2.81e-10	5.06e-08	-0.23	-0.19	Height;	chr20:35308459	chr20:35216462~35278131:-
BRCA	cis	rs7246657	0.943	rs7255952	ENSG00000267422.1	CTD-2554C21.1	-6.37	2.82e-10	5.06e-08	-0.29	-0.19	Coronary artery calcification;	chr19:37497895	chr19:37779686~37792865:+
BRCA	cis	rs6095360	0.7	rs36098998	ENSG00000222365.1	SNORD12B	-6.37	2.82e-10	5.06e-08	-0.24	-0.19	Intelligence (multi-trait analysis);	chr20:49071572	chr20:49280319~49280409:+
BRCA	cis	rs9992667	0.955	rs9992076	ENSG00000231160.8	KLF3-AS1	6.37	2.82e-10	5.07e-08	0.24	0.19	Eosinophil percentage of granulocytes;	chr4:38643046	chr4:38612701~38664883:-
BRCA	cis	rs9435732	0.778	rs3738815	ENSG00000186715.9	MST1L	6.37	2.82e-10	5.07e-08	0.24	0.19	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);	chr1:16988207	chr1:16754910~16770237:-
BRCA	cis	rs10208649	0.908	rs60776154	ENSG00000233266.1	HMGB1P31	6.37	2.82e-10	5.08e-08	0.47	0.19	Body mass index;	chr2:54026676	chr2:54051334~54051760:+
BRCA	cis	rs10208649	0.831	rs72906704	ENSG00000233266.1	HMGB1P31	6.37	2.82e-10	5.08e-08	0.47	0.19	Body mass index;	chr2:54028088	chr2:54051334~54051760:+
BRCA	cis	rs10208649	0.908	rs11884857	ENSG00000233266.1	HMGB1P31	6.37	2.82e-10	5.08e-08	0.47	0.19	Body mass index;	chr2:54033185	chr2:54051334~54051760:+
BRCA	cis	rs10208649	0.901	rs6748686	ENSG00000233266.1	HMGB1P31	6.37	2.82e-10	5.08e-08	0.47	0.19	Body mass index;	chr2:54037481	chr2:54051334~54051760:+
BRCA	cis	rs10208649	0.908	rs6719990	ENSG00000233266.1	HMGB1P31	6.37	2.82e-10	5.08e-08	0.47	0.19	Body mass index;	chr2:54037515	chr2:54051334~54051760:+
BRCA	cis	rs10208649	0.908	rs72906714	ENSG00000233266.1	HMGB1P31	6.37	2.82e-10	5.08e-08	0.47	0.19	Body mass index;	chr2:54038423	chr2:54051334~54051760:+
BRCA	cis	rs2286503	0.752	rs6461669	ENSG00000228649.7	AC005682.5	6.37	2.82e-10	5.08e-08	0.17	0.19	Fibrinogen;	chr7:22818447	chr7:22854178~22861579:+
BRCA	cis	rs697003	0.705	rs701926	ENSG00000231057.3	RP11-122M14.1	-6.37	2.83e-10	5.08e-08	-0.22	-0.19	Red cell distribution width;	chr1:211678277	chr1:211675762~211690103:+
BRCA	cis	rs1440410	0.798	rs11727441	ENSG00000250326.1	RP11-284M14.1	-6.37	2.83e-10	5.08e-08	-0.21	-0.19	Ischemic stroke;	chr4:143242602	chr4:142933195~143184861:-
BRCA	cis	rs1440410	0.798	rs10010367	ENSG00000250326.1	RP11-284M14.1	-6.37	2.83e-10	5.08e-08	-0.21	-0.19	Ischemic stroke;	chr4:143243669	chr4:142933195~143184861:-
BRCA	cis	rs13160562	0.666	rs26481	ENSG00000272109.1	CTD-2260A17.3	-6.37	2.83e-10	5.08e-08	-0.25	-0.19	Alcohol dependence;	chr5:96767648	chr5:96804353~96806105:+
BRCA	cis	rs4713118	0.513	rs202908	ENSG00000204709.4	LINC01556	6.37	2.83e-10	5.09e-08	0.26	0.19	Parkinson's disease;	chr6:28043773	chr6:28943877~28944537:+
BRCA	cis	rs6504622	0.905	rs2317997	ENSG00000262879.4	RP11-156P1.3	6.37	2.83e-10	5.09e-08	0.2	0.19	Orofacial clefts;	chr17:46950282	chr17:46984045~47100323:-
BRCA	cis	rs7208859	0.623	rs609063	ENSG00000263603.1	CTD-2349P21.5	-6.37	2.83e-10	5.09e-08	-0.35	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30624495	chr17:30729469~30731202:+
BRCA	cis	rs11096990	0.819	rs4974991	ENSG00000249207.1	RP11-360F5.1	6.37	2.84e-10	5.1e-08	0.22	0.19	Cognitive function;	chr4:39193147	chr4:39112677~39126818:-
BRCA	cis	rs250585	0.85	rs394908	ENSG00000260136.4	CTD-2270L9.4	-6.37	2.84e-10	5.1e-08	-0.21	-0.19	Egg allergy;	chr16:23451984	chr16:23452758~23457606:+
BRCA	cis	rs34779708	0.931	rs13376871	ENSG00000271335.4	RP11-324I22.4	6.37	2.84e-10	5.1e-08	0.2	0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35080128	chr10:35314552~35336401:-
BRCA	cis	rs8072100	0.713	rs9895776	ENSG00000228782.6	CTD-2026D20.3	6.37	2.84e-10	5.11e-08	0.21	0.19	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47408637	chr17:47450568~47492492:-
BRCA	cis	rs6095360	0.727	rs10485609	ENSG00000222365.1	SNORD12B	-6.37	2.85e-10	5.11e-08	-0.24	-0.19	Intelligence (multi-trait analysis);	chr20:49049075	chr20:49280319~49280409:+
BRCA	cis	rs6095360	0.727	rs35843274	ENSG00000222365.1	SNORD12B	-6.37	2.85e-10	5.11e-08	-0.24	-0.19	Intelligence (multi-trait analysis);	chr20:49049366	chr20:49280319~49280409:+
BRCA	cis	rs7617773	0.815	rs7624450	ENSG00000228638.1	FCF1P2	-6.37	2.85e-10	5.11e-08	-0.22	-0.19	Coronary artery disease;	chr3:48308885	chr3:48290793~48291375:-
BRCA	cis	rs853679	0.527	rs9461443	ENSG00000204709.4	LINC01556	6.37	2.85e-10	5.11e-08	0.28	0.19	Depression;	chr6:28226851	chr6:28943877~28944537:+
BRCA	cis	rs7608910	0.556	rs10181042	ENSG00000271889.1	RP11-493E12.1	-6.37	2.85e-10	5.12e-08	-0.24	-0.19	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;	chr2:60997124	chr2:61151433~61162105:-
BRCA	cis	rs7829975	0.617	rs4841072	ENSG00000233609.3	RP11-62H7.2	-6.37	2.85e-10	5.12e-08	-0.18	-0.19	Mood instability;	chr8:8933743	chr8:8961200~8979025:+
BRCA	cis	rs2836950	0.509	rs11088466	ENSG00000238141.2	BRWD1-AS1	-6.37	2.85e-10	5.12e-08	-0.22	-0.19	Menarche (age at onset);	chr21:39208091	chr21:39315707~39323218:+
BRCA	cis	rs8072100	0.738	rs3736438	ENSG00000228782.6	CTD-2026D20.3	6.37	2.85e-10	5.13e-08	0.21	0.19	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47409285	chr17:47450568~47492492:-
BRCA	cis	rs7809950	0.817	rs2237671	ENSG00000238832.1	snoU109	-6.37	2.86e-10	5.13e-08	-0.28	-0.19	Coronary artery disease;	chr7:107491083	chr7:107603363~107603507:+
BRCA	cis	rs1823913	0.599	rs2168166	ENSG00000280083.1	RP11-317J9.1	-6.37	2.86e-10	5.13e-08	-0.22	-0.19	Obesity-related traits;	chr2:191288063	chr2:191154118~191156070:-
BRCA	cis	rs12291225	0.679	rs1043237	ENSG00000251991.1	RNU7-49P	6.37	2.86e-10	5.14e-08	0.23	0.19	Sense of smell;	chr11:14267507	chr11:14478892~14478953:+
BRCA	cis	rs11096990	0.892	rs3733288	ENSG00000249207.1	RP11-360F5.1	6.37	2.86e-10	5.14e-08	0.23	0.19	Cognitive function;	chr4:39216949	chr4:39112677~39126818:-
BRCA	cis	rs793571	0.505	rs12591290	ENSG00000259250.1	RP11-50C13.1	-6.37	2.86e-10	5.14e-08	-0.35	-0.19	Schizophrenia;	chr15:58603305	chr15:58587507~58591676:+
BRCA	cis	rs2243480	0.901	rs35087093	ENSG00000228409.4	CCT6P1	6.37	2.86e-10	5.14e-08	0.26	0.19	Diabetic kidney disease;	chr7:65940221	chr7:65751142~65763354:+
BRCA	cis	rs7829975	0.623	rs10092965	ENSG00000254153.1	CTA-398F10.2	6.37	2.86e-10	5.14e-08	0.23	0.19	Mood instability;	chr8:8515975	chr8:8456909~8461337:-
BRCA	cis	rs2732480	0.538	rs2468943	ENSG00000257763.1	OR5BK1P	-6.37	2.87e-10	5.15e-08	-0.21	-0.19	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48353466	chr12:48355792~48356614:-
BRCA	cis	rs34929064	0.881	rs2067074	ENSG00000179428.2	AC073072.5	6.37	2.87e-10	5.15e-08	0.22	0.19	Major depression and alcohol dependence;	chr7:22681324	chr7:22725395~22727620:-
BRCA	cis	rs6095360	0.727	rs35640549	ENSG00000222365.1	SNORD12B	-6.37	2.87e-10	5.15e-08	-0.24	-0.19	Intelligence (multi-trait analysis);	chr20:49040009	chr20:49280319~49280409:+
BRCA	cis	rs875971	0.895	rs778700	ENSG00000224316.1	RP11-479O9.2	6.37	2.87e-10	5.15e-08	0.19	0.19	Aortic root size;	chr7:66401463	chr7:65773620~65802067:+
BRCA	cis	rs875971	1	rs778699	ENSG00000224316.1	RP11-479O9.2	6.37	2.87e-10	5.15e-08	0.19	0.19	Aortic root size;	chr7:66403303	chr7:65773620~65802067:+
BRCA	cis	rs34779708	0.966	rs4934735	ENSG00000271335.4	RP11-324I22.4	-6.37	2.87e-10	5.15e-08	-0.2	-0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35207802	chr10:35314552~35336401:-
BRCA	cis	rs2274273	0.662	rs2147970	ENSG00000258413.1	RP11-665C16.6	-6.37	2.87e-10	5.15e-08	-0.27	-0.19	Protein biomarker;	chr14:55193499	chr14:55262767~55272075:-
BRCA	cis	rs67981189	0.896	rs2158997	ENSG00000269927.1	RP6-91H8.3	-6.37	2.87e-10	5.16e-08	-0.24	-0.19	Schizophrenia;	chr14:71031077	chr14:71141125~71143253:-
BRCA	cis	rs2243480	1	rs160646	ENSG00000232546.1	RP11-458F8.1	-6.37	2.88e-10	5.16e-08	-0.26	-0.19	Diabetic kidney disease;	chr7:66091293	chr7:66848496~66858136:+
BRCA	cis	rs11098499	0.863	rs59732491	ENSG00000249244.1	RP11-548H18.2	6.37	2.88e-10	5.17e-08	0.23	0.19	Corneal astigmatism;	chr4:119568433	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.863	rs11723090	ENSG00000249244.1	RP11-548H18.2	6.37	2.88e-10	5.17e-08	0.23	0.19	Corneal astigmatism;	chr4:119569437	chr4:119391831~119395335:-
BRCA	cis	rs6951245	0.554	rs11761322	ENSG00000229043.2	AC091729.9	-6.37	2.88e-10	5.17e-08	-0.29	-0.19	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1112021	chr7:1160374~1165267:+
BRCA	cis	rs2638953	0.924	rs61920245	ENSG00000278733.1	RP11-425D17.1	-6.37	2.88e-10	5.17e-08	-0.25	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28196081	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.924	rs7957056	ENSG00000278733.1	RP11-425D17.1	-6.37	2.88e-10	5.17e-08	-0.25	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28203382	chr12:28185625~28186190:-
BRCA	cis	rs73193808	0.901	rs8128235	ENSG00000215533.7	LINC00189	-6.37	2.89e-10	5.18e-08	-0.28	-0.19	Coronary artery disease;	chr21:29193197	chr21:29193480~29288205:+
BRCA	cis	rs2288884	0.767	rs28379522	ENSG00000275055.1	CTC-471J1.11	-6.37	2.89e-10	5.18e-08	-0.26	-0.19	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52036234	chr19:52049007~52049754:+
BRCA	cis	rs34779708	0.733	rs11597184	ENSG00000271335.4	RP11-324I22.4	6.37	2.89e-10	5.18e-08	0.21	0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35108468	chr10:35314552~35336401:-
BRCA	cis	rs150658949	1	rs150658949	ENSG00000259087.4	RP11-356O9.2	6.37	2.89e-10	5.18e-08	0.2	0.19	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr14:37218926	chr14:37556158~37567095:-
BRCA	cis	rs9876781	1	rs28824259	ENSG00000229759.1	MRPS18AP1	6.37	2.89e-10	5.19e-08	0.22	0.19	Longevity;	chr3:48384185	chr3:48256350~48256938:-
BRCA	cis	rs9876781	1	rs12487542	ENSG00000229759.1	MRPS18AP1	6.37	2.89e-10	5.19e-08	0.22	0.19	Longevity;	chr3:48384586	chr3:48256350~48256938:-
BRCA	cis	rs9876781	1	rs73074358	ENSG00000229759.1	MRPS18AP1	6.37	2.89e-10	5.19e-08	0.22	0.19	Longevity;	chr3:48385757	chr3:48256350~48256938:-
BRCA	cis	rs9876781	0.967	rs34761139	ENSG00000229759.1	MRPS18AP1	6.37	2.89e-10	5.19e-08	0.22	0.19	Longevity;	chr3:48386489	chr3:48256350~48256938:-
BRCA	cis	rs9876781	0.868	rs9875280	ENSG00000229759.1	MRPS18AP1	6.37	2.89e-10	5.19e-08	0.22	0.19	Longevity;	chr3:48387420	chr3:48256350~48256938:-
BRCA	cis	rs9876781	1	rs6796491	ENSG00000229759.1	MRPS18AP1	6.37	2.89e-10	5.19e-08	0.22	0.19	Longevity;	chr3:48388977	chr3:48256350~48256938:-
BRCA	cis	rs2412819	0.545	rs3862143	ENSG00000205771.5	CATSPER2P1	6.37	2.89e-10	5.19e-08	0.28	0.19	Lung cancer;	chr15:43779282	chr15:43726918~43747094:-
BRCA	cis	rs1707322	0.964	rs785499	ENSG00000281133.1	AL355480.3	6.37	2.89e-10	5.19e-08	0.26	0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46126748	chr1:45580892~45580996:-
BRCA	cis	rs6951245	0.554	rs79367977	ENSG00000229043.2	AC091729.9	-6.37	2.89e-10	5.19e-08	-0.29	-0.19	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1113021	chr7:1160374~1165267:+
BRCA	cis	rs77972916	0.505	rs6756575	ENSG00000234936.1	AC010883.5	6.37	2.89e-10	5.19e-08	0.23	0.19	Granulocyte percentage of myeloid white cells;	chr2:43301380	chr2:43229573~43233394:+
BRCA	cis	rs11096990	0.892	rs11729098	ENSG00000249207.1	RP11-360F5.1	6.37	2.89e-10	5.19e-08	0.23	0.19	Cognitive function;	chr4:39232357	chr4:39112677~39126818:-
BRCA	cis	rs600231	0.708	rs1784860	ENSG00000245532.5	NEAT1	6.37	2.9e-10	5.2e-08	0.18	0.19	Bone mineral density;	chr11:65473241	chr11:65422774~65445540:+
BRCA	cis	rs853679	0.517	rs3757187	ENSG00000219392.1	RP1-265C24.5	-6.37	2.9e-10	5.2e-08	-0.29	-0.19	Depression;	chr6:28139876	chr6:28115628~28116551:+
BRCA	cis	rs34779708	0.966	rs17591857	ENSG00000271335.4	RP11-324I22.4	-6.37	2.9e-10	5.2e-08	-0.2	-0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35210115	chr10:35314552~35336401:-
BRCA	cis	rs1823913	0.599	rs35150635	ENSG00000280083.1	RP11-317J9.1	-6.37	2.9e-10	5.2e-08	-0.22	-0.19	Obesity-related traits;	chr2:191287303	chr2:191154118~191156070:-
BRCA	cis	rs2243480	0.711	rs2460426	ENSG00000229886.1	RP5-1132H15.3	-6.37	2.9e-10	5.21e-08	-0.34	-0.19	Diabetic kidney disease;	chr7:66158142	chr7:66025126~66031544:-
BRCA	cis	rs2243480	1	rs316313	ENSG00000232559.3	GS1-124K5.12	6.37	2.91e-10	5.22e-08	0.37	0.19	Diabetic kidney disease;	chr7:66128561	chr7:66554588~66576923:-
BRCA	cis	rs2243480	1	rs316312	ENSG00000232559.3	GS1-124K5.12	6.37	2.91e-10	5.22e-08	0.37	0.19	Diabetic kidney disease;	chr7:66131504	chr7:66554588~66576923:-
BRCA	cis	rs2243480	1	rs419603	ENSG00000232559.3	GS1-124K5.12	6.37	2.91e-10	5.22e-08	0.37	0.19	Diabetic kidney disease;	chr7:66132354	chr7:66554588~66576923:-
BRCA	cis	rs2243480	1	rs160634	ENSG00000229886.1	RP5-1132H15.3	-6.37	2.91e-10	5.22e-08	-0.32	-0.19	Diabetic kidney disease;	chr7:66063677	chr7:66025126~66031544:-
BRCA	cis	rs11977670	0.785	rs13225058	ENSG00000260231.1	JHDM1D-AS1	6.37	2.91e-10	5.22e-08	0.22	0.19	Breast cancer;	chr7:140246253	chr7:140177261~140179640:+
BRCA	cis	rs6951245	0.744	rs10265736	ENSG00000229043.2	AC091729.9	-6.37	2.91e-10	5.22e-08	-0.32	-0.19	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1132829	chr7:1160374~1165267:+
BRCA	cis	rs651907	0.557	rs13066768	ENSG00000244119.1	PDCL3P4	-6.37	2.91e-10	5.22e-08	-0.16	-0.19	Colorectal cancer;	chr3:101768076	chr3:101712472~101713191:+
BRCA	cis	rs2243480	1	rs431318	ENSG00000232546.1	RP11-458F8.1	-6.37	2.92e-10	5.23e-08	-0.26	-0.19	Diabetic kidney disease;	chr7:66046610	chr7:66848496~66858136:+
BRCA	cis	rs710913	0.816	rs1727098	ENSG00000237624.1	OXCT2P1	-6.37	2.92e-10	5.23e-08	-0.22	-0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39523655	chr1:39514956~39516490:+
BRCA	cis	rs875971	0.54	rs35510581	ENSG00000164669.11	INTS4P1	6.37	2.92e-10	5.23e-08	0.24	0.19	Aortic root size;	chr7:66113790	chr7:65141225~65234216:+
BRCA	cis	rs12594515	0.904	rs8032875	ENSG00000259200.1	RP11-718O11.1	-6.37	2.92e-10	5.24e-08	-0.22	-0.19	Weight;Waist circumference;	chr15:45705812	chr15:45705078~45931069:+
BRCA	cis	rs12594515	0.874	rs8032878	ENSG00000259200.1	RP11-718O11.1	-6.37	2.92e-10	5.24e-08	-0.22	-0.19	Weight;Waist circumference;	chr15:45705817	chr15:45705078~45931069:+
BRCA	cis	rs10208649	0.908	rs10199995	ENSG00000233266.1	HMGB1P31	6.36	2.93e-10	5.25e-08	0.47	0.19	Body mass index;	chr2:53981138	chr2:54051334~54051760:+
BRCA	cis	rs6840258	0.66	rs10516786	ENSG00000251411.1	RP11-397E7.4	-6.36	2.93e-10	5.25e-08	-0.27	-0.19	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86971189	chr4:86913266~86914817:-
BRCA	cis	rs9992667	0.956	rs73232890	ENSG00000231160.8	KLF3-AS1	6.36	2.93e-10	5.26e-08	0.26	0.19	Eosinophil percentage of granulocytes;	chr4:38683420	chr4:38612701~38664883:-
BRCA	cis	rs3126085	0.56	rs11204987	ENSG00000237975.5	FLG-AS1	6.36	2.93e-10	5.26e-08	0.26	0.19	Atopic dermatitis;	chr1:152370393	chr1:152168125~152445456:+
BRCA	cis	rs3126085	0.56	rs12027445	ENSG00000237975.5	FLG-AS1	6.36	2.93e-10	5.26e-08	0.26	0.19	Atopic dermatitis;	chr1:152372311	chr1:152168125~152445456:+
BRCA	cis	rs1707322	1	rs785493	ENSG00000281133.1	AL355480.3	6.36	2.93e-10	5.26e-08	0.26	0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46119187	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.964	rs785496	ENSG00000281133.1	AL355480.3	6.36	2.93e-10	5.26e-08	0.26	0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46122334	chr1:45580892~45580996:-
BRCA	cis	rs1707322	1	rs785497	ENSG00000281133.1	AL355480.3	6.36	2.93e-10	5.26e-08	0.26	0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46126231	chr1:45580892~45580996:-
BRCA	cis	rs847577	0.748	rs55784506	ENSG00000272950.1	RP11-307C18.1	6.36	2.93e-10	5.26e-08	0.25	0.19	Breast cancer;	chr7:98088889	chr7:98322853~98323430:+
BRCA	cis	rs7927771	0.542	rs7122217	ENSG00000280615.1	Y_RNA	-6.36	2.93e-10	5.26e-08	-0.22	-0.19	Subjective well-being;	chr11:47756368	chr11:47614898~47614994:-
BRCA	cis	rs7927771	0.524	rs12421563	ENSG00000280615.1	Y_RNA	-6.36	2.93e-10	5.26e-08	-0.22	-0.19	Subjective well-being;	chr11:47758670	chr11:47614898~47614994:-
BRCA	cis	rs6840258	0.825	rs72667747	ENSG00000251411.1	RP11-397E7.4	-6.36	2.93e-10	5.26e-08	-0.28	-0.19	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87000911	chr4:86913266~86914817:-
BRCA	cis	rs1979679	0.842	rs12049916	ENSG00000278733.1	RP11-425D17.1	6.36	2.94e-10	5.26e-08	0.25	0.19	Ossification of the posterior longitudinal ligament of the spine;	chr12:28207052	chr12:28185625~28186190:-
BRCA	cis	rs9880211	0.563	rs6793835	ENSG00000273486.1	RP11-731C17.2	-6.36	2.94e-10	5.27e-08	-0.25	-0.19	Height;Body mass index;	chr3:136101092	chr3:136837338~136839021:-
BRCA	cis	rs11096990	0.892	rs1901404	ENSG00000249207.1	RP11-360F5.1	6.36	2.94e-10	5.27e-08	0.22	0.19	Cognitive function;	chr4:39210990	chr4:39112677~39126818:-
BRCA	cis	rs6471393	0.964	rs2914941	ENSG00000253848.1	RP11-10N23.5	6.36	2.94e-10	5.27e-08	0.23	0.19	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93716983	chr8:93741193~93744534:+
BRCA	cis	rs35146811	0.586	rs12705067	ENSG00000235713.1	RP4-604G5.3	6.36	2.94e-10	5.27e-08	0.23	0.19	Coronary artery disease;	chr7:99997103	chr7:99992397~99993050:+
BRCA	cis	rs7246657	0.943	rs8111782	ENSG00000267422.1	CTD-2554C21.1	-6.36	2.95e-10	5.28e-08	-0.29	-0.19	Coronary artery calcification;	chr19:37377002	chr19:37779686~37792865:+
BRCA	cis	rs13113518	0.683	rs9761521	ENSG00000273257.1	RP11-177J6.1	6.36	2.95e-10	5.29e-08	0.26	0.19	Height;	chr4:55363436	chr4:55387949~55388271:+
BRCA	cis	rs13315649	0.639	rs73196928	ENSG00000242551.2	POU5F1P6	-6.36	2.95e-10	5.29e-08	-0.26	-0.19	Sum eosinophil basophil counts;	chr3:128670583	chr3:128674735~128677005:-
BRCA	cis	rs9291683	0.53	rs998675	ENSG00000250413.1	RP11-448G15.1	-6.36	2.95e-10	5.29e-08	-0.25	-0.19	Bone mineral density;	chr4:9947205	chr4:10006482~10009725:+
BRCA	cis	rs673078	0.66	rs61945212	ENSG00000275409.1	RP11-131L12.4	-6.36	2.95e-10	5.29e-08	-0.3	-0.19	Glucose homeostasis traits;	chr12:118252351	chr12:118430147~118430699:+
BRCA	cis	rs801193	0.66	rs10950049	ENSG00000224316.1	RP11-479O9.2	6.36	2.95e-10	5.29e-08	0.19	0.19	Aortic root size;	chr7:66765873	chr7:65773620~65802067:+
BRCA	cis	rs755249	0.567	rs4660214	ENSG00000237624.1	OXCT2P1	6.36	2.95e-10	5.29e-08	0.28	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39265878	chr1:39514956~39516490:+
BRCA	cis	rs2836950	0.509	rs4816618	ENSG00000255568.3	BRWD1-AS2	-6.36	2.95e-10	5.3e-08	-0.19	-0.19	Menarche (age at onset);	chr21:39227603	chr21:39313935~39314962:+
BRCA	cis	rs2836950	0.527	rs2836948	ENSG00000255568.3	BRWD1-AS2	-6.36	2.95e-10	5.3e-08	-0.19	-0.19	Menarche (age at onset);	chr21:39227751	chr21:39313935~39314962:+
BRCA	cis	rs78456975	1	rs11884854	ENSG00000231482.2	AC141930.2	-6.36	2.96e-10	5.3e-08	-0.27	-0.19	Placebo response in major depressive disorder (% change in symptom score);	chr2:1562382	chr2:1572554~1580311:-
BRCA	cis	rs3764021	1	rs3764021	ENSG00000256673.1	RP11-599J14.2	-6.36	2.96e-10	5.3e-08	-0.21	-0.19	Type 1 diabetes;	chr12:9681032	chr12:9398355~9414851:-
BRCA	cis	rs2732480	0.577	rs2732466	ENSG00000257763.1	OR5BK1P	6.36	2.96e-10	5.31e-08	0.21	0.19	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48338676	chr12:48355792~48356614:-
BRCA	cis	rs77972916	0.505	rs6719754	ENSG00000234936.1	AC010883.5	6.36	2.96e-10	5.31e-08	0.23	0.19	Granulocyte percentage of myeloid white cells;	chr2:43299247	chr2:43229573~43233394:+
BRCA	cis	rs4713118	0.869	rs6922574	ENSG00000220721.1	OR1F12	6.36	2.96e-10	5.31e-08	0.24	0.19	Parkinson's disease;	chr6:27725224	chr6:28073316~28074233:+
BRCA	cis	rs7829975	0.606	rs10112585	ENSG00000233609.3	RP11-62H7.2	-6.36	2.97e-10	5.32e-08	-0.18	-0.19	Mood instability;	chr8:8937520	chr8:8961200~8979025:+
BRCA	cis	rs4950322	0.518	rs55697094	ENSG00000278811.3	LINC00624	6.36	2.97e-10	5.32e-08	0.25	0.19	Protein quantitative trait loci;	chr1:147121205	chr1:147258885~147517875:-
BRCA	cis	rs2179367	0.543	rs9498328	ENSG00000216906.2	RP11-350J20.9	6.36	2.97e-10	5.32e-08	0.27	0.19	Dupuytren's disease;	chr6:149348715	chr6:149904243~149906418:+
BRCA	cis	rs12701220	0.5	rs6463224	ENSG00000229043.2	AC091729.9	-6.36	2.97e-10	5.32e-08	-0.28	-0.19	Bronchopulmonary dysplasia;	chr7:1100782	chr7:1160374~1165267:+
BRCA	cis	rs2638953	0.888	rs11610011	ENSG00000278733.1	RP11-425D17.1	-6.36	2.97e-10	5.32e-08	-0.25	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28202801	chr12:28185625~28186190:-
BRCA	cis	rs2243480	1	rs34970380	ENSG00000229886.1	RP5-1132H15.3	6.36	2.97e-10	5.33e-08	0.34	0.19	Diabetic kidney disease;	chr7:65966506	chr7:66025126~66031544:-
BRCA	cis	rs4372836	1	rs4666119	ENSG00000226833.4	AC097724.3	6.36	2.97e-10	5.33e-08	0.24	0.19	Body mass index;	chr2:28752824	chr2:28708953~28736205:-
BRCA	cis	rs2243480	1	rs35046236	ENSG00000228409.4	CCT6P1	6.36	2.97e-10	5.33e-08	0.26	0.19	Diabetic kidney disease;	chr7:65943626	chr7:65751142~65763354:+
BRCA	cis	rs2243480	1	rs36068983	ENSG00000228409.4	CCT6P1	6.36	2.97e-10	5.33e-08	0.26	0.19	Diabetic kidney disease;	chr7:65944004	chr7:65751142~65763354:+
BRCA	cis	rs2243480	1	rs68189316	ENSG00000228409.4	CCT6P1	6.36	2.97e-10	5.33e-08	0.26	0.19	Diabetic kidney disease;	chr7:65944182	chr7:65751142~65763354:+
BRCA	cis	rs228614	0.536	rs223419	ENSG00000251288.2	RP11-10L12.2	-6.36	2.97e-10	5.33e-08	-0.23	-0.19	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102808586	chr4:102751401~102752641:+
BRCA	cis	rs4950322	0.57	rs72692979	ENSG00000278811.3	LINC00624	6.36	2.98e-10	5.33e-08	0.26	0.19	Protein quantitative trait loci;	chr1:147336094	chr1:147258885~147517875:-
BRCA	cis	rs4072705	0.9	rs4836993	ENSG00000224020.1	MIR181A2HG	-6.36	2.98e-10	5.34e-08	-0.22	-0.19	Menarche (age at onset);	chr9:124796091	chr9:124658467~124698631:+
BRCA	cis	rs6570726	1	rs436066	ENSG00000235652.6	RP11-545I5.3	6.36	2.98e-10	5.34e-08	0.19	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145525991	chr6:145799409~145886585:+
BRCA	cis	rs853679	0.517	rs12174753	ENSG00000280107.1	AL022393.9	-6.36	2.98e-10	5.35e-08	-0.29	-0.19	Depression;	chr6:28074687	chr6:28170845~28172521:+
BRCA	cis	rs250585	0.85	rs152460	ENSG00000260136.4	CTD-2270L9.4	6.36	2.99e-10	5.35e-08	0.19	0.19	Egg allergy;	chr16:23562512	chr16:23452758~23457606:+
BRCA	cis	rs2492286	0.569	rs9289331	ENSG00000242551.2	POU5F1P6	-6.36	2.99e-10	5.36e-08	-0.28	-0.19	Eosinophil counts;	chr3:128635173	chr3:128674735~128677005:-
BRCA	cis	rs1124769	0.7	rs12900777	ENSG00000259378.1	DCAF13P3	6.36	2.99e-10	5.36e-08	0.27	0.19	Cognitive performance;	chr15:51072382	chr15:50944663~50945996:+
BRCA	cis	rs1124769	0.654	rs12593764	ENSG00000259378.1	DCAF13P3	6.36	2.99e-10	5.36e-08	0.27	0.19	Cognitive performance;	chr15:51072743	chr15:50944663~50945996:+
BRCA	cis	rs2645424	0.686	rs2294140	ENSG00000255046.1	RP11-297N6.4	-6.36	2.99e-10	5.36e-08	-0.22	-0.19	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);	chr8:11848168	chr8:11797928~11802568:-
BRCA	cis	rs6570726	1	rs404229	ENSG00000235652.6	RP11-545I5.3	6.36	2.99e-10	5.36e-08	0.19	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145547064	chr6:145799409~145886585:+
BRCA	cis	rs7674212	0.507	rs10516495	ENSG00000251288.2	RP11-10L12.2	-6.36	2.99e-10	5.36e-08	-0.24	-0.19	Type 2 diabetes;	chr4:102978933	chr4:102751401~102752641:+
BRCA	cis	rs2946504	0.822	rs2977097	ENSG00000251468.2	RP11-369K16.1	6.36	3e-10	5.37e-08	0.23	0.19	Type 2 diabetes;	chr8:12946592	chr8:12958387~12962200:+
BRCA	cis	rs853679	0.517	rs1947862	ENSG00000219392.1	RP1-265C24.5	-6.36	3e-10	5.37e-08	-0.29	-0.19	Depression;	chr6:28137418	chr6:28115628~28116551:+
BRCA	cis	rs6142102	0.961	rs1319363	ENSG00000275784.1	RP5-1125A11.6	-6.36	3e-10	5.37e-08	-0.23	-0.19	Skin pigmentation;	chr20:33954070	chr20:33989480~33991818:-
BRCA	cis	rs853679	0.55	rs1233701	ENSG00000219392.1	RP1-265C24.5	6.36	3e-10	5.37e-08	0.28	0.19	Depression;	chr6:28200948	chr6:28115628~28116551:+
BRCA	cis	rs2562456	0.917	rs2681392	ENSG00000268081.1	RP11-678G14.2	-6.36	3e-10	5.37e-08	-0.29	-0.19	Pain;	chr19:21513185	chr19:21554640~21569237:-
BRCA	cis	rs9307551	0.817	rs4975057	ENSG00000250334.4	LINC00989	-6.36	3e-10	5.38e-08	-0.26	-0.19	Refractive error;	chr4:79567191	chr4:79492416~79576460:+
BRCA	cis	rs11024102	0.925	rs7127818	ENSG00000184669.7	OR7E14P	-6.36	3e-10	5.38e-08	-0.3	-0.19	Glaucoma (primary angle closure);	chr11:16982543	chr11:17013998~17053024:+
BRCA	cis	rs2281558	1	rs2281558	ENSG00000125804.12	FAM182A	-6.36	3e-10	5.38e-08	-0.29	-0.19	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25259553	chr20:26054655~26086917:+
BRCA	cis	rs7911264	0.791	rs9420589	ENSG00000236493.2	EIF2S2P3	-6.36	3e-10	5.38e-08	-0.26	-0.19	Inflammatory bowel disease;	chr10:92690476	chr10:92668745~92669743:-
BRCA	cis	rs2243480	0.908	rs1532573	ENSG00000229886.1	RP5-1132H15.3	-6.36	3e-10	5.38e-08	-0.34	-0.19	Diabetic kidney disease;	chr7:66333815	chr7:66025126~66031544:-
BRCA	cis	rs710913	0.816	rs1180341	ENSG00000182109.6	RP11-69E11.4	-6.36	3e-10	5.38e-08	-0.21	-0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39527136	chr1:39522280~39546187:-
BRCA	cis	rs2243480	1	rs316307	ENSG00000230295.1	RP11-458F8.2	-6.36	3.01e-10	5.38e-08	-0.26	-0.19	Diabetic kidney disease;	chr7:66105184	chr7:66880708~66882981:+
BRCA	cis	rs17301013	0.507	rs72717608	ENSG00000227373.4	RP11-160H22.5	6.36	3.01e-10	5.39e-08	0.29	0.19	Systemic lupus erythematosus;	chr1:174788316	chr1:174115300~174160004:-
BRCA	cis	rs78456975	0.941	rs6755875	ENSG00000231482.2	AC141930.2	-6.36	3.01e-10	5.4e-08	-0.28	-0.19	Placebo response in major depressive disorder (% change in symptom score);	chr2:1553337	chr2:1572554~1580311:-
BRCA	cis	rs2911132	0.511	rs3198304	ENSG00000248734.2	CTD-2260A17.1	6.36	3.01e-10	5.4e-08	0.24	0.19	Urate levels (BMI interaction);	chr5:96775524	chr5:96784777~96785999:+
BRCA	cis	rs78456975	1	rs6720874	ENSG00000231482.2	AC141930.2	-6.36	3.02e-10	5.41e-08	-0.27	-0.19	Placebo response in major depressive disorder (% change in symptom score);	chr2:1576732	chr2:1572554~1580311:-
BRCA	cis	rs2243480	1	rs2462569	ENSG00000230295.1	RP11-458F8.2	6.36	3.02e-10	5.41e-08	0.24	0.19	Diabetic kidney disease;	chr7:66009859	chr7:66880708~66882981:+
BRCA	cis	rs2998286	0.723	rs332152	ENSG00000254635.4	WAC-AS1	-6.36	3.02e-10	5.41e-08	-0.28	-0.19	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28585602	chr10:28522652~28532743:-
BRCA	cis	rs10129255	0.5	rs8004923	ENSG00000274576.2	IGHV2-70	-6.36	3.02e-10	5.41e-08	-0.15	-0.19	Kawasaki disease;	chr14:106785926	chr14:106770577~106771020:-
BRCA	cis	rs875971	0.522	rs6960048	ENSG00000234585.5	CCT6P3	6.36	3.02e-10	5.41e-08	0.18	0.19	Aortic root size;	chr7:65943052	chr7:65038354~65074713:+
BRCA	cis	rs3764021	0.87	rs7970116	ENSG00000214776.8	RP11-726G1.1	-6.36	3.03e-10	5.42e-08	-0.21	-0.19	Type 1 diabetes;	chr12:9727518	chr12:9467552~9576275:+
BRCA	cis	rs67981189	0.865	rs2810115	ENSG00000258571.1	PTTG4P	6.36	3.03e-10	5.42e-08	0.21	0.19	Schizophrenia;	chr14:70928070	chr14:71085482~71085833:-
BRCA	cis	rs67981189	0.896	rs917065	ENSG00000258571.1	PTTG4P	6.36	3.03e-10	5.42e-08	0.21	0.19	Schizophrenia;	chr14:70931129	chr14:71085482~71085833:-
BRCA	cis	rs67981189	0.896	rs1018977	ENSG00000258571.1	PTTG4P	6.36	3.03e-10	5.42e-08	0.21	0.19	Schizophrenia;	chr14:70933936	chr14:71085482~71085833:-
BRCA	cis	rs67981189	0.752	rs2332477	ENSG00000258571.1	PTTG4P	6.36	3.03e-10	5.42e-08	0.21	0.19	Schizophrenia;	chr14:70936594	chr14:71085482~71085833:-
BRCA	cis	rs6840258	0.941	rs72667757	ENSG00000251411.1	RP11-397E7.4	-6.36	3.04e-10	5.43e-08	-0.28	-0.19	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87025842	chr4:86913266~86914817:-
BRCA	cis	rs1476670	0.565	rs942756	ENSG00000230615.5	RP5-1198O20.4	-6.36	3.04e-10	5.44e-08	-0.26	-0.19	Eotaxin levels;	chr1:44056602	chr1:44030443~44115913:+
BRCA	cis	rs2243480	1	rs2243480	ENSG00000229886.1	RP5-1132H15.3	6.36	3.04e-10	5.44e-08	0.35	0.19	Diabetic kidney disease;	chr7:66134209	chr7:66025126~66031544:-
BRCA	cis	rs2243480	1	rs316329	ENSG00000230295.1	RP11-458F8.2	-6.36	3.04e-10	5.45e-08	-0.25	-0.19	Diabetic kidney disease;	chr7:66143429	chr7:66880708~66882981:+
BRCA	cis	rs875971	0.545	rs801199	ENSG00000236529.1	RP13-254B10.1	-6.36	3.04e-10	5.45e-08	-0.24	-0.19	Aortic root size;	chr7:66560286	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.545	rs73152714	ENSG00000236529.1	RP13-254B10.1	6.36	3.04e-10	5.45e-08	0.24	0.19	Aortic root size;	chr7:66534641	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.545	rs4718364	ENSG00000236529.1	RP13-254B10.1	6.36	3.04e-10	5.45e-08	0.24	0.19	Aortic root size;	chr7:66536353	chr7:65840212~65840596:+
BRCA	cis	rs4950322	0.57	rs4950403	ENSG00000278811.3	LINC00624	6.36	3.04e-10	5.45e-08	0.26	0.19	Protein quantitative trait loci;	chr1:147319723	chr1:147258885~147517875:-
BRCA	cis	rs4950322	0.517	rs116479391	ENSG00000278811.3	LINC00624	6.36	3.04e-10	5.45e-08	0.26	0.19	Protein quantitative trait loci;	chr1:147320940	chr1:147258885~147517875:-
BRCA	cis	rs13113518	0.513	rs13147861	ENSG00000273257.1	RP11-177J6.1	6.36	3.05e-10	5.45e-08	0.26	0.19	Height;	chr4:55611014	chr4:55387949~55388271:+
BRCA	cis	rs853679	0.55	rs1233699	ENSG00000219392.1	RP1-265C24.5	-6.36	3.05e-10	5.46e-08	-0.28	-0.19	Depression;	chr6:28201380	chr6:28115628~28116551:+
BRCA	cis	rs10740039	0.81	rs2165691	ENSG00000254271.1	RP11-131N11.4	6.36	3.05e-10	5.46e-08	0.26	0.19	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60611891	chr10:60734342~60741828:+
BRCA	cis	rs1823913	0.637	rs4613316	ENSG00000280083.1	RP11-317J9.1	-6.36	3.06e-10	5.47e-08	-0.22	-0.19	Obesity-related traits;	chr2:191326074	chr2:191154118~191156070:-
BRCA	cis	rs6688613	1	rs7533688	ENSG00000225171.2	DUTP6	-6.36	3.06e-10	5.47e-08	-0.23	-0.19	Refractive astigmatism;	chr1:166974886	chr1:166868748~166869209:+
BRCA	cis	rs2348418	0.832	rs7136426	ENSG00000247934.4	RP11-967K21.1	6.36	3.06e-10	5.47e-08	0.22	0.19	Lung function (FEV1);Lung function (FVC);	chr12:28400129	chr12:28163298~28190738:-
BRCA	cis	rs13113518	0.841	rs7699867	ENSG00000223305.1	RN7SKP30	6.36	3.06e-10	5.48e-08	0.24	0.19	Height;	chr4:55483718	chr4:55540502~55540835:-
BRCA	cis	rs17253792	0.822	rs112374071	ENSG00000186615.9	KTN1-AS1	-6.36	3.07e-10	5.48e-08	-0.39	-0.19	Putamen volume;	chr14:55595201	chr14:55499278~55580110:-
BRCA	cis	rs1124769	0.719	rs4304967	ENSG00000259378.1	DCAF13P3	6.36	3.07e-10	5.48e-08	0.27	0.19	Cognitive performance;	chr15:51096981	chr15:50944663~50945996:+
BRCA	cis	rs1707322	1	rs785470	ENSG00000281133.1	AL355480.3	6.36	3.07e-10	5.48e-08	0.24	0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46053950	chr1:45580892~45580996:-
BRCA	cis	rs301901	0.796	rs6872681	ENSG00000250155.1	CTD-2353F22.1	6.36	3.07e-10	5.49e-08	0.22	0.19	Height;	chr5:37535278	chr5:36666214~36725195:-
BRCA	cis	rs1150668	0.796	rs9468372	ENSG00000220721.1	OR1F12	6.36	3.07e-10	5.49e-08	0.22	0.19	Pubertal anthropometrics;	chr6:28411584	chr6:28073316~28074233:+
BRCA	cis	rs944990	0.557	rs6479493	ENSG00000227603.1	RP11-165J3.6	-6.36	3.07e-10	5.49e-08	-0.2	-0.19	Body mass index;	chr9:93536690	chr9:93435332~93437121:-
BRCA	cis	rs801193	0.66	rs1016265	ENSG00000224316.1	RP11-479O9.2	6.36	3.08e-10	5.5e-08	0.19	0.19	Aortic root size;	chr7:66749580	chr7:65773620~65802067:+
BRCA	cis	rs801193	0.66	rs4610622	ENSG00000224316.1	RP11-479O9.2	6.36	3.08e-10	5.5e-08	0.19	0.19	Aortic root size;	chr7:66759510	chr7:65773620~65802067:+
BRCA	cis	rs897984	0.762	rs2054213	ENSG00000275263.1	RP11-1072A3.4	6.36	3.08e-10	5.51e-08	0.23	0.19	Dementia with Lewy bodies;	chr16:30960489	chr16:30956872~30957199:-
BRCA	cis	rs3764021	0.84	rs10743823	ENSG00000214776.8	RP11-726G1.1	6.36	3.08e-10	5.51e-08	0.21	0.19	Type 1 diabetes;	chr12:9728529	chr12:9467552~9576275:+
BRCA	cis	rs12468226	1	rs113877751	ENSG00000226261.1	AC064836.3	6.36	3.08e-10	5.51e-08	0.33	0.19	Urate levels;	chr2:202329998	chr2:202336024~202336727:-
BRCA	cis	rs12468226	0.935	rs113021930	ENSG00000226261.1	AC064836.3	6.36	3.08e-10	5.51e-08	0.33	0.19	Urate levels;	chr2:202330448	chr2:202336024~202336727:-
BRCA	cis	rs12468226	1	rs113491584	ENSG00000226261.1	AC064836.3	6.36	3.08e-10	5.51e-08	0.33	0.19	Urate levels;	chr2:202331724	chr2:202336024~202336727:-
BRCA	cis	rs6951245	0.529	rs76001997	ENSG00000229043.2	AC091729.9	-6.36	3.08e-10	5.51e-08	-0.29	-0.19	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1112979	chr7:1160374~1165267:+
BRCA	cis	rs3740713	0.669	rs2896526	ENSG00000256464.1	YWHABP2	6.36	3.08e-10	5.51e-08	0.31	0.19	Amyotrophic lateral sclerosis (sporadic);	chr11:18398259	chr11:18490243~18490955:-
BRCA	cis	rs2243480	1	rs313831	ENSG00000230295.1	RP11-458F8.2	-6.36	3.08e-10	5.51e-08	-0.27	-0.19	Diabetic kidney disease;	chr7:66086239	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs316331	ENSG00000229886.1	RP5-1132H15.3	-6.36	3.08e-10	5.52e-08	-0.34	-0.19	Diabetic kidney disease;	chr7:66139635	chr7:66025126~66031544:-
BRCA	cis	rs10461617	0.541	rs860581	ENSG00000271828.1	CTD-2310F14.1	6.36	3.09e-10	5.52e-08	0.3	0.19	Type 2 diabetes;	chr5:56854710	chr5:56927874~56929573:+
BRCA	cis	rs858239	0.932	rs1728320	ENSG00000230042.1	AK3P3	-6.36	3.09e-10	5.53e-08	-0.22	-0.19	Cerebrospinal fluid biomarker levels;	chr7:23280170	chr7:23129178~23129841:+
BRCA	cis	rs9907295	0.688	rs2376287	ENSG00000270977.1	AC015849.16	-6.36	3.09e-10	5.53e-08	-0.28	-0.19	Fibroblast growth factor basic levels;	chr17:35919865	chr17:35893707~35911023:-
BRCA	cis	rs9907295	0.688	rs4796133	ENSG00000270977.1	AC015849.16	-6.36	3.09e-10	5.53e-08	-0.28	-0.19	Fibroblast growth factor basic levels;	chr17:35920505	chr17:35893707~35911023:-
BRCA	cis	rs9907295	0.688	rs7213636	ENSG00000270977.1	AC015849.16	-6.36	3.09e-10	5.53e-08	-0.28	-0.19	Fibroblast growth factor basic levels;	chr17:35920944	chr17:35893707~35911023:-
BRCA	cis	rs9287719	0.601	rs759401	ENSG00000243819.4	RN7SL832P	6.36	3.09e-10	5.53e-08	0.2	0.19	Prostate cancer;	chr2:10569796	chr2:10690344~10692099:+
BRCA	cis	rs78487399	0.71	rs17031133	ENSG00000234936.1	AC010883.5	-6.36	3.09e-10	5.53e-08	-0.26	-0.19	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43617694	chr2:43229573~43233394:+
BRCA	cis	rs4660456	0.542	rs850009	ENSG00000237899.1	RP4-739H11.3	6.36	3.1e-10	5.54e-08	0.29	0.19	Platelet count;	chr1:40643593	chr1:40669089~40687588:-
BRCA	cis	rs1499614	1	rs1267818	ENSG00000230295.1	RP11-458F8.2	-6.36	3.1e-10	5.54e-08	-0.26	-0.19	Gout;	chr7:66642037	chr7:66880708~66882981:+
BRCA	cis	rs2638953	0.924	rs4573721	ENSG00000278733.1	RP11-425D17.1	-6.36	3.1e-10	5.54e-08	-0.25	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28194746	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.924	rs4554927	ENSG00000278733.1	RP11-425D17.1	-6.36	3.1e-10	5.54e-08	-0.25	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28194844	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.924	rs61920243	ENSG00000278733.1	RP11-425D17.1	-6.36	3.1e-10	5.54e-08	-0.25	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28195333	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.679	rs7974882	ENSG00000278733.1	RP11-425D17.1	-6.36	3.1e-10	5.54e-08	-0.25	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28195415	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.679	rs7961395	ENSG00000278733.1	RP11-425D17.1	-6.36	3.1e-10	5.54e-08	-0.25	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28195420	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.924	rs7974701	ENSG00000278733.1	RP11-425D17.1	-6.36	3.1e-10	5.54e-08	-0.25	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28195579	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.886	rs7961769	ENSG00000278733.1	RP11-425D17.1	-6.36	3.1e-10	5.54e-08	-0.25	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28195772	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.886	rs61920244	ENSG00000278733.1	RP11-425D17.1	-6.36	3.1e-10	5.54e-08	-0.25	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28195992	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.924	rs34378873	ENSG00000278733.1	RP11-425D17.1	-6.36	3.1e-10	5.54e-08	-0.25	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28196124	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.924	rs11049437	ENSG00000278733.1	RP11-425D17.1	-6.36	3.1e-10	5.54e-08	-0.25	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28196192	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.924	rs11049438	ENSG00000278733.1	RP11-425D17.1	-6.36	3.1e-10	5.54e-08	-0.25	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28196205	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.924	rs11049440	ENSG00000278733.1	RP11-425D17.1	-6.36	3.1e-10	5.54e-08	-0.25	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28196474	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.924	rs11049441	ENSG00000278733.1	RP11-425D17.1	-6.36	3.1e-10	5.54e-08	-0.25	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28196476	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.853	rs11049442	ENSG00000278733.1	RP11-425D17.1	-6.36	3.1e-10	5.54e-08	-0.25	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28197211	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.924	rs11049443	ENSG00000278733.1	RP11-425D17.1	-6.36	3.1e-10	5.54e-08	-0.25	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28197269	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.924	rs11049444	ENSG00000278733.1	RP11-425D17.1	-6.36	3.1e-10	5.54e-08	-0.25	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28197447	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.924	rs11049445	ENSG00000278733.1	RP11-425D17.1	-6.36	3.1e-10	5.54e-08	-0.25	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28197449	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.962	rs60193273	ENSG00000278733.1	RP11-425D17.1	-6.36	3.1e-10	5.54e-08	-0.25	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28197638	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.924	rs11049446	ENSG00000278733.1	RP11-425D17.1	-6.36	3.1e-10	5.54e-08	-0.25	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28197951	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.924	rs11049447	ENSG00000278733.1	RP11-425D17.1	-6.36	3.1e-10	5.54e-08	-0.25	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28197970	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.886	rs10843123	ENSG00000278733.1	RP11-425D17.1	-6.36	3.1e-10	5.54e-08	-0.25	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28198004	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.924	rs12146881	ENSG00000278733.1	RP11-425D17.1	-6.36	3.1e-10	5.54e-08	-0.25	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28198436	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.924	rs11049448	ENSG00000278733.1	RP11-425D17.1	-6.36	3.1e-10	5.54e-08	-0.25	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28198975	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.924	rs10843126	ENSG00000278733.1	RP11-425D17.1	-6.36	3.1e-10	5.54e-08	-0.25	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28199112	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.924	rs10843127	ENSG00000278733.1	RP11-425D17.1	-6.36	3.1e-10	5.54e-08	-0.25	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28199124	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.85	rs10843128	ENSG00000278733.1	RP11-425D17.1	-6.36	3.1e-10	5.54e-08	-0.25	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28199377	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.85	rs10843129	ENSG00000278733.1	RP11-425D17.1	-6.36	3.1e-10	5.54e-08	-0.25	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28199378	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.924	rs10843130	ENSG00000278733.1	RP11-425D17.1	-6.36	3.1e-10	5.54e-08	-0.25	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28199793	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.924	rs61920253	ENSG00000278733.1	RP11-425D17.1	-6.36	3.1e-10	5.54e-08	-0.25	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28202039	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.888	rs11612143	ENSG00000278733.1	RP11-425D17.1	-6.36	3.1e-10	5.54e-08	-0.25	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28202694	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.813	rs11609999	ENSG00000278733.1	RP11-425D17.1	-6.36	3.1e-10	5.54e-08	-0.25	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28202721	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.924	rs11049453	ENSG00000278733.1	RP11-425D17.1	-6.36	3.1e-10	5.54e-08	-0.25	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28202996	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.886	rs7957059	ENSG00000278733.1	RP11-425D17.1	-6.36	3.1e-10	5.54e-08	-0.25	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28203390	chr12:28185625~28186190:-
BRCA	cis	rs2243480	1	rs160655	ENSG00000228409.4	CCT6P1	6.36	3.1e-10	5.54e-08	0.28	0.19	Diabetic kidney disease;	chr7:66068227	chr7:65751142~65763354:+
BRCA	cis	rs754466	0.651	rs10824583	ENSG00000204049.1	RP11-126H7.4	-6.36	3.1e-10	5.54e-08	-0.23	-0.19	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77859644	chr10:77866875~77869610:+
BRCA	cis	rs1322639	0.614	rs7768154	ENSG00000261039.2	RP11-417E7.2	-6.36	3.1e-10	5.54e-08	-0.25	-0.19	Pulse pressure;	chr6:169165375	chr6:169175304~169182740:-
BRCA	cis	rs2337406	1	rs4774173	ENSG00000211972.2	IGHV3-66	6.36	3.1e-10	5.55e-08	0.18	0.19	Alzheimer's disease (late onset);	chr14:106682029	chr14:106675017~106675544:-
BRCA	cis	rs2243480	1	rs34933526	ENSG00000228409.4	CCT6P1	6.36	3.1e-10	5.55e-08	0.26	0.19	Diabetic kidney disease;	chr7:65918212	chr7:65751142~65763354:+
BRCA	cis	rs2243480	1	rs6949812	ENSG00000228409.4	CCT6P1	6.36	3.1e-10	5.55e-08	0.26	0.19	Diabetic kidney disease;	chr7:65922114	chr7:65751142~65763354:+
BRCA	cis	rs2243480	1	rs6970243	ENSG00000228409.4	CCT6P1	6.36	3.1e-10	5.55e-08	0.26	0.19	Diabetic kidney disease;	chr7:65923503	chr7:65751142~65763354:+
BRCA	cis	rs2243480	0.708	rs35310401	ENSG00000228409.4	CCT6P1	6.36	3.1e-10	5.55e-08	0.26	0.19	Diabetic kidney disease;	chr7:65925372	chr7:65751142~65763354:+
BRCA	cis	rs2243480	0.831	rs7806717	ENSG00000228409.4	CCT6P1	-6.36	3.1e-10	5.55e-08	-0.26	-0.19	Diabetic kidney disease;	chr7:65928187	chr7:65751142~65763354:+
BRCA	cis	rs2998286	0.862	rs2993980	ENSG00000254635.4	WAC-AS1	-6.36	3.11e-10	5.55e-08	-0.27	-0.19	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28506286	chr10:28522652~28532743:-
BRCA	cis	rs12594515	0.935	rs8042519	ENSG00000259200.1	RP11-718O11.1	-6.36	3.11e-10	5.55e-08	-0.22	-0.19	Weight;Waist circumference;	chr15:45704143	chr15:45705078~45931069:+
BRCA	cis	rs875971	0.862	rs949930	ENSG00000224316.1	RP11-479O9.2	-6.36	3.11e-10	5.56e-08	-0.19	-0.19	Aortic root size;	chr7:66301835	chr7:65773620~65802067:+
BRCA	cis	rs2638953	0.924	rs11049410	ENSG00000278733.1	RP11-425D17.1	-6.36	3.11e-10	5.56e-08	-0.26	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28183438	chr12:28185625~28186190:-
BRCA	cis	rs2243480	1	rs1618893	ENSG00000232546.1	RP11-458F8.1	-6.35	3.12e-10	5.57e-08	-0.24	-0.19	Diabetic kidney disease;	chr7:66631132	chr7:66848496~66858136:+
BRCA	cis	rs77972916	0.505	rs3851318	ENSG00000234936.1	AC010883.5	6.35	3.12e-10	5.57e-08	0.23	0.19	Granulocyte percentage of myeloid white cells;	chr2:43305669	chr2:43229573~43233394:+
BRCA	cis	rs9527	0.571	rs4917985	ENSG00000236937.2	PTGES3P4	6.35	3.12e-10	5.58e-08	0.25	0.19	Arsenic metabolism;	chr10:102864315	chr10:102845595~102845950:+
BRCA	cis	rs16978956	0.779	rs6045352	ENSG00000236474.1	GCNT1P1	-6.35	3.12e-10	5.58e-08	-0.23	-0.19	Body mass index;	chr20:18346462	chr20:18420160~18421454:-
BRCA	cis	rs6740322	0.895	rs6544643	ENSG00000234936.1	AC010883.5	6.35	3.13e-10	5.59e-08	0.22	0.19	Coronary artery disease;	chr2:43332933	chr2:43229573~43233394:+
BRCA	cis	rs9840812	0.592	rs12489577	ENSG00000273486.1	RP11-731C17.2	6.35	3.13e-10	5.59e-08	0.23	0.19	Fibrinogen levels;	chr3:136494303	chr3:136837338~136839021:-
BRCA	cis	rs5167	0.506	rs35193317	ENSG00000280087.1	CTB-129P6.7	-6.35	3.13e-10	5.59e-08	-0.23	-0.19	Blood protein levels;	chr19:44967087	chr19:44909375~44914968:+
BRCA	cis	rs34779708	0.966	rs878264	ENSG00000271335.4	RP11-324I22.4	6.35	3.13e-10	5.6e-08	0.2	0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35151653	chr10:35314552~35336401:-
BRCA	cis	rs34779708	0.931	rs12261654	ENSG00000271335.4	RP11-324I22.4	6.35	3.13e-10	5.6e-08	0.2	0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35033096	chr10:35314552~35336401:-
BRCA	cis	rs721917	0.507	rs2819101	ENSG00000244733.5	RP11-506M13.3	-6.35	3.14e-10	5.6e-08	-0.23	-0.19	Chronic obstructive pulmonary disease;	chr10:79936986	chr10:79660891~79677996:+
BRCA	cis	rs4691139	1	rs12498808	ENSG00000248632.1	RP11-366M4.11	6.35	3.14e-10	5.61e-08	0.2	0.19	Ovarian cancer in BRCA1 mutation carriers;	chr4:164985753	chr4:164968587~164970002:-
BRCA	cis	rs853679	0.517	rs3757185	ENSG00000219392.1	RP1-265C24.5	-6.35	3.14e-10	5.61e-08	-0.29	-0.19	Depression;	chr6:28139998	chr6:28115628~28116551:+
BRCA	cis	rs754466	0.651	rs11002316	ENSG00000204049.1	RP11-126H7.4	6.35	3.14e-10	5.61e-08	0.23	0.19	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77857753	chr10:77866875~77869610:+
BRCA	cis	rs9876781	1	rs7635522	ENSG00000229759.1	MRPS18AP1	6.35	3.14e-10	5.61e-08	0.21	0.19	Longevity;	chr3:48382166	chr3:48256350~48256938:-
BRCA	cis	rs853679	0.599	rs156743	ENSG00000220721.1	OR1F12	6.35	3.15e-10	5.62e-08	0.35	0.19	Depression;	chr6:27999311	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.517	rs56310871	ENSG00000280107.1	AL022393.9	-6.35	3.15e-10	5.62e-08	-0.29	-0.19	Depression;	chr6:28076704	chr6:28170845~28172521:+
BRCA	cis	rs67981189	0.896	rs7146591	ENSG00000269927.1	RP6-91H8.3	-6.35	3.15e-10	5.63e-08	-0.24	-0.19	Schizophrenia;	chr14:70971511	chr14:71141125~71143253:-
BRCA	cis	rs2243480	1	rs465359	ENSG00000230295.1	RP11-458F8.2	-6.35	3.15e-10	5.63e-08	-0.26	-0.19	Diabetic kidney disease;	chr7:66093177	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs462853	ENSG00000230295.1	RP11-458F8.2	-6.35	3.15e-10	5.63e-08	-0.26	-0.19	Diabetic kidney disease;	chr7:66093180	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs160644	ENSG00000230295.1	RP11-458F8.2	-6.35	3.15e-10	5.63e-08	-0.26	-0.19	Diabetic kidney disease;	chr7:66093199	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs160642	ENSG00000230295.1	RP11-458F8.2	-6.35	3.15e-10	5.63e-08	-0.26	-0.19	Diabetic kidney disease;	chr7:66093386	chr7:66880708~66882981:+
BRCA	cis	rs2243480	0.614	rs34032527	ENSG00000230295.1	RP11-458F8.2	-6.35	3.15e-10	5.63e-08	-0.26	-0.19	Diabetic kidney disease;	chr7:66100154	chr7:66880708~66882981:+
BRCA	cis	rs4713118	0.513	rs1225591	ENSG00000216901.1	AL022393.7	6.35	3.15e-10	5.63e-08	0.26	0.19	Parkinson's disease;	chr6:28180974	chr6:28176188~28176674:+
BRCA	cis	rs11971779	0.666	rs7786851	ENSG00000273391.1	RP11-634H22.1	-6.35	3.16e-10	5.64e-08	-0.22	-0.19	Diisocyanate-induced asthma;	chr7:139322274	chr7:139359032~139359566:-
BRCA	cis	rs2153535	0.585	rs9405400	ENSG00000230939.1	RP11-314C16.1	-6.35	3.16e-10	5.64e-08	-0.22	-0.19	Motion sickness;	chr6:8606895	chr6:8784178~8785445:+
BRCA	cis	rs10754283	0.967	rs1953821	ENSG00000231613.1	RP5-943J3.1	6.35	3.16e-10	5.64e-08	0.22	0.19	Amyotrophic lateral sclerosis (sporadic);	chr1:89641539	chr1:89788914~89790492:+
BRCA	cis	rs10129255	0.5	rs6576232	ENSG00000274576.2	IGHV2-70	-6.35	3.16e-10	5.64e-08	-0.15	-0.19	Kawasaki disease;	chr14:106787090	chr14:106770577~106771020:-
BRCA	cis	rs11096990	0.964	rs7678689	ENSG00000249207.1	RP11-360F5.1	6.35	3.16e-10	5.65e-08	0.22	0.19	Cognitive function;	chr4:39261140	chr4:39112677~39126818:-
BRCA	cis	rs8114671	0.836	rs6142280	ENSG00000269202.1	RP4-614O4.12	6.35	3.16e-10	5.65e-08	0.2	0.19	Height;	chr20:35034439	chr20:35201747~35203288:-
BRCA	cis	rs77972916	0.505	rs6727824	ENSG00000234936.1	AC010883.5	6.35	3.16e-10	5.65e-08	0.23	0.19	Granulocyte percentage of myeloid white cells;	chr2:43301238	chr2:43229573~43233394:+
BRCA	cis	rs4660456	0.504	rs491619	ENSG00000237899.1	RP4-739H11.3	6.35	3.16e-10	5.65e-08	0.29	0.19	Platelet count;	chr1:40641688	chr1:40669089~40687588:-
BRCA	cis	rs2115630	1	rs6496452	ENSG00000229212.6	RP11-561C5.4	6.35	3.17e-10	5.66e-08	0.21	0.19	P wave terminal force;	chr15:84829414	chr15:85205440~85234795:-
BRCA	cis	rs6840258	1	rs56395939	ENSG00000251411.1	RP11-397E7.4	-6.35	3.17e-10	5.67e-08	-0.26	-0.19	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87042481	chr4:86913266~86914817:-
BRCA	cis	rs7976269	0.537	rs4471475	ENSG00000257176.2	RP11-996F15.2	-6.35	3.18e-10	5.67e-08	-0.23	-0.19	Male-pattern baldness;	chr12:29022461	chr12:29280418~29317848:-
BRCA	cis	rs2300206	1	rs2300206	ENSG00000275784.1	RP5-1125A11.6	-6.35	3.18e-10	5.68e-08	-0.23	-0.19	Cancer (pleiotropy);Cancer;	chr20:34002002	chr20:33989480~33991818:-
BRCA	cis	rs250585	0.736	rs2040574	ENSG00000260136.4	CTD-2270L9.4	-6.35	3.18e-10	5.68e-08	-0.23	-0.19	Egg allergy;	chr16:23499005	chr16:23452758~23457606:+
BRCA	cis	rs7567389	0.573	rs11541137	ENSG00000236682.1	AC068282.3	-6.35	3.18e-10	5.68e-08	-0.3	-0.19	Self-rated health;	chr2:127388195	chr2:127389130~127400580:+
BRCA	cis	rs17772222	0.74	rs10138002	ENSG00000258983.2	RP11-507K2.2	-6.35	3.18e-10	5.68e-08	-0.2	-0.19	Coronary artery calcification;	chr14:88510071	chr14:88499334~88515502:+
BRCA	cis	rs2836950	0.565	rs8131132	ENSG00000238141.2	BRWD1-AS1	-6.35	3.18e-10	5.68e-08	-0.22	-0.19	Menarche (age at onset);	chr21:39166330	chr21:39315707~39323218:+
BRCA	cis	rs801193	0.904	rs4718405	ENSG00000236529.1	RP13-254B10.1	6.35	3.19e-10	5.69e-08	0.2	0.19	Aortic root size;	chr7:66789659	chr7:65840212~65840596:+
BRCA	cis	rs9291683	0.668	rs2241474	ENSG00000250413.1	RP11-448G15.1	-6.35	3.19e-10	5.69e-08	-0.26	-0.19	Bone mineral density;	chr4:10084391	chr4:10006482~10009725:+
BRCA	cis	rs2179367	0.632	rs9498329	ENSG00000216906.2	RP11-350J20.9	6.35	3.19e-10	5.69e-08	0.27	0.19	Dupuytren's disease;	chr6:149349941	chr6:149904243~149906418:+
BRCA	cis	rs858239	0.932	rs1637190	ENSG00000230042.1	AK3P3	-6.35	3.19e-10	5.7e-08	-0.22	-0.19	Cerebrospinal fluid biomarker levels;	chr7:23229446	chr7:23129178~23129841:+
BRCA	cis	rs919433	0.889	rs787998	ENSG00000231621.1	AC013264.2	-6.35	3.2e-10	5.71e-08	-0.18	-0.19	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197351368	chr2:197197991~197199273:+
BRCA	cis	rs7587476	0.906	rs17487827	ENSG00000229267.2	AC072062.1	-6.35	3.2e-10	5.71e-08	-0.27	-0.19	Neuroblastoma;	chr2:214779611	chr2:214810229~214963274:+
BRCA	cis	rs2348418	0.832	rs11049587	ENSG00000247934.4	RP11-967K21.1	6.35	3.2e-10	5.71e-08	0.22	0.19	Lung function (FEV1);Lung function (FVC);	chr12:28418090	chr12:28163298~28190738:-
BRCA	cis	rs10129255	0.957	rs10150241	ENSG00000211972.2	IGHV3-66	-6.35	3.21e-10	5.72e-08	-0.14	-0.19	Kawasaki disease;	chr14:106775945	chr14:106675017~106675544:-
BRCA	cis	rs11098499	0.78	rs12504773	ENSG00000249244.1	RP11-548H18.2	6.35	3.21e-10	5.73e-08	0.24	0.19	Corneal astigmatism;	chr4:119640994	chr4:119391831~119395335:-
BRCA	cis	rs1823913	0.637	rs13382985	ENSG00000280083.1	RP11-317J9.1	6.35	3.21e-10	5.73e-08	0.21	0.19	Obesity-related traits;	chr2:191306335	chr2:191154118~191156070:-
BRCA	cis	rs2288884	0.708	rs12460617	ENSG00000275055.1	CTC-471J1.11	-6.35	3.21e-10	5.73e-08	-0.26	-0.19	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52032581	chr19:52049007~52049754:+
BRCA	cis	rs7809950	0.817	rs10224503	ENSG00000238832.1	snoU109	-6.35	3.21e-10	5.73e-08	-0.27	-0.19	Coronary artery disease;	chr7:107435124	chr7:107603363~107603507:+
BRCA	cis	rs2348418	0.932	rs61922464	ENSG00000247934.4	RP11-967K21.1	6.35	3.21e-10	5.73e-08	0.22	0.19	Lung function (FEV1);Lung function (FVC);	chr12:28485665	chr12:28163298~28190738:-
BRCA	cis	rs2348418	0.932	rs11049661	ENSG00000247934.4	RP11-967K21.1	6.35	3.21e-10	5.73e-08	0.22	0.19	Lung function (FEV1);Lung function (FVC);	chr12:28486215	chr12:28163298~28190738:-
BRCA	cis	rs73193808	0.901	rs12626758	ENSG00000215533.7	LINC00189	-6.35	3.21e-10	5.73e-08	-0.28	-0.19	Coronary artery disease;	chr21:29194430	chr21:29193480~29288205:+
BRCA	cis	rs73193808	0.901	rs67211015	ENSG00000215533.7	LINC00189	-6.35	3.21e-10	5.73e-08	-0.28	-0.19	Coronary artery disease;	chr21:29194901	chr21:29193480~29288205:+
BRCA	cis	rs73193808	0.802	rs66691348	ENSG00000215533.7	LINC00189	-6.35	3.21e-10	5.73e-08	-0.28	-0.19	Coronary artery disease;	chr21:29195220	chr21:29193480~29288205:+
BRCA	cis	rs17253792	0.822	rs10483643	ENSG00000186615.9	KTN1-AS1	-6.35	3.22e-10	5.74e-08	-0.38	-0.19	Putamen volume;	chr14:55623213	chr14:55499278~55580110:-
BRCA	cis	rs17508449	0.865	rs4839330	ENSG00000232450.1	RP4-730K3.3	-6.35	3.22e-10	5.74e-08	-0.35	-0.19	Leprosy;	chr1:113594960	chr1:113698884~113699631:-
BRCA	cis	rs17508449	0.865	rs75296543	ENSG00000232450.1	RP4-730K3.3	-6.35	3.22e-10	5.74e-08	-0.35	-0.19	Leprosy;	chr1:113595664	chr1:113698884~113699631:-
BRCA	cis	rs875971	0.545	rs75840613	ENSG00000273024.4	INTS4P2	-6.35	3.22e-10	5.75e-08	-0.24	-0.19	Aortic root size;	chr7:66376399	chr7:65647864~65715661:+
BRCA	cis	rs7246657	0.943	rs7258692	ENSG00000226686.6	LINC01535	-6.35	3.22e-10	5.75e-08	-0.29	-0.19	Coronary artery calcification;	chr19:37327927	chr19:37251912~37265535:+
BRCA	cis	rs2243480	0.706	rs34466769	ENSG00000232546.1	RP11-458F8.1	-6.35	3.23e-10	5.76e-08	-0.22	-0.19	Diabetic kidney disease;	chr7:65988305	chr7:66848496~66858136:+
BRCA	cis	rs10483853	0.806	rs12586996	ENSG00000258695.2	RP3-414A15.2	6.35	3.23e-10	5.76e-08	0.3	0.19	Coronary artery calcification;	chr14:73342516	chr14:73522878~73530610:+
BRCA	cis	rs721917	0.506	rs2758547	ENSG00000244733.5	RP11-506M13.3	-6.35	3.23e-10	5.77e-08	-0.23	-0.19	Chronic obstructive pulmonary disease;	chr10:79937368	chr10:79660891~79677996:+
BRCA	cis	rs4713118	0.955	rs9393848	ENSG00000220721.1	OR1F12	6.35	3.23e-10	5.77e-08	0.24	0.19	Parkinson's disease;	chr6:27720590	chr6:28073316~28074233:+
BRCA	cis	rs227275	0.525	rs223461	ENSG00000251288.2	RP11-10L12.2	-6.35	3.23e-10	5.77e-08	-0.22	-0.19	Allergic disease (asthma, hay fever or eczema);	chr4:102782372	chr4:102751401~102752641:+
BRCA	cis	rs3733585	0.806	rs7375599	ENSG00000250413.1	RP11-448G15.1	-6.35	3.23e-10	5.77e-08	-0.25	-0.19	Cleft plate (environmental tobacco smoke interaction);	chr4:9953294	chr4:10006482~10009725:+
BRCA	cis	rs2243480	1	rs387676	ENSG00000230295.1	RP11-458F8.2	-6.35	3.23e-10	5.77e-08	-0.26	-0.19	Diabetic kidney disease;	chr7:66133233	chr7:66880708~66882981:+
BRCA	cis	rs1823913	0.599	rs55786000	ENSG00000280083.1	RP11-317J9.1	-6.35	3.24e-10	5.77e-08	-0.22	-0.19	Obesity-related traits;	chr2:191284500	chr2:191154118~191156070:-
BRCA	cis	rs2243480	1	rs437889	ENSG00000232546.1	RP11-458F8.1	-6.35	3.24e-10	5.78e-08	-0.26	-0.19	Diabetic kidney disease;	chr7:66044247	chr7:66848496~66858136:+
BRCA	cis	rs7829975	0.606	rs6422352	ENSG00000233609.3	RP11-62H7.2	-6.35	3.24e-10	5.78e-08	-0.18	-0.19	Mood instability;	chr8:8936683	chr8:8961200~8979025:+
BRCA	cis	rs1124769	0.748	rs72727114	ENSG00000259378.1	DCAF13P3	6.35	3.24e-10	5.78e-08	0.27	0.19	Cognitive performance;	chr15:51082720	chr15:50944663~50945996:+
BRCA	cis	rs1387259	0.931	rs11168474	ENSG00000273765.1	RP11-370I10.11	6.35	3.25e-10	5.79e-08	0.23	0.19	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48227601	chr12:48360920~48361377:+
BRCA	cis	rs2286503	0.78	rs12113458	ENSG00000228649.7	AC005682.5	6.35	3.25e-10	5.79e-08	0.17	0.19	Fibrinogen;	chr7:22816009	chr7:22854178~22861579:+
BRCA	cis	rs7598759	0.527	rs7571691	ENSG00000223198.1	RNU2-22P	-6.35	3.25e-10	5.79e-08	-0.23	-0.19	Noise-induced hearing loss;	chr2:231504690	chr2:231501990~231502201:-
BRCA	cis	rs11096990	0.892	rs6815686	ENSG00000249207.1	RP11-360F5.1	6.35	3.25e-10	5.8e-08	0.22	0.19	Cognitive function;	chr4:39198171	chr4:39112677~39126818:-
BRCA	cis	rs67981189	0.896	rs17108967	ENSG00000269927.1	RP6-91H8.3	6.35	3.26e-10	5.82e-08	0.24	0.19	Schizophrenia;	chr14:71075451	chr14:71141125~71143253:-
BRCA	cis	rs11098499	0.863	rs10019674	ENSG00000249244.1	RP11-548H18.2	-6.35	3.27e-10	5.82e-08	-0.24	-0.19	Corneal astigmatism;	chr4:119522334	chr4:119391831~119395335:-
BRCA	cis	rs2243480	1	rs73142166	ENSG00000232546.1	RP11-458F8.1	-6.35	3.27e-10	5.83e-08	-0.26	-0.19	Diabetic kidney disease;	chr7:65910845	chr7:66848496~66858136:+
BRCA	cis	rs7246657	0.941	rs67293224	ENSG00000267422.1	CTD-2554C21.1	-6.35	3.27e-10	5.84e-08	-0.3	-0.19	Coronary artery calcification;	chr19:37312346	chr19:37779686~37792865:+
BRCA	cis	rs6688613	1	rs6699159	ENSG00000225171.2	DUTP6	-6.35	3.27e-10	5.84e-08	-0.23	-0.19	Refractive astigmatism;	chr1:166976835	chr1:166868748~166869209:+
BRCA	cis	rs6688613	1	rs6665341	ENSG00000225171.2	DUTP6	-6.35	3.27e-10	5.84e-08	-0.23	-0.19	Refractive astigmatism;	chr1:166977781	chr1:166868748~166869209:+
BRCA	cis	rs12446554	0.509	rs56108048	ENSG00000261195.1	CTD-2380F24.1	-6.35	3.27e-10	5.84e-08	-0.28	-0.19	Obesity;	chr16:19698457	chr16:19761172~19766099:-
BRCA	cis	rs4950322	0.57	rs72692907	ENSG00000278811.3	LINC00624	6.35	3.28e-10	5.84e-08	0.26	0.19	Protein quantitative trait loci;	chr1:147301921	chr1:147258885~147517875:-
BRCA	cis	rs4950322	0.57	rs72692914	ENSG00000278811.3	LINC00624	6.35	3.28e-10	5.84e-08	0.26	0.19	Protein quantitative trait loci;	chr1:147302946	chr1:147258885~147517875:-
BRCA	cis	rs1823913	0.599	rs17346412	ENSG00000280083.1	RP11-317J9.1	-6.35	3.28e-10	5.84e-08	-0.22	-0.19	Obesity-related traits;	chr2:191285902	chr2:191154118~191156070:-
BRCA	cis	rs1823913	0.599	rs17412239	ENSG00000280083.1	RP11-317J9.1	-6.35	3.28e-10	5.84e-08	-0.22	-0.19	Obesity-related traits;	chr2:191285937	chr2:191154118~191156070:-
BRCA	cis	rs1823913	0.599	rs35098152	ENSG00000280083.1	RP11-317J9.1	-6.35	3.28e-10	5.84e-08	-0.22	-0.19	Obesity-related traits;	chr2:191286658	chr2:191154118~191156070:-
BRCA	cis	rs8002861	0.641	rs6561148	ENSG00000274001.1	RP11-5G9.5	6.35	3.28e-10	5.85e-08	0.23	0.19	Leprosy;	chr13:43852133	chr13:43877715~43878163:-
BRCA	cis	rs4948102	0.642	rs4948104	ENSG00000226278.1	PSPHP1	-6.35	3.28e-10	5.85e-08	-0.21	-0.19	Plasma homocysteine levels (post-methionine load test);	chr7:56074826	chr7:55764797~55773288:+
BRCA	cis	rs2562456	0.917	rs6511256	ENSG00000268081.1	RP11-678G14.2	-6.35	3.28e-10	5.85e-08	-0.3	-0.19	Pain;	chr19:21510513	chr19:21554640~21569237:-
BRCA	cis	rs2274273	0.662	rs66476033	ENSG00000258413.1	RP11-665C16.6	-6.35	3.29e-10	5.86e-08	-0.27	-0.19	Protein biomarker;	chr14:55194145	chr14:55262767~55272075:-
BRCA	cis	rs2274273	0.662	rs2094436	ENSG00000258413.1	RP11-665C16.6	-6.35	3.29e-10	5.86e-08	-0.27	-0.19	Protein biomarker;	chr14:55194777	chr14:55262767~55272075:-
BRCA	cis	rs7923609	0.756	rs7090758	ENSG00000232075.1	MRPL35P2	6.35	3.29e-10	5.86e-08	0.24	0.19	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63575555	chr10:63634317~63634827:-
BRCA	cis	rs2243480	1	rs316327	ENSG00000232559.3	GS1-124K5.12	-6.35	3.29e-10	5.86e-08	-0.35	-0.19	Diabetic kidney disease;	chr7:66144214	chr7:66554588~66576923:-
BRCA	cis	rs4950322	0.542	rs72692942	ENSG00000278811.3	LINC00624	6.35	3.29e-10	5.86e-08	0.26	0.19	Protein quantitative trait loci;	chr1:147318467	chr1:147258885~147517875:-
BRCA	cis	rs4950322	0.57	rs4950399	ENSG00000278811.3	LINC00624	6.35	3.29e-10	5.86e-08	0.26	0.19	Protein quantitative trait loci;	chr1:147319302	chr1:147258885~147517875:-
BRCA	cis	rs7520050	0.966	rs785479	ENSG00000280836.1	AL355480.1	6.35	3.29e-10	5.87e-08	0.22	0.19	Reticulocyte count;Red blood cell count;	chr1:46026472	chr1:45581219~45581321:-
BRCA	cis	rs3740713	0.669	rs34740438	ENSG00000256464.1	YWHABP2	6.35	3.29e-10	5.87e-08	0.33	0.19	Amyotrophic lateral sclerosis (sporadic);	chr11:18393783	chr11:18490243~18490955:-
BRCA	cis	rs875971	0.545	rs316305	ENSG00000273024.4	INTS4P2	6.35	3.3e-10	5.87e-08	0.24	0.19	Aortic root size;	chr7:66152984	chr7:65647864~65715661:+
BRCA	cis	rs10129255	0.5	rs10143242	ENSG00000274576.2	IGHV2-70	-6.35	3.3e-10	5.87e-08	-0.16	-0.19	Kawasaki disease;	chr14:106681814	chr14:106770577~106771020:-
BRCA	cis	rs2235642	0.893	rs2143285	ENSG00000280231.1	LA16c-380F5.3	-6.35	3.3e-10	5.88e-08	-0.25	-0.19	Coronary artery disease;	chr16:1543170	chr16:1553655~1554130:-
BRCA	cis	rs34779708	0.966	rs10508816	ENSG00000271335.4	RP11-324I22.4	6.35	3.3e-10	5.88e-08	0.2	0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35171048	chr10:35314552~35336401:-
BRCA	cis	rs9876781	1	rs2045554	ENSG00000229759.1	MRPS18AP1	-6.35	3.3e-10	5.89e-08	-0.22	-0.19	Longevity;	chr3:48453142	chr3:48256350~48256938:-
BRCA	cis	rs4761702	1	rs4761702	ENSG00000257322.4	RP11-511B23.2	-6.35	3.31e-10	5.89e-08	-0.25	-0.19	Immature fraction of reticulocytes;	chr12:93316116	chr12:93003415~93215679:-
BRCA	cis	rs172166	0.694	rs203884	ENSG00000216901.1	AL022393.7	6.35	3.31e-10	5.89e-08	0.25	0.19	Cardiac Troponin-T levels;	chr6:28109596	chr6:28176188~28176674:+
BRCA	cis	rs2489715	0.951	rs2801949	ENSG00000185904.10	LINC00839	6.35	3.31e-10	5.89e-08	0.27	0.19	Helix rolling;	chr10:42431295	chr10:42475543~42495336:+
BRCA	cis	rs73193808	0.901	rs8131103	ENSG00000215533.7	LINC00189	-6.34	3.31e-10	5.9e-08	-0.28	-0.19	Coronary artery disease;	chr21:29193427	chr21:29193480~29288205:+
BRCA	cis	rs957448	1	rs56716157	ENSG00000253175.1	RP11-267M23.6	6.34	3.31e-10	5.9e-08	0.26	0.19	Nonsyndromic cleft lip with cleft palate;	chr8:94530644	chr8:94565036~94565715:+
BRCA	cis	rs72772090	0.908	rs72772091	ENSG00000248734.2	CTD-2260A17.1	-6.34	3.32e-10	5.91e-08	-0.29	-0.19	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96704418	chr5:96784777~96785999:+
BRCA	cis	rs8072100	0.676	rs9908049	ENSG00000228782.6	CTD-2026D20.3	6.34	3.32e-10	5.91e-08	0.21	0.19	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47424730	chr17:47450568~47492492:-
BRCA	cis	rs3761847	0.5	rs7037673	ENSG00000226752.6	PSMD5-AS1	-6.34	3.32e-10	5.92e-08	-0.23	-0.19	Rheumatoid arthritis;	chr9:120978206	chr9:120824828~120854385:+
BRCA	cis	rs1440410	0.835	rs13150694	ENSG00000250326.1	RP11-284M14.1	-6.34	3.32e-10	5.92e-08	-0.21	-0.19	Ischemic stroke;	chr4:143155900	chr4:142933195~143184861:-
BRCA	cis	rs3760982	0.967	rs12463346	ENSG00000267058.1	RP11-15A1.3	-6.34	3.32e-10	5.92e-08	-0.22	-0.19	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43788092	chr19:43891804~43901805:-
BRCA	cis	rs2243480	1	rs313832	ENSG00000232559.3	GS1-124K5.12	6.34	3.33e-10	5.92e-08	0.38	0.19	Diabetic kidney disease;	chr7:66085904	chr7:66554588~66576923:-
BRCA	cis	rs7945705	0.875	rs10769947	ENSG00000254860.4	TMEM9B-AS1	-6.34	3.33e-10	5.92e-08	-0.18	-0.19	Hemoglobin concentration;	chr11:8736567	chr11:8964675~8977527:+
BRCA	cis	rs13113518	0.783	rs13111128	ENSG00000223305.1	RN7SKP30	6.34	3.33e-10	5.92e-08	0.24	0.19	Height;	chr4:55578154	chr4:55540502~55540835:-
BRCA	cis	rs13113518	0.812	rs4865003	ENSG00000223305.1	RN7SKP30	6.34	3.33e-10	5.93e-08	0.24	0.19	Height;	chr4:55514802	chr4:55540502~55540835:-
BRCA	cis	rs13113518	0.756	rs12510275	ENSG00000223305.1	RN7SKP30	6.34	3.33e-10	5.93e-08	0.24	0.19	Height;	chr4:55516548	chr4:55540502~55540835:-
BRCA	cis	rs13113518	0.812	rs12510327	ENSG00000223305.1	RN7SKP30	6.34	3.33e-10	5.93e-08	0.24	0.19	Height;	chr4:55516744	chr4:55540502~55540835:-
BRCA	cis	rs1440410	0.835	rs7685461	ENSG00000250326.1	RP11-284M14.1	-6.34	3.34e-10	5.94e-08	-0.21	-0.19	Ischemic stroke;	chr4:143133730	chr4:142933195~143184861:-
BRCA	cis	rs1440410	0.835	rs10857405	ENSG00000250326.1	RP11-284M14.1	-6.34	3.34e-10	5.94e-08	-0.21	-0.19	Ischemic stroke;	chr4:143134361	chr4:142933195~143184861:-
BRCA	cis	rs1440410	0.798	rs7666785	ENSG00000250326.1	RP11-284M14.1	-6.34	3.34e-10	5.94e-08	-0.21	-0.19	Ischemic stroke;	chr4:143139311	chr4:142933195~143184861:-
BRCA	cis	rs1440410	0.835	rs10004598	ENSG00000250326.1	RP11-284M14.1	-6.34	3.34e-10	5.94e-08	-0.21	-0.19	Ischemic stroke;	chr4:143141264	chr4:142933195~143184861:-
BRCA	cis	rs1440410	0.763	rs9631769	ENSG00000250326.1	RP11-284M14.1	-6.34	3.34e-10	5.94e-08	-0.21	-0.19	Ischemic stroke;	chr4:143144588	chr4:142933195~143184861:-
BRCA	cis	rs1440410	0.835	rs13107465	ENSG00000250326.1	RP11-284M14.1	-6.34	3.34e-10	5.94e-08	-0.21	-0.19	Ischemic stroke;	chr4:143147664	chr4:142933195~143184861:-
BRCA	cis	rs1440410	0.798	rs4511955	ENSG00000250326.1	RP11-284M14.1	-6.34	3.34e-10	5.94e-08	-0.21	-0.19	Ischemic stroke;	chr4:143149081	chr4:142933195~143184861:-
BRCA	cis	rs1440410	0.798	rs13140643	ENSG00000250326.1	RP11-284M14.1	-6.34	3.34e-10	5.94e-08	-0.21	-0.19	Ischemic stroke;	chr4:143149221	chr4:142933195~143184861:-
BRCA	cis	rs1440410	0.835	rs6817849	ENSG00000250326.1	RP11-284M14.1	-6.34	3.34e-10	5.94e-08	-0.21	-0.19	Ischemic stroke;	chr4:143154848	chr4:142933195~143184861:-
BRCA	cis	rs1440410	0.798	rs10012434	ENSG00000250326.1	RP11-284M14.1	-6.34	3.34e-10	5.94e-08	-0.21	-0.19	Ischemic stroke;	chr4:143156365	chr4:142933195~143184861:-
BRCA	cis	rs1440410	0.835	rs7687417	ENSG00000250326.1	RP11-284M14.1	-6.34	3.34e-10	5.94e-08	-0.21	-0.19	Ischemic stroke;	chr4:143158848	chr4:142933195~143184861:-
BRCA	cis	rs1440410	0.835	rs6537151	ENSG00000250326.1	RP11-284M14.1	-6.34	3.34e-10	5.95e-08	-0.21	-0.19	Ischemic stroke;	chr4:143146753	chr4:142933195~143184861:-
BRCA	cis	rs710913	0.717	rs2243761	ENSG00000237624.1	OXCT2P1	-6.34	3.34e-10	5.95e-08	-0.22	-0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39585944	chr1:39514956~39516490:+
BRCA	cis	rs3764021	0.743	rs7973535	ENSG00000214776.8	RP11-726G1.1	6.34	3.34e-10	5.95e-08	0.21	0.19	Type 1 diabetes;	chr12:9727801	chr12:9467552~9576275:+
BRCA	cis	rs3764021	0.87	rs7973638	ENSG00000214776.8	RP11-726G1.1	6.34	3.34e-10	5.95e-08	0.21	0.19	Type 1 diabetes;	chr12:9727845	chr12:9467552~9576275:+
BRCA	cis	rs494459	0.838	rs555649	ENSG00000278376.1	RP11-158I9.8	-6.34	3.34e-10	5.95e-08	-0.18	-0.19	Height;	chr11:118781100	chr11:118791254~118793137:+
BRCA	cis	rs853679	0.55	rs1237875	ENSG00000204709.4	LINC01556	-6.34	3.35e-10	5.96e-08	-0.27	-0.19	Depression;	chr6:28205232	chr6:28943877~28944537:+
BRCA	cis	rs853679	0.517	rs7755442	ENSG00000280107.1	AL022393.9	-6.34	3.35e-10	5.96e-08	-0.29	-0.19	Depression;	chr6:28071237	chr6:28170845~28172521:+
BRCA	cis	rs853679	0.517	rs55747925	ENSG00000280107.1	AL022393.9	-6.34	3.35e-10	5.96e-08	-0.29	-0.19	Depression;	chr6:28076559	chr6:28170845~28172521:+
BRCA	cis	rs853679	0.517	rs34716816	ENSG00000280107.1	AL022393.9	-6.34	3.35e-10	5.96e-08	-0.29	-0.19	Depression;	chr6:28078391	chr6:28170845~28172521:+
BRCA	cis	rs853679	0.517	rs9380049	ENSG00000280107.1	AL022393.9	-6.34	3.35e-10	5.96e-08	-0.29	-0.19	Depression;	chr6:28080757	chr6:28170845~28172521:+
BRCA	cis	rs853679	0.517	rs9380050	ENSG00000280107.1	AL022393.9	-6.34	3.35e-10	5.96e-08	-0.29	-0.19	Depression;	chr6:28080760	chr6:28170845~28172521:+
BRCA	cis	rs9291683	0.53	rs4697698	ENSG00000250413.1	RP11-448G15.1	-6.34	3.35e-10	5.96e-08	-0.25	-0.19	Bone mineral density;	chr4:9940953	chr4:10006482~10009725:+
BRCA	cis	rs9876781	1	rs1459242	ENSG00000229759.1	MRPS18AP1	-6.34	3.35e-10	5.96e-08	-0.21	-0.19	Longevity;	chr3:48372047	chr3:48256350~48256938:-
BRCA	cis	rs944990	0.686	rs6479485	ENSG00000227603.1	RP11-165J3.6	6.34	3.35e-10	5.96e-08	0.2	0.19	Body mass index;	chr9:93456969	chr9:93435332~93437121:-
BRCA	cis	rs2554380	0.55	rs62025822	ENSG00000230373.7	GOLGA6L5P	6.34	3.36e-10	5.98e-08	0.24	0.19	Height;	chr15:83870162	chr15:84507885~84516814:-
BRCA	cis	rs13113518	0.812	rs2048564	ENSG00000273257.1	RP11-177J6.1	6.34	3.36e-10	5.98e-08	0.25	0.19	Height;	chr4:55407965	chr4:55387949~55388271:+
BRCA	cis	rs1707322	0.717	rs3014246	ENSG00000281133.1	AL355480.3	6.34	3.37e-10	5.99e-08	0.25	0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45620405	chr1:45580892~45580996:-
BRCA	cis	rs7246657	0.943	rs10404920	ENSG00000267422.1	CTD-2554C21.1	-6.34	3.37e-10	5.99e-08	-0.29	-0.19	Coronary artery calcification;	chr19:37390654	chr19:37779686~37792865:+
BRCA	cis	rs2243480	1	rs383402	ENSG00000232546.1	RP11-458F8.1	6.34	3.37e-10	6e-08	0.25	0.19	Diabetic kidney disease;	chr7:66121666	chr7:66848496~66858136:+
BRCA	cis	rs9638182	0.673	rs13221253	ENSG00000274080.1	CTA-315H11.2	6.34	3.37e-10	6e-08	0.38	0.19	Triglycerides;	chr7:73507903	chr7:73609262~73611502:-
BRCA	cis	rs72772090	0.908	rs6864233	ENSG00000248734.2	CTD-2260A17.1	6.34	3.38e-10	6.01e-08	0.27	0.19	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96708977	chr5:96784777~96785999:+
BRCA	cis	rs2281558	0.876	rs12625157	ENSG00000125804.12	FAM182A	-6.34	3.38e-10	6.01e-08	-0.29	-0.19	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25364913	chr20:26054655~26086917:+
BRCA	cis	rs4372836	1	rs2276547	ENSG00000226833.4	AC097724.3	6.34	3.38e-10	6.01e-08	0.24	0.19	Body mass index;	chr2:28752241	chr2:28708953~28736205:-
BRCA	cis	rs34779708	0.966	rs7070427	ENSG00000271335.4	RP11-324I22.4	6.34	3.38e-10	6.02e-08	0.2	0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35196761	chr10:35314552~35336401:-
BRCA	cis	rs2998286	0.723	rs332142	ENSG00000254635.4	WAC-AS1	-6.34	3.38e-10	6.02e-08	-0.28	-0.19	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28575026	chr10:28522652~28532743:-
BRCA	cis	rs2998286	0.723	rs332143	ENSG00000254635.4	WAC-AS1	-6.34	3.38e-10	6.02e-08	-0.28	-0.19	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28575777	chr10:28522652~28532743:-
BRCA	cis	rs2179367	0.632	rs7349921	ENSG00000216906.2	RP11-350J20.9	6.34	3.38e-10	6.02e-08	0.27	0.19	Dupuytren's disease;	chr6:149392727	chr6:149904243~149906418:+
BRCA	cis	rs2179367	0.632	rs60153446	ENSG00000216906.2	RP11-350J20.9	6.34	3.38e-10	6.02e-08	0.27	0.19	Dupuytren's disease;	chr6:149393186	chr6:149904243~149906418:+
BRCA	cis	rs2179367	0.632	rs61259243	ENSG00000216906.2	RP11-350J20.9	6.34	3.38e-10	6.02e-08	0.27	0.19	Dupuytren's disease;	chr6:149393457	chr6:149904243~149906418:+
BRCA	cis	rs2179367	0.632	rs62426115	ENSG00000216906.2	RP11-350J20.9	6.34	3.38e-10	6.02e-08	0.27	0.19	Dupuytren's disease;	chr6:149393718	chr6:149904243~149906418:+
BRCA	cis	rs2179367	0.632	rs68080376	ENSG00000216906.2	RP11-350J20.9	6.34	3.38e-10	6.02e-08	0.27	0.19	Dupuytren's disease;	chr6:149393873	chr6:149904243~149906418:+
BRCA	cis	rs6095360	0.727	rs13036715	ENSG00000222365.1	SNORD12B	-6.34	3.39e-10	6.02e-08	-0.26	-0.19	Intelligence (multi-trait analysis);	chr20:49201278	chr20:49280319~49280409:+
BRCA	cis	rs12468226	1	rs112306637	ENSG00000226261.1	AC064836.3	6.34	3.39e-10	6.03e-08	0.33	0.19	Urate levels;	chr2:202334195	chr2:202336024~202336727:-
BRCA	cis	rs9876781	0.967	rs1870444	ENSG00000229759.1	MRPS18AP1	6.34	3.39e-10	6.03e-08	0.21	0.19	Longevity;	chr3:48445369	chr3:48256350~48256938:-
BRCA	cis	rs6095360	0.7	rs7262349	ENSG00000222365.1	SNORD12B	-6.34	3.39e-10	6.03e-08	-0.25	-0.19	Intelligence (multi-trait analysis);	chr20:49178768	chr20:49280319~49280409:+
BRCA	cis	rs875971	0.862	rs709596	ENSG00000224316.1	RP11-479O9.2	6.34	3.4e-10	6.04e-08	0.19	0.19	Aortic root size;	chr7:66360926	chr7:65773620~65802067:+
BRCA	cis	rs4713118	0.513	rs149959	ENSG00000204709.4	LINC01556	6.34	3.4e-10	6.05e-08	0.26	0.19	Parkinson's disease;	chr6:28046076	chr6:28943877~28944537:+
BRCA	cis	rs7829975	0.582	rs6983150	ENSG00000233609.3	RP11-62H7.2	-6.34	3.41e-10	6.07e-08	-0.18	-0.19	Mood instability;	chr8:8934916	chr8:8961200~8979025:+
BRCA	cis	rs6570726	1	rs373778	ENSG00000235652.6	RP11-545I5.3	6.34	3.41e-10	6.07e-08	0.19	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145552116	chr6:145799409~145886585:+
BRCA	cis	rs8072100	0.713	rs8075058	ENSG00000228782.6	CTD-2026D20.3	6.34	3.42e-10	6.08e-08	0.21	0.19	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47405491	chr17:47450568~47492492:-
BRCA	cis	rs2348418	0.864	rs2137071	ENSG00000247934.4	RP11-967K21.1	6.34	3.42e-10	6.08e-08	0.22	0.19	Lung function (FEV1);Lung function (FVC);	chr12:28563797	chr12:28163298~28190738:-
BRCA	cis	rs2348418	0.864	rs7968563	ENSG00000247934.4	RP11-967K21.1	6.34	3.42e-10	6.08e-08	0.22	0.19	Lung function (FEV1);Lung function (FVC);	chr12:28563844	chr12:28163298~28190738:-
BRCA	cis	rs2348418	0.864	rs2137072	ENSG00000247934.4	RP11-967K21.1	6.34	3.42e-10	6.08e-08	0.22	0.19	Lung function (FEV1);Lung function (FVC);	chr12:28563872	chr12:28163298~28190738:-
BRCA	cis	rs6928977	0.5	rs12211833	ENSG00000231028.7	LINC00271	-6.34	3.42e-10	6.08e-08	-0.21	-0.19	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135629066	chr6:135497801~135716055:+
BRCA	cis	rs17597773	0.527	rs2484698	ENSG00000272823.1	RP11-295M18.6	6.34	3.42e-10	6.09e-08	0.21	0.19	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220912723	chr1:220828676~220829211:-
BRCA	cis	rs2408955	0.501	rs8716	ENSG00000240399.1	RP1-228P16.1	6.34	3.42e-10	6.09e-08	0.22	0.19	Glycated hemoglobin levels;	chr12:48145699	chr12:48054813~48055591:-
BRCA	cis	rs2348418	0.864	rs6487687	ENSG00000247934.4	RP11-967K21.1	6.34	3.42e-10	6.09e-08	0.21	0.19	Lung function (FEV1);Lung function (FVC);	chr12:28558230	chr12:28163298~28190738:-
BRCA	cis	rs7246657	0.943	rs7408563	ENSG00000226686.6	LINC01535	-6.34	3.42e-10	6.09e-08	-0.29	-0.19	Coronary artery calcification;	chr19:37317683	chr19:37251912~37265535:+
BRCA	cis	rs1707322	1	rs1622208	ENSG00000281133.1	AL355480.3	6.34	3.42e-10	6.09e-08	0.25	0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46032703	chr1:45580892~45580996:-
BRCA	cis	rs301901	0.761	rs1533521	ENSG00000250155.1	CTD-2353F22.1	6.34	3.43e-10	6.09e-08	0.22	0.19	Height;	chr5:37540355	chr5:36666214~36725195:-
BRCA	cis	rs6570726	1	rs405622	ENSG00000235652.6	RP11-545I5.3	6.34	3.43e-10	6.1e-08	0.19	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145550761	chr6:145799409~145886585:+
BRCA	cis	rs6570726	1	rs455109	ENSG00000235652.6	RP11-545I5.3	6.34	3.43e-10	6.1e-08	0.19	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145551529	chr6:145799409~145886585:+
BRCA	cis	rs34779708	0.966	rs4934537	ENSG00000271335.4	RP11-324I22.4	6.34	3.43e-10	6.1e-08	0.21	0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35152584	chr10:35314552~35336401:-
BRCA	cis	rs34779708	0.966	rs12784482	ENSG00000271335.4	RP11-324I22.4	6.34	3.43e-10	6.1e-08	0.21	0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35157937	chr10:35314552~35336401:-
BRCA	cis	rs875971	0.895	rs4145009	ENSG00000224316.1	RP11-479O9.2	-6.34	3.44e-10	6.12e-08	-0.2	-0.19	Aortic root size;	chr7:66261628	chr7:65773620~65802067:+
BRCA	cis	rs904251	0.861	rs1757180	ENSG00000204110.6	RP1-153P14.8	-6.34	3.45e-10	6.13e-08	-0.21	-0.19	Cognitive performance;	chr6:37518369	chr6:37507348~37535616:+
BRCA	cis	rs2348418	0.932	rs7136886	ENSG00000247934.4	RP11-967K21.1	6.34	3.46e-10	6.14e-08	0.22	0.19	Lung function (FEV1);Lung function (FVC);	chr12:28460684	chr12:28163298~28190738:-
BRCA	cis	rs2243480	1	rs316322	ENSG00000232559.3	GS1-124K5.12	6.34	3.46e-10	6.15e-08	0.36	0.19	Diabetic kidney disease;	chr7:66146246	chr7:66554588~66576923:-
BRCA	cis	rs9326248	0.53	rs6589576	ENSG00000280143.1	AP000892.6	-6.34	3.46e-10	6.15e-08	-0.27	-0.19	Blood protein levels;	chr11:116865072	chr11:117204967~117210292:+
BRCA	cis	rs2665103	0.632	rs3902959	ENSG00000255769.6	GOLGA2P10	-6.34	3.46e-10	6.15e-08	-0.21	-0.19	Intelligence (multi-trait analysis);	chr15:82252586	chr15:82472993~82513950:-
BRCA	cis	rs5769707	0.609	rs135861	ENSG00000235111.1	RP1-29C18.8	-6.34	3.47e-10	6.16e-08	-0.21	-0.19	Monocyte percentage of white cells;Monocyte count;	chr22:49604470	chr22:49612657~49615716:-
BRCA	cis	rs875971	0.964	rs697969	ENSG00000224316.1	RP11-479O9.2	-6.34	3.47e-10	6.17e-08	-0.19	-0.19	Aortic root size;	chr7:66093491	chr7:65773620~65802067:+
BRCA	cis	rs875971	1	rs1182882	ENSG00000224316.1	RP11-479O9.2	-6.34	3.47e-10	6.17e-08	-0.19	-0.19	Aortic root size;	chr7:66097076	chr7:65773620~65802067:+
BRCA	cis	rs6504622	0.905	rs9898981	ENSG00000262879.4	RP11-156P1.3	6.34	3.47e-10	6.17e-08	0.19	0.19	Orofacial clefts;	chr17:46949349	chr17:46984045~47100323:-
BRCA	cis	rs710913	0.717	rs11206377	ENSG00000237624.1	OXCT2P1	6.34	3.48e-10	6.17e-08	0.22	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39583432	chr1:39514956~39516490:+
BRCA	cis	rs4763879	0.739	rs2114871	ENSG00000256673.1	RP11-599J14.2	6.34	3.48e-10	6.18e-08	0.22	0.19	Type 1 diabetes;	chr12:9676842	chr12:9398355~9414851:-
BRCA	cis	rs4908760	0.864	rs6674832	ENSG00000270282.1	RP5-1115A15.2	6.34	3.48e-10	6.18e-08	0.21	0.19	Vitiligo;	chr1:8631820	chr1:8512653~8513021:+
BRCA	cis	rs2243480	0.803	rs36127118	ENSG00000229886.1	RP5-1132H15.3	6.34	3.48e-10	6.18e-08	0.34	0.19	Diabetic kidney disease;	chr7:66100518	chr7:66025126~66031544:-
BRCA	cis	rs10129255	0.5	rs11627315	ENSG00000224373.3	IGHV4-59	6.34	3.48e-10	6.19e-08	0.11	0.19	Kawasaki disease;	chr14:106802182	chr14:106627249~106627825:-
BRCA	cis	rs11098499	0.954	rs7437420	ENSG00000249244.1	RP11-548H18.2	6.34	3.48e-10	6.19e-08	0.23	0.19	Corneal astigmatism;	chr4:119391748	chr4:119391831~119395335:-
BRCA	cis	rs1823913	0.561	rs60479498	ENSG00000280083.1	RP11-317J9.1	-6.34	3.49e-10	6.19e-08	-0.22	-0.19	Obesity-related traits;	chr2:191275197	chr2:191154118~191156070:-
BRCA	cis	rs651907	0.557	rs13077925	ENSG00000244119.1	PDCL3P4	6.34	3.49e-10	6.2e-08	0.16	0.19	Colorectal cancer;	chr3:101769337	chr3:101712472~101713191:+
BRCA	cis	rs2243480	0.901	rs778687	ENSG00000229886.1	RP5-1132H15.3	6.34	3.49e-10	6.2e-08	0.35	0.19	Diabetic kidney disease;	chr7:66370832	chr7:66025126~66031544:-
BRCA	cis	rs2243480	1	rs778704	ENSG00000229886.1	RP5-1132H15.3	6.34	3.49e-10	6.2e-08	0.35	0.19	Diabetic kidney disease;	chr7:66398480	chr7:66025126~66031544:-
BRCA	cis	rs2243480	0.901	rs778693	ENSG00000229886.1	RP5-1132H15.3	6.34	3.49e-10	6.2e-08	0.35	0.19	Diabetic kidney disease;	chr7:66407358	chr7:66025126~66031544:-
BRCA	cis	rs2243480	1	rs778691	ENSG00000229886.1	RP5-1132H15.3	6.34	3.49e-10	6.2e-08	0.35	0.19	Diabetic kidney disease;	chr7:66408105	chr7:66025126~66031544:-
BRCA	cis	rs2243480	1	rs13235972	ENSG00000229886.1	RP5-1132H15.3	6.34	3.49e-10	6.2e-08	0.35	0.19	Diabetic kidney disease;	chr7:66418618	chr7:66025126~66031544:-
BRCA	cis	rs2243480	1	rs34192067	ENSG00000229886.1	RP5-1132H15.3	6.34	3.49e-10	6.2e-08	0.35	0.19	Diabetic kidney disease;	chr7:66422670	chr7:66025126~66031544:-
BRCA	cis	rs853679	0.517	rs9368555	ENSG00000219392.1	RP1-265C24.5	-6.34	3.49e-10	6.2e-08	-0.29	-0.19	Depression;	chr6:28141189	chr6:28115628~28116551:+
BRCA	cis	rs853679	0.517	rs9393893	ENSG00000219392.1	RP1-265C24.5	-6.34	3.49e-10	6.2e-08	-0.29	-0.19	Depression;	chr6:28141484	chr6:28115628~28116551:+
BRCA	cis	rs4713118	0.581	rs200504	ENSG00000220721.1	OR1F12	6.34	3.5e-10	6.21e-08	0.28	0.19	Parkinson's disease;	chr6:27818042	chr6:28073316~28074233:+
BRCA	cis	rs2638953	0.924	rs10843125	ENSG00000278733.1	RP11-425D17.1	-6.34	3.5e-10	6.22e-08	-0.24	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28198308	chr12:28185625~28186190:-
BRCA	cis	rs2179367	0.632	rs9322179	ENSG00000216906.2	RP11-350J20.9	6.34	3.51e-10	6.22e-08	0.27	0.19	Dupuytren's disease;	chr6:149418664	chr6:149904243~149906418:+
BRCA	cis	rs301901	0.796	rs3941788	ENSG00000250155.1	CTD-2353F22.1	6.34	3.51e-10	6.23e-08	0.22	0.19	Height;	chr5:37498809	chr5:36666214~36725195:-
BRCA	cis	rs3733585	0.805	rs882222	ENSG00000250413.1	RP11-448G15.1	-6.34	3.51e-10	6.23e-08	-0.25	-0.19	Cleft plate (environmental tobacco smoke interaction);	chr4:9979670	chr4:10006482~10009725:+
BRCA	cis	rs9291683	0.53	rs882223	ENSG00000250413.1	RP11-448G15.1	-6.34	3.51e-10	6.23e-08	-0.25	-0.19	Bone mineral density;	chr4:9980001	chr4:10006482~10009725:+
BRCA	cis	rs4950322	0.57	rs72692920	ENSG00000278811.3	LINC00624	6.34	3.51e-10	6.23e-08	0.26	0.19	Protein quantitative trait loci;	chr1:147308501	chr1:147258885~147517875:-
BRCA	cis	rs7923609	0.756	rs6479908	ENSG00000232075.1	MRPL35P2	6.34	3.51e-10	6.24e-08	0.24	0.19	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63573888	chr10:63634317~63634827:-
BRCA	cis	rs853679	0.607	rs200489	ENSG00000220721.1	OR1F12	6.34	3.52e-10	6.24e-08	0.35	0.19	Depression;	chr6:27830479	chr6:28073316~28074233:+
BRCA	cis	rs6688613	1	rs6682062	ENSG00000225171.2	DUTP6	6.34	3.52e-10	6.24e-08	0.23	0.19	Refractive astigmatism;	chr1:166980742	chr1:166868748~166869209:+
BRCA	cis	rs7085104	0.572	rs284857	ENSG00000236937.2	PTGES3P4	-6.34	3.52e-10	6.25e-08	-0.24	-0.19	Immature fraction of reticulocytes;Schizophrenia;	chr10:102814306	chr10:102845595~102845950:+
BRCA	cis	rs9992667	0.955	rs12499028	ENSG00000231160.8	KLF3-AS1	6.34	3.52e-10	6.25e-08	0.24	0.19	Eosinophil percentage of granulocytes;	chr4:38638087	chr4:38612701~38664883:-
BRCA	cis	rs1322639	0.575	rs9294966	ENSG00000261039.2	RP11-417E7.2	-6.34	3.52e-10	6.25e-08	-0.25	-0.19	Pulse pressure;	chr6:169165223	chr6:169175304~169182740:-
BRCA	cis	rs754466	0.651	rs10824582	ENSG00000204049.1	RP11-126H7.4	6.33	3.53e-10	6.26e-08	0.23	0.19	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77843930	chr10:77866875~77869610:+
BRCA	cis	rs77972916	0.505	rs6753197	ENSG00000234936.1	AC010883.5	6.33	3.53e-10	6.26e-08	0.23	0.19	Granulocyte percentage of myeloid white cells;	chr2:43300823	chr2:43229573~43233394:+
BRCA	cis	rs6095360	0.727	rs35393280	ENSG00000222365.1	SNORD12B	-6.33	3.53e-10	6.26e-08	-0.24	-0.19	Intelligence (multi-trait analysis);	chr20:48927097	chr20:49280319~49280409:+
BRCA	cis	rs2348418	0.831	rs7137119	ENSG00000247934.4	RP11-967K21.1	6.33	3.53e-10	6.26e-08	0.21	0.19	Lung function (FEV1);Lung function (FVC);	chr12:28565058	chr12:28163298~28190738:-
BRCA	cis	rs5015933	0.815	rs13297440	ENSG00000232630.1	PRPS1P2	-6.33	3.53e-10	6.27e-08	-0.19	-0.19	Body mass index;	chr9:125324921	chr9:125150653~125151589:+
BRCA	cis	rs11098499	0.863	rs1010739	ENSG00000249244.1	RP11-548H18.2	6.33	3.54e-10	6.27e-08	0.23	0.19	Corneal astigmatism;	chr4:119542316	chr4:119391831~119395335:-
BRCA	cis	rs875971	0.545	rs1796219	ENSG00000273024.4	INTS4P2	6.33	3.54e-10	6.27e-08	0.25	0.19	Aortic root size;	chr7:66645977	chr7:65647864~65715661:+
BRCA	cis	rs6095360	0.7	rs11908024	ENSG00000222365.1	SNORD12B	-6.33	3.54e-10	6.28e-08	-0.24	-0.19	Intelligence (multi-trait analysis);	chr20:49081649	chr20:49280319~49280409:+
BRCA	cis	rs6095360	0.727	rs2075677	ENSG00000222365.1	SNORD12B	-6.33	3.54e-10	6.28e-08	-0.24	-0.19	Intelligence (multi-trait analysis);	chr20:49084487	chr20:49280319~49280409:+
BRCA	cis	rs78456975	0.943	rs10470006	ENSG00000231482.2	AC141930.2	-6.33	3.54e-10	6.29e-08	-0.27	-0.19	Placebo response in major depressive disorder (% change in symptom score);	chr2:1577199	chr2:1572554~1580311:-
BRCA	cis	rs6840360	0.582	rs11732918	ENSG00000270265.1	RP11-731D1.4	-6.33	3.55e-10	6.29e-08	-0.22	-0.19	Intelligence (multi-trait analysis);	chr4:151397893	chr4:151333775~151353224:-
BRCA	cis	rs4950322	0.57	rs113498894	ENSG00000278811.3	LINC00624	6.33	3.55e-10	6.29e-08	0.26	0.19	Protein quantitative trait loci;	chr1:147318880	chr1:147258885~147517875:-
BRCA	cis	rs2732480	0.557	rs2634682	ENSG00000257763.1	OR5BK1P	6.33	3.55e-10	6.3e-08	0.21	0.19	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48339160	chr12:48355792~48356614:-
BRCA	cis	rs1823913	0.599	rs17511445	ENSG00000280083.1	RP11-317J9.1	6.33	3.55e-10	6.3e-08	0.22	0.19	Obesity-related traits;	chr2:191279831	chr2:191154118~191156070:-
BRCA	cis	rs42648	1	rs42648	ENSG00000225498.1	AC002064.5	6.33	3.55e-10	6.3e-08	0.19	0.19	Homocysteine levels;	chr7:90348446	chr7:90312496~90322592:+
BRCA	cis	rs2380205	0.503	rs685852	ENSG00000232807.2	RP11-536K7.3	-6.33	3.55e-10	6.31e-08	-0.2	-0.19	Breast cancer;	chr10:5892654	chr10:5934270~5945900:-
BRCA	cis	rs1124769	0.748	rs72727115	ENSG00000259378.1	DCAF13P3	6.33	3.56e-10	6.32e-08	0.27	0.19	Cognitive performance;	chr15:51082852	chr15:50944663~50945996:+
BRCA	cis	rs6840360	0.582	rs4473638	ENSG00000270265.1	RP11-731D1.4	-6.33	3.56e-10	6.32e-08	-0.22	-0.19	Intelligence (multi-trait analysis);	chr4:151400994	chr4:151333775~151353224:-
BRCA	cis	rs6840360	0.548	rs4254751	ENSG00000270265.1	RP11-731D1.4	-6.33	3.56e-10	6.32e-08	-0.22	-0.19	Intelligence (multi-trait analysis);	chr4:151401419	chr4:151333775~151353224:-
BRCA	cis	rs6840258	1	rs72667752	ENSG00000251411.1	RP11-397E7.4	-6.33	3.56e-10	6.32e-08	-0.26	-0.19	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87018379	chr4:86913266~86914817:-
BRCA	cis	rs6840258	1	rs72667754	ENSG00000251411.1	RP11-397E7.4	-6.33	3.56e-10	6.32e-08	-0.26	-0.19	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87020909	chr4:86913266~86914817:-
BRCA	cis	rs1555322	0.53	rs8122819	ENSG00000279253.1	RP4-614O4.13	-6.33	3.57e-10	6.33e-08	-0.26	-0.19	Attention deficit hyperactivity disorder;	chr20:35293783	chr20:35262727~35264187:-
BRCA	cis	rs2638953	0.849	rs11049388	ENSG00000278733.1	RP11-425D17.1	-6.33	3.57e-10	6.33e-08	-0.25	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28169054	chr12:28185625~28186190:-
BRCA	cis	rs4713118	0.513	rs156739	ENSG00000204709.4	LINC01556	6.33	3.57e-10	6.33e-08	0.26	0.19	Parkinson's disease;	chr6:28045632	chr6:28943877~28944537:+
BRCA	cis	rs13178541	0.81	rs4466158	ENSG00000250378.1	RP11-119J18.1	-6.33	3.57e-10	6.33e-08	-0.27	-0.19	IgG glycosylation;	chr5:135829468	chr5:135812667~135826582:+
BRCA	cis	rs2348418	0.864	rs11049714	ENSG00000247934.4	RP11-967K21.1	6.33	3.57e-10	6.33e-08	0.21	0.19	Lung function (FEV1);Lung function (FVC);	chr12:28561162	chr12:28163298~28190738:-
BRCA	cis	rs2348418	0.864	rs7977817	ENSG00000247934.4	RP11-967K21.1	6.33	3.57e-10	6.33e-08	0.21	0.19	Lung function (FEV1);Lung function (FVC);	chr12:28562549	chr12:28163298~28190738:-
BRCA	cis	rs2348418	0.831	rs7977525	ENSG00000247934.4	RP11-967K21.1	6.33	3.57e-10	6.33e-08	0.21	0.19	Lung function (FEV1);Lung function (FVC);	chr12:28562584	chr12:28163298~28190738:-
BRCA	cis	rs2348418	0.864	rs7977850	ENSG00000247934.4	RP11-967K21.1	6.33	3.57e-10	6.33e-08	0.21	0.19	Lung function (FEV1);Lung function (FVC);	chr12:28562715	chr12:28163298~28190738:-
BRCA	cis	rs2348418	0.864	rs11609924	ENSG00000247934.4	RP11-967K21.1	6.33	3.57e-10	6.33e-08	0.21	0.19	Lung function (FEV1);Lung function (FVC);	chr12:28563197	chr12:28163298~28190738:-
BRCA	cis	rs2239547	0.603	rs17304995	ENSG00000242142.1	SERBP1P3	6.33	3.57e-10	6.34e-08	0.26	0.19	Schizophrenia;	chr3:53036739	chr3:53064283~53065091:-
BRCA	cis	rs875971	0.502	rs6460311	ENSG00000273024.4	INTS4P2	6.33	3.57e-10	6.34e-08	0.24	0.19	Aortic root size;	chr7:66646886	chr7:65647864~65715661:+
BRCA	cis	rs11098499	0.618	rs35265692	ENSG00000249244.1	RP11-548H18.2	6.33	3.58e-10	6.34e-08	0.23	0.19	Corneal astigmatism;	chr4:119403980	chr4:119391831~119395335:-
BRCA	cis	rs228614	0.51	rs223392	ENSG00000251288.2	RP11-10L12.2	-6.33	3.58e-10	6.35e-08	-0.23	-0.19	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102824599	chr4:102751401~102752641:+
BRCA	cis	rs7238033	0.624	rs7230298	ENSG00000267193.4	RP11-116O18.3	-6.33	3.58e-10	6.35e-08	-0.2	-0.19	Bladder cancer;	chr18:45732554	chr18:45669367~45747215:-
BRCA	cis	rs853679	0.55	rs1233699	ENSG00000204709.4	LINC01556	6.33	3.58e-10	6.35e-08	0.27	0.19	Depression;	chr6:28201380	chr6:28943877~28944537:+
BRCA	cis	rs2348418	0.798	rs4930826	ENSG00000247934.4	RP11-967K21.1	6.33	3.59e-10	6.36e-08	0.22	0.19	Lung function (FEV1);Lung function (FVC);	chr12:28574385	chr12:28163298~28190738:-
BRCA	cis	rs875971	1	rs1544549	ENSG00000224316.1	RP11-479O9.2	-6.33	3.59e-10	6.36e-08	-0.2	-0.19	Aortic root size;	chr7:66625676	chr7:65773620~65802067:+
BRCA	cis	rs853679	0.599	rs149943	ENSG00000220721.1	OR1F12	6.33	3.59e-10	6.37e-08	0.35	0.19	Depression;	chr6:28034610	chr6:28073316~28074233:+
BRCA	cis	rs2489715	0.951	rs2489718	ENSG00000185904.10	LINC00839	-6.33	3.59e-10	6.37e-08	-0.27	-0.19	Helix rolling;	chr10:42423490	chr10:42475543~42495336:+
BRCA	cis	rs1124769	0.625	rs12591735	ENSG00000259378.1	DCAF13P3	6.33	3.59e-10	6.37e-08	0.27	0.19	Cognitive performance;	chr15:51100089	chr15:50944663~50945996:+
BRCA	cis	rs3743162	0.553	rs4842994	ENSG00000225151.9	GOLGA2P7	6.33	3.6e-10	6.37e-08	0.26	0.19	Alzheimer's disease (age of onset);	chr15:84872568	chr15:84199311~84230136:-
BRCA	cis	rs2554380	0.55	rs62025825	ENSG00000230373.7	GOLGA6L5P	6.33	3.6e-10	6.38e-08	0.24	0.19	Height;	chr15:83872285	chr15:84507885~84516814:-
BRCA	cis	rs4950322	0.57	rs72692963	ENSG00000278811.3	LINC00624	6.33	3.6e-10	6.38e-08	0.26	0.19	Protein quantitative trait loci;	chr1:147331090	chr1:147258885~147517875:-
BRCA	cis	rs4950322	0.518	rs72692965	ENSG00000278811.3	LINC00624	6.33	3.6e-10	6.38e-08	0.26	0.19	Protein quantitative trait loci;	chr1:147332085	chr1:147258885~147517875:-
BRCA	cis	rs4950322	0.518	rs72692968	ENSG00000278811.3	LINC00624	6.33	3.6e-10	6.38e-08	0.26	0.19	Protein quantitative trait loci;	chr1:147332884	chr1:147258885~147517875:-
BRCA	cis	rs4950322	0.518	rs72692970	ENSG00000278811.3	LINC00624	6.33	3.6e-10	6.38e-08	0.26	0.19	Protein quantitative trait loci;	chr1:147332887	chr1:147258885~147517875:-
BRCA	cis	rs4950322	0.57	rs72692971	ENSG00000278811.3	LINC00624	6.33	3.6e-10	6.38e-08	0.26	0.19	Protein quantitative trait loci;	chr1:147333088	chr1:147258885~147517875:-
BRCA	cis	rs4950322	0.57	rs72692973	ENSG00000278811.3	LINC00624	6.33	3.6e-10	6.38e-08	0.26	0.19	Protein quantitative trait loci;	chr1:147333281	chr1:147258885~147517875:-
BRCA	cis	rs4950322	0.57	rs72692975	ENSG00000278811.3	LINC00624	6.33	3.6e-10	6.38e-08	0.26	0.19	Protein quantitative trait loci;	chr1:147333506	chr1:147258885~147517875:-
BRCA	cis	rs6951245	0.744	rs10265758	ENSG00000229043.2	AC091729.9	-6.33	3.6e-10	6.39e-08	-0.32	-0.19	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1132882	chr7:1160374~1165267:+
BRCA	cis	rs2638953	0.924	rs11049439	ENSG00000278733.1	RP11-425D17.1	-6.33	3.6e-10	6.39e-08	-0.24	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28196369	chr12:28185625~28186190:-
BRCA	cis	rs9880211	0.8	rs13433683	ENSG00000273486.1	RP11-731C17.2	-6.33	3.6e-10	6.39e-08	-0.26	-0.19	Height;Body mass index;	chr3:136799828	chr3:136837338~136839021:-
BRCA	cis	rs9291683	0.53	rs11723970	ENSG00000250413.1	RP11-448G15.1	-6.33	3.61e-10	6.39e-08	-0.25	-0.19	Bone mineral density;	chr4:9978838	chr4:10006482~10009725:+
BRCA	cis	rs7246657	0.943	rs1035479	ENSG00000226686.6	LINC01535	6.33	3.61e-10	6.39e-08	0.28	0.19	Coronary artery calcification;	chr19:37402398	chr19:37251912~37265535:+
BRCA	cis	rs651907	0.557	rs36002990	ENSG00000244119.1	PDCL3P4	6.33	3.61e-10	6.39e-08	0.16	0.19	Colorectal cancer;	chr3:101719018	chr3:101712472~101713191:+
BRCA	cis	rs651907	0.557	rs11720745	ENSG00000244119.1	PDCL3P4	6.33	3.61e-10	6.39e-08	0.16	0.19	Colorectal cancer;	chr3:101722846	chr3:101712472~101713191:+
BRCA	cis	rs651907	0.557	rs35117343	ENSG00000244119.1	PDCL3P4	6.33	3.61e-10	6.39e-08	0.16	0.19	Colorectal cancer;	chr3:101726282	chr3:101712472~101713191:+
BRCA	cis	rs8002861	0.664	rs1466005	ENSG00000274001.1	RP11-5G9.5	6.33	3.61e-10	6.4e-08	0.23	0.19	Leprosy;	chr13:43850074	chr13:43877715~43878163:-
BRCA	cis	rs7086627	0.515	rs7078254	ENSG00000226659.1	RP11-137H2.4	-6.33	3.61e-10	6.4e-08	-0.25	-0.19	Post bronchodilator FEV1;	chr10:80452437	chr10:80529597~80535942:-
BRCA	cis	rs2348418	0.831	rs1581074	ENSG00000247934.4	RP11-967K21.1	6.33	3.61e-10	6.4e-08	0.22	0.19	Lung function (FEV1);Lung function (FVC);	chr12:28571031	chr12:28163298~28190738:-
BRCA	cis	rs875971	1	rs778706	ENSG00000224316.1	RP11-479O9.2	6.33	3.61e-10	6.4e-08	0.19	0.19	Aortic root size;	chr7:66395437	chr7:65773620~65802067:+
BRCA	cis	rs1707322	1	rs1707303	ENSG00000281133.1	AL355480.3	6.33	3.61e-10	6.4e-08	0.25	0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46132601	chr1:45580892~45580996:-
BRCA	cis	rs2115630	1	rs2879828	ENSG00000229212.6	RP11-561C5.4	6.33	3.62e-10	6.41e-08	0.21	0.19	P wave terminal force;	chr15:84818746	chr15:85205440~85234795:-
BRCA	cis	rs7688540	0.723	rs7687112	ENSG00000211553.1	AC253576.2	-6.33	3.62e-10	6.41e-08	-0.28	-0.19	Facial morphology (factor 6, height of vermillion lower lip);	chr4:249767	chr4:136461~136568:+
BRCA	cis	rs34779708	0.966	rs11010135	ENSG00000271335.4	RP11-324I22.4	6.33	3.62e-10	6.42e-08	0.21	0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35229135	chr10:35314552~35336401:-
BRCA	cis	rs1552244	0.882	rs13064570	ENSG00000180385.7	EMC3-AS1	6.33	3.63e-10	6.43e-08	0.24	0.19	Alzheimer's disease;	chr3:9955861	chr3:9986893~10006990:+
BRCA	cis	rs6723226	0.572	rs176411	ENSG00000276334.1	AL133243.1	6.33	3.64e-10	6.44e-08	0.23	0.19	Intelligence (multi-trait analysis);	chr2:32418460	chr2:32521927~32523547:+
BRCA	cis	rs4713118	0.824	rs13211701	ENSG00000220721.1	OR1F12	6.33	3.64e-10	6.45e-08	0.24	0.19	Parkinson's disease;	chr6:27782300	chr6:28073316~28074233:+
BRCA	cis	rs4713118	0.824	rs9468229	ENSG00000220721.1	OR1F12	6.33	3.64e-10	6.45e-08	0.24	0.19	Parkinson's disease;	chr6:27782307	chr6:28073316~28074233:+
BRCA	cis	rs42490	1	rs431264	ENSG00000251136.7	RP11-37B2.1	-6.33	3.64e-10	6.45e-08	-0.18	-0.19	Leprosy;	chr8:89765282	chr8:89609409~89757727:-
BRCA	cis	rs16958440	0.867	rs12386076	ENSG00000267800.1	RP11-49K24.5	-6.33	3.64e-10	6.45e-08	-0.45	-0.19	Sitting height ratio;	chr18:47146969	chr18:47137018~47137290:+
BRCA	cis	rs202072	0.872	rs375661	ENSG00000272379.1	RP1-257A7.5	6.33	3.65e-10	6.47e-08	0.26	0.19	HIV-1 viral setpoint;	chr6:13279199	chr6:13290018~13290490:-
BRCA	cis	rs651907	0.535	rs13085776	ENSG00000244119.1	PDCL3P4	6.33	3.65e-10	6.47e-08	0.16	0.19	Colorectal cancer;	chr3:101786663	chr3:101712472~101713191:+
BRCA	cis	rs67311347	0.868	rs10865895	ENSG00000280739.1	EIF1B-AS1	6.33	3.65e-10	6.47e-08	0.22	0.19	Renal cell carcinoma;	chr3:40337186	chr3:40173145~40309698:-
BRCA	cis	rs6840258	0.825	rs79998318	ENSG00000251411.1	RP11-397E7.4	-6.33	3.65e-10	6.47e-08	-0.26	-0.19	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87033014	chr4:86913266~86914817:-
BRCA	cis	rs4948102	0.667	rs7811270	ENSG00000273720.1	RP11-613E4.4	-6.33	3.65e-10	6.47e-08	-0.24	-0.19	Plasma homocysteine levels (post-methionine load test);	chr7:56072297	chr7:55743073~55743457:+
BRCA	cis	rs73193808	1	rs2832249	ENSG00000215533.7	LINC00189	-6.33	3.66e-10	6.47e-08	-0.27	-0.19	Coronary artery disease;	chr21:29185330	chr21:29193480~29288205:+
BRCA	cis	rs2243480	1	rs1039664	ENSG00000228409.4	CCT6P1	6.33	3.66e-10	6.48e-08	0.26	0.19	Diabetic kidney disease;	chr7:65984729	chr7:65751142~65763354:+
BRCA	cis	rs17772222	0.74	rs61984675	ENSG00000258983.2	RP11-507K2.2	6.33	3.66e-10	6.48e-08	0.2	0.19	Coronary artery calcification;	chr14:88511236	chr14:88499334~88515502:+
BRCA	cis	rs875971	0.895	rs7788984	ENSG00000224316.1	RP11-479O9.2	6.33	3.66e-10	6.48e-08	0.19	0.19	Aortic root size;	chr7:66450629	chr7:65773620~65802067:+
BRCA	cis	rs11096990	0.964	rs11096987	ENSG00000249207.1	RP11-360F5.1	6.33	3.66e-10	6.49e-08	0.22	0.19	Cognitive function;	chr4:39257570	chr4:39112677~39126818:-
BRCA	cis	rs1823913	0.599	rs34262638	ENSG00000280083.1	RP11-317J9.1	-6.33	3.66e-10	6.49e-08	-0.22	-0.19	Obesity-related traits;	chr2:191279442	chr2:191154118~191156070:-
BRCA	cis	rs7829975	0.624	rs7823056	ENSG00000254153.1	CTA-398F10.2	6.33	3.67e-10	6.49e-08	0.23	0.19	Mood instability;	chr8:8525195	chr8:8456909~8461337:-
BRCA	cis	rs17772222	0.696	rs28666030	ENSG00000258983.2	RP11-507K2.2	6.33	3.67e-10	6.49e-08	0.21	0.19	Coronary artery calcification;	chr14:88511463	chr14:88499334~88515502:+
BRCA	cis	rs17772222	0.74	rs28493481	ENSG00000258983.2	RP11-507K2.2	6.33	3.67e-10	6.49e-08	0.21	0.19	Coronary artery calcification;	chr14:88511491	chr14:88499334~88515502:+
BRCA	cis	rs17253792	0.822	rs10148983	ENSG00000186615.9	KTN1-AS1	-6.33	3.67e-10	6.5e-08	-0.37	-0.19	Putamen volume;	chr14:55585161	chr14:55499278~55580110:-
BRCA	cis	rs10515750	0.588	rs62390102	ENSG00000248544.2	CTB-47B11.3	6.33	3.67e-10	6.5e-08	0.28	0.19	Lung function (FEV1/FVC);	chr5:157354934	chr5:157375741~157384950:-
BRCA	cis	rs2243480	0.901	rs57126451	ENSG00000228409.4	CCT6P1	6.33	3.67e-10	6.5e-08	0.26	0.19	Diabetic kidney disease;	chr7:65951319	chr7:65751142~65763354:+
BRCA	cis	rs4908760	0.832	rs11121209	ENSG00000270282.1	RP5-1115A15.2	6.33	3.68e-10	6.51e-08	0.21	0.19	Vitiligo;	chr1:8626803	chr1:8512653~8513021:+
BRCA	cis	rs516805	0.52	rs9388099	ENSG00000279453.1	RP3-425C14.4	6.33	3.68e-10	6.52e-08	0.21	0.19	Lymphocyte counts;	chr6:122566904	chr6:122436789~122439223:-
BRCA	cis	rs2732480	0.557	rs2732441	ENSG00000257763.1	OR5BK1P	6.33	3.69e-10	6.53e-08	0.21	0.19	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48329541	chr12:48355792~48356614:-
BRCA	cis	rs2732480	0.577	rs2732448	ENSG00000257763.1	OR5BK1P	6.33	3.69e-10	6.53e-08	0.21	0.19	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48336817	chr12:48355792~48356614:-
BRCA	cis	rs2638953	0.924	rs11049417	ENSG00000278733.1	RP11-425D17.1	-6.33	3.69e-10	6.53e-08	-0.24	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28192152	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.924	rs12372059	ENSG00000278733.1	RP11-425D17.1	-6.33	3.69e-10	6.53e-08	-0.24	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28192370	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.924	rs12372073	ENSG00000278733.1	RP11-425D17.1	-6.33	3.69e-10	6.53e-08	-0.24	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28192462	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.924	rs56318627	ENSG00000278733.1	RP11-425D17.1	-6.33	3.69e-10	6.53e-08	-0.24	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28192719	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.814	rs11049419	ENSG00000278733.1	RP11-425D17.1	-6.33	3.69e-10	6.53e-08	-0.24	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28192951	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.85	rs11049420	ENSG00000278733.1	RP11-425D17.1	-6.33	3.69e-10	6.53e-08	-0.24	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28193179	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.744	rs11049421	ENSG00000278733.1	RP11-425D17.1	-6.33	3.69e-10	6.53e-08	-0.24	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28193324	chr12:28185625~28186190:-
BRCA	cis	rs1823913	0.599	rs2124093	ENSG00000280083.1	RP11-317J9.1	-6.33	3.7e-10	6.54e-08	-0.22	-0.19	Obesity-related traits;	chr2:191288280	chr2:191154118~191156070:-
BRCA	cis	rs875971	0.522	rs1701760	ENSG00000234585.5	CCT6P3	6.33	3.7e-10	6.54e-08	0.18	0.19	Aortic root size;	chr7:66008701	chr7:65038354~65074713:+
BRCA	cis	rs4372836	0.796	rs7580078	ENSG00000226833.4	AC097724.3	6.33	3.7e-10	6.55e-08	0.24	0.19	Body mass index;	chr2:28774135	chr2:28708953~28736205:-
BRCA	cis	rs867371	0.82	rs7164362	ENSG00000259429.4	UBE2Q2P2	-6.33	3.7e-10	6.55e-08	-0.19	-0.19	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82194401	chr15:82355142~82420075:+
BRCA	cis	rs1552244	0.882	rs6443279	ENSG00000180385.7	EMC3-AS1	6.33	3.7e-10	6.55e-08	0.24	0.19	Alzheimer's disease;	chr3:10011915	chr3:9986893~10006990:+
BRCA	cis	rs7630852	0.841	rs9325377	ENSG00000272359.1	U4	-6.33	3.71e-10	6.56e-08	-0.23	-0.19	Eosinophil counts;	chr3:196779282	chr3:196747192~196747324:-
BRCA	cis	rs6840258	1	rs75550773	ENSG00000251411.1	RP11-397E7.4	-6.33	3.71e-10	6.57e-08	-0.26	-0.19	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87034271	chr4:86913266~86914817:-
BRCA	cis	rs673078	0.66	rs76842574	ENSG00000275409.1	RP11-131L12.4	-6.33	3.72e-10	6.57e-08	-0.24	-0.19	Glucose homeostasis traits;	chr12:118371789	chr12:118430147~118430699:+
BRCA	cis	rs8031584	0.918	rs11639169	ENSG00000260382.1	RP11-540B6.2	6.33	3.72e-10	6.57e-08	0.24	0.19	Huntington's disease progression;	chr15:30963235	chr15:30882267~30883231:-
BRCA	cis	rs13108904	0.775	rs2279282	ENSG00000254094.1	AC078852.1	-6.33	3.73e-10	6.59e-08	-0.21	-0.19	Obesity-related traits;	chr4:1222245	chr4:1356581~1358075:+
BRCA	cis	rs2378497	1	rs2800860	ENSG00000232679.1	RP11-400N13.3	6.33	3.73e-10	6.59e-08	0.25	0.19	Serum thyroid-stimulating hormone levels;	chr1:222009884	chr1:222041705~222064763:-
BRCA	cis	rs11671005	0.736	rs11668201	ENSG00000252334.1	RNU6-1337P	6.33	3.73e-10	6.6e-08	0.29	0.19	Mean platelet volume;	chr19:58492265	chr19:58483749~58483843:-
BRCA	cis	rs9876781	1	rs6442117	ENSG00000229759.1	MRPS18AP1	-6.33	3.73e-10	6.61e-08	-0.21	-0.19	Longevity;	chr3:48378407	chr3:48256350~48256938:-
BRCA	cis	rs6095360	0.689	rs7274851	ENSG00000222365.1	SNORD12B	-6.33	3.73e-10	6.61e-08	-0.25	-0.19	Intelligence (multi-trait analysis);	chr20:49177818	chr20:49280319~49280409:+
BRCA	cis	rs7246657	1	rs1823061	ENSG00000226686.6	LINC01535	-6.33	3.74e-10	6.61e-08	-0.29	-0.19	Coronary artery calcification;	chr19:37309724	chr19:37251912~37265535:+
BRCA	cis	rs875971	0.928	rs2036263	ENSG00000224316.1	RP11-479O9.2	-6.33	3.74e-10	6.61e-08	-0.19	-0.19	Aortic root size;	chr7:66335210	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.862	rs10240949	ENSG00000224316.1	RP11-479O9.2	-6.33	3.74e-10	6.61e-08	-0.19	-0.19	Aortic root size;	chr7:66339430	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.862	rs7782704	ENSG00000224316.1	RP11-479O9.2	-6.33	3.74e-10	6.61e-08	-0.19	-0.19	Aortic root size;	chr7:66340379	chr7:65773620~65802067:+
BRCA	cis	rs9638182	0.725	rs2074755	ENSG00000274080.1	CTA-315H11.2	-6.33	3.74e-10	6.61e-08	-0.4	-0.19	Triglycerides;	chr7:73462836	chr7:73609262~73611502:-
BRCA	cis	rs8114671	0.967	rs1415774	ENSG00000269202.1	RP4-614O4.12	6.33	3.74e-10	6.62e-08	0.2	0.19	Height;	chr20:35177813	chr20:35201747~35203288:-
BRCA	cis	rs801193	0.613	rs2659900	ENSG00000224316.1	RP11-479O9.2	6.33	3.74e-10	6.62e-08	0.19	0.19	Aortic root size;	chr7:66719456	chr7:65773620~65802067:+
BRCA	cis	rs42490	1	rs42490	ENSG00000251136.7	RP11-37B2.1	-6.33	3.74e-10	6.62e-08	-0.18	-0.19	Leprosy;	chr8:89766285	chr8:89609409~89757727:-
BRCA	cis	rs6095360	0.674	rs7269912	ENSG00000222365.1	SNORD12B	-6.33	3.74e-10	6.62e-08	-0.24	-0.19	Intelligence (multi-trait analysis);	chr20:49039661	chr20:49280319~49280409:+
BRCA	cis	rs6570726	0.967	rs9497316	ENSG00000235652.6	RP11-545I5.3	-6.33	3.74e-10	6.62e-08	-0.19	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145471251	chr6:145799409~145886585:+
BRCA	cis	rs875971	0.862	rs6959268	ENSG00000224316.1	RP11-479O9.2	-6.33	3.75e-10	6.63e-08	-0.19	-0.19	Aortic root size;	chr7:66347979	chr7:65773620~65802067:+
BRCA	cis	rs2348418	0.932	rs11049662	ENSG00000247934.4	RP11-967K21.1	6.33	3.75e-10	6.63e-08	0.22	0.19	Lung function (FEV1);Lung function (FVC);	chr12:28487344	chr12:28163298~28190738:-
BRCA	cis	rs2348418	0.932	rs7306581	ENSG00000247934.4	RP11-967K21.1	6.33	3.75e-10	6.63e-08	0.22	0.19	Lung function (FEV1);Lung function (FVC);	chr12:28488641	chr12:28163298~28190738:-
BRCA	cis	rs2243480	0.764	rs2460423	ENSG00000232559.3	GS1-124K5.12	6.32	3.75e-10	6.64e-08	0.37	0.19	Diabetic kidney disease;	chr7:66136229	chr7:66554588~66576923:-
BRCA	cis	rs4908760	0.73	rs10779704	ENSG00000270282.1	RP5-1115A15.2	6.32	3.75e-10	6.64e-08	0.21	0.19	Vitiligo;	chr1:8633478	chr1:8512653~8513021:+
BRCA	cis	rs17301013	0.507	rs72715262	ENSG00000227373.4	RP11-160H22.5	6.32	3.76e-10	6.64e-08	0.3	0.19	Systemic lupus erythematosus;	chr1:174607088	chr1:174115300~174160004:-
BRCA	cis	rs919433	0.726	rs11904247	ENSG00000231621.1	AC013264.2	-6.32	3.76e-10	6.65e-08	-0.19	-0.19	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197373700	chr2:197197991~197199273:+
BRCA	cis	rs4950322	0.515	rs76327075	ENSG00000278811.3	LINC00624	6.32	3.76e-10	6.65e-08	0.25	0.19	Protein quantitative trait loci;	chr1:147246319	chr1:147258885~147517875:-
BRCA	cis	rs7617773	0.78	rs36121690	ENSG00000228638.1	FCF1P2	-6.32	3.77e-10	6.66e-08	-0.22	-0.19	Coronary artery disease;	chr3:48304021	chr3:48290793~48291375:-
BRCA	cis	rs1552244	0.882	rs36006511	ENSG00000180385.7	EMC3-AS1	6.32	3.77e-10	6.66e-08	0.24	0.19	Alzheimer's disease;	chr3:10012507	chr3:9986893~10006990:+
BRCA	cis	rs2243480	1	rs35058610	ENSG00000228409.4	CCT6P1	6.32	3.77e-10	6.67e-08	0.26	0.19	Diabetic kidney disease;	chr7:65925938	chr7:65751142~65763354:+
BRCA	cis	rs2243480	1	rs1546059	ENSG00000229886.1	RP5-1132H15.3	-6.32	3.77e-10	6.67e-08	-0.34	-0.19	Diabetic kidney disease;	chr7:66189722	chr7:66025126~66031544:-
BRCA	cis	rs2243480	1	rs2420170	ENSG00000229886.1	RP5-1132H15.3	-6.32	3.77e-10	6.67e-08	-0.34	-0.19	Diabetic kidney disease;	chr7:66191066	chr7:66025126~66031544:-
BRCA	cis	rs6479891	0.818	rs9415700	ENSG00000232075.1	MRPL35P2	6.32	3.78e-10	6.68e-08	0.35	0.19	Arthritis (juvenile idiopathic);	chr10:63385805	chr10:63634317~63634827:-
BRCA	cis	rs6479891	1	rs9415701	ENSG00000232075.1	MRPL35P2	6.32	3.78e-10	6.68e-08	0.35	0.19	Arthritis (juvenile idiopathic);	chr10:63391749	chr10:63634317~63634827:-
BRCA	cis	rs721917	0.506	rs2819098	ENSG00000244733.5	RP11-506M13.3	-6.32	3.78e-10	6.69e-08	-0.23	-0.19	Chronic obstructive pulmonary disease;	chr10:79938341	chr10:79660891~79677996:+
BRCA	cis	rs2243480	1	rs464895	ENSG00000232546.1	RP11-458F8.1	-6.32	3.78e-10	6.69e-08	-0.27	-0.19	Diabetic kidney disease;	chr7:66062119	chr7:66848496~66858136:+
BRCA	cis	rs2243480	1	rs160633	ENSG00000232546.1	RP11-458F8.1	-6.32	3.78e-10	6.69e-08	-0.27	-0.19	Diabetic kidney disease;	chr7:66063241	chr7:66848496~66858136:+
BRCA	cis	rs7927771	0.524	rs10742820	ENSG00000280615.1	Y_RNA	-6.32	3.79e-10	6.69e-08	-0.22	-0.19	Subjective well-being;	chr11:47759505	chr11:47614898~47614994:-
BRCA	cis	rs2239547	0.603	rs59989280	ENSG00000242142.1	SERBP1P3	6.32	3.79e-10	6.7e-08	0.24	0.19	Schizophrenia;	chr3:53064859	chr3:53064283~53065091:-
BRCA	cis	rs2239547	0.603	rs6789219	ENSG00000242142.1	SERBP1P3	6.32	3.79e-10	6.7e-08	0.24	0.19	Schizophrenia;	chr3:53064922	chr3:53064283~53065091:-
BRCA	cis	rs651907	0.557	rs11914318	ENSG00000244119.1	PDCL3P4	6.32	3.79e-10	6.7e-08	0.16	0.19	Colorectal cancer;	chr3:101735014	chr3:101712472~101713191:+
BRCA	cis	rs7945705	0.846	rs905290	ENSG00000254860.4	TMEM9B-AS1	-6.32	3.79e-10	6.7e-08	-0.19	-0.19	Hemoglobin concentration;	chr11:8732182	chr11:8964675~8977527:+
BRCA	cis	rs17301013	0.507	rs17842156	ENSG00000227373.4	RP11-160H22.5	6.32	3.79e-10	6.71e-08	0.29	0.19	Systemic lupus erythematosus;	chr1:174715050	chr1:174115300~174160004:-
BRCA	cis	rs853679	0.517	rs4713150	ENSG00000204709.4	LINC01556	6.32	3.8e-10	6.71e-08	0.29	0.19	Depression;	chr6:28168434	chr6:28943877~28944537:+
BRCA	cis	rs4713118	0.527	rs4713151	ENSG00000204709.4	LINC01556	6.32	3.8e-10	6.71e-08	0.29	0.19	Parkinson's disease;	chr6:28168578	chr6:28943877~28944537:+
BRCA	cis	rs853679	0.517	rs9393901	ENSG00000204709.4	LINC01556	6.32	3.8e-10	6.71e-08	0.29	0.19	Depression;	chr6:28169019	chr6:28943877~28944537:+
BRCA	cis	rs853679	0.517	rs3173443	ENSG00000204709.4	LINC01556	6.32	3.8e-10	6.71e-08	0.29	0.19	Depression;	chr6:28169249	chr6:28943877~28944537:+
BRCA	cis	rs853679	0.517	rs4713152	ENSG00000204709.4	LINC01556	6.32	3.8e-10	6.71e-08	0.29	0.19	Depression;	chr6:28169676	chr6:28943877~28944537:+
BRCA	cis	rs853679	0.517	rs9348797	ENSG00000204709.4	LINC01556	6.32	3.8e-10	6.71e-08	0.29	0.19	Depression;	chr6:28169755	chr6:28943877~28944537:+
BRCA	cis	rs853679	0.517	rs9380062	ENSG00000204709.4	LINC01556	6.32	3.8e-10	6.71e-08	0.29	0.19	Depression;	chr6:28169791	chr6:28943877~28944537:+
BRCA	cis	rs853679	0.542	rs9380063	ENSG00000204709.4	LINC01556	6.32	3.8e-10	6.71e-08	0.29	0.19	Depression;	chr6:28170075	chr6:28943877~28944537:+
BRCA	cis	rs875971	0.895	rs12531677	ENSG00000224316.1	RP11-479O9.2	-6.32	3.8e-10	6.71e-08	-0.2	-0.19	Aortic root size;	chr7:66304099	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.862	rs7798630	ENSG00000224316.1	RP11-479O9.2	-6.32	3.8e-10	6.71e-08	-0.2	-0.19	Aortic root size;	chr7:66306492	chr7:65773620~65802067:+
BRCA	cis	rs16958440	0.867	rs79078752	ENSG00000267800.1	RP11-49K24.5	-6.32	3.8e-10	6.71e-08	-0.45	-0.19	Sitting height ratio;	chr18:47141091	chr18:47137018~47137290:+
BRCA	cis	rs16958440	0.867	rs61689863	ENSG00000267800.1	RP11-49K24.5	-6.32	3.8e-10	6.71e-08	-0.45	-0.19	Sitting height ratio;	chr18:47142786	chr18:47137018~47137290:+
BRCA	cis	rs16958440	0.867	rs80064497	ENSG00000267800.1	RP11-49K24.5	-6.32	3.8e-10	6.71e-08	-0.45	-0.19	Sitting height ratio;	chr18:47143282	chr18:47137018~47137290:+
BRCA	cis	rs16958440	0.867	rs78547658	ENSG00000267800.1	RP11-49K24.5	-6.32	3.8e-10	6.71e-08	-0.45	-0.19	Sitting height ratio;	chr18:47143481	chr18:47137018~47137290:+
BRCA	cis	rs16958440	0.867	rs12386092	ENSG00000267800.1	RP11-49K24.5	-6.32	3.8e-10	6.71e-08	-0.45	-0.19	Sitting height ratio;	chr18:47145687	chr18:47137018~47137290:+
BRCA	cis	rs875971	0.862	rs11984115	ENSG00000224316.1	RP11-479O9.2	-6.32	3.8e-10	6.72e-08	-0.2	-0.19	Aortic root size;	chr7:66308872	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.545	rs67775320	ENSG00000273024.4	INTS4P2	-6.32	3.8e-10	6.72e-08	-0.24	-0.19	Aortic root size;	chr7:66193792	chr7:65647864~65715661:+
BRCA	cis	rs12468226	0.938	rs12463937	ENSG00000226261.1	AC064836.3	6.32	3.8e-10	6.72e-08	0.33	0.19	Urate levels;	chr2:202246543	chr2:202336024~202336727:-
BRCA	cis	rs17264034	0.5	rs10475468	ENSG00000250786.1	SNHG18	-6.32	3.8e-10	6.72e-08	-0.23	-0.19	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9538645	chr5:9546200~9550609:+
BRCA	cis	rs7829975	0.593	rs2979241	ENSG00000254153.1	CTA-398F10.2	6.32	3.81e-10	6.74e-08	0.24	0.19	Mood instability;	chr8:8445843	chr8:8456909~8461337:-
BRCA	cis	rs13113518	0.812	rs12505880	ENSG00000273257.1	RP11-177J6.1	6.32	3.81e-10	6.74e-08	0.24	0.19	Height;	chr4:55440988	chr4:55387949~55388271:+
BRCA	cis	rs2243480	1	rs313832	ENSG00000230295.1	RP11-458F8.2	-6.32	3.82e-10	6.74e-08	-0.27	-0.19	Diabetic kidney disease;	chr7:66085904	chr7:66880708~66882981:+
BRCA	cis	rs8031584	0.918	rs1425292	ENSG00000260382.1	RP11-540B6.2	6.32	3.82e-10	6.74e-08	0.23	0.19	Huntington's disease progression;	chr15:30993219	chr15:30882267~30883231:-
BRCA	cis	rs7914558	0.752	rs7896519	ENSG00000236937.2	PTGES3P4	6.32	3.82e-10	6.75e-08	0.25	0.19	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103107106	chr10:102845595~102845950:+
BRCA	cis	rs1707322	0.686	rs2275085	ENSG00000281133.1	AL355480.3	6.32	3.82e-10	6.75e-08	0.25	0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45620180	chr1:45580892~45580996:-
BRCA	cis	rs2243480	1	rs316326	ENSG00000232559.3	GS1-124K5.12	6.32	3.83e-10	6.76e-08	0.36	0.19	Diabetic kidney disease;	chr7:66144466	chr7:66554588~66576923:-
BRCA	cis	rs2243480	1	rs316325	ENSG00000232559.3	GS1-124K5.12	6.32	3.83e-10	6.76e-08	0.36	0.19	Diabetic kidney disease;	chr7:66144531	chr7:66554588~66576923:-
BRCA	cis	rs755249	0.567	rs1126313	ENSG00000237624.1	OXCT2P1	-6.32	3.83e-10	6.77e-08	-0.28	-0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39174072	chr1:39514956~39516490:+
BRCA	cis	rs6688613	0.959	rs112416021	ENSG00000225171.2	DUTP6	-6.32	3.83e-10	6.77e-08	-0.23	-0.19	Refractive astigmatism;	chr1:166975508	chr1:166868748~166869209:+
BRCA	cis	rs2835345	0.531	rs2409816	ENSG00000230479.1	AP000695.6	6.32	3.83e-10	6.77e-08	0.19	0.19	Pulmonary function;	chr21:36453663	chr21:36430360~36481070:+
BRCA	cis	rs755249	0.509	rs710913	ENSG00000228060.1	RP11-69E11.8	6.32	3.84e-10	6.78e-08	0.19	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39524254	chr1:39565160~39573203:+
BRCA	cis	rs2645424	1	rs2645424	ENSG00000255046.1	RP11-297N6.4	-6.32	3.84e-10	6.79e-08	-0.23	-0.19	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);	chr8:11826954	chr8:11797928~11802568:-
BRCA	cis	rs67981189	0.865	rs2526876	ENSG00000258571.1	PTTG4P	6.32	3.84e-10	6.79e-08	0.21	0.19	Schizophrenia;	chr14:70911471	chr14:71085482~71085833:-
BRCA	cis	rs4718428	1	rs12534637	ENSG00000232546.1	RP11-458F8.1	-6.32	3.84e-10	6.79e-08	-0.17	-0.19	Corneal structure;	chr7:66862667	chr7:66848496~66858136:+
BRCA	cis	rs2243480	1	rs313831	ENSG00000232559.3	GS1-124K5.12	6.32	3.84e-10	6.79e-08	0.38	0.19	Diabetic kidney disease;	chr7:66086239	chr7:66554588~66576923:-
BRCA	cis	rs2732480	0.967	rs2732469	ENSG00000240399.1	RP1-228P16.1	6.32	3.84e-10	6.79e-08	0.21	0.19	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48319149	chr12:48054813~48055591:-
BRCA	cis	rs17711722	0.727	rs35850374	ENSG00000234585.5	CCT6P3	6.32	3.85e-10	6.79e-08	0.18	0.19	Calcium levels;	chr7:65892789	chr7:65038354~65074713:+
BRCA	cis	rs67981189	0.896	rs2010061	ENSG00000269927.1	RP6-91H8.3	-6.32	3.85e-10	6.8e-08	-0.24	-0.19	Schizophrenia;	chr14:70899479	chr14:71141125~71143253:-
BRCA	cis	rs2243480	1	rs427044	ENSG00000232546.1	RP11-458F8.1	-6.32	3.85e-10	6.8e-08	-0.26	-0.19	Diabetic kidney disease;	chr7:66043558	chr7:66848496~66858136:+
BRCA	cis	rs17711722	0.701	rs781145	ENSG00000234585.5	CCT6P3	6.32	3.85e-10	6.81e-08	0.18	0.19	Calcium levels;	chr7:65975383	chr7:65038354~65074713:+
BRCA	cis	rs301901	0.729	rs125682	ENSG00000250155.1	CTD-2353F22.1	-6.32	3.86e-10	6.81e-08	-0.21	-0.19	Height;	chr5:37337045	chr5:36666214~36725195:-
BRCA	cis	rs34779708	0.966	rs1545757	ENSG00000271335.4	RP11-324I22.4	6.32	3.86e-10	6.82e-08	0.21	0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35156660	chr10:35314552~35336401:-
BRCA	cis	rs7432375	0.61	rs60574021	ENSG00000239213.4	NCK1-AS1	6.32	3.86e-10	6.82e-08	0.2	0.19	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136801439	chr3:136841726~136862054:-
BRCA	cis	rs58873874	0.579	rs962459	ENSG00000251405.2	CTB-109A12.1	6.32	3.87e-10	6.84e-08	0.35	0.19	Bipolar disorder (body mass index interaction);	chr5:157346777	chr5:157362615~157460078:-
BRCA	cis	rs2732480	0.577	rs1489109	ENSG00000273765.1	RP11-370I10.11	6.32	3.88e-10	6.85e-08	0.24	0.19	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344997	chr12:48360920~48361377:+
BRCA	cis	rs2732480	0.577	rs1489108	ENSG00000273765.1	RP11-370I10.11	6.32	3.88e-10	6.85e-08	0.24	0.19	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344998	chr12:48360920~48361377:+
BRCA	cis	rs853679	0.517	rs9380047	ENSG00000280107.1	AL022393.9	-6.32	3.88e-10	6.85e-08	-0.29	-0.19	Depression;	chr6:28070115	chr6:28170845~28172521:+
BRCA	cis	rs34779708	0.966	rs17499247	ENSG00000271335.4	RP11-324I22.4	6.32	3.89e-10	6.87e-08	0.2	0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35137827	chr10:35314552~35336401:-
BRCA	cis	rs34779708	0.966	rs10827491	ENSG00000271335.4	RP11-324I22.4	6.32	3.89e-10	6.87e-08	0.2	0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35138467	chr10:35314552~35336401:-
BRCA	cis	rs2281558	0.917	rs3787080	ENSG00000125804.12	FAM182A	-6.32	3.89e-10	6.87e-08	-0.29	-0.19	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25251968	chr20:26054655~26086917:+
BRCA	cis	rs875971	0.545	rs313828	ENSG00000273024.4	INTS4P2	6.32	3.89e-10	6.87e-08	0.24	0.19	Aortic root size;	chr7:66087627	chr7:65647864~65715661:+
BRCA	cis	rs2179367	0.632	rs12197598	ENSG00000216906.2	RP11-350J20.9	6.32	3.9e-10	6.88e-08	0.27	0.19	Dupuytren's disease;	chr6:149385418	chr6:149904243~149906418:+
BRCA	cis	rs6061231	0.793	rs6061512	ENSG00000275437.1	RP5-908M14.10	6.32	3.9e-10	6.88e-08	0.22	0.19	Colorectal cancer;	chr20:62401873	chr20:62402236~62405935:-
BRCA	cis	rs42648	0.564	rs39267	ENSG00000225498.1	AC002064.5	6.32	3.9e-10	6.89e-08	0.18	0.19	Homocysteine levels;	chr7:90142195	chr7:90312496~90322592:+
BRCA	cis	rs7246657	0.943	rs13343471	ENSG00000226686.6	LINC01535	-6.32	3.9e-10	6.89e-08	-0.3	-0.19	Coronary artery calcification;	chr19:37441228	chr19:37251912~37265535:+
BRCA	cis	rs9992667	0.955	rs1491199	ENSG00000231160.8	KLF3-AS1	6.32	3.91e-10	6.9e-08	0.24	0.19	Eosinophil percentage of granulocytes;	chr4:38641393	chr4:38612701~38664883:-
BRCA	cis	rs4660456	0.504	rs587963	ENSG00000237899.1	RP4-739H11.3	6.32	3.91e-10	6.9e-08	0.29	0.19	Platelet count;	chr1:40640045	chr1:40669089~40687588:-
BRCA	cis	rs2638953	0.776	rs11513467	ENSG00000278733.1	RP11-425D17.1	-6.32	3.91e-10	6.9e-08	-0.24	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28210252	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.776	rs11519332	ENSG00000278733.1	RP11-425D17.1	-6.32	3.91e-10	6.9e-08	-0.24	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28210254	chr12:28185625~28186190:-
BRCA	cis	rs2998286	0.723	rs332187	ENSG00000254635.4	WAC-AS1	-6.32	3.91e-10	6.9e-08	-0.28	-0.19	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28624887	chr10:28522652~28532743:-
BRCA	cis	rs4950322	0.571	rs4373796	ENSG00000278811.3	LINC00624	6.32	3.92e-10	6.92e-08	0.26	0.19	Protein quantitative trait loci;	chr1:147316747	chr1:147258885~147517875:-
BRCA	cis	rs4950322	0.543	rs4568882	ENSG00000278811.3	LINC00624	6.32	3.92e-10	6.92e-08	0.26	0.19	Protein quantitative trait loci;	chr1:147316885	chr1:147258885~147517875:-
BRCA	cis	rs4950322	0.543	rs2883323	ENSG00000278811.3	LINC00624	6.32	3.92e-10	6.92e-08	0.26	0.19	Protein quantitative trait loci;	chr1:147316995	chr1:147258885~147517875:-
BRCA	cis	rs4950322	0.543	rs2883324	ENSG00000278811.3	LINC00624	6.32	3.92e-10	6.92e-08	0.26	0.19	Protein quantitative trait loci;	chr1:147317157	chr1:147258885~147517875:-
BRCA	cis	rs2098713	0.549	rs62359033	ENSG00000250155.1	CTD-2353F22.1	6.32	3.92e-10	6.92e-08	0.21	0.19	Telomere length;	chr5:37549741	chr5:36666214~36725195:-
BRCA	cis	rs651907	0.557	rs1031710	ENSG00000244119.1	PDCL3P4	6.32	3.92e-10	6.92e-08	0.16	0.19	Colorectal cancer;	chr3:101745051	chr3:101712472~101713191:+
BRCA	cis	rs651907	0.535	rs13065944	ENSG00000244119.1	PDCL3P4	6.32	3.92e-10	6.92e-08	0.16	0.19	Colorectal cancer;	chr3:101754244	chr3:101712472~101713191:+
BRCA	cis	rs853679	0.546	rs493161	ENSG00000220721.1	OR1F12	6.32	3.93e-10	6.93e-08	0.36	0.19	Depression;	chr6:27882936	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.546	rs13213152	ENSG00000220721.1	OR1F12	6.32	3.93e-10	6.94e-08	0.47	0.19	Depression;	chr6:28381921	chr6:28073316~28074233:+
BRCA	cis	rs1707322	0.655	rs3014240	ENSG00000281133.1	AL355480.3	6.32	3.93e-10	6.94e-08	0.25	0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45623553	chr1:45580892~45580996:-
BRCA	cis	rs1823913	0.599	rs13427761	ENSG00000280083.1	RP11-317J9.1	6.32	3.93e-10	6.94e-08	0.22	0.19	Obesity-related traits;	chr2:191269256	chr2:191154118~191156070:-
BRCA	cis	rs55702914	0.652	rs12151726	ENSG00000231621.1	AC013264.2	-6.32	3.94e-10	6.94e-08	-0.19	-0.19	Major depression and alcohol dependence;	chr2:197408867	chr2:197197991~197199273:+
BRCA	cis	rs2492286	0.597	rs7647337	ENSG00000242551.2	POU5F1P6	-6.32	3.94e-10	6.94e-08	-0.28	-0.19	Eosinophil counts;	chr3:128628353	chr3:128674735~128677005:-
BRCA	cis	rs7131987	0.621	rs3782506	ENSG00000257176.2	RP11-996F15.2	6.32	3.94e-10	6.95e-08	0.23	0.19	QT interval;	chr12:29292489	chr12:29280418~29317848:-
BRCA	cis	rs2243480	0.901	rs12530490	ENSG00000229886.1	RP5-1132H15.3	-6.32	3.94e-10	6.95e-08	-0.34	-0.19	Diabetic kidney disease;	chr7:66226660	chr7:66025126~66031544:-
BRCA	cis	rs2243480	1	rs7778911	ENSG00000229886.1	RP5-1132H15.3	-6.32	3.94e-10	6.95e-08	-0.34	-0.19	Diabetic kidney disease;	chr7:66229519	chr7:66025126~66031544:-
BRCA	cis	rs4761702	1	rs4761701	ENSG00000257322.4	RP11-511B23.2	-6.32	3.95e-10	6.96e-08	-0.25	-0.19	Immature fraction of reticulocytes;	chr12:93315956	chr12:93003415~93215679:-
BRCA	cis	rs2243480	1	rs431076	ENSG00000229886.1	RP5-1132H15.3	6.32	3.95e-10	6.96e-08	0.34	0.19	Diabetic kidney disease;	chr7:66135333	chr7:66025126~66031544:-
BRCA	cis	rs2243480	1	rs2460422	ENSG00000229886.1	RP5-1132H15.3	6.32	3.95e-10	6.96e-08	0.34	0.19	Diabetic kidney disease;	chr7:66136518	chr7:66025126~66031544:-
BRCA	cis	rs2243480	1	rs316334	ENSG00000229886.1	RP5-1132H15.3	6.32	3.95e-10	6.96e-08	0.34	0.19	Diabetic kidney disease;	chr7:66137139	chr7:66025126~66031544:-
BRCA	cis	rs9527	0.615	rs10883781	ENSG00000213061.2	PFN1P11	6.32	3.95e-10	6.96e-08	0.28	0.19	Arsenic metabolism;	chr10:102821373	chr10:102838011~102845473:-
BRCA	cis	rs17301013	0.531	rs4650958	ENSG00000227373.4	RP11-160H22.5	6.32	3.95e-10	6.96e-08	0.27	0.19	Systemic lupus erythematosus;	chr1:174178378	chr1:174115300~174160004:-
BRCA	cis	rs5015933	0.864	rs10819049	ENSG00000232630.1	PRPS1P2	-6.32	3.95e-10	6.97e-08	-0.18	-0.19	Body mass index;	chr9:125376805	chr9:125150653~125151589:+
BRCA	cis	rs875971	0.52	rs160645	ENSG00000273024.4	INTS4P2	6.32	3.95e-10	6.97e-08	0.24	0.19	Aortic root size;	chr7:66091320	chr7:65647864~65715661:+
BRCA	cis	rs4763879	0.739	rs2895988	ENSG00000256673.1	RP11-599J14.2	6.32	3.96e-10	6.98e-08	0.22	0.19	Type 1 diabetes;	chr12:9675831	chr12:9398355~9414851:-
BRCA	cis	rs3736858	0.825	rs3759445	ENSG00000261105.4	LMO7-AS1	-6.32	3.96e-10	6.98e-08	-0.29	-0.19	Interleukin-9 levels;	chr13:75816090	chr13:75604700~75635994:-
BRCA	cis	rs6840360	0.582	rs4696259	ENSG00000270265.1	RP11-731D1.4	-6.32	3.96e-10	6.98e-08	-0.21	-0.19	Intelligence (multi-trait analysis);	chr4:151389636	chr4:151333775~151353224:-
BRCA	cis	rs1823874	0.653	rs12902823	ENSG00000182397.13	DNM1P46	-6.32	3.96e-10	6.99e-08	-0.21	-0.19	IgG glycosylation;	chr15:99812013	chr15:99790156~99806927:-
BRCA	cis	rs9601248	0.627	rs2146593	ENSG00000227676.3	LINC01068	6.32	3.97e-10	6.99e-08	0.24	0.19	Major depressive disorder;	chr13:79605977	chr13:79566727~79571436:+
BRCA	cis	rs2115630	0.967	rs12595786	ENSG00000229212.6	RP11-561C5.4	6.32	3.97e-10	7e-08	0.21	0.19	P wave terminal force;	chr15:84793439	chr15:85205440~85234795:-
BRCA	cis	rs6142102	0.923	rs6059635	ENSG00000275784.1	RP5-1125A11.6	-6.32	3.98e-10	7.01e-08	-0.23	-0.19	Skin pigmentation;	chr20:34025687	chr20:33989480~33991818:-
BRCA	cis	rs1979679	0.842	rs1118097	ENSG00000278733.1	RP11-425D17.1	6.32	3.98e-10	7.02e-08	0.24	0.19	Ossification of the posterior longitudinal ligament of the spine;	chr12:28177156	chr12:28185625~28186190:-
BRCA	cis	rs12468226	0.938	rs12471060	ENSG00000226261.1	AC064836.3	6.32	3.98e-10	7.02e-08	0.33	0.19	Urate levels;	chr2:202309597	chr2:202336024~202336727:-
BRCA	cis	rs2153535	0.518	rs9406187	ENSG00000230939.1	RP11-314C16.1	-6.32	3.98e-10	7.02e-08	-0.23	-0.19	Motion sickness;	chr6:8654376	chr6:8784178~8785445:+
BRCA	cis	rs6095360	0.727	rs1556876	ENSG00000222365.1	SNORD12B	-6.32	3.99e-10	7.03e-08	-0.24	-0.19	Intelligence (multi-trait analysis);	chr20:49099914	chr20:49280319~49280409:+
BRCA	cis	rs721917	0.506	rs2819100	ENSG00000244733.5	RP11-506M13.3	-6.32	3.99e-10	7.04e-08	-0.23	-0.19	Chronic obstructive pulmonary disease;	chr10:79937163	chr10:79660891~79677996:+
BRCA	cis	rs42648	0.536	rs39270	ENSG00000225498.1	AC002064.5	6.31	3.99e-10	7.04e-08	0.18	0.19	Homocysteine levels;	chr7:90143312	chr7:90312496~90322592:+
BRCA	cis	rs2179367	0.552	rs11155652	ENSG00000216906.2	RP11-350J20.9	6.31	4e-10	7.04e-08	0.27	0.19	Dupuytren's disease;	chr6:149417849	chr6:149904243~149906418:+
BRCA	cis	rs2179367	0.632	rs12209364	ENSG00000216906.2	RP11-350J20.9	6.31	4e-10	7.04e-08	0.27	0.19	Dupuytren's disease;	chr6:149418062	chr6:149904243~149906418:+
BRCA	cis	rs2153535	0.553	rs2984099	ENSG00000230939.1	RP11-314C16.1	6.31	4e-10	7.04e-08	0.27	0.19	Motion sickness;	chr6:8637041	chr6:8784178~8785445:+
BRCA	cis	rs2348418	0.864	rs7960369	ENSG00000247934.4	RP11-967K21.1	6.31	4e-10	7.05e-08	0.21	0.19	Lung function (FEV1);Lung function (FVC);	chr12:28561569	chr12:28163298~28190738:-
BRCA	cis	rs4950322	0.57	rs80070044	ENSG00000278811.3	LINC00624	6.31	4e-10	7.05e-08	0.26	0.19	Protein quantitative trait loci;	chr1:147330238	chr1:147258885~147517875:-
BRCA	cis	rs7520050	0.966	rs1707336	ENSG00000280836.1	AL355480.1	6.31	4.01e-10	7.06e-08	0.22	0.19	Reticulocyte count;Red blood cell count;	chr1:46027788	chr1:45581219~45581321:-
BRCA	cis	rs13113518	0.812	rs13107810	ENSG00000273257.1	RP11-177J6.1	6.31	4.01e-10	7.07e-08	0.25	0.19	Height;	chr4:55542243	chr4:55387949~55388271:+
BRCA	cis	rs7432375	0.61	rs56695781	ENSG00000239213.4	NCK1-AS1	6.31	4.01e-10	7.07e-08	0.2	0.19	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136791759	chr3:136841726~136862054:-
BRCA	cis	rs34779708	0.931	rs7079205	ENSG00000271335.4	RP11-324I22.4	6.31	4.01e-10	7.07e-08	0.2	0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35035691	chr10:35314552~35336401:-
BRCA	cis	rs10129255	0.5	rs2105991	ENSG00000274576.2	IGHV2-70	-6.31	4.01e-10	7.07e-08	-0.16	-0.19	Kawasaki disease;	chr14:106682022	chr14:106770577~106771020:-
BRCA	cis	rs160451	0.966	rs160427	ENSG00000251136.7	RP11-37B2.1	6.31	4.01e-10	7.07e-08	0.18	0.19	Leprosy;	chr8:89659156	chr8:89609409~89757727:-
BRCA	cis	rs11098499	0.954	rs59866101	ENSG00000249244.1	RP11-548H18.2	6.31	4.01e-10	7.07e-08	0.23	0.19	Corneal astigmatism;	chr4:119375436	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.618	rs6858383	ENSG00000249244.1	RP11-548H18.2	6.31	4.01e-10	7.07e-08	0.23	0.19	Corneal astigmatism;	chr4:119375617	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.697	rs6832410	ENSG00000249244.1	RP11-548H18.2	6.31	4.01e-10	7.07e-08	0.23	0.19	Corneal astigmatism;	chr4:119375645	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.865	rs1112817	ENSG00000249244.1	RP11-548H18.2	6.31	4.01e-10	7.07e-08	0.23	0.19	Corneal astigmatism;	chr4:119376645	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.779	rs10016060	ENSG00000249244.1	RP11-548H18.2	6.31	4.01e-10	7.07e-08	0.23	0.19	Corneal astigmatism;	chr4:119377257	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.954	rs10005644	ENSG00000249244.1	RP11-548H18.2	6.31	4.01e-10	7.07e-08	0.23	0.19	Corneal astigmatism;	chr4:119377322	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.697	rs10016448	ENSG00000249244.1	RP11-548H18.2	6.31	4.01e-10	7.07e-08	0.23	0.19	Corneal astigmatism;	chr4:119377690	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.657	rs9996569	ENSG00000249244.1	RP11-548H18.2	6.31	4.01e-10	7.07e-08	0.23	0.19	Corneal astigmatism;	chr4:119377849	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.908	rs11729050	ENSG00000249244.1	RP11-548H18.2	6.31	4.01e-10	7.07e-08	0.23	0.19	Corneal astigmatism;	chr4:119378911	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.954	rs28429722	ENSG00000249244.1	RP11-548H18.2	6.31	4.01e-10	7.07e-08	0.23	0.19	Corneal astigmatism;	chr4:119378938	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.954	rs10014845	ENSG00000249244.1	RP11-548H18.2	6.31	4.01e-10	7.07e-08	0.23	0.19	Corneal astigmatism;	chr4:119379922	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.779	rs7674500	ENSG00000249244.1	RP11-548H18.2	6.31	4.01e-10	7.07e-08	0.23	0.19	Corneal astigmatism;	chr4:119382438	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.909	rs28884220	ENSG00000249244.1	RP11-548H18.2	6.31	4.01e-10	7.07e-08	0.23	0.19	Corneal astigmatism;	chr4:119386056	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.909	rs28793658	ENSG00000249244.1	RP11-548H18.2	6.31	4.01e-10	7.07e-08	0.23	0.19	Corneal astigmatism;	chr4:119386059	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.697	rs4373140	ENSG00000249244.1	RP11-548H18.2	6.31	4.01e-10	7.07e-08	0.23	0.19	Corneal astigmatism;	chr4:119386543	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.954	rs13113483	ENSG00000249244.1	RP11-548H18.2	6.31	4.01e-10	7.07e-08	0.23	0.19	Corneal astigmatism;	chr4:119387884	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.542	rs10440343	ENSG00000249244.1	RP11-548H18.2	6.31	4.01e-10	7.07e-08	0.23	0.19	Corneal astigmatism;	chr4:119388632	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.779	rs10011097	ENSG00000249244.1	RP11-548H18.2	6.31	4.01e-10	7.07e-08	0.23	0.19	Corneal astigmatism;	chr4:119389204	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.542	rs7677836	ENSG00000249244.1	RP11-548H18.2	6.31	4.01e-10	7.07e-08	0.23	0.19	Corneal astigmatism;	chr4:119389483	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.909	rs10002083	ENSG00000249244.1	RP11-548H18.2	6.31	4.01e-10	7.07e-08	0.23	0.19	Corneal astigmatism;	chr4:119389997	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.954	rs10024844	ENSG00000249244.1	RP11-548H18.2	6.31	4.01e-10	7.07e-08	0.23	0.19	Corneal astigmatism;	chr4:119390373	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.954	rs4345162	ENSG00000249244.1	RP11-548H18.2	6.31	4.01e-10	7.07e-08	0.23	0.19	Corneal astigmatism;	chr4:119391804	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.657	rs4463052	ENSG00000249244.1	RP11-548H18.2	6.31	4.01e-10	7.07e-08	0.23	0.19	Corneal astigmatism;	chr4:119392103	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.954	rs13151285	ENSG00000249244.1	RP11-548H18.2	6.31	4.01e-10	7.07e-08	0.23	0.19	Corneal astigmatism;	chr4:119393586	chr4:119391831~119395335:-
BRCA	cis	rs67981189	0.896	rs2526878	ENSG00000258571.1	PTTG4P	6.31	4.02e-10	7.07e-08	0.21	0.19	Schizophrenia;	chr14:70910578	chr14:71085482~71085833:-
BRCA	cis	rs9291683	0.507	rs6827754	ENSG00000250413.1	RP11-448G15.1	6.31	4.02e-10	7.07e-08	0.25	0.19	Bone mineral density;	chr4:10016529	chr4:10006482~10009725:+
BRCA	cis	rs7617773	0.78	rs7632297	ENSG00000228638.1	FCF1P2	-6.31	4.02e-10	7.08e-08	-0.22	-0.19	Coronary artery disease;	chr3:48306673	chr3:48290793~48291375:-
BRCA	cis	rs16958440	0.867	rs77348110	ENSG00000267800.1	RP11-49K24.5	-6.31	4.02e-10	7.08e-08	-0.45	-0.19	Sitting height ratio;	chr18:47147796	chr18:47137018~47137290:+
BRCA	cis	rs7246657	0.943	rs9917081	ENSG00000267422.1	CTD-2554C21.1	-6.31	4.03e-10	7.09e-08	-0.29	-0.19	Coronary artery calcification;	chr19:37385714	chr19:37779686~37792865:+
BRCA	cis	rs67981189	0.896	rs2526874	ENSG00000258571.1	PTTG4P	6.31	4.03e-10	7.09e-08	0.21	0.19	Schizophrenia;	chr14:70914502	chr14:71085482~71085833:-
BRCA	cis	rs6142102	0.651	rs1015361	ENSG00000275784.1	RP5-1125A11.6	6.31	4.03e-10	7.1e-08	0.23	0.19	Skin pigmentation;	chr20:34150880	chr20:33989480~33991818:-
BRCA	cis	rs9307551	1	rs9307545	ENSG00000250334.4	LINC00989	-6.31	4.03e-10	7.1e-08	-0.28	-0.19	Refractive error;	chr4:79595417	chr4:79492416~79576460:+
BRCA	cis	rs875971	0.545	rs1796222	ENSG00000273024.4	INTS4P2	6.31	4.04e-10	7.1e-08	0.24	0.19	Aortic root size;	chr7:66592167	chr7:65647864~65715661:+
BRCA	cis	rs2732480	0.577	rs2732466	ENSG00000273765.1	RP11-370I10.11	6.31	4.04e-10	7.11e-08	0.24	0.19	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48338676	chr12:48360920~48361377:+
BRCA	cis	rs2243480	0.901	rs3813708	ENSG00000228409.4	CCT6P1	6.31	4.04e-10	7.11e-08	0.27	0.19	Diabetic kidney disease;	chr7:65840645	chr7:65751142~65763354:+
BRCA	cis	rs227275	0.525	rs223462	ENSG00000251288.2	RP11-10L12.2	-6.31	4.04e-10	7.11e-08	-0.23	-0.19	Allergic disease (asthma, hay fever or eczema);	chr4:102780661	chr4:102751401~102752641:+
BRCA	cis	rs6723226	0.721	rs10172510	ENSG00000276334.1	AL133243.1	6.31	4.04e-10	7.11e-08	0.23	0.19	Intelligence (multi-trait analysis);	chr2:32395820	chr2:32521927~32523547:+
BRCA	cis	rs7615952	0.641	rs12488180	ENSG00000171084.14	FAM86JP	6.31	4.04e-10	7.11e-08	0.3	0.19	Blood pressure (smoking interaction);	chr3:126063393	chr3:125916620~125930024:+
BRCA	cis	rs754466	0.58	rs11002289	ENSG00000204049.1	RP11-126H7.4	6.31	4.04e-10	7.11e-08	0.24	0.19	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77772822	chr10:77866875~77869610:+
BRCA	cis	rs227275	0.556	rs223398	ENSG00000251288.2	RP11-10L12.2	-6.31	4.04e-10	7.11e-08	-0.23	-0.19	Allergic disease (asthma, hay fever or eczema);	chr4:102821256	chr4:102751401~102752641:+
BRCA	cis	rs2835345	0.511	rs2835356	ENSG00000230479.1	AP000695.6	6.31	4.05e-10	7.12e-08	0.2	0.19	Pulmonary function;	chr21:36444900	chr21:36430360~36481070:+
BRCA	cis	rs9291683	0.53	rs17246501	ENSG00000250413.1	RP11-448G15.1	-6.31	4.05e-10	7.13e-08	-0.25	-0.19	Bone mineral density;	chr4:9984086	chr4:10006482~10009725:+
BRCA	cis	rs11098499	0.866	rs3756156	ENSG00000249244.1	RP11-548H18.2	6.31	4.05e-10	7.13e-08	0.23	0.19	Corneal astigmatism;	chr4:119603686	chr4:119391831~119395335:-
BRCA	cis	rs72627509	0.638	rs1608165	ENSG00000269949.1	RP11-738E22.3	6.31	4.05e-10	7.13e-08	0.33	0.19	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:57028551	chr4:56960927~56961373:-
BRCA	cis	rs7829975	0.688	rs6995407	ENSG00000254153.1	CTA-398F10.2	6.31	4.05e-10	7.13e-08	0.23	0.19	Mood instability;	chr8:8527137	chr8:8456909~8461337:-
BRCA	cis	rs875971	0.862	rs7783779	ENSG00000224316.1	RP11-479O9.2	-6.31	4.07e-10	7.16e-08	-0.2	-0.19	Aortic root size;	chr7:66331639	chr7:65773620~65802067:+
BRCA	cis	rs34779708	0.966	rs34776628	ENSG00000271335.4	RP11-324I22.4	6.31	4.07e-10	7.16e-08	0.2	0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35137396	chr10:35314552~35336401:-
BRCA	cis	rs9516	1	rs10898990	ENSG00000254974.1	RP11-702H23.2	-6.31	4.07e-10	7.16e-08	-0.23	-0.19	Facial morphology (factor 15, philtrum width);	chr11:74454121	chr11:74485580~74486051:-
BRCA	cis	rs9516	1	rs10898991	ENSG00000254974.1	RP11-702H23.2	-6.31	4.07e-10	7.16e-08	-0.23	-0.19	Facial morphology (factor 15, philtrum width);	chr11:74454148	chr11:74485580~74486051:-
BRCA	cis	rs7923609	0.729	rs7902616	ENSG00000232075.1	MRPL35P2	6.31	4.07e-10	7.16e-08	0.24	0.19	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63576613	chr10:63634317~63634827:-
BRCA	cis	rs7923609	0.756	rs10822183	ENSG00000232075.1	MRPL35P2	6.31	4.07e-10	7.16e-08	0.24	0.19	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63577381	chr10:63634317~63634827:-
BRCA	cis	rs732716	0.889	rs62129355	ENSG00000267980.1	AC007292.6	-6.31	4.07e-10	7.16e-08	-0.24	-0.19	Mean corpuscular volume;	chr19:4397037	chr19:4363789~4364640:+
BRCA	cis	rs11148252	0.846	rs1056335	ENSG00000278238.1	RP11-245D16.4	-6.31	4.07e-10	7.17e-08	-0.21	-0.19	Lewy body disease;	chr13:52415728	chr13:52454775~52455331:-
BRCA	cis	rs11098499	0.863	rs13136462	ENSG00000249244.1	RP11-548H18.2	6.31	4.07e-10	7.17e-08	0.23	0.19	Corneal astigmatism;	chr4:119622018	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.954	rs3733524	ENSG00000249244.1	RP11-548H18.2	6.31	4.07e-10	7.17e-08	0.24	0.19	Corneal astigmatism;	chr4:119502574	chr4:119391831~119395335:-
BRCA	cis	rs11148252	0.846	rs13431	ENSG00000278238.1	RP11-245D16.4	-6.31	4.08e-10	7.17e-08	-0.21	-0.19	Lewy body disease;	chr13:52413342	chr13:52454775~52455331:-
BRCA	cis	rs9992667	0.868	rs113071828	ENSG00000231160.8	KLF3-AS1	6.31	4.08e-10	7.19e-08	0.24	0.19	Eosinophil percentage of granulocytes;	chr4:38664197	chr4:38612701~38664883:-
BRCA	cis	rs4950322	0.543	rs4453096	ENSG00000278811.3	LINC00624	6.31	4.09e-10	7.19e-08	0.26	0.19	Protein quantitative trait loci;	chr1:147316574	chr1:147258885~147517875:-
BRCA	cis	rs853679	0.607	rs13208096	ENSG00000220721.1	OR1F12	6.31	4.09e-10	7.19e-08	0.46	0.19	Depression;	chr6:28257533	chr6:28073316~28074233:+
BRCA	cis	rs3764021	0.506	rs10844468	ENSG00000214776.8	RP11-726G1.1	6.31	4.09e-10	7.19e-08	0.24	0.19	Type 1 diabetes;	chr12:9690799	chr12:9467552~9576275:+
BRCA	cis	rs1440410	0.835	rs28592151	ENSG00000250326.1	RP11-284M14.1	-6.31	4.09e-10	7.19e-08	-0.21	-0.19	Ischemic stroke;	chr4:143172971	chr4:142933195~143184861:-
BRCA	cis	rs1440410	0.835	rs7656276	ENSG00000250326.1	RP11-284M14.1	-6.31	4.09e-10	7.19e-08	-0.21	-0.19	Ischemic stroke;	chr4:143176396	chr4:142933195~143184861:-
BRCA	cis	rs1440410	0.798	rs10019249	ENSG00000250326.1	RP11-284M14.1	-6.31	4.09e-10	7.19e-08	-0.21	-0.19	Ischemic stroke;	chr4:143181040	chr4:142933195~143184861:-
BRCA	cis	rs42648	1	rs42656	ENSG00000225498.1	AC002064.5	6.31	4.09e-10	7.2e-08	0.18	0.19	Homocysteine levels;	chr7:90352322	chr7:90312496~90322592:+
BRCA	cis	rs7911264	0.703	rs7894183	ENSG00000236493.2	EIF2S2P3	6.31	4.1e-10	7.22e-08	0.26	0.19	Inflammatory bowel disease;	chr10:92622283	chr10:92668745~92669743:-
BRCA	cis	rs2243480	0.901	rs778730	ENSG00000229886.1	RP5-1132H15.3	6.31	4.11e-10	7.23e-08	0.34	0.19	Diabetic kidney disease;	chr7:66358338	chr7:66025126~66031544:-
BRCA	cis	rs4950322	0.547	rs17355509	ENSG00000278811.3	LINC00624	6.31	4.11e-10	7.23e-08	0.26	0.19	Protein quantitative trait loci;	chr1:147123139	chr1:147258885~147517875:-
BRCA	cis	rs1707322	1	rs785490	ENSG00000281133.1	AL355480.3	6.31	4.11e-10	7.23e-08	0.25	0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46111452	chr1:45580892~45580996:-
BRCA	cis	rs6688613	0.721	rs2312675	ENSG00000225171.2	DUTP6	-6.31	4.11e-10	7.23e-08	-0.26	-0.19	Refractive astigmatism;	chr1:166953296	chr1:166868748~166869209:+
BRCA	cis	rs1707322	0.717	rs2253862	ENSG00000281133.1	AL355480.3	6.31	4.12e-10	7.24e-08	0.25	0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45616288	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.717	rs2991988	ENSG00000281133.1	AL355480.3	6.31	4.12e-10	7.24e-08	0.25	0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45616759	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.717	rs2991989	ENSG00000281133.1	AL355480.3	6.31	4.12e-10	7.24e-08	0.25	0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45617293	chr1:45580892~45580996:-
BRCA	cis	rs853679	0.546	rs13213986	ENSG00000220721.1	OR1F12	6.31	4.12e-10	7.24e-08	0.47	0.19	Depression;	chr6:28390232	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.546	rs34546986	ENSG00000220721.1	OR1F12	6.31	4.12e-10	7.24e-08	0.47	0.19	Depression;	chr6:28394532	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.546	rs34871267	ENSG00000220721.1	OR1F12	6.31	4.12e-10	7.24e-08	0.47	0.19	Depression;	chr6:28396455	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.546	rs35883476	ENSG00000220721.1	OR1F12	6.31	4.12e-10	7.24e-08	0.47	0.19	Depression;	chr6:28400731	chr6:28073316~28074233:+
BRCA	cis	rs11096990	0.927	rs6845858	ENSG00000249207.1	RP11-360F5.1	6.31	4.12e-10	7.25e-08	0.23	0.19	Cognitive function;	chr4:39237099	chr4:39112677~39126818:-
BRCA	cis	rs7914558	1	rs943038	ENSG00000213061.2	PFN1P11	6.31	4.13e-10	7.26e-08	0.25	0.19	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103066504	chr10:102838011~102845473:-
BRCA	cis	rs755249	0.727	rs12028034	ENSG00000228060.1	RP11-69E11.8	6.31	4.13e-10	7.27e-08	0.2	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39574035	chr1:39565160~39573203:+
BRCA	cis	rs7617773	0.78	rs13082859	ENSG00000228638.1	FCF1P2	-6.31	4.14e-10	7.28e-08	-0.22	-0.19	Coronary artery disease;	chr3:48303185	chr3:48290793~48291375:-
BRCA	cis	rs7617773	0.78	rs35778847	ENSG00000228638.1	FCF1P2	-6.31	4.14e-10	7.28e-08	-0.22	-0.19	Coronary artery disease;	chr3:48305495	chr3:48290793~48291375:-
BRCA	cis	rs7617773	0.78	rs34749846	ENSG00000228638.1	FCF1P2	-6.31	4.14e-10	7.28e-08	-0.22	-0.19	Coronary artery disease;	chr3:48305678	chr3:48290793~48291375:-
BRCA	cis	rs7617773	0.78	rs79089926	ENSG00000228638.1	FCF1P2	-6.31	4.14e-10	7.28e-08	-0.22	-0.19	Coronary artery disease;	chr3:48307074	chr3:48290793~48291375:-
BRCA	cis	rs7819412	0.668	rs2409714	ENSG00000255046.1	RP11-297N6.4	6.31	4.14e-10	7.28e-08	0.22	0.19	Triglycerides;	chr8:11152608	chr8:11797928~11802568:-
BRCA	cis	rs1707322	0.929	rs785500	ENSG00000281133.1	AL355480.3	6.31	4.14e-10	7.28e-08	0.24	0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46127372	chr1:45580892~45580996:-
BRCA	cis	rs9467773	0.869	rs1796520	ENSG00000124549.13	BTN2A3P	-6.31	4.14e-10	7.29e-08	-0.2	-0.19	Intelligence (multi-trait analysis);	chr6:26410572	chr6:26421391~26432383:+
BRCA	cis	rs2243480	1	rs1499614	ENSG00000232546.1	RP11-458F8.1	-6.31	4.15e-10	7.29e-08	-0.25	-0.19	Diabetic kidney disease;	chr7:66265811	chr7:66848496~66858136:+
BRCA	cis	rs1124769	0.748	rs17647040	ENSG00000259378.1	DCAF13P3	-6.31	4.15e-10	7.29e-08	-0.27	-0.19	Cognitive performance;	chr15:51063729	chr15:50944663~50945996:+
BRCA	cis	rs9992667	0.911	rs12332031	ENSG00000231160.8	KLF3-AS1	6.31	4.16e-10	7.3e-08	0.24	0.19	Eosinophil percentage of granulocytes;	chr4:38651881	chr4:38612701~38664883:-
BRCA	cis	rs651907	0.535	rs9830943	ENSG00000244119.1	PDCL3P4	6.31	4.16e-10	7.31e-08	0.16	0.19	Colorectal cancer;	chr3:101710055	chr3:101712472~101713191:+
BRCA	cis	rs7746199	0.736	rs13209332	ENSG00000220721.1	OR1F12	6.31	4.16e-10	7.31e-08	0.45	0.19	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27552973	chr6:28073316~28074233:+
BRCA	cis	rs375066	0.623	rs1549953	ENSG00000267058.1	RP11-15A1.3	6.31	4.16e-10	7.31e-08	0.22	0.19	Breast cancer;	chr19:43844616	chr19:43891804~43901805:-
BRCA	cis	rs4948102	0.599	rs2230197	ENSG00000273720.1	RP11-613E4.4	-6.31	4.17e-10	7.33e-08	-0.24	-0.19	Plasma homocysteine levels (post-methionine load test);	chr7:56058667	chr7:55743073~55743457:+
BRCA	cis	rs2832191	0.933	rs2832236	ENSG00000215533.7	LINC00189	6.31	4.18e-10	7.34e-08	0.22	0.19	Dental caries;	chr21:29175281	chr21:29193480~29288205:+
BRCA	cis	rs34779708	0.966	rs12775799	ENSG00000271335.4	RP11-324I22.4	6.31	4.18e-10	7.34e-08	0.2	0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35199336	chr10:35314552~35336401:-
BRCA	cis	rs34779708	0.966	rs11010122	ENSG00000271335.4	RP11-324I22.4	6.31	4.18e-10	7.34e-08	0.2	0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35204590	chr10:35314552~35336401:-
BRCA	cis	rs34779708	0.9	rs73262807	ENSG00000271335.4	RP11-324I22.4	6.31	4.18e-10	7.34e-08	0.2	0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35207458	chr10:35314552~35336401:-
BRCA	cis	rs34779708	0.966	rs4934736	ENSG00000271335.4	RP11-324I22.4	6.31	4.18e-10	7.34e-08	0.2	0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35207940	chr10:35314552~35336401:-
BRCA	cis	rs8100891	0.614	rs6510243	ENSG00000267213.4	AC007773.2	-6.31	4.18e-10	7.35e-08	-0.22	-0.19	Neuroticism;	chr19:32342765	chr19:32390050~32405560:-
BRCA	cis	rs7617773	0.746	rs4130995	ENSG00000228638.1	FCF1P2	-6.31	4.19e-10	7.37e-08	-0.19	-0.19	Coronary artery disease;	chr3:48316765	chr3:48290793~48291375:-
BRCA	cis	rs875971	0.545	rs6961853	ENSG00000236529.1	RP13-254B10.1	6.31	4.19e-10	7.37e-08	0.24	0.19	Aortic root size;	chr7:66537035	chr7:65840212~65840596:+
BRCA	cis	rs7927771	0.524	rs2290851	ENSG00000280615.1	Y_RNA	-6.31	4.2e-10	7.37e-08	-0.22	-0.19	Subjective well-being;	chr11:47731818	chr11:47614898~47614994:-
BRCA	cis	rs638893	0.617	rs4938565	ENSG00000255239.1	AP002954.6	-6.31	4.2e-10	7.38e-08	-0.25	-0.19	Vitiligo;	chr11:118850289	chr11:118688039~118690600:-
BRCA	cis	rs875971	0.545	rs3735147	ENSG00000273024.4	INTS4P2	-6.31	4.2e-10	7.38e-08	-0.24	-0.19	Aortic root size;	chr7:66505541	chr7:65647864~65715661:+
BRCA	cis	rs7617773	0.78	rs11718350	ENSG00000228638.1	FCF1P2	-6.31	4.2e-10	7.38e-08	-0.22	-0.19	Coronary artery disease;	chr3:48319502	chr3:48290793~48291375:-
BRCA	cis	rs9876781	1	rs922075	ENSG00000229759.1	MRPS18AP1	-6.31	4.21e-10	7.4e-08	-0.21	-0.19	Longevity;	chr3:48447994	chr3:48256350~48256938:-
BRCA	cis	rs4950322	0.57	rs72692917	ENSG00000278811.3	LINC00624	6.31	4.22e-10	7.41e-08	0.26	0.19	Protein quantitative trait loci;	chr1:147304389	chr1:147258885~147517875:-
BRCA	cis	rs4950322	0.57	rs66580541	ENSG00000278811.3	LINC00624	6.31	4.22e-10	7.41e-08	0.26	0.19	Protein quantitative trait loci;	chr1:147308828	chr1:147258885~147517875:-
BRCA	cis	rs4950322	0.57	rs945742	ENSG00000278811.3	LINC00624	6.31	4.22e-10	7.41e-08	0.26	0.19	Protein quantitative trait loci;	chr1:147313437	chr1:147258885~147517875:-
BRCA	cis	rs34286592	1	rs4788187	ENSG00000214725.6	CDIPT-AS1	6.31	4.22e-10	7.41e-08	0.3	0.19	Multiple sclerosis;	chr16:29834364	chr16:29863593~29868053:+
BRCA	cis	rs7555523	0.887	rs4657471	ENSG00000224358.1	RP11-466F5.8	-6.31	4.22e-10	7.42e-08	-0.34	-0.19	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165717636	chr1:165768929~165775176:+
BRCA	cis	rs1823913	0.562	rs17347499	ENSG00000280083.1	RP11-317J9.1	-6.31	4.22e-10	7.42e-08	-0.22	-0.19	Obesity-related traits;	chr2:191301116	chr2:191154118~191156070:-
BRCA	cis	rs6570726	0.967	rs439017	ENSG00000235652.6	RP11-545I5.3	6.31	4.23e-10	7.42e-08	0.19	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145484987	chr6:145799409~145886585:+
BRCA	cis	rs420259	0.516	rs152455	ENSG00000260136.4	CTD-2270L9.4	6.31	4.23e-10	7.42e-08	0.19	0.19	Bipolar disorder;	chr16:23571752	chr16:23452758~23457606:+
BRCA	cis	rs2348418	0.864	rs7314984	ENSG00000247934.4	RP11-967K21.1	6.31	4.23e-10	7.43e-08	0.21	0.19	Lung function (FEV1);Lung function (FVC);	chr12:28557936	chr12:28163298~28190738:-
BRCA	cis	rs7246657	1	rs10426297	ENSG00000226686.6	LINC01535	-6.31	4.23e-10	7.44e-08	-0.29	-0.19	Coronary artery calcification;	chr19:37307471	chr19:37251912~37265535:+
BRCA	cis	rs7617773	0.78	rs35190747	ENSG00000228638.1	FCF1P2	-6.31	4.23e-10	7.44e-08	-0.22	-0.19	Coronary artery disease;	chr3:48301800	chr3:48290793~48291375:-
BRCA	cis	rs7617773	0.78	rs4511915	ENSG00000228638.1	FCF1P2	-6.31	4.23e-10	7.44e-08	-0.22	-0.19	Coronary artery disease;	chr3:48302368	chr3:48290793~48291375:-
BRCA	cis	rs7617773	0.78	rs13066758	ENSG00000228638.1	FCF1P2	-6.31	4.23e-10	7.44e-08	-0.22	-0.19	Coronary artery disease;	chr3:48302387	chr3:48290793~48291375:-
BRCA	cis	rs7617773	0.78	rs4392440	ENSG00000228638.1	FCF1P2	-6.31	4.23e-10	7.44e-08	-0.22	-0.19	Coronary artery disease;	chr3:48302430	chr3:48290793~48291375:-
BRCA	cis	rs875971	0.83	rs4718358	ENSG00000224316.1	RP11-479O9.2	6.31	4.24e-10	7.44e-08	0.19	0.19	Aortic root size;	chr7:66508681	chr7:65773620~65802067:+
BRCA	cis	rs919433	0.857	rs36071109	ENSG00000231621.1	AC013264.2	6.31	4.24e-10	7.45e-08	0.19	0.19	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197318467	chr2:197197991~197199273:+
BRCA	cis	rs11098499	1	rs6849889	ENSG00000249244.1	RP11-548H18.2	6.31	4.24e-10	7.45e-08	0.23	0.19	Corneal astigmatism;	chr4:119265193	chr4:119391831~119395335:-
BRCA	cis	rs673078	0.66	rs76621503	ENSG00000275409.1	RP11-131L12.4	-6.31	4.25e-10	7.46e-08	-0.3	-0.19	Glucose homeostasis traits;	chr12:118179370	chr12:118430147~118430699:+
BRCA	cis	rs7826238	0.623	rs2976893	ENSG00000254153.1	CTA-398F10.2	-6.3	4.25e-10	7.47e-08	-0.23	-0.19	Systolic blood pressure;	chr8:8480709	chr8:8456909~8461337:-
BRCA	cis	rs9308731	0.591	rs7569300	ENSG00000227992.1	AC108463.2	-6.3	4.25e-10	7.47e-08	-0.22	-0.19	Chronic lymphocytic leukemia;	chr2:111187296	chr2:111203964~111206215:-
BRCA	cis	rs9308731	0.569	rs7585054	ENSG00000227992.1	AC108463.2	-6.3	4.25e-10	7.47e-08	-0.22	-0.19	Chronic lymphocytic leukemia;	chr2:111187350	chr2:111203964~111206215:-
BRCA	cis	rs9308731	0.591	rs7588534	ENSG00000227992.1	AC108463.2	-6.3	4.25e-10	7.47e-08	-0.22	-0.19	Chronic lymphocytic leukemia;	chr2:111187510	chr2:111203964~111206215:-
BRCA	cis	rs875971	0.571	rs160647	ENSG00000273024.4	INTS4P2	6.3	4.26e-10	7.48e-08	0.24	0.19	Aortic root size;	chr7:66089365	chr7:65647864~65715661:+
BRCA	cis	rs2732480	0.538	rs2468943	ENSG00000273765.1	RP11-370I10.11	-6.3	4.26e-10	7.48e-08	-0.23	-0.19	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48353466	chr12:48360920~48361377:+
BRCA	cis	rs853679	0.546	rs200490	ENSG00000220721.1	OR1F12	6.3	4.27e-10	7.5e-08	0.34	0.19	Depression;	chr6:27829157	chr6:28073316~28074233:+
BRCA	cis	rs7246657	0.943	rs7252325	ENSG00000226686.6	LINC01535	-6.3	4.27e-10	7.5e-08	-0.28	-0.19	Coronary artery calcification;	chr19:37439743	chr19:37251912~37265535:+
BRCA	cis	rs7267979	0.789	rs6083820	ENSG00000204556.4	CTD-2514C3.1	6.3	4.27e-10	7.5e-08	0.27	0.19	Liver enzyme levels (alkaline phosphatase);	chr20:25373542	chr20:26018832~26020684:+
BRCA	cis	rs919433	0.68	rs2244271	ENSG00000231621.1	AC013264.2	-6.3	4.27e-10	7.5e-08	-0.18	-0.19	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197421857	chr2:197197991~197199273:+
BRCA	cis	rs16978956	0.803	rs2424171	ENSG00000236474.1	GCNT1P1	6.3	4.28e-10	7.5e-08	0.23	0.19	Body mass index;	chr20:18348172	chr20:18420160~18421454:-
BRCA	cis	rs67981189	0.865	rs2810117	ENSG00000258571.1	PTTG4P	6.3	4.28e-10	7.5e-08	0.21	0.19	Schizophrenia;	chr14:70924308	chr14:71085482~71085833:-
BRCA	cis	rs7086627	0.515	rs2125040	ENSG00000226659.1	RP11-137H2.4	-6.3	4.28e-10	7.5e-08	-0.25	-0.19	Post bronchodilator FEV1;	chr10:80448666	chr10:80529597~80535942:-
BRCA	cis	rs34779708	0.966	rs4934732	ENSG00000271335.4	RP11-324I22.4	6.3	4.28e-10	7.5e-08	0.2	0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35142756	chr10:35314552~35336401:-
BRCA	cis	rs8114671	0.869	rs2145559	ENSG00000269202.1	RP4-614O4.12	6.3	4.29e-10	7.53e-08	0.2	0.19	Height;	chr20:35063922	chr20:35201747~35203288:-
BRCA	cis	rs9638182	0.623	rs71556715	ENSG00000274080.1	CTA-315H11.2	6.3	4.29e-10	7.53e-08	0.38	0.19	Triglycerides;	chr7:73467477	chr7:73609262~73611502:-
BRCA	cis	rs9638182	0.725	rs7797566	ENSG00000274080.1	CTA-315H11.2	6.3	4.29e-10	7.53e-08	0.38	0.19	Triglycerides;	chr7:73482065	chr7:73609262~73611502:-
BRCA	cis	rs9638182	0.725	rs111837003	ENSG00000274080.1	CTA-315H11.2	6.3	4.29e-10	7.53e-08	0.38	0.19	Triglycerides;	chr7:73493129	chr7:73609262~73611502:-
BRCA	cis	rs13113518	0.812	rs12649507	ENSG00000273257.1	RP11-177J6.1	-6.3	4.29e-10	7.53e-08	-0.25	-0.19	Height;	chr4:55514317	chr4:55387949~55388271:+
BRCA	cis	rs67981189	0.896	rs2810098	ENSG00000269927.1	RP6-91H8.3	-6.3	4.29e-10	7.54e-08	-0.24	-0.19	Schizophrenia;	chr14:70967194	chr14:71141125~71143253:-
BRCA	cis	rs1124769	0.748	rs35111245	ENSG00000259378.1	DCAF13P3	6.3	4.3e-10	7.54e-08	0.28	0.19	Cognitive performance;	chr15:51069234	chr15:50944663~50945996:+
BRCA	cis	rs9307551	0.817	rs12511646	ENSG00000250334.4	LINC00989	-6.3	4.3e-10	7.54e-08	-0.26	-0.19	Refractive error;	chr4:79578700	chr4:79492416~79576460:+
BRCA	cis	rs2243480	1	rs73142122	ENSG00000228409.4	CCT6P1	6.3	4.3e-10	7.55e-08	0.27	0.19	Diabetic kidney disease;	chr7:65846311	chr7:65751142~65763354:+
BRCA	cis	rs2243480	0.901	rs73142137	ENSG00000228409.4	CCT6P1	6.3	4.3e-10	7.55e-08	0.27	0.19	Diabetic kidney disease;	chr7:65878455	chr7:65751142~65763354:+
BRCA	cis	rs2243480	1	rs13247184	ENSG00000228409.4	CCT6P1	6.3	4.3e-10	7.55e-08	0.27	0.19	Diabetic kidney disease;	chr7:65893941	chr7:65751142~65763354:+
BRCA	cis	rs2243480	1	rs35283677	ENSG00000228409.4	CCT6P1	6.3	4.3e-10	7.55e-08	0.27	0.19	Diabetic kidney disease;	chr7:65894246	chr7:65751142~65763354:+
BRCA	cis	rs2243480	1	rs35421653	ENSG00000228409.4	CCT6P1	6.3	4.3e-10	7.55e-08	0.27	0.19	Diabetic kidney disease;	chr7:65898442	chr7:65751142~65763354:+
BRCA	cis	rs4713118	0.955	rs9468203	ENSG00000220721.1	OR1F12	6.3	4.3e-10	7.55e-08	0.24	0.19	Parkinson's disease;	chr6:27720888	chr6:28073316~28074233:+
BRCA	cis	rs10129255	0.5	rs9324092	ENSG00000274576.2	IGHV2-70	6.3	4.31e-10	7.55e-08	0.16	0.19	Kawasaki disease;	chr14:106683806	chr14:106770577~106771020:-
BRCA	cis	rs875971	0.528	rs801213	ENSG00000236529.1	RP13-254B10.1	-6.3	4.31e-10	7.56e-08	-0.24	-0.19	Aortic root size;	chr7:66549931	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.545	rs801212	ENSG00000236529.1	RP13-254B10.1	-6.3	4.31e-10	7.56e-08	-0.24	-0.19	Aortic root size;	chr7:66550643	chr7:65840212~65840596:+
BRCA	cis	rs2179367	0.632	rs11155649	ENSG00000216906.2	RP11-350J20.9	6.3	4.32e-10	7.58e-08	0.27	0.19	Dupuytren's disease;	chr6:149405830	chr6:149904243~149906418:+
BRCA	cis	rs853679	0.517	rs4713135	ENSG00000280107.1	AL022393.9	-6.3	4.32e-10	7.58e-08	-0.28	-0.19	Depression;	chr6:28071808	chr6:28170845~28172521:+
BRCA	cis	rs11722228	0.522	rs7681250	ENSG00000261490.1	RP11-448G15.3	6.3	4.32e-10	7.58e-08	0.21	0.19	Urate levels;Serum uric acid levels;Gout;	chr4:10131389	chr4:10068089~10073019:-
BRCA	cis	rs11722228	0.522	rs7662229	ENSG00000261490.1	RP11-448G15.3	6.3	4.32e-10	7.58e-08	0.21	0.19	Urate levels;Serum uric acid levels;Gout;	chr4:10131390	chr4:10068089~10073019:-
BRCA	cis	rs10266483	0.515	rs6949304	ENSG00000271550.1	BNIP3P11	-6.3	4.32e-10	7.58e-08	-0.3	-0.19	Response to statin therapy;	chr7:64257903	chr7:64678954~64687393:-
BRCA	cis	rs4660456	0.504	rs587064	ENSG00000237899.1	RP4-739H11.3	6.3	4.33e-10	7.59e-08	0.29	0.19	Platelet count;	chr1:40640238	chr1:40669089~40687588:-
BRCA	cis	rs6142102	0.923	rs2268078	ENSG00000275784.1	RP5-1125A11.6	-6.3	4.34e-10	7.61e-08	-0.24	-0.19	Skin pigmentation;	chr20:34008898	chr20:33989480~33991818:-
BRCA	cis	rs7520050	0.966	rs785464	ENSG00000280836.1	AL355480.1	6.3	4.34e-10	7.61e-08	0.22	0.19	Reticulocyte count;Red blood cell count;	chr1:46057417	chr1:45581219~45581321:-
BRCA	cis	rs4950322	0.58	rs2083720	ENSG00000278811.3	LINC00624	6.3	4.34e-10	7.62e-08	0.25	0.19	Protein quantitative trait loci;	chr1:147122296	chr1:147258885~147517875:-
BRCA	cis	rs2531992	0.858	rs2230742	ENSG00000262185.1	RP11-462G12.1	6.3	4.34e-10	7.62e-08	0.29	0.19	Waist circumference;	chr16:3966675	chr16:3947609~3950444:-
BRCA	cis	rs5015933	0.767	rs12339434	ENSG00000232630.1	PRPS1P2	-6.3	4.35e-10	7.62e-08	-0.18	-0.19	Body mass index;	chr9:125376602	chr9:125150653~125151589:+
BRCA	cis	rs853679	0.55	rs1233707	ENSG00000219392.1	RP1-265C24.5	-6.3	4.35e-10	7.63e-08	-0.27	-0.19	Depression;	chr6:28205175	chr6:28115628~28116551:+
BRCA	cis	rs2348418	0.639	rs7969946	ENSG00000247934.4	RP11-967K21.1	-6.3	4.36e-10	7.64e-08	-0.22	-0.19	Lung function (FEV1);Lung function (FVC);	chr12:28111814	chr12:28163298~28190738:-
BRCA	cis	rs2280018	0.963	rs11075255	ENSG00000263335.1	AF001548.5	-6.3	4.36e-10	7.64e-08	-0.23	-0.19	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15072375	chr16:15726674~15732993:+
BRCA	cis	rs1823913	0.599	rs6732976	ENSG00000280083.1	RP11-317J9.1	6.3	4.36e-10	7.64e-08	0.22	0.19	Obesity-related traits;	chr2:191281004	chr2:191154118~191156070:-
BRCA	cis	rs875971	0.862	rs12537823	ENSG00000224316.1	RP11-479O9.2	6.3	4.36e-10	7.64e-08	0.19	0.19	Aortic root size;	chr7:66255897	chr7:65773620~65802067:+
BRCA	cis	rs853679	0.517	rs3757185	ENSG00000280107.1	AL022393.9	-6.3	4.36e-10	7.64e-08	-0.29	-0.19	Depression;	chr6:28139998	chr6:28170845~28172521:+
BRCA	cis	rs1707322	0.927	rs6690386	ENSG00000281133.1	AL355480.3	-6.3	4.36e-10	7.64e-08	-0.25	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45787339	chr1:45580892~45580996:-
BRCA	cis	rs2998286	0.678	rs332184	ENSG00000254635.4	WAC-AS1	-6.3	4.36e-10	7.65e-08	-0.31	-0.19	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28624042	chr10:28522652~28532743:-
BRCA	cis	rs4683346	0.616	rs2372110	ENSG00000173811.9	CCDC13-AS1	-6.3	4.36e-10	7.65e-08	-0.26	-0.19	Granulocyte percentage of myeloid white cells;	chr3:42778365	chr3:42732575~42746768:+
BRCA	cis	rs9876781	1	rs3214041	ENSG00000229759.1	MRPS18AP1	6.3	4.37e-10	7.65e-08	0.21	0.19	Longevity;	chr3:48413059	chr3:48256350~48256938:-
BRCA	cis	rs237743	1	rs2273145	ENSG00000222365.1	SNORD12B	-6.3	4.37e-10	7.65e-08	-0.26	-0.19	Height;	chr20:49223054	chr20:49280319~49280409:+
BRCA	cis	rs237743	1	rs11553387	ENSG00000222365.1	SNORD12B	-6.3	4.37e-10	7.65e-08	-0.26	-0.19	Height;	chr20:49225123	chr20:49280319~49280409:+
BRCA	cis	rs875971	0.545	rs316316	ENSG00000273024.4	INTS4P2	6.3	4.37e-10	7.67e-08	0.24	0.19	Aortic root size;	chr7:66149270	chr7:65647864~65715661:+
BRCA	cis	rs853679	0.55	rs9295762	ENSG00000219392.1	RP1-265C24.5	6.3	4.37e-10	7.67e-08	0.28	0.19	Depression;	chr6:28187640	chr6:28115628~28116551:+
BRCA	cis	rs7914558	1	rs11191542	ENSG00000213061.2	PFN1P11	6.3	4.38e-10	7.67e-08	0.25	0.19	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103064567	chr10:102838011~102845473:-
BRCA	cis	rs10129255	0.5	rs1024350	ENSG00000274576.2	IGHV2-70	-6.3	4.38e-10	7.67e-08	-0.16	-0.19	Kawasaki disease;	chr14:106685105	chr14:106770577~106771020:-
BRCA	cis	rs4683346	0.616	rs35584330	ENSG00000173811.9	CCDC13-AS1	-6.3	4.38e-10	7.67e-08	-0.26	-0.19	Granulocyte percentage of myeloid white cells;	chr3:42769748	chr3:42732575~42746768:+
BRCA	cis	rs7587476	0.906	rs2070096	ENSG00000229267.2	AC072062.1	-6.3	4.38e-10	7.68e-08	-0.27	-0.19	Neuroblastoma;	chr2:214780821	chr2:214810229~214963274:+
BRCA	cis	rs9876781	1	rs7634377	ENSG00000229759.1	MRPS18AP1	6.3	4.38e-10	7.68e-08	0.21	0.19	Longevity;	chr3:48379768	chr3:48256350~48256938:-
BRCA	cis	rs1707322	1	rs1707338	ENSG00000281133.1	AL355480.3	6.3	4.39e-10	7.69e-08	0.24	0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46046309	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.964	rs1707339	ENSG00000281133.1	AL355480.3	6.3	4.39e-10	7.69e-08	0.24	0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46047507	chr1:45580892~45580996:-
BRCA	cis	rs1707322	1	rs1768818	ENSG00000281133.1	AL355480.3	6.3	4.39e-10	7.69e-08	0.24	0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46048614	chr1:45580892~45580996:-
BRCA	cis	rs1707322	1	rs1768817	ENSG00000281133.1	AL355480.3	6.3	4.39e-10	7.69e-08	0.24	0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46048862	chr1:45580892~45580996:-
BRCA	cis	rs7045881	0.674	rs73438223	ENSG00000254396.1	RP11-56F10.3	6.3	4.39e-10	7.69e-08	0.33	0.19	Schizophrenia;	chr9:27041663	chr9:27102630~27104728:+
BRCA	cis	rs2243480	1	rs67728539	ENSG00000228409.4	CCT6P1	6.3	4.39e-10	7.69e-08	0.26	0.19	Diabetic kidney disease;	chr7:65913137	chr7:65751142~65763354:+
BRCA	cis	rs2554380	0.55	rs56159777	ENSG00000230373.7	GOLGA6L5P	6.3	4.39e-10	7.7e-08	0.24	0.19	Height;	chr15:83870527	chr15:84507885~84516814:-
BRCA	cis	rs2554380	0.55	rs4842919	ENSG00000230373.7	GOLGA6L5P	6.3	4.39e-10	7.7e-08	0.24	0.19	Height;	chr15:83870668	chr15:84507885~84516814:-
BRCA	cis	rs875971	0.545	rs75577046	ENSG00000273024.4	INTS4P2	-6.3	4.39e-10	7.7e-08	-0.24	-0.19	Aortic root size;	chr7:66493729	chr7:65647864~65715661:+
BRCA	cis	rs7598759	0.548	rs1584462	ENSG00000223198.1	RNU2-22P	-6.3	4.4e-10	7.7e-08	-0.23	-0.19	Noise-induced hearing loss;	chr2:231505087	chr2:231501990~231502201:-
BRCA	cis	rs55702914	0.71	rs1429419	ENSG00000231621.1	AC013264.2	6.3	4.4e-10	7.71e-08	0.19	0.19	Major depression and alcohol dependence;	chr2:197289823	chr2:197197991~197199273:+
BRCA	cis	rs7567389	0.677	rs7607907	ENSG00000236682.1	AC068282.3	6.3	4.4e-10	7.71e-08	0.28	0.19	Self-rated health;	chr2:127386710	chr2:127389130~127400580:+
BRCA	cis	rs2638953	0.744	rs11049426	ENSG00000247934.4	RP11-967K21.1	-6.3	4.41e-10	7.72e-08	-0.25	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28193573	chr12:28163298~28190738:-
BRCA	cis	rs77972916	0.505	rs1322	ENSG00000234936.1	AC010883.5	6.3	4.41e-10	7.73e-08	0.23	0.19	Granulocyte percentage of myeloid white cells;	chr2:43294028	chr2:43229573~43233394:+
BRCA	cis	rs7124681	0.584	rs4752792	ENSG00000280615.1	Y_RNA	-6.3	4.41e-10	7.73e-08	-0.22	-0.19	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:47794150	chr11:47614898~47614994:-
BRCA	cis	rs237743	1	rs13038202	ENSG00000222365.1	SNORD12B	-6.3	4.41e-10	7.73e-08	-0.26	-0.19	Height;	chr20:49219081	chr20:49280319~49280409:+
BRCA	cis	rs7976269	0.515	rs9300183	ENSG00000257176.2	RP11-996F15.2	-6.3	4.42e-10	7.73e-08	-0.23	-0.19	Male-pattern baldness;	chr12:29002316	chr12:29280418~29317848:-
BRCA	cis	rs17027258	0.609	rs4851005	ENSG00000234389.1	AC007278.3	-6.3	4.42e-10	7.73e-08	-0.19	-0.19	White blood cell types;	chr2:102395092	chr2:102438713~102440475:+
BRCA	cis	rs1150668	0.796	rs2247002	ENSG00000220721.1	OR1F12	6.3	4.43e-10	7.75e-08	0.21	0.19	Pubertal anthropometrics;	chr6:28430174	chr6:28073316~28074233:+
BRCA	cis	rs2243480	1	rs465359	ENSG00000229886.1	RP5-1132H15.3	6.3	4.43e-10	7.75e-08	0.34	0.19	Diabetic kidney disease;	chr7:66093177	chr7:66025126~66031544:-
BRCA	cis	rs2243480	1	rs462853	ENSG00000229886.1	RP5-1132H15.3	6.3	4.43e-10	7.75e-08	0.34	0.19	Diabetic kidney disease;	chr7:66093180	chr7:66025126~66031544:-
BRCA	cis	rs2243480	1	rs160644	ENSG00000229886.1	RP5-1132H15.3	6.3	4.43e-10	7.75e-08	0.34	0.19	Diabetic kidney disease;	chr7:66093199	chr7:66025126~66031544:-
BRCA	cis	rs2243480	1	rs160642	ENSG00000229886.1	RP5-1132H15.3	6.3	4.43e-10	7.75e-08	0.34	0.19	Diabetic kidney disease;	chr7:66093386	chr7:66025126~66031544:-
BRCA	cis	rs2243480	0.614	rs34032527	ENSG00000229886.1	RP5-1132H15.3	6.3	4.43e-10	7.75e-08	0.34	0.19	Diabetic kidney disease;	chr7:66100154	chr7:66025126~66031544:-
BRCA	cis	rs13113518	0.783	rs11943206	ENSG00000273257.1	RP11-177J6.1	6.3	4.43e-10	7.76e-08	0.25	0.19	Height;	chr4:55570843	chr4:55387949~55388271:+
BRCA	cis	rs1707322	1	rs4524994	ENSG00000281133.1	AL355480.3	-6.3	4.43e-10	7.76e-08	-0.24	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45904591	chr1:45580892~45580996:-
BRCA	cis	rs754466	0.58	rs12354903	ENSG00000204049.1	RP11-126H7.4	6.3	4.43e-10	7.77e-08	0.23	0.19	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77776707	chr10:77866875~77869610:+
BRCA	cis	rs8031584	0.958	rs34909055	ENSG00000260382.1	RP11-540B6.2	6.3	4.44e-10	7.77e-08	0.23	0.19	Huntington's disease progression;	chr15:30991967	chr15:30882267~30883231:-
BRCA	cis	rs858239	0.932	rs1624451	ENSG00000230042.1	AK3P3	6.3	4.44e-10	7.77e-08	0.22	0.19	Cerebrospinal fluid biomarker levels;	chr7:23222816	chr7:23129178~23129841:+
BRCA	cis	rs4713118	0.587	rs9393899	ENSG00000219392.1	RP1-265C24.5	-6.3	4.44e-10	7.77e-08	-0.29	-0.19	Parkinson's disease;	chr6:28165750	chr6:28115628~28116551:+
BRCA	cis	rs2919009	0.664	rs7906521	ENSG00000271670.1	RP11-95I16.4	6.3	4.44e-10	7.78e-08	0.25	0.19	Obesity-related traits;	chr10:120927034	chr10:120879256~120880667:-
BRCA	cis	rs72634501	0.716	rs4660165	ENSG00000228060.1	RP11-69E11.8	6.3	4.45e-10	7.78e-08	0.24	0.19	HDL cholesterol;	chr1:39112860	chr1:39565160~39573203:+
BRCA	cis	rs9876781	1	rs9311423	ENSG00000229759.1	MRPS18AP1	6.3	4.45e-10	7.79e-08	0.22	0.19	Longevity;	chr3:48378818	chr3:48256350~48256938:-
BRCA	cis	rs1322639	0.614	rs9294967	ENSG00000261039.2	RP11-417E7.2	6.3	4.45e-10	7.79e-08	0.25	0.19	Pulse pressure;	chr6:169165311	chr6:169175304~169182740:-
BRCA	cis	rs6142102	0.607	rs6088408	ENSG00000276073.1	RP5-1125A11.7	6.3	4.45e-10	7.8e-08	0.24	0.19	Skin pigmentation;	chr20:34146800	chr20:33985617~33988989:-
BRCA	cis	rs4713118	0.513	rs156738	ENSG00000204709.4	LINC01556	6.3	4.46e-10	7.8e-08	0.26	0.19	Parkinson's disease;	chr6:28046247	chr6:28943877~28944537:+
BRCA	cis	rs11098499	0.738	rs28408407	ENSG00000249244.1	RP11-548H18.2	6.3	4.46e-10	7.8e-08	0.22	0.19	Corneal astigmatism;	chr4:119454875	chr4:119391831~119395335:-
BRCA	cis	rs6095360	0.727	rs8118101	ENSG00000222365.1	SNORD12B	-6.3	4.46e-10	7.8e-08	-0.24	-0.19	Intelligence (multi-trait analysis);	chr20:49073301	chr20:49280319~49280409:+
BRCA	cis	rs6095360	0.727	rs7271812	ENSG00000222365.1	SNORD12B	-6.3	4.46e-10	7.8e-08	-0.24	-0.19	Intelligence (multi-trait analysis);	chr20:49076496	chr20:49280319~49280409:+
BRCA	cis	rs7247513	0.797	rs3815914	ENSG00000230310.1	CTD-2192J16.11	-6.3	4.46e-10	7.81e-08	-0.25	-0.19	Bipolar disorder;	chr19:12649850	chr19:12552597~12553644:+
BRCA	cis	rs72627509	0.68	rs3733309	ENSG00000269949.1	RP11-738E22.3	6.3	4.47e-10	7.82e-08	0.33	0.19	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56991022	chr4:56960927~56961373:-
BRCA	cis	rs7914558	0.966	rs11191518	ENSG00000213061.2	PFN1P11	6.3	4.47e-10	7.82e-08	0.25	0.19	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103023096	chr10:102838011~102845473:-
BRCA	cis	rs7615952	0.576	rs6780025	ENSG00000171084.14	FAM86JP	6.3	4.47e-10	7.82e-08	0.3	0.19	Blood pressure (smoking interaction);	chr3:126096781	chr3:125916620~125930024:+
BRCA	cis	rs7615952	0.576	rs6804482	ENSG00000171084.14	FAM86JP	6.3	4.47e-10	7.82e-08	0.3	0.19	Blood pressure (smoking interaction);	chr3:126096919	chr3:125916620~125930024:+
BRCA	cis	rs7555523	0.887	rs4657477	ENSG00000224358.1	RP11-466F5.8	-6.3	4.47e-10	7.82e-08	-0.31	-0.19	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165766938	chr1:165768929~165775176:+
BRCA	cis	rs710913	0.717	rs1180352	ENSG00000237624.1	OXCT2P1	-6.3	4.48e-10	7.85e-08	-0.22	-0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39542157	chr1:39514956~39516490:+
BRCA	cis	rs4713118	0.513	rs149972	ENSG00000216901.1	AL022393.7	6.3	4.48e-10	7.85e-08	0.25	0.19	Parkinson's disease;	chr6:28015449	chr6:28176188~28176674:+
BRCA	cis	rs4713118	0.513	rs149975	ENSG00000216901.1	AL022393.7	6.3	4.48e-10	7.85e-08	0.25	0.19	Parkinson's disease;	chr6:28018562	chr6:28176188~28176674:+
BRCA	cis	rs2243480	1	rs34136756	ENSG00000228409.4	CCT6P1	6.3	4.49e-10	7.85e-08	0.26	0.19	Diabetic kidney disease;	chr7:65916269	chr7:65751142~65763354:+
BRCA	cis	rs6095360	0.7	rs13042443	ENSG00000222365.1	SNORD12B	-6.3	4.49e-10	7.86e-08	-0.24	-0.19	Intelligence (multi-trait analysis);	chr20:49047217	chr20:49280319~49280409:+
BRCA	cis	rs6095360	0.727	rs2227946	ENSG00000222365.1	SNORD12B	-6.3	4.49e-10	7.86e-08	-0.24	-0.19	Intelligence (multi-trait analysis);	chr20:49068783	chr20:49280319~49280409:+
BRCA	cis	rs2243480	1	rs781157	ENSG00000230295.1	RP11-458F8.2	-6.3	4.49e-10	7.86e-08	-0.25	-0.19	Diabetic kidney disease;	chr7:66013324	chr7:66880708~66882981:+
BRCA	cis	rs9992667	0.955	rs1000571	ENSG00000231160.8	KLF3-AS1	6.3	4.49e-10	7.86e-08	0.24	0.19	Eosinophil percentage of granulocytes;	chr4:38661274	chr4:38612701~38664883:-
BRCA	cis	rs9992667	0.955	rs12507197	ENSG00000231160.8	KLF3-AS1	6.3	4.49e-10	7.86e-08	0.24	0.19	Eosinophil percentage of granulocytes;	chr4:38662039	chr4:38612701~38664883:-
BRCA	cis	rs9992667	0.955	rs60029573	ENSG00000231160.8	KLF3-AS1	6.3	4.49e-10	7.86e-08	0.24	0.19	Eosinophil percentage of granulocytes;	chr4:38662242	chr4:38612701~38664883:-
BRCA	cis	rs853679	0.517	rs3757187	ENSG00000280107.1	AL022393.9	-6.3	4.5e-10	7.88e-08	-0.29	-0.19	Depression;	chr6:28139876	chr6:28170845~28172521:+
BRCA	cis	rs7727544	0.836	rs10463892	ENSG00000233006.5	AC034220.3	6.3	4.5e-10	7.88e-08	0.14	0.19	Blood metabolite levels;	chr5:132263012	chr5:132311285~132369916:-
BRCA	cis	rs7727544	0.901	rs55633655	ENSG00000233006.5	AC034220.3	6.3	4.5e-10	7.88e-08	0.14	0.19	Blood metabolite levels;	chr5:132263063	chr5:132311285~132369916:-
BRCA	cis	rs1124769	0.719	rs1871460	ENSG00000259378.1	DCAF13P3	6.3	4.51e-10	7.89e-08	0.27	0.19	Cognitive performance;	chr15:50943272	chr15:50944663~50945996:+
BRCA	cis	rs11098499	0.954	rs10034623	ENSG00000249244.1	RP11-548H18.2	6.3	4.51e-10	7.89e-08	0.23	0.19	Corneal astigmatism;	chr4:119476674	chr4:119391831~119395335:-
BRCA	cis	rs7911264	0.739	rs7071905	ENSG00000236493.2	EIF2S2P3	6.3	4.52e-10	7.9e-08	0.26	0.19	Inflammatory bowel disease;	chr10:92626365	chr10:92668745~92669743:-
BRCA	cis	rs7911264	0.739	rs10882094	ENSG00000236493.2	EIF2S2P3	6.3	4.52e-10	7.9e-08	0.26	0.19	Inflammatory bowel disease;	chr10:92627919	chr10:92668745~92669743:-
BRCA	cis	rs2115630	1	rs8037423	ENSG00000229212.6	RP11-561C5.4	6.3	4.52e-10	7.91e-08	0.21	0.19	P wave terminal force;	chr15:84812263	chr15:85205440~85234795:-
BRCA	cis	rs42490	0.966	rs40377	ENSG00000251136.7	RP11-37B2.1	-6.29	4.52e-10	7.91e-08	-0.18	-0.19	Leprosy;	chr8:89769725	chr8:89609409~89757727:-
BRCA	cis	rs2638953	0.886	rs11049393	ENSG00000278733.1	RP11-425D17.1	-6.29	4.52e-10	7.92e-08	-0.25	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28170273	chr12:28185625~28186190:-
BRCA	cis	rs910316	0.673	rs2012627	ENSG00000279594.1	RP11-950C14.10	6.29	4.53e-10	7.92e-08	0.21	0.19	Height;	chr14:74976400	chr14:75011269~75012851:-
BRCA	cis	rs10971721	0.822	rs12377078	ENSG00000260947.1	RP11-384P7.7	-6.29	4.53e-10	7.92e-08	-0.35	-0.19	Body mass index;	chr9:33934823	chr9:33697459~33700986:+
BRCA	cis	rs9876781	1	rs6804774	ENSG00000229759.1	MRPS18AP1	6.29	4.53e-10	7.92e-08	0.22	0.19	Longevity;	chr3:48389129	chr3:48256350~48256938:-
BRCA	cis	rs55702914	0.775	rs17405686	ENSG00000231621.1	AC013264.2	-6.29	4.53e-10	7.92e-08	-0.18	-0.19	Major depression and alcohol dependence;	chr2:197377137	chr2:197197991~197199273:+
BRCA	cis	rs13178541	0.638	rs34465140	ENSG00000250378.1	RP11-119J18.1	-6.29	4.53e-10	7.93e-08	-0.24	-0.19	IgG glycosylation;	chr5:135713707	chr5:135812667~135826582:+
BRCA	cis	rs7914558	1	rs4917994	ENSG00000213061.2	PFN1P11	6.29	4.53e-10	7.93e-08	0.25	0.19	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103051942	chr10:102838011~102845473:-
BRCA	cis	rs7914558	1	rs2275271	ENSG00000213061.2	PFN1P11	6.29	4.53e-10	7.93e-08	0.25	0.19	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103054405	chr10:102838011~102845473:-
BRCA	cis	rs7914558	1	rs11191539	ENSG00000213061.2	PFN1P11	6.29	4.53e-10	7.93e-08	0.25	0.19	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103060013	chr10:102838011~102845473:-
BRCA	cis	rs2179367	0.632	rs55836833	ENSG00000216906.2	RP11-350J20.9	6.29	4.53e-10	7.93e-08	0.27	0.19	Dupuytren's disease;	chr6:149403736	chr6:149904243~149906418:+
BRCA	cis	rs4948102	0.642	rs766333	ENSG00000226278.1	PSPHP1	-6.29	4.54e-10	7.94e-08	-0.21	-0.19	Plasma homocysteine levels (post-methionine load test);	chr7:56059011	chr7:55764797~55773288:+
BRCA	cis	rs4713118	0.662	rs149970	ENSG00000204709.4	LINC01556	6.29	4.54e-10	7.94e-08	0.28	0.19	Parkinson's disease;	chr6:28012442	chr6:28943877~28944537:+
BRCA	cis	rs2998286	0.862	rs2807763	ENSG00000254635.4	WAC-AS1	6.29	4.54e-10	7.95e-08	0.26	0.19	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28528702	chr10:28522652~28532743:-
BRCA	cis	rs2179367	0.632	rs763590	ENSG00000216906.2	RP11-350J20.9	6.29	4.55e-10	7.95e-08	0.27	0.19	Dupuytren's disease;	chr6:149398831	chr6:149904243~149906418:+
BRCA	cis	rs2179367	0.632	rs17506789	ENSG00000216906.2	RP11-350J20.9	6.29	4.55e-10	7.95e-08	0.27	0.19	Dupuytren's disease;	chr6:149399710	chr6:149904243~149906418:+
BRCA	cis	rs2179367	0.586	rs34097428	ENSG00000216906.2	RP11-350J20.9	6.29	4.55e-10	7.95e-08	0.27	0.19	Dupuytren's disease;	chr6:149399822	chr6:149904243~149906418:+
BRCA	cis	rs2179367	0.632	rs12154153	ENSG00000216906.2	RP11-350J20.9	6.29	4.55e-10	7.95e-08	0.27	0.19	Dupuytren's disease;	chr6:149401686	chr6:149904243~149906418:+
BRCA	cis	rs1322639	0.614	rs6925201	ENSG00000261039.2	RP11-417E7.2	6.29	4.55e-10	7.96e-08	0.24	0.19	Pulse pressure;	chr6:169163262	chr6:169175304~169182740:-
BRCA	cis	rs270601	0.77	rs4361510	ENSG00000233006.5	AC034220.3	6.29	4.56e-10	7.97e-08	0.14	0.19	Acylcarnitine levels;	chr5:132263954	chr5:132311285~132369916:-
BRCA	cis	rs2243480	1	rs3885839	ENSG00000228409.4	CCT6P1	6.29	4.57e-10	7.99e-08	0.27	0.19	Diabetic kidney disease;	chr7:65825416	chr7:65751142~65763354:+
BRCA	cis	rs9992667	0.911	rs28656945	ENSG00000231160.8	KLF3-AS1	6.29	4.57e-10	8e-08	0.24	0.19	Eosinophil percentage of granulocytes;	chr4:38665125	chr4:38612701~38664883:-
BRCA	cis	rs7569084	1	rs7569084	ENSG00000204929.10	AC074391.1	-6.29	4.58e-10	8.01e-08	-0.24	-0.19	Sum eosinophil basophil counts;	chr2:65429835	chr2:65436711~66084639:+
BRCA	cis	rs1707322	1	rs11211219	ENSG00000281133.1	AL355480.3	-6.29	4.58e-10	8.02e-08	-0.24	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45893806	chr1:45580892~45580996:-
BRCA	cis	rs13108904	0.901	rs6851528	ENSG00000254094.1	AC078852.1	-6.29	4.59e-10	8.02e-08	-0.21	-0.19	Obesity-related traits;	chr4:1302221	chr4:1356581~1358075:+
BRCA	cis	rs9992667	0.955	rs2078179	ENSG00000231160.8	KLF3-AS1	6.29	4.59e-10	8.02e-08	0.24	0.19	Eosinophil percentage of granulocytes;	chr4:38662878	chr4:38612701~38664883:-
BRCA	cis	rs5015933	0.902	rs13291306	ENSG00000232630.1	PRPS1P2	-6.29	4.59e-10	8.02e-08	-0.18	-0.19	Body mass index;	chr9:125362519	chr9:125150653~125151589:+
BRCA	cis	rs875971	0.964	rs6945019	ENSG00000224316.1	RP11-479O9.2	6.29	4.59e-10	8.03e-08	0.19	0.19	Aortic root size;	chr7:66457471	chr7:65773620~65802067:+
BRCA	cis	rs1124769	0.719	rs12911168	ENSG00000259378.1	DCAF13P3	6.29	4.6e-10	8.05e-08	0.27	0.19	Cognitive performance;	chr15:51088391	chr15:50944663~50945996:+
BRCA	cis	rs2243480	1	rs313802	ENSG00000230295.1	RP11-458F8.2	-6.29	4.6e-10	8.05e-08	-0.26	-0.19	Diabetic kidney disease;	chr7:66051386	chr7:66880708~66882981:+
BRCA	cis	rs2243480	0.803	rs403089	ENSG00000230295.1	RP11-458F8.2	-6.29	4.6e-10	8.05e-08	-0.26	-0.19	Diabetic kidney disease;	chr7:66052736	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs458291	ENSG00000230295.1	RP11-458F8.2	-6.29	4.6e-10	8.05e-08	-0.26	-0.19	Diabetic kidney disease;	chr7:66055492	chr7:66880708~66882981:+
BRCA	cis	rs5769707	0.609	rs739247	ENSG00000235111.1	RP1-29C18.8	-6.29	4.61e-10	8.06e-08	-0.21	-0.19	Monocyte percentage of white cells;Monocyte count;	chr22:49603009	chr22:49612657~49615716:-
BRCA	cis	rs4948102	0.642	rs4948104	ENSG00000273720.1	RP11-613E4.4	-6.29	4.61e-10	8.06e-08	-0.24	-0.19	Plasma homocysteine levels (post-methionine load test);	chr7:56074826	chr7:55743073~55743457:+
BRCA	cis	rs2380205	0.682	rs3750657	ENSG00000232807.2	RP11-536K7.3	6.29	4.61e-10	8.06e-08	0.19	0.19	Breast cancer;	chr10:5884116	chr10:5934270~5945900:-
BRCA	cis	rs2408955	0.521	rs10875749	ENSG00000240399.1	RP1-228P16.1	-6.29	4.61e-10	8.06e-08	-0.22	-0.19	Glycated hemoglobin levels;	chr12:48138134	chr12:48054813~48055591:-
BRCA	cis	rs202072	0.769	rs495895	ENSG00000272379.1	RP1-257A7.5	6.29	4.62e-10	8.07e-08	0.27	0.19	HIV-1 viral setpoint;	chr6:13277683	chr6:13290018~13290490:-
BRCA	cis	rs7246657	0.508	rs1644702	ENSG00000276846.1	CTD-3220F14.3	6.29	4.62e-10	8.07e-08	0.3	0.19	Coronary artery calcification;	chr19:37001005	chr19:37314868~37315620:-
BRCA	cis	rs801193	0.742	rs9969300	ENSG00000237310.1	GS1-124K5.4	-6.29	4.62e-10	8.07e-08	-0.2	-0.19	Aortic root size;	chr7:66316659	chr7:66493706~66495474:+
BRCA	cis	rs4654783	0.505	rs7544210	ENSG00000228397.1	RP1-224A6.3	-6.29	4.62e-10	8.07e-08	-0.23	-0.19	Endometriosis;	chr1:22128649	chr1:22023994~22024968:-
BRCA	cis	rs7617773	0.78	rs36075665	ENSG00000228638.1	FCF1P2	-6.29	4.62e-10	8.07e-08	-0.22	-0.19	Coronary artery disease;	chr3:48301597	chr3:48290793~48291375:-
BRCA	cis	rs228614	0.536	rs223375	ENSG00000251288.2	RP11-10L12.2	-6.29	4.62e-10	8.07e-08	-0.23	-0.19	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102836484	chr4:102751401~102752641:+
BRCA	cis	rs1124769	0.748	rs12591434	ENSG00000259378.1	DCAF13P3	6.29	4.62e-10	8.08e-08	0.27	0.19	Cognitive performance;	chr15:51081782	chr15:50944663~50945996:+
BRCA	cis	rs78456975	0.943	rs13385274	ENSG00000231482.2	AC141930.2	-6.29	4.62e-10	8.08e-08	-0.27	-0.19	Placebo response in major depressive disorder (% change in symptom score);	chr2:1573019	chr2:1572554~1580311:-
BRCA	cis	rs6095360	0.727	rs13040426	ENSG00000222365.1	SNORD12B	-6.29	4.63e-10	8.09e-08	-0.24	-0.19	Intelligence (multi-trait analysis);	chr20:49097916	chr20:49280319~49280409:+
BRCA	cis	rs6088813	0.961	rs6060371	ENSG00000126005.14	MMP24-AS1	-6.29	4.63e-10	8.09e-08	-0.23	-0.19	Height;	chr20:35325519	chr20:35216462~35278131:-
BRCA	cis	rs1707322	0.685	rs11211177	ENSG00000234329.1	RP11-767N6.2	6.29	4.63e-10	8.09e-08	0.2	0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45760677	chr1:45651039~45651826:-
BRCA	cis	rs1124769	0.719	rs7176498	ENSG00000259378.1	DCAF13P3	6.29	4.63e-10	8.09e-08	0.27	0.19	Cognitive performance;	chr15:50944641	chr15:50944663~50945996:+
BRCA	cis	rs1124769	0.719	rs3784304	ENSG00000259378.1	DCAF13P3	6.29	4.63e-10	8.09e-08	0.27	0.19	Cognitive performance;	chr15:50945863	chr15:50944663~50945996:+
BRCA	cis	rs1124769	0.719	rs1955	ENSG00000259378.1	DCAF13P3	6.29	4.63e-10	8.09e-08	0.27	0.19	Cognitive performance;	chr15:50945898	chr15:50944663~50945996:+
BRCA	cis	rs1124769	0.719	rs1876784	ENSG00000259378.1	DCAF13P3	6.29	4.63e-10	8.09e-08	0.27	0.19	Cognitive performance;	chr15:50946758	chr15:50944663~50945996:+
BRCA	cis	rs8031584	0.918	rs61997138	ENSG00000260382.1	RP11-540B6.2	6.29	4.64e-10	8.11e-08	0.23	0.19	Huntington's disease progression;	chr15:30978573	chr15:30882267~30883231:-
BRCA	cis	rs6095360	0.727	rs17450430	ENSG00000222365.1	SNORD12B	-6.29	4.64e-10	8.11e-08	-0.25	-0.19	Intelligence (multi-trait analysis);	chr20:49155727	chr20:49280319~49280409:+
BRCA	cis	rs41369048	0.858	rs2784273	ENSG00000238078.1	LINC01352	-6.29	4.65e-10	8.12e-08	-0.26	-0.19	Eosinophil counts;Sum eosinophil basophil counts;	chr1:220907744	chr1:220829255~220832429:+
BRCA	cis	rs4950322	0.57	rs17356492	ENSG00000278811.3	LINC00624	6.29	4.65e-10	8.12e-08	0.26	0.19	Protein quantitative trait loci;	chr1:147296089	chr1:147258885~147517875:-
BRCA	cis	rs467650	1	rs468238	ENSG00000248489.1	CTD-2007H13.3	6.29	4.65e-10	8.13e-08	0.22	0.19	Venous thromboembolism (SNP x SNP interaction);	chr5:98640401	chr5:98929171~98995013:+
BRCA	cis	rs17508449	0.865	rs4838993	ENSG00000232450.1	RP4-730K3.3	-6.29	4.65e-10	8.13e-08	-0.34	-0.19	Leprosy;	chr1:113592511	chr1:113698884~113699631:-
BRCA	cis	rs2030746	0.899	rs11686154	ENSG00000237614.1	AC073257.2	6.29	4.65e-10	8.13e-08	0.23	0.19	LDL cholesterol;Total cholesterol levels;LDL cholesterol levels;	chr2:120553361	chr2:120542909~120544326:-
BRCA	cis	rs2243480	1	rs466983	ENSG00000230295.1	RP11-458F8.2	-6.29	4.66e-10	8.14e-08	-0.26	-0.19	Diabetic kidney disease;	chr7:66055509	chr7:66880708~66882981:+
BRCA	cis	rs34779708	0.966	rs113170867	ENSG00000271335.4	RP11-324I22.4	6.29	4.66e-10	8.14e-08	0.21	0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35161219	chr10:35314552~35336401:-
BRCA	cis	rs875971	0.545	rs66594357	ENSG00000273024.4	INTS4P2	-6.29	4.67e-10	8.15e-08	-0.24	-0.19	Aortic root size;	chr7:66327797	chr7:65647864~65715661:+
BRCA	cis	rs2836950	0.545	rs2836952	ENSG00000238141.2	BRWD1-AS1	-6.29	4.67e-10	8.16e-08	-0.22	-0.19	Menarche (age at onset);	chr21:39244725	chr21:39315707~39323218:+
BRCA	cis	rs2274273	1	rs6573006	ENSG00000258413.1	RP11-665C16.6	-6.29	4.67e-10	8.16e-08	-0.25	-0.19	Protein biomarker;	chr14:55143714	chr14:55262767~55272075:-
BRCA	cis	rs2836950	0.565	rs2836926	ENSG00000238141.2	BRWD1-AS1	-6.29	4.67e-10	8.16e-08	-0.22	-0.19	Menarche (age at onset);	chr21:39164864	chr21:39315707~39323218:+
BRCA	cis	rs9992667	1	rs10032639	ENSG00000231160.8	KLF3-AS1	6.29	4.67e-10	8.16e-08	0.24	0.19	Eosinophil percentage of granulocytes;	chr4:38673107	chr4:38612701~38664883:-
BRCA	cis	rs9880211	0.644	rs35352346	ENSG00000273486.1	RP11-731C17.2	6.29	4.68e-10	8.17e-08	0.23	0.19	Height;Body mass index;	chr3:136162646	chr3:136837338~136839021:-
BRCA	cis	rs10266483	0.545	rs73132069	ENSG00000271550.1	BNIP3P11	-6.29	4.68e-10	8.17e-08	-0.3	-0.19	Response to statin therapy;	chr7:64258440	chr7:64678954~64687393:-
BRCA	cis	rs9992667	0.664	rs112691446	ENSG00000231160.8	KLF3-AS1	6.29	4.71e-10	8.23e-08	0.24	0.19	Eosinophil percentage of granulocytes;	chr4:38663521	chr4:38612701~38664883:-
BRCA	cis	rs3760982	1	rs10405457	ENSG00000267058.1	RP11-15A1.3	-6.29	4.72e-10	8.23e-08	-0.21	-0.19	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43792430	chr19:43891804~43901805:-
BRCA	cis	rs12594515	1	rs8033148	ENSG00000259200.1	RP11-718O11.1	-6.29	4.72e-10	8.24e-08	-0.21	-0.19	Weight;Waist circumference;	chr15:45705731	chr15:45705078~45931069:+
BRCA	cis	rs875971	1	rs6460296	ENSG00000224316.1	RP11-479O9.2	6.29	4.72e-10	8.24e-08	0.19	0.19	Aortic root size;	chr7:66430152	chr7:65773620~65802067:+
BRCA	cis	rs4950322	0.748	rs17360812	ENSG00000278811.3	LINC00624	-6.29	4.72e-10	8.24e-08	-0.26	-0.19	Protein quantitative trait loci;	chr1:147355010	chr1:147258885~147517875:-
BRCA	cis	rs7615952	0.641	rs12495947	ENSG00000171084.14	FAM86JP	6.29	4.73e-10	8.26e-08	0.3	0.19	Blood pressure (smoking interaction);	chr3:126052855	chr3:125916620~125930024:+
BRCA	cis	rs7615952	0.641	rs6805074	ENSG00000171084.14	FAM86JP	6.29	4.73e-10	8.26e-08	0.3	0.19	Blood pressure (smoking interaction);	chr3:126053431	chr3:125916620~125930024:+
BRCA	cis	rs2179367	0.632	rs9498321	ENSG00000216906.2	RP11-350J20.9	6.29	4.73e-10	8.26e-08	0.28	0.19	Dupuytren's disease;	chr6:149322573	chr6:149904243~149906418:+
BRCA	cis	rs2179367	0.632	rs9498344	ENSG00000216906.2	RP11-350J20.9	6.29	4.74e-10	8.27e-08	0.27	0.19	Dupuytren's disease;	chr6:149401053	chr6:149904243~149906418:+
BRCA	cis	rs858239	1	rs156425	ENSG00000230042.1	AK3P3	6.29	4.74e-10	8.27e-08	0.22	0.19	Cerebrospinal fluid biomarker levels;	chr7:23269500	chr7:23129178~23129841:+
BRCA	cis	rs12594515	1	rs8032835	ENSG00000259200.1	RP11-718O11.1	-6.29	4.74e-10	8.27e-08	-0.21	-0.19	Weight;Waist circumference;	chr15:45705699	chr15:45705078~45931069:+
BRCA	cis	rs2179367	0.632	rs12196750	ENSG00000216906.2	RP11-350J20.9	6.29	4.74e-10	8.27e-08	0.27	0.19	Dupuytren's disease;	chr6:149413335	chr6:149904243~149906418:+
BRCA	cis	rs2836950	0.565	rs2836942	ENSG00000255568.3	BRWD1-AS2	-6.29	4.74e-10	8.27e-08	-0.18	-0.19	Menarche (age at onset);	chr21:39219455	chr21:39313935~39314962:+
BRCA	cis	rs6597981	0.604	rs7945912	ENSG00000255284.1	AP006621.5	6.29	4.75e-10	8.28e-08	0.17	0.19	Breast cancer;	chr11:750849	chr11:777578~784297:+
BRCA	cis	rs4950322	0.543	rs4950318	ENSG00000278811.3	LINC00624	6.29	4.75e-10	8.29e-08	0.26	0.19	Protein quantitative trait loci;	chr1:147316240	chr1:147258885~147517875:-
BRCA	cis	rs4950322	0.543	rs4950319	ENSG00000278811.3	LINC00624	6.29	4.75e-10	8.29e-08	0.26	0.19	Protein quantitative trait loci;	chr1:147316250	chr1:147258885~147517875:-
BRCA	cis	rs34779708	0.966	rs4934539	ENSG00000271335.4	RP11-324I22.4	6.29	4.75e-10	8.29e-08	0.2	0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35183271	chr10:35314552~35336401:-
BRCA	cis	rs227275	0.554	rs223466	ENSG00000251288.2	RP11-10L12.2	-6.29	4.75e-10	8.29e-08	-0.22	-0.19	Allergic disease (asthma, hay fever or eczema);	chr4:102780039	chr4:102751401~102752641:+
BRCA	cis	rs7617773	0.78	rs35297395	ENSG00000228638.1	FCF1P2	-6.29	4.75e-10	8.29e-08	-0.22	-0.19	Coronary artery disease;	chr3:48301392	chr3:48290793~48291375:-
BRCA	cis	rs853679	0.55	rs1237875	ENSG00000219392.1	RP1-265C24.5	6.29	4.75e-10	8.29e-08	0.27	0.19	Depression;	chr6:28205232	chr6:28115628~28116551:+
BRCA	cis	rs6840360	0.642	rs56301462	ENSG00000270265.1	RP11-731D1.4	-6.29	4.75e-10	8.29e-08	-0.22	-0.19	Intelligence (multi-trait analysis);	chr4:151530976	chr4:151333775~151353224:-
BRCA	cis	rs2348418	0.864	rs6487689	ENSG00000247934.4	RP11-967K21.1	6.29	4.76e-10	8.31e-08	0.21	0.19	Lung function (FEV1);Lung function (FVC);	chr12:28560101	chr12:28163298~28190738:-
BRCA	cis	rs13113518	0.783	rs12510400	ENSG00000223305.1	RN7SKP30	6.29	4.77e-10	8.32e-08	0.24	0.19	Height;	chr4:55577294	chr4:55540502~55540835:-
BRCA	cis	rs250585	1	rs7202661	ENSG00000260136.4	CTD-2270L9.4	-6.29	4.77e-10	8.33e-08	-0.23	-0.19	Egg allergy;	chr16:23492720	chr16:23452758~23457606:+
BRCA	cis	rs34779708	0.931	rs7099593	ENSG00000271335.4	RP11-324I22.4	6.29	4.78e-10	8.33e-08	0.2	0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35077950	chr10:35314552~35336401:-
BRCA	cis	rs34779708	0.931	rs13376801	ENSG00000271335.4	RP11-324I22.4	6.29	4.78e-10	8.33e-08	0.2	0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35081515	chr10:35314552~35336401:-
BRCA	cis	rs6504622	0.935	rs740617	ENSG00000262879.4	RP11-156P1.3	6.29	4.78e-10	8.34e-08	0.19	0.19	Orofacial clefts;	chr17:46950635	chr17:46984045~47100323:-
BRCA	cis	rs6669008	1	rs6669008	ENSG00000232450.1	RP4-730K3.3	-6.29	4.79e-10	8.35e-08	-0.24	-0.19	Bacteremia;	chr1:113623939	chr1:113698884~113699631:-
BRCA	cis	rs12468226	0.938	rs12464254	ENSG00000226261.1	AC064836.3	6.29	4.79e-10	8.36e-08	0.33	0.19	Urate levels;	chr2:202301641	chr2:202336024~202336727:-
BRCA	cis	rs16846053	0.515	rs971027	ENSG00000227403.1	AC009299.3	-6.29	4.8e-10	8.37e-08	-0.32	-0.19	Blood osmolality (transformed sodium);	chr2:161588104	chr2:161244739~161249050:+
BRCA	cis	rs6840258	1	rs7695426	ENSG00000251411.1	RP11-397E7.4	-6.29	4.8e-10	8.37e-08	-0.26	-0.19	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87000125	chr4:86913266~86914817:-
BRCA	cis	rs270601	0.77	rs61352298	ENSG00000233006.5	AC034220.3	6.29	4.8e-10	8.37e-08	0.14	0.19	Acylcarnitine levels;	chr5:132264896	chr5:132311285~132369916:-
BRCA	cis	rs270601	0.739	rs1979981	ENSG00000233006.5	AC034220.3	6.29	4.8e-10	8.37e-08	0.14	0.19	Acylcarnitine levels;	chr5:132266027	chr5:132311285~132369916:-
BRCA	cis	rs2243480	1	rs73150014	ENSG00000229886.1	RP5-1132H15.3	6.29	4.8e-10	8.38e-08	0.33	0.19	Diabetic kidney disease;	chr7:65985932	chr7:66025126~66031544:-
BRCA	cis	rs9876781	1	rs6776700	ENSG00000229759.1	MRPS18AP1	6.29	4.8e-10	8.38e-08	0.22	0.19	Longevity;	chr3:48455358	chr3:48256350~48256938:-
BRCA	cis	rs793571	0.505	rs9635351	ENSG00000259250.1	RP11-50C13.1	-6.29	4.8e-10	8.38e-08	-0.32	-0.19	Schizophrenia;	chr15:58625762	chr15:58587507~58591676:+
BRCA	cis	rs7923609	0.756	rs7077256	ENSG00000232075.1	MRPL35P2	6.29	4.81e-10	8.38e-08	0.24	0.19	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63576425	chr10:63634317~63634827:-
BRCA	cis	rs2638953	0.962	rs73261702	ENSG00000278733.1	RP11-425D17.1	-6.29	4.81e-10	8.39e-08	-0.24	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28204118	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.924	rs11049455	ENSG00000278733.1	RP11-425D17.1	-6.29	4.81e-10	8.39e-08	-0.24	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28204758	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.924	rs11049457	ENSG00000278733.1	RP11-425D17.1	-6.29	4.81e-10	8.39e-08	-0.24	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28205050	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.886	rs10843131	ENSG00000278733.1	RP11-425D17.1	-6.29	4.81e-10	8.39e-08	-0.24	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28205259	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.924	rs10843132	ENSG00000278733.1	RP11-425D17.1	-6.29	4.81e-10	8.39e-08	-0.24	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28205348	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.924	rs10843133	ENSG00000278733.1	RP11-425D17.1	-6.29	4.81e-10	8.39e-08	-0.24	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28205571	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.924	rs10843135	ENSG00000278733.1	RP11-425D17.1	-6.29	4.81e-10	8.39e-08	-0.24	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28205809	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.886	rs11049458	ENSG00000278733.1	RP11-425D17.1	-6.29	4.81e-10	8.39e-08	-0.24	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28205834	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.924	rs11049459	ENSG00000278733.1	RP11-425D17.1	-6.29	4.81e-10	8.39e-08	-0.24	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28206011	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.924	rs11049460	ENSG00000278733.1	RP11-425D17.1	-6.29	4.81e-10	8.39e-08	-0.24	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28206021	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.924	rs1824767	ENSG00000278733.1	RP11-425D17.1	-6.29	4.81e-10	8.39e-08	-0.24	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28206653	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.924	rs1824766	ENSG00000278733.1	RP11-425D17.1	-6.29	4.81e-10	8.39e-08	-0.24	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28206655	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.924	rs1585682	ENSG00000278733.1	RP11-425D17.1	-6.29	4.81e-10	8.39e-08	-0.24	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28206841	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.888	rs9645745	ENSG00000278733.1	RP11-425D17.1	-6.29	4.81e-10	8.39e-08	-0.24	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28207082	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.924	rs7973516	ENSG00000278733.1	RP11-425D17.1	-6.29	4.81e-10	8.39e-08	-0.24	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28207523	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.924	rs7973656	ENSG00000278733.1	RP11-425D17.1	-6.29	4.81e-10	8.39e-08	-0.24	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28207679	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.924	rs7971033	ENSG00000278733.1	RP11-425D17.1	-6.29	4.81e-10	8.39e-08	-0.24	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28208420	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.924	rs7956418	ENSG00000278733.1	RP11-425D17.1	-6.29	4.81e-10	8.39e-08	-0.24	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28208566	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.924	rs11519094	ENSG00000278733.1	RP11-425D17.1	-6.29	4.81e-10	8.39e-08	-0.24	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28209430	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.924	rs11513465	ENSG00000278733.1	RP11-425D17.1	-6.29	4.81e-10	8.39e-08	-0.24	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28209483	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.924	rs11513250	ENSG00000278733.1	RP11-425D17.1	-6.29	4.81e-10	8.39e-08	-0.24	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28209500	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.924	rs11519330	ENSG00000278733.1	RP11-425D17.1	-6.29	4.81e-10	8.39e-08	-0.24	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28209720	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.85	rs11519331	ENSG00000278733.1	RP11-425D17.1	-6.29	4.81e-10	8.39e-08	-0.24	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28209995	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.888	rs11513466	ENSG00000278733.1	RP11-425D17.1	-6.29	4.81e-10	8.39e-08	-0.24	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28210111	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.924	rs7298652	ENSG00000278733.1	RP11-425D17.1	-6.29	4.81e-10	8.39e-08	-0.24	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28210620	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.924	rs6487669	ENSG00000278733.1	RP11-425D17.1	-6.29	4.81e-10	8.39e-08	-0.24	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28210827	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.924	rs6487671	ENSG00000278733.1	RP11-425D17.1	-6.29	4.81e-10	8.39e-08	-0.24	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28210902	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.924	rs11049464	ENSG00000278733.1	RP11-425D17.1	-6.29	4.81e-10	8.39e-08	-0.24	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28211637	chr12:28185625~28186190:-
BRCA	cis	rs853679	0.517	rs9368556	ENSG00000204709.4	LINC01556	6.29	4.81e-10	8.39e-08	0.29	0.19	Depression;	chr6:28163375	chr6:28943877~28944537:+
BRCA	cis	rs853679	0.517	rs9368557	ENSG00000204709.4	LINC01556	6.29	4.81e-10	8.39e-08	0.29	0.19	Depression;	chr6:28163759	chr6:28943877~28944537:+
BRCA	cis	rs853679	0.517	rs9380059	ENSG00000204709.4	LINC01556	6.29	4.81e-10	8.39e-08	0.29	0.19	Depression;	chr6:28164580	chr6:28943877~28944537:+
BRCA	cis	rs853679	0.517	rs9380060	ENSG00000204709.4	LINC01556	6.29	4.81e-10	8.39e-08	0.29	0.19	Depression;	chr6:28164825	chr6:28943877~28944537:+
BRCA	cis	rs853679	0.517	rs35227624	ENSG00000204709.4	LINC01556	6.29	4.81e-10	8.39e-08	0.29	0.19	Depression;	chr6:28164948	chr6:28943877~28944537:+
BRCA	cis	rs853679	0.517	rs9380061	ENSG00000204709.4	LINC01556	6.29	4.81e-10	8.39e-08	0.29	0.19	Depression;	chr6:28165025	chr6:28943877~28944537:+
BRCA	cis	rs853679	0.517	rs9368558	ENSG00000204709.4	LINC01556	6.29	4.81e-10	8.39e-08	0.29	0.19	Depression;	chr6:28165528	chr6:28943877~28944537:+
BRCA	cis	rs10861661	0.963	rs12424054	ENSG00000260329.1	RP11-412D9.4	6.28	4.81e-10	8.39e-08	0.26	0.19	Triglyceride levels;	chr12:106792969	chr12:106954029~106955497:-
BRCA	cis	rs7911264	0.739	rs10882091	ENSG00000236493.2	EIF2S2P3	6.28	4.81e-10	8.39e-08	0.26	0.19	Inflammatory bowel disease;	chr10:92614620	chr10:92668745~92669743:-
BRCA	cis	rs9816784	0.525	rs422772	ENSG00000231464.1	AC024937.4	6.28	4.82e-10	8.4e-08	0.26	0.19	Mean corpuscular hemoglobin;	chr3:196079601	chr3:195996738~195998233:+
BRCA	cis	rs34779708	0.966	rs1478463	ENSG00000271335.4	RP11-324I22.4	6.28	4.82e-10	8.41e-08	0.2	0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35184107	chr10:35314552~35336401:-
BRCA	cis	rs9308731	0.591	rs7565473	ENSG00000227992.1	AC108463.2	-6.28	4.83e-10	8.42e-08	-0.22	-0.19	Chronic lymphocytic leukemia;	chr2:111186213	chr2:111203964~111206215:-
BRCA	cis	rs1707322	0.89	rs2297883	ENSG00000281133.1	AL355480.3	6.28	4.83e-10	8.42e-08	0.24	0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46045815	chr1:45580892~45580996:-
BRCA	cis	rs34779708	0.966	rs35146199	ENSG00000271335.4	RP11-324I22.4	6.28	4.84e-10	8.44e-08	0.21	0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35172011	chr10:35314552~35336401:-
BRCA	cis	rs9308731	0.591	rs3898882	ENSG00000227992.1	AC108463.2	-6.28	4.85e-10	8.45e-08	-0.22	-0.19	Chronic lymphocytic leukemia;	chr2:111189890	chr2:111203964~111206215:-
BRCA	cis	rs4908760	0.792	rs4908505	ENSG00000270282.1	RP5-1115A15.2	6.28	4.86e-10	8.47e-08	0.2	0.19	Vitiligo;	chr1:8668805	chr1:8512653~8513021:+
BRCA	cis	rs4950322	0.515	rs11239958	ENSG00000278811.3	LINC00624	6.28	4.86e-10	8.47e-08	0.25	0.19	Protein quantitative trait loci;	chr1:147247454	chr1:147258885~147517875:-
BRCA	cis	rs34779708	0.966	rs4934540	ENSG00000271335.4	RP11-324I22.4	6.28	4.87e-10	8.48e-08	0.2	0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35185771	chr10:35314552~35336401:-
BRCA	cis	rs2280018	0.963	rs4985147	ENSG00000263335.1	AF001548.5	-6.28	4.87e-10	8.48e-08	-0.23	-0.19	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15074903	chr16:15726674~15732993:+
BRCA	cis	rs8031584	0.541	rs2959037	ENSG00000270015.1	RP11-540B6.6	6.28	4.87e-10	8.48e-08	0.19	0.19	Huntington's disease progression;	chr15:30925961	chr15:30926514~30928407:+
BRCA	cis	rs420259	0.556	rs7187920	ENSG00000260136.4	CTD-2270L9.4	-6.28	4.87e-10	8.49e-08	-0.19	-0.19	Bipolar disorder;	chr16:23552180	chr16:23452758~23457606:+
BRCA	cis	rs2732480	0.557	rs2732441	ENSG00000273765.1	RP11-370I10.11	6.28	4.87e-10	8.49e-08	0.23	0.19	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48329541	chr12:48360920~48361377:+
BRCA	cis	rs2732480	0.577	rs2732448	ENSG00000273765.1	RP11-370I10.11	6.28	4.87e-10	8.49e-08	0.23	0.19	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48336817	chr12:48360920~48361377:+
BRCA	cis	rs6479891	1	rs2616630	ENSG00000232075.1	MRPL35P2	6.28	4.88e-10	8.5e-08	0.35	0.19	Arthritis (juvenile idiopathic);	chr10:63453579	chr10:63634317~63634827:-
BRCA	cis	rs6479891	1	rs2616629	ENSG00000232075.1	MRPL35P2	6.28	4.88e-10	8.5e-08	0.35	0.19	Arthritis (juvenile idiopathic);	chr10:63454056	chr10:63634317~63634827:-
BRCA	cis	rs8114671	0.836	rs6141526	ENSG00000269202.1	RP4-614O4.12	6.28	4.88e-10	8.5e-08	0.2	0.19	Height;	chr20:35027452	chr20:35201747~35203288:-
BRCA	cis	rs375066	0.623	rs1549955	ENSG00000267058.1	RP11-15A1.3	6.28	4.88e-10	8.5e-08	0.22	0.19	Breast cancer;	chr19:43845709	chr19:43891804~43901805:-
BRCA	cis	rs375066	0.599	rs8106802	ENSG00000267058.1	RP11-15A1.3	6.28	4.88e-10	8.5e-08	0.22	0.19	Breast cancer;	chr19:43845944	chr19:43891804~43901805:-
BRCA	cis	rs375066	0.623	rs6509120	ENSG00000267058.1	RP11-15A1.3	6.28	4.88e-10	8.5e-08	0.22	0.19	Breast cancer;	chr19:43846053	chr19:43891804~43901805:-
BRCA	cis	rs375066	0.586	rs2883946	ENSG00000267058.1	RP11-15A1.3	6.28	4.88e-10	8.5e-08	0.22	0.19	Breast cancer;	chr19:43848536	chr19:43891804~43901805:-
BRCA	cis	rs375066	0.585	rs2195981	ENSG00000267058.1	RP11-15A1.3	6.28	4.88e-10	8.5e-08	0.22	0.19	Breast cancer;	chr19:43848819	chr19:43891804~43901805:-
BRCA	cis	rs375066	0.623	rs2217669	ENSG00000267058.1	RP11-15A1.3	6.28	4.88e-10	8.5e-08	0.22	0.19	Breast cancer;	chr19:43848928	chr19:43891804~43901805:-
BRCA	cis	rs375066	0.623	rs2356438	ENSG00000267058.1	RP11-15A1.3	6.28	4.88e-10	8.5e-08	0.22	0.19	Breast cancer;	chr19:43848931	chr19:43891804~43901805:-
BRCA	cis	rs375066	0.599	rs2356439	ENSG00000267058.1	RP11-15A1.3	6.28	4.88e-10	8.5e-08	0.22	0.19	Breast cancer;	chr19:43848979	chr19:43891804~43901805:-
BRCA	cis	rs375066	0.623	rs7259647	ENSG00000267058.1	RP11-15A1.3	6.28	4.88e-10	8.5e-08	0.22	0.19	Breast cancer;	chr19:43849231	chr19:43891804~43901805:-
BRCA	cis	rs375066	0.623	rs1549956	ENSG00000267058.1	RP11-15A1.3	6.28	4.88e-10	8.5e-08	0.22	0.19	Breast cancer;	chr19:43849986	chr19:43891804~43901805:-
BRCA	cis	rs375066	0.623	rs1549957	ENSG00000267058.1	RP11-15A1.3	6.28	4.88e-10	8.5e-08	0.22	0.19	Breast cancer;	chr19:43850086	chr19:43891804~43901805:-
BRCA	cis	rs375066	0.623	rs1549959	ENSG00000267058.1	RP11-15A1.3	6.28	4.88e-10	8.5e-08	0.22	0.19	Breast cancer;	chr19:43850334	chr19:43891804~43901805:-
BRCA	cis	rs375066	0.623	rs7247863	ENSG00000267058.1	RP11-15A1.3	6.28	4.88e-10	8.5e-08	0.22	0.19	Breast cancer;	chr19:43850366	chr19:43891804~43901805:-
BRCA	cis	rs375066	0.623	rs62114569	ENSG00000267058.1	RP11-15A1.3	6.28	4.88e-10	8.5e-08	0.22	0.19	Breast cancer;	chr19:43850472	chr19:43891804~43901805:-
BRCA	cis	rs375066	0.599	rs10412955	ENSG00000267058.1	RP11-15A1.3	6.28	4.88e-10	8.5e-08	0.22	0.19	Breast cancer;	chr19:43850716	chr19:43891804~43901805:-
BRCA	cis	rs375066	0.623	rs1036246	ENSG00000267058.1	RP11-15A1.3	6.28	4.88e-10	8.5e-08	0.22	0.19	Breast cancer;	chr19:43851112	chr19:43891804~43901805:-
BRCA	cis	rs375066	0.623	rs1909	ENSG00000267058.1	RP11-15A1.3	6.28	4.88e-10	8.5e-08	0.22	0.19	Breast cancer;	chr19:43851365	chr19:43891804~43901805:-
BRCA	cis	rs7927771	0.524	rs10838782	ENSG00000280615.1	Y_RNA	6.28	4.88e-10	8.5e-08	0.22	0.19	Subjective well-being;	chr11:47856248	chr11:47614898~47614994:-
BRCA	cis	rs250585	1	rs3785408	ENSG00000260136.4	CTD-2270L9.4	-6.28	4.88e-10	8.5e-08	-0.23	-0.19	Egg allergy;	chr16:23508665	chr16:23452758~23457606:+
BRCA	cis	rs7829975	0.54	rs2976909	ENSG00000253981.4	ALG1L13P	-6.28	4.89e-10	8.53e-08	-0.23	-0.19	Mood instability;	chr8:8489180	chr8:8236003~8244667:-
BRCA	cis	rs875971	0.862	rs778734	ENSG00000224316.1	RP11-479O9.2	6.28	4.9e-10	8.53e-08	0.19	0.19	Aortic root size;	chr7:66349862	chr7:65773620~65802067:+
BRCA	cis	rs2179367	0.632	rs11155650	ENSG00000216906.2	RP11-350J20.9	6.28	4.9e-10	8.54e-08	0.27	0.19	Dupuytren's disease;	chr6:149407613	chr6:149904243~149906418:+
BRCA	cis	rs2179367	0.632	rs11155651	ENSG00000216906.2	RP11-350J20.9	6.28	4.9e-10	8.54e-08	0.27	0.19	Dupuytren's disease;	chr6:149408146	chr6:149904243~149906418:+
BRCA	cis	rs2179367	0.632	rs7896	ENSG00000216906.2	RP11-350J20.9	6.28	4.9e-10	8.54e-08	0.27	0.19	Dupuytren's disease;	chr6:149410340	chr6:149904243~149906418:+
BRCA	cis	rs2348418	0.864	rs7304540	ENSG00000247934.4	RP11-967K21.1	6.28	4.91e-10	8.55e-08	0.21	0.19	Lung function (FEV1);Lung function (FVC);	chr12:28560489	chr12:28163298~28190738:-
BRCA	cis	rs3858145	0.588	rs61854833	ENSG00000233590.1	RP11-153K11.3	-6.28	4.92e-10	8.57e-08	-0.26	-0.19	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68277570	chr10:68233251~68242379:-
BRCA	cis	rs2348418	0.864	rs1343859	ENSG00000247934.4	RP11-967K21.1	6.28	4.92e-10	8.58e-08	0.21	0.19	Lung function (FEV1);Lung function (FVC);	chr12:28559537	chr12:28163298~28190738:-
BRCA	cis	rs1501911	0.527	rs161934	ENSG00000248489.1	CTD-2007H13.3	-6.28	4.93e-10	8.58e-08	-0.21	-0.19	Lung function (FEV1/FVC);	chr5:98981283	chr5:98929171~98995013:+
BRCA	cis	rs270601	0.77	rs1007602	ENSG00000233006.5	AC034220.3	6.28	4.93e-10	8.58e-08	0.14	0.19	Acylcarnitine levels;	chr5:132266473	chr5:132311285~132369916:-
BRCA	cis	rs270601	0.71	rs4705852	ENSG00000233006.5	AC034220.3	6.28	4.93e-10	8.58e-08	0.14	0.19	Acylcarnitine levels;	chr5:132267114	chr5:132311285~132369916:-
BRCA	cis	rs4713118	0.662	rs149970	ENSG00000219392.1	RP1-265C24.5	-6.28	4.93e-10	8.58e-08	-0.28	-0.19	Parkinson's disease;	chr6:28012442	chr6:28115628~28116551:+
BRCA	cis	rs754466	0.58	rs10824571	ENSG00000204049.1	RP11-126H7.4	6.28	4.93e-10	8.58e-08	0.24	0.19	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77772173	chr10:77866875~77869610:+
BRCA	cis	rs2243480	1	rs35542501	ENSG00000228409.4	CCT6P1	6.28	4.93e-10	8.58e-08	0.26	0.19	Diabetic kidney disease;	chr7:65966228	chr7:65751142~65763354:+
BRCA	cis	rs2243480	0.708	rs781141	ENSG00000228409.4	CCT6P1	6.28	4.93e-10	8.58e-08	0.26	0.19	Diabetic kidney disease;	chr7:65973566	chr7:65751142~65763354:+
BRCA	cis	rs7567389	0.719	rs4150404	ENSG00000236682.1	AC068282.3	6.28	4.93e-10	8.59e-08	0.29	0.19	Self-rated health;	chr2:127292424	chr2:127389130~127400580:+
BRCA	cis	rs7617773	0.709	rs4404473	ENSG00000228638.1	FCF1P2	-6.28	4.94e-10	8.59e-08	-0.22	-0.19	Coronary artery disease;	chr3:48312136	chr3:48290793~48291375:-
BRCA	cis	rs2243480	1	rs1979823	ENSG00000229886.1	RP5-1132H15.3	-6.28	4.94e-10	8.6e-08	-0.34	-0.19	Diabetic kidney disease;	chr7:66239626	chr7:66025126~66031544:-
BRCA	cis	rs2179367	0.632	rs9498325	ENSG00000216906.2	RP11-350J20.9	6.28	4.94e-10	8.6e-08	0.27	0.19	Dupuytren's disease;	chr6:149345993	chr6:149904243~149906418:+
BRCA	cis	rs2179367	0.632	rs9498326	ENSG00000216906.2	RP11-350J20.9	6.28	4.94e-10	8.6e-08	0.27	0.19	Dupuytren's disease;	chr6:149346112	chr6:149904243~149906418:+
BRCA	cis	rs673078	0.66	rs17440433	ENSG00000275409.1	RP11-131L12.4	-6.28	4.94e-10	8.6e-08	-0.3	-0.19	Glucose homeostasis traits;	chr12:118201507	chr12:118430147~118430699:+
BRCA	cis	rs875971	0.545	rs73376401	ENSG00000273024.4	INTS4P2	-6.28	4.94e-10	8.61e-08	-0.24	-0.19	Aortic root size;	chr7:66174841	chr7:65647864~65715661:+
BRCA	cis	rs10129255	1	rs10129255	ENSG00000211972.2	IGHV3-66	-6.28	4.95e-10	8.62e-08	-0.15	-0.19	Kawasaki disease;	chr14:106767970	chr14:106675017~106675544:-
BRCA	cis	rs875971	0.522	rs1880556	ENSG00000234585.5	CCT6P3	6.28	4.95e-10	8.62e-08	0.18	0.19	Aortic root size;	chr7:65967557	chr7:65038354~65074713:+
BRCA	cis	rs13113518	0.812	rs13116035	ENSG00000273257.1	RP11-177J6.1	6.28	4.95e-10	8.62e-08	0.25	0.19	Height;	chr4:55561218	chr4:55387949~55388271:+
BRCA	cis	rs1124769	0.671	rs36004063	ENSG00000259378.1	DCAF13P3	6.28	4.96e-10	8.63e-08	0.27	0.19	Cognitive performance;	chr15:50938637	chr15:50944663~50945996:+
BRCA	cis	rs6142102	0.651	rs6088412	ENSG00000275784.1	RP5-1125A11.6	6.28	4.96e-10	8.63e-08	0.25	0.19	Skin pigmentation;	chr20:34154262	chr20:33989480~33991818:-
BRCA	cis	rs2842992	0.83	rs2842966	ENSG00000237927.1	RP3-393E18.2	-6.28	4.96e-10	8.63e-08	-0.27	-0.19	Age-related macular degeneration (geographic atrophy);	chr6:159720560	chr6:159586955~159589169:-
BRCA	cis	rs7621025	0.63	rs1681818	ENSG00000239213.4	NCK1-AS1	-6.28	4.97e-10	8.65e-08	-0.24	-0.19	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136754831	chr3:136841726~136862054:-
BRCA	cis	rs847577	0.651	rs10464490	ENSG00000272950.1	RP11-307C18.1	6.28	4.97e-10	8.65e-08	0.24	0.19	Breast cancer;	chr7:98086007	chr7:98322853~98323430:+
BRCA	cis	rs2980439	0.846	rs2980437	ENSG00000253981.4	ALG1L13P	-6.28	4.98e-10	8.66e-08	-0.23	-0.19	Neuroticism;	chr8:8237241	chr8:8236003~8244667:-
BRCA	cis	rs11722228	0.522	rs881641	ENSG00000261490.1	RP11-448G15.3	6.28	4.98e-10	8.67e-08	0.21	0.19	Urate levels;Serum uric acid levels;Gout;	chr4:10132123	chr4:10068089~10073019:-
BRCA	cis	rs9291683	0.53	rs73227883	ENSG00000250413.1	RP11-448G15.1	-6.28	4.98e-10	8.67e-08	-0.25	-0.19	Bone mineral density;	chr4:9977655	chr4:10006482~10009725:+
BRCA	cis	rs17660992	1	rs17660992	ENSG00000273837.1	LLNLR-470E3.1	-6.28	4.99e-10	8.68e-08	-0.21	-0.19	Blood protein levels;	chr19:51660695	chr19:51639478~51639931:-
BRCA	cis	rs6840360	0.806	rs11932383	ENSG00000270265.1	RP11-731D1.4	6.28	5e-10	8.7e-08	0.22	0.19	Intelligence (multi-trait analysis);	chr4:151794984	chr4:151333775~151353224:-
BRCA	cis	rs2836950	0.565	rs4816617	ENSG00000238141.2	BRWD1-AS1	-6.28	5e-10	8.7e-08	-0.21	-0.19	Menarche (age at onset);	chr21:39168764	chr21:39315707~39323218:+
BRCA	cis	rs853679	0.517	rs2273564	ENSG00000280107.1	AL022393.9	-6.28	5e-10	8.7e-08	-0.28	-0.19	Depression;	chr6:28089816	chr6:28170845~28172521:+
BRCA	cis	rs853679	0.517	rs1853097	ENSG00000280107.1	AL022393.9	-6.28	5e-10	8.7e-08	-0.28	-0.19	Depression;	chr6:28090857	chr6:28170845~28172521:+
BRCA	cis	rs853679	0.517	rs9393888	ENSG00000280107.1	AL022393.9	-6.28	5e-10	8.7e-08	-0.28	-0.19	Depression;	chr6:28091439	chr6:28170845~28172521:+
BRCA	cis	rs853679	0.517	rs3734573	ENSG00000280107.1	AL022393.9	-6.28	5e-10	8.7e-08	-0.28	-0.19	Depression;	chr6:28091659	chr6:28170845~28172521:+
BRCA	cis	rs853679	0.517	rs3823180	ENSG00000280107.1	AL022393.9	-6.28	5e-10	8.7e-08	-0.28	-0.19	Depression;	chr6:28093966	chr6:28170845~28172521:+
BRCA	cis	rs853679	0.517	rs9368551	ENSG00000280107.1	AL022393.9	-6.28	5e-10	8.7e-08	-0.28	-0.19	Depression;	chr6:28094014	chr6:28170845~28172521:+
BRCA	cis	rs9291683	0.507	rs3796837	ENSG00000250413.1	RP11-448G15.1	-6.28	5e-10	8.7e-08	-0.25	-0.19	Bone mineral density;	chr4:10009697	chr4:10006482~10009725:+
BRCA	cis	rs34779708	0.966	rs7913615	ENSG00000271335.4	RP11-324I22.4	6.28	5.01e-10	8.71e-08	0.2	0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35134029	chr10:35314552~35336401:-
BRCA	cis	rs42648	0.79	rs42637	ENSG00000225498.1	AC002064.5	6.28	5.01e-10	8.72e-08	0.19	0.19	Homocysteine levels;	chr7:90340517	chr7:90312496~90322592:+
BRCA	cis	rs2243480	1	rs6958420	ENSG00000229886.1	RP5-1132H15.3	-6.28	5.02e-10	8.73e-08	-0.34	-0.19	Diabetic kidney disease;	chr7:66286184	chr7:66025126~66031544:-
BRCA	cis	rs2243480	1	rs1392104	ENSG00000229886.1	RP5-1132H15.3	-6.28	5.02e-10	8.73e-08	-0.34	-0.19	Diabetic kidney disease;	chr7:66294120	chr7:66025126~66031544:-
BRCA	cis	rs2732480	0.577	rs2634684	ENSG00000273765.1	RP11-370I10.11	-6.28	5.02e-10	8.74e-08	-0.23	-0.19	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48337092	chr12:48360920~48361377:+
BRCA	cis	rs944990	0.557	rs7019001	ENSG00000227603.1	RP11-165J3.6	6.28	5.03e-10	8.75e-08	0.19	0.19	Body mass index;	chr9:93528942	chr9:93435332~93437121:-
BRCA	cis	rs944990	0.557	rs13292712	ENSG00000227603.1	RP11-165J3.6	6.28	5.03e-10	8.75e-08	0.19	0.19	Body mass index;	chr9:93534438	chr9:93435332~93437121:-
BRCA	cis	rs9652601	0.779	rs12935413	ENSG00000274038.1	RP11-66H6.4	-6.28	5.03e-10	8.76e-08	-0.22	-0.19	Systemic lupus erythematosus;	chr16:11116590	chr16:11056556~11057034:+
BRCA	cis	rs1440410	0.798	rs11100783	ENSG00000250326.1	RP11-284M14.1	-6.28	5.04e-10	8.76e-08	-0.21	-0.19	Ischemic stroke;	chr4:143241047	chr4:142933195~143184861:-
BRCA	cis	rs160451	1	rs160446	ENSG00000251136.7	RP11-37B2.1	6.28	5.04e-10	8.76e-08	0.18	0.19	Leprosy;	chr8:89647035	chr8:89609409~89757727:-
BRCA	cis	rs6688613	1	rs7528849	ENSG00000225171.2	DUTP6	-6.28	5.04e-10	8.76e-08	-0.23	-0.19	Refractive astigmatism;	chr1:166985633	chr1:166868748~166869209:+
BRCA	cis	rs11098499	0.909	rs1809406	ENSG00000249244.1	RP11-548H18.2	6.28	5.04e-10	8.77e-08	0.22	0.19	Corneal astigmatism;	chr4:119455967	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.865	rs2389809	ENSG00000249244.1	RP11-548H18.2	6.28	5.04e-10	8.77e-08	0.22	0.19	Corneal astigmatism;	chr4:119456244	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.909	rs9994810	ENSG00000249244.1	RP11-548H18.2	6.28	5.04e-10	8.77e-08	0.22	0.19	Corneal astigmatism;	chr4:119460435	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.697	rs10020027	ENSG00000249244.1	RP11-548H18.2	6.28	5.04e-10	8.77e-08	0.22	0.19	Corneal astigmatism;	chr4:119460724	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.779	rs7356491	ENSG00000249244.1	RP11-548H18.2	6.28	5.04e-10	8.77e-08	0.22	0.19	Corneal astigmatism;	chr4:119460819	chr4:119391831~119395335:-
BRCA	cis	rs853679	0.517	rs9357063	ENSG00000280107.1	AL022393.9	-6.28	5.04e-10	8.77e-08	-0.28	-0.19	Depression;	chr6:28092227	chr6:28170845~28172521:+
BRCA	cis	rs875971	0.862	rs778686	ENSG00000224316.1	RP11-479O9.2	6.28	5.05e-10	8.78e-08	0.19	0.19	Aortic root size;	chr7:66370923	chr7:65773620~65802067:+
BRCA	cis	rs72681920	0.881	rs17033	ENSG00000246090.5	RP11-696N14.1	-6.28	5.05e-10	8.78e-08	-0.3	-0.19	Alcohol dependence;	chr4:99307788	chr4:99088857~99301356:+
BRCA	cis	rs1823913	0.599	rs34840299	ENSG00000280083.1	RP11-317J9.1	-6.28	5.06e-10	8.79e-08	-0.22	-0.19	Obesity-related traits;	chr2:191280379	chr2:191154118~191156070:-
BRCA	cis	rs559928	0.606	rs61083753	ENSG00000236935.1	AP003774.1	6.28	5.06e-10	8.79e-08	0.25	0.19	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64125193	chr11:64325050~64329504:-
BRCA	cis	rs7914558	1	rs10786733	ENSG00000213061.2	PFN1P11	6.28	5.06e-10	8.8e-08	0.25	0.19	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103035190	chr10:102838011~102845473:-
BRCA	cis	rs11098499	0.909	rs28668716	ENSG00000249244.1	RP11-548H18.2	6.28	5.07e-10	8.81e-08	0.23	0.19	Corneal astigmatism;	chr4:119388720	chr4:119391831~119395335:-
BRCA	cis	rs17301013	0.861	rs61826916	ENSG00000227373.4	RP11-160H22.5	6.28	5.08e-10	8.84e-08	0.25	0.19	Systemic lupus erythematosus;	chr1:174616048	chr1:174115300~174160004:-
BRCA	cis	rs4072705	1	rs4836981	ENSG00000224020.1	MIR181A2HG	-6.28	5.09e-10	8.84e-08	-0.21	-0.19	Menarche (age at onset);	chr9:124577866	chr9:124658467~124698631:+
BRCA	cis	rs10740039	0.732	rs10159808	ENSG00000254271.1	RP11-131N11.4	6.28	5.09e-10	8.84e-08	0.26	0.19	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60602432	chr10:60734342~60741828:+
BRCA	cis	rs1979679	0.808	rs71452082	ENSG00000278733.1	RP11-425D17.1	6.28	5.09e-10	8.84e-08	0.24	0.19	Ossification of the posterior longitudinal ligament of the spine;	chr12:28221647	chr12:28185625~28186190:-
BRCA	cis	rs17301013	0.861	rs1793319	ENSG00000227373.4	RP11-160H22.5	6.28	5.09e-10	8.85e-08	0.26	0.19	Systemic lupus erythematosus;	chr1:174795470	chr1:174115300~174160004:-
BRCA	cis	rs2243480	1	rs160639	ENSG00000229886.1	RP5-1132H15.3	6.28	5.09e-10	8.86e-08	0.34	0.19	Diabetic kidney disease;	chr7:66115000	chr7:66025126~66031544:-
BRCA	cis	rs7567389	0.504	rs13030463	ENSG00000236682.1	AC068282.3	-6.28	5.1e-10	8.86e-08	-0.27	-0.19	Self-rated health;	chr2:127431295	chr2:127389130~127400580:+
BRCA	cis	rs2562456	0.917	rs10420016	ENSG00000268081.1	RP11-678G14.2	-6.28	5.1e-10	8.86e-08	-0.29	-0.19	Pain;	chr19:21505800	chr19:21554640~21569237:-
BRCA	cis	rs875971	0.545	rs316306	ENSG00000273024.4	INTS4P2	6.28	5.1e-10	8.86e-08	0.24	0.19	Aortic root size;	chr7:66153687	chr7:65647864~65715661:+
BRCA	cis	rs875971	1	rs4717292	ENSG00000224316.1	RP11-479O9.2	6.28	5.1e-10	8.87e-08	0.19	0.19	Aortic root size;	chr7:66430611	chr7:65773620~65802067:+
BRCA	cis	rs875971	1	rs35149210	ENSG00000224316.1	RP11-479O9.2	6.28	5.1e-10	8.87e-08	0.19	0.19	Aortic root size;	chr7:66464938	chr7:65773620~65802067:+
BRCA	cis	rs2998286	0.723	rs332177	ENSG00000254635.4	WAC-AS1	-6.28	5.12e-10	8.89e-08	-0.28	-0.19	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28618221	chr10:28522652~28532743:-
BRCA	cis	rs1707322	0.656	rs9429172	ENSG00000281133.1	AL355480.3	6.27	5.12e-10	8.9e-08	0.25	0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45626804	chr1:45580892~45580996:-
BRCA	cis	rs35612822	0.93	rs10194227	ENSG00000232485.2	AC098820.3	6.27	5.12e-10	8.9e-08	0.24	0.19	Kidney disease (early stage) in type 1 diabetes;	chr2:216517041	chr2:216479030~216498761:-
BRCA	cis	rs7615952	0.576	rs66671308	ENSG00000171084.14	FAM86JP	6.27	5.12e-10	8.9e-08	0.3	0.19	Blood pressure (smoking interaction);	chr3:126074683	chr3:125916620~125930024:+
BRCA	cis	rs72772090	0.908	rs11750510	ENSG00000248734.2	CTD-2260A17.1	-6.27	5.12e-10	8.91e-08	-0.3	-0.19	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96706391	chr5:96784777~96785999:+
BRCA	cis	rs11098499	0.865	rs4507344	ENSG00000249244.1	RP11-548H18.2	6.27	5.13e-10	8.91e-08	0.23	0.19	Corneal astigmatism;	chr4:119386330	chr4:119391831~119395335:-
BRCA	cis	rs2243480	1	rs316332	ENSG00000232559.3	GS1-124K5.12	6.27	5.14e-10	8.93e-08	0.36	0.19	Diabetic kidney disease;	chr7:66139312	chr7:66554588~66576923:-
BRCA	cis	rs2179367	0.632	rs62426068	ENSG00000216906.2	RP11-350J20.9	6.27	5.14e-10	8.93e-08	0.28	0.19	Dupuytren's disease;	chr6:149325795	chr6:149904243~149906418:+
BRCA	cis	rs2179367	0.632	rs62426069	ENSG00000216906.2	RP11-350J20.9	6.27	5.14e-10	8.93e-08	0.28	0.19	Dupuytren's disease;	chr6:149325804	chr6:149904243~149906418:+
BRCA	cis	rs2998286	0.723	rs332186	ENSG00000254635.4	WAC-AS1	-6.27	5.14e-10	8.94e-08	-0.28	-0.19	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28624674	chr10:28522652~28532743:-
BRCA	cis	rs4713118	0.513	rs149959	ENSG00000216901.1	AL022393.7	6.27	5.14e-10	8.94e-08	0.25	0.19	Parkinson's disease;	chr6:28046076	chr6:28176188~28176674:+
BRCA	cis	rs9307551	1	rs3943669	ENSG00000250334.4	LINC00989	-6.27	5.15e-10	8.94e-08	-0.29	-0.19	Refractive error;	chr4:79595389	chr4:79492416~79576460:+
BRCA	cis	rs2243480	1	rs35820085	ENSG00000232546.1	RP11-458F8.1	-6.27	5.15e-10	8.94e-08	-0.25	-0.19	Diabetic kidney disease;	chr7:65977771	chr7:66848496~66858136:+
BRCA	cis	rs875971	0.545	rs6460298	ENSG00000273024.4	INTS4P2	-6.27	5.15e-10	8.95e-08	-0.24	-0.19	Aortic root size;	chr7:66442783	chr7:65647864~65715661:+
BRCA	cis	rs4713118	0.513	rs156738	ENSG00000216901.1	AL022393.7	6.27	5.15e-10	8.95e-08	0.25	0.19	Parkinson's disease;	chr6:28046247	chr6:28176188~28176674:+
BRCA	cis	rs853679	0.517	rs6932109	ENSG00000204709.4	LINC01556	-6.27	5.16e-10	8.96e-08	-0.28	-0.19	Depression;	chr6:28110525	chr6:28943877~28944537:+
BRCA	cis	rs11024102	0.962	rs34927905	ENSG00000184669.7	OR7E14P	-6.27	5.16e-10	8.96e-08	-0.3	-0.19	Glaucoma (primary angle closure);	chr11:16979880	chr11:17013998~17053024:+
BRCA	cis	rs853679	0.546	rs200995	ENSG00000220721.1	OR1F12	-6.27	5.16e-10	8.97e-08	-0.35	-0.19	Depression;	chr6:27845916	chr6:28073316~28074233:+
BRCA	cis	rs3764021	0.527	rs10844456	ENSG00000214776.8	RP11-726G1.1	6.27	5.16e-10	8.97e-08	0.23	0.19	Type 1 diabetes;	chr12:9689319	chr12:9467552~9576275:+
BRCA	cis	rs853679	0.517	rs6922063	ENSG00000280107.1	AL022393.9	-6.27	5.16e-10	8.97e-08	-0.28	-0.19	Depression;	chr6:28126588	chr6:28170845~28172521:+
BRCA	cis	rs853679	0.517	rs2275508	ENSG00000280107.1	AL022393.9	-6.27	5.16e-10	8.97e-08	-0.28	-0.19	Depression;	chr6:28126953	chr6:28170845~28172521:+
BRCA	cis	rs853679	0.517	rs9393896	ENSG00000280107.1	AL022393.9	-6.27	5.16e-10	8.97e-08	-0.29	-0.19	Depression;	chr6:28159925	chr6:28170845~28172521:+
BRCA	cis	rs853679	0.517	rs9393897	ENSG00000280107.1	AL022393.9	-6.27	5.16e-10	8.97e-08	-0.29	-0.19	Depression;	chr6:28159932	chr6:28170845~28172521:+
BRCA	cis	rs944990	0.576	rs10821135	ENSG00000227603.1	RP11-165J3.6	6.27	5.17e-10	8.98e-08	0.2	0.19	Body mass index;	chr9:93476296	chr9:93435332~93437121:-
BRCA	cis	rs875971	0.545	rs1638724	ENSG00000236529.1	RP13-254B10.1	-6.27	5.17e-10	8.99e-08	-0.24	-0.19	Aortic root size;	chr7:66575494	chr7:65840212~65840596:+
BRCA	cis	rs7945705	0.738	rs11042067	ENSG00000254860.4	TMEM9B-AS1	6.27	5.17e-10	8.99e-08	0.18	0.19	Hemoglobin concentration;	chr11:8793906	chr11:8964675~8977527:+
BRCA	cis	rs6095360	0.727	rs1983528	ENSG00000222365.1	SNORD12B	6.27	5.18e-10	8.99e-08	0.24	0.19	Intelligence (multi-trait analysis);	chr20:49069753	chr20:49280319~49280409:+
BRCA	cis	rs2243480	1	rs316321	ENSG00000229886.1	RP5-1132H15.3	6.27	5.18e-10	8.99e-08	0.34	0.19	Diabetic kidney disease;	chr7:66146626	chr7:66025126~66031544:-
BRCA	cis	rs2243480	1	rs316318	ENSG00000229886.1	RP5-1132H15.3	6.27	5.18e-10	8.99e-08	0.34	0.19	Diabetic kidney disease;	chr7:66147917	chr7:66025126~66031544:-
BRCA	cis	rs2243480	1	rs316317	ENSG00000229886.1	RP5-1132H15.3	6.27	5.18e-10	8.99e-08	0.34	0.19	Diabetic kidney disease;	chr7:66148650	chr7:66025126~66031544:-
BRCA	cis	rs2243480	1	rs316304	ENSG00000229886.1	RP5-1132H15.3	6.27	5.18e-10	8.99e-08	0.34	0.19	Diabetic kidney disease;	chr7:66151907	chr7:66025126~66031544:-
BRCA	cis	rs516805	0.748	rs155463	ENSG00000279453.1	RP3-425C14.4	-6.27	5.18e-10	9e-08	-0.26	-0.19	Lymphocyte counts;	chr6:122501474	chr6:122436789~122439223:-
BRCA	cis	rs7617773	0.746	rs4371540	ENSG00000228638.1	FCF1P2	-6.27	5.19e-10	9.01e-08	-0.22	-0.19	Coronary artery disease;	chr3:48312053	chr3:48290793~48291375:-
BRCA	cis	rs7221109	0.677	rs8068721	ENSG00000278834.1	RP11-458J1.1	6.27	5.19e-10	9.01e-08	0.21	0.19	Type 1 diabetes;	chr17:40657572	chr17:40648300~40649718:+
BRCA	cis	rs8114671	0.869	rs66535333	ENSG00000269202.1	RP4-614O4.12	6.27	5.19e-10	9.01e-08	0.2	0.19	Height;	chr20:35068863	chr20:35201747~35203288:-
BRCA	cis	rs8114671	0.869	rs1544047	ENSG00000269202.1	RP4-614O4.12	6.27	5.19e-10	9.01e-08	0.2	0.19	Height;	chr20:35082950	chr20:35201747~35203288:-
BRCA	cis	rs8114671	0.836	rs17404569	ENSG00000269202.1	RP4-614O4.12	6.27	5.19e-10	9.01e-08	0.2	0.19	Height;	chr20:35086274	chr20:35201747~35203288:-
BRCA	cis	rs34779708	0.966	rs12761675	ENSG00000271335.4	RP11-324I22.4	-6.27	5.19e-10	9.02e-08	-0.2	-0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35149409	chr10:35314552~35336401:-
BRCA	cis	rs34779708	0.897	rs35784065	ENSG00000271335.4	RP11-324I22.4	6.27	5.19e-10	9.02e-08	0.2	0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35064646	chr10:35314552~35336401:-
BRCA	cis	rs301901	0.698	rs217838	ENSG00000250155.1	CTD-2353F22.1	6.27	5.2e-10	9.03e-08	0.21	0.19	Height;	chr5:37376194	chr5:36666214~36725195:-
BRCA	cis	rs13113518	0.812	rs11939580	ENSG00000273257.1	RP11-177J6.1	6.27	5.2e-10	9.03e-08	0.25	0.19	Height;	chr4:55517185	chr4:55387949~55388271:+
BRCA	cis	rs2832191	0.632	rs2246777	ENSG00000176054.6	RPL23P2	-6.27	5.21e-10	9.05e-08	-0.21	-0.19	Dental caries;	chr21:28937264	chr21:28997613~28998033:-
BRCA	cis	rs7086627	0.515	rs10887905	ENSG00000226659.1	RP11-137H2.4	-6.27	5.22e-10	9.06e-08	-0.24	-0.19	Post bronchodilator FEV1;	chr10:80451099	chr10:80529597~80535942:-
BRCA	cis	rs7086627	0.515	rs7077373	ENSG00000226659.1	RP11-137H2.4	-6.27	5.22e-10	9.06e-08	-0.24	-0.19	Post bronchodilator FEV1;	chr10:80451859	chr10:80529597~80535942:-
BRCA	cis	rs7086627	0.515	rs12245180	ENSG00000226659.1	RP11-137H2.4	-6.27	5.22e-10	9.06e-08	-0.24	-0.19	Post bronchodilator FEV1;	chr10:80452141	chr10:80529597~80535942:-
BRCA	cis	rs11098499	0.69	rs34818745	ENSG00000249244.1	RP11-548H18.2	6.27	5.22e-10	9.06e-08	0.23	0.19	Corneal astigmatism;	chr4:119335900	chr4:119391831~119395335:-
BRCA	cis	rs2836950	0.565	rs2836945	ENSG00000255568.3	BRWD1-AS2	-6.27	5.22e-10	9.06e-08	-0.18	-0.19	Menarche (age at onset);	chr21:39224831	chr21:39313935~39314962:+
BRCA	cis	rs4713118	0.824	rs2092075	ENSG00000220721.1	OR1F12	6.27	5.23e-10	9.08e-08	0.24	0.19	Parkinson's disease;	chr6:27781551	chr6:28073316~28074233:+
BRCA	cis	rs10129255	0.5	rs10131875	ENSG00000224373.3	IGHV4-59	6.27	5.23e-10	9.08e-08	0.11	0.19	Kawasaki disease;	chr14:106792798	chr14:106627249~106627825:-
BRCA	cis	rs8031584	0.918	rs61997140	ENSG00000260382.1	RP11-540B6.2	6.27	5.23e-10	9.08e-08	0.23	0.19	Huntington's disease progression;	chr15:30985109	chr15:30882267~30883231:-
BRCA	cis	rs6969780	1	rs739734	ENSG00000233429.8	HOTAIRM1	6.27	5.23e-10	9.08e-08	0.25	0.19	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27119786	chr7:27095647~27100265:+
BRCA	cis	rs673078	0.607	rs1060964	ENSG00000275409.1	RP11-131L12.4	-6.27	5.23e-10	9.08e-08	-0.26	-0.19	Glucose homeostasis traits;	chr12:118414906	chr12:118430147~118430699:+
BRCA	cis	rs875971	0.545	rs2420612	ENSG00000273024.4	INTS4P2	-6.27	5.24e-10	9.09e-08	-0.24	-0.19	Aortic root size;	chr7:66536825	chr7:65647864~65715661:+
BRCA	cis	rs7911264	0.739	rs6583827	ENSG00000236493.2	EIF2S2P3	6.27	5.24e-10	9.1e-08	0.26	0.19	Inflammatory bowel disease;	chr10:92598266	chr10:92668745~92669743:-
BRCA	cis	rs7911264	0.739	rs7096101	ENSG00000236493.2	EIF2S2P3	6.27	5.24e-10	9.1e-08	0.26	0.19	Inflammatory bowel disease;	chr10:92603171	chr10:92668745~92669743:-
BRCA	cis	rs10129255	0.5	rs11628999	ENSG00000224373.3	IGHV4-59	6.27	5.24e-10	9.1e-08	0.11	0.19	Kawasaki disease;	chr14:106800208	chr14:106627249~106627825:-
BRCA	cis	rs13113518	0.783	rs13111128	ENSG00000273257.1	RP11-177J6.1	6.27	5.25e-10	9.11e-08	0.25	0.19	Height;	chr4:55578154	chr4:55387949~55388271:+
BRCA	cis	rs17711722	0.701	rs781143	ENSG00000234585.5	CCT6P3	6.27	5.25e-10	9.11e-08	0.18	0.19	Calcium levels;	chr7:65974892	chr7:65038354~65074713:+
BRCA	cis	rs13113518	0.783	rs12510400	ENSG00000273257.1	RP11-177J6.1	6.27	5.25e-10	9.12e-08	0.25	0.19	Height;	chr4:55577294	chr4:55387949~55388271:+
BRCA	cis	rs875971	0.862	rs2088653	ENSG00000224316.1	RP11-479O9.2	-6.27	5.25e-10	9.12e-08	-0.19	-0.19	Aortic root size;	chr7:66343621	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.862	rs6460293	ENSG00000224316.1	RP11-479O9.2	-6.27	5.25e-10	9.12e-08	-0.19	-0.19	Aortic root size;	chr7:66345205	chr7:65773620~65802067:+
BRCA	cis	rs2281558	0.833	rs55792313	ENSG00000125804.12	FAM182A	-6.27	5.26e-10	9.12e-08	-0.28	-0.19	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25540619	chr20:26054655~26086917:+
BRCA	cis	rs9652601	0.959	rs9888908	ENSG00000274038.1	RP11-66H6.4	-6.27	5.26e-10	9.12e-08	-0.22	-0.19	Systemic lupus erythematosus;	chr16:11087387	chr16:11056556~11057034:+
BRCA	cis	rs4072705	1	rs4838196	ENSG00000224020.1	MIR181A2HG	-6.27	5.26e-10	9.13e-08	-0.21	-0.19	Menarche (age at onset);	chr9:124595399	chr9:124658467~124698631:+
BRCA	cis	rs1552244	0.882	rs3846168	ENSG00000180385.7	EMC3-AS1	6.27	5.26e-10	9.13e-08	0.24	0.19	Alzheimer's disease;	chr3:9955241	chr3:9986893~10006990:+
BRCA	cis	rs3794924	1	rs7233484	ENSG00000266521.1	RP11-650P15.1	6.27	5.26e-10	9.13e-08	0.35	0.19	Survival in colon cancer;	chr18:31474869	chr18:31496645~31497195:-
BRCA	cis	rs34779708	0.966	rs4934538	ENSG00000271335.4	RP11-324I22.4	6.27	5.28e-10	9.16e-08	0.2	0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35183222	chr10:35314552~35336401:-
BRCA	cis	rs228614	0.51	rs50034	ENSG00000251288.2	RP11-10L12.2	-6.27	5.28e-10	9.16e-08	-0.23	-0.19	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102832214	chr4:102751401~102752641:+
BRCA	cis	rs227275	0.556	rs223380	ENSG00000251288.2	RP11-10L12.2	-6.27	5.28e-10	9.16e-08	-0.23	-0.19	Allergic disease (asthma, hay fever or eczema);	chr4:102833343	chr4:102751401~102752641:+
BRCA	cis	rs227275	0.556	rs223379	ENSG00000251288.2	RP11-10L12.2	-6.27	5.28e-10	9.16e-08	-0.23	-0.19	Allergic disease (asthma, hay fever or eczema);	chr4:102833434	chr4:102751401~102752641:+
BRCA	cis	rs9467773	0.869	rs1796521	ENSG00000124549.13	BTN2A3P	-6.27	5.28e-10	9.16e-08	-0.2	-0.19	Intelligence (multi-trait analysis);	chr6:26421164	chr6:26421391~26432383:+
BRCA	cis	rs6479891	1	rs2466128	ENSG00000232075.1	MRPL35P2	6.27	5.28e-10	9.16e-08	0.34	0.19	Arthritis (juvenile idiopathic);	chr10:63448561	chr10:63634317~63634827:-
BRCA	cis	rs6479891	1	rs2719815	ENSG00000232075.1	MRPL35P2	6.27	5.28e-10	9.16e-08	0.34	0.19	Arthritis (juvenile idiopathic);	chr10:63450534	chr10:63634317~63634827:-
BRCA	cis	rs853679	0.546	rs200977	ENSG00000220721.1	OR1F12	6.27	5.29e-10	9.17e-08	0.36	0.19	Depression;	chr6:27886523	chr6:28073316~28074233:+
BRCA	cis	rs11098499	0.863	rs6833334	ENSG00000249244.1	RP11-548H18.2	6.27	5.29e-10	9.18e-08	0.23	0.19	Corneal astigmatism;	chr4:119583072	chr4:119391831~119395335:-
BRCA	cis	rs7914558	1	rs12255047	ENSG00000213061.2	PFN1P11	6.27	5.3e-10	9.19e-08	0.25	0.19	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103000995	chr10:102838011~102845473:-
BRCA	cis	rs6723226	0.521	rs1991626	ENSG00000276334.1	AL133243.1	-6.27	5.3e-10	9.2e-08	-0.23	-0.19	Intelligence (multi-trait analysis);	chr2:32377382	chr2:32521927~32523547:+
BRCA	cis	rs11096990	0.964	rs16988409	ENSG00000249207.1	RP11-360F5.1	-6.27	5.32e-10	9.23e-08	-0.22	-0.19	Cognitive function;	chr4:39267730	chr4:39112677~39126818:-
BRCA	cis	rs4713118	0.513	rs149954	ENSG00000216901.1	AL022393.7	6.27	5.32e-10	9.23e-08	0.25	0.19	Parkinson's disease;	chr6:28067468	chr6:28176188~28176674:+
BRCA	cis	rs2243480	1	rs313803	ENSG00000230295.1	RP11-458F8.2	-6.27	5.33e-10	9.24e-08	-0.26	-0.19	Diabetic kidney disease;	chr7:66049744	chr7:66880708~66882981:+
BRCA	cis	rs4683346	0.616	rs12639142	ENSG00000173811.9	CCDC13-AS1	-6.27	5.34e-10	9.25e-08	-0.26	-0.19	Granulocyte percentage of myeloid white cells;	chr3:42790040	chr3:42732575~42746768:+
BRCA	cis	rs4683346	0.616	rs34868846	ENSG00000173811.9	CCDC13-AS1	-6.27	5.34e-10	9.25e-08	-0.26	-0.19	Granulocyte percentage of myeloid white cells;	chr3:42791723	chr3:42732575~42746768:+
BRCA	cis	rs2998286	0.54	rs332158	ENSG00000254635.4	WAC-AS1	-6.27	5.34e-10	9.26e-08	-0.28	-0.19	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28595433	chr10:28522652~28532743:-
BRCA	cis	rs875971	0.545	rs6460276	ENSG00000273024.4	INTS4P2	-6.27	5.34e-10	9.26e-08	-0.24	-0.19	Aortic root size;	chr7:66182290	chr7:65647864~65715661:+
BRCA	cis	rs853679	0.517	rs9468298	ENSG00000280107.1	AL022393.9	-6.27	5.34e-10	9.26e-08	-0.29	-0.19	Depression;	chr6:28154567	chr6:28170845~28172521:+
BRCA	cis	rs853679	0.517	rs9295759	ENSG00000280107.1	AL022393.9	-6.27	5.34e-10	9.26e-08	-0.29	-0.19	Depression;	chr6:28156691	chr6:28170845~28172521:+
BRCA	cis	rs853679	0.517	rs9348796	ENSG00000280107.1	AL022393.9	-6.27	5.34e-10	9.26e-08	-0.29	-0.19	Depression;	chr6:28158424	chr6:28170845~28172521:+
BRCA	cis	rs853679	0.517	rs11552219	ENSG00000280107.1	AL022393.9	-6.27	5.34e-10	9.26e-08	-0.29	-0.19	Depression;	chr6:28159056	chr6:28170845~28172521:+
BRCA	cis	rs853679	0.517	rs9357066	ENSG00000280107.1	AL022393.9	-6.27	5.34e-10	9.26e-08	-0.29	-0.19	Depression;	chr6:28162053	chr6:28170845~28172521:+
BRCA	cis	rs11098499	0.909	rs11723757	ENSG00000249244.1	RP11-548H18.2	6.27	5.34e-10	9.26e-08	0.23	0.19	Corneal astigmatism;	chr4:119378514	chr4:119391831~119395335:-
BRCA	cis	rs2243480	1	rs6958289	ENSG00000229886.1	RP5-1132H15.3	-6.27	5.34e-10	9.26e-08	-0.34	-0.19	Diabetic kidney disease;	chr7:66192124	chr7:66025126~66031544:-
BRCA	cis	rs1707322	1	rs1707317	ENSG00000281133.1	AL355480.3	6.27	5.35e-10	9.27e-08	0.24	0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46044970	chr1:45580892~45580996:-
BRCA	cis	rs2243480	1	rs6964530	ENSG00000229886.1	RP5-1132H15.3	-6.27	5.35e-10	9.28e-08	-0.33	-0.19	Diabetic kidney disease;	chr7:66253864	chr7:66025126~66031544:-
BRCA	cis	rs17301013	0.507	rs1813136	ENSG00000227373.4	RP11-160H22.5	6.27	5.36e-10	9.29e-08	0.29	0.19	Systemic lupus erythematosus;	chr1:174756656	chr1:174115300~174160004:-
BRCA	cis	rs8031584	0.541	rs1983459	ENSG00000270015.1	RP11-540B6.6	-6.27	5.37e-10	9.3e-08	-0.19	-0.19	Huntington's disease progression;	chr15:30916546	chr15:30926514~30928407:+
BRCA	cis	rs7617773	0.743	rs7621785	ENSG00000228638.1	FCF1P2	-6.27	5.37e-10	9.31e-08	-0.22	-0.19	Coronary artery disease;	chr3:48302218	chr3:48290793~48291375:-
BRCA	cis	rs7617773	0.78	rs77044321	ENSG00000228638.1	FCF1P2	-6.27	5.37e-10	9.31e-08	-0.22	-0.19	Coronary artery disease;	chr3:48307824	chr3:48290793~48291375:-
BRCA	cis	rs7617773	0.743	rs13081633	ENSG00000228638.1	FCF1P2	-6.27	5.37e-10	9.31e-08	-0.22	-0.19	Coronary artery disease;	chr3:48315791	chr3:48290793~48291375:-
BRCA	cis	rs7520050	0.833	rs1085242	ENSG00000280836.1	AL355480.1	6.27	5.38e-10	9.32e-08	0.22	0.19	Reticulocyte count;Red blood cell count;	chr1:46078552	chr1:45581219~45581321:-
BRCA	cis	rs2243480	1	rs464895	ENSG00000228409.4	CCT6P1	6.27	5.38e-10	9.32e-08	0.28	0.19	Diabetic kidney disease;	chr7:66062119	chr7:65751142~65763354:+
BRCA	cis	rs875971	0.545	rs11770063	ENSG00000236529.1	RP13-254B10.1	6.27	5.38e-10	9.32e-08	0.24	0.19	Aortic root size;	chr7:66318029	chr7:65840212~65840596:+
BRCA	cis	rs2153535	0.518	rs9379225	ENSG00000230939.1	RP11-314C16.1	-6.27	5.39e-10	9.33e-08	-0.22	-0.19	Motion sickness;	chr6:8566027	chr6:8784178~8785445:+
BRCA	cis	rs11098499	0.739	rs4833612	ENSG00000248280.1	RP11-33B1.2	-6.27	5.39e-10	9.34e-08	-0.2	-0.19	Corneal astigmatism;	chr4:119226441	chr4:119440561~119450157:-
BRCA	cis	rs11098499	0.739	rs10013032	ENSG00000248280.1	RP11-33B1.2	-6.27	5.39e-10	9.34e-08	-0.2	-0.19	Corneal astigmatism;	chr4:119228264	chr4:119440561~119450157:-
BRCA	cis	rs7520050	0.931	rs1707333	ENSG00000280836.1	AL355480.1	6.27	5.39e-10	9.35e-08	0.22	0.19	Reticulocyte count;Red blood cell count;	chr1:46081363	chr1:45581219~45581321:-
BRCA	cis	rs10515750	0.53	rs13358909	ENSG00000248544.2	CTB-47B11.3	6.27	5.4e-10	9.35e-08	0.39	0.19	Lung function (FEV1/FVC);	chr5:157288824	chr5:157375741~157384950:-
BRCA	cis	rs875971	0.571	rs160641	ENSG00000273024.4	INTS4P2	6.27	5.4e-10	9.35e-08	0.24	0.19	Aortic root size;	chr7:66112359	chr7:65647864~65715661:+
BRCA	cis	rs12922040	1	rs12922040	ENSG00000263065.1	AF001548.6	-6.27	5.4e-10	9.35e-08	-0.23	-0.19	Serum uric acid levels in response to allopurinol in gout;	chr16:15775609	chr16:15741151~15741791:+
BRCA	cis	rs7927771	0.524	rs4752865	ENSG00000280615.1	Y_RNA	-6.27	5.4e-10	9.35e-08	-0.22	-0.19	Subjective well-being;	chr11:47738289	chr11:47614898~47614994:-
BRCA	cis	rs1823913	0.637	rs1378162	ENSG00000280083.1	RP11-317J9.1	-6.27	5.4e-10	9.36e-08	-0.22	-0.19	Obesity-related traits;	chr2:191298523	chr2:191154118~191156070:-
BRCA	cis	rs3747113	0.954	rs2298378	ENSG00000128262.7	POM121L9P	-6.27	5.4e-10	9.36e-08	-0.23	-0.19	Gut microbiome composition (summer);	chr22:24323637	chr22:24251828~24265525:+
BRCA	cis	rs6570726	1	rs441477	ENSG00000235652.6	RP11-545I5.3	6.27	5.41e-10	9.37e-08	0.18	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145527107	chr6:145799409~145886585:+
BRCA	cis	rs17213965	0.852	rs4781691	ENSG00000260872.1	RP11-680G24.5	-6.27	5.41e-10	9.37e-08	-0.28	-0.19	Waist-hip ratio;	chr16:15783798	chr16:15018106~15020488:-
BRCA	cis	rs875971	0.597	rs11763224	ENSG00000236529.1	RP13-254B10.1	6.27	5.41e-10	9.38e-08	0.24	0.19	Aortic root size;	chr7:66518628	chr7:65840212~65840596:+
BRCA	cis	rs1124769	0.748	rs12595551	ENSG00000259378.1	DCAF13P3	6.27	5.41e-10	9.38e-08	0.27	0.19	Cognitive performance;	chr15:51080985	chr15:50944663~50945996:+
BRCA	cis	rs1124769	0.778	rs12595600	ENSG00000259378.1	DCAF13P3	6.27	5.41e-10	9.38e-08	0.27	0.19	Cognitive performance;	chr15:51081106	chr15:50944663~50945996:+
BRCA	cis	rs6840258	1	rs7682652	ENSG00000251411.1	RP11-397E7.4	-6.27	5.42e-10	9.39e-08	-0.26	-0.19	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86992292	chr4:86913266~86914817:-
BRCA	cis	rs2243480	1	rs12698509	ENSG00000229886.1	RP5-1132H15.3	6.27	5.42e-10	9.39e-08	0.32	0.19	Diabetic kidney disease;	chr7:65953889	chr7:66025126~66031544:-
BRCA	cis	rs4950322	0.515	rs12060046	ENSG00000278811.3	LINC00624	6.27	5.42e-10	9.39e-08	0.24	0.19	Protein quantitative trait loci;	chr1:147249278	chr1:147258885~147517875:-
BRCA	cis	rs2348418	0.831	rs2348416	ENSG00000247934.4	RP11-967K21.1	6.27	5.43e-10	9.4e-08	0.22	0.19	Lung function (FEV1);Lung function (FVC);	chr12:28556283	chr12:28163298~28190738:-
BRCA	cis	rs3858145	0.588	rs78041174	ENSG00000233590.1	RP11-153K11.3	-6.27	5.43e-10	9.4e-08	-0.26	-0.19	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68279014	chr10:68233251~68242379:-
BRCA	cis	rs875971	1	rs2420820	ENSG00000224316.1	RP11-479O9.2	-6.27	5.43e-10	9.41e-08	-0.19	-0.19	Aortic root size;	chr7:66626920	chr7:65773620~65802067:+
BRCA	cis	rs6840360	0.539	rs1443087	ENSG00000270265.1	RP11-731D1.4	-6.27	5.44e-10	9.42e-08	-0.22	-0.19	Intelligence (multi-trait analysis);	chr4:151528943	chr4:151333775~151353224:-
BRCA	cis	rs6840360	0.642	rs1443088	ENSG00000270265.1	RP11-731D1.4	-6.27	5.44e-10	9.42e-08	-0.22	-0.19	Intelligence (multi-trait analysis);	chr4:151528974	chr4:151333775~151353224:-
BRCA	cis	rs2179367	0.632	rs9498335	ENSG00000216906.2	RP11-350J20.9	6.27	5.44e-10	9.42e-08	0.27	0.19	Dupuytren's disease;	chr6:149372648	chr6:149904243~149906418:+
BRCA	cis	rs7520050	0.966	rs1085243	ENSG00000280836.1	AL355480.1	6.27	5.44e-10	9.42e-08	0.22	0.19	Reticulocyte count;Red blood cell count;	chr1:46079096	chr1:45581219~45581321:-
BRCA	cis	rs7927771	0.524	rs7124396	ENSG00000280615.1	Y_RNA	-6.27	5.44e-10	9.42e-08	-0.22	-0.19	Subjective well-being;	chr11:47765882	chr11:47614898~47614994:-
BRCA	cis	rs721917	0.525	rs2819106	ENSG00000244733.5	RP11-506M13.3	-6.27	5.44e-10	9.42e-08	-0.23	-0.19	Chronic obstructive pulmonary disease;	chr10:79926324	chr10:79660891~79677996:+
BRCA	cis	rs7824557	0.505	rs2736313	ENSG00000255046.1	RP11-297N6.4	-6.26	5.45e-10	9.43e-08	-0.22	-0.19	Retinal vascular caliber;	chr8:11229433	chr8:11797928~11802568:-
BRCA	cis	rs2836950	0.545	rs2836959	ENSG00000238141.2	BRWD1-AS1	-6.26	5.45e-10	9.44e-08	-0.21	-0.19	Menarche (age at onset);	chr21:39251742	chr21:39315707~39323218:+
BRCA	cis	rs11722779	0.935	rs7681629	ENSG00000251288.2	RP11-10L12.2	-6.26	5.46e-10	9.45e-08	-0.23	-0.19	Schizophrenia;	chr4:102974407	chr4:102751401~102752641:+
BRCA	cis	rs11722779	0.844	rs17033381	ENSG00000251288.2	RP11-10L12.2	-6.26	5.46e-10	9.45e-08	-0.23	-0.19	Schizophrenia;	chr4:102974952	chr4:102751401~102752641:+
BRCA	cis	rs227275	0.556	rs4699045	ENSG00000251288.2	RP11-10L12.2	-6.26	5.46e-10	9.45e-08	-0.23	-0.19	Allergic disease (asthma, hay fever or eczema);	chr4:102977009	chr4:102751401~102752641:+
BRCA	cis	rs2243480	1	rs2420171	ENSG00000229886.1	RP5-1132H15.3	-6.26	5.46e-10	9.46e-08	-0.34	-0.19	Diabetic kidney disease;	chr7:66172773	chr7:66025126~66031544:-
BRCA	cis	rs11098499	0.739	rs6534130	ENSG00000248280.1	RP11-33B1.2	-6.26	5.46e-10	9.46e-08	-0.2	-0.19	Corneal astigmatism;	chr4:119210184	chr4:119440561~119450157:-
BRCA	cis	rs7246657	0.943	rs8109038	ENSG00000226686.6	LINC01535	6.26	5.47e-10	9.47e-08	0.29	0.19	Coronary artery calcification;	chr19:37524807	chr19:37251912~37265535:+
BRCA	cis	rs2638953	0.85	rs11049428	ENSG00000247934.4	RP11-967K21.1	-6.26	5.47e-10	9.47e-08	-0.24	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28194267	chr12:28163298~28190738:-
BRCA	cis	rs7615952	0.641	rs4422257	ENSG00000171084.14	FAM86JP	6.26	5.47e-10	9.48e-08	0.3	0.19	Blood pressure (smoking interaction);	chr3:126055520	chr3:125916620~125930024:+
BRCA	cis	rs7615952	0.641	rs66520539	ENSG00000171084.14	FAM86JP	6.26	5.47e-10	9.48e-08	0.3	0.19	Blood pressure (smoking interaction);	chr3:126061531	chr3:125916620~125930024:+
BRCA	cis	rs944990	0.597	rs10821162	ENSG00000227603.1	RP11-165J3.6	6.26	5.47e-10	9.48e-08	0.2	0.19	Body mass index;	chr9:93579042	chr9:93435332~93437121:-
BRCA	cis	rs783540	0.656	rs783538	ENSG00000278603.1	RP13-608F4.5	-6.26	5.48e-10	9.49e-08	-0.27	-0.19	Schizophrenia;	chr15:82584394	chr15:82472203~82472426:+
BRCA	cis	rs7567389	0.71	rs72848615	ENSG00000236682.1	AC068282.3	-6.26	5.49e-10	9.49e-08	-0.29	-0.19	Self-rated health;	chr2:127376022	chr2:127389130~127400580:+
BRCA	cis	rs10208649	0.808	rs77805752	ENSG00000233266.1	HMGB1P31	6.26	5.49e-10	9.5e-08	0.46	0.19	Body mass index;	chr2:54037506	chr2:54051334~54051760:+
BRCA	cis	rs7615952	0.576	rs12497295	ENSG00000171084.14	FAM86JP	6.26	5.49e-10	9.51e-08	0.3	0.19	Blood pressure (smoking interaction);	chr3:126099807	chr3:125916620~125930024:+
BRCA	cis	rs7615952	0.512	rs4646765	ENSG00000171084.14	FAM86JP	6.26	5.49e-10	9.51e-08	0.3	0.19	Blood pressure (smoking interaction);	chr3:126101864	chr3:125916620~125930024:+
BRCA	cis	rs7615952	0.576	rs4646763	ENSG00000171084.14	FAM86JP	6.26	5.49e-10	9.51e-08	0.3	0.19	Blood pressure (smoking interaction);	chr3:126103286	chr3:125916620~125930024:+
BRCA	cis	rs7615952	0.576	rs4646759	ENSG00000171084.14	FAM86JP	6.26	5.49e-10	9.51e-08	0.3	0.19	Blood pressure (smoking interaction);	chr3:126104103	chr3:125916620~125930024:+
BRCA	cis	rs6740322	0.748	rs6755601	ENSG00000234936.1	AC010883.5	6.26	5.5e-10	9.52e-08	0.21	0.19	Coronary artery disease;	chr2:43255905	chr2:43229573~43233394:+
BRCA	cis	rs4948102	0.597	rs12669623	ENSG00000226278.1	PSPHP1	-6.26	5.51e-10	9.53e-08	-0.21	-0.19	Plasma homocysteine levels (post-methionine load test);	chr7:56071486	chr7:55764797~55773288:+
BRCA	cis	rs1124769	0.719	rs17646917	ENSG00000259378.1	DCAF13P3	6.26	5.52e-10	9.55e-08	0.27	0.19	Cognitive performance;	chr15:50993929	chr15:50944663~50945996:+
BRCA	cis	rs34779708	0.966	rs10827493	ENSG00000271335.4	RP11-324I22.4	6.26	5.52e-10	9.55e-08	0.2	0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35166048	chr10:35314552~35336401:-
BRCA	cis	rs4950322	0.57	rs72692946	ENSG00000278811.3	LINC00624	6.26	5.53e-10	9.56e-08	0.26	0.19	Protein quantitative trait loci;	chr1:147319966	chr1:147258885~147517875:-
BRCA	cis	rs4950322	0.57	rs72692948	ENSG00000278811.3	LINC00624	6.26	5.53e-10	9.56e-08	0.26	0.19	Protein quantitative trait loci;	chr1:147320298	chr1:147258885~147517875:-
BRCA	cis	rs4950322	0.57	rs72692951	ENSG00000278811.3	LINC00624	6.26	5.53e-10	9.56e-08	0.26	0.19	Protein quantitative trait loci;	chr1:147320551	chr1:147258885~147517875:-
BRCA	cis	rs4950322	0.57	rs77118461	ENSG00000278811.3	LINC00624	6.26	5.53e-10	9.56e-08	0.26	0.19	Protein quantitative trait loci;	chr1:147320718	chr1:147258885~147517875:-
BRCA	cis	rs4950322	0.57	rs78681047	ENSG00000278811.3	LINC00624	6.26	5.53e-10	9.56e-08	0.26	0.19	Protein quantitative trait loci;	chr1:147321013	chr1:147258885~147517875:-
BRCA	cis	rs9876781	1	rs10470686	ENSG00000229759.1	MRPS18AP1	6.26	5.53e-10	9.56e-08	0.21	0.19	Longevity;	chr3:48408549	chr3:48256350~48256938:-
BRCA	cis	rs2348418	0.831	rs7299042	ENSG00000247934.4	RP11-967K21.1	6.26	5.53e-10	9.56e-08	0.22	0.19	Lung function (FEV1);Lung function (FVC);	chr12:28571750	chr12:28163298~28190738:-
BRCA	cis	rs8005677	1	rs1043209	ENSG00000257285.4	RP11-298I3.1	-6.26	5.53e-10	9.57e-08	-0.21	-0.19	Cognitive ability (multi-trait analysis);	chr14:22904777	chr14:22929609~22955562:+
BRCA	cis	rs9992667	0.955	rs11937257	ENSG00000231160.8	KLF3-AS1	6.26	5.53e-10	9.57e-08	0.24	0.19	Eosinophil percentage of granulocytes;	chr4:38643839	chr4:38612701~38664883:-
BRCA	cis	rs7238033	0.624	rs16978469	ENSG00000267193.4	RP11-116O18.3	6.26	5.54e-10	9.59e-08	0.2	0.19	Bladder cancer;	chr18:45725820	chr18:45669367~45747215:-
BRCA	cis	rs875971	0.755	rs10228885	ENSG00000224316.1	RP11-479O9.2	-6.26	5.56e-10	9.61e-08	-0.19	-0.19	Aortic root size;	chr7:66315542	chr7:65773620~65802067:+
BRCA	cis	rs4713118	0.587	rs9393899	ENSG00000280107.1	AL022393.9	-6.26	5.57e-10	9.63e-08	-0.29	-0.19	Parkinson's disease;	chr6:28165750	chr6:28170845~28172521:+
BRCA	cis	rs875971	0.545	rs11767262	ENSG00000273024.4	INTS4P2	-6.26	5.57e-10	9.63e-08	-0.24	-0.19	Aortic root size;	chr7:66302237	chr7:65647864~65715661:+
BRCA	cis	rs6840258	1	rs56050898	ENSG00000251411.1	RP11-397E7.4	-6.26	5.57e-10	9.63e-08	-0.26	-0.19	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87024223	chr4:86913266~86914817:-
BRCA	cis	rs1124769	0.719	rs56036336	ENSG00000259378.1	DCAF13P3	6.26	5.57e-10	9.64e-08	0.26	0.19	Cognitive performance;	chr15:51097090	chr15:50944663~50945996:+
BRCA	cis	rs78773383	0.505	rs13123782	ENSG00000249207.1	RP11-360F5.1	6.26	5.59e-10	9.66e-08	0.22	0.19	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr4:39375785	chr4:39112677~39126818:-
BRCA	cis	rs6688613	1	rs7545911	ENSG00000225171.2	DUTP6	-6.26	5.59e-10	9.67e-08	-0.22	-0.19	Refractive astigmatism;	chr1:166978444	chr1:166868748~166869209:+
BRCA	cis	rs1697139	0.935	rs1623654	ENSG00000249364.4	RP11-434D9.1	6.26	5.59e-10	9.67e-08	0.22	0.19	Breast cancer;	chr5:67216991	chr5:67379378~67805238:+
BRCA	cis	rs669446	0.533	rs11210913	ENSG00000237950.1	RP11-7O11.3	6.26	5.59e-10	9.68e-08	0.22	0.19	Amyotrophic lateral sclerosis (age of onset);	chr1:43756926	chr1:43944370~43946551:-
BRCA	cis	rs2243480	1	rs2465120	ENSG00000229886.1	RP5-1132H15.3	6.26	5.6e-10	9.68e-08	0.34	0.19	Diabetic kidney disease;	chr7:66155987	chr7:66025126~66031544:-
BRCA	cis	rs2243480	0.908	rs2460431	ENSG00000229886.1	RP5-1132H15.3	-6.26	5.6e-10	9.68e-08	-0.34	-0.19	Diabetic kidney disease;	chr7:66157859	chr7:66025126~66031544:-
BRCA	cis	rs2243480	1	rs4718309	ENSG00000229886.1	RP5-1132H15.3	-6.26	5.6e-10	9.68e-08	-0.34	-0.19	Diabetic kidney disease;	chr7:66162777	chr7:66025126~66031544:-
BRCA	cis	rs2243480	1	rs6460274	ENSG00000229886.1	RP5-1132H15.3	-6.26	5.6e-10	9.68e-08	-0.34	-0.19	Diabetic kidney disease;	chr7:66163497	chr7:66025126~66031544:-
BRCA	cis	rs2243480	1	rs7787230	ENSG00000229886.1	RP5-1132H15.3	-6.26	5.6e-10	9.68e-08	-0.34	-0.19	Diabetic kidney disease;	chr7:66164112	chr7:66025126~66031544:-
BRCA	cis	rs944990	0.576	rs6479484	ENSG00000227603.1	RP11-165J3.6	6.26	5.6e-10	9.68e-08	0.2	0.19	Body mass index;	chr9:93454288	chr9:93435332~93437121:-
BRCA	cis	rs853679	0.546	rs200949	ENSG00000220721.1	OR1F12	6.26	5.6e-10	9.68e-08	0.33	0.19	Depression;	chr6:27867657	chr6:28073316~28074233:+
BRCA	cis	rs2562456	0.917	rs2650805	ENSG00000268081.1	RP11-678G14.2	-6.26	5.6e-10	9.69e-08	-0.29	-0.19	Pain;	chr19:21505137	chr19:21554640~21569237:-
BRCA	cis	rs13113518	0.812	rs11133385	ENSG00000273257.1	RP11-177J6.1	6.26	5.6e-10	9.69e-08	0.25	0.19	Height;	chr4:55460485	chr4:55387949~55388271:+
BRCA	cis	rs17253792	0.687	rs10137995	ENSG00000186615.9	KTN1-AS1	-6.26	5.61e-10	9.7e-08	-0.31	-0.19	Putamen volume;	chr14:55706969	chr14:55499278~55580110:-
BRCA	cis	rs7615952	0.512	rs1077621	ENSG00000171084.14	FAM86JP	6.26	5.62e-10	9.71e-08	0.3	0.19	Blood pressure (smoking interaction);	chr3:126100956	chr3:125916620~125930024:+
BRCA	cis	rs45509595	0.841	rs9368531	ENSG00000220721.1	OR1F12	6.26	5.62e-10	9.72e-08	0.34	0.19	Breast cancer;	chr6:27814094	chr6:28073316~28074233:+
BRCA	cis	rs45509595	0.841	rs2747054	ENSG00000220721.1	OR1F12	6.26	5.62e-10	9.72e-08	0.34	0.19	Breast cancer;	chr6:27815581	chr6:28073316~28074233:+
BRCA	cis	rs17301013	0.507	rs2861005	ENSG00000227373.4	RP11-160H22.5	6.26	5.62e-10	9.72e-08	0.29	0.19	Systemic lupus erythematosus;	chr1:174711832	chr1:174115300~174160004:-
BRCA	cis	rs11098499	0.863	rs3822190	ENSG00000249244.1	RP11-548H18.2	6.26	5.63e-10	9.73e-08	0.23	0.19	Corneal astigmatism;	chr4:119506943	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.863	rs3822191	ENSG00000249244.1	RP11-548H18.2	6.26	5.63e-10	9.73e-08	0.23	0.19	Corneal astigmatism;	chr4:119506946	chr4:119391831~119395335:-
BRCA	cis	rs2998286	0.723	rs2807729	ENSG00000254635.4	WAC-AS1	6.26	5.63e-10	9.74e-08	0.31	0.19	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28526427	chr10:28522652~28532743:-
BRCA	cis	rs1552244	1	rs17032295	ENSG00000180385.7	EMC3-AS1	6.26	5.64e-10	9.75e-08	0.23	0.19	Alzheimer's disease;	chr3:10044996	chr3:9986893~10006990:+
BRCA	cis	rs7555523	0.887	rs4657476	ENSG00000224358.1	RP11-466F5.8	6.26	5.65e-10	9.77e-08	0.33	0.19	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165763424	chr1:165768929~165775176:+
BRCA	cis	rs3733585	0.683	rs13112015	ENSG00000250413.1	RP11-448G15.1	6.26	5.66e-10	9.78e-08	0.25	0.19	Cleft plate (environmental tobacco smoke interaction);	chr4:9932172	chr4:10006482~10009725:+
BRCA	cis	rs7131987	0.683	rs7954278	ENSG00000257176.2	RP11-996F15.2	-6.26	5.66e-10	9.79e-08	-0.23	-0.19	QT interval;	chr12:29306357	chr12:29280418~29317848:-
BRCA	cis	rs651907	0.535	rs11919389	ENSG00000244119.1	PDCL3P4	6.26	5.66e-10	9.79e-08	0.15	0.19	Colorectal cancer;	chr3:101705614	chr3:101712472~101713191:+
BRCA	cis	rs875971	0.522	rs2949690	ENSG00000234585.5	CCT6P3	-6.26	5.67e-10	9.79e-08	-0.18	-0.19	Aortic root size;	chr7:66018255	chr7:65038354~65074713:+
BRCA	cis	rs301901	0.698	rs217845	ENSG00000250155.1	CTD-2353F22.1	6.26	5.67e-10	9.8e-08	0.21	0.19	Height;	chr5:37367360	chr5:36666214~36725195:-
BRCA	cis	rs984222	0.508	rs2645303	ENSG00000231365.4	RP11-418J17.1	-6.26	5.68e-10	9.82e-08	-0.22	-0.19	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119012523	chr1:119140396~119275973:+
BRCA	cis	rs7613875	0.543	rs34034116	ENSG00000228008.1	CTD-2330K9.3	6.26	5.69e-10	9.83e-08	0.19	0.19	Body mass index;	chr3:49921723	chr3:49903845~49916937:+
BRCA	cis	rs7829975	0.606	rs11776838	ENSG00000233609.3	RP11-62H7.2	-6.26	5.69e-10	9.83e-08	-0.17	-0.19	Mood instability;	chr8:8937291	chr8:8961200~8979025:+
BRCA	cis	rs721917	0.506	rs2819097	ENSG00000244733.5	RP11-506M13.3	-6.26	5.69e-10	9.83e-08	-0.23	-0.19	Chronic obstructive pulmonary disease;	chr10:79940225	chr10:79660891~79677996:+
BRCA	cis	rs34779708	0.931	rs11596502	ENSG00000271335.4	RP11-324I22.4	6.26	5.69e-10	9.83e-08	0.2	0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35098259	chr10:35314552~35336401:-
BRCA	cis	rs9992667	1	rs68191221	ENSG00000231160.8	KLF3-AS1	6.26	5.7e-10	9.84e-08	0.24	0.19	Eosinophil percentage of granulocytes;	chr4:38675441	chr4:38612701~38664883:-
BRCA	cis	rs10129255	0.5	rs6576232	ENSG00000224373.3	IGHV4-59	6.26	5.7e-10	9.84e-08	0.11	0.19	Kawasaki disease;	chr14:106787090	chr14:106627249~106627825:-
BRCA	cis	rs853679	0.517	rs56364346	ENSG00000280107.1	AL022393.9	-6.26	5.71e-10	9.87e-08	-0.28	-0.19	Depression;	chr6:28082984	chr6:28170845~28172521:+
BRCA	cis	rs853679	0.517	rs9357061	ENSG00000280107.1	AL022393.9	-6.26	5.71e-10	9.87e-08	-0.28	-0.19	Depression;	chr6:28083994	chr6:28170845~28172521:+
BRCA	cis	rs853679	0.517	rs9368550	ENSG00000280107.1	AL022393.9	-6.26	5.71e-10	9.87e-08	-0.28	-0.19	Depression;	chr6:28084025	chr6:28170845~28172521:+
BRCA	cis	rs853679	0.542	rs2295594	ENSG00000280107.1	AL022393.9	-6.26	5.71e-10	9.87e-08	-0.28	-0.19	Depression;	chr6:28085319	chr6:28170845~28172521:+
BRCA	cis	rs2281558	0.876	rs2274890	ENSG00000125804.12	FAM182A	-6.26	5.72e-10	9.87e-08	-0.28	-0.19	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25320386	chr20:26054655~26086917:+
BRCA	cis	rs13113518	0.812	rs2035691	ENSG00000273257.1	RP11-177J6.1	6.26	5.72e-10	9.87e-08	0.25	0.19	Height;	chr4:55529786	chr4:55387949~55388271:+
BRCA	cis	rs13113518	0.756	rs11939652	ENSG00000273257.1	RP11-177J6.1	6.26	5.72e-10	9.87e-08	0.25	0.19	Height;	chr4:55532542	chr4:55387949~55388271:+
BRCA	cis	rs8114671	0.836	rs6142294	ENSG00000269202.1	RP4-614O4.12	6.26	5.72e-10	9.88e-08	0.2	0.19	Height;	chr20:35083694	chr20:35201747~35203288:-
BRCA	cis	rs8031584	0.505	rs2959036	ENSG00000270015.1	RP11-540B6.6	6.26	5.72e-10	9.88e-08	0.19	0.19	Huntington's disease progression;	chr15:30927539	chr15:30926514~30928407:+
BRCA	cis	rs6479891	1	rs16918599	ENSG00000232075.1	MRPL35P2	6.26	5.72e-10	9.89e-08	0.35	0.19	Arthritis (juvenile idiopathic);	chr10:63560319	chr10:63634317~63634827:-
BRCA	cis	rs755249	0.567	rs66531516	ENSG00000237624.1	OXCT2P1	6.26	5.73e-10	9.89e-08	0.27	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39163390	chr1:39514956~39516490:+
BRCA	cis	rs2263638	0.565	rs2488794	ENSG00000228701.1	TNKS2-AS1	-6.26	5.73e-10	9.89e-08	-0.3	-0.19	Airflow obstruction;	chr10:92408060	chr10:91782839~91798291:-
BRCA	cis	rs11098499	0.909	rs10020034	ENSG00000249244.1	RP11-548H18.2	6.26	5.73e-10	9.89e-08	0.23	0.19	Corneal astigmatism;	chr4:119373176	chr4:119391831~119395335:-
BRCA	cis	rs1499614	0.901	rs2178742	ENSG00000232559.3	GS1-124K5.12	6.26	5.73e-10	9.9e-08	0.37	0.19	Gout;	chr7:66732812	chr7:66554588~66576923:-
BRCA	cis	rs13113518	0.678	rs13149568	ENSG00000249700.7	SRD5A3-AS1	6.26	5.73e-10	9.9e-08	0.24	0.19	Height;	chr4:55370412	chr4:55363971~55395847:-
BRCA	cis	rs6479891	0.908	rs2616631	ENSG00000232075.1	MRPL35P2	6.26	5.73e-10	9.9e-08	0.34	0.19	Arthritis (juvenile idiopathic);	chr10:63448154	chr10:63634317~63634827:-
BRCA	cis	rs853679	0.513	rs9468296	ENSG00000280107.1	AL022393.9	-6.26	5.74e-10	9.91e-08	-0.29	-0.19	Depression;	chr6:28145952	chr6:28170845~28172521:+
BRCA	cis	rs2836950	0.501	rs35994303	ENSG00000238141.2	BRWD1-AS1	-6.26	5.75e-10	9.93e-08	-0.21	-0.19	Menarche (age at onset);	chr21:39314094	chr21:39315707~39323218:+
BRCA	cis	rs8103033	0.676	rs993983	ENSG00000226025.8	LGALS17A	-6.26	5.75e-10	9.93e-08	-0.21	-0.19	Obesity-related traits;	chr19:39660840	chr19:39679374~39686373:+
BRCA	cis	rs6479891	0.908	rs12412946	ENSG00000232075.1	MRPL35P2	6.26	5.75e-10	9.94e-08	0.35	0.19	Arthritis (juvenile idiopathic);	chr10:63529792	chr10:63634317~63634827:-
BRCA	cis	rs6479891	1	rs59035163	ENSG00000232075.1	MRPL35P2	6.26	5.75e-10	9.94e-08	0.35	0.19	Arthritis (juvenile idiopathic);	chr10:63532283	chr10:63634317~63634827:-
BRCA	cis	rs4950322	0.57	rs4950401	ENSG00000278811.3	LINC00624	6.26	5.76e-10	9.95e-08	0.26	0.19	Protein quantitative trait loci;	chr1:147319571	chr1:147258885~147517875:-
BRCA	cis	rs4950322	0.57	rs4950402	ENSG00000278811.3	LINC00624	6.26	5.76e-10	9.95e-08	0.26	0.19	Protein quantitative trait loci;	chr1:147319684	chr1:147258885~147517875:-
BRCA	cis	rs4950322	0.57	rs4950404	ENSG00000278811.3	LINC00624	6.26	5.76e-10	9.95e-08	0.26	0.19	Protein quantitative trait loci;	chr1:147319834	chr1:147258885~147517875:-
BRCA	cis	rs4950322	0.57	rs72692953	ENSG00000278811.3	LINC00624	6.26	5.76e-10	9.95e-08	0.26	0.19	Protein quantitative trait loci;	chr1:147321416	chr1:147258885~147517875:-
BRCA	cis	rs7945705	0.791	rs10769958	ENSG00000254860.4	TMEM9B-AS1	6.26	5.76e-10	9.95e-08	0.18	0.19	Hemoglobin concentration;	chr11:8793568	chr11:8964675~8977527:+
BRCA	cis	rs4763879	0.778	rs9332411	ENSG00000256673.1	RP11-599J14.2	6.26	5.77e-10	9.96e-08	0.21	0.19	Type 1 diabetes;	chr12:9681749	chr12:9398355~9414851:-
BRCA	cis	rs10129255	0.5	rs8004923	ENSG00000224373.3	IGHV4-59	6.26	5.78e-10	9.97e-08	0.11	0.19	Kawasaki disease;	chr14:106785926	chr14:106627249~106627825:-
BRCA	cis	rs2243480	1	rs465359	ENSG00000232559.3	GS1-124K5.12	6.26	5.78e-10	9.97e-08	0.36	0.19	Diabetic kidney disease;	chr7:66093177	chr7:66554588~66576923:-
BRCA	cis	rs2243480	1	rs462853	ENSG00000232559.3	GS1-124K5.12	6.26	5.78e-10	9.97e-08	0.36	0.19	Diabetic kidney disease;	chr7:66093180	chr7:66554588~66576923:-
BRCA	cis	rs2243480	1	rs160644	ENSG00000232559.3	GS1-124K5.12	6.26	5.78e-10	9.97e-08	0.36	0.19	Diabetic kidney disease;	chr7:66093199	chr7:66554588~66576923:-
BRCA	cis	rs2243480	1	rs160642	ENSG00000232559.3	GS1-124K5.12	6.26	5.78e-10	9.97e-08	0.36	0.19	Diabetic kidney disease;	chr7:66093386	chr7:66554588~66576923:-
BRCA	cis	rs2243480	0.614	rs34032527	ENSG00000232559.3	GS1-124K5.12	6.26	5.78e-10	9.97e-08	0.36	0.19	Diabetic kidney disease;	chr7:66100154	chr7:66554588~66576923:-
BRCA	cis	rs853679	0.55	rs9295762	ENSG00000204709.4	LINC01556	-6.26	5.78e-10	9.98e-08	-0.27	-0.19	Depression;	chr6:28187640	chr6:28943877~28944537:+
BRCA	cis	rs13113518	0.812	rs12505880	ENSG00000249700.7	SRD5A3-AS1	6.26	5.78e-10	9.99e-08	0.24	0.19	Height;	chr4:55440988	chr4:55363971~55395847:-
BRCA	cis	rs2348418	0.864	rs7304776	ENSG00000247934.4	RP11-967K21.1	6.26	5.79e-10	9.99e-08	0.21	0.19	Lung function (FEV1);Lung function (FVC);	chr12:28560634	chr12:28163298~28190738:-
BRCA	cis	rs1124769	0.719	rs12440387	ENSG00000259378.1	DCAF13P3	6.26	5.79e-10	9.99e-08	0.27	0.19	Cognitive performance;	chr15:50966473	chr15:50944663~50945996:+
BRCA	cis	rs7914558	0.966	rs10450373	ENSG00000213061.2	PFN1P11	6.25	5.79e-10	1e-07	0.25	0.19	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102968859	chr10:102838011~102845473:-
BRCA	cis	rs7914558	0.966	rs2065977	ENSG00000213061.2	PFN1P11	6.25	5.79e-10	1e-07	0.25	0.19	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102969658	chr10:102838011~102845473:-
BRCA	cis	rs7914558	0.966	rs12569617	ENSG00000213061.2	PFN1P11	6.25	5.79e-10	1e-07	0.25	0.19	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102970239	chr10:102838011~102845473:-
BRCA	cis	rs7914558	0.933	rs1538204	ENSG00000213061.2	PFN1P11	6.25	5.79e-10	1e-07	0.25	0.19	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102974136	chr10:102838011~102845473:-
BRCA	cis	rs9500256	0.967	rs4928431	ENSG00000215190.7	LINC00680	6.25	5.8e-10	1e-07	0.21	0.19	Eosinophilic esophagitis (pediatric);	chr6:57979980	chr6:57946074~57961501:-
BRCA	cis	rs7246657	0.765	rs10402455	ENSG00000226686.6	LINC01535	-6.25	5.8e-10	1e-07	-0.32	-0.19	Coronary artery calcification;	chr19:37237805	chr19:37251912~37265535:+
BRCA	cis	rs2179367	0.632	rs10155766	ENSG00000216906.2	RP11-350J20.9	6.25	5.8e-10	1e-07	0.27	0.19	Dupuytren's disease;	chr6:149364577	chr6:149904243~149906418:+
BRCA	cis	rs12681366	0.96	rs2930961	ENSG00000253704.1	RP11-267M23.4	6.25	5.81e-10	1e-07	0.2	0.19	Nonsyndromic cleft lip with cleft palate;	chr8:94431578	chr8:94553722~94569745:+
BRCA	cis	rs11148252	0.846	rs7985262	ENSG00000278238.1	RP11-245D16.4	-6.25	5.81e-10	1e-07	-0.2	-0.19	Lewy body disease;	chr13:52423026	chr13:52454775~52455331:-
BRCA	cis	rs3733585	0.753	rs12500805	ENSG00000250413.1	RP11-448G15.1	-6.25	5.81e-10	1e-07	-0.25	-0.19	Cleft plate (environmental tobacco smoke interaction);	chr4:10016355	chr4:10006482~10009725:+
BRCA	cis	rs2836950	0.565	rs3171465	ENSG00000238141.2	BRWD1-AS1	-6.25	5.81e-10	1e-07	-0.21	-0.19	Menarche (age at onset);	chr21:39180381	chr21:39315707~39323218:+
BRCA	cis	rs6479891	0.908	rs7078456	ENSG00000232075.1	MRPL35P2	-6.25	5.81e-10	1e-07	-0.33	-0.19	Arthritis (juvenile idiopathic);	chr10:63509719	chr10:63634317~63634827:-
BRCA	cis	rs858239	1	rs166663	ENSG00000230042.1	AK3P3	-6.25	5.82e-10	1e-07	-0.22	-0.19	Cerebrospinal fluid biomarker levels;	chr7:23277123	chr7:23129178~23129841:+
BRCA	cis	rs2919009	0.579	rs12258778	ENSG00000271670.1	RP11-95I16.4	-6.25	5.82e-10	1e-07	-0.24	-0.19	Obesity-related traits;	chr10:120868873	chr10:120879256~120880667:-
BRCA	cis	rs6840258	1	rs56390363	ENSG00000251411.1	RP11-397E7.4	-6.25	5.83e-10	1.01e-07	-0.26	-0.19	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87021935	chr4:86913266~86914817:-
BRCA	cis	rs853679	0.517	rs9368556	ENSG00000219392.1	RP1-265C24.5	-6.25	5.84e-10	1.01e-07	-0.29	-0.19	Depression;	chr6:28163375	chr6:28115628~28116551:+
BRCA	cis	rs853679	0.517	rs9368557	ENSG00000219392.1	RP1-265C24.5	-6.25	5.84e-10	1.01e-07	-0.29	-0.19	Depression;	chr6:28163759	chr6:28115628~28116551:+
BRCA	cis	rs853679	0.517	rs9380059	ENSG00000219392.1	RP1-265C24.5	-6.25	5.84e-10	1.01e-07	-0.29	-0.19	Depression;	chr6:28164580	chr6:28115628~28116551:+
BRCA	cis	rs853679	0.517	rs9380060	ENSG00000219392.1	RP1-265C24.5	-6.25	5.84e-10	1.01e-07	-0.29	-0.19	Depression;	chr6:28164825	chr6:28115628~28116551:+
BRCA	cis	rs853679	0.517	rs35227624	ENSG00000219392.1	RP1-265C24.5	-6.25	5.84e-10	1.01e-07	-0.29	-0.19	Depression;	chr6:28164948	chr6:28115628~28116551:+
BRCA	cis	rs853679	0.517	rs9380061	ENSG00000219392.1	RP1-265C24.5	-6.25	5.84e-10	1.01e-07	-0.29	-0.19	Depression;	chr6:28165025	chr6:28115628~28116551:+
BRCA	cis	rs853679	0.517	rs9368558	ENSG00000219392.1	RP1-265C24.5	-6.25	5.84e-10	1.01e-07	-0.29	-0.19	Depression;	chr6:28165528	chr6:28115628~28116551:+
BRCA	cis	rs7474896	0.537	rs1208587	ENSG00000226578.1	RP11-258F22.1	6.25	5.84e-10	1.01e-07	0.24	0.19	Obesity (extreme);	chr10:37918831	chr10:37775371~37784131:-
BRCA	cis	rs875971	0.522	rs1617484	ENSG00000237310.1	GS1-124K5.4	6.25	5.85e-10	1.01e-07	0.2	0.19	Aortic root size;	chr7:65998108	chr7:66493706~66495474:+
BRCA	cis	rs35762459	1	rs35762459	ENSG00000254860.4	TMEM9B-AS1	6.25	5.86e-10	1.01e-07	0.17	0.19	Immature fraction of reticulocytes;	chr11:8823106	chr11:8964675~8977527:+
BRCA	cis	rs2348418	0.864	rs2203088	ENSG00000247934.4	RP11-967K21.1	6.25	5.86e-10	1.01e-07	0.21	0.19	Lung function (FEV1);Lung function (FVC);	chr12:28556767	chr12:28163298~28190738:-
BRCA	cis	rs2348418	0.864	rs7312339	ENSG00000247934.4	RP11-967K21.1	6.25	5.87e-10	1.01e-07	0.21	0.19	Lung function (FEV1);Lung function (FVC);	chr12:28558751	chr12:28163298~28190738:-
BRCA	cis	rs1124769	0.719	rs936482	ENSG00000259378.1	DCAF13P3	-6.25	5.87e-10	1.01e-07	-0.27	-0.19	Cognitive performance;	chr15:50918444	chr15:50944663~50945996:+
BRCA	cis	rs1124769	0.719	rs7170310	ENSG00000259378.1	DCAF13P3	-6.25	5.87e-10	1.01e-07	-0.27	-0.19	Cognitive performance;	chr15:50918934	chr15:50944663~50945996:+
BRCA	cis	rs13113518	0.783	rs1586555	ENSG00000273257.1	RP11-177J6.1	6.25	5.87e-10	1.01e-07	0.25	0.19	Height;	chr4:55587104	chr4:55387949~55388271:+
BRCA	cis	rs6479891	0.915	rs16918601	ENSG00000232075.1	MRPL35P2	6.25	5.87e-10	1.01e-07	0.36	0.19	Arthritis (juvenile idiopathic);	chr10:63561291	chr10:63634317~63634827:-
BRCA	cis	rs1387259	0.929	rs11168460	ENSG00000257763.1	OR5BK1P	6.25	5.88e-10	1.01e-07	0.2	0.19	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48203582	chr12:48355792~48356614:-
BRCA	cis	rs8114671	0.836	rs734308	ENSG00000269202.1	RP4-614O4.12	6.25	5.88e-10	1.01e-07	0.2	0.19	Height;	chr20:34984293	chr20:35201747~35203288:-
BRCA	cis	rs4218	0.543	rs8025246	ENSG00000277144.1	RP11-59H7.4	-6.25	5.88e-10	1.01e-07	-0.23	-0.19	Social communication problems;	chr15:59025814	chr15:59115547~59116089:-
BRCA	cis	rs1876905	0.539	rs240987	ENSG00000271789.1	RP5-1112D6.7	-6.25	5.88e-10	1.01e-07	-0.29	-0.19	Mean corpuscular hemoglobin;	chr6:111268552	chr6:111297126~111298510:+
BRCA	cis	rs1559040	0.932	rs28368466	ENSG00000272156.1	RP11-477N3.1	-6.25	5.88e-10	1.01e-07	-0.28	-0.19	Sudden cardiac arrest;	chr2:54061824	chr2:54082554~54085066:+
BRCA	cis	rs7567389	0.677	rs61422716	ENSG00000236682.1	AC068282.3	-6.25	5.9e-10	1.02e-07	-0.29	-0.19	Self-rated health;	chr2:127330075	chr2:127389130~127400580:+
BRCA	cis	rs7567389	0.677	rs10496661	ENSG00000236682.1	AC068282.3	-6.25	5.9e-10	1.02e-07	-0.29	-0.19	Self-rated health;	chr2:127332568	chr2:127389130~127400580:+
BRCA	cis	rs7567389	0.677	rs11680877	ENSG00000236682.1	AC068282.3	-6.25	5.9e-10	1.02e-07	-0.29	-0.19	Self-rated health;	chr2:127332874	chr2:127389130~127400580:+
BRCA	cis	rs7567389	0.677	rs72848604	ENSG00000236682.1	AC068282.3	-6.25	5.9e-10	1.02e-07	-0.29	-0.19	Self-rated health;	chr2:127362542	chr2:127389130~127400580:+
BRCA	cis	rs875971	0.545	rs10950027	ENSG00000273024.4	INTS4P2	-6.25	5.9e-10	1.02e-07	-0.23	-0.19	Aortic root size;	chr7:66169164	chr7:65647864~65715661:+
BRCA	cis	rs17301013	0.507	rs3862941	ENSG00000227373.4	RP11-160H22.5	6.25	5.9e-10	1.02e-07	0.29	0.19	Systemic lupus erythematosus;	chr1:174689418	chr1:174115300~174160004:-
BRCA	cis	rs17301013	0.531	rs55688014	ENSG00000227373.4	RP11-160H22.5	6.25	5.9e-10	1.02e-07	0.29	0.19	Systemic lupus erythematosus;	chr1:174693321	chr1:174115300~174160004:-
BRCA	cis	rs9813712	0.571	rs9836814	ENSG00000228252.7	COL6A4P2	6.25	5.92e-10	1.02e-07	0.22	0.19	Response to amphetamines;	chr3:130216054	chr3:130212823~130273806:+
BRCA	cis	rs12468226	0.938	rs80282360	ENSG00000226261.1	AC064836.3	6.25	5.92e-10	1.02e-07	0.34	0.19	Urate levels;	chr2:202275121	chr2:202336024~202336727:-
BRCA	cis	rs4713118	0.824	rs9468223	ENSG00000220721.1	OR1F12	6.25	5.92e-10	1.02e-07	0.24	0.19	Parkinson's disease;	chr6:27772887	chr6:28073316~28074233:+
BRCA	cis	rs4713118	0.866	rs2179094	ENSG00000220721.1	OR1F12	6.25	5.92e-10	1.02e-07	0.24	0.19	Parkinson's disease;	chr6:27774046	chr6:28073316~28074233:+
BRCA	cis	rs7746199	0.736	rs13195636	ENSG00000220721.1	OR1F12	6.25	5.93e-10	1.02e-07	0.45	0.19	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27541714	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.55	rs1225598	ENSG00000219392.1	RP1-265C24.5	-6.25	5.94e-10	1.02e-07	-0.27	-0.19	Depression;	chr6:28193021	chr6:28115628~28116551:+
BRCA	cis	rs2153535	0.585	rs6934905	ENSG00000230939.1	RP11-314C16.1	-6.25	5.94e-10	1.02e-07	-0.22	-0.19	Motion sickness;	chr6:8661326	chr6:8784178~8785445:+
BRCA	cis	rs67766926	0.541	rs7586478	ENSG00000271889.1	RP11-493E12.1	6.25	5.95e-10	1.02e-07	0.29	0.19	Inflammatory skin disease;	chr2:61064772	chr2:61151433~61162105:-
BRCA	cis	rs875971	0.545	rs17138149	ENSG00000273024.4	INTS4P2	-6.25	5.95e-10	1.03e-07	-0.23	-0.19	Aortic root size;	chr7:66228193	chr7:65647864~65715661:+
BRCA	cis	rs911555	0.755	rs11627446	ENSG00000244691.1	RPL10AP1	-6.25	5.96e-10	1.03e-07	-0.24	-0.19	Intelligence (multi-trait analysis);	chr14:103480113	chr14:103412119~103412761:-
BRCA	cis	rs11098499	0.739	rs9884728	ENSG00000248280.1	RP11-33B1.2	-6.25	5.97e-10	1.03e-07	-0.19	-0.19	Corneal astigmatism;	chr4:119205924	chr4:119440561~119450157:-
BRCA	cis	rs6840258	0.941	rs6854749	ENSG00000251411.1	RP11-397E7.4	-6.25	5.97e-10	1.03e-07	-0.25	-0.19	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87047646	chr4:86913266~86914817:-
BRCA	cis	rs875971	0.929	rs34406470	ENSG00000224316.1	RP11-479O9.2	6.25	5.97e-10	1.03e-07	0.19	0.19	Aortic root size;	chr7:66464969	chr7:65773620~65802067:+
BRCA	cis	rs13126694	0.649	rs4615226	ENSG00000248429.4	RP11-597D13.9	6.25	5.97e-10	1.03e-07	0.17	0.19	Blood osmolality (transformed sodium);	chr4:157979297	chr4:158170752~158202877:+
BRCA	cis	rs7086627	0.515	rs10887901	ENSG00000226659.1	RP11-137H2.4	-6.25	5.98e-10	1.03e-07	-0.24	-0.19	Post bronchodilator FEV1;	chr10:80450825	chr10:80529597~80535942:-
BRCA	cis	rs4948102	0.642	rs6593297	ENSG00000273720.1	RP11-613E4.4	6.25	5.98e-10	1.03e-07	0.23	0.19	Plasma homocysteine levels (post-methionine load test);	chr7:56054365	chr7:55743073~55743457:+
BRCA	cis	rs875971	0.964	rs60193905	ENSG00000224316.1	RP11-479O9.2	6.25	5.98e-10	1.03e-07	0.19	0.19	Aortic root size;	chr7:66506273	chr7:65773620~65802067:+
BRCA	cis	rs4713118	0.513	rs149897	ENSG00000216901.1	AL022393.7	6.25	5.98e-10	1.03e-07	0.25	0.19	Parkinson's disease;	chr6:28038872	chr6:28176188~28176674:+
BRCA	cis	rs4713118	0.513	rs156734	ENSG00000216901.1	AL022393.7	6.25	5.98e-10	1.03e-07	0.25	0.19	Parkinson's disease;	chr6:28039579	chr6:28176188~28176674:+
BRCA	cis	rs78487399	0.908	rs6749617	ENSG00000234936.1	AC010883.5	-6.25	5.99e-10	1.03e-07	-0.25	-0.19	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43618190	chr2:43229573~43233394:+
BRCA	cis	rs6088813	0.961	rs2425062	ENSG00000126005.14	MMP24-AS1	-6.25	5.99e-10	1.03e-07	-0.22	-0.19	Height;	chr20:35335763	chr20:35216462~35278131:-
BRCA	cis	rs45509595	0.749	rs401763	ENSG00000220721.1	OR1F12	6.25	6e-10	1.03e-07	0.34	0.19	Breast cancer;	chr6:27814750	chr6:28073316~28074233:+
BRCA	cis	rs45509595	0.659	rs390764	ENSG00000220721.1	OR1F12	6.25	6e-10	1.03e-07	0.34	0.19	Breast cancer;	chr6:27814757	chr6:28073316~28074233:+
BRCA	cis	rs45509595	0.841	rs401754	ENSG00000220721.1	OR1F12	6.25	6e-10	1.03e-07	0.34	0.19	Breast cancer;	chr6:27814760	chr6:28073316~28074233:+
BRCA	cis	rs4713118	0.587	rs9393899	ENSG00000204709.4	LINC01556	6.25	6e-10	1.03e-07	0.29	0.19	Parkinson's disease;	chr6:28165750	chr6:28943877~28944537:+
BRCA	cis	rs2303759	0.918	rs8107548	ENSG00000268686.1	AC010524.2	-6.25	6e-10	1.03e-07	-0.3	-0.19	Multiple sclerosis;	chr19:49367386	chr19:49368705~49388081:-
BRCA	cis	rs853679	0.517	rs4713150	ENSG00000219392.1	RP1-265C24.5	-6.25	6e-10	1.03e-07	-0.29	-0.19	Depression;	chr6:28168434	chr6:28115628~28116551:+
BRCA	cis	rs4713118	0.527	rs4713151	ENSG00000219392.1	RP1-265C24.5	-6.25	6e-10	1.03e-07	-0.29	-0.19	Parkinson's disease;	chr6:28168578	chr6:28115628~28116551:+
BRCA	cis	rs853679	0.517	rs9393901	ENSG00000219392.1	RP1-265C24.5	-6.25	6e-10	1.03e-07	-0.29	-0.19	Depression;	chr6:28169019	chr6:28115628~28116551:+
BRCA	cis	rs853679	0.517	rs3173443	ENSG00000219392.1	RP1-265C24.5	-6.25	6e-10	1.03e-07	-0.29	-0.19	Depression;	chr6:28169249	chr6:28115628~28116551:+
BRCA	cis	rs853679	0.517	rs4713152	ENSG00000219392.1	RP1-265C24.5	-6.25	6e-10	1.03e-07	-0.29	-0.19	Depression;	chr6:28169676	chr6:28115628~28116551:+
BRCA	cis	rs853679	0.517	rs9348797	ENSG00000219392.1	RP1-265C24.5	-6.25	6e-10	1.03e-07	-0.29	-0.19	Depression;	chr6:28169755	chr6:28115628~28116551:+
BRCA	cis	rs853679	0.517	rs9380062	ENSG00000219392.1	RP1-265C24.5	-6.25	6e-10	1.03e-07	-0.29	-0.19	Depression;	chr6:28169791	chr6:28115628~28116551:+
BRCA	cis	rs853679	0.542	rs9380063	ENSG00000219392.1	RP1-265C24.5	-6.25	6e-10	1.03e-07	-0.29	-0.19	Depression;	chr6:28170075	chr6:28115628~28116551:+
BRCA	cis	rs853679	0.517	rs9357065	ENSG00000219392.1	RP1-265C24.5	-6.25	6.01e-10	1.03e-07	-0.29	-0.19	Depression;	chr6:28161802	chr6:28115628~28116551:+
BRCA	cis	rs6840258	0.943	rs72667748	ENSG00000251411.1	RP11-397E7.4	-6.25	6.01e-10	1.03e-07	-0.26	-0.19	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87005882	chr4:86913266~86914817:-
BRCA	cis	rs2179367	0.632	rs11155640	ENSG00000216906.2	RP11-350J20.9	6.25	6.02e-10	1.04e-07	0.27	0.19	Dupuytren's disease;	chr6:149323648	chr6:149904243~149906418:+
BRCA	cis	rs34929064	0.881	rs2961310	ENSG00000179428.2	AC073072.5	-6.25	6.02e-10	1.04e-07	-0.21	-0.19	Major depression and alcohol dependence;	chr7:22684788	chr7:22725395~22727620:-
BRCA	cis	rs7086627	0.515	rs11202957	ENSG00000226659.1	RP11-137H2.4	-6.25	6.02e-10	1.04e-07	-0.24	-0.19	Post bronchodilator FEV1;	chr10:80449836	chr10:80529597~80535942:-
BRCA	cis	rs7086627	0.515	rs11202959	ENSG00000226659.1	RP11-137H2.4	-6.25	6.02e-10	1.04e-07	-0.24	-0.19	Post bronchodilator FEV1;	chr10:80449916	chr10:80529597~80535942:-
BRCA	cis	rs7086627	0.515	rs11202960	ENSG00000226659.1	RP11-137H2.4	-6.25	6.02e-10	1.04e-07	-0.24	-0.19	Post bronchodilator FEV1;	chr10:80450051	chr10:80529597~80535942:-
BRCA	cis	rs7086627	0.515	rs10887894	ENSG00000226659.1	RP11-137H2.4	-6.25	6.02e-10	1.04e-07	-0.24	-0.19	Post bronchodilator FEV1;	chr10:80450196	chr10:80529597~80535942:-
BRCA	cis	rs7086627	0.515	rs10887895	ENSG00000226659.1	RP11-137H2.4	-6.25	6.02e-10	1.04e-07	-0.24	-0.19	Post bronchodilator FEV1;	chr10:80450255	chr10:80529597~80535942:-
BRCA	cis	rs8114671	0.562	rs959829	ENSG00000269202.1	RP4-614O4.12	6.25	6.02e-10	1.04e-07	0.2	0.19	Height;	chr20:34758244	chr20:35201747~35203288:-
BRCA	cis	rs919433	0.619	rs699318	ENSG00000231621.1	AC013264.2	-6.25	6.02e-10	1.04e-07	-0.18	-0.19	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197417019	chr2:197197991~197199273:+
BRCA	cis	rs2281636	0.723	rs3740078	ENSG00000233690.1	EBAG9P1	6.25	6.03e-10	1.04e-07	0.22	0.19	Obesity-related traits;	chr10:99685834	chr10:99697407~99697949:-
BRCA	cis	rs301901	0.793	rs11750212	ENSG00000250155.1	CTD-2353F22.1	6.25	6.03e-10	1.04e-07	0.21	0.19	Height;	chr5:37463644	chr5:36666214~36725195:-
BRCA	cis	rs34779708	0.966	rs12782948	ENSG00000271335.4	RP11-324I22.4	6.25	6.03e-10	1.04e-07	0.2	0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35161679	chr10:35314552~35336401:-
BRCA	cis	rs2274273	1	rs61508494	ENSG00000258413.1	RP11-665C16.6	-6.25	6.04e-10	1.04e-07	-0.24	-0.19	Protein biomarker;	chr14:55120579	chr14:55262767~55272075:-
BRCA	cis	rs6740322	0.793	rs9808360	ENSG00000234936.1	AC010883.5	6.25	6.04e-10	1.04e-07	0.21	0.19	Coronary artery disease;	chr2:43319696	chr2:43229573~43233394:+
BRCA	cis	rs13113518	0.812	rs4865003	ENSG00000273257.1	RP11-177J6.1	6.25	6.04e-10	1.04e-07	0.25	0.19	Height;	chr4:55514802	chr4:55387949~55388271:+
BRCA	cis	rs13113518	0.756	rs12510275	ENSG00000273257.1	RP11-177J6.1	6.25	6.04e-10	1.04e-07	0.25	0.19	Height;	chr4:55516548	chr4:55387949~55388271:+
BRCA	cis	rs13113518	0.812	rs12510327	ENSG00000273257.1	RP11-177J6.1	6.25	6.04e-10	1.04e-07	0.25	0.19	Height;	chr4:55516744	chr4:55387949~55388271:+
BRCA	cis	rs6479891	0.915	rs11812934	ENSG00000232075.1	MRPL35P2	6.25	6.05e-10	1.04e-07	0.35	0.19	Arthritis (juvenile idiopathic);	chr10:63560970	chr10:63634317~63634827:-
BRCA	cis	rs34779708	0.966	rs17499811	ENSG00000271335.4	RP11-324I22.4	6.25	6.05e-10	1.04e-07	0.2	0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35167287	chr10:35314552~35336401:-
BRCA	cis	rs6921919	0.583	rs9468355	ENSG00000204709.4	LINC01556	6.25	6.05e-10	1.04e-07	0.26	0.19	Autism spectrum disorder or schizophrenia;	chr6:28374100	chr6:28943877~28944537:+
BRCA	cis	rs4713118	0.568	rs9468213	ENSG00000220721.1	OR1F12	6.25	6.05e-10	1.04e-07	0.22	0.19	Parkinson's disease;	chr6:27738401	chr6:28073316~28074233:+
BRCA	cis	rs13108904	0.935	rs13148614	ENSG00000254094.1	AC078852.1	-6.25	6.06e-10	1.04e-07	-0.21	-0.19	Obesity-related traits;	chr4:1254569	chr4:1356581~1358075:+
BRCA	cis	rs2749097	0.609	rs3790858	ENSG00000244256.3	RN7SL130P	-6.25	6.08e-10	1.05e-07	-0.27	-0.19	Alcohol consumption (transferrin glycosylation);	chr1:63645877	chr1:63655743~63656047:+
BRCA	cis	rs4713118	0.619	rs200486	ENSG00000220721.1	OR1F12	6.25	6.09e-10	1.05e-07	0.27	0.19	Parkinson's disease;	chr6:27811728	chr6:28073316~28074233:+
BRCA	cis	rs1707322	1	rs11211222	ENSG00000281133.1	AL355480.3	-6.25	6.09e-10	1.05e-07	-0.24	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45902085	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.963	rs9787412	ENSG00000281133.1	AL355480.3	-6.25	6.09e-10	1.05e-07	-0.24	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45905924	chr1:45580892~45580996:-
BRCA	cis	rs1707322	1	rs4660896	ENSG00000281133.1	AL355480.3	-6.25	6.09e-10	1.05e-07	-0.24	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45906744	chr1:45580892~45580996:-
BRCA	cis	rs1707322	1	rs12133129	ENSG00000281133.1	AL355480.3	-6.25	6.09e-10	1.05e-07	-0.24	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45907676	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.963	rs4553121	ENSG00000281133.1	AL355480.3	-6.25	6.09e-10	1.05e-07	-0.24	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45909581	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.963	rs6690652	ENSG00000281133.1	AL355480.3	-6.25	6.09e-10	1.05e-07	-0.24	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45911020	chr1:45580892~45580996:-
BRCA	cis	rs6570726	0.791	rs1509214	ENSG00000270638.1	RP3-466P17.1	-6.25	6.09e-10	1.05e-07	-0.22	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145463470	chr6:145735570~145737218:+
BRCA	cis	rs6479891	0.73	rs16918600	ENSG00000232075.1	MRPL35P2	6.25	6.09e-10	1.05e-07	0.35	0.19	Arthritis (juvenile idiopathic);	chr10:63560690	chr10:63634317~63634827:-
BRCA	cis	rs10208649	0.908	rs7559651	ENSG00000233266.1	HMGB1P31	6.25	6.1e-10	1.05e-07	0.46	0.19	Body mass index;	chr2:53981801	chr2:54051334~54051760:+
BRCA	cis	rs17680741	1	rs17680741	ENSG00000226659.1	RP11-137H2.4	6.25	6.1e-10	1.05e-07	0.27	0.19	Coronary artery disease;	chr10:80491758	chr10:80529597~80535942:-
BRCA	cis	rs2911132	0.714	rs13167972	ENSG00000248734.2	CTD-2260A17.1	6.25	6.1e-10	1.05e-07	0.21	0.19	Urate levels (BMI interaction);	chr5:96761124	chr5:96784777~96785999:+
BRCA	cis	rs4713118	0.513	rs149958	ENSG00000204709.4	LINC01556	6.25	6.1e-10	1.05e-07	0.26	0.19	Parkinson's disease;	chr6:28045839	chr6:28943877~28944537:+
BRCA	cis	rs7474896	0.559	rs1208560	ENSG00000226578.1	RP11-258F22.1	6.25	6.1e-10	1.05e-07	0.24	0.19	Obesity (extreme);	chr10:37932690	chr10:37775371~37784131:-
BRCA	cis	rs2243480	0.908	rs55876148	ENSG00000229886.1	RP5-1132H15.3	6.25	6.11e-10	1.05e-07	0.34	0.19	Diabetic kidney disease;	chr7:65914813	chr7:66025126~66031544:-
BRCA	cis	rs6504622	0.935	rs17608961	ENSG00000262879.4	RP11-156P1.3	-6.25	6.11e-10	1.05e-07	-0.19	-0.19	Orofacial clefts;	chr17:46952302	chr17:46984045~47100323:-
BRCA	cis	rs875971	1	rs1981798	ENSG00000224316.1	RP11-479O9.2	6.25	6.11e-10	1.05e-07	0.19	0.19	Aortic root size;	chr7:66489916	chr7:65773620~65802067:+
BRCA	cis	rs2665103	0.61	rs56398167	ENSG00000255769.6	GOLGA2P10	-6.25	6.11e-10	1.05e-07	-0.21	-0.19	Intelligence (multi-trait analysis);	chr15:82237482	chr15:82472993~82513950:-
BRCA	cis	rs853679	0.517	rs9368556	ENSG00000280107.1	AL022393.9	-6.25	6.11e-10	1.05e-07	-0.29	-0.19	Depression;	chr6:28163375	chr6:28170845~28172521:+
BRCA	cis	rs853679	0.517	rs9368557	ENSG00000280107.1	AL022393.9	-6.25	6.11e-10	1.05e-07	-0.29	-0.19	Depression;	chr6:28163759	chr6:28170845~28172521:+
BRCA	cis	rs853679	0.517	rs9380059	ENSG00000280107.1	AL022393.9	-6.25	6.11e-10	1.05e-07	-0.29	-0.19	Depression;	chr6:28164580	chr6:28170845~28172521:+
BRCA	cis	rs853679	0.517	rs9380060	ENSG00000280107.1	AL022393.9	-6.25	6.11e-10	1.05e-07	-0.29	-0.19	Depression;	chr6:28164825	chr6:28170845~28172521:+
BRCA	cis	rs853679	0.517	rs35227624	ENSG00000280107.1	AL022393.9	-6.25	6.11e-10	1.05e-07	-0.29	-0.19	Depression;	chr6:28164948	chr6:28170845~28172521:+
BRCA	cis	rs853679	0.517	rs9380061	ENSG00000280107.1	AL022393.9	-6.25	6.11e-10	1.05e-07	-0.29	-0.19	Depression;	chr6:28165025	chr6:28170845~28172521:+
BRCA	cis	rs853679	0.517	rs9368558	ENSG00000280107.1	AL022393.9	-6.25	6.11e-10	1.05e-07	-0.29	-0.19	Depression;	chr6:28165528	chr6:28170845~28172521:+
BRCA	cis	rs10463554	0.716	rs152136	ENSG00000175749.11	EIF3KP1	6.25	6.12e-10	1.05e-07	0.25	0.19	Parkinson's disease;	chr5:103248167	chr5:103032376~103033031:+
BRCA	cis	rs2243480	1	rs12698509	ENSG00000228409.4	CCT6P1	6.25	6.12e-10	1.05e-07	0.25	0.19	Diabetic kidney disease;	chr7:65953889	chr7:65751142~65763354:+
BRCA	cis	rs710913	0.738	rs755247	ENSG00000237624.1	OXCT2P1	-6.25	6.12e-10	1.05e-07	-0.22	-0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39528873	chr1:39514956~39516490:+
BRCA	cis	rs710913	0.816	rs1180341	ENSG00000237624.1	OXCT2P1	-6.25	6.13e-10	1.05e-07	-0.22	-0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39527136	chr1:39514956~39516490:+
BRCA	cis	rs9816784	0.525	rs555412	ENSG00000231464.1	AC024937.4	6.25	6.14e-10	1.06e-07	0.26	0.19	Mean corpuscular hemoglobin;	chr3:196078047	chr3:195996738~195998233:+
BRCA	cis	rs2638953	0.924	rs11049403	ENSG00000278733.1	RP11-425D17.1	-6.25	6.14e-10	1.06e-07	-0.25	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28177105	chr12:28185625~28186190:-
BRCA	cis	rs17301013	0.581	rs72711501	ENSG00000227373.4	RP11-160H22.5	6.25	6.15e-10	1.06e-07	0.29	0.19	Systemic lupus erythematosus;	chr1:174233081	chr1:174115300~174160004:-
BRCA	cis	rs67340775	0.541	rs200964	ENSG00000220721.1	OR1F12	6.25	6.15e-10	1.06e-07	0.29	0.19	Lung cancer in ever smokers;	chr6:27899165	chr6:28073316~28074233:+
BRCA	cis	rs7914558	1	rs7914558	ENSG00000213061.2	PFN1P11	6.25	6.15e-10	1.06e-07	0.25	0.19	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103016151	chr10:102838011~102845473:-
BRCA	cis	rs228614	0.536	rs150897	ENSG00000251288.2	RP11-10L12.2	-6.25	6.16e-10	1.06e-07	-0.22	-0.19	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102769309	chr4:102751401~102752641:+
BRCA	cis	rs3805389	0.961	rs62308665	ENSG00000249700.7	SRD5A3-AS1	-6.25	6.16e-10	1.06e-07	-0.28	-0.19	Waist-to-hip ratio adjusted for body mass index;	chr4:55611630	chr4:55363971~55395847:-
BRCA	cis	rs9880211	1	rs6805316	ENSG00000239213.4	NCK1-AS1	6.25	6.16e-10	1.06e-07	0.24	0.19	Height;Body mass index;	chr3:136233270	chr3:136841726~136862054:-
BRCA	cis	rs2337406	1	rs17113276	ENSG00000211974.3	IGHV2-70	6.25	6.16e-10	1.06e-07	0.23	0.19	Alzheimer's disease (late onset);	chr14:106683485	chr14:106723574~106724093:-
BRCA	cis	rs11096990	0.891	rs61691409	ENSG00000249207.1	RP11-360F5.1	6.24	6.16e-10	1.06e-07	0.22	0.19	Cognitive function;	chr4:39243801	chr4:39112677~39126818:-
BRCA	cis	rs875971	0.545	rs67397473	ENSG00000273024.4	INTS4P2	-6.24	6.17e-10	1.06e-07	-0.23	-0.19	Aortic root size;	chr7:66168318	chr7:65647864~65715661:+
BRCA	cis	rs6688613	1	rs12569084	ENSG00000225171.2	DUTP6	-6.24	6.17e-10	1.06e-07	-0.22	-0.19	Refractive astigmatism;	chr1:166974115	chr1:166868748~166869209:+
BRCA	cis	rs34779708	0.931	rs1926556	ENSG00000271335.4	RP11-324I22.4	6.24	6.17e-10	1.06e-07	0.2	0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35055979	chr10:35314552~35336401:-
BRCA	cis	rs34779708	0.931	rs1926554	ENSG00000271335.4	RP11-324I22.4	6.24	6.17e-10	1.06e-07	0.2	0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35056041	chr10:35314552~35336401:-
BRCA	cis	rs34779708	0.931	rs4934710	ENSG00000271335.4	RP11-324I22.4	6.24	6.17e-10	1.06e-07	0.2	0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35061488	chr10:35314552~35336401:-
BRCA	cis	rs2638953	0.779	rs61920241	ENSG00000278733.1	RP11-425D17.1	-6.24	6.18e-10	1.06e-07	-0.24	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28195184	chr12:28185625~28186190:-
BRCA	cis	rs9467773	0.836	rs1624440	ENSG00000124549.13	BTN2A3P	-6.24	6.19e-10	1.06e-07	-0.2	-0.19	Intelligence (multi-trait analysis);	chr6:26433101	chr6:26421391~26432383:+
BRCA	cis	rs2243480	1	rs2257790	ENSG00000232559.3	GS1-124K5.12	6.24	6.19e-10	1.06e-07	0.36	0.19	Diabetic kidney disease;	chr7:66135463	chr7:66554588~66576923:-
BRCA	cis	rs2638953	0.924	rs7957382	ENSG00000278733.1	RP11-425D17.1	6.24	6.19e-10	1.06e-07	0.24	0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28203643	chr12:28185625~28186190:-
BRCA	cis	rs9880211	0.613	rs67109185	ENSG00000273486.1	RP11-731C17.2	6.24	6.2e-10	1.07e-07	0.23	0.19	Height;Body mass index;	chr3:136108550	chr3:136837338~136839021:-
BRCA	cis	rs7598759	0.548	rs11686485	ENSG00000223198.1	RNU2-22P	-6.24	6.2e-10	1.07e-07	-0.23	-0.19	Noise-induced hearing loss;	chr2:231495986	chr2:231501990~231502201:-
BRCA	cis	rs34779708	0.931	rs12771399	ENSG00000271335.4	RP11-324I22.4	6.24	6.21e-10	1.07e-07	0.21	0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35163449	chr10:35314552~35336401:-
BRCA	cis	rs801193	0.66	rs2659914	ENSG00000224316.1	RP11-479O9.2	6.24	6.21e-10	1.07e-07	0.19	0.19	Aortic root size;	chr7:66691927	chr7:65773620~65802067:+
BRCA	cis	rs801193	0.591	rs2707839	ENSG00000224316.1	RP11-479O9.2	6.24	6.21e-10	1.07e-07	0.19	0.19	Aortic root size;	chr7:66728097	chr7:65773620~65802067:+
BRCA	cis	rs4713118	0.513	rs149958	ENSG00000216901.1	AL022393.7	6.24	6.21e-10	1.07e-07	0.25	0.19	Parkinson's disease;	chr6:28045839	chr6:28176188~28176674:+
BRCA	cis	rs7809950	0.678	rs2237665	ENSG00000238832.1	snoU109	-6.24	6.22e-10	1.07e-07	-0.28	-0.19	Coronary artery disease;	chr7:107266553	chr7:107603363~107603507:+
BRCA	cis	rs6442522	0.768	rs3821638	ENSG00000249786.6	EAF1-AS1	6.24	6.22e-10	1.07e-07	0.2	0.19	Uric acid levels;	chr3:15469537	chr3:15436171~15455940:-
BRCA	cis	rs11098499	0.71	rs6851130	ENSG00000248280.1	RP11-33B1.2	-6.24	6.23e-10	1.07e-07	-0.19	-0.19	Corneal astigmatism;	chr4:119212557	chr4:119440561~119450157:-
BRCA	cis	rs13113518	0.783	rs6843722	ENSG00000273257.1	RP11-177J6.1	6.24	6.23e-10	1.07e-07	0.25	0.19	Height;	chr4:55465165	chr4:55387949~55388271:+
BRCA	cis	rs7247513	0.964	rs4804202	ENSG00000213290.4	PGK1P2	-6.24	6.25e-10	1.07e-07	-0.25	-0.19	Bipolar disorder;	chr19:12607805	chr19:12559571~12561105:+
BRCA	cis	rs2243480	1	rs781149	ENSG00000230295.1	RP11-458F8.2	-6.24	6.25e-10	1.07e-07	-0.25	-0.19	Diabetic kidney disease;	chr7:66016297	chr7:66880708~66882981:+
BRCA	cis	rs2243480	0.901	rs58207111	ENSG00000230295.1	RP11-458F8.2	-6.24	6.25e-10	1.07e-07	-0.25	-0.19	Diabetic kidney disease;	chr7:66021736	chr7:66880708~66882981:+
BRCA	cis	rs7809950	1	rs10276604	ENSG00000238832.1	snoU109	6.24	6.27e-10	1.08e-07	0.26	0.19	Coronary artery disease;	chr7:107576293	chr7:107603363~107603507:+
BRCA	cis	rs13113518	0.812	rs7667741	ENSG00000273257.1	RP11-177J6.1	6.24	6.27e-10	1.08e-07	0.25	0.19	Height;	chr4:55544621	chr4:55387949~55388271:+
BRCA	cis	rs2243480	0.706	rs34466769	ENSG00000273142.1	RP11-458F8.4	-6.24	6.27e-10	1.08e-07	-0.22	-0.19	Diabetic kidney disease;	chr7:65988305	chr7:66902857~66906297:+
BRCA	cis	rs13178541	0.566	rs6879940	ENSG00000250378.1	RP11-119J18.1	-6.24	6.27e-10	1.08e-07	-0.24	-0.19	IgG glycosylation;	chr5:135718040	chr5:135812667~135826582:+
BRCA	cis	rs4950322	0.58	rs72706441	ENSG00000278811.3	LINC00624	6.24	6.27e-10	1.08e-07	0.25	0.19	Protein quantitative trait loci;	chr1:147122601	chr1:147258885~147517875:-
BRCA	cis	rs9876781	1	rs7653691	ENSG00000229759.1	MRPS18AP1	-6.24	6.27e-10	1.08e-07	-0.21	-0.19	Longevity;	chr3:48378199	chr3:48256350~48256938:-
BRCA	cis	rs6479891	1	rs7087279	ENSG00000232075.1	MRPL35P2	-6.24	6.29e-10	1.08e-07	-0.33	-0.19	Arthritis (juvenile idiopathic);	chr10:63532176	chr10:63634317~63634827:-
BRCA	cis	rs7914558	0.966	rs11191438	ENSG00000213061.2	PFN1P11	6.24	6.29e-10	1.08e-07	0.25	0.19	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102878107	chr10:102838011~102845473:-
BRCA	cis	rs9527	0.614	rs4919691	ENSG00000236937.2	PTGES3P4	6.24	6.3e-10	1.08e-07	0.25	0.19	Arsenic metabolism;	chr10:102864718	chr10:102845595~102845950:+
BRCA	cis	rs11976180	1	rs2951364	ENSG00000273234.1	OR2A13P	-6.24	6.3e-10	1.08e-07	-0.25	-0.19	Obesity-related traits;	chr7:144057390	chr7:144142009~144142938:+
BRCA	cis	rs853679	0.517	rs4711164	ENSG00000280107.1	AL022393.9	-6.24	6.3e-10	1.08e-07	-0.29	-0.19	Depression;	chr6:28147378	chr6:28170845~28172521:+
BRCA	cis	rs853679	0.517	rs4711165	ENSG00000280107.1	AL022393.9	-6.24	6.3e-10	1.08e-07	-0.29	-0.19	Depression;	chr6:28147406	chr6:28170845~28172521:+
BRCA	cis	rs853679	0.517	rs4713148	ENSG00000280107.1	AL022393.9	-6.24	6.3e-10	1.08e-07	-0.29	-0.19	Depression;	chr6:28148143	chr6:28170845~28172521:+
BRCA	cis	rs853679	0.517	rs9348794	ENSG00000280107.1	AL022393.9	-6.24	6.3e-10	1.08e-07	-0.29	-0.19	Depression;	chr6:28149979	chr6:28170845~28172521:+
BRCA	cis	rs853679	0.517	rs9295758	ENSG00000280107.1	AL022393.9	-6.24	6.3e-10	1.08e-07	-0.29	-0.19	Depression;	chr6:28152885	chr6:28170845~28172521:+
BRCA	cis	rs853679	0.517	rs17774663	ENSG00000280107.1	AL022393.9	-6.24	6.3e-10	1.08e-07	-0.29	-0.19	Depression;	chr6:28153120	chr6:28170845~28172521:+
BRCA	cis	rs4372836	0.964	rs55721532	ENSG00000226833.4	AC097724.3	-6.24	6.3e-10	1.08e-07	-0.23	-0.19	Body mass index;	chr2:28716102	chr2:28708953~28736205:-
BRCA	cis	rs4713118	0.513	rs156739	ENSG00000216901.1	AL022393.7	6.24	6.31e-10	1.08e-07	0.25	0.19	Parkinson's disease;	chr6:28045632	chr6:28176188~28176674:+
BRCA	cis	rs919433	0.68	rs4685	ENSG00000231621.1	AC013264.2	6.24	6.31e-10	1.08e-07	0.18	0.19	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197393071	chr2:197197991~197199273:+
BRCA	cis	rs1707322	0.686	rs2050376	ENSG00000281133.1	AL355480.3	-6.24	6.32e-10	1.09e-07	-0.25	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45612958	chr1:45580892~45580996:-
BRCA	cis	rs2554380	0.542	rs7164141	ENSG00000230373.7	GOLGA6L5P	6.24	6.32e-10	1.09e-07	0.26	0.19	Height;	chr15:83824253	chr15:84507885~84516814:-
BRCA	cis	rs17301013	0.507	rs11806996	ENSG00000227373.4	RP11-160H22.5	6.24	6.33e-10	1.09e-07	0.3	0.19	Systemic lupus erythematosus;	chr1:174654784	chr1:174115300~174160004:-
BRCA	cis	rs13113518	0.783	rs11943206	ENSG00000223305.1	RN7SKP30	6.24	6.33e-10	1.09e-07	0.23	0.19	Height;	chr4:55570843	chr4:55540502~55540835:-
BRCA	cis	rs301901	0.828	rs10941337	ENSG00000250155.1	CTD-2353F22.1	6.24	6.34e-10	1.09e-07	0.22	0.19	Height;	chr5:37474023	chr5:36666214~36725195:-
BRCA	cis	rs7809950	0.817	rs2237678	ENSG00000238832.1	snoU109	-6.24	6.35e-10	1.09e-07	-0.28	-0.19	Coronary artery disease;	chr7:107562820	chr7:107603363~107603507:+
BRCA	cis	rs2692947	0.86	rs2579520	ENSG00000237510.6	AC008268.2	-6.24	6.35e-10	1.09e-07	-0.25	-0.19	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95994552	chr2:95789654~95800166:+
BRCA	cis	rs669446	0.562	rs4660260	ENSG00000237950.1	RP11-7O11.3	6.24	6.35e-10	1.09e-07	0.22	0.19	Amyotrophic lateral sclerosis (age of onset);	chr1:43729682	chr1:43944370~43946551:-
BRCA	cis	rs2348418	0.864	rs7957495	ENSG00000247934.4	RP11-967K21.1	-6.24	6.35e-10	1.09e-07	-0.21	-0.19	Lung function (FEV1);Lung function (FVC);	chr12:28564522	chr12:28163298~28190738:-
BRCA	cis	rs7598759	0.527	rs12987949	ENSG00000223198.1	RNU2-22P	-6.24	6.35e-10	1.09e-07	-0.23	-0.19	Noise-induced hearing loss;	chr2:231502800	chr2:231501990~231502201:-
BRCA	cis	rs7615952	0.599	rs67566088	ENSG00000171084.14	FAM86JP	6.24	6.36e-10	1.09e-07	0.29	0.19	Blood pressure (smoking interaction);	chr3:126050130	chr3:125916620~125930024:+
BRCA	cis	rs2378497	1	rs12117316	ENSG00000232679.1	RP11-400N13.3	6.24	6.36e-10	1.09e-07	0.25	0.19	Serum thyroid-stimulating hormone levels;	chr1:222012627	chr1:222041705~222064763:-
BRCA	cis	rs853679	0.517	rs2281588	ENSG00000280107.1	AL022393.9	-6.24	6.36e-10	1.09e-07	-0.28	-0.19	Depression;	chr6:28104824	chr6:28170845~28172521:+
BRCA	cis	rs7555523	0.83	rs6660601	ENSG00000224358.1	RP11-466F5.8	-6.24	6.37e-10	1.09e-07	-0.35	-0.19	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165726618	chr1:165768929~165775176:+
BRCA	cis	rs8072100	0.582	rs3826536	ENSG00000228782.6	CTD-2026D20.3	6.24	6.37e-10	1.09e-07	0.21	0.19	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47424601	chr17:47450568~47492492:-
BRCA	cis	rs6688613	0.694	rs12062326	ENSG00000225171.2	DUTP6	-6.24	6.37e-10	1.09e-07	-0.27	-0.19	Refractive astigmatism;	chr1:166850949	chr1:166868748~166869209:+
BRCA	cis	rs1823913	0.599	rs13027086	ENSG00000280083.1	RP11-317J9.1	-6.24	6.37e-10	1.09e-07	-0.22	-0.19	Obesity-related traits;	chr2:191294058	chr2:191154118~191156070:-
BRCA	cis	rs1707322	1	rs11211248	ENSG00000281133.1	AL355480.3	-6.24	6.37e-10	1.09e-07	-0.24	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46011172	chr1:45580892~45580996:-
BRCA	cis	rs9992667	0.955	rs28560778	ENSG00000231160.8	KLF3-AS1	6.24	6.38e-10	1.1e-07	0.23	0.19	Eosinophil percentage of granulocytes;	chr4:38609668	chr4:38612701~38664883:-
BRCA	cis	rs2243480	0.803	rs55700941	ENSG00000229886.1	RP5-1132H15.3	6.24	6.39e-10	1.1e-07	0.33	0.19	Diabetic kidney disease;	chr7:65924813	chr7:66025126~66031544:-
BRCA	cis	rs2243480	1	rs316327	ENSG00000232546.1	RP11-458F8.1	6.24	6.39e-10	1.1e-07	0.25	0.19	Diabetic kidney disease;	chr7:66144214	chr7:66848496~66858136:+
BRCA	cis	rs853679	0.599	rs149990	ENSG00000220721.1	OR1F12	6.24	6.39e-10	1.1e-07	0.35	0.19	Depression;	chr6:28030480	chr6:28073316~28074233:+
BRCA	cis	rs1322639	0.614	rs6900200	ENSG00000261039.2	RP11-417E7.2	-6.24	6.39e-10	1.1e-07	-0.24	-0.19	Pulse pressure;	chr6:169166078	chr6:169175304~169182740:-
BRCA	cis	rs669446	0.528	rs4660743	ENSG00000237950.1	RP11-7O11.3	6.24	6.4e-10	1.1e-07	0.22	0.19	Amyotrophic lateral sclerosis (age of onset);	chr1:43729733	chr1:43944370~43946551:-
BRCA	cis	rs11976180	1	rs1320893	ENSG00000273234.1	OR2A13P	-6.24	6.4e-10	1.1e-07	-0.25	-0.19	Obesity-related traits;	chr7:144055019	chr7:144142009~144142938:+
BRCA	cis	rs1124769	0.692	rs67889301	ENSG00000259378.1	DCAF13P3	6.24	6.4e-10	1.1e-07	0.27	0.19	Cognitive performance;	chr15:50973842	chr15:50944663~50945996:+
BRCA	cis	rs9287719	0.601	rs9287718	ENSG00000243819.4	RN7SL832P	-6.24	6.4e-10	1.1e-07	-0.19	-0.19	Prostate cancer;	chr2:10561503	chr2:10690344~10692099:+
BRCA	cis	rs67311347	0.955	rs9821036	ENSG00000280739.1	EIF1B-AS1	6.24	6.4e-10	1.1e-07	0.21	0.19	Renal cell carcinoma;	chr3:40337516	chr3:40173145~40309698:-
BRCA	cis	rs1223397	0.938	rs20499	ENSG00000215022.6	RP1-257A7.4	-6.24	6.4e-10	1.1e-07	-0.26	-0.19	Blood pressure;	chr6:13294772	chr6:13264861~13295586:-
BRCA	cis	rs9635324	0.516	rs7165012	ENSG00000223313.1	RNU6-516P	-6.24	6.41e-10	1.1e-07	-0.23	-0.19	Blood metabolite ratios;Blood metabolite levels;	chr15:40361837	chr15:40529570~40529673:+
BRCA	cis	rs7746199	0.736	rs34573979	ENSG00000220721.1	OR1F12	6.24	6.41e-10	1.1e-07	0.45	0.19	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27512747	chr6:28073316~28074233:+
BRCA	cis	rs2638953	0.924	rs79712894	ENSG00000278733.1	RP11-425D17.1	-6.24	6.42e-10	1.1e-07	-0.26	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28239400	chr12:28185625~28186190:-
BRCA	cis	rs2836950	0.565	rs2836942	ENSG00000238141.2	BRWD1-AS1	-6.24	6.43e-10	1.1e-07	-0.21	-0.19	Menarche (age at onset);	chr21:39219455	chr21:39315707~39323218:+
BRCA	cis	rs853679	0.517	rs9380058	ENSG00000219392.1	RP1-265C24.5	-6.24	6.43e-10	1.1e-07	-0.29	-0.19	Depression;	chr6:28159666	chr6:28115628~28116551:+
BRCA	cis	rs853679	0.517	rs9393898	ENSG00000219392.1	RP1-265C24.5	-6.24	6.43e-10	1.1e-07	-0.29	-0.19	Depression;	chr6:28162598	chr6:28115628~28116551:+
BRCA	cis	rs2742234	0.794	rs17153156	ENSG00000273008.1	RP11-351D16.3	6.24	6.43e-10	1.1e-07	0.21	0.19	Hirschsprung disease;	chr10:43209189	chr10:43136824~43138334:-
BRCA	cis	rs11098499	1	rs11098500	ENSG00000249244.1	RP11-548H18.2	6.24	6.44e-10	1.1e-07	0.23	0.19	Corneal astigmatism;	chr4:119298084	chr4:119391831~119395335:-
BRCA	cis	rs2179367	0.632	rs6920383	ENSG00000216906.2	RP11-350J20.9	6.24	6.44e-10	1.1e-07	0.27	0.19	Dupuytren's disease;	chr6:149356361	chr6:149904243~149906418:+
BRCA	cis	rs67311347	0.955	rs4974068	ENSG00000280739.1	EIF1B-AS1	6.24	6.44e-10	1.11e-07	0.21	0.19	Renal cell carcinoma;	chr3:40335438	chr3:40173145~40309698:-
BRCA	cis	rs11098499	0.739	rs7441137	ENSG00000248280.1	RP11-33B1.2	-6.24	6.45e-10	1.11e-07	-0.19	-0.19	Corneal astigmatism;	chr4:119212066	chr4:119440561~119450157:-
BRCA	cis	rs8054556	0.74	rs11649612	ENSG00000273724.1	RP11-347C12.12	-6.24	6.45e-10	1.11e-07	-0.22	-0.19	Autism spectrum disorder or schizophrenia;	chr16:29935349	chr16:30336400~30343336:+
BRCA	cis	rs6570726	0.935	rs400968	ENSG00000235652.6	RP11-545I5.3	6.24	6.46e-10	1.11e-07	0.18	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145498582	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.935	rs391820	ENSG00000235652.6	RP11-545I5.3	6.24	6.46e-10	1.11e-07	0.18	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145500148	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.875	rs1883407	ENSG00000235652.6	RP11-545I5.3	6.24	6.46e-10	1.11e-07	0.18	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145502296	chr6:145799409~145886585:+
BRCA	cis	rs2998286	0.822	rs2807737	ENSG00000254635.4	WAC-AS1	-6.24	6.46e-10	1.11e-07	-0.26	-0.19	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28501052	chr10:28522652~28532743:-
BRCA	cis	rs783540	0.632	rs17356528	ENSG00000278603.1	RP13-608F4.5	-6.24	6.46e-10	1.11e-07	-0.27	-0.19	Schizophrenia;	chr15:82636799	chr15:82472203~82472426:+
BRCA	cis	rs2243480	1	rs431076	ENSG00000232559.3	GS1-124K5.12	6.24	6.47e-10	1.11e-07	0.36	0.19	Diabetic kidney disease;	chr7:66135333	chr7:66554588~66576923:-
BRCA	cis	rs2243480	1	rs2460422	ENSG00000232559.3	GS1-124K5.12	6.24	6.47e-10	1.11e-07	0.36	0.19	Diabetic kidney disease;	chr7:66136518	chr7:66554588~66576923:-
BRCA	cis	rs2243480	1	rs316334	ENSG00000232559.3	GS1-124K5.12	6.24	6.47e-10	1.11e-07	0.36	0.19	Diabetic kidney disease;	chr7:66137139	chr7:66554588~66576923:-
BRCA	cis	rs1124769	0.692	rs12595526	ENSG00000259378.1	DCAF13P3	6.24	6.48e-10	1.11e-07	0.27	0.19	Cognitive performance;	chr15:50932824	chr15:50944663~50945996:+
BRCA	cis	rs4218	1	rs4218	ENSG00000259732.1	RP11-59H7.3	-6.24	6.5e-10	1.11e-07	-0.22	-0.19	Social communication problems;	chr15:59136459	chr15:59121034~59133250:+
BRCA	cis	rs853679	0.542	rs9393892	ENSG00000280107.1	AL022393.9	-6.24	6.51e-10	1.12e-07	-0.28	-0.19	Depression;	chr6:28113616	chr6:28170845~28172521:+
BRCA	cis	rs6570726	0.935	rs367612	ENSG00000235652.6	RP11-545I5.3	6.24	6.52e-10	1.12e-07	0.18	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145507851	chr6:145799409~145886585:+
BRCA	cis	rs6570726	0.905	rs375692	ENSG00000235652.6	RP11-545I5.3	6.24	6.52e-10	1.12e-07	0.18	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145519232	chr6:145799409~145886585:+
BRCA	cis	rs875971	0.895	rs4718349	ENSG00000224316.1	RP11-479O9.2	6.24	6.52e-10	1.12e-07	0.19	0.19	Aortic root size;	chr7:66444024	chr7:65773620~65802067:+
BRCA	cis	rs875971	1	rs2042133	ENSG00000224316.1	RP11-479O9.2	6.24	6.52e-10	1.12e-07	0.19	0.19	Aortic root size;	chr7:66466935	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.964	rs2161065	ENSG00000224316.1	RP11-479O9.2	6.24	6.52e-10	1.12e-07	0.19	0.19	Aortic root size;	chr7:66467918	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.862	rs12698521	ENSG00000224316.1	RP11-479O9.2	6.24	6.52e-10	1.12e-07	0.19	0.19	Aortic root size;	chr7:66474502	chr7:65773620~65802067:+
BRCA	cis	rs13113518	0.783	rs34534635	ENSG00000223305.1	RN7SKP30	6.24	6.52e-10	1.12e-07	0.24	0.19	Height;	chr4:55573424	chr4:55540502~55540835:-
BRCA	cis	rs13113518	0.783	rs7690837	ENSG00000223305.1	RN7SKP30	6.24	6.52e-10	1.12e-07	0.24	0.19	Height;	chr4:55575856	chr4:55540502~55540835:-
BRCA	cis	rs853679	0.517	rs9393891	ENSG00000280107.1	AL022393.9	-6.24	6.53e-10	1.12e-07	-0.28	-0.19	Depression;	chr6:28111382	chr6:28170845~28172521:+
BRCA	cis	rs853679	0.517	rs9468286	ENSG00000280107.1	AL022393.9	-6.24	6.53e-10	1.12e-07	-0.28	-0.19	Depression;	chr6:28111650	chr6:28170845~28172521:+
BRCA	cis	rs853679	0.517	rs9380055	ENSG00000280107.1	AL022393.9	-6.24	6.53e-10	1.12e-07	-0.28	-0.19	Depression;	chr6:28113851	chr6:28170845~28172521:+
BRCA	cis	rs853679	0.517	rs9368553	ENSG00000280107.1	AL022393.9	-6.24	6.53e-10	1.12e-07	-0.28	-0.19	Depression;	chr6:28114487	chr6:28170845~28172521:+
BRCA	cis	rs853679	0.517	rs9368554	ENSG00000280107.1	AL022393.9	-6.24	6.53e-10	1.12e-07	-0.28	-0.19	Depression;	chr6:28114933	chr6:28170845~28172521:+
BRCA	cis	rs853679	0.517	rs4713137	ENSG00000280107.1	AL022393.9	-6.24	6.53e-10	1.12e-07	-0.28	-0.19	Depression;	chr6:28115743	chr6:28170845~28172521:+
BRCA	cis	rs853679	0.517	rs9348793	ENSG00000280107.1	AL022393.9	-6.24	6.53e-10	1.12e-07	-0.28	-0.19	Depression;	chr6:28116411	chr6:28170845~28172521:+
BRCA	cis	rs4713118	0.586	rs6905516	ENSG00000280107.1	AL022393.9	-6.24	6.53e-10	1.12e-07	-0.28	-0.19	Parkinson's disease;	chr6:28118700	chr6:28170845~28172521:+
BRCA	cis	rs4713118	0.586	rs6905522	ENSG00000280107.1	AL022393.9	-6.24	6.53e-10	1.12e-07	-0.28	-0.19	Parkinson's disease;	chr6:28118701	chr6:28170845~28172521:+
BRCA	cis	rs4713118	0.586	rs9468290	ENSG00000280107.1	AL022393.9	-6.24	6.53e-10	1.12e-07	-0.28	-0.19	Parkinson's disease;	chr6:28119896	chr6:28170845~28172521:+
BRCA	cis	rs721917	0.506	rs2758555	ENSG00000244733.5	RP11-506M13.3	-6.24	6.53e-10	1.12e-07	-0.23	-0.19	Chronic obstructive pulmonary disease;	chr10:79931278	chr10:79660891~79677996:+
BRCA	cis	rs5015933	0.966	rs7870475	ENSG00000232630.1	PRPS1P2	-6.24	6.54e-10	1.12e-07	-0.18	-0.19	Body mass index;	chr9:125371755	chr9:125150653~125151589:+
BRCA	cis	rs1552244	1	rs3846177	ENSG00000180385.7	EMC3-AS1	6.24	6.54e-10	1.12e-07	0.23	0.19	Alzheimer's disease;	chr3:10026888	chr3:9986893~10006990:+
BRCA	cis	rs12468226	0.938	rs3731700	ENSG00000226261.1	AC064836.3	6.24	6.54e-10	1.12e-07	0.33	0.19	Urate levels;	chr2:202291213	chr2:202336024~202336727:-
BRCA	cis	rs42490	1	rs40544	ENSG00000251136.7	RP11-37B2.1	-6.24	6.55e-10	1.12e-07	-0.18	-0.19	Leprosy;	chr8:89768867	chr8:89609409~89757727:-
BRCA	cis	rs16958440	0.867	rs12326221	ENSG00000267800.1	RP11-49K24.5	-6.24	6.55e-10	1.12e-07	-0.46	-0.19	Sitting height ratio;	chr18:47156522	chr18:47137018~47137290:+
BRCA	cis	rs7124681	0.546	rs7941399	ENSG00000280615.1	Y_RNA	6.23	6.55e-10	1.12e-07	0.22	0.19	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:47868869	chr11:47614898~47614994:-
BRCA	cis	rs1552244	0.938	rs7652951	ENSG00000180385.7	EMC3-AS1	6.23	6.56e-10	1.12e-07	0.24	0.19	Alzheimer's disease;	chr3:10022079	chr3:9986893~10006990:+
BRCA	cis	rs1552244	1	rs7611218	ENSG00000180385.7	EMC3-AS1	6.23	6.56e-10	1.12e-07	0.24	0.19	Alzheimer's disease;	chr3:10022276	chr3:9986893~10006990:+
BRCA	cis	rs1552244	0.872	rs6803517	ENSG00000180385.7	EMC3-AS1	6.23	6.56e-10	1.12e-07	0.24	0.19	Alzheimer's disease;	chr3:10023742	chr3:9986893~10006990:+
BRCA	cis	rs1552244	1	rs9834980	ENSG00000180385.7	EMC3-AS1	6.23	6.56e-10	1.12e-07	0.24	0.19	Alzheimer's disease;	chr3:10023844	chr3:9986893~10006990:+
BRCA	cis	rs3764021	0.527	rs17806710	ENSG00000214776.8	RP11-726G1.1	6.23	6.58e-10	1.13e-07	0.23	0.19	Type 1 diabetes;	chr12:9688368	chr12:9467552~9576275:+
BRCA	cis	rs6840258	1	rs10516788	ENSG00000251411.1	RP11-397E7.4	-6.23	6.59e-10	1.13e-07	-0.25	-0.19	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87039705	chr4:86913266~86914817:-
BRCA	cis	rs6061231	0.798	rs2427308	ENSG00000275437.1	RP5-908M14.10	6.23	6.59e-10	1.13e-07	0.22	0.19	Colorectal cancer;	chr20:62394395	chr20:62402236~62405935:-
BRCA	cis	rs875971	0.522	rs1617484	ENSG00000234585.5	CCT6P3	6.23	6.59e-10	1.13e-07	0.18	0.19	Aortic root size;	chr7:65998108	chr7:65038354~65074713:+
BRCA	cis	rs2274273	1	rs1009977	ENSG00000258413.1	RP11-665C16.6	-6.23	6.6e-10	1.13e-07	-0.24	-0.19	Protein biomarker;	chr14:55136284	chr14:55262767~55272075:-
BRCA	cis	rs2115630	1	rs11073730	ENSG00000229212.6	RP11-561C5.4	6.23	6.6e-10	1.13e-07	0.21	0.19	P wave terminal force;	chr15:84811365	chr15:85205440~85234795:-
BRCA	cis	rs673078	0.607	rs884844	ENSG00000275409.1	RP11-131L12.4	-6.23	6.6e-10	1.13e-07	-0.27	-0.19	Glucose homeostasis traits;	chr12:118377033	chr12:118430147~118430699:+
BRCA	cis	rs2243480	1	rs34970380	ENSG00000164669.11	INTS4P1	6.23	6.61e-10	1.13e-07	0.37	0.19	Diabetic kidney disease;	chr7:65966506	chr7:65141225~65234216:+
BRCA	cis	rs34779708	0.966	rs1148245	ENSG00000271335.4	RP11-324I22.4	6.23	6.61e-10	1.13e-07	0.19	0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35222966	chr10:35314552~35336401:-
BRCA	cis	rs875971	0.545	rs2460427	ENSG00000273024.4	INTS4P2	6.23	6.61e-10	1.13e-07	0.23	0.19	Aortic root size;	chr7:66154218	chr7:65647864~65715661:+
BRCA	cis	rs6142102	0.812	rs4911375	ENSG00000275784.1	RP5-1125A11.6	-6.23	6.62e-10	1.13e-07	-0.23	-0.19	Skin pigmentation;	chr20:33928216	chr20:33989480~33991818:-
BRCA	cis	rs6142102	0.812	rs761238	ENSG00000275784.1	RP5-1125A11.6	6.23	6.62e-10	1.13e-07	0.23	0.19	Skin pigmentation;	chr20:33932182	chr20:33989480~33991818:-
BRCA	cis	rs2380205	0.546	rs636578	ENSG00000232807.2	RP11-536K7.3	-6.23	6.62e-10	1.13e-07	-0.2	-0.19	Breast cancer;	chr10:5896581	chr10:5934270~5945900:-
BRCA	cis	rs2179367	0.632	rs11155645	ENSG00000216906.2	RP11-350J20.9	6.23	6.63e-10	1.14e-07	0.27	0.19	Dupuytren's disease;	chr6:149360056	chr6:149904243~149906418:+
BRCA	cis	rs2179367	0.632	rs9498332	ENSG00000216906.2	RP11-350J20.9	6.23	6.63e-10	1.14e-07	0.27	0.19	Dupuytren's disease;	chr6:149367490	chr6:149904243~149906418:+
BRCA	cis	rs2179367	0.632	rs9498333	ENSG00000216906.2	RP11-350J20.9	6.23	6.63e-10	1.14e-07	0.27	0.19	Dupuytren's disease;	chr6:149368196	chr6:149904243~149906418:+
BRCA	cis	rs853679	0.517	rs1340004	ENSG00000219392.1	RP1-265C24.5	-6.23	6.63e-10	1.14e-07	-0.29	-0.19	Depression;	chr6:28135913	chr6:28115628~28116551:+
BRCA	cis	rs875971	0.522	rs781144	ENSG00000237310.1	GS1-124K5.4	6.23	6.64e-10	1.14e-07	0.19	0.19	Aortic root size;	chr7:65975357	chr7:66493706~66495474:+
BRCA	cis	rs42648	0.564	rs10224488	ENSG00000225498.1	AC002064.5	6.23	6.64e-10	1.14e-07	0.18	0.19	Homocysteine levels;	chr7:90180947	chr7:90312496~90322592:+
BRCA	cis	rs7923609	0.902	rs4633333	ENSG00000232075.1	MRPL35P2	-6.23	6.65e-10	1.14e-07	-0.24	-0.19	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63568779	chr10:63634317~63634827:-
BRCA	cis	rs7923609	0.902	rs10740136	ENSG00000232075.1	MRPL35P2	-6.23	6.65e-10	1.14e-07	-0.24	-0.19	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63569862	chr10:63634317~63634827:-
BRCA	cis	rs1499614	1	rs2659913	ENSG00000232559.3	GS1-124K5.12	6.23	6.65e-10	1.14e-07	0.36	0.19	Gout;	chr7:66692349	chr7:66554588~66576923:-
BRCA	cis	rs1499614	1	rs2659911	ENSG00000232559.3	GS1-124K5.12	6.23	6.65e-10	1.14e-07	0.36	0.19	Gout;	chr7:66693433	chr7:66554588~66576923:-
BRCA	cis	rs1499614	1	rs2707838	ENSG00000232559.3	GS1-124K5.12	6.23	6.65e-10	1.14e-07	0.36	0.19	Gout;	chr7:66694214	chr7:66554588~66576923:-
BRCA	cis	rs1499614	1	rs60326618	ENSG00000232559.3	GS1-124K5.12	6.23	6.65e-10	1.14e-07	0.36	0.19	Gout;	chr7:66701371	chr7:66554588~66576923:-
BRCA	cis	rs1499614	1	rs2707830	ENSG00000232559.3	GS1-124K5.12	6.23	6.65e-10	1.14e-07	0.36	0.19	Gout;	chr7:66702658	chr7:66554588~66576923:-
BRCA	cis	rs1499614	1	rs2707828	ENSG00000232559.3	GS1-124K5.12	6.23	6.65e-10	1.14e-07	0.36	0.19	Gout;	chr7:66706390	chr7:66554588~66576923:-
BRCA	cis	rs1499614	0.803	rs1922723	ENSG00000232559.3	GS1-124K5.12	6.23	6.65e-10	1.14e-07	0.36	0.19	Gout;	chr7:66710076	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.545	rs6460298	ENSG00000236529.1	RP13-254B10.1	6.23	6.65e-10	1.14e-07	0.23	0.19	Aortic root size;	chr7:66442783	chr7:65840212~65840596:+
BRCA	cis	rs1707322	0.928	rs10732844	ENSG00000281133.1	AL355480.3	-6.23	6.66e-10	1.14e-07	-0.24	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45907016	chr1:45580892~45580996:-
BRCA	cis	rs4691139	1	rs6536882	ENSG00000248632.1	RP11-366M4.11	6.23	6.66e-10	1.14e-07	0.2	0.19	Ovarian cancer in BRCA1 mutation carriers;	chr4:164979528	chr4:164968587~164970002:-
BRCA	cis	rs4691139	1	rs6536883	ENSG00000248632.1	RP11-366M4.11	6.23	6.66e-10	1.14e-07	0.2	0.19	Ovarian cancer in BRCA1 mutation carriers;	chr4:164979552	chr4:164968587~164970002:-
BRCA	cis	rs13126694	0.617	rs10008900	ENSG00000248429.4	RP11-597D13.9	6.23	6.67e-10	1.14e-07	0.17	0.19	Blood osmolality (transformed sodium);	chr4:157948827	chr4:158170752~158202877:+
BRCA	cis	rs2638953	0.924	rs11049472	ENSG00000278733.1	RP11-425D17.1	-6.23	6.67e-10	1.14e-07	-0.26	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28229772	chr12:28185625~28186190:-
BRCA	cis	rs7927771	0.507	rs12366244	ENSG00000280615.1	Y_RNA	6.23	6.68e-10	1.14e-07	0.22	0.19	Subjective well-being;	chr11:47860578	chr11:47614898~47614994:-
BRCA	cis	rs7927771	0.524	rs7933896	ENSG00000280615.1	Y_RNA	6.23	6.68e-10	1.14e-07	0.22	0.19	Subjective well-being;	chr11:47861230	chr11:47614898~47614994:-
BRCA	cis	rs2179367	0.632	rs9498324	ENSG00000216906.2	RP11-350J20.9	6.23	6.69e-10	1.14e-07	0.27	0.19	Dupuytren's disease;	chr6:149338973	chr6:149904243~149906418:+
BRCA	cis	rs2179367	0.632	rs55826712	ENSG00000216906.2	RP11-350J20.9	6.23	6.69e-10	1.14e-07	0.27	0.19	Dupuytren's disease;	chr6:149344716	chr6:149904243~149906418:+
BRCA	cis	rs30380	0.69	rs2042381	ENSG00000272109.1	CTD-2260A17.3	-6.23	6.69e-10	1.15e-07	-0.25	-0.19	Cerebrospinal fluid biomarker levels;	chr5:96852963	chr5:96804353~96806105:+
BRCA	cis	rs673078	0.66	rs17512219	ENSG00000275409.1	RP11-131L12.4	-6.23	6.7e-10	1.15e-07	-0.3	-0.19	Glucose homeostasis traits;	chr12:118211468	chr12:118430147~118430699:+
BRCA	cis	rs6095360	0.727	rs755588	ENSG00000222365.1	SNORD12B	-6.23	6.7e-10	1.15e-07	-0.24	-0.19	Intelligence (multi-trait analysis);	chr20:49104491	chr20:49280319~49280409:+
BRCA	cis	rs911555	0.755	rs11620897	ENSG00000244691.1	RPL10AP1	-6.23	6.71e-10	1.15e-07	-0.24	-0.19	Intelligence (multi-trait analysis);	chr14:103478524	chr14:103412119~103412761:-
BRCA	cis	rs13113518	0.812	rs6830409	ENSG00000273257.1	RP11-177J6.1	6.23	6.71e-10	1.15e-07	0.25	0.19	Height;	chr4:55522229	chr4:55387949~55388271:+
BRCA	cis	rs78456975	0.943	rs13391932	ENSG00000231482.2	AC141930.2	-6.23	6.72e-10	1.15e-07	-0.27	-0.19	Placebo response in major depressive disorder (% change in symptom score);	chr2:1573907	chr2:1572554~1580311:-
BRCA	cis	rs17301013	0.507	rs11799535	ENSG00000227373.4	RP11-160H22.5	6.23	6.74e-10	1.15e-07	0.29	0.19	Systemic lupus erythematosus;	chr1:174415790	chr1:174115300~174160004:-
BRCA	cis	rs2243480	1	rs313814	ENSG00000164669.11	INTS4P1	6.23	6.75e-10	1.15e-07	0.38	0.19	Diabetic kidney disease;	chr7:66038306	chr7:65141225~65234216:+
BRCA	cis	rs2098713	0.562	rs55794983	ENSG00000250155.1	CTD-2353F22.1	6.23	6.75e-10	1.16e-07	0.21	0.19	Telomere length;	chr5:37549046	chr5:36666214~36725195:-
BRCA	cis	rs67981189	0.727	rs221903	ENSG00000269927.1	RP6-91H8.3	-6.23	6.75e-10	1.16e-07	-0.23	-0.19	Schizophrenia;	chr14:71133491	chr14:71141125~71143253:-
BRCA	cis	rs7688540	0.8	rs10023604	ENSG00000275426.1	CH17-262A2.1	6.23	6.75e-10	1.16e-07	0.24	0.19	Facial morphology (factor 6, height of vermillion lower lip);	chr4:287249	chr4:149738~150317:+
BRCA	cis	rs7567389	0.719	rs4150402	ENSG00000236682.1	AC068282.3	-6.23	6.75e-10	1.16e-07	-0.29	-0.19	Self-rated health;	chr2:127292558	chr2:127389130~127400580:+
BRCA	cis	rs7567389	0.677	rs7556675	ENSG00000236682.1	AC068282.3	6.23	6.76e-10	1.16e-07	0.29	0.19	Self-rated health;	chr2:127296171	chr2:127389130~127400580:+
BRCA	cis	rs4372836	0.893	rs745645	ENSG00000226833.4	AC097724.3	-6.23	6.77e-10	1.16e-07	-0.23	-0.19	Body mass index;	chr2:28708705	chr2:28708953~28736205:-
BRCA	cis	rs1707322	0.964	rs6675259	ENSG00000281133.1	AL355480.3	6.23	6.77e-10	1.16e-07	0.25	0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46036623	chr1:45580892~45580996:-
BRCA	cis	rs875971	0.862	rs13226170	ENSG00000224316.1	RP11-479O9.2	6.23	6.77e-10	1.16e-07	0.19	0.19	Aortic root size;	chr7:66534311	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.862	rs2420611	ENSG00000224316.1	RP11-479O9.2	6.23	6.77e-10	1.16e-07	0.19	0.19	Aortic root size;	chr7:66534333	chr7:65773620~65802067:+
BRCA	cis	rs227275	0.556	rs4699044	ENSG00000251288.2	RP11-10L12.2	-6.23	6.77e-10	1.16e-07	-0.22	-0.19	Allergic disease (asthma, hay fever or eczema);	chr4:102976939	chr4:102751401~102752641:+
BRCA	cis	rs11096990	0.927	rs56009503	ENSG00000249207.1	RP11-360F5.1	6.23	6.78e-10	1.16e-07	0.22	0.19	Cognitive function;	chr4:39242642	chr4:39112677~39126818:-
BRCA	cis	rs11096990	0.964	rs7687651	ENSG00000249207.1	RP11-360F5.1	6.23	6.78e-10	1.16e-07	0.22	0.19	Cognitive function;	chr4:39243072	chr4:39112677~39126818:-
BRCA	cis	rs1499614	1	rs2659903	ENSG00000232559.3	GS1-124K5.12	6.23	6.78e-10	1.16e-07	0.36	0.19	Gout;	chr7:66715944	chr7:66554588~66576923:-
BRCA	cis	rs8054556	0.716	rs11642933	ENSG00000273724.1	RP11-347C12.12	-6.23	6.78e-10	1.16e-07	-0.21	-0.19	Autism spectrum disorder or schizophrenia;	chr16:29935387	chr16:30336400~30343336:+
BRCA	cis	rs754466	0.58	rs1344966	ENSG00000204049.1	RP11-126H7.4	6.23	6.8e-10	1.16e-07	0.23	0.19	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77774769	chr10:77866875~77869610:+
BRCA	cis	rs2179367	0.632	rs9485384	ENSG00000216906.2	RP11-350J20.9	6.23	6.8e-10	1.16e-07	0.27	0.19	Dupuytren's disease;	chr6:149328808	chr6:149904243~149906418:+
BRCA	cis	rs2243480	1	rs160646	ENSG00000232559.3	GS1-124K5.12	6.23	6.8e-10	1.16e-07	0.36	0.19	Diabetic kidney disease;	chr7:66091293	chr7:66554588~66576923:-
BRCA	cis	rs72681920	0.881	rs12507078	ENSG00000246090.5	RP11-696N14.1	-6.23	6.81e-10	1.17e-07	-0.31	-0.19	Alcohol dependence;	chr4:99204711	chr4:99088857~99301356:+
BRCA	cis	rs2243480	0.901	rs3813708	ENSG00000229886.1	RP5-1132H15.3	6.23	6.82e-10	1.17e-07	0.33	0.19	Diabetic kidney disease;	chr7:65840645	chr7:66025126~66031544:-
BRCA	cis	rs11098499	0.954	rs13107475	ENSG00000249244.1	RP11-548H18.2	6.23	6.83e-10	1.17e-07	0.22	0.19	Corneal astigmatism;	chr4:119471856	chr4:119391831~119395335:-
BRCA	cis	rs875971	0.545	rs1796219	ENSG00000236529.1	RP13-254B10.1	-6.23	6.83e-10	1.17e-07	-0.24	-0.19	Aortic root size;	chr7:66645977	chr7:65840212~65840596:+
BRCA	cis	rs1499614	1	rs2707840	ENSG00000232559.3	GS1-124K5.12	6.23	6.83e-10	1.17e-07	0.36	0.19	Gout;	chr7:66693028	chr7:66554588~66576923:-
BRCA	cis	rs7044106	0.762	rs10760107	ENSG00000238181.2	AHCYP2	-6.23	6.84e-10	1.17e-07	-0.25	-0.19	Hip circumference adjusted for BMI;	chr9:120621352	chr9:120720673~120721972:+
BRCA	cis	rs6479891	1	rs61853589	ENSG00000232075.1	MRPL35P2	6.23	6.84e-10	1.17e-07	0.34	0.19	Arthritis (juvenile idiopathic);	chr10:63427351	chr10:63634317~63634827:-
BRCA	cis	rs6479891	1	rs9414803	ENSG00000232075.1	MRPL35P2	6.23	6.84e-10	1.17e-07	0.34	0.19	Arthritis (juvenile idiopathic);	chr10:63428309	chr10:63634317~63634827:-
BRCA	cis	rs6479891	1	rs9415707	ENSG00000232075.1	MRPL35P2	6.23	6.84e-10	1.17e-07	0.34	0.19	Arthritis (juvenile idiopathic);	chr10:63428530	chr10:63634317~63634827:-
BRCA	cis	rs6479891	1	rs12413029	ENSG00000232075.1	MRPL35P2	6.23	6.84e-10	1.17e-07	0.34	0.19	Arthritis (juvenile idiopathic);	chr10:63429366	chr10:63634317~63634827:-
BRCA	cis	rs2998286	0.862	rs2486637	ENSG00000254635.4	WAC-AS1	-6.23	6.84e-10	1.17e-07	-0.26	-0.19	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28505085	chr10:28522652~28532743:-
BRCA	cis	rs6840258	1	rs17604480	ENSG00000251411.1	RP11-397E7.4	-6.23	6.84e-10	1.17e-07	-0.25	-0.19	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87048975	chr4:86913266~86914817:-
BRCA	cis	rs1387259	0.79	rs2732445	ENSG00000257763.1	OR5BK1P	6.23	6.85e-10	1.17e-07	0.21	0.19	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48251750	chr12:48355792~48356614:-
BRCA	cis	rs7567389	0.677	rs10850	ENSG00000236682.1	AC068282.3	6.23	6.85e-10	1.17e-07	0.29	0.19	Self-rated health;	chr2:127306369	chr2:127389130~127400580:+
BRCA	cis	rs875971	1	rs2420591	ENSG00000224316.1	RP11-479O9.2	6.23	6.86e-10	1.17e-07	0.19	0.19	Aortic root size;	chr7:66447394	chr7:65773620~65802067:+
BRCA	cis	rs10129255	0.53	rs11624912	ENSG00000274576.2	IGHV2-70	-6.23	6.86e-10	1.17e-07	-0.16	-0.19	Kawasaki disease;	chr14:106673891	chr14:106770577~106771020:-
BRCA	cis	rs801193	0.636	rs2659895	ENSG00000224316.1	RP11-479O9.2	6.23	6.86e-10	1.17e-07	0.19	0.19	Aortic root size;	chr7:66731484	chr7:65773620~65802067:+
BRCA	cis	rs6951245	0.706	rs28483034	ENSG00000229043.2	AC091729.9	-6.23	6.87e-10	1.17e-07	-0.31	-0.19	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1130535	chr7:1160374~1165267:+
BRCA	cis	rs17711722	0.727	rs2658585	ENSG00000234585.5	CCT6P3	6.23	6.87e-10	1.17e-07	0.18	0.19	Calcium levels;	chr7:65996954	chr7:65038354~65074713:+
BRCA	cis	rs1124769	0.719	rs12909839	ENSG00000259378.1	DCAF13P3	6.23	6.87e-10	1.17e-07	0.27	0.19	Cognitive performance;	chr15:50991923	chr15:50944663~50945996:+
BRCA	cis	rs3764021	0.527	rs11052426	ENSG00000214776.8	RP11-726G1.1	6.23	6.88e-10	1.18e-07	0.23	0.19	Type 1 diabetes;	chr12:9688330	chr12:9467552~9576275:+
BRCA	cis	rs42648	0.596	rs194507	ENSG00000225498.1	AC002064.5	-6.23	6.89e-10	1.18e-07	-0.18	-0.19	Homocysteine levels;	chr7:90214246	chr7:90312496~90322592:+
BRCA	cis	rs1124769	0.692	rs3825797	ENSG00000259378.1	DCAF13P3	6.23	6.9e-10	1.18e-07	0.27	0.19	Cognitive performance;	chr15:50933486	chr15:50944663~50945996:+
BRCA	cis	rs9880211	0.613	rs6799056	ENSG00000273486.1	RP11-731C17.2	6.23	6.9e-10	1.18e-07	0.23	0.19	Height;Body mass index;	chr3:136083508	chr3:136837338~136839021:-
BRCA	cis	rs4938303	0.718	rs10892020	ENSG00000254851.1	RP11-109L13.1	-6.23	6.91e-10	1.18e-07	-0.25	-0.19	Triglycerides;	chr11:116718936	chr11:117135528~117138582:+
BRCA	cis	rs7520050	1	rs785511	ENSG00000280836.1	AL355480.1	6.23	6.91e-10	1.18e-07	0.22	0.19	Reticulocyte count;Red blood cell count;	chr1:46068826	chr1:45581219~45581321:-
BRCA	cis	rs7520050	0.966	rs809775	ENSG00000280836.1	AL355480.1	6.23	6.91e-10	1.18e-07	0.22	0.19	Reticulocyte count;Red blood cell count;	chr1:46072368	chr1:45581219~45581321:-
BRCA	cis	rs72634501	0.568	rs590214	ENSG00000228060.1	RP11-69E11.8	-6.23	6.91e-10	1.18e-07	-0.2	-0.19	HDL cholesterol;	chr1:39146821	chr1:39565160~39573203:+
BRCA	cis	rs875971	0.545	rs7787063	ENSG00000273024.4	INTS4P2	-6.23	6.91e-10	1.18e-07	-0.23	-0.19	Aortic root size;	chr7:66164012	chr7:65647864~65715661:+
BRCA	cis	rs875971	0.545	rs12673308	ENSG00000273024.4	INTS4P2	-6.23	6.91e-10	1.18e-07	-0.23	-0.19	Aortic root size;	chr7:66166374	chr7:65647864~65715661:+
BRCA	cis	rs2408955	0.5	rs12816820	ENSG00000240399.1	RP1-228P16.1	6.23	6.92e-10	1.18e-07	0.22	0.19	Glycated hemoglobin levels;	chr12:48164542	chr12:48054813~48055591:-
BRCA	cis	rs375066	0.623	rs7254659	ENSG00000267058.1	RP11-15A1.3	6.23	6.93e-10	1.18e-07	0.22	0.19	Breast cancer;	chr19:43846537	chr19:43891804~43901805:-
BRCA	cis	rs2638953	0.815	rs1534340	ENSG00000278733.1	RP11-425D17.1	-6.23	6.93e-10	1.18e-07	-0.24	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28515550	chr12:28185625~28186190:-
BRCA	cis	rs17772222	0.74	rs11847417	ENSG00000258983.2	RP11-507K2.2	-6.23	6.94e-10	1.19e-07	-0.2	-0.19	Coronary artery calcification;	chr14:88510606	chr14:88499334~88515502:+
BRCA	cis	rs9807989	0.839	rs4988955	ENSG00000234389.1	AC007278.3	6.23	6.95e-10	1.19e-07	0.18	0.19	Asthma;	chr2:102351468	chr2:102438713~102440475:+
BRCA	cis	rs875971	0.545	rs3735147	ENSG00000236529.1	RP13-254B10.1	6.23	6.96e-10	1.19e-07	0.23	0.19	Aortic root size;	chr7:66505541	chr7:65840212~65840596:+
BRCA	cis	rs3781264	0.557	rs7092226	ENSG00000273450.1	RP11-76P2.4	6.23	6.96e-10	1.19e-07	0.26	0.19	Esophageal cancer and gastric cancer;	chr10:94352476	chr10:94314907~94315327:-
BRCA	cis	rs17301013	0.507	rs72715294	ENSG00000227373.4	RP11-160H22.5	6.23	6.96e-10	1.19e-07	0.29	0.19	Systemic lupus erythematosus;	chr1:174754922	chr1:174115300~174160004:-
BRCA	cis	rs9604573	0.869	rs7994900	ENSG00000233695.2	GAS6-AS1	6.22	6.97e-10	1.19e-07	0.23	0.19	Glycated hemoglobin levels;	chr13:113850161	chr13:113815630~113845744:+
BRCA	cis	rs2638953	0.886	rs7973241	ENSG00000278733.1	RP11-425D17.1	-6.22	6.97e-10	1.19e-07	-0.24	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28207583	chr12:28185625~28186190:-
BRCA	cis	rs6951245	0.678	rs28600085	ENSG00000229043.2	AC091729.9	-6.22	6.98e-10	1.19e-07	-0.31	-0.19	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1130000	chr7:1160374~1165267:+
BRCA	cis	rs17597773	0.598	rs11118616	ENSG00000272823.1	RP11-295M18.6	-6.22	6.99e-10	1.19e-07	-0.23	-0.19	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220832314	chr1:220828676~220829211:-
BRCA	cis	rs854765	0.547	rs4368210	ENSG00000281749.1	Y_RNA	-6.22	6.99e-10	1.19e-07	-0.22	-0.19	Total body bone mineral density;	chr17:17992776	chr17:18001101~18001195:-
BRCA	cis	rs7927771	0.524	rs7943464	ENSG00000280615.1	Y_RNA	6.22	7.01e-10	1.2e-07	0.22	0.19	Subjective well-being;	chr11:47865087	chr11:47614898~47614994:-
BRCA	cis	rs2179367	0.586	rs62426088	ENSG00000216906.2	RP11-350J20.9	6.22	7.01e-10	1.2e-07	0.27	0.19	Dupuytren's disease;	chr6:149339301	chr6:149904243~149906418:+
BRCA	cis	rs11976180	1	rs13243677	ENSG00000273234.1	OR2A13P	-6.22	7.02e-10	1.2e-07	-0.25	-0.19	Obesity-related traits;	chr7:144049479	chr7:144142009~144142938:+
BRCA	cis	rs875971	0.54	rs1723268	ENSG00000234585.5	CCT6P3	6.22	7.02e-10	1.2e-07	0.18	0.19	Aortic root size;	chr7:66008093	chr7:65038354~65074713:+
BRCA	cis	rs228614	0.51	rs223353	ENSG00000251288.2	RP11-10L12.2	-6.22	7.02e-10	1.2e-07	-0.22	-0.19	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102854547	chr4:102751401~102752641:+
BRCA	cis	rs228614	0.51	rs223352	ENSG00000251288.2	RP11-10L12.2	-6.22	7.02e-10	1.2e-07	-0.22	-0.19	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102855710	chr4:102751401~102752641:+
BRCA	cis	rs3764021	0.87	rs2401394	ENSG00000214776.8	RP11-726G1.1	6.22	7.02e-10	1.2e-07	0.21	0.19	Type 1 diabetes;	chr12:9726830	chr12:9467552~9576275:+
BRCA	cis	rs7520050	0.966	rs1768803	ENSG00000280836.1	AL355480.1	6.22	7.03e-10	1.2e-07	0.22	0.19	Reticulocyte count;Red blood cell count;	chr1:46080536	chr1:45581219~45581321:-
BRCA	cis	rs13108904	0.901	rs7695691	ENSG00000254094.1	AC078852.1	-6.22	7.03e-10	1.2e-07	-0.21	-0.19	Obesity-related traits;	chr4:1310844	chr4:1356581~1358075:+
BRCA	cis	rs875971	0.862	rs3893216	ENSG00000224316.1	RP11-479O9.2	-6.22	7.03e-10	1.2e-07	-0.19	-0.19	Aortic root size;	chr7:66325720	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.862	rs6958294	ENSG00000224316.1	RP11-479O9.2	-6.22	7.03e-10	1.2e-07	-0.19	-0.19	Aortic root size;	chr7:66329809	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.862	rs2088655	ENSG00000224316.1	RP11-479O9.2	-6.22	7.03e-10	1.2e-07	-0.19	-0.19	Aortic root size;	chr7:66330724	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.895	rs10447522	ENSG00000224316.1	RP11-479O9.2	-6.22	7.03e-10	1.2e-07	-0.19	-0.19	Aortic root size;	chr7:66331087	chr7:65773620~65802067:+
BRCA	cis	rs7182621	0.639	rs35049216	ENSG00000182397.13	DNM1P46	6.22	7.03e-10	1.2e-07	0.24	0.19	Colonoscopy-negative controls vs population controls;	chr15:99872562	chr15:99790156~99806927:-
BRCA	cis	rs6840360	0.806	rs13149588	ENSG00000270265.1	RP11-731D1.4	6.22	7.03e-10	1.2e-07	0.21	0.19	Intelligence (multi-trait analysis);	chr4:151796605	chr4:151333775~151353224:-
BRCA	cis	rs7246657	0.524	rs10411251	ENSG00000226686.6	LINC01535	-6.22	7.04e-10	1.2e-07	-0.31	-0.19	Coronary artery calcification;	chr19:36937853	chr19:37251912~37265535:+
BRCA	cis	rs2243480	0.803	rs36127118	ENSG00000232546.1	RP11-458F8.1	-6.22	7.05e-10	1.2e-07	-0.25	-0.19	Diabetic kidney disease;	chr7:66100518	chr7:66848496~66858136:+
BRCA	cis	rs11020821	0.828	rs16924603	ENSG00000255893.1	RP11-685N10.1	-6.22	7.05e-10	1.2e-07	-0.25	-0.19	Response to angiotensin II receptor blocker therapy;Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);	chr11:94522093	chr11:94472908~94473570:-
BRCA	cis	rs7615952	0.558	rs17334039	ENSG00000250012.1	RP11-124N2.1	-6.22	7.05e-10	1.2e-07	-0.26	-0.19	Blood pressure (smoking interaction);	chr3:125821465	chr3:126084220~126095349:+
BRCA	cis	rs875971	0.862	rs778736	ENSG00000224316.1	RP11-479O9.2	6.22	7.05e-10	1.2e-07	0.19	0.19	Aortic root size;	chr7:66348861	chr7:65773620~65802067:+
BRCA	cis	rs7615952	0.599	rs1875683	ENSG00000171084.14	FAM86JP	6.22	7.05e-10	1.2e-07	0.29	0.19	Blood pressure (smoking interaction);	chr3:126013638	chr3:125916620~125930024:+
BRCA	cis	rs4886920	0.672	rs11852322	ENSG00000260776.4	RP11-114H24.2	6.22	7.06e-10	1.2e-07	0.23	0.19	Neuroticism;	chr15:77829145	chr15:77914217~77926846:-
BRCA	cis	rs8031584	0.541	rs2955777	ENSG00000270015.1	RP11-540B6.6	6.22	7.07e-10	1.21e-07	0.19	0.19	Huntington's disease progression;	chr15:30927585	chr15:30926514~30928407:+
BRCA	cis	rs11976180	1	rs2961144	ENSG00000273234.1	OR2A13P	6.22	7.07e-10	1.21e-07	0.25	0.19	Obesity-related traits;	chr7:144050777	chr7:144142009~144142938:+
BRCA	cis	rs875971	0.895	rs10755833	ENSG00000224316.1	RP11-479O9.2	6.22	7.07e-10	1.21e-07	0.19	0.19	Aortic root size;	chr7:66448930	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.895	rs1833495	ENSG00000224316.1	RP11-479O9.2	6.22	7.07e-10	1.21e-07	0.19	0.19	Aortic root size;	chr7:66456608	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.964	rs6945032	ENSG00000224316.1	RP11-479O9.2	6.22	7.07e-10	1.21e-07	0.19	0.19	Aortic root size;	chr7:66457499	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.929	rs12673810	ENSG00000224316.1	RP11-479O9.2	6.22	7.07e-10	1.21e-07	0.19	0.19	Aortic root size;	chr7:66458866	chr7:65773620~65802067:+
BRCA	cis	rs875971	1	rs6961155	ENSG00000224316.1	RP11-479O9.2	6.22	7.07e-10	1.21e-07	0.19	0.19	Aortic root size;	chr7:66468308	chr7:65773620~65802067:+
BRCA	cis	rs875971	1	rs7789768	ENSG00000224316.1	RP11-479O9.2	6.22	7.07e-10	1.21e-07	0.19	0.19	Aortic root size;	chr7:66473993	chr7:65773620~65802067:+
BRCA	cis	rs875971	1	rs1363055	ENSG00000224316.1	RP11-479O9.2	6.22	7.07e-10	1.21e-07	0.19	0.19	Aortic root size;	chr7:66478288	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.964	rs9691480	ENSG00000224316.1	RP11-479O9.2	6.22	7.07e-10	1.21e-07	0.19	0.19	Aortic root size;	chr7:66479319	chr7:65773620~65802067:+
BRCA	cis	rs8103033	0.781	rs7248699	ENSG00000226025.8	LGALS17A	-6.22	7.07e-10	1.21e-07	-0.22	-0.19	Obesity-related traits;	chr19:39649338	chr19:39679374~39686373:+
BRCA	cis	rs8103033	0.781	rs7248784	ENSG00000226025.8	LGALS17A	-6.22	7.07e-10	1.21e-07	-0.22	-0.19	Obesity-related traits;	chr19:39649347	chr19:39679374~39686373:+
BRCA	cis	rs673078	0.607	rs61943398	ENSG00000275409.1	RP11-131L12.4	-6.22	7.08e-10	1.21e-07	-0.27	-0.19	Glucose homeostasis traits;	chr12:118393280	chr12:118430147~118430699:+
BRCA	cis	rs1707322	1	rs11211217	ENSG00000281133.1	AL355480.3	-6.22	7.08e-10	1.21e-07	-0.24	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45882557	chr1:45580892~45580996:-
BRCA	cis	rs2836950	0.545	rs2297256	ENSG00000238141.2	BRWD1-AS1	-6.22	7.09e-10	1.21e-07	-0.21	-0.19	Menarche (age at onset);	chr21:39186495	chr21:39315707~39323218:+
BRCA	cis	rs847577	0.748	rs13221897	ENSG00000272950.1	RP11-307C18.1	6.22	7.09e-10	1.21e-07	0.24	0.19	Breast cancer;	chr7:98090387	chr7:98322853~98323430:+
BRCA	cis	rs2638953	0.924	rs11049475	ENSG00000247934.4	RP11-967K21.1	-6.22	7.09e-10	1.21e-07	-0.25	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28239731	chr12:28163298~28190738:-
BRCA	cis	rs2742234	0.759	rs12241923	ENSG00000273008.1	RP11-351D16.3	6.22	7.09e-10	1.21e-07	0.21	0.19	Hirschsprung disease;	chr10:43217599	chr10:43136824~43138334:-
BRCA	cis	rs6928977	0.5	rs9494308	ENSG00000231028.7	LINC00271	6.22	7.1e-10	1.21e-07	0.2	0.19	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135627666	chr6:135497801~135716055:+
BRCA	cis	rs228614	0.51	rs223463	ENSG00000251288.2	RP11-10L12.2	-6.22	7.11e-10	1.21e-07	-0.22	-0.19	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102780620	chr4:102751401~102752641:+
BRCA	cis	rs4784227	1	rs4784227	ENSG00000279427.1	RP11-132F7.2	-6.22	7.11e-10	1.21e-07	-0.25	-0.19	Breast cancer (estrogen-receptor negative);Breast cancer;Parkinson's disease;	chr16:52565276	chr16:52436772~52437474:-
BRCA	cis	rs1124769	0.719	rs2291107	ENSG00000259378.1	DCAF13P3	6.22	7.12e-10	1.21e-07	0.27	0.19	Cognitive performance;	chr15:50941615	chr15:50944663~50945996:+
BRCA	cis	rs2060793	0.712	rs6486202	ENSG00000251991.1	RNU7-49P	6.22	7.12e-10	1.21e-07	0.21	0.19	Vitamin D levels;	chr11:14777260	chr11:14478892~14478953:+
BRCA	cis	rs17253792	0.915	rs76952651	ENSG00000186615.9	KTN1-AS1	-6.22	7.12e-10	1.22e-07	-0.39	-0.19	Putamen volume;	chr14:55722276	chr14:55499278~55580110:-
BRCA	cis	rs1124769	0.7	rs35573737	ENSG00000259378.1	DCAF13P3	6.22	7.13e-10	1.22e-07	0.27	0.19	Cognitive performance;	chr15:50924623	chr15:50944663~50945996:+
BRCA	cis	rs2243480	1	rs383402	ENSG00000229886.1	RP5-1132H15.3	-6.22	7.13e-10	1.22e-07	-0.33	-0.19	Diabetic kidney disease;	chr7:66121666	chr7:66025126~66031544:-
BRCA	cis	rs2243480	1	rs7804223	ENSG00000229886.1	RP5-1132H15.3	-6.22	7.14e-10	1.22e-07	-0.34	-0.19	Diabetic kidney disease;	chr7:66199572	chr7:66025126~66031544:-
BRCA	cis	rs7520050	0.966	rs4660910	ENSG00000280836.1	AL355480.1	6.22	7.14e-10	1.22e-07	0.22	0.19	Reticulocyte count;Red blood cell count;	chr1:46082730	chr1:45581219~45581321:-
BRCA	cis	rs228614	0.509	rs223480	ENSG00000251288.2	RP11-10L12.2	-6.22	7.14e-10	1.22e-07	-0.23	-0.19	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102766881	chr4:102751401~102752641:+
BRCA	cis	rs13126694	0.778	rs10013448	ENSG00000248429.4	RP11-597D13.9	6.22	7.15e-10	1.22e-07	0.17	0.19	Blood osmolality (transformed sodium);	chr4:158116101	chr4:158170752~158202877:+
BRCA	cis	rs853679	0.513	rs13437444	ENSG00000204709.4	LINC01556	6.22	7.15e-10	1.22e-07	0.32	0.19	Depression;	chr6:28103220	chr6:28943877~28944537:+
BRCA	cis	rs1707322	0.963	rs12022335	ENSG00000281133.1	AL355480.3	-6.22	7.16e-10	1.22e-07	-0.24	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45937060	chr1:45580892~45580996:-
BRCA	cis	rs7569084	0.687	rs6755006	ENSG00000237979.1	AC007389.1	-6.22	7.17e-10	1.22e-07	-0.24	-0.19	Sum eosinophil basophil counts;	chr2:65426008	chr2:65500993~65502138:-
BRCA	cis	rs7569084	0.687	rs6755128	ENSG00000237979.1	AC007389.1	-6.22	7.17e-10	1.22e-07	-0.24	-0.19	Sum eosinophil basophil counts;	chr2:65426065	chr2:65500993~65502138:-
BRCA	cis	rs42648	1	rs42649	ENSG00000225498.1	AC002064.5	6.22	7.17e-10	1.22e-07	0.18	0.19	Homocysteine levels;	chr7:90348475	chr7:90312496~90322592:+
BRCA	cis	rs9291683	0.509	rs998676	ENSG00000250413.1	RP11-448G15.1	6.22	7.18e-10	1.22e-07	0.24	0.19	Bone mineral density;	chr4:9946940	chr4:10006482~10009725:+
BRCA	cis	rs2235642	0.928	rs1057610	ENSG00000280231.1	LA16c-380F5.3	-6.22	7.18e-10	1.22e-07	-0.25	-0.19	Coronary artery disease;	chr16:1555536	chr16:1553655~1554130:-
BRCA	cis	rs1167832	0.645	rs1167829	ENSG00000205583.12	STAG3L1	-6.22	7.18e-10	1.22e-07	-0.27	-0.19	Ankle injury;	chr7:75535697	chr7:75359194~75395383:+
BRCA	cis	rs2243480	0.901	rs313808	ENSG00000232546.1	RP11-458F8.1	-6.22	7.18e-10	1.22e-07	-0.25	-0.19	Diabetic kidney disease;	chr7:66034886	chr7:66848496~66858136:+
BRCA	cis	rs8072100	0.713	rs9899859	ENSG00000228782.6	CTD-2026D20.3	6.22	7.18e-10	1.22e-07	0.21	0.19	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47435683	chr17:47450568~47492492:-
BRCA	cis	rs8072100	0.713	rs1912486	ENSG00000228782.6	CTD-2026D20.3	6.22	7.18e-10	1.22e-07	0.21	0.19	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47437801	chr17:47450568~47492492:-
BRCA	cis	rs8072100	0.667	rs1912485	ENSG00000228782.6	CTD-2026D20.3	6.22	7.18e-10	1.22e-07	0.21	0.19	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47438312	chr17:47450568~47492492:-
BRCA	cis	rs9311474	1	rs2276834	ENSG00000243224.1	RP5-1157M23.2	-6.22	7.18e-10	1.23e-07	-0.21	-0.19	Electroencephalogram traits;	chr3:52291743	chr3:52239258~52241097:+
BRCA	cis	rs2098713	0.535	rs56044522	ENSG00000250155.1	CTD-2353F22.1	6.22	7.19e-10	1.23e-07	0.21	0.19	Telomere length;	chr5:37582698	chr5:36666214~36725195:-
BRCA	cis	rs875971	0.862	rs6947339	ENSG00000224316.1	RP11-479O9.2	6.22	7.2e-10	1.23e-07	0.19	0.19	Aortic root size;	chr7:66423483	chr7:65773620~65802067:+
BRCA	cis	rs853679	0.517	rs1340004	ENSG00000280107.1	AL022393.9	-6.22	7.2e-10	1.23e-07	-0.29	-0.19	Depression;	chr6:28135913	chr6:28170845~28172521:+
BRCA	cis	rs875971	0.502	rs1796227	ENSG00000236529.1	RP13-254B10.1	-6.22	7.2e-10	1.23e-07	-0.24	-0.19	Aortic root size;	chr7:66622032	chr7:65840212~65840596:+
BRCA	cis	rs1707322	1	rs4660334	ENSG00000281133.1	AL355480.3	-6.22	7.22e-10	1.23e-07	-0.24	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45996454	chr1:45580892~45580996:-
BRCA	cis	rs875971	0.545	rs3936065	ENSG00000236529.1	RP13-254B10.1	6.22	7.22e-10	1.23e-07	0.24	0.19	Aortic root size;	chr7:66325577	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.545	rs4718335	ENSG00000236529.1	RP13-254B10.1	6.22	7.22e-10	1.23e-07	0.24	0.19	Aortic root size;	chr7:66339619	chr7:65840212~65840596:+
BRCA	cis	rs11098499	0.954	rs6849171	ENSG00000249244.1	RP11-548H18.2	6.22	7.22e-10	1.23e-07	0.22	0.19	Corneal astigmatism;	chr4:119488394	chr4:119391831~119395335:-
BRCA	cis	rs5015933	1	rs7357647	ENSG00000232630.1	PRPS1P2	-6.22	7.23e-10	1.23e-07	-0.18	-0.19	Body mass index;	chr9:125374554	chr9:125150653~125151589:+
BRCA	cis	rs4713118	0.513	rs149989	ENSG00000216901.1	AL022393.7	6.22	7.23e-10	1.23e-07	0.25	0.19	Parkinson's disease;	chr6:28030406	chr6:28176188~28176674:+
BRCA	cis	rs116139393	0.505	rs3801033	ENSG00000187953.9	PMS2CL	6.22	7.24e-10	1.23e-07	0.24	0.19	Alzheimer's disease (APOE e4 interaction);	chr7:6694472	chr7:6710128~6753862:+
BRCA	cis	rs4372836	0.964	rs2045884	ENSG00000226833.4	AC097724.3	6.22	7.25e-10	1.24e-07	0.24	0.19	Body mass index;	chr2:28741489	chr2:28708953~28736205:-
BRCA	cis	rs13113518	0.812	rs12649507	ENSG00000223305.1	RN7SKP30	-6.22	7.26e-10	1.24e-07	-0.23	-0.19	Height;	chr4:55514317	chr4:55540502~55540835:-
BRCA	cis	rs673078	0.607	rs17440956	ENSG00000275409.1	RP11-131L12.4	6.22	7.26e-10	1.24e-07	0.29	0.19	Glucose homeostasis traits;	chr12:118394639	chr12:118430147~118430699:+
BRCA	cis	rs2153535	0.518	rs4959493	ENSG00000230939.1	RP11-314C16.1	-6.22	7.26e-10	1.24e-07	-0.23	-0.19	Motion sickness;	chr6:8588503	chr6:8784178~8785445:+
BRCA	cis	rs754466	0.651	rs55738779	ENSG00000204049.1	RP11-126H7.4	6.22	7.26e-10	1.24e-07	0.23	0.19	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77892637	chr10:77866875~77869610:+
BRCA	cis	rs2274273	0.662	rs67588230	ENSG00000258413.1	RP11-665C16.6	-6.22	7.27e-10	1.24e-07	-0.26	-0.19	Protein biomarker;	chr14:55200312	chr14:55262767~55272075:-
BRCA	cis	rs6479891	1	rs72837025	ENSG00000232075.1	MRPL35P2	6.22	7.27e-10	1.24e-07	0.34	0.19	Arthritis (juvenile idiopathic);	chr10:63434731	chr10:63634317~63634827:-
BRCA	cis	rs4950322	0.57	rs6703892	ENSG00000278811.3	LINC00624	6.22	7.27e-10	1.24e-07	0.26	0.19	Protein quantitative trait loci;	chr1:147287627	chr1:147258885~147517875:-
BRCA	cis	rs7520050	0.902	rs9429088	ENSG00000280836.1	AL355480.1	6.22	7.27e-10	1.24e-07	0.22	0.19	Reticulocyte count;Red blood cell count;	chr1:46031828	chr1:45581219~45581321:-
BRCA	cis	rs7238033	0.663	rs12454680	ENSG00000267193.4	RP11-116O18.3	6.22	7.27e-10	1.24e-07	0.2	0.19	Bladder cancer;	chr18:45741452	chr18:45669367~45747215:-
BRCA	cis	rs9333029	0.524	rs2269232	ENSG00000238145.2	RP11-346M5.1	-6.22	7.29e-10	1.24e-07	-0.19	-0.19	Blood metabolite levels;	chr1:46935794	chr1:46891639~46892830:+
BRCA	cis	rs1707322	1	rs7553924	ENSG00000281133.1	AL355480.3	-6.22	7.29e-10	1.24e-07	-0.24	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45886952	chr1:45580892~45580996:-
BRCA	cis	rs1707322	1	rs4641257	ENSG00000281133.1	AL355480.3	-6.22	7.29e-10	1.24e-07	-0.24	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45887917	chr1:45580892~45580996:-
BRCA	cis	rs1707322	1	rs6693336	ENSG00000281133.1	AL355480.3	-6.22	7.29e-10	1.24e-07	-0.24	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45888923	chr1:45580892~45580996:-
BRCA	cis	rs2243480	1	rs56016656	ENSG00000232546.1	RP11-458F8.1	-6.22	7.3e-10	1.24e-07	-0.25	-0.19	Diabetic kidney disease;	chr7:65918494	chr7:66848496~66858136:+
BRCA	cis	rs2243480	1	rs56291018	ENSG00000232546.1	RP11-458F8.1	-6.22	7.3e-10	1.24e-07	-0.25	-0.19	Diabetic kidney disease;	chr7:65925352	chr7:66848496~66858136:+
BRCA	cis	rs2243480	1	rs36033484	ENSG00000232546.1	RP11-458F8.1	-6.22	7.3e-10	1.24e-07	-0.25	-0.19	Diabetic kidney disease;	chr7:65925571	chr7:66848496~66858136:+
BRCA	cis	rs2980439	0.818	rs2948294	ENSG00000253981.4	ALG1L13P	6.22	7.3e-10	1.24e-07	0.23	0.19	Neuroticism;	chr8:8237439	chr8:8236003~8244667:-
BRCA	cis	rs6583826	0.623	rs7921325	ENSG00000236493.2	EIF2S2P3	6.22	7.3e-10	1.24e-07	0.24	0.19	Type 2 diabetes;	chr10:92578895	chr10:92668745~92669743:-
BRCA	cis	rs9880211	0.58	rs56308637	ENSG00000273486.1	RP11-731C17.2	6.22	7.3e-10	1.24e-07	0.25	0.19	Height;Body mass index;	chr3:135920806	chr3:136837338~136839021:-
BRCA	cis	rs875971	0.862	rs1968126	ENSG00000224316.1	RP11-479O9.2	-6.22	7.3e-10	1.24e-07	-0.19	-0.19	Aortic root size;	chr7:66592017	chr7:65773620~65802067:+
BRCA	cis	rs8005677	1	rs11157930	ENSG00000257285.4	RP11-298I3.1	6.22	7.3e-10	1.24e-07	0.21	0.19	Cognitive ability (multi-trait analysis);	chr14:22933962	chr14:22929609~22955562:+
BRCA	cis	rs420259	0.516	rs120962	ENSG00000260136.4	CTD-2270L9.4	6.22	7.31e-10	1.25e-07	0.19	0.19	Bipolar disorder;	chr16:23578665	chr16:23452758~23457606:+
BRCA	cis	rs420259	0.516	rs120961	ENSG00000260136.4	CTD-2270L9.4	6.22	7.31e-10	1.25e-07	0.19	0.19	Bipolar disorder;	chr16:23578981	chr16:23452758~23457606:+
BRCA	cis	rs7086627	0.515	rs7088877	ENSG00000226659.1	RP11-137H2.4	-6.22	7.31e-10	1.25e-07	-0.24	-0.19	Post bronchodilator FEV1;	chr10:80449104	chr10:80529597~80535942:-
BRCA	cis	rs17253792	0.822	rs8018142	ENSG00000186615.9	KTN1-AS1	-6.22	7.31e-10	1.25e-07	-0.34	-0.19	Putamen volume;	chr14:55706570	chr14:55499278~55580110:-
BRCA	cis	rs2243480	0.803	rs55700941	ENSG00000164669.11	INTS4P1	6.22	7.31e-10	1.25e-07	0.37	0.19	Diabetic kidney disease;	chr7:65924813	chr7:65141225~65234216:+
BRCA	cis	rs202072	0.872	rs445714	ENSG00000272379.1	RP1-257A7.5	6.22	7.32e-10	1.25e-07	0.26	0.19	HIV-1 viral setpoint;	chr6:13280726	chr6:13290018~13290490:-
BRCA	cis	rs1499614	1	rs2141924	ENSG00000232559.3	GS1-124K5.12	6.22	7.34e-10	1.25e-07	0.37	0.19	Gout;	chr7:66721259	chr7:66554588~66576923:-
BRCA	cis	rs4763879	0.739	rs2895988	ENSG00000214776.8	RP11-726G1.1	-6.22	7.35e-10	1.25e-07	-0.21	-0.19	Type 1 diabetes;	chr12:9675831	chr12:9467552~9576275:+
BRCA	cis	rs7976269	0.537	rs2117992	ENSG00000275476.1	RP11-996F15.4	-6.22	7.36e-10	1.25e-07	-0.22	-0.19	Male-pattern baldness;	chr12:29070611	chr12:29277397~29277882:-
BRCA	cis	rs12922040	1	rs2075516	ENSG00000263065.1	AF001548.6	6.22	7.37e-10	1.25e-07	0.23	0.19	Serum uric acid levels in response to allopurinol in gout;	chr16:15775668	chr16:15741151~15741791:+
BRCA	cis	rs7520050	0.966	rs9429183	ENSG00000280836.1	AL355480.1	6.22	7.37e-10	1.26e-07	0.22	0.19	Reticulocyte count;Red blood cell count;	chr1:46058910	chr1:45581219~45581321:-
BRCA	cis	rs2638953	0.888	rs2061760	ENSG00000278733.1	RP11-425D17.1	-6.22	7.37e-10	1.26e-07	-0.26	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28234492	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.886	rs11049474	ENSG00000278733.1	RP11-425D17.1	-6.22	7.37e-10	1.26e-07	-0.26	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28235512	chr12:28185625~28186190:-
BRCA	cis	rs7618501	0.521	rs868891	ENSG00000228008.1	CTD-2330K9.3	6.22	7.39e-10	1.26e-07	0.19	0.19	Intelligence (multi-trait analysis);	chr3:49911638	chr3:49903845~49916937:+
BRCA	cis	rs7618501	0.521	rs11709573	ENSG00000228008.1	CTD-2330K9.3	6.22	7.39e-10	1.26e-07	0.19	0.19	Intelligence (multi-trait analysis);	chr3:49919195	chr3:49903845~49916937:+
BRCA	cis	rs7274963	0.704	rs2038231	ENSG00000236474.1	GCNT1P1	6.22	7.39e-10	1.26e-07	0.22	0.19	Body mass index;	chr20:18311987	chr20:18420160~18421454:-
BRCA	cis	rs7274963	0.738	rs2038232	ENSG00000236474.1	GCNT1P1	6.22	7.39e-10	1.26e-07	0.22	0.19	Body mass index;	chr20:18312012	chr20:18420160~18421454:-
BRCA	cis	rs1707322	1	rs7517560	ENSG00000281133.1	AL355480.3	-6.22	7.39e-10	1.26e-07	-0.24	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45960271	chr1:45580892~45580996:-
BRCA	cis	rs4713118	0.587	rs61471148	ENSG00000219392.1	RP1-265C24.5	-6.22	7.4e-10	1.26e-07	-0.29	-0.19	Parkinson's disease;	chr6:28069254	chr6:28115628~28116551:+
BRCA	cis	rs4950322	0.57	rs111370771	ENSG00000278811.3	LINC00624	6.22	7.4e-10	1.26e-07	0.26	0.19	Protein quantitative trait loci;	chr1:147261420	chr1:147258885~147517875:-
BRCA	cis	rs7246657	0.653	rs10406612	ENSG00000226686.6	LINC01535	-6.22	7.41e-10	1.26e-07	-0.32	-0.19	Coronary artery calcification;	chr19:37225709	chr19:37251912~37265535:+
BRCA	cis	rs9876781	1	rs9815103	ENSG00000229759.1	MRPS18AP1	6.22	7.41e-10	1.26e-07	0.22	0.19	Longevity;	chr3:48372725	chr3:48256350~48256938:-
BRCA	cis	rs2115630	1	rs55646601	ENSG00000229212.6	RP11-561C5.4	6.21	7.41e-10	1.26e-07	0.21	0.19	P wave terminal force;	chr15:84780337	chr15:85205440~85234795:-
BRCA	cis	rs9287719	0.578	rs7598541	ENSG00000243819.4	RN7SL832P	6.21	7.41e-10	1.26e-07	0.2	0.19	Prostate cancer;	chr2:10560390	chr2:10690344~10692099:+
BRCA	cis	rs875971	0.964	rs12668936	ENSG00000224316.1	RP11-479O9.2	6.21	7.42e-10	1.26e-07	0.19	0.19	Aortic root size;	chr7:66449417	chr7:65773620~65802067:+
BRCA	cis	rs7567389	0.677	rs4662720	ENSG00000236682.1	AC068282.3	6.21	7.43e-10	1.26e-07	0.29	0.19	Self-rated health;	chr2:127319031	chr2:127389130~127400580:+
BRCA	cis	rs10129255	0.518	rs2006284	ENSG00000274576.2	IGHV2-70	-6.21	7.43e-10	1.26e-07	-0.15	-0.19	Kawasaki disease;	chr14:106676185	chr14:106770577~106771020:-
BRCA	cis	rs4072705	1	rs4240487	ENSG00000224020.1	MIR181A2HG	-6.21	7.44e-10	1.27e-07	-0.21	-0.19	Menarche (age at onset);	chr9:124608028	chr9:124658467~124698631:+
BRCA	cis	rs116175783	0.793	rs3769956	ENSG00000227403.1	AC009299.3	-6.21	7.46e-10	1.27e-07	-0.37	-0.19	Intelligence (multi-trait analysis);	chr2:161420790	chr2:161244739~161249050:+
BRCA	cis	rs4713118	0.513	rs149941	ENSG00000216901.1	AL022393.7	6.21	7.46e-10	1.27e-07	0.25	0.19	Parkinson's disease;	chr6:28033255	chr6:28176188~28176674:+
BRCA	cis	rs2243480	1	rs313824	ENSG00000229886.1	RP5-1132H15.3	6.21	7.46e-10	1.27e-07	0.34	0.19	Diabetic kidney disease;	chr7:66116220	chr7:66025126~66031544:-
BRCA	cis	rs2243480	1	rs186378	ENSG00000229886.1	RP5-1132H15.3	6.21	7.46e-10	1.27e-07	0.34	0.19	Diabetic kidney disease;	chr7:66117071	chr7:66025126~66031544:-
BRCA	cis	rs2243480	1	rs160637	ENSG00000229886.1	RP5-1132H15.3	6.21	7.46e-10	1.27e-07	0.34	0.19	Diabetic kidney disease;	chr7:66119331	chr7:66025126~66031544:-
BRCA	cis	rs9638182	0.725	rs12056034	ENSG00000274080.1	CTA-315H11.2	6.21	7.46e-10	1.27e-07	0.39	0.19	Triglycerides;	chr7:73464315	chr7:73609262~73611502:-
BRCA	cis	rs9638182	0.725	rs35695283	ENSG00000274080.1	CTA-315H11.2	6.21	7.46e-10	1.27e-07	0.39	0.19	Triglycerides;	chr7:73479073	chr7:73609262~73611502:-
BRCA	cis	rs9638182	0.725	rs75229905	ENSG00000274080.1	CTA-315H11.2	6.21	7.46e-10	1.27e-07	0.39	0.19	Triglycerides;	chr7:73481616	chr7:73609262~73611502:-
BRCA	cis	rs9638182	0.725	rs13244268	ENSG00000274080.1	CTA-315H11.2	6.21	7.46e-10	1.27e-07	0.39	0.19	Triglycerides;	chr7:73497513	chr7:73609262~73611502:-
BRCA	cis	rs9638182	0.673	rs79862839	ENSG00000274080.1	CTA-315H11.2	6.21	7.46e-10	1.27e-07	0.39	0.19	Triglycerides;	chr7:73507279	chr7:73609262~73611502:-
BRCA	cis	rs375066	0.623	rs239949	ENSG00000267058.1	RP11-15A1.3	-6.21	7.46e-10	1.27e-07	-0.22	-0.19	Breast cancer;	chr19:43852475	chr19:43891804~43901805:-
BRCA	cis	rs853679	0.517	rs35193936	ENSG00000280107.1	AL022393.9	-6.21	7.47e-10	1.27e-07	-0.28	-0.19	Depression;	chr6:28108492	chr6:28170845~28172521:+
BRCA	cis	rs875971	0.522	rs781144	ENSG00000234585.5	CCT6P3	6.21	7.47e-10	1.27e-07	0.18	0.19	Aortic root size;	chr7:65975357	chr7:65038354~65074713:+
BRCA	cis	rs2974760	0.606	rs2858918	ENSG00000268836.1	LA16c-OS12.2	6.21	7.48e-10	1.27e-07	0.21	0.19	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr16:151184	chr16:185748~186294:-
BRCA	cis	rs1707322	1	rs4539075	ENSG00000281133.1	AL355480.3	-6.21	7.48e-10	1.27e-07	-0.24	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45892338	chr1:45580892~45580996:-
BRCA	cis	rs754466	0.58	rs2579176	ENSG00000204049.1	RP11-126H7.4	6.21	7.48e-10	1.27e-07	0.23	0.19	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77769592	chr10:77866875~77869610:+
BRCA	cis	rs2836950	0.509	rs4816618	ENSG00000238141.2	BRWD1-AS1	-6.21	7.49e-10	1.27e-07	-0.21	-0.19	Menarche (age at onset);	chr21:39227603	chr21:39315707~39323218:+
BRCA	cis	rs2836950	0.527	rs2836948	ENSG00000238141.2	BRWD1-AS1	-6.21	7.49e-10	1.27e-07	-0.21	-0.19	Menarche (age at onset);	chr21:39227751	chr21:39315707~39323218:+
BRCA	cis	rs853679	0.517	rs9468297	ENSG00000219392.1	RP1-265C24.5	-6.21	7.5e-10	1.28e-07	-0.29	-0.19	Depression;	chr6:28151096	chr6:28115628~28116551:+
BRCA	cis	rs2638953	0.886	rs11049429	ENSG00000247934.4	RP11-967K21.1	-6.21	7.52e-10	1.28e-07	-0.24	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28194332	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.779	rs11049432	ENSG00000247934.4	RP11-967K21.1	-6.21	7.52e-10	1.28e-07	-0.24	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28194454	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.85	rs4284426	ENSG00000247934.4	RP11-967K21.1	-6.21	7.52e-10	1.28e-07	-0.24	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28194543	chr12:28163298~28190738:-
BRCA	cis	rs8031584	0.56	rs7171208	ENSG00000260382.1	RP11-540B6.2	-6.21	7.52e-10	1.28e-07	-0.22	-0.19	Huntington's disease progression;	chr15:30906726	chr15:30882267~30883231:-
BRCA	cis	rs2243480	1	rs34529418	ENSG00000228409.4	CCT6P1	6.21	7.52e-10	1.28e-07	0.26	0.19	Diabetic kidney disease;	chr7:65938222	chr7:65751142~65763354:+
BRCA	cis	rs4660456	0.597	rs7518568	ENSG00000237899.1	RP4-739H11.3	6.21	7.53e-10	1.28e-07	0.24	0.19	Platelet count;	chr1:40708508	chr1:40669089~40687588:-
BRCA	cis	rs2337406	1	rs11845269	ENSG00000211972.2	IGHV3-66	6.21	7.53e-10	1.28e-07	0.17	0.19	Alzheimer's disease (late onset);	chr14:106683851	chr14:106675017~106675544:-
BRCA	cis	rs1823913	0.637	rs979967	ENSG00000280083.1	RP11-317J9.1	-6.21	7.54e-10	1.28e-07	-0.21	-0.19	Obesity-related traits;	chr2:191304695	chr2:191154118~191156070:-
BRCA	cis	rs875971	0.545	rs75577046	ENSG00000236529.1	RP13-254B10.1	6.21	7.54e-10	1.28e-07	0.23	0.19	Aortic root size;	chr7:66493729	chr7:65840212~65840596:+
BRCA	cis	rs9876781	0.624	rs12491849	ENSG00000244380.1	RP11-24C3.2	6.21	7.55e-10	1.28e-07	0.24	0.19	Longevity;	chr3:48489975	chr3:48440352~48446656:-
BRCA	cis	rs11722779	0.935	rs3857200	ENSG00000251288.2	RP11-10L12.2	-6.21	7.56e-10	1.29e-07	-0.23	-0.19	Schizophrenia;	chr4:103001864	chr4:102751401~102752641:+
BRCA	cis	rs17711722	0.701	rs55773927	ENSG00000234585.5	CCT6P3	6.21	7.56e-10	1.29e-07	0.18	0.19	Calcium levels;	chr7:65872915	chr7:65038354~65074713:+
BRCA	cis	rs2380205	0.682	rs7919785	ENSG00000232807.2	RP11-536K7.3	6.21	7.56e-10	1.29e-07	0.19	0.19	Breast cancer;	chr10:5884168	chr10:5934270~5945900:-
BRCA	cis	rs853679	0.517	rs56310871	ENSG00000204709.4	LINC01556	6.21	7.57e-10	1.29e-07	0.28	0.19	Depression;	chr6:28076704	chr6:28943877~28944537:+
BRCA	cis	rs1440410	0.835	rs4582112	ENSG00000250326.1	RP11-284M14.1	-6.21	7.58e-10	1.29e-07	-0.21	-0.19	Ischemic stroke;	chr4:143190579	chr4:142933195~143184861:-
BRCA	cis	rs1440410	0.798	rs13106497	ENSG00000250326.1	RP11-284M14.1	-6.21	7.58e-10	1.29e-07	-0.21	-0.19	Ischemic stroke;	chr4:143199527	chr4:142933195~143184861:-
BRCA	cis	rs9907295	0.688	rs28722787	ENSG00000270977.1	AC015849.16	-6.21	7.58e-10	1.29e-07	-0.28	-0.19	Fibroblast growth factor basic levels;	chr17:35922795	chr17:35893707~35911023:-
BRCA	cis	rs301901	0.698	rs217840	ENSG00000250155.1	CTD-2353F22.1	6.21	7.58e-10	1.29e-07	0.21	0.19	Height;	chr5:37373000	chr5:36666214~36725195:-
BRCA	cis	rs1124769	0.748	rs34013374	ENSG00000259378.1	DCAF13P3	6.21	7.58e-10	1.29e-07	0.27	0.19	Cognitive performance;	chr15:51076889	chr15:50944663~50945996:+
BRCA	cis	rs2638953	0.886	rs10843137	ENSG00000278733.1	RP11-425D17.1	-6.21	7.58e-10	1.29e-07	-0.24	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28218788	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.924	rs10843138	ENSG00000278733.1	RP11-425D17.1	-6.21	7.58e-10	1.29e-07	-0.24	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28219210	chr12:28185625~28186190:-
BRCA	cis	rs919433	0.68	rs2564389	ENSG00000231621.1	AC013264.2	-6.21	7.59e-10	1.29e-07	-0.18	-0.19	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197395374	chr2:197197991~197199273:+
BRCA	cis	rs5758511	0.689	rs17002947	ENSG00000205702.9	CYP2D7	-6.21	7.59e-10	1.29e-07	-0.2	-0.19	Birth weight;	chr22:42292526	chr22:42140203~42144577:-
BRCA	cis	rs7520050	0.966	rs785485	ENSG00000280836.1	AL355480.1	6.21	7.59e-10	1.29e-07	0.22	0.19	Reticulocyte count;Red blood cell count;	chr1:46108752	chr1:45581219~45581321:-
BRCA	cis	rs2303759	0.918	rs9749416	ENSG00000268686.1	AC010524.2	-6.21	7.6e-10	1.29e-07	-0.29	-0.19	Multiple sclerosis;	chr19:49381748	chr19:49368705~49388081:-
BRCA	cis	rs4925386	0.625	rs3810550	ENSG00000273619.1	RP5-908M14.9	-6.21	7.6e-10	1.29e-07	-0.18	-0.19	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62337061	chr20:62386303~62386970:-
BRCA	cis	rs853679	0.517	rs9393885	ENSG00000280107.1	AL022393.9	-6.21	7.6e-10	1.29e-07	-0.28	-0.19	Depression;	chr6:28082231	chr6:28170845~28172521:+
BRCA	cis	rs853679	0.517	rs9393886	ENSG00000280107.1	AL022393.9	-6.21	7.6e-10	1.29e-07	-0.28	-0.19	Depression;	chr6:28082261	chr6:28170845~28172521:+
BRCA	cis	rs4713118	0.515	rs9368549	ENSG00000280107.1	AL022393.9	-6.21	7.6e-10	1.29e-07	-0.28	-0.19	Parkinson's disease;	chr6:28082269	chr6:28170845~28172521:+
BRCA	cis	rs875971	0.895	rs12698520	ENSG00000224316.1	RP11-479O9.2	6.21	7.61e-10	1.29e-07	0.19	0.19	Aortic root size;	chr7:66453720	chr7:65773620~65802067:+
BRCA	cis	rs13113518	0.812	rs12500601	ENSG00000273257.1	RP11-177J6.1	6.21	7.61e-10	1.29e-07	0.25	0.19	Height;	chr4:55451489	chr4:55387949~55388271:+
BRCA	cis	rs2179367	0.632	rs66672129	ENSG00000216906.2	RP11-350J20.9	6.21	7.61e-10	1.29e-07	0.27	0.19	Dupuytren's disease;	chr6:149334387	chr6:149904243~149906418:+
BRCA	cis	rs2179367	0.632	rs9498322	ENSG00000216906.2	RP11-350J20.9	6.21	7.61e-10	1.29e-07	0.27	0.19	Dupuytren's disease;	chr6:149335950	chr6:149904243~149906418:+
BRCA	cis	rs2179367	0.632	rs9498323	ENSG00000216906.2	RP11-350J20.9	6.21	7.61e-10	1.29e-07	0.27	0.19	Dupuytren's disease;	chr6:149336077	chr6:149904243~149906418:+
BRCA	cis	rs2179367	0.632	rs12204793	ENSG00000216906.2	RP11-350J20.9	6.21	7.61e-10	1.29e-07	0.27	0.19	Dupuytren's disease;	chr6:149340102	chr6:149904243~149906418:+
BRCA	cis	rs516805	0.748	rs155460	ENSG00000279453.1	RP3-425C14.4	-6.21	7.63e-10	1.3e-07	-0.26	-0.19	Lymphocyte counts;	chr6:122499180	chr6:122436789~122439223:-
BRCA	cis	rs847577	0.722	rs1013886	ENSG00000272950.1	RP11-307C18.1	-6.21	7.63e-10	1.3e-07	-0.24	-0.19	Breast cancer;	chr7:98080549	chr7:98322853~98323430:+
BRCA	cis	rs7246657	0.551	rs10407224	ENSG00000276846.1	CTD-3220F14.3	6.21	7.65e-10	1.3e-07	0.29	0.19	Coronary artery calcification;	chr19:37160568	chr19:37314868~37315620:-
BRCA	cis	rs8005677	0.962	rs10130756	ENSG00000257285.4	RP11-298I3.1	6.21	7.65e-10	1.3e-07	0.21	0.19	Cognitive ability (multi-trait analysis);	chr14:22927391	chr14:22929609~22955562:+
BRCA	cis	rs2243480	1	rs313820	ENSG00000229886.1	RP5-1132H15.3	6.21	7.67e-10	1.3e-07	0.34	0.19	Diabetic kidney disease;	chr7:66109479	chr7:66025126~66031544:-
BRCA	cis	rs6840360	0.557	rs4696261	ENSG00000270265.1	RP11-731D1.4	-6.21	7.67e-10	1.3e-07	-0.21	-0.19	Intelligence (multi-trait analysis);	chr4:151401507	chr4:151333775~151353224:-
BRCA	cis	rs62103177	0.81	rs62103197	ENSG00000261126.6	RP11-795F19.1	6.21	7.68e-10	1.3e-07	0.31	0.19	Opioid sensitivity;	chr18:79872923	chr18:80046900~80095482:+
BRCA	cis	rs2060793	0.601	rs35321904	ENSG00000251991.1	RNU7-49P	6.21	7.69e-10	1.31e-07	0.21	0.19	Vitamin D levels;	chr11:14854914	chr11:14478892~14478953:+
BRCA	cis	rs8103033	0.786	rs6508898	ENSG00000226025.8	LGALS17A	-6.21	7.7e-10	1.31e-07	-0.21	-0.19	Obesity-related traits;	chr19:39661841	chr19:39679374~39686373:+
BRCA	cis	rs875971	0.545	rs10950029	ENSG00000273024.4	INTS4P2	-6.21	7.7e-10	1.31e-07	-0.23	-0.19	Aortic root size;	chr7:66169334	chr7:65647864~65715661:+
BRCA	cis	rs853679	0.517	rs9357065	ENSG00000280107.1	AL022393.9	-6.21	7.71e-10	1.31e-07	-0.29	-0.19	Depression;	chr6:28161802	chr6:28170845~28172521:+
BRCA	cis	rs13113518	0.812	rs13140590	ENSG00000273257.1	RP11-177J6.1	6.21	7.71e-10	1.31e-07	0.25	0.19	Height;	chr4:55548666	chr4:55387949~55388271:+
BRCA	cis	rs7555523	0.887	rs2790053	ENSG00000224358.1	RP11-466F5.8	-6.21	7.72e-10	1.31e-07	-0.34	-0.19	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165768467	chr1:165768929~165775176:+
BRCA	cis	rs2115630	1	rs56074163	ENSG00000229212.6	RP11-561C5.4	6.21	7.72e-10	1.31e-07	0.21	0.19	P wave terminal force;	chr15:84808101	chr15:85205440~85234795:-
BRCA	cis	rs11976180	1	rs1919951	ENSG00000273234.1	OR2A13P	-6.21	7.72e-10	1.31e-07	-0.26	-0.19	Obesity-related traits;	chr7:144071798	chr7:144142009~144142938:+
BRCA	cis	rs853679	0.517	rs9468297	ENSG00000280107.1	AL022393.9	-6.21	7.72e-10	1.31e-07	-0.29	-0.19	Depression;	chr6:28151096	chr6:28170845~28172521:+
BRCA	cis	rs1322639	0.574	rs9689193	ENSG00000261039.2	RP11-417E7.2	-6.21	7.72e-10	1.31e-07	-0.26	-0.19	Pulse pressure;	chr6:169187979	chr6:169175304~169182740:-
BRCA	cis	rs847577	0.748	rs940432	ENSG00000272950.1	RP11-307C18.1	6.21	7.73e-10	1.31e-07	0.24	0.19	Breast cancer;	chr7:98087171	chr7:98322853~98323430:+
BRCA	cis	rs847577	0.748	rs940431	ENSG00000272950.1	RP11-307C18.1	6.21	7.73e-10	1.31e-07	0.24	0.19	Breast cancer;	chr7:98087183	chr7:98322853~98323430:+
BRCA	cis	rs847577	0.748	rs940430	ENSG00000272950.1	RP11-307C18.1	6.21	7.73e-10	1.31e-07	0.24	0.19	Breast cancer;	chr7:98087228	chr7:98322853~98323430:+
BRCA	cis	rs755249	0.567	rs61779308	ENSG00000237624.1	OXCT2P1	6.21	7.73e-10	1.31e-07	0.29	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39472585	chr1:39514956~39516490:+
BRCA	cis	rs9326246	0.643	rs651821	ENSG00000254851.1	RP11-109L13.1	-6.21	7.73e-10	1.31e-07	-0.38	-0.19	Coronary artery disease;	chr11:116791863	chr11:117135528~117138582:+
BRCA	cis	rs11096990	0.964	rs6842390	ENSG00000249207.1	RP11-360F5.1	6.21	7.74e-10	1.31e-07	0.22	0.19	Cognitive function;	chr4:39261862	chr4:39112677~39126818:-
BRCA	cis	rs2732480	0.557	rs2634682	ENSG00000273765.1	RP11-370I10.11	6.21	7.74e-10	1.31e-07	0.23	0.19	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48339160	chr12:48360920~48361377:+
BRCA	cis	rs7274963	0.704	rs55767418	ENSG00000236474.1	GCNT1P1	6.21	7.74e-10	1.32e-07	0.22	0.19	Body mass index;	chr20:18310849	chr20:18420160~18421454:-
BRCA	cis	rs7520050	0.966	rs2486447	ENSG00000280836.1	AL355480.1	6.21	7.75e-10	1.32e-07	0.22	0.19	Reticulocyte count;Red blood cell count;	chr1:46080052	chr1:45581219~45581321:-
BRCA	cis	rs2243480	1	rs160655	ENSG00000232546.1	RP11-458F8.1	-6.21	7.75e-10	1.32e-07	-0.26	-0.19	Diabetic kidney disease;	chr7:66068227	chr7:66848496~66858136:+
BRCA	cis	rs8072100	0.701	rs2013383	ENSG00000228782.6	CTD-2026D20.3	6.21	7.75e-10	1.32e-07	0.21	0.19	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47713757	chr17:47450568~47492492:-
BRCA	cis	rs1124769	0.719	rs58137325	ENSG00000259378.1	DCAF13P3	6.21	7.75e-10	1.32e-07	0.27	0.19	Cognitive performance;	chr15:50922186	chr15:50944663~50945996:+
BRCA	cis	rs1124769	0.692	rs1147137	ENSG00000259378.1	DCAF13P3	-6.21	7.75e-10	1.32e-07	-0.27	-0.19	Cognitive performance;	chr15:50889686	chr15:50944663~50945996:+
BRCA	cis	rs1124769	0.719	rs2619689	ENSG00000259378.1	DCAF13P3	-6.21	7.75e-10	1.32e-07	-0.27	-0.19	Cognitive performance;	chr15:50892386	chr15:50944663~50945996:+
BRCA	cis	rs1124769	0.719	rs2619690	ENSG00000259378.1	DCAF13P3	-6.21	7.75e-10	1.32e-07	-0.27	-0.19	Cognitive performance;	chr15:50894018	chr15:50944663~50945996:+
BRCA	cis	rs1124769	0.719	rs1147134	ENSG00000259378.1	DCAF13P3	-6.21	7.75e-10	1.32e-07	-0.27	-0.19	Cognitive performance;	chr15:50896339	chr15:50944663~50945996:+
BRCA	cis	rs1124769	0.719	rs2663542	ENSG00000259378.1	DCAF13P3	-6.21	7.75e-10	1.32e-07	-0.27	-0.19	Cognitive performance;	chr15:50899224	chr15:50944663~50945996:+
BRCA	cis	rs1124769	0.719	rs1147132	ENSG00000259378.1	DCAF13P3	-6.21	7.75e-10	1.32e-07	-0.27	-0.19	Cognitive performance;	chr15:50900036	chr15:50944663~50945996:+
BRCA	cis	rs1124769	0.719	rs2663540	ENSG00000259378.1	DCAF13P3	-6.21	7.75e-10	1.32e-07	-0.27	-0.19	Cognitive performance;	chr15:50901062	chr15:50944663~50945996:+
BRCA	cis	rs1124769	0.719	rs1135397	ENSG00000259378.1	DCAF13P3	-6.21	7.75e-10	1.32e-07	-0.27	-0.19	Cognitive performance;	chr15:50907567	chr15:50944663~50945996:+
BRCA	cis	rs1124769	0.719	rs2614788	ENSG00000259378.1	DCAF13P3	-6.21	7.75e-10	1.32e-07	-0.27	-0.19	Cognitive performance;	chr15:50908084	chr15:50944663~50945996:+
BRCA	cis	rs1124769	0.719	rs2663531	ENSG00000259378.1	DCAF13P3	-6.21	7.75e-10	1.32e-07	-0.27	-0.19	Cognitive performance;	chr15:50912552	chr15:50944663~50945996:+
BRCA	cis	rs1124769	0.719	rs2663557	ENSG00000259378.1	DCAF13P3	-6.21	7.75e-10	1.32e-07	-0.27	-0.19	Cognitive performance;	chr15:50921427	chr15:50944663~50945996:+
BRCA	cis	rs240993	0.502	rs240966	ENSG00000230177.1	RP5-1112D6.4	-6.21	7.76e-10	1.32e-07	-0.24	-0.19	Inflammatory skin disease;Psoriasis;	chr6:111323462	chr6:111277932~111278742:+
BRCA	cis	rs754466	0.605	rs10824578	ENSG00000204049.1	RP11-126H7.4	6.21	7.77e-10	1.32e-07	0.22	0.19	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77818486	chr10:77866875~77869610:+
BRCA	cis	rs2243480	1	rs34560516	ENSG00000232546.1	RP11-458F8.1	-6.21	7.77e-10	1.32e-07	-0.25	-0.19	Diabetic kidney disease;	chr7:65939105	chr7:66848496~66858136:+
BRCA	cis	rs2243480	0.908	rs313822	ENSG00000232559.3	GS1-124K5.12	6.21	7.77e-10	1.32e-07	0.36	0.19	Diabetic kidney disease;	chr7:66108952	chr7:66554588~66576923:-
BRCA	cis	rs7086627	0.515	rs11202963	ENSG00000226659.1	RP11-137H2.4	-6.21	7.77e-10	1.32e-07	-0.24	-0.19	Post bronchodilator FEV1;	chr10:80450636	chr10:80529597~80535942:-
BRCA	cis	rs6095360	0.727	rs35752040	ENSG00000222365.1	SNORD12B	-6.21	7.78e-10	1.32e-07	-0.24	-0.19	Intelligence (multi-trait analysis);	chr20:49008063	chr20:49280319~49280409:+
BRCA	cis	rs875971	0.545	rs73148639	ENSG00000273024.4	INTS4P2	-6.21	7.78e-10	1.32e-07	-0.24	-0.19	Aortic root size;	chr7:66390342	chr7:65647864~65715661:+
BRCA	cis	rs7945705	0.846	rs11042055	ENSG00000254860.4	TMEM9B-AS1	-6.21	7.81e-10	1.33e-07	-0.19	-0.19	Hemoglobin concentration;	chr11:8735309	chr11:8964675~8977527:+
BRCA	cis	rs2179367	0.613	rs12207047	ENSG00000216906.2	RP11-350J20.9	6.21	7.81e-10	1.33e-07	0.27	0.19	Dupuytren's disease;	chr6:149423496	chr6:149904243~149906418:+
BRCA	cis	rs2919009	0.664	rs2289337	ENSG00000271670.1	RP11-95I16.4	6.21	7.82e-10	1.33e-07	0.24	0.19	Obesity-related traits;	chr10:120889970	chr10:120879256~120880667:-
BRCA	cis	rs8114671	0.836	rs2038504	ENSG00000269202.1	RP4-614O4.12	6.21	7.82e-10	1.33e-07	0.19	0.19	Height;	chr20:35060384	chr20:35201747~35203288:-
BRCA	cis	rs8114671	0.836	rs2104083	ENSG00000269202.1	RP4-614O4.12	6.21	7.82e-10	1.33e-07	0.19	0.19	Height;	chr20:35061330	chr20:35201747~35203288:-
BRCA	cis	rs8114671	0.839	rs2104084	ENSG00000269202.1	RP4-614O4.12	6.21	7.82e-10	1.33e-07	0.19	0.19	Height;	chr20:35061414	chr20:35201747~35203288:-
BRCA	cis	rs7587476	1	rs3768707	ENSG00000229267.2	AC072062.1	-6.21	7.83e-10	1.33e-07	-0.25	-0.19	Neuroblastoma;	chr2:214780411	chr2:214810229~214963274:+
BRCA	cis	rs11098499	0.908	rs28499576	ENSG00000249244.1	RP11-548H18.2	6.21	7.83e-10	1.33e-07	0.22	0.19	Corneal astigmatism;	chr4:119465522	chr4:119391831~119395335:-
BRCA	cis	rs875971	0.862	rs6460306	ENSG00000224316.1	RP11-479O9.2	-6.21	7.83e-10	1.33e-07	-0.19	-0.19	Aortic root size;	chr7:66595806	chr7:65773620~65802067:+
BRCA	cis	rs9307551	0.857	rs2196978	ENSG00000250334.4	LINC00989	6.21	7.84e-10	1.33e-07	0.26	0.19	Refractive error;	chr4:79614815	chr4:79492416~79576460:+
BRCA	cis	rs11722228	0.521	rs12501336	ENSG00000261490.1	RP11-448G15.3	6.21	7.84e-10	1.33e-07	0.22	0.19	Urate levels;Serum uric acid levels;Gout;	chr4:10135727	chr4:10068089~10073019:-
BRCA	cis	rs1322639	0.614	rs6900964	ENSG00000261039.2	RP11-417E7.2	-6.21	7.85e-10	1.33e-07	-0.24	-0.19	Pulse pressure;	chr6:169166668	chr6:169175304~169182740:-
BRCA	cis	rs2281558	0.833	rs12480853	ENSG00000125804.12	FAM182A	-6.21	7.86e-10	1.33e-07	-0.28	-0.19	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25542323	chr20:26054655~26086917:+
BRCA	cis	rs17253792	0.915	rs77252471	ENSG00000186615.9	KTN1-AS1	-6.21	7.86e-10	1.33e-07	-0.38	-0.19	Putamen volume;	chr14:55711357	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.915	rs78089630	ENSG00000186615.9	KTN1-AS1	-6.21	7.86e-10	1.33e-07	-0.38	-0.19	Putamen volume;	chr14:55711866	chr14:55499278~55580110:-
BRCA	cis	rs17253792	1	rs28616134	ENSG00000186615.9	KTN1-AS1	-6.21	7.86e-10	1.33e-07	-0.38	-0.19	Putamen volume;	chr14:55712084	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.915	rs28375514	ENSG00000186615.9	KTN1-AS1	-6.21	7.86e-10	1.33e-07	-0.38	-0.19	Putamen volume;	chr14:55713223	chr14:55499278~55580110:-
BRCA	cis	rs944990	0.557	rs10821155	ENSG00000227603.1	RP11-165J3.6	6.21	7.86e-10	1.33e-07	0.19	0.19	Body mass index;	chr9:93541996	chr9:93435332~93437121:-
BRCA	cis	rs67981189	0.835	rs2526855	ENSG00000258571.1	PTTG4P	6.21	7.87e-10	1.34e-07	0.21	0.19	Schizophrenia;	chr14:70946629	chr14:71085482~71085833:-
BRCA	cis	rs67981189	0.766	rs2526852	ENSG00000258571.1	PTTG4P	6.21	7.87e-10	1.34e-07	0.21	0.19	Schizophrenia;	chr14:70949450	chr14:71085482~71085833:-
BRCA	cis	rs7621025	0.617	rs12637102	ENSG00000239213.4	NCK1-AS1	6.21	7.88e-10	1.34e-07	0.23	0.19	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136493118	chr3:136841726~136862054:-
BRCA	cis	rs891378	1	rs10864180	ENSG00000274245.1	RP11-357P18.2	-6.21	7.88e-10	1.34e-07	-0.25	-0.19	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207272416	chr1:207372559~207373252:+
BRCA	cis	rs2115630	1	rs4633690	ENSG00000229212.6	RP11-561C5.4	6.2	7.88e-10	1.34e-07	0.21	0.19	P wave terminal force;	chr15:84818729	chr15:85205440~85234795:-
BRCA	cis	rs4713118	0.513	rs1225591	ENSG00000204709.4	LINC01556	6.2	7.89e-10	1.34e-07	0.26	0.19	Parkinson's disease;	chr6:28180974	chr6:28943877~28944537:+
BRCA	cis	rs853679	0.513	rs9468296	ENSG00000219392.1	RP1-265C24.5	-6.2	7.89e-10	1.34e-07	-0.29	-0.19	Depression;	chr6:28145952	chr6:28115628~28116551:+
BRCA	cis	rs7914558	0.966	rs7908280	ENSG00000213061.2	PFN1P11	6.2	7.89e-10	1.34e-07	0.25	0.19	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103057190	chr10:102838011~102845473:-
BRCA	cis	rs7238033	0.663	rs11660575	ENSG00000267193.4	RP11-116O18.3	6.2	7.89e-10	1.34e-07	0.2	0.19	Bladder cancer;	chr18:45740473	chr18:45669367~45747215:-
BRCA	cis	rs2836950	0.561	rs34705151	ENSG00000238141.2	BRWD1-AS1	-6.2	7.89e-10	1.34e-07	-0.21	-0.19	Menarche (age at onset);	chr21:39181418	chr21:39315707~39323218:+
BRCA	cis	rs9652601	0.959	rs12919083	ENSG00000274038.1	RP11-66H6.4	6.2	7.9e-10	1.34e-07	0.21	0.19	Systemic lupus erythematosus;	chr16:11095073	chr16:11056556~11057034:+
BRCA	cis	rs6688613	0.694	rs3820387	ENSG00000225171.2	DUTP6	-6.2	7.9e-10	1.34e-07	-0.27	-0.19	Refractive astigmatism;	chr1:166851047	chr1:166868748~166869209:+
BRCA	cis	rs7246657	0.551	rs4806414	ENSG00000276846.1	CTD-3220F14.3	6.2	7.91e-10	1.34e-07	0.29	0.19	Coronary artery calcification;	chr19:37147886	chr19:37314868~37315620:-
BRCA	cis	rs227275	0.554	rs223454	ENSG00000251288.2	RP11-10L12.2	-6.2	7.91e-10	1.34e-07	-0.22	-0.19	Allergic disease (asthma, hay fever or eczema);	chr4:102789773	chr4:102751401~102752641:+
BRCA	cis	rs12200782	0.505	rs7765920	ENSG00000241549.7	GUSBP2	6.2	7.91e-10	1.34e-07	0.24	0.19	Small cell lung carcinoma;	chr6:26514543	chr6:26871484~26956554:-
BRCA	cis	rs7914558	0.966	rs1971589	ENSG00000213061.2	PFN1P11	6.2	7.92e-10	1.34e-07	0.25	0.19	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102984649	chr10:102838011~102845473:-
BRCA	cis	rs853679	0.517	rs9468298	ENSG00000219392.1	RP1-265C24.5	-6.2	7.92e-10	1.34e-07	-0.29	-0.19	Depression;	chr6:28154567	chr6:28115628~28116551:+
BRCA	cis	rs853679	0.517	rs9295759	ENSG00000219392.1	RP1-265C24.5	-6.2	7.92e-10	1.34e-07	-0.29	-0.19	Depression;	chr6:28156691	chr6:28115628~28116551:+
BRCA	cis	rs853679	0.517	rs9348796	ENSG00000219392.1	RP1-265C24.5	-6.2	7.92e-10	1.34e-07	-0.29	-0.19	Depression;	chr6:28158424	chr6:28115628~28116551:+
BRCA	cis	rs853679	0.517	rs11552219	ENSG00000219392.1	RP1-265C24.5	-6.2	7.92e-10	1.34e-07	-0.29	-0.19	Depression;	chr6:28159056	chr6:28115628~28116551:+
BRCA	cis	rs853679	0.517	rs9357066	ENSG00000219392.1	RP1-265C24.5	-6.2	7.92e-10	1.34e-07	-0.29	-0.19	Depression;	chr6:28162053	chr6:28115628~28116551:+
BRCA	cis	rs7238033	0.624	rs8096571	ENSG00000267193.4	RP11-116O18.3	6.2	7.94e-10	1.35e-07	0.2	0.19	Bladder cancer;	chr18:45734508	chr18:45669367~45747215:-
BRCA	cis	rs13108904	0.935	rs4974575	ENSG00000254094.1	AC078852.1	-6.2	7.94e-10	1.35e-07	-0.2	-0.19	Obesity-related traits;	chr4:1258240	chr4:1356581~1358075:+
BRCA	cis	rs2243480	1	rs34193460	ENSG00000232546.1	RP11-458F8.1	-6.2	7.94e-10	1.35e-07	-0.25	-0.19	Diabetic kidney disease;	chr7:65928123	chr7:66848496~66858136:+
BRCA	cis	rs875971	0.862	rs778724	ENSG00000224316.1	RP11-479O9.2	6.2	7.94e-10	1.35e-07	0.19	0.19	Aortic root size;	chr7:66364304	chr7:65773620~65802067:+
BRCA	cis	rs6840258	1	rs72667759	ENSG00000251411.1	RP11-397E7.4	-6.2	7.95e-10	1.35e-07	-0.25	-0.19	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87031047	chr4:86913266~86914817:-
BRCA	cis	rs7246657	0.941	rs12982333	ENSG00000226686.6	LINC01535	-6.2	7.95e-10	1.35e-07	-0.29	-0.19	Coronary artery calcification;	chr19:37303822	chr19:37251912~37265535:+
BRCA	cis	rs7274963	0.673	rs55896321	ENSG00000236474.1	GCNT1P1	6.2	7.97e-10	1.35e-07	0.22	0.19	Body mass index;	chr20:18310758	chr20:18420160~18421454:-
BRCA	cis	rs858239	0.796	rs433395	ENSG00000230042.1	AK3P3	-6.2	7.98e-10	1.35e-07	-0.22	-0.19	Cerebrospinal fluid biomarker levels;	chr7:23362336	chr7:23129178~23129841:+
BRCA	cis	rs2243480	1	rs313807	ENSG00000232546.1	RP11-458F8.1	-6.2	7.99e-10	1.35e-07	-0.25	-0.19	Diabetic kidney disease;	chr7:66034494	chr7:66848496~66858136:+
BRCA	cis	rs1972460	0.506	rs62012050	ENSG00000259429.4	UBE2Q2P2	-6.2	8e-10	1.36e-07	-0.2	-0.19	Intelligence (multi-trait analysis);	chr15:82239933	chr15:82355142~82420075:+
BRCA	cis	rs4713118	0.513	rs149955	ENSG00000216901.1	AL022393.7	6.2	8e-10	1.36e-07	0.25	0.19	Parkinson's disease;	chr6:28068447	chr6:28176188~28176674:+
BRCA	cis	rs7914558	1	rs4917380	ENSG00000213061.2	PFN1P11	6.2	8.01e-10	1.36e-07	0.24	0.19	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103015578	chr10:102838011~102845473:-
BRCA	cis	rs11096990	0.964	rs35494908	ENSG00000249207.1	RP11-360F5.1	6.2	8.02e-10	1.36e-07	0.22	0.19	Cognitive function;	chr4:39252574	chr4:39112677~39126818:-
BRCA	cis	rs1707322	1	rs6671754	ENSG00000281133.1	AL355480.3	-6.2	8.02e-10	1.36e-07	-0.24	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45968318	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.963	rs6666763	ENSG00000281133.1	AL355480.3	-6.2	8.02e-10	1.36e-07	-0.24	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45970779	chr1:45580892~45580996:-
BRCA	cis	rs1707322	1	rs4489497	ENSG00000281133.1	AL355480.3	-6.2	8.02e-10	1.36e-07	-0.24	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45973026	chr1:45580892~45580996:-
BRCA	cis	rs1707322	1	rs11211235	ENSG00000281133.1	AL355480.3	-6.2	8.02e-10	1.36e-07	-0.24	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45974703	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.893	rs9919275	ENSG00000281133.1	AL355480.3	-6.2	8.02e-10	1.36e-07	-0.24	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45975688	chr1:45580892~45580996:-
BRCA	cis	rs1707322	1	rs11211236	ENSG00000281133.1	AL355480.3	-6.2	8.02e-10	1.36e-07	-0.24	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45978095	chr1:45580892~45580996:-
BRCA	cis	rs1707322	1	rs4660328	ENSG00000281133.1	AL355480.3	-6.2	8.02e-10	1.36e-07	-0.24	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45979159	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.928	rs61785614	ENSG00000281133.1	AL355480.3	-6.2	8.02e-10	1.36e-07	-0.24	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45980375	chr1:45580892~45580996:-
BRCA	cis	rs1707322	1	rs9793167	ENSG00000281133.1	AL355480.3	-6.2	8.02e-10	1.36e-07	-0.24	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45981128	chr1:45580892~45580996:-
BRCA	cis	rs1707322	1	rs11211237	ENSG00000281133.1	AL355480.3	-6.2	8.02e-10	1.36e-07	-0.24	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45981657	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.963	rs11211238	ENSG00000281133.1	AL355480.3	-6.2	8.02e-10	1.36e-07	-0.24	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45983743	chr1:45580892~45580996:-
BRCA	cis	rs1707322	1	rs4460583	ENSG00000281133.1	AL355480.3	-6.2	8.02e-10	1.36e-07	-0.24	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45984246	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.963	rs4459051	ENSG00000281133.1	AL355480.3	-6.2	8.02e-10	1.36e-07	-0.24	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45985531	chr1:45580892~45580996:-
BRCA	cis	rs1707322	1	rs11211239	ENSG00000281133.1	AL355480.3	-6.2	8.02e-10	1.36e-07	-0.24	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45986275	chr1:45580892~45580996:-
BRCA	cis	rs4950322	0.542	rs3766519	ENSG00000278811.3	LINC00624	6.2	8.02e-10	1.36e-07	0.25	0.19	Protein quantitative trait loci;	chr1:147214802	chr1:147258885~147517875:-
BRCA	cis	rs9308731	0.591	rs9308742	ENSG00000227992.1	AC108463.2	-6.2	8.03e-10	1.36e-07	-0.22	-0.19	Chronic lymphocytic leukemia;	chr2:111186044	chr2:111203964~111206215:-
BRCA	cis	rs6088813	0.883	rs2425061	ENSG00000126005.14	MMP24-AS1	-6.2	8.03e-10	1.36e-07	-0.22	-0.19	Height;	chr20:35327768	chr20:35216462~35278131:-
BRCA	cis	rs227275	0.525	rs13113923	ENSG00000251288.2	RP11-10L12.2	-6.2	8.03e-10	1.36e-07	-0.22	-0.19	Allergic disease (asthma, hay fever or eczema);	chr4:102918936	chr4:102751401~102752641:+
BRCA	cis	rs2378497	1	rs2790762	ENSG00000232679.1	RP11-400N13.3	-6.2	8.04e-10	1.36e-07	-0.27	-0.19	Serum thyroid-stimulating hormone levels;	chr1:222023668	chr1:222041705~222064763:-
BRCA	cis	rs11976180	1	rs2961118	ENSG00000273234.1	OR2A13P	-6.2	8.04e-10	1.36e-07	-0.25	-0.19	Obesity-related traits;	chr7:144058350	chr7:144142009~144142938:+
BRCA	cis	rs155076	0.938	rs261375	ENSG00000235438.6	ESRRAP2	-6.2	8.04e-10	1.36e-07	-0.27	-0.19	White matter hyperintensity burden;	chr13:21297743	chr13:21260015~21295003:+
BRCA	cis	rs2243480	0.803	rs34804747	ENSG00000228409.4	CCT6P1	6.2	8.05e-10	1.36e-07	0.26	0.19	Diabetic kidney disease;	chr7:65947955	chr7:65751142~65763354:+
BRCA	cis	rs2243480	1	rs59794892	ENSG00000228409.4	CCT6P1	6.2	8.05e-10	1.36e-07	0.26	0.19	Diabetic kidney disease;	chr7:65950886	chr7:65751142~65763354:+
BRCA	cis	rs2243480	0.803	rs36004293	ENSG00000228409.4	CCT6P1	6.2	8.05e-10	1.36e-07	0.26	0.19	Diabetic kidney disease;	chr7:65951525	chr7:65751142~65763354:+
BRCA	cis	rs2243480	0.803	rs35268390	ENSG00000228409.4	CCT6P1	6.2	8.05e-10	1.36e-07	0.26	0.19	Diabetic kidney disease;	chr7:65951549	chr7:65751142~65763354:+
BRCA	cis	rs420259	0.516	rs11642434	ENSG00000260136.4	CTD-2270L9.4	6.2	8.06e-10	1.37e-07	0.19	0.19	Bipolar disorder;	chr16:23528916	chr16:23452758~23457606:+
BRCA	cis	rs853679	0.517	rs9393890	ENSG00000280107.1	AL022393.9	-6.2	8.07e-10	1.37e-07	-0.28	-0.19	Depression;	chr6:28096077	chr6:28170845~28172521:+
BRCA	cis	rs853679	0.517	rs9366715	ENSG00000280107.1	AL022393.9	-6.2	8.07e-10	1.37e-07	-0.28	-0.19	Depression;	chr6:28096855	chr6:28170845~28172521:+
BRCA	cis	rs2153535	0.518	rs9285977	ENSG00000230939.1	RP11-314C16.1	-6.2	8.08e-10	1.37e-07	-0.22	-0.19	Motion sickness;	chr6:8572052	chr6:8784178~8785445:+
BRCA	cis	rs420259	0.516	rs9302410	ENSG00000260136.4	CTD-2270L9.4	-6.2	8.08e-10	1.37e-07	-0.19	-0.19	Bipolar disorder;	chr16:23500051	chr16:23452758~23457606:+
BRCA	cis	rs9308731	0.591	rs9808225	ENSG00000227992.1	AC108463.2	-6.2	8.08e-10	1.37e-07	-0.22	-0.19	Chronic lymphocytic leukemia;	chr2:111185937	chr2:111203964~111206215:-
BRCA	cis	rs9308731	0.591	rs7572367	ENSG00000227992.1	AC108463.2	-6.2	8.09e-10	1.37e-07	-0.22	-0.19	Chronic lymphocytic leukemia;	chr2:111185394	chr2:111203964~111206215:-
BRCA	cis	rs17301013	0.606	rs4650969	ENSG00000227373.4	RP11-160H22.5	6.2	8.09e-10	1.37e-07	0.28	0.19	Systemic lupus erythematosus;	chr1:174229622	chr1:174115300~174160004:-
BRCA	cis	rs13126694	0.778	rs6814979	ENSG00000251429.1	RP11-597D13.7	-6.2	8.1e-10	1.37e-07	-0.18	-0.19	Blood osmolality (transformed sodium);	chr4:158135798	chr4:158270378~158278676:+
BRCA	cis	rs6479891	1	rs9415708	ENSG00000232075.1	MRPL35P2	6.2	8.1e-10	1.37e-07	0.34	0.19	Arthritis (juvenile idiopathic);	chr10:63430282	chr10:63634317~63634827:-
BRCA	cis	rs7976269	0.559	rs10843304	ENSG00000275476.1	RP11-996F15.4	-6.2	8.11e-10	1.37e-07	-0.22	-0.19	Male-pattern baldness;	chr12:29071226	chr12:29277397~29277882:-
BRCA	cis	rs12701220	0.522	rs1881116	ENSG00000229043.2	AC091729.9	-6.2	8.12e-10	1.38e-07	-0.25	-0.19	Bronchopulmonary dysplasia;	chr7:1014322	chr7:1160374~1165267:+
BRCA	cis	rs3733585	0.682	rs13124563	ENSG00000250413.1	RP11-448G15.1	-6.2	8.12e-10	1.38e-07	-0.25	-0.19	Cleft plate (environmental tobacco smoke interaction);	chr4:9925929	chr4:10006482~10009725:+
BRCA	cis	rs6496044	0.547	rs7173125	ENSG00000259295.5	CSPG4P12	-6.2	8.14e-10	1.38e-07	-0.23	-0.19	Interstitial lung disease;	chr15:85512214	chr15:85191438~85213905:+
BRCA	cis	rs227275	0.556	rs6852141	ENSG00000251288.2	RP11-10L12.2	-6.2	8.14e-10	1.38e-07	-0.23	-0.19	Allergic disease (asthma, hay fever or eczema);	chr4:102986439	chr4:102751401~102752641:+
BRCA	cis	rs228614	0.509	rs4455415	ENSG00000251288.2	RP11-10L12.2	-6.2	8.14e-10	1.38e-07	-0.23	-0.19	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102993663	chr4:102751401~102752641:+
BRCA	cis	rs227275	0.525	rs6853193	ENSG00000251288.2	RP11-10L12.2	-6.2	8.14e-10	1.38e-07	-0.23	-0.19	Allergic disease (asthma, hay fever or eczema);	chr4:102994888	chr4:102751401~102752641:+
BRCA	cis	rs875971	0.862	rs4718377	ENSG00000224316.1	RP11-479O9.2	-6.2	8.14e-10	1.38e-07	-0.19	-0.19	Aortic root size;	chr7:66584691	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.862	rs10278014	ENSG00000224316.1	RP11-479O9.2	-6.2	8.14e-10	1.38e-07	-0.19	-0.19	Aortic root size;	chr7:66586277	chr7:65773620~65802067:+
BRCA	cis	rs7809950	0.817	rs3779495	ENSG00000238832.1	snoU109	6.2	8.15e-10	1.38e-07	0.28	0.19	Coronary artery disease;	chr7:107609815	chr7:107603363~107603507:+
BRCA	cis	rs4763879	0.634	rs12424826	ENSG00000256673.1	RP11-599J14.2	6.2	8.16e-10	1.38e-07	0.21	0.19	Type 1 diabetes;	chr12:9701981	chr12:9398355~9414851:-
BRCA	cis	rs2243480	1	rs422164	ENSG00000230295.1	RP11-458F8.2	-6.2	8.16e-10	1.38e-07	-0.25	-0.19	Diabetic kidney disease;	chr7:66121618	chr7:66880708~66882981:+
BRCA	cis	rs875971	0.522	rs7784623	ENSG00000234585.5	CCT6P3	6.2	8.16e-10	1.38e-07	0.18	0.19	Aortic root size;	chr7:65930047	chr7:65038354~65074713:+
BRCA	cis	rs7914558	0.933	rs10883814	ENSG00000213061.2	PFN1P11	6.2	8.16e-10	1.38e-07	0.25	0.19	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102977647	chr10:102838011~102845473:-
BRCA	cis	rs721917	0.525	rs2246111	ENSG00000244733.5	RP11-506M13.3	-6.2	8.16e-10	1.38e-07	-0.23	-0.19	Chronic obstructive pulmonary disease;	chr10:79929985	chr10:79660891~79677996:+
BRCA	cis	rs11976180	1	rs2961117	ENSG00000273234.1	OR2A13P	-6.2	8.17e-10	1.38e-07	-0.26	-0.19	Obesity-related traits;	chr7:144058160	chr7:144142009~144142938:+
BRCA	cis	rs1198430	1	rs946268	ENSG00000232482.2	RP4-654C18.1	-6.2	8.19e-10	1.39e-07	-0.28	-0.19	Total cholesterol levels;	chr1:23421273	chr1:23410832~23412146:+
BRCA	cis	rs853679	0.517	rs4713135	ENSG00000204709.4	LINC01556	6.2	8.2e-10	1.39e-07	0.28	0.19	Depression;	chr6:28071808	chr6:28943877~28944537:+
BRCA	cis	rs1707322	1	rs34444543	ENSG00000281133.1	AL355480.3	-6.2	8.21e-10	1.39e-07	-0.24	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45893190	chr1:45580892~45580996:-
BRCA	cis	rs9500256	0.655	rs12209098	ENSG00000215190.7	LINC00680	6.2	8.21e-10	1.39e-07	0.23	0.19	Eosinophilic esophagitis (pediatric);	chr6:58014194	chr6:57946074~57961501:-
BRCA	cis	rs1124769	0.672	rs2663530	ENSG00000259378.1	DCAF13P3	6.2	8.22e-10	1.39e-07	0.27	0.19	Cognitive performance;	chr15:50835453	chr15:50944663~50945996:+
BRCA	cis	rs1858037	0.867	rs61226353	ENSG00000204929.10	AC074391.1	6.2	8.22e-10	1.39e-07	0.25	0.19	Rheumatoid arthritis;	chr2:65363637	chr2:65436711~66084639:+
BRCA	cis	rs2276314	0.553	rs1789501	ENSG00000278986.1	RP11-723J4.3	6.2	8.23e-10	1.39e-07	0.22	0.19	Endometriosis;Drug-induced torsades de pointes;	chr18:36037097	chr18:35972151~35973916:+
BRCA	cis	rs11098499	1	rs58601355	ENSG00000249244.1	RP11-548H18.2	6.2	8.23e-10	1.39e-07	0.23	0.19	Corneal astigmatism;	chr4:119265212	chr4:119391831~119395335:-
BRCA	cis	rs17301013	0.507	rs12091076	ENSG00000227373.4	RP11-160H22.5	6.2	8.23e-10	1.39e-07	0.28	0.19	Systemic lupus erythematosus;	chr1:174321545	chr1:174115300~174160004:-
BRCA	cis	rs55702914	0.625	rs59757315	ENSG00000231621.1	AC013264.2	-6.2	8.23e-10	1.39e-07	-0.18	-0.19	Major depression and alcohol dependence;	chr2:197385489	chr2:197197991~197199273:+
BRCA	cis	rs3764021	0.87	rs2401395	ENSG00000214776.8	RP11-726G1.1	6.2	8.23e-10	1.39e-07	0.21	0.19	Type 1 diabetes;	chr12:9726944	chr12:9467552~9576275:+
BRCA	cis	rs2243480	1	rs4718269	ENSG00000229886.1	RP5-1132H15.3	-6.2	8.24e-10	1.39e-07	-0.32	-0.19	Diabetic kidney disease;	chr7:65735810	chr7:66025126~66031544:-
BRCA	cis	rs9992667	1	rs9992667	ENSG00000231160.8	KLF3-AS1	6.2	8.25e-10	1.4e-07	0.24	0.19	Eosinophil percentage of granulocytes;	chr4:38678565	chr4:38612701~38664883:-
BRCA	cis	rs6840360	0.582	rs11733820	ENSG00000270265.1	RP11-731D1.4	-6.2	8.25e-10	1.4e-07	-0.21	-0.19	Intelligence (multi-trait analysis);	chr4:151394987	chr4:151333775~151353224:-
BRCA	cis	rs2644899	0.785	rs2604895	ENSG00000268529.1	CYP2T3P	6.2	8.26e-10	1.4e-07	0.26	0.19	Post bronchodilator FEV1/FVC ratio;	chr19:40786358	chr19:41134722~41137308:+
BRCA	cis	rs13126694	0.682	rs6536288	ENSG00000248429.4	RP11-597D13.9	-6.2	8.26e-10	1.4e-07	-0.17	-0.19	Blood osmolality (transformed sodium);	chr4:157949748	chr4:158170752~158202877:+
BRCA	cis	rs7520050	0.966	rs1707321	ENSG00000280836.1	AL355480.1	6.2	8.27e-10	1.4e-07	0.22	0.19	Reticulocyte count;Red blood cell count;	chr1:46039637	chr1:45581219~45581321:-
BRCA	cis	rs853679	0.517	rs4711164	ENSG00000219392.1	RP1-265C24.5	-6.2	8.28e-10	1.4e-07	-0.29	-0.19	Depression;	chr6:28147378	chr6:28115628~28116551:+
BRCA	cis	rs853679	0.517	rs4711165	ENSG00000219392.1	RP1-265C24.5	-6.2	8.28e-10	1.4e-07	-0.29	-0.19	Depression;	chr6:28147406	chr6:28115628~28116551:+
BRCA	cis	rs853679	0.517	rs4713148	ENSG00000219392.1	RP1-265C24.5	-6.2	8.28e-10	1.4e-07	-0.29	-0.19	Depression;	chr6:28148143	chr6:28115628~28116551:+
BRCA	cis	rs853679	0.517	rs9348794	ENSG00000219392.1	RP1-265C24.5	-6.2	8.28e-10	1.4e-07	-0.29	-0.19	Depression;	chr6:28149979	chr6:28115628~28116551:+
BRCA	cis	rs853679	0.517	rs9295758	ENSG00000219392.1	RP1-265C24.5	-6.2	8.28e-10	1.4e-07	-0.29	-0.19	Depression;	chr6:28152885	chr6:28115628~28116551:+
BRCA	cis	rs853679	0.517	rs17774663	ENSG00000219392.1	RP1-265C24.5	-6.2	8.28e-10	1.4e-07	-0.29	-0.19	Depression;	chr6:28153120	chr6:28115628~28116551:+
BRCA	cis	rs6479891	1	rs12784772	ENSG00000232075.1	MRPL35P2	6.2	8.28e-10	1.4e-07	0.34	0.19	Arthritis (juvenile idiopathic);	chr10:63435695	chr10:63634317~63634827:-
BRCA	cis	rs6479891	1	rs77494594	ENSG00000232075.1	MRPL35P2	6.2	8.28e-10	1.4e-07	0.34	0.19	Arthritis (juvenile idiopathic);	chr10:63437549	chr10:63634317~63634827:-
BRCA	cis	rs2692947	0.702	rs4907291	ENSG00000237510.6	AC008268.2	6.2	8.29e-10	1.4e-07	0.24	0.19	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95988857	chr2:95789654~95800166:+
BRCA	cis	rs227275	0.556	rs10015289	ENSG00000251288.2	RP11-10L12.2	-6.2	8.29e-10	1.4e-07	-0.22	-0.19	Allergic disease (asthma, hay fever or eczema);	chr4:102984956	chr4:102751401~102752641:+
BRCA	cis	rs8002861	0.641	rs2028813	ENSG00000274001.1	RP11-5G9.5	6.2	8.31e-10	1.41e-07	0.22	0.19	Leprosy;	chr13:43847990	chr13:43877715~43878163:-
BRCA	cis	rs2243480	1	rs313814	ENSG00000230295.1	RP11-458F8.2	-6.2	8.31e-10	1.41e-07	-0.26	-0.19	Diabetic kidney disease;	chr7:66038306	chr7:66880708~66882981:+
BRCA	cis	rs4713118	0.696	rs2394002	ENSG00000220721.1	OR1F12	6.2	8.31e-10	1.41e-07	0.24	0.19	Parkinson's disease;	chr6:27780236	chr6:28073316~28074233:+
BRCA	cis	rs12468226	0.873	rs59293950	ENSG00000226261.1	AC064836.3	6.2	8.32e-10	1.41e-07	0.34	0.19	Urate levels;	chr2:202214069	chr2:202336024~202336727:-
BRCA	cis	rs1440410	0.835	rs9992189	ENSG00000250326.1	RP11-284M14.1	-6.2	8.33e-10	1.41e-07	-0.21	-0.19	Ischemic stroke;	chr4:143139575	chr4:142933195~143184861:-
BRCA	cis	rs2836950	0.565	rs2836943	ENSG00000255568.3	BRWD1-AS2	-6.2	8.33e-10	1.41e-07	-0.18	-0.19	Menarche (age at onset);	chr21:39220685	chr21:39313935~39314962:+
BRCA	cis	rs11976180	1	rs4726669	ENSG00000273234.1	OR2A13P	-6.2	8.33e-10	1.41e-07	-0.25	-0.19	Obesity-related traits;	chr7:144061098	chr7:144142009~144142938:+
BRCA	cis	rs755249	0.565	rs722357	ENSG00000228060.1	RP11-69E11.8	6.2	8.33e-10	1.41e-07	0.19	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39479096	chr1:39565160~39573203:+
BRCA	cis	rs2749097	0.825	rs2658432	ENSG00000244256.3	RN7SL130P	-6.2	8.35e-10	1.41e-07	-0.24	-0.19	Alcohol consumption (transferrin glycosylation);	chr1:63659153	chr1:63655743~63656047:+
BRCA	cis	rs7520050	0.966	rs4073846	ENSG00000280836.1	AL355480.1	-6.2	8.35e-10	1.41e-07	-0.22	-0.19	Reticulocyte count;Red blood cell count;	chr1:45997209	chr1:45581219~45581321:-
BRCA	cis	rs9308731	0.591	rs938095	ENSG00000227992.1	AC108463.2	6.2	8.35e-10	1.41e-07	0.21	0.19	Chronic lymphocytic leukemia;	chr2:111191232	chr2:111203964~111206215:-
BRCA	cis	rs755249	0.501	rs661316	ENSG00000228060.1	RP11-69E11.8	-6.2	8.35e-10	1.41e-07	-0.2	-0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39165625	chr1:39565160~39573203:+
BRCA	cis	rs7615952	0.688	rs12638224	ENSG00000250012.1	RP11-124N2.1	-6.2	8.36e-10	1.41e-07	-0.26	-0.19	Blood pressure (smoking interaction);	chr3:125822477	chr3:126084220~126095349:+
BRCA	cis	rs875971	0.545	rs10950025	ENSG00000273024.4	INTS4P2	-6.2	8.36e-10	1.41e-07	-0.23	-0.19	Aortic root size;	chr7:66158946	chr7:65647864~65715661:+
BRCA	cis	rs875971	0.52	rs12666485	ENSG00000273024.4	INTS4P2	-6.2	8.36e-10	1.41e-07	-0.23	-0.19	Aortic root size;	chr7:66160135	chr7:65647864~65715661:+
BRCA	cis	rs875971	0.545	rs67688847	ENSG00000273024.4	INTS4P2	-6.2	8.36e-10	1.41e-07	-0.23	-0.19	Aortic root size;	chr7:66161064	chr7:65647864~65715661:+
BRCA	cis	rs2235642	0.928	rs9932984	ENSG00000280231.1	LA16c-380F5.3	-6.2	8.36e-10	1.41e-07	-0.25	-0.19	Coronary artery disease;	chr16:1555050	chr16:1553655~1554130:-
BRCA	cis	rs11098499	0.739	rs2203039	ENSG00000248280.1	RP11-33B1.2	-6.2	8.36e-10	1.41e-07	-0.19	-0.19	Corneal astigmatism;	chr4:119211192	chr4:119440561~119450157:-
BRCA	cis	rs9307551	1	rs11098770	ENSG00000250334.4	LINC00989	-6.2	8.36e-10	1.41e-07	-0.27	-0.19	Refractive error;	chr4:79598850	chr4:79492416~79576460:+
BRCA	cis	rs7474896	0.559	rs2738185	ENSG00000226578.1	RP11-258F22.1	6.2	8.37e-10	1.42e-07	0.24	0.19	Obesity (extreme);	chr10:37958808	chr10:37775371~37784131:-
BRCA	cis	rs710913	0.717	rs2068473	ENSG00000182109.6	RP11-69E11.4	-6.2	8.37e-10	1.42e-07	-0.21	-0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39572925	chr1:39522280~39546187:-
BRCA	cis	rs2243480	1	rs73142162	ENSG00000229886.1	RP5-1132H15.3	6.2	8.38e-10	1.42e-07	0.33	0.19	Diabetic kidney disease;	chr7:65909309	chr7:66025126~66031544:-
BRCA	cis	rs9990333	1	rs9990333	ENSG00000242086.7	LINC00969	-6.19	8.39e-10	1.42e-07	-0.2	-0.19	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196100334	chr3:195658062~195739964:+
BRCA	cis	rs4713118	0.516	rs7739216	ENSG00000280107.1	AL022393.9	-6.19	8.39e-10	1.42e-07	-0.28	-0.19	Parkinson's disease;	chr6:28112168	chr6:28170845~28172521:+
BRCA	cis	rs853679	0.517	rs35512245	ENSG00000280107.1	AL022393.9	-6.19	8.39e-10	1.42e-07	-0.28	-0.19	Depression;	chr6:28112175	chr6:28170845~28172521:+
BRCA	cis	rs2243480	1	rs78803505	ENSG00000228409.4	CCT6P1	6.19	8.41e-10	1.42e-07	0.26	0.19	Diabetic kidney disease;	chr7:65917585	chr7:65751142~65763354:+
BRCA	cis	rs2243480	1	rs34577383	ENSG00000228409.4	CCT6P1	6.19	8.41e-10	1.42e-07	0.26	0.19	Diabetic kidney disease;	chr7:65920739	chr7:65751142~65763354:+
BRCA	cis	rs2243480	1	rs55895244	ENSG00000228409.4	CCT6P1	6.19	8.41e-10	1.42e-07	0.26	0.19	Diabetic kidney disease;	chr7:65922691	chr7:65751142~65763354:+
BRCA	cis	rs2243480	1	rs7795242	ENSG00000228409.4	CCT6P1	6.19	8.41e-10	1.42e-07	0.26	0.19	Diabetic kidney disease;	chr7:65925107	chr7:65751142~65763354:+
BRCA	cis	rs2243480	1	rs2177703	ENSG00000228409.4	CCT6P1	6.19	8.41e-10	1.42e-07	0.26	0.19	Diabetic kidney disease;	chr7:65926730	chr7:65751142~65763354:+
BRCA	cis	rs2243480	1	rs56985706	ENSG00000228409.4	CCT6P1	6.19	8.41e-10	1.42e-07	0.26	0.19	Diabetic kidney disease;	chr7:65929575	chr7:65751142~65763354:+
BRCA	cis	rs2243480	1	rs60683927	ENSG00000228409.4	CCT6P1	6.19	8.41e-10	1.42e-07	0.26	0.19	Diabetic kidney disease;	chr7:65929781	chr7:65751142~65763354:+
BRCA	cis	rs2243480	1	rs58062456	ENSG00000228409.4	CCT6P1	6.19	8.41e-10	1.42e-07	0.26	0.19	Diabetic kidney disease;	chr7:65929865	chr7:65751142~65763354:+
BRCA	cis	rs651907	0.557	rs56291106	ENSG00000244119.1	PDCL3P4	6.19	8.41e-10	1.42e-07	0.15	0.19	Colorectal cancer;	chr3:101658630	chr3:101712472~101713191:+
BRCA	cis	rs853679	0.517	rs4713150	ENSG00000280107.1	AL022393.9	-6.19	8.42e-10	1.42e-07	-0.28	-0.19	Depression;	chr6:28168434	chr6:28170845~28172521:+
BRCA	cis	rs4713118	0.527	rs4713151	ENSG00000280107.1	AL022393.9	-6.19	8.42e-10	1.42e-07	-0.28	-0.19	Parkinson's disease;	chr6:28168578	chr6:28170845~28172521:+
BRCA	cis	rs853679	0.517	rs9393901	ENSG00000280107.1	AL022393.9	-6.19	8.42e-10	1.42e-07	-0.28	-0.19	Depression;	chr6:28169019	chr6:28170845~28172521:+
BRCA	cis	rs853679	0.517	rs3173443	ENSG00000280107.1	AL022393.9	-6.19	8.42e-10	1.42e-07	-0.28	-0.19	Depression;	chr6:28169249	chr6:28170845~28172521:+
BRCA	cis	rs853679	0.517	rs4713152	ENSG00000280107.1	AL022393.9	-6.19	8.42e-10	1.42e-07	-0.28	-0.19	Depression;	chr6:28169676	chr6:28170845~28172521:+
BRCA	cis	rs853679	0.517	rs9348797	ENSG00000280107.1	AL022393.9	-6.19	8.42e-10	1.42e-07	-0.28	-0.19	Depression;	chr6:28169755	chr6:28170845~28172521:+
BRCA	cis	rs853679	0.517	rs9380062	ENSG00000280107.1	AL022393.9	-6.19	8.42e-10	1.42e-07	-0.28	-0.19	Depression;	chr6:28169791	chr6:28170845~28172521:+
BRCA	cis	rs853679	0.542	rs9380063	ENSG00000280107.1	AL022393.9	-6.19	8.42e-10	1.42e-07	-0.28	-0.19	Depression;	chr6:28170075	chr6:28170845~28172521:+
BRCA	cis	rs875971	0.862	rs1981799	ENSG00000224316.1	RP11-479O9.2	6.19	8.42e-10	1.42e-07	0.19	0.19	Aortic root size;	chr7:66490572	chr7:65773620~65802067:+
BRCA	cis	rs2243480	1	rs313832	ENSG00000228409.4	CCT6P1	6.19	8.42e-10	1.42e-07	0.27	0.19	Diabetic kidney disease;	chr7:66085904	chr7:65751142~65763354:+
BRCA	cis	rs875971	0.545	rs10950036	ENSG00000273024.4	INTS4P2	-6.19	8.42e-10	1.42e-07	-0.24	-0.19	Aortic root size;	chr7:66353241	chr7:65647864~65715661:+
BRCA	cis	rs11096990	0.855	rs2167494	ENSG00000249207.1	RP11-360F5.1	6.19	8.42e-10	1.42e-07	0.22	0.19	Cognitive function;	chr4:39214601	chr4:39112677~39126818:-
BRCA	cis	rs7615952	0.641	rs61048217	ENSG00000171084.14	FAM86JP	6.19	8.43e-10	1.42e-07	0.29	0.19	Blood pressure (smoking interaction);	chr3:126089062	chr3:125916620~125930024:+
BRCA	cis	rs7615952	0.641	rs60839048	ENSG00000171084.14	FAM86JP	6.19	8.43e-10	1.42e-07	0.29	0.19	Blood pressure (smoking interaction);	chr3:126089095	chr3:125916620~125930024:+
BRCA	cis	rs7615952	0.641	rs7640158	ENSG00000171084.14	FAM86JP	6.19	8.43e-10	1.42e-07	0.29	0.19	Blood pressure (smoking interaction);	chr3:126089168	chr3:125916620~125930024:+
BRCA	cis	rs7615952	0.641	rs2365019	ENSG00000171084.14	FAM86JP	6.19	8.43e-10	1.42e-07	0.29	0.19	Blood pressure (smoking interaction);	chr3:126089292	chr3:125916620~125930024:+
BRCA	cis	rs875971	0.825	rs1129531	ENSG00000224316.1	RP11-479O9.2	-6.19	8.43e-10	1.42e-07	-0.19	-0.19	Aortic root size;	chr7:66154117	chr7:65773620~65802067:+
BRCA	cis	rs7615952	0.688	rs12638240	ENSG00000250012.1	RP11-124N2.1	-6.19	8.44e-10	1.43e-07	-0.26	-0.19	Blood pressure (smoking interaction);	chr3:125822395	chr3:126084220~126095349:+
BRCA	cis	rs2638953	0.79	rs4357727	ENSG00000247934.4	RP11-967K21.1	6.19	8.44e-10	1.43e-07	0.23	0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28291989	chr12:28163298~28190738:-
BRCA	cis	rs853679	0.517	rs4713146	ENSG00000280107.1	AL022393.9	-6.19	8.45e-10	1.43e-07	-0.29	-0.19	Depression;	chr6:28143758	chr6:28170845~28172521:+
BRCA	cis	rs853679	0.517	rs9393894	ENSG00000280107.1	AL022393.9	-6.19	8.45e-10	1.43e-07	-0.29	-0.19	Depression;	chr6:28144784	chr6:28170845~28172521:+
BRCA	cis	rs2243480	1	rs57057549	ENSG00000232546.1	RP11-458F8.1	-6.19	8.45e-10	1.43e-07	-0.25	-0.19	Diabetic kidney disease;	chr7:65940751	chr7:66848496~66858136:+
BRCA	cis	rs7274963	0.704	rs68083607	ENSG00000236474.1	GCNT1P1	6.19	8.46e-10	1.43e-07	0.22	0.19	Body mass index;	chr20:18311239	chr20:18420160~18421454:-
BRCA	cis	rs7914558	1	rs10883824	ENSG00000213061.2	PFN1P11	6.19	8.46e-10	1.43e-07	0.25	0.19	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103053140	chr10:102838011~102845473:-
BRCA	cis	rs17345786	0.511	rs13061565	ENSG00000244119.1	PDCL3P4	6.19	8.47e-10	1.43e-07	0.15	0.19	Colonoscopy-negative controls vs population controls;	chr3:101673426	chr3:101712472~101713191:+
BRCA	cis	rs651907	0.557	rs7651404	ENSG00000244119.1	PDCL3P4	6.19	8.47e-10	1.43e-07	0.15	0.19	Colorectal cancer;	chr3:101674450	chr3:101712472~101713191:+
BRCA	cis	rs950169	0.579	rs11633088	ENSG00000259728.4	LINC00933	-6.19	8.48e-10	1.43e-07	-0.26	-0.19	Schizophrenia;	chr15:84003429	chr15:84570649~84580175:+
BRCA	cis	rs2115630	0.967	rs28595395	ENSG00000229212.6	RP11-561C5.4	6.19	8.48e-10	1.43e-07	0.21	0.19	P wave terminal force;	chr15:84791721	chr15:85205440~85234795:-
BRCA	cis	rs8031584	0.781	rs4779498	ENSG00000270015.1	RP11-540B6.6	-6.19	8.48e-10	1.43e-07	-0.2	-0.19	Huntington's disease progression;	chr15:30885273	chr15:30926514~30928407:+
BRCA	cis	rs5015933	0.801	rs2416961	ENSG00000232630.1	PRPS1P2	-6.19	8.49e-10	1.43e-07	-0.18	-0.19	Body mass index;	chr9:125378078	chr9:125150653~125151589:+
BRCA	cis	rs710913	0.816	rs1727098	ENSG00000182109.6	RP11-69E11.4	-6.19	8.5e-10	1.44e-07	-0.21	-0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39523655	chr1:39522280~39546187:-
BRCA	cis	rs2274273	0.686	rs68083077	ENSG00000258413.1	RP11-665C16.6	-6.19	8.5e-10	1.44e-07	-0.25	-0.19	Protein biomarker;	chr14:55107710	chr14:55262767~55272075:-
BRCA	cis	rs8103033	0.748	rs8101868	ENSG00000226025.8	LGALS17A	-6.19	8.5e-10	1.44e-07	-0.21	-0.19	Obesity-related traits;	chr19:39646090	chr19:39679374~39686373:+
BRCA	cis	rs2243480	0.908	rs55876148	ENSG00000232546.1	RP11-458F8.1	-6.19	8.5e-10	1.44e-07	-0.25	-0.19	Diabetic kidney disease;	chr7:65914813	chr7:66848496~66858136:+
BRCA	cis	rs1707322	1	rs1707337	ENSG00000281133.1	AL355480.3	6.19	8.51e-10	1.44e-07	0.23	0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46043097	chr1:45580892~45580996:-
BRCA	cis	rs1707322	1	rs1768807	ENSG00000281133.1	AL355480.3	6.19	8.51e-10	1.44e-07	0.23	0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46044898	chr1:45580892~45580996:-
BRCA	cis	rs853679	0.517	rs4713145	ENSG00000219392.1	RP1-265C24.5	-6.19	8.51e-10	1.44e-07	-0.28	-0.19	Depression;	chr6:28139049	chr6:28115628~28116551:+
BRCA	cis	rs858239	0.665	rs858306	ENSG00000230042.1	AK3P3	-6.19	8.51e-10	1.44e-07	-0.22	-0.19	Cerebrospinal fluid biomarker levels;	chr7:23203135	chr7:23129178~23129841:+
BRCA	cis	rs516805	0.781	rs502103	ENSG00000279453.1	RP3-425C14.4	-6.19	8.53e-10	1.44e-07	-0.25	-0.19	Lymphocyte counts;	chr6:122446062	chr6:122436789~122439223:-
BRCA	cis	rs6728642	0.614	rs113485946	ENSG00000230606.9	AC159540.1	6.19	8.54e-10	1.44e-07	0.4	0.19	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:97200705	chr2:97416165~97433527:-
BRCA	cis	rs4908760	0.827	rs1463053	ENSG00000270282.1	RP5-1115A15.2	6.19	8.55e-10	1.44e-07	0.2	0.19	Vitiligo;	chr1:8644978	chr1:8512653~8513021:+
BRCA	cis	rs1124769	0.719	rs1904430	ENSG00000259378.1	DCAF13P3	6.19	8.55e-10	1.44e-07	0.26	0.19	Cognitive performance;	chr15:50962822	chr15:50944663~50945996:+
BRCA	cis	rs34779708	0.966	rs12773647	ENSG00000271335.4	RP11-324I22.4	6.19	8.55e-10	1.44e-07	0.2	0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35151399	chr10:35314552~35336401:-
BRCA	cis	rs7914558	0.966	rs1890185	ENSG00000213061.2	PFN1P11	6.19	8.56e-10	1.45e-07	0.24	0.19	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102988961	chr10:102838011~102845473:-
BRCA	cis	rs1823913	0.637	rs1470962	ENSG00000280083.1	RP11-317J9.1	6.19	8.57e-10	1.45e-07	0.21	0.19	Obesity-related traits;	chr2:191270271	chr2:191154118~191156070:-
BRCA	cis	rs1697139	0.935	rs1625369	ENSG00000249364.4	RP11-434D9.1	6.19	8.57e-10	1.45e-07	0.22	0.19	Breast cancer;	chr5:67217194	chr5:67379378~67805238:+
BRCA	cis	rs1707322	1	rs12077546	ENSG00000281133.1	AL355480.3	-6.19	8.58e-10	1.45e-07	-0.24	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45966134	chr1:45580892~45580996:-
BRCA	cis	rs1707322	1	rs12124291	ENSG00000281133.1	AL355480.3	-6.19	8.58e-10	1.45e-07	-0.24	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45966460	chr1:45580892~45580996:-
BRCA	cis	rs375066	0.623	rs10416116	ENSG00000267058.1	RP11-15A1.3	6.19	8.58e-10	1.45e-07	0.22	0.19	Breast cancer;	chr19:43839584	chr19:43891804~43901805:-
BRCA	cis	rs375066	0.623	rs57096959	ENSG00000267058.1	RP11-15A1.3	6.19	8.58e-10	1.45e-07	0.22	0.19	Breast cancer;	chr19:43839818	chr19:43891804~43901805:-
BRCA	cis	rs375066	0.599	rs8112065	ENSG00000267058.1	RP11-15A1.3	6.19	8.58e-10	1.45e-07	0.22	0.19	Breast cancer;	chr19:43840070	chr19:43891804~43901805:-
BRCA	cis	rs375066	0.623	rs2356432	ENSG00000267058.1	RP11-15A1.3	6.19	8.58e-10	1.45e-07	0.22	0.19	Breast cancer;	chr19:43840266	chr19:43891804~43901805:-
BRCA	cis	rs375066	0.551	rs2163855	ENSG00000267058.1	RP11-15A1.3	6.19	8.58e-10	1.45e-07	0.22	0.19	Breast cancer;	chr19:43840571	chr19:43891804~43901805:-
BRCA	cis	rs375066	0.551	rs2356433	ENSG00000267058.1	RP11-15A1.3	6.19	8.58e-10	1.45e-07	0.22	0.19	Breast cancer;	chr19:43840585	chr19:43891804~43901805:-
BRCA	cis	rs375066	0.551	rs12608578	ENSG00000267058.1	RP11-15A1.3	6.19	8.58e-10	1.45e-07	0.22	0.19	Breast cancer;	chr19:43840980	chr19:43891804~43901805:-
BRCA	cis	rs375066	0.551	rs10405318	ENSG00000267058.1	RP11-15A1.3	6.19	8.58e-10	1.45e-07	0.22	0.19	Breast cancer;	chr19:43841143	chr19:43891804~43901805:-
BRCA	cis	rs375066	0.623	rs73052665	ENSG00000267058.1	RP11-15A1.3	6.19	8.58e-10	1.45e-07	0.22	0.19	Breast cancer;	chr19:43842069	chr19:43891804~43901805:-
BRCA	cis	rs375066	0.623	rs62118371	ENSG00000267058.1	RP11-15A1.3	6.19	8.58e-10	1.45e-07	0.22	0.19	Breast cancer;	chr19:43842218	chr19:43891804~43901805:-
BRCA	cis	rs375066	0.623	rs1994416	ENSG00000267058.1	RP11-15A1.3	6.19	8.58e-10	1.45e-07	0.22	0.19	Breast cancer;	chr19:43842291	chr19:43891804~43901805:-
BRCA	cis	rs375066	0.623	rs1994415	ENSG00000267058.1	RP11-15A1.3	6.19	8.58e-10	1.45e-07	0.22	0.19	Breast cancer;	chr19:43842391	chr19:43891804~43901805:-
BRCA	cis	rs375066	0.599	rs1994414	ENSG00000267058.1	RP11-15A1.3	6.19	8.58e-10	1.45e-07	0.22	0.19	Breast cancer;	chr19:43842438	chr19:43891804~43901805:-
BRCA	cis	rs375066	0.623	rs62118372	ENSG00000267058.1	RP11-15A1.3	6.19	8.58e-10	1.45e-07	0.22	0.19	Breast cancer;	chr19:43842781	chr19:43891804~43901805:-
BRCA	cis	rs375066	0.623	rs57133938	ENSG00000267058.1	RP11-15A1.3	6.19	8.58e-10	1.45e-07	0.22	0.19	Breast cancer;	chr19:43843046	chr19:43891804~43901805:-
BRCA	cis	rs375066	0.623	rs2356434	ENSG00000267058.1	RP11-15A1.3	6.19	8.58e-10	1.45e-07	0.22	0.19	Breast cancer;	chr19:43843525	chr19:43891804~43901805:-
BRCA	cis	rs375066	0.623	rs4511643	ENSG00000267058.1	RP11-15A1.3	6.19	8.58e-10	1.45e-07	0.22	0.19	Breast cancer;	chr19:43843597	chr19:43891804~43901805:-
BRCA	cis	rs375066	0.623	rs8099861	ENSG00000267058.1	RP11-15A1.3	6.19	8.58e-10	1.45e-07	0.22	0.19	Breast cancer;	chr19:43844097	chr19:43891804~43901805:-
BRCA	cis	rs7772486	0.79	rs9497424	ENSG00000270638.1	RP3-466P17.1	-6.19	8.59e-10	1.45e-07	-0.21	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145904135	chr6:145735570~145737218:+
BRCA	cis	rs2243480	0.803	rs36127118	ENSG00000230295.1	RP11-458F8.2	-6.19	8.59e-10	1.45e-07	-0.25	-0.19	Diabetic kidney disease;	chr7:66100518	chr7:66880708~66882981:+
BRCA	cis	rs9287719	0.578	rs10175555	ENSG00000243819.4	RN7SL832P	6.19	8.59e-10	1.45e-07	0.2	0.19	Prostate cancer;	chr2:10563107	chr2:10690344~10692099:+
BRCA	cis	rs13126694	0.743	rs12512643	ENSG00000248429.4	RP11-597D13.9	6.19	8.6e-10	1.45e-07	0.17	0.19	Blood osmolality (transformed sodium);	chr4:158115588	chr4:158170752~158202877:+
BRCA	cis	rs12501370	0.959	rs1876493	ENSG00000201736.1	RNA5SP160	-6.19	8.6e-10	1.45e-07	-0.24	-0.19	Iris color (L* coordinate);	chr4:41042921	chr4:40990154~40990273:+
BRCA	cis	rs7162943	1	rs7162943	ENSG00000260123.1	RP11-326A19.4	6.19	8.61e-10	1.45e-07	0.22	0.19	Mean platelet volume;	chr15:89072044	chr15:89041223~89082819:+
BRCA	cis	rs13113518	0.812	rs6849474	ENSG00000273257.1	RP11-177J6.1	6.19	8.61e-10	1.45e-07	0.24	0.19	Height;	chr4:55452295	chr4:55387949~55388271:+
BRCA	cis	rs5015933	0.801	rs7848571	ENSG00000232630.1	PRPS1P2	-6.19	8.63e-10	1.46e-07	-0.18	-0.19	Body mass index;	chr9:125378927	chr9:125150653~125151589:+
BRCA	cis	rs12478296	1	rs56292923	ENSG00000261186.2	RP11-341N2.1	-6.19	8.63e-10	1.46e-07	-0.3	-0.19	Obesity-related traits;	chr2:242097835	chr2:242087351~242088457:-
BRCA	cis	rs853679	0.517	rs9380056	ENSG00000219392.1	RP1-265C24.5	-6.19	8.65e-10	1.46e-07	-0.28	-0.19	Depression;	chr6:28136698	chr6:28115628~28116551:+
BRCA	cis	rs853679	0.517	rs9380057	ENSG00000219392.1	RP1-265C24.5	-6.19	8.65e-10	1.46e-07	-0.28	-0.19	Depression;	chr6:28136856	chr6:28115628~28116551:+
BRCA	cis	rs853679	0.517	rs6941992	ENSG00000219392.1	RP1-265C24.5	-6.19	8.65e-10	1.46e-07	-0.28	-0.19	Depression;	chr6:28138363	chr6:28115628~28116551:+
BRCA	cis	rs4713118	0.516	rs4713142	ENSG00000219392.1	RP1-265C24.5	-6.19	8.65e-10	1.46e-07	-0.28	-0.19	Parkinson's disease;	chr6:28138569	chr6:28115628~28116551:+
BRCA	cis	rs853679	0.517	rs4713143	ENSG00000219392.1	RP1-265C24.5	-6.19	8.65e-10	1.46e-07	-0.28	-0.19	Depression;	chr6:28138981	chr6:28115628~28116551:+
BRCA	cis	rs853679	0.517	rs4713144	ENSG00000219392.1	RP1-265C24.5	-6.19	8.65e-10	1.46e-07	-0.28	-0.19	Depression;	chr6:28139012	chr6:28115628~28116551:+
BRCA	cis	rs673078	0.607	rs7304342	ENSG00000275409.1	RP11-131L12.4	-6.19	8.65e-10	1.46e-07	-0.27	-0.19	Glucose homeostasis traits;	chr12:118390166	chr12:118430147~118430699:+
BRCA	cis	rs9311474	0.581	rs4687626	ENSG00000243224.1	RP5-1157M23.2	-6.19	8.65e-10	1.46e-07	-0.21	-0.19	Electroencephalogram traits;	chr3:52535082	chr3:52239258~52241097:+
BRCA	cis	rs11976180	1	rs7777389	ENSG00000273234.1	OR2A13P	-6.19	8.66e-10	1.46e-07	-0.26	-0.19	Obesity-related traits;	chr7:144047709	chr7:144142009~144142938:+
BRCA	cis	rs11976180	1	rs67239267	ENSG00000273234.1	OR2A13P	-6.19	8.66e-10	1.46e-07	-0.26	-0.19	Obesity-related traits;	chr7:144048023	chr7:144142009~144142938:+
BRCA	cis	rs516805	0.63	rs499825	ENSG00000279453.1	RP3-425C14.4	-6.19	8.66e-10	1.46e-07	-0.25	-0.19	Lymphocyte counts;	chr6:122454050	chr6:122436789~122439223:-
BRCA	cis	rs1555322	0.53	rs2425053	ENSG00000279253.1	RP4-614O4.13	-6.19	8.67e-10	1.46e-07	-0.25	-0.19	Attention deficit hyperactivity disorder;	chr20:35294017	chr20:35262727~35264187:-
BRCA	cis	rs910316	1	rs7156105	ENSG00000279594.1	RP11-950C14.10	6.19	8.68e-10	1.46e-07	0.21	0.19	Height;	chr14:75075251	chr14:75011269~75012851:-
BRCA	cis	rs853679	0.542	rs6934769	ENSG00000219392.1	RP1-265C24.5	-6.19	8.7e-10	1.47e-07	-0.28	-0.19	Depression;	chr6:28123153	chr6:28115628~28116551:+
BRCA	cis	rs853679	0.517	rs17711801	ENSG00000219392.1	RP1-265C24.5	-6.19	8.7e-10	1.47e-07	-0.28	-0.19	Depression;	chr6:28124529	chr6:28115628~28116551:+
BRCA	cis	rs4713118	0.527	rs9461433	ENSG00000219392.1	RP1-265C24.5	-6.19	8.7e-10	1.47e-07	-0.28	-0.19	Parkinson's disease;	chr6:28127394	chr6:28115628~28116551:+
BRCA	cis	rs853679	0.517	rs9468292	ENSG00000219392.1	RP1-265C24.5	-6.19	8.7e-10	1.47e-07	-0.28	-0.19	Depression;	chr6:28127577	chr6:28115628~28116551:+
BRCA	cis	rs17253792	0.915	rs78498383	ENSG00000186615.9	KTN1-AS1	-6.19	8.74e-10	1.47e-07	-0.38	-0.19	Putamen volume;	chr14:55710867	chr14:55499278~55580110:-
BRCA	cis	rs4950322	0.57	rs72691032	ENSG00000278811.3	LINC00624	6.19	8.74e-10	1.47e-07	0.26	0.19	Protein quantitative trait loci;	chr1:147261120	chr1:147258885~147517875:-
BRCA	cis	rs4950322	0.57	rs72691033	ENSG00000278811.3	LINC00624	6.19	8.74e-10	1.47e-07	0.26	0.19	Protein quantitative trait loci;	chr1:147261267	chr1:147258885~147517875:-
BRCA	cis	rs4713118	0.513	rs149962	ENSG00000216901.1	AL022393.7	6.19	8.74e-10	1.47e-07	0.25	0.19	Parkinson's disease;	chr6:28048140	chr6:28176188~28176674:+
BRCA	cis	rs172166	0.769	rs149965	ENSG00000216901.1	AL022393.7	6.19	8.74e-10	1.47e-07	0.25	0.19	Cardiac Troponin-T levels;	chr6:28050911	chr6:28176188~28176674:+
BRCA	cis	rs250585	0.736	rs465193	ENSG00000260136.4	CTD-2270L9.4	6.19	8.75e-10	1.48e-07	0.19	0.19	Egg allergy;	chr16:23585662	chr16:23452758~23457606:+
BRCA	cis	rs420259	0.516	rs801754	ENSG00000260136.4	CTD-2270L9.4	6.19	8.75e-10	1.48e-07	0.19	0.19	Bipolar disorder;	chr16:23586557	chr16:23452758~23457606:+
BRCA	cis	rs6479891	1	rs4746994	ENSG00000232075.1	MRPL35P2	6.19	8.76e-10	1.48e-07	0.34	0.19	Arthritis (juvenile idiopathic);	chr10:63145564	chr10:63634317~63634827:-
BRCA	cis	rs875971	0.545	rs35459055	ENSG00000273024.4	INTS4P2	-6.19	8.76e-10	1.48e-07	-0.23	-0.19	Aortic root size;	chr7:66479399	chr7:65647864~65715661:+
BRCA	cis	rs4907240	0.658	rs4907319	ENSG00000237510.6	AC008268.2	-6.19	8.76e-10	1.48e-07	-0.26	-0.19	Event-related brain oscillations;	chr2:96472788	chr2:95789654~95800166:+
BRCA	cis	rs8002861	0.619	rs9562516	ENSG00000274001.1	RP11-5G9.5	6.19	8.76e-10	1.48e-07	0.22	0.19	Leprosy;	chr13:43857602	chr13:43877715~43878163:-
BRCA	cis	rs7567389	0.535	rs4150416	ENSG00000236682.1	AC068282.3	6.19	8.77e-10	1.48e-07	0.26	0.19	Self-rated health;	chr2:127288972	chr2:127389130~127400580:+
BRCA	cis	rs6095360	0.727	rs8119476	ENSG00000222365.1	SNORD12B	-6.19	8.77e-10	1.48e-07	-0.24	-0.19	Intelligence (multi-trait analysis);	chr20:49073599	chr20:49280319~49280409:+
BRCA	cis	rs2933343	0.679	rs1091938	ENSG00000231305.3	RP11-723O4.2	6.19	8.77e-10	1.48e-07	0.21	0.19	IgG glycosylation;	chr3:128918182	chr3:128861313~128871540:-
BRCA	cis	rs228614	0.543	rs223330	ENSG00000251288.2	RP11-10L12.2	-6.19	8.78e-10	1.48e-07	-0.22	-0.19	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102872502	chr4:102751401~102752641:+
BRCA	cis	rs228614	0.51	rs223329	ENSG00000251288.2	RP11-10L12.2	-6.19	8.78e-10	1.48e-07	-0.22	-0.19	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102873031	chr4:102751401~102752641:+
BRCA	cis	rs853679	0.517	rs1947862	ENSG00000280107.1	AL022393.9	-6.19	8.78e-10	1.48e-07	-0.28	-0.19	Depression;	chr6:28137418	chr6:28170845~28172521:+
BRCA	cis	rs6569038	0.557	rs1342794	ENSG00000253194.1	RP11-351A11.1	6.19	8.78e-10	1.48e-07	0.24	0.19	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr6:119055182	chr6:118934785~119031541:+
BRCA	cis	rs7086627	0.515	rs1870147	ENSG00000226659.1	RP11-137H2.4	-6.19	8.78e-10	1.48e-07	-0.24	-0.19	Post bronchodilator FEV1;	chr10:80452785	chr10:80529597~80535942:-
BRCA	cis	rs1167827	0.71	rs1167836	ENSG00000165178.9	NCF1C	6.19	8.79e-10	1.48e-07	0.16	0.19	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75539580	chr7:75156639~75172044:-
BRCA	cis	rs2115630	0.967	rs7171167	ENSG00000229212.6	RP11-561C5.4	6.19	8.79e-10	1.48e-07	0.21	0.19	P wave terminal force;	chr15:84695892	chr15:85205440~85234795:-
BRCA	cis	rs2367970	0.57	rs7123583	ENSG00000254851.1	RP11-109L13.1	6.19	8.8e-10	1.48e-07	0.25	0.19	HDL cholesterol;	chr11:116729305	chr11:117135528~117138582:+
BRCA	cis	rs11671005	0.504	rs3794963	ENSG00000269600.1	AC016629.3	6.19	8.8e-10	1.48e-07	0.26	0.19	Mean platelet volume;	chr19:58559684	chr19:58593896~58599355:-
BRCA	cis	rs13113518	0.812	rs4864996	ENSG00000273257.1	RP11-177J6.1	6.19	8.81e-10	1.48e-07	0.24	0.19	Height;	chr4:55452921	chr4:55387949~55388271:+
BRCA	cis	rs1440410	0.798	rs13128884	ENSG00000250326.1	RP11-284M14.1	-6.19	8.81e-10	1.49e-07	-0.21	-0.19	Ischemic stroke;	chr4:143186669	chr4:142933195~143184861:-
BRCA	cis	rs2243480	1	rs313831	ENSG00000228409.4	CCT6P1	6.19	8.83e-10	1.49e-07	0.27	0.19	Diabetic kidney disease;	chr7:66086239	chr7:65751142~65763354:+
BRCA	cis	rs801193	0.66	rs2659897	ENSG00000224316.1	RP11-479O9.2	-6.19	8.83e-10	1.49e-07	-0.19	-0.19	Aortic root size;	chr7:66722728	chr7:65773620~65802067:+
BRCA	cis	rs9876781	1	rs6442118	ENSG00000229759.1	MRPS18AP1	6.19	8.83e-10	1.49e-07	0.21	0.19	Longevity;	chr3:48398582	chr3:48256350~48256938:-
BRCA	cis	rs7191700	0.644	rs12149160	ENSG00000262636.1	CTD-3088G3.4	-6.19	8.84e-10	1.49e-07	-0.25	-0.19	Multiple sclerosis;	chr16:11345446	chr16:11380859~11381118:-
BRCA	cis	rs853679	0.598	rs9380054	ENSG00000280107.1	AL022393.9	-6.19	8.85e-10	1.49e-07	-0.28	-0.19	Depression;	chr6:28099759	chr6:28170845~28172521:+
BRCA	cis	rs4713118	0.547	rs2116981	ENSG00000280107.1	AL022393.9	-6.19	8.85e-10	1.49e-07	-0.28	-0.19	Parkinson's disease;	chr6:28100173	chr6:28170845~28172521:+
BRCA	cis	rs853679	0.517	rs9368552	ENSG00000280107.1	AL022393.9	-6.19	8.85e-10	1.49e-07	-0.28	-0.19	Depression;	chr6:28100648	chr6:28170845~28172521:+
BRCA	cis	rs853679	0.542	rs34131763	ENSG00000280107.1	AL022393.9	-6.19	8.85e-10	1.49e-07	-0.28	-0.19	Depression;	chr6:28107222	chr6:28170845~28172521:+
BRCA	cis	rs13126694	0.679	rs4072170	ENSG00000248429.4	RP11-597D13.9	6.19	8.85e-10	1.49e-07	0.17	0.19	Blood osmolality (transformed sodium);	chr4:157980683	chr4:158170752~158202877:+
BRCA	cis	rs17301013	0.507	rs4652797	ENSG00000227373.4	RP11-160H22.5	6.19	8.85e-10	1.49e-07	0.29	0.19	Systemic lupus erythematosus;	chr1:174791236	chr1:174115300~174160004:-
BRCA	cis	rs2834288	0.535	rs9982605	ENSG00000273102.1	AP000569.9	6.19	8.86e-10	1.49e-07	0.21	0.19	Gut microbiota (bacterial taxa);	chr21:33961205	chr21:33967101~33968573:-
BRCA	cis	rs2153535	0.518	rs9505510	ENSG00000230939.1	RP11-314C16.1	-6.19	8.86e-10	1.49e-07	-0.23	-0.19	Motion sickness;	chr6:8657603	chr6:8784178~8785445:+
BRCA	cis	rs4700393	0.517	rs13158594	ENSG00000272308.1	RP11-231G3.1	6.19	8.88e-10	1.5e-07	0.25	0.19	Intelligence (multi-trait analysis);	chr5:60794183	chr5:60866457~60866935:-
BRCA	cis	rs2998286	0.723	rs332121	ENSG00000254635.4	WAC-AS1	-6.19	8.89e-10	1.5e-07	-0.27	-0.19	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28552285	chr10:28522652~28532743:-
BRCA	cis	rs2998286	0.572	rs332124	ENSG00000254635.4	WAC-AS1	-6.19	8.89e-10	1.5e-07	-0.27	-0.19	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28553545	chr10:28522652~28532743:-
BRCA	cis	rs875971	0.83	rs12673450	ENSG00000224316.1	RP11-479O9.2	6.19	8.89e-10	1.5e-07	0.2	0.19	Aortic root size;	chr7:66544233	chr7:65773620~65802067:+
BRCA	cis	rs330048	0.525	rs10112237	ENSG00000253893.2	FAM85B	6.19	8.9e-10	1.5e-07	0.23	0.19	Systemic lupus erythematosus;	chr8:9215219	chr8:8167819~8226614:-
BRCA	cis	rs34779708	0.897	rs4934716	ENSG00000271335.4	RP11-324I22.4	6.19	8.9e-10	1.5e-07	0.19	0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35080371	chr10:35314552~35336401:-
BRCA	cis	rs2243480	1	rs422164	ENSG00000232559.3	GS1-124K5.12	6.19	8.9e-10	1.5e-07	0.36	0.19	Diabetic kidney disease;	chr7:66121618	chr7:66554588~66576923:-
BRCA	cis	rs228614	0.51	rs223313	ENSG00000251288.2	RP11-10L12.2	-6.18	8.91e-10	1.5e-07	-0.22	-0.19	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102886563	chr4:102751401~102752641:+
BRCA	cis	rs17597773	0.635	rs1494368	ENSG00000272823.1	RP11-295M18.6	-6.18	8.92e-10	1.5e-07	-0.23	-0.19	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220830826	chr1:220828676~220829211:-
BRCA	cis	rs11668609	0.81	rs10407383	ENSG00000268442.1	CTD-2027I19.2	6.18	8.92e-10	1.5e-07	0.27	0.19	Response to taxane treatment (docetaxel);	chr19:24134099	chr19:24162370~24163425:-
BRCA	cis	rs2749097	0.825	rs2819176	ENSG00000244256.3	RN7SL130P	-6.18	8.92e-10	1.5e-07	-0.24	-0.19	Alcohol consumption (transferrin glycosylation);	chr1:63659159	chr1:63655743~63656047:+
BRCA	cis	rs6061231	0.724	rs1570027	ENSG00000275437.1	RP5-908M14.10	6.18	8.92e-10	1.5e-07	0.22	0.19	Colorectal cancer;	chr20:62393540	chr20:62402236~62405935:-
BRCA	cis	rs4948102	0.597	rs12669623	ENSG00000273720.1	RP11-613E4.4	-6.18	8.92e-10	1.5e-07	-0.23	-0.19	Plasma homocysteine levels (post-methionine load test);	chr7:56071486	chr7:55743073~55743457:+
BRCA	cis	rs2281636	0.754	rs7087826	ENSG00000233690.1	EBAG9P1	6.18	8.92e-10	1.5e-07	0.2	0.19	Obesity-related traits;	chr10:99604588	chr10:99697407~99697949:-
BRCA	cis	rs2179367	0.632	rs9498334	ENSG00000216906.2	RP11-350J20.9	6.18	8.93e-10	1.5e-07	0.27	0.19	Dupuytren's disease;	chr6:149370902	chr6:149904243~149906418:+
BRCA	cis	rs6583826	0.596	rs6583825	ENSG00000236493.2	EIF2S2P3	6.18	8.94e-10	1.5e-07	0.24	0.19	Type 2 diabetes;	chr10:92585470	chr10:92668745~92669743:-
BRCA	cis	rs600231	0.708	rs3132767	ENSG00000245532.5	NEAT1	6.18	8.94e-10	1.51e-07	0.17	0.19	Bone mineral density;	chr11:65467389	chr11:65422774~65445540:+
BRCA	cis	rs853679	0.517	rs36078605	ENSG00000280107.1	AL022393.9	-6.18	8.94e-10	1.51e-07	-0.28	-0.19	Depression;	chr6:28110254	chr6:28170845~28172521:+
BRCA	cis	rs2998286	0.723	rs332126	ENSG00000254635.4	WAC-AS1	-6.18	8.94e-10	1.51e-07	-0.27	-0.19	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28556866	chr10:28522652~28532743:-
BRCA	cis	rs2998286	0.723	rs332128	ENSG00000254635.4	WAC-AS1	-6.18	8.94e-10	1.51e-07	-0.27	-0.19	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28559399	chr10:28522652~28532743:-
BRCA	cis	rs72627509	0.638	rs78272732	ENSG00000269949.1	RP11-738E22.3	6.18	8.95e-10	1.51e-07	0.33	0.19	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:57004371	chr4:56960927~56961373:-
BRCA	cis	rs228614	0.51	rs223324	ENSG00000251288.2	RP11-10L12.2	-6.18	8.96e-10	1.51e-07	-0.22	-0.19	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102876177	chr4:102751401~102752641:+
BRCA	cis	rs853679	0.517	rs9295761	ENSG00000219392.1	RP1-265C24.5	-6.18	8.96e-10	1.51e-07	-0.29	-0.19	Depression;	chr6:28180209	chr6:28115628~28116551:+
BRCA	cis	rs875971	0.522	rs4718286	ENSG00000234585.5	CCT6P3	6.18	8.96e-10	1.51e-07	0.18	0.19	Aortic root size;	chr7:65827777	chr7:65038354~65074713:+
BRCA	cis	rs17711722	0.585	rs6942660	ENSG00000234585.5	CCT6P3	6.18	8.96e-10	1.51e-07	0.18	0.19	Calcium levels;	chr7:65837419	chr7:65038354~65074713:+
BRCA	cis	rs34779708	0.931	rs34375045	ENSG00000271335.4	RP11-324I22.4	6.18	8.97e-10	1.51e-07	0.2	0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35073428	chr10:35314552~35336401:-
BRCA	cis	rs867371	0.929	rs7176075	ENSG00000276710.3	CSPG4P8	-6.18	8.97e-10	1.51e-07	-0.2	-0.19	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82178998	chr15:82459472~82477258:+
BRCA	cis	rs8005677	1	rs8006409	ENSG00000257285.4	RP11-298I3.1	6.18	8.97e-10	1.51e-07	0.21	0.19	Cognitive ability (multi-trait analysis);	chr14:22927302	chr14:22929609~22955562:+
BRCA	cis	rs7247513	0.964	rs12979795	ENSG00000213290.4	PGK1P2	6.18	8.97e-10	1.51e-07	0.25	0.19	Bipolar disorder;	chr19:12607033	chr19:12559571~12561105:+
BRCA	cis	rs7044106	0.791	rs7043969	ENSG00000238181.2	AHCYP2	-6.18	8.98e-10	1.51e-07	-0.25	-0.19	Hip circumference adjusted for BMI;	chr9:120731711	chr9:120720673~120721972:+
BRCA	cis	rs1707322	1	rs4454479	ENSG00000281133.1	AL355480.3	-6.18	9e-10	1.51e-07	-0.24	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45957883	chr1:45580892~45580996:-
BRCA	cis	rs1823874	0.72	rs7162911	ENSG00000182397.13	DNM1P46	-6.18	9.01e-10	1.52e-07	-0.2	-0.19	IgG glycosylation;	chr15:99814845	chr15:99790156~99806927:-
BRCA	cis	rs11098499	0.954	rs3733520	ENSG00000249244.1	RP11-548H18.2	6.18	9.02e-10	1.52e-07	0.22	0.19	Corneal astigmatism;	chr4:119502325	chr4:119391831~119395335:-
BRCA	cis	rs690037	0.528	rs568833	ENSG00000272498.1	RP11-415F23.3	6.18	9.02e-10	1.52e-07	0.18	0.19	Optic nerve measurement (cup-to-disc ratio);Optic nerve measurement (cup area);	chr3:16326329	chr3:16339308~16339871:+
BRCA	cis	rs4683346	0.616	rs11922832	ENSG00000173811.9	CCDC13-AS1	-6.18	9.03e-10	1.52e-07	-0.25	-0.19	Granulocyte percentage of myeloid white cells;	chr3:42775829	chr3:42732575~42746768:+
BRCA	cis	rs13126694	0.778	rs7692254	ENSG00000248429.4	RP11-597D13.9	6.18	9.03e-10	1.52e-07	0.17	0.19	Blood osmolality (transformed sodium);	chr4:158134140	chr4:158170752~158202877:+
BRCA	cis	rs4713118	0.615	rs57252182	ENSG00000220721.1	OR1F12	6.18	9.03e-10	1.52e-07	0.22	0.19	Parkinson's disease;	chr6:27752470	chr6:28073316~28074233:+
BRCA	cis	rs7520050	0.966	rs785488	ENSG00000280836.1	AL355480.1	6.18	9.04e-10	1.52e-07	0.22	0.19	Reticulocyte count;Red blood cell count;	chr1:46110423	chr1:45581219~45581321:-
BRCA	cis	rs7520050	0.966	rs785489	ENSG00000280836.1	AL355480.1	6.18	9.04e-10	1.52e-07	0.22	0.19	Reticulocyte count;Red blood cell count;	chr1:46110718	chr1:45581219~45581321:-
BRCA	cis	rs6840360	0.582	rs2709827	ENSG00000270265.1	RP11-731D1.4	-6.18	9.05e-10	1.52e-07	-0.21	-0.19	Intelligence (multi-trait analysis);	chr4:151410100	chr4:151333775~151353224:-
BRCA	cis	rs11098499	0.954	rs28572238	ENSG00000249244.1	RP11-548H18.2	6.18	9.06e-10	1.52e-07	0.22	0.19	Corneal astigmatism;	chr4:119395531	chr4:119391831~119395335:-
BRCA	cis	rs2274273	1	rs8011834	ENSG00000258413.1	RP11-665C16.6	-6.18	9.06e-10	1.52e-07	-0.24	-0.19	Protein biomarker;	chr14:55159259	chr14:55262767~55272075:-
BRCA	cis	rs875971	0.545	rs7783889	ENSG00000273024.4	INTS4P2	-6.18	9.07e-10	1.53e-07	-0.24	-0.19	Aortic root size;	chr7:66283366	chr7:65647864~65715661:+
BRCA	cis	rs1552244	0.882	rs67631672	ENSG00000180385.7	EMC3-AS1	6.18	9.08e-10	1.53e-07	0.23	0.19	Alzheimer's disease;	chr3:9963084	chr3:9986893~10006990:+
BRCA	cis	rs3805389	1	rs3805389	ENSG00000249700.7	SRD5A3-AS1	-6.18	9.08e-10	1.53e-07	-0.27	-0.19	Waist-to-hip ratio adjusted for body mass index;	chr4:55616583	chr4:55363971~55395847:-
BRCA	cis	rs875971	0.54	rs736270	ENSG00000237310.1	GS1-124K5.4	6.18	9.08e-10	1.53e-07	0.2	0.19	Aortic root size;	chr7:65963835	chr7:66493706~66495474:+
BRCA	cis	rs13113518	0.729	rs11133377	ENSG00000223305.1	RN7SKP30	6.18	9.08e-10	1.53e-07	0.26	0.19	Height;	chr4:55413708	chr4:55540502~55540835:-
BRCA	cis	rs3805389	0.924	rs10029142	ENSG00000249700.7	SRD5A3-AS1	-6.18	9.08e-10	1.53e-07	-0.27	-0.19	Waist-to-hip ratio adjusted for body mass index;	chr4:55612967	chr4:55363971~55395847:-
BRCA	cis	rs7914558	0.966	rs10748836	ENSG00000213061.2	PFN1P11	6.18	9.09e-10	1.53e-07	0.25	0.19	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102934160	chr10:102838011~102845473:-
BRCA	cis	rs375066	0.623	rs1549954	ENSG00000267058.1	RP11-15A1.3	6.18	9.09e-10	1.53e-07	0.22	0.19	Breast cancer;	chr19:43844653	chr19:43891804~43901805:-
BRCA	cis	rs6061231	0.793	rs2427320	ENSG00000275437.1	RP5-908M14.10	6.18	9.09e-10	1.53e-07	0.22	0.19	Colorectal cancer;	chr20:62401667	chr20:62402236~62405935:-
BRCA	cis	rs853679	0.517	rs9393896	ENSG00000219392.1	RP1-265C24.5	-6.18	9.11e-10	1.53e-07	-0.29	-0.19	Depression;	chr6:28159925	chr6:28115628~28116551:+
BRCA	cis	rs853679	0.517	rs9393897	ENSG00000219392.1	RP1-265C24.5	-6.18	9.11e-10	1.53e-07	-0.29	-0.19	Depression;	chr6:28159932	chr6:28115628~28116551:+
BRCA	cis	rs2243480	1	rs313814	ENSG00000228409.4	CCT6P1	6.18	9.12e-10	1.53e-07	0.27	0.19	Diabetic kidney disease;	chr7:66038306	chr7:65751142~65763354:+
BRCA	cis	rs4700393	0.517	rs12523070	ENSG00000272308.1	RP11-231G3.1	6.18	9.12e-10	1.53e-07	0.25	0.19	Intelligence (multi-trait analysis);	chr5:60795496	chr5:60866457~60866935:-
BRCA	cis	rs1858037	0.867	rs4671660	ENSG00000204929.10	AC074391.1	6.18	9.12e-10	1.53e-07	0.25	0.19	Rheumatoid arthritis;	chr2:65349302	chr2:65436711~66084639:+
BRCA	cis	rs7520050	0.966	rs785491	ENSG00000280836.1	AL355480.1	6.18	9.13e-10	1.53e-07	0.22	0.19	Reticulocyte count;Red blood cell count;	chr1:46117746	chr1:45581219~45581321:-
BRCA	cis	rs4964805	0.559	rs1469999	ENSG00000257681.1	RP11-341G23.4	-6.18	9.13e-10	1.54e-07	-0.25	-0.19	Attention deficit hyperactivity disorder;	chr12:103814333	chr12:103746315~103768858:-
BRCA	cis	rs1395	0.744	rs11126936	ENSG00000234072.1	AC074117.10	6.18	9.14e-10	1.54e-07	0.2	0.19	Blood metabolite levels;	chr2:27260233	chr2:27356246~27367622:+
BRCA	cis	rs847577	0.722	rs6951277	ENSG00000272950.1	RP11-307C18.1	6.18	9.14e-10	1.54e-07	0.24	0.19	Breast cancer;	chr7:98082471	chr7:98322853~98323430:+
BRCA	cis	rs2243480	1	rs11538349	ENSG00000228409.4	CCT6P1	6.18	9.14e-10	1.54e-07	0.25	0.19	Diabetic kidney disease;	chr7:65956884	chr7:65751142~65763354:+
BRCA	cis	rs875971	0.83	rs778711	ENSG00000224316.1	RP11-479O9.2	6.18	9.15e-10	1.54e-07	0.19	0.19	Aortic root size;	chr7:66386670	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.862	rs1083554	ENSG00000224316.1	RP11-479O9.2	6.18	9.15e-10	1.54e-07	0.19	0.19	Aortic root size;	chr7:66387354	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.862	rs778707	ENSG00000224316.1	RP11-479O9.2	6.18	9.15e-10	1.54e-07	0.19	0.19	Aortic root size;	chr7:66392040	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.862	rs778705	ENSG00000224316.1	RP11-479O9.2	6.18	9.15e-10	1.54e-07	0.19	0.19	Aortic root size;	chr7:66396128	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.862	rs778697	ENSG00000224316.1	RP11-479O9.2	6.18	9.15e-10	1.54e-07	0.19	0.19	Aortic root size;	chr7:66405439	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.798	rs7789615	ENSG00000224316.1	RP11-479O9.2	6.18	9.15e-10	1.54e-07	0.19	0.19	Aortic root size;	chr7:66413674	chr7:65773620~65802067:+
BRCA	cis	rs7911264	0.739	rs7914814	ENSG00000236493.2	EIF2S2P3	6.18	9.15e-10	1.54e-07	0.25	0.19	Inflammatory bowel disease;	chr10:92623193	chr10:92668745~92669743:-
BRCA	cis	rs7809950	0.678	rs7803151	ENSG00000238832.1	snoU109	-6.18	9.15e-10	1.54e-07	-0.28	-0.19	Coronary artery disease;	chr7:107293801	chr7:107603363~107603507:+
BRCA	cis	rs67311347	0.544	rs2278927	ENSG00000280739.1	EIF1B-AS1	6.18	9.15e-10	1.54e-07	0.2	0.19	Renal cell carcinoma;	chr3:40308956	chr3:40173145~40309698:-
BRCA	cis	rs1707322	1	rs4073847	ENSG00000281133.1	AL355480.3	6.18	9.15e-10	1.54e-07	0.24	0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45997340	chr1:45580892~45580996:-
BRCA	cis	rs858239	0.508	rs2390754	ENSG00000230042.1	AK3P3	-6.18	9.15e-10	1.54e-07	-0.22	-0.19	Cerebrospinal fluid biomarker levels;	chr7:23150875	chr7:23129178~23129841:+
BRCA	cis	rs7914558	0.901	rs1926034	ENSG00000213061.2	PFN1P11	6.18	9.16e-10	1.54e-07	0.25	0.19	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103069345	chr10:102838011~102845473:-
BRCA	cis	rs2243480	1	rs316327	ENSG00000228409.4	CCT6P1	-6.18	9.17e-10	1.54e-07	-0.25	-0.19	Diabetic kidney disease;	chr7:66144214	chr7:65751142~65763354:+
BRCA	cis	rs10888838	1	rs6621	ENSG00000198711.5	SSBP3-AS1	6.18	9.17e-10	1.54e-07	0.25	0.19	Mitochondrial DNA levels;	chr1:54218252	chr1:54236440~54239063:+
BRCA	cis	rs228614	0.51	rs223349	ENSG00000251288.2	RP11-10L12.2	-6.18	9.18e-10	1.54e-07	-0.22	-0.19	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102857277	chr4:102751401~102752641:+
BRCA	cis	rs6504622	0.935	rs62075889	ENSG00000262879.4	RP11-156P1.3	-6.18	9.18e-10	1.54e-07	-0.19	-0.19	Orofacial clefts;	chr17:46950671	chr17:46984045~47100323:-
BRCA	cis	rs6504622	1	rs12940071	ENSG00000262879.4	RP11-156P1.3	-6.18	9.18e-10	1.54e-07	-0.19	-0.19	Orofacial clefts;	chr17:46950686	chr17:46984045~47100323:-
BRCA	cis	rs793571	0.518	rs12912327	ENSG00000259250.1	RP11-50C13.1	-6.18	9.19e-10	1.54e-07	-0.32	-0.19	Schizophrenia;	chr15:58693935	chr15:58587507~58591676:+
BRCA	cis	rs7615952	0.599	rs6766327	ENSG00000171084.14	FAM86JP	6.18	9.22e-10	1.55e-07	0.29	0.19	Blood pressure (smoking interaction);	chr3:126004834	chr3:125916620~125930024:+
BRCA	cis	rs6504622	0.934	rs3760377	ENSG00000262879.4	RP11-156P1.3	-6.18	9.22e-10	1.55e-07	-0.19	-0.19	Orofacial clefts;	chr17:46964713	chr17:46984045~47100323:-
BRCA	cis	rs7182621	0.639	rs12906068	ENSG00000182397.13	DNM1P46	6.18	9.22e-10	1.55e-07	0.23	0.19	Colonoscopy-negative controls vs population controls;	chr15:99873422	chr15:99790156~99806927:-
BRCA	cis	rs9308731	1	rs2015454	ENSG00000227992.1	AC108463.2	-6.18	9.23e-10	1.55e-07	-0.22	-0.19	Chronic lymphocytic leukemia;	chr2:111114571	chr2:111203964~111206215:-
BRCA	cis	rs853679	0.517	rs1947863	ENSG00000219392.1	RP1-265C24.5	-6.18	9.23e-10	1.55e-07	-0.28	-0.19	Depression;	chr6:28131566	chr6:28115628~28116551:+
BRCA	cis	rs2243480	1	rs10807701	ENSG00000232559.3	GS1-124K5.12	-6.18	9.25e-10	1.55e-07	-0.35	-0.19	Diabetic kidney disease;	chr7:66259699	chr7:66554588~66576923:-
BRCA	cis	rs11722779	0.903	rs6830193	ENSG00000251288.2	RP11-10L12.2	-6.18	9.25e-10	1.55e-07	-0.22	-0.19	Schizophrenia;	chr4:102955457	chr4:102751401~102752641:+
BRCA	cis	rs2115630	0.645	rs1107179	ENSG00000259728.4	LINC00933	6.18	9.26e-10	1.56e-07	0.22	0.19	P wave terminal force;	chr15:84655131	chr15:84570649~84580175:+
BRCA	cis	rs3805389	1	rs28564902	ENSG00000249700.7	SRD5A3-AS1	-6.18	9.27e-10	1.56e-07	-0.27	-0.19	Waist-to-hip ratio adjusted for body mass index;	chr4:55613324	chr4:55363971~55395847:-
BRCA	cis	rs2243480	1	rs402418	ENSG00000230295.1	RP11-458F8.2	-6.18	9.28e-10	1.56e-07	-0.25	-0.19	Diabetic kidney disease;	chr7:66044482	chr7:66880708~66882981:+
BRCA	cis	rs10028773	0.515	rs9994651	ENSG00000245958.5	RP11-33B1.1	-6.18	9.28e-10	1.56e-07	-0.18	-0.19	Educational attainment;	chr4:119666648	chr4:119454791~119552025:+
BRCA	cis	rs2832191	0.716	rs7509628	ENSG00000176054.6	RPL23P2	6.18	9.29e-10	1.56e-07	0.2	0.19	Dental caries;	chr21:29081931	chr21:28997613~28998033:-
BRCA	cis	rs6095360	0.727	rs7274221	ENSG00000222365.1	SNORD12B	-6.18	9.3e-10	1.56e-07	-0.24	-0.19	Intelligence (multi-trait analysis);	chr20:49006961	chr20:49280319~49280409:+
BRCA	cis	rs66887589	0.616	rs7659403	ENSG00000245958.5	RP11-33B1.1	-6.18	9.3e-10	1.56e-07	-0.17	-0.19	Diastolic blood pressure;	chr4:119286099	chr4:119454791~119552025:+
BRCA	cis	rs6142102	0.812	rs6059554	ENSG00000275784.1	RP5-1125A11.6	-6.18	9.31e-10	1.56e-07	-0.23	-0.19	Skin pigmentation;	chr20:33926286	chr20:33989480~33991818:-
BRCA	cis	rs301901	0.569	rs217846	ENSG00000250155.1	CTD-2353F22.1	6.18	9.31e-10	1.56e-07	0.21	0.19	Height;	chr5:37367180	chr5:36666214~36725195:-
BRCA	cis	rs7246657	0.943	rs713256	ENSG00000267422.1	CTD-2554C21.1	-6.18	9.31e-10	1.56e-07	-0.28	-0.19	Coronary artery calcification;	chr19:37374463	chr19:37779686~37792865:+
BRCA	cis	rs301901	0.698	rs4869505	ENSG00000250155.1	CTD-2353F22.1	6.18	9.31e-10	1.56e-07	0.21	0.19	Height;	chr5:37425888	chr5:36666214~36725195:-
BRCA	cis	rs1150668	0.796	rs728122	ENSG00000220721.1	OR1F12	6.18	9.31e-10	1.56e-07	0.21	0.19	Pubertal anthropometrics;	chr6:28431347	chr6:28073316~28074233:+
BRCA	cis	rs7520050	0.898	rs785502	ENSG00000280836.1	AL355480.1	6.18	9.32e-10	1.56e-07	0.22	0.19	Reticulocyte count;Red blood cell count;	chr1:46115772	chr1:45581219~45581321:-
BRCA	cis	rs13113518	0.812	rs2412648	ENSG00000273257.1	RP11-177J6.1	6.18	9.33e-10	1.57e-07	0.24	0.19	Height;	chr4:55454900	chr4:55387949~55388271:+
BRCA	cis	rs13113518	0.812	rs12512737	ENSG00000273257.1	RP11-177J6.1	6.18	9.33e-10	1.57e-07	0.24	0.19	Height;	chr4:55454938	chr4:55387949~55388271:+
BRCA	cis	rs13113518	0.812	rs13125984	ENSG00000273257.1	RP11-177J6.1	6.18	9.33e-10	1.57e-07	0.24	0.19	Height;	chr4:55455102	chr4:55387949~55388271:+
BRCA	cis	rs6504622	1	rs11079745	ENSG00000262879.4	RP11-156P1.3	-6.18	9.33e-10	1.57e-07	-0.19	-0.19	Orofacial clefts;	chr17:46966781	chr17:46984045~47100323:-
BRCA	cis	rs6088813	0.961	rs6088791	ENSG00000126005.14	MMP24-AS1	-6.18	9.33e-10	1.57e-07	-0.22	-0.19	Height;	chr20:35320106	chr20:35216462~35278131:-
BRCA	cis	rs10266483	0.545	rs114664455	ENSG00000271550.1	BNIP3P11	-6.18	9.34e-10	1.57e-07	-0.3	-0.19	Response to statin therapy;	chr7:64263634	chr7:64678954~64687393:-
BRCA	cis	rs2412819	0.597	rs7181912	ENSG00000205771.5	CATSPER2P1	6.18	9.35e-10	1.57e-07	0.27	0.19	Lung cancer;	chr15:43770676	chr15:43726918~43747094:-
BRCA	cis	rs875971	0.862	rs6978028	ENSG00000224316.1	RP11-479O9.2	6.18	9.35e-10	1.57e-07	0.19	0.19	Aortic root size;	chr7:66421313	chr7:65773620~65802067:+
BRCA	cis	rs8005677	0.962	rs8003934	ENSG00000257285.4	RP11-298I3.1	6.18	9.35e-10	1.57e-07	0.21	0.19	Cognitive ability (multi-trait analysis);	chr14:22931933	chr14:22929609~22955562:+
BRCA	cis	rs7520050	0.966	rs785503	ENSG00000280836.1	AL355480.1	6.18	9.35e-10	1.57e-07	0.22	0.19	Reticulocyte count;Red blood cell count;	chr1:46130196	chr1:45581219~45581321:-
BRCA	cis	rs10129255	0.957	rs10137980	ENSG00000211972.2	IGHV3-66	6.18	9.36e-10	1.57e-07	0.14	0.19	Kawasaki disease;	chr14:106775735	chr14:106675017~106675544:-
BRCA	cis	rs9813712	0.571	rs9855426	ENSG00000228252.7	COL6A4P2	6.18	9.37e-10	1.57e-07	0.22	0.19	Response to amphetamines;	chr3:130214475	chr3:130212823~130273806:+
BRCA	cis	rs2638953	0.888	rs1871152	ENSG00000278733.1	RP11-425D17.1	6.18	9.38e-10	1.57e-07	0.23	0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28226893	chr12:28185625~28186190:-
BRCA	cis	rs6570726	1	rs444564	ENSG00000235652.6	RP11-545I5.3	6.18	9.38e-10	1.58e-07	0.18	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145538659	chr6:145799409~145886585:+
BRCA	cis	rs1440410	0.866	rs13139457	ENSG00000250326.1	RP11-284M14.1	-6.18	9.39e-10	1.58e-07	-0.21	-0.19	Ischemic stroke;	chr4:143192647	chr4:142933195~143184861:-
BRCA	cis	rs9543976	1	rs73223968	ENSG00000261105.4	LMO7-AS1	-6.18	9.39e-10	1.58e-07	-0.33	-0.19	Diabetic retinopathy;	chr13:75567585	chr13:75604700~75635994:-
BRCA	cis	rs9543976	1	rs2296146	ENSG00000261105.4	LMO7-AS1	-6.18	9.39e-10	1.58e-07	-0.33	-0.19	Diabetic retinopathy;	chr13:75569436	chr13:75604700~75635994:-
BRCA	cis	rs11009175	1	rs12146170	ENSG00000273038.2	RP11-479G22.8	-6.18	9.4e-10	1.58e-07	-0.34	-0.19	Depression (quantitative trait);	chr10:33022104	chr10:32887255~32889311:-
BRCA	cis	rs2243480	1	rs4718317	ENSG00000229886.1	RP5-1132H15.3	-6.18	9.41e-10	1.58e-07	-0.32	-0.19	Diabetic kidney disease;	chr7:66183914	chr7:66025126~66031544:-
BRCA	cis	rs875971	1	rs6956179	ENSG00000224316.1	RP11-479O9.2	-6.18	9.42e-10	1.58e-07	-0.18	-0.19	Aortic root size;	chr7:66341672	chr7:65773620~65802067:+
BRCA	cis	rs2243480	0.803	rs423187	ENSG00000230295.1	RP11-458F8.2	-6.18	9.42e-10	1.58e-07	-0.26	-0.19	Diabetic kidney disease;	chr7:66044512	chr7:66880708~66882981:+
BRCA	cis	rs9992667	0.955	rs6855993	ENSG00000231160.8	KLF3-AS1	6.18	9.43e-10	1.58e-07	0.22	0.19	Eosinophil percentage of granulocytes;	chr4:38607291	chr4:38612701~38664883:-
BRCA	cis	rs2554380	0.628	rs4843158	ENSG00000230373.7	GOLGA6L5P	-6.18	9.44e-10	1.58e-07	-0.23	-0.19	Height;	chr15:83802884	chr15:84507885~84516814:-
BRCA	cis	rs6740322	0.793	rs13414908	ENSG00000234936.1	AC010883.5	6.18	9.44e-10	1.58e-07	0.21	0.19	Coronary artery disease;	chr2:43319519	chr2:43229573~43233394:+
BRCA	cis	rs4691139	1	rs12512283	ENSG00000248632.1	RP11-366M4.11	6.18	9.45e-10	1.59e-07	0.19	0.19	Ovarian cancer in BRCA1 mutation carriers;	chr4:164987775	chr4:164968587~164970002:-
BRCA	cis	rs4691139	1	rs9917978	ENSG00000248632.1	RP11-366M4.11	6.18	9.46e-10	1.59e-07	0.19	0.19	Ovarian cancer in BRCA1 mutation carriers;	chr4:164963991	chr4:164968587~164970002:-
BRCA	cis	rs10129255	0.518	rs7143784	ENSG00000274576.2	IGHV2-70	-6.18	9.46e-10	1.59e-07	-0.15	-0.19	Kawasaki disease;	chr14:106687277	chr14:106770577~106771020:-
BRCA	cis	rs13126694	0.682	rs9991381	ENSG00000248429.4	RP11-597D13.9	6.18	9.47e-10	1.59e-07	0.17	0.19	Blood osmolality (transformed sodium);	chr4:157982239	chr4:158170752~158202877:+
BRCA	cis	rs1322639	0.614	rs6908401	ENSG00000261039.2	RP11-417E7.2	6.18	9.47e-10	1.59e-07	0.23	0.19	Pulse pressure;	chr6:169164621	chr6:169175304~169182740:-
BRCA	cis	rs6570726	1	rs951143	ENSG00000235652.6	RP11-545I5.3	6.17	9.49e-10	1.59e-07	0.18	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145611440	chr6:145799409~145886585:+
BRCA	cis	rs11976180	1	rs2371244	ENSG00000273234.1	OR2A13P	-6.17	9.5e-10	1.59e-07	-0.25	-0.19	Obesity-related traits;	chr7:144060518	chr7:144142009~144142938:+
BRCA	cis	rs911555	0.755	rs2273702	ENSG00000244691.1	RPL10AP1	6.17	9.51e-10	1.6e-07	0.23	0.19	Intelligence (multi-trait analysis);	chr14:103451845	chr14:103412119~103412761:-
BRCA	cis	rs875971	0.545	rs12670811	ENSG00000273024.4	INTS4P2	-6.17	9.51e-10	1.6e-07	-0.23	-0.19	Aortic root size;	chr7:66358032	chr7:65647864~65715661:+
BRCA	cis	rs7621025	0.63	rs1681816	ENSG00000273486.1	RP11-731C17.2	-6.17	9.52e-10	1.6e-07	-0.23	-0.19	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136755920	chr3:136837338~136839021:-
BRCA	cis	rs853679	0.55	rs6901017	ENSG00000204709.4	LINC01556	6.17	9.52e-10	1.6e-07	0.27	0.19	Depression;	chr6:28184805	chr6:28943877~28944537:+
BRCA	cis	rs9467773	0.565	rs6925047	ENSG00000241549.7	GUSBP2	6.17	9.53e-10	1.6e-07	0.21	0.19	Intelligence (multi-trait analysis);	chr6:26521207	chr6:26871484~26956554:-
BRCA	cis	rs6442522	0.678	rs12494919	ENSG00000249786.6	EAF1-AS1	6.17	9.53e-10	1.6e-07	0.19	0.19	Uric acid levels;	chr3:15456765	chr3:15436171~15455940:-
BRCA	cis	rs13178541	0.745	rs9986164	ENSG00000250378.1	RP11-119J18.1	-6.17	9.54e-10	1.6e-07	-0.26	-0.19	IgG glycosylation;	chr5:135827074	chr5:135812667~135826582:+
BRCA	cis	rs13178541	0.81	rs9986268	ENSG00000250378.1	RP11-119J18.1	-6.17	9.54e-10	1.6e-07	-0.26	-0.19	IgG glycosylation;	chr5:135827124	chr5:135812667~135826582:+
BRCA	cis	rs7809950	0.678	rs62483641	ENSG00000238832.1	snoU109	-6.17	9.55e-10	1.6e-07	-0.28	-0.19	Coronary artery disease;	chr7:107261296	chr7:107603363~107603507:+
BRCA	cis	rs2638953	0.924	rs11049471	ENSG00000278733.1	RP11-425D17.1	-6.17	9.56e-10	1.6e-07	-0.24	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28228259	chr12:28185625~28186190:-
BRCA	cis	rs7520050	0.966	rs785494	ENSG00000280836.1	AL355480.1	6.17	9.56e-10	1.6e-07	0.22	0.19	Reticulocyte count;Red blood cell count;	chr1:46120954	chr1:45581219~45581321:-
BRCA	cis	rs1979679	0.842	rs7316299	ENSG00000278733.1	RP11-425D17.1	6.17	9.56e-10	1.6e-07	0.23	0.19	Ossification of the posterior longitudinal ligament of the spine;	chr12:28179757	chr12:28185625~28186190:-
BRCA	cis	rs4691139	1	rs9991678	ENSG00000248632.1	RP11-366M4.11	6.17	9.57e-10	1.6e-07	0.19	0.19	Ovarian cancer in BRCA1 mutation carriers;	chr4:164963887	chr4:164968587~164970002:-
BRCA	cis	rs2832191	0.716	rs1888440	ENSG00000176054.6	RPL23P2	6.17	9.57e-10	1.61e-07	0.2	0.19	Dental caries;	chr21:29082163	chr21:28997613~28998033:-
BRCA	cis	rs7086627	0.515	rs10887896	ENSG00000226659.1	RP11-137H2.4	-6.17	9.57e-10	1.61e-07	-0.24	-0.19	Post bronchodilator FEV1;	chr10:80450388	chr10:80529597~80535942:-
BRCA	cis	rs7086627	0.515	rs10887899	ENSG00000226659.1	RP11-137H2.4	-6.17	9.57e-10	1.61e-07	-0.24	-0.19	Post bronchodilator FEV1;	chr10:80450458	chr10:80529597~80535942:-
BRCA	cis	rs9307551	0.817	rs7667469	ENSG00000250334.4	LINC00989	-6.17	9.57e-10	1.61e-07	-0.26	-0.19	Refractive error;	chr4:79576538	chr4:79492416~79576460:+
BRCA	cis	rs6479891	1	rs10437345	ENSG00000232075.1	MRPL35P2	-6.17	9.58e-10	1.61e-07	-0.32	-0.19	Arthritis (juvenile idiopathic);	chr10:63443186	chr10:63634317~63634827:-
BRCA	cis	rs4886920	0.638	rs12912467	ENSG00000260776.4	RP11-114H24.2	6.17	9.58e-10	1.61e-07	0.23	0.19	Neuroticism;	chr15:77828111	chr15:77914217~77926846:-
BRCA	cis	rs13126694	0.744	rs10049927	ENSG00000248429.4	RP11-597D13.9	6.17	9.58e-10	1.61e-07	0.17	0.19	Blood osmolality (transformed sodium);	chr4:157998056	chr4:158170752~158202877:+
BRCA	cis	rs875971	0.862	rs2909688	ENSG00000224316.1	RP11-479O9.2	6.17	9.59e-10	1.61e-07	0.19	0.19	Aortic root size;	chr7:66376625	chr7:65773620~65802067:+
BRCA	cis	rs7474896	0.515	rs2738203	ENSG00000226578.1	RP11-258F22.1	6.17	9.59e-10	1.61e-07	0.26	0.19	Obesity (extreme);	chr10:37988668	chr10:37775371~37784131:-
BRCA	cis	rs467650	0.853	rs154205	ENSG00000248489.1	CTD-2007H13.3	6.17	9.6e-10	1.61e-07	0.21	0.19	Venous thromboembolism (SNP x SNP interaction);	chr5:98649598	chr5:98929171~98995013:+
BRCA	cis	rs1440410	0.835	rs11100771	ENSG00000250326.1	RP11-284M14.1	6.17	9.61e-10	1.61e-07	0.2	0.19	Ischemic stroke;	chr4:143132728	chr4:142933195~143184861:-
BRCA	cis	rs6728642	0.808	rs114192053	ENSG00000230606.9	AC159540.1	6.17	9.61e-10	1.61e-07	0.4	0.19	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:97206169	chr2:97416165~97433527:-
BRCA	cis	rs4713118	0.516	rs7739216	ENSG00000219392.1	RP1-265C24.5	-6.17	9.61e-10	1.61e-07	-0.28	-0.19	Parkinson's disease;	chr6:28112168	chr6:28115628~28116551:+
BRCA	cis	rs853679	0.517	rs35512245	ENSG00000219392.1	RP1-265C24.5	-6.17	9.61e-10	1.61e-07	-0.28	-0.19	Depression;	chr6:28112175	chr6:28115628~28116551:+
BRCA	cis	rs6095360	0.727	rs34841991	ENSG00000222365.1	SNORD12B	-6.17	9.61e-10	1.61e-07	-0.24	-0.19	Intelligence (multi-trait analysis);	chr20:49130437	chr20:49280319~49280409:+
BRCA	cis	rs651907	0.535	rs1460097	ENSG00000244119.1	PDCL3P4	6.17	9.61e-10	1.61e-07	0.15	0.19	Colorectal cancer;	chr3:101778725	chr3:101712472~101713191:+
BRCA	cis	rs9307551	1	rs13104009	ENSG00000250334.4	LINC00989	-6.17	9.61e-10	1.61e-07	-0.29	-0.19	Refractive error;	chr4:79609584	chr4:79492416~79576460:+
BRCA	cis	rs11790994	0.524	rs12352803	ENSG00000175611.10	LINC00476	6.17	9.63e-10	1.61e-07	0.27	0.19	Inattentive symptoms;	chr9:95721614	chr9:95759231~95875977:-
BRCA	cis	rs6688613	1	rs1327866	ENSG00000225171.2	DUTP6	6.17	9.64e-10	1.62e-07	0.22	0.19	Refractive astigmatism;	chr1:166983673	chr1:166868748~166869209:+
BRCA	cis	rs2243480	1	rs34970380	ENSG00000232546.1	RP11-458F8.1	-6.17	9.65e-10	1.62e-07	-0.25	-0.19	Diabetic kidney disease;	chr7:65966506	chr7:66848496~66858136:+
BRCA	cis	rs8103033	0.786	rs2270028	ENSG00000226025.8	LGALS17A	-6.17	9.66e-10	1.62e-07	-0.21	-0.19	Obesity-related traits;	chr19:39642185	chr19:39679374~39686373:+
BRCA	cis	rs8103033	0.786	rs2270029	ENSG00000226025.8	LGALS17A	-6.17	9.66e-10	1.62e-07	-0.21	-0.19	Obesity-related traits;	chr19:39642360	chr19:39679374~39686373:+
BRCA	cis	rs2243480	1	rs6964245	ENSG00000232559.3	GS1-124K5.12	-6.17	9.66e-10	1.62e-07	-0.35	-0.19	Diabetic kidney disease;	chr7:66253730	chr7:66554588~66576923:-
BRCA	cis	rs4763879	0.739	rs2114871	ENSG00000214776.8	RP11-726G1.1	-6.17	9.67e-10	1.62e-07	-0.21	-0.19	Type 1 diabetes;	chr12:9676842	chr12:9467552~9576275:+
BRCA	cis	rs1707322	1	rs1707322	ENSG00000281133.1	AL355480.3	-6.17	9.68e-10	1.62e-07	-0.23	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46039475	chr1:45580892~45580996:-
BRCA	cis	rs1823913	0.599	rs13001899	ENSG00000280083.1	RP11-317J9.1	-6.17	9.69e-10	1.62e-07	-0.22	-0.19	Obesity-related traits;	chr2:191285442	chr2:191154118~191156070:-
BRCA	cis	rs7911264	0.739	rs10786050	ENSG00000236493.2	EIF2S2P3	6.17	9.69e-10	1.62e-07	0.25	0.19	Inflammatory bowel disease;	chr10:92607473	chr10:92668745~92669743:-
BRCA	cis	rs2638953	0.924	rs11049468	ENSG00000278733.1	RP11-425D17.1	-6.17	9.71e-10	1.63e-07	-0.25	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28215684	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.924	rs11049469	ENSG00000278733.1	RP11-425D17.1	-6.17	9.71e-10	1.63e-07	-0.25	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28216729	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.886	rs11049470	ENSG00000278733.1	RP11-425D17.1	-6.17	9.71e-10	1.63e-07	-0.25	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28221449	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.924	rs10843140	ENSG00000278733.1	RP11-425D17.1	-6.17	9.71e-10	1.63e-07	-0.25	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28227273	chr12:28185625~28186190:-
BRCA	cis	rs250585	0.538	rs7186729	ENSG00000260136.4	CTD-2270L9.4	-6.17	9.71e-10	1.63e-07	-0.22	-0.19	Egg allergy;	chr16:23514773	chr16:23452758~23457606:+
BRCA	cis	rs2998286	0.723	rs332131	ENSG00000254635.4	WAC-AS1	-6.17	9.71e-10	1.63e-07	-0.27	-0.19	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28564933	chr10:28522652~28532743:-
BRCA	cis	rs7247513	0.79	rs17476839	ENSG00000230310.1	CTD-2192J16.11	6.17	9.72e-10	1.63e-07	0.24	0.19	Bipolar disorder;	chr19:12651969	chr19:12552597~12553644:+
BRCA	cis	rs10050311	0.698	rs10516778	ENSG00000251411.1	RP11-397E7.4	-6.17	9.72e-10	1.63e-07	-0.27	-0.19	Insulin-related traits;	chr4:86714898	chr4:86913266~86914817:-
BRCA	cis	rs10050311	0.698	rs17454154	ENSG00000251411.1	RP11-397E7.4	-6.17	9.72e-10	1.63e-07	-0.27	-0.19	Insulin-related traits;	chr4:86715007	chr4:86913266~86914817:-
BRCA	cis	rs10050311	0.698	rs78818211	ENSG00000251411.1	RP11-397E7.4	-6.17	9.72e-10	1.63e-07	-0.27	-0.19	Insulin-related traits;	chr4:86715235	chr4:86913266~86914817:-
BRCA	cis	rs2239547	0.563	rs4302374	ENSG00000242142.1	SERBP1P3	6.17	9.72e-10	1.63e-07	0.24	0.19	Schizophrenia;	chr3:52871786	chr3:53064283~53065091:-
BRCA	cis	rs67340775	0.541	rs169287	ENSG00000220721.1	OR1F12	6.17	9.73e-10	1.63e-07	0.28	0.19	Lung cancer in ever smokers;	chr6:27886982	chr6:28073316~28074233:+
BRCA	cis	rs7914558	0.966	rs10786727	ENSG00000213061.2	PFN1P11	6.17	9.73e-10	1.63e-07	0.25	0.19	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102938766	chr10:102838011~102845473:-
BRCA	cis	rs3764021	0.87	rs2192437	ENSG00000214776.8	RP11-726G1.1	6.17	9.75e-10	1.63e-07	0.2	0.19	Type 1 diabetes;	chr12:9726639	chr12:9467552~9576275:+
BRCA	cis	rs3764021	0.87	rs10844617	ENSG00000214776.8	RP11-726G1.1	6.17	9.75e-10	1.63e-07	0.2	0.19	Type 1 diabetes;	chr12:9726772	chr12:9467552~9576275:+
BRCA	cis	rs1707322	1	rs10890378	ENSG00000281133.1	AL355480.3	6.17	9.76e-10	1.63e-07	0.24	0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45944985	chr1:45580892~45580996:-
BRCA	cis	rs7809950	0.861	rs10264412	ENSG00000238832.1	snoU109	-6.17	9.76e-10	1.63e-07	-0.28	-0.19	Coronary artery disease;	chr7:107543432	chr7:107603363~107603507:+
BRCA	cis	rs9527	0.662	rs4919686	ENSG00000236937.2	PTGES3P4	6.17	9.76e-10	1.64e-07	0.28	0.19	Arsenic metabolism;	chr10:102832492	chr10:102845595~102845950:+
BRCA	cis	rs7923609	0.902	rs10733793	ENSG00000232075.1	MRPL35P2	-6.17	9.76e-10	1.64e-07	-0.23	-0.19	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63564049	chr10:63634317~63634827:-
BRCA	cis	rs754466	0.651	rs7895188	ENSG00000204049.1	RP11-126H7.4	-6.17	9.77e-10	1.64e-07	-0.22	-0.19	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77863620	chr10:77866875~77869610:+
BRCA	cis	rs10266483	0.576	rs2863327	ENSG00000271550.1	BNIP3P11	-6.17	9.77e-10	1.64e-07	-0.3	-0.19	Response to statin therapy;	chr7:64268698	chr7:64678954~64687393:-
BRCA	cis	rs4660456	0.572	rs10789191	ENSG00000237899.1	RP4-739H11.3	6.17	9.77e-10	1.64e-07	0.24	0.19	Platelet count;	chr1:40690819	chr1:40669089~40687588:-
BRCA	cis	rs7555523	0.778	rs2790052	ENSG00000224358.1	RP11-466F5.8	-6.17	9.78e-10	1.64e-07	-0.34	-0.19	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165769226	chr1:165768929~165775176:+
BRCA	cis	rs7914558	0.966	rs10883805	ENSG00000213061.2	PFN1P11	6.17	9.78e-10	1.64e-07	0.25	0.19	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102948494	chr10:102838011~102845473:-
BRCA	cis	rs7914558	0.933	rs10786729	ENSG00000213061.2	PFN1P11	6.17	9.78e-10	1.64e-07	0.25	0.19	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102959621	chr10:102838011~102845473:-
BRCA	cis	rs4718428	0.705	rs4717328	ENSG00000230295.1	RP11-458F8.2	-6.17	9.78e-10	1.64e-07	-0.17	-0.19	Corneal structure;	chr7:66887678	chr7:66880708~66882981:+
BRCA	cis	rs66887589	0.616	rs11098497	ENSG00000245958.5	RP11-33B1.1	-6.17	9.78e-10	1.64e-07	-0.17	-0.19	Diastolic blood pressure;	chr4:119265913	chr4:119454791~119552025:+
BRCA	cis	rs3733585	0.781	rs6449183	ENSG00000250413.1	RP11-448G15.1	6.17	9.8e-10	1.64e-07	0.24	0.19	Cleft plate (environmental tobacco smoke interaction);	chr4:9969067	chr4:10006482~10009725:+
BRCA	cis	rs13113518	0.783	rs1586555	ENSG00000223305.1	RN7SKP30	6.17	9.8e-10	1.64e-07	0.23	0.19	Height;	chr4:55587104	chr4:55540502~55540835:-
BRCA	cis	rs2115630	1	rs7183401	ENSG00000229212.6	RP11-561C5.4	6.17	9.81e-10	1.64e-07	0.2	0.19	P wave terminal force;	chr15:84828713	chr15:85205440~85234795:-
BRCA	cis	rs17301013	0.507	rs72717617	ENSG00000227373.4	RP11-160H22.5	6.17	9.83e-10	1.65e-07	0.29	0.19	Systemic lupus erythematosus;	chr1:174815514	chr1:174115300~174160004:-
BRCA	cis	rs4948102	0.642	rs766333	ENSG00000273720.1	RP11-613E4.4	-6.17	9.85e-10	1.65e-07	-0.23	-0.19	Plasma homocysteine levels (post-methionine load test);	chr7:56059011	chr7:55743073~55743457:+
BRCA	cis	rs2638953	0.924	rs7969582	ENSG00000278733.1	RP11-425D17.1	6.17	9.86e-10	1.65e-07	0.24	0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28236725	chr12:28185625~28186190:-
BRCA	cis	rs1707322	1	rs4660336	ENSG00000281133.1	AL355480.3	6.17	9.88e-10	1.65e-07	0.23	0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46022304	chr1:45580892~45580996:-
BRCA	cis	rs2153535	0.561	rs9328474	ENSG00000230939.1	RP11-314C16.1	-6.17	9.89e-10	1.66e-07	-0.22	-0.19	Motion sickness;	chr6:8506770	chr6:8784178~8785445:+
BRCA	cis	rs4664293	0.801	rs7607143	ENSG00000226266.5	AC009961.3	-6.17	9.89e-10	1.66e-07	-0.24	-0.19	Monocyte percentage of white cells;	chr2:159728250	chr2:159670708~159712435:-
BRCA	cis	rs4664293	0.833	rs10170336	ENSG00000226266.5	AC009961.3	-6.17	9.89e-10	1.66e-07	-0.24	-0.19	Monocyte percentage of white cells;	chr2:159732832	chr2:159670708~159712435:-
BRCA	cis	rs2638953	0.924	rs11049417	ENSG00000247934.4	RP11-967K21.1	-6.17	9.91e-10	1.66e-07	-0.24	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28192152	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.924	rs12372059	ENSG00000247934.4	RP11-967K21.1	-6.17	9.91e-10	1.66e-07	-0.24	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28192370	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.924	rs12372073	ENSG00000247934.4	RP11-967K21.1	-6.17	9.91e-10	1.66e-07	-0.24	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28192462	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.924	rs56318627	ENSG00000247934.4	RP11-967K21.1	-6.17	9.91e-10	1.66e-07	-0.24	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28192719	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.814	rs11049419	ENSG00000247934.4	RP11-967K21.1	-6.17	9.91e-10	1.66e-07	-0.24	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28192951	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.85	rs11049420	ENSG00000247934.4	RP11-967K21.1	-6.17	9.91e-10	1.66e-07	-0.24	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28193179	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.744	rs11049421	ENSG00000247934.4	RP11-967K21.1	-6.17	9.91e-10	1.66e-07	-0.24	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28193324	chr12:28163298~28190738:-
BRCA	cis	rs11722779	0.844	rs3974602	ENSG00000251288.2	RP11-10L12.2	-6.17	9.91e-10	1.66e-07	-0.22	-0.19	Schizophrenia;	chr4:102928840	chr4:102751401~102752641:+
BRCA	cis	rs2243480	1	rs778679	ENSG00000232559.3	GS1-124K5.12	6.17	9.91e-10	1.66e-07	0.36	0.19	Diabetic kidney disease;	chr7:66375924	chr7:66554588~66576923:-
BRCA	cis	rs7045881	0.674	rs78770866	ENSG00000254396.1	RP11-56F10.3	6.17	9.91e-10	1.66e-07	0.33	0.19	Schizophrenia;	chr9:27046470	chr9:27102630~27104728:+
BRCA	cis	rs2179367	0.632	rs11155642	ENSG00000216906.2	RP11-350J20.9	6.17	9.92e-10	1.66e-07	0.27	0.19	Dupuytren's disease;	chr6:149332984	chr6:149904243~149906418:+
BRCA	cis	rs919433	0.648	rs787975	ENSG00000231621.1	AC013264.2	-6.17	9.93e-10	1.66e-07	-0.18	-0.19	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197383404	chr2:197197991~197199273:+
BRCA	cis	rs2562456	0.92	rs2650784	ENSG00000268081.1	RP11-678G14.2	-6.17	9.94e-10	1.66e-07	-0.27	-0.19	Pain;	chr19:21483795	chr19:21554640~21569237:-
BRCA	cis	rs853679	0.517	rs4713146	ENSG00000219392.1	RP1-265C24.5	-6.17	9.94e-10	1.66e-07	-0.29	-0.19	Depression;	chr6:28143758	chr6:28115628~28116551:+
BRCA	cis	rs853679	0.517	rs9393894	ENSG00000219392.1	RP1-265C24.5	-6.17	9.94e-10	1.66e-07	-0.29	-0.19	Depression;	chr6:28144784	chr6:28115628~28116551:+
BRCA	cis	rs11098499	0.697	rs4560394	ENSG00000249244.1	RP11-548H18.2	6.17	9.94e-10	1.66e-07	0.22	0.19	Corneal astigmatism;	chr4:119392280	chr4:119391831~119395335:-
BRCA	cis	rs4713118	0.587	rs61471148	ENSG00000280107.1	AL022393.9	-6.17	9.95e-10	1.66e-07	-0.28	-0.19	Parkinson's disease;	chr6:28069254	chr6:28170845~28172521:+
BRCA	cis	rs9467773	0.525	rs1535274	ENSG00000241549.7	GUSBP2	6.17	9.95e-10	1.67e-07	0.21	0.19	Intelligence (multi-trait analysis);	chr6:26520519	chr6:26871484~26956554:-
BRCA	cis	rs2274273	0.967	rs2094102	ENSG00000258413.1	RP11-665C16.6	-6.17	9.95e-10	1.67e-07	-0.24	-0.19	Protein biomarker;	chr14:55124380	chr14:55262767~55272075:-
BRCA	cis	rs9880211	1	rs6805316	ENSG00000273486.1	RP11-731C17.2	6.17	9.96e-10	1.67e-07	0.24	0.19	Height;Body mass index;	chr3:136233270	chr3:136837338~136839021:-
BRCA	cis	rs10129255	0.957	rs11846893	ENSG00000211972.2	IGHV3-66	6.17	9.96e-10	1.67e-07	0.14	0.19	Kawasaki disease;	chr14:106779068	chr14:106675017~106675544:-
BRCA	cis	rs7809950	0.678	rs12670688	ENSG00000238832.1	snoU109	6.17	9.97e-10	1.67e-07	0.29	0.19	Coronary artery disease;	chr7:107180571	chr7:107603363~107603507:+
BRCA	cis	rs853679	0.607	rs67040724	ENSG00000220721.1	OR1F12	6.17	9.97e-10	1.67e-07	0.45	0.19	Depression;	chr6:27937731	chr6:28073316~28074233:+
BRCA	cis	rs11098499	0.739	rs9996382	ENSG00000248280.1	RP11-33B1.2	6.17	9.97e-10	1.67e-07	0.19	0.19	Corneal astigmatism;	chr4:119229857	chr4:119440561~119450157:-
BRCA	cis	rs13126694	0.71	rs6847800	ENSG00000248429.4	RP11-597D13.9	6.17	9.98e-10	1.67e-07	0.17	0.19	Blood osmolality (transformed sodium);	chr4:158011724	chr4:158170752~158202877:+
BRCA	cis	rs891378	1	rs7545125	ENSG00000274245.1	RP11-357P18.2	-6.17	9.99e-10	1.67e-07	-0.27	-0.19	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207251382	chr1:207372559~207373252:+
BRCA	cis	rs4691139	1	rs10517825	ENSG00000248632.1	RP11-366M4.11	-6.17	9.99e-10	1.67e-07	-0.19	-0.19	Ovarian cancer in BRCA1 mutation carriers;	chr4:164972334	chr4:164968587~164970002:-
BRCA	cis	rs4950322	0.515	rs17160050	ENSG00000278811.3	LINC00624	6.17	9.99e-10	1.67e-07	0.24	0.19	Protein quantitative trait loci;	chr1:147255558	chr1:147258885~147517875:-
BRCA	cis	rs875971	0.545	rs1796222	ENSG00000236529.1	RP13-254B10.1	-6.17	9.99e-10	1.67e-07	-0.24	-0.19	Aortic root size;	chr7:66592167	chr7:65840212~65840596:+
BRCA	cis	rs420259	0.516	rs11642395	ENSG00000260136.4	CTD-2270L9.4	-6.17	1e-09	1.67e-07	-0.19	-0.19	Bipolar disorder;	chr16:23545240	chr16:23452758~23457606:+
BRCA	cis	rs420259	0.516	rs2106454	ENSG00000260136.4	CTD-2270L9.4	-6.17	1e-09	1.67e-07	-0.19	-0.19	Bipolar disorder;	chr16:23549077	chr16:23452758~23457606:+
BRCA	cis	rs801193	0.66	rs974239	ENSG00000224316.1	RP11-479O9.2	6.17	1e-09	1.67e-07	0.19	0.19	Aortic root size;	chr7:66748504	chr7:65773620~65802067:+
BRCA	cis	rs4763879	0.729	rs10844472	ENSG00000256673.1	RP11-599J14.2	6.17	1e-09	1.68e-07	0.21	0.19	Type 1 diabetes;	chr12:9691137	chr12:9398355~9414851:-
BRCA	cis	rs2235642	0.928	rs2076435	ENSG00000280231.1	LA16c-380F5.3	-6.17	1e-09	1.68e-07	-0.24	-0.19	Coronary artery disease;	chr16:1557573	chr16:1553655~1554130:-
BRCA	cis	rs7555523	0.887	rs10800155	ENSG00000224358.1	RP11-466F5.8	-6.17	1e-09	1.68e-07	-0.31	-0.19	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165754533	chr1:165768929~165775176:+
BRCA	cis	rs250585	0.736	rs250583	ENSG00000260136.4	CTD-2270L9.4	-6.17	1e-09	1.68e-07	-0.18	-0.19	Egg allergy;	chr16:23392189	chr16:23452758~23457606:+
BRCA	cis	rs3731570	0.818	rs66730758	ENSG00000231621.1	AC013264.2	-6.17	1e-09	1.68e-07	-0.17	-0.19	Morning vs. evening chronotype;	chr2:197476277	chr2:197197991~197199273:+
BRCA	cis	rs55702914	0.628	rs11883902	ENSG00000231621.1	AC013264.2	-6.17	1e-09	1.68e-07	-0.17	-0.19	Major depression and alcohol dependence;	chr2:197476601	chr2:197197991~197199273:+
BRCA	cis	rs4763879	0.778	rs11052497	ENSG00000214776.8	RP11-726G1.1	-6.17	1e-09	1.68e-07	-0.21	-0.19	Type 1 diabetes;	chr12:9696679	chr12:9467552~9576275:+
BRCA	cis	rs6545883	1	rs6545883	ENSG00000271889.1	RP11-493E12.1	6.17	1e-09	1.68e-07	0.24	0.19	Tuberculosis;	chr2:61545122	chr2:61151433~61162105:-
BRCA	cis	rs516805	0.748	rs562616	ENSG00000279453.1	RP3-425C14.4	-6.17	1.01e-09	1.68e-07	-0.25	-0.19	Lymphocyte counts;	chr6:122467041	chr6:122436789~122439223:-
BRCA	cis	rs3126085	0.515	rs12032854	ENSG00000237975.5	FLG-AS1	6.16	1.01e-09	1.68e-07	0.25	0.19	Atopic dermatitis;	chr1:152374885	chr1:152168125~152445456:+
BRCA	cis	rs3126085	0.515	rs6668321	ENSG00000237975.5	FLG-AS1	6.16	1.01e-09	1.68e-07	0.24	0.19	Atopic dermatitis;	chr1:152381464	chr1:152168125~152445456:+
BRCA	cis	rs2098713	0.599	rs12152831	ENSG00000250155.1	CTD-2353F22.1	6.16	1.01e-09	1.68e-07	0.21	0.19	Telomere length;	chr5:37555215	chr5:36666214~36725195:-
BRCA	cis	rs11148252	0.846	rs4886077	ENSG00000278238.1	RP11-245D16.4	-6.16	1.01e-09	1.68e-07	-0.2	-0.19	Lewy body disease;	chr13:52424562	chr13:52454775~52455331:-
BRCA	cis	rs11148252	0.846	rs8001624	ENSG00000278238.1	RP11-245D16.4	-6.16	1.01e-09	1.68e-07	-0.2	-0.19	Lewy body disease;	chr13:52428860	chr13:52454775~52455331:-
BRCA	cis	rs2243480	0.901	rs34807232	ENSG00000232559.3	GS1-124K5.12	6.16	1.01e-09	1.68e-07	0.36	0.19	Diabetic kidney disease;	chr7:66500146	chr7:66554588~66576923:-
BRCA	cis	rs2243480	0.901	rs35823062	ENSG00000232559.3	GS1-124K5.12	6.16	1.01e-09	1.68e-07	0.36	0.19	Diabetic kidney disease;	chr7:66500834	chr7:66554588~66576923:-
BRCA	cis	rs2243480	1	rs7794661	ENSG00000229886.1	RP5-1132H15.3	6.16	1.01e-09	1.68e-07	0.32	0.19	Diabetic kidney disease;	chr7:65924743	chr7:66025126~66031544:-
BRCA	cis	rs853679	0.517	rs4713141	ENSG00000219392.1	RP1-265C24.5	-6.16	1.01e-09	1.69e-07	-0.28	-0.19	Depression;	chr6:28133900	chr6:28115628~28116551:+
BRCA	cis	rs2732480	0.5	rs7297824	ENSG00000257763.1	OR5BK1P	6.16	1.01e-09	1.69e-07	0.2	0.19	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48204867	chr12:48355792~48356614:-
BRCA	cis	rs7397814	0.558	rs4764447	ENSG00000260423.1	RP13-735L24.1	6.16	1.01e-09	1.69e-07	0.2	0.19	IgG glycosylation;	chr12:9426513	chr12:9367464~9397617:+
BRCA	cis	rs1707322	0.963	rs10890371	ENSG00000281133.1	AL355480.3	-6.16	1.01e-09	1.69e-07	-0.24	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45925225	chr1:45580892~45580996:-
BRCA	cis	rs1707322	1	rs10890372	ENSG00000281133.1	AL355480.3	-6.16	1.01e-09	1.69e-07	-0.24	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45925348	chr1:45580892~45580996:-
BRCA	cis	rs42648	0.564	rs11563564	ENSG00000225498.1	AC002064.5	6.16	1.01e-09	1.69e-07	0.18	0.19	Homocysteine levels;	chr7:90187387	chr7:90312496~90322592:+
BRCA	cis	rs11722779	0.935	rs6533046	ENSG00000251288.2	RP11-10L12.2	-6.16	1.01e-09	1.69e-07	-0.22	-0.19	Schizophrenia;	chr4:102965917	chr4:102751401~102752641:+
BRCA	cis	rs7520050	0.966	rs785492	ENSG00000280836.1	AL355480.1	6.16	1.01e-09	1.69e-07	0.22	0.19	Reticulocyte count;Red blood cell count;	chr1:46117935	chr1:45581219~45581321:-
BRCA	cis	rs7569084	0.687	rs12614851	ENSG00000237979.1	AC007389.1	6.16	1.01e-09	1.69e-07	0.24	0.19	Sum eosinophil basophil counts;	chr2:65458050	chr2:65500993~65502138:-
BRCA	cis	rs673078	0.615	rs61943397	ENSG00000275409.1	RP11-131L12.4	-6.16	1.01e-09	1.69e-07	-0.26	-0.19	Glucose homeostasis traits;	chr12:118390996	chr12:118430147~118430699:+
BRCA	cis	rs16958440	0.867	rs58061761	ENSG00000267800.1	RP11-49K24.5	-6.16	1.01e-09	1.69e-07	-0.45	-0.19	Sitting height ratio;	chr18:47159794	chr18:47137018~47137290:+
BRCA	cis	rs3813567	0.759	rs12595350	ENSG00000261143.1	ADAMTS7P3	-6.16	1.02e-09	1.7e-07	-0.32	-0.19	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78661122	chr15:77976042~77993057:+
BRCA	cis	rs9876781	1	rs6442119	ENSG00000229759.1	MRPS18AP1	6.16	1.02e-09	1.7e-07	0.21	0.19	Longevity;	chr3:48398713	chr3:48256350~48256938:-
BRCA	cis	rs4713118	0.629	rs203890	ENSG00000219392.1	RP1-265C24.5	-6.16	1.02e-09	1.7e-07	-0.28	-0.19	Parkinson's disease;	chr6:28054470	chr6:28115628~28116551:+
BRCA	cis	rs1876905	0.597	rs191631	ENSG00000271789.1	RP5-1112D6.7	-6.16	1.02e-09	1.7e-07	-0.28	-0.19	Mean corpuscular hemoglobin;	chr6:111226862	chr6:111297126~111298510:+
BRCA	cis	rs853679	0.542	rs6934769	ENSG00000280107.1	AL022393.9	-6.16	1.02e-09	1.7e-07	-0.28	-0.19	Depression;	chr6:28123153	chr6:28170845~28172521:+
BRCA	cis	rs853679	0.517	rs17711801	ENSG00000280107.1	AL022393.9	-6.16	1.02e-09	1.7e-07	-0.28	-0.19	Depression;	chr6:28124529	chr6:28170845~28172521:+
BRCA	cis	rs4713118	0.527	rs9461433	ENSG00000280107.1	AL022393.9	-6.16	1.02e-09	1.7e-07	-0.28	-0.19	Parkinson's disease;	chr6:28127394	chr6:28170845~28172521:+
BRCA	cis	rs853679	0.517	rs9468292	ENSG00000280107.1	AL022393.9	-6.16	1.02e-09	1.7e-07	-0.28	-0.19	Depression;	chr6:28127577	chr6:28170845~28172521:+
BRCA	cis	rs875971	1	rs12533997	ENSG00000224316.1	RP11-479O9.2	6.16	1.02e-09	1.7e-07	0.19	0.19	Aortic root size;	chr7:66500390	chr7:65773620~65802067:+
BRCA	cis	rs9287719	0.601	rs6751436	ENSG00000243819.4	RN7SL832P	6.16	1.02e-09	1.7e-07	0.19	0.19	Prostate cancer;	chr2:10583736	chr2:10690344~10692099:+
BRCA	cis	rs875971	0.862	rs13536	ENSG00000224316.1	RP11-479O9.2	-6.16	1.02e-09	1.7e-07	-0.19	-0.19	Aortic root size;	chr7:66554203	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.862	rs801209	ENSG00000224316.1	RP11-479O9.2	-6.16	1.02e-09	1.7e-07	-0.19	-0.19	Aortic root size;	chr7:66554403	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.862	rs801206	ENSG00000224316.1	RP11-479O9.2	-6.16	1.02e-09	1.7e-07	-0.19	-0.19	Aortic root size;	chr7:66556979	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.862	rs801204	ENSG00000224316.1	RP11-479O9.2	-6.16	1.02e-09	1.7e-07	-0.19	-0.19	Aortic root size;	chr7:66557934	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.862	rs801203	ENSG00000224316.1	RP11-479O9.2	-6.16	1.02e-09	1.7e-07	-0.19	-0.19	Aortic root size;	chr7:66558025	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.862	rs13232191	ENSG00000224316.1	RP11-479O9.2	6.16	1.02e-09	1.7e-07	0.19	0.19	Aortic root size;	chr7:66521661	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.862	rs10950043	ENSG00000224316.1	RP11-479O9.2	6.16	1.02e-09	1.7e-07	0.19	0.19	Aortic root size;	chr7:66523623	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.862	rs17747530	ENSG00000224316.1	RP11-479O9.2	6.16	1.02e-09	1.7e-07	0.19	0.19	Aortic root size;	chr7:66529742	chr7:65773620~65802067:+
BRCA	cis	rs651907	0.557	rs34624546	ENSG00000244119.1	PDCL3P4	6.16	1.02e-09	1.71e-07	0.15	0.19	Colorectal cancer;	chr3:101655382	chr3:101712472~101713191:+
BRCA	cis	rs2489715	0.951	rs2489703	ENSG00000185904.10	LINC00839	-6.16	1.02e-09	1.71e-07	-0.27	-0.19	Helix rolling;	chr10:42397264	chr10:42475543~42495336:+
BRCA	cis	rs853679	0.55	rs1233701	ENSG00000204709.4	LINC01556	-6.16	1.02e-09	1.71e-07	-0.26	-0.19	Depression;	chr6:28200948	chr6:28943877~28944537:+
BRCA	cis	rs897984	0.806	rs12924903	ENSG00000260911.2	RP11-196G11.2	6.16	1.02e-09	1.71e-07	0.17	0.19	Dementia with Lewy bodies;	chr16:30917649	chr16:31043150~31049868:+
BRCA	cis	rs875971	1	rs6957199	ENSG00000224316.1	RP11-479O9.2	6.16	1.02e-09	1.71e-07	0.19	0.19	Aortic root size;	chr7:66513532	chr7:65773620~65802067:+
BRCA	cis	rs160451	1	rs160448	ENSG00000251136.7	RP11-37B2.1	6.16	1.02e-09	1.71e-07	0.18	0.19	Leprosy;	chr8:89647622	chr8:89609409~89757727:-
BRCA	cis	rs7914558	0.966	rs7096269	ENSG00000213061.2	PFN1P11	6.16	1.02e-09	1.71e-07	0.24	0.19	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102976964	chr10:102838011~102845473:-
BRCA	cis	rs1440410	0.835	rs28649839	ENSG00000250326.1	RP11-284M14.1	-6.16	1.03e-09	1.71e-07	-0.21	-0.19	Ischemic stroke;	chr4:143225047	chr4:142933195~143184861:-
BRCA	cis	rs1707322	0.963	rs11211202	ENSG00000281133.1	AL355480.3	-6.16	1.03e-09	1.72e-07	-0.23	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45826710	chr1:45580892~45580996:-
BRCA	cis	rs8002861	0.664	rs9533686	ENSG00000274001.1	RP11-5G9.5	6.16	1.03e-09	1.72e-07	0.22	0.19	Leprosy;	chr13:43894358	chr13:43877715~43878163:-
BRCA	cis	rs2836950	0.565	rs7279497	ENSG00000238141.2	BRWD1-AS1	6.16	1.03e-09	1.72e-07	0.21	0.19	Menarche (age at onset);	chr21:39159380	chr21:39315707~39323218:+
BRCA	cis	rs516805	0.706	rs541551	ENSG00000279453.1	RP3-425C14.4	-6.16	1.03e-09	1.72e-07	-0.25	-0.19	Lymphocyte counts;	chr6:122462736	chr6:122436789~122439223:-
BRCA	cis	rs17301013	0.507	rs72715240	ENSG00000227373.4	RP11-160H22.5	6.16	1.03e-09	1.72e-07	0.29	0.19	Systemic lupus erythematosus;	chr1:174560838	chr1:174115300~174160004:-
BRCA	cis	rs853679	0.517	rs9393891	ENSG00000219392.1	RP1-265C24.5	-6.16	1.03e-09	1.72e-07	-0.28	-0.19	Depression;	chr6:28111382	chr6:28115628~28116551:+
BRCA	cis	rs853679	0.517	rs9468286	ENSG00000219392.1	RP1-265C24.5	-6.16	1.03e-09	1.72e-07	-0.28	-0.19	Depression;	chr6:28111650	chr6:28115628~28116551:+
BRCA	cis	rs853679	0.517	rs9380055	ENSG00000219392.1	RP1-265C24.5	-6.16	1.03e-09	1.72e-07	-0.28	-0.19	Depression;	chr6:28113851	chr6:28115628~28116551:+
BRCA	cis	rs853679	0.517	rs9368553	ENSG00000219392.1	RP1-265C24.5	-6.16	1.03e-09	1.72e-07	-0.28	-0.19	Depression;	chr6:28114487	chr6:28115628~28116551:+
BRCA	cis	rs853679	0.517	rs9368554	ENSG00000219392.1	RP1-265C24.5	-6.16	1.03e-09	1.72e-07	-0.28	-0.19	Depression;	chr6:28114933	chr6:28115628~28116551:+
BRCA	cis	rs853679	0.517	rs4713137	ENSG00000219392.1	RP1-265C24.5	-6.16	1.03e-09	1.72e-07	-0.28	-0.19	Depression;	chr6:28115743	chr6:28115628~28116551:+
BRCA	cis	rs853679	0.517	rs9348793	ENSG00000219392.1	RP1-265C24.5	-6.16	1.03e-09	1.72e-07	-0.28	-0.19	Depression;	chr6:28116411	chr6:28115628~28116551:+
BRCA	cis	rs4713118	0.586	rs6905516	ENSG00000219392.1	RP1-265C24.5	-6.16	1.03e-09	1.72e-07	-0.28	-0.19	Parkinson's disease;	chr6:28118700	chr6:28115628~28116551:+
BRCA	cis	rs4713118	0.586	rs6905522	ENSG00000219392.1	RP1-265C24.5	-6.16	1.03e-09	1.72e-07	-0.28	-0.19	Parkinson's disease;	chr6:28118701	chr6:28115628~28116551:+
BRCA	cis	rs4713118	0.586	rs9468290	ENSG00000219392.1	RP1-265C24.5	-6.16	1.03e-09	1.72e-07	-0.28	-0.19	Parkinson's disease;	chr6:28119896	chr6:28115628~28116551:+
BRCA	cis	rs6570726	0.935	rs430561	ENSG00000235652.6	RP11-545I5.3	6.16	1.03e-09	1.72e-07	0.18	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145492004	chr6:145799409~145886585:+
BRCA	cis	rs8054556	0.787	rs12444108	ENSG00000273724.1	RP11-347C12.12	-6.16	1.03e-09	1.72e-07	-0.21	-0.19	Autism spectrum disorder or schizophrenia;	chr16:30016373	chr16:30336400~30343336:+
BRCA	cis	rs7255436	0.965	rs11666233	ENSG00000269386.4	RAB11B-AS1	6.16	1.03e-09	1.72e-07	0.2	0.19	HDL cholesterol;	chr19:8387161	chr19:8374373~8390685:-
BRCA	cis	rs8031584	0.541	rs2959037	ENSG00000260382.1	RP11-540B6.2	-6.16	1.03e-09	1.73e-07	-0.21	-0.19	Huntington's disease progression;	chr15:30925961	chr15:30882267~30883231:-
BRCA	cis	rs4691139	1	rs6821283	ENSG00000248632.1	RP11-366M4.11	6.16	1.03e-09	1.73e-07	0.19	0.19	Ovarian cancer in BRCA1 mutation carriers;	chr4:164980493	chr4:164968587~164970002:-
BRCA	cis	rs7045881	0.674	rs62542704	ENSG00000254396.1	RP11-56F10.3	6.16	1.03e-09	1.73e-07	0.33	0.19	Schizophrenia;	chr9:27047243	chr9:27102630~27104728:+
BRCA	cis	rs875971	0.862	rs2024192	ENSG00000224316.1	RP11-479O9.2	-6.16	1.03e-09	1.73e-07	-0.19	-0.19	Aortic root size;	chr7:66576460	chr7:65773620~65802067:+
BRCA	cis	rs1440410	0.798	rs10001113	ENSG00000250326.1	RP11-284M14.1	-6.16	1.03e-09	1.73e-07	-0.21	-0.19	Ischemic stroke;	chr4:143215252	chr4:142933195~143184861:-
BRCA	cis	rs78456975	1	rs13414537	ENSG00000231482.2	AC141930.2	-6.16	1.03e-09	1.73e-07	-0.28	-0.19	Placebo response in major depressive disorder (% change in symptom score);	chr2:1552558	chr2:1572554~1580311:-
BRCA	cis	rs17301013	0.507	rs4652512	ENSG00000227373.4	RP11-160H22.5	6.16	1.03e-09	1.73e-07	0.29	0.19	Systemic lupus erythematosus;	chr1:174515519	chr1:174115300~174160004:-
BRCA	cis	rs17301013	0.507	rs57512497	ENSG00000227373.4	RP11-160H22.5	6.16	1.03e-09	1.73e-07	0.29	0.19	Systemic lupus erythematosus;	chr1:174518346	chr1:174115300~174160004:-
BRCA	cis	rs7567389	0.677	rs72846002	ENSG00000236682.1	AC068282.3	-6.16	1.03e-09	1.73e-07	-0.28	-0.19	Self-rated health;	chr2:127360571	chr2:127389130~127400580:+
BRCA	cis	rs875971	0.545	rs1796217	ENSG00000273024.4	INTS4P2	6.16	1.03e-09	1.73e-07	0.23	0.19	Aortic root size;	chr7:66620931	chr7:65647864~65715661:+
BRCA	cis	rs1555322	0.872	rs2425046	ENSG00000279253.1	RP4-614O4.13	-6.16	1.04e-09	1.73e-07	-0.32	-0.19	Attention deficit hyperactivity disorder;	chr20:35283858	chr20:35262727~35264187:-
BRCA	cis	rs2179367	0.632	rs12211357	ENSG00000216906.2	RP11-350J20.9	6.16	1.04e-09	1.73e-07	0.27	0.19	Dupuytren's disease;	chr6:149331148	chr6:149904243~149906418:+
BRCA	cis	rs2836950	0.52	rs59916147	ENSG00000238141.2	BRWD1-AS1	-6.16	1.04e-09	1.73e-07	-0.21	-0.19	Menarche (age at onset);	chr21:39262776	chr21:39315707~39323218:+
BRCA	cis	rs42648	0.564	rs10270950	ENSG00000225498.1	AC002064.5	6.16	1.04e-09	1.73e-07	0.18	0.19	Homocysteine levels;	chr7:90177982	chr7:90312496~90322592:+
BRCA	cis	rs9876781	1	rs725310	ENSG00000229759.1	MRPS18AP1	-6.16	1.04e-09	1.73e-07	-0.2	-0.19	Longevity;	chr3:48377081	chr3:48256350~48256938:-
BRCA	cis	rs2243480	1	rs67536397	ENSG00000232559.3	GS1-124K5.12	6.16	1.04e-09	1.73e-07	0.36	0.19	Diabetic kidney disease;	chr7:66482930	chr7:66554588~66576923:-
BRCA	cis	rs2243480	1	rs58669269	ENSG00000232559.3	GS1-124K5.12	6.16	1.04e-09	1.73e-07	0.36	0.19	Diabetic kidney disease;	chr7:66486966	chr7:66554588~66576923:-
BRCA	cis	rs1223397	0.938	rs3817741	ENSG00000215022.6	RP1-257A7.4	6.16	1.04e-09	1.73e-07	0.25	0.19	Blood pressure;	chr6:13279275	chr6:13264861~13295586:-
BRCA	cis	rs853679	0.517	rs12332979	ENSG00000219392.1	RP1-265C24.5	-6.16	1.04e-09	1.74e-07	-0.29	-0.19	Depression;	chr6:28173770	chr6:28115628~28116551:+
BRCA	cis	rs853679	0.517	rs67878650	ENSG00000219392.1	RP1-265C24.5	-6.16	1.04e-09	1.74e-07	-0.29	-0.19	Depression;	chr6:28174809	chr6:28115628~28116551:+
BRCA	cis	rs853679	0.569	rs9348798	ENSG00000219392.1	RP1-265C24.5	-6.16	1.04e-09	1.74e-07	-0.29	-0.19	Depression;	chr6:28175233	chr6:28115628~28116551:+
BRCA	cis	rs853679	0.517	rs9380065	ENSG00000219392.1	RP1-265C24.5	-6.16	1.04e-09	1.74e-07	-0.29	-0.19	Depression;	chr6:28176973	chr6:28115628~28116551:+
BRCA	cis	rs17253792	0.732	rs8017891	ENSG00000186615.9	KTN1-AS1	6.16	1.04e-09	1.74e-07	0.33	0.19	Putamen volume;	chr14:55706249	chr14:55499278~55580110:-
BRCA	cis	rs6840258	1	rs56201818	ENSG00000251411.1	RP11-397E7.4	-6.16	1.04e-09	1.74e-07	-0.25	-0.19	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87031481	chr4:86913266~86914817:-
BRCA	cis	rs1858037	0.867	rs953312	ENSG00000204929.10	AC074391.1	6.16	1.04e-09	1.74e-07	0.25	0.19	Rheumatoid arthritis;	chr2:65340556	chr2:65436711~66084639:+
BRCA	cis	rs1858037	0.867	rs9789444	ENSG00000204929.10	AC074391.1	6.16	1.04e-09	1.74e-07	0.25	0.19	Rheumatoid arthritis;	chr2:65342093	chr2:65436711~66084639:+
BRCA	cis	rs4072705	1	rs4524900	ENSG00000224020.1	MIR181A2HG	-6.16	1.04e-09	1.74e-07	-0.21	-0.19	Menarche (age at onset);	chr9:124580930	chr9:124658467~124698631:+
BRCA	cis	rs2980439	0.818	rs2948294	ENSG00000254153.1	CTA-398F10.2	6.16	1.04e-09	1.74e-07	0.24	0.19	Neuroticism;	chr8:8237439	chr8:8456909~8461337:-
BRCA	cis	rs11098499	1	rs13116504	ENSG00000249244.1	RP11-548H18.2	6.16	1.04e-09	1.74e-07	0.22	0.19	Corneal astigmatism;	chr4:119288257	chr4:119391831~119395335:-
BRCA	cis	rs7746199	0.736	rs13210634	ENSG00000220721.1	OR1F12	6.16	1.04e-09	1.74e-07	0.44	0.19	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27678713	chr6:28073316~28074233:+
BRCA	cis	rs7746199	0.736	rs13215275	ENSG00000220721.1	OR1F12	6.16	1.04e-09	1.74e-07	0.44	0.19	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27679730	chr6:28073316~28074233:+
BRCA	cis	rs7746199	0.736	rs17749927	ENSG00000220721.1	OR1F12	6.16	1.04e-09	1.74e-07	0.44	0.19	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27702197	chr6:28073316~28074233:+
BRCA	cis	rs651907	0.535	rs13059470	ENSG00000244119.1	PDCL3P4	-6.16	1.04e-09	1.74e-07	-0.15	-0.19	Colorectal cancer;	chr3:101705956	chr3:101712472~101713191:+
BRCA	cis	rs2836950	0.545	rs2836940	ENSG00000238141.2	BRWD1-AS1	-6.16	1.05e-09	1.74e-07	-0.21	-0.19	Menarche (age at onset);	chr21:39216770	chr21:39315707~39323218:+
BRCA	cis	rs1707322	1	rs10890365	ENSG00000281133.1	AL355480.3	-6.16	1.05e-09	1.75e-07	-0.24	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45893676	chr1:45580892~45580996:-
BRCA	cis	rs1552244	1	rs35198334	ENSG00000180385.7	EMC3-AS1	6.16	1.05e-09	1.75e-07	0.24	0.19	Alzheimer's disease;	chr3:10062869	chr3:9986893~10006990:+
BRCA	cis	rs2179367	0.632	rs2143075	ENSG00000216906.2	RP11-350J20.9	6.16	1.05e-09	1.75e-07	0.27	0.19	Dupuytren's disease;	chr6:149425507	chr6:149904243~149906418:+
BRCA	cis	rs3805389	1	rs10026676	ENSG00000249700.7	SRD5A3-AS1	-6.16	1.05e-09	1.75e-07	-0.27	-0.19	Waist-to-hip ratio adjusted for body mass index;	chr4:55612585	chr4:55363971~55395847:-
BRCA	cis	rs3814244	0.966	rs10784666	ENSG00000236946.2	HNRNPA1P70	6.16	1.05e-09	1.75e-07	0.15	0.19	Itch intensity from mosquito bite adjusted by bite size;	chr12:68021923	chr12:68035767~68036853:+
BRCA	cis	rs3814244	0.966	rs10784667	ENSG00000236946.2	HNRNPA1P70	6.16	1.05e-09	1.75e-07	0.15	0.19	Itch intensity from mosquito bite adjusted by bite size;	chr12:68021996	chr12:68035767~68036853:+
BRCA	cis	rs2998286	0.723	rs332151	ENSG00000254635.4	WAC-AS1	-6.16	1.05e-09	1.75e-07	-0.27	-0.19	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28585331	chr10:28522652~28532743:-
BRCA	cis	rs6840258	1	rs72667765	ENSG00000251411.1	RP11-397E7.4	-6.16	1.05e-09	1.75e-07	-0.25	-0.19	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87044790	chr4:86913266~86914817:-
BRCA	cis	rs11024102	0.925	rs7123383	ENSG00000184669.7	OR7E14P	-6.16	1.05e-09	1.75e-07	-0.29	-0.19	Glaucoma (primary angle closure);	chr11:16981438	chr11:17013998~17053024:+
BRCA	cis	rs73222236	0.787	rs6783337	ENSG00000273486.1	RP11-731C17.2	6.16	1.05e-09	1.75e-07	0.22	0.19	Coronary artery disease;	chr3:136333895	chr3:136837338~136839021:-
BRCA	cis	rs13178541	0.81	rs878068	ENSG00000250378.1	RP11-119J18.1	6.16	1.05e-09	1.75e-07	0.26	0.19	IgG glycosylation;	chr5:135826667	chr5:135812667~135826582:+
BRCA	cis	rs2243480	1	rs2707844	ENSG00000232559.3	GS1-124K5.12	6.16	1.05e-09	1.75e-07	0.36	0.19	Diabetic kidney disease;	chr7:66594522	chr7:66554588~66576923:-
BRCA	cis	rs2243480	1	rs1796220	ENSG00000232559.3	GS1-124K5.12	6.16	1.05e-09	1.75e-07	0.36	0.19	Diabetic kidney disease;	chr7:66597113	chr7:66554588~66576923:-
BRCA	cis	rs2243480	1	rs2707831	ENSG00000232559.3	GS1-124K5.12	6.16	1.05e-09	1.75e-07	0.36	0.19	Diabetic kidney disease;	chr7:66597524	chr7:66554588~66576923:-
BRCA	cis	rs783540	0.656	rs783524	ENSG00000278603.1	RP13-608F4.5	-6.16	1.05e-09	1.75e-07	-0.27	-0.19	Schizophrenia;	chr15:82615393	chr15:82472203~82472426:+
BRCA	cis	rs783540	0.592	rs2567632	ENSG00000278603.1	RP13-608F4.5	-6.16	1.05e-09	1.75e-07	-0.27	-0.19	Schizophrenia;	chr15:82616053	chr15:82472203~82472426:+
BRCA	cis	rs875971	1	rs12532998	ENSG00000224316.1	RP11-479O9.2	6.16	1.05e-09	1.75e-07	0.19	0.19	Aortic root size;	chr7:66502472	chr7:65773620~65802067:+
BRCA	cis	rs7914558	1	rs12780843	ENSG00000213061.2	PFN1P11	6.16	1.05e-09	1.75e-07	0.24	0.19	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103009578	chr10:102838011~102845473:-
BRCA	cis	rs1707322	1	rs7532204	ENSG00000281133.1	AL355480.3	6.16	1.05e-09	1.75e-07	0.23	0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46019403	chr1:45580892~45580996:-
BRCA	cis	rs45509595	0.822	rs200484	ENSG00000220721.1	OR1F12	6.16	1.05e-09	1.75e-07	0.33	0.19	Breast cancer;	chr6:27807896	chr6:28073316~28074233:+
BRCA	cis	rs3733585	0.683	rs6449140	ENSG00000250413.1	RP11-448G15.1	6.16	1.05e-09	1.75e-07	0.25	0.19	Cleft plate (environmental tobacco smoke interaction);	chr4:9934813	chr4:10006482~10009725:+
BRCA	cis	rs10895987	0.955	rs7113761	ENSG00000254614.2	AP003068.23	6.16	1.05e-09	1.76e-07	0.28	0.19	Blood protein levels;	chr11:65159251	chr11:65177606~65181834:-
BRCA	cis	rs2243480	0.901	rs73148097	ENSG00000232546.1	RP11-458F8.1	-6.16	1.05e-09	1.76e-07	-0.25	-0.19	Diabetic kidney disease;	chr7:65966800	chr7:66848496~66858136:+
BRCA	cis	rs2243480	1	rs906134	ENSG00000232546.1	RP11-458F8.1	-6.16	1.05e-09	1.76e-07	-0.25	-0.19	Diabetic kidney disease;	chr7:65979301	chr7:66848496~66858136:+
BRCA	cis	rs7255436	1	rs7255436	ENSG00000269386.4	RAB11B-AS1	6.16	1.05e-09	1.76e-07	0.21	0.19	HDL cholesterol;	chr19:8368312	chr19:8374373~8390685:-
BRCA	cis	rs7208859	0.673	rs3816780	ENSG00000263603.1	CTD-2349P21.5	-6.16	1.05e-09	1.76e-07	-0.32	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30834340	chr17:30729469~30731202:+
BRCA	cis	rs2836950	0.585	rs1029004	ENSG00000238141.2	BRWD1-AS1	-6.16	1.06e-09	1.76e-07	-0.21	-0.19	Menarche (age at onset);	chr21:39243417	chr21:39315707~39323218:+
BRCA	cis	rs3858145	0.588	rs76854765	ENSG00000233590.1	RP11-153K11.3	-6.16	1.06e-09	1.76e-07	-0.25	-0.19	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68277699	chr10:68233251~68242379:-
BRCA	cis	rs6570726	0.905	rs377143	ENSG00000235652.6	RP11-545I5.3	6.16	1.06e-09	1.76e-07	0.18	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145513084	chr6:145799409~145886585:+
BRCA	cis	rs8072100	0.701	rs8078309	ENSG00000228782.6	CTD-2026D20.3	6.16	1.06e-09	1.76e-07	0.21	0.19	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47696706	chr17:47450568~47492492:-
BRCA	cis	rs3764021	0.527	rs10844427	ENSG00000214776.8	RP11-726G1.1	6.16	1.06e-09	1.76e-07	0.23	0.19	Type 1 diabetes;	chr12:9681798	chr12:9467552~9576275:+
BRCA	cis	rs875971	0.502	rs6460311	ENSG00000236529.1	RP13-254B10.1	-6.16	1.06e-09	1.76e-07	-0.24	-0.19	Aortic root size;	chr7:66646886	chr7:65840212~65840596:+
BRCA	cis	rs755249	0.501	rs2484133	ENSG00000228060.1	RP11-69E11.8	-6.16	1.06e-09	1.77e-07	-0.2	-0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39188322	chr1:39565160~39573203:+
BRCA	cis	rs420259	0.516	rs120963	ENSG00000260136.4	CTD-2270L9.4	6.16	1.06e-09	1.77e-07	0.19	0.19	Bipolar disorder;	chr16:23596749	chr16:23452758~23457606:+
BRCA	cis	rs875971	0.545	rs2279757	ENSG00000236529.1	RP13-254B10.1	6.16	1.06e-09	1.77e-07	0.24	0.19	Aortic root size;	chr7:66363676	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.545	rs11766183	ENSG00000236529.1	RP13-254B10.1	6.16	1.06e-09	1.77e-07	0.24	0.19	Aortic root size;	chr7:66374173	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.545	rs1065265	ENSG00000236529.1	RP13-254B10.1	6.16	1.06e-09	1.77e-07	0.24	0.19	Aortic root size;	chr7:66376216	chr7:65840212~65840596:+
BRCA	cis	rs9308731	0.591	rs55878194	ENSG00000227992.1	AC108463.2	-6.16	1.06e-09	1.77e-07	-0.21	-0.19	Chronic lymphocytic leukemia;	chr2:111182897	chr2:111203964~111206215:-
BRCA	cis	rs11098499	0.865	rs4001305	ENSG00000249244.1	RP11-548H18.2	6.16	1.06e-09	1.77e-07	0.22	0.19	Corneal astigmatism;	chr4:119438081	chr4:119391831~119395335:-
BRCA	cis	rs7688540	0.8	rs12506277	ENSG00000275426.1	CH17-262A2.1	6.16	1.06e-09	1.77e-07	0.24	0.19	Facial morphology (factor 6, height of vermillion lower lip);	chr4:293860	chr4:149738~150317:+
BRCA	cis	rs6928977	0.5	rs6941629	ENSG00000231028.7	LINC00271	-6.16	1.06e-09	1.77e-07	-0.2	-0.19	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135621634	chr6:135497801~135716055:+
BRCA	cis	rs9907295	1	rs11650409	ENSG00000270977.1	AC015849.16	6.16	1.06e-09	1.77e-07	0.31	0.19	Fibroblast growth factor basic levels;	chr17:35907949	chr17:35893707~35911023:-
BRCA	cis	rs853679	0.517	rs36078605	ENSG00000204709.4	LINC01556	6.16	1.06e-09	1.77e-07	0.27	0.19	Depression;	chr6:28110254	chr6:28943877~28944537:+
BRCA	cis	rs13126694	0.778	rs4691454	ENSG00000248429.4	RP11-597D13.9	6.16	1.06e-09	1.77e-07	0.17	0.19	Blood osmolality (transformed sodium);	chr4:158117101	chr4:158170752~158202877:+
BRCA	cis	rs7923609	0.936	rs10761779	ENSG00000232075.1	MRPL35P2	-6.16	1.06e-09	1.77e-07	-0.23	-0.19	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63515167	chr10:63634317~63634827:-
BRCA	cis	rs412050	0.501	rs2876980	ENSG00000224086.5	LL22NC03-86G7.1	6.16	1.06e-09	1.77e-07	0.28	0.19	Attention deficit hyperactivity disorder;	chr22:21752246	chr22:21938293~21977632:+
BRCA	cis	rs4713118	0.662	rs9357060	ENSG00000219392.1	RP1-265C24.5	-6.16	1.06e-09	1.77e-07	-0.28	-0.19	Parkinson's disease;	chr6:28056708	chr6:28115628~28116551:+
BRCA	cis	rs4713118	0.662	rs9468271	ENSG00000219392.1	RP1-265C24.5	-6.16	1.06e-09	1.77e-07	-0.28	-0.19	Parkinson's disease;	chr6:28056792	chr6:28115628~28116551:+
BRCA	cis	rs1707322	1	rs11211243	ENSG00000281133.1	AL355480.3	-6.16	1.06e-09	1.77e-07	-0.24	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45989761	chr1:45580892~45580996:-
BRCA	cis	rs1707322	1	rs11211244	ENSG00000281133.1	AL355480.3	-6.16	1.06e-09	1.77e-07	-0.24	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45991001	chr1:45580892~45580996:-
BRCA	cis	rs6969780	1	rs1801085	ENSG00000233429.8	HOTAIRM1	6.16	1.06e-09	1.77e-07	0.24	0.19	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27128971	chr7:27095647~27100265:+
BRCA	cis	rs11722779	0.935	rs3974481	ENSG00000251288.2	RP11-10L12.2	-6.16	1.07e-09	1.78e-07	-0.22	-0.19	Schizophrenia;	chr4:102956834	chr4:102751401~102752641:+
BRCA	cis	rs2243480	1	rs313814	ENSG00000232559.3	GS1-124K5.12	6.16	1.07e-09	1.78e-07	0.36	0.19	Diabetic kidney disease;	chr7:66038306	chr7:66554588~66576923:-
BRCA	cis	rs7927771	0.524	rs10838771	ENSG00000280615.1	Y_RNA	-6.16	1.07e-09	1.78e-07	-0.21	-0.19	Subjective well-being;	chr11:47809780	chr11:47614898~47614994:-
BRCA	cis	rs13113518	0.783	rs34534635	ENSG00000273257.1	RP11-177J6.1	6.16	1.07e-09	1.78e-07	0.25	0.19	Height;	chr4:55573424	chr4:55387949~55388271:+
BRCA	cis	rs13113518	0.783	rs7690837	ENSG00000273257.1	RP11-177J6.1	6.16	1.07e-09	1.78e-07	0.25	0.19	Height;	chr4:55575856	chr4:55387949~55388271:+
BRCA	cis	rs1552244	1	rs13319597	ENSG00000180385.7	EMC3-AS1	-6.16	1.07e-09	1.78e-07	-0.23	-0.19	Alzheimer's disease;	chr3:10084628	chr3:9986893~10006990:+
BRCA	cis	rs2832191	0.74	rs13048618	ENSG00000176054.6	RPL23P2	6.16	1.07e-09	1.78e-07	0.2	0.19	Dental caries;	chr21:29086363	chr21:28997613~28998033:-
BRCA	cis	rs7809950	0.817	rs17154091	ENSG00000238832.1	snoU109	-6.16	1.07e-09	1.78e-07	-0.28	-0.19	Coronary artery disease;	chr7:107444345	chr7:107603363~107603507:+
BRCA	cis	rs1979679	0.842	rs7139154	ENSG00000278733.1	RP11-425D17.1	6.16	1.07e-09	1.78e-07	0.23	0.19	Ossification of the posterior longitudinal ligament of the spine;	chr12:28181603	chr12:28185625~28186190:-
BRCA	cis	rs2243480	1	rs2462569	ENSG00000232546.1	RP11-458F8.1	6.16	1.07e-09	1.78e-07	0.24	0.19	Diabetic kidney disease;	chr7:66009859	chr7:66848496~66858136:+
BRCA	cis	rs1707322	0.835	rs946525	ENSG00000281133.1	AL355480.3	6.16	1.07e-09	1.78e-07	0.23	0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46021605	chr1:45580892~45580996:-
BRCA	cis	rs1707322	1	rs946524	ENSG00000281133.1	AL355480.3	6.16	1.07e-09	1.78e-07	0.23	0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46021888	chr1:45580892~45580996:-
BRCA	cis	rs2243480	0.803	rs160649	ENSG00000230295.1	RP11-458F8.2	-6.16	1.07e-09	1.78e-07	-0.26	-0.19	Diabetic kidney disease;	chr7:66078212	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs160648	ENSG00000230295.1	RP11-458F8.2	-6.16	1.07e-09	1.78e-07	-0.26	-0.19	Diabetic kidney disease;	chr7:66078397	chr7:66880708~66882981:+
BRCA	cis	rs5015933	0.734	rs4838261	ENSG00000232630.1	PRPS1P2	-6.15	1.07e-09	1.78e-07	-0.18	-0.19	Body mass index;	chr9:125386970	chr9:125150653~125151589:+
BRCA	cis	rs13178541	0.873	rs11749405	ENSG00000250378.1	RP11-119J18.1	-6.15	1.07e-09	1.78e-07	-0.26	-0.19	IgG glycosylation;	chr5:135804386	chr5:135812667~135826582:+
BRCA	cis	rs2842992	0.83	rs1475123	ENSG00000237927.1	RP3-393E18.2	-6.15	1.07e-09	1.79e-07	-0.27	-0.19	Age-related macular degeneration (geographic atrophy);	chr6:159756975	chr6:159586955~159589169:-
BRCA	cis	rs655720	1	rs655720	ENSG00000273486.1	RP11-731C17.2	6.15	1.07e-09	1.79e-07	0.22	0.19	Coronary artery disease;	chr3:136384425	chr3:136837338~136839021:-
BRCA	cis	rs2243480	1	rs34560516	ENSG00000164669.11	INTS4P1	6.15	1.07e-09	1.79e-07	0.36	0.19	Diabetic kidney disease;	chr7:65939105	chr7:65141225~65234216:+
BRCA	cis	rs4718428	0.672	rs13241598	ENSG00000230295.1	RP11-458F8.2	-6.15	1.07e-09	1.79e-07	-0.17	-0.19	Corneal structure;	chr7:66835665	chr7:66880708~66882981:+
BRCA	cis	rs8005677	1	rs2295685	ENSG00000257285.4	RP11-298I3.1	6.15	1.07e-09	1.79e-07	0.21	0.19	Cognitive ability (multi-trait analysis);	chr14:22928944	chr14:22929609~22955562:+
BRCA	cis	rs67981189	0.758	rs221921	ENSG00000258571.1	PTTG4P	6.15	1.07e-09	1.79e-07	0.21	0.19	Schizophrenia;	chr14:71119411	chr14:71085482~71085833:-
BRCA	cis	rs16958440	0.867	rs80106524	ENSG00000267800.1	RP11-49K24.5	-6.15	1.07e-09	1.79e-07	-0.45	-0.19	Sitting height ratio;	chr18:47150268	chr18:47137018~47137290:+
BRCA	cis	rs16958440	0.867	rs79712753	ENSG00000267800.1	RP11-49K24.5	-6.15	1.07e-09	1.79e-07	-0.45	-0.19	Sitting height ratio;	chr18:47150356	chr18:47137018~47137290:+
BRCA	cis	rs16958440	0.867	rs3809965	ENSG00000267800.1	RP11-49K24.5	-6.15	1.07e-09	1.79e-07	-0.45	-0.19	Sitting height ratio;	chr18:47150501	chr18:47137018~47137290:+
BRCA	cis	rs16958440	0.867	rs74411203	ENSG00000267800.1	RP11-49K24.5	-6.15	1.07e-09	1.79e-07	-0.45	-0.19	Sitting height ratio;	chr18:47151095	chr18:47137018~47137290:+
BRCA	cis	rs16958440	0.867	rs74346439	ENSG00000267800.1	RP11-49K24.5	-6.15	1.07e-09	1.79e-07	-0.45	-0.19	Sitting height ratio;	chr18:47151096	chr18:47137018~47137290:+
BRCA	cis	rs16958440	0.867	rs3809966	ENSG00000267800.1	RP11-49K24.5	-6.15	1.07e-09	1.79e-07	-0.45	-0.19	Sitting height ratio;	chr18:47151256	chr18:47137018~47137290:+
BRCA	cis	rs16958440	0.867	rs12326457	ENSG00000267800.1	RP11-49K24.5	-6.15	1.07e-09	1.79e-07	-0.45	-0.19	Sitting height ratio;	chr18:47152054	chr18:47137018~47137290:+
BRCA	cis	rs16958440	0.867	rs12326465	ENSG00000267800.1	RP11-49K24.5	-6.15	1.07e-09	1.79e-07	-0.45	-0.19	Sitting height ratio;	chr18:47152274	chr18:47137018~47137290:+
BRCA	cis	rs16958440	0.867	rs75934126	ENSG00000267800.1	RP11-49K24.5	-6.15	1.07e-09	1.79e-07	-0.45	-0.19	Sitting height ratio;	chr18:47153410	chr18:47137018~47137290:+
BRCA	cis	rs875971	0.895	rs3857684	ENSG00000224316.1	RP11-479O9.2	6.15	1.08e-09	1.79e-07	0.19	0.19	Aortic root size;	chr7:66473171	chr7:65773620~65802067:+
BRCA	cis	rs9393777	0.92	rs34150729	ENSG00000220721.1	OR1F12	6.15	1.08e-09	1.79e-07	0.44	0.19	Intelligence (multi-trait analysis);	chr6:27420975	chr6:28073316~28074233:+
BRCA	cis	rs9393777	0.92	rs13191227	ENSG00000220721.1	OR1F12	6.15	1.08e-09	1.79e-07	0.44	0.19	Intelligence (multi-trait analysis);	chr6:27422336	chr6:28073316~28074233:+
BRCA	cis	rs7927771	0.524	rs10838784	ENSG00000280615.1	Y_RNA	6.15	1.08e-09	1.79e-07	0.22	0.19	Subjective well-being;	chr11:47860789	chr11:47614898~47614994:-
BRCA	cis	rs875971	1	rs12698523	ENSG00000224316.1	RP11-479O9.2	6.15	1.08e-09	1.8e-07	0.19	0.19	Aortic root size;	chr7:66503126	chr7:65773620~65802067:+
BRCA	cis	rs2243480	1	rs464895	ENSG00000232559.3	GS1-124K5.12	6.15	1.08e-09	1.8e-07	0.37	0.19	Diabetic kidney disease;	chr7:66062119	chr7:66554588~66576923:-
BRCA	cis	rs2243480	0.901	rs13237344	ENSG00000232559.3	GS1-124K5.12	6.15	1.08e-09	1.8e-07	0.36	0.19	Diabetic kidney disease;	chr7:66557269	chr7:66554588~66576923:-
BRCA	cis	rs4713118	0.513	rs202908	ENSG00000216901.1	AL022393.7	6.15	1.08e-09	1.8e-07	0.25	0.19	Parkinson's disease;	chr6:28043773	chr6:28176188~28176674:+
BRCA	cis	rs4950322	0.748	rs17356680	ENSG00000278811.3	LINC00624	6.15	1.08e-09	1.8e-07	0.26	0.19	Protein quantitative trait loci;	chr1:147354934	chr1:147258885~147517875:-
BRCA	cis	rs7238033	0.624	rs9949609	ENSG00000267193.4	RP11-116O18.3	6.15	1.08e-09	1.8e-07	0.2	0.19	Bladder cancer;	chr18:45733163	chr18:45669367~45747215:-
BRCA	cis	rs4372836	0.964	rs17007191	ENSG00000226833.4	AC097724.3	-6.15	1.08e-09	1.8e-07	-0.23	-0.19	Body mass index;	chr2:28709636	chr2:28708953~28736205:-
BRCA	cis	rs7238033	0.647	rs8095657	ENSG00000267193.4	RP11-116O18.3	6.15	1.08e-09	1.8e-07	0.2	0.19	Bladder cancer;	chr18:45734580	chr18:45669367~45747215:-
BRCA	cis	rs7927771	0.524	rs7929725	ENSG00000280615.1	Y_RNA	6.15	1.08e-09	1.8e-07	0.22	0.19	Subjective well-being;	chr11:47860188	chr11:47614898~47614994:-
BRCA	cis	rs853679	0.517	rs6922063	ENSG00000219392.1	RP1-265C24.5	-6.15	1.08e-09	1.8e-07	-0.28	-0.19	Depression;	chr6:28126588	chr6:28115628~28116551:+
BRCA	cis	rs853679	0.517	rs2275508	ENSG00000219392.1	RP1-265C24.5	-6.15	1.08e-09	1.8e-07	-0.28	-0.19	Depression;	chr6:28126953	chr6:28115628~28116551:+
BRCA	cis	rs7238033	0.624	rs9946832	ENSG00000267193.4	RP11-116O18.3	6.15	1.08e-09	1.8e-07	0.2	0.19	Bladder cancer;	chr18:45732825	chr18:45669367~45747215:-
BRCA	cis	rs7238033	0.624	rs9946998	ENSG00000267193.4	RP11-116O18.3	6.15	1.08e-09	1.8e-07	0.2	0.19	Bladder cancer;	chr18:45732857	chr18:45669367~45747215:-
BRCA	cis	rs9341808	0.727	rs9352809	ENSG00000272129.1	RP11-250B2.6	6.15	1.08e-09	1.81e-07	0.23	0.19	Sitting height ratio;	chr6:80289599	chr6:80355424~80356859:+
BRCA	cis	rs13113518	0.678	rs13149568	ENSG00000273257.1	RP11-177J6.1	6.15	1.08e-09	1.81e-07	0.24	0.19	Height;	chr4:55370412	chr4:55387949~55388271:+
BRCA	cis	rs8114671	0.836	rs3746432	ENSG00000269202.1	RP4-614O4.12	6.15	1.09e-09	1.81e-07	0.19	0.19	Height;	chr20:35004960	chr20:35201747~35203288:-
BRCA	cis	rs7131987	0.565	rs7968883	ENSG00000257176.2	RP11-996F15.2	6.15	1.09e-09	1.81e-07	0.22	0.19	QT interval;	chr12:29241258	chr12:29280418~29317848:-
BRCA	cis	rs8114671	0.773	rs3746438	ENSG00000269202.1	RP4-614O4.12	6.15	1.09e-09	1.81e-07	0.19	0.19	Height;	chr20:34996486	chr20:35201747~35203288:-
BRCA	cis	rs3858145	0.588	rs61854831	ENSG00000233590.1	RP11-153K11.3	-6.15	1.09e-09	1.81e-07	-0.25	-0.19	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68276080	chr10:68233251~68242379:-
BRCA	cis	rs3858145	0.588	rs55888445	ENSG00000233590.1	RP11-153K11.3	-6.15	1.09e-09	1.81e-07	-0.25	-0.19	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68276699	chr10:68233251~68242379:-
BRCA	cis	rs3126085	0.935	rs11584427	ENSG00000237975.5	FLG-AS1	6.15	1.09e-09	1.81e-07	0.3	0.19	Atopic dermatitis;	chr1:152327312	chr1:152168125~152445456:+
BRCA	cis	rs1707322	1	rs785480	ENSG00000281133.1	AL355480.3	-6.15	1.09e-09	1.81e-07	-0.23	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46026492	chr1:45580892~45580996:-
BRCA	cis	rs1150668	0.83	rs2859365	ENSG00000220721.1	OR1F12	-6.15	1.09e-09	1.81e-07	-0.21	-0.19	Pubertal anthropometrics;	chr6:28423688	chr6:28073316~28074233:+
BRCA	cis	rs160451	0.933	rs218888	ENSG00000251136.7	RP11-37B2.1	-6.15	1.09e-09	1.81e-07	-0.18	-0.19	Leprosy;	chr8:89679693	chr8:89609409~89757727:-
BRCA	cis	rs2098713	0.599	rs12652658	ENSG00000250155.1	CTD-2353F22.1	6.15	1.09e-09	1.81e-07	0.21	0.19	Telomere length;	chr5:37555461	chr5:36666214~36725195:-
BRCA	cis	rs42648	0.564	rs11563947	ENSG00000225498.1	AC002064.5	-6.15	1.09e-09	1.82e-07	-0.18	-0.19	Homocysteine levels;	chr7:90179450	chr7:90312496~90322592:+
BRCA	cis	rs6061231	0.837	rs6061235	ENSG00000275437.1	RP5-908M14.10	6.15	1.09e-09	1.82e-07	0.22	0.19	Colorectal cancer;	chr20:62403468	chr20:62402236~62405935:-
BRCA	cis	rs7927771	0.507	rs1483988	ENSG00000280615.1	Y_RNA	6.15	1.09e-09	1.82e-07	0.22	0.19	Subjective well-being;	chr11:47877478	chr11:47614898~47614994:-
BRCA	cis	rs16958440	0.867	rs12326412	ENSG00000267800.1	RP11-49K24.5	-6.15	1.09e-09	1.82e-07	-0.45	-0.19	Sitting height ratio;	chr18:47157223	chr18:47137018~47137290:+
BRCA	cis	rs16958440	0.867	rs77615793	ENSG00000267800.1	RP11-49K24.5	-6.15	1.09e-09	1.82e-07	-0.45	-0.19	Sitting height ratio;	chr18:47158093	chr18:47137018~47137290:+
BRCA	cis	rs16958440	0.867	rs75287977	ENSG00000267800.1	RP11-49K24.5	-6.15	1.09e-09	1.82e-07	-0.45	-0.19	Sitting height ratio;	chr18:47160452	chr18:47137018~47137290:+
BRCA	cis	rs16958440	0.867	rs28578518	ENSG00000267800.1	RP11-49K24.5	-6.15	1.09e-09	1.82e-07	-0.45	-0.19	Sitting height ratio;	chr18:47161177	chr18:47137018~47137290:+
BRCA	cis	rs16958440	0.867	rs28587821	ENSG00000267800.1	RP11-49K24.5	-6.15	1.09e-09	1.82e-07	-0.45	-0.19	Sitting height ratio;	chr18:47161535	chr18:47137018~47137290:+
BRCA	cis	rs16958440	0.867	rs77599321	ENSG00000267800.1	RP11-49K24.5	-6.15	1.09e-09	1.82e-07	-0.45	-0.19	Sitting height ratio;	chr18:47163271	chr18:47137018~47137290:+
BRCA	cis	rs16958440	0.867	rs75901436	ENSG00000267800.1	RP11-49K24.5	-6.15	1.09e-09	1.82e-07	-0.45	-0.19	Sitting height ratio;	chr18:47163273	chr18:47137018~47137290:+
BRCA	cis	rs16958440	0.867	rs74845165	ENSG00000267800.1	RP11-49K24.5	-6.15	1.09e-09	1.82e-07	-0.45	-0.19	Sitting height ratio;	chr18:47164481	chr18:47137018~47137290:+
BRCA	cis	rs16958440	0.867	rs114475395	ENSG00000267800.1	RP11-49K24.5	-6.15	1.09e-09	1.82e-07	-0.45	-0.19	Sitting height ratio;	chr18:47164639	chr18:47137018~47137290:+
BRCA	cis	rs16958440	0.867	rs16949157	ENSG00000267800.1	RP11-49K24.5	-6.15	1.09e-09	1.82e-07	-0.45	-0.19	Sitting height ratio;	chr18:47164953	chr18:47137018~47137290:+
BRCA	cis	rs16958440	0.867	rs75808931	ENSG00000267800.1	RP11-49K24.5	-6.15	1.09e-09	1.82e-07	-0.45	-0.19	Sitting height ratio;	chr18:47166671	chr18:47137018~47137290:+
BRCA	cis	rs16958440	0.867	rs59217333	ENSG00000267800.1	RP11-49K24.5	-6.15	1.09e-09	1.82e-07	-0.45	-0.19	Sitting height ratio;	chr18:47168473	chr18:47137018~47137290:+
BRCA	cis	rs16958440	0.867	rs10083937	ENSG00000267800.1	RP11-49K24.5	-6.15	1.09e-09	1.82e-07	-0.45	-0.19	Sitting height ratio;	chr18:47169231	chr18:47137018~47137290:+
BRCA	cis	rs16958440	0.867	rs80006910	ENSG00000267800.1	RP11-49K24.5	-6.15	1.09e-09	1.82e-07	-0.45	-0.19	Sitting height ratio;	chr18:47170011	chr18:47137018~47137290:+
BRCA	cis	rs12681366	1	rs2930971	ENSG00000253704.1	RP11-267M23.4	6.15	1.09e-09	1.82e-07	0.2	0.19	Nonsyndromic cleft lip with cleft palate;	chr8:94420319	chr8:94553722~94569745:+
BRCA	cis	rs6095360	0.727	rs13044004	ENSG00000222365.1	SNORD12B	-6.15	1.09e-09	1.82e-07	-0.24	-0.19	Intelligence (multi-trait analysis);	chr20:49101834	chr20:49280319~49280409:+
BRCA	cis	rs944990	0.538	rs10761234	ENSG00000227603.1	RP11-165J3.6	6.15	1.09e-09	1.82e-07	0.19	0.19	Body mass index;	chr9:93545230	chr9:93435332~93437121:-
BRCA	cis	rs2562456	1	rs2359155	ENSG00000268081.1	RP11-678G14.2	-6.15	1.09e-09	1.82e-07	-0.27	-0.19	Pain;	chr19:21489067	chr19:21554640~21569237:-
BRCA	cis	rs2243480	1	rs778729	ENSG00000232559.3	GS1-124K5.12	6.15	1.09e-09	1.82e-07	0.36	0.19	Diabetic kidney disease;	chr7:66359432	chr7:66554588~66576923:-
BRCA	cis	rs1707322	1	rs6675222	ENSG00000281133.1	AL355480.3	-6.15	1.09e-09	1.82e-07	-0.23	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45860904	chr1:45580892~45580996:-
BRCA	cis	rs1707322	1	rs4660895	ENSG00000281133.1	AL355480.3	-6.15	1.09e-09	1.82e-07	-0.23	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45864067	chr1:45580892~45580996:-
BRCA	cis	rs1707322	1	rs4660318	ENSG00000281133.1	AL355480.3	-6.15	1.09e-09	1.82e-07	-0.23	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45869204	chr1:45580892~45580996:-
BRCA	cis	rs1707322	1	rs10890360	ENSG00000281133.1	AL355480.3	-6.15	1.09e-09	1.82e-07	-0.23	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45872772	chr1:45580892~45580996:-
BRCA	cis	rs1124769	0.671	rs11070822	ENSG00000259378.1	DCAF13P3	6.15	1.09e-09	1.82e-07	0.27	0.19	Cognitive performance;	chr15:50950585	chr15:50944663~50945996:+
BRCA	cis	rs9876781	1	rs2885510	ENSG00000229759.1	MRPS18AP1	-6.15	1.09e-09	1.82e-07	-0.21	-0.19	Longevity;	chr3:48376736	chr3:48256350~48256938:-
BRCA	cis	rs9876781	1	rs725309	ENSG00000229759.1	MRPS18AP1	-6.15	1.09e-09	1.82e-07	-0.21	-0.19	Longevity;	chr3:48377218	chr3:48256350~48256938:-
BRCA	cis	rs991427	0.643	rs17018718	ENSG00000258100.1	RP11-121E16.1	-6.15	1.1e-09	1.82e-07	-0.31	-0.19	Systolic blood pressure (alcohol consumption interaction);	chr12:91104422	chr12:91362196~91368606:+
BRCA	cis	rs1707322	1	rs7527079	ENSG00000281133.1	AL355480.3	-6.15	1.1e-09	1.83e-07	-0.24	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45947778	chr1:45580892~45580996:-
BRCA	cis	rs1707322	1	rs34446427	ENSG00000281133.1	AL355480.3	-6.15	1.1e-09	1.83e-07	-0.24	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45951983	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.963	rs4660900	ENSG00000281133.1	AL355480.3	-6.15	1.1e-09	1.83e-07	-0.24	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45953933	chr1:45580892~45580996:-
BRCA	cis	rs2732480	0.5	rs7315820	ENSG00000257763.1	OR5BK1P	6.15	1.1e-09	1.83e-07	0.2	0.19	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48205155	chr12:48355792~48356614:-
BRCA	cis	rs9341808	0.754	rs9352808	ENSG00000272129.1	RP11-250B2.6	6.15	1.1e-09	1.83e-07	0.23	0.19	Sitting height ratio;	chr6:80287625	chr6:80355424~80356859:+
BRCA	cis	rs10838708	1	rs10838708	ENSG00000280615.1	Y_RNA	-6.15	1.1e-09	1.83e-07	-0.22	-0.19	Height;	chr11:47419962	chr11:47614898~47614994:-
BRCA	cis	rs875971	0.756	rs2901210	ENSG00000224316.1	RP11-479O9.2	-6.15	1.1e-09	1.83e-07	-0.19	-0.19	Aortic root size;	chr7:66552518	chr7:65773620~65802067:+
BRCA	cis	rs853679	0.55	rs6901017	ENSG00000219392.1	RP1-265C24.5	-6.15	1.1e-09	1.83e-07	-0.27	-0.19	Depression;	chr6:28184805	chr6:28115628~28116551:+
BRCA	cis	rs4950322	0.57	rs4301678	ENSG00000278811.3	LINC00624	6.15	1.1e-09	1.83e-07	0.26	0.19	Protein quantitative trait loci;	chr1:147261907	chr1:147258885~147517875:-
BRCA	cis	rs2153535	0.618	rs11243267	ENSG00000230939.1	RP11-314C16.1	-6.15	1.1e-09	1.83e-07	-0.22	-0.19	Motion sickness;	chr6:8662287	chr6:8784178~8785445:+
BRCA	cis	rs73193808	1	rs2832232	ENSG00000215533.7	LINC00189	-6.15	1.11e-09	1.84e-07	-0.27	-0.19	Coronary artery disease;	chr21:29168238	chr21:29193480~29288205:+
BRCA	cis	rs2836950	0.501	rs11088470	ENSG00000238141.2	BRWD1-AS1	-6.15	1.11e-09	1.84e-07	-0.21	-0.19	Menarche (age at onset);	chr21:39317236	chr21:39315707~39323218:+
BRCA	cis	rs2836950	0.501	rs2836983	ENSG00000238141.2	BRWD1-AS1	-6.15	1.11e-09	1.84e-07	-0.21	-0.19	Menarche (age at onset);	chr21:39317410	chr21:39315707~39323218:+
BRCA	cis	rs2836950	0.52	rs8133927	ENSG00000238141.2	BRWD1-AS1	-6.15	1.11e-09	1.84e-07	-0.21	-0.19	Menarche (age at onset);	chr21:39318035	chr21:39315707~39323218:+
BRCA	cis	rs2836950	0.52	rs8133928	ENSG00000238141.2	BRWD1-AS1	-6.15	1.11e-09	1.84e-07	-0.21	-0.19	Menarche (age at onset);	chr21:39318037	chr21:39315707~39323218:+
BRCA	cis	rs6142102	0.778	rs6059555	ENSG00000275784.1	RP5-1125A11.6	-6.15	1.11e-09	1.84e-07	-0.23	-0.19	Skin pigmentation;	chr20:33926518	chr20:33989480~33991818:-
BRCA	cis	rs875971	0.929	rs12535036	ENSG00000224316.1	RP11-479O9.2	6.15	1.11e-09	1.84e-07	0.19	0.19	Aortic root size;	chr7:66499076	chr7:65773620~65802067:+
BRCA	cis	rs875971	1	rs6970030	ENSG00000224316.1	RP11-479O9.2	6.15	1.11e-09	1.84e-07	0.19	0.19	Aortic root size;	chr7:66503692	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.928	rs6970357	ENSG00000224316.1	RP11-479O9.2	6.15	1.11e-09	1.84e-07	0.19	0.19	Aortic root size;	chr7:66503891	chr7:65773620~65802067:+
BRCA	cis	rs853679	0.517	rs17711344	ENSG00000219392.1	RP1-265C24.5	6.15	1.11e-09	1.84e-07	0.28	0.19	Depression;	chr6:28109824	chr6:28115628~28116551:+
BRCA	cis	rs7238033	0.641	rs8086499	ENSG00000267193.4	RP11-116O18.3	6.15	1.11e-09	1.84e-07	0.2	0.19	Bladder cancer;	chr18:45741447	chr18:45669367~45747215:-
BRCA	cis	rs2998286	0.723	rs2772435	ENSG00000254635.4	WAC-AS1	-6.15	1.11e-09	1.84e-07	-0.27	-0.19	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28546534	chr10:28522652~28532743:-
BRCA	cis	rs2998286	0.723	rs2807759	ENSG00000254635.4	WAC-AS1	-6.15	1.11e-09	1.84e-07	-0.27	-0.19	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28548682	chr10:28522652~28532743:-
BRCA	cis	rs66887589	0.616	rs11098498	ENSG00000245958.5	RP11-33B1.1	-6.15	1.11e-09	1.84e-07	-0.17	-0.19	Diastolic blood pressure;	chr4:119265964	chr4:119454791~119552025:+
BRCA	cis	rs7176527	0.579	rs366717	ENSG00000229212.6	RP11-561C5.4	6.15	1.11e-09	1.85e-07	0.26	0.19	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84544848	chr15:85205440~85234795:-
BRCA	cis	rs2153535	0.609	rs2146159	ENSG00000230939.1	RP11-314C16.1	-6.15	1.11e-09	1.85e-07	-0.22	-0.19	Motion sickness;	chr6:8667222	chr6:8784178~8785445:+
BRCA	cis	rs11976180	1	rs2951363	ENSG00000273234.1	OR2A13P	-6.15	1.11e-09	1.85e-07	-0.25	-0.19	Obesity-related traits;	chr7:144057631	chr7:144142009~144142938:+
BRCA	cis	rs4886920	0.672	rs4886926	ENSG00000260776.4	RP11-114H24.2	6.15	1.11e-09	1.85e-07	0.22	0.19	Neuroticism;	chr15:77829770	chr15:77914217~77926846:-
BRCA	cis	rs3761847	0.508	rs4837813	ENSG00000226752.6	PSMD5-AS1	-6.15	1.11e-09	1.85e-07	-0.22	-0.19	Rheumatoid arthritis;	chr9:121172185	chr9:120824828~120854385:+
BRCA	cis	rs250585	1	rs4968018	ENSG00000260136.4	CTD-2270L9.4	-6.15	1.11e-09	1.85e-07	-0.22	-0.19	Egg allergy;	chr16:23531810	chr16:23452758~23457606:+
BRCA	cis	rs420259	0.516	rs432477	ENSG00000260136.4	CTD-2270L9.4	6.15	1.11e-09	1.85e-07	0.19	0.19	Bipolar disorder;	chr16:23589252	chr16:23452758~23457606:+
BRCA	cis	rs420259	0.516	rs460477	ENSG00000260136.4	CTD-2270L9.4	6.15	1.11e-09	1.85e-07	0.19	0.19	Bipolar disorder;	chr16:23589916	chr16:23452758~23457606:+
BRCA	cis	rs7914558	1	rs7094843	ENSG00000213061.2	PFN1P11	6.15	1.11e-09	1.85e-07	0.24	0.19	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103046897	chr10:102838011~102845473:-
BRCA	cis	rs875971	0.862	rs10256544	ENSG00000224316.1	RP11-479O9.2	6.15	1.12e-09	1.85e-07	0.19	0.19	Aortic root size;	chr7:66210141	chr7:65773620~65802067:+
BRCA	cis	rs4908760	0.613	rs12024032	ENSG00000270282.1	RP5-1115A15.2	-6.15	1.12e-09	1.85e-07	-0.2	-0.19	Vitiligo;	chr1:8748126	chr1:8512653~8513021:+
BRCA	cis	rs1707322	1	rs4660903	ENSG00000281133.1	AL355480.3	-6.15	1.12e-09	1.86e-07	-0.24	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45991929	chr1:45580892~45580996:-
BRCA	cis	rs160451	1	rs160441	ENSG00000251136.7	RP11-37B2.1	6.15	1.12e-09	1.86e-07	0.18	0.19	Leprosy;	chr8:89644760	chr8:89609409~89757727:-
BRCA	cis	rs7520050	0.966	rs785481	ENSG00000280836.1	AL355480.1	6.15	1.12e-09	1.86e-07	0.22	0.19	Reticulocyte count;Red blood cell count;	chr1:46088846	chr1:45581219~45581321:-
BRCA	cis	rs875971	0.862	rs35378740	ENSG00000224316.1	RP11-479O9.2	6.15	1.12e-09	1.86e-07	0.19	0.19	Aortic root size;	chr7:66522725	chr7:65773620~65802067:+
BRCA	cis	rs16958440	0.867	rs76922914	ENSG00000267800.1	RP11-49K24.5	-6.15	1.12e-09	1.86e-07	-0.45	-0.19	Sitting height ratio;	chr18:47162083	chr18:47137018~47137290:+
BRCA	cis	rs8114671	0.804	rs3803936	ENSG00000269202.1	RP4-614O4.12	6.15	1.12e-09	1.86e-07	0.19	0.19	Height;	chr20:35044972	chr20:35201747~35203288:-
BRCA	cis	rs8114671	0.836	rs13042358	ENSG00000269202.1	RP4-614O4.12	6.15	1.12e-09	1.86e-07	0.19	0.19	Height;	chr20:35046676	chr20:35201747~35203288:-
BRCA	cis	rs7914558	1	rs943036	ENSG00000213061.2	PFN1P11	6.15	1.12e-09	1.86e-07	0.25	0.19	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103076290	chr10:102838011~102845473:-
BRCA	cis	rs7208859	0.673	rs9889755	ENSG00000263603.1	CTD-2349P21.5	6.15	1.12e-09	1.86e-07	0.3	0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30907487	chr17:30729469~30731202:+
BRCA	cis	rs227275	0.556	rs11731885	ENSG00000251288.2	RP11-10L12.2	-6.15	1.12e-09	1.86e-07	-0.22	-0.19	Allergic disease (asthma, hay fever or eczema);	chr4:103010913	chr4:102751401~102752641:+
BRCA	cis	rs6479891	1	rs12412012	ENSG00000232075.1	MRPL35P2	6.15	1.12e-09	1.86e-07	0.34	0.19	Arthritis (juvenile idiopathic);	chr10:63556003	chr10:63634317~63634827:-
BRCA	cis	rs6479891	1	rs61579729	ENSG00000232075.1	MRPL35P2	6.15	1.12e-09	1.86e-07	0.34	0.19	Arthritis (juvenile idiopathic);	chr10:63559553	chr10:63634317~63634827:-
BRCA	cis	rs853679	0.517	rs9393895	ENSG00000204709.4	LINC01556	6.15	1.12e-09	1.87e-07	0.28	0.19	Depression;	chr6:28159843	chr6:28943877~28944537:+
BRCA	cis	rs10504130	0.569	rs9650179	ENSG00000272024.1	RP11-546K22.3	-6.15	1.12e-09	1.87e-07	-0.27	-0.19	Venous thromboembolism (SNP x SNP interaction);	chr8:51912127	chr8:51950284~51950690:+
BRCA	cis	rs10992756	0.551	rs883784	ENSG00000227603.1	RP11-165J3.6	6.15	1.12e-09	1.87e-07	0.19	0.19	Intelligence (multi-trait analysis);	chr9:93519954	chr9:93435332~93437121:-
BRCA	cis	rs17711722	1	rs17711722	ENSG00000234585.5	CCT6P3	-6.15	1.12e-09	1.87e-07	-0.18	-0.19	Calcium levels;	chr7:65806210	chr7:65038354~65074713:+
BRCA	cis	rs875971	0.964	rs6978429	ENSG00000224316.1	RP11-479O9.2	6.15	1.12e-09	1.87e-07	0.19	0.19	Aortic root size;	chr7:66494889	chr7:65773620~65802067:+
BRCA	cis	rs875971	1	rs4718357	ENSG00000224316.1	RP11-479O9.2	6.15	1.12e-09	1.87e-07	0.19	0.19	Aortic root size;	chr7:66495891	chr7:65773620~65802067:+
BRCA	cis	rs2243480	1	rs781157	ENSG00000232546.1	RP11-458F8.1	-6.15	1.12e-09	1.87e-07	-0.24	-0.19	Diabetic kidney disease;	chr7:66013324	chr7:66848496~66858136:+
BRCA	cis	rs2836950	0.501	rs2836980	ENSG00000238141.2	BRWD1-AS1	-6.15	1.12e-09	1.87e-07	-0.21	-0.19	Menarche (age at onset);	chr21:39315692	chr21:39315707~39323218:+
BRCA	cis	rs4713118	0.513	rs9368547	ENSG00000216901.1	AL022393.7	6.15	1.13e-09	1.87e-07	0.25	0.19	Parkinson's disease;	chr6:28060289	chr6:28176188~28176674:+
BRCA	cis	rs4713118	0.513	rs183244	ENSG00000216901.1	AL022393.7	6.15	1.13e-09	1.87e-07	0.25	0.19	Parkinson's disease;	chr6:28064060	chr6:28176188~28176674:+
BRCA	cis	rs17301013	0.507	rs72715218	ENSG00000227373.4	RP11-160H22.5	6.15	1.13e-09	1.87e-07	0.29	0.19	Systemic lupus erythematosus;	chr1:174529056	chr1:174115300~174160004:-
BRCA	cis	rs9287719	0.614	rs10929678	ENSG00000243819.4	RN7SL832P	6.15	1.13e-09	1.87e-07	0.19	0.19	Prostate cancer;	chr2:10582969	chr2:10690344~10692099:+
BRCA	cis	rs1476670	0.71	rs4660763	ENSG00000230615.5	RP5-1198O20.4	-6.15	1.13e-09	1.87e-07	-0.27	-0.19	Eotaxin levels;	chr1:44037904	chr1:44030443~44115913:+
BRCA	cis	rs11098499	0.738	rs72918577	ENSG00000249244.1	RP11-548H18.2	6.15	1.13e-09	1.87e-07	0.22	0.19	Corneal astigmatism;	chr4:119405546	chr4:119391831~119395335:-
BRCA	cis	rs9992667	0.955	rs10025499	ENSG00000231160.8	KLF3-AS1	6.15	1.13e-09	1.87e-07	0.22	0.19	Eosinophil percentage of granulocytes;	chr4:38619373	chr4:38612701~38664883:-
BRCA	cis	rs1707322	1	rs6682683	ENSG00000281133.1	AL355480.3	-6.15	1.13e-09	1.88e-07	-0.23	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45876665	chr1:45580892~45580996:-
BRCA	cis	rs2243480	1	rs437889	ENSG00000230295.1	RP11-458F8.2	-6.15	1.13e-09	1.88e-07	-0.25	-0.19	Diabetic kidney disease;	chr7:66044247	chr7:66880708~66882981:+
BRCA	cis	rs10504130	0.735	rs12681203	ENSG00000272024.1	RP11-546K22.3	-6.15	1.13e-09	1.88e-07	-0.29	-0.19	Venous thromboembolism (SNP x SNP interaction);	chr8:51925292	chr8:51950284~51950690:+
BRCA	cis	rs1124769	0.672	rs12050528	ENSG00000259378.1	DCAF13P3	6.15	1.13e-09	1.88e-07	0.27	0.19	Cognitive performance;	chr15:50810917	chr15:50944663~50945996:+
BRCA	cis	rs6840360	1	rs6846114	ENSG00000270265.1	RP11-731D1.4	6.15	1.13e-09	1.88e-07	0.22	0.19	Intelligence (multi-trait analysis);	chr4:151683406	chr4:151333775~151353224:-
BRCA	cis	rs6840258	1	rs72667753	ENSG00000251411.1	RP11-397E7.4	-6.15	1.13e-09	1.88e-07	-0.25	-0.19	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87019860	chr4:86913266~86914817:-
BRCA	cis	rs1440410	0.666	rs2165302	ENSG00000250326.1	RP11-284M14.1	-6.15	1.13e-09	1.88e-07	-0.21	-0.19	Ischemic stroke;	chr4:143234744	chr4:142933195~143184861:-
BRCA	cis	rs9867325	0.778	rs9877089	ENSG00000273486.1	RP11-731C17.2	6.15	1.13e-09	1.88e-07	0.28	0.19	Body mass index;	chr3:136937751	chr3:136837338~136839021:-
BRCA	cis	rs1707322	0.717	rs3014245	ENSG00000281133.1	AL355480.3	6.15	1.13e-09	1.88e-07	0.24	0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45621241	chr1:45580892~45580996:-
BRCA	cis	rs669446	0.562	rs11210907	ENSG00000237950.1	RP11-7O11.3	6.15	1.13e-09	1.88e-07	0.21	0.19	Amyotrophic lateral sclerosis (age of onset);	chr1:43726088	chr1:43944370~43946551:-
BRCA	cis	rs7178375	1	rs7169064	ENSG00000270055.1	CTD-3092A11.2	-6.15	1.14e-09	1.88e-07	-0.27	-0.19	Hypertriglyceridemia;	chr15:30918659	chr15:30487963~30490313:+
BRCA	cis	rs2243480	1	rs35542501	ENSG00000229886.1	RP5-1132H15.3	6.15	1.14e-09	1.88e-07	0.32	0.19	Diabetic kidney disease;	chr7:65966228	chr7:66025126~66031544:-
BRCA	cis	rs2243480	0.708	rs781141	ENSG00000229886.1	RP5-1132H15.3	6.15	1.14e-09	1.88e-07	0.32	0.19	Diabetic kidney disease;	chr7:65973566	chr7:66025126~66031544:-
BRCA	cis	rs2243480	1	rs431318	ENSG00000230295.1	RP11-458F8.2	-6.15	1.14e-09	1.88e-07	-0.25	-0.19	Diabetic kidney disease;	chr7:66046610	chr7:66880708~66882981:+
BRCA	cis	rs1124769	0.685	rs2574754	ENSG00000259378.1	DCAF13P3	6.14	1.14e-09	1.89e-07	0.27	0.19	Cognitive performance;	chr15:50832242	chr15:50944663~50945996:+
BRCA	cis	rs1387259	0.57	rs12368659	ENSG00000240399.1	RP1-228P16.1	6.14	1.14e-09	1.89e-07	0.21	0.19	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48168516	chr12:48054813~48055591:-
BRCA	cis	rs11024102	1	rs11024101	ENSG00000184669.7	OR7E14P	-6.14	1.14e-09	1.89e-07	-0.29	-0.19	Glaucoma (primary angle closure);	chr11:16983997	chr11:17013998~17053024:+
BRCA	cis	rs10888838	1	rs33988698	ENSG00000198711.5	SSBP3-AS1	6.14	1.14e-09	1.89e-07	0.25	0.19	Mitochondrial DNA levels;	chr1:54220182	chr1:54236440~54239063:+
BRCA	cis	rs1858037	0.867	rs55945621	ENSG00000204929.10	AC074391.1	6.14	1.14e-09	1.89e-07	0.25	0.19	Rheumatoid arthritis;	chr2:65388220	chr2:65436711~66084639:+
BRCA	cis	rs853679	0.517	rs4713145	ENSG00000280107.1	AL022393.9	-6.14	1.14e-09	1.89e-07	-0.28	-0.19	Depression;	chr6:28139049	chr6:28170845~28172521:+
BRCA	cis	rs2243480	1	rs313809	ENSG00000232546.1	RP11-458F8.1	-6.14	1.14e-09	1.9e-07	-0.25	-0.19	Diabetic kidney disease;	chr7:66034996	chr7:66848496~66858136:+
BRCA	cis	rs853679	0.517	rs35193936	ENSG00000204709.4	LINC01556	6.14	1.14e-09	1.9e-07	0.27	0.19	Depression;	chr6:28108492	chr6:28943877~28944537:+
BRCA	cis	rs11098499	0.909	rs28714195	ENSG00000249244.1	RP11-548H18.2	6.14	1.14e-09	1.9e-07	0.22	0.19	Corneal astigmatism;	chr4:119395795	chr4:119391831~119395335:-
BRCA	cis	rs1707322	0.752	rs11211145	ENSG00000281133.1	AL355480.3	-6.14	1.14e-09	1.9e-07	-0.24	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45642819	chr1:45580892~45580996:-
BRCA	cis	rs3761847	0.5	rs10760132	ENSG00000226752.6	PSMD5-AS1	-6.14	1.14e-09	1.9e-07	-0.22	-0.19	Rheumatoid arthritis;	chr9:120977715	chr9:120824828~120854385:+
BRCA	cis	rs858239	0.799	rs10279941	ENSG00000230042.1	AK3P3	-6.14	1.15e-09	1.9e-07	-0.22	-0.19	Cerebrospinal fluid biomarker levels;	chr7:23330889	chr7:23129178~23129841:+
BRCA	cis	rs10504130	0.696	rs79740712	ENSG00000272024.1	RP11-546K22.3	-6.14	1.15e-09	1.9e-07	-0.29	-0.19	Venous thromboembolism (SNP x SNP interaction);	chr8:51925750	chr8:51950284~51950690:+
BRCA	cis	rs10504130	0.696	rs77958054	ENSG00000272024.1	RP11-546K22.3	-6.14	1.15e-09	1.9e-07	-0.29	-0.19	Venous thromboembolism (SNP x SNP interaction);	chr8:51926157	chr8:51950284~51950690:+
BRCA	cis	rs7246657	0.598	rs10417545	ENSG00000226686.6	LINC01535	-6.14	1.15e-09	1.9e-07	-0.32	-0.19	Coronary artery calcification;	chr19:37163361	chr19:37251912~37265535:+
BRCA	cis	rs6740322	0.895	rs10172375	ENSG00000234936.1	AC010883.5	6.14	1.15e-09	1.9e-07	0.21	0.19	Coronary artery disease;	chr2:43344908	chr2:43229573~43233394:+
BRCA	cis	rs17301013	0.507	rs55667039	ENSG00000227373.4	RP11-160H22.5	6.14	1.15e-09	1.9e-07	0.28	0.19	Systemic lupus erythematosus;	chr1:174698699	chr1:174115300~174160004:-
BRCA	cis	rs4718428	0.662	rs34577323	ENSG00000230295.1	RP11-458F8.2	-6.14	1.15e-09	1.9e-07	-0.17	-0.19	Corneal structure;	chr7:66845054	chr7:66880708~66882981:+
BRCA	cis	rs9840812	0.691	rs833752	ENSG00000239213.4	NCK1-AS1	6.14	1.15e-09	1.91e-07	0.23	0.19	Fibrinogen levels;	chr3:136536327	chr3:136841726~136862054:-
BRCA	cis	rs853679	0.517	rs7755442	ENSG00000204709.4	LINC01556	6.14	1.15e-09	1.91e-07	0.27	0.19	Depression;	chr6:28071237	chr6:28943877~28944537:+
BRCA	cis	rs853679	0.517	rs55747925	ENSG00000204709.4	LINC01556	6.14	1.15e-09	1.91e-07	0.27	0.19	Depression;	chr6:28076559	chr6:28943877~28944537:+
BRCA	cis	rs853679	0.517	rs34716816	ENSG00000204709.4	LINC01556	6.14	1.15e-09	1.91e-07	0.27	0.19	Depression;	chr6:28078391	chr6:28943877~28944537:+
BRCA	cis	rs853679	0.517	rs9380049	ENSG00000204709.4	LINC01556	6.14	1.15e-09	1.91e-07	0.27	0.19	Depression;	chr6:28080757	chr6:28943877~28944537:+
BRCA	cis	rs853679	0.517	rs9380050	ENSG00000204709.4	LINC01556	6.14	1.15e-09	1.91e-07	0.27	0.19	Depression;	chr6:28080760	chr6:28943877~28944537:+
BRCA	cis	rs227275	0.525	rs10032234	ENSG00000251288.2	RP11-10L12.2	-6.14	1.15e-09	1.91e-07	-0.22	-0.19	Allergic disease (asthma, hay fever or eczema);	chr4:102980538	chr4:102751401~102752641:+
BRCA	cis	rs227275	0.525	rs28845922	ENSG00000251288.2	RP11-10L12.2	-6.14	1.15e-09	1.91e-07	-0.22	-0.19	Allergic disease (asthma, hay fever or eczema);	chr4:102981959	chr4:102751401~102752641:+
BRCA	cis	rs7086627	0.515	rs10887903	ENSG00000226659.1	RP11-137H2.4	-6.14	1.15e-09	1.91e-07	-0.24	-0.19	Post bronchodilator FEV1;	chr10:80450885	chr10:80529597~80535942:-
BRCA	cis	rs7923609	0.756	rs7910951	ENSG00000232075.1	MRPL35P2	6.14	1.15e-09	1.91e-07	0.24	0.19	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63578544	chr10:63634317~63634827:-
BRCA	cis	rs7923609	0.756	rs7911761	ENSG00000232075.1	MRPL35P2	6.14	1.15e-09	1.91e-07	0.24	0.19	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63578993	chr10:63634317~63634827:-
BRCA	cis	rs2243480	1	rs3885839	ENSG00000229886.1	RP5-1132H15.3	6.14	1.15e-09	1.91e-07	0.33	0.19	Diabetic kidney disease;	chr7:65825416	chr7:66025126~66031544:-
BRCA	cis	rs2524005	1	rs2524005	ENSG00000272236.1	XXbac-BPG170G13.32	-6.14	1.15e-09	1.91e-07	-0.28	-0.19	Bipolar disorder and schizophrenia;	chr6:29931900	chr6:29751965~29752207:-
BRCA	cis	rs11722228	0.508	rs73212864	ENSG00000261490.1	RP11-448G15.3	6.14	1.15e-09	1.91e-07	0.22	0.19	Urate levels;Serum uric acid levels;Gout;	chr4:10102567	chr4:10068089~10073019:-
BRCA	cis	rs651907	0.557	rs13081846	ENSG00000244119.1	PDCL3P4	6.14	1.15e-09	1.91e-07	0.15	0.19	Colorectal cancer;	chr3:101664477	chr3:101712472~101713191:+
BRCA	cis	rs853679	0.607	rs72846780	ENSG00000220721.1	OR1F12	6.14	1.16e-09	1.92e-07	0.46	0.19	Depression;	chr6:28151277	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.607	rs13205911	ENSG00000220721.1	OR1F12	6.14	1.16e-09	1.92e-07	0.46	0.19	Depression;	chr6:28156336	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.607	rs13197176	ENSG00000220721.1	OR1F12	6.14	1.16e-09	1.92e-07	0.46	0.19	Depression;	chr6:28161454	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.607	rs13201308	ENSG00000220721.1	OR1F12	6.14	1.16e-09	1.92e-07	0.46	0.19	Depression;	chr6:28162311	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.607	rs34505829	ENSG00000220721.1	OR1F12	6.14	1.16e-09	1.92e-07	0.46	0.19	Depression;	chr6:28165461	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.607	rs35098436	ENSG00000220721.1	OR1F12	6.14	1.16e-09	1.92e-07	0.46	0.19	Depression;	chr6:28166443	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.607	rs72846794	ENSG00000220721.1	OR1F12	6.14	1.16e-09	1.92e-07	0.46	0.19	Depression;	chr6:28169721	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.607	rs13217984	ENSG00000220721.1	OR1F12	6.14	1.16e-09	1.92e-07	0.46	0.19	Depression;	chr6:28171932	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.505	rs35781323	ENSG00000220721.1	OR1F12	6.14	1.16e-09	1.92e-07	0.46	0.19	Depression;	chr6:28177054	chr6:28073316~28074233:+
BRCA	cis	rs2522056	0.808	rs17771891	ENSG00000233006.5	AC034220.3	6.14	1.16e-09	1.92e-07	0.17	0.19	Fibrinogen;Lymphocyte counts;	chr5:132408510	chr5:132311285~132369916:-
BRCA	cis	rs228614	0.517	rs3886722	ENSG00000251288.2	RP11-10L12.2	-6.14	1.16e-09	1.92e-07	-0.22	-0.19	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102983084	chr4:102751401~102752641:+
BRCA	cis	rs875971	0.825	rs10281499	ENSG00000224316.1	RP11-479O9.2	-6.14	1.16e-09	1.92e-07	-0.19	-0.19	Aortic root size;	chr7:66583979	chr7:65773620~65802067:+
BRCA	cis	rs41369048	0.858	rs1572384	ENSG00000238078.1	LINC01352	-6.14	1.16e-09	1.92e-07	-0.26	-0.19	Eosinophil counts;Sum eosinophil basophil counts;	chr1:220907383	chr1:220829255~220832429:+
BRCA	cis	rs7178375	1	rs10163148	ENSG00000270055.1	CTD-3092A11.2	-6.14	1.16e-09	1.92e-07	-0.26	-0.19	Hypertriglyceridemia;	chr15:30920481	chr15:30487963~30490313:+
BRCA	cis	rs7914558	0.966	rs3902934	ENSG00000213061.2	PFN1P11	6.14	1.16e-09	1.92e-07	0.24	0.19	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102986892	chr10:102838011~102845473:-
BRCA	cis	rs7246657	0.653	rs10402050	ENSG00000226686.6	LINC01535	-6.14	1.16e-09	1.92e-07	-0.32	-0.19	Coronary artery calcification;	chr19:37198056	chr19:37251912~37265535:+
BRCA	cis	rs10515750	0.588	rs73815868	ENSG00000248544.2	CTB-47B11.3	6.14	1.16e-09	1.92e-07	0.27	0.19	Lung function (FEV1/FVC);	chr5:157363429	chr5:157375741~157384950:-
BRCA	cis	rs17301013	0.507	rs17842157	ENSG00000227373.4	RP11-160H22.5	6.14	1.16e-09	1.92e-07	0.28	0.19	Systemic lupus erythematosus;	chr1:174719442	chr1:174115300~174160004:-
BRCA	cis	rs5015933	0.801	rs6478703	ENSG00000232630.1	PRPS1P2	6.14	1.16e-09	1.92e-07	0.18	0.19	Body mass index;	chr9:125379069	chr9:125150653~125151589:+
BRCA	cis	rs7238033	0.624	rs7229967	ENSG00000267193.4	RP11-116O18.3	6.14	1.16e-09	1.92e-07	0.2	0.19	Bladder cancer;	chr18:45732403	chr18:45669367~45747215:-
BRCA	cis	rs2243480	1	rs56016656	ENSG00000164669.11	INTS4P1	6.14	1.16e-09	1.92e-07	0.36	0.19	Diabetic kidney disease;	chr7:65918494	chr7:65141225~65234216:+
BRCA	cis	rs2243480	1	rs56291018	ENSG00000164669.11	INTS4P1	6.14	1.16e-09	1.92e-07	0.36	0.19	Diabetic kidney disease;	chr7:65925352	chr7:65141225~65234216:+
BRCA	cis	rs2243480	1	rs36033484	ENSG00000164669.11	INTS4P1	6.14	1.16e-09	1.92e-07	0.36	0.19	Diabetic kidney disease;	chr7:65925571	chr7:65141225~65234216:+
BRCA	cis	rs2832191	0.716	rs1543652	ENSG00000176054.6	RPL23P2	6.14	1.16e-09	1.92e-07	0.2	0.19	Dental caries;	chr21:29075679	chr21:28997613~28998033:-
BRCA	cis	rs875971	1	rs7789554	ENSG00000224316.1	RP11-479O9.2	6.14	1.16e-09	1.92e-07	0.19	0.19	Aortic root size;	chr7:66481051	chr7:65773620~65802067:+
BRCA	cis	rs875971	1	rs4717300	ENSG00000224316.1	RP11-479O9.2	6.14	1.16e-09	1.92e-07	0.19	0.19	Aortic root size;	chr7:66482393	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.895	rs1974769	ENSG00000224316.1	RP11-479O9.2	6.14	1.16e-09	1.92e-07	0.19	0.19	Aortic root size;	chr7:66485627	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.895	rs6460300	ENSG00000224316.1	RP11-479O9.2	6.14	1.16e-09	1.92e-07	0.19	0.19	Aortic root size;	chr7:66487937	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.862	rs7803416	ENSG00000224316.1	RP11-479O9.2	6.14	1.16e-09	1.92e-07	0.19	0.19	Aortic root size;	chr7:66489212	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.964	rs2277911	ENSG00000224316.1	RP11-479O9.2	6.14	1.16e-09	1.92e-07	0.19	0.19	Aortic root size;	chr7:66493638	chr7:65773620~65802067:+
BRCA	cis	rs755249	0.565	rs7539279	ENSG00000228060.1	RP11-69E11.8	6.14	1.16e-09	1.93e-07	0.19	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39584896	chr1:39565160~39573203:+
BRCA	cis	rs11148252	0.846	rs7323666	ENSG00000278238.1	RP11-245D16.4	-6.14	1.16e-09	1.93e-07	-0.2	-0.19	Lewy body disease;	chr13:52431923	chr13:52454775~52455331:-
BRCA	cis	rs2998286	0.862	rs4237390	ENSG00000254635.4	WAC-AS1	-6.14	1.16e-09	1.93e-07	-0.26	-0.19	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28504497	chr10:28522652~28532743:-
BRCA	cis	rs12701220	0.857	rs1057558	ENSG00000229043.2	AC091729.9	-6.14	1.16e-09	1.93e-07	-0.27	-0.19	Bronchopulmonary dysplasia;	chr7:1022730	chr7:1160374~1165267:+
BRCA	cis	rs442309	0.532	rs10995301	ENSG00000238280.1	RP11-436D10.3	6.14	1.17e-09	1.93e-07	0.26	0.19	Vogt-Koyanagi-Harada syndrome;	chr10:62747535	chr10:62793562~62805887:-
BRCA	cis	rs7432375	0.61	rs4420814	ENSG00000239213.4	NCK1-AS1	6.14	1.17e-09	1.93e-07	0.19	0.19	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136794440	chr3:136841726~136862054:-
BRCA	cis	rs250585	0.79	rs2285521	ENSG00000260136.4	CTD-2270L9.4	-6.14	1.17e-09	1.93e-07	-0.22	-0.19	Egg allergy;	chr16:23510459	chr16:23452758~23457606:+
BRCA	cis	rs1858037	0.867	rs876933	ENSG00000204929.10	AC074391.1	6.14	1.17e-09	1.93e-07	0.25	0.19	Rheumatoid arthritis;	chr2:65382303	chr2:65436711~66084639:+
BRCA	cis	rs2243480	1	rs1873494	ENSG00000232559.3	GS1-124K5.12	-6.14	1.17e-09	1.93e-07	-0.35	-0.19	Diabetic kidney disease;	chr7:66184912	chr7:66554588~66576923:-
BRCA	cis	rs2243480	1	rs6959002	ENSG00000232559.3	GS1-124K5.12	-6.14	1.17e-09	1.93e-07	-0.35	-0.19	Diabetic kidney disease;	chr7:66185509	chr7:66554588~66576923:-
BRCA	cis	rs780096	0.967	rs1260333	ENSG00000234072.1	AC074117.10	-6.14	1.17e-09	1.93e-07	-0.17	-0.19	Total body bone mineral density;	chr2:27525757	chr2:27356246~27367622:+
BRCA	cis	rs11148252	0.744	rs4884354	ENSG00000278238.1	RP11-245D16.4	-6.14	1.17e-09	1.93e-07	-0.2	-0.19	Lewy body disease;	chr13:52443339	chr13:52454775~52455331:-
BRCA	cis	rs7255436	0.928	rs7250870	ENSG00000269386.4	RAB11B-AS1	6.14	1.17e-09	1.93e-07	0.21	0.19	HDL cholesterol;	chr19:8388798	chr19:8374373~8390685:-
BRCA	cis	rs7178375	1	rs4779797	ENSG00000215302.7	CTD-3092A11.1	6.14	1.17e-09	1.93e-07	0.28	0.19	Hypertriglyceridemia;	chr15:30916222	chr15:30470779~30507623:+
BRCA	cis	rs2638953	0.924	rs11049467	ENSG00000278733.1	RP11-425D17.1	-6.14	1.17e-09	1.94e-07	-0.25	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28215602	chr12:28185625~28186190:-
BRCA	cis	rs1707322	0.686	rs1547924	ENSG00000281133.1	AL355480.3	-6.14	1.17e-09	1.94e-07	-0.24	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45619440	chr1:45580892~45580996:-
BRCA	cis	rs2998286	0.723	rs231202	ENSG00000254635.4	WAC-AS1	-6.14	1.17e-09	1.94e-07	-0.27	-0.19	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28560111	chr10:28522652~28532743:-
BRCA	cis	rs13126694	0.71	rs13137826	ENSG00000248429.4	RP11-597D13.9	6.14	1.17e-09	1.94e-07	0.17	0.19	Blood osmolality (transformed sodium);	chr4:158001354	chr4:158170752~158202877:+
BRCA	cis	rs2243480	1	rs1499613	ENSG00000232559.3	GS1-124K5.12	-6.14	1.17e-09	1.94e-07	-0.35	-0.19	Diabetic kidney disease;	chr7:66265873	chr7:66554588~66576923:-
BRCA	cis	rs6471393	0.964	rs11549490	ENSG00000253848.1	RP11-10N23.5	-6.14	1.17e-09	1.94e-07	-0.23	-0.19	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93732822	chr8:93741193~93744534:+
BRCA	cis	rs858239	0.896	rs1637192	ENSG00000230042.1	AK3P3	-6.14	1.17e-09	1.94e-07	-0.21	-0.19	Cerebrospinal fluid biomarker levels;	chr7:23220895	chr7:23129178~23129841:+
BRCA	cis	rs853679	0.517	rs56364346	ENSG00000204709.4	LINC01556	6.14	1.17e-09	1.94e-07	0.27	0.19	Depression;	chr6:28082984	chr6:28943877~28944537:+
BRCA	cis	rs853679	0.517	rs9357061	ENSG00000204709.4	LINC01556	6.14	1.17e-09	1.94e-07	0.27	0.19	Depression;	chr6:28083994	chr6:28943877~28944537:+
BRCA	cis	rs853679	0.517	rs9368550	ENSG00000204709.4	LINC01556	6.14	1.17e-09	1.94e-07	0.27	0.19	Depression;	chr6:28084025	chr6:28943877~28944537:+
BRCA	cis	rs853679	0.542	rs2295594	ENSG00000204709.4	LINC01556	6.14	1.17e-09	1.94e-07	0.27	0.19	Depression;	chr6:28085319	chr6:28943877~28944537:+
BRCA	cis	rs7976269	0.559	rs10771477	ENSG00000275476.1	RP11-996F15.4	-6.14	1.18e-09	1.95e-07	-0.21	-0.19	Male-pattern baldness;	chr12:29074137	chr12:29277397~29277882:-
BRCA	cis	rs7976269	0.559	rs10843307	ENSG00000275476.1	RP11-996F15.4	-6.14	1.18e-09	1.95e-07	-0.21	-0.19	Male-pattern baldness;	chr12:29074710	chr12:29277397~29277882:-
BRCA	cis	rs3858145	0.588	rs736535	ENSG00000233590.1	RP11-153K11.3	-6.14	1.18e-09	1.95e-07	-0.26	-0.19	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68284159	chr10:68233251~68242379:-
BRCA	cis	rs11098499	0.863	rs3736115	ENSG00000249244.1	RP11-548H18.2	-6.14	1.18e-09	1.95e-07	-0.22	-0.19	Corneal astigmatism;	chr4:119567548	chr4:119391831~119395335:-
BRCA	cis	rs875971	0.862	rs778684	ENSG00000224316.1	RP11-479O9.2	6.14	1.18e-09	1.95e-07	0.19	0.19	Aortic root size;	chr7:66371416	chr7:65773620~65802067:+
BRCA	cis	rs3764021	0.527	rs3764022	ENSG00000214776.8	RP11-726G1.1	6.14	1.18e-09	1.95e-07	0.23	0.19	Type 1 diabetes;	chr12:9680928	chr12:9467552~9576275:+
BRCA	cis	rs7829975	0.593	rs2921077	ENSG00000254153.1	CTA-398F10.2	6.14	1.18e-09	1.95e-07	0.22	0.19	Mood instability;	chr8:8446992	chr8:8456909~8461337:-
BRCA	cis	rs651907	0.557	rs11711079	ENSG00000244119.1	PDCL3P4	6.14	1.18e-09	1.95e-07	0.15	0.19	Colorectal cancer;	chr3:101668074	chr3:101712472~101713191:+
BRCA	cis	rs4763879	0.778	rs1056151	ENSG00000256673.1	RP11-599J14.2	6.14	1.18e-09	1.95e-07	0.21	0.19	Type 1 diabetes;	chr12:9698427	chr12:9398355~9414851:-
BRCA	cis	rs6840360	0.582	rs1372976	ENSG00000270265.1	RP11-731D1.4	-6.14	1.18e-09	1.95e-07	-0.21	-0.19	Intelligence (multi-trait analysis);	chr4:151530301	chr4:151333775~151353224:-
BRCA	cis	rs1979679	0.842	rs1841964	ENSG00000278733.1	RP11-425D17.1	-6.14	1.18e-09	1.96e-07	-0.23	-0.19	Ossification of the posterior longitudinal ligament of the spine;	chr12:28190100	chr12:28185625~28186190:-
BRCA	cis	rs6442522	0.678	rs11128745	ENSG00000249786.6	EAF1-AS1	6.14	1.18e-09	1.96e-07	0.19	0.19	Uric acid levels;	chr3:15456754	chr3:15436171~15455940:-
BRCA	cis	rs67340775	0.834	rs13218875	ENSG00000220721.1	OR1F12	6.14	1.19e-09	1.96e-07	0.45	0.19	Lung cancer in ever smokers;	chr6:27916234	chr6:28073316~28074233:+
BRCA	cis	rs2562456	0.874	rs2562408	ENSG00000268081.1	RP11-678G14.2	-6.14	1.19e-09	1.96e-07	-0.29	-0.19	Pain;	chr19:21527079	chr19:21554640~21569237:-
BRCA	cis	rs1979679	0.842	rs11049373	ENSG00000278733.1	RP11-425D17.1	6.14	1.19e-09	1.96e-07	0.23	0.19	Ossification of the posterior longitudinal ligament of the spine;	chr12:28148881	chr12:28185625~28186190:-
BRCA	cis	rs7772486	0.686	rs1292336	ENSG00000270638.1	RP3-466P17.1	-6.14	1.19e-09	1.96e-07	-0.21	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145646682	chr6:145735570~145737218:+
BRCA	cis	rs3858145	0.588	rs4142048	ENSG00000233590.1	RP11-153K11.3	-6.14	1.19e-09	1.96e-07	-0.26	-0.19	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68284274	chr10:68233251~68242379:-
BRCA	cis	rs516805	0.706	rs572674	ENSG00000279453.1	RP3-425C14.4	-6.14	1.19e-09	1.96e-07	-0.25	-0.19	Lymphocyte counts;	chr6:122411239	chr6:122436789~122439223:-
BRCA	cis	rs67311347	0.955	rs6764102	ENSG00000280739.1	EIF1B-AS1	6.14	1.19e-09	1.96e-07	0.21	0.19	Renal cell carcinoma;	chr3:40336662	chr3:40173145~40309698:-
BRCA	cis	rs34034915	1	rs34034915	ENSG00000220721.1	OR1F12	6.14	1.19e-09	1.96e-07	0.22	0.19	Hepatitis A;	chr6:27752924	chr6:28073316~28074233:+
BRCA	cis	rs4713118	0.527	rs36042294	ENSG00000220721.1	OR1F12	6.14	1.19e-09	1.96e-07	0.22	0.19	Parkinson's disease;	chr6:27752933	chr6:28073316~28074233:+
BRCA	cis	rs7772486	0.686	rs9403739	ENSG00000270638.1	RP3-466P17.1	-6.14	1.19e-09	1.97e-07	-0.22	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145694221	chr6:145735570~145737218:+
BRCA	cis	rs2243480	1	rs78803505	ENSG00000229886.1	RP5-1132H15.3	6.14	1.19e-09	1.97e-07	0.32	0.19	Diabetic kidney disease;	chr7:65917585	chr7:66025126~66031544:-
BRCA	cis	rs2243480	1	rs34577383	ENSG00000229886.1	RP5-1132H15.3	6.14	1.19e-09	1.97e-07	0.32	0.19	Diabetic kidney disease;	chr7:65920739	chr7:66025126~66031544:-
BRCA	cis	rs2243480	1	rs55895244	ENSG00000229886.1	RP5-1132H15.3	6.14	1.19e-09	1.97e-07	0.32	0.19	Diabetic kidney disease;	chr7:65922691	chr7:66025126~66031544:-
BRCA	cis	rs2243480	1	rs7795242	ENSG00000229886.1	RP5-1132H15.3	6.14	1.19e-09	1.97e-07	0.32	0.19	Diabetic kidney disease;	chr7:65925107	chr7:66025126~66031544:-
BRCA	cis	rs2243480	1	rs2177703	ENSG00000229886.1	RP5-1132H15.3	6.14	1.19e-09	1.97e-07	0.32	0.19	Diabetic kidney disease;	chr7:65926730	chr7:66025126~66031544:-
BRCA	cis	rs2243480	1	rs56985706	ENSG00000229886.1	RP5-1132H15.3	6.14	1.19e-09	1.97e-07	0.32	0.19	Diabetic kidney disease;	chr7:65929575	chr7:66025126~66031544:-
BRCA	cis	rs2243480	1	rs60683927	ENSG00000229886.1	RP5-1132H15.3	6.14	1.19e-09	1.97e-07	0.32	0.19	Diabetic kidney disease;	chr7:65929781	chr7:66025126~66031544:-
BRCA	cis	rs2243480	1	rs58062456	ENSG00000229886.1	RP5-1132H15.3	6.14	1.19e-09	1.97e-07	0.32	0.19	Diabetic kidney disease;	chr7:65929865	chr7:66025126~66031544:-
BRCA	cis	rs2281636	0.754	rs7092699	ENSG00000233690.1	EBAG9P1	6.14	1.19e-09	1.97e-07	0.2	0.19	Obesity-related traits;	chr10:99605545	chr10:99697407~99697949:-
BRCA	cis	rs9652601	0.959	rs12925642	ENSG00000274038.1	RP11-66H6.4	-6.14	1.19e-09	1.97e-07	-0.21	-0.19	Systemic lupus erythematosus;	chr16:11077745	chr16:11056556~11057034:+
BRCA	cis	rs5742933	1	rs5743061	ENSG00000253559.1	OSGEPL1-AS1	6.14	1.19e-09	1.97e-07	0.25	0.19	Ferritin levels;	chr2:189829540	chr2:189762704~189765556:+
BRCA	cis	rs860818	1	rs858277	ENSG00000226816.2	AC005082.12	-6.14	1.19e-09	1.97e-07	-0.46	-0.19	Initial pursuit acceleration;	chr7:23212642	chr7:23206013~23208045:+
BRCA	cis	rs7976269	0.537	rs10843303	ENSG00000275476.1	RP11-996F15.4	-6.14	1.19e-09	1.97e-07	-0.21	-0.19	Male-pattern baldness;	chr12:29069435	chr12:29277397~29277882:-
BRCA	cis	rs9638182	0.673	rs13233571	ENSG00000274080.1	CTA-315H11.2	6.14	1.19e-09	1.97e-07	0.38	0.19	Triglycerides;	chr7:73556901	chr7:73609262~73611502:-
BRCA	cis	rs9638182	0.614	rs13234157	ENSG00000274080.1	CTA-315H11.2	6.14	1.19e-09	1.97e-07	0.38	0.19	Triglycerides;	chr7:73557398	chr7:73609262~73611502:-
BRCA	cis	rs2243480	1	rs34529418	ENSG00000229886.1	RP5-1132H15.3	6.14	1.19e-09	1.97e-07	0.32	0.19	Diabetic kidney disease;	chr7:65938222	chr7:66025126~66031544:-
BRCA	cis	rs1858037	0.867	rs72621551	ENSG00000204929.10	AC074391.1	6.14	1.19e-09	1.97e-07	0.25	0.19	Rheumatoid arthritis;	chr2:65388087	chr2:65436711~66084639:+
BRCA	cis	rs910316	1	rs876402	ENSG00000279594.1	RP11-950C14.10	-6.14	1.19e-09	1.98e-07	-0.21	-0.19	Height;	chr14:75135159	chr14:75011269~75012851:-
BRCA	cis	rs7617773	0.817	rs34225441	ENSG00000228638.1	FCF1P2	-6.14	1.19e-09	1.98e-07	-0.21	-0.19	Coronary artery disease;	chr3:48267401	chr3:48290793~48291375:-
BRCA	cis	rs11722228	0.549	rs62288521	ENSG00000261490.1	RP11-448G15.3	6.14	1.19e-09	1.98e-07	0.22	0.19	Urate levels;Serum uric acid levels;Gout;	chr4:10098148	chr4:10068089~10073019:-
BRCA	cis	rs7520050	0.966	rs6429582	ENSG00000280836.1	AL355480.1	-6.14	1.2e-09	1.98e-07	-0.22	-0.19	Reticulocyte count;Red blood cell count;	chr1:45856171	chr1:45581219~45581321:-
BRCA	cis	rs8103033	0.786	rs4802053	ENSG00000226025.8	LGALS17A	-6.14	1.2e-09	1.98e-07	-0.21	-0.19	Obesity-related traits;	chr19:39656599	chr19:39679374~39686373:+
BRCA	cis	rs10771431	0.81	rs10771418	ENSG00000111788.10	RP11-22B23.1	6.14	1.2e-09	1.98e-07	0.17	0.19	Breast size;	chr12:9206399	chr12:9277235~9313241:+
BRCA	cis	rs228614	0.51	rs223410	ENSG00000251288.2	RP11-10L12.2	-6.14	1.2e-09	1.98e-07	-0.22	-0.19	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102813568	chr4:102751401~102752641:+
BRCA	cis	rs2834288	0.5	rs7283594	ENSG00000273102.1	AP000569.9	-6.14	1.2e-09	1.98e-07	-0.21	-0.19	Gut microbiota (bacterial taxa);	chr21:33962798	chr21:33967101~33968573:-
BRCA	cis	rs375066	0.623	rs239948	ENSG00000267058.1	RP11-15A1.3	-6.14	1.2e-09	1.98e-07	-0.21	-0.19	Breast cancer;	chr19:43852735	chr19:43891804~43901805:-
BRCA	cis	rs732716	0.853	rs12459922	ENSG00000267980.1	AC007292.6	-6.14	1.2e-09	1.98e-07	-0.23	-0.19	Mean corpuscular volume;	chr19:4455865	chr19:4363789~4364640:+
BRCA	cis	rs875971	0.862	rs6955837	ENSG00000224316.1	RP11-479O9.2	-6.14	1.2e-09	1.98e-07	-0.19	-0.19	Aortic root size;	chr7:66578155	chr7:65773620~65802067:+
BRCA	cis	rs2243480	1	rs2961102	ENSG00000232546.1	RP11-458F8.1	-6.14	1.2e-09	1.98e-07	-0.25	-0.19	Diabetic kidney disease;	chr7:65959671	chr7:66848496~66858136:+
BRCA	cis	rs2243480	0.803	rs160649	ENSG00000232546.1	RP11-458F8.1	-6.14	1.2e-09	1.98e-07	-0.25	-0.19	Diabetic kidney disease;	chr7:66078212	chr7:66848496~66858136:+
BRCA	cis	rs2243480	1	rs160648	ENSG00000232546.1	RP11-458F8.1	-6.14	1.2e-09	1.98e-07	-0.25	-0.19	Diabetic kidney disease;	chr7:66078397	chr7:66848496~66858136:+
BRCA	cis	rs420259	0.516	rs717998	ENSG00000260136.4	CTD-2270L9.4	-6.14	1.2e-09	1.98e-07	-0.19	-0.19	Bipolar disorder;	chr16:23549450	chr16:23452758~23457606:+
BRCA	cis	rs13126694	0.778	rs10000610	ENSG00000248429.4	RP11-597D13.9	6.14	1.2e-09	1.98e-07	0.16	0.19	Blood osmolality (transformed sodium);	chr4:158112023	chr4:158170752~158202877:+
BRCA	cis	rs2562456	0.834	rs2173727	ENSG00000268081.1	RP11-678G14.2	-6.14	1.2e-09	1.99e-07	-0.28	-0.19	Pain;	chr19:21491155	chr19:21554640~21569237:-
BRCA	cis	rs2243480	1	rs160655	ENSG00000230295.1	RP11-458F8.2	-6.14	1.2e-09	1.99e-07	-0.25	-0.19	Diabetic kidney disease;	chr7:66068227	chr7:66880708~66882981:+
BRCA	cis	rs17301013	0.507	rs2060158	ENSG00000227373.4	RP11-160H22.5	6.14	1.2e-09	1.99e-07	0.29	0.19	Systemic lupus erythematosus;	chr1:174667379	chr1:174115300~174160004:-
BRCA	cis	rs10129255	0.957	rs10136560	ENSG00000211972.2	IGHV3-66	6.14	1.2e-09	1.99e-07	0.15	0.19	Kawasaki disease;	chr14:106787630	chr14:106675017~106675544:-
BRCA	cis	rs7274963	0.65	rs7262053	ENSG00000236474.1	GCNT1P1	6.14	1.2e-09	1.99e-07	0.22	0.19	Body mass index;	chr20:18310581	chr20:18420160~18421454:-
BRCA	cis	rs7274963	0.704	rs7262066	ENSG00000236474.1	GCNT1P1	6.14	1.2e-09	1.99e-07	0.22	0.19	Body mass index;	chr20:18310666	chr20:18420160~18421454:-
BRCA	cis	rs8005677	0.962	rs11157931	ENSG00000257285.4	RP11-298I3.1	6.14	1.2e-09	1.99e-07	0.21	0.19	Cognitive ability (multi-trait analysis);	chr14:22933984	chr14:22929609~22955562:+
BRCA	cis	rs34779708	0.931	rs4934711	ENSG00000271335.4	RP11-324I22.4	6.14	1.21e-09	1.99e-07	0.19	0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35071382	chr10:35314552~35336401:-
BRCA	cis	rs42648	0.566	rs13247629	ENSG00000225498.1	AC002064.5	6.14	1.21e-09	1.99e-07	0.18	0.19	Homocysteine levels;	chr7:90260271	chr7:90312496~90322592:+
BRCA	cis	rs10050311	0.698	rs4693780	ENSG00000251411.1	RP11-397E7.4	6.14	1.21e-09	1.99e-07	0.26	0.19	Insulin-related traits;	chr4:86720066	chr4:86913266~86914817:-
BRCA	cis	rs2243480	1	rs313807	ENSG00000230295.1	RP11-458F8.2	-6.13	1.21e-09	2e-07	-0.24	-0.19	Diabetic kidney disease;	chr7:66034494	chr7:66880708~66882981:+
BRCA	cis	rs911555	0.755	rs7147664	ENSG00000244691.1	RPL10AP1	-6.13	1.21e-09	2e-07	-0.24	-0.19	Intelligence (multi-trait analysis);	chr14:103497083	chr14:103412119~103412761:-
BRCA	cis	rs9880211	0.613	rs6767060	ENSG00000239213.4	NCK1-AS1	6.13	1.21e-09	2e-07	0.23	0.19	Height;Body mass index;	chr3:136148248	chr3:136841726~136862054:-
BRCA	cis	rs2179367	0.632	rs9285520	ENSG00000216906.2	RP11-350J20.9	-6.13	1.21e-09	2e-07	-0.26	-0.19	Dupuytren's disease;	chr6:149372001	chr6:149904243~149906418:+
BRCA	cis	rs17301013	0.507	rs72713591	ENSG00000227373.4	RP11-160H22.5	6.13	1.21e-09	2e-07	0.28	0.19	Systemic lupus erythematosus;	chr1:174442956	chr1:174115300~174160004:-
BRCA	cis	rs904251	0.861	rs2776877	ENSG00000204110.6	RP1-153P14.8	-6.13	1.22e-09	2.01e-07	-0.21	-0.19	Cognitive performance;	chr6:37519359	chr6:37507348~37535616:+
BRCA	cis	rs904251	0.864	rs2797801	ENSG00000204110.6	RP1-153P14.8	-6.13	1.22e-09	2.01e-07	-0.21	-0.19	Cognitive performance;	chr6:37519385	chr6:37507348~37535616:+
BRCA	cis	rs6570726	1	rs374464	ENSG00000235652.6	RP11-545I5.3	6.13	1.22e-09	2.01e-07	0.18	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145525543	chr6:145799409~145886585:+
BRCA	cis	rs6570726	1	rs450076	ENSG00000235652.6	RP11-545I5.3	6.13	1.22e-09	2.01e-07	0.18	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145526519	chr6:145799409~145886585:+
BRCA	cis	rs1555322	0.53	rs2250205	ENSG00000261582.1	RP4-614O4.11	-6.13	1.22e-09	2.01e-07	-0.21	-0.19	Attention deficit hyperactivity disorder;	chr20:35280121	chr20:35267885~35280043:-
BRCA	cis	rs875971	0.545	rs1796226	ENSG00000273024.4	INTS4P2	-6.13	1.22e-09	2.01e-07	-0.23	-0.19	Aortic root size;	chr7:66622723	chr7:65647864~65715661:+
BRCA	cis	rs2836950	0.501	rs4818018	ENSG00000238141.2	BRWD1-AS1	-6.13	1.22e-09	2.01e-07	-0.21	-0.19	Menarche (age at onset);	chr21:39322146	chr21:39315707~39323218:+
BRCA	cis	rs2836950	0.501	rs4818019	ENSG00000238141.2	BRWD1-AS1	-6.13	1.22e-09	2.01e-07	-0.21	-0.19	Menarche (age at onset);	chr21:39322530	chr21:39315707~39323218:+
BRCA	cis	rs7191700	0.674	rs12597893	ENSG00000262636.1	CTD-3088G3.4	6.13	1.22e-09	2.01e-07	0.25	0.19	Multiple sclerosis;	chr16:11332474	chr16:11380859~11381118:-
BRCA	cis	rs853679	0.517	rs9380056	ENSG00000280107.1	AL022393.9	-6.13	1.22e-09	2.01e-07	-0.28	-0.19	Depression;	chr6:28136698	chr6:28170845~28172521:+
BRCA	cis	rs853679	0.517	rs9380057	ENSG00000280107.1	AL022393.9	-6.13	1.22e-09	2.01e-07	-0.28	-0.19	Depression;	chr6:28136856	chr6:28170845~28172521:+
BRCA	cis	rs853679	0.517	rs6941992	ENSG00000280107.1	AL022393.9	-6.13	1.22e-09	2.01e-07	-0.28	-0.19	Depression;	chr6:28138363	chr6:28170845~28172521:+
BRCA	cis	rs4713118	0.516	rs4713142	ENSG00000280107.1	AL022393.9	-6.13	1.22e-09	2.01e-07	-0.28	-0.19	Parkinson's disease;	chr6:28138569	chr6:28170845~28172521:+
BRCA	cis	rs853679	0.517	rs4713143	ENSG00000280107.1	AL022393.9	-6.13	1.22e-09	2.01e-07	-0.28	-0.19	Depression;	chr6:28138981	chr6:28170845~28172521:+
BRCA	cis	rs853679	0.517	rs4713144	ENSG00000280107.1	AL022393.9	-6.13	1.22e-09	2.01e-07	-0.28	-0.19	Depression;	chr6:28139012	chr6:28170845~28172521:+
BRCA	cis	rs2638953	0.886	rs11049615	ENSG00000278733.1	RP11-425D17.1	-6.13	1.22e-09	2.01e-07	-0.25	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28452152	chr12:28185625~28186190:-
BRCA	cis	rs1707322	1	rs785478	ENSG00000281133.1	AL355480.3	6.13	1.22e-09	2.01e-07	0.23	0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46025963	chr1:45580892~45580996:-
BRCA	cis	rs780096	1	rs780096	ENSG00000234072.1	AC074117.10	-6.13	1.22e-09	2.01e-07	-0.17	-0.19	Total body bone mineral density;	chr2:27518205	chr2:27356246~27367622:+
BRCA	cis	rs13113518	0.776	rs13124436	ENSG00000273257.1	RP11-177J6.1	6.13	1.22e-09	2.02e-07	0.24	0.19	Height;	chr4:55502504	chr4:55387949~55388271:+
BRCA	cis	rs67311347	0.911	rs6776044	ENSG00000280739.1	EIF1B-AS1	6.13	1.22e-09	2.02e-07	0.21	0.19	Renal cell carcinoma;	chr3:40336012	chr3:40173145~40309698:-
BRCA	cis	rs8103033	0.786	rs7245574	ENSG00000226025.8	LGALS17A	-6.13	1.22e-09	2.02e-07	-0.21	-0.19	Obesity-related traits;	chr19:39657462	chr19:39679374~39686373:+
BRCA	cis	rs34779708	0.966	rs35079558	ENSG00000271335.4	RP11-324I22.4	6.13	1.22e-09	2.02e-07	0.2	0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35190958	chr10:35314552~35336401:-
BRCA	cis	rs6569038	0.508	rs9398499	ENSG00000253194.1	RP11-351A11.1	6.13	1.22e-09	2.02e-07	0.23	0.19	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr6:119035170	chr6:118934785~119031541:+
BRCA	cis	rs2288884	0.945	rs78336183	ENSG00000275055.1	CTC-471J1.11	-6.13	1.22e-09	2.02e-07	-0.27	-0.19	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52058230	chr19:52049007~52049754:+
BRCA	cis	rs3858145	0.588	rs4142049	ENSG00000233590.1	RP11-153K11.3	-6.13	1.23e-09	2.02e-07	-0.26	-0.19	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68284695	chr10:68233251~68242379:-
BRCA	cis	rs3858145	0.588	rs7081284	ENSG00000233590.1	RP11-153K11.3	-6.13	1.23e-09	2.02e-07	-0.26	-0.19	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68285035	chr10:68233251~68242379:-
BRCA	cis	rs111326718	1	rs111326718	ENSG00000213061.2	PFN1P11	6.13	1.23e-09	2.02e-07	0.24	0.19	Reticulocyte count;	chr10:103011454	chr10:102838011~102845473:-
BRCA	cis	rs7914558	1	rs7071373	ENSG00000213061.2	PFN1P11	6.13	1.23e-09	2.02e-07	0.24	0.19	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103012165	chr10:102838011~102845473:-
BRCA	cis	rs2243480	1	rs427044	ENSG00000232559.3	GS1-124K5.12	6.13	1.23e-09	2.02e-07	0.36	0.19	Diabetic kidney disease;	chr7:66043558	chr7:66554588~66576923:-
BRCA	cis	rs228614	0.51	rs223378	ENSG00000251288.2	RP11-10L12.2	-6.13	1.23e-09	2.02e-07	-0.22	-0.19	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102833488	chr4:102751401~102752641:+
BRCA	cis	rs875971	0.767	rs1643394	ENSG00000224316.1	RP11-479O9.2	6.13	1.23e-09	2.03e-07	0.19	0.19	Aortic root size;	chr7:66371107	chr7:65773620~65802067:+
BRCA	cis	rs11976180	1	rs2961119	ENSG00000273234.1	OR2A13P	-6.13	1.23e-09	2.03e-07	-0.25	-0.19	Obesity-related traits;	chr7:144058759	chr7:144142009~144142938:+
BRCA	cis	rs853679	0.517	rs9393895	ENSG00000280107.1	AL022393.9	-6.13	1.23e-09	2.03e-07	-0.28	-0.19	Depression;	chr6:28159843	chr6:28170845~28172521:+
BRCA	cis	rs4834770	1	rs878375	ENSG00000249244.1	RP11-548H18.2	6.13	1.23e-09	2.03e-07	0.2	0.19	Blood protein levels;	chr4:119316419	chr4:119391831~119395335:-
BRCA	cis	rs1124769	0.748	rs12591500	ENSG00000259378.1	DCAF13P3	6.13	1.23e-09	2.03e-07	0.27	0.19	Cognitive performance;	chr15:51072895	chr15:50944663~50945996:+
BRCA	cis	rs1160985	1	rs1160985	ENSG00000214855.8	APOC1P1	-6.13	1.23e-09	2.03e-07	-0.22	-0.19	C-reactive protein;LDL cholesterol;Lipid traits;Gut microbiota (functional units);LDL cholesterol levels;	chr19:44900155	chr19:44926804~44931386:+
BRCA	cis	rs8114671	0.527	rs6060112	ENSG00000269202.1	RP4-614O4.12	-6.13	1.23e-09	2.03e-07	-0.2	-0.19	Height;	chr20:34901473	chr20:35201747~35203288:-
BRCA	cis	rs4950322	0.517	rs114823926	ENSG00000278811.3	LINC00624	6.13	1.23e-09	2.03e-07	0.25	0.19	Protein quantitative trait loci;	chr1:147281805	chr1:147258885~147517875:-
BRCA	cis	rs7598759	0.548	rs11693738	ENSG00000223198.1	RNU2-22P	-6.13	1.23e-09	2.03e-07	-0.23	-0.19	Noise-induced hearing loss;	chr2:231495773	chr2:231501990~231502201:-
BRCA	cis	rs875971	0.861	rs801215	ENSG00000224316.1	RP11-479O9.2	-6.13	1.23e-09	2.03e-07	-0.19	-0.19	Aortic root size;	chr7:66546951	chr7:65773620~65802067:+
BRCA	cis	rs4691139	1	rs10007789	ENSG00000248632.1	RP11-366M4.11	6.13	1.23e-09	2.03e-07	0.19	0.19	Ovarian cancer in BRCA1 mutation carriers;	chr4:164969225	chr4:164968587~164970002:-
BRCA	cis	rs9333029	0.524	rs4333799	ENSG00000238145.2	RP11-346M5.1	-6.13	1.23e-09	2.04e-07	-0.19	-0.19	Blood metabolite levels;	chr1:46945876	chr1:46891639~46892830:+
BRCA	cis	rs9333029	0.524	rs4262476	ENSG00000238145.2	RP11-346M5.1	-6.13	1.23e-09	2.04e-07	-0.19	-0.19	Blood metabolite levels;	chr1:46946017	chr1:46891639~46892830:+
BRCA	cis	rs66887589	0.777	rs4643791	ENSG00000245958.5	RP11-33B1.1	6.13	1.23e-09	2.04e-07	0.16	0.19	Diastolic blood pressure;	chr4:119344464	chr4:119454791~119552025:+
BRCA	cis	rs227275	0.554	rs223404	ENSG00000251288.2	RP11-10L12.2	-6.13	1.23e-09	2.04e-07	-0.22	-0.19	Allergic disease (asthma, hay fever or eczema);	chr4:102816951	chr4:102751401~102752641:+
BRCA	cis	rs1858037	0.867	rs964505	ENSG00000204929.10	AC074391.1	6.13	1.24e-09	2.04e-07	0.25	0.19	Rheumatoid arthritis;	chr2:65396055	chr2:65436711~66084639:+
BRCA	cis	rs2235642	0.826	rs8053605	ENSG00000280231.1	LA16c-380F5.3	-6.13	1.24e-09	2.04e-07	-0.24	-0.19	Coronary artery disease;	chr16:1544157	chr16:1553655~1554130:-
BRCA	cis	rs13126694	0.744	rs28635553	ENSG00000248429.4	RP11-597D13.9	6.13	1.24e-09	2.04e-07	0.17	0.19	Blood osmolality (transformed sodium);	chr4:158010962	chr4:158170752~158202877:+
BRCA	cis	rs2179367	0.632	rs9485389	ENSG00000216906.2	RP11-350J20.9	-6.13	1.24e-09	2.04e-07	-0.27	-0.19	Dupuytren's disease;	chr6:149420078	chr6:149904243~149906418:+
BRCA	cis	rs9287719	0.601	rs12692412	ENSG00000243819.4	RN7SL832P	-6.13	1.24e-09	2.04e-07	-0.19	-0.19	Prostate cancer;	chr2:10579928	chr2:10690344~10692099:+
BRCA	cis	rs4950322	0.57	rs111370771	ENSG00000244371.2	PFN1P8	-6.13	1.24e-09	2.04e-07	-0.26	-0.19	Protein quantitative trait loci;	chr1:147261420	chr1:146957117~146957659:-
BRCA	cis	rs2243480	1	rs437889	ENSG00000164669.11	INTS4P1	6.13	1.24e-09	2.04e-07	0.37	0.19	Diabetic kidney disease;	chr7:66044247	chr7:65141225~65234216:+
BRCA	cis	rs2832191	0.74	rs2012645	ENSG00000176054.6	RPL23P2	6.13	1.24e-09	2.04e-07	0.2	0.19	Dental caries;	chr21:29073640	chr21:28997613~28998033:-
BRCA	cis	rs2832191	0.716	rs2692625	ENSG00000176054.6	RPL23P2	6.13	1.24e-09	2.04e-07	0.2	0.19	Dental caries;	chr21:29074039	chr21:28997613~28998033:-
BRCA	cis	rs2974760	0.606	rs6600143	ENSG00000268836.1	LA16c-OS12.2	-6.13	1.24e-09	2.04e-07	-0.21	-0.19	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr16:151390	chr16:185748~186294:-
BRCA	cis	rs2835345	0.596	rs2409817	ENSG00000230479.1	AP000695.6	6.13	1.24e-09	2.04e-07	0.19	0.19	Pulmonary function;	chr21:36455410	chr21:36430360~36481070:+
BRCA	cis	rs1440410	0.835	rs4132266	ENSG00000250326.1	RP11-284M14.1	-6.13	1.24e-09	2.04e-07	-0.21	-0.19	Ischemic stroke;	chr4:143165092	chr4:142933195~143184861:-
BRCA	cis	rs2732480	0.5	rs12828309	ENSG00000257763.1	OR5BK1P	6.13	1.24e-09	2.04e-07	0.2	0.19	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48247377	chr12:48355792~48356614:-
BRCA	cis	rs2286503	0.78	rs929464	ENSG00000228649.7	AC005682.5	6.13	1.24e-09	2.05e-07	0.16	0.19	Fibrinogen;	chr7:22835151	chr7:22854178~22861579:+
BRCA	cis	rs16958440	0.867	rs77149690	ENSG00000267800.1	RP11-49K24.5	-6.13	1.24e-09	2.05e-07	-0.45	-0.19	Sitting height ratio;	chr18:47170772	chr18:47137018~47137290:+
BRCA	cis	rs16958440	0.867	rs79285649	ENSG00000267800.1	RP11-49K24.5	-6.13	1.24e-09	2.05e-07	-0.45	-0.19	Sitting height ratio;	chr18:47172648	chr18:47137018~47137290:+
BRCA	cis	rs16958440	0.867	rs57744138	ENSG00000267800.1	RP11-49K24.5	-6.13	1.24e-09	2.05e-07	-0.45	-0.19	Sitting height ratio;	chr18:47174111	chr18:47137018~47137290:+
BRCA	cis	rs16958440	0.867	rs16949275	ENSG00000267800.1	RP11-49K24.5	-6.13	1.24e-09	2.05e-07	-0.45	-0.19	Sitting height ratio;	chr18:47174332	chr18:47137018~47137290:+
BRCA	cis	rs721917	0.525	rs2758545	ENSG00000244733.5	RP11-506M13.3	-6.13	1.24e-09	2.05e-07	-0.23	-0.19	Chronic obstructive pulmonary disease;	chr10:79940334	chr10:79660891~79677996:+
BRCA	cis	rs17301013	0.507	rs74128393	ENSG00000227373.4	RP11-160H22.5	6.13	1.24e-09	2.05e-07	0.28	0.19	Systemic lupus erythematosus;	chr1:174407961	chr1:174115300~174160004:-
BRCA	cis	rs2243480	1	rs73142122	ENSG00000229886.1	RP5-1132H15.3	6.13	1.25e-09	2.06e-07	0.33	0.19	Diabetic kidney disease;	chr7:65846311	chr7:66025126~66031544:-
BRCA	cis	rs2243480	0.901	rs73142137	ENSG00000229886.1	RP5-1132H15.3	6.13	1.25e-09	2.06e-07	0.33	0.19	Diabetic kidney disease;	chr7:65878455	chr7:66025126~66031544:-
BRCA	cis	rs2243480	1	rs13247184	ENSG00000229886.1	RP5-1132H15.3	6.13	1.25e-09	2.06e-07	0.33	0.19	Diabetic kidney disease;	chr7:65893941	chr7:66025126~66031544:-
BRCA	cis	rs2243480	1	rs35283677	ENSG00000229886.1	RP5-1132H15.3	6.13	1.25e-09	2.06e-07	0.33	0.19	Diabetic kidney disease;	chr7:65894246	chr7:66025126~66031544:-
BRCA	cis	rs2243480	1	rs35421653	ENSG00000229886.1	RP5-1132H15.3	6.13	1.25e-09	2.06e-07	0.33	0.19	Diabetic kidney disease;	chr7:65898442	chr7:66025126~66031544:-
BRCA	cis	rs2832191	0.967	rs2251377	ENSG00000215533.7	LINC00189	-6.13	1.25e-09	2.06e-07	-0.21	-0.19	Dental caries;	chr21:29158278	chr21:29193480~29288205:+
BRCA	cis	rs16958440	0.867	rs2117373	ENSG00000267800.1	RP11-49K24.5	-6.13	1.25e-09	2.06e-07	-0.41	-0.19	Sitting height ratio;	chr18:47145463	chr18:47137018~47137290:+
BRCA	cis	rs10129255	0.957	rs12590735	ENSG00000224373.3	IGHV4-59	6.13	1.25e-09	2.06e-07	0.12	0.19	Kawasaki disease;	chr14:106779660	chr14:106627249~106627825:-
BRCA	cis	rs4713118	0.513	rs149962	ENSG00000204709.4	LINC01556	6.13	1.25e-09	2.06e-07	0.25	0.19	Parkinson's disease;	chr6:28048140	chr6:28943877~28944537:+
BRCA	cis	rs172166	0.769	rs149965	ENSG00000204709.4	LINC01556	6.13	1.25e-09	2.06e-07	0.25	0.19	Cardiac Troponin-T levels;	chr6:28050911	chr6:28943877~28944537:+
BRCA	cis	rs42648	0.536	rs13242882	ENSG00000225498.1	AC002064.5	6.13	1.25e-09	2.06e-07	0.18	0.19	Homocysteine levels;	chr7:90170739	chr7:90312496~90322592:+
BRCA	cis	rs42648	0.535	rs6978118	ENSG00000225498.1	AC002064.5	6.13	1.25e-09	2.06e-07	0.18	0.19	Homocysteine levels;	chr7:90170927	chr7:90312496~90322592:+
BRCA	cis	rs6840258	1	rs114701347	ENSG00000251411.1	RP11-397E7.4	-6.13	1.25e-09	2.06e-07	-0.24	-0.19	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87043849	chr4:86913266~86914817:-
BRCA	cis	rs669446	0.562	rs10890273	ENSG00000237950.1	RP11-7O11.3	6.13	1.25e-09	2.06e-07	0.21	0.19	Amyotrophic lateral sclerosis (age of onset);	chr1:43720773	chr1:43944370~43946551:-
BRCA	cis	rs853679	0.607	rs34662244	ENSG00000220721.1	OR1F12	6.13	1.25e-09	2.06e-07	0.46	0.19	Depression;	chr6:28106103	chr6:28073316~28074233:+
BRCA	cis	rs35952432	1	rs35952432	ENSG00000220721.1	OR1F12	6.13	1.25e-09	2.06e-07	0.46	0.19	Lung cancer;	chr6:28107123	chr6:28073316~28074233:+
BRCA	cis	rs875971	0.545	rs1638724	ENSG00000273024.4	INTS4P2	6.13	1.25e-09	2.07e-07	0.23	0.19	Aortic root size;	chr7:66575494	chr7:65647864~65715661:+
BRCA	cis	rs9816784	0.525	rs41301371	ENSG00000231464.1	AC024937.4	6.13	1.25e-09	2.07e-07	0.25	0.19	Mean corpuscular hemoglobin;	chr3:196072696	chr3:195996738~195998233:+
BRCA	cis	rs875971	0.929	rs10950041	ENSG00000224316.1	RP11-479O9.2	6.13	1.25e-09	2.07e-07	0.19	0.19	Aortic root size;	chr7:66508888	chr7:65773620~65802067:+
BRCA	cis	rs9311474	0.935	rs7622851	ENSG00000243224.1	RP5-1157M23.2	-6.13	1.25e-09	2.07e-07	-0.21	-0.19	Electroencephalogram traits;	chr3:52299655	chr3:52239258~52241097:+
BRCA	cis	rs7772486	0.727	rs10223508	ENSG00000270638.1	RP3-466P17.1	-6.13	1.25e-09	2.07e-07	-0.22	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145964069	chr6:145735570~145737218:+
BRCA	cis	rs2243480	1	rs1167613	ENSG00000230295.1	RP11-458F8.2	-6.13	1.25e-09	2.07e-07	-0.24	-0.19	Diabetic kidney disease;	chr7:66022452	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs313799	ENSG00000230295.1	RP11-458F8.2	-6.13	1.25e-09	2.07e-07	-0.24	-0.19	Diabetic kidney disease;	chr7:66029343	chr7:66880708~66882981:+
BRCA	cis	rs8114671	0.836	rs6060165	ENSG00000269202.1	RP4-614O4.12	6.13	1.26e-09	2.07e-07	0.19	0.19	Height;	chr20:35031677	chr20:35201747~35203288:-
BRCA	cis	rs9992667	0.955	rs28510735	ENSG00000231160.8	KLF3-AS1	6.13	1.26e-09	2.07e-07	0.22	0.19	Eosinophil percentage of granulocytes;	chr4:38612320	chr4:38612701~38664883:-
BRCA	cis	rs2179367	0.632	rs10872636	ENSG00000216906.2	RP11-350J20.9	6.13	1.26e-09	2.07e-07	0.26	0.19	Dupuytren's disease;	chr6:149353678	chr6:149904243~149906418:+
BRCA	cis	rs9311474	1	rs9311474	ENSG00000243224.1	RP5-1157M23.2	-6.13	1.26e-09	2.07e-07	-0.21	-0.19	Electroencephalogram traits;	chr3:52304836	chr3:52239258~52241097:+
BRCA	cis	rs78456975	1	rs7584264	ENSG00000231482.2	AC141930.2	-6.13	1.26e-09	2.08e-07	-0.26	-0.19	Placebo response in major depressive disorder (% change in symptom score);	chr2:1561783	chr2:1572554~1580311:-
BRCA	cis	rs62025270	0.547	rs1026722	ENSG00000202081.1	RNU6-1280P	6.13	1.26e-09	2.08e-07	0.24	0.19	Idiopathic pulmonary fibrosis;	chr15:85576168	chr15:85651522~85651628:-
BRCA	cis	rs11722228	0.549	rs73212863	ENSG00000261490.1	RP11-448G15.3	6.13	1.26e-09	2.08e-07	0.22	0.19	Urate levels;Serum uric acid levels;Gout;	chr4:10102549	chr4:10068089~10073019:-
BRCA	cis	rs2638953	0.924	rs1841962	ENSG00000278733.1	RP11-425D17.1	6.13	1.26e-09	2.08e-07	0.23	0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28220919	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.924	rs7961407	ENSG00000247934.4	RP11-967K21.1	-6.13	1.26e-09	2.08e-07	-0.24	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28195482	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.924	rs7974904	ENSG00000247934.4	RP11-967K21.1	-6.13	1.26e-09	2.08e-07	-0.24	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28195491	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.924	rs7974979	ENSG00000247934.4	RP11-967K21.1	-6.13	1.26e-09	2.08e-07	-0.24	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28195496	chr12:28163298~28190738:-
BRCA	cis	rs2243480	0.808	rs12698508	ENSG00000232546.1	RP11-458F8.1	-6.13	1.26e-09	2.08e-07	-0.25	-0.19	Diabetic kidney disease;	chr7:65946971	chr7:66848496~66858136:+
BRCA	cis	rs6479891	1	rs868798	ENSG00000232075.1	MRPL35P2	6.13	1.26e-09	2.08e-07	0.34	0.19	Arthritis (juvenile idiopathic);	chr10:63135250	chr10:63634317~63634827:-
BRCA	cis	rs2638953	0.924	rs11049454	ENSG00000278733.1	RP11-425D17.1	-6.13	1.26e-09	2.08e-07	-0.25	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28204755	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.924	rs10843134	ENSG00000278733.1	RP11-425D17.1	-6.13	1.26e-09	2.08e-07	-0.25	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28205710	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.924	rs1824768	ENSG00000278733.1	RP11-425D17.1	-6.13	1.26e-09	2.08e-07	-0.25	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28206530	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.886	rs11049465	ENSG00000278733.1	RP11-425D17.1	-6.13	1.26e-09	2.08e-07	-0.25	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28212086	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.924	rs7980441	ENSG00000278733.1	RP11-425D17.1	-6.13	1.26e-09	2.08e-07	-0.25	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28214748	chr12:28185625~28186190:-
BRCA	cis	rs4266144	0.562	rs2086667	ENSG00000244515.1	KRT18P34	-6.13	1.27e-09	2.09e-07	-0.25	-0.19	Coronary artery disease;	chr3:157118728	chr3:157162663~157163932:-
BRCA	cis	rs17711722	0.64	rs13237956	ENSG00000234585.5	CCT6P3	6.13	1.27e-09	2.09e-07	0.18	0.19	Calcium levels;	chr7:65853042	chr7:65038354~65074713:+
BRCA	cis	rs6088813	1	rs4911178	ENSG00000126005.14	MMP24-AS1	6.13	1.27e-09	2.09e-07	0.22	0.19	Height;	chr20:35364817	chr20:35216462~35278131:-
BRCA	cis	rs875971	0.516	rs6945322	ENSG00000234585.5	CCT6P3	6.13	1.27e-09	2.09e-07	0.18	0.19	Aortic root size;	chr7:65871069	chr7:65038354~65074713:+
BRCA	cis	rs875971	0.83	rs778715	ENSG00000224316.1	RP11-479O9.2	6.13	1.27e-09	2.09e-07	0.19	0.19	Aortic root size;	chr7:66384222	chr7:65773620~65802067:+
BRCA	cis	rs2243480	1	rs316331	ENSG00000232546.1	RP11-458F8.1	6.13	1.27e-09	2.09e-07	0.24	0.19	Diabetic kidney disease;	chr7:66139635	chr7:66848496~66858136:+
BRCA	cis	rs11976180	1	rs13226728	ENSG00000273234.1	OR2A13P	-6.13	1.27e-09	2.09e-07	-0.25	-0.19	Obesity-related traits;	chr7:144049485	chr7:144142009~144142938:+
BRCA	cis	rs6840258	0.825	rs72667751	ENSG00000251411.1	RP11-397E7.4	-6.13	1.27e-09	2.09e-07	-0.25	-0.19	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87015227	chr4:86913266~86914817:-
BRCA	cis	rs2280018	0.963	rs12928424	ENSG00000263335.1	AF001548.5	-6.13	1.27e-09	2.09e-07	-0.22	-0.19	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15056916	chr16:15726674~15732993:+
BRCA	cis	rs2243480	0.708	rs35825036	ENSG00000232559.3	GS1-124K5.12	6.13	1.27e-09	2.09e-07	0.35	0.19	Diabetic kidney disease;	chr7:66521515	chr7:66554588~66576923:-
BRCA	cis	rs2243480	1	rs13237037	ENSG00000232559.3	GS1-124K5.12	6.13	1.27e-09	2.09e-07	0.35	0.19	Diabetic kidney disease;	chr7:66532895	chr7:66554588~66576923:-
BRCA	cis	rs2243480	1	rs1796228	ENSG00000232559.3	GS1-124K5.12	6.13	1.27e-09	2.09e-07	0.35	0.19	Diabetic kidney disease;	chr7:66568097	chr7:66554588~66576923:-
BRCA	cis	rs67981189	0.821	rs34257131	ENSG00000258571.1	PTTG4P	-6.13	1.27e-09	2.09e-07	-0.21	-0.19	Schizophrenia;	chr14:71053723	chr14:71085482~71085833:-
BRCA	cis	rs67981189	0.821	rs12896370	ENSG00000258571.1	PTTG4P	-6.13	1.27e-09	2.09e-07	-0.21	-0.19	Schizophrenia;	chr14:71054623	chr14:71085482~71085833:-
BRCA	cis	rs67981189	0.821	rs2286310	ENSG00000258571.1	PTTG4P	-6.13	1.27e-09	2.09e-07	-0.21	-0.19	Schizophrenia;	chr14:71056888	chr14:71085482~71085833:-
BRCA	cis	rs11089937	0.585	rs6001229	ENSG00000211639.2	IGLV4-60	-6.13	1.27e-09	2.09e-07	-0.19	-0.19	Periodontitis (PAL4Q3);	chr22:22187693	chr22:22162199~22162681:+
BRCA	cis	rs227275	0.554	rs223314	ENSG00000251288.2	RP11-10L12.2	-6.13	1.27e-09	2.09e-07	-0.22	-0.19	Allergic disease (asthma, hay fever or eczema);	chr4:102884642	chr4:102751401~102752641:+
BRCA	cis	rs228614	0.51	rs7254	ENSG00000251288.2	RP11-10L12.2	-6.13	1.27e-09	2.09e-07	-0.22	-0.19	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102888488	chr4:102751401~102752641:+
BRCA	cis	rs11722779	0.566	rs6822658	ENSG00000251288.2	RP11-10L12.2	-6.13	1.27e-09	2.09e-07	-0.22	-0.19	Schizophrenia;	chr4:102891964	chr4:102751401~102752641:+
BRCA	cis	rs228614	0.51	rs6823625	ENSG00000251288.2	RP11-10L12.2	-6.13	1.27e-09	2.09e-07	-0.22	-0.19	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102892437	chr4:102751401~102752641:+
BRCA	cis	rs228614	0.51	rs6846762	ENSG00000251288.2	RP11-10L12.2	-6.13	1.27e-09	2.09e-07	-0.22	-0.19	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102892577	chr4:102751401~102752641:+
BRCA	cis	rs228614	0.51	rs4699032	ENSG00000251288.2	RP11-10L12.2	-6.13	1.27e-09	2.09e-07	-0.22	-0.19	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102892724	chr4:102751401~102752641:+
BRCA	cis	rs1440410	0.798	rs4690775	ENSG00000250326.1	RP11-284M14.1	-6.13	1.27e-09	2.09e-07	-0.21	-0.19	Ischemic stroke;	chr4:143164707	chr4:142933195~143184861:-
BRCA	cis	rs2098713	0.599	rs62359042	ENSG00000250155.1	CTD-2353F22.1	6.13	1.27e-09	2.09e-07	0.21	0.19	Telomere length;	chr5:37577604	chr5:36666214~36725195:-
BRCA	cis	rs7246657	0.941	rs10418729	ENSG00000267422.1	CTD-2554C21.1	-6.13	1.27e-09	2.1e-07	-0.28	-0.19	Coronary artery calcification;	chr19:37246163	chr19:37779686~37792865:+
BRCA	cis	rs9467773	0.565	rs4343916	ENSG00000241549.7	GUSBP2	6.13	1.27e-09	2.1e-07	0.21	0.19	Intelligence (multi-trait analysis);	chr6:26522447	chr6:26871484~26956554:-
BRCA	cis	rs11976180	1	rs2961115	ENSG00000273234.1	OR2A13P	-6.13	1.27e-09	2.1e-07	-0.25	-0.19	Obesity-related traits;	chr7:144056278	chr7:144142009~144142938:+
BRCA	cis	rs11098499	0.526	rs10026625	ENSG00000245958.5	RP11-33B1.1	-6.13	1.27e-09	2.1e-07	-0.17	-0.19	Corneal astigmatism;	chr4:119358981	chr4:119454791~119552025:+
BRCA	cis	rs1707322	1	rs10158032	ENSG00000281133.1	AL355480.3	-6.13	1.27e-09	2.1e-07	-0.23	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45867029	chr1:45580892~45580996:-
BRCA	cis	rs1707322	1	rs4660906	ENSG00000281133.1	AL355480.3	-6.13	1.27e-09	2.1e-07	-0.24	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46005188	chr1:45580892~45580996:-
BRCA	cis	rs10895987	1	rs11227126	ENSG00000254614.2	AP003068.23	6.13	1.28e-09	2.1e-07	0.29	0.19	Blood protein levels;	chr11:65140591	chr11:65177606~65181834:-
BRCA	cis	rs1707322	0.717	rs2275086	ENSG00000281133.1	AL355480.3	6.13	1.28e-09	2.1e-07	0.24	0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45620207	chr1:45580892~45580996:-
BRCA	cis	rs7772486	0.79	rs9386141	ENSG00000270638.1	RP3-466P17.1	-6.13	1.28e-09	2.11e-07	-0.21	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145947487	chr6:145735570~145737218:+
BRCA	cis	rs2243480	1	rs160633	ENSG00000164669.11	INTS4P1	6.13	1.28e-09	2.11e-07	0.38	0.19	Diabetic kidney disease;	chr7:66063241	chr7:65141225~65234216:+
BRCA	cis	rs55702914	0.742	rs34555121	ENSG00000231621.1	AC013264.2	-6.13	1.28e-09	2.11e-07	-0.19	-0.19	Major depression and alcohol dependence;	chr2:197301329	chr2:197197991~197199273:+
BRCA	cis	rs792448	0.603	rs12024665	ENSG00000226251.4	RP11-15I11.3	-6.13	1.28e-09	2.11e-07	-0.23	-0.19	White blood cell count (basophil);	chr1:212326553	chr1:212225278~212238977:-
BRCA	cis	rs9311474	0.607	rs28661185	ENSG00000243224.1	RP5-1157M23.2	-6.13	1.28e-09	2.11e-07	-0.2	-0.19	Electroencephalogram traits;	chr3:52533172	chr3:52239258~52241097:+
BRCA	cis	rs1979679	0.842	rs11049411	ENSG00000278733.1	RP11-425D17.1	6.13	1.28e-09	2.11e-07	0.23	0.19	Ossification of the posterior longitudinal ligament of the spine;	chr12:28184723	chr12:28185625~28186190:-
BRCA	cis	rs2243480	1	rs73150014	ENSG00000164669.11	INTS4P1	6.13	1.28e-09	2.11e-07	0.36	0.19	Diabetic kidney disease;	chr7:65985932	chr7:65141225~65234216:+
BRCA	cis	rs911555	0.713	rs10162425	ENSG00000244691.1	RPL10AP1	-6.12	1.28e-09	2.11e-07	-0.24	-0.19	Intelligence (multi-trait analysis);	chr14:103465284	chr14:103412119~103412761:-
BRCA	cis	rs1707322	1	rs11211200	ENSG00000281133.1	AL355480.3	-6.12	1.28e-09	2.11e-07	-0.23	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45822680	chr1:45580892~45580996:-
BRCA	cis	rs2115630	0.754	rs12595321	ENSG00000229212.6	RP11-561C5.4	6.12	1.28e-09	2.11e-07	0.21	0.19	P wave terminal force;	chr15:84788038	chr15:85205440~85234795:-
BRCA	cis	rs17597773	0.638	rs12139139	ENSG00000272823.1	RP11-295M18.6	-6.12	1.29e-09	2.12e-07	-0.22	-0.19	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220827284	chr1:220828676~220829211:-
BRCA	cis	rs2243480	1	rs34702770	ENSG00000232546.1	RP11-458F8.1	-6.12	1.29e-09	2.12e-07	-0.24	-0.19	Diabetic kidney disease;	chr7:65879836	chr7:66848496~66858136:+
BRCA	cis	rs2243480	1	rs34637256	ENSG00000232546.1	RP11-458F8.1	-6.12	1.29e-09	2.12e-07	-0.24	-0.19	Diabetic kidney disease;	chr7:65895144	chr7:66848496~66858136:+
BRCA	cis	rs2243480	0.615	rs34363376	ENSG00000232559.3	GS1-124K5.12	6.12	1.29e-09	2.12e-07	0.36	0.19	Diabetic kidney disease;	chr7:66474549	chr7:66554588~66576923:-
BRCA	cis	rs1707322	1	rs4660889	ENSG00000281133.1	AL355480.3	-6.12	1.29e-09	2.12e-07	-0.23	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45831659	chr1:45580892~45580996:-
BRCA	cis	rs6479891	1	rs72837056	ENSG00000232075.1	MRPL35P2	6.12	1.29e-09	2.12e-07	0.34	0.19	Arthritis (juvenile idiopathic);	chr10:63500718	chr10:63634317~63634827:-
BRCA	cis	rs6479891	0.818	rs11815969	ENSG00000232075.1	MRPL35P2	6.12	1.29e-09	2.12e-07	0.34	0.19	Arthritis (juvenile idiopathic);	chr10:63506095	chr10:63634317~63634827:-
BRCA	cis	rs10504130	0.696	rs78238505	ENSG00000272024.1	RP11-546K22.3	-6.12	1.29e-09	2.12e-07	-0.29	-0.19	Venous thromboembolism (SNP x SNP interaction);	chr8:51915578	chr8:51950284~51950690:+
BRCA	cis	rs651907	0.535	rs17412601	ENSG00000244119.1	PDCL3P4	6.12	1.29e-09	2.12e-07	0.15	0.19	Colorectal cancer;	chr3:101780431	chr3:101712472~101713191:+
BRCA	cis	rs7587476	0.906	rs16852750	ENSG00000229267.2	AC072062.1	-6.12	1.29e-09	2.12e-07	-0.26	-0.19	Neuroblastoma;	chr2:214781959	chr2:214810229~214963274:+
BRCA	cis	rs7587476	0.906	rs3768713	ENSG00000229267.2	AC072062.1	-6.12	1.29e-09	2.13e-07	-0.26	-0.19	Neuroblastoma;	chr2:214772781	chr2:214810229~214963274:+
BRCA	cis	rs74225573	1	rs74225573	ENSG00000230337.1	RP4-635E18.6	-6.12	1.29e-09	2.13e-07	-0.45	-0.19	Corneal curvature;	chr1:11220937	chr1:11099675~11102100:+
BRCA	cis	rs7246657	1	rs6508710	ENSG00000226686.6	LINC01535	-6.12	1.29e-09	2.13e-07	-0.28	-0.19	Coronary artery calcification;	chr19:37258984	chr19:37251912~37265535:+
BRCA	cis	rs34779708	0.931	rs13377158	ENSG00000271335.4	RP11-324I22.4	-6.12	1.29e-09	2.13e-07	-0.19	-0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35081537	chr10:35314552~35336401:-
BRCA	cis	rs2243480	1	rs1723270	ENSG00000232546.1	RP11-458F8.1	-6.12	1.29e-09	2.13e-07	-0.25	-0.19	Diabetic kidney disease;	chr7:66004843	chr7:66848496~66858136:+
BRCA	cis	rs5015933	0.832	rs2841332	ENSG00000232630.1	PRPS1P2	-6.12	1.29e-09	2.13e-07	-0.17	-0.19	Body mass index;	chr9:125367578	chr9:125150653~125151589:+
BRCA	cis	rs2280018	1	rs2280018	ENSG00000263335.1	AF001548.5	-6.12	1.29e-09	2.13e-07	-0.22	-0.19	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15056976	chr16:15726674~15732993:+
BRCA	cis	rs2153535	0.585	rs6597343	ENSG00000230939.1	RP11-314C16.1	-6.12	1.29e-09	2.13e-07	-0.22	-0.19	Motion sickness;	chr6:8620270	chr6:8784178~8785445:+
BRCA	cis	rs2749097	0.545	rs7541882	ENSG00000244256.3	RN7SL130P	-6.12	1.3e-09	2.13e-07	-0.25	-0.19	Alcohol consumption (transferrin glycosylation);	chr1:63655898	chr1:63655743~63656047:+
BRCA	cis	rs67981189	0.806	rs2810107	ENSG00000258571.1	PTTG4P	6.12	1.3e-09	2.13e-07	0.2	0.19	Schizophrenia;	chr14:70954340	chr14:71085482~71085833:-
BRCA	cis	rs2243480	0.803	rs34804747	ENSG00000229886.1	RP5-1132H15.3	6.12	1.3e-09	2.13e-07	0.32	0.19	Diabetic kidney disease;	chr7:65947955	chr7:66025126~66031544:-
BRCA	cis	rs2243480	1	rs59794892	ENSG00000229886.1	RP5-1132H15.3	6.12	1.3e-09	2.13e-07	0.32	0.19	Diabetic kidney disease;	chr7:65950886	chr7:66025126~66031544:-
BRCA	cis	rs2243480	0.803	rs36004293	ENSG00000229886.1	RP5-1132H15.3	6.12	1.3e-09	2.13e-07	0.32	0.19	Diabetic kidney disease;	chr7:65951525	chr7:66025126~66031544:-
BRCA	cis	rs2243480	0.803	rs35268390	ENSG00000229886.1	RP5-1132H15.3	6.12	1.3e-09	2.13e-07	0.32	0.19	Diabetic kidney disease;	chr7:65951549	chr7:66025126~66031544:-
BRCA	cis	rs853679	0.517	rs12332979	ENSG00000280107.1	AL022393.9	-6.12	1.3e-09	2.13e-07	-0.28	-0.19	Depression;	chr6:28173770	chr6:28170845~28172521:+
BRCA	cis	rs853679	0.517	rs67878650	ENSG00000280107.1	AL022393.9	-6.12	1.3e-09	2.13e-07	-0.28	-0.19	Depression;	chr6:28174809	chr6:28170845~28172521:+
BRCA	cis	rs853679	0.569	rs9348798	ENSG00000280107.1	AL022393.9	-6.12	1.3e-09	2.13e-07	-0.28	-0.19	Depression;	chr6:28175233	chr6:28170845~28172521:+
BRCA	cis	rs853679	0.517	rs9380065	ENSG00000280107.1	AL022393.9	-6.12	1.3e-09	2.13e-07	-0.28	-0.19	Depression;	chr6:28176973	chr6:28170845~28172521:+
BRCA	cis	rs875971	0.545	rs1267814	ENSG00000273024.4	INTS4P2	6.12	1.3e-09	2.14e-07	0.23	0.19	Aortic root size;	chr7:66579422	chr7:65647864~65715661:+
BRCA	cis	rs2153535	0.518	rs1998265	ENSG00000230939.1	RP11-314C16.1	-6.12	1.3e-09	2.14e-07	-0.22	-0.19	Motion sickness;	chr6:8651929	chr6:8784178~8785445:+
BRCA	cis	rs1440410	0.835	rs10029373	ENSG00000250326.1	RP11-284M14.1	-6.12	1.3e-09	2.14e-07	-0.2	-0.19	Ischemic stroke;	chr4:143208965	chr4:142933195~143184861:-
BRCA	cis	rs853679	0.517	rs3757187	ENSG00000204709.4	LINC01556	6.12	1.3e-09	2.14e-07	0.28	0.19	Depression;	chr6:28139876	chr6:28943877~28944537:+
BRCA	cis	rs2243480	1	rs781142	ENSG00000229886.1	RP5-1132H15.3	6.12	1.3e-09	2.14e-07	0.32	0.19	Diabetic kidney disease;	chr7:65973791	chr7:66025126~66031544:-
BRCA	cis	rs1707322	1	rs7547189	ENSG00000281133.1	AL355480.3	-6.12	1.3e-09	2.14e-07	-0.23	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45853842	chr1:45580892~45580996:-
BRCA	cis	rs1707322	1	rs7547284	ENSG00000281133.1	AL355480.3	-6.12	1.3e-09	2.14e-07	-0.23	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45853893	chr1:45580892~45580996:-
BRCA	cis	rs1707322	1	rs11211205	ENSG00000281133.1	AL355480.3	-6.12	1.3e-09	2.14e-07	-0.23	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45856202	chr1:45580892~45580996:-
BRCA	cis	rs853679	0.545	rs35949109	ENSG00000220721.1	OR1F12	6.12	1.3e-09	2.14e-07	0.33	0.19	Depression;	chr6:28058148	chr6:28073316~28074233:+
BRCA	cis	rs7520050	0.966	rs1768816	ENSG00000280836.1	AL355480.1	6.12	1.31e-09	2.15e-07	0.22	0.19	Reticulocyte count;Red blood cell count;	chr1:46062927	chr1:45581219~45581321:-
BRCA	cis	rs10208649	0.808	rs6730494	ENSG00000233266.1	HMGB1P31	6.12	1.31e-09	2.15e-07	0.44	0.19	Body mass index;	chr2:53992049	chr2:54051334~54051760:+
BRCA	cis	rs1193	0.913	rs1850138	ENSG00000231259.4	AC125232.1	-6.12	1.31e-09	2.15e-07	-0.24	-0.19	High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;High light scatter reticulocyte count;	chr2:86762343	chr2:87031815~87053069:-
BRCA	cis	rs1193	1	rs6706378	ENSG00000231259.4	AC125232.1	-6.12	1.31e-09	2.15e-07	-0.24	-0.19	High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;High light scatter reticulocyte count;	chr2:86766537	chr2:87031815~87053069:-
BRCA	cis	rs1193	1	rs938486	ENSG00000231259.4	AC125232.1	-6.12	1.31e-09	2.15e-07	-0.24	-0.19	High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;High light scatter reticulocyte count;	chr2:86767596	chr2:87031815~87053069:-
BRCA	cis	rs10888838	1	rs2026045	ENSG00000198711.5	SSBP3-AS1	6.12	1.31e-09	2.15e-07	0.24	0.19	Mitochondrial DNA levels;	chr1:54219522	chr1:54236440~54239063:+
BRCA	cis	rs6479891	0.915	rs2616628	ENSG00000232075.1	MRPL35P2	6.12	1.31e-09	2.15e-07	0.33	0.19	Arthritis (juvenile idiopathic);	chr10:63460197	chr10:63634317~63634827:-
BRCA	cis	rs6479891	1	rs2393980	ENSG00000232075.1	MRPL35P2	6.12	1.31e-09	2.15e-07	0.33	0.19	Arthritis (juvenile idiopathic);	chr10:63464750	chr10:63634317~63634827:-
BRCA	cis	rs10050311	0.698	rs3775238	ENSG00000251411.1	RP11-397E7.4	-6.12	1.31e-09	2.15e-07	-0.27	-0.19	Insulin-related traits;	chr4:86712231	chr4:86913266~86914817:-
BRCA	cis	rs1198430	1	rs1198431	ENSG00000232482.2	RP4-654C18.1	6.12	1.31e-09	2.15e-07	0.28	0.19	Total cholesterol levels;	chr1:23429223	chr1:23410832~23412146:+
BRCA	cis	rs7914558	1	rs7920251	ENSG00000213061.2	PFN1P11	6.12	1.31e-09	2.15e-07	0.25	0.19	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103190440	chr10:102838011~102845473:-
BRCA	cis	rs6569038	0.533	rs12526935	ENSG00000253194.1	RP11-351A11.1	-6.12	1.31e-09	2.15e-07	-0.23	-0.19	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr6:119052747	chr6:118934785~119031541:+
BRCA	cis	rs7809950	0.678	rs75617662	ENSG00000238832.1	snoU109	-6.12	1.31e-09	2.15e-07	-0.28	-0.19	Coronary artery disease;	chr7:107389994	chr7:107603363~107603507:+
BRCA	cis	rs7809950	0.678	rs7790080	ENSG00000238832.1	snoU109	-6.12	1.31e-09	2.15e-07	-0.28	-0.19	Coronary artery disease;	chr7:107390877	chr7:107603363~107603507:+
BRCA	cis	rs301901	0.796	rs4869520	ENSG00000250155.1	CTD-2353F22.1	6.12	1.31e-09	2.15e-07	0.21	0.19	Height;	chr5:37508981	chr5:36666214~36725195:-
BRCA	cis	rs10504130	0.735	rs12679287	ENSG00000272024.1	RP11-546K22.3	-6.12	1.31e-09	2.16e-07	-0.29	-0.19	Venous thromboembolism (SNP x SNP interaction);	chr8:51925568	chr8:51950284~51950690:+
BRCA	cis	rs17301013	0.507	rs72713528	ENSG00000227373.4	RP11-160H22.5	6.12	1.31e-09	2.16e-07	0.28	0.19	Systemic lupus erythematosus;	chr1:174319862	chr1:174115300~174160004:-
BRCA	cis	rs1707322	0.752	rs11211145	ENSG00000234329.1	RP11-767N6.2	6.12	1.31e-09	2.16e-07	0.2	0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45642819	chr1:45651039~45651826:-
BRCA	cis	rs1823913	0.538	rs35311234	ENSG00000280083.1	RP11-317J9.1	-6.12	1.31e-09	2.16e-07	-0.22	-0.19	Obesity-related traits;	chr2:191316952	chr2:191154118~191156070:-
BRCA	cis	rs875971	0.502	rs1796227	ENSG00000273024.4	INTS4P2	6.12	1.31e-09	2.16e-07	0.24	0.19	Aortic root size;	chr7:66622032	chr7:65647864~65715661:+
BRCA	cis	rs2235642	0.893	rs2076442	ENSG00000280231.1	LA16c-380F5.3	-6.12	1.32e-09	2.16e-07	-0.24	-0.19	Coronary artery disease;	chr16:1541111	chr16:1553655~1554130:-
BRCA	cis	rs420259	0.516	rs2369009	ENSG00000260136.4	CTD-2270L9.4	-6.12	1.32e-09	2.16e-07	-0.19	-0.19	Bipolar disorder;	chr16:23544405	chr16:23452758~23457606:+
BRCA	cis	rs1193	0.955	rs6726451	ENSG00000231259.4	AC125232.1	-6.12	1.32e-09	2.16e-07	-0.24	-0.19	High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;High light scatter reticulocyte count;	chr2:86760648	chr2:87031815~87053069:-
BRCA	cis	rs2562456	0.874	rs9304986	ENSG00000268081.1	RP11-678G14.2	-6.12	1.32e-09	2.16e-07	-0.28	-0.19	Pain;	chr19:21499260	chr19:21554640~21569237:-
BRCA	cis	rs2492286	0.529	rs11918394	ENSG00000242551.2	POU5F1P6	-6.12	1.32e-09	2.17e-07	-0.28	-0.19	Eosinophil counts;	chr3:128649868	chr3:128674735~128677005:-
BRCA	cis	rs755249	0.565	rs4660846	ENSG00000228060.1	RP11-69E11.8	6.12	1.32e-09	2.17e-07	0.19	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39583839	chr1:39565160~39573203:+
BRCA	cis	rs8005677	1	rs7145494	ENSG00000257285.4	RP11-298I3.1	6.12	1.32e-09	2.17e-07	0.21	0.19	Cognitive ability (multi-trait analysis);	chr14:22930581	chr14:22929609~22955562:+
BRCA	cis	rs8005677	1	rs7155857	ENSG00000257285.4	RP11-298I3.1	6.12	1.32e-09	2.17e-07	0.21	0.19	Cognitive ability (multi-trait analysis);	chr14:22930850	chr14:22929609~22955562:+
BRCA	cis	rs7520050	0.966	rs785520	ENSG00000280836.1	AL355480.1	6.12	1.32e-09	2.17e-07	0.22	0.19	Reticulocyte count;Red blood cell count;	chr1:46103164	chr1:45581219~45581321:-
BRCA	cis	rs11722779	0.658	rs6533044	ENSG00000251288.2	RP11-10L12.2	-6.12	1.32e-09	2.17e-07	-0.22	-0.19	Schizophrenia;	chr4:102965261	chr4:102751401~102752641:+
BRCA	cis	rs8114671	0.836	rs6142284	ENSG00000269202.1	RP4-614O4.12	6.12	1.32e-09	2.18e-07	0.19	0.19	Height;	chr20:35053564	chr20:35201747~35203288:-
BRCA	cis	rs651907	0.557	rs2303474	ENSG00000244119.1	PDCL3P4	6.12	1.33e-09	2.18e-07	0.16	0.19	Colorectal cancer;	chr3:101653055	chr3:101712472~101713191:+
BRCA	cis	rs12468226	0.873	rs12472035	ENSG00000226261.1	AC064836.3	6.12	1.33e-09	2.18e-07	0.33	0.19	Urate levels;	chr2:202221970	chr2:202336024~202336727:-
BRCA	cis	rs2732480	0.5	rs12829841	ENSG00000257763.1	OR5BK1P	6.12	1.33e-09	2.18e-07	0.2	0.19	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48234956	chr12:48355792~48356614:-
BRCA	cis	rs2732480	0.523	rs34286639	ENSG00000257763.1	OR5BK1P	6.12	1.33e-09	2.18e-07	0.2	0.19	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48235261	chr12:48355792~48356614:-
BRCA	cis	rs7615952	0.576	rs1127717	ENSG00000250012.1	RP11-124N2.1	-6.12	1.33e-09	2.18e-07	-0.25	-0.19	Blood pressure (smoking interaction);	chr3:126107216	chr3:126084220~126095349:+
BRCA	cis	rs7923837	0.656	rs2497306	ENSG00000236493.2	EIF2S2P3	-6.12	1.33e-09	2.18e-07	-0.24	-0.19	Multiple sclerosis;Body mass index;	chr10:92725454	chr10:92668745~92669743:-
BRCA	cis	rs6142102	0.778	rs4911374	ENSG00000275784.1	RP5-1125A11.6	-6.12	1.33e-09	2.18e-07	-0.23	-0.19	Skin pigmentation;	chr20:33928195	chr20:33989480~33991818:-
BRCA	cis	rs4713118	0.516	rs6931858	ENSG00000219392.1	RP1-265C24.5	-6.12	1.33e-09	2.18e-07	-0.28	-0.19	Parkinson's disease;	chr6:28110633	chr6:28115628~28116551:+
BRCA	cis	rs4763879	0.778	rs11052497	ENSG00000256673.1	RP11-599J14.2	6.12	1.33e-09	2.18e-07	0.21	0.19	Type 1 diabetes;	chr12:9696679	chr12:9398355~9414851:-
BRCA	cis	rs56046484	0.778	rs1606119	ENSG00000259295.5	CSPG4P12	6.12	1.33e-09	2.19e-07	0.24	0.19	Testicular germ cell tumor;	chr15:85128148	chr15:85191438~85213905:+
BRCA	cis	rs9652601	0.648	rs7197422	ENSG00000274038.1	RP11-66H6.4	-6.12	1.33e-09	2.19e-07	-0.21	-0.19	Systemic lupus erythematosus;	chr16:11027214	chr16:11056556~11057034:+
BRCA	cis	rs867371	1	rs9944197	ENSG00000276710.3	CSPG4P8	-6.12	1.33e-09	2.19e-07	-0.2	-0.19	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82158261	chr15:82459472~82477258:+
BRCA	cis	rs7487075	0.78	rs12320197	ENSG00000257261.4	RP11-96H19.1	6.12	1.33e-09	2.19e-07	0.2	0.19	Itch intensity from mosquito bite;	chr12:46345100	chr12:46383679~46876159:+
BRCA	cis	rs1707322	0.928	rs6681068	ENSG00000281133.1	AL355480.3	-6.12	1.33e-09	2.19e-07	-0.24	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45932710	chr1:45580892~45580996:-
BRCA	cis	rs853679	0.517	rs9393890	ENSG00000204709.4	LINC01556	6.12	1.33e-09	2.19e-07	0.27	0.19	Depression;	chr6:28096077	chr6:28943877~28944537:+
BRCA	cis	rs853679	0.517	rs9366715	ENSG00000204709.4	LINC01556	6.12	1.33e-09	2.19e-07	0.27	0.19	Depression;	chr6:28096855	chr6:28943877~28944537:+
BRCA	cis	rs7129556	1	rs7129556	ENSG00000255449.1	RP11-91P24.6	-6.12	1.33e-09	2.19e-07	-0.26	-0.19	Weight loss (gastric bypass surgery);	chr11:77589003	chr11:77866412~77870091:-
BRCA	cis	rs10129255	0.744	rs28517388	ENSG00000224373.3	IGHV4-59	6.12	1.33e-09	2.19e-07	0.13	0.19	Kawasaki disease;	chr14:106704323	chr14:106627249~106627825:-
BRCA	cis	rs2243480	1	rs35058610	ENSG00000229886.1	RP5-1132H15.3	6.12	1.34e-09	2.19e-07	0.32	0.19	Diabetic kidney disease;	chr7:65925938	chr7:66025126~66031544:-
BRCA	cis	rs1713985	0.508	rs1277282	ENSG00000269949.1	RP11-738E22.3	6.12	1.34e-09	2.19e-07	0.34	0.19	Age-related macular degeneration;	chr4:56989653	chr4:56960927~56961373:-
BRCA	cis	rs9423406	0.501	rs7075810	ENSG00000224034.1	RP11-445P17.8	-6.12	1.34e-09	2.19e-07	-0.3	-0.19	Intelligence;	chr10:5283321	chr10:5266033~5271236:-
BRCA	cis	rs13108904	0.935	rs3755920	ENSG00000254094.1	AC078852.1	-6.12	1.34e-09	2.2e-07	-0.2	-0.19	Obesity-related traits;	chr4:1249829	chr4:1356581~1358075:+
BRCA	cis	rs853679	0.517	rs4713145	ENSG00000204709.4	LINC01556	6.12	1.34e-09	2.2e-07	0.27	0.19	Depression;	chr6:28139049	chr6:28943877~28944537:+
BRCA	cis	rs9876781	0.967	rs2885509	ENSG00000229759.1	MRPS18AP1	-6.12	1.34e-09	2.2e-07	-0.21	-0.19	Longevity;	chr3:48376729	chr3:48256350~48256938:-
BRCA	cis	rs853679	0.517	rs1904841	ENSG00000204709.4	LINC01556	6.12	1.34e-09	2.2e-07	0.28	0.19	Depression;	chr6:28140307	chr6:28943877~28944537:+
BRCA	cis	rs11976180	1	rs1320894	ENSG00000273234.1	OR2A13P	-6.12	1.34e-09	2.2e-07	-0.25	-0.19	Obesity-related traits;	chr7:144054709	chr7:144142009~144142938:+
BRCA	cis	rs11976180	1	rs2951369	ENSG00000273234.1	OR2A13P	-6.12	1.34e-09	2.2e-07	-0.25	-0.19	Obesity-related traits;	chr7:144055545	chr7:144142009~144142938:+
BRCA	cis	rs875971	0.522	rs1880556	ENSG00000237310.1	GS1-124K5.4	6.12	1.34e-09	2.2e-07	0.19	0.19	Aortic root size;	chr7:65967557	chr7:66493706~66495474:+
BRCA	cis	rs2836950	0.52	rs8130240	ENSG00000238141.2	BRWD1-AS1	-6.12	1.34e-09	2.2e-07	-0.21	-0.19	Menarche (age at onset);	chr21:39166182	chr21:39315707~39323218:+
BRCA	cis	rs7914558	0.901	rs35525740	ENSG00000213061.2	PFN1P11	6.12	1.34e-09	2.2e-07	0.24	0.19	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103181355	chr10:102838011~102845473:-
BRCA	cis	rs7914558	0.869	rs10883842	ENSG00000213061.2	PFN1P11	6.12	1.34e-09	2.2e-07	0.24	0.19	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103181832	chr10:102838011~102845473:-
BRCA	cis	rs853679	0.517	rs9295761	ENSG00000280107.1	AL022393.9	-6.12	1.34e-09	2.2e-07	-0.28	-0.19	Depression;	chr6:28180209	chr6:28170845~28172521:+
BRCA	cis	rs250585	1	rs152457	ENSG00000260136.4	CTD-2270L9.4	6.12	1.34e-09	2.21e-07	0.22	0.19	Egg allergy;	chr16:23570357	chr16:23452758~23457606:+
BRCA	cis	rs853679	0.517	rs1947863	ENSG00000280107.1	AL022393.9	-6.12	1.34e-09	2.21e-07	-0.28	-0.19	Depression;	chr6:28131566	chr6:28170845~28172521:+
BRCA	cis	rs17301013	0.507	rs2281010	ENSG00000227373.4	RP11-160H22.5	6.12	1.35e-09	2.21e-07	0.28	0.19	Systemic lupus erythematosus;	chr1:174509917	chr1:174115300~174160004:-
BRCA	cis	rs7976269	0.583	rs2117997	ENSG00000257176.2	RP11-996F15.2	6.12	1.35e-09	2.21e-07	0.23	0.19	Male-pattern baldness;	chr12:29143428	chr12:29280418~29317848:-
BRCA	cis	rs227275	0.525	rs10028116	ENSG00000251288.2	RP11-10L12.2	-6.12	1.35e-09	2.21e-07	-0.22	-0.19	Allergic disease (asthma, hay fever or eczema);	chr4:102931421	chr4:102751401~102752641:+
BRCA	cis	rs2281636	0.723	rs11190195	ENSG00000233690.1	EBAG9P1	-6.12	1.35e-09	2.21e-07	-0.21	-0.19	Obesity-related traits;	chr10:99626710	chr10:99697407~99697949:-
BRCA	cis	rs2834288	0.535	rs7275560	ENSG00000273102.1	AP000569.9	-6.12	1.35e-09	2.21e-07	-0.21	-0.19	Gut microbiota (bacterial taxa);	chr21:33956140	chr21:33967101~33968573:-
BRCA	cis	rs2834288	0.535	rs2834306	ENSG00000273102.1	AP000569.9	-6.12	1.35e-09	2.21e-07	-0.21	-0.19	Gut microbiota (bacterial taxa);	chr21:33957563	chr21:33967101~33968573:-
BRCA	cis	rs4950322	0.57	rs72691032	ENSG00000244371.2	PFN1P8	-6.12	1.35e-09	2.21e-07	-0.26	-0.19	Protein quantitative trait loci;	chr1:147261120	chr1:146957117~146957659:-
BRCA	cis	rs4950322	0.57	rs72691033	ENSG00000244371.2	PFN1P8	-6.12	1.35e-09	2.21e-07	-0.26	-0.19	Protein quantitative trait loci;	chr1:147261267	chr1:146957117~146957659:-
BRCA	cis	rs13113518	0.812	rs4865001	ENSG00000273257.1	RP11-177J6.1	6.12	1.35e-09	2.21e-07	0.24	0.19	Height;	chr4:55490176	chr4:55387949~55388271:+
BRCA	cis	rs13113518	0.756	rs7658446	ENSG00000273257.1	RP11-177J6.1	6.12	1.35e-09	2.21e-07	0.24	0.19	Height;	chr4:55495262	chr4:55387949~55388271:+
BRCA	cis	rs7131987	0.565	rs6487797	ENSG00000257176.2	RP11-996F15.2	6.12	1.35e-09	2.22e-07	0.21	0.19	QT interval;	chr12:29270063	chr12:29280418~29317848:-
BRCA	cis	rs13113518	0.812	rs12505880	ENSG00000223305.1	RN7SKP30	6.12	1.35e-09	2.22e-07	0.22	0.19	Height;	chr4:55440988	chr4:55540502~55540835:-
BRCA	cis	rs6860806	0.507	rs274570	ENSG00000233006.5	AC034220.3	-6.12	1.35e-09	2.22e-07	-0.16	-0.19	Breast cancer;	chr5:132377534	chr5:132311285~132369916:-
BRCA	cis	rs516805	0.667	rs2606600	ENSG00000279453.1	RP3-425C14.4	6.12	1.35e-09	2.22e-07	0.28	0.19	Lymphocyte counts;	chr6:122204398	chr6:122436789~122439223:-
BRCA	cis	rs2153535	0.56	rs9405406	ENSG00000230939.1	RP11-314C16.1	-6.12	1.35e-09	2.22e-07	-0.22	-0.19	Motion sickness;	chr6:8654625	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.585	rs1998364	ENSG00000230939.1	RP11-314C16.1	-6.12	1.35e-09	2.22e-07	-0.22	-0.19	Motion sickness;	chr6:8657091	chr6:8784178~8785445:+
BRCA	cis	rs4713118	0.513	rs149942	ENSG00000216901.1	AL022393.7	6.12	1.35e-09	2.22e-07	0.25	0.19	Parkinson's disease;	chr6:28033832	chr6:28176188~28176674:+
BRCA	cis	rs4713118	0.513	rs149944	ENSG00000216901.1	AL022393.7	6.12	1.35e-09	2.22e-07	0.25	0.19	Parkinson's disease;	chr6:28035040	chr6:28176188~28176674:+
BRCA	cis	rs4713118	0.513	rs149945	ENSG00000216901.1	AL022393.7	6.12	1.35e-09	2.22e-07	0.25	0.19	Parkinson's disease;	chr6:28035075	chr6:28176188~28176674:+
BRCA	cis	rs34779708	0.966	rs12775548	ENSG00000271335.4	RP11-324I22.4	6.12	1.36e-09	2.22e-07	0.2	0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35190576	chr10:35314552~35336401:-
BRCA	cis	rs67981189	0.821	rs61990419	ENSG00000258571.1	PTTG4P	-6.12	1.36e-09	2.23e-07	-0.21	-0.19	Schizophrenia;	chr14:71069570	chr14:71085482~71085833:-
BRCA	cis	rs853679	0.517	rs12174753	ENSG00000204709.4	LINC01556	6.12	1.36e-09	2.23e-07	0.27	0.19	Depression;	chr6:28074687	chr6:28943877~28944537:+
BRCA	cis	rs867371	0.502	rs28610286	ENSG00000255769.6	GOLGA2P10	-6.12	1.36e-09	2.23e-07	-0.2	-0.19	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82233314	chr15:82472993~82513950:-
BRCA	cis	rs2153535	0.518	rs1328859	ENSG00000230939.1	RP11-314C16.1	-6.12	1.36e-09	2.23e-07	-0.22	-0.19	Motion sickness;	chr6:8562582	chr6:8784178~8785445:+
BRCA	cis	rs875971	0.545	rs7811204	ENSG00000236529.1	RP13-254B10.1	6.12	1.36e-09	2.23e-07	0.24	0.19	Aortic root size;	chr7:66387213	chr7:65840212~65840596:+
BRCA	cis	rs12468226	0.938	rs80315897	ENSG00000226261.1	AC064836.3	6.12	1.36e-09	2.23e-07	0.32	0.19	Urate levels;	chr2:202318044	chr2:202336024~202336727:-
BRCA	cis	rs875971	0.862	rs801195	ENSG00000224316.1	RP11-479O9.2	-6.12	1.36e-09	2.23e-07	-0.19	-0.19	Aortic root size;	chr7:66561128	chr7:65773620~65802067:+
BRCA	cis	rs4713118	0.629	rs203889	ENSG00000219392.1	RP1-265C24.5	-6.12	1.36e-09	2.24e-07	-0.27	-0.19	Parkinson's disease;	chr6:28053997	chr6:28115628~28116551:+
BRCA	cis	rs875971	0.929	rs6970860	ENSG00000224316.1	RP11-479O9.2	6.11	1.36e-09	2.24e-07	0.19	0.19	Aortic root size;	chr7:66511647	chr7:65773620~65802067:+
BRCA	cis	rs227275	0.554	rs223409	ENSG00000251288.2	RP11-10L12.2	-6.11	1.36e-09	2.24e-07	-0.22	-0.19	Allergic disease (asthma, hay fever or eczema);	chr4:102815023	chr4:102751401~102752641:+
BRCA	cis	rs17301013	0.507	rs41266050	ENSG00000227373.4	RP11-160H22.5	6.11	1.37e-09	2.24e-07	0.28	0.19	Systemic lupus erythematosus;	chr1:174547861	chr1:174115300~174160004:-
BRCA	cis	rs904251	0.766	rs1757175	ENSG00000204110.6	RP1-153P14.8	-6.11	1.37e-09	2.24e-07	-0.21	-0.19	Cognitive performance;	chr6:37518918	chr6:37507348~37535616:+
BRCA	cis	rs904251	0.828	rs1757174	ENSG00000204110.6	RP1-153P14.8	-6.11	1.37e-09	2.24e-07	-0.21	-0.19	Cognitive performance;	chr6:37518919	chr6:37507348~37535616:+
BRCA	cis	rs2243480	1	rs160633	ENSG00000232559.3	GS1-124K5.12	6.11	1.37e-09	2.25e-07	0.37	0.19	Diabetic kidney disease;	chr7:66063241	chr7:66554588~66576923:-
BRCA	cis	rs17345786	0.511	rs1138818	ENSG00000244119.1	PDCL3P4	6.11	1.37e-09	2.25e-07	0.15	0.19	Colonoscopy-negative controls vs population controls;	chr3:101680739	chr3:101712472~101713191:+
BRCA	cis	rs853679	0.546	rs175597	ENSG00000220721.1	OR1F12	6.11	1.37e-09	2.25e-07	0.34	0.19	Depression;	chr6:27842848	chr6:28073316~28074233:+
BRCA	cis	rs7945705	0.715	rs10840123	ENSG00000254860.4	TMEM9B-AS1	-6.11	1.37e-09	2.25e-07	-0.18	-0.19	Hemoglobin concentration;	chr11:8797468	chr11:8964675~8977527:+
BRCA	cis	rs600231	0.598	rs2508712	ENSG00000245532.5	NEAT1	6.11	1.37e-09	2.25e-07	0.17	0.19	Bone mineral density;	chr11:65464790	chr11:65422774~65445540:+
BRCA	cis	rs7044106	0.708	rs1324472	ENSG00000238181.2	AHCYP2	-6.11	1.37e-09	2.25e-07	-0.24	-0.19	Hip circumference adjusted for BMI;	chr9:120612832	chr9:120720673~120721972:+
BRCA	cis	rs17711722	0.675	rs6947132	ENSG00000234585.5	CCT6P3	-6.11	1.37e-09	2.25e-07	-0.18	-0.19	Calcium levels;	chr7:65808508	chr7:65038354~65074713:+
BRCA	cis	rs4984778	0.717	rs2738892	ENSG00000260182.1	RP11-616M22.5	6.11	1.37e-09	2.25e-07	0.22	0.19	Blood protein levels;	chr16:1218758	chr16:1257339~1258074:+
BRCA	cis	rs7246657	1	rs35398388	ENSG00000267422.1	CTD-2554C21.1	-6.11	1.37e-09	2.25e-07	-0.29	-0.19	Coronary artery calcification;	chr19:37249456	chr19:37779686~37792865:+
BRCA	cis	rs7246657	1	rs7247672	ENSG00000267422.1	CTD-2554C21.1	-6.11	1.37e-09	2.25e-07	-0.29	-0.19	Coronary artery calcification;	chr19:37253026	chr19:37779686~37792865:+
BRCA	cis	rs7246657	1	rs8110011	ENSG00000267422.1	CTD-2554C21.1	-6.11	1.37e-09	2.25e-07	-0.29	-0.19	Coronary artery calcification;	chr19:37254911	chr19:37779686~37792865:+
BRCA	cis	rs1858037	0.867	rs871974	ENSG00000204929.10	AC074391.1	-6.11	1.37e-09	2.25e-07	-0.25	-0.19	Rheumatoid arthritis;	chr2:65330153	chr2:65436711~66084639:+
BRCA	cis	rs2562456	0.874	rs2562417	ENSG00000268081.1	RP11-678G14.2	-6.11	1.37e-09	2.25e-07	-0.29	-0.19	Pain;	chr19:21528400	chr19:21554640~21569237:-
BRCA	cis	rs13126694	0.744	rs10003459	ENSG00000251429.1	RP11-597D13.7	-6.11	1.38e-09	2.25e-07	-0.18	-0.19	Blood osmolality (transformed sodium);	chr4:158095602	chr4:158270378~158278676:+
BRCA	cis	rs13113518	0.812	rs4864543	ENSG00000273257.1	RP11-177J6.1	6.11	1.38e-09	2.26e-07	0.24	0.19	Height;	chr4:55490228	chr4:55387949~55388271:+
BRCA	cis	rs13113518	0.812	rs6825774	ENSG00000273257.1	RP11-177J6.1	6.11	1.38e-09	2.26e-07	0.24	0.19	Height;	chr4:55491150	chr4:55387949~55388271:+
BRCA	cis	rs13113518	0.812	rs3805153	ENSG00000273257.1	RP11-177J6.1	6.11	1.38e-09	2.26e-07	0.24	0.19	Height;	chr4:55493557	chr4:55387949~55388271:+
BRCA	cis	rs847577	0.722	rs7790736	ENSG00000272950.1	RP11-307C18.1	6.11	1.38e-09	2.26e-07	0.24	0.19	Breast cancer;	chr7:98083727	chr7:98322853~98323430:+
BRCA	cis	rs7520050	0.966	rs2275426	ENSG00000280836.1	AL355480.1	6.11	1.38e-09	2.26e-07	0.22	0.19	Reticulocyte count;Red blood cell count;	chr1:46021880	chr1:45581219~45581321:-
BRCA	cis	rs1387259	0.839	rs7487682	ENSG00000273765.1	RP11-370I10.11	-6.11	1.38e-09	2.26e-07	-0.22	-0.19	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48185882	chr12:48360920~48361377:+
BRCA	cis	rs2638953	0.924	rs11049418	ENSG00000278733.1	RP11-425D17.1	-6.11	1.38e-09	2.26e-07	-0.25	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28192154	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.924	rs12367188	ENSG00000278733.1	RP11-425D17.1	-6.11	1.38e-09	2.26e-07	-0.25	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28192511	chr12:28185625~28186190:-
BRCA	cis	rs17301013	0.507	rs2901820	ENSG00000227373.4	RP11-160H22.5	6.11	1.38e-09	2.26e-07	0.29	0.19	Systemic lupus erythematosus;	chr1:174505201	chr1:174115300~174160004:-
BRCA	cis	rs860818	1	rs1728344	ENSG00000226816.2	AC005082.12	6.11	1.38e-09	2.26e-07	0.45	0.19	Initial pursuit acceleration;	chr7:23210425	chr7:23206013~23208045:+
BRCA	cis	rs860818	1	rs858281	ENSG00000226816.2	AC005082.12	6.11	1.38e-09	2.26e-07	0.45	0.19	Initial pursuit acceleration;	chr7:23210948	chr7:23206013~23208045:+
BRCA	cis	rs860818	1	rs858280	ENSG00000226816.2	AC005082.12	6.11	1.38e-09	2.26e-07	0.45	0.19	Initial pursuit acceleration;	chr7:23211255	chr7:23206013~23208045:+
BRCA	cis	rs860818	1	rs6955934	ENSG00000226816.2	AC005082.12	6.11	1.38e-09	2.26e-07	0.45	0.19	Initial pursuit acceleration;	chr7:23211880	chr7:23206013~23208045:+
BRCA	cis	rs2243480	0.803	rs13224048	ENSG00000232559.3	GS1-124K5.12	6.11	1.38e-09	2.26e-07	0.35	0.19	Diabetic kidney disease;	chr7:66528779	chr7:66554588~66576923:-
BRCA	cis	rs17301013	0.507	rs55748748	ENSG00000227373.4	RP11-160H22.5	6.11	1.38e-09	2.26e-07	0.28	0.19	Systemic lupus erythematosus;	chr1:174546252	chr1:174115300~174160004:-
BRCA	cis	rs6688613	1	rs6695162	ENSG00000225171.2	DUTP6	-6.11	1.38e-09	2.26e-07	-0.22	-0.19	Refractive astigmatism;	chr1:166984218	chr1:166868748~166869209:+
BRCA	cis	rs1707322	0.964	rs7546237	ENSG00000281133.1	AL355480.3	-6.11	1.38e-09	2.26e-07	-0.23	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45819938	chr1:45580892~45580996:-
BRCA	cis	rs2153535	0.585	rs6900539	ENSG00000230939.1	RP11-314C16.1	-6.11	1.38e-09	2.27e-07	-0.22	-0.19	Motion sickness;	chr6:8592054	chr6:8784178~8785445:+
BRCA	cis	rs2243480	0.831	rs57294491	ENSG00000229886.1	RP5-1132H15.3	-6.11	1.38e-09	2.27e-07	-0.33	-0.19	Diabetic kidney disease;	chr7:66219914	chr7:66025126~66031544:-
BRCA	cis	rs301901	0.796	rs1517789	ENSG00000250155.1	CTD-2353F22.1	6.11	1.39e-09	2.27e-07	0.21	0.19	Height;	chr5:37510578	chr5:36666214~36725195:-
BRCA	cis	rs4660456	0.529	rs61779237	ENSG00000237899.1	RP4-739H11.3	6.11	1.39e-09	2.27e-07	0.24	0.19	Platelet count;	chr1:40685300	chr1:40669089~40687588:-
BRCA	cis	rs6750795	0.87	rs6754952	ENSG00000223198.1	RNU2-22P	6.11	1.39e-09	2.27e-07	0.23	0.19	Height;	chr2:231516534	chr2:231501990~231502201:-
BRCA	cis	rs6442522	0.678	rs13085575	ENSG00000249786.6	EAF1-AS1	6.11	1.39e-09	2.28e-07	0.19	0.19	Uric acid levels;	chr3:15457823	chr3:15436171~15455940:-
BRCA	cis	rs6728642	0.808	rs113319086	ENSG00000230606.9	AC159540.1	6.11	1.39e-09	2.28e-07	0.4	0.19	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:96967530	chr2:97416165~97433527:-
BRCA	cis	rs2243480	1	rs1267820	ENSG00000232559.3	GS1-124K5.12	6.11	1.39e-09	2.28e-07	0.36	0.19	Diabetic kidney disease;	chr7:66585308	chr7:66554588~66576923:-
BRCA	cis	rs1667284	0.555	rs1551006	ENSG00000266521.1	RP11-650P15.1	6.11	1.39e-09	2.28e-07	0.22	0.19	Problematic alcohol use in trauma-exposed individuals;	chr18:31653282	chr18:31496645~31497195:-
BRCA	cis	rs8072100	0.701	rs6503807	ENSG00000228782.6	CTD-2026D20.3	6.11	1.39e-09	2.28e-07	0.21	0.19	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47695566	chr17:47450568~47492492:-
BRCA	cis	rs9987353	0.566	rs13260067	ENSG00000253893.2	FAM85B	6.11	1.4e-09	2.28e-07	0.25	0.19	Recombination measurement;	chr8:9213523	chr8:8167819~8226614:-
BRCA	cis	rs67981189	0.784	rs58984901	ENSG00000258571.1	PTTG4P	-6.11	1.4e-09	2.29e-07	-0.21	-0.19	Schizophrenia;	chr14:71085271	chr14:71085482~71085833:-
BRCA	cis	rs6570726	0.818	rs952405	ENSG00000270638.1	RP3-466P17.1	6.11	1.4e-09	2.29e-07	0.21	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145604816	chr6:145735570~145737218:+
BRCA	cis	rs875971	0.83	rs809025	ENSG00000224316.1	RP11-479O9.2	6.11	1.4e-09	2.29e-07	0.19	0.19	Aortic root size;	chr7:66384832	chr7:65773620~65802067:+
BRCA	cis	rs2243480	1	rs4718334	ENSG00000229886.1	RP5-1132H15.3	-6.11	1.4e-09	2.29e-07	-0.33	-0.19	Diabetic kidney disease;	chr7:66324467	chr7:66025126~66031544:-
BRCA	cis	rs7746199	0.736	rs58616630	ENSG00000220721.1	OR1F12	6.11	1.4e-09	2.29e-07	0.44	0.19	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27506936	chr6:28073316~28074233:+
BRCA	cis	rs2749097	0.825	rs10889436	ENSG00000244256.3	RN7SL130P	-6.11	1.4e-09	2.29e-07	-0.24	-0.19	Alcohol consumption (transferrin glycosylation);	chr1:63658226	chr1:63655743~63656047:+
BRCA	cis	rs2243480	1	rs1638734	ENSG00000228409.4	CCT6P1	6.11	1.4e-09	2.29e-07	0.26	0.19	Diabetic kidney disease;	chr7:66632552	chr7:65751142~65763354:+
BRCA	cis	rs1697139	0.935	rs1627990	ENSG00000249364.4	RP11-434D9.1	6.11	1.4e-09	2.3e-07	0.21	0.19	Breast cancer;	chr5:67217498	chr5:67379378~67805238:+
BRCA	cis	rs9880211	0.613	rs12330335	ENSG00000239213.4	NCK1-AS1	6.11	1.41e-09	2.3e-07	0.24	0.19	Height;Body mass index;	chr3:136134690	chr3:136841726~136862054:-
BRCA	cis	rs11096990	0.892	rs11931354	ENSG00000249207.1	RP11-360F5.1	6.11	1.41e-09	2.31e-07	0.22	0.19	Cognitive function;	chr4:39229856	chr4:39112677~39126818:-
BRCA	cis	rs9341808	0.754	rs3805885	ENSG00000272129.1	RP11-250B2.6	-6.11	1.41e-09	2.31e-07	-0.23	-0.19	Sitting height ratio;	chr6:80287034	chr6:80355424~80356859:+
BRCA	cis	rs1124769	0.748	rs12442459	ENSG00000259378.1	DCAF13P3	6.11	1.41e-09	2.31e-07	0.27	0.19	Cognitive performance;	chr15:51074518	chr15:50944663~50945996:+
BRCA	cis	rs7569084	0.663	rs1437461	ENSG00000237979.1	AC007389.1	6.11	1.41e-09	2.31e-07	0.24	0.19	Sum eosinophil basophil counts;	chr2:65452578	chr2:65500993~65502138:-
BRCA	cis	rs7569084	0.687	rs7562559	ENSG00000237979.1	AC007389.1	6.11	1.41e-09	2.31e-07	0.24	0.19	Sum eosinophil basophil counts;	chr2:65452719	chr2:65500993~65502138:-
BRCA	cis	rs7809950	0.678	rs13230144	ENSG00000238832.1	snoU109	-6.11	1.41e-09	2.31e-07	-0.27	-0.19	Coronary artery disease;	chr7:107268727	chr7:107603363~107603507:+
BRCA	cis	rs5015933	0.902	rs7872015	ENSG00000232630.1	PRPS1P2	-6.11	1.41e-09	2.31e-07	-0.17	-0.19	Body mass index;	chr9:125368854	chr9:125150653~125151589:+
BRCA	cis	rs875971	0.545	rs6950988	ENSG00000273024.4	INTS4P2	-6.11	1.41e-09	2.31e-07	-0.23	-0.19	Aortic root size;	chr7:66511428	chr7:65647864~65715661:+
BRCA	cis	rs858239	0.539	rs2390757	ENSG00000230042.1	AK3P3	-6.11	1.41e-09	2.31e-07	-0.22	-0.19	Cerebrospinal fluid biomarker levels;	chr7:23151873	chr7:23129178~23129841:+
BRCA	cis	rs11009175	1	rs11009175	ENSG00000273038.2	RP11-479G22.8	-6.11	1.41e-09	2.31e-07	-0.34	-0.19	Depression (quantitative trait);	chr10:33005847	chr10:32887255~32889311:-
BRCA	cis	rs910316	0.763	rs175057	ENSG00000279594.1	RP11-950C14.10	-6.11	1.41e-09	2.31e-07	-0.21	-0.19	Height;	chr14:75022929	chr14:75011269~75012851:-
BRCA	cis	rs67981189	0.896	rs2526846	ENSG00000258571.1	PTTG4P	6.11	1.41e-09	2.31e-07	0.2	0.19	Schizophrenia;	chr14:70957538	chr14:71085482~71085833:-
BRCA	cis	rs9907295	0.688	rs4796135	ENSG00000270977.1	AC015849.16	-6.11	1.41e-09	2.32e-07	-0.28	-0.19	Fibroblast growth factor basic levels;	chr17:35924236	chr17:35893707~35911023:-
BRCA	cis	rs9907295	0.688	rs4796136	ENSG00000270977.1	AC015849.16	-6.11	1.41e-09	2.32e-07	-0.28	-0.19	Fibroblast growth factor basic levels;	chr17:35924397	chr17:35893707~35911023:-
BRCA	cis	rs9907295	0.688	rs4796137	ENSG00000270977.1	AC015849.16	-6.11	1.41e-09	2.32e-07	-0.28	-0.19	Fibroblast growth factor basic levels;	chr17:35924448	chr17:35893707~35911023:-
BRCA	cis	rs56114371	0.53	rs2056923	ENSG00000220721.1	OR1F12	6.11	1.42e-09	2.32e-07	0.28	0.19	Breast cancer;	chr6:27722160	chr6:28073316~28074233:+
BRCA	cis	rs4763879	0.778	rs2895989	ENSG00000214776.8	RP11-726G1.1	-6.11	1.42e-09	2.32e-07	-0.21	-0.19	Type 1 diabetes;	chr12:9688735	chr12:9467552~9576275:+
BRCA	cis	rs2836950	0.545	rs8132424	ENSG00000238141.2	BRWD1-AS1	6.11	1.42e-09	2.32e-07	0.21	0.19	Menarche (age at onset);	chr21:39212486	chr21:39315707~39323218:+
BRCA	cis	rs2380205	0.504	rs591878	ENSG00000232807.2	RP11-536K7.3	6.11	1.42e-09	2.32e-07	0.19	0.19	Breast cancer;	chr10:5893474	chr10:5934270~5945900:-
BRCA	cis	rs2243480	0.711	rs1626926	ENSG00000229886.1	RP5-1132H15.3	6.11	1.42e-09	2.32e-07	0.32	0.19	Diabetic kidney disease;	chr7:65970805	chr7:66025126~66031544:-
BRCA	cis	rs228614	0.51	rs6830407	ENSG00000251288.2	RP11-10L12.2	-6.11	1.42e-09	2.32e-07	-0.22	-0.19	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102895366	chr4:102751401~102752641:+
BRCA	cis	rs8103033	0.786	rs6508899	ENSG00000226025.8	LGALS17A	6.11	1.42e-09	2.33e-07	0.21	0.19	Obesity-related traits;	chr19:39661982	chr19:39679374~39686373:+
BRCA	cis	rs4950322	0.57	rs17360443	ENSG00000278811.3	LINC00624	6.11	1.42e-09	2.33e-07	0.25	0.19	Protein quantitative trait loci;	chr1:147279737	chr1:147258885~147517875:-
BRCA	cis	rs7520050	0.966	rs1085244	ENSG00000280836.1	AL355480.1	6.11	1.42e-09	2.33e-07	0.22	0.19	Reticulocyte count;Red blood cell count;	chr1:46098008	chr1:45581219~45581321:-
BRCA	cis	rs7520050	0.966	rs6662641	ENSG00000280836.1	AL355480.1	6.11	1.42e-09	2.33e-07	0.22	0.19	Reticulocyte count;Red blood cell count;	chr1:46105837	chr1:45581219~45581321:-
BRCA	cis	rs7520050	0.966	rs1707335	ENSG00000280836.1	AL355480.1	6.11	1.42e-09	2.33e-07	0.22	0.19	Reticulocyte count;Red blood cell count;	chr1:46106249	chr1:45581219~45581321:-
BRCA	cis	rs8114671	0.836	rs4911461	ENSG00000269202.1	RP4-614O4.12	6.11	1.42e-09	2.33e-07	0.19	0.19	Height;	chr20:35042190	chr20:35201747~35203288:-
BRCA	cis	rs853679	0.517	rs9393896	ENSG00000204709.4	LINC01556	6.11	1.43e-09	2.33e-07	0.28	0.19	Depression;	chr6:28159925	chr6:28943877~28944537:+
BRCA	cis	rs853679	0.517	rs9393897	ENSG00000204709.4	LINC01556	6.11	1.43e-09	2.33e-07	0.28	0.19	Depression;	chr6:28159932	chr6:28943877~28944537:+
BRCA	cis	rs9307551	0.857	rs7662551	ENSG00000250334.4	LINC00989	-6.11	1.43e-09	2.33e-07	-0.27	-0.19	Refractive error;	chr4:79616484	chr4:79492416~79576460:+
BRCA	cis	rs2060793	0.835	rs1037379	ENSG00000251991.1	RNU7-49P	6.11	1.43e-09	2.33e-07	0.21	0.19	Vitamin D levels;	chr11:14831238	chr11:14478892~14478953:+
BRCA	cis	rs73193808	1	rs73193819	ENSG00000215533.7	LINC00189	-6.11	1.43e-09	2.33e-07	-0.27	-0.19	Coronary artery disease;	chr21:29172336	chr21:29193480~29288205:+
BRCA	cis	rs73193808	1	rs73193820	ENSG00000215533.7	LINC00189	-6.11	1.43e-09	2.33e-07	-0.27	-0.19	Coronary artery disease;	chr21:29172348	chr21:29193480~29288205:+
BRCA	cis	rs2153535	0.585	rs9328500	ENSG00000230939.1	RP11-314C16.1	6.11	1.43e-09	2.34e-07	0.22	0.19	Motion sickness;	chr6:8658838	chr6:8784178~8785445:+
BRCA	cis	rs227275	0.525	rs6533050	ENSG00000251288.2	RP11-10L12.2	-6.11	1.43e-09	2.34e-07	-0.22	-0.19	Allergic disease (asthma, hay fever or eczema);	chr4:102979044	chr4:102751401~102752641:+
BRCA	cis	rs651907	0.557	rs17411983	ENSG00000244119.1	PDCL3P4	-6.11	1.43e-09	2.34e-07	-0.15	-0.19	Colorectal cancer;	chr3:101680282	chr3:101712472~101713191:+
BRCA	cis	rs34779708	0.868	rs2384352	ENSG00000271335.4	RP11-324I22.4	6.11	1.43e-09	2.34e-07	0.2	0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35203904	chr10:35314552~35336401:-
BRCA	cis	rs2243480	1	rs1553174	ENSG00000232559.3	GS1-124K5.12	-6.11	1.43e-09	2.34e-07	-0.35	-0.19	Diabetic kidney disease;	chr7:66266207	chr7:66554588~66576923:-
BRCA	cis	rs2243480	1	rs10950032	ENSG00000232559.3	GS1-124K5.12	-6.11	1.43e-09	2.34e-07	-0.35	-0.19	Diabetic kidney disease;	chr7:66273604	chr7:66554588~66576923:-
BRCA	cis	rs7246657	0.525	rs1667357	ENSG00000276846.1	CTD-3220F14.3	6.11	1.43e-09	2.35e-07	0.28	0.19	Coronary artery calcification;	chr19:36993450	chr19:37314868~37315620:-
BRCA	cis	rs7246657	0.525	rs1667359	ENSG00000276846.1	CTD-3220F14.3	6.11	1.43e-09	2.35e-07	0.28	0.19	Coronary artery calcification;	chr19:36995270	chr19:37314868~37315620:-
BRCA	cis	rs7520050	0.966	rs10890363	ENSG00000280836.1	AL355480.1	-6.11	1.43e-09	2.35e-07	-0.22	-0.19	Reticulocyte count;Red blood cell count;	chr1:45890476	chr1:45581219~45581321:-
BRCA	cis	rs2243480	1	rs11538349	ENSG00000229886.1	RP5-1132H15.3	6.11	1.44e-09	2.35e-07	0.32	0.19	Diabetic kidney disease;	chr7:65956884	chr7:66025126~66031544:-
BRCA	cis	rs9652601	1	rs9652601	ENSG00000274038.1	RP11-66H6.4	-6.11	1.44e-09	2.35e-07	-0.21	-0.19	Systemic lupus erythematosus;	chr16:11080508	chr16:11056556~11057034:+
BRCA	cis	rs2732480	0.538	rs1387259	ENSG00000257763.1	OR5BK1P	-6.11	1.44e-09	2.35e-07	-0.2	-0.19	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48309739	chr12:48355792~48356614:-
BRCA	cis	rs1476670	0.71	rs2485993	ENSG00000230615.5	RP5-1198O20.4	6.11	1.44e-09	2.35e-07	0.28	0.19	Eotaxin levels;	chr1:44037368	chr1:44030443~44115913:+
BRCA	cis	rs11039216	1	rs11039216	ENSG00000280615.1	Y_RNA	6.11	1.44e-09	2.36e-07	0.21	0.19	Neuroticism;	chr11:47385041	chr11:47614898~47614994:-
BRCA	cis	rs2153535	0.518	rs9393054	ENSG00000230939.1	RP11-314C16.1	-6.11	1.44e-09	2.36e-07	-0.22	-0.19	Motion sickness;	chr6:8647209	chr6:8784178~8785445:+
BRCA	cis	rs2243480	1	rs1167613	ENSG00000232546.1	RP11-458F8.1	-6.11	1.44e-09	2.36e-07	-0.24	-0.19	Diabetic kidney disease;	chr7:66022452	chr7:66848496~66858136:+
BRCA	cis	rs2243480	1	rs313799	ENSG00000232546.1	RP11-458F8.1	-6.11	1.44e-09	2.36e-07	-0.24	-0.19	Diabetic kidney disease;	chr7:66029343	chr7:66848496~66858136:+
BRCA	cis	rs1823913	0.637	rs6722183	ENSG00000280083.1	RP11-317J9.1	6.11	1.44e-09	2.36e-07	0.21	0.19	Obesity-related traits;	chr2:191333203	chr2:191154118~191156070:-
BRCA	cis	rs253959	0.545	rs6896147	ENSG00000272265.1	CTD-2287O16.4	-6.11	1.45e-09	2.36e-07	-0.23	-0.19	Bipolar disorder and schizophrenia;	chr5:116089699	chr5:116078110~116078570:-
BRCA	cis	rs911555	0.723	rs11160751	ENSG00000244691.1	RPL10AP1	-6.11	1.45e-09	2.36e-07	-0.24	-0.19	Intelligence (multi-trait analysis);	chr14:103459403	chr14:103412119~103412761:-
BRCA	cis	rs875971	0.825	rs801202	ENSG00000224316.1	RP11-479O9.2	-6.11	1.45e-09	2.37e-07	-0.19	-0.19	Aortic root size;	chr7:66558942	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.767	rs61348003	ENSG00000224316.1	RP11-479O9.2	6.11	1.45e-09	2.37e-07	0.19	0.19	Aortic root size;	chr7:66540947	chr7:65773620~65802067:+
BRCA	cis	rs6583826	0.712	rs6583823	ENSG00000236493.2	EIF2S2P3	6.1	1.45e-09	2.37e-07	0.24	0.19	Type 2 diabetes;	chr10:92584658	chr10:92668745~92669743:-
BRCA	cis	rs13108904	0.901	rs12641735	ENSG00000254094.1	AC078852.1	-6.1	1.45e-09	2.37e-07	-0.2	-0.19	Obesity-related traits;	chr4:1310646	chr4:1356581~1358075:+
BRCA	cis	rs2243480	1	rs431318	ENSG00000164669.11	INTS4P1	6.1	1.45e-09	2.37e-07	0.37	0.19	Diabetic kidney disease;	chr7:66046610	chr7:65141225~65234216:+
BRCA	cis	rs754466	0.58	rs12356063	ENSG00000204049.1	RP11-126H7.4	6.1	1.45e-09	2.37e-07	0.22	0.19	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77798373	chr10:77866875~77869610:+
BRCA	cis	rs651907	0.557	rs7629753	ENSG00000244119.1	PDCL3P4	-6.1	1.45e-09	2.37e-07	-0.15	-0.19	Colorectal cancer;	chr3:101653078	chr3:101712472~101713191:+
BRCA	cis	rs78456975	1	rs6744743	ENSG00000231482.2	AC141930.2	6.1	1.45e-09	2.38e-07	0.27	0.19	Placebo response in major depressive disorder (% change in symptom score);	chr2:1554389	chr2:1572554~1580311:-
BRCA	cis	rs10129255	0.917	rs8022493	ENSG00000211972.2	IGHV3-66	6.1	1.45e-09	2.38e-07	0.14	0.19	Kawasaki disease;	chr14:106781820	chr14:106675017~106675544:-
BRCA	cis	rs8031584	0.541	rs2955777	ENSG00000260382.1	RP11-540B6.2	-6.1	1.46e-09	2.38e-07	-0.21	-0.19	Huntington's disease progression;	chr15:30927585	chr15:30882267~30883231:-
BRCA	cis	rs10266483	0.545	rs7777148	ENSG00000271550.1	BNIP3P11	-6.1	1.46e-09	2.38e-07	-0.29	-0.19	Response to statin therapy;	chr7:64285795	chr7:64678954~64687393:-
BRCA	cis	rs858239	0.508	rs7805085	ENSG00000230042.1	AK3P3	-6.1	1.46e-09	2.38e-07	-0.22	-0.19	Cerebrospinal fluid biomarker levels;	chr7:23150624	chr7:23129178~23129841:+
BRCA	cis	rs1707322	1	rs6695421	ENSG00000281133.1	AL355480.3	-6.1	1.46e-09	2.38e-07	-0.23	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45914535	chr1:45580892~45580996:-
BRCA	cis	rs34779708	0.931	rs35126129	ENSG00000271335.4	RP11-324I22.4	6.1	1.46e-09	2.38e-07	0.2	0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35163213	chr10:35314552~35336401:-
BRCA	cis	rs1387259	0.929	rs11168484	ENSG00000257763.1	OR5BK1P	6.1	1.46e-09	2.39e-07	0.2	0.19	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48239806	chr12:48355792~48356614:-
BRCA	cis	rs7160336	0.738	rs7161721	ENSG00000259065.1	RP5-1021I20.1	-6.1	1.46e-09	2.39e-07	-0.21	-0.19	Blood protein levels;	chr14:74031630	chr14:73787360~73803270:+
BRCA	cis	rs9545047	0.604	rs2876740	ENSG00000227354.5	RBM26-AS1	-6.1	1.46e-09	2.39e-07	-0.2	-0.19	Schizophrenia;	chr13:79409829	chr13:79406309~79424328:+
BRCA	cis	rs10129255	0.957	rs8022165	ENSG00000211972.2	IGHV3-66	6.1	1.46e-09	2.39e-07	0.14	0.19	Kawasaki disease;	chr14:106781682	chr14:106675017~106675544:-
BRCA	cis	rs6840360	1	rs10007167	ENSG00000270265.1	RP11-731D1.4	-6.1	1.46e-09	2.39e-07	-0.22	-0.19	Intelligence (multi-trait analysis);	chr4:151682503	chr4:151333775~151353224:-
BRCA	cis	rs42648	0.564	rs7783739	ENSG00000225498.1	AC002064.5	6.1	1.47e-09	2.39e-07	0.18	0.19	Homocysteine levels;	chr7:90172473	chr7:90312496~90322592:+
BRCA	cis	rs42648	0.564	rs10257064	ENSG00000225498.1	AC002064.5	6.1	1.47e-09	2.39e-07	0.18	0.19	Homocysteine levels;	chr7:90173282	chr7:90312496~90322592:+
BRCA	cis	rs911555	0.755	rs7148567	ENSG00000244691.1	RPL10AP1	-6.1	1.47e-09	2.39e-07	-0.23	-0.19	Intelligence (multi-trait analysis);	chr14:103415897	chr14:103412119~103412761:-
BRCA	cis	rs911555	0.755	rs10144051	ENSG00000244691.1	RPL10AP1	-6.1	1.47e-09	2.39e-07	-0.23	-0.19	Intelligence (multi-trait analysis);	chr14:103419594	chr14:103412119~103412761:-
BRCA	cis	rs7238033	0.62	rs11082469	ENSG00000267193.4	RP11-116O18.3	6.1	1.47e-09	2.39e-07	0.2	0.19	Bladder cancer;	chr18:45741304	chr18:45669367~45747215:-
BRCA	cis	rs1014246	0.826	rs4752004	ENSG00000232767.1	RP11-498B4.5	-6.1	1.47e-09	2.4e-07	-0.18	-0.19	Age at smoking initiation in chronic obstructive pulmonary disease;	chr10:116713698	chr10:116670103~116672739:+
BRCA	cis	rs875971	0.862	rs801194	ENSG00000224316.1	RP11-479O9.2	-6.1	1.47e-09	2.4e-07	-0.19	-0.19	Aortic root size;	chr7:66563508	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.862	rs11765791	ENSG00000224316.1	RP11-479O9.2	6.1	1.47e-09	2.4e-07	0.19	0.19	Aortic root size;	chr7:66471587	chr7:65773620~65802067:+
BRCA	cis	rs1124769	0.719	rs11070833	ENSG00000259378.1	DCAF13P3	6.1	1.47e-09	2.4e-07	0.25	0.19	Cognitive performance;	chr15:51087164	chr15:50944663~50945996:+
BRCA	cis	rs4713118	0.513	rs149950	ENSG00000216901.1	AL022393.7	6.1	1.47e-09	2.4e-07	0.24	0.19	Parkinson's disease;	chr6:28065261	chr6:28176188~28176674:+
BRCA	cis	rs4713118	0.513	rs149951	ENSG00000216901.1	AL022393.7	6.1	1.47e-09	2.4e-07	0.24	0.19	Parkinson's disease;	chr6:28065309	chr6:28176188~28176674:+
BRCA	cis	rs7914558	0.966	rs3977751	ENSG00000213061.2	PFN1P11	6.1	1.47e-09	2.41e-07	0.24	0.19	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103160475	chr10:102838011~102845473:-
BRCA	cis	rs228614	0.51	rs4699033	ENSG00000251288.2	RP11-10L12.2	-6.1	1.47e-09	2.41e-07	-0.22	-0.19	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102897577	chr4:102751401~102752641:+
BRCA	cis	rs7246657	0.55	rs10411176	ENSG00000226686.6	LINC01535	-6.1	1.48e-09	2.41e-07	-0.32	-0.19	Coronary artery calcification;	chr19:37196051	chr19:37251912~37265535:+
BRCA	cis	rs8103033	0.676	rs1988274	ENSG00000226025.8	LGALS17A	-6.1	1.48e-09	2.41e-07	-0.21	-0.19	Obesity-related traits;	chr19:39664258	chr19:39679374~39686373:+
BRCA	cis	rs8002861	0.935	rs1822969	ENSG00000274001.1	RP11-5G9.5	6.1	1.48e-09	2.41e-07	0.21	0.19	Leprosy;	chr13:43844028	chr13:43877715~43878163:-
BRCA	cis	rs1979679	0.659	rs11049461	ENSG00000278733.1	RP11-425D17.1	6.1	1.48e-09	2.41e-07	0.25	0.19	Ossification of the posterior longitudinal ligament of the spine;	chr12:28207688	chr12:28185625~28186190:-
BRCA	cis	rs919433	0.68	rs2565160	ENSG00000231621.1	AC013264.2	-6.1	1.48e-09	2.41e-07	-0.18	-0.19	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197421750	chr2:197197991~197199273:+
BRCA	cis	rs8002861	0.935	rs1819595	ENSG00000274001.1	RP11-5G9.5	6.1	1.48e-09	2.41e-07	0.21	0.19	Leprosy;	chr13:43855580	chr13:43877715~43878163:-
BRCA	cis	rs228614	0.51	rs223356	ENSG00000251288.2	RP11-10L12.2	-6.1	1.48e-09	2.42e-07	-0.22	-0.19	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102852344	chr4:102751401~102752641:+
BRCA	cis	rs853679	0.517	rs3757185	ENSG00000204709.4	LINC01556	6.1	1.48e-09	2.42e-07	0.28	0.19	Depression;	chr6:28139998	chr6:28943877~28944537:+
BRCA	cis	rs10266483	0.515	rs17689514	ENSG00000271550.1	BNIP3P11	-6.1	1.48e-09	2.42e-07	-0.29	-0.19	Response to statin therapy;	chr7:64279269	chr7:64678954~64687393:-
BRCA	cis	rs13113518	0.783	rs6843997	ENSG00000273257.1	RP11-177J6.1	6.1	1.48e-09	2.42e-07	0.24	0.19	Height;	chr4:55508982	chr4:55387949~55388271:+
BRCA	cis	rs1707322	0.927	rs11211194	ENSG00000281133.1	AL355480.3	-6.1	1.48e-09	2.42e-07	-0.24	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45816412	chr1:45580892~45580996:-
BRCA	cis	rs867371	0.502	rs1846908	ENSG00000255769.6	GOLGA2P10	-6.1	1.48e-09	2.42e-07	-0.2	-0.19	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82230185	chr15:82472993~82513950:-
BRCA	cis	rs2665103	0.655	rs1501367	ENSG00000255769.6	GOLGA2P10	-6.1	1.48e-09	2.42e-07	-0.2	-0.19	Intelligence (multi-trait analysis);	chr15:82230475	chr15:82472993~82513950:-
BRCA	cis	rs2243480	1	rs402418	ENSG00000164669.11	INTS4P1	6.1	1.48e-09	2.42e-07	0.37	0.19	Diabetic kidney disease;	chr7:66044482	chr7:65141225~65234216:+
BRCA	cis	rs4072705	1	rs4836980	ENSG00000224020.1	MIR181A2HG	-6.1	1.48e-09	2.42e-07	-0.2	-0.19	Menarche (age at onset);	chr9:124576884	chr9:124658467~124698631:+
BRCA	cis	rs853679	0.517	rs9357065	ENSG00000204709.4	LINC01556	6.1	1.48e-09	2.42e-07	0.28	0.19	Depression;	chr6:28161802	chr6:28943877~28944537:+
BRCA	cis	rs1440410	0.835	rs11933603	ENSG00000250326.1	RP11-284M14.1	-6.1	1.49e-09	2.42e-07	-0.2	-0.19	Ischemic stroke;	chr4:143212704	chr4:142933195~143184861:-
BRCA	cis	rs11098499	0.739	rs951570	ENSG00000248280.1	RP11-33B1.2	-6.1	1.49e-09	2.43e-07	-0.19	-0.19	Corneal astigmatism;	chr4:119229312	chr4:119440561~119450157:-
BRCA	cis	rs55702914	0.628	rs17730989	ENSG00000231621.1	AC013264.2	-6.1	1.49e-09	2.43e-07	-0.17	-0.19	Major depression and alcohol dependence;	chr2:197497800	chr2:197197991~197199273:+
BRCA	cis	rs710913	0.745	rs67563067	ENSG00000237624.1	OXCT2P1	-6.1	1.49e-09	2.43e-07	-0.22	-0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39581323	chr1:39514956~39516490:+
BRCA	cis	rs10504130	0.696	rs12676835	ENSG00000272024.1	RP11-546K22.3	-6.1	1.49e-09	2.43e-07	-0.29	-0.19	Venous thromboembolism (SNP x SNP interaction);	chr8:51919770	chr8:51950284~51950690:+
BRCA	cis	rs10504130	0.696	rs12677407	ENSG00000272024.1	RP11-546K22.3	-6.1	1.49e-09	2.43e-07	-0.29	-0.19	Venous thromboembolism (SNP x SNP interaction);	chr8:51920718	chr8:51950284~51950690:+
BRCA	cis	rs10504130	0.696	rs59602923	ENSG00000272024.1	RP11-546K22.3	-6.1	1.49e-09	2.43e-07	-0.29	-0.19	Venous thromboembolism (SNP x SNP interaction);	chr8:51923565	chr8:51950284~51950690:+
BRCA	cis	rs10504130	0.696	rs113096282	ENSG00000272024.1	RP11-546K22.3	-6.1	1.49e-09	2.43e-07	-0.29	-0.19	Venous thromboembolism (SNP x SNP interaction);	chr8:51924206	chr8:51950284~51950690:+
BRCA	cis	rs10504130	0.735	rs77362085	ENSG00000272024.1	RP11-546K22.3	-6.1	1.49e-09	2.43e-07	-0.29	-0.19	Venous thromboembolism (SNP x SNP interaction);	chr8:51924398	chr8:51950284~51950690:+
BRCA	cis	rs2281558	0.833	rs6115202	ENSG00000125804.12	FAM182A	6.1	1.49e-09	2.43e-07	0.27	0.19	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25516902	chr20:26054655~26086917:+
BRCA	cis	rs8103033	0.786	rs2190912	ENSG00000226025.8	LGALS17A	-6.1	1.49e-09	2.43e-07	-0.21	-0.19	Obesity-related traits;	chr19:39656982	chr19:39679374~39686373:+
BRCA	cis	rs8103033	0.786	rs2190913	ENSG00000226025.8	LGALS17A	-6.1	1.49e-09	2.43e-07	-0.21	-0.19	Obesity-related traits;	chr19:39656984	chr19:39679374~39686373:+
BRCA	cis	rs1707322	0.686	rs2050376	ENSG00000234329.1	RP11-767N6.2	6.1	1.49e-09	2.43e-07	0.2	0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45612958	chr1:45651039~45651826:-
BRCA	cis	rs6088813	1	rs4911492	ENSG00000126005.14	MMP24-AS1	6.1	1.49e-09	2.43e-07	0.22	0.19	Height;	chr20:35363996	chr20:35216462~35278131:-
BRCA	cis	rs10129255	0.957	rs10140904	ENSG00000224373.3	IGHV4-59	6.1	1.49e-09	2.43e-07	0.11	0.19	Kawasaki disease;	chr14:106776558	chr14:106627249~106627825:-
BRCA	cis	rs4713118	0.662	rs149901	ENSG00000219392.1	RP1-265C24.5	-6.1	1.49e-09	2.43e-07	-0.27	-0.19	Parkinson's disease;	chr6:27997725	chr6:28115628~28116551:+
BRCA	cis	rs721917	0.526	rs2256574	ENSG00000244733.5	RP11-506M13.3	-6.1	1.49e-09	2.43e-07	-0.22	-0.19	Chronic obstructive pulmonary disease;	chr10:79925283	chr10:79660891~79677996:+
BRCA	cis	rs11668609	0.938	rs8110507	ENSG00000268442.1	CTD-2027I19.2	6.1	1.49e-09	2.44e-07	0.25	0.19	Response to taxane treatment (docetaxel);	chr19:24099470	chr19:24162370~24163425:-
BRCA	cis	rs2243480	0.901	rs57126451	ENSG00000229886.1	RP5-1132H15.3	6.1	1.5e-09	2.44e-07	0.32	0.19	Diabetic kidney disease;	chr7:65951319	chr7:66025126~66031544:-
BRCA	cis	rs420259	0.516	rs9931842	ENSG00000260136.4	CTD-2270L9.4	-6.1	1.5e-09	2.44e-07	-0.19	-0.19	Bipolar disorder;	chr16:23513237	chr16:23452758~23457606:+
BRCA	cis	rs420259	0.516	rs2072061	ENSG00000260136.4	CTD-2270L9.4	-6.1	1.5e-09	2.44e-07	-0.19	-0.19	Bipolar disorder;	chr16:23529902	chr16:23452758~23457606:+
BRCA	cis	rs516805	0.748	rs563084	ENSG00000279114.1	RP3-425C14.5	6.1	1.5e-09	2.45e-07	0.22	0.19	Lymphocyte counts;	chr6:122397105	chr6:122471923~122484161:+
BRCA	cis	rs467650	0.553	rs40807	ENSG00000248489.1	CTD-2007H13.3	6.1	1.5e-09	2.45e-07	0.24	0.19	Venous thromboembolism (SNP x SNP interaction);	chr5:98646095	chr5:98929171~98995013:+
BRCA	cis	rs2243480	0.831	rs7806717	ENSG00000229886.1	RP5-1132H15.3	-6.1	1.5e-09	2.45e-07	-0.32	-0.19	Diabetic kidney disease;	chr7:65928187	chr7:66025126~66031544:-
BRCA	cis	rs2243480	1	rs34933526	ENSG00000229886.1	RP5-1132H15.3	6.1	1.5e-09	2.45e-07	0.32	0.19	Diabetic kidney disease;	chr7:65918212	chr7:66025126~66031544:-
BRCA	cis	rs2243480	1	rs6949812	ENSG00000229886.1	RP5-1132H15.3	6.1	1.5e-09	2.45e-07	0.32	0.19	Diabetic kidney disease;	chr7:65922114	chr7:66025126~66031544:-
BRCA	cis	rs2243480	1	rs6970243	ENSG00000229886.1	RP5-1132H15.3	6.1	1.5e-09	2.45e-07	0.32	0.19	Diabetic kidney disease;	chr7:65923503	chr7:66025126~66031544:-
BRCA	cis	rs2243480	0.708	rs35310401	ENSG00000229886.1	RP5-1132H15.3	6.1	1.5e-09	2.45e-07	0.32	0.19	Diabetic kidney disease;	chr7:65925372	chr7:66025126~66031544:-
BRCA	cis	rs7621025	0.691	rs9845762	ENSG00000239213.4	NCK1-AS1	6.1	1.5e-09	2.45e-07	0.21	0.19	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136637622	chr3:136841726~136862054:-
BRCA	cis	rs8114671	0.662	rs6088664	ENSG00000269202.1	RP4-614O4.12	-6.1	1.5e-09	2.45e-07	-0.19	-0.19	Height;	chr20:34963297	chr20:35201747~35203288:-
BRCA	cis	rs875971	0.545	rs6969224	ENSG00000236529.1	RP13-254B10.1	6.1	1.5e-09	2.45e-07	0.24	0.19	Aortic root size;	chr7:66370011	chr7:65840212~65840596:+
BRCA	cis	rs7255436	0.965	rs11668346	ENSG00000269386.4	RAB11B-AS1	6.1	1.5e-09	2.45e-07	0.2	0.19	HDL cholesterol;	chr19:8385970	chr19:8374373~8390685:-
BRCA	cis	rs7255436	0.965	rs12981318	ENSG00000269386.4	RAB11B-AS1	6.1	1.5e-09	2.45e-07	0.2	0.19	HDL cholesterol;	chr19:8386546	chr19:8374373~8390685:-
BRCA	cis	rs7255436	0.965	rs7351098	ENSG00000269386.4	RAB11B-AS1	6.1	1.5e-09	2.45e-07	0.2	0.19	HDL cholesterol;	chr19:8386787	chr19:8374373~8390685:-
BRCA	cis	rs5015933	0.966	rs10986724	ENSG00000232630.1	PRPS1P2	6.1	1.5e-09	2.45e-07	0.17	0.19	Body mass index;	chr9:125369240	chr9:125150653~125151589:+
BRCA	cis	rs17301013	0.606	rs77379897	ENSG00000227373.4	RP11-160H22.5	6.1	1.5e-09	2.45e-07	0.28	0.19	Systemic lupus erythematosus;	chr1:174169373	chr1:174115300~174160004:-
BRCA	cis	rs1387259	0.931	rs1107654	ENSG00000257763.1	OR5BK1P	6.1	1.5e-09	2.45e-07	0.2	0.19	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48287314	chr12:48355792~48356614:-
BRCA	cis	rs6840360	0.557	rs1143036	ENSG00000270265.1	RP11-731D1.4	-6.1	1.5e-09	2.45e-07	-0.21	-0.19	Intelligence (multi-trait analysis);	chr4:151408252	chr4:151333775~151353224:-
BRCA	cis	rs442309	0.687	rs10995282	ENSG00000238280.1	RP11-436D10.3	-6.1	1.51e-09	2.46e-07	-0.25	-0.19	Vogt-Koyanagi-Harada syndrome;	chr10:62711531	chr10:62793562~62805887:-
BRCA	cis	rs875971	0.83	rs6976714	ENSG00000224316.1	RP11-479O9.2	6.1	1.51e-09	2.46e-07	0.19	0.19	Aortic root size;	chr7:66426474	chr7:65773620~65802067:+
BRCA	cis	rs1440410	0.835	rs11737209	ENSG00000250326.1	RP11-284M14.1	-6.1	1.51e-09	2.46e-07	-0.2	-0.19	Ischemic stroke;	chr4:143211519	chr4:142933195~143184861:-
BRCA	cis	rs2243480	0.901	rs778732	ENSG00000229886.1	RP5-1132H15.3	6.1	1.51e-09	2.46e-07	0.34	0.19	Diabetic kidney disease;	chr7:66357373	chr7:66025126~66031544:-
BRCA	cis	rs7569084	0.687	rs1437462	ENSG00000237979.1	AC007389.1	6.1	1.51e-09	2.46e-07	0.24	0.19	Sum eosinophil basophil counts;	chr2:65449559	chr2:65500993~65502138:-
BRCA	cis	rs2688608	0.592	rs10762563	ENSG00000271816.1	BMS1P4	6.1	1.51e-09	2.46e-07	0.18	0.19	Inflammatory bowel disease;	chr10:73765044	chr10:73699151~73730487:-
BRCA	cis	rs2243480	1	rs1723269	ENSG00000232546.1	RP11-458F8.1	-6.1	1.51e-09	2.46e-07	-0.25	-0.19	Diabetic kidney disease;	chr7:66007799	chr7:66848496~66858136:+
BRCA	cis	rs13113518	0.783	rs12508367	ENSG00000273257.1	RP11-177J6.1	6.1	1.51e-09	2.46e-07	0.24	0.19	Height;	chr4:55509442	chr4:55387949~55388271:+
BRCA	cis	rs13113518	0.812	rs2272073	ENSG00000273257.1	RP11-177J6.1	6.1	1.51e-09	2.46e-07	0.24	0.19	Height;	chr4:55510177	chr4:55387949~55388271:+
BRCA	cis	rs467650	0.553	rs27706	ENSG00000248489.1	CTD-2007H13.3	6.1	1.51e-09	2.47e-07	0.24	0.19	Venous thromboembolism (SNP x SNP interaction);	chr5:98646475	chr5:98929171~98995013:+
BRCA	cis	rs853679	0.517	rs9380056	ENSG00000204709.4	LINC01556	6.1	1.52e-09	2.47e-07	0.27	0.19	Depression;	chr6:28136698	chr6:28943877~28944537:+
BRCA	cis	rs853679	0.517	rs9380057	ENSG00000204709.4	LINC01556	6.1	1.52e-09	2.47e-07	0.27	0.19	Depression;	chr6:28136856	chr6:28943877~28944537:+
BRCA	cis	rs853679	0.517	rs6941992	ENSG00000204709.4	LINC01556	6.1	1.52e-09	2.47e-07	0.27	0.19	Depression;	chr6:28138363	chr6:28943877~28944537:+
BRCA	cis	rs4713118	0.516	rs4713142	ENSG00000204709.4	LINC01556	6.1	1.52e-09	2.47e-07	0.27	0.19	Parkinson's disease;	chr6:28138569	chr6:28943877~28944537:+
BRCA	cis	rs853679	0.517	rs4713143	ENSG00000204709.4	LINC01556	6.1	1.52e-09	2.47e-07	0.27	0.19	Depression;	chr6:28138981	chr6:28943877~28944537:+
BRCA	cis	rs853679	0.517	rs4713144	ENSG00000204709.4	LINC01556	6.1	1.52e-09	2.47e-07	0.27	0.19	Depression;	chr6:28139012	chr6:28943877~28944537:+
BRCA	cis	rs2243480	0.764	rs2460423	ENSG00000228409.4	CCT6P1	6.1	1.52e-09	2.47e-07	0.26	0.19	Diabetic kidney disease;	chr7:66136229	chr7:65751142~65763354:+
BRCA	cis	rs875971	0.862	rs778702	ENSG00000224316.1	RP11-479O9.2	6.1	1.52e-09	2.47e-07	0.19	0.19	Aortic root size;	chr7:66399848	chr7:65773620~65802067:+
BRCA	cis	rs7927771	0.524	rs7929014	ENSG00000280615.1	Y_RNA	6.1	1.52e-09	2.47e-07	0.22	0.19	Subjective well-being;	chr11:47754731	chr11:47614898~47614994:-
BRCA	cis	rs34779708	0.931	rs11010083	ENSG00000271335.4	RP11-324I22.4	6.1	1.52e-09	2.48e-07	0.19	0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35062603	chr10:35314552~35336401:-
BRCA	cis	rs853679	0.517	rs9368555	ENSG00000204709.4	LINC01556	6.1	1.52e-09	2.48e-07	0.28	0.19	Depression;	chr6:28141189	chr6:28943877~28944537:+
BRCA	cis	rs853679	0.517	rs9393893	ENSG00000204709.4	LINC01556	6.1	1.52e-09	2.48e-07	0.28	0.19	Depression;	chr6:28141484	chr6:28943877~28944537:+
BRCA	cis	rs2243480	1	rs160633	ENSG00000228409.4	CCT6P1	6.1	1.52e-09	2.48e-07	0.27	0.19	Diabetic kidney disease;	chr7:66063241	chr7:65751142~65763354:+
BRCA	cis	rs34779708	0.966	rs17500582	ENSG00000271335.4	RP11-324I22.4	6.1	1.52e-09	2.48e-07	0.19	0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35209860	chr10:35314552~35336401:-
BRCA	cis	rs2243480	1	rs160652	ENSG00000228409.4	CCT6P1	6.1	1.52e-09	2.49e-07	0.27	0.19	Diabetic kidney disease;	chr7:66073444	chr7:65751142~65763354:+
BRCA	cis	rs2836950	0.502	rs2150411	ENSG00000238141.2	BRWD1-AS1	-6.1	1.52e-09	2.49e-07	-0.21	-0.19	Menarche (age at onset);	chr21:39202626	chr21:39315707~39323218:+
BRCA	cis	rs2836950	0.545	rs4818001	ENSG00000238141.2	BRWD1-AS1	-6.1	1.52e-09	2.49e-07	-0.21	-0.19	Menarche (age at onset);	chr21:39203162	chr21:39315707~39323218:+
BRCA	cis	rs30380	0.586	rs28119	ENSG00000272109.1	CTD-2260A17.3	-6.1	1.53e-09	2.49e-07	-0.26	-0.19	Cerebrospinal fluid biomarker levels;	chr5:96796030	chr5:96804353~96806105:+
BRCA	cis	rs4950322	0.57	rs4301678	ENSG00000244371.2	PFN1P8	-6.1	1.53e-09	2.49e-07	-0.26	-0.19	Protein quantitative trait loci;	chr1:147261907	chr1:146957117~146957659:-
BRCA	cis	rs7809950	0.678	rs4730235	ENSG00000238832.1	snoU109	-6.1	1.53e-09	2.49e-07	-0.27	-0.19	Coronary artery disease;	chr7:107382061	chr7:107603363~107603507:+
BRCA	cis	rs1823913	0.599	rs17414109	ENSG00000280083.1	RP11-317J9.1	-6.1	1.53e-09	2.49e-07	-0.22	-0.19	Obesity-related traits;	chr2:191310675	chr2:191154118~191156070:-
BRCA	cis	rs67981189	0.896	rs2010061	ENSG00000258571.1	PTTG4P	6.1	1.53e-09	2.49e-07	0.2	0.19	Schizophrenia;	chr14:70899479	chr14:71085482~71085833:-
BRCA	cis	rs853679	0.517	rs16893666	ENSG00000204709.4	LINC01556	-6.1	1.53e-09	2.49e-07	-0.27	-0.19	Depression;	chr6:28086929	chr6:28943877~28944537:+
BRCA	cis	rs853679	0.598	rs9380054	ENSG00000204709.4	LINC01556	6.1	1.53e-09	2.49e-07	0.27	0.19	Depression;	chr6:28099759	chr6:28943877~28944537:+
BRCA	cis	rs4713118	0.547	rs2116981	ENSG00000204709.4	LINC01556	6.1	1.53e-09	2.49e-07	0.27	0.19	Parkinson's disease;	chr6:28100173	chr6:28943877~28944537:+
BRCA	cis	rs853679	0.517	rs9368552	ENSG00000204709.4	LINC01556	6.1	1.53e-09	2.49e-07	0.27	0.19	Depression;	chr6:28100648	chr6:28943877~28944537:+
BRCA	cis	rs853679	0.542	rs34131763	ENSG00000204709.4	LINC01556	6.1	1.53e-09	2.49e-07	0.27	0.19	Depression;	chr6:28107222	chr6:28943877~28944537:+
BRCA	cis	rs9652601	0.959	rs7200940	ENSG00000274038.1	RP11-66H6.4	6.1	1.53e-09	2.49e-07	0.21	0.19	Systemic lupus erythematosus;	chr16:11070710	chr16:11056556~11057034:+
BRCA	cis	rs6061231	0.624	rs8668	ENSG00000275437.1	RP5-908M14.10	-6.1	1.53e-09	2.49e-07	-0.19	-0.19	Colorectal cancer;	chr20:62389008	chr20:62402236~62405935:-
BRCA	cis	rs4700393	0.517	rs71592686	ENSG00000272308.1	RP11-231G3.1	6.1	1.53e-09	2.49e-07	0.24	0.19	Intelligence (multi-trait analysis);	chr5:60825444	chr5:60866457~60866935:-
BRCA	cis	rs853679	0.546	rs200990	ENSG00000220721.1	OR1F12	6.1	1.53e-09	2.49e-07	0.33	0.19	Depression;	chr6:27848045	chr6:28073316~28074233:+
BRCA	cis	rs9840812	0.728	rs6439646	ENSG00000239213.4	NCK1-AS1	6.1	1.53e-09	2.49e-07	0.23	0.19	Fibrinogen levels;	chr3:136554721	chr3:136841726~136862054:-
BRCA	cis	rs9828933	0.938	rs2578011	ENSG00000280620.1	SCAANT1	6.1	1.53e-09	2.5e-07	0.28	0.19	Type 2 diabetes;	chr3:64019143	chr3:63911518~63911772:-
BRCA	cis	rs8031584	0.541	rs2955797	ENSG00000260382.1	RP11-540B6.2	-6.1	1.53e-09	2.5e-07	-0.21	-0.19	Huntington's disease progression;	chr15:30918778	chr15:30882267~30883231:-
BRCA	cis	rs7746199	0.736	rs17693963	ENSG00000220721.1	OR1F12	6.1	1.53e-09	2.5e-07	0.4	0.19	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27742386	chr6:28073316~28074233:+
BRCA	cis	rs67311347	0.911	rs6775936	ENSG00000280739.1	EIF1B-AS1	6.1	1.54e-09	2.5e-07	0.21	0.19	Renal cell carcinoma;	chr3:40335908	chr3:40173145~40309698:-
BRCA	cis	rs6088813	0.922	rs4911493	ENSG00000126005.14	MMP24-AS1	6.1	1.54e-09	2.5e-07	0.22	0.19	Height;	chr20:35372996	chr20:35216462~35278131:-
BRCA	cis	rs4763879	0.739	rs7310460	ENSG00000256673.1	RP11-599J14.2	6.1	1.54e-09	2.5e-07	0.21	0.19	Type 1 diabetes;	chr12:9688177	chr12:9398355~9414851:-
BRCA	cis	rs7772486	0.686	rs1045820	ENSG00000270638.1	RP3-466P17.1	6.1	1.54e-09	2.5e-07	0.21	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145625944	chr6:145735570~145737218:+
BRCA	cis	rs6840258	1	rs6840258	ENSG00000251411.1	RP11-397E7.4	-6.1	1.54e-09	2.5e-07	-0.24	-0.19	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87052516	chr4:86913266~86914817:-
BRCA	cis	rs1823913	0.637	rs13010441	ENSG00000280083.1	RP11-317J9.1	-6.1	1.54e-09	2.51e-07	-0.22	-0.19	Obesity-related traits;	chr2:191303903	chr2:191154118~191156070:-
BRCA	cis	rs2427308	0.643	rs477859	ENSG00000273619.1	RP5-908M14.9	6.09	1.54e-09	2.51e-07	0.17	0.19	Colorectal cancer;	chr20:62362541	chr20:62386303~62386970:-
BRCA	cis	rs1707322	0.963	rs10789484	ENSG00000281133.1	AL355480.3	-6.09	1.54e-09	2.51e-07	-0.23	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45941306	chr1:45580892~45580996:-
BRCA	cis	rs858239	0.508	rs7805071	ENSG00000230042.1	AK3P3	-6.09	1.54e-09	2.51e-07	-0.21	-0.19	Cerebrospinal fluid biomarker levels;	chr7:23150593	chr7:23129178~23129841:+
BRCA	cis	rs673078	0.66	rs61943535	ENSG00000275409.1	RP11-131L12.4	-6.09	1.54e-09	2.51e-07	-0.29	-0.19	Glucose homeostasis traits;	chr12:118168307	chr12:118430147~118430699:+
BRCA	cis	rs9425766	0.679	rs2901785	ENSG00000227373.4	RP11-160H22.5	6.09	1.54e-09	2.51e-07	0.24	0.19	Life satisfaction;	chr1:174135605	chr1:174115300~174160004:-
BRCA	cis	rs4950322	0.542	rs28381210	ENSG00000278811.3	LINC00624	6.09	1.55e-09	2.52e-07	0.25	0.19	Protein quantitative trait loci;	chr1:147201925	chr1:147258885~147517875:-
BRCA	cis	rs1707322	0.686	rs1541131	ENSG00000281133.1	AL355480.3	6.09	1.55e-09	2.52e-07	0.24	0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45619262	chr1:45580892~45580996:-
BRCA	cis	rs17301013	0.507	rs72717618	ENSG00000227373.4	RP11-160H22.5	6.09	1.55e-09	2.52e-07	0.29	0.19	Systemic lupus erythematosus;	chr1:174816839	chr1:174115300~174160004:-
BRCA	cis	rs4713118	0.662	rs9393881	ENSG00000219392.1	RP1-265C24.5	-6.09	1.55e-09	2.52e-07	-0.27	-0.19	Parkinson's disease;	chr6:28055973	chr6:28115628~28116551:+
BRCA	cis	rs227275	0.525	rs11097796	ENSG00000251288.2	RP11-10L12.2	-6.09	1.55e-09	2.52e-07	-0.22	-0.19	Allergic disease (asthma, hay fever or eczema);	chr4:103002401	chr4:102751401~102752641:+
BRCA	cis	rs227275	0.525	rs11097797	ENSG00000251288.2	RP11-10L12.2	-6.09	1.55e-09	2.52e-07	-0.22	-0.19	Allergic disease (asthma, hay fever or eczema);	chr4:103002507	chr4:102751401~102752641:+
BRCA	cis	rs227275	0.525	rs13117110	ENSG00000251288.2	RP11-10L12.2	-6.09	1.55e-09	2.52e-07	-0.22	-0.19	Allergic disease (asthma, hay fever or eczema);	chr4:103003981	chr4:102751401~102752641:+
BRCA	cis	rs227275	0.525	rs13144033	ENSG00000251288.2	RP11-10L12.2	-6.09	1.55e-09	2.52e-07	-0.22	-0.19	Allergic disease (asthma, hay fever or eczema);	chr4:103004032	chr4:102751401~102752641:+
BRCA	cis	rs227275	0.525	rs10029073	ENSG00000251288.2	RP11-10L12.2	-6.09	1.55e-09	2.52e-07	-0.22	-0.19	Allergic disease (asthma, hay fever or eczema);	chr4:103006991	chr4:102751401~102752641:+
BRCA	cis	rs7182621	0.639	rs35248328	ENSG00000182397.13	DNM1P46	6.09	1.55e-09	2.52e-07	0.23	0.19	Colonoscopy-negative controls vs population controls;	chr15:99873399	chr15:99790156~99806927:-
BRCA	cis	rs7044106	0.762	rs10818471	ENSG00000238181.2	AHCYP2	-6.09	1.55e-09	2.53e-07	-0.24	-0.19	Hip circumference adjusted for BMI;	chr9:120631767	chr9:120720673~120721972:+
BRCA	cis	rs4718428	0.672	rs36038499	ENSG00000230295.1	RP11-458F8.2	-6.09	1.55e-09	2.53e-07	-0.17	-0.19	Corneal structure;	chr7:66824628	chr7:66880708~66882981:+
BRCA	cis	rs755249	0.567	rs41270799	ENSG00000237624.1	OXCT2P1	6.09	1.55e-09	2.53e-07	0.27	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39282990	chr1:39514956~39516490:+
BRCA	cis	rs10515750	0.588	rs11749220	ENSG00000248544.2	CTB-47B11.3	6.09	1.55e-09	2.53e-07	0.27	0.19	Lung function (FEV1/FVC);	chr5:157362486	chr5:157375741~157384950:-
BRCA	cis	rs3858145	0.588	rs2305083	ENSG00000233590.1	RP11-153K11.3	-6.09	1.55e-09	2.53e-07	-0.26	-0.19	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68285180	chr10:68233251~68242379:-
BRCA	cis	rs2243480	1	rs427044	ENSG00000230295.1	RP11-458F8.2	-6.09	1.55e-09	2.53e-07	-0.25	-0.19	Diabetic kidney disease;	chr7:66043558	chr7:66880708~66882981:+
BRCA	cis	rs2179367	0.613	rs12207261	ENSG00000216906.2	RP11-350J20.9	6.09	1.56e-09	2.53e-07	0.26	0.19	Dupuytren's disease;	chr6:149423722	chr6:149904243~149906418:+
BRCA	cis	rs4664293	0.605	rs890095	ENSG00000226266.5	AC009961.3	6.09	1.56e-09	2.53e-07	0.23	0.19	Monocyte percentage of white cells;	chr2:159604708	chr2:159670708~159712435:-
BRCA	cis	rs11722228	0.522	rs1109472	ENSG00000261490.1	RP11-448G15.3	6.09	1.56e-09	2.54e-07	0.2	0.19	Urate levels;Serum uric acid levels;Gout;	chr4:10132824	chr4:10068089~10073019:-
BRCA	cis	rs7914558	1	rs7077291	ENSG00000213061.2	PFN1P11	6.09	1.56e-09	2.54e-07	0.24	0.19	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103185994	chr10:102838011~102845473:-
BRCA	cis	rs11668609	1	rs2099360	ENSG00000268442.1	CTD-2027I19.2	6.09	1.56e-09	2.54e-07	0.25	0.19	Response to taxane treatment (docetaxel);	chr19:24147361	chr19:24162370~24163425:-
BRCA	cis	rs11668609	1	rs2082493	ENSG00000268442.1	CTD-2027I19.2	6.09	1.56e-09	2.54e-07	0.25	0.19	Response to taxane treatment (docetaxel);	chr19:24147554	chr19:24162370~24163425:-
BRCA	cis	rs10028773	0.515	rs9994488	ENSG00000245958.5	RP11-33B1.1	-6.09	1.56e-09	2.54e-07	-0.18	-0.19	Educational attainment;	chr4:119666626	chr4:119454791~119552025:+
BRCA	cis	rs2243480	1	rs316307	ENSG00000232559.3	GS1-124K5.12	6.09	1.56e-09	2.54e-07	0.36	0.19	Diabetic kidney disease;	chr7:66105184	chr7:66554588~66576923:-
BRCA	cis	rs2243480	0.803	rs423187	ENSG00000232559.3	GS1-124K5.12	6.09	1.56e-09	2.55e-07	0.36	0.19	Diabetic kidney disease;	chr7:66044512	chr7:66554588~66576923:-
BRCA	cis	rs1499614	1	rs1267818	ENSG00000228409.4	CCT6P1	6.09	1.56e-09	2.55e-07	0.26	0.19	Gout;	chr7:66642037	chr7:65751142~65763354:+
BRCA	cis	rs10504130	0.696	rs76649327	ENSG00000272024.1	RP11-546K22.3	-6.09	1.57e-09	2.55e-07	-0.29	-0.19	Venous thromboembolism (SNP x SNP interaction);	chr8:51917219	chr8:51950284~51950690:+
BRCA	cis	rs1552244	1	rs35741213	ENSG00000180385.7	EMC3-AS1	6.09	1.57e-09	2.55e-07	0.23	0.19	Alzheimer's disease;	chr3:10045977	chr3:9986893~10006990:+
BRCA	cis	rs577676	0.586	rs656539	ENSG00000271811.1	RP1-79C4.4	6.09	1.57e-09	2.56e-07	0.22	0.19	Prevalent atrial fibrillation;	chr1:170637213	chr1:170667381~170669425:+
BRCA	cis	rs853679	0.517	rs1904840	ENSG00000204709.4	LINC01556	6.09	1.57e-09	2.56e-07	0.28	0.19	Depression;	chr6:28140454	chr6:28943877~28944537:+
BRCA	cis	rs2832191	0.967	rs1999321	ENSG00000215533.7	LINC00189	-6.09	1.57e-09	2.56e-07	-0.21	-0.19	Dental caries;	chr21:29157912	chr21:29193480~29288205:+
BRCA	cis	rs10510102	0.516	rs3936070	ENSG00000276742.1	RP11-500G22.4	6.09	1.57e-09	2.56e-07	0.34	0.19	Breast cancer;	chr10:121974440	chr10:121956782~121957098:+
BRCA	cis	rs875971	0.862	rs778680	ENSG00000224316.1	RP11-479O9.2	6.09	1.57e-09	2.56e-07	0.19	0.19	Aortic root size;	chr7:66375427	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.862	rs11769079	ENSG00000224316.1	RP11-479O9.2	6.09	1.57e-09	2.56e-07	0.19	0.19	Aortic root size;	chr7:66377141	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.862	rs1695820	ENSG00000224316.1	RP11-479O9.2	6.09	1.57e-09	2.56e-07	0.19	0.19	Aortic root size;	chr7:66379576	chr7:65773620~65802067:+
BRCA	cis	rs7255436	0.965	rs7254882	ENSG00000269386.4	RAB11B-AS1	6.09	1.57e-09	2.56e-07	0.2	0.19	HDL cholesterol;	chr19:8388938	chr19:8374373~8390685:-
BRCA	cis	rs7587476	0.626	rs4672729	ENSG00000229267.2	AC072062.1	6.09	1.57e-09	2.56e-07	0.22	0.19	Neuroblastoma;	chr2:214778759	chr2:214810229~214963274:+
BRCA	cis	rs853679	0.542	rs9393892	ENSG00000219392.1	RP1-265C24.5	-6.09	1.57e-09	2.56e-07	-0.28	-0.19	Depression;	chr6:28113616	chr6:28115628~28116551:+
BRCA	cis	rs4908760	0.827	rs10864362	ENSG00000270282.1	RP5-1115A15.2	6.09	1.57e-09	2.56e-07	0.2	0.19	Vitiligo;	chr1:8672395	chr1:8512653~8513021:+
BRCA	cis	rs591584	0.73	rs11020836	ENSG00000255893.1	RP11-685N10.1	-6.09	1.58e-09	2.56e-07	-0.22	-0.19	Macrophage Migration Inhibitory Factor levels;	chr11:94575726	chr11:94472908~94473570:-
BRCA	cis	rs1552244	0.81	rs7612908	ENSG00000180385.7	EMC3-AS1	6.09	1.58e-09	2.56e-07	0.23	0.19	Alzheimer's disease;	chr3:10047464	chr3:9986893~10006990:+
BRCA	cis	rs1552244	0.81	rs6809572	ENSG00000180385.7	EMC3-AS1	6.09	1.58e-09	2.56e-07	0.23	0.19	Alzheimer's disease;	chr3:10058461	chr3:9986893~10006990:+
BRCA	cis	rs1552244	1	rs112847840	ENSG00000180385.7	EMC3-AS1	6.09	1.58e-09	2.56e-07	0.23	0.19	Alzheimer's disease;	chr3:10059968	chr3:9986893~10006990:+
BRCA	cis	rs1552244	1	rs722509	ENSG00000180385.7	EMC3-AS1	6.09	1.58e-09	2.56e-07	0.23	0.19	Alzheimer's disease;	chr3:10060693	chr3:9986893~10006990:+
BRCA	cis	rs8114671	0.804	rs6060139	ENSG00000269202.1	RP4-614O4.12	-6.09	1.58e-09	2.56e-07	-0.19	-0.19	Height;	chr20:34978696	chr20:35201747~35203288:-
BRCA	cis	rs732716	0.853	rs72990643	ENSG00000267980.1	AC007292.6	-6.09	1.58e-09	2.57e-07	-0.23	-0.19	Mean corpuscular volume;	chr19:4454739	chr19:4363789~4364640:+
BRCA	cis	rs1440410	0.798	rs4690779	ENSG00000250326.1	RP11-284M14.1	-6.09	1.58e-09	2.57e-07	-0.2	-0.19	Ischemic stroke;	chr4:143198780	chr4:142933195~143184861:-
BRCA	cis	rs9308731	0.644	rs1837369	ENSG00000227992.1	AC108463.2	-6.09	1.58e-09	2.57e-07	-0.21	-0.19	Chronic lymphocytic leukemia;	chr2:111116699	chr2:111203964~111206215:-
BRCA	cis	rs1979679	0.842	rs2127315	ENSG00000278733.1	RP11-425D17.1	6.09	1.58e-09	2.57e-07	0.23	0.19	Ossification of the posterior longitudinal ligament of the spine;	chr12:28156247	chr12:28185625~28186190:-
BRCA	cis	rs13126694	0.778	rs12503001	ENSG00000248429.4	RP11-597D13.9	6.09	1.58e-09	2.57e-07	0.17	0.19	Blood osmolality (transformed sodium);	chr4:158100822	chr4:158170752~158202877:+
BRCA	cis	rs2732480	0.5	rs2932093	ENSG00000257763.1	OR5BK1P	6.09	1.58e-09	2.57e-07	0.2	0.19	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48254488	chr12:48355792~48356614:-
BRCA	cis	rs2243480	1	rs4718270	ENSG00000164669.11	INTS4P1	6.09	1.58e-09	2.57e-07	0.36	0.19	Diabetic kidney disease;	chr7:65737415	chr7:65141225~65234216:+
BRCA	cis	rs2239547	0.522	rs6445550	ENSG00000242142.1	SERBP1P3	6.09	1.58e-09	2.57e-07	0.23	0.19	Schizophrenia;	chr3:52949418	chr3:53064283~53065091:-
BRCA	cis	rs651907	0.557	rs7651721	ENSG00000244119.1	PDCL3P4	6.09	1.58e-09	2.57e-07	0.15	0.19	Colorectal cancer;	chr3:101674739	chr3:101712472~101713191:+
BRCA	cis	rs3733585	0.781	rs13103690	ENSG00000250413.1	RP11-448G15.1	6.09	1.58e-09	2.58e-07	0.24	0.19	Cleft plate (environmental tobacco smoke interaction);	chr4:9971154	chr4:10006482~10009725:+
BRCA	cis	rs1555322	0.872	rs2425048	ENSG00000279253.1	RP4-614O4.13	-6.09	1.58e-09	2.58e-07	-0.32	-0.19	Attention deficit hyperactivity disorder;	chr20:35284920	chr20:35262727~35264187:-
BRCA	cis	rs875971	0.862	rs1643375	ENSG00000224316.1	RP11-479O9.2	6.09	1.58e-09	2.58e-07	0.19	0.19	Aortic root size;	chr7:66407690	chr7:65773620~65802067:+
BRCA	cis	rs7520050	0.966	rs7556615	ENSG00000280836.1	AL355480.1	6.09	1.58e-09	2.58e-07	0.22	0.19	Reticulocyte count;Red blood cell count;	chr1:45995697	chr1:45581219~45581321:-
BRCA	cis	rs2489715	0.859	rs2489701	ENSG00000185904.10	LINC00839	-6.09	1.59e-09	2.58e-07	-0.26	-0.19	Helix rolling;	chr10:42400735	chr10:42475543~42495336:+
BRCA	cis	rs2243480	1	rs437889	ENSG00000232559.3	GS1-124K5.12	6.09	1.59e-09	2.58e-07	0.36	0.19	Diabetic kidney disease;	chr7:66044247	chr7:66554588~66576923:-
BRCA	cis	rs11722228	0.549	rs73212830	ENSG00000261490.1	RP11-448G15.3	6.09	1.59e-09	2.58e-07	0.22	0.19	Urate levels;Serum uric acid levels;Gout;	chr4:10077135	chr4:10068089~10073019:-
BRCA	cis	rs875971	0.522	rs34973832	ENSG00000234585.5	CCT6P3	6.09	1.59e-09	2.58e-07	0.18	0.19	Aortic root size;	chr7:65931217	chr7:65038354~65074713:+
BRCA	cis	rs867371	1	rs1846911	ENSG00000276710.3	CSPG4P8	-6.09	1.59e-09	2.58e-07	-0.2	-0.19	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82176309	chr15:82459472~82477258:+
BRCA	cis	rs4700393	0.517	rs71592685	ENSG00000272308.1	RP11-231G3.1	6.09	1.59e-09	2.59e-07	0.25	0.19	Intelligence (multi-trait analysis);	chr5:60825411	chr5:60866457~60866935:-
BRCA	cis	rs2243480	0.901	rs313808	ENSG00000230295.1	RP11-458F8.2	-6.09	1.59e-09	2.59e-07	-0.24	-0.19	Diabetic kidney disease;	chr7:66034886	chr7:66880708~66882981:+
BRCA	cis	rs919433	0.68	rs2605039	ENSG00000231621.1	AC013264.2	-6.09	1.59e-09	2.59e-07	-0.18	-0.19	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197498127	chr2:197197991~197199273:+
BRCA	cis	rs828999	1	rs828999	ENSG00000280186.1	RP11-483I13.6	-6.09	1.6e-09	2.59e-07	-0.21	-0.19	Monocyte percentage of white cells;	chr1:108202312	chr1:108200413~108202743:+
BRCA	cis	rs6570726	0.846	rs7762536	ENSG00000270638.1	RP3-466P17.1	6.09	1.6e-09	2.6e-07	0.21	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145602009	chr6:145735570~145737218:+
BRCA	cis	rs7493	1	rs12026	ENSG00000233942.1	AC004012.1	6.09	1.6e-09	2.6e-07	0.23	0.19	Yu-Zhi constitution type in type 2 diabetes;	chr7:95411704	chr7:95471835~95473998:+
BRCA	cis	rs1707322	1	rs10890375	ENSG00000281133.1	AL355480.3	-6.09	1.6e-09	2.6e-07	-0.24	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45940909	chr1:45580892~45580996:-
BRCA	cis	rs1707322	1	rs10890377	ENSG00000281133.1	AL355480.3	-6.09	1.6e-09	2.6e-07	-0.24	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45940922	chr1:45580892~45580996:-
BRCA	cis	rs7493	1	rs6968305	ENSG00000233942.1	AC004012.1	6.09	1.6e-09	2.6e-07	0.23	0.19	Yu-Zhi constitution type in type 2 diabetes;	chr7:95413217	chr7:95471835~95473998:+
BRCA	cis	rs7914558	1	rs1890184	ENSG00000213061.2	PFN1P11	6.09	1.6e-09	2.6e-07	0.24	0.19	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102988702	chr10:102838011~102845473:-
BRCA	cis	rs9876781	1	rs11712561	ENSG00000229759.1	MRPS18AP1	6.09	1.6e-09	2.6e-07	0.21	0.19	Longevity;	chr3:48393807	chr3:48256350~48256938:-
BRCA	cis	rs7246657	0.653	rs10401525	ENSG00000226686.6	LINC01535	-6.09	1.6e-09	2.6e-07	-0.32	-0.19	Coronary artery calcification;	chr19:37168077	chr19:37251912~37265535:+
BRCA	cis	rs3227	0.626	rs3818528	ENSG00000224557.6	HLA-DPB2	-6.09	1.6e-09	2.61e-07	-0.22	-0.19	Educational attainment;	chr6:33693314	chr6:33112451~33129084:+
BRCA	cis	rs2638953	0.924	rs11049478	ENSG00000278733.1	RP11-425D17.1	-6.09	1.6e-09	2.61e-07	-0.25	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28244827	chr12:28185625~28186190:-
BRCA	cis	rs7809950	0.817	rs58052742	ENSG00000238832.1	snoU109	6.09	1.6e-09	2.61e-07	0.27	0.19	Coronary artery disease;	chr7:107569558	chr7:107603363~107603507:+
BRCA	cis	rs651907	0.557	rs1056579	ENSG00000244119.1	PDCL3P4	6.09	1.61e-09	2.61e-07	0.15	0.19	Colorectal cancer;	chr3:101679033	chr3:101712472~101713191:+
BRCA	cis	rs7493	1	rs17166875	ENSG00000233942.1	AC004012.1	6.09	1.61e-09	2.61e-07	0.23	0.19	Yu-Zhi constitution type in type 2 diabetes;	chr7:95411959	chr7:95471835~95473998:+
BRCA	cis	rs34779708	0.931	rs11010132	ENSG00000271335.4	RP11-324I22.4	6.09	1.61e-09	2.62e-07	0.19	0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35228337	chr10:35314552~35336401:-
BRCA	cis	rs7567389	0.719	rs4150499	ENSG00000236682.1	AC068282.3	6.09	1.61e-09	2.62e-07	0.28	0.19	Self-rated health;	chr2:127271216	chr2:127389130~127400580:+
BRCA	cis	rs6570726	0.791	rs952406	ENSG00000270638.1	RP3-466P17.1	6.09	1.61e-09	2.62e-07	0.21	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145604480	chr6:145735570~145737218:+
BRCA	cis	rs2288884	0.708	rs59104696	ENSG00000275055.1	CTC-471J1.11	-6.09	1.61e-09	2.62e-07	-0.26	-0.19	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52051917	chr19:52049007~52049754:+
BRCA	cis	rs4266144	0.562	rs56357317	ENSG00000244515.1	KRT18P34	-6.09	1.61e-09	2.62e-07	-0.24	-0.19	Coronary artery disease;	chr3:157117385	chr3:157162663~157163932:-
BRCA	cis	rs875971	0.862	rs6962717	ENSG00000224316.1	RP11-479O9.2	6.09	1.62e-09	2.62e-07	0.19	0.19	Aortic root size;	chr7:66418748	chr7:65773620~65802067:+
BRCA	cis	rs2919009	0.544	rs7917351	ENSG00000271670.1	RP11-95I16.4	6.09	1.62e-09	2.63e-07	0.23	0.19	Obesity-related traits;	chr10:120852260	chr10:120879256~120880667:-
BRCA	cis	rs911555	0.755	rs10148970	ENSG00000244691.1	RPL10AP1	-6.09	1.62e-09	2.63e-07	-0.23	-0.19	Intelligence (multi-trait analysis);	chr14:103425663	chr14:103412119~103412761:-
BRCA	cis	rs2243480	0.901	rs35087093	ENSG00000229886.1	RP5-1132H15.3	6.09	1.62e-09	2.63e-07	0.32	0.19	Diabetic kidney disease;	chr7:65940221	chr7:66025126~66031544:-
BRCA	cis	rs9287719	0.601	rs12995465	ENSG00000243819.4	RN7SL832P	6.09	1.62e-09	2.63e-07	0.19	0.19	Prostate cancer;	chr2:10576702	chr2:10690344~10692099:+
BRCA	cis	rs7927771	0.524	rs2170815	ENSG00000280615.1	Y_RNA	6.09	1.62e-09	2.64e-07	0.22	0.19	Subjective well-being;	chr11:47854358	chr11:47614898~47614994:-
BRCA	cis	rs910316	1	rs3742778	ENSG00000279594.1	RP11-950C14.10	-6.09	1.62e-09	2.64e-07	-0.21	-0.19	Height;	chr14:75071514	chr14:75011269~75012851:-
BRCA	cis	rs2239547	0.563	rs4687699	ENSG00000242142.1	SERBP1P3	6.09	1.62e-09	2.64e-07	0.22	0.19	Schizophrenia;	chr3:53067208	chr3:53064283~53065091:-
BRCA	cis	rs875971	0.755	rs76288834	ENSG00000224316.1	RP11-479O9.2	-6.09	1.63e-09	2.64e-07	-0.19	-0.19	Aortic root size;	chr7:66604815	chr7:65773620~65802067:+
BRCA	cis	rs7246657	0.653	rs10414983	ENSG00000226686.6	LINC01535	-6.09	1.63e-09	2.64e-07	-0.32	-0.19	Coronary artery calcification;	chr19:37174830	chr19:37251912~37265535:+
BRCA	cis	rs7246657	0.598	rs10405372	ENSG00000226686.6	LINC01535	-6.09	1.63e-09	2.64e-07	-0.32	-0.19	Coronary artery calcification;	chr19:37177873	chr19:37251912~37265535:+
BRCA	cis	rs7246657	0.653	rs4805207	ENSG00000226686.6	LINC01535	-6.09	1.63e-09	2.64e-07	-0.32	-0.19	Coronary artery calcification;	chr19:37182831	chr19:37251912~37265535:+
BRCA	cis	rs10504130	0.696	rs12676780	ENSG00000272024.1	RP11-546K22.3	-6.09	1.63e-09	2.65e-07	-0.29	-0.19	Venous thromboembolism (SNP x SNP interaction);	chr8:51919420	chr8:51950284~51950690:+
BRCA	cis	rs4713118	0.824	rs7759217	ENSG00000220721.1	OR1F12	6.09	1.63e-09	2.65e-07	0.23	0.19	Parkinson's disease;	chr6:27762684	chr6:28073316~28074233:+
BRCA	cis	rs4713118	0.784	rs9468219	ENSG00000220721.1	OR1F12	6.09	1.63e-09	2.65e-07	0.23	0.19	Parkinson's disease;	chr6:27763976	chr6:28073316~28074233:+
BRCA	cis	rs2562456	0.876	rs11085468	ENSG00000268081.1	RP11-678G14.2	6.09	1.63e-09	2.65e-07	0.28	0.19	Pain;	chr19:21569087	chr19:21554640~21569237:-
BRCA	cis	rs6951245	0.554	rs58210047	ENSG00000229043.2	AC091729.9	-6.09	1.63e-09	2.65e-07	-0.28	-0.19	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1109745	chr7:1160374~1165267:+
BRCA	cis	rs1823913	0.599	rs1454754	ENSG00000280083.1	RP11-317J9.1	-6.09	1.63e-09	2.65e-07	-0.22	-0.19	Obesity-related traits;	chr2:191303562	chr2:191154118~191156070:-
BRCA	cis	rs2243480	1	rs35046236	ENSG00000229886.1	RP5-1132H15.3	6.09	1.63e-09	2.65e-07	0.32	0.19	Diabetic kidney disease;	chr7:65943626	chr7:66025126~66031544:-
BRCA	cis	rs2243480	1	rs36068983	ENSG00000229886.1	RP5-1132H15.3	6.09	1.63e-09	2.65e-07	0.32	0.19	Diabetic kidney disease;	chr7:65944004	chr7:66025126~66031544:-
BRCA	cis	rs2243480	1	rs68189316	ENSG00000229886.1	RP5-1132H15.3	6.09	1.63e-09	2.65e-07	0.32	0.19	Diabetic kidney disease;	chr7:65944182	chr7:66025126~66031544:-
BRCA	cis	rs10504130	0.696	rs76717135	ENSG00000272024.1	RP11-546K22.3	-6.09	1.63e-09	2.65e-07	-0.29	-0.19	Venous thromboembolism (SNP x SNP interaction);	chr8:51917672	chr8:51950284~51950690:+
BRCA	cis	rs10504130	0.696	rs17212256	ENSG00000272024.1	RP11-546K22.3	-6.09	1.63e-09	2.65e-07	-0.29	-0.19	Venous thromboembolism (SNP x SNP interaction);	chr8:51919058	chr8:51950284~51950690:+
BRCA	cis	rs2243480	1	rs402418	ENSG00000232559.3	GS1-124K5.12	6.09	1.63e-09	2.65e-07	0.36	0.19	Diabetic kidney disease;	chr7:66044482	chr7:66554588~66576923:-
BRCA	cis	rs7927771	0.507	rs11039432	ENSG00000280615.1	Y_RNA	6.09	1.63e-09	2.65e-07	0.22	0.19	Subjective well-being;	chr11:47851775	chr11:47614898~47614994:-
BRCA	cis	rs77204473	0.744	rs12420200	ENSG00000254851.1	RP11-109L13.1	-6.09	1.63e-09	2.65e-07	-0.35	-0.19	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117127590	chr11:117135528~117138582:+
BRCA	cis	rs227275	0.556	rs6815526	ENSG00000251288.2	RP11-10L12.2	-6.09	1.63e-09	2.65e-07	-0.22	-0.19	Allergic disease (asthma, hay fever or eczema);	chr4:102899729	chr4:102751401~102752641:+
BRCA	cis	rs227275	0.556	rs6824070	ENSG00000251288.2	RP11-10L12.2	-6.09	1.63e-09	2.65e-07	-0.22	-0.19	Allergic disease (asthma, hay fever or eczema);	chr4:102901676	chr4:102751401~102752641:+
BRCA	cis	rs11722779	0.935	rs6856176	ENSG00000251288.2	RP11-10L12.2	-6.09	1.63e-09	2.65e-07	-0.22	-0.19	Schizophrenia;	chr4:102902574	chr4:102751401~102752641:+
BRCA	cis	rs853679	0.517	rs9393884	ENSG00000204709.4	LINC01556	6.08	1.64e-09	2.66e-07	0.27	0.19	Depression;	chr6:28079011	chr6:28943877~28944537:+
BRCA	cis	rs7914558	1	rs67908413	ENSG00000213061.2	PFN1P11	6.08	1.64e-09	2.66e-07	0.24	0.19	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103005232	chr10:102838011~102845473:-
BRCA	cis	rs1387259	0.859	rs2054905	ENSG00000257763.1	OR5BK1P	6.08	1.64e-09	2.66e-07	0.2	0.19	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48294168	chr12:48355792~48356614:-
BRCA	cis	rs904251	0.797	rs2776878	ENSG00000204110.6	RP1-153P14.8	-6.08	1.64e-09	2.66e-07	-0.21	-0.19	Cognitive performance;	chr6:37519497	chr6:37507348~37535616:+
BRCA	cis	rs1193	1	rs2367379	ENSG00000231259.4	AC125232.1	-6.08	1.64e-09	2.67e-07	-0.23	-0.19	High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;High light scatter reticulocyte count;	chr2:86767314	chr2:87031815~87053069:-
BRCA	cis	rs9990333	0.544	rs11915082	ENSG00000231464.1	AC024937.4	6.08	1.64e-09	2.67e-07	0.24	0.19	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196082268	chr3:195996738~195998233:+
BRCA	cis	rs8031584	0.56	rs1056118	ENSG00000260382.1	RP11-540B6.2	-6.08	1.65e-09	2.67e-07	-0.21	-0.19	Huntington's disease progression;	chr15:30911583	chr15:30882267~30883231:-
BRCA	cis	rs875971	0.767	rs12668005	ENSG00000224316.1	RP11-479O9.2	6.08	1.65e-09	2.68e-07	0.19	0.19	Aortic root size;	chr7:66444034	chr7:65773620~65802067:+
BRCA	cis	rs6088813	0.961	rs6060369	ENSG00000126005.14	MMP24-AS1	-6.08	1.65e-09	2.68e-07	-0.22	-0.19	Height;	chr20:35319358	chr20:35216462~35278131:-
BRCA	cis	rs11671005	0.61	rs3794966	ENSG00000269600.1	AC016629.3	-6.08	1.65e-09	2.68e-07	-0.29	-0.19	Mean platelet volume;	chr19:58557629	chr19:58593896~58599355:-
BRCA	cis	rs375066	0.623	rs10421861	ENSG00000267058.1	RP11-15A1.3	6.08	1.65e-09	2.68e-07	0.21	0.19	Breast cancer;	chr19:43846955	chr19:43891804~43901805:-
BRCA	cis	rs6479891	1	rs6479899	ENSG00000232075.1	MRPL35P2	-6.08	1.65e-09	2.68e-07	-0.32	-0.19	Arthritis (juvenile idiopathic);	chr10:63379287	chr10:63634317~63634827:-
BRCA	cis	rs34779708	0.833	rs12777517	ENSG00000271335.4	RP11-324I22.4	6.08	1.65e-09	2.68e-07	0.2	0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35184999	chr10:35314552~35336401:-
BRCA	cis	rs2179367	0.568	rs62426092	ENSG00000216906.2	RP11-350J20.9	6.08	1.65e-09	2.68e-07	0.26	0.19	Dupuytren's disease;	chr6:149352720	chr6:149904243~149906418:+
BRCA	cis	rs2269241	0.636	rs61765292	ENSG00000244256.3	RN7SL130P	-6.08	1.65e-09	2.68e-07	-0.25	-0.19	Type 1 diabetes;	chr1:63647788	chr1:63655743~63656047:+
BRCA	cis	rs7238033	0.56	rs8083653	ENSG00000267193.4	RP11-116O18.3	6.08	1.65e-09	2.68e-07	0.2	0.19	Bladder cancer;	chr18:45735062	chr18:45669367~45747215:-
BRCA	cis	rs651907	0.557	rs3806653	ENSG00000244119.1	PDCL3P4	6.08	1.66e-09	2.69e-07	0.15	0.19	Colorectal cancer;	chr3:101678128	chr3:101712472~101713191:+
BRCA	cis	rs757081	0.507	rs10832727	ENSG00000184669.7	OR7E14P	-6.08	1.66e-09	2.69e-07	-0.27	-0.19	Systolic blood pressure;	chr11:17043742	chr11:17013998~17053024:+
BRCA	cis	rs45509595	0.841	rs200501	ENSG00000220721.1	OR1F12	6.08	1.66e-09	2.69e-07	0.33	0.19	Breast cancer;	chr6:27821164	chr6:28073316~28074233:+
BRCA	cis	rs2276314	0.512	rs1789506	ENSG00000278986.1	RP11-723J4.3	6.08	1.66e-09	2.7e-07	0.22	0.19	Endometriosis;Drug-induced torsades de pointes;	chr18:36045407	chr18:35972151~35973916:+
BRCA	cis	rs2243480	1	rs427044	ENSG00000164669.11	INTS4P1	6.08	1.66e-09	2.7e-07	0.37	0.19	Diabetic kidney disease;	chr7:66043558	chr7:65141225~65234216:+
BRCA	cis	rs9907295	0.818	rs9303692	ENSG00000271013.1	AC015849.15	6.08	1.66e-09	2.7e-07	0.23	0.19	Fibroblast growth factor basic levels;	chr17:35861492	chr17:35912635~35918010:-
BRCA	cis	rs17301013	0.606	rs72713505	ENSG00000227373.4	RP11-160H22.5	6.08	1.66e-09	2.7e-07	0.28	0.19	Systemic lupus erythematosus;	chr1:174255911	chr1:174115300~174160004:-
BRCA	cis	rs9992667	0.91	rs28681431	ENSG00000231160.8	KLF3-AS1	6.08	1.67e-09	2.7e-07	0.23	0.19	Eosinophil percentage of granulocytes;	chr4:38686307	chr4:38612701~38664883:-
BRCA	cis	rs651907	0.557	rs7612283	ENSG00000244119.1	PDCL3P4	6.08	1.67e-09	2.7e-07	0.15	0.19	Colorectal cancer;	chr3:101716075	chr3:101712472~101713191:+
BRCA	cis	rs651907	0.557	rs34457525	ENSG00000244119.1	PDCL3P4	6.08	1.67e-09	2.7e-07	0.15	0.19	Colorectal cancer;	chr3:101716381	chr3:101712472~101713191:+
BRCA	cis	rs934734	0.532	rs10184881	ENSG00000204929.10	AC074391.1	-6.08	1.67e-09	2.7e-07	-0.23	-0.19	Rheumatoid arthritis;	chr2:65457018	chr2:65436711~66084639:+
BRCA	cis	rs2638953	0.849	rs11049388	ENSG00000247934.4	RP11-967K21.1	-6.08	1.67e-09	2.71e-07	-0.24	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28169054	chr12:28163298~28190738:-
BRCA	cis	rs919433	0.68	rs788017	ENSG00000231621.1	AC013264.2	-6.08	1.67e-09	2.71e-07	-0.18	-0.19	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197400449	chr2:197197991~197199273:+
BRCA	cis	rs732716	0.853	rs1127888	ENSG00000267980.1	AC007292.6	-6.08	1.67e-09	2.71e-07	-0.23	-0.19	Mean corpuscular volume;	chr19:4454086	chr19:4363789~4364640:+
BRCA	cis	rs8072100	0.713	rs11079776	ENSG00000228782.6	CTD-2026D20.3	6.08	1.67e-09	2.71e-07	0.2	0.19	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47469527	chr17:47450568~47492492:-
BRCA	cis	rs13113518	0.783	rs11133389	ENSG00000273257.1	RP11-177J6.1	6.08	1.67e-09	2.71e-07	0.24	0.19	Height;	chr4:55486718	chr4:55387949~55388271:+
BRCA	cis	rs2281558	0.754	rs73597824	ENSG00000125804.12	FAM182A	-6.08	1.67e-09	2.71e-07	-0.27	-0.19	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25610841	chr20:26054655~26086917:+
BRCA	cis	rs11159086	0.938	rs11623040	ENSG00000259005.1	RP3-449M8.6	6.08	1.67e-09	2.71e-07	0.35	0.19	Advanced glycation end-product levels;	chr14:74496743	chr14:74474007~74474864:-
BRCA	cis	rs11722228	0.549	rs2241488	ENSG00000261490.1	RP11-448G15.3	6.08	1.67e-09	2.71e-07	0.21	0.19	Urate levels;Serum uric acid levels;Gout;	chr4:10099507	chr4:10068089~10073019:-
BRCA	cis	rs11722779	0.838	rs4533776	ENSG00000251288.2	RP11-10L12.2	-6.08	1.67e-09	2.72e-07	-0.21	-0.19	Schizophrenia;	chr4:102912732	chr4:102751401~102752641:+
BRCA	cis	rs227932	0.764	rs78660981	ENSG00000234286.1	AC006026.13	-6.08	1.68e-09	2.72e-07	-0.31	-0.19	Schizophrenia;	chr7:23719296	chr7:23680195~23680786:-
BRCA	cis	rs4713118	0.616	rs9348789	ENSG00000219392.1	RP1-265C24.5	-6.08	1.68e-09	2.72e-07	-0.28	-0.19	Parkinson's disease;	chr6:28057708	chr6:28115628~28116551:+
BRCA	cis	rs7897654	0.571	rs12765002	ENSG00000213061.2	PFN1P11	6.08	1.68e-09	2.72e-07	0.28	0.19	Schizophrenia;	chr10:102875591	chr10:102838011~102845473:-
BRCA	cis	rs12655019	0.92	rs7731829	ENSG00000271828.1	CTD-2310F14.1	6.08	1.68e-09	2.72e-07	0.34	0.19	Breast cancer (early onset);	chr5:56911884	chr5:56927874~56929573:+
BRCA	cis	rs2243480	1	rs781149	ENSG00000232546.1	RP11-458F8.1	-6.08	1.68e-09	2.73e-07	-0.24	-0.19	Diabetic kidney disease;	chr7:66016297	chr7:66848496~66858136:+
BRCA	cis	rs2243480	0.901	rs58207111	ENSG00000232546.1	RP11-458F8.1	-6.08	1.68e-09	2.73e-07	-0.24	-0.19	Diabetic kidney disease;	chr7:66021736	chr7:66848496~66858136:+
BRCA	cis	rs755249	0.567	rs3818806	ENSG00000237624.1	OXCT2P1	6.08	1.68e-09	2.73e-07	0.27	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39282599	chr1:39514956~39516490:+
BRCA	cis	rs7914558	1	rs10509757	ENSG00000213061.2	PFN1P11	6.08	1.68e-09	2.73e-07	0.24	0.19	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102993203	chr10:102838011~102845473:-
BRCA	cis	rs651907	0.535	rs11717638	ENSG00000244119.1	PDCL3P4	6.08	1.68e-09	2.73e-07	0.15	0.19	Colorectal cancer;	chr3:101786624	chr3:101712472~101713191:+
BRCA	cis	rs227275	0.525	rs4596243	ENSG00000251288.2	RP11-10L12.2	-6.08	1.68e-09	2.73e-07	-0.22	-0.19	Allergic disease (asthma, hay fever or eczema);	chr4:102964411	chr4:102751401~102752641:+
BRCA	cis	rs904251	0.861	rs2776875	ENSG00000204110.6	RP1-153P14.8	-6.08	1.68e-09	2.73e-07	-0.21	-0.19	Cognitive performance;	chr6:37519020	chr6:37507348~37535616:+
BRCA	cis	rs2243480	0.708	rs13242216	ENSG00000232559.3	GS1-124K5.12	6.08	1.68e-09	2.73e-07	0.35	0.19	Diabetic kidney disease;	chr7:66433290	chr7:66554588~66576923:-
BRCA	cis	rs2834288	0.535	rs8129694	ENSG00000273102.1	AP000569.9	-6.08	1.69e-09	2.73e-07	-0.2	-0.19	Gut microbiota (bacterial taxa);	chr21:33954795	chr21:33967101~33968573:-
BRCA	cis	rs6728642	1	rs113863815	ENSG00000230606.9	AC159540.1	6.08	1.69e-09	2.74e-07	0.4	0.19	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:96992076	chr2:97416165~97433527:-
BRCA	cis	rs904251	0.861	rs1757183	ENSG00000204110.6	RP1-153P14.8	6.08	1.69e-09	2.74e-07	0.2	0.19	Cognitive performance;	chr6:37517014	chr6:37507348~37535616:+
BRCA	cis	rs11098499	1	rs35643470	ENSG00000249244.1	RP11-548H18.2	6.08	1.69e-09	2.74e-07	0.22	0.19	Corneal astigmatism;	chr4:119263793	chr4:119391831~119395335:-
BRCA	cis	rs925255	0.678	rs6547853	ENSG00000270210.1	RP11-373D23.3	6.08	1.69e-09	2.74e-07	0.24	0.19	Inflammatory bowel disease;Crohn's disease;	chr2:28423934	chr2:28425945~28426719:+
BRCA	cis	rs1552244	0.935	rs7652190	ENSG00000180385.7	EMC3-AS1	6.08	1.69e-09	2.74e-07	0.23	0.19	Alzheimer's disease;	chr3:10063466	chr3:9986893~10006990:+
BRCA	cis	rs1552244	1	rs7619340	ENSG00000180385.7	EMC3-AS1	6.08	1.69e-09	2.74e-07	0.23	0.19	Alzheimer's disease;	chr3:10066494	chr3:9986893~10006990:+
BRCA	cis	rs875971	0.522	rs9530	ENSG00000234585.5	CCT6P3	6.08	1.69e-09	2.74e-07	0.18	0.19	Aortic root size;	chr7:65960907	chr7:65038354~65074713:+
BRCA	cis	rs7923837	0.634	rs61862780	ENSG00000236493.2	EIF2S2P3	-6.08	1.69e-09	2.74e-07	-0.25	-0.19	Multiple sclerosis;Body mass index;	chr10:92708886	chr10:92668745~92669743:-
BRCA	cis	rs17508449	0.819	rs79198040	ENSG00000232450.1	RP4-730K3.3	-6.08	1.69e-09	2.74e-07	-0.33	-0.19	Leprosy;	chr1:113746069	chr1:113698884~113699631:-
BRCA	cis	rs2243480	1	rs427044	ENSG00000228409.4	CCT6P1	6.08	1.69e-09	2.74e-07	0.26	0.19	Diabetic kidney disease;	chr7:66043558	chr7:65751142~65763354:+
BRCA	cis	rs4713118	0.615	rs9295747	ENSG00000220721.1	OR1F12	-6.08	1.69e-09	2.74e-07	-0.22	-0.19	Parkinson's disease;	chr6:27769214	chr6:28073316~28074233:+
BRCA	cis	rs2303759	0.958	rs1465697	ENSG00000268686.1	AC010524.2	-6.08	1.69e-09	2.75e-07	-0.29	-0.19	Multiple sclerosis;	chr19:49333989	chr19:49368705~49388081:-
BRCA	cis	rs7923837	0.634	rs1544210	ENSG00000236493.2	EIF2S2P3	-6.08	1.7e-09	2.76e-07	-0.24	-0.19	Multiple sclerosis;Body mass index;	chr10:92728044	chr10:92668745~92669743:-
BRCA	cis	rs910316	1	rs175443	ENSG00000279594.1	RP11-950C14.10	-6.08	1.71e-09	2.77e-07	-0.2	-0.19	Height;	chr14:75135260	chr14:75011269~75012851:-
BRCA	cis	rs2732480	0.5	rs2732461	ENSG00000257763.1	OR5BK1P	6.08	1.71e-09	2.77e-07	0.2	0.19	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48299019	chr12:48355792~48356614:-
BRCA	cis	rs801193	0.742	rs9969300	ENSG00000236529.1	RP13-254B10.1	-6.08	1.71e-09	2.77e-07	-0.2	-0.19	Aortic root size;	chr7:66316659	chr7:65840212~65840596:+
BRCA	cis	rs11098499	0.909	rs28555550	ENSG00000249244.1	RP11-548H18.2	6.08	1.71e-09	2.77e-07	0.22	0.19	Corneal astigmatism;	chr4:119289885	chr4:119391831~119395335:-
BRCA	cis	rs11098499	1	rs28419773	ENSG00000249244.1	RP11-548H18.2	6.08	1.71e-09	2.77e-07	0.22	0.19	Corneal astigmatism;	chr4:119289906	chr4:119391831~119395335:-
BRCA	cis	rs5015933	0.815	rs1333055	ENSG00000232630.1	PRPS1P2	-6.08	1.71e-09	2.77e-07	-0.17	-0.19	Body mass index;	chr9:125307948	chr9:125150653~125151589:+
BRCA	cis	rs4713118	0.662	rs9380045	ENSG00000219392.1	RP1-265C24.5	-6.08	1.71e-09	2.77e-07	-0.28	-0.19	Parkinson's disease;	chr6:28057501	chr6:28115628~28116551:+
BRCA	cis	rs4664293	0.801	rs6432552	ENSG00000226266.5	AC009961.3	-6.08	1.71e-09	2.78e-07	-0.23	-0.19	Monocyte percentage of white cells;	chr2:159717613	chr2:159670708~159712435:-
BRCA	cis	rs2243480	1	rs160652	ENSG00000232546.1	RP11-458F8.1	-6.08	1.71e-09	2.78e-07	-0.26	-0.19	Diabetic kidney disease;	chr7:66073444	chr7:66848496~66858136:+
BRCA	cis	rs9291683	0.526	rs6827785	ENSG00000250413.1	RP11-448G15.1	-6.08	1.72e-09	2.78e-07	-0.24	-0.19	Bone mineral density;	chr4:10016581	chr4:10006482~10009725:+
BRCA	cis	rs7569084	0.687	rs11126038	ENSG00000237979.1	AC007389.1	6.08	1.72e-09	2.78e-07	0.24	0.19	Sum eosinophil basophil counts;	chr2:65436100	chr2:65500993~65502138:-
BRCA	cis	rs7569084	0.663	rs11694714	ENSG00000237979.1	AC007389.1	6.08	1.72e-09	2.78e-07	0.24	0.19	Sum eosinophil basophil counts;	chr2:65436802	chr2:65500993~65502138:-
BRCA	cis	rs17508449	0.865	rs80348557	ENSG00000232450.1	RP4-730K3.3	-6.08	1.72e-09	2.78e-07	-0.33	-0.19	Leprosy;	chr1:113608494	chr1:113698884~113699631:-
BRCA	cis	rs5015933	0.788	rs568409	ENSG00000232630.1	PRPS1P2	-6.08	1.72e-09	2.78e-07	-0.17	-0.18	Body mass index;	chr9:125309994	chr9:125150653~125151589:+
BRCA	cis	rs7772486	0.846	rs2492856	ENSG00000270638.1	RP3-466P17.1	6.08	1.72e-09	2.78e-07	0.21	0.18	Lobe attachment (rater-scored or self-reported);	chr6:146002792	chr6:145735570~145737218:+
BRCA	cis	rs7914558	1	rs7077097	ENSG00000213061.2	PFN1P11	6.08	1.72e-09	2.79e-07	0.24	0.18	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103185706	chr10:102838011~102845473:-
BRCA	cis	rs4691139	1	rs4691139	ENSG00000248632.1	RP11-366M4.11	6.08	1.72e-09	2.79e-07	0.19	0.18	Ovarian cancer in BRCA1 mutation carriers;	chr4:164987569	chr4:164968587~164970002:-
BRCA	cis	rs227275	0.525	rs3974485	ENSG00000251288.2	RP11-10L12.2	-6.08	1.72e-09	2.79e-07	-0.22	-0.18	Allergic disease (asthma, hay fever or eczema);	chr4:102993283	chr4:102751401~102752641:+
BRCA	cis	rs227275	0.525	rs6533052	ENSG00000251288.2	RP11-10L12.2	-6.08	1.73e-09	2.79e-07	-0.22	-0.18	Allergic disease (asthma, hay fever or eczema);	chr4:102990624	chr4:102751401~102752641:+
BRCA	cis	rs227275	0.525	rs3974608	ENSG00000251288.2	RP11-10L12.2	-6.08	1.73e-09	2.79e-07	-0.21	-0.18	Allergic disease (asthma, hay fever or eczema);	chr4:102925641	chr4:102751401~102752641:+
BRCA	cis	rs7131987	0.526	rs7954375	ENSG00000275476.1	RP11-996F15.4	6.08	1.73e-09	2.8e-07	0.21	0.18	QT interval;	chr12:29241487	chr12:29277397~29277882:-
BRCA	cis	rs7267979	0.816	rs6115094	ENSG00000277938.1	RP5-965G21.3	6.08	1.73e-09	2.8e-07	0.22	0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25230191	chr20:25229150~25231933:+
BRCA	cis	rs853679	0.517	rs9380058	ENSG00000204709.4	LINC01556	6.08	1.73e-09	2.8e-07	0.28	0.18	Depression;	chr6:28159666	chr6:28943877~28944537:+
BRCA	cis	rs853679	0.517	rs9393898	ENSG00000204709.4	LINC01556	6.08	1.73e-09	2.8e-07	0.28	0.18	Depression;	chr6:28162598	chr6:28943877~28944537:+
BRCA	cis	rs2638953	0.853	rs10506037	ENSG00000278733.1	RP11-425D17.1	-6.08	1.73e-09	2.8e-07	-0.25	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28498213	chr12:28185625~28186190:-
BRCA	cis	rs853679	0.517	rs4713141	ENSG00000280107.1	AL022393.9	-6.08	1.73e-09	2.8e-07	-0.28	-0.18	Depression;	chr6:28133900	chr6:28170845~28172521:+
BRCA	cis	rs8005677	1	rs4982710	ENSG00000257285.4	RP11-298I3.1	6.08	1.73e-09	2.8e-07	0.2	0.18	Cognitive ability (multi-trait analysis);	chr14:22929693	chr14:22929609~22955562:+
BRCA	cis	rs1193	0.802	rs6706606	ENSG00000231259.4	AC125232.1	-6.08	1.73e-09	2.8e-07	-0.23	-0.18	High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;High light scatter reticulocyte count;	chr2:86766647	chr2:87031815~87053069:-
BRCA	cis	rs34779708	0.931	rs34954932	ENSG00000271335.4	RP11-324I22.4	6.08	1.73e-09	2.8e-07	0.19	0.18	Inflammatory bowel disease;Crohn's disease;	chr10:35121879	chr10:35314552~35336401:-
BRCA	cis	rs8054556	0.74	rs9936474	ENSG00000273724.1	RP11-347C12.12	-6.08	1.73e-09	2.81e-07	-0.21	-0.18	Autism spectrum disorder or schizophrenia;	chr16:29921370	chr16:30336400~30343336:+
BRCA	cis	rs651907	0.514	rs10936744	ENSG00000244119.1	PDCL3P4	6.07	1.74e-09	2.81e-07	0.15	0.18	Colorectal cancer;	chr3:101714596	chr3:101712472~101713191:+
BRCA	cis	rs7487075	0.78	rs12296120	ENSG00000257261.4	RP11-96H19.1	6.07	1.74e-09	2.81e-07	0.19	0.18	Itch intensity from mosquito bite;	chr12:46343808	chr12:46383679~46876159:+
BRCA	cis	rs2348418	0.864	rs2175464	ENSG00000247934.4	RP11-967K21.1	-6.07	1.74e-09	2.81e-07	-0.21	-0.18	Lung function (FEV1);Lung function (FVC);	chr12:28564178	chr12:28163298~28190738:-
BRCA	cis	rs1707322	1	rs6657720	ENSG00000281133.1	AL355480.3	-6.07	1.74e-09	2.81e-07	-0.23	-0.18	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45920597	chr1:45580892~45580996:-
BRCA	cis	rs1707322	1	rs7526369	ENSG00000281133.1	AL355480.3	-6.07	1.74e-09	2.81e-07	-0.23	-0.18	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45924888	chr1:45580892~45580996:-
BRCA	cis	rs10510102	0.935	rs11200201	ENSG00000226864.1	ATE1-AS1	6.07	1.74e-09	2.81e-07	0.32	0.18	Breast cancer;	chr10:121864790	chr10:121928312~121951965:+
BRCA	cis	rs875971	0.522	rs4718285	ENSG00000234585.5	CCT6P3	6.07	1.74e-09	2.81e-07	0.18	0.18	Aortic root size;	chr7:65827018	chr7:65038354~65074713:+
BRCA	cis	rs910316	0.935	rs175076	ENSG00000279594.1	RP11-950C14.10	-6.07	1.74e-09	2.82e-07	-0.2	-0.18	Height;	chr14:75038783	chr14:75011269~75012851:-
BRCA	cis	rs7520050	0.966	rs6675726	ENSG00000280836.1	AL355480.1	6.07	1.74e-09	2.82e-07	0.22	0.18	Reticulocyte count;Red blood cell count;	chr1:46094971	chr1:45581219~45581321:-
BRCA	cis	rs853679	0.546	rs200953	ENSG00000220721.1	OR1F12	6.07	1.74e-09	2.82e-07	0.33	0.18	Depression;	chr6:27869489	chr6:28073316~28074233:+
BRCA	cis	rs7914558	0.966	rs11191471	ENSG00000213061.2	PFN1P11	6.07	1.74e-09	2.82e-07	0.24	0.18	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102942293	chr10:102838011~102845473:-
BRCA	cis	rs853679	0.546	rs35017208	ENSG00000220721.1	OR1F12	6.07	1.74e-09	2.82e-07	0.44	0.18	Depression;	chr6:28377505	chr6:28073316~28074233:+
BRCA	cis	rs30380	0.734	rs27044	ENSG00000272109.1	CTD-2260A17.3	-6.07	1.74e-09	2.82e-07	-0.25	-0.18	Cerebrospinal fluid biomarker levels;	chr5:96783148	chr5:96804353~96806105:+
BRCA	cis	rs2836950	0.545	rs2836922	ENSG00000238141.2	BRWD1-AS1	-6.07	1.75e-09	2.83e-07	-0.21	-0.18	Menarche (age at onset);	chr21:39144382	chr21:39315707~39323218:+
BRCA	cis	rs12073837	0.5	rs11118610	ENSG00000272823.1	RP11-295M18.6	-6.07	1.75e-09	2.83e-07	-0.19	-0.18	F-cell distribution;	chr1:220816744	chr1:220828676~220829211:-
BRCA	cis	rs250585	0.736	rs30010	ENSG00000260136.4	CTD-2270L9.4	6.07	1.75e-09	2.83e-07	0.18	0.18	Egg allergy;	chr16:23411337	chr16:23452758~23457606:+
BRCA	cis	rs250585	0.736	rs40817	ENSG00000260136.4	CTD-2270L9.4	6.07	1.75e-09	2.83e-07	0.18	0.18	Egg allergy;	chr16:23411351	chr16:23452758~23457606:+
BRCA	cis	rs11976180	1	rs1919950	ENSG00000273234.1	OR2A13P	-6.07	1.75e-09	2.84e-07	-0.25	-0.18	Obesity-related traits;	chr7:144070805	chr7:144142009~144142938:+
BRCA	cis	rs17301013	0.606	rs6666588	ENSG00000227373.4	RP11-160H22.5	6.07	1.76e-09	2.84e-07	0.28	0.18	Systemic lupus erythematosus;	chr1:174248972	chr1:174115300~174160004:-
BRCA	cis	rs17301013	0.606	rs72713504	ENSG00000227373.4	RP11-160H22.5	6.07	1.76e-09	2.84e-07	0.28	0.18	Systemic lupus erythematosus;	chr1:174251916	chr1:174115300~174160004:-
BRCA	cis	rs2153535	0.518	rs926533	ENSG00000230939.1	RP11-314C16.1	-6.07	1.76e-09	2.84e-07	-0.22	-0.18	Motion sickness;	chr6:8556529	chr6:8784178~8785445:+
BRCA	cis	rs7520050	0.966	rs785495	ENSG00000280836.1	AL355480.1	6.07	1.76e-09	2.84e-07	0.22	0.18	Reticulocyte count;Red blood cell count;	chr1:46122215	chr1:45581219~45581321:-
BRCA	cis	rs7178375	1	rs9806159	ENSG00000270055.1	CTD-3092A11.2	-6.07	1.76e-09	2.85e-07	-0.26	-0.18	Hypertriglyceridemia;	chr15:30917451	chr15:30487963~30490313:+
BRCA	cis	rs4950322	0.543	rs4950318	ENSG00000244371.2	PFN1P8	-6.07	1.76e-09	2.85e-07	-0.26	-0.18	Protein quantitative trait loci;	chr1:147316240	chr1:146957117~146957659:-
BRCA	cis	rs4950322	0.543	rs4950319	ENSG00000244371.2	PFN1P8	-6.07	1.76e-09	2.85e-07	-0.26	-0.18	Protein quantitative trait loci;	chr1:147316250	chr1:146957117~146957659:-
BRCA	cis	rs2235642	0.507	rs2235643	ENSG00000280231.1	LA16c-380F5.3	6.07	1.76e-09	2.85e-07	0.26	0.18	Coronary artery disease;	chr16:1535114	chr16:1553655~1554130:-
BRCA	cis	rs4683346	0.616	rs3843369	ENSG00000173811.9	CCDC13-AS1	-6.07	1.76e-09	2.85e-07	-0.25	-0.18	Granulocyte percentage of myeloid white cells;	chr3:42765556	chr3:42732575~42746768:+
BRCA	cis	rs13126694	0.75	rs2346782	ENSG00000248429.4	RP11-597D13.9	6.07	1.76e-09	2.85e-07	0.17	0.18	Blood osmolality (transformed sodium);	chr4:158147143	chr4:158170752~158202877:+
BRCA	cis	rs2153535	0.585	rs1328867	ENSG00000230939.1	RP11-314C16.1	-6.07	1.76e-09	2.85e-07	-0.22	-0.18	Motion sickness;	chr6:8652454	chr6:8784178~8785445:+
BRCA	cis	rs1707322	1	rs10890355	ENSG00000281133.1	AL355480.3	-6.07	1.77e-09	2.85e-07	-0.23	-0.18	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45851676	chr1:45580892~45580996:-
BRCA	cis	rs1707322	1	rs11211204	ENSG00000281133.1	AL355480.3	-6.07	1.77e-09	2.85e-07	-0.23	-0.18	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45852192	chr1:45580892~45580996:-
BRCA	cis	rs3126085	0.935	rs11586114	ENSG00000237975.5	FLG-AS1	6.07	1.77e-09	2.86e-07	0.29	0.18	Atopic dermatitis;	chr1:152327291	chr1:152168125~152445456:+
BRCA	cis	rs228614	0.51	rs223465	ENSG00000251288.2	RP11-10L12.2	-6.07	1.77e-09	2.86e-07	-0.22	-0.18	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102780174	chr4:102751401~102752641:+
BRCA	cis	rs228614	0.51	rs223464	ENSG00000251288.2	RP11-10L12.2	-6.07	1.77e-09	2.86e-07	-0.22	-0.18	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102780603	chr4:102751401~102752641:+
BRCA	cis	rs7567389	0.677	rs72848616	ENSG00000236682.1	AC068282.3	-6.07	1.77e-09	2.86e-07	-0.28	-0.18	Self-rated health;	chr2:127377521	chr2:127389130~127400580:+
BRCA	cis	rs7567389	0.71	rs72848618	ENSG00000236682.1	AC068282.3	-6.07	1.77e-09	2.86e-07	-0.28	-0.18	Self-rated health;	chr2:127377749	chr2:127389130~127400580:+
BRCA	cis	rs71520386	0.561	rs10274260	ENSG00000228649.7	AC005682.5	-6.07	1.77e-09	2.86e-07	-0.18	-0.18	Fibrinogen levels;	chr7:22805227	chr7:22854178~22861579:+
BRCA	cis	rs6688613	1	rs7550698	ENSG00000225171.2	DUTP6	-6.07	1.77e-09	2.86e-07	-0.22	-0.18	Refractive astigmatism;	chr1:166981844	chr1:166868748~166869209:+
BRCA	cis	rs1387259	0.899	rs7307566	ENSG00000257763.1	OR5BK1P	6.07	1.77e-09	2.86e-07	0.2	0.18	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48210899	chr12:48355792~48356614:-
BRCA	cis	rs919433	0.68	rs788022	ENSG00000231621.1	AC013264.2	-6.07	1.77e-09	2.86e-07	-0.18	-0.18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197415862	chr2:197197991~197199273:+
BRCA	cis	rs919433	0.68	rs699319	ENSG00000231621.1	AC013264.2	-6.07	1.77e-09	2.86e-07	-0.18	-0.18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197417052	chr2:197197991~197199273:+
BRCA	cis	rs875971	0.508	rs10258739	ENSG00000273024.4	INTS4P2	6.07	1.77e-09	2.86e-07	0.2	0.18	Aortic root size;	chr7:66597948	chr7:65647864~65715661:+
BRCA	cis	rs4718428	0.705	rs4718422	ENSG00000230295.1	RP11-458F8.2	-6.07	1.77e-09	2.87e-07	-0.17	-0.18	Corneal structure;	chr7:66894282	chr7:66880708~66882981:+
BRCA	cis	rs911555	0.723	rs6575986	ENSG00000244691.1	RPL10AP1	-6.07	1.77e-09	2.87e-07	-0.23	-0.18	Intelligence (multi-trait analysis);	chr14:103420334	chr14:103412119~103412761:-
BRCA	cis	rs904251	0.828	rs2797803	ENSG00000204110.6	RP1-153P14.8	-6.07	1.78e-09	2.87e-07	-0.21	-0.18	Cognitive performance;	chr6:37519564	chr6:37507348~37535616:+
BRCA	cis	rs17711722	0.528	rs73138179	ENSG00000237310.1	GS1-124K5.4	6.07	1.78e-09	2.87e-07	0.21	0.18	Calcium levels;	chr7:65829495	chr7:66493706~66495474:+
BRCA	cis	rs651907	0.557	rs13069443	ENSG00000244119.1	PDCL3P4	6.07	1.78e-09	2.87e-07	0.15	0.18	Colorectal cancer;	chr3:101654461	chr3:101712472~101713191:+
BRCA	cis	rs1858037	0.867	rs67817304	ENSG00000204929.10	AC074391.1	6.07	1.78e-09	2.87e-07	0.25	0.18	Rheumatoid arthritis;	chr2:65346982	chr2:65436711~66084639:+
BRCA	cis	rs7923609	0.902	rs10822182	ENSG00000232075.1	MRPL35P2	-6.07	1.78e-09	2.88e-07	-0.23	-0.18	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63565718	chr10:63634317~63634827:-
BRCA	cis	rs6095360	0.727	rs13040292	ENSG00000222365.1	SNORD12B	-6.07	1.78e-09	2.88e-07	-0.24	-0.18	Intelligence (multi-trait analysis);	chr20:49105045	chr20:49280319~49280409:+
BRCA	cis	rs228614	0.51	rs223468	ENSG00000251288.2	RP11-10L12.2	-6.07	1.78e-09	2.88e-07	-0.22	-0.18	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102779265	chr4:102751401~102752641:+
BRCA	cis	rs7255436	0.965	rs11666003	ENSG00000269386.4	RAB11B-AS1	6.07	1.78e-09	2.88e-07	0.2	0.18	HDL cholesterol;	chr19:8387218	chr19:8374373~8390685:-
BRCA	cis	rs13108904	0.967	rs62293658	ENSG00000254094.1	AC078852.1	6.07	1.78e-09	2.88e-07	0.2	0.18	Obesity-related traits;	chr4:1282628	chr4:1356581~1358075:+
BRCA	cis	rs17301013	0.507	rs7521109	ENSG00000227373.4	RP11-160H22.5	6.07	1.78e-09	2.88e-07	0.29	0.18	Systemic lupus erythematosus;	chr1:174802629	chr1:174115300~174160004:-
BRCA	cis	rs7238033	0.581	rs7229753	ENSG00000267193.4	RP11-116O18.3	6.07	1.78e-09	2.88e-07	0.2	0.18	Bladder cancer;	chr18:45732495	chr18:45669367~45747215:-
BRCA	cis	rs2732480	0.5	rs2450986	ENSG00000257763.1	OR5BK1P	6.07	1.79e-09	2.89e-07	0.2	0.18	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48267905	chr12:48355792~48356614:-
BRCA	cis	rs228614	0.51	rs223470	ENSG00000251288.2	RP11-10L12.2	-6.07	1.79e-09	2.89e-07	-0.22	-0.18	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102778004	chr4:102751401~102752641:+
BRCA	cis	rs2243480	1	rs1039664	ENSG00000164669.11	INTS4P1	6.07	1.79e-09	2.89e-07	0.35	0.18	Diabetic kidney disease;	chr7:65984729	chr7:65141225~65234216:+
BRCA	cis	rs7246967	0.673	rs16994997	ENSG00000198153.8	ZNF849P	-6.07	1.79e-09	2.89e-07	-0.27	-0.18	Bronchopulmonary dysplasia;	chr19:22696808	chr19:22685167~22686732:+
BRCA	cis	rs853679	0.517	rs12332979	ENSG00000204709.4	LINC01556	6.07	1.79e-09	2.89e-07	0.28	0.18	Depression;	chr6:28173770	chr6:28943877~28944537:+
BRCA	cis	rs853679	0.517	rs67878650	ENSG00000204709.4	LINC01556	6.07	1.79e-09	2.89e-07	0.28	0.18	Depression;	chr6:28174809	chr6:28943877~28944537:+
BRCA	cis	rs853679	0.569	rs9348798	ENSG00000204709.4	LINC01556	6.07	1.79e-09	2.89e-07	0.28	0.18	Depression;	chr6:28175233	chr6:28943877~28944537:+
BRCA	cis	rs853679	0.517	rs9380065	ENSG00000204709.4	LINC01556	6.07	1.79e-09	2.89e-07	0.28	0.18	Depression;	chr6:28176973	chr6:28943877~28944537:+
BRCA	cis	rs2836950	0.545	rs2836956	ENSG00000255568.3	BRWD1-AS2	6.07	1.79e-09	2.89e-07	0.18	0.18	Menarche (age at onset);	chr21:39251092	chr21:39313935~39314962:+
BRCA	cis	rs7617773	0.817	rs9830016	ENSG00000199476.1	Y_RNA	-6.07	1.79e-09	2.89e-07	-0.25	-0.18	Coronary artery disease;	chr3:48241004	chr3:48288587~48288694:+
BRCA	cis	rs227275	0.556	rs11722779	ENSG00000251288.2	RP11-10L12.2	-6.07	1.79e-09	2.9e-07	-0.22	-0.18	Allergic disease (asthma, hay fever or eczema);	chr4:102906331	chr4:102751401~102752641:+
BRCA	cis	rs7923837	0.574	rs2488075	ENSG00000236493.2	EIF2S2P3	-6.07	1.79e-09	2.9e-07	-0.24	-0.18	Multiple sclerosis;Body mass index;	chr10:92730417	chr10:92668745~92669743:-
BRCA	cis	rs9813712	0.595	rs1453239	ENSG00000228252.7	COL6A4P2	-6.07	1.79e-09	2.9e-07	-0.22	-0.18	Response to amphetamines;	chr3:130288915	chr3:130212823~130273806:+
BRCA	cis	rs8114671	0.628	rs6060130	ENSG00000269202.1	RP4-614O4.12	-6.07	1.79e-09	2.9e-07	-0.19	-0.18	Height;	chr20:34961516	chr20:35201747~35203288:-
BRCA	cis	rs9992667	0.955	rs73232881	ENSG00000231160.8	KLF3-AS1	6.07	1.8e-09	2.9e-07	0.24	0.18	Eosinophil percentage of granulocytes;	chr4:38662510	chr4:38612701~38664883:-
BRCA	cis	rs7247513	0.964	rs12979795	ENSG00000230310.1	CTD-2192J16.11	6.07	1.8e-09	2.91e-07	0.23	0.18	Bipolar disorder;	chr19:12607033	chr19:12552597~12553644:+
BRCA	cis	rs1193	1	rs6711696	ENSG00000231259.4	AC125232.1	-6.07	1.8e-09	2.91e-07	-0.23	-0.18	High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;High light scatter reticulocyte count;	chr2:86760860	chr2:87031815~87053069:-
BRCA	cis	rs6479891	0.818	rs2393976	ENSG00000232075.1	MRPL35P2	6.07	1.8e-09	2.91e-07	0.33	0.18	Arthritis (juvenile idiopathic);	chr10:63493679	chr10:63634317~63634827:-
BRCA	cis	rs755249	0.532	rs2296173	ENSG00000237624.1	OXCT2P1	6.07	1.8e-09	2.91e-07	0.27	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39447679	chr1:39514956~39516490:+
BRCA	cis	rs755249	0.567	rs3118014	ENSG00000237624.1	OXCT2P1	6.07	1.8e-09	2.91e-07	0.27	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39448418	chr1:39514956~39516490:+
BRCA	cis	rs5015933	1	rs5015933	ENSG00000232630.1	PRPS1P2	-6.07	1.8e-09	2.91e-07	-0.18	-0.18	Body mass index;	chr9:125375139	chr9:125150653~125151589:+
BRCA	cis	rs17301013	0.606	rs4650968	ENSG00000227373.4	RP11-160H22.5	6.07	1.8e-09	2.91e-07	0.28	0.18	Systemic lupus erythematosus;	chr1:174223322	chr1:174115300~174160004:-
BRCA	cis	rs5167	0.743	rs57204168	ENSG00000280087.1	CTB-129P6.7	6.07	1.8e-09	2.91e-07	0.24	0.18	Blood protein levels;	chr19:44993518	chr19:44909375~44914968:+
BRCA	cis	rs1552244	1	rs7637888	ENSG00000180385.7	EMC3-AS1	6.07	1.8e-09	2.91e-07	0.23	0.18	Alzheimer's disease;	chr3:10039038	chr3:9986893~10006990:+
BRCA	cis	rs2243480	1	rs1964692	ENSG00000232546.1	RP11-458F8.1	-6.07	1.81e-09	2.92e-07	-0.24	-0.18	Diabetic kidney disease;	chr7:65989196	chr7:66848496~66858136:+
BRCA	cis	rs2243480	1	rs1723270	ENSG00000164669.11	INTS4P1	6.07	1.81e-09	2.92e-07	0.36	0.18	Diabetic kidney disease;	chr7:66004843	chr7:65141225~65234216:+
BRCA	cis	rs7914558	0.966	rs10883817	ENSG00000213061.2	PFN1P11	6.07	1.81e-09	2.92e-07	0.24	0.18	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102995674	chr10:102838011~102845473:-
BRCA	cis	rs367615	0.68	rs2256556	ENSG00000249476.1	CTD-2587M2.1	-6.07	1.81e-09	2.92e-07	-0.22	-0.18	Colorectal cancer (SNP x SNP interaction);	chr5:109629206	chr5:109237120~109326369:-
BRCA	cis	rs910316	1	rs910316	ENSG00000279594.1	RP11-950C14.10	6.07	1.81e-09	2.92e-07	0.21	0.18	Height;	chr14:75159339	chr14:75011269~75012851:-
BRCA	cis	rs516805	0.667	rs2606609	ENSG00000279453.1	RP3-425C14.4	6.07	1.81e-09	2.93e-07	0.26	0.18	Lymphocyte counts;	chr6:122190346	chr6:122436789~122439223:-
BRCA	cis	rs7927771	0.524	rs12226431	ENSG00000280615.1	Y_RNA	6.07	1.81e-09	2.93e-07	0.22	0.18	Subjective well-being;	chr11:47784304	chr11:47614898~47614994:-
BRCA	cis	rs911555	0.755	rs4143998	ENSG00000244691.1	RPL10AP1	-6.07	1.81e-09	2.93e-07	-0.23	-0.18	Intelligence (multi-trait analysis);	chr14:103488910	chr14:103412119~103412761:-
BRCA	cis	rs911555	0.755	rs1138400	ENSG00000244691.1	RPL10AP1	-6.07	1.81e-09	2.93e-07	-0.23	-0.18	Intelligence (multi-trait analysis);	chr14:103490496	chr14:103412119~103412761:-
BRCA	cis	rs13113518	0.812	rs1522114	ENSG00000273257.1	RP11-177J6.1	6.07	1.82e-09	2.93e-07	0.24	0.18	Height;	chr4:55489895	chr4:55387949~55388271:+
BRCA	cis	rs2638953	0.924	rs10843139	ENSG00000278733.1	RP11-425D17.1	-6.07	1.82e-09	2.93e-07	-0.25	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28227160	chr12:28185625~28186190:-
BRCA	cis	rs2841233	0.692	rs2028416	ENSG00000258701.1	LINC00638	6.07	1.82e-09	2.93e-07	0.2	0.18	IgG glycosylation;	chr14:104882215	chr14:104821201~104823718:+
BRCA	cis	rs944990	0.557	rs7035504	ENSG00000227603.1	RP11-165J3.6	6.07	1.82e-09	2.94e-07	0.19	0.18	Body mass index;	chr9:93528639	chr9:93435332~93437121:-
BRCA	cis	rs17826219	0.568	rs11658027	ENSG00000280069.1	CTD-2349P21.3	6.07	1.82e-09	2.94e-07	0.26	0.18	Body mass index;	chr17:30767864	chr17:30738182~30740275:+
BRCA	cis	rs1387259	0.929	rs2634666	ENSG00000257763.1	OR5BK1P	6.07	1.82e-09	2.94e-07	0.2	0.18	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48269887	chr12:48355792~48356614:-
BRCA	cis	rs2243480	1	rs431318	ENSG00000232559.3	GS1-124K5.12	6.07	1.82e-09	2.94e-07	0.36	0.18	Diabetic kidney disease;	chr7:66046610	chr7:66554588~66576923:-
BRCA	cis	rs754466	0.58	rs10824573	ENSG00000204049.1	RP11-126H7.4	6.07	1.82e-09	2.94e-07	0.23	0.18	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77781211	chr10:77866875~77869610:+
BRCA	cis	rs2153535	0.585	rs7770688	ENSG00000230939.1	RP11-314C16.1	-6.07	1.82e-09	2.94e-07	-0.21	-0.18	Motion sickness;	chr6:8648663	chr6:8784178~8785445:+
BRCA	cis	rs16949788	1	rs7169463	ENSG00000261351.2	CTD-3185P2.1	-6.07	1.82e-09	2.94e-07	-0.37	-0.18	Spherical equivalent (joint analysis main effects and education interaction);	chr15:66453591	chr15:66488658~66492109:-
BRCA	cis	rs1707322	1	rs4390216	ENSG00000281133.1	AL355480.3	-6.07	1.82e-09	2.94e-07	-0.23	-0.18	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45800784	chr1:45580892~45580996:-
BRCA	cis	rs853679	0.517	rs9380047	ENSG00000204709.4	LINC01556	6.07	1.82e-09	2.95e-07	0.27	0.18	Depression;	chr6:28070115	chr6:28943877~28944537:+
BRCA	cis	rs7976269	0.559	rs1344853	ENSG00000275476.1	RP11-996F15.4	-6.07	1.83e-09	2.95e-07	-0.21	-0.18	Male-pattern baldness;	chr12:29058623	chr12:29277397~29277882:-
BRCA	cis	rs228614	0.536	rs223327	ENSG00000251288.2	RP11-10L12.2	-6.07	1.83e-09	2.95e-07	-0.22	-0.18	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102873560	chr4:102751401~102752641:+
BRCA	cis	rs228614	0.51	rs223326	ENSG00000251288.2	RP11-10L12.2	-6.07	1.83e-09	2.95e-07	-0.22	-0.18	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102873770	chr4:102751401~102752641:+
BRCA	cis	rs875971	0.862	rs9791712	ENSG00000224316.1	RP11-479O9.2	-6.07	1.83e-09	2.95e-07	-0.19	-0.18	Aortic root size;	chr7:66640176	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.862	rs9791713	ENSG00000224316.1	RP11-479O9.2	-6.07	1.83e-09	2.95e-07	-0.19	-0.18	Aortic root size;	chr7:66640211	chr7:65773620~65802067:+
BRCA	cis	rs853679	0.546	rs36092177	ENSG00000220721.1	OR1F12	6.07	1.83e-09	2.95e-07	0.44	0.18	Depression;	chr6:28390030	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.546	rs2232429	ENSG00000220721.1	OR1F12	6.07	1.83e-09	2.95e-07	0.44	0.18	Depression;	chr6:28391855	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.546	rs2232426	ENSG00000220721.1	OR1F12	6.07	1.83e-09	2.95e-07	0.44	0.18	Depression;	chr6:28392882	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.546	rs2232423	ENSG00000220721.1	OR1F12	6.07	1.83e-09	2.95e-07	0.44	0.18	Depression;	chr6:28398374	chr6:28073316~28074233:+
BRCA	cis	rs1876905	0.597	rs191631	ENSG00000272356.1	RP5-1112D6.8	-6.07	1.83e-09	2.95e-07	-0.25	-0.18	Mean corpuscular hemoglobin;	chr6:111226862	chr6:111309203~111313517:+
BRCA	cis	rs875971	0.825	rs66981195	ENSG00000224316.1	RP11-479O9.2	-6.07	1.83e-09	2.96e-07	-0.19	-0.18	Aortic root size;	chr7:66614048	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.862	rs3926380	ENSG00000224316.1	RP11-479O9.2	-6.07	1.83e-09	2.96e-07	-0.19	-0.18	Aortic root size;	chr7:66615658	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.825	rs1860472	ENSG00000224316.1	RP11-479O9.2	-6.07	1.83e-09	2.96e-07	-0.19	-0.18	Aortic root size;	chr7:66617736	chr7:65773620~65802067:+
BRCA	cis	rs4700393	0.517	rs13183561	ENSG00000272308.1	RP11-231G3.1	6.07	1.83e-09	2.96e-07	0.25	0.18	Intelligence (multi-trait analysis);	chr5:60803976	chr5:60866457~60866935:-
BRCA	cis	rs754466	0.651	rs2004382	ENSG00000204049.1	RP11-126H7.4	6.07	1.83e-09	2.96e-07	0.23	0.18	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77890593	chr10:77866875~77869610:+
BRCA	cis	rs9880211	0.718	rs56398805	ENSG00000239213.4	NCK1-AS1	6.07	1.84e-09	2.97e-07	0.22	0.18	Height;Body mass index;	chr3:136213558	chr3:136841726~136862054:-
BRCA	cis	rs1707322	1	rs11211228	ENSG00000281133.1	AL355480.3	-6.07	1.84e-09	2.97e-07	-0.23	-0.18	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45934168	chr1:45580892~45580996:-
BRCA	cis	rs1707322	0.963	rs11211229	ENSG00000281133.1	AL355480.3	-6.07	1.84e-09	2.97e-07	-0.23	-0.18	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45934845	chr1:45580892~45580996:-
BRCA	cis	rs1707322	1	rs9803784	ENSG00000281133.1	AL355480.3	-6.07	1.84e-09	2.97e-07	-0.23	-0.18	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45936235	chr1:45580892~45580996:-
BRCA	cis	rs2380205	0.651	rs7907053	ENSG00000232807.2	RP11-536K7.3	6.06	1.85e-09	2.98e-07	0.18	0.18	Breast cancer;	chr10:5884191	chr10:5934270~5945900:-
BRCA	cis	rs2732480	0.538	rs1387260	ENSG00000257763.1	OR5BK1P	6.06	1.85e-09	2.98e-07	0.2	0.18	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48309308	chr12:48355792~48356614:-
BRCA	cis	rs2281636	0.625	rs7075305	ENSG00000233690.1	EBAG9P1	-6.06	1.85e-09	2.98e-07	-0.22	-0.18	Obesity-related traits;	chr10:99604767	chr10:99697407~99697949:-
BRCA	cis	rs6479891	1	rs4746974	ENSG00000232075.1	MRPL35P2	6.06	1.85e-09	2.98e-07	0.34	0.18	Arthritis (juvenile idiopathic);	chr10:63132292	chr10:63634317~63634827:-
BRCA	cis	rs10895987	1	rs12280510	ENSG00000254614.2	AP003068.23	6.06	1.85e-09	2.98e-07	0.29	0.18	Blood protein levels;	chr11:65147076	chr11:65177606~65181834:-
BRCA	cis	rs420259	0.516	rs4968008	ENSG00000260136.4	CTD-2270L9.4	6.06	1.85e-09	2.98e-07	0.18	0.18	Bipolar disorder;	chr16:23479032	chr16:23452758~23457606:+
BRCA	cis	rs7615952	0.599	rs2270986	ENSG00000171084.14	FAM86JP	6.06	1.85e-09	2.98e-07	0.29	0.18	Blood pressure (smoking interaction);	chr3:125982256	chr3:125916620~125930024:+
BRCA	cis	rs7615952	0.599	rs12496921	ENSG00000171084.14	FAM86JP	6.06	1.85e-09	2.98e-07	0.29	0.18	Blood pressure (smoking interaction);	chr3:125983105	chr3:125916620~125930024:+
BRCA	cis	rs2732480	0.5	rs1552550	ENSG00000257763.1	OR5BK1P	6.06	1.85e-09	2.99e-07	0.2	0.18	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48249568	chr12:48355792~48356614:-
BRCA	cis	rs2732480	0.5	rs2450991	ENSG00000257763.1	OR5BK1P	6.06	1.85e-09	2.99e-07	0.2	0.18	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48257838	chr12:48355792~48356614:-
BRCA	cis	rs875971	0.862	rs6460307	ENSG00000224316.1	RP11-479O9.2	6.06	1.85e-09	2.99e-07	0.19	0.18	Aortic root size;	chr7:66595884	chr7:65773620~65802067:+
BRCA	cis	rs897984	0.762	rs2305880	ENSG00000275263.1	RP11-1072A3.4	6.06	1.85e-09	2.99e-07	0.22	0.18	Dementia with Lewy bodies;	chr16:30988141	chr16:30956872~30957199:-
BRCA	cis	rs2832191	0.655	rs2247110	ENSG00000176054.6	RPL23P2	-6.06	1.86e-09	2.99e-07	-0.2	-0.18	Dental caries;	chr21:28951566	chr21:28997613~28998033:-
BRCA	cis	rs1124769	0.719	rs2663536	ENSG00000259378.1	DCAF13P3	-6.06	1.86e-09	2.99e-07	-0.27	-0.18	Cognitive performance;	chr15:50902784	chr15:50944663~50945996:+
BRCA	cis	rs227275	0.556	rs7676765	ENSG00000251288.2	RP11-10L12.2	6.06	1.86e-09	2.99e-07	0.22	0.18	Allergic disease (asthma, hay fever or eczema);	chr4:103016776	chr4:102751401~102752641:+
BRCA	cis	rs17301013	0.507	rs4652652	ENSG00000227373.4	RP11-160H22.5	6.06	1.86e-09	3e-07	0.29	0.18	Systemic lupus erythematosus;	chr1:174596582	chr1:174115300~174160004:-
BRCA	cis	rs17301013	0.507	rs4651103	ENSG00000227373.4	RP11-160H22.5	6.06	1.86e-09	3e-07	0.29	0.18	Systemic lupus erythematosus;	chr1:174596750	chr1:174115300~174160004:-
BRCA	cis	rs17301013	0.507	rs4615901	ENSG00000227373.4	RP11-160H22.5	6.06	1.86e-09	3e-07	0.29	0.18	Systemic lupus erythematosus;	chr1:174609432	chr1:174115300~174160004:-
BRCA	cis	rs8114671	0.836	rs62213676	ENSG00000269202.1	RP4-614O4.12	6.06	1.86e-09	3e-07	0.19	0.18	Height;	chr20:35024873	chr20:35201747~35203288:-
BRCA	cis	rs2153535	0.585	rs1041279	ENSG00000230939.1	RP11-314C16.1	-6.06	1.86e-09	3e-07	-0.22	-0.18	Motion sickness;	chr6:8650293	chr6:8784178~8785445:+
BRCA	cis	rs17253792	0.822	rs10151664	ENSG00000186615.9	KTN1-AS1	-6.06	1.86e-09	3e-07	-0.31	-0.18	Putamen volume;	chr14:55562815	chr14:55499278~55580110:-
BRCA	cis	rs7927771	0.524	rs10838777	ENSG00000280615.1	Y_RNA	6.06	1.86e-09	3e-07	0.22	0.18	Subjective well-being;	chr11:47839402	chr11:47614898~47614994:-
BRCA	cis	rs7927771	0.524	rs10458915	ENSG00000280615.1	Y_RNA	6.06	1.86e-09	3e-07	0.22	0.18	Subjective well-being;	chr11:47842840	chr11:47614898~47614994:-
BRCA	cis	rs7927771	0.524	rs10742824	ENSG00000280615.1	Y_RNA	6.06	1.86e-09	3e-07	0.22	0.18	Subjective well-being;	chr11:47843290	chr11:47614898~47614994:-
BRCA	cis	rs7927771	0.542	rs10769300	ENSG00000280615.1	Y_RNA	6.06	1.86e-09	3e-07	0.22	0.18	Subjective well-being;	chr11:47844008	chr11:47614898~47614994:-
BRCA	cis	rs7927771	0.524	rs11039431	ENSG00000280615.1	Y_RNA	6.06	1.86e-09	3e-07	0.22	0.18	Subjective well-being;	chr11:47850460	chr11:47614898~47614994:-
BRCA	cis	rs9467773	0.935	rs4573	ENSG00000124549.13	BTN2A3P	6.06	1.86e-09	3e-07	0.2	0.18	Intelligence (multi-trait analysis);	chr6:26546580	chr6:26421391~26432383:+
BRCA	cis	rs6442522	1	rs6442522	ENSG00000249786.6	EAF1-AS1	6.06	1.87e-09	3.01e-07	0.19	0.18	Uric acid levels;	chr3:15399049	chr3:15436171~15455940:-
BRCA	cis	rs910316	0.934	rs4903278	ENSG00000279594.1	RP11-950C14.10	6.06	1.87e-09	3.01e-07	0.2	0.18	Height;	chr14:75068316	chr14:75011269~75012851:-
BRCA	cis	rs7772486	0.686	rs4896828	ENSG00000270638.1	RP3-466P17.1	6.06	1.87e-09	3.01e-07	0.21	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145632203	chr6:145735570~145737218:+
BRCA	cis	rs7772486	0.686	rs6570701	ENSG00000270638.1	RP3-466P17.1	6.06	1.87e-09	3.01e-07	0.21	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145632954	chr6:145735570~145737218:+
BRCA	cis	rs2898681	0.528	rs73814883	ENSG00000248375.1	RP11-177B4.1	-6.06	1.87e-09	3.01e-07	-0.35	-0.18	Optic nerve measurement (cup area);	chr4:52861887	chr4:52720081~52720831:-
BRCA	cis	rs34779708	0.966	rs34630580	ENSG00000271335.4	RP11-324I22.4	6.06	1.87e-09	3.02e-07	0.2	0.18	Inflammatory bowel disease;Crohn's disease;	chr10:35160300	chr10:35314552~35336401:-
BRCA	cis	rs2836950	0.565	rs2836934	ENSG00000238141.2	BRWD1-AS1	-6.06	1.87e-09	3.02e-07	-0.21	-0.18	Menarche (age at onset);	chr21:39192959	chr21:39315707~39323218:+
BRCA	cis	rs2288884	0.767	rs3450	ENSG00000275055.1	CTC-471J1.11	-6.06	1.87e-09	3.02e-07	-0.26	-0.18	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52049746	chr19:52049007~52049754:+
BRCA	cis	rs910316	1	rs10149880	ENSG00000279594.1	RP11-950C14.10	-6.06	1.88e-09	3.03e-07	-0.21	-0.18	Height;	chr14:75166305	chr14:75011269~75012851:-
BRCA	cis	rs11722779	0.873	rs6533041	ENSG00000251288.2	RP11-10L12.2	-6.06	1.88e-09	3.03e-07	-0.21	-0.18	Schizophrenia;	chr4:102951615	chr4:102751401~102752641:+
BRCA	cis	rs17301013	0.507	rs2142863	ENSG00000227373.4	RP11-160H22.5	6.06	1.88e-09	3.03e-07	0.28	0.18	Systemic lupus erythematosus;	chr1:174301582	chr1:174115300~174160004:-
BRCA	cis	rs867371	1	rs8041868	ENSG00000276710.3	CSPG4P8	-6.06	1.88e-09	3.03e-07	-0.2	-0.18	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82179985	chr15:82459472~82477258:+
BRCA	cis	rs11722779	0.935	rs3857199	ENSG00000251288.2	RP11-10L12.2	-6.06	1.88e-09	3.03e-07	-0.21	-0.18	Schizophrenia;	chr4:102957991	chr4:102751401~102752641:+
BRCA	cis	rs897984	0.684	rs6950	ENSG00000275263.1	RP11-1072A3.4	6.06	1.88e-09	3.04e-07	0.22	0.18	Dementia with Lewy bodies;	chr16:30984348	chr16:30956872~30957199:-
BRCA	cis	rs55702914	0.628	rs6745660	ENSG00000231621.1	AC013264.2	-6.06	1.88e-09	3.04e-07	-0.17	-0.18	Major depression and alcohol dependence;	chr2:197484812	chr2:197197991~197199273:+
BRCA	cis	rs2243480	1	rs160652	ENSG00000232559.3	GS1-124K5.12	6.06	1.89e-09	3.04e-07	0.37	0.18	Diabetic kidney disease;	chr7:66073444	chr7:66554588~66576923:-
BRCA	cis	rs853679	0.517	rs868987	ENSG00000204709.4	LINC01556	-6.06	1.89e-09	3.04e-07	-0.28	-0.18	Depression;	chr6:28142370	chr6:28943877~28944537:+
BRCA	cis	rs7124681	0.565	rs2904127	ENSG00000280615.1	Y_RNA	6.06	1.89e-09	3.05e-07	0.22	0.18	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:47795738	chr11:47614898~47614994:-
BRCA	cis	rs7927771	0.524	rs11039402	ENSG00000280615.1	Y_RNA	6.06	1.89e-09	3.05e-07	0.22	0.18	Subjective well-being;	chr11:47804538	chr11:47614898~47614994:-
BRCA	cis	rs7927771	0.524	rs6485786	ENSG00000280615.1	Y_RNA	6.06	1.89e-09	3.05e-07	0.22	0.18	Subjective well-being;	chr11:47815856	chr11:47614898~47614994:-
BRCA	cis	rs7927771	0.524	rs11039415	ENSG00000280615.1	Y_RNA	6.06	1.89e-09	3.05e-07	0.22	0.18	Subjective well-being;	chr11:47824262	chr11:47614898~47614994:-
BRCA	cis	rs7927771	0.524	rs7110300	ENSG00000280615.1	Y_RNA	6.06	1.89e-09	3.05e-07	0.22	0.18	Subjective well-being;	chr11:47826890	chr11:47614898~47614994:-
BRCA	cis	rs7927771	0.524	rs9633830	ENSG00000280615.1	Y_RNA	6.06	1.89e-09	3.05e-07	0.22	0.18	Subjective well-being;	chr11:47827918	chr11:47614898~47614994:-
BRCA	cis	rs7927771	0.524	rs11039419	ENSG00000280615.1	Y_RNA	6.06	1.89e-09	3.05e-07	0.22	0.18	Subjective well-being;	chr11:47829802	chr11:47614898~47614994:-
BRCA	cis	rs250585	0.704	rs11861636	ENSG00000260136.4	CTD-2270L9.4	6.06	1.89e-09	3.05e-07	0.18	0.18	Egg allergy;	chr16:23428676	chr16:23452758~23457606:+
BRCA	cis	rs250585	0.736	rs250551	ENSG00000260136.4	CTD-2270L9.4	6.06	1.89e-09	3.05e-07	0.18	0.18	Egg allergy;	chr16:23429290	chr16:23452758~23457606:+
BRCA	cis	rs516805	0.706	rs572674	ENSG00000279114.1	RP3-425C14.5	-6.06	1.89e-09	3.05e-07	-0.22	-0.18	Lymphocyte counts;	chr6:122411239	chr6:122471923~122484161:+
BRCA	cis	rs1858037	0.836	rs17475335	ENSG00000204929.10	AC074391.1	6.06	1.9e-09	3.05e-07	0.25	0.18	Rheumatoid arthritis;	chr2:65378646	chr2:65436711~66084639:+
BRCA	cis	rs11722779	0.692	rs223414	ENSG00000251288.2	RP11-10L12.2	-6.06	1.9e-09	3.06e-07	-0.21	-0.18	Schizophrenia;	chr4:102811688	chr4:102751401~102752641:+
BRCA	cis	rs2243480	1	rs387676	ENSG00000228409.4	CCT6P1	6.06	1.9e-09	3.06e-07	0.26	0.18	Diabetic kidney disease;	chr7:66133233	chr7:65751142~65763354:+
BRCA	cis	rs4664293	0.801	rs7589771	ENSG00000226266.5	AC009961.3	-6.06	1.9e-09	3.06e-07	-0.23	-0.18	Monocyte percentage of white cells;	chr2:159727621	chr2:159670708~159712435:-
BRCA	cis	rs2243480	1	rs4718315	ENSG00000232559.3	GS1-124K5.12	-6.06	1.9e-09	3.06e-07	-0.35	-0.18	Diabetic kidney disease;	chr7:66183554	chr7:66554588~66576923:-
BRCA	cis	rs2243480	1	rs4718316	ENSG00000232559.3	GS1-124K5.12	-6.06	1.9e-09	3.06e-07	-0.35	-0.18	Diabetic kidney disease;	chr7:66183744	chr7:66554588~66576923:-
BRCA	cis	rs2638953	0.888	rs11610011	ENSG00000247934.4	RP11-967K21.1	-6.06	1.9e-09	3.06e-07	-0.24	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28202801	chr12:28163298~28190738:-
BRCA	cis	rs10129255	0.957	rs10136781	ENSG00000211972.2	IGHV3-66	6.06	1.9e-09	3.07e-07	0.13	0.18	Kawasaki disease;	chr14:106780451	chr14:106675017~106675544:-
BRCA	cis	rs2243480	1	rs35396113	ENSG00000232546.1	RP11-458F8.1	-6.06	1.9e-09	3.07e-07	-0.24	-0.18	Diabetic kidney disease;	chr7:66030474	chr7:66848496~66858136:+
BRCA	cis	rs5015933	0.815	rs10986718	ENSG00000232630.1	PRPS1P2	-6.06	1.91e-09	3.07e-07	-0.17	-0.18	Body mass index;	chr9:125350617	chr9:125150653~125151589:+
BRCA	cis	rs9291683	0.546	rs10939672	ENSG00000250413.1	RP11-448G15.1	-6.06	1.91e-09	3.07e-07	-0.24	-0.18	Bone mineral density;	chr4:10050512	chr4:10006482~10009725:+
BRCA	cis	rs2836950	0.565	rs2836945	ENSG00000238141.2	BRWD1-AS1	-6.06	1.91e-09	3.07e-07	-0.21	-0.18	Menarche (age at onset);	chr21:39224831	chr21:39315707~39323218:+
BRCA	cis	rs2492286	0.518	rs2712418	ENSG00000242551.2	POU5F1P6	-6.06	1.91e-09	3.07e-07	-0.25	-0.18	Eosinophil counts;	chr3:128624793	chr3:128674735~128677005:-
BRCA	cis	rs2243480	1	rs1723267	ENSG00000232546.1	RP11-458F8.1	-6.06	1.91e-09	3.08e-07	-0.24	-0.18	Diabetic kidney disease;	chr7:66008327	chr7:66848496~66858136:+
BRCA	cis	rs17301013	0.507	rs72715259	ENSG00000227373.4	RP11-160H22.5	6.06	1.91e-09	3.08e-07	0.29	0.18	Systemic lupus erythematosus;	chr1:174604590	chr1:174115300~174160004:-
BRCA	cis	rs2348418	0.715	rs1355471	ENSG00000247934.4	RP11-967K21.1	-6.06	1.91e-09	3.08e-07	-0.2	-0.18	Lung function (FEV1);Lung function (FVC);	chr12:28568792	chr12:28163298~28190738:-
BRCA	cis	rs17301013	0.507	rs60811893	ENSG00000227373.4	RP11-160H22.5	6.06	1.91e-09	3.08e-07	0.28	0.18	Systemic lupus erythematosus;	chr1:174765968	chr1:174115300~174160004:-
BRCA	cis	rs227275	0.525	rs7688940	ENSG00000251288.2	RP11-10L12.2	-6.06	1.91e-09	3.08e-07	-0.22	-0.18	Allergic disease (asthma, hay fever or eczema);	chr4:102994153	chr4:102751401~102752641:+
BRCA	cis	rs227275	0.525	rs7672319	ENSG00000251288.2	RP11-10L12.2	-6.06	1.92e-09	3.08e-07	-0.22	-0.18	Allergic disease (asthma, hay fever or eczema);	chr4:102990002	chr4:102751401~102752641:+
BRCA	cis	rs227275	0.525	rs6533051	ENSG00000251288.2	RP11-10L12.2	-6.06	1.92e-09	3.08e-07	-0.22	-0.18	Allergic disease (asthma, hay fever or eczema);	chr4:102990065	chr4:102751401~102752641:+
BRCA	cis	rs11009175	1	rs11009172	ENSG00000273038.2	RP11-479G22.8	-6.06	1.92e-09	3.08e-07	-0.34	-0.18	Depression (quantitative trait);	chr10:33003367	chr10:32887255~32889311:-
BRCA	cis	rs5015933	0.736	rs10125995	ENSG00000232630.1	PRPS1P2	-6.06	1.92e-09	3.08e-07	-0.18	-0.18	Body mass index;	chr9:125383663	chr9:125150653~125151589:+
BRCA	cis	rs8114671	0.562	rs2273683	ENSG00000269202.1	RP4-614O4.12	-6.06	1.92e-09	3.08e-07	-0.2	-0.18	Height;	chr20:34921720	chr20:35201747~35203288:-
BRCA	cis	rs919433	0.648	rs3097384	ENSG00000231621.1	AC013264.2	-6.06	1.92e-09	3.09e-07	-0.18	-0.18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197414110	chr2:197197991~197199273:+
BRCA	cis	rs42648	1	rs42658	ENSG00000225498.1	AC002064.5	6.06	1.92e-09	3.09e-07	0.18	0.18	Homocysteine levels;	chr7:90352601	chr7:90312496~90322592:+
BRCA	cis	rs72681920	0.748	rs72679874	ENSG00000246090.5	RP11-696N14.1	-6.06	1.92e-09	3.09e-07	-0.3	-0.18	Alcohol dependence;	chr4:99260777	chr4:99088857~99301356:+
BRCA	cis	rs11671005	0.735	rs3764532	ENSG00000252334.1	RNU6-1337P	6.06	1.92e-09	3.09e-07	0.27	0.18	Mean platelet volume;	chr19:58417855	chr19:58483749~58483843:-
BRCA	cis	rs2692947	0.759	rs1917890	ENSG00000237510.6	AC008268.2	6.06	1.92e-09	3.09e-07	0.25	0.18	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96006253	chr2:95789654~95800166:+
BRCA	cis	rs7772486	0.686	rs4896833	ENSG00000270638.1	RP3-466P17.1	6.06	1.93e-09	3.1e-07	0.21	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145644537	chr6:145735570~145737218:+
BRCA	cis	rs227275	0.525	rs2086499	ENSG00000251288.2	RP11-10L12.2	-6.06	1.93e-09	3.1e-07	-0.22	-0.18	Allergic disease (asthma, hay fever or eczema);	chr4:103008672	chr4:102751401~102752641:+
BRCA	cis	rs1193	0.955	rs7561172	ENSG00000231259.4	AC125232.1	-6.06	1.93e-09	3.1e-07	-0.23	-0.18	High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;High light scatter reticulocyte count;	chr2:86772752	chr2:87031815~87053069:-
BRCA	cis	rs7238033	0.663	rs11082468	ENSG00000267193.4	RP11-116O18.3	6.06	1.93e-09	3.1e-07	0.2	0.18	Bladder cancer;	chr18:45741063	chr18:45669367~45747215:-
BRCA	cis	rs6597981	0.675	rs4963120	ENSG00000255142.1	AP006621.6	-6.06	1.93e-09	3.1e-07	-0.16	-0.18	Breast cancer;	chr11:825777	chr11:781645~782105:+
BRCA	cis	rs516805	0.748	rs563084	ENSG00000279453.1	RP3-425C14.4	6.06	1.93e-09	3.1e-07	0.25	0.18	Lymphocyte counts;	chr6:122397105	chr6:122436789~122439223:-
BRCA	cis	rs910316	0.874	rs61980828	ENSG00000279594.1	RP11-950C14.10	-6.06	1.93e-09	3.11e-07	-0.21	-0.18	Height;	chr14:75163675	chr14:75011269~75012851:-
BRCA	cis	rs7191700	0.712	rs7187741	ENSG00000262636.1	CTD-3088G3.4	-6.06	1.93e-09	3.11e-07	-0.23	-0.18	Multiple sclerosis;	chr16:11339246	chr16:11380859~11381118:-
BRCA	cis	rs7520050	0.897	rs4440807	ENSG00000280836.1	AL355480.1	6.06	1.93e-09	3.11e-07	0.21	0.18	Reticulocyte count;Red blood cell count;	chr1:46005206	chr1:45581219~45581321:-
BRCA	cis	rs910316	1	rs175442	ENSG00000279594.1	RP11-950C14.10	-6.06	1.94e-09	3.11e-07	-0.2	-0.18	Height;	chr14:75136861	chr14:75011269~75012851:-
BRCA	cis	rs6840360	0.904	rs6825241	ENSG00000270265.1	RP11-731D1.4	-6.06	1.94e-09	3.11e-07	-0.21	-0.18	Intelligence (multi-trait analysis);	chr4:151622631	chr4:151333775~151353224:-
BRCA	cis	rs13126694	0.743	rs12512643	ENSG00000251429.1	RP11-597D13.7	6.06	1.94e-09	3.11e-07	0.18	0.18	Blood osmolality (transformed sodium);	chr4:158115588	chr4:158270378~158278676:+
BRCA	cis	rs11971779	0.793	rs9632774	ENSG00000273391.1	RP11-634H22.1	6.06	1.94e-09	3.12e-07	0.2	0.18	Diisocyanate-induced asthma;	chr7:139452816	chr7:139359032~139359566:-
BRCA	cis	rs755249	0.545	rs12037073	ENSG00000228060.1	RP11-69E11.8	6.06	1.94e-09	3.12e-07	0.19	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39581225	chr1:39565160~39573203:+
BRCA	cis	rs1198430	0.929	rs1210852	ENSG00000232482.2	RP4-654C18.1	-6.06	1.94e-09	3.12e-07	-0.28	-0.18	Total cholesterol levels;	chr1:23427040	chr1:23410832~23412146:+
BRCA	cis	rs2834288	0.535	rs8132681	ENSG00000273102.1	AP000569.9	6.06	1.94e-09	3.12e-07	0.21	0.18	Gut microbiota (bacterial taxa);	chr21:33950035	chr21:33967101~33968573:-
BRCA	cis	rs904251	0.861	rs1757169	ENSG00000204110.6	RP1-153P14.8	-6.06	1.94e-09	3.12e-07	-0.2	-0.18	Cognitive performance;	chr6:37519300	chr6:37507348~37535616:+
BRCA	cis	rs250585	1	rs6497672	ENSG00000260136.4	CTD-2270L9.4	-6.06	1.94e-09	3.12e-07	-0.22	-0.18	Egg allergy;	chr16:23532974	chr16:23452758~23457606:+
BRCA	cis	rs17597773	0.638	rs12145674	ENSG00000272823.1	RP11-295M18.6	6.06	1.94e-09	3.13e-07	0.22	0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220826931	chr1:220828676~220829211:-
BRCA	cis	rs754466	0.606	rs3740250	ENSG00000204049.1	RP11-126H7.4	6.06	1.95e-09	3.13e-07	0.22	0.18	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77820343	chr10:77866875~77869610:+
BRCA	cis	rs13126694	0.682	rs4504305	ENSG00000248429.4	RP11-597D13.9	6.06	1.95e-09	3.13e-07	0.17	0.18	Blood osmolality (transformed sodium);	chr4:157982801	chr4:158170752~158202877:+
BRCA	cis	rs1440410	0.835	rs4234886	ENSG00000250326.1	RP11-284M14.1	-6.06	1.95e-09	3.13e-07	-0.2	-0.18	Ischemic stroke;	chr4:143203339	chr4:142933195~143184861:-
BRCA	cis	rs13113518	0.729	rs13120134	ENSG00000223305.1	RN7SKP30	6.06	1.95e-09	3.13e-07	0.25	0.18	Height;	chr4:55415153	chr4:55540502~55540835:-
BRCA	cis	rs1160985	0.967	rs741780	ENSG00000214855.8	APOC1P1	-6.06	1.95e-09	3.14e-07	-0.22	-0.18	C-reactive protein;LDL cholesterol;Lipid traits;Gut microbiota (functional units);LDL cholesterol levels;	chr19:44901174	chr19:44926804~44931386:+
BRCA	cis	rs375066	0.599	rs62118368	ENSG00000267058.1	RP11-15A1.3	6.06	1.95e-09	3.14e-07	0.22	0.18	Breast cancer;	chr19:43838290	chr19:43891804~43901805:-
BRCA	cis	rs375066	0.623	rs62118369	ENSG00000267058.1	RP11-15A1.3	6.06	1.95e-09	3.14e-07	0.22	0.18	Breast cancer;	chr19:43838352	chr19:43891804~43901805:-
BRCA	cis	rs375066	0.623	rs7253002	ENSG00000267058.1	RP11-15A1.3	6.06	1.95e-09	3.14e-07	0.22	0.18	Breast cancer;	chr19:43838825	chr19:43891804~43901805:-
BRCA	cis	rs8005677	1	rs4982712	ENSG00000257285.4	RP11-298I3.1	6.06	1.95e-09	3.14e-07	0.21	0.18	Cognitive ability (multi-trait analysis);	chr14:22934519	chr14:22929609~22955562:+
BRCA	cis	rs651907	0.535	rs34263427	ENSG00000244119.1	PDCL3P4	6.06	1.95e-09	3.14e-07	0.15	0.18	Colorectal cancer;	chr3:101788961	chr3:101712472~101713191:+
BRCA	cis	rs202072	0.872	rs377704	ENSG00000272379.1	RP1-257A7.5	6.06	1.95e-09	3.14e-07	0.26	0.18	HIV-1 viral setpoint;	chr6:13279787	chr6:13290018~13290490:-
BRCA	cis	rs2638953	0.853	rs11049679	ENSG00000278733.1	RP11-425D17.1	-6.06	1.96e-09	3.15e-07	-0.25	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28508161	chr12:28185625~28186190:-
BRCA	cis	rs2644899	0.75	rs2604869	ENSG00000268529.1	CYP2T3P	-6.05	1.96e-09	3.15e-07	-0.25	-0.18	Post bronchodilator FEV1/FVC ratio;	chr19:40777788	chr19:41134722~41137308:+
BRCA	cis	rs7246967	0.673	rs35731237	ENSG00000198153.8	ZNF849P	-6.05	1.96e-09	3.15e-07	-0.27	-0.18	Bronchopulmonary dysplasia;	chr19:22637708	chr19:22685167~22686732:+
BRCA	cis	rs7246967	0.673	rs12979173	ENSG00000198153.8	ZNF849P	-6.05	1.96e-09	3.15e-07	-0.27	-0.18	Bronchopulmonary dysplasia;	chr19:22637879	chr19:22685167~22686732:+
BRCA	cis	rs7246967	0.673	rs12979848	ENSG00000198153.8	ZNF849P	-6.05	1.96e-09	3.15e-07	-0.27	-0.18	Bronchopulmonary dysplasia;	chr19:22637996	chr19:22685167~22686732:+
BRCA	cis	rs7246967	0.551	rs6511367	ENSG00000198153.8	ZNF849P	-6.05	1.96e-09	3.15e-07	-0.27	-0.18	Bronchopulmonary dysplasia;	chr19:22638468	chr19:22685167~22686732:+
BRCA	cis	rs858239	0.698	rs858295	ENSG00000230042.1	AK3P3	-6.05	1.96e-09	3.15e-07	-0.21	-0.18	Cerebrospinal fluid biomarker levels;	chr7:23205950	chr7:23129178~23129841:+
BRCA	cis	rs7914558	0.966	rs4917997	ENSG00000213061.2	PFN1P11	6.05	1.96e-09	3.15e-07	0.24	0.18	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103185456	chr10:102838011~102845473:-
BRCA	cis	rs1707322	1	rs7519181	ENSG00000281133.1	AL355480.3	-6.05	1.96e-09	3.15e-07	-0.23	-0.18	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45922157	chr1:45580892~45580996:-
BRCA	cis	rs375066	0.623	rs7253384	ENSG00000267058.1	RP11-15A1.3	6.05	1.96e-09	3.15e-07	0.22	0.18	Breast cancer;	chr19:43839091	chr19:43891804~43901805:-
BRCA	cis	rs375066	0.623	rs7253606	ENSG00000267058.1	RP11-15A1.3	6.05	1.96e-09	3.15e-07	0.22	0.18	Breast cancer;	chr19:43839126	chr19:43891804~43901805:-
BRCA	cis	rs7182621	0.546	rs12906587	ENSG00000182397.13	DNM1P46	-6.05	1.96e-09	3.15e-07	-0.22	-0.18	Colonoscopy-negative controls vs population controls;	chr15:99837114	chr15:99790156~99806927:-
BRCA	cis	rs420259	0.516	rs2040573	ENSG00000260136.4	CTD-2270L9.4	-6.05	1.96e-09	3.15e-07	-0.18	-0.18	Bipolar disorder;	chr16:23518411	chr16:23452758~23457606:+
BRCA	cis	rs420259	0.516	rs11074565	ENSG00000260136.4	CTD-2270L9.4	-6.05	1.96e-09	3.15e-07	-0.18	-0.18	Bipolar disorder;	chr16:23521687	chr16:23452758~23457606:+
BRCA	cis	rs4713118	0.662	rs9380046	ENSG00000219392.1	RP1-265C24.5	-6.05	1.96e-09	3.15e-07	-0.27	-0.18	Parkinson's disease;	chr6:28062721	chr6:28115628~28116551:+
BRCA	cis	rs34779708	0.966	rs12769484	ENSG00000271335.4	RP11-324I22.4	6.05	1.96e-09	3.16e-07	0.2	0.18	Inflammatory bowel disease;Crohn's disease;	chr10:35176818	chr10:35314552~35336401:-
BRCA	cis	rs1552244	1	rs7628448	ENSG00000180385.7	EMC3-AS1	6.05	1.97e-09	3.16e-07	0.24	0.18	Alzheimer's disease;	chr3:10105144	chr3:9986893~10006990:+
BRCA	cis	rs7246657	0.598	rs28660259	ENSG00000226686.6	LINC01535	-6.05	1.97e-09	3.16e-07	-0.32	-0.18	Coronary artery calcification;	chr19:37167779	chr19:37251912~37265535:+
BRCA	cis	rs6442522	1	rs11918807	ENSG00000249786.6	EAF1-AS1	6.05	1.97e-09	3.16e-07	0.19	0.18	Uric acid levels;	chr3:15404770	chr3:15436171~15455940:-
BRCA	cis	rs1440410	0.835	rs13133090	ENSG00000250326.1	RP11-284M14.1	-6.05	1.97e-09	3.16e-07	-0.2	-0.18	Ischemic stroke;	chr4:143155916	chr4:142933195~143184861:-
BRCA	cis	rs10510102	0.516	rs11200300	ENSG00000276742.1	RP11-500G22.4	6.05	1.97e-09	3.16e-07	0.34	0.18	Breast cancer;	chr10:121977489	chr10:121956782~121957098:+
BRCA	cis	rs4072705	0.967	rs10739650	ENSG00000224020.1	MIR181A2HG	-6.05	1.97e-09	3.16e-07	-0.2	-0.18	Menarche (age at onset);	chr9:124561497	chr9:124658467~124698631:+
BRCA	cis	rs73193808	0.901	rs2832271	ENSG00000215533.7	LINC00189	-6.05	1.97e-09	3.16e-07	-0.27	-0.18	Coronary artery disease;	chr21:29223865	chr21:29193480~29288205:+
BRCA	cis	rs73193808	0.901	rs1997568	ENSG00000215533.7	LINC00189	-6.05	1.97e-09	3.17e-07	-0.27	-0.18	Coronary artery disease;	chr21:29213260	chr21:29193480~29288205:+
BRCA	cis	rs7493	0.901	rs13226149	ENSG00000233942.1	AC004012.1	6.05	1.97e-09	3.17e-07	0.24	0.18	Yu-Zhi constitution type in type 2 diabetes;	chr7:95396288	chr7:95471835~95473998:+
BRCA	cis	rs2638953	0.962	rs10843143	ENSG00000278733.1	RP11-425D17.1	-6.05	1.97e-09	3.17e-07	-0.25	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28253484	chr12:28185625~28186190:-
BRCA	cis	rs30380	0.506	rs469735	ENSG00000272109.1	CTD-2260A17.3	-6.05	1.97e-09	3.17e-07	-0.26	-0.18	Cerebrospinal fluid biomarker levels;	chr5:96794311	chr5:96804353~96806105:+
BRCA	cis	rs7809950	0.678	rs62483640	ENSG00000238832.1	snoU109	-6.05	1.98e-09	3.17e-07	-0.28	-0.18	Coronary artery disease;	chr7:107259769	chr7:107603363~107603507:+
BRCA	cis	rs875971	0.508	rs10242423	ENSG00000273024.4	INTS4P2	6.05	1.98e-09	3.18e-07	0.2	0.18	Aortic root size;	chr7:66594188	chr7:65647864~65715661:+
BRCA	cis	rs875971	0.508	rs10253883	ENSG00000273024.4	INTS4P2	6.05	1.98e-09	3.18e-07	0.2	0.18	Aortic root size;	chr7:66596151	chr7:65647864~65715661:+
BRCA	cis	rs1559040	1	rs72800725	ENSG00000272156.1	RP11-477N3.1	-6.05	1.98e-09	3.18e-07	-0.28	-0.18	Sudden cardiac arrest;	chr2:54074000	chr2:54082554~54085066:+
BRCA	cis	rs17301013	0.507	rs72715281	ENSG00000227373.4	RP11-160H22.5	6.05	1.98e-09	3.18e-07	0.28	0.18	Systemic lupus erythematosus;	chr1:174711533	chr1:174115300~174160004:-
BRCA	cis	rs11758351	1	rs17598927	ENSG00000241549.7	GUSBP2	6.05	1.98e-09	3.18e-07	0.28	0.18	Renal underexcretion gout;Gout;	chr6:26184412	chr6:26871484~26956554:-
BRCA	cis	rs8114671	0.742	rs6058161	ENSG00000269202.1	RP4-614O4.12	6.05	1.98e-09	3.18e-07	0.19	0.18	Height;	chr20:35032223	chr20:35201747~35203288:-
BRCA	cis	rs4718428	1	rs1830070	ENSG00000232546.1	RP11-458F8.1	-6.05	1.98e-09	3.18e-07	-0.16	-0.18	Corneal structure;	chr7:66884684	chr7:66848496~66858136:+
BRCA	cis	rs2243480	1	rs316313	ENSG00000228409.4	CCT6P1	6.05	1.98e-09	3.19e-07	0.26	0.18	Diabetic kidney disease;	chr7:66128561	chr7:65751142~65763354:+
BRCA	cis	rs2243480	1	rs316312	ENSG00000228409.4	CCT6P1	6.05	1.98e-09	3.19e-07	0.26	0.18	Diabetic kidney disease;	chr7:66131504	chr7:65751142~65763354:+
BRCA	cis	rs2243480	1	rs419603	ENSG00000228409.4	CCT6P1	6.05	1.98e-09	3.19e-07	0.26	0.18	Diabetic kidney disease;	chr7:66132354	chr7:65751142~65763354:+
BRCA	cis	rs2749097	0.825	rs11208260	ENSG00000244256.3	RN7SL130P	-6.05	1.98e-09	3.19e-07	-0.24	-0.18	Alcohol consumption (transferrin glycosylation);	chr1:63657608	chr1:63655743~63656047:+
BRCA	cis	rs10761482	0.5	rs1890926	ENSG00000254271.1	RP11-131N11.4	6.05	1.99e-09	3.19e-07	0.24	0.18	Schizophrenia;	chr10:60530347	chr10:60734342~60741828:+
BRCA	cis	rs420259	0.516	rs2106458	ENSG00000260136.4	CTD-2270L9.4	-6.05	1.99e-09	3.19e-07	-0.18	-0.18	Bipolar disorder;	chr16:23520110	chr16:23452758~23457606:+
BRCA	cis	rs853679	0.517	rs9295761	ENSG00000204709.4	LINC01556	6.05	1.99e-09	3.19e-07	0.28	0.18	Depression;	chr6:28180209	chr6:28943877~28944537:+
BRCA	cis	rs919433	0.68	rs788018	ENSG00000231621.1	AC013264.2	-6.05	1.99e-09	3.19e-07	-0.18	-0.18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197400802	chr2:197197991~197199273:+
BRCA	cis	rs9311474	0.607	rs34005367	ENSG00000243224.1	RP5-1157M23.2	-6.05	1.99e-09	3.19e-07	-0.2	-0.18	Electroencephalogram traits;	chr3:52524888	chr3:52239258~52241097:+
BRCA	cis	rs250585	0.764	rs4967958	ENSG00000260136.4	CTD-2270L9.4	-6.05	1.99e-09	3.2e-07	-0.2	-0.18	Egg allergy;	chr16:23516802	chr16:23452758~23457606:+
BRCA	cis	rs2732480	0.577	rs2634681	ENSG00000240399.1	RP1-228P16.1	-6.05	1.99e-09	3.2e-07	-0.2	-0.18	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48339301	chr12:48054813~48055591:-
BRCA	cis	rs3764021	1	rs7977720	ENSG00000256673.1	RP11-599J14.2	-6.05	1.99e-09	3.2e-07	-0.2	-0.18	Type 1 diabetes;	chr12:9713753	chr12:9398355~9414851:-
BRCA	cis	rs2243480	0.901	rs12530490	ENSG00000232559.3	GS1-124K5.12	-6.05	1.99e-09	3.2e-07	-0.35	-0.18	Diabetic kidney disease;	chr7:66226660	chr7:66554588~66576923:-
BRCA	cis	rs2243480	1	rs7778911	ENSG00000232559.3	GS1-124K5.12	-6.05	1.99e-09	3.2e-07	-0.35	-0.18	Diabetic kidney disease;	chr7:66229519	chr7:66554588~66576923:-
BRCA	cis	rs4664293	0.801	rs7590595	ENSG00000226266.5	AC009961.3	-6.05	1.99e-09	3.2e-07	-0.23	-0.18	Monocyte percentage of white cells;	chr2:159715198	chr2:159670708~159712435:-
BRCA	cis	rs1387259	0.723	rs2732488	ENSG00000226413.2	OR8T1P	6.05	1.99e-09	3.2e-07	0.25	0.18	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48377661	chr12:48442030~48442947:-
BRCA	cis	rs1387259	0.758	rs2634670	ENSG00000226413.2	OR8T1P	6.05	1.99e-09	3.2e-07	0.25	0.18	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48378094	chr12:48442030~48442947:-
BRCA	cis	rs9287719	0.578	rs13425171	ENSG00000243819.4	RN7SL832P	6.05	1.99e-09	3.2e-07	0.19	0.18	Prostate cancer;	chr2:10591840	chr2:10690344~10692099:+
BRCA	cis	rs9992667	0.955	rs6819274	ENSG00000231160.8	KLF3-AS1	6.05	2e-09	3.2e-07	0.22	0.18	Eosinophil percentage of granulocytes;	chr4:38614306	chr4:38612701~38664883:-
BRCA	cis	rs11098499	0.955	rs11944880	ENSG00000249244.1	RP11-548H18.2	-6.05	2e-09	3.21e-07	-0.22	-0.18	Corneal astigmatism;	chr4:119238179	chr4:119391831~119395335:-
BRCA	cis	rs8031584	0.505	rs2959036	ENSG00000260382.1	RP11-540B6.2	-6.05	2e-09	3.21e-07	-0.21	-0.18	Huntington's disease progression;	chr15:30927539	chr15:30882267~30883231:-
BRCA	cis	rs7688540	0.8	rs12510827	ENSG00000275426.1	CH17-262A2.1	6.05	2e-09	3.21e-07	0.24	0.18	Facial morphology (factor 6, height of vermillion lower lip);	chr4:259015	chr4:149738~150317:+
BRCA	cis	rs35612822	0.93	rs13034451	ENSG00000232485.2	AC098820.3	-6.05	2e-09	3.21e-07	-0.24	-0.18	Kidney disease (early stage) in type 1 diabetes;	chr2:216513058	chr2:216479030~216498761:-
BRCA	cis	rs2836950	0.545	rs1888489	ENSG00000238141.2	BRWD1-AS1	-6.05	2e-09	3.21e-07	-0.21	-0.18	Menarche (age at onset);	chr21:39161238	chr21:39315707~39323218:+
BRCA	cis	rs467650	0.553	rs149508	ENSG00000248489.1	CTD-2007H13.3	6.05	2e-09	3.21e-07	0.24	0.18	Venous thromboembolism (SNP x SNP interaction);	chr5:98642741	chr5:98929171~98995013:+
BRCA	cis	rs875971	0.862	rs6971059	ENSG00000224316.1	RP11-479O9.2	-6.05	2e-09	3.22e-07	-0.19	-0.18	Aortic root size;	chr7:66602045	chr7:65773620~65802067:+
BRCA	cis	rs17301013	0.507	rs11805578	ENSG00000227373.4	RP11-160H22.5	6.05	2e-09	3.22e-07	0.29	0.18	Systemic lupus erythematosus;	chr1:174573174	chr1:174115300~174160004:-
BRCA	cis	rs1555322	0.872	rs2425046	ENSG00000261582.1	RP4-614O4.11	-6.05	2e-09	3.22e-07	-0.26	-0.18	Attention deficit hyperactivity disorder;	chr20:35283858	chr20:35267885~35280043:-
BRCA	cis	rs13287066	0.692	rs7020852	ENSG00000227603.1	RP11-165J3.6	6.05	2.01e-09	3.22e-07	0.2	0.18	Intelligence (multi-trait analysis);	chr9:93400978	chr9:93435332~93437121:-
BRCA	cis	rs867371	1	rs8037224	ENSG00000276710.3	CSPG4P8	-6.05	2.01e-09	3.22e-07	-0.2	-0.18	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82172189	chr15:82459472~82477258:+
BRCA	cis	rs875971	0.798	rs12698522	ENSG00000224316.1	RP11-479O9.2	6.05	2.01e-09	3.22e-07	0.19	0.18	Aortic root size;	chr7:66502354	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.83	rs28714531	ENSG00000224316.1	RP11-479O9.2	6.05	2.01e-09	3.22e-07	0.19	0.18	Aortic root size;	chr7:66503250	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.862	rs12698526	ENSG00000224316.1	RP11-479O9.2	6.05	2.01e-09	3.22e-07	0.19	0.18	Aortic root size;	chr7:66504118	chr7:65773620~65802067:+
BRCA	cis	rs9311474	0.607	rs4475032	ENSG00000243224.1	RP5-1157M23.2	-6.05	2.01e-09	3.22e-07	-0.2	-0.18	Electroencephalogram traits;	chr3:52526005	chr3:52239258~52241097:+
BRCA	cis	rs7927771	0.524	rs10838774	ENSG00000280615.1	Y_RNA	6.05	2.01e-09	3.22e-07	0.22	0.18	Subjective well-being;	chr11:47834562	chr11:47614898~47614994:-
BRCA	cis	rs853679	0.517	rs9393885	ENSG00000204709.4	LINC01556	6.05	2.01e-09	3.22e-07	0.27	0.18	Depression;	chr6:28082231	chr6:28943877~28944537:+
BRCA	cis	rs853679	0.517	rs9393886	ENSG00000204709.4	LINC01556	6.05	2.01e-09	3.22e-07	0.27	0.18	Depression;	chr6:28082261	chr6:28943877~28944537:+
BRCA	cis	rs4713118	0.515	rs9368549	ENSG00000204709.4	LINC01556	6.05	2.01e-09	3.22e-07	0.27	0.18	Parkinson's disease;	chr6:28082269	chr6:28943877~28944537:+
BRCA	cis	rs10129255	0.5	rs4774008	ENSG00000274576.2	IGHV2-70	-6.05	2.01e-09	3.23e-07	-0.15	-0.18	Kawasaki disease;	chr14:106681273	chr14:106770577~106771020:-
BRCA	cis	rs6142102	0.923	rs6059586	ENSG00000275784.1	RP5-1125A11.6	-6.05	2.01e-09	3.23e-07	-0.21	-0.18	Skin pigmentation;	chr20:33952695	chr20:33989480~33991818:-
BRCA	cis	rs250585	0.736	rs250579	ENSG00000260136.4	CTD-2270L9.4	6.05	2.01e-09	3.23e-07	0.18	0.18	Egg allergy;	chr16:23414264	chr16:23452758~23457606:+
BRCA	cis	rs651907	0.557	rs11925001	ENSG00000244119.1	PDCL3P4	6.05	2.01e-09	3.23e-07	0.15	0.18	Colorectal cancer;	chr3:101655122	chr3:101712472~101713191:+
BRCA	cis	rs651907	0.514	rs55654108	ENSG00000244119.1	PDCL3P4	6.05	2.01e-09	3.23e-07	0.15	0.18	Colorectal cancer;	chr3:101706859	chr3:101712472~101713191:+
BRCA	cis	rs7569084	0.687	rs4671663	ENSG00000237979.1	AC007389.1	6.05	2.01e-09	3.23e-07	0.24	0.18	Sum eosinophil basophil counts;	chr2:65434400	chr2:65500993~65502138:-
BRCA	cis	rs75422866	0.867	rs117022227	ENSG00000280054.1	RP1-197B17.7	6.05	2.01e-09	3.23e-07	0.47	0.18	Pneumonia;	chr12:47633282	chr12:47728151~47730598:-
BRCA	cis	rs2243480	1	rs6974723	ENSG00000232559.3	GS1-124K5.12	-6.05	2.01e-09	3.23e-07	-0.35	-0.18	Diabetic kidney disease;	chr7:66172952	chr7:66554588~66576923:-
BRCA	cis	rs2243480	1	rs9769882	ENSG00000232559.3	GS1-124K5.12	-6.05	2.01e-09	3.23e-07	-0.35	-0.18	Diabetic kidney disease;	chr7:66177938	chr7:66554588~66576923:-
BRCA	cis	rs2243480	1	rs6966322	ENSG00000232559.3	GS1-124K5.12	-6.05	2.01e-09	3.23e-07	-0.35	-0.18	Diabetic kidney disease;	chr7:66181767	chr7:66554588~66576923:-
BRCA	cis	rs2243480	1	rs4145008	ENSG00000232559.3	GS1-124K5.12	-6.05	2.01e-09	3.23e-07	-0.35	-0.18	Diabetic kidney disease;	chr7:66182524	chr7:66554588~66576923:-
BRCA	cis	rs227275	0.531	rs223460	ENSG00000251288.2	RP11-10L12.2	-6.05	2.01e-09	3.23e-07	-0.22	-0.18	Allergic disease (asthma, hay fever or eczema);	chr4:102782903	chr4:102751401~102752641:+
BRCA	cis	rs12534093	0.602	rs11765452	ENSG00000234286.1	AC006026.13	-6.05	2.02e-09	3.24e-07	-0.22	-0.18	Infant length;Height;	chr7:23542936	chr7:23680195~23680786:-
BRCA	cis	rs2404602	0.563	rs12914005	ENSG00000259422.1	RP11-593F23.1	6.05	2.02e-09	3.24e-07	0.23	0.18	Blood metabolite levels;	chr15:76473326	chr15:76174891~76181486:-
BRCA	cis	rs2404602	0.536	rs7163946	ENSG00000259422.1	RP11-593F23.1	6.05	2.02e-09	3.24e-07	0.23	0.18	Blood metabolite levels;	chr15:76473708	chr15:76174891~76181486:-
BRCA	cis	rs3733585	0.781	rs13103879	ENSG00000250413.1	RP11-448G15.1	6.05	2.02e-09	3.24e-07	0.24	0.18	Cleft plate (environmental tobacco smoke interaction);	chr4:9971255	chr4:10006482~10009725:+
BRCA	cis	rs853679	0.542	rs6934769	ENSG00000204709.4	LINC01556	6.05	2.02e-09	3.24e-07	0.27	0.18	Depression;	chr6:28123153	chr6:28943877~28944537:+
BRCA	cis	rs853679	0.517	rs17711801	ENSG00000204709.4	LINC01556	6.05	2.02e-09	3.24e-07	0.27	0.18	Depression;	chr6:28124529	chr6:28943877~28944537:+
BRCA	cis	rs4713118	0.527	rs9461433	ENSG00000204709.4	LINC01556	6.05	2.02e-09	3.24e-07	0.27	0.18	Parkinson's disease;	chr6:28127394	chr6:28943877~28944537:+
BRCA	cis	rs853679	0.517	rs9468292	ENSG00000204709.4	LINC01556	6.05	2.02e-09	3.24e-07	0.27	0.18	Depression;	chr6:28127577	chr6:28943877~28944537:+
BRCA	cis	rs7189233	0.955	rs8054299	ENSG00000279344.1	RP11-44F14.7	-6.05	2.02e-09	3.24e-07	-0.2	-0.18	Intelligence (multi-trait analysis);	chr16:53464743	chr16:53478957~53481550:-
BRCA	cis	rs10129255	0.957	rs12590799	ENSG00000211972.2	IGHV3-66	6.05	2.02e-09	3.24e-07	0.13	0.18	Kawasaki disease;	chr14:106779713	chr14:106675017~106675544:-
BRCA	cis	rs9840812	0.691	rs1070232	ENSG00000239213.4	NCK1-AS1	6.05	2.02e-09	3.24e-07	0.23	0.18	Fibrinogen levels;	chr3:136529245	chr3:136841726~136862054:-
BRCA	cis	rs2404602	0.536	rs7165025	ENSG00000259422.1	RP11-593F23.1	6.05	2.02e-09	3.24e-07	0.23	0.18	Blood metabolite levels;	chr15:76474093	chr15:76174891~76181486:-
BRCA	cis	rs1707322	1	rs946527	ENSG00000281133.1	AL355480.3	-6.05	2.02e-09	3.24e-07	-0.23	-0.18	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46020298	chr1:45580892~45580996:-
BRCA	cis	rs853679	0.607	rs35749575	ENSG00000220721.1	OR1F12	6.05	2.02e-09	3.24e-07	0.45	0.18	Depression;	chr6:28147040	chr6:28073316~28074233:+
BRCA	cis	rs755249	1	rs2293476	ENSG00000182109.6	RP11-69E11.4	-6.05	2.02e-09	3.24e-07	-0.25	-0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39571175	chr1:39522280~39546187:-
BRCA	cis	rs9907295	0.818	rs4796112	ENSG00000270977.1	AC015849.16	6.05	2.02e-09	3.24e-07	0.29	0.18	Fibroblast growth factor basic levels;	chr17:35831722	chr17:35893707~35911023:-
BRCA	cis	rs10129255	0.518	rs10150460	ENSG00000274576.2	IGHV2-70	6.05	2.02e-09	3.24e-07	0.15	0.18	Kawasaki disease;	chr14:106677179	chr14:106770577~106771020:-
BRCA	cis	rs9545047	0.604	rs7983344	ENSG00000227354.5	RBM26-AS1	-6.05	2.02e-09	3.24e-07	-0.2	-0.18	Schizophrenia;	chr13:79299295	chr13:79406309~79424328:+
BRCA	cis	rs987360	1	rs6847311	ENSG00000248869.4	RP11-138I17.1	-6.05	2.02e-09	3.25e-07	-0.18	-0.18	Temperament;	chr4:137300533	chr4:136796722~137212799:-
BRCA	cis	rs853679	0.517	rs9468298	ENSG00000204709.4	LINC01556	6.05	2.03e-09	3.25e-07	0.28	0.18	Depression;	chr6:28154567	chr6:28943877~28944537:+
BRCA	cis	rs853679	0.517	rs9295759	ENSG00000204709.4	LINC01556	6.05	2.03e-09	3.25e-07	0.28	0.18	Depression;	chr6:28156691	chr6:28943877~28944537:+
BRCA	cis	rs853679	0.517	rs9348796	ENSG00000204709.4	LINC01556	6.05	2.03e-09	3.25e-07	0.28	0.18	Depression;	chr6:28158424	chr6:28943877~28944537:+
BRCA	cis	rs853679	0.517	rs11552219	ENSG00000204709.4	LINC01556	6.05	2.03e-09	3.25e-07	0.28	0.18	Depression;	chr6:28159056	chr6:28943877~28944537:+
BRCA	cis	rs853679	0.517	rs9357066	ENSG00000204709.4	LINC01556	6.05	2.03e-09	3.25e-07	0.28	0.18	Depression;	chr6:28162053	chr6:28943877~28944537:+
BRCA	cis	rs6840258	1	rs767315	ENSG00000251411.1	RP11-397E7.4	-6.05	2.03e-09	3.25e-07	-0.24	-0.18	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87039283	chr4:86913266~86914817:-
BRCA	cis	rs6479891	1	rs4745706	ENSG00000232075.1	MRPL35P2	6.05	2.03e-09	3.25e-07	0.33	0.18	Arthritis (juvenile idiopathic);	chr10:63399820	chr10:63634317~63634827:-
BRCA	cis	rs6479891	1	rs12415038	ENSG00000232075.1	MRPL35P2	6.05	2.03e-09	3.25e-07	0.33	0.18	Arthritis (juvenile idiopathic);	chr10:63401098	chr10:63634317~63634827:-
BRCA	cis	rs910316	0.967	rs11159121	ENSG00000279594.1	RP11-950C14.10	-6.05	2.03e-09	3.26e-07	-0.2	-0.18	Height;	chr14:75199326	chr14:75011269~75012851:-
BRCA	cis	rs2836950	0.565	rs2836930	ENSG00000238141.2	BRWD1-AS1	-6.05	2.03e-09	3.26e-07	-0.21	-0.18	Menarche (age at onset);	chr21:39173730	chr21:39315707~39323218:+
BRCA	cis	rs7615952	0.641	rs6438951	ENSG00000171084.14	FAM86JP	6.05	2.03e-09	3.26e-07	0.28	0.18	Blood pressure (smoking interaction);	chr3:125978156	chr3:125916620~125930024:+
BRCA	cis	rs7569084	0.687	rs11692813	ENSG00000237979.1	AC007389.1	6.05	2.03e-09	3.26e-07	0.24	0.18	Sum eosinophil basophil counts;	chr2:65435172	chr2:65500993~65502138:-
BRCA	cis	rs577676	0.564	rs644784	ENSG00000271811.1	RP1-79C4.4	6.05	2.03e-09	3.26e-07	0.22	0.18	Prevalent atrial fibrillation;	chr1:170636945	chr1:170667381~170669425:+
BRCA	cis	rs2243480	1	rs422164	ENSG00000228409.4	CCT6P1	6.05	2.04e-09	3.27e-07	0.26	0.18	Diabetic kidney disease;	chr7:66121618	chr7:65751142~65763354:+
BRCA	cis	rs853679	0.517	rs9393891	ENSG00000204709.4	LINC01556	6.05	2.04e-09	3.27e-07	0.27	0.18	Depression;	chr6:28111382	chr6:28943877~28944537:+
BRCA	cis	rs853679	0.517	rs9468286	ENSG00000204709.4	LINC01556	6.05	2.04e-09	3.27e-07	0.27	0.18	Depression;	chr6:28111650	chr6:28943877~28944537:+
BRCA	cis	rs853679	0.517	rs9380055	ENSG00000204709.4	LINC01556	6.05	2.04e-09	3.27e-07	0.27	0.18	Depression;	chr6:28113851	chr6:28943877~28944537:+
BRCA	cis	rs853679	0.517	rs9368553	ENSG00000204709.4	LINC01556	6.05	2.04e-09	3.27e-07	0.27	0.18	Depression;	chr6:28114487	chr6:28943877~28944537:+
BRCA	cis	rs853679	0.517	rs9368554	ENSG00000204709.4	LINC01556	6.05	2.04e-09	3.27e-07	0.27	0.18	Depression;	chr6:28114933	chr6:28943877~28944537:+
BRCA	cis	rs853679	0.517	rs4713137	ENSG00000204709.4	LINC01556	6.05	2.04e-09	3.27e-07	0.27	0.18	Depression;	chr6:28115743	chr6:28943877~28944537:+
BRCA	cis	rs853679	0.517	rs9348793	ENSG00000204709.4	LINC01556	6.05	2.04e-09	3.27e-07	0.27	0.18	Depression;	chr6:28116411	chr6:28943877~28944537:+
BRCA	cis	rs4713118	0.586	rs6905516	ENSG00000204709.4	LINC01556	6.05	2.04e-09	3.27e-07	0.27	0.18	Parkinson's disease;	chr6:28118700	chr6:28943877~28944537:+
BRCA	cis	rs4713118	0.586	rs6905522	ENSG00000204709.4	LINC01556	6.05	2.04e-09	3.27e-07	0.27	0.18	Parkinson's disease;	chr6:28118701	chr6:28943877~28944537:+
BRCA	cis	rs4713118	0.586	rs9468290	ENSG00000204709.4	LINC01556	6.05	2.04e-09	3.27e-07	0.27	0.18	Parkinson's disease;	chr6:28119896	chr6:28943877~28944537:+
BRCA	cis	rs2243480	1	rs431076	ENSG00000228409.4	CCT6P1	6.05	2.04e-09	3.27e-07	0.26	0.18	Diabetic kidney disease;	chr7:66135333	chr7:65751142~65763354:+
BRCA	cis	rs2243480	1	rs2460422	ENSG00000228409.4	CCT6P1	6.05	2.04e-09	3.27e-07	0.26	0.18	Diabetic kidney disease;	chr7:66136518	chr7:65751142~65763354:+
BRCA	cis	rs2243480	1	rs316334	ENSG00000228409.4	CCT6P1	6.05	2.04e-09	3.27e-07	0.26	0.18	Diabetic kidney disease;	chr7:66137139	chr7:65751142~65763354:+
BRCA	cis	rs853679	0.607	rs201002	ENSG00000220721.1	OR1F12	6.05	2.04e-09	3.27e-07	0.32	0.18	Depression;	chr6:27840414	chr6:28073316~28074233:+
BRCA	cis	rs4718428	0.705	rs13231140	ENSG00000230295.1	RP11-458F8.2	-6.05	2.04e-09	3.28e-07	-0.17	-0.18	Corneal structure;	chr7:66896631	chr7:66880708~66882981:+
BRCA	cis	rs13113518	0.812	rs12501746	ENSG00000273257.1	RP11-177J6.1	6.05	2.04e-09	3.28e-07	0.24	0.18	Height;	chr4:55437438	chr4:55387949~55388271:+
BRCA	cis	rs2098713	0.599	rs1812818	ENSG00000250155.1	CTD-2353F22.1	6.05	2.04e-09	3.28e-07	0.2	0.18	Telomere length;	chr5:37546652	chr5:36666214~36725195:-
BRCA	cis	rs792448	0.603	rs4951588	ENSG00000226251.4	RP11-15I11.3	-6.05	2.05e-09	3.28e-07	-0.22	-0.18	White blood cell count (basophil);	chr1:212327091	chr1:212225278~212238977:-
BRCA	cis	rs669446	0.562	rs4660259	ENSG00000237950.1	RP11-7O11.3	6.05	2.05e-09	3.28e-07	0.21	0.18	Amyotrophic lateral sclerosis (age of onset);	chr1:43728863	chr1:43944370~43946551:-
BRCA	cis	rs2179367	0.632	rs59820585	ENSG00000216906.2	RP11-350J20.9	6.05	2.05e-09	3.28e-07	0.26	0.18	Dupuytren's disease;	chr6:149350249	chr6:149904243~149906418:+
BRCA	cis	rs2179367	0.632	rs56924465	ENSG00000216906.2	RP11-350J20.9	6.05	2.05e-09	3.28e-07	0.26	0.18	Dupuytren's disease;	chr6:149350270	chr6:149904243~149906418:+
BRCA	cis	rs2243480	1	rs160634	ENSG00000228409.4	CCT6P1	-6.05	2.05e-09	3.28e-07	-0.24	-0.18	Diabetic kidney disease;	chr7:66063677	chr7:65751142~65763354:+
BRCA	cis	rs78487399	0.908	rs6725688	ENSG00000234936.1	AC010883.5	6.05	2.05e-09	3.29e-07	0.25	0.18	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43619414	chr2:43229573~43233394:+
BRCA	cis	rs7772486	0.79	rs10223507	ENSG00000270638.1	RP3-466P17.1	-6.05	2.05e-09	3.29e-07	-0.21	-0.18	Lobe attachment (rater-scored or self-reported);	chr6:145964068	chr6:145735570~145737218:+
BRCA	cis	rs11722228	0.508	rs61335146	ENSG00000261490.1	RP11-448G15.3	6.05	2.05e-09	3.29e-07	0.19	0.18	Urate levels;Serum uric acid levels;Gout;	chr4:10129169	chr4:10068089~10073019:-
BRCA	cis	rs73193808	0.901	rs2056864	ENSG00000215533.7	LINC00189	-6.05	2.05e-09	3.29e-07	-0.27	-0.18	Coronary artery disease;	chr21:29196085	chr21:29193480~29288205:+
BRCA	cis	rs7688540	0.771	rs78343340	ENSG00000211553.1	AC253576.2	-6.05	2.06e-09	3.29e-07	-0.29	-0.18	Facial morphology (factor 6, height of vermillion lower lip);	chr4:273648	chr4:136461~136568:+
BRCA	cis	rs875971	1	rs3735148	ENSG00000224316.1	RP11-479O9.2	6.05	2.06e-09	3.29e-07	0.18	0.18	Aortic root size;	chr7:66506022	chr7:65773620~65802067:+
BRCA	cis	rs7914558	0.966	rs943035	ENSG00000213061.2	PFN1P11	6.05	2.06e-09	3.3e-07	0.24	0.18	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103079395	chr10:102838011~102845473:-
BRCA	cis	rs7914558	0.966	rs7921574	ENSG00000213061.2	PFN1P11	6.05	2.06e-09	3.3e-07	0.24	0.18	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103081213	chr10:102838011~102845473:-
BRCA	cis	rs227275	0.525	rs4698867	ENSG00000251288.2	RP11-10L12.2	-6.05	2.06e-09	3.3e-07	-0.21	-0.18	Allergic disease (asthma, hay fever or eczema);	chr4:102961049	chr4:102751401~102752641:+
BRCA	cis	rs227275	0.525	rs7663876	ENSG00000251288.2	RP11-10L12.2	-6.05	2.06e-09	3.3e-07	-0.21	-0.18	Allergic disease (asthma, hay fever or eczema);	chr4:102966174	chr4:102751401~102752641:+
BRCA	cis	rs2243480	1	rs313803	ENSG00000164669.11	INTS4P1	6.05	2.06e-09	3.3e-07	0.37	0.18	Diabetic kidney disease;	chr7:66049744	chr7:65141225~65234216:+
BRCA	cis	rs2274273	1	rs7142704	ENSG00000258413.1	RP11-665C16.6	-6.05	2.06e-09	3.3e-07	-0.24	-0.18	Protein biomarker;	chr14:55163885	chr14:55262767~55272075:-
BRCA	cis	rs227275	0.525	rs5028609	ENSG00000251288.2	RP11-10L12.2	-6.05	2.06e-09	3.3e-07	-0.21	-0.18	Allergic disease (asthma, hay fever or eczema);	chr4:102959294	chr4:102751401~102752641:+
BRCA	cis	rs227275	0.525	rs6815540	ENSG00000251288.2	RP11-10L12.2	-6.05	2.06e-09	3.3e-07	-0.21	-0.18	Allergic disease (asthma, hay fever or eczema);	chr4:102959922	chr4:102751401~102752641:+
BRCA	cis	rs2638953	0.924	rs12320545	ENSG00000278733.1	RP11-425D17.1	6.05	2.06e-09	3.3e-07	0.23	0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28248047	chr12:28185625~28186190:-
BRCA	cis	rs875971	0.505	rs6955582	ENSG00000234585.5	CCT6P3	6.05	2.06e-09	3.31e-07	0.18	0.18	Aortic root size;	chr7:65966699	chr7:65038354~65074713:+
BRCA	cis	rs7083	0.716	rs687740	ENSG00000254851.1	RP11-109L13.1	-6.05	2.06e-09	3.31e-07	-0.23	-0.18	Blood protein levels;	chr11:117306887	chr11:117135528~117138582:+
BRCA	cis	rs10129255	0.957	rs11847726	ENSG00000224373.3	IGHV4-59	6.05	2.06e-09	3.31e-07	0.12	0.18	Kawasaki disease;	chr14:106779116	chr14:106627249~106627825:-
BRCA	cis	rs17711722	0.523	rs365896	ENSG00000275400.1	RP4-756H11.5	6.05	2.07e-09	3.31e-07	0.22	0.18	Calcium levels;	chr7:66045710	chr7:66553805~66554199:-
BRCA	cis	rs1014246	0.848	rs10787718	ENSG00000232767.1	RP11-498B4.5	6.05	2.07e-09	3.31e-07	0.21	0.18	Age at smoking initiation in chronic obstructive pulmonary disease;	chr10:116708137	chr10:116670103~116672739:+
BRCA	cis	rs7246657	0.653	rs10425441	ENSG00000226686.6	LINC01535	-6.05	2.07e-09	3.31e-07	-0.31	-0.18	Coronary artery calcification;	chr19:37179746	chr19:37251912~37265535:+
BRCA	cis	rs2243480	1	rs35432774	ENSG00000228409.4	CCT6P1	6.05	2.07e-09	3.31e-07	0.25	0.18	Diabetic kidney disease;	chr7:65928032	chr7:65751142~65763354:+
BRCA	cis	rs2243480	1	rs34136756	ENSG00000229886.1	RP5-1132H15.3	6.05	2.07e-09	3.31e-07	0.32	0.18	Diabetic kidney disease;	chr7:65916269	chr7:66025126~66031544:-
BRCA	cis	rs2408955	0.521	rs10875753	ENSG00000240399.1	RP1-228P16.1	6.05	2.07e-09	3.32e-07	0.21	0.18	Glycated hemoglobin levels;	chr12:48163358	chr12:48054813~48055591:-
BRCA	cis	rs2836950	0.545	rs11700449	ENSG00000238141.2	BRWD1-AS1	-6.05	2.07e-09	3.32e-07	-0.21	-0.18	Menarche (age at onset);	chr21:39150493	chr21:39315707~39323218:+
BRCA	cis	rs7520050	0.966	rs1707304	ENSG00000280836.1	AL355480.1	6.05	2.07e-09	3.32e-07	0.22	0.18	Reticulocyte count;Red blood cell count;	chr1:46132597	chr1:45581219~45581321:-
BRCA	cis	rs7569084	0.663	rs11126037	ENSG00000237979.1	AC007389.1	6.05	2.07e-09	3.32e-07	0.24	0.18	Sum eosinophil basophil counts;	chr2:65436024	chr2:65500993~65502138:-
BRCA	cis	rs17301013	0.566	rs72711492	ENSG00000227373.4	RP11-160H22.5	6.05	2.07e-09	3.32e-07	0.28	0.18	Systemic lupus erythematosus;	chr1:174195464	chr1:174115300~174160004:-
BRCA	cis	rs2243480	1	rs781150	ENSG00000232546.1	RP11-458F8.1	-6.05	2.07e-09	3.32e-07	-0.24	-0.18	Diabetic kidney disease;	chr7:66015986	chr7:66848496~66858136:+
BRCA	cis	rs2243480	1	rs313798	ENSG00000232546.1	RP11-458F8.1	-6.05	2.07e-09	3.32e-07	-0.24	-0.18	Diabetic kidney disease;	chr7:66028044	chr7:66848496~66858136:+
BRCA	cis	rs7927771	0.524	rs6485773	ENSG00000280615.1	Y_RNA	6.05	2.07e-09	3.32e-07	0.22	0.18	Subjective well-being;	chr11:47741957	chr11:47614898~47614994:-
BRCA	cis	rs7927771	0.524	rs7932703	ENSG00000280615.1	Y_RNA	6.05	2.07e-09	3.32e-07	0.22	0.18	Subjective well-being;	chr11:47748384	chr11:47614898~47614994:-
BRCA	cis	rs7927771	0.524	rs10838758	ENSG00000280615.1	Y_RNA	6.05	2.07e-09	3.32e-07	0.22	0.18	Subjective well-being;	chr11:47749924	chr11:47614898~47614994:-
BRCA	cis	rs7927771	0.524	rs10838760	ENSG00000280615.1	Y_RNA	6.05	2.07e-09	3.32e-07	0.22	0.18	Subjective well-being;	chr11:47764862	chr11:47614898~47614994:-
BRCA	cis	rs7927771	0.524	rs7111576	ENSG00000280615.1	Y_RNA	6.05	2.07e-09	3.32e-07	0.22	0.18	Subjective well-being;	chr11:47765893	chr11:47614898~47614994:-
BRCA	cis	rs7927771	0.507	rs7111606	ENSG00000280615.1	Y_RNA	6.05	2.07e-09	3.32e-07	0.22	0.18	Subjective well-being;	chr11:47765986	chr11:47614898~47614994:-
BRCA	cis	rs7927771	0.524	rs61895760	ENSG00000280615.1	Y_RNA	6.05	2.07e-09	3.32e-07	0.22	0.18	Subjective well-being;	chr11:47772986	chr11:47614898~47614994:-
BRCA	cis	rs7927771	0.524	rs10838763	ENSG00000280615.1	Y_RNA	6.05	2.07e-09	3.32e-07	0.22	0.18	Subjective well-being;	chr11:47773250	chr11:47614898~47614994:-
BRCA	cis	rs4950322	0.748	rs56392137	ENSG00000278811.3	LINC00624	6.05	2.07e-09	3.32e-07	0.26	0.18	Protein quantitative trait loci;	chr1:147352450	chr1:147258885~147517875:-
BRCA	cis	rs6434928	1	rs6434928	ENSG00000231621.1	AC013264.2	-6.05	2.08e-09	3.32e-07	-0.18	-0.18	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr2:197439853	chr2:197197991~197199273:+
BRCA	cis	rs2243480	0.901	rs2456483	ENSG00000164669.11	INTS4P1	6.05	2.08e-09	3.33e-07	0.36	0.18	Diabetic kidney disease;	chr7:65996588	chr7:65141225~65234216:+
BRCA	cis	rs2243480	1	rs1701750	ENSG00000164669.11	INTS4P1	6.05	2.08e-09	3.33e-07	0.36	0.18	Diabetic kidney disease;	chr7:66002158	chr7:65141225~65234216:+
BRCA	cis	rs73193808	1	rs2832228	ENSG00000215533.7	LINC00189	-6.04	2.08e-09	3.33e-07	-0.27	-0.18	Coronary artery disease;	chr21:29162364	chr21:29193480~29288205:+
BRCA	cis	rs10129255	0.785	rs10150044	ENSG00000211972.2	IGHV3-66	6.04	2.08e-09	3.33e-07	0.14	0.18	Kawasaki disease;	chr14:106775695	chr14:106675017~106675544:-
BRCA	cis	rs7927771	0.542	rs3886262	ENSG00000280615.1	Y_RNA	6.04	2.08e-09	3.33e-07	0.22	0.18	Subjective well-being;	chr11:47795458	chr11:47614898~47614994:-
BRCA	cis	rs2281636	0.691	rs6584306	ENSG00000233690.1	EBAG9P1	6.04	2.08e-09	3.33e-07	0.21	0.18	Obesity-related traits;	chr10:99662739	chr10:99697407~99697949:-
BRCA	cis	rs253959	0.672	rs1133186	ENSG00000272265.1	CTD-2287O16.4	6.04	2.08e-09	3.34e-07	0.21	0.18	Bipolar disorder and schizophrenia;	chr5:116084718	chr5:116078110~116078570:-
BRCA	cis	rs763121	0.853	rs138713	ENSG00000273076.1	RP3-508I15.22	6.04	2.09e-09	3.34e-07	0.21	0.18	Menopause (age at onset);	chr22:38746610	chr22:38743495~38743910:+
BRCA	cis	rs1476670	0.661	rs10157253	ENSG00000230615.5	RP5-1198O20.4	-6.04	2.09e-09	3.34e-07	-0.26	-0.18	Eotaxin levels;	chr1:44039974	chr1:44030443~44115913:+
BRCA	cis	rs227275	0.556	rs28367331	ENSG00000251288.2	RP11-10L12.2	-6.04	2.09e-09	3.35e-07	-0.22	-0.18	Allergic disease (asthma, hay fever or eczema);	chr4:102900734	chr4:102751401~102752641:+
BRCA	cis	rs1552244	1	rs6772315	ENSG00000180385.7	EMC3-AS1	6.04	2.09e-09	3.35e-07	0.23	0.18	Alzheimer's disease;	chr3:10071960	chr3:9986893~10006990:+
BRCA	cis	rs160451	0.966	rs160450	ENSG00000251136.7	RP11-37B2.1	6.04	2.09e-09	3.35e-07	0.18	0.18	Leprosy;	chr8:89650354	chr8:89609409~89757727:-
BRCA	cis	rs160451	1	rs160451	ENSG00000251136.7	RP11-37B2.1	6.04	2.09e-09	3.35e-07	0.18	0.18	Leprosy;	chr8:89650713	chr8:89609409~89757727:-
BRCA	cis	rs7044106	0.762	rs7357638	ENSG00000238181.2	AHCYP2	-6.04	2.09e-09	3.35e-07	-0.24	-0.18	Hip circumference adjusted for BMI;	chr9:120626926	chr9:120720673~120721972:+
BRCA	cis	rs67981189	0.896	rs12883437	ENSG00000258571.1	PTTG4P	-6.04	2.09e-09	3.35e-07	-0.2	-0.18	Schizophrenia;	chr14:70998064	chr14:71085482~71085833:-
BRCA	cis	rs67311347	0.713	rs4974018	ENSG00000280739.1	EIF1B-AS1	6.04	2.09e-09	3.35e-07	0.21	0.18	Renal cell carcinoma;	chr3:40265928	chr3:40173145~40309698:-
BRCA	cis	rs9880211	0.563	rs6769762	ENSG00000239213.4	NCK1-AS1	6.04	2.1e-09	3.35e-07	0.24	0.18	Height;Body mass index;	chr3:136189336	chr3:136841726~136862054:-
BRCA	cis	rs7238033	0.624	rs17674709	ENSG00000267193.4	RP11-116O18.3	6.04	2.1e-09	3.36e-07	0.2	0.18	Bladder cancer;	chr18:45731415	chr18:45669367~45747215:-
BRCA	cis	rs7238033	0.602	rs10460034	ENSG00000267193.4	RP11-116O18.3	6.04	2.1e-09	3.36e-07	0.2	0.18	Bladder cancer;	chr18:45731434	chr18:45669367~45747215:-
BRCA	cis	rs7238033	0.624	rs8099449	ENSG00000267193.4	RP11-116O18.3	6.04	2.1e-09	3.36e-07	0.2	0.18	Bladder cancer;	chr18:45731731	chr18:45669367~45747215:-
BRCA	cis	rs2243480	1	rs313802	ENSG00000164669.11	INTS4P1	6.04	2.1e-09	3.36e-07	0.37	0.18	Diabetic kidney disease;	chr7:66051386	chr7:65141225~65234216:+
BRCA	cis	rs2243480	0.803	rs403089	ENSG00000164669.11	INTS4P1	6.04	2.1e-09	3.36e-07	0.37	0.18	Diabetic kidney disease;	chr7:66052736	chr7:65141225~65234216:+
BRCA	cis	rs2243480	1	rs458291	ENSG00000164669.11	INTS4P1	6.04	2.1e-09	3.36e-07	0.37	0.18	Diabetic kidney disease;	chr7:66055492	chr7:65141225~65234216:+
BRCA	cis	rs2638953	0.924	rs11049384	ENSG00000278733.1	RP11-425D17.1	-6.04	2.1e-09	3.36e-07	-0.24	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28166089	chr12:28185625~28186190:-
BRCA	cis	rs34792	0.626	rs153784	ENSG00000207425.1	Y_RNA	-6.04	2.1e-09	3.36e-07	-0.23	-0.18	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15508734	chr16:14915457~14915556:-
BRCA	cis	rs17301013	0.606	rs56375942	ENSG00000227373.4	RP11-160H22.5	6.04	2.1e-09	3.36e-07	0.28	0.18	Systemic lupus erythematosus;	chr1:174176206	chr1:174115300~174160004:-
BRCA	cis	rs9876781	1	rs9864371	ENSG00000229759.1	MRPS18AP1	6.04	2.1e-09	3.37e-07	0.21	0.18	Longevity;	chr3:48385276	chr3:48256350~48256938:-
BRCA	cis	rs7945705	0.791	rs12421789	ENSG00000254860.4	TMEM9B-AS1	6.04	2.11e-09	3.37e-07	0.17	0.18	Hemoglobin concentration;	chr11:8792409	chr11:8964675~8977527:+
BRCA	cis	rs2235642	0.893	rs2076445	ENSG00000280231.1	LA16c-380F5.3	-6.04	2.11e-09	3.38e-07	-0.24	-0.18	Coronary artery disease;	chr16:1542265	chr16:1553655~1554130:-
BRCA	cis	rs4761702	0.524	rs12581099	ENSG00000257252.4	RP11-486A14.2	-6.04	2.11e-09	3.38e-07	-0.3	-0.18	Immature fraction of reticulocytes;	chr12:93333720	chr12:93317135~93377736:-
BRCA	cis	rs7246657	0.714	rs12972195	ENSG00000226686.6	LINC01535	-6.04	2.12e-09	3.39e-07	-0.28	-0.18	Coronary artery calcification;	chr19:37261603	chr19:37251912~37265535:+
BRCA	cis	rs34779708	0.931	rs55724039	ENSG00000271335.4	RP11-324I22.4	6.04	2.12e-09	3.39e-07	0.2	0.18	Inflammatory bowel disease;Crohn's disease;	chr10:35176469	chr10:35314552~35336401:-
BRCA	cis	rs2644899	0.859	rs2545755	ENSG00000268529.1	CYP2T3P	6.04	2.12e-09	3.39e-07	0.25	0.18	Post bronchodilator FEV1/FVC ratio;	chr19:40787257	chr19:41134722~41137308:+
BRCA	cis	rs66887589	0.775	rs6843229	ENSG00000245958.5	RP11-33B1.1	-6.04	2.12e-09	3.39e-07	-0.16	-0.18	Diastolic blood pressure;	chr4:119502932	chr4:119454791~119552025:+
BRCA	cis	rs2235642	0.928	rs56289115	ENSG00000280231.1	LA16c-380F5.3	-6.04	2.12e-09	3.39e-07	-0.24	-0.18	Coronary artery disease;	chr16:1558933	chr16:1553655~1554130:-
BRCA	cis	rs6723226	0.75	rs3769597	ENSG00000276334.1	AL133243.1	6.04	2.12e-09	3.39e-07	0.22	0.18	Intelligence (multi-trait analysis);	chr2:32466332	chr2:32521927~32523547:+
BRCA	cis	rs2281558	0.793	rs6115227	ENSG00000125804.12	FAM182A	-6.04	2.12e-09	3.39e-07	-0.27	-0.18	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25610741	chr20:26054655~26086917:+
BRCA	cis	rs1440410	0.835	rs4513514	ENSG00000250326.1	RP11-284M14.1	-6.04	2.12e-09	3.4e-07	-0.2	-0.18	Ischemic stroke;	chr4:143218559	chr4:142933195~143184861:-
BRCA	cis	rs17301013	0.507	rs72717616	ENSG00000227373.4	RP11-160H22.5	6.04	2.12e-09	3.4e-07	0.29	0.18	Systemic lupus erythematosus;	chr1:174812711	chr1:174115300~174160004:-
BRCA	cis	rs1707322	1	rs10890350	ENSG00000281133.1	AL355480.3	-6.04	2.12e-09	3.4e-07	-0.23	-0.18	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45796706	chr1:45580892~45580996:-
BRCA	cis	rs7772486	0.79	rs9485024	ENSG00000270638.1	RP3-466P17.1	-6.04	2.13e-09	3.4e-07	-0.21	-0.18	Lobe attachment (rater-scored or self-reported);	chr6:145821351	chr6:145735570~145737218:+
BRCA	cis	rs73193808	1	rs73193808	ENSG00000215533.7	LINC00189	-6.04	2.13e-09	3.4e-07	-0.27	-0.18	Coronary artery disease;	chr21:29162981	chr21:29193480~29288205:+
BRCA	cis	rs7772486	0.686	rs702305	ENSG00000270638.1	RP3-466P17.1	-6.04	2.13e-09	3.4e-07	-0.21	-0.18	Lobe attachment (rater-scored or self-reported);	chr6:145652704	chr6:145735570~145737218:+
BRCA	cis	rs875971	0.545	rs1909508	ENSG00000273024.4	INTS4P2	-6.04	2.13e-09	3.4e-07	-0.23	-0.18	Aortic root size;	chr7:66301366	chr7:65647864~65715661:+
BRCA	cis	rs9467773	0.838	rs3734540	ENSG00000124549.13	BTN2A3P	6.04	2.13e-09	3.4e-07	0.19	0.18	Intelligence (multi-trait analysis);	chr6:26463093	chr6:26421391~26432383:+
BRCA	cis	rs12655019	0.92	rs75167082	ENSG00000271828.1	CTD-2310F14.1	6.04	2.13e-09	3.41e-07	0.34	0.18	Breast cancer (early onset);	chr5:56915577	chr5:56927874~56929573:+
BRCA	cis	rs12681366	1	rs12681366	ENSG00000253704.1	RP11-267M23.4	6.04	2.13e-09	3.41e-07	0.19	0.18	Nonsyndromic cleft lip with cleft palate;	chr8:94389037	chr8:94553722~94569745:+
BRCA	cis	rs74233809	0.901	rs3824755	ENSG00000213277.3	MARCKSL1P1	6.04	2.13e-09	3.41e-07	0.31	0.18	Birth weight;	chr10:102836092	chr10:103175554~103176094:+
BRCA	cis	rs1124769	0.719	rs7170302	ENSG00000259378.1	DCAF13P3	-6.04	2.13e-09	3.41e-07	-0.26	-0.18	Cognitive performance;	chr15:50918913	chr15:50944663~50945996:+
BRCA	cis	rs7615952	0.576	rs4646748	ENSG00000171084.14	FAM86JP	6.04	2.13e-09	3.41e-07	0.29	0.18	Blood pressure (smoking interaction);	chr3:126107486	chr3:125916620~125930024:+
BRCA	cis	rs11105298	0.891	rs10858869	ENSG00000270344.2	RP11-734K2.4	6.04	2.13e-09	3.41e-07	0.21	0.18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89463834	chr12:89525654~89548005:+
BRCA	cis	rs11105298	0.891	rs10858871	ENSG00000270344.2	RP11-734K2.4	6.04	2.13e-09	3.41e-07	0.21	0.18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89477836	chr12:89525654~89548005:+
BRCA	cis	rs74233809	0.515	rs72841270	ENSG00000213277.3	MARCKSL1P1	6.04	2.14e-09	3.41e-07	0.29	0.18	Birth weight;	chr10:102882480	chr10:103175554~103176094:+
BRCA	cis	rs7238033	0.624	rs10460036	ENSG00000267193.4	RP11-116O18.3	6.04	2.14e-09	3.42e-07	0.2	0.18	Bladder cancer;	chr18:45731601	chr18:45669367~45747215:-
BRCA	cis	rs442309	0.687	rs10822058	ENSG00000238280.1	RP11-436D10.3	-6.04	2.14e-09	3.42e-07	-0.26	-0.18	Vogt-Koyanagi-Harada syndrome;	chr10:62763822	chr10:62793562~62805887:-
BRCA	cis	rs4713118	0.662	rs9468274	ENSG00000219392.1	RP1-265C24.5	-6.04	2.14e-09	3.42e-07	-0.27	-0.18	Parkinson's disease;	chr6:28058299	chr6:28115628~28116551:+
BRCA	cis	rs4713118	0.662	rs9468275	ENSG00000219392.1	RP1-265C24.5	-6.04	2.14e-09	3.42e-07	-0.27	-0.18	Parkinson's disease;	chr6:28058358	chr6:28115628~28116551:+
BRCA	cis	rs4713118	0.662	rs9468276	ENSG00000219392.1	RP1-265C24.5	-6.04	2.14e-09	3.42e-07	-0.27	-0.18	Parkinson's disease;	chr6:28059910	chr6:28115628~28116551:+
BRCA	cis	rs4713118	0.662	rs9468277	ENSG00000219392.1	RP1-265C24.5	-6.04	2.14e-09	3.42e-07	-0.27	-0.18	Parkinson's disease;	chr6:28060612	chr6:28115628~28116551:+
BRCA	cis	rs4713118	0.662	rs9468278	ENSG00000219392.1	RP1-265C24.5	-6.04	2.14e-09	3.42e-07	-0.27	-0.18	Parkinson's disease;	chr6:28060704	chr6:28115628~28116551:+
BRCA	cis	rs4713118	0.662	rs13218430	ENSG00000219392.1	RP1-265C24.5	-6.04	2.14e-09	3.42e-07	-0.27	-0.18	Parkinson's disease;	chr6:28062059	chr6:28115628~28116551:+
BRCA	cis	rs875971	0.825	rs28480509	ENSG00000224316.1	RP11-479O9.2	-6.04	2.14e-09	3.42e-07	-0.19	-0.18	Aortic root size;	chr7:66634237	chr7:65773620~65802067:+
BRCA	cis	rs7615952	1	rs7616044	ENSG00000171084.14	FAM86JP	6.04	2.14e-09	3.42e-07	0.3	0.18	Blood pressure (smoking interaction);	chr3:125930511	chr3:125916620~125930024:+
BRCA	cis	rs30380	0.69	rs27432	ENSG00000272109.1	CTD-2260A17.3	-6.04	2.14e-09	3.42e-07	-0.24	-0.18	Cerebrospinal fluid biomarker levels;	chr5:96783569	chr5:96804353~96806105:+
BRCA	cis	rs2638953	0.886	rs7957503	ENSG00000278733.1	RP11-425D17.1	-6.04	2.14e-09	3.42e-07	-0.23	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28203762	chr12:28185625~28186190:-
BRCA	cis	rs11976180	1	rs2951368	ENSG00000273234.1	OR2A13P	-6.04	2.14e-09	3.43e-07	-0.24	-0.18	Obesity-related traits;	chr7:144055728	chr7:144142009~144142938:+
BRCA	cis	rs9333029	0.524	rs1126743	ENSG00000238145.2	RP11-346M5.1	-6.04	2.15e-09	3.43e-07	-0.19	-0.18	Blood metabolite levels;	chr1:46930301	chr1:46891639~46892830:+
BRCA	cis	rs9333029	0.524	rs4660978	ENSG00000238145.2	RP11-346M5.1	-6.04	2.15e-09	3.43e-07	-0.19	-0.18	Blood metabolite levels;	chr1:46930626	chr1:46891639~46892830:+
BRCA	cis	rs9333029	0.524	rs4233506	ENSG00000238145.2	RP11-346M5.1	-6.04	2.15e-09	3.43e-07	-0.19	-0.18	Blood metabolite levels;	chr1:46931258	chr1:46891639~46892830:+
BRCA	cis	rs7635879	0.716	rs1078813	ENSG00000230102.6	RP11-407B7.1	6.04	2.15e-09	3.43e-07	0.22	0.18	Breastfeeding duration;	chr3:194015030	chr3:194005259~194070970:-
BRCA	cis	rs6088813	1	rs6142359	ENSG00000126005.14	MMP24-AS1	6.04	2.15e-09	3.43e-07	0.21	0.18	Height;	chr20:35372647	chr20:35216462~35278131:-
BRCA	cis	rs911555	0.755	rs9671414	ENSG00000244691.1	RPL10AP1	6.04	2.15e-09	3.44e-07	0.24	0.18	Intelligence (multi-trait analysis);	chr14:103500962	chr14:103412119~103412761:-
BRCA	cis	rs591584	0.59	rs7107559	ENSG00000255893.1	RP11-685N10.1	6.04	2.15e-09	3.44e-07	0.21	0.18	Macrophage Migration Inhibitory Factor levels;	chr11:94590508	chr11:94472908~94473570:-
BRCA	cis	rs11671005	0.693	rs11669665	ENSG00000252334.1	RNU6-1337P	6.04	2.15e-09	3.44e-07	0.27	0.18	Mean platelet volume;	chr19:58420518	chr19:58483749~58483843:-
BRCA	cis	rs11671005	0.735	rs11881000	ENSG00000252334.1	RNU6-1337P	6.04	2.15e-09	3.44e-07	0.27	0.18	Mean platelet volume;	chr19:58421421	chr19:58483749~58483843:-
BRCA	cis	rs7772486	0.79	rs9791313	ENSG00000270638.1	RP3-466P17.1	-6.04	2.16e-09	3.44e-07	-0.21	-0.18	Lobe attachment (rater-scored or self-reported);	chr6:145945036	chr6:145735570~145737218:+
BRCA	cis	rs2243480	1	rs937108	ENSG00000229886.1	RP5-1132H15.3	6.04	2.16e-09	3.45e-07	0.32	0.18	Diabetic kidney disease;	chr7:65963465	chr7:66025126~66031544:-
BRCA	cis	rs801193	0.548	rs2659904	ENSG00000224316.1	RP11-479O9.2	6.04	2.16e-09	3.45e-07	0.19	0.18	Aortic root size;	chr7:66713615	chr7:65773620~65802067:+
BRCA	cis	rs4660456	0.572	rs1008204	ENSG00000237899.1	RP4-739H11.3	6.04	2.16e-09	3.45e-07	0.23	0.18	Platelet count;	chr1:40700189	chr1:40669089~40687588:-
BRCA	cis	rs4950322	0.57	rs17160051	ENSG00000244371.2	PFN1P8	-6.04	2.16e-09	3.45e-07	-0.25	-0.18	Protein quantitative trait loci;	chr1:147255733	chr1:146957117~146957659:-
BRCA	cis	rs34286592	1	rs3976455	ENSG00000214725.6	CDIPT-AS1	-6.04	2.16e-09	3.45e-07	-0.3	-0.18	Multiple sclerosis;	chr16:29850126	chr16:29863593~29868053:+
BRCA	cis	rs9992667	0.911	rs28360925	ENSG00000231160.8	KLF3-AS1	6.04	2.16e-09	3.45e-07	0.22	0.18	Eosinophil percentage of granulocytes;	chr4:38615676	chr4:38612701~38664883:-
BRCA	cis	rs13113518	0.812	rs12648271	ENSG00000223305.1	RN7SKP30	6.04	2.16e-09	3.45e-07	0.25	0.18	Height;	chr4:55501955	chr4:55540502~55540835:-
BRCA	cis	rs904251	0.772	rs1224127	ENSG00000204110.6	RP1-153P14.8	-6.04	2.16e-09	3.45e-07	-0.22	-0.18	Cognitive performance;	chr6:37449780	chr6:37507348~37535616:+
BRCA	cis	rs67981189	0.865	rs2810071	ENSG00000258571.1	PTTG4P	6.04	2.16e-09	3.45e-07	0.2	0.18	Schizophrenia;	chr14:70920931	chr14:71085482~71085833:-
BRCA	cis	rs8103278	0.507	rs2041975	ENSG00000267395.4	AC074212.6	-6.04	2.16e-09	3.46e-07	-0.19	-0.18	Coronary artery disease;	chr19:45735297	chr19:45767796~45772504:+
BRCA	cis	rs227275	0.525	rs223332	ENSG00000251288.2	RP11-10L12.2	-6.04	2.16e-09	3.46e-07	-0.22	-0.18	Allergic disease (asthma, hay fever or eczema);	chr4:102869029	chr4:102751401~102752641:+
BRCA	cis	rs875971	0.929	rs4122249	ENSG00000224316.1	RP11-479O9.2	6.04	2.16e-09	3.46e-07	0.18	0.18	Aortic root size;	chr7:66455949	chr7:65773620~65802067:+
BRCA	cis	rs1552244	1	rs7648104	ENSG00000180385.7	EMC3-AS1	6.04	2.16e-09	3.46e-07	0.23	0.18	Alzheimer's disease;	chr3:10031627	chr3:9986893~10006990:+
BRCA	cis	rs1552244	1	rs113771705	ENSG00000180385.7	EMC3-AS1	6.04	2.16e-09	3.46e-07	0.23	0.18	Alzheimer's disease;	chr3:10034299	chr3:9986893~10006990:+
BRCA	cis	rs1552244	1	rs17032277	ENSG00000180385.7	EMC3-AS1	6.04	2.16e-09	3.46e-07	0.23	0.18	Alzheimer's disease;	chr3:10035339	chr3:9986893~10006990:+
BRCA	cis	rs1552244	1	rs17032278	ENSG00000180385.7	EMC3-AS1	6.04	2.16e-09	3.46e-07	0.23	0.18	Alzheimer's disease;	chr3:10036271	chr3:9986893~10006990:+
BRCA	cis	rs1552244	1	rs66797209	ENSG00000180385.7	EMC3-AS1	6.04	2.16e-09	3.46e-07	0.23	0.18	Alzheimer's disease;	chr3:10036842	chr3:9986893~10006990:+
BRCA	cis	rs1552244	1	rs7631678	ENSG00000180385.7	EMC3-AS1	6.04	2.16e-09	3.46e-07	0.23	0.18	Alzheimer's disease;	chr3:10037132	chr3:9986893~10006990:+
BRCA	cis	rs853679	0.517	rs6922063	ENSG00000204709.4	LINC01556	6.04	2.16e-09	3.46e-07	0.27	0.18	Depression;	chr6:28126588	chr6:28943877~28944537:+
BRCA	cis	rs853679	0.517	rs2275508	ENSG00000204709.4	LINC01556	6.04	2.16e-09	3.46e-07	0.27	0.18	Depression;	chr6:28126953	chr6:28943877~28944537:+
BRCA	cis	rs4072705	0.605	rs10986358	ENSG00000224020.1	MIR181A2HG	-6.04	2.17e-09	3.46e-07	-0.24	-0.18	Menarche (age at onset);	chr9:124531906	chr9:124658467~124698631:+
BRCA	cis	rs2562456	0.755	rs1879234	ENSG00000268081.1	RP11-678G14.2	-6.04	2.17e-09	3.46e-07	-0.28	-0.18	Pain;	chr19:21521677	chr19:21554640~21569237:-
BRCA	cis	rs1211375	0.628	rs3859141	ENSG00000268836.1	LA16c-OS12.2	6.04	2.17e-09	3.47e-07	0.18	0.18	Mean corpuscular volume;Hematology traits;Mean corpuscular hemoglobin;	chr16:195080	chr16:185748~186294:-
BRCA	cis	rs2280018	1	rs2280017	ENSG00000263335.1	AF001548.5	6.04	2.18e-09	3.47e-07	0.22	0.18	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15057504	chr16:15726674~15732993:+
BRCA	cis	rs867371	1	rs1501372	ENSG00000276710.3	CSPG4P8	-6.04	2.18e-09	3.48e-07	-0.2	-0.18	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82176114	chr15:82459472~82477258:+
BRCA	cis	rs1075265	0.518	rs13414393	ENSG00000272156.1	RP11-477N3.1	-6.04	2.18e-09	3.48e-07	-0.19	-0.18	Chronotype;Morning vs. evening chronotype;	chr2:54048025	chr2:54082554~54085066:+
BRCA	cis	rs34779708	0.931	rs17591135	ENSG00000271335.4	RP11-324I22.4	6.04	2.18e-09	3.48e-07	0.2	0.18	Inflammatory bowel disease;Crohn's disease;	chr10:35176262	chr10:35314552~35336401:-
BRCA	cis	rs6479891	1	rs61853635	ENSG00000232075.1	MRPL35P2	6.04	2.18e-09	3.48e-07	0.33	0.18	Arthritis (juvenile idiopathic);	chr10:63516750	chr10:63634317~63634827:-
BRCA	cis	rs7927771	0.524	rs7114813	ENSG00000280615.1	Y_RNA	6.04	2.19e-09	3.49e-07	0.22	0.18	Subjective well-being;	chr11:47779549	chr11:47614898~47614994:-
BRCA	cis	rs875971	0.651	rs313829	ENSG00000236529.1	RP13-254B10.1	-6.04	2.19e-09	3.49e-07	-0.22	-0.18	Aortic root size;	chr7:66087510	chr7:65840212~65840596:+
BRCA	cis	rs2055375	0.643	rs173946	ENSG00000215032.2	GNL3LP1	6.04	2.19e-09	3.49e-07	0.24	0.18	Intelligence (multi-trait analysis);	chr5:61192470	chr5:60891935~60893577:-
BRCA	cis	rs2980439	0.846	rs2980437	ENSG00000254153.1	CTA-398F10.2	-6.04	2.19e-09	3.49e-07	-0.23	-0.18	Neuroticism;	chr8:8237241	chr8:8456909~8461337:-
BRCA	cis	rs7238033	0.663	rs11082467	ENSG00000267193.4	RP11-116O18.3	6.04	2.19e-09	3.49e-07	0.2	0.18	Bladder cancer;	chr18:45738679	chr18:45669367~45747215:-
BRCA	cis	rs904251	0.861	rs1757173	ENSG00000204110.6	RP1-153P14.8	-6.04	2.19e-09	3.49e-07	-0.2	-0.18	Cognitive performance;	chr6:37519176	chr6:37507348~37535616:+
BRCA	cis	rs17301013	0.507	rs12066700	ENSG00000227373.4	RP11-160H22.5	6.04	2.19e-09	3.49e-07	0.28	0.18	Systemic lupus erythematosus;	chr1:174282054	chr1:174115300~174160004:-
BRCA	cis	rs17301013	0.507	rs12060460	ENSG00000227373.4	RP11-160H22.5	6.04	2.19e-09	3.49e-07	0.28	0.18	Systemic lupus erythematosus;	chr1:174284513	chr1:174115300~174160004:-
BRCA	cis	rs867371	1	rs7173339	ENSG00000276710.3	CSPG4P8	-6.04	2.19e-09	3.49e-07	-0.2	-0.18	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82175253	chr15:82459472~82477258:+
BRCA	cis	rs10899021	1	rs61900636	ENSG00000279353.1	RP11-864N7.4	6.04	2.19e-09	3.5e-07	0.37	0.18	Response to metformin (IC50);	chr11:74648546	chr11:74698231~74699658:-
BRCA	cis	rs2288884	0.708	rs61574510	ENSG00000275055.1	CTC-471J1.11	-6.04	2.19e-09	3.5e-07	-0.25	-0.18	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52017354	chr19:52049007~52049754:+
BRCA	cis	rs2692947	1	rs2692947	ENSG00000237510.6	AC008268.2	6.04	2.2e-09	3.5e-07	0.24	0.18	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96008368	chr2:95789654~95800166:+
BRCA	cis	rs2919009	0.664	rs10510083	ENSG00000271670.1	RP11-95I16.4	6.04	2.2e-09	3.51e-07	0.23	0.18	Obesity-related traits;	chr10:120925013	chr10:120879256~120880667:-
BRCA	cis	rs1876905	0.597	rs354551	ENSG00000271789.1	RP5-1112D6.7	-6.04	2.2e-09	3.51e-07	-0.28	-0.18	Mean corpuscular hemoglobin;	chr6:111224337	chr6:111297126~111298510:+
BRCA	cis	rs11671005	0.735	rs12986387	ENSG00000252334.1	RNU6-1337P	6.04	2.2e-09	3.51e-07	0.27	0.18	Mean platelet volume;	chr19:58415848	chr19:58483749~58483843:-
BRCA	cis	rs11671005	0.735	rs11667723	ENSG00000252334.1	RNU6-1337P	6.04	2.2e-09	3.51e-07	0.27	0.18	Mean platelet volume;	chr19:58416122	chr19:58483749~58483843:-
BRCA	cis	rs11671005	0.735	rs11668789	ENSG00000252334.1	RNU6-1337P	6.04	2.2e-09	3.51e-07	0.27	0.18	Mean platelet volume;	chr19:58416942	chr19:58483749~58483843:-
BRCA	cis	rs6061231	0.837	rs6121558	ENSG00000275437.1	RP5-908M14.10	6.04	2.2e-09	3.51e-07	0.21	0.18	Colorectal cancer;	chr20:62386309	chr20:62402236~62405935:-
BRCA	cis	rs2153535	0.561	rs9405404	ENSG00000230939.1	RP11-314C16.1	-6.04	2.2e-09	3.51e-07	-0.21	-0.18	Motion sickness;	chr6:8646583	chr6:8784178~8785445:+
BRCA	cis	rs13113518	0.812	rs11932712	ENSG00000273257.1	RP11-177J6.1	6.04	2.2e-09	3.51e-07	0.24	0.18	Height;	chr4:55436423	chr4:55387949~55388271:+
BRCA	cis	rs7772486	0.701	rs2244308	ENSG00000270638.1	RP3-466P17.1	6.04	2.2e-09	3.51e-07	0.21	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145892570	chr6:145735570~145737218:+
BRCA	cis	rs7615952	0.515	rs7630575	ENSG00000171084.14	FAM86JP	6.04	2.2e-09	3.51e-07	0.28	0.18	Blood pressure (smoking interaction);	chr3:125963487	chr3:125916620~125930024:+
BRCA	cis	rs7688540	0.771	rs79366248	ENSG00000211553.1	AC253576.2	-6.04	2.2e-09	3.51e-07	-0.29	-0.18	Facial morphology (factor 6, height of vermillion lower lip);	chr4:272870	chr4:136461~136568:+
BRCA	cis	rs4865169	0.871	rs9918067	ENSG00000269949.1	RP11-738E22.3	-6.04	2.2e-09	3.52e-07	-0.21	-0.18	Breast cancer;	chr4:57004378	chr4:56960927~56961373:-
BRCA	cis	rs748404	0.723	rs11853991	ENSG00000205771.5	CATSPER2P1	-6.04	2.2e-09	3.52e-07	-0.23	-0.18	Lung cancer;	chr15:43265351	chr15:43726918~43747094:-
BRCA	cis	rs858239	0.665	rs858305	ENSG00000230042.1	AK3P3	6.04	2.2e-09	3.52e-07	0.21	0.18	Cerebrospinal fluid biomarker levels;	chr7:23203211	chr7:23129178~23129841:+
BRCA	cis	rs754466	0.58	rs10824575	ENSG00000204049.1	RP11-126H7.4	6.03	2.21e-09	3.52e-07	0.22	0.18	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77789289	chr10:77866875~77869610:+
BRCA	cis	rs8114671	0.562	rs2064454	ENSG00000269202.1	RP4-614O4.12	-6.03	2.21e-09	3.53e-07	-0.2	-0.18	Height;	chr20:34908366	chr20:35201747~35203288:-
BRCA	cis	rs1707322	0.964	rs10437063	ENSG00000281133.1	AL355480.3	-6.03	2.21e-09	3.53e-07	-0.23	-0.18	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45807994	chr1:45580892~45580996:-
BRCA	cis	rs1707322	1	rs6676982	ENSG00000281133.1	AL355480.3	-6.03	2.21e-09	3.53e-07	-0.23	-0.18	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45809729	chr1:45580892~45580996:-
BRCA	cis	rs651907	0.557	rs34376498	ENSG00000244119.1	PDCL3P4	6.03	2.21e-09	3.53e-07	0.15	0.18	Colorectal cancer;	chr3:101761312	chr3:101712472~101713191:+
BRCA	cis	rs30380	0.632	rs26491	ENSG00000272109.1	CTD-2260A17.3	-6.03	2.21e-09	3.53e-07	-0.26	-0.18	Cerebrospinal fluid biomarker levels;	chr5:96798410	chr5:96804353~96806105:+
BRCA	cis	rs4803480	0.935	rs1476769	ENSG00000270164.1	LINC01480	-6.03	2.22e-09	3.53e-07	-0.23	-0.18	Schizophrenia;	chr19:41577925	chr19:41535183~41536904:+
BRCA	cis	rs4803480	0.873	rs1476770	ENSG00000270164.1	LINC01480	-6.03	2.22e-09	3.53e-07	-0.23	-0.18	Schizophrenia;	chr19:41578033	chr19:41535183~41536904:+
BRCA	cis	rs7914558	1	rs10748838	ENSG00000213061.2	PFN1P11	6.03	2.22e-09	3.53e-07	0.24	0.18	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103184229	chr10:102838011~102845473:-
BRCA	cis	rs7914558	0.966	rs3758543	ENSG00000213061.2	PFN1P11	6.03	2.22e-09	3.53e-07	0.24	0.18	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103184987	chr10:102838011~102845473:-
BRCA	cis	rs270601	0.77	rs932019	ENSG00000233006.5	AC034220.3	6.03	2.22e-09	3.54e-07	0.14	0.18	Acylcarnitine levels;	chr5:132263677	chr5:132311285~132369916:-
BRCA	cis	rs6442522	0.737	rs905640	ENSG00000249786.6	EAF1-AS1	6.03	2.22e-09	3.54e-07	0.19	0.18	Uric acid levels;	chr3:15454333	chr3:15436171~15455940:-
BRCA	cis	rs7824557	0.614	rs2736286	ENSG00000154316.13	TDH	6.03	2.22e-09	3.54e-07	0.23	0.18	Retinal vascular caliber;	chr8:11369595	chr8:11339637~11368452:+
BRCA	cis	rs12655019	0.92	rs12654125	ENSG00000271828.1	CTD-2310F14.1	6.03	2.22e-09	3.54e-07	0.34	0.18	Breast cancer (early onset);	chr5:56919926	chr5:56927874~56929573:+
BRCA	cis	rs7976269	0.609	rs4931141	ENSG00000275476.1	RP11-996F15.4	-6.03	2.22e-09	3.54e-07	-0.21	-0.18	Male-pattern baldness;	chr12:29057763	chr12:29277397~29277882:-
BRCA	cis	rs7809950	0.678	rs2237659	ENSG00000238832.1	snoU109	6.03	2.22e-09	3.54e-07	0.28	0.18	Coronary artery disease;	chr7:107207047	chr7:107603363~107603507:+
BRCA	cis	rs6479891	1	rs7099425	ENSG00000232075.1	MRPL35P2	-6.03	2.22e-09	3.55e-07	-0.32	-0.18	Arthritis (juvenile idiopathic);	chr10:63200957	chr10:63634317~63634827:-
BRCA	cis	rs6479891	1	rs4746119	ENSG00000232075.1	MRPL35P2	6.03	2.22e-09	3.55e-07	0.33	0.18	Arthritis (juvenile idiopathic);	chr10:63370157	chr10:63634317~63634827:-
BRCA	cis	rs754466	0.58	rs11002294	ENSG00000204049.1	RP11-126H7.4	6.03	2.23e-09	3.55e-07	0.22	0.18	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77780830	chr10:77866875~77869610:+
BRCA	cis	rs2153535	0.585	rs2224480	ENSG00000230939.1	RP11-314C16.1	-6.03	2.23e-09	3.55e-07	-0.21	-0.18	Motion sickness;	chr6:8647646	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.518	rs6912560	ENSG00000230939.1	RP11-314C16.1	-6.03	2.23e-09	3.55e-07	-0.22	-0.18	Motion sickness;	chr6:8563878	chr6:8784178~8785445:+
BRCA	cis	rs4718428	0.705	rs62465692	ENSG00000230295.1	RP11-458F8.2	-6.03	2.23e-09	3.55e-07	-0.17	-0.18	Corneal structure;	chr7:66830758	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs316330	ENSG00000228409.4	CCT6P1	6.03	2.23e-09	3.56e-07	0.26	0.18	Diabetic kidney disease;	chr7:66140385	chr7:65751142~65763354:+
BRCA	cis	rs67311347	1	rs17078941	ENSG00000280739.1	EIF1B-AS1	-6.03	2.23e-09	3.56e-07	-0.22	-0.18	Renal cell carcinoma;	chr3:40409397	chr3:40173145~40309698:-
BRCA	cis	rs10129255	0.957	rs12589190	ENSG00000211972.2	IGHV3-66	6.03	2.23e-09	3.56e-07	0.14	0.18	Kawasaki disease;	chr14:106783079	chr14:106675017~106675544:-
BRCA	cis	rs9341808	0.556	rs2223875	ENSG00000272129.1	RP11-250B2.6	6.03	2.23e-09	3.56e-07	0.22	0.18	Sitting height ratio;	chr6:80335735	chr6:80355424~80356859:+
BRCA	cis	rs9341808	0.587	rs3805859	ENSG00000272129.1	RP11-250B2.6	6.03	2.23e-09	3.56e-07	0.22	0.18	Sitting height ratio;	chr6:80339229	chr6:80355424~80356859:+
BRCA	cis	rs7618501	0.521	rs34654589	ENSG00000228008.1	CTD-2330K9.3	6.03	2.24e-09	3.56e-07	0.18	0.18	Intelligence (multi-trait analysis);	chr3:49874016	chr3:49903845~49916937:+
BRCA	cis	rs11668609	0.872	rs4416149	ENSG00000268442.1	CTD-2027I19.2	6.03	2.24e-09	3.57e-07	0.25	0.18	Response to taxane treatment (docetaxel);	chr19:24093551	chr19:24162370~24163425:-
BRCA	cis	rs67981189	0.529	rs2526850	ENSG00000258571.1	PTTG4P	6.03	2.24e-09	3.57e-07	0.21	0.18	Schizophrenia;	chr14:70950532	chr14:71085482~71085833:-
BRCA	cis	rs853679	0.517	rs1340004	ENSG00000204709.4	LINC01556	6.03	2.24e-09	3.57e-07	0.27	0.18	Depression;	chr6:28135913	chr6:28943877~28944537:+
BRCA	cis	rs5015933	0.815	rs12553785	ENSG00000232630.1	PRPS1P2	-6.03	2.24e-09	3.57e-07	-0.17	-0.18	Body mass index;	chr9:125314262	chr9:125150653~125151589:+
BRCA	cis	rs34779708	0.931	rs17582416	ENSG00000271335.4	RP11-324I22.4	6.03	2.24e-09	3.57e-07	0.19	0.18	Inflammatory bowel disease;Crohn's disease;	chr10:34998722	chr10:35314552~35336401:-
BRCA	cis	rs7772486	0.875	rs864390	ENSG00000270638.1	RP3-466P17.1	6.03	2.24e-09	3.58e-07	0.21	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145993899	chr6:145735570~145737218:+
BRCA	cis	rs13126694	0.778	rs6814979	ENSG00000248429.4	RP11-597D13.9	-6.03	2.25e-09	3.58e-07	-0.16	-0.18	Blood osmolality (transformed sodium);	chr4:158135798	chr4:158170752~158202877:+
BRCA	cis	rs2842992	1	rs2758322	ENSG00000237927.1	RP3-393E18.2	-6.03	2.25e-09	3.58e-07	-0.26	-0.18	Age-related macular degeneration (geographic atrophy);	chr6:159654156	chr6:159586955~159589169:-
BRCA	cis	rs858239	0.669	rs6461687	ENSG00000230042.1	AK3P3	-6.03	2.25e-09	3.58e-07	-0.21	-0.18	Cerebrospinal fluid biomarker levels;	chr7:23076961	chr7:23129178~23129841:+
BRCA	cis	rs62103177	0.81	rs62103195	ENSG00000261126.6	RP11-795F19.1	6.03	2.25e-09	3.58e-07	0.3	0.18	Opioid sensitivity;	chr18:79869693	chr18:80046900~80095482:+
BRCA	cis	rs73198271	0.74	rs1039910	ENSG00000253893.2	FAM85B	6.03	2.25e-09	3.58e-07	0.25	0.18	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8790556	chr8:8167819~8226614:-
BRCA	cis	rs13178541	0.641	rs2345448	ENSG00000250378.1	RP11-119J18.1	6.03	2.25e-09	3.59e-07	0.24	0.18	IgG glycosylation;	chr5:135804128	chr5:135812667~135826582:+
BRCA	cis	rs9308731	0.666	rs4849402	ENSG00000227992.1	AC108463.2	-6.03	2.25e-09	3.59e-07	-0.21	-0.18	Chronic lymphocytic leukemia;	chr2:111116355	chr2:111203964~111206215:-
BRCA	cis	rs853679	0.517	rs9468297	ENSG00000204709.4	LINC01556	6.03	2.25e-09	3.59e-07	0.28	0.18	Depression;	chr6:28151096	chr6:28943877~28944537:+
BRCA	cis	rs2274273	1	rs66871576	ENSG00000258413.1	RP11-665C16.6	-6.03	2.25e-09	3.59e-07	-0.23	-0.18	Protein biomarker;	chr14:55162332	chr14:55262767~55272075:-
BRCA	cis	rs67311347	0.869	rs9832311	ENSG00000280739.1	EIF1B-AS1	6.03	2.25e-09	3.59e-07	0.2	0.18	Renal cell carcinoma;	chr3:40339831	chr3:40173145~40309698:-
BRCA	cis	rs9308731	0.644	rs4849403	ENSG00000227992.1	AC108463.2	-6.03	2.25e-09	3.59e-07	-0.21	-0.18	Chronic lymphocytic leukemia;	chr2:111116460	chr2:111203964~111206215:-
BRCA	cis	rs2348418	0.831	rs7296538	ENSG00000247934.4	RP11-967K21.1	-6.03	2.26e-09	3.6e-07	-0.2	-0.18	Lung function (FEV1);Lung function (FVC);	chr12:28558850	chr12:28163298~28190738:-
BRCA	cis	rs793571	0.554	rs12906714	ENSG00000259250.1	RP11-50C13.1	-6.03	2.26e-09	3.6e-07	-0.32	-0.18	Schizophrenia;	chr15:58632821	chr15:58587507~58591676:+
BRCA	cis	rs7520050	0.966	rs11589562	ENSG00000280836.1	AL355480.1	-6.03	2.26e-09	3.6e-07	-0.22	-0.18	Reticulocyte count;Red blood cell count;	chr1:46001049	chr1:45581219~45581321:-
BRCA	cis	rs45509595	0.841	rs370155	ENSG00000220721.1	OR1F12	6.03	2.26e-09	3.61e-07	0.32	0.18	Breast cancer;	chr6:27814253	chr6:28073316~28074233:+
BRCA	cis	rs6928977	0.5	rs3734213	ENSG00000231028.7	LINC00271	-6.03	2.27e-09	3.61e-07	-0.19	-0.18	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135620170	chr6:135497801~135716055:+
BRCA	cis	rs7246967	0.673	rs8103012	ENSG00000198153.8	ZNF849P	-6.03	2.27e-09	3.62e-07	-0.27	-0.18	Bronchopulmonary dysplasia;	chr19:22696483	chr19:22685167~22686732:+
BRCA	cis	rs4713118	0.824	rs9366702	ENSG00000220721.1	OR1F12	6.03	2.27e-09	3.62e-07	0.23	0.18	Parkinson's disease;	chr6:27766691	chr6:28073316~28074233:+
BRCA	cis	rs950169	0.579	rs12912716	ENSG00000259728.4	LINC00933	6.03	2.27e-09	3.62e-07	0.27	0.18	Schizophrenia;	chr15:83995511	chr15:84570649~84580175:+
BRCA	cis	rs2243480	1	rs1723270	ENSG00000230295.1	RP11-458F8.2	-6.03	2.27e-09	3.62e-07	-0.24	-0.18	Diabetic kidney disease;	chr7:66004843	chr7:66880708~66882981:+
BRCA	cis	rs6479891	1	rs9414780	ENSG00000232075.1	MRPL35P2	6.03	2.27e-09	3.62e-07	0.32	0.18	Arthritis (juvenile idiopathic);	chr10:63241673	chr10:63634317~63634827:-
BRCA	cis	rs6479891	1	rs7070052	ENSG00000232075.1	MRPL35P2	-6.03	2.27e-09	3.62e-07	-0.32	-0.18	Arthritis (juvenile idiopathic);	chr10:63144054	chr10:63634317~63634827:-
BRCA	cis	rs1124769	0.672	rs12591438	ENSG00000259378.1	DCAF13P3	6.03	2.28e-09	3.63e-07	0.26	0.18	Cognitive performance;	chr15:50850995	chr15:50944663~50945996:+
BRCA	cis	rs2288884	0.767	rs3752119	ENSG00000275055.1	CTC-471J1.11	-6.03	2.28e-09	3.63e-07	-0.26	-0.18	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52048245	chr19:52049007~52049754:+
BRCA	cis	rs2834288	0.5	rs766423	ENSG00000273102.1	AP000569.9	6.03	2.28e-09	3.63e-07	0.21	0.18	Gut microbiota (bacterial taxa);	chr21:33962711	chr21:33967101~33968573:-
BRCA	cis	rs2243480	1	rs13310597	ENSG00000228409.4	CCT6P1	6.03	2.28e-09	3.63e-07	0.26	0.18	Diabetic kidney disease;	chr7:66133553	chr7:65751142~65763354:+
BRCA	cis	rs673078	0.607	rs17512483	ENSG00000275409.1	RP11-131L12.4	6.03	2.28e-09	3.64e-07	0.29	0.18	Glucose homeostasis traits;	chr12:118312380	chr12:118430147~118430699:+
BRCA	cis	rs1552244	1	rs7651058	ENSG00000180385.7	EMC3-AS1	6.03	2.28e-09	3.64e-07	0.23	0.18	Alzheimer's disease;	chr3:10025280	chr3:9986893~10006990:+
BRCA	cis	rs910316	1	rs2098297	ENSG00000279594.1	RP11-950C14.10	-6.03	2.29e-09	3.64e-07	-0.2	-0.18	Height;	chr14:75152415	chr14:75011269~75012851:-
BRCA	cis	rs2911132	0.506	rs7705827	ENSG00000248734.2	CTD-2260A17.1	6.03	2.29e-09	3.64e-07	0.22	0.18	Urate levels (BMI interaction);	chr5:96746729	chr5:96784777~96785999:+
BRCA	cis	rs227275	0.556	rs4235407	ENSG00000251288.2	RP11-10L12.2	-6.03	2.29e-09	3.64e-07	-0.22	-0.18	Allergic disease (asthma, hay fever or eczema);	chr4:102897427	chr4:102751401~102752641:+
BRCA	cis	rs7618501	0.521	rs11130222	ENSG00000228008.1	CTD-2330K9.3	6.03	2.29e-09	3.65e-07	0.18	0.18	Intelligence (multi-trait analysis);	chr3:49863627	chr3:49903845~49916937:+
BRCA	cis	rs227275	0.525	rs3974604	ENSG00000251288.2	RP11-10L12.2	-6.03	2.29e-09	3.65e-07	-0.22	-0.18	Allergic disease (asthma, hay fever or eczema);	chr4:102928601	chr4:102751401~102752641:+
BRCA	cis	rs1552244	1	rs76041173	ENSG00000180385.7	EMC3-AS1	6.03	2.29e-09	3.65e-07	0.23	0.18	Alzheimer's disease;	chr3:10037011	chr3:9986893~10006990:+
BRCA	cis	rs7045881	0.61	rs62542672	ENSG00000254396.1	RP11-56F10.3	6.03	2.3e-09	3.65e-07	0.32	0.18	Schizophrenia;	chr9:27022938	chr9:27102630~27104728:+
BRCA	cis	rs944990	0.557	rs952288	ENSG00000227603.1	RP11-165J3.6	6.03	2.3e-09	3.66e-07	0.19	0.18	Body mass index;	chr9:93502629	chr9:93435332~93437121:-
BRCA	cis	rs2665103	0.589	rs3858953	ENSG00000255769.6	GOLGA2P10	-6.03	2.3e-09	3.66e-07	-0.2	-0.18	Intelligence (multi-trait analysis);	chr15:82238049	chr15:82472993~82513950:-
BRCA	cis	rs34792	0.688	rs153782	ENSG00000207425.1	Y_RNA	6.03	2.3e-09	3.66e-07	0.22	0.18	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15507763	chr16:14915457~14915556:-
BRCA	cis	rs4713118	0.516	rs7739216	ENSG00000204709.4	LINC01556	6.03	2.3e-09	3.66e-07	0.27	0.18	Parkinson's disease;	chr6:28112168	chr6:28943877~28944537:+
BRCA	cis	rs853679	0.517	rs35512245	ENSG00000204709.4	LINC01556	6.03	2.3e-09	3.66e-07	0.27	0.18	Depression;	chr6:28112175	chr6:28943877~28944537:+
BRCA	cis	rs11098499	0.575	rs9996586	ENSG00000245958.5	RP11-33B1.1	-6.03	2.3e-09	3.66e-07	-0.16	-0.18	Corneal astigmatism;	chr4:119405787	chr4:119454791~119552025:+
BRCA	cis	rs17301013	0.507	rs16846861	ENSG00000227373.4	RP11-160H22.5	6.03	2.3e-09	3.66e-07	0.27	0.18	Systemic lupus erythematosus;	chr1:174338731	chr1:174115300~174160004:-
BRCA	cis	rs1552244	1	rs6786638	ENSG00000180385.7	EMC3-AS1	6.03	2.3e-09	3.66e-07	0.23	0.18	Alzheimer's disease;	chr3:10076391	chr3:9986893~10006990:+
BRCA	cis	rs2243480	1	rs2462569	ENSG00000164669.11	INTS4P1	-6.03	2.3e-09	3.67e-07	-0.34	-0.18	Diabetic kidney disease;	chr7:66009859	chr7:65141225~65234216:+
BRCA	cis	rs67981189	0.858	rs17108877	ENSG00000258571.1	PTTG4P	-6.03	2.3e-09	3.67e-07	-0.2	-0.18	Schizophrenia;	chr14:71007092	chr14:71085482~71085833:-
BRCA	cis	rs8002861	0.935	rs7319725	ENSG00000274001.1	RP11-5G9.5	6.03	2.3e-09	3.67e-07	0.2	0.18	Leprosy;	chr13:43871285	chr13:43877715~43878163:-
BRCA	cis	rs1576263	0.504	rs1854411	ENSG00000230939.1	RP11-314C16.1	-6.03	2.31e-09	3.67e-07	-0.22	-0.18	Photic sneeze reflex;	chr6:8545771	chr6:8784178~8785445:+
BRCA	cis	rs2644899	0.859	rs2604893	ENSG00000268529.1	CYP2T3P	6.03	2.31e-09	3.67e-07	0.25	0.18	Post bronchodilator FEV1/FVC ratio;	chr19:40787638	chr19:41134722~41137308:+
BRCA	cis	rs2153535	0.585	rs9379238	ENSG00000230939.1	RP11-314C16.1	-6.03	2.31e-09	3.67e-07	-0.21	-0.18	Motion sickness;	chr6:8667806	chr6:8784178~8785445:+
BRCA	cis	rs13126694	0.744	rs7691516	ENSG00000248429.4	RP11-597D13.9	6.03	2.31e-09	3.67e-07	0.17	0.18	Blood osmolality (transformed sodium);	chr4:158073326	chr4:158170752~158202877:+
BRCA	cis	rs875971	0.825	rs7384021	ENSG00000224316.1	RP11-479O9.2	-6.03	2.31e-09	3.67e-07	-0.19	-0.18	Aortic root size;	chr7:66612917	chr7:65773620~65802067:+
BRCA	cis	rs2337406	0.587	rs10139664	ENSG00000254174.1	IGHV1-12	6.03	2.31e-09	3.68e-07	0.19	0.18	Alzheimer's disease (late onset);	chr14:106647254	chr14:106122420~106122709:-
BRCA	cis	rs7617773	0.746	rs11713476	ENSG00000228638.1	FCF1P2	-6.03	2.31e-09	3.68e-07	-0.2	-0.18	Coronary artery disease;	chr3:48333944	chr3:48290793~48291375:-
BRCA	cis	rs2638953	0.924	rs11049439	ENSG00000247934.4	RP11-967K21.1	-6.03	2.31e-09	3.68e-07	-0.24	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28196369	chr12:28163298~28190738:-
BRCA	cis	rs2732480	0.577	rs2634684	ENSG00000257763.1	OR5BK1P	-6.03	2.32e-09	3.69e-07	-0.2	-0.18	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48337092	chr12:48355792~48356614:-
BRCA	cis	rs754466	0.58	rs12357670	ENSG00000204049.1	RP11-126H7.4	6.03	2.32e-09	3.69e-07	0.22	0.18	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77798422	chr10:77866875~77869610:+
BRCA	cis	rs875971	0.545	rs4718348	ENSG00000273024.4	INTS4P2	-6.03	2.32e-09	3.69e-07	-0.23	-0.18	Aortic root size;	chr7:66441589	chr7:65647864~65715661:+
BRCA	cis	rs7124681	0.584	rs12226590	ENSG00000280615.1	Y_RNA	6.03	2.32e-09	3.69e-07	0.22	0.18	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:47550256	chr11:47614898~47614994:-
BRCA	cis	rs4950322	0.543	rs4453096	ENSG00000244371.2	PFN1P8	-6.03	2.32e-09	3.69e-07	-0.26	-0.18	Protein quantitative trait loci;	chr1:147316574	chr1:146957117~146957659:-
BRCA	cis	rs11096990	0.964	rs9998591	ENSG00000249207.1	RP11-360F5.1	-6.03	2.32e-09	3.69e-07	-0.22	-0.18	Cognitive function;	chr4:39240491	chr4:39112677~39126818:-
BRCA	cis	rs9341808	0.5	rs2223873	ENSG00000272129.1	RP11-250B2.6	6.03	2.32e-09	3.69e-07	0.22	0.18	Sitting height ratio;	chr6:80338571	chr6:80355424~80356859:+
BRCA	cis	rs9649213	0.593	rs6967576	ENSG00000272950.1	RP11-307C18.1	-6.03	2.32e-09	3.7e-07	-0.23	-0.18	Prostate cancer (SNP x SNP interaction);	chr7:98387061	chr7:98322853~98323430:+
BRCA	cis	rs2115630	0.791	rs2008262	ENSG00000229212.6	RP11-561C5.4	6.03	2.32e-09	3.7e-07	0.21	0.18	P wave terminal force;	chr15:84762039	chr15:85205440~85234795:-
BRCA	cis	rs7620503	1	rs6805429	ENSG00000228221.4	LINC00578	6.03	2.32e-09	3.7e-07	0.21	0.18	Corneal structure;	chr3:177581481	chr3:177441921~177752305:+
BRCA	cis	rs13113518	0.841	rs7699867	ENSG00000273257.1	RP11-177J6.1	6.03	2.32e-09	3.7e-07	0.24	0.18	Height;	chr4:55483718	chr4:55387949~55388271:+
BRCA	cis	rs227275	0.554	rs9307281	ENSG00000251288.2	RP11-10L12.2	-6.03	2.33e-09	3.7e-07	-0.21	-0.18	Allergic disease (asthma, hay fever or eczema);	chr4:102934971	chr4:102751401~102752641:+
BRCA	cis	rs11722779	0.903	rs6533037	ENSG00000251288.2	RP11-10L12.2	-6.03	2.33e-09	3.7e-07	-0.21	-0.18	Schizophrenia;	chr4:102935865	chr4:102751401~102752641:+
BRCA	cis	rs11722779	0.903	rs4530634	ENSG00000251288.2	RP11-10L12.2	-6.03	2.33e-09	3.7e-07	-0.21	-0.18	Schizophrenia;	chr4:102937924	chr4:102751401~102752641:+
BRCA	cis	rs227275	0.525	rs7676943	ENSG00000251288.2	RP11-10L12.2	-6.03	2.33e-09	3.7e-07	-0.21	-0.18	Allergic disease (asthma, hay fever or eczema);	chr4:102938135	chr4:102751401~102752641:+
BRCA	cis	rs227275	0.525	rs6419160	ENSG00000251288.2	RP11-10L12.2	-6.03	2.33e-09	3.7e-07	-0.21	-0.18	Allergic disease (asthma, hay fever or eczema);	chr4:102938648	chr4:102751401~102752641:+
BRCA	cis	rs11722779	0.838	rs3974494	ENSG00000251288.2	RP11-10L12.2	-6.03	2.33e-09	3.7e-07	-0.21	-0.18	Schizophrenia;	chr4:102945323	chr4:102751401~102752641:+
BRCA	cis	rs7914558	1	rs3740387	ENSG00000213061.2	PFN1P11	6.03	2.33e-09	3.7e-07	0.24	0.18	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103089711	chr10:102838011~102845473:-
BRCA	cis	rs12655019	0.92	rs2271202	ENSG00000271828.1	CTD-2310F14.1	6.03	2.33e-09	3.7e-07	0.34	0.18	Breast cancer (early onset);	chr5:56912714	chr5:56927874~56929573:+
BRCA	cis	rs7238033	0.663	rs11877630	ENSG00000267193.4	RP11-116O18.3	6.03	2.33e-09	3.71e-07	0.2	0.18	Bladder cancer;	chr18:45738012	chr18:45669367~45747215:-
BRCA	cis	rs10129255	1	rs11621409	ENSG00000224373.3	IGHV4-59	6.03	2.33e-09	3.71e-07	0.13	0.18	Kawasaki disease;	chr14:106695603	chr14:106627249~106627825:-
BRCA	cis	rs1823913	0.599	rs17511410	ENSG00000280083.1	RP11-317J9.1	-6.03	2.34e-09	3.72e-07	-0.21	-0.18	Obesity-related traits;	chr2:191278043	chr2:191154118~191156070:-
BRCA	cis	rs1476670	0.683	rs813642	ENSG00000230615.5	RP5-1198O20.4	-6.03	2.34e-09	3.72e-07	-0.27	-0.18	Eotaxin levels;	chr1:44040748	chr1:44030443~44115913:+
BRCA	cis	rs6570726	0.967	rs418662	ENSG00000235652.6	RP11-545I5.3	6.03	2.34e-09	3.72e-07	0.18	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145527696	chr6:145799409~145886585:+
BRCA	cis	rs67981189	0.821	rs8007026	ENSG00000258571.1	PTTG4P	-6.03	2.34e-09	3.72e-07	-0.2	-0.18	Schizophrenia;	chr14:70997667	chr14:71085482~71085833:-
BRCA	cis	rs8030379	1	rs4842923	ENSG00000230373.7	GOLGA6L5P	-6.03	2.34e-09	3.72e-07	-0.2	-0.18	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83913152	chr15:84507885~84516814:-
BRCA	cis	rs59169624	0.662	rs1648228	ENSG00000255160.4	RP11-428C19.5	-6.02	2.34e-09	3.73e-07	-0.25	-0.18	Parental extreme longevity (95 years and older);	chr11:19267837	chr11:19299883~19308358:+
BRCA	cis	rs2243480	1	rs2533288	ENSG00000232559.3	GS1-124K5.12	6.02	2.34e-09	3.73e-07	0.35	0.18	Diabetic kidney disease;	chr7:66591724	chr7:66554588~66576923:-
BRCA	cis	rs7914558	1	rs7911789	ENSG00000213061.2	PFN1P11	6.02	2.35e-09	3.73e-07	0.24	0.18	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102996617	chr10:102838011~102845473:-
BRCA	cis	rs853679	0.517	rs1947863	ENSG00000204709.4	LINC01556	6.02	2.35e-09	3.73e-07	0.27	0.18	Depression;	chr6:28131566	chr6:28943877~28944537:+
BRCA	cis	rs17253792	0.545	rs12893061	ENSG00000186615.9	KTN1-AS1	-6.02	2.35e-09	3.74e-07	-0.37	-0.18	Putamen volume;	chr14:55549379	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.545	rs12893676	ENSG00000186615.9	KTN1-AS1	-6.02	2.35e-09	3.74e-07	-0.37	-0.18	Putamen volume;	chr14:55549441	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.545	rs12894613	ENSG00000186615.9	KTN1-AS1	-6.02	2.35e-09	3.74e-07	-0.37	-0.18	Putamen volume;	chr14:55549503	chr14:55499278~55580110:-
BRCA	cis	rs10129255	0.957	rs8019272	ENSG00000211972.2	IGHV3-66	6.02	2.35e-09	3.74e-07	0.14	0.18	Kawasaki disease;	chr14:106784709	chr14:106675017~106675544:-
BRCA	cis	rs2098713	0.535	rs11748123	ENSG00000250155.1	CTD-2353F22.1	6.02	2.35e-09	3.74e-07	0.2	0.18	Telomere length;	chr5:37575317	chr5:36666214~36725195:-
BRCA	cis	rs9341808	0.727	rs9361599	ENSG00000272129.1	RP11-250B2.6	6.02	2.35e-09	3.74e-07	0.22	0.18	Sitting height ratio;	chr6:80315525	chr6:80355424~80356859:+
BRCA	cis	rs459482	0.508	rs461093	ENSG00000228318.3	AP001610.5	6.02	2.35e-09	3.74e-07	0.21	0.18	IgG glycosylation;	chr21:41428263	chr21:41441056~41445708:-
BRCA	cis	rs10510102	0.872	rs11200267	ENSG00000226864.1	ATE1-AS1	6.02	2.35e-09	3.74e-07	0.33	0.18	Breast cancer;	chr10:121929851	chr10:121928312~121951965:+
BRCA	cis	rs853679	0.513	rs9468296	ENSG00000204709.4	LINC01556	6.02	2.36e-09	3.75e-07	0.27	0.18	Depression;	chr6:28145952	chr6:28943877~28944537:+
BRCA	cis	rs867371	1	rs13380317	ENSG00000276710.3	CSPG4P8	6.02	2.36e-09	3.75e-07	0.19	0.18	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82214449	chr15:82459472~82477258:+
BRCA	cis	rs75422866	0.867	rs73102140	ENSG00000280054.1	RP1-197B17.7	6.02	2.36e-09	3.75e-07	0.46	0.18	Pneumonia;	chr12:47647497	chr12:47728151~47730598:-
BRCA	cis	rs75422866	0.867	rs73102148	ENSG00000280054.1	RP1-197B17.7	6.02	2.36e-09	3.75e-07	0.46	0.18	Pneumonia;	chr12:47648013	chr12:47728151~47730598:-
BRCA	cis	rs75422866	0.867	rs73102151	ENSG00000280054.1	RP1-197B17.7	6.02	2.36e-09	3.75e-07	0.46	0.18	Pneumonia;	chr12:47648023	chr12:47728151~47730598:-
BRCA	cis	rs5758659	0.716	rs86669	ENSG00000281538.1	RP4-669P10.20	6.02	2.36e-09	3.75e-07	0.18	0.18	Cognitive function;	chr22:42284794	chr22:42138060~42139726:+
BRCA	cis	rs7976269	0.559	rs4930848	ENSG00000275476.1	RP11-996F15.4	-6.02	2.36e-09	3.76e-07	-0.21	-0.18	Male-pattern baldness;	chr12:29068441	chr12:29277397~29277882:-
BRCA	cis	rs9545047	0.604	rs1856997	ENSG00000227354.5	RBM26-AS1	6.02	2.37e-09	3.76e-07	0.21	0.18	Schizophrenia;	chr13:79287487	chr13:79406309~79424328:+
BRCA	cis	rs1552244	1	rs58275763	ENSG00000180385.7	EMC3-AS1	6.02	2.37e-09	3.76e-07	0.23	0.18	Alzheimer's disease;	chr3:10101590	chr3:9986893~10006990:+
BRCA	cis	rs67340775	0.541	rs200966	ENSG00000220721.1	OR1F12	6.02	2.37e-09	3.76e-07	0.27	0.18	Lung cancer in ever smokers;	chr6:27894374	chr6:28073316~28074233:+
BRCA	cis	rs11668609	1	rs919812	ENSG00000268442.1	CTD-2027I19.2	6.02	2.37e-09	3.77e-07	0.25	0.18	Response to taxane treatment (docetaxel);	chr19:24163425	chr19:24162370~24163425:-
BRCA	cis	rs6840258	1	rs17012234	ENSG00000251411.1	RP11-397E7.4	6.02	2.37e-09	3.77e-07	0.24	0.18	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86990539	chr4:86913266~86914817:-
BRCA	cis	rs1440410	0.798	rs11724872	ENSG00000250326.1	RP11-284M14.1	-6.02	2.37e-09	3.77e-07	-0.2	-0.18	Ischemic stroke;	chr4:143219512	chr4:142933195~143184861:-
BRCA	cis	rs227275	0.554	rs223363	ENSG00000251288.2	RP11-10L12.2	-6.02	2.37e-09	3.77e-07	-0.21	-0.18	Allergic disease (asthma, hay fever or eczema);	chr4:102846182	chr4:102751401~102752641:+
BRCA	cis	rs11098499	1	rs11726229	ENSG00000249244.1	RP11-548H18.2	6.02	2.37e-09	3.77e-07	0.22	0.18	Corneal astigmatism;	chr4:119290425	chr4:119391831~119395335:-
BRCA	cis	rs295490	0.748	rs77327267	ENSG00000272656.1	RP11-219D15.3	6.02	2.37e-09	3.77e-07	0.43	0.18	PR interval in Tripanosoma cruzi seropositivity;	chr3:139341667	chr3:139349024~139349371:-
BRCA	cis	rs1440410	0.798	rs1440416	ENSG00000250326.1	RP11-284M14.1	-6.02	2.38e-09	3.77e-07	-0.2	-0.18	Ischemic stroke;	chr4:143233882	chr4:142933195~143184861:-
BRCA	cis	rs755249	0.567	rs3768302	ENSG00000237624.1	OXCT2P1	6.02	2.38e-09	3.77e-07	0.27	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39414647	chr1:39514956~39516490:+
BRCA	cis	rs1707322	1	rs4660905	ENSG00000281133.1	AL355480.3	6.02	2.38e-09	3.78e-07	0.23	0.18	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45995915	chr1:45580892~45580996:-
BRCA	cis	rs4654783	0.671	rs3765351	ENSG00000228397.1	RP1-224A6.3	6.02	2.39e-09	3.8e-07	0.23	0.18	Endometriosis;	chr1:22119498	chr1:22023994~22024968:-
BRCA	cis	rs6142102	0.659	rs6057945	ENSG00000275784.1	RP5-1125A11.6	-6.02	2.4e-09	3.81e-07	-0.22	-0.18	Skin pigmentation;	chr20:33929374	chr20:33989480~33991818:-
BRCA	cis	rs4865169	0.967	rs10023088	ENSG00000269949.1	RP11-738E22.3	6.02	2.4e-09	3.81e-07	0.21	0.18	Breast cancer;	chr4:57018269	chr4:56960927~56961373:-
BRCA	cis	rs9890032	1	rs9890032	ENSG00000263531.1	RP13-753N3.1	-6.02	2.4e-09	3.81e-07	-0.23	-0.18	Hip circumference adjusted for BMI;	chr17:30838916	chr17:30863921~30864940:-
BRCA	cis	rs7809950	0.817	rs2712224	ENSG00000238832.1	snoU109	-6.02	2.4e-09	3.81e-07	-0.27	-0.18	Coronary artery disease;	chr7:107540790	chr7:107603363~107603507:+
BRCA	cis	rs8114671	0.836	rs2425012	ENSG00000269202.1	RP4-614O4.12	6.02	2.4e-09	3.81e-07	0.19	0.18	Height;	chr20:34994152	chr20:35201747~35203288:-
BRCA	cis	rs10829156	0.625	rs10828906	ENSG00000240291.1	RP11-499P20.2	6.02	2.4e-09	3.81e-07	0.2	0.18	Sudden cardiac arrest;	chr10:18552866	chr10:18513115~18545651:-
BRCA	cis	rs2243480	1	rs160643	ENSG00000232546.1	RP11-458F8.1	-6.02	2.4e-09	3.82e-07	-0.23	-0.18	Diabetic kidney disease;	chr7:66093235	chr7:66848496~66858136:+
BRCA	cis	rs875971	1	rs7781698	ENSG00000224316.1	RP11-479O9.2	6.02	2.4e-09	3.82e-07	0.18	0.18	Aortic root size;	chr7:66431325	chr7:65773620~65802067:+
BRCA	cis	rs919433	0.68	rs12621129	ENSG00000231621.1	AC013264.2	6.02	2.4e-09	3.82e-07	0.18	0.18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197400626	chr2:197197991~197199273:+
BRCA	cis	rs2278702	0.943	rs3743408	ENSG00000259495.2	RP11-210M15.2	6.02	2.4e-09	3.82e-07	0.25	0.18	Bipolar disorder;	chr15:80397993	chr15:80344853~80403575:-
BRCA	cis	rs7520050	0.898	rs34175029	ENSG00000280836.1	AL355480.1	6.02	2.41e-09	3.82e-07	0.21	0.18	Reticulocyte count;Red blood cell count;	chr1:46018199	chr1:45581219~45581321:-
BRCA	cis	rs6570726	0.846	rs4896824	ENSG00000270638.1	RP3-466P17.1	6.02	2.41e-09	3.83e-07	0.21	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145605912	chr6:145735570~145737218:+
BRCA	cis	rs4713118	0.662	rs464312	ENSG00000219392.1	RP1-265C24.5	-6.02	2.41e-09	3.83e-07	-0.27	-0.18	Parkinson's disease;	chr6:27999813	chr6:28115628~28116551:+
BRCA	cis	rs4713118	0.662	rs469228	ENSG00000219392.1	RP1-265C24.5	-6.02	2.41e-09	3.83e-07	-0.27	-0.18	Parkinson's disease;	chr6:28002926	chr6:28115628~28116551:+
BRCA	cis	rs4713118	0.54	rs469227	ENSG00000219392.1	RP1-265C24.5	-6.02	2.41e-09	3.83e-07	-0.27	-0.18	Parkinson's disease;	chr6:28002927	chr6:28115628~28116551:+
BRCA	cis	rs4713118	0.662	rs149948	ENSG00000219392.1	RP1-265C24.5	-6.02	2.41e-09	3.83e-07	-0.27	-0.18	Parkinson's disease;	chr6:28007039	chr6:28115628~28116551:+
BRCA	cis	rs516805	0.634	rs2816159	ENSG00000279453.1	RP3-425C14.4	-6.02	2.41e-09	3.83e-07	-0.27	-0.18	Lymphocyte counts;	chr6:122121982	chr6:122436789~122439223:-
BRCA	cis	rs7569084	0.687	rs1370394	ENSG00000237979.1	AC007389.1	6.02	2.41e-09	3.83e-07	0.24	0.18	Sum eosinophil basophil counts;	chr2:65453176	chr2:65500993~65502138:-
BRCA	cis	rs867371	1	rs2088858	ENSG00000276710.3	CSPG4P8	-6.02	2.41e-09	3.83e-07	-0.2	-0.18	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82182408	chr15:82459472~82477258:+
BRCA	cis	rs867371	1	rs4778982	ENSG00000276710.3	CSPG4P8	-6.02	2.41e-09	3.83e-07	-0.2	-0.18	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82182931	chr15:82459472~82477258:+
BRCA	cis	rs867371	1	rs2867579	ENSG00000276710.3	CSPG4P8	-6.02	2.41e-09	3.83e-07	-0.2	-0.18	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82183043	chr15:82459472~82477258:+
BRCA	cis	rs867371	1	rs881308	ENSG00000276710.3	CSPG4P8	-6.02	2.41e-09	3.83e-07	-0.2	-0.18	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82183456	chr15:82459472~82477258:+
BRCA	cis	rs651907	0.557	rs62284199	ENSG00000244119.1	PDCL3P4	6.02	2.42e-09	3.84e-07	0.15	0.18	Colorectal cancer;	chr3:101759687	chr3:101712472~101713191:+
BRCA	cis	rs10129255	0.957	rs2013423	ENSG00000280411.1	IGHV1-69-2	-6.02	2.42e-09	3.84e-07	-0.14	-0.18	Kawasaki disease;	chr14:106690675	chr14:106762092~106762588:-
BRCA	cis	rs10129255	0.957	rs56134540	ENSG00000280411.1	IGHV1-69-2	-6.02	2.42e-09	3.84e-07	-0.14	-0.18	Kawasaki disease;	chr14:106691290	chr14:106762092~106762588:-
BRCA	cis	rs2834288	0.535	rs4816468	ENSG00000273102.1	AP000569.9	6.02	2.42e-09	3.84e-07	0.2	0.18	Gut microbiota (bacterial taxa);	chr21:33952235	chr21:33967101~33968573:-
BRCA	cis	rs2834288	0.536	rs8129513	ENSG00000273102.1	AP000569.9	6.02	2.42e-09	3.84e-07	0.2	0.18	Gut microbiota (bacterial taxa);	chr21:33952615	chr21:33967101~33968573:-
BRCA	cis	rs2098713	0.544	rs13188741	ENSG00000250155.1	CTD-2353F22.1	-6.02	2.42e-09	3.84e-07	-0.22	-0.18	Telomere length;	chr5:37432269	chr5:36666214~36725195:-
BRCA	cis	rs7621025	0.691	rs4678438	ENSG00000239213.4	NCK1-AS1	6.02	2.42e-09	3.84e-07	0.21	0.18	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136626078	chr3:136841726~136862054:-
BRCA	cis	rs867371	0.502	rs7176926	ENSG00000255769.6	GOLGA2P10	-6.02	2.42e-09	3.84e-07	-0.2	-0.18	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82245753	chr15:82472993~82513950:-
BRCA	cis	rs911555	0.673	rs7144271	ENSG00000244691.1	RPL10AP1	-6.02	2.42e-09	3.84e-07	-0.23	-0.18	Intelligence (multi-trait analysis);	chr14:103424337	chr14:103412119~103412761:-
BRCA	cis	rs12073837	0.5	rs11118610	ENSG00000238078.1	LINC01352	-6.02	2.42e-09	3.84e-07	-0.19	-0.18	F-cell distribution;	chr1:220816744	chr1:220829255~220832429:+
BRCA	cis	rs2243480	0.908	rs4718273	ENSG00000164669.11	INTS4P1	-6.02	2.42e-09	3.84e-07	-0.35	-0.18	Diabetic kidney disease;	chr7:65751112	chr7:65141225~65234216:+
BRCA	cis	rs10504130	0.696	rs75833886	ENSG00000272024.1	RP11-546K22.3	-6.02	2.42e-09	3.85e-07	-0.29	-0.18	Venous thromboembolism (SNP x SNP interaction);	chr8:51929844	chr8:51950284~51950690:+
BRCA	cis	rs10504130	0.696	rs17284746	ENSG00000272024.1	RP11-546K22.3	-6.02	2.42e-09	3.85e-07	-0.29	-0.18	Venous thromboembolism (SNP x SNP interaction);	chr8:51930320	chr8:51950284~51950690:+
BRCA	cis	rs9287719	0.601	rs1861299	ENSG00000243819.4	RN7SL832P	6.02	2.43e-09	3.85e-07	0.19	0.18	Prostate cancer;	chr2:10623631	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.601	rs1861300	ENSG00000243819.4	RN7SL832P	6.02	2.43e-09	3.85e-07	0.19	0.18	Prostate cancer;	chr2:10623835	chr2:10690344~10692099:+
BRCA	cis	rs12468226	0.873	rs12470401	ENSG00000226261.1	AC064836.3	6.02	2.43e-09	3.85e-07	0.33	0.18	Urate levels;	chr2:202236436	chr2:202336024~202336727:-
BRCA	cis	rs3805389	1	rs3805383	ENSG00000249700.7	SRD5A3-AS1	-6.02	2.43e-09	3.85e-07	-0.27	-0.18	Waist-to-hip ratio adjusted for body mass index;	chr4:55609171	chr4:55363971~55395847:-
BRCA	cis	rs6688613	1	rs17551703	ENSG00000225171.2	DUTP6	-6.02	2.43e-09	3.86e-07	-0.22	-0.18	Refractive astigmatism;	chr1:166988642	chr1:166868748~166869209:+
BRCA	cis	rs7914558	1	rs7067970	ENSG00000213061.2	PFN1P11	6.02	2.43e-09	3.86e-07	0.24	0.18	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103154113	chr10:102838011~102845473:-
BRCA	cis	rs2489715	0.951	rs2505845	ENSG00000185904.10	LINC00839	-6.02	2.43e-09	3.86e-07	-0.27	-0.18	Helix rolling;	chr10:42397206	chr10:42475543~42495336:+
BRCA	cis	rs1823913	0.637	rs2067610	ENSG00000280083.1	RP11-317J9.1	-6.02	2.44e-09	3.87e-07	-0.21	-0.18	Obesity-related traits;	chr2:191299251	chr2:191154118~191156070:-
BRCA	cis	rs12468226	1	rs16839077	ENSG00000226261.1	AC064836.3	6.02	2.44e-09	3.88e-07	0.31	0.18	Urate levels;	chr2:202343970	chr2:202336024~202336727:-
BRCA	cis	rs875971	0.545	rs4441996	ENSG00000228409.4	CCT6P1	6.02	2.45e-09	3.88e-07	0.18	0.18	Aortic root size;	chr7:66123233	chr7:65751142~65763354:+
BRCA	cis	rs2732480	0.5	rs11168464	ENSG00000257763.1	OR5BK1P	6.02	2.45e-09	3.88e-07	0.2	0.18	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48208332	chr12:48355792~48356614:-
BRCA	cis	rs853679	0.517	rs9380052	ENSG00000219392.1	RP1-265C24.5	-6.02	2.45e-09	3.88e-07	-0.28	-0.18	Depression;	chr6:28096845	chr6:28115628~28116551:+
BRCA	cis	rs2998286	0.815	rs332132	ENSG00000254635.4	WAC-AS1	-6.02	2.45e-09	3.88e-07	-0.26	-0.18	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28565185	chr10:28522652~28532743:-
BRCA	cis	rs2243480	1	rs1723269	ENSG00000230295.1	RP11-458F8.2	-6.02	2.45e-09	3.89e-07	-0.24	-0.18	Diabetic kidney disease;	chr7:66007799	chr7:66880708~66882981:+
BRCA	cis	rs1440410	0.866	rs4637346	ENSG00000250326.1	RP11-284M14.1	-6.02	2.45e-09	3.89e-07	-0.2	-0.18	Ischemic stroke;	chr4:143212890	chr4:142933195~143184861:-
BRCA	cis	rs7914558	0.966	rs10786745	ENSG00000213061.2	PFN1P11	6.02	2.45e-09	3.89e-07	0.24	0.18	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103197070	chr10:102838011~102845473:-
BRCA	cis	rs17253792	0.915	rs77161327	ENSG00000186615.9	KTN1-AS1	-6.02	2.45e-09	3.89e-07	-0.38	-0.18	Putamen volume;	chr14:55711847	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.915	rs79100824	ENSG00000186615.9	KTN1-AS1	-6.02	2.45e-09	3.89e-07	-0.38	-0.18	Putamen volume;	chr14:55712888	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.915	rs79894275	ENSG00000186615.9	KTN1-AS1	-6.02	2.45e-09	3.89e-07	-0.38	-0.18	Putamen volume;	chr14:55713567	chr14:55499278~55580110:-
BRCA	cis	rs2051773	0.567	rs6486348	ENSG00000184669.7	OR7E14P	-6.02	2.45e-09	3.89e-07	-0.27	-0.18	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);	chr11:17036227	chr11:17013998~17053024:+
BRCA	cis	rs4950322	0.542	rs56080828	ENSG00000278811.3	LINC00624	6.02	2.46e-09	3.89e-07	0.24	0.18	Protein quantitative trait loci;	chr1:147183447	chr1:147258885~147517875:-
BRCA	cis	rs2153535	0.585	rs9393056	ENSG00000230939.1	RP11-314C16.1	-6.02	2.46e-09	3.9e-07	-0.22	-0.18	Motion sickness;	chr6:8667641	chr6:8784178~8785445:+
BRCA	cis	rs9341808	0.754	rs9352817	ENSG00000272129.1	RP11-250B2.6	6.02	2.46e-09	3.9e-07	0.22	0.18	Sitting height ratio;	chr6:80316162	chr6:80355424~80356859:+
BRCA	cis	rs7615952	0.576	rs2276726	ENSG00000250012.1	RP11-124N2.1	-6.02	2.46e-09	3.9e-07	-0.24	-0.18	Blood pressure (smoking interaction);	chr3:126107444	chr3:126084220~126095349:+
BRCA	cis	rs7976269	0.609	rs7310276	ENSG00000275476.1	RP11-996F15.4	6.02	2.46e-09	3.9e-07	0.21	0.18	Male-pattern baldness;	chr12:29054128	chr12:29277397~29277882:-
BRCA	cis	rs2243480	1	rs781157	ENSG00000164669.11	INTS4P1	6.02	2.46e-09	3.91e-07	0.35	0.18	Diabetic kidney disease;	chr7:66013324	chr7:65141225~65234216:+
BRCA	cis	rs875971	0.862	rs11763189	ENSG00000224316.1	RP11-479O9.2	6.02	2.47e-09	3.91e-07	0.19	0.18	Aortic root size;	chr7:66518542	chr7:65773620~65802067:+
BRCA	cis	rs2638953	0.924	rs4573721	ENSG00000247934.4	RP11-967K21.1	-6.02	2.47e-09	3.91e-07	-0.24	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28194746	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.924	rs4554927	ENSG00000247934.4	RP11-967K21.1	-6.02	2.47e-09	3.91e-07	-0.24	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28194844	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.924	rs61920243	ENSG00000247934.4	RP11-967K21.1	-6.02	2.47e-09	3.91e-07	-0.24	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28195333	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.679	rs7974882	ENSG00000247934.4	RP11-967K21.1	-6.02	2.47e-09	3.91e-07	-0.24	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28195415	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.679	rs7961395	ENSG00000247934.4	RP11-967K21.1	-6.02	2.47e-09	3.91e-07	-0.24	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28195420	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.924	rs7974701	ENSG00000247934.4	RP11-967K21.1	-6.02	2.47e-09	3.91e-07	-0.24	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28195579	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.886	rs7961769	ENSG00000247934.4	RP11-967K21.1	-6.02	2.47e-09	3.91e-07	-0.24	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28195772	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.886	rs61920244	ENSG00000247934.4	RP11-967K21.1	-6.02	2.47e-09	3.91e-07	-0.24	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28195992	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.924	rs34378873	ENSG00000247934.4	RP11-967K21.1	-6.02	2.47e-09	3.91e-07	-0.24	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28196124	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.924	rs11049437	ENSG00000247934.4	RP11-967K21.1	-6.02	2.47e-09	3.91e-07	-0.24	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28196192	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.924	rs11049438	ENSG00000247934.4	RP11-967K21.1	-6.02	2.47e-09	3.91e-07	-0.24	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28196205	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.924	rs11049440	ENSG00000247934.4	RP11-967K21.1	-6.02	2.47e-09	3.91e-07	-0.24	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28196474	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.924	rs11049441	ENSG00000247934.4	RP11-967K21.1	-6.02	2.47e-09	3.91e-07	-0.24	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28196476	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.853	rs11049442	ENSG00000247934.4	RP11-967K21.1	-6.02	2.47e-09	3.91e-07	-0.24	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28197211	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.924	rs11049443	ENSG00000247934.4	RP11-967K21.1	-6.02	2.47e-09	3.91e-07	-0.24	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28197269	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.924	rs11049444	ENSG00000247934.4	RP11-967K21.1	-6.02	2.47e-09	3.91e-07	-0.24	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28197447	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.924	rs11049445	ENSG00000247934.4	RP11-967K21.1	-6.02	2.47e-09	3.91e-07	-0.24	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28197449	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.962	rs60193273	ENSG00000247934.4	RP11-967K21.1	-6.02	2.47e-09	3.91e-07	-0.24	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28197638	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.924	rs11049446	ENSG00000247934.4	RP11-967K21.1	-6.02	2.47e-09	3.91e-07	-0.24	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28197951	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.924	rs11049447	ENSG00000247934.4	RP11-967K21.1	-6.02	2.47e-09	3.91e-07	-0.24	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28197970	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.886	rs10843123	ENSG00000247934.4	RP11-967K21.1	-6.02	2.47e-09	3.91e-07	-0.24	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28198004	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.924	rs12146881	ENSG00000247934.4	RP11-967K21.1	-6.02	2.47e-09	3.91e-07	-0.24	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28198436	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.924	rs11049448	ENSG00000247934.4	RP11-967K21.1	-6.02	2.47e-09	3.91e-07	-0.24	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28198975	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.924	rs10843126	ENSG00000247934.4	RP11-967K21.1	-6.02	2.47e-09	3.91e-07	-0.24	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28199112	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.924	rs10843127	ENSG00000247934.4	RP11-967K21.1	-6.02	2.47e-09	3.91e-07	-0.24	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28199124	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.85	rs10843128	ENSG00000247934.4	RP11-967K21.1	-6.02	2.47e-09	3.91e-07	-0.24	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28199377	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.85	rs10843129	ENSG00000247934.4	RP11-967K21.1	-6.02	2.47e-09	3.91e-07	-0.24	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28199378	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.924	rs10843130	ENSG00000247934.4	RP11-967K21.1	-6.02	2.47e-09	3.91e-07	-0.24	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28199793	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.924	rs61920253	ENSG00000247934.4	RP11-967K21.1	-6.02	2.47e-09	3.91e-07	-0.24	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28202039	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.888	rs11612143	ENSG00000247934.4	RP11-967K21.1	-6.02	2.47e-09	3.91e-07	-0.24	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28202694	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.813	rs11609999	ENSG00000247934.4	RP11-967K21.1	-6.02	2.47e-09	3.91e-07	-0.24	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28202721	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.924	rs11049453	ENSG00000247934.4	RP11-967K21.1	-6.02	2.47e-09	3.91e-07	-0.24	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28202996	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.886	rs7957059	ENSG00000247934.4	RP11-967K21.1	-6.02	2.47e-09	3.91e-07	-0.24	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28203390	chr12:28163298~28190738:-
BRCA	cis	rs7809950	0.817	rs62483725	ENSG00000238832.1	snoU109	-6.02	2.47e-09	3.91e-07	-0.27	-0.18	Coronary artery disease;	chr7:107561130	chr7:107603363~107603507:+
BRCA	cis	rs853679	0.546	rs200981	ENSG00000220721.1	OR1F12	6.02	2.47e-09	3.92e-07	0.33	0.18	Depression;	chr6:27865396	chr6:28073316~28074233:+
BRCA	cis	rs4763879	0.729	rs10844472	ENSG00000214776.8	RP11-726G1.1	-6.02	2.48e-09	3.93e-07	-0.21	-0.18	Type 1 diabetes;	chr12:9691137	chr12:9467552~9576275:+
BRCA	cis	rs4713118	0.662	rs9393881	ENSG00000204709.4	LINC01556	6.02	2.48e-09	3.93e-07	0.26	0.18	Parkinson's disease;	chr6:28055973	chr6:28943877~28944537:+
BRCA	cis	rs7772486	0.79	rs2247206	ENSG00000270638.1	RP3-466P17.1	6.02	2.48e-09	3.93e-07	0.21	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145895048	chr6:145735570~145737218:+
BRCA	cis	rs7772486	0.764	rs2247211	ENSG00000270638.1	RP3-466P17.1	6.02	2.48e-09	3.93e-07	0.21	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145895243	chr6:145735570~145737218:+
BRCA	cis	rs228614	0.514	rs59550147	ENSG00000251288.2	RP11-10L12.2	-6.02	2.48e-09	3.93e-07	-0.21	-0.18	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102914239	chr4:102751401~102752641:+
BRCA	cis	rs75422866	0.867	rs35044089	ENSG00000280054.1	RP1-197B17.7	6.02	2.48e-09	3.93e-07	0.46	0.18	Pneumonia;	chr12:47610881	chr12:47728151~47730598:-
BRCA	cis	rs75422866	0.867	rs78912815	ENSG00000280054.1	RP1-197B17.7	6.02	2.48e-09	3.93e-07	0.46	0.18	Pneumonia;	chr12:47612065	chr12:47728151~47730598:-
BRCA	cis	rs875971	0.651	rs2420596	ENSG00000224316.1	RP11-479O9.2	6.01	2.49e-09	3.94e-07	0.19	0.18	Aortic root size;	chr7:66450996	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.52	rs2420597	ENSG00000224316.1	RP11-479O9.2	6.01	2.49e-09	3.94e-07	0.19	0.18	Aortic root size;	chr7:66450999	chr7:65773620~65802067:+
BRCA	cis	rs875971	1	rs6958271	ENSG00000224316.1	RP11-479O9.2	6.01	2.49e-09	3.94e-07	0.18	0.18	Aortic root size;	chr7:66514344	chr7:65773620~65802067:+
BRCA	cis	rs875971	1	rs6958277	ENSG00000224316.1	RP11-479O9.2	6.01	2.49e-09	3.94e-07	0.18	0.18	Aortic root size;	chr7:66514362	chr7:65773620~65802067:+
BRCA	cis	rs858239	0.539	rs4559148	ENSG00000230042.1	AK3P3	-6.01	2.49e-09	3.94e-07	-0.21	-0.18	Cerebrospinal fluid biomarker levels;	chr7:23146348	chr7:23129178~23129841:+
BRCA	cis	rs7569084	0.687	rs12993075	ENSG00000237979.1	AC007389.1	6.01	2.49e-09	3.95e-07	0.23	0.18	Sum eosinophil basophil counts;	chr2:65431010	chr2:65500993~65502138:-
BRCA	cis	rs2836950	0.565	rs7276046	ENSG00000238141.2	BRWD1-AS1	-6.01	2.49e-09	3.95e-07	-0.21	-0.18	Menarche (age at onset);	chr21:39209367	chr21:39315707~39323218:+
BRCA	cis	rs2836950	0.545	rs8132143	ENSG00000238141.2	BRWD1-AS1	-6.01	2.49e-09	3.95e-07	-0.21	-0.18	Menarche (age at onset);	chr21:39212332	chr21:39315707~39323218:+
BRCA	cis	rs2243480	1	rs1701758	ENSG00000164669.11	INTS4P1	6.01	2.49e-09	3.95e-07	0.35	0.18	Diabetic kidney disease;	chr7:66005214	chr7:65141225~65234216:+
BRCA	cis	rs34779708	0.966	rs1057108	ENSG00000271335.4	RP11-324I22.4	6.01	2.49e-09	3.95e-07	0.19	0.18	Inflammatory bowel disease;Crohn's disease;	chr10:35196021	chr10:35314552~35336401:-
BRCA	cis	rs17508449	0.819	rs4839332	ENSG00000232450.1	RP4-730K3.3	-6.01	2.5e-09	3.95e-07	-0.33	-0.18	Leprosy;	chr1:113619569	chr1:113698884~113699631:-
BRCA	cis	rs1559040	0.932	rs10208690	ENSG00000272156.1	RP11-477N3.1	6.01	2.5e-09	3.96e-07	0.27	0.18	Sudden cardiac arrest;	chr2:54066783	chr2:54082554~54085066:+
BRCA	cis	rs3126085	0.935	rs6666382	ENSG00000237975.5	FLG-AS1	6.01	2.5e-09	3.96e-07	0.25	0.18	Atopic dermatitis;	chr1:152244750	chr1:152168125~152445456:+
BRCA	cis	rs2933343	0.729	rs6767104	ENSG00000231305.3	RP11-723O4.2	-6.01	2.5e-09	3.96e-07	-0.2	-0.18	IgG glycosylation;	chr3:128929274	chr3:128861313~128871540:-
BRCA	cis	rs2235642	1	rs2235642	ENSG00000280231.1	LA16c-380F5.3	-6.01	2.5e-09	3.96e-07	-0.24	-0.18	Coronary artery disease;	chr16:1534865	chr16:1553655~1554130:-
BRCA	cis	rs4950322	0.542	rs3766520	ENSG00000278811.3	LINC00624	6.01	2.5e-09	3.96e-07	0.25	0.18	Protein quantitative trait loci;	chr1:147214658	chr1:147258885~147517875:-
BRCA	cis	rs1552244	0.882	rs13099136	ENSG00000232901.1	CYCSP10	6.01	2.5e-09	3.96e-07	0.25	0.18	Alzheimer's disease;	chr3:9989747	chr3:10000647~10000940:-
BRCA	cis	rs2243480	1	rs160639	ENSG00000232559.3	GS1-124K5.12	6.01	2.5e-09	3.96e-07	0.35	0.18	Diabetic kidney disease;	chr7:66115000	chr7:66554588~66576923:-
BRCA	cis	rs4718428	1	rs1830070	ENSG00000273142.1	RP11-458F8.4	-6.01	2.5e-09	3.96e-07	-0.16	-0.18	Corneal structure;	chr7:66884684	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs56016656	ENSG00000230295.1	RP11-458F8.2	-6.01	2.5e-09	3.97e-07	-0.24	-0.18	Diabetic kidney disease;	chr7:65918494	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs56291018	ENSG00000230295.1	RP11-458F8.2	-6.01	2.5e-09	3.97e-07	-0.24	-0.18	Diabetic kidney disease;	chr7:65925352	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs36033484	ENSG00000230295.1	RP11-458F8.2	-6.01	2.5e-09	3.97e-07	-0.24	-0.18	Diabetic kidney disease;	chr7:65925571	chr7:66880708~66882981:+
BRCA	cis	rs6088813	1	rs4911491	ENSG00000126005.14	MMP24-AS1	6.01	2.5e-09	3.97e-07	0.21	0.18	Height;	chr20:35359482	chr20:35216462~35278131:-
BRCA	cis	rs10129255	0.957	rs7493713	ENSG00000211972.2	IGHV3-66	6.01	2.5e-09	3.97e-07	0.13	0.18	Kawasaki disease;	chr14:106783685	chr14:106675017~106675544:-
BRCA	cis	rs10129255	0.912	rs35468694	ENSG00000211972.2	IGHV3-66	6.01	2.5e-09	3.97e-07	0.13	0.18	Kawasaki disease;	chr14:106784199	chr14:106675017~106675544:-
BRCA	cis	rs202072	0.769	rs445591	ENSG00000272379.1	RP1-257A7.5	6.01	2.51e-09	3.97e-07	0.26	0.18	HIV-1 viral setpoint;	chr6:13280634	chr6:13290018~13290490:-
BRCA	cis	rs5167	0.539	rs4803783	ENSG00000280087.1	CTB-129P6.7	-6.01	2.51e-09	3.97e-07	-0.23	-0.18	Blood protein levels;	chr19:44967201	chr19:44909375~44914968:+
BRCA	cis	rs7587476	0.626	rs7593780	ENSG00000229267.2	AC072062.1	-6.01	2.51e-09	3.97e-07	-0.22	-0.18	Neuroblastoma;	chr2:214775672	chr2:214810229~214963274:+
BRCA	cis	rs42490	0.576	rs432457	ENSG00000251136.7	RP11-37B2.1	-6.01	2.51e-09	3.97e-07	-0.19	-0.18	Leprosy;	chr8:89853680	chr8:89609409~89757727:-
BRCA	cis	rs9287719	0.556	rs10168351	ENSG00000243819.4	RN7SL832P	6.01	2.51e-09	3.97e-07	0.19	0.18	Prostate cancer;	chr2:10596684	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.578	rs10168852	ENSG00000243819.4	RN7SL832P	6.01	2.51e-09	3.97e-07	0.19	0.18	Prostate cancer;	chr2:10606197	chr2:10690344~10692099:+
BRCA	cis	rs2836950	0.545	rs11700813	ENSG00000255568.3	BRWD1-AS2	-6.01	2.51e-09	3.98e-07	-0.18	-0.18	Menarche (age at onset);	chr21:39145543	chr21:39313935~39314962:+
BRCA	cis	rs2274273	0.967	rs17832359	ENSG00000258413.1	RP11-665C16.6	-6.01	2.51e-09	3.98e-07	-0.23	-0.18	Protein biomarker;	chr14:55149223	chr14:55262767~55272075:-
BRCA	cis	rs12681366	1	rs2960122	ENSG00000253704.1	RP11-267M23.4	6.01	2.51e-09	3.98e-07	0.19	0.18	Nonsyndromic cleft lip with cleft palate;	chr8:94419858	chr8:94553722~94569745:+
BRCA	cis	rs2243480	0.901	rs1701759	ENSG00000164669.11	INTS4P1	6.01	2.51e-09	3.98e-07	0.35	0.18	Diabetic kidney disease;	chr7:66005945	chr7:65141225~65234216:+
BRCA	cis	rs56114371	0.53	rs9348774	ENSG00000220721.1	OR1F12	6.01	2.52e-09	3.99e-07	0.26	0.18	Breast cancer;	chr6:27721151	chr6:28073316~28074233:+
BRCA	cis	rs75422866	0.867	rs73102188	ENSG00000280054.1	RP1-197B17.7	6.01	2.52e-09	3.99e-07	0.46	0.18	Pneumonia;	chr12:47662993	chr12:47728151~47730598:-
BRCA	cis	rs75422866	0.867	rs73102195	ENSG00000280054.1	RP1-197B17.7	6.01	2.52e-09	3.99e-07	0.46	0.18	Pneumonia;	chr12:47666309	chr12:47728151~47730598:-
BRCA	cis	rs75422866	0.867	rs73102201	ENSG00000280054.1	RP1-197B17.7	6.01	2.52e-09	3.99e-07	0.46	0.18	Pneumonia;	chr12:47669269	chr12:47728151~47730598:-
BRCA	cis	rs75422866	0.867	rs73104104	ENSG00000280054.1	RP1-197B17.7	6.01	2.52e-09	3.99e-07	0.46	0.18	Pneumonia;	chr12:47671986	chr12:47728151~47730598:-
BRCA	cis	rs75422866	0.867	rs73104111	ENSG00000280054.1	RP1-197B17.7	6.01	2.52e-09	3.99e-07	0.46	0.18	Pneumonia;	chr12:47673994	chr12:47728151~47730598:-
BRCA	cis	rs11671005	0.61	rs8103813	ENSG00000269600.1	AC016629.3	-6.01	2.52e-09	3.99e-07	-0.29	-0.18	Mean platelet volume;	chr19:58561317	chr19:58593896~58599355:-
BRCA	cis	rs227275	0.554	rs149576	ENSG00000251288.2	RP11-10L12.2	-6.01	2.52e-09	3.99e-07	-0.21	-0.18	Allergic disease (asthma, hay fever or eczema);	chr4:102811411	chr4:102751401~102752641:+
BRCA	cis	rs9527	1	rs12416687	ENSG00000213061.2	PFN1P11	6.01	2.52e-09	3.99e-07	0.28	0.18	Arsenic metabolism;	chr10:102869254	chr10:102838011~102845473:-
BRCA	cis	rs858239	0.539	rs10247268	ENSG00000230042.1	AK3P3	-6.01	2.52e-09	3.99e-07	-0.21	-0.18	Cerebrospinal fluid biomarker levels;	chr7:23147560	chr7:23129178~23129841:+
BRCA	cis	rs858239	0.539	rs6461694	ENSG00000230042.1	AK3P3	-6.01	2.52e-09	3.99e-07	-0.21	-0.18	Cerebrospinal fluid biomarker levels;	chr7:23148160	chr7:23129178~23129841:+
BRCA	cis	rs6088813	1	rs6087698	ENSG00000126005.14	MMP24-AS1	6.01	2.52e-09	3.99e-07	0.21	0.18	Height;	chr20:35361116	chr20:35216462~35278131:-
BRCA	cis	rs6088813	1	rs6141546	ENSG00000126005.14	MMP24-AS1	6.01	2.52e-09	3.99e-07	0.21	0.18	Height;	chr20:35361479	chr20:35216462~35278131:-
BRCA	cis	rs4664293	0.585	rs13019325	ENSG00000226266.5	AC009961.3	6.01	2.52e-09	3.99e-07	0.22	0.18	Monocyte percentage of white cells;	chr2:159772479	chr2:159670708~159712435:-
BRCA	cis	rs763121	0.962	rs138711	ENSG00000273076.1	RP3-508I15.22	6.01	2.52e-09	3.99e-07	0.25	0.18	Menopause (age at onset);	chr22:38743908	chr22:38743495~38743910:+
BRCA	cis	rs875971	0.789	rs7808013	ENSG00000224316.1	RP11-479O9.2	-6.01	2.53e-09	4e-07	-0.19	-0.18	Aortic root size;	chr7:66606209	chr7:65773620~65802067:+
BRCA	cis	rs669446	0.533	rs3862228	ENSG00000237950.1	RP11-7O11.3	6.01	2.53e-09	4.01e-07	0.21	0.18	Amyotrophic lateral sclerosis (age of onset);	chr1:43731274	chr1:43944370~43946551:-
BRCA	cis	rs9311474	0.607	rs4234633	ENSG00000243224.1	RP5-1157M23.2	-6.01	2.53e-09	4.01e-07	-0.2	-0.18	Electroencephalogram traits;	chr3:52523022	chr3:52239258~52241097:+
BRCA	cis	rs227275	0.554	rs223399	ENSG00000251288.2	RP11-10L12.2	-6.01	2.53e-09	4.01e-07	-0.21	-0.18	Allergic disease (asthma, hay fever or eczema);	chr4:102820800	chr4:102751401~102752641:+
BRCA	cis	rs7914558	0.966	rs10748839	ENSG00000213061.2	PFN1P11	6.01	2.53e-09	4.01e-07	0.24	0.18	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103193790	chr10:102838011~102845473:-
BRCA	cis	rs9513627	0.573	rs12431100	ENSG00000280710.1	RP11-214F16.8	-6.01	2.53e-09	4.01e-07	-0.24	-0.18	Obesity-related traits;	chr13:99532664	chr13:99498524~99501315:+
BRCA	cis	rs2562456	0.876	rs11085467	ENSG00000268081.1	RP11-678G14.2	6.01	2.53e-09	4.01e-07	0.28	0.18	Pain;	chr19:21569041	chr19:21554640~21569237:-
BRCA	cis	rs2834288	0.535	rs881228	ENSG00000273102.1	AP000569.9	6.01	2.54e-09	4.02e-07	0.2	0.18	Gut microbiota (bacterial taxa);	chr21:33950387	chr21:33967101~33968573:-
BRCA	cis	rs2243480	1	rs4149468	ENSG00000232559.3	GS1-124K5.12	6.01	2.54e-09	4.02e-07	0.35	0.18	Diabetic kidney disease;	chr7:66360703	chr7:66554588~66576923:-
BRCA	cis	rs6088813	0.961	rs745931	ENSG00000126005.14	MMP24-AS1	6.01	2.54e-09	4.02e-07	0.21	0.18	Height;	chr20:35368201	chr20:35216462~35278131:-
BRCA	cis	rs1198430	1	rs1198434	ENSG00000232482.2	RP4-654C18.1	-6.01	2.54e-09	4.02e-07	-0.29	-0.18	Total cholesterol levels;	chr1:23431641	chr1:23410832~23412146:+
BRCA	cis	rs17253792	0.915	rs74580958	ENSG00000186615.9	KTN1-AS1	-6.01	2.54e-09	4.02e-07	-0.38	-0.18	Putamen volume;	chr14:55714793	chr14:55499278~55580110:-
BRCA	cis	rs1552244	0.935	rs7649243	ENSG00000180385.7	EMC3-AS1	6.01	2.54e-09	4.02e-07	0.23	0.18	Alzheimer's disease;	chr3:10047786	chr3:9986893~10006990:+
BRCA	cis	rs1552244	1	rs7615646	ENSG00000180385.7	EMC3-AS1	6.01	2.54e-09	4.02e-07	0.23	0.18	Alzheimer's disease;	chr3:10048089	chr3:9986893~10006990:+
BRCA	cis	rs1552244	1	rs6793396	ENSG00000180385.7	EMC3-AS1	6.01	2.54e-09	4.02e-07	0.23	0.18	Alzheimer's disease;	chr3:10069243	chr3:9986893~10006990:+
BRCA	cis	rs1552244	0.935	rs7621551	ENSG00000180385.7	EMC3-AS1	6.01	2.54e-09	4.02e-07	0.23	0.18	Alzheimer's disease;	chr3:10072521	chr3:9986893~10006990:+
BRCA	cis	rs7615952	0.688	rs17334074	ENSG00000250012.1	RP11-124N2.1	6.01	2.54e-09	4.02e-07	0.25	0.18	Blood pressure (smoking interaction);	chr3:125821617	chr3:126084220~126095349:+
BRCA	cis	rs853679	0.628	rs9368560	ENSG00000219392.1	RP1-265C24.5	-6.01	2.54e-09	4.03e-07	-0.27	-0.18	Depression;	chr6:28192182	chr6:28115628~28116551:+
BRCA	cis	rs4713118	0.662	rs149969	ENSG00000204709.4	LINC01556	6.01	2.55e-09	4.03e-07	0.26	0.18	Parkinson's disease;	chr6:28009959	chr6:28943877~28944537:+
BRCA	cis	rs228614	0.51	rs223400	ENSG00000251288.2	RP11-10L12.2	-6.01	2.55e-09	4.03e-07	-0.22	-0.18	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102820439	chr4:102751401~102752641:+
BRCA	cis	rs11722228	0.521	rs62288520	ENSG00000261490.1	RP11-448G15.3	6.01	2.55e-09	4.04e-07	0.21	0.18	Urate levels;Serum uric acid levels;Gout;	chr4:10098050	chr4:10068089~10073019:-
BRCA	cis	rs7772486	0.79	rs9497435	ENSG00000270638.1	RP3-466P17.1	-6.01	2.55e-09	4.04e-07	-0.21	-0.18	Lobe attachment (rater-scored or self-reported);	chr6:145944204	chr6:145735570~145737218:+
BRCA	cis	rs13118159	0.55	rs4974612	ENSG00000254094.1	AC078852.1	-6.01	2.55e-09	4.04e-07	-0.23	-0.18	Longevity;	chr4:1370755	chr4:1356581~1358075:+
BRCA	cis	rs11722228	0.508	rs3822246	ENSG00000261490.1	RP11-448G15.3	6.01	2.56e-09	4.05e-07	0.21	0.18	Urate levels;Serum uric acid levels;Gout;	chr4:10093074	chr4:10068089~10073019:-
BRCA	cis	rs4718428	0.705	rs4717331	ENSG00000230295.1	RP11-458F8.2	-6.01	2.56e-09	4.05e-07	-0.17	-0.18	Corneal structure;	chr7:66913899	chr7:66880708~66882981:+
BRCA	cis	rs755249	0.532	rs17343193	ENSG00000237624.1	OXCT2P1	6.01	2.56e-09	4.05e-07	0.27	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39415796	chr1:39514956~39516490:+
BRCA	cis	rs11098499	0.739	rs10031033	ENSG00000248280.1	RP11-33B1.2	6.01	2.56e-09	4.05e-07	0.18	0.18	Corneal astigmatism;	chr4:119230297	chr4:119440561~119450157:-
BRCA	cis	rs7914558	0.932	rs4307650	ENSG00000213061.2	PFN1P11	6.01	2.56e-09	4.05e-07	0.24	0.18	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103200095	chr10:102838011~102845473:-
BRCA	cis	rs13126694	0.778	rs7692254	ENSG00000251429.1	RP11-597D13.7	6.01	2.56e-09	4.05e-07	0.18	0.18	Blood osmolality (transformed sodium);	chr4:158134140	chr4:158270378~158278676:+
BRCA	cis	rs7208859	0.623	rs3794796	ENSG00000265443.1	CTD-2349P21.6	-6.01	2.56e-09	4.06e-07	-0.3	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30803862	chr17:30726305~30727564:-
BRCA	cis	rs2243480	1	rs464895	ENSG00000164669.11	INTS4P1	6.01	2.57e-09	4.06e-07	0.38	0.18	Diabetic kidney disease;	chr7:66062119	chr7:65141225~65234216:+
BRCA	cis	rs853679	0.542	rs9393892	ENSG00000204709.4	LINC01556	6.01	2.57e-09	4.06e-07	0.27	0.18	Depression;	chr6:28113616	chr6:28943877~28944537:+
BRCA	cis	rs2243480	1	rs6964530	ENSG00000232559.3	GS1-124K5.12	-6.01	2.57e-09	4.06e-07	-0.34	-0.18	Diabetic kidney disease;	chr7:66253864	chr7:66554588~66576923:-
BRCA	cis	rs7493	1	rs2286232	ENSG00000233942.1	AC004012.1	6.01	2.57e-09	4.07e-07	0.23	0.18	Yu-Zhi constitution type in type 2 diabetes;	chr7:95410133	chr7:95471835~95473998:+
BRCA	cis	rs9467773	0.869	rs742090	ENSG00000124549.13	BTN2A3P	-6.01	2.57e-09	4.07e-07	-0.19	-0.18	Intelligence (multi-trait analysis);	chr6:26415409	chr6:26421391~26432383:+
BRCA	cis	rs780096	0.967	rs1313566	ENSG00000234072.1	AC074117.10	-6.01	2.57e-09	4.07e-07	-0.17	-0.18	Total body bone mineral density;	chr2:27526037	chr2:27356246~27367622:+
BRCA	cis	rs1440410	0.835	rs6820538	ENSG00000250326.1	RP11-284M14.1	-6.01	2.57e-09	4.07e-07	-0.2	-0.18	Ischemic stroke;	chr4:143207923	chr4:142933195~143184861:-
BRCA	cis	rs9840812	0.567	rs2655008	ENSG00000273486.1	RP11-731C17.2	6.01	2.58e-09	4.07e-07	0.22	0.18	Fibrinogen levels;	chr3:136404933	chr3:136837338~136839021:-
BRCA	cis	rs42490	0.51	rs7003919	ENSG00000251136.7	RP11-37B2.1	6.01	2.58e-09	4.08e-07	0.17	0.18	Leprosy;	chr8:89688185	chr8:89609409~89757727:-
BRCA	cis	rs2933343	0.729	rs1683780	ENSG00000231305.3	RP11-723O4.2	6.01	2.58e-09	4.08e-07	0.2	0.18	IgG glycosylation;	chr3:128921396	chr3:128861313~128871540:-
BRCA	cis	rs6479891	1	rs9414800	ENSG00000232075.1	MRPL35P2	6.01	2.58e-09	4.08e-07	0.33	0.18	Arthritis (juvenile idiopathic);	chr10:63371522	chr10:63634317~63634827:-
BRCA	cis	rs67981189	0.896	rs17108925	ENSG00000258571.1	PTTG4P	-6.01	2.58e-09	4.08e-07	-0.2	-0.18	Schizophrenia;	chr14:71033010	chr14:71085482~71085833:-
BRCA	cis	rs67981189	0.896	rs28374308	ENSG00000258571.1	PTTG4P	-6.01	2.58e-09	4.08e-07	-0.2	-0.18	Schizophrenia;	chr14:71035040	chr14:71085482~71085833:-
BRCA	cis	rs67981189	0.896	rs8016506	ENSG00000258571.1	PTTG4P	-6.01	2.58e-09	4.08e-07	-0.2	-0.18	Schizophrenia;	chr14:71039600	chr14:71085482~71085833:-
BRCA	cis	rs67981189	0.858	rs35631530	ENSG00000258571.1	PTTG4P	-6.01	2.58e-09	4.08e-07	-0.2	-0.18	Schizophrenia;	chr14:71041312	chr14:71085482~71085833:-
BRCA	cis	rs2235642	1	rs2076438	ENSG00000280231.1	LA16c-380F5.3	-6.01	2.58e-09	4.09e-07	-0.24	-0.18	Coronary artery disease;	chr16:1534617	chr16:1553655~1554130:-
BRCA	cis	rs9287719	0.601	rs6755281	ENSG00000243819.4	RN7SL832P	6.01	2.59e-09	4.09e-07	0.19	0.18	Prostate cancer;	chr2:10629729	chr2:10690344~10692099:+
BRCA	cis	rs2835345	0.507	rs7280011	ENSG00000230479.1	AP000695.6	6.01	2.59e-09	4.09e-07	0.19	0.18	Pulmonary function;	chr21:36455256	chr21:36430360~36481070:+
BRCA	cis	rs2243480	0.522	rs1638736	ENSG00000232546.1	RP11-458F8.1	-6.01	2.59e-09	4.09e-07	-0.29	-0.18	Diabetic kidney disease;	chr7:66627321	chr7:66848496~66858136:+
BRCA	cis	rs2243480	1	rs34560516	ENSG00000230295.1	RP11-458F8.2	-6.01	2.59e-09	4.09e-07	-0.24	-0.18	Diabetic kidney disease;	chr7:65939105	chr7:66880708~66882981:+
BRCA	cis	rs67981189	1	rs67981189	ENSG00000258571.1	PTTG4P	-6.01	2.59e-09	4.09e-07	-0.2	-0.18	Schizophrenia;	chr14:71005509	chr14:71085482~71085833:-
BRCA	cis	rs67981189	0.896	rs7145484	ENSG00000258571.1	PTTG4P	-6.01	2.59e-09	4.09e-07	-0.2	-0.18	Schizophrenia;	chr14:71006820	chr14:71085482~71085833:-
BRCA	cis	rs847577	0.722	rs7790120	ENSG00000272950.1	RP11-307C18.1	6.01	2.59e-09	4.1e-07	0.24	0.18	Breast cancer;	chr7:98083519	chr7:98322853~98323430:+
BRCA	cis	rs227275	0.586	rs223448	ENSG00000251288.2	RP11-10L12.2	-6.01	2.59e-09	4.1e-07	-0.21	-0.18	Allergic disease (asthma, hay fever or eczema);	chr4:102792189	chr4:102751401~102752641:+
BRCA	cis	rs9500256	0.903	rs726783	ENSG00000215190.7	LINC00680	-6.01	2.59e-09	4.1e-07	-0.21	-0.18	Eosinophilic esophagitis (pediatric);	chr6:58006583	chr6:57946074~57961501:-
BRCA	cis	rs4664293	0.605	rs12991516	ENSG00000226266.5	AC009961.3	-6.01	2.59e-09	4.1e-07	-0.22	-0.18	Monocyte percentage of white cells;	chr2:159585554	chr2:159670708~159712435:-
BRCA	cis	rs755249	0.567	rs61783376	ENSG00000237624.1	OXCT2P1	6.01	2.6e-09	4.1e-07	0.27	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39303328	chr1:39514956~39516490:+
BRCA	cis	rs755249	0.567	rs4660636	ENSG00000237624.1	OXCT2P1	6.01	2.6e-09	4.1e-07	0.27	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39304555	chr1:39514956~39516490:+
BRCA	cis	rs2243480	1	rs3885839	ENSG00000164669.11	INTS4P1	6.01	2.6e-09	4.1e-07	0.36	0.18	Diabetic kidney disease;	chr7:65825416	chr7:65141225~65234216:+
BRCA	cis	rs2243480	1	rs34193460	ENSG00000230295.1	RP11-458F8.2	-6.01	2.6e-09	4.11e-07	-0.24	-0.18	Diabetic kidney disease;	chr7:65928123	chr7:66880708~66882981:+
BRCA	cis	rs7520050	0.831	rs61783170	ENSG00000280836.1	AL355480.1	6.01	2.6e-09	4.11e-07	0.22	0.18	Reticulocyte count;Red blood cell count;	chr1:45790657	chr1:45581219~45581321:-
BRCA	cis	rs9876781	1	rs9883759	ENSG00000229759.1	MRPS18AP1	6.01	2.6e-09	4.12e-07	0.21	0.18	Longevity;	chr3:48422209	chr3:48256350~48256938:-
BRCA	cis	rs9876781	1	rs6442120	ENSG00000229759.1	MRPS18AP1	6.01	2.6e-09	4.12e-07	0.21	0.18	Longevity;	chr3:48423094	chr3:48256350~48256938:-
BRCA	cis	rs17711722	0.701	rs4467826	ENSG00000234585.5	CCT6P3	6.01	2.61e-09	4.12e-07	0.17	0.18	Calcium levels;	chr7:65903721	chr7:65038354~65074713:+
BRCA	cis	rs202072	0.725	rs445590	ENSG00000272379.1	RP1-257A7.5	6.01	2.61e-09	4.13e-07	0.25	0.18	HIV-1 viral setpoint;	chr6:13280632	chr6:13290018~13290490:-
BRCA	cis	rs853679	0.517	rs4713146	ENSG00000204709.4	LINC01556	6.01	2.61e-09	4.13e-07	0.27	0.18	Depression;	chr6:28143758	chr6:28943877~28944537:+
BRCA	cis	rs853679	0.517	rs9393894	ENSG00000204709.4	LINC01556	6.01	2.61e-09	4.13e-07	0.27	0.18	Depression;	chr6:28144784	chr6:28943877~28944537:+
BRCA	cis	rs910316	0.967	rs175505	ENSG00000279594.1	RP11-950C14.10	-6.01	2.61e-09	4.13e-07	-0.2	-0.18	Height;	chr14:75062916	chr14:75011269~75012851:-
BRCA	cis	rs4072705	0.869	rs2416951	ENSG00000224020.1	MIR181A2HG	-6.01	2.61e-09	4.13e-07	-0.21	-0.18	Menarche (age at onset);	chr9:124788324	chr9:124658467~124698631:+
BRCA	cis	rs6723226	0.721	rs3769600	ENSG00000276334.1	AL133243.1	-6.01	2.61e-09	4.13e-07	-0.22	-0.18	Intelligence (multi-trait analysis);	chr2:32391811	chr2:32521927~32523547:+
BRCA	cis	rs651907	0.535	rs34161138	ENSG00000244119.1	PDCL3P4	6.01	2.62e-09	4.14e-07	0.15	0.18	Colorectal cancer;	chr3:101791544	chr3:101712472~101713191:+
BRCA	cis	rs8114671	0.836	rs745849	ENSG00000269202.1	RP4-614O4.12	6.01	2.62e-09	4.14e-07	0.19	0.18	Height;	chr20:34984375	chr20:35201747~35203288:-
BRCA	cis	rs4713118	0.662	rs149946	ENSG00000219392.1	RP1-265C24.5	6.01	2.62e-09	4.14e-07	0.27	0.18	Parkinson's disease;	chr6:28002253	chr6:28115628~28116551:+
BRCA	cis	rs442309	0.574	rs7895364	ENSG00000238280.1	RP11-436D10.3	-6.01	2.62e-09	4.14e-07	-0.25	-0.18	Vogt-Koyanagi-Harada syndrome;	chr10:62725053	chr10:62793562~62805887:-
BRCA	cis	rs10266483	0.545	rs1812912	ENSG00000271550.1	BNIP3P11	-6.01	2.62e-09	4.14e-07	-0.29	-0.18	Response to statin therapy;	chr7:64282891	chr7:64678954~64687393:-
BRCA	cis	rs1061377	0.748	rs12649085	ENSG00000249685.1	RP11-360F5.3	6.01	2.62e-09	4.14e-07	0.22	0.18	Uric acid levels;	chr4:39106459	chr4:39133913~39135608:+
BRCA	cis	rs763121	0.853	rs138712	ENSG00000273076.1	RP3-508I15.22	6.01	2.62e-09	4.15e-07	0.21	0.18	Menopause (age at onset);	chr22:38745595	chr22:38743495~38743910:+
BRCA	cis	rs56104184	0.775	rs56146968	ENSG00000235191.1	NUCB1-AS1	6.01	2.62e-09	4.15e-07	0.33	0.18	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr19:48895590	chr19:48910930~48918891:-
BRCA	cis	rs7044106	0.718	rs1960421	ENSG00000238181.2	AHCYP2	-6.01	2.63e-09	4.15e-07	-0.24	-0.18	Hip circumference adjusted for BMI;	chr9:120632616	chr9:120720673~120721972:+
BRCA	cis	rs9652601	0.959	rs2041670	ENSG00000274038.1	RP11-66H6.4	-6.01	2.63e-09	4.15e-07	-0.21	-0.18	Systemic lupus erythematosus;	chr16:11080795	chr16:11056556~11057034:+
BRCA	cis	rs7246657	0.551	rs12972146	ENSG00000276846.1	CTD-3220F14.3	6.01	2.63e-09	4.16e-07	0.29	0.18	Coronary artery calcification;	chr19:37135193	chr19:37314868~37315620:-
BRCA	cis	rs2243480	1	rs35432774	ENSG00000229886.1	RP5-1132H15.3	6.01	2.63e-09	4.16e-07	0.31	0.18	Diabetic kidney disease;	chr7:65928032	chr7:66025126~66031544:-
BRCA	cis	rs2243480	1	rs313824	ENSG00000232559.3	GS1-124K5.12	6.01	2.63e-09	4.16e-07	0.35	0.18	Diabetic kidney disease;	chr7:66116220	chr7:66554588~66576923:-
BRCA	cis	rs2243480	1	rs186378	ENSG00000232559.3	GS1-124K5.12	6.01	2.63e-09	4.16e-07	0.35	0.18	Diabetic kidney disease;	chr7:66117071	chr7:66554588~66576923:-
BRCA	cis	rs2243480	1	rs160637	ENSG00000232559.3	GS1-124K5.12	6.01	2.63e-09	4.16e-07	0.35	0.18	Diabetic kidney disease;	chr7:66119331	chr7:66554588~66576923:-
BRCA	cis	rs11976180	1	rs2951372	ENSG00000273234.1	OR2A13P	-6.01	2.63e-09	4.16e-07	-0.24	-0.18	Obesity-related traits;	chr7:144052410	chr7:144142009~144142938:+
BRCA	cis	rs7615952	0.576	rs2276727	ENSG00000171084.14	FAM86JP	6.01	2.64e-09	4.16e-07	0.28	0.18	Blood pressure (smoking interaction);	chr3:126107400	chr3:125916620~125930024:+
BRCA	cis	rs5015933	0.902	rs2291858	ENSG00000232630.1	PRPS1P2	-6.01	2.64e-09	4.17e-07	-0.17	-0.18	Body mass index;	chr9:125366503	chr9:125150653~125151589:+
BRCA	cis	rs1499614	1	rs1638731	ENSG00000232559.3	GS1-124K5.12	6.01	2.64e-09	4.17e-07	0.35	0.18	Gout;	chr7:66679692	chr7:66554588~66576923:-
BRCA	cis	rs1499614	1	rs1882655	ENSG00000232559.3	GS1-124K5.12	-6.01	2.64e-09	4.17e-07	-0.35	-0.18	Gout;	chr7:66682070	chr7:66554588~66576923:-
BRCA	cis	rs1499614	0.831	rs3800822	ENSG00000232559.3	GS1-124K5.12	-6.01	2.64e-09	4.17e-07	-0.35	-0.18	Gout;	chr7:66682162	chr7:66554588~66576923:-
BRCA	cis	rs755249	0.567	rs113214136	ENSG00000237624.1	OXCT2P1	6.01	2.64e-09	4.17e-07	0.27	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39408867	chr1:39514956~39516490:+
BRCA	cis	rs755249	0.567	rs61779300	ENSG00000237624.1	OXCT2P1	6.01	2.64e-09	4.17e-07	0.27	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39420091	chr1:39514956~39516490:+
BRCA	cis	rs11722228	0.549	rs41268389	ENSG00000261490.1	RP11-448G15.3	6	2.64e-09	4.17e-07	0.21	0.18	Urate levels;Serum uric acid levels;Gout;	chr4:10097653	chr4:10068089~10073019:-
BRCA	cis	rs2243480	1	rs1964692	ENSG00000164669.11	INTS4P1	6	2.64e-09	4.18e-07	0.35	0.18	Diabetic kidney disease;	chr7:65989196	chr7:65141225~65234216:+
BRCA	cis	rs7474896	0.537	rs2749588	ENSG00000226578.1	RP11-258F22.1	-6	2.65e-09	4.18e-07	-0.23	-0.18	Obesity (extreme);	chr10:37980529	chr10:37775371~37784131:-
BRCA	cis	rs7615952	0.576	rs2276729	ENSG00000250012.1	RP11-124N2.1	-6	2.65e-09	4.18e-07	-0.24	-0.18	Blood pressure (smoking interaction);	chr3:126107371	chr3:126084220~126095349:+
BRCA	cis	rs2749097	0.825	rs2749100	ENSG00000244256.3	RN7SL130P	6	2.65e-09	4.18e-07	0.23	0.18	Alcohol consumption (transferrin glycosylation);	chr1:63659308	chr1:63655743~63656047:+
BRCA	cis	rs1440410	0.798	rs10026015	ENSG00000250326.1	RP11-284M14.1	-6	2.65e-09	4.18e-07	-0.2	-0.18	Ischemic stroke;	chr4:143248486	chr4:142933195~143184861:-
BRCA	cis	rs651907	0.514	rs11706494	ENSG00000244119.1	PDCL3P4	6	2.65e-09	4.18e-07	0.15	0.18	Colorectal cancer;	chr3:101790631	chr3:101712472~101713191:+
BRCA	cis	rs651907	0.535	rs34063583	ENSG00000244119.1	PDCL3P4	6	2.65e-09	4.18e-07	0.15	0.18	Colorectal cancer;	chr3:101791104	chr3:101712472~101713191:+
BRCA	cis	rs7809950	0.678	rs7777950	ENSG00000238832.1	snoU109	-6	2.65e-09	4.19e-07	-0.27	-0.18	Coronary artery disease;	chr7:107364227	chr7:107603363~107603507:+
BRCA	cis	rs6442522	1	rs6762167	ENSG00000249786.6	EAF1-AS1	-6	2.65e-09	4.19e-07	-0.19	-0.18	Uric acid levels;	chr3:15403530	chr3:15436171~15455940:-
BRCA	cis	rs875971	0.862	rs1167408	ENSG00000224316.1	RP11-479O9.2	-6	2.65e-09	4.19e-07	-0.19	-0.18	Aortic root size;	chr7:66091121	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.83	rs1167406	ENSG00000224316.1	RP11-479O9.2	-6	2.65e-09	4.19e-07	-0.19	-0.18	Aortic root size;	chr7:66091949	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.862	rs1167399	ENSG00000224316.1	RP11-479O9.2	-6	2.65e-09	4.19e-07	-0.19	-0.18	Aortic root size;	chr7:66096890	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.862	rs57866200	ENSG00000224316.1	RP11-479O9.2	-6	2.65e-09	4.19e-07	-0.19	-0.18	Aortic root size;	chr7:66100405	chr7:65773620~65802067:+
BRCA	cis	rs11671005	0.695	rs8106061	ENSG00000252334.1	RNU6-1337P	6	2.65e-09	4.19e-07	0.27	0.18	Mean platelet volume;	chr19:58406623	chr19:58483749~58483843:-
BRCA	cis	rs293748	1	rs293748	ENSG00000250155.1	CTD-2353F22.1	-6	2.65e-09	4.19e-07	-0.25	-0.18	Obesity-related traits;	chr5:36900741	chr5:36666214~36725195:-
BRCA	cis	rs9876781	1	rs3774808	ENSG00000229759.1	MRPS18AP1	6	2.66e-09	4.19e-07	0.21	0.18	Longevity;	chr3:48440237	chr3:48256350~48256938:-
BRCA	cis	rs919433	0.68	rs788023	ENSG00000231621.1	AC013264.2	-6	2.66e-09	4.19e-07	-0.18	-0.18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197418581	chr2:197197991~197199273:+
BRCA	cis	rs919433	0.68	rs2565161	ENSG00000231621.1	AC013264.2	-6	2.66e-09	4.19e-07	-0.18	-0.18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197420830	chr2:197197991~197199273:+
BRCA	cis	rs651907	0.557	rs3094297	ENSG00000244119.1	PDCL3P4	6	2.66e-09	4.2e-07	0.15	0.18	Colorectal cancer;	chr3:101680416	chr3:101712472~101713191:+
BRCA	cis	rs6728642	1	rs113934577	ENSG00000230606.9	AC159540.1	6	2.66e-09	4.2e-07	0.39	0.18	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:97222310	chr2:97416165~97433527:-
BRCA	cis	rs5167	0.743	rs8111069	ENSG00000280087.1	CTB-129P6.7	6	2.66e-09	4.2e-07	0.24	0.18	Blood protein levels;	chr19:44980181	chr19:44909375~44914968:+
BRCA	cis	rs227275	0.554	rs223316	ENSG00000251288.2	RP11-10L12.2	-6	2.66e-09	4.2e-07	-0.22	-0.18	Allergic disease (asthma, hay fever or eczema);	chr4:102881949	chr4:102751401~102752641:+
BRCA	cis	rs11105298	0.891	rs10777184	ENSG00000270344.2	RP11-734K2.4	6	2.66e-09	4.2e-07	0.21	0.18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89525791	chr12:89525654~89548005:+
BRCA	cis	rs5015933	0.778	rs10819046	ENSG00000232630.1	PRPS1P2	-6	2.66e-09	4.2e-07	-0.17	-0.18	Body mass index;	chr9:125349961	chr9:125150653~125151589:+
BRCA	cis	rs228614	0.51	rs223452	ENSG00000251288.2	RP11-10L12.2	-6	2.66e-09	4.2e-07	-0.22	-0.18	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102790277	chr4:102751401~102752641:+
BRCA	cis	rs11976180	1	rs1533266	ENSG00000273234.1	OR2A13P	-6	2.66e-09	4.2e-07	-0.25	-0.18	Obesity-related traits;	chr7:144069621	chr7:144142009~144142938:+
BRCA	cis	rs10129255	1	rs10134517	ENSG00000211972.2	IGHV3-66	6	2.66e-09	4.2e-07	0.14	0.18	Kawasaki disease;	chr14:106718498	chr14:106675017~106675544:-
BRCA	cis	rs2688608	0.592	rs10824032	ENSG00000271816.1	BMS1P4	6	2.66e-09	4.2e-07	0.18	0.18	Inflammatory bowel disease;	chr10:73768372	chr10:73699151~73730487:-
BRCA	cis	rs1876905	0.597	rs1150076	ENSG00000271789.1	RP5-1112D6.7	-6	2.67e-09	4.21e-07	-0.27	-0.18	Mean corpuscular hemoglobin;	chr6:111227227	chr6:111297126~111298510:+
BRCA	cis	rs2638953	0.924	rs11524516	ENSG00000278733.1	RP11-425D17.1	-6	2.67e-09	4.21e-07	-0.25	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28209517	chr12:28185625~28186190:-
BRCA	cis	rs7474896	0.559	rs1024202	ENSG00000226578.1	RP11-258F22.1	6	2.67e-09	4.21e-07	0.24	0.18	Obesity (extreme);	chr10:37990049	chr10:37775371~37784131:-
BRCA	cis	rs7474896	0.537	rs1022449	ENSG00000226578.1	RP11-258F22.1	6	2.67e-09	4.21e-07	0.24	0.18	Obesity (extreme);	chr10:37990539	chr10:37775371~37784131:-
BRCA	cis	rs7911264	0.967	rs9419741	ENSG00000236493.2	EIF2S2P3	-6	2.67e-09	4.21e-07	-0.24	-0.18	Inflammatory bowel disease;	chr10:92670768	chr10:92668745~92669743:-
BRCA	cis	rs2153535	0.518	rs1328868	ENSG00000230939.1	RP11-314C16.1	-6	2.67e-09	4.21e-07	-0.22	-0.18	Motion sickness;	chr6:8652345	chr6:8784178~8785445:+
BRCA	cis	rs12893668	0.572	rs4900591	ENSG00000269940.1	RP11-73M18.7	6	2.67e-09	4.21e-07	0.2	0.18	Reticulocyte count;	chr14:103688541	chr14:103694560~103695170:+
BRCA	cis	rs7809950	0.678	rs2107317	ENSG00000238832.1	snoU109	-6	2.67e-09	4.21e-07	-0.28	-0.18	Coronary artery disease;	chr7:107259240	chr7:107603363~107603507:+
BRCA	cis	rs2243480	1	rs73142122	ENSG00000164669.11	INTS4P1	6	2.67e-09	4.22e-07	0.36	0.18	Diabetic kidney disease;	chr7:65846311	chr7:65141225~65234216:+
BRCA	cis	rs2243480	0.901	rs73142137	ENSG00000164669.11	INTS4P1	6	2.67e-09	4.22e-07	0.36	0.18	Diabetic kidney disease;	chr7:65878455	chr7:65141225~65234216:+
BRCA	cis	rs2243480	1	rs13247184	ENSG00000164669.11	INTS4P1	6	2.67e-09	4.22e-07	0.36	0.18	Diabetic kidney disease;	chr7:65893941	chr7:65141225~65234216:+
BRCA	cis	rs2243480	1	rs35283677	ENSG00000164669.11	INTS4P1	6	2.67e-09	4.22e-07	0.36	0.18	Diabetic kidney disease;	chr7:65894246	chr7:65141225~65234216:+
BRCA	cis	rs2243480	1	rs35421653	ENSG00000164669.11	INTS4P1	6	2.67e-09	4.22e-07	0.36	0.18	Diabetic kidney disease;	chr7:65898442	chr7:65141225~65234216:+
BRCA	cis	rs4763879	0.865	rs4763839	ENSG00000214776.8	RP11-726G1.1	-6	2.67e-09	4.22e-07	-0.21	-0.18	Type 1 diabetes;	chr12:9730104	chr12:9467552~9576275:+
BRCA	cis	rs5758511	0.68	rs5758684	ENSG00000205702.9	CYP2D7	6	2.67e-09	4.22e-07	0.2	0.18	Birth weight;	chr22:42253503	chr22:42140203~42144577:-
BRCA	cis	rs6688613	0.685	rs2142615	ENSG00000225171.2	DUTP6	-6	2.68e-09	4.22e-07	-0.25	-0.18	Refractive astigmatism;	chr1:166953494	chr1:166868748~166869209:+
BRCA	cis	rs9880211	0.613	rs13079205	ENSG00000239213.4	NCK1-AS1	6	2.68e-09	4.23e-07	0.23	0.18	Height;Body mass index;	chr3:136081851	chr3:136841726~136862054:-
BRCA	cis	rs2638953	0.924	rs10843125	ENSG00000247934.4	RP11-967K21.1	-6	2.68e-09	4.24e-07	-0.24	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28198308	chr12:28163298~28190738:-
BRCA	cis	rs7260598	0.71	rs10423819	ENSG00000268442.1	CTD-2027I19.2	6	2.68e-09	4.24e-07	0.26	0.18	Response to taxane treatment (placlitaxel);	chr19:24153857	chr19:24162370~24163425:-
BRCA	cis	rs2243480	0.803	rs55700941	ENSG00000232546.1	RP11-458F8.1	-6	2.69e-09	4.24e-07	-0.24	-0.18	Diabetic kidney disease;	chr7:65924813	chr7:66848496~66858136:+
BRCA	cis	rs1707322	0.682	rs3014241	ENSG00000281133.1	AL355480.3	6	2.69e-09	4.24e-07	0.24	0.18	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45622207	chr1:45580892~45580996:-
BRCA	cis	rs2243480	1	rs57057549	ENSG00000230295.1	RP11-458F8.2	-6	2.69e-09	4.24e-07	-0.24	-0.18	Diabetic kidney disease;	chr7:65940751	chr7:66880708~66882981:+
BRCA	cis	rs7809950	0.678	rs7788330	ENSG00000238832.1	snoU109	-6	2.69e-09	4.24e-07	-0.27	-0.18	Coronary artery disease;	chr7:107345203	chr7:107603363~107603507:+
BRCA	cis	rs66887589	0.56	rs9684327	ENSG00000245958.5	RP11-33B1.1	-6	2.69e-09	4.24e-07	-0.16	-0.18	Diastolic blood pressure;	chr4:119444286	chr4:119454791~119552025:+
BRCA	cis	rs1387259	0.929	rs2956703	ENSG00000257763.1	OR5BK1P	6	2.69e-09	4.25e-07	0.19	0.18	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48276511	chr12:48355792~48356614:-
BRCA	cis	rs4683346	0.581	rs339684	ENSG00000173811.9	CCDC13-AS1	-6	2.69e-09	4.25e-07	-0.23	-0.18	Granulocyte percentage of myeloid white cells;	chr3:42742143	chr3:42732575~42746768:+
BRCA	cis	rs7246657	1	rs10426297	ENSG00000267422.1	CTD-2554C21.1	-6	2.7e-09	4.26e-07	-0.28	-0.18	Coronary artery calcification;	chr19:37307471	chr19:37779686~37792865:+
BRCA	cis	rs853679	0.517	rs4711164	ENSG00000204709.4	LINC01556	6	2.71e-09	4.27e-07	0.27	0.18	Depression;	chr6:28147378	chr6:28943877~28944537:+
BRCA	cis	rs853679	0.517	rs4711165	ENSG00000204709.4	LINC01556	6	2.71e-09	4.27e-07	0.27	0.18	Depression;	chr6:28147406	chr6:28943877~28944537:+
BRCA	cis	rs853679	0.517	rs4713148	ENSG00000204709.4	LINC01556	6	2.71e-09	4.27e-07	0.27	0.18	Depression;	chr6:28148143	chr6:28943877~28944537:+
BRCA	cis	rs853679	0.517	rs9348794	ENSG00000204709.4	LINC01556	6	2.71e-09	4.27e-07	0.27	0.18	Depression;	chr6:28149979	chr6:28943877~28944537:+
BRCA	cis	rs853679	0.517	rs9295758	ENSG00000204709.4	LINC01556	6	2.71e-09	4.27e-07	0.27	0.18	Depression;	chr6:28152885	chr6:28943877~28944537:+
BRCA	cis	rs853679	0.517	rs17774663	ENSG00000204709.4	LINC01556	6	2.71e-09	4.27e-07	0.27	0.18	Depression;	chr6:28153120	chr6:28943877~28944537:+
BRCA	cis	rs10515750	0.5	rs10038502	ENSG00000251405.2	CTB-109A12.1	6	2.71e-09	4.27e-07	0.28	0.18	Lung function (FEV1/FVC);	chr5:157279695	chr5:157362615~157460078:-
BRCA	cis	rs7914558	1	rs11191577	ENSG00000213061.2	PFN1P11	6	2.71e-09	4.28e-07	0.24	0.18	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103142408	chr10:102838011~102845473:-
BRCA	cis	rs9907295	0.688	rs9890583	ENSG00000270977.1	AC015849.16	-6	2.71e-09	4.28e-07	-0.27	-0.18	Fibroblast growth factor basic levels;	chr17:35919389	chr17:35893707~35911023:-
BRCA	cis	rs7221109	0.677	rs917593	ENSG00000278834.1	RP11-458J1.1	6	2.71e-09	4.28e-07	0.2	0.18	Type 1 diabetes;	chr17:40660274	chr17:40648300~40649718:+
BRCA	cis	rs7772486	0.875	rs2814871	ENSG00000270638.1	RP3-466P17.1	6	2.71e-09	4.28e-07	0.21	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145991138	chr6:145735570~145737218:+
BRCA	cis	rs2732480	0.577	rs2732457	ENSG00000273765.1	RP11-370I10.11	-6	2.72e-09	4.28e-07	-0.22	-0.18	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48364596	chr12:48360920~48361377:+
BRCA	cis	rs6442522	0.673	rs1869855	ENSG00000249786.6	EAF1-AS1	6	2.72e-09	4.28e-07	0.19	0.18	Uric acid levels;	chr3:15459635	chr3:15436171~15455940:-
BRCA	cis	rs10504130	0.696	rs79069311	ENSG00000272024.1	RP11-546K22.3	-6	2.72e-09	4.28e-07	-0.28	-0.18	Venous thromboembolism (SNP x SNP interaction);	chr8:51926891	chr8:51950284~51950690:+
BRCA	cis	rs10504130	0.696	rs60796336	ENSG00000272024.1	RP11-546K22.3	-6	2.72e-09	4.28e-07	-0.28	-0.18	Venous thromboembolism (SNP x SNP interaction);	chr8:51928310	chr8:51950284~51950690:+
BRCA	cis	rs228614	0.536	rs223420	ENSG00000251288.2	RP11-10L12.2	-6	2.72e-09	4.29e-07	-0.22	-0.18	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102806853	chr4:102751401~102752641:+
BRCA	cis	rs6740322	0.644	rs11690918	ENSG00000234936.1	AC010883.5	6	2.72e-09	4.29e-07	0.21	0.18	Coronary artery disease;	chr2:43246973	chr2:43229573~43233394:+
BRCA	cis	rs7246657	0.941	rs7259618	ENSG00000267422.1	CTD-2554C21.1	-6	2.72e-09	4.29e-07	-0.28	-0.18	Coronary artery calcification;	chr19:37259817	chr19:37779686~37792865:+
BRCA	cis	rs2562456	0.917	rs6511253	ENSG00000268081.1	RP11-678G14.2	-6	2.72e-09	4.29e-07	-0.28	-0.18	Pain;	chr19:21495996	chr19:21554640~21569237:-
BRCA	cis	rs7978895	0.692	rs7315835	ENSG00000258331.1	RP11-118A3.1	6	2.72e-09	4.29e-07	0.18	0.18	Type 2 diabetes;	chr12:43171926	chr12:43155315~43163110:+
BRCA	cis	rs853679	0.517	rs9357063	ENSG00000204709.4	LINC01556	6	2.73e-09	4.3e-07	0.27	0.18	Depression;	chr6:28092227	chr6:28943877~28944537:+
BRCA	cis	rs7520050	0.966	rs34102169	ENSG00000280836.1	AL355480.1	6	2.73e-09	4.3e-07	0.21	0.18	Reticulocyte count;Red blood cell count;	chr1:45959192	chr1:45581219~45581321:-
BRCA	cis	rs2243480	0.901	rs2949697	ENSG00000164669.11	INTS4P1	6	2.73e-09	4.3e-07	0.35	0.18	Diabetic kidney disease;	chr7:65999249	chr7:65141225~65234216:+
BRCA	cis	rs2276314	0.512	rs1789515	ENSG00000278986.1	RP11-723J4.3	6	2.73e-09	4.31e-07	0.21	0.18	Endometriosis;Drug-induced torsades de pointes;	chr18:36055930	chr18:35972151~35973916:+
BRCA	cis	rs7569084	0.687	rs1344891	ENSG00000237979.1	AC007389.1	6	2.73e-09	4.31e-07	0.23	0.18	Sum eosinophil basophil counts;	chr2:65458890	chr2:65500993~65502138:-
BRCA	cis	rs1552244	1	rs61052895	ENSG00000180385.7	EMC3-AS1	6	2.74e-09	4.32e-07	0.23	0.18	Alzheimer's disease;	chr3:10105832	chr3:9986893~10006990:+
BRCA	cis	rs11976180	1	rs2961132	ENSG00000273234.1	OR2A13P	-6	2.74e-09	4.32e-07	-0.25	-0.18	Obesity-related traits;	chr7:144071035	chr7:144142009~144142938:+
BRCA	cis	rs2281636	0.6	rs56901709	ENSG00000233690.1	EBAG9P1	6	2.74e-09	4.32e-07	0.21	0.18	Obesity-related traits;	chr10:99639205	chr10:99697407~99697949:-
BRCA	cis	rs11671005	0.693	rs11084542	ENSG00000252334.1	RNU6-1337P	6	2.74e-09	4.32e-07	0.27	0.18	Mean platelet volume;	chr19:58420732	chr19:58483749~58483843:-
BRCA	cis	rs4908760	0.669	rs4908506	ENSG00000270282.1	RP5-1115A15.2	6	2.75e-09	4.33e-07	0.19	0.18	Vitiligo;	chr1:8668919	chr1:8512653~8513021:+
BRCA	cis	rs1876905	0.539	rs240987	ENSG00000272356.1	RP5-1112D6.8	-6	2.75e-09	4.33e-07	-0.25	-0.18	Mean corpuscular hemoglobin;	chr6:111268552	chr6:111309203~111313517:+
BRCA	cis	rs4713118	0.662	rs175954	ENSG00000219392.1	RP1-265C24.5	-6	2.75e-09	4.33e-07	-0.28	-0.18	Parkinson's disease;	chr6:28043807	chr6:28115628~28116551:+
BRCA	cis	rs11841001	0.915	rs9600526	ENSG00000261105.4	LMO7-AS1	6	2.75e-09	4.33e-07	0.32	0.18	Corneal astigmatism;	chr13:75683251	chr13:75604700~75635994:-
BRCA	cis	rs75422866	0.867	rs73104103	ENSG00000280054.1	RP1-197B17.7	6	2.75e-09	4.33e-07	0.46	0.18	Pneumonia;	chr12:47669604	chr12:47728151~47730598:-
BRCA	cis	rs9287719	0.601	rs10084172	ENSG00000243819.4	RN7SL832P	6	2.75e-09	4.34e-07	0.19	0.18	Prostate cancer;	chr2:10631102	chr2:10690344~10692099:+
BRCA	cis	rs910316	0.967	rs4903292	ENSG00000279594.1	RP11-950C14.10	6	2.75e-09	4.34e-07	0.2	0.18	Height;	chr14:75189542	chr14:75011269~75012851:-
BRCA	cis	rs2243480	0.908	rs55876148	ENSG00000164669.11	INTS4P1	6	2.76e-09	4.35e-07	0.36	0.18	Diabetic kidney disease;	chr7:65914813	chr7:65141225~65234216:+
BRCA	cis	rs1862618	0.853	rs9283717	ENSG00000271828.1	CTD-2310F14.1	6	2.76e-09	4.35e-07	0.26	0.18	Initial pursuit acceleration;	chr5:56782832	chr5:56927874~56929573:+
BRCA	cis	rs11105298	0.891	rs10858898	ENSG00000270344.2	RP11-734K2.4	6	2.76e-09	4.35e-07	0.21	0.18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89528334	chr12:89525654~89548005:+
BRCA	cis	rs2115536	0.64	rs934134	ENSG00000278600.1	RP11-81A1.6	-6	2.76e-09	4.35e-07	-0.16	-0.18	Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Eosinophil counts;Neutrophil percentage of granulocytes;	chr15:79875876	chr15:79920195~79922455:-
BRCA	cis	rs1113500	0.787	rs2336126	ENSG00000226822.1	RP11-356N1.2	6	2.76e-09	4.35e-07	0.24	0.18	Growth-regulated protein alpha levels;	chr1:108098283	chr1:108071482~108074519:+
BRCA	cis	rs72634501	0.716	rs4660165	ENSG00000237624.1	OXCT2P1	-6	2.76e-09	4.35e-07	-0.27	-0.18	HDL cholesterol;	chr1:39112860	chr1:39514956~39516490:+
BRCA	cis	rs7772486	0.719	rs4391282	ENSG00000270638.1	RP3-466P17.1	-6	2.76e-09	4.35e-07	-0.21	-0.18	Lobe attachment (rater-scored or self-reported);	chr6:145955644	chr6:145735570~145737218:+
BRCA	cis	rs1552244	0.935	rs35148833	ENSG00000180385.7	EMC3-AS1	6	2.77e-09	4.36e-07	0.23	0.18	Alzheimer's disease;	chr3:10075253	chr3:9986893~10006990:+
BRCA	cis	rs1387259	0.839	rs7487682	ENSG00000240399.1	RP1-228P16.1	-6	2.77e-09	4.36e-07	-0.21	-0.18	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48185882	chr12:48054813~48055591:-
BRCA	cis	rs1014246	0.778	rs12256473	ENSG00000232767.1	RP11-498B4.5	-6	2.77e-09	4.36e-07	-0.21	-0.18	Age at smoking initiation in chronic obstructive pulmonary disease;	chr10:116718937	chr10:116670103~116672739:+
BRCA	cis	rs17597773	0.638	rs7530074	ENSG00000272823.1	RP11-295M18.6	-6	2.77e-09	4.36e-07	-0.2	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220815924	chr1:220828676~220829211:-
BRCA	cis	rs875971	0.798	rs57739047	ENSG00000224316.1	RP11-479O9.2	6	2.77e-09	4.36e-07	0.19	0.18	Aortic root size;	chr7:66507579	chr7:65773620~65802067:+
BRCA	cis	rs6088580	0.524	rs2378251	ENSG00000269202.1	RP4-614O4.12	6	2.77e-09	4.36e-07	0.19	0.18	Glomerular filtration rate (creatinine);	chr20:34688946	chr20:35201747~35203288:-
BRCA	cis	rs2842992	0.958	rs2758318	ENSG00000237927.1	RP3-393E18.2	-6	2.77e-09	4.37e-07	-0.25	-0.18	Age-related macular degeneration (geographic atrophy);	chr6:159648605	chr6:159586955~159589169:-
BRCA	cis	rs7246657	0.653	rs4805208	ENSG00000226686.6	LINC01535	-6	2.77e-09	4.37e-07	-0.31	-0.18	Coronary artery calcification;	chr19:37183357	chr19:37251912~37265535:+
BRCA	cis	rs2153535	0.585	rs7763881	ENSG00000230939.1	RP11-314C16.1	6	2.77e-09	4.37e-07	0.21	0.18	Motion sickness;	chr6:8653014	chr6:8784178~8785445:+
BRCA	cis	rs2834288	0.535	rs4816469	ENSG00000273102.1	AP000569.9	6	2.77e-09	4.37e-07	0.2	0.18	Gut microbiota (bacterial taxa);	chr21:33952321	chr21:33967101~33968573:-
BRCA	cis	rs17264034	1	rs17264034	ENSG00000250786.1	SNHG18	-6	2.78e-09	4.37e-07	-0.29	-0.18	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9557490	chr5:9546200~9550609:+
BRCA	cis	rs7809950	0.678	rs7788271	ENSG00000238832.1	snoU109	-6	2.78e-09	4.38e-07	-0.27	-0.18	Coronary artery disease;	chr7:107345428	chr7:107603363~107603507:+
BRCA	cis	rs2115536	0.692	rs8036559	ENSG00000278600.1	RP11-81A1.6	-6	2.78e-09	4.38e-07	-0.16	-0.18	Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Eosinophil counts;Neutrophil percentage of granulocytes;	chr15:79878221	chr15:79920195~79922455:-
BRCA	cis	rs2638953	0.924	rs61920245	ENSG00000247934.4	RP11-967K21.1	-6	2.78e-09	4.38e-07	-0.24	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28196081	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.924	rs7957056	ENSG00000247934.4	RP11-967K21.1	-6	2.78e-09	4.38e-07	-0.24	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28203382	chr12:28163298~28190738:-
BRCA	cis	rs11671005	0.735	rs35652377	ENSG00000252334.1	RNU6-1337P	6	2.78e-09	4.38e-07	0.27	0.18	Mean platelet volume;	chr19:58417833	chr19:58483749~58483843:-
BRCA	cis	rs11671005	0.735	rs3088284	ENSG00000252334.1	RNU6-1337P	6	2.78e-09	4.38e-07	0.27	0.18	Mean platelet volume;	chr19:58418060	chr19:58483749~58483843:-
BRCA	cis	rs11671005	0.735	rs12981649	ENSG00000252334.1	RNU6-1337P	6	2.78e-09	4.38e-07	0.27	0.18	Mean platelet volume;	chr19:58418676	chr19:58483749~58483843:-
BRCA	cis	rs7238033	0.663	rs8086631	ENSG00000267193.4	RP11-116O18.3	6	2.78e-09	4.38e-07	0.2	0.18	Bladder cancer;	chr18:45741477	chr18:45669367~45747215:-
BRCA	cis	rs35612822	0.93	rs998102	ENSG00000232485.2	AC098820.3	-6	2.78e-09	4.38e-07	-0.24	-0.18	Kidney disease (early stage) in type 1 diabetes;	chr2:216504463	chr2:216479030~216498761:-
BRCA	cis	rs755249	0.567	rs6668369	ENSG00000237624.1	OXCT2P1	6	2.79e-09	4.39e-07	0.27	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39382675	chr1:39514956~39516490:+
BRCA	cis	rs755249	0.567	rs41270821	ENSG00000237624.1	OXCT2P1	6	2.79e-09	4.39e-07	0.28	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39458060	chr1:39514956~39516490:+
BRCA	cis	rs755249	0.567	rs2296175	ENSG00000237624.1	OXCT2P1	6	2.79e-09	4.39e-07	0.28	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39458726	chr1:39514956~39516490:+
BRCA	cis	rs9880211	0.613	rs28519617	ENSG00000239213.4	NCK1-AS1	6	2.79e-09	4.39e-07	0.23	0.18	Height;Body mass index;	chr3:136156088	chr3:136841726~136862054:-
BRCA	cis	rs9880211	0.613	rs28669017	ENSG00000239213.4	NCK1-AS1	6	2.79e-09	4.39e-07	0.23	0.18	Height;Body mass index;	chr3:136156090	chr3:136841726~136862054:-
BRCA	cis	rs17301013	0.606	rs6656491	ENSG00000227373.4	RP11-160H22.5	6	2.79e-09	4.39e-07	0.28	0.18	Systemic lupus erythematosus;	chr1:174127524	chr1:174115300~174160004:-
BRCA	cis	rs17301013	0.581	rs72711457	ENSG00000227373.4	RP11-160H22.5	6	2.79e-09	4.39e-07	0.28	0.18	Systemic lupus erythematosus;	chr1:174135385	chr1:174115300~174160004:-
BRCA	cis	rs250585	0.736	rs3096175	ENSG00000260136.4	CTD-2270L9.4	6	2.79e-09	4.39e-07	0.18	0.18	Egg allergy;	chr16:23446262	chr16:23452758~23457606:+
BRCA	cis	rs853679	0.517	rs2273564	ENSG00000204709.4	LINC01556	6	2.79e-09	4.39e-07	0.27	0.18	Depression;	chr6:28089816	chr6:28943877~28944537:+
BRCA	cis	rs853679	0.517	rs1853097	ENSG00000204709.4	LINC01556	6	2.79e-09	4.39e-07	0.27	0.18	Depression;	chr6:28090857	chr6:28943877~28944537:+
BRCA	cis	rs853679	0.517	rs9393888	ENSG00000204709.4	LINC01556	6	2.79e-09	4.39e-07	0.27	0.18	Depression;	chr6:28091439	chr6:28943877~28944537:+
BRCA	cis	rs853679	0.517	rs3734573	ENSG00000204709.4	LINC01556	6	2.79e-09	4.39e-07	0.27	0.18	Depression;	chr6:28091659	chr6:28943877~28944537:+
BRCA	cis	rs853679	0.517	rs3823180	ENSG00000204709.4	LINC01556	6	2.79e-09	4.39e-07	0.27	0.18	Depression;	chr6:28093966	chr6:28943877~28944537:+
BRCA	cis	rs853679	0.517	rs9368551	ENSG00000204709.4	LINC01556	6	2.79e-09	4.39e-07	0.27	0.18	Depression;	chr6:28094014	chr6:28943877~28944537:+
BRCA	cis	rs2243480	1	rs781156	ENSG00000232546.1	RP11-458F8.1	-6	2.79e-09	4.39e-07	-0.24	-0.18	Diabetic kidney disease;	chr7:66014154	chr7:66848496~66858136:+
BRCA	cis	rs2243480	1	rs451396	ENSG00000232546.1	RP11-458F8.1	-6	2.79e-09	4.39e-07	-0.24	-0.18	Diabetic kidney disease;	chr7:66019087	chr7:66848496~66858136:+
BRCA	cis	rs2243480	1	rs1715235	ENSG00000232546.1	RP11-458F8.1	-6	2.79e-09	4.39e-07	-0.24	-0.18	Diabetic kidney disease;	chr7:66023407	chr7:66848496~66858136:+
BRCA	cis	rs35612822	0.897	rs12994218	ENSG00000232485.2	AC098820.3	-6	2.79e-09	4.4e-07	-0.24	-0.18	Kidney disease (early stage) in type 1 diabetes;	chr2:216511128	chr2:216479030~216498761:-
BRCA	cis	rs875971	0.545	rs316328	ENSG00000228409.4	CCT6P1	6	2.79e-09	4.4e-07	0.17	0.18	Aortic root size;	chr7:66143851	chr7:65751142~65763354:+
BRCA	cis	rs950169	0.614	rs765524	ENSG00000259728.4	LINC00933	6	2.79e-09	4.4e-07	0.26	0.18	Schizophrenia;	chr15:84013030	chr15:84570649~84580175:+
BRCA	cis	rs45509595	0.841	rs200485	ENSG00000220721.1	OR1F12	6	2.8e-09	4.4e-07	0.32	0.18	Breast cancer;	chr6:27807919	chr6:28073316~28074233:+
BRCA	cis	rs9333029	0.524	rs3890011	ENSG00000238145.2	RP11-346M5.1	6	2.8e-09	4.4e-07	0.18	0.18	Blood metabolite levels;	chr1:46933071	chr1:46891639~46892830:+
BRCA	cis	rs11668609	0.935	rs10412575	ENSG00000268442.1	CTD-2027I19.2	6	2.8e-09	4.4e-07	0.26	0.18	Response to taxane treatment (docetaxel);	chr19:24186084	chr19:24162370~24163425:-
BRCA	cis	rs3733585	0.654	rs4447863	ENSG00000250413.1	RP11-448G15.1	6	2.8e-09	4.4e-07	0.24	0.18	Cleft plate (environmental tobacco smoke interaction);	chr4:9937345	chr4:10006482~10009725:+
BRCA	cis	rs17508449	0.819	rs79667495	ENSG00000232450.1	RP4-730K3.3	-5.99	2.8e-09	4.41e-07	-0.33	-0.18	Leprosy;	chr1:113648707	chr1:113698884~113699631:-
BRCA	cis	rs875971	0.83	rs6950137	ENSG00000224316.1	RP11-479O9.2	5.99	2.8e-09	4.41e-07	0.19	0.18	Aortic root size;	chr7:66511623	chr7:65773620~65802067:+
BRCA	cis	rs669446	0.529	rs6697354	ENSG00000237950.1	RP11-7O11.3	5.99	2.8e-09	4.41e-07	0.21	0.18	Amyotrophic lateral sclerosis (age of onset);	chr1:43685344	chr1:43944370~43946551:-
BRCA	cis	rs897984	0.762	rs897986	ENSG00000275263.1	RP11-1072A3.4	5.99	2.81e-09	4.42e-07	0.22	0.18	Dementia with Lewy bodies;	chr16:30969581	chr16:30956872~30957199:-
BRCA	cis	rs10129255	0.556	rs8010005	ENSG00000274576.2	IGHV2-70	-5.99	2.81e-09	4.42e-07	-0.15	-0.18	Kawasaki disease;	chr14:106777987	chr14:106770577~106771020:-
BRCA	cis	rs10129255	0.556	rs6576224	ENSG00000274576.2	IGHV2-70	-5.99	2.81e-09	4.42e-07	-0.15	-0.18	Kawasaki disease;	chr14:106777997	chr14:106770577~106771020:-
BRCA	cis	rs10129255	0.518	rs8010020	ENSG00000274576.2	IGHV2-70	-5.99	2.81e-09	4.42e-07	-0.15	-0.18	Kawasaki disease;	chr14:106778016	chr14:106770577~106771020:-
BRCA	cis	rs7746199	0.736	rs13192965	ENSG00000220721.1	OR1F12	5.99	2.81e-09	4.42e-07	0.43	0.18	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27704046	chr6:28073316~28074233:+
BRCA	cis	rs7520050	0.966	rs11810993	ENSG00000280836.1	AL355480.1	5.99	2.81e-09	4.43e-07	0.21	0.18	Reticulocyte count;Red blood cell count;	chr1:46013121	chr1:45581219~45581321:-
BRCA	cis	rs17301013	0.507	rs72715260	ENSG00000227373.4	RP11-160H22.5	5.99	2.81e-09	4.43e-07	0.28	0.18	Systemic lupus erythematosus;	chr1:174604995	chr1:174115300~174160004:-
BRCA	cis	rs1552244	1	rs6442150	ENSG00000180385.7	EMC3-AS1	5.99	2.81e-09	4.43e-07	0.23	0.18	Alzheimer's disease;	chr3:10080891	chr3:9986893~10006990:+
BRCA	cis	rs875971	0.545	rs73146609	ENSG00000228409.4	CCT6P1	-5.99	2.82e-09	4.43e-07	-0.19	-0.18	Aortic root size;	chr7:66302477	chr7:65751142~65763354:+
BRCA	cis	rs875971	0.545	rs2173571	ENSG00000228409.4	CCT6P1	-5.99	2.82e-09	4.43e-07	-0.19	-0.18	Aortic root size;	chr7:66305392	chr7:65751142~65763354:+
BRCA	cis	rs9308731	0.591	rs879623	ENSG00000227992.1	AC108463.2	-5.99	2.82e-09	4.44e-07	-0.21	-0.18	Chronic lymphocytic leukemia;	chr2:111189247	chr2:111203964~111206215:-
BRCA	cis	rs5167	0.75	rs3786505	ENSG00000280087.1	CTB-129P6.7	5.99	2.82e-09	4.44e-07	0.23	0.18	Blood protein levels;	chr19:44987312	chr19:44909375~44914968:+
BRCA	cis	rs7914558	1	rs10883826	ENSG00000213061.2	PFN1P11	5.99	2.82e-09	4.44e-07	0.24	0.18	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103071062	chr10:102838011~102845473:-
BRCA	cis	rs17597773	0.638	rs17596850	ENSG00000272823.1	RP11-295M18.6	-5.99	2.82e-09	4.44e-07	-0.22	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220819001	chr1:220828676~220829211:-
BRCA	cis	rs2638953	0.924	rs10843124	ENSG00000247934.4	RP11-967K21.1	-5.99	2.83e-09	4.45e-07	-0.24	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28198189	chr12:28163298~28190738:-
BRCA	cis	rs17508449	0.71	rs6699022	ENSG00000232450.1	RP4-730K3.3	-5.99	2.83e-09	4.45e-07	-0.31	-0.18	Leprosy;	chr1:113567013	chr1:113698884~113699631:-
BRCA	cis	rs17508449	0.736	rs79470224	ENSG00000232450.1	RP4-730K3.3	-5.99	2.83e-09	4.45e-07	-0.31	-0.18	Leprosy;	chr1:113567163	chr1:113698884~113699631:-
BRCA	cis	rs2832191	0.703	rs2853827	ENSG00000176054.6	RPL23P2	5.99	2.83e-09	4.45e-07	0.2	0.18	Dental caries;	chr21:29071275	chr21:28997613~28998033:-
BRCA	cis	rs7587476	1	rs2121285	ENSG00000229267.2	AC072062.1	5.99	2.83e-09	4.45e-07	0.25	0.18	Neuroblastoma;	chr2:214791444	chr2:214810229~214963274:+
BRCA	cis	rs6088813	1	rs6142373	ENSG00000126005.14	MMP24-AS1	5.99	2.83e-09	4.46e-07	0.21	0.18	Height;	chr20:35395511	chr20:35216462~35278131:-
BRCA	cis	rs6088813	1	rs6579234	ENSG00000126005.14	MMP24-AS1	5.99	2.83e-09	4.46e-07	0.21	0.18	Height;	chr20:35395682	chr20:35216462~35278131:-
BRCA	cis	rs3770081	1	rs3770066	ENSG00000273080.1	RP11-301O19.1	-5.99	2.84e-09	4.46e-07	-0.41	-0.18	Facial emotion recognition (sad faces);	chr2:86165227	chr2:86195590~86196049:+
BRCA	cis	rs7927771	0.524	rs1563821	ENSG00000280615.1	Y_RNA	5.99	2.84e-09	4.46e-07	0.21	0.18	Subjective well-being;	chr11:47735016	chr11:47614898~47614994:-
BRCA	cis	rs9287719	0.578	rs62127189	ENSG00000243819.4	RN7SL832P	5.99	2.84e-09	4.46e-07	0.19	0.18	Prostate cancer;	chr2:10621200	chr2:10690344~10692099:+
BRCA	cis	rs250585	0.85	rs7186974	ENSG00000260136.4	CTD-2270L9.4	5.99	2.84e-09	4.47e-07	0.2	0.18	Egg allergy;	chr16:23534157	chr16:23452758~23457606:+
BRCA	cis	rs7520050	0.966	rs7550746	ENSG00000280836.1	AL355480.1	5.99	2.84e-09	4.47e-07	0.21	0.18	Reticulocyte count;Red blood cell count;	chr1:45886047	chr1:45581219~45581321:-
BRCA	cis	rs11722228	0.549	rs56146302	ENSG00000261490.1	RP11-448G15.3	5.99	2.84e-09	4.47e-07	0.21	0.18	Urate levels;Serum uric acid levels;Gout;	chr4:10079428	chr4:10068089~10073019:-
BRCA	cis	rs11722228	0.549	rs55848383	ENSG00000261490.1	RP11-448G15.3	5.99	2.84e-09	4.47e-07	0.21	0.18	Urate levels;Serum uric acid levels;Gout;	chr4:10079493	chr4:10068089~10073019:-
BRCA	cis	rs7246657	1	rs1529957	ENSG00000226686.6	LINC01535	-5.99	2.84e-09	4.47e-07	-0.28	-0.18	Coronary artery calcification;	chr19:37248899	chr19:37251912~37265535:+
BRCA	cis	rs6570726	0.846	rs9376954	ENSG00000270638.1	RP3-466P17.1	5.99	2.85e-09	4.47e-07	0.21	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145622601	chr6:145735570~145737218:+
BRCA	cis	rs2665103	0.61	rs1972460	ENSG00000255769.6	GOLGA2P10	-5.99	2.85e-09	4.47e-07	-0.2	-0.18	Intelligence (multi-trait analysis);	chr15:82238289	chr15:82472993~82513950:-
BRCA	cis	rs12291225	0.877	rs2303974	ENSG00000251991.1	RNU7-49P	5.99	2.85e-09	4.47e-07	0.22	0.18	Sense of smell;	chr11:14243433	chr11:14478892~14478953:+
BRCA	cis	rs2243480	1	rs778729	ENSG00000228409.4	CCT6P1	5.99	2.85e-09	4.47e-07	0.26	0.18	Diabetic kidney disease;	chr7:66359432	chr7:65751142~65763354:+
BRCA	cis	rs2115630	0.967	rs8028490	ENSG00000229212.6	RP11-561C5.4	5.99	2.85e-09	4.48e-07	0.2	0.18	P wave terminal force;	chr15:84734657	chr15:85205440~85234795:-
BRCA	cis	rs10129255	0.518	rs10136903	ENSG00000274576.2	IGHV2-70	-5.99	2.85e-09	4.48e-07	-0.15	-0.18	Kawasaki disease;	chr14:106778866	chr14:106770577~106771020:-
BRCA	cis	rs4372836	0.897	rs6707130	ENSG00000226833.4	AC097724.3	5.99	2.85e-09	4.48e-07	0.22	0.18	Body mass index;	chr2:28750410	chr2:28708953~28736205:-
BRCA	cis	rs2243480	1	rs35820085	ENSG00000230295.1	RP11-458F8.2	-5.99	2.85e-09	4.48e-07	-0.24	-0.18	Diabetic kidney disease;	chr7:65977771	chr7:66880708~66882981:+
BRCA	cis	rs72681920	0.881	rs58584512	ENSG00000246090.5	RP11-696N14.1	-5.99	2.85e-09	4.48e-07	-0.3	-0.18	Alcohol dependence;	chr4:99226296	chr4:99088857~99301356:+
BRCA	cis	rs72681920	0.881	rs58660705	ENSG00000246090.5	RP11-696N14.1	-5.99	2.85e-09	4.48e-07	-0.3	-0.18	Alcohol dependence;	chr4:99235853	chr4:99088857~99301356:+
BRCA	cis	rs72681920	0.786	rs7654607	ENSG00000246090.5	RP11-696N14.1	-5.99	2.85e-09	4.48e-07	-0.3	-0.18	Alcohol dependence;	chr4:99236512	chr4:99088857~99301356:+
BRCA	cis	rs72681920	0.881	rs12501204	ENSG00000246090.5	RP11-696N14.1	-5.99	2.85e-09	4.48e-07	-0.3	-0.18	Alcohol dependence;	chr4:99240005	chr4:99088857~99301356:+
BRCA	cis	rs11722228	0.508	rs3796826	ENSG00000261490.1	RP11-448G15.3	5.99	2.85e-09	4.48e-07	0.21	0.18	Urate levels;Serum uric acid levels;Gout;	chr4:10091104	chr4:10068089~10073019:-
BRCA	cis	rs11722228	0.508	rs3796825	ENSG00000261490.1	RP11-448G15.3	5.99	2.85e-09	4.48e-07	0.21	0.18	Urate levels;Serum uric acid levels;Gout;	chr4:10091255	chr4:10068089~10073019:-
BRCA	cis	rs11671005	0.693	rs34230465	ENSG00000252334.1	RNU6-1337P	5.99	2.85e-09	4.48e-07	0.27	0.18	Mean platelet volume;	chr19:58432209	chr19:58483749~58483843:-
BRCA	cis	rs7569084	0.663	rs4671128	ENSG00000237979.1	AC007389.1	5.99	2.85e-09	4.49e-07	0.23	0.18	Sum eosinophil basophil counts;	chr2:65438130	chr2:65500993~65502138:-
BRCA	cis	rs2644899	0.859	rs2545757	ENSG00000268529.1	CYP2T3P	5.99	2.86e-09	4.49e-07	0.25	0.18	Post bronchodilator FEV1/FVC ratio;	chr19:40791397	chr19:41134722~41137308:+
BRCA	cis	rs1979679	0.842	rs34043014	ENSG00000278733.1	RP11-425D17.1	5.99	2.86e-09	4.5e-07	0.22	0.18	Ossification of the posterior longitudinal ligament of the spine;	chr12:28171359	chr12:28185625~28186190:-
BRCA	cis	rs1979679	0.842	rs10492370	ENSG00000278733.1	RP11-425D17.1	5.99	2.86e-09	4.5e-07	0.22	0.18	Ossification of the posterior longitudinal ligament of the spine;	chr12:28171900	chr12:28185625~28186190:-
BRCA	cis	rs1552244	0.938	rs34750074	ENSG00000180385.7	EMC3-AS1	5.99	2.87e-09	4.5e-07	0.23	0.18	Alzheimer's disease;	chr3:10050056	chr3:9986893~10006990:+
BRCA	cis	rs755249	0.567	rs61779306	ENSG00000237624.1	OXCT2P1	5.99	2.87e-09	4.51e-07	0.28	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39456754	chr1:39514956~39516490:+
BRCA	cis	rs9543976	1	rs2031236	ENSG00000261105.4	LMO7-AS1	-5.99	2.87e-09	4.51e-07	-0.31	-0.18	Diabetic retinopathy;	chr13:75595641	chr13:75604700~75635994:-
BRCA	cis	rs301901	0.664	rs4504403	ENSG00000250155.1	CTD-2353F22.1	5.99	2.87e-09	4.51e-07	0.21	0.18	Height;	chr5:37481330	chr5:36666214~36725195:-
BRCA	cis	rs7267979	0.509	rs6115218	ENSG00000274973.1	RP13-401N8.7	-5.99	2.87e-09	4.52e-07	-0.22	-0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25585849	chr20:25845497~25845862:+
BRCA	cis	rs11763147	1	rs11763147	ENSG00000234585.5	CCT6P3	-5.99	2.88e-09	4.52e-07	-0.17	-0.18	Corneal structure;	chr7:65861834	chr7:65038354~65074713:+
BRCA	cis	rs2688608	0.836	rs2675668	ENSG00000271816.1	BMS1P4	5.99	2.88e-09	4.53e-07	0.18	0.18	Inflammatory bowel disease;	chr10:73876390	chr10:73699151~73730487:-
BRCA	cis	rs7772486	0.686	rs857875	ENSG00000270638.1	RP3-466P17.1	-5.99	2.88e-09	4.53e-07	-0.21	-0.18	Lobe attachment (rater-scored or self-reported);	chr6:145658897	chr6:145735570~145737218:+
BRCA	cis	rs4604234	0.614	rs73479932	ENSG00000272129.1	RP11-250B2.6	-5.99	2.89e-09	4.53e-07	-0.46	-0.18	Cancer;	chr6:80132154	chr6:80355424~80356859:+
BRCA	cis	rs34792	0.554	rs12708796	ENSG00000207425.1	Y_RNA	-5.99	2.89e-09	4.53e-07	-0.22	-0.18	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15535980	chr16:14915457~14915556:-
BRCA	cis	rs2015599	0.549	rs7134187	ENSG00000275476.1	RP11-996F15.4	-5.99	2.89e-09	4.54e-07	-0.2	-0.18	Platelet count;Mean platelet volume;	chr12:29294113	chr12:29277397~29277882:-
BRCA	cis	rs12893668	0.543	rs1799796	ENSG00000269910.1	RP11-73M18.10	5.99	2.89e-09	4.54e-07	0.19	0.18	Reticulocyte count;	chr14:103699590	chr14:103694516~103695050:-
BRCA	cis	rs2562456	0.682	rs11085464	ENSG00000268081.1	RP11-678G14.2	5.99	2.89e-09	4.54e-07	0.27	0.18	Pain;	chr19:21568976	chr19:21554640~21569237:-
BRCA	cis	rs2644899	0.793	rs2644916	ENSG00000268529.1	CYP2T3P	5.99	2.89e-09	4.55e-07	0.25	0.18	Post bronchodilator FEV1/FVC ratio;	chr19:40803306	chr19:41134722~41137308:+
BRCA	cis	rs17253792	0.915	rs75862063	ENSG00000186615.9	KTN1-AS1	-5.99	2.9e-09	4.55e-07	-0.38	-0.18	Putamen volume;	chr14:55711051	chr14:55499278~55580110:-
BRCA	cis	rs2337406	0.587	rs10129888	ENSG00000254174.1	IGHV1-12	5.99	2.9e-09	4.55e-07	0.18	0.18	Alzheimer's disease (late onset);	chr14:106647421	chr14:106122420~106122709:-
BRCA	cis	rs2243480	1	rs313803	ENSG00000232559.3	GS1-124K5.12	5.99	2.9e-09	4.55e-07	0.35	0.18	Diabetic kidney disease;	chr7:66049744	chr7:66554588~66576923:-
BRCA	cis	rs651907	0.514	rs12636047	ENSG00000244119.1	PDCL3P4	5.99	2.9e-09	4.56e-07	0.15	0.18	Colorectal cancer;	chr3:101715605	chr3:101712472~101713191:+
BRCA	cis	rs12893668	0.572	rs1606	ENSG00000269910.1	RP11-73M18.10	5.99	2.9e-09	4.56e-07	0.19	0.18	Reticulocyte count;	chr14:103694944	chr14:103694516~103695050:-
BRCA	cis	rs9309711	0.736	rs13412581	ENSG00000225234.1	TRAPPC12-AS1	-5.99	2.91e-09	4.56e-07	-0.22	-0.18	Neurofibrillary tangles;	chr2:3493416	chr2:3481242~3482409:-
BRCA	cis	rs9876781	1	rs1109227	ENSG00000229759.1	MRPS18AP1	5.99	2.91e-09	4.56e-07	0.21	0.18	Longevity;	chr3:48437797	chr3:48256350~48256938:-
BRCA	cis	rs11098499	0.954	rs4309825	ENSG00000249244.1	RP11-548H18.2	-5.99	2.91e-09	4.56e-07	-0.21	-0.18	Corneal astigmatism;	chr4:119393726	chr4:119391831~119395335:-
BRCA	cis	rs5167	0.781	rs909134	ENSG00000280087.1	CTB-129P6.7	5.99	2.91e-09	4.57e-07	0.23	0.18	Blood protein levels;	chr19:44989803	chr19:44909375~44914968:+
BRCA	cis	rs12468226	0.689	rs73989731	ENSG00000273456.1	RP11-686O6.2	5.99	2.91e-09	4.57e-07	0.26	0.18	Urate levels;	chr2:202109309	chr2:202374932~202375604:-
BRCA	cis	rs2243480	1	rs1039664	ENSG00000232546.1	RP11-458F8.1	-5.99	2.91e-09	4.57e-07	-0.24	-0.18	Diabetic kidney disease;	chr7:65984729	chr7:66848496~66858136:+
BRCA	cis	rs6479891	1	rs9415696	ENSG00000232075.1	MRPL35P2	5.99	2.91e-09	4.57e-07	0.33	0.18	Arthritis (juvenile idiopathic);	chr10:63374588	chr10:63634317~63634827:-
BRCA	cis	rs6479891	1	rs9415697	ENSG00000232075.1	MRPL35P2	5.99	2.91e-09	4.57e-07	0.33	0.18	Arthritis (juvenile idiopathic);	chr10:63375377	chr10:63634317~63634827:-
BRCA	cis	rs6479891	1	rs724553	ENSG00000232075.1	MRPL35P2	5.99	2.91e-09	4.57e-07	0.33	0.18	Arthritis (juvenile idiopathic);	chr10:63380624	chr10:63634317~63634827:-
BRCA	cis	rs897984	0.721	rs28360557	ENSG00000275263.1	RP11-1072A3.4	5.99	2.91e-09	4.57e-07	0.22	0.18	Dementia with Lewy bodies;	chr16:30971939	chr16:30956872~30957199:-
BRCA	cis	rs7246657	0.941	rs12982333	ENSG00000267422.1	CTD-2554C21.1	-5.99	2.91e-09	4.57e-07	-0.27	-0.18	Coronary artery calcification;	chr19:37303822	chr19:37779686~37792865:+
BRCA	cis	rs10833905	0.938	rs10833931	ENSG00000246225.5	RP11-17A1.3	5.99	2.91e-09	4.58e-07	0.26	0.18	Sudden cardiac arrest;	chr11:23075707	chr11:22829380~22945393:+
BRCA	cis	rs4660214	0.724	rs2484751	ENSG00000228060.1	RP11-69E11.8	5.99	2.92e-09	4.58e-07	0.2	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39282867	chr1:39565160~39573203:+
BRCA	cis	rs1160985	0.967	rs1038026	ENSG00000214855.8	APOC1P1	-5.99	2.92e-09	4.58e-07	-0.21	-0.18	C-reactive protein;LDL cholesterol;Lipid traits;Gut microbiota (functional units);LDL cholesterol levels;	chr19:44901805	chr19:44926804~44931386:+
BRCA	cis	rs9840812	0.623	rs4678433	ENSG00000273486.1	RP11-731C17.2	5.99	2.92e-09	4.59e-07	0.22	0.18	Fibrinogen levels;	chr3:136546840	chr3:136837338~136839021:-
BRCA	cis	rs2243480	1	rs35820085	ENSG00000164669.11	INTS4P1	5.99	2.92e-09	4.59e-07	0.35	0.18	Diabetic kidney disease;	chr7:65977771	chr7:65141225~65234216:+
BRCA	cis	rs2243480	0.711	rs2420172	ENSG00000232559.3	GS1-124K5.12	-5.99	2.92e-09	4.59e-07	-0.34	-0.18	Diabetic kidney disease;	chr7:66170354	chr7:66554588~66576923:-
BRCA	cis	rs9840812	0.61	rs34967300	ENSG00000273486.1	RP11-731C17.2	-5.99	2.92e-09	4.59e-07	-0.25	-0.18	Fibrinogen levels;	chr3:136549976	chr3:136837338~136839021:-
BRCA	cis	rs755249	0.567	rs61779284	ENSG00000237624.1	OXCT2P1	5.99	2.93e-09	4.59e-07	0.27	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39389505	chr1:39514956~39516490:+
BRCA	cis	rs5758511	0.773	rs73165164	ENSG00000205702.9	CYP2D7	5.99	2.93e-09	4.59e-07	0.18	0.18	Birth weight;	chr22:41959545	chr22:42140203~42144577:-
BRCA	cis	rs867371	0.502	rs8025964	ENSG00000255769.6	GOLGA2P10	-5.99	2.93e-09	4.6e-07	-0.2	-0.18	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82229429	chr15:82472993~82513950:-
BRCA	cis	rs17508449	0.819	rs3761934	ENSG00000232450.1	RP4-730K3.3	-5.99	2.93e-09	4.6e-07	-0.33	-0.18	Leprosy;	chr1:113646445	chr1:113698884~113699631:-
BRCA	cis	rs1707322	1	rs6687301	ENSG00000281133.1	AL355480.3	-5.99	2.93e-09	4.6e-07	-0.23	-0.18	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45917180	chr1:45580892~45580996:-
BRCA	cis	rs7927771	0.542	rs7102205	ENSG00000280615.1	Y_RNA	5.99	2.93e-09	4.6e-07	0.22	0.18	Subjective well-being;	chr11:47723822	chr11:47614898~47614994:-
BRCA	cis	rs10129255	0.957	rs8009073	ENSG00000224373.3	IGHV4-59	5.99	2.93e-09	4.6e-07	0.12	0.18	Kawasaki disease;	chr14:106777278	chr14:106627249~106627825:-
BRCA	cis	rs1124769	0.672	rs2619696	ENSG00000259378.1	DCAF13P3	-5.99	2.93e-09	4.6e-07	-0.26	-0.18	Cognitive performance;	chr15:50868814	chr15:50944663~50945996:+
BRCA	cis	rs9652601	0.959	rs9652582	ENSG00000274038.1	RP11-66H6.4	-5.99	2.93e-09	4.6e-07	-0.21	-0.18	Systemic lupus erythematosus;	chr16:11080707	chr16:11056556~11057034:+
BRCA	cis	rs7911264	0.967	rs2488087	ENSG00000236493.2	EIF2S2P3	-5.99	2.94e-09	4.61e-07	-0.24	-0.18	Inflammatory bowel disease;	chr10:92686284	chr10:92668745~92669743:-
BRCA	cis	rs67981189	0.896	rs2526890	ENSG00000258571.1	PTTG4P	5.99	2.94e-09	4.61e-07	0.2	0.18	Schizophrenia;	chr14:70963410	chr14:71085482~71085833:-
BRCA	cis	rs904251	0.772	rs2252920	ENSG00000204110.6	RP1-153P14.8	-5.99	2.94e-09	4.61e-07	-0.22	-0.18	Cognitive performance;	chr6:37450551	chr6:37507348~37535616:+
BRCA	cis	rs2554380	0.6	rs6602986	ENSG00000230373.7	GOLGA6L5P	-5.99	2.94e-09	4.61e-07	-0.23	-0.18	Height;	chr15:83778347	chr15:84507885~84516814:-
BRCA	cis	rs9876781	0.9	rs1037773	ENSG00000229759.1	MRPS18AP1	5.99	2.94e-09	4.62e-07	0.21	0.18	Longevity;	chr3:48426493	chr3:48256350~48256938:-
BRCA	cis	rs9876781	1	rs2279077	ENSG00000229759.1	MRPS18AP1	5.99	2.94e-09	4.62e-07	0.21	0.18	Longevity;	chr3:48432839	chr3:48256350~48256938:-
BRCA	cis	rs4218	0.532	rs17236369	ENSG00000277144.1	RP11-59H7.4	-5.99	2.94e-09	4.62e-07	-0.22	-0.18	Social communication problems;	chr15:59021656	chr15:59115547~59116089:-
BRCA	cis	rs7520050	0.966	rs12049588	ENSG00000280836.1	AL355480.1	5.99	2.94e-09	4.62e-07	0.21	0.18	Reticulocyte count;Red blood cell count;	chr1:46006750	chr1:45581219~45581321:-
BRCA	cis	rs7520050	0.966	rs12021587	ENSG00000280836.1	AL355480.1	5.99	2.94e-09	4.62e-07	0.21	0.18	Reticulocyte count;Red blood cell count;	chr1:46007087	chr1:45581219~45581321:-
BRCA	cis	rs4604234	0.614	rs59155686	ENSG00000272129.1	RP11-250B2.6	-5.99	2.95e-09	4.62e-07	-0.45	-0.18	Cancer;	chr6:80141499	chr6:80355424~80356859:+
BRCA	cis	rs755249	0.567	rs2018212	ENSG00000237624.1	OXCT2P1	5.99	2.95e-09	4.62e-07	0.27	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39439916	chr1:39514956~39516490:+
BRCA	cis	rs755249	0.567	rs4660751	ENSG00000237624.1	OXCT2P1	5.99	2.95e-09	4.62e-07	0.27	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39440201	chr1:39514956~39516490:+
BRCA	cis	rs11105298	0.891	rs10858899	ENSG00000270344.2	RP11-734K2.4	5.99	2.95e-09	4.62e-07	0.21	0.18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89530034	chr12:89525654~89548005:+
BRCA	cis	rs7789940	1	rs76024966	ENSG00000186704.9	DTX2P1	5.99	2.95e-09	4.63e-07	0.22	0.18	Multiple sclerosis;	chr7:76365704	chr7:76978617~77004308:+
BRCA	cis	rs7208859	0.673	rs73263776	ENSG00000265443.1	CTD-2349P21.6	-5.99	2.95e-09	4.63e-07	-0.31	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30884313	chr17:30726305~30727564:-
BRCA	cis	rs7208859	0.623	rs11650271	ENSG00000265443.1	CTD-2349P21.6	-5.99	2.95e-09	4.63e-07	-0.31	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30886925	chr17:30726305~30727564:-
BRCA	cis	rs853679	0.517	rs9393895	ENSG00000219392.1	RP1-265C24.5	-5.99	2.95e-09	4.63e-07	-0.28	-0.18	Depression;	chr6:28159843	chr6:28115628~28116551:+
BRCA	cis	rs6583826	0.712	rs7099761	ENSG00000236493.2	EIF2S2P3	5.99	2.95e-09	4.63e-07	0.23	0.18	Type 2 diabetes;	chr10:92576042	chr10:92668745~92669743:-
BRCA	cis	rs6088813	1	rs6088816	ENSG00000126005.14	MMP24-AS1	5.99	2.96e-09	4.64e-07	0.21	0.18	Height;	chr20:35394632	chr20:35216462~35278131:-
BRCA	cis	rs7567389	0.677	rs72845991	ENSG00000236682.1	AC068282.3	-5.99	2.96e-09	4.64e-07	-0.28	-0.18	Self-rated health;	chr2:127350331	chr2:127389130~127400580:+
BRCA	cis	rs17597773	0.638	rs6541161	ENSG00000272823.1	RP11-295M18.6	-5.99	2.97e-09	4.65e-07	-0.2	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220820922	chr1:220828676~220829211:-
BRCA	cis	rs2337406	1	rs11845269	ENSG00000254174.1	IGHV1-12	5.99	2.97e-09	4.65e-07	0.19	0.18	Alzheimer's disease (late onset);	chr14:106683851	chr14:106122420~106122709:-
BRCA	cis	rs7555523	0.887	rs7518099	ENSG00000224358.1	RP11-466F5.8	-5.99	2.97e-09	4.66e-07	-0.32	-0.18	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165767643	chr1:165768929~165775176:+
BRCA	cis	rs72681920	0.881	rs2010612	ENSG00000246090.5	RP11-696N14.1	-5.99	2.97e-09	4.66e-07	-0.3	-0.18	Alcohol dependence;	chr4:99250082	chr4:99088857~99301356:+
BRCA	cis	rs67981189	0.778	rs989501	ENSG00000258571.1	PTTG4P	5.99	2.97e-09	4.66e-07	0.2	0.18	Schizophrenia;	chr14:70894697	chr14:71085482~71085833:-
BRCA	cis	rs7246967	0.611	rs73022711	ENSG00000198153.8	ZNF849P	-5.98	2.97e-09	4.66e-07	-0.27	-0.18	Bronchopulmonary dysplasia;	chr19:22692602	chr19:22685167~22686732:+
BRCA	cis	rs7246967	0.673	rs73022713	ENSG00000198153.8	ZNF849P	-5.98	2.97e-09	4.66e-07	-0.27	-0.18	Bronchopulmonary dysplasia;	chr19:22693420	chr19:22685167~22686732:+
BRCA	cis	rs7246967	0.673	rs57027767	ENSG00000198153.8	ZNF849P	-5.98	2.97e-09	4.66e-07	-0.27	-0.18	Bronchopulmonary dysplasia;	chr19:22693733	chr19:22685167~22686732:+
BRCA	cis	rs7246967	0.673	rs62120313	ENSG00000198153.8	ZNF849P	-5.98	2.97e-09	4.66e-07	-0.27	-0.18	Bronchopulmonary dysplasia;	chr19:22694381	chr19:22685167~22686732:+
BRCA	cis	rs7246967	0.673	rs7248107	ENSG00000198153.8	ZNF849P	-5.98	2.97e-09	4.66e-07	-0.27	-0.18	Bronchopulmonary dysplasia;	chr19:22695727	chr19:22685167~22686732:+
BRCA	cis	rs7246967	0.551	rs8102812	ENSG00000198153.8	ZNF849P	-5.98	2.97e-09	4.66e-07	-0.27	-0.18	Bronchopulmonary dysplasia;	chr19:22696441	chr19:22685167~22686732:+
BRCA	cis	rs7246967	0.673	rs8106215	ENSG00000198153.8	ZNF849P	-5.98	2.97e-09	4.66e-07	-0.27	-0.18	Bronchopulmonary dysplasia;	chr19:22696644	chr19:22685167~22686732:+
BRCA	cis	rs7246967	0.611	rs34806882	ENSG00000198153.8	ZNF849P	-5.98	2.97e-09	4.66e-07	-0.27	-0.18	Bronchopulmonary dysplasia;	chr19:22697302	chr19:22685167~22686732:+
BRCA	cis	rs7246967	0.673	rs57736314	ENSG00000198153.8	ZNF849P	-5.98	2.97e-09	4.66e-07	-0.27	-0.18	Bronchopulmonary dysplasia;	chr19:22697470	chr19:22685167~22686732:+
BRCA	cis	rs7246967	0.673	rs3853649	ENSG00000198153.8	ZNF849P	-5.98	2.97e-09	4.66e-07	-0.27	-0.18	Bronchopulmonary dysplasia;	chr19:22697658	chr19:22685167~22686732:+
BRCA	cis	rs7246967	0.673	rs3853650	ENSG00000198153.8	ZNF849P	-5.98	2.97e-09	4.66e-07	-0.27	-0.18	Bronchopulmonary dysplasia;	chr19:22697688	chr19:22685167~22686732:+
BRCA	cis	rs7246967	0.673	rs3844578	ENSG00000198153.8	ZNF849P	-5.98	2.97e-09	4.66e-07	-0.27	-0.18	Bronchopulmonary dysplasia;	chr19:22697808	chr19:22685167~22686732:+
BRCA	cis	rs7246967	0.551	rs3925175	ENSG00000198153.8	ZNF849P	-5.98	2.97e-09	4.66e-07	-0.27	-0.18	Bronchopulmonary dysplasia;	chr19:22698156	chr19:22685167~22686732:+
BRCA	cis	rs7246967	0.551	rs7257333	ENSG00000198153.8	ZNF849P	-5.98	2.97e-09	4.66e-07	-0.27	-0.18	Bronchopulmonary dysplasia;	chr19:22698347	chr19:22685167~22686732:+
BRCA	cis	rs7246967	0.673	rs7245540	ENSG00000198153.8	ZNF849P	-5.98	2.97e-09	4.66e-07	-0.27	-0.18	Bronchopulmonary dysplasia;	chr19:22698702	chr19:22685167~22686732:+
BRCA	cis	rs11105298	0.786	rs10858897	ENSG00000270344.2	RP11-734K2.4	5.98	2.98e-09	4.67e-07	0.21	0.18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89528255	chr12:89525654~89548005:+
BRCA	cis	rs227275	0.524	rs150894	ENSG00000251288.2	RP11-10L12.2	-5.98	2.98e-09	4.67e-07	-0.21	-0.18	Allergic disease (asthma, hay fever or eczema);	chr4:102811541	chr4:102751401~102752641:+
BRCA	cis	rs9880211	0.562	rs13068210	ENSG00000239213.4	NCK1-AS1	5.98	2.98e-09	4.67e-07	0.23	0.18	Height;Body mass index;	chr3:136186704	chr3:136841726~136862054:-
BRCA	cis	rs250585	0.85	rs4968016	ENSG00000260136.4	CTD-2270L9.4	-5.98	2.98e-09	4.67e-07	-0.2	-0.18	Egg allergy;	chr16:23518768	chr16:23452758~23457606:+
BRCA	cis	rs2051773	0.51	rs11024129	ENSG00000184669.7	OR7E14P	-5.98	2.98e-09	4.68e-07	-0.26	-0.18	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);	chr11:17034870	chr11:17013998~17053024:+
BRCA	cis	rs2051773	0.51	rs11024130	ENSG00000184669.7	OR7E14P	-5.98	2.98e-09	4.68e-07	-0.26	-0.18	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);	chr11:17034878	chr11:17013998~17053024:+
BRCA	cis	rs2051773	0.51	rs11024131	ENSG00000184669.7	OR7E14P	-5.98	2.98e-09	4.68e-07	-0.26	-0.18	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);	chr11:17034893	chr11:17013998~17053024:+
BRCA	cis	rs17253792	0.915	rs28663681	ENSG00000186615.9	KTN1-AS1	-5.98	2.99e-09	4.68e-07	-0.38	-0.18	Putamen volume;	chr14:55712102	chr14:55499278~55580110:-
BRCA	cis	rs2638953	0.962	rs11049488	ENSG00000278733.1	RP11-425D17.1	-5.98	2.99e-09	4.69e-07	-0.25	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28259439	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.962	rs57618147	ENSG00000278733.1	RP11-425D17.1	-5.98	2.99e-09	4.69e-07	-0.25	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28259902	chr12:28185625~28186190:-
BRCA	cis	rs7829975	0.54	rs2976909	ENSG00000173295.6	FAM86B3P	-5.98	2.99e-09	4.69e-07	-0.2	-0.18	Mood instability;	chr8:8489180	chr8:8228595~8244865:+
BRCA	cis	rs7520050	0.966	rs12139630	ENSG00000280836.1	AL355480.1	5.98	2.99e-09	4.69e-07	0.21	0.18	Reticulocyte count;Red blood cell count;	chr1:45885263	chr1:45581219~45581321:-
BRCA	cis	rs10208649	0.908	rs11904365	ENSG00000233266.1	HMGB1P31	-5.98	2.99e-09	4.69e-07	-0.42	-0.18	Body mass index;	chr2:53998444	chr2:54051334~54051760:+
BRCA	cis	rs6142102	0.812	rs6059558	ENSG00000275784.1	RP5-1125A11.6	-5.98	2.99e-09	4.69e-07	-0.22	-0.18	Skin pigmentation;	chr20:33929024	chr20:33989480~33991818:-
BRCA	cis	rs1322639	0.571	rs13204417	ENSG00000261039.2	RP11-417E7.2	5.98	3e-09	4.69e-07	0.17	0.18	Pulse pressure;	chr6:169175260	chr6:169175304~169182740:-
BRCA	cis	rs7809950	0.723	rs62483633	ENSG00000238832.1	snoU109	-5.98	3e-09	4.7e-07	-0.27	-0.18	Coronary artery disease;	chr7:107236199	chr7:107603363~107603507:+
BRCA	cis	rs13113518	0.513	rs13132085	ENSG00000223305.1	RN7SKP30	-5.98	3e-09	4.7e-07	-0.23	-0.18	Height;	chr4:55593918	chr4:55540502~55540835:-
BRCA	cis	rs1552244	0.81	rs35711405	ENSG00000180385.7	EMC3-AS1	5.98	3e-09	4.7e-07	0.23	0.18	Alzheimer's disease;	chr3:10075255	chr3:9986893~10006990:+
BRCA	cis	rs919433	0.68	rs2565163	ENSG00000231621.1	AC013264.2	-5.98	3e-09	4.7e-07	-0.18	-0.18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197489690	chr2:197197991~197199273:+
BRCA	cis	rs4604234	0.614	rs73479918	ENSG00000272129.1	RP11-250B2.6	-5.98	3e-09	4.7e-07	-0.46	-0.18	Cancer;	chr6:80130255	chr6:80355424~80356859:+
BRCA	cis	rs7238033	0.641	rs11877028	ENSG00000267193.4	RP11-116O18.3	5.98	3e-09	4.7e-07	0.2	0.18	Bladder cancer;	chr18:45737901	chr18:45669367~45747215:-
BRCA	cis	rs651907	0.557	rs7651406	ENSG00000244119.1	PDCL3P4	5.98	3e-09	4.71e-07	0.15	0.18	Colorectal cancer;	chr3:101674452	chr3:101712472~101713191:+
BRCA	cis	rs6095360	0.727	rs35989889	ENSG00000222365.1	SNORD12B	-5.98	3.01e-09	4.71e-07	-0.23	-0.18	Intelligence (multi-trait analysis);	chr20:49100816	chr20:49280319~49280409:+
BRCA	cis	rs651907	0.557	rs3094295	ENSG00000244119.1	PDCL3P4	5.98	3.01e-09	4.71e-07	0.15	0.18	Colorectal cancer;	chr3:101683151	chr3:101712472~101713191:+
BRCA	cis	rs2243480	1	rs7456042	ENSG00000228409.4	CCT6P1	5.98	3.01e-09	4.72e-07	0.25	0.18	Diabetic kidney disease;	chr7:65834791	chr7:65751142~65763354:+
BRCA	cis	rs2243480	1	rs73142121	ENSG00000228409.4	CCT6P1	5.98	3.01e-09	4.72e-07	0.25	0.18	Diabetic kidney disease;	chr7:65846219	chr7:65751142~65763354:+
BRCA	cis	rs2243480	1	rs34702770	ENSG00000228409.4	CCT6P1	5.98	3.01e-09	4.72e-07	0.25	0.18	Diabetic kidney disease;	chr7:65879836	chr7:65751142~65763354:+
BRCA	cis	rs2243480	1	rs34637256	ENSG00000228409.4	CCT6P1	5.98	3.01e-09	4.72e-07	0.25	0.18	Diabetic kidney disease;	chr7:65895144	chr7:65751142~65763354:+
BRCA	cis	rs9291683	0.546	rs13120348	ENSG00000250413.1	RP11-448G15.1	5.98	3.01e-09	4.72e-07	0.24	0.18	Bone mineral density;	chr4:10051531	chr4:10006482~10009725:+
BRCA	cis	rs2051773	0.567	rs6486346	ENSG00000184669.7	OR7E14P	-5.98	3.01e-09	4.72e-07	-0.26	-0.18	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);	chr11:17028343	chr11:17013998~17053024:+
BRCA	cis	rs2051773	0.567	rs6486347	ENSG00000184669.7	OR7E14P	-5.98	3.01e-09	4.72e-07	-0.26	-0.18	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);	chr11:17028461	chr11:17013998~17053024:+
BRCA	cis	rs77204473	1	rs17120157	ENSG00000254851.1	RP11-109L13.1	-5.98	3.01e-09	4.72e-07	-0.39	-0.18	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116941912	chr11:117135528~117138582:+
BRCA	cis	rs1859596	1	rs1017039	ENSG00000234456.6	MAGI2-AS3	5.98	3.01e-09	4.72e-07	0.12	0.18	Reading or mathematical ability;	chr7:79481476	chr7:79452877~79471208:+
BRCA	cis	rs1859596	1	rs1017040	ENSG00000234456.6	MAGI2-AS3	5.98	3.01e-09	4.72e-07	0.12	0.18	Reading or mathematical ability;	chr7:79481522	chr7:79452877~79471208:+
BRCA	cis	rs919433	0.68	rs788021	ENSG00000231621.1	AC013264.2	-5.98	3.02e-09	4.72e-07	-0.18	-0.18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197428967	chr2:197197991~197199273:+
BRCA	cis	rs13178541	0.81	rs11959218	ENSG00000250378.1	RP11-119J18.1	-5.98	3.02e-09	4.73e-07	-0.25	-0.18	IgG glycosylation;	chr5:135809526	chr5:135812667~135826582:+
BRCA	cis	rs7688540	0.771	rs11729365	ENSG00000211553.1	AC253576.2	-5.98	3.02e-09	4.73e-07	-0.28	-0.18	Facial morphology (factor 6, height of vermillion lower lip);	chr4:278735	chr4:136461~136568:+
BRCA	cis	rs4664293	0.546	rs12469866	ENSG00000226266.5	AC009961.3	5.98	3.03e-09	4.74e-07	0.22	0.18	Monocyte percentage of white cells;	chr2:159766119	chr2:159670708~159712435:-
BRCA	cis	rs7688540	0.8	rs12501727	ENSG00000275426.1	CH17-262A2.1	5.98	3.03e-09	4.75e-07	0.23	0.18	Facial morphology (factor 6, height of vermillion lower lip);	chr4:294285	chr4:149738~150317:+
BRCA	cis	rs6442522	0.643	rs7620149	ENSG00000249786.6	EAF1-AS1	-5.98	3.03e-09	4.75e-07	-0.19	-0.18	Uric acid levels;	chr3:15459389	chr3:15436171~15455940:-
BRCA	cis	rs651907	0.535	rs4342086	ENSG00000244119.1	PDCL3P4	5.98	3.03e-09	4.75e-07	0.15	0.18	Colorectal cancer;	chr3:101784921	chr3:101712472~101713191:+
BRCA	cis	rs6479891	1	rs72829170	ENSG00000232075.1	MRPL35P2	5.98	3.03e-09	4.75e-07	0.33	0.18	Arthritis (juvenile idiopathic);	chr10:63180529	chr10:63634317~63634827:-
BRCA	cis	rs17301013	0.581	rs56158362	ENSG00000227373.4	RP11-160H22.5	5.98	3.03e-09	4.75e-07	0.28	0.18	Systemic lupus erythematosus;	chr1:174166437	chr1:174115300~174160004:-
BRCA	cis	rs4834770	0.718	rs4833618	ENSG00000249244.1	RP11-548H18.2	-5.98	3.04e-09	4.75e-07	-0.2	-0.18	Blood protein levels;	chr4:119388345	chr4:119391831~119395335:-
BRCA	cis	rs669446	0.562	rs6429636	ENSG00000237950.1	RP11-7O11.3	5.98	3.04e-09	4.76e-07	0.21	0.18	Amyotrophic lateral sclerosis (age of onset);	chr1:43717869	chr1:43944370~43946551:-
BRCA	cis	rs7520050	0.933	rs12045165	ENSG00000280836.1	AL355480.1	5.98	3.04e-09	4.76e-07	0.21	0.18	Reticulocyte count;Red blood cell count;	chr1:45790350	chr1:45581219~45581321:-
BRCA	cis	rs7772486	0.754	rs6570703	ENSG00000270638.1	RP3-466P17.1	5.98	3.04e-09	4.76e-07	0.21	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145635916	chr6:145735570~145737218:+
BRCA	cis	rs7255436	0.83	rs4350678	ENSG00000269386.4	RAB11B-AS1	5.98	3.04e-09	4.76e-07	0.2	0.18	HDL cholesterol;	chr19:8382482	chr19:8374373~8390685:-
BRCA	cis	rs7255436	0.931	rs7249520	ENSG00000269386.4	RAB11B-AS1	5.98	3.04e-09	4.76e-07	0.2	0.18	HDL cholesterol;	chr19:8381172	chr19:8374373~8390685:-
BRCA	cis	rs7255436	0.965	rs7249624	ENSG00000269386.4	RAB11B-AS1	5.98	3.04e-09	4.76e-07	0.2	0.18	HDL cholesterol;	chr19:8381251	chr19:8374373~8390685:-
BRCA	cis	rs12073837	0.784	rs35730037	ENSG00000272823.1	RP11-295M18.6	-5.98	3.04e-09	4.76e-07	-0.2	-0.18	F-cell distribution;	chr1:220815403	chr1:220828676~220829211:-
BRCA	cis	rs2243480	1	rs1964692	ENSG00000230295.1	RP11-458F8.2	-5.98	3.04e-09	4.76e-07	-0.24	-0.18	Diabetic kidney disease;	chr7:65989196	chr7:66880708~66882981:+
BRCA	cis	rs7474896	0.526	rs1208716	ENSG00000120555.12	SEPT7P9	5.98	3.05e-09	4.77e-07	0.26	0.18	Obesity (extreme);	chr10:37800345	chr10:38383069~38402916:-
BRCA	cis	rs6142102	0.812	rs6059578	ENSG00000275784.1	RP5-1125A11.6	-5.98	3.05e-09	4.77e-07	-0.23	-0.18	Skin pigmentation;	chr20:33939900	chr20:33989480~33991818:-
BRCA	cis	rs74233809	0.901	rs1004467	ENSG00000213277.3	MARCKSL1P1	5.98	3.05e-09	4.77e-07	0.31	0.18	Birth weight;	chr10:102834750	chr10:103175554~103176094:+
BRCA	cis	rs75422866	0.867	rs79113930	ENSG00000280054.1	RP1-197B17.7	5.98	3.05e-09	4.77e-07	0.46	0.18	Pneumonia;	chr12:47600628	chr12:47728151~47730598:-
BRCA	cis	rs7617773	0.78	rs11706277	ENSG00000228638.1	FCF1P2	-5.98	3.05e-09	4.77e-07	-0.21	-0.18	Coronary artery disease;	chr3:48318943	chr3:48290793~48291375:-
BRCA	cis	rs792448	0.701	rs1774247	ENSG00000226251.4	RP11-15I11.3	-5.98	3.05e-09	4.78e-07	-0.23	-0.18	White blood cell count (basophil);	chr1:212376015	chr1:212225278~212238977:-
BRCA	cis	rs67981189	0.896	rs12892739	ENSG00000269927.1	RP6-91H8.3	5.98	3.05e-09	4.78e-07	0.23	0.18	Schizophrenia;	chr14:70983891	chr14:71141125~71143253:-
BRCA	cis	rs395157	0.591	rs395967	ENSG00000249911.1	LINC01265	5.98	3.06e-09	4.78e-07	0.21	0.18	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr5:38842857	chr5:38710367~38720273:-
BRCA	cis	rs2708377	0.789	rs3911150	ENSG00000247157.5	LINC01252	-5.98	3.06e-09	4.78e-07	-0.34	-0.18	Bitter taste perception;	chr12:11049649	chr12:11548030~11590369:+
BRCA	cis	rs2243480	1	rs73150014	ENSG00000232546.1	RP11-458F8.1	-5.98	3.06e-09	4.78e-07	-0.24	-0.18	Diabetic kidney disease;	chr7:65985932	chr7:66848496~66858136:+
BRCA	cis	rs2297363	0.502	rs4709395	ENSG00000213073.4	RP11-288H12.3	-5.98	3.06e-09	4.78e-07	-0.19	-0.18	Total cholesterol levels;Blood protein levels;	chr6:160057757	chr6:160093082~160096212:+
BRCA	cis	rs2638953	0.853	rs10843195	ENSG00000278733.1	RP11-425D17.1	-5.98	3.06e-09	4.78e-07	-0.24	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28513633	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.853	rs10843196	ENSG00000278733.1	RP11-425D17.1	-5.98	3.06e-09	4.78e-07	-0.24	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28513660	chr12:28185625~28186190:-
BRCA	cis	rs12073837	0.784	rs61830288	ENSG00000272823.1	RP11-295M18.6	-5.98	3.06e-09	4.78e-07	-0.2	-0.18	F-cell distribution;	chr1:220815399	chr1:220828676~220829211:-
BRCA	cis	rs12073837	0.784	rs61830289	ENSG00000272823.1	RP11-295M18.6	-5.98	3.06e-09	4.78e-07	-0.2	-0.18	F-cell distribution;	chr1:220815400	chr1:220828676~220829211:-
BRCA	cis	rs2732480	1	rs2732480	ENSG00000240399.1	RP1-228P16.1	-5.98	3.06e-09	4.78e-07	-0.2	-0.18	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48342520	chr12:48054813~48055591:-
BRCA	cis	rs2243480	1	rs313809	ENSG00000230295.1	RP11-458F8.2	-5.98	3.06e-09	4.78e-07	-0.24	-0.18	Diabetic kidney disease;	chr7:66034996	chr7:66880708~66882981:+
BRCA	cis	rs3764021	0.527	rs10844503	ENSG00000214776.8	RP11-726G1.1	5.98	3.06e-09	4.78e-07	0.23	0.18	Type 1 diabetes;	chr12:9701660	chr12:9467552~9576275:+
BRCA	cis	rs2243480	1	rs35396113	ENSG00000230295.1	RP11-458F8.2	-5.98	3.06e-09	4.78e-07	-0.24	-0.18	Diabetic kidney disease;	chr7:66030474	chr7:66880708~66882981:+
BRCA	cis	rs591584	0.59	rs7126782	ENSG00000255893.1	RP11-685N10.1	-5.98	3.06e-09	4.79e-07	-0.21	-0.18	Macrophage Migration Inhibitory Factor levels;	chr11:94590674	chr11:94472908~94473570:-
BRCA	cis	rs710913	0.717	rs11206377	ENSG00000182109.6	RP11-69E11.4	5.98	3.06e-09	4.79e-07	0.2	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39583432	chr1:39522280~39546187:-
BRCA	cis	rs2562456	0.917	rs2562466	ENSG00000268081.1	RP11-678G14.2	-5.98	3.06e-09	4.79e-07	-0.28	-0.18	Pain;	chr19:21531402	chr19:21554640~21569237:-
BRCA	cis	rs9992667	0.955	rs1962053	ENSG00000231160.8	KLF3-AS1	5.98	3.06e-09	4.79e-07	0.22	0.18	Eosinophil percentage of granulocytes;	chr4:38610736	chr4:38612701~38664883:-
BRCA	cis	rs12655019	0.92	rs6450410	ENSG00000271828.1	CTD-2310F14.1	5.98	3.06e-09	4.79e-07	0.33	0.18	Breast cancer (early onset);	chr5:56910874	chr5:56927874~56929573:+
BRCA	cis	rs4908760	0.827	rs7513420	ENSG00000270282.1	RP5-1115A15.2	5.98	3.07e-09	4.8e-07	0.2	0.18	Vitiligo;	chr1:8620985	chr1:8512653~8513021:+
BRCA	cis	rs1124769	0.672	rs8043017	ENSG00000259378.1	DCAF13P3	5.98	3.07e-09	4.8e-07	0.26	0.18	Cognitive performance;	chr15:50871799	chr15:50944663~50945996:+
BRCA	cis	rs6088813	1	rs1540927	ENSG00000126005.14	MMP24-AS1	5.98	3.07e-09	4.8e-07	0.21	0.18	Height;	chr20:35343541	chr20:35216462~35278131:-
BRCA	cis	rs5015933	0.788	rs13289976	ENSG00000232630.1	PRPS1P2	-5.98	3.07e-09	4.8e-07	-0.17	-0.18	Body mass index;	chr9:125293178	chr9:125150653~125151589:+
BRCA	cis	rs2810114	1	rs2810114	ENSG00000258571.1	PTTG4P	5.98	3.07e-09	4.81e-07	0.21	0.18	Alcohol dependence;	chr14:70928887	chr14:71085482~71085833:-
BRCA	cis	rs2638953	0.815	rs10843193	ENSG00000278733.1	RP11-425D17.1	-5.98	3.07e-09	4.81e-07	-0.24	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28509763	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.853	rs7485676	ENSG00000278733.1	RP11-425D17.1	-5.98	3.07e-09	4.81e-07	-0.24	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28510734	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.853	rs1355473	ENSG00000278733.1	RP11-425D17.1	-5.98	3.07e-09	4.81e-07	-0.24	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28463632	chr12:28185625~28186190:-
BRCA	cis	rs4950322	0.57	rs72691012	ENSG00000278811.3	LINC00624	5.98	3.07e-09	4.81e-07	0.24	0.18	Protein quantitative trait loci;	chr1:147239751	chr1:147258885~147517875:-
BRCA	cis	rs2638953	0.886	rs11049617	ENSG00000278733.1	RP11-425D17.1	-5.98	3.08e-09	4.81e-07	-0.25	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28453344	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.924	rs11049618	ENSG00000278733.1	RP11-425D17.1	-5.98	3.08e-09	4.81e-07	-0.25	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28453371	chr12:28185625~28186190:-
BRCA	cis	rs12655019	0.92	rs12514633	ENSG00000271828.1	CTD-2310F14.1	5.98	3.08e-09	4.82e-07	0.35	0.18	Breast cancer (early onset);	chr5:56940186	chr5:56927874~56929573:+
BRCA	cis	rs3805389	0.924	rs2412665	ENSG00000249700.7	SRD5A3-AS1	-5.98	3.08e-09	4.82e-07	-0.27	-0.18	Waist-to-hip ratio adjusted for body mass index;	chr4:55606812	chr4:55363971~55395847:-
BRCA	cis	rs2276314	0.532	rs11081927	ENSG00000278986.1	RP11-723J4.3	-5.98	3.08e-09	4.82e-07	-0.21	-0.18	Endometriosis;Drug-induced torsades de pointes;	chr18:36034319	chr18:35972151~35973916:+
BRCA	cis	rs10504130	0.696	rs113323463	ENSG00000272024.1	RP11-546K22.3	-5.98	3.09e-09	4.82e-07	-0.28	-0.18	Venous thromboembolism (SNP x SNP interaction);	chr8:51912737	chr8:51950284~51950690:+
BRCA	cis	rs10504130	0.696	rs111926180	ENSG00000272024.1	RP11-546K22.3	-5.98	3.09e-09	4.82e-07	-0.28	-0.18	Venous thromboembolism (SNP x SNP interaction);	chr8:51913101	chr8:51950284~51950690:+
BRCA	cis	rs710913	0.691	rs1180351	ENSG00000182109.6	RP11-69E11.4	-5.98	3.09e-09	4.83e-07	-0.2	-0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39541605	chr1:39522280~39546187:-
BRCA	cis	rs2288884	0.708	rs11665783	ENSG00000275055.1	CTC-471J1.11	-5.98	3.09e-09	4.83e-07	-0.25	-0.18	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52014641	chr19:52049007~52049754:+
BRCA	cis	rs2286503	0.752	rs59538378	ENSG00000228649.7	AC005682.5	5.98	3.09e-09	4.83e-07	0.16	0.18	Fibrinogen;	chr7:22837478	chr7:22854178~22861579:+
BRCA	cis	rs2638953	0.924	rs12372372	ENSG00000247934.4	RP11-967K21.1	-5.98	3.09e-09	4.83e-07	-0.24	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28147877	chr12:28163298~28190738:-
BRCA	cis	rs227932	0.571	rs3801898	ENSG00000234286.1	AC006026.13	-5.98	3.09e-09	4.83e-07	-0.32	-0.18	Schizophrenia;	chr7:23762526	chr7:23680195~23680786:-
BRCA	cis	rs669446	0.528	rs7538463	ENSG00000237950.1	RP11-7O11.3	5.98	3.09e-09	4.83e-07	0.21	0.18	Amyotrophic lateral sclerosis (age of onset);	chr1:43730745	chr1:43944370~43946551:-
BRCA	cis	rs8054556	1	rs4283241	ENSG00000273724.1	RP11-347C12.12	5.98	3.09e-09	4.83e-07	0.2	0.18	Autism spectrum disorder or schizophrenia;	chr16:29977028	chr16:30336400~30343336:+
BRCA	cis	rs875971	0.862	rs778720	ENSG00000224316.1	RP11-479O9.2	-5.98	3.09e-09	4.84e-07	-0.19	-0.18	Aortic root size;	chr7:66381288	chr7:65773620~65802067:+
BRCA	cis	rs2836950	0.501	rs4818018	ENSG00000255568.3	BRWD1-AS2	-5.98	3.09e-09	4.84e-07	-0.17	-0.18	Menarche (age at onset);	chr21:39322146	chr21:39313935~39314962:+
BRCA	cis	rs2836950	0.501	rs4818019	ENSG00000255568.3	BRWD1-AS2	-5.98	3.09e-09	4.84e-07	-0.17	-0.18	Menarche (age at onset);	chr21:39322530	chr21:39313935~39314962:+
BRCA	cis	rs2403083	0.505	rs2291786	ENSG00000258256.1	RP11-219B4.5	5.98	3.09e-09	4.84e-07	0.21	0.18	Plasma amyloid beta peptide concentrations (ABx-40);	chr8:85230496	chr8:85222446~85245717:-
BRCA	cis	rs7914558	1	rs8139	ENSG00000213061.2	PFN1P11	5.98	3.1e-09	4.84e-07	0.24	0.18	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103088366	chr10:102838011~102845473:-
BRCA	cis	rs7772486	0.686	rs6570705	ENSG00000270638.1	RP3-466P17.1	5.98	3.1e-09	4.84e-07	0.21	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145640065	chr6:145735570~145737218:+
BRCA	cis	rs2834288	0.613	rs2040113	ENSG00000273102.1	AP000569.9	5.98	3.1e-09	4.84e-07	0.19	0.18	Gut microbiota (bacterial taxa);	chr21:33908879	chr21:33967101~33968573:-
BRCA	cis	rs8114671	0.586	rs734111	ENSG00000269202.1	RP4-614O4.12	-5.98	3.1e-09	4.85e-07	-0.2	-0.18	Height;	chr20:34945933	chr20:35201747~35203288:-
BRCA	cis	rs17597773	0.638	rs10495152	ENSG00000272823.1	RP11-295M18.6	-5.98	3.1e-09	4.85e-07	-0.2	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220817013	chr1:220828676~220829211:-
BRCA	cis	rs12073837	0.784	rs6673877	ENSG00000272823.1	RP11-295M18.6	-5.98	3.1e-09	4.85e-07	-0.2	-0.18	F-cell distribution;	chr1:220817642	chr1:220828676~220829211:-
BRCA	cis	rs910316	1	rs13099	ENSG00000279594.1	RP11-950C14.10	-5.98	3.1e-09	4.85e-07	-0.2	-0.18	Height;	chr14:75132452	chr14:75011269~75012851:-
BRCA	cis	rs7772486	0.686	rs9497395	ENSG00000270638.1	RP3-466P17.1	-5.98	3.11e-09	4.86e-07	-0.21	-0.18	Lobe attachment (rater-scored or self-reported);	chr6:145692456	chr6:145735570~145737218:+
BRCA	cis	rs867371	1	rs11855089	ENSG00000276710.3	CSPG4P8	-5.98	3.11e-09	4.86e-07	-0.2	-0.18	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82154924	chr15:82459472~82477258:+
BRCA	cis	rs7520050	0.966	rs6668284	ENSG00000280836.1	AL355480.1	5.98	3.12e-09	4.87e-07	0.21	0.18	Reticulocyte count;Red blood cell count;	chr1:45888838	chr1:45581219~45581321:-
BRCA	cis	rs559928	0.557	rs7122408	ENSG00000236935.1	AP003774.1	5.98	3.12e-09	4.87e-07	0.26	0.18	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64131354	chr11:64325050~64329504:-
BRCA	cis	rs4763879	0.778	rs2895989	ENSG00000256673.1	RP11-599J14.2	5.98	3.12e-09	4.88e-07	0.2	0.18	Type 1 diabetes;	chr12:9688735	chr12:9398355~9414851:-
BRCA	cis	rs4950322	0.57	rs4950409	ENSG00000244371.2	PFN1P8	-5.98	3.12e-09	4.88e-07	-0.26	-0.18	Protein quantitative trait loci;	chr1:147335879	chr1:146957117~146957659:-
BRCA	cis	rs4950322	0.57	rs72692980	ENSG00000244371.2	PFN1P8	-5.98	3.12e-09	4.88e-07	-0.26	-0.18	Protein quantitative trait loci;	chr1:147337830	chr1:146957117~146957659:-
BRCA	cis	rs755249	0.567	rs72661961	ENSG00000237624.1	OXCT2P1	5.98	3.12e-09	4.88e-07	0.27	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39366096	chr1:39514956~39516490:+
BRCA	cis	rs755249	0.532	rs61779277	ENSG00000237624.1	OXCT2P1	5.98	3.12e-09	4.88e-07	0.27	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39367863	chr1:39514956~39516490:+
BRCA	cis	rs755249	0.532	rs61779278	ENSG00000237624.1	OXCT2P1	5.98	3.12e-09	4.88e-07	0.27	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39368945	chr1:39514956~39516490:+
BRCA	cis	rs755249	0.567	rs2296172	ENSG00000237624.1	OXCT2P1	5.98	3.12e-09	4.88e-07	0.27	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39370145	chr1:39514956~39516490:+
BRCA	cis	rs755249	0.567	rs61779279	ENSG00000237624.1	OXCT2P1	5.98	3.12e-09	4.88e-07	0.27	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39371430	chr1:39514956~39516490:+
BRCA	cis	rs11671005	0.735	rs11084543	ENSG00000252334.1	RNU6-1337P	5.98	3.13e-09	4.89e-07	0.27	0.18	Mean platelet volume;	chr19:58421334	chr19:58483749~58483843:-
BRCA	cis	rs11671005	0.735	rs12981875	ENSG00000252334.1	RNU6-1337P	5.98	3.13e-09	4.89e-07	0.27	0.18	Mean platelet volume;	chr19:58423763	chr19:58483749~58483843:-
BRCA	cis	rs2243480	1	rs313820	ENSG00000232559.3	GS1-124K5.12	5.98	3.13e-09	4.89e-07	0.35	0.18	Diabetic kidney disease;	chr7:66109479	chr7:66554588~66576923:-
BRCA	cis	rs9880211	0.613	rs34864445	ENSG00000239213.4	NCK1-AS1	5.98	3.13e-09	4.89e-07	0.23	0.18	Height;Body mass index;	chr3:136104082	chr3:136841726~136862054:-
BRCA	cis	rs7520050	1	rs12143096	ENSG00000280836.1	AL355480.1	5.98	3.13e-09	4.89e-07	0.21	0.18	Reticulocyte count;Red blood cell count;	chr1:46004091	chr1:45581219~45581321:-
BRCA	cis	rs17597773	0.674	rs11118619	ENSG00000272823.1	RP11-295M18.6	-5.98	3.13e-09	4.89e-07	-0.22	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220838921	chr1:220828676~220829211:-
BRCA	cis	rs7246657	0.943	rs8106839	ENSG00000226686.6	LINC01535	-5.98	3.13e-09	4.89e-07	-0.27	-0.18	Coronary artery calcification;	chr19:37467573	chr19:37251912~37265535:+
BRCA	cis	rs34792	0.554	rs62039131	ENSG00000207425.1	Y_RNA	-5.98	3.13e-09	4.9e-07	-0.23	-0.18	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15528701	chr16:14915457~14915556:-
BRCA	cis	rs4908760	0.613	rs2401189	ENSG00000270282.1	RP5-1115A15.2	5.98	3.13e-09	4.9e-07	0.19	0.18	Vitiligo;	chr1:8758541	chr1:8512653~8513021:+
BRCA	cis	rs9311474	0.597	rs6778735	ENSG00000243224.1	RP5-1157M23.2	-5.98	3.14e-09	4.9e-07	-0.19	-0.18	Electroencephalogram traits;	chr3:52531084	chr3:52239258~52241097:+
BRCA	cis	rs867371	1	rs13380319	ENSG00000276710.3	CSPG4P8	-5.98	3.14e-09	4.9e-07	-0.19	-0.18	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82214526	chr15:82459472~82477258:+
BRCA	cis	rs2179367	0.6	rs1001305	ENSG00000216906.2	RP11-350J20.9	5.98	3.14e-09	4.91e-07	0.27	0.18	Dupuytren's disease;	chr6:149436808	chr6:149904243~149906418:+
BRCA	cis	rs72615157	0.628	rs7801070	ENSG00000242294.5	STAG3L5P	5.98	3.15e-09	4.91e-07	0.16	0.18	Lung function (FEV1/FVC);	chr7:100249524	chr7:100336079~100351900:+
BRCA	cis	rs2243480	1	rs316322	ENSG00000228409.4	CCT6P1	5.98	3.15e-09	4.91e-07	0.25	0.18	Diabetic kidney disease;	chr7:66146246	chr7:65751142~65763354:+
BRCA	cis	rs67981189	0.529	rs2526857	ENSG00000258571.1	PTTG4P	5.98	3.15e-09	4.91e-07	0.21	0.18	Schizophrenia;	chr14:70945909	chr14:71085482~71085833:-
BRCA	cis	rs2998286	0.862	rs2790460	ENSG00000254635.4	WAC-AS1	-5.98	3.15e-09	4.92e-07	-0.25	-0.18	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28502093	chr10:28522652~28532743:-
BRCA	cis	rs6504622	0.791	rs758392	ENSG00000262879.4	RP11-156P1.3	-5.98	3.15e-09	4.92e-07	-0.18	-0.18	Orofacial clefts;	chr17:46940493	chr17:46984045~47100323:-
BRCA	cis	rs11098499	1	rs7659194	ENSG00000249244.1	RP11-548H18.2	5.98	3.15e-09	4.92e-07	0.22	0.18	Corneal astigmatism;	chr4:119285992	chr4:119391831~119395335:-
BRCA	cis	rs227275	0.525	rs724446	ENSG00000251288.2	RP11-10L12.2	-5.98	3.15e-09	4.92e-07	-0.21	-0.18	Allergic disease (asthma, hay fever or eczema);	chr4:103010206	chr4:102751401~102752641:+
BRCA	cis	rs73198271	0.74	rs1039912	ENSG00000253893.2	FAM85B	5.98	3.15e-09	4.92e-07	0.26	0.18	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8790719	chr8:8167819~8226614:-
BRCA	cis	rs1499614	0.522	rs13247442	ENSG00000232546.1	RP11-458F8.1	-5.97	3.16e-09	4.93e-07	-0.31	-0.18	Gout;	chr7:66723871	chr7:66848496~66858136:+
BRCA	cis	rs7246657	0.551	rs10407224	ENSG00000226686.6	LINC01535	-5.97	3.16e-09	4.93e-07	-0.31	-0.18	Coronary artery calcification;	chr19:37160568	chr19:37251912~37265535:+
BRCA	cis	rs3794924	1	rs7236328	ENSG00000266521.1	RP11-650P15.1	-5.97	3.16e-09	4.93e-07	-0.32	-0.18	Survival in colon cancer;	chr18:31475130	chr18:31496645~31497195:-
BRCA	cis	rs9311474	0.607	rs4687625	ENSG00000243224.1	RP5-1157M23.2	-5.97	3.16e-09	4.93e-07	-0.2	-0.18	Electroencephalogram traits;	chr3:52529702	chr3:52239258~52241097:+
BRCA	cis	rs3764021	0.87	rs7976584	ENSG00000214776.8	RP11-726G1.1	5.97	3.16e-09	4.93e-07	0.2	0.18	Type 1 diabetes;	chr12:9726059	chr12:9467552~9576275:+
BRCA	cis	rs5769707	0.609	rs2007024	ENSG00000235111.1	RP1-29C18.8	-5.97	3.16e-09	4.93e-07	-0.2	-0.18	Monocyte percentage of white cells;Monocyte count;	chr22:49595167	chr22:49612657~49615716:-
BRCA	cis	rs7520050	0.966	rs12144263	ENSG00000280836.1	AL355480.1	5.97	3.16e-09	4.93e-07	0.21	0.18	Reticulocyte count;Red blood cell count;	chr1:45886774	chr1:45581219~45581321:-
BRCA	cis	rs2562456	0.917	rs9304987	ENSG00000268081.1	RP11-678G14.2	-5.97	3.16e-09	4.94e-07	-0.27	-0.18	Pain;	chr19:21499472	chr19:21554640~21569237:-
BRCA	cis	rs11098499	0.863	rs3775854	ENSG00000249244.1	RP11-548H18.2	5.97	3.16e-09	4.94e-07	0.22	0.18	Corneal astigmatism;	chr4:119550816	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.863	rs6853998	ENSG00000249244.1	RP11-548H18.2	5.97	3.16e-09	4.94e-07	0.22	0.18	Corneal astigmatism;	chr4:119554705	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.863	rs6858777	ENSG00000249244.1	RP11-548H18.2	5.97	3.16e-09	4.94e-07	0.22	0.18	Corneal astigmatism;	chr4:119554811	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.863	rs11731756	ENSG00000249244.1	RP11-548H18.2	5.97	3.16e-09	4.94e-07	0.22	0.18	Corneal astigmatism;	chr4:119557541	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.863	rs34308924	ENSG00000249244.1	RP11-548H18.2	5.97	3.16e-09	4.94e-07	0.22	0.18	Corneal astigmatism;	chr4:119560276	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.863	rs2170276	ENSG00000249244.1	RP11-548H18.2	5.97	3.16e-09	4.94e-07	0.22	0.18	Corneal astigmatism;	chr4:119564669	chr4:119391831~119395335:-
BRCA	cis	rs6088813	1	rs6087705	ENSG00000126005.14	MMP24-AS1	5.97	3.17e-09	4.95e-07	0.21	0.18	Height;	chr20:35413447	chr20:35216462~35278131:-
BRCA	cis	rs12655019	0.92	rs113772507	ENSG00000271828.1	CTD-2310F14.1	5.97	3.17e-09	4.95e-07	0.34	0.18	Breast cancer (early onset);	chr5:56929449	chr5:56927874~56929573:+
BRCA	cis	rs12655019	0.92	rs16886510	ENSG00000271828.1	CTD-2310F14.1	5.97	3.17e-09	4.95e-07	0.34	0.18	Breast cancer (early onset);	chr5:56932618	chr5:56927874~56929573:+
BRCA	cis	rs12655019	0.92	rs78075120	ENSG00000271828.1	CTD-2310F14.1	5.97	3.17e-09	4.95e-07	0.34	0.18	Breast cancer (early onset);	chr5:56932640	chr5:56927874~56929573:+
BRCA	cis	rs2749097	0.609	rs12122838	ENSG00000244256.3	RN7SL130P	-5.97	3.17e-09	4.95e-07	-0.26	-0.18	Alcohol consumption (transferrin glycosylation);	chr1:63646498	chr1:63655743~63656047:+
BRCA	cis	rs17680741	1	rs7093808	ENSG00000226659.1	RP11-137H2.4	5.97	3.18e-09	4.96e-07	0.26	0.18	Coronary artery disease;	chr10:80491293	chr10:80529597~80535942:-
BRCA	cis	rs2243480	1	rs781150	ENSG00000230295.1	RP11-458F8.2	-5.97	3.18e-09	4.96e-07	-0.24	-0.18	Diabetic kidney disease;	chr7:66015986	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs313798	ENSG00000230295.1	RP11-458F8.2	-5.97	3.18e-09	4.96e-07	-0.24	-0.18	Diabetic kidney disease;	chr7:66028044	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs778679	ENSG00000228409.4	CCT6P1	5.97	3.18e-09	4.97e-07	0.26	0.18	Diabetic kidney disease;	chr7:66375924	chr7:65751142~65763354:+
BRCA	cis	rs66887589	0.807	rs9799664	ENSG00000245958.5	RP11-33B1.1	-5.97	3.19e-09	4.97e-07	-0.16	-0.18	Diastolic blood pressure;	chr4:119405523	chr4:119454791~119552025:+
BRCA	cis	rs2998286	0.862	rs1416816	ENSG00000254635.4	WAC-AS1	-5.97	3.19e-09	4.98e-07	-0.24	-0.18	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28503491	chr10:28522652~28532743:-
BRCA	cis	rs2243480	1	rs67728539	ENSG00000229886.1	RP5-1132H15.3	5.97	3.19e-09	4.98e-07	0.32	0.18	Diabetic kidney disease;	chr7:65913137	chr7:66025126~66031544:-
BRCA	cis	rs7937	0.693	rs17726276	ENSG00000268529.1	CYP2T3P	-5.97	3.19e-09	4.98e-07	-0.21	-0.18	Chronic obstructive pulmonary disease;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;	chr19:40785214	chr19:41134722~41137308:+
BRCA	cis	rs11742741	0.539	rs6880304	ENSG00000248874.4	C5orf17	-5.97	3.19e-09	4.98e-07	-0.24	-0.18	Educational attainment;	chr5:24113952	chr5:23951348~24178263:+
BRCA	cis	rs442309	0.687	rs10822054	ENSG00000238280.1	RP11-436D10.3	-5.97	3.19e-09	4.98e-07	-0.25	-0.18	Vogt-Koyanagi-Harada syndrome;	chr10:62720492	chr10:62793562~62805887:-
BRCA	cis	rs4372836	1	rs2169748	ENSG00000226833.4	AC097724.3	-5.97	3.2e-09	4.99e-07	-0.23	-0.18	Body mass index;	chr2:28734887	chr2:28708953~28736205:-
BRCA	cis	rs12893668	0.572	rs1606	ENSG00000269940.1	RP11-73M18.7	5.97	3.2e-09	4.99e-07	0.2	0.18	Reticulocyte count;	chr14:103694944	chr14:103694560~103695170:+
BRCA	cis	rs2243480	0.908	rs313822	ENSG00000229886.1	RP5-1132H15.3	5.97	3.2e-09	4.99e-07	0.33	0.18	Diabetic kidney disease;	chr7:66108952	chr7:66025126~66031544:-
BRCA	cis	rs6479891	1	rs4745729	ENSG00000232075.1	MRPL35P2	5.97	3.2e-09	4.99e-07	0.33	0.18	Arthritis (juvenile idiopathic);	chr10:63517323	chr10:63634317~63634827:-
BRCA	cis	rs6479891	1	rs12416349	ENSG00000232075.1	MRPL35P2	5.97	3.2e-09	4.99e-07	0.33	0.18	Arthritis (juvenile idiopathic);	chr10:63517783	chr10:63634317~63634827:-
BRCA	cis	rs8114671	0.836	rs6058154	ENSG00000269202.1	RP4-614O4.12	5.97	3.2e-09	4.99e-07	0.19	0.18	Height;	chr20:34998031	chr20:35201747~35203288:-
BRCA	cis	rs250585	0.85	rs6497673	ENSG00000260136.4	CTD-2270L9.4	-5.97	3.2e-09	4.99e-07	-0.2	-0.18	Egg allergy;	chr16:23534390	chr16:23452758~23457606:+
BRCA	cis	rs2243480	1	rs466983	ENSG00000232559.3	GS1-124K5.12	5.97	3.2e-09	4.99e-07	0.35	0.18	Diabetic kidney disease;	chr7:66055509	chr7:66554588~66576923:-
BRCA	cis	rs2638953	0.741	rs10843194	ENSG00000278733.1	RP11-425D17.1	-5.97	3.2e-09	5e-07	-0.24	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28510237	chr12:28185625~28186190:-
BRCA	cis	rs754466	0.58	rs11002301	ENSG00000204049.1	RP11-126H7.4	5.97	3.2e-09	5e-07	0.21	0.18	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77814320	chr10:77866875~77869610:+
BRCA	cis	rs6738825	0.606	rs10931784	ENSG00000231621.1	AC013264.2	-5.97	3.21e-09	5e-07	-0.17	-0.18	Crohn's disease;	chr2:197540912	chr2:197197991~197199273:+
BRCA	cis	rs7772486	0.754	rs4360151	ENSG00000270638.1	RP3-466P17.1	-5.97	3.21e-09	5e-07	-0.21	-0.18	Lobe attachment (rater-scored or self-reported);	chr6:145933943	chr6:145735570~145737218:+
BRCA	cis	rs1800795	0.553	rs1524099	ENSG00000179428.2	AC073072.5	-5.97	3.21e-09	5e-07	-0.2	-0.18	Cerebrospinal fluid clusterin levels in APOEe4- carriers;	chr7:22742038	chr7:22725395~22727620:-
BRCA	cis	rs250585	0.736	rs30012	ENSG00000260136.4	CTD-2270L9.4	5.97	3.21e-09	5.01e-07	0.18	0.18	Egg allergy;	chr16:23409622	chr16:23452758~23457606:+
BRCA	cis	rs7493	1	rs2299263	ENSG00000233942.1	AC004012.1	-5.97	3.21e-09	5.01e-07	-0.23	-0.18	Yu-Zhi constitution type in type 2 diabetes;	chr7:95411099	chr7:95471835~95473998:+
BRCA	cis	rs9308731	0.966	rs1877331	ENSG00000227992.1	AC108463.2	-5.97	3.21e-09	5.01e-07	-0.21	-0.18	Chronic lymphocytic leukemia;	chr2:111148933	chr2:111203964~111206215:-
BRCA	cis	rs67981189	0.896	rs2810100	ENSG00000258571.1	PTTG4P	5.97	3.22e-09	5.01e-07	0.2	0.18	Schizophrenia;	chr14:70965455	chr14:71085482~71085833:-
BRCA	cis	rs559928	0.597	rs2186572	ENSG00000236935.1	AP003774.1	5.97	3.22e-09	5.02e-07	0.26	0.18	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64128415	chr11:64325050~64329504:-
BRCA	cis	rs4713118	0.662	rs156744	ENSG00000219392.1	RP1-265C24.5	-5.97	3.22e-09	5.02e-07	-0.27	-0.18	Parkinson's disease;	chr6:27999496	chr6:28115628~28116551:+
BRCA	cis	rs4713118	0.662	rs149947	ENSG00000219392.1	RP1-265C24.5	-5.97	3.22e-09	5.02e-07	-0.27	-0.18	Parkinson's disease;	chr6:28004655	chr6:28115628~28116551:+
BRCA	cis	rs2911132	0.506	rs1862609	ENSG00000248734.2	CTD-2260A17.1	5.97	3.23e-09	5.03e-07	0.22	0.18	Urate levels (BMI interaction);	chr5:96750986	chr5:96784777~96785999:+
BRCA	cis	rs8005677	0.611	rs11624528	ENSG00000279656.1	RP11-298I3.6	5.97	3.23e-09	5.03e-07	0.22	0.18	Cognitive ability (multi-trait analysis);	chr14:22989947	chr14:23023083~23024217:-
BRCA	cis	rs34792	0.554	rs12919246	ENSG00000207425.1	Y_RNA	-5.97	3.23e-09	5.04e-07	-0.22	-0.18	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15533103	chr16:14915457~14915556:-
BRCA	cis	rs4660456	0.504	rs2253835	ENSG00000237899.1	RP4-739H11.3	5.97	3.24e-09	5.04e-07	0.29	0.18	Platelet count;	chr1:40635900	chr1:40669089~40687588:-
BRCA	cis	rs5167	0.781	rs2075619	ENSG00000280087.1	CTB-129P6.7	5.97	3.24e-09	5.05e-07	0.23	0.18	Blood protein levels;	chr19:44992424	chr19:44909375~44914968:+
BRCA	cis	rs7493	0.95	rs7785846	ENSG00000233942.1	AC004012.1	5.97	3.24e-09	5.05e-07	0.23	0.18	Yu-Zhi constitution type in type 2 diabetes;	chr7:95404529	chr7:95471835~95473998:+
BRCA	cis	rs11105298	0.891	rs11105312	ENSG00000270344.2	RP11-734K2.4	5.97	3.24e-09	5.05e-07	0.21	0.18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89526956	chr12:89525654~89548005:+
BRCA	cis	rs11105298	0.891	rs10777185	ENSG00000270344.2	RP11-734K2.4	5.97	3.24e-09	5.05e-07	0.21	0.18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89527498	chr12:89525654~89548005:+
BRCA	cis	rs6479891	1	rs12413730	ENSG00000232075.1	MRPL35P2	5.97	3.24e-09	5.06e-07	0.33	0.18	Arthritis (juvenile idiopathic);	chr10:63204388	chr10:63634317~63634827:-
BRCA	cis	rs651907	0.557	rs11712748	ENSG00000244119.1	PDCL3P4	5.97	3.24e-09	5.06e-07	0.15	0.18	Colorectal cancer;	chr3:101664718	chr3:101712472~101713191:+
BRCA	cis	rs516805	0.748	rs511279	ENSG00000279453.1	RP3-425C14.4	-5.97	3.24e-09	5.06e-07	-0.25	-0.18	Lymphocyte counts;	chr6:122451385	chr6:122436789~122439223:-
BRCA	cis	rs6565180	0.962	rs11642676	ENSG00000183604.13	SMG1P5	-5.97	3.25e-09	5.06e-07	-0.2	-0.18	Tonsillectomy;	chr16:30360334	chr16:30267553~30335374:-
BRCA	cis	rs72681920	0.881	rs12512110	ENSG00000246090.5	RP11-696N14.1	5.97	3.25e-09	5.06e-07	0.28	0.18	Alcohol dependence;	chr4:99274658	chr4:99088857~99301356:+
BRCA	cis	rs7897654	0.571	rs7920697	ENSG00000213061.2	PFN1P11	5.97	3.25e-09	5.07e-07	0.27	0.18	Schizophrenia;	chr10:102873580	chr10:102838011~102845473:-
BRCA	cis	rs72634501	0.54	rs16826036	ENSG00000237624.1	OXCT2P1	5.97	3.25e-09	5.07e-07	0.27	0.18	HDL cholesterol;	chr1:39292127	chr1:39514956~39516490:+
BRCA	cis	rs755249	0.567	rs16826038	ENSG00000237624.1	OXCT2P1	5.97	3.25e-09	5.07e-07	0.27	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39292962	chr1:39514956~39516490:+
BRCA	cis	rs755249	0.567	rs61782157	ENSG00000237624.1	OXCT2P1	5.97	3.25e-09	5.07e-07	0.27	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39297217	chr1:39514956~39516490:+
BRCA	cis	rs755249	0.567	rs41270803	ENSG00000237624.1	OXCT2P1	5.97	3.25e-09	5.07e-07	0.27	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39300369	chr1:39514956~39516490:+
BRCA	cis	rs7927771	0.524	rs3816605	ENSG00000280615.1	Y_RNA	5.97	3.26e-09	5.07e-07	0.21	0.18	Subjective well-being;	chr11:47835701	chr11:47614898~47614994:-
BRCA	cis	rs9876781	1	rs7630741	ENSG00000229759.1	MRPS18AP1	5.97	3.26e-09	5.08e-07	0.21	0.18	Longevity;	chr3:48378233	chr3:48256350~48256938:-
BRCA	cis	rs559928	0.597	rs947939	ENSG00000236935.1	AP003774.1	5.97	3.26e-09	5.08e-07	0.25	0.18	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64117815	chr11:64325050~64329504:-
BRCA	cis	rs669446	0.562	rs3791036	ENSG00000237950.1	RP11-7O11.3	5.97	3.26e-09	5.09e-07	0.21	0.18	Amyotrophic lateral sclerosis (age of onset);	chr1:43689712	chr1:43944370~43946551:-
BRCA	cis	rs2051773	0.538	rs4468326	ENSG00000184669.7	OR7E14P	-5.97	3.27e-09	5.09e-07	-0.27	-0.18	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);	chr11:17019487	chr11:17013998~17053024:+
BRCA	cis	rs1552244	1	rs35220123	ENSG00000180385.7	EMC3-AS1	5.97	3.27e-09	5.09e-07	0.23	0.18	Alzheimer's disease;	chr3:10041485	chr3:9986893~10006990:+
BRCA	cis	rs1552244	0.935	rs4441636	ENSG00000180385.7	EMC3-AS1	5.97	3.27e-09	5.09e-07	0.23	0.18	Alzheimer's disease;	chr3:10042192	chr3:9986893~10006990:+
BRCA	cis	rs6570726	0.967	rs441364	ENSG00000235652.6	RP11-545I5.3	5.97	3.27e-09	5.09e-07	0.18	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145532526	chr6:145799409~145886585:+
BRCA	cis	rs9341808	0.754	rs6907729	ENSG00000272129.1	RP11-250B2.6	-5.97	3.27e-09	5.09e-07	-0.22	-0.18	Sitting height ratio;	chr6:80295205	chr6:80355424~80356859:+
BRCA	cis	rs8114671	0.836	rs6120778	ENSG00000269202.1	RP4-614O4.12	-5.97	3.27e-09	5.1e-07	-0.19	-0.18	Height;	chr20:34977366	chr20:35201747~35203288:-
BRCA	cis	rs7208859	0.673	rs2269915	ENSG00000265443.1	CTD-2349P21.6	-5.97	3.28e-09	5.1e-07	-0.31	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30906326	chr17:30726305~30727564:-
BRCA	cis	rs7208859	0.673	rs2269916	ENSG00000265443.1	CTD-2349P21.6	-5.97	3.28e-09	5.1e-07	-0.31	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30906745	chr17:30726305~30727564:-
BRCA	cis	rs7208859	0.673	rs11649765	ENSG00000265443.1	CTD-2349P21.6	-5.97	3.28e-09	5.1e-07	-0.31	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30906870	chr17:30726305~30727564:-
BRCA	cis	rs2489715	1	rs2505842	ENSG00000185904.10	LINC00839	-5.97	3.28e-09	5.11e-07	-0.26	-0.18	Helix rolling;	chr10:42392112	chr10:42475543~42495336:+
BRCA	cis	rs875971	0.862	rs709609	ENSG00000224316.1	RP11-479O9.2	-5.97	3.28e-09	5.11e-07	-0.19	-0.18	Aortic root size;	chr7:66095574	chr7:65773620~65802067:+
BRCA	cis	rs7493	0.95	rs12704794	ENSG00000233942.1	AC004012.1	5.97	3.28e-09	5.11e-07	0.23	0.18	Yu-Zhi constitution type in type 2 diabetes;	chr7:95406821	chr7:95471835~95473998:+
BRCA	cis	rs2243480	1	rs313813	ENSG00000164669.11	INTS4P1	5.97	3.28e-09	5.11e-07	0.36	0.18	Diabetic kidney disease;	chr7:66038513	chr7:65141225~65234216:+
BRCA	cis	rs11105298	0.891	rs11105313	ENSG00000270344.2	RP11-734K2.4	-5.97	3.28e-09	5.11e-07	-0.21	-0.18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89529599	chr12:89525654~89548005:+
BRCA	cis	rs2243480	1	rs1618893	ENSG00000230295.1	RP11-458F8.2	-5.97	3.28e-09	5.11e-07	-0.23	-0.18	Diabetic kidney disease;	chr7:66631132	chr7:66880708~66882981:+
BRCA	cis	rs9291683	0.51	rs4318649	ENSG00000250413.1	RP11-448G15.1	-5.97	3.28e-09	5.11e-07	-0.24	-0.18	Bone mineral density;	chr4:10015191	chr4:10006482~10009725:+
BRCA	cis	rs3733585	0.746	rs4318650	ENSG00000250413.1	RP11-448G15.1	-5.97	3.28e-09	5.11e-07	-0.24	-0.18	Cleft plate (environmental tobacco smoke interaction);	chr4:10015244	chr4:10006482~10009725:+
BRCA	cis	rs875971	0.545	rs73378304	ENSG00000228409.4	CCT6P1	-5.97	3.28e-09	5.12e-07	-0.18	-0.18	Aortic root size;	chr7:66175760	chr7:65751142~65763354:+
BRCA	cis	rs2051773	0.539	rs34902253	ENSG00000184669.7	OR7E14P	-5.97	3.28e-09	5.12e-07	-0.26	-0.18	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);	chr11:17027833	chr11:17013998~17053024:+
BRCA	cis	rs17301013	0.507	rs2183202	ENSG00000227373.4	RP11-160H22.5	5.97	3.29e-09	5.12e-07	0.28	0.18	Systemic lupus erythematosus;	chr1:174824553	chr1:174115300~174160004:-
BRCA	cis	rs11098499	1	rs11098499	ENSG00000249244.1	RP11-548H18.2	5.97	3.29e-09	5.12e-07	0.22	0.18	Corneal astigmatism;	chr4:119266456	chr4:119391831~119395335:-
BRCA	cis	rs755249	0.567	rs61779285	ENSG00000237624.1	OXCT2P1	5.97	3.29e-09	5.13e-07	0.27	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39401383	chr1:39514956~39516490:+
BRCA	cis	rs11722228	0.549	rs3796818	ENSG00000261490.1	RP11-448G15.3	5.97	3.29e-09	5.13e-07	0.21	0.18	Urate levels;Serum uric acid levels;Gout;	chr4:10096352	chr4:10068089~10073019:-
BRCA	cis	rs2638953	0.924	rs17801442	ENSG00000278733.1	RP11-425D17.1	-5.97	3.3e-09	5.13e-07	-0.23	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28165627	chr12:28185625~28186190:-
BRCA	cis	rs66887589	0.627	rs3872807	ENSG00000245958.5	RP11-33B1.1	-5.97	3.3e-09	5.13e-07	-0.16	-0.18	Diastolic blood pressure;	chr4:119439096	chr4:119454791~119552025:+
BRCA	cis	rs227275	0.556	rs724447	ENSG00000251288.2	RP11-10L12.2	5.97	3.3e-09	5.13e-07	0.22	0.18	Allergic disease (asthma, hay fever or eczema);	chr4:103010149	chr4:102751401~102752641:+
BRCA	cis	rs67981189	0.896	rs7157250	ENSG00000258571.1	PTTG4P	-5.97	3.3e-09	5.14e-07	-0.2	-0.18	Schizophrenia;	chr14:70991112	chr14:71085482~71085833:-
BRCA	cis	rs4660456	0.619	rs753753	ENSG00000237899.1	RP4-739H11.3	-5.97	3.3e-09	5.14e-07	-0.23	-0.18	Platelet count;	chr1:40771716	chr1:40669089~40687588:-
BRCA	cis	rs11671005	0.693	rs11668821	ENSG00000252334.1	RNU6-1337P	5.97	3.31e-09	5.15e-07	0.28	0.18	Mean platelet volume;	chr19:58444446	chr19:58483749~58483843:-
BRCA	cis	rs11671005	0.616	rs12980907	ENSG00000252334.1	RNU6-1337P	5.97	3.31e-09	5.15e-07	0.28	0.18	Mean platelet volume;	chr19:58444959	chr19:58483749~58483843:-
BRCA	cis	rs754466	0.58	rs10824577	ENSG00000204049.1	RP11-126H7.4	5.97	3.31e-09	5.15e-07	0.21	0.18	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77817650	chr10:77866875~77869610:+
BRCA	cis	rs7809950	0.635	rs62483629	ENSG00000238832.1	snoU109	-5.97	3.31e-09	5.15e-07	-0.28	-0.18	Coronary artery disease;	chr7:107225733	chr7:107603363~107603507:+
BRCA	cis	rs42648	0.591	rs11770630	ENSG00000225498.1	AC002064.5	5.97	3.31e-09	5.16e-07	0.17	0.18	Homocysteine levels;	chr7:90175927	chr7:90312496~90322592:+
BRCA	cis	rs17508449	0.819	rs41352847	ENSG00000232450.1	RP4-730K3.3	-5.97	3.31e-09	5.16e-07	-0.33	-0.18	Leprosy;	chr1:113647258	chr1:113698884~113699631:-
BRCA	cis	rs17508449	0.819	rs4839000	ENSG00000232450.1	RP4-730K3.3	-5.97	3.32e-09	5.16e-07	-0.33	-0.18	Leprosy;	chr1:113737513	chr1:113698884~113699631:-
BRCA	cis	rs2281558	0.876	rs6115135	ENSG00000125804.12	FAM182A	-5.97	3.32e-09	5.16e-07	-0.27	-0.18	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25299242	chr20:26054655~26086917:+
BRCA	cis	rs2836950	0.545	rs2836959	ENSG00000255568.3	BRWD1-AS2	-5.97	3.32e-09	5.17e-07	-0.17	-0.18	Menarche (age at onset);	chr21:39251742	chr21:39313935~39314962:+
BRCA	cis	rs11105298	1	rs11105298	ENSG00000270344.2	RP11-734K2.4	-5.97	3.32e-09	5.17e-07	-0.21	-0.18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89482366	chr12:89525654~89548005:+
BRCA	cis	rs73193808	0.951	rs1999323	ENSG00000215533.7	LINC00189	-5.97	3.32e-09	5.18e-07	-0.27	-0.18	Coronary artery disease;	chr21:29161807	chr21:29193480~29288205:+
BRCA	cis	rs13126694	0.744	rs28477319	ENSG00000251429.1	RP11-597D13.7	5.97	3.33e-09	5.18e-07	0.18	0.18	Blood osmolality (transformed sodium);	chr4:158095785	chr4:158270378~158278676:+
BRCA	cis	rs7238033	0.624	rs12455090	ENSG00000267193.4	RP11-116O18.3	-5.97	3.33e-09	5.18e-07	-0.2	-0.18	Bladder cancer;	chr18:45733402	chr18:45669367~45747215:-
BRCA	cis	rs2562456	0.561	rs12610883	ENSG00000268081.1	RP11-678G14.2	5.97	3.33e-09	5.18e-07	0.28	0.18	Pain;	chr19:21567257	chr19:21554640~21569237:-
BRCA	cis	rs2562456	0.837	rs11085462	ENSG00000268081.1	RP11-678G14.2	5.97	3.33e-09	5.18e-07	0.28	0.18	Pain;	chr19:21567449	chr19:21554640~21569237:-
BRCA	cis	rs2243480	1	rs313802	ENSG00000232559.3	GS1-124K5.12	5.97	3.33e-09	5.18e-07	0.35	0.18	Diabetic kidney disease;	chr7:66051386	chr7:66554588~66576923:-
BRCA	cis	rs2243480	0.803	rs403089	ENSG00000232559.3	GS1-124K5.12	5.97	3.33e-09	5.18e-07	0.35	0.18	Diabetic kidney disease;	chr7:66052736	chr7:66554588~66576923:-
BRCA	cis	rs2243480	1	rs458291	ENSG00000232559.3	GS1-124K5.12	5.97	3.33e-09	5.18e-07	0.35	0.18	Diabetic kidney disease;	chr7:66055492	chr7:66554588~66576923:-
BRCA	cis	rs2153535	0.585	rs9393053	ENSG00000230939.1	RP11-314C16.1	-5.97	3.34e-09	5.19e-07	-0.21	-0.18	Motion sickness;	chr6:8644947	chr6:8784178~8785445:+
BRCA	cis	rs780096	1	rs780095	ENSG00000234072.1	AC074117.10	-5.97	3.34e-09	5.19e-07	-0.17	-0.18	Total body bone mineral density;	chr2:27518238	chr2:27356246~27367622:+
BRCA	cis	rs2243480	1	rs316307	ENSG00000229886.1	RP5-1132H15.3	5.97	3.34e-09	5.19e-07	0.33	0.18	Diabetic kidney disease;	chr7:66105184	chr7:66025126~66031544:-
BRCA	cis	rs17508449	0.819	rs78394484	ENSG00000232450.1	RP4-730K3.3	-5.97	3.34e-09	5.19e-07	-0.33	-0.18	Leprosy;	chr1:113740136	chr1:113698884~113699631:-
BRCA	cis	rs9308731	0.666	rs724710	ENSG00000227992.1	AC108463.2	5.97	3.34e-09	5.2e-07	0.22	0.18	Chronic lymphocytic leukemia;	chr2:111150114	chr2:111203964~111206215:-
BRCA	cis	rs4654783	0.627	rs1046310	ENSG00000228397.1	RP1-224A6.3	5.97	3.34e-09	5.2e-07	0.23	0.18	Endometriosis;	chr1:22117394	chr1:22023994~22024968:-
BRCA	cis	rs7897654	0.571	rs12767543	ENSG00000213061.2	PFN1P11	5.96	3.35e-09	5.21e-07	0.27	0.18	Schizophrenia;	chr10:102871906	chr10:102838011~102845473:-
BRCA	cis	rs6832769	0.922	rs9993675	ENSG00000223305.1	RN7SKP30	5.96	3.35e-09	5.21e-07	0.23	0.18	Personality dimensions;	chr4:55377355	chr4:55540502~55540835:-
BRCA	cis	rs6479891	1	rs61855465	ENSG00000232075.1	MRPL35P2	5.96	3.35e-09	5.21e-07	0.33	0.18	Arthritis (juvenile idiopathic);	chr10:63196847	chr10:63634317~63634827:-
BRCA	cis	rs2274273	1	rs11621351	ENSG00000258413.1	RP11-665C16.6	-5.96	3.35e-09	5.22e-07	-0.23	-0.18	Protein biomarker;	chr14:55150022	chr14:55262767~55272075:-
BRCA	cis	rs17508449	0.819	rs79220465	ENSG00000232450.1	RP4-730K3.3	-5.96	3.36e-09	5.22e-07	-0.33	-0.18	Leprosy;	chr1:113628719	chr1:113698884~113699631:-
BRCA	cis	rs2645424	1	rs962366	ENSG00000255046.1	RP11-297N6.4	5.96	3.36e-09	5.22e-07	0.2	0.18	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);	chr8:11826894	chr8:11797928~11802568:-
BRCA	cis	rs7191700	0.644	rs918738	ENSG00000262636.1	CTD-3088G3.4	-5.96	3.36e-09	5.22e-07	-0.24	-0.18	Multiple sclerosis;	chr16:11345822	chr16:11380859~11381118:-
BRCA	cis	rs7598759	0.548	rs6750795	ENSG00000223198.1	RNU2-22P	-5.96	3.36e-09	5.22e-07	-0.23	-0.18	Noise-induced hearing loss;	chr2:231513520	chr2:231501990~231502201:-
BRCA	cis	rs7829975	0.572	rs28730413	ENSG00000233609.3	RP11-62H7.2	-5.96	3.36e-09	5.23e-07	-0.17	-0.18	Mood instability;	chr8:8937937	chr8:8961200~8979025:+
BRCA	cis	rs9353324	1	rs9353324	ENSG00000203875.9	SNHG5	-5.96	3.36e-09	5.23e-07	-0.35	-0.18	Interferon gamma-induced protein 10 levels;	chr6:85653156	chr6:85660950~85678736:-
BRCA	cis	rs227275	0.554	rs223436	ENSG00000251288.2	RP11-10L12.2	-5.96	3.37e-09	5.24e-07	-0.21	-0.18	Allergic disease (asthma, hay fever or eczema);	chr4:102798749	chr4:102751401~102752641:+
BRCA	cis	rs227275	0.554	rs223439	ENSG00000251288.2	RP11-10L12.2	-5.96	3.37e-09	5.24e-07	-0.21	-0.18	Allergic disease (asthma, hay fever or eczema);	chr4:102798377	chr4:102751401~102752641:+
BRCA	cis	rs78487399	0.908	rs6731636	ENSG00000234936.1	AC010883.5	5.96	3.37e-09	5.25e-07	0.24	0.18	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43615907	chr2:43229573~43233394:+
BRCA	cis	rs2243480	1	rs1979823	ENSG00000232559.3	GS1-124K5.12	-5.96	3.37e-09	5.25e-07	-0.35	-0.18	Diabetic kidney disease;	chr7:66239626	chr7:66554588~66576923:-
BRCA	cis	rs910316	0.935	rs11159119	ENSG00000279594.1	RP11-950C14.10	-5.96	3.37e-09	5.25e-07	-0.2	-0.18	Height;	chr14:75170264	chr14:75011269~75012851:-
BRCA	cis	rs9307551	0.948	rs2165386	ENSG00000250334.4	LINC00989	-5.96	3.38e-09	5.25e-07	-0.27	-0.18	Refractive error;	chr4:79582248	chr4:79492416~79576460:+
BRCA	cis	rs9307551	0.948	rs1440853	ENSG00000250334.4	LINC00989	-5.96	3.38e-09	5.25e-07	-0.27	-0.18	Refractive error;	chr4:79585493	chr4:79492416~79576460:+
BRCA	cis	rs2980436	1	rs2980436	ENSG00000173295.6	FAM86B3P	-5.96	3.38e-09	5.26e-07	-0.2	-0.18	Schizophrenia;	chr8:8234503	chr8:8228595~8244865:+
BRCA	cis	rs2562456	0.917	rs2681376	ENSG00000268081.1	RP11-678G14.2	-5.96	3.38e-09	5.26e-07	-0.28	-0.18	Pain;	chr19:21532723	chr19:21554640~21569237:-
BRCA	cis	rs6088813	1	rs6087702	ENSG00000126005.14	MMP24-AS1	5.96	3.38e-09	5.26e-07	0.21	0.18	Height;	chr20:35408142	chr20:35216462~35278131:-
BRCA	cis	rs7927771	0.542	rs6485775	ENSG00000280615.1	Y_RNA	-5.96	3.38e-09	5.26e-07	-0.21	-0.18	Subjective well-being;	chr11:47751966	chr11:47614898~47614994:-
BRCA	cis	rs6723226	0.65	rs6729952	ENSG00000276517.1	AL133243.2	-5.96	3.39e-09	5.26e-07	-0.22	-0.18	Intelligence (multi-trait analysis);	chr2:32539855	chr2:32526504~32529507:+
BRCA	cis	rs867371	1	rs8041924	ENSG00000276710.3	CSPG4P8	-5.96	3.4e-09	5.28e-07	-0.19	-0.18	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82181320	chr15:82459472~82477258:+
BRCA	cis	rs7246967	0.673	rs16999519	ENSG00000198153.8	ZNF849P	5.96	3.4e-09	5.28e-07	0.27	0.18	Bronchopulmonary dysplasia;	chr19:22631274	chr19:22685167~22686732:+
BRCA	cis	rs7772486	0.686	rs4896827	ENSG00000270638.1	RP3-466P17.1	5.96	3.4e-09	5.28e-07	0.21	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145632202	chr6:145735570~145737218:+
BRCA	cis	rs7809950	0.773	rs2237668	ENSG00000238832.1	snoU109	-5.96	3.4e-09	5.28e-07	-0.27	-0.18	Coronary artery disease;	chr7:107409764	chr7:107603363~107603507:+
BRCA	cis	rs12073837	0.5	rs2807845	ENSG00000238078.1	LINC01352	-5.96	3.4e-09	5.29e-07	-0.19	-0.18	F-cell distribution;	chr1:220822945	chr1:220829255~220832429:+
BRCA	cis	rs67981189	0.896	rs8003227	ENSG00000258571.1	PTTG4P	-5.96	3.4e-09	5.29e-07	-0.2	-0.18	Schizophrenia;	chr14:71093635	chr14:71085482~71085833:-
BRCA	cis	rs875971	0.798	rs6460304	ENSG00000224316.1	RP11-479O9.2	5.96	3.4e-09	5.29e-07	0.18	0.18	Aortic root size;	chr7:66499741	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.862	rs6945775	ENSG00000224316.1	RP11-479O9.2	5.96	3.4e-09	5.29e-07	0.18	0.18	Aortic root size;	chr7:66503987	chr7:65773620~65802067:+
BRCA	cis	rs17597773	0.638	rs7553447	ENSG00000272823.1	RP11-295M18.6	-5.96	3.4e-09	5.29e-07	-0.2	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220816192	chr1:220828676~220829211:-
BRCA	cis	rs17772222	0.682	rs1864744	ENSG00000258789.1	RP11-507K2.3	5.96	3.4e-09	5.29e-07	0.2	0.18	Coronary artery calcification;	chr14:88484662	chr14:88551597~88552493:+
BRCA	cis	rs9880211	0.563	rs1393787	ENSG00000239213.4	NCK1-AS1	5.96	3.41e-09	5.3e-07	0.24	0.18	Height;Body mass index;	chr3:136135359	chr3:136841726~136862054:-
BRCA	cis	rs227932	0.51	rs10950957	ENSG00000234286.1	AC006026.13	5.96	3.41e-09	5.31e-07	0.26	0.18	Schizophrenia;	chr7:23723661	chr7:23680195~23680786:-
BRCA	cis	rs375066	0.592	rs349045	ENSG00000267058.1	RP11-15A1.3	5.96	3.42e-09	5.31e-07	0.2	0.18	Breast cancer;	chr19:43795740	chr19:43891804~43901805:-
BRCA	cis	rs66887589	0.774	rs9307477	ENSG00000245958.5	RP11-33B1.1	-5.96	3.42e-09	5.31e-07	-0.16	-0.18	Diastolic blood pressure;	chr4:119500654	chr4:119454791~119552025:+
BRCA	cis	rs1552244	1	rs2272123	ENSG00000180385.7	EMC3-AS1	5.96	3.42e-09	5.32e-07	0.23	0.18	Alzheimer's disease;	chr3:10098431	chr3:9986893~10006990:+
BRCA	cis	rs984222	0.527	rs2645291	ENSG00000231365.4	RP11-418J17.1	-5.96	3.42e-09	5.32e-07	-0.21	-0.18	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119029918	chr1:119140396~119275973:+
BRCA	cis	rs467650	0.553	rs40173	ENSG00000248489.1	CTD-2007H13.3	5.96	3.42e-09	5.32e-07	0.23	0.18	Venous thromboembolism (SNP x SNP interaction);	chr5:98647713	chr5:98929171~98995013:+
BRCA	cis	rs467650	0.553	rs27020	ENSG00000248489.1	CTD-2007H13.3	5.96	3.42e-09	5.32e-07	0.23	0.18	Venous thromboembolism (SNP x SNP interaction);	chr5:98647962	chr5:98929171~98995013:+
BRCA	cis	rs17807185	0.653	rs7802732	ENSG00000214293.7	APTR	5.96	3.42e-09	5.32e-07	0.21	0.18	Height;	chr7:77658613	chr7:77657660~77696265:-
BRCA	cis	rs11790994	0.524	rs2119	ENSG00000175611.10	LINC00476	5.96	3.42e-09	5.32e-07	0.26	0.18	Inattentive symptoms;	chr9:95726860	chr9:95759231~95875977:-
BRCA	cis	rs2274273	0.624	rs2026633	ENSG00000258413.1	RP11-665C16.6	-5.96	3.42e-09	5.32e-07	-0.23	-0.18	Protein biomarker;	chr14:55322459	chr14:55262767~55272075:-
BRCA	cis	rs755249	0.567	rs4660603	ENSG00000237624.1	OXCT2P1	-5.96	3.42e-09	5.32e-07	-0.26	-0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39270662	chr1:39514956~39516490:+
BRCA	cis	rs875971	0.508	rs6947808	ENSG00000273024.4	INTS4P2	5.96	3.43e-09	5.33e-07	0.2	0.18	Aortic root size;	chr7:66580095	chr7:65647864~65715661:+
BRCA	cis	rs12468226	0.689	rs60584169	ENSG00000273456.1	RP11-686O6.2	5.96	3.43e-09	5.33e-07	0.26	0.18	Urate levels;	chr2:202111695	chr2:202374932~202375604:-
BRCA	cis	rs1707322	0.752	rs6662164	ENSG00000281133.1	AL355480.3	-5.96	3.43e-09	5.33e-07	-0.23	-0.18	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45680558	chr1:45580892~45580996:-
BRCA	cis	rs4664293	0.51	rs72961735	ENSG00000226266.5	AC009961.3	5.96	3.43e-09	5.33e-07	0.23	0.18	Monocyte percentage of white cells;	chr2:159708009	chr2:159670708~159712435:-
BRCA	cis	rs6088813	1	rs6088825	ENSG00000126005.14	MMP24-AS1	5.96	3.44e-09	5.34e-07	0.21	0.18	Height;	chr20:35408169	chr20:35216462~35278131:-
BRCA	cis	rs6088813	1	rs6088820	ENSG00000126005.14	MMP24-AS1	5.96	3.44e-09	5.34e-07	0.21	0.18	Height;	chr20:35399495	chr20:35216462~35278131:-
BRCA	cis	rs2153535	0.585	rs9505512	ENSG00000230939.1	RP11-314C16.1	-5.96	3.44e-09	5.34e-07	-0.21	-0.18	Motion sickness;	chr6:8667337	chr6:8784178~8785445:+
BRCA	cis	rs10771431	0.817	rs10843149	ENSG00000111788.10	RP11-22B23.1	5.96	3.44e-09	5.35e-07	0.16	0.18	Breast size;	chr12:9209471	chr12:9277235~9313241:+
BRCA	cis	rs11098499	0.863	rs3822195	ENSG00000249244.1	RP11-548H18.2	5.96	3.44e-09	5.35e-07	0.22	0.18	Corneal astigmatism;	chr4:119550505	chr4:119391831~119395335:-
BRCA	cis	rs55702914	0.805	rs11888760	ENSG00000231621.1	AC013264.2	5.96	3.45e-09	5.35e-07	0.17	0.18	Major depression and alcohol dependence;	chr2:197379025	chr2:197197991~197199273:+
BRCA	cis	rs7950696	1	rs7950696	ENSG00000280615.1	Y_RNA	5.96	3.45e-09	5.35e-07	0.21	0.18	Platelet count;	chr11:47459981	chr11:47614898~47614994:-
BRCA	cis	rs2834288	0.535	rs881229	ENSG00000273102.1	AP000569.9	5.96	3.45e-09	5.36e-07	0.2	0.18	Gut microbiota (bacterial taxa);	chr21:33950417	chr21:33967101~33968573:-
BRCA	cis	rs7432375	0.61	rs6793936	ENSG00000239213.4	NCK1-AS1	5.96	3.45e-09	5.36e-07	0.19	0.18	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136790951	chr3:136841726~136862054:-
BRCA	cis	rs17253792	0.915	rs28537145	ENSG00000186615.9	KTN1-AS1	-5.96	3.45e-09	5.36e-07	-0.37	-0.18	Putamen volume;	chr14:55712401	chr14:55499278~55580110:-
BRCA	cis	rs8054556	0.74	rs4407079	ENSG00000273724.1	RP11-347C12.12	-5.96	3.45e-09	5.36e-07	-0.2	-0.18	Autism spectrum disorder or schizophrenia;	chr16:29920578	chr16:30336400~30343336:+
BRCA	cis	rs9510787	0.514	rs11843149	ENSG00000205861.10	C1QTNF9B-AS1	-5.96	3.45e-09	5.36e-07	-0.24	-0.18	Nasopharyngeal carcinoma;	chr13:23684197	chr13:23888889~23897263:+
BRCA	cis	rs7493	1	rs12155103	ENSG00000233942.1	AC004012.1	5.96	3.45e-09	5.36e-07	0.23	0.18	Yu-Zhi constitution type in type 2 diabetes;	chr7:95407819	chr7:95471835~95473998:+
BRCA	cis	rs7493	0.95	rs6961624	ENSG00000233942.1	AC004012.1	5.96	3.45e-09	5.36e-07	0.23	0.18	Yu-Zhi constitution type in type 2 diabetes;	chr7:95408349	chr7:95471835~95473998:+
BRCA	cis	rs7924176	0.601	rs1874152	ENSG00000213731.2	RAB5CP1	-5.96	3.45e-09	5.36e-07	-0.21	-0.18	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74076361	chr10:74423435~74424014:-
BRCA	cis	rs61160187	0.673	rs3958943	ENSG00000215032.2	GNL3LP1	-5.96	3.45e-09	5.36e-07	-0.23	-0.18	Educational attainment (years of education);Educational attainment (college completion);	chr5:60580922	chr5:60891935~60893577:-
BRCA	cis	rs12655019	0.92	rs74865790	ENSG00000271828.1	CTD-2310F14.1	5.96	3.45e-09	5.36e-07	0.33	0.18	Breast cancer (early onset);	chr5:56923871	chr5:56927874~56929573:+
BRCA	cis	rs2239547	0.522	rs6771610	ENSG00000242142.1	SERBP1P3	5.96	3.45e-09	5.37e-07	0.22	0.18	Schizophrenia;	chr3:52992088	chr3:53064283~53065091:-
BRCA	cis	rs4718428	1	rs12534637	ENSG00000273142.1	RP11-458F8.4	-5.96	3.45e-09	5.37e-07	-0.16	-0.18	Corneal structure;	chr7:66862667	chr7:66902857~66906297:+
BRCA	cis	rs12893668	0.572	rs35011804	ENSG00000269940.1	RP11-73M18.7	5.96	3.46e-09	5.37e-07	0.2	0.18	Reticulocyte count;	chr14:103685063	chr14:103694560~103695170:+
BRCA	cis	rs7520050	0.966	rs946529	ENSG00000280836.1	AL355480.1	5.96	3.46e-09	5.38e-07	0.21	0.18	Reticulocyte count;Red blood cell count;	chr1:46019876	chr1:45581219~45581321:-
BRCA	cis	rs8002861	0.664	rs2325089	ENSG00000274001.1	RP11-5G9.5	-5.96	3.47e-09	5.38e-07	-0.21	-0.18	Leprosy;	chr13:43876086	chr13:43877715~43878163:-
BRCA	cis	rs853679	0.517	rs4713141	ENSG00000204709.4	LINC01556	5.96	3.47e-09	5.38e-07	0.27	0.18	Depression;	chr6:28133900	chr6:28943877~28944537:+
BRCA	cis	rs30380	0.69	rs2911139	ENSG00000272109.1	CTD-2260A17.3	-5.96	3.47e-09	5.39e-07	-0.24	-0.18	Cerebrospinal fluid biomarker levels;	chr5:96843890	chr5:96804353~96806105:+
BRCA	cis	rs13108904	0.901	rs7673398	ENSG00000254094.1	AC078852.1	-5.96	3.48e-09	5.4e-07	-0.19	-0.18	Obesity-related traits;	chr4:1306289	chr4:1356581~1358075:+
BRCA	cis	rs559928	0.606	rs7941773	ENSG00000236935.1	AP003774.1	5.96	3.48e-09	5.4e-07	0.25	0.18	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64185287	chr11:64325050~64329504:-
BRCA	cis	rs6088813	1	rs6142376	ENSG00000126005.14	MMP24-AS1	5.96	3.48e-09	5.4e-07	0.21	0.18	Height;	chr20:35404958	chr20:35216462~35278131:-
BRCA	cis	rs1552244	0.51	rs13075308	ENSG00000232901.1	CYCSP10	5.96	3.48e-09	5.4e-07	0.25	0.18	Alzheimer's disease;	chr3:9993241	chr3:10000647~10000940:-
BRCA	cis	rs1552244	0.626	rs2886396	ENSG00000232901.1	CYCSP10	5.96	3.48e-09	5.4e-07	0.25	0.18	Alzheimer's disease;	chr3:9995986	chr3:10000647~10000940:-
BRCA	cis	rs1552244	0.882	rs13088350	ENSG00000232901.1	CYCSP10	5.96	3.48e-09	5.4e-07	0.25	0.18	Alzheimer's disease;	chr3:10002942	chr3:10000647~10000940:-
BRCA	cis	rs2243480	1	rs1723267	ENSG00000230295.1	RP11-458F8.2	-5.96	3.48e-09	5.41e-07	-0.24	-0.18	Diabetic kidney disease;	chr7:66008327	chr7:66880708~66882981:+
BRCA	cis	rs12655019	0.92	rs75713680	ENSG00000271828.1	CTD-2310F14.1	5.96	3.49e-09	5.41e-07	0.34	0.18	Breast cancer (early onset);	chr5:56942377	chr5:56927874~56929573:+
BRCA	cis	rs4886920	0.672	rs12437900	ENSG00000260776.4	RP11-114H24.2	5.96	3.49e-09	5.41e-07	0.22	0.18	Neuroticism;	chr15:77841796	chr15:77914217~77926846:-
BRCA	cis	rs12893668	0.572	rs4900591	ENSG00000269910.1	RP11-73M18.10	5.96	3.49e-09	5.41e-07	0.19	0.18	Reticulocyte count;	chr14:103688541	chr14:103694516~103695050:-
BRCA	cis	rs1707322	0.721	rs6699418	ENSG00000234329.1	RP11-767N6.2	5.96	3.49e-09	5.42e-07	0.19	0.18	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634509	chr1:45651039~45651826:-
BRCA	cis	rs1707322	0.721	rs4431884	ENSG00000234329.1	RP11-767N6.2	5.96	3.49e-09	5.42e-07	0.19	0.18	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45635651	chr1:45651039~45651826:-
BRCA	cis	rs1707322	0.65	rs4660879	ENSG00000234329.1	RP11-767N6.2	5.96	3.49e-09	5.42e-07	0.19	0.18	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45639729	chr1:45651039~45651826:-
BRCA	cis	rs10895987	0.955	rs7114094	ENSG00000254614.2	AP003068.23	5.96	3.49e-09	5.42e-07	0.28	0.18	Blood protein levels;	chr11:65159740	chr11:65177606~65181834:-
BRCA	cis	rs7772486	0.654	rs702321	ENSG00000270638.1	RP3-466P17.1	-5.96	3.5e-09	5.43e-07	-0.21	-0.18	Lobe attachment (rater-scored or self-reported);	chr6:145685559	chr6:145735570~145737218:+
BRCA	cis	rs7487075	0.93	rs4076248	ENSG00000257261.4	RP11-96H19.1	5.96	3.5e-09	5.43e-07	0.2	0.18	Itch intensity from mosquito bite;	chr12:46439822	chr12:46383679~46876159:+
BRCA	cis	rs2243480	0.901	rs313808	ENSG00000164669.11	INTS4P1	5.96	3.5e-09	5.43e-07	0.35	0.18	Diabetic kidney disease;	chr7:66034886	chr7:65141225~65234216:+
BRCA	cis	rs2117029	1	rs11168839	ENSG00000258017.1	RP11-386G11.10	5.96	3.5e-09	5.43e-07	0.23	0.18	Intelligence (multi-trait analysis);	chr12:49063852	chr12:49127782~49147869:+
BRCA	cis	rs13108904	0.875	rs1732099	ENSG00000254094.1	AC078852.1	5.96	3.5e-09	5.44e-07	0.19	0.18	Obesity-related traits;	chr4:1288908	chr4:1356581~1358075:+
BRCA	cis	rs67981189	0.529	rs2526868	ENSG00000258571.1	PTTG4P	5.96	3.5e-09	5.44e-07	0.21	0.18	Schizophrenia;	chr14:70923672	chr14:71085482~71085833:-
BRCA	cis	rs8002861	0.87	rs2875541	ENSG00000274001.1	RP11-5G9.5	5.96	3.51e-09	5.44e-07	0.2	0.18	Leprosy;	chr13:43843305	chr13:43877715~43878163:-
BRCA	cis	rs9840812	0.656	rs4678437	ENSG00000239213.4	NCK1-AS1	5.96	3.51e-09	5.44e-07	0.21	0.18	Fibrinogen levels;	chr3:136598823	chr3:136841726~136862054:-
BRCA	cis	rs755249	0.567	rs3768301	ENSG00000237624.1	OXCT2P1	5.96	3.51e-09	5.44e-07	0.27	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39405121	chr1:39514956~39516490:+
BRCA	cis	rs10129255	0.518	rs12590732	ENSG00000274576.2	IGHV2-70	5.96	3.51e-09	5.44e-07	0.14	0.18	Kawasaki disease;	chr14:106779612	chr14:106770577~106771020:-
BRCA	cis	rs17597773	0.638	rs6668666	ENSG00000272823.1	RP11-295M18.6	-5.96	3.51e-09	5.45e-07	-0.22	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220826069	chr1:220828676~220829211:-
BRCA	cis	rs227275	0.554	rs223424	ENSG00000251288.2	RP11-10L12.2	-5.96	3.51e-09	5.45e-07	-0.21	-0.18	Allergic disease (asthma, hay fever or eczema);	chr4:102804177	chr4:102751401~102752641:+
BRCA	cis	rs227275	0.524	rs223423	ENSG00000251288.2	RP11-10L12.2	-5.96	3.51e-09	5.45e-07	-0.21	-0.18	Allergic disease (asthma, hay fever or eczema);	chr4:102804737	chr4:102751401~102752641:+
BRCA	cis	rs9880211	0.613	rs10222451	ENSG00000239213.4	NCK1-AS1	5.96	3.51e-09	5.45e-07	0.23	0.18	Height;Body mass index;	chr3:136158571	chr3:136841726~136862054:-
BRCA	cis	rs4763879	0.778	rs7977940	ENSG00000214776.8	RP11-726G1.1	-5.96	3.51e-09	5.45e-07	-0.2	-0.18	Type 1 diabetes;	chr12:9686320	chr12:9467552~9576275:+
BRCA	cis	rs5167	0.781	rs11672748	ENSG00000280087.1	CTB-129P6.7	5.96	3.52e-09	5.46e-07	0.23	0.18	Blood protein levels;	chr19:44986934	chr19:44909375~44914968:+
BRCA	cis	rs62025270	0.576	rs55639123	ENSG00000202081.1	RNU6-1280P	-5.96	3.52e-09	5.46e-07	-0.27	-0.18	Idiopathic pulmonary fibrosis;	chr15:85617037	chr15:85651522~85651628:-
BRCA	cis	rs875971	0.502	rs2946580	ENSG00000228409.4	CCT6P1	5.96	3.52e-09	5.46e-07	0.18	0.18	Aortic root size;	chr7:66066855	chr7:65751142~65763354:+
BRCA	cis	rs11976180	0.953	rs2951355	ENSG00000273234.1	OR2A13P	-5.96	3.52e-09	5.46e-07	-0.24	-0.18	Obesity-related traits;	chr7:144063469	chr7:144142009~144142938:+
BRCA	cis	rs11976180	1	rs2951354	ENSG00000273234.1	OR2A13P	-5.96	3.52e-09	5.46e-07	-0.24	-0.18	Obesity-related traits;	chr7:144063908	chr7:144142009~144142938:+
BRCA	cis	rs11976180	1	rs2961125	ENSG00000273234.1	OR2A13P	-5.96	3.52e-09	5.46e-07	-0.24	-0.18	Obesity-related traits;	chr7:144064677	chr7:144142009~144142938:+
BRCA	cis	rs11976180	1	rs2961126	ENSG00000273234.1	OR2A13P	-5.96	3.52e-09	5.46e-07	-0.24	-0.18	Obesity-related traits;	chr7:144065643	chr7:144142009~144142938:+
BRCA	cis	rs11976180	0.953	rs2961127	ENSG00000273234.1	OR2A13P	-5.96	3.52e-09	5.46e-07	-0.24	-0.18	Obesity-related traits;	chr7:144065644	chr7:144142009~144142938:+
BRCA	cis	rs11976180	1	rs1919948	ENSG00000273234.1	OR2A13P	-5.96	3.52e-09	5.46e-07	-0.24	-0.18	Obesity-related traits;	chr7:144065750	chr7:144142009~144142938:+
BRCA	cis	rs11976180	1	rs2961128	ENSG00000273234.1	OR2A13P	-5.96	3.52e-09	5.46e-07	-0.24	-0.18	Obesity-related traits;	chr7:144066390	chr7:144142009~144142938:+
BRCA	cis	rs11976180	1	rs2371248	ENSG00000273234.1	OR2A13P	-5.96	3.52e-09	5.46e-07	-0.24	-0.18	Obesity-related traits;	chr7:144067096	chr7:144142009~144142938:+
BRCA	cis	rs710913	0.745	rs1180334	ENSG00000182109.6	RP11-69E11.4	-5.96	3.52e-09	5.46e-07	-0.2	-0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39555972	chr1:39522280~39546187:-
BRCA	cis	rs7238033	0.641	rs56044725	ENSG00000267193.4	RP11-116O18.3	5.96	3.52e-09	5.47e-07	0.2	0.18	Bladder cancer;	chr18:45741598	chr18:45669367~45747215:-
BRCA	cis	rs2243480	0.522	rs73150635	ENSG00000232546.1	RP11-458F8.1	-5.96	3.53e-09	5.48e-07	-0.3	-0.18	Diabetic kidney disease;	chr7:66507503	chr7:66848496~66858136:+
BRCA	cis	rs28472312	0.894	rs7498491	ENSG00000251417.2	RP11-1348G14.4	-5.96	3.53e-09	5.48e-07	-0.23	-0.18	Intelligence (multi-trait analysis);	chr16:28832747	chr16:28802743~28817828:+
BRCA	cis	rs13126694	0.62	rs6844184	ENSG00000251429.1	RP11-597D13.7	5.96	3.54e-09	5.48e-07	0.18	0.18	Blood osmolality (transformed sodium);	chr4:158094156	chr4:158270378~158278676:+
BRCA	cis	rs42648	0.507	rs4397318	ENSG00000225498.1	AC002064.5	-5.96	3.54e-09	5.48e-07	-0.17	-0.18	Homocysteine levels;	chr7:90098955	chr7:90312496~90322592:+
BRCA	cis	rs4683346	0.616	rs3846063	ENSG00000173811.9	CCDC13-AS1	5.96	3.54e-09	5.49e-07	0.25	0.18	Granulocyte percentage of myeloid white cells;	chr3:42762336	chr3:42732575~42746768:+
BRCA	cis	rs12655019	0.92	rs16886525	ENSG00000271828.1	CTD-2310F14.1	5.96	3.54e-09	5.49e-07	0.34	0.18	Breast cancer (early onset);	chr5:56941838	chr5:56927874~56929573:+
BRCA	cis	rs755249	0.529	rs4660732	ENSG00000237624.1	OXCT2P1	5.96	3.54e-09	5.5e-07	0.27	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39397543	chr1:39514956~39516490:+
BRCA	cis	rs17597773	0.638	rs11118615	ENSG00000272823.1	RP11-295M18.6	-5.96	3.54e-09	5.5e-07	-0.22	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220823271	chr1:220828676~220829211:-
BRCA	cis	rs250585	1	rs152454	ENSG00000260136.4	CTD-2270L9.4	-5.96	3.55e-09	5.5e-07	-0.21	-0.18	Egg allergy;	chr16:23571790	chr16:23452758~23457606:+
BRCA	cis	rs7131987	0.565	rs7300032	ENSG00000275476.1	RP11-996F15.4	5.96	3.55e-09	5.5e-07	0.2	0.18	QT interval;	chr12:29256859	chr12:29277397~29277882:-
BRCA	cis	rs7131987	0.547	rs4370971	ENSG00000275476.1	RP11-996F15.4	5.96	3.55e-09	5.5e-07	0.2	0.18	QT interval;	chr12:29257066	chr12:29277397~29277882:-
BRCA	cis	rs75422866	0.867	rs73113139	ENSG00000280054.1	RP1-197B17.7	5.95	3.55e-09	5.51e-07	0.46	0.18	Pneumonia;	chr12:47622826	chr12:47728151~47730598:-
BRCA	cis	rs7247513	0.866	rs2861405	ENSG00000213290.4	PGK1P2	-5.95	3.55e-09	5.51e-07	-0.25	-0.18	Bipolar disorder;	chr19:12611518	chr19:12559571~12561105:+
BRCA	cis	rs2243480	1	rs937108	ENSG00000164669.11	INTS4P1	5.95	3.55e-09	5.51e-07	0.35	0.18	Diabetic kidney disease;	chr7:65963465	chr7:65141225~65234216:+
BRCA	cis	rs73193808	0.901	rs1997570	ENSG00000215533.7	LINC00189	-5.95	3.56e-09	5.51e-07	-0.27	-0.18	Coronary artery disease;	chr21:29212989	chr21:29193480~29288205:+
BRCA	cis	rs2836950	0.565	rs8130320	ENSG00000238141.2	BRWD1-AS1	-5.95	3.56e-09	5.51e-07	-0.2	-0.18	Menarche (age at onset);	chr21:39208332	chr21:39315707~39323218:+
BRCA	cis	rs3814244	0.933	rs10878725	ENSG00000236946.2	HNRNPA1P70	5.95	3.56e-09	5.52e-07	0.15	0.18	Itch intensity from mosquito bite adjusted by bite size;	chr12:68020930	chr12:68035767~68036853:+
BRCA	cis	rs8031584	0.56	rs7171208	ENSG00000270015.1	RP11-540B6.6	5.95	3.56e-09	5.52e-07	0.18	0.18	Huntington's disease progression;	chr15:30906726	chr15:30926514~30928407:+
BRCA	cis	rs75422866	0.717	rs73113159	ENSG00000280054.1	RP1-197B17.7	5.95	3.56e-09	5.53e-07	0.46	0.18	Pneumonia;	chr12:47631318	chr12:47728151~47730598:-
BRCA	cis	rs75422866	0.717	rs73113161	ENSG00000280054.1	RP1-197B17.7	5.95	3.56e-09	5.53e-07	0.46	0.18	Pneumonia;	chr12:47632361	chr12:47728151~47730598:-
BRCA	cis	rs6496044	0.507	rs2467096	ENSG00000259295.5	CSPG4P12	-5.95	3.57e-09	5.53e-07	-0.22	-0.18	Interstitial lung disease;	chr15:85667447	chr15:85191438~85213905:+
BRCA	cis	rs7772486	0.764	rs9399569	ENSG00000270638.1	RP3-466P17.1	-5.95	3.57e-09	5.53e-07	-0.21	-0.18	Lobe attachment (rater-scored or self-reported);	chr6:145921806	chr6:145735570~145737218:+
BRCA	cis	rs7709377	0.556	rs10155643	ENSG00000271918.1	CTD-2287O16.5	-5.95	3.57e-09	5.53e-07	-0.17	-0.18	Metabolite levels  (X-11787);	chr5:116284322	chr5:116083807~116085416:-
BRCA	cis	rs6088813	0.961	rs1886691	ENSG00000126005.14	MMP24-AS1	5.95	3.57e-09	5.53e-07	0.21	0.18	Height;	chr20:35398468	chr20:35216462~35278131:-
BRCA	cis	rs13118159	0.55	rs4974611	ENSG00000254094.1	AC078852.1	-5.95	3.57e-09	5.53e-07	-0.22	-0.18	Longevity;	chr4:1364661	chr4:1356581~1358075:+
BRCA	cis	rs2288884	0.767	rs58329304	ENSG00000275055.1	CTC-471J1.11	-5.95	3.57e-09	5.54e-07	-0.25	-0.18	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52031919	chr19:52049007~52049754:+
BRCA	cis	rs7555523	0.778	rs4233408	ENSG00000224358.1	RP11-466F5.8	-5.95	3.57e-09	5.54e-07	-0.28	-0.18	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165743723	chr1:165768929~165775176:+
BRCA	cis	rs13126694	0.744	rs9968557	ENSG00000251429.1	RP11-597D13.7	5.95	3.58e-09	5.55e-07	0.18	0.18	Blood osmolality (transformed sodium);	chr4:158098673	chr4:158270378~158278676:+
BRCA	cis	rs910316	1	rs175436	ENSG00000279594.1	RP11-950C14.10	-5.95	3.58e-09	5.55e-07	-0.2	-0.18	Height;	chr14:75141980	chr14:75011269~75012851:-
BRCA	cis	rs7613875	0.641	rs2624845	ENSG00000228008.1	CTD-2330K9.3	-5.95	3.58e-09	5.55e-07	-0.18	-0.18	Body mass index;	chr3:50025004	chr3:49903845~49916937:+
BRCA	cis	rs1395	0.744	rs57881048	ENSG00000234072.1	AC074117.10	-5.95	3.58e-09	5.55e-07	-0.19	-0.18	Blood metabolite levels;	chr2:27251297	chr2:27356246~27367622:+
BRCA	cis	rs1395	0.71	rs2083363	ENSG00000234072.1	AC074117.10	-5.95	3.58e-09	5.55e-07	-0.19	-0.18	Blood metabolite levels;	chr2:27252450	chr2:27356246~27367622:+
BRCA	cis	rs1395	0.744	rs11126932	ENSG00000234072.1	AC074117.10	-5.95	3.58e-09	5.55e-07	-0.19	-0.18	Blood metabolite levels;	chr2:27253414	chr2:27356246~27367622:+
BRCA	cis	rs1395	0.744	rs11126935	ENSG00000234072.1	AC074117.10	-5.95	3.58e-09	5.55e-07	-0.19	-0.18	Blood metabolite levels;	chr2:27253872	chr2:27356246~27367622:+
BRCA	cis	rs2243480	1	rs12698509	ENSG00000232546.1	RP11-458F8.1	-5.95	3.59e-09	5.56e-07	-0.23	-0.18	Diabetic kidney disease;	chr7:65953889	chr7:66848496~66858136:+
BRCA	cis	rs9307551	0.948	rs4389603	ENSG00000250334.4	LINC00989	-5.95	3.59e-09	5.56e-07	-0.28	-0.18	Refractive error;	chr4:79567720	chr4:79492416~79576460:+
BRCA	cis	rs17301013	0.606	rs1407127	ENSG00000227373.4	RP11-160H22.5	-5.95	3.59e-09	5.56e-07	-0.27	-0.18	Systemic lupus erythematosus;	chr1:174119548	chr1:174115300~174160004:-
BRCA	cis	rs3733585	0.781	rs57250714	ENSG00000250413.1	RP11-448G15.1	-5.95	3.59e-09	5.56e-07	-0.24	-0.18	Cleft plate (environmental tobacco smoke interaction);	chr4:9982905	chr4:10006482~10009725:+
BRCA	cis	rs9393777	0.92	rs13196692	ENSG00000220721.1	OR1F12	5.95	3.59e-09	5.57e-07	0.42	0.18	Intelligence (multi-trait analysis);	chr6:27411340	chr6:28073316~28074233:+
BRCA	cis	rs1552244	0.744	rs6763366	ENSG00000232901.1	CYCSP10	5.95	3.59e-09	5.57e-07	0.25	0.18	Alzheimer's disease;	chr3:9991860	chr3:10000647~10000940:-
BRCA	cis	rs8002861	0.781	rs9525857	ENSG00000274001.1	RP11-5G9.5	5.95	3.6e-09	5.57e-07	0.2	0.18	Leprosy;	chr13:43862936	chr13:43877715~43878163:-
BRCA	cis	rs6723226	0.503	rs4952262	ENSG00000276334.1	AL133243.1	-5.95	3.6e-09	5.57e-07	-0.22	-0.18	Intelligence (multi-trait analysis);	chr2:32372166	chr2:32521927~32523547:+
BRCA	cis	rs6479891	1	rs4746138	ENSG00000232075.1	MRPL35P2	5.95	3.6e-09	5.57e-07	0.32	0.18	Arthritis (juvenile idiopathic);	chr10:63481981	chr10:63634317~63634827:-
BRCA	cis	rs7246657	1	rs35398388	ENSG00000226686.6	LINC01535	-5.95	3.6e-09	5.58e-07	-0.28	-0.18	Coronary artery calcification;	chr19:37249456	chr19:37251912~37265535:+
BRCA	cis	rs7246657	1	rs7247672	ENSG00000226686.6	LINC01535	-5.95	3.6e-09	5.58e-07	-0.28	-0.18	Coronary artery calcification;	chr19:37253026	chr19:37251912~37265535:+
BRCA	cis	rs7246657	1	rs8110011	ENSG00000226686.6	LINC01535	-5.95	3.6e-09	5.58e-07	-0.28	-0.18	Coronary artery calcification;	chr19:37254911	chr19:37251912~37265535:+
BRCA	cis	rs7085104	0.727	rs12773892	ENSG00000213061.2	PFN1P11	5.95	3.6e-09	5.58e-07	0.27	0.18	Immature fraction of reticulocytes;Schizophrenia;	chr10:102871420	chr10:102838011~102845473:-
BRCA	cis	rs10911251	0.546	rs10911260	ENSG00000224468.3	RP11-181K3.4	5.95	3.6e-09	5.58e-07	0.19	0.18	Colorectal cancer;	chr1:183137095	chr1:183138402~183141282:-
BRCA	cis	rs4218	0.531	rs12101733	ENSG00000277144.1	RP11-59H7.4	-5.95	3.6e-09	5.58e-07	-0.22	-0.18	Social communication problems;	chr15:59047566	chr15:59115547~59116089:-
BRCA	cis	rs2288884	0.731	rs11673450	ENSG00000275055.1	CTC-471J1.11	-5.95	3.61e-09	5.58e-07	-0.25	-0.18	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52037441	chr19:52049007~52049754:+
BRCA	cis	rs2288884	0.731	rs11673398	ENSG00000275055.1	CTC-471J1.11	-5.95	3.61e-09	5.58e-07	-0.25	-0.18	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52037444	chr19:52049007~52049754:+
BRCA	cis	rs2288884	0.767	rs17835716	ENSG00000275055.1	CTC-471J1.11	-5.95	3.61e-09	5.58e-07	-0.25	-0.18	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52047789	chr19:52049007~52049754:+
BRCA	cis	rs4787491	0.729	rs11150584	ENSG00000273724.1	RP11-347C12.12	-5.95	3.61e-09	5.59e-07	-0.2	-0.18	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30028357	chr16:30336400~30343336:+
BRCA	cis	rs295490	0.748	rs75866638	ENSG00000272656.1	RP11-219D15.3	5.95	3.61e-09	5.59e-07	0.43	0.18	PR interval in Tripanosoma cruzi seropositivity;	chr3:139338830	chr3:139349024~139349371:-
BRCA	cis	rs944990	0.576	rs883782	ENSG00000227603.1	RP11-165J3.6	5.95	3.61e-09	5.59e-07	0.19	0.18	Body mass index;	chr9:93520003	chr9:93435332~93437121:-
BRCA	cis	rs2638953	0.962	rs11049370	ENSG00000247934.4	RP11-967K21.1	-5.95	3.61e-09	5.6e-07	-0.24	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28146904	chr12:28163298~28190738:-
BRCA	cis	rs867371	1	rs7166570	ENSG00000276710.3	CSPG4P8	-5.95	3.62e-09	5.6e-07	-0.19	-0.18	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82173880	chr15:82459472~82477258:+
BRCA	cis	rs39841	1	rs39841	ENSG00000272109.1	CTD-2260A17.3	-5.95	3.62e-09	5.6e-07	-0.24	-0.18	Inflammatory skin disease;	chr5:96784466	chr5:96804353~96806105:+
BRCA	cis	rs30380	0.734	rs30376	ENSG00000272109.1	CTD-2260A17.3	-5.95	3.62e-09	5.6e-07	-0.24	-0.18	Cerebrospinal fluid biomarker levels;	chr5:96784555	chr5:96804353~96806105:+
BRCA	cis	rs35612822	0.897	rs1983218	ENSG00000232485.2	AC098820.3	-5.95	3.62e-09	5.61e-07	-0.23	-0.18	Kidney disease (early stage) in type 1 diabetes;	chr2:216471922	chr2:216479030~216498761:-
BRCA	cis	rs8002861	0.87	rs9525855	ENSG00000274001.1	RP11-5G9.5	5.95	3.62e-09	5.61e-07	0.2	0.18	Leprosy;	chr13:43857524	chr13:43877715~43878163:-
BRCA	cis	rs17301013	0.507	rs61528155	ENSG00000227373.4	RP11-160H22.5	5.95	3.63e-09	5.62e-07	0.28	0.18	Systemic lupus erythematosus;	chr1:174276140	chr1:174115300~174160004:-
BRCA	cis	rs9990333	0.862	rs6806599	ENSG00000242086.7	LINC00969	-5.95	3.63e-09	5.62e-07	-0.2	-0.18	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196089280	chr3:195658062~195739964:+
BRCA	cis	rs11098499	0.866	rs72676074	ENSG00000249244.1	RP11-548H18.2	5.95	3.63e-09	5.62e-07	0.21	0.18	Corneal astigmatism;	chr4:119438686	chr4:119391831~119395335:-
BRCA	cis	rs12893668	0.572	rs7148857	ENSG00000269940.1	RP11-73M18.7	5.95	3.63e-09	5.62e-07	0.2	0.18	Reticulocyte count;	chr14:103676900	chr14:103694560~103695170:+
BRCA	cis	rs2243480	0.901	rs2949697	ENSG00000232546.1	RP11-458F8.1	-5.95	3.63e-09	5.62e-07	-0.24	-0.18	Diabetic kidney disease;	chr7:65999249	chr7:66848496~66858136:+
BRCA	cis	rs5758659	0.679	rs134870	ENSG00000281538.1	RP4-669P10.20	5.95	3.63e-09	5.63e-07	0.18	0.18	Cognitive function;	chr22:42256311	chr22:42138060~42139726:+
BRCA	cis	rs2115630	1	rs58581703	ENSG00000229212.6	RP11-561C5.4	5.95	3.63e-09	5.63e-07	0.2	0.18	P wave terminal force;	chr15:84733704	chr15:85205440~85234795:-
BRCA	cis	rs7688540	0.771	rs74984113	ENSG00000211553.1	AC253576.2	-5.95	3.64e-09	5.63e-07	-0.29	-0.18	Facial morphology (factor 6, height of vermillion lower lip);	chr4:256733	chr4:136461~136568:+
BRCA	cis	rs250585	0.85	rs9707	ENSG00000260136.4	CTD-2270L9.4	-5.95	3.64e-09	5.63e-07	-0.2	-0.18	Egg allergy;	chr16:23522777	chr16:23452758~23457606:+
BRCA	cis	rs250585	0.736	rs6497669	ENSG00000260136.4	CTD-2270L9.4	-5.95	3.64e-09	5.63e-07	-0.2	-0.18	Egg allergy;	chr16:23522928	chr16:23452758~23457606:+
BRCA	cis	rs6479891	1	rs12415984	ENSG00000232075.1	MRPL35P2	5.95	3.64e-09	5.63e-07	0.33	0.18	Arthritis (juvenile idiopathic);	chr10:63150528	chr10:63634317~63634827:-
BRCA	cis	rs853679	0.517	rs2281588	ENSG00000204709.4	LINC01556	5.95	3.64e-09	5.63e-07	0.27	0.18	Depression;	chr6:28104824	chr6:28943877~28944537:+
BRCA	cis	rs77972916	0.536	rs11694173	ENSG00000234936.1	AC010883.5	-5.95	3.64e-09	5.63e-07	-0.23	-0.18	Granulocyte percentage of myeloid white cells;	chr2:43363760	chr2:43229573~43233394:+
BRCA	cis	rs7923609	0.967	rs3999089	ENSG00000232075.1	MRPL35P2	5.95	3.64e-09	5.64e-07	0.23	0.18	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63444048	chr10:63634317~63634827:-
BRCA	cis	rs853679	0.517	rs1947862	ENSG00000204709.4	LINC01556	5.95	3.64e-09	5.64e-07	0.27	0.18	Depression;	chr6:28137418	chr6:28943877~28944537:+
BRCA	cis	rs991427	0.643	rs17018629	ENSG00000258100.1	RP11-121E16.1	-5.95	3.64e-09	5.64e-07	-0.29	-0.18	Systolic blood pressure (alcohol consumption interaction);	chr12:91059783	chr12:91362196~91368606:+
BRCA	cis	rs6928977	0.675	rs7750586	ENSG00000231028.7	LINC00271	5.95	3.65e-09	5.65e-07	0.19	0.18	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135506535	chr6:135497801~135716055:+
BRCA	cis	rs910316	0.763	rs175435	ENSG00000279594.1	RP11-950C14.10	5.95	3.65e-09	5.65e-07	0.2	0.18	Height;	chr14:75145322	chr14:75011269~75012851:-
BRCA	cis	rs1858037	0.867	rs4671658	ENSG00000204929.10	AC074391.1	-5.95	3.65e-09	5.65e-07	-0.24	-0.18	Rheumatoid arthritis;	chr2:65334258	chr2:65436711~66084639:+
BRCA	cis	rs4604234	0.614	rs78131248	ENSG00000272129.1	RP11-250B2.6	-5.95	3.65e-09	5.66e-07	-0.46	-0.18	Cancer;	chr6:80176949	chr6:80355424~80356859:+
BRCA	cis	rs4604234	0.614	rs3805923	ENSG00000272129.1	RP11-250B2.6	-5.95	3.65e-09	5.66e-07	-0.46	-0.18	Cancer;	chr6:80177802	chr6:80355424~80356859:+
BRCA	cis	rs227275	0.554	rs223442	ENSG00000251288.2	RP11-10L12.2	-5.95	3.66e-09	5.66e-07	-0.21	-0.18	Allergic disease (asthma, hay fever or eczema);	chr4:102793960	chr4:102751401~102752641:+
BRCA	cis	rs227275	0.554	rs223441	ENSG00000251288.2	RP11-10L12.2	-5.95	3.66e-09	5.66e-07	-0.21	-0.18	Allergic disease (asthma, hay fever or eczema);	chr4:102794228	chr4:102751401~102752641:+
BRCA	cis	rs6750795	0.765	rs6742387	ENSG00000223198.1	RNU2-22P	-5.95	3.66e-09	5.66e-07	-0.22	-0.18	Height;	chr2:231490121	chr2:231501990~231502201:-
BRCA	cis	rs7598759	0.548	rs1823328	ENSG00000223198.1	RNU2-22P	-5.95	3.66e-09	5.66e-07	-0.22	-0.18	Noise-induced hearing loss;	chr2:231490473	chr2:231501990~231502201:-
BRCA	cis	rs17680741	0.955	rs55943223	ENSG00000226659.1	RP11-137H2.4	5.95	3.66e-09	5.66e-07	0.26	0.18	Coronary artery disease;	chr10:80490816	chr10:80529597~80535942:-
BRCA	cis	rs2836950	0.565	rs2836943	ENSG00000238141.2	BRWD1-AS1	-5.95	3.66e-09	5.66e-07	-0.21	-0.18	Menarche (age at onset);	chr21:39220685	chr21:39315707~39323218:+
BRCA	cis	rs2638953	0.776	rs11513467	ENSG00000247934.4	RP11-967K21.1	-5.95	3.66e-09	5.67e-07	-0.23	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28210252	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.776	rs11519332	ENSG00000247934.4	RP11-967K21.1	-5.95	3.66e-09	5.67e-07	-0.23	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28210254	chr12:28163298~28190738:-
BRCA	cis	rs2098713	0.544	rs2056870	ENSG00000250155.1	CTD-2353F22.1	-5.95	3.66e-09	5.67e-07	-0.21	-0.18	Telomere length;	chr5:37424947	chr5:36666214~36725195:-
BRCA	cis	rs853679	0.546	rs71537572	ENSG00000220721.1	OR1F12	5.95	3.67e-09	5.67e-07	0.43	0.18	Depression;	chr6:28002937	chr6:28073316~28074233:+
BRCA	cis	rs875971	0.545	rs12671152	ENSG00000273024.4	INTS4P2	-5.95	3.67e-09	5.67e-07	-0.23	-0.18	Aortic root size;	chr7:66311140	chr7:65647864~65715661:+
BRCA	cis	rs7772486	0.686	rs9497380	ENSG00000270638.1	RP3-466P17.1	5.95	3.67e-09	5.68e-07	0.21	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145634169	chr6:145735570~145737218:+
BRCA	cis	rs1160985	0.967	rs760136	ENSG00000214855.8	APOC1P1	-5.95	3.67e-09	5.68e-07	-0.21	-0.18	C-reactive protein;LDL cholesterol;Lipid traits;Gut microbiota (functional units);LDL cholesterol levels;	chr19:44900601	chr19:44926804~44931386:+
BRCA	cis	rs754466	0.606	rs11002310	ENSG00000204049.1	RP11-126H7.4	5.95	3.67e-09	5.68e-07	0.22	0.18	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77836272	chr10:77866875~77869610:+
BRCA	cis	rs8114671	0.562	rs7263157	ENSG00000269202.1	RP4-614O4.12	-5.95	3.67e-09	5.68e-07	-0.19	-0.18	Height;	chr20:34871324	chr20:35201747~35203288:-
BRCA	cis	rs858239	0.539	rs4377861	ENSG00000230042.1	AK3P3	-5.95	3.68e-09	5.69e-07	-0.21	-0.18	Cerebrospinal fluid biomarker levels;	chr7:23146350	chr7:23129178~23129841:+
BRCA	cis	rs2836950	0.565	rs2836931	ENSG00000238141.2	BRWD1-AS1	-5.95	3.68e-09	5.69e-07	-0.2	-0.18	Menarche (age at onset);	chr21:39174643	chr21:39315707~39323218:+
BRCA	cis	rs2243480	1	rs1546059	ENSG00000232559.3	GS1-124K5.12	-5.95	3.68e-09	5.69e-07	-0.34	-0.18	Diabetic kidney disease;	chr7:66189722	chr7:66554588~66576923:-
BRCA	cis	rs2243480	1	rs2420170	ENSG00000232559.3	GS1-124K5.12	-5.95	3.68e-09	5.69e-07	-0.34	-0.18	Diabetic kidney disease;	chr7:66191066	chr7:66554588~66576923:-
BRCA	cis	rs10129255	0.957	rs28887506	ENSG00000224373.3	IGHV4-59	5.95	3.68e-09	5.7e-07	0.12	0.18	Kawasaki disease;	chr14:106785589	chr14:106627249~106627825:-
BRCA	cis	rs2898681	0.614	rs28758563	ENSG00000248375.1	RP11-177B4.1	-5.95	3.68e-09	5.7e-07	-0.28	-0.18	Optic nerve measurement (cup area);	chr4:52811610	chr4:52720081~52720831:-
BRCA	cis	rs2562456	0.917	rs2681377	ENSG00000268081.1	RP11-678G14.2	-5.95	3.68e-09	5.7e-07	-0.28	-0.18	Pain;	chr19:21533718	chr19:21554640~21569237:-
BRCA	cis	rs10740039	0.516	rs6479717	ENSG00000254271.1	RP11-131N11.4	5.95	3.69e-09	5.7e-07	0.24	0.18	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60559530	chr10:60734342~60741828:+
BRCA	cis	rs2243480	0.803	rs35480979	ENSG00000228409.4	CCT6P1	5.95	3.69e-09	5.7e-07	0.25	0.18	Diabetic kidney disease;	chr7:65892097	chr7:65751142~65763354:+
BRCA	cis	rs2243480	1	rs35391607	ENSG00000228409.4	CCT6P1	5.95	3.69e-09	5.7e-07	0.25	0.18	Diabetic kidney disease;	chr7:65895842	chr7:65751142~65763354:+
BRCA	cis	rs2243480	1	rs13220979	ENSG00000228409.4	CCT6P1	5.95	3.69e-09	5.7e-07	0.25	0.18	Diabetic kidney disease;	chr7:65898217	chr7:65751142~65763354:+
BRCA	cis	rs2243480	1	rs34974928	ENSG00000228409.4	CCT6P1	5.95	3.69e-09	5.7e-07	0.25	0.18	Diabetic kidney disease;	chr7:65899019	chr7:65751142~65763354:+
BRCA	cis	rs42648	0.518	rs12535435	ENSG00000225498.1	AC002064.5	5.95	3.69e-09	5.71e-07	0.17	0.18	Homocysteine levels;	chr7:90201503	chr7:90312496~90322592:+
BRCA	cis	rs4950322	0.571	rs4373796	ENSG00000244371.2	PFN1P8	-5.95	3.7e-09	5.72e-07	-0.26	-0.18	Protein quantitative trait loci;	chr1:147316747	chr1:146957117~146957659:-
BRCA	cis	rs4950322	0.543	rs4568882	ENSG00000244371.2	PFN1P8	-5.95	3.7e-09	5.72e-07	-0.26	-0.18	Protein quantitative trait loci;	chr1:147316885	chr1:146957117~146957659:-
BRCA	cis	rs4950322	0.543	rs2883323	ENSG00000244371.2	PFN1P8	-5.95	3.7e-09	5.72e-07	-0.26	-0.18	Protein quantitative trait loci;	chr1:147316995	chr1:146957117~146957659:-
BRCA	cis	rs4950322	0.543	rs2883324	ENSG00000244371.2	PFN1P8	-5.95	3.7e-09	5.72e-07	-0.26	-0.18	Protein quantitative trait loci;	chr1:147317157	chr1:146957117~146957659:-
BRCA	cis	rs8114671	0.662	rs3761143	ENSG00000269202.1	RP4-614O4.12	-5.95	3.7e-09	5.72e-07	-0.19	-0.18	Height;	chr20:34957942	chr20:35201747~35203288:-
BRCA	cis	rs2018683	0.624	rs1006521	ENSG00000228421.2	AC005013.5	5.95	3.7e-09	5.73e-07	0.23	0.18	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28956604	chr7:28957667~28959345:+
BRCA	cis	rs9533799	0.559	rs9533796	ENSG00000227258.4	SMIM2-AS1	-5.95	3.71e-09	5.74e-07	-0.24	-0.18	Amyotrophic lateral sclerosis;	chr13:44216310	chr13:44110451~44240517:+
BRCA	cis	rs10129255	1	rs10141557	ENSG00000280411.1	IGHV1-69-2	-5.95	3.72e-09	5.75e-07	-0.14	-0.18	Kawasaki disease;	chr14:106767990	chr14:106762092~106762588:-
BRCA	cis	rs4718428	0.607	rs66954441	ENSG00000230295.1	RP11-458F8.2	-5.95	3.72e-09	5.75e-07	-0.17	-0.18	Corneal structure;	chr7:66904222	chr7:66880708~66882981:+
BRCA	cis	rs42648	0.535	rs39198	ENSG00000225498.1	AC002064.5	5.95	3.72e-09	5.75e-07	0.17	0.18	Homocysteine levels;	chr7:90104504	chr7:90312496~90322592:+
BRCA	cis	rs227275	0.554	rs223395	ENSG00000251288.2	RP11-10L12.2	-5.95	3.72e-09	5.75e-07	-0.21	-0.18	Allergic disease (asthma, hay fever or eczema);	chr4:102823801	chr4:102751401~102752641:+
BRCA	cis	rs1552244	1	rs6764168	ENSG00000180385.7	EMC3-AS1	5.95	3.72e-09	5.76e-07	0.23	0.18	Alzheimer's disease;	chr3:10082121	chr3:9986893~10006990:+
BRCA	cis	rs13108904	0.935	rs2293633	ENSG00000254094.1	AC078852.1	-5.95	3.72e-09	5.76e-07	-0.19	-0.18	Obesity-related traits;	chr4:1297852	chr4:1356581~1358075:+
BRCA	cis	rs4908760	0.613	rs12403640	ENSG00000270282.1	RP5-1115A15.2	5.95	3.73e-09	5.76e-07	0.19	0.18	Vitiligo;	chr1:8757804	chr1:8512653~8513021:+
BRCA	cis	rs62388641	0.802	rs13202504	ENSG00000218027.2	RP11-157J24.1	-5.95	3.73e-09	5.76e-07	-0.3	-0.18	Daytime sleep phenotypes;	chr6:1537640	chr6:1513698~1515289:-
BRCA	cis	rs867371	0.502	rs3759800	ENSG00000255769.6	GOLGA2P10	5.95	3.73e-09	5.77e-07	0.2	0.18	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82240622	chr15:82472993~82513950:-
BRCA	cis	rs56104184	0.723	rs1058483	ENSG00000235191.1	NUCB1-AS1	5.95	3.73e-09	5.77e-07	0.33	0.18	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr19:48904403	chr19:48910930~48918891:-
BRCA	cis	rs919433	0.68	rs6710530	ENSG00000231621.1	AC013264.2	-5.95	3.74e-09	5.77e-07	-0.17	-0.18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197412827	chr2:197197991~197199273:+
BRCA	cis	rs8031584	0.541	rs1983459	ENSG00000260382.1	RP11-540B6.2	5.95	3.74e-09	5.78e-07	0.21	0.18	Huntington's disease progression;	chr15:30916546	chr15:30882267~30883231:-
BRCA	cis	rs17301013	0.606	rs6668008	ENSG00000227373.4	RP11-160H22.5	5.95	3.74e-09	5.78e-07	0.27	0.18	Systemic lupus erythematosus;	chr1:174138752	chr1:174115300~174160004:-
BRCA	cis	rs962856	0.822	rs1944911	ENSG00000236780.4	AC078941.1	5.95	3.74e-09	5.78e-07	0.23	0.18	Pancreatic cancer;	chr2:67420029	chr2:67123357~67215319:-
BRCA	cis	rs2836950	0.52	rs1980407	ENSG00000238141.2	BRWD1-AS1	-5.95	3.74e-09	5.78e-07	-0.2	-0.18	Menarche (age at onset);	chr21:39172035	chr21:39315707~39323218:+
BRCA	cis	rs10510102	0.623	rs10159856	ENSG00000276742.1	RP11-500G22.4	5.95	3.74e-09	5.79e-07	0.32	0.18	Breast cancer;	chr10:121988292	chr10:121956782~121957098:+
BRCA	cis	rs2408955	0.504	rs11168441	ENSG00000240399.1	RP1-228P16.1	5.95	3.74e-09	5.79e-07	0.21	0.18	Glycated hemoglobin levels;	chr12:48182271	chr12:48054813~48055591:-
BRCA	cis	rs5015933	0.902	rs10819047	ENSG00000232630.1	PRPS1P2	-5.95	3.75e-09	5.79e-07	-0.17	-0.18	Body mass index;	chr9:125365133	chr9:125150653~125151589:+
BRCA	cis	rs755249	0.567	rs76111861	ENSG00000237624.1	OXCT2P1	5.95	3.75e-09	5.79e-07	0.27	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39377018	chr1:39514956~39516490:+
BRCA	cis	rs755249	0.567	rs72661965	ENSG00000237624.1	OXCT2P1	5.95	3.75e-09	5.79e-07	0.27	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39380918	chr1:39514956~39516490:+
BRCA	cis	rs9876781	1	rs11130170	ENSG00000229759.1	MRPS18AP1	5.95	3.75e-09	5.79e-07	0.2	0.18	Longevity;	chr3:48408490	chr3:48256350~48256938:-
BRCA	cis	rs67311347	0.544	rs7644643	ENSG00000280739.1	EIF1B-AS1	-5.95	3.75e-09	5.79e-07	-0.19	-0.18	Renal cell carcinoma;	chr3:40308718	chr3:40173145~40309698:-
BRCA	cis	rs9311474	0.502	rs4687624	ENSG00000243224.1	RP5-1157M23.2	-5.95	3.75e-09	5.8e-07	-0.2	-0.18	Electroencephalogram traits;	chr3:52529556	chr3:52239258~52241097:+
BRCA	cis	rs875971	0.545	rs17138149	ENSG00000228409.4	CCT6P1	-5.95	3.75e-09	5.8e-07	-0.18	-0.18	Aortic root size;	chr7:66228193	chr7:65751142~65763354:+
BRCA	cis	rs78487399	0.908	rs55640722	ENSG00000234936.1	AC010883.5	5.95	3.76e-09	5.81e-07	0.24	0.18	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43618901	chr2:43229573~43233394:+
BRCA	cis	rs12655019	0.92	rs1466007	ENSG00000271828.1	CTD-2310F14.1	5.95	3.76e-09	5.81e-07	0.33	0.18	Breast cancer (early onset);	chr5:56917812	chr5:56927874~56929573:+
BRCA	cis	rs754466	0.58	rs11002293	ENSG00000204049.1	RP11-126H7.4	5.95	3.76e-09	5.81e-07	0.22	0.18	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77778207	chr10:77866875~77869610:+
BRCA	cis	rs2098713	0.561	rs55960353	ENSG00000250155.1	CTD-2353F22.1	5.95	3.76e-09	5.81e-07	0.2	0.18	Telomere length;	chr5:37599484	chr5:36666214~36725195:-
BRCA	cis	rs7927771	0.542	rs7108479	ENSG00000280615.1	Y_RNA	5.95	3.76e-09	5.82e-07	0.21	0.18	Subjective well-being;	chr11:47759908	chr11:47614898~47614994:-
BRCA	cis	rs1395	0.744	rs7600932	ENSG00000234072.1	AC074117.10	-5.95	3.77e-09	5.82e-07	-0.19	-0.18	Blood metabolite levels;	chr2:27252001	chr2:27356246~27367622:+
BRCA	cis	rs2638953	0.819	rs10843146	ENSG00000278733.1	RP11-425D17.1	-5.94	3.77e-09	5.82e-07	-0.25	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28268352	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.962	rs61922975	ENSG00000278733.1	RP11-425D17.1	-5.94	3.77e-09	5.82e-07	-0.25	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28283705	chr12:28185625~28186190:-
BRCA	cis	rs7914558	1	rs10786740	ENSG00000213061.2	PFN1P11	5.94	3.77e-09	5.82e-07	0.24	0.18	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103175836	chr10:102838011~102845473:-
BRCA	cis	rs72627509	0.68	rs79641006	ENSG00000269949.1	RP11-738E22.3	5.94	3.78e-09	5.83e-07	0.32	0.18	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56981277	chr4:56960927~56961373:-
BRCA	cis	rs7208859	0.623	rs11658022	ENSG00000265443.1	CTD-2349P21.6	-5.94	3.78e-09	5.83e-07	-0.31	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30758341	chr17:30726305~30727564:-
BRCA	cis	rs2243480	0.803	rs55700941	ENSG00000230295.1	RP11-458F8.2	-5.94	3.78e-09	5.83e-07	-0.24	-0.18	Diabetic kidney disease;	chr7:65924813	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs313807	ENSG00000164669.11	INTS4P1	5.94	3.78e-09	5.84e-07	0.35	0.18	Diabetic kidney disease;	chr7:66034494	chr7:65141225~65234216:+
BRCA	cis	rs7772486	0.686	rs1337839	ENSG00000270638.1	RP3-466P17.1	-5.94	3.78e-09	5.84e-07	-0.21	-0.18	Lobe attachment (rater-scored or self-reported);	chr6:145689103	chr6:145735570~145737218:+
BRCA	cis	rs6750795	0.569	rs1667313	ENSG00000223198.1	RNU2-22P	-5.94	3.78e-09	5.84e-07	-0.22	-0.18	Height;	chr2:231543307	chr2:231501990~231502201:-
BRCA	cis	rs867371	1	rs1392976	ENSG00000276710.3	CSPG4P8	5.94	3.79e-09	5.85e-07	0.19	0.18	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82153834	chr15:82459472~82477258:+
BRCA	cis	rs2153535	0.518	rs2183113	ENSG00000230939.1	RP11-314C16.1	-5.94	3.79e-09	5.85e-07	-0.22	-0.18	Motion sickness;	chr6:8528305	chr6:8784178~8785445:+
BRCA	cis	rs73193808	0.901	rs2065274	ENSG00000215533.7	LINC00189	-5.94	3.79e-09	5.85e-07	-0.27	-0.18	Coronary artery disease;	chr21:29197521	chr21:29193480~29288205:+
BRCA	cis	rs17301013	0.507	rs72715300	ENSG00000227373.4	RP11-160H22.5	5.94	3.8e-09	5.86e-07	0.28	0.18	Systemic lupus erythematosus;	chr1:174768405	chr1:174115300~174160004:-
BRCA	cis	rs67981189	0.896	rs1859468	ENSG00000258571.1	PTTG4P	5.94	3.8e-09	5.86e-07	0.2	0.18	Schizophrenia;	chr14:70935573	chr14:71085482~71085833:-
BRCA	cis	rs7246657	0.551	rs4806413	ENSG00000276846.1	CTD-3220F14.3	5.94	3.8e-09	5.86e-07	0.29	0.18	Coronary artery calcification;	chr19:37126814	chr19:37314868~37315620:-
BRCA	cis	rs7927771	0.524	rs11039329	ENSG00000280615.1	Y_RNA	5.94	3.8e-09	5.87e-07	0.21	0.18	Subjective well-being;	chr11:47663356	chr11:47614898~47614994:-
BRCA	cis	rs7927771	0.524	rs12785949	ENSG00000280615.1	Y_RNA	5.94	3.8e-09	5.87e-07	0.21	0.18	Subjective well-being;	chr11:47708218	chr11:47614898~47614994:-
BRCA	cis	rs4950322	0.57	rs4950400	ENSG00000278811.3	LINC00624	-5.94	3.8e-09	5.87e-07	-0.25	-0.18	Protein quantitative trait loci;	chr1:147319383	chr1:147258885~147517875:-
BRCA	cis	rs651907	0.535	rs35810977	ENSG00000244119.1	PDCL3P4	5.94	3.81e-09	5.88e-07	0.15	0.18	Colorectal cancer;	chr3:101812536	chr3:101712472~101713191:+
BRCA	cis	rs2562456	0.917	rs2562468	ENSG00000268081.1	RP11-678G14.2	-5.94	3.81e-09	5.89e-07	-0.28	-0.18	Pain;	chr19:21532048	chr19:21554640~21569237:-
BRCA	cis	rs2562456	0.917	rs2562471	ENSG00000268081.1	RP11-678G14.2	-5.94	3.81e-09	5.89e-07	-0.28	-0.18	Pain;	chr19:21533017	chr19:21554640~21569237:-
BRCA	cis	rs6570726	0.846	rs9399559	ENSG00000270638.1	RP3-466P17.1	5.94	3.82e-09	5.9e-07	0.21	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145624642	chr6:145735570~145737218:+
BRCA	cis	rs67981189	0.896	rs221922	ENSG00000258571.1	PTTG4P	5.94	3.82e-09	5.9e-07	0.2	0.18	Schizophrenia;	chr14:71118396	chr14:71085482~71085833:-
BRCA	cis	rs10129255	0.5	rs988134	ENSG00000274576.2	IGHV2-70	-5.94	3.83e-09	5.9e-07	-0.15	-0.18	Kawasaki disease;	chr14:106776698	chr14:106770577~106771020:-
BRCA	cis	rs10129255	0.5	rs988133	ENSG00000274576.2	IGHV2-70	-5.94	3.83e-09	5.9e-07	-0.15	-0.18	Kawasaki disease;	chr14:106776724	chr14:106770577~106771020:-
BRCA	cis	rs13108904	0.518	rs4974603	ENSG00000254094.1	AC078852.1	-5.94	3.83e-09	5.91e-07	-0.21	-0.18	Obesity-related traits;	chr4:1349380	chr4:1356581~1358075:+
BRCA	cis	rs2281558	0.876	rs2281562	ENSG00000125804.12	FAM182A	-5.94	3.83e-09	5.91e-07	-0.27	-0.18	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25292726	chr20:26054655~26086917:+
BRCA	cis	rs6570726	0.846	rs1935616	ENSG00000270638.1	RP3-466P17.1	5.94	3.83e-09	5.91e-07	0.21	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145622376	chr6:145735570~145737218:+
BRCA	cis	rs1979679	0.842	rs36097532	ENSG00000278733.1	RP11-425D17.1	5.94	3.83e-09	5.91e-07	0.22	0.18	Ossification of the posterior longitudinal ligament of the spine;	chr12:28228557	chr12:28185625~28186190:-
BRCA	cis	rs9876781	1	rs7651407	ENSG00000229759.1	MRPS18AP1	5.94	3.83e-09	5.91e-07	0.2	0.18	Longevity;	chr3:48402409	chr3:48256350~48256938:-
BRCA	cis	rs10504130	0.696	rs76522329	ENSG00000272024.1	RP11-546K22.3	-5.94	3.83e-09	5.92e-07	-0.28	-0.18	Venous thromboembolism (SNP x SNP interaction);	chr8:51928822	chr8:51950284~51950690:+
BRCA	cis	rs73198271	0.74	rs10092720	ENSG00000253893.2	FAM85B	5.94	3.84e-09	5.93e-07	0.24	0.18	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8791607	chr8:8167819~8226614:-
BRCA	cis	rs2243480	1	rs1723267	ENSG00000164669.11	INTS4P1	5.94	3.84e-09	5.93e-07	0.35	0.18	Diabetic kidney disease;	chr7:66008327	chr7:65141225~65234216:+
BRCA	cis	rs919433	0.68	rs2564383	ENSG00000231621.1	AC013264.2	-5.94	3.84e-09	5.93e-07	-0.17	-0.18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197446138	chr2:197197991~197199273:+
BRCA	cis	rs1876905	0.597	rs354551	ENSG00000272356.1	RP5-1112D6.8	-5.94	3.85e-09	5.93e-07	-0.25	-0.18	Mean corpuscular hemoglobin;	chr6:111224337	chr6:111309203~111313517:+
BRCA	cis	rs2243480	1	rs2420171	ENSG00000232559.3	GS1-124K5.12	-5.94	3.85e-09	5.94e-07	-0.34	-0.18	Diabetic kidney disease;	chr7:66172773	chr7:66554588~66576923:-
BRCA	cis	rs4787491	0.729	rs3814878	ENSG00000273724.1	RP11-347C12.12	-5.94	3.85e-09	5.94e-07	-0.2	-0.18	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30030645	chr16:30336400~30343336:+
BRCA	cis	rs4803480	0.935	rs758349	ENSG00000270164.1	LINC01480	-5.94	3.85e-09	5.94e-07	-0.22	-0.18	Schizophrenia;	chr19:41578753	chr19:41535183~41536904:+
BRCA	cis	rs3738443	0.599	rs6693807	ENSG00000259865.1	RP11-488L18.10	-5.94	3.85e-09	5.94e-07	-0.17	-0.18	Alcohol dependence;	chr1:247230353	chr1:247187281~247188526:-
BRCA	cis	rs34779708	0.966	rs2126984	ENSG00000271335.4	RP11-324I22.4	5.94	3.85e-09	5.94e-07	0.18	0.18	Inflammatory bowel disease;Crohn's disease;	chr10:35121363	chr10:35314552~35336401:-
BRCA	cis	rs17597773	0.638	rs7530176	ENSG00000272823.1	RP11-295M18.6	-5.94	3.86e-09	5.95e-07	-0.2	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220816040	chr1:220828676~220829211:-
BRCA	cis	rs1823913	0.599	rs17346475	ENSG00000280083.1	RP11-317J9.1	5.94	3.86e-09	5.95e-07	0.21	0.18	Obesity-related traits;	chr2:191288488	chr2:191154118~191156070:-
BRCA	cis	rs1552244	0.808	rs7615088	ENSG00000232901.1	CYCSP10	5.94	3.86e-09	5.95e-07	0.25	0.18	Alzheimer's disease;	chr3:9994212	chr3:10000647~10000940:-
BRCA	cis	rs1552244	0.882	rs61429272	ENSG00000232901.1	CYCSP10	5.94	3.86e-09	5.95e-07	0.25	0.18	Alzheimer's disease;	chr3:9995636	chr3:10000647~10000940:-
BRCA	cis	rs1552244	0.882	rs9757159	ENSG00000232901.1	CYCSP10	5.94	3.86e-09	5.95e-07	0.25	0.18	Alzheimer's disease;	chr3:9997482	chr3:10000647~10000940:-
BRCA	cis	rs1552244	0.816	rs17050701	ENSG00000232901.1	CYCSP10	5.94	3.86e-09	5.95e-07	0.25	0.18	Alzheimer's disease;	chr3:9999870	chr3:10000647~10000940:-
BRCA	cis	rs1552244	0.882	rs55840655	ENSG00000232901.1	CYCSP10	5.94	3.86e-09	5.95e-07	0.25	0.18	Alzheimer's disease;	chr3:10001006	chr3:10000647~10000940:-
BRCA	cis	rs1552244	0.816	rs56387520	ENSG00000232901.1	CYCSP10	5.94	3.86e-09	5.95e-07	0.25	0.18	Alzheimer's disease;	chr3:10001098	chr3:10000647~10000940:-
BRCA	cis	rs1552244	0.882	rs56224841	ENSG00000232901.1	CYCSP10	5.94	3.86e-09	5.95e-07	0.25	0.18	Alzheimer's disease;	chr3:10002330	chr3:10000647~10000940:-
BRCA	cis	rs34779708	0.966	rs1213392	ENSG00000271335.4	RP11-324I22.4	5.94	3.87e-09	5.97e-07	0.18	0.18	Inflammatory bowel disease;Crohn's disease;	chr10:35141357	chr10:35314552~35336401:-
BRCA	cis	rs8054556	0.765	rs11150574	ENSG00000273724.1	RP11-347C12.12	-5.94	3.87e-09	5.97e-07	-0.2	-0.18	Autism spectrum disorder or schizophrenia;	chr16:29923498	chr16:30336400~30343336:+
BRCA	cis	rs7131987	0.565	rs6487797	ENSG00000275476.1	RP11-996F15.4	5.94	3.87e-09	5.98e-07	0.2	0.18	QT interval;	chr12:29270063	chr12:29277397~29277882:-
BRCA	cis	rs875971	0.571	rs78668714	ENSG00000236529.1	RP13-254B10.1	5.94	3.88e-09	5.98e-07	0.23	0.18	Aortic root size;	chr7:66474464	chr7:65840212~65840596:+
BRCA	cis	rs669446	0.562	rs10890275	ENSG00000237950.1	RP11-7O11.3	5.94	3.88e-09	5.98e-07	0.21	0.18	Amyotrophic lateral sclerosis (age of onset);	chr1:43728545	chr1:43944370~43946551:-
BRCA	cis	rs875971	0.545	rs2707851	ENSG00000273024.4	INTS4P2	5.94	3.88e-09	5.99e-07	0.23	0.18	Aortic root size;	chr7:66624178	chr7:65647864~65715661:+
BRCA	cis	rs2836950	0.565	rs2836931	ENSG00000255568.3	BRWD1-AS2	-5.94	3.89e-09	5.99e-07	-0.17	-0.18	Menarche (age at onset);	chr21:39174643	chr21:39313935~39314962:+
BRCA	cis	rs13108904	0.901	rs7668661	ENSG00000254094.1	AC078852.1	-5.94	3.89e-09	5.99e-07	-0.19	-0.18	Obesity-related traits;	chr4:1306384	chr4:1356581~1358075:+
BRCA	cis	rs7131987	0.565	rs7971296	ENSG00000275476.1	RP11-996F15.4	5.94	3.89e-09	6e-07	0.2	0.18	QT interval;	chr12:29263297	chr12:29277397~29277882:-
BRCA	cis	rs7131987	0.605	rs1120528	ENSG00000275476.1	RP11-996F15.4	5.94	3.89e-09	6e-07	0.2	0.18	QT interval;	chr12:29264237	chr12:29277397~29277882:-
BRCA	cis	rs7131987	0.585	rs6487795	ENSG00000275476.1	RP11-996F15.4	5.94	3.89e-09	6e-07	0.2	0.18	QT interval;	chr12:29266228	chr12:29277397~29277882:-
BRCA	cis	rs559928	0.606	rs57021319	ENSG00000236935.1	AP003774.1	5.94	3.89e-09	6e-07	0.25	0.18	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64188630	chr11:64325050~64329504:-
BRCA	cis	rs516805	0.63	rs2606606	ENSG00000279453.1	RP3-425C14.4	-5.94	3.89e-09	6e-07	-0.27	-0.18	Lymphocyte counts;	chr6:122201126	chr6:122436789~122439223:-
BRCA	cis	rs42648	0.564	rs11563340	ENSG00000225498.1	AC002064.5	5.94	3.89e-09	6e-07	0.17	0.18	Homocysteine levels;	chr7:90180265	chr7:90312496~90322592:+
BRCA	cis	rs12893668	0.543	rs1799796	ENSG00000269940.1	RP11-73M18.7	5.94	3.89e-09	6e-07	0.2	0.18	Reticulocyte count;	chr14:103699590	chr14:103694560~103695170:+
BRCA	cis	rs2732480	0.5	rs11168468	ENSG00000257763.1	OR5BK1P	5.94	3.9e-09	6.01e-07	0.19	0.18	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48218682	chr12:48355792~48356614:-
BRCA	cis	rs7221109	0.625	rs2008469	ENSG00000278834.1	RP11-458J1.1	5.94	3.9e-09	6.01e-07	0.2	0.18	Type 1 diabetes;	chr17:40660343	chr17:40648300~40649718:+
BRCA	cis	rs7221109	0.677	rs12943859	ENSG00000278834.1	RP11-458J1.1	5.94	3.9e-09	6.01e-07	0.2	0.18	Type 1 diabetes;	chr17:40661128	chr17:40648300~40649718:+
BRCA	cis	rs853679	0.607	rs67662114	ENSG00000220721.1	OR1F12	5.94	3.9e-09	6.01e-07	0.43	0.18	Depression;	chr6:27964523	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.607	rs13216117	ENSG00000220721.1	OR1F12	5.94	3.9e-09	6.01e-07	0.43	0.18	Depression;	chr6:27970706	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.607	rs36101351	ENSG00000220721.1	OR1F12	5.94	3.9e-09	6.01e-07	0.43	0.18	Depression;	chr6:27975591	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.607	rs28360499	ENSG00000220721.1	OR1F12	5.94	3.9e-09	6.01e-07	0.43	0.18	Depression;	chr6:27977618	chr6:28073316~28074233:+
BRCA	cis	rs6565180	1	rs11646130	ENSG00000183604.13	SMG1P5	-5.94	3.9e-09	6.01e-07	-0.19	-0.18	Tonsillectomy;	chr16:30365638	chr16:30267553~30335374:-
BRCA	cis	rs227275	0.525	rs11737544	ENSG00000251288.2	RP11-10L12.2	-5.94	3.9e-09	6.02e-07	-0.21	-0.18	Allergic disease (asthma, hay fever or eczema);	chr4:102983877	chr4:102751401~102752641:+
BRCA	cis	rs253959	0.629	rs10054121	ENSG00000272265.1	CTD-2287O16.4	5.94	3.91e-09	6.02e-07	0.21	0.18	Bipolar disorder and schizophrenia;	chr5:116084271	chr5:116078110~116078570:-
BRCA	cis	rs944990	0.557	rs4237221	ENSG00000227603.1	RP11-165J3.6	5.94	3.91e-09	6.03e-07	0.19	0.18	Body mass index;	chr9:93533821	chr9:93435332~93437121:-
BRCA	cis	rs7897654	0.571	rs12771681	ENSG00000213061.2	PFN1P11	5.94	3.91e-09	6.03e-07	0.27	0.18	Schizophrenia;	chr10:102875863	chr10:102838011~102845473:-
BRCA	cis	rs7493	1	rs2068604	ENSG00000233942.1	AC004012.1	5.94	3.92e-09	6.04e-07	0.23	0.18	Yu-Zhi constitution type in type 2 diabetes;	chr7:95412230	chr7:95471835~95473998:+
BRCA	cis	rs875971	0.545	rs7810213	ENSG00000236529.1	RP13-254B10.1	5.94	3.93e-09	6.05e-07	0.23	0.18	Aortic root size;	chr7:66481592	chr7:65840212~65840596:+
BRCA	cis	rs6723226	0.842	rs1901355	ENSG00000276334.1	AL133243.1	-5.94	3.93e-09	6.05e-07	-0.24	-0.18	Intelligence (multi-trait analysis);	chr2:32610597	chr2:32521927~32523547:+
BRCA	cis	rs42490	0.51	rs218917	ENSG00000251136.7	RP11-37B2.1	-5.94	3.93e-09	6.05e-07	-0.17	-0.18	Leprosy;	chr8:89688902	chr8:89609409~89757727:-
BRCA	cis	rs7772486	0.622	rs1292333	ENSG00000270638.1	RP3-466P17.1	-5.94	3.93e-09	6.06e-07	-0.21	-0.18	Lobe attachment (rater-scored or self-reported);	chr6:145661208	chr6:145735570~145737218:+
BRCA	cis	rs7520050	0.966	rs4660317	ENSG00000280836.1	AL355480.1	5.94	3.93e-09	6.06e-07	0.21	0.18	Reticulocyte count;Red blood cell count;	chr1:45860554	chr1:45581219~45581321:-
BRCA	cis	rs7520050	0.966	rs10749860	ENSG00000280836.1	AL355480.1	5.94	3.93e-09	6.06e-07	0.21	0.18	Reticulocyte count;Red blood cell count;	chr1:45862538	chr1:45581219~45581321:-
BRCA	cis	rs7520050	0.931	rs6688365	ENSG00000280836.1	AL355480.1	5.94	3.93e-09	6.06e-07	0.21	0.18	Reticulocyte count;Red blood cell count;	chr1:45864212	chr1:45581219~45581321:-
BRCA	cis	rs7520050	0.966	rs6656992	ENSG00000280836.1	AL355480.1	5.94	3.93e-09	6.06e-07	0.21	0.18	Reticulocyte count;Red blood cell count;	chr1:45867396	chr1:45581219~45581321:-
BRCA	cis	rs7520050	0.966	rs61783220	ENSG00000280836.1	AL355480.1	5.94	3.93e-09	6.06e-07	0.21	0.18	Reticulocyte count;Red blood cell count;	chr1:45869640	chr1:45581219~45581321:-
BRCA	cis	rs7520050	0.966	rs7540325	ENSG00000280836.1	AL355480.1	5.94	3.93e-09	6.06e-07	0.21	0.18	Reticulocyte count;Red blood cell count;	chr1:45872545	chr1:45581219~45581321:-
BRCA	cis	rs7520050	1	rs7540699	ENSG00000280836.1	AL355480.1	5.94	3.93e-09	6.06e-07	0.21	0.18	Reticulocyte count;Red blood cell count;	chr1:45872913	chr1:45581219~45581321:-
BRCA	cis	rs7520050	0.966	rs4660319	ENSG00000280836.1	AL355480.1	5.94	3.93e-09	6.06e-07	0.21	0.18	Reticulocyte count;Red blood cell count;	chr1:45875951	chr1:45581219~45581321:-
BRCA	cis	rs7520050	0.931	rs11211213	ENSG00000280836.1	AL355480.1	5.94	3.93e-09	6.06e-07	0.21	0.18	Reticulocyte count;Red blood cell count;	chr1:45876845	chr1:45581219~45581321:-
BRCA	cis	rs7927771	0.524	rs10838775	ENSG00000280615.1	Y_RNA	5.94	3.93e-09	6.06e-07	0.21	0.18	Subjective well-being;	chr11:47834830	chr11:47614898~47614994:-
BRCA	cis	rs17508449	0.732	rs75746385	ENSG00000232450.1	RP4-730K3.3	-5.94	3.94e-09	6.07e-07	-0.33	-0.18	Leprosy;	chr1:113758270	chr1:113698884~113699631:-
BRCA	cis	rs11671005	0.735	rs11667591	ENSG00000252334.1	RNU6-1337P	5.94	3.94e-09	6.07e-07	0.27	0.18	Mean platelet volume;	chr19:58426270	chr19:58483749~58483843:-
BRCA	cis	rs853679	0.517	rs9393887	ENSG00000204709.4	LINC01556	5.94	3.94e-09	6.07e-07	0.27	0.18	Depression;	chr6:28091242	chr6:28943877~28944537:+
BRCA	cis	rs9341808	0.528	rs2322753	ENSG00000272129.1	RP11-250B2.6	5.94	3.95e-09	6.08e-07	0.22	0.18	Sitting height ratio;	chr6:80333148	chr6:80355424~80356859:+
BRCA	cis	rs4660456	0.576	rs2780948	ENSG00000237899.1	RP4-739H11.3	-5.94	3.95e-09	6.08e-07	-0.23	-0.18	Platelet count;	chr1:40776205	chr1:40669089~40687588:-
BRCA	cis	rs7131987	0.546	rs7299648	ENSG00000275476.1	RP11-996F15.4	5.94	3.95e-09	6.08e-07	0.2	0.18	QT interval;	chr12:29256797	chr12:29277397~29277882:-
BRCA	cis	rs7131987	0.565	rs7316026	ENSG00000275476.1	RP11-996F15.4	5.94	3.95e-09	6.08e-07	0.2	0.18	QT interval;	chr12:29258881	chr12:29277397~29277882:-
BRCA	cis	rs7131987	0.565	rs6487792	ENSG00000275476.1	RP11-996F15.4	5.94	3.95e-09	6.08e-07	0.2	0.18	QT interval;	chr12:29259743	chr12:29277397~29277882:-
BRCA	cis	rs7131987	0.585	rs2194517	ENSG00000275476.1	RP11-996F15.4	5.94	3.95e-09	6.08e-07	0.2	0.18	QT interval;	chr12:29260002	chr12:29277397~29277882:-
BRCA	cis	rs2836950	0.565	rs7278297	ENSG00000255568.3	BRWD1-AS2	-5.94	3.95e-09	6.09e-07	-0.17	-0.18	Menarche (age at onset);	chr21:39253826	chr21:39313935~39314962:+
BRCA	cis	rs10129255	0.556	rs6576222	ENSG00000274576.2	IGHV2-70	-5.94	3.96e-09	6.1e-07	-0.15	-0.18	Kawasaki disease;	chr14:106776442	chr14:106770577~106771020:-
BRCA	cis	rs2288884	0.767	rs12462359	ENSG00000275055.1	CTC-471J1.11	-5.94	3.96e-09	6.11e-07	-0.25	-0.18	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52032168	chr19:52049007~52049754:+
BRCA	cis	rs2153535	0.585	rs6915130	ENSG00000230939.1	RP11-314C16.1	-5.94	3.97e-09	6.11e-07	-0.21	-0.18	Motion sickness;	chr6:8661262	chr6:8784178~8785445:+
BRCA	cis	rs2380205	0.546	rs649537	ENSG00000232807.2	RP11-536K7.3	-5.94	3.97e-09	6.11e-07	-0.18	-0.18	Breast cancer;	chr10:5903709	chr10:5934270~5945900:-
BRCA	cis	rs4908760	0.827	rs7556169	ENSG00000270282.1	RP5-1115A15.2	-5.94	3.97e-09	6.11e-07	-0.19	-0.18	Vitiligo;	chr1:8681342	chr1:8512653~8513021:+
BRCA	cis	rs690037	0.528	rs568833	ENSG00000271964.1	RP11-415F23.2	-5.94	3.97e-09	6.11e-07	-0.18	-0.18	Optic nerve measurement (cup-to-disc ratio);Optic nerve measurement (cup area);	chr3:16326329	chr3:16314439~16314987:+
BRCA	cis	rs10129255	0.536	rs6576223	ENSG00000274576.2	IGHV2-70	-5.94	3.98e-09	6.13e-07	-0.15	-0.18	Kawasaki disease;	chr14:106776448	chr14:106770577~106771020:-
BRCA	cis	rs2562456	0.792	rs2562398	ENSG00000268081.1	RP11-678G14.2	-5.94	3.98e-09	6.13e-07	-0.28	-0.18	Pain;	chr19:21540147	chr19:21554640~21569237:-
BRCA	cis	rs59169624	0.699	rs1698894	ENSG00000255160.4	RP11-428C19.5	-5.94	3.99e-09	6.14e-07	-0.24	-0.18	Parental extreme longevity (95 years and older);	chr11:19259335	chr11:19299883~19308358:+
BRCA	cis	rs7772486	0.79	rs9497425	ENSG00000270638.1	RP3-466P17.1	-5.94	3.99e-09	6.14e-07	-0.21	-0.18	Lobe attachment (rater-scored or self-reported);	chr6:145913061	chr6:145735570~145737218:+
BRCA	cis	rs6479891	1	rs4747045	ENSG00000232075.1	MRPL35P2	5.94	3.99e-09	6.15e-07	0.33	0.18	Arthritis (juvenile idiopathic);	chr10:63166722	chr10:63634317~63634827:-
BRCA	cis	rs17301013	0.606	rs55698100	ENSG00000227373.4	RP11-160H22.5	5.94	3.99e-09	6.15e-07	0.27	0.18	Systemic lupus erythematosus;	chr1:174258295	chr1:174115300~174160004:-
BRCA	cis	rs2638953	0.962	rs73261702	ENSG00000247934.4	RP11-967K21.1	-5.94	3.99e-09	6.15e-07	-0.23	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28204118	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.924	rs11049455	ENSG00000247934.4	RP11-967K21.1	-5.94	3.99e-09	6.15e-07	-0.23	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28204758	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.924	rs11049457	ENSG00000247934.4	RP11-967K21.1	-5.94	3.99e-09	6.15e-07	-0.23	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28205050	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.886	rs10843131	ENSG00000247934.4	RP11-967K21.1	-5.94	3.99e-09	6.15e-07	-0.23	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28205259	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.924	rs10843132	ENSG00000247934.4	RP11-967K21.1	-5.94	3.99e-09	6.15e-07	-0.23	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28205348	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.924	rs10843133	ENSG00000247934.4	RP11-967K21.1	-5.94	3.99e-09	6.15e-07	-0.23	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28205571	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.924	rs10843135	ENSG00000247934.4	RP11-967K21.1	-5.94	3.99e-09	6.15e-07	-0.23	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28205809	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.886	rs11049458	ENSG00000247934.4	RP11-967K21.1	-5.94	3.99e-09	6.15e-07	-0.23	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28205834	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.924	rs11049459	ENSG00000247934.4	RP11-967K21.1	-5.94	3.99e-09	6.15e-07	-0.23	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28206011	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.924	rs11049460	ENSG00000247934.4	RP11-967K21.1	-5.94	3.99e-09	6.15e-07	-0.23	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28206021	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.924	rs1824767	ENSG00000247934.4	RP11-967K21.1	-5.94	3.99e-09	6.15e-07	-0.23	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28206653	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.924	rs1824766	ENSG00000247934.4	RP11-967K21.1	-5.94	3.99e-09	6.15e-07	-0.23	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28206655	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.924	rs1585682	ENSG00000247934.4	RP11-967K21.1	-5.94	3.99e-09	6.15e-07	-0.23	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28206841	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.888	rs9645745	ENSG00000247934.4	RP11-967K21.1	-5.94	3.99e-09	6.15e-07	-0.23	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28207082	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.924	rs7973516	ENSG00000247934.4	RP11-967K21.1	-5.94	3.99e-09	6.15e-07	-0.23	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28207523	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.924	rs7973656	ENSG00000247934.4	RP11-967K21.1	-5.94	3.99e-09	6.15e-07	-0.23	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28207679	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.924	rs7971033	ENSG00000247934.4	RP11-967K21.1	-5.94	3.99e-09	6.15e-07	-0.23	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28208420	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.924	rs7956418	ENSG00000247934.4	RP11-967K21.1	-5.94	3.99e-09	6.15e-07	-0.23	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28208566	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.924	rs11519094	ENSG00000247934.4	RP11-967K21.1	-5.94	3.99e-09	6.15e-07	-0.23	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28209430	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.924	rs11513465	ENSG00000247934.4	RP11-967K21.1	-5.94	3.99e-09	6.15e-07	-0.23	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28209483	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.924	rs11513250	ENSG00000247934.4	RP11-967K21.1	-5.94	3.99e-09	6.15e-07	-0.23	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28209500	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.924	rs11519330	ENSG00000247934.4	RP11-967K21.1	-5.94	3.99e-09	6.15e-07	-0.23	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28209720	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.85	rs11519331	ENSG00000247934.4	RP11-967K21.1	-5.94	3.99e-09	6.15e-07	-0.23	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28209995	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.888	rs11513466	ENSG00000247934.4	RP11-967K21.1	-5.94	3.99e-09	6.15e-07	-0.23	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28210111	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.924	rs7298652	ENSG00000247934.4	RP11-967K21.1	-5.94	3.99e-09	6.15e-07	-0.23	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28210620	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.924	rs6487669	ENSG00000247934.4	RP11-967K21.1	-5.94	3.99e-09	6.15e-07	-0.23	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28210827	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.924	rs6487671	ENSG00000247934.4	RP11-967K21.1	-5.94	3.99e-09	6.15e-07	-0.23	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28210902	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.924	rs11049464	ENSG00000247934.4	RP11-967K21.1	-5.94	3.99e-09	6.15e-07	-0.23	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28211637	chr12:28163298~28190738:-
BRCA	cis	rs2836950	0.501	rs11088470	ENSG00000255568.3	BRWD1-AS2	-5.93	4e-09	6.15e-07	-0.17	-0.18	Menarche (age at onset);	chr21:39317236	chr21:39313935~39314962:+
BRCA	cis	rs2836950	0.501	rs2836983	ENSG00000255568.3	BRWD1-AS2	-5.93	4e-09	6.15e-07	-0.17	-0.18	Menarche (age at onset);	chr21:39317410	chr21:39313935~39314962:+
BRCA	cis	rs2836950	0.52	rs8133927	ENSG00000255568.3	BRWD1-AS2	-5.93	4e-09	6.15e-07	-0.17	-0.18	Menarche (age at onset);	chr21:39318035	chr21:39313935~39314962:+
BRCA	cis	rs2836950	0.52	rs8133928	ENSG00000255568.3	BRWD1-AS2	-5.93	4e-09	6.15e-07	-0.17	-0.18	Menarche (age at onset);	chr21:39318037	chr21:39313935~39314962:+
BRCA	cis	rs2836950	0.565	rs2836930	ENSG00000255568.3	BRWD1-AS2	-5.93	4e-09	6.16e-07	-0.17	-0.18	Menarche (age at onset);	chr21:39173730	chr21:39313935~39314962:+
BRCA	cis	rs7044106	0.762	rs7044226	ENSG00000238181.2	AHCYP2	-5.93	4e-09	6.16e-07	-0.23	-0.18	Hip circumference adjusted for BMI;	chr9:120704050	chr9:120720673~120721972:+
BRCA	cis	rs75422866	0.867	rs73104152	ENSG00000280054.1	RP1-197B17.7	5.93	4.01e-09	6.16e-07	0.46	0.18	Pneumonia;	chr12:47699091	chr12:47728151~47730598:-
BRCA	cis	rs75422866	0.867	rs73104155	ENSG00000280054.1	RP1-197B17.7	5.93	4.01e-09	6.16e-07	0.46	0.18	Pneumonia;	chr12:47700790	chr12:47728151~47730598:-
BRCA	cis	rs9990333	0.544	rs112577972	ENSG00000231464.1	AC024937.4	5.93	4.01e-09	6.16e-07	0.24	0.18	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196098278	chr3:195996738~195998233:+
BRCA	cis	rs11671005	0.735	rs1122955	ENSG00000252334.1	RNU6-1337P	5.93	4.01e-09	6.17e-07	0.27	0.18	Mean platelet volume;	chr19:58434836	chr19:58483749~58483843:-
BRCA	cis	rs651907	0.535	rs13084113	ENSG00000244119.1	PDCL3P4	5.93	4.01e-09	6.18e-07	0.15	0.18	Colorectal cancer;	chr3:101815195	chr3:101712472~101713191:+
BRCA	cis	rs4763879	0.739	rs12582584	ENSG00000214776.8	RP11-726G1.1	-5.93	4.01e-09	6.18e-07	-0.2	-0.18	Type 1 diabetes;	chr12:9671542	chr12:9467552~9576275:+
BRCA	cis	rs4718428	0.705	rs12698547	ENSG00000230295.1	RP11-458F8.2	-5.93	4.02e-09	6.19e-07	-0.17	-0.18	Corneal structure;	chr7:66813271	chr7:66880708~66882981:+
BRCA	cis	rs11098499	0.954	rs6847248	ENSG00000249244.1	RP11-548H18.2	5.93	4.03e-09	6.2e-07	0.23	0.18	Corneal astigmatism;	chr4:119304800	chr4:119391831~119395335:-
BRCA	cis	rs7567389	0.671	rs11692990	ENSG00000236682.1	AC068282.3	-5.93	4.04e-09	6.21e-07	-0.28	-0.18	Self-rated health;	chr2:127354614	chr2:127389130~127400580:+
BRCA	cis	rs7688540	0.771	rs11722521	ENSG00000211553.1	AC253576.2	-5.93	4.04e-09	6.21e-07	-0.28	-0.18	Facial morphology (factor 6, height of vermillion lower lip);	chr4:282976	chr4:136461~136568:+
BRCA	cis	rs9341808	0.727	rs4706834	ENSG00000272129.1	RP11-250B2.6	5.93	4.05e-09	6.22e-07	0.22	0.18	Sitting height ratio;	chr6:80302888	chr6:80355424~80356859:+
BRCA	cis	rs11098499	0.73	rs12505735	ENSG00000249244.1	RP11-548H18.2	5.93	4.05e-09	6.22e-07	0.22	0.18	Corneal astigmatism;	chr4:119611801	chr4:119391831~119395335:-
BRCA	cis	rs4604234	0.614	rs11962441	ENSG00000272129.1	RP11-250B2.6	-5.93	4.05e-09	6.23e-07	-0.46	-0.18	Cancer;	chr6:80155705	chr6:80355424~80356859:+
BRCA	cis	rs4713675	0.565	rs4713670	ENSG00000224557.6	HLA-DPB2	5.93	4.05e-09	6.23e-07	0.21	0.18	Plateletcrit;	chr6:33732105	chr6:33112451~33129084:+
BRCA	cis	rs7914558	0.933	rs2066323	ENSG00000213061.2	PFN1P11	5.93	4.05e-09	6.23e-07	0.24	0.18	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103111604	chr10:102838011~102845473:-
BRCA	cis	rs7976269	0.515	rs11049999	ENSG00000275476.1	RP11-996F15.4	-5.93	4.05e-09	6.23e-07	-0.21	-0.18	Male-pattern baldness;	chr12:29042854	chr12:29277397~29277882:-
BRCA	cis	rs875971	0.545	rs73150604	ENSG00000236529.1	RP13-254B10.1	5.93	4.05e-09	6.23e-07	0.23	0.18	Aortic root size;	chr7:66480545	chr7:65840212~65840596:+
BRCA	cis	rs10129255	0.957	rs10132367	ENSG00000280411.1	IGHV1-69-2	-5.93	4.05e-09	6.24e-07	-0.14	-0.18	Kawasaki disease;	chr14:106690981	chr14:106762092~106762588:-
BRCA	cis	rs11671005	0.735	rs45617039	ENSG00000252334.1	RNU6-1337P	5.93	4.05e-09	6.24e-07	0.27	0.18	Mean platelet volume;	chr19:58439729	chr19:58483749~58483843:-
BRCA	cis	rs7976269	0.609	rs1344855	ENSG00000257176.2	RP11-996F15.2	5.93	4.06e-09	6.24e-07	0.22	0.18	Male-pattern baldness;	chr12:29065605	chr12:29280418~29317848:-
BRCA	cis	rs11671005	0.735	rs11668814	ENSG00000252334.1	RNU6-1337P	5.93	4.06e-09	6.24e-07	0.27	0.18	Mean platelet volume;	chr19:58435466	chr19:58483749~58483843:-
BRCA	cis	rs9393777	0.92	rs13207689	ENSG00000220721.1	OR1F12	5.93	4.06e-09	6.24e-07	0.42	0.18	Intelligence (multi-trait analysis);	chr6:27401925	chr6:28073316~28074233:+
BRCA	cis	rs13108904	0.901	rs12509700	ENSG00000254094.1	AC078852.1	-5.93	4.06e-09	6.24e-07	-0.19	-0.18	Obesity-related traits;	chr4:1302533	chr4:1356581~1358075:+
BRCA	cis	rs12655019	0.92	rs79354983	ENSG00000271828.1	CTD-2310F14.1	5.93	4.06e-09	6.25e-07	0.34	0.18	Breast cancer (early onset);	chr5:56925710	chr5:56927874~56929573:+
BRCA	cis	rs7927771	0.524	rs754434	ENSG00000280615.1	Y_RNA	5.93	4.06e-09	6.25e-07	0.21	0.18	Subjective well-being;	chr11:47792728	chr11:47614898~47614994:-
BRCA	cis	rs6479901	0.512	rs6415875	ENSG00000232075.1	MRPL35P2	-5.93	4.07e-09	6.25e-07	-0.33	-0.18	Intelligence (multi-trait analysis);	chr10:63226657	chr10:63634317~63634827:-
BRCA	cis	rs6479901	0.512	rs4439410	ENSG00000232075.1	MRPL35P2	-5.93	4.07e-09	6.25e-07	-0.33	-0.18	Intelligence (multi-trait analysis);	chr10:63239012	chr10:63634317~63634827:-
BRCA	cis	rs2243480	1	rs1167613	ENSG00000164669.11	INTS4P1	5.93	4.07e-09	6.25e-07	0.35	0.18	Diabetic kidney disease;	chr7:66022452	chr7:65141225~65234216:+
BRCA	cis	rs2243480	1	rs313799	ENSG00000164669.11	INTS4P1	5.93	4.07e-09	6.25e-07	0.35	0.18	Diabetic kidney disease;	chr7:66029343	chr7:65141225~65234216:+
BRCA	cis	rs2562456	0.793	rs7259708	ENSG00000268081.1	RP11-678G14.2	5.93	4.07e-09	6.25e-07	0.27	0.18	Pain;	chr19:21567846	chr19:21554640~21569237:-
BRCA	cis	rs9308731	0.568	rs6754736	ENSG00000227992.1	AC108463.2	-5.93	4.07e-09	6.25e-07	-0.21	-0.18	Chronic lymphocytic leukemia;	chr2:111190964	chr2:111203964~111206215:-
BRCA	cis	rs2243480	1	rs781149	ENSG00000164669.11	INTS4P1	5.93	4.07e-09	6.26e-07	0.35	0.18	Diabetic kidney disease;	chr7:66016297	chr7:65141225~65234216:+
BRCA	cis	rs2243480	0.901	rs58207111	ENSG00000164669.11	INTS4P1	5.93	4.07e-09	6.26e-07	0.35	0.18	Diabetic kidney disease;	chr7:66021736	chr7:65141225~65234216:+
BRCA	cis	rs10129255	0.518	rs8009612	ENSG00000274576.2	IGHV2-70	-5.93	4.08e-09	6.27e-07	-0.15	-0.18	Kawasaki disease;	chr14:106777510	chr14:106770577~106771020:-
BRCA	cis	rs7772486	0.79	rs9497427	ENSG00000270638.1	RP3-466P17.1	-5.93	4.08e-09	6.27e-07	-0.21	-0.18	Lobe attachment (rater-scored or self-reported);	chr6:145917166	chr6:145735570~145737218:+
BRCA	cis	rs67311347	1	rs9822909	ENSG00000280739.1	EIF1B-AS1	5.93	4.08e-09	6.27e-07	0.22	0.18	Renal cell carcinoma;	chr3:40415593	chr3:40173145~40309698:-
BRCA	cis	rs2098713	0.561	rs12655908	ENSG00000250155.1	CTD-2353F22.1	5.93	4.08e-09	6.27e-07	0.2	0.18	Telomere length;	chr5:37595793	chr5:36666214~36725195:-
BRCA	cis	rs2098713	0.561	rs4869530	ENSG00000250155.1	CTD-2353F22.1	5.93	4.08e-09	6.27e-07	0.2	0.18	Telomere length;	chr5:37598468	chr5:36666214~36725195:-
BRCA	cis	rs2644899	0.859	rs2644898	ENSG00000268529.1	CYP2T3P	5.93	4.09e-09	6.28e-07	0.25	0.18	Post bronchodilator FEV1/FVC ratio;	chr19:40793110	chr19:41134722~41137308:+
BRCA	cis	rs2644899	0.785	rs7249450	ENSG00000268529.1	CYP2T3P	5.93	4.09e-09	6.28e-07	0.25	0.18	Post bronchodilator FEV1/FVC ratio;	chr19:40794866	chr19:41134722~41137308:+
BRCA	cis	rs2644899	0.821	rs4803368	ENSG00000268529.1	CYP2T3P	5.93	4.09e-09	6.28e-07	0.25	0.18	Post bronchodilator FEV1/FVC ratio;	chr19:40795809	chr19:41134722~41137308:+
BRCA	cis	rs2243480	1	rs35396113	ENSG00000164669.11	INTS4P1	5.93	4.09e-09	6.28e-07	0.35	0.18	Diabetic kidney disease;	chr7:66030474	chr7:65141225~65234216:+
BRCA	cis	rs867371	0.502	rs2047679	ENSG00000255769.6	GOLGA2P10	-5.93	4.09e-09	6.29e-07	-0.2	-0.18	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82239540	chr15:82472993~82513950:-
BRCA	cis	rs10129255	0.518	rs8009594	ENSG00000274576.2	IGHV2-70	-5.93	4.09e-09	6.29e-07	-0.15	-0.18	Kawasaki disease;	chr14:106777494	chr14:106770577~106771020:-
BRCA	cis	rs7238033	0.663	rs11665385	ENSG00000267193.4	RP11-116O18.3	-5.93	4.09e-09	6.29e-07	-0.2	-0.18	Bladder cancer;	chr18:45738781	chr18:45669367~45747215:-
BRCA	cis	rs8002861	0.754	rs4053664	ENSG00000274001.1	RP11-5G9.5	5.93	4.1e-09	6.3e-07	0.2	0.18	Leprosy;	chr13:43855036	chr13:43877715~43878163:-
BRCA	cis	rs10129255	0.5	rs6576230	ENSG00000274576.2	IGHV2-70	-5.93	4.11e-09	6.31e-07	-0.15	-0.18	Kawasaki disease;	chr14:106778539	chr14:106770577~106771020:-
BRCA	cis	rs2638953	0.924	rs11049476	ENSG00000278733.1	RP11-425D17.1	-5.93	4.11e-09	6.31e-07	-0.23	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28244242	chr12:28185625~28186190:-
BRCA	cis	rs77972916	0.505	rs11899984	ENSG00000234936.1	AC010883.5	5.93	4.11e-09	6.32e-07	0.21	0.18	Granulocyte percentage of myeloid white cells;	chr2:43351107	chr2:43229573~43233394:+
BRCA	cis	rs1862618	0.853	rs10051747	ENSG00000271828.1	CTD-2310F14.1	5.93	4.11e-09	6.32e-07	0.26	0.18	Initial pursuit acceleration;	chr5:56787462	chr5:56927874~56929573:+
BRCA	cis	rs9311474	0.967	rs610060	ENSG00000243224.1	RP5-1157M23.2	5.93	4.11e-09	6.32e-07	0.2	0.18	Electroencephalogram traits;	chr3:52239405	chr3:52239258~52241097:+
BRCA	cis	rs984222	0.527	rs2247883	ENSG00000231365.4	RP11-418J17.1	-5.93	4.11e-09	6.32e-07	-0.21	-0.18	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119035214	chr1:119140396~119275973:+
BRCA	cis	rs8103278	0.507	rs4802275	ENSG00000267395.4	AC074212.6	-5.93	4.11e-09	6.32e-07	-0.18	-0.18	Coronary artery disease;	chr19:45757117	chr19:45767796~45772504:+
BRCA	cis	rs2179367	0.537	rs6911411	ENSG00000268592.3	RAET1E-AS1	5.93	4.12e-09	6.34e-07	0.28	0.18	Dupuytren's disease;	chr6:149366954	chr6:149863494~149919507:+
BRCA	cis	rs2832191	0.716	rs1984012	ENSG00000176054.6	RPL23P2	5.93	4.12e-09	6.34e-07	0.19	0.18	Dental caries;	chr21:29020151	chr21:28997613~28998033:-
BRCA	cis	rs7914558	1	rs4917996	ENSG00000213061.2	PFN1P11	5.93	4.13e-09	6.34e-07	0.24	0.18	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103166072	chr10:102838011~102845473:-
BRCA	cis	rs7914558	1	rs6584540	ENSG00000213061.2	PFN1P11	5.93	4.13e-09	6.34e-07	0.24	0.18	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103167877	chr10:102838011~102845473:-
BRCA	cis	rs7914558	1	rs7081075	ENSG00000213061.2	PFN1P11	5.93	4.13e-09	6.34e-07	0.24	0.18	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103169434	chr10:102838011~102845473:-
BRCA	cis	rs4218	0.636	rs4775116	ENSG00000277144.1	RP11-59H7.4	5.93	4.13e-09	6.35e-07	0.23	0.18	Social communication problems;	chr15:59135608	chr15:59115547~59116089:-
BRCA	cis	rs7927771	0.524	rs10742817	ENSG00000280615.1	Y_RNA	-5.93	4.13e-09	6.35e-07	-0.21	-0.18	Subjective well-being;	chr11:47667791	chr11:47614898~47614994:-
BRCA	cis	rs2288884	0.767	rs12460118	ENSG00000275055.1	CTC-471J1.11	-5.93	4.14e-09	6.36e-07	-0.25	-0.18	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52032550	chr19:52049007~52049754:+
BRCA	cis	rs2243480	1	rs781156	ENSG00000230295.1	RP11-458F8.2	-5.93	4.14e-09	6.36e-07	-0.24	-0.18	Diabetic kidney disease;	chr7:66014154	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs451396	ENSG00000230295.1	RP11-458F8.2	-5.93	4.14e-09	6.36e-07	-0.24	-0.18	Diabetic kidney disease;	chr7:66019087	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs1715235	ENSG00000230295.1	RP11-458F8.2	-5.93	4.14e-09	6.36e-07	-0.24	-0.18	Diabetic kidney disease;	chr7:66023407	chr7:66880708~66882981:+
BRCA	cis	rs867371	1	rs1174543	ENSG00000276710.3	CSPG4P8	5.93	4.15e-09	6.37e-07	0.19	0.18	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82155732	chr15:82459472~82477258:+
BRCA	cis	rs1440410	0.798	rs34168479	ENSG00000250326.1	RP11-284M14.1	-5.93	4.15e-09	6.37e-07	-0.2	-0.18	Ischemic stroke;	chr4:143219439	chr4:142933195~143184861:-
BRCA	cis	rs75422866	1	rs73102120	ENSG00000280054.1	RP1-197B17.7	5.93	4.15e-09	6.37e-07	0.46	0.18	Pneumonia;	chr12:47637280	chr12:47728151~47730598:-
BRCA	cis	rs75422866	0.867	rs12422974	ENSG00000280054.1	RP1-197B17.7	5.93	4.15e-09	6.37e-07	0.46	0.18	Pneumonia;	chr12:47644559	chr12:47728151~47730598:-
BRCA	cis	rs75422866	0.867	rs73102127	ENSG00000280054.1	RP1-197B17.7	5.93	4.15e-09	6.37e-07	0.46	0.18	Pneumonia;	chr12:47645341	chr12:47728151~47730598:-
BRCA	cis	rs75422866	0.867	rs73102166	ENSG00000280054.1	RP1-197B17.7	5.93	4.15e-09	6.37e-07	0.46	0.18	Pneumonia;	chr12:47653769	chr12:47728151~47730598:-
BRCA	cis	rs75422866	0.867	rs73102171	ENSG00000280054.1	RP1-197B17.7	5.93	4.15e-09	6.37e-07	0.46	0.18	Pneumonia;	chr12:47656077	chr12:47728151~47730598:-
BRCA	cis	rs75422866	0.867	rs76100981	ENSG00000280054.1	RP1-197B17.7	5.93	4.15e-09	6.37e-07	0.46	0.18	Pneumonia;	chr12:47660092	chr12:47728151~47730598:-
BRCA	cis	rs72627509	0.638	rs78933653	ENSG00000269949.1	RP11-738E22.3	5.93	4.16e-09	6.38e-07	0.32	0.18	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56988674	chr4:56960927~56961373:-
BRCA	cis	rs2058059	0.636	rs2961005	ENSG00000225648.4	SBDSP1	5.93	4.16e-09	6.38e-07	0.29	0.18	Subcutaneous adipose tissue;	chr7:72675517	chr7:72829425~72836701:+
BRCA	cis	rs7976269	0.609	rs4931142	ENSG00000275476.1	RP11-996F15.4	-5.93	4.16e-09	6.39e-07	-0.21	-0.18	Male-pattern baldness;	chr12:29057877	chr12:29277397~29277882:-
BRCA	cis	rs9840812	0.61	rs34967300	ENSG00000239213.4	NCK1-AS1	-5.93	4.16e-09	6.39e-07	-0.24	-0.18	Fibrinogen levels;	chr3:136549976	chr3:136841726~136862054:-
BRCA	cis	rs2836950	0.565	rs8134214	ENSG00000238141.2	BRWD1-AS1	-5.93	4.16e-09	6.39e-07	-0.2	-0.18	Menarche (age at onset);	chr21:39170441	chr21:39315707~39323218:+
BRCA	cis	rs7246657	1	rs12709812	ENSG00000267422.1	CTD-2554C21.1	5.93	4.17e-09	6.4e-07	0.27	0.18	Coronary artery calcification;	chr19:37303948	chr19:37779686~37792865:+
BRCA	cis	rs7246657	0.509	rs10426093	ENSG00000276846.1	CTD-3220F14.3	5.93	4.17e-09	6.4e-07	0.28	0.18	Coronary artery calcification;	chr19:37124727	chr19:37314868~37315620:-
BRCA	cis	rs1707322	0.963	rs34907901	ENSG00000281133.1	AL355480.3	-5.93	4.17e-09	6.4e-07	-0.23	-0.18	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45939542	chr1:45580892~45580996:-
BRCA	cis	rs58873874	0.579	rs962459	ENSG00000248544.2	CTB-47B11.3	5.93	4.18e-09	6.42e-07	0.31	0.18	Bipolar disorder (body mass index interaction);	chr5:157346777	chr5:157375741~157384950:-
BRCA	cis	rs2638953	0.779	rs61920241	ENSG00000247934.4	RP11-967K21.1	-5.93	4.18e-09	6.42e-07	-0.24	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28195184	chr12:28163298~28190738:-
BRCA	cis	rs1555322	0.53	rs6058224	ENSG00000269202.1	RP4-614O4.12	-5.93	4.18e-09	6.42e-07	-0.21	-0.18	Attention deficit hyperactivity disorder;	chr20:35293971	chr20:35201747~35203288:-
BRCA	cis	rs1552244	0.882	rs2030564	ENSG00000232901.1	CYCSP10	5.93	4.18e-09	6.42e-07	0.25	0.18	Alzheimer's disease;	chr3:9997360	chr3:10000647~10000940:-
BRCA	cis	rs6479891	0.818	rs59215788	ENSG00000232075.1	MRPL35P2	5.93	4.19e-09	6.43e-07	0.32	0.18	Arthritis (juvenile idiopathic);	chr10:63474074	chr10:63634317~63634827:-
BRCA	cis	rs6479891	1	rs59246603	ENSG00000232075.1	MRPL35P2	5.93	4.19e-09	6.43e-07	0.32	0.18	Arthritis (juvenile idiopathic);	chr10:63474182	chr10:63634317~63634827:-
BRCA	cis	rs2638953	0.962	rs716687	ENSG00000278733.1	RP11-425D17.1	-5.93	4.19e-09	6.43e-07	-0.25	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28261517	chr12:28185625~28186190:-
BRCA	cis	rs2243480	0.901	rs2949697	ENSG00000230295.1	RP11-458F8.2	-5.93	4.19e-09	6.43e-07	-0.24	-0.18	Diabetic kidney disease;	chr7:65999249	chr7:66880708~66882981:+
BRCA	cis	rs75422866	0.867	rs73102168	ENSG00000280054.1	RP1-197B17.7	5.93	4.19e-09	6.44e-07	0.46	0.18	Pneumonia;	chr12:47654010	chr12:47728151~47730598:-
BRCA	cis	rs6570726	0.846	rs6914304	ENSG00000270638.1	RP3-466P17.1	5.93	4.19e-09	6.44e-07	0.21	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145599881	chr6:145735570~145737218:+
BRCA	cis	rs673078	0.66	rs7961312	ENSG00000275409.1	RP11-131L12.4	-5.93	4.2e-09	6.45e-07	-0.3	-0.18	Glucose homeostasis traits;	chr12:118324431	chr12:118430147~118430699:+
BRCA	cis	rs72681920	0.881	rs60468511	ENSG00000246090.5	RP11-696N14.1	-5.93	4.2e-09	6.45e-07	-0.3	-0.18	Alcohol dependence;	chr4:99235975	chr4:99088857~99301356:+
BRCA	cis	rs72681920	0.786	rs60345995	ENSG00000246090.5	RP11-696N14.1	-5.93	4.2e-09	6.45e-07	-0.3	-0.18	Alcohol dependence;	chr4:99236614	chr4:99088857~99301356:+
BRCA	cis	rs2562456	0.917	rs2650793	ENSG00000268081.1	RP11-678G14.2	-5.93	4.2e-09	6.45e-07	-0.26	-0.18	Pain;	chr19:21493313	chr19:21554640~21569237:-
BRCA	cis	rs17253792	0.915	rs75296402	ENSG00000186615.9	KTN1-AS1	-5.93	4.21e-09	6.45e-07	-0.38	-0.18	Putamen volume;	chr14:55715773	chr14:55499278~55580110:-
BRCA	cis	rs9923856	0.519	rs9923455	ENSG00000274038.1	RP11-66H6.4	-5.93	4.21e-09	6.46e-07	-0.2	-0.18	Atopic dermatitis;Adult asthma;	chr16:11038007	chr16:11056556~11057034:+
BRCA	cis	rs2836950	0.501	rs2836980	ENSG00000255568.3	BRWD1-AS2	-5.93	4.21e-09	6.46e-07	-0.17	-0.18	Menarche (age at onset);	chr21:39315692	chr21:39313935~39314962:+
BRCA	cis	rs7927771	0.524	rs10769299	ENSG00000280615.1	Y_RNA	5.93	4.21e-09	6.46e-07	0.21	0.18	Subjective well-being;	chr11:47843608	chr11:47614898~47614994:-
BRCA	cis	rs7124681	0.584	rs7950674	ENSG00000280615.1	Y_RNA	5.93	4.21e-09	6.46e-07	0.21	0.18	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:47849465	chr11:47614898~47614994:-
BRCA	cis	rs67981189	0.896	rs4132849	ENSG00000258571.1	PTTG4P	-5.93	4.21e-09	6.47e-07	-0.2	-0.18	Schizophrenia;	chr14:70992806	chr14:71085482~71085833:-
BRCA	cis	rs67981189	0.821	rs56021283	ENSG00000258571.1	PTTG4P	-5.93	4.21e-09	6.47e-07	-0.2	-0.18	Schizophrenia;	chr14:70996042	chr14:71085482~71085833:-
BRCA	cis	rs754466	0.58	rs1054608	ENSG00000204049.1	RP11-126H7.4	5.93	4.22e-09	6.47e-07	0.21	0.18	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77783550	chr10:77866875~77869610:+
BRCA	cis	rs7208859	0.623	rs9914242	ENSG00000265443.1	CTD-2349P21.6	-5.93	4.22e-09	6.48e-07	-0.29	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30889227	chr17:30726305~30727564:-
BRCA	cis	rs2348418	0.647	rs938081	ENSG00000247934.4	RP11-967K21.1	5.93	4.22e-09	6.48e-07	0.2	0.18	Lung function (FEV1);Lung function (FVC);	chr12:28567680	chr12:28163298~28190738:-
BRCA	cis	rs10129255	0.957	rs1024349	ENSG00000280411.1	IGHV1-69-2	-5.93	4.22e-09	6.48e-07	-0.13	-0.18	Kawasaki disease;	chr14:106689997	chr14:106762092~106762588:-
BRCA	cis	rs2638953	0.962	rs61922976	ENSG00000278733.1	RP11-425D17.1	-5.93	4.23e-09	6.48e-07	-0.25	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28283837	chr12:28185625~28186190:-
BRCA	cis	rs66887589	0.616	rs6822808	ENSG00000245958.5	RP11-33B1.1	-5.93	4.23e-09	6.49e-07	-0.16	-0.18	Diastolic blood pressure;	chr4:119296210	chr4:119454791~119552025:+
BRCA	cis	rs30380	0.573	rs469783	ENSG00000272109.1	CTD-2260A17.3	-5.93	4.23e-09	6.49e-07	-0.23	-0.18	Cerebrospinal fluid biomarker levels;	chr5:96785820	chr5:96804353~96806105:+
BRCA	cis	rs673078	0.615	rs61943528	ENSG00000275409.1	RP11-131L12.4	-5.93	4.23e-09	6.49e-07	-0.29	-0.18	Glucose homeostasis traits;	chr12:118163134	chr12:118430147~118430699:+
BRCA	cis	rs755249	0.565	rs12138051	ENSG00000228060.1	RP11-69E11.8	5.93	4.23e-09	6.49e-07	0.18	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39482552	chr1:39565160~39573203:+
BRCA	cis	rs755249	0.564	rs6691194	ENSG00000228060.1	RP11-69E11.8	5.93	4.23e-09	6.49e-07	0.18	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39483069	chr1:39565160~39573203:+
BRCA	cis	rs2562456	0.917	rs2650825	ENSG00000268658.4	LINC00664	5.93	4.23e-09	6.49e-07	0.3	0.18	Pain;	chr19:21516423	chr19:21483374~21503238:+
BRCA	cis	rs227275	0.554	rs223421	ENSG00000251288.2	RP11-10L12.2	-5.93	4.23e-09	6.49e-07	-0.21	-0.18	Allergic disease (asthma, hay fever or eczema);	chr4:102805861	chr4:102751401~102752641:+
BRCA	cis	rs7927771	0.524	rs10838732	ENSG00000280615.1	Y_RNA	5.93	4.23e-09	6.49e-07	0.21	0.18	Subjective well-being;	chr11:47586388	chr11:47614898~47614994:-
BRCA	cis	rs10515750	0.588	rs56656884	ENSG00000248544.2	CTB-47B11.3	5.93	4.23e-09	6.49e-07	0.26	0.18	Lung function (FEV1/FVC);	chr5:157361963	chr5:157375741~157384950:-
BRCA	cis	rs2153535	0.518	rs6597336	ENSG00000230939.1	RP11-314C16.1	-5.93	4.23e-09	6.5e-07	-0.22	-0.18	Motion sickness;	chr6:8530663	chr6:8784178~8785445:+
BRCA	cis	rs2348418	0.715	rs11049720	ENSG00000247934.4	RP11-967K21.1	5.93	4.23e-09	6.5e-07	0.2	0.18	Lung function (FEV1);Lung function (FVC);	chr12:28567477	chr12:28163298~28190738:-
BRCA	cis	rs2348418	0.715	rs11049719	ENSG00000247934.4	RP11-967K21.1	5.93	4.24e-09	6.5e-07	0.2	0.18	Lung function (FEV1);Lung function (FVC);	chr12:28567446	chr12:28163298~28190738:-
BRCA	cis	rs250585	0.688	rs30017	ENSG00000260136.4	CTD-2270L9.4	5.93	4.24e-09	6.5e-07	0.18	0.18	Egg allergy;	chr16:23400989	chr16:23452758~23457606:+
BRCA	cis	rs2638953	0.888	rs10843189	ENSG00000278733.1	RP11-425D17.1	-5.93	4.24e-09	6.5e-07	-0.24	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28506985	chr12:28185625~28186190:-
BRCA	cis	rs4218	0.531	rs6494065	ENSG00000277144.1	RP11-59H7.4	5.93	4.24e-09	6.5e-07	0.22	0.18	Social communication problems;	chr15:59053249	chr15:59115547~59116089:-
BRCA	cis	rs2243480	0.803	rs423187	ENSG00000228409.4	CCT6P1	5.92	4.24e-09	6.5e-07	0.26	0.18	Diabetic kidney disease;	chr7:66044512	chr7:65751142~65763354:+
BRCA	cis	rs7615952	0.688	rs9754526	ENSG00000250012.1	RP11-124N2.1	-5.92	4.24e-09	6.51e-07	-0.25	-0.18	Blood pressure (smoking interaction);	chr3:125824023	chr3:126084220~126095349:+
BRCA	cis	rs2243480	1	rs34970380	ENSG00000230295.1	RP11-458F8.2	-5.92	4.24e-09	6.51e-07	-0.24	-0.18	Diabetic kidney disease;	chr7:65966506	chr7:66880708~66882981:+
BRCA	cis	rs2348418	0.715	rs12307612	ENSG00000247934.4	RP11-967K21.1	5.92	4.24e-09	6.51e-07	0.2	0.18	Lung function (FEV1);Lung function (FVC);	chr12:28566713	chr12:28163298~28190738:-
BRCA	cis	rs2348418	0.715	rs12307709	ENSG00000247934.4	RP11-967K21.1	5.92	4.24e-09	6.51e-07	0.2	0.18	Lung function (FEV1);Lung function (FVC);	chr12:28566767	chr12:28163298~28190738:-
BRCA	cis	rs4372836	0.964	rs2293553	ENSG00000226833.4	AC097724.3	-5.92	4.25e-09	6.51e-07	-0.23	-0.18	Body mass index;	chr2:28709418	chr2:28708953~28736205:-
BRCA	cis	rs904251	0.802	rs2646933	ENSG00000204110.6	RP1-153P14.8	-5.92	4.25e-09	6.51e-07	-0.21	-0.18	Cognitive performance;	chr6:37434294	chr6:37507348~37535616:+
BRCA	cis	rs9880211	0.613	rs28535121	ENSG00000239213.4	NCK1-AS1	5.92	4.25e-09	6.52e-07	0.23	0.18	Height;Body mass index;	chr3:136173956	chr3:136841726~136862054:-
BRCA	cis	rs2303319	1	rs3769959	ENSG00000227403.1	AC009299.3	-5.92	4.25e-09	6.52e-07	-0.46	-0.18	Cognitive function;	chr2:161392695	chr2:161244739~161249050:+
BRCA	cis	rs9545047	0.604	rs7332367	ENSG00000227354.5	RBM26-AS1	-5.92	4.25e-09	6.52e-07	-0.19	-0.18	Schizophrenia;	chr13:79339816	chr13:79406309~79424328:+
BRCA	cis	rs442309	0.687	rs10822057	ENSG00000238280.1	RP11-436D10.3	-5.92	4.26e-09	6.53e-07	-0.25	-0.18	Vogt-Koyanagi-Harada syndrome;	chr10:62760391	chr10:62793562~62805887:-
BRCA	cis	rs1858037	0.867	rs67453645	ENSG00000204929.10	AC074391.1	5.92	4.26e-09	6.53e-07	0.24	0.18	Rheumatoid arthritis;	chr2:65358908	chr2:65436711~66084639:+
BRCA	cis	rs6679677	0.543	rs1230680	ENSG00000232450.1	RP4-730K3.3	-5.92	4.26e-09	6.53e-07	-0.32	-0.18	Rheumatoid arthritis;Monokine induced by gamma interferon levels;Type 1 diabetes;Hypothyroidism;Systemic lupus erythematosus;Pediatric autoimmune diseases;Crohn's disease;Antineutrophil cytoplasmic antibody-associated vasculitis;	chr1:113754148	chr1:113698884~113699631:-
BRCA	cis	rs9880211	0.613	rs9834966	ENSG00000239213.4	NCK1-AS1	5.92	4.26e-09	6.54e-07	0.23	0.18	Height;Body mass index;	chr3:136089778	chr3:136841726~136862054:-
BRCA	cis	rs7927771	0.524	rs7123952	ENSG00000280615.1	Y_RNA	5.92	4.26e-09	6.54e-07	0.21	0.18	Subjective well-being;	chr11:47830505	chr11:47614898~47614994:-
BRCA	cis	rs7200543	1	rs2740	ENSG00000260872.1	RP11-680G24.5	-5.92	4.27e-09	6.54e-07	-0.19	-0.18	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15038251	chr16:15018106~15020488:-
BRCA	cis	rs710913	0.717	rs1180349	ENSG00000182109.6	RP11-69E11.4	-5.92	4.28e-09	6.55e-07	-0.2	-0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39540380	chr1:39522280~39546187:-
BRCA	cis	rs42490	0.625	rs425312	ENSG00000251136.7	RP11-37B2.1	-5.92	4.28e-09	6.55e-07	-0.17	-0.18	Leprosy;	chr8:89834127	chr8:89609409~89757727:-
BRCA	cis	rs4604234	0.614	rs73479950	ENSG00000272129.1	RP11-250B2.6	-5.92	4.28e-09	6.56e-07	-0.46	-0.18	Cancer;	chr6:80167590	chr6:80355424~80356859:+
BRCA	cis	rs4604234	0.614	rs73479953	ENSG00000272129.1	RP11-250B2.6	-5.92	4.28e-09	6.56e-07	-0.46	-0.18	Cancer;	chr6:80167654	chr6:80355424~80356859:+
BRCA	cis	rs1440410	0.835	rs10029243	ENSG00000250326.1	RP11-284M14.1	-5.92	4.28e-09	6.56e-07	-0.2	-0.18	Ischemic stroke;	chr4:143139591	chr4:142933195~143184861:-
BRCA	cis	rs73193808	0.851	rs2018158	ENSG00000215533.7	LINC00189	-5.92	4.28e-09	6.56e-07	-0.26	-0.18	Coronary artery disease;	chr21:29216482	chr21:29193480~29288205:+
BRCA	cis	rs2638953	0.853	rs11049693	ENSG00000278733.1	RP11-425D17.1	-5.92	4.28e-09	6.56e-07	-0.22	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28525011	chr12:28185625~28186190:-
BRCA	cis	rs10740039	0.516	rs1975443	ENSG00000254271.1	RP11-131N11.4	5.92	4.28e-09	6.56e-07	0.24	0.18	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60561584	chr10:60734342~60741828:+
BRCA	cis	rs6840360	0.904	rs73862064	ENSG00000270265.1	RP11-731D1.4	-5.92	4.29e-09	6.57e-07	-0.2	-0.18	Intelligence (multi-trait analysis);	chr4:151581948	chr4:151333775~151353224:-
BRCA	cis	rs2638953	0.893	rs10843192	ENSG00000278733.1	RP11-425D17.1	-5.92	4.29e-09	6.57e-07	-0.22	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28508756	chr12:28185625~28186190:-
BRCA	cis	rs8114671	0.804	rs6088666	ENSG00000269202.1	RP4-614O4.12	-5.92	4.29e-09	6.58e-07	-0.19	-0.18	Height;	chr20:34976767	chr20:35201747~35203288:-
BRCA	cis	rs240993	0.516	rs240981	ENSG00000230177.1	RP5-1112D6.4	-5.92	4.29e-09	6.58e-07	-0.24	-0.18	Inflammatory skin disease;Psoriasis;	chr6:111289990	chr6:111277932~111278742:+
BRCA	cis	rs160451	0.934	rs160422	ENSG00000251136.7	RP11-37B2.1	5.92	4.3e-09	6.58e-07	0.17	0.18	Leprosy;	chr8:89657610	chr8:89609409~89757727:-
BRCA	cis	rs9308731	0.556	rs10166773	ENSG00000227992.1	AC108463.2	-5.92	4.3e-09	6.58e-07	-0.21	-0.18	Chronic lymphocytic leukemia;	chr2:111179358	chr2:111203964~111206215:-
BRCA	cis	rs9308731	0.548	rs7581735	ENSG00000227992.1	AC108463.2	-5.92	4.3e-09	6.58e-07	-0.21	-0.18	Chronic lymphocytic leukemia;	chr2:111180137	chr2:111203964~111206215:-
BRCA	cis	rs2836950	0.501	rs11702505	ENSG00000238141.2	BRWD1-AS1	-5.92	4.3e-09	6.59e-07	-0.21	-0.18	Menarche (age at onset);	chr21:39328688	chr21:39315707~39323218:+
BRCA	cis	rs2836950	0.501	rs2836985	ENSG00000238141.2	BRWD1-AS1	-5.92	4.3e-09	6.59e-07	-0.21	-0.18	Menarche (age at onset);	chr21:39329243	chr21:39315707~39323218:+
BRCA	cis	rs5015933	0.788	rs10114684	ENSG00000232630.1	PRPS1P2	-5.92	4.3e-09	6.59e-07	-0.17	-0.18	Body mass index;	chr9:125340586	chr9:125150653~125151589:+
BRCA	cis	rs4588572	0.644	rs10942856	ENSG00000245556.2	SCAMP1-AS1	5.92	4.3e-09	6.59e-07	0.21	0.18	Triglycerides;	chr5:78450376	chr5:78342365~78360507:-
BRCA	cis	rs12655019	0.92	rs1466010	ENSG00000271828.1	CTD-2310F14.1	5.92	4.31e-09	6.6e-07	0.34	0.18	Breast cancer (early onset);	chr5:56917329	chr5:56927874~56929573:+
BRCA	cis	rs2277027	0.541	rs56168343	ENSG00000251405.2	CTB-109A12.1	5.92	4.31e-09	6.6e-07	0.33	0.18	Pulmonary function;Pulmonary function (smoking interaction);	chr5:157501000	chr5:157362615~157460078:-
BRCA	cis	rs11098499	0.82	rs6829903	ENSG00000249244.1	RP11-548H18.2	5.92	4.31e-09	6.6e-07	0.22	0.18	Corneal astigmatism;	chr4:119585729	chr4:119391831~119395335:-
BRCA	cis	rs4713118	0.523	rs2179096	ENSG00000220721.1	OR1F12	5.92	4.31e-09	6.6e-07	0.21	0.18	Parkinson's disease;	chr6:27698141	chr6:28073316~28074233:+
BRCA	cis	rs559928	0.606	rs55970968	ENSG00000236935.1	AP003774.1	5.92	4.31e-09	6.6e-07	0.25	0.18	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64193961	chr11:64325050~64329504:-
BRCA	cis	rs853679	0.546	rs200996	ENSG00000220721.1	OR1F12	5.92	4.31e-09	6.6e-07	0.33	0.18	Depression;	chr6:27844050	chr6:28073316~28074233:+
BRCA	cis	rs4908768	0.501	rs12061328	ENSG00000270282.1	RP5-1115A15.2	5.92	4.31e-09	6.61e-07	0.19	0.18	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8471903	chr1:8512653~8513021:+
BRCA	cis	rs801193	0.569	rs13226966	ENSG00000224316.1	RP11-479O9.2	5.92	4.31e-09	6.61e-07	0.18	0.18	Aortic root size;	chr7:66768636	chr7:65773620~65802067:+
BRCA	cis	rs42648	0.564	rs12154563	ENSG00000225498.1	AC002064.5	5.92	4.31e-09	6.61e-07	0.17	0.18	Homocysteine levels;	chr7:90198912	chr7:90312496~90322592:+
BRCA	cis	rs42648	0.564	rs259134	ENSG00000225498.1	AC002064.5	5.92	4.31e-09	6.61e-07	0.17	0.18	Homocysteine levels;	chr7:90166538	chr7:90312496~90322592:+
BRCA	cis	rs1876905	0.597	rs1150076	ENSG00000272356.1	RP5-1112D6.8	-5.92	4.31e-09	6.61e-07	-0.24	-0.18	Mean corpuscular hemoglobin;	chr6:111227227	chr6:111309203~111313517:+
BRCA	cis	rs710913	0.717	rs1180352	ENSG00000182109.6	RP11-69E11.4	-5.92	4.32e-09	6.61e-07	-0.2	-0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39542157	chr1:39522280~39546187:-
BRCA	cis	rs9880211	0.563	rs6792630	ENSG00000239213.4	NCK1-AS1	5.92	4.32e-09	6.61e-07	0.23	0.18	Height;Body mass index;	chr3:136106059	chr3:136841726~136862054:-
BRCA	cis	rs6688613	1	rs6699520	ENSG00000225171.2	DUTP6	-5.92	4.32e-09	6.61e-07	-0.21	-0.18	Refractive astigmatism;	chr1:166986168	chr1:166868748~166869209:+
BRCA	cis	rs6688613	1	rs10918605	ENSG00000225171.2	DUTP6	-5.92	4.32e-09	6.61e-07	-0.21	-0.18	Refractive astigmatism;	chr1:166986401	chr1:166868748~166869209:+
BRCA	cis	rs6688613	1	rs7554962	ENSG00000225171.2	DUTP6	-5.92	4.32e-09	6.61e-07	-0.21	-0.18	Refractive astigmatism;	chr1:166987060	chr1:166868748~166869209:+
BRCA	cis	rs6688613	1	rs6427049	ENSG00000225171.2	DUTP6	-5.92	4.32e-09	6.61e-07	-0.21	-0.18	Refractive astigmatism;	chr1:166987356	chr1:166868748~166869209:+
BRCA	cis	rs6688613	1	rs10918606	ENSG00000225171.2	DUTP6	-5.92	4.32e-09	6.61e-07	-0.21	-0.18	Refractive astigmatism;	chr1:166988012	chr1:166868748~166869209:+
BRCA	cis	rs67981189	0.896	rs58133478	ENSG00000258571.1	PTTG4P	-5.92	4.32e-09	6.62e-07	-0.2	-0.18	Schizophrenia;	chr14:71058370	chr14:71085482~71085833:-
BRCA	cis	rs5015933	0.778	rs10819045	ENSG00000232630.1	PRPS1P2	-5.92	4.32e-09	6.62e-07	-0.17	-0.18	Body mass index;	chr9:125321886	chr9:125150653~125151589:+
BRCA	cis	rs4660456	0.596	rs1534956	ENSG00000237899.1	RP4-739H11.3	5.92	4.32e-09	6.62e-07	0.23	0.18	Platelet count;	chr1:40720771	chr1:40669089~40687588:-
BRCA	cis	rs9341808	0.754	rs3793000	ENSG00000272129.1	RP11-250B2.6	5.92	4.33e-09	6.63e-07	0.22	0.18	Sitting height ratio;	chr6:80285420	chr6:80355424~80356859:+
BRCA	cis	rs9308731	0.591	rs13398360	ENSG00000227992.1	AC108463.2	-5.92	4.33e-09	6.64e-07	-0.21	-0.18	Chronic lymphocytic leukemia;	chr2:111180363	chr2:111203964~111206215:-
BRCA	cis	rs9659323	0.7	rs2885226	ENSG00000231365.4	RP11-418J17.1	-5.92	4.34e-09	6.64e-07	-0.21	-0.18	Body mass index;	chr1:119081540	chr1:119140396~119275973:+
BRCA	cis	rs77972916	0.611	rs61552842	ENSG00000234936.1	AC010883.5	5.92	4.34e-09	6.65e-07	0.21	0.18	Granulocyte percentage of myeloid white cells;	chr2:43356897	chr2:43229573~43233394:+
BRCA	cis	rs2638953	0.924	rs7955094	ENSG00000278733.1	RP11-425D17.1	-5.92	4.34e-09	6.65e-07	-0.23	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28157097	chr12:28185625~28186190:-
BRCA	cis	rs11098499	0.863	rs12498539	ENSG00000249244.1	RP11-548H18.2	5.92	4.34e-09	6.65e-07	0.22	0.18	Corneal astigmatism;	chr4:119547215	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.863	rs3822194	ENSG00000249244.1	RP11-548H18.2	5.92	4.34e-09	6.65e-07	0.22	0.18	Corneal astigmatism;	chr4:119550493	chr4:119391831~119395335:-
BRCA	cis	rs7221109	0.633	rs7209735	ENSG00000278834.1	RP11-458J1.1	5.92	4.35e-09	6.66e-07	0.2	0.18	Type 1 diabetes;	chr17:40662346	chr17:40648300~40649718:+
BRCA	cis	rs867371	0.892	rs4344697	ENSG00000276710.3	CSPG4P8	-5.92	4.35e-09	6.67e-07	-0.2	-0.18	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82252873	chr15:82459472~82477258:+
BRCA	cis	rs673078	0.571	rs7954330	ENSG00000275409.1	RP11-131L12.4	-5.92	4.36e-09	6.68e-07	-0.27	-0.18	Glucose homeostasis traits;	chr12:118275284	chr12:118430147~118430699:+
BRCA	cis	rs13118159	0.55	rs2878607	ENSG00000254094.1	AC078852.1	-5.92	4.36e-09	6.68e-07	-0.22	-0.18	Longevity;	chr4:1359522	chr4:1356581~1358075:+
BRCA	cis	rs7674212	0.57	rs2711899	ENSG00000248740.4	RP11-328K4.1	5.92	4.36e-09	6.68e-07	0.21	0.18	Type 2 diabetes;	chr4:103141257	chr4:103256159~103453658:+
BRCA	cis	rs2276314	0.512	rs7234973	ENSG00000278986.1	RP11-723J4.3	-5.92	4.36e-09	6.68e-07	-0.22	-0.18	Endometriosis;Drug-induced torsades de pointes;	chr18:35870373	chr18:35972151~35973916:+
BRCA	cis	rs7746199	0.736	rs10484399	ENSG00000220721.1	OR1F12	5.92	4.36e-09	6.68e-07	0.4	0.18	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27566749	chr6:28073316~28074233:+
BRCA	cis	rs6479891	1	rs16918567	ENSG00000232075.1	MRPL35P2	5.92	4.37e-09	6.68e-07	0.33	0.18	Arthritis (juvenile idiopathic);	chr10:63534910	chr10:63634317~63634827:-
BRCA	cis	rs7688540	0.771	rs11722197	ENSG00000211553.1	AC253576.2	-5.92	4.37e-09	6.7e-07	-0.28	-0.18	Facial morphology (factor 6, height of vermillion lower lip);	chr4:287918	chr4:136461~136568:+
BRCA	cis	rs7688540	0.771	rs11723261	ENSG00000211553.1	AC253576.2	-5.92	4.37e-09	6.7e-07	-0.28	-0.18	Facial morphology (factor 6, height of vermillion lower lip);	chr4:288710	chr4:136461~136568:+
BRCA	cis	rs875971	0.862	rs1860469	ENSG00000224316.1	RP11-479O9.2	-5.92	4.38e-09	6.7e-07	-0.19	-0.18	Aortic root size;	chr7:66641888	chr7:65773620~65802067:+
BRCA	cis	rs7809950	0.678	rs62482507	ENSG00000238832.1	snoU109	-5.92	4.38e-09	6.7e-07	-0.27	-0.18	Coronary artery disease;	chr7:107384043	chr7:107603363~107603507:+
BRCA	cis	rs7819412	0.595	rs2409712	ENSG00000255046.1	RP11-297N6.4	5.92	4.38e-09	6.7e-07	0.21	0.18	Triglycerides;	chr8:11129327	chr8:11797928~11802568:-
BRCA	cis	rs12893668	0.572	rs11846404	ENSG00000269940.1	RP11-73M18.7	5.92	4.38e-09	6.71e-07	0.2	0.18	Reticulocyte count;	chr14:103689771	chr14:103694560~103695170:+
BRCA	cis	rs910316	1	rs175449	ENSG00000279594.1	RP11-950C14.10	-5.92	4.38e-09	6.71e-07	-0.2	-0.18	Height;	chr14:75124143	chr14:75011269~75012851:-
BRCA	cis	rs910316	0.935	rs175448	ENSG00000279594.1	RP11-950C14.10	-5.92	4.38e-09	6.71e-07	-0.2	-0.18	Height;	chr14:75124368	chr14:75011269~75012851:-
BRCA	cis	rs651907	0.557	rs34947019	ENSG00000244119.1	PDCL3P4	5.92	4.38e-09	6.71e-07	0.15	0.18	Colorectal cancer;	chr3:101813391	chr3:101712472~101713191:+
BRCA	cis	rs1555322	0.53	rs6060341	ENSG00000269202.1	RP4-614O4.12	5.92	4.38e-09	6.71e-07	0.21	0.18	Attention deficit hyperactivity disorder;	chr20:35275830	chr20:35201747~35203288:-
BRCA	cis	rs41369048	0.858	rs2807866	ENSG00000238078.1	LINC01352	-5.92	4.39e-09	6.72e-07	-0.24	-0.18	Eosinophil counts;Sum eosinophil basophil counts;	chr1:220907587	chr1:220829255~220832429:+
BRCA	cis	rs12817211	0.524	rs10876000	ENSG00000272368.2	RP4-605O3.4	-5.92	4.39e-09	6.72e-07	-0.18	-0.18	Colorectal or endometrial cancer;	chr12:50128431	chr12:50112197~50165618:+
BRCA	cis	rs227275	0.554	rs223422	ENSG00000251288.2	RP11-10L12.2	-5.92	4.39e-09	6.72e-07	-0.21	-0.18	Allergic disease (asthma, hay fever or eczema);	chr4:102805616	chr4:102751401~102752641:+
BRCA	cis	rs962856	0.964	rs600388	ENSG00000236780.4	AC078941.1	5.92	4.4e-09	6.73e-07	0.23	0.18	Pancreatic cancer;	chr2:67429677	chr2:67123357~67215319:-
BRCA	cis	rs113835537	0.735	rs519380	ENSG00000255517.5	CTD-3074O7.5	-5.92	4.4e-09	6.73e-07	-0.26	-0.18	Airway imaging phenotypes;	chr11:66641938	chr11:66473490~66480233:-
BRCA	cis	rs7131987	0.565	rs1991113	ENSG00000257176.2	RP11-996F15.2	-5.92	4.4e-09	6.73e-07	-0.21	-0.18	QT interval;	chr12:29239070	chr12:29280418~29317848:-
BRCA	cis	rs2832191	0.692	rs2776240	ENSG00000176054.6	RPL23P2	5.92	4.4e-09	6.73e-07	0.19	0.18	Dental caries;	chr21:28938317	chr21:28997613~28998033:-
BRCA	cis	rs10510102	0.516	rs12242799	ENSG00000276742.1	RP11-500G22.4	5.92	4.41e-09	6.74e-07	0.33	0.18	Breast cancer;	chr10:121980067	chr10:121956782~121957098:+
BRCA	cis	rs9309711	0.736	rs28619526	ENSG00000225234.1	TRAPPC12-AS1	-5.92	4.41e-09	6.74e-07	-0.21	-0.18	Neurofibrillary tangles;	chr2:3493033	chr2:3481242~3482409:-
BRCA	cis	rs1707322	0.717	rs3014237	ENSG00000281133.1	AL355480.3	5.92	4.41e-09	6.75e-07	0.23	0.18	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45624580	chr1:45580892~45580996:-
BRCA	cis	rs1499614	1	rs2707832	ENSG00000228409.4	CCT6P1	5.92	4.41e-09	6.75e-07	0.25	0.18	Gout;	chr7:66671562	chr7:65751142~65763354:+
BRCA	cis	rs7124681	0.565	rs2203712	ENSG00000280615.1	Y_RNA	5.92	4.42e-09	6.76e-07	0.21	0.18	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:47513412	chr11:47614898~47614994:-
BRCA	cis	rs2243480	0.901	rs73148097	ENSG00000230295.1	RP11-458F8.2	-5.92	4.42e-09	6.77e-07	-0.24	-0.18	Diabetic kidney disease;	chr7:65966800	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs906134	ENSG00000230295.1	RP11-458F8.2	-5.92	4.42e-09	6.77e-07	-0.24	-0.18	Diabetic kidney disease;	chr7:65979301	chr7:66880708~66882981:+
BRCA	cis	rs10129255	1	rs10134517	ENSG00000211974.3	IGHV2-70	5.92	4.43e-09	6.77e-07	0.19	0.18	Kawasaki disease;	chr14:106718498	chr14:106723574~106724093:-
BRCA	cis	rs10771431	0.817	rs17202253	ENSG00000111788.10	RP11-22B23.1	5.92	4.43e-09	6.78e-07	0.16	0.18	Breast size;	chr12:9209254	chr12:9277235~9313241:+
BRCA	cis	rs7911264	0.905	rs7918084	ENSG00000236493.2	EIF2S2P3	5.92	4.43e-09	6.78e-07	0.23	0.18	Inflammatory bowel disease;	chr10:92669710	chr10:92668745~92669743:-
BRCA	cis	rs10129255	0.5	rs7161740	ENSG00000274576.2	IGHV2-70	-5.92	4.44e-09	6.79e-07	-0.15	-0.18	Kawasaki disease;	chr14:106776119	chr14:106770577~106771020:-
BRCA	cis	rs673078	0.66	rs7974718	ENSG00000275409.1	RP11-131L12.4	-5.92	4.44e-09	6.79e-07	-0.24	-0.18	Glucose homeostasis traits;	chr12:118243258	chr12:118430147~118430699:+
BRCA	cis	rs7914558	1	rs7896547	ENSG00000213061.2	PFN1P11	5.92	4.44e-09	6.8e-07	0.24	0.18	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103107201	chr10:102838011~102845473:-
BRCA	cis	rs801193	0.569	rs13242290	ENSG00000224316.1	RP11-479O9.2	-5.92	4.45e-09	6.8e-07	-0.18	-0.18	Aortic root size;	chr7:66656898	chr7:65773620~65802067:+
BRCA	cis	rs1020064	0.609	rs2576748	ENSG00000235319.1	AC012360.4	5.92	4.45e-09	6.81e-07	0.24	0.18	AIDS;	chr2:105294801	chr2:105324210~105330529:+
BRCA	cis	rs673078	0.607	rs16948230	ENSG00000275409.1	RP11-131L12.4	-5.92	4.45e-09	6.81e-07	-0.27	-0.18	Glucose homeostasis traits;	chr12:118277086	chr12:118430147~118430699:+
BRCA	cis	rs2832191	0.716	rs2297252	ENSG00000176054.6	RPL23P2	5.92	4.46e-09	6.82e-07	0.19	0.18	Dental caries;	chr21:29004783	chr21:28997613~28998033:-
BRCA	cis	rs2243480	1	rs11538349	ENSG00000164669.11	INTS4P1	5.92	4.46e-09	6.82e-07	0.34	0.18	Diabetic kidney disease;	chr7:65956884	chr7:65141225~65234216:+
BRCA	cis	rs4664293	0.769	rs2729726	ENSG00000226266.5	AC009961.3	-5.92	4.47e-09	6.83e-07	-0.23	-0.18	Monocyte percentage of white cells;	chr2:159811597	chr2:159670708~159712435:-
BRCA	cis	rs4664293	0.738	rs1549580	ENSG00000226266.5	AC009961.3	-5.92	4.47e-09	6.83e-07	-0.23	-0.18	Monocyte percentage of white cells;	chr2:159812177	chr2:159670708~159712435:-
BRCA	cis	rs56104184	0.775	rs56317021	ENSG00000235191.1	NUCB1-AS1	5.92	4.47e-09	6.84e-07	0.33	0.18	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr19:48892703	chr19:48910930~48918891:-
BRCA	cis	rs12893668	0.514	rs3212090	ENSG00000269910.1	RP11-73M18.10	5.92	4.47e-09	6.84e-07	0.19	0.18	Reticulocyte count;	chr14:103702526	chr14:103694516~103695050:-
BRCA	cis	rs2348418	0.864	rs2137073	ENSG00000247934.4	RP11-967K21.1	-5.92	4.47e-09	6.84e-07	-0.2	-0.18	Lung function (FEV1);Lung function (FVC);	chr12:28564151	chr12:28163298~28190738:-
BRCA	cis	rs2832191	0.692	rs2254872	ENSG00000176054.6	RPL23P2	5.92	4.48e-09	6.85e-07	0.19	0.18	Dental caries;	chr21:29042403	chr21:28997613~28998033:-
BRCA	cis	rs6479891	0.908	rs61853639	ENSG00000232075.1	MRPL35P2	5.92	4.48e-09	6.85e-07	0.33	0.18	Arthritis (juvenile idiopathic);	chr10:63545353	chr10:63634317~63634827:-
BRCA	cis	rs2243480	1	rs34815098	ENSG00000228409.4	CCT6P1	5.92	4.48e-09	6.85e-07	0.25	0.18	Diabetic kidney disease;	chr7:65827267	chr7:65751142~65763354:+
BRCA	cis	rs2243480	1	rs35735127	ENSG00000228409.4	CCT6P1	5.92	4.48e-09	6.85e-07	0.25	0.18	Diabetic kidney disease;	chr7:65835436	chr7:65751142~65763354:+
BRCA	cis	rs2243480	0.901	rs35256305	ENSG00000228409.4	CCT6P1	5.92	4.48e-09	6.85e-07	0.25	0.18	Diabetic kidney disease;	chr7:65841418	chr7:65751142~65763354:+
BRCA	cis	rs2243480	0.803	rs34004500	ENSG00000228409.4	CCT6P1	5.92	4.48e-09	6.85e-07	0.25	0.18	Diabetic kidney disease;	chr7:65847191	chr7:65751142~65763354:+
BRCA	cis	rs2243480	1	rs35825738	ENSG00000228409.4	CCT6P1	5.92	4.48e-09	6.85e-07	0.25	0.18	Diabetic kidney disease;	chr7:65853040	chr7:65751142~65763354:+
BRCA	cis	rs6688613	0.694	rs2075946	ENSG00000225171.2	DUTP6	-5.92	4.48e-09	6.85e-07	-0.25	-0.18	Refractive astigmatism;	chr1:166849329	chr1:166868748~166869209:+
BRCA	cis	rs6479891	1	rs4469774	ENSG00000232075.1	MRPL35P2	5.92	4.48e-09	6.85e-07	0.32	0.18	Arthritis (juvenile idiopathic);	chr10:63550017	chr10:63634317~63634827:-
BRCA	cis	rs17597773	0.674	rs12073837	ENSG00000272823.1	RP11-295M18.6	-5.92	4.49e-09	6.86e-07	-0.21	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220836863	chr1:220828676~220829211:-
BRCA	cis	rs2115630	0.967	rs11073702	ENSG00000229212.6	RP11-561C5.4	5.92	4.49e-09	6.86e-07	0.2	0.18	P wave terminal force;	chr15:84766840	chr15:85205440~85234795:-
BRCA	cis	rs17301013	0.507	rs72713512	ENSG00000227373.4	RP11-160H22.5	5.92	4.49e-09	6.86e-07	0.24	0.18	Systemic lupus erythematosus;	chr1:174283505	chr1:174115300~174160004:-
BRCA	cis	rs12468226	0.938	rs3843338	ENSG00000226261.1	AC064836.3	-5.92	4.49e-09	6.86e-07	-0.3	-0.18	Urate levels;	chr2:202246102	chr2:202336024~202336727:-
BRCA	cis	rs6479891	1	rs12411988	ENSG00000232075.1	MRPL35P2	-5.92	4.49e-09	6.86e-07	-0.33	-0.18	Arthritis (juvenile idiopathic);	chr10:63555637	chr10:63634317~63634827:-
BRCA	cis	rs56114371	0.53	rs9357045	ENSG00000220721.1	OR1F12	5.92	4.49e-09	6.86e-07	0.25	0.18	Breast cancer;	chr6:27721148	chr6:28073316~28074233:+
BRCA	cis	rs7914558	1	rs10883837	ENSG00000213061.2	PFN1P11	5.92	4.49e-09	6.87e-07	0.24	0.18	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103136729	chr10:102838011~102845473:-
BRCA	cis	rs7914558	0.966	rs746293	ENSG00000213061.2	PFN1P11	5.92	4.49e-09	6.87e-07	0.24	0.18	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103137497	chr10:102838011~102845473:-
BRCA	cis	rs7520050	0.966	rs10890354	ENSG00000280836.1	AL355480.1	5.92	4.49e-09	6.87e-07	0.21	0.18	Reticulocyte count;Red blood cell count;	chr1:45839675	chr1:45581219~45581321:-
BRCA	cis	rs4908760	0.613	rs12028160	ENSG00000270282.1	RP5-1115A15.2	-5.91	4.5e-09	6.87e-07	-0.19	-0.18	Vitiligo;	chr1:8752155	chr1:8512653~8513021:+
BRCA	cis	rs16978956	0.779	rs2424169	ENSG00000236474.1	GCNT1P1	-5.91	4.5e-09	6.88e-07	-0.22	-0.18	Body mass index;	chr20:18346801	chr20:18420160~18421454:-
BRCA	cis	rs11722779	0.873	rs223384	ENSG00000251288.2	RP11-10L12.2	-5.91	4.51e-09	6.89e-07	-0.21	-0.18	Schizophrenia;	chr4:102829976	chr4:102751401~102752641:+
BRCA	cis	rs227275	0.554	rs223383	ENSG00000251288.2	RP11-10L12.2	-5.91	4.51e-09	6.89e-07	-0.21	-0.18	Allergic disease (asthma, hay fever or eczema);	chr4:102830094	chr4:102751401~102752641:+
BRCA	cis	rs7927771	0.524	rs7933184	ENSG00000280615.1	Y_RNA	5.91	4.51e-09	6.89e-07	0.21	0.18	Subjective well-being;	chr11:47660850	chr11:47614898~47614994:-
BRCA	cis	rs2919009	0.882	rs3011384	ENSG00000271670.1	RP11-95I16.4	5.91	4.51e-09	6.89e-07	0.23	0.18	Obesity-related traits;	chr10:120833599	chr10:120879256~120880667:-
BRCA	cis	rs13126694	0.71	rs9995402	ENSG00000251429.1	RP11-597D13.7	5.91	4.51e-09	6.89e-07	0.18	0.18	Blood osmolality (transformed sodium);	chr4:158105262	chr4:158270378~158278676:+
BRCA	cis	rs13126694	0.71	rs34237515	ENSG00000251429.1	RP11-597D13.7	5.91	4.51e-09	6.89e-07	0.18	0.18	Blood osmolality (transformed sodium);	chr4:158105607	chr4:158270378~158278676:+
BRCA	cis	rs73193808	0.901	rs2832262	ENSG00000215533.7	LINC00189	-5.91	4.51e-09	6.89e-07	-0.27	-0.18	Coronary artery disease;	chr21:29214771	chr21:29193480~29288205:+
BRCA	cis	rs8098244	0.571	rs72876000	ENSG00000264745.1	TTC39C-AS1	-5.91	4.51e-09	6.89e-07	-0.28	-0.18	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23989446	chr18:23994213~24015339:-
BRCA	cis	rs875971	0.862	rs4718383	ENSG00000224316.1	RP11-479O9.2	-5.91	4.51e-09	6.89e-07	-0.19	-0.18	Aortic root size;	chr7:66643422	chr7:65773620~65802067:+
BRCA	cis	rs73193808	0.851	rs66903141	ENSG00000215533.7	LINC00189	-5.91	4.51e-09	6.89e-07	-0.27	-0.18	Coronary artery disease;	chr21:29229214	chr21:29193480~29288205:+
BRCA	cis	rs2243480	1	rs313831	ENSG00000232546.1	RP11-458F8.1	-5.91	4.51e-09	6.89e-07	-0.25	-0.18	Diabetic kidney disease;	chr7:66086239	chr7:66848496~66858136:+
BRCA	cis	rs8048589	0.948	rs71385189	ENSG00000175604.2	RP11-276H1.3	-5.91	4.51e-09	6.89e-07	-0.27	-0.18	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);	chr16:12088322	chr16:12086746~12090302:-
BRCA	cis	rs4950322	0.57	rs72692979	ENSG00000244371.2	PFN1P8	-5.91	4.52e-09	6.91e-07	-0.25	-0.18	Protein quantitative trait loci;	chr1:147336094	chr1:146957117~146957659:-
BRCA	cis	rs2404602	0.692	rs1867197	ENSG00000259422.1	RP11-593F23.1	-5.91	4.52e-09	6.91e-07	-0.22	-0.18	Blood metabolite levels;	chr15:76617690	chr15:76174891~76181486:-
BRCA	cis	rs10129255	0.957	rs10150241	ENSG00000224373.3	IGHV4-59	-5.91	4.52e-09	6.91e-07	-0.11	-0.18	Kawasaki disease;	chr14:106775945	chr14:106627249~106627825:-
BRCA	cis	rs2836950	0.545	rs11700813	ENSG00000238141.2	BRWD1-AS1	-5.91	4.53e-09	6.92e-07	-0.21	-0.18	Menarche (age at onset);	chr21:39145543	chr21:39315707~39323218:+
BRCA	cis	rs7646881	0.812	rs7624161	ENSG00000240207.5	RP11-379F4.4	-5.91	4.53e-09	6.93e-07	-0.28	-0.18	Tetralogy of Fallot;	chr3:158742125	chr3:158732263~158784070:+
BRCA	cis	rs7646881	0.812	rs113166116	ENSG00000240207.5	RP11-379F4.4	-5.91	4.53e-09	6.93e-07	-0.28	-0.18	Tetralogy of Fallot;	chr3:158742467	chr3:158732263~158784070:+
BRCA	cis	rs984222	0.527	rs2794315	ENSG00000231365.4	RP11-418J17.1	-5.91	4.54e-09	6.94e-07	-0.21	-0.18	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119035043	chr1:119140396~119275973:+
BRCA	cis	rs9287719	0.649	rs7589694	ENSG00000243819.4	RN7SL832P	5.91	4.55e-09	6.95e-07	0.18	0.18	Prostate cancer;	chr2:10560748	chr2:10690344~10692099:+
BRCA	cis	rs9992667	0.91	rs4535339	ENSG00000231160.8	KLF3-AS1	5.91	4.55e-09	6.96e-07	0.23	0.18	Eosinophil percentage of granulocytes;	chr4:38687607	chr4:38612701~38664883:-
BRCA	cis	rs7520050	0.931	rs6697557	ENSG00000280836.1	AL355480.1	5.91	4.56e-09	6.96e-07	0.21	0.18	Reticulocyte count;Red blood cell count;	chr1:45842137	chr1:45581219~45581321:-
BRCA	cis	rs2235642	0.821	rs2281234	ENSG00000280231.1	LA16c-380F5.3	-5.91	4.56e-09	6.96e-07	-0.23	-0.18	Coronary artery disease;	chr16:1552937	chr16:1553655~1554130:-
BRCA	cis	rs160451	0.933	rs218889	ENSG00000251136.7	RP11-37B2.1	-5.91	4.56e-09	6.96e-07	-0.17	-0.18	Leprosy;	chr8:89679935	chr8:89609409~89757727:-
BRCA	cis	rs10740039	0.516	rs2068044	ENSG00000254271.1	RP11-131N11.4	5.91	4.56e-09	6.96e-07	0.24	0.18	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60560679	chr10:60734342~60741828:+
BRCA	cis	rs9311474	0.607	rs13076398	ENSG00000243224.1	RP5-1157M23.2	-5.91	4.56e-09	6.97e-07	-0.2	-0.18	Electroencephalogram traits;	chr3:52539080	chr3:52239258~52241097:+
BRCA	cis	rs2732480	0.5	rs1387257	ENSG00000257763.1	OR5BK1P	5.91	4.56e-09	6.97e-07	0.19	0.18	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48242883	chr12:48355792~48356614:-
BRCA	cis	rs160451	0.966	rs218886	ENSG00000251136.7	RP11-37B2.1	-5.91	4.56e-09	6.97e-07	-0.17	-0.18	Leprosy;	chr8:89678365	chr8:89609409~89757727:-
BRCA	cis	rs42648	0.508	rs39204	ENSG00000225498.1	AC002064.5	5.91	4.57e-09	6.97e-07	0.17	0.18	Homocysteine levels;	chr7:90105004	chr7:90312496~90322592:+
BRCA	cis	rs67981189	0.896	rs4048474	ENSG00000258571.1	PTTG4P	-5.91	4.57e-09	6.97e-07	-0.2	-0.18	Schizophrenia;	chr14:71060982	chr14:71085482~71085833:-
BRCA	cis	rs7520050	0.933	rs11211203	ENSG00000280836.1	AL355480.1	5.91	4.57e-09	6.97e-07	0.21	0.18	Reticulocyte count;Red blood cell count;	chr1:45849920	chr1:45581219~45581321:-
BRCA	cis	rs75422866	0.867	rs73104115	ENSG00000280054.1	RP1-197B17.7	5.91	4.57e-09	6.98e-07	0.46	0.18	Pneumonia;	chr12:47684843	chr12:47728151~47730598:-
BRCA	cis	rs75422866	0.867	rs73104116	ENSG00000280054.1	RP1-197B17.7	5.91	4.57e-09	6.98e-07	0.46	0.18	Pneumonia;	chr12:47685023	chr12:47728151~47730598:-
BRCA	cis	rs875971	0.522	rs709604	ENSG00000234585.5	CCT6P3	-5.91	4.57e-09	6.98e-07	-0.17	-0.18	Aortic root size;	chr7:66032447	chr7:65038354~65074713:+
BRCA	cis	rs17301013	0.507	rs12072050	ENSG00000227373.4	RP11-160H22.5	5.91	4.57e-09	6.98e-07	0.28	0.18	Systemic lupus erythematosus;	chr1:174269648	chr1:174115300~174160004:-
BRCA	cis	rs9308731	0.591	rs6542350	ENSG00000227992.1	AC108463.2	-5.91	4.57e-09	6.98e-07	-0.21	-0.18	Chronic lymphocytic leukemia;	chr2:111187163	chr2:111203964~111206215:-
BRCA	cis	rs651907	0.535	rs11716558	ENSG00000244119.1	PDCL3P4	5.91	4.57e-09	6.98e-07	0.15	0.18	Colorectal cancer;	chr3:101809637	chr3:101712472~101713191:+
BRCA	cis	rs7520050	0.966	rs6701614	ENSG00000280836.1	AL355480.1	5.91	4.58e-09	6.99e-07	0.21	0.18	Reticulocyte count;Red blood cell count;	chr1:45843748	chr1:45581219~45581321:-
BRCA	cis	rs11098499	0.955	rs1397608	ENSG00000249244.1	RP11-548H18.2	5.91	4.58e-09	6.99e-07	0.21	0.18	Corneal astigmatism;	chr4:119240589	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.955	rs7685268	ENSG00000249244.1	RP11-548H18.2	5.91	4.58e-09	6.99e-07	0.21	0.18	Corneal astigmatism;	chr4:119241033	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.955	rs7684942	ENSG00000249244.1	RP11-548H18.2	5.91	4.58e-09	6.99e-07	0.21	0.18	Corneal astigmatism;	chr4:119241046	chr4:119391831~119395335:-
BRCA	cis	rs5758511	0.773	rs62240999	ENSG00000205702.9	CYP2D7	5.91	4.58e-09	6.99e-07	0.18	0.18	Birth weight;	chr22:41959559	chr22:42140203~42144577:-
BRCA	cis	rs2562456	0.876	rs11085465	ENSG00000268081.1	RP11-678G14.2	-5.91	4.58e-09	7e-07	-0.27	-0.18	Pain;	chr19:21568988	chr19:21554640~21569237:-
BRCA	cis	rs2243480	0.615	rs34363376	ENSG00000228409.4	CCT6P1	5.91	4.59e-09	7e-07	0.25	0.18	Diabetic kidney disease;	chr7:66474549	chr7:65751142~65763354:+
BRCA	cis	rs1858037	0.867	rs2118305	ENSG00000204929.10	AC074391.1	5.91	4.59e-09	7e-07	0.24	0.18	Rheumatoid arthritis;	chr2:65378086	chr2:65436711~66084639:+
BRCA	cis	rs12655019	0.92	rs12657064	ENSG00000271828.1	CTD-2310F14.1	5.91	4.59e-09	7.01e-07	0.33	0.18	Breast cancer (early onset);	chr5:56925172	chr5:56927874~56929573:+
BRCA	cis	rs651907	0.557	rs3806654	ENSG00000244119.1	PDCL3P4	5.91	4.61e-09	7.03e-07	0.14	0.18	Colorectal cancer;	chr3:101677685	chr3:101712472~101713191:+
BRCA	cis	rs4835473	0.897	rs2590034	ENSG00000249741.2	RP11-673E1.3	-5.91	4.61e-09	7.03e-07	-0.19	-0.18	Immature fraction of reticulocytes;	chr4:143926778	chr4:143911514~143912053:-
BRCA	cis	rs6442522	0.898	rs2219251	ENSG00000249786.6	EAF1-AS1	5.91	4.61e-09	7.04e-07	0.18	0.18	Uric acid levels;	chr3:15387661	chr3:15436171~15455940:-
BRCA	cis	rs2243480	1	rs2961102	ENSG00000164669.11	INTS4P1	5.91	4.61e-09	7.04e-07	0.35	0.18	Diabetic kidney disease;	chr7:65959671	chr7:65141225~65234216:+
BRCA	cis	rs2836950	0.565	rs2150413	ENSG00000238141.2	BRWD1-AS1	-5.91	4.62e-09	7.04e-07	-0.2	-0.18	Menarche (age at onset);	chr21:39242952	chr21:39315707~39323218:+
BRCA	cis	rs2836950	0.52	rs1980407	ENSG00000255568.3	BRWD1-AS2	-5.91	4.62e-09	7.05e-07	-0.17	-0.18	Menarche (age at onset);	chr21:39172035	chr21:39313935~39314962:+
BRCA	cis	rs6951245	0.554	rs11544331	ENSG00000229043.2	AC091729.9	-5.91	4.62e-09	7.05e-07	-0.28	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1091775	chr7:1160374~1165267:+
BRCA	cis	rs7520050	0.966	rs12409773	ENSG00000280836.1	AL355480.1	5.91	4.62e-09	7.05e-07	0.21	0.18	Reticulocyte count;Red blood cell count;	chr1:45893159	chr1:45581219~45581321:-
BRCA	cis	rs7520050	1	rs12410070	ENSG00000280836.1	AL355480.1	5.91	4.62e-09	7.05e-07	0.21	0.18	Reticulocyte count;Red blood cell count;	chr1:45893210	chr1:45581219~45581321:-
BRCA	cis	rs7520050	0.966	rs12410071	ENSG00000280836.1	AL355480.1	5.91	4.62e-09	7.05e-07	0.21	0.18	Reticulocyte count;Red blood cell count;	chr1:45893214	chr1:45581219~45581321:-
BRCA	cis	rs2749097	0.609	rs11208257	ENSG00000244256.3	RN7SL130P	-5.91	4.62e-09	7.05e-07	-0.25	-0.18	Alcohol consumption (transferrin glycosylation);	chr1:63648630	chr1:63655743~63656047:+
BRCA	cis	rs224090	0.523	rs12220700	ENSG00000238280.1	RP11-436D10.3	-5.91	4.62e-09	7.05e-07	-0.25	-0.18	Crohn's disease;	chr10:62801746	chr10:62793562~62805887:-
BRCA	cis	rs9880211	0.613	rs6439629	ENSG00000239213.4	NCK1-AS1	5.91	4.62e-09	7.05e-07	0.22	0.18	Height;Body mass index;	chr3:136182428	chr3:136841726~136862054:-
BRCA	cis	rs11098499	0.913	rs10010696	ENSG00000249244.1	RP11-548H18.2	5.91	4.64e-09	7.07e-07	0.22	0.18	Corneal astigmatism;	chr4:119243148	chr4:119391831~119395335:-
BRCA	cis	rs227275	0.554	rs223388	ENSG00000251288.2	RP11-10L12.2	-5.91	4.64e-09	7.07e-07	-0.21	-0.18	Allergic disease (asthma, hay fever or eczema);	chr4:102828287	chr4:102751401~102752641:+
BRCA	cis	rs227275	0.554	rs223386	ENSG00000251288.2	RP11-10L12.2	-5.91	4.64e-09	7.07e-07	-0.21	-0.18	Allergic disease (asthma, hay fever or eczema);	chr4:102829111	chr4:102751401~102752641:+
BRCA	cis	rs227275	0.554	rs223385	ENSG00000251288.2	RP11-10L12.2	-5.91	4.64e-09	7.07e-07	-0.21	-0.18	Allergic disease (asthma, hay fever or eczema);	chr4:102829159	chr4:102751401~102752641:+
BRCA	cis	rs13126694	0.75	rs6833295	ENSG00000248429.4	RP11-597D13.9	5.91	4.64e-09	7.07e-07	0.16	0.18	Blood osmolality (transformed sodium);	chr4:158143520	chr4:158170752~158202877:+
BRCA	cis	rs651907	0.535	rs12633089	ENSG00000244119.1	PDCL3P4	5.91	4.64e-09	7.08e-07	0.15	0.18	Colorectal cancer;	chr3:101809919	chr3:101712472~101713191:+
BRCA	cis	rs7914558	0.966	rs12571568	ENSG00000213061.2	PFN1P11	5.91	4.64e-09	7.08e-07	0.24	0.18	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103131639	chr10:102838011~102845473:-
BRCA	cis	rs7914558	0.966	rs12766205	ENSG00000213061.2	PFN1P11	5.91	4.64e-09	7.08e-07	0.24	0.18	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103133811	chr10:102838011~102845473:-
BRCA	cis	rs9308731	0.591	rs10199020	ENSG00000227992.1	AC108463.2	-5.91	4.64e-09	7.08e-07	-0.21	-0.18	Chronic lymphocytic leukemia;	chr2:111188879	chr2:111203964~111206215:-
BRCA	cis	rs7809950	0.817	rs4727678	ENSG00000238832.1	snoU109	-5.91	4.65e-09	7.09e-07	-0.26	-0.18	Coronary artery disease;	chr7:107443190	chr7:107603363~107603507:+
BRCA	cis	rs7809950	0.817	rs4727679	ENSG00000238832.1	snoU109	-5.91	4.65e-09	7.09e-07	-0.26	-0.18	Coronary artery disease;	chr7:107444573	chr7:107603363~107603507:+
BRCA	cis	rs12817211	0.524	rs2204683	ENSG00000272368.2	RP4-605O3.4	-5.91	4.65e-09	7.09e-07	-0.18	-0.18	Colorectal or endometrial cancer;	chr12:50128593	chr12:50112197~50165618:+
BRCA	cis	rs6969780	1	rs6969780	ENSG00000233429.8	HOTAIRM1	5.91	4.65e-09	7.09e-07	0.23	0.18	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27119517	chr7:27095647~27100265:+
BRCA	cis	rs801193	0.548	rs2109297	ENSG00000224316.1	RP11-479O9.2	-5.91	4.65e-09	7.1e-07	-0.18	-0.18	Aortic root size;	chr7:66657397	chr7:65773620~65802067:+
BRCA	cis	rs765787	0.53	rs12909987	ENSG00000259520.4	CTD-2651B20.3	5.91	4.66e-09	7.1e-07	0.21	0.18	Uric acid levels;	chr15:45220009	chr15:45251580~45279251:-
BRCA	cis	rs11976180	1	rs1919949	ENSG00000273234.1	OR2A13P	-5.91	4.66e-09	7.11e-07	-0.24	-0.18	Obesity-related traits;	chr7:144070630	chr7:144142009~144142938:+
BRCA	cis	rs2243480	1	rs316321	ENSG00000232559.3	GS1-124K5.12	5.91	4.66e-09	7.11e-07	0.34	0.18	Diabetic kidney disease;	chr7:66146626	chr7:66554588~66576923:-
BRCA	cis	rs2243480	1	rs316318	ENSG00000232559.3	GS1-124K5.12	5.91	4.66e-09	7.11e-07	0.34	0.18	Diabetic kidney disease;	chr7:66147917	chr7:66554588~66576923:-
BRCA	cis	rs2243480	1	rs316317	ENSG00000232559.3	GS1-124K5.12	5.91	4.66e-09	7.11e-07	0.34	0.18	Diabetic kidney disease;	chr7:66148650	chr7:66554588~66576923:-
BRCA	cis	rs2243480	1	rs316304	ENSG00000232559.3	GS1-124K5.12	5.91	4.66e-09	7.11e-07	0.34	0.18	Diabetic kidney disease;	chr7:66151907	chr7:66554588~66576923:-
BRCA	cis	rs2836950	0.52	rs8130240	ENSG00000255568.3	BRWD1-AS2	-5.91	4.66e-09	7.11e-07	-0.17	-0.18	Menarche (age at onset);	chr21:39166182	chr21:39313935~39314962:+
BRCA	cis	rs12237653	0.72	rs10812210	ENSG00000236404.7	VLDLR-AS1	-5.91	4.66e-09	7.11e-07	-0.3	-0.18	Gambling;	chr9:2536828	chr9:2422702~2643359:-
BRCA	cis	rs67981189	0.896	rs2526877	ENSG00000258571.1	PTTG4P	5.91	4.67e-09	7.12e-07	0.2	0.18	Schizophrenia;	chr14:70966605	chr14:71085482~71085833:-
BRCA	cis	rs1823913	0.599	rs13002286	ENSG00000280083.1	RP11-317J9.1	5.91	4.67e-09	7.12e-07	0.21	0.18	Obesity-related traits;	chr2:191285626	chr2:191154118~191156070:-
BRCA	cis	rs7927771	0.507	rs10838759	ENSG00000280615.1	Y_RNA	5.91	4.68e-09	7.14e-07	0.21	0.18	Subjective well-being;	chr11:47763795	chr11:47614898~47614994:-
BRCA	cis	rs7927771	0.524	rs11039377	ENSG00000280615.1	Y_RNA	5.91	4.68e-09	7.14e-07	0.21	0.18	Subjective well-being;	chr11:47768224	chr11:47614898~47614994:-
BRCA	cis	rs13178541	0.552	rs6881599	ENSG00000250378.1	RP11-119J18.1	-5.91	4.68e-09	7.14e-07	-0.23	-0.18	IgG glycosylation;	chr5:135705961	chr5:135812667~135826582:+
BRCA	cis	rs2911132	0.506	rs10037212	ENSG00000248734.2	CTD-2260A17.1	-5.91	4.69e-09	7.15e-07	-0.22	-0.18	Urate levels (BMI interaction);	chr5:96749072	chr5:96784777~96785999:+
BRCA	cis	rs2281636	1	rs10786569	ENSG00000233690.1	EBAG9P1	5.91	4.69e-09	7.15e-07	0.19	0.18	Obesity-related traits;	chr10:99753828	chr10:99697407~99697949:-
BRCA	cis	rs2638953	0.815	rs11049683	ENSG00000278733.1	RP11-425D17.1	-5.91	4.69e-09	7.15e-07	-0.24	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28509597	chr12:28185625~28186190:-
BRCA	cis	rs6088813	1	rs2425065	ENSG00000126005.14	MMP24-AS1	-5.91	4.69e-09	7.16e-07	-0.21	-0.18	Height;	chr20:35338465	chr20:35216462~35278131:-
BRCA	cis	rs2243480	0.901	rs73148097	ENSG00000164669.11	INTS4P1	5.91	4.7e-09	7.16e-07	0.35	0.18	Diabetic kidney disease;	chr7:65966800	chr7:65141225~65234216:+
BRCA	cis	rs2243480	1	rs906134	ENSG00000164669.11	INTS4P1	5.91	4.7e-09	7.16e-07	0.35	0.18	Diabetic kidney disease;	chr7:65979301	chr7:65141225~65234216:+
BRCA	cis	rs4819052	0.851	rs13052344	ENSG00000184274.3	LINC00315	-5.91	4.7e-09	7.16e-07	-0.25	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45256186	chr21:45300245~45305257:-
BRCA	cis	rs4819052	0.851	rs28501512	ENSG00000184274.3	LINC00315	-5.91	4.7e-09	7.16e-07	-0.25	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45256787	chr21:45300245~45305257:-
BRCA	cis	rs1876905	0.539	rs457497	ENSG00000271789.1	RP5-1112D6.7	5.91	4.7e-09	7.16e-07	0.27	0.18	Mean corpuscular hemoglobin;	chr6:111301346	chr6:111297126~111298510:+
BRCA	cis	rs240993	0.516	rs173287	ENSG00000230177.1	RP5-1112D6.4	-5.91	4.7e-09	7.16e-07	-0.24	-0.18	Inflammatory skin disease;Psoriasis;	chr6:111276236	chr6:111277932~111278742:+
BRCA	cis	rs228614	0.51	rs150893	ENSG00000251288.2	RP11-10L12.2	5.91	4.7e-09	7.16e-07	0.21	0.18	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102817075	chr4:102751401~102752641:+
BRCA	cis	rs11976180	1	rs1533267	ENSG00000273234.1	OR2A13P	-5.91	4.7e-09	7.16e-07	-0.24	-0.18	Obesity-related traits;	chr7:144069347	chr7:144142009~144142938:+
BRCA	cis	rs4713118	0.824	rs2179095	ENSG00000220721.1	OR1F12	-5.91	4.7e-09	7.16e-07	-0.22	-0.18	Parkinson's disease;	chr6:27783079	chr6:28073316~28074233:+
BRCA	cis	rs34779708	0.966	rs12257770	ENSG00000271335.4	RP11-324I22.4	5.91	4.7e-09	7.17e-07	0.18	0.18	Inflammatory bowel disease;Crohn's disease;	chr10:35228306	chr10:35314552~35336401:-
BRCA	cis	rs4763879	0.634	rs7974396	ENSG00000256673.1	RP11-599J14.2	5.91	4.7e-09	7.17e-07	0.2	0.18	Type 1 diabetes;	chr12:9708101	chr12:9398355~9414851:-
BRCA	cis	rs2341534	1	rs2341534	ENSG00000258413.1	RP11-665C16.6	-5.91	4.71e-09	7.17e-07	-0.27	-0.18	Morning vs. evening chronotype;	chr14:55318019	chr14:55262767~55272075:-
BRCA	cis	rs1440410	0.83	rs300939	ENSG00000250326.1	RP11-284M14.1	-5.91	4.71e-09	7.18e-07	-0.2	-0.18	Ischemic stroke;	chr4:143252059	chr4:142933195~143184861:-
BRCA	cis	rs16949788	1	rs41315964	ENSG00000261351.2	CTD-3185P2.1	-5.91	4.71e-09	7.18e-07	-0.36	-0.18	Spherical equivalent (joint analysis main effects and education interaction);	chr15:66487360	chr15:66488658~66492109:-
BRCA	cis	rs16949788	1	rs41306345	ENSG00000261351.2	CTD-3185P2.1	-5.91	4.71e-09	7.18e-07	-0.36	-0.18	Spherical equivalent (joint analysis main effects and education interaction);	chr15:66489710	chr15:66488658~66492109:-
BRCA	cis	rs13118159	0.509	rs4974556	ENSG00000254094.1	AC078852.1	-5.91	4.71e-09	7.18e-07	-0.22	-0.18	Longevity;	chr4:1364353	chr4:1356581~1358075:+
BRCA	cis	rs66887589	0.807	rs13134517	ENSG00000245958.5	RP11-33B1.1	-5.91	4.71e-09	7.18e-07	-0.16	-0.18	Diastolic blood pressure;	chr4:119484107	chr4:119454791~119552025:+
BRCA	cis	rs66887589	0.837	rs6534135	ENSG00000245958.5	RP11-33B1.1	-5.91	4.71e-09	7.18e-07	-0.16	-0.18	Diastolic blood pressure;	chr4:119485147	chr4:119454791~119552025:+
BRCA	cis	rs4713118	0.662	rs464312	ENSG00000204709.4	LINC01556	5.91	4.72e-09	7.19e-07	0.26	0.18	Parkinson's disease;	chr6:27999813	chr6:28943877~28944537:+
BRCA	cis	rs4713118	0.662	rs469228	ENSG00000204709.4	LINC01556	5.91	4.72e-09	7.19e-07	0.26	0.18	Parkinson's disease;	chr6:28002926	chr6:28943877~28944537:+
BRCA	cis	rs4713118	0.54	rs469227	ENSG00000204709.4	LINC01556	5.91	4.72e-09	7.19e-07	0.26	0.18	Parkinson's disease;	chr6:28002927	chr6:28943877~28944537:+
BRCA	cis	rs4713118	0.662	rs149948	ENSG00000204709.4	LINC01556	5.91	4.72e-09	7.19e-07	0.26	0.18	Parkinson's disease;	chr6:28007039	chr6:28943877~28944537:+
BRCA	cis	rs6723226	0.679	rs116617324	ENSG00000276334.1	AL133243.1	-5.91	4.72e-09	7.19e-07	-0.22	-0.18	Intelligence (multi-trait analysis);	chr2:32397641	chr2:32521927~32523547:+
BRCA	cis	rs8031584	0.56	rs1056118	ENSG00000270015.1	RP11-540B6.6	5.91	4.72e-09	7.19e-07	0.18	0.18	Huntington's disease progression;	chr15:30911583	chr15:30926514~30928407:+
BRCA	cis	rs754466	0.58	rs2289309	ENSG00000204049.1	RP11-126H7.4	5.91	4.72e-09	7.19e-07	0.21	0.18	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77811350	chr10:77866875~77869610:+
BRCA	cis	rs67311347	0.955	rs4974067	ENSG00000280739.1	EIF1B-AS1	5.91	4.72e-09	7.19e-07	0.2	0.18	Renal cell carcinoma;	chr3:40333060	chr3:40173145~40309698:-
BRCA	cis	rs56104184	0.775	rs117016425	ENSG00000235191.1	NUCB1-AS1	5.91	4.73e-09	7.2e-07	0.33	0.18	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr19:48896959	chr19:48910930~48918891:-
BRCA	cis	rs2153535	0.585	rs11243268	ENSG00000230939.1	RP11-314C16.1	-5.91	4.73e-09	7.21e-07	-0.21	-0.18	Motion sickness;	chr6:8662375	chr6:8784178~8785445:+
BRCA	cis	rs34779708	0.966	rs12260130	ENSG00000271335.4	RP11-324I22.4	5.91	4.73e-09	7.21e-07	0.19	0.18	Inflammatory bowel disease;Crohn's disease;	chr10:35178743	chr10:35314552~35336401:-
BRCA	cis	rs11976180	1	rs1533268	ENSG00000273234.1	OR2A13P	-5.91	4.73e-09	7.21e-07	-0.24	-0.18	Obesity-related traits;	chr7:144069265	chr7:144142009~144142938:+
BRCA	cis	rs6479891	0.915	rs4281380	ENSG00000232075.1	MRPL35P2	-5.91	4.73e-09	7.21e-07	-0.33	-0.18	Arthritis (juvenile idiopathic);	chr10:63227938	chr10:63634317~63634827:-
BRCA	cis	rs112521149	1	rs112521149	ENSG00000242349.4	NPPA-AS1	-5.91	4.73e-09	7.21e-07	-0.31	-0.18	Mean corpuscular volume;	chr1:11829758	chr1:11841017~11848079:+
BRCA	cis	rs2179367	0.537	rs6911411	ENSG00000216906.2	RP11-350J20.9	5.91	4.73e-09	7.21e-07	0.28	0.18	Dupuytren's disease;	chr6:149366954	chr6:149904243~149906418:+
BRCA	cis	rs4819052	0.808	rs11909411	ENSG00000184274.3	LINC00315	-5.91	4.74e-09	7.22e-07	-0.25	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45256641	chr21:45300245~45305257:-
BRCA	cis	rs4819052	0.851	rs28676615	ENSG00000184274.3	LINC00315	-5.91	4.74e-09	7.22e-07	-0.25	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45256661	chr21:45300245~45305257:-
BRCA	cis	rs9876781	1	rs13091785	ENSG00000229759.1	MRPS18AP1	5.91	4.74e-09	7.22e-07	0.2	0.18	Longevity;	chr3:48452692	chr3:48256350~48256938:-
BRCA	cis	rs2644899	0.75	rs2607414	ENSG00000268529.1	CYP2T3P	-5.91	4.75e-09	7.24e-07	-0.24	-0.18	Post bronchodilator FEV1/FVC ratio;	chr19:40761224	chr19:41134722~41137308:+
BRCA	cis	rs875971	0.545	rs1796226	ENSG00000228409.4	CCT6P1	-5.91	4.76e-09	7.25e-07	-0.18	-0.18	Aortic root size;	chr7:66622723	chr7:65751142~65763354:+
BRCA	cis	rs651907	0.557	rs13099674	ENSG00000244119.1	PDCL3P4	5.91	4.76e-09	7.25e-07	0.14	0.18	Colorectal cancer;	chr3:101770785	chr3:101712472~101713191:+
BRCA	cis	rs67981189	0.529	rs2526872	ENSG00000258571.1	PTTG4P	5.91	4.76e-09	7.25e-07	0.21	0.18	Schizophrenia;	chr14:70918168	chr14:71085482~71085833:-
BRCA	cis	rs301901	0.556	rs13176996	ENSG00000250155.1	CTD-2353F22.1	-5.91	4.76e-09	7.25e-07	-0.23	-0.18	Height;	chr5:37178659	chr5:36666214~36725195:-
BRCA	cis	rs227932	0.614	rs4722260	ENSG00000234286.1	AC006026.13	5.91	4.76e-09	7.25e-07	0.27	0.18	Schizophrenia;	chr7:23719851	chr7:23680195~23680786:-
BRCA	cis	rs2243480	0.901	rs57126451	ENSG00000164669.11	INTS4P1	5.91	4.76e-09	7.25e-07	0.34	0.18	Diabetic kidney disease;	chr7:65951319	chr7:65141225~65234216:+
BRCA	cis	rs1193	0.955	rs1049458	ENSG00000231259.4	AC125232.1	5.91	4.76e-09	7.25e-07	0.22	0.18	High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;High light scatter reticulocyte count;	chr2:86776074	chr2:87031815~87053069:-
BRCA	cis	rs17597773	0.674	rs2378425	ENSG00000272823.1	RP11-295M18.6	-5.91	4.76e-09	7.25e-07	-0.21	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220842716	chr1:220828676~220829211:-
BRCA	cis	rs34779708	0.897	rs9665538	ENSG00000271335.4	RP11-324I22.4	5.91	4.77e-09	7.26e-07	0.19	0.18	Inflammatory bowel disease;Crohn's disease;	chr10:35172110	chr10:35314552~35336401:-
BRCA	cis	rs2836950	0.545	rs11700449	ENSG00000255568.3	BRWD1-AS2	-5.91	4.77e-09	7.26e-07	-0.17	-0.18	Menarche (age at onset);	chr21:39150493	chr21:39313935~39314962:+
BRCA	cis	rs2638953	0.962	rs11049495	ENSG00000278733.1	RP11-425D17.1	-5.91	4.77e-09	7.26e-07	-0.25	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28264795	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.962	rs11049496	ENSG00000278733.1	RP11-425D17.1	-5.91	4.77e-09	7.26e-07	-0.25	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28267327	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.889	rs2045887	ENSG00000278733.1	RP11-425D17.1	-5.91	4.77e-09	7.26e-07	-0.25	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28270825	chr12:28185625~28186190:-
BRCA	cis	rs13287066	0.74	rs10761223	ENSG00000227603.1	RP11-165J3.6	5.9	4.77e-09	7.27e-07	0.19	0.18	Intelligence (multi-trait analysis);	chr9:93404028	chr9:93435332~93437121:-
BRCA	cis	rs11722228	0.522	rs73212817	ENSG00000261490.1	RP11-448G15.3	5.9	4.77e-09	7.27e-07	0.21	0.18	Urate levels;Serum uric acid levels;Gout;	chr4:10062387	chr4:10068089~10073019:-
BRCA	cis	rs7772486	0.875	rs1331645	ENSG00000235652.6	RP11-545I5.3	5.9	4.78e-09	7.27e-07	0.18	0.18	Lobe attachment (rater-scored or self-reported);	chr6:146077271	chr6:145799409~145886585:+
BRCA	cis	rs67981189	0.896	rs3814871	ENSG00000258571.1	PTTG4P	-5.9	4.78e-09	7.27e-07	-0.2	-0.18	Schizophrenia;	chr14:70978071	chr14:71085482~71085833:-
BRCA	cis	rs9308731	0.644	rs1054873	ENSG00000227992.1	AC108463.2	-5.9	4.78e-09	7.28e-07	-0.21	-0.18	Chronic lymphocytic leukemia;	chr2:111118571	chr2:111203964~111206215:-
BRCA	cis	rs12468226	0.752	rs34829484	ENSG00000273456.1	RP11-686O6.2	-5.9	4.78e-09	7.28e-07	-0.24	-0.18	Urate levels;	chr2:202137267	chr2:202374932~202375604:-
BRCA	cis	rs42648	0.564	rs6465248	ENSG00000225498.1	AC002064.5	5.9	4.78e-09	7.28e-07	0.17	0.18	Homocysteine levels;	chr7:90195426	chr7:90312496~90322592:+
BRCA	cis	rs9907295	1	rs11655533	ENSG00000271013.1	AC015849.15	-5.9	4.79e-09	7.29e-07	-0.27	-0.18	Fibroblast growth factor basic levels;	chr17:35908002	chr17:35912635~35918010:-
BRCA	cis	rs2638953	0.962	rs11049621	ENSG00000278733.1	RP11-425D17.1	-5.9	4.79e-09	7.29e-07	-0.22	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28456074	chr12:28185625~28186190:-
BRCA	cis	rs13113518	0.513	rs13147861	ENSG00000223305.1	RN7SKP30	5.9	4.79e-09	7.29e-07	0.23	0.18	Height;	chr4:55611014	chr4:55540502~55540835:-
BRCA	cis	rs8002861	0.935	rs7320988	ENSG00000274001.1	RP11-5G9.5	5.9	4.79e-09	7.29e-07	0.2	0.18	Leprosy;	chr13:43839387	chr13:43877715~43878163:-
BRCA	cis	rs4372836	0.964	rs56240884	ENSG00000226833.4	AC097724.3	-5.9	4.79e-09	7.3e-07	-0.23	-0.18	Body mass index;	chr2:28717288	chr2:28708953~28736205:-
BRCA	cis	rs2836950	0.805	rs2836961	ENSG00000238141.2	BRWD1-AS1	-5.9	4.79e-09	7.3e-07	-0.21	-0.18	Menarche (age at onset);	chr21:39255094	chr21:39315707~39323218:+
BRCA	cis	rs2898681	0.614	rs62338810	ENSG00000248375.1	RP11-177B4.1	-5.9	4.8e-09	7.3e-07	-0.28	-0.18	Optic nerve measurement (cup area);	chr4:52812340	chr4:52720081~52720831:-
BRCA	cis	rs2274273	0.638	rs3759667	ENSG00000258413.1	RP11-665C16.6	-5.9	4.8e-09	7.3e-07	-0.25	-0.18	Protein biomarker;	chr14:55191703	chr14:55262767~55272075:-
BRCA	cis	rs651907	0.514	rs12636046	ENSG00000244119.1	PDCL3P4	5.9	4.8e-09	7.3e-07	0.15	0.18	Colorectal cancer;	chr3:101715604	chr3:101712472~101713191:+
BRCA	cis	rs7246657	0.525	rs997516	ENSG00000226686.6	LINC01535	-5.9	4.8e-09	7.31e-07	-0.3	-0.18	Coronary artery calcification;	chr19:36983362	chr19:37251912~37265535:+
BRCA	cis	rs2243480	1	rs316326	ENSG00000228409.4	CCT6P1	5.9	4.8e-09	7.31e-07	0.25	0.18	Diabetic kidney disease;	chr7:66144466	chr7:65751142~65763354:+
BRCA	cis	rs2243480	1	rs316325	ENSG00000228409.4	CCT6P1	5.9	4.8e-09	7.31e-07	0.25	0.18	Diabetic kidney disease;	chr7:66144531	chr7:65751142~65763354:+
BRCA	cis	rs4372836	0.964	rs34627117	ENSG00000226833.4	AC097724.3	-5.9	4.81e-09	7.32e-07	-0.23	-0.18	Body mass index;	chr2:28707610	chr2:28708953~28736205:-
BRCA	cis	rs4699052	0.787	rs2169508	ENSG00000248740.4	RP11-328K4.1	5.9	4.81e-09	7.32e-07	0.21	0.18	Testicular germ cell tumor;	chr4:103145733	chr4:103256159~103453658:+
BRCA	cis	rs7208859	0.673	rs2433	ENSG00000265443.1	CTD-2349P21.6	-5.9	4.81e-09	7.33e-07	-0.31	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30899210	chr17:30726305~30727564:-
BRCA	cis	rs2337406	0.587	rs10150642	ENSG00000223648.3	IGHV3-64	-5.9	4.82e-09	7.33e-07	-0.18	-0.18	Alzheimer's disease (late onset);	chr14:106647269	chr14:106643132~106658258:-
BRCA	cis	rs9527	0.662	rs4919687	ENSG00000236937.2	PTGES3P4	5.9	4.82e-09	7.33e-07	0.25	0.18	Arsenic metabolism;	chr10:102835491	chr10:102845595~102845950:+
BRCA	cis	rs516805	0.667	rs2606598	ENSG00000279453.1	RP3-425C14.4	5.9	4.82e-09	7.34e-07	0.27	0.18	Lymphocyte counts;	chr6:122206501	chr6:122436789~122439223:-
BRCA	cis	rs78487399	0.808	rs6705351	ENSG00000234936.1	AC010883.5	5.9	4.83e-09	7.35e-07	0.24	0.18	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43615998	chr2:43229573~43233394:+
BRCA	cis	rs10510102	0.808	rs11200296	ENSG00000226864.1	ATE1-AS1	5.9	4.84e-09	7.36e-07	0.34	0.18	Breast cancer;	chr10:121971956	chr10:121928312~121951965:+
BRCA	cis	rs10504130	1	rs16916961	ENSG00000272024.1	RP11-546K22.3	-5.9	4.84e-09	7.36e-07	-0.32	-0.18	Venous thromboembolism (SNP x SNP interaction);	chr8:51918618	chr8:51950284~51950690:+
BRCA	cis	rs4372836	0.894	rs55877710	ENSG00000226833.4	AC097724.3	-5.9	4.84e-09	7.36e-07	-0.23	-0.18	Body mass index;	chr2:28706442	chr2:28708953~28736205:-
BRCA	cis	rs4372836	0.929	rs55883854	ENSG00000226833.4	AC097724.3	-5.9	4.84e-09	7.36e-07	-0.23	-0.18	Body mass index;	chr2:28706675	chr2:28708953~28736205:-
BRCA	cis	rs71520386	0.583	rs28799344	ENSG00000228649.7	AC005682.5	-5.9	4.84e-09	7.36e-07	-0.17	-0.18	Fibrinogen levels;	chr7:22805647	chr7:22854178~22861579:+
BRCA	cis	rs9907295	0.748	rs4251719	ENSG00000270977.1	AC015849.16	-5.9	4.84e-09	7.37e-07	-0.27	-0.18	Fibroblast growth factor basic levels;	chr17:35815358	chr17:35893707~35911023:-
BRCA	cis	rs7200543	1	rs6498540	ENSG00000260872.1	RP11-680G24.5	-5.9	4.84e-09	7.37e-07	-0.2	-0.18	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15036737	chr16:15018106~15020488:-
BRCA	cis	rs7208859	0.623	rs122898	ENSG00000265443.1	CTD-2349P21.6	5.9	4.85e-09	7.37e-07	0.29	0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30578236	chr17:30726305~30727564:-
BRCA	cis	rs228614	0.51	rs223397	ENSG00000251288.2	RP11-10L12.2	-5.9	4.85e-09	7.37e-07	-0.22	-0.18	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102821494	chr4:102751401~102752641:+
BRCA	cis	rs755249	0.565	rs9729677	ENSG00000228060.1	RP11-69E11.8	5.9	4.85e-09	7.37e-07	0.18	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39587137	chr1:39565160~39573203:+
BRCA	cis	rs12893668	0.572	rs35011804	ENSG00000269910.1	RP11-73M18.10	5.9	4.85e-09	7.37e-07	0.19	0.18	Reticulocyte count;	chr14:103685063	chr14:103694516~103695050:-
BRCA	cis	rs897984	0.645	rs9938550	ENSG00000275263.1	RP11-1072A3.4	5.9	4.85e-09	7.37e-07	0.21	0.18	Dementia with Lewy bodies;	chr16:30987821	chr16:30956872~30957199:-
BRCA	cis	rs2243480	1	rs35046236	ENSG00000164669.11	INTS4P1	5.9	4.85e-09	7.38e-07	0.34	0.18	Diabetic kidney disease;	chr7:65943626	chr7:65141225~65234216:+
BRCA	cis	rs2243480	1	rs36068983	ENSG00000164669.11	INTS4P1	5.9	4.85e-09	7.38e-07	0.34	0.18	Diabetic kidney disease;	chr7:65944004	chr7:65141225~65234216:+
BRCA	cis	rs2243480	1	rs68189316	ENSG00000164669.11	INTS4P1	5.9	4.85e-09	7.38e-07	0.34	0.18	Diabetic kidney disease;	chr7:65944182	chr7:65141225~65234216:+
BRCA	cis	rs17221829	0.702	rs2075536	ENSG00000280385.1	AP000648.5	5.9	4.86e-09	7.39e-07	0.2	0.18	Anxiety in major depressive disorder;	chr11:89674223	chr11:90193614~90198120:+
BRCA	cis	rs891378	1	rs1429906	ENSG00000274245.1	RP11-357P18.2	-5.9	4.87e-09	7.41e-07	-0.24	-0.18	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207246982	chr1:207372559~207373252:+
BRCA	cis	rs7201929	1	rs7201929	ENSG00000251417.2	RP11-1348G14.4	-5.9	4.87e-09	7.41e-07	-0.21	-0.18	QT interval;	chr16:28860645	chr16:28802743~28817828:+
BRCA	cis	rs67981189	0.896	rs17108822	ENSG00000258571.1	PTTG4P	-5.9	4.88e-09	7.42e-07	-0.2	-0.18	Schizophrenia;	chr14:70979189	chr14:71085482~71085833:-
BRCA	cis	rs67981189	0.896	rs8012728	ENSG00000258571.1	PTTG4P	-5.9	4.88e-09	7.42e-07	-0.2	-0.18	Schizophrenia;	chr14:70981231	chr14:71085482~71085833:-
BRCA	cis	rs67981189	0.896	rs34731365	ENSG00000258571.1	PTTG4P	-5.9	4.88e-09	7.42e-07	-0.2	-0.18	Schizophrenia;	chr14:70982877	chr14:71085482~71085833:-
BRCA	cis	rs754466	0.58	rs10762763	ENSG00000204049.1	RP11-126H7.4	5.9	4.88e-09	7.42e-07	0.21	0.18	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77801045	chr10:77866875~77869610:+
BRCA	cis	rs7772486	0.651	rs1292338	ENSG00000270638.1	RP3-466P17.1	-5.9	4.88e-09	7.43e-07	-0.2	-0.18	Lobe attachment (rater-scored or self-reported);	chr6:145646335	chr6:145735570~145737218:+
BRCA	cis	rs10050311	1	rs10050311	ENSG00000251411.1	RP11-397E7.4	-5.9	4.89e-09	7.43e-07	-0.26	-0.18	Insulin-related traits;	chr4:86833266	chr4:86913266~86914817:-
BRCA	cis	rs801193	0.569	rs2013908	ENSG00000224316.1	RP11-479O9.2	-5.9	4.89e-09	7.43e-07	-0.18	-0.18	Aortic root size;	chr7:66656082	chr7:65773620~65802067:+
BRCA	cis	rs17301013	0.606	rs56239105	ENSG00000227373.4	RP11-160H22.5	5.9	4.89e-09	7.44e-07	0.27	0.18	Systemic lupus erythematosus;	chr1:174179346	chr1:174115300~174160004:-
BRCA	cis	rs9840812	0.645	rs13068119	ENSG00000273486.1	RP11-731C17.2	-5.9	4.89e-09	7.44e-07	-0.24	-0.18	Fibrinogen levels;	chr3:136487527	chr3:136837338~136839021:-
BRCA	cis	rs9880211	0.563	rs9881400	ENSG00000239213.4	NCK1-AS1	5.9	4.89e-09	7.44e-07	0.23	0.18	Height;Body mass index;	chr3:136142824	chr3:136841726~136862054:-
BRCA	cis	rs72681920	0.881	rs4699734	ENSG00000246090.5	RP11-696N14.1	-5.9	4.9e-09	7.45e-07	-0.3	-0.18	Alcohol dependence;	chr4:99218209	chr4:99088857~99301356:+
BRCA	cis	rs7772486	0.875	rs1330939	ENSG00000270638.1	RP3-466P17.1	5.9	4.9e-09	7.45e-07	0.2	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145987382	chr6:145735570~145737218:+
BRCA	cis	rs2153535	0.585	rs7739573	ENSG00000230939.1	RP11-314C16.1	5.9	4.9e-09	7.45e-07	0.21	0.18	Motion sickness;	chr6:8659671	chr6:8784178~8785445:+
BRCA	cis	rs295490	0.748	rs17394620	ENSG00000272656.1	RP11-219D15.3	5.9	4.91e-09	7.46e-07	0.43	0.18	PR interval in Tripanosoma cruzi seropositivity;	chr3:139348541	chr3:139349024~139349371:-
BRCA	cis	rs13118159	0.509	rs7688922	ENSG00000254094.1	AC078852.1	-5.9	4.91e-09	7.46e-07	-0.22	-0.18	Longevity;	chr4:1367223	chr4:1356581~1358075:+
BRCA	cis	rs2243480	1	rs34136756	ENSG00000232546.1	RP11-458F8.1	-5.9	4.91e-09	7.46e-07	-0.23	-0.18	Diabetic kidney disease;	chr7:65916269	chr7:66848496~66858136:+
BRCA	cis	rs202072	0.872	rs413120	ENSG00000272379.1	RP1-257A7.5	-5.9	4.91e-09	7.47e-07	-0.24	-0.18	HIV-1 viral setpoint;	chr6:13280409	chr6:13290018~13290490:-
BRCA	cis	rs801193	0.569	rs6951302	ENSG00000224316.1	RP11-479O9.2	-5.9	4.91e-09	7.47e-07	-0.18	-0.18	Aortic root size;	chr7:66667525	chr7:65773620~65802067:+
BRCA	cis	rs7927771	0.524	rs11039392	ENSG00000280615.1	Y_RNA	5.9	4.91e-09	7.47e-07	0.21	0.18	Subjective well-being;	chr11:47777201	chr11:47614898~47614994:-
BRCA	cis	rs2235642	0.821	rs8051895	ENSG00000280231.1	LA16c-380F5.3	-5.9	4.92e-09	7.48e-07	-0.23	-0.18	Coronary artery disease;	chr16:1552810	chr16:1553655~1554130:-
BRCA	cis	rs250585	0.92	rs8046051	ENSG00000260136.4	CTD-2270L9.4	-5.9	4.93e-09	7.49e-07	-0.22	-0.18	Egg allergy;	chr16:23527345	chr16:23452758~23457606:+
BRCA	cis	rs875971	0.543	rs801191	ENSG00000273024.4	INTS4P2	5.9	4.93e-09	7.49e-07	0.2	0.18	Aortic root size;	chr7:66567968	chr7:65647864~65715661:+
BRCA	cis	rs9376098	0.737	rs12205603	ENSG00000232876.1	CTA-212D2.2	-5.9	4.93e-09	7.49e-07	-0.26	-0.18	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr6:135178949	chr6:135055033~135060550:+
BRCA	cis	rs42648	0.564	rs39283	ENSG00000225498.1	AC002064.5	5.9	4.93e-09	7.49e-07	0.17	0.18	Homocysteine levels;	chr7:90159492	chr7:90312496~90322592:+
BRCA	cis	rs1345301	1	rs12475055	ENSG00000234389.1	AC007278.3	5.9	4.93e-09	7.49e-07	0.17	0.18	Waist circumference;	chr2:102262431	chr2:102438713~102440475:+
BRCA	cis	rs42648	0.535	rs10952994	ENSG00000225498.1	AC002064.5	-5.9	4.93e-09	7.5e-07	-0.17	-0.18	Homocysteine levels;	chr7:90124545	chr7:90312496~90322592:+
BRCA	cis	rs2243480	1	rs2961102	ENSG00000230295.1	RP11-458F8.2	-5.9	4.93e-09	7.5e-07	-0.24	-0.18	Diabetic kidney disease;	chr7:65959671	chr7:66880708~66882981:+
BRCA	cis	rs754466	0.606	rs55854323	ENSG00000204049.1	RP11-126H7.4	5.9	4.94e-09	7.51e-07	0.22	0.18	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77830146	chr10:77866875~77869610:+
BRCA	cis	rs7567389	0.637	rs4150421	ENSG00000236682.1	AC068282.3	5.9	4.94e-09	7.51e-07	0.27	0.18	Self-rated health;	chr2:127287354	chr2:127389130~127400580:+
BRCA	cis	rs6142102	0.812	rs761236	ENSG00000275784.1	RP5-1125A11.6	-5.9	4.94e-09	7.51e-07	-0.22	-0.18	Skin pigmentation;	chr20:33932245	chr20:33989480~33991818:-
BRCA	cis	rs2243480	1	rs13247184	ENSG00000230295.1	RP11-458F8.2	-5.9	4.94e-09	7.51e-07	-0.24	-0.18	Diabetic kidney disease;	chr7:65893941	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs35283677	ENSG00000230295.1	RP11-458F8.2	-5.9	4.94e-09	7.51e-07	-0.24	-0.18	Diabetic kidney disease;	chr7:65894246	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs35421653	ENSG00000230295.1	RP11-458F8.2	-5.9	4.94e-09	7.51e-07	-0.24	-0.18	Diabetic kidney disease;	chr7:65898442	chr7:66880708~66882981:+
BRCA	cis	rs7221109	0.592	rs917595	ENSG00000278834.1	RP11-458J1.1	5.9	4.95e-09	7.51e-07	0.2	0.18	Type 1 diabetes;	chr17:40663246	chr17:40648300~40649718:+
BRCA	cis	rs1395	0.744	rs9653564	ENSG00000234072.1	AC074117.10	-5.9	4.95e-09	7.53e-07	-0.19	-0.18	Blood metabolite levels;	chr2:27249750	chr2:27356246~27367622:+
BRCA	cis	rs2732480	0.557	rs2409004	ENSG00000257763.1	OR5BK1P	5.9	4.95e-09	7.53e-07	0.19	0.18	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48327668	chr12:48355792~48356614:-
BRCA	cis	rs7809950	0.678	rs77395658	ENSG00000238832.1	snoU109	-5.9	4.95e-09	7.53e-07	-0.27	-0.18	Coronary artery disease;	chr7:107360206	chr7:107603363~107603507:+
BRCA	cis	rs34286592	1	rs9938630	ENSG00000214725.6	CDIPT-AS1	-5.9	4.95e-09	7.53e-07	-0.28	-0.18	Multiple sclerosis;	chr16:29825787	chr16:29863593~29868053:+
BRCA	cis	rs754466	0.58	rs2579178	ENSG00000204049.1	RP11-126H7.4	-5.9	4.96e-09	7.54e-07	-0.22	-0.18	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77769457	chr10:77866875~77869610:+
BRCA	cis	rs2243480	1	rs781142	ENSG00000164669.11	INTS4P1	5.9	4.96e-09	7.54e-07	0.34	0.18	Diabetic kidney disease;	chr7:65973791	chr7:65141225~65234216:+
BRCA	cis	rs2810114	0.916	rs2526851	ENSG00000258571.1	PTTG4P	5.9	4.96e-09	7.54e-07	0.21	0.18	Alcohol dependence;	chr14:70949563	chr14:71085482~71085833:-
BRCA	cis	rs2911132	0.66	rs754615	ENSG00000248734.2	CTD-2260A17.1	5.9	4.96e-09	7.54e-07	0.2	0.18	Urate levels (BMI interaction);	chr5:96750630	chr5:96784777~96785999:+
BRCA	cis	rs801193	0.569	rs3846973	ENSG00000224316.1	RP11-479O9.2	-5.9	4.96e-09	7.54e-07	-0.18	-0.18	Aortic root size;	chr7:66655048	chr7:65773620~65802067:+
BRCA	cis	rs8054556	0.513	rs12596042	ENSG00000273724.1	RP11-347C12.12	-5.9	4.97e-09	7.55e-07	-0.2	-0.18	Autism spectrum disorder or schizophrenia;	chr16:29923433	chr16:30336400~30343336:+
BRCA	cis	rs7615952	0.512	rs34085484	ENSG00000171084.14	FAM86JP	5.9	4.97e-09	7.55e-07	0.28	0.18	Blood pressure (smoking interaction);	chr3:125825343	chr3:125916620~125930024:+
BRCA	cis	rs7615952	0.608	rs35668111	ENSG00000171084.14	FAM86JP	5.9	4.97e-09	7.55e-07	0.28	0.18	Blood pressure (smoking interaction);	chr3:125825792	chr3:125916620~125930024:+
BRCA	cis	rs12893668	0.572	rs7148857	ENSG00000269910.1	RP11-73M18.10	5.9	4.98e-09	7.56e-07	0.19	0.18	Reticulocyte count;	chr14:103676900	chr14:103694516~103695050:-
BRCA	cis	rs4664293	0.585	rs10460301	ENSG00000226266.5	AC009961.3	5.9	4.98e-09	7.56e-07	0.22	0.18	Monocyte percentage of white cells;	chr2:159778566	chr2:159670708~159712435:-
BRCA	cis	rs2288884	0.943	rs11671792	ENSG00000275055.1	CTC-471J1.11	-5.9	4.98e-09	7.56e-07	-0.27	-0.18	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52078430	chr19:52049007~52049754:+
BRCA	cis	rs1555322	0.505	rs639763	ENSG00000269202.1	RP4-614O4.12	-5.9	4.98e-09	7.56e-07	-0.22	-0.18	Attention deficit hyperactivity disorder;	chr20:35274101	chr20:35201747~35203288:-
BRCA	cis	rs10515750	0.588	rs11134720	ENSG00000248544.2	CTB-47B11.3	5.9	4.98e-09	7.56e-07	0.26	0.18	Lung function (FEV1/FVC);	chr5:157358662	chr5:157375741~157384950:-
BRCA	cis	rs6088813	0.922	rs6088800	ENSG00000126005.14	MMP24-AS1	5.9	4.98e-09	7.57e-07	0.21	0.18	Height;	chr20:35346634	chr20:35216462~35278131:-
BRCA	cis	rs7914558	1	rs1926030	ENSG00000213061.2	PFN1P11	5.9	4.98e-09	7.57e-07	0.23	0.18	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103095899	chr10:102838011~102845473:-
BRCA	cis	rs7124681	0.585	rs10838773	ENSG00000280615.1	Y_RNA	5.9	4.99e-09	7.58e-07	0.21	0.18	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:47812794	chr11:47614898~47614994:-
BRCA	cis	rs6442522	0.966	rs6792128	ENSG00000249786.6	EAF1-AS1	5.9	4.99e-09	7.58e-07	0.18	0.18	Uric acid levels;	chr3:15417350	chr3:15436171~15455940:-
BRCA	cis	rs10129255	0.83	rs61997609	ENSG00000280411.1	IGHV1-69-2	-5.9	4.99e-09	7.58e-07	-0.14	-0.18	Kawasaki disease;	chr14:106692376	chr14:106762092~106762588:-
BRCA	cis	rs2243480	1	rs73142162	ENSG00000230295.1	RP11-458F8.2	-5.9	4.99e-09	7.58e-07	-0.24	-0.18	Diabetic kidney disease;	chr7:65909309	chr7:66880708~66882981:+
BRCA	cis	rs71520386	0.583	rs35322907	ENSG00000228649.7	AC005682.5	-5.9	4.99e-09	7.58e-07	-0.17	-0.18	Fibrinogen levels;	chr7:22806592	chr7:22854178~22861579:+
BRCA	cis	rs732716	0.813	rs760369	ENSG00000267980.1	AC007292.6	5.9	4.99e-09	7.58e-07	0.22	0.18	Mean corpuscular volume;	chr19:4449290	chr19:4363789~4364640:+
BRCA	cis	rs2836950	0.527	rs2836958	ENSG00000255568.3	BRWD1-AS2	-5.9	4.99e-09	7.58e-07	-0.17	-0.18	Menarche (age at onset);	chr21:39251600	chr21:39313935~39314962:+
BRCA	cis	rs2832191	0.935	rs11910475	ENSG00000215533.7	LINC00189	5.9	5e-09	7.59e-07	0.2	0.18	Dental caries;	chr21:29147381	chr21:29193480~29288205:+
BRCA	cis	rs6472827	0.953	rs4455819	ENSG00000253983.2	RP1-16A9.1	-5.9	5e-09	7.59e-07	-0.31	-0.18	Uterine fibroids;	chr8:74210566	chr8:74199396~74208441:+
BRCA	cis	rs56104184	0.775	rs73061699	ENSG00000235191.1	NUCB1-AS1	5.9	5e-09	7.59e-07	0.33	0.18	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr19:48897254	chr19:48910930~48918891:-
BRCA	cis	rs227275	0.554	rs150895	ENSG00000251288.2	RP11-10L12.2	-5.9	5e-09	7.59e-07	-0.21	-0.18	Allergic disease (asthma, hay fever or eczema);	chr4:102791432	chr4:102751401~102752641:+
BRCA	cis	rs2115536	0.73	rs4238512	ENSG00000278600.1	RP11-81A1.6	5.9	5e-09	7.6e-07	0.16	0.18	Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Eosinophil counts;Neutrophil percentage of granulocytes;	chr15:79891556	chr15:79920195~79922455:-
BRCA	cis	rs11105298	0.838	rs10858862	ENSG00000270344.2	RP11-734K2.4	5.9	5e-09	7.6e-07	0.21	0.18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89448276	chr12:89525654~89548005:+
BRCA	cis	rs1124769	0.719	rs2614774	ENSG00000259378.1	DCAF13P3	-5.9	5e-09	7.6e-07	-0.26	-0.18	Cognitive performance;	chr15:50877678	chr15:50944663~50945996:+
BRCA	cis	rs2243480	1	rs316331	ENSG00000230295.1	RP11-458F8.2	5.9	5.01e-09	7.6e-07	0.24	0.18	Diabetic kidney disease;	chr7:66139635	chr7:66880708~66882981:+
BRCA	cis	rs2243480	0.808	rs12698508	ENSG00000230295.1	RP11-458F8.2	-5.9	5.01e-09	7.6e-07	-0.24	-0.18	Diabetic kidney disease;	chr7:65946971	chr7:66880708~66882981:+
BRCA	cis	rs7976269	0.609	rs2117993	ENSG00000275476.1	RP11-996F15.4	-5.9	5.01e-09	7.61e-07	-0.21	-0.18	Male-pattern baldness;	chr12:29060041	chr12:29277397~29277882:-
BRCA	cis	rs2239547	0.563	rs9876403	ENSG00000242142.1	SERBP1P3	5.9	5.02e-09	7.62e-07	0.23	0.18	Schizophrenia;	chr3:52882900	chr3:53064283~53065091:-
BRCA	cis	rs2274273	0.745	rs56262555	ENSG00000258413.1	RP11-665C16.6	-5.9	5.02e-09	7.62e-07	-0.23	-0.18	Protein biomarker;	chr14:55095244	chr14:55262767~55272075:-
BRCA	cis	rs2243480	1	rs1499614	ENSG00000229886.1	RP5-1132H15.3	5.9	5.02e-09	7.63e-07	0.31	0.18	Diabetic kidney disease;	chr7:66265811	chr7:66025126~66031544:-
BRCA	cis	rs7914558	1	rs7899084	ENSG00000213061.2	PFN1P11	5.9	5.03e-09	7.63e-07	0.23	0.18	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103112790	chr10:102838011~102845473:-
BRCA	cis	rs4654783	0.521	rs59709264	ENSG00000228397.1	RP1-224A6.3	5.9	5.03e-09	7.63e-07	0.23	0.18	Endometriosis;	chr1:22122832	chr1:22023994~22024968:-
BRCA	cis	rs7246967	0.673	rs2361021	ENSG00000198153.8	ZNF849P	-5.9	5.03e-09	7.64e-07	-0.27	-0.18	Bronchopulmonary dysplasia;	chr19:22633522	chr19:22685167~22686732:+
BRCA	cis	rs7246967	0.611	rs2361022	ENSG00000198153.8	ZNF849P	-5.9	5.03e-09	7.64e-07	-0.27	-0.18	Bronchopulmonary dysplasia;	chr19:22633731	chr19:22685167~22686732:+
BRCA	cis	rs7246967	0.673	rs2361023	ENSG00000198153.8	ZNF849P	-5.9	5.03e-09	7.64e-07	-0.27	-0.18	Bronchopulmonary dysplasia;	chr19:22634065	chr19:22685167~22686732:+
BRCA	cis	rs7897654	0.571	rs12764049	ENSG00000213061.2	PFN1P11	5.9	5.03e-09	7.64e-07	0.27	0.18	Schizophrenia;	chr10:102875199	chr10:102838011~102845473:-
BRCA	cis	rs8114671	0.836	rs2425006	ENSG00000269202.1	RP4-614O4.12	5.9	5.04e-09	7.65e-07	0.18	0.18	Height;	chr20:34983425	chr20:35201747~35203288:-
BRCA	cis	rs7221109	0.585	rs6503547	ENSG00000278834.1	RP11-458J1.1	5.9	5.04e-09	7.65e-07	0.2	0.18	Type 1 diabetes;	chr17:40662956	chr17:40648300~40649718:+
BRCA	cis	rs1823913	0.599	rs12988037	ENSG00000280083.1	RP11-317J9.1	-5.9	5.04e-09	7.65e-07	-0.2	-0.18	Obesity-related traits;	chr2:191306419	chr2:191154118~191156070:-
BRCA	cis	rs4835473	0.897	rs4835454	ENSG00000249741.2	RP11-673E1.3	-5.9	5.04e-09	7.65e-07	-0.19	-0.18	Immature fraction of reticulocytes;	chr4:143730081	chr4:143911514~143912053:-
BRCA	cis	rs34792	0.525	rs12708795	ENSG00000207425.1	Y_RNA	-5.9	5.04e-09	7.65e-07	-0.22	-0.18	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15533861	chr16:14915457~14915556:-
BRCA	cis	rs7246967	0.673	rs4933027	ENSG00000198153.8	ZNF849P	5.9	5.05e-09	7.66e-07	0.26	0.18	Bronchopulmonary dysplasia;	chr19:22721170	chr19:22685167~22686732:+
BRCA	cis	rs2243480	1	rs466983	ENSG00000228409.4	CCT6P1	5.9	5.05e-09	7.67e-07	0.26	0.18	Diabetic kidney disease;	chr7:66055509	chr7:65751142~65763354:+
BRCA	cis	rs6442522	1	rs9847430	ENSG00000249786.6	EAF1-AS1	5.9	5.05e-09	7.67e-07	0.18	0.18	Uric acid levels;	chr3:15408133	chr3:15436171~15455940:-
BRCA	cis	rs4718428	0.705	rs28648401	ENSG00000230295.1	RP11-458F8.2	-5.9	5.06e-09	7.67e-07	-0.17	-0.18	Corneal structure;	chr7:66902145	chr7:66880708~66882981:+
BRCA	cis	rs17301013	0.507	rs55844798	ENSG00000227373.4	RP11-160H22.5	5.89	5.06e-09	7.67e-07	0.27	0.18	Systemic lupus erythematosus;	chr1:174768973	chr1:174115300~174160004:-
BRCA	cis	rs516805	0.748	rs577744	ENSG00000279453.1	RP3-425C14.4	-5.89	5.06e-09	7.67e-07	-0.24	-0.18	Lymphocyte counts;	chr6:122447712	chr6:122436789~122439223:-
BRCA	cis	rs2749097	0.877	rs7519583	ENSG00000244256.3	RN7SL130P	-5.89	5.06e-09	7.67e-07	-0.24	-0.18	Alcohol consumption (transferrin glycosylation);	chr1:63656013	chr1:63655743~63656047:+
BRCA	cis	rs56114371	0.777	rs200483	ENSG00000220721.1	OR1F12	5.89	5.07e-09	7.69e-07	0.31	0.18	Breast cancer;	chr6:27807046	chr6:28073316~28074233:+
BRCA	cis	rs6142102	0.607	rs6088408	ENSG00000275784.1	RP5-1125A11.6	5.89	5.07e-09	7.69e-07	0.23	0.18	Skin pigmentation;	chr20:34146800	chr20:33989480~33991818:-
BRCA	cis	rs1198872	0.892	rs1198864	ENSG00000272275.1	RP11-791G15.2	-5.89	5.07e-09	7.69e-07	-0.22	-0.18	Cardiac Troponin-T levels;	chr2:10760869	chr2:10767875~10770058:-
BRCA	cis	rs1858037	0.867	rs57913336	ENSG00000204929.10	AC074391.1	5.89	5.08e-09	7.7e-07	0.24	0.18	Rheumatoid arthritis;	chr2:65360485	chr2:65436711~66084639:+
BRCA	cis	rs227275	0.554	rs223457	ENSG00000251288.2	RP11-10L12.2	-5.89	5.08e-09	7.71e-07	-0.21	-0.18	Allergic disease (asthma, hay fever or eczema);	chr4:102788506	chr4:102751401~102752641:+
BRCA	cis	rs7615952	1	rs7615952	ENSG00000171084.14	FAM86JP	-5.89	5.09e-09	7.71e-07	-0.29	-0.18	Blood pressure (smoking interaction);	chr3:125930560	chr3:125916620~125930024:+
BRCA	cis	rs10510102	0.935	rs7083278	ENSG00000226864.1	ATE1-AS1	5.89	5.09e-09	7.72e-07	0.32	0.18	Breast cancer;	chr10:121853758	chr10:121928312~121951965:+
BRCA	cis	rs2115630	0.905	rs6496401	ENSG00000229212.6	RP11-561C5.4	5.89	5.09e-09	7.72e-07	0.2	0.18	P wave terminal force;	chr15:84754562	chr15:85205440~85234795:-
BRCA	cis	rs2832191	0.679	rs2705659	ENSG00000176054.6	RPL23P2	5.89	5.09e-09	7.72e-07	0.19	0.18	Dental caries;	chr21:28991587	chr21:28997613~28998033:-
BRCA	cis	rs34792	0.554	rs62039130	ENSG00000207425.1	Y_RNA	-5.89	5.1e-09	7.73e-07	-0.23	-0.18	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15518277	chr16:14915457~14915556:-
BRCA	cis	rs7493	1	rs2299264	ENSG00000233942.1	AC004012.1	5.89	5.1e-09	7.73e-07	0.23	0.18	Yu-Zhi constitution type in type 2 diabetes;	chr7:95417396	chr7:95471835~95473998:+
BRCA	cis	rs10129255	0.957	rs8009464	ENSG00000224373.3	IGHV4-59	5.89	5.1e-09	7.73e-07	0.11	0.18	Kawasaki disease;	chr14:106777611	chr14:106627249~106627825:-
BRCA	cis	rs9307551	0.619	rs11736348	ENSG00000250334.4	LINC00989	-5.89	5.1e-09	7.73e-07	-0.26	-0.18	Refractive error;	chr4:79498711	chr4:79492416~79576460:+
BRCA	cis	rs9527	0.662	rs10786714	ENSG00000236937.2	PTGES3P4	5.89	5.1e-09	7.74e-07	0.25	0.18	Arsenic metabolism;	chr10:102838849	chr10:102845595~102845950:+
BRCA	cis	rs7493	1	rs17876124	ENSG00000233942.1	AC004012.1	5.89	5.1e-09	7.74e-07	0.23	0.18	Yu-Zhi constitution type in type 2 diabetes;	chr7:95415946	chr7:95471835~95473998:+
BRCA	cis	rs7493	0.95	rs56265549	ENSG00000233942.1	AC004012.1	5.89	5.1e-09	7.74e-07	0.23	0.18	Yu-Zhi constitution type in type 2 diabetes;	chr7:95417843	chr7:95471835~95473998:+
BRCA	cis	rs1440410	0.835	rs6827229	ENSG00000250326.1	RP11-284M14.1	-5.89	5.1e-09	7.74e-07	-0.2	-0.18	Ischemic stroke;	chr4:143219223	chr4:142933195~143184861:-
BRCA	cis	rs7819412	0.525	rs10086521	ENSG00000255046.1	RP11-297N6.4	5.89	5.11e-09	7.74e-07	0.22	0.18	Triglycerides;	chr8:10926259	chr8:11797928~11802568:-
BRCA	cis	rs30380	0.69	rs2216752	ENSG00000272109.1	CTD-2260A17.3	5.89	5.11e-09	7.75e-07	0.24	0.18	Cerebrospinal fluid biomarker levels;	chr5:96849764	chr5:96804353~96806105:+
BRCA	cis	rs2732480	0.538	rs2732462	ENSG00000240399.1	RP1-228P16.1	5.89	5.11e-09	7.75e-07	0.21	0.18	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48302601	chr12:48054813~48055591:-
BRCA	cis	rs2288884	1	rs2288884	ENSG00000275055.1	CTC-471J1.11	-5.89	5.11e-09	7.75e-07	-0.27	-0.18	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52029018	chr19:52049007~52049754:+
BRCA	cis	rs7927771	0.524	rs6485763	ENSG00000280615.1	Y_RNA	5.89	5.11e-09	7.75e-07	0.21	0.18	Subjective well-being;	chr11:47605750	chr11:47614898~47614994:-
BRCA	cis	rs10129255	0.5	rs34326748	ENSG00000274576.2	IGHV2-70	-5.89	5.12e-09	7.76e-07	-0.14	-0.18	Kawasaki disease;	chr14:106782523	chr14:106770577~106771020:-
BRCA	cis	rs10129255	0.5	rs10143385	ENSG00000274576.2	IGHV2-70	-5.89	5.12e-09	7.76e-07	-0.14	-0.18	Kawasaki disease;	chr14:106782559	chr14:106770577~106771020:-
BRCA	cis	rs2278034	0.578	rs881753	ENSG00000271662.1	RP11-141C7.3	5.89	5.12e-09	7.76e-07	0.21	0.18	Bronchopulmonary dysplasia;	chr3:195879899	chr3:195650146~195651472:-
BRCA	cis	rs67981189	0.896	rs34763296	ENSG00000258571.1	PTTG4P	-5.89	5.12e-09	7.77e-07	-0.2	-0.18	Schizophrenia;	chr14:71083458	chr14:71085482~71085833:-
BRCA	cis	rs7520050	0.902	rs4638056	ENSG00000280836.1	AL355480.1	5.89	5.14e-09	7.79e-07	0.21	0.18	Reticulocyte count;Red blood cell count;	chr1:45992481	chr1:45581219~45581321:-
BRCA	cis	rs7520050	0.931	rs11576305	ENSG00000280836.1	AL355480.1	5.89	5.14e-09	7.79e-07	0.21	0.18	Reticulocyte count;Red blood cell count;	chr1:45994374	chr1:45581219~45581321:-
BRCA	cis	rs17301013	0.581	rs4652204	ENSG00000227373.4	RP11-160H22.5	5.89	5.14e-09	7.79e-07	0.27	0.18	Systemic lupus erythematosus;	chr1:174150682	chr1:174115300~174160004:-
BRCA	cis	rs559928	0.597	rs2096706	ENSG00000236935.1	AP003774.1	5.89	5.14e-09	7.79e-07	0.25	0.18	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64156974	chr11:64325050~64329504:-
BRCA	cis	rs12501370	0.643	rs17588795	ENSG00000201736.1	RNA5SP160	5.89	5.14e-09	7.8e-07	0.24	0.18	Iris color (L* coordinate);	chr4:41062773	chr4:40990154~40990273:+
BRCA	cis	rs13118159	0.509	rs4974554	ENSG00000254094.1	AC078852.1	-5.89	5.14e-09	7.8e-07	-0.22	-0.18	Longevity;	chr4:1363179	chr4:1356581~1358075:+
BRCA	cis	rs7314031	1	rs7314031	ENSG00000226469.1	ADAM1B	5.89	5.15e-09	7.8e-07	0.28	0.18	Reticulocyte count;Reticulocyte fraction of red cells;	chr12:112392775	chr12:111927018~111929017:+
BRCA	cis	rs2243480	1	rs73142166	ENSG00000230295.1	RP11-458F8.2	-5.89	5.15e-09	7.8e-07	-0.24	-0.18	Diabetic kidney disease;	chr7:65910845	chr7:66880708~66882981:+
BRCA	cis	rs801193	0.591	rs9986881	ENSG00000228409.4	CCT6P1	-5.89	5.15e-09	7.81e-07	-0.16	-0.18	Aortic root size;	chr7:66708053	chr7:65751142~65763354:+
BRCA	cis	rs2842992	1	rs2842992	ENSG00000237927.1	RP3-393E18.2	-5.89	5.15e-09	7.81e-07	-0.25	-0.18	Age-related macular degeneration (geographic atrophy);	chr6:159650127	chr6:159586955~159589169:-
BRCA	cis	rs2288884	1	rs56808319	ENSG00000275055.1	CTC-471J1.11	-5.89	5.15e-09	7.81e-07	-0.27	-0.18	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52074621	chr19:52049007~52049754:+
BRCA	cis	rs2638953	0.672	rs10843203	ENSG00000278733.1	RP11-425D17.1	-5.89	5.16e-09	7.82e-07	-0.24	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28563555	chr12:28185625~28186190:-
BRCA	cis	rs11976180	1	rs1540894	ENSG00000273234.1	OR2A13P	-5.89	5.16e-09	7.82e-07	-0.25	-0.18	Obesity-related traits;	chr7:144070583	chr7:144142009~144142938:+
BRCA	cis	rs10895987	1	rs10895987	ENSG00000254614.2	AP003068.23	-5.89	5.17e-09	7.83e-07	-0.28	-0.18	Blood protein levels;	chr11:65137437	chr11:65177606~65181834:-
BRCA	cis	rs754466	0.58	rs10824576	ENSG00000204049.1	RP11-126H7.4	5.89	5.17e-09	7.84e-07	0.21	0.18	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77806282	chr10:77866875~77869610:+
BRCA	cis	rs651907	0.535	rs61396602	ENSG00000244119.1	PDCL3P4	5.89	5.17e-09	7.84e-07	0.15	0.18	Colorectal cancer;	chr3:101790202	chr3:101712472~101713191:+
BRCA	cis	rs7520050	0.933	rs4504835	ENSG00000280836.1	AL355480.1	5.89	5.18e-09	7.84e-07	0.21	0.18	Reticulocyte count;Red blood cell count;	chr1:45989899	chr1:45581219~45581321:-
BRCA	cis	rs7045881	0.674	rs62542705	ENSG00000254396.1	RP11-56F10.3	5.89	5.18e-09	7.85e-07	0.31	0.18	Schizophrenia;	chr9:27050025	chr9:27102630~27104728:+
BRCA	cis	rs250585	1	rs1610	ENSG00000260136.4	CTD-2270L9.4	-5.89	5.18e-09	7.85e-07	-0.21	-0.18	Egg allergy;	chr16:23570832	chr16:23452758~23457606:+
BRCA	cis	rs295490	0.748	rs79654016	ENSG00000272656.1	RP11-219D15.3	5.89	5.19e-09	7.86e-07	0.42	0.18	PR interval in Tripanosoma cruzi seropositivity;	chr3:139374644	chr3:139349024~139349371:-
BRCA	cis	rs2235642	0.785	rs1057983	ENSG00000280231.1	LA16c-380F5.3	-5.89	5.19e-09	7.86e-07	-0.23	-0.18	Coronary artery disease;	chr16:1610273	chr16:1553655~1554130:-
BRCA	cis	rs9287719	0.649	rs10929683	ENSG00000243819.4	RN7SL832P	-5.89	5.2e-09	7.88e-07	-0.18	-0.18	Prostate cancer;	chr2:10592082	chr2:10690344~10692099:+
BRCA	cis	rs6928977	0.675	rs9399148	ENSG00000231028.7	LINC00271	5.89	5.21e-09	7.89e-07	0.19	0.18	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135523221	chr6:135497801~135716055:+
BRCA	cis	rs67981189	0.752	rs221902	ENSG00000258571.1	PTTG4P	5.89	5.21e-09	7.89e-07	0.2	0.18	Schizophrenia;	chr14:71134362	chr14:71085482~71085833:-
BRCA	cis	rs7246657	0.508	rs1628959	ENSG00000276846.1	CTD-3220F14.3	5.89	5.21e-09	7.9e-07	0.28	0.18	Coronary artery calcification;	chr19:36999474	chr19:37314868~37315620:-
BRCA	cis	rs1823913	0.599	rs55685315	ENSG00000280083.1	RP11-317J9.1	-5.89	5.22e-09	7.91e-07	-0.2	-0.18	Obesity-related traits;	chr2:191306451	chr2:191154118~191156070:-
BRCA	cis	rs2638953	0.853	rs10843191	ENSG00000278733.1	RP11-425D17.1	-5.89	5.23e-09	7.92e-07	-0.24	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28507594	chr12:28185625~28186190:-
BRCA	cis	rs17301013	0.606	rs4652179	ENSG00000227373.4	RP11-160H22.5	5.89	5.23e-09	7.92e-07	0.27	0.18	Systemic lupus erythematosus;	chr1:174107185	chr1:174115300~174160004:-
BRCA	cis	rs17301013	0.581	rs17353198	ENSG00000227373.4	RP11-160H22.5	5.89	5.23e-09	7.92e-07	0.27	0.18	Systemic lupus erythematosus;	chr1:174107439	chr1:174115300~174160004:-
BRCA	cis	rs17301013	0.606	rs17350991	ENSG00000227373.4	RP11-160H22.5	5.89	5.23e-09	7.92e-07	0.27	0.18	Systemic lupus erythematosus;	chr1:174114330	chr1:174115300~174160004:-
BRCA	cis	rs858239	0.669	rs6461688	ENSG00000230042.1	AK3P3	-5.89	5.23e-09	7.93e-07	-0.21	-0.18	Cerebrospinal fluid biomarker levels;	chr7:23076996	chr7:23129178~23129841:+
BRCA	cis	rs10129255	0.5	rs8006888	ENSG00000274576.2	IGHV2-70	-5.89	5.23e-09	7.93e-07	-0.14	-0.18	Kawasaki disease;	chr14:106782219	chr14:106770577~106771020:-
BRCA	cis	rs2243480	1	rs316331	ENSG00000228409.4	CCT6P1	-5.89	5.23e-09	7.93e-07	-0.25	-0.18	Diabetic kidney disease;	chr7:66139635	chr7:65751142~65763354:+
BRCA	cis	rs1552244	1	rs7615764	ENSG00000180385.7	EMC3-AS1	5.89	5.24e-09	7.93e-07	0.23	0.18	Alzheimer's disease;	chr3:10040908	chr3:9986893~10006990:+
BRCA	cis	rs2015599	0.549	rs3782508	ENSG00000257176.2	RP11-996F15.2	5.89	5.24e-09	7.93e-07	0.21	0.18	Platelet count;Mean platelet volume;	chr12:29298446	chr12:29280418~29317848:-
BRCA	cis	rs6479891	1	rs12414159	ENSG00000232075.1	MRPL35P2	5.89	5.24e-09	7.93e-07	0.32	0.18	Arthritis (juvenile idiopathic);	chr10:63479017	chr10:63634317~63634827:-
BRCA	cis	rs6479891	1	rs10995543	ENSG00000232075.1	MRPL35P2	5.89	5.24e-09	7.93e-07	0.32	0.18	Arthritis (juvenile idiopathic);	chr10:63479787	chr10:63634317~63634827:-
BRCA	cis	rs17597773	0.674	rs12089958	ENSG00000272823.1	RP11-295M18.6	-5.89	5.24e-09	7.94e-07	-0.21	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220828021	chr1:220828676~220829211:-
BRCA	cis	rs2098713	0.561	rs4869440	ENSG00000250155.1	CTD-2353F22.1	5.89	5.24e-09	7.94e-07	0.2	0.18	Telomere length;	chr5:37600839	chr5:36666214~36725195:-
BRCA	cis	rs270601	0.739	rs3900945	ENSG00000233006.5	AC034220.3	5.89	5.24e-09	7.94e-07	0.13	0.18	Acylcarnitine levels;	chr5:132257177	chr5:132311285~132369916:-
BRCA	cis	rs7727544	0.684	rs272874	ENSG00000233006.5	AC034220.3	-5.89	5.25e-09	7.95e-07	-0.14	-0.18	Blood metabolite levels;	chr5:132339353	chr5:132311285~132369916:-
BRCA	cis	rs11105298	0.891	rs10858896	ENSG00000270344.2	RP11-734K2.4	5.89	5.25e-09	7.95e-07	0.21	0.18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89526407	chr12:89525654~89548005:+
BRCA	cis	rs11105298	0.786	rs10777186	ENSG00000270344.2	RP11-734K2.4	5.89	5.25e-09	7.95e-07	0.21	0.18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89527500	chr12:89525654~89548005:+
BRCA	cis	rs2732480	0.557	rs923397	ENSG00000257763.1	OR5BK1P	5.89	5.25e-09	7.95e-07	0.19	0.18	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48326609	chr12:48355792~48356614:-
BRCA	cis	rs12468226	0.938	rs6435139	ENSG00000226261.1	AC064836.3	-5.89	5.25e-09	7.95e-07	-0.3	-0.18	Urate levels;	chr2:202255145	chr2:202336024~202336727:-
BRCA	cis	rs2274273	1	rs72718804	ENSG00000258413.1	RP11-665C16.6	-5.89	5.26e-09	7.96e-07	-0.23	-0.18	Protein biomarker;	chr14:55163892	chr14:55262767~55272075:-
BRCA	cis	rs12655019	0.92	rs76797434	ENSG00000271828.1	CTD-2310F14.1	5.89	5.26e-09	7.96e-07	0.34	0.18	Breast cancer (early onset);	chr5:56945862	chr5:56927874~56929573:+
BRCA	cis	rs2153535	0.518	rs9328485	ENSG00000230939.1	RP11-314C16.1	-5.89	5.26e-09	7.96e-07	-0.22	-0.18	Motion sickness;	chr6:8524831	chr6:8784178~8785445:+
BRCA	cis	rs11098499	0.863	rs7669520	ENSG00000249244.1	RP11-548H18.2	5.89	5.26e-09	7.96e-07	0.22	0.18	Corneal astigmatism;	chr4:119594123	chr4:119391831~119395335:-
BRCA	cis	rs10740039	0.516	rs9731224	ENSG00000254271.1	RP11-131N11.4	5.89	5.26e-09	7.97e-07	0.24	0.18	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60583390	chr10:60734342~60741828:+
BRCA	cis	rs2115630	1	rs11854291	ENSG00000229212.6	RP11-561C5.4	5.89	5.27e-09	7.97e-07	0.2	0.18	P wave terminal force;	chr15:84820477	chr15:85205440~85234795:-
BRCA	cis	rs12893668	0.572	rs2273175	ENSG00000269910.1	RP11-73M18.10	5.89	5.27e-09	7.97e-07	0.19	0.18	Reticulocyte count;	chr14:103693804	chr14:103694516~103695050:-
BRCA	cis	rs160451	1	rs160424	ENSG00000251136.7	RP11-37B2.1	5.89	5.27e-09	7.98e-07	0.17	0.18	Leprosy;	chr8:89658452	chr8:89609409~89757727:-
BRCA	cis	rs7809950	0.678	rs982447	ENSG00000238832.1	snoU109	-5.89	5.28e-09	7.99e-07	-0.26	-0.18	Coronary artery disease;	chr7:107333089	chr7:107603363~107603507:+
BRCA	cis	rs10740039	0.516	rs2154392	ENSG00000254271.1	RP11-131N11.4	5.89	5.28e-09	7.99e-07	0.24	0.18	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60557728	chr10:60734342~60741828:+
BRCA	cis	rs17301013	0.606	rs56152378	ENSG00000227373.4	RP11-160H22.5	5.89	5.28e-09	7.99e-07	0.27	0.18	Systemic lupus erythematosus;	chr1:174106480	chr1:174115300~174160004:-
BRCA	cis	rs42490	0.506	rs160429	ENSG00000251136.7	RP11-37B2.1	5.89	5.28e-09	7.99e-07	0.17	0.18	Leprosy;	chr8:89661255	chr8:89609409~89757727:-
BRCA	cis	rs2098713	0.561	rs11949124	ENSG00000250155.1	CTD-2353F22.1	5.89	5.28e-09	7.99e-07	0.2	0.18	Telomere length;	chr5:37590362	chr5:36666214~36725195:-
BRCA	cis	rs2098713	0.561	rs57015453	ENSG00000250155.1	CTD-2353F22.1	5.89	5.28e-09	7.99e-07	0.2	0.18	Telomere length;	chr5:37596878	chr5:36666214~36725195:-
BRCA	cis	rs987724	0.778	rs2321295	ENSG00000240875.4	LINC00886	-5.89	5.29e-09	8e-07	-0.21	-0.18	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156944556	chr3:156747346~156817062:-
BRCA	cis	rs7914558	0.966	rs10748837	ENSG00000213061.2	PFN1P11	5.89	5.29e-09	8e-07	0.23	0.18	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103120479	chr10:102838011~102845473:-
BRCA	cis	rs801193	0.591	rs4506088	ENSG00000224316.1	RP11-479O9.2	-5.89	5.3e-09	8.02e-07	-0.18	-0.18	Aortic root size;	chr7:66670470	chr7:65773620~65802067:+
BRCA	cis	rs7727544	1	rs10076701	ENSG00000233006.5	AC034220.3	5.89	5.3e-09	8.02e-07	0.13	0.18	Blood metabolite levels;	chr5:132260726	chr5:132311285~132369916:-
BRCA	cis	rs2638953	0.924	rs11049384	ENSG00000247934.4	RP11-967K21.1	-5.89	5.3e-09	8.02e-07	-0.23	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28166089	chr12:28163298~28190738:-
BRCA	cis	rs12893668	0.514	rs3212090	ENSG00000269940.1	RP11-73M18.7	5.89	5.3e-09	8.02e-07	0.2	0.18	Reticulocyte count;	chr14:103702526	chr14:103694560~103695170:+
BRCA	cis	rs9880211	0.644	rs6799320	ENSG00000239213.4	NCK1-AS1	5.89	5.31e-09	8.03e-07	0.23	0.18	Height;Body mass index;	chr3:136083597	chr3:136841726~136862054:-
BRCA	cis	rs9880211	0.613	rs9653930	ENSG00000239213.4	NCK1-AS1	5.89	5.31e-09	8.03e-07	0.23	0.18	Height;Body mass index;	chr3:136091472	chr3:136841726~136862054:-
BRCA	cis	rs1713985	0.508	rs1277286	ENSG00000269949.1	RP11-738E22.3	-5.89	5.31e-09	8.03e-07	-0.33	-0.18	Age-related macular degeneration;	chr4:56988132	chr4:56960927~56961373:-
BRCA	cis	rs2638953	0.886	rs7973241	ENSG00000247934.4	RP11-967K21.1	-5.89	5.31e-09	8.03e-07	-0.23	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28207583	chr12:28163298~28190738:-
BRCA	cis	rs77972916	0.505	rs34247383	ENSG00000234936.1	AC010883.5	5.89	5.31e-09	8.04e-07	0.22	0.18	Granulocyte percentage of myeloid white cells;	chr2:43305641	chr2:43229573~43233394:+
BRCA	cis	rs6539247	0.509	rs2374584	ENSG00000257890.1	RP11-114F10.2	-5.89	5.32e-09	8.04e-07	-0.21	-0.18	Attention function in attention deficit hyperactive disorder;	chr12:106052210	chr12:106050961~106058254:-
BRCA	cis	rs1979679	0.842	rs981494	ENSG00000278733.1	RP11-425D17.1	-5.89	5.32e-09	8.04e-07	-0.22	-0.18	Ossification of the posterior longitudinal ligament of the spine;	chr12:28172916	chr12:28185625~28186190:-
BRCA	cis	rs10129255	0.536	rs10142951	ENSG00000274576.2	IGHV2-70	-5.89	5.32e-09	8.05e-07	-0.14	-0.18	Kawasaki disease;	chr14:106782337	chr14:106770577~106771020:-
BRCA	cis	rs11671005	0.735	rs34873624	ENSG00000252334.1	RNU6-1337P	5.89	5.32e-09	8.05e-07	0.27	0.18	Mean platelet volume;	chr19:58432035	chr19:58483749~58483843:-
BRCA	cis	rs11671005	0.735	rs3764529	ENSG00000252334.1	RNU6-1337P	5.89	5.32e-09	8.05e-07	0.27	0.18	Mean platelet volume;	chr19:58433722	chr19:58483749~58483843:-
BRCA	cis	rs2834288	0.536	rs762356	ENSG00000273102.1	AP000569.9	5.89	5.33e-09	8.05e-07	0.21	0.18	Gut microbiota (bacterial taxa);	chr21:33964582	chr21:33967101~33968573:-
BRCA	cis	rs3740713	1	rs35593189	ENSG00000256464.1	YWHABP2	5.89	5.33e-09	8.06e-07	0.31	0.18	Amyotrophic lateral sclerosis (sporadic);	chr11:18446831	chr11:18490243~18490955:-
BRCA	cis	rs2274273	0.638	rs11622636	ENSG00000258413.1	RP11-665C16.6	-5.89	5.33e-09	8.06e-07	-0.25	-0.18	Protein biomarker;	chr14:55181122	chr14:55262767~55272075:-
BRCA	cis	rs1858037	0.867	rs1553675	ENSG00000204929.10	AC074391.1	-5.89	5.33e-09	8.06e-07	-0.24	-0.18	Rheumatoid arthritis;	chr2:65343173	chr2:65436711~66084639:+
BRCA	cis	rs516805	0.667	rs2606624	ENSG00000279453.1	RP3-425C14.4	-5.89	5.34e-09	8.07e-07	-0.26	-0.18	Lymphocyte counts;	chr6:122168693	chr6:122436789~122439223:-
BRCA	cis	rs11671005	0.651	rs11878203	ENSG00000252334.1	RNU6-1337P	5.89	5.34e-09	8.07e-07	0.26	0.18	Mean platelet volume;	chr19:58408683	chr19:58483749~58483843:-
BRCA	cis	rs2638953	0.962	rs2172299	ENSG00000278733.1	RP11-425D17.1	-5.89	5.35e-09	8.08e-07	-0.24	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28280180	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.962	rs11049503	ENSG00000278733.1	RP11-425D17.1	-5.89	5.35e-09	8.08e-07	-0.24	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28282714	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.962	rs61922974	ENSG00000278733.1	RP11-425D17.1	-5.89	5.35e-09	8.08e-07	-0.24	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28283302	chr12:28185625~28186190:-
BRCA	cis	rs35849525	1	rs35849525	ENSG00000228008.1	CTD-2330K9.3	5.89	5.35e-09	8.08e-07	0.21	0.18	Intelligence (multi-trait analysis);	chr3:50029917	chr3:49903845~49916937:+
BRCA	cis	rs6095360	0.727	rs7274612	ENSG00000222365.1	SNORD12B	5.89	5.35e-09	8.09e-07	0.22	0.18	Intelligence (multi-trait analysis);	chr20:49086284	chr20:49280319~49280409:+
BRCA	cis	rs2243480	0.803	rs34804747	ENSG00000164669.11	INTS4P1	5.89	5.36e-09	8.1e-07	0.34	0.18	Diabetic kidney disease;	chr7:65947955	chr7:65141225~65234216:+
BRCA	cis	rs2243480	1	rs59794892	ENSG00000164669.11	INTS4P1	5.89	5.36e-09	8.1e-07	0.34	0.18	Diabetic kidney disease;	chr7:65950886	chr7:65141225~65234216:+
BRCA	cis	rs2243480	0.803	rs36004293	ENSG00000164669.11	INTS4P1	5.89	5.36e-09	8.1e-07	0.34	0.18	Diabetic kidney disease;	chr7:65951525	chr7:65141225~65234216:+
BRCA	cis	rs2243480	0.803	rs35268390	ENSG00000164669.11	INTS4P1	5.89	5.36e-09	8.1e-07	0.34	0.18	Diabetic kidney disease;	chr7:65951549	chr7:65141225~65234216:+
BRCA	cis	rs2243480	0.522	rs12698511	ENSG00000232546.1	RP11-458F8.1	-5.88	5.36e-09	8.1e-07	-0.29	-0.18	Diabetic kidney disease;	chr7:66009932	chr7:66848496~66858136:+
BRCA	cis	rs2638953	0.925	rs61920563	ENSG00000278733.1	RP11-425D17.1	-5.88	5.36e-09	8.1e-07	-0.27	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28332760	chr12:28185625~28186190:-
BRCA	cis	rs67981189	0.896	rs17108804	ENSG00000258571.1	PTTG4P	5.88	5.36e-09	8.11e-07	0.2	0.18	Schizophrenia;	chr14:70974807	chr14:71085482~71085833:-
BRCA	cis	rs2832191	0.692	rs8134627	ENSG00000176054.6	RPL23P2	-5.88	5.37e-09	8.12e-07	-0.19	-0.18	Dental caries;	chr21:28976747	chr21:28997613~28998033:-
BRCA	cis	rs4699052	1	rs6533059	ENSG00000248740.4	RP11-328K4.1	5.88	5.37e-09	8.12e-07	0.2	0.18	Testicular germ cell tumor;	chr4:103212219	chr4:103256159~103453658:+
BRCA	cis	rs2243480	1	rs73150014	ENSG00000230295.1	RP11-458F8.2	-5.88	5.37e-09	8.12e-07	-0.24	-0.18	Diabetic kidney disease;	chr7:65985932	chr7:66880708~66882981:+
BRCA	cis	rs56104184	0.775	rs73061689	ENSG00000235191.1	NUCB1-AS1	5.88	5.37e-09	8.12e-07	0.33	0.18	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr19:48893957	chr19:48910930~48918891:-
BRCA	cis	rs56104184	0.775	rs73061692	ENSG00000235191.1	NUCB1-AS1	5.88	5.37e-09	8.12e-07	0.33	0.18	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr19:48896419	chr19:48910930~48918891:-
BRCA	cis	rs10129255	0.701	rs2005643	ENSG00000224373.3	IGHV4-59	5.88	5.38e-09	8.12e-07	0.11	0.18	Kawasaki disease;	chr14:106676288	chr14:106627249~106627825:-
BRCA	cis	rs56104184	0.615	rs73061693	ENSG00000235191.1	NUCB1-AS1	5.88	5.38e-09	8.13e-07	0.33	0.18	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr19:48896684	chr19:48910930~48918891:-
BRCA	cis	rs56104184	0.775	rs73061694	ENSG00000235191.1	NUCB1-AS1	5.88	5.38e-09	8.13e-07	0.33	0.18	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr19:48896721	chr19:48910930~48918891:-
BRCA	cis	rs56104184	0.775	rs73061695	ENSG00000235191.1	NUCB1-AS1	5.88	5.38e-09	8.13e-07	0.33	0.18	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr19:48896731	chr19:48910930~48918891:-
BRCA	cis	rs56104184	0.775	rs73061697	ENSG00000235191.1	NUCB1-AS1	5.88	5.38e-09	8.13e-07	0.33	0.18	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr19:48896743	chr19:48910930~48918891:-
BRCA	cis	rs651907	0.535	rs34743741	ENSG00000244119.1	PDCL3P4	5.88	5.38e-09	8.13e-07	0.15	0.18	Colorectal cancer;	chr3:101813604	chr3:101712472~101713191:+
BRCA	cis	rs934734	0.673	rs7575614	ENSG00000204929.10	AC074391.1	5.88	5.38e-09	8.13e-07	0.22	0.18	Rheumatoid arthritis;	chr2:65462666	chr2:65436711~66084639:+
BRCA	cis	rs6738825	0.565	rs3792158	ENSG00000231621.1	AC013264.2	-5.88	5.39e-09	8.14e-07	-0.17	-0.18	Crohn's disease;	chr2:197542453	chr2:197197991~197199273:+
BRCA	cis	rs7555523	1	rs7555523	ENSG00000224358.1	RP11-466F5.8	-5.88	5.39e-09	8.14e-07	-0.32	-0.18	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165749742	chr1:165768929~165775176:+
BRCA	cis	rs2904967	1	rs487989	ENSG00000254614.2	AP003068.23	5.88	5.39e-09	8.15e-07	0.33	0.18	Mean corpuscular volume;	chr11:65297219	chr11:65177606~65181834:-
BRCA	cis	rs1614887	1	rs1614887	ENSG00000124549.13	BTN2A3P	5.88	5.39e-09	8.15e-07	0.19	0.18	Lobe attachment (rater-scored or self-reported);Intelligence (multi-trait analysis);	chr6:26392793	chr6:26421391~26432383:+
BRCA	cis	rs8054556	0.539	rs12596543	ENSG00000273724.1	RP11-347C12.12	-5.88	5.39e-09	8.15e-07	-0.2	-0.18	Autism spectrum disorder or schizophrenia;	chr16:30017814	chr16:30336400~30343336:+
BRCA	cis	rs6088813	1	rs2425066	ENSG00000126005.14	MMP24-AS1	-5.88	5.4e-09	8.15e-07	-0.21	-0.18	Height;	chr20:35339203	chr20:35216462~35278131:-
BRCA	cis	rs6688613	0.84	rs6660048	ENSG00000225171.2	DUTP6	5.88	5.4e-09	8.16e-07	0.23	0.18	Refractive astigmatism;	chr1:166984949	chr1:166868748~166869209:+
BRCA	cis	rs858239	0.633	rs858300	ENSG00000230042.1	AK3P3	-5.88	5.4e-09	8.16e-07	-0.21	-0.18	Cerebrospinal fluid biomarker levels;	chr7:23205012	chr7:23129178~23129841:+
BRCA	cis	rs11105298	0.891	rs10858894	ENSG00000270344.2	RP11-734K2.4	5.88	5.4e-09	8.16e-07	0.21	0.18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89520484	chr12:89525654~89548005:+
BRCA	cis	rs11105298	0.891	rs11105310	ENSG00000270344.2	RP11-734K2.4	5.88	5.4e-09	8.16e-07	0.21	0.18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89524900	chr12:89525654~89548005:+
BRCA	cis	rs13126694	0.71	rs13137826	ENSG00000251429.1	RP11-597D13.7	5.88	5.41e-09	8.16e-07	0.17	0.18	Blood osmolality (transformed sodium);	chr4:158001354	chr4:158270378~158278676:+
BRCA	cis	rs4664293	0.769	rs1365798	ENSG00000226266.5	AC009961.3	5.88	5.41e-09	8.17e-07	0.23	0.18	Monocyte percentage of white cells;	chr2:159795853	chr2:159670708~159712435:-
BRCA	cis	rs9527	0.615	rs4919685	ENSG00000236937.2	PTGES3P4	5.88	5.41e-09	8.18e-07	0.26	0.18	Arsenic metabolism;	chr10:102827605	chr10:102845595~102845950:+
BRCA	cis	rs6479891	1	rs61853336	ENSG00000232075.1	MRPL35P2	5.88	5.41e-09	8.18e-07	0.33	0.18	Arthritis (juvenile idiopathic);	chr10:63140115	chr10:63634317~63634827:-
BRCA	cis	rs2562152	0.706	rs216598	ENSG00000226942.2	IL9RP3	-5.88	5.43e-09	8.21e-07	-0.28	-0.18	Glioblastoma;	chr16:58586	chr16:29336~38321:-
BRCA	cis	rs651907	0.535	rs2290859	ENSG00000244119.1	PDCL3P4	5.88	5.44e-09	8.21e-07	0.15	0.18	Colorectal cancer;	chr3:101806781	chr3:101712472~101713191:+
BRCA	cis	rs8103033	0.824	rs35457488	ENSG00000268088.1	AC093063.2	-5.88	5.44e-09	8.21e-07	-0.19	-0.18	Obesity-related traits;	chr19:39646532	chr19:39693925~39696258:+
BRCA	cis	rs2243480	0.803	rs55700941	ENSG00000232559.3	GS1-124K5.12	5.88	5.44e-09	8.21e-07	0.34	0.18	Diabetic kidney disease;	chr7:65924813	chr7:66554588~66576923:-
BRCA	cis	rs9652601	0.622	rs17804470	ENSG00000274038.1	RP11-66H6.4	-5.88	5.44e-09	8.21e-07	-0.19	-0.18	Systemic lupus erythematosus;	chr16:11006111	chr16:11056556~11057034:+
BRCA	cis	rs1124769	0.719	rs12916845	ENSG00000259378.1	DCAF13P3	5.88	5.44e-09	8.22e-07	0.24	0.18	Cognitive performance;	chr15:50936255	chr15:50944663~50945996:+
BRCA	cis	rs12681366	0.708	rs2930962	ENSG00000253704.1	RP11-267M23.4	5.88	5.44e-09	8.22e-07	0.19	0.18	Nonsyndromic cleft lip with cleft palate;	chr8:94433277	chr8:94553722~94569745:+
BRCA	cis	rs2243480	1	rs313809	ENSG00000232559.3	GS1-124K5.12	5.88	5.45e-09	8.22e-07	0.34	0.18	Diabetic kidney disease;	chr7:66034996	chr7:66554588~66576923:-
BRCA	cis	rs5758511	0.773	rs62240997	ENSG00000205702.9	CYP2D7	5.88	5.45e-09	8.23e-07	0.18	0.18	Birth weight;	chr22:41958563	chr22:42140203~42144577:-
BRCA	cis	rs5015933	0.801	rs3104546	ENSG00000232630.1	PRPS1P2	-5.88	5.45e-09	8.24e-07	-0.18	-0.18	Body mass index;	chr9:125375390	chr9:125150653~125151589:+
BRCA	cis	rs72681920	0.881	rs12504443	ENSG00000246090.5	RP11-696N14.1	-5.88	5.46e-09	8.24e-07	-0.3	-0.18	Alcohol dependence;	chr4:99252001	chr4:99088857~99301356:+
BRCA	cis	rs7688540	0.771	rs7665727	ENSG00000211553.1	AC253576.2	-5.88	5.46e-09	8.24e-07	-0.28	-0.18	Facial morphology (factor 6, height of vermillion lower lip);	chr4:283268	chr4:136461~136568:+
BRCA	cis	rs1124769	0.719	rs7176496	ENSG00000259378.1	DCAF13P3	5.88	5.46e-09	8.24e-07	0.24	0.18	Cognitive performance;	chr15:50944640	chr15:50944663~50945996:+
BRCA	cis	rs7772486	0.686	rs1292337	ENSG00000270638.1	RP3-466P17.1	-5.88	5.46e-09	8.24e-07	-0.2	-0.18	Lobe attachment (rater-scored or self-reported);	chr6:145646671	chr6:145735570~145737218:+
BRCA	cis	rs3126085	0.935	rs1496049	ENSG00000237975.5	FLG-AS1	5.88	5.47e-09	8.25e-07	0.25	0.18	Atopic dermatitis;	chr1:152189473	chr1:152168125~152445456:+
BRCA	cis	rs2803122	0.846	rs10738535	ENSG00000273226.1	RP11-513M16.8	-5.88	5.47e-09	8.25e-07	-0.19	-0.18	Pulse pressure;	chr9:19299364	chr9:19375451~19375996:+
BRCA	cis	rs10510102	0.516	rs12244921	ENSG00000276742.1	RP11-500G22.4	5.88	5.47e-09	8.26e-07	0.31	0.18	Breast cancer;	chr10:121990342	chr10:121956782~121957098:+
BRCA	cis	rs4763879	0.778	rs9332411	ENSG00000214776.8	RP11-726G1.1	-5.88	5.47e-09	8.26e-07	-0.2	-0.18	Type 1 diabetes;	chr12:9681749	chr12:9467552~9576275:+
BRCA	cis	rs2749097	1	rs61765315	ENSG00000244256.3	RN7SL130P	-5.88	5.48e-09	8.26e-07	-0.26	-0.18	Alcohol consumption (transferrin glycosylation);	chr1:63662638	chr1:63655743~63656047:+
BRCA	cis	rs250585	0.736	rs30015	ENSG00000260136.4	CTD-2270L9.4	5.88	5.48e-09	8.27e-07	0.18	0.18	Egg allergy;	chr16:23402453	chr16:23452758~23457606:+
BRCA	cis	rs6479891	1	rs12414796	ENSG00000232075.1	MRPL35P2	5.88	5.48e-09	8.27e-07	0.32	0.18	Arthritis (juvenile idiopathic);	chr10:63543327	chr10:63634317~63634827:-
BRCA	cis	rs7923609	0.869	rs9971352	ENSG00000232075.1	MRPL35P2	-5.88	5.48e-09	8.27e-07	-0.22	-0.18	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63505348	chr10:63634317~63634827:-
BRCA	cis	rs2243480	1	rs34933526	ENSG00000232546.1	RP11-458F8.1	-5.88	5.48e-09	8.27e-07	-0.23	-0.18	Diabetic kidney disease;	chr7:65918212	chr7:66848496~66858136:+
BRCA	cis	rs2243480	1	rs6949812	ENSG00000232546.1	RP11-458F8.1	-5.88	5.48e-09	8.27e-07	-0.23	-0.18	Diabetic kidney disease;	chr7:65922114	chr7:66848496~66858136:+
BRCA	cis	rs2243480	1	rs6970243	ENSG00000232546.1	RP11-458F8.1	-5.88	5.48e-09	8.27e-07	-0.23	-0.18	Diabetic kidney disease;	chr7:65923503	chr7:66848496~66858136:+
BRCA	cis	rs2243480	0.708	rs35310401	ENSG00000232546.1	RP11-458F8.1	-5.88	5.48e-09	8.27e-07	-0.23	-0.18	Diabetic kidney disease;	chr7:65925372	chr7:66848496~66858136:+
BRCA	cis	rs2243480	0.831	rs7806717	ENSG00000232546.1	RP11-458F8.1	5.88	5.48e-09	8.27e-07	0.23	0.18	Diabetic kidney disease;	chr7:65928187	chr7:66848496~66858136:+
BRCA	cis	rs7201929	1	rs8061877	ENSG00000251417.2	RP11-1348G14.4	5.88	5.49e-09	8.28e-07	0.22	0.18	QT interval;	chr16:28845498	chr16:28802743~28817828:+
BRCA	cis	rs12612619	0.732	rs1078809	ENSG00000229122.1	AGBL5-IT1	5.88	5.49e-09	8.28e-07	0.19	0.18	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27066047	chr2:27061038~27061815:+
BRCA	cis	rs516805	0.667	rs2606610	ENSG00000279453.1	RP3-425C14.4	-5.88	5.49e-09	8.29e-07	-0.26	-0.18	Lymphocyte counts;	chr6:122189959	chr6:122436789~122439223:-
BRCA	cis	rs17711722	0.523	rs365896	ENSG00000237310.1	GS1-124K5.4	-5.88	5.5e-09	8.29e-07	-0.19	-0.18	Calcium levels;	chr7:66045710	chr7:66493706~66495474:+
BRCA	cis	rs2243480	0.808	rs12698508	ENSG00000164669.11	INTS4P1	5.88	5.5e-09	8.3e-07	0.35	0.18	Diabetic kidney disease;	chr7:65946971	chr7:65141225~65234216:+
BRCA	cis	rs2638953	0.962	rs11049493	ENSG00000278733.1	RP11-425D17.1	-5.88	5.51e-09	8.31e-07	-0.24	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28263115	chr12:28185625~28186190:-
BRCA	cis	rs10129255	0.957	rs10142859	ENSG00000224373.3	IGHV4-59	5.88	5.51e-09	8.31e-07	0.11	0.18	Kawasaki disease;	chr14:106782238	chr14:106627249~106627825:-
BRCA	cis	rs853679	0.607	rs34166054	ENSG00000220721.1	OR1F12	5.88	5.51e-09	8.31e-07	0.44	0.18	Depression;	chr6:28098023	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.607	rs13203816	ENSG00000220721.1	OR1F12	5.88	5.51e-09	8.31e-07	0.44	0.18	Depression;	chr6:28111820	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.556	rs34588114	ENSG00000220721.1	OR1F12	5.88	5.51e-09	8.31e-07	0.44	0.18	Depression;	chr6:28112850	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.607	rs68188794	ENSG00000220721.1	OR1F12	5.88	5.51e-09	8.31e-07	0.44	0.18	Depression;	chr6:28112999	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.546	rs34371502	ENSG00000220721.1	OR1F12	5.88	5.51e-09	8.31e-07	0.44	0.18	Depression;	chr6:28113980	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.607	rs66886492	ENSG00000220721.1	OR1F12	5.88	5.51e-09	8.31e-07	0.44	0.18	Depression;	chr6:28121953	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.607	rs35345226	ENSG00000220721.1	OR1F12	5.88	5.51e-09	8.31e-07	0.44	0.18	Depression;	chr6:28123802	chr6:28073316~28074233:+
BRCA	cis	rs7474896	0.537	rs1779068	ENSG00000226578.1	RP11-258F22.1	5.88	5.51e-09	8.31e-07	0.24	0.18	Obesity (extreme);	chr10:37961857	chr10:37775371~37784131:-
BRCA	cis	rs7789940	1	rs758944	ENSG00000186704.9	DTX2P1	5.88	5.51e-09	8.32e-07	0.22	0.18	Multiple sclerosis;	chr7:76323980	chr7:76978617~77004308:+
BRCA	cis	rs11168351	1	rs11168351	ENSG00000240399.1	RP1-228P16.1	5.88	5.51e-09	8.32e-07	0.21	0.18	Bipolar disorder and schizophrenia;	chr12:48009982	chr12:48054813~48055591:-
BRCA	cis	rs8002861	0.84	rs1819597	ENSG00000274001.1	RP11-5G9.5	5.88	5.51e-09	8.32e-07	0.2	0.18	Leprosy;	chr13:43855417	chr13:43877715~43878163:-
BRCA	cis	rs8002861	0.84	rs1819596	ENSG00000274001.1	RP11-5G9.5	5.88	5.51e-09	8.32e-07	0.2	0.18	Leprosy;	chr13:43855418	chr13:43877715~43878163:-
BRCA	cis	rs11148252	0.819	rs7336679	ENSG00000278238.1	RP11-245D16.4	-5.88	5.52e-09	8.32e-07	-0.19	-0.18	Lewy body disease;	chr13:52469198	chr13:52454775~52455331:-
BRCA	cis	rs7829975	0.686	rs907180	ENSG00000254153.1	CTA-398F10.2	5.88	5.52e-09	8.32e-07	0.21	0.18	Mood instability;	chr8:8845317	chr8:8456909~8461337:-
BRCA	cis	rs1499614	1	rs1267817	ENSG00000228409.4	CCT6P1	5.88	5.52e-09	8.33e-07	0.25	0.18	Gout;	chr7:66645053	chr7:65751142~65763354:+
BRCA	cis	rs9907295	1	rs9913488	ENSG00000271013.1	AC015849.15	-5.88	5.53e-09	8.33e-07	-0.27	-0.18	Fibroblast growth factor basic levels;	chr17:35906447	chr17:35912635~35918010:-
BRCA	cis	rs9907295	1	rs9912571	ENSG00000271013.1	AC015849.15	-5.88	5.53e-09	8.33e-07	-0.27	-0.18	Fibroblast growth factor basic levels;	chr17:35906782	chr17:35912635~35918010:-
BRCA	cis	rs9907295	1	rs9912793	ENSG00000271013.1	AC015849.15	-5.88	5.53e-09	8.33e-07	-0.27	-0.18	Fibroblast growth factor basic levels;	chr17:35906867	chr17:35912635~35918010:-
BRCA	cis	rs17597773	0.674	rs2279638	ENSG00000272823.1	RP11-295M18.6	-5.88	5.53e-09	8.34e-07	-0.21	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220828445	chr1:220828676~220829211:-
BRCA	cis	rs7493	0.851	rs11770903	ENSG00000233942.1	AC004012.1	5.88	5.53e-09	8.35e-07	0.23	0.18	Yu-Zhi constitution type in type 2 diabetes;	chr7:95397015	chr7:95471835~95473998:+
BRCA	cis	rs13126694	0.62	rs6844184	ENSG00000248429.4	RP11-597D13.9	5.88	5.53e-09	8.35e-07	0.16	0.18	Blood osmolality (transformed sodium);	chr4:158094156	chr4:158170752~158202877:+
BRCA	cis	rs7044106	0.791	rs4836830	ENSG00000238181.2	AHCYP2	-5.88	5.54e-09	8.35e-07	-0.23	-0.18	Hip circumference adjusted for BMI;	chr9:120721390	chr9:120720673~120721972:+
BRCA	cis	rs911555	0.755	rs6575988	ENSG00000244691.1	RPL10AP1	5.88	5.54e-09	8.36e-07	0.23	0.18	Intelligence (multi-trait analysis);	chr14:103434490	chr14:103412119~103412761:-
BRCA	cis	rs11098499	0.913	rs67073020	ENSG00000249244.1	RP11-548H18.2	5.88	5.54e-09	8.36e-07	0.22	0.18	Corneal astigmatism;	chr4:119231402	chr4:119391831~119395335:-
BRCA	cis	rs2243480	1	rs781142	ENSG00000232546.1	RP11-458F8.1	-5.88	5.55e-09	8.37e-07	-0.23	-0.18	Diabetic kidney disease;	chr7:65973791	chr7:66848496~66858136:+
BRCA	cis	rs12893668	0.572	rs11540512	ENSG00000269940.1	RP11-73M18.7	5.88	5.56e-09	8.38e-07	0.2	0.18	Reticulocyte count;	chr14:103681040	chr14:103694560~103695170:+
BRCA	cis	rs10510102	0.872	rs12259144	ENSG00000226864.1	ATE1-AS1	5.88	5.56e-09	8.38e-07	0.34	0.18	Breast cancer;	chr10:121965433	chr10:121928312~121951965:+
BRCA	cis	rs516805	0.748	rs577744	ENSG00000279114.1	RP3-425C14.5	-5.88	5.56e-09	8.38e-07	-0.22	-0.18	Lymphocyte counts;	chr6:122447712	chr6:122471923~122484161:+
BRCA	cis	rs42648	0.564	rs7777651	ENSG00000225498.1	AC002064.5	5.88	5.56e-09	8.38e-07	0.17	0.18	Homocysteine levels;	chr7:90193030	chr7:90312496~90322592:+
BRCA	cis	rs7577696	0.597	rs375050	ENSG00000272716.1	RP11-563N4.1	5.88	5.56e-09	8.39e-07	0.21	0.18	Inflammatory biomarkers;	chr2:32188696	chr2:32165046~32165757:-
BRCA	cis	rs6688613	0.759	rs61815132	ENSG00000225171.2	DUTP6	-5.88	5.57e-09	8.4e-07	-0.25	-0.18	Refractive astigmatism;	chr1:166951674	chr1:166868748~166869209:+
BRCA	cis	rs7238033	0.609	rs28898869	ENSG00000267193.4	RP11-116O18.3	5.88	5.57e-09	8.4e-07	0.19	0.18	Bladder cancer;	chr18:45735626	chr18:45669367~45747215:-
BRCA	cis	rs783540	0.5	rs1313494	ENSG00000278603.1	RP13-608F4.5	-5.88	5.58e-09	8.41e-07	-0.27	-0.18	Schizophrenia;	chr15:82605530	chr15:82472203~82472426:+
BRCA	cis	rs4372836	0.929	rs11675572	ENSG00000226833.4	AC097724.3	-5.88	5.58e-09	8.41e-07	-0.23	-0.18	Body mass index;	chr2:28708510	chr2:28708953~28736205:-
BRCA	cis	rs2153535	0.585	rs9392233	ENSG00000230939.1	RP11-314C16.1	-5.88	5.58e-09	8.41e-07	-0.21	-0.18	Motion sickness;	chr6:8645042	chr6:8784178~8785445:+
BRCA	cis	rs6479891	1	rs11814792	ENSG00000232075.1	MRPL35P2	5.88	5.58e-09	8.41e-07	0.32	0.18	Arthritis (juvenile idiopathic);	chr10:63157799	chr10:63634317~63634827:-
BRCA	cis	rs6479891	1	rs12413415	ENSG00000232075.1	MRPL35P2	5.88	5.58e-09	8.41e-07	0.32	0.18	Arthritis (juvenile idiopathic);	chr10:63159751	chr10:63634317~63634827:-
BRCA	cis	rs9291683	0.546	rs6829727	ENSG00000250413.1	RP11-448G15.1	-5.88	5.58e-09	8.41e-07	-0.24	-0.18	Bone mineral density;	chr4:10050048	chr4:10006482~10009725:+
BRCA	cis	rs12893668	0.572	rs4906356	ENSG00000269940.1	RP11-73M18.7	5.88	5.58e-09	8.41e-07	0.2	0.18	Reticulocyte count;	chr14:103672364	chr14:103694560~103695170:+
BRCA	cis	rs11159086	0.793	rs11621693	ENSG00000270000.1	RP3-449M8.9	5.88	5.58e-09	8.42e-07	0.27	0.18	Advanced glycation end-product levels;	chr14:74472631	chr14:74471930~74472360:-
BRCA	cis	rs2562456	0.917	rs11085463	ENSG00000268081.1	RP11-678G14.2	5.88	5.58e-09	8.42e-07	0.26	0.18	Pain;	chr19:21568500	chr19:21554640~21569237:-
BRCA	cis	rs2810114	0.76	rs2810105	ENSG00000258571.1	PTTG4P	5.88	5.59e-09	8.42e-07	0.21	0.18	Alcohol dependence;	chr14:70957934	chr14:71085482~71085833:-
BRCA	cis	rs2235642	0.691	rs2281235	ENSG00000280231.1	LA16c-380F5.3	-5.88	5.59e-09	8.43e-07	-0.23	-0.18	Coronary artery disease;	chr16:1553534	chr16:1553655~1554130:-
BRCA	cis	rs853679	0.505	rs200992	ENSG00000220721.1	OR1F12	5.88	5.59e-09	8.43e-07	0.33	0.18	Depression;	chr6:27846899	chr6:28073316~28074233:+
BRCA	cis	rs2239547	0.522	rs2336669	ENSG00000242142.1	SERBP1P3	-5.88	5.6e-09	8.44e-07	-0.22	-0.18	Schizophrenia;	chr3:52960122	chr3:53064283~53065091:-
BRCA	cis	rs1552244	0.748	rs113890152	ENSG00000180385.7	EMC3-AS1	5.88	5.61e-09	8.45e-07	0.23	0.18	Alzheimer's disease;	chr3:10044302	chr3:9986893~10006990:+
BRCA	cis	rs4835473	0.932	rs7664248	ENSG00000249741.2	RP11-673E1.3	-5.88	5.61e-09	8.45e-07	-0.19	-0.18	Immature fraction of reticulocytes;	chr4:143732554	chr4:143911514~143912053:-
BRCA	cis	rs2243480	1	rs316329	ENSG00000228409.4	CCT6P1	5.88	5.62e-09	8.47e-07	0.24	0.18	Diabetic kidney disease;	chr7:66143429	chr7:65751142~65763354:+
BRCA	cis	rs2243480	0.711	rs1626926	ENSG00000164669.11	INTS4P1	5.88	5.62e-09	8.47e-07	0.34	0.18	Diabetic kidney disease;	chr7:65970805	chr7:65141225~65234216:+
BRCA	cis	rs7688540	0.8	rs6837796	ENSG00000275426.1	CH17-262A2.1	5.88	5.62e-09	8.47e-07	0.22	0.18	Facial morphology (factor 6, height of vermillion lower lip);	chr4:278733	chr4:149738~150317:+
BRCA	cis	rs9341808	0.754	rs9294173	ENSG00000272129.1	RP11-250B2.6	5.88	5.62e-09	8.47e-07	0.22	0.18	Sitting height ratio;	chr6:80281913	chr6:80355424~80356859:+
BRCA	cis	rs12893668	0.603	rs12896171	ENSG00000269940.1	RP11-73M18.7	5.88	5.62e-09	8.47e-07	0.2	0.18	Reticulocyte count;	chr14:103669629	chr14:103694560~103695170:+
BRCA	cis	rs2303759	0.626	rs12982246	ENSG00000268686.1	AC010524.2	-5.88	5.62e-09	8.47e-07	-0.28	-0.18	Multiple sclerosis;	chr19:49297912	chr19:49368705~49388081:-
BRCA	cis	rs35612822	0.897	rs2738290	ENSG00000232485.2	AC098820.3	5.88	5.62e-09	8.47e-07	0.22	0.18	Kidney disease (early stage) in type 1 diabetes;	chr2:216487530	chr2:216479030~216498761:-
BRCA	cis	rs11105298	0.786	rs10858867	ENSG00000270344.2	RP11-734K2.4	5.88	5.63e-09	8.48e-07	0.21	0.18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89457389	chr12:89525654~89548005:+
BRCA	cis	rs11105298	0.786	rs3803128	ENSG00000270344.2	RP11-734K2.4	5.88	5.63e-09	8.48e-07	0.21	0.18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89466542	chr12:89525654~89548005:+
BRCA	cis	rs11105298	0.891	rs10506972	ENSG00000270344.2	RP11-734K2.4	5.88	5.63e-09	8.48e-07	0.21	0.18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89467752	chr12:89525654~89548005:+
BRCA	cis	rs11105298	0.891	rs12228177	ENSG00000270344.2	RP11-734K2.4	5.88	5.63e-09	8.48e-07	0.21	0.18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89468253	chr12:89525654~89548005:+
BRCA	cis	rs3893377	0.848	rs10023845	ENSG00000214846.4	RP11-115L11.1	-5.88	5.63e-09	8.49e-07	-0.24	-0.18	Current cigarettes per day in chronic obstructive pulmonary disease;	chr4:15739628	chr4:15730962~15731627:-
BRCA	cis	rs6442522	1	rs13075694	ENSG00000249786.6	EAF1-AS1	5.88	5.64e-09	8.5e-07	0.18	0.18	Uric acid levels;	chr3:15408893	chr3:15436171~15455940:-
BRCA	cis	rs6442522	1	rs13075773	ENSG00000249786.6	EAF1-AS1	5.88	5.64e-09	8.5e-07	0.18	0.18	Uric acid levels;	chr3:15409062	chr3:15436171~15455940:-
BRCA	cis	rs7587476	0.906	rs17487792	ENSG00000229267.2	AC072062.1	5.88	5.64e-09	8.5e-07	0.26	0.18	Neuroblastoma;	chr2:214778776	chr2:214810229~214963274:+
BRCA	cis	rs4713118	0.738	rs200465	ENSG00000220721.1	OR1F12	5.88	5.64e-09	8.5e-07	0.22	0.18	Parkinson's disease;	chr6:27789875	chr6:28073316~28074233:+
BRCA	cis	rs4787491	0.704	rs35605010	ENSG00000273724.1	RP11-347C12.12	-5.88	5.64e-09	8.5e-07	-0.2	-0.18	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30022107	chr16:30336400~30343336:+
BRCA	cis	rs250585	0.703	rs7204605	ENSG00000260136.4	CTD-2270L9.4	-5.88	5.64e-09	8.5e-07	-0.2	-0.18	Egg allergy;	chr16:23542259	chr16:23452758~23457606:+
BRCA	cis	rs910316	0.967	rs175498	ENSG00000279594.1	RP11-950C14.10	-5.88	5.65e-09	8.51e-07	-0.2	-0.18	Height;	chr14:75069666	chr14:75011269~75012851:-
BRCA	cis	rs9907295	0.901	rs4796118	ENSG00000270977.1	AC015849.16	-5.88	5.65e-09	8.51e-07	-0.29	-0.18	Fibroblast growth factor basic levels;	chr17:35858804	chr17:35893707~35911023:-
BRCA	cis	rs13126694	0.75	rs6833295	ENSG00000251429.1	RP11-597D13.7	5.88	5.65e-09	8.52e-07	0.17	0.18	Blood osmolality (transformed sodium);	chr4:158143520	chr4:158270378~158278676:+
BRCA	cis	rs2288884	1	rs12609219	ENSG00000275055.1	CTC-471J1.11	-5.88	5.65e-09	8.52e-07	-0.27	-0.18	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52077743	chr19:52049007~52049754:+
BRCA	cis	rs10761482	0.5	rs1892547	ENSG00000254271.1	RP11-131N11.4	5.88	5.66e-09	8.52e-07	0.24	0.18	Schizophrenia;	chr10:60533200	chr10:60734342~60741828:+
BRCA	cis	rs867371	0.519	rs1566560	ENSG00000255769.6	GOLGA2P10	-5.88	5.66e-09	8.52e-07	-0.2	-0.18	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82232116	chr15:82472993~82513950:-
BRCA	cis	rs867371	0.519	rs1566559	ENSG00000255769.6	GOLGA2P10	-5.88	5.66e-09	8.52e-07	-0.2	-0.18	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82232120	chr15:82472993~82513950:-
BRCA	cis	rs11098499	0.82	rs11737395	ENSG00000249244.1	RP11-548H18.2	5.88	5.66e-09	8.53e-07	0.22	0.18	Corneal astigmatism;	chr4:119599549	chr4:119391831~119395335:-
BRCA	cis	rs7246657	0.525	rs10405238	ENSG00000226686.6	LINC01535	-5.88	5.66e-09	8.53e-07	-0.3	-0.18	Coronary artery calcification;	chr19:36997153	chr19:37251912~37265535:+
BRCA	cis	rs7976269	0.559	rs10771471	ENSG00000275476.1	RP11-996F15.4	-5.88	5.67e-09	8.54e-07	-0.2	-0.18	Male-pattern baldness;	chr12:29050894	chr12:29277397~29277882:-
BRCA	cis	rs2638953	0.815	rs7139060	ENSG00000278733.1	RP11-425D17.1	-5.88	5.67e-09	8.54e-07	-0.22	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28540211	chr12:28185625~28186190:-
BRCA	cis	rs2243480	1	rs35432774	ENSG00000164669.11	INTS4P1	5.88	5.67e-09	8.54e-07	0.34	0.18	Diabetic kidney disease;	chr7:65928032	chr7:65141225~65234216:+
BRCA	cis	rs755249	0.567	rs3754346	ENSG00000237624.1	OXCT2P1	5.88	5.67e-09	8.54e-07	0.26	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39349288	chr1:39514956~39516490:+
BRCA	cis	rs755249	0.567	rs16826093	ENSG00000237624.1	OXCT2P1	5.88	5.67e-09	8.54e-07	0.26	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39349471	chr1:39514956~39516490:+
BRCA	cis	rs755249	0.567	rs17264671	ENSG00000237624.1	OXCT2P1	5.88	5.67e-09	8.54e-07	0.26	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39352380	chr1:39514956~39516490:+
BRCA	cis	rs755249	0.567	rs4660690	ENSG00000237624.1	OXCT2P1	5.88	5.67e-09	8.54e-07	0.26	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39353831	chr1:39514956~39516490:+
BRCA	cis	rs6095360	0.727	rs71351953	ENSG00000222365.1	SNORD12B	-5.88	5.68e-09	8.55e-07	-0.24	-0.18	Intelligence (multi-trait analysis);	chr20:48958210	chr20:49280319~49280409:+
BRCA	cis	rs651907	0.557	rs3864012	ENSG00000244119.1	PDCL3P4	5.88	5.68e-09	8.55e-07	0.14	0.18	Colorectal cancer;	chr3:101678779	chr3:101712472~101713191:+
BRCA	cis	rs4718428	0.705	rs4718424	ENSG00000230295.1	RP11-458F8.2	-5.88	5.68e-09	8.56e-07	-0.16	-0.18	Corneal structure;	chr7:66911108	chr7:66880708~66882981:+
BRCA	cis	rs4691139	0.901	rs9762579	ENSG00000248632.1	RP11-366M4.11	5.88	5.68e-09	8.56e-07	0.19	0.18	Ovarian cancer in BRCA1 mutation carriers;	chr4:164956838	chr4:164968587~164970002:-
BRCA	cis	rs7567389	0.677	rs72845997	ENSG00000236682.1	AC068282.3	-5.88	5.68e-09	8.56e-07	-0.27	-0.18	Self-rated health;	chr2:127352506	chr2:127389130~127400580:+
BRCA	cis	rs11105298	0.891	rs4842661	ENSG00000270344.2	RP11-734K2.4	5.88	5.68e-09	8.56e-07	0.22	0.18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89536622	chr12:89525654~89548005:+
BRCA	cis	rs2749097	0.609	rs11576729	ENSG00000244256.3	RN7SL130P	-5.87	5.69e-09	8.57e-07	-0.25	-0.18	Alcohol consumption (transferrin glycosylation);	chr1:63648758	chr1:63655743~63656047:+
BRCA	cis	rs10761482	0.5	rs1938524	ENSG00000254271.1	RP11-131N11.4	5.87	5.69e-09	8.57e-07	0.24	0.18	Schizophrenia;	chr10:60543815	chr10:60734342~60741828:+
BRCA	cis	rs2030746	0.836	rs6724056	ENSG00000237614.1	AC073257.2	5.87	5.69e-09	8.57e-07	0.22	0.18	LDL cholesterol;Total cholesterol levels;LDL cholesterol levels;	chr2:120549811	chr2:120542909~120544326:-
BRCA	cis	rs11668609	1	rs11668609	ENSG00000268442.1	CTD-2027I19.2	5.87	5.69e-09	8.57e-07	0.24	0.18	Response to taxane treatment (docetaxel);	chr19:24172691	chr19:24162370~24163425:-
BRCA	cis	rs897984	0.683	rs8046001	ENSG00000260911.2	RP11-196G11.2	5.87	5.7e-09	8.58e-07	0.17	0.18	Dementia with Lewy bodies;	chr16:30822000	chr16:31043150~31049868:+
BRCA	cis	rs2836950	0.545	rs1888489	ENSG00000255568.3	BRWD1-AS2	-5.87	5.7e-09	8.58e-07	-0.17	-0.18	Menarche (age at onset);	chr21:39161238	chr21:39313935~39314962:+
BRCA	cis	rs10515750	0.5	rs10038502	ENSG00000248544.2	CTB-47B11.3	5.87	5.7e-09	8.58e-07	0.26	0.18	Lung function (FEV1/FVC);	chr5:157279695	chr5:157375741~157384950:-
BRCA	cis	rs7201929	0.801	rs9933198	ENSG00000251417.2	RP11-1348G14.4	5.87	5.7e-09	8.59e-07	0.22	0.18	QT interval;	chr16:28877088	chr16:28802743~28817828:+
BRCA	cis	rs9840812	0.596	rs571513	ENSG00000239213.4	NCK1-AS1	5.87	5.7e-09	8.59e-07	0.22	0.18	Fibrinogen levels;	chr3:136376193	chr3:136841726~136862054:-
BRCA	cis	rs934734	0.673	rs6742215	ENSG00000204929.10	AC074391.1	5.87	5.71e-09	8.6e-07	0.22	0.18	Rheumatoid arthritis;	chr2:65463362	chr2:65436711~66084639:+
BRCA	cis	rs14027	0.64	rs7843304	ENSG00000279347.1	RP11-85I17.2	-5.87	5.72e-09	8.61e-07	-0.17	-0.18	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119770796	chr8:119838736~119840385:-
BRCA	cis	rs2692947	0.55	rs12623771	ENSG00000237510.6	AC008268.2	5.87	5.73e-09	8.62e-07	0.23	0.18	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95967756	chr2:95789654~95800166:+
BRCA	cis	rs10050311	0.8	rs2230600	ENSG00000251411.1	RP11-397E7.4	5.87	5.73e-09	8.63e-07	0.26	0.18	Insulin-related traits;	chr4:86769845	chr4:86913266~86914817:-
BRCA	cis	rs10129255	0.518	rs11847766	ENSG00000274576.2	IGHV2-70	-5.87	5.73e-09	8.63e-07	-0.14	-0.18	Kawasaki disease;	chr14:106779186	chr14:106770577~106771020:-
BRCA	cis	rs67981189	0.896	rs34049963	ENSG00000258571.1	PTTG4P	-5.87	5.74e-09	8.63e-07	-0.2	-0.18	Schizophrenia;	chr14:70974029	chr14:71085482~71085833:-
BRCA	cis	rs2280018	0.526	rs2941257	ENSG00000263335.1	AF001548.5	-5.87	5.74e-09	8.64e-07	-0.23	-0.18	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15072588	chr16:15726674~15732993:+
BRCA	cis	rs9291683	0.509	rs10939671	ENSG00000250413.1	RP11-448G15.1	-5.87	5.74e-09	8.64e-07	-0.24	-0.18	Bone mineral density;	chr4:10049191	chr4:10006482~10009725:+
BRCA	cis	rs4950322	0.748	rs17356680	ENSG00000244371.2	PFN1P8	-5.87	5.74e-09	8.65e-07	-0.26	-0.18	Protein quantitative trait loci;	chr1:147354934	chr1:146957117~146957659:-
BRCA	cis	rs3736858	1	rs2296093	ENSG00000261105.4	LMO7-AS1	-5.87	5.75e-09	8.65e-07	-0.29	-0.18	Interleukin-9 levels;	chr13:75856325	chr13:75604700~75635994:-
BRCA	cis	rs2638953	0.924	rs12372372	ENSG00000278733.1	RP11-425D17.1	-5.87	5.75e-09	8.65e-07	-0.23	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28147877	chr12:28185625~28186190:-
BRCA	cis	rs67981189	0.896	rs3814869	ENSG00000258571.1	PTTG4P	-5.87	5.75e-09	8.65e-07	-0.2	-0.18	Schizophrenia;	chr14:71028982	chr14:71085482~71085833:-
BRCA	cis	rs10129255	0.5	rs6576225	ENSG00000274576.2	IGHV2-70	-5.87	5.76e-09	8.67e-07	-0.14	-0.18	Kawasaki disease;	chr14:106778120	chr14:106770577~106771020:-
BRCA	cis	rs10129255	0.5	rs6576226	ENSG00000274576.2	IGHV2-70	-5.87	5.76e-09	8.67e-07	-0.14	-0.18	Kawasaki disease;	chr14:106778135	chr14:106770577~106771020:-
BRCA	cis	rs5015933	0.815	rs359597	ENSG00000232630.1	PRPS1P2	-5.87	5.76e-09	8.67e-07	-0.17	-0.18	Body mass index;	chr9:125274312	chr9:125150653~125151589:+
BRCA	cis	rs10829156	0.66	rs11014830	ENSG00000240291.1	RP11-499P20.2	5.87	5.76e-09	8.67e-07	0.19	0.18	Sudden cardiac arrest;	chr10:18551504	chr10:18513115~18545651:-
BRCA	cis	rs2243480	1	rs781150	ENSG00000232559.3	GS1-124K5.12	5.87	5.77e-09	8.68e-07	0.34	0.18	Diabetic kidney disease;	chr7:66015986	chr7:66554588~66576923:-
BRCA	cis	rs2243480	1	rs313798	ENSG00000232559.3	GS1-124K5.12	5.87	5.77e-09	8.68e-07	0.34	0.18	Diabetic kidney disease;	chr7:66028044	chr7:66554588~66576923:-
BRCA	cis	rs17301013	0.507	rs6687616	ENSG00000227373.4	RP11-160H22.5	5.87	5.77e-09	8.68e-07	0.28	0.18	Systemic lupus erythematosus;	chr1:174840322	chr1:174115300~174160004:-
BRCA	cis	rs2832191	0.632	rs1984011	ENSG00000176054.6	RPL23P2	-5.87	5.77e-09	8.68e-07	-0.19	-0.18	Dental caries;	chr21:28965509	chr21:28997613~28998033:-
BRCA	cis	rs2243480	1	rs35058610	ENSG00000232546.1	RP11-458F8.1	-5.87	5.77e-09	8.68e-07	-0.23	-0.18	Diabetic kidney disease;	chr7:65925938	chr7:66848496~66858136:+
BRCA	cis	rs2153535	0.585	rs9378564	ENSG00000230939.1	RP11-314C16.1	-5.87	5.77e-09	8.68e-07	-0.21	-0.18	Motion sickness;	chr6:8639694	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.585	rs9379233	ENSG00000230939.1	RP11-314C16.1	-5.87	5.77e-09	8.68e-07	-0.21	-0.18	Motion sickness;	chr6:8639729	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.585	rs9505505	ENSG00000230939.1	RP11-314C16.1	-5.87	5.77e-09	8.68e-07	-0.21	-0.18	Motion sickness;	chr6:8640246	chr6:8784178~8785445:+
BRCA	cis	rs910316	0.967	rs175502	ENSG00000279594.1	RP11-950C14.10	-5.87	5.78e-09	8.69e-07	-0.2	-0.18	Height;	chr14:75066976	chr14:75011269~75012851:-
BRCA	cis	rs10266483	0.545	rs12540100	ENSG00000271550.1	BNIP3P11	5.87	5.78e-09	8.69e-07	0.28	0.18	Response to statin therapy;	chr7:64289924	chr7:64678954~64687393:-
BRCA	cis	rs6490294	0.571	rs11066118	ENSG00000226469.1	ADAM1B	5.87	5.78e-09	8.69e-07	0.28	0.18	Mean platelet volume;	chr12:111996348	chr12:111927018~111929017:+
BRCA	cis	rs793571	0.554	rs17301954	ENSG00000259250.1	RP11-50C13.1	-5.87	5.78e-09	8.69e-07	-0.32	-0.18	Schizophrenia;	chr15:58708232	chr15:58587507~58591676:+
BRCA	cis	rs737008	0.5	rs7189239	ENSG00000262636.1	CTD-3088G3.4	5.87	5.78e-09	8.7e-07	0.24	0.18	Obesity-related traits;	chr16:11308658	chr16:11380859~11381118:-
BRCA	cis	rs17711722	0.523	rs313812	ENSG00000237310.1	GS1-124K5.4	-5.87	5.79e-09	8.7e-07	-0.19	-0.18	Calcium levels;	chr7:66040056	chr7:66493706~66495474:+
BRCA	cis	rs5758511	0.68	rs5758682	ENSG00000205702.9	CYP2D7	5.87	5.79e-09	8.71e-07	0.19	0.18	Birth weight;	chr22:42249196	chr22:42140203~42144577:-
BRCA	cis	rs6088580	0.524	rs6087612	ENSG00000269202.1	RP4-614O4.12	5.87	5.8e-09	8.72e-07	0.18	0.18	Glomerular filtration rate (creatinine);	chr20:34643018	chr20:35201747~35203288:-
BRCA	cis	rs10129255	0.5	rs8022547	ENSG00000274576.2	IGHV2-70	-5.87	5.8e-09	8.73e-07	-0.14	-0.18	Kawasaki disease;	chr14:106781985	chr14:106770577~106771020:-
BRCA	cis	rs5758511	0.773	rs12167978	ENSG00000205702.9	CYP2D7	5.87	5.8e-09	8.73e-07	0.18	0.18	Birth weight;	chr22:41950471	chr22:42140203~42144577:-
BRCA	cis	rs385076	0.503	rs212702	ENSG00000272716.1	RP11-563N4.1	5.87	5.8e-09	8.73e-07	0.23	0.18	Interleukin-18 levels;	chr2:32219181	chr2:32165046~32165757:-
BRCA	cis	rs7221109	0.533	rs7210983	ENSG00000278834.1	RP11-458J1.1	5.87	5.8e-09	8.73e-07	0.2	0.18	Type 1 diabetes;	chr17:40660862	chr17:40648300~40649718:+
BRCA	cis	rs7976269	0.609	rs10843300	ENSG00000275476.1	RP11-996F15.4	-5.87	5.81e-09	8.74e-07	-0.2	-0.18	Male-pattern baldness;	chr12:29060934	chr12:29277397~29277882:-
BRCA	cis	rs253959	0.672	rs4920903	ENSG00000272265.1	CTD-2287O16.4	5.87	5.81e-09	8.74e-07	0.2	0.18	Bipolar disorder and schizophrenia;	chr5:116085892	chr5:116078110~116078570:-
BRCA	cis	rs42648	0.536	rs2158747	ENSG00000225498.1	AC002064.5	5.87	5.81e-09	8.74e-07	0.17	0.18	Homocysteine levels;	chr7:90169107	chr7:90312496~90322592:+
BRCA	cis	rs4713118	0.662	rs149901	ENSG00000204709.4	LINC01556	5.87	5.81e-09	8.74e-07	0.26	0.18	Parkinson's disease;	chr6:27997725	chr6:28943877~28944537:+
BRCA	cis	rs4886920	0.605	rs12912080	ENSG00000260776.4	RP11-114H24.2	5.87	5.81e-09	8.74e-07	0.22	0.18	Neuroticism;	chr15:77834416	chr15:77914217~77926846:-
BRCA	cis	rs11920570	0.526	rs3828362	ENSG00000272758.4	RP11-299J3.8	5.87	5.81e-09	8.74e-07	0.18	0.18	Resting heart rate;	chr3:122412930	chr3:122416207~122443180:+
BRCA	cis	rs2243480	1	rs4548056	ENSG00000164669.11	INTS4P1	5.87	5.82e-09	8.75e-07	0.35	0.18	Diabetic kidney disease;	chr7:65833886	chr7:65141225~65234216:+
BRCA	cis	rs1499614	0.901	rs3936	ENSG00000228409.4	CCT6P1	5.87	5.82e-09	8.75e-07	0.25	0.18	Gout;	chr7:66661502	chr7:65751142~65763354:+
BRCA	cis	rs9638182	0.83	rs34346326	ENSG00000274080.1	CTA-315H11.2	5.87	5.82e-09	8.75e-07	0.32	0.18	Triglycerides;	chr7:73601851	chr7:73609262~73611502:-
BRCA	cis	rs2243480	1	rs160652	ENSG00000164669.11	INTS4P1	5.87	5.82e-09	8.75e-07	0.37	0.18	Diabetic kidney disease;	chr7:66073444	chr7:65141225~65234216:+
BRCA	cis	rs2243480	0.901	rs35087093	ENSG00000232546.1	RP11-458F8.1	-5.87	5.82e-09	8.75e-07	-0.23	-0.18	Diabetic kidney disease;	chr7:65940221	chr7:66848496~66858136:+
BRCA	cis	rs755249	0.567	rs41270807	ENSG00000237624.1	OXCT2P1	5.87	5.83e-09	8.76e-07	0.26	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39336143	chr1:39514956~39516490:+
BRCA	cis	rs755249	0.53	rs16826087	ENSG00000237624.1	OXCT2P1	5.87	5.83e-09	8.76e-07	0.26	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39346846	chr1:39514956~39516490:+
BRCA	cis	rs755249	0.567	rs41270811	ENSG00000237624.1	OXCT2P1	5.87	5.83e-09	8.76e-07	0.26	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39349672	chr1:39514956~39516490:+
BRCA	cis	rs755249	0.567	rs61779274	ENSG00000237624.1	OXCT2P1	5.87	5.83e-09	8.76e-07	0.26	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39351269	chr1:39514956~39516490:+
BRCA	cis	rs11722779	0.81	rs223417	ENSG00000251288.2	RP11-10L12.2	-5.87	5.83e-09	8.76e-07	-0.21	-0.18	Schizophrenia;	chr4:102810568	chr4:102751401~102752641:+
BRCA	cis	rs11722779	0.805	rs223416	ENSG00000251288.2	RP11-10L12.2	-5.87	5.83e-09	8.76e-07	-0.21	-0.18	Schizophrenia;	chr4:102810580	chr4:102751401~102752641:+
BRCA	cis	rs9500256	0.934	rs1343391	ENSG00000215190.7	LINC00680	-5.87	5.83e-09	8.77e-07	-0.2	-0.18	Eosinophilic esophagitis (pediatric);	chr6:58017876	chr6:57946074~57961501:-
BRCA	cis	rs1552244	1	rs17032299	ENSG00000232901.1	CYCSP10	5.87	5.83e-09	8.77e-07	0.25	0.18	Alzheimer's disease;	chr3:10045954	chr3:10000647~10000940:-
BRCA	cis	rs962856	0.964	rs4671183	ENSG00000236780.4	AC078941.1	5.87	5.84e-09	8.78e-07	0.23	0.18	Pancreatic cancer;	chr2:67416545	chr2:67123357~67215319:-
BRCA	cis	rs13126694	0.778	rs12503001	ENSG00000251429.1	RP11-597D13.7	5.87	5.84e-09	8.78e-07	0.18	0.18	Blood osmolality (transformed sodium);	chr4:158100822	chr4:158270378~158278676:+
BRCA	cis	rs523522	0.962	rs3893104	ENSG00000278344.1	RP11-18C24.8	5.87	5.84e-09	8.79e-07	0.25	0.18	High light scatter reticulocyte count;	chr12:120466133	chr12:120500735~120501090:-
BRCA	cis	rs7772486	0.686	rs9376956	ENSG00000270638.1	RP3-466P17.1	5.87	5.85e-09	8.79e-07	0.2	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145628708	chr6:145735570~145737218:+
BRCA	cis	rs7772486	0.658	rs6570706	ENSG00000270638.1	RP3-466P17.1	5.87	5.85e-09	8.79e-07	0.2	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145641786	chr6:145735570~145737218:+
BRCA	cis	rs13126694	0.744	rs7682867	ENSG00000248429.4	RP11-597D13.9	5.87	5.85e-09	8.79e-07	0.16	0.18	Blood osmolality (transformed sodium);	chr4:158026735	chr4:158170752~158202877:+
BRCA	cis	rs7927771	0.524	rs7101597	ENSG00000280615.1	Y_RNA	5.87	5.85e-09	8.8e-07	0.21	0.18	Subjective well-being;	chr11:47776365	chr11:47614898~47614994:-
BRCA	cis	rs9638182	0.945	rs35368205	ENSG00000274080.1	CTA-315H11.2	5.87	5.86e-09	8.81e-07	0.32	0.18	Triglycerides;	chr7:73603327	chr7:73609262~73611502:-
BRCA	cis	rs7520050	0.966	rs4076006	ENSG00000280836.1	AL355480.1	5.87	5.86e-09	8.81e-07	0.21	0.18	Reticulocyte count;Red blood cell count;	chr1:45972404	chr1:45581219~45581321:-
BRCA	cis	rs7520050	0.966	rs11211234	ENSG00000280836.1	AL355480.1	5.87	5.86e-09	8.81e-07	0.21	0.18	Reticulocyte count;Red blood cell count;	chr1:45973115	chr1:45581219~45581321:-
BRCA	cis	rs10510102	0.748	rs11200297	ENSG00000226864.1	ATE1-AS1	5.87	5.86e-09	8.81e-07	0.32	0.18	Breast cancer;	chr10:121972916	chr10:121928312~121951965:+
BRCA	cis	rs442309	0.687	rs7084016	ENSG00000238280.1	RP11-436D10.3	-5.87	5.86e-09	8.81e-07	-0.25	-0.18	Vogt-Koyanagi-Harada syndrome;	chr10:62720681	chr10:62793562~62805887:-
BRCA	cis	rs875971	0.545	rs13311962	ENSG00000273024.4	INTS4P2	5.87	5.86e-09	8.81e-07	0.22	0.18	Aortic root size;	chr7:66603142	chr7:65647864~65715661:+
BRCA	cis	rs2153535	0.536	rs1328876	ENSG00000230939.1	RP11-314C16.1	-5.87	5.86e-09	8.82e-07	-0.21	-0.18	Motion sickness;	chr6:8620940	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.585	rs1328875	ENSG00000230939.1	RP11-314C16.1	-5.87	5.86e-09	8.82e-07	-0.21	-0.18	Motion sickness;	chr6:8620946	chr6:8784178~8785445:+
BRCA	cis	rs11722228	0.549	rs73212828	ENSG00000261490.1	RP11-448G15.3	5.87	5.87e-09	8.82e-07	0.21	0.18	Urate levels;Serum uric acid levels;Gout;	chr4:10077132	chr4:10068089~10073019:-
BRCA	cis	rs2250402	0.51	rs6492926	ENSG00000248508.5	SRP14-AS1	5.87	5.87e-09	8.83e-07	0.38	0.18	Corneal curvature;	chr15:40033628	chr15:40039311~40067290:+
BRCA	cis	rs2243480	1	rs35396113	ENSG00000232559.3	GS1-124K5.12	5.87	5.88e-09	8.84e-07	0.34	0.18	Diabetic kidney disease;	chr7:66030474	chr7:66554588~66576923:-
BRCA	cis	rs10761482	0.5	rs1574466	ENSG00000254271.1	RP11-131N11.4	5.87	5.89e-09	8.85e-07	0.24	0.18	Schizophrenia;	chr10:60534634	chr10:60734342~60741828:+
BRCA	cis	rs9992667	0.91	rs17428945	ENSG00000231160.8	KLF3-AS1	5.87	5.89e-09	8.86e-07	0.22	0.18	Eosinophil percentage of granulocytes;	chr4:38688124	chr4:38612701~38664883:-
BRCA	cis	rs11668609	0.935	rs8113172	ENSG00000268442.1	CTD-2027I19.2	5.87	5.89e-09	8.86e-07	0.25	0.18	Response to taxane treatment (docetaxel);	chr19:24121251	chr19:24162370~24163425:-
BRCA	cis	rs6088580	0.524	rs6088560	ENSG00000269202.1	RP4-614O4.12	5.87	5.89e-09	8.86e-07	0.18	0.18	Glomerular filtration rate (creatinine);	chr20:34640745	chr20:35201747~35203288:-
BRCA	cis	rs6163	0.588	rs11191392	ENSG00000236937.2	PTGES3P4	5.87	5.89e-09	8.86e-07	0.22	0.18	Waist circumference;Hip circumference;	chr10:102767194	chr10:102845595~102845950:+
BRCA	cis	rs651907	0.535	rs11711903	ENSG00000244119.1	PDCL3P4	5.87	5.9e-09	8.86e-07	0.15	0.18	Colorectal cancer;	chr3:101781904	chr3:101712472~101713191:+
BRCA	cis	rs7474896	0.537	rs2472149	ENSG00000226578.1	RP11-258F22.1	5.87	5.9e-09	8.87e-07	0.23	0.18	Obesity (extreme);	chr10:37973268	chr10:37775371~37784131:-
BRCA	cis	rs17711722	0.523	rs313812	ENSG00000275400.1	RP4-756H11.5	5.87	5.91e-09	8.87e-07	0.21	0.18	Calcium levels;	chr7:66040056	chr7:66553805~66554199:-
BRCA	cis	rs1598856	1	rs93059	ENSG00000246560.2	RP11-10L12.4	5.87	5.91e-09	8.89e-07	0.2	0.18	Primary biliary cholangitis;	chr4:102547361	chr4:102828055~102844075:+
BRCA	cis	rs1124769	0.719	rs12593342	ENSG00000259378.1	DCAF13P3	5.87	5.92e-09	8.89e-07	0.24	0.18	Cognitive performance;	chr15:50971967	chr15:50944663~50945996:+
BRCA	cis	rs42648	0.564	rs17863031	ENSG00000225498.1	AC002064.5	5.87	5.92e-09	8.9e-07	0.17	0.18	Homocysteine levels;	chr7:90176499	chr7:90312496~90322592:+
BRCA	cis	rs516805	0.63	rs2606596	ENSG00000279453.1	RP3-425C14.4	-5.87	5.92e-09	8.9e-07	-0.26	-0.18	Lymphocyte counts;	chr6:122211597	chr6:122436789~122439223:-
BRCA	cis	rs7809950	0.723	rs2237662	ENSG00000238832.1	snoU109	-5.87	5.93e-09	8.91e-07	-0.27	-0.18	Coronary artery disease;	chr7:107233620	chr7:107603363~107603507:+
BRCA	cis	rs2638953	0.925	rs11049491	ENSG00000278733.1	RP11-425D17.1	-5.87	5.93e-09	8.91e-07	-0.24	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28262340	chr12:28185625~28186190:-
BRCA	cis	rs919433	0.68	rs1116734	ENSG00000231621.1	AC013264.2	-5.87	5.94e-09	8.93e-07	-0.17	-0.18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197500319	chr2:197197991~197199273:+
BRCA	cis	rs2243480	1	rs6958289	ENSG00000232559.3	GS1-124K5.12	-5.87	5.95e-09	8.94e-07	-0.34	-0.18	Diabetic kidney disease;	chr7:66192124	chr7:66554588~66576923:-
BRCA	cis	rs2638953	0.924	rs17801442	ENSG00000247934.4	RP11-967K21.1	-5.87	5.95e-09	8.94e-07	-0.23	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28165627	chr12:28163298~28190738:-
BRCA	cis	rs9907295	1	rs11653282	ENSG00000270977.1	AC015849.16	-5.87	5.95e-09	8.94e-07	-0.27	-0.18	Fibroblast growth factor basic levels;	chr17:35909742	chr17:35893707~35911023:-
BRCA	cis	rs5758511	0.68	rs5758686	ENSG00000205702.9	CYP2D7	5.87	5.96e-09	8.95e-07	0.19	0.18	Birth weight;	chr22:42259371	chr22:42140203~42144577:-
BRCA	cis	rs2243480	1	rs1039664	ENSG00000230295.1	RP11-458F8.2	-5.87	5.96e-09	8.95e-07	-0.23	-0.18	Diabetic kidney disease;	chr7:65984729	chr7:66880708~66882981:+
BRCA	cis	rs2337406	0.925	rs2011167	ENSG00000211972.2	IGHV3-66	5.87	5.96e-09	8.95e-07	0.18	0.18	Alzheimer's disease (late onset);	chr14:106680831	chr14:106675017~106675544:-
BRCA	cis	rs62025270	0.632	rs56153788	ENSG00000202081.1	RNU6-1280P	-5.87	5.96e-09	8.95e-07	-0.26	-0.18	Idiopathic pulmonary fibrosis;	chr15:85627761	chr15:85651522~85651628:-
BRCA	cis	rs651907	0.557	rs17347644	ENSG00000244119.1	PDCL3P4	5.87	5.97e-09	8.96e-07	0.15	0.18	Colorectal cancer;	chr3:101828889	chr3:101712472~101713191:+
BRCA	cis	rs7246657	1	rs1823061	ENSG00000267422.1	CTD-2554C21.1	-5.87	5.97e-09	8.97e-07	-0.27	-0.18	Coronary artery calcification;	chr19:37309724	chr19:37779686~37792865:+
BRCA	cis	rs1552244	0.882	rs13064570	ENSG00000232901.1	CYCSP10	5.87	5.98e-09	8.99e-07	0.25	0.18	Alzheimer's disease;	chr3:9955861	chr3:10000647~10000940:-
BRCA	cis	rs4908768	0.501	rs6577499	ENSG00000270282.1	RP5-1115A15.2	-5.87	5.99e-09	8.99e-07	-0.19	-0.18	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8552045	chr1:8512653~8513021:+
BRCA	cis	rs7246760	0.867	rs58461110	ENSG00000277587.1	CTD-3116E22.8	-5.87	6e-09	9e-07	-0.35	-0.18	Pursuit maintenance gain;	chr19:9722714	chr19:9721903~9722410:+
BRCA	cis	rs7246760	0.867	rs55800282	ENSG00000277587.1	CTD-3116E22.8	-5.87	6e-09	9e-07	-0.35	-0.18	Pursuit maintenance gain;	chr19:9722854	chr19:9721903~9722410:+
BRCA	cis	rs2790457	0.958	rs2790444	ENSG00000254635.4	WAC-AS1	-5.87	6.01e-09	9.02e-07	-0.21	-0.18	Multiple myeloma;	chr10:28536760	chr10:28522652~28532743:-
BRCA	cis	rs755249	0.588	rs2275767	ENSG00000228060.1	RP11-69E11.8	5.87	6.02e-09	9.03e-07	0.18	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39479625	chr1:39565160~39573203:+
BRCA	cis	rs2692947	0.76	rs2438924	ENSG00000237510.6	AC008268.2	5.87	6.02e-09	9.04e-07	0.23	0.18	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95979321	chr2:95789654~95800166:+
BRCA	cis	rs2692947	0.826	rs7423942	ENSG00000237510.6	AC008268.2	5.87	6.02e-09	9.04e-07	0.23	0.18	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95979509	chr2:95789654~95800166:+
BRCA	cis	rs10740039	0.516	rs7072678	ENSG00000254271.1	RP11-131N11.4	-5.87	6.02e-09	9.04e-07	-0.24	-0.18	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60585011	chr10:60734342~60741828:+
BRCA	cis	rs1713985	0.508	rs4865171	ENSG00000269949.1	RP11-738E22.3	5.86	6.03e-09	9.05e-07	0.32	0.18	Age-related macular degeneration;	chr4:57026477	chr4:56960927~56961373:-
BRCA	cis	rs4950322	0.57	rs72692907	ENSG00000244371.2	PFN1P8	-5.86	6.04e-09	9.06e-07	-0.25	-0.18	Protein quantitative trait loci;	chr1:147301921	chr1:146957117~146957659:-
BRCA	cis	rs4950322	0.57	rs72692914	ENSG00000244371.2	PFN1P8	-5.86	6.04e-09	9.06e-07	-0.25	-0.18	Protein quantitative trait loci;	chr1:147302946	chr1:146957117~146957659:-
BRCA	cis	rs2153535	0.585	rs9393057	ENSG00000230939.1	RP11-314C16.1	5.86	6.04e-09	9.06e-07	0.2	0.18	Motion sickness;	chr6:8668067	chr6:8784178~8785445:+
BRCA	cis	rs2243480	1	rs7794661	ENSG00000232546.1	RP11-458F8.1	-5.86	6.04e-09	9.07e-07	-0.23	-0.18	Diabetic kidney disease;	chr7:65924743	chr7:66848496~66858136:+
BRCA	cis	rs875971	0.502	rs2465121	ENSG00000228409.4	CCT6P1	5.86	6.04e-09	9.07e-07	0.18	0.18	Aortic root size;	chr7:66156017	chr7:65751142~65763354:+
BRCA	cis	rs7577696	0.606	rs212747	ENSG00000272716.1	RP11-563N4.1	5.86	6.06e-09	9.09e-07	0.21	0.18	Inflammatory biomarkers;	chr2:32189635	chr2:32165046~32165757:-
BRCA	cis	rs2243480	1	rs316327	ENSG00000230295.1	RP11-458F8.2	5.86	6.06e-09	9.09e-07	0.23	0.18	Diabetic kidney disease;	chr7:66144214	chr7:66880708~66882981:+
BRCA	cis	rs4950322	0.57	rs72692917	ENSG00000244371.2	PFN1P8	-5.86	6.06e-09	9.1e-07	-0.25	-0.18	Protein quantitative trait loci;	chr1:147304389	chr1:146957117~146957659:-
BRCA	cis	rs4950322	0.57	rs66580541	ENSG00000244371.2	PFN1P8	-5.86	6.06e-09	9.1e-07	-0.25	-0.18	Protein quantitative trait loci;	chr1:147308828	chr1:146957117~146957659:-
BRCA	cis	rs4950322	0.57	rs945742	ENSG00000244371.2	PFN1P8	-5.86	6.06e-09	9.1e-07	-0.25	-0.18	Protein quantitative trait loci;	chr1:147313437	chr1:146957117~146957659:-
BRCA	cis	rs875971	0.545	rs7810213	ENSG00000228409.4	CCT6P1	-5.86	6.07e-09	9.11e-07	-0.18	-0.18	Aortic root size;	chr7:66481592	chr7:65751142~65763354:+
BRCA	cis	rs73198271	0.74	rs1039911	ENSG00000253893.2	FAM85B	5.86	6.08e-09	9.12e-07	0.25	0.18	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8790696	chr8:8167819~8226614:-
BRCA	cis	rs7520050	0.966	rs6695809	ENSG00000280836.1	AL355480.1	5.86	6.08e-09	9.13e-07	0.21	0.18	Reticulocyte count;Red blood cell count;	chr1:45819789	chr1:45581219~45581321:-
BRCA	cis	rs10888838	0.941	rs11206305	ENSG00000198711.5	SSBP3-AS1	5.86	6.08e-09	9.13e-07	0.25	0.18	Mitochondrial DNA levels;	chr1:54222538	chr1:54236440~54239063:+
BRCA	cis	rs10129255	0.957	rs12590667	ENSG00000211972.2	IGHV3-66	-5.86	6.09e-09	9.13e-07	-0.13	-0.18	Kawasaki disease;	chr14:106779223	chr14:106675017~106675544:-
BRCA	cis	rs2836950	0.565	rs2150414	ENSG00000238141.2	BRWD1-AS1	-5.86	6.09e-09	9.13e-07	-0.2	-0.18	Menarche (age at onset);	chr21:39243062	chr21:39315707~39323218:+
BRCA	cis	rs673078	0.66	rs56708462	ENSG00000275409.1	RP11-131L12.4	-5.86	6.09e-09	9.13e-07	-0.27	-0.18	Glucose homeostasis traits;	chr12:118284135	chr12:118430147~118430699:+
BRCA	cis	rs7772486	0.686	rs1337841	ENSG00000270638.1	RP3-466P17.1	-5.86	6.09e-09	9.13e-07	-0.2	-0.18	Lobe attachment (rater-scored or self-reported);	chr6:145738351	chr6:145735570~145737218:+
BRCA	cis	rs2243480	0.711	rs1626926	ENSG00000232546.1	RP11-458F8.1	-5.86	6.09e-09	9.14e-07	-0.23	-0.18	Diabetic kidney disease;	chr7:65970805	chr7:66848496~66858136:+
BRCA	cis	rs910316	0.967	rs175451	ENSG00000279594.1	RP11-950C14.10	-5.86	6.1e-09	9.15e-07	-0.2	-0.18	Height;	chr14:75123026	chr14:75011269~75012851:-
BRCA	cis	rs2243480	0.708	rs13242216	ENSG00000228409.4	CCT6P1	5.86	6.1e-09	9.15e-07	0.25	0.18	Diabetic kidney disease;	chr7:66433290	chr7:65751142~65763354:+
BRCA	cis	rs3930017	1	rs3930017	ENSG00000225726.1	AC007000.10	-5.86	6.1e-09	9.16e-07	-0.2	-0.18	Body mass index;	chr7:77091265	chr7:77071751~77072237:-
BRCA	cis	rs7615952	0.575	rs35949599	ENSG00000171084.14	FAM86JP	5.86	6.11e-09	9.16e-07	0.28	0.18	Blood pressure (smoking interaction);	chr3:125825359	chr3:125916620~125930024:+
BRCA	cis	rs2153535	0.561	rs9406184	ENSG00000230939.1	RP11-314C16.1	-5.86	6.11e-09	9.16e-07	-0.21	-0.18	Motion sickness;	chr6:8642681	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.585	rs11243263	ENSG00000230939.1	RP11-314C16.1	-5.86	6.11e-09	9.16e-07	-0.21	-0.18	Motion sickness;	chr6:8642880	chr6:8784178~8785445:+
BRCA	cis	rs11105298	0.891	rs11105309	ENSG00000270344.2	RP11-734K2.4	5.86	6.11e-09	9.16e-07	0.21	0.18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89516073	chr12:89525654~89548005:+
BRCA	cis	rs651907	0.557	rs62284198	ENSG00000244119.1	PDCL3P4	5.86	6.11e-09	9.16e-07	0.14	0.18	Colorectal cancer;	chr3:101755855	chr3:101712472~101713191:+
BRCA	cis	rs651907	0.557	rs2318090	ENSG00000244119.1	PDCL3P4	5.86	6.11e-09	9.16e-07	0.14	0.18	Colorectal cancer;	chr3:101756089	chr3:101712472~101713191:+
BRCA	cis	rs1476670	0.69	rs6677372	ENSG00000230615.5	RP5-1198O20.4	-5.86	6.11e-09	9.17e-07	-0.25	-0.18	Eotaxin levels;	chr1:44040117	chr1:44030443~44115913:+
BRCA	cis	rs13126694	0.744	rs10049927	ENSG00000251429.1	RP11-597D13.7	5.86	6.12e-09	9.17e-07	0.17	0.18	Blood osmolality (transformed sodium);	chr4:157998056	chr4:158270378~158278676:+
BRCA	cis	rs9652601	0.959	rs9931397	ENSG00000274038.1	RP11-66H6.4	-5.86	6.13e-09	9.2e-07	-0.21	-0.18	Systemic lupus erythematosus;	chr16:11083537	chr16:11056556~11057034:+
BRCA	cis	rs7923609	0.967	rs7085018	ENSG00000232075.1	MRPL35P2	-5.86	6.14e-09	9.2e-07	-0.22	-0.18	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63526907	chr10:63634317~63634827:-
BRCA	cis	rs7923609	0.841	rs7920036	ENSG00000232075.1	MRPL35P2	-5.86	6.14e-09	9.2e-07	-0.22	-0.18	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63534100	chr10:63634317~63634827:-
BRCA	cis	rs10129255	0.913	rs10140943	ENSG00000280411.1	IGHV1-69-2	-5.86	6.15e-09	9.22e-07	-0.14	-0.18	Kawasaki disease;	chr14:106767441	chr14:106762092~106762588:-
BRCA	cis	rs4950322	0.802	rs72694705	ENSG00000278811.3	LINC00624	5.86	6.15e-09	9.23e-07	0.24	0.18	Protein quantitative trait loci;	chr1:147362313	chr1:147258885~147517875:-
BRCA	cis	rs1823913	0.599	rs13015653	ENSG00000280083.1	RP11-317J9.1	-5.86	6.15e-09	9.23e-07	-0.21	-0.18	Obesity-related traits;	chr2:191306813	chr2:191154118~191156070:-
BRCA	cis	rs1823913	0.599	rs12994212	ENSG00000280083.1	RP11-317J9.1	-5.86	6.15e-09	9.23e-07	-0.21	-0.18	Obesity-related traits;	chr2:191306910	chr2:191154118~191156070:-
BRCA	cis	rs1823913	0.599	rs12994236	ENSG00000280083.1	RP11-317J9.1	-5.86	6.15e-09	9.23e-07	-0.21	-0.18	Obesity-related traits;	chr2:191306991	chr2:191154118~191156070:-
BRCA	cis	rs1823913	0.599	rs35495506	ENSG00000280083.1	RP11-317J9.1	-5.86	6.15e-09	9.23e-07	-0.21	-0.18	Obesity-related traits;	chr2:191307551	chr2:191154118~191156070:-
BRCA	cis	rs1823913	0.599	rs34691559	ENSG00000280083.1	RP11-317J9.1	-5.86	6.15e-09	9.23e-07	-0.21	-0.18	Obesity-related traits;	chr2:191307688	chr2:191154118~191156070:-
BRCA	cis	rs1823913	0.561	rs55790432	ENSG00000280083.1	RP11-317J9.1	-5.86	6.15e-09	9.23e-07	-0.21	-0.18	Obesity-related traits;	chr2:191307722	chr2:191154118~191156070:-
BRCA	cis	rs9907295	0.681	rs9912284	ENSG00000271013.1	AC015849.15	-5.86	6.16e-09	9.23e-07	-0.27	-0.18	Fibroblast growth factor basic levels;	chr17:35906638	chr17:35912635~35918010:-
BRCA	cis	rs17036350	1	rs17036350	ENSG00000230337.1	RP4-635E18.6	-5.86	6.16e-09	9.24e-07	-0.43	-0.18	Corneal curvature;	chr1:11111169	chr1:11099675~11102100:+
BRCA	cis	rs1859596	0.966	rs726655	ENSG00000234456.6	MAGI2-AS3	5.86	6.17e-09	9.25e-07	0.12	0.18	Reading or mathematical ability;	chr7:79467259	chr7:79452877~79471208:+
BRCA	cis	rs7927592	0.913	rs11228292	ENSG00000212093.1	AP000807.1	5.86	6.18e-09	9.26e-07	0.2	0.18	Total body bone mineral density;	chr11:68612304	chr11:68506083~68506166:-
BRCA	cis	rs516805	0.667	rs2816078	ENSG00000279453.1	RP3-425C14.4	-5.86	6.18e-09	9.26e-07	-0.26	-0.18	Lymphocyte counts;	chr6:122201755	chr6:122436789~122439223:-
BRCA	cis	rs35612822	0.93	rs13015080	ENSG00000232485.2	AC098820.3	-5.86	6.19e-09	9.27e-07	-0.23	-0.18	Kidney disease (early stage) in type 1 diabetes;	chr2:216519759	chr2:216479030~216498761:-
BRCA	cis	rs559928	0.606	rs12419038	ENSG00000236935.1	AP003774.1	5.86	6.19e-09	9.28e-07	0.23	0.18	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64145264	chr11:64325050~64329504:-
BRCA	cis	rs516805	0.561	rs9490497	ENSG00000279453.1	RP3-425C14.4	-5.86	6.19e-09	9.28e-07	-0.29	-0.18	Lymphocyte counts;	chr6:122615904	chr6:122436789~122439223:-
BRCA	cis	rs2243480	1	rs313803	ENSG00000228409.4	CCT6P1	5.86	6.19e-09	9.28e-07	0.25	0.18	Diabetic kidney disease;	chr7:66049744	chr7:65751142~65763354:+
BRCA	cis	rs2243480	1	rs35542501	ENSG00000164669.11	INTS4P1	5.86	6.2e-09	9.29e-07	0.34	0.18	Diabetic kidney disease;	chr7:65966228	chr7:65141225~65234216:+
BRCA	cis	rs2243480	0.708	rs781141	ENSG00000164669.11	INTS4P1	5.86	6.2e-09	9.29e-07	0.34	0.18	Diabetic kidney disease;	chr7:65973566	chr7:65141225~65234216:+
BRCA	cis	rs55692411	0.537	rs35012435	ENSG00000228008.1	CTD-2330K9.3	5.86	6.2e-09	9.29e-07	0.21	0.18	Intelligence (multi-trait analysis);	chr3:49994407	chr3:49903845~49916937:+
BRCA	cis	rs3811273	0.614	rs4982597	ENSG00000211816.2	TRAV38-1	-5.86	6.2e-09	9.29e-07	-0.21	-0.18	Periodontal disease-related phenotypes;	chr14:22267065	chr14:22271968~22272563:+
BRCA	cis	rs2015599	0.549	rs6487802	ENSG00000257176.2	RP11-996F15.2	5.86	6.2e-09	9.3e-07	0.21	0.18	Platelet count;Mean platelet volume;	chr12:29299480	chr12:29280418~29317848:-
BRCA	cis	rs875971	0.545	rs3735147	ENSG00000228409.4	CCT6P1	-5.86	6.21e-09	9.31e-07	-0.18	-0.18	Aortic root size;	chr7:66505541	chr7:65751142~65763354:+
BRCA	cis	rs2243480	0.808	rs12698508	ENSG00000232559.3	GS1-124K5.12	5.86	6.21e-09	9.31e-07	0.33	0.18	Diabetic kidney disease;	chr7:65946971	chr7:66554588~66576923:-
BRCA	cis	rs2638953	0.962	rs11049370	ENSG00000278733.1	RP11-425D17.1	-5.86	6.21e-09	9.31e-07	-0.23	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28146904	chr12:28185625~28186190:-
BRCA	cis	rs2749097	0.609	rs3790857	ENSG00000244256.3	RN7SL130P	5.86	6.22e-09	9.31e-07	0.25	0.18	Alcohol consumption (transferrin glycosylation);	chr1:63646195	chr1:63655743~63656047:+
BRCA	cis	rs934734	0.532	rs6546151	ENSG00000204929.10	AC074391.1	-5.86	6.22e-09	9.32e-07	-0.22	-0.18	Rheumatoid arthritis;	chr2:65449449	chr2:65436711~66084639:+
BRCA	cis	rs4713118	0.662	rs149961	ENSG00000219392.1	RP1-265C24.5	-5.86	6.22e-09	9.32e-07	-0.27	-0.18	Parkinson's disease;	chr6:28047791	chr6:28115628~28116551:+
BRCA	cis	rs4604234	0.803	rs11967081	ENSG00000272129.1	RP11-250B2.6	5.86	6.22e-09	9.32e-07	0.44	0.18	Cancer;	chr6:80255623	chr6:80355424~80356859:+
BRCA	cis	rs11098499	0.863	rs2306457	ENSG00000249244.1	RP11-548H18.2	5.86	6.22e-09	9.32e-07	0.22	0.18	Corneal astigmatism;	chr4:119551684	chr4:119391831~119395335:-
BRCA	cis	rs9880211	0.613	rs13081671	ENSG00000273486.1	RP11-731C17.2	5.86	6.22e-09	9.32e-07	0.21	0.18	Height;Body mass index;	chr3:136157707	chr3:136837338~136839021:-
BRCA	cis	rs3814244	1	rs3814244	ENSG00000236946.2	HNRNPA1P70	5.86	6.22e-09	9.32e-07	0.15	0.18	Itch intensity from mosquito bite adjusted by bite size;	chr12:68019691	chr12:68035767~68036853:+
BRCA	cis	rs9840812	0.623	rs1394092	ENSG00000273486.1	RP11-731C17.2	5.86	6.22e-09	9.33e-07	0.21	0.18	Fibrinogen levels;	chr3:136477229	chr3:136837338~136839021:-
BRCA	cis	rs897984	0.683	rs8050330	ENSG00000260911.2	RP11-196G11.2	5.86	6.22e-09	9.33e-07	0.16	0.18	Dementia with Lewy bodies;	chr16:30813649	chr16:31043150~31049868:+
BRCA	cis	rs35146811	0.586	rs6946168	ENSG00000214313.7	AZGP1P1	5.86	6.22e-09	9.33e-07	0.2	0.18	Coronary artery disease;	chr7:100000663	chr7:99980762~99987535:+
BRCA	cis	rs67981189	0.896	rs2526882	ENSG00000258571.1	PTTG4P	5.86	6.23e-09	9.33e-07	0.2	0.18	Schizophrenia;	chr14:70907985	chr14:71085482~71085833:-
BRCA	cis	rs2239547	0.563	rs6797399	ENSG00000242142.1	SERBP1P3	5.86	6.23e-09	9.33e-07	0.23	0.18	Schizophrenia;	chr3:52871901	chr3:53064283~53065091:-
BRCA	cis	rs755249	0.501	rs621807	ENSG00000228060.1	RP11-69E11.8	-5.86	6.23e-09	9.34e-07	-0.19	-0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39376771	chr1:39565160~39573203:+
BRCA	cis	rs2554380	0.628	rs7177929	ENSG00000230373.7	GOLGA6L5P	-5.86	6.24e-09	9.35e-07	-0.22	-0.18	Height;	chr15:83809927	chr15:84507885~84516814:-
BRCA	cis	rs2732480	0.577	rs2450994	ENSG00000257763.1	OR5BK1P	5.86	6.25e-09	9.37e-07	0.19	0.18	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48328049	chr12:48355792~48356614:-
BRCA	cis	rs2834188	1	rs2409488	ENSG00000272659.1	AP000295.10	-5.86	6.26e-09	9.38e-07	-0.27	-0.18	Narcolepsy;	chr21:33316609	chr21:33309491~33310181:+
BRCA	cis	rs17597773	0.674	rs1494372	ENSG00000272823.1	RP11-295M18.6	-5.86	6.26e-09	9.38e-07	-0.21	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220841279	chr1:220828676~220829211:-
BRCA	cis	rs4950322	0.57	rs11800580	ENSG00000244371.2	PFN1P8	5.86	6.27e-09	9.39e-07	0.24	0.18	Protein quantitative trait loci;	chr1:147261053	chr1:146957117~146957659:-
BRCA	cis	rs7688540	0.8	rs2353599	ENSG00000275426.1	CH17-262A2.1	5.86	6.27e-09	9.39e-07	0.22	0.18	Facial morphology (factor 6, height of vermillion lower lip);	chr4:286637	chr4:149738~150317:+
BRCA	cis	rs559928	0.606	rs56207008	ENSG00000236935.1	AP003774.1	5.86	6.27e-09	9.4e-07	0.25	0.18	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64115743	chr11:64325050~64329504:-
BRCA	cis	rs7613875	0.6	rs2624832	ENSG00000228008.1	CTD-2330K9.3	5.86	6.27e-09	9.4e-07	0.18	0.18	Body mass index;	chr3:49993425	chr3:49903845~49916937:+
BRCA	cis	rs2243480	1	rs4718269	ENSG00000164669.11	INTS4P1	-5.86	6.28e-09	9.4e-07	-0.33	-0.18	Diabetic kidney disease;	chr7:65735810	chr7:65141225~65234216:+
BRCA	cis	rs35146811	0.586	rs1076237	ENSG00000214313.7	AZGP1P1	5.86	6.28e-09	9.4e-07	0.19	0.18	Coronary artery disease;	chr7:99987818	chr7:99980762~99987535:+
BRCA	cis	rs7618501	0.521	rs6774354	ENSG00000228008.1	CTD-2330K9.3	5.86	6.28e-09	9.41e-07	0.17	0.18	Intelligence (multi-trait analysis);	chr3:49924347	chr3:49903845~49916937:+
BRCA	cis	rs17301013	0.606	rs17300775	ENSG00000227373.4	RP11-160H22.5	5.86	6.28e-09	9.41e-07	0.27	0.18	Systemic lupus erythematosus;	chr1:174191901	chr1:174115300~174160004:-
BRCA	cis	rs2243480	1	rs4718333	ENSG00000232559.3	GS1-124K5.12	-5.86	6.29e-09	9.41e-07	-0.34	-0.18	Diabetic kidney disease;	chr7:66307771	chr7:66554588~66576923:-
BRCA	cis	rs2243480	1	rs7792391	ENSG00000232559.3	GS1-124K5.12	-5.86	6.29e-09	9.41e-07	-0.34	-0.18	Diabetic kidney disease;	chr7:66308442	chr7:66554588~66576923:-
BRCA	cis	rs7646881	0.812	rs7635704	ENSG00000240207.5	RP11-379F4.4	-5.86	6.29e-09	9.42e-07	-0.27	-0.18	Tetralogy of Fallot;	chr3:158741931	chr3:158732263~158784070:+
BRCA	cis	rs55702914	0.628	rs55658871	ENSG00000231621.1	AC013264.2	-5.86	6.29e-09	9.42e-07	-0.16	-0.18	Major depression and alcohol dependence;	chr2:197413847	chr2:197197991~197199273:+
BRCA	cis	rs8114671	0.585	rs2236271	ENSG00000269202.1	RP4-614O4.12	5.86	6.3e-09	9.43e-07	0.19	0.18	Height;	chr20:34936037	chr20:35201747~35203288:-
BRCA	cis	rs12073837	0.5	rs4143772	ENSG00000272823.1	RP11-295M18.6	-5.86	6.3e-09	9.43e-07	-0.19	-0.18	F-cell distribution;	chr1:220815004	chr1:220828676~220829211:-
BRCA	cis	rs801193	0.773	rs801207	ENSG00000273024.4	INTS4P2	5.86	6.3e-09	9.44e-07	0.2	0.18	Aortic root size;	chr7:66555603	chr7:65647864~65715661:+
BRCA	cis	rs9652601	0.959	rs12708715	ENSG00000274038.1	RP11-66H6.4	-5.86	6.3e-09	9.44e-07	-0.21	-0.18	Systemic lupus erythematosus;	chr16:11083967	chr16:11056556~11057034:+
BRCA	cis	rs17508449	0.819	rs76726048	ENSG00000232450.1	RP4-730K3.3	-5.86	6.31e-09	9.44e-07	-0.33	-0.18	Leprosy;	chr1:113664077	chr1:113698884~113699631:-
BRCA	cis	rs2153535	0.585	rs1033803	ENSG00000230939.1	RP11-314C16.1	-5.86	6.31e-09	9.45e-07	-0.21	-0.18	Motion sickness;	chr6:8674779	chr6:8784178~8785445:+
BRCA	cis	rs2638953	0.814	rs60960895	ENSG00000278733.1	RP11-425D17.1	-5.86	6.32e-09	9.46e-07	-0.24	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28454499	chr12:28185625~28186190:-
BRCA	cis	rs7474896	0.537	rs1208591	ENSG00000226578.1	RP11-258F22.1	-5.86	6.32e-09	9.46e-07	-0.23	-0.18	Obesity (extreme);	chr10:37923574	chr10:37775371~37784131:-
BRCA	cis	rs4907240	0.921	rs2278563	ENSG00000237510.6	AC008268.2	-5.86	6.32e-09	9.46e-07	-0.26	-0.18	Event-related brain oscillations;	chr2:96546956	chr2:95789654~95800166:+
BRCA	cis	rs16846053	0.71	rs13006199	ENSG00000227403.1	AC009299.3	5.86	6.33e-09	9.47e-07	0.3	0.18	Blood osmolality (transformed sodium);	chr2:161770258	chr2:161244739~161249050:+
BRCA	cis	rs1193	0.789	rs6735763	ENSG00000231259.4	AC125232.1	-5.86	6.33e-09	9.48e-07	-0.23	-0.18	High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;High light scatter reticulocyte count;	chr2:86692746	chr2:87031815~87053069:-
BRCA	cis	rs227275	0.554	rs223359	ENSG00000251288.2	RP11-10L12.2	-5.86	6.34e-09	9.49e-07	-0.21	-0.18	Allergic disease (asthma, hay fever or eczema);	chr4:102849422	chr4:102751401~102752641:+
BRCA	cis	rs30380	0.632	rs26497	ENSG00000272109.1	CTD-2260A17.3	-5.86	6.34e-09	9.5e-07	-0.25	-0.18	Cerebrospinal fluid biomarker levels;	chr5:96803064	chr5:96804353~96806105:+
BRCA	cis	rs250585	0.736	rs250559	ENSG00000260136.4	CTD-2270L9.4	5.86	6.35e-09	9.5e-07	0.18	0.18	Egg allergy;	chr16:23441503	chr16:23452758~23457606:+
BRCA	cis	rs13126694	0.744	rs4521391	ENSG00000248429.4	RP11-597D13.9	5.86	6.35e-09	9.51e-07	0.16	0.18	Blood osmolality (transformed sodium);	chr4:158017310	chr4:158170752~158202877:+
BRCA	cis	rs35612822	0.866	rs2738287	ENSG00000232485.2	AC098820.3	-5.86	6.36e-09	9.51e-07	-0.23	-0.18	Kidney disease (early stage) in type 1 diabetes;	chr2:216485113	chr2:216479030~216498761:-
BRCA	cis	rs2243480	1	rs313832	ENSG00000232546.1	RP11-458F8.1	-5.86	6.36e-09	9.51e-07	-0.25	-0.18	Diabetic kidney disease;	chr7:66085904	chr7:66848496~66858136:+
BRCA	cis	rs11977670	0.781	rs12703654	ENSG00000260231.1	JHDM1D-AS1	-5.86	6.36e-09	9.51e-07	-0.19	-0.18	Breast cancer;	chr7:140254840	chr7:140177261~140179640:+
BRCA	cis	rs17301013	0.606	rs56404641	ENSG00000227373.4	RP11-160H22.5	5.86	6.36e-09	9.52e-07	0.27	0.18	Systemic lupus erythematosus;	chr1:174176323	chr1:174115300~174160004:-
BRCA	cis	rs9308731	0.777	rs590097	ENSG00000227992.1	AC108463.2	-5.86	6.36e-09	9.52e-07	-0.22	-0.18	Chronic lymphocytic leukemia;	chr2:111176530	chr2:111203964~111206215:-
BRCA	cis	rs7246657	1	rs7246657	ENSG00000226686.6	LINC01535	5.86	6.36e-09	9.52e-07	0.27	0.18	Coronary artery calcification;	chr19:37256206	chr19:37251912~37265535:+
BRCA	cis	rs1198430	1	rs1198432	ENSG00000232482.2	RP4-654C18.1	5.86	6.37e-09	9.54e-07	0.27	0.18	Total cholesterol levels;	chr1:23429662	chr1:23410832~23412146:+
BRCA	cis	rs7208859	0.673	rs61348930	ENSG00000265443.1	CTD-2349P21.6	-5.86	6.39e-09	9.55e-07	-0.3	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30894745	chr17:30726305~30727564:-
BRCA	cis	rs7208859	0.614	rs28758251	ENSG00000265443.1	CTD-2349P21.6	-5.86	6.39e-09	9.55e-07	-0.3	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30896294	chr17:30726305~30727564:-
BRCA	cis	rs7208859	0.673	rs9899943	ENSG00000265443.1	CTD-2349P21.6	-5.86	6.39e-09	9.55e-07	-0.3	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30896907	chr17:30726305~30727564:-
BRCA	cis	rs7208859	0.673	rs11080138	ENSG00000265443.1	CTD-2349P21.6	-5.86	6.39e-09	9.55e-07	-0.3	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30897524	chr17:30726305~30727564:-
BRCA	cis	rs7208859	0.673	rs73265612	ENSG00000265443.1	CTD-2349P21.6	-5.86	6.39e-09	9.55e-07	-0.3	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30898965	chr17:30726305~30727564:-
BRCA	cis	rs7208859	0.673	rs11658435	ENSG00000265443.1	CTD-2349P21.6	-5.86	6.39e-09	9.55e-07	-0.3	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30901543	chr17:30726305~30727564:-
BRCA	cis	rs7208859	0.673	rs73265624	ENSG00000265443.1	CTD-2349P21.6	-5.86	6.39e-09	9.55e-07	-0.3	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30905048	chr17:30726305~30727564:-
BRCA	cis	rs11105298	0.891	rs10858872	ENSG00000270344.2	RP11-734K2.4	5.86	6.39e-09	9.55e-07	0.21	0.18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89479155	chr12:89525654~89548005:+
BRCA	cis	rs55702914	0.712	rs10931778	ENSG00000231621.1	AC013264.2	5.85	6.39e-09	9.57e-07	0.17	0.18	Major depression and alcohol dependence;	chr2:197284198	chr2:197197991~197199273:+
BRCA	cis	rs17301013	0.606	rs57407575	ENSG00000227373.4	RP11-160H22.5	5.85	6.4e-09	9.57e-07	0.27	0.18	Systemic lupus erythematosus;	chr1:174115504	chr1:174115300~174160004:-
BRCA	cis	rs2348418	0.715	rs1912782	ENSG00000247934.4	RP11-967K21.1	5.85	6.4e-09	9.57e-07	0.2	0.18	Lung function (FEV1);Lung function (FVC);	chr12:28568774	chr12:28163298~28190738:-
BRCA	cis	rs7976269	0.515	rs10743637	ENSG00000257176.2	RP11-996F15.2	5.85	6.4e-09	9.58e-07	0.21	0.18	Male-pattern baldness;	chr12:29025962	chr12:29280418~29317848:-
BRCA	cis	rs4835473	0.932	rs1839449	ENSG00000249741.2	RP11-673E1.3	-5.85	6.41e-09	9.59e-07	-0.19	-0.18	Immature fraction of reticulocytes;	chr4:143730222	chr4:143911514~143912053:-
BRCA	cis	rs7615952	0.599	rs2333408	ENSG00000171084.14	FAM86JP	5.85	6.42e-09	9.6e-07	0.26	0.18	Blood pressure (smoking interaction);	chr3:126013255	chr3:125916620~125930024:+
BRCA	cis	rs904251	0.965	rs1317563	ENSG00000204110.6	RP1-153P14.8	-5.85	6.42e-09	9.61e-07	-0.2	-0.18	Cognitive performance;	chr6:37484078	chr6:37507348~37535616:+
BRCA	cis	rs4832312	1	rs4832312	ENSG00000231259.4	AC125232.1	-5.85	6.43e-09	9.61e-07	-0.22	-0.18	Mean corpuscular volume;Mean corpuscular hemoglobin;Reticulocyte fraction of red cells;	chr2:86762839	chr2:87031815~87053069:-
BRCA	cis	rs7567389	0.719	rs4150476	ENSG00000236682.1	AC068282.3	5.85	6.44e-09	9.62e-07	0.27	0.18	Self-rated health;	chr2:127275246	chr2:127389130~127400580:+
BRCA	cis	rs2835345	0.563	rs58602880	ENSG00000279365.1	KB-176G8.1	5.85	6.45e-09	9.64e-07	0.25	0.18	Pulmonary function;	chr21:36454610	chr21:36485867~36487760:+
BRCA	cis	rs801193	0.569	rs881285	ENSG00000224316.1	RP11-479O9.2	-5.85	6.45e-09	9.64e-07	-0.18	-0.18	Aortic root size;	chr7:66654433	chr7:65773620~65802067:+
BRCA	cis	rs7613875	0.537	rs6446195	ENSG00000228008.1	CTD-2330K9.3	-5.85	6.45e-09	9.64e-07	-0.17	-0.18	Body mass index;	chr3:50033420	chr3:49903845~49916937:+
BRCA	cis	rs2243480	1	rs7804223	ENSG00000232559.3	GS1-124K5.12	-5.85	6.45e-09	9.64e-07	-0.34	-0.18	Diabetic kidney disease;	chr7:66199572	chr7:66554588~66576923:-
BRCA	cis	rs10515750	0.588	rs2289851	ENSG00000248544.2	CTB-47B11.3	5.85	6.45e-09	9.65e-07	0.26	0.18	Lung function (FEV1/FVC);	chr5:157359160	chr5:157375741~157384950:-
BRCA	cis	rs7809950	0.593	rs62482503	ENSG00000238832.1	snoU109	-5.85	6.45e-09	9.65e-07	-0.26	-0.18	Coronary artery disease;	chr7:107347543	chr7:107603363~107603507:+
BRCA	cis	rs73193808	1	rs2832227	ENSG00000215533.7	LINC00189	-5.85	6.47e-09	9.67e-07	-0.26	-0.18	Coronary artery disease;	chr21:29160755	chr21:29193480~29288205:+
BRCA	cis	rs2243480	1	rs2961102	ENSG00000232559.3	GS1-124K5.12	5.85	6.47e-09	9.67e-07	0.33	0.18	Diabetic kidney disease;	chr7:65959671	chr7:66554588~66576923:-
BRCA	cis	rs11668609	1	rs8100931	ENSG00000268442.1	CTD-2027I19.2	5.85	6.48e-09	9.68e-07	0.25	0.18	Response to taxane treatment (docetaxel);	chr19:24175770	chr19:24162370~24163425:-
BRCA	cis	rs12893668	0.572	rs12590968	ENSG00000269940.1	RP11-73M18.7	5.85	6.48e-09	9.68e-07	0.2	0.18	Reticulocyte count;	chr14:103670296	chr14:103694560~103695170:+
BRCA	cis	rs7923609	0.936	rs10761778	ENSG00000232075.1	MRPL35P2	-5.85	6.48e-09	9.69e-07	-0.22	-0.18	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63514022	chr10:63634317~63634827:-
BRCA	cis	rs9402743	0.671	rs9376115	ENSG00000231028.7	LINC00271	5.85	6.48e-09	9.69e-07	0.19	0.18	Systemic lupus erythematosus;	chr6:135616579	chr6:135497801~135716055:+
BRCA	cis	rs7493	1	rs3779492	ENSG00000233942.1	AC004012.1	5.85	6.48e-09	9.69e-07	0.22	0.18	Yu-Zhi constitution type in type 2 diabetes;	chr7:95414871	chr7:95471835~95473998:+
BRCA	cis	rs7493	1	rs2040993	ENSG00000233942.1	AC004012.1	5.85	6.48e-09	9.69e-07	0.22	0.18	Yu-Zhi constitution type in type 2 diabetes;	chr7:95417988	chr7:95471835~95473998:+
BRCA	cis	rs853679	0.546	rs71537572	ENSG00000204709.4	LINC01556	5.85	6.48e-09	9.69e-07	0.48	0.18	Depression;	chr6:28002937	chr6:28943877~28944537:+
BRCA	cis	rs2015599	0.516	rs10450679	ENSG00000257176.2	RP11-996F15.2	5.85	6.48e-09	9.69e-07	0.21	0.18	Platelet count;Mean platelet volume;	chr12:29298823	chr12:29280418~29317848:-
BRCA	cis	rs755249	0.501	rs4660669	ENSG00000228060.1	RP11-69E11.8	5.85	6.49e-09	9.69e-07	0.19	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39341786	chr1:39565160~39573203:+
BRCA	cis	rs1555322	0.53	rs2425042	ENSG00000269202.1	RP4-614O4.12	-5.85	6.49e-09	9.7e-07	-0.21	-0.18	Attention deficit hyperactivity disorder;	chr20:35278092	chr20:35201747~35203288:-
BRCA	cis	rs651907	0.557	rs11924013	ENSG00000244119.1	PDCL3P4	5.85	6.49e-09	9.7e-07	0.14	0.18	Colorectal cancer;	chr3:101647854	chr3:101712472~101713191:+
BRCA	cis	rs3213958	0.574	rs1440154	ENSG00000249274.1	PDLIM1P4	-5.85	6.5e-09	9.71e-07	-0.27	-0.18	Blood protein levels;	chr3:98826022	chr3:98782188~98783193:+
BRCA	cis	rs2303759	0.709	rs3760667	ENSG00000268686.1	AC010524.2	-5.85	6.5e-09	9.71e-07	-0.29	-0.18	Multiple sclerosis;	chr19:49311575	chr19:49368705~49388081:-
BRCA	cis	rs11668609	0.748	rs8112938	ENSG00000268442.1	CTD-2027I19.2	5.85	6.5e-09	9.72e-07	0.24	0.18	Response to taxane treatment (docetaxel);	chr19:24169654	chr19:24162370~24163425:-
BRCA	cis	rs9287719	0.674	rs12620209	ENSG00000243819.4	RN7SL832P	5.85	6.51e-09	9.73e-07	0.18	0.18	Prostate cancer;	chr2:10580315	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.674	rs12622551	ENSG00000243819.4	RN7SL832P	5.85	6.51e-09	9.73e-07	0.18	0.18	Prostate cancer;	chr2:10580317	chr2:10690344~10692099:+
BRCA	cis	rs11668609	1	rs7260280	ENSG00000268442.1	CTD-2027I19.2	5.85	6.51e-09	9.73e-07	0.24	0.18	Response to taxane treatment (docetaxel);	chr19:24140020	chr19:24162370~24163425:-
BRCA	cis	rs2235642	0.821	rs2281236	ENSG00000280231.1	LA16c-380F5.3	-5.85	6.52e-09	9.74e-07	-0.23	-0.18	Coronary artery disease;	chr16:1553575	chr16:1553655~1554130:-
BRCA	cis	rs2243480	1	rs437889	ENSG00000228409.4	CCT6P1	5.85	6.53e-09	9.75e-07	0.25	0.18	Diabetic kidney disease;	chr7:66044247	chr7:65751142~65763354:+
BRCA	cis	rs9309473	1	rs6736866	ENSG00000163016.8	ALMS1P	5.85	6.53e-09	9.75e-07	0.23	0.18	Metabolite levels;	chr2:73434858	chr2:73644919~73685576:+
BRCA	cis	rs9990333	0.521	rs3862281	ENSG00000231464.1	AC024937.4	5.85	6.53e-09	9.75e-07	0.23	0.18	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196092985	chr3:195996738~195998233:+
BRCA	cis	rs2998286	0.862	rs1416817	ENSG00000254635.4	WAC-AS1	-5.85	6.53e-09	9.76e-07	-0.24	-0.18	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28503548	chr10:28522652~28532743:-
BRCA	cis	rs4950322	0.542	rs72692942	ENSG00000244371.2	PFN1P8	-5.85	6.53e-09	9.76e-07	-0.25	-0.18	Protein quantitative trait loci;	chr1:147318467	chr1:146957117~146957659:-
BRCA	cis	rs4950322	0.57	rs4950399	ENSG00000244371.2	PFN1P8	-5.85	6.53e-09	9.76e-07	-0.25	-0.18	Protein quantitative trait loci;	chr1:147319302	chr1:146957117~146957659:-
BRCA	cis	rs9990333	0.544	rs73208092	ENSG00000231464.1	AC024937.4	5.85	6.54e-09	9.76e-07	0.23	0.18	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196091703	chr3:195996738~195998233:+
BRCA	cis	rs2243480	0.901	rs35087093	ENSG00000164669.11	INTS4P1	5.85	6.54e-09	9.76e-07	0.34	0.18	Diabetic kidney disease;	chr7:65940221	chr7:65141225~65234216:+
BRCA	cis	rs2749097	0.609	rs10889435	ENSG00000244256.3	RN7SL130P	-5.85	6.54e-09	9.76e-07	-0.24	-0.18	Alcohol consumption (transferrin glycosylation);	chr1:63648285	chr1:63655743~63656047:+
BRCA	cis	rs17818399	1	rs17818399	ENSG00000279254.1	RP11-536C12.1	-5.85	6.54e-09	9.77e-07	-0.23	-0.18	Height;	chr2:46598887	chr2:46668870~46670778:+
BRCA	cis	rs9353324	1	rs78362791	ENSG00000203875.9	SNHG5	-5.85	6.54e-09	9.77e-07	-0.48	-0.18	Interferon gamma-induced protein 10 levels;	chr6:86032858	chr6:85660950~85678736:-
BRCA	cis	rs3805389	0.962	rs28708716	ENSG00000249700.7	SRD5A3-AS1	-5.85	6.54e-09	9.77e-07	-0.26	-0.18	Waist-to-hip ratio adjusted for body mass index;	chr4:55596308	chr4:55363971~55395847:-
BRCA	cis	rs2243480	1	rs402418	ENSG00000228409.4	CCT6P1	5.85	6.55e-09	9.78e-07	0.25	0.18	Diabetic kidney disease;	chr7:66044482	chr7:65751142~65763354:+
BRCA	cis	rs2243480	1	rs73150014	ENSG00000232559.3	GS1-124K5.12	5.85	6.56e-09	9.79e-07	0.34	0.18	Diabetic kidney disease;	chr7:65985932	chr7:66554588~66576923:-
BRCA	cis	rs2638953	1	rs2638953	ENSG00000278733.1	RP11-425D17.1	5.85	6.56e-09	9.79e-07	0.22	0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28381482	chr12:28185625~28186190:-
BRCA	cis	rs42648	0.564	rs17867585	ENSG00000225498.1	AC002064.5	5.85	6.56e-09	9.79e-07	0.17	0.18	Homocysteine levels;	chr7:90189860	chr7:90312496~90322592:+
BRCA	cis	rs2274273	0.686	rs57033289	ENSG00000258413.1	RP11-665C16.6	-5.85	6.56e-09	9.79e-07	-0.25	-0.18	Protein biomarker;	chr14:55156599	chr14:55262767~55272075:-
BRCA	cis	rs2274273	0.686	rs11624679	ENSG00000258413.1	RP11-665C16.6	-5.85	6.56e-09	9.79e-07	-0.25	-0.18	Protein biomarker;	chr14:55157526	chr14:55262767~55272075:-
BRCA	cis	rs710913	0.745	rs67563067	ENSG00000182109.6	RP11-69E11.4	-5.85	6.56e-09	9.8e-07	-0.2	-0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39581323	chr1:39522280~39546187:-
BRCA	cis	rs875971	0.545	rs73378304	ENSG00000273024.4	INTS4P2	-5.85	6.57e-09	9.81e-07	-0.21	-0.18	Aortic root size;	chr7:66175760	chr7:65647864~65715661:+
BRCA	cis	rs6951245	0.529	rs10262070	ENSG00000229043.2	AC091729.9	-5.85	6.57e-09	9.81e-07	-0.27	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1102102	chr7:1160374~1165267:+
BRCA	cis	rs651907	0.535	rs11714444	ENSG00000244119.1	PDCL3P4	5.85	6.58e-09	9.82e-07	0.15	0.18	Colorectal cancer;	chr3:101794838	chr3:101712472~101713191:+
BRCA	cis	rs651907	0.557	rs59596156	ENSG00000244119.1	PDCL3P4	5.85	6.58e-09	9.82e-07	0.14	0.18	Colorectal cancer;	chr3:101675373	chr3:101712472~101713191:+
BRCA	cis	rs73222236	0.825	rs34962604	ENSG00000273486.1	RP11-731C17.2	5.85	6.58e-09	9.83e-07	0.2	0.18	Coronary artery disease;	chr3:136511148	chr3:136837338~136839021:-
BRCA	cis	rs2243480	0.908	rs55876148	ENSG00000232559.3	GS1-124K5.12	5.85	6.59e-09	9.83e-07	0.34	0.18	Diabetic kidney disease;	chr7:65914813	chr7:66554588~66576923:-
BRCA	cis	rs7567389	0.719	rs1011019	ENSG00000236682.1	AC068282.3	5.85	6.59e-09	9.84e-07	0.27	0.18	Self-rated health;	chr2:127279984	chr2:127389130~127400580:+
BRCA	cis	rs7688540	0.771	rs11723615	ENSG00000211553.1	AC253576.2	-5.85	6.6e-09	9.85e-07	-0.28	-0.18	Facial morphology (factor 6, height of vermillion lower lip);	chr4:283194	chr4:136461~136568:+
BRCA	cis	rs11105298	0.891	rs10858864	ENSG00000270344.2	RP11-734K2.4	5.85	6.6e-09	9.85e-07	0.21	0.18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89452453	chr12:89525654~89548005:+
BRCA	cis	rs11105298	0.891	rs10858865	ENSG00000270344.2	RP11-734K2.4	5.85	6.6e-09	9.85e-07	0.21	0.18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89452699	chr12:89525654~89548005:+
BRCA	cis	rs10392	0.571	rs4812350	ENSG00000274825.1	RP4-616B8.5	-5.85	6.6e-09	9.86e-07	-0.18	-0.18	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;	chr20:39002549	chr20:38955910~38956547:+
BRCA	cis	rs17767294	1	rs17767294	ENSG00000220721.1	OR1F12	5.85	6.61e-09	9.86e-07	0.33	0.18	Parkinson's disease;	chr6:28086420	chr6:28073316~28074233:+
BRCA	cis	rs8048589	0.948	rs35053871	ENSG00000175604.2	RP11-276H1.3	-5.85	6.61e-09	9.87e-07	-0.27	-0.18	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);	chr16:12088580	chr16:12086746~12090302:-
BRCA	cis	rs1552244	1	rs111392584	ENSG00000180385.7	EMC3-AS1	5.85	6.61e-09	9.87e-07	0.23	0.18	Alzheimer's disease;	chr3:10034307	chr3:9986893~10006990:+
BRCA	cis	rs1552244	1	rs17032276	ENSG00000180385.7	EMC3-AS1	5.85	6.61e-09	9.87e-07	0.23	0.18	Alzheimer's disease;	chr3:10035291	chr3:9986893~10006990:+
BRCA	cis	rs2832191	0.716	rs2249028	ENSG00000176054.6	RPL23P2	5.85	6.62e-09	9.88e-07	0.19	0.18	Dental caries;	chr21:28993001	chr21:28997613~28998033:-
BRCA	cis	rs4713118	0.629	rs149899	ENSG00000219392.1	RP1-265C24.5	-5.85	6.62e-09	9.88e-07	-0.27	-0.18	Parkinson's disease;	chr6:28052201	chr6:28115628~28116551:+
BRCA	cis	rs4713118	0.629	rs172165	ENSG00000219392.1	RP1-265C24.5	-5.85	6.62e-09	9.88e-07	-0.27	-0.18	Parkinson's disease;	chr6:28053036	chr6:28115628~28116551:+
BRCA	cis	rs4908760	0.965	rs12080583	ENSG00000270282.1	RP5-1115A15.2	5.85	6.63e-09	9.89e-07	0.19	0.18	Vitiligo;	chr1:8464817	chr1:8512653~8513021:+
BRCA	cis	rs7493	0.901	rs17879517	ENSG00000233942.1	AC004012.1	5.85	6.63e-09	9.9e-07	0.22	0.18	Yu-Zhi constitution type in type 2 diabetes;	chr7:95401334	chr7:95471835~95473998:+
BRCA	cis	rs12893668	0.572	rs11846404	ENSG00000269910.1	RP11-73M18.10	5.85	6.64e-09	9.91e-07	0.19	0.18	Reticulocyte count;	chr14:103689771	chr14:103694516~103695050:-
BRCA	cis	rs2836950	0.501	rs13047518	ENSG00000255568.3	BRWD1-AS2	-5.85	6.64e-09	9.91e-07	-0.17	-0.18	Menarche (age at onset);	chr21:39335381	chr21:39313935~39314962:+
BRCA	cis	rs7665090	1	rs10027437	ENSG00000246560.2	RP11-10L12.4	5.85	6.65e-09	9.92e-07	0.19	0.18	Primary biliary cholangitis;	chr4:102636094	chr4:102828055~102844075:+
BRCA	cis	rs2243480	1	rs73142162	ENSG00000164669.11	INTS4P1	5.85	6.65e-09	9.93e-07	0.35	0.18	Diabetic kidney disease;	chr7:65909309	chr7:65141225~65234216:+
BRCA	cis	rs72681920	0.881	rs4699381	ENSG00000246090.5	RP11-696N14.1	-5.85	6.66e-09	9.93e-07	-0.3	-0.18	Alcohol dependence;	chr4:99247823	chr4:99088857~99301356:+
BRCA	cis	rs72681920	0.881	rs72679867	ENSG00000246090.5	RP11-696N14.1	-5.85	6.66e-09	9.93e-07	-0.3	-0.18	Alcohol dependence;	chr4:99248640	chr4:99088857~99301356:+
BRCA	cis	rs73222236	0.825	rs9858457	ENSG00000273486.1	RP11-731C17.2	5.85	6.66e-09	9.94e-07	0.2	0.18	Coronary artery disease;	chr3:136530735	chr3:136837338~136839021:-
BRCA	cis	rs10129255	1	rs8012033	ENSG00000280411.1	IGHV1-69-2	-5.85	6.67e-09	9.96e-07	-0.13	-0.18	Kawasaki disease;	chr14:106678854	chr14:106762092~106762588:-
BRCA	cis	rs4950322	0.57	rs72691102	ENSG00000244371.2	PFN1P8	-5.85	6.68e-09	9.97e-07	-0.25	-0.18	Protein quantitative trait loci;	chr1:147301189	chr1:146957117~146957659:-
BRCA	cis	rs4950322	0.57	rs72692904	ENSG00000244371.2	PFN1P8	-5.85	6.68e-09	9.97e-07	-0.25	-0.18	Protein quantitative trait loci;	chr1:147301437	chr1:146957117~146957659:-
BRCA	cis	rs4950322	0.57	rs72692905	ENSG00000244371.2	PFN1P8	-5.85	6.68e-09	9.97e-07	-0.25	-0.18	Protein quantitative trait loci;	chr1:147301560	chr1:146957117~146957659:-
BRCA	cis	rs11668609	0.81	rs9305015	ENSG00000268442.1	CTD-2027I19.2	-5.85	6.68e-09	9.97e-07	-0.25	-0.18	Response to taxane treatment (docetaxel);	chr19:24157700	chr19:24162370~24163425:-
BRCA	cis	rs910316	1	rs12889472	ENSG00000279594.1	RP11-950C14.10	5.85	6.68e-09	9.97e-07	0.2	0.18	Height;	chr14:75077276	chr14:75011269~75012851:-
BRCA	cis	rs2179367	0.537	rs12192159	ENSG00000216906.2	RP11-350J20.9	5.85	6.7e-09	9.99e-07	0.27	0.18	Dupuytren's disease;	chr6:149445969	chr6:149904243~149906418:+
BRCA	cis	rs6928977	0.538	rs17064702	ENSG00000231028.7	LINC00271	-5.85	6.7e-09	1e-06	-0.19	-0.18	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135607114	chr6:135497801~135716055:+
BRCA	cis	rs10129255	0.719	rs7156660	ENSG00000224373.3	IGHV4-59	5.85	6.7e-09	1e-06	0.11	0.18	Kawasaki disease;	chr14:106673171	chr14:106627249~106627825:-
BRCA	cis	rs2243480	0.901	rs73148097	ENSG00000232559.3	GS1-124K5.12	5.85	6.71e-09	1e-06	0.33	0.18	Diabetic kidney disease;	chr7:65966800	chr7:66554588~66576923:-
BRCA	cis	rs2243480	1	rs906134	ENSG00000232559.3	GS1-124K5.12	5.85	6.71e-09	1e-06	0.33	0.18	Diabetic kidney disease;	chr7:65979301	chr7:66554588~66576923:-
BRCA	cis	rs9813712	0.595	rs12490957	ENSG00000228252.7	COL6A4P2	5.85	6.71e-09	1e-06	0.21	0.18	Response to amphetamines;	chr3:130287851	chr3:130212823~130273806:+
BRCA	cis	rs7520050	0.931	rs6686134	ENSG00000280836.1	AL355480.1	5.85	6.72e-09	1e-06	0.21	0.18	Reticulocyte count;Red blood cell count;	chr1:45912596	chr1:45581219~45581321:-
BRCA	cis	rs4415084	0.966	rs4479849	ENSG00000251141.4	RP11-53O19.1	-5.85	6.72e-09	1e-06	-0.17	-0.18	Breast cancer;	chr5:44643904	chr5:44744900~44808777:-
BRCA	cis	rs2904967	0.929	rs673147	ENSG00000254614.2	AP003068.23	5.85	6.72e-09	1e-06	0.33	0.18	Mean corpuscular volume;	chr11:65292956	chr11:65177606~65181834:-
BRCA	cis	rs7432375	0.61	rs56163507	ENSG00000239213.4	NCK1-AS1	5.85	6.73e-09	1e-06	0.19	0.18	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136797214	chr3:136841726~136862054:-
BRCA	cis	rs858239	0.73	rs858290	ENSG00000230042.1	AK3P3	-5.85	6.74e-09	1.01e-06	-0.2	-0.18	Cerebrospinal fluid biomarker levels;	chr7:23208417	chr7:23129178~23129841:+
BRCA	cis	rs11722228	0.522	rs73212808	ENSG00000261490.1	RP11-448G15.3	5.85	6.74e-09	1.01e-06	0.2	0.18	Urate levels;Serum uric acid levels;Gout;	chr4:10053815	chr4:10068089~10073019:-
BRCA	cis	rs2243480	0.901	rs313808	ENSG00000232559.3	GS1-124K5.12	5.85	6.74e-09	1.01e-06	0.33	0.18	Diabetic kidney disease;	chr7:66034886	chr7:66554588~66576923:-
BRCA	cis	rs7809950	0.678	rs2301801	ENSG00000238832.1	snoU109	-5.85	6.75e-09	1.01e-06	-0.27	-0.18	Coronary artery disease;	chr7:107230301	chr7:107603363~107603507:+
BRCA	cis	rs66887589	0.837	rs7661498	ENSG00000245958.5	RP11-33B1.1	-5.85	6.75e-09	1.01e-06	-0.16	-0.18	Diastolic blood pressure;	chr4:119486953	chr4:119454791~119552025:+
BRCA	cis	rs72681920	0.881	rs12504321	ENSG00000246090.5	RP11-696N14.1	-5.85	6.75e-09	1.01e-06	-0.27	-0.18	Alcohol dependence;	chr4:99281548	chr4:99088857~99301356:+
BRCA	cis	rs72681920	0.881	rs12504365	ENSG00000246090.5	RP11-696N14.1	-5.85	6.75e-09	1.01e-06	-0.27	-0.18	Alcohol dependence;	chr4:99281880	chr4:99088857~99301356:+
BRCA	cis	rs72681920	0.881	rs28364304	ENSG00000246090.5	RP11-696N14.1	-5.85	6.75e-09	1.01e-06	-0.27	-0.18	Alcohol dependence;	chr4:99285755	chr4:99088857~99301356:+
BRCA	cis	rs2153535	0.539	rs4960436	ENSG00000230939.1	RP11-314C16.1	-5.85	6.75e-09	1.01e-06	-0.21	-0.18	Motion sickness;	chr6:8532237	chr6:8784178~8785445:+
BRCA	cis	rs793571	0.505	rs2305421	ENSG00000259250.1	RP11-50C13.1	-5.85	6.75e-09	1.01e-06	-0.31	-0.18	Schizophrenia;	chr15:58610884	chr15:58587507~58591676:+
BRCA	cis	rs2688608	0.901	rs2675671	ENSG00000271816.1	BMS1P4	5.85	6.76e-09	1.01e-06	0.17	0.18	Inflammatory bowel disease;	chr10:73873002	chr10:73699151~73730487:-
BRCA	cis	rs67340775	0.541	rs200973	ENSG00000220721.1	OR1F12	5.85	6.76e-09	1.01e-06	0.26	0.18	Lung cancer in ever smokers;	chr6:27890643	chr6:28073316~28074233:+
BRCA	cis	rs2243480	1	rs34193460	ENSG00000232559.3	GS1-124K5.12	5.85	6.77e-09	1.01e-06	0.33	0.18	Diabetic kidney disease;	chr7:65928123	chr7:66554588~66576923:-
BRCA	cis	rs300890	0.513	rs72719163	ENSG00000250326.1	RP11-284M14.1	5.84	6.77e-09	1.01e-06	0.21	0.18	Nasopharyngeal carcinoma;	chr4:143130799	chr4:142933195~143184861:-
BRCA	cis	rs2243480	1	rs431318	ENSG00000228409.4	CCT6P1	5.84	6.77e-09	1.01e-06	0.25	0.18	Diabetic kidney disease;	chr7:66046610	chr7:65751142~65763354:+
BRCA	cis	rs4835473	0.932	rs1813908	ENSG00000249741.2	RP11-673E1.3	-5.84	6.77e-09	1.01e-06	-0.19	-0.18	Immature fraction of reticulocytes;	chr4:143728174	chr4:143911514~143912053:-
BRCA	cis	rs7829975	0.742	rs1533059	ENSG00000233609.3	RP11-62H7.2	-5.84	6.77e-09	1.01e-06	-0.17	-0.18	Mood instability;	chr8:8827443	chr8:8961200~8979025:+
BRCA	cis	rs7493	1	rs6961773	ENSG00000233942.1	AC004012.1	5.84	6.78e-09	1.01e-06	0.22	0.18	Yu-Zhi constitution type in type 2 diabetes;	chr7:95408406	chr7:95471835~95473998:+
BRCA	cis	rs1859596	1	rs2158706	ENSG00000234456.6	MAGI2-AS3	5.84	6.78e-09	1.01e-06	0.12	0.18	Reading or mathematical ability;	chr7:79469955	chr7:79452877~79471208:+
BRCA	cis	rs792448	0.743	rs3767863	ENSG00000226251.4	RP11-15I11.3	-5.84	6.79e-09	1.01e-06	-0.22	-0.18	White blood cell count (basophil);	chr1:212364365	chr1:212225278~212238977:-
BRCA	cis	rs4763879	0.778	rs1044771	ENSG00000214776.8	RP11-726G1.1	-5.84	6.79e-09	1.01e-06	-0.2	-0.18	Type 1 diabetes;	chr12:9699333	chr12:9467552~9576275:+
BRCA	cis	rs1697139	1	rs1697139	ENSG00000249364.4	RP11-434D9.1	5.84	6.8e-09	1.01e-06	0.21	0.18	Breast cancer;	chr5:67215707	chr5:67379378~67805238:+
BRCA	cis	rs17826219	0.568	rs11658027	ENSG00000265443.1	CTD-2349P21.6	5.84	6.8e-09	1.01e-06	0.28	0.18	Body mass index;	chr17:30767864	chr17:30726305~30727564:-
BRCA	cis	rs847577	0.674	rs7790479	ENSG00000272950.1	RP11-307C18.1	5.84	6.8e-09	1.01e-06	0.23	0.18	Breast cancer;	chr7:98083789	chr7:98322853~98323430:+
BRCA	cis	rs7493	1	rs7493	ENSG00000233942.1	AC004012.1	-5.84	6.8e-09	1.01e-06	-0.22	-0.18	Yu-Zhi constitution type in type 2 diabetes;	chr7:95405463	chr7:95471835~95473998:+
BRCA	cis	rs67981189	0.896	rs7146932	ENSG00000258571.1	PTTG4P	-5.84	6.8e-09	1.01e-06	-0.2	-0.18	Schizophrenia;	chr14:71010328	chr14:71085482~71085833:-
BRCA	cis	rs10504130	0.569	rs9650305	ENSG00000272024.1	RP11-546K22.3	-5.84	6.8e-09	1.01e-06	-0.27	-0.18	Venous thromboembolism (SNP x SNP interaction);	chr8:51912113	chr8:51950284~51950690:+
BRCA	cis	rs10504130	0.569	rs9650180	ENSG00000272024.1	RP11-546K22.3	-5.84	6.8e-09	1.01e-06	-0.27	-0.18	Venous thromboembolism (SNP x SNP interaction);	chr8:51912306	chr8:51950284~51950690:+
BRCA	cis	rs6479891	1	rs4746149	ENSG00000232075.1	MRPL35P2	-5.84	6.81e-09	1.01e-06	-0.3	-0.18	Arthritis (juvenile idiopathic);	chr10:63497633	chr10:63634317~63634827:-
BRCA	cis	rs9393777	0.92	rs13195040	ENSG00000220721.1	OR1F12	-5.84	6.81e-09	1.01e-06	-0.37	-0.18	Intelligence (multi-trait analysis);	chr6:27446145	chr6:28073316~28074233:+
BRCA	cis	rs7772486	0.686	rs857879	ENSG00000270638.1	RP3-466P17.1	-5.84	6.81e-09	1.01e-06	-0.2	-0.18	Lobe attachment (rater-scored or self-reported);	chr6:145652907	chr6:145735570~145737218:+
BRCA	cis	rs2145598	0.802	rs2147610	ENSG00000279636.2	LINC00216	-5.84	6.82e-09	1.02e-06	-0.18	-0.18	Coronary artery disease;	chr14:58380269	chr14:58288033~58289158:+
BRCA	cis	rs10829156	0.66	rs10828901	ENSG00000240291.1	RP11-499P20.2	5.84	6.82e-09	1.02e-06	0.19	0.18	Sudden cardiac arrest;	chr10:18552161	chr10:18513115~18545651:-
BRCA	cis	rs2243480	1	rs34970380	ENSG00000232559.3	GS1-124K5.12	5.84	6.83e-09	1.02e-06	0.33	0.18	Diabetic kidney disease;	chr7:65966506	chr7:66554588~66576923:-
BRCA	cis	rs2274273	0.686	rs2296489	ENSG00000258413.1	RP11-665C16.6	-5.84	6.83e-09	1.02e-06	-0.25	-0.18	Protein biomarker;	chr14:55158259	chr14:55262767~55272075:-
BRCA	cis	rs3813567	0.759	rs12594550	ENSG00000261143.1	ADAMTS7P3	5.84	6.84e-09	1.02e-06	0.29	0.18	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78666695	chr15:77976042~77993057:+
BRCA	cis	rs2337406	1	rs17095456	ENSG00000211972.2	IGHV3-66	5.84	6.84e-09	1.02e-06	0.17	0.18	Alzheimer's disease (late onset);	chr14:106676559	chr14:106675017~106675544:-
BRCA	cis	rs7520050	0.966	rs11211241	ENSG00000280836.1	AL355480.1	5.84	6.85e-09	1.02e-06	0.21	0.18	Reticulocyte count;Red blood cell count;	chr1:45987011	chr1:45581219~45581321:-
BRCA	cis	rs801193	0.591	rs721717	ENSG00000224316.1	RP11-479O9.2	-5.84	6.85e-09	1.02e-06	-0.18	-0.18	Aortic root size;	chr7:66665305	chr7:65773620~65802067:+
BRCA	cis	rs1476670	0.683	rs2057967	ENSG00000230615.5	RP5-1198O20.4	-5.84	6.85e-09	1.02e-06	-0.25	-0.18	Eotaxin levels;	chr1:44049774	chr1:44030443~44115913:+
BRCA	cis	rs2115630	1	rs1030863	ENSG00000229212.6	RP11-561C5.4	5.84	6.86e-09	1.02e-06	0.19	0.18	P wave terminal force;	chr15:84739404	chr15:85205440~85234795:-
BRCA	cis	rs875971	0.528	rs801213	ENSG00000273024.4	INTS4P2	5.84	6.86e-09	1.02e-06	0.22	0.18	Aortic root size;	chr7:66549931	chr7:65647864~65715661:+
BRCA	cis	rs875971	0.545	rs801212	ENSG00000273024.4	INTS4P2	5.84	6.86e-09	1.02e-06	0.22	0.18	Aortic root size;	chr7:66550643	chr7:65647864~65715661:+
BRCA	cis	rs11671005	0.735	rs11668420	ENSG00000252334.1	RNU6-1337P	5.84	6.87e-09	1.02e-06	0.26	0.18	Mean platelet volume;	chr19:58426469	chr19:58483749~58483843:-
BRCA	cis	rs4713118	0.621	rs9295756	ENSG00000280107.1	AL022393.9	-5.84	6.87e-09	1.02e-06	-0.27	-0.18	Parkinson's disease;	chr6:28065618	chr6:28170845~28172521:+
BRCA	cis	rs17597773	0.638	rs4143773	ENSG00000272823.1	RP11-295M18.6	-5.84	6.88e-09	1.02e-06	-0.21	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220814900	chr1:220828676~220829211:-
BRCA	cis	rs55702914	0.742	rs6744206	ENSG00000231621.1	AC013264.2	5.84	6.88e-09	1.02e-06	0.17	0.18	Major depression and alcohol dependence;	chr2:197283798	chr2:197197991~197199273:+
BRCA	cis	rs6940116	1	rs6940116	ENSG00000220721.1	OR1F12	5.84	6.88e-09	1.02e-06	0.27	0.18	Intelligence (multi-trait analysis);Autism spectrum disorder or schizophrenia;	chr6:27740953	chr6:28073316~28074233:+
BRCA	cis	rs2243480	1	rs56016656	ENSG00000232559.3	GS1-124K5.12	5.84	6.88e-09	1.02e-06	0.33	0.18	Diabetic kidney disease;	chr7:65918494	chr7:66554588~66576923:-
BRCA	cis	rs2243480	1	rs56291018	ENSG00000232559.3	GS1-124K5.12	5.84	6.88e-09	1.02e-06	0.33	0.18	Diabetic kidney disease;	chr7:65925352	chr7:66554588~66576923:-
BRCA	cis	rs2243480	1	rs36033484	ENSG00000232559.3	GS1-124K5.12	5.84	6.88e-09	1.02e-06	0.33	0.18	Diabetic kidney disease;	chr7:65925571	chr7:66554588~66576923:-
BRCA	cis	rs6088813	0.925	rs1540928	ENSG00000126005.14	MMP24-AS1	5.84	6.89e-09	1.03e-06	0.21	0.18	Height;	chr20:35374042	chr20:35216462~35278131:-
BRCA	cis	rs651907	0.535	rs13094753	ENSG00000244119.1	PDCL3P4	5.84	6.89e-09	1.03e-06	0.15	0.18	Colorectal cancer;	chr3:101806238	chr3:101712472~101713191:+
BRCA	cis	rs10761482	0.5	rs6479716	ENSG00000254271.1	RP11-131N11.4	5.84	6.89e-09	1.03e-06	0.24	0.18	Schizophrenia;	chr10:60542800	chr10:60734342~60741828:+
BRCA	cis	rs4803480	1	rs11882144	ENSG00000270164.1	LINC01480	-5.84	6.9e-09	1.03e-06	-0.22	-0.18	Schizophrenia;	chr19:41566244	chr19:41535183~41536904:+
BRCA	cis	rs5771242	0.776	rs6010198	ENSG00000273253.2	RP3-402G11.26	5.84	6.9e-09	1.03e-06	0.21	0.18	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);	chr22:50172199	chr22:50199090~50200837:-
BRCA	cis	rs7618501	0.501	rs35275715	ENSG00000228008.1	CTD-2330K9.3	5.84	6.9e-09	1.03e-06	0.17	0.18	Intelligence (multi-trait analysis);	chr3:49921715	chr3:49903845~49916937:+
BRCA	cis	rs6738825	0.565	rs17787829	ENSG00000231621.1	AC013264.2	-5.84	6.9e-09	1.03e-06	-0.16	-0.18	Crohn's disease;	chr2:197555074	chr2:197197991~197199273:+
BRCA	cis	rs10129255	0.957	rs10142918	ENSG00000224373.3	IGHV4-59	5.84	6.92e-09	1.03e-06	0.11	0.18	Kawasaki disease;	chr14:106782206	chr14:106627249~106627825:-
BRCA	cis	rs875971	0.862	rs10274883	ENSG00000224316.1	RP11-479O9.2	-5.84	6.92e-09	1.03e-06	-0.18	-0.18	Aortic root size;	chr7:66651104	chr7:65773620~65802067:+
BRCA	cis	rs11105298	0.891	rs10858852	ENSG00000270344.2	RP11-734K2.4	5.84	6.92e-09	1.03e-06	0.21	0.18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89439561	chr12:89525654~89548005:+
BRCA	cis	rs11105298	0.891	rs4842653	ENSG00000270344.2	RP11-734K2.4	5.84	6.92e-09	1.03e-06	0.21	0.18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89440336	chr12:89525654~89548005:+
BRCA	cis	rs11105298	0.891	rs4842654	ENSG00000270344.2	RP11-734K2.4	5.84	6.92e-09	1.03e-06	0.21	0.18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89440651	chr12:89525654~89548005:+
BRCA	cis	rs2836950	0.565	rs8134214	ENSG00000255568.3	BRWD1-AS2	-5.84	6.93e-09	1.03e-06	-0.17	-0.18	Menarche (age at onset);	chr21:39170441	chr21:39313935~39314962:+
BRCA	cis	rs467650	1	rs469930	ENSG00000248489.1	CTD-2007H13.3	-5.84	6.93e-09	1.03e-06	-0.2	-0.18	Venous thromboembolism (SNP x SNP interaction);	chr5:98633416	chr5:98929171~98995013:+
BRCA	cis	rs763121	0.889	rs6001209	ENSG00000228274.3	RP3-508I15.9	5.84	6.93e-09	1.03e-06	0.19	0.18	Menopause (age at onset);	chr22:38725247	chr22:38667585~38681820:-
BRCA	cis	rs2115630	1	rs11854313	ENSG00000229212.6	RP11-561C5.4	5.84	6.93e-09	1.03e-06	0.19	0.18	P wave terminal force;	chr15:84760817	chr15:85205440~85234795:-
BRCA	cis	rs1559040	0.932	rs72800765	ENSG00000272156.1	RP11-477N3.1	-5.84	6.94e-09	1.03e-06	-0.29	-0.18	Sudden cardiac arrest;	chr2:54135930	chr2:54082554~54085066:+
BRCA	cis	rs4718428	0.705	rs13220977	ENSG00000230295.1	RP11-458F8.2	5.84	6.94e-09	1.03e-06	0.16	0.18	Corneal structure;	chr7:66872661	chr7:66880708~66882981:+
BRCA	cis	rs2274273	0.805	rs8012156	ENSG00000258413.1	RP11-665C16.6	-5.84	6.94e-09	1.03e-06	-0.23	-0.18	Protein biomarker;	chr14:55085782	chr14:55262767~55272075:-
BRCA	cis	rs10510102	0.516	rs78586895	ENSG00000276742.1	RP11-500G22.4	5.84	6.95e-09	1.03e-06	0.33	0.18	Breast cancer;	chr10:121977081	chr10:121956782~121957098:+
BRCA	cis	rs62025270	0.632	rs17636096	ENSG00000202081.1	RNU6-1280P	-5.84	6.95e-09	1.03e-06	-0.26	-0.18	Idiopathic pulmonary fibrosis;	chr15:85675503	chr15:85651522~85651628:-
BRCA	cis	rs875971	0.545	rs6961853	ENSG00000273024.4	INTS4P2	-5.84	6.96e-09	1.04e-06	-0.22	-0.18	Aortic root size;	chr7:66537035	chr7:65647864~65715661:+
BRCA	cis	rs30380	0.553	rs27527	ENSG00000272109.1	CTD-2260A17.3	-5.84	6.96e-09	1.04e-06	-0.26	-0.18	Cerebrospinal fluid biomarker levels;	chr5:96816265	chr5:96804353~96806105:+
BRCA	cis	rs11992162	0.967	rs10108320	ENSG00000254866.2	DEFB109P3	5.84	6.96e-09	1.04e-06	0.23	0.18	Monocyte count;	chr8:11974754	chr8:12150895~12151134:-
BRCA	cis	rs13126694	0.71	rs6847800	ENSG00000251429.1	RP11-597D13.7	5.84	6.96e-09	1.04e-06	0.17	0.18	Blood osmolality (transformed sodium);	chr4:158011724	chr4:158270378~158278676:+
BRCA	cis	rs11758351	1	rs77957229	ENSG00000241549.7	GUSBP2	-5.84	6.97e-09	1.04e-06	-0.27	-0.18	Renal underexcretion gout;Gout;	chr6:26184998	chr6:26871484~26956554:-
BRCA	cis	rs7487075	0.619	rs6582657	ENSG00000274723.1	RP11-618L22.1	5.84	6.97e-09	1.04e-06	0.22	0.18	Itch intensity from mosquito bite;	chr12:46462236	chr12:46970504~46972155:+
BRCA	cis	rs6088813	0.961	rs981819	ENSG00000126005.14	MMP24-AS1	-5.84	6.97e-09	1.04e-06	-0.21	-0.18	Height;	chr20:35336309	chr20:35216462~35278131:-
BRCA	cis	rs6088813	0.961	rs981818	ENSG00000126005.14	MMP24-AS1	-5.84	6.97e-09	1.04e-06	-0.21	-0.18	Height;	chr20:35336327	chr20:35216462~35278131:-
BRCA	cis	rs3743162	1	rs12909280	ENSG00000225151.9	GOLGA2P7	-5.84	6.98e-09	1.04e-06	-0.24	-0.18	Alzheimer's disease (age of onset);	chr15:84886125	chr15:84199311~84230136:-
BRCA	cis	rs7520050	0.966	rs6680380	ENSG00000280836.1	AL355480.1	5.84	6.98e-09	1.04e-06	0.21	0.18	Reticulocyte count;Red blood cell count;	chr1:45834517	chr1:45581219~45581321:-
BRCA	cis	rs7712401	1	rs7712401	ENSG00000249996.1	RP11-359P5.1	5.84	6.98e-09	1.04e-06	0.21	0.18	Mean platelet volume;	chr5:123038764	chr5:123036271~123054667:+
BRCA	cis	rs3213958	0.574	rs8179927	ENSG00000249274.1	PDLIM1P4	-5.84	6.98e-09	1.04e-06	-0.27	-0.18	Blood protein levels;	chr3:98830307	chr3:98782188~98783193:+
BRCA	cis	rs9527	0.615	rs11191401	ENSG00000236937.2	PTGES3P4	5.84	6.99e-09	1.04e-06	0.25	0.18	Arsenic metabolism;	chr10:102813646	chr10:102845595~102845950:+
BRCA	cis	rs2243480	0.711	rs2460426	ENSG00000232559.3	GS1-124K5.12	-5.84	6.99e-09	1.04e-06	-0.34	-0.18	Diabetic kidney disease;	chr7:66158142	chr7:66554588~66576923:-
BRCA	cis	rs6940638	0.615	rs9393801	ENSG00000216901.1	AL022393.7	5.84	6.99e-09	1.04e-06	0.22	0.18	Intelligence (multi-trait analysis);	chr6:27274902	chr6:28176188~28176674:+
BRCA	cis	rs11671005	0.735	rs3826682	ENSG00000252334.1	RNU6-1337P	5.84	6.99e-09	1.04e-06	0.26	0.18	Mean platelet volume;	chr19:58407381	chr19:58483749~58483843:-
BRCA	cis	rs10946940	0.632	rs9366698	ENSG00000216901.1	AL022393.7	5.84	7e-09	1.04e-06	0.23	0.18	Systemic lupus erythematosus;	chr6:27704256	chr6:28176188~28176674:+
BRCA	cis	rs13423976	0.631	rs4670876	ENSG00000231367.4	AC016995.3	5.84	7e-09	1.04e-06	0.2	0.18	Gut microbiome composition (summer);	chr2:38508948	chr2:38406719~38515740:-
BRCA	cis	rs2243480	1	rs316331	ENSG00000164669.11	INTS4P1	-5.84	7.01e-09	1.04e-06	-0.34	-0.18	Diabetic kidney disease;	chr7:66139635	chr7:65141225~65234216:+
BRCA	cis	rs9308731	0.644	rs7577824	ENSG00000227992.1	AC108463.2	-5.84	7.01e-09	1.04e-06	-0.21	-0.18	Chronic lymphocytic leukemia;	chr2:111119186	chr2:111203964~111206215:-
BRCA	cis	rs6479891	1	rs72837070	ENSG00000232075.1	MRPL35P2	5.84	7.01e-09	1.04e-06	0.32	0.18	Arthritis (juvenile idiopathic);	chr10:63514919	chr10:63634317~63634827:-
BRCA	cis	rs2098713	0.561	rs62359058	ENSG00000250155.1	CTD-2353F22.1	5.84	7.02e-09	1.04e-06	0.2	0.18	Telomere length;	chr5:37592593	chr5:36666214~36725195:-
BRCA	cis	rs2243480	0.901	rs2456483	ENSG00000230295.1	RP11-458F8.2	-5.84	7.02e-09	1.04e-06	-0.23	-0.18	Diabetic kidney disease;	chr7:65996588	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs1701750	ENSG00000230295.1	RP11-458F8.2	-5.84	7.02e-09	1.04e-06	-0.23	-0.18	Diabetic kidney disease;	chr7:66002158	chr7:66880708~66882981:+
BRCA	cis	rs67981189	0.546	rs2810075	ENSG00000258571.1	PTTG4P	5.84	7.02e-09	1.04e-06	0.21	0.18	Schizophrenia;	chr14:70908363	chr14:71085482~71085833:-
BRCA	cis	rs1552244	1	rs55822690	ENSG00000180385.7	EMC3-AS1	5.84	7.03e-09	1.05e-06	0.22	0.18	Alzheimer's disease;	chr3:10086319	chr3:9986893~10006990:+
BRCA	cis	rs2235642	0.787	rs2235646	ENSG00000280231.1	LA16c-380F5.3	-5.84	7.03e-09	1.05e-06	-0.23	-0.18	Coronary artery disease;	chr16:1551286	chr16:1553655~1554130:-
BRCA	cis	rs2281558	0.876	rs6107025	ENSG00000125804.12	FAM182A	-5.84	7.03e-09	1.05e-06	-0.27	-0.18	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25299244	chr20:26054655~26086917:+
BRCA	cis	rs4950322	0.57	rs113498894	ENSG00000244371.2	PFN1P8	-5.84	7.03e-09	1.05e-06	-0.25	-0.18	Protein quantitative trait loci;	chr1:147318880	chr1:146957117~146957659:-
BRCA	cis	rs875971	0.545	rs2420612	ENSG00000236529.1	RP13-254B10.1	5.84	7.03e-09	1.05e-06	0.23	0.18	Aortic root size;	chr7:66536825	chr7:65840212~65840596:+
BRCA	cis	rs4950322	0.57	rs4950403	ENSG00000244371.2	PFN1P8	-5.84	7.03e-09	1.05e-06	-0.25	-0.18	Protein quantitative trait loci;	chr1:147319723	chr1:146957117~146957659:-
BRCA	cis	rs4950322	0.517	rs116479391	ENSG00000244371.2	PFN1P8	-5.84	7.03e-09	1.05e-06	-0.25	-0.18	Protein quantitative trait loci;	chr1:147320940	chr1:146957117~146957659:-
BRCA	cis	rs7618501	0.521	rs952594	ENSG00000228008.1	CTD-2330K9.3	5.84	7.04e-09	1.05e-06	0.17	0.18	Intelligence (multi-trait analysis);	chr3:49870590	chr3:49903845~49916937:+
BRCA	cis	rs2832191	0.692	rs2245517	ENSG00000176054.6	RPL23P2	5.84	7.04e-09	1.05e-06	0.19	0.18	Dental caries;	chr21:28985647	chr21:28997613~28998033:-
BRCA	cis	rs1979679	0.959	rs75757272	ENSG00000278733.1	RP11-425D17.1	5.84	7.04e-09	1.05e-06	0.24	0.18	Ossification of the posterior longitudinal ligament of the spine;	chr12:28251809	chr12:28185625~28186190:-
BRCA	cis	rs9640161	0.83	rs3735165	ENSG00000261305.1	RP4-584D14.7	5.84	7.04e-09	1.05e-06	0.25	0.18	Blood protein levels;Circulating chemerin levels;	chr7:150371282	chr7:150341771~150342607:+
BRCA	cis	rs55692411	0.537	rs71326904	ENSG00000228008.1	CTD-2330K9.3	5.84	7.04e-09	1.05e-06	0.21	0.18	Intelligence (multi-trait analysis);	chr3:49953627	chr3:49903845~49916937:+
BRCA	cis	rs2243480	1	rs781156	ENSG00000164669.11	INTS4P1	5.84	7.05e-09	1.05e-06	0.34	0.18	Diabetic kidney disease;	chr7:66014154	chr7:65141225~65234216:+
BRCA	cis	rs2243480	1	rs451396	ENSG00000164669.11	INTS4P1	5.84	7.05e-09	1.05e-06	0.34	0.18	Diabetic kidney disease;	chr7:66019087	chr7:65141225~65234216:+
BRCA	cis	rs2243480	1	rs1715235	ENSG00000164669.11	INTS4P1	5.84	7.05e-09	1.05e-06	0.34	0.18	Diabetic kidney disease;	chr7:66023407	chr7:65141225~65234216:+
BRCA	cis	rs2253762	0.507	rs75383663	ENSG00000276742.1	RP11-500G22.4	5.84	7.05e-09	1.05e-06	0.3	0.18	Breast cancer;	chr10:121993340	chr10:121956782~121957098:+
BRCA	cis	rs253959	0.545	rs4921057	ENSG00000272265.1	CTD-2287O16.4	5.84	7.06e-09	1.05e-06	0.22	0.18	Bipolar disorder and schizophrenia;	chr5:116090723	chr5:116078110~116078570:-
BRCA	cis	rs7914558	0.966	rs10786719	ENSG00000213061.2	PFN1P11	-5.84	7.06e-09	1.05e-06	-0.23	-0.18	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102878235	chr10:102838011~102845473:-
BRCA	cis	rs11105306	1	rs11105306	ENSG00000270344.2	RP11-734K2.4	5.84	7.06e-09	1.05e-06	0.21	0.18	NT-proBNP levels in acute coronary syndrome;	chr12:89503611	chr12:89525654~89548005:+
BRCA	cis	rs7267979	0.744	rs6050463	ENSG00000277938.1	RP5-965G21.3	5.84	7.07e-09	1.05e-06	0.21	0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25228354	chr20:25229150~25231933:+
BRCA	cis	rs2243480	0.831	rs7806717	ENSG00000164669.11	INTS4P1	-5.84	7.07e-09	1.05e-06	-0.34	-0.18	Diabetic kidney disease;	chr7:65928187	chr7:65141225~65234216:+
BRCA	cis	rs2243480	1	rs34933526	ENSG00000164669.11	INTS4P1	5.84	7.07e-09	1.05e-06	0.34	0.18	Diabetic kidney disease;	chr7:65918212	chr7:65141225~65234216:+
BRCA	cis	rs2243480	1	rs6949812	ENSG00000164669.11	INTS4P1	5.84	7.07e-09	1.05e-06	0.34	0.18	Diabetic kidney disease;	chr7:65922114	chr7:65141225~65234216:+
BRCA	cis	rs2243480	1	rs6970243	ENSG00000164669.11	INTS4P1	5.84	7.07e-09	1.05e-06	0.34	0.18	Diabetic kidney disease;	chr7:65923503	chr7:65141225~65234216:+
BRCA	cis	rs2243480	0.708	rs35310401	ENSG00000164669.11	INTS4P1	5.84	7.07e-09	1.05e-06	0.34	0.18	Diabetic kidney disease;	chr7:65925372	chr7:65141225~65234216:+
BRCA	cis	rs10895987	1	rs9971407	ENSG00000254614.2	AP003068.23	5.84	7.07e-09	1.05e-06	0.28	0.18	Blood protein levels;	chr11:65130754	chr11:65177606~65181834:-
BRCA	cis	rs6928977	0.538	rs9494290	ENSG00000231028.7	LINC00271	-5.84	7.08e-09	1.05e-06	-0.19	-0.18	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135596407	chr6:135497801~135716055:+
BRCA	cis	rs2239547	0.563	rs6445547	ENSG00000242142.1	SERBP1P3	5.84	7.08e-09	1.05e-06	0.23	0.18	Schizophrenia;	chr3:52874561	chr3:53064283~53065091:-
BRCA	cis	rs1858037	0.765	rs67404371	ENSG00000204929.10	AC074391.1	5.84	7.08e-09	1.05e-06	0.24	0.18	Rheumatoid arthritis;	chr2:65370137	chr2:65436711~66084639:+
BRCA	cis	rs9527	1	rs4919690	ENSG00000236937.2	PTGES3P4	-5.84	7.08e-09	1.05e-06	-0.26	-0.18	Arsenic metabolism;	chr10:102856743	chr10:102845595~102845950:+
BRCA	cis	rs858239	0.699	rs1881201	ENSG00000230042.1	AK3P3	5.84	7.08e-09	1.05e-06	0.2	0.18	Cerebrospinal fluid biomarker levels;	chr7:23154394	chr7:23129178~23129841:+
BRCA	cis	rs2638953	0.85	rs59879751	ENSG00000278733.1	RP11-425D17.1	-5.84	7.08e-09	1.05e-06	-0.24	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28454490	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.924	rs59193275	ENSG00000278733.1	RP11-425D17.1	-5.84	7.08e-09	1.05e-06	-0.24	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28454560	chr12:28185625~28186190:-
BRCA	cis	rs9341808	0.754	rs9341811	ENSG00000272129.1	RP11-250B2.6	5.84	7.08e-09	1.05e-06	0.22	0.18	Sitting height ratio;	chr6:80272984	chr6:80355424~80356859:+
BRCA	cis	rs7246657	0.525	rs10410594	ENSG00000226686.6	LINC01535	-5.84	7.09e-09	1.05e-06	-0.3	-0.18	Coronary artery calcification;	chr19:36986856	chr19:37251912~37265535:+
BRCA	cis	rs10129255	0.5	rs2105989	ENSG00000274576.2	IGHV2-70	-5.84	7.1e-09	1.06e-06	-0.15	-0.18	Kawasaki disease;	chr14:106682199	chr14:106770577~106771020:-
BRCA	cis	rs7246657	0.941	rs7259618	ENSG00000226686.6	LINC01535	-5.84	7.1e-09	1.06e-06	-0.28	-0.18	Coronary artery calcification;	chr19:37259817	chr19:37251912~37265535:+
BRCA	cis	rs2348418	0.715	rs7971717	ENSG00000247934.4	RP11-967K21.1	5.84	7.11e-09	1.06e-06	0.2	0.18	Lung function (FEV1);Lung function (FVC);	chr12:28570087	chr12:28163298~28190738:-
BRCA	cis	rs2348418	0.681	rs10843207	ENSG00000247934.4	RP11-967K21.1	5.84	7.11e-09	1.06e-06	0.2	0.18	Lung function (FEV1);Lung function (FVC);	chr12:28569929	chr12:28163298~28190738:-
BRCA	cis	rs2337406	0.587	rs10150642	ENSG00000254174.1	IGHV1-12	-5.84	7.11e-09	1.06e-06	-0.17	-0.18	Alzheimer's disease (late onset);	chr14:106647269	chr14:106122420~106122709:-
BRCA	cis	rs56104184	0.723	rs73063515	ENSG00000235191.1	NUCB1-AS1	5.84	7.12e-09	1.06e-06	0.32	0.18	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr19:48904458	chr19:48910930~48918891:-
BRCA	cis	rs56104184	0.668	rs73063523	ENSG00000235191.1	NUCB1-AS1	5.84	7.12e-09	1.06e-06	0.32	0.18	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr19:48905686	chr19:48910930~48918891:-
BRCA	cis	rs2243480	1	rs1701758	ENSG00000230295.1	RP11-458F8.2	-5.84	7.12e-09	1.06e-06	-0.23	-0.18	Diabetic kidney disease;	chr7:66005214	chr7:66880708~66882981:+
BRCA	cis	rs6496044	0.507	rs410522	ENSG00000259295.5	CSPG4P12	-5.84	7.12e-09	1.06e-06	-0.22	-0.18	Interstitial lung disease;	chr15:85663813	chr15:85191438~85213905:+
BRCA	cis	rs9545047	0.604	rs9565491	ENSG00000227354.5	RBM26-AS1	-5.84	7.12e-09	1.06e-06	-0.19	-0.18	Schizophrenia;	chr13:79346037	chr13:79406309~79424328:+
BRCA	cis	rs4908768	0.501	rs11121186	ENSG00000270282.1	RP5-1115A15.2	5.84	7.13e-09	1.06e-06	0.19	0.18	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8480281	chr1:8512653~8513021:+
BRCA	cis	rs30380	0.587	rs151940	ENSG00000272109.1	CTD-2260A17.3	-5.84	7.13e-09	1.06e-06	-0.26	-0.18	Cerebrospinal fluid biomarker levels;	chr5:96812074	chr5:96804353~96806105:+
BRCA	cis	rs8114671	0.562	rs2378292	ENSG00000269202.1	RP4-614O4.12	-5.84	7.13e-09	1.06e-06	-0.19	-0.18	Height;	chr20:34897375	chr20:35201747~35203288:-
BRCA	cis	rs35146811	0.586	rs10267231	ENSG00000214313.7	AZGP1P1	5.84	7.13e-09	1.06e-06	0.19	0.18	Coronary artery disease;	chr7:99997857	chr7:99980762~99987535:+
BRCA	cis	rs2638953	0.893	rs10771432	ENSG00000278733.1	RP11-425D17.1	-5.84	7.14e-09	1.06e-06	-0.22	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28507798	chr12:28185625~28186190:-
BRCA	cis	rs12893668	0.572	rs34000399	ENSG00000269910.1	RP11-73M18.10	5.84	7.15e-09	1.06e-06	0.19	0.18	Reticulocyte count;	chr14:103635080	chr14:103694516~103695050:-
BRCA	cis	rs11668609	1	rs4452076	ENSG00000268442.1	CTD-2027I19.2	5.84	7.15e-09	1.06e-06	0.24	0.18	Response to taxane treatment (docetaxel);	chr19:24143981	chr19:24162370~24163425:-
BRCA	cis	rs7567389	0.719	rs4150471	ENSG00000236682.1	AC068282.3	5.84	7.16e-09	1.06e-06	0.27	0.18	Self-rated health;	chr2:127276963	chr2:127389130~127400580:+
BRCA	cis	rs4654783	0.627	rs2092322	ENSG00000228397.1	RP1-224A6.3	-5.84	7.16e-09	1.06e-06	-0.22	-0.18	Endometriosis;	chr1:22109230	chr1:22023994~22024968:-
BRCA	cis	rs9318086	0.537	rs7993131	ENSG00000205861.10	C1QTNF9B-AS1	5.84	7.16e-09	1.06e-06	0.23	0.18	Myopia (pathological);	chr13:23723014	chr13:23888889~23897263:+
BRCA	cis	rs736408	0.5	rs2878762	ENSG00000242142.1	SERBP1P3	5.84	7.17e-09	1.06e-06	0.22	0.18	Bipolar disorder;	chr3:52884986	chr3:53064283~53065091:-
BRCA	cis	rs2253762	0.507	rs11200310	ENSG00000276742.1	RP11-500G22.4	5.84	7.17e-09	1.07e-06	0.3	0.18	Breast cancer;	chr10:121989944	chr10:121956782~121957098:+
BRCA	cis	rs2098713	0.535	rs1126290	ENSG00000250155.1	CTD-2353F22.1	5.84	7.17e-09	1.07e-06	0.2	0.18	Telomere length;	chr5:37588398	chr5:36666214~36725195:-
BRCA	cis	rs2274273	0.967	rs10137409	ENSG00000258413.1	RP11-665C16.6	-5.84	7.17e-09	1.07e-06	-0.22	-0.18	Protein biomarker;	chr14:55144723	chr14:55262767~55272075:-
BRCA	cis	rs651907	0.535	rs12631513	ENSG00000244119.1	PDCL3P4	5.84	7.17e-09	1.07e-06	0.15	0.18	Colorectal cancer;	chr3:101798632	chr3:101712472~101713191:+
BRCA	cis	rs651907	0.535	rs13094911	ENSG00000244119.1	PDCL3P4	5.84	7.17e-09	1.07e-06	0.15	0.18	Colorectal cancer;	chr3:101800177	chr3:101712472~101713191:+
BRCA	cis	rs651907	0.535	rs11712309	ENSG00000244119.1	PDCL3P4	5.84	7.17e-09	1.07e-06	0.15	0.18	Colorectal cancer;	chr3:101800253	chr3:101712472~101713191:+
BRCA	cis	rs651907	0.535	rs35799195	ENSG00000244119.1	PDCL3P4	5.84	7.17e-09	1.07e-06	0.15	0.18	Colorectal cancer;	chr3:101803083	chr3:101712472~101713191:+
BRCA	cis	rs2562456	0.958	rs2562508	ENSG00000268081.1	RP11-678G14.2	-5.83	7.18e-09	1.07e-06	-0.27	-0.18	Pain;	chr19:21543479	chr19:21554640~21569237:-
BRCA	cis	rs2243480	1	rs4718269	ENSG00000228409.4	CCT6P1	-5.83	7.18e-09	1.07e-06	-0.24	-0.18	Diabetic kidney disease;	chr7:65735810	chr7:65751142~65763354:+
BRCA	cis	rs2288884	0.634	rs74476955	ENSG00000275055.1	CTC-471J1.11	-5.83	7.18e-09	1.07e-06	-0.28	-0.18	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:51997806	chr19:52049007~52049754:+
BRCA	cis	rs2288884	0.596	rs12459638	ENSG00000275055.1	CTC-471J1.11	-5.83	7.18e-09	1.07e-06	-0.28	-0.18	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:51998549	chr19:52049007~52049754:+
BRCA	cis	rs11722779	0.903	rs13130741	ENSG00000251288.2	RP11-10L12.2	-5.83	7.19e-09	1.07e-06	-0.21	-0.18	Schizophrenia;	chr4:103035799	chr4:102751401~102752641:+
BRCA	cis	rs7246967	0.673	rs4933026	ENSG00000198153.8	ZNF849P	-5.83	7.19e-09	1.07e-06	-0.26	-0.18	Bronchopulmonary dysplasia;	chr19:22691690	chr19:22685167~22686732:+
BRCA	cis	rs4713118	0.597	rs172166	ENSG00000219392.1	RP1-265C24.5	-5.83	7.19e-09	1.07e-06	-0.26	-0.18	Parkinson's disease;	chr6:28053042	chr6:28115628~28116551:+
BRCA	cis	rs2554380	0.628	rs7175491	ENSG00000230373.7	GOLGA6L5P	-5.83	7.19e-09	1.07e-06	-0.22	-0.18	Height;	chr15:83806187	chr15:84507885~84516814:-
BRCA	cis	rs113835537	0.627	rs4630309	ENSG00000255517.5	CTD-3074O7.5	5.83	7.19e-09	1.07e-06	0.24	0.18	Airway imaging phenotypes;	chr11:66565601	chr11:66473490~66480233:-
BRCA	cis	rs3930017	1	rs3930016	ENSG00000225726.1	AC007000.10	-5.83	7.2e-09	1.07e-06	-0.2	-0.18	Body mass index;	chr7:77091132	chr7:77071751~77072237:-
BRCA	cis	rs10888838	1	rs10888840	ENSG00000198711.5	SSBP3-AS1	5.83	7.2e-09	1.07e-06	0.23	0.18	Mitochondrial DNA levels;	chr1:54217740	chr1:54236440~54239063:+
BRCA	cis	rs13118159	0.55	rs13123016	ENSG00000254094.1	AC078852.1	-5.83	7.21e-09	1.07e-06	-0.22	-0.18	Longevity;	chr4:1347101	chr4:1356581~1358075:+
BRCA	cis	rs35146811	0.622	rs6946204	ENSG00000214313.7	AZGP1P1	5.83	7.21e-09	1.07e-06	0.19	0.18	Coronary artery disease;	chr7:99991502	chr7:99980762~99987535:+
BRCA	cis	rs35146811	0.586	rs6964754	ENSG00000214313.7	AZGP1P1	5.83	7.21e-09	1.07e-06	0.19	0.18	Coronary artery disease;	chr7:99991781	chr7:99980762~99987535:+
BRCA	cis	rs10129255	0.957	rs10137980	ENSG00000224373.3	IGHV4-59	5.83	7.21e-09	1.07e-06	0.11	0.18	Kawasaki disease;	chr14:106775735	chr14:106627249~106627825:-
BRCA	cis	rs11098499	0.955	rs11931312	ENSG00000249244.1	RP11-548H18.2	5.83	7.21e-09	1.07e-06	0.21	0.18	Corneal astigmatism;	chr4:119237868	chr4:119391831~119395335:-
BRCA	cis	rs56104184	0.775	rs56149557	ENSG00000235191.1	NUCB1-AS1	5.83	7.21e-09	1.07e-06	0.32	0.18	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr19:48898127	chr19:48910930~48918891:-
BRCA	cis	rs56104184	0.775	rs55981795	ENSG00000235191.1	NUCB1-AS1	5.83	7.21e-09	1.07e-06	0.32	0.18	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr19:48898695	chr19:48910930~48918891:-
BRCA	cis	rs56104184	0.775	rs117744769	ENSG00000235191.1	NUCB1-AS1	5.83	7.21e-09	1.07e-06	0.32	0.18	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr19:48899429	chr19:48910930~48918891:-
BRCA	cis	rs56104184	0.775	rs73063505	ENSG00000235191.1	NUCB1-AS1	5.83	7.21e-09	1.07e-06	0.32	0.18	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr19:48899508	chr19:48910930~48918891:-
BRCA	cis	rs56104184	0.775	rs56349331	ENSG00000235191.1	NUCB1-AS1	5.83	7.21e-09	1.07e-06	0.32	0.18	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr19:48899752	chr19:48910930~48918891:-
BRCA	cis	rs56104184	0.775	rs55756106	ENSG00000235191.1	NUCB1-AS1	5.83	7.21e-09	1.07e-06	0.32	0.18	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr19:48899798	chr19:48910930~48918891:-
BRCA	cis	rs56104184	0.775	rs55737338	ENSG00000235191.1	NUCB1-AS1	5.83	7.21e-09	1.07e-06	0.32	0.18	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr19:48899884	chr19:48910930~48918891:-
BRCA	cis	rs7520050	0.902	rs1355642	ENSG00000280836.1	AL355480.1	5.83	7.21e-09	1.07e-06	0.21	0.18	Reticulocyte count;Red blood cell count;	chr1:46133231	chr1:45581219~45581321:-
BRCA	cis	rs4718428	1	rs4718428	ENSG00000232546.1	RP11-458F8.1	-5.83	7.21e-09	1.07e-06	-0.15	-0.18	Corneal structure;	chr7:66956459	chr7:66848496~66858136:+
BRCA	cis	rs7665090	0.528	rs3774968	ENSG00000246560.2	RP11-10L12.4	5.83	7.22e-09	1.07e-06	0.2	0.18	Primary biliary cholangitis;	chr4:102609955	chr4:102828055~102844075:+
BRCA	cis	rs910316	1	rs10136948	ENSG00000279594.1	RP11-950C14.10	5.83	7.22e-09	1.07e-06	0.2	0.18	Height;	chr14:75044372	chr14:75011269~75012851:-
BRCA	cis	rs11105298	0.891	rs10858889	ENSG00000270344.2	RP11-734K2.4	5.83	7.22e-09	1.07e-06	0.2	0.18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89508827	chr12:89525654~89548005:+
BRCA	cis	rs7474896	0.559	rs1208645	ENSG00000120555.12	SEPT7P9	-5.83	7.22e-09	1.07e-06	-0.25	-0.18	Obesity (extreme);	chr10:37843159	chr10:38383069~38402916:-
BRCA	cis	rs2836950	0.52	rs59916147	ENSG00000255568.3	BRWD1-AS2	-5.83	7.22e-09	1.07e-06	-0.17	-0.18	Menarche (age at onset);	chr21:39262776	chr21:39313935~39314962:+
BRCA	cis	rs8103278	0.507	rs4802276	ENSG00000267395.4	AC074212.6	-5.83	7.23e-09	1.07e-06	-0.18	-0.18	Coronary artery disease;	chr19:45757490	chr19:45767796~45772504:+
BRCA	cis	rs11105298	0.891	rs10858851	ENSG00000270344.2	RP11-734K2.4	5.83	7.23e-09	1.07e-06	0.21	0.18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89437093	chr12:89525654~89548005:+
BRCA	cis	rs202072	0.872	rs202045	ENSG00000272379.1	RP1-257A7.5	5.83	7.24e-09	1.08e-06	0.25	0.18	HIV-1 viral setpoint;	chr6:13275682	chr6:13290018~13290490:-
BRCA	cis	rs30380	0.666	rs26512	ENSG00000272109.1	CTD-2260A17.3	-5.83	7.24e-09	1.08e-06	-0.25	-0.18	Cerebrospinal fluid biomarker levels;	chr5:96792697	chr5:96804353~96806105:+
BRCA	cis	rs11098499	0.863	rs9884402	ENSG00000249244.1	RP11-548H18.2	5.83	7.26e-09	1.08e-06	0.21	0.18	Corneal astigmatism;	chr4:119568827	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.731	rs9995026	ENSG00000249244.1	RP11-548H18.2	5.83	7.26e-09	1.08e-06	0.21	0.18	Corneal astigmatism;	chr4:119569344	chr4:119391831~119395335:-
BRCA	cis	rs754466	0.58	rs10430529	ENSG00000204049.1	RP11-126H7.4	5.83	7.26e-09	1.08e-06	0.22	0.18	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77822865	chr10:77866875~77869610:+
BRCA	cis	rs10740039	0.516	rs1938546	ENSG00000254271.1	RP11-131N11.4	5.83	7.26e-09	1.08e-06	0.24	0.18	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60556228	chr10:60734342~60741828:+
BRCA	cis	rs17253792	0.545	rs17745459	ENSG00000186615.9	KTN1-AS1	-5.83	7.27e-09	1.08e-06	-0.36	-0.18	Putamen volume;	chr14:55541831	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.545	rs34446601	ENSG00000186615.9	KTN1-AS1	-5.83	7.27e-09	1.08e-06	-0.36	-0.18	Putamen volume;	chr14:55543868	chr14:55499278~55580110:-
BRCA	cis	rs6479891	1	rs4525102	ENSG00000232075.1	MRPL35P2	-5.83	7.27e-09	1.08e-06	-0.32	-0.18	Arthritis (juvenile idiopathic);	chr10:63326513	chr10:63634317~63634827:-
BRCA	cis	rs6570726	0.846	rs6570698	ENSG00000270638.1	RP3-466P17.1	5.83	7.27e-09	1.08e-06	0.2	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145597499	chr6:145735570~145737218:+
BRCA	cis	rs9907295	0.901	rs9907121	ENSG00000270977.1	AC015849.16	-5.83	7.28e-09	1.08e-06	-0.28	-0.18	Fibroblast growth factor basic levels;	chr17:35849074	chr17:35893707~35911023:-
BRCA	cis	rs673078	0.66	rs73205526	ENSG00000275409.1	RP11-131L12.4	-5.83	7.28e-09	1.08e-06	-0.27	-0.18	Glucose homeostasis traits;	chr12:118273172	chr12:118430147~118430699:+
BRCA	cis	rs6442522	0.644	rs6442528	ENSG00000249786.6	EAF1-AS1	5.83	7.28e-09	1.08e-06	0.18	0.18	Uric acid levels;	chr3:15463717	chr3:15436171~15455940:-
BRCA	cis	rs6479891	0.841	rs7085869	ENSG00000232075.1	MRPL35P2	-5.83	7.29e-09	1.08e-06	-0.32	-0.18	Arthritis (juvenile idiopathic);	chr10:63310403	chr10:63634317~63634827:-
BRCA	cis	rs6479891	0.818	rs9299455	ENSG00000232075.1	MRPL35P2	-5.83	7.29e-09	1.08e-06	-0.32	-0.18	Arthritis (juvenile idiopathic);	chr10:63313841	chr10:63634317~63634827:-
BRCA	cis	rs11105298	0.891	rs1054807	ENSG00000270344.2	RP11-734K2.4	5.83	7.29e-09	1.08e-06	0.21	0.18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89519642	chr12:89525654~89548005:+
BRCA	cis	rs516805	0.667	rs2045354	ENSG00000279453.1	RP3-425C14.4	-5.83	7.29e-09	1.08e-06	-0.26	-0.18	Lymphocyte counts;	chr6:122209244	chr6:122436789~122439223:-
BRCA	cis	rs4578769	0.569	rs12326874	ENSG00000273232.1	RP11-370A5.2	5.83	7.29e-09	1.08e-06	0.22	0.18	Eosinophil percentage of white cells;	chr18:22926670	chr18:22882825~22883357:-
BRCA	cis	rs2243480	1	rs34529418	ENSG00000164669.11	INTS4P1	5.83	7.3e-09	1.08e-06	0.34	0.18	Diabetic kidney disease;	chr7:65938222	chr7:65141225~65234216:+
BRCA	cis	rs1124769	0.719	rs2619692	ENSG00000259378.1	DCAF13P3	-5.83	7.3e-09	1.08e-06	-0.24	-0.18	Cognitive performance;	chr15:50902968	chr15:50944663~50945996:+
BRCA	cis	rs2803122	0.838	rs7046816	ENSG00000273226.1	RP11-513M16.8	-5.83	7.31e-09	1.08e-06	-0.19	-0.18	Pulse pressure;	chr9:19220506	chr9:19375451~19375996:+
BRCA	cis	rs78579285	0.583	rs1061238	ENSG00000278341.1	RP5-1142A6.10	5.83	7.31e-09	1.08e-06	0.35	0.18	Joint mobility (Beighton score);	chr16:88715442	chr16:88708956~88710437:-
BRCA	cis	rs10129255	0.912	rs6576227	ENSG00000224373.3	IGHV4-59	5.83	7.31e-09	1.08e-06	0.11	0.18	Kawasaki disease;	chr14:106778202	chr14:106627249~106627825:-
BRCA	cis	rs10129255	0.957	rs6576228	ENSG00000224373.3	IGHV4-59	5.83	7.31e-09	1.08e-06	0.11	0.18	Kawasaki disease;	chr14:106778401	chr14:106627249~106627825:-
BRCA	cis	rs2243480	1	rs4548056	ENSG00000228409.4	CCT6P1	5.83	7.31e-09	1.09e-06	0.25	0.18	Diabetic kidney disease;	chr7:65833886	chr7:65751142~65763354:+
BRCA	cis	rs7246967	0.551	rs16998998	ENSG00000198153.8	ZNF849P	-5.83	7.32e-09	1.09e-06	-0.26	-0.18	Bronchopulmonary dysplasia;	chr19:22728314	chr19:22685167~22686732:+
BRCA	cis	rs7246967	0.673	rs9677019	ENSG00000198153.8	ZNF849P	-5.83	7.32e-09	1.09e-06	-0.26	-0.18	Bronchopulmonary dysplasia;	chr19:22729857	chr19:22685167~22686732:+
BRCA	cis	rs73193808	0.851	rs12482584	ENSG00000215533.7	LINC00189	-5.83	7.32e-09	1.09e-06	-0.26	-0.18	Coronary artery disease;	chr21:29233532	chr21:29193480~29288205:+
BRCA	cis	rs651907	0.557	rs7645391	ENSG00000244119.1	PDCL3P4	5.83	7.33e-09	1.09e-06	0.14	0.18	Colorectal cancer;	chr3:101642662	chr3:101712472~101713191:+
BRCA	cis	rs875971	0.545	rs3936065	ENSG00000228409.4	CCT6P1	-5.83	7.33e-09	1.09e-06	-0.18	-0.18	Aortic root size;	chr7:66325577	chr7:65751142~65763354:+
BRCA	cis	rs875971	0.545	rs4718335	ENSG00000228409.4	CCT6P1	-5.83	7.33e-09	1.09e-06	-0.18	-0.18	Aortic root size;	chr7:66339619	chr7:65751142~65763354:+
BRCA	cis	rs4950322	0.518	rs61838951	ENSG00000278811.3	LINC00624	5.83	7.34e-09	1.09e-06	0.23	0.18	Protein quantitative trait loci;	chr1:147116081	chr1:147258885~147517875:-
BRCA	cis	rs17253792	0.545	rs35466279	ENSG00000186615.9	KTN1-AS1	-5.83	7.34e-09	1.09e-06	-0.36	-0.18	Putamen volume;	chr14:55550304	chr14:55499278~55580110:-
BRCA	cis	rs9990333	0.562	rs56038600	ENSG00000231464.1	AC024937.4	5.83	7.34e-09	1.09e-06	0.23	0.18	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196090109	chr3:195996738~195998233:+
BRCA	cis	rs5015933	0.815	rs10819043	ENSG00000232630.1	PRPS1P2	-5.83	7.34e-09	1.09e-06	-0.16	-0.18	Body mass index;	chr9:125274966	chr9:125150653~125151589:+
BRCA	cis	rs2243480	1	rs2243480	ENSG00000228409.4	CCT6P1	5.83	7.35e-09	1.09e-06	0.25	0.18	Diabetic kidney disease;	chr7:66134209	chr7:65751142~65763354:+
BRCA	cis	rs2303759	0.666	rs66967196	ENSG00000268686.1	AC010524.2	-5.83	7.35e-09	1.09e-06	-0.29	-0.18	Multiple sclerosis;	chr19:49305637	chr19:49368705~49388081:-
BRCA	cis	rs2638953	0.925	rs11049510	ENSG00000278733.1	RP11-425D17.1	-5.83	7.35e-09	1.09e-06	-0.24	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28290839	chr12:28185625~28186190:-
BRCA	cis	rs910316	1	rs175426	ENSG00000279594.1	RP11-950C14.10	-5.83	7.35e-09	1.09e-06	-0.2	-0.18	Height;	chr14:75157431	chr14:75011269~75012851:-
BRCA	cis	rs7772486	0.875	rs2777477	ENSG00000270638.1	RP3-466P17.1	5.83	7.35e-09	1.09e-06	0.2	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145984355	chr6:145735570~145737218:+
BRCA	cis	rs7976269	0.609	rs2117994	ENSG00000275476.1	RP11-996F15.4	-5.83	7.35e-09	1.09e-06	-0.2	-0.18	Male-pattern baldness;	chr12:29054666	chr12:29277397~29277882:-
BRCA	cis	rs7976269	0.583	rs6487753	ENSG00000275476.1	RP11-996F15.4	-5.83	7.35e-09	1.09e-06	-0.2	-0.18	Male-pattern baldness;	chr12:29056103	chr12:29277397~29277882:-
BRCA	cis	rs7976269	0.583	rs6487754	ENSG00000275476.1	RP11-996F15.4	-5.83	7.35e-09	1.09e-06	-0.2	-0.18	Male-pattern baldness;	chr12:29056104	chr12:29277397~29277882:-
BRCA	cis	rs7976269	0.609	rs6487755	ENSG00000275476.1	RP11-996F15.4	-5.83	7.35e-09	1.09e-06	-0.2	-0.18	Male-pattern baldness;	chr12:29056156	chr12:29277397~29277882:-
BRCA	cis	rs2732480	0.5	rs7966829	ENSG00000257763.1	OR5BK1P	5.83	7.35e-09	1.09e-06	0.19	0.18	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48221820	chr12:48355792~48356614:-
BRCA	cis	rs13126694	0.744	rs28635553	ENSG00000251429.1	RP11-597D13.7	5.83	7.36e-09	1.09e-06	0.17	0.18	Blood osmolality (transformed sodium);	chr4:158010962	chr4:158270378~158278676:+
BRCA	cis	rs4927850	1	rs10881563	ENSG00000207650.1	MIR570	5.83	7.36e-09	1.09e-06	0.22	0.18	Pancreatic cancer;	chr3:196023354	chr3:195699401~195699497:+
BRCA	cis	rs6088813	1	rs6088799	ENSG00000126005.14	MMP24-AS1	5.83	7.37e-09	1.09e-06	0.21	0.18	Height;	chr20:35346498	chr20:35216462~35278131:-
BRCA	cis	rs1499614	0.901	rs2178742	ENSG00000228409.4	CCT6P1	5.83	7.37e-09	1.09e-06	0.25	0.18	Gout;	chr7:66732812	chr7:65751142~65763354:+
BRCA	cis	rs1440410	0.83	rs1470130	ENSG00000250326.1	RP11-284M14.1	-5.83	7.37e-09	1.09e-06	-0.2	-0.18	Ischemic stroke;	chr4:143257749	chr4:142933195~143184861:-
BRCA	cis	rs5758511	0.731	rs58302269	ENSG00000205702.9	CYP2D7	5.83	7.37e-09	1.09e-06	0.18	0.18	Birth weight;	chr22:41955305	chr22:42140203~42144577:-
BRCA	cis	rs6570726	0.846	rs426874	ENSG00000270638.1	RP3-466P17.1	5.83	7.39e-09	1.1e-06	0.2	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145559494	chr6:145735570~145737218:+
BRCA	cis	rs17711722	0.51	rs11767457	ENSG00000182722.5	SEPHS1P1	-5.83	7.4e-09	1.1e-06	-0.23	-0.18	Calcium levels;	chr7:65825628	chr7:64852397~64853354:-
BRCA	cis	rs10829156	0.699	rs4747353	ENSG00000240291.1	RP11-499P20.2	5.83	7.4e-09	1.1e-06	0.2	0.18	Sudden cardiac arrest;	chr10:18548028	chr10:18513115~18545651:-
BRCA	cis	rs11098499	0.955	rs35434465	ENSG00000249244.1	RP11-548H18.2	5.83	7.4e-09	1.1e-06	0.21	0.18	Corneal astigmatism;	chr4:119248223	chr4:119391831~119395335:-
BRCA	cis	rs59169624	0.699	rs1698896	ENSG00000255160.4	RP11-428C19.5	-5.83	7.4e-09	1.1e-06	-0.24	-0.18	Parental extreme longevity (95 years and older);	chr11:19258628	chr11:19299883~19308358:+
BRCA	cis	rs13108904	0.901	rs1680073	ENSG00000254094.1	AC078852.1	5.83	7.41e-09	1.1e-06	0.19	0.18	Obesity-related traits;	chr4:1286549	chr4:1356581~1358075:+
BRCA	cis	rs875971	0.508	rs10950045	ENSG00000273024.4	INTS4P2	5.83	7.41e-09	1.1e-06	0.19	0.18	Aortic root size;	chr7:66601386	chr7:65647864~65715661:+
BRCA	cis	rs801193	0.839	rs6968619	ENSG00000273024.4	INTS4P2	5.83	7.41e-09	1.1e-06	0.19	0.18	Aortic root size;	chr7:66603880	chr7:65647864~65715661:+
BRCA	cis	rs801193	0.805	rs12532355	ENSG00000273024.4	INTS4P2	5.83	7.41e-09	1.1e-06	0.19	0.18	Aortic root size;	chr7:66605597	chr7:65647864~65715661:+
BRCA	cis	rs1014246	0.813	rs11197805	ENSG00000232767.1	RP11-498B4.5	-5.83	7.41e-09	1.1e-06	-0.21	-0.18	Age at smoking initiation in chronic obstructive pulmonary disease;	chr10:116720166	chr10:116670103~116672739:+
BRCA	cis	rs6442522	0.64	rs3773447	ENSG00000249786.6	EAF1-AS1	5.83	7.41e-09	1.1e-06	0.18	0.18	Uric acid levels;	chr3:15478512	chr3:15436171~15455940:-
BRCA	cis	rs6479891	1	rs7899715	ENSG00000232075.1	MRPL35P2	-5.83	7.41e-09	1.1e-06	-0.32	-0.18	Arthritis (juvenile idiopathic);	chr10:63318695	chr10:63634317~63634827:-
BRCA	cis	rs875971	0.545	rs6969224	ENSG00000228409.4	CCT6P1	-5.83	7.41e-09	1.1e-06	-0.18	-0.18	Aortic root size;	chr7:66370011	chr7:65751142~65763354:+
BRCA	cis	rs7520050	0.966	rs4660321	ENSG00000280836.1	AL355480.1	5.83	7.41e-09	1.1e-06	0.21	0.18	Reticulocyte count;Red blood cell count;	chr1:45901088	chr1:45581219~45581321:-
BRCA	cis	rs7520050	0.931	rs6698247	ENSG00000280836.1	AL355480.1	5.83	7.41e-09	1.1e-06	0.21	0.18	Reticulocyte count;Red blood cell count;	chr1:45905814	chr1:45581219~45581321:-
BRCA	cis	rs7520050	0.966	rs6675946	ENSG00000280836.1	AL355480.1	5.83	7.41e-09	1.1e-06	0.21	0.18	Reticulocyte count;Red blood cell count;	chr1:45906102	chr1:45581219~45581321:-
BRCA	cis	rs7520050	0.931	rs7526678	ENSG00000280836.1	AL355480.1	5.83	7.41e-09	1.1e-06	0.21	0.18	Reticulocyte count;Red blood cell count;	chr1:45908487	chr1:45581219~45581321:-
BRCA	cis	rs2638953	0.853	rs11049679	ENSG00000247934.4	RP11-967K21.1	-5.83	7.41e-09	1.1e-06	-0.24	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28508161	chr12:28163298~28190738:-
BRCA	cis	rs3764021	0.933	rs2268146	ENSG00000256673.1	RP11-599J14.2	-5.83	7.41e-09	1.1e-06	-0.2	-0.18	Type 1 diabetes;	chr12:9716675	chr12:9398355~9414851:-
BRCA	cis	rs13108904	0.905	rs1680074	ENSG00000254094.1	AC078852.1	5.83	7.41e-09	1.1e-06	0.19	0.18	Obesity-related traits;	chr4:1285833	chr4:1356581~1358075:+
BRCA	cis	rs2692947	0.695	rs12464148	ENSG00000237510.6	AC008268.2	5.83	7.42e-09	1.1e-06	0.23	0.18	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95930962	chr2:95789654~95800166:+
BRCA	cis	rs754466	0.58	rs2289308	ENSG00000204049.1	RP11-126H7.4	5.83	7.42e-09	1.1e-06	0.22	0.18	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77819493	chr10:77866875~77869610:+
BRCA	cis	rs2998286	0.643	rs332181	ENSG00000254635.4	WAC-AS1	-5.83	7.42e-09	1.1e-06	-0.26	-0.18	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28621187	chr10:28522652~28532743:-
BRCA	cis	rs62025270	0.632	rs62022918	ENSG00000202081.1	RNU6-1280P	-5.83	7.42e-09	1.1e-06	-0.26	-0.18	Idiopathic pulmonary fibrosis;	chr15:85675053	chr15:85651522~85651628:-
BRCA	cis	rs2911132	0.621	rs17480169	ENSG00000248734.2	CTD-2260A17.1	5.83	7.43e-09	1.1e-06	0.21	0.18	Urate levels (BMI interaction);	chr5:96753363	chr5:96784777~96785999:+
BRCA	cis	rs2904967	0.537	rs7116674	ENSG00000254614.2	AP003068.23	5.83	7.43e-09	1.1e-06	0.36	0.18	Mean corpuscular volume;	chr11:65195487	chr11:65177606~65181834:-
BRCA	cis	rs910316	0.967	rs8007539	ENSG00000279594.1	RP11-950C14.10	-5.83	7.43e-09	1.1e-06	-0.2	-0.18	Height;	chr14:75198250	chr14:75011269~75012851:-
BRCA	cis	rs2274273	1	rs2075603	ENSG00000258413.1	RP11-665C16.6	-5.83	7.44e-09	1.1e-06	-0.23	-0.18	Protein biomarker;	chr14:55143237	chr14:55262767~55272075:-
BRCA	cis	rs875971	0.571	rs78668714	ENSG00000228409.4	CCT6P1	-5.83	7.44e-09	1.1e-06	-0.18	-0.18	Aortic root size;	chr7:66474464	chr7:65751142~65763354:+
BRCA	cis	rs300890	0.513	rs72719159	ENSG00000250326.1	RP11-284M14.1	5.83	7.45e-09	1.1e-06	0.21	0.18	Nasopharyngeal carcinoma;	chr4:143129943	chr4:142933195~143184861:-
BRCA	cis	rs2179367	0.632	rs2143075	ENSG00000223701.3	RAET1E-AS1	5.83	7.46e-09	1.1e-06	0.26	0.18	Dupuytren's disease;	chr6:149425507	chr6:149884431~149919508:+
BRCA	cis	rs2243480	1	rs57057549	ENSG00000164669.11	INTS4P1	5.83	7.46e-09	1.11e-06	0.34	0.18	Diabetic kidney disease;	chr7:65940751	chr7:65141225~65234216:+
BRCA	cis	rs6479891	1	rs9414793	ENSG00000232075.1	MRPL35P2	-5.83	7.46e-09	1.11e-06	-0.32	-0.18	Arthritis (juvenile idiopathic);	chr10:63315349	chr10:63634317~63634827:-
BRCA	cis	rs2243480	0.522	rs73150635	ENSG00000228409.4	CCT6P1	5.83	7.46e-09	1.11e-06	0.31	0.18	Diabetic kidney disease;	chr7:66507503	chr7:65751142~65763354:+
BRCA	cis	rs11976180	1	rs2951308	ENSG00000273234.1	OR2A13P	5.83	7.47e-09	1.11e-06	0.24	0.18	Obesity-related traits;	chr7:144070056	chr7:144142009~144142938:+
BRCA	cis	rs67766926	0.537	rs17539345	ENSG00000271889.1	RP11-493E12.1	5.83	7.47e-09	1.11e-06	0.26	0.18	Inflammatory skin disease;	chr2:61022966	chr2:61151433~61162105:-
BRCA	cis	rs2243480	1	rs34815098	ENSG00000229886.1	RP5-1132H15.3	5.83	7.47e-09	1.11e-06	0.31	0.18	Diabetic kidney disease;	chr7:65827267	chr7:66025126~66031544:-
BRCA	cis	rs2243480	1	rs35735127	ENSG00000229886.1	RP5-1132H15.3	5.83	7.47e-09	1.11e-06	0.31	0.18	Diabetic kidney disease;	chr7:65835436	chr7:66025126~66031544:-
BRCA	cis	rs2243480	0.901	rs35256305	ENSG00000229886.1	RP5-1132H15.3	5.83	7.47e-09	1.11e-06	0.31	0.18	Diabetic kidney disease;	chr7:65841418	chr7:66025126~66031544:-
BRCA	cis	rs2243480	0.803	rs34004500	ENSG00000229886.1	RP5-1132H15.3	5.83	7.47e-09	1.11e-06	0.31	0.18	Diabetic kidney disease;	chr7:65847191	chr7:66025126~66031544:-
BRCA	cis	rs2243480	1	rs35825738	ENSG00000229886.1	RP5-1132H15.3	5.83	7.47e-09	1.11e-06	0.31	0.18	Diabetic kidney disease;	chr7:65853040	chr7:66025126~66031544:-
BRCA	cis	rs2243480	0.901	rs3813708	ENSG00000164669.11	INTS4P1	5.83	7.48e-09	1.11e-06	0.35	0.18	Diabetic kidney disease;	chr7:65840645	chr7:65141225~65234216:+
BRCA	cis	rs7789940	0.904	rs6948661	ENSG00000186704.9	DTX2P1	5.83	7.48e-09	1.11e-06	0.22	0.18	Multiple sclerosis;	chr7:76332330	chr7:76978617~77004308:+
BRCA	cis	rs7201929	1	rs7499878	ENSG00000251417.2	RP11-1348G14.4	5.83	7.49e-09	1.11e-06	0.22	0.18	QT interval;	chr16:28857143	chr16:28802743~28817828:+
BRCA	cis	rs8031584	0.672	rs17815726	ENSG00000260382.1	RP11-540B6.2	-5.83	7.5e-09	1.11e-06	-0.24	-0.18	Huntington's disease progression;	chr15:31021049	chr15:30882267~30883231:-
BRCA	cis	rs7474896	0.559	rs1735629	ENSG00000120555.12	SEPT7P9	-5.83	7.51e-09	1.11e-06	-0.25	-0.18	Obesity (extreme);	chr10:37889381	chr10:38383069~38402916:-
BRCA	cis	rs17711722	0.523	rs365896	ENSG00000222364.1	RNU6-96P	5.83	7.51e-09	1.11e-06	0.21	0.18	Calcium levels;	chr7:66045710	chr7:66395191~66395286:+
BRCA	cis	rs202072	0.872	rs202046	ENSG00000272379.1	RP1-257A7.5	5.83	7.51e-09	1.11e-06	0.25	0.18	HIV-1 viral setpoint;	chr6:13275338	chr6:13290018~13290490:-
BRCA	cis	rs2638953	0.962	rs9300176	ENSG00000278733.1	RP11-425D17.1	5.83	7.51e-09	1.11e-06	0.22	0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28368584	chr12:28185625~28186190:-
BRCA	cis	rs9376098	0.737	rs9399141	ENSG00000232876.1	CTA-212D2.2	5.83	7.51e-09	1.11e-06	0.25	0.18	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr6:135174436	chr6:135055033~135060550:+
BRCA	cis	rs13108904	0.539	rs11247997	ENSG00000254094.1	AC078852.1	-5.83	7.53e-09	1.11e-06	-0.22	-0.18	Obesity-related traits;	chr4:1367269	chr4:1356581~1358075:+
BRCA	cis	rs72681920	0.881	rs28364333	ENSG00000246090.5	RP11-696N14.1	-5.83	7.53e-09	1.12e-06	-0.27	-0.18	Alcohol dependence;	chr4:99278996	chr4:99088857~99301356:+
BRCA	cis	rs2015599	0.549	rs6487803	ENSG00000257176.2	RP11-996F15.2	5.83	7.53e-09	1.12e-06	0.21	0.18	Platelet count;Mean platelet volume;	chr12:29299760	chr12:29280418~29317848:-
BRCA	cis	rs2015599	0.549	rs7954990	ENSG00000257176.2	RP11-996F15.2	5.83	7.53e-09	1.12e-06	0.21	0.18	Platelet count;Mean platelet volume;	chr12:29299841	chr12:29280418~29317848:-
BRCA	cis	rs2638953	0.962	rs11049505	ENSG00000278733.1	RP11-425D17.1	-5.83	7.53e-09	1.12e-06	-0.24	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28288087	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.962	rs11049509	ENSG00000278733.1	RP11-425D17.1	-5.83	7.53e-09	1.12e-06	-0.24	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28290055	chr12:28185625~28186190:-
BRCA	cis	rs6442522	0.678	rs878946	ENSG00000249786.6	EAF1-AS1	5.83	7.54e-09	1.12e-06	0.19	0.18	Uric acid levels;	chr3:15467705	chr3:15436171~15455940:-
BRCA	cis	rs6442522	0.678	rs3773452	ENSG00000249786.6	EAF1-AS1	5.83	7.54e-09	1.12e-06	0.19	0.18	Uric acid levels;	chr3:15468447	chr3:15436171~15455940:-
BRCA	cis	rs6479891	1	rs11818194	ENSG00000232075.1	MRPL35P2	5.83	7.54e-09	1.12e-06	0.32	0.18	Arthritis (juvenile idiopathic);	chr10:63420692	chr10:63634317~63634827:-
BRCA	cis	rs8098244	0.737	rs1258147	ENSG00000264745.1	TTC39C-AS1	-5.83	7.55e-09	1.12e-06	-0.25	-0.18	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23939672	chr18:23994213~24015339:-
BRCA	cis	rs2243480	1	rs57057549	ENSG00000232559.3	GS1-124K5.12	5.83	7.55e-09	1.12e-06	0.33	0.18	Diabetic kidney disease;	chr7:65940751	chr7:66554588~66576923:-
BRCA	cis	rs2638953	0.853	rs11049519	ENSG00000278733.1	RP11-425D17.1	-5.83	7.56e-09	1.12e-06	-0.26	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28307285	chr12:28185625~28186190:-
BRCA	cis	rs7308116	0.505	rs9919721	ENSG00000274395.1	RP11-554D14.8	-5.83	7.56e-09	1.12e-06	-0.21	-0.18	Pelvic organ prolapse (moderate/severe);	chr12:107827783	chr12:107835541~107836555:-
BRCA	cis	rs7520050	0.872	rs2486445	ENSG00000280836.1	AL355480.1	5.83	7.56e-09	1.12e-06	0.21	0.18	Reticulocyte count;Red blood cell count;	chr1:46139697	chr1:45581219~45581321:-
BRCA	cis	rs11098499	1	rs10029750	ENSG00000249244.1	RP11-548H18.2	5.83	7.56e-09	1.12e-06	0.21	0.18	Corneal astigmatism;	chr4:119251388	chr4:119391831~119395335:-
BRCA	cis	rs875971	0.545	rs73152714	ENSG00000273024.4	INTS4P2	-5.83	7.56e-09	1.12e-06	-0.22	-0.18	Aortic root size;	chr7:66534641	chr7:65647864~65715661:+
BRCA	cis	rs875971	0.545	rs4718364	ENSG00000273024.4	INTS4P2	-5.83	7.56e-09	1.12e-06	-0.22	-0.18	Aortic root size;	chr7:66536353	chr7:65647864~65715661:+
BRCA	cis	rs875971	0.545	rs801199	ENSG00000273024.4	INTS4P2	5.83	7.56e-09	1.12e-06	0.22	0.18	Aortic root size;	chr7:66560286	chr7:65647864~65715661:+
BRCA	cis	rs4654783	0.627	rs66766977	ENSG00000228397.1	RP1-224A6.3	5.83	7.57e-09	1.12e-06	0.22	0.18	Endometriosis;	chr1:22104599	chr1:22023994~22024968:-
BRCA	cis	rs7727544	0.618	rs2631367	ENSG00000233006.5	AC034220.3	-5.83	7.57e-09	1.12e-06	-0.13	-0.18	Blood metabolite levels;	chr5:132369766	chr5:132311285~132369916:-
BRCA	cis	rs875971	0.505	rs1167386	ENSG00000273024.4	INTS4P2	5.83	7.57e-09	1.12e-06	0.2	0.18	Aortic root size;	chr7:66048109	chr7:65647864~65715661:+
BRCA	cis	rs6951245	0.638	rs74976697	ENSG00000229043.2	AC091729.9	-5.83	7.58e-09	1.12e-06	-0.29	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1120869	chr7:1160374~1165267:+
BRCA	cis	rs467650	0.927	rs154207	ENSG00000248489.1	CTD-2007H13.3	5.83	7.58e-09	1.12e-06	0.2	0.18	Venous thromboembolism (SNP x SNP interaction);	chr5:98627686	chr5:98929171~98995013:+
BRCA	cis	rs2243480	0.803	rs35480979	ENSG00000229886.1	RP5-1132H15.3	5.83	7.59e-09	1.12e-06	0.31	0.18	Diabetic kidney disease;	chr7:65892097	chr7:66025126~66031544:-
BRCA	cis	rs2243480	1	rs35391607	ENSG00000229886.1	RP5-1132H15.3	5.83	7.59e-09	1.12e-06	0.31	0.18	Diabetic kidney disease;	chr7:65895842	chr7:66025126~66031544:-
BRCA	cis	rs2243480	1	rs13220979	ENSG00000229886.1	RP5-1132H15.3	5.83	7.59e-09	1.12e-06	0.31	0.18	Diabetic kidney disease;	chr7:65898217	chr7:66025126~66031544:-
BRCA	cis	rs2243480	1	rs34974928	ENSG00000229886.1	RP5-1132H15.3	5.83	7.59e-09	1.12e-06	0.31	0.18	Diabetic kidney disease;	chr7:65899019	chr7:66025126~66031544:-
BRCA	cis	rs6442522	0.673	rs7628975	ENSG00000249786.6	EAF1-AS1	-5.82	7.61e-09	1.13e-06	-0.18	-0.18	Uric acid levels;	chr3:15460623	chr3:15436171~15455940:-
BRCA	cis	rs1707322	0.717	rs3014249	ENSG00000234329.1	RP11-767N6.2	-5.82	7.61e-09	1.13e-06	-0.19	-0.18	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613821	chr1:45651039~45651826:-
BRCA	cis	rs7134599	0.543	rs7316231	ENSG00000255733.4	IFNG-AS1	5.82	7.61e-09	1.13e-06	0.14	0.18	Inflammatory bowel disease;Ulcerative colitis;	chr12:68075862	chr12:67989445~68234686:+
BRCA	cis	rs7208859	0.623	rs9895785	ENSG00000265443.1	CTD-2349P21.6	5.82	7.61e-09	1.13e-06	0.28	0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780690	chr17:30726305~30727564:-
BRCA	cis	rs7520050	0.966	rs7522601	ENSG00000280836.1	AL355480.1	5.82	7.62e-09	1.13e-06	0.21	0.18	Reticulocyte count;Red blood cell count;	chr1:45953349	chr1:45581219~45581321:-
BRCA	cis	rs7520050	0.966	rs10789487	ENSG00000280836.1	AL355480.1	5.82	7.62e-09	1.13e-06	0.21	0.18	Reticulocyte count;Red blood cell count;	chr1:45954549	chr1:45581219~45581321:-
BRCA	cis	rs12893668	0.572	rs4906356	ENSG00000269910.1	RP11-73M18.10	5.82	7.62e-09	1.13e-06	0.19	0.18	Reticulocyte count;	chr14:103672364	chr14:103694516~103695050:-
BRCA	cis	rs12893668	0.603	rs12896171	ENSG00000269910.1	RP11-73M18.10	5.82	7.62e-09	1.13e-06	0.19	0.18	Reticulocyte count;	chr14:103669629	chr14:103694516~103695050:-
BRCA	cis	rs7131987	0.565	rs10743651	ENSG00000275476.1	RP11-996F15.4	5.82	7.63e-09	1.13e-06	0.2	0.18	QT interval;	chr12:29255006	chr12:29277397~29277882:-
BRCA	cis	rs7520050	0.808	rs11211195	ENSG00000280836.1	AL355480.1	5.82	7.63e-09	1.13e-06	0.21	0.18	Reticulocyte count;Red blood cell count;	chr1:45816623	chr1:45581219~45581321:-
BRCA	cis	rs7520050	0.808	rs11211196	ENSG00000280836.1	AL355480.1	5.82	7.63e-09	1.13e-06	0.21	0.18	Reticulocyte count;Red blood cell count;	chr1:45816624	chr1:45581219~45581321:-
BRCA	cis	rs7927771	0.524	rs12362318	ENSG00000280615.1	Y_RNA	5.82	7.63e-09	1.13e-06	0.21	0.18	Subjective well-being;	chr11:47661119	chr11:47614898~47614994:-
BRCA	cis	rs1707322	1	rs7538978	ENSG00000281133.1	AL355480.3	5.82	7.63e-09	1.13e-06	0.22	0.18	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46039382	chr1:45580892~45580996:-
BRCA	cis	rs30380	0.632	rs27434	ENSG00000272109.1	CTD-2260A17.3	-5.82	7.63e-09	1.13e-06	-0.25	-0.18	Cerebrospinal fluid biomarker levels;	chr5:96793809	chr5:96804353~96806105:+
BRCA	cis	rs7772486	0.624	rs6930154	ENSG00000270638.1	RP3-466P17.1	-5.82	7.63e-09	1.13e-06	-0.2	-0.18	Lobe attachment (rater-scored or self-reported);	chr6:145704526	chr6:145735570~145737218:+
BRCA	cis	rs4908760	0.86	rs11121202	ENSG00000270282.1	RP5-1115A15.2	5.82	7.64e-09	1.13e-06	0.19	0.18	Vitiligo;	chr1:8579298	chr1:8512653~8513021:+
BRCA	cis	rs2832191	0.716	rs9983051	ENSG00000176054.6	RPL23P2	5.82	7.64e-09	1.13e-06	0.19	0.18	Dental caries;	chr21:28999569	chr21:28997613~28998033:-
BRCA	cis	rs10888838	0.756	rs11206306	ENSG00000198711.5	SSBP3-AS1	5.82	7.64e-09	1.13e-06	0.25	0.18	Mitochondrial DNA levels;	chr1:54224092	chr1:54236440~54239063:+
BRCA	cis	rs6490294	0.571	rs12312538	ENSG00000226469.1	ADAM1B	5.82	7.64e-09	1.13e-06	0.28	0.18	Mean platelet volume;	chr12:112051717	chr12:111927018~111929017:+
BRCA	cis	rs2288884	0.806	rs17779439	ENSG00000275055.1	CTC-471J1.11	-5.82	7.65e-09	1.13e-06	-0.26	-0.18	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52080738	chr19:52049007~52049754:+
BRCA	cis	rs4950322	0.57	rs72692963	ENSG00000244371.2	PFN1P8	-5.82	7.65e-09	1.13e-06	-0.25	-0.18	Protein quantitative trait loci;	chr1:147331090	chr1:146957117~146957659:-
BRCA	cis	rs4950322	0.518	rs72692965	ENSG00000244371.2	PFN1P8	-5.82	7.65e-09	1.13e-06	-0.25	-0.18	Protein quantitative trait loci;	chr1:147332085	chr1:146957117~146957659:-
BRCA	cis	rs4950322	0.518	rs72692968	ENSG00000244371.2	PFN1P8	-5.82	7.65e-09	1.13e-06	-0.25	-0.18	Protein quantitative trait loci;	chr1:147332884	chr1:146957117~146957659:-
BRCA	cis	rs4950322	0.518	rs72692970	ENSG00000244371.2	PFN1P8	-5.82	7.65e-09	1.13e-06	-0.25	-0.18	Protein quantitative trait loci;	chr1:147332887	chr1:146957117~146957659:-
BRCA	cis	rs4950322	0.57	rs72692971	ENSG00000244371.2	PFN1P8	-5.82	7.65e-09	1.13e-06	-0.25	-0.18	Protein quantitative trait loci;	chr1:147333088	chr1:146957117~146957659:-
BRCA	cis	rs4950322	0.57	rs72692973	ENSG00000244371.2	PFN1P8	-5.82	7.65e-09	1.13e-06	-0.25	-0.18	Protein quantitative trait loci;	chr1:147333281	chr1:146957117~146957659:-
BRCA	cis	rs4950322	0.57	rs72692975	ENSG00000244371.2	PFN1P8	-5.82	7.65e-09	1.13e-06	-0.25	-0.18	Protein quantitative trait loci;	chr1:147333506	chr1:146957117~146957659:-
BRCA	cis	rs6442522	0.678	rs3773451	ENSG00000249786.6	EAF1-AS1	5.82	7.65e-09	1.13e-06	0.19	0.18	Uric acid levels;	chr3:15468626	chr3:15436171~15455940:-
BRCA	cis	rs2243480	1	rs937108	ENSG00000232546.1	RP11-458F8.1	-5.82	7.66e-09	1.13e-06	-0.23	-0.18	Diabetic kidney disease;	chr7:65963465	chr7:66848496~66858136:+
BRCA	cis	rs4718428	0.705	rs12536410	ENSG00000230295.1	RP11-458F8.2	-5.82	7.66e-09	1.13e-06	-0.17	-0.18	Corneal structure;	chr7:66789303	chr7:66880708~66882981:+
BRCA	cis	rs919433	0.68	rs7605813	ENSG00000231621.1	AC013264.2	-5.82	7.67e-09	1.13e-06	-0.17	-0.18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197510605	chr2:197197991~197199273:+
BRCA	cis	rs7927771	0.524	rs7942074	ENSG00000280615.1	Y_RNA	5.82	7.67e-09	1.13e-06	0.21	0.18	Subjective well-being;	chr11:47698957	chr11:47614898~47614994:-
BRCA	cis	rs7131987	0.617	rs3764953	ENSG00000275476.1	RP11-996F15.4	-5.82	7.67e-09	1.13e-06	-0.21	-0.18	QT interval;	chr12:29349303	chr12:29277397~29277882:-
BRCA	cis	rs2243480	1	rs34560516	ENSG00000232559.3	GS1-124K5.12	5.82	7.67e-09	1.14e-06	0.33	0.18	Diabetic kidney disease;	chr7:65939105	chr7:66554588~66576923:-
BRCA	cis	rs17711722	0.523	rs313812	ENSG00000222364.1	RNU6-96P	5.82	7.67e-09	1.14e-06	0.21	0.18	Calcium levels;	chr7:66040056	chr7:66395191~66395286:+
BRCA	cis	rs904251	0.861	rs1757171	ENSG00000204110.6	RP1-153P14.8	-5.82	7.68e-09	1.14e-06	-0.2	-0.18	Cognitive performance;	chr6:37519268	chr6:37507348~37535616:+
BRCA	cis	rs801193	0.844	rs732465	ENSG00000273024.4	INTS4P2	-5.82	7.68e-09	1.14e-06	-0.19	-0.18	Aortic root size;	chr7:66533463	chr7:65647864~65715661:+
BRCA	cis	rs7587476	1	rs7587476	ENSG00000229267.2	AC072062.1	5.82	7.7e-09	1.14e-06	0.24	0.18	Neuroblastoma;	chr2:214789163	chr2:214810229~214963274:+
BRCA	cis	rs1555322	0.53	rs7004	ENSG00000269202.1	RP4-614O4.12	-5.82	7.7e-09	1.14e-06	-0.21	-0.18	Attention deficit hyperactivity disorder;	chr20:35278950	chr20:35201747~35203288:-
BRCA	cis	rs2243480	1	rs7456042	ENSG00000229886.1	RP5-1132H15.3	5.82	7.7e-09	1.14e-06	0.31	0.18	Diabetic kidney disease;	chr7:65834791	chr7:66025126~66031544:-
BRCA	cis	rs2243480	1	rs73142121	ENSG00000229886.1	RP5-1132H15.3	5.82	7.7e-09	1.14e-06	0.31	0.18	Diabetic kidney disease;	chr7:65846219	chr7:66025126~66031544:-
BRCA	cis	rs2243480	1	rs34702770	ENSG00000229886.1	RP5-1132H15.3	5.82	7.7e-09	1.14e-06	0.31	0.18	Diabetic kidney disease;	chr7:65879836	chr7:66025126~66031544:-
BRCA	cis	rs2243480	1	rs34637256	ENSG00000229886.1	RP5-1132H15.3	5.82	7.7e-09	1.14e-06	0.31	0.18	Diabetic kidney disease;	chr7:65895144	chr7:66025126~66031544:-
BRCA	cis	rs4578769	0.531	rs12969559	ENSG00000273232.1	RP11-370A5.2	5.82	7.71e-09	1.14e-06	0.22	0.18	Eosinophil percentage of white cells;	chr18:22913702	chr18:22882825~22883357:-
BRCA	cis	rs6969780	0.778	rs2465276	ENSG00000233429.8	HOTAIRM1	5.82	7.71e-09	1.14e-06	0.23	0.18	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27106098	chr7:27095647~27100265:+
BRCA	cis	rs638893	0.528	rs521910	ENSG00000255239.1	AP002954.6	-5.82	7.72e-09	1.14e-06	-0.28	-0.18	Vitiligo;	chr11:118739920	chr11:118688039~118690600:-
BRCA	cis	rs7577696	0.597	rs212751	ENSG00000272716.1	RP11-563N4.1	5.82	7.72e-09	1.14e-06	0.21	0.18	Inflammatory biomarkers;	chr2:32193739	chr2:32165046~32165757:-
BRCA	cis	rs7577696	0.626	rs212754	ENSG00000272716.1	RP11-563N4.1	5.82	7.72e-09	1.14e-06	0.21	0.18	Inflammatory biomarkers;	chr2:32196559	chr2:32165046~32165757:-
BRCA	cis	rs600231	0.665	rs1621277	ENSG00000245532.5	NEAT1	-5.82	7.72e-09	1.14e-06	-0.16	-0.18	Bone mineral density;	chr11:65454483	chr11:65422774~65445540:+
BRCA	cis	rs577676	0.586	rs12566725	ENSG00000271811.1	RP1-79C4.4	5.82	7.72e-09	1.14e-06	0.21	0.18	Prevalent atrial fibrillation;	chr1:170632794	chr1:170667381~170669425:+
BRCA	cis	rs6597981	0.592	rs10902218	ENSG00000255284.1	AP006621.5	-5.82	7.73e-09	1.14e-06	-0.16	-0.18	Breast cancer;	chr11:743813	chr11:777578~784297:+
BRCA	cis	rs9545047	0.604	rs912639	ENSG00000227354.5	RBM26-AS1	-5.82	7.74e-09	1.14e-06	-0.19	-0.18	Schizophrenia;	chr13:79409788	chr13:79406309~79424328:+
BRCA	cis	rs55692411	0.517	rs62262106	ENSG00000228008.1	CTD-2330K9.3	5.82	7.74e-09	1.14e-06	0.21	0.18	Intelligence (multi-trait analysis);	chr3:49953994	chr3:49903845~49916937:+
BRCA	cis	rs253959	0.672	rs4921056	ENSG00000272265.1	CTD-2287O16.4	5.82	7.75e-09	1.15e-06	0.2	0.18	Bipolar disorder and schizophrenia;	chr5:116087237	chr5:116078110~116078570:-
BRCA	cis	rs42648	0.564	rs13224065	ENSG00000225498.1	AC002064.5	5.82	7.75e-09	1.15e-06	0.17	0.18	Homocysteine levels;	chr7:90173049	chr7:90312496~90322592:+
BRCA	cis	rs757081	0.533	rs7949405	ENSG00000184669.7	OR7E14P	-5.82	7.76e-09	1.15e-06	-0.26	-0.18	Systolic blood pressure;	chr11:17063645	chr11:17013998~17053024:+
BRCA	cis	rs67981189	0.789	rs12101246	ENSG00000258571.1	PTTG4P	-5.82	7.77e-09	1.15e-06	-0.2	-0.18	Schizophrenia;	chr14:71084618	chr14:71085482~71085833:-
BRCA	cis	rs755249	0.567	rs1537817	ENSG00000237624.1	OXCT2P1	-5.82	7.78e-09	1.15e-06	-0.25	-0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39173981	chr1:39514956~39516490:+
BRCA	cis	rs2243480	1	rs78803505	ENSG00000164669.11	INTS4P1	5.82	7.78e-09	1.15e-06	0.34	0.18	Diabetic kidney disease;	chr7:65917585	chr7:65141225~65234216:+
BRCA	cis	rs2243480	1	rs34577383	ENSG00000164669.11	INTS4P1	5.82	7.78e-09	1.15e-06	0.34	0.18	Diabetic kidney disease;	chr7:65920739	chr7:65141225~65234216:+
BRCA	cis	rs2243480	1	rs55895244	ENSG00000164669.11	INTS4P1	5.82	7.78e-09	1.15e-06	0.34	0.18	Diabetic kidney disease;	chr7:65922691	chr7:65141225~65234216:+
BRCA	cis	rs2243480	1	rs7795242	ENSG00000164669.11	INTS4P1	5.82	7.78e-09	1.15e-06	0.34	0.18	Diabetic kidney disease;	chr7:65925107	chr7:65141225~65234216:+
BRCA	cis	rs2243480	1	rs2177703	ENSG00000164669.11	INTS4P1	5.82	7.78e-09	1.15e-06	0.34	0.18	Diabetic kidney disease;	chr7:65926730	chr7:65141225~65234216:+
BRCA	cis	rs2243480	1	rs56985706	ENSG00000164669.11	INTS4P1	5.82	7.78e-09	1.15e-06	0.34	0.18	Diabetic kidney disease;	chr7:65929575	chr7:65141225~65234216:+
BRCA	cis	rs2243480	1	rs60683927	ENSG00000164669.11	INTS4P1	5.82	7.78e-09	1.15e-06	0.34	0.18	Diabetic kidney disease;	chr7:65929781	chr7:65141225~65234216:+
BRCA	cis	rs2243480	1	rs58062456	ENSG00000164669.11	INTS4P1	5.82	7.78e-09	1.15e-06	0.34	0.18	Diabetic kidney disease;	chr7:65929865	chr7:65141225~65234216:+
BRCA	cis	rs3764021	0.933	rs10492165	ENSG00000214776.8	RP11-726G1.1	5.82	7.78e-09	1.15e-06	0.19	0.18	Type 1 diabetes;	chr12:9733365	chr12:9467552~9576275:+
BRCA	cis	rs6479891	1	rs2893922	ENSG00000232075.1	MRPL35P2	-5.82	7.79e-09	1.15e-06	-0.31	-0.18	Arthritis (juvenile idiopathic);	chr10:63487259	chr10:63634317~63634827:-
BRCA	cis	rs7648466	0.592	rs7616215	ENSG00000223552.1	RP11-24F11.2	-5.82	7.8e-09	1.15e-06	-0.18	-0.18	Eotaxin levels;	chr3:46164194	chr3:46364955~46407059:-
BRCA	cis	rs7809950	0.815	rs62482495	ENSG00000238832.1	snoU109	-5.82	7.8e-09	1.15e-06	-0.26	-0.18	Coronary artery disease;	chr7:107324564	chr7:107603363~107603507:+
BRCA	cis	rs77972916	0.561	rs10167415	ENSG00000234936.1	AC010883.5	5.82	7.8e-09	1.15e-06	0.23	0.18	Granulocyte percentage of myeloid white cells;	chr2:43325321	chr2:43229573~43233394:+
BRCA	cis	rs42648	0.564	rs6956980	ENSG00000225498.1	AC002064.5	5.82	7.8e-09	1.15e-06	0.17	0.18	Homocysteine levels;	chr7:90174320	chr7:90312496~90322592:+
BRCA	cis	rs2836950	0.502	rs2150411	ENSG00000255568.3	BRWD1-AS2	-5.82	7.8e-09	1.15e-06	-0.17	-0.18	Menarche (age at onset);	chr21:39202626	chr21:39313935~39314962:+
BRCA	cis	rs2836950	0.545	rs4818001	ENSG00000255568.3	BRWD1-AS2	-5.82	7.8e-09	1.15e-06	-0.17	-0.18	Menarche (age at onset);	chr21:39203162	chr21:39313935~39314962:+
BRCA	cis	rs11098499	0.604	rs2389887	ENSG00000249244.1	RP11-548H18.2	5.82	7.81e-09	1.15e-06	0.22	0.18	Corneal astigmatism;	chr4:119649489	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.604	rs34278750	ENSG00000249244.1	RP11-548H18.2	5.82	7.81e-09	1.15e-06	0.22	0.18	Corneal astigmatism;	chr4:119649981	chr4:119391831~119395335:-
BRCA	cis	rs911555	0.576	rs8015723	ENSG00000244691.1	RPL10AP1	5.82	7.81e-09	1.15e-06	0.23	0.18	Intelligence (multi-trait analysis);	chr14:103429572	chr14:103412119~103412761:-
BRCA	cis	rs2243480	1	rs313802	ENSG00000228409.4	CCT6P1	5.82	7.81e-09	1.15e-06	0.25	0.18	Diabetic kidney disease;	chr7:66051386	chr7:65751142~65763354:+
BRCA	cis	rs2243480	0.803	rs403089	ENSG00000228409.4	CCT6P1	5.82	7.81e-09	1.15e-06	0.25	0.18	Diabetic kidney disease;	chr7:66052736	chr7:65751142~65763354:+
BRCA	cis	rs2243480	1	rs458291	ENSG00000228409.4	CCT6P1	5.82	7.81e-09	1.15e-06	0.25	0.18	Diabetic kidney disease;	chr7:66055492	chr7:65751142~65763354:+
BRCA	cis	rs651907	0.557	rs35850993	ENSG00000244119.1	PDCL3P4	5.82	7.81e-09	1.15e-06	0.14	0.18	Colorectal cancer;	chr3:101718589	chr3:101712472~101713191:+
BRCA	cis	rs6762477	0.505	rs17304079	ENSG00000228008.1	CTD-2330K9.3	5.82	7.82e-09	1.15e-06	0.21	0.18	Menarche (age at onset);	chr3:50047720	chr3:49903845~49916937:+
BRCA	cis	rs56104184	0.775	rs17272700	ENSG00000235191.1	NUCB1-AS1	5.82	7.82e-09	1.16e-06	0.32	0.18	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr19:48888513	chr19:48910930~48918891:-
BRCA	cis	rs2274273	1	rs4644	ENSG00000258413.1	RP11-665C16.6	-5.82	7.83e-09	1.16e-06	-0.23	-0.18	Protein biomarker;	chr14:55138217	chr14:55262767~55272075:-
BRCA	cis	rs741738	1	rs741738	ENSG00000251661.3	RP11-326C3.11	-5.82	7.83e-09	1.16e-06	-0.22	-0.18	Granulocyte percentage of myeloid white cells;	chr11:309508	chr11:318640~325631:+
BRCA	cis	rs42648	0.564	rs39284	ENSG00000225498.1	AC002064.5	5.82	7.83e-09	1.16e-06	0.17	0.18	Homocysteine levels;	chr7:90162667	chr7:90312496~90322592:+
BRCA	cis	rs12501370	0.765	rs6858702	ENSG00000201736.1	RNA5SP160	5.82	7.83e-09	1.16e-06	0.24	0.18	Iris color (L* coordinate);	chr4:41045985	chr4:40990154~40990273:+
BRCA	cis	rs853679	0.628	rs9368560	ENSG00000204709.4	LINC01556	5.82	7.84e-09	1.16e-06	0.26	0.18	Depression;	chr6:28192182	chr6:28943877~28944537:+
BRCA	cis	rs10129255	0.826	rs7150693	ENSG00000211974.3	IGHV2-70	5.82	7.84e-09	1.16e-06	0.19	0.18	Kawasaki disease;	chr14:106705382	chr14:106723574~106724093:-
BRCA	cis	rs10129255	0.869	rs7150549	ENSG00000211974.3	IGHV2-70	5.82	7.84e-09	1.16e-06	0.19	0.18	Kawasaki disease;	chr14:106705441	chr14:106723574~106724093:-
BRCA	cis	rs16949788	1	rs16949793	ENSG00000261351.2	CTD-3185P2.1	5.82	7.85e-09	1.16e-06	0.35	0.18	Spherical equivalent (joint analysis main effects and education interaction);	chr15:66301610	chr15:66488658~66492109:-
BRCA	cis	rs2243480	1	rs160643	ENSG00000230295.1	RP11-458F8.2	-5.82	7.86e-09	1.16e-06	-0.22	-0.18	Diabetic kidney disease;	chr7:66093235	chr7:66880708~66882981:+
BRCA	cis	rs7178375	1	rs1474382	ENSG00000270015.1	RP11-540B6.6	5.82	7.86e-09	1.16e-06	0.22	0.18	Hypertriglyceridemia;	chr15:30922446	chr15:30926514~30928407:+
BRCA	cis	rs6088813	0.961	rs2425063	ENSG00000126005.14	MMP24-AS1	-5.82	7.87e-09	1.16e-06	-0.21	-0.18	Height;	chr20:35336470	chr20:35216462~35278131:-
BRCA	cis	rs34779708	0.966	rs2505639	ENSG00000271335.4	RP11-324I22.4	-5.82	7.87e-09	1.16e-06	-0.18	-0.18	Inflammatory bowel disease;Crohn's disease;	chr10:35185493	chr10:35314552~35336401:-
BRCA	cis	rs3764021	0.87	rs10844622	ENSG00000214776.8	RP11-726G1.1	5.82	7.88e-09	1.16e-06	0.19	0.18	Type 1 diabetes;	chr12:9732486	chr12:9467552~9576275:+
BRCA	cis	rs2288884	0.806	rs60193983	ENSG00000275055.1	CTC-471J1.11	-5.82	7.88e-09	1.16e-06	-0.26	-0.18	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52082659	chr19:52049007~52049754:+
BRCA	cis	rs8103278	0.507	rs16939	ENSG00000267395.4	AC074212.6	-5.82	7.88e-09	1.16e-06	-0.18	-0.18	Coronary artery disease;	chr19:45772798	chr19:45767796~45772504:+
BRCA	cis	rs30380	0.632	rs27640	ENSG00000272109.1	CTD-2260A17.3	-5.82	7.89e-09	1.17e-06	-0.25	-0.18	Cerebrospinal fluid biomarker levels;	chr5:96792202	chr5:96804353~96806105:+
BRCA	cis	rs4713675	0.584	rs7759668	ENSG00000224557.6	HLA-DPB2	5.82	7.89e-09	1.17e-06	0.21	0.18	Plateletcrit;	chr6:33702629	chr6:33112451~33129084:+
BRCA	cis	rs1859596	0.932	rs2269989	ENSG00000234456.6	MAGI2-AS3	5.82	7.9e-09	1.17e-06	0.12	0.18	Reading or mathematical ability;	chr7:79460715	chr7:79452877~79471208:+
BRCA	cis	rs250585	0.736	rs30014	ENSG00000260136.4	CTD-2270L9.4	5.82	7.9e-09	1.17e-06	0.18	0.18	Egg allergy;	chr16:23404577	chr16:23452758~23457606:+
BRCA	cis	rs9287719	0.649	rs12476554	ENSG00000243819.4	RN7SL832P	5.82	7.9e-09	1.17e-06	0.18	0.18	Prostate cancer;	chr2:10587621	chr2:10690344~10692099:+
BRCA	cis	rs673078	0.66	rs7973455	ENSG00000275409.1	RP11-131L12.4	-5.82	7.91e-09	1.17e-06	-0.27	-0.18	Glucose homeostasis traits;	chr12:118247490	chr12:118430147~118430699:+
BRCA	cis	rs2243480	1	rs2257790	ENSG00000164669.11	INTS4P1	5.82	7.91e-09	1.17e-06	0.35	0.18	Diabetic kidney disease;	chr7:66135463	chr7:65141225~65234216:+
BRCA	cis	rs12468226	1	rs13389798	ENSG00000226261.1	AC064836.3	5.82	7.92e-09	1.17e-06	0.3	0.18	Urate levels;	chr2:202348370	chr2:202336024~202336727:-
BRCA	cis	rs7246967	0.673	rs937078	ENSG00000198153.8	ZNF849P	-5.82	7.92e-09	1.17e-06	-0.26	-0.18	Bronchopulmonary dysplasia;	chr19:22628865	chr19:22685167~22686732:+
BRCA	cis	rs7246967	0.673	rs12978794	ENSG00000198153.8	ZNF849P	-5.82	7.92e-09	1.17e-06	-0.26	-0.18	Bronchopulmonary dysplasia;	chr19:22629332	chr19:22685167~22686732:+
BRCA	cis	rs7246967	0.673	rs4932782	ENSG00000198153.8	ZNF849P	-5.82	7.92e-09	1.17e-06	-0.26	-0.18	Bronchopulmonary dysplasia;	chr19:22629999	chr19:22685167~22686732:+
BRCA	cis	rs7246967	0.611	rs66866654	ENSG00000198153.8	ZNF849P	-5.82	7.92e-09	1.17e-06	-0.26	-0.18	Bronchopulmonary dysplasia;	chr19:22630937	chr19:22685167~22686732:+
BRCA	cis	rs7246967	0.673	rs73028776	ENSG00000198153.8	ZNF849P	-5.82	7.92e-09	1.17e-06	-0.26	-0.18	Bronchopulmonary dysplasia;	chr19:22630938	chr19:22685167~22686732:+
BRCA	cis	rs7809950	0.637	rs3801964	ENSG00000238832.1	snoU109	-5.82	7.92e-09	1.17e-06	-0.27	-0.18	Coronary artery disease;	chr7:107195797	chr7:107603363~107603507:+
BRCA	cis	rs12893668	0.572	rs11540512	ENSG00000269910.1	RP11-73M18.10	5.82	7.93e-09	1.17e-06	0.19	0.18	Reticulocyte count;	chr14:103681040	chr14:103694516~103695050:-
BRCA	cis	rs459482	0.587	rs468207	ENSG00000228318.3	AP001610.5	5.82	7.93e-09	1.17e-06	0.21	0.18	IgG glycosylation;	chr21:41436088	chr21:41441056~41445708:-
BRCA	cis	rs2638953	0.962	rs61922977	ENSG00000278733.1	RP11-425D17.1	-5.82	7.94e-09	1.17e-06	-0.24	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28286889	chr12:28185625~28186190:-
BRCA	cis	rs6479891	0.524	rs10740107	ENSG00000232075.1	MRPL35P2	-5.82	7.94e-09	1.17e-06	-0.29	-0.18	Arthritis (juvenile idiopathic);	chr10:63184557	chr10:63634317~63634827:-
BRCA	cis	rs858239	0.676	rs274032	ENSG00000230042.1	AK3P3	-5.82	7.94e-09	1.17e-06	-0.21	-0.18	Cerebrospinal fluid biomarker levels;	chr7:23334940	chr7:23129178~23129841:+
BRCA	cis	rs7772486	0.686	rs10872579	ENSG00000270638.1	RP3-466P17.1	5.82	7.95e-09	1.17e-06	0.2	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145644876	chr6:145735570~145737218:+
BRCA	cis	rs227275	0.525	rs17215211	ENSG00000251288.2	RP11-10L12.2	-5.82	7.96e-09	1.17e-06	-0.21	-0.18	Allergic disease (asthma, hay fever or eczema);	chr4:103025961	chr4:102751401~102752641:+
BRCA	cis	rs6479901	0.895	rs7916224	ENSG00000232075.1	MRPL35P2	-5.82	7.96e-09	1.17e-06	-0.26	-0.18	Intelligence (multi-trait analysis);	chr10:63144843	chr10:63634317~63634827:-
BRCA	cis	rs755249	0.958	rs61781370	ENSG00000182109.6	RP11-69E11.4	5.82	7.97e-09	1.18e-06	0.24	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39579628	chr1:39522280~39546187:-
BRCA	cis	rs338389	0.542	rs6494709	ENSG00000260657.2	RP11-315D16.4	-5.82	7.98e-09	1.18e-06	-0.24	-0.18	Survival in rectal cancer;	chr15:68001672	chr15:68267792~68277994:-
BRCA	cis	rs6088580	0.543	rs13042351	ENSG00000269202.1	RP4-614O4.12	5.82	7.98e-09	1.18e-06	0.18	0.18	Glomerular filtration rate (creatinine);	chr20:34650769	chr20:35201747~35203288:-
BRCA	cis	rs7630852	1	rs7626440	ENSG00000272359.1	U4	-5.82	7.98e-09	1.18e-06	-0.21	-0.18	Eosinophil counts;	chr3:196778019	chr3:196747192~196747324:-
BRCA	cis	rs9291683	0.546	rs6820188	ENSG00000250413.1	RP11-448G15.1	-5.82	7.98e-09	1.18e-06	-0.23	-0.18	Bone mineral density;	chr4:10050031	chr4:10006482~10009725:+
BRCA	cis	rs4950322	0.634	rs7542951	ENSG00000244371.2	PFN1P8	-5.82	7.98e-09	1.18e-06	-0.25	-0.18	Protein quantitative trait loci;	chr1:147340308	chr1:146957117~146957659:-
BRCA	cis	rs2153535	0.585	rs4960449	ENSG00000230939.1	RP11-314C16.1	-5.82	7.98e-09	1.18e-06	-0.21	-0.18	Motion sickness;	chr6:8625762	chr6:8784178~8785445:+
BRCA	cis	rs3805389	0.961	rs9996936	ENSG00000249700.7	SRD5A3-AS1	-5.82	7.99e-09	1.18e-06	-0.26	-0.18	Waist-to-hip ratio adjusted for body mass index;	chr4:55601472	chr4:55363971~55395847:-
BRCA	cis	rs42490	0.546	rs160437	ENSG00000251136.7	RP11-37B2.1	5.82	7.99e-09	1.18e-06	0.17	0.18	Leprosy;	chr8:89669656	chr8:89609409~89757727:-
BRCA	cis	rs2638953	0.853	rs10843178	ENSG00000278733.1	RP11-425D17.1	-5.82	7.99e-09	1.18e-06	-0.23	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28460501	chr12:28185625~28186190:-
BRCA	cis	rs13126694	0.682	rs9991381	ENSG00000251429.1	RP11-597D13.7	5.82	7.99e-09	1.18e-06	0.17	0.18	Blood osmolality (transformed sodium);	chr4:157982239	chr4:158270378~158278676:+
BRCA	cis	rs516805	0.748	rs511279	ENSG00000279114.1	RP3-425C14.5	-5.82	8.01e-09	1.18e-06	-0.22	-0.18	Lymphocyte counts;	chr6:122451385	chr6:122471923~122484161:+
BRCA	cis	rs2243480	1	rs35058610	ENSG00000164669.11	INTS4P1	5.82	8.01e-09	1.18e-06	0.34	0.18	Diabetic kidney disease;	chr7:65925938	chr7:65141225~65234216:+
BRCA	cis	rs9527	0.615	rs10883781	ENSG00000236937.2	PTGES3P4	5.82	8.02e-09	1.18e-06	0.25	0.18	Arsenic metabolism;	chr10:102821373	chr10:102845595~102845950:+
BRCA	cis	rs59169624	0.625	rs1698895	ENSG00000255160.4	RP11-428C19.5	-5.82	8.02e-09	1.18e-06	-0.24	-0.18	Parental extreme longevity (95 years and older);	chr11:19259233	chr11:19299883~19308358:+
BRCA	cis	rs4713118	0.621	rs9295755	ENSG00000280107.1	AL022393.9	5.82	8.03e-09	1.18e-06	0.27	0.18	Parkinson's disease;	chr6:28065396	chr6:28170845~28172521:+
BRCA	cis	rs516805	0.748	rs155467	ENSG00000279453.1	RP3-425C14.4	-5.82	8.03e-09	1.18e-06	-0.24	-0.18	Lymphocyte counts;	chr6:122512451	chr6:122436789~122439223:-
BRCA	cis	rs73193808	0.901	rs1997569	ENSG00000215533.7	LINC00189	-5.82	8.03e-09	1.18e-06	-0.26	-0.18	Coronary artery disease;	chr21:29213027	chr21:29193480~29288205:+
BRCA	cis	rs6504622	0.967	rs9889762	ENSG00000262879.4	RP11-156P1.3	5.82	8.04e-09	1.18e-06	0.18	0.18	Orofacial clefts;	chr17:46949000	chr17:46984045~47100323:-
BRCA	cis	rs2243480	1	rs781156	ENSG00000232559.3	GS1-124K5.12	5.82	8.04e-09	1.19e-06	0.33	0.18	Diabetic kidney disease;	chr7:66014154	chr7:66554588~66576923:-
BRCA	cis	rs2243480	1	rs451396	ENSG00000232559.3	GS1-124K5.12	5.82	8.04e-09	1.19e-06	0.33	0.18	Diabetic kidney disease;	chr7:66019087	chr7:66554588~66576923:-
BRCA	cis	rs2243480	1	rs1715235	ENSG00000232559.3	GS1-124K5.12	5.82	8.04e-09	1.19e-06	0.33	0.18	Diabetic kidney disease;	chr7:66023407	chr7:66554588~66576923:-
BRCA	cis	rs1040	0.69	rs9393165	ENSG00000261039.2	RP11-417E7.2	-5.82	8.04e-09	1.19e-06	-0.17	-0.18	Joint mobility (Beighton score);	chr6:169220152	chr6:169175304~169182740:-
BRCA	cis	rs2243480	1	rs34193460	ENSG00000164669.11	INTS4P1	5.82	8.04e-09	1.19e-06	0.34	0.18	Diabetic kidney disease;	chr7:65928123	chr7:65141225~65234216:+
BRCA	cis	rs12681366	0.734	rs3019146	ENSG00000253704.1	RP11-267M23.4	5.82	8.04e-09	1.19e-06	0.18	0.18	Nonsyndromic cleft lip with cleft palate;	chr8:94401878	chr8:94553722~94569745:+
BRCA	cis	rs7772486	0.875	rs2748490	ENSG00000270638.1	RP3-466P17.1	5.82	8.04e-09	1.19e-06	0.2	0.18	Lobe attachment (rater-scored or self-reported);	chr6:146008545	chr6:145735570~145737218:+
BRCA	cis	rs1440410	0.798	rs9992285	ENSG00000250326.1	RP11-284M14.1	-5.82	8.05e-09	1.19e-06	-0.2	-0.18	Ischemic stroke;	chr4:143139670	chr4:142933195~143184861:-
BRCA	cis	rs2153535	0.585	rs9393048	ENSG00000230939.1	RP11-314C16.1	-5.82	8.05e-09	1.19e-06	-0.21	-0.18	Motion sickness;	chr6:8626321	chr6:8784178~8785445:+
BRCA	cis	rs1859596	0.932	rs2269990	ENSG00000234456.6	MAGI2-AS3	5.82	8.05e-09	1.19e-06	0.11	0.18	Reading or mathematical ability;	chr7:79460720	chr7:79452877~79471208:+
BRCA	cis	rs8114671	0.562	rs2425005	ENSG00000269202.1	RP4-614O4.12	5.81	8.06e-09	1.19e-06	0.2	0.18	Height;	chr20:34819912	chr20:35201747~35203288:-
BRCA	cis	rs12681366	0.919	rs13248829	ENSG00000253704.1	RP11-267M23.4	5.81	8.06e-09	1.19e-06	0.19	0.18	Nonsyndromic cleft lip with cleft palate;	chr8:94476750	chr8:94553722~94569745:+
BRCA	cis	rs4908768	0.501	rs1463050	ENSG00000270282.1	RP5-1115A15.2	5.81	8.07e-09	1.19e-06	0.19	0.18	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8536983	chr1:8512653~8513021:+
BRCA	cis	rs828999	0.642	rs10881512	ENSG00000280186.1	RP11-483I13.6	-5.81	8.09e-09	1.19e-06	-0.2	-0.18	Monocyte percentage of white cells;	chr1:108175437	chr1:108200413~108202743:+
BRCA	cis	rs7246760	0.867	rs8102257	ENSG00000277587.1	CTD-3116E22.8	-5.81	8.09e-09	1.19e-06	-0.34	-0.18	Pursuit maintenance gain;	chr19:9720119	chr19:9721903~9722410:+
BRCA	cis	rs11098499	0.955	rs1511015	ENSG00000249244.1	RP11-548H18.2	5.81	8.09e-09	1.19e-06	0.21	0.18	Corneal astigmatism;	chr4:119249318	chr4:119391831~119395335:-
BRCA	cis	rs6688613	0.84	rs6695609	ENSG00000225171.2	DUTP6	5.81	8.1e-09	1.19e-06	0.23	0.18	Refractive astigmatism;	chr1:166984629	chr1:166868748~166869209:+
BRCA	cis	rs2243480	1	rs35825738	ENSG00000232546.1	RP11-458F8.1	-5.81	8.11e-09	1.19e-06	-0.23	-0.18	Diabetic kidney disease;	chr7:65853040	chr7:66848496~66858136:+
BRCA	cis	rs8133949	0.638	rs2839429	ENSG00000237232.6	ZNF295-AS1	5.81	8.12e-09	1.2e-06	0.32	0.18	Hand grip strength;	chr21:41982063	chr21:42009194~42024924:+
BRCA	cis	rs828999	0.688	rs10881513	ENSG00000280186.1	RP11-483I13.6	-5.81	8.13e-09	1.2e-06	-0.2	-0.18	Monocyte percentage of white cells;	chr1:108176577	chr1:108200413~108202743:+
BRCA	cis	rs828999	0.688	rs2053433	ENSG00000280186.1	RP11-483I13.6	-5.81	8.13e-09	1.2e-06	-0.2	-0.18	Monocyte percentage of white cells;	chr1:108181438	chr1:108200413~108202743:+
BRCA	cis	rs4664293	0.528	rs12477092	ENSG00000226266.5	AC009961.3	5.81	8.13e-09	1.2e-06	0.22	0.18	Monocyte percentage of white cells;	chr2:159577170	chr2:159670708~159712435:-
BRCA	cis	rs804280	0.662	rs11784693	ENSG00000255046.1	RP11-297N6.4	5.81	8.13e-09	1.2e-06	0.23	0.18	Myopia (pathological);	chr8:11753165	chr8:11797928~11802568:-
BRCA	cis	rs897984	0.806	rs1458202	ENSG00000275263.1	RP11-1072A3.4	-5.81	8.13e-09	1.2e-06	-0.21	-0.18	Dementia with Lewy bodies;	chr16:30941881	chr16:30956872~30957199:-
BRCA	cis	rs10129255	0.957	rs10141009	ENSG00000224373.3	IGHV4-59	5.81	8.14e-09	1.2e-06	0.11	0.18	Kawasaki disease;	chr14:106776695	chr14:106627249~106627825:-
BRCA	cis	rs55966801	0.898	rs11602248	ENSG00000277290.1	RP11-326C3.16	-5.81	8.14e-09	1.2e-06	-0.22	-0.18	Plateletcrit;	chr11:231305	chr11:243099~243483:-
BRCA	cis	rs1858037	0.867	rs6727013	ENSG00000204929.10	AC074391.1	5.81	8.15e-09	1.2e-06	0.24	0.18	Rheumatoid arthritis;	chr2:65331241	chr2:65436711~66084639:+
BRCA	cis	rs7131987	0.621	rs57803026	ENSG00000275476.1	RP11-996F15.4	-5.81	8.15e-09	1.2e-06	-0.21	-0.18	QT interval;	chr12:29344573	chr12:29277397~29277882:-
BRCA	cis	rs7809950	0.678	rs6949634	ENSG00000238832.1	snoU109	-5.81	8.15e-09	1.2e-06	-0.26	-0.18	Coronary artery disease;	chr7:107344239	chr7:107603363~107603507:+
BRCA	cis	rs35849525	0.776	rs7615318	ENSG00000228008.1	CTD-2330K9.3	5.81	8.16e-09	1.2e-06	0.21	0.18	Intelligence (multi-trait analysis);	chr3:49950042	chr3:49903845~49916937:+
BRCA	cis	rs11105298	0.891	rs10777162	ENSG00000270344.2	RP11-734K2.4	5.81	8.17e-09	1.2e-06	0.2	0.18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89436746	chr12:89525654~89548005:+
BRCA	cis	rs7772486	0.875	rs2748502	ENSG00000270638.1	RP3-466P17.1	5.81	8.17e-09	1.2e-06	0.2	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145977103	chr6:145735570~145737218:+
BRCA	cis	rs7246657	0.551	rs4806414	ENSG00000226686.6	LINC01535	-5.81	8.19e-09	1.21e-06	-0.3	-0.18	Coronary artery calcification;	chr19:37147886	chr19:37251912~37265535:+
BRCA	cis	rs73222236	0.825	rs35644083	ENSG00000273486.1	RP11-731C17.2	5.81	8.2e-09	1.21e-06	0.2	0.18	Coronary artery disease;	chr3:136503626	chr3:136837338~136839021:-
BRCA	cis	rs875971	0.545	rs316324	ENSG00000228409.4	CCT6P1	5.81	8.2e-09	1.21e-06	0.17	0.18	Aortic root size;	chr7:66145627	chr7:65751142~65763354:+
BRCA	cis	rs875971	0.545	rs316323	ENSG00000228409.4	CCT6P1	5.81	8.2e-09	1.21e-06	0.17	0.18	Aortic root size;	chr7:66146002	chr7:65751142~65763354:+
BRCA	cis	rs2153535	0.585	rs1328873	ENSG00000230939.1	RP11-314C16.1	-5.81	8.2e-09	1.21e-06	-0.2	-0.18	Motion sickness;	chr6:8621171	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.585	rs9393047	ENSG00000230939.1	RP11-314C16.1	-5.81	8.2e-09	1.21e-06	-0.2	-0.18	Motion sickness;	chr6:8622373	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.585	rs9505495	ENSG00000230939.1	RP11-314C16.1	-5.81	8.2e-09	1.21e-06	-0.2	-0.18	Motion sickness;	chr6:8622963	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.585	rs9328499	ENSG00000230939.1	RP11-314C16.1	-5.81	8.2e-09	1.21e-06	-0.2	-0.18	Motion sickness;	chr6:8623546	chr6:8784178~8785445:+
BRCA	cis	rs2333194	0.844	rs17182286	ENSG00000258695.2	RP3-414A15.2	-5.81	8.21e-09	1.21e-06	-0.22	-0.18	Bipolar disorder with mood-incongruent psychosis;	chr14:73282200	chr14:73522878~73530610:+
BRCA	cis	rs12612619	0.704	rs6742004	ENSG00000229122.1	AGBL5-IT1	5.81	8.21e-09	1.21e-06	0.19	0.18	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27086791	chr2:27061038~27061815:+
BRCA	cis	rs11722779	0.935	rs7676736	ENSG00000251288.2	RP11-10L12.2	-5.81	8.22e-09	1.21e-06	-0.21	-0.18	Schizophrenia;	chr4:103016729	chr4:102751401~102752641:+
BRCA	cis	rs7621025	0.662	rs3856637	ENSG00000239213.4	NCK1-AS1	5.81	8.22e-09	1.21e-06	0.2	0.18	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136672353	chr3:136841726~136862054:-
BRCA	cis	rs9341808	0.59	rs4706841	ENSG00000272129.1	RP11-250B2.6	5.81	8.22e-09	1.21e-06	0.22	0.18	Sitting height ratio;	chr6:80348110	chr6:80355424~80356859:+
BRCA	cis	rs2153535	0.585	rs9379237	ENSG00000230939.1	RP11-314C16.1	-5.81	8.22e-09	1.21e-06	-0.2	-0.18	Motion sickness;	chr6:8654330	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.609	rs1328864	ENSG00000230939.1	RP11-314C16.1	-5.81	8.22e-09	1.21e-06	-0.2	-0.18	Motion sickness;	chr6:8656048	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.585	rs7450731	ENSG00000230939.1	RP11-314C16.1	-5.81	8.22e-09	1.21e-06	-0.2	-0.18	Motion sickness;	chr6:8656501	chr6:8784178~8785445:+
BRCA	cis	rs2243480	1	rs35820085	ENSG00000232559.3	GS1-124K5.12	5.81	8.24e-09	1.21e-06	0.33	0.18	Diabetic kidney disease;	chr7:65977771	chr7:66554588~66576923:-
BRCA	cis	rs3733585	0.699	rs6449171	ENSG00000250413.1	RP11-448G15.1	-5.81	8.24e-09	1.21e-06	-0.23	-0.18	Cleft plate (environmental tobacco smoke interaction);	chr4:9964374	chr4:10006482~10009725:+
BRCA	cis	rs9376098	0.708	rs9321490	ENSG00000232876.1	CTA-212D2.2	-5.81	8.24e-09	1.21e-06	-0.25	-0.18	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr6:135173737	chr6:135055033~135060550:+
BRCA	cis	rs2243480	0.711	rs1626926	ENSG00000232559.3	GS1-124K5.12	5.81	8.25e-09	1.21e-06	0.33	0.18	Diabetic kidney disease;	chr7:65970805	chr7:66554588~66576923:-
BRCA	cis	rs7044106	0.762	rs1547267	ENSG00000238181.2	AHCYP2	-5.81	8.26e-09	1.22e-06	-0.23	-0.18	Hip circumference adjusted for BMI;	chr9:120646458	chr9:120720673~120721972:+
BRCA	cis	rs9840812	0.645	rs9883916	ENSG00000273486.1	RP11-731C17.2	5.81	8.26e-09	1.22e-06	0.23	0.18	Fibrinogen levels;	chr3:136489946	chr3:136837338~136839021:-
BRCA	cis	rs7976269	0.609	rs4931137	ENSG00000275476.1	RP11-996F15.4	-5.81	8.26e-09	1.22e-06	-0.2	-0.18	Male-pattern baldness;	chr12:29049701	chr12:29277397~29277882:-
BRCA	cis	rs2243480	1	rs12698509	ENSG00000164669.11	INTS4P1	5.81	8.26e-09	1.22e-06	0.33	0.18	Diabetic kidney disease;	chr7:65953889	chr7:65141225~65234216:+
BRCA	cis	rs35612822	0.797	rs7590302	ENSG00000232485.2	AC098820.3	-5.81	8.26e-09	1.22e-06	-0.23	-0.18	Kidney disease (early stage) in type 1 diabetes;	chr2:216466178	chr2:216479030~216498761:-
BRCA	cis	rs4950322	0.857	rs55790545	ENSG00000278811.3	LINC00624	5.81	8.27e-09	1.22e-06	0.24	0.18	Protein quantitative trait loci;	chr1:147366649	chr1:147258885~147517875:-
BRCA	cis	rs4950322	0.857	rs7522219	ENSG00000278811.3	LINC00624	5.81	8.27e-09	1.22e-06	0.24	0.18	Protein quantitative trait loci;	chr1:147366904	chr1:147258885~147517875:-
BRCA	cis	rs12893668	0.572	rs12590968	ENSG00000269910.1	RP11-73M18.10	5.81	8.27e-09	1.22e-06	0.19	0.18	Reticulocyte count;	chr14:103670296	chr14:103694516~103695050:-
BRCA	cis	rs72772090	0.908	rs17086588	ENSG00000248734.2	CTD-2260A17.1	5.81	8.27e-09	1.22e-06	0.25	0.18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96709210	chr5:96784777~96785999:+
BRCA	cis	rs957448	0.687	rs10104041	ENSG00000253175.1	RP11-267M23.6	5.81	8.28e-09	1.22e-06	0.21	0.18	Nonsyndromic cleft lip with cleft palate;	chr8:94559374	chr8:94565036~94565715:+
BRCA	cis	rs12612619	0.732	rs6547401	ENSG00000229122.1	AGBL5-IT1	5.81	8.28e-09	1.22e-06	0.19	0.18	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27061977	chr2:27061038~27061815:+
BRCA	cis	rs9880211	0.613	rs6786582	ENSG00000239213.4	NCK1-AS1	-5.81	8.28e-09	1.22e-06	-0.23	-0.18	Height;Body mass index;	chr3:136180142	chr3:136841726~136862054:-
BRCA	cis	rs7916697	0.52	rs12265247	ENSG00000233590.1	RP11-153K11.3	-5.81	8.28e-09	1.22e-06	-0.22	-0.18	Optic disc area;	chr10:68278641	chr10:68233251~68242379:-
BRCA	cis	rs9308731	0.605	rs6754738	ENSG00000227992.1	AC108463.2	-5.81	8.29e-09	1.22e-06	-0.2	-0.18	Chronic lymphocytic leukemia;	chr2:111190966	chr2:111203964~111206215:-
BRCA	cis	rs2243480	0.901	rs1701759	ENSG00000230295.1	RP11-458F8.2	-5.81	8.29e-09	1.22e-06	-0.23	-0.18	Diabetic kidney disease;	chr7:66005945	chr7:66880708~66882981:+
BRCA	cis	rs7044106	0.762	rs1547268	ENSG00000238181.2	AHCYP2	-5.81	8.29e-09	1.22e-06	-0.23	-0.18	Hip circumference adjusted for BMI;	chr9:120646410	chr9:120720673~120721972:+
BRCA	cis	rs17818399	0.89	rs34544165	ENSG00000279254.1	RP11-536C12.1	-5.81	8.29e-09	1.22e-06	-0.22	-0.18	Height;	chr2:46609767	chr2:46668870~46670778:+
BRCA	cis	rs2732480	0.577	rs2634681	ENSG00000273765.1	RP11-370I10.11	-5.81	8.29e-09	1.22e-06	-0.2	-0.18	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48339301	chr12:48360920~48361377:+
BRCA	cis	rs4908760	0.864	rs12136766	ENSG00000270282.1	RP5-1115A15.2	5.81	8.3e-09	1.22e-06	0.19	0.18	Vitiligo;	chr1:8603762	chr1:8512653~8513021:+
BRCA	cis	rs6061231	1	rs11696991	ENSG00000275437.1	RP5-908M14.10	5.81	8.3e-09	1.22e-06	0.19	0.18	Colorectal cancer;	chr20:62384638	chr20:62402236~62405935:-
BRCA	cis	rs3213958	0.533	rs3772100	ENSG00000249274.1	PDLIM1P4	-5.81	8.3e-09	1.22e-06	-0.27	-0.18	Blood protein levels;	chr3:98782236	chr3:98782188~98783193:+
BRCA	cis	rs10510102	0.688	rs74570569	ENSG00000226864.1	ATE1-AS1	5.81	8.31e-09	1.22e-06	0.32	0.18	Breast cancer;	chr10:121945347	chr10:121928312~121951965:+
BRCA	cis	rs7520050	0.966	rs4376778	ENSG00000280836.1	AL355480.1	5.81	8.33e-09	1.23e-06	0.21	0.18	Reticulocyte count;Red blood cell count;	chr1:45823174	chr1:45581219~45581321:-
BRCA	cis	rs7520050	0.966	rs6672898	ENSG00000280836.1	AL355480.1	5.81	8.33e-09	1.23e-06	0.21	0.18	Reticulocyte count;Red blood cell count;	chr1:45824916	chr1:45581219~45581321:-
BRCA	cis	rs6688613	0.729	rs2072742	ENSG00000225171.2	DUTP6	-5.81	8.33e-09	1.23e-06	-0.25	-0.18	Refractive astigmatism;	chr1:166960436	chr1:166868748~166869209:+
BRCA	cis	rs7520050	0.966	rs11211208	ENSG00000280836.1	AL355480.1	5.81	8.34e-09	1.23e-06	0.21	0.18	Reticulocyte count;Red blood cell count;	chr1:45868584	chr1:45581219~45581321:-
BRCA	cis	rs1043099	0.556	rs4820846	ENSG00000279699.1	RP1-102K2.9	-5.81	8.35e-09	1.23e-06	-0.22	-0.18	Rheumatoid arthritis;	chr22:30404379	chr22:30275215~30276951:-
BRCA	cis	rs73222236	0.825	rs6439638	ENSG00000273486.1	RP11-731C17.2	5.81	8.35e-09	1.23e-06	0.2	0.18	Coronary artery disease;	chr3:136338990	chr3:136837338~136839021:-
BRCA	cis	rs577676	0.586	rs666419	ENSG00000271811.1	RP1-79C4.4	5.81	8.36e-09	1.23e-06	0.21	0.18	Prevalent atrial fibrillation;	chr1:170645103	chr1:170667381~170669425:+
BRCA	cis	rs228614	0.51	rs170565	ENSG00000251288.2	RP11-10L12.2	-5.81	8.36e-09	1.23e-06	-0.21	-0.18	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102798277	chr4:102751401~102752641:+
BRCA	cis	rs1707322	1	rs12077974	ENSG00000281133.1	AL355480.3	-5.81	8.36e-09	1.23e-06	-0.23	-0.18	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45918469	chr1:45580892~45580996:-
BRCA	cis	rs10761482	0.5	rs1892546	ENSG00000254271.1	RP11-131N11.4	5.81	8.36e-09	1.23e-06	0.24	0.18	Schizophrenia;	chr10:60534258	chr10:60734342~60741828:+
BRCA	cis	rs2243480	1	rs35046236	ENSG00000232546.1	RP11-458F8.1	-5.81	8.38e-09	1.23e-06	-0.23	-0.18	Diabetic kidney disease;	chr7:65943626	chr7:66848496~66858136:+
BRCA	cis	rs2243480	1	rs36068983	ENSG00000232546.1	RP11-458F8.1	-5.81	8.38e-09	1.23e-06	-0.23	-0.18	Diabetic kidney disease;	chr7:65944004	chr7:66848496~66858136:+
BRCA	cis	rs2243480	1	rs68189316	ENSG00000232546.1	RP11-458F8.1	-5.81	8.38e-09	1.23e-06	-0.23	-0.18	Diabetic kidney disease;	chr7:65944182	chr7:66848496~66858136:+
BRCA	cis	rs8098244	0.683	rs4488534	ENSG00000264745.1	TTC39C-AS1	5.81	8.38e-09	1.23e-06	0.21	0.18	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23852486	chr18:23994213~24015339:-
BRCA	cis	rs6951245	0.638	rs4720486	ENSG00000229043.2	AC091729.9	-5.81	8.39e-09	1.23e-06	-0.27	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1107128	chr7:1160374~1165267:+
BRCA	cis	rs12501370	0.721	rs12650957	ENSG00000201736.1	RNA5SP160	5.81	8.39e-09	1.23e-06	0.24	0.18	Iris color (L* coordinate);	chr4:41062300	chr4:40990154~40990273:+
BRCA	cis	rs12501370	0.721	rs12641331	ENSG00000201736.1	RNA5SP160	5.81	8.39e-09	1.23e-06	0.24	0.18	Iris color (L* coordinate);	chr4:41062623	chr4:40990154~40990273:+
BRCA	cis	rs7520050	0.966	rs12564541	ENSG00000280836.1	AL355480.1	5.81	8.4e-09	1.24e-06	0.21	0.18	Reticulocyte count;Red blood cell count;	chr1:45914565	chr1:45581219~45581321:-
BRCA	cis	rs10829156	0.699	rs6482516	ENSG00000240291.1	RP11-499P20.2	5.81	8.41e-09	1.24e-06	0.19	0.18	Sudden cardiac arrest;	chr10:18550421	chr10:18513115~18545651:-
BRCA	cis	rs516805	0.564	rs2679658	ENSG00000279453.1	RP3-425C14.4	-5.81	8.41e-09	1.24e-06	-0.26	-0.18	Lymphocyte counts;	chr6:122109293	chr6:122436789~122439223:-
BRCA	cis	rs1193	1	rs2367378	ENSG00000231259.4	AC125232.1	-5.81	8.41e-09	1.24e-06	-0.22	-0.18	High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;High light scatter reticulocyte count;	chr2:86771090	chr2:87031815~87053069:-
BRCA	cis	rs1193	1	rs10201422	ENSG00000231259.4	AC125232.1	-5.81	8.41e-09	1.24e-06	-0.22	-0.18	High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;High light scatter reticulocyte count;	chr2:86772048	chr2:87031815~87053069:-
BRCA	cis	rs2098713	0.575	rs11745000	ENSG00000250155.1	CTD-2353F22.1	-5.81	8.41e-09	1.24e-06	-0.21	-0.18	Telomere length;	chr5:37476980	chr5:36666214~36725195:-
BRCA	cis	rs2115630	0.905	rs1975277	ENSG00000229212.6	RP11-561C5.4	5.81	8.42e-09	1.24e-06	0.2	0.18	P wave terminal force;	chr15:84786327	chr15:85205440~85234795:-
BRCA	cis	rs73222236	0.825	rs9834631	ENSG00000273486.1	RP11-731C17.2	5.81	8.42e-09	1.24e-06	0.2	0.18	Coronary artery disease;	chr3:136577757	chr3:136837338~136839021:-
BRCA	cis	rs1387259	0.69	rs1601985	ENSG00000226413.2	OR8T1P	5.81	8.42e-09	1.24e-06	0.24	0.18	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48368131	chr12:48442030~48442947:-
BRCA	cis	rs699371	0.507	rs10149538	ENSG00000259005.1	RP3-449M8.6	5.81	8.42e-09	1.24e-06	0.21	0.18	Height;	chr14:74458694	chr14:74474007~74474864:-
BRCA	cis	rs6479891	1	rs9414799	ENSG00000232075.1	MRPL35P2	5.81	8.43e-09	1.24e-06	0.32	0.18	Arthritis (juvenile idiopathic);	chr10:63369842	chr10:63634317~63634827:-
BRCA	cis	rs1193	0.802	rs12714203	ENSG00000231259.4	AC125232.1	-5.81	8.43e-09	1.24e-06	-0.22	-0.18	High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;High light scatter reticulocyte count;	chr2:86766651	chr2:87031815~87053069:-
BRCA	cis	rs2638953	0.777	rs11049689	ENSG00000278733.1	RP11-425D17.1	-5.81	8.43e-09	1.24e-06	-0.24	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28519177	chr12:28185625~28186190:-
BRCA	cis	rs35146811	0.586	rs10267212	ENSG00000214313.7	AZGP1P1	5.81	8.43e-09	1.24e-06	0.19	0.18	Coronary artery disease;	chr7:99997799	chr7:99980762~99987535:+
BRCA	cis	rs2243480	0.803	rs35480979	ENSG00000232546.1	RP11-458F8.1	-5.81	8.44e-09	1.24e-06	-0.23	-0.18	Diabetic kidney disease;	chr7:65892097	chr7:66848496~66858136:+
BRCA	cis	rs2243480	1	rs35391607	ENSG00000232546.1	RP11-458F8.1	-5.81	8.44e-09	1.24e-06	-0.23	-0.18	Diabetic kidney disease;	chr7:65895842	chr7:66848496~66858136:+
BRCA	cis	rs2243480	1	rs13220979	ENSG00000232546.1	RP11-458F8.1	-5.81	8.44e-09	1.24e-06	-0.23	-0.18	Diabetic kidney disease;	chr7:65898217	chr7:66848496~66858136:+
BRCA	cis	rs2243480	1	rs34974928	ENSG00000232546.1	RP11-458F8.1	-5.81	8.44e-09	1.24e-06	-0.23	-0.18	Diabetic kidney disease;	chr7:65899019	chr7:66848496~66858136:+
BRCA	cis	rs13126694	0.778	rs13106004	ENSG00000251429.1	RP11-597D13.7	5.81	8.44e-09	1.24e-06	0.17	0.18	Blood osmolality (transformed sodium);	chr4:158104532	chr4:158270378~158278676:+
BRCA	cis	rs13126694	0.744	rs13106234	ENSG00000251429.1	RP11-597D13.7	5.81	8.44e-09	1.24e-06	0.17	0.18	Blood osmolality (transformed sodium);	chr4:158104618	chr4:158270378~158278676:+
BRCA	cis	rs7927771	0.524	rs7943213	ENSG00000280615.1	Y_RNA	5.81	8.44e-09	1.24e-06	0.21	0.18	Subjective well-being;	chr11:47693972	chr11:47614898~47614994:-
BRCA	cis	rs7772486	0.659	rs9376957	ENSG00000270638.1	RP3-466P17.1	-5.81	8.45e-09	1.24e-06	-0.2	-0.18	Lobe attachment (rater-scored or self-reported);	chr6:145689928	chr6:145735570~145737218:+
BRCA	cis	rs2243480	1	rs1167613	ENSG00000228409.4	CCT6P1	5.81	8.46e-09	1.24e-06	0.24	0.18	Diabetic kidney disease;	chr7:66022452	chr7:65751142~65763354:+
BRCA	cis	rs2243480	1	rs313799	ENSG00000228409.4	CCT6P1	5.81	8.46e-09	1.24e-06	0.24	0.18	Diabetic kidney disease;	chr7:66029343	chr7:65751142~65763354:+
BRCA	cis	rs10129255	0.5	rs2105989	ENSG00000224373.3	IGHV4-59	5.81	8.46e-09	1.24e-06	0.1	0.18	Kawasaki disease;	chr14:106682199	chr14:106627249~106627825:-
BRCA	cis	rs950169	0.614	rs12911536	ENSG00000259728.4	LINC00933	5.81	8.47e-09	1.24e-06	0.26	0.18	Schizophrenia;	chr15:84004278	chr15:84570649~84580175:+
BRCA	cis	rs72681920	0.881	rs17028765	ENSG00000246090.5	RP11-696N14.1	-5.81	8.47e-09	1.25e-06	-0.27	-0.18	Alcohol dependence;	chr4:99267239	chr4:99088857~99301356:+
BRCA	cis	rs10510102	0.872	rs11200268	ENSG00000226864.1	ATE1-AS1	5.81	8.48e-09	1.25e-06	0.32	0.18	Breast cancer;	chr10:121932661	chr10:121928312~121951965:+
BRCA	cis	rs10510102	0.872	rs11200269	ENSG00000226864.1	ATE1-AS1	5.81	8.48e-09	1.25e-06	0.32	0.18	Breast cancer;	chr10:121934021	chr10:121928312~121951965:+
BRCA	cis	rs10510102	0.872	rs11498944	ENSG00000226864.1	ATE1-AS1	5.81	8.48e-09	1.25e-06	0.32	0.18	Breast cancer;	chr10:121938748	chr10:121928312~121951965:+
BRCA	cis	rs10510102	0.81	rs12267347	ENSG00000226864.1	ATE1-AS1	5.81	8.48e-09	1.25e-06	0.32	0.18	Breast cancer;	chr10:121939110	chr10:121928312~121951965:+
BRCA	cis	rs10510102	0.808	rs12253007	ENSG00000226864.1	ATE1-AS1	5.81	8.48e-09	1.25e-06	0.32	0.18	Breast cancer;	chr10:121939360	chr10:121928312~121951965:+
BRCA	cis	rs62025270	0.632	rs62022919	ENSG00000202081.1	RNU6-1280P	-5.81	8.48e-09	1.25e-06	-0.26	-0.18	Idiopathic pulmonary fibrosis;	chr15:85675079	chr15:85651522~85651628:-
BRCA	cis	rs4908768	0.501	rs1463051	ENSG00000270282.1	RP5-1115A15.2	-5.81	8.48e-09	1.25e-06	-0.19	-0.18	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8536834	chr1:8512653~8513021:+
BRCA	cis	rs2998286	0.784	rs998362	ENSG00000254635.4	WAC-AS1	-5.81	8.49e-09	1.25e-06	-0.24	-0.18	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28528129	chr10:28522652~28532743:-
BRCA	cis	rs4713118	0.516	rs6931858	ENSG00000280107.1	AL022393.9	-5.81	8.5e-09	1.25e-06	-0.26	-0.18	Parkinson's disease;	chr6:28110633	chr6:28170845~28172521:+
BRCA	cis	rs7976269	0.609	rs7135891	ENSG00000275476.1	RP11-996F15.4	-5.81	8.5e-09	1.25e-06	-0.2	-0.18	Male-pattern baldness;	chr12:29053944	chr12:29277397~29277882:-
BRCA	cis	rs7520050	0.966	rs7539932	ENSG00000280836.1	AL355480.1	5.81	8.51e-09	1.25e-06	0.21	0.18	Reticulocyte count;Red blood cell count;	chr1:45826682	chr1:45581219~45581321:-
BRCA	cis	rs7520050	0.966	rs61783200	ENSG00000280836.1	AL355480.1	5.81	8.51e-09	1.25e-06	0.21	0.18	Reticulocyte count;Red blood cell count;	chr1:45831731	chr1:45581219~45581321:-
BRCA	cis	rs7615952	0.599	rs66532274	ENSG00000171084.14	FAM86JP	5.81	8.52e-09	1.25e-06	0.26	0.18	Blood pressure (smoking interaction);	chr3:126013002	chr3:125916620~125930024:+
BRCA	cis	rs6088813	0.857	rs1886692	ENSG00000126005.14	MMP24-AS1	5.81	8.52e-09	1.25e-06	0.21	0.18	Height;	chr20:35398746	chr20:35216462~35278131:-
BRCA	cis	rs7474896	0.559	rs1024202	ENSG00000120555.12	SEPT7P9	-5.81	8.53e-09	1.25e-06	-0.25	-0.18	Obesity (extreme);	chr10:37990049	chr10:38383069~38402916:-
BRCA	cis	rs7474896	0.537	rs1022449	ENSG00000120555.12	SEPT7P9	-5.81	8.53e-09	1.25e-06	-0.25	-0.18	Obesity (extreme);	chr10:37990539	chr10:38383069~38402916:-
BRCA	cis	rs2274273	1	rs57970196	ENSG00000258413.1	RP11-665C16.6	-5.81	8.53e-09	1.25e-06	-0.23	-0.18	Protein biomarker;	chr14:55133687	chr14:55262767~55272075:-
BRCA	cis	rs897984	0.683	rs72799316	ENSG00000260911.2	RP11-196G11.2	5.8	8.54e-09	1.25e-06	0.16	0.18	Dementia with Lewy bodies;	chr16:30815884	chr16:31043150~31049868:+
BRCA	cis	rs8002861	0.664	rs895266	ENSG00000274001.1	RP11-5G9.5	5.8	8.54e-09	1.25e-06	0.21	0.18	Leprosy;	chr13:43887043	chr13:43877715~43878163:-
BRCA	cis	rs4699052	1	rs4699052	ENSG00000248740.4	RP11-328K4.1	5.8	8.55e-09	1.26e-06	0.2	0.18	Testicular germ cell tumor;	chr4:103216633	chr4:103256159~103453658:+
BRCA	cis	rs577676	0.586	rs12068805	ENSG00000271811.1	RP1-79C4.4	5.8	8.55e-09	1.26e-06	0.21	0.18	Prevalent atrial fibrillation;	chr1:170632172	chr1:170667381~170669425:+
BRCA	cis	rs2832191	0.74	rs2853830	ENSG00000176054.6	RPL23P2	5.8	8.56e-09	1.26e-06	0.19	0.18	Dental caries;	chr21:29044503	chr21:28997613~28998033:-
BRCA	cis	rs11671005	0.735	rs11670871	ENSG00000252334.1	RNU6-1337P	-5.8	8.56e-09	1.26e-06	-0.26	-0.18	Mean platelet volume;	chr19:58429147	chr19:58483749~58483843:-
BRCA	cis	rs12893668	0.572	rs4900590	ENSG00000269940.1	RP11-73M18.7	5.8	8.56e-09	1.26e-06	0.2	0.18	Reticulocyte count;	chr14:103680084	chr14:103694560~103695170:+
BRCA	cis	rs35146811	0.66	rs6465760	ENSG00000214313.7	AZGP1P1	-5.8	8.56e-09	1.26e-06	-0.19	-0.18	Coronary artery disease;	chr7:99993795	chr7:99980762~99987535:+
BRCA	cis	rs2348418	0.715	rs10843206	ENSG00000247934.4	RP11-967K21.1	5.8	8.56e-09	1.26e-06	0.2	0.18	Lung function (FEV1);Lung function (FVC);	chr12:28569823	chr12:28163298~28190738:-
BRCA	cis	rs2243480	0.901	rs57126451	ENSG00000232546.1	RP11-458F8.1	-5.8	8.57e-09	1.26e-06	-0.23	-0.18	Diabetic kidney disease;	chr7:65951319	chr7:66848496~66858136:+
BRCA	cis	rs9308731	1	rs6542334	ENSG00000227992.1	AC108463.2	-5.8	8.58e-09	1.26e-06	-0.21	-0.18	Chronic lymphocytic leukemia;	chr2:111149637	chr2:111203964~111206215:-
BRCA	cis	rs9840812	0.645	rs13068119	ENSG00000239213.4	NCK1-AS1	-5.8	8.58e-09	1.26e-06	-0.23	-0.18	Fibrinogen levels;	chr3:136487527	chr3:136841726~136862054:-
BRCA	cis	rs2836950	0.501	rs2836984	ENSG00000238141.2	BRWD1-AS1	-5.8	8.59e-09	1.26e-06	-0.2	-0.18	Menarche (age at onset);	chr21:39329023	chr21:39315707~39323218:+
BRCA	cis	rs2115630	1	rs10220733	ENSG00000229212.6	RP11-561C5.4	5.8	8.6e-09	1.26e-06	0.19	0.18	P wave terminal force;	chr15:84737633	chr15:85205440~85234795:-
BRCA	cis	rs2836950	0.501	rs13047518	ENSG00000238141.2	BRWD1-AS1	-5.8	8.6e-09	1.26e-06	-0.2	-0.18	Menarche (age at onset);	chr21:39335381	chr21:39315707~39323218:+
BRCA	cis	rs7809950	0.678	rs17154040	ENSG00000238832.1	snoU109	5.8	8.6e-09	1.26e-06	0.26	0.18	Coronary artery disease;	chr7:107364801	chr7:107603363~107603507:+
BRCA	cis	rs2832191	0.729	rs2832201	ENSG00000176054.6	RPL23P2	-5.8	8.6e-09	1.26e-06	-0.19	-0.18	Dental caries;	chr21:29127520	chr21:28997613~28998033:-
BRCA	cis	rs375066	0.551	rs11879541	ENSG00000267058.1	RP11-15A1.3	5.8	8.6e-09	1.26e-06	0.21	0.18	Breast cancer;	chr19:43827291	chr19:43891804~43901805:-
BRCA	cis	rs375066	0.526	rs17712224	ENSG00000267058.1	RP11-15A1.3	5.8	8.6e-09	1.26e-06	0.21	0.18	Breast cancer;	chr19:43827442	chr19:43891804~43901805:-
BRCA	cis	rs375066	0.551	rs10500286	ENSG00000267058.1	RP11-15A1.3	5.8	8.6e-09	1.26e-06	0.21	0.18	Breast cancer;	chr19:43827461	chr19:43891804~43901805:-
BRCA	cis	rs59169624	0.699	rs73424622	ENSG00000255160.4	RP11-428C19.5	5.8	8.61e-09	1.26e-06	0.24	0.18	Parental extreme longevity (95 years and older);	chr11:19261341	chr11:19299883~19308358:+
BRCA	cis	rs30380	0.587	rs469674	ENSG00000272109.1	CTD-2260A17.3	-5.8	8.61e-09	1.26e-06	-0.25	-0.18	Cerebrospinal fluid biomarker levels;	chr5:96794312	chr5:96804353~96806105:+
BRCA	cis	rs828999	0.688	rs12047867	ENSG00000280186.1	RP11-483I13.6	-5.8	8.61e-09	1.26e-06	-0.2	-0.18	Monocyte percentage of white cells;	chr1:108184285	chr1:108200413~108202743:+
BRCA	cis	rs9307551	0.619	rs1561639	ENSG00000250334.4	LINC00989	-5.8	8.61e-09	1.26e-06	-0.25	-0.18	Refractive error;	chr4:79498986	chr4:79492416~79576460:+
BRCA	cis	rs442309	0.687	rs10995283	ENSG00000238280.1	RP11-436D10.3	-5.8	8.63e-09	1.27e-06	-0.25	-0.18	Vogt-Koyanagi-Harada syndrome;	chr10:62714628	chr10:62793562~62805887:-
BRCA	cis	rs8002861	0.935	rs7318147	ENSG00000274001.1	RP11-5G9.5	-5.8	8.63e-09	1.27e-06	-0.21	-0.18	Leprosy;	chr13:43871017	chr13:43877715~43878163:-
BRCA	cis	rs3213958	0.574	rs16846347	ENSG00000249274.1	PDLIM1P4	-5.8	8.63e-09	1.27e-06	-0.26	-0.18	Blood protein levels;	chr3:98777624	chr3:98782188~98783193:+
BRCA	cis	rs6088813	1	rs6088815	ENSG00000126005.14	MMP24-AS1	5.8	8.63e-09	1.27e-06	0.21	0.18	Height;	chr20:35388671	chr20:35216462~35278131:-
BRCA	cis	rs2638953	0.962	rs11049518	ENSG00000278733.1	RP11-425D17.1	-5.8	8.63e-09	1.27e-06	-0.24	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28303728	chr12:28185625~28186190:-
BRCA	cis	rs7923837	0.554	rs7077418	ENSG00000236493.2	EIF2S2P3	5.8	8.64e-09	1.27e-06	0.25	0.18	Multiple sclerosis;Body mass index;	chr10:92536041	chr10:92668745~92669743:-
BRCA	cis	rs16928809	1	rs16928809	ENSG00000183562.3	CTC-343N3.1	5.8	8.64e-09	1.27e-06	0.29	0.18	Bilirubin levels;	chr11:2915722	chr11:2989863~2991344:+
BRCA	cis	rs4803480	0.872	rs2058149	ENSG00000270164.1	LINC01480	-5.8	8.64e-09	1.27e-06	-0.22	-0.18	Schizophrenia;	chr19:41580312	chr19:41535183~41536904:+
BRCA	cis	rs2243480	0.901	rs1701759	ENSG00000232559.3	GS1-124K5.12	5.8	8.64e-09	1.27e-06	0.33	0.18	Diabetic kidney disease;	chr7:66005945	chr7:66554588~66576923:-
BRCA	cis	rs7200543	1	rs4985154	ENSG00000260872.1	RP11-680G24.5	-5.8	8.65e-09	1.27e-06	-0.19	-0.18	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15037785	chr16:15018106~15020488:-
BRCA	cis	rs867371	1	rs6495643	ENSG00000276710.3	CSPG4P8	-5.8	8.65e-09	1.27e-06	-0.19	-0.18	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82186913	chr15:82459472~82477258:+
BRCA	cis	rs875971	0.545	rs75577046	ENSG00000228409.4	CCT6P1	-5.8	8.65e-09	1.27e-06	-0.18	-0.18	Aortic root size;	chr7:66493729	chr7:65751142~65763354:+
BRCA	cis	rs10510102	0.872	rs7076727	ENSG00000226864.1	ATE1-AS1	5.8	8.65e-09	1.27e-06	0.32	0.18	Breast cancer;	chr10:121947000	chr10:121928312~121951965:+
BRCA	cis	rs10510102	0.745	rs7076882	ENSG00000226864.1	ATE1-AS1	5.8	8.65e-09	1.27e-06	0.32	0.18	Breast cancer;	chr10:121947039	chr10:121928312~121951965:+
BRCA	cis	rs10510102	0.872	rs7077035	ENSG00000226864.1	ATE1-AS1	5.8	8.65e-09	1.27e-06	0.32	0.18	Breast cancer;	chr10:121947130	chr10:121928312~121951965:+
BRCA	cis	rs2253762	0.54	rs4752631	ENSG00000276742.1	RP11-500G22.4	5.8	8.66e-09	1.27e-06	0.3	0.18	Breast cancer;	chr10:121996442	chr10:121956782~121957098:+
BRCA	cis	rs1014246	0.807	rs12771069	ENSG00000232767.1	RP11-498B4.5	-5.8	8.66e-09	1.27e-06	-0.21	-0.18	Age at smoking initiation in chronic obstructive pulmonary disease;	chr10:116712165	chr10:116670103~116672739:+
BRCA	cis	rs6565180	0.888	rs12447833	ENSG00000183604.13	SMG1P5	5.8	8.67e-09	1.27e-06	0.19	0.18	Tonsillectomy;	chr16:30378993	chr16:30267553~30335374:-
BRCA	cis	rs2051773	0.567	rs77545208	ENSG00000184669.7	OR7E14P	-5.8	8.68e-09	1.27e-06	-0.26	-0.18	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);	chr11:17026200	chr11:17013998~17053024:+
BRCA	cis	rs17597773	0.638	rs7544735	ENSG00000272823.1	RP11-295M18.6	5.8	8.68e-09	1.27e-06	0.21	0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220825571	chr1:220828676~220829211:-
BRCA	cis	rs13108904	0.846	rs3775100	ENSG00000254094.1	AC078852.1	-5.8	8.69e-09	1.28e-06	-0.19	-0.18	Obesity-related traits;	chr4:1231318	chr4:1356581~1358075:+
BRCA	cis	rs651907	0.557	rs3094296	ENSG00000244119.1	PDCL3P4	5.8	8.7e-09	1.28e-06	0.14	0.18	Colorectal cancer;	chr3:101681323	chr3:101712472~101713191:+
BRCA	cis	rs11098499	0.913	rs11098496	ENSG00000249244.1	RP11-548H18.2	5.8	8.7e-09	1.28e-06	0.21	0.18	Corneal astigmatism;	chr4:119246311	chr4:119391831~119395335:-
BRCA	cis	rs10129255	0.957	rs10141052	ENSG00000224373.3	IGHV4-59	5.8	8.7e-09	1.28e-06	0.11	0.18	Kawasaki disease;	chr14:106776528	chr14:106627249~106627825:-
BRCA	cis	rs7927771	0.524	rs10742814	ENSG00000280615.1	Y_RNA	5.8	8.7e-09	1.28e-06	0.21	0.18	Subjective well-being;	chr11:47532785	chr11:47614898~47614994:-
BRCA	cis	rs16846053	0.71	rs13022437	ENSG00000227403.1	AC009299.3	-5.8	8.71e-09	1.28e-06	-0.29	-0.18	Blood osmolality (transformed sodium);	chr2:161765775	chr2:161244739~161249050:+
BRCA	cis	rs10739663	0.52	rs3122935	ENSG00000232630.1	PRPS1P2	5.8	8.71e-09	1.28e-06	0.17	0.18	Resting heart rate;	chr9:125391924	chr9:125150653~125151589:+
BRCA	cis	rs3213958	0.574	rs1822017	ENSG00000249274.1	PDLIM1P4	-5.8	8.72e-09	1.28e-06	-0.27	-0.18	Blood protein levels;	chr3:98800637	chr3:98782188~98783193:+
BRCA	cis	rs11976180	1	rs6464573	ENSG00000273234.1	OR2A13P	5.8	8.72e-09	1.28e-06	0.24	0.18	Obesity-related traits;	chr7:144051005	chr7:144142009~144142938:+
BRCA	cis	rs67981189	0.865	rs34488204	ENSG00000258571.1	PTTG4P	-5.8	8.72e-09	1.28e-06	-0.19	-0.18	Schizophrenia;	chr14:71028571	chr14:71085482~71085833:-
BRCA	cis	rs78456975	0.622	rs11888851	ENSG00000231482.2	AC141930.2	-5.8	8.73e-09	1.28e-06	-0.24	-0.18	Placebo response in major depressive disorder (% change in symptom score);	chr2:1514482	chr2:1572554~1580311:-
BRCA	cis	rs30380	0.632	rs26489	ENSG00000272109.1	CTD-2260A17.3	-5.8	8.73e-09	1.28e-06	-0.25	-0.18	Cerebrospinal fluid biomarker levels;	chr5:96797724	chr5:96804353~96806105:+
BRCA	cis	rs2243480	0.901	rs2900904	ENSG00000164669.11	INTS4P1	5.8	8.73e-09	1.28e-06	0.34	0.18	Diabetic kidney disease;	chr7:65739282	chr7:65141225~65234216:+
BRCA	cis	rs7618501	0.521	rs2352984	ENSG00000228008.1	CTD-2330K9.3	5.8	8.74e-09	1.28e-06	0.17	0.18	Intelligence (multi-trait analysis);	chr3:49911295	chr3:49903845~49916937:+
BRCA	cis	rs6088813	1	rs62211529	ENSG00000126005.14	MMP24-AS1	5.8	8.74e-09	1.28e-06	0.21	0.18	Height;	chr20:35371512	chr20:35216462~35278131:-
BRCA	cis	rs755249	0.501	rs2490945	ENSG00000228060.1	RP11-69E11.8	-5.8	8.75e-09	1.28e-06	-0.19	-0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39371672	chr1:39565160~39573203:+
BRCA	cis	rs5758511	0.731	rs5751186	ENSG00000205702.9	CYP2D7	-5.8	8.75e-09	1.28e-06	-0.18	-0.18	Birth weight;	chr22:41953706	chr22:42140203~42144577:-
BRCA	cis	rs4718428	0.705	rs68168107	ENSG00000230295.1	RP11-458F8.2	-5.8	8.75e-09	1.28e-06	-0.16	-0.18	Corneal structure;	chr7:66790251	chr7:66880708~66882981:+
BRCA	cis	rs12468226	0.679	rs6435133	ENSG00000226261.1	AC064836.3	-5.8	8.75e-09	1.28e-06	-0.3	-0.18	Urate levels;	chr2:202209237	chr2:202336024~202336727:-
BRCA	cis	rs12468226	0.817	rs12693965	ENSG00000226261.1	AC064836.3	-5.8	8.75e-09	1.28e-06	-0.3	-0.18	Urate levels;	chr2:202210188	chr2:202336024~202336727:-
BRCA	cis	rs12468226	0.873	rs3769817	ENSG00000226261.1	AC064836.3	-5.8	8.75e-09	1.28e-06	-0.3	-0.18	Urate levels;	chr2:202214584	chr2:202336024~202336727:-
BRCA	cis	rs12468226	0.873	rs6435134	ENSG00000226261.1	AC064836.3	-5.8	8.75e-09	1.28e-06	-0.3	-0.18	Urate levels;	chr2:202214857	chr2:202336024~202336727:-
BRCA	cis	rs12468226	0.817	rs6435135	ENSG00000226261.1	AC064836.3	-5.8	8.75e-09	1.28e-06	-0.3	-0.18	Urate levels;	chr2:202217469	chr2:202336024~202336727:-
BRCA	cis	rs59169624	0.699	rs2553970	ENSG00000255160.4	RP11-428C19.5	-5.8	8.75e-09	1.28e-06	-0.24	-0.18	Parental extreme longevity (95 years and older);	chr11:19257144	chr11:19299883~19308358:+
BRCA	cis	rs13118159	0.573	rs7664763	ENSG00000254094.1	AC078852.1	-5.8	8.76e-09	1.28e-06	-0.22	-0.18	Longevity;	chr4:1358517	chr4:1356581~1358075:+
BRCA	cis	rs12594515	0.694	rs2068295	ENSG00000259200.1	RP11-718O11.1	-5.8	8.77e-09	1.29e-06	-0.2	-0.18	Weight;Waist circumference;	chr15:45693348	chr15:45705078~45931069:+
BRCA	cis	rs1124769	0.672	rs12909760	ENSG00000259378.1	DCAF13P3	5.8	8.78e-09	1.29e-06	0.25	0.18	Cognitive performance;	chr15:50870064	chr15:50944663~50945996:+
BRCA	cis	rs8114671	0.57	rs3761144	ENSG00000269202.1	RP4-614O4.12	-5.8	8.78e-09	1.29e-06	-0.18	-0.18	Height;	chr20:34956272	chr20:35201747~35203288:-
BRCA	cis	rs17711722	0.565	rs4275112	ENSG00000222364.1	RNU6-96P	5.8	8.78e-09	1.29e-06	0.21	0.18	Calcium levels;	chr7:65733651	chr7:66395191~66395286:+
BRCA	cis	rs2243480	1	rs1499614	ENSG00000232559.3	GS1-124K5.12	5.8	8.79e-09	1.29e-06	0.33	0.18	Diabetic kidney disease;	chr7:66265811	chr7:66554588~66576923:-
BRCA	cis	rs6490294	0.571	rs7959011	ENSG00000226469.1	ADAM1B	5.8	8.8e-09	1.29e-06	0.28	0.18	Mean platelet volume;	chr12:112063433	chr12:111927018~111929017:+
BRCA	cis	rs227275	0.527	rs223308	ENSG00000251288.2	RP11-10L12.2	-5.8	8.82e-09	1.29e-06	-0.21	-0.18	Allergic disease (asthma, hay fever or eczema);	chr4:102891342	chr4:102751401~102752641:+
BRCA	cis	rs4415084	0.966	rs1898701	ENSG00000251141.4	RP11-53O19.1	5.8	8.82e-09	1.29e-06	0.17	0.18	Breast cancer;	chr5:44695327	chr5:44744900~44808777:-
BRCA	cis	rs6479891	0.915	rs9415699	ENSG00000232075.1	MRPL35P2	-5.8	8.82e-09	1.29e-06	-0.32	-0.18	Arthritis (juvenile idiopathic);	chr10:63383798	chr10:63634317~63634827:-
BRCA	cis	rs73222236	0.825	rs6776841	ENSG00000273486.1	RP11-731C17.2	5.8	8.83e-09	1.29e-06	0.2	0.18	Coronary artery disease;	chr3:136323322	chr3:136837338~136839021:-
BRCA	cis	rs2274273	1	rs74617736	ENSG00000258413.1	RP11-665C16.6	-5.8	8.84e-09	1.3e-06	-0.22	-0.18	Protein biomarker;	chr14:55154201	chr14:55262767~55272075:-
BRCA	cis	rs2790457	0.518	rs2993984	ENSG00000254635.4	WAC-AS1	-5.8	8.84e-09	1.3e-06	-0.21	-0.18	Multiple myeloma;	chr10:28509727	chr10:28522652~28532743:-
BRCA	cis	rs12073837	0.5	rs2807845	ENSG00000272823.1	RP11-295M18.6	-5.8	8.84e-09	1.3e-06	-0.18	-0.18	F-cell distribution;	chr1:220822945	chr1:220828676~220829211:-
BRCA	cis	rs6969780	1	rs73071548	ENSG00000233429.8	HOTAIRM1	5.8	8.84e-09	1.3e-06	0.23	0.18	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27107811	chr7:27095647~27100265:+
BRCA	cis	rs600231	0.706	rs4244811	ENSG00000245532.5	NEAT1	-5.8	8.85e-09	1.3e-06	-0.17	-0.18	Bone mineral density;	chr11:65553309	chr11:65422774~65445540:+
BRCA	cis	rs2638953	0.962	rs11049515	ENSG00000278733.1	RP11-425D17.1	-5.8	8.85e-09	1.3e-06	-0.24	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28299564	chr12:28185625~28186190:-
BRCA	cis	rs2638953	1	rs11049516	ENSG00000278733.1	RP11-425D17.1	-5.8	8.85e-09	1.3e-06	-0.24	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28299649	chr12:28185625~28186190:-
BRCA	cis	rs67981189	0.529	rs2526858	ENSG00000258571.1	PTTG4P	5.8	8.85e-09	1.3e-06	0.21	0.18	Schizophrenia;	chr14:70945623	chr14:71085482~71085833:-
BRCA	cis	rs1014246	0.848	rs11197799	ENSG00000232767.1	RP11-498B4.5	-5.8	8.86e-09	1.3e-06	-0.19	-0.18	Age at smoking initiation in chronic obstructive pulmonary disease;	chr10:116698139	chr10:116670103~116672739:+
BRCA	cis	rs16949788	0.793	rs78483581	ENSG00000261351.2	CTD-3185P2.1	-5.8	8.86e-09	1.3e-06	-0.35	-0.18	Spherical equivalent (joint analysis main effects and education interaction);	chr15:66477027	chr15:66488658~66492109:-
BRCA	cis	rs16949788	1	rs76847935	ENSG00000261351.2	CTD-3185P2.1	-5.8	8.86e-09	1.3e-06	-0.35	-0.18	Spherical equivalent (joint analysis main effects and education interaction);	chr15:66477275	chr15:66488658~66492109:-
BRCA	cis	rs910316	0.967	rs4899549	ENSG00000279594.1	RP11-950C14.10	-5.8	8.86e-09	1.3e-06	-0.2	-0.18	Height;	chr14:75180791	chr14:75011269~75012851:-
BRCA	cis	rs910316	0.967	rs4899550	ENSG00000279594.1	RP11-950C14.10	-5.8	8.86e-09	1.3e-06	-0.2	-0.18	Height;	chr14:75180963	chr14:75011269~75012851:-
BRCA	cis	rs4787491	0.729	rs4238960	ENSG00000273724.1	RP11-347C12.12	-5.8	8.87e-09	1.3e-06	-0.19	-0.18	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30027327	chr16:30336400~30343336:+
BRCA	cis	rs944990	0.513	rs10821144	ENSG00000227603.1	RP11-165J3.6	5.8	8.88e-09	1.3e-06	0.18	0.18	Body mass index;	chr9:93502976	chr9:93435332~93437121:-
BRCA	cis	rs2638953	0.886	rs10843137	ENSG00000247934.4	RP11-967K21.1	-5.8	8.88e-09	1.3e-06	-0.23	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28218788	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.924	rs10843138	ENSG00000247934.4	RP11-967K21.1	-5.8	8.88e-09	1.3e-06	-0.23	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28219210	chr12:28163298~28190738:-
BRCA	cis	rs2243480	0.908	rs1532573	ENSG00000232559.3	GS1-124K5.12	-5.8	8.89e-09	1.3e-06	-0.34	-0.18	Diabetic kidney disease;	chr7:66333815	chr7:66554588~66576923:-
BRCA	cis	rs2638953	0.889	rs11049481	ENSG00000278733.1	RP11-425D17.1	-5.8	8.9e-09	1.3e-06	-0.24	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28252087	chr12:28185625~28186190:-
BRCA	cis	rs17508449	1	rs17508449	ENSG00000232450.1	RP4-730K3.3	-5.8	8.9e-09	1.3e-06	-0.31	-0.18	Leprosy;	chr1:113542523	chr1:113698884~113699631:-
BRCA	cis	rs1440410	0.835	rs11940580	ENSG00000250326.1	RP11-284M14.1	-5.8	8.92e-09	1.31e-06	-0.2	-0.18	Ischemic stroke;	chr4:143240372	chr4:142933195~143184861:-
BRCA	cis	rs5758511	0.634	rs1001587	ENSG00000205702.9	CYP2D7	5.8	8.92e-09	1.31e-06	0.19	0.18	Birth weight;	chr22:42274105	chr22:42140203~42144577:-
BRCA	cis	rs7914558	0.902	rs7092200	ENSG00000213061.2	PFN1P11	5.8	8.92e-09	1.31e-06	0.23	0.18	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103085115	chr10:102838011~102845473:-
BRCA	cis	rs12594515	0.694	rs2068294	ENSG00000259200.1	RP11-718O11.1	-5.8	8.92e-09	1.31e-06	-0.2	-0.18	Weight;Waist circumference;	chr15:45693350	chr15:45705078~45931069:+
BRCA	cis	rs9840812	0.522	rs699165	ENSG00000239213.4	NCK1-AS1	5.8	8.92e-09	1.31e-06	0.22	0.18	Fibrinogen levels;	chr3:136505855	chr3:136841726~136862054:-
BRCA	cis	rs4718428	0.672	rs12530806	ENSG00000230295.1	RP11-458F8.2	-5.8	8.92e-09	1.31e-06	-0.16	-0.18	Corneal structure;	chr7:66925737	chr7:66880708~66882981:+
BRCA	cis	rs17711722	0.522	rs4642526	ENSG00000222364.1	RNU6-96P	-5.8	8.94e-09	1.31e-06	-0.21	-0.18	Calcium levels;	chr7:65751755	chr7:66395191~66395286:+
BRCA	cis	rs858239	0.73	rs858289	ENSG00000230042.1	AK3P3	-5.8	8.94e-09	1.31e-06	-0.2	-0.18	Cerebrospinal fluid biomarker levels;	chr7:23208539	chr7:23129178~23129841:+
BRCA	cis	rs11098499	0.955	rs1511018	ENSG00000249244.1	RP11-548H18.2	5.8	8.94e-09	1.31e-06	0.21	0.18	Corneal astigmatism;	chr4:119240425	chr4:119391831~119395335:-
BRCA	cis	rs2243480	0.522	rs431168	ENSG00000232546.1	RP11-458F8.1	-5.8	8.95e-09	1.31e-06	-0.29	-0.18	Diabetic kidney disease;	chr7:66046617	chr7:66848496~66858136:+
BRCA	cis	rs4713118	0.621	rs4713132	ENSG00000280107.1	AL022393.9	-5.8	8.95e-09	1.31e-06	-0.27	-0.18	Parkinson's disease;	chr6:28066257	chr6:28170845~28172521:+
BRCA	cis	rs4713118	0.621	rs4713133	ENSG00000280107.1	AL022393.9	-5.8	8.95e-09	1.31e-06	-0.27	-0.18	Parkinson's disease;	chr6:28066263	chr6:28170845~28172521:+
BRCA	cis	rs4713118	0.621	rs4713134	ENSG00000280107.1	AL022393.9	-5.8	8.95e-09	1.31e-06	-0.27	-0.18	Parkinson's disease;	chr6:28066343	chr6:28170845~28172521:+
BRCA	cis	rs35612822	0.897	rs1110998	ENSG00000232485.2	AC098820.3	5.8	8.96e-09	1.31e-06	0.23	0.18	Kidney disease (early stage) in type 1 diabetes;	chr2:216479229	chr2:216479030~216498761:-
BRCA	cis	rs875971	0.545	rs73150604	ENSG00000228409.4	CCT6P1	-5.8	8.96e-09	1.31e-06	-0.18	-0.18	Aortic root size;	chr7:66480545	chr7:65751142~65763354:+
BRCA	cis	rs66887589	0.967	rs1480933	ENSG00000245958.5	RP11-33B1.1	-5.8	8.97e-09	1.31e-06	-0.16	-0.18	Diastolic blood pressure;	chr4:119512093	chr4:119454791~119552025:+
BRCA	cis	rs7520050	0.966	rs4545281	ENSG00000280836.1	AL355480.1	5.8	8.98e-09	1.31e-06	0.2	0.18	Reticulocyte count;Red blood cell count;	chr1:45894382	chr1:45581219~45581321:-
BRCA	cis	rs4950322	0.518	rs11811023	ENSG00000278811.3	LINC00624	-5.8	8.98e-09	1.32e-06	-0.21	-0.18	Protein quantitative trait loci;	chr1:147109536	chr1:147258885~147517875:-
BRCA	cis	rs6442522	0.678	rs878945	ENSG00000249786.6	EAF1-AS1	5.8	8.99e-09	1.32e-06	0.19	0.18	Uric acid levels;	chr3:15467820	chr3:15436171~15455940:-
BRCA	cis	rs6714710	0.603	rs1470483	ENSG00000230606.9	AC159540.1	-5.8	9e-09	1.32e-06	-0.22	-0.18	Posterior cortical atrophy and Alzheimer's disease;	chr2:97777431	chr2:97416165~97433527:-
BRCA	cis	rs1707322	0.928	rs7527244	ENSG00000281133.1	AL355480.3	-5.8	9.01e-09	1.32e-06	-0.22	-0.18	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45903100	chr1:45580892~45580996:-
BRCA	cis	rs2998286	0.862	rs946594	ENSG00000254635.4	WAC-AS1	-5.8	9.02e-09	1.32e-06	-0.24	-0.18	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28503318	chr10:28522652~28532743:-
BRCA	cis	rs6142102	0.812	rs725478	ENSG00000275784.1	RP5-1125A11.6	5.8	9.03e-09	1.32e-06	0.22	0.18	Skin pigmentation;	chr20:33930548	chr20:33989480~33991818:-
BRCA	cis	rs1858037	0.836	rs1396209	ENSG00000204929.10	AC074391.1	5.8	9.03e-09	1.32e-06	0.24	0.18	Rheumatoid arthritis;	chr2:65374100	chr2:65436711~66084639:+
BRCA	cis	rs66887589	0.616	rs11731675	ENSG00000245958.5	RP11-33B1.1	-5.79	9.05e-09	1.32e-06	-0.16	-0.18	Diastolic blood pressure;	chr4:119291359	chr4:119454791~119552025:+
BRCA	cis	rs12893668	0.572	rs34000399	ENSG00000269940.1	RP11-73M18.7	5.79	9.06e-09	1.33e-06	0.2	0.18	Reticulocyte count;	chr14:103635080	chr14:103694560~103695170:+
BRCA	cis	rs7208859	0.623	rs11657662	ENSG00000265443.1	CTD-2349P21.6	5.79	9.06e-09	1.33e-06	0.29	0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30749329	chr17:30726305~30727564:-
BRCA	cis	rs253959	0.545	rs4920905	ENSG00000272265.1	CTD-2287O16.4	5.79	9.06e-09	1.33e-06	0.22	0.18	Bipolar disorder and schizophrenia;	chr5:116090771	chr5:116078110~116078570:-
BRCA	cis	rs2638953	0.962	rs61922969	ENSG00000278733.1	RP11-425D17.1	-5.79	9.06e-09	1.33e-06	-0.24	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28261721	chr12:28185625~28186190:-
BRCA	cis	rs2243480	1	rs34136756	ENSG00000164669.11	INTS4P1	5.79	9.07e-09	1.33e-06	0.34	0.18	Diabetic kidney disease;	chr7:65916269	chr7:65141225~65234216:+
BRCA	cis	rs1499614	0.803	rs1796229	ENSG00000228409.4	CCT6P1	5.79	9.07e-09	1.33e-06	0.25	0.18	Gout;	chr7:66654674	chr7:65751142~65763354:+
BRCA	cis	rs10129255	0.957	rs4387509	ENSG00000211974.3	IGHV2-70	5.79	9.07e-09	1.33e-06	0.19	0.18	Kawasaki disease;	chr14:106704386	chr14:106723574~106724093:-
BRCA	cis	rs73081554	0.611	rs13071861	ENSG00000272360.1	RP11-359I18.5	-5.79	9.07e-09	1.33e-06	-0.26	-0.18	Rheumatoid arthritis;	chr3:58385605	chr3:58490830~58491291:-
BRCA	cis	rs516805	0.633	rs9490414	ENSG00000279453.1	RP3-425C14.4	5.79	9.09e-09	1.33e-06	0.25	0.18	Lymphocyte counts;	chr6:122245612	chr6:122436789~122439223:-
BRCA	cis	rs2243480	1	rs4718270	ENSG00000232559.3	GS1-124K5.12	5.79	9.1e-09	1.33e-06	0.33	0.18	Diabetic kidney disease;	chr7:65737415	chr7:66554588~66576923:-
BRCA	cis	rs7045881	0.558	rs62542707	ENSG00000254396.1	RP11-56F10.3	5.79	9.11e-09	1.33e-06	0.3	0.18	Schizophrenia;	chr9:27066936	chr9:27102630~27104728:+
BRCA	cis	rs17508449	0.909	rs7514649	ENSG00000232450.1	RP4-730K3.3	-5.79	9.11e-09	1.33e-06	-0.31	-0.18	Leprosy;	chr1:113537200	chr1:113698884~113699631:-
BRCA	cis	rs16958445	1	rs16958445	ENSG00000247240.6	UBL7-AS1	5.79	9.12e-09	1.33e-06	0.43	0.18	Exfoliation glaucoma or exfoliation syndrome;	chr15:73884216	chr15:74461265~74481302:+
BRCA	cis	rs516805	0.63	rs1379098	ENSG00000279453.1	RP3-425C14.4	-5.79	9.12e-09	1.34e-06	-0.25	-0.18	Lymphocyte counts;	chr6:122121672	chr6:122436789~122439223:-
BRCA	cis	rs7923837	0.683	rs11187078	ENSG00000236493.2	EIF2S2P3	5.79	9.12e-09	1.34e-06	0.25	0.18	Multiple sclerosis;Body mass index;	chr10:92580948	chr10:92668745~92669743:-
BRCA	cis	rs9652601	0.959	rs9934969	ENSG00000274038.1	RP11-66H6.4	-5.79	9.13e-09	1.34e-06	-0.2	-0.18	Systemic lupus erythematosus;	chr16:11072145	chr16:11056556~11057034:+
BRCA	cis	rs4604234	0.803	rs73463522	ENSG00000272129.1	RP11-250B2.6	-5.79	9.14e-09	1.34e-06	-0.44	-0.18	Cancer;	chr6:80270041	chr6:80355424~80356859:+
BRCA	cis	rs5758511	0.773	rs1894714	ENSG00000205702.9	CYP2D7	-5.79	9.14e-09	1.34e-06	-0.18	-0.18	Birth weight;	chr22:41953130	chr22:42140203~42144577:-
BRCA	cis	rs4588572	0.644	rs6873144	ENSG00000245556.2	SCAMP1-AS1	-5.79	9.14e-09	1.34e-06	-0.21	-0.18	Triglycerides;	chr5:78445960	chr5:78342365~78360507:-
BRCA	cis	rs4588572	0.606	rs4290994	ENSG00000245556.2	SCAMP1-AS1	-5.79	9.14e-09	1.34e-06	-0.21	-0.18	Triglycerides;	chr5:78446429	chr5:78342365~78360507:-
BRCA	cis	rs67981189	0.896	rs7153237	ENSG00000258571.1	PTTG4P	-5.79	9.14e-09	1.34e-06	-0.19	-0.18	Schizophrenia;	chr14:71021937	chr14:71085482~71085833:-
BRCA	cis	rs4718428	1	rs4718428	ENSG00000273142.1	RP11-458F8.4	-5.79	9.14e-09	1.34e-06	-0.16	-0.18	Corneal structure;	chr7:66956459	chr7:66902857~66906297:+
BRCA	cis	rs11719291	0.831	rs11715177	ENSG00000270441.1	RP11-694I15.7	5.79	9.15e-09	1.34e-06	0.32	0.18	Cognitive function;	chr3:48726461	chr3:49140086~49160851:-
BRCA	cis	rs2243480	0.901	rs313808	ENSG00000228409.4	CCT6P1	5.79	9.15e-09	1.34e-06	0.24	0.18	Diabetic kidney disease;	chr7:66034886	chr7:65751142~65763354:+
BRCA	cis	rs801193	0.839	rs12534943	ENSG00000273024.4	INTS4P2	5.79	9.16e-09	1.34e-06	0.19	0.18	Aortic root size;	chr7:66605533	chr7:65647864~65715661:+
BRCA	cis	rs728616	0.764	rs11201025	ENSG00000225484.5	NUTM2B-AS1	-5.79	9.16e-09	1.34e-06	-0.36	-0.18	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79982402	chr10:79663088~79826594:-
BRCA	cis	rs9308731	0.568	rs28723045	ENSG00000227992.1	AC108463.2	-5.79	9.17e-09	1.34e-06	-0.2	-0.18	Chronic lymphocytic leukemia;	chr2:111178121	chr2:111203964~111206215:-
BRCA	cis	rs4927850	1	rs7625570	ENSG00000207650.1	MIR570	5.79	9.17e-09	1.34e-06	0.21	0.18	Pancreatic cancer;	chr3:196020527	chr3:195699401~195699497:+
BRCA	cis	rs11098499	0.955	rs35197422	ENSG00000249244.1	RP11-548H18.2	5.79	9.17e-09	1.34e-06	0.21	0.18	Corneal astigmatism;	chr4:119248159	chr4:119391831~119395335:-
BRCA	cis	rs7200543	1	rs34614532	ENSG00000260872.1	RP11-680G24.5	-5.79	9.17e-09	1.34e-06	-0.19	-0.18	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15039051	chr16:15018106~15020488:-
BRCA	cis	rs7520050	0.966	rs11211199	ENSG00000280836.1	AL355480.1	5.79	9.17e-09	1.34e-06	0.2	0.18	Reticulocyte count;Red blood cell count;	chr1:45822197	chr1:45581219~45581321:-
BRCA	cis	rs2919009	1	rs2919009	ENSG00000271670.1	RP11-95I16.4	5.79	9.18e-09	1.34e-06	0.22	0.18	Obesity-related traits;	chr10:120831861	chr10:120879256~120880667:-
BRCA	cis	rs7772486	0.686	rs2179323	ENSG00000270638.1	RP3-466P17.1	-5.79	9.19e-09	1.34e-06	-0.2	-0.18	Lobe attachment (rater-scored or self-reported);	chr6:145661650	chr6:145735570~145737218:+
BRCA	cis	rs4835473	0.932	rs7670010	ENSG00000249741.2	RP11-673E1.3	-5.79	9.19e-09	1.34e-06	-0.19	-0.18	Immature fraction of reticulocytes;	chr4:143821679	chr4:143911514~143912053:-
BRCA	cis	rs828999	0.715	rs34406538	ENSG00000280186.1	RP11-483I13.6	-5.79	9.19e-09	1.34e-06	-0.2	-0.18	Monocyte percentage of white cells;	chr1:108176846	chr1:108200413~108202743:+
BRCA	cis	rs2638953	0.849	rs10843172	ENSG00000278733.1	RP11-425D17.1	-5.79	9.2e-09	1.35e-06	-0.24	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28452300	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.777	rs11049681	ENSG00000278733.1	RP11-425D17.1	-5.79	9.21e-09	1.35e-06	-0.23	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28508722	chr12:28185625~28186190:-
BRCA	cis	rs2243480	1	rs781142	ENSG00000232559.3	GS1-124K5.12	5.79	9.22e-09	1.35e-06	0.33	0.18	Diabetic kidney disease;	chr7:65973791	chr7:66554588~66576923:-
BRCA	cis	rs301901	0.54	rs13188782	ENSG00000250155.1	CTD-2353F22.1	-5.79	9.22e-09	1.35e-06	-0.21	-0.18	Height;	chr5:37476142	chr5:36666214~36725195:-
BRCA	cis	rs10129255	0.784	rs7147210	ENSG00000211974.3	IGHV2-70	5.79	9.24e-09	1.35e-06	0.19	0.18	Kawasaki disease;	chr14:106705271	chr14:106723574~106724093:-
BRCA	cis	rs4713118	0.516	rs6931858	ENSG00000204709.4	LINC01556	5.79	9.25e-09	1.35e-06	0.26	0.18	Parkinson's disease;	chr6:28110633	chr6:28943877~28944537:+
BRCA	cis	rs34286592	1	rs7201519	ENSG00000214725.6	CDIPT-AS1	-5.79	9.25e-09	1.35e-06	-0.3	-0.18	Multiple sclerosis;	chr16:29848656	chr16:29863593~29868053:+
BRCA	cis	rs7976269	0.609	rs2082943	ENSG00000275476.1	RP11-996F15.4	-5.79	9.26e-09	1.35e-06	-0.2	-0.18	Male-pattern baldness;	chr12:29050251	chr12:29277397~29277882:-
BRCA	cis	rs7208859	0.524	rs73988172	ENSG00000265443.1	CTD-2349P21.6	-5.79	9.26e-09	1.35e-06	-0.28	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759314	chr17:30726305~30727564:-
BRCA	cis	rs7200543	1	rs1135999	ENSG00000260872.1	RP11-680G24.5	-5.79	9.26e-09	1.35e-06	-0.19	-0.18	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15038105	chr16:15018106~15020488:-
BRCA	cis	rs2153535	0.561	rs2181194	ENSG00000230939.1	RP11-314C16.1	-5.79	9.26e-09	1.35e-06	-0.2	-0.18	Motion sickness;	chr6:8667318	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.561	rs9505511	ENSG00000230939.1	RP11-314C16.1	-5.79	9.26e-09	1.35e-06	-0.2	-0.18	Motion sickness;	chr6:8667322	chr6:8784178~8785445:+
BRCA	cis	rs8098244	0.597	rs12958312	ENSG00000264745.1	TTC39C-AS1	-5.79	9.26e-09	1.35e-06	-0.21	-0.18	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23784372	chr18:23994213~24015339:-
BRCA	cis	rs2243480	0.901	rs34807232	ENSG00000228409.4	CCT6P1	5.79	9.27e-09	1.35e-06	0.25	0.18	Diabetic kidney disease;	chr7:66500146	chr7:65751142~65763354:+
BRCA	cis	rs2243480	0.901	rs35823062	ENSG00000228409.4	CCT6P1	5.79	9.27e-09	1.35e-06	0.25	0.18	Diabetic kidney disease;	chr7:66500834	chr7:65751142~65763354:+
BRCA	cis	rs3764021	0.87	rs10844597	ENSG00000214776.8	RP11-726G1.1	5.79	9.27e-09	1.36e-06	0.19	0.18	Type 1 diabetes;	chr12:9722303	chr12:9467552~9576275:+
BRCA	cis	rs11668609	0.935	rs7257096	ENSG00000268442.1	CTD-2027I19.2	5.79	9.27e-09	1.36e-06	0.24	0.18	Response to taxane treatment (docetaxel);	chr19:24098965	chr19:24162370~24163425:-
BRCA	cis	rs227275	0.525	rs1080081	ENSG00000251288.2	RP11-10L12.2	-5.79	9.28e-09	1.36e-06	-0.21	-0.18	Allergic disease (asthma, hay fever or eczema);	chr4:103029268	chr4:102751401~102752641:+
BRCA	cis	rs227275	0.525	rs4699049	ENSG00000251288.2	RP11-10L12.2	-5.79	9.28e-09	1.36e-06	-0.21	-0.18	Allergic disease (asthma, hay fever or eczema);	chr4:103030467	chr4:102751401~102752641:+
BRCA	cis	rs950169	0.614	rs12903883	ENSG00000259728.4	LINC00933	5.79	9.28e-09	1.36e-06	0.26	0.18	Schizophrenia;	chr15:84011801	chr15:84570649~84580175:+
BRCA	cis	rs957448	0.698	rs116348949	ENSG00000253175.1	RP11-267M23.6	5.79	9.28e-09	1.36e-06	0.21	0.18	Nonsyndromic cleft lip with cleft palate;	chr8:94557488	chr8:94565036~94565715:+
BRCA	cis	rs721917	0.506	rs4320898	ENSG00000244733.5	RP11-506M13.3	-5.79	9.29e-09	1.36e-06	-0.21	-0.18	Chronic obstructive pulmonary disease;	chr10:79891322	chr10:79660891~79677996:+
BRCA	cis	rs721917	0.506	rs4322333	ENSG00000244733.5	RP11-506M13.3	-5.79	9.29e-09	1.36e-06	-0.21	-0.18	Chronic obstructive pulmonary disease;	chr10:79891340	chr10:79660891~79677996:+
BRCA	cis	rs2051773	0.567	rs11024113	ENSG00000184669.7	OR7E14P	-5.79	9.29e-09	1.36e-06	-0.26	-0.18	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);	chr11:17020897	chr11:17013998~17053024:+
BRCA	cis	rs7520050	0.553	rs2993263	ENSG00000280836.1	AL355480.1	-5.79	9.29e-09	1.36e-06	-0.2	-0.18	Reticulocyte count;Red blood cell count;	chr1:45555958	chr1:45581219~45581321:-
BRCA	cis	rs11098499	0.955	rs1551	ENSG00000249244.1	RP11-548H18.2	5.79	9.29e-09	1.36e-06	0.21	0.18	Corneal astigmatism;	chr4:119237345	chr4:119391831~119395335:-
BRCA	cis	rs2562456	0.876	rs62110163	ENSG00000268081.1	RP11-678G14.2	5.79	9.29e-09	1.36e-06	0.27	0.18	Pain;	chr19:21546020	chr19:21554640~21569237:-
BRCA	cis	rs2562456	0.761	rs35008138	ENSG00000268081.1	RP11-678G14.2	5.79	9.29e-09	1.36e-06	0.27	0.18	Pain;	chr19:21548822	chr19:21554640~21569237:-
BRCA	cis	rs2562456	0.833	rs2681388	ENSG00000268081.1	RP11-678G14.2	5.79	9.29e-09	1.36e-06	0.27	0.18	Pain;	chr19:21549451	chr19:21554640~21569237:-
BRCA	cis	rs2562456	0.876	rs2681370	ENSG00000268081.1	RP11-678G14.2	5.79	9.29e-09	1.36e-06	0.27	0.18	Pain;	chr19:21554036	chr19:21554640~21569237:-
BRCA	cis	rs2562456	0.876	rs11668606	ENSG00000268081.1	RP11-678G14.2	5.79	9.29e-09	1.36e-06	0.27	0.18	Pain;	chr19:21554618	chr19:21554640~21569237:-
BRCA	cis	rs2562456	0.876	rs2681395	ENSG00000268081.1	RP11-678G14.2	5.79	9.29e-09	1.36e-06	0.27	0.18	Pain;	chr19:21555338	chr19:21554640~21569237:-
BRCA	cis	rs7200543	1	rs1121	ENSG00000260872.1	RP11-680G24.5	-5.79	9.29e-09	1.36e-06	-0.19	-0.18	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15037219	chr16:15018106~15020488:-
BRCA	cis	rs2579519	0.547	rs2463560	ENSG00000237510.6	AC008268.2	5.79	9.31e-09	1.36e-06	0.23	0.18	Diastolic blood pressure;	chr2:95929841	chr2:95789654~95800166:+
BRCA	cis	rs4908768	0.501	rs35865480	ENSG00000270282.1	RP5-1115A15.2	5.79	9.31e-09	1.36e-06	0.19	0.18	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8543718	chr1:8512653~8513021:+
BRCA	cis	rs2638953	0.962	rs10843158	ENSG00000278733.1	RP11-425D17.1	5.79	9.31e-09	1.36e-06	0.23	0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28354259	chr12:28185625~28186190:-
BRCA	cis	rs853679	0.517	rs9283884	ENSG00000280107.1	AL022393.9	5.79	9.31e-09	1.36e-06	0.26	0.18	Depression;	chr6:28167882	chr6:28170845~28172521:+
BRCA	cis	rs4950322	0.58	rs17359629	ENSG00000278811.3	LINC00624	5.79	9.31e-09	1.36e-06	0.22	0.18	Protein quantitative trait loci;	chr1:147121537	chr1:147258885~147517875:-
BRCA	cis	rs72681920	0.881	rs12506882	ENSG00000246090.5	RP11-696N14.1	-5.79	9.31e-09	1.36e-06	-0.26	-0.18	Alcohol dependence;	chr4:99264274	chr4:99088857~99301356:+
BRCA	cis	rs72681920	0.881	rs58827689	ENSG00000246090.5	RP11-696N14.1	-5.79	9.31e-09	1.36e-06	-0.26	-0.18	Alcohol dependence;	chr4:99264906	chr4:99088857~99301356:+
BRCA	cis	rs67766926	0.541	rs10172306	ENSG00000271889.1	RP11-493E12.1	5.79	9.32e-09	1.36e-06	0.27	0.18	Inflammatory skin disease;	chr2:61077242	chr2:61151433~61162105:-
BRCA	cis	rs73198271	0.74	rs67766414	ENSG00000253893.2	FAM85B	5.79	9.32e-09	1.36e-06	0.24	0.18	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8792023	chr8:8167819~8226614:-
BRCA	cis	rs783540	0.5	rs7163840	ENSG00000278603.1	RP13-608F4.5	-5.79	9.33e-09	1.36e-06	-0.27	-0.18	Schizophrenia;	chr15:82729551	chr15:82472203~82472426:+
BRCA	cis	rs4664293	0.51	rs57575372	ENSG00000226266.5	AC009961.3	5.79	9.33e-09	1.36e-06	0.22	0.18	Monocyte percentage of white cells;	chr2:159569253	chr2:159670708~159712435:-
BRCA	cis	rs4950322	0.57	rs4950401	ENSG00000244371.2	PFN1P8	-5.79	9.34e-09	1.36e-06	-0.25	-0.18	Protein quantitative trait loci;	chr1:147319571	chr1:146957117~146957659:-
BRCA	cis	rs4950322	0.57	rs4950402	ENSG00000244371.2	PFN1P8	-5.79	9.34e-09	1.36e-06	-0.25	-0.18	Protein quantitative trait loci;	chr1:147319684	chr1:146957117~146957659:-
BRCA	cis	rs4950322	0.57	rs4950404	ENSG00000244371.2	PFN1P8	-5.79	9.34e-09	1.36e-06	-0.25	-0.18	Protein quantitative trait loci;	chr1:147319834	chr1:146957117~146957659:-
BRCA	cis	rs4950322	0.57	rs72692953	ENSG00000244371.2	PFN1P8	-5.79	9.34e-09	1.36e-06	-0.25	-0.18	Protein quantitative trait loci;	chr1:147321416	chr1:146957117~146957659:-
BRCA	cis	rs7493	0.95	rs17166868	ENSG00000233942.1	AC004012.1	5.79	9.34e-09	1.36e-06	0.22	0.18	Yu-Zhi constitution type in type 2 diabetes;	chr7:95404104	chr7:95471835~95473998:+
BRCA	cis	rs6088580	0.543	rs4911158	ENSG00000269202.1	RP4-614O4.12	5.79	9.34e-09	1.37e-06	0.18	0.18	Glomerular filtration rate (creatinine);	chr20:34651708	chr20:35201747~35203288:-
BRCA	cis	rs1198430	1	rs1198439	ENSG00000232482.2	RP4-654C18.1	-5.79	9.35e-09	1.37e-06	-0.26	-0.18	Total cholesterol levels;	chr1:23423100	chr1:23410832~23412146:+
BRCA	cis	rs7200543	1	rs1136001	ENSG00000260872.1	RP11-680G24.5	-5.79	9.35e-09	1.37e-06	-0.19	-0.18	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15038117	chr16:15018106~15020488:-
BRCA	cis	rs2098713	0.544	rs13181312	ENSG00000250155.1	CTD-2353F22.1	-5.79	9.36e-09	1.37e-06	-0.21	-0.18	Telomere length;	chr5:37470861	chr5:36666214~36725195:-
BRCA	cis	rs2098713	0.575	rs11739453	ENSG00000250155.1	CTD-2353F22.1	-5.79	9.36e-09	1.37e-06	-0.21	-0.18	Telomere length;	chr5:37471040	chr5:36666214~36725195:-
BRCA	cis	rs4907240	0.806	rs4907237	ENSG00000237510.6	AC008268.2	-5.79	9.36e-09	1.37e-06	-0.25	-0.18	Event-related brain oscillations;	chr2:96524760	chr2:95789654~95800166:+
BRCA	cis	rs2274273	1	rs10140857	ENSG00000258413.1	RP11-665C16.6	-5.79	9.37e-09	1.37e-06	-0.22	-0.18	Protein biomarker;	chr14:55152893	chr14:55262767~55272075:-
BRCA	cis	rs11722779	0.933	rs7695096	ENSG00000251288.2	RP11-10L12.2	-5.79	9.38e-09	1.37e-06	-0.21	-0.18	Schizophrenia;	chr4:103011399	chr4:102751401~102752641:+
BRCA	cis	rs4908760	0.613	rs4908511	ENSG00000270282.1	RP5-1115A15.2	-5.79	9.39e-09	1.37e-06	-0.18	-0.18	Vitiligo;	chr1:8752331	chr1:8512653~8513021:+
BRCA	cis	rs11668609	0.872	rs11668697	ENSG00000268442.1	CTD-2027I19.2	5.79	9.39e-09	1.37e-06	0.24	0.18	Response to taxane treatment (docetaxel);	chr19:24108247	chr19:24162370~24163425:-
BRCA	cis	rs875971	0.862	rs6460302	ENSG00000224316.1	RP11-479O9.2	5.79	9.39e-09	1.37e-06	0.18	0.18	Aortic root size;	chr7:66495270	chr7:65773620~65802067:+
BRCA	cis	rs1476670	0.71	rs751442	ENSG00000230615.5	RP5-1198O20.4	-5.79	9.4e-09	1.37e-06	-0.26	-0.18	Eotaxin levels;	chr1:44043879	chr1:44030443~44115913:+
BRCA	cis	rs673078	0.615	rs16948204	ENSG00000275409.1	RP11-131L12.4	-5.79	9.4e-09	1.37e-06	-0.26	-0.18	Glucose homeostasis traits;	chr12:118258252	chr12:118430147~118430699:+
BRCA	cis	rs673078	0.66	rs7303417	ENSG00000275409.1	RP11-131L12.4	-5.79	9.4e-09	1.37e-06	-0.26	-0.18	Glucose homeostasis traits;	chr12:118258859	chr12:118430147~118430699:+
BRCA	cis	rs673078	0.66	rs7965350	ENSG00000275409.1	RP11-131L12.4	-5.79	9.4e-09	1.37e-06	-0.26	-0.18	Glucose homeostasis traits;	chr12:118266710	chr12:118430147~118430699:+
BRCA	cis	rs673078	0.66	rs17433217	ENSG00000275409.1	RP11-131L12.4	-5.79	9.4e-09	1.37e-06	-0.26	-0.18	Glucose homeostasis traits;	chr12:118269076	chr12:118430147~118430699:+
BRCA	cis	rs2243480	0.901	rs2900904	ENSG00000232559.3	GS1-124K5.12	5.79	9.4e-09	1.37e-06	0.33	0.18	Diabetic kidney disease;	chr7:65739282	chr7:66554588~66576923:-
BRCA	cis	rs9287719	0.649	rs10182589	ENSG00000243819.4	RN7SL832P	5.79	9.4e-09	1.37e-06	0.18	0.18	Prostate cancer;	chr2:10580538	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.649	rs10208103	ENSG00000243819.4	RN7SL832P	5.79	9.4e-09	1.37e-06	0.18	0.18	Prostate cancer;	chr2:10580741	chr2:10690344~10692099:+
BRCA	cis	rs7772486	0.686	rs9497396	ENSG00000270638.1	RP3-466P17.1	-5.79	9.41e-09	1.37e-06	-0.2	-0.18	Lobe attachment (rater-scored or self-reported);	chr6:145693827	chr6:145735570~145737218:+
BRCA	cis	rs10129255	0.913	rs28861466	ENSG00000211974.3	IGHV2-70	5.79	9.42e-09	1.38e-06	0.19	0.18	Kawasaki disease;	chr14:106718572	chr14:106723574~106724093:-
BRCA	cis	rs7829975	0.742	rs1533058	ENSG00000253981.4	ALG1L13P	5.79	9.43e-09	1.38e-06	0.2	0.18	Mood instability;	chr8:8827680	chr8:8236003~8244667:-
BRCA	cis	rs2243480	1	rs67536397	ENSG00000228409.4	CCT6P1	5.79	9.43e-09	1.38e-06	0.25	0.18	Diabetic kidney disease;	chr7:66482930	chr7:65751142~65763354:+
BRCA	cis	rs2243480	1	rs58669269	ENSG00000228409.4	CCT6P1	5.79	9.43e-09	1.38e-06	0.25	0.18	Diabetic kidney disease;	chr7:66486966	chr7:65751142~65763354:+
BRCA	cis	rs7613875	0.62	rs13079006	ENSG00000228008.1	CTD-2330K9.3	5.79	9.43e-09	1.38e-06	0.17	0.18	Body mass index;	chr3:49959491	chr3:49903845~49916937:+
BRCA	cis	rs12655019	0.92	rs3756586	ENSG00000271828.1	CTD-2310F14.1	5.79	9.44e-09	1.38e-06	0.32	0.18	Breast cancer (early onset);	chr5:56921369	chr5:56927874~56929573:+
BRCA	cis	rs7927771	0.507	rs10838754	ENSG00000280615.1	Y_RNA	5.79	9.44e-09	1.38e-06	0.21	0.18	Subjective well-being;	chr11:47736980	chr11:47614898~47614994:-
BRCA	cis	rs2638953	0.924	rs10843169	ENSG00000278733.1	RP11-425D17.1	5.79	9.45e-09	1.38e-06	0.24	0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28430051	chr12:28185625~28186190:-
BRCA	cis	rs4908760	0.965	rs301814	ENSG00000270282.1	RP5-1115A15.2	5.79	9.46e-09	1.38e-06	0.19	0.18	Vitiligo;	chr1:8450517	chr1:8512653~8513021:+
BRCA	cis	rs227275	0.525	rs13150426	ENSG00000251288.2	RP11-10L12.2	-5.79	9.46e-09	1.38e-06	-0.21	-0.18	Allergic disease (asthma, hay fever or eczema);	chr4:103013743	chr4:102751401~102752641:+
BRCA	cis	rs13126694	0.839	rs66490968	ENSG00000248429.4	RP11-597D13.9	5.79	9.46e-09	1.38e-06	0.16	0.18	Blood osmolality (transformed sodium);	chr4:157994770	chr4:158170752~158202877:+
BRCA	cis	rs35146811	0.586	rs12705067	ENSG00000214313.7	AZGP1P1	5.79	9.48e-09	1.38e-06	0.19	0.18	Coronary artery disease;	chr7:99997103	chr7:99980762~99987535:+
BRCA	cis	rs8098244	0.737	rs1154237	ENSG00000264745.1	TTC39C-AS1	-5.79	9.48e-09	1.38e-06	-0.26	-0.18	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23935225	chr18:23994213~24015339:-
BRCA	cis	rs875971	0.545	rs75840613	ENSG00000228409.4	CCT6P1	-5.79	9.49e-09	1.38e-06	-0.18	-0.18	Aortic root size;	chr7:66376399	chr7:65751142~65763354:+
BRCA	cis	rs2638953	0.893	rs7969086	ENSG00000278733.1	RP11-425D17.1	5.79	9.49e-09	1.38e-06	0.22	0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28507273	chr12:28185625~28186190:-
BRCA	cis	rs1440410	0.83	rs1440411	ENSG00000250326.1	RP11-284M14.1	-5.79	9.49e-09	1.39e-06	-0.19	-0.18	Ischemic stroke;	chr4:143237132	chr4:142933195~143184861:-
BRCA	cis	rs1167832	0.645	rs1167828	ENSG00000205583.12	STAG3L1	-5.79	9.51e-09	1.39e-06	-0.25	-0.18	Ankle injury;	chr7:75534076	chr7:75359194~75395383:+
BRCA	cis	rs559928	0.593	rs112275221	ENSG00000236935.1	AP003774.1	5.79	9.51e-09	1.39e-06	0.25	0.18	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64169522	chr11:64325050~64329504:-
BRCA	cis	rs11098499	0.566	rs17051356	ENSG00000249244.1	RP11-548H18.2	5.79	9.53e-09	1.39e-06	0.22	0.18	Corneal astigmatism;	chr4:119664153	chr4:119391831~119395335:-
BRCA	cis	rs227275	0.556	rs3886723	ENSG00000251288.2	RP11-10L12.2	-5.79	9.53e-09	1.39e-06	-0.2	-0.18	Allergic disease (asthma, hay fever or eczema);	chr4:102983013	chr4:102751401~102752641:+
BRCA	cis	rs523522	0.962	rs9040	ENSG00000278344.1	RP11-18C24.8	5.79	9.53e-09	1.39e-06	0.25	0.18	High light scatter reticulocyte count;	chr12:120462471	chr12:120500735~120501090:-
BRCA	cis	rs875971	0.545	rs1796222	ENSG00000228409.4	CCT6P1	5.79	9.55e-09	1.39e-06	0.18	0.18	Aortic root size;	chr7:66592167	chr7:65751142~65763354:+
BRCA	cis	rs2243480	1	rs35432774	ENSG00000232546.1	RP11-458F8.1	-5.79	9.55e-09	1.39e-06	-0.23	-0.18	Diabetic kidney disease;	chr7:65928032	chr7:66848496~66858136:+
BRCA	cis	rs2749097	1	rs11208263	ENSG00000244256.3	RN7SL130P	-5.79	9.56e-09	1.39e-06	-0.26	-0.18	Alcohol consumption (transferrin glycosylation);	chr1:63659259	chr1:63655743~63656047:+
BRCA	cis	rs2288884	1	rs11673286	ENSG00000275055.1	CTC-471J1.11	-5.79	9.56e-09	1.39e-06	-0.26	-0.18	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52037065	chr19:52049007~52049754:+
BRCA	cis	rs2243480	1	rs313807	ENSG00000228409.4	CCT6P1	5.79	9.56e-09	1.4e-06	0.24	0.18	Diabetic kidney disease;	chr7:66034494	chr7:65751142~65763354:+
BRCA	cis	rs9393692	0.905	rs2393592	ENSG00000241549.7	GUSBP2	-5.79	9.57e-09	1.4e-06	-0.19	-0.18	Educational attainment;	chr6:26285332	chr6:26871484~26956554:-
BRCA	cis	rs9990333	0.562	rs73210005	ENSG00000231464.1	AC024937.4	5.78	9.59e-09	1.4e-06	0.23	0.18	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196100441	chr3:195996738~195998233:+
BRCA	cis	rs2274273	1	rs67098772	ENSG00000258413.1	RP11-665C16.6	-5.78	9.6e-09	1.4e-06	-0.23	-0.18	Protein biomarker;	chr14:55128524	chr14:55262767~55272075:-
BRCA	cis	rs2274273	1	rs2147972	ENSG00000258413.1	RP11-665C16.6	-5.78	9.6e-09	1.4e-06	-0.23	-0.18	Protein biomarker;	chr14:55131312	chr14:55262767~55272075:-
BRCA	cis	rs793571	0.554	rs12908261	ENSG00000259250.1	RP11-50C13.1	-5.78	9.61e-09	1.4e-06	-0.31	-0.18	Schizophrenia;	chr15:58701582	chr15:58587507~58591676:+
BRCA	cis	rs13126694	0.744	rs4077776	ENSG00000251429.1	RP11-597D13.7	5.78	9.63e-09	1.41e-06	0.17	0.18	Blood osmolality (transformed sodium);	chr4:158008446	chr4:158270378~158278676:+
BRCA	cis	rs66887589	0.616	rs13113885	ENSG00000245958.5	RP11-33B1.1	-5.78	9.65e-09	1.41e-06	-0.17	-0.18	Diastolic blood pressure;	chr4:119300021	chr4:119454791~119552025:+
BRCA	cis	rs2638953	0.64	rs11049729	ENSG00000247934.4	RP11-967K21.1	5.78	9.65e-09	1.41e-06	0.24	0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28586694	chr12:28163298~28190738:-
BRCA	cis	rs991427	0.643	rs76912709	ENSG00000258100.1	RP11-121E16.1	-5.78	9.66e-09	1.41e-06	-0.35	-0.18	Systolic blood pressure (alcohol consumption interaction);	chr12:90966388	chr12:91362196~91368606:+
BRCA	cis	rs10129255	0.5	rs8014529	ENSG00000274576.2	IGHV2-70	-5.78	9.67e-09	1.41e-06	-0.14	-0.18	Kawasaki disease;	chr14:106784065	chr14:106770577~106771020:-
BRCA	cis	rs2274273	0.686	rs2182207	ENSG00000258413.1	RP11-665C16.6	-5.78	9.68e-09	1.41e-06	-0.24	-0.18	Protein biomarker;	chr14:55123085	chr14:55262767~55272075:-
BRCA	cis	rs295490	0.748	rs77705963	ENSG00000272656.1	RP11-219D15.3	5.78	9.68e-09	1.41e-06	0.41	0.18	PR interval in Tripanosoma cruzi seropositivity;	chr3:139341843	chr3:139349024~139349371:-
BRCA	cis	rs10740039	0.516	rs2893840	ENSG00000254271.1	RP11-131N11.4	5.78	9.68e-09	1.41e-06	0.23	0.18	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60554257	chr10:60734342~60741828:+
BRCA	cis	rs673078	0.66	rs7962185	ENSG00000275409.1	RP11-131L12.4	-5.78	9.69e-09	1.41e-06	-0.27	-0.18	Glucose homeostasis traits;	chr12:118287842	chr12:118430147~118430699:+
BRCA	cis	rs13118159	0.55	rs10016557	ENSG00000254094.1	AC078852.1	5.78	9.69e-09	1.41e-06	0.22	0.18	Longevity;	chr4:1369840	chr4:1356581~1358075:+
BRCA	cis	rs9308731	0.966	rs3827536	ENSG00000227992.1	AC108463.2	-5.78	9.69e-09	1.41e-06	-0.21	-0.18	Chronic lymphocytic leukemia;	chr2:111163164	chr2:111203964~111206215:-
BRCA	cis	rs7923609	0.967	rs7082470	ENSG00000232075.1	MRPL35P2	-5.78	9.69e-09	1.41e-06	-0.22	-0.18	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63517266	chr10:63634317~63634827:-
BRCA	cis	rs7923609	0.846	rs7075901	ENSG00000232075.1	MRPL35P2	-5.78	9.69e-09	1.41e-06	-0.22	-0.18	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63521234	chr10:63634317~63634827:-
BRCA	cis	rs919433	0.68	rs6434930	ENSG00000231621.1	AC013264.2	-5.78	9.69e-09	1.41e-06	-0.16	-0.18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197504646	chr2:197197991~197199273:+
BRCA	cis	rs7586673	0.621	rs4999196	ENSG00000227403.1	AC009299.3	-5.78	9.7e-09	1.41e-06	-0.32	-0.18	Intelligence (multi-trait analysis);	chr2:161114824	chr2:161244739~161249050:+
BRCA	cis	rs7567389	0.719	rs4662718	ENSG00000236682.1	AC068282.3	5.78	9.7e-09	1.41e-06	0.27	0.18	Self-rated health;	chr2:127257791	chr2:127389130~127400580:+
BRCA	cis	rs2243480	1	rs10247526	ENSG00000232559.3	GS1-124K5.12	-5.78	9.7e-09	1.41e-06	-0.34	-0.18	Diabetic kidney disease;	chr7:66315709	chr7:66554588~66576923:-
BRCA	cis	rs4948102	0.551	rs4275190	ENSG00000226278.1	PSPHP1	-5.78	9.71e-09	1.42e-06	-0.19	-0.18	Plasma homocysteine levels (post-methionine load test);	chr7:56036695	chr7:55764797~55773288:+
BRCA	cis	rs4853525	0.59	rs10198852	ENSG00000235852.1	AC005540.3	5.78	9.71e-09	1.42e-06	0.22	0.18	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190863606	chr2:190880797~190882059:-
BRCA	cis	rs11668609	1	rs10414556	ENSG00000268442.1	CTD-2027I19.2	5.78	9.72e-09	1.42e-06	0.25	0.18	Response to taxane treatment (docetaxel);	chr19:24186167	chr19:24162370~24163425:-
BRCA	cis	rs7474896	0.583	rs1208770	ENSG00000120555.12	SEPT7P9	5.78	9.73e-09	1.42e-06	0.25	0.18	Obesity (extreme);	chr10:37755755	chr10:38383069~38402916:-
BRCA	cis	rs7474896	0.526	rs1742235	ENSG00000120555.12	SEPT7P9	5.78	9.73e-09	1.42e-06	0.25	0.18	Obesity (extreme);	chr10:37763328	chr10:38383069~38402916:-
BRCA	cis	rs4713118	0.621	rs9368548	ENSG00000280107.1	AL022393.9	-5.78	9.73e-09	1.42e-06	-0.27	-0.18	Parkinson's disease;	chr6:28066959	chr6:28170845~28172521:+
BRCA	cis	rs42490	0.868	rs1605997	ENSG00000251136.7	RP11-37B2.1	5.78	9.73e-09	1.42e-06	0.17	0.18	Leprosy;	chr8:89655885	chr8:89609409~89757727:-
BRCA	cis	rs4927850	1	rs10881564	ENSG00000207650.1	MIR570	5.78	9.73e-09	1.42e-06	0.21	0.18	Pancreatic cancer;	chr3:196023455	chr3:195699401~195699497:+
BRCA	cis	rs4908760	0.868	rs12131864	ENSG00000270282.1	RP5-1115A15.2	5.78	9.75e-09	1.42e-06	0.19	0.18	Vitiligo;	chr1:8531103	chr1:8512653~8513021:+
BRCA	cis	rs516805	0.568	rs56290570	ENSG00000279453.1	RP3-425C14.4	5.78	9.77e-09	1.42e-06	0.25	0.18	Lymphocyte counts;	chr6:122240177	chr6:122436789~122439223:-
BRCA	cis	rs9435732	1	rs9435732	ENSG00000186715.9	MST1L	5.78	9.77e-09	1.42e-06	0.19	0.18	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);	chr1:16981663	chr1:16754910~16770237:-
BRCA	cis	rs1858037	0.836	rs2576923	ENSG00000204929.10	AC074391.1	-5.78	9.77e-09	1.42e-06	-0.24	-0.18	Rheumatoid arthritis;	chr2:65406750	chr2:65436711~66084639:+
BRCA	cis	rs2288884	0.943	rs12611112	ENSG00000275055.1	CTC-471J1.11	-5.78	9.78e-09	1.42e-06	-0.26	-0.18	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52071686	chr19:52049007~52049754:+
BRCA	cis	rs2288884	1	rs17835749	ENSG00000275055.1	CTC-471J1.11	-5.78	9.78e-09	1.42e-06	-0.26	-0.18	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52075442	chr19:52049007~52049754:+
BRCA	cis	rs9880211	0.563	rs67589653	ENSG00000239213.4	NCK1-AS1	5.78	9.78e-09	1.42e-06	0.23	0.18	Height;Body mass index;	chr3:136092732	chr3:136841726~136862054:-
BRCA	cis	rs9880211	0.563	rs10512990	ENSG00000239213.4	NCK1-AS1	5.78	9.78e-09	1.42e-06	0.23	0.18	Height;Body mass index;	chr3:136095785	chr3:136841726~136862054:-
BRCA	cis	rs6088580	0.524	rs6142210	ENSG00000269202.1	RP4-614O4.12	5.78	9.78e-09	1.43e-06	0.18	0.18	Glomerular filtration rate (creatinine);	chr20:34635208	chr20:35201747~35203288:-
BRCA	cis	rs651907	0.557	rs34181125	ENSG00000244119.1	PDCL3P4	5.78	9.79e-09	1.43e-06	0.14	0.18	Colorectal cancer;	chr3:101771434	chr3:101712472~101713191:+
BRCA	cis	rs55692411	0.537	rs35375092	ENSG00000228008.1	CTD-2330K9.3	5.78	9.81e-09	1.43e-06	0.21	0.18	Intelligence (multi-trait analysis);	chr3:50027841	chr3:49903845~49916937:+
BRCA	cis	rs1862618	1	rs1862618	ENSG00000271828.1	CTD-2310F14.1	5.78	9.81e-09	1.43e-06	0.24	0.18	Initial pursuit acceleration;	chr5:56800488	chr5:56927874~56929573:+
BRCA	cis	rs2638953	0.924	rs11049610	ENSG00000278733.1	RP11-425D17.1	-5.78	9.82e-09	1.43e-06	-0.24	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28446674	chr12:28185625~28186190:-
BRCA	cis	rs2243480	0.908	rs55876148	ENSG00000230295.1	RP11-458F8.2	-5.78	9.83e-09	1.43e-06	-0.24	-0.18	Diabetic kidney disease;	chr7:65914813	chr7:66880708~66882981:+
BRCA	cis	rs4834770	0.746	rs2389747	ENSG00000249244.1	RP11-548H18.2	5.78	9.84e-09	1.43e-06	0.19	0.18	Blood protein levels;	chr4:119314947	chr4:119391831~119395335:-
BRCA	cis	rs4834770	0.717	rs1022146	ENSG00000249244.1	RP11-548H18.2	5.78	9.84e-09	1.43e-06	0.19	0.18	Blood protein levels;	chr4:119314948	chr4:119391831~119395335:-
BRCA	cis	rs2253762	0.54	rs77032313	ENSG00000276742.1	RP11-500G22.4	5.78	9.85e-09	1.43e-06	0.3	0.18	Breast cancer;	chr10:121995687	chr10:121956782~121957098:+
BRCA	cis	rs7208859	0.673	rs9911989	ENSG00000265443.1	CTD-2349P21.6	5.78	9.85e-09	1.43e-06	0.3	0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30910684	chr17:30726305~30727564:-
BRCA	cis	rs721917	0.506	rs2244451	ENSG00000244733.5	RP11-506M13.3	-5.78	9.85e-09	1.43e-06	-0.21	-0.18	Chronic obstructive pulmonary disease;	chr10:79885234	chr10:79660891~79677996:+
BRCA	cis	rs875971	0.545	rs2420612	ENSG00000228409.4	CCT6P1	-5.78	9.85e-09	1.43e-06	-0.18	-0.18	Aortic root size;	chr7:66536825	chr7:65751142~65763354:+
BRCA	cis	rs9847710	0.901	rs2564937	ENSG00000242142.1	SERBP1P3	5.78	9.86e-09	1.44e-06	0.21	0.18	Ulcerative colitis;	chr3:52991843	chr3:53064283~53065091:-
BRCA	cis	rs9840812	0.691	rs7621025	ENSG00000239213.4	NCK1-AS1	5.78	9.87e-09	1.44e-06	0.21	0.18	Fibrinogen levels;	chr3:136553404	chr3:136841726~136862054:-
BRCA	cis	rs7927771	0.56	rs4752858	ENSG00000280615.1	Y_RNA	-5.78	9.87e-09	1.44e-06	-0.2	-0.18	Subjective well-being;	chr11:47664277	chr11:47614898~47614994:-
BRCA	cis	rs7238033	0.663	rs11877720	ENSG00000267193.4	RP11-116O18.3	5.78	9.87e-09	1.44e-06	0.19	0.18	Bladder cancer;	chr18:45738290	chr18:45669367~45747215:-
BRCA	cis	rs7338174	0.655	rs9316535	ENSG00000231856.2	RP11-327P2.5	5.78	9.88e-09	1.44e-06	0.41	0.18	Mitochondrial DNA levels;	chr13:51329329	chr13:51803838~51813832:+
BRCA	cis	rs2404602	0.536	rs12915248	ENSG00000259422.1	RP11-593F23.1	5.78	9.88e-09	1.44e-06	0.22	0.18	Blood metabolite levels;	chr15:76473274	chr15:76174891~76181486:-
BRCA	cis	rs2243480	1	rs709607	ENSG00000232546.1	RP11-458F8.1	5.78	9.88e-09	1.44e-06	0.23	0.18	Diabetic kidney disease;	chr7:65984554	chr7:66848496~66858136:+
BRCA	cis	rs875971	0.545	rs2279757	ENSG00000228409.4	CCT6P1	-5.78	9.89e-09	1.44e-06	-0.18	-0.18	Aortic root size;	chr7:66363676	chr7:65751142~65763354:+
BRCA	cis	rs875971	0.545	rs11766183	ENSG00000228409.4	CCT6P1	-5.78	9.89e-09	1.44e-06	-0.18	-0.18	Aortic root size;	chr7:66374173	chr7:65751142~65763354:+
BRCA	cis	rs875971	0.545	rs1065265	ENSG00000228409.4	CCT6P1	-5.78	9.89e-09	1.44e-06	-0.18	-0.18	Aortic root size;	chr7:66376216	chr7:65751142~65763354:+
BRCA	cis	rs66887589	0.592	rs28580295	ENSG00000249244.1	RP11-548H18.2	5.78	9.89e-09	1.44e-06	0.19	0.18	Diastolic blood pressure;	chr4:119357718	chr4:119391831~119395335:-
BRCA	cis	rs58785573	0.624	rs337605	ENSG00000231160.8	KLF3-AS1	-5.78	9.89e-09	1.44e-06	-0.17	-0.18	Lymphocyte percentage of white cells;	chr4:38646132	chr4:38612701~38664883:-
BRCA	cis	rs7432375	0.61	rs7621932	ENSG00000239213.4	NCK1-AS1	5.78	9.9e-09	1.44e-06	0.18	0.18	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136798174	chr3:136841726~136862054:-
BRCA	cis	rs7432375	0.61	rs7633629	ENSG00000239213.4	NCK1-AS1	5.78	9.9e-09	1.44e-06	0.18	0.18	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136798186	chr3:136841726~136862054:-
BRCA	cis	rs3764021	0.84	rs12304510	ENSG00000214776.8	RP11-726G1.1	5.78	9.9e-09	1.44e-06	0.19	0.18	Type 1 diabetes;	chr12:9732930	chr12:9467552~9576275:+
BRCA	cis	rs2704588	0.542	rs11734924	ENSG00000270720.1	RP11-84C13.2	5.78	9.91e-09	1.44e-06	0.31	0.18	Longevity;	chr4:89107365	chr4:89119284~89119871:+
BRCA	cis	rs9876781	1	rs9881491	ENSG00000229759.1	MRPS18AP1	5.78	9.91e-09	1.44e-06	0.2	0.18	Longevity;	chr3:48446507	chr3:48256350~48256938:-
BRCA	cis	rs2638953	0.886	rs10843168	ENSG00000278733.1	RP11-425D17.1	-5.78	9.92e-09	1.44e-06	-0.24	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28430038	chr12:28185625~28186190:-
BRCA	cis	rs30380	0.632	rs26500	ENSG00000272109.1	CTD-2260A17.3	-5.78	9.92e-09	1.44e-06	-0.25	-0.18	Cerebrospinal fluid biomarker levels;	chr5:96798009	chr5:96804353~96806105:+
BRCA	cis	rs2274273	1	rs67805055	ENSG00000258413.1	RP11-665C16.6	-5.78	9.92e-09	1.44e-06	-0.22	-0.18	Protein biomarker;	chr14:55120834	chr14:55262767~55272075:-
BRCA	cis	rs2274273	1	rs2274273	ENSG00000258413.1	RP11-665C16.6	5.78	9.93e-09	1.45e-06	0.22	0.18	Protein biomarker;	chr14:55147918	chr14:55262767~55272075:-
BRCA	cis	rs7587476	0.768	rs9789462	ENSG00000229267.2	AC072062.1	-5.78	9.94e-09	1.45e-06	-0.23	-0.18	Neuroblastoma;	chr2:214778216	chr2:214810229~214963274:+
BRCA	cis	rs7493	0.95	rs17879277	ENSG00000233942.1	AC004012.1	5.78	9.94e-09	1.45e-06	0.22	0.18	Yu-Zhi constitution type in type 2 diabetes;	chr7:95401320	chr7:95471835~95473998:+
BRCA	cis	rs7045881	0.558	rs17694631	ENSG00000254396.1	RP11-56F10.3	-5.78	9.96e-09	1.45e-06	-0.3	-0.18	Schizophrenia;	chr9:27066072	chr9:27102630~27104728:+
BRCA	cis	rs14027	0.64	rs2326378	ENSG00000279347.1	RP11-85I17.2	-5.78	9.96e-09	1.45e-06	-0.17	-0.18	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119764355	chr8:119838736~119840385:-
BRCA	cis	rs2834188	1	rs9982088	ENSG00000272659.1	AP000295.10	-5.78	9.96e-09	1.45e-06	-0.27	-0.18	Narcolepsy;	chr21:33314536	chr21:33309491~33310181:+
BRCA	cis	rs2243480	1	rs35432774	ENSG00000230295.1	RP11-458F8.2	-5.78	9.97e-09	1.45e-06	-0.23	-0.18	Diabetic kidney disease;	chr7:65928032	chr7:66880708~66882981:+
BRCA	cis	rs9545047	0.604	rs9574410	ENSG00000227354.5	RBM26-AS1	-5.78	9.97e-09	1.45e-06	-0.19	-0.18	Schizophrenia;	chr13:79343091	chr13:79406309~79424328:+
BRCA	cis	rs2274273	1	rs7140872	ENSG00000258413.1	RP11-665C16.6	-5.78	9.97e-09	1.45e-06	-0.22	-0.18	Protein biomarker;	chr14:55146026	chr14:55262767~55272075:-
BRCA	cis	rs2638953	0.815	rs61922546	ENSG00000278733.1	RP11-425D17.1	-5.78	9.98e-09	1.45e-06	-0.24	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28524632	chr12:28185625~28186190:-
BRCA	cis	rs7520050	0.966	rs6661910	ENSG00000280836.1	AL355480.1	5.78	9.98e-09	1.45e-06	0.2	0.18	Reticulocyte count;Red blood cell count;	chr1:45824960	chr1:45581219~45581321:-
BRCA	cis	rs10129255	0.912	rs8011090	ENSG00000280411.1	IGHV1-69-2	-5.78	9.99e-09	1.45e-06	-0.13	-0.18	Kawasaki disease;	chr14:106678896	chr14:106762092~106762588:-
BRCA	cis	rs4415084	1	rs2165010	ENSG00000251141.4	RP11-53O19.1	5.78	9.99e-09	1.45e-06	0.16	0.18	Breast cancer;	chr5:44706678	chr5:44744900~44808777:-
BRCA	cis	rs2638953	0.815	rs10843186	ENSG00000278733.1	RP11-425D17.1	-5.78	1e-08	1.46e-06	-0.23	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28482921	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.815	rs1511551	ENSG00000278733.1	RP11-425D17.1	-5.78	1e-08	1.46e-06	-0.23	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28483897	chr12:28185625~28186190:-
BRCA	cis	rs2562456	0.72	rs6511250	ENSG00000268081.1	RP11-678G14.2	-5.78	1e-08	1.46e-06	-0.27	-0.18	Pain;	chr19:21473244	chr19:21554640~21569237:-
BRCA	cis	rs763121	0.853	rs5750672	ENSG00000228274.3	RP3-508I15.9	5.78	1e-08	1.46e-06	0.2	0.18	Menopause (age at onset);	chr22:38708163	chr22:38667585~38681820:-
BRCA	cis	rs1440410	0.835	rs10016850	ENSG00000250326.1	RP11-284M14.1	-5.78	1e-08	1.46e-06	-0.19	-0.18	Ischemic stroke;	chr4:143135694	chr4:142933195~143184861:-
BRCA	cis	rs1440410	0.795	rs11728962	ENSG00000250326.1	RP11-284M14.1	-5.78	1e-08	1.46e-06	-0.19	-0.18	Ischemic stroke;	chr4:143158718	chr4:142933195~143184861:-
BRCA	cis	rs944990	0.576	rs6479492	ENSG00000227603.1	RP11-165J3.6	5.78	1e-08	1.46e-06	0.18	0.18	Body mass index;	chr9:93513684	chr9:93435332~93437121:-
BRCA	cis	rs721917	0.506	rs2758558	ENSG00000244733.5	RP11-506M13.3	-5.78	1e-08	1.46e-06	-0.21	-0.18	Chronic obstructive pulmonary disease;	chr10:79923822	chr10:79660891~79677996:+
BRCA	cis	rs7474896	0.559	rs1735641	ENSG00000120555.12	SEPT7P9	-5.78	1e-08	1.46e-06	-0.25	-0.18	Obesity (extreme);	chr10:37895924	chr10:38383069~38402916:-
BRCA	cis	rs7613875	0.521	rs4688754	ENSG00000228008.1	CTD-2330K9.3	-5.78	1e-08	1.46e-06	-0.17	-0.18	Body mass index;	chr3:50037208	chr3:49903845~49916937:+
BRCA	cis	rs1707322	0.506	rs2991983	ENSG00000234329.1	RP11-767N6.2	-5.78	1e-08	1.46e-06	-0.18	-0.18	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613719	chr1:45651039~45651826:-
BRCA	cis	rs7131987	0.65	rs11050187	ENSG00000275476.1	RP11-996F15.4	-5.78	1e-08	1.46e-06	-0.21	-0.18	QT interval;	chr12:29319943	chr12:29277397~29277882:-
BRCA	cis	rs12893668	0.572	rs4906350	ENSG00000269910.1	RP11-73M18.10	5.78	1e-08	1.46e-06	0.19	0.18	Reticulocyte count;	chr14:103645457	chr14:103694516~103695050:-
BRCA	cis	rs2337406	1	rs10459466	ENSG00000211972.2	IGHV3-66	5.78	1e-08	1.46e-06	0.18	0.18	Alzheimer's disease (late onset);	chr14:106689255	chr14:106675017~106675544:-
BRCA	cis	rs2638953	0.924	rs11049385	ENSG00000278733.1	RP11-425D17.1	-5.78	1e-08	1.46e-06	-0.24	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28167559	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.924	rs11049387	ENSG00000278733.1	RP11-425D17.1	-5.78	1e-08	1.46e-06	-0.24	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28167609	chr12:28185625~28186190:-
BRCA	cis	rs9545047	0.604	rs2274555	ENSG00000227354.5	RBM26-AS1	-5.78	1e-08	1.46e-06	-0.19	-0.18	Schizophrenia;	chr13:79344188	chr13:79406309~79424328:+
BRCA	cis	rs7688540	0.8	rs6857106	ENSG00000275426.1	CH17-262A2.1	-5.78	1e-08	1.46e-06	-0.22	-0.18	Facial morphology (factor 6, height of vermillion lower lip);	chr4:255641	chr4:149738~150317:+
BRCA	cis	rs867371	0.964	rs7169961	ENSG00000276710.3	CSPG4P8	-5.78	1.01e-08	1.46e-06	-0.19	-0.18	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82186588	chr15:82459472~82477258:+
BRCA	cis	rs9652601	0.92	rs12923098	ENSG00000274038.1	RP11-66H6.4	-5.78	1.01e-08	1.46e-06	-0.2	-0.18	Systemic lupus erythematosus;	chr16:11083196	chr16:11056556~11057034:+
BRCA	cis	rs7618915	0.547	rs33967311	ENSG00000243224.1	RP5-1157M23.2	-5.78	1.01e-08	1.46e-06	-0.2	-0.18	Bipolar disorder;	chr3:52649848	chr3:52239258~52241097:+
BRCA	cis	rs4713675	0.584	rs9394163	ENSG00000224557.6	HLA-DPB2	-5.78	1.01e-08	1.46e-06	-0.2	-0.18	Plateletcrit;	chr6:33714637	chr6:33112451~33129084:+
BRCA	cis	rs2243480	1	rs2462569	ENSG00000228409.4	CCT6P1	-5.78	1.01e-08	1.46e-06	-0.23	-0.18	Diabetic kidney disease;	chr7:66009859	chr7:65751142~65763354:+
BRCA	cis	rs2288884	0.943	rs75722407	ENSG00000275055.1	CTC-471J1.11	-5.78	1.01e-08	1.47e-06	-0.26	-0.18	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52021989	chr19:52049007~52049754:+
BRCA	cis	rs9595908	0.785	rs4120131	ENSG00000212293.1	SNORA16	-5.78	1.01e-08	1.47e-06	-0.19	-0.18	Body mass index;	chr13:32702949	chr13:32420390~32420516:-
BRCA	cis	rs1555322	0.872	rs2425048	ENSG00000261582.1	RP4-614O4.11	-5.78	1.01e-08	1.47e-06	-0.26	-0.18	Attention deficit hyperactivity disorder;	chr20:35284920	chr20:35267885~35280043:-
BRCA	cis	rs2638953	0.924	rs11049619	ENSG00000278733.1	RP11-425D17.1	-5.78	1.01e-08	1.47e-06	-0.24	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28453495	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.924	rs60703205	ENSG00000278733.1	RP11-425D17.1	-5.78	1.01e-08	1.47e-06	-0.24	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28454371	chr12:28185625~28186190:-
BRCA	cis	rs853679	0.517	rs9380052	ENSG00000204709.4	LINC01556	5.78	1.01e-08	1.47e-06	0.26	0.18	Depression;	chr6:28096845	chr6:28943877~28944537:+
BRCA	cis	rs7945705	0.791	rs4579928	ENSG00000254860.4	TMEM9B-AS1	-5.78	1.01e-08	1.47e-06	-0.16	-0.18	Hemoglobin concentration;	chr11:8794157	chr11:8964675~8977527:+
BRCA	cis	rs9545047	0.564	rs7336186	ENSG00000227354.5	RBM26-AS1	-5.78	1.01e-08	1.47e-06	-0.19	-0.18	Schizophrenia;	chr13:79385497	chr13:79406309~79424328:+
BRCA	cis	rs9545047	0.604	rs2182009	ENSG00000227354.5	RBM26-AS1	-5.78	1.01e-08	1.47e-06	-0.19	-0.18	Schizophrenia;	chr13:79397781	chr13:79406309~79424328:+
BRCA	cis	rs9545047	0.604	rs4605023	ENSG00000227354.5	RBM26-AS1	-5.78	1.01e-08	1.47e-06	-0.19	-0.18	Schizophrenia;	chr13:79398700	chr13:79406309~79424328:+
BRCA	cis	rs9545047	0.604	rs12877507	ENSG00000227354.5	RBM26-AS1	-5.78	1.01e-08	1.47e-06	-0.19	-0.18	Schizophrenia;	chr13:79401822	chr13:79406309~79424328:+
BRCA	cis	rs2098713	0.614	rs13155645	ENSG00000250155.1	CTD-2353F22.1	-5.78	1.01e-08	1.47e-06	-0.21	-0.18	Telomere length;	chr5:37476899	chr5:36666214~36725195:-
BRCA	cis	rs7598759	0.527	rs4973417	ENSG00000223198.1	RNU2-22P	-5.78	1.01e-08	1.47e-06	-0.22	-0.18	Noise-induced hearing loss;	chr2:231484925	chr2:231501990~231502201:-
BRCA	cis	rs2243480	1	rs1723269	ENSG00000232559.3	GS1-124K5.12	5.78	1.01e-08	1.47e-06	0.33	0.18	Diabetic kidney disease;	chr7:66007799	chr7:66554588~66576923:-
BRCA	cis	rs2243480	0.901	rs2456483	ENSG00000232546.1	RP11-458F8.1	-5.78	1.01e-08	1.47e-06	-0.23	-0.18	Diabetic kidney disease;	chr7:65996588	chr7:66848496~66858136:+
BRCA	cis	rs2243480	1	rs1701750	ENSG00000232546.1	RP11-458F8.1	-5.78	1.01e-08	1.47e-06	-0.23	-0.18	Diabetic kidney disease;	chr7:66002158	chr7:66848496~66858136:+
BRCA	cis	rs7238033	0.624	rs7234310	ENSG00000267193.4	RP11-116O18.3	5.78	1.01e-08	1.47e-06	0.19	0.18	Bladder cancer;	chr18:45726828	chr18:45669367~45747215:-
BRCA	cis	rs13126694	0.744	rs7682867	ENSG00000251429.1	RP11-597D13.7	5.78	1.01e-08	1.47e-06	0.17	0.18	Blood osmolality (transformed sodium);	chr4:158026735	chr4:158270378~158278676:+
BRCA	cis	rs10510102	0.872	rs12246728	ENSG00000226864.1	ATE1-AS1	5.78	1.01e-08	1.47e-06	0.33	0.18	Breast cancer;	chr10:121966618	chr10:121928312~121951965:+
BRCA	cis	rs10510102	0.872	rs12261371	ENSG00000226864.1	ATE1-AS1	5.78	1.01e-08	1.47e-06	0.33	0.18	Breast cancer;	chr10:121966686	chr10:121928312~121951965:+
BRCA	cis	rs10510102	0.872	rs11200292	ENSG00000226864.1	ATE1-AS1	5.78	1.01e-08	1.47e-06	0.33	0.18	Breast cancer;	chr10:121967383	chr10:121928312~121951965:+
BRCA	cis	rs10510102	0.808	rs17102804	ENSG00000226864.1	ATE1-AS1	5.78	1.01e-08	1.47e-06	0.33	0.18	Breast cancer;	chr10:121968365	chr10:121928312~121951965:+
BRCA	cis	rs7927771	0.524	rs10838740	ENSG00000280615.1	Y_RNA	5.78	1.01e-08	1.47e-06	0.21	0.18	Subjective well-being;	chr11:47658428	chr11:47614898~47614994:-
BRCA	cis	rs6490294	0.571	rs7295294	ENSG00000226469.1	ADAM1B	5.78	1.01e-08	1.47e-06	0.28	0.18	Mean platelet volume;	chr12:112027089	chr12:111927018~111929017:+
BRCA	cis	rs7238033	0.624	rs7233769	ENSG00000267193.4	RP11-116O18.3	5.78	1.01e-08	1.47e-06	0.19	0.18	Bladder cancer;	chr18:45726716	chr18:45669367~45747215:-
BRCA	cis	rs1193	1	rs1193	ENSG00000231259.4	AC125232.1	-5.78	1.01e-08	1.47e-06	-0.22	-0.18	High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;High light scatter reticulocyte count;	chr2:86775106	chr2:87031815~87053069:-
BRCA	cis	rs11668609	1	rs919813	ENSG00000268442.1	CTD-2027I19.2	5.78	1.01e-08	1.47e-06	0.24	0.18	Response to taxane treatment (docetaxel);	chr19:24163431	chr19:24162370~24163425:-
BRCA	cis	rs2243480	1	rs1701758	ENSG00000232559.3	GS1-124K5.12	5.78	1.01e-08	1.47e-06	0.33	0.18	Diabetic kidney disease;	chr7:66005214	chr7:66554588~66576923:-
BRCA	cis	rs9545047	0.604	rs9565496	ENSG00000227354.5	RBM26-AS1	-5.77	1.02e-08	1.48e-06	-0.19	-0.18	Schizophrenia;	chr13:79398751	chr13:79406309~79424328:+
BRCA	cis	rs651907	0.535	rs11707250	ENSG00000244119.1	PDCL3P4	-5.77	1.02e-08	1.48e-06	-0.14	-0.18	Colorectal cancer;	chr3:101790527	chr3:101712472~101713191:+
BRCA	cis	rs13126694	0.75	rs2346782	ENSG00000251429.1	RP11-597D13.7	5.77	1.02e-08	1.48e-06	0.17	0.18	Blood osmolality (transformed sodium);	chr4:158147143	chr4:158270378~158278676:+
BRCA	cis	rs11668609	1	rs12609544	ENSG00000268442.1	CTD-2027I19.2	5.77	1.02e-08	1.48e-06	0.24	0.18	Response to taxane treatment (docetaxel);	chr19:24142763	chr19:24162370~24163425:-
BRCA	cis	rs7976269	0.609	rs11050010	ENSG00000275476.1	RP11-996F15.4	-5.77	1.02e-08	1.48e-06	-0.2	-0.18	Male-pattern baldness;	chr12:29061952	chr12:29277397~29277882:-
BRCA	cis	rs7976269	0.609	rs2196480	ENSG00000275476.1	RP11-996F15.4	-5.77	1.02e-08	1.48e-06	-0.2	-0.18	Male-pattern baldness;	chr12:29062850	chr12:29277397~29277882:-
BRCA	cis	rs7976269	0.537	rs10743642	ENSG00000275476.1	RP11-996F15.4	-5.77	1.02e-08	1.48e-06	-0.2	-0.18	Male-pattern baldness;	chr12:29063557	chr12:29277397~29277882:-
BRCA	cis	rs7976269	0.609	rs10771472	ENSG00000275476.1	RP11-996F15.4	-5.77	1.02e-08	1.48e-06	-0.2	-0.18	Male-pattern baldness;	chr12:29063930	chr12:29277397~29277882:-
BRCA	cis	rs9287719	0.649	rs2024433	ENSG00000243819.4	RN7SL832P	5.77	1.02e-08	1.48e-06	0.18	0.18	Prostate cancer;	chr2:10591378	chr2:10690344~10692099:+
BRCA	cis	rs6570726	0.846	rs6570700	ENSG00000270638.1	RP3-466P17.1	5.77	1.02e-08	1.48e-06	0.2	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145610416	chr6:145735570~145737218:+
BRCA	cis	rs6570726	0.846	rs870491	ENSG00000270638.1	RP3-466P17.1	5.77	1.02e-08	1.48e-06	0.2	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145612254	chr6:145735570~145737218:+
BRCA	cis	rs875971	0.505	rs1167385	ENSG00000273024.4	INTS4P2	5.77	1.02e-08	1.48e-06	0.19	0.18	Aortic root size;	chr7:66048321	chr7:65647864~65715661:+
BRCA	cis	rs4664293	0.546	rs72956113	ENSG00000226266.5	AC009961.3	5.77	1.02e-08	1.48e-06	0.22	0.18	Monocyte percentage of white cells;	chr2:159631132	chr2:159670708~159712435:-
BRCA	cis	rs12468226	0.689	rs73989733	ENSG00000273456.1	RP11-686O6.2	5.77	1.02e-08	1.48e-06	0.25	0.18	Urate levels;	chr2:202115241	chr2:202374932~202375604:-
BRCA	cis	rs3740713	1	rs79199586	ENSG00000256464.1	YWHABP2	5.77	1.02e-08	1.48e-06	0.33	0.18	Amyotrophic lateral sclerosis (sporadic);	chr11:18430599	chr11:18490243~18490955:-
BRCA	cis	rs2243480	1	rs6460260	ENSG00000232559.3	GS1-124K5.12	-5.77	1.02e-08	1.48e-06	-0.33	-0.18	Diabetic kidney disease;	chr7:65750468	chr7:66554588~66576923:-
BRCA	cis	rs2243480	1	rs6460261	ENSG00000232559.3	GS1-124K5.12	-5.77	1.02e-08	1.48e-06	-0.33	-0.18	Diabetic kidney disease;	chr7:65750593	chr7:66554588~66576923:-
BRCA	cis	rs5758511	0.689	rs11913578	ENSG00000205702.9	CYP2D7	5.77	1.02e-08	1.48e-06	0.18	0.18	Birth weight;	chr22:41951387	chr22:42140203~42144577:-
BRCA	cis	rs1979679	0.842	rs7138497	ENSG00000278733.1	RP11-425D17.1	5.77	1.02e-08	1.48e-06	0.22	0.18	Ossification of the posterior longitudinal ligament of the spine;	chr12:28242918	chr12:28185625~28186190:-
BRCA	cis	rs17213965	0.561	rs9929522	ENSG00000207425.1	Y_RNA	-5.77	1.02e-08	1.49e-06	-0.23	-0.18	Waist-hip ratio;	chr16:15785903	chr16:14915457~14915556:-
BRCA	cis	rs7617773	0.78	rs13084616	ENSG00000199476.1	Y_RNA	5.77	1.02e-08	1.49e-06	0.26	0.18	Coronary artery disease;	chr3:48298209	chr3:48288587~48288694:+
BRCA	cis	rs1859596	0.966	rs1034796	ENSG00000234456.6	MAGI2-AS3	5.77	1.02e-08	1.49e-06	0.11	0.18	Reading or mathematical ability;	chr7:79474220	chr7:79452877~79471208:+
BRCA	cis	rs7267979	0.789	rs6076347	ENSG00000204556.4	CTD-2514C3.1	5.77	1.02e-08	1.49e-06	0.24	0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25418154	chr20:26018832~26020684:+
BRCA	cis	rs523522	0.847	rs11065132	ENSG00000278344.1	RP11-18C24.8	5.77	1.02e-08	1.49e-06	0.24	0.18	High light scatter reticulocyte count;	chr12:120470656	chr12:120500735~120501090:-
BRCA	cis	rs523522	0.962	rs4767902	ENSG00000278344.1	RP11-18C24.8	5.77	1.02e-08	1.49e-06	0.24	0.18	High light scatter reticulocyte count;	chr12:120472201	chr12:120500735~120501090:-
BRCA	cis	rs523522	0.962	rs10849753	ENSG00000278344.1	RP11-18C24.8	5.77	1.02e-08	1.49e-06	0.24	0.18	High light scatter reticulocyte count;	chr12:120473010	chr12:120500735~120501090:-
BRCA	cis	rs1499614	1	rs2141924	ENSG00000228409.4	CCT6P1	5.77	1.03e-08	1.49e-06	0.25	0.18	Gout;	chr7:66721259	chr7:65751142~65763354:+
BRCA	cis	rs227275	0.525	rs4699046	ENSG00000251288.2	RP11-10L12.2	-5.77	1.03e-08	1.49e-06	-0.21	-0.18	Allergic disease (asthma, hay fever or eczema);	chr4:103004514	chr4:102751401~102752641:+
BRCA	cis	rs227275	0.525	rs4699047	ENSG00000251288.2	RP11-10L12.2	-5.77	1.03e-08	1.49e-06	-0.21	-0.18	Allergic disease (asthma, hay fever or eczema);	chr4:103005385	chr4:102751401~102752641:+
BRCA	cis	rs227275	0.525	rs28778380	ENSG00000251288.2	RP11-10L12.2	-5.77	1.03e-08	1.49e-06	-0.21	-0.18	Allergic disease (asthma, hay fever or eczema);	chr4:103006416	chr4:102751401~102752641:+
BRCA	cis	rs13113518	0.678	rs13149568	ENSG00000223305.1	RN7SKP30	5.77	1.03e-08	1.49e-06	0.22	0.18	Height;	chr4:55370412	chr4:55540502~55540835:-
BRCA	cis	rs7789940	1	rs11765693	ENSG00000186704.9	DTX2P1	5.77	1.03e-08	1.49e-06	0.21	0.18	Multiple sclerosis;	chr7:76356056	chr7:76978617~77004308:+
BRCA	cis	rs7789940	1	rs73140069	ENSG00000186704.9	DTX2P1	5.77	1.03e-08	1.49e-06	0.21	0.18	Multiple sclerosis;	chr7:76357473	chr7:76978617~77004308:+
BRCA	cis	rs2153535	0.56	rs9379239	ENSG00000230939.1	RP11-314C16.1	-5.77	1.03e-08	1.49e-06	-0.2	-0.18	Motion sickness;	chr6:8670263	chr6:8784178~8785445:+
BRCA	cis	rs1799949	1	rs8070085	ENSG00000236383.6	LINC00854	5.77	1.03e-08	1.49e-06	0.18	0.18	Menopause (age at onset);	chr17:43189967	chr17:43216941~43305976:-
BRCA	cis	rs720475	0.732	rs7784282	ENSG00000170356.8	OR2A20P	5.77	1.03e-08	1.49e-06	0.25	0.18	Breast cancer;	chr7:144431561	chr7:144250045~144252957:-
BRCA	cis	rs250585	0.736	rs499812	ENSG00000260136.4	CTD-2270L9.4	5.77	1.03e-08	1.49e-06	0.18	0.18	Egg allergy;	chr16:23399098	chr16:23452758~23457606:+
BRCA	cis	rs11671005	0.735	rs56292587	ENSG00000252334.1	RNU6-1337P	5.77	1.03e-08	1.49e-06	0.26	0.18	Mean platelet volume;	chr19:58407699	chr19:58483749~58483843:-
BRCA	cis	rs11671005	0.735	rs56290606	ENSG00000252334.1	RNU6-1337P	5.77	1.03e-08	1.49e-06	0.26	0.18	Mean platelet volume;	chr19:58407953	chr19:58483749~58483843:-
BRCA	cis	rs11671005	0.735	rs11878198	ENSG00000252334.1	RNU6-1337P	5.77	1.03e-08	1.49e-06	0.26	0.18	Mean platelet volume;	chr19:58408935	chr19:58483749~58483843:-
BRCA	cis	rs11671005	0.735	rs11666716	ENSG00000252334.1	RNU6-1337P	5.77	1.03e-08	1.49e-06	0.26	0.18	Mean platelet volume;	chr19:58409585	chr19:58483749~58483843:-
BRCA	cis	rs11671005	0.735	rs34511020	ENSG00000252334.1	RNU6-1337P	5.77	1.03e-08	1.49e-06	0.26	0.18	Mean platelet volume;	chr19:58409929	chr19:58483749~58483843:-
BRCA	cis	rs11671005	0.735	rs11666303	ENSG00000252334.1	RNU6-1337P	5.77	1.03e-08	1.49e-06	0.26	0.18	Mean platelet volume;	chr19:58411135	chr19:58483749~58483843:-
BRCA	cis	rs7200543	1	rs2740	ENSG00000275910.1	RP11-680G24.6	-5.77	1.03e-08	1.5e-06	-0.21	-0.18	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15038251	chr16:15015828~15016390:-
BRCA	cis	rs7577696	0.512	rs9789593	ENSG00000272716.1	RP11-563N4.1	-5.77	1.03e-08	1.5e-06	-0.21	-0.18	Inflammatory biomarkers;	chr2:32156041	chr2:32165046~32165757:-
BRCA	cis	rs2243480	1	rs1723270	ENSG00000232559.3	GS1-124K5.12	5.77	1.03e-08	1.5e-06	0.33	0.18	Diabetic kidney disease;	chr7:66004843	chr7:66554588~66576923:-
BRCA	cis	rs2911132	0.564	rs13181579	ENSG00000248734.2	CTD-2260A17.1	5.77	1.03e-08	1.5e-06	0.21	0.18	Urate levels (BMI interaction);	chr5:96755234	chr5:96784777~96785999:+
BRCA	cis	rs2243480	0.908	rs4718273	ENSG00000232559.3	GS1-124K5.12	-5.77	1.03e-08	1.5e-06	-0.33	-0.18	Diabetic kidney disease;	chr7:65751112	chr7:66554588~66576923:-
BRCA	cis	rs227275	0.525	rs4623004	ENSG00000251288.2	RP11-10L12.2	-5.77	1.04e-08	1.5e-06	-0.21	-0.18	Allergic disease (asthma, hay fever or eczema);	chr4:103000141	chr4:102751401~102752641:+
BRCA	cis	rs6545883	0.839	rs778764	ENSG00000270820.4	RP11-355B11.2	5.77	1.04e-08	1.5e-06	0.2	0.18	Tuberculosis;	chr2:61558545	chr2:61471188~61484130:+
BRCA	cis	rs1850744	0.702	rs4974812	ENSG00000163612.10	FAM86KP	5.77	1.04e-08	1.5e-06	0.47	0.18	Economic and political preferences;	chr4:9612974	chr4:9153296~9165451:+
BRCA	cis	rs7923609	0.967	rs7920058	ENSG00000232075.1	MRPL35P2	-5.77	1.04e-08	1.5e-06	-0.22	-0.18	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63534164	chr10:63634317~63634827:-
BRCA	cis	rs3213958	0.509	rs73136060	ENSG00000249274.1	PDLIM1P4	-5.77	1.04e-08	1.5e-06	-0.26	-0.18	Blood protein levels;	chr3:98792641	chr3:98782188~98783193:+
BRCA	cis	rs3213958	0.574	rs2278599	ENSG00000249274.1	PDLIM1P4	-5.77	1.04e-08	1.5e-06	-0.26	-0.18	Blood protein levels;	chr3:98793344	chr3:98782188~98783193:+
BRCA	cis	rs8114671	0.562	rs4911164	ENSG00000269202.1	RP4-614O4.12	-5.77	1.04e-08	1.5e-06	-0.19	-0.18	Height;	chr20:34891685	chr20:35201747~35203288:-
BRCA	cis	rs7618501	0.633	rs11925192	ENSG00000228008.1	CTD-2330K9.3	5.77	1.04e-08	1.51e-06	0.17	0.18	Intelligence (multi-trait analysis);	chr3:50001231	chr3:49903845~49916937:+
BRCA	cis	rs516805	0.667	rs2606608	ENSG00000279453.1	RP3-425C14.4	-5.77	1.04e-08	1.51e-06	-0.25	-0.18	Lymphocyte counts;	chr6:122195051	chr6:122436789~122439223:-
BRCA	cis	rs9309473	1	rs1403284	ENSG00000163016.8	ALMS1P	-5.77	1.04e-08	1.51e-06	-0.23	-0.18	Metabolite levels;	chr2:73499535	chr2:73644919~73685576:+
BRCA	cis	rs10129255	0.957	rs8022165	ENSG00000224373.3	IGHV4-59	5.77	1.04e-08	1.51e-06	0.11	0.18	Kawasaki disease;	chr14:106781682	chr14:106627249~106627825:-
BRCA	cis	rs13113518	0.738	rs6849883	ENSG00000223305.1	RN7SKP30	5.77	1.04e-08	1.51e-06	0.22	0.18	Height;	chr4:55387515	chr4:55540502~55540835:-
BRCA	cis	rs17772222	0.655	rs10150594	ENSG00000258789.1	RP11-507K2.3	-5.77	1.04e-08	1.51e-06	-0.19	-0.18	Coronary artery calcification;	chr14:88489613	chr14:88551597~88552493:+
BRCA	cis	rs7804306	1	rs13225545	ENSG00000233264.2	AC006042.8	5.77	1.04e-08	1.51e-06	0.39	0.18	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8027509	chr7:7980312~7982228:+
BRCA	cis	rs2303319	1	rs2303319	ENSG00000227403.1	AC009299.3	5.77	1.04e-08	1.51e-06	0.45	0.18	Cognitive function;	chr2:161368153	chr2:161244739~161249050:+
BRCA	cis	rs1853665	1	rs9383993	ENSG00000268592.3	RAET1E-AS1	-5.77	1.04e-08	1.51e-06	-0.26	-0.18	Radiation response;	chr6:149978163	chr6:149863494~149919507:+
BRCA	cis	rs7829975	0.742	rs1533058	ENSG00000254153.1	CTA-398F10.2	5.77	1.04e-08	1.51e-06	0.21	0.18	Mood instability;	chr8:8827680	chr8:8456909~8461337:-
BRCA	cis	rs11722228	0.522	rs77691548	ENSG00000261490.1	RP11-448G15.3	5.77	1.04e-08	1.51e-06	0.2	0.18	Urate levels;Serum uric acid levels;Gout;	chr4:10134491	chr4:10068089~10073019:-
BRCA	cis	rs13423976	0.572	rs11893988	ENSG00000231367.4	AC016995.3	5.77	1.04e-08	1.51e-06	0.19	0.18	Gut microbiome composition (summer);	chr2:38515630	chr2:38406719~38515740:-
BRCA	cis	rs10208649	0.908	rs11889527	ENSG00000233266.1	HMGB1P31	5.77	1.04e-08	1.51e-06	0.41	0.18	Body mass index;	chr2:53999178	chr2:54051334~54051760:+
BRCA	cis	rs7620503	0.516	rs1566409	ENSG00000228561.2	RP11-114M1.1	5.77	1.04e-08	1.52e-06	0.23	0.18	Corneal structure;	chr3:177616400	chr3:177683627~177691250:+
BRCA	cis	rs7474896	0.537	rs2505255	ENSG00000120555.12	SEPT7P9	5.77	1.05e-08	1.52e-06	0.24	0.18	Obesity (extreme);	chr10:38070714	chr10:38383069~38402916:-
BRCA	cis	rs300890	0.513	rs2323077	ENSG00000250326.1	RP11-284M14.1	-5.77	1.05e-08	1.52e-06	-0.2	-0.18	Nasopharyngeal carcinoma;	chr4:143231032	chr4:142933195~143184861:-
BRCA	cis	rs12468226	1	rs75040639	ENSG00000226261.1	AC064836.3	5.77	1.05e-08	1.52e-06	0.3	0.18	Urate levels;	chr2:202486973	chr2:202336024~202336727:-
BRCA	cis	rs875971	0.545	rs1638735	ENSG00000273024.4	INTS4P2	-5.77	1.05e-08	1.52e-06	-0.22	-0.18	Aortic root size;	chr7:66630751	chr7:65647864~65715661:+
BRCA	cis	rs1707322	0.682	rs10890335	ENSG00000234329.1	RP11-767N6.2	5.77	1.05e-08	1.52e-06	0.18	0.18	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634722	chr1:45651039~45651826:-
BRCA	cis	rs1124769	0.719	rs1147140	ENSG00000259378.1	DCAF13P3	-5.77	1.05e-08	1.52e-06	-0.25	-0.18	Cognitive performance;	chr15:50878226	chr15:50944663~50945996:+
BRCA	cis	rs673078	0.66	rs7970481	ENSG00000275409.1	RP11-131L12.4	-5.77	1.05e-08	1.52e-06	-0.26	-0.18	Glucose homeostasis traits;	chr12:118242112	chr12:118430147~118430699:+
BRCA	cis	rs673078	0.66	rs58113338	ENSG00000275409.1	RP11-131L12.4	-5.77	1.05e-08	1.52e-06	-0.26	-0.18	Glucose homeostasis traits;	chr12:118251335	chr12:118430147~118430699:+
BRCA	cis	rs12468226	1	rs76021735	ENSG00000226261.1	AC064836.3	5.77	1.05e-08	1.52e-06	0.31	0.18	Urate levels;	chr2:202511476	chr2:202336024~202336727:-
BRCA	cis	rs2253762	0.507	rs10159998	ENSG00000276742.1	RP11-500G22.4	5.77	1.05e-08	1.52e-06	0.3	0.18	Breast cancer;	chr10:121994550	chr10:121956782~121957098:+
BRCA	cis	rs2253762	0.54	rs11200311	ENSG00000276742.1	RP11-500G22.4	5.77	1.05e-08	1.52e-06	0.3	0.18	Breast cancer;	chr10:121995094	chr10:121956782~121957098:+
BRCA	cis	rs2253762	0.54	rs79069897	ENSG00000276742.1	RP11-500G22.4	5.77	1.05e-08	1.52e-06	0.3	0.18	Breast cancer;	chr10:121995680	chr10:121956782~121957098:+
BRCA	cis	rs4819052	0.632	rs4819050	ENSG00000184274.3	LINC00315	-5.77	1.05e-08	1.52e-06	-0.23	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45273028	chr21:45300245~45305257:-
BRCA	cis	rs4950322	0.57	rs80070044	ENSG00000244371.2	PFN1P8	-5.77	1.05e-08	1.52e-06	-0.25	-0.18	Protein quantitative trait loci;	chr1:147330238	chr1:146957117~146957659:-
BRCA	cis	rs2243480	0.803	rs423187	ENSG00000164669.11	INTS4P1	5.77	1.05e-08	1.52e-06	0.35	0.18	Diabetic kidney disease;	chr7:66044512	chr7:65141225~65234216:+
BRCA	cis	rs7107356	1	rs7107356	ENSG00000280615.1	Y_RNA	5.77	1.05e-08	1.52e-06	0.2	0.18	Neuroticism (multi-trait analysis);Neuroticism;	chr11:47654618	chr11:47614898~47614994:-
BRCA	cis	rs2243480	1	rs313831	ENSG00000164669.11	INTS4P1	5.77	1.05e-08	1.52e-06	0.36	0.18	Diabetic kidney disease;	chr7:66086239	chr7:65141225~65234216:+
BRCA	cis	rs600231	0.651	rs2846862	ENSG00000173727.10	CMB9-22P13.1	5.77	1.05e-08	1.52e-06	0.23	0.18	Bone mineral density;	chr11:65452319	chr11:65455258~65466720:+
BRCA	cis	rs300890	0.513	rs72719160	ENSG00000250326.1	RP11-284M14.1	5.77	1.05e-08	1.52e-06	0.21	0.18	Nasopharyngeal carcinoma;	chr4:143130123	chr4:142933195~143184861:-
BRCA	cis	rs9308731	0.591	rs60982612	ENSG00000227992.1	AC108463.2	-5.77	1.05e-08	1.52e-06	-0.2	-0.18	Chronic lymphocytic leukemia;	chr2:111183362	chr2:111203964~111206215:-
BRCA	cis	rs12468226	1	rs57080353	ENSG00000226261.1	AC064836.3	5.77	1.05e-08	1.52e-06	0.31	0.18	Urate levels;	chr2:202511824	chr2:202336024~202336727:-
BRCA	cis	rs12468226	0.81	rs3736578	ENSG00000226261.1	AC064836.3	5.77	1.05e-08	1.52e-06	0.31	0.18	Urate levels;	chr2:202519989	chr2:202336024~202336727:-
BRCA	cis	rs12468226	1	rs116439150	ENSG00000226261.1	AC064836.3	5.77	1.05e-08	1.52e-06	0.31	0.18	Urate levels;	chr2:202523814	chr2:202336024~202336727:-
BRCA	cis	rs12468226	1	rs12467409	ENSG00000226261.1	AC064836.3	5.77	1.05e-08	1.52e-06	0.31	0.18	Urate levels;	chr2:202529625	chr2:202336024~202336727:-
BRCA	cis	rs4713118	0.662	rs156744	ENSG00000204709.4	LINC01556	5.77	1.05e-08	1.52e-06	0.26	0.18	Parkinson's disease;	chr6:27999496	chr6:28943877~28944537:+
BRCA	cis	rs4713118	0.662	rs149947	ENSG00000204709.4	LINC01556	5.77	1.05e-08	1.52e-06	0.26	0.18	Parkinson's disease;	chr6:28004655	chr6:28943877~28944537:+
BRCA	cis	rs12468226	0.872	rs115187557	ENSG00000226261.1	AC064836.3	5.77	1.05e-08	1.53e-06	0.3	0.18	Urate levels;	chr2:202495351	chr2:202336024~202336727:-
BRCA	cis	rs853679	0.607	rs71559070	ENSG00000220721.1	OR1F12	5.77	1.05e-08	1.53e-06	0.43	0.18	Depression;	chr6:28071151	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.607	rs35902873	ENSG00000220721.1	OR1F12	5.77	1.05e-08	1.53e-06	0.43	0.18	Depression;	chr6:28091171	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.607	rs13197574	ENSG00000220721.1	OR1F12	5.77	1.05e-08	1.53e-06	0.43	0.18	Depression;	chr6:28092461	chr6:28073316~28074233:+
BRCA	cis	rs10740039	0.516	rs1009410	ENSG00000254271.1	RP11-131N11.4	5.77	1.05e-08	1.53e-06	0.23	0.18	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60595039	chr10:60734342~60741828:+
BRCA	cis	rs10129255	0.826	rs7150693	ENSG00000224373.3	IGHV4-59	5.77	1.06e-08	1.53e-06	0.12	0.18	Kawasaki disease;	chr14:106705382	chr14:106627249~106627825:-
BRCA	cis	rs10129255	0.869	rs7150549	ENSG00000224373.3	IGHV4-59	5.77	1.06e-08	1.53e-06	0.12	0.18	Kawasaki disease;	chr14:106705441	chr14:106627249~106627825:-
BRCA	cis	rs7777677	0.925	rs6956269	ENSG00000211750.2	TRBV24-1	-5.77	1.06e-08	1.53e-06	-0.16	-0.18	Alcoholic chronic pancreatitis;	chr7:142661303	chr7:142656701~142657213:+
BRCA	cis	rs11668609	1	rs10412517	ENSG00000268442.1	CTD-2027I19.2	5.77	1.06e-08	1.53e-06	0.24	0.18	Response to taxane treatment (docetaxel);	chr19:24119111	chr19:24162370~24163425:-
BRCA	cis	rs17301013	0.507	rs2860954	ENSG00000227373.4	RP11-160H22.5	5.77	1.06e-08	1.53e-06	0.26	0.18	Systemic lupus erythematosus;	chr1:174344313	chr1:174115300~174160004:-
BRCA	cis	rs17301013	0.507	rs60864659	ENSG00000227373.4	RP11-160H22.5	5.77	1.06e-08	1.53e-06	0.26	0.18	Systemic lupus erythematosus;	chr1:174344641	chr1:174115300~174160004:-
BRCA	cis	rs9467773	1	rs12526680	ENSG00000124549.13	BTN2A3P	5.77	1.06e-08	1.53e-06	0.18	0.18	Intelligence (multi-trait analysis);	chr6:26550726	chr6:26421391~26432383:+
BRCA	cis	rs10888838	0.756	rs11206307	ENSG00000198711.5	SSBP3-AS1	5.77	1.06e-08	1.53e-06	0.25	0.18	Mitochondrial DNA levels;	chr1:54224289	chr1:54236440~54239063:+
BRCA	cis	rs7618501	0.572	rs4688756	ENSG00000228008.1	CTD-2330K9.3	5.77	1.06e-08	1.53e-06	0.17	0.18	Intelligence (multi-trait analysis);	chr3:50002761	chr3:49903845~49916937:+
BRCA	cis	rs721917	0.525	rs1054053	ENSG00000244733.5	RP11-506M13.3	-5.77	1.06e-08	1.53e-06	-0.21	-0.18	Chronic obstructive pulmonary disease;	chr10:79922889	chr10:79660891~79677996:+
BRCA	cis	rs2243480	0.901	rs2456483	ENSG00000232559.3	GS1-124K5.12	5.77	1.06e-08	1.53e-06	0.33	0.18	Diabetic kidney disease;	chr7:65996588	chr7:66554588~66576923:-
BRCA	cis	rs2243480	1	rs1701750	ENSG00000232559.3	GS1-124K5.12	5.77	1.06e-08	1.53e-06	0.33	0.18	Diabetic kidney disease;	chr7:66002158	chr7:66554588~66576923:-
BRCA	cis	rs2243480	1	rs313807	ENSG00000232559.3	GS1-124K5.12	5.77	1.06e-08	1.53e-06	0.33	0.18	Diabetic kidney disease;	chr7:66034494	chr7:66554588~66576923:-
BRCA	cis	rs6840360	1	rs6840678	ENSG00000270265.1	RP11-731D1.4	5.77	1.06e-08	1.53e-06	0.2	0.18	Intelligence (multi-trait analysis);	chr4:151683179	chr4:151333775~151353224:-
BRCA	cis	rs4604234	0.522	rs73479968	ENSG00000272129.1	RP11-250B2.6	-5.77	1.06e-08	1.53e-06	-0.45	-0.18	Cancer;	chr6:80190753	chr6:80355424~80356859:+
BRCA	cis	rs35934224	0.891	rs12158214	ENSG00000232926.1	AC000078.5	5.77	1.06e-08	1.53e-06	0.22	0.18	Glaucoma (primary open-angle);	chr22:19884168	chr22:19887289~19887970:+
BRCA	cis	rs7809950	0.678	rs2237661	ENSG00000238832.1	snoU109	-5.77	1.06e-08	1.53e-06	-0.26	-0.18	Coronary artery disease;	chr7:107222678	chr7:107603363~107603507:+
BRCA	cis	rs6088580	0.524	rs6088570	ENSG00000269202.1	RP4-614O4.12	5.77	1.06e-08	1.53e-06	0.18	0.18	Glomerular filtration rate (creatinine);	chr20:34680491	chr20:35201747~35203288:-
BRCA	cis	rs16846053	0.71	rs6755071	ENSG00000227403.1	AC009299.3	5.77	1.06e-08	1.54e-06	0.29	0.18	Blood osmolality (transformed sodium);	chr2:161748720	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.71	rs973940	ENSG00000227403.1	AC009299.3	5.77	1.06e-08	1.54e-06	0.29	0.18	Blood osmolality (transformed sodium);	chr2:161750890	chr2:161244739~161249050:+
BRCA	cis	rs17826219	0.561	rs4794869	ENSG00000263531.1	RP13-753N3.1	5.77	1.06e-08	1.54e-06	0.5	0.18	Body mass index;	chr17:30364082	chr17:30863921~30864940:-
BRCA	cis	rs4662750	0.527	rs10164978	ENSG00000236682.1	AC068282.3	5.77	1.06e-08	1.54e-06	0.24	0.18	Renal cell carcinoma;	chr2:127627649	chr2:127389130~127400580:+
BRCA	cis	rs651907	0.535	rs36060163	ENSG00000244119.1	PDCL3P4	5.77	1.06e-08	1.54e-06	0.14	0.18	Colorectal cancer;	chr3:101642119	chr3:101712472~101713191:+
BRCA	cis	rs2274273	1	rs15870	ENSG00000258413.1	RP11-665C16.6	-5.77	1.06e-08	1.54e-06	-0.22	-0.18	Protein biomarker;	chr14:55152593	chr14:55262767~55272075:-
BRCA	cis	rs12073837	0.5	rs4143772	ENSG00000238078.1	LINC01352	-5.77	1.06e-08	1.54e-06	-0.18	-0.18	F-cell distribution;	chr1:220815004	chr1:220829255~220832429:+
BRCA	cis	rs2243480	1	rs1701758	ENSG00000232546.1	RP11-458F8.1	-5.77	1.06e-08	1.54e-06	-0.23	-0.18	Diabetic kidney disease;	chr7:66005214	chr7:66848496~66858136:+
BRCA	cis	rs10129255	0.5	rs59939897	ENSG00000274576.2	IGHV2-70	-5.77	1.06e-08	1.54e-06	-0.14	-0.18	Kawasaki disease;	chr14:106783414	chr14:106770577~106771020:-
BRCA	cis	rs10510102	0.872	rs7916008	ENSG00000226864.1	ATE1-AS1	5.77	1.06e-08	1.54e-06	0.32	0.18	Breast cancer;	chr10:121943578	chr10:121928312~121951965:+
BRCA	cis	rs10510102	0.872	rs7916380	ENSG00000226864.1	ATE1-AS1	5.77	1.06e-08	1.54e-06	0.32	0.18	Breast cancer;	chr10:121943773	chr10:121928312~121951965:+
BRCA	cis	rs10510102	0.808	rs7920024	ENSG00000226864.1	ATE1-AS1	5.77	1.06e-08	1.54e-06	0.32	0.18	Breast cancer;	chr10:121944063	chr10:121928312~121951965:+
BRCA	cis	rs10740039	0.516	rs1348281	ENSG00000254271.1	RP11-131N11.4	-5.77	1.07e-08	1.54e-06	-0.23	-0.18	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60596475	chr10:60734342~60741828:+
BRCA	cis	rs6479891	0.722	rs4746951	ENSG00000232075.1	MRPL35P2	5.77	1.07e-08	1.54e-06	0.3	0.18	Arthritis (juvenile idiopathic);	chr10:63123839	chr10:63634317~63634827:-
BRCA	cis	rs6490294	0.571	rs6489824	ENSG00000226469.1	ADAM1B	5.77	1.07e-08	1.54e-06	0.28	0.18	Mean platelet volume;	chr12:112030613	chr12:111927018~111929017:+
BRCA	cis	rs2243480	1	rs781157	ENSG00000228409.4	CCT6P1	5.77	1.07e-08	1.54e-06	0.24	0.18	Diabetic kidney disease;	chr7:66013324	chr7:65751142~65763354:+
BRCA	cis	rs78487399	0.908	rs17031088	ENSG00000234936.1	AC010883.5	5.77	1.07e-08	1.54e-06	0.23	0.18	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43579951	chr2:43229573~43233394:+
BRCA	cis	rs559928	0.548	rs11231713	ENSG00000236935.1	AP003774.1	5.77	1.07e-08	1.55e-06	0.24	0.18	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64164377	chr11:64325050~64329504:-
BRCA	cis	rs673078	0.66	rs17512142	ENSG00000275409.1	RP11-131L12.4	-5.77	1.07e-08	1.55e-06	-0.29	-0.18	Glucose homeostasis traits;	chr12:118186186	chr12:118430147~118430699:+
BRCA	cis	rs13108904	0.875	rs3822017	ENSG00000254094.1	AC078852.1	-5.77	1.07e-08	1.55e-06	-0.19	-0.18	Obesity-related traits;	chr4:1242524	chr4:1356581~1358075:+
BRCA	cis	rs1559040	1	rs35641543	ENSG00000272156.1	RP11-477N3.1	-5.77	1.07e-08	1.55e-06	-0.29	-0.18	Sudden cardiac arrest;	chr2:54120176	chr2:54082554~54085066:+
BRCA	cis	rs1014246	0.848	rs11197798	ENSG00000232767.1	RP11-498B4.5	-5.77	1.07e-08	1.55e-06	-0.19	-0.18	Age at smoking initiation in chronic obstructive pulmonary disease;	chr10:116697766	chr10:116670103~116672739:+
BRCA	cis	rs4761470	0.577	rs3803070	ENSG00000258365.1	RP11-1105G2.3	-5.77	1.07e-08	1.55e-06	-0.22	-0.18	Estradiol plasma levels (breast cancer);	chr12:94294912	chr12:94277758~94282844:-
BRCA	cis	rs7789940	1	rs2072435	ENSG00000186704.9	DTX2P1	5.77	1.07e-08	1.55e-06	0.21	0.18	Multiple sclerosis;	chr7:76329871	chr7:76978617~77004308:+
BRCA	cis	rs7520050	0.872	rs1707308	ENSG00000280836.1	AL355480.1	5.77	1.07e-08	1.55e-06	0.21	0.18	Reticulocyte count;Red blood cell count;	chr1:46138643	chr1:45581219~45581321:-
BRCA	cis	rs7923609	0.936	rs10822160	ENSG00000232075.1	MRPL35P2	-5.77	1.07e-08	1.55e-06	-0.22	-0.18	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63353036	chr10:63634317~63634827:-
BRCA	cis	rs721917	0.506	rs2265961	ENSG00000244733.5	RP11-506M13.3	-5.77	1.07e-08	1.55e-06	-0.21	-0.18	Chronic obstructive pulmonary disease;	chr10:79886101	chr10:79660891~79677996:+
BRCA	cis	rs721917	0.506	rs7088752	ENSG00000244733.5	RP11-506M13.3	-5.77	1.07e-08	1.55e-06	-0.21	-0.18	Chronic obstructive pulmonary disease;	chr10:79886704	chr10:79660891~79677996:+
BRCA	cis	rs721917	0.506	rs7078242	ENSG00000244733.5	RP11-506M13.3	-5.77	1.07e-08	1.55e-06	-0.21	-0.18	Chronic obstructive pulmonary disease;	chr10:79886885	chr10:79660891~79677996:+
BRCA	cis	rs721917	0.525	rs2244001	ENSG00000244733.5	RP11-506M13.3	-5.77	1.07e-08	1.55e-06	-0.21	-0.18	Chronic obstructive pulmonary disease;	chr10:79888813	chr10:79660891~79677996:+
BRCA	cis	rs721917	0.506	rs1811886	ENSG00000244733.5	RP11-506M13.3	-5.77	1.07e-08	1.55e-06	-0.21	-0.18	Chronic obstructive pulmonary disease;	chr10:79889812	chr10:79660891~79677996:+
BRCA	cis	rs1707322	1	rs6661500	ENSG00000281133.1	AL355480.3	-5.77	1.07e-08	1.55e-06	-0.22	-0.18	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45999990	chr1:45580892~45580996:-
BRCA	cis	rs2243480	1	rs313832	ENSG00000164669.11	INTS4P1	5.77	1.07e-08	1.55e-06	0.36	0.18	Diabetic kidney disease;	chr7:66085904	chr7:65141225~65234216:+
BRCA	cis	rs42648	0.508	rs39201	ENSG00000225498.1	AC002064.5	-5.77	1.07e-08	1.55e-06	-0.17	-0.18	Homocysteine levels;	chr7:90104790	chr7:90312496~90322592:+
BRCA	cis	rs516805	0.667	rs2045352	ENSG00000279453.1	RP3-425C14.4	-5.77	1.07e-08	1.55e-06	-0.24	-0.18	Lymphocyte counts;	chr6:122119694	chr6:122436789~122439223:-
BRCA	cis	rs17508449	0.819	rs2146018	ENSG00000232450.1	RP4-730K3.3	-5.77	1.07e-08	1.55e-06	-0.32	-0.18	Leprosy;	chr1:113652708	chr1:113698884~113699631:-
BRCA	cis	rs4908768	0.501	rs7551849	ENSG00000270282.1	RP5-1115A15.2	5.77	1.07e-08	1.55e-06	0.19	0.18	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8479403	chr1:8512653~8513021:+
BRCA	cis	rs10510102	0.872	rs11814703	ENSG00000226864.1	ATE1-AS1	5.77	1.07e-08	1.55e-06	0.33	0.18	Breast cancer;	chr10:121964774	chr10:121928312~121951965:+
BRCA	cis	rs7608910	0.668	rs6754585	ENSG00000271889.1	RP11-493E12.1	5.77	1.07e-08	1.55e-06	0.22	0.18	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;	chr2:60995008	chr2:61151433~61162105:-
BRCA	cis	rs2243480	1	rs34703416	ENSG00000228409.4	CCT6P1	5.77	1.07e-08	1.55e-06	0.24	0.18	Diabetic kidney disease;	chr7:65835655	chr7:65751142~65763354:+
BRCA	cis	rs4718428	0.672	rs4718412	ENSG00000230295.1	RP11-458F8.2	5.77	1.07e-08	1.55e-06	0.16	0.18	Corneal structure;	chr7:66821880	chr7:66880708~66882981:+
BRCA	cis	rs11009175	1	rs10827169	ENSG00000273038.2	RP11-479G22.8	-5.77	1.07e-08	1.55e-06	-0.3	-0.18	Depression (quantitative trait);	chr10:32999502	chr10:32887255~32889311:-
BRCA	cis	rs2179367	0.613	rs62426122	ENSG00000216906.2	RP11-350J20.9	5.77	1.07e-08	1.55e-06	0.24	0.18	Dupuytren's disease;	chr6:149427449	chr6:149904243~149906418:+
BRCA	cis	rs2115536	0.692	rs6495450	ENSG00000278600.1	RP11-81A1.6	-5.77	1.07e-08	1.55e-06	-0.15	-0.18	Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Eosinophil counts;Neutrophil percentage of granulocytes;	chr15:79870157	chr15:79920195~79922455:-
BRCA	cis	rs950169	0.579	rs62027818	ENSG00000259728.4	LINC00933	5.77	1.07e-08	1.56e-06	0.26	0.18	Schizophrenia;	chr15:83992393	chr15:84570649~84580175:+
BRCA	cis	rs11976180	1	rs2371247	ENSG00000273234.1	OR2A13P	-5.77	1.07e-08	1.56e-06	-0.24	-0.18	Obesity-related traits;	chr7:144067086	chr7:144142009~144142938:+
BRCA	cis	rs442309	0.687	rs11599754	ENSG00000238280.1	RP11-436D10.3	-5.76	1.08e-08	1.56e-06	-0.24	-0.18	Vogt-Koyanagi-Harada syndrome;	chr10:62706891	chr10:62793562~62805887:-
BRCA	cis	rs295490	0.748	rs77869711	ENSG00000272656.1	RP11-219D15.3	5.76	1.08e-08	1.56e-06	0.42	0.18	PR interval in Tripanosoma cruzi seropositivity;	chr3:139348416	chr3:139349024~139349371:-
BRCA	cis	rs8031584	0.697	rs8036176	ENSG00000259845.1	HERC2P10	5.76	1.08e-08	1.56e-06	0.21	0.18	Huntington's disease progression;	chr15:30883066	chr15:30815271~30844153:+
BRCA	cis	rs9847710	0.967	rs2564934	ENSG00000242142.1	SERBP1P3	5.76	1.08e-08	1.56e-06	0.2	0.18	Ulcerative colitis;	chr3:52990564	chr3:53064283~53065091:-
BRCA	cis	rs1552244	0.816	rs13059144	ENSG00000232901.1	CYCSP10	5.76	1.08e-08	1.56e-06	0.24	0.18	Alzheimer's disease;	chr3:9968513	chr3:10000647~10000940:-
BRCA	cis	rs72615157	0.539	rs12673441	ENSG00000214313.7	AZGP1P1	-5.76	1.08e-08	1.56e-06	-0.19	-0.18	Lung function (FEV1/FVC);	chr7:100072705	chr7:99980762~99987535:+
BRCA	cis	rs2836950	0.565	rs2150413	ENSG00000255568.3	BRWD1-AS2	-5.76	1.08e-08	1.56e-06	-0.17	-0.18	Menarche (age at onset);	chr21:39242952	chr21:39313935~39314962:+
BRCA	cis	rs7567389	0.671	rs72845993	ENSG00000236682.1	AC068282.3	-5.76	1.08e-08	1.56e-06	-0.26	-0.18	Self-rated health;	chr2:127351025	chr2:127389130~127400580:+
BRCA	cis	rs4927850	0.881	rs7624638	ENSG00000207650.1	MIR570	5.76	1.08e-08	1.56e-06	0.21	0.18	Pancreatic cancer;	chr3:196021858	chr3:195699401~195699497:+
BRCA	cis	rs6547705	0.858	rs6750263	ENSG00000231259.4	AC125232.1	-5.76	1.08e-08	1.56e-06	-0.27	-0.18	Progressive supranuclear palsy;	chr2:86766405	chr2:87031815~87053069:-
BRCA	cis	rs1979679	0.842	rs11049380	ENSG00000278733.1	RP11-425D17.1	5.76	1.08e-08	1.56e-06	0.22	0.18	Ossification of the posterior longitudinal ligament of the spine;	chr12:28160904	chr12:28185625~28186190:-
BRCA	cis	rs1979679	0.842	rs2035271	ENSG00000278733.1	RP11-425D17.1	5.76	1.08e-08	1.56e-06	0.22	0.18	Ossification of the posterior longitudinal ligament of the spine;	chr12:28165638	chr12:28185625~28186190:-
BRCA	cis	rs11098499	0.604	rs10022185	ENSG00000249244.1	RP11-548H18.2	5.76	1.08e-08	1.57e-06	0.22	0.18	Corneal astigmatism;	chr4:119650610	chr4:119391831~119395335:-
BRCA	cis	rs4218	0.543	rs4775110	ENSG00000277144.1	RP11-59H7.4	-5.76	1.08e-08	1.57e-06	-0.21	-0.18	Social communication problems;	chr15:59023685	chr15:59115547~59116089:-
BRCA	cis	rs7587476	1	rs1542173	ENSG00000229267.2	AC072062.1	5.76	1.08e-08	1.57e-06	0.24	0.18	Neuroblastoma;	chr2:214792836	chr2:214810229~214963274:+
BRCA	cis	rs2243480	1	rs781142	ENSG00000230295.1	RP11-458F8.2	-5.76	1.08e-08	1.57e-06	-0.23	-0.18	Diabetic kidney disease;	chr7:65973791	chr7:66880708~66882981:+
BRCA	cis	rs34792	0.554	rs4597346	ENSG00000207425.1	Y_RNA	-5.76	1.08e-08	1.57e-06	-0.22	-0.18	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15529889	chr16:14915457~14915556:-
BRCA	cis	rs9287719	0.649	rs10929684	ENSG00000243819.4	RN7SL832P	-5.76	1.08e-08	1.57e-06	-0.18	-0.18	Prostate cancer;	chr2:10592098	chr2:10690344~10692099:+
BRCA	cis	rs754466	0.606	rs11002309	ENSG00000204049.1	RP11-126H7.4	5.76	1.08e-08	1.57e-06	0.21	0.18	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77835173	chr10:77866875~77869610:+
BRCA	cis	rs67981189	0.519	rs2526879	ENSG00000258571.1	PTTG4P	5.76	1.08e-08	1.57e-06	0.21	0.18	Schizophrenia;	chr14:70910501	chr14:71085482~71085833:-
BRCA	cis	rs2274273	1	rs3825613	ENSG00000258413.1	RP11-665C16.6	-5.76	1.08e-08	1.57e-06	-0.22	-0.18	Protein biomarker;	chr14:55126454	chr14:55262767~55272075:-
BRCA	cis	rs7615952	0.515	rs4267608	ENSG00000171084.14	FAM86JP	5.76	1.08e-08	1.57e-06	0.27	0.18	Blood pressure (smoking interaction);	chr3:125961657	chr3:125916620~125930024:+
BRCA	cis	rs6547705	0.858	rs2271666	ENSG00000231259.4	AC125232.1	-5.76	1.09e-08	1.57e-06	-0.27	-0.18	Progressive supranuclear palsy;	chr2:86770425	chr2:87031815~87053069:-
BRCA	cis	rs875971	0.545	rs4718325	ENSG00000228409.4	CCT6P1	-5.76	1.09e-08	1.57e-06	-0.18	-0.18	Aortic root size;	chr7:66215323	chr7:65751142~65763354:+
BRCA	cis	rs875971	0.545	rs7811204	ENSG00000228409.4	CCT6P1	-5.76	1.09e-08	1.57e-06	-0.18	-0.18	Aortic root size;	chr7:66387213	chr7:65751142~65763354:+
BRCA	cis	rs3213958	0.574	rs11914715	ENSG00000249274.1	PDLIM1P4	-5.76	1.09e-08	1.57e-06	-0.27	-0.18	Blood protein levels;	chr3:98780118	chr3:98782188~98783193:+
BRCA	cis	rs4218	0.871	rs2414621	ENSG00000277144.1	RP11-59H7.4	-5.76	1.09e-08	1.57e-06	-0.23	-0.18	Social communication problems;	chr15:59142129	chr15:59115547~59116089:-
BRCA	cis	rs3733585	0.699	rs28610447	ENSG00000250413.1	RP11-448G15.1	5.76	1.09e-08	1.57e-06	0.23	0.18	Cleft plate (environmental tobacco smoke interaction);	chr4:9969893	chr4:10006482~10009725:+
BRCA	cis	rs3733585	0.624	rs58130873	ENSG00000250413.1	RP11-448G15.1	5.76	1.09e-08	1.57e-06	0.23	0.18	Cleft plate (environmental tobacco smoke interaction);	chr4:9970457	chr4:10006482~10009725:+
BRCA	cis	rs910316	0.789	rs175444	ENSG00000279594.1	RP11-950C14.10	-5.76	1.09e-08	1.57e-06	-0.19	-0.18	Height;	chr14:75135079	chr14:75011269~75012851:-
BRCA	cis	rs7976269	0.609	rs7979788	ENSG00000275476.1	RP11-996F15.4	-5.76	1.09e-08	1.57e-06	-0.2	-0.18	Male-pattern baldness;	chr12:29064827	chr12:29277397~29277882:-
BRCA	cis	rs559928	0.606	rs11605856	ENSG00000236935.1	AP003774.1	5.76	1.09e-08	1.57e-06	0.24	0.18	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64158056	chr11:64325050~64329504:-
BRCA	cis	rs559928	0.606	rs11231710	ENSG00000236935.1	AP003774.1	5.76	1.09e-08	1.57e-06	0.24	0.18	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64158271	chr11:64325050~64329504:-
BRCA	cis	rs12468226	0.81	rs77090459	ENSG00000226261.1	AC064836.3	5.76	1.09e-08	1.58e-06	0.31	0.18	Urate levels;	chr2:202542132	chr2:202336024~202336727:-
BRCA	cis	rs2153535	0.585	rs9406188	ENSG00000230939.1	RP11-314C16.1	-5.76	1.09e-08	1.58e-06	-0.2	-0.18	Motion sickness;	chr6:8667604	chr6:8784178~8785445:+
BRCA	cis	rs7927771	0.524	rs3758655	ENSG00000280615.1	Y_RNA	5.76	1.09e-08	1.58e-06	0.21	0.18	Subjective well-being;	chr11:47682391	chr11:47614898~47614994:-
BRCA	cis	rs7927771	0.524	rs7936948	ENSG00000280615.1	Y_RNA	5.76	1.09e-08	1.58e-06	0.21	0.18	Subjective well-being;	chr11:47682648	chr11:47614898~47614994:-
BRCA	cis	rs7927771	0.524	rs10838746	ENSG00000280615.1	Y_RNA	5.76	1.09e-08	1.58e-06	0.21	0.18	Subjective well-being;	chr11:47684739	chr11:47614898~47614994:-
BRCA	cis	rs7124681	0.584	rs10769285	ENSG00000280615.1	Y_RNA	5.76	1.09e-08	1.58e-06	0.21	0.18	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:47687660	chr11:47614898~47614994:-
BRCA	cis	rs2638953	0.853	rs3911810	ENSG00000278733.1	RP11-425D17.1	-5.76	1.09e-08	1.58e-06	-0.23	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28461669	chr12:28185625~28186190:-
BRCA	cis	rs3930017	1	rs7783809	ENSG00000225726.1	AC007000.10	-5.76	1.09e-08	1.58e-06	-0.2	-0.18	Body mass index;	chr7:77090234	chr7:77071751~77072237:-
BRCA	cis	rs12681366	0.801	rs6981551	ENSG00000253704.1	RP11-267M23.4	5.76	1.09e-08	1.58e-06	0.2	0.18	Nonsyndromic cleft lip with cleft palate;	chr8:94466421	chr8:94553722~94569745:+
BRCA	cis	rs17772222	0.682	rs28371093	ENSG00000258789.1	RP11-507K2.3	-5.76	1.09e-08	1.58e-06	-0.19	-0.18	Coronary artery calcification;	chr14:88486112	chr14:88551597~88552493:+
BRCA	cis	rs2281636	0.898	rs7903514	ENSG00000233690.1	EBAG9P1	5.76	1.09e-08	1.58e-06	0.18	0.18	Obesity-related traits;	chr10:99705951	chr10:99697407~99697949:-
BRCA	cis	rs7246967	0.611	rs62120457	ENSG00000198153.8	ZNF849P	-5.76	1.09e-08	1.58e-06	-0.26	-0.18	Bronchopulmonary dysplasia;	chr19:22775717	chr19:22685167~22686732:+
BRCA	cis	rs4578769	0.788	rs12962334	ENSG00000265939.1	UBE2CP2	5.76	1.09e-08	1.58e-06	0.19	0.18	Eosinophil percentage of white cells;	chr18:22897971	chr18:22900486~22900995:-
BRCA	cis	rs2688608	0.869	rs2250140	ENSG00000271816.1	BMS1P4	5.76	1.09e-08	1.58e-06	0.17	0.18	Inflammatory bowel disease;	chr10:73853123	chr10:73699151~73730487:-
BRCA	cis	rs2638953	0.853	rs11049666	ENSG00000278733.1	RP11-425D17.1	-5.76	1.09e-08	1.58e-06	-0.24	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28496138	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.853	rs11049667	ENSG00000278733.1	RP11-425D17.1	-5.76	1.09e-08	1.58e-06	-0.24	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28496942	chr12:28185625~28186190:-
BRCA	cis	rs4713118	0.621	rs10484403	ENSG00000280107.1	AL022393.9	-5.76	1.09e-08	1.58e-06	-0.26	-0.18	Parkinson's disease;	chr6:28065745	chr6:28170845~28172521:+
BRCA	cis	rs1440410	0.835	rs13121583	ENSG00000250326.1	RP11-284M14.1	-5.76	1.1e-08	1.58e-06	-0.19	-0.18	Ischemic stroke;	chr4:143149432	chr4:142933195~143184861:-
BRCA	cis	rs8098244	0.683	rs4334381	ENSG00000264745.1	TTC39C-AS1	5.76	1.1e-08	1.58e-06	0.21	0.18	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23852485	chr18:23994213~24015339:-
BRCA	cis	rs6088580	0.505	rs6141503	ENSG00000269202.1	RP4-614O4.12	5.76	1.1e-08	1.59e-06	0.18	0.18	Glomerular filtration rate (creatinine);	chr20:34686665	chr20:35201747~35203288:-
BRCA	cis	rs4834770	1	rs4336213	ENSG00000248280.1	RP11-33B1.2	5.76	1.1e-08	1.59e-06	0.17	0.18	Blood protein levels;	chr4:119315314	chr4:119440561~119450157:-
BRCA	cis	rs13108904	0.901	rs6826029	ENSG00000254094.1	AC078852.1	-5.76	1.1e-08	1.59e-06	-0.19	-0.18	Obesity-related traits;	chr4:1313901	chr4:1356581~1358075:+
BRCA	cis	rs1707322	0.721	rs6429574	ENSG00000234329.1	RP11-767N6.2	5.76	1.1e-08	1.59e-06	0.18	0.18	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45668382	chr1:45651039~45651826:-
BRCA	cis	rs7927771	0.524	rs7939420	ENSG00000280615.1	Y_RNA	-5.76	1.1e-08	1.59e-06	-0.2	-0.18	Subjective well-being;	chr11:47702386	chr11:47614898~47614994:-
BRCA	cis	rs4664293	0.51	rs12469374	ENSG00000226266.5	AC009961.3	5.76	1.1e-08	1.59e-06	0.22	0.18	Monocyte percentage of white cells;	chr2:159720393	chr2:159670708~159712435:-
BRCA	cis	rs6840360	0.901	rs1561915	ENSG00000270265.1	RP11-731D1.4	-5.76	1.1e-08	1.59e-06	-0.19	-0.18	Intelligence (multi-trait analysis);	chr4:151558572	chr4:151333775~151353224:-
BRCA	cis	rs4835473	0.897	rs7662736	ENSG00000249741.2	RP11-673E1.3	-5.76	1.1e-08	1.59e-06	-0.18	-0.18	Immature fraction of reticulocytes;	chr4:143958036	chr4:143911514~143912053:-
BRCA	cis	rs2638953	0.925	rs17432330	ENSG00000278733.1	RP11-425D17.1	-5.76	1.1e-08	1.59e-06	-0.24	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28292336	chr12:28185625~28186190:-
BRCA	cis	rs7923609	0.905	rs7092784	ENSG00000232075.1	MRPL35P2	-5.76	1.1e-08	1.59e-06	-0.22	-0.18	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63454989	chr10:63634317~63634827:-
BRCA	cis	rs9992667	0.704	rs3900761	ENSG00000231160.8	KLF3-AS1	-5.76	1.1e-08	1.59e-06	-0.26	-0.18	Eosinophil percentage of granulocytes;	chr4:38609961	chr4:38612701~38664883:-
BRCA	cis	rs8114671	0.562	rs6088621	ENSG00000269202.1	RP4-614O4.12	-5.76	1.1e-08	1.59e-06	-0.18	-0.18	Height;	chr20:34830937	chr20:35201747~35203288:-
BRCA	cis	rs6565180	0.963	rs4787642	ENSG00000183604.13	SMG1P5	-5.76	1.1e-08	1.59e-06	-0.18	-0.18	Tonsillectomy;	chr16:30348087	chr16:30267553~30335374:-
BRCA	cis	rs2638953	0.924	rs11049613	ENSG00000278733.1	RP11-425D17.1	-5.76	1.1e-08	1.6e-06	-0.24	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28449859	chr12:28185625~28186190:-
BRCA	cis	rs11976180	1	rs2951353	ENSG00000273234.1	OR2A13P	-5.76	1.11e-08	1.6e-06	-0.24	-0.18	Obesity-related traits;	chr7:144064023	chr7:144142009~144142938:+
BRCA	cis	rs6088813	1	rs4911494	ENSG00000126005.14	MMP24-AS1	5.76	1.11e-08	1.6e-06	0.21	0.18	Height;	chr20:35384111	chr20:35216462~35278131:-
BRCA	cis	rs6088813	0.767	rs4911179	ENSG00000126005.14	MMP24-AS1	5.76	1.11e-08	1.6e-06	0.21	0.18	Height;	chr20:35385096	chr20:35216462~35278131:-
BRCA	cis	rs6088813	1	rs6142370	ENSG00000126005.14	MMP24-AS1	5.76	1.11e-08	1.6e-06	0.21	0.18	Height;	chr20:35385575	chr20:35216462~35278131:-
BRCA	cis	rs6088813	1	rs6141549	ENSG00000126005.14	MMP24-AS1	5.76	1.11e-08	1.6e-06	0.21	0.18	Height;	chr20:35386248	chr20:35216462~35278131:-
BRCA	cis	rs6088813	1	rs6088812	ENSG00000126005.14	MMP24-AS1	5.76	1.11e-08	1.6e-06	0.21	0.18	Height;	chr20:35386360	chr20:35216462~35278131:-
BRCA	cis	rs6088813	1	rs6088813	ENSG00000126005.14	MMP24-AS1	5.76	1.11e-08	1.6e-06	0.21	0.18	Height;	chr20:35387378	chr20:35216462~35278131:-
BRCA	cis	rs9527	0.83	rs12249194	ENSG00000213061.2	PFN1P11	5.76	1.11e-08	1.6e-06	0.25	0.18	Arsenic metabolism;	chr10:102883941	chr10:102838011~102845473:-
BRCA	cis	rs7777677	0.925	rs4726547	ENSG00000211750.2	TRBV24-1	-5.76	1.11e-08	1.6e-06	-0.16	-0.18	Alcoholic chronic pancreatitis;	chr7:142662750	chr7:142656701~142657213:+
BRCA	cis	rs2803122	0.871	rs3802333	ENSG00000273226.1	RP11-513M16.8	-5.76	1.11e-08	1.6e-06	-0.19	-0.18	Pulse pressure;	chr9:19232137	chr9:19375451~19375996:+
BRCA	cis	rs1979679	0.842	rs60025108	ENSG00000278733.1	RP11-425D17.1	5.76	1.11e-08	1.6e-06	0.22	0.18	Ossification of the posterior longitudinal ligament of the spine;	chr12:28168238	chr12:28185625~28186190:-
BRCA	cis	rs1979679	0.842	rs7487773	ENSG00000278733.1	RP11-425D17.1	5.76	1.11e-08	1.6e-06	0.22	0.18	Ossification of the posterior longitudinal ligament of the spine;	chr12:28168418	chr12:28185625~28186190:-
BRCA	cis	rs62025270	0.632	rs111906684	ENSG00000202081.1	RNU6-1280P	-5.76	1.11e-08	1.6e-06	-0.26	-0.18	Idiopathic pulmonary fibrosis;	chr15:85678705	chr15:85651522~85651628:-
BRCA	cis	rs7178375	1	rs12907055	ENSG00000270055.1	CTD-3092A11.2	-5.76	1.11e-08	1.6e-06	-0.25	-0.18	Hypertriglyceridemia;	chr15:30912091	chr15:30487963~30490313:+
BRCA	cis	rs7923609	0.902	rs7897379	ENSG00000232075.1	MRPL35P2	-5.76	1.11e-08	1.6e-06	-0.22	-0.18	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63541965	chr10:63634317~63634827:-
BRCA	cis	rs35612822	0.823	rs1983219	ENSG00000232485.2	AC098820.3	-5.76	1.11e-08	1.6e-06	-0.23	-0.18	Kidney disease (early stage) in type 1 diabetes;	chr2:216471861	chr2:216479030~216498761:-
BRCA	cis	rs2688608	0.868	rs2688625	ENSG00000271816.1	BMS1P4	5.76	1.11e-08	1.6e-06	0.17	0.18	Inflammatory bowel disease;	chr10:73871790	chr10:73699151~73730487:-
BRCA	cis	rs2688608	0.901	rs2633312	ENSG00000271816.1	BMS1P4	5.76	1.11e-08	1.6e-06	0.17	0.18	Inflammatory bowel disease;	chr10:73871997	chr10:73699151~73730487:-
BRCA	cis	rs250585	0.736	rs250581	ENSG00000260136.4	CTD-2270L9.4	5.76	1.11e-08	1.6e-06	0.17	0.18	Egg allergy;	chr16:23400516	chr16:23452758~23457606:+
BRCA	cis	rs516805	0.667	rs7771090	ENSG00000279453.1	RP3-425C14.4	-5.76	1.11e-08	1.6e-06	-0.24	-0.18	Lymphocyte counts;	chr6:122339732	chr6:122436789~122439223:-
BRCA	cis	rs2153535	0.585	rs4960448	ENSG00000230939.1	RP11-314C16.1	-5.76	1.11e-08	1.6e-06	-0.2	-0.18	Motion sickness;	chr6:8624438	chr6:8784178~8785445:+
BRCA	cis	rs7044106	0.762	rs7024046	ENSG00000238181.2	AHCYP2	-5.76	1.11e-08	1.6e-06	-0.23	-0.18	Hip circumference adjusted for BMI;	chr9:120656900	chr9:120720673~120721972:+
BRCA	cis	rs2562456	0.724	rs58001930	ENSG00000268081.1	RP11-678G14.2	5.76	1.11e-08	1.61e-06	0.27	0.18	Pain;	chr19:21560061	chr19:21554640~21569237:-
BRCA	cis	rs9868809	0.505	rs28793701	ENSG00000270441.1	RP11-694I15.7	5.76	1.11e-08	1.61e-06	0.32	0.18	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48725250	chr3:49140086~49160851:-
BRCA	cis	rs2243480	1	rs4149468	ENSG00000228409.4	CCT6P1	5.76	1.11e-08	1.61e-06	0.25	0.18	Diabetic kidney disease;	chr7:66360703	chr7:65751142~65763354:+
BRCA	cis	rs4713118	0.629	rs203888	ENSG00000204709.4	LINC01556	5.76	1.11e-08	1.61e-06	0.25	0.18	Parkinson's disease;	chr6:28053811	chr6:28943877~28944537:+
BRCA	cis	rs8002861	0.84	rs7989353	ENSG00000274001.1	RP11-5G9.5	5.76	1.11e-08	1.61e-06	0.2	0.18	Leprosy;	chr13:43864821	chr13:43877715~43878163:-
BRCA	cis	rs11105298	0.891	rs11105316	ENSG00000270344.2	RP11-734K2.4	5.76	1.11e-08	1.61e-06	0.2	0.18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89531423	chr12:89525654~89548005:+
BRCA	cis	rs875971	0.545	rs73142265	ENSG00000228409.4	CCT6P1	-5.76	1.11e-08	1.61e-06	-0.18	-0.18	Aortic root size;	chr7:66234510	chr7:65751142~65763354:+
BRCA	cis	rs793571	0.554	rs12439231	ENSG00000259250.1	RP11-50C13.1	-5.76	1.11e-08	1.61e-06	-0.31	-0.18	Schizophrenia;	chr15:58733396	chr15:58587507~58591676:+
BRCA	cis	rs828999	0.688	rs1340532	ENSG00000280186.1	RP11-483I13.6	-5.76	1.12e-08	1.61e-06	-0.2	-0.18	Monocyte percentage of white cells;	chr1:108172389	chr1:108200413~108202743:+
BRCA	cis	rs7613875	0.62	rs3774734	ENSG00000228008.1	CTD-2330K9.3	-5.76	1.12e-08	1.61e-06	-0.17	-0.18	Body mass index;	chr3:50071359	chr3:49903845~49916937:+
BRCA	cis	rs7927592	0.913	rs10896338	ENSG00000212093.1	AP000807.1	5.76	1.12e-08	1.61e-06	0.2	0.18	Total body bone mineral density;	chr11:68531892	chr11:68506083~68506166:-
BRCA	cis	rs7927592	0.913	rs7115374	ENSG00000212093.1	AP000807.1	5.76	1.12e-08	1.61e-06	0.2	0.18	Total body bone mineral density;	chr11:68532608	chr11:68506083~68506166:-
BRCA	cis	rs11105298	0.891	rs10858881	ENSG00000270344.2	RP11-734K2.4	5.76	1.12e-08	1.61e-06	0.2	0.18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89497697	chr12:89525654~89548005:+
BRCA	cis	rs10129255	0.784	rs7147210	ENSG00000224373.3	IGHV4-59	5.76	1.12e-08	1.61e-06	0.12	0.18	Kawasaki disease;	chr14:106705271	chr14:106627249~106627825:-
BRCA	cis	rs2243480	1	rs34815098	ENSG00000164669.11	INTS4P1	5.76	1.12e-08	1.61e-06	0.34	0.18	Diabetic kidney disease;	chr7:65827267	chr7:65141225~65234216:+
BRCA	cis	rs2243480	1	rs35735127	ENSG00000164669.11	INTS4P1	5.76	1.12e-08	1.61e-06	0.34	0.18	Diabetic kidney disease;	chr7:65835436	chr7:65141225~65234216:+
BRCA	cis	rs2243480	0.901	rs35256305	ENSG00000164669.11	INTS4P1	5.76	1.12e-08	1.61e-06	0.34	0.18	Diabetic kidney disease;	chr7:65841418	chr7:65141225~65234216:+
BRCA	cis	rs2243480	0.803	rs34004500	ENSG00000164669.11	INTS4P1	5.76	1.12e-08	1.61e-06	0.34	0.18	Diabetic kidney disease;	chr7:65847191	chr7:65141225~65234216:+
BRCA	cis	rs2243480	1	rs35825738	ENSG00000164669.11	INTS4P1	5.76	1.12e-08	1.61e-06	0.34	0.18	Diabetic kidney disease;	chr7:65853040	chr7:65141225~65234216:+
BRCA	cis	rs721917	0.525	rs2258874	ENSG00000244733.5	RP11-506M13.3	-5.76	1.12e-08	1.61e-06	-0.21	-0.18	Chronic obstructive pulmonary disease;	chr10:79919400	chr10:79660891~79677996:+
BRCA	cis	rs1124769	0.748	rs11070834	ENSG00000259378.1	DCAF13P3	5.76	1.12e-08	1.61e-06	0.25	0.18	Cognitive performance;	chr15:51087339	chr15:50944663~50945996:+
BRCA	cis	rs2243480	1	rs1167613	ENSG00000232559.3	GS1-124K5.12	5.76	1.12e-08	1.61e-06	0.33	0.18	Diabetic kidney disease;	chr7:66022452	chr7:66554588~66576923:-
BRCA	cis	rs2243480	1	rs313799	ENSG00000232559.3	GS1-124K5.12	5.76	1.12e-08	1.61e-06	0.33	0.18	Diabetic kidney disease;	chr7:66029343	chr7:66554588~66576923:-
BRCA	cis	rs7620503	0.506	rs2242401	ENSG00000228561.2	RP11-114M1.1	5.76	1.12e-08	1.61e-06	0.23	0.18	Corneal structure;	chr3:177620492	chr3:177683627~177691250:+
BRCA	cis	rs4604234	0.522	rs74614428	ENSG00000272129.1	RP11-250B2.6	-5.76	1.12e-08	1.62e-06	-0.45	-0.18	Cancer;	chr6:80200459	chr6:80355424~80356859:+
BRCA	cis	rs467650	0.553	rs469946	ENSG00000248489.1	CTD-2007H13.3	5.76	1.12e-08	1.62e-06	0.22	0.18	Venous thromboembolism (SNP x SNP interaction);	chr5:98653345	chr5:98929171~98995013:+
BRCA	cis	rs442309	0.687	rs10995294	ENSG00000238280.1	RP11-436D10.3	-5.76	1.12e-08	1.62e-06	-0.24	-0.18	Vogt-Koyanagi-Harada syndrome;	chr10:62723157	chr10:62793562~62805887:-
BRCA	cis	rs227275	0.525	rs4698874	ENSG00000251288.2	RP11-10L12.2	-5.76	1.12e-08	1.62e-06	-0.21	-0.18	Allergic disease (asthma, hay fever or eczema);	chr4:103009354	chr4:102751401~102752641:+
BRCA	cis	rs6479891	1	rs4133250	ENSG00000232075.1	MRPL35P2	-5.76	1.12e-08	1.62e-06	-0.32	-0.18	Arthritis (juvenile idiopathic);	chr10:63332645	chr10:63634317~63634827:-
BRCA	cis	rs6479891	1	rs10995506	ENSG00000232075.1	MRPL35P2	-5.76	1.12e-08	1.62e-06	-0.32	-0.18	Arthritis (juvenile idiopathic);	chr10:63334706	chr10:63634317~63634827:-
BRCA	cis	rs6479891	1	rs10740117	ENSG00000232075.1	MRPL35P2	-5.76	1.12e-08	1.62e-06	-0.32	-0.18	Arthritis (juvenile idiopathic);	chr10:63338517	chr10:63634317~63634827:-
BRCA	cis	rs6479891	1	rs6479894	ENSG00000232075.1	MRPL35P2	-5.76	1.12e-08	1.62e-06	-0.32	-0.18	Arthritis (juvenile idiopathic);	chr10:63338981	chr10:63634317~63634827:-
BRCA	cis	rs6479891	1	rs10733790	ENSG00000232075.1	MRPL35P2	-5.76	1.12e-08	1.62e-06	-0.32	-0.18	Arthritis (juvenile idiopathic);	chr10:63340574	chr10:63634317~63634827:-
BRCA	cis	rs6479891	0.915	rs7091664	ENSG00000232075.1	MRPL35P2	-5.76	1.12e-08	1.62e-06	-0.32	-0.18	Arthritis (juvenile idiopathic);	chr10:63342040	chr10:63634317~63634827:-
BRCA	cis	rs9291683	0.546	rs12504565	ENSG00000250413.1	RP11-448G15.1	-5.76	1.12e-08	1.62e-06	-0.23	-0.18	Bone mineral density;	chr4:10043521	chr4:10006482~10009725:+
BRCA	cis	rs9291683	0.546	rs7442336	ENSG00000250413.1	RP11-448G15.1	-5.76	1.12e-08	1.62e-06	-0.23	-0.18	Bone mineral density;	chr4:10044159	chr4:10006482~10009725:+
BRCA	cis	rs228614	0.51	rs223358	ENSG00000251288.2	RP11-10L12.2	-5.76	1.12e-08	1.62e-06	-0.21	-0.18	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102849637	chr4:102751401~102752641:+
BRCA	cis	rs1552244	0.882	rs13063098	ENSG00000232901.1	CYCSP10	5.76	1.12e-08	1.62e-06	0.24	0.18	Alzheimer's disease;	chr3:9968235	chr3:10000647~10000940:-
BRCA	cis	rs2253762	0.54	rs11200313	ENSG00000276742.1	RP11-500G22.4	5.76	1.12e-08	1.62e-06	0.3	0.18	Breast cancer;	chr10:121996523	chr10:121956782~121957098:+
BRCA	cis	rs2253762	0.54	rs10887036	ENSG00000276742.1	RP11-500G22.4	5.76	1.12e-08	1.62e-06	0.3	0.18	Breast cancer;	chr10:121997570	chr10:121956782~121957098:+
BRCA	cis	rs2253762	0.54	rs10887037	ENSG00000276742.1	RP11-500G22.4	5.76	1.12e-08	1.62e-06	0.3	0.18	Breast cancer;	chr10:121997572	chr10:121956782~121957098:+
BRCA	cis	rs4415084	1	rs1821936	ENSG00000251141.4	RP11-53O19.1	5.76	1.12e-08	1.62e-06	0.16	0.18	Breast cancer;	chr5:44699380	chr5:44744900~44808777:-
BRCA	cis	rs7809950	0.678	rs2237660	ENSG00000238832.1	snoU109	-5.76	1.12e-08	1.62e-06	-0.26	-0.18	Coronary artery disease;	chr7:107222518	chr7:107603363~107603507:+
BRCA	cis	rs516805	0.597	rs2816157	ENSG00000279453.1	RP3-425C14.4	-5.76	1.12e-08	1.62e-06	-0.25	-0.18	Lymphocyte counts;	chr6:122124400	chr6:122436789~122439223:-
BRCA	cis	rs10761482	0.5	rs1938538	ENSG00000254271.1	RP11-131N11.4	5.76	1.13e-08	1.62e-06	0.24	0.18	Schizophrenia;	chr10:60538475	chr10:60734342~60741828:+
BRCA	cis	rs2288884	1	rs80278704	ENSG00000275055.1	CTC-471J1.11	-5.76	1.13e-08	1.62e-06	-0.26	-0.18	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52045930	chr19:52049007~52049754:+
BRCA	cis	rs2288884	1	rs11669540	ENSG00000275055.1	CTC-471J1.11	-5.76	1.13e-08	1.62e-06	-0.26	-0.18	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52046486	chr19:52049007~52049754:+
BRCA	cis	rs2288884	1	rs78543982	ENSG00000275055.1	CTC-471J1.11	-5.76	1.13e-08	1.62e-06	-0.26	-0.18	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52047614	chr19:52049007~52049754:+
BRCA	cis	rs2288884	0.943	rs3752120	ENSG00000275055.1	CTC-471J1.11	-5.76	1.13e-08	1.62e-06	-0.26	-0.18	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52048768	chr19:52049007~52049754:+
BRCA	cis	rs375066	0.551	rs10408461	ENSG00000267058.1	RP11-15A1.3	5.76	1.13e-08	1.62e-06	0.21	0.18	Breast cancer;	chr19:43826620	chr19:43891804~43901805:-
BRCA	cis	rs2638953	0.962	rs11049482	ENSG00000278733.1	RP11-425D17.1	-5.76	1.13e-08	1.62e-06	-0.24	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28252088	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.962	rs11049484	ENSG00000278733.1	RP11-425D17.1	-5.76	1.13e-08	1.62e-06	-0.24	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28252254	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.962	rs11049485	ENSG00000278733.1	RP11-425D17.1	-5.76	1.13e-08	1.62e-06	-0.24	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28252522	chr12:28185625~28186190:-
BRCA	cis	rs4650994	0.544	rs6682815	ENSG00000273384.1	RP5-1098D14.1	5.76	1.13e-08	1.63e-06	0.22	0.18	HDL cholesterol;HDL cholesterol levels;	chr1:178531974	chr1:178651706~178652282:+
BRCA	cis	rs3764021	0.87	rs10772085	ENSG00000214776.8	RP11-726G1.1	5.76	1.13e-08	1.63e-06	0.19	0.18	Type 1 diabetes;	chr12:9724281	chr12:9467552~9576275:+
BRCA	cis	rs12893668	0.572	rs4900590	ENSG00000269910.1	RP11-73M18.10	5.76	1.13e-08	1.63e-06	0.19	0.18	Reticulocyte count;	chr14:103680084	chr14:103694516~103695050:-
BRCA	cis	rs2153535	0.518	rs9393051	ENSG00000230939.1	RP11-314C16.1	-5.76	1.13e-08	1.63e-06	-0.21	-0.18	Motion sickness;	chr6:8638726	chr6:8784178~8785445:+
BRCA	cis	rs2562456	0.754	rs55771551	ENSG00000268081.1	RP11-678G14.2	5.76	1.13e-08	1.63e-06	0.27	0.18	Pain;	chr19:21563578	chr19:21554640~21569237:-
BRCA	cis	rs10822145	1	rs10822145	ENSG00000232075.1	MRPL35P2	-5.76	1.13e-08	1.63e-06	-0.22	-0.18	Triglycerides;	chr10:63174788	chr10:63634317~63634827:-
BRCA	cis	rs7308116	0.546	rs10861811	ENSG00000274395.1	RP11-554D14.8	-5.76	1.13e-08	1.63e-06	-0.21	-0.18	Pelvic organ prolapse (moderate/severe);	chr12:107830463	chr12:107835541~107836555:-
BRCA	cis	rs7789940	0.951	rs7779014	ENSG00000186704.9	DTX2P1	5.76	1.13e-08	1.63e-06	0.21	0.18	Multiple sclerosis;	chr7:76346269	chr7:76978617~77004308:+
BRCA	cis	rs7178375	0.941	rs4779796	ENSG00000270055.1	CTD-3092A11.2	-5.76	1.13e-08	1.63e-06	-0.25	-0.18	Hypertriglyceridemia;	chr15:30915847	chr15:30487963~30490313:+
BRCA	cis	rs17508449	0.819	rs74524050	ENSG00000232450.1	RP4-730K3.3	-5.76	1.13e-08	1.63e-06	-0.32	-0.18	Leprosy;	chr1:113688585	chr1:113698884~113699631:-
BRCA	cis	rs4415084	1	rs1371027	ENSG00000251141.4	RP11-53O19.1	5.76	1.13e-08	1.63e-06	0.16	0.18	Breast cancer;	chr5:44699755	chr5:44744900~44808777:-
BRCA	cis	rs4415084	0.966	rs714130	ENSG00000251141.4	RP11-53O19.1	5.76	1.13e-08	1.63e-06	0.16	0.18	Breast cancer;	chr5:44701316	chr5:44744900~44808777:-
BRCA	cis	rs227275	0.525	rs9917919	ENSG00000251288.2	RP11-10L12.2	-5.76	1.13e-08	1.63e-06	-0.2	-0.18	Allergic disease (asthma, hay fever or eczema);	chr4:102918497	chr4:102751401~102752641:+
BRCA	cis	rs754466	0.606	rs10824581	ENSG00000204049.1	RP11-126H7.4	5.76	1.13e-08	1.63e-06	0.22	0.18	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77839743	chr10:77866875~77869610:+
BRCA	cis	rs891378	1	rs2802236	ENSG00000274245.1	RP11-357P18.2	5.76	1.13e-08	1.63e-06	0.24	0.18	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207298844	chr1:207372559~207373252:+
BRCA	cis	rs59169624	0.699	rs12272533	ENSG00000255160.4	RP11-428C19.5	5.76	1.13e-08	1.63e-06	0.24	0.18	Parental extreme longevity (95 years and older);	chr11:19255838	chr11:19299883~19308358:+
BRCA	cis	rs10129255	0.917	rs8022493	ENSG00000224373.3	IGHV4-59	5.76	1.13e-08	1.63e-06	0.11	0.18	Kawasaki disease;	chr14:106781820	chr14:106627249~106627825:-
BRCA	cis	rs7923609	0.967	rs2393986	ENSG00000232075.1	MRPL35P2	-5.76	1.13e-08	1.63e-06	-0.22	-0.18	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63560246	chr10:63634317~63634827:-
BRCA	cis	rs2243480	0.522	rs12698511	ENSG00000273142.1	RP11-458F8.4	-5.76	1.13e-08	1.63e-06	-0.29	-0.18	Diabetic kidney disease;	chr7:66009932	chr7:66902857~66906297:+
BRCA	cis	rs17253792	0.915	rs17832389	ENSG00000186615.9	KTN1-AS1	-5.76	1.13e-08	1.63e-06	-0.36	-0.18	Putamen volume;	chr14:55719118	chr14:55499278~55580110:-
BRCA	cis	rs721917	0.506	rs2819113	ENSG00000244733.5	RP11-506M13.3	-5.76	1.13e-08	1.63e-06	-0.21	-0.18	Chronic obstructive pulmonary disease;	chr10:79890987	chr10:79660891~79677996:+
BRCA	cis	rs754466	0.606	rs11002308	ENSG00000204049.1	RP11-126H7.4	5.76	1.14e-08	1.64e-06	0.21	0.18	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77835038	chr10:77866875~77869610:+
BRCA	cis	rs2898681	0.581	rs28618986	ENSG00000248375.1	RP11-177B4.1	-5.76	1.14e-08	1.64e-06	-0.24	-0.18	Optic nerve measurement (cup area);	chr4:52811735	chr4:52720081~52720831:-
BRCA	cis	rs7267979	0.816	rs8115257	ENSG00000277938.1	RP5-965G21.3	5.76	1.14e-08	1.64e-06	0.21	0.18	Liver enzyme levels (alkaline phosphatase);	chr20:25227295	chr20:25229150~25231933:+
BRCA	cis	rs61160187	0.51	rs6893642	ENSG00000272308.1	RP11-231G3.1	-5.76	1.14e-08	1.64e-06	-0.19	-0.18	Educational attainment (years of education);Educational attainment (college completion);	chr5:60821896	chr5:60866457~60866935:-
BRCA	cis	rs61160187	0.51	rs3936423	ENSG00000272308.1	RP11-231G3.1	-5.76	1.14e-08	1.64e-06	-0.19	-0.18	Educational attainment (years of education);Educational attainment (college completion);	chr5:60823134	chr5:60866457~60866935:-
BRCA	cis	rs61160187	0.51	rs1445293	ENSG00000272308.1	RP11-231G3.1	-5.76	1.14e-08	1.64e-06	-0.19	-0.18	Educational attainment (years of education);Educational attainment (college completion);	chr5:60823910	chr5:60866457~60866935:-
BRCA	cis	rs1707322	0.682	rs10890334	ENSG00000234329.1	RP11-767N6.2	5.76	1.14e-08	1.64e-06	0.18	0.18	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634706	chr1:45651039~45651826:-
BRCA	cis	rs2243480	0.831	rs57294491	ENSG00000232559.3	GS1-124K5.12	-5.76	1.14e-08	1.64e-06	-0.34	-0.18	Diabetic kidney disease;	chr7:66219914	chr7:66554588~66576923:-
BRCA	cis	rs2153535	0.585	rs7766729	ENSG00000230939.1	RP11-314C16.1	-5.76	1.14e-08	1.64e-06	-0.2	-0.18	Motion sickness;	chr6:8627408	chr6:8784178~8785445:+
BRCA	cis	rs4908768	0.501	rs6577494	ENSG00000270282.1	RP5-1115A15.2	5.76	1.14e-08	1.64e-06	0.19	0.18	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8516866	chr1:8512653~8513021:+
BRCA	cis	rs667920	0.575	rs9861150	ENSG00000273486.1	RP11-731C17.2	5.75	1.14e-08	1.64e-06	0.24	0.18	Coronary artery disease;	chr3:136464478	chr3:136837338~136839021:-
BRCA	cis	rs9308731	0.614	rs6755484	ENSG00000227992.1	AC108463.2	-5.75	1.14e-08	1.64e-06	-0.2	-0.18	Chronic lymphocytic leukemia;	chr2:111191519	chr2:111203964~111206215:-
BRCA	cis	rs2638953	0.924	rs7957382	ENSG00000247934.4	RP11-967K21.1	5.75	1.14e-08	1.64e-06	0.23	0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28203643	chr12:28163298~28190738:-
BRCA	cis	rs2253762	0.507	rs12264894	ENSG00000276742.1	RP11-500G22.4	5.75	1.14e-08	1.64e-06	0.31	0.18	Breast cancer;	chr10:121992087	chr10:121956782~121957098:+
BRCA	cis	rs9545047	0.604	rs9574419	ENSG00000227354.5	RBM26-AS1	-5.75	1.14e-08	1.64e-06	-0.19	-0.18	Schizophrenia;	chr13:79402337	chr13:79406309~79424328:+
BRCA	cis	rs2243480	1	rs34703416	ENSG00000229886.1	RP5-1132H15.3	5.75	1.14e-08	1.64e-06	0.31	0.18	Diabetic kidney disease;	chr7:65835655	chr7:66025126~66031544:-
BRCA	cis	rs2153535	0.585	rs6932720	ENSG00000230939.1	RP11-314C16.1	-5.75	1.14e-08	1.65e-06	-0.2	-0.18	Motion sickness;	chr6:8644999	chr6:8784178~8785445:+
BRCA	cis	rs6088580	0.524	rs7269596	ENSG00000269202.1	RP4-614O4.12	5.75	1.14e-08	1.65e-06	0.18	0.18	Glomerular filtration rate (creatinine);	chr20:34641259	chr20:35201747~35203288:-
BRCA	cis	rs7927592	0.871	rs55953412	ENSG00000212093.1	AP000807.1	5.75	1.14e-08	1.65e-06	0.2	0.18	Total body bone mineral density;	chr11:68560815	chr11:68506083~68506166:-
BRCA	cis	rs7927592	0.913	rs7102898	ENSG00000212093.1	AP000807.1	5.75	1.14e-08	1.65e-06	0.2	0.18	Total body bone mineral density;	chr11:68561402	chr11:68506083~68506166:-
BRCA	cis	rs10129255	0.5	rs12101190	ENSG00000274576.2	IGHV2-70	-5.75	1.14e-08	1.65e-06	-0.14	-0.18	Kawasaki disease;	chr14:106784149	chr14:106770577~106771020:-
BRCA	cis	rs10129255	0.518	rs8004895	ENSG00000274576.2	IGHV2-70	-5.75	1.14e-08	1.65e-06	-0.14	-0.18	Kawasaki disease;	chr14:106785139	chr14:106770577~106771020:-
BRCA	cis	rs919433	0.68	rs7582536	ENSG00000231621.1	AC013264.2	5.75	1.14e-08	1.65e-06	0.17	0.18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197571379	chr2:197197991~197199273:+
BRCA	cis	rs56104184	0.725	rs1466896	ENSG00000235191.1	NUCB1-AS1	5.75	1.15e-08	1.65e-06	0.31	0.18	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr19:48881996	chr19:48910930~48918891:-
BRCA	cis	rs7809950	0.678	rs79902674	ENSG00000238832.1	snoU109	-5.75	1.15e-08	1.65e-06	-0.26	-0.18	Coronary artery disease;	chr7:107226053	chr7:107603363~107603507:+
BRCA	cis	rs6442522	0.644	rs6783160	ENSG00000249786.6	EAF1-AS1	5.75	1.15e-08	1.65e-06	0.18	0.18	Uric acid levels;	chr3:15467511	chr3:15436171~15455940:-
BRCA	cis	rs9309473	1	rs11899740	ENSG00000163016.8	ALMS1P	5.75	1.15e-08	1.65e-06	0.23	0.18	Metabolite levels;	chr2:73404084	chr2:73644919~73685576:+
BRCA	cis	rs4908768	0.501	rs6702060	ENSG00000270282.1	RP5-1115A15.2	5.75	1.15e-08	1.66e-06	0.19	0.18	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8546965	chr1:8512653~8513021:+
BRCA	cis	rs910316	0.967	rs119076	ENSG00000279594.1	RP11-950C14.10	-5.75	1.15e-08	1.66e-06	-0.19	-0.18	Height;	chr14:75105716	chr14:75011269~75012851:-
BRCA	cis	rs11098499	0.955	rs13129661	ENSG00000249244.1	RP11-548H18.2	5.75	1.15e-08	1.66e-06	0.21	0.18	Corneal astigmatism;	chr4:119231754	chr4:119391831~119395335:-
BRCA	cis	rs2243480	0.901	rs1701759	ENSG00000232546.1	RP11-458F8.1	-5.75	1.15e-08	1.66e-06	-0.23	-0.18	Diabetic kidney disease;	chr7:66005945	chr7:66848496~66858136:+
BRCA	cis	rs1707322	1	rs10890380	ENSG00000281133.1	AL355480.3	-5.75	1.15e-08	1.66e-06	-0.22	-0.18	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45983797	chr1:45580892~45580996:-
BRCA	cis	rs2911132	0.564	rs28580505	ENSG00000248734.2	CTD-2260A17.1	5.75	1.15e-08	1.66e-06	0.21	0.18	Urate levels (BMI interaction);	chr5:96765516	chr5:96784777~96785999:+
BRCA	cis	rs2638953	0.853	rs3926041	ENSG00000278733.1	RP11-425D17.1	-5.75	1.15e-08	1.66e-06	-0.23	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28461776	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.888	rs11049407	ENSG00000247934.4	RP11-967K21.1	-5.75	1.15e-08	1.66e-06	-0.22	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28181431	chr12:28163298~28190738:-
BRCA	cis	rs1476670	0.71	rs2477616	ENSG00000230615.5	RP5-1198O20.4	-5.75	1.15e-08	1.66e-06	-0.26	-0.18	Eotaxin levels;	chr1:44039137	chr1:44030443~44115913:+
BRCA	cis	rs7923609	0.812	rs10761753	ENSG00000232075.1	MRPL35P2	-5.75	1.16e-08	1.66e-06	-0.22	-0.18	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63402143	chr10:63634317~63634827:-
BRCA	cis	rs4588572	0.644	rs6870646	ENSG00000245556.2	SCAMP1-AS1	-5.75	1.16e-08	1.67e-06	-0.21	-0.18	Triglycerides;	chr5:78445258	chr5:78342365~78360507:-
BRCA	cis	rs7927592	0.913	rs67605986	ENSG00000212093.1	AP000807.1	5.75	1.16e-08	1.67e-06	0.2	0.18	Total body bone mineral density;	chr11:68533487	chr11:68506083~68506166:-
BRCA	cis	rs7789940	1	rs17149161	ENSG00000186704.9	DTX2P1	5.75	1.16e-08	1.67e-06	0.21	0.18	Multiple sclerosis;	chr7:76348912	chr7:76978617~77004308:+
BRCA	cis	rs11722779	0.869	rs223350	ENSG00000251288.2	RP11-10L12.2	-5.75	1.16e-08	1.67e-06	-0.21	-0.18	Schizophrenia;	chr4:102856899	chr4:102751401~102752641:+
BRCA	cis	rs4415084	1	rs2013513	ENSG00000251141.4	RP11-53O19.1	5.75	1.16e-08	1.67e-06	0.16	0.18	Breast cancer;	chr5:44702204	chr5:44744900~44808777:-
BRCA	cis	rs922692	0.967	rs11633351	ENSG00000261143.1	ADAMTS7P3	5.75	1.16e-08	1.67e-06	0.23	0.18	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78764473	chr15:77976042~77993057:+
BRCA	cis	rs2274273	0.967	rs11622740	ENSG00000258413.1	RP11-665C16.6	-5.75	1.16e-08	1.67e-06	-0.22	-0.18	Protein biomarker;	chr14:55151126	chr14:55262767~55272075:-
BRCA	cis	rs1707322	0.716	rs6694889	ENSG00000234329.1	RP11-767N6.2	5.75	1.16e-08	1.67e-06	0.18	0.18	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45636134	chr1:45651039~45651826:-
BRCA	cis	rs1707322	0.682	rs12041197	ENSG00000234329.1	RP11-767N6.2	5.75	1.16e-08	1.67e-06	0.18	0.18	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45638792	chr1:45651039~45651826:-
BRCA	cis	rs6088580	0.524	rs1853056	ENSG00000269202.1	RP4-614O4.12	5.75	1.16e-08	1.67e-06	0.18	0.18	Glomerular filtration rate (creatinine);	chr20:34674254	chr20:35201747~35203288:-
BRCA	cis	rs755249	0.509	rs11206378	ENSG00000228060.1	RP11-69E11.8	5.75	1.16e-08	1.67e-06	0.18	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39583512	chr1:39565160~39573203:+
BRCA	cis	rs4835473	0.897	rs924234	ENSG00000249741.2	RP11-673E1.3	-5.75	1.16e-08	1.67e-06	-0.19	-0.18	Immature fraction of reticulocytes;	chr4:143706799	chr4:143911514~143912053:-
BRCA	cis	rs9652601	0.622	rs8049882	ENSG00000274038.1	RP11-66H6.4	-5.75	1.16e-08	1.67e-06	-0.19	-0.18	Systemic lupus erythematosus;	chr16:11025629	chr16:11056556~11057034:+
BRCA	cis	rs858239	0.539	rs6975852	ENSG00000230042.1	AK3P3	-5.75	1.16e-08	1.67e-06	-0.2	-0.18	Cerebrospinal fluid biomarker levels;	chr7:23147035	chr7:23129178~23129841:+
BRCA	cis	rs2243480	1	rs160639	ENSG00000164669.11	INTS4P1	5.75	1.16e-08	1.67e-06	0.34	0.18	Diabetic kidney disease;	chr7:66115000	chr7:65141225~65234216:+
BRCA	cis	rs4927850	0.709	rs6783079	ENSG00000242086.7	LINC00969	5.75	1.16e-08	1.67e-06	0.23	0.18	Pancreatic cancer;	chr3:195925837	chr3:195658062~195739964:+
BRCA	cis	rs4927850	0.709	rs6765762	ENSG00000242086.7	LINC00969	5.75	1.16e-08	1.67e-06	0.23	0.18	Pancreatic cancer;	chr3:195925980	chr3:195658062~195739964:+
BRCA	cis	rs67311347	0.544	rs2123998	ENSG00000280739.1	EIF1B-AS1	-5.75	1.16e-08	1.67e-06	-0.19	-0.18	Renal cell carcinoma;	chr3:40317514	chr3:40173145~40309698:-
BRCA	cis	rs2562456	1	rs2562456	ENSG00000268081.1	RP11-678G14.2	5.75	1.16e-08	1.68e-06	0.25	0.18	Pain;	chr19:21483408	chr19:21554640~21569237:-
BRCA	cis	rs2243480	1	rs313824	ENSG00000228409.4	CCT6P1	5.75	1.16e-08	1.68e-06	0.25	0.18	Diabetic kidney disease;	chr7:66116220	chr7:65751142~65763354:+
BRCA	cis	rs2243480	1	rs186378	ENSG00000228409.4	CCT6P1	5.75	1.16e-08	1.68e-06	0.25	0.18	Diabetic kidney disease;	chr7:66117071	chr7:65751142~65763354:+
BRCA	cis	rs2243480	1	rs160637	ENSG00000228409.4	CCT6P1	5.75	1.16e-08	1.68e-06	0.25	0.18	Diabetic kidney disease;	chr7:66119331	chr7:65751142~65763354:+
BRCA	cis	rs78487399	0.908	rs76765584	ENSG00000234936.1	AC010883.5	5.75	1.16e-08	1.68e-06	0.23	0.18	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43580895	chr2:43229573~43233394:+
BRCA	cis	rs2243480	0.901	rs778687	ENSG00000232559.3	GS1-124K5.12	5.75	1.17e-08	1.68e-06	0.34	0.18	Diabetic kidney disease;	chr7:66370832	chr7:66554588~66576923:-
BRCA	cis	rs2243480	1	rs778704	ENSG00000232559.3	GS1-124K5.12	5.75	1.17e-08	1.68e-06	0.34	0.18	Diabetic kidney disease;	chr7:66398480	chr7:66554588~66576923:-
BRCA	cis	rs2243480	0.901	rs778693	ENSG00000232559.3	GS1-124K5.12	5.75	1.17e-08	1.68e-06	0.34	0.18	Diabetic kidney disease;	chr7:66407358	chr7:66554588~66576923:-
BRCA	cis	rs2243480	1	rs778691	ENSG00000232559.3	GS1-124K5.12	5.75	1.17e-08	1.68e-06	0.34	0.18	Diabetic kidney disease;	chr7:66408105	chr7:66554588~66576923:-
BRCA	cis	rs2243480	1	rs13235972	ENSG00000232559.3	GS1-124K5.12	5.75	1.17e-08	1.68e-06	0.34	0.18	Diabetic kidney disease;	chr7:66418618	chr7:66554588~66576923:-
BRCA	cis	rs2243480	1	rs34192067	ENSG00000232559.3	GS1-124K5.12	5.75	1.17e-08	1.68e-06	0.34	0.18	Diabetic kidney disease;	chr7:66422670	chr7:66554588~66576923:-
BRCA	cis	rs516805	0.667	rs2816139	ENSG00000279453.1	RP3-425C14.4	-5.75	1.17e-08	1.68e-06	-0.26	-0.18	Lymphocyte counts;	chr6:122182267	chr6:122436789~122439223:-
BRCA	cis	rs9652601	0.622	rs8045749	ENSG00000274038.1	RP11-66H6.4	-5.75	1.17e-08	1.68e-06	-0.19	-0.18	Systemic lupus erythematosus;	chr16:11025796	chr16:11056556~11057034:+
BRCA	cis	rs3740713	1	rs75740864	ENSG00000256464.1	YWHABP2	5.75	1.17e-08	1.68e-06	0.3	0.18	Amyotrophic lateral sclerosis (sporadic);	chr11:18449142	chr11:18490243~18490955:-
BRCA	cis	rs11763147	1	rs11763147	ENSG00000273024.4	INTS4P2	5.75	1.17e-08	1.68e-06	0.19	0.18	Corneal structure;	chr7:65861834	chr7:65647864~65715661:+
BRCA	cis	rs875971	0.545	rs6460298	ENSG00000228409.4	CCT6P1	-5.75	1.17e-08	1.68e-06	-0.18	-0.18	Aortic root size;	chr7:66442783	chr7:65751142~65763354:+
BRCA	cis	rs2638953	0.886	rs12371462	ENSG00000278733.1	RP11-425D17.1	-5.75	1.17e-08	1.68e-06	-0.24	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28168770	chr12:28185625~28186190:-
BRCA	cis	rs6479901	0.557	rs7920768	ENSG00000232075.1	MRPL35P2	-5.75	1.17e-08	1.68e-06	-0.32	-0.18	Intelligence (multi-trait analysis);	chr10:63300754	chr10:63634317~63634827:-
BRCA	cis	rs9291683	0.546	rs13139055	ENSG00000250413.1	RP11-448G15.1	-5.75	1.17e-08	1.68e-06	-0.23	-0.18	Bone mineral density;	chr4:10037300	chr4:10006482~10009725:+
BRCA	cis	rs2638953	0.962	rs61922978	ENSG00000278733.1	RP11-425D17.1	-5.75	1.17e-08	1.68e-06	-0.24	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28292075	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.962	rs12372448	ENSG00000278733.1	RP11-425D17.1	-5.75	1.17e-08	1.68e-06	-0.24	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28293956	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.925	rs11049511	ENSG00000278733.1	RP11-425D17.1	-5.75	1.17e-08	1.68e-06	-0.24	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28294393	chr12:28185625~28186190:-
BRCA	cis	rs875971	0.545	rs316305	ENSG00000228409.4	CCT6P1	5.75	1.17e-08	1.69e-06	0.17	0.18	Aortic root size;	chr7:66152984	chr7:65751142~65763354:+
BRCA	cis	rs9868809	0.881	rs7631574	ENSG00000270441.1	RP11-694I15.7	-5.75	1.17e-08	1.69e-06	-0.28	-0.18	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48625613	chr3:49140086~49160851:-
BRCA	cis	rs1552244	1	rs61052895	ENSG00000232901.1	CYCSP10	5.75	1.17e-08	1.69e-06	0.25	0.18	Alzheimer's disease;	chr3:10105832	chr3:10000647~10000940:-
BRCA	cis	rs6728642	1	rs80303184	ENSG00000230606.9	AC159540.1	5.75	1.17e-08	1.69e-06	0.38	0.18	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:97349066	chr2:97416165~97433527:-
BRCA	cis	rs2274273	0.967	rs67756714	ENSG00000258413.1	RP11-665C16.6	-5.75	1.17e-08	1.69e-06	-0.22	-0.18	Protein biomarker;	chr14:55123105	chr14:55262767~55272075:-
BRCA	cis	rs6728642	0.561	rs62152901	ENSG00000230606.9	AC159540.1	5.75	1.17e-08	1.69e-06	0.28	0.18	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:96899161	chr2:97416165~97433527:-
BRCA	cis	rs1823913	0.599	rs13020656	ENSG00000280083.1	RP11-317J9.1	-5.75	1.17e-08	1.69e-06	-0.2	-0.18	Obesity-related traits;	chr2:191314197	chr2:191154118~191156070:-
BRCA	cis	rs2243480	0.803	rs35480979	ENSG00000164669.11	INTS4P1	5.75	1.18e-08	1.69e-06	0.34	0.18	Diabetic kidney disease;	chr7:65892097	chr7:65141225~65234216:+
BRCA	cis	rs2243480	1	rs35391607	ENSG00000164669.11	INTS4P1	5.75	1.18e-08	1.69e-06	0.34	0.18	Diabetic kidney disease;	chr7:65895842	chr7:65141225~65234216:+
BRCA	cis	rs2243480	1	rs13220979	ENSG00000164669.11	INTS4P1	5.75	1.18e-08	1.69e-06	0.34	0.18	Diabetic kidney disease;	chr7:65898217	chr7:65141225~65234216:+
BRCA	cis	rs2243480	1	rs34974928	ENSG00000164669.11	INTS4P1	5.75	1.18e-08	1.69e-06	0.34	0.18	Diabetic kidney disease;	chr7:65899019	chr7:65141225~65234216:+
BRCA	cis	rs4415084	1	rs10805686	ENSG00000251141.4	RP11-53O19.1	5.75	1.18e-08	1.69e-06	0.16	0.18	Breast cancer;	chr5:44662026	chr5:44744900~44808777:-
BRCA	cis	rs11105298	0.891	rs12369195	ENSG00000270344.2	RP11-734K2.4	5.75	1.18e-08	1.69e-06	0.21	0.18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89541195	chr12:89525654~89548005:+
BRCA	cis	rs250585	1	rs4968013	ENSG00000260136.4	CTD-2270L9.4	5.75	1.18e-08	1.69e-06	0.21	0.18	Egg allergy;	chr16:23501271	chr16:23452758~23457606:+
BRCA	cis	rs17772222	0.511	rs1013794	ENSG00000258983.2	RP11-507K2.2	5.75	1.18e-08	1.69e-06	0.18	0.18	Coronary artery calcification;	chr14:88847401	chr14:88499334~88515502:+
BRCA	cis	rs7923609	1	rs7073746	ENSG00000232075.1	MRPL35P2	-5.75	1.18e-08	1.69e-06	-0.22	-0.18	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63144311	chr10:63634317~63634827:-
BRCA	cis	rs1823874	0.581	rs12910401	ENSG00000259363.4	CTD-2054N24.2	-5.75	1.18e-08	1.69e-06	-0.21	-0.18	IgG glycosylation;	chr15:99799692	chr15:99807023~99877148:+
BRCA	cis	rs11098499	1	rs28374891	ENSG00000249244.1	RP11-548H18.2	5.75	1.18e-08	1.69e-06	0.21	0.18	Corneal astigmatism;	chr4:119262395	chr4:119391831~119395335:-
BRCA	cis	rs11722228	0.508	rs2241472	ENSG00000261490.1	RP11-448G15.3	5.75	1.18e-08	1.7e-06	0.2	0.18	Urate levels;Serum uric acid levels;Gout;	chr4:10084278	chr4:10068089~10073019:-
BRCA	cis	rs2250402	0.51	rs2291621	ENSG00000248508.5	SRP14-AS1	5.75	1.18e-08	1.7e-06	0.38	0.18	Corneal curvature;	chr15:40032636	chr15:40039311~40067290:+
BRCA	cis	rs7927592	0.913	rs67005337	ENSG00000212093.1	AP000807.1	5.75	1.18e-08	1.7e-06	0.2	0.18	Total body bone mineral density;	chr11:68540290	chr11:68506083~68506166:-
BRCA	cis	rs10888838	0.941	rs11585887	ENSG00000198711.5	SSBP3-AS1	5.75	1.18e-08	1.7e-06	0.23	0.18	Mitochondrial DNA levels;	chr1:54221850	chr1:54236440~54239063:+
BRCA	cis	rs721917	0.506	rs927452	ENSG00000244733.5	RP11-506M13.3	-5.75	1.18e-08	1.7e-06	-0.21	-0.18	Chronic obstructive pulmonary disease;	chr10:79892510	chr10:79660891~79677996:+
BRCA	cis	rs2303319	0.901	rs62188141	ENSG00000227403.1	AC009299.3	5.75	1.18e-08	1.7e-06	0.45	0.18	Cognitive function;	chr2:161417380	chr2:161244739~161249050:+
BRCA	cis	rs7200543	1	rs4985124	ENSG00000260872.1	RP11-680G24.5	-5.75	1.18e-08	1.7e-06	-0.18	-0.18	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15031584	chr16:15018106~15020488:-
BRCA	cis	rs10504130	1	rs16916961	ENSG00000253844.1	RP11-546K22.1	-5.75	1.18e-08	1.7e-06	-0.31	-0.18	Venous thromboembolism (SNP x SNP interaction);	chr8:51918618	chr8:51961458~52022974:+
BRCA	cis	rs2098713	0.586	rs61435914	ENSG00000250155.1	CTD-2353F22.1	5.75	1.18e-08	1.7e-06	0.19	0.18	Telomere length;	chr5:37607239	chr5:36666214~36725195:-
BRCA	cis	rs13126694	0.633	rs4388135	ENSG00000248429.4	RP11-597D13.9	5.75	1.19e-08	1.7e-06	0.16	0.18	Blood osmolality (transformed sodium);	chr4:158093301	chr4:158170752~158202877:+
BRCA	cis	rs7246657	0.943	rs7255952	ENSG00000226686.6	LINC01535	-5.75	1.19e-08	1.7e-06	-0.26	-0.18	Coronary artery calcification;	chr19:37497895	chr19:37251912~37265535:+
BRCA	cis	rs12612619	0.704	rs6754356	ENSG00000229122.1	AGBL5-IT1	5.75	1.19e-08	1.71e-06	0.19	0.18	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27092153	chr2:27061038~27061815:+
BRCA	cis	rs875971	0.545	rs67775320	ENSG00000228409.4	CCT6P1	-5.75	1.19e-08	1.71e-06	-0.17	-0.18	Aortic root size;	chr7:66193792	chr7:65751142~65763354:+
BRCA	cis	rs2243480	1	rs13310597	ENSG00000164669.11	INTS4P1	5.75	1.19e-08	1.71e-06	0.34	0.18	Diabetic kidney disease;	chr7:66133553	chr7:65141225~65234216:+
BRCA	cis	rs6969780	0.778	rs61384251	ENSG00000233429.8	HOTAIRM1	5.75	1.19e-08	1.71e-06	0.23	0.18	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27106583	chr7:27095647~27100265:+
BRCA	cis	rs7208859	0.673	rs73263776	ENSG00000266490.1	CTD-2349P21.9	5.75	1.19e-08	1.71e-06	0.27	0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30884313	chr17:30792372~30792833:+
BRCA	cis	rs7208859	0.623	rs11650271	ENSG00000266490.1	CTD-2349P21.9	5.75	1.19e-08	1.71e-06	0.27	0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30886925	chr17:30792372~30792833:+
BRCA	cis	rs12681366	0.708	rs3019154	ENSG00000253704.1	RP11-267M23.4	5.75	1.19e-08	1.71e-06	0.18	0.18	Nonsyndromic cleft lip with cleft palate;	chr8:94434280	chr8:94553722~94569745:+
BRCA	cis	rs12681366	0.708	rs3019279	ENSG00000253704.1	RP11-267M23.4	5.75	1.19e-08	1.71e-06	0.18	0.18	Nonsyndromic cleft lip with cleft palate;	chr8:94435677	chr8:94553722~94569745:+
BRCA	cis	rs4604234	0.803	rs3805893	ENSG00000272129.1	RP11-250B2.6	-5.75	1.19e-08	1.71e-06	-0.43	-0.18	Cancer;	chr6:80285761	chr6:80355424~80356859:+
BRCA	cis	rs1707322	1	rs3922887	ENSG00000281133.1	AL355480.3	-5.75	1.19e-08	1.71e-06	-0.22	-0.18	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46008130	chr1:45580892~45580996:-
BRCA	cis	rs1707322	1	rs3922886	ENSG00000281133.1	AL355480.3	-5.75	1.19e-08	1.71e-06	-0.22	-0.18	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46008230	chr1:45580892~45580996:-
BRCA	cis	rs73222236	0.737	rs9854328	ENSG00000273486.1	RP11-731C17.2	5.75	1.19e-08	1.71e-06	0.19	0.18	Coronary artery disease;	chr3:136350878	chr3:136837338~136839021:-
BRCA	cis	rs755249	0.727	rs16826349	ENSG00000228060.1	RP11-69E11.8	-5.75	1.19e-08	1.71e-06	-0.18	-0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39573264	chr1:39565160~39573203:+
BRCA	cis	rs7618501	0.669	rs7634084	ENSG00000228008.1	CTD-2330K9.3	5.75	1.19e-08	1.71e-06	0.17	0.18	Intelligence (multi-trait analysis);	chr3:49912401	chr3:49903845~49916937:+
BRCA	cis	rs950169	0.579	rs12913054	ENSG00000259728.4	LINC00933	5.75	1.19e-08	1.71e-06	0.26	0.18	Schizophrenia;	chr15:83995704	chr15:84570649~84580175:+
BRCA	cis	rs2243480	1	rs6460260	ENSG00000164669.11	INTS4P1	-5.75	1.19e-08	1.72e-06	-0.34	-0.18	Diabetic kidney disease;	chr7:65750468	chr7:65141225~65234216:+
BRCA	cis	rs2243480	1	rs6460261	ENSG00000164669.11	INTS4P1	-5.75	1.19e-08	1.72e-06	-0.34	-0.18	Diabetic kidney disease;	chr7:65750593	chr7:65141225~65234216:+
BRCA	cis	rs12817211	0.502	rs12819883	ENSG00000272368.2	RP4-605O3.4	-5.75	1.19e-08	1.72e-06	-0.18	-0.18	Colorectal or endometrial cancer;	chr12:50140005	chr12:50112197~50165618:+
BRCA	cis	rs13126694	0.778	rs13106004	ENSG00000248429.4	RP11-597D13.9	5.75	1.2e-08	1.72e-06	0.16	0.18	Blood osmolality (transformed sodium);	chr4:158104532	chr4:158170752~158202877:+
BRCA	cis	rs13126694	0.744	rs13106234	ENSG00000248429.4	RP11-597D13.9	5.75	1.2e-08	1.72e-06	0.16	0.18	Blood osmolality (transformed sodium);	chr4:158104618	chr4:158170752~158202877:+
BRCA	cis	rs10510102	0.872	rs12265369	ENSG00000226864.1	ATE1-AS1	5.75	1.2e-08	1.72e-06	0.33	0.18	Breast cancer;	chr10:121968455	chr10:121928312~121951965:+
BRCA	cis	rs10510102	0.872	rs12265542	ENSG00000226864.1	ATE1-AS1	5.75	1.2e-08	1.72e-06	0.33	0.18	Breast cancer;	chr10:121968740	chr10:121928312~121951965:+
BRCA	cis	rs10510102	0.872	rs11200293	ENSG00000226864.1	ATE1-AS1	5.75	1.2e-08	1.72e-06	0.33	0.18	Breast cancer;	chr10:121969195	chr10:121928312~121951965:+
BRCA	cis	rs7613875	0.62	rs17657664	ENSG00000228008.1	CTD-2330K9.3	5.75	1.2e-08	1.72e-06	0.17	0.18	Body mass index;	chr3:49994575	chr3:49903845~49916937:+
BRCA	cis	rs4819052	0.851	rs2236444	ENSG00000184274.3	LINC00315	-5.75	1.2e-08	1.72e-06	-0.24	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258311	chr21:45300245~45305257:-
BRCA	cis	rs7618501	0.521	rs2883059	ENSG00000228008.1	CTD-2330K9.3	-5.75	1.2e-08	1.72e-06	-0.17	-0.18	Intelligence (multi-trait analysis);	chr3:49864727	chr3:49903845~49916937:+
BRCA	cis	rs2638953	0.853	rs10843179	ENSG00000278733.1	RP11-425D17.1	5.75	1.2e-08	1.72e-06	0.23	0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28462125	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.741	rs10843199	ENSG00000278733.1	RP11-425D17.1	5.75	1.2e-08	1.72e-06	0.24	0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28535711	chr12:28185625~28186190:-
BRCA	cis	rs13126694	0.633	rs4388135	ENSG00000251429.1	RP11-597D13.7	5.75	1.2e-08	1.72e-06	0.17	0.18	Blood osmolality (transformed sodium);	chr4:158093301	chr4:158270378~158278676:+
BRCA	cis	rs2832191	0.74	rs2832168	ENSG00000176054.6	RPL23P2	5.75	1.2e-08	1.72e-06	0.19	0.18	Dental caries;	chr21:29091374	chr21:28997613~28998033:-
BRCA	cis	rs4835473	0.932	rs1450250	ENSG00000249741.2	RP11-673E1.3	-5.75	1.2e-08	1.72e-06	-0.19	-0.18	Immature fraction of reticulocytes;	chr4:143731873	chr4:143911514~143912053:-
BRCA	cis	rs516805	0.748	rs562616	ENSG00000279114.1	RP3-425C14.5	-5.75	1.2e-08	1.72e-06	-0.21	-0.18	Lymphocyte counts;	chr6:122467041	chr6:122471923~122484161:+
BRCA	cis	rs7646881	0.767	rs58152433	ENSG00000240207.5	RP11-379F4.4	-5.75	1.2e-08	1.72e-06	-0.27	-0.18	Tetralogy of Fallot;	chr3:158738851	chr3:158732263~158784070:+
BRCA	cis	rs7254192	0.625	rs736625	ENSG00000268529.1	CYP2T3P	5.75	1.2e-08	1.72e-06	0.21	0.18	Post bronchodilator FEV1;	chr19:40759296	chr19:41134722~41137308:+
BRCA	cis	rs873549	0.883	rs6604700	ENSG00000232679.1	RP11-400N13.3	5.75	1.2e-08	1.73e-06	0.2	0.18	Keloid;	chr1:222093982	chr1:222041705~222064763:-
BRCA	cis	rs6832769	0.961	rs1873092	ENSG00000272969.1	RP11-528I4.2	-5.75	1.2e-08	1.73e-06	-0.22	-0.18	Personality dimensions;	chr4:55578133	chr4:55547112~55547889:+
BRCA	cis	rs8114671	0.662	rs6058146	ENSG00000269202.1	RP4-614O4.12	-5.75	1.21e-08	1.73e-06	-0.18	-0.18	Height;	chr20:34952726	chr20:35201747~35203288:-
BRCA	cis	rs4950322	0.57	rs17356184	ENSG00000244371.2	PFN1P8	-5.75	1.21e-08	1.73e-06	-0.24	-0.18	Protein quantitative trait loci;	chr1:147262943	chr1:146957117~146957659:-
BRCA	cis	rs4950322	0.57	rs4950392	ENSG00000244371.2	PFN1P8	-5.75	1.21e-08	1.73e-06	-0.24	-0.18	Protein quantitative trait loci;	chr1:147264889	chr1:146957117~146957659:-
BRCA	cis	rs7927771	0.524	rs10838739	ENSG00000280615.1	Y_RNA	-5.74	1.21e-08	1.73e-06	-0.2	-0.18	Subjective well-being;	chr11:47651191	chr11:47614898~47614994:-
BRCA	cis	rs7474896	0.537	rs1779068	ENSG00000120555.12	SEPT7P9	-5.74	1.21e-08	1.73e-06	-0.25	-0.18	Obesity (extreme);	chr10:37961857	chr10:38383069~38402916:-
BRCA	cis	rs295490	0.748	rs2291555	ENSG00000272656.1	RP11-219D15.3	5.74	1.21e-08	1.73e-06	0.41	0.18	PR interval in Tripanosoma cruzi seropositivity;	chr3:139355352	chr3:139349024~139349371:-
BRCA	cis	rs227275	0.554	rs223382	ENSG00000251288.2	RP11-10L12.2	-5.74	1.21e-08	1.73e-06	-0.21	-0.18	Allergic disease (asthma, hay fever or eczema);	chr4:102831145	chr4:102751401~102752641:+
BRCA	cis	rs1075265	0.749	rs2357693	ENSG00000235937.1	AC008280.1	5.74	1.21e-08	1.74e-06	0.19	0.18	Chronotype;Morning vs. evening chronotype;	chr2:53735699	chr2:54029552~54030682:-
BRCA	cis	rs7493	0.95	rs7785705	ENSG00000233942.1	AC004012.1	5.74	1.21e-08	1.74e-06	0.22	0.18	Yu-Zhi constitution type in type 2 diabetes;	chr7:95404491	chr7:95471835~95473998:+
BRCA	cis	rs7493	1	rs7786401	ENSG00000233942.1	AC004012.1	5.74	1.21e-08	1.74e-06	0.22	0.18	Yu-Zhi constitution type in type 2 diabetes;	chr7:95404689	chr7:95471835~95473998:+
BRCA	cis	rs1707322	0.721	rs10789468	ENSG00000234329.1	RP11-767N6.2	5.74	1.21e-08	1.74e-06	0.18	0.18	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45658886	chr1:45651039~45651826:-
BRCA	cis	rs2243480	1	rs35046236	ENSG00000232559.3	GS1-124K5.12	5.74	1.21e-08	1.74e-06	0.32	0.18	Diabetic kidney disease;	chr7:65943626	chr7:66554588~66576923:-
BRCA	cis	rs2243480	1	rs36068983	ENSG00000232559.3	GS1-124K5.12	5.74	1.21e-08	1.74e-06	0.32	0.18	Diabetic kidney disease;	chr7:65944004	chr7:66554588~66576923:-
BRCA	cis	rs2243480	1	rs68189316	ENSG00000232559.3	GS1-124K5.12	5.74	1.21e-08	1.74e-06	0.32	0.18	Diabetic kidney disease;	chr7:65944182	chr7:66554588~66576923:-
BRCA	cis	rs11105298	0.891	rs11105299	ENSG00000270344.2	RP11-734K2.4	5.74	1.21e-08	1.74e-06	0.2	0.18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89484166	chr12:89525654~89548005:+
BRCA	cis	rs11105298	0.891	rs1008764	ENSG00000270344.2	RP11-734K2.4	5.74	1.21e-08	1.74e-06	0.2	0.18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89493872	chr12:89525654~89548005:+
BRCA	cis	rs3760982	0.585	rs11673534	ENSG00000267058.1	RP11-15A1.3	-5.74	1.21e-08	1.74e-06	-0.2	-0.18	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43794732	chr19:43891804~43901805:-
BRCA	cis	rs3760982	0.585	rs11673490	ENSG00000267058.1	RP11-15A1.3	-5.74	1.21e-08	1.74e-06	-0.2	-0.18	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43794733	chr19:43891804~43901805:-
BRCA	cis	rs3760982	0.585	rs11083724	ENSG00000267058.1	RP11-15A1.3	-5.74	1.21e-08	1.74e-06	-0.2	-0.18	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43794836	chr19:43891804~43901805:-
BRCA	cis	rs2836950	0.565	rs7276046	ENSG00000255568.3	BRWD1-AS2	-5.74	1.21e-08	1.74e-06	-0.17	-0.18	Menarche (age at onset);	chr21:39209367	chr21:39313935~39314962:+
BRCA	cis	rs6479901	0.895	rs10761722	ENSG00000232075.1	MRPL35P2	-5.74	1.21e-08	1.74e-06	-0.25	-0.18	Intelligence (multi-trait analysis);	chr10:63195287	chr10:63634317~63634827:-
BRCA	cis	rs10129255	0.5	rs6576231	ENSG00000274576.2	IGHV2-70	-5.74	1.21e-08	1.74e-06	-0.14	-0.18	Kawasaki disease;	chr14:106783693	chr14:106770577~106771020:-
BRCA	cis	rs67311347	1	rs4973993	ENSG00000280739.1	EIF1B-AS1	5.74	1.21e-08	1.74e-06	0.21	0.18	Renal cell carcinoma;	chr3:40411469	chr3:40173145~40309698:-
BRCA	cis	rs67311347	1	rs4973994	ENSG00000280739.1	EIF1B-AS1	5.74	1.21e-08	1.74e-06	0.21	0.18	Renal cell carcinoma;	chr3:40411533	chr3:40173145~40309698:-
BRCA	cis	rs9847710	0.967	rs2564931	ENSG00000242142.1	SERBP1P3	5.74	1.21e-08	1.74e-06	0.2	0.18	Ulcerative colitis;	chr3:52986543	chr3:53064283~53065091:-
BRCA	cis	rs2836950	0.545	rs8132143	ENSG00000255568.3	BRWD1-AS2	-5.74	1.21e-08	1.74e-06	-0.17	-0.18	Menarche (age at onset);	chr21:39212332	chr21:39313935~39314962:+
BRCA	cis	rs7618501	0.633	rs9861216	ENSG00000228008.1	CTD-2330K9.3	-5.74	1.21e-08	1.74e-06	-0.17	-0.18	Intelligence (multi-trait analysis);	chr3:50021906	chr3:49903845~49916937:+
BRCA	cis	rs2179367	0.6	rs9498352	ENSG00000216906.2	RP11-350J20.9	5.74	1.21e-08	1.74e-06	0.26	0.18	Dupuytren's disease;	chr6:149439108	chr6:149904243~149906418:+
BRCA	cis	rs4908760	0.864	rs6701331	ENSG00000270282.1	RP5-1115A15.2	5.74	1.21e-08	1.74e-06	0.19	0.18	Vitiligo;	chr1:8610147	chr1:8512653~8513021:+
BRCA	cis	rs4237845	0.591	rs4760344	ENSG00000257159.1	RP11-58A17.3	5.74	1.21e-08	1.74e-06	0.22	0.18	Intelligence (multi-trait analysis);	chr12:57927000	chr12:57967058~57968399:+
BRCA	cis	rs12893668	0.572	rs4906350	ENSG00000269940.1	RP11-73M18.7	5.74	1.21e-08	1.74e-06	0.19	0.18	Reticulocyte count;	chr14:103645457	chr14:103694560~103695170:+
BRCA	cis	rs2645424	0.519	rs17154027	ENSG00000255046.1	RP11-297N6.4	-5.74	1.22e-08	1.74e-06	-0.2	-0.18	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);	chr8:11856343	chr8:11797928~11802568:-
BRCA	cis	rs1859596	1	rs7791832	ENSG00000234456.6	MAGI2-AS3	5.74	1.22e-08	1.74e-06	0.11	0.18	Reading or mathematical ability;	chr7:79459270	chr7:79452877~79471208:+
BRCA	cis	rs17818399	1	rs62136864	ENSG00000279254.1	RP11-536C12.1	-5.74	1.22e-08	1.74e-06	-0.22	-0.18	Height;	chr2:46601985	chr2:46668870~46670778:+
BRCA	cis	rs2243480	1	rs937108	ENSG00000232559.3	GS1-124K5.12	5.74	1.22e-08	1.75e-06	0.32	0.18	Diabetic kidney disease;	chr7:65963465	chr7:66554588~66576923:-
BRCA	cis	rs801193	0.569	rs7782587	ENSG00000224316.1	RP11-479O9.2	5.74	1.22e-08	1.75e-06	0.18	0.18	Aortic root size;	chr7:66701485	chr7:65773620~65802067:+
BRCA	cis	rs9907295	1	rs11653282	ENSG00000271013.1	AC015849.15	-5.74	1.22e-08	1.75e-06	-0.24	-0.18	Fibroblast growth factor basic levels;	chr17:35909742	chr17:35912635~35918010:-
BRCA	cis	rs12893668	0.603	rs61637848	ENSG00000269910.1	RP11-73M18.10	5.74	1.22e-08	1.75e-06	0.19	0.18	Reticulocyte count;	chr14:103629694	chr14:103694516~103695050:-
BRCA	cis	rs30380	0.688	rs27524	ENSG00000248734.2	CTD-2260A17.1	5.74	1.22e-08	1.75e-06	0.19	0.18	Cerebrospinal fluid biomarker levels;	chr5:96766240	chr5:96784777~96785999:+
BRCA	cis	rs2243480	1	rs7794661	ENSG00000232559.3	GS1-124K5.12	5.74	1.22e-08	1.75e-06	0.32	0.18	Diabetic kidney disease;	chr7:65924743	chr7:66554588~66576923:-
BRCA	cis	rs2836950	0.545	rs8132424	ENSG00000255568.3	BRWD1-AS2	5.74	1.22e-08	1.75e-06	0.17	0.18	Menarche (age at onset);	chr21:39212486	chr21:39313935~39314962:+
BRCA	cis	rs6840258	0.891	rs151451	ENSG00000251411.1	RP11-397E7.4	-5.74	1.22e-08	1.75e-06	-0.25	-0.18	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87085215	chr4:86913266~86914817:-
BRCA	cis	rs11790994	0.524	rs6478742	ENSG00000175611.10	LINC00476	5.74	1.22e-08	1.75e-06	0.25	0.18	Inattentive symptoms;	chr9:95722449	chr9:95759231~95875977:-
BRCA	cis	rs13126694	0.617	rs10008900	ENSG00000251429.1	RP11-597D13.7	5.74	1.22e-08	1.75e-06	0.17	0.18	Blood osmolality (transformed sodium);	chr4:157948827	chr4:158270378~158278676:+
BRCA	cis	rs7923609	0.967	rs10740134	ENSG00000232075.1	MRPL35P2	-5.74	1.22e-08	1.75e-06	-0.22	-0.18	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63555673	chr10:63634317~63634827:-
BRCA	cis	rs793571	0.505	rs28722857	ENSG00000259250.1	RP11-50C13.1	-5.74	1.22e-08	1.76e-06	-0.3	-0.18	Schizophrenia;	chr15:58633876	chr15:58587507~58591676:+
BRCA	cis	rs867371	0.82	rs12443224	ENSG00000259429.4	UBE2Q2P2	-5.74	1.22e-08	1.76e-06	-0.17	-0.18	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82203269	chr15:82355142~82420075:+
BRCA	cis	rs11722779	0.838	rs6821247	ENSG00000251288.2	RP11-10L12.2	-5.74	1.23e-08	1.76e-06	-0.2	-0.18	Schizophrenia;	chr4:102913483	chr4:102751401~102752641:+
BRCA	cis	rs7809950	0.678	rs12672451	ENSG00000238832.1	snoU109	-5.74	1.23e-08	1.76e-06	-0.26	-0.18	Coronary artery disease;	chr7:107213372	chr7:107603363~107603507:+
BRCA	cis	rs875971	0.862	rs11773628	ENSG00000224316.1	RP11-479O9.2	-5.74	1.23e-08	1.76e-06	-0.18	-0.18	Aortic root size;	chr7:66517644	chr7:65773620~65802067:+
BRCA	cis	rs910316	1	rs2300601	ENSG00000279594.1	RP11-950C14.10	5.74	1.23e-08	1.76e-06	0.2	0.18	Height;	chr14:75172868	chr14:75011269~75012851:-
BRCA	cis	rs7772486	0.623	rs735535	ENSG00000270638.1	RP3-466P17.1	-5.74	1.23e-08	1.76e-06	-0.2	-0.18	Lobe attachment (rater-scored or self-reported);	chr6:145715693	chr6:145735570~145737218:+
BRCA	cis	rs75422866	0.867	rs73113143	ENSG00000280054.1	RP1-197B17.7	5.74	1.23e-08	1.76e-06	0.44	0.18	Pneumonia;	chr12:47623060	chr12:47728151~47730598:-
BRCA	cis	rs2638953	0.777	rs10843181	ENSG00000278733.1	RP11-425D17.1	-5.74	1.23e-08	1.76e-06	-0.23	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28462824	chr12:28185625~28186190:-
BRCA	cis	rs7493	0.95	rs17880101	ENSG00000233942.1	AC004012.1	5.74	1.23e-08	1.76e-06	0.22	0.18	Yu-Zhi constitution type in type 2 diabetes;	chr7:95402145	chr7:95471835~95473998:+
BRCA	cis	rs7131987	0.65	rs16934135	ENSG00000275476.1	RP11-996F15.4	-5.74	1.23e-08	1.76e-06	-0.21	-0.18	QT interval;	chr12:29331030	chr12:29277397~29277882:-
BRCA	cis	rs7520050	0.933	rs6656022	ENSG00000280836.1	AL355480.1	5.74	1.23e-08	1.76e-06	0.21	0.18	Reticulocyte count;Red blood cell count;	chr1:45928643	chr1:45581219~45581321:-
BRCA	cis	rs9309473	1	rs6755217	ENSG00000163016.8	ALMS1P	5.74	1.23e-08	1.76e-06	0.23	0.18	Metabolite levels;	chr2:73414157	chr2:73644919~73685576:+
BRCA	cis	rs4950322	0.57	rs72692920	ENSG00000244371.2	PFN1P8	-5.74	1.23e-08	1.76e-06	-0.24	-0.18	Protein quantitative trait loci;	chr1:147308501	chr1:146957117~146957659:-
BRCA	cis	rs2058059	0.636	rs3015917	ENSG00000225648.4	SBDSP1	-5.74	1.23e-08	1.76e-06	-0.28	-0.18	Subcutaneous adipose tissue;	chr7:72679494	chr7:72829425~72836701:+
BRCA	cis	rs7567389	0.785	rs4150474	ENSG00000236682.1	AC068282.3	5.74	1.23e-08	1.76e-06	0.26	0.18	Self-rated health;	chr2:127275751	chr2:127389130~127400580:+
BRCA	cis	rs72799341	0.706	rs11865499	ENSG00000260911.2	RP11-196G11.2	5.74	1.23e-08	1.76e-06	0.17	0.18	Diastolic blood pressure;	chr16:31120929	chr16:31043150~31049868:+
BRCA	cis	rs6088580	0.524	rs6088552	ENSG00000269202.1	RP4-614O4.12	5.74	1.23e-08	1.76e-06	0.18	0.18	Glomerular filtration rate (creatinine);	chr20:34638687	chr20:35201747~35203288:-
BRCA	cis	rs2243480	0.803	rs36127118	ENSG00000164669.11	INTS4P1	5.74	1.23e-08	1.76e-06	0.34	0.18	Diabetic kidney disease;	chr7:66100518	chr7:65141225~65234216:+
BRCA	cis	rs11671005	0.735	rs34152946	ENSG00000252334.1	RNU6-1337P	5.74	1.23e-08	1.77e-06	0.26	0.18	Mean platelet volume;	chr19:58411896	chr19:58483749~58483843:-
BRCA	cis	rs7520050	0.931	rs11211198	ENSG00000280836.1	AL355480.1	5.74	1.23e-08	1.77e-06	0.2	0.18	Reticulocyte count;Red blood cell count;	chr1:45817001	chr1:45581219~45581321:-
BRCA	cis	rs7520050	0.966	rs10890352	ENSG00000280836.1	AL355480.1	5.74	1.23e-08	1.77e-06	0.2	0.18	Reticulocyte count;Red blood cell count;	chr1:45817956	chr1:45581219~45581321:-
BRCA	cis	rs7520050	0.966	rs6700597	ENSG00000280836.1	AL355480.1	5.74	1.23e-08	1.77e-06	0.2	0.18	Reticulocyte count;Red blood cell count;	chr1:45818574	chr1:45581219~45581321:-
BRCA	cis	rs6442522	1	rs9841038	ENSG00000249786.6	EAF1-AS1	5.74	1.23e-08	1.77e-06	0.18	0.18	Uric acid levels;	chr3:15412479	chr3:15436171~15455940:-
BRCA	cis	rs7829975	0.742	rs1533059	ENSG00000254153.1	CTA-398F10.2	-5.74	1.23e-08	1.77e-06	-0.21	-0.18	Mood instability;	chr8:8827443	chr8:8456909~8461337:-
BRCA	cis	rs577676	0.586	rs2022373	ENSG00000271811.1	RP1-79C4.4	5.74	1.24e-08	1.77e-06	0.2	0.18	Prevalent atrial fibrillation;	chr1:170619453	chr1:170667381~170669425:+
BRCA	cis	rs67981189	0.896	rs12100737	ENSG00000258571.1	PTTG4P	5.74	1.24e-08	1.77e-06	0.19	0.18	Schizophrenia;	chr14:71004383	chr14:71085482~71085833:-
BRCA	cis	rs7044106	0.762	rs4837789	ENSG00000238181.2	AHCYP2	-5.74	1.24e-08	1.77e-06	-0.23	-0.18	Hip circumference adjusted for BMI;	chr9:120663978	chr9:120720673~120721972:+
BRCA	cis	rs2243480	1	rs73142166	ENSG00000164669.11	INTS4P1	5.74	1.24e-08	1.77e-06	0.34	0.18	Diabetic kidney disease;	chr7:65910845	chr7:65141225~65234216:+
BRCA	cis	rs5015933	0.734	rs10126025	ENSG00000232630.1	PRPS1P2	-5.74	1.24e-08	1.78e-06	-0.16	-0.18	Body mass index;	chr9:125383785	chr9:125150653~125151589:+
BRCA	cis	rs34779708	0.897	rs7900480	ENSG00000271335.4	RP11-324I22.4	-5.74	1.24e-08	1.78e-06	-0.18	-0.18	Inflammatory bowel disease;Crohn's disease;	chr10:35049771	chr10:35314552~35336401:-
BRCA	cis	rs4218	0.531	rs8026611	ENSG00000277144.1	RP11-59H7.4	-5.74	1.24e-08	1.78e-06	-0.21	-0.18	Social communication problems;	chr15:59048927	chr15:59115547~59116089:-
BRCA	cis	rs12468226	0.817	rs2350360	ENSG00000226261.1	AC064836.3	-5.74	1.24e-08	1.78e-06	-0.29	-0.18	Urate levels;	chr2:202222980	chr2:202336024~202336727:-
BRCA	cis	rs2179367	0.632	rs9498338	ENSG00000223701.3	RAET1E-AS1	5.74	1.24e-08	1.78e-06	0.25	0.18	Dupuytren's disease;	chr6:149376428	chr6:149884431~149919508:+
BRCA	cis	rs516805	0.63	rs2606642	ENSG00000279453.1	RP3-425C14.4	5.74	1.24e-08	1.78e-06	0.24	0.18	Lymphocyte counts;	chr6:122103758	chr6:122436789~122439223:-
BRCA	cis	rs61160187	0.51	rs6872863	ENSG00000272308.1	RP11-231G3.1	-5.74	1.24e-08	1.78e-06	-0.19	-0.18	Educational attainment (years of education);Educational attainment (college completion);	chr5:60792321	chr5:60866457~60866935:-
BRCA	cis	rs61160187	0.527	rs6873181	ENSG00000272308.1	RP11-231G3.1	-5.74	1.24e-08	1.78e-06	-0.19	-0.18	Educational attainment (years of education);Educational attainment (college completion);	chr5:60792423	chr5:60866457~60866935:-
BRCA	cis	rs61160187	0.527	rs6894672	ENSG00000272308.1	RP11-231G3.1	-5.74	1.24e-08	1.78e-06	-0.19	-0.18	Educational attainment (years of education);Educational attainment (college completion);	chr5:60792428	chr5:60866457~60866935:-
BRCA	cis	rs7086627	0.515	rs10887900	ENSG00000226659.1	RP11-137H2.4	-5.74	1.24e-08	1.78e-06	-0.23	-0.18	Post bronchodilator FEV1;	chr10:80450509	chr10:80529597~80535942:-
BRCA	cis	rs34792	0.688	rs170168	ENSG00000207425.1	Y_RNA	-5.74	1.25e-08	1.78e-06	-0.22	-0.18	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15507138	chr16:14915457~14915556:-
BRCA	cis	rs2688608	0.839	rs2633311	ENSG00000271816.1	BMS1P4	-5.74	1.25e-08	1.78e-06	-0.17	-0.18	Inflammatory bowel disease;	chr10:73838341	chr10:73699151~73730487:-
BRCA	cis	rs2832191	0.692	rs2245734	ENSG00000176054.6	RPL23P2	5.74	1.25e-08	1.78e-06	0.19	0.18	Dental caries;	chr21:28987644	chr21:28997613~28998033:-
BRCA	cis	rs4718428	0.705	rs3800817	ENSG00000230295.1	RP11-458F8.2	-5.74	1.25e-08	1.79e-06	-0.16	-0.18	Corneal structure;	chr7:66798563	chr7:66880708~66882981:+
BRCA	cis	rs7772486	0.875	rs2748497	ENSG00000270638.1	RP3-466P17.1	5.74	1.25e-08	1.79e-06	0.2	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145998281	chr6:145735570~145737218:+
BRCA	cis	rs2179367	0.632	rs9498336	ENSG00000223701.3	RAET1E-AS1	5.74	1.25e-08	1.79e-06	0.25	0.18	Dupuytren's disease;	chr6:149374208	chr6:149884431~149919508:+
BRCA	cis	rs2179367	0.632	rs1980774	ENSG00000223701.3	RAET1E-AS1	5.74	1.25e-08	1.79e-06	0.25	0.18	Dupuytren's disease;	chr6:149375030	chr6:149884431~149919508:+
BRCA	cis	rs2179367	0.632	rs9498337	ENSG00000223701.3	RAET1E-AS1	5.74	1.25e-08	1.79e-06	0.25	0.18	Dupuytren's disease;	chr6:149375970	chr6:149884431~149919508:+
BRCA	cis	rs7246967	0.673	rs62120125	ENSG00000198153.8	ZNF849P	-5.74	1.25e-08	1.79e-06	-0.26	-0.18	Bronchopulmonary dysplasia;	chr19:22772297	chr19:22685167~22686732:+
BRCA	cis	rs7246967	0.611	rs2194113	ENSG00000198153.8	ZNF849P	-5.74	1.25e-08	1.79e-06	-0.26	-0.18	Bronchopulmonary dysplasia;	chr19:22775273	chr19:22685167~22686732:+
BRCA	cis	rs7246967	0.673	rs55744741	ENSG00000198153.8	ZNF849P	-5.74	1.25e-08	1.79e-06	-0.26	-0.18	Bronchopulmonary dysplasia;	chr19:22777171	chr19:22685167~22686732:+
BRCA	cis	rs7246967	0.673	rs4933036	ENSG00000198153.8	ZNF849P	-5.74	1.25e-08	1.79e-06	-0.26	-0.18	Bronchopulmonary dysplasia;	chr19:22780267	chr19:22685167~22686732:+
BRCA	cis	rs7246967	0.673	rs35061555	ENSG00000198153.8	ZNF849P	-5.74	1.25e-08	1.79e-06	-0.26	-0.18	Bronchopulmonary dysplasia;	chr19:22780964	chr19:22685167~22686732:+
BRCA	cis	rs6969780	1	rs6948297	ENSG00000233429.8	HOTAIRM1	5.74	1.25e-08	1.79e-06	0.23	0.18	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27109785	chr7:27095647~27100265:+
BRCA	cis	rs1005277	0.683	rs7923868	ENSG00000226578.1	RP11-258F22.1	-5.74	1.25e-08	1.79e-06	-0.19	-0.18	Extrinsic epigenetic age acceleration;	chr10:37700838	chr10:37775371~37784131:-
BRCA	cis	rs9990333	0.562	rs75681503	ENSG00000231464.1	AC024937.4	5.74	1.25e-08	1.79e-06	0.23	0.18	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196095414	chr3:195996738~195998233:+
BRCA	cis	rs67766926	0.541	rs13412375	ENSG00000271889.1	RP11-493E12.1	5.74	1.25e-08	1.79e-06	0.26	0.18	Inflammatory skin disease;	chr2:61066988	chr2:61151433~61162105:-
BRCA	cis	rs2638953	0.741	rs12184491	ENSG00000278733.1	RP11-425D17.1	-5.74	1.25e-08	1.79e-06	-0.24	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28535619	chr12:28185625~28186190:-
BRCA	cis	rs7577696	0.597	rs13006495	ENSG00000272716.1	RP11-563N4.1	-5.74	1.25e-08	1.79e-06	-0.21	-0.18	Inflammatory biomarkers;	chr2:32130421	chr2:32165046~32165757:-
BRCA	cis	rs6432852	0.516	rs2304002	ENSG00000232411.1	AC009495.3	5.74	1.25e-08	1.79e-06	0.2	0.18	Diabetic kidney disease;	chr2:165857585	chr2:165833048~165839098:-
BRCA	cis	rs7308116	0.546	rs61938612	ENSG00000274395.1	RP11-554D14.8	-5.74	1.25e-08	1.79e-06	-0.21	-0.18	Pelvic organ prolapse (moderate/severe);	chr12:107828556	chr12:107835541~107836555:-
BRCA	cis	rs10895987	1	rs72932837	ENSG00000254614.2	AP003068.23	5.74	1.26e-08	1.8e-06	0.28	0.18	Blood protein levels;	chr11:65109268	chr11:65177606~65181834:-
BRCA	cis	rs2243480	0.908	rs313822	ENSG00000228409.4	CCT6P1	5.74	1.26e-08	1.8e-06	0.25	0.18	Diabetic kidney disease;	chr7:66108952	chr7:65751142~65763354:+
BRCA	cis	rs1552244	0.935	rs7618815	ENSG00000180385.7	EMC3-AS1	5.74	1.26e-08	1.8e-06	0.22	0.18	Alzheimer's disease;	chr3:10109361	chr3:9986893~10006990:+
BRCA	cis	rs1552244	1	rs7652935	ENSG00000180385.7	EMC3-AS1	5.74	1.26e-08	1.8e-06	0.22	0.18	Alzheimer's disease;	chr3:10109454	chr3:9986893~10006990:+
BRCA	cis	rs1552244	1	rs67134728	ENSG00000180385.7	EMC3-AS1	5.74	1.26e-08	1.8e-06	0.22	0.18	Alzheimer's disease;	chr3:10109747	chr3:9986893~10006990:+
BRCA	cis	rs11098499	0.566	rs7664440	ENSG00000249244.1	RP11-548H18.2	5.74	1.26e-08	1.8e-06	0.22	0.18	Corneal astigmatism;	chr4:119657385	chr4:119391831~119395335:-
BRCA	cis	rs7976269	0.609	rs4402335	ENSG00000275476.1	RP11-996F15.4	-5.74	1.26e-08	1.8e-06	-0.2	-0.18	Male-pattern baldness;	chr12:29052836	chr12:29277397~29277882:-
BRCA	cis	rs73222236	0.825	rs9860801	ENSG00000273486.1	RP11-731C17.2	5.74	1.26e-08	1.8e-06	0.2	0.17	Coronary artery disease;	chr3:136369196	chr3:136837338~136839021:-
BRCA	cis	rs13423976	0.631	rs4566347	ENSG00000231367.4	AC016995.3	5.74	1.26e-08	1.8e-06	0.19	0.17	Gut microbiome composition (summer);	chr2:38515498	chr2:38406719~38515740:-
BRCA	cis	rs7131987	0.565	rs4412790	ENSG00000275476.1	RP11-996F15.4	5.74	1.26e-08	1.8e-06	0.19	0.17	QT interval;	chr12:29253828	chr12:29277397~29277882:-
BRCA	cis	rs2834188	0.924	rs2850015	ENSG00000272659.1	AP000295.10	-5.74	1.26e-08	1.8e-06	-0.26	-0.17	Narcolepsy;	chr21:33324959	chr21:33309491~33310181:+
BRCA	cis	rs7976269	0.609	rs10771470	ENSG00000275476.1	RP11-996F15.4	-5.74	1.26e-08	1.8e-06	-0.2	-0.17	Male-pattern baldness;	chr12:29050620	chr12:29277397~29277882:-
BRCA	cis	rs7976269	0.609	rs10743641	ENSG00000275476.1	RP11-996F15.4	-5.74	1.26e-08	1.8e-06	-0.2	-0.17	Male-pattern baldness;	chr12:29050819	chr12:29277397~29277882:-
BRCA	cis	rs7976269	0.609	rs4930846	ENSG00000275476.1	RP11-996F15.4	-5.74	1.26e-08	1.8e-06	-0.2	-0.17	Male-pattern baldness;	chr12:29051306	chr12:29277397~29277882:-
BRCA	cis	rs1858037	0.806	rs12612780	ENSG00000204929.10	AC074391.1	5.74	1.26e-08	1.8e-06	0.23	0.17	Rheumatoid arthritis;	chr2:65355967	chr2:65436711~66084639:+
BRCA	cis	rs690037	0.641	rs538525	ENSG00000271964.1	RP11-415F23.2	5.74	1.26e-08	1.81e-06	0.18	0.17	Optic nerve measurement (cup-to-disc ratio);Optic nerve measurement (cup area);	chr3:16334772	chr3:16314439~16314987:+
BRCA	cis	rs1707322	0.896	rs946528	ENSG00000281133.1	AL355480.3	5.74	1.27e-08	1.81e-06	0.22	0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46019890	chr1:45580892~45580996:-
BRCA	cis	rs2919009	0.664	rs55968513	ENSG00000271670.1	RP11-95I16.4	5.74	1.27e-08	1.81e-06	0.22	0.17	Obesity-related traits;	chr10:120859067	chr10:120879256~120880667:-
BRCA	cis	rs11668609	1	rs66972560	ENSG00000268442.1	CTD-2027I19.2	5.74	1.27e-08	1.81e-06	0.24	0.17	Response to taxane treatment (docetaxel);	chr19:24178138	chr19:24162370~24163425:-
BRCA	cis	rs1552244	0.882	rs13066757	ENSG00000232901.1	CYCSP10	5.74	1.27e-08	1.81e-06	0.25	0.17	Alzheimer's disease;	chr3:10003346	chr3:10000647~10000940:-
BRCA	cis	rs1075265	0.722	rs2111623	ENSG00000235937.1	AC008280.1	-5.74	1.27e-08	1.81e-06	-0.19	-0.17	Chronotype;Morning vs. evening chronotype;	chr2:53757820	chr2:54029552~54030682:-
BRCA	cis	rs2243480	0.711	rs1626926	ENSG00000230295.1	RP11-458F8.2	-5.74	1.27e-08	1.81e-06	-0.23	-0.17	Diabetic kidney disease;	chr7:65970805	chr7:66880708~66882981:+
BRCA	cis	rs2337406	0.539	rs2583292	ENSG00000211974.3	IGHV2-70	-5.74	1.27e-08	1.81e-06	-0.21	-0.17	Alzheimer's disease (late onset);	chr14:106649040	chr14:106723574~106724093:-
BRCA	cis	rs9545047	0.604	rs7319212	ENSG00000227354.5	RBM26-AS1	-5.74	1.27e-08	1.82e-06	-0.19	-0.17	Schizophrenia;	chr13:79365404	chr13:79406309~79424328:+
BRCA	cis	rs9545047	0.604	rs7319252	ENSG00000227354.5	RBM26-AS1	-5.74	1.27e-08	1.82e-06	-0.19	-0.17	Schizophrenia;	chr13:79365471	chr13:79406309~79424328:+
BRCA	cis	rs9545047	0.604	rs9318633	ENSG00000227354.5	RBM26-AS1	-5.74	1.27e-08	1.82e-06	-0.19	-0.17	Schizophrenia;	chr13:79369113	chr13:79406309~79424328:+
BRCA	cis	rs9545047	0.604	rs12872328	ENSG00000227354.5	RBM26-AS1	-5.74	1.27e-08	1.82e-06	-0.19	-0.17	Schizophrenia;	chr13:79370489	chr13:79406309~79424328:+
BRCA	cis	rs9545047	0.604	rs2182010	ENSG00000227354.5	RBM26-AS1	-5.74	1.27e-08	1.82e-06	-0.19	-0.17	Schizophrenia;	chr13:79370618	chr13:79406309~79424328:+
BRCA	cis	rs9545047	0.604	rs35476664	ENSG00000227354.5	RBM26-AS1	-5.74	1.27e-08	1.82e-06	-0.19	-0.17	Schizophrenia;	chr13:79375462	chr13:79406309~79424328:+
BRCA	cis	rs10510102	0.872	rs11200277	ENSG00000226864.1	ATE1-AS1	5.74	1.27e-08	1.82e-06	0.32	0.17	Breast cancer;	chr10:121944295	chr10:121928312~121951965:+
BRCA	cis	rs4950322	0.57	rs72691041	ENSG00000244371.2	PFN1P8	-5.74	1.27e-08	1.82e-06	-0.24	-0.17	Protein quantitative trait loci;	chr1:147267084	chr1:146957117~146957659:-
BRCA	cis	rs2243480	1	rs4718334	ENSG00000232559.3	GS1-124K5.12	-5.74	1.27e-08	1.82e-06	-0.33	-0.17	Diabetic kidney disease;	chr7:66324467	chr7:66554588~66576923:-
BRCA	cis	rs8098244	0.597	rs1154247	ENSG00000264745.1	TTC39C-AS1	-5.74	1.27e-08	1.82e-06	-0.24	-0.17	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23984452	chr18:23994213~24015339:-
BRCA	cis	rs2243480	1	rs4718333	ENSG00000228409.4	CCT6P1	-5.74	1.27e-08	1.82e-06	-0.25	-0.17	Diabetic kidney disease;	chr7:66307771	chr7:65751142~65763354:+
BRCA	cis	rs2243480	1	rs7792391	ENSG00000228409.4	CCT6P1	-5.74	1.27e-08	1.82e-06	-0.25	-0.17	Diabetic kidney disease;	chr7:66308442	chr7:65751142~65763354:+
BRCA	cis	rs6088813	1	rs6141548	ENSG00000126005.14	MMP24-AS1	5.74	1.27e-08	1.82e-06	0.21	0.17	Height;	chr20:35383282	chr20:35216462~35278131:-
BRCA	cis	rs2153535	0.536	rs78180822	ENSG00000230939.1	RP11-314C16.1	-5.74	1.27e-08	1.82e-06	-0.2	-0.17	Motion sickness;	chr6:8620941	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.561	rs9405407	ENSG00000230939.1	RP11-314C16.1	-5.74	1.27e-08	1.82e-06	-0.2	-0.17	Motion sickness;	chr6:8665199	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.585	rs9378566	ENSG00000230939.1	RP11-314C16.1	-5.74	1.27e-08	1.82e-06	-0.2	-0.17	Motion sickness;	chr6:8665203	chr6:8784178~8785445:+
BRCA	cis	rs4700393	0.967	rs4700394	ENSG00000272308.1	RP11-231G3.1	5.74	1.27e-08	1.82e-06	0.19	0.17	Intelligence (multi-trait analysis);	chr5:60821375	chr5:60866457~60866935:-
BRCA	cis	rs11098499	0.955	rs56386062	ENSG00000249244.1	RP11-548H18.2	5.74	1.28e-08	1.82e-06	0.21	0.17	Corneal astigmatism;	chr4:119233980	chr4:119391831~119395335:-
BRCA	cis	rs4819052	0.885	rs28576202	ENSG00000184274.3	LINC00315	-5.74	1.28e-08	1.82e-06	-0.24	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45254769	chr21:45300245~45305257:-
BRCA	cis	rs801193	0.569	rs6978178	ENSG00000224316.1	RP11-479O9.2	-5.74	1.28e-08	1.82e-06	-0.18	-0.17	Aortic root size;	chr7:66658097	chr7:65773620~65802067:+
BRCA	cis	rs919433	0.68	rs7568250	ENSG00000231621.1	AC013264.2	-5.74	1.28e-08	1.82e-06	-0.17	-0.17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197544887	chr2:197197991~197199273:+
BRCA	cis	rs651907	0.535	rs34648996	ENSG00000244119.1	PDCL3P4	5.73	1.28e-08	1.82e-06	0.14	0.17	Colorectal cancer;	chr3:101792358	chr3:101712472~101713191:+
BRCA	cis	rs9545047	0.567	rs9574420	ENSG00000227354.5	RBM26-AS1	-5.73	1.28e-08	1.82e-06	-0.19	-0.17	Schizophrenia;	chr13:79404342	chr13:79406309~79424328:+
BRCA	cis	rs11668609	0.81	rs8105851	ENSG00000268442.1	CTD-2027I19.2	5.73	1.28e-08	1.83e-06	0.24	0.17	Response to taxane treatment (docetaxel);	chr19:24080533	chr19:24162370~24163425:-
BRCA	cis	rs4604234	0.614	rs3749896	ENSG00000272129.1	RP11-250B2.6	-5.73	1.28e-08	1.83e-06	-0.45	-0.17	Cancer;	chr6:80203260	chr6:80355424~80356859:+
BRCA	cis	rs77972916	0.536	rs11679731	ENSG00000234936.1	AC010883.5	5.73	1.28e-08	1.83e-06	0.22	0.17	Granulocyte percentage of myeloid white cells;	chr2:43361925	chr2:43229573~43233394:+
BRCA	cis	rs2098713	0.575	rs10461981	ENSG00000250155.1	CTD-2353F22.1	-5.73	1.28e-08	1.83e-06	-0.21	-0.17	Telomere length;	chr5:37470124	chr5:36666214~36725195:-
BRCA	cis	rs2638953	0.853	rs11049622	ENSG00000278733.1	RP11-425D17.1	-5.73	1.28e-08	1.83e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28457637	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.888	rs10843177	ENSG00000278733.1	RP11-425D17.1	-5.73	1.28e-08	1.83e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28457737	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.853	rs10771428	ENSG00000278733.1	RP11-425D17.1	-5.73	1.28e-08	1.83e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28458070	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.853	rs10506035	ENSG00000278733.1	RP11-425D17.1	-5.73	1.28e-08	1.83e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28458159	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.815	rs11049627	ENSG00000278733.1	RP11-425D17.1	-5.73	1.28e-08	1.83e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28459389	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.853	rs11049628	ENSG00000278733.1	RP11-425D17.1	-5.73	1.28e-08	1.83e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28459781	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.853	rs11049629	ENSG00000278733.1	RP11-425D17.1	-5.73	1.28e-08	1.83e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28459856	chr12:28185625~28186190:-
BRCA	cis	rs1198430	0.683	rs1198433	ENSG00000232482.2	RP4-654C18.1	-5.73	1.28e-08	1.83e-06	-0.24	-0.17	Total cholesterol levels;	chr1:23430202	chr1:23410832~23412146:+
BRCA	cis	rs1440410	0.56	rs4395451	ENSG00000250326.1	RP11-284M14.1	-5.73	1.28e-08	1.83e-06	-0.21	-0.17	Ischemic stroke;	chr4:143155872	chr4:142933195~143184861:-
BRCA	cis	rs300890	0.513	rs7680365	ENSG00000250326.1	RP11-284M14.1	-5.73	1.28e-08	1.83e-06	-0.21	-0.17	Nasopharyngeal carcinoma;	chr4:143157603	chr4:142933195~143184861:-
BRCA	cis	rs300890	0.513	rs72719180	ENSG00000250326.1	RP11-284M14.1	5.73	1.28e-08	1.83e-06	0.21	0.17	Nasopharyngeal carcinoma;	chr4:143140520	chr4:142933195~143184861:-
BRCA	cis	rs300890	0.513	rs4566607	ENSG00000250326.1	RP11-284M14.1	5.73	1.28e-08	1.83e-06	0.21	0.17	Nasopharyngeal carcinoma;	chr4:143141089	chr4:142933195~143184861:-
BRCA	cis	rs300890	0.513	rs72719182	ENSG00000250326.1	RP11-284M14.1	5.73	1.28e-08	1.83e-06	0.21	0.17	Nasopharyngeal carcinoma;	chr4:143147652	chr4:142933195~143184861:-
BRCA	cis	rs300890	0.513	rs7685464	ENSG00000250326.1	RP11-284M14.1	5.73	1.28e-08	1.83e-06	0.21	0.17	Nasopharyngeal carcinoma;	chr4:143151285	chr4:142933195~143184861:-
BRCA	cis	rs300890	0.513	rs12500240	ENSG00000250326.1	RP11-284M14.1	5.73	1.28e-08	1.83e-06	0.21	0.17	Nasopharyngeal carcinoma;	chr4:143151507	chr4:142933195~143184861:-
BRCA	cis	rs300890	0.513	rs11100775	ENSG00000250326.1	RP11-284M14.1	5.73	1.28e-08	1.83e-06	0.21	0.17	Nasopharyngeal carcinoma;	chr4:143152759	chr4:142933195~143184861:-
BRCA	cis	rs7208859	0.673	rs11657270	ENSG00000265443.1	CTD-2349P21.6	-5.73	1.28e-08	1.83e-06	-0.29	-0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887369	chr17:30726305~30727564:-
BRCA	cis	rs71636778	0.509	rs34026879	ENSG00000260063.1	RP5-968P14.2	-5.73	1.28e-08	1.83e-06	-0.39	-0.17	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26741747	chr1:26692132~26694131:-
BRCA	cis	rs71636778	0.509	rs34693293	ENSG00000260063.1	RP5-968P14.2	-5.73	1.28e-08	1.83e-06	-0.39	-0.17	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26742480	chr1:26692132~26694131:-
BRCA	cis	rs71636778	0.509	rs35560426	ENSG00000260063.1	RP5-968P14.2	-5.73	1.28e-08	1.83e-06	-0.39	-0.17	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26742678	chr1:26692132~26694131:-
BRCA	cis	rs71636778	0.509	rs58421016	ENSG00000260063.1	RP5-968P14.2	-5.73	1.28e-08	1.83e-06	-0.39	-0.17	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26744038	chr1:26692132~26694131:-
BRCA	cis	rs71636778	0.642	rs12752833	ENSG00000260063.1	RP5-968P14.2	-5.73	1.28e-08	1.83e-06	-0.39	-0.17	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26747433	chr1:26692132~26694131:-
BRCA	cis	rs71636778	0.509	rs115772301	ENSG00000260063.1	RP5-968P14.2	-5.73	1.28e-08	1.83e-06	-0.39	-0.17	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26749193	chr1:26692132~26694131:-
BRCA	cis	rs41307935	0.643	rs34909427	ENSG00000260063.1	RP5-968P14.2	-5.73	1.28e-08	1.83e-06	-0.39	-0.17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26750763	chr1:26692132~26694131:-
BRCA	cis	rs41307935	0.908	rs12735646	ENSG00000260063.1	RP5-968P14.2	-5.73	1.28e-08	1.83e-06	-0.39	-0.17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26751875	chr1:26692132~26694131:-
BRCA	cis	rs9990333	0.562	rs55970879	ENSG00000231464.1	AC024937.4	5.73	1.28e-08	1.83e-06	0.23	0.17	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196095095	chr3:195996738~195998233:+
BRCA	cis	rs295490	0.748	rs78490940	ENSG00000272656.1	RP11-219D15.3	5.73	1.28e-08	1.83e-06	0.41	0.17	PR interval in Tripanosoma cruzi seropositivity;	chr3:139370333	chr3:139349024~139349371:-
BRCA	cis	rs7615952	0.576	rs2276729	ENSG00000171084.14	FAM86JP	5.73	1.28e-08	1.83e-06	0.26	0.17	Blood pressure (smoking interaction);	chr3:126107371	chr3:125916620~125930024:+
BRCA	cis	rs875971	0.545	rs1909508	ENSG00000228409.4	CCT6P1	-5.73	1.28e-08	1.84e-06	-0.17	-0.17	Aortic root size;	chr7:66301366	chr7:65751142~65763354:+
BRCA	cis	rs2998286	0.723	rs332190	ENSG00000254635.4	WAC-AS1	-5.73	1.29e-08	1.84e-06	-0.28	-0.17	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28630899	chr10:28522652~28532743:-
BRCA	cis	rs12701220	0.522	rs12701455	ENSG00000229043.2	AC091729.9	-5.73	1.29e-08	1.84e-06	-0.23	-0.17	Bronchopulmonary dysplasia;	chr7:1015773	chr7:1160374~1165267:+
BRCA	cis	rs4908768	0.539	rs7537982	ENSG00000270282.1	RP5-1115A15.2	5.73	1.29e-08	1.84e-06	0.19	0.17	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8583948	chr1:8512653~8513021:+
BRCA	cis	rs6088580	0.524	rs6087616	ENSG00000269202.1	RP4-614O4.12	5.73	1.29e-08	1.84e-06	0.18	0.17	Glomerular filtration rate (creatinine);	chr20:34675229	chr20:35201747~35203288:-
BRCA	cis	rs12893668	0.603	rs61637848	ENSG00000269940.1	RP11-73M18.7	5.73	1.29e-08	1.84e-06	0.19	0.17	Reticulocyte count;	chr14:103629694	chr14:103694560~103695170:+
BRCA	cis	rs9527	0.662	rs743575	ENSG00000236937.2	PTGES3P4	5.73	1.29e-08	1.84e-06	0.25	0.17	Arsenic metabolism;	chr10:102835149	chr10:102845595~102845950:+
BRCA	cis	rs3814244	0.897	rs4141135	ENSG00000236946.2	HNRNPA1P70	-5.73	1.29e-08	1.84e-06	-0.14	-0.17	Itch intensity from mosquito bite adjusted by bite size;	chr12:68025050	chr12:68035767~68036853:+
BRCA	cis	rs9291683	0.546	rs13146686	ENSG00000250413.1	RP11-448G15.1	-5.73	1.29e-08	1.84e-06	-0.23	-0.17	Bone mineral density;	chr4:10033309	chr4:10006482~10009725:+
BRCA	cis	rs754466	0.58	rs10430530	ENSG00000204049.1	RP11-126H7.4	5.73	1.29e-08	1.84e-06	0.21	0.17	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77823054	chr10:77866875~77869610:+
BRCA	cis	rs2288884	1	rs58817690	ENSG00000275055.1	CTC-471J1.11	-5.73	1.29e-08	1.84e-06	-0.26	-0.17	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52033439	chr19:52049007~52049754:+
BRCA	cis	rs7247513	0.964	rs8100964	ENSG00000213290.4	PGK1P2	-5.73	1.29e-08	1.84e-06	-0.24	-0.17	Bipolar disorder;	chr19:12609817	chr19:12559571~12561105:+
BRCA	cis	rs9876781	1	rs9812647	ENSG00000229759.1	MRPS18AP1	-5.73	1.29e-08	1.84e-06	-0.2	-0.17	Longevity;	chr3:48407507	chr3:48256350~48256938:-
BRCA	cis	rs2243480	0.901	rs57126451	ENSG00000232559.3	GS1-124K5.12	5.73	1.29e-08	1.84e-06	0.32	0.17	Diabetic kidney disease;	chr7:65951319	chr7:66554588~66576923:-
BRCA	cis	rs3892630	0.878	rs1061686	ENSG00000267567.1	CTD-2538C1.3	-5.73	1.29e-08	1.85e-06	-0.28	-0.17	Red blood cell traits;	chr19:32713638	chr19:32718298~32719595:-
BRCA	cis	rs2638953	0.924	rs11049608	ENSG00000278733.1	RP11-425D17.1	-5.73	1.29e-08	1.85e-06	-0.24	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28445528	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.924	rs11049609	ENSG00000278733.1	RP11-425D17.1	-5.73	1.29e-08	1.85e-06	-0.24	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28445732	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.924	rs11049612	ENSG00000278733.1	RP11-425D17.1	-5.73	1.29e-08	1.85e-06	-0.24	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28449160	chr12:28185625~28186190:-
BRCA	cis	rs9921338	0.54	rs2868410	ENSG00000263080.1	RP11-485G7.5	5.73	1.29e-08	1.85e-06	0.23	0.17	Vein graft stenosis in coronary artery bypass grafting;	chr16:11334244	chr16:11341809~11345211:-
BRCA	cis	rs295490	0.748	rs41399544	ENSG00000272656.1	RP11-219D15.3	5.73	1.3e-08	1.85e-06	0.4	0.17	PR interval in Tripanosoma cruzi seropositivity;	chr3:139356303	chr3:139349024~139349371:-
BRCA	cis	rs2115630	1	rs6496441	ENSG00000229212.6	RP11-561C5.4	5.73	1.3e-08	1.85e-06	0.19	0.17	P wave terminal force;	chr15:84820117	chr15:85205440~85234795:-
BRCA	cis	rs9840812	0.637	rs698270	ENSG00000239213.4	NCK1-AS1	5.73	1.3e-08	1.85e-06	0.22	0.17	Fibrinogen levels;	chr3:136390670	chr3:136841726~136862054:-
BRCA	cis	rs7246657	0.551	rs11084873	ENSG00000276846.1	CTD-3220F14.3	5.73	1.3e-08	1.85e-06	0.27	0.17	Coronary artery calcification;	chr19:37093008	chr19:37314868~37315620:-
BRCA	cis	rs4950322	0.57	rs80270233	ENSG00000244371.2	PFN1P8	-5.73	1.3e-08	1.85e-06	-0.24	-0.17	Protein quantitative trait loci;	chr1:147263320	chr1:146957117~146957659:-
BRCA	cis	rs4950322	0.57	rs17356240	ENSG00000244371.2	PFN1P8	-5.73	1.3e-08	1.85e-06	-0.24	-0.17	Protein quantitative trait loci;	chr1:147269877	chr1:146957117~146957659:-
BRCA	cis	rs4950322	0.57	rs1999820	ENSG00000244371.2	PFN1P8	-5.73	1.3e-08	1.85e-06	-0.24	-0.17	Protein quantitative trait loci;	chr1:147270329	chr1:146957117~146957659:-
BRCA	cis	rs4950322	0.57	rs4950316	ENSG00000244371.2	PFN1P8	-5.73	1.3e-08	1.85e-06	-0.24	-0.17	Protein quantitative trait loci;	chr1:147273712	chr1:146957117~146957659:-
BRCA	cis	rs6452524	0.508	rs256795	ENSG00000281327.1	LINC01338	-5.73	1.3e-08	1.85e-06	-0.21	-0.17	Hypertension (SNP x SNP interaction);	chr5:83001543	chr5:82850864~82859836:-
BRCA	cis	rs875971	0.545	rs11770063	ENSG00000228409.4	CCT6P1	-5.73	1.3e-08	1.86e-06	-0.18	-0.17	Aortic root size;	chr7:66318029	chr7:65751142~65763354:+
BRCA	cis	rs7246657	0.943	rs6508733	ENSG00000267422.1	CTD-2554C21.1	-5.73	1.3e-08	1.86e-06	-0.25	-0.17	Coronary artery calcification;	chr19:37509646	chr19:37779686~37792865:+
BRCA	cis	rs6570726	0.791	rs9373464	ENSG00000270638.1	RP3-466P17.1	5.73	1.3e-08	1.86e-06	0.2	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145586031	chr6:145735570~145737218:+
BRCA	cis	rs2243480	1	rs316313	ENSG00000164669.11	INTS4P1	5.73	1.3e-08	1.86e-06	0.34	0.17	Diabetic kidney disease;	chr7:66128561	chr7:65141225~65234216:+
BRCA	cis	rs2243480	1	rs316312	ENSG00000164669.11	INTS4P1	5.73	1.3e-08	1.86e-06	0.34	0.17	Diabetic kidney disease;	chr7:66131504	chr7:65141225~65234216:+
BRCA	cis	rs2243480	1	rs419603	ENSG00000164669.11	INTS4P1	5.73	1.3e-08	1.86e-06	0.34	0.17	Diabetic kidney disease;	chr7:66132354	chr7:65141225~65234216:+
BRCA	cis	rs7044106	0.762	rs4142158	ENSG00000238181.2	AHCYP2	-5.73	1.3e-08	1.86e-06	-0.23	-0.17	Hip circumference adjusted for BMI;	chr9:120648541	chr9:120720673~120721972:+
BRCA	cis	rs12468226	1	rs58288071	ENSG00000226261.1	AC064836.3	5.73	1.3e-08	1.86e-06	0.3	0.17	Urate levels;	chr2:202350016	chr2:202336024~202336727:-
BRCA	cis	rs755249	0.501	rs1889830	ENSG00000228060.1	RP11-69E11.8	5.73	1.3e-08	1.86e-06	0.19	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39264500	chr1:39565160~39573203:+
BRCA	cis	rs7238033	0.624	rs11877062	ENSG00000267193.4	RP11-116O18.3	5.73	1.3e-08	1.86e-06	0.19	0.17	Bladder cancer;	chr18:45727281	chr18:45669367~45747215:-
BRCA	cis	rs7923609	0.811	rs3847325	ENSG00000232075.1	MRPL35P2	5.73	1.31e-08	1.86e-06	0.22	0.17	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63571751	chr10:63634317~63634827:-
BRCA	cis	rs6540731	0.905	rs11119883	ENSG00000229983.1	RP11-15I11.2	5.73	1.31e-08	1.86e-06	0.2	0.17	Intelligence (childhood);	chr1:212213918	chr1:212168207~212190259:+
BRCA	cis	rs875971	0.545	rs73142233	ENSG00000228409.4	CCT6P1	-5.73	1.31e-08	1.86e-06	-0.18	-0.17	Aortic root size;	chr7:66221293	chr7:65751142~65763354:+
BRCA	cis	rs2638953	0.962	rs10843159	ENSG00000278733.1	RP11-425D17.1	-5.73	1.31e-08	1.86e-06	-0.24	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28354597	chr12:28185625~28186190:-
BRCA	cis	rs4787491	0.729	rs7191849	ENSG00000273724.1	RP11-347C12.12	-5.73	1.31e-08	1.86e-06	-0.19	-0.17	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30011836	chr16:30336400~30343336:+
BRCA	cis	rs2638953	0.893	rs7313862	ENSG00000278733.1	RP11-425D17.1	-5.73	1.31e-08	1.86e-06	-0.21	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28458846	chr12:28185625~28186190:-
BRCA	cis	rs2243480	1	rs35058610	ENSG00000232559.3	GS1-124K5.12	5.73	1.31e-08	1.86e-06	0.32	0.17	Diabetic kidney disease;	chr7:65925938	chr7:66554588~66576923:-
BRCA	cis	rs4853525	0.59	rs11893307	ENSG00000235852.1	AC005540.3	-5.73	1.31e-08	1.87e-06	-0.22	-0.17	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190863318	chr2:190880797~190882059:-
BRCA	cis	rs2243480	1	rs35058610	ENSG00000230295.1	RP11-458F8.2	-5.73	1.31e-08	1.87e-06	-0.23	-0.17	Diabetic kidney disease;	chr7:65925938	chr7:66880708~66882981:+
BRCA	cis	rs56114371	0.777	rs200482	ENSG00000220721.1	OR1F12	5.73	1.31e-08	1.87e-06	0.3	0.17	Breast cancer;	chr6:27806126	chr6:28073316~28074233:+
BRCA	cis	rs2243480	1	rs34933526	ENSG00000232559.3	GS1-124K5.12	5.73	1.31e-08	1.87e-06	0.32	0.17	Diabetic kidney disease;	chr7:65918212	chr7:66554588~66576923:-
BRCA	cis	rs2243480	1	rs6949812	ENSG00000232559.3	GS1-124K5.12	5.73	1.31e-08	1.87e-06	0.32	0.17	Diabetic kidney disease;	chr7:65922114	chr7:66554588~66576923:-
BRCA	cis	rs2243480	1	rs6970243	ENSG00000232559.3	GS1-124K5.12	5.73	1.31e-08	1.87e-06	0.32	0.17	Diabetic kidney disease;	chr7:65923503	chr7:66554588~66576923:-
BRCA	cis	rs2243480	0.708	rs35310401	ENSG00000232559.3	GS1-124K5.12	5.73	1.31e-08	1.87e-06	0.32	0.17	Diabetic kidney disease;	chr7:65925372	chr7:66554588~66576923:-
BRCA	cis	rs2243480	0.831	rs7806717	ENSG00000232559.3	GS1-124K5.12	-5.73	1.31e-08	1.87e-06	-0.32	-0.17	Diabetic kidney disease;	chr7:65928187	chr7:66554588~66576923:-
BRCA	cis	rs7246657	0.551	rs12978093	ENSG00000276846.1	CTD-3220F14.3	5.73	1.31e-08	1.87e-06	0.27	0.17	Coronary artery calcification;	chr19:37093514	chr19:37314868~37315620:-
BRCA	cis	rs875971	1	rs2087647	ENSG00000164669.11	INTS4P1	5.73	1.31e-08	1.87e-06	0.21	0.17	Aortic root size;	chr7:66128201	chr7:65141225~65234216:+
BRCA	cis	rs6570726	0.791	rs4332001	ENSG00000270638.1	RP3-466P17.1	5.73	1.31e-08	1.87e-06	0.2	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145613705	chr6:145735570~145737218:+
BRCA	cis	rs2243480	1	rs12698509	ENSG00000232559.3	GS1-124K5.12	5.73	1.31e-08	1.87e-06	0.32	0.17	Diabetic kidney disease;	chr7:65953889	chr7:66554588~66576923:-
BRCA	cis	rs1859596	1	rs4727869	ENSG00000234456.6	MAGI2-AS3	5.73	1.31e-08	1.87e-06	0.11	0.17	Reading or mathematical ability;	chr7:79461824	chr7:79452877~79471208:+
BRCA	cis	rs7809950	0.678	rs2395868	ENSG00000238832.1	snoU109	5.73	1.31e-08	1.87e-06	0.25	0.17	Coronary artery disease;	chr7:107257055	chr7:107603363~107603507:+
BRCA	cis	rs12999373	0.523	rs9678953	ENSG00000223751.1	AC116609.2	-5.73	1.31e-08	1.87e-06	-0.24	-0.17	Response to fenofibrate (adiponectin levels);Uric acid levels;	chr2:694759	chr2:742488~747767:+
BRCA	cis	rs875971	0.54	rs736270	ENSG00000234585.5	CCT6P3	5.73	1.31e-08	1.87e-06	0.17	0.17	Aortic root size;	chr7:65963835	chr7:65038354~65074713:+
BRCA	cis	rs34286592	0.929	rs1057451	ENSG00000214725.6	CDIPT-AS1	-5.73	1.32e-08	1.88e-06	-0.27	-0.17	Multiple sclerosis;	chr16:29822167	chr16:29863593~29868053:+
BRCA	cis	rs13160562	0.666	rs28096	ENSG00000272109.1	CTD-2260A17.3	-5.73	1.32e-08	1.88e-06	-0.23	-0.17	Alcohol dependence;	chr5:96773540	chr5:96804353~96806105:+
BRCA	cis	rs2098713	0.537	rs512562	ENSG00000250155.1	CTD-2353F22.1	5.73	1.32e-08	1.88e-06	0.2	0.17	Telomere length;	chr5:37543019	chr5:36666214~36725195:-
BRCA	cis	rs2179367	0.6	rs9498353	ENSG00000216906.2	RP11-350J20.9	5.73	1.32e-08	1.88e-06	0.26	0.17	Dupuytren's disease;	chr6:149439860	chr6:149904243~149906418:+
BRCA	cis	rs2280018	0.526	rs1510148	ENSG00000263335.1	AF001548.5	-5.73	1.32e-08	1.88e-06	-0.22	-0.17	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15073522	chr16:15726674~15732993:+
BRCA	cis	rs2998286	0.862	rs2998285	ENSG00000254635.4	WAC-AS1	5.73	1.32e-08	1.88e-06	0.24	0.17	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28504310	chr10:28522652~28532743:-
BRCA	cis	rs1552244	1	rs68045038	ENSG00000180385.7	EMC3-AS1	5.73	1.32e-08	1.88e-06	0.22	0.17	Alzheimer's disease;	chr3:10110144	chr3:9986893~10006990:+
BRCA	cis	rs7647973	0.6	rs11920267	ENSG00000225399.4	RP11-3B7.1	5.73	1.32e-08	1.88e-06	0.17	0.17	Menarche (age at onset);	chr3:49238531	chr3:49260085~49261316:+
BRCA	cis	rs2243480	1	rs387676	ENSG00000164669.11	INTS4P1	5.73	1.32e-08	1.88e-06	0.34	0.17	Diabetic kidney disease;	chr7:66133233	chr7:65141225~65234216:+
BRCA	cis	rs673078	0.66	rs117091919	ENSG00000275409.1	RP11-131L12.4	-5.73	1.32e-08	1.88e-06	-0.29	-0.17	Glucose homeostasis traits;	chr12:118273228	chr12:118430147~118430699:+
BRCA	cis	rs673078	0.66	rs7314987	ENSG00000275409.1	RP11-131L12.4	-5.73	1.32e-08	1.88e-06	-0.29	-0.17	Glucose homeostasis traits;	chr12:118274072	chr12:118430147~118430699:+
BRCA	cis	rs1707322	0.717	rs1547925	ENSG00000281133.1	AL355480.3	5.73	1.32e-08	1.88e-06	0.23	0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45619684	chr1:45580892~45580996:-
BRCA	cis	rs1552244	0.882	rs56332224	ENSG00000232901.1	CYCSP10	5.73	1.32e-08	1.88e-06	0.24	0.17	Alzheimer's disease;	chr3:9995637	chr3:10000647~10000940:-
BRCA	cis	rs34524635	1	rs34524635	ENSG00000232075.1	MRPL35P2	-5.73	1.32e-08	1.89e-06	-0.22	-0.17	Vascular endothelial growth factor levels;	chr10:63501417	chr10:63634317~63634827:-
BRCA	cis	rs9813712	0.547	rs6807290	ENSG00000228252.7	COL6A4P2	5.73	1.32e-08	1.89e-06	0.21	0.17	Response to amphetamines;	chr3:130297952	chr3:130212823~130273806:+
BRCA	cis	rs4908768	0.501	rs6577502	ENSG00000270282.1	RP5-1115A15.2	5.73	1.32e-08	1.89e-06	0.19	0.17	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8555518	chr1:8512653~8513021:+
BRCA	cis	rs7927592	0.913	rs11228276	ENSG00000212093.1	AP000807.1	5.73	1.32e-08	1.89e-06	0.2	0.17	Total body bone mineral density;	chr11:68540057	chr11:68506083~68506166:-
BRCA	cis	rs59169624	0.699	rs7102126	ENSG00000255160.4	RP11-428C19.5	5.73	1.32e-08	1.89e-06	0.23	0.17	Parental extreme longevity (95 years and older);	chr11:19277579	chr11:19299883~19308358:+
BRCA	cis	rs10510102	0.872	rs79865971	ENSG00000226864.1	ATE1-AS1	5.73	1.33e-08	1.89e-06	0.32	0.17	Breast cancer;	chr10:121941208	chr10:121928312~121951965:+
BRCA	cis	rs10510102	0.872	rs74318512	ENSG00000226864.1	ATE1-AS1	5.73	1.33e-08	1.89e-06	0.32	0.17	Breast cancer;	chr10:121941465	chr10:121928312~121951965:+
BRCA	cis	rs10510102	0.872	rs12257207	ENSG00000226864.1	ATE1-AS1	5.73	1.33e-08	1.89e-06	0.32	0.17	Breast cancer;	chr10:121941737	chr10:121928312~121951965:+
BRCA	cis	rs7772486	0.566	rs735536	ENSG00000270638.1	RP3-466P17.1	-5.73	1.33e-08	1.89e-06	-0.2	-0.17	Lobe attachment (rater-scored or self-reported);	chr6:145715696	chr6:145735570~145737218:+
BRCA	cis	rs301901	0.531	rs34555613	ENSG00000250155.1	CTD-2353F22.1	-5.73	1.33e-08	1.89e-06	-0.2	-0.17	Height;	chr5:37456193	chr5:36666214~36725195:-
BRCA	cis	rs2098713	0.575	rs12516683	ENSG00000250155.1	CTD-2353F22.1	-5.73	1.33e-08	1.89e-06	-0.2	-0.17	Telomere length;	chr5:37456710	chr5:36666214~36725195:-
BRCA	cis	rs1861628	0.512	rs6435953	ENSG00000237930.1	AC007563.4	5.73	1.33e-08	1.89e-06	0.26	0.17	Serum thyroid-stimulating hormone levels;Hypothyroidism;	chr2:216763364	chr2:216785774~216786144:-
BRCA	cis	rs4908768	0.501	rs6577488	ENSG00000270282.1	RP5-1115A15.2	5.73	1.33e-08	1.89e-06	0.19	0.17	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8474469	chr1:8512653~8513021:+
BRCA	cis	rs4908768	0.501	rs4351668	ENSG00000270282.1	RP5-1115A15.2	5.73	1.33e-08	1.89e-06	0.19	0.17	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8475758	chr1:8512653~8513021:+
BRCA	cis	rs78487399	0.908	rs61754256	ENSG00000234936.1	AC010883.5	5.73	1.33e-08	1.89e-06	0.23	0.17	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43578600	chr2:43229573~43233394:+
BRCA	cis	rs875971	0.545	rs11767262	ENSG00000228409.4	CCT6P1	-5.73	1.33e-08	1.89e-06	-0.17	-0.17	Aortic root size;	chr7:66302237	chr7:65751142~65763354:+
BRCA	cis	rs7976269	0.609	rs1344854	ENSG00000275476.1	RP11-996F15.4	5.73	1.33e-08	1.89e-06	0.2	0.17	Male-pattern baldness;	chr12:29065440	chr12:29277397~29277882:-
BRCA	cis	rs7246657	0.943	rs8106839	ENSG00000267422.1	CTD-2554C21.1	-5.73	1.33e-08	1.89e-06	-0.26	-0.17	Coronary artery calcification;	chr19:37467573	chr19:37779686~37792865:+
BRCA	cis	rs10208649	0.908	rs10181332	ENSG00000233266.1	HMGB1P31	5.73	1.33e-08	1.89e-06	0.44	0.17	Body mass index;	chr2:54118288	chr2:54051334~54051760:+
BRCA	cis	rs4835473	0.897	rs4835095	ENSG00000249741.2	RP11-673E1.3	-5.73	1.33e-08	1.89e-06	-0.18	-0.17	Immature fraction of reticulocytes;	chr4:143960431	chr4:143911514~143912053:-
BRCA	cis	rs4835473	0.831	rs2667353	ENSG00000249741.2	RP11-673E1.3	-5.73	1.33e-08	1.89e-06	-0.18	-0.17	Immature fraction of reticulocytes;	chr4:143960462	chr4:143911514~143912053:-
BRCA	cis	rs7923609	0.967	rs7912893	ENSG00000232075.1	MRPL35P2	-5.73	1.33e-08	1.9e-06	-0.22	-0.17	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63402240	chr10:63634317~63634827:-
BRCA	cis	rs7923609	0.967	rs7896783	ENSG00000232075.1	MRPL35P2	-5.73	1.33e-08	1.9e-06	-0.22	-0.17	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63402393	chr10:63634317~63634827:-
BRCA	cis	rs7923609	0.967	rs10761762	ENSG00000232075.1	MRPL35P2	-5.73	1.33e-08	1.9e-06	-0.22	-0.17	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63424957	chr10:63634317~63634827:-
BRCA	cis	rs7923609	0.934	rs10761763	ENSG00000232075.1	MRPL35P2	-5.73	1.33e-08	1.9e-06	-0.22	-0.17	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63428558	chr10:63634317~63634827:-
BRCA	cis	rs7923609	0.967	rs3740331	ENSG00000232075.1	MRPL35P2	-5.73	1.33e-08	1.9e-06	-0.22	-0.17	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63432528	chr10:63634317~63634827:-
BRCA	cis	rs7923609	0.967	rs3956912	ENSG00000232075.1	MRPL35P2	-5.73	1.33e-08	1.9e-06	-0.22	-0.17	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63446121	chr10:63634317~63634827:-
BRCA	cis	rs7923609	0.967	rs10509186	ENSG00000232075.1	MRPL35P2	-5.73	1.33e-08	1.9e-06	-0.22	-0.17	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63447258	chr10:63634317~63634827:-
BRCA	cis	rs7923609	0.967	rs7085621	ENSG00000232075.1	MRPL35P2	-5.73	1.33e-08	1.9e-06	-0.22	-0.17	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63449166	chr10:63634317~63634827:-
BRCA	cis	rs7923609	0.936	rs10740125	ENSG00000232075.1	MRPL35P2	-5.73	1.33e-08	1.9e-06	-0.22	-0.17	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63449849	chr10:63634317~63634827:-
BRCA	cis	rs7923609	0.967	rs10740126	ENSG00000232075.1	MRPL35P2	-5.73	1.33e-08	1.9e-06	-0.22	-0.17	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63451175	chr10:63634317~63634827:-
BRCA	cis	rs9545047	0.604	rs1324870	ENSG00000227354.5	RBM26-AS1	-5.73	1.33e-08	1.9e-06	-0.19	-0.17	Schizophrenia;	chr13:79297911	chr13:79406309~79424328:+
BRCA	cis	rs2098713	0.569	rs533889	ENSG00000250155.1	CTD-2353F22.1	5.73	1.33e-08	1.9e-06	0.2	0.17	Telomere length;	chr5:37533613	chr5:36666214~36725195:-
BRCA	cis	rs375066	0.551	rs10500287	ENSG00000267058.1	RP11-15A1.3	5.73	1.34e-08	1.9e-06	0.2	0.17	Breast cancer;	chr19:43827818	chr19:43891804~43901805:-
BRCA	cis	rs4415084	1	rs7720551	ENSG00000251141.4	RP11-53O19.1	5.73	1.34e-08	1.9e-06	0.17	0.17	Breast cancer;	chr5:44664375	chr5:44744900~44808777:-
BRCA	cis	rs875971	0.545	rs73142245	ENSG00000228409.4	CCT6P1	-5.73	1.34e-08	1.9e-06	-0.18	-0.17	Aortic root size;	chr7:66226662	chr7:65751142~65763354:+
BRCA	cis	rs7976269	0.609	rs4141946	ENSG00000257176.2	RP11-996F15.2	-5.73	1.34e-08	1.9e-06	-0.21	-0.17	Male-pattern baldness;	chr12:29066432	chr12:29280418~29317848:-
BRCA	cis	rs4835473	0.771	rs4835097	ENSG00000249741.2	RP11-673E1.3	-5.73	1.34e-08	1.9e-06	-0.19	-0.17	Immature fraction of reticulocytes;	chr4:143960687	chr4:143911514~143912053:-
BRCA	cis	rs2638953	0.893	rs1464011	ENSG00000247934.4	RP11-967K21.1	-5.73	1.34e-08	1.9e-06	-0.22	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28516871	chr12:28163298~28190738:-
BRCA	cis	rs9545047	0.547	rs1590465	ENSG00000227354.5	RBM26-AS1	-5.73	1.34e-08	1.91e-06	-0.19	-0.17	Schizophrenia;	chr13:79393998	chr13:79406309~79424328:+
BRCA	cis	rs2274273	1	rs1047556	ENSG00000258413.1	RP11-665C16.6	-5.73	1.34e-08	1.91e-06	-0.22	-0.17	Protein biomarker;	chr14:55133564	chr14:55262767~55272075:-
BRCA	cis	rs4415084	1	rs13176502	ENSG00000251141.4	RP11-53O19.1	5.73	1.34e-08	1.91e-06	0.16	0.17	Breast cancer;	chr5:44697806	chr5:44744900~44808777:-
BRCA	cis	rs2638953	0.925	rs11049545	ENSG00000278733.1	RP11-425D17.1	-5.73	1.34e-08	1.91e-06	-0.24	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28344965	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.962	rs11049547	ENSG00000278733.1	RP11-425D17.1	-5.73	1.34e-08	1.91e-06	-0.24	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28346945	chr12:28185625~28186190:-
BRCA	cis	rs295490	0.748	rs116416768	ENSG00000272656.1	RP11-219D15.3	5.73	1.34e-08	1.91e-06	0.41	0.17	PR interval in Tripanosoma cruzi seropositivity;	chr3:139382294	chr3:139349024~139349371:-
BRCA	cis	rs2288884	1	rs79817140	ENSG00000275055.1	CTC-471J1.11	-5.73	1.34e-08	1.91e-06	-0.26	-0.17	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52068404	chr19:52049007~52049754:+
BRCA	cis	rs2288884	1	rs11669385	ENSG00000275055.1	CTC-471J1.11	-5.73	1.34e-08	1.91e-06	-0.26	-0.17	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52068699	chr19:52049007~52049754:+
BRCA	cis	rs2288884	1	rs72483951	ENSG00000275055.1	CTC-471J1.11	-5.73	1.34e-08	1.91e-06	-0.26	-0.17	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52070429	chr19:52049007~52049754:+
BRCA	cis	rs1395	0.571	rs114507490	ENSG00000234072.1	AC074117.10	-5.73	1.34e-08	1.91e-06	-0.2	-0.17	Blood metabolite levels;	chr2:27304378	chr2:27356246~27367622:+
BRCA	cis	rs2153535	0.585	rs9406183	ENSG00000230939.1	RP11-314C16.1	5.73	1.34e-08	1.91e-06	0.2	0.17	Motion sickness;	chr6:8639538	chr6:8784178~8785445:+
BRCA	cis	rs2098713	0.537	rs12109722	ENSG00000250155.1	CTD-2353F22.1	-5.73	1.34e-08	1.91e-06	-0.2	-0.17	Telomere length;	chr5:37489522	chr5:36666214~36725195:-
BRCA	cis	rs12681366	0.647	rs12545262	ENSG00000253704.1	RP11-267M23.4	5.73	1.34e-08	1.91e-06	0.18	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94392813	chr8:94553722~94569745:+
BRCA	cis	rs7577696	0.513	rs212685	ENSG00000272716.1	RP11-563N4.1	5.73	1.34e-08	1.91e-06	0.21	0.17	Inflammatory biomarkers;	chr2:32209632	chr2:32165046~32165757:-
BRCA	cis	rs7131987	0.621	rs6487805	ENSG00000275476.1	RP11-996F15.4	5.73	1.35e-08	1.91e-06	0.21	0.17	QT interval;	chr12:29304617	chr12:29277397~29277882:-
BRCA	cis	rs78487399	0.908	rs12474102	ENSG00000234936.1	AC010883.5	5.73	1.35e-08	1.92e-06	0.23	0.17	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43608431	chr2:43229573~43233394:+
BRCA	cis	rs6088813	1	rs6087704	ENSG00000126005.14	MMP24-AS1	5.73	1.35e-08	1.92e-06	0.21	0.17	Height;	chr20:35413255	chr20:35216462~35278131:-
BRCA	cis	rs4908768	0.501	rs1473420	ENSG00000270282.1	RP5-1115A15.2	5.73	1.35e-08	1.92e-06	0.19	0.17	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8556779	chr1:8512653~8513021:+
BRCA	cis	rs2153535	0.585	rs9328501	ENSG00000230939.1	RP11-314C16.1	-5.73	1.35e-08	1.92e-06	-0.2	-0.17	Motion sickness;	chr6:8669287	chr6:8784178~8785445:+
BRCA	cis	rs12468226	0.873	rs6761131	ENSG00000226261.1	AC064836.3	-5.73	1.35e-08	1.92e-06	-0.29	-0.17	Urate levels;	chr2:202237675	chr2:202336024~202336727:-
BRCA	cis	rs875971	1	rs6958484	ENSG00000164669.11	INTS4P1	5.73	1.35e-08	1.92e-06	0.21	0.17	Aortic root size;	chr7:66134459	chr7:65141225~65234216:+
BRCA	cis	rs7646881	0.812	rs7624408	ENSG00000240207.5	RP11-379F4.4	-5.73	1.35e-08	1.92e-06	-0.27	-0.17	Tetralogy of Fallot;	chr3:158742269	chr3:158732263~158784070:+
BRCA	cis	rs7646881	0.812	rs7636023	ENSG00000240207.5	RP11-379F4.4	-5.73	1.35e-08	1.92e-06	-0.27	-0.17	Tetralogy of Fallot;	chr3:158742270	chr3:158732263~158784070:+
BRCA	cis	rs7646881	0.812	rs73017536	ENSG00000240207.5	RP11-379F4.4	-5.73	1.35e-08	1.92e-06	-0.27	-0.17	Tetralogy of Fallot;	chr3:158742813	chr3:158732263~158784070:+
BRCA	cis	rs7646881	0.812	rs73017540	ENSG00000240207.5	RP11-379F4.4	-5.73	1.35e-08	1.92e-06	-0.27	-0.17	Tetralogy of Fallot;	chr3:158742999	chr3:158732263~158784070:+
BRCA	cis	rs9907295	1	rs11657908	ENSG00000270977.1	AC015849.16	-5.73	1.35e-08	1.92e-06	-0.29	-0.17	Fibroblast growth factor basic levels;	chr17:35908993	chr17:35893707~35911023:-
BRCA	cis	rs4604234	0.803	rs28839510	ENSG00000272129.1	RP11-250B2.6	-5.73	1.35e-08	1.92e-06	-0.43	-0.17	Cancer;	chr6:80312266	chr6:80355424~80356859:+
BRCA	cis	rs8114671	0.562	rs6088647	ENSG00000269202.1	RP4-614O4.12	-5.72	1.35e-08	1.92e-06	-0.18	-0.17	Height;	chr20:34918194	chr20:35201747~35203288:-
BRCA	cis	rs8114671	0.562	rs2223881	ENSG00000269202.1	RP4-614O4.12	-5.72	1.35e-08	1.92e-06	-0.18	-0.17	Height;	chr20:34918660	chr20:35201747~35203288:-
BRCA	cis	rs6570726	0.791	rs9322029	ENSG00000270638.1	RP3-466P17.1	5.72	1.35e-08	1.93e-06	0.2	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145585547	chr6:145735570~145737218:+
BRCA	cis	rs2638953	0.962	rs7303747	ENSG00000247934.4	RP11-967K21.1	-5.72	1.35e-08	1.93e-06	-0.24	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28241969	chr12:28163298~28190738:-
BRCA	cis	rs12468226	0.938	rs10931993	ENSG00000226261.1	AC064836.3	5.72	1.35e-08	1.93e-06	0.29	0.17	Urate levels;	chr2:202243017	chr2:202336024~202336727:-
BRCA	cis	rs11098499	0.82	rs2389885	ENSG00000249244.1	RP11-548H18.2	5.72	1.35e-08	1.93e-06	0.22	0.17	Corneal astigmatism;	chr4:119612776	chr4:119391831~119395335:-
BRCA	cis	rs7976269	0.609	rs2196482	ENSG00000275476.1	RP11-996F15.4	-5.72	1.35e-08	1.93e-06	-0.2	-0.17	Male-pattern baldness;	chr12:29052559	chr12:29277397~29277882:-
BRCA	cis	rs7976269	0.609	rs2217906	ENSG00000275476.1	RP11-996F15.4	-5.72	1.35e-08	1.93e-06	-0.2	-0.17	Male-pattern baldness;	chr12:29052626	chr12:29277397~29277882:-
BRCA	cis	rs2243480	1	rs313820	ENSG00000228409.4	CCT6P1	5.72	1.35e-08	1.93e-06	0.25	0.17	Diabetic kidney disease;	chr7:66109479	chr7:65751142~65763354:+
BRCA	cis	rs2810114	0.916	rs2810099	ENSG00000258571.1	PTTG4P	5.72	1.35e-08	1.93e-06	0.2	0.17	Alcohol dependence;	chr14:70965704	chr14:71085482~71085833:-
BRCA	cis	rs73222236	0.75	rs9811261	ENSG00000273486.1	RP11-731C17.2	5.72	1.36e-08	1.93e-06	0.2	0.17	Coronary artery disease;	chr3:136379717	chr3:136837338~136839021:-
BRCA	cis	rs6163	0.588	rs67506723	ENSG00000213061.2	PFN1P11	5.72	1.36e-08	1.93e-06	0.22	0.17	Waist circumference;Hip circumference;	chr10:102749307	chr10:102838011~102845473:-
BRCA	cis	rs1552244	1	rs61077902	ENSG00000180385.7	EMC3-AS1	5.72	1.36e-08	1.93e-06	0.22	0.17	Alzheimer's disease;	chr3:10084469	chr3:9986893~10006990:+
BRCA	cis	rs9545047	0.553	rs7332004	ENSG00000227354.5	RBM26-AS1	-5.72	1.36e-08	1.93e-06	-0.19	-0.17	Schizophrenia;	chr13:79364128	chr13:79406309~79424328:+
BRCA	cis	rs55702914	1	rs55702914	ENSG00000231621.1	AC013264.2	-5.72	1.36e-08	1.93e-06	-0.17	-0.17	Major depression and alcohol dependence;	chr2:197349672	chr2:197197991~197199273:+
BRCA	cis	rs4588572	0.644	rs7714871	ENSG00000245556.2	SCAMP1-AS1	-5.72	1.36e-08	1.93e-06	-0.21	-0.17	Triglycerides;	chr5:78458445	chr5:78342365~78360507:-
BRCA	cis	rs7927592	0.913	rs7123564	ENSG00000212093.1	AP000807.1	5.72	1.36e-08	1.93e-06	0.2	0.17	Total body bone mineral density;	chr11:68594696	chr11:68506083~68506166:-
BRCA	cis	rs4908768	0.501	rs11121201	ENSG00000270282.1	RP5-1115A15.2	5.72	1.36e-08	1.93e-06	0.19	0.17	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8572732	chr1:8512653~8513021:+
BRCA	cis	rs7246967	0.673	rs9676498	ENSG00000198153.8	ZNF849P	-5.72	1.36e-08	1.94e-06	-0.26	-0.17	Bronchopulmonary dysplasia;	chr19:22727708	chr19:22685167~22686732:+
BRCA	cis	rs10129255	0.957	rs17113284	ENSG00000280411.1	IGHV1-69-2	5.72	1.36e-08	1.94e-06	0.13	0.17	Kawasaki disease;	chr14:106684476	chr14:106762092~106762588:-
BRCA	cis	rs67311347	0.713	rs9861194	ENSG00000280739.1	EIF1B-AS1	5.72	1.36e-08	1.94e-06	0.2	0.17	Renal cell carcinoma;	chr3:40267734	chr3:40173145~40309698:-
BRCA	cis	rs4218	0.859	rs1486878	ENSG00000259732.1	RP11-59H7.3	-5.72	1.36e-08	1.94e-06	-0.21	-0.17	Social communication problems;	chr15:59123268	chr15:59121034~59133250:+
BRCA	cis	rs7131987	0.622	rs7294598	ENSG00000275476.1	RP11-996F15.4	5.72	1.36e-08	1.94e-06	0.21	0.17	QT interval;	chr12:29379056	chr12:29277397~29277882:-
BRCA	cis	rs2522056	1	rs2057655	ENSG00000233006.5	AC034220.3	5.72	1.36e-08	1.94e-06	0.15	0.17	Fibrinogen;Lymphocyte counts;	chr5:132471932	chr5:132311285~132369916:-
BRCA	cis	rs9308731	0.644	rs1837368	ENSG00000227992.1	AC108463.2	-5.72	1.36e-08	1.94e-06	-0.2	-0.17	Chronic lymphocytic leukemia;	chr2:111116931	chr2:111203964~111206215:-
BRCA	cis	rs7308116	0.505	rs11113519	ENSG00000274395.1	RP11-554D14.8	-5.72	1.36e-08	1.94e-06	-0.21	-0.17	Pelvic organ prolapse (moderate/severe);	chr12:107826999	chr12:107835541~107836555:-
BRCA	cis	rs11105298	0.891	rs12369685	ENSG00000270344.2	RP11-734K2.4	5.72	1.36e-08	1.94e-06	0.21	0.17	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89535128	chr12:89525654~89548005:+
BRCA	cis	rs1552244	1	rs17032396	ENSG00000180385.7	EMC3-AS1	-5.72	1.36e-08	1.94e-06	-0.22	-0.17	Alzheimer's disease;	chr3:10111875	chr3:9986893~10006990:+
BRCA	cis	rs2274273	1	rs7493394	ENSG00000258413.1	RP11-665C16.6	-5.72	1.36e-08	1.94e-06	-0.22	-0.17	Protein biomarker;	chr14:55151037	chr14:55262767~55272075:-
BRCA	cis	rs875971	0.597	rs11763224	ENSG00000273024.4	INTS4P2	-5.72	1.37e-08	1.94e-06	-0.22	-0.17	Aortic root size;	chr7:66518628	chr7:65647864~65715661:+
BRCA	cis	rs2253762	0.507	rs10159582	ENSG00000276742.1	RP11-500G22.4	5.72	1.37e-08	1.94e-06	0.3	0.17	Breast cancer;	chr10:121993110	chr10:121956782~121957098:+
BRCA	cis	rs2253762	0.507	rs10159583	ENSG00000276742.1	RP11-500G22.4	5.72	1.37e-08	1.94e-06	0.3	0.17	Breast cancer;	chr10:121993154	chr10:121956782~121957098:+
BRCA	cis	rs2243480	1	rs34933526	ENSG00000230295.1	RP11-458F8.2	-5.72	1.37e-08	1.94e-06	-0.23	-0.17	Diabetic kidney disease;	chr7:65918212	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs6949812	ENSG00000230295.1	RP11-458F8.2	-5.72	1.37e-08	1.94e-06	-0.23	-0.17	Diabetic kidney disease;	chr7:65922114	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs6970243	ENSG00000230295.1	RP11-458F8.2	-5.72	1.37e-08	1.94e-06	-0.23	-0.17	Diabetic kidney disease;	chr7:65923503	chr7:66880708~66882981:+
BRCA	cis	rs2243480	0.708	rs35310401	ENSG00000230295.1	RP11-458F8.2	-5.72	1.37e-08	1.94e-06	-0.23	-0.17	Diabetic kidney disease;	chr7:65925372	chr7:66880708~66882981:+
BRCA	cis	rs2243480	0.831	rs7806717	ENSG00000230295.1	RP11-458F8.2	5.72	1.37e-08	1.94e-06	0.23	0.17	Diabetic kidney disease;	chr7:65928187	chr7:66880708~66882981:+
BRCA	cis	rs875971	1	rs6961717	ENSG00000164669.11	INTS4P1	5.72	1.37e-08	1.94e-06	0.21	0.17	Aortic root size;	chr7:66122550	chr7:65141225~65234216:+
BRCA	cis	rs1713985	0.508	rs1277283	ENSG00000269949.1	RP11-738E22.3	-5.72	1.37e-08	1.94e-06	-0.31	-0.17	Age-related macular degeneration;	chr4:56989475	chr4:56960927~56961373:-
BRCA	cis	rs7809950	0.598	rs2283038	ENSG00000238832.1	snoU109	-5.72	1.37e-08	1.94e-06	-0.27	-0.17	Coronary artery disease;	chr7:107194965	chr7:107603363~107603507:+
BRCA	cis	rs227275	0.554	rs223357	ENSG00000251288.2	RP11-10L12.2	-5.72	1.37e-08	1.95e-06	-0.2	-0.17	Allergic disease (asthma, hay fever or eczema);	chr4:102851095	chr4:102751401~102752641:+
BRCA	cis	rs2243480	0.908	rs2460431	ENSG00000232559.3	GS1-124K5.12	-5.72	1.37e-08	1.95e-06	-0.33	-0.17	Diabetic kidney disease;	chr7:66157859	chr7:66554588~66576923:-
BRCA	cis	rs2243480	1	rs4718309	ENSG00000232559.3	GS1-124K5.12	-5.72	1.37e-08	1.95e-06	-0.33	-0.17	Diabetic kidney disease;	chr7:66162777	chr7:66554588~66576923:-
BRCA	cis	rs2243480	1	rs6460274	ENSG00000232559.3	GS1-124K5.12	-5.72	1.37e-08	1.95e-06	-0.33	-0.17	Diabetic kidney disease;	chr7:66163497	chr7:66554588~66576923:-
BRCA	cis	rs2243480	1	rs7787230	ENSG00000232559.3	GS1-124K5.12	-5.72	1.37e-08	1.95e-06	-0.33	-0.17	Diabetic kidney disease;	chr7:66164112	chr7:66554588~66576923:-
BRCA	cis	rs2243480	1	rs2465120	ENSG00000232559.3	GS1-124K5.12	5.72	1.37e-08	1.95e-06	0.33	0.17	Diabetic kidney disease;	chr7:66155987	chr7:66554588~66576923:-
BRCA	cis	rs4664293	0.51	rs66537229	ENSG00000226266.5	AC009961.3	5.72	1.37e-08	1.95e-06	0.22	0.17	Monocyte percentage of white cells;	chr2:159624095	chr2:159670708~159712435:-
BRCA	cis	rs783540	0.521	rs1259176	ENSG00000278603.1	RP13-608F4.5	-5.72	1.37e-08	1.95e-06	-0.26	-0.17	Schizophrenia;	chr15:82602149	chr15:82472203~82472426:+
BRCA	cis	rs858239	0.699	rs1881200	ENSG00000230042.1	AK3P3	5.72	1.37e-08	1.95e-06	0.2	0.17	Cerebrospinal fluid biomarker levels;	chr7:23162018	chr7:23129178~23129841:+
BRCA	cis	rs7474896	0.559	rs1212108	ENSG00000120555.12	SEPT7P9	5.72	1.37e-08	1.95e-06	0.25	0.17	Obesity (extreme);	chr10:37805394	chr10:38383069~38402916:-
BRCA	cis	rs10761482	0.5	rs7072229	ENSG00000254271.1	RP11-131N11.4	5.72	1.37e-08	1.95e-06	0.23	0.17	Schizophrenia;	chr10:60524462	chr10:60734342~60741828:+
BRCA	cis	rs6570726	0.902	rs973855	ENSG00000270638.1	RP3-466P17.1	-5.72	1.37e-08	1.95e-06	-0.19	-0.17	Lobe attachment (rater-scored or self-reported);	chr6:145460714	chr6:145735570~145737218:+
BRCA	cis	rs4950322	0.57	rs3737855	ENSG00000244371.2	PFN1P8	-5.72	1.37e-08	1.95e-06	-0.24	-0.17	Protein quantitative trait loci;	chr1:147271257	chr1:146957117~146957659:-
BRCA	cis	rs875971	0.545	rs10950029	ENSG00000228409.4	CCT6P1	-5.72	1.37e-08	1.95e-06	-0.17	-0.17	Aortic root size;	chr7:66169334	chr7:65751142~65763354:+
BRCA	cis	rs7772486	0.846	rs2748496	ENSG00000270638.1	RP3-466P17.1	5.72	1.38e-08	1.96e-06	0.2	0.17	Lobe attachment (rater-scored or self-reported);	chr6:146000693	chr6:145735570~145737218:+
BRCA	cis	rs1832007	0.554	rs34179396	ENSG00000224034.1	RP11-445P17.8	-5.72	1.38e-08	1.96e-06	-0.27	-0.17	Triglyceride levels;Triglycerides;	chr10:5278817	chr10:5266033~5271236:-
BRCA	cis	rs61160187	0.51	rs4700393	ENSG00000272308.1	RP11-231G3.1	-5.72	1.38e-08	1.96e-06	-0.19	-0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:60802440	chr5:60866457~60866935:-
BRCA	cis	rs9652601	0.959	rs2058531	ENSG00000274038.1	RP11-66H6.4	-5.72	1.38e-08	1.96e-06	-0.2	-0.17	Systemic lupus erythematosus;	chr16:11078252	chr16:11056556~11057034:+
BRCA	cis	rs73222236	0.825	rs9833162	ENSG00000273486.1	RP11-731C17.2	5.72	1.38e-08	1.96e-06	0.2	0.17	Coronary artery disease;	chr3:136316895	chr3:136837338~136839021:-
BRCA	cis	rs10504130	0.569	rs35032384	ENSG00000272024.1	RP11-546K22.3	-5.72	1.38e-08	1.96e-06	-0.26	-0.17	Venous thromboembolism (SNP x SNP interaction);	chr8:51910524	chr8:51950284~51950690:+
BRCA	cis	rs228614	0.51	rs223377	ENSG00000251288.2	RP11-10L12.2	-5.72	1.38e-08	1.96e-06	-0.2	-0.17	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102834919	chr4:102751401~102752641:+
BRCA	cis	rs3213958	0.574	rs1827158	ENSG00000249274.1	PDLIM1P4	5.72	1.38e-08	1.96e-06	0.26	0.17	Blood protein levels;	chr3:98902821	chr3:98782188~98783193:+
BRCA	cis	rs61160187	0.673	rs10062240	ENSG00000215032.2	GNL3LP1	-5.72	1.38e-08	1.96e-06	-0.21	-0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:60782585	chr5:60891935~60893577:-
BRCA	cis	rs7923609	0.967	rs10761752	ENSG00000232075.1	MRPL35P2	-5.72	1.38e-08	1.96e-06	-0.22	-0.17	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63400561	chr10:63634317~63634827:-
BRCA	cis	rs6688613	0.685	rs10918599	ENSG00000225171.2	DUTP6	-5.72	1.38e-08	1.96e-06	-0.23	-0.17	Refractive astigmatism;	chr1:166949549	chr1:166868748~166869209:+
BRCA	cis	rs1707322	0.717	rs1135812	ENSG00000234329.1	RP11-767N6.2	5.72	1.38e-08	1.96e-06	0.18	0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45629600	chr1:45651039~45651826:-
BRCA	cis	rs1707322	0.752	rs6703748	ENSG00000234329.1	RP11-767N6.2	5.72	1.38e-08	1.96e-06	0.18	0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45630304	chr1:45651039~45651826:-
BRCA	cis	rs4415084	0.966	rs36068815	ENSG00000251141.4	RP11-53O19.1	5.72	1.38e-08	1.96e-06	0.17	0.17	Breast cancer;	chr5:44645896	chr5:44744900~44808777:-
BRCA	cis	rs7246657	0.653	rs28701616	ENSG00000226686.6	LINC01535	-5.72	1.38e-08	1.96e-06	-0.3	-0.17	Coronary artery calcification;	chr19:37190196	chr19:37251912~37265535:+
BRCA	cis	rs10510102	0.516	rs10219133	ENSG00000276742.1	RP11-500G22.4	5.72	1.38e-08	1.96e-06	0.32	0.17	Breast cancer;	chr10:121987898	chr10:121956782~121957098:+
BRCA	cis	rs2638953	0.924	rs11049416	ENSG00000247934.4	RP11-967K21.1	5.72	1.38e-08	1.96e-06	0.24	0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28190305	chr12:28163298~28190738:-
BRCA	cis	rs7131987	0.718	rs7976961	ENSG00000275476.1	RP11-996F15.4	-5.72	1.38e-08	1.96e-06	-0.21	-0.17	QT interval;	chr12:29310155	chr12:29277397~29277882:-
BRCA	cis	rs9311474	0.659	rs1133415	ENSG00000243224.1	RP5-1157M23.2	-5.72	1.38e-08	1.97e-06	-0.19	-0.17	Electroencephalogram traits;	chr3:52541815	chr3:52239258~52241097:+
BRCA	cis	rs7238033	0.56	rs2170974	ENSG00000267193.4	RP11-116O18.3	5.72	1.38e-08	1.97e-06	0.19	0.17	Bladder cancer;	chr18:45728845	chr18:45669367~45747215:-
BRCA	cis	rs7238033	0.624	rs9967412	ENSG00000267193.4	RP11-116O18.3	5.72	1.38e-08	1.97e-06	0.19	0.17	Bladder cancer;	chr18:45728924	chr18:45669367~45747215:-
BRCA	cis	rs7238033	0.624	rs4479340	ENSG00000267193.4	RP11-116O18.3	5.72	1.38e-08	1.97e-06	0.19	0.17	Bladder cancer;	chr18:45728990	chr18:45669367~45747215:-
BRCA	cis	rs7238033	0.624	rs4316845	ENSG00000267193.4	RP11-116O18.3	5.72	1.38e-08	1.97e-06	0.19	0.17	Bladder cancer;	chr18:45729170	chr18:45669367~45747215:-
BRCA	cis	rs7208859	0.573	rs55661352	ENSG00000265443.1	CTD-2349P21.6	-5.72	1.38e-08	1.97e-06	-0.3	-0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30718610	chr17:30726305~30727564:-
BRCA	cis	rs9311474	0.607	rs11711421	ENSG00000243224.1	RP5-1157M23.2	-5.72	1.38e-08	1.97e-06	-0.19	-0.17	Electroencephalogram traits;	chr3:52527763	chr3:52239258~52241097:+
BRCA	cis	rs27434	0.821	rs28337	ENSG00000272109.1	CTD-2260A17.3	-5.72	1.38e-08	1.97e-06	-0.24	-0.17	Ankylosing spondylitis;	chr5:96789611	chr5:96804353~96806105:+
BRCA	cis	rs17818399	0.962	rs7565274	ENSG00000279254.1	RP11-536C12.1	-5.72	1.39e-08	1.97e-06	-0.22	-0.17	Height;	chr2:46614722	chr2:46668870~46670778:+
BRCA	cis	rs7308116	0.546	rs1807840	ENSG00000274395.1	RP11-554D14.8	-5.72	1.39e-08	1.97e-06	-0.21	-0.17	Pelvic organ prolapse (moderate/severe);	chr12:107824641	chr12:107835541~107836555:-
BRCA	cis	rs7308116	0.528	rs1807841	ENSG00000274395.1	RP11-554D14.8	-5.72	1.39e-08	1.97e-06	-0.21	-0.17	Pelvic organ prolapse (moderate/severe);	chr12:107824706	chr12:107835541~107836555:-
BRCA	cis	rs7308116	0.51	rs1807842	ENSG00000274395.1	RP11-554D14.8	-5.72	1.39e-08	1.97e-06	-0.21	-0.17	Pelvic organ prolapse (moderate/severe);	chr12:107824759	chr12:107835541~107836555:-
BRCA	cis	rs7308116	0.546	rs9919690	ENSG00000274395.1	RP11-554D14.8	-5.72	1.39e-08	1.97e-06	-0.21	-0.17	Pelvic organ prolapse (moderate/severe);	chr12:107825691	chr12:107835541~107836555:-
BRCA	cis	rs7308116	0.528	rs7137750	ENSG00000274395.1	RP11-554D14.8	-5.72	1.39e-08	1.97e-06	-0.21	-0.17	Pelvic organ prolapse (moderate/severe);	chr12:107825861	chr12:107835541~107836555:-
BRCA	cis	rs7308116	0.546	rs7295706	ENSG00000274395.1	RP11-554D14.8	-5.72	1.39e-08	1.97e-06	-0.21	-0.17	Pelvic organ prolapse (moderate/severe);	chr12:107826044	chr12:107835541~107836555:-
BRCA	cis	rs7308116	0.528	rs7295729	ENSG00000274395.1	RP11-554D14.8	-5.72	1.39e-08	1.97e-06	-0.21	-0.17	Pelvic organ prolapse (moderate/severe);	chr12:107826148	chr12:107835541~107836555:-
BRCA	cis	rs7308116	0.505	rs11113518	ENSG00000274395.1	RP11-554D14.8	-5.72	1.39e-08	1.97e-06	-0.21	-0.17	Pelvic organ prolapse (moderate/severe);	chr12:107826964	chr12:107835541~107836555:-
BRCA	cis	rs7308116	0.505	rs11113522	ENSG00000274395.1	RP11-554D14.8	-5.72	1.39e-08	1.97e-06	-0.21	-0.17	Pelvic organ prolapse (moderate/severe);	chr12:107827096	chr12:107835541~107836555:-
BRCA	cis	rs7308116	0.505	rs9919716	ENSG00000274395.1	RP11-554D14.8	-5.72	1.39e-08	1.97e-06	-0.21	-0.17	Pelvic organ prolapse (moderate/severe);	chr12:107827545	chr12:107835541~107836555:-
BRCA	cis	rs7308116	0.505	rs9919715	ENSG00000274395.1	RP11-554D14.8	-5.72	1.39e-08	1.97e-06	-0.21	-0.17	Pelvic organ prolapse (moderate/severe);	chr12:107827561	chr12:107835541~107836555:-
BRCA	cis	rs7308116	0.505	rs9919719	ENSG00000274395.1	RP11-554D14.8	-5.72	1.39e-08	1.97e-06	-0.21	-0.17	Pelvic organ prolapse (moderate/severe);	chr12:107827686	chr12:107835541~107836555:-
BRCA	cis	rs12612619	0.732	rs10865461	ENSG00000229122.1	AGBL5-IT1	5.72	1.39e-08	1.97e-06	0.18	0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27069783	chr2:27061038~27061815:+
BRCA	cis	rs9545047	0.604	rs9574406	ENSG00000227354.5	RBM26-AS1	-5.72	1.39e-08	1.97e-06	-0.19	-0.17	Schizophrenia;	chr13:79338982	chr13:79406309~79424328:+
BRCA	cis	rs6738825	0.547	rs67616109	ENSG00000231621.1	AC013264.2	-5.72	1.39e-08	1.97e-06	-0.16	-0.17	Crohn's disease;	chr2:197544766	chr2:197197991~197199273:+
BRCA	cis	rs42490	0.664	rs421411	ENSG00000251136.7	RP11-37B2.1	-5.72	1.39e-08	1.97e-06	-0.16	-0.17	Leprosy;	chr8:89808665	chr8:89609409~89757727:-
BRCA	cis	rs4908760	0.827	rs11121210	ENSG00000270282.1	RP5-1115A15.2	5.72	1.39e-08	1.97e-06	0.18	0.17	Vitiligo;	chr1:8648470	chr1:8512653~8513021:+
BRCA	cis	rs7044106	0.762	rs7849566	ENSG00000238181.2	AHCYP2	-5.72	1.39e-08	1.97e-06	-0.22	-0.17	Hip circumference adjusted for BMI;	chr9:120698491	chr9:120720673~120721972:+
BRCA	cis	rs67981189	0.529	rs17108862	ENSG00000258571.1	PTTG4P	-5.72	1.39e-08	1.97e-06	-0.2	-0.17	Schizophrenia;	chr14:70997949	chr14:71085482~71085833:-
BRCA	cis	rs950169	0.579	rs881983	ENSG00000259728.4	LINC00933	5.72	1.39e-08	1.97e-06	0.25	0.17	Schizophrenia;	chr15:83978556	chr15:84570649~84580175:+
BRCA	cis	rs7927771	0.524	rs2242081	ENSG00000280615.1	Y_RNA	5.72	1.39e-08	1.97e-06	0.21	0.17	Subjective well-being;	chr11:47478715	chr11:47614898~47614994:-
BRCA	cis	rs5758511	0.689	rs5758691	ENSG00000205702.9	CYP2D7	5.72	1.39e-08	1.97e-06	0.18	0.17	Birth weight;	chr22:42272498	chr22:42140203~42144577:-
BRCA	cis	rs2153535	0.585	rs9378565	ENSG00000230939.1	RP11-314C16.1	-5.72	1.39e-08	1.97e-06	-0.2	-0.17	Motion sickness;	chr6:8664580	chr6:8784178~8785445:+
BRCA	cis	rs7238033	0.602	rs8088163	ENSG00000267193.4	RP11-116O18.3	5.72	1.39e-08	1.97e-06	0.19	0.17	Bladder cancer;	chr18:45729844	chr18:45669367~45747215:-
BRCA	cis	rs10752881	1	rs6658501	ENSG00000224468.3	RP11-181K3.4	5.72	1.39e-08	1.98e-06	0.18	0.17	Colorectal cancer;	chr1:183022282	chr1:183138402~183141282:-
BRCA	cis	rs2243480	1	rs35542501	ENSG00000232559.3	GS1-124K5.12	5.72	1.39e-08	1.98e-06	0.32	0.17	Diabetic kidney disease;	chr7:65966228	chr7:66554588~66576923:-
BRCA	cis	rs2243480	0.708	rs781141	ENSG00000232559.3	GS1-124K5.12	5.72	1.39e-08	1.98e-06	0.32	0.17	Diabetic kidney disease;	chr7:65973566	chr7:66554588~66576923:-
BRCA	cis	rs17508449	0.819	rs17359281	ENSG00000232450.1	RP4-730K3.3	5.72	1.39e-08	1.98e-06	0.31	0.17	Leprosy;	chr1:113643337	chr1:113698884~113699631:-
BRCA	cis	rs7772486	0.875	rs56181683	ENSG00000270638.1	RP3-466P17.1	-5.72	1.39e-08	1.98e-06	-0.2	-0.17	Lobe attachment (rater-scored or self-reported);	chr6:145965484	chr6:145735570~145737218:+
BRCA	cis	rs78487399	0.71	rs6759383	ENSG00000234936.1	AC010883.5	5.72	1.39e-08	1.98e-06	0.23	0.17	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43578089	chr2:43229573~43233394:+
BRCA	cis	rs4835473	0.897	rs1450249	ENSG00000249741.2	RP11-673E1.3	-5.72	1.4e-08	1.98e-06	-0.19	-0.17	Immature fraction of reticulocytes;	chr4:143724425	chr4:143911514~143912053:-
BRCA	cis	rs2153535	0.56	rs1328866	ENSG00000230939.1	RP11-314C16.1	-5.72	1.4e-08	1.98e-06	-0.2	-0.17	Motion sickness;	chr6:8653283	chr6:8784178~8785445:+
BRCA	cis	rs2911132	0.621	rs28432918	ENSG00000248734.2	CTD-2260A17.1	5.72	1.4e-08	1.98e-06	0.21	0.17	Urate levels (BMI interaction);	chr5:96765522	chr5:96784777~96785999:+
BRCA	cis	rs12681366	0.708	rs12680029	ENSG00000253704.1	RP11-267M23.4	5.72	1.4e-08	1.98e-06	0.18	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94392418	chr8:94553722~94569745:+
BRCA	cis	rs7923609	0.934	rs10761771	ENSG00000232075.1	MRPL35P2	-5.72	1.4e-08	1.99e-06	-0.22	-0.17	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63470404	chr10:63634317~63634827:-
BRCA	cis	rs7923609	0.869	rs10733792	ENSG00000232075.1	MRPL35P2	-5.72	1.4e-08	1.99e-06	-0.22	-0.17	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63472779	chr10:63634317~63634827:-
BRCA	cis	rs7923609	0.838	rs7909960	ENSG00000232075.1	MRPL35P2	-5.72	1.4e-08	1.99e-06	-0.22	-0.17	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63479417	chr10:63634317~63634827:-
BRCA	cis	rs7923609	0.967	rs7915779	ENSG00000232075.1	MRPL35P2	-5.72	1.4e-08	1.99e-06	-0.22	-0.17	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63484484	chr10:63634317~63634827:-
BRCA	cis	rs7923609	0.967	rs2393977	ENSG00000232075.1	MRPL35P2	-5.72	1.4e-08	1.99e-06	-0.22	-0.17	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63487849	chr10:63634317~63634827:-
BRCA	cis	rs7923609	0.967	rs10509189	ENSG00000232075.1	MRPL35P2	-5.72	1.4e-08	1.99e-06	-0.22	-0.17	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63504366	chr10:63634317~63634827:-
BRCA	cis	rs7923609	0.967	rs4486511	ENSG00000232075.1	MRPL35P2	-5.72	1.4e-08	1.99e-06	-0.22	-0.17	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63504506	chr10:63634317~63634827:-
BRCA	cis	rs9652601	0.622	rs1861548	ENSG00000274038.1	RP11-66H6.4	-5.72	1.4e-08	1.99e-06	-0.19	-0.17	Systemic lupus erythematosus;	chr16:11024643	chr16:11056556~11057034:+
BRCA	cis	rs853679	0.607	rs67662114	ENSG00000204709.4	LINC01556	5.72	1.4e-08	1.99e-06	0.47	0.17	Depression;	chr6:27964523	chr6:28943877~28944537:+
BRCA	cis	rs853679	0.607	rs13216117	ENSG00000204709.4	LINC01556	5.72	1.4e-08	1.99e-06	0.47	0.17	Depression;	chr6:27970706	chr6:28943877~28944537:+
BRCA	cis	rs853679	0.607	rs36101351	ENSG00000204709.4	LINC01556	5.72	1.4e-08	1.99e-06	0.47	0.17	Depression;	chr6:27975591	chr6:28943877~28944537:+
BRCA	cis	rs853679	0.607	rs28360499	ENSG00000204709.4	LINC01556	5.72	1.4e-08	1.99e-06	0.47	0.17	Depression;	chr6:27977618	chr6:28943877~28944537:+
BRCA	cis	rs9868809	0.505	rs56735597	ENSG00000270441.1	RP11-694I15.7	5.72	1.4e-08	1.99e-06	0.33	0.17	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48727735	chr3:49140086~49160851:-
BRCA	cis	rs4950322	0.57	rs17356219	ENSG00000244371.2	PFN1P8	-5.72	1.4e-08	1.99e-06	-0.24	-0.17	Protein quantitative trait loci;	chr1:147265684	chr1:146957117~146957659:-
BRCA	cis	rs4950322	0.57	rs17356233	ENSG00000244371.2	PFN1P8	-5.72	1.4e-08	1.99e-06	-0.24	-0.17	Protein quantitative trait loci;	chr1:147268843	chr1:146957117~146957659:-
BRCA	cis	rs911555	0.57	rs11625397	ENSG00000244691.1	RPL10AP1	5.72	1.4e-08	1.99e-06	0.21	0.17	Intelligence (multi-trait analysis);	chr14:103561220	chr14:103412119~103412761:-
BRCA	cis	rs4819052	0.655	rs2330103	ENSG00000184274.3	LINC00315	-5.72	1.4e-08	1.99e-06	-0.22	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45274599	chr21:45300245~45305257:-
BRCA	cis	rs7702057	0.53	rs17138834	ENSG00000271918.1	CTD-2287O16.5	-5.72	1.4e-08	1.99e-06	-0.24	-0.17	Amyotrophic lateral sclerosis;	chr5:116076625	chr5:116083807~116085416:-
BRCA	cis	rs1665050	0.598	rs8041221	ENSG00000277144.1	RP11-59H7.4	-5.72	1.4e-08	1.99e-06	-0.21	-0.17	Atopic dermatitis;	chr15:59042609	chr15:59115547~59116089:-
BRCA	cis	rs11098499	0.955	rs6815725	ENSG00000249244.1	RP11-548H18.2	5.72	1.41e-08	1.99e-06	0.21	0.17	Corneal astigmatism;	chr4:119237255	chr4:119391831~119395335:-
BRCA	cis	rs4950322	0.57	rs6703892	ENSG00000244371.2	PFN1P8	-5.72	1.41e-08	1.99e-06	-0.24	-0.17	Protein quantitative trait loci;	chr1:147287627	chr1:146957117~146957659:-
BRCA	cis	rs1552244	0.882	rs66559400	ENSG00000232901.1	CYCSP10	5.72	1.41e-08	1.99e-06	0.24	0.17	Alzheimer's disease;	chr3:9970867	chr3:10000647~10000940:-
BRCA	cis	rs2243480	1	rs431076	ENSG00000164669.11	INTS4P1	5.72	1.41e-08	1.99e-06	0.34	0.17	Diabetic kidney disease;	chr7:66135333	chr7:65141225~65234216:+
BRCA	cis	rs2243480	1	rs2460422	ENSG00000164669.11	INTS4P1	5.72	1.41e-08	1.99e-06	0.34	0.17	Diabetic kidney disease;	chr7:66136518	chr7:65141225~65234216:+
BRCA	cis	rs2243480	1	rs316334	ENSG00000164669.11	INTS4P1	5.72	1.41e-08	1.99e-06	0.34	0.17	Diabetic kidney disease;	chr7:66137139	chr7:65141225~65234216:+
BRCA	cis	rs10129255	0.956	rs10137268	ENSG00000211974.3	IGHV2-70	5.72	1.41e-08	2e-06	0.19	0.17	Kawasaki disease;	chr14:106697402	chr14:106723574~106724093:-
BRCA	cis	rs7238033	0.624	rs8087241	ENSG00000267193.4	RP11-116O18.3	5.72	1.41e-08	2e-06	0.19	0.17	Bladder cancer;	chr18:45729738	chr18:45669367~45747215:-
BRCA	cis	rs9840812	0.535	rs695983	ENSG00000273486.1	RP11-731C17.2	5.72	1.41e-08	2e-06	0.2	0.17	Fibrinogen levels;	chr3:136345705	chr3:136837338~136839021:-
BRCA	cis	rs728616	0.614	rs3934643	ENSG00000225484.5	NUTM2B-AS1	-5.72	1.41e-08	2e-06	-0.35	-0.17	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79977061	chr10:79663088~79826594:-
BRCA	cis	rs55692411	0.537	rs13071931	ENSG00000228008.1	CTD-2330K9.3	5.72	1.41e-08	2e-06	0.2	0.17	Intelligence (multi-trait analysis);	chr3:50025445	chr3:49903845~49916937:+
BRCA	cis	rs4819052	0.807	rs7283915	ENSG00000184274.3	LINC00315	-5.72	1.41e-08	2e-06	-0.24	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251373	chr21:45300245~45305257:-
BRCA	cis	rs4819052	0.851	rs13047104	ENSG00000184274.3	LINC00315	-5.72	1.41e-08	2e-06	-0.24	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45253647	chr21:45300245~45305257:-
BRCA	cis	rs2243480	0.901	rs35087093	ENSG00000230295.1	RP11-458F8.2	-5.72	1.41e-08	2e-06	-0.23	-0.17	Diabetic kidney disease;	chr7:65940221	chr7:66880708~66882981:+
BRCA	cis	rs75422866	0.867	rs75568526	ENSG00000280054.1	RP1-197B17.7	5.72	1.41e-08	2e-06	0.43	0.17	Pneumonia;	chr12:47649718	chr12:47728151~47730598:-
BRCA	cis	rs75422866	0.867	rs116302411	ENSG00000280054.1	RP1-197B17.7	5.72	1.41e-08	2e-06	0.43	0.17	Pneumonia;	chr12:47649788	chr12:47728151~47730598:-
BRCA	cis	rs3764021	0.87	rs11052710	ENSG00000214776.8	RP11-726G1.1	5.72	1.41e-08	2e-06	0.19	0.17	Type 1 diabetes;	chr12:9723754	chr12:9467552~9576275:+
BRCA	cis	rs7520050	0.966	rs11579634	ENSG00000280836.1	AL355480.1	-5.72	1.41e-08	2e-06	-0.2	-0.17	Reticulocyte count;Red blood cell count;	chr1:46000719	chr1:45581219~45581321:-
BRCA	cis	rs11098499	0.955	rs13114751	ENSG00000249244.1	RP11-548H18.2	5.72	1.41e-08	2e-06	0.21	0.17	Corneal astigmatism;	chr4:119235462	chr4:119391831~119395335:-
BRCA	cis	rs9341808	0.754	rs6916405	ENSG00000272129.1	RP11-250B2.6	5.72	1.41e-08	2e-06	0.22	0.17	Sitting height ratio;	chr6:80314471	chr6:80355424~80356859:+
BRCA	cis	rs13108904	0.875	rs1564509	ENSG00000254094.1	AC078852.1	-5.72	1.41e-08	2e-06	-0.19	-0.17	Obesity-related traits;	chr4:1242774	chr4:1356581~1358075:+
BRCA	cis	rs9308731	0.692	rs604126	ENSG00000227992.1	AC108463.2	-5.72	1.41e-08	2e-06	-0.22	-0.17	Chronic lymphocytic leukemia;	chr2:111185623	chr2:111203964~111206215:-
BRCA	cis	rs7927771	0.524	rs11039345	ENSG00000280615.1	Y_RNA	5.72	1.41e-08	2e-06	0.2	0.17	Subjective well-being;	chr11:47698676	chr11:47614898~47614994:-
BRCA	cis	rs9545047	0.584	rs9565485	ENSG00000227354.5	RBM26-AS1	-5.72	1.41e-08	2.01e-06	-0.19	-0.17	Schizophrenia;	chr13:79307428	chr13:79406309~79424328:+
BRCA	cis	rs6570726	0.764	rs9403731	ENSG00000270638.1	RP3-466P17.1	5.72	1.41e-08	2.01e-06	0.2	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145586801	chr6:145735570~145737218:+
BRCA	cis	rs1862618	0.853	rs1423621	ENSG00000271828.1	CTD-2310F14.1	5.72	1.41e-08	2.01e-06	0.23	0.17	Initial pursuit acceleration;	chr5:56805208	chr5:56927874~56929573:+
BRCA	cis	rs10504130	0.569	rs34372756	ENSG00000272024.1	RP11-546K22.3	-5.72	1.41e-08	2.01e-06	-0.26	-0.17	Venous thromboembolism (SNP x SNP interaction);	chr8:51908796	chr8:51950284~51950690:+
BRCA	cis	rs8114671	0.562	rs1801310	ENSG00000269202.1	RP4-614O4.12	-5.72	1.42e-08	2.01e-06	-0.18	-0.17	Height;	chr20:34929211	chr20:35201747~35203288:-
BRCA	cis	rs1707322	1	rs12403666	ENSG00000281133.1	AL355480.3	-5.72	1.42e-08	2.01e-06	-0.22	-0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45965949	chr1:45580892~45580996:-
BRCA	cis	rs12681366	0.839	rs2930964	ENSG00000253704.1	RP11-267M23.4	5.72	1.42e-08	2.01e-06	0.2	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94435906	chr8:94553722~94569745:+
BRCA	cis	rs7247513	0.964	rs8105902	ENSG00000213290.4	PGK1P2	-5.72	1.42e-08	2.01e-06	-0.24	-0.17	Bipolar disorder;	chr19:12607537	chr19:12559571~12561105:+
BRCA	cis	rs11668609	1	rs3844579	ENSG00000268442.1	CTD-2027I19.2	5.72	1.42e-08	2.01e-06	0.24	0.17	Response to taxane treatment (docetaxel);	chr19:24120337	chr19:24162370~24163425:-
BRCA	cis	rs295490	0.748	rs58060926	ENSG00000272656.1	RP11-219D15.3	5.72	1.42e-08	2.01e-06	0.41	0.17	PR interval in Tripanosoma cruzi seropositivity;	chr3:139356577	chr3:139349024~139349371:-
BRCA	cis	rs295490	0.748	rs78116750	ENSG00000272656.1	RP11-219D15.3	5.72	1.42e-08	2.01e-06	0.41	0.17	PR interval in Tripanosoma cruzi seropositivity;	chr3:139356886	chr3:139349024~139349371:-
BRCA	cis	rs295490	0.748	rs74365525	ENSG00000272656.1	RP11-219D15.3	5.72	1.42e-08	2.01e-06	0.41	0.17	PR interval in Tripanosoma cruzi seropositivity;	chr3:139357107	chr3:139349024~139349371:-
BRCA	cis	rs295490	0.667	rs80049554	ENSG00000272656.1	RP11-219D15.3	5.72	1.42e-08	2.01e-06	0.41	0.17	PR interval in Tripanosoma cruzi seropositivity;	chr3:139357161	chr3:139349024~139349371:-
BRCA	cis	rs295490	0.748	rs2307031	ENSG00000272656.1	RP11-219D15.3	5.72	1.42e-08	2.01e-06	0.41	0.17	PR interval in Tripanosoma cruzi seropositivity;	chr3:139357978	chr3:139349024~139349371:-
BRCA	cis	rs295490	0.915	rs79695313	ENSG00000272656.1	RP11-219D15.3	5.72	1.42e-08	2.01e-06	0.41	0.17	PR interval in Tripanosoma cruzi seropositivity;	chr3:139358335	chr3:139349024~139349371:-
BRCA	cis	rs12439619	0.508	rs11856561	ENSG00000255769.6	GOLGA2P10	-5.72	1.42e-08	2.01e-06	-0.2	-0.17	Intelligence (multi-trait analysis);	chr15:82161415	chr15:82472993~82513950:-
BRCA	cis	rs2562456	0.876	rs62110202	ENSG00000268081.1	RP11-678G14.2	5.72	1.42e-08	2.01e-06	0.26	0.17	Pain;	chr19:21571799	chr19:21554640~21569237:-
BRCA	cis	rs875971	0.545	rs10261710	ENSG00000228409.4	CCT6P1	-5.72	1.42e-08	2.01e-06	-0.18	-0.17	Aortic root size;	chr7:66249202	chr7:65751142~65763354:+
BRCA	cis	rs595244	0.831	rs55694948	ENSG00000259705.1	RP11-227D13.1	5.72	1.42e-08	2.01e-06	0.25	0.17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48465935	chr15:48645951~48652016:+
BRCA	cis	rs2153535	0.585	rs1328865	ENSG00000230939.1	RP11-314C16.1	-5.72	1.42e-08	2.01e-06	-0.2	-0.17	Motion sickness;	chr6:8653454	chr6:8784178~8785445:+
BRCA	cis	rs801193	0.591	rs9986881	ENSG00000222364.1	RNU6-96P	-5.72	1.42e-08	2.01e-06	-0.21	-0.17	Aortic root size;	chr7:66708053	chr7:66395191~66395286:+
BRCA	cis	rs516805	0.63	rs499825	ENSG00000279114.1	RP3-425C14.5	-5.72	1.42e-08	2.01e-06	-0.21	-0.17	Lymphocyte counts;	chr6:122454050	chr6:122471923~122484161:+
BRCA	cis	rs34286592	0.929	rs10204	ENSG00000214725.6	CDIPT-AS1	-5.72	1.42e-08	2.01e-06	-0.27	-0.17	Multiple sclerosis;	chr16:29815217	chr16:29863593~29868053:+
BRCA	cis	rs9527	0.83	rs11191442	ENSG00000213061.2	PFN1P11	5.72	1.42e-08	2.01e-06	0.25	0.17	Arsenic metabolism;	chr10:102883839	chr10:102838011~102845473:-
BRCA	cis	rs7577696	0.597	rs11691939	ENSG00000272716.1	RP11-563N4.1	5.72	1.42e-08	2.02e-06	0.21	0.17	Inflammatory biomarkers;	chr2:32114492	chr2:32165046~32165757:-
BRCA	cis	rs75422866	0.867	rs73113117	ENSG00000280054.1	RP1-197B17.7	5.72	1.42e-08	2.02e-06	0.43	0.17	Pneumonia;	chr12:47617299	chr12:47728151~47730598:-
BRCA	cis	rs12612619	0.732	rs1053609	ENSG00000229122.1	AGBL5-IT1	5.72	1.42e-08	2.02e-06	0.19	0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27070282	chr2:27061038~27061815:+
BRCA	cis	rs4927850	0.958	rs1975582	ENSG00000207650.1	MIR570	5.72	1.42e-08	2.02e-06	0.21	0.17	Pancreatic cancer;	chr3:196024568	chr3:195699401~195699497:+
BRCA	cis	rs13126694	0.679	rs4072170	ENSG00000251429.1	RP11-597D13.7	5.72	1.43e-08	2.02e-06	0.17	0.17	Blood osmolality (transformed sodium);	chr4:157980683	chr4:158270378~158278676:+
BRCA	cis	rs5758511	0.68	rs739147	ENSG00000205702.9	CYP2D7	5.72	1.43e-08	2.02e-06	0.18	0.17	Birth weight;	chr22:42275060	chr22:42140203~42144577:-
BRCA	cis	rs7923609	0.811	rs4746204	ENSG00000232075.1	MRPL35P2	5.72	1.43e-08	2.02e-06	0.22	0.17	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63568758	chr10:63634317~63634827:-
BRCA	cis	rs7923609	0.783	rs7907451	ENSG00000232075.1	MRPL35P2	5.72	1.43e-08	2.02e-06	0.22	0.17	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63568980	chr10:63634317~63634827:-
BRCA	cis	rs67981189	0.529	rs17108808	ENSG00000258571.1	PTTG4P	-5.72	1.43e-08	2.02e-06	-0.2	-0.17	Schizophrenia;	chr14:70974835	chr14:71085482~71085833:-
BRCA	cis	rs11742741	0.579	rs4701424	ENSG00000248874.4	C5orf17	-5.72	1.43e-08	2.02e-06	-0.23	-0.17	Educational attainment;	chr5:24108437	chr5:23951348~24178263:+
BRCA	cis	rs7914558	0.902	rs3736922	ENSG00000213061.2	PFN1P11	-5.72	1.43e-08	2.02e-06	-0.23	-0.17	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103090875	chr10:102838011~102845473:-
BRCA	cis	rs2179367	0.586	rs9498341	ENSG00000223701.3	RAET1E-AS1	5.72	1.43e-08	2.02e-06	0.25	0.17	Dupuytren's disease;	chr6:149379737	chr6:149884431~149919508:+
BRCA	cis	rs2179367	0.632	rs9498342	ENSG00000223701.3	RAET1E-AS1	5.72	1.43e-08	2.02e-06	0.25	0.17	Dupuytren's disease;	chr6:149379806	chr6:149884431~149919508:+
BRCA	cis	rs2179367	0.632	rs12191079	ENSG00000223701.3	RAET1E-AS1	5.72	1.43e-08	2.02e-06	0.25	0.17	Dupuytren's disease;	chr6:149380333	chr6:149884431~149919508:+
BRCA	cis	rs2179367	0.632	rs12204461	ENSG00000223701.3	RAET1E-AS1	5.72	1.43e-08	2.02e-06	0.25	0.17	Dupuytren's disease;	chr6:149380399	chr6:149884431~149919508:+
BRCA	cis	rs4835473	0.864	rs1849132	ENSG00000249741.2	RP11-673E1.3	-5.72	1.43e-08	2.02e-06	-0.18	-0.17	Immature fraction of reticulocytes;	chr4:143958309	chr4:143911514~143912053:-
BRCA	cis	rs4835473	0.9	rs13123407	ENSG00000249741.2	RP11-673E1.3	-5.72	1.43e-08	2.02e-06	-0.18	-0.17	Immature fraction of reticulocytes;	chr4:143958713	chr4:143911514~143912053:-
BRCA	cis	rs4835473	0.897	rs61611095	ENSG00000249741.2	RP11-673E1.3	-5.72	1.43e-08	2.02e-06	-0.18	-0.17	Immature fraction of reticulocytes;	chr4:143958802	chr4:143911514~143912053:-
BRCA	cis	rs4835473	0.9	rs4835449	ENSG00000249741.2	RP11-673E1.3	-5.72	1.43e-08	2.02e-06	-0.18	-0.17	Immature fraction of reticulocytes;	chr4:143958830	chr4:143911514~143912053:-
BRCA	cis	rs4835473	0.932	rs1838516	ENSG00000249741.2	RP11-673E1.3	-5.72	1.43e-08	2.02e-06	-0.18	-0.17	Immature fraction of reticulocytes;	chr4:143962082	chr4:143911514~143912053:-
BRCA	cis	rs4664293	0.51	rs66571608	ENSG00000226266.5	AC009961.3	5.72	1.43e-08	2.02e-06	0.22	0.17	Monocyte percentage of white cells;	chr2:159635851	chr2:159670708~159712435:-
BRCA	cis	rs7487075	0.93	rs11183468	ENSG00000257261.4	RP11-96H19.1	5.72	1.43e-08	2.02e-06	0.19	0.17	Itch intensity from mosquito bite;	chr12:46412478	chr12:46383679~46876159:+
BRCA	cis	rs227275	0.525	rs7685399	ENSG00000251288.2	RP11-10L12.2	-5.72	1.43e-08	2.03e-06	-0.2	-0.17	Allergic disease (asthma, hay fever or eczema);	chr4:102991926	chr4:102751401~102752641:+
BRCA	cis	rs227275	0.525	rs2866417	ENSG00000251288.2	RP11-10L12.2	-5.72	1.43e-08	2.03e-06	-0.2	-0.17	Allergic disease (asthma, hay fever or eczema);	chr4:102993481	chr4:102751401~102752641:+
BRCA	cis	rs9545047	0.604	rs28579970	ENSG00000227354.5	RBM26-AS1	-5.72	1.43e-08	2.03e-06	-0.19	-0.17	Schizophrenia;	chr13:79308726	chr13:79406309~79424328:+
BRCA	cis	rs12681366	0.734	rs4735292	ENSG00000253704.1	RP11-267M23.4	5.71	1.43e-08	2.03e-06	0.18	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94396503	chr8:94553722~94569745:+
BRCA	cis	rs3760982	0.52	rs425578	ENSG00000267058.1	RP11-15A1.3	5.71	1.43e-08	2.03e-06	0.2	0.17	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43798104	chr19:43891804~43901805:-
BRCA	cis	rs7238033	0.624	rs11877086	ENSG00000267193.4	RP11-116O18.3	5.71	1.43e-08	2.03e-06	0.19	0.17	Bladder cancer;	chr18:45727373	chr18:45669367~45747215:-
BRCA	cis	rs7238033	0.624	rs9304321	ENSG00000267193.4	RP11-116O18.3	5.71	1.43e-08	2.03e-06	0.19	0.17	Bladder cancer;	chr18:45728223	chr18:45669367~45747215:-
BRCA	cis	rs7238033	0.624	rs9304323	ENSG00000267193.4	RP11-116O18.3	5.71	1.43e-08	2.03e-06	0.19	0.17	Bladder cancer;	chr18:45728350	chr18:45669367~45747215:-
BRCA	cis	rs11098499	0.604	rs17051352	ENSG00000249244.1	RP11-548H18.2	5.71	1.43e-08	2.03e-06	0.22	0.17	Corneal astigmatism;	chr4:119660272	chr4:119391831~119395335:-
BRCA	cis	rs7618501	0.521	rs3796386	ENSG00000228008.1	CTD-2330K9.3	5.71	1.43e-08	2.03e-06	0.17	0.17	Intelligence (multi-trait analysis);	chr3:49862362	chr3:49903845~49916937:+
BRCA	cis	rs9545047	0.604	rs1980883	ENSG00000227354.5	RBM26-AS1	-5.71	1.43e-08	2.03e-06	-0.19	-0.17	Schizophrenia;	chr13:79310629	chr13:79406309~79424328:+
BRCA	cis	rs875971	1	rs3981131	ENSG00000224316.1	RP11-479O9.2	5.71	1.43e-08	2.03e-06	0.17	0.17	Aortic root size;	chr7:66486690	chr7:65773620~65802067:+
BRCA	cis	rs7246760	0.867	rs1820114	ENSG00000277587.1	CTD-3116E22.8	-5.71	1.44e-08	2.03e-06	-0.34	-0.17	Pursuit maintenance gain;	chr19:9695016	chr19:9721903~9722410:+
BRCA	cis	rs2243480	1	rs313813	ENSG00000228409.4	CCT6P1	5.71	1.44e-08	2.03e-06	0.25	0.17	Diabetic kidney disease;	chr7:66038513	chr7:65751142~65763354:+
BRCA	cis	rs11671005	0.735	rs3826684	ENSG00000252334.1	RNU6-1337P	5.71	1.44e-08	2.03e-06	0.26	0.17	Mean platelet volume;	chr19:58407338	chr19:58483749~58483843:-
BRCA	cis	rs11671005	0.735	rs3826683	ENSG00000252334.1	RNU6-1337P	5.71	1.44e-08	2.03e-06	0.26	0.17	Mean platelet volume;	chr19:58407366	chr19:58483749~58483843:-
BRCA	cis	rs11671005	0.735	rs3826681	ENSG00000252334.1	RNU6-1337P	5.71	1.44e-08	2.03e-06	0.26	0.17	Mean platelet volume;	chr19:58407397	chr19:58483749~58483843:-
BRCA	cis	rs4834770	1	rs4336213	ENSG00000249244.1	RP11-548H18.2	5.71	1.44e-08	2.04e-06	0.19	0.17	Blood protein levels;	chr4:119315314	chr4:119391831~119395335:-
BRCA	cis	rs5758511	0.773	rs9623482	ENSG00000205702.9	CYP2D7	5.71	1.44e-08	2.04e-06	0.18	0.17	Birth weight;	chr22:41964570	chr22:42140203~42144577:-
BRCA	cis	rs61160187	0.51	rs4482855	ENSG00000272308.1	RP11-231G3.1	-5.71	1.44e-08	2.04e-06	-0.19	-0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:60800670	chr5:60866457~60866935:-
BRCA	cis	rs741668	0.931	rs17350833	ENSG00000235903.6	CPB2-AS1	5.71	1.44e-08	2.04e-06	0.23	0.17	Cerebrospinal fluid clusterin levels;	chr13:45963622	chr13:46052806~46113332:+
BRCA	cis	rs1707322	0.752	rs11211146	ENSG00000234329.1	RP11-767N6.2	5.71	1.44e-08	2.04e-06	0.18	0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45644122	chr1:45651039~45651826:-
BRCA	cis	rs1707322	0.752	rs11211147	ENSG00000234329.1	RP11-767N6.2	5.71	1.44e-08	2.04e-06	0.18	0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45644422	chr1:45651039~45651826:-
BRCA	cis	rs6840258	0.891	rs10032710	ENSG00000251411.1	RP11-397E7.4	-5.71	1.44e-08	2.04e-06	-0.24	-0.17	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87145107	chr4:86913266~86914817:-
BRCA	cis	rs2638953	0.889	rs10843157	ENSG00000278733.1	RP11-425D17.1	-5.71	1.44e-08	2.04e-06	-0.24	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28346417	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.962	rs11049548	ENSG00000278733.1	RP11-425D17.1	-5.71	1.44e-08	2.04e-06	-0.24	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28350789	chr12:28185625~28186190:-
BRCA	cis	rs7124681	0.528	rs74608150	ENSG00000280615.1	Y_RNA	5.71	1.44e-08	2.04e-06	0.2	0.17	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:47674662	chr11:47614898~47614994:-
BRCA	cis	rs1387259	0.839	rs7486941	ENSG00000240399.1	RP1-228P16.1	-5.71	1.44e-08	2.04e-06	-0.19	-0.17	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48184848	chr12:48054813~48055591:-
BRCA	cis	rs6540731	1	rs4500383	ENSG00000229983.1	RP11-15I11.2	5.71	1.44e-08	2.04e-06	0.21	0.17	Intelligence (childhood);	chr1:212218254	chr1:212168207~212190259:+
BRCA	cis	rs2243480	0.764	rs2460423	ENSG00000164669.11	INTS4P1	5.71	1.44e-08	2.05e-06	0.34	0.17	Diabetic kidney disease;	chr7:66136229	chr7:65141225~65234216:+
BRCA	cis	rs559928	0.556	rs11607903	ENSG00000236935.1	AP003774.1	5.71	1.45e-08	2.05e-06	0.24	0.17	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64164668	chr11:64325050~64329504:-
BRCA	cis	rs559928	0.606	rs55942618	ENSG00000236935.1	AP003774.1	5.71	1.45e-08	2.05e-06	0.24	0.17	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64168533	chr11:64325050~64329504:-
BRCA	cis	rs559928	0.606	rs76653616	ENSG00000236935.1	AP003774.1	5.71	1.45e-08	2.05e-06	0.24	0.17	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64168667	chr11:64325050~64329504:-
BRCA	cis	rs10761482	0.5	rs7080540	ENSG00000254271.1	RP11-131N11.4	5.71	1.45e-08	2.05e-06	0.24	0.17	Schizophrenia;	chr10:60538828	chr10:60734342~60741828:+
BRCA	cis	rs442309	0.64	rs11597299	ENSG00000238280.1	RP11-436D10.3	-5.71	1.45e-08	2.05e-06	-0.24	-0.17	Vogt-Koyanagi-Harada syndrome;	chr10:62706515	chr10:62793562~62805887:-
BRCA	cis	rs1552244	0.938	rs67667957	ENSG00000180385.7	EMC3-AS1	5.71	1.45e-08	2.05e-06	0.22	0.17	Alzheimer's disease;	chr3:10125580	chr3:9986893~10006990:+
BRCA	cis	rs1862618	0.853	rs1423620	ENSG00000271828.1	CTD-2310F14.1	5.71	1.45e-08	2.05e-06	0.24	0.17	Initial pursuit acceleration;	chr5:56805169	chr5:56927874~56929573:+
BRCA	cis	rs755249	0.958	rs2068663	ENSG00000182109.6	RP11-69E11.4	5.71	1.45e-08	2.05e-06	0.24	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39572899	chr1:39522280~39546187:-
BRCA	cis	rs2250402	0.51	rs2291619	ENSG00000248508.5	SRP14-AS1	-5.71	1.45e-08	2.05e-06	-0.37	-0.17	Corneal curvature;	chr15:40036832	chr15:40039311~40067290:+
BRCA	cis	rs2274273	0.71	rs67395212	ENSG00000258413.1	RP11-665C16.6	-5.71	1.45e-08	2.05e-06	-0.24	-0.17	Protein biomarker;	chr14:55125221	chr14:55262767~55272075:-
BRCA	cis	rs7608910	0.896	rs55776317	ENSG00000271889.1	RP11-493E12.1	5.71	1.45e-08	2.05e-06	0.22	0.17	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;	chr2:60964860	chr2:61151433~61162105:-
BRCA	cis	rs2153535	0.585	rs2208540	ENSG00000230939.1	RP11-314C16.1	-5.71	1.45e-08	2.06e-06	-0.2	-0.17	Motion sickness;	chr6:8627147	chr6:8784178~8785445:+
BRCA	cis	rs2638953	0.962	rs12370271	ENSG00000278733.1	RP11-425D17.1	-5.71	1.45e-08	2.06e-06	-0.24	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28313840	chr12:28185625~28186190:-
BRCA	cis	rs253959	0.595	rs11241361	ENSG00000272265.1	CTD-2287O16.4	5.71	1.45e-08	2.06e-06	0.22	0.17	Bipolar disorder and schizophrenia;	chr5:116112611	chr5:116078110~116078570:-
BRCA	cis	rs523522	0.923	rs2235217	ENSG00000278344.1	RP11-18C24.8	5.71	1.45e-08	2.06e-06	0.24	0.17	High light scatter reticulocyte count;	chr12:120446525	chr12:120500735~120501090:-
BRCA	cis	rs7474896	0.537	rs1208683	ENSG00000120555.12	SEPT7P9	-5.71	1.46e-08	2.06e-06	-0.25	-0.17	Obesity (extreme);	chr10:37804795	chr10:38383069~38402916:-
BRCA	cis	rs9650657	0.537	rs11250092	ENSG00000255046.1	RP11-297N6.4	-5.71	1.46e-08	2.06e-06	-0.2	-0.17	Neuroticism;	chr8:10929033	chr8:11797928~11802568:-
BRCA	cis	rs2243480	1	rs1964692	ENSG00000232559.3	GS1-124K5.12	5.71	1.46e-08	2.06e-06	0.33	0.17	Diabetic kidney disease;	chr7:65989196	chr7:66554588~66576923:-
BRCA	cis	rs2274273	1	rs10149435	ENSG00000258413.1	RP11-665C16.6	-5.71	1.46e-08	2.06e-06	-0.22	-0.17	Protein biomarker;	chr14:55160771	chr14:55262767~55272075:-
BRCA	cis	rs17818399	0.926	rs7590693	ENSG00000279254.1	RP11-536C12.1	-5.71	1.46e-08	2.06e-06	-0.22	-0.17	Height;	chr2:46596853	chr2:46668870~46670778:+
BRCA	cis	rs2115536	0.73	rs12898642	ENSG00000278600.1	RP11-81A1.6	-5.71	1.46e-08	2.06e-06	-0.15	-0.17	Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Eosinophil counts;Neutrophil percentage of granulocytes;	chr15:79889708	chr15:79920195~79922455:-
BRCA	cis	rs1345301	1	rs12470560	ENSG00000234389.1	AC007278.3	-5.71	1.46e-08	2.07e-06	-0.16	-0.17	Waist circumference;	chr2:102252380	chr2:102438713~102440475:+
BRCA	cis	rs577676	0.586	rs10489231	ENSG00000271811.1	RP1-79C4.4	-5.71	1.46e-08	2.07e-06	-0.2	-0.17	Prevalent atrial fibrillation;	chr1:170620296	chr1:170667381~170669425:+
BRCA	cis	rs10129255	0.957	rs12590799	ENSG00000224373.3	IGHV4-59	5.71	1.46e-08	2.07e-06	0.1	0.17	Kawasaki disease;	chr14:106779713	chr14:106627249~106627825:-
BRCA	cis	rs1014246	0.848	rs10787716	ENSG00000232767.1	RP11-498B4.5	-5.71	1.46e-08	2.07e-06	-0.19	-0.17	Age at smoking initiation in chronic obstructive pulmonary disease;	chr10:116700064	chr10:116670103~116672739:+
BRCA	cis	rs2243480	0.901	rs35087093	ENSG00000232559.3	GS1-124K5.12	5.71	1.46e-08	2.07e-06	0.32	0.17	Diabetic kidney disease;	chr7:65940221	chr7:66554588~66576923:-
BRCA	cis	rs1722141	0.67	rs2965073	ENSG00000229628.1	AC073115.7	5.71	1.46e-08	2.07e-06	0.25	0.17	Sitting height ratio;	chr7:45941524	chr7:45990905~46000898:+
BRCA	cis	rs2904967	0.929	rs655433	ENSG00000254614.2	AP003068.23	5.71	1.46e-08	2.07e-06	0.33	0.17	Mean corpuscular volume;	chr11:65301804	chr11:65177606~65181834:-
BRCA	cis	rs7308116	0.505	rs11113521	ENSG00000274395.1	RP11-554D14.8	-5.71	1.46e-08	2.07e-06	-0.21	-0.17	Pelvic organ prolapse (moderate/severe);	chr12:107827089	chr12:107835541~107836555:-
BRCA	cis	rs4950322	0.57	rs72692946	ENSG00000244371.2	PFN1P8	-5.71	1.46e-08	2.07e-06	-0.24	-0.17	Protein quantitative trait loci;	chr1:147319966	chr1:146957117~146957659:-
BRCA	cis	rs4950322	0.57	rs72692948	ENSG00000244371.2	PFN1P8	-5.71	1.46e-08	2.07e-06	-0.24	-0.17	Protein quantitative trait loci;	chr1:147320298	chr1:146957117~146957659:-
BRCA	cis	rs4950322	0.57	rs72692951	ENSG00000244371.2	PFN1P8	-5.71	1.46e-08	2.07e-06	-0.24	-0.17	Protein quantitative trait loci;	chr1:147320551	chr1:146957117~146957659:-
BRCA	cis	rs4950322	0.57	rs77118461	ENSG00000244371.2	PFN1P8	-5.71	1.46e-08	2.07e-06	-0.24	-0.17	Protein quantitative trait loci;	chr1:147320718	chr1:146957117~146957659:-
BRCA	cis	rs4950322	0.57	rs78681047	ENSG00000244371.2	PFN1P8	-5.71	1.46e-08	2.07e-06	-0.24	-0.17	Protein quantitative trait loci;	chr1:147321013	chr1:146957117~146957659:-
BRCA	cis	rs1559040	1	rs1559039	ENSG00000272156.1	RP11-477N3.1	-5.71	1.46e-08	2.07e-06	-0.26	-0.17	Sudden cardiac arrest;	chr2:54120695	chr2:54082554~54085066:+
BRCA	cis	rs7474896	0.559	rs1208779	ENSG00000120555.12	SEPT7P9	5.71	1.47e-08	2.07e-06	0.24	0.17	Obesity (extreme);	chr10:37788801	chr10:38383069~38402916:-
BRCA	cis	rs8114671	0.527	rs6060068	ENSG00000269202.1	RP4-614O4.12	-5.71	1.47e-08	2.08e-06	-0.18	-0.17	Height;	chr20:34828017	chr20:35201747~35203288:-
BRCA	cis	rs300890	0.513	rs72719179	ENSG00000250326.1	RP11-284M14.1	5.71	1.47e-08	2.08e-06	0.21	0.17	Nasopharyngeal carcinoma;	chr4:143140280	chr4:142933195~143184861:-
BRCA	cis	rs8048589	0.898	rs11648235	ENSG00000175604.2	RP11-276H1.3	-5.71	1.47e-08	2.08e-06	-0.26	-0.17	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);	chr16:12087222	chr16:12086746~12090302:-
BRCA	cis	rs4834770	1	rs878375	ENSG00000248280.1	RP11-33B1.2	5.71	1.47e-08	2.08e-06	0.16	0.17	Blood protein levels;	chr4:119316419	chr4:119440561~119450157:-
BRCA	cis	rs7520050	0.966	rs11211230	ENSG00000280836.1	AL355480.1	5.71	1.47e-08	2.08e-06	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:45941095	chr1:45581219~45581321:-
BRCA	cis	rs1707322	0.964	rs10890358	ENSG00000281133.1	AL355480.3	-5.71	1.47e-08	2.08e-06	-0.22	-0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45853353	chr1:45580892~45580996:-
BRCA	cis	rs8114671	0.562	rs4911450	ENSG00000269202.1	RP4-614O4.12	-5.71	1.47e-08	2.08e-06	-0.18	-0.17	Height;	chr20:34924603	chr20:35201747~35203288:-
BRCA	cis	rs9847710	0.967	rs2564938	ENSG00000242142.1	SERBP1P3	5.71	1.47e-08	2.08e-06	0.2	0.17	Ulcerative colitis;	chr3:52992368	chr3:53064283~53065091:-
BRCA	cis	rs7927592	0.913	rs2282563	ENSG00000212093.1	AP000807.1	5.71	1.47e-08	2.08e-06	0.2	0.17	Total body bone mineral density;	chr11:68565732	chr11:68506083~68506166:-
BRCA	cis	rs1552244	0.882	rs113268531	ENSG00000180385.7	EMC3-AS1	5.71	1.47e-08	2.08e-06	0.22	0.17	Alzheimer's disease;	chr3:10125385	chr3:9986893~10006990:+
BRCA	cis	rs1552244	0.938	rs56274701	ENSG00000180385.7	EMC3-AS1	5.71	1.47e-08	2.08e-06	0.22	0.17	Alzheimer's disease;	chr3:10126106	chr3:9986893~10006990:+
BRCA	cis	rs673078	0.66	rs61945206	ENSG00000275409.1	RP11-131L12.4	-5.71	1.47e-08	2.08e-06	-0.26	-0.17	Glucose homeostasis traits;	chr12:118238295	chr12:118430147~118430699:+
BRCA	cis	rs2243480	1	rs466983	ENSG00000164669.11	INTS4P1	5.71	1.47e-08	2.08e-06	0.35	0.17	Diabetic kidney disease;	chr7:66055509	chr7:65141225~65234216:+
BRCA	cis	rs5758511	0.68	rs1001586	ENSG00000205702.9	CYP2D7	5.71	1.47e-08	2.08e-06	0.18	0.17	Birth weight;	chr22:42274287	chr22:42140203~42144577:-
BRCA	cis	rs4803480	0.935	rs9304595	ENSG00000270164.1	LINC01480	5.71	1.47e-08	2.08e-06	0.21	0.17	Schizophrenia;	chr19:41571639	chr19:41535183~41536904:+
BRCA	cis	rs651386	0.529	rs2206063	ENSG00000271811.1	RP1-79C4.4	-5.71	1.47e-08	2.08e-06	-0.2	-0.17	Atrial fibrillation;	chr1:170615956	chr1:170667381~170669425:+
BRCA	cis	rs4908760	0.899	rs6577496	ENSG00000270282.1	RP5-1115A15.2	5.71	1.47e-08	2.08e-06	0.19	0.17	Vitiligo;	chr1:8521168	chr1:8512653~8513021:+
BRCA	cis	rs2919009	0.712	rs2241847	ENSG00000271670.1	RP11-95I16.4	5.71	1.47e-08	2.09e-06	0.22	0.17	Obesity-related traits;	chr10:120858159	chr10:120879256~120880667:-
BRCA	cis	rs7044106	0.791	rs10818473	ENSG00000238181.2	AHCYP2	-5.71	1.48e-08	2.09e-06	-0.23	-0.17	Hip circumference adjusted for BMI;	chr9:120721877	chr9:120720673~120721972:+
BRCA	cis	rs516805	0.781	rs502103	ENSG00000279114.1	RP3-425C14.5	-5.71	1.48e-08	2.09e-06	-0.21	-0.17	Lymphocyte counts;	chr6:122446062	chr6:122471923~122484161:+
BRCA	cis	rs2662776	0.521	rs2815268	ENSG00000232995.6	RGS5	-5.71	1.48e-08	2.09e-06	-0.19	-0.17	Lead levels in blood;	chr1:163190945	chr1:163244505~163321894:-
BRCA	cis	rs7520050	0.966	rs7556436	ENSG00000280836.1	AL355480.1	-5.71	1.48e-08	2.09e-06	-0.2	-0.17	Reticulocyte count;Red blood cell count;	chr1:45898208	chr1:45581219~45581321:-
BRCA	cis	rs7246657	0.551	rs28462002	ENSG00000276846.1	CTD-3220F14.3	5.71	1.48e-08	2.09e-06	0.27	0.17	Coronary artery calcification;	chr19:37143560	chr19:37314868~37315620:-
BRCA	cis	rs4218	0.505	rs6494064	ENSG00000277144.1	RP11-59H7.4	5.71	1.48e-08	2.09e-06	0.21	0.17	Social communication problems;	chr15:59053192	chr15:59115547~59116089:-
BRCA	cis	rs7131987	0.65	rs10843377	ENSG00000275476.1	RP11-996F15.4	5.71	1.48e-08	2.09e-06	0.21	0.17	QT interval;	chr12:29284120	chr12:29277397~29277882:-
BRCA	cis	rs9876781	0.967	rs9876891	ENSG00000229759.1	MRPS18AP1	5.71	1.48e-08	2.09e-06	0.2	0.17	Longevity;	chr3:48440024	chr3:48256350~48256938:-
BRCA	cis	rs673078	0.66	rs16948193	ENSG00000275409.1	RP11-131L12.4	-5.71	1.48e-08	2.09e-06	-0.26	-0.17	Glucose homeostasis traits;	chr12:118227115	chr12:118430147~118430699:+
BRCA	cis	rs673078	0.66	rs61945187	ENSG00000275409.1	RP11-131L12.4	-5.71	1.48e-08	2.09e-06	-0.26	-0.17	Glucose homeostasis traits;	chr12:118228989	chr12:118430147~118430699:+
BRCA	cis	rs6088813	1	rs6142358	ENSG00000126005.14	MMP24-AS1	-5.71	1.48e-08	2.09e-06	-0.21	-0.17	Height;	chr20:35372505	chr20:35216462~35278131:-
BRCA	cis	rs7923609	0.783	rs7100409	ENSG00000232075.1	MRPL35P2	5.71	1.48e-08	2.09e-06	0.22	0.17	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63570435	chr10:63634317~63634827:-
BRCA	cis	rs7923609	0.703	rs7100413	ENSG00000232075.1	MRPL35P2	5.71	1.48e-08	2.09e-06	0.22	0.17	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63570448	chr10:63634317~63634827:-
BRCA	cis	rs7238033	0.624	rs4310958	ENSG00000267193.4	RP11-116O18.3	5.71	1.48e-08	2.09e-06	0.19	0.17	Bladder cancer;	chr18:45729390	chr18:45669367~45747215:-
BRCA	cis	rs3764021	0.933	rs2268146	ENSG00000214776.8	RP11-726G1.1	5.71	1.48e-08	2.09e-06	0.19	0.17	Type 1 diabetes;	chr12:9716675	chr12:9467552~9576275:+
BRCA	cis	rs754466	0.58	rs2579177	ENSG00000204049.1	RP11-126H7.4	5.71	1.48e-08	2.09e-06	0.21	0.17	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77769487	chr10:77866875~77869610:+
BRCA	cis	rs6442522	0.678	rs2345106	ENSG00000249786.6	EAF1-AS1	5.71	1.48e-08	2.09e-06	0.18	0.17	Uric acid levels;	chr3:15467521	chr3:15436171~15455940:-
BRCA	cis	rs55702914	0.628	rs67657812	ENSG00000231621.1	AC013264.2	-5.71	1.48e-08	2.1e-06	-0.16	-0.17	Major depression and alcohol dependence;	chr2:197522677	chr2:197197991~197199273:+
BRCA	cis	rs875971	0.545	rs6460281	ENSG00000228409.4	CCT6P1	-5.71	1.48e-08	2.1e-06	-0.17	-0.17	Aortic root size;	chr7:66216128	chr7:65751142~65763354:+
BRCA	cis	rs6570726	0.791	rs9403730	ENSG00000270638.1	RP3-466P17.1	5.71	1.49e-08	2.1e-06	0.2	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145586097	chr6:145735570~145737218:+
BRCA	cis	rs7119038	0.818	rs10892287	ENSG00000255239.1	AP002954.6	5.71	1.49e-08	2.1e-06	0.24	0.17	Sjögren's syndrome;	chr11:118772290	chr11:118688039~118690600:-
BRCA	cis	rs2243480	1	rs7794661	ENSG00000230295.1	RP11-458F8.2	-5.71	1.49e-08	2.1e-06	-0.23	-0.17	Diabetic kidney disease;	chr7:65924743	chr7:66880708~66882981:+
BRCA	cis	rs7613875	0.62	rs7624030	ENSG00000228008.1	CTD-2330K9.3	-5.71	1.49e-08	2.1e-06	-0.17	-0.17	Body mass index;	chr3:50033846	chr3:49903845~49916937:+
BRCA	cis	rs7044106	0.791	rs7036766	ENSG00000238181.2	AHCYP2	-5.71	1.49e-08	2.1e-06	-0.23	-0.17	Hip circumference adjusted for BMI;	chr9:120717343	chr9:120720673~120721972:+
BRCA	cis	rs7555523	0.887	rs2814471	ENSG00000224358.1	RP11-466F5.8	-5.71	1.49e-08	2.1e-06	-0.31	-0.17	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165770361	chr1:165768929~165775176:+
BRCA	cis	rs7520050	0.931	rs11211189	ENSG00000280836.1	AL355480.1	5.71	1.49e-08	2.1e-06	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:45795912	chr1:45581219~45581321:-
BRCA	cis	rs7520050	0.966	rs12411269	ENSG00000280836.1	AL355480.1	5.71	1.49e-08	2.1e-06	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:45805380	chr1:45581219~45581321:-
BRCA	cis	rs1345301	1	rs12474199	ENSG00000234389.1	AC007278.3	-5.71	1.49e-08	2.1e-06	-0.16	-0.17	Waist circumference;	chr2:102252520	chr2:102438713~102440475:+
BRCA	cis	rs9990343	0.543	rs3181039	ENSG00000223552.1	RP11-24F11.2	5.71	1.49e-08	2.1e-06	0.19	0.17	Brain structure;	chr3:46380347	chr3:46364955~46407059:-
BRCA	cis	rs9813712	0.595	rs1901787	ENSG00000228252.7	COL6A4P2	5.71	1.49e-08	2.11e-06	0.21	0.17	Response to amphetamines;	chr3:130288678	chr3:130212823~130273806:+
BRCA	cis	rs2058059	0.512	rs3015937	ENSG00000225648.4	SBDSP1	-5.71	1.49e-08	2.11e-06	-0.28	-0.17	Subcutaneous adipose tissue;	chr7:72698883	chr7:72829425~72836701:+
BRCA	cis	rs1707322	1	rs7531911	ENSG00000281133.1	AL355480.3	-5.71	1.49e-08	2.11e-06	-0.22	-0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45864751	chr1:45580892~45580996:-
BRCA	cis	rs1707322	1	rs10890359	ENSG00000281133.1	AL355480.3	-5.71	1.49e-08	2.11e-06	-0.22	-0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45870963	chr1:45580892~45580996:-
BRCA	cis	rs2502757	0.871	rs2510234	ENSG00000225756.1	DBH-AS1	-5.71	1.49e-08	2.11e-06	-0.18	-0.17	Asthma;	chr9:133725247	chr9:133654586~133657313:-
BRCA	cis	rs13126694	1	rs13126694	ENSG00000248429.4	RP11-597D13.9	-5.71	1.49e-08	2.11e-06	-0.15	-0.17	Blood osmolality (transformed sodium);	chr4:158177632	chr4:158170752~158202877:+
BRCA	cis	rs910316	0.737	rs175048	ENSG00000279594.1	RP11-950C14.10	-5.71	1.49e-08	2.11e-06	-0.19	-0.17	Height;	chr14:75013191	chr14:75011269~75012851:-
BRCA	cis	rs816535	1	rs816535	ENSG00000230772.1	VN1R108P	5.71	1.49e-08	2.11e-06	0.25	0.17	Parkinson disease and lewy body pathology;	chr20:26275360	chr20:25734264~25735093:+
BRCA	cis	rs6832769	1	rs4865010	ENSG00000223305.1	RN7SKP30	-5.71	1.49e-08	2.11e-06	-0.22	-0.17	Personality dimensions;	chr4:55548795	chr4:55540502~55540835:-
BRCA	cis	rs11722228	0.508	rs9732	ENSG00000261490.1	RP11-448G15.3	5.71	1.49e-08	2.11e-06	0.19	0.17	Urate levels;Serum uric acid levels;Gout;	chr4:10075034	chr4:10068089~10073019:-
BRCA	cis	rs11105298	0.891	rs11105302	ENSG00000270344.2	RP11-734K2.4	-5.71	1.49e-08	2.11e-06	-0.19	-0.17	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89497589	chr12:89525654~89548005:+
BRCA	cis	rs2638953	0.924	rs11049607	ENSG00000278733.1	RP11-425D17.1	-5.71	1.49e-08	2.11e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28444574	chr12:28185625~28186190:-
BRCA	cis	rs7923837	0.687	rs1111875	ENSG00000236493.2	EIF2S2P3	5.71	1.5e-08	2.11e-06	0.22	0.17	Multiple sclerosis;Body mass index;	chr10:92703125	chr10:92668745~92669743:-
BRCA	cis	rs2239547	0.522	rs6770957	ENSG00000242142.1	SERBP1P3	5.71	1.5e-08	2.11e-06	0.21	0.17	Schizophrenia;	chr3:52961400	chr3:53064283~53065091:-
BRCA	cis	rs2239547	0.522	rs7652131	ENSG00000242142.1	SERBP1P3	5.71	1.5e-08	2.11e-06	0.21	0.17	Schizophrenia;	chr3:52963138	chr3:53064283~53065091:-
BRCA	cis	rs2554380	0.628	rs2401130	ENSG00000230373.7	GOLGA6L5P	-5.71	1.5e-08	2.11e-06	-0.21	-0.17	Height;	chr15:83801983	chr15:84507885~84516814:-
BRCA	cis	rs2554380	0.628	rs2401131	ENSG00000230373.7	GOLGA6L5P	-5.71	1.5e-08	2.11e-06	-0.21	-0.17	Height;	chr15:83802144	chr15:84507885~84516814:-
BRCA	cis	rs2834188	0.889	rs1467849	ENSG00000272659.1	AP000295.10	-5.71	1.5e-08	2.12e-06	-0.26	-0.17	Narcolepsy;	chr21:33309764	chr21:33309491~33310181:+
BRCA	cis	rs2717559	0.683	rs2717611	ENSG00000253196.1	RP11-706C16.7	-5.71	1.5e-08	2.12e-06	-0.17	-0.17	Urinary tract infection frequency;	chr8:142798511	chr8:142763116~142766427:+
BRCA	cis	rs1862618	0.853	rs6450409	ENSG00000271828.1	CTD-2310F14.1	5.71	1.5e-08	2.12e-06	0.24	0.17	Initial pursuit acceleration;	chr5:56805572	chr5:56927874~56929573:+
BRCA	cis	rs13423976	0.6	rs2373404	ENSG00000231367.4	AC016995.3	5.71	1.5e-08	2.12e-06	0.19	0.17	Gut microbiome composition (summer);	chr2:38512959	chr2:38406719~38515740:-
BRCA	cis	rs9840812	0.728	rs12635723	ENSG00000239213.4	NCK1-AS1	5.71	1.5e-08	2.12e-06	0.21	0.17	Fibrinogen levels;	chr3:136581890	chr3:136841726~136862054:-
BRCA	cis	rs2243480	1	rs781149	ENSG00000232559.3	GS1-124K5.12	5.71	1.5e-08	2.12e-06	0.32	0.17	Diabetic kidney disease;	chr7:66016297	chr7:66554588~66576923:-
BRCA	cis	rs2243480	0.901	rs58207111	ENSG00000232559.3	GS1-124K5.12	5.71	1.5e-08	2.12e-06	0.32	0.17	Diabetic kidney disease;	chr7:66021736	chr7:66554588~66576923:-
BRCA	cis	rs11098499	0.955	rs4145951	ENSG00000249244.1	RP11-548H18.2	5.71	1.5e-08	2.12e-06	0.21	0.17	Corneal astigmatism;	chr4:119234662	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.955	rs35916640	ENSG00000249244.1	RP11-548H18.2	5.71	1.5e-08	2.12e-06	0.21	0.17	Corneal astigmatism;	chr4:119234697	chr4:119391831~119395335:-
BRCA	cis	rs3760982	0.585	rs1386502	ENSG00000267058.1	RP11-15A1.3	-5.71	1.5e-08	2.12e-06	-0.2	-0.17	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43789204	chr19:43891804~43901805:-
BRCA	cis	rs5758511	0.633	rs5751258	ENSG00000205702.9	CYP2D7	5.71	1.5e-08	2.12e-06	0.18	0.17	Birth weight;	chr22:42267865	chr22:42140203~42144577:-
BRCA	cis	rs4819052	0.851	rs28622522	ENSG00000184274.3	LINC00315	-5.71	1.5e-08	2.12e-06	-0.24	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45256684	chr21:45300245~45305257:-
BRCA	cis	rs6442522	0.678	rs12634346	ENSG00000249786.6	EAF1-AS1	5.71	1.5e-08	2.12e-06	0.18	0.17	Uric acid levels;	chr3:15458788	chr3:15436171~15455940:-
BRCA	cis	rs523522	0.962	rs10774549	ENSG00000278344.1	RP11-18C24.8	5.71	1.5e-08	2.12e-06	0.24	0.17	High light scatter reticulocyte count;	chr12:120453369	chr12:120500735~120501090:-
BRCA	cis	rs523522	1	rs523522	ENSG00000278344.1	RP11-18C24.8	5.71	1.5e-08	2.12e-06	0.24	0.17	High light scatter reticulocyte count;	chr12:120582447	chr12:120500735~120501090:-
BRCA	cis	rs7772486	0.686	rs9390349	ENSG00000270638.1	RP3-466P17.1	-5.71	1.5e-08	2.12e-06	-0.2	-0.17	Lobe attachment (rater-scored or self-reported);	chr6:145733294	chr6:145735570~145737218:+
BRCA	cis	rs7772486	0.686	rs2072911	ENSG00000270638.1	RP3-466P17.1	-5.71	1.5e-08	2.12e-06	-0.2	-0.17	Lobe attachment (rater-scored or self-reported);	chr6:145735665	chr6:145735570~145737218:+
BRCA	cis	rs62025270	0.632	rs62022920	ENSG00000202081.1	RNU6-1280P	-5.71	1.51e-08	2.12e-06	-0.25	-0.17	Idiopathic pulmonary fibrosis;	chr15:85680159	chr15:85651522~85651628:-
BRCA	cis	rs73222236	0.825	rs7644471	ENSG00000273486.1	RP11-731C17.2	5.71	1.51e-08	2.12e-06	0.2	0.17	Coronary artery disease;	chr3:136565719	chr3:136837338~136839021:-
BRCA	cis	rs467650	0.853	rs294031	ENSG00000248489.1	CTD-2007H13.3	5.71	1.51e-08	2.13e-06	0.2	0.17	Venous thromboembolism (SNP x SNP interaction);	chr5:98690903	chr5:98929171~98995013:+
BRCA	cis	rs467650	0.747	rs382202	ENSG00000248489.1	CTD-2007H13.3	5.71	1.51e-08	2.13e-06	0.2	0.17	Venous thromboembolism (SNP x SNP interaction);	chr5:98693015	chr5:98929171~98995013:+
BRCA	cis	rs875971	0.505	rs2462573	ENSG00000273024.4	INTS4P2	5.71	1.51e-08	2.13e-06	0.19	0.17	Aortic root size;	chr7:66042405	chr7:65647864~65715661:+
BRCA	cis	rs577676	0.586	rs533603	ENSG00000271811.1	RP1-79C4.4	5.71	1.51e-08	2.13e-06	0.2	0.17	Prevalent atrial fibrillation;	chr1:170639527	chr1:170667381~170669425:+
BRCA	cis	rs67981189	0.529	rs2810096	ENSG00000258571.1	PTTG4P	5.71	1.51e-08	2.13e-06	0.2	0.17	Schizophrenia;	chr14:70968583	chr14:71085482~71085833:-
BRCA	cis	rs2492286	0.518	rs2712412	ENSG00000242551.2	POU5F1P6	-5.71	1.51e-08	2.13e-06	-0.24	-0.17	Eosinophil counts;	chr3:128647208	chr3:128674735~128677005:-
BRCA	cis	rs9640161	0.83	rs6722	ENSG00000261305.1	RP4-584D14.7	5.71	1.51e-08	2.13e-06	0.24	0.17	Blood protein levels;Circulating chemerin levels;	chr7:150371844	chr7:150341771~150342607:+
BRCA	cis	rs739525	0.518	rs178268	ENSG00000272829.1	XXbac-B135H6.18	5.71	1.51e-08	2.13e-06	0.17	0.17	Testicular germ cell tumor;	chr22:20975977	chr22:20981361~20981755:-
BRCA	cis	rs4950322	0.57	rs79810882	ENSG00000278811.3	LINC00624	5.71	1.51e-08	2.13e-06	0.24	0.17	Protein quantitative trait loci;	chr1:147235575	chr1:147258885~147517875:-
BRCA	cis	rs577676	0.586	rs578928	ENSG00000271811.1	RP1-79C4.4	5.71	1.51e-08	2.13e-06	0.2	0.17	Prevalent atrial fibrillation;	chr1:170640602	chr1:170667381~170669425:+
BRCA	cis	rs7555523	0.887	rs2251768	ENSG00000224358.1	RP11-466F5.8	-5.71	1.51e-08	2.13e-06	-0.31	-0.17	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165769074	chr1:165768929~165775176:+
BRCA	cis	rs755249	0.501	rs2484749	ENSG00000228060.1	RP11-69E11.8	5.71	1.51e-08	2.13e-06	0.19	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39293283	chr1:39565160~39573203:+
BRCA	cis	rs7493	1	rs17876123	ENSG00000233942.1	AC004012.1	5.71	1.51e-08	2.13e-06	0.22	0.17	Yu-Zhi constitution type in type 2 diabetes;	chr7:95415995	chr7:95471835~95473998:+
BRCA	cis	rs7493	1	rs1034809	ENSG00000233942.1	AC004012.1	5.71	1.51e-08	2.13e-06	0.22	0.17	Yu-Zhi constitution type in type 2 diabetes;	chr7:95422340	chr7:95471835~95473998:+
BRCA	cis	rs7493	1	rs2158806	ENSG00000233942.1	AC004012.1	5.71	1.51e-08	2.13e-06	0.22	0.17	Yu-Zhi constitution type in type 2 diabetes;	chr7:95422686	chr7:95471835~95473998:+
BRCA	cis	rs755249	0.753	rs72663529	ENSG00000182109.6	RP11-69E11.4	5.71	1.51e-08	2.14e-06	0.2	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39557684	chr1:39522280~39546187:-
BRCA	cis	rs793571	0.554	rs28536555	ENSG00000259250.1	RP11-50C13.1	-5.71	1.51e-08	2.14e-06	-0.31	-0.17	Schizophrenia;	chr15:58730403	chr15:58587507~58591676:+
BRCA	cis	rs875971	0.545	rs313830	ENSG00000228409.4	CCT6P1	5.71	1.51e-08	2.14e-06	0.18	0.17	Aortic root size;	chr7:66086944	chr7:65751142~65763354:+
BRCA	cis	rs9840812	0.725	rs696517	ENSG00000239213.4	NCK1-AS1	5.71	1.51e-08	2.14e-06	0.23	0.17	Fibrinogen levels;	chr3:136348813	chr3:136841726~136862054:-
BRCA	cis	rs10911251	0.546	rs20560	ENSG00000224468.3	RP11-181K3.4	-5.71	1.51e-08	2.14e-06	-0.19	-0.17	Colorectal cancer;	chr1:183136399	chr1:183138402~183141282:-
BRCA	cis	rs873549	0.877	rs1530313	ENSG00000232679.1	RP11-400N13.3	5.71	1.51e-08	2.14e-06	0.2	0.17	Keloid;	chr1:222100668	chr1:222041705~222064763:-
BRCA	cis	rs873549	0.959	rs7524005	ENSG00000232679.1	RP11-400N13.3	5.71	1.51e-08	2.14e-06	0.2	0.17	Keloid;	chr1:222100977	chr1:222041705~222064763:-
BRCA	cis	rs873549	1	rs7555836	ENSG00000232679.1	RP11-400N13.3	5.71	1.51e-08	2.14e-06	0.2	0.17	Keloid;	chr1:222101090	chr1:222041705~222064763:-
BRCA	cis	rs9840812	0.623	rs9854084	ENSG00000239213.4	NCK1-AS1	5.7	1.52e-08	2.14e-06	0.21	0.17	Fibrinogen levels;	chr3:136475901	chr3:136841726~136862054:-
BRCA	cis	rs9287719	0.625	rs12473787	ENSG00000243819.4	RN7SL832P	5.7	1.52e-08	2.14e-06	0.18	0.17	Prostate cancer;	chr2:10577068	chr2:10690344~10692099:+
BRCA	cis	rs9880211	0.606	rs9852406	ENSG00000273486.1	RP11-731C17.2	5.7	1.52e-08	2.14e-06	0.23	0.17	Height;Body mass index;	chr3:135906656	chr3:136837338~136839021:-
BRCA	cis	rs2998286	0.723	rs332162	ENSG00000254635.4	WAC-AS1	-5.7	1.52e-08	2.14e-06	-0.25	-0.17	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28599960	chr10:28522652~28532743:-
BRCA	cis	rs2153535	0.553	rs6932565	ENSG00000230939.1	RP11-314C16.1	-5.7	1.52e-08	2.14e-06	-0.2	-0.17	Motion sickness;	chr6:8644926	chr6:8784178~8785445:+
BRCA	cis	rs2834188	0.924	rs2040107	ENSG00000272659.1	AP000295.10	5.7	1.52e-08	2.14e-06	0.26	0.17	Narcolepsy;	chr21:33303657	chr21:33309491~33310181:+
BRCA	cis	rs2395909	1	rs2395909	ENSG00000238832.1	snoU109	5.7	1.52e-08	2.14e-06	0.22	0.17	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr7:107652218	chr7:107603363~107603507:+
BRCA	cis	rs2303319	1	rs1559629	ENSG00000227403.1	AC009299.3	5.7	1.52e-08	2.14e-06	0.44	0.17	Cognitive function;	chr2:161414217	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.792	rs6714082	ENSG00000227403.1	AC009299.3	5.7	1.52e-08	2.14e-06	0.29	0.17	Blood osmolality (transformed sodium);	chr2:161743646	chr2:161244739~161249050:+
BRCA	cis	rs253959	0.545	rs6896147	ENSG00000271918.1	CTD-2287O16.5	-5.7	1.52e-08	2.14e-06	-0.15	-0.17	Bipolar disorder and schizophrenia;	chr5:116089699	chr5:116083807~116085416:-
BRCA	cis	rs2243480	0.901	rs13237344	ENSG00000228409.4	CCT6P1	5.7	1.52e-08	2.14e-06	0.25	0.17	Diabetic kidney disease;	chr7:66557269	chr7:65751142~65763354:+
BRCA	cis	rs2243480	1	rs160646	ENSG00000228409.4	CCT6P1	5.7	1.52e-08	2.15e-06	0.25	0.17	Diabetic kidney disease;	chr7:66091293	chr7:65751142~65763354:+
BRCA	cis	rs7131987	0.65	rs11050208	ENSG00000257176.2	RP11-996F15.2	-5.7	1.52e-08	2.15e-06	-0.23	-0.17	QT interval;	chr12:29357436	chr12:29280418~29317848:-
BRCA	cis	rs853679	0.55	rs1233699	ENSG00000280107.1	AL022393.9	-5.7	1.52e-08	2.15e-06	-0.25	-0.17	Depression;	chr6:28201380	chr6:28170845~28172521:+
BRCA	cis	rs2243480	1	rs1267820	ENSG00000228409.4	CCT6P1	5.7	1.52e-08	2.15e-06	0.25	0.17	Diabetic kidney disease;	chr7:66585308	chr7:65751142~65763354:+
BRCA	cis	rs2239547	0.563	rs9839035	ENSG00000242142.1	SERBP1P3	5.7	1.52e-08	2.15e-06	0.22	0.17	Schizophrenia;	chr3:52875861	chr3:53064283~53065091:-
BRCA	cis	rs7238033	0.624	rs10432193	ENSG00000267193.4	RP11-116O18.3	5.7	1.52e-08	2.15e-06	0.19	0.17	Bladder cancer;	chr18:45727107	chr18:45669367~45747215:-
BRCA	cis	rs2098713	0.535	rs2176478	ENSG00000250155.1	CTD-2353F22.1	5.7	1.52e-08	2.15e-06	0.19	0.17	Telomere length;	chr5:37626939	chr5:36666214~36725195:-
BRCA	cis	rs9840812	0.655	rs4452981	ENSG00000239213.4	NCK1-AS1	5.7	1.52e-08	2.15e-06	0.21	0.17	Fibrinogen levels;	chr3:136588925	chr3:136841726~136862054:-
BRCA	cis	rs8114671	0.562	rs8117491	ENSG00000269202.1	RP4-614O4.12	-5.7	1.53e-08	2.15e-06	-0.18	-0.17	Height;	chr20:34922317	chr20:35201747~35203288:-
BRCA	cis	rs7577696	0.695	rs11676475	ENSG00000272716.1	RP11-563N4.1	-5.7	1.53e-08	2.15e-06	-0.19	-0.17	Inflammatory biomarkers;	chr2:32164121	chr2:32165046~32165757:-
BRCA	cis	rs9813712	0.595	rs1453240	ENSG00000228252.7	COL6A4P2	-5.7	1.53e-08	2.16e-06	-0.21	-0.17	Response to amphetamines;	chr3:130282849	chr3:130212823~130273806:+
BRCA	cis	rs516805	0.667	rs2606650	ENSG00000279453.1	RP3-425C14.4	-5.7	1.53e-08	2.16e-06	-0.24	-0.17	Lymphocyte counts;	chr6:122123443	chr6:122436789~122439223:-
BRCA	cis	rs516805	0.562	rs2816156	ENSG00000279453.1	RP3-425C14.4	-5.7	1.53e-08	2.16e-06	-0.24	-0.17	Lymphocyte counts;	chr6:122124569	chr6:122436789~122439223:-
BRCA	cis	rs66887589	0.616	rs11732621	ENSG00000249244.1	RP11-548H18.2	5.7	1.53e-08	2.16e-06	0.19	0.17	Diastolic blood pressure;	chr4:119291728	chr4:119391831~119395335:-
BRCA	cis	rs1167832	1	rs1167832	ENSG00000205583.12	STAG3L1	5.7	1.53e-08	2.16e-06	0.26	0.17	Ankle injury;	chr7:75537904	chr7:75359194~75395383:+
BRCA	cis	rs7397814	0.558	rs4764447	ENSG00000255753.1	RP11-22B23.2	-5.7	1.53e-08	2.16e-06	-0.19	-0.17	IgG glycosylation;	chr12:9426513	chr12:9314402~9316173:-
BRCA	cis	rs1707322	1	rs4660331	ENSG00000281133.1	AL355480.3	-5.7	1.53e-08	2.16e-06	-0.22	-0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45993111	chr1:45580892~45580996:-
BRCA	cis	rs1707322	1	rs12097799	ENSG00000281133.1	AL355480.3	-5.7	1.53e-08	2.16e-06	-0.22	-0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45994214	chr1:45580892~45580996:-
BRCA	cis	rs11992162	1	rs7460395	ENSG00000227888.4	FAM66A	5.7	1.53e-08	2.16e-06	0.22	0.17	Monocyte count;	chr8:11977866	chr8:12362019~12388296:+
BRCA	cis	rs2638953	0.886	rs11049615	ENSG00000247934.4	RP11-967K21.1	-5.7	1.53e-08	2.16e-06	-0.24	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28452152	chr12:28163298~28190738:-
BRCA	cis	rs1387259	0.931	rs11168474	ENSG00000257763.1	OR5BK1P	5.7	1.53e-08	2.16e-06	0.19	0.17	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48227601	chr12:48355792~48356614:-
BRCA	cis	rs7927592	0.913	rs12285993	ENSG00000212093.1	AP000807.1	5.7	1.53e-08	2.16e-06	0.2	0.17	Total body bone mineral density;	chr11:68535070	chr11:68506083~68506166:-
BRCA	cis	rs2098713	0.535	rs56288111	ENSG00000250155.1	CTD-2353F22.1	5.7	1.53e-08	2.16e-06	0.19	0.17	Telomere length;	chr5:37619340	chr5:36666214~36725195:-
BRCA	cis	rs7569084	0.687	rs35839762	ENSG00000237979.1	AC007389.1	5.7	1.53e-08	2.16e-06	0.22	0.17	Sum eosinophil basophil counts;	chr2:65441318	chr2:65500993~65502138:-
BRCA	cis	rs828999	0.715	rs11185295	ENSG00000280186.1	RP11-483I13.6	-5.7	1.53e-08	2.16e-06	-0.19	-0.17	Monocyte percentage of white cells;	chr1:108168452	chr1:108200413~108202743:+
BRCA	cis	rs9307551	0.619	rs7690520	ENSG00000250334.4	LINC00989	-5.7	1.54e-08	2.17e-06	-0.23	-0.17	Refractive error;	chr4:79507806	chr4:79492416~79576460:+
BRCA	cis	rs10761482	0.5	rs10821790	ENSG00000254271.1	RP11-131N11.4	5.7	1.54e-08	2.17e-06	0.23	0.17	Schizophrenia;	chr10:60529009	chr10:60734342~60741828:+
BRCA	cis	rs10208649	1	rs72904915	ENSG00000233266.1	HMGB1P31	5.7	1.54e-08	2.17e-06	0.41	0.17	Body mass index;	chr2:54000213	chr2:54051334~54051760:+
BRCA	cis	rs2638953	0.924	rs11049507	ENSG00000278733.1	RP11-425D17.1	-5.7	1.54e-08	2.17e-06	-0.24	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28289554	chr12:28185625~28186190:-
BRCA	cis	rs2732480	0.577	rs1489109	ENSG00000257735.1	RP11-370I10.6	5.7	1.54e-08	2.17e-06	0.22	0.17	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344997	chr12:48350945~48442411:+
BRCA	cis	rs2732480	0.577	rs1489108	ENSG00000257735.1	RP11-370I10.6	5.7	1.54e-08	2.17e-06	0.22	0.17	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344998	chr12:48350945~48442411:+
BRCA	cis	rs2098713	0.544	rs2056871	ENSG00000250155.1	CTD-2353F22.1	5.7	1.54e-08	2.17e-06	0.2	0.17	Telomere length;	chr5:37424753	chr5:36666214~36725195:-
BRCA	cis	rs2243480	1	rs160655	ENSG00000164669.11	INTS4P1	5.7	1.54e-08	2.17e-06	0.35	0.17	Diabetic kidney disease;	chr7:66068227	chr7:65141225~65234216:+
BRCA	cis	rs2836950	0.565	rs2150414	ENSG00000255568.3	BRWD1-AS2	-5.7	1.54e-08	2.17e-06	-0.17	-0.17	Menarche (age at onset);	chr21:39243062	chr21:39313935~39314962:+
BRCA	cis	rs4819052	0.851	rs35871601	ENSG00000184274.3	LINC00315	-5.7	1.54e-08	2.17e-06	-0.24	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45255299	chr21:45300245~45305257:-
BRCA	cis	rs2235642	0.75	rs2974845	ENSG00000260989.1	LA16c-395F10.2	-5.7	1.54e-08	2.17e-06	-0.18	-0.17	Coronary artery disease;	chr16:1598161	chr16:1580527~1610328:+
BRCA	cis	rs559928	0.597	rs11600667	ENSG00000236935.1	AP003774.1	5.7	1.54e-08	2.17e-06	0.24	0.17	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64208711	chr11:64325050~64329504:-
BRCA	cis	rs4908768	0.501	rs12046643	ENSG00000270282.1	RP5-1115A15.2	5.7	1.54e-08	2.17e-06	0.19	0.17	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8487806	chr1:8512653~8513021:+
BRCA	cis	rs1075265	0.749	rs6738369	ENSG00000235937.1	AC008280.1	5.7	1.54e-08	2.17e-06	0.19	0.17	Chronotype;Morning vs. evening chronotype;	chr2:53756547	chr2:54029552~54030682:-
BRCA	cis	rs10761482	0.5	rs7906760	ENSG00000254271.1	RP11-131N11.4	5.7	1.54e-08	2.17e-06	0.23	0.17	Schizophrenia;	chr10:60526895	chr10:60734342~60741828:+
BRCA	cis	rs4835473	0.8	rs1849133	ENSG00000249741.2	RP11-673E1.3	-5.7	1.54e-08	2.17e-06	-0.18	-0.17	Immature fraction of reticulocytes;	chr4:143958262	chr4:143911514~143912053:-
BRCA	cis	rs2243480	1	rs160646	ENSG00000164669.11	INTS4P1	5.7	1.54e-08	2.17e-06	0.34	0.17	Diabetic kidney disease;	chr7:66091293	chr7:65141225~65234216:+
BRCA	cis	rs7567389	0.583	rs11683427	ENSG00000236682.1	AC068282.3	-5.7	1.54e-08	2.18e-06	-0.27	-0.17	Self-rated health;	chr2:127198967	chr2:127389130~127400580:+
BRCA	cis	rs227275	0.525	rs4699039	ENSG00000251288.2	RP11-10L12.2	-5.7	1.55e-08	2.18e-06	-0.2	-0.17	Allergic disease (asthma, hay fever or eczema);	chr4:102958354	chr4:102751401~102752641:+
BRCA	cis	rs2638953	0.853	rs11049670	ENSG00000278733.1	RP11-425D17.1	5.7	1.55e-08	2.18e-06	0.23	0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28499342	chr12:28185625~28186190:-
BRCA	cis	rs1876905	0.597	rs1150076	ENSG00000230177.1	RP5-1112D6.4	-5.7	1.55e-08	2.18e-06	-0.25	-0.17	Mean corpuscular hemoglobin;	chr6:111227227	chr6:111277932~111278742:+
BRCA	cis	rs2243480	1	rs2707844	ENSG00000228409.4	CCT6P1	5.7	1.55e-08	2.18e-06	0.24	0.17	Diabetic kidney disease;	chr7:66594522	chr7:65751142~65763354:+
BRCA	cis	rs2243480	1	rs1796220	ENSG00000228409.4	CCT6P1	5.7	1.55e-08	2.18e-06	0.24	0.17	Diabetic kidney disease;	chr7:66597113	chr7:65751142~65763354:+
BRCA	cis	rs2243480	1	rs2707831	ENSG00000228409.4	CCT6P1	5.7	1.55e-08	2.18e-06	0.24	0.17	Diabetic kidney disease;	chr7:66597524	chr7:65751142~65763354:+
BRCA	cis	rs2836950	0.762	rs8134638	ENSG00000238141.2	BRWD1-AS1	-5.7	1.55e-08	2.18e-06	-0.2	-0.17	Menarche (age at onset);	chr21:39272244	chr21:39315707~39323218:+
BRCA	cis	rs11098499	0.955	rs1511019	ENSG00000249244.1	RP11-548H18.2	5.7	1.55e-08	2.18e-06	0.21	0.17	Corneal astigmatism;	chr4:119244852	chr4:119391831~119395335:-
BRCA	cis	rs7493	1	rs3735586	ENSG00000233942.1	AC004012.1	5.7	1.55e-08	2.18e-06	0.22	0.17	Yu-Zhi constitution type in type 2 diabetes;	chr7:95406270	chr7:95471835~95473998:+
BRCA	cis	rs227275	0.525	rs4699037	ENSG00000251288.2	RP11-10L12.2	-5.7	1.55e-08	2.18e-06	-0.2	-0.17	Allergic disease (asthma, hay fever or eczema);	chr4:102957010	chr4:102751401~102752641:+
BRCA	cis	rs227275	0.556	rs3857198	ENSG00000251288.2	RP11-10L12.2	-5.7	1.55e-08	2.18e-06	-0.2	-0.17	Allergic disease (asthma, hay fever or eczema);	chr4:102957720	chr4:102751401~102752641:+
BRCA	cis	rs6490294	0.571	rs11066117	ENSG00000226469.1	ADAM1B	5.7	1.55e-08	2.18e-06	0.27	0.17	Mean platelet volume;	chr12:111994905	chr12:111927018~111929017:+
BRCA	cis	rs459482	0.508	rs467558	ENSG00000228318.3	AP001610.5	5.7	1.55e-08	2.18e-06	0.2	0.17	IgG glycosylation;	chr21:41439468	chr21:41441056~41445708:-
BRCA	cis	rs11098499	1	rs3749591	ENSG00000249244.1	RP11-548H18.2	5.7	1.55e-08	2.18e-06	0.22	0.17	Corneal astigmatism;	chr4:119292875	chr4:119391831~119395335:-
BRCA	cis	rs754466	0.606	rs12356375	ENSG00000204049.1	RP11-126H7.4	5.7	1.55e-08	2.18e-06	0.21	0.17	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77834756	chr10:77866875~77869610:+
BRCA	cis	rs7267979	0.903	rs6050482	ENSG00000277938.1	RP5-965G21.3	5.7	1.55e-08	2.18e-06	0.21	0.17	Liver enzyme levels (alkaline phosphatase);	chr20:25245691	chr20:25229150~25231933:+
BRCA	cis	rs7520050	0.966	rs7515491	ENSG00000280836.1	AL355480.1	5.7	1.55e-08	2.18e-06	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:45889407	chr1:45581219~45581321:-
BRCA	cis	rs7923837	0.65	rs3781241	ENSG00000236493.2	EIF2S2P3	5.7	1.55e-08	2.18e-06	0.25	0.17	Multiple sclerosis;Body mass index;	chr10:92456753	chr10:92668745~92669743:-
BRCA	cis	rs12468226	0.873	rs78798541	ENSG00000226261.1	AC064836.3	5.7	1.55e-08	2.18e-06	0.31	0.17	Urate levels;	chr2:202194708	chr2:202336024~202336727:-
BRCA	cis	rs7044106	0.791	rs4837793	ENSG00000238181.2	AHCYP2	-5.7	1.55e-08	2.19e-06	-0.23	-0.17	Hip circumference adjusted for BMI;	chr9:120721343	chr9:120720673~120721972:+
BRCA	cis	rs6163	0.54	rs11191385	ENSG00000213061.2	PFN1P11	5.7	1.55e-08	2.19e-06	0.25	0.17	Waist circumference;Hip circumference;	chr10:102753292	chr10:102838011~102845473:-
BRCA	cis	rs1552244	1	rs17032414	ENSG00000180385.7	EMC3-AS1	5.7	1.55e-08	2.19e-06	0.21	0.17	Alzheimer's disease;	chr3:10116618	chr3:9986893~10006990:+
BRCA	cis	rs2303319	0.892	rs58627659	ENSG00000227403.1	AC009299.3	5.7	1.55e-08	2.19e-06	0.44	0.17	Cognitive function;	chr2:161394399	chr2:161244739~161249050:+
BRCA	cis	rs2303319	1	rs62188133	ENSG00000227403.1	AC009299.3	5.7	1.55e-08	2.19e-06	0.44	0.17	Cognitive function;	chr2:161396924	chr2:161244739~161249050:+
BRCA	cis	rs9287719	0.649	rs10190774	ENSG00000243819.4	RN7SL832P	5.7	1.55e-08	2.19e-06	0.17	0.17	Prostate cancer;	chr2:10578620	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.649	rs10188373	ENSG00000243819.4	RN7SL832P	5.7	1.55e-08	2.19e-06	0.17	0.17	Prostate cancer;	chr2:10578676	chr2:10690344~10692099:+
BRCA	cis	rs7647973	0.58	rs4955432	ENSG00000225399.4	RP11-3B7.1	5.7	1.56e-08	2.19e-06	0.16	0.17	Menarche (age at onset);	chr3:49229339	chr3:49260085~49261316:+
BRCA	cis	rs10510102	0.872	rs7907815	ENSG00000226864.1	ATE1-AS1	5.7	1.56e-08	2.19e-06	0.31	0.17	Breast cancer;	chr10:121965951	chr10:121928312~121951965:+
BRCA	cis	rs11098499	0.954	rs13145352	ENSG00000260091.1	RP11-33B1.4	5.7	1.56e-08	2.19e-06	0.16	0.17	Corneal astigmatism;	chr4:119488808	chr4:119409333~119410233:+
BRCA	cis	rs6088580	0.524	rs6088564	ENSG00000269202.1	RP4-614O4.12	5.7	1.56e-08	2.19e-06	0.18	0.17	Glomerular filtration rate (creatinine);	chr20:34661640	chr20:35201747~35203288:-
BRCA	cis	rs6088580	0.524	rs11167241	ENSG00000269202.1	RP4-614O4.12	5.7	1.56e-08	2.19e-06	0.18	0.17	Glomerular filtration rate (creatinine);	chr20:34663031	chr20:35201747~35203288:-
BRCA	cis	rs6088580	0.505	rs6142219	ENSG00000269202.1	RP4-614O4.12	5.7	1.56e-08	2.19e-06	0.18	0.17	Glomerular filtration rate (creatinine);	chr20:34668541	chr20:35201747~35203288:-
BRCA	cis	rs6479891	1	rs9415692	ENSG00000232075.1	MRPL35P2	5.7	1.56e-08	2.19e-06	0.32	0.17	Arthritis (juvenile idiopathic);	chr10:63355392	chr10:63634317~63634827:-
BRCA	cis	rs6442522	0.615	rs13060973	ENSG00000249786.6	EAF1-AS1	-5.7	1.56e-08	2.2e-06	-0.18	-0.17	Uric acid levels;	chr3:15459426	chr3:15436171~15455940:-
BRCA	cis	rs2239547	0.563	rs4687560	ENSG00000242142.1	SERBP1P3	5.7	1.56e-08	2.2e-06	0.22	0.17	Schizophrenia;	chr3:52864105	chr3:53064283~53065091:-
BRCA	cis	rs7923609	0.967	rs10761766	ENSG00000232075.1	MRPL35P2	-5.7	1.56e-08	2.2e-06	-0.22	-0.17	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63430567	chr10:63634317~63634827:-
BRCA	cis	rs2274273	1	rs3742566	ENSG00000258413.1	RP11-665C16.6	-5.7	1.56e-08	2.2e-06	-0.22	-0.17	Protein biomarker;	chr14:55129121	chr14:55262767~55272075:-
BRCA	cis	rs2638953	0.962	rs11049611	ENSG00000278733.1	RP11-425D17.1	-5.7	1.56e-08	2.2e-06	-0.24	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28447311	chr12:28185625~28186190:-
BRCA	cis	rs7927771	0.524	rs4539273	ENSG00000280615.1	Y_RNA	-5.7	1.56e-08	2.2e-06	-0.2	-0.17	Subjective well-being;	chr11:47673147	chr11:47614898~47614994:-
BRCA	cis	rs11098499	0.913	rs35271032	ENSG00000249244.1	RP11-548H18.2	5.7	1.57e-08	2.2e-06	0.21	0.17	Corneal astigmatism;	chr4:119235504	chr4:119391831~119395335:-
BRCA	cis	rs17508449	1	rs79381435	ENSG00000232450.1	RP4-730K3.3	-5.7	1.57e-08	2.2e-06	-0.3	-0.17	Leprosy;	chr1:113543054	chr1:113698884~113699631:-
BRCA	cis	rs6570726	0.905	rs1355146	ENSG00000270638.1	RP3-466P17.1	-5.7	1.57e-08	2.2e-06	-0.19	-0.17	Lobe attachment (rater-scored or self-reported);	chr6:145460605	chr6:145735570~145737218:+
BRCA	cis	rs227275	0.554	rs223339	ENSG00000251288.2	RP11-10L12.2	-5.7	1.57e-08	2.2e-06	-0.2	-0.17	Allergic disease (asthma, hay fever or eczema);	chr4:102864700	chr4:102751401~102752641:+
BRCA	cis	rs853679	0.527	rs9461443	ENSG00000216901.1	AL022393.7	5.7	1.57e-08	2.2e-06	0.24	0.17	Depression;	chr6:28226851	chr6:28176188~28176674:+
BRCA	cis	rs9545047	0.604	rs9285310	ENSG00000227354.5	RBM26-AS1	-5.7	1.57e-08	2.21e-06	-0.19	-0.17	Schizophrenia;	chr13:79328340	chr13:79406309~79424328:+
BRCA	cis	rs9545047	0.625	rs9593391	ENSG00000227354.5	RBM26-AS1	-5.7	1.57e-08	2.21e-06	-0.19	-0.17	Schizophrenia;	chr13:79329168	chr13:79406309~79424328:+
BRCA	cis	rs7520050	0.966	rs61102033	ENSG00000280836.1	AL355480.1	5.7	1.57e-08	2.21e-06	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:45916769	chr1:45581219~45581321:-
BRCA	cis	rs3764021	0.87	rs2401393	ENSG00000214776.8	RP11-726G1.1	5.7	1.57e-08	2.21e-06	0.19	0.17	Type 1 diabetes;	chr12:9726488	chr12:9467552~9576275:+
BRCA	cis	rs11723261	0.621	rs6599306	ENSG00000211553.1	AC253576.2	5.7	1.57e-08	2.21e-06	0.28	0.17	Immune response to smallpox vaccine (IL-6);	chr4:149655	chr4:136461~136568:+
BRCA	cis	rs61160187	0.604	rs7704338	ENSG00000215032.2	GNL3LP1	5.7	1.57e-08	2.21e-06	0.21	0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:60690328	chr5:60891935~60893577:-
BRCA	cis	rs9287719	0.686	rs10174605	ENSG00000243819.4	RN7SL832P	5.7	1.57e-08	2.21e-06	0.17	0.17	Prostate cancer;	chr2:10585106	chr2:10690344~10692099:+
BRCA	cis	rs10129255	0.912	rs67410411	ENSG00000280411.1	IGHV1-69-2	-5.7	1.57e-08	2.21e-06	-0.13	-0.17	Kawasaki disease;	chr14:106680324	chr14:106762092~106762588:-
BRCA	cis	rs7246657	0.943	rs7252325	ENSG00000267422.1	CTD-2554C21.1	-5.7	1.57e-08	2.21e-06	-0.25	-0.17	Coronary artery calcification;	chr19:37439743	chr19:37779686~37792865:+
BRCA	cis	rs2243480	1	rs35432774	ENSG00000232559.3	GS1-124K5.12	5.7	1.57e-08	2.21e-06	0.32	0.17	Diabetic kidney disease;	chr7:65928032	chr7:66554588~66576923:-
BRCA	cis	rs10129255	0.957	rs10136781	ENSG00000224373.3	IGHV4-59	5.7	1.57e-08	2.21e-06	0.1	0.17	Kawasaki disease;	chr14:106780451	chr14:106627249~106627825:-
BRCA	cis	rs7246657	0.722	rs2972438	ENSG00000276846.1	CTD-3220F14.3	5.7	1.58e-08	2.22e-06	0.24	0.17	Coronary artery calcification;	chr19:37719946	chr19:37314868~37315620:-
BRCA	cis	rs2638953	0.815	rs10843188	ENSG00000278733.1	RP11-425D17.1	-5.7	1.58e-08	2.22e-06	-0.21	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28504200	chr12:28185625~28186190:-
BRCA	cis	rs7520050	0.966	rs7524495	ENSG00000280836.1	AL355480.1	5.7	1.58e-08	2.22e-06	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:45801260	chr1:45581219~45581321:-
BRCA	cis	rs2303319	1	rs12471336	ENSG00000227403.1	AC009299.3	-5.7	1.58e-08	2.22e-06	-0.44	-0.17	Cognitive function;	chr2:161408678	chr2:161244739~161249050:+
BRCA	cis	rs59169624	0.699	rs66999204	ENSG00000255160.4	RP11-428C19.5	5.7	1.58e-08	2.23e-06	0.23	0.17	Parental extreme longevity (95 years and older);	chr11:19277356	chr11:19299883~19308358:+
BRCA	cis	rs2243480	1	rs6958420	ENSG00000232559.3	GS1-124K5.12	-5.7	1.58e-08	2.23e-06	-0.33	-0.17	Diabetic kidney disease;	chr7:66286184	chr7:66554588~66576923:-
BRCA	cis	rs2243480	1	rs1392104	ENSG00000232559.3	GS1-124K5.12	-5.7	1.58e-08	2.23e-06	-0.33	-0.17	Diabetic kidney disease;	chr7:66294120	chr7:66554588~66576923:-
BRCA	cis	rs673078	0.66	rs73205512	ENSG00000275409.1	RP11-131L12.4	-5.7	1.58e-08	2.23e-06	-0.26	-0.17	Glucose homeostasis traits;	chr12:118235770	chr12:118430147~118430699:+
BRCA	cis	rs7238033	0.624	rs9304322	ENSG00000267193.4	RP11-116O18.3	5.7	1.58e-08	2.23e-06	0.19	0.17	Bladder cancer;	chr18:45728233	chr18:45669367~45747215:-
BRCA	cis	rs2243480	1	rs7456042	ENSG00000164669.11	INTS4P1	5.7	1.58e-08	2.23e-06	0.33	0.17	Diabetic kidney disease;	chr7:65834791	chr7:65141225~65234216:+
BRCA	cis	rs2243480	1	rs73142121	ENSG00000164669.11	INTS4P1	5.7	1.58e-08	2.23e-06	0.33	0.17	Diabetic kidney disease;	chr7:65846219	chr7:65141225~65234216:+
BRCA	cis	rs2243480	1	rs34702770	ENSG00000164669.11	INTS4P1	5.7	1.58e-08	2.23e-06	0.33	0.17	Diabetic kidney disease;	chr7:65879836	chr7:65141225~65234216:+
BRCA	cis	rs2243480	1	rs34637256	ENSG00000164669.11	INTS4P1	5.7	1.58e-08	2.23e-06	0.33	0.17	Diabetic kidney disease;	chr7:65895144	chr7:65141225~65234216:+
BRCA	cis	rs2281636	0.858	rs7068079	ENSG00000233690.1	EBAG9P1	-5.7	1.59e-08	2.23e-06	-0.18	-0.17	Obesity-related traits;	chr10:99607558	chr10:99697407~99697949:-
BRCA	cis	rs9545047	0.604	rs9318634	ENSG00000227354.5	RBM26-AS1	-5.7	1.59e-08	2.23e-06	-0.19	-0.17	Schizophrenia;	chr13:79369303	chr13:79406309~79424328:+
BRCA	cis	rs9308731	1	rs13396983	ENSG00000227992.1	AC108463.2	-5.7	1.59e-08	2.23e-06	-0.2	-0.17	Chronic lymphocytic leukemia;	chr2:111143021	chr2:111203964~111206215:-
BRCA	cis	rs9291683	0.507	rs6845554	ENSG00000250413.1	RP11-448G15.1	-5.7	1.59e-08	2.23e-06	-0.23	-0.17	Bone mineral density;	chr4:10011549	chr4:10006482~10009725:+
BRCA	cis	rs1559040	1	rs6721034	ENSG00000272156.1	RP11-477N3.1	-5.7	1.59e-08	2.23e-06	-0.28	-0.17	Sudden cardiac arrest;	chr2:54120170	chr2:54082554~54085066:+
BRCA	cis	rs11722228	0.522	rs12504600	ENSG00000261490.1	RP11-448G15.3	5.7	1.59e-08	2.23e-06	0.2	0.17	Urate levels;Serum uric acid levels;Gout;	chr4:10065514	chr4:10068089~10073019:-
BRCA	cis	rs9925964	0.933	rs8050894	ENSG00000232748.3	RP11-196G11.6	5.7	1.59e-08	2.24e-06	0.21	0.17	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31093188	chr16:31056460~31062803:+
BRCA	cis	rs270601	0.69	rs162907	ENSG00000233006.5	AC034220.3	-5.7	1.59e-08	2.24e-06	-0.13	-0.17	Acylcarnitine levels;	chr5:132244459	chr5:132311285~132369916:-
BRCA	cis	rs2980436	1	rs2980436	ENSG00000233609.3	RP11-62H7.2	-5.7	1.6e-08	2.24e-06	-0.17	-0.17	Schizophrenia;	chr8:8234503	chr8:8961200~8979025:+
BRCA	cis	rs7246967	0.673	rs2112610	ENSG00000198153.8	ZNF849P	-5.7	1.6e-08	2.25e-06	-0.26	-0.17	Bronchopulmonary dysplasia;	chr19:22734049	chr19:22685167~22686732:+
BRCA	cis	rs9652601	0.959	rs11865121	ENSG00000274038.1	RP11-66H6.4	-5.7	1.6e-08	2.25e-06	-0.2	-0.17	Systemic lupus erythematosus;	chr16:11072831	chr16:11056556~11057034:+
BRCA	cis	rs12439619	0.846	rs28470877	ENSG00000255769.6	GOLGA2P10	-5.7	1.6e-08	2.25e-06	-0.25	-0.17	Intelligence (multi-trait analysis);	chr15:82245797	chr15:82472993~82513950:-
BRCA	cis	rs6432852	0.516	rs12477613	ENSG00000232411.1	AC009495.3	5.7	1.6e-08	2.25e-06	0.2	0.17	Diabetic kidney disease;	chr2:165860674	chr2:165833048~165839098:-
BRCA	cis	rs9652601	0.622	rs2286974	ENSG00000274038.1	RP11-66H6.4	-5.7	1.6e-08	2.25e-06	-0.19	-0.17	Systemic lupus erythematosus;	chr16:11020655	chr16:11056556~11057034:+
BRCA	cis	rs9545047	0.604	rs9565483	ENSG00000227354.5	RBM26-AS1	-5.7	1.6e-08	2.25e-06	-0.19	-0.17	Schizophrenia;	chr13:79294001	chr13:79406309~79424328:+
BRCA	cis	rs237743	1	rs1567865	ENSG00000222365.1	SNORD12B	-5.69	1.6e-08	2.26e-06	-0.25	-0.17	Height;	chr20:49265430	chr20:49280319~49280409:+
BRCA	cis	rs9545047	0.604	rs9318623	ENSG00000227354.5	RBM26-AS1	-5.69	1.61e-08	2.26e-06	-0.19	-0.17	Schizophrenia;	chr13:79346913	chr13:79406309~79424328:+
BRCA	cis	rs9545047	0.564	rs7998837	ENSG00000227354.5	RBM26-AS1	-5.69	1.61e-08	2.26e-06	-0.19	-0.17	Schizophrenia;	chr13:79349190	chr13:79406309~79424328:+
BRCA	cis	rs227275	0.554	rs223319	ENSG00000251288.2	RP11-10L12.2	-5.69	1.61e-08	2.26e-06	-0.2	-0.17	Allergic disease (asthma, hay fever or eczema);	chr4:102881157	chr4:102751401~102752641:+
BRCA	cis	rs228614	0.509	rs223318	ENSG00000251288.2	RP11-10L12.2	-5.69	1.61e-08	2.26e-06	-0.2	-0.17	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102881422	chr4:102751401~102752641:+
BRCA	cis	rs227275	0.554	rs223315	ENSG00000251288.2	RP11-10L12.2	-5.69	1.61e-08	2.26e-06	-0.2	-0.17	Allergic disease (asthma, hay fever or eczema);	chr4:102884286	chr4:102751401~102752641:+
BRCA	cis	rs2638953	0.924	rs7955118	ENSG00000278733.1	RP11-425D17.1	-5.69	1.61e-08	2.26e-06	-0.24	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28157159	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.924	rs7955237	ENSG00000278733.1	RP11-425D17.1	-5.69	1.61e-08	2.26e-06	-0.24	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28157272	chr12:28185625~28186190:-
BRCA	cis	rs1005277	0.557	rs2983338	ENSG00000263064.2	RP11-291L22.7	5.69	1.61e-08	2.26e-06	0.21	0.17	Extrinsic epigenetic age acceleration;	chr10:38261806	chr10:38448689~38448949:+
BRCA	cis	rs2243480	1	rs1723269	ENSG00000164669.11	INTS4P1	5.69	1.61e-08	2.26e-06	0.34	0.17	Diabetic kidney disease;	chr7:66007799	chr7:65141225~65234216:+
BRCA	cis	rs12612619	0.732	rs1866654	ENSG00000229122.1	AGBL5-IT1	5.69	1.61e-08	2.26e-06	0.18	0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27040254	chr2:27061038~27061815:+
BRCA	cis	rs67981189	0.529	rs61990380	ENSG00000258571.1	PTTG4P	-5.69	1.61e-08	2.26e-06	-0.2	-0.17	Schizophrenia;	chr14:71005229	chr14:71085482~71085833:-
BRCA	cis	rs6088813	1	rs6142379	ENSG00000126005.14	MMP24-AS1	5.69	1.61e-08	2.26e-06	0.2	0.17	Height;	chr20:35411464	chr20:35216462~35278131:-
BRCA	cis	rs7246760	0.867	rs66927855	ENSG00000277587.1	CTD-3116E22.8	-5.69	1.61e-08	2.27e-06	-0.34	-0.17	Pursuit maintenance gain;	chr19:9701052	chr19:9721903~9722410:+
BRCA	cis	rs516805	0.63	rs2606656	ENSG00000279453.1	RP3-425C14.4	-5.69	1.61e-08	2.27e-06	-0.25	-0.17	Lymphocyte counts;	chr6:122153088	chr6:122436789~122439223:-
BRCA	cis	rs10740039	0.516	rs10761526	ENSG00000254271.1	RP11-131N11.4	5.69	1.61e-08	2.27e-06	0.23	0.17	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60594661	chr10:60734342~60741828:+
BRCA	cis	rs793571	0.554	rs12441912	ENSG00000259250.1	RP11-50C13.1	-5.69	1.62e-08	2.27e-06	-0.31	-0.17	Schizophrenia;	chr15:58701495	chr15:58587507~58591676:+
BRCA	cis	rs55702914	0.539	rs787990	ENSG00000231621.1	AC013264.2	-5.69	1.62e-08	2.27e-06	-0.16	-0.17	Major depression and alcohol dependence;	chr2:197460266	chr2:197197991~197199273:+
BRCA	cis	rs250585	0.736	rs193937	ENSG00000260136.4	CTD-2270L9.4	5.69	1.62e-08	2.27e-06	0.17	0.17	Egg allergy;	chr16:23425037	chr16:23452758~23457606:+
BRCA	cis	rs2243480	1	rs316332	ENSG00000164669.11	INTS4P1	5.69	1.62e-08	2.27e-06	0.33	0.17	Diabetic kidney disease;	chr7:66139312	chr7:65141225~65234216:+
BRCA	cis	rs4664293	0.51	rs3903306	ENSG00000226266.5	AC009961.3	5.69	1.62e-08	2.27e-06	0.22	0.17	Monocyte percentage of white cells;	chr2:159592171	chr2:159670708~159712435:-
BRCA	cis	rs467650	0.553	rs469731	ENSG00000248489.1	CTD-2007H13.3	-5.69	1.62e-08	2.28e-06	-0.22	-0.17	Venous thromboembolism (SNP x SNP interaction);	chr5:98651703	chr5:98929171~98995013:+
BRCA	cis	rs6570726	0.818	rs9390338	ENSG00000270638.1	RP3-466P17.1	5.69	1.62e-08	2.28e-06	0.2	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145587129	chr6:145735570~145737218:+
BRCA	cis	rs6570726	0.791	rs6570693	ENSG00000270638.1	RP3-466P17.1	5.69	1.62e-08	2.28e-06	0.2	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145589705	chr6:145735570~145737218:+
BRCA	cis	rs6570726	0.791	rs6570694	ENSG00000270638.1	RP3-466P17.1	5.69	1.62e-08	2.28e-06	0.2	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145590068	chr6:145735570~145737218:+
BRCA	cis	rs6570726	0.791	rs6570695	ENSG00000270638.1	RP3-466P17.1	5.69	1.62e-08	2.28e-06	0.2	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145590150	chr6:145735570~145737218:+
BRCA	cis	rs6570726	0.764	rs9386125	ENSG00000270638.1	RP3-466P17.1	5.69	1.62e-08	2.28e-06	0.2	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145590541	chr6:145735570~145737218:+
BRCA	cis	rs6570726	0.791	rs9373466	ENSG00000270638.1	RP3-466P17.1	5.69	1.62e-08	2.28e-06	0.2	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145590880	chr6:145735570~145737218:+
BRCA	cis	rs10504130	0.569	rs11775587	ENSG00000272024.1	RP11-546K22.3	5.69	1.62e-08	2.28e-06	0.25	0.17	Venous thromboembolism (SNP x SNP interaction);	chr8:51907605	chr8:51950284~51950690:+
BRCA	cis	rs559928	0.606	rs56311067	ENSG00000236935.1	AP003774.1	5.69	1.63e-08	2.28e-06	0.24	0.17	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64164135	chr11:64325050~64329504:-
BRCA	cis	rs7923609	1	rs10761723	ENSG00000232075.1	MRPL35P2	-5.69	1.63e-08	2.29e-06	-0.22	-0.17	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63195821	chr10:63634317~63634827:-
BRCA	cis	rs11098499	1	rs6837898	ENSG00000249244.1	RP11-548H18.2	5.69	1.63e-08	2.29e-06	0.21	0.17	Corneal astigmatism;	chr4:119257999	chr4:119391831~119395335:-
BRCA	cis	rs1722141	0.634	rs2453850	ENSG00000229628.1	AC073115.7	5.69	1.63e-08	2.29e-06	0.25	0.17	Sitting height ratio;	chr7:45941135	chr7:45990905~46000898:+
BRCA	cis	rs2638953	0.962	rs3782517	ENSG00000278733.1	RP11-425D17.1	-5.69	1.63e-08	2.29e-06	-0.24	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28310254	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.962	rs11049524	ENSG00000278733.1	RP11-425D17.1	-5.69	1.63e-08	2.29e-06	-0.24	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28311956	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.962	rs11049525	ENSG00000278733.1	RP11-425D17.1	-5.69	1.63e-08	2.29e-06	-0.24	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28313227	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.962	rs12371974	ENSG00000278733.1	RP11-425D17.1	-5.69	1.63e-08	2.29e-06	-0.24	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28313969	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.962	rs11049526	ENSG00000278733.1	RP11-425D17.1	-5.69	1.63e-08	2.29e-06	-0.24	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28314751	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.962	rs11049527	ENSG00000278733.1	RP11-425D17.1	-5.69	1.63e-08	2.29e-06	-0.24	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28317667	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.925	rs11049528	ENSG00000278733.1	RP11-425D17.1	-5.69	1.63e-08	2.29e-06	-0.24	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28317914	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.962	rs10843153	ENSG00000278733.1	RP11-425D17.1	-5.69	1.63e-08	2.29e-06	-0.24	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28319168	chr12:28185625~28186190:-
BRCA	cis	rs7804306	1	rs34059590	ENSG00000233264.2	AC006042.8	5.69	1.63e-08	2.29e-06	0.38	0.17	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8026584	chr7:7980312~7982228:+
BRCA	cis	rs12681366	0.839	rs3019278	ENSG00000253704.1	RP11-267M23.4	5.69	1.63e-08	2.29e-06	0.2	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94434339	chr8:94553722~94569745:+
BRCA	cis	rs2638953	0.815	rs11049696	ENSG00000278733.1	RP11-425D17.1	-5.69	1.63e-08	2.29e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28528922	chr12:28185625~28186190:-
BRCA	cis	rs35849525	0.814	rs35491931	ENSG00000228008.1	CTD-2330K9.3	5.69	1.63e-08	2.29e-06	0.2	0.17	Intelligence (multi-trait analysis);	chr3:49956029	chr3:49903845~49916937:+
BRCA	cis	rs7246657	0.524	rs28542490	ENSG00000226686.6	LINC01535	-5.69	1.63e-08	2.29e-06	-0.28	-0.17	Coronary artery calcification;	chr19:36965682	chr19:37251912~37265535:+
BRCA	cis	rs2098713	0.537	rs57898883	ENSG00000250155.1	CTD-2353F22.1	-5.69	1.64e-08	2.3e-06	-0.2	-0.17	Telomere length;	chr5:37517831	chr5:36666214~36725195:-
BRCA	cis	rs11105298	0.891	rs10858900	ENSG00000270344.2	RP11-734K2.4	5.69	1.64e-08	2.3e-06	0.2	0.17	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89531304	chr12:89525654~89548005:+
BRCA	cis	rs59169624	0.699	rs7102210	ENSG00000255160.4	RP11-428C19.5	5.69	1.64e-08	2.3e-06	0.23	0.17	Parental extreme longevity (95 years and older);	chr11:19277603	chr11:19299883~19308358:+
BRCA	cis	rs4865169	1	rs4865169	ENSG00000269949.1	RP11-738E22.3	-5.69	1.64e-08	2.3e-06	-0.2	-0.17	Breast cancer;	chr4:57013626	chr4:56960927~56961373:-
BRCA	cis	rs10936632	0.536	rs10936633	ENSG00000242578.1	RP11-469J4.3	5.69	1.64e-08	2.3e-06	0.2	0.17	Prostate cancer;	chr3:170440340	chr3:170410512~170418615:+
BRCA	cis	rs12908161	0.515	rs12907646	ENSG00000259728.4	LINC00933	5.69	1.64e-08	2.3e-06	0.25	0.17	Schizophrenia;	chr15:84860265	chr15:84570649~84580175:+
BRCA	cis	rs9287719	0.649	rs12618726	ENSG00000243819.4	RN7SL832P	5.69	1.64e-08	2.3e-06	0.17	0.17	Prostate cancer;	chr2:10588249	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.649	rs6714787	ENSG00000243819.4	RN7SL832P	5.69	1.64e-08	2.3e-06	0.17	0.17	Prostate cancer;	chr2:10588906	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.649	rs2024432	ENSG00000243819.4	RN7SL832P	5.69	1.64e-08	2.3e-06	0.17	0.17	Prostate cancer;	chr2:10591348	chr2:10690344~10692099:+
BRCA	cis	rs2638953	0.925	rs11049604	ENSG00000278733.1	RP11-425D17.1	-5.69	1.64e-08	2.3e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28443092	chr12:28185625~28186190:-
BRCA	cis	rs2288884	0.943	rs1433089	ENSG00000275055.1	CTC-471J1.11	-5.69	1.64e-08	2.3e-06	-0.26	-0.17	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52003732	chr19:52049007~52049754:+
BRCA	cis	rs2562456	0.833	rs2562507	ENSG00000268081.1	RP11-678G14.2	-5.69	1.64e-08	2.3e-06	-0.26	-0.17	Pain;	chr19:21543535	chr19:21554640~21569237:-
BRCA	cis	rs891378	0.92	rs4611012	ENSG00000274245.1	RP11-357P18.2	-5.69	1.64e-08	2.3e-06	-0.23	-0.17	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207263470	chr1:207372559~207373252:+
BRCA	cis	rs891378	1	rs6540896	ENSG00000274245.1	RP11-357P18.2	-5.69	1.64e-08	2.3e-06	-0.23	-0.17	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207267506	chr1:207372559~207373252:+
BRCA	cis	rs2638953	0.925	rs11049567	ENSG00000278733.1	RP11-425D17.1	5.69	1.64e-08	2.31e-06	0.23	0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28385502	chr12:28185625~28186190:-
BRCA	cis	rs2030746	0.899	rs3843846	ENSG00000237614.1	AC073257.2	5.69	1.65e-08	2.31e-06	0.21	0.17	LDL cholesterol;Total cholesterol levels;LDL cholesterol levels;	chr2:120554223	chr2:120542909~120544326:-
BRCA	cis	rs950776	0.518	rs4886571	ENSG00000279373.1	RP11-650L12.4	-5.69	1.65e-08	2.31e-06	-0.21	-0.17	Sudden cardiac arrest;	chr15:78541416	chr15:78537681~78538946:+
BRCA	cis	rs9992667	0.955	rs922334	ENSG00000231160.8	KLF3-AS1	5.69	1.65e-08	2.31e-06	0.21	0.17	Eosinophil percentage of granulocytes;	chr4:38615137	chr4:38612701~38664883:-
BRCA	cis	rs12501370	0.721	rs12511269	ENSG00000201736.1	RNA5SP160	5.69	1.65e-08	2.31e-06	0.23	0.17	Iris color (L* coordinate);	chr4:41058604	chr4:40990154~40990273:+
BRCA	cis	rs8054556	0.787	rs3814877	ENSG00000273724.1	RP11-347C12.12	-5.69	1.65e-08	2.32e-06	-0.19	-0.17	Autism spectrum disorder or schizophrenia;	chr16:30031356	chr16:30336400~30343336:+
BRCA	cis	rs2153535	0.585	rs9379236	ENSG00000230939.1	RP11-314C16.1	-5.69	1.66e-08	2.32e-06	-0.2	-0.17	Motion sickness;	chr6:8651792	chr6:8784178~8785445:+
BRCA	cis	rs11098499	0.604	rs12642411	ENSG00000249244.1	RP11-548H18.2	5.69	1.66e-08	2.32e-06	0.22	0.17	Corneal astigmatism;	chr4:119659370	chr4:119391831~119395335:-
BRCA	cis	rs73222236	0.783	rs67214626	ENSG00000273486.1	RP11-731C17.2	5.69	1.66e-08	2.32e-06	0.2	0.17	Coronary artery disease;	chr3:136270534	chr3:136837338~136839021:-
BRCA	cis	rs10129255	0.5	rs9324092	ENSG00000224373.3	IGHV4-59	-5.69	1.66e-08	2.32e-06	-0.1	-0.17	Kawasaki disease;	chr14:106683806	chr14:106627249~106627825:-
BRCA	cis	rs1223397	0.938	rs9395602	ENSG00000215022.6	RP1-257A7.4	-5.69	1.66e-08	2.33e-06	-0.24	-0.17	Blood pressure;	chr6:13278521	chr6:13264861~13295586:-
BRCA	cis	rs516805	0.665	rs2606648	ENSG00000279453.1	RP3-425C14.4	-5.69	1.66e-08	2.33e-06	-0.24	-0.17	Lymphocyte counts;	chr6:122119554	chr6:122436789~122439223:-
BRCA	cis	rs9308731	0.931	rs616130	ENSG00000227992.1	AC108463.2	-5.69	1.66e-08	2.33e-06	-0.2	-0.17	Chronic lymphocytic leukemia;	chr2:111155104	chr2:111203964~111206215:-
BRCA	cis	rs2243480	1	rs34136756	ENSG00000230295.1	RP11-458F8.2	-5.69	1.66e-08	2.33e-06	-0.23	-0.17	Diabetic kidney disease;	chr7:65916269	chr7:66880708~66882981:+
BRCA	cis	rs7772486	0.686	rs9485019	ENSG00000270638.1	RP3-466P17.1	-5.69	1.66e-08	2.33e-06	-0.2	-0.17	Lobe attachment (rater-scored or self-reported);	chr6:145725245	chr6:145735570~145737218:+
BRCA	cis	rs1395	0.744	rs11126934	ENSG00000234072.1	AC074117.10	-5.69	1.66e-08	2.33e-06	-0.18	-0.17	Blood metabolite levels;	chr2:27253745	chr2:27356246~27367622:+
BRCA	cis	rs2243480	1	rs1723267	ENSG00000232559.3	GS1-124K5.12	5.69	1.66e-08	2.33e-06	0.33	0.17	Diabetic kidney disease;	chr7:66008327	chr7:66554588~66576923:-
BRCA	cis	rs1440410	0.795	rs12506120	ENSG00000250326.1	RP11-284M14.1	-5.69	1.66e-08	2.33e-06	-0.19	-0.17	Ischemic stroke;	chr4:143269295	chr4:142933195~143184861:-
BRCA	cis	rs7577696	0.814	rs479333	ENSG00000272716.1	RP11-563N4.1	-5.69	1.66e-08	2.33e-06	-0.19	-0.17	Inflammatory biomarkers;	chr2:32264089	chr2:32165046~32165757:-
BRCA	cis	rs17767294	0.612	rs9461424	ENSG00000219392.1	RP1-265C24.5	-5.69	1.66e-08	2.33e-06	-0.34	-0.17	Parkinson's disease;	chr6:27951623	chr6:28115628~28116551:+
BRCA	cis	rs11955398	0.522	rs12522154	ENSG00000215032.2	GNL3LP1	-5.69	1.66e-08	2.33e-06	-0.22	-0.17	Intelligence (multi-trait analysis);	chr5:60885673	chr5:60891935~60893577:-
BRCA	cis	rs2638953	0.815	rs58416107	ENSG00000278733.1	RP11-425D17.1	-5.69	1.66e-08	2.33e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28543645	chr12:28185625~28186190:-
BRCA	cis	rs11098499	0.604	rs2389886	ENSG00000249244.1	RP11-548H18.2	5.69	1.66e-08	2.33e-06	0.22	0.17	Corneal astigmatism;	chr4:119649267	chr4:119391831~119395335:-
BRCA	cis	rs7829975	0.742	rs12547493	ENSG00000254153.1	CTA-398F10.2	-5.69	1.67e-08	2.33e-06	-0.21	-0.17	Mood instability;	chr8:8804024	chr8:8456909~8461337:-
BRCA	cis	rs7246967	0.541	rs16999009	ENSG00000198153.8	ZNF849P	5.69	1.67e-08	2.33e-06	0.26	0.17	Bronchopulmonary dysplasia;	chr19:22726856	chr19:22685167~22686732:+
BRCA	cis	rs853679	0.55	rs9295762	ENSG00000280107.1	AL022393.9	5.69	1.67e-08	2.33e-06	0.25	0.17	Depression;	chr6:28187640	chr6:28170845~28172521:+
BRCA	cis	rs11671005	0.735	rs11084544	ENSG00000252334.1	RNU6-1337P	5.69	1.67e-08	2.33e-06	0.26	0.17	Mean platelet volume;	chr19:58428760	chr19:58483749~58483843:-
BRCA	cis	rs13108904	0.935	rs922698	ENSG00000254094.1	AC078852.1	5.69	1.67e-08	2.33e-06	0.19	0.17	Obesity-related traits;	chr4:1288934	chr4:1356581~1358075:+
BRCA	cis	rs875971	0.545	rs1638724	ENSG00000228409.4	CCT6P1	5.69	1.67e-08	2.34e-06	0.17	0.17	Aortic root size;	chr7:66575494	chr7:65751142~65763354:+
BRCA	cis	rs1707322	0.721	rs4415615	ENSG00000234329.1	RP11-767N6.2	5.69	1.67e-08	2.34e-06	0.18	0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45666437	chr1:45651039~45651826:-
BRCA	cis	rs755249	0.727	rs16826349	ENSG00000182109.6	RP11-69E11.4	5.69	1.67e-08	2.34e-06	0.2	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39573264	chr1:39522280~39546187:-
BRCA	cis	rs9287719	0.649	rs9973456	ENSG00000243819.4	RN7SL832P	5.69	1.67e-08	2.34e-06	0.17	0.17	Prostate cancer;	chr2:10578004	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.649	rs10175884	ENSG00000243819.4	RN7SL832P	5.69	1.67e-08	2.34e-06	0.17	0.17	Prostate cancer;	chr2:10578408	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.649	rs10190673	ENSG00000243819.4	RN7SL832P	5.69	1.67e-08	2.34e-06	0.17	0.17	Prostate cancer;	chr2:10578492	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.649	rs10198971	ENSG00000243819.4	RN7SL832P	5.69	1.67e-08	2.34e-06	0.17	0.17	Prostate cancer;	chr2:10578573	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.649	rs2884232	ENSG00000243819.4	RN7SL832P	5.69	1.67e-08	2.34e-06	0.17	0.17	Prostate cancer;	chr2:10579553	chr2:10690344~10692099:+
BRCA	cis	rs11722779	0.901	rs28674656	ENSG00000251288.2	RP11-10L12.2	-5.69	1.67e-08	2.34e-06	-0.2	-0.17	Schizophrenia;	chr4:102944396	chr4:102751401~102752641:+
BRCA	cis	rs2243480	0.901	rs2949697	ENSG00000232559.3	GS1-124K5.12	5.69	1.67e-08	2.34e-06	0.32	0.17	Diabetic kidney disease;	chr7:65999249	chr7:66554588~66576923:-
BRCA	cis	rs228614	0.51	rs223328	ENSG00000251288.2	RP11-10L12.2	-5.69	1.67e-08	2.34e-06	-0.2	-0.17	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102873379	chr4:102751401~102752641:+
BRCA	cis	rs6840360	0.967	rs10049728	ENSG00000270265.1	RP11-731D1.4	-5.69	1.67e-08	2.34e-06	-0.19	-0.17	Intelligence (multi-trait analysis);	chr4:151750969	chr4:151333775~151353224:-
BRCA	cis	rs6840360	0.967	rs7684350	ENSG00000270265.1	RP11-731D1.4	-5.69	1.67e-08	2.34e-06	-0.19	-0.17	Intelligence (multi-trait analysis);	chr4:151751730	chr4:151333775~151353224:-
BRCA	cis	rs2239557	0.539	rs7161037	ENSG00000259065.1	RP5-1021I20.1	-5.69	1.67e-08	2.34e-06	-0.25	-0.17	Common traits (Other);	chr14:73966426	chr14:73787360~73803270:+
BRCA	cis	rs934734	0.532	rs6752053	ENSG00000204929.10	AC074391.1	-5.69	1.67e-08	2.34e-06	-0.21	-0.17	Rheumatoid arthritis;	chr2:65439540	chr2:65436711~66084639:+
BRCA	cis	rs228614	0.536	rs223325	ENSG00000251288.2	RP11-10L12.2	-5.69	1.67e-08	2.34e-06	-0.2	-0.17	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102875751	chr4:102751401~102752641:+
BRCA	cis	rs7927771	0.507	rs7119517	ENSG00000280615.1	Y_RNA	5.69	1.67e-08	2.34e-06	0.2	0.17	Subjective well-being;	chr11:47653764	chr11:47614898~47614994:-
BRCA	cis	rs1707322	0.686	rs2152078	ENSG00000234329.1	RP11-767N6.2	-5.69	1.68e-08	2.35e-06	-0.18	-0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45589928	chr1:45651039~45651826:-
BRCA	cis	rs1707322	0.686	rs2991979	ENSG00000234329.1	RP11-767N6.2	-5.69	1.68e-08	2.35e-06	-0.18	-0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45590186	chr1:45651039~45651826:-
BRCA	cis	rs385076	0.502	rs13013695	ENSG00000272716.1	RP11-563N4.1	-5.69	1.68e-08	2.35e-06	-0.21	-0.17	Interleukin-18 levels;	chr2:32166162	chr2:32165046~32165757:-
BRCA	cis	rs9308731	1	rs9308731	ENSG00000227992.1	AC108463.2	-5.69	1.68e-08	2.35e-06	-0.2	-0.17	Chronic lymphocytic leukemia;	chr2:111150685	chr2:111203964~111206215:-
BRCA	cis	rs227275	0.556	rs6821173	ENSG00000251288.2	RP11-10L12.2	-5.69	1.68e-08	2.35e-06	-0.2	-0.17	Allergic disease (asthma, hay fever or eczema);	chr4:102966404	chr4:102751401~102752641:+
BRCA	cis	rs673078	0.66	rs61945224	ENSG00000275409.1	RP11-131L12.4	-5.69	1.68e-08	2.35e-06	-0.29	-0.17	Glucose homeostasis traits;	chr12:118288623	chr12:118430147~118430699:+
BRCA	cis	rs673078	0.66	rs61945225	ENSG00000275409.1	RP11-131L12.4	-5.69	1.68e-08	2.35e-06	-0.29	-0.17	Glucose homeostasis traits;	chr12:118288960	chr12:118430147~118430699:+
BRCA	cis	rs7577696	0.524	rs212696	ENSG00000272716.1	RP11-563N4.1	5.69	1.68e-08	2.35e-06	0.22	0.17	Inflammatory biomarkers;	chr2:32216616	chr2:32165046~32165757:-
BRCA	cis	rs30380	0.587	rs30185	ENSG00000272109.1	CTD-2260A17.3	-5.69	1.68e-08	2.35e-06	-0.24	-0.17	Cerebrospinal fluid biomarker levels;	chr5:96789762	chr5:96804353~96806105:+
BRCA	cis	rs2832191	0.791	rs2832202	ENSG00000215533.7	LINC00189	5.69	1.68e-08	2.35e-06	0.19	0.17	Dental caries;	chr21:29129021	chr21:29193480~29288205:+
BRCA	cis	rs2638953	0.962	rs61922979	ENSG00000278733.1	RP11-425D17.1	-5.69	1.68e-08	2.35e-06	-0.24	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28301218	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.962	rs11049517	ENSG00000278733.1	RP11-425D17.1	-5.69	1.68e-08	2.35e-06	-0.24	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28301627	chr12:28185625~28186190:-
BRCA	cis	rs300890	0.513	rs72719173	ENSG00000250326.1	RP11-284M14.1	5.69	1.68e-08	2.35e-06	0.21	0.17	Nasopharyngeal carcinoma;	chr4:143134728	chr4:142933195~143184861:-
BRCA	cis	rs1707322	0.752	rs12062535	ENSG00000234329.1	RP11-767N6.2	5.69	1.68e-08	2.35e-06	0.18	0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45757208	chr1:45651039~45651826:-
BRCA	cis	rs950169	0.544	rs62021193	ENSG00000259295.5	CSPG4P12	5.69	1.68e-08	2.35e-06	0.24	0.17	Schizophrenia;	chr15:84627352	chr15:85191438~85213905:+
BRCA	cis	rs897984	0.806	rs8050588	ENSG00000275263.1	RP11-1072A3.4	-5.69	1.68e-08	2.35e-06	-0.21	-0.17	Dementia with Lewy bodies;	chr16:30926478	chr16:30956872~30957199:-
BRCA	cis	rs2227564	0.62	rs11000765	ENSG00000271816.1	BMS1P4	5.69	1.68e-08	2.36e-06	0.18	0.17	Crohn's disease;Inflammatory bowel disease;	chr10:73752694	chr10:73699151~73730487:-
BRCA	cis	rs9341808	0.718	rs9352801	ENSG00000272129.1	RP11-250B2.6	5.69	1.68e-08	2.36e-06	0.22	0.17	Sitting height ratio;	chr6:80107751	chr6:80355424~80356859:+
BRCA	cis	rs9816784	0.576	rs12631246	ENSG00000231464.1	AC024937.4	5.69	1.68e-08	2.36e-06	0.23	0.17	Mean corpuscular hemoglobin;	chr3:196094713	chr3:195996738~195998233:+
BRCA	cis	rs55702914	0.628	rs12151767	ENSG00000231621.1	AC013264.2	-5.69	1.68e-08	2.36e-06	-0.16	-0.17	Major depression and alcohol dependence;	chr2:197410205	chr2:197197991~197199273:+
BRCA	cis	rs1075265	0.588	rs1477258	ENSG00000235937.1	AC008280.1	5.69	1.68e-08	2.36e-06	0.19	0.17	Chronotype;Morning vs. evening chronotype;	chr2:54000031	chr2:54029552~54030682:-
BRCA	cis	rs4489787	1	rs2731073	ENSG00000240399.1	RP1-228P16.1	5.69	1.68e-08	2.36e-06	0.31	0.17	Prostate cancer (SNP x SNP interaction);	chr12:48525773	chr12:48054813~48055591:-
BRCA	cis	rs7238033	0.624	rs8090908	ENSG00000267193.4	RP11-116O18.3	5.69	1.69e-08	2.36e-06	0.19	0.17	Bladder cancer;	chr18:45730222	chr18:45669367~45747215:-
BRCA	cis	rs2638953	0.924	rs7969582	ENSG00000247934.4	RP11-967K21.1	5.69	1.69e-08	2.36e-06	0.22	0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28236725	chr12:28163298~28190738:-
BRCA	cis	rs2098713	0.535	rs1589116	ENSG00000250155.1	CTD-2353F22.1	5.69	1.69e-08	2.36e-06	0.19	0.17	Telomere length;	chr5:37629567	chr5:36666214~36725195:-
BRCA	cis	rs651907	0.535	rs17347156	ENSG00000244119.1	PDCL3P4	5.69	1.69e-08	2.36e-06	0.14	0.17	Colorectal cancer;	chr3:101785830	chr3:101712472~101713191:+
BRCA	cis	rs4718428	0.705	rs10267335	ENSG00000230295.1	RP11-458F8.2	-5.69	1.69e-08	2.36e-06	-0.16	-0.17	Corneal structure;	chr7:66938233	chr7:66880708~66882981:+
BRCA	cis	rs2239557	0.57	rs7157377	ENSG00000259065.1	RP5-1021I20.1	-5.69	1.69e-08	2.37e-06	-0.26	-0.17	Common traits (Other);	chr14:73974473	chr14:73787360~73803270:+
BRCA	cis	rs516805	0.667	rs9632500	ENSG00000279453.1	RP3-425C14.4	5.69	1.69e-08	2.37e-06	0.25	0.17	Lymphocyte counts;	chr6:122251472	chr6:122436789~122439223:-
BRCA	cis	rs9291683	0.507	rs3775940	ENSG00000250413.1	RP11-448G15.1	-5.69	1.69e-08	2.37e-06	-0.23	-0.17	Bone mineral density;	chr4:10023539	chr4:10006482~10009725:+
BRCA	cis	rs673078	0.607	rs7302387	ENSG00000275409.1	RP11-131L12.4	-5.69	1.69e-08	2.37e-06	-0.29	-0.17	Glucose homeostasis traits;	chr12:118316546	chr12:118430147~118430699:+
BRCA	cis	rs7615952	0.688	rs9754526	ENSG00000171084.14	FAM86JP	5.69	1.69e-08	2.37e-06	0.27	0.17	Blood pressure (smoking interaction);	chr3:125824023	chr3:125916620~125930024:+
BRCA	cis	rs2235642	0.75	rs2755185	ENSG00000260989.1	LA16c-395F10.2	-5.69	1.69e-08	2.37e-06	-0.18	-0.17	Coronary artery disease;	chr16:1595826	chr16:1580527~1610328:+
BRCA	cis	rs875971	0.522	rs1917563	ENSG00000273024.4	INTS4P2	5.69	1.69e-08	2.37e-06	0.19	0.17	Aortic root size;	chr7:65950660	chr7:65647864~65715661:+
BRCA	cis	rs2732480	0.557	rs2732454	ENSG00000257763.1	OR5BK1P	5.69	1.7e-08	2.37e-06	0.18	0.17	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48325894	chr12:48355792~48356614:-
BRCA	cis	rs10129255	0.913	rs10140943	ENSG00000224373.3	IGHV4-59	5.69	1.7e-08	2.37e-06	0.11	0.17	Kawasaki disease;	chr14:106767441	chr14:106627249~106627825:-
BRCA	cis	rs4908768	0.501	rs7527389	ENSG00000270282.1	RP5-1115A15.2	5.69	1.7e-08	2.38e-06	0.19	0.17	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8496485	chr1:8512653~8513021:+
BRCA	cis	rs7246967	0.551	rs7249473	ENSG00000198153.8	ZNF849P	-5.69	1.7e-08	2.38e-06	-0.26	-0.17	Bronchopulmonary dysplasia;	chr19:22723892	chr19:22685167~22686732:+
BRCA	cis	rs300890	0.513	rs4309787	ENSG00000250326.1	RP11-284M14.1	5.68	1.7e-08	2.38e-06	0.21	0.17	Nasopharyngeal carcinoma;	chr4:143128069	chr4:142933195~143184861:-
BRCA	cis	rs4604234	0.803	rs73463519	ENSG00000272129.1	RP11-250B2.6	-5.68	1.7e-08	2.38e-06	-0.43	-0.17	Cancer;	chr6:80266862	chr6:80355424~80356859:+
BRCA	cis	rs2688608	0.901	rs2664280	ENSG00000271816.1	BMS1P4	-5.68	1.7e-08	2.38e-06	-0.17	-0.17	Inflammatory bowel disease;	chr10:73857586	chr10:73699151~73730487:-
BRCA	cis	rs2439831	0.702	rs28699233	ENSG00000205771.5	CATSPER2P1	-5.68	1.7e-08	2.38e-06	-0.34	-0.17	Lung cancer in ever smokers;	chr15:43830668	chr15:43726918~43747094:-
BRCA	cis	rs7772486	0.686	rs9403741	ENSG00000270638.1	RP3-466P17.1	-5.68	1.7e-08	2.38e-06	-0.2	-0.17	Lobe attachment (rater-scored or self-reported);	chr6:145709412	chr6:145735570~145737218:+
BRCA	cis	rs253959	0.607	rs1396497	ENSG00000272265.1	CTD-2287O16.4	5.68	1.7e-08	2.38e-06	0.21	0.17	Bipolar disorder and schizophrenia;	chr5:116091719	chr5:116078110~116078570:-
BRCA	cis	rs12468226	0.938	rs4675274	ENSG00000226261.1	AC064836.3	-5.68	1.7e-08	2.38e-06	-0.29	-0.17	Urate levels;	chr2:202243145	chr2:202336024~202336727:-
BRCA	cis	rs875971	0.8	rs427557	ENSG00000164669.11	INTS4P1	-5.68	1.7e-08	2.38e-06	-0.22	-0.17	Aortic root size;	chr7:66054263	chr7:65141225~65234216:+
BRCA	cis	rs10504130	0.696	rs11785805	ENSG00000272024.1	RP11-546K22.3	-5.68	1.7e-08	2.38e-06	-0.27	-0.17	Venous thromboembolism (SNP x SNP interaction);	chr8:51929310	chr8:51950284~51950690:+
BRCA	cis	rs9659323	0.67	rs12095067	ENSG00000231365.4	RP11-418J17.1	-5.68	1.7e-08	2.38e-06	-0.2	-0.17	Body mass index;	chr1:119093110	chr1:119140396~119275973:+
BRCA	cis	rs62025270	0.632	rs17571078	ENSG00000202081.1	RNU6-1280P	-5.68	1.7e-08	2.38e-06	-0.25	-0.17	Idiopathic pulmonary fibrosis;	chr15:85597248	chr15:85651522~85651628:-
BRCA	cis	rs7772486	0.79	rs1832362	ENSG00000270638.1	RP3-466P17.1	5.68	1.7e-08	2.38e-06	0.2	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145858819	chr6:145735570~145737218:+
BRCA	cis	rs59169624	0.699	rs4757776	ENSG00000255160.4	RP11-428C19.5	-5.68	1.7e-08	2.38e-06	-0.23	-0.17	Parental extreme longevity (95 years and older);	chr11:19255321	chr11:19299883~19308358:+
BRCA	cis	rs7178375	1	rs35162264	ENSG00000270055.1	CTD-3092A11.2	-5.68	1.7e-08	2.38e-06	-0.25	-0.17	Hypertriglyceridemia;	chr15:30908480	chr15:30487963~30490313:+
BRCA	cis	rs2803122	0.775	rs10118150	ENSG00000273226.1	RP11-513M16.8	-5.68	1.7e-08	2.39e-06	-0.19	-0.17	Pulse pressure;	chr9:19235482	chr9:19375451~19375996:+
BRCA	cis	rs673078	0.66	rs61945190	ENSG00000275409.1	RP11-131L12.4	-5.68	1.71e-08	2.39e-06	-0.26	-0.17	Glucose homeostasis traits;	chr12:118231345	chr12:118430147~118430699:+
BRCA	cis	rs7618501	0.699	rs9821675	ENSG00000228008.1	CTD-2330K9.3	5.68	1.71e-08	2.39e-06	0.17	0.17	Intelligence (multi-trait analysis);	chr3:49865111	chr3:49903845~49916937:+
BRCA	cis	rs875971	0.522	rs6960048	ENSG00000273024.4	INTS4P2	-5.68	1.71e-08	2.39e-06	-0.19	-0.17	Aortic root size;	chr7:65943052	chr7:65647864~65715661:+
BRCA	cis	rs295490	0.748	rs17316181	ENSG00000272656.1	RP11-219D15.3	5.68	1.71e-08	2.39e-06	0.42	0.17	PR interval in Tripanosoma cruzi seropositivity;	chr3:139350851	chr3:139349024~139349371:-
BRCA	cis	rs295490	0.748	rs61613889	ENSG00000272656.1	RP11-219D15.3	5.68	1.71e-08	2.39e-06	0.42	0.17	PR interval in Tripanosoma cruzi seropositivity;	chr3:139352279	chr3:139349024~139349371:-
BRCA	cis	rs295490	0.748	rs59958973	ENSG00000272656.1	RP11-219D15.3	5.68	1.71e-08	2.39e-06	0.42	0.17	PR interval in Tripanosoma cruzi seropositivity;	chr3:139352385	chr3:139349024~139349371:-
BRCA	cis	rs875971	0.658	rs432667	ENSG00000164669.11	INTS4P1	-5.68	1.71e-08	2.39e-06	-0.22	-0.17	Aortic root size;	chr7:66049646	chr7:65141225~65234216:+
BRCA	cis	rs67981189	0.896	rs17108967	ENSG00000258571.1	PTTG4P	-5.68	1.71e-08	2.39e-06	-0.19	-0.17	Schizophrenia;	chr14:71075451	chr14:71085482~71085833:-
BRCA	cis	rs2303759	0.709	rs8102658	ENSG00000268686.1	AC010524.2	-5.68	1.71e-08	2.39e-06	-0.28	-0.17	Multiple sclerosis;	chr19:49325598	chr19:49368705~49388081:-
BRCA	cis	rs7927592	0.913	rs3740631	ENSG00000212093.1	AP000807.1	5.68	1.71e-08	2.39e-06	0.2	0.17	Total body bone mineral density;	chr11:68574254	chr11:68506083~68506166:-
BRCA	cis	rs7927592	0.913	rs3824850	ENSG00000212093.1	AP000807.1	5.68	1.71e-08	2.39e-06	0.2	0.17	Total body bone mineral density;	chr11:68574405	chr11:68506083~68506166:-
BRCA	cis	rs7927592	0.913	rs3740629	ENSG00000212093.1	AP000807.1	5.68	1.71e-08	2.39e-06	0.2	0.17	Total body bone mineral density;	chr11:68576125	chr11:68506083~68506166:-
BRCA	cis	rs2749097	0.609	rs1911109	ENSG00000244256.3	RN7SL130P	-5.68	1.71e-08	2.39e-06	-0.23	-0.17	Alcohol consumption (transferrin glycosylation);	chr1:63648989	chr1:63655743~63656047:+
BRCA	cis	rs801193	0.569	rs11772819	ENSG00000224316.1	RP11-479O9.2	5.68	1.71e-08	2.39e-06	0.18	0.17	Aortic root size;	chr7:66752983	chr7:65773620~65802067:+
BRCA	cis	rs801193	0.569	rs7800620	ENSG00000224316.1	RP11-479O9.2	5.68	1.71e-08	2.39e-06	0.18	0.17	Aortic root size;	chr7:66758701	chr7:65773620~65802067:+
BRCA	cis	rs7923609	0.967	rs10761751	ENSG00000232075.1	MRPL35P2	-5.68	1.71e-08	2.39e-06	-0.22	-0.17	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63395125	chr10:63634317~63634827:-
BRCA	cis	rs7789940	0.857	rs12532935	ENSG00000280388.1	RP11-229D13.3	-5.68	1.71e-08	2.4e-06	-0.19	-0.17	Multiple sclerosis;	chr7:76310381	chr7:76043977~76045963:-
BRCA	cis	rs1075265	0.518	rs13414393	ENSG00000233266.1	HMGB1P31	5.68	1.71e-08	2.4e-06	0.21	0.17	Chronotype;Morning vs. evening chronotype;	chr2:54048025	chr2:54051334~54051760:+
BRCA	cis	rs9545047	0.604	rs9565486	ENSG00000227354.5	RBM26-AS1	-5.68	1.71e-08	2.4e-06	-0.19	-0.17	Schizophrenia;	chr13:79317469	chr13:79406309~79424328:+
BRCA	cis	rs7923609	0.934	rs7923544	ENSG00000232075.1	MRPL35P2	-5.68	1.71e-08	2.4e-06	-0.22	-0.17	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63422496	chr10:63634317~63634827:-
BRCA	cis	rs55702914	0.809	rs2376407	ENSG00000231621.1	AC013264.2	5.68	1.71e-08	2.4e-06	0.17	0.17	Major depression and alcohol dependence;	chr2:197318741	chr2:197197991~197199273:+
BRCA	cis	rs2911132	0.564	rs17401719	ENSG00000248734.2	CTD-2260A17.1	-5.68	1.72e-08	2.4e-06	-0.2	-0.17	Urate levels (BMI interaction);	chr5:96753342	chr5:96784777~96785999:+
BRCA	cis	rs4950322	0.57	rs2354428	ENSG00000244371.2	PFN1P8	-5.68	1.72e-08	2.4e-06	-0.24	-0.17	Protein quantitative trait loci;	chr1:147277512	chr1:146957117~146957659:-
BRCA	cis	rs9467773	0.649	rs2145318	ENSG00000124549.13	BTN2A3P	5.68	1.72e-08	2.4e-06	0.18	0.17	Intelligence (multi-trait analysis);	chr6:26496375	chr6:26421391~26432383:+
BRCA	cis	rs1005277	0.579	rs2800485	ENSG00000263064.2	RP11-291L22.7	5.68	1.72e-08	2.4e-06	0.21	0.17	Extrinsic epigenetic age acceleration;	chr10:38253660	chr10:38448689~38448949:+
BRCA	cis	rs6088813	1	rs224329	ENSG00000126005.14	MMP24-AS1	-5.68	1.72e-08	2.4e-06	-0.2	-0.17	Height;	chr20:35431781	chr20:35216462~35278131:-
BRCA	cis	rs4927850	1	rs7614767	ENSG00000207650.1	MIR570	5.68	1.72e-08	2.41e-06	0.2	0.17	Pancreatic cancer;	chr3:196026580	chr3:195699401~195699497:+
BRCA	cis	rs1040	0.727	rs7382431	ENSG00000261039.2	RP11-417E7.2	-5.68	1.72e-08	2.41e-06	-0.17	-0.17	Joint mobility (Beighton score);	chr6:169221734	chr6:169175304~169182740:-
BRCA	cis	rs7772486	0.754	rs702323	ENSG00000270638.1	RP3-466P17.1	-5.68	1.73e-08	2.41e-06	-0.2	-0.17	Lobe attachment (rater-scored or self-reported);	chr6:145687138	chr6:145735570~145737218:+
BRCA	cis	rs4819052	0.851	rs2838865	ENSG00000184274.3	LINC00315	-5.68	1.73e-08	2.42e-06	-0.24	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45292384	chr21:45300245~45305257:-
BRCA	cis	rs12468226	0.873	rs2350358	ENSG00000226261.1	AC064836.3	-5.68	1.73e-08	2.42e-06	-0.28	-0.17	Urate levels;	chr2:202199771	chr2:202336024~202336727:-
BRCA	cis	rs11105298	0.891	rs10858879	ENSG00000270344.2	RP11-734K2.4	-5.68	1.73e-08	2.42e-06	-0.2	-0.17	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89492801	chr12:89525654~89548005:+
BRCA	cis	rs910316	1	rs11623413	ENSG00000279594.1	RP11-950C14.10	-5.68	1.73e-08	2.42e-06	-0.19	-0.17	Height;	chr14:75122121	chr14:75011269~75012851:-
BRCA	cis	rs1345301	1	rs1420093	ENSG00000234389.1	AC007278.3	-5.68	1.73e-08	2.42e-06	-0.16	-0.17	Waist circumference;	chr2:102253998	chr2:102438713~102440475:+
BRCA	cis	rs7647973	0.58	rs2117938	ENSG00000225399.4	RP11-3B7.1	-5.68	1.73e-08	2.42e-06	-0.16	-0.17	Menarche (age at onset);	chr3:49226417	chr3:49260085~49261316:+
BRCA	cis	rs2638953	0.924	rs11049620	ENSG00000278733.1	RP11-425D17.1	-5.68	1.73e-08	2.42e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28454698	chr12:28185625~28186190:-
BRCA	cis	rs2919009	0.545	rs11199680	ENSG00000271670.1	RP11-95I16.4	-5.68	1.73e-08	2.42e-06	-0.2	-0.17	Obesity-related traits;	chr10:120957788	chr10:120879256~120880667:-
BRCA	cis	rs34286592	1	rs28599680	ENSG00000214725.6	CDIPT-AS1	-5.68	1.74e-08	2.43e-06	-0.29	-0.17	Multiple sclerosis;	chr16:29849364	chr16:29863593~29868053:+
BRCA	cis	rs2948294	0.588	rs4840913	ENSG00000254153.1	CTA-398F10.2	5.68	1.74e-08	2.43e-06	0.23	0.17	Red cell distribution width;	chr8:8259384	chr8:8456909~8461337:-
BRCA	cis	rs1707322	0.686	rs3014251	ENSG00000234329.1	RP11-767N6.2	-5.68	1.74e-08	2.43e-06	-0.18	-0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45611756	chr1:45651039~45651826:-
BRCA	cis	rs7927592	0.913	rs10896346	ENSG00000212093.1	AP000807.1	5.68	1.74e-08	2.43e-06	0.2	0.17	Total body bone mineral density;	chr11:68585203	chr11:68506083~68506166:-
BRCA	cis	rs7927592	0.913	rs10896347	ENSG00000212093.1	AP000807.1	5.68	1.74e-08	2.43e-06	0.2	0.17	Total body bone mineral density;	chr11:68585659	chr11:68506083~68506166:-
BRCA	cis	rs7927592	0.913	rs6591344	ENSG00000212093.1	AP000807.1	5.68	1.74e-08	2.43e-06	0.2	0.17	Total body bone mineral density;	chr11:68593405	chr11:68506083~68506166:-
BRCA	cis	rs7927592	0.913	rs7127948	ENSG00000212093.1	AP000807.1	5.68	1.74e-08	2.43e-06	0.2	0.17	Total body bone mineral density;	chr11:68595594	chr11:68506083~68506166:-
BRCA	cis	rs12787909	1	rs12787909	ENSG00000278768.1	BACE1-AS	5.68	1.74e-08	2.43e-06	0.34	0.17	Lipoprotein (a) - cholesterol levels;	chr11:117675767	chr11:117290874~117293571:+
BRCA	cis	rs7308116	0.546	rs4381407	ENSG00000274395.1	RP11-554D14.8	-5.68	1.74e-08	2.43e-06	-0.2	-0.17	Pelvic organ prolapse (moderate/severe);	chr12:107824077	chr12:107835541~107836555:-
BRCA	cis	rs4950322	1	rs4950322	ENSG00000278811.3	LINC00624	-5.68	1.74e-08	2.43e-06	-0.24	-0.17	Protein quantitative trait loci;	chr1:147383114	chr1:147258885~147517875:-
BRCA	cis	rs2235642	0.75	rs1894649	ENSG00000260989.1	LA16c-395F10.2	-5.68	1.74e-08	2.43e-06	-0.18	-0.17	Coronary artery disease;	chr16:1607283	chr16:1580527~1610328:+
BRCA	cis	rs17495987	0.626	rs17494629	ENSG00000219545.8	UMAD1	5.68	1.74e-08	2.43e-06	0.23	0.17	Tonsillectomy;	chr7:7831900	chr7:7640711~8004059:+
BRCA	cis	rs1707322	1	rs34694458	ENSG00000281133.1	AL355480.3	-5.68	1.74e-08	2.43e-06	-0.22	-0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45867024	chr1:45580892~45580996:-
BRCA	cis	rs5758511	0.68	rs5758684	ENSG00000233903.2	Z83851.4	5.68	1.74e-08	2.43e-06	0.27	0.17	Birth weight;	chr22:42253503	chr22:42276355~42277052:+
BRCA	cis	rs1395	0.744	rs11126929	ENSG00000234072.1	AC074117.10	5.68	1.74e-08	2.43e-06	0.18	0.17	Blood metabolite levels;	chr2:27249159	chr2:27356246~27367622:+
BRCA	cis	rs6479901	0.512	rs7100372	ENSG00000232075.1	MRPL35P2	-5.68	1.74e-08	2.43e-06	-0.31	-0.17	Intelligence (multi-trait analysis);	chr10:63304484	chr10:63634317~63634827:-
BRCA	cis	rs6479891	0.778	rs7896676	ENSG00000232075.1	MRPL35P2	-5.68	1.74e-08	2.43e-06	-0.31	-0.17	Arthritis (juvenile idiopathic);	chr10:63305542	chr10:63634317~63634827:-
BRCA	cis	rs6479891	0.915	rs7896677	ENSG00000232075.1	MRPL35P2	-5.68	1.74e-08	2.43e-06	-0.31	-0.17	Arthritis (juvenile idiopathic);	chr10:63305545	chr10:63634317~63634827:-
BRCA	cis	rs9545047	0.584	rs7995243	ENSG00000227354.5	RBM26-AS1	-5.68	1.75e-08	2.44e-06	-0.19	-0.17	Schizophrenia;	chr13:79358645	chr13:79406309~79424328:+
BRCA	cis	rs1552244	1	rs67006488	ENSG00000180385.7	EMC3-AS1	5.68	1.75e-08	2.44e-06	0.22	0.17	Alzheimer's disease;	chr3:10111309	chr3:9986893~10006990:+
BRCA	cis	rs1552244	1	rs6764068	ENSG00000180385.7	EMC3-AS1	5.68	1.75e-08	2.44e-06	0.22	0.17	Alzheimer's disease;	chr3:10112158	chr3:9986893~10006990:+
BRCA	cis	rs1552244	1	rs113522867	ENSG00000180385.7	EMC3-AS1	5.68	1.75e-08	2.44e-06	0.22	0.17	Alzheimer's disease;	chr3:10112819	chr3:9986893~10006990:+
BRCA	cis	rs55702914	0.628	rs56718086	ENSG00000231621.1	AC013264.2	-5.68	1.75e-08	2.44e-06	-0.16	-0.17	Major depression and alcohol dependence;	chr2:197396872	chr2:197197991~197199273:+
BRCA	cis	rs10833905	0.938	rs10766999	ENSG00000246225.5	RP11-17A1.3	-5.68	1.75e-08	2.44e-06	-0.24	-0.17	Sudden cardiac arrest;	chr11:23056757	chr11:22829380~22945393:+
BRCA	cis	rs66887589	0.592	rs62320740	ENSG00000249244.1	RP11-548H18.2	5.68	1.75e-08	2.44e-06	0.19	0.17	Diastolic blood pressure;	chr4:119358331	chr4:119391831~119395335:-
BRCA	cis	rs9309473	0.607	rs6546824	ENSG00000163016.8	ALMS1P	5.68	1.75e-08	2.44e-06	0.21	0.17	Metabolite levels;	chr2:73360203	chr2:73644919~73685576:+
BRCA	cis	rs8098244	0.683	rs1941524	ENSG00000264745.1	TTC39C-AS1	-5.68	1.75e-08	2.44e-06	-0.2	-0.17	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23865299	chr18:23994213~24015339:-
BRCA	cis	rs9308731	0.64	rs10204044	ENSG00000227992.1	AC108463.2	5.68	1.75e-08	2.44e-06	0.22	0.17	Chronic lymphocytic leukemia;	chr2:111137967	chr2:111203964~111206215:-
BRCA	cis	rs2239557	0.508	rs12588108	ENSG00000259065.1	RP5-1021I20.1	-5.68	1.75e-08	2.44e-06	-0.26	-0.17	Common traits (Other);	chr14:73865775	chr14:73787360~73803270:+
BRCA	cis	rs4604234	0.711	rs73463560	ENSG00000272129.1	RP11-250B2.6	-5.68	1.75e-08	2.44e-06	-0.42	-0.17	Cancer;	chr6:80288806	chr6:80355424~80356859:+
BRCA	cis	rs5015933	0.801	rs11999662	ENSG00000232630.1	PRPS1P2	-5.68	1.75e-08	2.45e-06	-0.17	-0.17	Body mass index;	chr9:125381649	chr9:125150653~125151589:+
BRCA	cis	rs13126694	0.649	rs4615226	ENSG00000251429.1	RP11-597D13.7	5.68	1.76e-08	2.45e-06	0.17	0.17	Blood osmolality (transformed sodium);	chr4:157979297	chr4:158270378~158278676:+
BRCA	cis	rs7131987	0.65	rs3782509	ENSG00000275476.1	RP11-996F15.4	-5.68	1.76e-08	2.45e-06	-0.21	-0.17	QT interval;	chr12:29300845	chr12:29277397~29277882:-
BRCA	cis	rs8098244	0.861	rs8099617	ENSG00000264745.1	TTC39C-AS1	5.68	1.76e-08	2.45e-06	0.22	0.17	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23828815	chr18:23994213~24015339:-
BRCA	cis	rs2098713	0.537	rs538209	ENSG00000250155.1	CTD-2353F22.1	5.68	1.76e-08	2.45e-06	0.2	0.17	Telomere length;	chr5:37543495	chr5:36666214~36725195:-
BRCA	cis	rs7618501	0.516	rs2856236	ENSG00000228008.1	CTD-2330K9.3	-5.68	1.76e-08	2.45e-06	-0.17	-0.17	Intelligence (multi-trait analysis);	chr3:50124284	chr3:49903845~49916937:+
BRCA	cis	rs4908768	0.501	rs6669503	ENSG00000270282.1	RP5-1115A15.2	5.68	1.76e-08	2.46e-06	0.18	0.17	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8504241	chr1:8512653~8513021:+
BRCA	cis	rs10129255	0.957	rs8014696	ENSG00000224373.3	IGHV4-59	-5.68	1.76e-08	2.46e-06	-0.11	-0.17	Kawasaki disease;	chr14:106769752	chr14:106627249~106627825:-
BRCA	cis	rs1707322	0.752	rs28550303	ENSG00000234329.1	RP11-767N6.2	5.68	1.76e-08	2.46e-06	0.18	0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45723242	chr1:45651039~45651826:-
BRCA	cis	rs228614	0.51	rs223412	ENSG00000251288.2	RP11-10L12.2	-5.68	1.76e-08	2.46e-06	-0.2	-0.17	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102812443	chr4:102751401~102752641:+
BRCA	cis	rs7927592	0.956	rs60212556	ENSG00000212093.1	AP000807.1	5.68	1.76e-08	2.46e-06	0.2	0.17	Total body bone mineral density;	chr11:68538026	chr11:68506083~68506166:-
BRCA	cis	rs2638953	0.853	rs2141203	ENSG00000278733.1	RP11-425D17.1	-5.68	1.76e-08	2.46e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28461928	chr12:28185625~28186190:-
BRCA	cis	rs867371	0.896	rs6495647	ENSG00000276710.3	CSPG4P8	-5.68	1.76e-08	2.46e-06	-0.19	-0.17	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82244708	chr15:82459472~82477258:+
BRCA	cis	rs10761482	0.5	rs4540900	ENSG00000254271.1	RP11-131N11.4	5.68	1.76e-08	2.46e-06	0.24	0.17	Schizophrenia;	chr10:60548976	chr10:60734342~60741828:+
BRCA	cis	rs6570726	0.791	rs6570692	ENSG00000270638.1	RP3-466P17.1	5.68	1.76e-08	2.46e-06	0.2	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145583265	chr6:145735570~145737218:+
BRCA	cis	rs7824557	0.591	rs2043510	ENSG00000154316.13	TDH	5.68	1.76e-08	2.46e-06	0.23	0.17	Retinal vascular caliber;	chr8:11367659	chr8:11339637~11368452:+
BRCA	cis	rs2243480	1	rs781149	ENSG00000228409.4	CCT6P1	5.68	1.77e-08	2.47e-06	0.24	0.17	Diabetic kidney disease;	chr7:66016297	chr7:65751142~65763354:+
BRCA	cis	rs2243480	0.901	rs58207111	ENSG00000228409.4	CCT6P1	5.68	1.77e-08	2.47e-06	0.24	0.17	Diabetic kidney disease;	chr7:66021736	chr7:65751142~65763354:+
BRCA	cis	rs2749097	0.609	rs2269234	ENSG00000244256.3	RN7SL130P	-5.68	1.77e-08	2.47e-06	-0.23	-0.17	Alcohol consumption (transferrin glycosylation);	chr1:63653305	chr1:63655743~63656047:+
BRCA	cis	rs11955398	0.502	rs10052649	ENSG00000215032.2	GNL3LP1	-5.68	1.77e-08	2.47e-06	-0.22	-0.17	Intelligence (multi-trait analysis);	chr5:60859157	chr5:60891935~60893577:-
BRCA	cis	rs1555322	0.53	rs2425053	ENSG00000269202.1	RP4-614O4.12	-5.68	1.77e-08	2.47e-06	-0.2	-0.17	Attention deficit hyperactivity disorder;	chr20:35294017	chr20:35201747~35203288:-
BRCA	cis	rs7809950	0.53	rs34021916	ENSG00000238832.1	snoU109	-5.68	1.77e-08	2.47e-06	-0.25	-0.17	Coronary artery disease;	chr7:107177456	chr7:107603363~107603507:+
BRCA	cis	rs916888	0.773	rs9896243	ENSG00000261575.2	RP11-259G18.1	5.68	1.77e-08	2.47e-06	0.26	0.17	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:46267037~46268694:+
BRCA	cis	rs4699052	1	rs6533060	ENSG00000248740.4	RP11-328K4.1	5.68	1.77e-08	2.47e-06	0.2	0.17	Testicular germ cell tumor;	chr4:103218839	chr4:103256159~103453658:+
BRCA	cis	rs8114671	0.562	rs34837802	ENSG00000269202.1	RP4-614O4.12	-5.68	1.77e-08	2.47e-06	-0.18	-0.17	Height;	chr20:34837105	chr20:35201747~35203288:-
BRCA	cis	rs516805	0.631	rs2606647	ENSG00000279453.1	RP3-425C14.4	-5.68	1.77e-08	2.47e-06	-0.25	-0.17	Lymphocyte counts;	chr6:122118967	chr6:122436789~122439223:-
BRCA	cis	rs7927592	0.913	rs4988291	ENSG00000212093.1	AP000807.1	5.68	1.77e-08	2.47e-06	0.2	0.17	Total body bone mineral density;	chr11:68614139	chr11:68506083~68506166:-
BRCA	cis	rs7927592	0.871	rs12941	ENSG00000212093.1	AP000807.1	5.68	1.77e-08	2.47e-06	0.2	0.17	Total body bone mineral density;	chr11:68614725	chr11:68506083~68506166:-
BRCA	cis	rs2273788	0.527	rs4978448	ENSG00000204173.9	LRRC37A5P	5.68	1.77e-08	2.47e-06	0.19	0.17	Monocyte count;	chr9:111580861	chr9:111602831~111631289:-
BRCA	cis	rs9308731	0.966	rs36018702	ENSG00000227992.1	AC108463.2	5.68	1.77e-08	2.48e-06	0.2	0.17	Chronic lymphocytic leukemia;	chr2:111170796	chr2:111203964~111206215:-
BRCA	cis	rs10899021	1	rs61900635	ENSG00000279353.1	RP11-864N7.4	5.68	1.78e-08	2.48e-06	0.35	0.17	Response to metformin (IC50);	chr11:74647965	chr11:74698231~74699658:-
BRCA	cis	rs944990	0.557	rs4743927	ENSG00000227603.1	RP11-165J3.6	5.68	1.78e-08	2.48e-06	0.18	0.17	Body mass index;	chr9:93510364	chr9:93435332~93437121:-
BRCA	cis	rs9527	1	rs12416687	ENSG00000236937.2	PTGES3P4	5.68	1.78e-08	2.48e-06	0.26	0.17	Arsenic metabolism;	chr10:102869254	chr10:102845595~102845950:+
BRCA	cis	rs2243480	0.708	rs35825036	ENSG00000228409.4	CCT6P1	5.68	1.78e-08	2.48e-06	0.24	0.17	Diabetic kidney disease;	chr7:66521515	chr7:65751142~65763354:+
BRCA	cis	rs2243480	1	rs13237037	ENSG00000228409.4	CCT6P1	5.68	1.78e-08	2.48e-06	0.24	0.17	Diabetic kidney disease;	chr7:66532895	chr7:65751142~65763354:+
BRCA	cis	rs2243480	1	rs1796228	ENSG00000228409.4	CCT6P1	5.68	1.78e-08	2.48e-06	0.24	0.17	Diabetic kidney disease;	chr7:66568097	chr7:65751142~65763354:+
BRCA	cis	rs9828933	0.752	rs73117082	ENSG00000280620.1	SCAANT1	5.68	1.78e-08	2.48e-06	0.31	0.17	Type 2 diabetes;	chr3:63961889	chr3:63911518~63911772:-
BRCA	cis	rs673078	0.66	rs61945217	ENSG00000275409.1	RP11-131L12.4	-5.68	1.78e-08	2.48e-06	-0.28	-0.17	Glucose homeostasis traits;	chr12:118261194	chr12:118430147~118430699:+
BRCA	cis	rs523522	0.926	rs10849766	ENSG00000278344.1	RP11-18C24.8	5.68	1.78e-08	2.49e-06	0.24	0.17	High light scatter reticulocyte count;	chr12:120588091	chr12:120500735~120501090:-
BRCA	cis	rs13423976	0.631	rs2373405	ENSG00000231367.4	AC016995.3	5.68	1.78e-08	2.49e-06	0.19	0.17	Gut microbiome composition (summer);	chr2:38513072	chr2:38406719~38515740:-
BRCA	cis	rs4718428	0.96	rs6460317	ENSG00000232546.1	RP11-458F8.1	-5.68	1.78e-08	2.49e-06	-0.15	-0.17	Corneal structure;	chr7:66925268	chr7:66848496~66858136:+
BRCA	cis	rs7045881	0.674	rs62542706	ENSG00000254396.1	RP11-56F10.3	5.68	1.79e-08	2.49e-06	0.3	0.17	Schizophrenia;	chr9:27054959	chr9:27102630~27104728:+
BRCA	cis	rs12468226	1	rs116635509	ENSG00000226261.1	AC064836.3	5.68	1.79e-08	2.49e-06	0.3	0.17	Urate levels;	chr2:202460027	chr2:202336024~202336727:-
BRCA	cis	rs7200543	1	rs7200543	ENSG00000260872.1	RP11-680G24.5	5.68	1.79e-08	2.49e-06	0.18	0.17	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15036113	chr16:15018106~15020488:-
BRCA	cis	rs7615952	0.599	rs6438955	ENSG00000171084.14	FAM86JP	5.68	1.79e-08	2.49e-06	0.25	0.17	Blood pressure (smoking interaction);	chr3:126011490	chr3:125916620~125930024:+
BRCA	cis	rs10752881	1	rs4454510	ENSG00000224468.3	RP11-181K3.4	5.68	1.79e-08	2.49e-06	0.18	0.17	Colorectal cancer;	chr1:183013168	chr1:183138402~183141282:-
BRCA	cis	rs793571	0.554	rs8029805	ENSG00000259250.1	RP11-50C13.1	5.68	1.79e-08	2.49e-06	0.29	0.17	Schizophrenia;	chr15:58713723	chr15:58587507~58591676:+
BRCA	cis	rs10761482	0.5	rs10994411	ENSG00000254271.1	RP11-131N11.4	5.68	1.79e-08	2.5e-06	0.23	0.17	Schizophrenia;	chr10:60545050	chr10:60734342~60741828:+
BRCA	cis	rs3764021	0.87	rs10743819	ENSG00000214776.8	RP11-726G1.1	5.68	1.79e-08	2.5e-06	0.19	0.17	Type 1 diabetes;	chr12:9724172	chr12:9467552~9576275:+
BRCA	cis	rs2638953	0.853	rs11049632	ENSG00000278733.1	RP11-425D17.1	-5.68	1.79e-08	2.5e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28461130	chr12:28185625~28186190:-
BRCA	cis	rs7045881	0.808	rs7039400	ENSG00000254396.1	RP11-56F10.3	5.68	1.79e-08	2.5e-06	0.29	0.17	Schizophrenia;	chr9:26946251	chr9:27102630~27104728:+
BRCA	cis	rs2243480	1	rs67728539	ENSG00000164669.11	INTS4P1	5.68	1.79e-08	2.5e-06	0.33	0.17	Diabetic kidney disease;	chr7:65913137	chr7:65141225~65234216:+
BRCA	cis	rs66887589	0.592	rs11731571	ENSG00000249244.1	RP11-548H18.2	5.68	1.79e-08	2.5e-06	0.19	0.17	Diastolic blood pressure;	chr4:119300030	chr4:119391831~119395335:-
BRCA	cis	rs1499614	1	rs2707840	ENSG00000228409.4	CCT6P1	5.67	1.8e-08	2.51e-06	0.25	0.17	Gout;	chr7:66693028	chr7:65751142~65763354:+
BRCA	cis	rs9545047	0.625	rs7338170	ENSG00000227354.5	RBM26-AS1	-5.67	1.8e-08	2.51e-06	-0.19	-0.17	Schizophrenia;	chr13:79286030	chr13:79406309~79424328:+
BRCA	cis	rs4950322	0.634	rs4950415	ENSG00000278811.3	LINC00624	5.67	1.8e-08	2.51e-06	0.24	0.17	Protein quantitative trait loci;	chr1:147350951	chr1:147258885~147517875:-
BRCA	cis	rs9840812	0.592	rs35418151	ENSG00000239213.4	NCK1-AS1	5.67	1.8e-08	2.51e-06	0.21	0.17	Fibrinogen levels;	chr3:136443779	chr3:136841726~136862054:-
BRCA	cis	rs2243480	1	rs422164	ENSG00000164669.11	INTS4P1	5.67	1.8e-08	2.51e-06	0.34	0.17	Diabetic kidney disease;	chr7:66121618	chr7:65141225~65234216:+
BRCA	cis	rs2288884	0.943	rs11084131	ENSG00000275055.1	CTC-471J1.11	-5.67	1.81e-08	2.52e-06	-0.26	-0.17	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52011193	chr19:52049007~52049754:+
BRCA	cis	rs2288884	0.943	rs11084132	ENSG00000275055.1	CTC-471J1.11	-5.67	1.81e-08	2.52e-06	-0.26	-0.17	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52011327	chr19:52049007~52049754:+
BRCA	cis	rs2243480	1	rs4548056	ENSG00000229886.1	RP5-1132H15.3	5.67	1.81e-08	2.52e-06	0.3	0.17	Diabetic kidney disease;	chr7:65833886	chr7:66025126~66031544:-
BRCA	cis	rs9545047	0.604	rs9601226	ENSG00000227354.5	RBM26-AS1	-5.67	1.81e-08	2.52e-06	-0.19	-0.17	Schizophrenia;	chr13:79403400	chr13:79406309~79424328:+
BRCA	cis	rs12612619	0.732	rs11679681	ENSG00000229122.1	AGBL5-IT1	5.67	1.81e-08	2.52e-06	0.18	0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27075611	chr2:27061038~27061815:+
BRCA	cis	rs904251	0.772	rs2776906	ENSG00000204110.6	RP1-153P14.8	-5.67	1.81e-08	2.52e-06	-0.2	-0.17	Cognitive performance;	chr6:37463981	chr6:37507348~37535616:+
BRCA	cis	rs1014246	0.826	rs1900508	ENSG00000232767.1	RP11-498B4.5	5.67	1.81e-08	2.52e-06	0.17	0.17	Age at smoking initiation in chronic obstructive pulmonary disease;	chr10:116711239	chr10:116670103~116672739:+
BRCA	cis	rs4950322	0.57	rs72691054	ENSG00000244371.2	PFN1P8	-5.67	1.81e-08	2.52e-06	-0.24	-0.17	Protein quantitative trait loci;	chr1:147277942	chr1:146957117~146957659:-
BRCA	cis	rs7246657	1	rs12709812	ENSG00000226686.6	LINC01535	5.67	1.81e-08	2.52e-06	0.27	0.17	Coronary artery calcification;	chr19:37303948	chr19:37251912~37265535:+
BRCA	cis	rs755249	0.727	rs2242500	ENSG00000228060.1	RP11-69E11.8	-5.67	1.81e-08	2.52e-06	-0.18	-0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39572230	chr1:39565160~39573203:+
BRCA	cis	rs9992667	0.955	rs73232876	ENSG00000231160.8	KLF3-AS1	5.67	1.81e-08	2.52e-06	0.22	0.17	Eosinophil percentage of granulocytes;	chr4:38645888	chr4:38612701~38664883:-
BRCA	cis	rs227275	0.525	rs1383733	ENSG00000251288.2	RP11-10L12.2	-5.67	1.81e-08	2.52e-06	-0.2	-0.17	Allergic disease (asthma, hay fever or eczema);	chr4:102995297	chr4:102751401~102752641:+
BRCA	cis	rs73222236	0.787	rs6806795	ENSG00000273486.1	RP11-731C17.2	5.67	1.81e-08	2.52e-06	0.19	0.17	Coronary artery disease;	chr3:136587297	chr3:136837338~136839021:-
BRCA	cis	rs4908768	0.501	rs1922983	ENSG00000270282.1	RP5-1115A15.2	5.67	1.81e-08	2.52e-06	0.18	0.17	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8471266	chr1:8512653~8513021:+
BRCA	cis	rs2638953	0.962	rs10843152	ENSG00000278733.1	RP11-425D17.1	-5.67	1.81e-08	2.53e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28319090	chr12:28185625~28186190:-
BRCA	cis	rs7246967	0.611	rs16999571	ENSG00000198153.8	ZNF849P	-5.67	1.81e-08	2.53e-06	-0.26	-0.17	Bronchopulmonary dysplasia;	chr19:22721962	chr19:22685167~22686732:+
BRCA	cis	rs35146811	0.52	rs1015538	ENSG00000235713.1	RP4-604G5.3	-5.67	1.81e-08	2.53e-06	-0.19	-0.17	Coronary artery disease;	chr7:100028412	chr7:99992397~99993050:+
BRCA	cis	rs10129255	0.957	rs28887506	ENSG00000280411.1	IGHV1-69-2	-5.67	1.82e-08	2.53e-06	-0.13	-0.17	Kawasaki disease;	chr14:106785589	chr14:106762092~106762588:-
BRCA	cis	rs7246760	0.867	rs61011126	ENSG00000277587.1	CTD-3116E22.8	-5.67	1.82e-08	2.53e-06	-0.34	-0.17	Pursuit maintenance gain;	chr19:9703745	chr19:9721903~9722410:+
BRCA	cis	rs7613875	0.663	rs6762477	ENSG00000228008.1	CTD-2330K9.3	-5.67	1.82e-08	2.53e-06	-0.17	-0.17	Body mass index;	chr3:50055776	chr3:49903845~49916937:+
BRCA	cis	rs7665090	0.714	rs5026475	ENSG00000246560.2	RP11-10L12.4	5.67	1.82e-08	2.54e-06	0.19	0.17	Primary biliary cholangitis;	chr4:102633664	chr4:102828055~102844075:+
BRCA	cis	rs6840360	1	rs17360475	ENSG00000270265.1	RP11-731D1.4	5.67	1.82e-08	2.54e-06	0.19	0.17	Intelligence (multi-trait analysis);	chr4:151750488	chr4:151333775~151353224:-
BRCA	cis	rs2638953	0.815	rs117066882	ENSG00000278733.1	RP11-425D17.1	-5.67	1.82e-08	2.54e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28477287	chr12:28185625~28186190:-
BRCA	cis	rs7567389	0.719	rs6738690	ENSG00000236682.1	AC068282.3	5.67	1.82e-08	2.54e-06	0.27	0.17	Self-rated health;	chr2:127235149	chr2:127389130~127400580:+
BRCA	cis	rs673078	0.66	rs7977403	ENSG00000275409.1	RP11-131L12.4	-5.67	1.83e-08	2.54e-06	-0.26	-0.17	Glucose homeostasis traits;	chr12:118233446	chr12:118430147~118430699:+
BRCA	cis	rs4908760	0.965	rs10864353	ENSG00000270282.1	RP5-1115A15.2	5.67	1.83e-08	2.54e-06	0.19	0.17	Vitiligo;	chr1:8489656	chr1:8512653~8513021:+
BRCA	cis	rs2235642	0.75	rs2859310	ENSG00000280231.1	LA16c-380F5.3	5.67	1.83e-08	2.54e-06	0.23	0.17	Coronary artery disease;	chr16:1606764	chr16:1553655~1554130:-
BRCA	cis	rs2243480	1	rs73142122	ENSG00000232559.3	GS1-124K5.12	5.67	1.83e-08	2.54e-06	0.33	0.17	Diabetic kidney disease;	chr7:65846311	chr7:66554588~66576923:-
BRCA	cis	rs2243480	0.901	rs73142137	ENSG00000232559.3	GS1-124K5.12	5.67	1.83e-08	2.54e-06	0.33	0.17	Diabetic kidney disease;	chr7:65878455	chr7:66554588~66576923:-
BRCA	cis	rs2243480	1	rs13247184	ENSG00000232559.3	GS1-124K5.12	5.67	1.83e-08	2.54e-06	0.33	0.17	Diabetic kidney disease;	chr7:65893941	chr7:66554588~66576923:-
BRCA	cis	rs2243480	1	rs35283677	ENSG00000232559.3	GS1-124K5.12	5.67	1.83e-08	2.54e-06	0.33	0.17	Diabetic kidney disease;	chr7:65894246	chr7:66554588~66576923:-
BRCA	cis	rs2243480	1	rs35421653	ENSG00000232559.3	GS1-124K5.12	5.67	1.83e-08	2.54e-06	0.33	0.17	Diabetic kidney disease;	chr7:65898442	chr7:66554588~66576923:-
BRCA	cis	rs7923837	0.717	rs6583813	ENSG00000236493.2	EIF2S2P3	5.67	1.83e-08	2.55e-06	0.25	0.17	Multiple sclerosis;Body mass index;	chr10:92450182	chr10:92668745~92669743:-
BRCA	cis	rs1075265	0.716	rs7573991	ENSG00000235937.1	AC008280.1	5.67	1.83e-08	2.55e-06	0.19	0.17	Chronotype;Morning vs. evening chronotype;	chr2:53726830	chr2:54029552~54030682:-
BRCA	cis	rs7119038	0.818	rs6589684	ENSG00000255239.1	AP002954.6	5.67	1.83e-08	2.55e-06	0.23	0.17	Sjögren's syndrome;	chr11:118740248	chr11:118688039~118690600:-
BRCA	cis	rs13108904	0.56	rs11247994	ENSG00000254094.1	AC078852.1	-5.67	1.83e-08	2.55e-06	-0.21	-0.17	Obesity-related traits;	chr4:1349932	chr4:1356581~1358075:+
BRCA	cis	rs891378	0.959	rs1864370	ENSG00000274245.1	RP11-357P18.2	-5.67	1.83e-08	2.55e-06	-0.23	-0.17	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207245687	chr1:207372559~207373252:+
BRCA	cis	rs853679	0.607	rs34662244	ENSG00000204709.4	LINC01556	5.67	1.83e-08	2.55e-06	0.48	0.17	Depression;	chr6:28106103	chr6:28943877~28944537:+
BRCA	cis	rs35952432	1	rs35952432	ENSG00000204709.4	LINC01556	5.67	1.83e-08	2.55e-06	0.48	0.17	Lung cancer;	chr6:28107123	chr6:28943877~28944537:+
BRCA	cis	rs4908768	0.501	rs4908761	ENSG00000270282.1	RP5-1115A15.2	5.67	1.83e-08	2.55e-06	0.18	0.17	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8492159	chr1:8512653~8513021:+
BRCA	cis	rs9813712	0.595	rs1453238	ENSG00000228252.7	COL6A4P2	5.67	1.83e-08	2.55e-06	0.21	0.17	Response to amphetamines;	chr3:130290494	chr3:130212823~130273806:+
BRCA	cis	rs253959	0.545	rs11241362	ENSG00000272265.1	CTD-2287O16.4	5.67	1.83e-08	2.55e-06	0.22	0.17	Bipolar disorder and schizophrenia;	chr5:116112630	chr5:116078110~116078570:-
BRCA	cis	rs71520386	0.898	rs12536144	ENSG00000228649.7	AC005682.5	-5.67	1.83e-08	2.55e-06	-0.2	-0.17	Fibrinogen levels;	chr7:22782890	chr7:22854178~22861579:+
BRCA	cis	rs11722779	0.844	rs10003326	ENSG00000251288.2	RP11-10L12.2	-5.67	1.83e-08	2.55e-06	-0.21	-0.17	Schizophrenia;	chr4:102948193	chr4:102751401~102752641:+
BRCA	cis	rs1499614	1	rs2659903	ENSG00000228409.4	CCT6P1	5.67	1.83e-08	2.55e-06	0.25	0.17	Gout;	chr7:66715944	chr7:65751142~65763354:+
BRCA	cis	rs2243480	1	rs316307	ENSG00000228409.4	CCT6P1	5.67	1.83e-08	2.55e-06	0.24	0.17	Diabetic kidney disease;	chr7:66105184	chr7:65751142~65763354:+
BRCA	cis	rs4908768	0.501	rs7520617	ENSG00000270282.1	RP5-1115A15.2	5.67	1.84e-08	2.55e-06	0.18	0.17	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8513658	chr1:8512653~8513021:+
BRCA	cis	rs10129255	0.912	rs8009135	ENSG00000224373.3	IGHV4-59	5.67	1.84e-08	2.56e-06	0.11	0.17	Kawasaki disease;	chr14:106777528	chr14:106627249~106627825:-
BRCA	cis	rs4664293	0.51	rs66589863	ENSG00000226266.5	AC009961.3	5.67	1.84e-08	2.56e-06	0.22	0.17	Monocyte percentage of white cells;	chr2:159649684	chr2:159670708~159712435:-
BRCA	cis	rs891378	0.874	rs59036171	ENSG00000274245.1	RP11-357P18.2	-5.67	1.84e-08	2.56e-06	-0.23	-0.17	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207271583	chr1:207372559~207373252:+
BRCA	cis	rs2243480	1	rs34136756	ENSG00000232559.3	GS1-124K5.12	5.67	1.84e-08	2.56e-06	0.32	0.17	Diabetic kidney disease;	chr7:65916269	chr7:66554588~66576923:-
BRCA	cis	rs12681366	0.663	rs6980687	ENSG00000253704.1	RP11-267M23.4	5.67	1.84e-08	2.56e-06	0.18	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94469685	chr8:94553722~94569745:+
BRCA	cis	rs4907240	0.731	rs2118836	ENSG00000237510.6	AC008268.2	-5.67	1.84e-08	2.56e-06	-0.23	-0.17	Event-related brain oscillations;	chr2:96497235	chr2:95789654~95800166:+
BRCA	cis	rs2898681	0.561	rs58577680	ENSG00000248375.1	RP11-177B4.1	-5.67	1.84e-08	2.56e-06	-0.28	-0.17	Optic nerve measurement (cup area);	chr4:52868127	chr4:52720081~52720831:-
BRCA	cis	rs2243480	0.803	rs13224048	ENSG00000228409.4	CCT6P1	5.67	1.84e-08	2.57e-06	0.24	0.17	Diabetic kidney disease;	chr7:66528779	chr7:65751142~65763354:+
BRCA	cis	rs10510102	0.688	rs11812208	ENSG00000226864.1	ATE1-AS1	5.67	1.85e-08	2.57e-06	0.32	0.17	Breast cancer;	chr10:121924831	chr10:121928312~121951965:+
BRCA	cis	rs10510102	0.935	rs77447688	ENSG00000226864.1	ATE1-AS1	5.67	1.85e-08	2.57e-06	0.32	0.17	Breast cancer;	chr10:121925721	chr10:121928312~121951965:+
BRCA	cis	rs2803122	0.871	rs10733360	ENSG00000273226.1	RP11-513M16.8	-5.67	1.85e-08	2.57e-06	-0.19	-0.17	Pulse pressure;	chr9:19221580	chr9:19375451~19375996:+
BRCA	cis	rs2239547	0.522	rs2581801	ENSG00000242142.1	SERBP1P3	-5.67	1.85e-08	2.57e-06	-0.21	-0.17	Schizophrenia;	chr3:52938891	chr3:53064283~53065091:-
BRCA	cis	rs17508449	0.819	rs77892281	ENSG00000232450.1	RP4-730K3.3	-5.67	1.85e-08	2.57e-06	-0.29	-0.17	Leprosy;	chr1:113620995	chr1:113698884~113699631:-
BRCA	cis	rs9341808	0.718	rs35447745	ENSG00000272129.1	RP11-250B2.6	5.67	1.85e-08	2.57e-06	0.22	0.17	Sitting height ratio;	chr6:80107031	chr6:80355424~80356859:+
BRCA	cis	rs12893668	0.572	rs2273175	ENSG00000269940.1	RP11-73M18.7	5.67	1.85e-08	2.58e-06	0.19	0.17	Reticulocyte count;	chr14:103693804	chr14:103694560~103695170:+
BRCA	cis	rs2638953	0.962	rs61920564	ENSG00000278733.1	RP11-425D17.1	-5.67	1.85e-08	2.58e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28357000	chr12:28185625~28186190:-
BRCA	cis	rs7927592	0.956	rs10896341	ENSG00000212093.1	AP000807.1	5.67	1.85e-08	2.58e-06	0.2	0.17	Total body bone mineral density;	chr11:68545712	chr11:68506083~68506166:-
BRCA	cis	rs7618501	0.699	rs1317154	ENSG00000228008.1	CTD-2330K9.3	5.67	1.86e-08	2.58e-06	0.17	0.17	Intelligence (multi-trait analysis);	chr3:49872651	chr3:49903845~49916937:+
BRCA	cis	rs7520050	0.966	rs4134386	ENSG00000280836.1	AL355480.1	5.67	1.86e-08	2.58e-06	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:45929417	chr1:45581219~45581321:-
BRCA	cis	rs7520050	0.966	rs12561806	ENSG00000280836.1	AL355480.1	5.67	1.86e-08	2.58e-06	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:45931104	chr1:45581219~45581321:-
BRCA	cis	rs559928	0.606	rs17773078	ENSG00000236935.1	AP003774.1	5.67	1.86e-08	2.58e-06	0.24	0.17	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64138752	chr11:64325050~64329504:-
BRCA	cis	rs559928	0.556	rs734762	ENSG00000236935.1	AP003774.1	5.67	1.86e-08	2.58e-06	0.24	0.17	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64144717	chr11:64325050~64329504:-
BRCA	cis	rs559928	0.606	rs12417635	ENSG00000236935.1	AP003774.1	5.67	1.86e-08	2.58e-06	0.24	0.17	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64145256	chr11:64325050~64329504:-
BRCA	cis	rs7246760	0.867	rs57999229	ENSG00000277587.1	CTD-3116E22.8	-5.67	1.86e-08	2.58e-06	-0.34	-0.17	Pursuit maintenance gain;	chr19:9706681	chr19:9721903~9722410:+
BRCA	cis	rs62025270	0.632	rs74025655	ENSG00000202081.1	RNU6-1280P	-5.67	1.86e-08	2.58e-06	-0.24	-0.17	Idiopathic pulmonary fibrosis;	chr15:85674319	chr15:85651522~85651628:-
BRCA	cis	rs7308116	0.51	rs4356284	ENSG00000274395.1	RP11-554D14.8	-5.67	1.86e-08	2.58e-06	-0.2	-0.17	Pelvic organ prolapse (moderate/severe);	chr12:107824237	chr12:107835541~107836555:-
BRCA	cis	rs2638953	0.962	rs3825246	ENSG00000278733.1	RP11-425D17.1	-5.67	1.86e-08	2.58e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28310186	chr12:28185625~28186190:-
BRCA	cis	rs67981189	0.788	rs34093157	ENSG00000258571.1	PTTG4P	-5.67	1.86e-08	2.59e-06	-0.19	-0.17	Schizophrenia;	chr14:71101966	chr14:71085482~71085833:-
BRCA	cis	rs2179367	0.632	rs12196656	ENSG00000223701.3	RAET1E-AS1	5.67	1.86e-08	2.59e-06	0.25	0.17	Dupuytren's disease;	chr6:149383104	chr6:149884431~149919508:+
BRCA	cis	rs2179367	0.632	rs12211570	ENSG00000223701.3	RAET1E-AS1	5.67	1.86e-08	2.59e-06	0.25	0.17	Dupuytren's disease;	chr6:149383616	chr6:149884431~149919508:+
BRCA	cis	rs2179367	0.568	rs11155647	ENSG00000223701.3	RAET1E-AS1	5.67	1.86e-08	2.59e-06	0.25	0.17	Dupuytren's disease;	chr6:149384499	chr6:149884431~149919508:+
BRCA	cis	rs2015599	0.549	rs3782508	ENSG00000275476.1	RP11-996F15.4	5.67	1.86e-08	2.59e-06	0.19	0.17	Platelet count;Mean platelet volume;	chr12:29298446	chr12:29277397~29277882:-
BRCA	cis	rs516805	0.706	rs541551	ENSG00000279114.1	RP3-425C14.5	-5.67	1.86e-08	2.59e-06	-0.21	-0.17	Lymphocyte counts;	chr6:122462736	chr6:122471923~122484161:+
BRCA	cis	rs3733585	0.605	rs4697708	ENSG00000250413.1	RP11-448G15.1	5.67	1.86e-08	2.59e-06	0.23	0.17	Cleft plate (environmental tobacco smoke interaction);	chr4:10119565	chr4:10006482~10009725:+
BRCA	cis	rs4819052	0.851	rs28442024	ENSG00000184274.3	LINC00315	-5.67	1.86e-08	2.59e-06	-0.23	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45254560	chr21:45300245~45305257:-
BRCA	cis	rs4578769	0.531	rs12969559	ENSG00000265939.1	UBE2CP2	5.67	1.86e-08	2.59e-06	0.19	0.17	Eosinophil percentage of white cells;	chr18:22913702	chr18:22900486~22900995:-
BRCA	cis	rs7493	0.755	rs13228784	ENSG00000233942.1	AC004012.1	5.67	1.87e-08	2.59e-06	0.22	0.17	Yu-Zhi constitution type in type 2 diabetes;	chr7:95331513	chr7:95471835~95473998:+
BRCA	cis	rs1707322	0.752	rs11211152	ENSG00000234329.1	RP11-767N6.2	5.67	1.87e-08	2.59e-06	0.18	0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45648485	chr1:45651039~45651826:-
BRCA	cis	rs1707322	0.752	rs4607935	ENSG00000234329.1	RP11-767N6.2	5.67	1.87e-08	2.59e-06	0.18	0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45651489	chr1:45651039~45651826:-
BRCA	cis	rs1707322	0.681	rs12048866	ENSG00000234329.1	RP11-767N6.2	5.67	1.87e-08	2.59e-06	0.18	0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45651820	chr1:45651039~45651826:-
BRCA	cis	rs1707322	0.752	rs3811436	ENSG00000234329.1	RP11-767N6.2	5.67	1.87e-08	2.59e-06	0.18	0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45660208	chr1:45651039~45651826:-
BRCA	cis	rs1707322	0.752	rs12024590	ENSG00000234329.1	RP11-767N6.2	5.67	1.87e-08	2.59e-06	0.18	0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45661824	chr1:45651039~45651826:-
BRCA	cis	rs1707322	0.752	rs12027622	ENSG00000234329.1	RP11-767N6.2	5.67	1.87e-08	2.59e-06	0.18	0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45664580	chr1:45651039~45651826:-
BRCA	cis	rs1707322	0.752	rs7529699	ENSG00000234329.1	RP11-767N6.2	5.67	1.87e-08	2.59e-06	0.18	0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45668962	chr1:45651039~45651826:-
BRCA	cis	rs1707322	0.716	rs6699444	ENSG00000234329.1	RP11-767N6.2	5.67	1.87e-08	2.59e-06	0.18	0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45669448	chr1:45651039~45651826:-
BRCA	cis	rs1707322	0.752	rs10430105	ENSG00000234329.1	RP11-767N6.2	5.67	1.87e-08	2.59e-06	0.18	0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45673204	chr1:45651039~45651826:-
BRCA	cis	rs7646881	0.812	rs73017539	ENSG00000240207.5	RP11-379F4.4	-5.67	1.87e-08	2.59e-06	-0.27	-0.17	Tetralogy of Fallot;	chr3:158742954	chr3:158732263~158784070:+
BRCA	cis	rs11668609	0.938	rs28720079	ENSG00000268442.1	CTD-2027I19.2	5.67	1.87e-08	2.6e-06	0.24	0.17	Response to taxane treatment (docetaxel);	chr19:24184823	chr19:24162370~24163425:-
BRCA	cis	rs12681366	0.801	rs12682524	ENSG00000253704.1	RP11-267M23.4	5.67	1.87e-08	2.6e-06	0.2	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94472071	chr8:94553722~94569745:+
BRCA	cis	rs2098713	0.537	rs578236	ENSG00000250155.1	CTD-2353F22.1	5.67	1.87e-08	2.6e-06	0.2	0.17	Telomere length;	chr5:37538958	chr5:36666214~36725195:-
BRCA	cis	rs600231	0.706	rs10896016	ENSG00000245532.5	NEAT1	-5.67	1.87e-08	2.6e-06	-0.17	-0.17	Bone mineral density;	chr11:65568234	chr11:65422774~65445540:+
BRCA	cis	rs6570726	0.967	rs1396648	ENSG00000270638.1	RP3-466P17.1	-5.67	1.87e-08	2.6e-06	-0.19	-0.17	Lobe attachment (rater-scored or self-reported);	chr6:145464112	chr6:145735570~145737218:+
BRCA	cis	rs5758511	0.68	rs5758688	ENSG00000233903.2	Z83851.4	5.67	1.87e-08	2.6e-06	0.27	0.17	Birth weight;	chr22:42266495	chr22:42276355~42277052:+
BRCA	cis	rs4787491	0.729	rs4788213	ENSG00000273724.1	RP11-347C12.12	-5.67	1.87e-08	2.6e-06	-0.19	-0.17	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30023203	chr16:30336400~30343336:+
BRCA	cis	rs4787491	0.679	rs7204852	ENSG00000273724.1	RP11-347C12.12	-5.67	1.87e-08	2.6e-06	-0.19	-0.17	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30028857	chr16:30336400~30343336:+
BRCA	cis	rs4787491	0.729	rs12446378	ENSG00000273724.1	RP11-347C12.12	-5.67	1.87e-08	2.6e-06	-0.19	-0.17	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30031789	chr16:30336400~30343336:+
BRCA	cis	rs2638953	0.64	rs11049729	ENSG00000278733.1	RP11-425D17.1	5.67	1.87e-08	2.6e-06	0.23	0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28586694	chr12:28185625~28186190:-
BRCA	cis	rs2098713	0.535	rs4869538	ENSG00000250155.1	CTD-2353F22.1	5.67	1.87e-08	2.6e-06	0.19	0.17	Telomere length;	chr5:37624065	chr5:36666214~36725195:-
BRCA	cis	rs7520050	0.931	rs11211224	ENSG00000280836.1	AL355480.1	5.67	1.87e-08	2.6e-06	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:45918716	chr1:45581219~45581321:-
BRCA	cis	rs9545047	0.604	rs9318641	ENSG00000227354.5	RBM26-AS1	-5.67	1.88e-08	2.61e-06	-0.19	-0.17	Schizophrenia;	chr13:79426545	chr13:79406309~79424328:+
BRCA	cis	rs4713118	0.587	rs61471148	ENSG00000204709.4	LINC01556	5.67	1.88e-08	2.61e-06	0.26	0.17	Parkinson's disease;	chr6:28069254	chr6:28943877~28944537:+
BRCA	cis	rs4713118	0.662	rs149946	ENSG00000204709.4	LINC01556	-5.67	1.88e-08	2.61e-06	-0.25	-0.17	Parkinson's disease;	chr6:28002253	chr6:28943877~28944537:+
BRCA	cis	rs8113308	0.689	rs8112515	ENSG00000269483.1	AC006272.1	5.67	1.88e-08	2.61e-06	0.29	0.17	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51987997	chr19:51839924~51843324:-
BRCA	cis	rs710913	0.745	rs1180334	ENSG00000228060.1	RP11-69E11.8	5.67	1.88e-08	2.61e-06	0.17	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39555972	chr1:39565160~39573203:+
BRCA	cis	rs2337406	0.925	rs76288499	ENSG00000211972.2	IGHV3-66	5.67	1.88e-08	2.61e-06	0.17	0.17	Alzheimer's disease (late onset);	chr14:106686309	chr14:106675017~106675544:-
BRCA	cis	rs227275	0.525	rs28445579	ENSG00000251288.2	RP11-10L12.2	-5.67	1.88e-08	2.61e-06	-0.2	-0.17	Allergic disease (asthma, hay fever or eczema);	chr4:103016438	chr4:102751401~102752641:+
BRCA	cis	rs2288884	0.541	rs7508746	ENSG00000275055.1	CTC-471J1.11	-5.67	1.88e-08	2.61e-06	-0.28	-0.17	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:51990246	chr19:52049007~52049754:+
BRCA	cis	rs9545047	0.604	rs9574411	ENSG00000227354.5	RBM26-AS1	-5.67	1.88e-08	2.61e-06	-0.18	-0.17	Schizophrenia;	chr13:79354342	chr13:79406309~79424328:+
BRCA	cis	rs73193808	0.901	rs8135008	ENSG00000215533.7	LINC00189	5.67	1.88e-08	2.61e-06	0.25	0.17	Coronary artery disease;	chr21:29222780	chr21:29193480~29288205:+
BRCA	cis	rs1859596	0.691	rs10226488	ENSG00000234456.6	MAGI2-AS3	5.67	1.88e-08	2.61e-06	0.11	0.17	Reading or mathematical ability;	chr7:79459192	chr7:79452877~79471208:+
BRCA	cis	rs11159086	0.793	rs1029703	ENSG00000270000.1	RP3-449M8.9	5.67	1.88e-08	2.61e-06	0.26	0.17	Advanced glycation end-product levels;	chr14:74473899	chr14:74471930~74472360:-
BRCA	cis	rs2280018	0.526	rs2966128	ENSG00000263335.1	AF001548.5	-5.67	1.88e-08	2.61e-06	-0.22	-0.17	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15059532	chr16:15726674~15732993:+
BRCA	cis	rs7927771	0.524	rs7107922	ENSG00000280615.1	Y_RNA	5.67	1.88e-08	2.61e-06	0.2	0.17	Subjective well-being;	chr11:47647737	chr11:47614898~47614994:-
BRCA	cis	rs2749097	1	rs8294	ENSG00000244256.3	RN7SL130P	-5.67	1.88e-08	2.62e-06	-0.26	-0.17	Alcohol consumption (transferrin glycosylation);	chr1:63659697	chr1:63655743~63656047:+
BRCA	cis	rs891378	1	rs7522701	ENSG00000274245.1	RP11-357P18.2	-5.67	1.88e-08	2.62e-06	-0.23	-0.17	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207237620	chr1:207372559~207373252:+
BRCA	cis	rs78487399	0.71	rs11899863	ENSG00000234936.1	AC010883.5	5.67	1.89e-08	2.62e-06	0.29	0.17	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43391680	chr2:43229573~43233394:+
BRCA	cis	rs1552244	0.882	rs36006511	ENSG00000232901.1	CYCSP10	5.67	1.89e-08	2.62e-06	0.24	0.17	Alzheimer's disease;	chr3:10012507	chr3:10000647~10000940:-
BRCA	cis	rs71636778	0.509	rs12760759	ENSG00000260063.1	RP5-968P14.2	5.67	1.89e-08	2.62e-06	0.36	0.17	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26831853	chr1:26692132~26694131:-
BRCA	cis	rs202072	0.652	rs1223393	ENSG00000272379.1	RP1-257A7.5	-5.67	1.89e-08	2.62e-06	-0.27	-0.17	HIV-1 viral setpoint;	chr6:13265102	chr6:13290018~13290490:-
BRCA	cis	rs8031584	0.679	rs34017474	ENSG00000215302.7	CTD-3092A11.1	-5.67	1.89e-08	2.62e-06	-0.21	-0.17	Huntington's disease progression;	chr15:30938408	chr15:30470779~30507623:+
BRCA	cis	rs2638953	0.815	rs11049682	ENSG00000278733.1	RP11-425D17.1	-5.67	1.89e-08	2.62e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28509062	chr12:28185625~28186190:-
BRCA	cis	rs7221109	0.601	rs7209404	ENSG00000278834.1	RP11-458J1.1	5.67	1.89e-08	2.62e-06	0.19	0.17	Type 1 diabetes;	chr17:40668150	chr17:40648300~40649718:+
BRCA	cis	rs7221109	0.645	rs7223332	ENSG00000278834.1	RP11-458J1.1	5.67	1.89e-08	2.62e-06	0.19	0.17	Type 1 diabetes;	chr17:40668384	chr17:40648300~40649718:+
BRCA	cis	rs12439619	0.921	rs56042848	ENSG00000259429.4	UBE2Q2P2	-5.67	1.89e-08	2.62e-06	-0.19	-0.17	Intelligence (multi-trait analysis);	chr15:82235244	chr15:82355142~82420075:+
BRCA	cis	rs7572733	0.592	rs17731449	ENSG00000231621.1	AC013264.2	-5.67	1.89e-08	2.63e-06	-0.16	-0.17	Dermatomyositis;	chr2:197601116	chr2:197197991~197199273:+
BRCA	cis	rs2644899	0.75	rs2249835	ENSG00000268529.1	CYP2T3P	5.67	1.89e-08	2.63e-06	0.23	0.17	Post bronchodilator FEV1/FVC ratio;	chr19:40763861	chr19:41134722~41137308:+
BRCA	cis	rs11668609	1	rs10413344	ENSG00000268442.1	CTD-2027I19.2	5.67	1.89e-08	2.63e-06	0.25	0.17	Response to taxane treatment (docetaxel);	chr19:24186158	chr19:24162370~24163425:-
BRCA	cis	rs4763879	1	rs4763879	ENSG00000214776.8	RP11-726G1.1	5.67	1.89e-08	2.63e-06	0.2	0.17	Type 1 diabetes;	chr12:9757568	chr12:9467552~9576275:+
BRCA	cis	rs72681920	0.881	rs113289860	ENSG00000246090.5	RP11-696N14.1	-5.67	1.89e-08	2.63e-06	-0.26	-0.17	Alcohol dependence;	chr4:99260754	chr4:99088857~99301356:+
BRCA	cis	rs12817211	0.502	rs3741562	ENSG00000272368.2	RP4-605O3.4	-5.67	1.89e-08	2.63e-06	-0.17	-0.17	Colorectal or endometrial cancer;	chr12:50135953	chr12:50112197~50165618:+
BRCA	cis	rs10129255	0.957	rs11847726	ENSG00000280411.1	IGHV1-69-2	-5.67	1.9e-08	2.63e-06	-0.13	-0.17	Kawasaki disease;	chr14:106779116	chr14:106762092~106762588:-
BRCA	cis	rs2408955	0.515	rs10875742	ENSG00000240399.1	RP1-228P16.1	-5.67	1.9e-08	2.63e-06	-0.19	-0.17	Glycated hemoglobin levels;	chr12:48099591	chr12:48054813~48055591:-
BRCA	cis	rs42490	0.664	rs422559	ENSG00000251136.7	RP11-37B2.1	-5.67	1.9e-08	2.63e-06	-0.16	-0.17	Leprosy;	chr8:89809121	chr8:89609409~89757727:-
BRCA	cis	rs67981189	0.501	rs3829954	ENSG00000258571.1	PTTG4P	-5.67	1.9e-08	2.64e-06	-0.2	-0.17	Schizophrenia;	chr14:70988823	chr14:71085482~71085833:-
BRCA	cis	rs9527	0.83	rs10883790	ENSG00000213061.2	PFN1P11	5.67	1.9e-08	2.64e-06	0.25	0.17	Arsenic metabolism;	chr10:102881198	chr10:102838011~102845473:-
BRCA	cis	rs9527	0.83	rs11191440	ENSG00000213061.2	PFN1P11	5.67	1.9e-08	2.64e-06	0.25	0.17	Arsenic metabolism;	chr10:102881754	chr10:102838011~102845473:-
BRCA	cis	rs30380	0.632	rs30186	ENSG00000272109.1	CTD-2260A17.3	-5.67	1.9e-08	2.64e-06	-0.24	-0.17	Cerebrospinal fluid biomarker levels;	chr5:96788744	chr5:96804353~96806105:+
BRCA	cis	rs673078	0.66	rs11068891	ENSG00000275409.1	RP11-131L12.4	5.67	1.9e-08	2.64e-06	0.23	0.17	Glucose homeostasis traits;	chr12:118259814	chr12:118430147~118430699:+
BRCA	cis	rs9545047	0.604	rs9601217	ENSG00000227354.5	RBM26-AS1	-5.66	1.9e-08	2.64e-06	-0.18	-0.17	Schizophrenia;	chr13:79359797	chr13:79406309~79424328:+
BRCA	cis	rs42490	0.664	rs43226	ENSG00000251136.7	RP11-37B2.1	-5.66	1.9e-08	2.64e-06	-0.16	-0.17	Leprosy;	chr8:89809048	chr8:89609409~89757727:-
BRCA	cis	rs7493	1	rs2299265	ENSG00000233942.1	AC004012.1	5.66	1.9e-08	2.64e-06	0.22	0.17	Yu-Zhi constitution type in type 2 diabetes;	chr7:95419558	chr7:95471835~95473998:+
BRCA	cis	rs858239	0.712	rs200717	ENSG00000230042.1	AK3P3	-5.66	1.9e-08	2.64e-06	-0.2	-0.17	Cerebrospinal fluid biomarker levels;	chr7:23352652	chr7:23129178~23129841:+
BRCA	cis	rs7308116	0.565	rs2303481	ENSG00000274395.1	RP11-554D14.8	-5.66	1.9e-08	2.64e-06	-0.2	-0.17	Pelvic organ prolapse (moderate/severe);	chr12:107832456	chr12:107835541~107836555:-
BRCA	cis	rs7246967	0.673	rs34126042	ENSG00000198153.8	ZNF849P	-5.66	1.9e-08	2.64e-06	-0.26	-0.17	Bronchopulmonary dysplasia;	chr19:22726416	chr19:22685167~22686732:+
BRCA	cis	rs7927592	0.913	rs7925275	ENSG00000212093.1	AP000807.1	5.66	1.9e-08	2.64e-06	0.2	0.17	Total body bone mineral density;	chr11:68522965	chr11:68506083~68506166:-
BRCA	cis	rs1499614	1	rs2659913	ENSG00000228409.4	CCT6P1	5.66	1.9e-08	2.64e-06	0.24	0.17	Gout;	chr7:66692349	chr7:65751142~65763354:+
BRCA	cis	rs1499614	1	rs2659911	ENSG00000228409.4	CCT6P1	5.66	1.9e-08	2.64e-06	0.24	0.17	Gout;	chr7:66693433	chr7:65751142~65763354:+
BRCA	cis	rs1499614	1	rs2707838	ENSG00000228409.4	CCT6P1	5.66	1.9e-08	2.64e-06	0.24	0.17	Gout;	chr7:66694214	chr7:65751142~65763354:+
BRCA	cis	rs1499614	1	rs60326618	ENSG00000228409.4	CCT6P1	5.66	1.9e-08	2.64e-06	0.24	0.17	Gout;	chr7:66701371	chr7:65751142~65763354:+
BRCA	cis	rs1499614	1	rs2707830	ENSG00000228409.4	CCT6P1	5.66	1.9e-08	2.64e-06	0.24	0.17	Gout;	chr7:66702658	chr7:65751142~65763354:+
BRCA	cis	rs1499614	1	rs2707828	ENSG00000228409.4	CCT6P1	5.66	1.9e-08	2.64e-06	0.24	0.17	Gout;	chr7:66706390	chr7:65751142~65763354:+
BRCA	cis	rs1499614	0.803	rs1922723	ENSG00000228409.4	CCT6P1	5.66	1.9e-08	2.64e-06	0.24	0.17	Gout;	chr7:66710076	chr7:65751142~65763354:+
BRCA	cis	rs253959	0.545	rs2416425	ENSG00000272265.1	CTD-2287O16.4	5.66	1.9e-08	2.64e-06	0.22	0.17	Bipolar disorder and schizophrenia;	chr5:116101727	chr5:116078110~116078570:-
BRCA	cis	rs6570726	0.818	rs9399555	ENSG00000270638.1	RP3-466P17.1	5.66	1.91e-08	2.65e-06	0.2	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145556418	chr6:145735570~145737218:+
BRCA	cis	rs2673908	1	rs2075803	ENSG00000268581.1	SIGLEC18P	5.66	1.91e-08	2.65e-06	0.19	0.17	Cerebrospinal fluid biomarker levels;Granulocyte percentage of myeloid white cells;Monocyte percentage of white cells;	chr19:51125272	chr19:51119987~51122965:+
BRCA	cis	rs2303319	1	rs10490568	ENSG00000227403.1	AC009299.3	-5.66	1.91e-08	2.65e-06	-0.43	-0.17	Cognitive function;	chr2:161395910	chr2:161244739~161249050:+
BRCA	cis	rs2638953	0.853	rs3782515	ENSG00000278733.1	RP11-425D17.1	-5.66	1.91e-08	2.65e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28310511	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.962	rs11049521	ENSG00000278733.1	RP11-425D17.1	-5.66	1.91e-08	2.65e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28310976	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.962	rs10843151	ENSG00000278733.1	RP11-425D17.1	-5.66	1.91e-08	2.65e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28318386	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.962	rs10506029	ENSG00000278733.1	RP11-425D17.1	-5.66	1.91e-08	2.65e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28320302	chr12:28185625~28186190:-
BRCA	cis	rs9652601	0.622	rs3901386	ENSG00000274038.1	RP11-66H6.4	-5.66	1.91e-08	2.65e-06	-0.19	-0.17	Systemic lupus erythematosus;	chr16:11048863	chr16:11056556~11057034:+
BRCA	cis	rs12030196	0.778	rs12748496	ENSG00000230812.4	LINC01358	5.66	1.91e-08	2.65e-06	0.18	0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr1:59020879	chr1:59020387~59044614:+
BRCA	cis	rs2638953	0.853	rs3898068	ENSG00000278733.1	RP11-425D17.1	-5.66	1.91e-08	2.65e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28457084	chr12:28185625~28186190:-
BRCA	cis	rs1707322	1	rs10890353	ENSG00000281133.1	AL355480.3	-5.66	1.91e-08	2.65e-06	-0.22	-0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45832711	chr1:45580892~45580996:-
BRCA	cis	rs673078	0.607	rs2784	ENSG00000275409.1	RP11-131L12.4	-5.66	1.91e-08	2.66e-06	-0.28	-0.17	Glucose homeostasis traits;	chr12:118311745	chr12:118430147~118430699:+
BRCA	cis	rs2243480	1	rs383402	ENSG00000230295.1	RP11-458F8.2	5.66	1.91e-08	2.66e-06	0.22	0.17	Diabetic kidney disease;	chr7:66121666	chr7:66880708~66882981:+
BRCA	cis	rs853679	0.607	rs34166054	ENSG00000204709.4	LINC01556	5.66	1.92e-08	2.66e-06	0.47	0.17	Depression;	chr6:28098023	chr6:28943877~28944537:+
BRCA	cis	rs853679	0.607	rs13203816	ENSG00000204709.4	LINC01556	5.66	1.92e-08	2.66e-06	0.47	0.17	Depression;	chr6:28111820	chr6:28943877~28944537:+
BRCA	cis	rs853679	0.556	rs34588114	ENSG00000204709.4	LINC01556	5.66	1.92e-08	2.66e-06	0.47	0.17	Depression;	chr6:28112850	chr6:28943877~28944537:+
BRCA	cis	rs853679	0.607	rs68188794	ENSG00000204709.4	LINC01556	5.66	1.92e-08	2.66e-06	0.47	0.17	Depression;	chr6:28112999	chr6:28943877~28944537:+
BRCA	cis	rs853679	0.546	rs34371502	ENSG00000204709.4	LINC01556	5.66	1.92e-08	2.66e-06	0.47	0.17	Depression;	chr6:28113980	chr6:28943877~28944537:+
BRCA	cis	rs853679	0.607	rs66886492	ENSG00000204709.4	LINC01556	5.66	1.92e-08	2.66e-06	0.47	0.17	Depression;	chr6:28121953	chr6:28943877~28944537:+
BRCA	cis	rs853679	0.607	rs35345226	ENSG00000204709.4	LINC01556	5.66	1.92e-08	2.66e-06	0.47	0.17	Depression;	chr6:28123802	chr6:28943877~28944537:+
BRCA	cis	rs559928	0.606	rs60394481	ENSG00000236935.1	AP003774.1	5.66	1.92e-08	2.66e-06	0.24	0.17	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64141563	chr11:64325050~64329504:-
BRCA	cis	rs4699052	0.963	rs56144793	ENSG00000248740.4	RP11-328K4.1	5.66	1.92e-08	2.66e-06	0.2	0.17	Testicular germ cell tumor;	chr4:103229496	chr4:103256159~103453658:+
BRCA	cis	rs227275	0.554	rs223333	ENSG00000251288.2	RP11-10L12.2	-5.66	1.92e-08	2.66e-06	-0.2	-0.17	Allergic disease (asthma, hay fever or eczema);	chr4:102868653	chr4:102751401~102752641:+
BRCA	cis	rs1598856	0.873	rs230510	ENSG00000246560.2	RP11-10L12.4	-5.66	1.92e-08	2.66e-06	-0.19	-0.17	Primary biliary cholangitis;	chr4:102555009	chr4:102828055~102844075:+
BRCA	cis	rs1552244	1	rs68067759	ENSG00000180385.7	EMC3-AS1	5.66	1.92e-08	2.66e-06	0.22	0.17	Alzheimer's disease;	chr3:10108851	chr3:9986893~10006990:+
BRCA	cis	rs2058059	0.636	rs2960948	ENSG00000225648.4	SBDSP1	-5.66	1.92e-08	2.67e-06	-0.28	-0.17	Subcutaneous adipose tissue;	chr7:72685439	chr7:72829425~72836701:+
BRCA	cis	rs2638953	0.962	rs11049550	ENSG00000278733.1	RP11-425D17.1	-5.66	1.92e-08	2.67e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28358591	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.962	rs11049552	ENSG00000278733.1	RP11-425D17.1	-5.66	1.92e-08	2.67e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28361466	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.962	rs11049553	ENSG00000278733.1	RP11-425D17.1	-5.66	1.92e-08	2.67e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28361611	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.962	rs11049554	ENSG00000278733.1	RP11-425D17.1	-5.66	1.92e-08	2.67e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28362819	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.962	rs12371222	ENSG00000278733.1	RP11-425D17.1	-5.66	1.92e-08	2.67e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28363245	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.962	rs11049555	ENSG00000278733.1	RP11-425D17.1	-5.66	1.92e-08	2.67e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28364919	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.962	rs11049556	ENSG00000278733.1	RP11-425D17.1	-5.66	1.92e-08	2.67e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28365626	chr12:28185625~28186190:-
BRCA	cis	rs4699052	0.963	rs11097801	ENSG00000248740.4	RP11-328K4.1	5.66	1.92e-08	2.67e-06	0.2	0.17	Testicular germ cell tumor;	chr4:103229166	chr4:103256159~103453658:+
BRCA	cis	rs7520050	0.931	rs35743647	ENSG00000280836.1	AL355480.1	5.66	1.93e-08	2.67e-06	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:45941580	chr1:45581219~45581321:-
BRCA	cis	rs9467773	0.935	rs1884947	ENSG00000124549.13	BTN2A3P	5.66	1.93e-08	2.67e-06	0.18	0.17	Intelligence (multi-trait analysis);	chr6:26553045	chr6:26421391~26432383:+
BRCA	cis	rs853679	0.607	rs35749575	ENSG00000204709.4	LINC01556	5.66	1.93e-08	2.67e-06	0.47	0.17	Depression;	chr6:28147040	chr6:28943877~28944537:+
BRCA	cis	rs6163	0.508	rs11191381	ENSG00000213061.2	PFN1P11	5.66	1.93e-08	2.67e-06	0.25	0.17	Waist circumference;Hip circumference;	chr10:102733687	chr10:102838011~102845473:-
BRCA	cis	rs2638953	0.962	rs11049514	ENSG00000278733.1	RP11-425D17.1	-5.66	1.93e-08	2.67e-06	-0.24	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28299461	chr12:28185625~28186190:-
BRCA	cis	rs6570726	0.791	rs6902404	ENSG00000270638.1	RP3-466P17.1	5.66	1.93e-08	2.67e-06	0.2	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145584118	chr6:145735570~145737218:+
BRCA	cis	rs875971	0.545	rs316306	ENSG00000228409.4	CCT6P1	5.66	1.93e-08	2.67e-06	0.17	0.17	Aortic root size;	chr7:66153687	chr7:65751142~65763354:+
BRCA	cis	rs61160187	0.604	rs7704338	ENSG00000272308.1	RP11-231G3.1	-5.66	1.93e-08	2.67e-06	-0.19	-0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:60690328	chr5:60866457~60866935:-
BRCA	cis	rs34286592	1	rs3815824	ENSG00000214725.6	CDIPT-AS1	-5.66	1.93e-08	2.67e-06	-0.29	-0.17	Multiple sclerosis;	chr16:29841539	chr16:29863593~29868053:+
BRCA	cis	rs853679	0.546	rs483143	ENSG00000220721.1	OR1F12	5.66	1.93e-08	2.68e-06	0.32	0.17	Depression;	chr6:27878966	chr6:28073316~28074233:+
BRCA	cis	rs17597773	0.674	rs1494371	ENSG00000272823.1	RP11-295M18.6	-5.66	1.93e-08	2.68e-06	-0.2	-0.17	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220841256	chr1:220828676~220829211:-
BRCA	cis	rs4787491	0.765	rs8054507	ENSG00000273724.1	RP11-347C12.12	-5.66	1.93e-08	2.68e-06	-0.19	-0.17	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30034721	chr16:30336400~30343336:+
BRCA	cis	rs7927592	0.913	rs12284933	ENSG00000212093.1	AP000807.1	5.66	1.93e-08	2.68e-06	0.2	0.17	Total body bone mineral density;	chr11:68552021	chr11:68506083~68506166:-
BRCA	cis	rs3020264	0.627	rs2912064	ENSG00000271743.1	CTD-2541M15.3	5.66	1.93e-08	2.68e-06	0.21	0.17	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 24 weeks);	chr8:6631189	chr8:6615604~6617198:-
BRCA	cis	rs55702914	0.628	rs788016	ENSG00000231621.1	AC013264.2	5.66	1.93e-08	2.68e-06	0.16	0.17	Major depression and alcohol dependence;	chr2:197487569	chr2:197197991~197199273:+
BRCA	cis	rs7618501	0.521	rs55692411	ENSG00000228008.1	CTD-2330K9.3	5.66	1.93e-08	2.68e-06	0.17	0.17	Intelligence (multi-trait analysis);	chr3:49873722	chr3:49903845~49916937:+
BRCA	cis	rs13126694	0.744	rs4521391	ENSG00000251429.1	RP11-597D13.7	5.66	1.93e-08	2.68e-06	0.17	0.17	Blood osmolality (transformed sodium);	chr4:158017310	chr4:158270378~158278676:+
BRCA	cis	rs7520050	0.966	rs12405451	ENSG00000280836.1	AL355480.1	5.66	1.93e-08	2.68e-06	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:45918654	chr1:45581219~45581321:-
BRCA	cis	rs9876781	1	rs9838618	ENSG00000229759.1	MRPS18AP1	5.66	1.94e-08	2.68e-06	0.19	0.17	Longevity;	chr3:48445949	chr3:48256350~48256938:-
BRCA	cis	rs1552244	0.882	rs6443279	ENSG00000232901.1	CYCSP10	5.66	1.94e-08	2.68e-06	0.24	0.17	Alzheimer's disease;	chr3:10011915	chr3:10000647~10000940:-
BRCA	cis	rs6940638	0.662	rs6915678	ENSG00000216901.1	AL022393.7	5.66	1.94e-08	2.68e-06	0.21	0.17	Intelligence (multi-trait analysis);	chr6:27268087	chr6:28176188~28176674:+
BRCA	cis	rs2098713	0.537	rs565691	ENSG00000250155.1	CTD-2353F22.1	5.66	1.94e-08	2.68e-06	0.2	0.17	Telomere length;	chr5:37544232	chr5:36666214~36725195:-
BRCA	cis	rs1707322	0.752	rs28719889	ENSG00000234329.1	RP11-767N6.2	5.66	1.94e-08	2.68e-06	0.18	0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45736611	chr1:45651039~45651826:-
BRCA	cis	rs7044106	0.791	rs10984998	ENSG00000238181.2	AHCYP2	-5.66	1.94e-08	2.69e-06	-0.22	-0.17	Hip circumference adjusted for BMI;	chr9:120719238	chr9:120720673~120721972:+
BRCA	cis	rs950776	0.518	rs55690619	ENSG00000279373.1	RP11-650L12.4	-5.66	1.94e-08	2.69e-06	-0.21	-0.17	Sudden cardiac arrest;	chr15:78541270	chr15:78537681~78538946:+
BRCA	cis	rs2834188	0.924	rs2834177	ENSG00000272659.1	AP000295.10	-5.66	1.94e-08	2.69e-06	-0.26	-0.17	Narcolepsy;	chr21:33304501	chr21:33309491~33310181:+
BRCA	cis	rs2898681	0.581	rs10003908	ENSG00000248375.1	RP11-177B4.1	-5.66	1.94e-08	2.69e-06	-0.24	-0.17	Optic nerve measurement (cup area);	chr4:52814922	chr4:52720081~52720831:-
BRCA	cis	rs801193	0.569	rs11761542	ENSG00000224316.1	RP11-479O9.2	5.66	1.94e-08	2.69e-06	0.18	0.17	Aortic root size;	chr7:66753209	chr7:65773620~65802067:+
BRCA	cis	rs2638953	0.64	rs1511549	ENSG00000278733.1	RP11-425D17.1	-5.66	1.94e-08	2.69e-06	-0.21	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28578968	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.64	rs11049718	ENSG00000278733.1	RP11-425D17.1	-5.66	1.94e-08	2.69e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28565739	chr12:28185625~28186190:-
BRCA	cis	rs2098713	0.537	rs517694	ENSG00000250155.1	CTD-2353F22.1	5.66	1.94e-08	2.69e-06	0.2	0.17	Telomere length;	chr5:37536951	chr5:36666214~36725195:-
BRCA	cis	rs6928977	0.675	rs6908428	ENSG00000231028.7	LINC00271	-5.66	1.94e-08	2.69e-06	-0.18	-0.17	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135472568	chr6:135497801~135716055:+
BRCA	cis	rs6088580	0.524	rs6088567	ENSG00000269202.1	RP4-614O4.12	5.66	1.94e-08	2.69e-06	0.18	0.17	Glomerular filtration rate (creatinine);	chr20:34676068	chr20:35201747~35203288:-
BRCA	cis	rs6088580	0.524	rs6088568	ENSG00000269202.1	RP4-614O4.12	5.66	1.94e-08	2.69e-06	0.18	0.17	Glomerular filtration rate (creatinine);	chr20:34678167	chr20:35201747~35203288:-
BRCA	cis	rs6088580	0.524	rs1321306	ENSG00000269202.1	RP4-614O4.12	5.66	1.94e-08	2.69e-06	0.18	0.17	Glomerular filtration rate (creatinine);	chr20:34678575	chr20:35201747~35203288:-
BRCA	cis	rs9287719	0.649	rs12617968	ENSG00000243819.4	RN7SL832P	5.66	1.94e-08	2.69e-06	0.17	0.17	Prostate cancer;	chr2:10581819	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.614	rs12329184	ENSG00000243819.4	RN7SL832P	5.66	1.94e-08	2.69e-06	0.17	0.17	Prostate cancer;	chr2:10582638	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.614	rs10929681	ENSG00000243819.4	RN7SL832P	5.66	1.94e-08	2.69e-06	0.17	0.17	Prostate cancer;	chr2:10583157	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.614	rs6711473	ENSG00000243819.4	RN7SL832P	5.66	1.94e-08	2.69e-06	0.17	0.17	Prostate cancer;	chr2:10583248	chr2:10690344~10692099:+
BRCA	cis	rs2015599	0.516	rs10450679	ENSG00000275476.1	RP11-996F15.4	5.66	1.95e-08	2.7e-06	0.19	0.17	Platelet count;Mean platelet volume;	chr12:29298823	chr12:29277397~29277882:-
BRCA	cis	rs62025270	0.632	rs3169119	ENSG00000259295.5	CSPG4P12	-5.66	1.95e-08	2.7e-06	-0.27	-0.17	Idiopathic pulmonary fibrosis;	chr15:85748038	chr15:85191438~85213905:+
BRCA	cis	rs2243480	1	rs3885839	ENSG00000232559.3	GS1-124K5.12	5.66	1.95e-08	2.7e-06	0.33	0.17	Diabetic kidney disease;	chr7:65825416	chr7:66554588~66576923:-
BRCA	cis	rs5015933	0.703	rs7037034	ENSG00000232630.1	PRPS1P2	-5.66	1.95e-08	2.7e-06	-0.17	-0.17	Body mass index;	chr9:125382358	chr9:125150653~125151589:+
BRCA	cis	rs7651446	0.649	rs62275649	ENSG00000240875.4	LINC00886	-5.66	1.95e-08	2.7e-06	-0.38	-0.17	Ovarian cancer;Epithelial ovarian cancer;	chr3:156644009	chr3:156747346~156817062:-
BRCA	cis	rs8114671	0.552	rs2024635	ENSG00000269202.1	RP4-614O4.12	-5.66	1.95e-08	2.7e-06	-0.18	-0.17	Height;	chr20:34834811	chr20:35201747~35203288:-
BRCA	cis	rs2562456	0.516	rs56072098	ENSG00000268081.1	RP11-678G14.2	-5.66	1.95e-08	2.7e-06	-0.26	-0.17	Pain;	chr19:21469158	chr19:21554640~21569237:-
BRCA	cis	rs67981189	0.57	rs67188216	ENSG00000258571.1	PTTG4P	-5.66	1.95e-08	2.71e-06	-0.2	-0.17	Schizophrenia;	chr14:71042607	chr14:71085482~71085833:-
BRCA	cis	rs8002861	0.87	rs4942251	ENSG00000274001.1	RP11-5G9.5	5.66	1.95e-08	2.71e-06	0.19	0.17	Leprosy;	chr13:43865912	chr13:43877715~43878163:-
BRCA	cis	rs9652601	0.748	rs8064154	ENSG00000274038.1	RP11-66H6.4	-5.66	1.95e-08	2.71e-06	-0.2	-0.17	Systemic lupus erythematosus;	chr16:11125562	chr16:11056556~11057034:+
BRCA	cis	rs792448	0.527	rs11119887	ENSG00000229983.1	RP11-15I11.2	5.66	1.95e-08	2.71e-06	0.2	0.17	White blood cell count (basophil);	chr1:212234220	chr1:212168207~212190259:+
BRCA	cis	rs395157	0.591	rs357286	ENSG00000249911.1	LINC01265	5.66	1.95e-08	2.71e-06	0.2	0.17	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr5:38837759	chr5:38710367~38720273:-
BRCA	cis	rs2638953	0.886	rs11049594	ENSG00000278733.1	RP11-425D17.1	5.66	1.96e-08	2.71e-06	0.23	0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28430368	chr12:28185625~28186190:-
BRCA	cis	rs7809950	0.678	rs3801966	ENSG00000238832.1	snoU109	-5.66	1.96e-08	2.71e-06	-0.26	-0.17	Coronary artery disease;	chr7:107184135	chr7:107603363~107603507:+
BRCA	cis	rs10761482	0.544	rs1938544	ENSG00000254271.1	RP11-131N11.4	5.66	1.96e-08	2.71e-06	0.23	0.17	Schizophrenia;	chr10:60524901	chr10:60734342~60741828:+
BRCA	cis	rs10761482	0.5	rs1938543	ENSG00000254271.1	RP11-131N11.4	5.66	1.96e-08	2.71e-06	0.23	0.17	Schizophrenia;	chr10:60524902	chr10:60734342~60741828:+
BRCA	cis	rs6088813	0.885	rs6142353	ENSG00000126005.14	MMP24-AS1	5.66	1.96e-08	2.71e-06	0.2	0.17	Height;	chr20:35354882	chr20:35216462~35278131:-
BRCA	cis	rs6088813	1	rs735531	ENSG00000126005.14	MMP24-AS1	5.66	1.96e-08	2.71e-06	0.2	0.17	Height;	chr20:35359927	chr20:35216462~35278131:-
BRCA	cis	rs2832191	0.935	rs67287920	ENSG00000215533.7	LINC00189	5.66	1.96e-08	2.71e-06	0.19	0.17	Dental caries;	chr21:29151198	chr21:29193480~29288205:+
BRCA	cis	rs2288884	1	rs2043298	ENSG00000275055.1	CTC-471J1.11	5.66	1.96e-08	2.71e-06	0.25	0.17	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52069814	chr19:52049007~52049754:+
BRCA	cis	rs10129255	0.5	rs2105991	ENSG00000224373.3	IGHV4-59	5.66	1.96e-08	2.71e-06	0.1	0.17	Kawasaki disease;	chr14:106682022	chr14:106627249~106627825:-
BRCA	cis	rs17711722	0.528	rs73138179	ENSG00000182722.5	SEPHS1P1	-5.66	1.96e-08	2.71e-06	-0.23	-0.17	Calcium levels;	chr7:65829495	chr7:64852397~64853354:-
BRCA	cis	rs13113518	0.507	rs11943456	ENSG00000249700.7	SRD5A3-AS1	5.66	1.96e-08	2.72e-06	0.22	0.17	Height;	chr4:55410167	chr4:55363971~55395847:-
BRCA	cis	rs2115536	0.692	rs6495451	ENSG00000278600.1	RP11-81A1.6	-5.66	1.96e-08	2.72e-06	-0.15	-0.17	Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Eosinophil counts;Neutrophil percentage of granulocytes;	chr15:79871711	chr15:79920195~79922455:-
BRCA	cis	rs2638953	0.64	rs1511548	ENSG00000278733.1	RP11-425D17.1	-5.66	1.96e-08	2.72e-06	-0.21	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28579057	chr12:28185625~28186190:-
BRCA	cis	rs61160187	0.698	rs11955398	ENSG00000215032.2	GNL3LP1	5.66	1.97e-08	2.72e-06	0.21	0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:60685258	chr5:60891935~60893577:-
BRCA	cis	rs10740039	0.516	rs2393675	ENSG00000254271.1	RP11-131N11.4	5.66	1.97e-08	2.72e-06	0.23	0.17	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60590990	chr10:60734342~60741828:+
BRCA	cis	rs7308116	0.51	rs4592471	ENSG00000274395.1	RP11-554D14.8	-5.66	1.97e-08	2.73e-06	-0.2	-0.17	Pelvic organ prolapse (moderate/severe);	chr12:107824127	chr12:107835541~107836555:-
BRCA	cis	rs4907240	0.694	rs11164095	ENSG00000237510.6	AC008268.2	-5.66	1.97e-08	2.73e-06	-0.24	-0.17	Event-related brain oscillations;	chr2:96489471	chr2:95789654~95800166:+
BRCA	cis	rs4604234	0.522	rs73482011	ENSG00000272129.1	RP11-250B2.6	-5.66	1.97e-08	2.73e-06	-0.44	-0.17	Cancer;	chr6:80210306	chr6:80355424~80356859:+
BRCA	cis	rs7923837	0.683	rs61875362	ENSG00000236493.2	EIF2S2P3	5.66	1.97e-08	2.73e-06	0.24	0.17	Multiple sclerosis;Body mass index;	chr10:92448640	chr10:92668745~92669743:-
BRCA	cis	rs7208859	0.623	rs122898	ENSG00000280069.1	CTD-2349P21.3	5.66	1.97e-08	2.73e-06	0.25	0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30578236	chr17:30738182~30740275:+
BRCA	cis	rs30380	0.553	rs152280	ENSG00000272109.1	CTD-2260A17.3	-5.66	1.97e-08	2.73e-06	-0.25	-0.17	Cerebrospinal fluid biomarker levels;	chr5:96826239	chr5:96804353~96806105:+
BRCA	cis	rs2243480	1	rs465359	ENSG00000164669.11	INTS4P1	5.66	1.97e-08	2.73e-06	0.34	0.17	Diabetic kidney disease;	chr7:66093177	chr7:65141225~65234216:+
BRCA	cis	rs2243480	1	rs462853	ENSG00000164669.11	INTS4P1	5.66	1.97e-08	2.73e-06	0.34	0.17	Diabetic kidney disease;	chr7:66093180	chr7:65141225~65234216:+
BRCA	cis	rs2243480	1	rs160644	ENSG00000164669.11	INTS4P1	5.66	1.97e-08	2.73e-06	0.34	0.17	Diabetic kidney disease;	chr7:66093199	chr7:65141225~65234216:+
BRCA	cis	rs2243480	1	rs160642	ENSG00000164669.11	INTS4P1	5.66	1.97e-08	2.73e-06	0.34	0.17	Diabetic kidney disease;	chr7:66093386	chr7:65141225~65234216:+
BRCA	cis	rs2243480	0.614	rs34032527	ENSG00000164669.11	INTS4P1	5.66	1.97e-08	2.73e-06	0.34	0.17	Diabetic kidney disease;	chr7:66100154	chr7:65141225~65234216:+
BRCA	cis	rs9402743	0.671	rs2143681	ENSG00000231028.7	LINC00271	-5.66	1.97e-08	2.73e-06	-0.18	-0.17	Systemic lupus erythematosus;	chr6:135611867	chr6:135497801~135716055:+
BRCA	cis	rs7927592	0.913	rs59056571	ENSG00000212093.1	AP000807.1	5.66	1.97e-08	2.73e-06	0.2	0.17	Total body bone mineral density;	chr11:68505505	chr11:68506083~68506166:-
BRCA	cis	rs873549	1	rs873549	ENSG00000232679.1	RP11-400N13.3	5.66	1.98e-08	2.74e-06	0.19	0.17	Keloid;	chr1:222098425	chr1:222041705~222064763:-
BRCA	cis	rs61160187	0.698	rs72755157	ENSG00000215032.2	GNL3LP1	5.66	1.98e-08	2.74e-06	0.21	0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:60651559	chr5:60891935~60893577:-
BRCA	cis	rs4713118	0.615	rs9348772	ENSG00000216901.1	AL022393.7	5.66	1.98e-08	2.74e-06	0.21	0.17	Parkinson's disease;	chr6:27688311	chr6:28176188~28176674:+
BRCA	cis	rs11123406	0.723	rs60665449	ENSG00000230499.1	AC108463.1	5.66	1.98e-08	2.74e-06	0.22	0.17	Type 2 diabetes;	chr2:111202110	chr2:111195963~111206494:+
BRCA	cis	rs2933343	0.679	rs1091938	ENSG00000261159.1	RP11-723O4.9	5.66	1.98e-08	2.75e-06	0.18	0.17	IgG glycosylation;	chr3:128918182	chr3:128859716~128860526:-
BRCA	cis	rs7487075	0.558	rs3847985	ENSG00000257261.4	RP11-96H19.1	5.66	1.99e-08	2.75e-06	0.18	0.17	Itch intensity from mosquito bite;	chr12:46261504	chr12:46383679~46876159:+
BRCA	cis	rs1707322	1	rs4298677	ENSG00000281133.1	AL355480.3	-5.66	1.99e-08	2.75e-06	-0.22	-0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45840947	chr1:45580892~45580996:-
BRCA	cis	rs2243480	1	rs73142166	ENSG00000232559.3	GS1-124K5.12	5.66	1.99e-08	2.75e-06	0.33	0.17	Diabetic kidney disease;	chr7:65910845	chr7:66554588~66576923:-
BRCA	cis	rs4650994	0.507	rs12141152	ENSG00000273384.1	RP5-1098D14.1	5.66	1.99e-08	2.76e-06	0.22	0.17	HDL cholesterol;HDL cholesterol levels;	chr1:178545030	chr1:178651706~178652282:+
BRCA	cis	rs7923609	0.905	rs10740129	ENSG00000232075.1	MRPL35P2	-5.66	1.99e-08	2.76e-06	-0.21	-0.17	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63491048	chr10:63634317~63634827:-
BRCA	cis	rs2836950	0.501	rs62223052	ENSG00000238141.2	BRWD1-AS1	-5.66	1.99e-08	2.76e-06	-0.2	-0.17	Menarche (age at onset);	chr21:39336776	chr21:39315707~39323218:+
BRCA	cis	rs4415084	1	rs12522626	ENSG00000251141.4	RP11-53O19.1	5.66	2e-08	2.76e-06	0.16	0.17	Breast cancer;	chr5:44685596	chr5:44744900~44808777:-
BRCA	cis	rs1697139	1	rs1705397	ENSG00000249364.4	RP11-434D9.1	-5.66	2e-08	2.76e-06	-0.21	-0.17	Breast cancer;	chr5:67215234	chr5:67379378~67805238:+
BRCA	cis	rs2998286	0.774	rs2790442	ENSG00000254635.4	WAC-AS1	-5.66	2e-08	2.76e-06	-0.28	-0.17	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28539597	chr10:28522652~28532743:-
BRCA	cis	rs67981189	0.529	rs8014273	ENSG00000258571.1	PTTG4P	-5.66	2e-08	2.76e-06	-0.2	-0.17	Schizophrenia;	chr14:71043113	chr14:71085482~71085833:-
BRCA	cis	rs73607972	0.597	rs1111487	ENSG00000275191.1	RP11-36I17.2	5.66	2e-08	2.77e-06	0.24	0.17	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53528217	chr16:53628256~53628816:-
BRCA	cis	rs910316	0.967	rs4384542	ENSG00000279594.1	RP11-950C14.10	-5.66	2e-08	2.77e-06	-0.19	-0.17	Height;	chr14:75191310	chr14:75011269~75012851:-
BRCA	cis	rs6479891	1	rs4466712	ENSG00000232075.1	MRPL35P2	5.66	2e-08	2.77e-06	0.31	0.17	Arthritis (juvenile idiopathic);	chr10:63173508	chr10:63634317~63634827:-
BRCA	cis	rs853679	0.769	rs7752608	ENSG00000220721.1	OR1F12	5.66	2e-08	2.77e-06	0.33	0.17	Depression;	chr6:28333418	chr6:28073316~28074233:+
BRCA	cis	rs10129255	0.957	rs12590735	ENSG00000280411.1	IGHV1-69-2	-5.66	2e-08	2.77e-06	-0.13	-0.17	Kawasaki disease;	chr14:106779660	chr14:106762092~106762588:-
BRCA	cis	rs4218	0.681	rs58335303	ENSG00000277144.1	RP11-59H7.4	-5.66	2e-08	2.77e-06	-0.22	-0.17	Social communication problems;	chr15:59073206	chr15:59115547~59116089:-
BRCA	cis	rs4950322	0.515	rs72691016	ENSG00000244371.2	PFN1P8	-5.66	2e-08	2.77e-06	-0.23	-0.17	Protein quantitative trait loci;	chr1:147245375	chr1:146957117~146957659:-
BRCA	cis	rs2179367	0.632	rs12197598	ENSG00000223701.3	RAET1E-AS1	5.66	2e-08	2.77e-06	0.25	0.17	Dupuytren's disease;	chr6:149385418	chr6:149884431~149919508:+
BRCA	cis	rs4819052	0.851	rs2838845	ENSG00000184274.3	LINC00315	-5.66	2.01e-08	2.77e-06	-0.23	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250897	chr21:45300245~45305257:-
BRCA	cis	rs12468226	0.873	rs79071680	ENSG00000226261.1	AC064836.3	5.66	2.01e-08	2.77e-06	0.31	0.17	Urate levels;	chr2:202191520	chr2:202336024~202336727:-
BRCA	cis	rs12468226	0.873	rs79860867	ENSG00000226261.1	AC064836.3	5.66	2.01e-08	2.77e-06	0.31	0.17	Urate levels;	chr2:202192397	chr2:202336024~202336727:-
BRCA	cis	rs227275	0.527	rs223338	ENSG00000251288.2	RP11-10L12.2	-5.66	2.01e-08	2.78e-06	-0.21	-0.17	Allergic disease (asthma, hay fever or eczema);	chr4:102864959	chr4:102751401~102752641:+
BRCA	cis	rs301901	0.507	rs12516086	ENSG00000250155.1	CTD-2353F22.1	-5.66	2.01e-08	2.78e-06	-0.2	-0.17	Height;	chr5:37473085	chr5:36666214~36725195:-
BRCA	cis	rs6570726	0.902	rs9390326	ENSG00000270638.1	RP3-466P17.1	-5.66	2.01e-08	2.78e-06	-0.19	-0.17	Lobe attachment (rater-scored or self-reported);	chr6:145470086	chr6:145735570~145737218:+
BRCA	cis	rs10029851	1	rs10029851	ENSG00000234492.4	RPL34-AS1	5.66	2.01e-08	2.78e-06	0.24	0.17	Amyotrophic lateral sclerosis (sporadic);	chr4:108706869	chr4:108538190~108620460:-
BRCA	cis	rs4588572	0.644	rs10061149	ENSG00000245556.2	SCAMP1-AS1	-5.66	2.01e-08	2.78e-06	-0.2	-0.17	Triglycerides;	chr5:78448377	chr5:78342365~78360507:-
BRCA	cis	rs9402743	0.635	rs9373135	ENSG00000231028.7	LINC00271	-5.66	2.01e-08	2.78e-06	-0.18	-0.17	Systemic lupus erythematosus;	chr6:135611101	chr6:135497801~135716055:+
BRCA	cis	rs9402743	0.564	rs9376113	ENSG00000231028.7	LINC00271	-5.66	2.01e-08	2.78e-06	-0.18	-0.17	Systemic lupus erythematosus;	chr6:135612254	chr6:135497801~135716055:+
BRCA	cis	rs9402743	0.671	rs6934482	ENSG00000231028.7	LINC00271	-5.66	2.01e-08	2.78e-06	-0.18	-0.17	Systemic lupus erythematosus;	chr6:135612363	chr6:135497801~135716055:+
BRCA	cis	rs9402743	0.671	rs9402724	ENSG00000231028.7	LINC00271	-5.66	2.01e-08	2.78e-06	-0.18	-0.17	Systemic lupus erythematosus;	chr6:135614046	chr6:135497801~135716055:+
BRCA	cis	rs9402743	0.564	rs2327649	ENSG00000231028.7	LINC00271	-5.66	2.01e-08	2.78e-06	-0.18	-0.17	Systemic lupus erythematosus;	chr6:135615097	chr6:135497801~135716055:+
BRCA	cis	rs2832191	0.791	rs2832199	ENSG00000215533.7	LINC00189	5.66	2.01e-08	2.78e-06	0.19	0.17	Dental caries;	chr21:29126180	chr21:29193480~29288205:+
BRCA	cis	rs9311474	0.659	rs7638808	ENSG00000243224.1	RP5-1157M23.2	5.66	2.01e-08	2.78e-06	0.18	0.17	Electroencephalogram traits;	chr3:52538040	chr3:52239258~52241097:+
BRCA	cis	rs2734839	0.507	rs2245805	ENSG00000270179.1	RP11-159N11.4	-5.66	2.01e-08	2.78e-06	-0.19	-0.17	Information processing speed;	chr11:113419977	chr11:113368478~113369117:+
BRCA	cis	rs9659323	0.67	rs17023223	ENSG00000231365.4	RP11-418J17.1	-5.65	2.01e-08	2.78e-06	-0.2	-0.17	Body mass index;	chr1:119088551	chr1:119140396~119275973:+
BRCA	cis	rs2638953	0.962	rs11049570	ENSG00000278733.1	RP11-425D17.1	-5.65	2.01e-08	2.78e-06	-0.24	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28390218	chr12:28185625~28186190:-
BRCA	cis	rs2243480	0.803	rs34804747	ENSG00000232559.3	GS1-124K5.12	5.65	2.02e-08	2.79e-06	0.32	0.17	Diabetic kidney disease;	chr7:65947955	chr7:66554588~66576923:-
BRCA	cis	rs2243480	1	rs59794892	ENSG00000232559.3	GS1-124K5.12	5.65	2.02e-08	2.79e-06	0.32	0.17	Diabetic kidney disease;	chr7:65950886	chr7:66554588~66576923:-
BRCA	cis	rs2243480	0.803	rs36004293	ENSG00000232559.3	GS1-124K5.12	5.65	2.02e-08	2.79e-06	0.32	0.17	Diabetic kidney disease;	chr7:65951525	chr7:66554588~66576923:-
BRCA	cis	rs2243480	0.803	rs35268390	ENSG00000232559.3	GS1-124K5.12	5.65	2.02e-08	2.79e-06	0.32	0.17	Diabetic kidney disease;	chr7:65951549	chr7:66554588~66576923:-
BRCA	cis	rs7131987	0.65	rs7973786	ENSG00000275476.1	RP11-996F15.4	-5.65	2.02e-08	2.79e-06	-0.2	-0.17	QT interval;	chr12:29309811	chr12:29277397~29277882:-
BRCA	cis	rs7674212	0.541	rs2720464	ENSG00000248740.4	RP11-328K4.1	5.65	2.02e-08	2.79e-06	0.2	0.17	Type 2 diabetes;	chr4:103152044	chr4:103256159~103453658:+
BRCA	cis	rs7246967	0.673	rs36029703	ENSG00000198153.8	ZNF849P	-5.65	2.02e-08	2.79e-06	-0.26	-0.17	Bronchopulmonary dysplasia;	chr19:22723386	chr19:22685167~22686732:+
BRCA	cis	rs4908768	0.501	rs7518608	ENSG00000270282.1	RP5-1115A15.2	5.65	2.02e-08	2.79e-06	0.18	0.17	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8497260	chr1:8512653~8513021:+
BRCA	cis	rs467650	0.714	rs171529	ENSG00000248489.1	CTD-2007H13.3	5.65	2.02e-08	2.79e-06	0.19	0.17	Venous thromboembolism (SNP x SNP interaction);	chr5:98593098	chr5:98929171~98995013:+
BRCA	cis	rs2153535	0.518	rs6926976	ENSG00000230939.1	RP11-314C16.1	5.65	2.02e-08	2.79e-06	0.21	0.17	Motion sickness;	chr6:8622045	chr6:8784178~8785445:+
BRCA	cis	rs7246967	0.673	rs34676724	ENSG00000198153.8	ZNF849P	-5.65	2.02e-08	2.79e-06	-0.26	-0.17	Bronchopulmonary dysplasia;	chr19:22735671	chr19:22685167~22686732:+
BRCA	cis	rs7246967	0.673	rs16999580	ENSG00000198153.8	ZNF849P	-5.65	2.02e-08	2.79e-06	-0.26	-0.17	Bronchopulmonary dysplasia;	chr19:22740685	chr19:22685167~22686732:+
BRCA	cis	rs7246967	0.673	rs55684269	ENSG00000198153.8	ZNF849P	-5.65	2.02e-08	2.79e-06	-0.26	-0.17	Bronchopulmonary dysplasia;	chr19:22741745	chr19:22685167~22686732:+
BRCA	cis	rs7246967	0.673	rs34003335	ENSG00000198153.8	ZNF849P	-5.65	2.02e-08	2.79e-06	-0.26	-0.17	Bronchopulmonary dysplasia;	chr19:22742800	chr19:22685167~22686732:+
BRCA	cis	rs7246967	0.673	rs12974988	ENSG00000198153.8	ZNF849P	-5.65	2.02e-08	2.79e-06	-0.26	-0.17	Bronchopulmonary dysplasia;	chr19:22743163	chr19:22685167~22686732:+
BRCA	cis	rs7246967	0.673	rs2194112	ENSG00000198153.8	ZNF849P	-5.65	2.02e-08	2.79e-06	-0.26	-0.17	Bronchopulmonary dysplasia;	chr19:22743387	chr19:22685167~22686732:+
BRCA	cis	rs7246967	0.551	rs34907478	ENSG00000198153.8	ZNF849P	-5.65	2.02e-08	2.79e-06	-0.26	-0.17	Bronchopulmonary dysplasia;	chr19:22746029	chr19:22685167~22686732:+
BRCA	cis	rs7246967	0.673	rs12985495	ENSG00000198153.8	ZNF849P	-5.65	2.02e-08	2.79e-06	-0.26	-0.17	Bronchopulmonary dysplasia;	chr19:22747576	chr19:22685167~22686732:+
BRCA	cis	rs7246967	0.673	rs8103430	ENSG00000198153.8	ZNF849P	-5.65	2.02e-08	2.79e-06	-0.26	-0.17	Bronchopulmonary dysplasia;	chr19:22748696	chr19:22685167~22686732:+
BRCA	cis	rs7246967	0.673	rs34174596	ENSG00000198153.8	ZNF849P	-5.65	2.02e-08	2.79e-06	-0.26	-0.17	Bronchopulmonary dysplasia;	chr19:22750717	chr19:22685167~22686732:+
BRCA	cis	rs7246967	0.551	rs8103204	ENSG00000198153.8	ZNF849P	-5.65	2.02e-08	2.79e-06	-0.26	-0.17	Bronchopulmonary dysplasia;	chr19:22753715	chr19:22685167~22686732:+
BRCA	cis	rs7246967	0.604	rs58653025	ENSG00000198153.8	ZNF849P	-5.65	2.02e-08	2.79e-06	-0.26	-0.17	Bronchopulmonary dysplasia;	chr19:22758815	chr19:22685167~22686732:+
BRCA	cis	rs7246967	0.611	rs16999598	ENSG00000198153.8	ZNF849P	-5.65	2.02e-08	2.79e-06	-0.26	-0.17	Bronchopulmonary dysplasia;	chr19:22760323	chr19:22685167~22686732:+
BRCA	cis	rs7246967	0.673	rs34726149	ENSG00000198153.8	ZNF849P	-5.65	2.02e-08	2.79e-06	-0.26	-0.17	Bronchopulmonary dysplasia;	chr19:22769309	chr19:22685167~22686732:+
BRCA	cis	rs7246967	0.673	rs12985825	ENSG00000198153.8	ZNF849P	-5.65	2.02e-08	2.79e-06	-0.26	-0.17	Bronchopulmonary dysplasia;	chr19:22770649	chr19:22685167~22686732:+
BRCA	cis	rs9652601	0.622	rs1985372	ENSG00000274038.1	RP11-66H6.4	-5.65	2.02e-08	2.79e-06	-0.19	-0.17	Systemic lupus erythematosus;	chr16:11020982	chr16:11056556~11057034:+
BRCA	cis	rs2243480	1	rs12698509	ENSG00000230295.1	RP11-458F8.2	-5.65	2.02e-08	2.79e-06	-0.22	-0.17	Diabetic kidney disease;	chr7:65953889	chr7:66880708~66882981:+
BRCA	cis	rs10129255	0.518	rs2006284	ENSG00000224373.3	IGHV4-59	5.65	2.02e-08	2.79e-06	0.1	0.17	Kawasaki disease;	chr14:106676185	chr14:106627249~106627825:-
BRCA	cis	rs13287066	0.74	rs4744238	ENSG00000227603.1	RP11-165J3.6	5.65	2.02e-08	2.8e-06	0.18	0.17	Intelligence (multi-trait analysis);	chr9:93401702	chr9:93435332~93437121:-
BRCA	cis	rs62025270	0.632	rs62023935	ENSG00000202081.1	RNU6-1280P	-5.65	2.02e-08	2.8e-06	-0.25	-0.17	Idiopathic pulmonary fibrosis;	chr15:85605604	chr15:85651522~85651628:-
BRCA	cis	rs55702914	0.628	rs3731570	ENSG00000231621.1	AC013264.2	-5.65	2.02e-08	2.8e-06	-0.17	-0.17	Major depression and alcohol dependence;	chr2:197453059	chr2:197197991~197199273:+
BRCA	cis	rs2153535	0.518	rs9406181	ENSG00000230939.1	RP11-314C16.1	-5.65	2.02e-08	2.8e-06	-0.2	-0.17	Motion sickness;	chr6:8569069	chr6:8784178~8785445:+
BRCA	cis	rs7615952	0.512	rs34085484	ENSG00000250012.1	RP11-124N2.1	-5.65	2.02e-08	2.8e-06	-0.24	-0.17	Blood pressure (smoking interaction);	chr3:125825343	chr3:126084220~126095349:+
BRCA	cis	rs7615952	0.608	rs35668111	ENSG00000250012.1	RP11-124N2.1	-5.65	2.02e-08	2.8e-06	-0.24	-0.17	Blood pressure (smoking interaction);	chr3:125825792	chr3:126084220~126095349:+
BRCA	cis	rs295490	0.748	rs56993164	ENSG00000272656.1	RP11-219D15.3	5.65	2.03e-08	2.8e-06	0.4	0.17	PR interval in Tripanosoma cruzi seropositivity;	chr3:139388391	chr3:139349024~139349371:-
BRCA	cis	rs2015599	0.549	rs6487802	ENSG00000275476.1	RP11-996F15.4	5.65	2.03e-08	2.8e-06	0.19	0.17	Platelet count;Mean platelet volume;	chr12:29299480	chr12:29277397~29277882:-
BRCA	cis	rs1552244	1	rs66838678	ENSG00000180385.7	EMC3-AS1	5.65	2.03e-08	2.8e-06	0.22	0.17	Alzheimer's disease;	chr3:10108666	chr3:9986893~10006990:+
BRCA	cis	rs2911132	0.564	rs7356594	ENSG00000248734.2	CTD-2260A17.1	5.65	2.03e-08	2.8e-06	0.2	0.17	Urate levels (BMI interaction);	chr5:96760485	chr5:96784777~96785999:+
BRCA	cis	rs2281636	0.929	rs7913190	ENSG00000233690.1	EBAG9P1	5.65	2.03e-08	2.8e-06	0.19	0.17	Obesity-related traits;	chr10:99738639	chr10:99697407~99697949:-
BRCA	cis	rs853679	0.55	rs1225598	ENSG00000280107.1	AL022393.9	-5.65	2.03e-08	2.8e-06	-0.25	-0.17	Depression;	chr6:28193021	chr6:28170845~28172521:+
BRCA	cis	rs8114671	0.527	rs2295352	ENSG00000269202.1	RP4-614O4.12	5.65	2.03e-08	2.8e-06	0.17	0.17	Height;	chr20:34732251	chr20:35201747~35203288:-
BRCA	cis	rs2638953	0.924	rs11049471	ENSG00000247934.4	RP11-967K21.1	-5.65	2.03e-08	2.81e-06	-0.22	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28228259	chr12:28163298~28190738:-
BRCA	cis	rs6095360	0.7	rs67623477	ENSG00000222365.1	SNORD12B	-5.65	2.03e-08	2.81e-06	-0.23	-0.17	Intelligence (multi-trait analysis);	chr20:49052640	chr20:49280319~49280409:+
BRCA	cis	rs6479891	1	rs1904295	ENSG00000232075.1	MRPL35P2	-5.65	2.03e-08	2.81e-06	-0.31	-0.17	Arthritis (juvenile idiopathic);	chr10:63223116	chr10:63634317~63634827:-
BRCA	cis	rs6479891	0.908	rs11819167	ENSG00000232075.1	MRPL35P2	5.65	2.03e-08	2.81e-06	0.31	0.17	Arthritis (juvenile idiopathic);	chr10:63216409	chr10:63634317~63634827:-
BRCA	cis	rs7927592	0.913	rs66752716	ENSG00000212093.1	AP000807.1	5.65	2.03e-08	2.81e-06	0.2	0.17	Total body bone mineral density;	chr11:68506158	chr11:68506083~68506166:-
BRCA	cis	rs7927592	0.913	rs11228262	ENSG00000212093.1	AP000807.1	5.65	2.03e-08	2.81e-06	0.2	0.17	Total body bone mineral density;	chr11:68507439	chr11:68506083~68506166:-
BRCA	cis	rs7927592	0.913	rs55883802	ENSG00000212093.1	AP000807.1	5.65	2.03e-08	2.81e-06	0.2	0.17	Total body bone mineral density;	chr11:68511361	chr11:68506083~68506166:-
BRCA	cis	rs9287719	0.649	rs12621977	ENSG00000243819.4	RN7SL832P	5.65	2.04e-08	2.81e-06	0.17	0.17	Prostate cancer;	chr2:10581805	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.614	rs12622053	ENSG00000243819.4	RN7SL832P	5.65	2.04e-08	2.81e-06	0.17	0.17	Prostate cancer;	chr2:10582014	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.624	rs10211190	ENSG00000243819.4	RN7SL832P	5.65	2.04e-08	2.81e-06	0.17	0.17	Prostate cancer;	chr2:10585302	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.649	rs10166765	ENSG00000243819.4	RN7SL832P	5.65	2.04e-08	2.81e-06	0.17	0.17	Prostate cancer;	chr2:10585547	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.649	rs6720112	ENSG00000243819.4	RN7SL832P	5.65	2.04e-08	2.81e-06	0.17	0.17	Prostate cancer;	chr2:10585593	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.649	rs6730247	ENSG00000243819.4	RN7SL832P	5.65	2.04e-08	2.81e-06	0.17	0.17	Prostate cancer;	chr2:10585762	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.649	rs6717431	ENSG00000243819.4	RN7SL832P	5.65	2.04e-08	2.81e-06	0.17	0.17	Prostate cancer;	chr2:10585920	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.6	rs10197187	ENSG00000243819.4	RN7SL832P	5.65	2.04e-08	2.81e-06	0.17	0.17	Prostate cancer;	chr2:10586513	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.624	rs10199635	ENSG00000243819.4	RN7SL832P	5.65	2.04e-08	2.81e-06	0.17	0.17	Prostate cancer;	chr2:10586514	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.624	rs10199831	ENSG00000243819.4	RN7SL832P	5.65	2.04e-08	2.81e-06	0.17	0.17	Prostate cancer;	chr2:10586737	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.624	rs10187659	ENSG00000243819.4	RN7SL832P	5.65	2.04e-08	2.81e-06	0.17	0.17	Prostate cancer;	chr2:10586834	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.649	rs10202370	ENSG00000243819.4	RN7SL832P	5.65	2.04e-08	2.81e-06	0.17	0.17	Prostate cancer;	chr2:10586917	chr2:10690344~10692099:+
BRCA	cis	rs2153535	0.518	rs9328493	ENSG00000230939.1	RP11-314C16.1	-5.65	2.04e-08	2.81e-06	-0.2	-0.17	Motion sickness;	chr6:8569066	chr6:8784178~8785445:+
BRCA	cis	rs2179367	0.632	rs10155766	ENSG00000223701.3	RAET1E-AS1	5.65	2.04e-08	2.82e-06	0.25	0.17	Dupuytren's disease;	chr6:149364577	chr6:149884431~149919508:+
BRCA	cis	rs875971	0.564	rs313804	ENSG00000164669.11	INTS4P1	-5.65	2.04e-08	2.82e-06	-0.21	-0.17	Aortic root size;	chr7:66049635	chr7:65141225~65234216:+
BRCA	cis	rs875971	0.662	rs448725	ENSG00000164669.11	INTS4P1	-5.65	2.04e-08	2.82e-06	-0.21	-0.17	Aortic root size;	chr7:66049641	chr7:65141225~65234216:+
BRCA	cis	rs4699052	0.928	rs2126473	ENSG00000248740.4	RP11-328K4.1	5.65	2.04e-08	2.82e-06	0.19	0.17	Testicular germ cell tumor;	chr4:103220376	chr4:103256159~103453658:+
BRCA	cis	rs4699052	0.963	rs6816055	ENSG00000248740.4	RP11-328K4.1	5.65	2.04e-08	2.82e-06	0.19	0.17	Testicular germ cell tumor;	chr4:103222003	chr4:103256159~103453658:+
BRCA	cis	rs2638953	0.815	rs11049709	ENSG00000278733.1	RP11-425D17.1	-5.65	2.04e-08	2.82e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28545099	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.782	rs11049710	ENSG00000278733.1	RP11-425D17.1	-5.65	2.04e-08	2.82e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28546231	chr12:28185625~28186190:-
BRCA	cis	rs8114671	0.562	rs6088622	ENSG00000269202.1	RP4-614O4.12	-5.65	2.04e-08	2.82e-06	-0.18	-0.17	Height;	chr20:34832174	chr20:35201747~35203288:-
BRCA	cis	rs2638953	0.815	rs11049708	ENSG00000278733.1	RP11-425D17.1	-5.65	2.04e-08	2.82e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28544881	chr12:28185625~28186190:-
BRCA	cis	rs13126694	0.744	rs28477319	ENSG00000248429.4	RP11-597D13.9	5.65	2.04e-08	2.82e-06	0.16	0.17	Blood osmolality (transformed sodium);	chr4:158095785	chr4:158170752~158202877:+
BRCA	cis	rs2015599	0.549	rs6487803	ENSG00000275476.1	RP11-996F15.4	5.65	2.04e-08	2.82e-06	0.19	0.17	Platelet count;Mean platelet volume;	chr12:29299760	chr12:29277397~29277882:-
BRCA	cis	rs2015599	0.549	rs7954990	ENSG00000275476.1	RP11-996F15.4	5.65	2.04e-08	2.82e-06	0.19	0.17	Platelet count;Mean platelet volume;	chr12:29299841	chr12:29277397~29277882:-
BRCA	cis	rs2243480	0.901	rs57126451	ENSG00000230295.1	RP11-458F8.2	-5.65	2.04e-08	2.82e-06	-0.22	-0.17	Diabetic kidney disease;	chr7:65951319	chr7:66880708~66882981:+
BRCA	cis	rs55702914	0.628	rs11902195	ENSG00000231621.1	AC013264.2	-5.65	2.05e-08	2.82e-06	-0.16	-0.17	Major depression and alcohol dependence;	chr2:197451646	chr2:197197991~197199273:+
BRCA	cis	rs2115630	0.967	rs10438428	ENSG00000229212.6	RP11-561C5.4	5.65	2.05e-08	2.82e-06	0.19	0.17	P wave terminal force;	chr15:84787514	chr15:85205440~85234795:-
BRCA	cis	rs9467773	0.935	rs1056668	ENSG00000124549.13	BTN2A3P	5.65	2.05e-08	2.83e-06	0.18	0.17	Intelligence (multi-trait analysis);	chr6:26510377	chr6:26421391~26432383:+
BRCA	cis	rs7044106	0.762	rs1867254	ENSG00000238181.2	AHCYP2	-5.65	2.05e-08	2.83e-06	-0.22	-0.17	Hip circumference adjusted for BMI;	chr9:120666800	chr9:120720673~120721972:+
BRCA	cis	rs7308116	0.546	rs10861813	ENSG00000274395.1	RP11-554D14.8	-5.65	2.05e-08	2.83e-06	-0.2	-0.17	Pelvic organ prolapse (moderate/severe);	chr12:107830680	chr12:107835541~107836555:-
BRCA	cis	rs7308116	0.546	rs10861814	ENSG00000274395.1	RP11-554D14.8	-5.65	2.05e-08	2.83e-06	-0.2	-0.17	Pelvic organ prolapse (moderate/severe);	chr12:107830800	chr12:107835541~107836555:-
BRCA	cis	rs7308116	0.546	rs11113529	ENSG00000274395.1	RP11-554D14.8	-5.65	2.05e-08	2.83e-06	-0.2	-0.17	Pelvic organ prolapse (moderate/severe);	chr12:107831185	chr12:107835541~107836555:-
BRCA	cis	rs7615952	0.688	rs12638224	ENSG00000171084.14	FAM86JP	5.65	2.05e-08	2.83e-06	0.27	0.17	Blood pressure (smoking interaction);	chr3:125822477	chr3:125916620~125930024:+
BRCA	cis	rs1858037	0.867	rs1039765	ENSG00000204929.10	AC074391.1	-5.65	2.05e-08	2.83e-06	-0.23	-0.17	Rheumatoid arthritis;	chr2:65387228	chr2:65436711~66084639:+
BRCA	cis	rs7577696	0.597	rs56322034	ENSG00000272716.1	RP11-563N4.1	-5.65	2.05e-08	2.84e-06	-0.21	-0.17	Inflammatory biomarkers;	chr2:32127944	chr2:32165046~32165757:-
BRCA	cis	rs7487075	0.504	rs7312682	ENSG00000257261.4	RP11-96H19.1	5.65	2.05e-08	2.84e-06	0.18	0.17	Itch intensity from mosquito bite;	chr12:46254215	chr12:46383679~46876159:+
BRCA	cis	rs7487075	0.558	rs12580460	ENSG00000257261.4	RP11-96H19.1	5.65	2.05e-08	2.84e-06	0.18	0.17	Itch intensity from mosquito bite;	chr12:46255200	chr12:46383679~46876159:+
BRCA	cis	rs61160187	0.527	rs6449500	ENSG00000272308.1	RP11-231G3.1	-5.65	2.06e-08	2.84e-06	-0.19	-0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:60788076	chr5:60866457~60866935:-
BRCA	cis	rs7246967	0.673	rs6511383	ENSG00000198153.8	ZNF849P	-5.65	2.06e-08	2.84e-06	-0.26	-0.17	Bronchopulmonary dysplasia;	chr19:22774098	chr19:22685167~22686732:+
BRCA	cis	rs7246967	0.673	rs59621958	ENSG00000198153.8	ZNF849P	-5.65	2.06e-08	2.84e-06	-0.26	-0.17	Bronchopulmonary dysplasia;	chr19:22757857	chr19:22685167~22686732:+
BRCA	cis	rs61160187	0.604	rs7719611	ENSG00000215032.2	GNL3LP1	5.65	2.06e-08	2.84e-06	0.21	0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:60692720	chr5:60891935~60893577:-
BRCA	cis	rs5758511	0.68	rs1107554	ENSG00000205702.9	CYP2D7	5.65	2.06e-08	2.84e-06	0.18	0.17	Birth weight;	chr22:42271588	chr22:42140203~42144577:-
BRCA	cis	rs7246967	0.673	rs2361260	ENSG00000198153.8	ZNF849P	5.65	2.06e-08	2.84e-06	0.26	0.17	Bronchopulmonary dysplasia;	chr19:22731342	chr19:22685167~22686732:+
BRCA	cis	rs585510	1	rs585510	ENSG00000278344.1	RP11-18C24.8	5.65	2.06e-08	2.84e-06	0.24	0.17	Reticulocyte fraction of red cells;	chr12:120562330	chr12:120500735~120501090:-
BRCA	cis	rs8114671	0.562	rs6058137	ENSG00000269202.1	RP4-614O4.12	-5.65	2.06e-08	2.84e-06	-0.18	-0.17	Height;	chr20:34887271	chr20:35201747~35203288:-
BRCA	cis	rs1707322	1	rs11211223	ENSG00000281133.1	AL355480.3	-5.65	2.06e-08	2.84e-06	-0.22	-0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45914933	chr1:45580892~45580996:-
BRCA	cis	rs9990333	0.562	rs12632706	ENSG00000231464.1	AC024937.4	5.65	2.06e-08	2.84e-06	0.22	0.17	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196088723	chr3:195996738~195998233:+
BRCA	cis	rs13118159	0.55	rs4974617	ENSG00000254094.1	AC078852.1	-5.65	2.06e-08	2.84e-06	-0.21	-0.17	Longevity;	chr4:1379870	chr4:1356581~1358075:+
BRCA	cis	rs2255336	0.702	rs7964772	ENSG00000245648.1	RP11-277P12.20	5.65	2.06e-08	2.84e-06	0.27	0.17	Blood protein levels;	chr12:10367498	chr12:10363769~10398506:+
BRCA	cis	rs62025270	0.632	rs62022915	ENSG00000202081.1	RNU6-1280P	-5.65	2.06e-08	2.85e-06	-0.26	-0.17	Idiopathic pulmonary fibrosis;	chr15:85670365	chr15:85651522~85651628:-
BRCA	cis	rs4950322	0.57	rs72691095	ENSG00000244371.2	PFN1P8	-5.65	2.06e-08	2.85e-06	-0.24	-0.17	Protein quantitative trait loci;	chr1:147298305	chr1:146957117~146957659:-
BRCA	cis	rs6095360	0.727	rs17448715	ENSG00000222365.1	SNORD12B	-5.65	2.06e-08	2.85e-06	-0.23	-0.17	Intelligence (multi-trait analysis);	chr20:49075206	chr20:49280319~49280409:+
BRCA	cis	rs42648	0.564	rs6975005	ENSG00000225498.1	AC002064.5	-5.65	2.07e-08	2.85e-06	-0.16	-0.17	Homocysteine levels;	chr7:90197414	chr7:90312496~90322592:+
BRCA	cis	rs710913	0.717	rs2243761	ENSG00000182109.6	RP11-69E11.4	-5.65	2.07e-08	2.85e-06	-0.19	-0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39585944	chr1:39522280~39546187:-
BRCA	cis	rs2243480	1	rs313824	ENSG00000164669.11	INTS4P1	5.65	2.07e-08	2.85e-06	0.34	0.17	Diabetic kidney disease;	chr7:66116220	chr7:65141225~65234216:+
BRCA	cis	rs2243480	1	rs186378	ENSG00000164669.11	INTS4P1	5.65	2.07e-08	2.85e-06	0.34	0.17	Diabetic kidney disease;	chr7:66117071	chr7:65141225~65234216:+
BRCA	cis	rs2243480	1	rs160637	ENSG00000164669.11	INTS4P1	5.65	2.07e-08	2.85e-06	0.34	0.17	Diabetic kidney disease;	chr7:66119331	chr7:65141225~65234216:+
BRCA	cis	rs7044106	0.762	rs1158553	ENSG00000238181.2	AHCYP2	-5.65	2.07e-08	2.85e-06	-0.22	-0.17	Hip circumference adjusted for BMI;	chr9:120638696	chr9:120720673~120721972:+
BRCA	cis	rs7044106	0.791	rs7036196	ENSG00000238181.2	AHCYP2	-5.65	2.07e-08	2.85e-06	-0.22	-0.17	Hip circumference adjusted for BMI;	chr9:120717179	chr9:120720673~120721972:+
BRCA	cis	rs673078	0.66	rs10507286	ENSG00000275409.1	RP11-131L12.4	-5.65	2.07e-08	2.85e-06	-0.26	-0.17	Glucose homeostasis traits;	chr12:118197101	chr12:118430147~118430699:+
BRCA	cis	rs7927592	0.871	rs113020558	ENSG00000212093.1	AP000807.1	5.65	2.07e-08	2.86e-06	0.2	0.17	Total body bone mineral density;	chr11:68529364	chr11:68506083~68506166:-
BRCA	cis	rs11159086	0.793	rs12433382	ENSG00000270000.1	RP3-449M8.9	5.65	2.07e-08	2.86e-06	0.26	0.17	Advanced glycation end-product levels;	chr14:74482940	chr14:74471930~74472360:-
BRCA	cis	rs2014572	0.733	rs1019071	ENSG00000268379.1	CTC-360J11.4	5.65	2.07e-08	2.86e-06	0.21	0.17	Hyperactive-impulsive symptoms;	chr19:57248848	chr19:57175233~57177921:+
BRCA	cis	rs4787491	0.679	rs12933575	ENSG00000273724.1	RP11-347C12.12	-5.65	2.07e-08	2.86e-06	-0.19	-0.17	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30011243	chr16:30336400~30343336:+
BRCA	cis	rs891378	1	rs10864178	ENSG00000274245.1	RP11-357P18.2	-5.65	2.07e-08	2.86e-06	-0.23	-0.17	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207272333	chr1:207372559~207373252:+
BRCA	cis	rs1707322	0.717	rs3014237	ENSG00000234329.1	RP11-767N6.2	-5.65	2.08e-08	2.87e-06	-0.18	-0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45624580	chr1:45651039~45651826:-
BRCA	cis	rs77972916	0.536	rs62137421	ENSG00000234936.1	AC010883.5	5.65	2.08e-08	2.87e-06	0.22	0.17	Granulocyte percentage of myeloid white cells;	chr2:43366952	chr2:43229573~43233394:+
BRCA	cis	rs11009175	0.556	rs1815241	ENSG00000273038.2	RP11-479G22.8	-5.65	2.08e-08	2.87e-06	-0.23	-0.17	Depression (quantitative trait);	chr10:33018096	chr10:32887255~32889311:-
BRCA	cis	rs6479891	1	rs12416113	ENSG00000232075.1	MRPL35P2	5.65	2.08e-08	2.87e-06	0.31	0.17	Arthritis (juvenile idiopathic);	chr10:63136717	chr10:63634317~63634827:-
BRCA	cis	rs2348418	0.715	rs4931083	ENSG00000247934.4	RP11-967K21.1	-5.65	2.08e-08	2.87e-06	-0.19	-0.17	Lung function (FEV1);Lung function (FVC);	chr12:28568952	chr12:28163298~28190738:-
BRCA	cis	rs891378	0.959	rs6703860	ENSG00000274245.1	RP11-357P18.2	-5.65	2.08e-08	2.87e-06	-0.23	-0.17	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207270226	chr1:207372559~207373252:+
BRCA	cis	rs2522056	1	rs1003533	ENSG00000233006.5	AC034220.3	-5.65	2.08e-08	2.87e-06	-0.15	-0.17	Fibrinogen;Lymphocyte counts;	chr5:132419959	chr5:132311285~132369916:-
BRCA	cis	rs1440410	0.897	rs9999826	ENSG00000250326.1	RP11-284M14.1	-5.65	2.08e-08	2.87e-06	-0.19	-0.17	Ischemic stroke;	chr4:143115304	chr4:142933195~143184861:-
BRCA	cis	rs6545883	0.931	rs778756	ENSG00000270820.4	RP11-355B11.2	5.65	2.08e-08	2.87e-06	0.19	0.17	Tuberculosis;	chr2:61554859	chr2:61471188~61484130:+
BRCA	cis	rs4908768	0.501	rs6577491	ENSG00000270282.1	RP5-1115A15.2	5.65	2.09e-08	2.87e-06	0.18	0.17	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8514913	chr1:8512653~8513021:+
BRCA	cis	rs4763879	1	rs917911	ENSG00000214776.8	RP11-726G1.1	-5.65	2.09e-08	2.88e-06	-0.2	-0.17	Type 1 diabetes;	chr12:9753255	chr12:9467552~9576275:+
BRCA	cis	rs4934494	0.677	rs11185780	ENSG00000240996.1	RP11-80H5.7	5.65	2.09e-08	2.88e-06	0.24	0.17	Red blood cell count;	chr10:89603867	chr10:89694295~89697928:-
BRCA	cis	rs728616	0.867	rs61860044	ENSG00000225484.5	NUTM2B-AS1	-5.65	2.09e-08	2.88e-06	-0.47	-0.17	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80186782	chr10:79663088~79826594:-
BRCA	cis	rs4415084	0.966	rs10805685	ENSG00000251141.4	RP11-53O19.1	5.65	2.09e-08	2.88e-06	0.16	0.17	Breast cancer;	chr5:44661856	chr5:44744900~44808777:-
BRCA	cis	rs67311347	1	rs6762251	ENSG00000280739.1	EIF1B-AS1	-5.65	2.09e-08	2.88e-06	-0.19	-0.17	Renal cell carcinoma;	chr3:40489645	chr3:40173145~40309698:-
BRCA	cis	rs12681366	0.734	rs28641679	ENSG00000253704.1	RP11-267M23.4	5.65	2.09e-08	2.88e-06	0.18	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94394465	chr8:94553722~94569745:+
BRCA	cis	rs13126694	0.71	rs9995402	ENSG00000248429.4	RP11-597D13.9	5.65	2.09e-08	2.88e-06	0.16	0.17	Blood osmolality (transformed sodium);	chr4:158105262	chr4:158170752~158202877:+
BRCA	cis	rs13126694	0.71	rs34237515	ENSG00000248429.4	RP11-597D13.9	5.65	2.09e-08	2.88e-06	0.16	0.17	Blood osmolality (transformed sodium);	chr4:158105607	chr4:158170752~158202877:+
BRCA	cis	rs6540731	0.905	rs12028026	ENSG00000229983.1	RP11-15I11.2	5.65	2.09e-08	2.88e-06	0.2	0.17	Intelligence (childhood);	chr1:212216793	chr1:212168207~212190259:+
BRCA	cis	rs2293400	0.627	rs876435	ENSG00000245025.2	RP11-875O11.1	-5.65	2.1e-08	2.89e-06	-0.16	-0.17	TRAIL levels;	chr8:23016020	chr8:22984596~23019335:-
BRCA	cis	rs442309	0.551	rs10995305	ENSG00000238280.1	RP11-436D10.3	-5.65	2.1e-08	2.89e-06	-0.23	-0.17	Vogt-Koyanagi-Harada syndrome;	chr10:62781150	chr10:62793562~62805887:-
BRCA	cis	rs4713118	0.662	rs149969	ENSG00000219392.1	RP1-265C24.5	-5.65	2.1e-08	2.89e-06	-0.25	-0.17	Parkinson's disease;	chr6:28009959	chr6:28115628~28116551:+
BRCA	cis	rs875971	0.83	rs427575	ENSG00000164669.11	INTS4P1	-5.65	2.1e-08	2.89e-06	-0.21	-0.17	Aortic root size;	chr7:66054232	chr7:65141225~65234216:+
BRCA	cis	rs2243480	1	rs11538349	ENSG00000232559.3	GS1-124K5.12	5.65	2.1e-08	2.89e-06	0.32	0.17	Diabetic kidney disease;	chr7:65956884	chr7:66554588~66576923:-
BRCA	cis	rs2243480	1	rs1873494	ENSG00000228409.4	CCT6P1	-5.65	2.1e-08	2.89e-06	-0.24	-0.17	Diabetic kidney disease;	chr7:66184912	chr7:65751142~65763354:+
BRCA	cis	rs2243480	1	rs6959002	ENSG00000228409.4	CCT6P1	-5.65	2.1e-08	2.89e-06	-0.24	-0.17	Diabetic kidney disease;	chr7:66185509	chr7:65751142~65763354:+
BRCA	cis	rs873549	1	rs10863688	ENSG00000232679.1	RP11-400N13.3	5.65	2.1e-08	2.89e-06	0.2	0.17	Keloid;	chr1:222093432	chr1:222041705~222064763:-
BRCA	cis	rs4578769	0.788	rs12962334	ENSG00000273232.1	RP11-370A5.2	5.65	2.1e-08	2.89e-06	0.21	0.17	Eosinophil percentage of white cells;	chr18:22897971	chr18:22882825~22883357:-
BRCA	cis	rs7772486	0.79	rs2254288	ENSG00000270638.1	RP3-466P17.1	5.65	2.1e-08	2.89e-06	0.2	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145883334	chr6:145735570~145737218:+
BRCA	cis	rs853679	0.517	rs9380052	ENSG00000280107.1	AL022393.9	-5.65	2.1e-08	2.9e-06	-0.26	-0.17	Depression;	chr6:28096845	chr6:28170845~28172521:+
BRCA	cis	rs9309473	0.554	rs4330127	ENSG00000163016.8	ALMS1P	5.65	2.1e-08	2.9e-06	0.21	0.17	Metabolite levels;	chr2:73354192	chr2:73644919~73685576:+
BRCA	cis	rs6490294	0.571	rs7309841	ENSG00000226469.1	ADAM1B	5.65	2.1e-08	2.9e-06	0.27	0.17	Mean platelet volume;	chr12:112127249	chr12:111927018~111929017:+
BRCA	cis	rs6490294	0.571	rs7294753	ENSG00000226469.1	ADAM1B	5.65	2.1e-08	2.9e-06	0.27	0.17	Mean platelet volume;	chr12:112129646	chr12:111927018~111929017:+
BRCA	cis	rs66887589	0.616	rs6843509	ENSG00000245958.5	RP11-33B1.1	-5.65	2.11e-08	2.9e-06	-0.16	-0.17	Diastolic blood pressure;	chr4:119299041	chr4:119454791~119552025:+
BRCA	cis	rs2638953	0.853	rs11049641	ENSG00000278733.1	RP11-425D17.1	-5.65	2.11e-08	2.9e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28471160	chr12:28185625~28186190:-
BRCA	cis	rs523522	0.962	rs1050187	ENSG00000278344.1	RP11-18C24.8	-5.65	2.11e-08	2.9e-06	-0.24	-0.17	High light scatter reticulocyte count;	chr12:120464308	chr12:120500735~120501090:-
BRCA	cis	rs6570726	0.791	rs441290	ENSG00000270638.1	RP3-466P17.1	5.65	2.11e-08	2.9e-06	0.19	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145562047	chr6:145735570~145737218:+
BRCA	cis	rs4700393	0.517	rs12516248	ENSG00000272308.1	RP11-231G3.1	5.65	2.11e-08	2.91e-06	0.23	0.17	Intelligence (multi-trait analysis);	chr5:60835824	chr5:60866457~60866935:-
BRCA	cis	rs61160187	0.698	rs1379116	ENSG00000215032.2	GNL3LP1	5.65	2.11e-08	2.91e-06	0.21	0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:60646573	chr5:60891935~60893577:-
BRCA	cis	rs61160187	0.673	rs2198865	ENSG00000215032.2	GNL3LP1	5.65	2.11e-08	2.91e-06	0.21	0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:60658230	chr5:60891935~60893577:-
BRCA	cis	rs61160187	0.698	rs17387940	ENSG00000215032.2	GNL3LP1	5.65	2.11e-08	2.91e-06	0.21	0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:60671889	chr5:60891935~60893577:-
BRCA	cis	rs61160187	0.698	rs56726435	ENSG00000215032.2	GNL3LP1	5.65	2.11e-08	2.91e-06	0.21	0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:60679237	chr5:60891935~60893577:-
BRCA	cis	rs61160187	0.698	rs11741754	ENSG00000215032.2	GNL3LP1	5.65	2.11e-08	2.91e-06	0.21	0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:60681231	chr5:60891935~60893577:-
BRCA	cis	rs2638953	0.79	rs11049653	ENSG00000278733.1	RP11-425D17.1	-5.65	2.11e-08	2.91e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28479882	chr12:28185625~28186190:-
BRCA	cis	rs8054556	0.787	rs12325400	ENSG00000273724.1	RP11-347C12.12	-5.65	2.11e-08	2.91e-06	-0.2	-0.17	Autism spectrum disorder or schizophrenia;	chr16:30012465	chr16:30336400~30343336:+
BRCA	cis	rs6688613	0.685	rs2235184	ENSG00000225171.2	DUTP6	5.65	2.11e-08	2.91e-06	0.24	0.17	Refractive astigmatism;	chr1:166901291	chr1:166868748~166869209:+
BRCA	cis	rs10129255	0.785	rs10150044	ENSG00000224373.3	IGHV4-59	5.65	2.11e-08	2.91e-06	0.1	0.17	Kawasaki disease;	chr14:106775695	chr14:106627249~106627825:-
BRCA	cis	rs17767294	0.522	rs41270589	ENSG00000204709.4	LINC01556	5.65	2.12e-08	2.91e-06	0.48	0.17	Parkinson's disease;	chr6:28435663	chr6:28943877~28944537:+
BRCA	cis	rs2749097	0.609	rs2269235	ENSG00000244256.3	RN7SL130P	-5.65	2.12e-08	2.91e-06	-0.23	-0.17	Alcohol consumption (transferrin glycosylation);	chr1:63653244	chr1:63655743~63656047:+
BRCA	cis	rs7617773	0.817	rs6800492	ENSG00000199476.1	Y_RNA	-5.65	2.12e-08	2.92e-06	-0.24	-0.17	Coronary artery disease;	chr3:48282400	chr3:48288587~48288694:+
BRCA	cis	rs6088580	0.524	rs6088569	ENSG00000269202.1	RP4-614O4.12	5.65	2.12e-08	2.92e-06	0.18	0.17	Glomerular filtration rate (creatinine);	chr20:34680395	chr20:35201747~35203288:-
BRCA	cis	rs2749097	1	rs11208259	ENSG00000244256.3	RN7SL130P	-5.65	2.12e-08	2.92e-06	-0.26	-0.17	Alcohol consumption (transferrin glycosylation);	chr1:63657549	chr1:63655743~63656047:+
BRCA	cis	rs4713118	0.662	rs149900	ENSG00000219392.1	RP1-265C24.5	-5.65	2.12e-08	2.92e-06	-0.26	-0.17	Parkinson's disease;	chr6:28046819	chr6:28115628~28116551:+
BRCA	cis	rs7267979	0.706	rs6037069	ENSG00000277938.1	RP5-965G21.3	5.65	2.12e-08	2.92e-06	0.21	0.17	Liver enzyme levels (alkaline phosphatase);	chr20:25253530	chr20:25229150~25231933:+
BRCA	cis	rs67981189	0.529	rs61990379	ENSG00000258571.1	PTTG4P	-5.65	2.12e-08	2.92e-06	-0.2	-0.17	Schizophrenia;	chr14:71000353	chr14:71085482~71085833:-
BRCA	cis	rs7608910	0.77	rs10191951	ENSG00000271889.1	RP11-493E12.1	5.65	2.13e-08	2.93e-06	0.22	0.17	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;	chr2:60970655	chr2:61151433~61162105:-
BRCA	cis	rs2522056	0.808	rs7704457	ENSG00000233006.5	AC034220.3	5.65	2.13e-08	2.93e-06	0.15	0.17	Fibrinogen;Lymphocyte counts;	chr5:132409098	chr5:132311285~132369916:-
BRCA	cis	rs1275468	0.731	rs1480001	ENSG00000257497.2	RP11-585P4.5	-5.65	2.13e-08	2.93e-06	-0.25	-0.17	Polycystic ovary syndrome;	chr12:75586939	chr12:75483454~75489820:-
BRCA	cis	rs2638953	0.821	rs76265865	ENSG00000278733.1	RP11-425D17.1	-5.64	2.13e-08	2.93e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28504107	chr12:28185625~28186190:-
BRCA	cis	rs9291683	0.507	rs6849273	ENSG00000250413.1	RP11-448G15.1	-5.64	2.13e-08	2.93e-06	-0.22	-0.17	Bone mineral density;	chr4:10019971	chr4:10006482~10009725:+
BRCA	cis	rs7923609	0.967	rs7095571	ENSG00000232075.1	MRPL35P2	-5.64	2.13e-08	2.94e-06	-0.22	-0.17	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63391199	chr10:63634317~63634827:-
BRCA	cis	rs12681366	0.708	rs12680213	ENSG00000253704.1	RP11-267M23.4	5.64	2.14e-08	2.94e-06	0.18	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94387588	chr8:94553722~94569745:+
BRCA	cis	rs794185	0.652	rs2633844	ENSG00000231249.1	ITPR1-AS1	-5.64	2.14e-08	2.94e-06	-0.2	-0.17	Multiple sclerosis--Brain Glutamate Levels;	chr3:4470207	chr3:4490891~4493163:-
BRCA	cis	rs4819052	0.851	rs2838858	ENSG00000184274.3	LINC00315	-5.64	2.14e-08	2.94e-06	-0.23	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45261178	chr21:45300245~45305257:-
BRCA	cis	rs1707322	0.627	rs3014213	ENSG00000234329.1	RP11-767N6.2	-5.64	2.14e-08	2.94e-06	-0.18	-0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45579850	chr1:45651039~45651826:-
BRCA	cis	rs6570726	0.791	rs6902410	ENSG00000270638.1	RP3-466P17.1	5.64	2.14e-08	2.94e-06	0.2	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145584125	chr6:145735570~145737218:+
BRCA	cis	rs6840360	0.642	rs2724577	ENSG00000270265.1	RP11-731D1.4	-5.64	2.14e-08	2.94e-06	-0.21	-0.17	Intelligence (multi-trait analysis);	chr4:151433753	chr4:151333775~151353224:-
BRCA	cis	rs950169	0.58	rs17598114	ENSG00000259295.5	CSPG4P12	5.64	2.14e-08	2.94e-06	0.24	0.17	Schizophrenia;	chr15:84628086	chr15:85191438~85213905:+
BRCA	cis	rs2832191	0.967	rs3787660	ENSG00000215533.7	LINC00189	-5.64	2.14e-08	2.94e-06	-0.19	-0.17	Dental caries;	chr21:29148586	chr21:29193480~29288205:+
BRCA	cis	rs467650	0.853	rs457260	ENSG00000248489.1	CTD-2007H13.3	5.64	2.14e-08	2.94e-06	0.2	0.17	Venous thromboembolism (SNP x SNP interaction);	chr5:98689031	chr5:98929171~98995013:+
BRCA	cis	rs7772486	0.79	rs9376968	ENSG00000270638.1	RP3-466P17.1	5.64	2.14e-08	2.94e-06	0.19	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145859228	chr6:145735570~145737218:+
BRCA	cis	rs595982	0.527	rs73061656	ENSG00000235191.1	NUCB1-AS1	5.64	2.14e-08	2.95e-06	0.3	0.17	Red cell distribution width;	chr19:48869098	chr19:48910930~48918891:-
BRCA	cis	rs595982	0.527	rs73061658	ENSG00000235191.1	NUCB1-AS1	5.64	2.14e-08	2.95e-06	0.3	0.17	Red cell distribution width;	chr19:48869119	chr19:48910930~48918891:-
BRCA	cis	rs4713118	0.629	rs203888	ENSG00000219392.1	RP1-265C24.5	-5.64	2.14e-08	2.95e-06	-0.25	-0.17	Parkinson's disease;	chr6:28053811	chr6:28115628~28116551:+
BRCA	cis	rs2832077	0.505	rs9305386	ENSG00000215533.7	LINC00189	-5.64	2.14e-08	2.95e-06	-0.28	-0.17	Cognitive test performance;	chr21:29014430	chr21:29193480~29288205:+
BRCA	cis	rs9287719	0.614	rs10929679	ENSG00000243819.4	RN7SL832P	5.64	2.14e-08	2.95e-06	0.17	0.17	Prostate cancer;	chr2:10582982	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.614	rs10929680	ENSG00000243819.4	RN7SL832P	5.64	2.14e-08	2.95e-06	0.17	0.17	Prostate cancer;	chr2:10583000	chr2:10690344~10692099:+
BRCA	cis	rs3740713	1	rs1848048	ENSG00000256464.1	YWHABP2	5.64	2.14e-08	2.95e-06	0.3	0.17	Amyotrophic lateral sclerosis (sporadic);	chr11:18447449	chr11:18490243~18490955:-
BRCA	cis	rs3740713	1	rs16935432	ENSG00000256464.1	YWHABP2	5.64	2.14e-08	2.95e-06	0.3	0.17	Amyotrophic lateral sclerosis (sporadic);	chr11:18448940	chr11:18490243~18490955:-
BRCA	cis	rs3740713	1	rs73440625	ENSG00000256464.1	YWHABP2	5.64	2.14e-08	2.95e-06	0.3	0.17	Amyotrophic lateral sclerosis (sporadic);	chr11:18449253	chr11:18490243~18490955:-
BRCA	cis	rs3740713	1	rs76599129	ENSG00000256464.1	YWHABP2	5.64	2.14e-08	2.95e-06	0.3	0.17	Amyotrophic lateral sclerosis (sporadic);	chr11:18450080	chr11:18490243~18490955:-
BRCA	cis	rs2836950	0.501	rs11702505	ENSG00000255568.3	BRWD1-AS2	-5.64	2.15e-08	2.95e-06	-0.17	-0.17	Menarche (age at onset);	chr21:39328688	chr21:39313935~39314962:+
BRCA	cis	rs2836950	0.501	rs2836985	ENSG00000255568.3	BRWD1-AS2	-5.64	2.15e-08	2.95e-06	-0.17	-0.17	Menarche (age at onset);	chr21:39329243	chr21:39313935~39314962:+
BRCA	cis	rs3733585	0.736	rs4543113	ENSG00000250413.1	RP11-448G15.1	-5.64	2.15e-08	2.95e-06	-0.23	-0.17	Cleft plate (environmental tobacco smoke interaction);	chr4:10006681	chr4:10006482~10009725:+
BRCA	cis	rs853679	0.55	rs34477097	ENSG00000216901.1	AL022393.7	5.64	2.15e-08	2.95e-06	0.24	0.17	Depression;	chr6:28229408	chr6:28176188~28176674:+
BRCA	cis	rs13113518	0.507	rs4549456	ENSG00000249700.7	SRD5A3-AS1	5.64	2.15e-08	2.96e-06	0.22	0.17	Height;	chr4:55398586	chr4:55363971~55395847:-
BRCA	cis	rs1979679	1	rs11049487	ENSG00000278733.1	RP11-425D17.1	5.64	2.15e-08	2.96e-06	0.22	0.17	Ossification of the posterior longitudinal ligament of the spine;	chr12:28254157	chr12:28185625~28186190:-
BRCA	cis	rs651907	0.557	rs11917569	ENSG00000244119.1	PDCL3P4	5.64	2.15e-08	2.96e-06	0.14	0.17	Colorectal cancer;	chr3:101636219	chr3:101712472~101713191:+
BRCA	cis	rs651907	0.557	rs11917682	ENSG00000244119.1	PDCL3P4	5.64	2.15e-08	2.96e-06	0.14	0.17	Colorectal cancer;	chr3:101636583	chr3:101712472~101713191:+
BRCA	cis	rs6088813	0.925	rs4353719	ENSG00000126005.14	MMP24-AS1	5.64	2.15e-08	2.96e-06	0.2	0.17	Height;	chr20:35389546	chr20:35216462~35278131:-
BRCA	cis	rs6088813	0.89	rs6088817	ENSG00000126005.14	MMP24-AS1	5.64	2.15e-08	2.96e-06	0.2	0.17	Height;	chr20:35397173	chr20:35216462~35278131:-
BRCA	cis	rs6088813	1	rs6142374	ENSG00000126005.14	MMP24-AS1	5.64	2.15e-08	2.96e-06	0.2	0.17	Height;	chr20:35397765	chr20:35216462~35278131:-
BRCA	cis	rs10129255	0.556	rs8010005	ENSG00000224373.3	IGHV4-59	5.64	2.15e-08	2.96e-06	0.1	0.17	Kawasaki disease;	chr14:106777987	chr14:106627249~106627825:-
BRCA	cis	rs10129255	0.556	rs6576224	ENSG00000224373.3	IGHV4-59	5.64	2.15e-08	2.96e-06	0.1	0.17	Kawasaki disease;	chr14:106777997	chr14:106627249~106627825:-
BRCA	cis	rs10129255	0.518	rs8010020	ENSG00000224373.3	IGHV4-59	5.64	2.15e-08	2.96e-06	0.1	0.17	Kawasaki disease;	chr14:106778016	chr14:106627249~106627825:-
BRCA	cis	rs4950322	0.58	rs2014106	ENSG00000278811.3	LINC00624	5.64	2.15e-08	2.96e-06	0.23	0.17	Protein quantitative trait loci;	chr1:147118499	chr1:147258885~147517875:-
BRCA	cis	rs11671005	0.695	rs12972898	ENSG00000252334.1	RNU6-1337P	5.64	2.15e-08	2.96e-06	0.27	0.17	Mean platelet volume;	chr19:58445521	chr19:58483749~58483843:-
BRCA	cis	rs7308116	0.546	rs7488052	ENSG00000274395.1	RP11-554D14.8	-5.64	2.15e-08	2.96e-06	-0.2	-0.17	Pelvic organ prolapse (moderate/severe);	chr12:107829339	chr12:107835541~107836555:-
BRCA	cis	rs10129255	0.83	rs61997609	ENSG00000224373.3	IGHV4-59	5.64	2.15e-08	2.96e-06	0.11	0.17	Kawasaki disease;	chr14:106692376	chr14:106627249~106627825:-
BRCA	cis	rs7927592	0.913	rs3758643	ENSG00000212093.1	AP000807.1	5.64	2.15e-08	2.96e-06	0.2	0.17	Total body bone mineral density;	chr11:68599725	chr11:68506083~68506166:-
BRCA	cis	rs17680741	1	rs12260962	ENSG00000226659.1	RP11-137H2.4	5.64	2.15e-08	2.96e-06	0.24	0.17	Coronary artery disease;	chr10:80503070	chr10:80529597~80535942:-
BRCA	cis	rs7674212	0.541	rs4699050	ENSG00000246560.2	RP11-10L12.4	5.64	2.15e-08	2.96e-06	0.19	0.17	Type 2 diabetes;	chr4:103193140	chr4:102828055~102844075:+
BRCA	cis	rs7674212	0.541	rs17217473	ENSG00000246560.2	RP11-10L12.4	5.64	2.15e-08	2.96e-06	0.19	0.17	Type 2 diabetes;	chr4:103193585	chr4:102828055~102844075:+
BRCA	cis	rs5758511	0.773	rs11913631	ENSG00000205702.9	CYP2D7	5.64	2.16e-08	2.97e-06	0.17	0.17	Birth weight;	chr22:41951367	chr22:42140203~42144577:-
BRCA	cis	rs2739330	0.731	rs5751792	ENSG00000228039.3	KB-1125A3.10	5.64	2.16e-08	2.97e-06	0.2	0.17	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23963780~23964374:+
BRCA	cis	rs7577696	0.695	rs7588883	ENSG00000272716.1	RP11-563N4.1	-5.64	2.16e-08	2.97e-06	-0.19	-0.17	Inflammatory biomarkers;	chr2:32172198	chr2:32165046~32165757:-
BRCA	cis	rs7493	0.853	rs11770901	ENSG00000233942.1	AC004012.1	5.64	2.16e-08	2.97e-06	0.22	0.17	Yu-Zhi constitution type in type 2 diabetes;	chr7:95425168	chr7:95471835~95473998:+
BRCA	cis	rs13178541	0.81	rs4976496	ENSG00000250378.1	RP11-119J18.1	-5.64	2.16e-08	2.97e-06	-0.24	-0.17	IgG glycosylation;	chr5:135850086	chr5:135812667~135826582:+
BRCA	cis	rs6490294	0.528	rs60690688	ENSG00000226469.1	ADAM1B	5.64	2.16e-08	2.97e-06	0.27	0.17	Mean platelet volume;	chr12:112104179	chr12:111927018~111929017:+
BRCA	cis	rs720475	0.732	rs17195725	ENSG00000170356.8	OR2A20P	-5.64	2.16e-08	2.97e-06	-0.26	-0.17	Breast cancer;	chr7:144440044	chr7:144250045~144252957:-
BRCA	cis	rs7618915	0.547	rs11714419	ENSG00000243224.1	RP5-1157M23.2	-5.64	2.16e-08	2.97e-06	-0.19	-0.17	Bipolar disorder;	chr3:52594800	chr3:52239258~52241097:+
BRCA	cis	rs73222236	0.787	rs34379561	ENSG00000273486.1	RP11-731C17.2	5.64	2.16e-08	2.97e-06	0.19	0.17	Coronary artery disease;	chr3:136464374	chr3:136837338~136839021:-
BRCA	cis	rs875971	0.505	rs1723275	ENSG00000273024.4	INTS4P2	5.64	2.16e-08	2.97e-06	0.19	0.17	Aortic root size;	chr7:66039646	chr7:65647864~65715661:+
BRCA	cis	rs710913	0.618	rs6587	ENSG00000182109.6	RP11-69E11.4	5.64	2.16e-08	2.98e-06	0.19	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39624273	chr1:39522280~39546187:-
BRCA	cis	rs4578769	0.569	rs12326874	ENSG00000265939.1	UBE2CP2	5.64	2.16e-08	2.98e-06	0.19	0.17	Eosinophil percentage of white cells;	chr18:22926670	chr18:22900486~22900995:-
BRCA	cis	rs4835473	0.897	rs28825455	ENSG00000249741.2	RP11-673E1.3	-5.64	2.17e-08	2.98e-06	-0.19	-0.17	Immature fraction of reticulocytes;	chr4:143707593	chr4:143911514~143912053:-
BRCA	cis	rs3805389	0.962	rs28708716	ENSG00000273257.1	RP11-177J6.1	-5.64	2.17e-08	2.98e-06	-0.25	-0.17	Waist-to-hip ratio adjusted for body mass index;	chr4:55596308	chr4:55387949~55388271:+
BRCA	cis	rs11742741	0.539	rs13168500	ENSG00000248874.4	C5orf17	-5.64	2.17e-08	2.98e-06	-0.22	-0.17	Educational attainment;	chr5:24094615	chr5:23951348~24178263:+
BRCA	cis	rs73222236	0.825	rs9866535	ENSG00000273486.1	RP11-731C17.2	5.64	2.17e-08	2.98e-06	0.19	0.17	Coronary artery disease;	chr3:136465513	chr3:136837338~136839021:-
BRCA	cis	rs2243480	1	rs67728539	ENSG00000232559.3	GS1-124K5.12	5.64	2.17e-08	2.98e-06	0.32	0.17	Diabetic kidney disease;	chr7:65913137	chr7:66554588~66576923:-
BRCA	cis	rs1707322	0.721	rs10890343	ENSG00000234329.1	RP11-767N6.2	5.64	2.17e-08	2.98e-06	0.18	0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692250	chr1:45651039~45651826:-
BRCA	cis	rs2243480	1	rs78803505	ENSG00000232559.3	GS1-124K5.12	5.64	2.17e-08	2.99e-06	0.32	0.17	Diabetic kidney disease;	chr7:65917585	chr7:66554588~66576923:-
BRCA	cis	rs2243480	1	rs34577383	ENSG00000232559.3	GS1-124K5.12	5.64	2.17e-08	2.99e-06	0.32	0.17	Diabetic kidney disease;	chr7:65920739	chr7:66554588~66576923:-
BRCA	cis	rs2243480	1	rs55895244	ENSG00000232559.3	GS1-124K5.12	5.64	2.17e-08	2.99e-06	0.32	0.17	Diabetic kidney disease;	chr7:65922691	chr7:66554588~66576923:-
BRCA	cis	rs2243480	1	rs7795242	ENSG00000232559.3	GS1-124K5.12	5.64	2.17e-08	2.99e-06	0.32	0.17	Diabetic kidney disease;	chr7:65925107	chr7:66554588~66576923:-
BRCA	cis	rs2243480	1	rs2177703	ENSG00000232559.3	GS1-124K5.12	5.64	2.17e-08	2.99e-06	0.32	0.17	Diabetic kidney disease;	chr7:65926730	chr7:66554588~66576923:-
BRCA	cis	rs2243480	1	rs56985706	ENSG00000232559.3	GS1-124K5.12	5.64	2.17e-08	2.99e-06	0.32	0.17	Diabetic kidney disease;	chr7:65929575	chr7:66554588~66576923:-
BRCA	cis	rs2243480	1	rs60683927	ENSG00000232559.3	GS1-124K5.12	5.64	2.17e-08	2.99e-06	0.32	0.17	Diabetic kidney disease;	chr7:65929781	chr7:66554588~66576923:-
BRCA	cis	rs2243480	1	rs58062456	ENSG00000232559.3	GS1-124K5.12	5.64	2.17e-08	2.99e-06	0.32	0.17	Diabetic kidney disease;	chr7:65929865	chr7:66554588~66576923:-
BRCA	cis	rs7247513	0.79	rs17476839	ENSG00000213290.4	PGK1P2	5.64	2.18e-08	2.99e-06	0.23	0.17	Bipolar disorder;	chr19:12651969	chr19:12559571~12561105:+
BRCA	cis	rs801193	0.569	rs2659893	ENSG00000224316.1	RP11-479O9.2	5.64	2.18e-08	2.99e-06	0.17	0.17	Aortic root size;	chr7:66735006	chr7:65773620~65802067:+
BRCA	cis	rs801193	0.569	rs2659892	ENSG00000224316.1	RP11-479O9.2	5.64	2.18e-08	2.99e-06	0.17	0.17	Aortic root size;	chr7:66735318	chr7:65773620~65802067:+
BRCA	cis	rs801193	0.569	rs2707847	ENSG00000224316.1	RP11-479O9.2	5.64	2.18e-08	2.99e-06	0.17	0.17	Aortic root size;	chr7:66737884	chr7:65773620~65802067:+
BRCA	cis	rs2243480	1	rs34529418	ENSG00000232559.3	GS1-124K5.12	5.64	2.18e-08	2.99e-06	0.32	0.17	Diabetic kidney disease;	chr7:65938222	chr7:66554588~66576923:-
BRCA	cis	rs10129255	0.957	rs10136817	ENSG00000280411.1	IGHV1-69-2	-5.64	2.18e-08	2.99e-06	-0.13	-0.17	Kawasaki disease;	chr14:106787730	chr14:106762092~106762588:-
BRCA	cis	rs7493	0.755	rs2375001	ENSG00000233942.1	AC004012.1	5.64	2.18e-08	2.99e-06	0.22	0.17	Yu-Zhi constitution type in type 2 diabetes;	chr7:95335328	chr7:95471835~95473998:+
BRCA	cis	rs17711722	0.701	rs4467826	ENSG00000273024.4	INTS4P2	-5.64	2.18e-08	2.99e-06	-0.19	-0.17	Calcium levels;	chr7:65903721	chr7:65647864~65715661:+
BRCA	cis	rs7927592	0.871	rs17603185	ENSG00000212093.1	AP000807.1	5.64	2.18e-08	3e-06	0.19	0.17	Total body bone mineral density;	chr11:68608773	chr11:68506083~68506166:-
BRCA	cis	rs1124769	0.654	rs28591334	ENSG00000259378.1	DCAF13P3	5.64	2.18e-08	3e-06	0.25	0.17	Cognitive performance;	chr15:51187393	chr15:50944663~50945996:+
BRCA	cis	rs8114671	0.836	rs1885114	ENSG00000269202.1	RP4-614O4.12	5.64	2.18e-08	3e-06	0.18	0.17	Height;	chr20:34989558	chr20:35201747~35203288:-
BRCA	cis	rs651386	0.529	rs576736	ENSG00000271811.1	RP1-79C4.4	5.64	2.18e-08	3e-06	0.19	0.17	Atrial fibrillation;	chr1:170618074	chr1:170667381~170669425:+
BRCA	cis	rs7927592	0.913	rs11228293	ENSG00000212093.1	AP000807.1	5.64	2.18e-08	3e-06	0.19	0.17	Total body bone mineral density;	chr11:68617178	chr11:68506083~68506166:-
BRCA	cis	rs7493	0.901	rs11764079	ENSG00000233942.1	AC004012.1	-5.64	2.18e-08	3e-06	-0.22	-0.17	Yu-Zhi constitution type in type 2 diabetes;	chr7:95396917	chr7:95471835~95473998:+
BRCA	cis	rs55702914	0.746	rs4850425	ENSG00000231621.1	AC013264.2	5.64	2.18e-08	3e-06	0.17	0.17	Major depression and alcohol dependence;	chr2:197288062	chr2:197197991~197199273:+
BRCA	cis	rs4835473	0.864	rs1597446	ENSG00000249741.2	RP11-673E1.3	-5.64	2.18e-08	3e-06	-0.19	-0.17	Immature fraction of reticulocytes;	chr4:143708338	chr4:143911514~143912053:-
BRCA	cis	rs4835473	0.835	rs1450247	ENSG00000249741.2	RP11-673E1.3	-5.64	2.18e-08	3e-06	-0.19	-0.17	Immature fraction of reticulocytes;	chr4:143708529	chr4:143911514~143912053:-
BRCA	cis	rs4835473	0.897	rs7681914	ENSG00000249741.2	RP11-673E1.3	-5.64	2.18e-08	3e-06	-0.19	-0.17	Immature fraction of reticulocytes;	chr4:143708838	chr4:143911514~143912053:-
BRCA	cis	rs4835473	0.864	rs7682096	ENSG00000249741.2	RP11-673E1.3	-5.64	2.18e-08	3e-06	-0.19	-0.17	Immature fraction of reticulocytes;	chr4:143708892	chr4:143911514~143912053:-
BRCA	cis	rs763121	0.813	rs4821807	ENSG00000228274.3	RP3-508I15.9	-5.64	2.19e-08	3e-06	-0.19	-0.17	Menopause (age at onset);	chr22:38669577	chr22:38667585~38681820:-
BRCA	cis	rs4950322	0.57	rs72691090	ENSG00000244371.2	PFN1P8	-5.64	2.19e-08	3e-06	-0.24	-0.17	Protein quantitative trait loci;	chr1:147297884	chr1:146957117~146957659:-
BRCA	cis	rs2836950	0.805	rs62223042	ENSG00000238141.2	BRWD1-AS1	-5.64	2.19e-08	3e-06	-0.2	-0.17	Menarche (age at onset);	chr21:39311814	chr21:39315707~39323218:+
BRCA	cis	rs7487075	0.558	rs7959095	ENSG00000257261.4	RP11-96H19.1	5.64	2.19e-08	3e-06	0.18	0.17	Itch intensity from mosquito bite;	chr12:46239545	chr12:46383679~46876159:+
BRCA	cis	rs1552244	1	rs113153120	ENSG00000180385.7	EMC3-AS1	5.64	2.19e-08	3e-06	0.21	0.17	Alzheimer's disease;	chr3:10114714	chr3:9986893~10006990:+
BRCA	cis	rs1552244	1	rs112509186	ENSG00000180385.7	EMC3-AS1	5.64	2.19e-08	3e-06	0.21	0.17	Alzheimer's disease;	chr3:10114849	chr3:9986893~10006990:+
BRCA	cis	rs8072100	0.738	rs9895509	ENSG00000228782.6	CTD-2026D20.3	-5.64	2.19e-08	3e-06	-0.19	-0.17	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47472252	chr17:47450568~47492492:-
BRCA	cis	rs919433	0.68	rs7590010	ENSG00000231621.1	AC013264.2	-5.64	2.19e-08	3e-06	-0.16	-0.17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197535944	chr2:197197991~197199273:+
BRCA	cis	rs13108904	0.935	rs1680072	ENSG00000254094.1	AC078852.1	5.64	2.19e-08	3.01e-06	0.18	0.17	Obesity-related traits;	chr4:1287907	chr4:1356581~1358075:+
BRCA	cis	rs1707322	0.752	rs6678444	ENSG00000234329.1	RP11-767N6.2	5.64	2.19e-08	3.01e-06	0.18	0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45764175	chr1:45651039~45651826:-
BRCA	cis	rs7238033	0.686	rs3819177	ENSG00000267193.4	RP11-116O18.3	5.64	2.19e-08	3.01e-06	0.19	0.17	Bladder cancer;	chr18:45736145	chr18:45669367~45747215:-
BRCA	cis	rs4819052	0.851	rs4819040	ENSG00000184274.3	LINC00315	-5.64	2.19e-08	3.01e-06	-0.23	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239847	chr21:45300245~45305257:-
BRCA	cis	rs2098713	0.569	rs13189481	ENSG00000250155.1	CTD-2353F22.1	-5.64	2.19e-08	3.01e-06	-0.2	-0.17	Telomere length;	chr5:37499415	chr5:36666214~36725195:-
BRCA	cis	rs2098713	0.569	rs10941340	ENSG00000250155.1	CTD-2353F22.1	-5.64	2.19e-08	3.01e-06	-0.2	-0.17	Telomere length;	chr5:37502569	chr5:36666214~36725195:-
BRCA	cis	rs2098713	0.569	rs35187630	ENSG00000250155.1	CTD-2353F22.1	-5.64	2.19e-08	3.01e-06	-0.2	-0.17	Telomere length;	chr5:37503660	chr5:36666214~36725195:-
BRCA	cis	rs2153535	0.518	rs9505503	ENSG00000230939.1	RP11-314C16.1	-5.64	2.2e-08	3.01e-06	-0.21	-0.17	Motion sickness;	chr6:8638572	chr6:8784178~8785445:+
BRCA	cis	rs1722141	0.6	rs1525819	ENSG00000229628.1	AC073115.7	5.64	2.2e-08	3.02e-06	0.25	0.17	Sitting height ratio;	chr7:45945301	chr7:45990905~46000898:+
BRCA	cis	rs873549	0.959	rs6604701	ENSG00000232679.1	RP11-400N13.3	5.64	2.2e-08	3.02e-06	0.2	0.17	Keloid;	chr1:222094158	chr1:222041705~222064763:-
BRCA	cis	rs873549	1	rs6604702	ENSG00000232679.1	RP11-400N13.3	5.64	2.2e-08	3.02e-06	0.2	0.17	Keloid;	chr1:222094181	chr1:222041705~222064763:-
BRCA	cis	rs873549	1	rs3910712	ENSG00000232679.1	RP11-400N13.3	5.64	2.2e-08	3.02e-06	0.2	0.17	Keloid;	chr1:222094609	chr1:222041705~222064763:-
BRCA	cis	rs873549	1	rs3910711	ENSG00000232679.1	RP11-400N13.3	5.64	2.2e-08	3.02e-06	0.2	0.17	Keloid;	chr1:222094622	chr1:222041705~222064763:-
BRCA	cis	rs2562456	0.833	rs2562487	ENSG00000268081.1	RP11-678G14.2	5.64	2.2e-08	3.02e-06	0.27	0.17	Pain;	chr19:21468580	chr19:21554640~21569237:-
BRCA	cis	rs9309473	0.948	rs13392691	ENSG00000163016.8	ALMS1P	5.64	2.2e-08	3.02e-06	0.22	0.17	Metabolite levels;	chr2:73521853	chr2:73644919~73685576:+
BRCA	cis	rs2250402	0.51	rs8031319	ENSG00000248508.5	SRP14-AS1	5.64	2.2e-08	3.02e-06	0.37	0.17	Corneal curvature;	chr15:40031491	chr15:40039311~40067290:+
BRCA	cis	rs2243480	1	rs2533288	ENSG00000228409.4	CCT6P1	5.64	2.2e-08	3.02e-06	0.24	0.17	Diabetic kidney disease;	chr7:66591724	chr7:65751142~65763354:+
BRCA	cis	rs9287719	0.649	rs10184776	ENSG00000243819.4	RN7SL832P	5.64	2.2e-08	3.02e-06	0.17	0.17	Prostate cancer;	chr2:10586320	chr2:10690344~10692099:+
BRCA	cis	rs13178541	0.553	rs4976374	ENSG00000250378.1	RP11-119J18.1	-5.64	2.2e-08	3.02e-06	-0.24	-0.17	IgG glycosylation;	chr5:135853131	chr5:135812667~135826582:+
BRCA	cis	rs5758659	0.729	rs134866	ENSG00000281538.1	RP4-669P10.20	5.64	2.2e-08	3.02e-06	0.17	0.17	Cognitive function;	chr22:42254657	chr22:42138060~42139726:+
BRCA	cis	rs6570726	0.72	rs412623	ENSG00000270638.1	RP3-466P17.1	5.64	2.2e-08	3.02e-06	0.19	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145562121	chr6:145735570~145737218:+
BRCA	cis	rs73222236	0.75	rs6439642	ENSG00000273486.1	RP11-731C17.2	5.64	2.2e-08	3.02e-06	0.19	0.17	Coronary artery disease;	chr3:136473965	chr3:136837338~136839021:-
BRCA	cis	rs73222236	0.857	rs16843991	ENSG00000273486.1	RP11-731C17.2	5.64	2.2e-08	3.02e-06	0.19	0.17	Coronary artery disease;	chr3:136477186	chr3:136837338~136839021:-
BRCA	cis	rs2280018	0.526	rs2966129	ENSG00000263335.1	AF001548.5	5.64	2.2e-08	3.02e-06	0.22	0.17	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15059070	chr16:15726674~15732993:+
BRCA	cis	rs73222236	0.825	rs6804194	ENSG00000273486.1	RP11-731C17.2	5.64	2.2e-08	3.03e-06	0.19	0.17	Coronary artery disease;	chr3:136441890	chr3:136837338~136839021:-
BRCA	cis	rs62025270	0.688	rs10163064	ENSG00000259295.5	CSPG4P12	-5.64	2.2e-08	3.03e-06	-0.26	-0.17	Idiopathic pulmonary fibrosis;	chr15:85734289	chr15:85191438~85213905:+
BRCA	cis	rs4950322	0.857	rs72693002	ENSG00000278811.3	LINC00624	5.64	2.21e-08	3.03e-06	0.23	0.17	Protein quantitative trait loci;	chr1:147357593	chr1:147258885~147517875:-
BRCA	cis	rs4950322	0.857	rs72694703	ENSG00000278811.3	LINC00624	5.64	2.21e-08	3.03e-06	0.23	0.17	Protein quantitative trait loci;	chr1:147358427	chr1:147258885~147517875:-
BRCA	cis	rs4415084	0.966	rs34762678	ENSG00000251141.4	RP11-53O19.1	5.64	2.21e-08	3.03e-06	0.16	0.17	Breast cancer;	chr5:44705412	chr5:44744900~44808777:-
BRCA	cis	rs62025270	0.688	rs11073516	ENSG00000259295.5	CSPG4P12	-5.64	2.21e-08	3.03e-06	-0.27	-0.17	Idiopathic pulmonary fibrosis;	chr15:85741996	chr15:85191438~85213905:+
BRCA	cis	rs7577696	0.695	rs12997026	ENSG00000272716.1	RP11-563N4.1	-5.64	2.21e-08	3.03e-06	-0.19	-0.17	Inflammatory biomarkers;	chr2:32169238	chr2:32165046~32165757:-
BRCA	cis	rs454217	0.74	rs430709	ENSG00000277851.1	RP11-756G20.1	5.64	2.21e-08	3.04e-06	0.19	0.17	Smoking quantity;	chr12:92325836	chr12:92247756~92363832:-
BRCA	cis	rs1707322	1	rs12060274	ENSG00000281133.1	AL355480.3	-5.64	2.21e-08	3.04e-06	-0.22	-0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45825390	chr1:45580892~45580996:-
BRCA	cis	rs690037	0.673	rs690573	ENSG00000271964.1	RP11-415F23.2	-5.64	2.22e-08	3.04e-06	-0.18	-0.17	Optic nerve measurement (cup-to-disc ratio);Optic nerve measurement (cup area);	chr3:16334933	chr3:16314439~16314987:+
BRCA	cis	rs375066	0.592	rs349048	ENSG00000267058.1	RP11-15A1.3	5.64	2.22e-08	3.04e-06	0.19	0.17	Breast cancer;	chr19:43796785	chr19:43891804~43901805:-
BRCA	cis	rs4831760	0.519	rs7841137	ENSG00000250483.1	PPM1AP1	-5.64	2.22e-08	3.04e-06	-0.19	-0.17	Pulmonary function decline;	chr8:15687643	chr8:15806149~15807283:-
BRCA	cis	rs73193808	0.802	rs7281059	ENSG00000215533.7	LINC00189	-5.64	2.22e-08	3.04e-06	-0.25	-0.17	Coronary artery disease;	chr21:29216947	chr21:29193480~29288205:+
BRCA	cis	rs4218	0.689	rs12440692	ENSG00000277144.1	RP11-59H7.4	-5.64	2.22e-08	3.05e-06	-0.22	-0.17	Social communication problems;	chr15:59090671	chr15:59115547~59116089:-
BRCA	cis	rs523522	0.962	rs603574	ENSG00000278344.1	RP11-18C24.8	5.64	2.22e-08	3.05e-06	0.23	0.17	High light scatter reticulocyte count;	chr12:120560640	chr12:120500735~120501090:-
BRCA	cis	rs1823874	0.581	rs9920347	ENSG00000259363.4	CTD-2054N24.2	5.64	2.22e-08	3.05e-06	0.2	0.17	IgG glycosylation;	chr15:99799126	chr15:99807023~99877148:+
BRCA	cis	rs4819052	0.851	rs35064782	ENSG00000184274.3	LINC00315	-5.64	2.22e-08	3.05e-06	-0.24	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45254445	chr21:45300245~45305257:-
BRCA	cis	rs7923609	0.811	rs3847326	ENSG00000232075.1	MRPL35P2	5.64	2.22e-08	3.05e-06	0.22	0.17	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63572099	chr10:63634317~63634827:-
BRCA	cis	rs4819052	0.851	rs4819049	ENSG00000184274.3	LINC00315	-5.64	2.22e-08	3.05e-06	-0.23	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45253171	chr21:45300245~45305257:-
BRCA	cis	rs1387259	0.723	rs2732488	ENSG00000257763.1	OR5BK1P	5.64	2.23e-08	3.06e-06	0.19	0.17	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48377661	chr12:48355792~48356614:-
BRCA	cis	rs1387259	0.758	rs2634670	ENSG00000257763.1	OR5BK1P	5.64	2.23e-08	3.06e-06	0.19	0.17	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48378094	chr12:48355792~48356614:-
BRCA	cis	rs2803122	0.84	rs10757036	ENSG00000273226.1	RP11-513M16.8	-5.64	2.23e-08	3.06e-06	-0.18	-0.17	Pulse pressure;	chr9:19236127	chr9:19375451~19375996:+
BRCA	cis	rs4787491	0.729	rs11642399	ENSG00000273724.1	RP11-347C12.12	-5.64	2.23e-08	3.06e-06	-0.19	-0.17	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30048272	chr16:30336400~30343336:+
BRCA	cis	rs4650994	0.525	rs2493864	ENSG00000273384.1	RP5-1098D14.1	5.64	2.23e-08	3.06e-06	0.22	0.17	HDL cholesterol;HDL cholesterol levels;	chr1:178575868	chr1:178651706~178652282:+
BRCA	cis	rs9291683	0.526	rs12506122	ENSG00000250413.1	RP11-448G15.1	-5.64	2.23e-08	3.06e-06	-0.22	-0.17	Bone mineral density;	chr4:10031914	chr4:10006482~10009725:+
BRCA	cis	rs8002861	0.81	rs9533664	ENSG00000274001.1	RP11-5G9.5	5.64	2.23e-08	3.06e-06	0.19	0.17	Leprosy;	chr13:43866391	chr13:43877715~43878163:-
BRCA	cis	rs2688608	0.839	rs2633310	ENSG00000271816.1	BMS1P4	-5.64	2.23e-08	3.06e-06	-0.17	-0.17	Inflammatory bowel disease;	chr10:73834292	chr10:73699151~73730487:-
BRCA	cis	rs7308116	0.546	rs2162309	ENSG00000274395.1	RP11-554D14.8	-5.64	2.23e-08	3.06e-06	-0.2	-0.17	Pelvic organ prolapse (moderate/severe);	chr12:107828304	chr12:107835541~107836555:-
BRCA	cis	rs7308116	0.546	rs11113524	ENSG00000274395.1	RP11-554D14.8	-5.64	2.23e-08	3.06e-06	-0.2	-0.17	Pelvic organ prolapse (moderate/severe);	chr12:107828370	chr12:107835541~107836555:-
BRCA	cis	rs7308116	0.546	rs61938613	ENSG00000274395.1	RP11-554D14.8	-5.64	2.23e-08	3.06e-06	-0.2	-0.17	Pelvic organ prolapse (moderate/severe);	chr12:107828591	chr12:107835541~107836555:-
BRCA	cis	rs13178541	0.872	rs4447978	ENSG00000250378.1	RP11-119J18.1	5.64	2.23e-08	3.06e-06	0.23	0.17	IgG glycosylation;	chr5:135839129	chr5:135812667~135826582:+
BRCA	cis	rs919433	0.713	rs10172961	ENSG00000231621.1	AC013264.2	-5.64	2.23e-08	3.06e-06	-0.16	-0.17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197582135	chr2:197197991~197199273:+
BRCA	cis	rs1665050	0.652	rs9302206	ENSG00000277144.1	RP11-59H7.4	-5.64	2.23e-08	3.06e-06	-0.21	-0.17	Atopic dermatitis;	chr15:59017274	chr15:59115547~59116089:-
BRCA	cis	rs919433	0.68	rs1563340	ENSG00000231621.1	AC013264.2	-5.64	2.23e-08	3.07e-06	-0.17	-0.17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197549989	chr2:197197991~197199273:+
BRCA	cis	rs10129255	0.833	rs61997797	ENSG00000280411.1	IGHV1-69-2	-5.64	2.24e-08	3.07e-06	-0.13	-0.17	Kawasaki disease;	chr14:106815190	chr14:106762092~106762588:-
BRCA	cis	rs10510102	0.872	rs56108883	ENSG00000226864.1	ATE1-AS1	5.64	2.24e-08	3.07e-06	0.32	0.17	Breast cancer;	chr10:121825567	chr10:121928312~121951965:+
BRCA	cis	rs4718428	0.705	rs13227468	ENSG00000230295.1	RP11-458F8.2	-5.64	2.24e-08	3.07e-06	-0.16	-0.17	Corneal structure;	chr7:66968576	chr7:66880708~66882981:+
BRCA	cis	rs2243480	0.803	rs160649	ENSG00000164669.11	INTS4P1	5.64	2.24e-08	3.07e-06	0.34	0.17	Diabetic kidney disease;	chr7:66078212	chr7:65141225~65234216:+
BRCA	cis	rs2243480	1	rs160648	ENSG00000164669.11	INTS4P1	5.64	2.24e-08	3.07e-06	0.34	0.17	Diabetic kidney disease;	chr7:66078397	chr7:65141225~65234216:+
BRCA	cis	rs1859596	0.966	rs4730881	ENSG00000234456.6	MAGI2-AS3	5.64	2.24e-08	3.07e-06	0.11	0.17	Reading or mathematical ability;	chr7:79482675	chr7:79452877~79471208:+
BRCA	cis	rs673078	0.66	rs17512407	ENSG00000275409.1	RP11-131L12.4	-5.64	2.24e-08	3.07e-06	-0.28	-0.17	Glucose homeostasis traits;	chr12:118292705	chr12:118430147~118430699:+
BRCA	cis	rs673078	0.66	rs61946064	ENSG00000275409.1	RP11-131L12.4	-5.64	2.24e-08	3.07e-06	-0.28	-0.17	Glucose homeostasis traits;	chr12:118294495	chr12:118430147~118430699:+
BRCA	cis	rs4588572	0.644	rs891150	ENSG00000245556.2	SCAMP1-AS1	-5.64	2.24e-08	3.07e-06	-0.2	-0.17	Triglycerides;	chr5:78465971	chr5:78342365~78360507:-
BRCA	cis	rs9309473	0.687	rs12465867	ENSG00000163016.8	ALMS1P	5.64	2.24e-08	3.07e-06	0.21	0.17	Metabolite levels;	chr2:73384974	chr2:73644919~73685576:+
BRCA	cis	rs9309473	0.583	rs35885918	ENSG00000163016.8	ALMS1P	5.64	2.24e-08	3.07e-06	0.21	0.17	Metabolite levels;	chr2:73385106	chr2:73644919~73685576:+
BRCA	cis	rs4819052	0.851	rs1056100	ENSG00000184274.3	LINC00315	-5.64	2.24e-08	3.07e-06	-0.23	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258796	chr21:45300245~45305257:-
BRCA	cis	rs6688613	0.729	rs10918603	ENSG00000225171.2	DUTP6	-5.64	2.24e-08	3.07e-06	-0.24	-0.17	Refractive astigmatism;	chr1:166967266	chr1:166868748~166869209:+
BRCA	cis	rs35612822	0.897	rs2280043	ENSG00000232485.2	AC098820.3	-5.64	2.24e-08	3.07e-06	-0.22	-0.17	Kidney disease (early stage) in type 1 diabetes;	chr2:216477673	chr2:216479030~216498761:-
BRCA	cis	rs11105298	0.891	rs10858909	ENSG00000270344.2	RP11-734K2.4	5.64	2.24e-08	3.08e-06	0.2	0.17	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89541610	chr12:89525654~89548005:+
BRCA	cis	rs962856	0.964	rs11890812	ENSG00000236780.4	AC078941.1	5.64	2.25e-08	3.08e-06	0.22	0.17	Pancreatic cancer;	chr2:67392883	chr2:67123357~67215319:-
BRCA	cis	rs875971	0.522	rs10807697	ENSG00000273024.4	INTS4P2	-5.64	2.25e-08	3.08e-06	-0.19	-0.17	Aortic root size;	chr7:65951183	chr7:65647864~65715661:+
BRCA	cis	rs7804306	1	rs35143180	ENSG00000233264.2	AC006042.8	5.64	2.25e-08	3.08e-06	0.38	0.17	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8017141	chr7:7980312~7982228:+
BRCA	cis	rs7618501	0.601	rs2624825	ENSG00000228008.1	CTD-2330K9.3	-5.64	2.25e-08	3.08e-06	-0.17	-0.17	Intelligence (multi-trait analysis);	chr3:50117556	chr3:49903845~49916937:+
BRCA	cis	rs763121	0.889	rs6001209	ENSG00000225450.1	RP3-508I15.14	5.64	2.25e-08	3.08e-06	0.18	0.17	Menopause (age at onset);	chr22:38725247	chr22:38739003~38749041:+
BRCA	cis	rs3764021	0.87	rs10466829	ENSG00000214776.8	RP11-726G1.1	5.64	2.25e-08	3.08e-06	0.19	0.17	Type 1 diabetes;	chr12:9723495	chr12:9467552~9576275:+
BRCA	cis	rs595982	0.527	rs73061659	ENSG00000235191.1	NUCB1-AS1	5.64	2.25e-08	3.08e-06	0.3	0.17	Red cell distribution width;	chr19:48870299	chr19:48910930~48918891:-
BRCA	cis	rs7927771	0.524	rs4752860	ENSG00000280615.1	Y_RNA	-5.64	2.25e-08	3.09e-06	-0.2	-0.17	Subjective well-being;	chr11:47683463	chr11:47614898~47614994:-
BRCA	cis	rs7927771	0.542	rs11039336	ENSG00000280615.1	Y_RNA	-5.64	2.25e-08	3.09e-06	-0.2	-0.17	Subjective well-being;	chr11:47684589	chr11:47614898~47614994:-
BRCA	cis	rs2638953	0.853	rs11049668	ENSG00000278733.1	RP11-425D17.1	-5.63	2.25e-08	3.09e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28497680	chr12:28185625~28186190:-
BRCA	cis	rs42648	0.564	rs1541428	ENSG00000225498.1	AC002064.5	5.63	2.26e-08	3.09e-06	0.16	0.17	Homocysteine levels;	chr7:90206965	chr7:90312496~90322592:+
BRCA	cis	rs9287719	0.649	rs2160258	ENSG00000243819.4	RN7SL832P	5.63	2.26e-08	3.1e-06	0.17	0.17	Prostate cancer;	chr2:10577095	chr2:10690344~10692099:+
BRCA	cis	rs375066	0.592	rs349047	ENSG00000267058.1	RP11-15A1.3	5.63	2.26e-08	3.1e-06	0.19	0.17	Breast cancer;	chr19:43796732	chr19:43891804~43901805:-
BRCA	cis	rs72799341	0.706	rs59735493	ENSG00000260911.2	RP11-196G11.2	5.63	2.26e-08	3.1e-06	0.16	0.17	Diastolic blood pressure;	chr16:31121779	chr16:31043150~31049868:+
BRCA	cis	rs2179367	0.632	rs6920383	ENSG00000223701.3	RAET1E-AS1	5.63	2.26e-08	3.1e-06	0.25	0.17	Dupuytren's disease;	chr6:149356361	chr6:149884431~149919508:+
BRCA	cis	rs12681366	0.734	rs6991077	ENSG00000253704.1	RP11-267M23.4	5.63	2.26e-08	3.1e-06	0.18	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94375577	chr8:94553722~94569745:+
BRCA	cis	rs228614	0.51	rs65671	ENSG00000251288.2	RP11-10L12.2	-5.63	2.26e-08	3.1e-06	-0.2	-0.17	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102801081	chr4:102751401~102752641:+
BRCA	cis	rs1979679	0.76	rs16932640	ENSG00000278733.1	RP11-425D17.1	5.63	2.26e-08	3.1e-06	0.21	0.17	Ossification of the posterior longitudinal ligament of the spine;	chr12:28142034	chr12:28185625~28186190:-
BRCA	cis	rs1552244	0.882	rs2130813	ENSG00000232901.1	CYCSP10	5.63	2.26e-08	3.1e-06	0.24	0.17	Alzheimer's disease;	chr3:9997022	chr3:10000647~10000940:-
BRCA	cis	rs1552244	0.882	rs17081288	ENSG00000232901.1	CYCSP10	5.63	2.26e-08	3.1e-06	0.24	0.17	Alzheimer's disease;	chr3:10000429	chr3:10000647~10000940:-
BRCA	cis	rs1552244	0.816	rs56271597	ENSG00000232901.1	CYCSP10	5.63	2.26e-08	3.1e-06	0.24	0.17	Alzheimer's disease;	chr3:10001106	chr3:10000647~10000940:-
BRCA	cis	rs987360	0.931	rs1426002	ENSG00000248869.4	RP11-138I17.1	5.63	2.26e-08	3.1e-06	0.17	0.17	Temperament;	chr4:137299011	chr4:136796722~137212799:-
BRCA	cis	rs4835473	0.77	rs4835096	ENSG00000249741.2	RP11-673E1.3	-5.63	2.27e-08	3.1e-06	-0.18	-0.17	Immature fraction of reticulocytes;	chr4:143960685	chr4:143911514~143912053:-
BRCA	cis	rs4950322	0.518	rs56151278	ENSG00000278811.3	LINC00624	5.63	2.27e-08	3.11e-06	0.23	0.17	Protein quantitative trait loci;	chr1:147117421	chr1:147258885~147517875:-
BRCA	cis	rs2638953	0.886	rs10492369	ENSG00000247934.4	RP11-967K21.1	5.63	2.27e-08	3.11e-06	0.23	0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28172185	chr12:28163298~28190738:-
BRCA	cis	rs2904967	1	rs636928	ENSG00000254614.2	AP003068.23	5.63	2.27e-08	3.11e-06	0.32	0.17	Mean corpuscular volume;	chr11:65326013	chr11:65177606~65181834:-
BRCA	cis	rs860295	0.702	rs11264375	ENSG00000160766.13	GBAP1	5.63	2.27e-08	3.11e-06	0.18	0.17	Body mass index;	chr1:155454274	chr1:155213821~155227422:-
BRCA	cis	rs1859596	1	rs4560732	ENSG00000234456.6	MAGI2-AS3	5.63	2.27e-08	3.11e-06	0.11	0.17	Reading or mathematical ability;	chr7:79486307	chr7:79452877~79471208:+
BRCA	cis	rs300890	0.536	rs632359	ENSG00000250326.1	RP11-284M14.1	-5.63	2.27e-08	3.11e-06	-0.21	-0.17	Nasopharyngeal carcinoma;	chr4:143246830	chr4:142933195~143184861:-
BRCA	cis	rs8114671	0.562	rs6088635	ENSG00000269202.1	RP4-614O4.12	-5.63	2.27e-08	3.11e-06	-0.18	-0.17	Height;	chr20:34878698	chr20:35201747~35203288:-
BRCA	cis	rs7520050	0.933	rs6680211	ENSG00000280836.1	AL355480.1	5.63	2.27e-08	3.11e-06	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:45849335	chr1:45581219~45581321:-
BRCA	cis	rs13423976	0.546	rs10184164	ENSG00000231367.4	AC016995.3	5.63	2.27e-08	3.11e-06	0.19	0.17	Gut microbiome composition (summer);	chr2:38514411	chr2:38406719~38515740:-
BRCA	cis	rs13126694	0.744	rs10003459	ENSG00000248429.4	RP11-597D13.9	-5.63	2.27e-08	3.11e-06	-0.16	-0.17	Blood osmolality (transformed sodium);	chr4:158095602	chr4:158170752~158202877:+
BRCA	cis	rs13118159	0.509	rs1882098	ENSG00000254094.1	AC078852.1	-5.63	2.27e-08	3.12e-06	-0.21	-0.17	Longevity;	chr4:1358643	chr4:1356581~1358075:+
BRCA	cis	rs516805	0.667	rs2606617	ENSG00000279453.1	RP3-425C14.4	-5.63	2.27e-08	3.12e-06	-0.24	-0.17	Lymphocyte counts;	chr6:122182619	chr6:122436789~122439223:-
BRCA	cis	rs7520050	0.933	rs9787208	ENSG00000280836.1	AL355480.1	5.63	2.28e-08	3.12e-06	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:45848944	chr1:45581219~45581321:-
BRCA	cis	rs7520050	0.966	rs6677007	ENSG00000280836.1	AL355480.1	5.63	2.28e-08	3.12e-06	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:45934918	chr1:45581219~45581321:-
BRCA	cis	rs7520050	0.966	rs4660898	ENSG00000280836.1	AL355480.1	5.63	2.28e-08	3.12e-06	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:45936499	chr1:45581219~45581321:-
BRCA	cis	rs875971	0.545	rs2460427	ENSG00000228409.4	CCT6P1	5.63	2.28e-08	3.12e-06	0.17	0.17	Aortic root size;	chr7:66154218	chr7:65751142~65763354:+
BRCA	cis	rs1552244	0.882	rs3846168	ENSG00000232901.1	CYCSP10	5.63	2.28e-08	3.12e-06	0.24	0.17	Alzheimer's disease;	chr3:9955241	chr3:10000647~10000940:-
BRCA	cis	rs7927592	0.871	rs11228284	ENSG00000212093.1	AP000807.1	5.63	2.28e-08	3.12e-06	0.2	0.17	Total body bone mineral density;	chr11:68555299	chr11:68506083~68506166:-
BRCA	cis	rs2638953	0.924	rs17801436	ENSG00000278733.1	RP11-425D17.1	-5.63	2.28e-08	3.12e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28165421	chr12:28185625~28186190:-
BRCA	cis	rs11159086	0.729	rs8015872	ENSG00000270000.1	RP3-449M8.9	5.63	2.28e-08	3.13e-06	0.26	0.17	Advanced glycation end-product levels;	chr14:74475529	chr14:74471930~74472360:-
BRCA	cis	rs9309473	0.607	rs11686504	ENSG00000163016.8	ALMS1P	5.63	2.29e-08	3.13e-06	0.21	0.17	Metabolite levels;	chr2:73352684	chr2:73644919~73685576:+
BRCA	cis	rs4908760	0.965	rs10864356	ENSG00000270282.1	RP5-1115A15.2	5.63	2.29e-08	3.13e-06	0.18	0.17	Vitiligo;	chr1:8509812	chr1:8512653~8513021:+
BRCA	cis	rs4908768	0.501	rs11121194	ENSG00000270282.1	RP5-1115A15.2	5.63	2.29e-08	3.13e-06	0.18	0.17	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8509847	chr1:8512653~8513021:+
BRCA	cis	rs9341808	0.754	rs10733162	ENSG00000272129.1	RP11-250B2.6	5.63	2.29e-08	3.13e-06	0.21	0.17	Sitting height ratio;	chr6:80313672	chr6:80355424~80356859:+
BRCA	cis	rs73193808	0.901	rs8132759	ENSG00000215533.7	LINC00189	-5.63	2.29e-08	3.14e-06	-0.25	-0.17	Coronary artery disease;	chr21:29218630	chr21:29193480~29288205:+
BRCA	cis	rs6951245	0.554	rs4724294	ENSG00000229043.2	AC091729.9	-5.63	2.29e-08	3.14e-06	-0.26	-0.17	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1100059	chr7:1160374~1165267:+
BRCA	cis	rs7927592	0.913	rs948316	ENSG00000212093.1	AP000807.1	5.63	2.29e-08	3.14e-06	0.2	0.17	Total body bone mineral density;	chr11:68542202	chr11:68506083~68506166:-
BRCA	cis	rs7567389	0.719	rs6744237	ENSG00000236682.1	AC068282.3	5.63	2.29e-08	3.14e-06	0.27	0.17	Self-rated health;	chr2:127246469	chr2:127389130~127400580:+
BRCA	cis	rs7772486	0.754	rs9386133	ENSG00000270638.1	RP3-466P17.1	5.63	2.29e-08	3.14e-06	0.2	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145820077	chr6:145735570~145737218:+
BRCA	cis	rs2692947	0.759	rs11687113	ENSG00000237510.6	AC008268.2	5.63	2.3e-08	3.15e-06	0.23	0.17	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95992840	chr2:95789654~95800166:+
BRCA	cis	rs910316	0.934	rs7141705	ENSG00000279594.1	RP11-950C14.10	-5.63	2.3e-08	3.15e-06	-0.19	-0.17	Height;	chr14:75188649	chr14:75011269~75012851:-
BRCA	cis	rs4713118	0.869	rs4713121	ENSG00000216901.1	AL022393.7	5.63	2.3e-08	3.15e-06	0.23	0.17	Parkinson's disease;	chr6:27754285	chr6:28176188~28176674:+
BRCA	cis	rs7520050	0.966	rs10789475	ENSG00000280836.1	AL355480.1	5.63	2.3e-08	3.15e-06	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:45838505	chr1:45581219~45581321:-
BRCA	cis	rs7615952	0.599	rs6438953	ENSG00000171084.14	FAM86JP	5.63	2.3e-08	3.15e-06	0.25	0.17	Blood pressure (smoking interaction);	chr3:126006108	chr3:125916620~125930024:+
BRCA	cis	rs7615952	0.599	rs1044215	ENSG00000171084.14	FAM86JP	5.63	2.3e-08	3.15e-06	0.25	0.17	Blood pressure (smoking interaction);	chr3:126006716	chr3:125916620~125930024:+
BRCA	cis	rs250585	1	rs7203580	ENSG00000260136.4	CTD-2270L9.4	-5.63	2.3e-08	3.15e-06	-0.2	-0.17	Egg allergy;	chr16:23492927	chr16:23452758~23457606:+
BRCA	cis	rs4650994	0.525	rs4076563	ENSG00000273384.1	RP5-1098D14.1	5.63	2.3e-08	3.15e-06	0.22	0.17	HDL cholesterol;HDL cholesterol levels;	chr1:178547766	chr1:178651706~178652282:+
BRCA	cis	rs4650994	0.525	rs4650996	ENSG00000273384.1	RP5-1098D14.1	5.63	2.3e-08	3.15e-06	0.22	0.17	HDL cholesterol;HDL cholesterol levels;	chr1:178548230	chr1:178651706~178652282:+
BRCA	cis	rs6750795	0.569	rs1797387	ENSG00000223198.1	RNU2-22P	-5.63	2.3e-08	3.15e-06	-0.21	-0.17	Height;	chr2:231549981	chr2:231501990~231502201:-
BRCA	cis	rs13108904	0.518	rs4974602	ENSG00000254094.1	AC078852.1	-5.63	2.3e-08	3.15e-06	-0.21	-0.17	Obesity-related traits;	chr4:1348603	chr4:1356581~1358075:+
BRCA	cis	rs667920	0.575	rs9861150	ENSG00000239213.4	NCK1-AS1	5.63	2.3e-08	3.15e-06	0.23	0.17	Coronary artery disease;	chr3:136464478	chr3:136841726~136862054:-
BRCA	cis	rs4835473	0.897	rs12505617	ENSG00000249741.2	RP11-673E1.3	-5.63	2.3e-08	3.15e-06	-0.19	-0.17	Immature fraction of reticulocytes;	chr4:143723522	chr4:143911514~143912053:-
BRCA	cis	rs55692411	0.537	rs62262118	ENSG00000228008.1	CTD-2330K9.3	5.63	2.3e-08	3.15e-06	0.2	0.17	Intelligence (multi-trait analysis);	chr3:49966153	chr3:49903845~49916937:+
BRCA	cis	rs7923609	1	rs4399232	ENSG00000232075.1	MRPL35P2	-5.63	2.3e-08	3.15e-06	-0.21	-0.17	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63239730	chr10:63634317~63634827:-
BRCA	cis	rs7567389	0.719	rs4662713	ENSG00000236682.1	AC068282.3	5.63	2.31e-08	3.15e-06	0.26	0.17	Self-rated health;	chr2:127236527	chr2:127389130~127400580:+
BRCA	cis	rs4950322	0.515	rs17160050	ENSG00000244371.2	PFN1P8	-5.63	2.31e-08	3.16e-06	-0.23	-0.17	Protein quantitative trait loci;	chr1:147255558	chr1:146957117~146957659:-
BRCA	cis	rs7520050	0.933	rs6666743	ENSG00000280836.1	AL355480.1	5.63	2.31e-08	3.16e-06	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:45845603	chr1:45581219~45581321:-
BRCA	cis	rs853679	0.607	rs72846780	ENSG00000204709.4	LINC01556	5.63	2.31e-08	3.16e-06	0.47	0.17	Depression;	chr6:28151277	chr6:28943877~28944537:+
BRCA	cis	rs853679	0.607	rs13205911	ENSG00000204709.4	LINC01556	5.63	2.31e-08	3.16e-06	0.47	0.17	Depression;	chr6:28156336	chr6:28943877~28944537:+
BRCA	cis	rs853679	0.607	rs13197176	ENSG00000204709.4	LINC01556	5.63	2.31e-08	3.16e-06	0.47	0.17	Depression;	chr6:28161454	chr6:28943877~28944537:+
BRCA	cis	rs853679	0.607	rs13201308	ENSG00000204709.4	LINC01556	5.63	2.31e-08	3.16e-06	0.47	0.17	Depression;	chr6:28162311	chr6:28943877~28944537:+
BRCA	cis	rs853679	0.607	rs34505829	ENSG00000204709.4	LINC01556	5.63	2.31e-08	3.16e-06	0.47	0.17	Depression;	chr6:28165461	chr6:28943877~28944537:+
BRCA	cis	rs853679	0.607	rs35098436	ENSG00000204709.4	LINC01556	5.63	2.31e-08	3.16e-06	0.47	0.17	Depression;	chr6:28166443	chr6:28943877~28944537:+
BRCA	cis	rs853679	0.607	rs72846794	ENSG00000204709.4	LINC01556	5.63	2.31e-08	3.16e-06	0.47	0.17	Depression;	chr6:28169721	chr6:28943877~28944537:+
BRCA	cis	rs853679	0.607	rs13217984	ENSG00000204709.4	LINC01556	5.63	2.31e-08	3.16e-06	0.47	0.17	Depression;	chr6:28171932	chr6:28943877~28944537:+
BRCA	cis	rs853679	0.505	rs35781323	ENSG00000204709.4	LINC01556	5.63	2.31e-08	3.16e-06	0.47	0.17	Depression;	chr6:28177054	chr6:28943877~28944537:+
BRCA	cis	rs4950322	0.517	rs114823926	ENSG00000244371.2	PFN1P8	-5.63	2.31e-08	3.16e-06	-0.24	-0.17	Protein quantitative trait loci;	chr1:147281805	chr1:146957117~146957659:-
BRCA	cis	rs11098499	0.604	rs2389882	ENSG00000249244.1	RP11-548H18.2	5.63	2.31e-08	3.16e-06	0.21	0.17	Corneal astigmatism;	chr4:119645578	chr4:119391831~119395335:-
BRCA	cis	rs2502757	0.871	rs2510235	ENSG00000225756.1	DBH-AS1	-5.63	2.31e-08	3.16e-06	-0.18	-0.17	Asthma;	chr9:133725256	chr9:133654586~133657313:-
BRCA	cis	rs12501370	0.721	rs17588767	ENSG00000201736.1	RNA5SP160	-5.63	2.31e-08	3.17e-06	-0.23	-0.17	Iris color (L* coordinate);	chr4:41061246	chr4:40990154~40990273:+
BRCA	cis	rs3733585	0.699	rs4473653	ENSG00000250413.1	RP11-448G15.1	5.63	2.32e-08	3.17e-06	0.22	0.17	Cleft plate (environmental tobacco smoke interaction);	chr4:9969434	chr4:10006482~10009725:+
BRCA	cis	rs1014246	0.813	rs1014245	ENSG00000232767.1	RP11-498B4.5	-5.63	2.32e-08	3.17e-06	-0.19	-0.17	Age at smoking initiation in chronic obstructive pulmonary disease;	chr10:116706618	chr10:116670103~116672739:+
BRCA	cis	rs2098713	0.569	rs13155335	ENSG00000250155.1	CTD-2353F22.1	-5.63	2.32e-08	3.17e-06	-0.2	-0.17	Telomere length;	chr5:37506809	chr5:36666214~36725195:-
BRCA	cis	rs454217	0.715	rs400708	ENSG00000277851.1	RP11-756G20.1	5.63	2.32e-08	3.17e-06	0.19	0.17	Smoking quantity;	chr12:92320502	chr12:92247756~92363832:-
BRCA	cis	rs4908760	0.931	rs1463049	ENSG00000270282.1	RP5-1115A15.2	5.63	2.32e-08	3.17e-06	0.18	0.17	Vitiligo;	chr1:8537049	chr1:8512653~8513021:+
BRCA	cis	rs10875943	0.751	rs56222401	ENSG00000258017.1	RP11-386G11.10	-5.63	2.32e-08	3.17e-06	-0.24	-0.17	Prostate cancer;	chr12:49278931	chr12:49127782~49147869:+
BRCA	cis	rs8098244	0.894	rs8099763	ENSG00000264745.1	TTC39C-AS1	5.63	2.32e-08	3.18e-06	0.22	0.17	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23829100	chr18:23994213~24015339:-
BRCA	cis	rs910316	0.763	rs175047	ENSG00000279594.1	RP11-950C14.10	-5.63	2.32e-08	3.18e-06	-0.19	-0.17	Height;	chr14:75012336	chr14:75011269~75012851:-
BRCA	cis	rs3743162	0.553	rs4842994	ENSG00000259728.4	LINC00933	-5.63	2.32e-08	3.18e-06	-0.24	-0.17	Alzheimer's disease (age of onset);	chr15:84872568	chr15:84570649~84580175:+
BRCA	cis	rs7923609	1	rs4379723	ENSG00000232075.1	MRPL35P2	-5.63	2.32e-08	3.18e-06	-0.21	-0.17	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63203689	chr10:63634317~63634827:-
BRCA	cis	rs7923609	1	rs10822149	ENSG00000232075.1	MRPL35P2	-5.63	2.32e-08	3.18e-06	-0.21	-0.17	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63227652	chr10:63634317~63634827:-
BRCA	cis	rs7923609	1	rs10761727	ENSG00000232075.1	MRPL35P2	-5.63	2.32e-08	3.18e-06	-0.21	-0.17	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63235733	chr10:63634317~63634827:-
BRCA	cis	rs7923609	0.967	rs10761729	ENSG00000232075.1	MRPL35P2	-5.63	2.32e-08	3.18e-06	-0.21	-0.17	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63235844	chr10:63634317~63634827:-
BRCA	cis	rs4664293	0.51	rs2042781	ENSG00000226266.5	AC009961.3	5.63	2.33e-08	3.18e-06	0.21	0.17	Monocyte percentage of white cells;	chr2:159789899	chr2:159670708~159712435:-
BRCA	cis	rs73222236	0.825	rs9819496	ENSG00000273486.1	RP11-731C17.2	5.63	2.33e-08	3.18e-06	0.19	0.17	Coronary artery disease;	chr3:136421036	chr3:136837338~136839021:-
BRCA	cis	rs4604234	0.522	rs3805914	ENSG00000272129.1	RP11-250B2.6	5.63	2.33e-08	3.18e-06	0.38	0.17	Cancer;	chr6:80206269	chr6:80355424~80356859:+
BRCA	cis	rs8114671	0.562	rs8116657	ENSG00000269202.1	RP4-614O4.12	-5.63	2.33e-08	3.18e-06	-0.18	-0.17	Height;	chr20:34888671	chr20:35201747~35203288:-
BRCA	cis	rs62025270	0.632	rs55981798	ENSG00000202081.1	RNU6-1280P	-5.63	2.33e-08	3.18e-06	-0.25	-0.17	Idiopathic pulmonary fibrosis;	chr15:85600869	chr15:85651522~85651628:-
BRCA	cis	rs62025270	0.576	rs17633959	ENSG00000202081.1	RNU6-1280P	-5.63	2.33e-08	3.18e-06	-0.25	-0.17	Idiopathic pulmonary fibrosis;	chr15:85600950	chr15:85651522~85651628:-
BRCA	cis	rs853679	0.55	rs1233707	ENSG00000280107.1	AL022393.9	-5.63	2.33e-08	3.18e-06	-0.24	-0.17	Depression;	chr6:28205175	chr6:28170845~28172521:+
BRCA	cis	rs66887589	0.616	rs11732621	ENSG00000245958.5	RP11-33B1.1	-5.63	2.33e-08	3.18e-06	-0.16	-0.17	Diastolic blood pressure;	chr4:119291728	chr4:119454791~119552025:+
BRCA	cis	rs12439619	0.508	rs11856561	ENSG00000259429.4	UBE2Q2P2	-5.63	2.33e-08	3.19e-06	-0.17	-0.17	Intelligence (multi-trait analysis);	chr15:82161415	chr15:82355142~82420075:+
BRCA	cis	rs873549	1	rs2378519	ENSG00000232679.1	RP11-400N13.3	5.63	2.33e-08	3.19e-06	0.2	0.17	Keloid;	chr1:222100526	chr1:222041705~222064763:-
BRCA	cis	rs73198271	0.583	rs11781985	ENSG00000253893.2	FAM85B	-5.63	2.33e-08	3.19e-06	-0.24	-0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8732273	chr8:8167819~8226614:-
BRCA	cis	rs891378	0.92	rs10864156	ENSG00000274245.1	RP11-357P18.2	-5.63	2.33e-08	3.19e-06	-0.23	-0.17	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207240416	chr1:207372559~207373252:+
BRCA	cis	rs11671005	0.735	rs34188294	ENSG00000252334.1	RNU6-1337P	5.63	2.33e-08	3.19e-06	0.26	0.17	Mean platelet volume;	chr19:58408190	chr19:58483749~58483843:-
BRCA	cis	rs2243480	1	rs1039664	ENSG00000232559.3	GS1-124K5.12	5.63	2.33e-08	3.19e-06	0.32	0.17	Diabetic kidney disease;	chr7:65984729	chr7:66554588~66576923:-
BRCA	cis	rs6969780	0.778	rs11564055	ENSG00000233429.8	HOTAIRM1	5.63	2.34e-08	3.19e-06	0.22	0.17	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27105731	chr7:27095647~27100265:+
BRCA	cis	rs6969780	0.778	rs2428434	ENSG00000233429.8	HOTAIRM1	5.63	2.34e-08	3.19e-06	0.22	0.17	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27106116	chr7:27095647~27100265:+
BRCA	cis	rs7308116	0.546	rs61938642	ENSG00000274395.1	RP11-554D14.8	-5.63	2.34e-08	3.2e-06	-0.2	-0.17	Pelvic organ prolapse (moderate/severe);	chr12:107831405	chr12:107835541~107836555:-
BRCA	cis	rs7308116	0.546	rs11833836	ENSG00000274395.1	RP11-554D14.8	-5.63	2.34e-08	3.2e-06	-0.2	-0.17	Pelvic organ prolapse (moderate/severe);	chr12:107831555	chr12:107835541~107836555:-
BRCA	cis	rs7308116	0.546	rs877463	ENSG00000274395.1	RP11-554D14.8	-5.63	2.34e-08	3.2e-06	-0.2	-0.17	Pelvic organ prolapse (moderate/severe);	chr12:107832040	chr12:107835541~107836555:-
BRCA	cis	rs7308116	0.528	rs2081583	ENSG00000274395.1	RP11-554D14.8	-5.63	2.34e-08	3.2e-06	-0.2	-0.17	Pelvic organ prolapse (moderate/severe);	chr12:107832514	chr12:107835541~107836555:-
BRCA	cis	rs1555322	0.53	rs2425044	ENSG00000269202.1	RP4-614O4.12	-5.63	2.34e-08	3.2e-06	-0.21	-0.17	Attention deficit hyperactivity disorder;	chr20:35281932	chr20:35201747~35203288:-
BRCA	cis	rs8098244	0.964	rs2082047	ENSG00000264745.1	TTC39C-AS1	5.63	2.34e-08	3.2e-06	0.23	0.17	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23909922	chr18:23994213~24015339:-
BRCA	cis	rs8180040	0.966	rs12636851	ENSG00000276925.1	RP11-708J19.3	-5.63	2.34e-08	3.2e-06	-0.2	-0.17	Colorectal cancer;	chr3:47422077	chr3:47469777~47469987:+
BRCA	cis	rs6479891	1	rs16918573	ENSG00000232075.1	MRPL35P2	5.63	2.35e-08	3.21e-06	0.31	0.17	Arthritis (juvenile idiopathic);	chr10:63541045	chr10:63634317~63634827:-
BRCA	cis	rs651907	0.535	rs58658478	ENSG00000244119.1	PDCL3P4	5.63	2.35e-08	3.21e-06	0.14	0.17	Colorectal cancer;	chr3:101792823	chr3:101712472~101713191:+
BRCA	cis	rs300890	0.513	rs6812522	ENSG00000250326.1	RP11-284M14.1	-5.63	2.35e-08	3.21e-06	-0.21	-0.17	Nasopharyngeal carcinoma;	chr4:143176918	chr4:142933195~143184861:-
BRCA	cis	rs300890	0.513	rs7692813	ENSG00000250326.1	RP11-284M14.1	-5.63	2.35e-08	3.21e-06	-0.21	-0.17	Nasopharyngeal carcinoma;	chr4:143177940	chr4:142933195~143184861:-
BRCA	cis	rs300890	0.513	rs12640698	ENSG00000250326.1	RP11-284M14.1	-5.63	2.35e-08	3.21e-06	-0.21	-0.17	Nasopharyngeal carcinoma;	chr4:143182941	chr4:142933195~143184861:-
BRCA	cis	rs1440410	0.536	rs11100779	ENSG00000250326.1	RP11-284M14.1	-5.63	2.35e-08	3.21e-06	-0.21	-0.17	Ischemic stroke;	chr4:143183611	chr4:142933195~143184861:-
BRCA	cis	rs5758511	0.633	rs5751258	ENSG00000233903.2	Z83851.4	5.63	2.35e-08	3.21e-06	0.26	0.17	Birth weight;	chr22:42267865	chr22:42276355~42277052:+
BRCA	cis	rs10761482	0.5	rs10740030	ENSG00000254271.1	RP11-131N11.4	5.63	2.35e-08	3.21e-06	0.23	0.17	Schizophrenia;	chr10:60532054	chr10:60734342~60741828:+
BRCA	cis	rs7674212	0.541	rs2720471	ENSG00000248740.4	RP11-328K4.1	5.63	2.35e-08	3.21e-06	0.2	0.17	Type 2 diabetes;	chr4:103102683	chr4:103256159~103453658:+
BRCA	cis	rs2638953	0.853	rs10506037	ENSG00000247934.4	RP11-967K21.1	-5.63	2.35e-08	3.21e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28498213	chr12:28163298~28190738:-
BRCA	cis	rs11159086	0.793	rs8021664	ENSG00000270000.1	RP3-449M8.9	5.63	2.35e-08	3.21e-06	0.26	0.17	Advanced glycation end-product levels;	chr14:74476592	chr14:74471930~74472360:-
BRCA	cis	rs801193	0.569	rs2707824	ENSG00000224316.1	RP11-479O9.2	5.63	2.35e-08	3.21e-06	0.17	0.17	Aortic root size;	chr7:66724256	chr7:65773620~65802067:+
BRCA	cis	rs4588572	0.644	rs6882191	ENSG00000245556.2	SCAMP1-AS1	-5.63	2.35e-08	3.21e-06	-0.2	-0.17	Triglycerides;	chr5:78447274	chr5:78342365~78360507:-
BRCA	cis	rs9308731	0.591	rs10439396	ENSG00000227992.1	AC108463.2	-5.63	2.35e-08	3.22e-06	-0.2	-0.17	Chronic lymphocytic leukemia;	chr2:111178399	chr2:111203964~111206215:-
BRCA	cis	rs853679	0.55	rs1150689	ENSG00000280107.1	AL022393.9	-5.63	2.35e-08	3.22e-06	-0.24	-0.17	Depression;	chr6:28197321	chr6:28170845~28172521:+
BRCA	cis	rs853679	0.55	rs1225599	ENSG00000280107.1	AL022393.9	-5.63	2.35e-08	3.22e-06	-0.24	-0.17	Depression;	chr6:28197412	chr6:28170845~28172521:+
BRCA	cis	rs853679	0.574	rs1233705	ENSG00000280107.1	AL022393.9	-5.63	2.35e-08	3.22e-06	-0.24	-0.17	Depression;	chr6:28198669	chr6:28170845~28172521:+
BRCA	cis	rs4664293	0.528	rs56027129	ENSG00000226266.5	AC009961.3	5.63	2.35e-08	3.22e-06	0.22	0.17	Monocyte percentage of white cells;	chr2:159600091	chr2:159670708~159712435:-
BRCA	cis	rs2253762	0.54	rs79547192	ENSG00000276742.1	RP11-500G22.4	5.63	2.36e-08	3.22e-06	0.3	0.17	Breast cancer;	chr10:121998664	chr10:121956782~121957098:+
BRCA	cis	rs801193	0.527	rs2707837	ENSG00000224316.1	RP11-479O9.2	5.63	2.36e-08	3.22e-06	0.17	0.17	Aortic root size;	chr7:66716086	chr7:65773620~65802067:+
BRCA	cis	rs1075265	0.587	rs2542585	ENSG00000235937.1	AC008280.1	5.63	2.36e-08	3.22e-06	0.19	0.17	Chronotype;Morning vs. evening chronotype;	chr2:53786407	chr2:54029552~54030682:-
BRCA	cis	rs467650	0.853	rs456470	ENSG00000248489.1	CTD-2007H13.3	5.63	2.36e-08	3.22e-06	0.2	0.17	Venous thromboembolism (SNP x SNP interaction);	chr5:98687777	chr5:98929171~98995013:+
BRCA	cis	rs919433	0.51	rs34631382	ENSG00000231621.1	AC013264.2	-5.63	2.36e-08	3.22e-06	-0.16	-0.17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197525285	chr2:197197991~197199273:+
BRCA	cis	rs7308116	0.546	rs7488087	ENSG00000274395.1	RP11-554D14.8	-5.63	2.36e-08	3.22e-06	-0.2	-0.17	Pelvic organ prolapse (moderate/severe);	chr12:107829479	chr12:107835541~107836555:-
BRCA	cis	rs7308116	0.546	rs12306039	ENSG00000274395.1	RP11-554D14.8	-5.63	2.36e-08	3.22e-06	-0.2	-0.17	Pelvic organ prolapse (moderate/severe);	chr12:107829581	chr12:107835541~107836555:-
BRCA	cis	rs7308116	0.546	rs12306046	ENSG00000274395.1	RP11-554D14.8	-5.63	2.36e-08	3.22e-06	-0.2	-0.17	Pelvic organ prolapse (moderate/severe);	chr12:107829616	chr12:107835541~107836555:-
BRCA	cis	rs4604234	0.803	rs73463531	ENSG00000272129.1	RP11-250B2.6	-5.63	2.36e-08	3.22e-06	-0.42	-0.17	Cancer;	chr6:80274328	chr6:80355424~80356859:+
BRCA	cis	rs61160187	0.66	rs12517207	ENSG00000215032.2	GNL3LP1	5.63	2.36e-08	3.23e-06	0.21	0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:60697441	chr5:60891935~60893577:-
BRCA	cis	rs7976269	0.559	rs9651838	ENSG00000257176.2	RP11-996F15.2	5.63	2.36e-08	3.23e-06	0.2	0.17	Male-pattern baldness;	chr12:28999700	chr12:29280418~29317848:-
BRCA	cis	rs2749097	0.609	rs2269238	ENSG00000244256.3	RN7SL130P	5.63	2.36e-08	3.23e-06	0.23	0.17	Alcohol consumption (transferrin glycosylation);	chr1:63651866	chr1:63655743~63656047:+
BRCA	cis	rs13108904	0.539	rs13141169	ENSG00000254094.1	AC078852.1	-5.63	2.36e-08	3.23e-06	-0.21	-0.17	Obesity-related traits;	chr4:1346565	chr4:1356581~1358075:+
BRCA	cis	rs490234	0.552	rs3122938	ENSG00000232630.1	PRPS1P2	5.63	2.37e-08	3.23e-06	0.17	0.17	Mean arterial pressure;	chr9:125395047	chr9:125150653~125151589:+
BRCA	cis	rs7208859	0.673	rs2269915	ENSG00000266490.1	CTD-2349P21.9	5.63	2.37e-08	3.23e-06	0.27	0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30906326	chr17:30792372~30792833:+
BRCA	cis	rs7208859	0.673	rs2269916	ENSG00000266490.1	CTD-2349P21.9	5.63	2.37e-08	3.23e-06	0.27	0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30906745	chr17:30792372~30792833:+
BRCA	cis	rs7208859	0.673	rs11649765	ENSG00000266490.1	CTD-2349P21.9	5.63	2.37e-08	3.23e-06	0.27	0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30906870	chr17:30792372~30792833:+
BRCA	cis	rs1707322	0.964	rs6697830	ENSG00000281133.1	AL355480.3	-5.63	2.37e-08	3.23e-06	-0.21	-0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45824805	chr1:45580892~45580996:-
BRCA	cis	rs721917	0.506	rs2758543	ENSG00000244733.5	RP11-506M13.3	-5.63	2.37e-08	3.23e-06	-0.2	-0.17	Chronic obstructive pulmonary disease;	chr10:79902710	chr10:79660891~79677996:+
BRCA	cis	rs721917	0.525	rs2250473	ENSG00000244733.5	RP11-506M13.3	-5.63	2.37e-08	3.23e-06	-0.2	-0.17	Chronic obstructive pulmonary disease;	chr10:79904639	chr10:79660891~79677996:+
BRCA	cis	rs9402743	0.671	rs6925684	ENSG00000231028.7	LINC00271	-5.63	2.37e-08	3.23e-06	-0.18	-0.17	Systemic lupus erythematosus;	chr6:135615740	chr6:135497801~135716055:+
BRCA	cis	rs9402743	0.671	rs6905536	ENSG00000231028.7	LINC00271	-5.63	2.37e-08	3.23e-06	-0.18	-0.17	Systemic lupus erythematosus;	chr6:135615865	chr6:135497801~135716055:+
BRCA	cis	rs9402743	0.671	rs6905555	ENSG00000231028.7	LINC00271	-5.63	2.37e-08	3.23e-06	-0.18	-0.17	Systemic lupus erythematosus;	chr6:135615894	chr6:135497801~135716055:+
BRCA	cis	rs9402743	0.671	rs9402725	ENSG00000231028.7	LINC00271	-5.63	2.37e-08	3.23e-06	-0.18	-0.17	Systemic lupus erythematosus;	chr6:135616509	chr6:135497801~135716055:+
BRCA	cis	rs7772486	0.79	rs1133832	ENSG00000270638.1	RP3-466P17.1	-5.63	2.37e-08	3.24e-06	-0.19	-0.17	Lobe attachment (rater-scored or self-reported);	chr6:145884468	chr6:145735570~145737218:+
BRCA	cis	rs10208649	1	rs13417051	ENSG00000233266.1	HMGB1P31	-5.63	2.37e-08	3.24e-06	-0.38	-0.17	Body mass index;	chr2:53874635	chr2:54051334~54051760:+
BRCA	cis	rs202072	0.872	rs202042	ENSG00000272379.1	RP1-257A7.5	-5.63	2.37e-08	3.24e-06	-0.23	-0.17	HIV-1 viral setpoint;	chr6:13277482	chr6:13290018~13290490:-
BRCA	cis	rs13287066	0.669	rs10992728	ENSG00000227603.1	RP11-165J3.6	5.63	2.37e-08	3.24e-06	0.18	0.17	Intelligence (multi-trait analysis);	chr9:93416386	chr9:93435332~93437121:-
BRCA	cis	rs4713118	0.696	rs2394002	ENSG00000216901.1	AL022393.7	5.63	2.37e-08	3.24e-06	0.23	0.17	Parkinson's disease;	chr6:27780236	chr6:28176188~28176674:+
BRCA	cis	rs6547705	0.581	rs1400032	ENSG00000231259.4	AC125232.1	-5.63	2.38e-08	3.24e-06	-0.27	-0.17	Progressive supranuclear palsy;	chr2:86696060	chr2:87031815~87053069:-
BRCA	cis	rs10129255	0.5	rs6576225	ENSG00000224373.3	IGHV4-59	5.63	2.38e-08	3.24e-06	0.1	0.17	Kawasaki disease;	chr14:106778120	chr14:106627249~106627825:-
BRCA	cis	rs10129255	0.5	rs6576226	ENSG00000224373.3	IGHV4-59	5.63	2.38e-08	3.24e-06	0.1	0.17	Kawasaki disease;	chr14:106778135	chr14:106627249~106627825:-
BRCA	cis	rs10392	0.543	rs1733	ENSG00000274825.1	RP4-616B8.5	-5.63	2.38e-08	3.25e-06	-0.17	-0.17	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;	chr20:38952863	chr20:38955910~38956547:+
BRCA	cis	rs73198271	0.74	rs964771	ENSG00000253893.2	FAM85B	-5.63	2.38e-08	3.25e-06	-0.22	-0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8793429	chr8:8167819~8226614:-
BRCA	cis	rs7208859	0.623	rs73269923	ENSG00000280069.1	CTD-2349P21.3	-5.63	2.38e-08	3.25e-06	-0.26	-0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775553	chr17:30738182~30740275:+
BRCA	cis	rs13108904	0.935	rs1732100	ENSG00000254094.1	AC078852.1	5.63	2.38e-08	3.25e-06	0.18	0.17	Obesity-related traits;	chr4:1287973	chr4:1356581~1358075:+
BRCA	cis	rs12468226	1	rs76528043	ENSG00000226261.1	AC064836.3	5.63	2.38e-08	3.25e-06	0.3	0.17	Urate levels;	chr2:202466116	chr2:202336024~202336727:-
BRCA	cis	rs12468226	1	rs12468226	ENSG00000226261.1	AC064836.3	5.63	2.38e-08	3.25e-06	0.3	0.17	Urate levels;	chr2:202472278	chr2:202336024~202336727:-
BRCA	cis	rs7308116	0.528	rs1895930	ENSG00000274395.1	RP11-554D14.8	-5.62	2.38e-08	3.25e-06	-0.2	-0.17	Pelvic organ prolapse (moderate/severe);	chr12:107823800	chr12:107835541~107836555:-
BRCA	cis	rs7308116	0.546	rs4122430	ENSG00000274395.1	RP11-554D14.8	-5.62	2.38e-08	3.25e-06	-0.2	-0.17	Pelvic organ prolapse (moderate/severe);	chr12:107823835	chr12:107835541~107836555:-
BRCA	cis	rs7617773	0.78	rs13090538	ENSG00000199476.1	Y_RNA	-5.62	2.39e-08	3.26e-06	-0.25	-0.17	Coronary artery disease;	chr3:48329279	chr3:48288587~48288694:+
BRCA	cis	rs13126694	0.71	rs6848159	ENSG00000248429.4	RP11-597D13.9	-5.62	2.39e-08	3.26e-06	-0.15	-0.17	Blood osmolality (transformed sodium);	chr4:158051130	chr4:158170752~158202877:+
BRCA	cis	rs3733585	0.775	rs13124007	ENSG00000250413.1	RP11-448G15.1	-5.62	2.39e-08	3.26e-06	-0.23	-0.17	Cleft plate (environmental tobacco smoke interaction);	chr4:10042307	chr4:10006482~10009725:+
BRCA	cis	rs9291683	0.566	rs13144709	ENSG00000250413.1	RP11-448G15.1	-5.62	2.39e-08	3.26e-06	-0.23	-0.17	Bone mineral density;	chr4:10042558	chr4:10006482~10009725:+
BRCA	cis	rs9291683	0.546	rs13110307	ENSG00000250413.1	RP11-448G15.1	-5.62	2.39e-08	3.26e-06	-0.23	-0.17	Bone mineral density;	chr4:10042740	chr4:10006482~10009725:+
BRCA	cis	rs9291683	0.566	rs13122689	ENSG00000250413.1	RP11-448G15.1	-5.62	2.39e-08	3.26e-06	-0.23	-0.17	Bone mineral density;	chr4:10043024	chr4:10006482~10009725:+
BRCA	cis	rs9291683	0.546	rs13129453	ENSG00000250413.1	RP11-448G15.1	-5.62	2.39e-08	3.26e-06	-0.23	-0.17	Bone mineral density;	chr4:10043160	chr4:10006482~10009725:+
BRCA	cis	rs72799341	1	rs7200879	ENSG00000260911.2	RP11-196G11.2	5.62	2.39e-08	3.26e-06	0.19	0.17	Diastolic blood pressure;	chr16:30936251	chr16:31043150~31049868:+
BRCA	cis	rs2239547	0.522	rs2710345	ENSG00000242142.1	SERBP1P3	-5.62	2.39e-08	3.27e-06	-0.21	-0.17	Schizophrenia;	chr3:52942059	chr3:53064283~53065091:-
BRCA	cis	rs1707322	0.716	rs28375469	ENSG00000234329.1	RP11-767N6.2	5.62	2.39e-08	3.27e-06	0.18	0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45729703	chr1:45651039~45651826:-
BRCA	cis	rs1707322	0.752	rs28545085	ENSG00000234329.1	RP11-767N6.2	5.62	2.39e-08	3.27e-06	0.18	0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45736278	chr1:45651039~45651826:-
BRCA	cis	rs1707322	0.752	rs28812624	ENSG00000234329.1	RP11-767N6.2	5.62	2.39e-08	3.27e-06	0.18	0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45738064	chr1:45651039~45651826:-
BRCA	cis	rs1707322	0.752	rs28507722	ENSG00000234329.1	RP11-767N6.2	5.62	2.39e-08	3.27e-06	0.18	0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45740868	chr1:45651039~45651826:-
BRCA	cis	rs1707322	0.752	rs28568986	ENSG00000234329.1	RP11-767N6.2	5.62	2.39e-08	3.27e-06	0.18	0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45742071	chr1:45651039~45651826:-
BRCA	cis	rs1707322	0.717	rs28396194	ENSG00000234329.1	RP11-767N6.2	5.62	2.39e-08	3.27e-06	0.18	0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45747555	chr1:45651039~45651826:-
BRCA	cis	rs1707322	0.717	rs28752166	ENSG00000234329.1	RP11-767N6.2	5.62	2.39e-08	3.27e-06	0.18	0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45747637	chr1:45651039~45651826:-
BRCA	cis	rs1707322	0.717	rs10890345	ENSG00000234329.1	RP11-767N6.2	5.62	2.39e-08	3.27e-06	0.18	0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45748255	chr1:45651039~45651826:-
BRCA	cis	rs1707322	0.721	rs10789471	ENSG00000234329.1	RP11-767N6.2	5.62	2.39e-08	3.27e-06	0.18	0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45749947	chr1:45651039~45651826:-
BRCA	cis	rs1707322	0.752	rs11211173	ENSG00000234329.1	RP11-767N6.2	5.62	2.39e-08	3.27e-06	0.18	0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45753704	chr1:45651039~45651826:-
BRCA	cis	rs4713118	0.662	rs9380046	ENSG00000204709.4	LINC01556	5.62	2.39e-08	3.27e-06	0.25	0.17	Parkinson's disease;	chr6:28062721	chr6:28943877~28944537:+
BRCA	cis	rs2243480	0.901	rs3813708	ENSG00000232559.3	GS1-124K5.12	5.62	2.39e-08	3.27e-06	0.32	0.17	Diabetic kidney disease;	chr7:65840645	chr7:66554588~66576923:-
BRCA	cis	rs375066	0.592	rs349046	ENSG00000267058.1	RP11-15A1.3	5.62	2.39e-08	3.27e-06	0.19	0.17	Breast cancer;	chr19:43796474	chr19:43891804~43901805:-
BRCA	cis	rs59169624	0.681	rs2553968	ENSG00000255160.4	RP11-428C19.5	-5.62	2.39e-08	3.27e-06	-0.23	-0.17	Parental extreme longevity (95 years and older);	chr11:19260023	chr11:19299883~19308358:+
BRCA	cis	rs7191700	0.673	rs12325495	ENSG00000262636.1	CTD-3088G3.4	5.62	2.39e-08	3.27e-06	0.23	0.17	Multiple sclerosis;	chr16:11324471	chr16:11380859~11381118:-
BRCA	cis	rs950776	0.518	rs4243083	ENSG00000279373.1	RP11-650L12.4	-5.62	2.4e-08	3.27e-06	-0.21	-0.17	Sudden cardiac arrest;	chr15:78541488	chr15:78537681~78538946:+
BRCA	cis	rs4819052	0.851	rs1056101	ENSG00000184274.3	LINC00315	-5.62	2.4e-08	3.27e-06	-0.23	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258787	chr21:45300245~45305257:-
BRCA	cis	rs8098244	1	rs4800514	ENSG00000264745.1	TTC39C-AS1	5.62	2.4e-08	3.27e-06	0.22	0.17	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23818150	chr18:23994213~24015339:-
BRCA	cis	rs7746199	0.736	rs6904596	ENSG00000220721.1	OR1F12	5.62	2.4e-08	3.28e-06	0.33	0.17	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27523520	chr6:28073316~28074233:+
BRCA	cis	rs2998286	0.813	rs2790430	ENSG00000254635.4	WAC-AS1	-5.62	2.4e-08	3.28e-06	-0.27	-0.17	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28498865	chr10:28522652~28532743:-
BRCA	cis	rs1014246	0.826	rs7921785	ENSG00000232767.1	RP11-498B4.5	5.62	2.4e-08	3.28e-06	0.17	0.17	Age at smoking initiation in chronic obstructive pulmonary disease;	chr10:116711147	chr10:116670103~116672739:+
BRCA	cis	rs2179367	0.632	rs11155645	ENSG00000223701.3	RAET1E-AS1	5.62	2.4e-08	3.28e-06	0.25	0.17	Dupuytren's disease;	chr6:149360056	chr6:149884431~149919508:+
BRCA	cis	rs2179367	0.632	rs9498332	ENSG00000223701.3	RAET1E-AS1	5.62	2.4e-08	3.28e-06	0.25	0.17	Dupuytren's disease;	chr6:149367490	chr6:149884431~149919508:+
BRCA	cis	rs2179367	0.632	rs9498333	ENSG00000223701.3	RAET1E-AS1	5.62	2.4e-08	3.28e-06	0.25	0.17	Dupuytren's disease;	chr6:149368196	chr6:149884431~149919508:+
BRCA	cis	rs12468226	0.873	rs6435138	ENSG00000226261.1	AC064836.3	-5.62	2.4e-08	3.28e-06	-0.29	-0.17	Urate levels;	chr2:202234310	chr2:202336024~202336727:-
BRCA	cis	rs67981189	0.529	rs8010063	ENSG00000258571.1	PTTG4P	-5.62	2.4e-08	3.28e-06	-0.2	-0.17	Schizophrenia;	chr14:71043408	chr14:71085482~71085833:-
BRCA	cis	rs6479891	1	rs4746195	ENSG00000232075.1	MRPL35P2	5.62	2.41e-08	3.28e-06	0.31	0.17	Arthritis (juvenile idiopathic);	chr10:63547893	chr10:63634317~63634827:-
BRCA	cis	rs9527	0.641	rs4919684	ENSG00000236937.2	PTGES3P4	5.62	2.41e-08	3.28e-06	0.24	0.17	Arsenic metabolism;	chr10:102827267	chr10:102845595~102845950:+
BRCA	cis	rs991427	0.643	rs73197008	ENSG00000258100.1	RP11-121E16.1	-5.62	2.41e-08	3.28e-06	-0.29	-0.17	Systolic blood pressure (alcohol consumption interaction);	chr12:91058165	chr12:91362196~91368606:+
BRCA	cis	rs13126694	0.933	rs6830475	ENSG00000248429.4	RP11-597D13.9	5.62	2.41e-08	3.29e-06	0.15	0.17	Blood osmolality (transformed sodium);	chr4:158155527	chr4:158170752~158202877:+
BRCA	cis	rs2451932	0.555	rs10064975	ENSG00000251050.1	RP11-168A11.4	-5.62	2.41e-08	3.29e-06	-0.19	-0.17	LDL peak particle diameter (total fat intake interaction);	chr5:79981392	chr5:80019609~80019920:+
BRCA	cis	rs4713118	0.662	rs9468274	ENSG00000204709.4	LINC01556	5.62	2.41e-08	3.29e-06	0.25	0.17	Parkinson's disease;	chr6:28058299	chr6:28943877~28944537:+
BRCA	cis	rs4713118	0.662	rs9468275	ENSG00000204709.4	LINC01556	5.62	2.41e-08	3.29e-06	0.25	0.17	Parkinson's disease;	chr6:28058358	chr6:28943877~28944537:+
BRCA	cis	rs4713118	0.662	rs9468276	ENSG00000204709.4	LINC01556	5.62	2.41e-08	3.29e-06	0.25	0.17	Parkinson's disease;	chr6:28059910	chr6:28943877~28944537:+
BRCA	cis	rs4713118	0.662	rs9468277	ENSG00000204709.4	LINC01556	5.62	2.41e-08	3.29e-06	0.25	0.17	Parkinson's disease;	chr6:28060612	chr6:28943877~28944537:+
BRCA	cis	rs4713118	0.662	rs9468278	ENSG00000204709.4	LINC01556	5.62	2.41e-08	3.29e-06	0.25	0.17	Parkinson's disease;	chr6:28060704	chr6:28943877~28944537:+
BRCA	cis	rs4713118	0.662	rs13218430	ENSG00000204709.4	LINC01556	5.62	2.41e-08	3.29e-06	0.25	0.17	Parkinson's disease;	chr6:28062059	chr6:28943877~28944537:+
BRCA	cis	rs11758351	1	rs80095925	ENSG00000241549.7	GUSBP2	-5.62	2.41e-08	3.29e-06	-0.27	-0.17	Renal underexcretion gout;Gout;	chr6:26184714	chr6:26871484~26956554:-
BRCA	cis	rs11758351	1	rs77961951	ENSG00000241549.7	GUSBP2	-5.62	2.41e-08	3.29e-06	-0.27	-0.17	Renal underexcretion gout;Gout;	chr6:26185847	chr6:26871484~26956554:-
BRCA	cis	rs4950322	0.58	rs4950371	ENSG00000278811.3	LINC00624	5.62	2.42e-08	3.3e-06	0.23	0.17	Protein quantitative trait loci;	chr1:147114243	chr1:147258885~147517875:-
BRCA	cis	rs67981189	0.858	rs221927	ENSG00000258571.1	PTTG4P	5.62	2.42e-08	3.3e-06	0.19	0.17	Schizophrenia;	chr14:71112024	chr14:71085482~71085833:-
BRCA	cis	rs7308116	0.546	rs10861815	ENSG00000274395.1	RP11-554D14.8	-5.62	2.42e-08	3.3e-06	-0.2	-0.17	Pelvic organ prolapse (moderate/severe);	chr12:107831625	chr12:107835541~107836555:-
BRCA	cis	rs7927592	0.913	rs7109294	ENSG00000212093.1	AP000807.1	5.62	2.42e-08	3.3e-06	0.19	0.17	Total body bone mineral density;	chr11:68564625	chr11:68506083~68506166:-
BRCA	cis	rs2243480	1	rs78803505	ENSG00000232546.1	RP11-458F8.1	-5.62	2.42e-08	3.3e-06	-0.22	-0.17	Diabetic kidney disease;	chr7:65917585	chr7:66848496~66858136:+
BRCA	cis	rs2243480	1	rs34577383	ENSG00000232546.1	RP11-458F8.1	-5.62	2.42e-08	3.3e-06	-0.22	-0.17	Diabetic kidney disease;	chr7:65920739	chr7:66848496~66858136:+
BRCA	cis	rs2243480	1	rs55895244	ENSG00000232546.1	RP11-458F8.1	-5.62	2.42e-08	3.3e-06	-0.22	-0.17	Diabetic kidney disease;	chr7:65922691	chr7:66848496~66858136:+
BRCA	cis	rs2243480	1	rs7795242	ENSG00000232546.1	RP11-458F8.1	-5.62	2.42e-08	3.3e-06	-0.22	-0.17	Diabetic kidney disease;	chr7:65925107	chr7:66848496~66858136:+
BRCA	cis	rs2243480	1	rs2177703	ENSG00000232546.1	RP11-458F8.1	-5.62	2.42e-08	3.3e-06	-0.22	-0.17	Diabetic kidney disease;	chr7:65926730	chr7:66848496~66858136:+
BRCA	cis	rs2243480	1	rs56985706	ENSG00000232546.1	RP11-458F8.1	-5.62	2.42e-08	3.3e-06	-0.22	-0.17	Diabetic kidney disease;	chr7:65929575	chr7:66848496~66858136:+
BRCA	cis	rs2243480	1	rs60683927	ENSG00000232546.1	RP11-458F8.1	-5.62	2.42e-08	3.3e-06	-0.22	-0.17	Diabetic kidney disease;	chr7:65929781	chr7:66848496~66858136:+
BRCA	cis	rs2243480	1	rs58062456	ENSG00000232546.1	RP11-458F8.1	-5.62	2.42e-08	3.3e-06	-0.22	-0.17	Diabetic kidney disease;	chr7:65929865	chr7:66848496~66858136:+
BRCA	cis	rs2562456	0.837	rs62110205	ENSG00000268081.1	RP11-678G14.2	5.62	2.42e-08	3.3e-06	0.26	0.17	Pain;	chr19:21577269	chr19:21554640~21569237:-
BRCA	cis	rs7618501	0.602	rs2071206	ENSG00000228008.1	CTD-2330K9.3	-5.62	2.42e-08	3.3e-06	-0.16	-0.17	Intelligence (multi-trait analysis);	chr3:50122676	chr3:49903845~49916937:+
BRCA	cis	rs6688613	1	rs6656999	ENSG00000225171.2	DUTP6	-5.62	2.42e-08	3.3e-06	-0.2	-0.17	Refractive astigmatism;	chr1:166987570	chr1:166868748~166869209:+
BRCA	cis	rs7923609	1	rs10822163	ENSG00000232075.1	MRPL35P2	-5.62	2.43e-08	3.31e-06	-0.21	-0.17	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63364338	chr10:63634317~63634827:-
BRCA	cis	rs295490	0.748	rs74877536	ENSG00000272656.1	RP11-219D15.3	5.62	2.43e-08	3.31e-06	0.41	0.17	PR interval in Tripanosoma cruzi seropositivity;	chr3:139344277	chr3:139349024~139349371:-
BRCA	cis	rs295490	0.748	rs1602628	ENSG00000272656.1	RP11-219D15.3	5.62	2.43e-08	3.31e-06	0.41	0.17	PR interval in Tripanosoma cruzi seropositivity;	chr3:139345532	chr3:139349024~139349371:-
BRCA	cis	rs295490	0.667	rs59960641	ENSG00000272656.1	RP11-219D15.3	5.62	2.43e-08	3.31e-06	0.41	0.17	PR interval in Tripanosoma cruzi seropositivity;	chr3:139346587	chr3:139349024~139349371:-
BRCA	cis	rs2288884	1	rs76768215	ENSG00000275055.1	CTC-471J1.11	-5.62	2.43e-08	3.31e-06	-0.25	-0.17	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52069370	chr19:52049007~52049754:+
BRCA	cis	rs516805	0.667	rs928011	ENSG00000279453.1	RP3-425C14.4	5.62	2.43e-08	3.32e-06	0.24	0.17	Lymphocyte counts;	chr6:122248991	chr6:122436789~122439223:-
BRCA	cis	rs733592	0.599	rs12819124	ENSG00000240399.1	RP1-228P16.1	5.62	2.43e-08	3.32e-06	0.19	0.17	Plateletcrit;	chr12:48015271	chr12:48054813~48055591:-
BRCA	cis	rs7608910	0.668	rs10207958	ENSG00000271889.1	RP11-493E12.1	5.62	2.43e-08	3.32e-06	0.21	0.17	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;	chr2:60998195	chr2:61151433~61162105:-
BRCA	cis	rs853679	0.55	rs1233704	ENSG00000280107.1	AL022393.9	5.62	2.44e-08	3.32e-06	0.24	0.17	Depression;	chr6:28199145	chr6:28170845~28172521:+
BRCA	cis	rs7178375	1	rs35162264	ENSG00000270015.1	RP11-540B6.6	5.62	2.44e-08	3.32e-06	0.21	0.17	Hypertriglyceridemia;	chr15:30908480	chr15:30926514~30928407:+
BRCA	cis	rs7577696	0.597	rs2280968	ENSG00000272716.1	RP11-563N4.1	-5.62	2.44e-08	3.32e-06	-0.2	-0.17	Inflammatory biomarkers;	chr2:32064971	chr2:32165046~32165757:-
BRCA	cis	rs7577696	0.597	rs7556942	ENSG00000272716.1	RP11-563N4.1	-5.62	2.44e-08	3.32e-06	-0.2	-0.17	Inflammatory biomarkers;	chr2:32070625	chr2:32165046~32165757:-
BRCA	cis	rs801193	0.569	rs2659907	ENSG00000224316.1	RP11-479O9.2	5.62	2.44e-08	3.32e-06	0.17	0.17	Aortic root size;	chr7:66699045	chr7:65773620~65802067:+
BRCA	cis	rs7613875	0.58	rs11709503	ENSG00000228008.1	CTD-2330K9.3	5.62	2.44e-08	3.33e-06	0.17	0.17	Body mass index;	chr3:49953734	chr3:49903845~49916937:+
BRCA	cis	rs5758511	0.68	rs5758682	ENSG00000233903.2	Z83851.4	5.62	2.44e-08	3.33e-06	0.27	0.17	Birth weight;	chr22:42249196	chr22:42276355~42277052:+
BRCA	cis	rs7772486	0.875	rs2777483	ENSG00000270638.1	RP3-466P17.1	5.62	2.44e-08	3.33e-06	0.2	0.17	Lobe attachment (rater-scored or self-reported);	chr6:146008099	chr6:145735570~145737218:+
BRCA	cis	rs2303759	0.709	rs10414921	ENSG00000268686.1	AC010524.2	-5.62	2.44e-08	3.33e-06	-0.28	-0.17	Multiple sclerosis;	chr19:49319790	chr19:49368705~49388081:-
BRCA	cis	rs2303759	0.709	rs10411679	ENSG00000268686.1	AC010524.2	-5.62	2.44e-08	3.33e-06	-0.28	-0.17	Multiple sclerosis;	chr19:49323223	chr19:49368705~49388081:-
BRCA	cis	rs11098499	1	rs12506395	ENSG00000249244.1	RP11-548H18.2	5.62	2.45e-08	3.34e-06	0.21	0.17	Corneal astigmatism;	chr4:119263939	chr4:119391831~119395335:-
BRCA	cis	rs8114671	0.562	rs6087644	ENSG00000269202.1	RP4-614O4.12	-5.62	2.45e-08	3.34e-06	-0.18	-0.17	Height;	chr20:34893114	chr20:35201747~35203288:-
BRCA	cis	rs2235642	0.893	rs2076440	ENSG00000280231.1	LA16c-380F5.3	-5.62	2.45e-08	3.34e-06	-0.23	-0.17	Coronary artery disease;	chr16:1537321	chr16:1553655~1554130:-
BRCA	cis	rs2946504	0.822	rs2977095	ENSG00000251468.2	RP11-369K16.1	5.62	2.45e-08	3.34e-06	0.21	0.17	Type 2 diabetes;	chr8:12947706	chr8:12958387~12962200:+
BRCA	cis	rs7923609	0.935	rs10995477	ENSG00000232075.1	MRPL35P2	-5.62	2.45e-08	3.34e-06	-0.21	-0.17	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63250912	chr10:63634317~63634827:-
BRCA	cis	rs875971	0.83	rs587360	ENSG00000164669.11	INTS4P1	-5.62	2.45e-08	3.34e-06	-0.21	-0.17	Aortic root size;	chr7:66057711	chr7:65141225~65234216:+
BRCA	cis	rs2239547	0.657	rs6445538	ENSG00000242142.1	SERBP1P3	5.62	2.45e-08	3.34e-06	0.21	0.17	Schizophrenia;	chr3:52840272	chr3:53064283~53065091:-
BRCA	cis	rs17711722	0.74	rs7809991	ENSG00000273024.4	INTS4P2	-5.62	2.45e-08	3.34e-06	-0.19	-0.17	Calcium levels;	chr7:65941231	chr7:65647864~65715661:+
BRCA	cis	rs301901	0.581	rs6881383	ENSG00000250155.1	CTD-2353F22.1	5.62	2.45e-08	3.34e-06	0.19	0.17	Height;	chr5:37545897	chr5:36666214~36725195:-
BRCA	cis	rs7520050	0.843	rs1707334	ENSG00000280836.1	AL355480.1	5.62	2.45e-08	3.34e-06	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:46140056	chr1:45581219~45581321:-
BRCA	cis	rs3213958	0.574	rs73136045	ENSG00000249274.1	PDLIM1P4	-5.62	2.45e-08	3.34e-06	-0.26	-0.17	Blood protein levels;	chr3:98785149	chr3:98782188~98783193:+
BRCA	cis	rs9393692	0.905	rs4412192	ENSG00000241549.7	GUSBP2	5.62	2.46e-08	3.35e-06	0.19	0.17	Educational attainment;	chr6:26290149	chr6:26871484~26956554:-
BRCA	cis	rs7308116	0.528	rs61938641	ENSG00000274395.1	RP11-554D14.8	-5.62	2.46e-08	3.35e-06	-0.2	-0.17	Pelvic organ prolapse (moderate/severe);	chr12:107831289	chr12:107835541~107836555:-
BRCA	cis	rs9393777	0.92	rs41269265	ENSG00000220721.1	OR1F12	5.62	2.46e-08	3.35e-06	0.37	0.17	Intelligence (multi-trait analysis);	chr6:27457570	chr6:28073316~28074233:+
BRCA	cis	rs10129255	1	rs9324091	ENSG00000280411.1	IGHV1-69-2	-5.62	2.46e-08	3.35e-06	-0.13	-0.17	Kawasaki disease;	chr14:106676625	chr14:106762092~106762588:-
BRCA	cis	rs9545047	0.604	rs12875039	ENSG00000227354.5	RBM26-AS1	-5.62	2.46e-08	3.35e-06	-0.18	-0.17	Schizophrenia;	chr13:79327449	chr13:79406309~79424328:+
BRCA	cis	rs8098244	0.894	rs9304392	ENSG00000264745.1	TTC39C-AS1	5.62	2.46e-08	3.35e-06	0.22	0.17	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23831440	chr18:23994213~24015339:-
BRCA	cis	rs4835473	0.8	rs1849134	ENSG00000249741.2	RP11-673E1.3	-5.62	2.46e-08	3.35e-06	-0.18	-0.17	Immature fraction of reticulocytes;	chr4:143958260	chr4:143911514~143912053:-
BRCA	cis	rs66887589	0.616	rs1052633	ENSG00000245958.5	RP11-33B1.1	-5.62	2.46e-08	3.35e-06	-0.16	-0.17	Diastolic blood pressure;	chr4:119294159	chr4:119454791~119552025:+
BRCA	cis	rs2998286	0.678	rs332114	ENSG00000254635.4	WAC-AS1	5.62	2.46e-08	3.35e-06	0.24	0.17	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28636772	chr10:28522652~28532743:-
BRCA	cis	rs7829975	0.742	rs12547493	ENSG00000233609.3	RP11-62H7.2	-5.62	2.46e-08	3.36e-06	-0.16	-0.17	Mood instability;	chr8:8804024	chr8:8961200~8979025:+
BRCA	cis	rs2638953	0.853	rs10843185	ENSG00000278733.1	RP11-425D17.1	-5.62	2.46e-08	3.36e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28473778	chr12:28185625~28186190:-
BRCA	cis	rs6479901	0.557	rs12773283	ENSG00000232075.1	MRPL35P2	-5.62	2.46e-08	3.36e-06	-0.28	-0.17	Intelligence (multi-trait analysis);	chr10:63298464	chr10:63634317~63634827:-
BRCA	cis	rs2288884	1	rs76368799	ENSG00000275055.1	CTC-471J1.11	-5.62	2.46e-08	3.36e-06	-0.25	-0.17	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52058254	chr19:52049007~52049754:+
BRCA	cis	rs9309473	0.607	rs10198301	ENSG00000163016.8	ALMS1P	5.62	2.47e-08	3.36e-06	0.21	0.17	Metabolite levels;	chr2:73354472	chr2:73644919~73685576:+
BRCA	cis	rs7824557	0.564	rs7839307	ENSG00000154316.13	TDH	-5.62	2.47e-08	3.36e-06	-0.21	-0.17	Retinal vascular caliber;	chr8:11341283	chr8:11339637~11368452:+
BRCA	cis	rs2933343	0.729	rs6767104	ENSG00000261159.1	RP11-723O4.9	-5.62	2.47e-08	3.37e-06	-0.18	-0.17	IgG glycosylation;	chr3:128929274	chr3:128859716~128860526:-
BRCA	cis	rs7208859	0.623	rs9898084	ENSG00000265443.1	CTD-2349P21.6	-5.62	2.47e-08	3.37e-06	-0.27	-0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30755316	chr17:30726305~30727564:-
BRCA	cis	rs1665050	0.842	rs1665049	ENSG00000277144.1	RP11-59H7.4	5.62	2.48e-08	3.37e-06	0.22	0.17	Atopic dermatitis;	chr15:58998453	chr15:59115547~59116089:-
BRCA	cis	rs10510102	0.872	rs12240306	ENSG00000226864.1	ATE1-AS1	5.62	2.48e-08	3.37e-06	0.32	0.17	Breast cancer;	chr10:121963391	chr10:121928312~121951965:+
BRCA	cis	rs10510102	0.872	rs12240308	ENSG00000226864.1	ATE1-AS1	5.62	2.48e-08	3.37e-06	0.32	0.17	Breast cancer;	chr10:121963407	chr10:121928312~121951965:+
BRCA	cis	rs2243480	1	rs313809	ENSG00000164669.11	INTS4P1	5.62	2.48e-08	3.37e-06	0.33	0.17	Diabetic kidney disease;	chr7:66034996	chr7:65141225~65234216:+
BRCA	cis	rs4372836	0.964	rs4531886	ENSG00000226833.4	AC097724.3	-5.62	2.48e-08	3.37e-06	-0.22	-0.17	Body mass index;	chr2:28695098	chr2:28708953~28736205:-
BRCA	cis	rs6832769	1	rs3805154	ENSG00000223305.1	RN7SKP30	5.62	2.48e-08	3.38e-06	0.22	0.17	Personality dimensions;	chr4:55497760	chr4:55540502~55540835:-
BRCA	cis	rs295490	0.748	rs80248005	ENSG00000272656.1	RP11-219D15.3	5.62	2.48e-08	3.38e-06	0.41	0.17	PR interval in Tripanosoma cruzi seropositivity;	chr3:139347834	chr3:139349024~139349371:-
BRCA	cis	rs13126694	0.744	rs10005901	ENSG00000248429.4	RP11-597D13.9	5.62	2.48e-08	3.38e-06	0.15	0.17	Blood osmolality (transformed sodium);	chr4:158041750	chr4:158170752~158202877:+
BRCA	cis	rs2243480	1	rs34529418	ENSG00000232546.1	RP11-458F8.1	-5.62	2.48e-08	3.38e-06	-0.22	-0.17	Diabetic kidney disease;	chr7:65938222	chr7:66848496~66858136:+
BRCA	cis	rs6088813	1	rs6088823	ENSG00000126005.14	MMP24-AS1	5.62	2.48e-08	3.38e-06	0.2	0.17	Height;	chr20:35406462	chr20:35216462~35278131:-
BRCA	cis	rs6088813	1	rs6087703	ENSG00000126005.14	MMP24-AS1	5.62	2.48e-08	3.38e-06	0.2	0.17	Height;	chr20:35408630	chr20:35216462~35278131:-
BRCA	cis	rs6714710	0.535	rs13033383	ENSG00000230606.9	AC159540.1	-5.62	2.48e-08	3.38e-06	-0.21	-0.17	Posterior cortical atrophy and Alzheimer's disease;	chr2:97723050	chr2:97416165~97433527:-
BRCA	cis	rs59169624	0.699	rs796968	ENSG00000255160.4	RP11-428C19.5	-5.62	2.48e-08	3.38e-06	-0.23	-0.17	Parental extreme longevity (95 years and older);	chr11:19255652	chr11:19299883~19308358:+
BRCA	cis	rs4787491	0.729	rs4788212	ENSG00000273724.1	RP11-347C12.12	5.62	2.48e-08	3.38e-06	0.19	0.17	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30023148	chr16:30336400~30343336:+
BRCA	cis	rs11159086	0.793	rs11845370	ENSG00000270000.1	RP3-449M8.9	5.62	2.48e-08	3.38e-06	0.26	0.17	Advanced glycation end-product levels;	chr14:74481587	chr14:74471930~74472360:-
BRCA	cis	rs11159086	0.793	rs3784035	ENSG00000270000.1	RP3-449M8.9	5.62	2.48e-08	3.38e-06	0.26	0.17	Advanced glycation end-product levels;	chr14:74482221	chr14:74471930~74472360:-
BRCA	cis	rs11159086	0.793	rs10148268	ENSG00000270000.1	RP3-449M8.9	5.62	2.48e-08	3.38e-06	0.26	0.17	Advanced glycation end-product levels;	chr14:74484261	chr14:74471930~74472360:-
BRCA	cis	rs2638953	0.815	rs10843193	ENSG00000247934.4	RP11-967K21.1	-5.62	2.48e-08	3.38e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28509763	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.853	rs7485676	ENSG00000247934.4	RP11-967K21.1	-5.62	2.48e-08	3.38e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28510734	chr12:28163298~28190738:-
BRCA	cis	rs1713985	0.508	rs1718862	ENSG00000269949.1	RP11-738E22.3	-5.62	2.49e-08	3.38e-06	-0.32	-0.17	Age-related macular degeneration;	chr4:57023166	chr4:56960927~56961373:-
BRCA	cis	rs6728642	0.519	rs6721921	ENSG00000230606.9	AC159540.1	5.62	2.49e-08	3.38e-06	0.27	0.17	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:96900764	chr2:97416165~97433527:-
BRCA	cis	rs6728642	0.519	rs59131346	ENSG00000230606.9	AC159540.1	5.62	2.49e-08	3.38e-06	0.27	0.17	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:96901031	chr2:97416165~97433527:-
BRCA	cis	rs7772486	0.632	rs9386128	ENSG00000270638.1	RP3-466P17.1	-5.62	2.49e-08	3.39e-06	-0.2	-0.17	Lobe attachment (rater-scored or self-reported);	chr6:145727917	chr6:145735570~145737218:+
BRCA	cis	rs2276314	0.512	rs4393644	ENSG00000278986.1	RP11-723J4.3	-5.62	2.49e-08	3.39e-06	-0.21	-0.17	Endometriosis;Drug-induced torsades de pointes;	chr18:35878684	chr18:35972151~35973916:+
BRCA	cis	rs4415084	1	rs10462079	ENSG00000251141.4	RP11-53O19.1	5.62	2.49e-08	3.39e-06	0.16	0.17	Breast cancer;	chr5:44700008	chr5:44744900~44808777:-
BRCA	cis	rs4415084	1	rs13179137	ENSG00000251141.4	RP11-53O19.1	5.62	2.49e-08	3.39e-06	0.16	0.17	Breast cancer;	chr5:44702590	chr5:44744900~44808777:-
BRCA	cis	rs4372836	1	rs11127188	ENSG00000226833.4	AC097724.3	5.62	2.49e-08	3.39e-06	0.21	0.17	Body mass index;	chr2:28749986	chr2:28708953~28736205:-
BRCA	cis	rs2644899	0.715	rs2607415	ENSG00000268529.1	CYP2T3P	5.62	2.49e-08	3.39e-06	0.23	0.17	Post bronchodilator FEV1/FVC ratio;	chr19:40756782	chr19:41134722~41137308:+
BRCA	cis	rs7474896	0.526	rs1208633	ENSG00000120555.12	SEPT7P9	-5.62	2.49e-08	3.39e-06	-0.24	-0.17	Obesity (extreme);	chr10:37867945	chr10:38383069~38402916:-
BRCA	cis	rs7474896	0.559	rs1779075	ENSG00000120555.12	SEPT7P9	-5.62	2.49e-08	3.39e-06	-0.24	-0.17	Obesity (extreme);	chr10:37878602	chr10:38383069~38402916:-
BRCA	cis	rs7927771	0.524	rs7129797	ENSG00000280615.1	Y_RNA	5.62	2.49e-08	3.39e-06	0.2	0.17	Subjective well-being;	chr11:47645615	chr11:47614898~47614994:-
BRCA	cis	rs3733585	0.753	rs1122141	ENSG00000250413.1	RP11-448G15.1	5.62	2.49e-08	3.39e-06	0.22	0.17	Cleft plate (environmental tobacco smoke interaction);	chr4:9945654	chr4:10006482~10009725:+
BRCA	cis	rs4664293	0.51	rs72961751	ENSG00000226266.5	AC009961.3	5.62	2.49e-08	3.4e-06	0.21	0.17	Monocyte percentage of white cells;	chr2:159738067	chr2:159670708~159712435:-
BRCA	cis	rs7789940	1	rs7789940	ENSG00000186704.9	DTX2P1	5.62	2.5e-08	3.4e-06	0.21	0.17	Multiple sclerosis;	chr7:76321913	chr7:76978617~77004308:+
BRCA	cis	rs2243480	1	rs35046236	ENSG00000230295.1	RP11-458F8.2	-5.62	2.5e-08	3.4e-06	-0.22	-0.17	Diabetic kidney disease;	chr7:65943626	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs36068983	ENSG00000230295.1	RP11-458F8.2	-5.62	2.5e-08	3.4e-06	-0.22	-0.17	Diabetic kidney disease;	chr7:65944004	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs68189316	ENSG00000230295.1	RP11-458F8.2	-5.62	2.5e-08	3.4e-06	-0.22	-0.17	Diabetic kidney disease;	chr7:65944182	chr7:66880708~66882981:+
BRCA	cis	rs7615952	0.599	rs6803160	ENSG00000171084.14	FAM86JP	5.62	2.5e-08	3.4e-06	0.26	0.17	Blood pressure (smoking interaction);	chr3:125990711	chr3:125916620~125930024:+
BRCA	cis	rs1552244	0.938	rs7652951	ENSG00000232901.1	CYCSP10	5.62	2.5e-08	3.4e-06	0.24	0.17	Alzheimer's disease;	chr3:10022079	chr3:10000647~10000940:-
BRCA	cis	rs1552244	1	rs7611218	ENSG00000232901.1	CYCSP10	5.62	2.5e-08	3.4e-06	0.24	0.17	Alzheimer's disease;	chr3:10022276	chr3:10000647~10000940:-
BRCA	cis	rs1552244	0.872	rs6803517	ENSG00000232901.1	CYCSP10	5.62	2.5e-08	3.4e-06	0.24	0.17	Alzheimer's disease;	chr3:10023742	chr3:10000647~10000940:-
BRCA	cis	rs1552244	1	rs9834980	ENSG00000232901.1	CYCSP10	5.62	2.5e-08	3.4e-06	0.24	0.17	Alzheimer's disease;	chr3:10023844	chr3:10000647~10000940:-
BRCA	cis	rs7613875	0.62	rs2526747	ENSG00000228008.1	CTD-2330K9.3	5.62	2.5e-08	3.4e-06	0.17	0.17	Body mass index;	chr3:50045481	chr3:49903845~49916937:+
BRCA	cis	rs4834770	1	rs878374	ENSG00000248280.1	RP11-33B1.2	5.62	2.5e-08	3.4e-06	0.16	0.17	Blood protein levels;	chr4:119316409	chr4:119440561~119450157:-
BRCA	cis	rs7200543	1	rs7200543	ENSG00000275910.1	RP11-680G24.6	5.62	2.5e-08	3.4e-06	0.2	0.17	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15036113	chr16:15015828~15016390:-
BRCA	cis	rs7238033	0.663	rs7234986	ENSG00000267193.4	RP11-116O18.3	5.62	2.5e-08	3.4e-06	0.18	0.17	Bladder cancer;	chr18:45740639	chr18:45669367~45747215:-
BRCA	cis	rs6728642	1	rs75297860	ENSG00000230606.9	AC159540.1	5.62	2.5e-08	3.4e-06	0.37	0.17	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:96934341	chr2:97416165~97433527:-
BRCA	cis	rs875971	0.545	rs6979636	ENSG00000228409.4	CCT6P1	-5.62	2.5e-08	3.4e-06	-0.17	-0.17	Aortic root size;	chr7:66276638	chr7:65751142~65763354:+
BRCA	cis	rs11098499	1	rs1011054	ENSG00000248280.1	RP11-33B1.2	-5.62	2.5e-08	3.41e-06	-0.18	-0.17	Corneal astigmatism;	chr4:119281232	chr4:119440561~119450157:-
BRCA	cis	rs7246967	0.673	rs34671960	ENSG00000198153.8	ZNF849P	-5.62	2.5e-08	3.41e-06	-0.26	-0.17	Bronchopulmonary dysplasia;	chr19:22765891	chr19:22685167~22686732:+
BRCA	cis	rs7618501	0.633	rs35065728	ENSG00000228008.1	CTD-2330K9.3	5.62	2.5e-08	3.41e-06	0.17	0.17	Intelligence (multi-trait analysis);	chr3:49971743	chr3:49903845~49916937:+
BRCA	cis	rs7824557	0.606	rs2736273	ENSG00000154316.13	TDH	-5.62	2.5e-08	3.41e-06	-0.22	-0.17	Retinal vascular caliber;	chr8:11342429	chr8:11339637~11368452:+
BRCA	cis	rs5758511	0.633	rs5758689	ENSG00000233903.2	Z83851.4	5.62	2.51e-08	3.41e-06	0.26	0.17	Birth weight;	chr22:42268966	chr22:42276355~42277052:+
BRCA	cis	rs7200543	1	rs14347	ENSG00000260872.1	RP11-680G24.5	-5.62	2.51e-08	3.41e-06	-0.18	-0.17	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15040032	chr16:15018106~15020488:-
BRCA	cis	rs1757171	0.534	rs2797793	ENSG00000204110.6	RP1-153P14.8	5.62	2.51e-08	3.41e-06	0.19	0.17	Cognitive performance;	chr6:37509486	chr6:37507348~37535616:+
BRCA	cis	rs7927592	0.913	rs11228287	ENSG00000212093.1	AP000807.1	5.62	2.51e-08	3.42e-06	0.19	0.17	Total body bone mineral density;	chr11:68582286	chr11:68506083~68506166:-
BRCA	cis	rs1707322	1	rs10789486	ENSG00000281133.1	AL355480.3	-5.62	2.51e-08	3.42e-06	-0.22	-0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45942995	chr1:45580892~45580996:-
BRCA	cis	rs13178541	0.81	rs2304078	ENSG00000250378.1	RP11-119J18.1	-5.62	2.51e-08	3.42e-06	-0.24	-0.17	IgG glycosylation;	chr5:135852525	chr5:135812667~135826582:+
BRCA	cis	rs1193	1	rs1049457	ENSG00000231259.4	AC125232.1	5.62	2.51e-08	3.42e-06	0.21	0.17	High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;High light scatter reticulocyte count;	chr2:86775905	chr2:87031815~87053069:-
BRCA	cis	rs10129255	0.957	rs2007467	ENSG00000224373.3	IGHV4-59	-5.62	2.52e-08	3.42e-06	-0.11	-0.17	Kawasaki disease;	chr14:106771605	chr14:106627249~106627825:-
BRCA	cis	rs891378	1	rs6664815	ENSG00000274245.1	RP11-357P18.2	-5.62	2.52e-08	3.42e-06	-0.22	-0.17	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207242218	chr1:207372559~207373252:+
BRCA	cis	rs7772486	0.743	rs9403742	ENSG00000270638.1	RP3-466P17.1	5.62	2.52e-08	3.43e-06	0.19	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145739057	chr6:145735570~145737218:+
BRCA	cis	rs2638953	0.924	rs9669509	ENSG00000278733.1	RP11-425D17.1	-5.61	2.52e-08	3.43e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28443507	chr12:28185625~28186190:-
BRCA	cis	rs2562456	0.833	rs62110428	ENSG00000268535.1	RP11-420K14.3	5.61	2.52e-08	3.43e-06	0.26	0.17	Pain;	chr19:21430854	chr19:21709522~21710191:+
BRCA	cis	rs2337406	0.587	rs10139664	ENSG00000223648.3	IGHV3-64	5.61	2.52e-08	3.43e-06	0.17	0.17	Alzheimer's disease (late onset);	chr14:106647254	chr14:106643132~106658258:-
BRCA	cis	rs4950322	0.57	rs72691097	ENSG00000244371.2	PFN1P8	-5.61	2.52e-08	3.43e-06	-0.24	-0.17	Protein quantitative trait loci;	chr1:147299711	chr1:146957117~146957659:-
BRCA	cis	rs4950322	0.57	rs72691098	ENSG00000244371.2	PFN1P8	-5.61	2.52e-08	3.43e-06	-0.24	-0.17	Protein quantitative trait loci;	chr1:147300142	chr1:146957117~146957659:-
BRCA	cis	rs2153535	0.585	rs1328858	ENSG00000230939.1	RP11-314C16.1	5.61	2.52e-08	3.43e-06	0.2	0.17	Motion sickness;	chr6:8563218	chr6:8784178~8785445:+
BRCA	cis	rs42648	0.564	rs6465249	ENSG00000225498.1	AC002064.5	5.61	2.52e-08	3.43e-06	0.16	0.17	Homocysteine levels;	chr7:90195439	chr7:90312496~90322592:+
BRCA	cis	rs875971	0.545	rs313828	ENSG00000228409.4	CCT6P1	5.61	2.52e-08	3.43e-06	0.17	0.17	Aortic root size;	chr7:66087627	chr7:65751142~65763354:+
BRCA	cis	rs873549	1	rs753962	ENSG00000232679.1	RP11-400N13.3	5.61	2.52e-08	3.43e-06	0.2	0.17	Keloid;	chr1:222099722	chr1:222041705~222064763:-
BRCA	cis	rs860295	0.702	rs11264366	ENSG00000160766.13	GBAP1	-5.61	2.52e-08	3.43e-06	-0.18	-0.17	Body mass index;	chr1:155365620	chr1:155213821~155227422:-
BRCA	cis	rs17277546	0.588	rs13242458	ENSG00000235713.1	RP4-604G5.3	5.61	2.52e-08	3.43e-06	0.31	0.17	Dehydroepiandrosterone sulphate levels;Metabolic traits;	chr7:100097508	chr7:99992397~99993050:+
BRCA	cis	rs6700559	0.703	rs10919993	ENSG00000260088.1	RP11-92G12.3	5.61	2.53e-08	3.43e-06	0.21	0.17	Coronary artery disease;	chr1:200658184	chr1:200669507~200694250:+
BRCA	cis	rs2638953	0.853	rs12370338	ENSG00000278733.1	RP11-425D17.1	-5.61	2.53e-08	3.43e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28486787	chr12:28185625~28186190:-
BRCA	cis	rs9393777	0.92	rs67859638	ENSG00000220721.1	OR1F12	5.61	2.53e-08	3.44e-06	0.42	0.17	Intelligence (multi-trait analysis);	chr6:27390199	chr6:28073316~28074233:+
BRCA	cis	rs2638953	0.85	rs10843112	ENSG00000278733.1	RP11-425D17.1	-5.61	2.53e-08	3.44e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28144614	chr12:28185625~28186190:-
BRCA	cis	rs4835473	0.897	rs7695328	ENSG00000249741.2	RP11-673E1.3	-5.61	2.53e-08	3.44e-06	-0.18	-0.17	Immature fraction of reticulocytes;	chr4:143703768	chr4:143911514~143912053:-
BRCA	cis	rs6750795	0.542	rs1797388	ENSG00000223198.1	RNU2-22P	-5.61	2.53e-08	3.44e-06	-0.21	-0.17	Height;	chr2:231551270	chr2:231501990~231502201:-
BRCA	cis	rs6570726	0.791	rs1509213	ENSG00000270638.1	RP3-466P17.1	-5.61	2.53e-08	3.44e-06	-0.2	-0.17	Lobe attachment (rater-scored or self-reported);	chr6:145462224	chr6:145735570~145737218:+
BRCA	cis	rs10510102	0.935	rs11200263	ENSG00000226864.1	ATE1-AS1	5.61	2.53e-08	3.44e-06	0.32	0.17	Breast cancer;	chr10:121922836	chr10:121928312~121951965:+
BRCA	cis	rs1979679	1	rs1979679	ENSG00000278733.1	RP11-425D17.1	5.61	2.53e-08	3.44e-06	0.22	0.17	Ossification of the posterior longitudinal ligament of the spine;	chr12:28253582	chr12:28185625~28186190:-
BRCA	cis	rs7474896	0.559	rs2753880	ENSG00000120555.12	SEPT7P9	-5.61	2.53e-08	3.44e-06	-0.24	-0.17	Obesity (extreme);	chr10:37884410	chr10:38383069~38402916:-
BRCA	cis	rs7044106	0.762	rs1530370	ENSG00000238181.2	AHCYP2	-5.61	2.54e-08	3.45e-06	-0.22	-0.17	Hip circumference adjusted for BMI;	chr9:120662274	chr9:120720673~120721972:+
BRCA	cis	rs66887589	0.777	rs10015883	ENSG00000245958.5	RP11-33B1.1	-5.61	2.54e-08	3.45e-06	-0.15	-0.17	Diastolic blood pressure;	chr4:119346991	chr4:119454791~119552025:+
BRCA	cis	rs6088813	1	rs1406947	ENSG00000126005.14	MMP24-AS1	5.61	2.54e-08	3.45e-06	0.2	0.17	Height;	chr20:35381727	chr20:35216462~35278131:-
BRCA	cis	rs2638953	0.924	rs7955094	ENSG00000247934.4	RP11-967K21.1	-5.61	2.54e-08	3.45e-06	-0.22	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28157097	chr12:28163298~28190738:-
BRCA	cis	rs3096299	0.617	rs2353030	ENSG00000274627.1	RP11-104N10.2	-5.61	2.54e-08	3.45e-06	-0.17	-0.17	Multiple myeloma (IgH translocation);	chr16:89339419	chr16:89516797~89522217:+
BRCA	cis	rs72615157	0.613	rs56089143	ENSG00000242294.5	STAG3L5P	5.61	2.54e-08	3.45e-06	0.16	0.17	Lung function (FEV1/FVC);	chr7:100222221	chr7:100336079~100351900:+
BRCA	cis	rs9419788	0.605	rs2274224	ENSG00000273450.1	RP11-76P2.4	5.61	2.54e-08	3.46e-06	0.21	0.17	Personality traits in bipolar disorder;	chr10:94279840	chr10:94314907~94315327:-
BRCA	cis	rs875971	0.52	rs160645	ENSG00000228409.4	CCT6P1	5.61	2.54e-08	3.46e-06	0.17	0.17	Aortic root size;	chr7:66091320	chr7:65751142~65763354:+
BRCA	cis	rs9990333	0.562	rs56224853	ENSG00000231464.1	AC024937.4	5.61	2.54e-08	3.46e-06	0.22	0.17	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196102005	chr3:195996738~195998233:+
BRCA	cis	rs9990333	0.544	rs73210008	ENSG00000231464.1	AC024937.4	5.61	2.54e-08	3.46e-06	0.22	0.17	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196102260	chr3:195996738~195998233:+
BRCA	cis	rs2638953	0.924	rs12369144	ENSG00000278733.1	RP11-425D17.1	-5.61	2.55e-08	3.46e-06	-0.24	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28341109	chr12:28185625~28186190:-
BRCA	cis	rs950776	1	rs950776	ENSG00000261762.1	RP11-650L12.2	5.61	2.55e-08	3.46e-06	0.2	0.17	Sudden cardiac arrest;	chr15:78633676	chr15:78589123~78591276:-
BRCA	cis	rs55702914	1	rs56234206	ENSG00000231621.1	AC013264.2	-5.61	2.55e-08	3.47e-06	-0.16	-0.17	Major depression and alcohol dependence;	chr2:197351271	chr2:197197991~197199273:+
BRCA	cis	rs7620503	1	rs34332266	ENSG00000228221.4	LINC00578	5.61	2.55e-08	3.47e-06	0.2	0.17	Corneal structure;	chr3:177581273	chr3:177441921~177752305:+
BRCA	cis	rs2243480	1	rs937108	ENSG00000230295.1	RP11-458F8.2	-5.61	2.55e-08	3.47e-06	-0.22	-0.17	Diabetic kidney disease;	chr7:65963465	chr7:66880708~66882981:+
BRCA	cis	rs9309473	0.95	rs11689588	ENSG00000163016.8	ALMS1P	5.61	2.56e-08	3.47e-06	0.22	0.17	Metabolite levels;	chr2:73546564	chr2:73644919~73685576:+
BRCA	cis	rs6088813	1	rs6088821	ENSG00000126005.14	MMP24-AS1	5.61	2.56e-08	3.48e-06	0.2	0.17	Height;	chr20:35399773	chr20:35216462~35278131:-
BRCA	cis	rs4819052	0.851	rs28616694	ENSG00000184274.3	LINC00315	-5.61	2.56e-08	3.48e-06	-0.24	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45254871	chr21:45300245~45305257:-
BRCA	cis	rs7520050	0.966	rs6669522	ENSG00000280836.1	AL355480.1	5.61	2.56e-08	3.48e-06	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:45932269	chr1:45581219~45581321:-
BRCA	cis	rs5167	0.777	rs56784978	ENSG00000280087.1	CTB-129P6.7	5.61	2.56e-08	3.48e-06	0.22	0.17	Blood protein levels;	chr19:44996130	chr19:44909375~44914968:+
BRCA	cis	rs736408	0.509	rs13083798	ENSG00000243224.1	RP5-1157M23.2	-5.61	2.56e-08	3.48e-06	-0.18	-0.17	Bipolar disorder;	chr3:52615732	chr3:52239258~52241097:+
BRCA	cis	rs2638953	0.853	rs11049656	ENSG00000278733.1	RP11-425D17.1	-5.61	2.57e-08	3.49e-06	-0.21	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28481705	chr12:28185625~28186190:-
BRCA	cis	rs10510102	0.516	rs61071865	ENSG00000276742.1	RP11-500G22.4	5.61	2.57e-08	3.49e-06	0.31	0.17	Breast cancer;	chr10:121986236	chr10:121956782~121957098:+
BRCA	cis	rs9652601	0.779	rs12708716	ENSG00000274038.1	RP11-66H6.4	5.61	2.57e-08	3.49e-06	0.19	0.17	Systemic lupus erythematosus;	chr16:11086016	chr16:11056556~11057034:+
BRCA	cis	rs10129255	0.744	rs28517388	ENSG00000211974.3	IGHV2-70	5.61	2.58e-08	3.5e-06	0.19	0.17	Kawasaki disease;	chr14:106704323	chr14:106723574~106724093:-
BRCA	cis	rs7824557	0.606	rs1435277	ENSG00000154316.13	TDH	-5.61	2.58e-08	3.5e-06	-0.21	-0.17	Retinal vascular caliber;	chr8:11339461	chr8:11339637~11368452:+
BRCA	cis	rs115344852	0.585	rs1016069	ENSG00000216901.1	AL022393.7	5.61	2.58e-08	3.5e-06	0.23	0.17	Epithelial ovarian cancer;	chr6:28472641	chr6:28176188~28176674:+
BRCA	cis	rs1345301	1	rs10200410	ENSG00000234389.1	AC007278.3	-5.61	2.58e-08	3.5e-06	-0.16	-0.17	Waist circumference;	chr2:102254411	chr2:102438713~102440475:+
BRCA	cis	rs2834188	0.889	rs2040108	ENSG00000272659.1	AP000295.10	-5.61	2.58e-08	3.5e-06	-0.25	-0.17	Narcolepsy;	chr21:33303853	chr21:33309491~33310181:+
BRCA	cis	rs4700393	0.517	rs17332108	ENSG00000272308.1	RP11-231G3.1	-5.61	2.58e-08	3.5e-06	-0.23	-0.17	Intelligence (multi-trait analysis);	chr5:60836057	chr5:60866457~60866935:-
BRCA	cis	rs12712135	0.652	rs11465727	ENSG00000234389.1	AC007278.3	-5.61	2.58e-08	3.51e-06	-0.15	-0.17	Blood protein levels;	chr2:102448043	chr2:102438713~102440475:+
BRCA	cis	rs6442522	0.678	rs13059607	ENSG00000249786.6	EAF1-AS1	5.61	2.58e-08	3.51e-06	0.18	0.17	Uric acid levels;	chr3:15465901	chr3:15436171~15455940:-
BRCA	cis	rs6442522	0.678	rs3732722	ENSG00000249786.6	EAF1-AS1	5.61	2.58e-08	3.51e-06	0.18	0.17	Uric acid levels;	chr3:15466254	chr3:15436171~15455940:-
BRCA	cis	rs523522	0.962	rs687873	ENSG00000278344.1	RP11-18C24.8	5.61	2.58e-08	3.51e-06	0.23	0.17	High light scatter reticulocyte count;	chr12:120581831	chr12:120500735~120501090:-
BRCA	cis	rs523522	0.962	rs670568	ENSG00000278344.1	RP11-18C24.8	5.61	2.58e-08	3.51e-06	0.23	0.17	High light scatter reticulocyte count;	chr12:120583403	chr12:120500735~120501090:-
BRCA	cis	rs523522	0.962	rs655530	ENSG00000278344.1	RP11-18C24.8	5.61	2.58e-08	3.51e-06	0.23	0.17	High light scatter reticulocyte count;	chr12:120584472	chr12:120500735~120501090:-
BRCA	cis	rs7246760	0.867	rs16981648	ENSG00000277587.1	CTD-3116E22.8	-5.61	2.58e-08	3.51e-06	-0.33	-0.17	Pursuit maintenance gain;	chr19:9693748	chr19:9721903~9722410:+
BRCA	cis	rs1395	0.744	rs1122227	ENSG00000234072.1	AC074117.10	-5.61	2.58e-08	3.51e-06	-0.19	-0.17	Blood metabolite levels;	chr2:27321418	chr2:27356246~27367622:+
BRCA	cis	rs2243480	0.901	rs12530490	ENSG00000228409.4	CCT6P1	-5.61	2.59e-08	3.51e-06	-0.24	-0.17	Diabetic kidney disease;	chr7:66226660	chr7:65751142~65763354:+
BRCA	cis	rs2243480	1	rs7778911	ENSG00000228409.4	CCT6P1	-5.61	2.59e-08	3.51e-06	-0.24	-0.17	Diabetic kidney disease;	chr7:66229519	chr7:65751142~65763354:+
BRCA	cis	rs7487075	0.558	rs4768692	ENSG00000257261.4	RP11-96H19.1	5.61	2.59e-08	3.51e-06	0.18	0.17	Itch intensity from mosquito bite;	chr12:46245852	chr12:46383679~46876159:+
BRCA	cis	rs6545883	0.931	rs778756	ENSG00000271889.1	RP11-493E12.1	5.61	2.59e-08	3.51e-06	0.22	0.17	Tuberculosis;	chr2:61554859	chr2:61151433~61162105:-
BRCA	cis	rs7674212	0.57	rs1031804	ENSG00000248740.4	RP11-328K4.1	5.61	2.59e-08	3.52e-06	0.2	0.17	Type 2 diabetes;	chr4:103144892	chr4:103256159~103453658:+
BRCA	cis	rs2638953	0.777	rs10843181	ENSG00000247934.4	RP11-967K21.1	-5.61	2.59e-08	3.52e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28462824	chr12:28163298~28190738:-
BRCA	cis	rs9309473	0.606	rs6759452	ENSG00000163016.8	ALMS1P	5.61	2.59e-08	3.52e-06	0.28	0.17	Metabolite levels;	chr2:73651225	chr2:73644919~73685576:+
BRCA	cis	rs72799341	0.706	rs889555	ENSG00000260911.2	RP11-196G11.2	5.61	2.59e-08	3.52e-06	0.16	0.17	Diastolic blood pressure;	chr16:31111250	chr16:31043150~31049868:+
BRCA	cis	rs7772486	0.79	rs9403750	ENSG00000270638.1	RP3-466P17.1	5.61	2.59e-08	3.52e-06	0.19	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145846626	chr6:145735570~145737218:+
BRCA	cis	rs7493	0.806	rs17876090	ENSG00000233942.1	AC004012.1	5.61	2.59e-08	3.52e-06	0.22	0.17	Yu-Zhi constitution type in type 2 diabetes;	chr7:95424092	chr7:95471835~95473998:+
BRCA	cis	rs7976269	0.583	rs7955393	ENSG00000275476.1	RP11-996F15.4	-5.61	2.59e-08	3.52e-06	-0.2	-0.17	Male-pattern baldness;	chr12:29065773	chr12:29277397~29277882:-
BRCA	cis	rs6570726	0.791	rs448939	ENSG00000270638.1	RP3-466P17.1	5.61	2.59e-08	3.52e-06	0.19	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145487184	chr6:145735570~145737218:+
BRCA	cis	rs9990333	0.562	rs58079878	ENSG00000231464.1	AC024937.4	5.61	2.6e-08	3.53e-06	0.22	0.17	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196100620	chr3:195996738~195998233:+
BRCA	cis	rs12681366	0.761	rs2930963	ENSG00000253704.1	RP11-267M23.4	5.61	2.6e-08	3.53e-06	0.2	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94434892	chr8:94553722~94569745:+
BRCA	cis	rs2562456	0.754	rs112195516	ENSG00000268535.1	RP11-420K14.3	5.61	2.6e-08	3.53e-06	0.26	0.17	Pain;	chr19:21410849	chr19:21709522~21710191:+
BRCA	cis	rs1005277	0.579	rs1780133	ENSG00000263064.2	RP11-291L22.7	5.61	2.6e-08	3.53e-06	0.21	0.17	Extrinsic epigenetic age acceleration;	chr10:38210581	chr10:38448689~38448949:+
BRCA	cis	rs62025270	0.522	rs16943120	ENSG00000202081.1	RNU6-1280P	-5.61	2.61e-08	3.54e-06	-0.25	-0.17	Idiopathic pulmonary fibrosis;	chr15:85683066	chr15:85651522~85651628:-
BRCA	cis	rs4908768	0.501	rs6668508	ENSG00000270282.1	RP5-1115A15.2	5.61	2.61e-08	3.54e-06	0.18	0.17	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8514059	chr1:8512653~8513021:+
BRCA	cis	rs12655019	0.92	rs76869724	ENSG00000271828.1	CTD-2310F14.1	5.61	2.61e-08	3.54e-06	0.33	0.17	Breast cancer (early onset);	chr5:56932668	chr5:56927874~56929573:+
BRCA	cis	rs72799341	1	rs72799341	ENSG00000260911.2	RP11-196G11.2	5.61	2.61e-08	3.54e-06	0.19	0.17	Diastolic blood pressure;	chr16:30925422	chr16:31043150~31049868:+
BRCA	cis	rs13178541	1	rs13178541	ENSG00000250378.1	RP11-119J18.1	-5.61	2.61e-08	3.54e-06	-0.23	-0.17	IgG glycosylation;	chr5:135828929	chr5:135812667~135826582:+
BRCA	cis	rs11159086	0.793	rs10147316	ENSG00000270000.1	RP3-449M8.9	5.61	2.61e-08	3.54e-06	0.26	0.17	Advanced glycation end-product levels;	chr14:74475688	chr14:74471930~74472360:-
BRCA	cis	rs11159086	0.838	rs10147963	ENSG00000270000.1	RP3-449M8.9	5.61	2.61e-08	3.54e-06	0.26	0.17	Advanced glycation end-product levels;	chr14:74476091	chr14:74471930~74472360:-
BRCA	cis	rs10829156	0.66	rs7918933	ENSG00000240291.1	RP11-499P20.2	5.61	2.61e-08	3.54e-06	0.2	0.17	Sudden cardiac arrest;	chr10:18517434	chr10:18513115~18545651:-
BRCA	cis	rs6088813	0.857	rs6142378	ENSG00000126005.14	MMP24-AS1	5.61	2.61e-08	3.54e-06	0.2	0.17	Height;	chr20:35409488	chr20:35216462~35278131:-
BRCA	cis	rs6088813	1	rs56306402	ENSG00000126005.14	MMP24-AS1	5.61	2.61e-08	3.55e-06	0.2	0.17	Height;	chr20:35349901	chr20:35216462~35278131:-
BRCA	cis	rs9393692	0.875	rs6939589	ENSG00000241549.7	GUSBP2	5.61	2.62e-08	3.55e-06	0.18	0.17	Educational attainment;	chr6:26288975	chr6:26871484~26956554:-
BRCA	cis	rs7923837	0.683	rs10882071	ENSG00000236493.2	EIF2S2P3	5.61	2.62e-08	3.55e-06	0.24	0.17	Multiple sclerosis;Body mass index;	chr10:92500348	chr10:92668745~92669743:-
BRCA	cis	rs10129255	0.957	rs8009073	ENSG00000280411.1	IGHV1-69-2	-5.61	2.62e-08	3.55e-06	-0.13	-0.17	Kawasaki disease;	chr14:106777278	chr14:106762092~106762588:-
BRCA	cis	rs2243480	1	rs4548056	ENSG00000232559.3	GS1-124K5.12	5.61	2.62e-08	3.55e-06	0.32	0.17	Diabetic kidney disease;	chr7:65833886	chr7:66554588~66576923:-
BRCA	cis	rs755249	0.727	rs2242500	ENSG00000182109.6	RP11-69E11.4	5.61	2.62e-08	3.55e-06	0.2	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39572230	chr1:39522280~39546187:-
BRCA	cis	rs2243480	1	rs316307	ENSG00000164669.11	INTS4P1	5.61	2.62e-08	3.55e-06	0.34	0.17	Diabetic kidney disease;	chr7:66105184	chr7:65141225~65234216:+
BRCA	cis	rs2051773	0.567	rs11024116	ENSG00000184669.7	OR7E14P	-5.61	2.62e-08	3.55e-06	-0.25	-0.17	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);	chr11:17024339	chr11:17013998~17053024:+
BRCA	cis	rs2153535	0.585	rs4959494	ENSG00000230939.1	RP11-314C16.1	-5.61	2.62e-08	3.56e-06	-0.2	-0.17	Motion sickness;	chr6:8640935	chr6:8784178~8785445:+
BRCA	cis	rs11783469	0.522	rs11781808	ENSG00000253390.1	CTC-756D1.2	-5.61	2.62e-08	3.56e-06	-0.27	-0.17	Reticulocyte count;	chr8:23399392	chr8:23458601~23484971:+
BRCA	cis	rs1075265	0.756	rs2542576	ENSG00000235937.1	AC008280.1	5.61	2.62e-08	3.56e-06	0.18	0.17	Chronotype;Morning vs. evening chronotype;	chr2:53821659	chr2:54029552~54030682:-
BRCA	cis	rs7176527	1	rs7176527	ENSG00000230373.7	GOLGA6L5P	5.61	2.62e-08	3.56e-06	0.25	0.17	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84597563	chr15:84507885~84516814:-
BRCA	cis	rs67981189	0.789	rs2810073	ENSG00000258571.1	PTTG4P	5.61	2.63e-08	3.56e-06	0.19	0.17	Schizophrenia;	chr14:70917131	chr14:71085482~71085833:-
BRCA	cis	rs2243480	1	rs34637256	ENSG00000230295.1	RP11-458F8.2	-5.61	2.63e-08	3.56e-06	-0.22	-0.17	Diabetic kidney disease;	chr7:65895144	chr7:66880708~66882981:+
BRCA	cis	rs4713118	0.869	rs7773070	ENSG00000216901.1	AL022393.7	5.61	2.63e-08	3.56e-06	0.23	0.17	Parkinson's disease;	chr6:27761048	chr6:28176188~28176674:+
BRCA	cis	rs757081	0.667	rs214933	ENSG00000184669.7	OR7E14P	-5.61	2.63e-08	3.57e-06	-0.25	-0.17	Systolic blood pressure;	chr11:17173037	chr11:17013998~17053024:+
BRCA	cis	rs9545047	0.604	rs1853830	ENSG00000227354.5	RBM26-AS1	-5.61	2.63e-08	3.57e-06	-0.19	-0.17	Schizophrenia;	chr13:79406877	chr13:79406309~79424328:+
BRCA	cis	rs5758511	0.773	rs7288749	ENSG00000205702.9	CYP2D7	5.61	2.63e-08	3.57e-06	0.18	0.17	Birth weight;	chr22:41960426	chr22:42140203~42144577:-
BRCA	cis	rs62388641	0.813	rs62390562	ENSG00000218027.2	RP11-157J24.1	-5.61	2.63e-08	3.57e-06	-0.26	-0.17	Daytime sleep phenotypes;	chr6:1551467	chr6:1513698~1515289:-
BRCA	cis	rs7302981	0.967	rs7136570	ENSG00000272368.2	RP4-605O3.4	-5.61	2.63e-08	3.57e-06	-0.18	-0.17	Systolic blood pressure;	chr12:50136153	chr12:50112197~50165618:+
BRCA	cis	rs673078	0.66	rs16948234	ENSG00000275409.1	RP11-131L12.4	5.61	2.63e-08	3.57e-06	0.26	0.17	Glucose homeostasis traits;	chr12:118282464	chr12:118430147~118430699:+
BRCA	cis	rs6095360	0.727	rs6095391	ENSG00000222365.1	SNORD12B	-5.61	2.63e-08	3.57e-06	-0.23	-0.17	Intelligence (multi-trait analysis);	chr20:49002298	chr20:49280319~49280409:+
BRCA	cis	rs828999	0.586	rs7555404	ENSG00000280186.1	RP11-483I13.6	-5.61	2.63e-08	3.57e-06	-0.19	-0.17	Monocyte percentage of white cells;	chr1:108182936	chr1:108200413~108202743:+
BRCA	cis	rs7618501	0.633	rs2856234	ENSG00000228008.1	CTD-2330K9.3	-5.61	2.63e-08	3.57e-06	-0.16	-0.17	Intelligence (multi-trait analysis);	chr3:50101709	chr3:49903845~49916937:+
BRCA	cis	rs4787491	0.729	rs11544328	ENSG00000273724.1	RP11-347C12.12	-5.61	2.64e-08	3.57e-06	-0.19	-0.17	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30025807	chr16:30336400~30343336:+
BRCA	cis	rs67981189	0.778	rs2189807	ENSG00000258571.1	PTTG4P	-5.61	2.64e-08	3.57e-06	-0.19	-0.17	Schizophrenia;	chr14:70896314	chr14:71085482~71085833:-
BRCA	cis	rs7246657	0.551	rs10419174	ENSG00000276846.1	CTD-3220F14.3	5.61	2.64e-08	3.57e-06	0.27	0.17	Coronary artery calcification;	chr19:37114439	chr19:37314868~37315620:-
BRCA	cis	rs7131987	0.683	rs3782511	ENSG00000275476.1	RP11-996F15.4	-5.61	2.64e-08	3.58e-06	-0.21	-0.17	QT interval;	chr12:29343291	chr12:29277397~29277882:-
BRCA	cis	rs721917	0.525	rs2758541	ENSG00000244733.5	RP11-506M13.3	-5.61	2.64e-08	3.58e-06	-0.2	-0.17	Chronic obstructive pulmonary disease;	chr10:79895801	chr10:79660891~79677996:+
BRCA	cis	rs9527	1	rs9527	ENSG00000236937.2	PTGES3P4	5.61	2.64e-08	3.58e-06	0.26	0.17	Arsenic metabolism;	chr10:102863821	chr10:102845595~102845950:+
BRCA	cis	rs61160187	0.604	rs7719611	ENSG00000272308.1	RP11-231G3.1	-5.61	2.64e-08	3.58e-06	-0.19	-0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:60692720	chr5:60866457~60866935:-
BRCA	cis	rs875971	0.545	rs73376401	ENSG00000228409.4	CCT6P1	-5.61	2.65e-08	3.59e-06	-0.17	-0.17	Aortic root size;	chr7:66174841	chr7:65751142~65763354:+
BRCA	cis	rs11105298	0.891	rs11105319	ENSG00000270344.2	RP11-734K2.4	5.61	2.65e-08	3.59e-06	0.2	0.17	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89533400	chr12:89525654~89548005:+
BRCA	cis	rs2638953	0.711	rs11049605	ENSG00000278733.1	RP11-425D17.1	-5.61	2.65e-08	3.59e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28443132	chr12:28185625~28186190:-
BRCA	cis	rs6951245	0.58	rs78894484	ENSG00000229043.2	AC091729.9	-5.61	2.65e-08	3.59e-06	-0.26	-0.17	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1099085	chr7:1160374~1165267:+
BRCA	cis	rs4950322	0.518	rs4950306	ENSG00000278811.3	LINC00624	5.61	2.65e-08	3.59e-06	0.22	0.17	Protein quantitative trait loci;	chr1:147117838	chr1:147258885~147517875:-
BRCA	cis	rs2179367	0.632	rs9498334	ENSG00000223701.3	RAET1E-AS1	5.61	2.65e-08	3.59e-06	0.25	0.17	Dupuytren's disease;	chr6:149370902	chr6:149884431~149919508:+
BRCA	cis	rs16949788	1	rs74521803	ENSG00000261351.2	CTD-3185P2.1	-5.61	2.65e-08	3.59e-06	-0.35	-0.17	Spherical equivalent (joint analysis main effects and education interaction);	chr15:66539923	chr15:66488658~66492109:-
BRCA	cis	rs801193	0.569	rs2659908	ENSG00000224316.1	RP11-479O9.2	5.61	2.65e-08	3.6e-06	0.17	0.17	Aortic root size;	chr7:66695835	chr7:65773620~65802067:+
BRCA	cis	rs66887589	0.592	rs2175383	ENSG00000245958.5	RP11-33B1.1	-5.61	2.65e-08	3.6e-06	-0.16	-0.17	Diastolic blood pressure;	chr4:119294681	chr4:119454791~119552025:+
BRCA	cis	rs10129255	0.957	rs8005468	ENSG00000280411.1	IGHV1-69-2	-5.61	2.65e-08	3.6e-06	-0.12	-0.17	Kawasaki disease;	chr14:106686431	chr14:106762092~106762588:-
BRCA	cis	rs1707322	0.721	rs10430124	ENSG00000234329.1	RP11-767N6.2	5.61	2.66e-08	3.6e-06	0.18	0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755945	chr1:45651039~45651826:-
BRCA	cis	rs1876905	0.539	rs240987	ENSG00000230177.1	RP5-1112D6.4	-5.61	2.66e-08	3.6e-06	-0.26	-0.17	Mean corpuscular hemoglobin;	chr6:111268552	chr6:111277932~111278742:+
BRCA	cis	rs9828933	0.752	rs28675788	ENSG00000280620.1	SCAANT1	5.61	2.66e-08	3.6e-06	0.3	0.17	Type 2 diabetes;	chr3:63956512	chr3:63911518~63911772:-
BRCA	cis	rs2803122	0.745	rs10811143	ENSG00000273226.1	RP11-513M16.8	-5.61	2.66e-08	3.6e-06	-0.18	-0.17	Pulse pressure;	chr9:19240221	chr9:19375451~19375996:+
BRCA	cis	rs875971	0.571	rs160641	ENSG00000228409.4	CCT6P1	5.61	2.66e-08	3.6e-06	0.17	0.17	Aortic root size;	chr7:66112359	chr7:65751142~65763354:+
BRCA	cis	rs4950322	0.58	rs17355474	ENSG00000278811.3	LINC00624	5.61	2.66e-08	3.6e-06	0.22	0.17	Protein quantitative trait loci;	chr1:147120541	chr1:147258885~147517875:-
BRCA	cis	rs2613964	0.504	rs2399465	ENSG00000240057.4	RP11-572M11.4	-5.61	2.66e-08	3.6e-06	-0.17	-0.17	Pediatric bone mineral content (spine);Pediatric bone mineral density (spine);	chr3:113129145	chr3:113019532~113183301:+
BRCA	cis	rs2613964	0.504	rs2399466	ENSG00000240057.4	RP11-572M11.4	-5.61	2.66e-08	3.6e-06	-0.17	-0.17	Pediatric bone mineral content (spine);Pediatric bone mineral density (spine);	chr3:113129190	chr3:113019532~113183301:+
BRCA	cis	rs2613964	0.504	rs7617193	ENSG00000240057.4	RP11-572M11.4	-5.61	2.66e-08	3.6e-06	-0.17	-0.17	Pediatric bone mineral content (spine);Pediatric bone mineral density (spine);	chr3:113130004	chr3:113019532~113183301:+
BRCA	cis	rs4218	0.531	rs1374156	ENSG00000277144.1	RP11-59H7.4	-5.61	2.66e-08	3.61e-06	-0.21	-0.17	Social communication problems;	chr15:59046746	chr15:59115547~59116089:-
BRCA	cis	rs2179367	0.6	rs11155654	ENSG00000216906.2	RP11-350J20.9	5.61	2.66e-08	3.61e-06	0.25	0.17	Dupuytren's disease;	chr6:149442001	chr6:149904243~149906418:+
BRCA	cis	rs2153535	0.585	rs11243264	ENSG00000230939.1	RP11-314C16.1	-5.61	2.66e-08	3.61e-06	-0.2	-0.17	Motion sickness;	chr6:8642912	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.585	rs11243265	ENSG00000230939.1	RP11-314C16.1	-5.61	2.66e-08	3.61e-06	-0.2	-0.17	Motion sickness;	chr6:8642925	chr6:8784178~8785445:+
BRCA	cis	rs16949788	1	rs76623374	ENSG00000261351.2	CTD-3185P2.1	-5.61	2.66e-08	3.61e-06	-0.34	-0.17	Spherical equivalent (joint analysis main effects and education interaction);	chr15:66475530	chr15:66488658~66492109:-
BRCA	cis	rs17508449	0.865	rs4838994	ENSG00000232450.1	RP4-730K3.3	5.6	2.67e-08	3.61e-06	0.31	0.17	Leprosy;	chr1:113608984	chr1:113698884~113699631:-
BRCA	cis	rs7772486	0.902	rs2748500	ENSG00000270638.1	RP3-466P17.1	5.6	2.67e-08	3.61e-06	0.19	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145993716	chr6:145735570~145737218:+
BRCA	cis	rs919433	0.589	rs7601800	ENSG00000231621.1	AC013264.2	-5.6	2.67e-08	3.62e-06	-0.16	-0.17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197530375	chr2:197197991~197199273:+
BRCA	cis	rs7927592	0.913	rs11228268	ENSG00000212093.1	AP000807.1	5.6	2.67e-08	3.62e-06	0.2	0.17	Total body bone mineral density;	chr11:68519979	chr11:68506083~68506166:-
BRCA	cis	rs2834188	1	rs2252931	ENSG00000272659.1	AP000295.10	-5.6	2.67e-08	3.62e-06	-0.25	-0.17	Narcolepsy;	chr21:33332014	chr21:33309491~33310181:+
BRCA	cis	rs16949788	1	rs79097157	ENSG00000261351.2	CTD-3185P2.1	-5.6	2.67e-08	3.62e-06	-0.34	-0.17	Spherical equivalent (joint analysis main effects and education interaction);	chr15:66472476	chr15:66488658~66492109:-
BRCA	cis	rs4835473	0.897	rs7682128	ENSG00000249741.2	RP11-673E1.3	-5.6	2.67e-08	3.62e-06	-0.18	-0.17	Immature fraction of reticulocytes;	chr4:143708950	chr4:143911514~143912053:-
BRCA	cis	rs4835473	0.897	rs7687317	ENSG00000249741.2	RP11-673E1.3	-5.6	2.67e-08	3.62e-06	-0.18	-0.17	Immature fraction of reticulocytes;	chr4:143709010	chr4:143911514~143912053:-
BRCA	cis	rs2153535	0.585	rs4959495	ENSG00000230939.1	RP11-314C16.1	-5.6	2.67e-08	3.62e-06	-0.2	-0.17	Motion sickness;	chr6:8641186	chr6:8784178~8785445:+
BRCA	cis	rs2243480	1	rs781150	ENSG00000164669.11	INTS4P1	5.6	2.67e-08	3.62e-06	0.33	0.17	Diabetic kidney disease;	chr7:66015986	chr7:65141225~65234216:+
BRCA	cis	rs2243480	1	rs313798	ENSG00000164669.11	INTS4P1	5.6	2.67e-08	3.62e-06	0.33	0.17	Diabetic kidney disease;	chr7:66028044	chr7:65141225~65234216:+
BRCA	cis	rs13126694	0.744	rs7657303	ENSG00000248429.4	RP11-597D13.9	-5.6	2.67e-08	3.62e-06	-0.15	-0.17	Blood osmolality (transformed sodium);	chr4:157992992	chr4:158170752~158202877:+
BRCA	cis	rs1713985	0.508	rs2687239	ENSG00000269949.1	RP11-738E22.3	-5.6	2.68e-08	3.62e-06	-0.32	-0.17	Age-related macular degeneration;	chr4:57012468	chr4:56960927~56961373:-
BRCA	cis	rs1713985	0.508	rs1718866	ENSG00000269949.1	RP11-738E22.3	-5.6	2.68e-08	3.62e-06	-0.32	-0.17	Age-related macular degeneration;	chr4:57017009	chr4:56960927~56961373:-
BRCA	cis	rs1707322	0.752	rs11488313	ENSG00000234329.1	RP11-767N6.2	5.6	2.68e-08	3.62e-06	0.18	0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45759108	chr1:45651039~45651826:-
BRCA	cis	rs34286592	0.929	rs9939514	ENSG00000214725.6	CDIPT-AS1	-5.6	2.68e-08	3.62e-06	-0.28	-0.17	Multiple sclerosis;	chr16:29844410	chr16:29863593~29868053:+
BRCA	cis	rs6545883	0.811	rs778753	ENSG00000270820.4	RP11-355B11.2	5.6	2.68e-08	3.63e-06	0.19	0.17	Tuberculosis;	chr2:61553065	chr2:61471188~61484130:+
BRCA	cis	rs2832191	0.967	rs2832216	ENSG00000215533.7	LINC00189	-5.6	2.68e-08	3.63e-06	-0.19	-0.17	Dental caries;	chr21:29149600	chr21:29193480~29288205:+
BRCA	cis	rs2243480	1	rs35542501	ENSG00000232546.1	RP11-458F8.1	-5.6	2.68e-08	3.63e-06	-0.22	-0.17	Diabetic kidney disease;	chr7:65966228	chr7:66848496~66858136:+
BRCA	cis	rs2243480	0.708	rs781141	ENSG00000232546.1	RP11-458F8.1	-5.6	2.68e-08	3.63e-06	-0.22	-0.17	Diabetic kidney disease;	chr7:65973566	chr7:66848496~66858136:+
BRCA	cis	rs10510102	0.516	rs10159759	ENSG00000276742.1	RP11-500G22.4	5.6	2.68e-08	3.63e-06	0.31	0.17	Breast cancer;	chr10:121986533	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.516	rs10159589	ENSG00000276742.1	RP11-500G22.4	5.6	2.68e-08	3.63e-06	0.31	0.17	Breast cancer;	chr10:121986659	chr10:121956782~121957098:+
BRCA	cis	rs9652601	0.622	rs9935174	ENSG00000274038.1	RP11-66H6.4	-5.6	2.68e-08	3.63e-06	-0.19	-0.17	Systemic lupus erythematosus;	chr16:11017490	chr16:11056556~11057034:+
BRCA	cis	rs9393692	0.905	rs34916901	ENSG00000241549.7	GUSBP2	-5.6	2.68e-08	3.63e-06	-0.19	-0.17	Educational attainment;	chr6:26285921	chr6:26871484~26956554:-
BRCA	cis	rs875971	0.545	rs6460276	ENSG00000228409.4	CCT6P1	-5.6	2.68e-08	3.63e-06	-0.17	-0.17	Aortic root size;	chr7:66182290	chr7:65751142~65763354:+
BRCA	cis	rs4908768	0.501	rs6677736	ENSG00000270282.1	RP5-1115A15.2	5.6	2.68e-08	3.64e-06	0.18	0.17	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8492744	chr1:8512653~8513021:+
BRCA	cis	rs2562456	0.833	rs2968078	ENSG00000268081.1	RP11-678G14.2	-5.6	2.69e-08	3.64e-06	-0.26	-0.17	Pain;	chr19:21458942	chr19:21554640~21569237:-
BRCA	cis	rs1707322	0.752	rs61784793	ENSG00000234329.1	RP11-767N6.2	5.6	2.69e-08	3.64e-06	0.18	0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45683613	chr1:45651039~45651826:-
BRCA	cis	rs891378	1	rs6703857	ENSG00000274245.1	RP11-357P18.2	-5.6	2.69e-08	3.64e-06	-0.23	-0.17	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207270208	chr1:207372559~207373252:+
BRCA	cis	rs4588572	0.606	rs6859161	ENSG00000245556.2	SCAMP1-AS1	-5.6	2.69e-08	3.64e-06	-0.2	-0.17	Triglycerides;	chr5:78446952	chr5:78342365~78360507:-
BRCA	cis	rs6828577	0.56	rs2631147	ENSG00000269893.5	SNHG8	5.6	2.69e-08	3.64e-06	0.18	0.17	Perioperative myocardial infarction in coronary artery bypass surgery;	chr4:118534699	chr4:118278709~118279823:+
BRCA	cis	rs3764021	1	rs7977720	ENSG00000214776.8	RP11-726G1.1	5.6	2.69e-08	3.64e-06	0.19	0.17	Type 1 diabetes;	chr12:9713753	chr12:9467552~9576275:+
BRCA	cis	rs2638953	0.924	rs11049386	ENSG00000278733.1	RP11-425D17.1	-5.6	2.69e-08	3.64e-06	-0.24	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28167603	chr12:28185625~28186190:-
BRCA	cis	rs2243480	1	rs35542501	ENSG00000230295.1	RP11-458F8.2	-5.6	2.69e-08	3.64e-06	-0.22	-0.17	Diabetic kidney disease;	chr7:65966228	chr7:66880708~66882981:+
BRCA	cis	rs2243480	0.708	rs781141	ENSG00000230295.1	RP11-458F8.2	-5.6	2.69e-08	3.64e-06	-0.22	-0.17	Diabetic kidney disease;	chr7:65973566	chr7:66880708~66882981:+
BRCA	cis	rs375066	0.592	rs10401203	ENSG00000267058.1	RP11-15A1.3	5.6	2.69e-08	3.64e-06	0.19	0.17	Breast cancer;	chr19:43795514	chr19:43891804~43901805:-
BRCA	cis	rs10129255	0.556	rs6576222	ENSG00000224373.3	IGHV4-59	5.6	2.69e-08	3.65e-06	0.1	0.17	Kawasaki disease;	chr14:106776442	chr14:106627249~106627825:-
BRCA	cis	rs13113518	0.507	rs4549456	ENSG00000273257.1	RP11-177J6.1	5.6	2.69e-08	3.65e-06	0.23	0.17	Height;	chr4:55398586	chr4:55387949~55388271:+
BRCA	cis	rs9659323	0.622	rs6689568	ENSG00000231365.4	RP11-418J17.1	-5.6	2.7e-08	3.65e-06	-0.22	-0.17	Body mass index;	chr1:118960338	chr1:119140396~119275973:+
BRCA	cis	rs2243480	1	rs73142162	ENSG00000232559.3	GS1-124K5.12	5.6	2.7e-08	3.65e-06	0.32	0.17	Diabetic kidney disease;	chr7:65909309	chr7:66554588~66576923:-
BRCA	cis	rs13126694	0.682	rs6536288	ENSG00000251429.1	RP11-597D13.7	-5.6	2.7e-08	3.65e-06	-0.17	-0.17	Blood osmolality (transformed sodium);	chr4:157949748	chr4:158270378~158278676:+
BRCA	cis	rs17685	0.593	rs56265719	ENSG00000280388.1	RP11-229D13.3	-5.6	2.7e-08	3.65e-06	-0.18	-0.17	Coffee consumption (cups per day);Coffee consumption;	chr7:76166951	chr7:76043977~76045963:-
BRCA	cis	rs523522	0.962	rs10849754	ENSG00000278344.1	RP11-18C24.8	5.6	2.7e-08	3.65e-06	0.23	0.17	High light scatter reticulocyte count;	chr12:120502615	chr12:120500735~120501090:-
BRCA	cis	rs12468226	1	rs74508472	ENSG00000226261.1	AC064836.3	5.6	2.7e-08	3.65e-06	0.29	0.17	Urate levels;	chr2:202517290	chr2:202336024~202336727:-
BRCA	cis	rs67981189	0.529	rs61990387	ENSG00000258571.1	PTTG4P	-5.6	2.7e-08	3.66e-06	-0.2	-0.17	Schizophrenia;	chr14:71024850	chr14:71085482~71085833:-
BRCA	cis	rs11159086	0.793	rs1860108	ENSG00000270000.1	RP3-449M8.9	5.6	2.7e-08	3.66e-06	0.26	0.17	Advanced glycation end-product levels;	chr14:74478562	chr14:74471930~74472360:-
BRCA	cis	rs10129255	0.957	rs4387509	ENSG00000224373.3	IGHV4-59	5.6	2.7e-08	3.66e-06	0.11	0.17	Kawasaki disease;	chr14:106704386	chr14:106627249~106627825:-
BRCA	cis	rs7267979	0.873	rs6037062	ENSG00000277938.1	RP5-965G21.3	5.6	2.7e-08	3.66e-06	0.21	0.17	Liver enzyme levels (alkaline phosphatase);	chr20:25222256	chr20:25229150~25231933:+
BRCA	cis	rs7577696	0.695	rs4952209	ENSG00000272716.1	RP11-563N4.1	5.6	2.7e-08	3.66e-06	0.19	0.17	Inflammatory biomarkers;	chr2:32160964	chr2:32165046~32165757:-
BRCA	cis	rs783540	0.521	rs28719490	ENSG00000278603.1	RP13-608F4.5	5.6	2.71e-08	3.66e-06	0.26	0.17	Schizophrenia;	chr15:82720688	chr15:82472203~82472426:+
BRCA	cis	rs7308116	0.546	rs10861812	ENSG00000274395.1	RP11-554D14.8	-5.6	2.71e-08	3.66e-06	-0.2	-0.17	Pelvic organ prolapse (moderate/severe);	chr12:107830496	chr12:107835541~107836555:-
BRCA	cis	rs3213958	0.574	rs17852693	ENSG00000249274.1	PDLIM1P4	-5.6	2.71e-08	3.67e-06	-0.26	-0.17	Blood protein levels;	chr3:98901153	chr3:98782188~98783193:+
BRCA	cis	rs7085104	0.727	rs12773892	ENSG00000236937.2	PTGES3P4	5.6	2.71e-08	3.67e-06	0.25	0.17	Immature fraction of reticulocytes;Schizophrenia;	chr10:102871420	chr10:102845595~102845950:+
BRCA	cis	rs6723226	0.772	rs2366894	ENSG00000276517.1	AL133243.2	-5.6	2.71e-08	3.67e-06	-0.21	-0.17	Intelligence (multi-trait analysis);	chr2:32488639	chr2:32526504~32529507:+
BRCA	cis	rs10129255	0.536	rs6576223	ENSG00000224373.3	IGHV4-59	5.6	2.71e-08	3.67e-06	0.1	0.17	Kawasaki disease;	chr14:106776448	chr14:106627249~106627825:-
BRCA	cis	rs9652601	0.881	rs11860603	ENSG00000274038.1	RP11-66H6.4	-5.6	2.71e-08	3.67e-06	-0.2	-0.17	Systemic lupus erythematosus;	chr16:11071160	chr16:11056556~11057034:+
BRCA	cis	rs9652601	0.959	rs7198621	ENSG00000274038.1	RP11-66H6.4	-5.6	2.71e-08	3.67e-06	-0.2	-0.17	Systemic lupus erythematosus;	chr16:11073601	chr16:11056556~11057034:+
BRCA	cis	rs12655019	0.92	rs74455703	ENSG00000271828.1	CTD-2310F14.1	5.6	2.71e-08	3.67e-06	0.33	0.17	Breast cancer (early onset);	chr5:56949442	chr5:56927874~56929573:+
BRCA	cis	rs2562456	0.833	rs11666447	ENSG00000268535.1	RP11-420K14.3	5.6	2.71e-08	3.67e-06	0.26	0.17	Pain;	chr19:21416270	chr19:21709522~21710191:+
BRCA	cis	rs783540	0.5	rs7178459	ENSG00000278603.1	RP13-608F4.5	5.6	2.71e-08	3.67e-06	0.26	0.17	Schizophrenia;	chr15:82729632	chr15:82472203~82472426:+
BRCA	cis	rs6490294	0.571	rs2272308	ENSG00000226469.1	ADAM1B	5.6	2.71e-08	3.67e-06	0.26	0.17	Mean platelet volume;	chr12:112163446	chr12:111927018~111929017:+
BRCA	cis	rs41307935	0.822	rs71636786	ENSG00000260063.1	RP5-968P14.2	-5.6	2.71e-08	3.67e-06	-0.37	-0.17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26851434	chr1:26692132~26694131:-
BRCA	cis	rs6095360	0.727	rs35971376	ENSG00000222365.1	SNORD12B	-5.6	2.71e-08	3.67e-06	-0.24	-0.17	Intelligence (multi-trait analysis);	chr20:49105171	chr20:49280319~49280409:+
BRCA	cis	rs2243480	1	rs781157	ENSG00000232559.3	GS1-124K5.12	5.6	2.71e-08	3.67e-06	0.32	0.17	Diabetic kidney disease;	chr7:66013324	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.66	rs801193	ENSG00000273024.4	INTS4P2	5.6	2.72e-08	3.67e-06	0.19	0.17	Aortic root size;	chr7:66565625	chr7:65647864~65715661:+
BRCA	cis	rs12681366	0.761	rs2197003	ENSG00000253704.1	RP11-267M23.4	5.6	2.72e-08	3.67e-06	0.19	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94444758	chr8:94553722~94569745:+
BRCA	cis	rs12681366	0.801	rs2921386	ENSG00000253704.1	RP11-267M23.4	5.6	2.72e-08	3.67e-06	0.19	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94446672	chr8:94553722~94569745:+
BRCA	cis	rs35146811	0.807	rs6953441	ENSG00000235713.1	RP4-604G5.3	5.6	2.72e-08	3.67e-06	0.21	0.17	Coronary artery disease;	chr7:100019444	chr7:99992397~99993050:+
BRCA	cis	rs35146811	0.771	rs6465762	ENSG00000235713.1	RP4-604G5.3	5.6	2.72e-08	3.67e-06	0.21	0.17	Coronary artery disease;	chr7:100022931	chr7:99992397~99993050:+
BRCA	cis	rs10129255	0.913	rs28861466	ENSG00000224373.3	IGHV4-59	5.6	2.72e-08	3.68e-06	0.11	0.17	Kawasaki disease;	chr14:106718572	chr14:106627249~106627825:-
BRCA	cis	rs7976269	0.559	rs10771473	ENSG00000275476.1	RP11-996F15.4	-5.6	2.72e-08	3.68e-06	-0.19	-0.17	Male-pattern baldness;	chr12:29068729	chr12:29277397~29277882:-
BRCA	cis	rs4927850	0.957	rs4927851	ENSG00000207650.1	MIR570	5.6	2.72e-08	3.68e-06	0.21	0.17	Pancreatic cancer;	chr3:196024982	chr3:195699401~195699497:+
BRCA	cis	rs62025270	0.632	rs1807309	ENSG00000202081.1	RNU6-1280P	-5.6	2.72e-08	3.68e-06	-0.25	-0.17	Idiopathic pulmonary fibrosis;	chr15:85668526	chr15:85651522~85651628:-
BRCA	cis	rs523522	0.923	rs3916065	ENSG00000278344.1	RP11-18C24.8	5.6	2.72e-08	3.68e-06	0.23	0.17	High light scatter reticulocyte count;	chr12:120496821	chr12:120500735~120501090:-
BRCA	cis	rs2732480	0.538	rs2468943	ENSG00000257735.1	RP11-370I10.6	-5.6	2.72e-08	3.68e-06	-0.21	-0.17	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48353466	chr12:48350945~48442411:+
BRCA	cis	rs210138	1	rs210137	ENSG00000197251.3	LINC00336	5.6	2.72e-08	3.68e-06	0.25	0.17	Testicular germ cell tumor;	chr6:33574701	chr6:33586106~33593338:-
BRCA	cis	rs2688608	0.901	rs2459446	ENSG00000271816.1	BMS1P4	-5.6	2.72e-08	3.68e-06	-0.17	-0.17	Inflammatory bowel disease;	chr10:73841838	chr10:73699151~73730487:-
BRCA	cis	rs4950322	0.58	rs7514970	ENSG00000278811.3	LINC00624	5.6	2.73e-08	3.69e-06	0.22	0.17	Protein quantitative trait loci;	chr1:147120516	chr1:147258885~147517875:-
BRCA	cis	rs2153535	0.585	rs1328874	ENSG00000230939.1	RP11-314C16.1	-5.6	2.73e-08	3.69e-06	-0.19	-0.17	Motion sickness;	chr6:8621010	chr6:8784178~8785445:+
BRCA	cis	rs1707322	1	rs6429588	ENSG00000281133.1	AL355480.3	-5.6	2.73e-08	3.69e-06	-0.22	-0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45988386	chr1:45580892~45580996:-
BRCA	cis	rs7829975	0.742	rs1533058	ENSG00000233609.3	RP11-62H7.2	5.6	2.73e-08	3.69e-06	0.16	0.17	Mood instability;	chr8:8827680	chr8:8961200~8979025:+
BRCA	cis	rs2834188	0.924	rs6517160	ENSG00000272659.1	AP000295.10	-5.6	2.73e-08	3.69e-06	-0.25	-0.17	Narcolepsy;	chr21:33311207	chr21:33309491~33310181:+
BRCA	cis	rs2834188	0.924	rs2409487	ENSG00000272659.1	AP000295.10	-5.6	2.73e-08	3.69e-06	-0.25	-0.17	Narcolepsy;	chr21:33312653	chr21:33309491~33310181:+
BRCA	cis	rs2645424	0.525	rs17814426	ENSG00000255046.1	RP11-297N6.4	5.6	2.73e-08	3.69e-06	0.19	0.17	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);	chr8:11856796	chr8:11797928~11802568:-
BRCA	cis	rs2638953	0.741	rs10843194	ENSG00000247934.4	RP11-967K21.1	-5.6	2.73e-08	3.69e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28510237	chr12:28163298~28190738:-
BRCA	cis	rs1707322	0.656	rs3014210	ENSG00000234329.1	RP11-767N6.2	-5.6	2.74e-08	3.7e-06	-0.18	-0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45600936	chr1:45651039~45651826:-
BRCA	cis	rs2179367	0.632	rs9498344	ENSG00000223701.3	RAET1E-AS1	5.6	2.74e-08	3.7e-06	0.25	0.17	Dupuytren's disease;	chr6:149401053	chr6:149884431~149919508:+
BRCA	cis	rs3733585	0.725	rs10939636	ENSG00000250413.1	RP11-448G15.1	5.6	2.74e-08	3.7e-06	0.22	0.17	Cleft plate (environmental tobacco smoke interaction);	chr4:9971016	chr4:10006482~10009725:+
BRCA	cis	rs11955398	0.502	rs158922	ENSG00000215032.2	GNL3LP1	5.6	2.74e-08	3.7e-06	0.22	0.17	Intelligence (multi-trait analysis);	chr5:60945159	chr5:60891935~60893577:-
BRCA	cis	rs4713118	0.662	rs9357060	ENSG00000204709.4	LINC01556	5.6	2.74e-08	3.71e-06	0.25	0.17	Parkinson's disease;	chr6:28056708	chr6:28943877~28944537:+
BRCA	cis	rs4713118	0.662	rs9468271	ENSG00000204709.4	LINC01556	5.6	2.74e-08	3.71e-06	0.25	0.17	Parkinson's disease;	chr6:28056792	chr6:28943877~28944537:+
BRCA	cis	rs5758511	0.68	rs1107553	ENSG00000205702.9	CYP2D7	5.6	2.74e-08	3.71e-06	0.18	0.17	Birth weight;	chr22:42271467	chr22:42140203~42144577:-
BRCA	cis	rs7923609	0.934	rs2893919	ENSG00000232075.1	MRPL35P2	-5.6	2.74e-08	3.71e-06	-0.21	-0.17	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63375018	chr10:63634317~63634827:-
BRCA	cis	rs7923609	0.967	rs2393966	ENSG00000232075.1	MRPL35P2	-5.6	2.74e-08	3.71e-06	-0.21	-0.17	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63375054	chr10:63634317~63634827:-
BRCA	cis	rs4415084	0.966	rs16901937	ENSG00000251141.4	RP11-53O19.1	5.6	2.75e-08	3.71e-06	0.16	0.17	Breast cancer;	chr5:44709039	chr5:44744900~44808777:-
BRCA	cis	rs2179367	0.632	rs763590	ENSG00000223701.3	RAET1E-AS1	5.6	2.75e-08	3.71e-06	0.25	0.17	Dupuytren's disease;	chr6:149398831	chr6:149884431~149919508:+
BRCA	cis	rs2179367	0.632	rs17506789	ENSG00000223701.3	RAET1E-AS1	5.6	2.75e-08	3.71e-06	0.25	0.17	Dupuytren's disease;	chr6:149399710	chr6:149884431~149919508:+
BRCA	cis	rs2179367	0.586	rs34097428	ENSG00000223701.3	RAET1E-AS1	5.6	2.75e-08	3.71e-06	0.25	0.17	Dupuytren's disease;	chr6:149399822	chr6:149884431~149919508:+
BRCA	cis	rs2179367	0.632	rs12154153	ENSG00000223701.3	RAET1E-AS1	5.6	2.75e-08	3.71e-06	0.25	0.17	Dupuytren's disease;	chr6:149401686	chr6:149884431~149919508:+
BRCA	cis	rs9545047	0.604	rs7987193	ENSG00000227354.5	RBM26-AS1	-5.6	2.75e-08	3.71e-06	-0.18	-0.17	Schizophrenia;	chr13:79408449	chr13:79406309~79424328:+
BRCA	cis	rs7897654	0.571	rs12767543	ENSG00000236937.2	PTGES3P4	5.6	2.75e-08	3.71e-06	0.25	0.17	Schizophrenia;	chr10:102871906	chr10:102845595~102845950:+
BRCA	cis	rs253959	0.564	rs4921064	ENSG00000272265.1	CTD-2287O16.4	5.6	2.75e-08	3.72e-06	0.21	0.17	Bipolar disorder and schizophrenia;	chr5:116111637	chr5:116078110~116078570:-
BRCA	cis	rs1552244	0.882	rs17050660	ENSG00000232901.1	CYCSP10	-5.6	2.75e-08	3.72e-06	-0.23	-0.17	Alzheimer's disease;	chr3:9960088	chr3:10000647~10000940:-
BRCA	cis	rs2898681	0.581	rs11938140	ENSG00000248375.1	RP11-177B4.1	-5.6	2.75e-08	3.72e-06	-0.24	-0.17	Optic nerve measurement (cup area);	chr4:52811890	chr4:52720081~52720831:-
BRCA	cis	rs873549	1	rs7546082	ENSG00000232679.1	RP11-400N13.3	-5.6	2.75e-08	3.72e-06	-0.2	-0.17	Keloid;	chr1:222092759	chr1:222041705~222064763:-
BRCA	cis	rs4713118	0.824	rs742046	ENSG00000220721.1	OR1F12	5.6	2.75e-08	3.72e-06	0.21	0.17	Parkinson's disease;	chr6:27771475	chr6:28073316~28074233:+
BRCA	cis	rs2243480	1	rs34703416	ENSG00000164669.11	INTS4P1	5.6	2.75e-08	3.72e-06	0.33	0.17	Diabetic kidney disease;	chr7:65835655	chr7:65141225~65234216:+
BRCA	cis	rs9300255	0.722	rs12298826	ENSG00000235423.7	RP11-282O18.3	-5.6	2.76e-08	3.73e-06	-0.22	-0.17	Neutrophil percentage of white cells;	chr12:123344481	chr12:123252030~123261483:-
BRCA	cis	rs2179367	0.632	rs2341774	ENSG00000223701.3	RAET1E-AS1	5.6	2.76e-08	3.73e-06	0.25	0.17	Dupuytren's disease;	chr6:149425014	chr6:149884431~149919508:+
BRCA	cis	rs17818399	0.962	rs2122715	ENSG00000279254.1	RP11-536C12.1	-5.6	2.76e-08	3.73e-06	-0.22	-0.17	Height;	chr2:46618710	chr2:46668870~46670778:+
BRCA	cis	rs6600671	1	rs4844380	ENSG00000275538.1	RNVU1-19	5.6	2.76e-08	3.73e-06	0.2	0.17	Hip geometry;	chr1:121451764	chr1:120850819~120850985:-
BRCA	cis	rs7615952	0.576	rs1127717	ENSG00000171084.14	FAM86JP	5.6	2.76e-08	3.73e-06	0.26	0.17	Blood pressure (smoking interaction);	chr3:126107216	chr3:125916620~125930024:+
BRCA	cis	rs2638953	0.924	rs2272361	ENSG00000278733.1	RP11-425D17.1	-5.6	2.76e-08	3.73e-06	-0.21	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28450037	chr12:28185625~28186190:-
BRCA	cis	rs2688482	0.557	rs2550236	ENSG00000207650.1	MIR570	5.6	2.77e-08	3.74e-06	0.26	0.17	Lung disease severity in cystic fibrosis;	chr3:195795450	chr3:195699401~195699497:+
BRCA	cis	rs375066	0.592	rs349050	ENSG00000267058.1	RP11-15A1.3	5.6	2.77e-08	3.74e-06	0.19	0.17	Breast cancer;	chr19:43797273	chr19:43891804~43901805:-
BRCA	cis	rs4718428	0.705	rs11028	ENSG00000230295.1	RP11-458F8.2	-5.6	2.77e-08	3.74e-06	-0.15	-0.17	Corneal structure;	chr7:66811230	chr7:66880708~66882981:+
BRCA	cis	rs12681366	0.734	rs2919672	ENSG00000253704.1	RP11-267M23.4	5.6	2.77e-08	3.74e-06	0.18	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94424919	chr8:94553722~94569745:+
BRCA	cis	rs6088580	0.524	rs7274854	ENSG00000269202.1	RP4-614O4.12	-5.6	2.77e-08	3.74e-06	-0.17	-0.17	Glomerular filtration rate (creatinine);	chr20:34640868	chr20:35201747~35203288:-
BRCA	cis	rs13423976	0.586	rs12617556	ENSG00000231367.4	AC016995.3	5.6	2.77e-08	3.75e-06	0.19	0.17	Gut microbiome composition (summer);	chr2:38514972	chr2:38406719~38515740:-
BRCA	cis	rs2505998	0.833	rs2742243	ENSG00000273008.1	RP11-351D16.3	-5.6	2.77e-08	3.75e-06	-0.2	-0.17	Hirschsprung disease;	chr10:43106301	chr10:43136824~43138334:-
BRCA	cis	rs4950322	0.57	rs72691093	ENSG00000244371.2	PFN1P8	-5.6	2.78e-08	3.75e-06	-0.24	-0.17	Protein quantitative trait loci;	chr1:147297977	chr1:146957117~146957659:-
BRCA	cis	rs4950322	0.57	rs76236344	ENSG00000244371.2	PFN1P8	-5.6	2.78e-08	3.75e-06	-0.24	-0.17	Protein quantitative trait loci;	chr1:147297989	chr1:146957117~146957659:-
BRCA	cis	rs1552244	1	rs56394721	ENSG00000180385.7	EMC3-AS1	5.6	2.78e-08	3.75e-06	0.22	0.17	Alzheimer's disease;	chr3:10109111	chr3:9986893~10006990:+
BRCA	cis	rs2638953	0.853	rs10506036	ENSG00000278733.1	RP11-425D17.1	5.6	2.78e-08	3.75e-06	0.23	0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28497632	chr12:28185625~28186190:-
BRCA	cis	rs13118159	0.55	rs2336081	ENSG00000254094.1	AC078852.1	5.6	2.78e-08	3.75e-06	0.21	0.17	Longevity;	chr4:1356534	chr4:1356581~1358075:+
BRCA	cis	rs4699052	0.963	rs6533066	ENSG00000248740.4	RP11-328K4.1	5.6	2.78e-08	3.75e-06	0.2	0.17	Testicular germ cell tumor;	chr4:103242450	chr4:103256159~103453658:+
BRCA	cis	rs875971	0.545	rs12671152	ENSG00000228409.4	CCT6P1	-5.6	2.78e-08	3.76e-06	-0.17	-0.17	Aortic root size;	chr7:66311140	chr7:65751142~65763354:+
BRCA	cis	rs4713118	0.824	rs9366702	ENSG00000216901.1	AL022393.7	5.6	2.79e-08	3.76e-06	0.23	0.17	Parkinson's disease;	chr6:27766691	chr6:28176188~28176674:+
BRCA	cis	rs1387259	0.69	rs1601985	ENSG00000257763.1	OR5BK1P	5.6	2.79e-08	3.76e-06	0.19	0.17	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48368131	chr12:48355792~48356614:-
BRCA	cis	rs783540	0.5	rs783541	ENSG00000255769.6	GOLGA2P10	5.6	2.79e-08	3.77e-06	0.22	0.17	Schizophrenia;	chr15:82586310	chr15:82472993~82513950:-
BRCA	cis	rs73081554	0.611	rs35975336	ENSG00000272360.1	RP11-359I18.5	-5.6	2.79e-08	3.77e-06	-0.26	-0.17	Rheumatoid arthritis;	chr3:58465907	chr3:58490830~58491291:-
BRCA	cis	rs2638953	0.962	rs10843143	ENSG00000247934.4	RP11-967K21.1	-5.6	2.79e-08	3.77e-06	-0.24	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28253484	chr12:28163298~28190738:-
BRCA	cis	rs1552244	1	rs35198334	ENSG00000232901.1	CYCSP10	5.6	2.79e-08	3.77e-06	0.24	0.17	Alzheimer's disease;	chr3:10062869	chr3:10000647~10000940:-
BRCA	cis	rs7178375	1	rs7178375	ENSG00000270015.1	RP11-540B6.6	5.6	2.79e-08	3.77e-06	0.22	0.17	Hypertriglyceridemia;	chr15:30923732	chr15:30926514~30928407:+
BRCA	cis	rs858239	0.698	rs4265084	ENSG00000230042.1	AK3P3	-5.6	2.79e-08	3.77e-06	-0.2	-0.17	Cerebrospinal fluid biomarker levels;	chr7:23367621	chr7:23129178~23129841:+
BRCA	cis	rs792448	0.501	rs11119880	ENSG00000229983.1	RP11-15I11.2	5.6	2.79e-08	3.77e-06	0.21	0.17	White blood cell count (basophil);	chr1:212205143	chr1:212168207~212190259:+
BRCA	cis	rs7923609	1	rs4310508	ENSG00000232075.1	MRPL35P2	-5.6	2.8e-08	3.77e-06	-0.21	-0.17	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63378813	chr10:63634317~63634827:-
BRCA	cis	rs7923609	1	rs7910927	ENSG00000232075.1	MRPL35P2	-5.6	2.8e-08	3.77e-06	-0.21	-0.17	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63379150	chr10:63634317~63634827:-
BRCA	cis	rs8177876	0.642	rs12445303	ENSG00000261838.4	RP11-303E16.6	-5.6	2.8e-08	3.78e-06	-0.3	-0.17	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081968	chr16:81069854~81076598:+
BRCA	cis	rs8002861	0.935	rs9533672	ENSG00000274001.1	RP11-5G9.5	5.6	2.8e-08	3.78e-06	0.19	0.17	Leprosy;	chr13:43877044	chr13:43877715~43878163:-
BRCA	cis	rs2638953	0.853	rs12367657	ENSG00000278733.1	RP11-425D17.1	-5.6	2.8e-08	3.78e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28475816	chr12:28185625~28186190:-
BRCA	cis	rs8030379	1	rs1564472	ENSG00000230373.7	GOLGA6L5P	-5.6	2.8e-08	3.78e-06	-0.19	-0.17	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83901041	chr15:84507885~84516814:-
BRCA	cis	rs67981189	0.896	rs2810098	ENSG00000258571.1	PTTG4P	5.6	2.8e-08	3.78e-06	0.19	0.17	Schizophrenia;	chr14:70967194	chr14:71085482~71085833:-
BRCA	cis	rs55702914	0.602	rs2564372	ENSG00000231621.1	AC013264.2	-5.6	2.8e-08	3.79e-06	-0.16	-0.17	Major depression and alcohol dependence;	chr2:197443089	chr2:197197991~197199273:+
BRCA	cis	rs7620503	1	rs35168340	ENSG00000228221.4	LINC00578	5.6	2.81e-08	3.79e-06	0.2	0.17	Corneal structure;	chr3:177581264	chr3:177441921~177752305:+
BRCA	cis	rs7620503	0.918	rs34316712	ENSG00000228221.4	LINC00578	5.6	2.81e-08	3.79e-06	0.2	0.17	Corneal structure;	chr3:177581277	chr3:177441921~177752305:+
BRCA	cis	rs873549	0.785	rs7549980	ENSG00000232679.1	RP11-400N13.3	5.6	2.81e-08	3.79e-06	0.2	0.17	Keloid;	chr1:222095156	chr1:222041705~222064763:-
BRCA	cis	rs873549	1	rs7552392	ENSG00000232679.1	RP11-400N13.3	5.6	2.81e-08	3.79e-06	0.2	0.17	Keloid;	chr1:222095349	chr1:222041705~222064763:-
BRCA	cis	rs873549	1	rs6703147	ENSG00000232679.1	RP11-400N13.3	5.6	2.81e-08	3.79e-06	0.2	0.17	Keloid;	chr1:222095423	chr1:222041705~222064763:-
BRCA	cis	rs873549	1	rs6703389	ENSG00000232679.1	RP11-400N13.3	5.6	2.81e-08	3.79e-06	0.2	0.17	Keloid;	chr1:222095609	chr1:222041705~222064763:-
BRCA	cis	rs523522	0.885	rs524735	ENSG00000278344.1	RP11-18C24.8	5.6	2.81e-08	3.79e-06	0.23	0.17	High light scatter reticulocyte count;	chr12:120584296	chr12:120500735~120501090:-
BRCA	cis	rs1953600	0.729	rs2819872	ENSG00000226659.1	RP11-137H2.4	5.6	2.81e-08	3.79e-06	0.22	0.17	Sarcoidosis;	chr10:80146513	chr10:80529597~80535942:-
BRCA	cis	rs6688613	0.729	rs7545806	ENSG00000225171.2	DUTP6	-5.6	2.81e-08	3.79e-06	-0.24	-0.17	Refractive astigmatism;	chr1:166969318	chr1:166868748~166869209:+
BRCA	cis	rs8054556	1	rs9932196	ENSG00000273724.1	RP11-347C12.12	-5.6	2.81e-08	3.79e-06	-0.19	-0.17	Autism spectrum disorder or schizophrenia;	chr16:29971798	chr16:30336400~30343336:+
BRCA	cis	rs9652601	0.622	rs1003603	ENSG00000274038.1	RP11-66H6.4	-5.6	2.81e-08	3.79e-06	-0.19	-0.17	Systemic lupus erythematosus;	chr16:11020766	chr16:11056556~11057034:+
BRCA	cis	rs8002861	0.781	rs7322781	ENSG00000274001.1	RP11-5G9.5	5.6	2.81e-08	3.79e-06	0.19	0.17	Leprosy;	chr13:43868102	chr13:43877715~43878163:-
BRCA	cis	rs873549	1	rs3910710	ENSG00000232679.1	RP11-400N13.3	5.6	2.81e-08	3.79e-06	0.2	0.17	Keloid;	chr1:222094781	chr1:222041705~222064763:-
BRCA	cis	rs9925964	0.933	rs2303222	ENSG00000232748.3	RP11-196G11.6	5.6	2.81e-08	3.79e-06	0.21	0.17	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31074149	chr16:31056460~31062803:+
BRCA	cis	rs17213965	0.561	rs11866891	ENSG00000260872.1	RP11-680G24.5	-5.6	2.81e-08	3.8e-06	-0.21	-0.17	Waist-hip ratio;	chr16:15781561	chr16:15018106~15020488:-
BRCA	cis	rs6951245	0.554	rs78999139	ENSG00000229043.2	AC091729.9	-5.6	2.81e-08	3.8e-06	-0.26	-0.17	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1098889	chr7:1160374~1165267:+
BRCA	cis	rs7923609	1	rs7923609	ENSG00000232075.1	MRPL35P2	-5.6	2.81e-08	3.8e-06	-0.21	-0.17	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63374062	chr10:63634317~63634827:-
BRCA	cis	rs4835473	0.897	rs6537171	ENSG00000249741.2	RP11-673E1.3	-5.6	2.81e-08	3.8e-06	-0.18	-0.17	Immature fraction of reticulocytes;	chr4:143709222	chr4:143911514~143912053:-
BRCA	cis	rs7923837	0.651	rs11187033	ENSG00000236493.2	EIF2S2P3	5.6	2.81e-08	3.8e-06	0.24	0.17	Multiple sclerosis;Body mass index;	chr10:92502602	chr10:92668745~92669743:-
BRCA	cis	rs300890	0.513	rs10002888	ENSG00000250326.1	RP11-284M14.1	-5.6	2.81e-08	3.8e-06	-0.21	-0.17	Nasopharyngeal carcinoma;	chr4:143248559	chr4:142933195~143184861:-
BRCA	cis	rs6490294	0.571	rs57168159	ENSG00000226469.1	ADAM1B	5.6	2.82e-08	3.8e-06	0.26	0.17	Mean platelet volume;	chr12:112189041	chr12:111927018~111929017:+
BRCA	cis	rs10761750	1	rs10761750	ENSG00000232075.1	MRPL35P2	-5.6	2.82e-08	3.8e-06	-0.21	-0.17	Vascular endothelial growth factor levels;	chr10:63368859	chr10:63634317~63634827:-
BRCA	cis	rs4936099	0.646	rs4937514	ENSG00000175773.11	RP11-121M22.1	5.6	2.82e-08	3.8e-06	0.19	0.17	Optic cup area;Vertical cup-disc ratio;	chr11:130394620	chr11:130314993~130403657:+
BRCA	cis	rs875971	0.522	rs4718286	ENSG00000213640.3	EEF1DP4	-5.6	2.82e-08	3.8e-06	-0.21	-0.17	Aortic root size;	chr7:65827777	chr7:64862999~64864370:+
BRCA	cis	rs17711722	0.585	rs6942660	ENSG00000213640.3	EEF1DP4	-5.6	2.82e-08	3.8e-06	-0.21	-0.17	Calcium levels;	chr7:65837419	chr7:64862999~64864370:+
BRCA	cis	rs7923609	0.967	rs6479896	ENSG00000232075.1	MRPL35P2	-5.6	2.82e-08	3.8e-06	-0.21	-0.17	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63367072	chr10:63634317~63634827:-
BRCA	cis	rs7613875	0.62	rs34312088	ENSG00000228008.1	CTD-2330K9.3	5.59	2.82e-08	3.8e-06	0.17	0.17	Body mass index;	chr3:49994700	chr3:49903845~49916937:+
BRCA	cis	rs1707322	0.717	rs11211161	ENSG00000234329.1	RP11-767N6.2	5.59	2.82e-08	3.8e-06	0.18	0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45682466	chr1:45651039~45651826:-
BRCA	cis	rs66887589	0.616	rs6843509	ENSG00000249244.1	RP11-548H18.2	5.59	2.82e-08	3.81e-06	0.19	0.17	Diastolic blood pressure;	chr4:119299041	chr4:119391831~119395335:-
BRCA	cis	rs2243480	1	rs2257790	ENSG00000228409.4	CCT6P1	5.59	2.82e-08	3.81e-06	0.24	0.17	Diabetic kidney disease;	chr7:66135463	chr7:65751142~65763354:+
BRCA	cis	rs9510787	0.538	rs12430043	ENSG00000205861.10	C1QTNF9B-AS1	-5.59	2.83e-08	3.81e-06	-0.23	-0.17	Nasopharyngeal carcinoma;	chr13:23682221	chr13:23888889~23897263:+
BRCA	cis	rs2281636	1	rs11190263	ENSG00000233690.1	EBAG9P1	5.59	2.83e-08	3.81e-06	0.18	0.17	Obesity-related traits;	chr10:99746626	chr10:99697407~99697949:-
BRCA	cis	rs17508449	0.819	rs4839331	ENSG00000232450.1	RP4-730K3.3	-5.59	2.83e-08	3.81e-06	-0.29	-0.17	Leprosy;	chr1:113619009	chr1:113698884~113699631:-
BRCA	cis	rs12681366	0.708	rs1011249	ENSG00000253704.1	RP11-267M23.4	5.59	2.83e-08	3.82e-06	0.18	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94425833	chr8:94553722~94569745:+
BRCA	cis	rs9300255	0.722	rs34997336	ENSG00000235423.7	RP11-282O18.3	-5.59	2.84e-08	3.82e-06	-0.22	-0.17	Neutrophil percentage of white cells;	chr12:123344569	chr12:123252030~123261483:-
BRCA	cis	rs7569084	0.687	rs934731	ENSG00000237979.1	AC007389.1	5.59	2.84e-08	3.82e-06	0.22	0.17	Sum eosinophil basophil counts;	chr2:65456353	chr2:65500993~65502138:-
BRCA	cis	rs10027350	0.964	rs2302565	ENSG00000281501.1	SEPSECS-AS1	5.59	2.84e-08	3.83e-06	0.2	0.17	Childhood ear infection;	chr4:25144685	chr4:25160641~25201440:+
BRCA	cis	rs10129255	0.5	rs6576230	ENSG00000224373.3	IGHV4-59	5.59	2.84e-08	3.83e-06	0.1	0.17	Kawasaki disease;	chr14:106778539	chr14:106627249~106627825:-
BRCA	cis	rs10129255	0.518	rs8009612	ENSG00000224373.3	IGHV4-59	5.59	2.84e-08	3.83e-06	0.1	0.17	Kawasaki disease;	chr14:106777510	chr14:106627249~106627825:-
BRCA	cis	rs6061231	1	rs13043313	ENSG00000275437.1	RP5-908M14.10	5.59	2.84e-08	3.83e-06	0.18	0.17	Colorectal cancer;	chr20:62383213	chr20:62402236~62405935:-
BRCA	cis	rs7178375	1	rs7169064	ENSG00000270015.1	RP11-540B6.6	5.59	2.84e-08	3.83e-06	0.21	0.17	Hypertriglyceridemia;	chr15:30918659	chr15:30926514~30928407:+
BRCA	cis	rs72615157	0.539	rs72615159	ENSG00000214313.7	AZGP1P1	-5.59	2.84e-08	3.83e-06	-0.19	-0.17	Lung function (FEV1/FVC);	chr7:100076663	chr7:99980762~99987535:+
BRCA	cis	rs7493	0.76	rs17876092	ENSG00000233942.1	AC004012.1	5.59	2.84e-08	3.83e-06	0.22	0.17	Yu-Zhi constitution type in type 2 diabetes;	chr7:95424001	chr7:95471835~95473998:+
BRCA	cis	rs2638953	0.853	rs1918418	ENSG00000278733.1	RP11-425D17.1	-5.59	2.84e-08	3.84e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28483789	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.853	rs1511550	ENSG00000278733.1	RP11-425D17.1	-5.59	2.84e-08	3.84e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28484182	chr12:28185625~28186190:-
BRCA	cis	rs7200543	1	rs4985154	ENSG00000275910.1	RP11-680G24.6	-5.59	2.85e-08	3.84e-06	-0.2	-0.17	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15037785	chr16:15015828~15016390:-
BRCA	cis	rs2732480	0.538	rs1387260	ENSG00000240399.1	RP1-228P16.1	5.59	2.85e-08	3.84e-06	0.2	0.17	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48309308	chr12:48054813~48055591:-
BRCA	cis	rs7976269	0.609	rs6487744	ENSG00000275476.1	RP11-996F15.4	-5.59	2.85e-08	3.84e-06	-0.2	-0.17	Male-pattern baldness;	chr12:29030756	chr12:29277397~29277882:-
BRCA	cis	rs2898681	0.521	rs115874483	ENSG00000248375.1	RP11-177B4.1	-5.59	2.85e-08	3.84e-06	-0.28	-0.17	Optic nerve measurement (cup area);	chr4:52862105	chr4:52720081~52720831:-
BRCA	cis	rs1707322	0.721	rs11211178	ENSG00000234329.1	RP11-767N6.2	5.59	2.85e-08	3.84e-06	0.18	0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45761894	chr1:45651039~45651826:-
BRCA	cis	rs8054556	0.787	rs1140239	ENSG00000273724.1	RP11-347C12.12	-5.59	2.85e-08	3.85e-06	-0.2	-0.17	Autism spectrum disorder or schizophrenia;	chr16:30010081	chr16:30336400~30343336:+
BRCA	cis	rs9545047	0.604	rs9574416	ENSG00000227354.5	RBM26-AS1	-5.59	2.85e-08	3.85e-06	-0.18	-0.17	Schizophrenia;	chr13:79388577	chr13:79406309~79424328:+
BRCA	cis	rs6479891	1	rs7081275	ENSG00000232075.1	MRPL35P2	-5.59	2.86e-08	3.85e-06	-0.31	-0.17	Arthritis (juvenile idiopathic);	chr10:63346791	chr10:63634317~63634827:-
BRCA	cis	rs7487075	0.93	rs4076484	ENSG00000257261.4	RP11-96H19.1	5.59	2.86e-08	3.85e-06	0.19	0.17	Itch intensity from mosquito bite;	chr12:46440129	chr12:46383679~46876159:+
BRCA	cis	rs7487075	0.823	rs34472481	ENSG00000257261.4	RP11-96H19.1	5.59	2.86e-08	3.85e-06	0.19	0.17	Itch intensity from mosquito bite;	chr12:46442565	chr12:46383679~46876159:+
BRCA	cis	rs1211375	0.606	rs1203977	ENSG00000268836.1	LA16c-OS12.2	-5.59	2.86e-08	3.85e-06	-0.17	-0.17	Mean corpuscular volume;Hematology traits;Mean corpuscular hemoglobin;	chr16:206279	chr16:185748~186294:-
BRCA	cis	rs7618501	0.633	rs6446193	ENSG00000228008.1	CTD-2330K9.3	-5.59	2.86e-08	3.85e-06	-0.16	-0.17	Intelligence (multi-trait analysis);	chr3:50022325	chr3:49903845~49916937:+
BRCA	cis	rs467650	0.853	rs373773	ENSG00000248489.1	CTD-2007H13.3	5.59	2.86e-08	3.85e-06	0.2	0.17	Venous thromboembolism (SNP x SNP interaction);	chr5:98684911	chr5:98929171~98995013:+
BRCA	cis	rs6163	0.508	rs12776506	ENSG00000213061.2	PFN1P11	5.59	2.86e-08	3.85e-06	0.24	0.17	Waist circumference;Hip circumference;	chr10:102773071	chr10:102838011~102845473:-
BRCA	cis	rs858239	0.73	rs10255155	ENSG00000230042.1	AK3P3	5.59	2.86e-08	3.86e-06	0.2	0.17	Cerebrospinal fluid biomarker levels;	chr7:23362528	chr7:23129178~23129841:+
BRCA	cis	rs7267979	0.844	rs6050477	ENSG00000204556.4	CTD-2514C3.1	5.59	2.87e-08	3.86e-06	0.24	0.17	Liver enzyme levels (alkaline phosphatase);	chr20:25240911	chr20:26018832~26020684:+
BRCA	cis	rs301901	0.514	rs10073063	ENSG00000250155.1	CTD-2353F22.1	-5.59	2.87e-08	3.86e-06	-0.2	-0.17	Height;	chr5:37259873	chr5:36666214~36725195:-
BRCA	cis	rs7615952	0.688	rs12638240	ENSG00000171084.14	FAM86JP	5.59	2.87e-08	3.87e-06	0.26	0.17	Blood pressure (smoking interaction);	chr3:125822395	chr3:125916620~125930024:+
BRCA	cis	rs7927771	0.524	rs2869024	ENSG00000280615.1	Y_RNA	-5.59	2.87e-08	3.87e-06	-0.2	-0.17	Subjective well-being;	chr11:47652549	chr11:47614898~47614994:-
BRCA	cis	rs2243480	1	rs958550	ENSG00000229886.1	RP5-1132H15.3	-5.59	2.87e-08	3.87e-06	-0.29	-0.17	Diabetic kidney disease;	chr7:66170692	chr7:66025126~66031544:-
BRCA	cis	rs7772486	0.686	rs1004752	ENSG00000270638.1	RP3-466P17.1	-5.59	2.87e-08	3.87e-06	-0.19	-0.17	Lobe attachment (rater-scored or self-reported);	chr6:145716686	chr6:145735570~145737218:+
BRCA	cis	rs7772486	0.686	rs9390347	ENSG00000270638.1	RP3-466P17.1	-5.59	2.87e-08	3.87e-06	-0.19	-0.17	Lobe attachment (rater-scored or self-reported);	chr6:145723611	chr6:145735570~145737218:+
BRCA	cis	rs7772486	0.686	rs9390348	ENSG00000270638.1	RP3-466P17.1	-5.59	2.87e-08	3.87e-06	-0.19	-0.17	Lobe attachment (rater-scored or self-reported);	chr6:145723612	chr6:145735570~145737218:+
BRCA	cis	rs1552244	1	rs6772315	ENSG00000232901.1	CYCSP10	5.59	2.87e-08	3.87e-06	0.24	0.17	Alzheimer's disease;	chr3:10071960	chr3:10000647~10000940:-
BRCA	cis	rs673078	0.615	rs73222058	ENSG00000275409.1	RP11-131L12.4	-5.59	2.87e-08	3.87e-06	-0.22	-0.17	Glucose homeostasis traits;	chr12:118221066	chr12:118430147~118430699:+
BRCA	cis	rs7923837	0.683	rs10509645	ENSG00000236493.2	EIF2S2P3	5.59	2.87e-08	3.87e-06	0.24	0.17	Multiple sclerosis;Body mass index;	chr10:92518109	chr10:92668745~92669743:-
BRCA	cis	rs577676	0.586	rs549449	ENSG00000271811.1	RP1-79C4.4	5.59	2.87e-08	3.87e-06	0.2	0.17	Prevalent atrial fibrillation;	chr1:170641569	chr1:170667381~170669425:+
BRCA	cis	rs7615952	0.599	rs6779141	ENSG00000171084.14	FAM86JP	5.59	2.88e-08	3.87e-06	0.26	0.17	Blood pressure (smoking interaction);	chr3:125991152	chr3:125916620~125930024:+
BRCA	cis	rs6490294	0.571	rs6489830	ENSG00000226469.1	ADAM1B	5.59	2.88e-08	3.88e-06	0.27	0.17	Mean platelet volume;	chr12:112144736	chr12:111927018~111929017:+
BRCA	cis	rs6490294	0.571	rs12422864	ENSG00000226469.1	ADAM1B	5.59	2.88e-08	3.88e-06	0.27	0.17	Mean platelet volume;	chr12:112146397	chr12:111927018~111929017:+
BRCA	cis	rs4578769	0.836	rs3844227	ENSG00000265939.1	UBE2CP2	5.59	2.88e-08	3.88e-06	0.2	0.17	Eosinophil percentage of white cells;	chr18:22871067	chr18:22900486~22900995:-
BRCA	cis	rs8064024	0.676	rs2075467	ENSG00000267077.1	RP11-127I20.5	-5.59	2.88e-08	3.88e-06	-0.17	-0.17	Cancer;	chr16:4823241	chr16:4795265~4796532:-
BRCA	cis	rs2688482	0.557	rs3103952	ENSG00000207650.1	MIR570	5.59	2.88e-08	3.88e-06	0.27	0.17	Lung disease severity in cystic fibrosis;	chr3:195795819	chr3:195699401~195699497:+
BRCA	cis	rs11157436	0.958	rs6572313	ENSG00000211813.2	TRAV34	5.59	2.88e-08	3.88e-06	0.19	0.17	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22214070	chr14:22207522~22208129:+
BRCA	cis	rs467650	0.714	rs39785	ENSG00000248489.1	CTD-2007H13.3	-5.59	2.88e-08	3.88e-06	-0.19	-0.17	Venous thromboembolism (SNP x SNP interaction);	chr5:98579523	chr5:98929171~98995013:+
BRCA	cis	rs3892630	0.878	rs7246451	ENSG00000267567.1	CTD-2538C1.3	5.59	2.88e-08	3.88e-06	0.28	0.17	Red blood cell traits;	chr19:32718708	chr19:32718298~32719595:-
BRCA	cis	rs7613875	0.62	rs17657688	ENSG00000228008.1	CTD-2330K9.3	-5.59	2.88e-08	3.89e-06	-0.16	-0.17	Body mass index;	chr3:49995795	chr3:49903845~49916937:+
BRCA	cis	rs699371	0.507	rs10149787	ENSG00000259005.1	RP3-449M8.6	-5.59	2.89e-08	3.89e-06	-0.2	-0.17	Height;	chr14:74458749	chr14:74474007~74474864:-
BRCA	cis	rs2638953	0.815	rs11049684	ENSG00000278733.1	RP11-425D17.1	-5.59	2.89e-08	3.89e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28512426	chr12:28185625~28186190:-
BRCA	cis	rs1440410	0.835	rs34342939	ENSG00000250326.1	RP11-284M14.1	-5.59	2.89e-08	3.89e-06	-0.19	-0.17	Ischemic stroke;	chr4:143240517	chr4:142933195~143184861:-
BRCA	cis	rs2243480	1	rs1553174	ENSG00000228409.4	CCT6P1	-5.59	2.89e-08	3.89e-06	-0.24	-0.17	Diabetic kidney disease;	chr7:66266207	chr7:65751142~65763354:+
BRCA	cis	rs2243480	1	rs10950032	ENSG00000228409.4	CCT6P1	-5.59	2.89e-08	3.89e-06	-0.24	-0.17	Diabetic kidney disease;	chr7:66273604	chr7:65751142~65763354:+
BRCA	cis	rs2243480	1	rs78803505	ENSG00000230295.1	RP11-458F8.2	-5.59	2.89e-08	3.89e-06	-0.22	-0.17	Diabetic kidney disease;	chr7:65917585	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs34577383	ENSG00000230295.1	RP11-458F8.2	-5.59	2.89e-08	3.89e-06	-0.22	-0.17	Diabetic kidney disease;	chr7:65920739	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs55895244	ENSG00000230295.1	RP11-458F8.2	-5.59	2.89e-08	3.89e-06	-0.22	-0.17	Diabetic kidney disease;	chr7:65922691	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs7795242	ENSG00000230295.1	RP11-458F8.2	-5.59	2.89e-08	3.89e-06	-0.22	-0.17	Diabetic kidney disease;	chr7:65925107	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs2177703	ENSG00000230295.1	RP11-458F8.2	-5.59	2.89e-08	3.89e-06	-0.22	-0.17	Diabetic kidney disease;	chr7:65926730	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs56985706	ENSG00000230295.1	RP11-458F8.2	-5.59	2.89e-08	3.89e-06	-0.22	-0.17	Diabetic kidney disease;	chr7:65929575	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs60683927	ENSG00000230295.1	RP11-458F8.2	-5.59	2.89e-08	3.89e-06	-0.22	-0.17	Diabetic kidney disease;	chr7:65929781	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs58062456	ENSG00000230295.1	RP11-458F8.2	-5.59	2.89e-08	3.89e-06	-0.22	-0.17	Diabetic kidney disease;	chr7:65929865	chr7:66880708~66882981:+
BRCA	cis	rs10129255	1	rs11621409	ENSG00000280411.1	IGHV1-69-2	-5.59	2.89e-08	3.89e-06	-0.13	-0.17	Kawasaki disease;	chr14:106695603	chr14:106762092~106762588:-
BRCA	cis	rs3213958	0.574	rs55988144	ENSG00000249274.1	PDLIM1P4	-5.59	2.89e-08	3.9e-06	-0.26	-0.17	Blood protein levels;	chr3:98902108	chr3:98782188~98783193:+
BRCA	cis	rs2638953	0.886	rs11049572	ENSG00000278733.1	RP11-425D17.1	-5.59	2.89e-08	3.9e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28397268	chr12:28185625~28186190:-
BRCA	cis	rs7772486	0.806	rs4075695	ENSG00000270638.1	RP3-466P17.1	-5.59	2.9e-08	3.9e-06	-0.19	-0.17	Lobe attachment (rater-scored or self-reported);	chr6:145929823	chr6:145735570~145737218:+
BRCA	cis	rs7044106	0.791	rs3904196	ENSG00000238181.2	AHCYP2	-5.59	2.9e-08	3.9e-06	-0.22	-0.17	Hip circumference adjusted for BMI;	chr9:120718091	chr9:120720673~120721972:+
BRCA	cis	rs523522	0.962	rs9788155	ENSG00000278344.1	RP11-18C24.8	5.59	2.9e-08	3.9e-06	0.23	0.17	High light scatter reticulocyte count;	chr12:120500605	chr12:120500735~120501090:-
BRCA	cis	rs4908768	0.539	rs6666191	ENSG00000270282.1	RP5-1115A15.2	5.59	2.9e-08	3.9e-06	0.19	0.17	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8598383	chr1:8512653~8513021:+
BRCA	cis	rs1345301	1	rs13405355	ENSG00000234389.1	AC007278.3	-5.59	2.9e-08	3.91e-06	-0.16	-0.17	Waist circumference;	chr2:102261746	chr2:102438713~102440475:+
BRCA	cis	rs516805	0.64	rs55768410	ENSG00000279453.1	RP3-425C14.4	5.59	2.9e-08	3.91e-06	0.24	0.17	Lymphocyte counts;	chr6:122358588	chr6:122436789~122439223:-
BRCA	cis	rs2638953	0.962	rs11049533	ENSG00000278733.1	RP11-425D17.1	-5.59	2.9e-08	3.91e-06	-0.24	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28327471	chr12:28185625~28186190:-
BRCA	cis	rs7308116	0.51	rs7485663	ENSG00000274395.1	RP11-554D14.8	-5.59	2.9e-08	3.91e-06	-0.2	-0.17	Pelvic organ prolapse (moderate/severe);	chr12:107829361	chr12:107835541~107836555:-
BRCA	cis	rs7308116	0.546	rs7488082	ENSG00000274395.1	RP11-554D14.8	-5.59	2.9e-08	3.91e-06	-0.2	-0.17	Pelvic organ prolapse (moderate/severe);	chr12:107829381	chr12:107835541~107836555:-
BRCA	cis	rs7308116	0.51	rs7488084	ENSG00000274395.1	RP11-554D14.8	-5.59	2.9e-08	3.91e-06	-0.2	-0.17	Pelvic organ prolapse (moderate/severe);	chr12:107829391	chr12:107835541~107836555:-
BRCA	cis	rs7829975	0.659	rs4382480	ENSG00000253981.4	ALG1L13P	5.59	2.9e-08	3.91e-06	0.19	0.17	Mood instability;	chr8:8863963	chr8:8236003~8244667:-
BRCA	cis	rs12681366	0.734	rs2931633	ENSG00000253704.1	RP11-267M23.4	5.59	2.9e-08	3.91e-06	0.18	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94410492	chr8:94553722~94569745:+
BRCA	cis	rs2732480	0.5	rs2932093	ENSG00000240399.1	RP1-228P16.1	5.59	2.91e-08	3.91e-06	0.2	0.17	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48254488	chr12:48054813~48055591:-
BRCA	cis	rs10129255	0.833	rs7156689	ENSG00000280411.1	IGHV1-69-2	-5.59	2.91e-08	3.91e-06	-0.13	-0.17	Kawasaki disease;	chr14:106816039	chr14:106762092~106762588:-
BRCA	cis	rs2153535	0.56	rs7748421	ENSG00000230939.1	RP11-314C16.1	-5.59	2.91e-08	3.92e-06	-0.2	-0.17	Motion sickness;	chr6:8636271	chr6:8784178~8785445:+
BRCA	cis	rs2439831	0.557	rs13329084	ENSG00000275601.1	AC011330.13	5.59	2.91e-08	3.92e-06	0.31	0.17	Lung cancer in ever smokers;	chr15:43858865	chr15:43642389~43643023:-
BRCA	cis	rs10129255	1	rs61997605	ENSG00000280411.1	IGHV1-69-2	-5.59	2.91e-08	3.92e-06	-0.13	-0.17	Kawasaki disease;	chr14:106678368	chr14:106762092~106762588:-
BRCA	cis	rs61160187	0.51	rs10072745	ENSG00000272308.1	RP11-231G3.1	-5.59	2.91e-08	3.92e-06	-0.19	-0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:60787448	chr5:60866457~60866935:-
BRCA	cis	rs4671400	0.571	rs28480287	ENSG00000271889.1	RP11-493E12.1	-5.59	2.91e-08	3.92e-06	-0.26	-0.17	3-hydroxypropylmercapturic acid levels in smokers;	chr2:61262154	chr2:61151433~61162105:-
BRCA	cis	rs4699052	1	rs7661702	ENSG00000248740.4	RP11-328K4.1	5.59	2.91e-08	3.92e-06	0.19	0.17	Testicular germ cell tumor;	chr4:103218972	chr4:103256159~103453658:+
BRCA	cis	rs7493	0.901	rs2237586	ENSG00000233942.1	AC004012.1	5.59	2.92e-08	3.93e-06	0.22	0.17	Yu-Zhi constitution type in type 2 diabetes;	chr7:95421740	chr7:95471835~95473998:+
BRCA	cis	rs7493	0.853	rs35686517	ENSG00000233942.1	AC004012.1	5.59	2.92e-08	3.93e-06	0.22	0.17	Yu-Zhi constitution type in type 2 diabetes;	chr7:95423299	chr7:95471835~95473998:+
BRCA	cis	rs1552244	1	rs67852463	ENSG00000180385.7	EMC3-AS1	5.59	2.92e-08	3.93e-06	0.22	0.17	Alzheimer's disease;	chr3:10115521	chr3:9986893~10006990:+
BRCA	cis	rs2898681	0.519	rs6554057	ENSG00000248375.1	RP11-177B4.1	-5.59	2.92e-08	3.93e-06	-0.27	-0.17	Optic nerve measurement (cup area);	chr4:52863980	chr4:52720081~52720831:-
BRCA	cis	rs2898681	0.519	rs6848200	ENSG00000248375.1	RP11-177B4.1	-5.59	2.92e-08	3.93e-06	-0.27	-0.17	Optic nerve measurement (cup area);	chr4:52864014	chr4:52720081~52720831:-
BRCA	cis	rs9309473	0.687	rs6747145	ENSG00000163016.8	ALMS1P	5.59	2.92e-08	3.93e-06	0.21	0.17	Metabolite levels;	chr2:73382049	chr2:73644919~73685576:+
BRCA	cis	rs9393692	0.905	rs1124999	ENSG00000241549.7	GUSBP2	-5.59	2.92e-08	3.93e-06	-0.19	-0.17	Educational attainment;	chr6:26286815	chr6:26871484~26956554:-
BRCA	cis	rs7923609	0.811	rs7899657	ENSG00000232075.1	MRPL35P2	5.59	2.92e-08	3.94e-06	0.21	0.17	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63563505	chr10:63634317~63634827:-
BRCA	cis	rs7772486	0.686	rs2092263	ENSG00000270638.1	RP3-466P17.1	-5.59	2.93e-08	3.94e-06	-0.19	-0.17	Lobe attachment (rater-scored or self-reported);	chr6:145708551	chr6:145735570~145737218:+
BRCA	cis	rs8180040	0.966	rs3736177	ENSG00000276925.1	RP11-708J19.3	5.59	2.93e-08	3.94e-06	0.2	0.17	Colorectal cancer;	chr3:47409921	chr3:47469777~47469987:+
BRCA	cis	rs9287719	0.649	rs9973374	ENSG00000243819.4	RN7SL832P	5.59	2.93e-08	3.94e-06	0.17	0.17	Prostate cancer;	chr2:10576258	chr2:10690344~10692099:+
BRCA	cis	rs11154801	0.634	rs6941396	ENSG00000231028.7	LINC00271	-5.59	2.93e-08	3.94e-06	-0.18	-0.17	Multiple sclerosis;	chr6:135606388	chr6:135497801~135716055:+
BRCA	cis	rs875971	0.545	rs73376394	ENSG00000273024.4	INTS4P2	-5.59	2.93e-08	3.94e-06	-0.21	-0.17	Aortic root size;	chr7:66172694	chr7:65647864~65715661:+
BRCA	cis	rs523522	0.962	rs10849759	ENSG00000278344.1	RP11-18C24.8	5.59	2.93e-08	3.94e-06	0.23	0.17	High light scatter reticulocyte count;	chr12:120556685	chr12:120500735~120501090:-
BRCA	cis	rs638893	0.578	rs500254	ENSG00000255239.1	AP002954.6	-5.59	2.93e-08	3.95e-06	-0.28	-0.17	Vitiligo;	chr11:118808071	chr11:118688039~118690600:-
BRCA	cis	rs1440410	0.93	rs4618266	ENSG00000250326.1	RP11-284M14.1	-5.59	2.93e-08	3.95e-06	-0.18	-0.17	Ischemic stroke;	chr4:143114974	chr4:142933195~143184861:-
BRCA	cis	rs11159086	0.793	rs1029702	ENSG00000270000.1	RP3-449M8.9	5.59	2.94e-08	3.95e-06	0.26	0.17	Advanced glycation end-product levels;	chr14:74473909	chr14:74471930~74472360:-
BRCA	cis	rs804280	0.509	rs12719915	ENSG00000270154.1	RP11-419I17.1	-5.59	2.94e-08	3.95e-06	-0.2	-0.17	Myopia (pathological);	chr8:11928746	chr8:12476462~12477122:+
BRCA	cis	rs10885396	1	rs10885396	ENSG00000233547.1	RP11-57H14.2	-5.59	2.94e-08	3.95e-06	-0.18	-0.17	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr10:112951996	chr10:112950646~112951875:-
BRCA	cis	rs6840360	0.837	rs4696294	ENSG00000270265.1	RP11-731D1.4	5.59	2.94e-08	3.95e-06	0.19	0.17	Intelligence (multi-trait analysis);	chr4:151791937	chr4:151333775~151353224:-
BRCA	cis	rs2688608	0.901	rs2664282	ENSG00000271816.1	BMS1P4	5.59	2.94e-08	3.96e-06	0.17	0.17	Inflammatory bowel disease;	chr10:73860999	chr10:73699151~73730487:-
BRCA	cis	rs11719291	0.915	rs9834996	ENSG00000270441.1	RP11-694I15.7	5.59	2.94e-08	3.96e-06	0.31	0.17	Cognitive function;	chr3:48717444	chr3:49140086~49160851:-
BRCA	cis	rs2911132	0.568	rs3797814	ENSG00000248734.2	CTD-2260A17.1	5.59	2.94e-08	3.96e-06	0.2	0.17	Urate levels (BMI interaction);	chr5:96756222	chr5:96784777~96785999:+
BRCA	cis	rs12144309	0.554	rs1970559	ENSG00000232450.1	RP4-730K3.3	5.59	2.94e-08	3.96e-06	0.22	0.17	Coronary artery disease;	chr1:113834526	chr1:113698884~113699631:-
BRCA	cis	rs875971	0.545	rs316328	ENSG00000273024.4	INTS4P2	5.59	2.95e-08	3.96e-06	0.2	0.17	Aortic root size;	chr7:66143851	chr7:65647864~65715661:+
BRCA	cis	rs7246657	0.943	rs1035479	ENSG00000267422.1	CTD-2554C21.1	5.59	2.95e-08	3.97e-06	0.24	0.17	Coronary artery calcification;	chr19:37402398	chr19:37779686~37792865:+
BRCA	cis	rs2505998	0.833	rs2742244	ENSG00000273008.1	RP11-351D16.3	-5.59	2.95e-08	3.97e-06	-0.2	-0.17	Hirschsprung disease;	chr10:43108144	chr10:43136824~43138334:-
BRCA	cis	rs1707322	0.752	rs4586014	ENSG00000234329.1	RP11-767N6.2	5.59	2.95e-08	3.97e-06	0.18	0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45684771	chr1:45651039~45651826:-
BRCA	cis	rs1707322	0.648	rs4439382	ENSG00000234329.1	RP11-767N6.2	5.59	2.95e-08	3.97e-06	0.18	0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45685133	chr1:45651039~45651826:-
BRCA	cis	rs9287719	0.649	rs6722126	ENSG00000243819.4	RN7SL832P	5.59	2.95e-08	3.97e-06	0.17	0.17	Prostate cancer;	chr2:10581516	chr2:10690344~10692099:+
BRCA	cis	rs577676	0.586	rs639720	ENSG00000271811.1	RP1-79C4.4	5.59	2.95e-08	3.97e-06	0.2	0.17	Prevalent atrial fibrillation;	chr1:170643785	chr1:170667381~170669425:+
BRCA	cis	rs577676	0.586	rs593173	ENSG00000271811.1	RP1-79C4.4	5.59	2.95e-08	3.97e-06	0.2	0.17	Prevalent atrial fibrillation;	chr1:170646719	chr1:170667381~170669425:+
BRCA	cis	rs7772486	0.624	rs9485018	ENSG00000270638.1	RP3-466P17.1	-5.59	2.95e-08	3.97e-06	-0.19	-0.17	Lobe attachment (rater-scored or self-reported);	chr6:145704595	chr6:145735570~145737218:+
BRCA	cis	rs755249	0.588	rs2275767	ENSG00000237624.1	OXCT2P1	-5.59	2.95e-08	3.97e-06	-0.2	-0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39479625	chr1:39514956~39516490:+
BRCA	cis	rs73081554	0.611	rs4681851	ENSG00000272360.1	RP11-359I18.5	-5.59	2.95e-08	3.97e-06	-0.25	-0.17	Rheumatoid arthritis;	chr3:58410164	chr3:58490830~58491291:-
BRCA	cis	rs919433	0.68	rs67580728	ENSG00000231621.1	AC013264.2	-5.59	2.95e-08	3.97e-06	-0.16	-0.17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197566534	chr2:197197991~197199273:+
BRCA	cis	rs7927592	0.956	rs10896343	ENSG00000212093.1	AP000807.1	5.59	2.96e-08	3.98e-06	0.19	0.17	Total body bone mineral density;	chr11:68550392	chr11:68506083~68506166:-
BRCA	cis	rs490234	0.552	rs2841327	ENSG00000232630.1	PRPS1P2	-5.59	2.96e-08	3.98e-06	-0.17	-0.17	Mean arterial pressure;	chr9:125394224	chr9:125150653~125151589:+
BRCA	cis	rs10885396	0.967	rs7094463	ENSG00000233547.1	RP11-57H14.2	5.59	2.96e-08	3.98e-06	0.18	0.17	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr10:112952224	chr10:112950646~112951875:-
BRCA	cis	rs6570726	0.967	rs9403706	ENSG00000270638.1	RP3-466P17.1	-5.59	2.96e-08	3.98e-06	-0.19	-0.17	Lobe attachment (rater-scored or self-reported);	chr6:145474051	chr6:145735570~145737218:+
BRCA	cis	rs2243480	1	rs67728539	ENSG00000232546.1	RP11-458F8.1	-5.59	2.96e-08	3.98e-06	-0.22	-0.17	Diabetic kidney disease;	chr7:65913137	chr7:66848496~66858136:+
BRCA	cis	rs9307551	0.741	rs6824396	ENSG00000250334.4	LINC00989	-5.59	2.96e-08	3.98e-06	-0.24	-0.17	Refractive error;	chr4:79541178	chr4:79492416~79576460:+
BRCA	cis	rs7927592	0.913	rs7104345	ENSG00000212093.1	AP000807.1	5.59	2.96e-08	3.99e-06	0.19	0.17	Total body bone mineral density;	chr11:68549304	chr11:68506083~68506166:-
BRCA	cis	rs2243480	1	rs34529418	ENSG00000230295.1	RP11-458F8.2	-5.59	2.96e-08	3.99e-06	-0.22	-0.17	Diabetic kidney disease;	chr7:65938222	chr7:66880708~66882981:+
BRCA	cis	rs250585	1	rs538023	ENSG00000260136.4	CTD-2270L9.4	5.59	2.97e-08	3.99e-06	0.2	0.17	Egg allergy;	chr16:23451180	chr16:23452758~23457606:+
BRCA	cis	rs375066	0.62	rs10401170	ENSG00000267058.1	RP11-15A1.3	5.59	2.97e-08	3.99e-06	0.19	0.17	Breast cancer;	chr19:43795471	chr19:43891804~43901805:-
BRCA	cis	rs2243480	1	rs1499613	ENSG00000228409.4	CCT6P1	-5.59	2.97e-08	4e-06	-0.24	-0.17	Diabetic kidney disease;	chr7:66265873	chr7:65751142~65763354:+
BRCA	cis	rs10752881	1	rs10752885	ENSG00000224468.3	RP11-181K3.4	-5.59	2.97e-08	4e-06	-0.18	-0.17	Colorectal cancer;	chr1:183013743	chr1:183138402~183141282:-
BRCA	cis	rs1707322	0.686	rs11211179	ENSG00000234329.1	RP11-767N6.2	5.59	2.98e-08	4e-06	0.17	0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45762410	chr1:45651039~45651826:-
BRCA	cis	rs1707322	0.721	rs10157795	ENSG00000234329.1	RP11-767N6.2	5.59	2.98e-08	4e-06	0.17	0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45762520	chr1:45651039~45651826:-
BRCA	cis	rs801193	0.591	rs9986881	ENSG00000275400.1	RP4-756H11.5	-5.59	2.98e-08	4e-06	-0.2	-0.17	Aortic root size;	chr7:66708053	chr7:66553805~66554199:-
BRCA	cis	rs4907240	0.961	rs12471390	ENSG00000237510.6	AC008268.2	-5.59	2.98e-08	4e-06	-0.24	-0.17	Event-related brain oscillations;	chr2:96657221	chr2:95789654~95800166:+
BRCA	cis	rs7493	0.853	rs17166879	ENSG00000233942.1	AC004012.1	5.58	2.98e-08	4.01e-06	0.22	0.17	Yu-Zhi constitution type in type 2 diabetes;	chr7:95424103	chr7:95471835~95473998:+
BRCA	cis	rs11955398	0.502	rs162249	ENSG00000215032.2	GNL3LP1	5.58	2.98e-08	4.01e-06	0.22	0.17	Intelligence (multi-trait analysis);	chr5:60999753	chr5:60891935~60893577:-
BRCA	cis	rs4950322	0.542	rs4950384	ENSG00000278811.3	LINC00624	5.58	2.98e-08	4.01e-06	0.22	0.17	Protein quantitative trait loci;	chr1:147177310	chr1:147258885~147517875:-
BRCA	cis	rs7246657	0.943	rs2126977	ENSG00000267422.1	CTD-2554C21.1	5.58	2.98e-08	4.01e-06	0.25	0.17	Coronary artery calcification;	chr19:37504845	chr19:37779686~37792865:+
BRCA	cis	rs7617773	0.817	rs9818937	ENSG00000199476.1	Y_RNA	-5.58	2.99e-08	4.01e-06	-0.24	-0.17	Coronary artery disease;	chr3:48283791	chr3:48288587~48288694:+
BRCA	cis	rs73193808	1	rs2832230	ENSG00000215533.7	LINC00189	5.58	2.99e-08	4.02e-06	0.24	0.17	Coronary artery disease;	chr21:29164391	chr21:29193480~29288205:+
BRCA	cis	rs2562456	0.917	rs11085463	ENSG00000268658.4	LINC00664	5.58	2.99e-08	4.02e-06	0.25	0.17	Pain;	chr19:21568500	chr19:21483374~21503238:+
BRCA	cis	rs13108904	0.517	rs13128825	ENSG00000254094.1	AC078852.1	-5.58	2.99e-08	4.02e-06	-0.2	-0.17	Obesity-related traits;	chr4:1340219	chr4:1356581~1358075:+
BRCA	cis	rs250585	0.736	rs4968006	ENSG00000260136.4	CTD-2270L9.4	-5.58	2.99e-08	4.02e-06	-0.19	-0.17	Egg allergy;	chr16:23476710	chr16:23452758~23457606:+
BRCA	cis	rs5758511	0.68	rs5758688	ENSG00000205702.9	CYP2D7	5.58	3e-08	4.03e-06	0.18	0.17	Birth weight;	chr22:42266495	chr22:42140203~42144577:-
BRCA	cis	rs4908760	0.86	rs11121202	ENSG00000232912.4	RP5-1115A15.1	5.58	3e-08	4.03e-06	0.17	0.17	Vitiligo;	chr1:8579298	chr1:8424645~8434838:+
BRCA	cis	rs2638953	0.853	rs1355474	ENSG00000278733.1	RP11-425D17.1	-5.58	3e-08	4.03e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28463599	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.64	rs10843204	ENSG00000278733.1	RP11-425D17.1	-5.58	3e-08	4.03e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28568028	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.64	rs10843205	ENSG00000278733.1	RP11-425D17.1	-5.58	3e-08	4.03e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28568220	chr12:28185625~28186190:-
BRCA	cis	rs801193	0.548	rs2659891	ENSG00000224316.1	RP11-479O9.2	5.58	3e-08	4.03e-06	0.17	0.17	Aortic root size;	chr7:66736127	chr7:65773620~65802067:+
BRCA	cis	rs801193	0.548	rs7805152	ENSG00000224316.1	RP11-479O9.2	5.58	3e-08	4.03e-06	0.17	0.17	Aortic root size;	chr7:66744266	chr7:65773620~65802067:+
BRCA	cis	rs875971	0.545	rs316316	ENSG00000228409.4	CCT6P1	5.58	3e-08	4.03e-06	0.17	0.17	Aortic root size;	chr7:66149270	chr7:65751142~65763354:+
BRCA	cis	rs1559040	0.932	rs72800719	ENSG00000272156.1	RP11-477N3.1	-5.58	3e-08	4.03e-06	-0.28	-0.17	Sudden cardiac arrest;	chr2:54053058	chr2:54082554~54085066:+
BRCA	cis	rs13423976	0.631	rs7582463	ENSG00000231367.4	AC016995.3	-5.58	3e-08	4.03e-06	-0.19	-0.17	Gut microbiome composition (summer);	chr2:38511226	chr2:38406719~38515740:-
BRCA	cis	rs9287719	0.649	rs10929677	ENSG00000243819.4	RN7SL832P	5.58	3e-08	4.03e-06	0.17	0.17	Prostate cancer;	chr2:10577422	chr2:10690344~10692099:+
BRCA	cis	rs2638953	0.64	rs11049723	ENSG00000278733.1	RP11-425D17.1	5.58	3e-08	4.03e-06	0.23	0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28575903	chr12:28185625~28186190:-
BRCA	cis	rs7620503	0.959	rs6797636	ENSG00000228221.4	LINC00578	5.58	3.01e-08	4.04e-06	0.2	0.17	Corneal structure;	chr3:177591654	chr3:177441921~177752305:+
BRCA	cis	rs189798	0.807	rs9949	ENSG00000253893.2	FAM85B	-5.58	3.01e-08	4.04e-06	-0.25	-0.17	Myopia (pathological);	chr8:9137002	chr8:8167819~8226614:-
BRCA	cis	rs736408	0.608	rs2239547	ENSG00000242142.1	SERBP1P3	5.58	3.01e-08	4.05e-06	0.21	0.17	Bipolar disorder;	chr3:52821213	chr3:53064283~53065091:-
BRCA	cis	rs11009175	0.615	rs10763904	ENSG00000273038.2	RP11-479G22.8	-5.58	3.01e-08	4.05e-06	-0.23	-0.17	Depression (quantitative trait);	chr10:33016162	chr10:32887255~32889311:-
BRCA	cis	rs11009175	0.556	rs10763905	ENSG00000273038.2	RP11-479G22.8	-5.58	3.01e-08	4.05e-06	-0.23	-0.17	Depression (quantitative trait);	chr10:33016168	chr10:32887255~32889311:-
BRCA	cis	rs9307551	0.584	rs2119421	ENSG00000250334.4	LINC00989	-5.58	3.01e-08	4.05e-06	-0.24	-0.17	Refractive error;	chr4:79529168	chr4:79492416~79576460:+
BRCA	cis	rs1552244	0.935	rs7652190	ENSG00000232901.1	CYCSP10	5.58	3.02e-08	4.05e-06	0.24	0.17	Alzheimer's disease;	chr3:10063466	chr3:10000647~10000940:-
BRCA	cis	rs1552244	1	rs7619340	ENSG00000232901.1	CYCSP10	5.58	3.02e-08	4.05e-06	0.24	0.17	Alzheimer's disease;	chr3:10066494	chr3:10000647~10000940:-
BRCA	cis	rs12681366	0.801	rs12549544	ENSG00000253704.1	RP11-267M23.4	5.58	3.02e-08	4.05e-06	0.2	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94471329	chr8:94553722~94569745:+
BRCA	cis	rs42648	0.564	rs12155202	ENSG00000225498.1	AC002064.5	5.58	3.02e-08	4.05e-06	0.16	0.17	Homocysteine levels;	chr7:90198810	chr7:90312496~90322592:+
BRCA	cis	rs14027	0.596	rs28576821	ENSG00000279347.1	RP11-85I17.2	-5.58	3.02e-08	4.05e-06	-0.16	-0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119752777	chr8:119838736~119840385:-
BRCA	cis	rs3808502	0.549	rs7831039	ENSG00000270154.1	RP11-419I17.1	-5.58	3.02e-08	4.06e-06	-0.2	-0.17	Neuroticism;	chr8:11570128	chr8:12476462~12477122:+
BRCA	cis	rs253959	0.532	rs10045890	ENSG00000272265.1	CTD-2287O16.4	5.58	3.02e-08	4.06e-06	0.21	0.17	Bipolar disorder and schizophrenia;	chr5:116112188	chr5:116078110~116078570:-
BRCA	cis	rs1555322	0.505	rs591590	ENSG00000269202.1	RP4-614O4.12	5.58	3.02e-08	4.06e-06	0.2	0.17	Attention deficit hyperactivity disorder;	chr20:35278225	chr20:35201747~35203288:-
BRCA	cis	rs442309	0.687	rs11815005	ENSG00000238280.1	RP11-436D10.3	-5.58	3.02e-08	4.06e-06	-0.23	-0.17	Vogt-Koyanagi-Harada syndrome;	chr10:62696987	chr10:62793562~62805887:-
BRCA	cis	rs2179367	0.632	rs7349921	ENSG00000223701.3	RAET1E-AS1	5.58	3.03e-08	4.07e-06	0.24	0.17	Dupuytren's disease;	chr6:149392727	chr6:149884431~149919508:+
BRCA	cis	rs2179367	0.632	rs60153446	ENSG00000223701.3	RAET1E-AS1	5.58	3.03e-08	4.07e-06	0.24	0.17	Dupuytren's disease;	chr6:149393186	chr6:149884431~149919508:+
BRCA	cis	rs2179367	0.632	rs61259243	ENSG00000223701.3	RAET1E-AS1	5.58	3.03e-08	4.07e-06	0.24	0.17	Dupuytren's disease;	chr6:149393457	chr6:149884431~149919508:+
BRCA	cis	rs2179367	0.632	rs62426115	ENSG00000223701.3	RAET1E-AS1	5.58	3.03e-08	4.07e-06	0.24	0.17	Dupuytren's disease;	chr6:149393718	chr6:149884431~149919508:+
BRCA	cis	rs2179367	0.632	rs68080376	ENSG00000223701.3	RAET1E-AS1	5.58	3.03e-08	4.07e-06	0.24	0.17	Dupuytren's disease;	chr6:149393873	chr6:149884431~149919508:+
BRCA	cis	rs67981189	0.892	rs221899	ENSG00000258571.1	PTTG4P	-5.58	3.03e-08	4.07e-06	-0.19	-0.17	Schizophrenia;	chr14:71138551	chr14:71085482~71085833:-
BRCA	cis	rs4713675	0.584	rs4711339	ENSG00000224557.6	HLA-DPB2	-5.58	3.03e-08	4.07e-06	-0.2	-0.17	Plateletcrit;	chr6:33699422	chr6:33112451~33129084:+
BRCA	cis	rs745109	0.504	rs74432925	ENSG00000273080.1	RP11-301O19.1	5.58	3.03e-08	4.07e-06	0.27	0.17	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86386592	chr2:86195590~86196049:+
BRCA	cis	rs1859596	0.934	rs2365423	ENSG00000234456.6	MAGI2-AS3	5.58	3.04e-08	4.08e-06	0.11	0.17	Reading or mathematical ability;	chr7:79485440	chr7:79452877~79471208:+
BRCA	cis	rs1859596	0.903	rs2365424	ENSG00000234456.6	MAGI2-AS3	5.58	3.04e-08	4.08e-06	0.11	0.17	Reading or mathematical ability;	chr7:79485459	chr7:79452877~79471208:+
BRCA	cis	rs9309473	0.95	rs73947808	ENSG00000163016.8	ALMS1P	5.58	3.04e-08	4.08e-06	0.23	0.17	Metabolite levels;	chr2:73494123	chr2:73644919~73685576:+
BRCA	cis	rs160451	1	rs160449	ENSG00000251136.7	RP11-37B2.1	5.58	3.04e-08	4.08e-06	0.17	0.17	Leprosy;	chr8:89648287	chr8:89609409~89757727:-
BRCA	cis	rs2303319	1	rs76063526	ENSG00000227403.1	AC009299.3	5.58	3.04e-08	4.08e-06	0.43	0.17	Cognitive function;	chr2:161374323	chr2:161244739~161249050:+
BRCA	cis	rs2303319	1	rs62188121	ENSG00000227403.1	AC009299.3	5.58	3.04e-08	4.08e-06	0.43	0.17	Cognitive function;	chr2:161375574	chr2:161244739~161249050:+
BRCA	cis	rs6490294	0.528	rs7980579	ENSG00000226469.1	ADAM1B	5.58	3.04e-08	4.09e-06	0.27	0.17	Mean platelet volume;	chr12:112009556	chr12:111927018~111929017:+
BRCA	cis	rs6490294	0.571	rs7952986	ENSG00000226469.1	ADAM1B	5.58	3.04e-08	4.09e-06	0.27	0.17	Mean platelet volume;	chr12:112010358	chr12:111927018~111929017:+
BRCA	cis	rs6490294	0.571	rs7132863	ENSG00000226469.1	ADAM1B	5.58	3.04e-08	4.09e-06	0.27	0.17	Mean platelet volume;	chr12:112011079	chr12:111927018~111929017:+
BRCA	cis	rs6490294	0.571	rs11066128	ENSG00000226469.1	ADAM1B	5.58	3.04e-08	4.09e-06	0.27	0.17	Mean platelet volume;	chr12:112012950	chr12:111927018~111929017:+
BRCA	cis	rs7923609	0.87	rs10822156	ENSG00000232075.1	MRPL35P2	-5.58	3.05e-08	4.09e-06	-0.21	-0.17	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63320967	chr10:63634317~63634827:-
BRCA	cis	rs3760982	0.813	rs10426528	ENSG00000267058.1	RP11-15A1.3	-5.58	3.05e-08	4.09e-06	-0.19	-0.17	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43795146	chr19:43891804~43901805:-
BRCA	cis	rs2732480	0.538	rs1387260	ENSG00000226413.2	OR8T1P	5.58	3.05e-08	4.09e-06	0.24	0.17	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48309308	chr12:48442030~48442947:-
BRCA	cis	rs4835473	0.932	rs4835013	ENSG00000249741.2	RP11-673E1.3	-5.58	3.05e-08	4.09e-06	-0.18	-0.17	Immature fraction of reticulocytes;	chr4:143748485	chr4:143911514~143912053:-
BRCA	cis	rs2337406	0.539	rs2583292	ENSG00000211970.3	IGHV4-61	5.58	3.05e-08	4.09e-06	0.14	0.17	Alzheimer's disease (late onset);	chr14:106649040	chr14:106639119~106639657:-
BRCA	cis	rs9638182	0.945	rs13247874	ENSG00000274080.1	CTA-315H11.2	5.58	3.05e-08	4.09e-06	0.31	0.17	Triglycerides;	chr7:73596112	chr7:73609262~73611502:-
BRCA	cis	rs420259	0.516	rs11074562	ENSG00000260136.4	CTD-2270L9.4	-5.58	3.05e-08	4.1e-06	-0.17	-0.17	Bipolar disorder;	chr16:23488379	chr16:23452758~23457606:+
BRCA	cis	rs7927592	0.913	rs6591340	ENSG00000212093.1	AP000807.1	5.58	3.05e-08	4.1e-06	0.2	0.17	Total body bone mineral density;	chr11:68530168	chr11:68506083~68506166:-
BRCA	cis	rs10510102	0.935	rs11200183	ENSG00000226864.1	ATE1-AS1	5.58	3.05e-08	4.1e-06	0.32	0.17	Breast cancer;	chr10:121829908	chr10:121928312~121951965:+
BRCA	cis	rs11105298	0.838	rs4842488	ENSG00000270344.2	RP11-734K2.4	5.58	3.06e-08	4.1e-06	0.2	0.17	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89487787	chr12:89525654~89548005:+
BRCA	cis	rs11105298	0.891	rs6538189	ENSG00000270344.2	RP11-734K2.4	5.58	3.06e-08	4.1e-06	0.2	0.17	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89492146	chr12:89525654~89548005:+
BRCA	cis	rs12681366	0.801	rs55963151	ENSG00000253704.1	RP11-267M23.4	5.58	3.06e-08	4.1e-06	0.2	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94466198	chr8:94553722~94569745:+
BRCA	cis	rs1005277	0.579	rs1780136	ENSG00000263064.2	RP11-291L22.7	5.58	3.06e-08	4.1e-06	0.21	0.17	Extrinsic epigenetic age acceleration;	chr10:38212525	chr10:38448689~38448949:+
BRCA	cis	rs1005277	0.579	rs1780138	ENSG00000263064.2	RP11-291L22.7	5.58	3.06e-08	4.1e-06	0.21	0.17	Extrinsic epigenetic age acceleration;	chr10:38212726	chr10:38448689~38448949:+
BRCA	cis	rs1005277	0.579	rs1780139	ENSG00000263064.2	RP11-291L22.7	5.58	3.06e-08	4.1e-06	0.21	0.17	Extrinsic epigenetic age acceleration;	chr10:38214090	chr10:38448689~38448949:+
BRCA	cis	rs1005277	0.602	rs1780141	ENSG00000263064.2	RP11-291L22.7	5.58	3.06e-08	4.1e-06	0.21	0.17	Extrinsic epigenetic age acceleration;	chr10:38215371	chr10:38448689~38448949:+
BRCA	cis	rs375066	0.62	rs349049	ENSG00000267058.1	RP11-15A1.3	5.58	3.06e-08	4.1e-06	0.19	0.17	Breast cancer;	chr19:43797248	chr19:43891804~43901805:-
BRCA	cis	rs6728642	0.519	rs4260285	ENSG00000230606.9	AC159540.1	5.58	3.06e-08	4.1e-06	0.27	0.17	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:96904344	chr2:97416165~97433527:-
BRCA	cis	rs5758511	0.68	rs1107553	ENSG00000233903.2	Z83851.4	5.58	3.06e-08	4.1e-06	0.26	0.17	Birth weight;	chr22:42271467	chr22:42276355~42277052:+
BRCA	cis	rs523522	0.962	rs4767905	ENSG00000278344.1	RP11-18C24.8	5.58	3.06e-08	4.1e-06	0.23	0.17	High light scatter reticulocyte count;	chr12:120493032	chr12:120500735~120501090:-
BRCA	cis	rs7927771	0.524	rs7107792	ENSG00000280615.1	Y_RNA	5.58	3.06e-08	4.1e-06	0.2	0.17	Subjective well-being;	chr11:47647697	chr11:47614898~47614994:-
BRCA	cis	rs4908768	0.501	rs2045820	ENSG00000270282.1	RP5-1115A15.2	5.58	3.06e-08	4.1e-06	0.18	0.17	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8678076	chr1:8512653~8513021:+
BRCA	cis	rs237743	0.963	rs73611371	ENSG00000222365.1	SNORD12B	-5.58	3.06e-08	4.1e-06	-0.24	-0.17	Height;	chr20:49218618	chr20:49280319~49280409:+
BRCA	cis	rs72799341	1	rs1458201	ENSG00000260911.2	RP11-196G11.2	5.58	3.06e-08	4.11e-06	0.18	0.17	Diastolic blood pressure;	chr16:30904808	chr16:31043150~31049868:+
BRCA	cis	rs721917	0.506	rs2758561	ENSG00000244733.5	RP11-506M13.3	-5.58	3.06e-08	4.11e-06	-0.2	-0.17	Chronic obstructive pulmonary disease;	chr10:79909718	chr10:79660891~79677996:+
BRCA	cis	rs919433	0.648	rs6434933	ENSG00000231621.1	AC013264.2	-5.58	3.06e-08	4.11e-06	-0.16	-0.17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197562236	chr2:197197991~197199273:+
BRCA	cis	rs860295	0.702	rs11264380	ENSG00000160766.13	GBAP1	-5.58	3.06e-08	4.11e-06	-0.18	-0.17	Body mass index;	chr1:155550353	chr1:155213821~155227422:-
BRCA	cis	rs4819052	0.765	rs2838852	ENSG00000184274.3	LINC00315	-5.58	3.06e-08	4.11e-06	-0.24	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45257122	chr21:45300245~45305257:-
BRCA	cis	rs3213958	0.574	rs55730510	ENSG00000249274.1	PDLIM1P4	-5.58	3.07e-08	4.11e-06	-0.26	-0.17	Blood protein levels;	chr3:98900191	chr3:98782188~98783193:+
BRCA	cis	rs11722779	0.775	rs223341	ENSG00000251288.2	RP11-10L12.2	-5.58	3.07e-08	4.12e-06	-0.2	-0.17	Schizophrenia;	chr4:102862343	chr4:102751401~102752641:+
BRCA	cis	rs4713118	0.739	rs2893931	ENSG00000216901.1	AL022393.7	5.58	3.07e-08	4.12e-06	0.23	0.17	Parkinson's disease;	chr6:27780231	chr6:28176188~28176674:+
BRCA	cis	rs3740713	1	rs3740713	ENSG00000256464.1	YWHABP2	5.58	3.07e-08	4.12e-06	0.32	0.17	Amyotrophic lateral sclerosis (sporadic);	chr11:18429549	chr11:18490243~18490955:-
BRCA	cis	rs950169	0.545	rs4354897	ENSG00000259728.4	LINC00933	5.58	3.08e-08	4.12e-06	0.25	0.17	Schizophrenia;	chr15:83976219	chr15:84570649~84580175:+
BRCA	cis	rs13178541	0.81	rs7705245	ENSG00000250378.1	RP11-119J18.1	-5.58	3.08e-08	4.12e-06	-0.24	-0.17	IgG glycosylation;	chr5:135849056	chr5:135812667~135826582:+
BRCA	cis	rs6840360	0.726	rs6816292	ENSG00000270265.1	RP11-731D1.4	5.58	3.08e-08	4.13e-06	0.2	0.17	Intelligence (multi-trait analysis);	chr4:151809391	chr4:151333775~151353224:-
BRCA	cis	rs62025270	0.632	rs62022943	ENSG00000259295.5	CSPG4P12	-5.58	3.08e-08	4.13e-06	-0.26	-0.17	Idiopathic pulmonary fibrosis;	chr15:85716239	chr15:85191438~85213905:+
BRCA	cis	rs875971	0.571	rs160647	ENSG00000228409.4	CCT6P1	5.58	3.09e-08	4.14e-06	0.17	0.17	Aortic root size;	chr7:66089365	chr7:65751142~65763354:+
BRCA	cis	rs4713118	0.616	rs9348789	ENSG00000204709.4	LINC01556	5.58	3.09e-08	4.14e-06	0.25	0.17	Parkinson's disease;	chr6:28057708	chr6:28943877~28944537:+
BRCA	cis	rs55702914	0.935	rs67735550	ENSG00000231621.1	AC013264.2	-5.58	3.09e-08	4.14e-06	-0.16	-0.17	Major depression and alcohol dependence;	chr2:197364729	chr2:197197991~197199273:+
BRCA	cis	rs2153535	0.518	rs9392232	ENSG00000230939.1	RP11-314C16.1	-5.58	3.09e-08	4.15e-06	-0.21	-0.17	Motion sickness;	chr6:8636211	chr6:8784178~8785445:+
BRCA	cis	rs240993	0.516	rs240968	ENSG00000230177.1	RP5-1112D6.4	-5.58	3.1e-08	4.15e-06	-0.23	-0.17	Inflammatory skin disease;Psoriasis;	chr6:111311517	chr6:111277932~111278742:+
BRCA	cis	rs10752881	1	rs10797802	ENSG00000224468.3	RP11-181K3.4	5.58	3.1e-08	4.15e-06	0.18	0.17	Colorectal cancer;	chr1:183004023	chr1:183138402~183141282:-
BRCA	cis	rs4908760	0.864	rs1953827	ENSG00000270282.1	RP5-1115A15.2	5.58	3.1e-08	4.15e-06	0.18	0.17	Vitiligo;	chr1:8619789	chr1:8512653~8513021:+
BRCA	cis	rs6088813	1	rs6060402	ENSG00000126005.14	MMP24-AS1	5.58	3.1e-08	4.15e-06	0.2	0.17	Height;	chr20:35417437	chr20:35216462~35278131:-
BRCA	cis	rs67311347	0.544	rs2887965	ENSG00000280739.1	EIF1B-AS1	-5.58	3.1e-08	4.16e-06	-0.18	-0.17	Renal cell carcinoma;	chr3:40292663	chr3:40173145~40309698:-
BRCA	cis	rs11742741	0.579	rs1593895	ENSG00000248874.4	C5orf17	-5.58	3.1e-08	4.16e-06	-0.22	-0.17	Educational attainment;	chr5:24115865	chr5:23951348~24178263:+
BRCA	cis	rs11051970	0.559	rs2270786	ENSG00000274964.1	RP11-817I4.1	-5.58	3.1e-08	4.16e-06	-0.25	-0.17	Response to tocilizumab in rheumatoid arthritis;	chr12:32337830	chr12:32339368~32340724:+
BRCA	cis	rs11742741	0.539	rs11743753	ENSG00000248874.4	C5orf17	5.58	3.1e-08	4.16e-06	0.22	0.17	Educational attainment;	chr5:24093021	chr5:23951348~24178263:+
BRCA	cis	rs9907295	1	rs9303693	ENSG00000270977.1	AC015849.16	-5.58	3.1e-08	4.16e-06	-0.29	-0.17	Fibroblast growth factor basic levels;	chr17:35913595	chr17:35893707~35911023:-
BRCA	cis	rs11722228	0.522	rs73212880	ENSG00000261490.1	RP11-448G15.3	5.58	3.11e-08	4.16e-06	0.2	0.17	Urate levels;Serum uric acid levels;Gout;	chr4:10114068	chr4:10068089~10073019:-
BRCA	cis	rs11123406	0.723	rs60665449	ENSG00000227992.1	AC108463.2	5.58	3.11e-08	4.16e-06	0.21	0.17	Type 2 diabetes;	chr2:111202110	chr2:111203964~111206215:-
BRCA	cis	rs6750795	0.569	rs1667308	ENSG00000223198.1	RNU2-22P	-5.58	3.11e-08	4.17e-06	-0.2	-0.17	Height;	chr2:231541633	chr2:231501990~231502201:-
BRCA	cis	rs2638953	0.853	rs10843191	ENSG00000247934.4	RP11-967K21.1	-5.58	3.11e-08	4.17e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28507594	chr12:28163298~28190738:-
BRCA	cis	rs853679	0.55	rs6901017	ENSG00000280107.1	AL022393.9	-5.58	3.11e-08	4.17e-06	-0.24	-0.17	Depression;	chr6:28184805	chr6:28170845~28172521:+
BRCA	cis	rs300890	0.513	rs9998017	ENSG00000250326.1	RP11-284M14.1	-5.58	3.11e-08	4.17e-06	-0.2	-0.17	Nasopharyngeal carcinoma;	chr4:143184229	chr4:142933195~143184861:-
BRCA	cis	rs4927850	0.918	rs4361313	ENSG00000207650.1	MIR570	5.58	3.11e-08	4.17e-06	0.21	0.17	Pancreatic cancer;	chr3:196025389	chr3:195699401~195699497:+
BRCA	cis	rs516805	0.667	rs1456706	ENSG00000279453.1	RP3-425C14.4	-5.58	3.11e-08	4.17e-06	-0.24	-0.17	Lymphocyte counts;	chr6:122134801	chr6:122436789~122439223:-
BRCA	cis	rs516805	0.667	rs2606651	ENSG00000279453.1	RP3-425C14.4	-5.58	3.11e-08	4.17e-06	-0.24	-0.17	Lymphocyte counts;	chr6:122136475	chr6:122436789~122439223:-
BRCA	cis	rs1823874	0.581	rs12905599	ENSG00000259363.4	CTD-2054N24.2	-5.58	3.12e-08	4.17e-06	-0.21	-0.17	IgG glycosylation;	chr15:99799733	chr15:99807023~99877148:+
BRCA	cis	rs7308116	0.546	rs10778580	ENSG00000274395.1	RP11-554D14.8	-5.58	3.12e-08	4.18e-06	-0.2	-0.17	Pelvic organ prolapse (moderate/severe);	chr12:107837024	chr12:107835541~107836555:-
BRCA	cis	rs7520050	0.966	rs10890361	ENSG00000280836.1	AL355480.1	5.58	3.12e-08	4.18e-06	0.19	0.17	Reticulocyte count;Red blood cell count;	chr1:45880562	chr1:45581219~45581321:-
BRCA	cis	rs4699052	1	rs7694190	ENSG00000248740.4	RP11-328K4.1	5.58	3.12e-08	4.18e-06	0.19	0.17	Testicular germ cell tumor;	chr4:103246860	chr4:103256159~103453658:+
BRCA	cis	rs523522	0.962	rs7471	ENSG00000278344.1	RP11-18C24.8	5.58	3.12e-08	4.18e-06	0.23	0.17	High light scatter reticulocyte count;	chr12:120503412	chr12:120500735~120501090:-
BRCA	cis	rs9341808	0.718	rs9361584	ENSG00000272129.1	RP11-250B2.6	5.58	3.12e-08	4.18e-06	0.22	0.17	Sitting height ratio;	chr6:80110229	chr6:80355424~80356859:+
BRCA	cis	rs17508449	1	rs17461918	ENSG00000232450.1	RP4-730K3.3	-5.58	3.12e-08	4.18e-06	-0.3	-0.17	Leprosy;	chr1:113538822	chr1:113698884~113699631:-
BRCA	cis	rs4907240	0.735	rs1122238	ENSG00000237510.6	AC008268.2	-5.58	3.12e-08	4.18e-06	-0.23	-0.17	Event-related brain oscillations;	chr2:96521180	chr2:95789654~95800166:+
BRCA	cis	rs7772486	0.875	rs2814866	ENSG00000270638.1	RP3-466P17.1	5.58	3.12e-08	4.19e-06	0.19	0.17	Lobe attachment (rater-scored or self-reported);	chr6:146018278	chr6:145735570~145737218:+
BRCA	cis	rs2269241	0.85	rs2269247	ENSG00000244256.3	RN7SL130P	-5.58	3.13e-08	4.19e-06	-0.24	-0.17	Type 1 diabetes;	chr1:63641613	chr1:63655743~63656047:+
BRCA	cis	rs13126694	0.744	rs10005901	ENSG00000251429.1	RP11-597D13.7	5.58	3.13e-08	4.19e-06	0.16	0.17	Blood osmolality (transformed sodium);	chr4:158041750	chr4:158270378~158278676:+
BRCA	cis	rs875971	0.522	rs2008188	ENSG00000273024.4	INTS4P2	-5.58	3.13e-08	4.19e-06	-0.19	-0.17	Aortic root size;	chr7:65964026	chr7:65647864~65715661:+
BRCA	cis	rs57339844	1	rs57339844	ENSG00000273080.1	RP11-301O19.1	-5.58	3.13e-08	4.19e-06	-0.2	-0.17	Mean platelet volume;	chr2:85891155	chr2:86195590~86196049:+
BRCA	cis	rs2562456	0.833	rs11666525	ENSG00000268535.1	RP11-420K14.3	5.58	3.14e-08	4.2e-06	0.26	0.17	Pain;	chr19:21416503	chr19:21709522~21710191:+
BRCA	cis	rs9907295	1	rs11650409	ENSG00000271013.1	AC015849.15	5.58	3.14e-08	4.2e-06	0.25	0.17	Fibroblast growth factor basic levels;	chr17:35907949	chr17:35912635~35918010:-
BRCA	cis	rs2638953	0.888	rs10843189	ENSG00000247934.4	RP11-967K21.1	-5.58	3.14e-08	4.2e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28506985	chr12:28163298~28190738:-
BRCA	cis	rs11009175	0.556	rs7923985	ENSG00000273038.2	RP11-479G22.8	-5.58	3.14e-08	4.21e-06	-0.23	-0.17	Depression (quantitative trait);	chr10:33015690	chr10:32887255~32889311:-
BRCA	cis	rs6832769	1	rs6824057	ENSG00000272969.1	RP11-528I4.2	5.58	3.14e-08	4.21e-06	0.21	0.17	Personality dimensions;	chr4:55501111	chr4:55547112~55547889:+
BRCA	cis	rs6832769	1	rs12646078	ENSG00000272969.1	RP11-528I4.2	5.58	3.14e-08	4.21e-06	0.21	0.17	Personality dimensions;	chr4:55502037	chr4:55547112~55547889:+
BRCA	cis	rs673078	0.66	rs78690826	ENSG00000275409.1	RP11-131L12.4	-5.58	3.14e-08	4.21e-06	-0.28	-0.17	Glucose homeostasis traits;	chr12:118176693	chr12:118430147~118430699:+
BRCA	cis	rs754466	0.58	rs1058198	ENSG00000204049.1	RP11-126H7.4	5.58	3.14e-08	4.21e-06	0.2	0.17	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77806874	chr10:77866875~77869610:+
BRCA	cis	rs6570726	0.791	rs7765687	ENSG00000270638.1	RP3-466P17.1	5.58	3.14e-08	4.21e-06	0.19	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145593964	chr6:145735570~145737218:+
BRCA	cis	rs10844706	0.699	rs10772079	ENSG00000214776.8	RP11-726G1.1	5.58	3.14e-08	4.21e-06	0.2	0.17	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9721798	chr12:9467552~9576275:+
BRCA	cis	rs7772486	0.686	rs1415744	ENSG00000270638.1	RP3-466P17.1	5.58	3.14e-08	4.21e-06	0.19	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145701395	chr6:145735570~145737218:+
BRCA	cis	rs7772486	0.875	rs2328712	ENSG00000270638.1	RP3-466P17.1	5.58	3.15e-08	4.21e-06	0.19	0.17	Lobe attachment (rater-scored or self-reported);	chr6:146023427	chr6:145735570~145737218:+
BRCA	cis	rs4908768	0.501	rs11121199	ENSG00000270282.1	RP5-1115A15.2	5.58	3.15e-08	4.22e-06	0.18	0.17	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8540133	chr1:8512653~8513021:+
BRCA	cis	rs2051773	0.567	rs12293395	ENSG00000184669.7	OR7E14P	5.58	3.15e-08	4.22e-06	0.25	0.17	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);	chr11:17026114	chr11:17013998~17053024:+
BRCA	cis	rs34929064	0.918	rs2961300	ENSG00000179428.2	AC073072.5	5.58	3.15e-08	4.22e-06	0.19	0.17	Major depression and alcohol dependence;	chr7:22669165	chr7:22725395~22727620:-
BRCA	cis	rs17711722	0.522	rs4642526	ENSG00000237310.1	GS1-124K5.4	5.57	3.15e-08	4.22e-06	0.18	0.17	Calcium levels;	chr7:65751755	chr7:66493706~66495474:+
BRCA	cis	rs42490	0.614	rs452694	ENSG00000251136.7	RP11-37B2.1	-5.57	3.15e-08	4.22e-06	-0.16	-0.17	Leprosy;	chr8:89808293	chr8:89609409~89757727:-
BRCA	cis	rs42490	0.59	rs447611	ENSG00000251136.7	RP11-37B2.1	-5.57	3.15e-08	4.22e-06	-0.16	-0.17	Leprosy;	chr8:89808359	chr8:89609409~89757727:-
BRCA	cis	rs7688540	0.8	rs9328738	ENSG00000275426.1	CH17-262A2.1	-5.57	3.16e-08	4.22e-06	-0.21	-0.17	Facial morphology (factor 6, height of vermillion lower lip);	chr4:284407	chr4:149738~150317:+
BRCA	cis	rs2638953	0.962	rs9645730	ENSG00000278733.1	RP11-425D17.1	-5.57	3.16e-08	4.23e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28317151	chr12:28185625~28186190:-
BRCA	cis	rs12681366	0.708	rs2930958	ENSG00000253704.1	RP11-267M23.4	5.57	3.16e-08	4.23e-06	0.18	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94428325	chr8:94553722~94569745:+
BRCA	cis	rs2638953	0.853	rs10843180	ENSG00000278733.1	RP11-425D17.1	-5.57	3.16e-08	4.23e-06	-0.22	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28462221	chr12:28185625~28186190:-
BRCA	cis	rs7044106	0.791	rs4836829	ENSG00000238181.2	AHCYP2	-5.57	3.16e-08	4.23e-06	-0.22	-0.17	Hip circumference adjusted for BMI;	chr9:120720469	chr9:120720673~120721972:+
BRCA	cis	rs2179367	0.632	rs11155642	ENSG00000223701.3	RAET1E-AS1	5.57	3.16e-08	4.23e-06	0.24	0.17	Dupuytren's disease;	chr6:149332984	chr6:149884431~149919508:+
BRCA	cis	rs9990333	0.622	rs57783901	ENSG00000242086.7	LINC00969	5.57	3.16e-08	4.23e-06	0.18	0.17	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196089486	chr3:195658062~195739964:+
BRCA	cis	rs1552244	1	rs3846177	ENSG00000232901.1	CYCSP10	5.57	3.16e-08	4.23e-06	0.23	0.17	Alzheimer's disease;	chr3:10026888	chr3:10000647~10000940:-
BRCA	cis	rs8114671	0.586	rs6087634	ENSG00000269202.1	RP4-614O4.12	-5.57	3.16e-08	4.23e-06	-0.17	-0.17	Height;	chr20:34826006	chr20:35201747~35203288:-
BRCA	cis	rs4650994	0.525	rs10913574	ENSG00000273384.1	RP5-1098D14.1	5.57	3.17e-08	4.24e-06	0.21	0.17	HDL cholesterol;HDL cholesterol levels;	chr1:178567347	chr1:178651706~178652282:+
BRCA	cis	rs7493	0.755	rs34774523	ENSG00000233942.1	AC004012.1	5.57	3.17e-08	4.24e-06	0.22	0.17	Yu-Zhi constitution type in type 2 diabetes;	chr7:95332830	chr7:95471835~95473998:+
BRCA	cis	rs6570726	0.967	rs413880	ENSG00000270638.1	RP3-466P17.1	5.57	3.17e-08	4.24e-06	0.19	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145483686	chr6:145735570~145737218:+
BRCA	cis	rs7617773	0.779	rs9833309	ENSG00000199476.1	Y_RNA	-5.57	3.17e-08	4.25e-06	-0.24	-0.17	Coronary artery disease;	chr3:48285960	chr3:48288587~48288694:+
BRCA	cis	rs7617773	0.817	rs9853804	ENSG00000199476.1	Y_RNA	-5.57	3.17e-08	4.25e-06	-0.24	-0.17	Coronary artery disease;	chr3:48286239	chr3:48288587~48288694:+
BRCA	cis	rs7617773	0.817	rs9834095	ENSG00000199476.1	Y_RNA	-5.57	3.17e-08	4.25e-06	-0.24	-0.17	Coronary artery disease;	chr3:48286261	chr3:48288587~48288694:+
BRCA	cis	rs7308116	0.546	rs7488122	ENSG00000274395.1	RP11-554D14.8	-5.57	3.18e-08	4.25e-06	-0.2	-0.17	Pelvic organ prolapse (moderate/severe);	chr12:107829407	chr12:107835541~107836555:-
BRCA	cis	rs597539	0.652	rs496616	ENSG00000261625.1	RP11-554A11.4	-5.57	3.18e-08	4.26e-06	-0.17	-0.17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68905332	chr11:69000765~69002048:-
BRCA	cis	rs7208859	0.673	rs9911989	ENSG00000280069.1	CTD-2349P21.3	5.57	3.18e-08	4.26e-06	0.26	0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30910684	chr17:30738182~30740275:+
BRCA	cis	rs2898681	0.519	rs73814886	ENSG00000248375.1	RP11-177B4.1	-5.57	3.18e-08	4.26e-06	-0.27	-0.17	Optic nerve measurement (cup area);	chr4:52867084	chr4:52720081~52720831:-
BRCA	cis	rs454217	0.74	rs373627	ENSG00000277851.1	RP11-756G20.1	5.57	3.19e-08	4.26e-06	0.19	0.17	Smoking quantity;	chr12:92325837	chr12:92247756~92363832:-
BRCA	cis	rs7911264	0.572	rs7071912	ENSG00000236493.2	EIF2S2P3	5.57	3.19e-08	4.26e-06	0.22	0.17	Inflammatory bowel disease;	chr10:92656472	chr10:92668745~92669743:-
BRCA	cis	rs1707322	0.721	rs10890341	ENSG00000234329.1	RP11-767N6.2	5.57	3.19e-08	4.26e-06	0.18	0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45681568	chr1:45651039~45651826:-
BRCA	cis	rs35306767	0.953	rs11253520	ENSG00000229869.1	RP11-363N22.2	5.57	3.19e-08	4.27e-06	0.22	0.17	Eosinophil percentage of granulocytes;	chr10:930021	chr10:933026~942743:+
BRCA	cis	rs2303319	1	rs78555127	ENSG00000227403.1	AC009299.3	5.57	3.19e-08	4.27e-06	0.45	0.17	Cognitive function;	chr2:161414749	chr2:161244739~161249050:+
BRCA	cis	rs7620503	1	rs35921520	ENSG00000228221.4	LINC00578	5.57	3.19e-08	4.27e-06	0.2	0.17	Corneal structure;	chr3:177581444	chr3:177441921~177752305:+
BRCA	cis	rs14027	0.64	rs6994604	ENSG00000279347.1	RP11-85I17.2	-5.57	3.19e-08	4.27e-06	-0.16	-0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119746463	chr8:119838736~119840385:-
BRCA	cis	rs14027	0.64	rs7837213	ENSG00000279347.1	RP11-85I17.2	-5.57	3.19e-08	4.27e-06	-0.16	-0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119750459	chr8:119838736~119840385:-
BRCA	cis	rs14027	0.64	rs16893109	ENSG00000279347.1	RP11-85I17.2	-5.57	3.19e-08	4.27e-06	-0.16	-0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119756309	chr8:119838736~119840385:-
BRCA	cis	rs14027	0.64	rs7011974	ENSG00000279347.1	RP11-85I17.2	-5.57	3.19e-08	4.27e-06	-0.16	-0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119759623	chr8:119838736~119840385:-
BRCA	cis	rs14027	0.64	rs9693207	ENSG00000279347.1	RP11-85I17.2	-5.57	3.19e-08	4.27e-06	-0.16	-0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119759815	chr8:119838736~119840385:-
BRCA	cis	rs4784227	0.627	rs12922061	ENSG00000279427.1	RP11-132F7.2	-5.57	3.19e-08	4.27e-06	-0.23	-0.17	Breast cancer (estrogen-receptor negative);Breast cancer;Parkinson's disease;	chr16:52601088	chr16:52436772~52437474:-
BRCA	cis	rs9291683	0.546	rs4529049	ENSG00000250413.1	RP11-448G15.1	-5.57	3.19e-08	4.27e-06	-0.22	-0.17	Bone mineral density;	chr4:10043765	chr4:10006482~10009725:+
BRCA	cis	rs7897654	0.571	rs7920697	ENSG00000236937.2	PTGES3P4	5.57	3.19e-08	4.27e-06	0.25	0.17	Schizophrenia;	chr10:102873580	chr10:102845595~102845950:+
BRCA	cis	rs2638953	0.924	rs10843170	ENSG00000278733.1	RP11-425D17.1	-5.57	3.19e-08	4.27e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28430118	chr12:28185625~28186190:-
BRCA	cis	rs539096	0.872	rs2004899	ENSG00000236200.4	KDM4A-AS1	-5.57	3.19e-08	4.27e-06	-0.21	-0.17	Intelligence (multi-trait analysis);	chr1:43579794	chr1:43699765~43708138:-
BRCA	cis	rs523522	0.892	rs4767916	ENSG00000278344.1	RP11-18C24.8	5.57	3.2e-08	4.28e-06	0.23	0.17	High light scatter reticulocyte count;	chr12:120586229	chr12:120500735~120501090:-
BRCA	cis	rs1552244	1	rs7637888	ENSG00000232901.1	CYCSP10	5.57	3.2e-08	4.28e-06	0.24	0.17	Alzheimer's disease;	chr3:10039038	chr3:10000647~10000940:-
BRCA	cis	rs1552244	1	rs17032295	ENSG00000232901.1	CYCSP10	5.57	3.2e-08	4.28e-06	0.23	0.17	Alzheimer's disease;	chr3:10044996	chr3:10000647~10000940:-
BRCA	cis	rs7674212	0.541	rs4699050	ENSG00000251288.2	RP11-10L12.2	-5.57	3.2e-08	4.28e-06	-0.21	-0.17	Type 2 diabetes;	chr4:103193140	chr4:102751401~102752641:+
BRCA	cis	rs7674212	0.541	rs17217473	ENSG00000251288.2	RP11-10L12.2	-5.57	3.2e-08	4.28e-06	-0.21	-0.17	Type 2 diabetes;	chr4:103193585	chr4:102751401~102752641:+
BRCA	cis	rs875971	0.505	rs6955582	ENSG00000273024.4	INTS4P2	-5.57	3.2e-08	4.28e-06	-0.19	-0.17	Aortic root size;	chr7:65966699	chr7:65647864~65715661:+
BRCA	cis	rs10510102	0.872	rs12258234	ENSG00000226864.1	ATE1-AS1	5.57	3.2e-08	4.28e-06	0.31	0.17	Breast cancer;	chr10:121952828	chr10:121928312~121951965:+
BRCA	cis	rs10510102	0.515	rs11200285	ENSG00000226864.1	ATE1-AS1	5.57	3.2e-08	4.28e-06	0.31	0.17	Breast cancer;	chr10:121953931	chr10:121928312~121951965:+
BRCA	cis	rs10510102	0.872	rs75831447	ENSG00000226864.1	ATE1-AS1	5.57	3.2e-08	4.28e-06	0.31	0.17	Breast cancer;	chr10:121953963	chr10:121928312~121951965:+
BRCA	cis	rs10510102	0.63	rs79960726	ENSG00000226864.1	ATE1-AS1	5.57	3.2e-08	4.28e-06	0.31	0.17	Breast cancer;	chr10:121954358	chr10:121928312~121951965:+
BRCA	cis	rs7923609	0.783	rs4746203	ENSG00000232075.1	MRPL35P2	5.57	3.2e-08	4.28e-06	0.21	0.17	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63564237	chr10:63634317~63634827:-
BRCA	cis	rs2638953	0.925	rs11049598	ENSG00000278733.1	RP11-425D17.1	-5.57	3.2e-08	4.28e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28436160	chr12:28185625~28186190:-
BRCA	cis	rs2235642	0.859	rs12599207	ENSG00000280231.1	LA16c-380F5.3	-5.57	3.2e-08	4.29e-06	-0.22	-0.17	Coronary artery disease;	chr16:1556444	chr16:1553655~1554130:-
BRCA	cis	rs12681366	0.734	rs716770	ENSG00000253704.1	RP11-267M23.4	5.57	3.21e-08	4.29e-06	0.18	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94378693	chr8:94553722~94569745:+
BRCA	cis	rs12681366	0.734	rs10504936	ENSG00000253704.1	RP11-267M23.4	5.57	3.21e-08	4.29e-06	0.18	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94379827	chr8:94553722~94569745:+
BRCA	cis	rs12681366	0.734	rs10112606	ENSG00000253704.1	RP11-267M23.4	5.57	3.21e-08	4.29e-06	0.18	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94383838	chr8:94553722~94569745:+
BRCA	cis	rs754466	0.606	rs56402185	ENSG00000204049.1	RP11-126H7.4	5.57	3.21e-08	4.29e-06	0.2	0.17	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77826090	chr10:77866875~77869610:+
BRCA	cis	rs6496044	0.963	rs7165300	ENSG00000202081.1	RNU6-1280P	5.57	3.21e-08	4.29e-06	0.2	0.17	Interstitial lung disease;	chr15:85526838	chr15:85651522~85651628:-
BRCA	cis	rs2562456	0.876	rs10424079	ENSG00000268535.1	RP11-420K14.3	5.57	3.21e-08	4.29e-06	0.24	0.17	Pain;	chr19:21406377	chr19:21709522~21710191:+
BRCA	cis	rs6540731	1	rs6540731	ENSG00000229983.1	RP11-15I11.2	-5.57	3.21e-08	4.3e-06	-0.2	-0.17	Intelligence (childhood);	chr1:212218821	chr1:212168207~212190259:+
BRCA	cis	rs1075265	0.749	rs2692518	ENSG00000235937.1	AC008280.1	5.57	3.21e-08	4.3e-06	0.18	0.17	Chronotype;Morning vs. evening chronotype;	chr2:53804746	chr2:54029552~54030682:-
BRCA	cis	rs13108904	0.935	rs2199956	ENSG00000254094.1	AC078852.1	-5.57	3.21e-08	4.3e-06	-0.18	-0.17	Obesity-related traits;	chr4:1255131	chr4:1356581~1358075:+
BRCA	cis	rs13126694	0.744	rs7657303	ENSG00000251429.1	RP11-597D13.7	-5.57	3.22e-08	4.3e-06	-0.16	-0.17	Blood osmolality (transformed sodium);	chr4:157992992	chr4:158270378~158278676:+
BRCA	cis	rs9527	0.662	rs10883783	ENSG00000236937.2	PTGES3P4	5.57	3.22e-08	4.3e-06	0.24	0.17	Arsenic metabolism;	chr10:102831395	chr10:102845595~102845950:+
BRCA	cis	rs10129255	0.957	rs8019272	ENSG00000224373.3	IGHV4-59	5.57	3.22e-08	4.31e-06	0.1	0.17	Kawasaki disease;	chr14:106784709	chr14:106627249~106627825:-
BRCA	cis	rs4819052	0.679	rs2236450	ENSG00000184274.3	LINC00315	-5.57	3.22e-08	4.31e-06	-0.22	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45282638	chr21:45300245~45305257:-
BRCA	cis	rs7772486	0.875	rs2492855	ENSG00000270638.1	RP3-466P17.1	5.57	3.22e-08	4.31e-06	0.19	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145975790	chr6:145735570~145737218:+
BRCA	cis	rs7246760	0.867	rs68041339	ENSG00000277587.1	CTD-3116E22.8	-5.57	3.22e-08	4.31e-06	-0.33	-0.17	Pursuit maintenance gain;	chr19:9708175	chr19:9721903~9722410:+
BRCA	cis	rs7246760	0.867	rs56377135	ENSG00000277587.1	CTD-3116E22.8	-5.57	3.22e-08	4.31e-06	-0.33	-0.17	Pursuit maintenance gain;	chr19:9709440	chr19:9721903~9722410:+
BRCA	cis	rs7246760	0.867	rs55914342	ENSG00000277587.1	CTD-3116E22.8	-5.57	3.22e-08	4.31e-06	-0.33	-0.17	Pursuit maintenance gain;	chr19:9713771	chr19:9721903~9722410:+
BRCA	cis	rs7178375	1	rs10163148	ENSG00000270015.1	RP11-540B6.6	5.57	3.22e-08	4.31e-06	0.21	0.17	Hypertriglyceridemia;	chr15:30920481	chr15:30926514~30928407:+
BRCA	cis	rs17772222	0.511	rs12879875	ENSG00000258983.2	RP11-507K2.2	5.57	3.22e-08	4.31e-06	0.17	0.17	Coronary artery calcification;	chr14:88840206	chr14:88499334~88515502:+
BRCA	cis	rs17772222	0.511	rs17124903	ENSG00000258983.2	RP11-507K2.2	5.57	3.22e-08	4.31e-06	0.17	0.17	Coronary artery calcification;	chr14:88842934	chr14:88499334~88515502:+
BRCA	cis	rs7621025	0.69	rs11715257	ENSG00000239213.4	NCK1-AS1	5.57	3.23e-08	4.31e-06	0.21	0.17	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136463211	chr3:136841726~136862054:-
BRCA	cis	rs6832769	0.961	rs10009593	ENSG00000223305.1	RN7SKP30	-5.57	3.23e-08	4.32e-06	-0.22	-0.17	Personality dimensions;	chr4:55570514	chr4:55540502~55540835:-
BRCA	cis	rs8098244	1	rs1941520	ENSG00000264745.1	TTC39C-AS1	5.57	3.23e-08	4.32e-06	0.22	0.17	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23824732	chr18:23994213~24015339:-
BRCA	cis	rs2638953	0.853	rs10843195	ENSG00000247934.4	RP11-967K21.1	-5.57	3.24e-08	4.32e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28513633	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.853	rs10843196	ENSG00000247934.4	RP11-967K21.1	-5.57	3.24e-08	4.32e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28513660	chr12:28163298~28190738:-
BRCA	cis	rs4803480	1	rs4803480	ENSG00000270164.1	LINC01480	-5.57	3.24e-08	4.33e-06	-0.21	-0.17	Schizophrenia;	chr19:41559909	chr19:41535183~41536904:+
BRCA	cis	rs4835473	0.932	rs7669198	ENSG00000249741.2	RP11-673E1.3	5.57	3.24e-08	4.33e-06	0.19	0.17	Immature fraction of reticulocytes;	chr4:143821229	chr4:143911514~143912053:-
BRCA	cis	rs42648	0.564	rs7777170	ENSG00000225498.1	AC002064.5	5.57	3.24e-08	4.33e-06	0.16	0.17	Homocysteine levels;	chr7:90192968	chr7:90312496~90322592:+
BRCA	cis	rs42648	0.564	rs7777282	ENSG00000225498.1	AC002064.5	5.57	3.24e-08	4.33e-06	0.16	0.17	Homocysteine levels;	chr7:90192991	chr7:90312496~90322592:+
BRCA	cis	rs2562456	0.876	rs2359144	ENSG00000268535.1	RP11-420K14.3	5.57	3.24e-08	4.33e-06	0.24	0.17	Pain;	chr19:21407834	chr19:21709522~21710191:+
BRCA	cis	rs2562456	0.876	rs4638726	ENSG00000268535.1	RP11-420K14.3	5.57	3.24e-08	4.33e-06	0.24	0.17	Pain;	chr19:21409710	chr19:21709522~21710191:+
BRCA	cis	rs11123406	0.723	rs4849463	ENSG00000230499.1	AC108463.1	5.57	3.24e-08	4.33e-06	0.21	0.17	Type 2 diabetes;	chr2:111201277	chr2:111195963~111206494:+
BRCA	cis	rs875971	0.545	rs221986	ENSG00000228409.4	CCT6P1	5.57	3.24e-08	4.33e-06	0.17	0.17	Aortic root size;	chr7:66105323	chr7:65751142~65763354:+
BRCA	cis	rs2638953	0.853	rs11049642	ENSG00000278733.1	RP11-425D17.1	-5.57	3.25e-08	4.34e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28471325	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.853	rs11049643	ENSG00000278733.1	RP11-425D17.1	-5.57	3.25e-08	4.34e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28471581	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.777	rs11049644	ENSG00000278733.1	RP11-425D17.1	-5.57	3.25e-08	4.34e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28471724	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.853	rs11049645	ENSG00000278733.1	RP11-425D17.1	-5.57	3.25e-08	4.34e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28472615	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.853	rs10843184	ENSG00000278733.1	RP11-425D17.1	-5.57	3.25e-08	4.34e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28473339	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.815	rs61920658	ENSG00000278733.1	RP11-425D17.1	-5.57	3.25e-08	4.34e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28475519	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.853	rs11049646	ENSG00000278733.1	RP11-425D17.1	-5.57	3.25e-08	4.34e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28476139	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.815	rs11049654	ENSG00000278733.1	RP11-425D17.1	-5.57	3.25e-08	4.34e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28480502	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.853	rs11049657	ENSG00000278733.1	RP11-425D17.1	-5.57	3.25e-08	4.34e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28481746	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.853	rs11049659	ENSG00000278733.1	RP11-425D17.1	-5.57	3.25e-08	4.34e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28482147	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.853	rs1355475	ENSG00000278733.1	RP11-425D17.1	-5.57	3.25e-08	4.34e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28482398	chr12:28185625~28186190:-
BRCA	cis	rs7577696	0.568	rs7574000	ENSG00000272716.1	RP11-563N4.1	-5.57	3.25e-08	4.34e-06	-0.2	-0.17	Inflammatory biomarkers;	chr2:32117819	chr2:32165046~32165757:-
BRCA	cis	rs754466	0.58	rs2289311	ENSG00000204049.1	RP11-126H7.4	5.57	3.25e-08	4.34e-06	0.2	0.17	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77805897	chr10:77866875~77869610:+
BRCA	cis	rs2904967	0.852	rs667341	ENSG00000254614.2	AP003068.23	5.57	3.25e-08	4.34e-06	0.31	0.17	Mean corpuscular volume;	chr11:65282711	chr11:65177606~65181834:-
BRCA	cis	rs7923837	0.651	rs3824735	ENSG00000236493.2	EIF2S2P3	5.57	3.25e-08	4.35e-06	0.24	0.17	Multiple sclerosis;Body mass index;	chr10:92594447	chr10:92668745~92669743:-
BRCA	cis	rs3764021	0.87	rs2401391	ENSG00000214776.8	RP11-726G1.1	5.57	3.26e-08	4.35e-06	0.19	0.17	Type 1 diabetes;	chr12:9725987	chr12:9467552~9576275:+
BRCA	cis	rs2998286	0.636	rs332112	ENSG00000254635.4	WAC-AS1	5.57	3.26e-08	4.35e-06	0.23	0.17	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28633879	chr10:28522652~28532743:-
BRCA	cis	rs755249	0.51	rs582883	ENSG00000228060.1	RP11-69E11.8	-5.57	3.26e-08	4.35e-06	-0.18	-0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39369868	chr1:39565160~39573203:+
BRCA	cis	rs2243480	1	rs34815098	ENSG00000232559.3	GS1-124K5.12	5.57	3.26e-08	4.35e-06	0.32	0.17	Diabetic kidney disease;	chr7:65827267	chr7:66554588~66576923:-
BRCA	cis	rs2243480	1	rs35735127	ENSG00000232559.3	GS1-124K5.12	5.57	3.26e-08	4.35e-06	0.32	0.17	Diabetic kidney disease;	chr7:65835436	chr7:66554588~66576923:-
BRCA	cis	rs2243480	0.901	rs35256305	ENSG00000232559.3	GS1-124K5.12	5.57	3.26e-08	4.35e-06	0.32	0.17	Diabetic kidney disease;	chr7:65841418	chr7:66554588~66576923:-
BRCA	cis	rs2243480	0.803	rs34004500	ENSG00000232559.3	GS1-124K5.12	5.57	3.26e-08	4.35e-06	0.32	0.17	Diabetic kidney disease;	chr7:65847191	chr7:66554588~66576923:-
BRCA	cis	rs2243480	1	rs35825738	ENSG00000232559.3	GS1-124K5.12	5.57	3.26e-08	4.35e-06	0.32	0.17	Diabetic kidney disease;	chr7:65853040	chr7:66554588~66576923:-
BRCA	cis	rs1387259	0.931	rs1107654	ENSG00000240399.1	RP1-228P16.1	5.57	3.26e-08	4.35e-06	0.2	0.17	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48287314	chr12:48054813~48055591:-
BRCA	cis	rs10895987	0.83	rs12292693	ENSG00000254614.2	AP003068.23	-5.57	3.26e-08	4.35e-06	-0.26	-0.17	Blood protein levels;	chr11:65169248	chr11:65177606~65181834:-
BRCA	cis	rs793571	0.554	rs28489732	ENSG00000259250.1	RP11-50C13.1	-5.57	3.26e-08	4.36e-06	-0.3	-0.17	Schizophrenia;	chr15:58721154	chr15:58587507~58591676:+
BRCA	cis	rs9287719	0.967	rs6721739	ENSG00000243819.4	RN7SL832P	-5.57	3.26e-08	4.36e-06	-0.17	-0.17	Prostate cancer;	chr2:10611120	chr2:10690344~10692099:+
BRCA	cis	rs919433	0.68	rs3792160	ENSG00000231621.1	AC013264.2	-5.57	3.27e-08	4.36e-06	-0.16	-0.17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197538795	chr2:197197991~197199273:+
BRCA	cis	rs1552244	1	rs35741213	ENSG00000232901.1	CYCSP10	5.57	3.27e-08	4.36e-06	0.24	0.17	Alzheimer's disease;	chr3:10045977	chr3:10000647~10000940:-
BRCA	cis	rs6490294	0.571	rs7965087	ENSG00000226469.1	ADAM1B	5.57	3.27e-08	4.36e-06	0.26	0.17	Mean platelet volume;	chr12:112110758	chr12:111927018~111929017:+
BRCA	cis	rs1552244	1	rs76041173	ENSG00000232901.1	CYCSP10	5.57	3.27e-08	4.36e-06	0.24	0.17	Alzheimer's disease;	chr3:10037011	chr3:10000647~10000940:-
BRCA	cis	rs2898681	0.519	rs7670068	ENSG00000248375.1	RP11-177B4.1	-5.57	3.27e-08	4.36e-06	-0.27	-0.17	Optic nerve measurement (cup area);	chr4:52867817	chr4:52720081~52720831:-
BRCA	cis	rs13108904	0.935	rs6853002	ENSG00000254094.1	AC078852.1	-5.57	3.27e-08	4.36e-06	-0.18	-0.17	Obesity-related traits;	chr4:1302203	chr4:1356581~1358075:+
BRCA	cis	rs13423976	0.663	rs7559097	ENSG00000231367.4	AC016995.3	-5.57	3.27e-08	4.37e-06	-0.18	-0.17	Gut microbiome composition (summer);	chr2:38517625	chr2:38406719~38515740:-
BRCA	cis	rs12468226	1	rs16824599	ENSG00000226261.1	AC064836.3	5.57	3.27e-08	4.37e-06	0.3	0.17	Urate levels;	chr2:202358243	chr2:202336024~202336727:-
BRCA	cis	rs10129255	0.5	rs10143242	ENSG00000224373.3	IGHV4-59	5.57	3.27e-08	4.37e-06	0.1	0.17	Kawasaki disease;	chr14:106681814	chr14:106627249~106627825:-
BRCA	cis	rs1859596	1	rs1859598	ENSG00000234456.6	MAGI2-AS3	5.57	3.27e-08	4.37e-06	0.11	0.17	Reading or mathematical ability;	chr7:79484678	chr7:79452877~79471208:+
BRCA	cis	rs1859596	1	rs4727886	ENSG00000234456.6	MAGI2-AS3	5.57	3.27e-08	4.37e-06	0.11	0.17	Reading or mathematical ability;	chr7:79485656	chr7:79452877~79471208:+
BRCA	cis	rs1707322	0.686	rs2230658	ENSG00000234329.1	RP11-767N6.2	-5.57	3.28e-08	4.37e-06	-0.18	-0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613182	chr1:45651039~45651826:-
BRCA	cis	rs1979679	0.918	rs786711	ENSG00000278733.1	RP11-425D17.1	5.57	3.28e-08	4.38e-06	0.22	0.17	Ossification of the posterior longitudinal ligament of the spine;	chr12:28406330	chr12:28185625~28186190:-
BRCA	cis	rs453301	0.653	rs7016139	ENSG00000233609.3	RP11-62H7.2	-5.57	3.28e-08	4.38e-06	-0.16	-0.17	Joint mobility (Beighton score);	chr8:9037960	chr8:8961200~8979025:+
BRCA	cis	rs7493	0.755	rs17166861	ENSG00000233942.1	AC004012.1	5.57	3.28e-08	4.38e-06	0.22	0.17	Yu-Zhi constitution type in type 2 diabetes;	chr7:95391290	chr7:95471835~95473998:+
BRCA	cis	rs4907240	0.961	rs66727130	ENSG00000237510.6	AC008268.2	-5.57	3.29e-08	4.39e-06	-0.24	-0.17	Event-related brain oscillations;	chr2:96659254	chr2:95789654~95800166:+
BRCA	cis	rs7819412	0.875	rs11250121	ENSG00000255046.1	RP11-297N6.4	5.57	3.29e-08	4.39e-06	0.2	0.17	Triglycerides;	chr8:11202802	chr8:11797928~11802568:-
BRCA	cis	rs2638953	0.924	rs11049476	ENSG00000247934.4	RP11-967K21.1	-5.57	3.29e-08	4.39e-06	-0.22	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28244242	chr12:28163298~28190738:-
BRCA	cis	rs1707322	0.752	rs11211169	ENSG00000234329.1	RP11-767N6.2	5.57	3.29e-08	4.39e-06	0.18	0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45701037	chr1:45651039~45651826:-
BRCA	cis	rs2638953	0.886	rs11049576	ENSG00000278733.1	RP11-425D17.1	-5.57	3.29e-08	4.39e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28412347	chr12:28185625~28186190:-
BRCA	cis	rs6832769	0.922	rs9993675	ENSG00000272969.1	RP11-528I4.2	5.57	3.29e-08	4.39e-06	0.2	0.17	Personality dimensions;	chr4:55377355	chr4:55547112~55547889:+
BRCA	cis	rs67766926	0.587	rs10207939	ENSG00000271889.1	RP11-493E12.1	5.57	3.29e-08	4.4e-06	0.25	0.17	Inflammatory skin disease;	chr2:61026280	chr2:61151433~61162105:-
BRCA	cis	rs3003214	1	rs3003214	ENSG00000225401.2	TGIF2P1	5.57	3.29e-08	4.4e-06	0.2	0.17	Dementia and core Alzheimer's disease neuropathologic changes;	chr1:244441734	chr1:244394976~244395660:-
BRCA	cis	rs6570726	0.846	rs6899900	ENSG00000270638.1	RP3-466P17.1	5.57	3.29e-08	4.4e-06	0.19	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145562737	chr6:145735570~145737218:+
BRCA	cis	rs2281636	0.931	rs2300984	ENSG00000233690.1	EBAG9P1	5.57	3.29e-08	4.4e-06	0.18	0.17	Obesity-related traits;	chr10:99717100	chr10:99697407~99697949:-
BRCA	cis	rs2281636	0.894	rs2300985	ENSG00000233690.1	EBAG9P1	5.57	3.29e-08	4.4e-06	0.18	0.17	Obesity-related traits;	chr10:99717148	chr10:99697407~99697949:-
BRCA	cis	rs17772222	0.511	rs10150833	ENSG00000258983.2	RP11-507K2.2	5.57	3.3e-08	4.4e-06	0.17	0.17	Coronary artery calcification;	chr14:88843296	chr14:88499334~88515502:+
BRCA	cis	rs1552244	0.872	rs115331527	ENSG00000180385.7	EMC3-AS1	5.57	3.3e-08	4.4e-06	0.21	0.17	Alzheimer's disease;	chr3:10112820	chr3:9986893~10006990:+
BRCA	cis	rs2253762	0.507	rs4752630	ENSG00000276742.1	RP11-500G22.4	5.57	3.3e-08	4.4e-06	0.28	0.17	Breast cancer;	chr10:121991440	chr10:121956782~121957098:+
BRCA	cis	rs2638953	0.853	rs11614463	ENSG00000278733.1	RP11-425D17.1	-5.57	3.3e-08	4.4e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28467278	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.853	rs10843183	ENSG00000278733.1	RP11-425D17.1	-5.57	3.3e-08	4.4e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28467775	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.853	rs11494781	ENSG00000278733.1	RP11-425D17.1	-5.57	3.3e-08	4.4e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28469166	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.853	rs11049638	ENSG00000278733.1	RP11-425D17.1	-5.57	3.3e-08	4.4e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28469687	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.853	rs11049639	ENSG00000278733.1	RP11-425D17.1	-5.57	3.3e-08	4.4e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28469868	chr12:28185625~28186190:-
BRCA	cis	rs17270561	0.514	rs10946805	ENSG00000272462.2	U91328.19	-5.57	3.3e-08	4.41e-06	-0.25	-0.17	Iron status biomarkers;	chr6:26077663	chr6:25992662~26001775:+
BRCA	cis	rs7772486	0.817	rs2748491	ENSG00000270638.1	RP3-466P17.1	5.57	3.3e-08	4.41e-06	0.2	0.17	Lobe attachment (rater-scored or self-reported);	chr6:146006623	chr6:145735570~145737218:+
BRCA	cis	rs873549	1	rs7517086	ENSG00000232679.1	RP11-400N13.3	5.57	3.3e-08	4.41e-06	0.2	0.17	Keloid;	chr1:222097983	chr1:222041705~222064763:-
BRCA	cis	rs4950322	0.518	rs61838938	ENSG00000278811.3	LINC00624	5.57	3.3e-08	4.41e-06	0.21	0.17	Protein quantitative trait loci;	chr1:147105943	chr1:147258885~147517875:-
BRCA	cis	rs4950322	0.529	rs11809327	ENSG00000278811.3	LINC00624	5.57	3.3e-08	4.41e-06	0.21	0.17	Protein quantitative trait loci;	chr1:147106679	chr1:147258885~147517875:-
BRCA	cis	rs4950322	0.563	rs11809328	ENSG00000278811.3	LINC00624	5.57	3.3e-08	4.41e-06	0.21	0.17	Protein quantitative trait loci;	chr1:147106681	chr1:147258885~147517875:-
BRCA	cis	rs2243480	1	rs313820	ENSG00000164669.11	INTS4P1	5.57	3.3e-08	4.41e-06	0.34	0.17	Diabetic kidney disease;	chr7:66109479	chr7:65141225~65234216:+
BRCA	cis	rs7474896	0.515	rs675628	ENSG00000120555.12	SEPT7P9	-5.57	3.31e-08	4.41e-06	-0.24	-0.17	Obesity (extreme);	chr10:38016403	chr10:38383069~38402916:-
BRCA	cis	rs2239547	0.522	rs9846976	ENSG00000242142.1	SERBP1P3	5.57	3.31e-08	4.41e-06	0.2	0.17	Schizophrenia;	chr3:52973979	chr3:53064283~53065091:-
BRCA	cis	rs4512344	0.509	rs2409784	ENSG00000154316.13	TDH	5.57	3.31e-08	4.41e-06	0.21	0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:11539347	chr8:11339637~11368452:+
BRCA	cis	rs4950322	0.542	rs3766519	ENSG00000244371.2	PFN1P8	-5.57	3.31e-08	4.41e-06	-0.24	-0.17	Protein quantitative trait loci;	chr1:147214802	chr1:146957117~146957659:-
BRCA	cis	rs1075265	0.508	rs12621225	ENSG00000272156.1	RP11-477N3.1	-5.57	3.31e-08	4.41e-06	-0.18	-0.17	Chronotype;Morning vs. evening chronotype;	chr2:53710040	chr2:54082554~54085066:+
BRCA	cis	rs78487399	0.908	rs55855805	ENSG00000234936.1	AC010883.5	5.57	3.31e-08	4.42e-06	0.22	0.17	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43581351	chr2:43229573~43233394:+
BRCA	cis	rs17253792	0.545	rs3742570	ENSG00000186615.9	KTN1-AS1	-5.57	3.31e-08	4.42e-06	-0.34	-0.17	Putamen volume;	chr14:55549716	chr14:55499278~55580110:-
BRCA	cis	rs12655019	0.92	rs16886497	ENSG00000271828.1	CTD-2310F14.1	5.57	3.31e-08	4.42e-06	0.33	0.17	Breast cancer (early onset);	chr5:56924887	chr5:56927874~56929573:+
BRCA	cis	rs9652601	0.779	rs11648679	ENSG00000274038.1	RP11-66H6.4	-5.57	3.31e-08	4.42e-06	-0.19	-0.17	Systemic lupus erythematosus;	chr16:11082127	chr16:11056556~11057034:+
BRCA	cis	rs6479901	0.895	rs7918743	ENSG00000232075.1	MRPL35P2	-5.57	3.32e-08	4.43e-06	-0.25	-0.17	Intelligence (multi-trait analysis);	chr10:63333302	chr10:63634317~63634827:-
BRCA	cis	rs2303319	1	rs12467117	ENSG00000227403.1	AC009299.3	5.57	3.32e-08	4.43e-06	0.43	0.17	Cognitive function;	chr2:161369804	chr2:161244739~161249050:+
BRCA	cis	rs2898290	0.592	rs2736342	ENSG00000270154.1	RP11-419I17.1	-5.57	3.32e-08	4.43e-06	-0.19	-0.17	Systolic blood pressure;	chr8:11489780	chr8:12476462~12477122:+
BRCA	cis	rs67766926	0.587	rs9309333	ENSG00000271889.1	RP11-493E12.1	-5.57	3.32e-08	4.43e-06	-0.25	-0.17	Inflammatory skin disease;	chr2:61005570	chr2:61151433~61162105:-
BRCA	cis	rs1707322	0.752	rs28890893	ENSG00000234329.1	RP11-767N6.2	5.57	3.32e-08	4.43e-06	0.18	0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45720904	chr1:45651039~45651826:-
BRCA	cis	rs1124769	0.654	rs12904291	ENSG00000259378.1	DCAF13P3	5.57	3.32e-08	4.43e-06	0.24	0.17	Cognitive performance;	chr15:51187708	chr15:50944663~50945996:+
BRCA	cis	rs853679	0.607	rs71559070	ENSG00000204709.4	LINC01556	5.57	3.32e-08	4.43e-06	0.46	0.17	Depression;	chr6:28071151	chr6:28943877~28944537:+
BRCA	cis	rs853679	0.607	rs35902873	ENSG00000204709.4	LINC01556	5.57	3.32e-08	4.43e-06	0.46	0.17	Depression;	chr6:28091171	chr6:28943877~28944537:+
BRCA	cis	rs853679	0.607	rs13197574	ENSG00000204709.4	LINC01556	5.57	3.32e-08	4.43e-06	0.46	0.17	Depression;	chr6:28092461	chr6:28943877~28944537:+
BRCA	cis	rs10510102	0.872	rs10887003	ENSG00000226864.1	ATE1-AS1	5.57	3.32e-08	4.43e-06	0.3	0.17	Breast cancer;	chr10:121864660	chr10:121928312~121951965:+
BRCA	cis	rs7308116	0.546	rs10861810	ENSG00000274395.1	RP11-554D14.8	-5.57	3.33e-08	4.44e-06	-0.2	-0.17	Pelvic organ prolapse (moderate/severe);	chr12:107830405	chr12:107835541~107836555:-
BRCA	cis	rs2153535	0.585	rs1885203	ENSG00000230939.1	RP11-314C16.1	-5.57	3.33e-08	4.44e-06	-0.2	-0.17	Motion sickness;	chr6:8633646	chr6:8784178~8785445:+
BRCA	cis	rs7569084	0.64	rs11126039	ENSG00000237979.1	AC007389.1	5.57	3.33e-08	4.44e-06	0.22	0.17	Sum eosinophil basophil counts;	chr2:65457953	chr2:65500993~65502138:-
BRCA	cis	rs10510102	0.872	rs116521083	ENSG00000226864.1	ATE1-AS1	5.57	3.33e-08	4.44e-06	0.31	0.17	Breast cancer;	chr10:121950611	chr10:121928312~121951965:+
BRCA	cis	rs10510102	0.81	rs34738294	ENSG00000226864.1	ATE1-AS1	5.57	3.33e-08	4.44e-06	0.31	0.17	Breast cancer;	chr10:121951357	chr10:121928312~121951965:+
BRCA	cis	rs1722141	0.67	rs788766	ENSG00000229628.1	AC073115.7	5.57	3.33e-08	4.44e-06	0.25	0.17	Sitting height ratio;	chr7:45957944	chr7:45990905~46000898:+
BRCA	cis	rs999943	0.774	rs12205634	ENSG00000224557.6	HLA-DPB2	-5.57	3.33e-08	4.44e-06	-0.24	-0.17	Obesity (extreme);	chr6:33643890	chr6:33112451~33129084:+
BRCA	cis	rs2243480	0.803	rs35480979	ENSG00000232559.3	GS1-124K5.12	5.56	3.33e-08	4.45e-06	0.31	0.17	Diabetic kidney disease;	chr7:65892097	chr7:66554588~66576923:-
BRCA	cis	rs2243480	1	rs35391607	ENSG00000232559.3	GS1-124K5.12	5.56	3.33e-08	4.45e-06	0.31	0.17	Diabetic kidney disease;	chr7:65895842	chr7:66554588~66576923:-
BRCA	cis	rs2243480	1	rs13220979	ENSG00000232559.3	GS1-124K5.12	5.56	3.33e-08	4.45e-06	0.31	0.17	Diabetic kidney disease;	chr7:65898217	chr7:66554588~66576923:-
BRCA	cis	rs2243480	1	rs34974928	ENSG00000232559.3	GS1-124K5.12	5.56	3.33e-08	4.45e-06	0.31	0.17	Diabetic kidney disease;	chr7:65899019	chr7:66554588~66576923:-
BRCA	cis	rs595244	1	rs1036476	ENSG00000259705.1	RP11-227D13.1	5.56	3.33e-08	4.45e-06	0.32	0.17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48622578	chr15:48645951~48652016:+
BRCA	cis	rs9308731	0.644	rs1837367	ENSG00000227992.1	AC108463.2	-5.56	3.34e-08	4.45e-06	-0.19	-0.17	Chronic lymphocytic leukemia;	chr2:111116974	chr2:111203964~111206215:-
BRCA	cis	rs875971	0.545	rs73136346	ENSG00000228409.4	CCT6P1	5.56	3.34e-08	4.45e-06	0.17	0.17	Aortic root size;	chr7:66101095	chr7:65751142~65763354:+
BRCA	cis	rs1859596	1	rs1859596	ENSG00000234456.6	MAGI2-AS3	-5.56	3.34e-08	4.45e-06	-0.11	-0.17	Reading or mathematical ability;	chr7:79480326	chr7:79452877~79471208:+
BRCA	cis	rs7772486	0.875	rs2748485	ENSG00000270638.1	RP3-466P17.1	5.56	3.34e-08	4.45e-06	0.19	0.17	Lobe attachment (rater-scored or self-reported);	chr6:146011285	chr6:145735570~145737218:+
BRCA	cis	rs7665090	0.528	rs4235405	ENSG00000246560.2	RP11-10L12.4	5.56	3.34e-08	4.45e-06	0.19	0.17	Primary biliary cholangitis;	chr4:102595654	chr4:102828055~102844075:+
BRCA	cis	rs6088813	1	rs2248393	ENSG00000126005.14	MMP24-AS1	-5.56	3.34e-08	4.45e-06	-0.2	-0.17	Height;	chr20:35338300	chr20:35216462~35278131:-
BRCA	cis	rs7044106	0.791	rs2416799	ENSG00000238181.2	AHCYP2	-5.56	3.35e-08	4.46e-06	-0.22	-0.17	Hip circumference adjusted for BMI;	chr9:120718588	chr9:120720673~120721972:+
BRCA	cis	rs7200543	1	rs34614532	ENSG00000275910.1	RP11-680G24.6	-5.56	3.35e-08	4.46e-06	-0.2	-0.17	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15039051	chr16:15015828~15016390:-
BRCA	cis	rs7247513	0.797	rs3815914	ENSG00000213290.4	PGK1P2	-5.56	3.35e-08	4.46e-06	-0.23	-0.17	Bipolar disorder;	chr19:12649850	chr19:12559571~12561105:+
BRCA	cis	rs2933343	0.729	rs1683780	ENSG00000261159.1	RP11-723O4.9	5.56	3.35e-08	4.46e-06	0.18	0.17	IgG glycosylation;	chr3:128921396	chr3:128859716~128860526:-
BRCA	cis	rs2288884	0.649	rs11667001	ENSG00000275055.1	CTC-471J1.11	-5.56	3.35e-08	4.46e-06	-0.26	-0.17	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52049416	chr19:52049007~52049754:+
BRCA	cis	rs17685	0.712	rs11770149	ENSG00000280388.1	RP11-229D13.3	-5.56	3.35e-08	4.47e-06	-0.18	-0.17	Coffee consumption (cups per day);Coffee consumption;	chr7:76162326	chr7:76043977~76045963:-
BRCA	cis	rs1707322	1	rs7538978	ENSG00000234329.1	RP11-767N6.2	-5.56	3.35e-08	4.47e-06	-0.17	-0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46039382	chr1:45651039~45651826:-
BRCA	cis	rs13108904	0.539	rs13141992	ENSG00000254094.1	AC078852.1	-5.56	3.35e-08	4.47e-06	-0.21	-0.17	Obesity-related traits;	chr4:1346977	chr4:1356581~1358075:+
BRCA	cis	rs55702914	0.655	rs787982	ENSG00000231621.1	AC013264.2	-5.56	3.36e-08	4.47e-06	-0.16	-0.17	Major depression and alcohol dependence;	chr2:197450810	chr2:197197991~197199273:+
BRCA	cis	rs8054556	0.787	rs11642612	ENSG00000273724.1	RP11-347C12.12	-5.56	3.36e-08	4.47e-06	-0.2	-0.17	Autism spectrum disorder or schizophrenia;	chr16:30018874	chr16:30336400~30343336:+
BRCA	cis	rs8054556	0.787	rs11150581	ENSG00000273724.1	RP11-347C12.12	-5.56	3.36e-08	4.47e-06	-0.2	-0.17	Autism spectrum disorder or schizophrenia;	chr16:30019378	chr16:30336400~30343336:+
BRCA	cis	rs8054556	0.633	rs12928610	ENSG00000273724.1	RP11-347C12.12	-5.56	3.36e-08	4.48e-06	-0.19	-0.17	Autism spectrum disorder or schizophrenia;	chr16:30004701	chr16:30336400~30343336:+
BRCA	cis	rs1193	0.913	rs13297	ENSG00000231259.4	AC125232.1	-5.56	3.36e-08	4.48e-06	-0.21	-0.17	High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;High light scatter reticulocyte count;	chr2:86775583	chr2:87031815~87053069:-
BRCA	cis	rs9907295	1	rs11653016	ENSG00000270977.1	AC015849.16	-5.56	3.36e-08	4.48e-06	-0.29	-0.17	Fibroblast growth factor basic levels;	chr17:35909756	chr17:35893707~35911023:-
BRCA	cis	rs9907295	1	rs9889977	ENSG00000270977.1	AC015849.16	-5.56	3.36e-08	4.48e-06	-0.29	-0.17	Fibroblast growth factor basic levels;	chr17:35910691	chr17:35893707~35911023:-
BRCA	cis	rs9907295	1	rs9894799	ENSG00000270977.1	AC015849.16	-5.56	3.36e-08	4.48e-06	-0.29	-0.17	Fibroblast growth factor basic levels;	chr17:35911085	chr17:35893707~35911023:-
BRCA	cis	rs9907295	1	rs9903590	ENSG00000270977.1	AC015849.16	-5.56	3.36e-08	4.48e-06	-0.29	-0.17	Fibroblast growth factor basic levels;	chr17:35911286	chr17:35893707~35911023:-
BRCA	cis	rs9907295	1	rs9897665	ENSG00000270977.1	AC015849.16	-5.56	3.36e-08	4.48e-06	-0.29	-0.17	Fibroblast growth factor basic levels;	chr17:35911595	chr17:35893707~35911023:-
BRCA	cis	rs9907295	1	rs9912049	ENSG00000270977.1	AC015849.16	-5.56	3.36e-08	4.48e-06	-0.29	-0.17	Fibroblast growth factor basic levels;	chr17:35912530	chr17:35893707~35911023:-
BRCA	cis	rs9907295	1	rs9911016	ENSG00000270977.1	AC015849.16	-5.56	3.36e-08	4.48e-06	-0.29	-0.17	Fibroblast growth factor basic levels;	chr17:35913349	chr17:35893707~35911023:-
BRCA	cis	rs9907295	1	rs9912894	ENSG00000270977.1	AC015849.16	-5.56	3.36e-08	4.48e-06	-0.29	-0.17	Fibroblast growth factor basic levels;	chr17:35913452	chr17:35893707~35911023:-
BRCA	cis	rs9907295	1	rs9914468	ENSG00000270977.1	AC015849.16	-5.56	3.36e-08	4.48e-06	-0.29	-0.17	Fibroblast growth factor basic levels;	chr17:35913727	chr17:35893707~35911023:-
BRCA	cis	rs9907295	1	rs9893004	ENSG00000270977.1	AC015849.16	-5.56	3.36e-08	4.48e-06	-0.29	-0.17	Fibroblast growth factor basic levels;	chr17:35913855	chr17:35893707~35911023:-
BRCA	cis	rs9907295	1	rs9899215	ENSG00000270977.1	AC015849.16	-5.56	3.36e-08	4.48e-06	-0.29	-0.17	Fibroblast growth factor basic levels;	chr17:35914215	chr17:35893707~35911023:-
BRCA	cis	rs9907295	1	rs9907145	ENSG00000270977.1	AC015849.16	-5.56	3.36e-08	4.48e-06	-0.29	-0.17	Fibroblast growth factor basic levels;	chr17:35915237	chr17:35893707~35911023:-
BRCA	cis	rs4664293	0.51	rs747707	ENSG00000226266.5	AC009961.3	5.56	3.36e-08	4.48e-06	0.21	0.17	Monocyte percentage of white cells;	chr2:159609003	chr2:159670708~159712435:-
BRCA	cis	rs3213958	0.574	rs12203	ENSG00000249274.1	PDLIM1P4	5.56	3.36e-08	4.48e-06	0.25	0.17	Blood protein levels;	chr3:98795197	chr3:98782188~98783193:+
BRCA	cis	rs4713118	0.662	rs9380045	ENSG00000204709.4	LINC01556	5.56	3.36e-08	4.48e-06	0.25	0.17	Parkinson's disease;	chr6:28057501	chr6:28943877~28944537:+
BRCA	cis	rs17301013	0.932	rs1793297	ENSG00000227373.4	RP11-160H22.5	-5.56	3.36e-08	4.48e-06	-0.22	-0.17	Systemic lupus erythematosus;	chr1:174784411	chr1:174115300~174160004:-
BRCA	cis	rs4691139	0.903	rs6835415	ENSG00000248632.1	RP11-366M4.11	5.56	3.36e-08	4.48e-06	0.17	0.17	Ovarian cancer in BRCA1 mutation carriers;	chr4:164998932	chr4:164968587~164970002:-
BRCA	cis	rs11098499	0.955	rs13113112	ENSG00000249244.1	RP11-548H18.2	5.56	3.37e-08	4.49e-06	0.21	0.17	Corneal astigmatism;	chr4:119234885	chr4:119391831~119395335:-
BRCA	cis	rs4835473	0.932	rs1849112	ENSG00000249741.2	RP11-673E1.3	-5.56	3.37e-08	4.49e-06	-0.18	-0.17	Immature fraction of reticulocytes;	chr4:143962502	chr4:143911514~143912053:-
BRCA	cis	rs9300255	0.602	rs1727317	ENSG00000235423.7	RP11-282O18.3	5.56	3.37e-08	4.49e-06	0.24	0.17	Neutrophil percentage of white cells;	chr12:123134395	chr12:123252030~123261483:-
BRCA	cis	rs3733585	0.699	rs6852441	ENSG00000250413.1	RP11-448G15.1	5.56	3.37e-08	4.49e-06	0.22	0.17	Cleft plate (environmental tobacco smoke interaction);	chr4:9972120	chr4:10006482~10009725:+
BRCA	cis	rs13126694	0.682	rs4504305	ENSG00000251429.1	RP11-597D13.7	5.56	3.37e-08	4.49e-06	0.17	0.17	Blood osmolality (transformed sodium);	chr4:157982801	chr4:158270378~158278676:+
BRCA	cis	rs2638953	0.962	rs11049537	ENSG00000278733.1	RP11-425D17.1	-5.56	3.37e-08	4.49e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28331239	chr12:28185625~28186190:-
BRCA	cis	rs3760982	0.585	rs67648499	ENSG00000267058.1	RP11-15A1.3	-5.56	3.37e-08	4.49e-06	-0.2	-0.17	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43789903	chr19:43891804~43901805:-
BRCA	cis	rs6723226	0.881	rs10181198	ENSG00000276334.1	AL133243.1	5.56	3.37e-08	4.49e-06	0.22	0.17	Intelligence (multi-trait analysis);	chr2:32461514	chr2:32521927~32523547:+
BRCA	cis	rs2638953	0.853	rs10506038	ENSG00000278733.1	RP11-425D17.1	5.56	3.38e-08	4.5e-06	0.22	0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28506239	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.962	rs12371059	ENSG00000278733.1	RP11-425D17.1	-5.56	3.38e-08	4.5e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28375375	chr12:28185625~28186190:-
BRCA	cis	rs6570726	0.846	rs6919684	ENSG00000270638.1	RP3-466P17.1	5.56	3.38e-08	4.5e-06	0.19	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145562665	chr6:145735570~145737218:+
BRCA	cis	rs4908768	0.501	rs2016084	ENSG00000270282.1	RP5-1115A15.2	5.56	3.38e-08	4.5e-06	0.18	0.17	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8553359	chr1:8512653~8513021:+
BRCA	cis	rs67981189	0.896	rs4391999	ENSG00000258571.1	PTTG4P	-5.56	3.38e-08	4.5e-06	-0.19	-0.17	Schizophrenia;	chr14:70978696	chr14:71085482~71085833:-
BRCA	cis	rs17213965	0.852	rs4781692	ENSG00000275910.1	RP11-680G24.6	5.56	3.38e-08	4.5e-06	0.27	0.17	Waist-hip ratio;	chr16:15784296	chr16:15015828~15016390:-
BRCA	cis	rs10885396	0.967	rs7094871	ENSG00000233547.1	RP11-57H14.2	-5.56	3.38e-08	4.5e-06	-0.18	-0.17	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr10:112952395	chr10:112950646~112951875:-
BRCA	cis	rs991427	0.643	rs17018627	ENSG00000258100.1	RP11-121E16.1	5.56	3.38e-08	4.5e-06	0.28	0.17	Systolic blood pressure (alcohol consumption interaction);	chr12:91059593	chr12:91362196~91368606:+
BRCA	cis	rs516805	0.667	rs9320856	ENSG00000279453.1	RP3-425C14.4	-5.56	3.39e-08	4.51e-06	-0.24	-0.17	Lymphocyte counts;	chr6:122219888	chr6:122436789~122439223:-
BRCA	cis	rs1707322	0.682	rs12037459	ENSG00000234329.1	RP11-767N6.2	5.56	3.39e-08	4.51e-06	0.18	0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45629287	chr1:45651039~45651826:-
BRCA	cis	rs13108904	0.875	rs10024013	ENSG00000254094.1	AC078852.1	5.56	3.39e-08	4.51e-06	0.18	0.17	Obesity-related traits;	chr4:1287004	chr4:1356581~1358075:+
BRCA	cis	rs4415084	1	rs12187196	ENSG00000251141.4	RP11-53O19.1	5.56	3.39e-08	4.51e-06	0.16	0.17	Breast cancer;	chr5:44683717	chr5:44744900~44808777:-
BRCA	cis	rs7308116	0.528	rs10778581	ENSG00000274395.1	RP11-554D14.8	-5.56	3.39e-08	4.51e-06	-0.2	-0.17	Pelvic organ prolapse (moderate/severe);	chr12:107837355	chr12:107835541~107836555:-
BRCA	cis	rs26949	0.554	rs11742421	ENSG00000215032.2	GNL3LP1	5.56	3.39e-08	4.51e-06	0.21	0.17	Intelligence (multi-trait analysis);	chr5:60681590	chr5:60891935~60893577:-
BRCA	cis	rs2624839	0.679	rs2624835	ENSG00000228008.1	CTD-2330K9.3	5.56	3.39e-08	4.51e-06	0.18	0.17	Intelligence (multi-trait analysis);	chr3:50171616	chr3:49903845~49916937:+
BRCA	cis	rs1979679	0.918	rs7312574	ENSG00000278733.1	RP11-425D17.1	-5.56	3.39e-08	4.51e-06	-0.22	-0.17	Ossification of the posterior longitudinal ligament of the spine;	chr12:28514977	chr12:28185625~28186190:-
BRCA	cis	rs7772486	0.846	rs1854901	ENSG00000270638.1	RP3-466P17.1	5.56	3.39e-08	4.51e-06	0.19	0.17	Lobe attachment (rater-scored or self-reported);	chr6:146004549	chr6:145735570~145737218:+
BRCA	cis	rs6095360	0.69	rs1115535	ENSG00000222365.1	SNORD12B	-5.56	3.39e-08	4.52e-06	-0.22	-0.17	Intelligence (multi-trait analysis);	chr20:48974027	chr20:49280319~49280409:+
BRCA	cis	rs2337406	0.587	rs10129888	ENSG00000223648.3	IGHV3-64	5.56	3.39e-08	4.52e-06	0.17	0.17	Alzheimer's disease (late onset);	chr14:106647421	chr14:106643132~106658258:-
BRCA	cis	rs7520050	0.933	rs6694340	ENSG00000280836.1	AL355480.1	5.56	3.39e-08	4.52e-06	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:45823744	chr1:45581219~45581321:-
BRCA	cis	rs523522	0.962	rs11065145	ENSG00000278344.1	RP11-18C24.8	5.56	3.4e-08	4.52e-06	0.23	0.17	High light scatter reticulocyte count;	chr12:120509616	chr12:120500735~120501090:-
BRCA	cis	rs523522	0.924	rs11065150	ENSG00000278344.1	RP11-18C24.8	5.56	3.4e-08	4.52e-06	0.23	0.17	High light scatter reticulocyte count;	chr12:120521072	chr12:120500735~120501090:-
BRCA	cis	rs6928977	0.675	rs11154803	ENSG00000231028.7	LINC00271	-5.56	3.4e-08	4.52e-06	-0.18	-0.17	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135477707	chr6:135497801~135716055:+
BRCA	cis	rs6832769	1	rs6837710	ENSG00000272969.1	RP11-528I4.2	5.56	3.4e-08	4.52e-06	0.21	0.17	Personality dimensions;	chr4:55508288	chr4:55547112~55547889:+
BRCA	cis	rs4664293	0.51	rs6731277	ENSG00000226266.5	AC009961.3	5.56	3.4e-08	4.52e-06	0.21	0.17	Monocyte percentage of white cells;	chr2:159610606	chr2:159670708~159712435:-
BRCA	cis	rs7493	0.853	rs2299266	ENSG00000233942.1	AC004012.1	5.56	3.4e-08	4.53e-06	0.21	0.17	Yu-Zhi constitution type in type 2 diabetes;	chr7:95419761	chr7:95471835~95473998:+
BRCA	cis	rs8040855	0.599	rs4643289	ENSG00000259774.1	RP11-182J1.13	-5.56	3.4e-08	4.53e-06	-0.19	-0.17	Bulimia nervosa;	chr15:85183483	chr15:84422618~84425882:+
BRCA	cis	rs4950322	0.518	rs61838936	ENSG00000278811.3	LINC00624	5.56	3.41e-08	4.53e-06	0.22	0.17	Protein quantitative trait loci;	chr1:147098422	chr1:147258885~147517875:-
BRCA	cis	rs7107174	0.901	rs10899496	ENSG00000251323.2	RP11-452H21.4	5.56	3.41e-08	4.53e-06	0.22	0.17	Testicular germ cell tumor;	chr11:78412785	chr11:78423982~78429836:-
BRCA	cis	rs9638182	1	rs9638180	ENSG00000274080.1	CTA-315H11.2	5.56	3.41e-08	4.54e-06	0.3	0.17	Triglycerides;	chr7:73584622	chr7:73609262~73611502:-
BRCA	cis	rs10740039	0.516	rs7072017	ENSG00000254271.1	RP11-131N11.4	5.56	3.41e-08	4.54e-06	0.23	0.17	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60584568	chr10:60734342~60741828:+
BRCA	cis	rs2732480	0.577	rs2634680	ENSG00000226413.2	OR8T1P	5.56	3.41e-08	4.54e-06	0.23	0.17	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48340781	chr12:48442030~48442947:-
BRCA	cis	rs2732480	0.577	rs2634678	ENSG00000226413.2	OR8T1P	5.56	3.41e-08	4.54e-06	0.23	0.17	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48341755	chr12:48442030~48442947:-
BRCA	cis	rs4787491	0.729	rs8043883	ENSG00000273724.1	RP11-347C12.12	-5.56	3.41e-08	4.54e-06	-0.19	-0.17	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30033260	chr16:30336400~30343336:+
BRCA	cis	rs7569084	0.687	rs7577452	ENSG00000237979.1	AC007389.1	5.56	3.41e-08	4.54e-06	0.22	0.17	Sum eosinophil basophil counts;	chr2:65456694	chr2:65500993~65502138:-
BRCA	cis	rs453301	0.624	rs330049	ENSG00000253981.4	ALG1L13P	5.56	3.41e-08	4.54e-06	0.19	0.17	Joint mobility (Beighton score);	chr8:9229789	chr8:8236003~8244667:-
BRCA	cis	rs66887589	0.72	rs11724758	ENSG00000245958.5	RP11-33B1.1	-5.56	3.41e-08	4.54e-06	-0.15	-0.17	Diastolic blood pressure;	chr4:119318723	chr4:119454791~119552025:+
BRCA	cis	rs2732480	0.5	rs2450986	ENSG00000240399.1	RP1-228P16.1	5.56	3.41e-08	4.54e-06	0.2	0.17	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48267905	chr12:48054813~48055591:-
BRCA	cis	rs2153535	0.585	rs9328498	ENSG00000230939.1	RP11-314C16.1	-5.56	3.42e-08	4.55e-06	-0.19	-0.17	Motion sickness;	chr6:8623536	chr6:8784178~8785445:+
BRCA	cis	rs523522	0.962	rs651627	ENSG00000278344.1	RP11-18C24.8	5.56	3.42e-08	4.55e-06	0.23	0.17	High light scatter reticulocyte count;	chr12:120571395	chr12:120500735~120501090:-
BRCA	cis	rs523522	0.962	rs3759394	ENSG00000278344.1	RP11-18C24.8	5.56	3.42e-08	4.55e-06	0.23	0.17	High light scatter reticulocyte count;	chr12:120495370	chr12:120500735~120501090:-
BRCA	cis	rs523522	0.962	rs2233676	ENSG00000278344.1	RP11-18C24.8	5.56	3.42e-08	4.55e-06	0.23	0.17	High light scatter reticulocyte count;	chr12:120495804	chr12:120500735~120501090:-
BRCA	cis	rs1023500	1	rs7293091	ENSG00000205702.9	CYP2D7	-5.56	3.42e-08	4.55e-06	-0.17	-0.17	Schizophrenia;	chr22:41945304	chr22:42140203~42144577:-
BRCA	cis	rs2638953	0.924	rs1841962	ENSG00000247934.4	RP11-967K21.1	5.56	3.42e-08	4.55e-06	0.22	0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28220919	chr12:28163298~28190738:-
BRCA	cis	rs7208859	0.623	rs9898084	ENSG00000280069.1	CTD-2349P21.3	-5.56	3.42e-08	4.56e-06	-0.24	-0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30755316	chr17:30738182~30740275:+
BRCA	cis	rs11123406	0.501	rs62160380	ENSG00000227992.1	AC108463.2	5.56	3.43e-08	4.56e-06	0.24	0.17	Type 2 diabetes;	chr2:111213187	chr2:111203964~111206215:-
BRCA	cis	rs2179367	0.881	rs2744432	ENSG00000216906.2	RP11-350J20.9	-5.56	3.43e-08	4.56e-06	-0.21	-0.17	Dupuytren's disease;	chr6:149422735	chr6:149904243~149906418:+
BRCA	cis	rs17597773	0.674	rs903319	ENSG00000272823.1	RP11-295M18.6	-5.56	3.43e-08	4.56e-06	-0.21	-0.17	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220812469	chr1:220828676~220829211:-
BRCA	cis	rs6547705	0.748	rs13010845	ENSG00000231259.4	AC125232.1	-5.56	3.43e-08	4.56e-06	-0.26	-0.17	Progressive supranuclear palsy;	chr2:86662353	chr2:87031815~87053069:-
BRCA	cis	rs210138	1	rs210138	ENSG00000197251.3	LINC00336	-5.56	3.43e-08	4.56e-06	-0.24	-0.17	Testicular germ cell tumor;	chr6:33574761	chr6:33586106~33593338:-
BRCA	cis	rs6565180	1	rs12930787	ENSG00000183604.13	SMG1P5	-5.56	3.43e-08	4.57e-06	-0.18	-0.17	Tonsillectomy;	chr16:30369982	chr16:30267553~30335374:-
BRCA	cis	rs651386	0.505	rs10753817	ENSG00000271811.1	RP1-79C4.4	5.56	3.43e-08	4.57e-06	0.19	0.17	Atrial fibrillation;	chr1:170622667	chr1:170667381~170669425:+
BRCA	cis	rs6570726	0.764	rs4896821	ENSG00000270638.1	RP3-466P17.1	5.56	3.44e-08	4.57e-06	0.19	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145575045	chr6:145735570~145737218:+
BRCA	cis	rs12681366	0.801	rs2011246	ENSG00000253704.1	RP11-267M23.4	5.56	3.44e-08	4.57e-06	0.2	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94450846	chr8:94553722~94569745:+
BRCA	cis	rs1440410	0.795	rs13119330	ENSG00000250326.1	RP11-284M14.1	-5.56	3.44e-08	4.57e-06	-0.18	-0.17	Ischemic stroke;	chr4:143264416	chr4:142933195~143184861:-
BRCA	cis	rs4834770	0.668	rs11737086	ENSG00000178636.7	RP11-455G16.1	5.56	3.44e-08	4.57e-06	0.22	0.17	Blood protein levels;	chr4:119205962	chr4:119192773~119212644:-
BRCA	cis	rs9341808	0.718	rs4437429	ENSG00000272129.1	RP11-250B2.6	5.56	3.44e-08	4.57e-06	0.22	0.17	Sitting height ratio;	chr6:80118875	chr6:80355424~80356859:+
BRCA	cis	rs9287719	0.649	rs12104950	ENSG00000243819.4	RN7SL832P	5.56	3.44e-08	4.57e-06	0.17	0.17	Prostate cancer;	chr2:10591979	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.649	rs10803724	ENSG00000243819.4	RN7SL832P	5.56	3.44e-08	4.57e-06	0.17	0.17	Prostate cancer;	chr2:10592197	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.649	rs10803725	ENSG00000243819.4	RN7SL832P	5.56	3.44e-08	4.57e-06	0.17	0.17	Prostate cancer;	chr2:10592220	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.649	rs10929685	ENSG00000243819.4	RN7SL832P	5.56	3.44e-08	4.57e-06	0.17	0.17	Prostate cancer;	chr2:10592673	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.649	rs10183359	ENSG00000243819.4	RN7SL832P	5.56	3.44e-08	4.57e-06	0.17	0.17	Prostate cancer;	chr2:10592918	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.624	rs10172926	ENSG00000243819.4	RN7SL832P	5.56	3.44e-08	4.57e-06	0.17	0.17	Prostate cancer;	chr2:10593128	chr2:10690344~10692099:+
BRCA	cis	rs6928977	0.637	rs9647635	ENSG00000231028.7	LINC00271	5.56	3.44e-08	4.57e-06	0.18	0.17	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135519918	chr6:135497801~135716055:+
BRCA	cis	rs875971	0.66	rs10272357	ENSG00000273024.4	INTS4P2	5.56	3.44e-08	4.57e-06	0.19	0.17	Aortic root size;	chr7:66598087	chr7:65647864~65715661:+
BRCA	cis	rs2153535	0.585	rs9393050	ENSG00000230939.1	RP11-314C16.1	-5.56	3.44e-08	4.57e-06	-0.2	-0.17	Motion sickness;	chr6:8635219	chr6:8784178~8785445:+
BRCA	cis	rs9308731	0.591	rs6732491	ENSG00000227992.1	AC108463.2	-5.56	3.44e-08	4.58e-06	-0.2	-0.17	Chronic lymphocytic leukemia;	chr2:111181143	chr2:111203964~111206215:-
BRCA	cis	rs9638182	1	rs9638182	ENSG00000274080.1	CTA-315H11.2	5.56	3.44e-08	4.58e-06	0.3	0.17	Triglycerides;	chr7:73584775	chr7:73609262~73611502:-
BRCA	cis	rs1552244	1	rs67569278	ENSG00000232901.1	CYCSP10	5.56	3.44e-08	4.58e-06	0.24	0.17	Alzheimer's disease;	chr3:10108209	chr3:10000647~10000940:-
BRCA	cis	rs7674212	0.537	rs2623060	ENSG00000248740.4	RP11-328K4.1	5.56	3.44e-08	4.58e-06	0.19	0.17	Type 2 diabetes;	chr4:103126347	chr4:103256159~103453658:+
BRCA	cis	rs7493	0.755	rs116306774	ENSG00000233942.1	AC004012.1	5.56	3.44e-08	4.58e-06	0.22	0.17	Yu-Zhi constitution type in type 2 diabetes;	chr7:95387664	chr7:95471835~95473998:+
BRCA	cis	rs673078	0.66	rs61945176	ENSG00000275409.1	RP11-131L12.4	-5.56	3.45e-08	4.58e-06	-0.23	-0.17	Glucose homeostasis traits;	chr12:118204735	chr12:118430147~118430699:+
BRCA	cis	rs2243480	1	rs11538349	ENSG00000232546.1	RP11-458F8.1	-5.56	3.45e-08	4.58e-06	-0.22	-0.17	Diabetic kidney disease;	chr7:65956884	chr7:66848496~66858136:+
BRCA	cis	rs7520050	0.933	rs12565042	ENSG00000280836.1	AL355480.1	5.56	3.45e-08	4.58e-06	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:45833438	chr1:45581219~45581321:-
BRCA	cis	rs7308116	0.546	rs7977408	ENSG00000274395.1	RP11-554D14.8	-5.56	3.45e-08	4.59e-06	-0.2	-0.17	Pelvic organ prolapse (moderate/severe);	chr12:107830214	chr12:107835541~107836555:-
BRCA	cis	rs5758659	0.819	rs134871	ENSG00000281538.1	RP4-669P10.20	5.56	3.45e-08	4.59e-06	0.17	0.17	Cognitive function;	chr22:42256710	chr22:42138060~42139726:+
BRCA	cis	rs7214842	0.772	rs7219473	ENSG00000225751.2	AC087501.1	-5.56	3.45e-08	4.59e-06	-0.21	-0.17	HDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;	chr17:9446859	chr17:9452197~9470014:+
BRCA	cis	rs10829156	0.699	rs10764584	ENSG00000240291.1	RP11-499P20.2	-5.56	3.45e-08	4.59e-06	-0.19	-0.17	Sudden cardiac arrest;	chr10:18546396	chr10:18513115~18545651:-
BRCA	cis	rs11105298	0.891	rs10777163	ENSG00000270344.2	RP11-734K2.4	5.56	3.45e-08	4.59e-06	0.19	0.17	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89436943	chr12:89525654~89548005:+
BRCA	cis	rs10129255	1	rs11627342	ENSG00000280411.1	IGHV1-69-2	-5.56	3.45e-08	4.59e-06	-0.13	-0.17	Kawasaki disease;	chr14:106675823	chr14:106762092~106762588:-
BRCA	cis	rs490049	1	rs490049	ENSG00000281026.1	N4BP2L2-IT2	5.56	3.45e-08	4.59e-06	0.29	0.17	Diabetic kidney disease;	chr13:32990725	chr13:32504506~32509395:-
BRCA	cis	rs10510102	0.872	rs12247367	ENSG00000226864.1	ATE1-AS1	5.56	3.46e-08	4.59e-06	0.31	0.17	Breast cancer;	chr10:121961556	chr10:121928312~121951965:+
BRCA	cis	rs2243480	1	rs7456042	ENSG00000232559.3	GS1-124K5.12	5.56	3.46e-08	4.59e-06	0.32	0.17	Diabetic kidney disease;	chr7:65834791	chr7:66554588~66576923:-
BRCA	cis	rs2243480	1	rs73142121	ENSG00000232559.3	GS1-124K5.12	5.56	3.46e-08	4.59e-06	0.32	0.17	Diabetic kidney disease;	chr7:65846219	chr7:66554588~66576923:-
BRCA	cis	rs2243480	1	rs34702770	ENSG00000232559.3	GS1-124K5.12	5.56	3.46e-08	4.59e-06	0.32	0.17	Diabetic kidney disease;	chr7:65879836	chr7:66554588~66576923:-
BRCA	cis	rs2243480	1	rs34637256	ENSG00000232559.3	GS1-124K5.12	5.56	3.46e-08	4.59e-06	0.32	0.17	Diabetic kidney disease;	chr7:65895144	chr7:66554588~66576923:-
BRCA	cis	rs4950322	0.542	rs17159924	ENSG00000244371.2	PFN1P8	-5.56	3.46e-08	4.59e-06	-0.22	-0.17	Protein quantitative trait loci;	chr1:147199463	chr1:146957117~146957659:-
BRCA	cis	rs7520050	0.933	rs6661163	ENSG00000280836.1	AL355480.1	5.56	3.46e-08	4.59e-06	0.2	0.17	Reticulocyte count;Red blood cell count;	chr1:45789332	chr1:45581219~45581321:-
BRCA	cis	rs2098713	0.502	rs1985183	ENSG00000250155.1	CTD-2353F22.1	5.56	3.46e-08	4.6e-06	0.2	0.17	Telomere length;	chr5:37541779	chr5:36666214~36725195:-
BRCA	cis	rs1555322	0.53	rs2425043	ENSG00000269202.1	RP4-614O4.12	-5.56	3.46e-08	4.6e-06	-0.2	-0.17	Attention deficit hyperactivity disorder;	chr20:35280899	chr20:35201747~35203288:-
BRCA	cis	rs4218	0.528	rs57557135	ENSG00000277144.1	RP11-59H7.4	-5.56	3.46e-08	4.6e-06	-0.21	-0.17	Social communication problems;	chr15:59054018	chr15:59115547~59116089:-
BRCA	cis	rs7620503	0.959	rs7637965	ENSG00000228221.4	LINC00578	5.56	3.47e-08	4.6e-06	0.2	0.17	Corneal structure;	chr3:177589854	chr3:177441921~177752305:+
BRCA	cis	rs9341808	0.727	rs1324120	ENSG00000272129.1	RP11-250B2.6	5.56	3.47e-08	4.61e-06	0.21	0.17	Sitting height ratio;	chr6:80266408	chr6:80355424~80356859:+
BRCA	cis	rs270601	0.71	rs371709	ENSG00000233006.5	AC034220.3	5.56	3.47e-08	4.61e-06	0.13	0.17	Acylcarnitine levels;	chr5:132247547	chr5:132311285~132369916:-
BRCA	cis	rs7809950	0.599	rs2237658	ENSG00000238832.1	snoU109	-5.56	3.47e-08	4.61e-06	-0.25	-0.17	Coronary artery disease;	chr7:107197421	chr7:107603363~107603507:+
BRCA	cis	rs4819052	0.851	rs13050359	ENSG00000184274.3	LINC00315	-5.56	3.47e-08	4.61e-06	-0.23	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45252756	chr21:45300245~45305257:-
BRCA	cis	rs934734	0.532	rs7569113	ENSG00000204929.10	AC074391.1	5.56	3.48e-08	4.62e-06	0.21	0.17	Rheumatoid arthritis;	chr2:65429907	chr2:65436711~66084639:+
BRCA	cis	rs375066	0.551	rs1565057	ENSG00000267058.1	RP11-15A1.3	5.56	3.48e-08	4.62e-06	0.2	0.17	Breast cancer;	chr19:43829040	chr19:43891804~43901805:-
BRCA	cis	rs828999	0.688	rs7535267	ENSG00000280186.1	RP11-483I13.6	-5.56	3.48e-08	4.62e-06	-0.19	-0.17	Monocyte percentage of white cells;	chr1:108159084	chr1:108200413~108202743:+
BRCA	cis	rs5758511	0.596	rs55644935	ENSG00000233903.2	Z83851.4	5.56	3.48e-08	4.62e-06	0.25	0.17	Birth weight;	chr22:42270063	chr22:42276355~42277052:+
BRCA	cis	rs10129255	0.518	rs11847766	ENSG00000224373.3	IGHV4-59	5.56	3.48e-08	4.62e-06	0.1	0.17	Kawasaki disease;	chr14:106779186	chr14:106627249~106627825:-
BRCA	cis	rs673078	0.66	rs75752792	ENSG00000275409.1	RP11-131L12.4	-5.56	3.48e-08	4.62e-06	-0.26	-0.17	Glucose homeostasis traits;	chr12:118187005	chr12:118430147~118430699:+
BRCA	cis	rs673078	0.66	rs75571641	ENSG00000275409.1	RP11-131L12.4	-5.56	3.48e-08	4.62e-06	-0.26	-0.17	Glucose homeostasis traits;	chr12:118187012	chr12:118430147~118430699:+
BRCA	cis	rs9868809	0.505	rs9877685	ENSG00000270441.1	RP11-694I15.7	5.56	3.48e-08	4.63e-06	0.3	0.17	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48711155	chr3:49140086~49160851:-
BRCA	cis	rs9868809	0.505	rs13063223	ENSG00000270441.1	RP11-694I15.7	5.56	3.48e-08	4.63e-06	0.3	0.17	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48712907	chr3:49140086~49160851:-
BRCA	cis	rs891378	1	rs10864175	ENSG00000274245.1	RP11-357P18.2	-5.56	3.48e-08	4.63e-06	-0.22	-0.17	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207260004	chr1:207372559~207373252:+
BRCA	cis	rs6479891	1	rs7895348	ENSG00000232075.1	MRPL35P2	-5.56	3.49e-08	4.63e-06	-0.31	-0.17	Arthritis (juvenile idiopathic);	chr10:63349781	chr10:63634317~63634827:-
BRCA	cis	rs2235642	0.717	rs9937922	ENSG00000260989.1	LA16c-395F10.2	-5.56	3.49e-08	4.63e-06	-0.18	-0.17	Coronary artery disease;	chr16:1608153	chr16:1580527~1610328:+
BRCA	cis	rs11319879	1	rs11319879	ENSG00000236493.2	EIF2S2P3	5.56	3.49e-08	4.63e-06	0.22	0.17	Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;	chr10:92693719	chr10:92668745~92669743:-
BRCA	cis	rs9309473	0.632	rs6706179	ENSG00000163016.8	ALMS1P	5.56	3.49e-08	4.63e-06	0.21	0.17	Metabolite levels;	chr2:73351449	chr2:73644919~73685576:+
BRCA	cis	rs7630852	1	rs7630852	ENSG00000272359.1	U4	-5.56	3.49e-08	4.64e-06	-0.21	-0.17	Eosinophil counts;	chr3:196781680	chr3:196747192~196747324:-
BRCA	cis	rs2281558	0.837	rs67676850	ENSG00000230772.1	VN1R108P	-5.56	3.49e-08	4.64e-06	-0.22	-0.17	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25388781	chr20:25734264~25735093:+
BRCA	cis	rs8054556	0.787	rs11649274	ENSG00000273724.1	RP11-347C12.12	-5.56	3.49e-08	4.64e-06	-0.2	-0.17	Autism spectrum disorder or schizophrenia;	chr16:30015148	chr16:30336400~30343336:+
BRCA	cis	rs5758659	0.652	rs4822084	ENSG00000227370.1	RP4-669P10.19	5.56	3.5e-08	4.64e-06	0.19	0.17	Cognitive function;	chr22:42039864	chr22:42132543~42132998:+
BRCA	cis	rs4415084	1	rs58144701	ENSG00000251141.4	RP11-53O19.1	5.56	3.5e-08	4.64e-06	0.16	0.17	Breast cancer;	chr5:44676095	chr5:44744900~44808777:-
BRCA	cis	rs12681366	1	rs67808321	ENSG00000253704.1	RP11-267M23.4	5.56	3.5e-08	4.64e-06	0.18	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94373317	chr8:94553722~94569745:+
BRCA	cis	rs17508449	0.732	rs74610368	ENSG00000232450.1	RP4-730K3.3	-5.56	3.5e-08	4.65e-06	-0.31	-0.17	Leprosy;	chr1:113742681	chr1:113698884~113699631:-
BRCA	cis	rs7267979	0.586	rs6083776	ENSG00000277938.1	RP5-965G21.3	5.56	3.5e-08	4.65e-06	0.2	0.17	Liver enzyme levels (alkaline phosphatase);	chr20:25205480	chr20:25229150~25231933:+
BRCA	cis	rs7267979	0.586	rs1473695	ENSG00000277938.1	RP5-965G21.3	5.56	3.5e-08	4.65e-06	0.2	0.17	Liver enzyme levels (alkaline phosphatase);	chr20:25206329	chr20:25229150~25231933:+
BRCA	cis	rs745109	0.504	rs75610186	ENSG00000273080.1	RP11-301O19.1	5.56	3.5e-08	4.65e-06	0.28	0.17	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86372933	chr2:86195590~86196049:+
BRCA	cis	rs828999	0.688	rs10218769	ENSG00000280186.1	RP11-483I13.6	-5.56	3.5e-08	4.65e-06	-0.19	-0.17	Monocyte percentage of white cells;	chr1:108170622	chr1:108200413~108202743:+
BRCA	cis	rs828999	0.628	rs10218750	ENSG00000280186.1	RP11-483I13.6	-5.56	3.5e-08	4.65e-06	-0.19	-0.17	Monocyte percentage of white cells;	chr1:108170694	chr1:108200413~108202743:+
BRCA	cis	rs673078	0.66	rs61945180	ENSG00000275409.1	RP11-131L12.4	-5.56	3.5e-08	4.65e-06	-0.26	-0.17	Glucose homeostasis traits;	chr12:118216335	chr12:118430147~118430699:+
BRCA	cis	rs673078	0.66	rs61945181	ENSG00000275409.1	RP11-131L12.4	-5.56	3.5e-08	4.65e-06	-0.26	-0.17	Glucose homeostasis traits;	chr12:118216651	chr12:118430147~118430699:+
BRCA	cis	rs4372836	1	rs6707848	ENSG00000226833.4	AC097724.3	5.56	3.5e-08	4.65e-06	0.21	0.17	Body mass index;	chr2:28765217	chr2:28708953~28736205:-
BRCA	cis	rs2898681	0.519	rs76606067	ENSG00000248375.1	RP11-177B4.1	-5.56	3.51e-08	4.65e-06	-0.27	-0.17	Optic nerve measurement (cup area);	chr4:52862054	chr4:52720081~52720831:-
BRCA	cis	rs62025270	0.593	rs62022926	ENSG00000202081.1	RNU6-1280P	-5.56	3.51e-08	4.65e-06	-0.26	-0.17	Idiopathic pulmonary fibrosis;	chr15:85696261	chr15:85651522~85651628:-
BRCA	cis	rs17508449	0.819	rs77551704	ENSG00000232450.1	RP4-730K3.3	-5.56	3.51e-08	4.66e-06	-0.31	-0.17	Leprosy;	chr1:113692564	chr1:113698884~113699631:-
BRCA	cis	rs4713118	0.824	rs2179095	ENSG00000216901.1	AL022393.7	-5.56	3.51e-08	4.66e-06	-0.23	-0.17	Parkinson's disease;	chr6:27783079	chr6:28176188~28176674:+
BRCA	cis	rs9341808	0.718	rs9359408	ENSG00000272129.1	RP11-250B2.6	5.56	3.51e-08	4.66e-06	0.22	0.17	Sitting height ratio;	chr6:80110415	chr6:80355424~80356859:+
BRCA	cis	rs17508449	0.775	rs4839336	ENSG00000232450.1	RP4-730K3.3	-5.56	3.51e-08	4.66e-06	-0.31	-0.17	Leprosy;	chr1:113691523	chr1:113698884~113699631:-
BRCA	cis	rs7200543	1	rs1135999	ENSG00000275910.1	RP11-680G24.6	-5.56	3.52e-08	4.67e-06	-0.2	-0.17	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15038105	chr16:15015828~15016390:-
BRCA	cis	rs7927592	0.913	rs2236708	ENSG00000212093.1	AP000807.1	5.56	3.52e-08	4.67e-06	0.19	0.17	Total body bone mineral density;	chr11:68610577	chr11:68506083~68506166:-
BRCA	cis	rs710913	0.691	rs1180351	ENSG00000228060.1	RP11-69E11.8	5.56	3.52e-08	4.67e-06	0.17	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39541605	chr1:39565160~39573203:+
BRCA	cis	rs10510102	0.516	rs10437506	ENSG00000276742.1	RP11-500G22.4	5.56	3.52e-08	4.67e-06	0.31	0.17	Breast cancer;	chr10:121984011	chr10:121956782~121957098:+
BRCA	cis	rs10510102	0.516	rs74461504	ENSG00000276742.1	RP11-500G22.4	5.56	3.52e-08	4.67e-06	0.31	0.17	Breast cancer;	chr10:121986077	chr10:121956782~121957098:+
BRCA	cis	rs6832769	0.961	rs6817663	ENSG00000272969.1	RP11-528I4.2	-5.56	3.52e-08	4.67e-06	-0.21	-0.17	Personality dimensions;	chr4:55581048	chr4:55547112~55547889:+
BRCA	cis	rs2835345	0.563	rs60727080	ENSG00000279365.1	KB-176G8.1	5.56	3.52e-08	4.67e-06	0.23	0.17	Pulmonary function;	chr21:36454876	chr21:36485867~36487760:+
BRCA	cis	rs7927592	0.913	rs67947146	ENSG00000212093.1	AP000807.1	5.56	3.52e-08	4.67e-06	0.19	0.17	Total body bone mineral density;	chr11:68547512	chr11:68506083~68506166:-
BRCA	cis	rs4908768	0.539	rs6670508	ENSG00000270282.1	RP5-1115A15.2	5.56	3.52e-08	4.68e-06	0.18	0.17	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8587858	chr1:8512653~8513021:+
BRCA	cis	rs2732480	0.557	rs2732441	ENSG00000226413.2	OR8T1P	5.56	3.52e-08	4.68e-06	0.23	0.17	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48329541	chr12:48442030~48442947:-
BRCA	cis	rs2732480	0.577	rs2732448	ENSG00000226413.2	OR8T1P	5.56	3.52e-08	4.68e-06	0.23	0.17	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48336817	chr12:48442030~48442947:-
BRCA	cis	rs4908768	0.501	rs12756257	ENSG00000270282.1	RP5-1115A15.2	5.55	3.52e-08	4.68e-06	0.18	0.17	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8556874	chr1:8512653~8513021:+
BRCA	cis	rs73198271	0.586	rs3789850	ENSG00000253893.2	FAM85B	5.55	3.53e-08	4.68e-06	0.22	0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8829335	chr8:8167819~8226614:-
BRCA	cis	rs2732480	0.577	rs2634680	ENSG00000257735.1	RP11-370I10.6	5.55	3.53e-08	4.68e-06	0.22	0.17	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48340781	chr12:48350945~48442411:+
BRCA	cis	rs2732480	0.577	rs2634678	ENSG00000257735.1	RP11-370I10.6	5.55	3.53e-08	4.68e-06	0.22	0.17	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48341755	chr12:48350945~48442411:+
BRCA	cis	rs7178375	1	rs7178533	ENSG00000270015.1	RP11-540B6.6	5.55	3.53e-08	4.68e-06	0.21	0.17	Hypertriglyceridemia;	chr15:30923773	chr15:30926514~30928407:+
BRCA	cis	rs4908760	0.965	rs7542312	ENSG00000270282.1	RP5-1115A15.2	5.55	3.53e-08	4.68e-06	0.18	0.17	Vitiligo;	chr1:8513412	chr1:8512653~8513021:+
BRCA	cis	rs2489715	0.904	rs2489702	ENSG00000185904.10	LINC00839	-5.55	3.53e-08	4.69e-06	-0.24	-0.17	Helix rolling;	chr10:42398364	chr10:42475543~42495336:+
BRCA	cis	rs873549	1	rs873548	ENSG00000232679.1	RP11-400N13.3	5.55	3.53e-08	4.69e-06	0.2	0.17	Keloid;	chr1:222098598	chr1:222041705~222064763:-
BRCA	cis	rs7824557	0.628	rs7820301	ENSG00000154316.13	TDH	-5.55	3.53e-08	4.69e-06	-0.22	-0.17	Retinal vascular caliber;	chr8:11371163	chr8:11339637~11368452:+
BRCA	cis	rs2243480	1	rs7794661	ENSG00000164669.11	INTS4P1	5.55	3.53e-08	4.69e-06	0.32	0.17	Diabetic kidney disease;	chr7:65924743	chr7:65141225~65234216:+
BRCA	cis	rs67981189	0.896	rs12892739	ENSG00000258571.1	PTTG4P	-5.55	3.54e-08	4.69e-06	-0.19	-0.17	Schizophrenia;	chr14:70983891	chr14:71085482~71085833:-
BRCA	cis	rs11159086	0.793	rs12432412	ENSG00000270000.1	RP3-449M8.9	5.55	3.54e-08	4.7e-06	0.25	0.17	Advanced glycation end-product levels;	chr14:74474294	chr14:74471930~74472360:-
BRCA	cis	rs11159086	0.793	rs1029700	ENSG00000270000.1	RP3-449M8.9	5.55	3.54e-08	4.7e-06	0.25	0.17	Advanced glycation end-product levels;	chr14:74474309	chr14:74471930~74472360:-
BRCA	cis	rs11159086	0.793	rs1029699	ENSG00000270000.1	RP3-449M8.9	5.55	3.54e-08	4.7e-06	0.25	0.17	Advanced glycation end-product levels;	chr14:74474790	chr14:74471930~74472360:-
BRCA	cis	rs11955398	0.502	rs162251	ENSG00000215032.2	GNL3LP1	5.55	3.54e-08	4.7e-06	0.22	0.17	Intelligence (multi-trait analysis);	chr5:60996457	chr5:60891935~60893577:-
BRCA	cis	rs295490	0.748	rs1602626	ENSG00000272656.1	RP11-219D15.3	-5.55	3.54e-08	4.7e-06	-0.39	-0.17	PR interval in Tripanosoma cruzi seropositivity;	chr3:139364928	chr3:139349024~139349371:-
BRCA	cis	rs7620503	0.959	rs11708469	ENSG00000228221.4	LINC00578	5.55	3.54e-08	4.7e-06	0.2	0.17	Corneal structure;	chr3:177590930	chr3:177441921~177752305:+
BRCA	cis	rs11105298	0.891	rs11105287	ENSG00000270344.2	RP11-734K2.4	5.55	3.55e-08	4.7e-06	0.19	0.17	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89435693	chr12:89525654~89548005:+
BRCA	cis	rs4819052	0.851	rs35560973	ENSG00000184274.3	LINC00315	-5.55	3.55e-08	4.7e-06	-0.23	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45242658	chr21:45300245~45305257:-
BRCA	cis	rs944990	0.538	rs10115234	ENSG00000227603.1	RP11-165J3.6	-5.55	3.55e-08	4.71e-06	-0.17	-0.17	Body mass index;	chr9:93538990	chr9:93435332~93437121:-
BRCA	cis	rs2834188	0.924	rs2007849	ENSG00000272659.1	AP000295.10	-5.55	3.55e-08	4.71e-06	-0.25	-0.17	Narcolepsy;	chr21:33308811	chr21:33309491~33310181:+
BRCA	cis	rs8098244	0.737	rs1258152	ENSG00000264745.1	TTC39C-AS1	-5.55	3.55e-08	4.71e-06	-0.26	-0.17	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23948377	chr18:23994213~24015339:-
BRCA	cis	rs9545047	0.604	rs9318640	ENSG00000227354.5	RBM26-AS1	-5.55	3.55e-08	4.71e-06	-0.18	-0.17	Schizophrenia;	chr13:79426527	chr13:79406309~79424328:+
BRCA	cis	rs4834770	1	rs10034579	ENSG00000249244.1	RP11-548H18.2	5.55	3.55e-08	4.71e-06	0.19	0.17	Blood protein levels;	chr4:119322874	chr4:119391831~119395335:-
BRCA	cis	rs4908768	0.539	rs7547411	ENSG00000270282.1	RP5-1115A15.2	5.55	3.55e-08	4.71e-06	0.18	0.17	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8578086	chr1:8512653~8513021:+
BRCA	cis	rs4835473	0.932	rs4585249	ENSG00000249741.2	RP11-673E1.3	5.55	3.56e-08	4.72e-06	0.18	0.17	Immature fraction of reticulocytes;	chr4:143981173	chr4:143911514~143912053:-
BRCA	cis	rs7923609	1	rs7070296	ENSG00000232075.1	MRPL35P2	-5.55	3.56e-08	4.72e-06	-0.21	-0.17	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63310678	chr10:63634317~63634827:-
BRCA	cis	rs2348418	0.681	rs10771435	ENSG00000247934.4	RP11-967K21.1	5.55	3.56e-08	4.72e-06	0.19	0.17	Lung function (FEV1);Lung function (FVC);	chr12:28582769	chr12:28163298~28190738:-
BRCA	cis	rs1979679	0.918	rs2169755	ENSG00000278733.1	RP11-425D17.1	5.55	3.56e-08	4.72e-06	0.21	0.17	Ossification of the posterior longitudinal ligament of the spine;	chr12:28338224	chr12:28185625~28186190:-
BRCA	cis	rs2692947	0.759	rs2949885	ENSG00000237510.6	AC008268.2	5.55	3.56e-08	4.72e-06	0.23	0.17	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95996667	chr2:95789654~95800166:+
BRCA	cis	rs2235642	0.75	rs763152	ENSG00000260989.1	LA16c-395F10.2	-5.55	3.56e-08	4.72e-06	-0.18	-0.17	Coronary artery disease;	chr16:1608055	chr16:1580527~1610328:+
BRCA	cis	rs35849525	0.814	rs7635601	ENSG00000228008.1	CTD-2330K9.3	5.55	3.56e-08	4.72e-06	0.19	0.17	Intelligence (multi-trait analysis);	chr3:50006573	chr3:49903845~49916937:+
BRCA	cis	rs2638953	0.815	rs11049680	ENSG00000278733.1	RP11-425D17.1	-5.55	3.56e-08	4.72e-06	-0.22	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28508436	chr12:28185625~28186190:-
BRCA	cis	rs3213958	0.533	rs73140009	ENSG00000249274.1	PDLIM1P4	-5.55	3.57e-08	4.73e-06	-0.26	-0.17	Blood protein levels;	chr3:98907890	chr3:98782188~98783193:+
BRCA	cis	rs7302981	0.667	rs7136648	ENSG00000272368.2	RP4-605O3.4	5.55	3.57e-08	4.73e-06	0.18	0.17	Systolic blood pressure;	chr12:50231039	chr12:50112197~50165618:+
BRCA	cis	rs3740713	1	rs73440615	ENSG00000256464.1	YWHABP2	5.55	3.57e-08	4.73e-06	0.29	0.17	Amyotrophic lateral sclerosis (sporadic);	chr11:18445736	chr11:18490243~18490955:-
BRCA	cis	rs7927592	0.956	rs12365160	ENSG00000212093.1	AP000807.1	5.55	3.57e-08	4.74e-06	0.19	0.17	Total body bone mineral density;	chr11:68482951	chr11:68506083~68506166:-
BRCA	cis	rs7927592	0.956	rs11228256	ENSG00000212093.1	AP000807.1	5.55	3.57e-08	4.74e-06	0.19	0.17	Total body bone mineral density;	chr11:68483992	chr11:68506083~68506166:-
BRCA	cis	rs1552244	0.81	rs7612908	ENSG00000232901.1	CYCSP10	5.55	3.57e-08	4.74e-06	0.24	0.17	Alzheimer's disease;	chr3:10047464	chr3:10000647~10000940:-
BRCA	cis	rs1552244	0.81	rs6809572	ENSG00000232901.1	CYCSP10	5.55	3.57e-08	4.74e-06	0.24	0.17	Alzheimer's disease;	chr3:10058461	chr3:10000647~10000940:-
BRCA	cis	rs1552244	1	rs112847840	ENSG00000232901.1	CYCSP10	5.55	3.57e-08	4.74e-06	0.24	0.17	Alzheimer's disease;	chr3:10059968	chr3:10000647~10000940:-
BRCA	cis	rs1552244	1	rs722509	ENSG00000232901.1	CYCSP10	5.55	3.57e-08	4.74e-06	0.24	0.17	Alzheimer's disease;	chr3:10060693	chr3:10000647~10000940:-
BRCA	cis	rs2522056	0.808	rs1016988	ENSG00000233006.5	AC034220.3	-5.55	3.57e-08	4.74e-06	-0.15	-0.17	Fibrinogen;Lymphocyte counts;	chr5:132408882	chr5:132311285~132369916:-
BRCA	cis	rs55702914	0.809	rs6738721	ENSG00000231621.1	AC013264.2	5.55	3.58e-08	4.74e-06	0.17	0.17	Major depression and alcohol dependence;	chr2:197317610	chr2:197197991~197199273:+
BRCA	cis	rs1979679	0.918	rs786707	ENSG00000278733.1	RP11-425D17.1	5.55	3.58e-08	4.74e-06	0.22	0.17	Ossification of the posterior longitudinal ligament of the spine;	chr12:28420714	chr12:28185625~28186190:-
BRCA	cis	rs7474896	0.583	rs1735621	ENSG00000120555.12	SEPT7P9	-5.55	3.58e-08	4.74e-06	-0.24	-0.17	Obesity (extreme);	chr10:37878795	chr10:38383069~38402916:-
BRCA	cis	rs10888838	0.941	rs10888841	ENSG00000198711.5	SSBP3-AS1	5.55	3.58e-08	4.74e-06	0.22	0.17	Mitochondrial DNA levels;	chr1:54221392	chr1:54236440~54239063:+
BRCA	cis	rs6570726	0.791	rs1935612	ENSG00000270638.1	RP3-466P17.1	5.55	3.58e-08	4.75e-06	0.19	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145584954	chr6:145735570~145737218:+
BRCA	cis	rs4835473	0.897	rs2219912	ENSG00000249741.2	RP11-673E1.3	-5.55	3.58e-08	4.75e-06	-0.18	-0.17	Immature fraction of reticulocytes;	chr4:143707909	chr4:143911514~143912053:-
BRCA	cis	rs7308116	0.546	rs6539370	ENSG00000274395.1	RP11-554D14.8	5.55	3.58e-08	4.75e-06	0.2	0.17	Pelvic organ prolapse (moderate/severe);	chr12:107836051	chr12:107835541~107836555:-
BRCA	cis	rs2179367	0.632	rs9498325	ENSG00000223701.3	RAET1E-AS1	5.55	3.59e-08	4.75e-06	0.24	0.17	Dupuytren's disease;	chr6:149345993	chr6:149884431~149919508:+
BRCA	cis	rs2179367	0.632	rs9498326	ENSG00000223701.3	RAET1E-AS1	5.55	3.59e-08	4.75e-06	0.24	0.17	Dupuytren's disease;	chr6:149346112	chr6:149884431~149919508:+
BRCA	cis	rs9341808	0.718	rs11962614	ENSG00000272129.1	RP11-250B2.6	5.55	3.59e-08	4.76e-06	0.22	0.17	Sitting height ratio;	chr6:80113589	chr6:80355424~80356859:+
BRCA	cis	rs9341808	0.718	rs12208016	ENSG00000272129.1	RP11-250B2.6	5.55	3.59e-08	4.76e-06	0.22	0.17	Sitting height ratio;	chr6:80113846	chr6:80355424~80356859:+
BRCA	cis	rs9341808	0.718	rs9448886	ENSG00000272129.1	RP11-250B2.6	5.55	3.59e-08	4.76e-06	0.22	0.17	Sitting height ratio;	chr6:80116184	chr6:80355424~80356859:+
BRCA	cis	rs9341808	0.683	rs9359409	ENSG00000272129.1	RP11-250B2.6	5.55	3.59e-08	4.76e-06	0.22	0.17	Sitting height ratio;	chr6:80117180	chr6:80355424~80356859:+
BRCA	cis	rs9309473	0.607	rs7573719	ENSG00000163016.8	ALMS1P	5.55	3.59e-08	4.76e-06	0.2	0.17	Metabolite levels;	chr2:73355858	chr2:73644919~73685576:+
BRCA	cis	rs34286592	1	rs4787480	ENSG00000214725.6	CDIPT-AS1	-5.55	3.59e-08	4.76e-06	-0.28	-0.17	Multiple sclerosis;	chr16:29845995	chr16:29863593~29868053:+
BRCA	cis	rs10129255	0.5	rs7161740	ENSG00000224373.3	IGHV4-59	5.55	3.59e-08	4.76e-06	0.1	0.17	Kawasaki disease;	chr14:106776119	chr14:106627249~106627825:-
BRCA	cis	rs1555322	0.53	rs2297789	ENSG00000269202.1	RP4-614O4.12	-5.55	3.59e-08	4.76e-06	-0.2	-0.17	Attention deficit hyperactivity disorder;	chr20:35279445	chr20:35201747~35203288:-
BRCA	cis	rs11742741	0.579	rs13184473	ENSG00000248874.4	C5orf17	-5.55	3.59e-08	4.76e-06	-0.22	-0.17	Educational attainment;	chr5:24110968	chr5:23951348~24178263:+
BRCA	cis	rs12712135	0.709	rs11465729	ENSG00000234389.1	AC007278.3	-5.55	3.59e-08	4.76e-06	-0.15	-0.17	Blood protein levels;	chr2:102448052	chr2:102438713~102440475:+
BRCA	cis	rs597539	0.652	rs668576	ENSG00000261625.1	RP11-554A11.4	-5.55	3.59e-08	4.76e-06	-0.17	-0.17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68900740	chr11:69000765~69002048:-
BRCA	cis	rs597539	0.652	rs482172	ENSG00000261625.1	RP11-554A11.4	-5.55	3.59e-08	4.76e-06	-0.17	-0.17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68900969	chr11:69000765~69002048:-
BRCA	cis	rs7927592	0.913	rs4084149	ENSG00000212093.1	AP000807.1	5.55	3.59e-08	4.76e-06	0.2	0.17	Total body bone mineral density;	chr11:68521099	chr11:68506083~68506166:-
BRCA	cis	rs62025270	0.632	rs78572940	ENSG00000202081.1	RNU6-1280P	-5.55	3.6e-08	4.77e-06	-0.25	-0.17	Idiopathic pulmonary fibrosis;	chr15:85696539	chr15:85651522~85651628:-
BRCA	cis	rs10788972	0.873	rs4926619	ENSG00000225183.1	RP4-758J24.4	-5.55	3.6e-08	4.77e-06	-0.21	-0.17	Parkinson disease and lewy body pathology;	chr1:54092428	chr1:54089856~54090093:+
BRCA	cis	rs9840812	0.623	rs1145106	ENSG00000273486.1	RP11-731C17.2	5.55	3.6e-08	4.77e-06	0.2	0.17	Fibrinogen levels;	chr3:136393075	chr3:136837338~136839021:-
BRCA	cis	rs1075265	0.584	rs1862122	ENSG00000235937.1	AC008280.1	-5.55	3.6e-08	4.77e-06	-0.19	-0.17	Chronotype;Morning vs. evening chronotype;	chr2:54052992	chr2:54029552~54030682:-
BRCA	cis	rs6142102	0.812	rs6059574	ENSG00000275784.1	RP5-1125A11.6	5.55	3.6e-08	4.77e-06	0.2	0.17	Skin pigmentation;	chr20:33935366	chr20:33989480~33991818:-
BRCA	cis	rs4835473	0.897	rs55945293	ENSG00000249741.2	RP11-673E1.3	5.55	3.6e-08	4.77e-06	0.18	0.17	Immature fraction of reticulocytes;	chr4:143704766	chr4:143911514~143912053:-
BRCA	cis	rs5758511	0.68	rs1001586	ENSG00000233903.2	Z83851.4	5.55	3.6e-08	4.77e-06	0.26	0.17	Birth weight;	chr22:42274287	chr22:42276355~42277052:+
BRCA	cis	rs2243480	1	rs465359	ENSG00000228409.4	CCT6P1	5.55	3.6e-08	4.78e-06	0.24	0.17	Diabetic kidney disease;	chr7:66093177	chr7:65751142~65763354:+
BRCA	cis	rs2243480	1	rs462853	ENSG00000228409.4	CCT6P1	5.55	3.6e-08	4.78e-06	0.24	0.17	Diabetic kidney disease;	chr7:66093180	chr7:65751142~65763354:+
BRCA	cis	rs2243480	1	rs160644	ENSG00000228409.4	CCT6P1	5.55	3.6e-08	4.78e-06	0.24	0.17	Diabetic kidney disease;	chr7:66093199	chr7:65751142~65763354:+
BRCA	cis	rs2243480	1	rs160642	ENSG00000228409.4	CCT6P1	5.55	3.6e-08	4.78e-06	0.24	0.17	Diabetic kidney disease;	chr7:66093386	chr7:65751142~65763354:+
BRCA	cis	rs2243480	0.614	rs34032527	ENSG00000228409.4	CCT6P1	5.55	3.6e-08	4.78e-06	0.24	0.17	Diabetic kidney disease;	chr7:66100154	chr7:65751142~65763354:+
BRCA	cis	rs9311474	0.581	rs13621	ENSG00000243224.1	RP5-1157M23.2	-5.55	3.61e-08	4.78e-06	-0.18	-0.17	Electroencephalogram traits;	chr3:52524117	chr3:52239258~52241097:+
BRCA	cis	rs9341808	0.718	rs9443734	ENSG00000272129.1	RP11-250B2.6	5.55	3.61e-08	4.78e-06	0.22	0.17	Sitting height ratio;	chr6:80110576	chr6:80355424~80356859:+
BRCA	cis	rs73222236	0.794	rs60614489	ENSG00000273486.1	RP11-731C17.2	5.55	3.61e-08	4.78e-06	0.19	0.17	Coronary artery disease;	chr3:136268136	chr3:136837338~136839021:-
BRCA	cis	rs11742741	0.539	rs34635633	ENSG00000248874.4	C5orf17	-5.55	3.61e-08	4.78e-06	-0.22	-0.17	Educational attainment;	chr5:24105391	chr5:23951348~24178263:+
BRCA	cis	rs2303759	0.709	rs8102574	ENSG00000268686.1	AC010524.2	-5.55	3.61e-08	4.78e-06	-0.27	-0.17	Multiple sclerosis;	chr19:49325640	chr19:49368705~49388081:-
BRCA	cis	rs11722779	0.844	rs223345	ENSG00000251288.2	RP11-10L12.2	-5.55	3.61e-08	4.79e-06	-0.2	-0.17	Schizophrenia;	chr4:102859366	chr4:102751401~102752641:+
BRCA	cis	rs11722779	0.873	rs223344	ENSG00000251288.2	RP11-10L12.2	-5.55	3.61e-08	4.79e-06	-0.2	-0.17	Schizophrenia;	chr4:102859765	chr4:102751401~102752641:+
BRCA	cis	rs3213958	0.574	rs10935518	ENSG00000249274.1	PDLIM1P4	-5.55	3.61e-08	4.79e-06	-0.26	-0.17	Blood protein levels;	chr3:98896767	chr3:98782188~98783193:+
BRCA	cis	rs5758511	0.68	rs739147	ENSG00000233903.2	Z83851.4	5.55	3.61e-08	4.79e-06	0.26	0.17	Birth weight;	chr22:42275060	chr22:42276355~42277052:+
BRCA	cis	rs4907240	0.77	rs4907236	ENSG00000237510.6	AC008268.2	-5.55	3.62e-08	4.79e-06	-0.23	-0.17	Event-related brain oscillations;	chr2:96521868	chr2:95789654~95800166:+
BRCA	cis	rs4819052	0.808	rs2246697	ENSG00000184274.3	LINC00315	-5.55	3.62e-08	4.79e-06	-0.23	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45270084	chr21:45300245~45305257:-
BRCA	cis	rs4819052	0.819	rs7279136	ENSG00000184274.3	LINC00315	-5.55	3.62e-08	4.79e-06	-0.23	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45272372	chr21:45300245~45305257:-
BRCA	cis	rs4819052	0.788	rs4819051	ENSG00000184274.3	LINC00315	-5.55	3.62e-08	4.79e-06	-0.23	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45273213	chr21:45300245~45305257:-
BRCA	cis	rs4819052	0.819	rs8134084	ENSG00000184274.3	LINC00315	-5.55	3.62e-08	4.79e-06	-0.23	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45273380	chr21:45300245~45305257:-
BRCA	cis	rs4819052	0.851	rs7276828	ENSG00000184274.3	LINC00315	-5.55	3.62e-08	4.79e-06	-0.23	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45275124	chr21:45300245~45305257:-
BRCA	cis	rs4819052	0.851	rs7281263	ENSG00000184274.3	LINC00315	-5.55	3.62e-08	4.79e-06	-0.23	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45275691	chr21:45300245~45305257:-
BRCA	cis	rs4819052	0.851	rs914214	ENSG00000184274.3	LINC00315	-5.55	3.62e-08	4.79e-06	-0.23	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45277905	chr21:45300245~45305257:-
BRCA	cis	rs74233809	0.551	rs3740393	ENSG00000213277.3	MARCKSL1P1	5.55	3.62e-08	4.79e-06	0.26	0.17	Birth weight;	chr10:102876898	chr10:103175554~103176094:+
BRCA	cis	rs4700393	0.967	rs921897	ENSG00000272308.1	RP11-231G3.1	-5.55	3.62e-08	4.79e-06	-0.19	-0.17	Intelligence (multi-trait analysis);	chr5:60793310	chr5:60866457~60866935:-
BRCA	cis	rs2243480	0.803	rs34804747	ENSG00000232546.1	RP11-458F8.1	-5.55	3.62e-08	4.8e-06	-0.22	-0.17	Diabetic kidney disease;	chr7:65947955	chr7:66848496~66858136:+
BRCA	cis	rs2243480	1	rs59794892	ENSG00000232546.1	RP11-458F8.1	-5.55	3.62e-08	4.8e-06	-0.22	-0.17	Diabetic kidney disease;	chr7:65950886	chr7:66848496~66858136:+
BRCA	cis	rs2243480	0.803	rs36004293	ENSG00000232546.1	RP11-458F8.1	-5.55	3.62e-08	4.8e-06	-0.22	-0.17	Diabetic kidney disease;	chr7:65951525	chr7:66848496~66858136:+
BRCA	cis	rs2243480	0.803	rs35268390	ENSG00000232546.1	RP11-458F8.1	-5.55	3.62e-08	4.8e-06	-0.22	-0.17	Diabetic kidney disease;	chr7:65951549	chr7:66848496~66858136:+
BRCA	cis	rs7618501	0.633	rs13060128	ENSG00000228008.1	CTD-2330K9.3	5.55	3.62e-08	4.8e-06	0.17	0.17	Intelligence (multi-trait analysis);	chr3:49987595	chr3:49903845~49916937:+
BRCA	cis	rs61160187	0.51	rs10076679	ENSG00000272308.1	RP11-231G3.1	-5.55	3.63e-08	4.8e-06	-0.19	-0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:60795124	chr5:60866457~60866935:-
BRCA	cis	rs61160187	0.527	rs10076742	ENSG00000272308.1	RP11-231G3.1	-5.55	3.63e-08	4.8e-06	-0.19	-0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:60795219	chr5:60866457~60866935:-
BRCA	cis	rs61160187	0.527	rs6890201	ENSG00000272308.1	RP11-231G3.1	-5.55	3.63e-08	4.8e-06	-0.19	-0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:60795365	chr5:60866457~60866935:-
BRCA	cis	rs61160187	0.51	rs6875456	ENSG00000272308.1	RP11-231G3.1	-5.55	3.63e-08	4.8e-06	-0.19	-0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:60795503	chr5:60866457~60866935:-
BRCA	cis	rs61160187	0.51	rs6894750	ENSG00000272308.1	RP11-231G3.1	-5.55	3.63e-08	4.8e-06	-0.19	-0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:60795729	chr5:60866457~60866935:-
BRCA	cis	rs59169624	0.699	rs7102551	ENSG00000255160.4	RP11-428C19.5	5.55	3.63e-08	4.8e-06	0.23	0.17	Parental extreme longevity (95 years and older);	chr11:19277873	chr11:19299883~19308358:+
BRCA	cis	rs577676	0.586	rs12031871	ENSG00000271811.1	RP1-79C4.4	5.55	3.63e-08	4.8e-06	0.19	0.17	Prevalent atrial fibrillation;	chr1:170621426	chr1:170667381~170669425:+
BRCA	cis	rs10510102	0.872	rs12246693	ENSG00000226864.1	ATE1-AS1	5.55	3.63e-08	4.81e-06	0.31	0.17	Breast cancer;	chr10:121957373	chr10:121928312~121951965:+
BRCA	cis	rs10510102	0.872	rs12248806	ENSG00000226864.1	ATE1-AS1	5.55	3.63e-08	4.81e-06	0.31	0.17	Breast cancer;	chr10:121958638	chr10:121928312~121951965:+
BRCA	cis	rs10510102	0.872	rs12255832	ENSG00000226864.1	ATE1-AS1	5.55	3.63e-08	4.81e-06	0.31	0.17	Breast cancer;	chr10:121958762	chr10:121928312~121951965:+
BRCA	cis	rs11148252	0.74	rs7981050	ENSG00000278238.1	RP11-245D16.4	-5.55	3.63e-08	4.81e-06	-0.18	-0.17	Lewy body disease;	chr13:52181014	chr13:52454775~52455331:-
BRCA	cis	rs2638953	0.925	rs11049549	ENSG00000278733.1	RP11-425D17.1	-5.55	3.63e-08	4.81e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28357808	chr12:28185625~28186190:-
BRCA	cis	rs7044106	0.762	rs966396	ENSG00000238181.2	AHCYP2	-5.55	3.63e-08	4.81e-06	-0.22	-0.17	Hip circumference adjusted for BMI;	chr9:120691003	chr9:120720673~120721972:+
BRCA	cis	rs56104184	0.723	rs116909499	ENSG00000235191.1	NUCB1-AS1	5.55	3.64e-08	4.81e-06	0.3	0.17	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr19:48904476	chr19:48910930~48918891:-
BRCA	cis	rs56104184	0.723	rs73063522	ENSG00000235191.1	NUCB1-AS1	5.55	3.64e-08	4.81e-06	0.3	0.17	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr19:48905101	chr19:48910930~48918891:-
BRCA	cis	rs56104184	0.723	rs73063524	ENSG00000235191.1	NUCB1-AS1	5.55	3.64e-08	4.81e-06	0.3	0.17	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr19:48905747	chr19:48910930~48918891:-
BRCA	cis	rs1598856	0.932	rs230530	ENSG00000246560.2	RP11-10L12.4	-5.55	3.64e-08	4.81e-06	-0.19	-0.17	Primary biliary cholangitis;	chr4:102532823	chr4:102828055~102844075:+
BRCA	cis	rs17507216	0.591	rs7163848	ENSG00000255769.6	GOLGA2P10	-5.55	3.64e-08	4.81e-06	-0.25	-0.17	Excessive daytime sleepiness;	chr15:82729563	chr15:82472993~82513950:-
BRCA	cis	rs1850744	1	rs1850744	ENSG00000163612.10	FAM86KP	-5.55	3.64e-08	4.81e-06	-0.41	-0.17	Economic and political preferences;	chr4:9789088	chr4:9153296~9165451:+
BRCA	cis	rs9308731	0.644	rs1837366	ENSG00000227992.1	AC108463.2	-5.55	3.64e-08	4.81e-06	-0.2	-0.17	Chronic lymphocytic leukemia;	chr2:111117052	chr2:111203964~111206215:-
BRCA	cis	rs673078	0.66	rs61945183	ENSG00000275409.1	RP11-131L12.4	-5.55	3.64e-08	4.82e-06	-0.26	-0.17	Glucose homeostasis traits;	chr12:118221966	chr12:118430147~118430699:+
BRCA	cis	rs2303319	1	rs16845807	ENSG00000227403.1	AC009299.3	5.55	3.64e-08	4.82e-06	0.43	0.17	Cognitive function;	chr2:161390888	chr2:161244739~161249050:+
BRCA	cis	rs17772222	0.682	rs8017689	ENSG00000258789.1	RP11-507K2.3	-5.55	3.64e-08	4.82e-06	-0.19	-0.17	Coronary artery calcification;	chr14:88483442	chr14:88551597~88552493:+
BRCA	cis	rs523522	0.923	rs10774553	ENSG00000278344.1	RP11-18C24.8	5.55	3.64e-08	4.82e-06	0.23	0.17	High light scatter reticulocyte count;	chr12:120517181	chr12:120500735~120501090:-
BRCA	cis	rs523522	0.962	rs11065149	ENSG00000278344.1	RP11-18C24.8	5.55	3.64e-08	4.82e-06	0.23	0.17	High light scatter reticulocyte count;	chr12:120519160	chr12:120500735~120501090:-
BRCA	cis	rs9341808	0.718	rs12203867	ENSG00000272129.1	RP11-250B2.6	5.55	3.64e-08	4.82e-06	0.22	0.17	Sitting height ratio;	chr6:80111116	chr6:80355424~80356859:+
BRCA	cis	rs755249	0.545	rs12037073	ENSG00000182109.6	RP11-69E11.4	-5.55	3.64e-08	4.82e-06	-0.19	-0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39581225	chr1:39522280~39546187:-
BRCA	cis	rs2255336	0.578	rs7980379	ENSG00000245648.1	RP11-277P12.20	5.55	3.64e-08	4.82e-06	0.26	0.17	Blood protein levels;	chr12:10367591	chr12:10363769~10398506:+
BRCA	cis	rs7829975	0.56	rs17154599	ENSG00000254153.1	CTA-398F10.2	-5.55	3.65e-08	4.82e-06	-0.21	-0.17	Mood instability;	chr8:8693908	chr8:8456909~8461337:-
BRCA	cis	rs736408	0.561	rs2276815	ENSG00000242142.1	SERBP1P3	5.55	3.65e-08	4.83e-06	0.21	0.17	Bipolar disorder;	chr3:52819731	chr3:53064283~53065091:-
BRCA	cis	rs801193	0.569	rs4717315	ENSG00000224316.1	RP11-479O9.2	5.55	3.65e-08	4.83e-06	0.17	0.17	Aortic root size;	chr7:66713338	chr7:65773620~65802067:+
BRCA	cis	rs42648	0.564	rs6465244	ENSG00000225498.1	AC002064.5	5.55	3.65e-08	4.83e-06	0.16	0.17	Homocysteine levels;	chr7:90191568	chr7:90312496~90322592:+
BRCA	cis	rs30380	0.632	rs26496	ENSG00000272109.1	CTD-2260A17.3	-5.55	3.65e-08	4.83e-06	-0.24	-0.17	Cerebrospinal fluid biomarker levels;	chr5:96802179	chr5:96804353~96806105:+
BRCA	cis	rs4950322	0.57	rs4950400	ENSG00000244371.2	PFN1P8	5.55	3.65e-08	4.83e-06	0.24	0.17	Protein quantitative trait loci;	chr1:147319383	chr1:146957117~146957659:-
BRCA	cis	rs2836950	0.501	rs2836984	ENSG00000255568.3	BRWD1-AS2	-5.55	3.66e-08	4.84e-06	-0.16	-0.17	Menarche (age at onset);	chr21:39329023	chr21:39313935~39314962:+
BRCA	cis	rs2274273	0.686	rs66531545	ENSG00000258413.1	RP11-665C16.6	-5.55	3.66e-08	4.84e-06	-0.23	-0.17	Protein biomarker;	chr14:55120742	chr14:55262767~55272075:-
BRCA	cis	rs10129255	0.957	rs7493713	ENSG00000224373.3	IGHV4-59	5.55	3.66e-08	4.84e-06	0.1	0.17	Kawasaki disease;	chr14:106783685	chr14:106627249~106627825:-
BRCA	cis	rs10129255	0.912	rs35468694	ENSG00000224373.3	IGHV4-59	5.55	3.66e-08	4.84e-06	0.1	0.17	Kawasaki disease;	chr14:106784199	chr14:106627249~106627825:-
BRCA	cis	rs853679	0.55	rs1237875	ENSG00000280107.1	AL022393.9	5.55	3.66e-08	4.84e-06	0.24	0.17	Depression;	chr6:28205232	chr6:28170845~28172521:+
BRCA	cis	rs9840812	0.728	rs12630999	ENSG00000239213.4	NCK1-AS1	5.55	3.66e-08	4.85e-06	0.21	0.17	Fibrinogen levels;	chr3:136582085	chr3:136841726~136862054:-
BRCA	cis	rs2898681	0.581	rs731073	ENSG00000248375.1	RP11-177B4.1	-5.55	3.66e-08	4.85e-06	-0.23	-0.17	Optic nerve measurement (cup area);	chr4:52813923	chr4:52720081~52720831:-
BRCA	cis	rs1440410	0.536	rs13137565	ENSG00000250326.1	RP11-284M14.1	-5.55	3.67e-08	4.85e-06	-0.2	-0.17	Ischemic stroke;	chr4:143184545	chr4:142933195~143184861:-
BRCA	cis	rs2243480	1	rs410128	ENSG00000229886.1	RP5-1132H15.3	5.55	3.67e-08	4.85e-06	0.31	0.17	Diabetic kidney disease;	chr7:66138186	chr7:66025126~66031544:-
BRCA	cis	rs7615952	0.558	rs17334039	ENSG00000171084.14	FAM86JP	5.55	3.67e-08	4.85e-06	0.26	0.17	Blood pressure (smoking interaction);	chr3:125821465	chr3:125916620~125930024:+
BRCA	cis	rs9467773	1	rs9467783	ENSG00000124549.13	BTN2A3P	5.55	3.67e-08	4.85e-06	0.17	0.17	Intelligence (multi-trait analysis);	chr6:26542666	chr6:26421391~26432383:+
BRCA	cis	rs1707322	0.716	rs10890342	ENSG00000234329.1	RP11-767N6.2	5.55	3.67e-08	4.85e-06	0.18	0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45691415	chr1:45651039~45651826:-
BRCA	cis	rs1707322	0.752	rs6658700	ENSG00000234329.1	RP11-767N6.2	5.55	3.67e-08	4.85e-06	0.18	0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45694588	chr1:45651039~45651826:-
BRCA	cis	rs1707322	0.752	rs12047629	ENSG00000234329.1	RP11-767N6.2	5.55	3.67e-08	4.85e-06	0.18	0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45697130	chr1:45651039~45651826:-
BRCA	cis	rs1707322	0.752	rs11211171	ENSG00000234329.1	RP11-767N6.2	5.55	3.67e-08	4.85e-06	0.18	0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45702970	chr1:45651039~45651826:-
BRCA	cis	rs1707322	0.752	rs28623463	ENSG00000234329.1	RP11-767N6.2	5.55	3.67e-08	4.85e-06	0.18	0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45705086	chr1:45651039~45651826:-
BRCA	cis	rs1707322	0.716	rs28370457	ENSG00000234329.1	RP11-767N6.2	5.55	3.67e-08	4.85e-06	0.18	0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45706390	chr1:45651039~45651826:-
BRCA	cis	rs1075265	0.655	rs13432632	ENSG00000235937.1	AC008280.1	5.55	3.67e-08	4.85e-06	0.19	0.17	Chronotype;Morning vs. evening chronotype;	chr2:53713586	chr2:54029552~54030682:-
BRCA	cis	rs863750	0.687	rs825482	ENSG00000275389.1	RP11-214K3.24	-5.55	3.67e-08	4.85e-06	-0.21	-0.17	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-hip ratio;	chr12:124091069	chr12:124085761~124088598:+
BRCA	cis	rs13118159	0.55	rs4974614	ENSG00000254094.1	AC078852.1	-5.55	3.67e-08	4.86e-06	-0.21	-0.17	Longevity;	chr4:1379701	chr4:1356581~1358075:+
BRCA	cis	rs1707322	0.655	rs3014240	ENSG00000234329.1	RP11-767N6.2	-5.55	3.67e-08	4.86e-06	-0.18	-0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45623553	chr1:45651039~45651826:-
BRCA	cis	rs9311474	0.629	rs7636227	ENSG00000243224.1	RP5-1157M23.2	-5.55	3.68e-08	4.86e-06	-0.18	-0.17	Electroencephalogram traits;	chr3:52532666	chr3:52239258~52241097:+
BRCA	cis	rs1552244	1	rs17032283	ENSG00000180385.7	EMC3-AS1	5.55	3.68e-08	4.87e-06	0.21	0.17	Alzheimer's disease;	chr3:10039861	chr3:9986893~10006990:+
BRCA	cis	rs4664293	0.51	rs890096	ENSG00000226266.5	AC009961.3	5.55	3.68e-08	4.87e-06	0.21	0.17	Monocyte percentage of white cells;	chr2:159604849	chr2:159670708~159712435:-
BRCA	cis	rs17597773	0.674	rs12117818	ENSG00000272823.1	RP11-295M18.6	-5.55	3.68e-08	4.87e-06	-0.21	-0.17	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220828141	chr1:220828676~220829211:-
BRCA	cis	rs673078	0.66	rs17512177	ENSG00000275409.1	RP11-131L12.4	-5.55	3.69e-08	4.87e-06	-0.26	-0.17	Glucose homeostasis traits;	chr12:118192335	chr12:118430147~118430699:+
BRCA	cis	rs673078	0.66	rs17512198	ENSG00000275409.1	RP11-131L12.4	-5.55	3.69e-08	4.87e-06	-0.26	-0.17	Glucose homeostasis traits;	chr12:118194217	chr12:118430147~118430699:+
BRCA	cis	rs745109	0.504	rs76654460	ENSG00000273080.1	RP11-301O19.1	5.55	3.69e-08	4.87e-06	0.27	0.17	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86378757	chr2:86195590~86196049:+
BRCA	cis	rs4834770	0.668	rs6833072	ENSG00000178636.7	RP11-455G16.1	5.55	3.69e-08	4.88e-06	0.21	0.17	Blood protein levels;	chr4:119212737	chr4:119192773~119212644:-
BRCA	cis	rs523522	0.962	rs55848094	ENSG00000278344.1	RP11-18C24.8	5.55	3.69e-08	4.88e-06	0.23	0.17	High light scatter reticulocyte count;	chr12:120528856	chr12:120500735~120501090:-
BRCA	cis	rs523522	0.962	rs3742052	ENSG00000278344.1	RP11-18C24.8	5.55	3.69e-08	4.88e-06	0.23	0.17	High light scatter reticulocyte count;	chr12:120529118	chr12:120500735~120501090:-
BRCA	cis	rs523522	0.962	rs10849758	ENSG00000278344.1	RP11-18C24.8	5.55	3.69e-08	4.88e-06	0.23	0.17	High light scatter reticulocyte count;	chr12:120533346	chr12:120500735~120501090:-
BRCA	cis	rs997295	0.592	rs12594849	ENSG00000270964.1	RP11-502I4.3	-5.55	3.69e-08	4.88e-06	-0.19	-0.17	Motion sickness;	chr15:67424234	chr15:67541072~67542604:-
BRCA	cis	rs10129255	0.53	rs11624912	ENSG00000224373.3	IGHV4-59	5.55	3.69e-08	4.88e-06	0.1	0.17	Kawasaki disease;	chr14:106673891	chr14:106627249~106627825:-
BRCA	cis	rs1005277	0.579	rs1621040	ENSG00000263064.2	RP11-291L22.7	5.55	3.7e-08	4.89e-06	0.21	0.17	Extrinsic epigenetic age acceleration;	chr10:38208304	chr10:38448689~38448949:+
BRCA	cis	rs7474896	0.515	rs594594	ENSG00000120555.12	SEPT7P9	-5.55	3.7e-08	4.89e-06	-0.24	-0.17	Obesity (extreme);	chr10:38018795	chr10:38383069~38402916:-
BRCA	cis	rs863750	0.687	rs825461	ENSG00000275389.1	RP11-214K3.24	-5.55	3.7e-08	4.89e-06	-0.22	-0.17	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-hip ratio;	chr12:124077256	chr12:124085761~124088598:+
BRCA	cis	rs7577696	0.888	rs494569	ENSG00000272716.1	RP11-563N4.1	5.55	3.7e-08	4.89e-06	0.19	0.17	Inflammatory biomarkers;	chr2:32244553	chr2:32165046~32165757:-
BRCA	cis	rs4853525	0.59	rs1921910	ENSG00000235852.1	AC005540.3	5.55	3.7e-08	4.9e-06	0.21	0.17	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190859206	chr2:190880797~190882059:-
BRCA	cis	rs228614	0.534	rs223387	ENSG00000251288.2	RP11-10L12.2	-5.55	3.71e-08	4.9e-06	-0.2	-0.17	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102828359	chr4:102751401~102752641:+
BRCA	cis	rs17213965	0.561	rs9929598	ENSG00000207425.1	Y_RNA	-5.55	3.71e-08	4.9e-06	-0.22	-0.17	Waist-hip ratio;	chr16:15786153	chr16:14915457~14915556:-
BRCA	cis	rs7308116	0.546	rs1895925	ENSG00000274395.1	RP11-554D14.8	-5.55	3.71e-08	4.91e-06	-0.2	-0.17	Pelvic organ prolapse (moderate/severe);	chr12:107833992	chr12:107835541~107836555:-
BRCA	cis	rs3733585	0.699	rs7683283	ENSG00000250413.1	RP11-448G15.1	5.55	3.72e-08	4.91e-06	0.22	0.17	Cleft plate (environmental tobacco smoke interaction);	chr4:9968350	chr4:10006482~10009725:+
BRCA	cis	rs4650994	0.525	rs2493865	ENSG00000273384.1	RP5-1098D14.1	-5.55	3.72e-08	4.91e-06	-0.21	-0.17	HDL cholesterol;HDL cholesterol levels;	chr1:178575881	chr1:178651706~178652282:+
BRCA	cis	rs56322409	0.686	rs1409709	ENSG00000226688.5	ENTPD1-AS1	5.55	3.72e-08	4.91e-06	0.18	0.17	Blood metabolite levels;	chr10:95612802	chr10:95753206~96090238:-
BRCA	cis	rs7045881	0.674	rs3429	ENSG00000254396.1	RP11-56F10.3	5.55	3.72e-08	4.92e-06	0.29	0.17	Schizophrenia;	chr9:27062723	chr9:27102630~27104728:+
BRCA	cis	rs1707322	0.717	rs12023439	ENSG00000234329.1	RP11-767N6.2	5.55	3.72e-08	4.92e-06	0.18	0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45638964	chr1:45651039~45651826:-
BRCA	cis	rs9341808	0.718	rs9448893	ENSG00000272129.1	RP11-250B2.6	5.55	3.72e-08	4.92e-06	0.21	0.17	Sitting height ratio;	chr6:80127522	chr6:80355424~80356859:+
BRCA	cis	rs7923837	0.651	rs10882085	ENSG00000236493.2	EIF2S2P3	5.55	3.72e-08	4.92e-06	0.24	0.17	Multiple sclerosis;Body mass index;	chr10:92605125	chr10:92668745~92669743:-
BRCA	cis	rs2638953	0.924	rs11049600	ENSG00000278733.1	RP11-425D17.1	-5.55	3.72e-08	4.92e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28439061	chr12:28185625~28186190:-
BRCA	cis	rs4664293	0.631	rs13019272	ENSG00000226266.5	AC009961.3	-5.55	3.72e-08	4.92e-06	-0.21	-0.17	Monocyte percentage of white cells;	chr2:159802352	chr2:159670708~159712435:-
BRCA	cis	rs67981189	0.896	rs2158997	ENSG00000258571.1	PTTG4P	5.54	3.73e-08	4.92e-06	0.18	0.17	Schizophrenia;	chr14:71031077	chr14:71085482~71085833:-
BRCA	cis	rs2098713	0.537	rs13163168	ENSG00000250155.1	CTD-2353F22.1	-5.54	3.73e-08	4.92e-06	-0.2	-0.17	Telomere length;	chr5:37487015	chr5:36666214~36725195:-
BRCA	cis	rs338389	0.586	rs338387	ENSG00000260657.2	RP11-315D16.4	5.54	3.73e-08	4.93e-06	0.21	0.17	Survival in rectal cancer;	chr15:67968644	chr15:68267792~68277994:-
BRCA	cis	rs6832769	1	rs6812042	ENSG00000223305.1	RN7SKP30	5.54	3.73e-08	4.93e-06	0.22	0.17	Personality dimensions;	chr4:55529912	chr4:55540502~55540835:-
BRCA	cis	rs7923837	0.65	rs10882098	ENSG00000236493.2	EIF2S2P3	5.54	3.73e-08	4.93e-06	0.23	0.17	Multiple sclerosis;Body mass index;	chr10:92685036	chr10:92668745~92669743:-
BRCA	cis	rs10740039	0.516	rs7088259	ENSG00000254271.1	RP11-131N11.4	5.54	3.73e-08	4.93e-06	0.23	0.17	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60559094	chr10:60734342~60741828:+
BRCA	cis	rs7923609	1	rs4400684	ENSG00000232075.1	MRPL35P2	-5.54	3.73e-08	4.93e-06	-0.21	-0.17	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63252927	chr10:63634317~63634827:-
BRCA	cis	rs7923609	0.967	rs4454603	ENSG00000232075.1	MRPL35P2	-5.54	3.73e-08	4.93e-06	-0.21	-0.17	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63252990	chr10:63634317~63634827:-
BRCA	cis	rs7923609	1	rs4595427	ENSG00000232075.1	MRPL35P2	-5.54	3.73e-08	4.93e-06	-0.21	-0.17	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63253184	chr10:63634317~63634827:-
BRCA	cis	rs7923609	0.936	rs4405189	ENSG00000232075.1	MRPL35P2	-5.54	3.73e-08	4.93e-06	-0.21	-0.17	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63254175	chr10:63634317~63634827:-
BRCA	cis	rs10129255	0.719	rs7156660	ENSG00000280411.1	IGHV1-69-2	-5.54	3.73e-08	4.93e-06	-0.12	-0.17	Kawasaki disease;	chr14:106673171	chr14:106762092~106762588:-
BRCA	cis	rs9341808	0.718	rs10080237	ENSG00000272129.1	RP11-250B2.6	5.54	3.74e-08	4.93e-06	0.21	0.17	Sitting height ratio;	chr6:80144753	chr6:80355424~80356859:+
BRCA	cis	rs7615952	0.599	rs16834938	ENSG00000171084.14	FAM86JP	5.54	3.74e-08	4.94e-06	0.25	0.17	Blood pressure (smoking interaction);	chr3:125987203	chr3:125916620~125930024:+
BRCA	cis	rs7308116	0.51	rs1895931	ENSG00000274395.1	RP11-554D14.8	-5.54	3.74e-08	4.94e-06	-0.2	-0.17	Pelvic organ prolapse (moderate/severe);	chr12:107823359	chr12:107835541~107836555:-
BRCA	cis	rs4722166	0.645	rs1404006	ENSG00000225541.1	AC002480.5	-5.54	3.74e-08	4.94e-06	-0.18	-0.17	Lung cancer;	chr7:22755458	chr7:22571607~22661792:-
BRCA	cis	rs1552244	0.882	rs13089863	ENSG00000232901.1	CYCSP10	-5.54	3.74e-08	4.94e-06	-0.25	-0.17	Alzheimer's disease;	chr3:9990575	chr3:10000647~10000940:-
BRCA	cis	rs721917	0.506	rs7073842	ENSG00000244733.5	RP11-506M13.3	-5.54	3.74e-08	4.94e-06	-0.2	-0.17	Chronic obstructive pulmonary disease;	chr10:79896644	chr10:79660891~79677996:+
BRCA	cis	rs3805389	1	rs3805383	ENSG00000273257.1	RP11-177J6.1	-5.54	3.74e-08	4.94e-06	-0.25	-0.17	Waist-to-hip ratio adjusted for body mass index;	chr4:55609171	chr4:55387949~55388271:+
BRCA	cis	rs8031584	0.678	rs3122	ENSG00000259845.1	HERC2P10	-5.54	3.74e-08	4.95e-06	-0.2	-0.17	Huntington's disease progression;	chr15:30878087	chr15:30815271~30844153:+
BRCA	cis	rs4950322	0.542	rs3766520	ENSG00000244371.2	PFN1P8	-5.54	3.75e-08	4.95e-06	-0.24	-0.17	Protein quantitative trait loci;	chr1:147214658	chr1:146957117~146957659:-
BRCA	cis	rs875971	0.545	rs1638735	ENSG00000232546.1	RP11-458F8.1	5.54	3.75e-08	4.95e-06	0.16	0.17	Aortic root size;	chr7:66630751	chr7:66848496~66858136:+
BRCA	cis	rs5758511	0.633	rs5758689	ENSG00000205702.9	CYP2D7	5.54	3.75e-08	4.95e-06	0.18	0.17	Birth weight;	chr22:42268966	chr22:42140203~42144577:-
BRCA	cis	rs2638953	0.925	rs11049584	ENSG00000278733.1	RP11-425D17.1	-5.54	3.75e-08	4.95e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28417879	chr12:28185625~28186190:-
BRCA	cis	rs3733585	0.699	rs6449202	ENSG00000250413.1	RP11-448G15.1	5.54	3.75e-08	4.95e-06	0.22	0.17	Cleft plate (environmental tobacco smoke interaction);	chr4:9972419	chr4:10006482~10009725:+
BRCA	cis	rs1440410	0.804	rs28470858	ENSG00000250326.1	RP11-284M14.1	-5.54	3.75e-08	4.95e-06	-0.19	-0.17	Ischemic stroke;	chr4:143187008	chr4:142933195~143184861:-
BRCA	cis	rs1440410	0.835	rs4574353	ENSG00000250326.1	RP11-284M14.1	-5.54	3.75e-08	4.95e-06	-0.19	-0.17	Ischemic stroke;	chr4:143187488	chr4:142933195~143184861:-
BRCA	cis	rs1440410	0.835	rs4690777	ENSG00000250326.1	RP11-284M14.1	-5.54	3.75e-08	4.95e-06	-0.19	-0.17	Ischemic stroke;	chr4:143188382	chr4:142933195~143184861:-
BRCA	cis	rs7308116	0.546	rs9804825	ENSG00000274395.1	RP11-554D14.8	-5.54	3.75e-08	4.96e-06	-0.2	-0.17	Pelvic organ prolapse (moderate/severe);	chr12:107818287	chr12:107835541~107836555:-
BRCA	cis	rs9847710	0.967	rs4687694	ENSG00000242142.1	SERBP1P3	5.54	3.75e-08	4.96e-06	0.19	0.17	Ulcerative colitis;	chr3:53015031	chr3:53064283~53065091:-
BRCA	cis	rs2243480	0.908	rs313822	ENSG00000164669.11	INTS4P1	5.54	3.76e-08	4.96e-06	0.34	0.17	Diabetic kidney disease;	chr7:66108952	chr7:65141225~65234216:+
BRCA	cis	rs5758511	0.68	rs5758698	ENSG00000233903.2	Z83851.4	5.54	3.76e-08	4.96e-06	0.26	0.17	Birth weight;	chr22:42288812	chr22:42276355~42277052:+
BRCA	cis	rs10740039	0.516	rs1442551	ENSG00000254271.1	RP11-131N11.4	5.54	3.76e-08	4.96e-06	0.23	0.17	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60564733	chr10:60734342~60741828:+
BRCA	cis	rs2638953	0.962	rs11049541	ENSG00000278733.1	RP11-425D17.1	-5.54	3.76e-08	4.96e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28341781	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.889	rs11049543	ENSG00000278733.1	RP11-425D17.1	-5.54	3.76e-08	4.96e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28342124	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.962	rs11049544	ENSG00000278733.1	RP11-425D17.1	-5.54	3.76e-08	4.96e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28342348	chr12:28185625~28186190:-
BRCA	cis	rs10875943	0.751	rs11168962	ENSG00000258017.1	RP11-386G11.10	-5.54	3.76e-08	4.96e-06	-0.24	-0.17	Prostate cancer;	chr12:49278956	chr12:49127782~49147869:+
BRCA	cis	rs2898681	0.614	rs10016904	ENSG00000248375.1	RP11-177B4.1	-5.54	3.76e-08	4.96e-06	-0.24	-0.17	Optic nerve measurement (cup area);	chr4:52828129	chr4:52720081~52720831:-
BRCA	cis	rs253959	0.545	rs7734133	ENSG00000272265.1	CTD-2287O16.4	5.54	3.76e-08	4.97e-06	0.21	0.17	Bipolar disorder and schizophrenia;	chr5:116096418	chr5:116078110~116078570:-
BRCA	cis	rs2337406	1	rs17113276	ENSG00000223648.3	IGHV3-64	-5.54	3.77e-08	4.97e-06	-0.17	-0.17	Alzheimer's disease (late onset);	chr14:106683485	chr14:106643132~106658258:-
BRCA	cis	rs1823913	0.503	rs6434464	ENSG00000280083.1	RP11-317J9.1	5.54	3.77e-08	4.97e-06	0.19	0.17	Obesity-related traits;	chr2:191341120	chr2:191154118~191156070:-
BRCA	cis	rs7134599	0.561	rs4913395	ENSG00000255733.4	IFNG-AS1	-5.54	3.77e-08	4.97e-06	-0.14	-0.17	Inflammatory bowel disease;Ulcerative colitis;	chr12:68076705	chr12:67989445~68234686:+
BRCA	cis	rs1552244	1	rs7648104	ENSG00000232901.1	CYCSP10	5.54	3.77e-08	4.97e-06	0.24	0.17	Alzheimer's disease;	chr3:10031627	chr3:10000647~10000940:-
BRCA	cis	rs1552244	1	rs113771705	ENSG00000232901.1	CYCSP10	5.54	3.77e-08	4.97e-06	0.24	0.17	Alzheimer's disease;	chr3:10034299	chr3:10000647~10000940:-
BRCA	cis	rs1552244	1	rs17032277	ENSG00000232901.1	CYCSP10	5.54	3.77e-08	4.97e-06	0.24	0.17	Alzheimer's disease;	chr3:10035339	chr3:10000647~10000940:-
BRCA	cis	rs1552244	1	rs17032278	ENSG00000232901.1	CYCSP10	5.54	3.77e-08	4.97e-06	0.24	0.17	Alzheimer's disease;	chr3:10036271	chr3:10000647~10000940:-
BRCA	cis	rs1552244	1	rs66797209	ENSG00000232901.1	CYCSP10	5.54	3.77e-08	4.97e-06	0.24	0.17	Alzheimer's disease;	chr3:10036842	chr3:10000647~10000940:-
BRCA	cis	rs1552244	1	rs7631678	ENSG00000232901.1	CYCSP10	5.54	3.77e-08	4.97e-06	0.24	0.17	Alzheimer's disease;	chr3:10037132	chr3:10000647~10000940:-
BRCA	cis	rs950169	0.58	rs17532346	ENSG00000259295.5	CSPG4P12	5.54	3.77e-08	4.97e-06	0.24	0.17	Schizophrenia;	chr15:84628264	chr15:85191438~85213905:+
BRCA	cis	rs7474896	0.515	rs2749582	ENSG00000120555.12	SEPT7P9	-5.54	3.77e-08	4.97e-06	-0.23	-0.17	Obesity (extreme);	chr10:37986356	chr10:38383069~38402916:-
BRCA	cis	rs2243480	1	rs709607	ENSG00000164669.11	INTS4P1	-5.54	3.77e-08	4.97e-06	-0.32	-0.17	Diabetic kidney disease;	chr7:65984554	chr7:65141225~65234216:+
BRCA	cis	rs987360	0.931	rs1593445	ENSG00000248869.4	RP11-138I17.1	-5.54	3.77e-08	4.97e-06	-0.17	-0.17	Temperament;	chr4:137296693	chr4:136796722~137212799:-
BRCA	cis	rs55757919	1	rs55757919	ENSG00000231742.4	LINC01273	5.54	3.77e-08	4.98e-06	0.24	0.17	Monocyte percentage of white cells;	chr20:50132011	chr20:50172550~50176671:+
BRCA	cis	rs2179367	0.543	rs9498328	ENSG00000223701.3	RAET1E-AS1	5.54	3.78e-08	4.98e-06	0.24	0.17	Dupuytren's disease;	chr6:149348715	chr6:149884431~149919508:+
BRCA	cis	rs227932	0.867	rs116981	ENSG00000234286.1	AC006026.13	-5.54	3.78e-08	4.99e-06	-0.28	-0.17	Schizophrenia;	chr7:23590849	chr7:23680195~23680786:-
BRCA	cis	rs7620503	0.959	rs6443476	ENSG00000228221.4	LINC00578	5.54	3.78e-08	4.99e-06	0.2	0.17	Corneal structure;	chr3:177589907	chr3:177441921~177752305:+
BRCA	cis	rs7620503	0.959	rs6443477	ENSG00000228221.4	LINC00578	5.54	3.78e-08	4.99e-06	0.2	0.17	Corneal structure;	chr3:177590145	chr3:177441921~177752305:+
BRCA	cis	rs7620503	0.959	rs6769466	ENSG00000228221.4	LINC00578	5.54	3.78e-08	4.99e-06	0.2	0.17	Corneal structure;	chr3:177590226	chr3:177441921~177752305:+
BRCA	cis	rs7800418	0.578	rs10244951	ENSG00000214870.7	AC004540.5	-5.54	3.78e-08	4.99e-06	-0.21	-0.17	Cognitive function;	chr7:26586399	chr7:26398593~26494256:+
BRCA	cis	rs617791	0.53	rs10896073	ENSG00000255320.1	RP11-755F10.1	5.54	3.79e-08	4.99e-06	0.23	0.17	Breast cancer;	chr11:65995343	chr11:66244840~66246239:-
BRCA	cis	rs2239547	0.522	rs2336162	ENSG00000242142.1	SERBP1P3	-5.54	3.79e-08	5e-06	-0.2	-0.17	Schizophrenia;	chr3:52917503	chr3:53064283~53065091:-
BRCA	cis	rs7577696	0.554	rs35978916	ENSG00000272716.1	RP11-563N4.1	-5.54	3.79e-08	5e-06	-0.21	-0.17	Inflammatory biomarkers;	chr2:32175566	chr2:32165046~32165757:-
BRCA	cis	rs11673344	0.536	rs7259272	ENSG00000267422.1	CTD-2554C21.1	5.54	3.79e-08	5.01e-06	0.21	0.17	Obesity-related traits;	chr19:37692214	chr19:37779686~37792865:+
BRCA	cis	rs6545883	0.929	rs13413337	ENSG00000270820.4	RP11-355B11.2	5.54	3.8e-08	5.01e-06	0.19	0.17	Tuberculosis;	chr2:61519988	chr2:61471188~61484130:+
BRCA	cis	rs7178375	1	rs4779797	ENSG00000270015.1	RP11-540B6.6	-5.54	3.8e-08	5.01e-06	-0.2	-0.17	Hypertriglyceridemia;	chr15:30916222	chr15:30926514~30928407:+
BRCA	cis	rs4950322	0.748	rs56392137	ENSG00000244371.2	PFN1P8	-5.54	3.8e-08	5.01e-06	-0.24	-0.17	Protein quantitative trait loci;	chr1:147352450	chr1:146957117~146957659:-
BRCA	cis	rs7577696	0.695	rs4952252	ENSG00000272716.1	RP11-563N4.1	-5.54	3.8e-08	5.02e-06	-0.18	-0.17	Inflammatory biomarkers;	chr2:32157892	chr2:32165046~32165757:-
BRCA	cis	rs301901	0.581	rs10941343	ENSG00000250155.1	CTD-2353F22.1	5.54	3.8e-08	5.02e-06	0.18	0.17	Height;	chr5:37543239	chr5:36666214~36725195:-
BRCA	cis	rs301901	0.573	rs12652433	ENSG00000250155.1	CTD-2353F22.1	5.54	3.8e-08	5.02e-06	0.18	0.17	Height;	chr5:37543358	chr5:36666214~36725195:-
BRCA	cis	rs3805389	0.924	rs2412665	ENSG00000273257.1	RP11-177J6.1	-5.54	3.8e-08	5.02e-06	-0.25	-0.17	Waist-to-hip ratio adjusted for body mass index;	chr4:55606812	chr4:55387949~55388271:+
BRCA	cis	rs6840360	0.642	rs2709822	ENSG00000278978.1	RP11-164P12.5	-5.54	3.81e-08	5.02e-06	-0.19	-0.17	Intelligence (multi-trait analysis);	chr4:151430348	chr4:151669786~151670503:+
BRCA	cis	rs1552244	1	rs35220123	ENSG00000232901.1	CYCSP10	5.54	3.81e-08	5.02e-06	0.24	0.17	Alzheimer's disease;	chr3:10041485	chr3:10000647~10000940:-
BRCA	cis	rs1552244	0.935	rs4441636	ENSG00000232901.1	CYCSP10	5.54	3.81e-08	5.02e-06	0.24	0.17	Alzheimer's disease;	chr3:10042192	chr3:10000647~10000940:-
BRCA	cis	rs2638953	0.861	rs11049685	ENSG00000247934.4	RP11-967K21.1	-5.54	3.81e-08	5.02e-06	-0.21	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28512775	chr12:28163298~28190738:-
BRCA	cis	rs9659323	0.64	rs11800444	ENSG00000231365.4	RP11-418J17.1	-5.54	3.81e-08	5.02e-06	-0.2	-0.17	Body mass index;	chr1:119097052	chr1:119140396~119275973:+
BRCA	cis	rs6832769	1	rs6554286	ENSG00000272969.1	RP11-528I4.2	-5.54	3.81e-08	5.03e-06	-0.21	-0.17	Personality dimensions;	chr4:55534137	chr4:55547112~55547889:+
BRCA	cis	rs4699052	1	rs4699055	ENSG00000248740.4	RP11-328K4.1	5.54	3.81e-08	5.03e-06	0.19	0.17	Testicular germ cell tumor;	chr4:103233343	chr4:103256159~103453658:+
BRCA	cis	rs6750795	0.507	rs1667320	ENSG00000223198.1	RNU2-22P	-5.54	3.81e-08	5.03e-06	-0.2	-0.17	Height;	chr2:231553603	chr2:231501990~231502201:-
BRCA	cis	rs2303319	1	rs62188139	ENSG00000227403.1	AC009299.3	5.54	3.81e-08	5.03e-06	0.43	0.17	Cognitive function;	chr2:161413264	chr2:161244739~161249050:+
BRCA	cis	rs2303319	1	rs62188140	ENSG00000227403.1	AC009299.3	5.54	3.81e-08	5.03e-06	0.43	0.17	Cognitive function;	chr2:161413355	chr2:161244739~161249050:+
BRCA	cis	rs600231	0.706	rs1111934	ENSG00000245532.5	NEAT1	5.54	3.82e-08	5.03e-06	0.17	0.17	Bone mineral density;	chr11:65561921	chr11:65422774~65445540:+
BRCA	cis	rs6700559	0.74	rs4387211	ENSG00000260088.1	RP11-92G12.3	-5.54	3.82e-08	5.03e-06	-0.21	-0.17	Coronary artery disease;	chr1:200676810	chr1:200669507~200694250:+
BRCA	cis	rs9341808	0.718	rs9443735	ENSG00000272129.1	RP11-250B2.6	5.54	3.82e-08	5.03e-06	0.22	0.17	Sitting height ratio;	chr6:80110757	chr6:80355424~80356859:+
BRCA	cis	rs7308116	0.546	rs7972643	ENSG00000274395.1	RP11-554D14.8	-5.54	3.82e-08	5.04e-06	-0.2	-0.17	Pelvic organ prolapse (moderate/severe);	chr12:107834298	chr12:107835541~107836555:-
BRCA	cis	rs7308116	0.546	rs2374729	ENSG00000274395.1	RP11-554D14.8	-5.54	3.82e-08	5.04e-06	-0.2	-0.17	Pelvic organ prolapse (moderate/severe);	chr12:107834545	chr12:107835541~107836555:-
BRCA	cis	rs7927592	0.913	rs12272917	ENSG00000212093.1	AP000807.1	5.54	3.82e-08	5.04e-06	0.2	0.17	Total body bone mineral density;	chr11:68495902	chr11:68506083~68506166:-
BRCA	cis	rs904251	0.772	rs10692	ENSG00000204110.6	RP1-153P14.8	-5.54	3.82e-08	5.04e-06	-0.2	-0.17	Cognitive performance;	chr6:37483138	chr6:37507348~37535616:+
BRCA	cis	rs4819052	0.851	rs7275870	ENSG00000184274.3	LINC00315	-5.54	3.82e-08	5.04e-06	-0.23	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251299	chr21:45300245~45305257:-
BRCA	cis	rs4819052	0.851	rs7275874	ENSG00000184274.3	LINC00315	-5.54	3.82e-08	5.04e-06	-0.23	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251308	chr21:45300245~45305257:-
BRCA	cis	rs1005277	0.541	rs1740741	ENSG00000263064.2	RP11-291L22.7	5.54	3.83e-08	5.05e-06	0.21	0.17	Extrinsic epigenetic age acceleration;	chr10:38226406	chr10:38448689~38448949:+
BRCA	cis	rs1005277	0.528	rs2057228	ENSG00000263064.2	RP11-291L22.7	5.54	3.83e-08	5.05e-06	0.21	0.17	Extrinsic epigenetic age acceleration;	chr10:38226838	chr10:38448689~38448949:+
BRCA	cis	rs4713118	0.662	rs149946	ENSG00000280107.1	AL022393.9	5.54	3.83e-08	5.05e-06	0.25	0.17	Parkinson's disease;	chr6:28002253	chr6:28170845~28172521:+
BRCA	cis	rs4819052	0.851	rs914218	ENSG00000184274.3	LINC00315	-5.54	3.83e-08	5.05e-06	-0.23	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45278530	chr21:45300245~45305257:-
BRCA	cis	rs1014246	0.848	rs10749227	ENSG00000232767.1	RP11-498B4.5	-5.54	3.83e-08	5.05e-06	-0.19	-0.17	Age at smoking initiation in chronic obstructive pulmonary disease;	chr10:116709120	chr10:116670103~116672739:+
BRCA	cis	rs3760982	0.585	rs67704568	ENSG00000267058.1	RP11-15A1.3	-5.54	3.83e-08	5.05e-06	-0.2	-0.17	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43789867	chr19:43891804~43901805:-
BRCA	cis	rs763121	0.853	rs5757231	ENSG00000228274.3	RP3-508I15.9	5.54	3.84e-08	5.06e-06	0.19	0.17	Menopause (age at onset);	chr22:38675653	chr22:38667585~38681820:-
BRCA	cis	rs4819052	0.684	rs914216	ENSG00000184274.3	LINC00315	-5.54	3.85e-08	5.07e-06	-0.23	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45278383	chr21:45300245~45305257:-
BRCA	cis	rs10740039	0.516	rs2393646	ENSG00000254271.1	RP11-131N11.4	5.54	3.85e-08	5.07e-06	0.23	0.17	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60559676	chr10:60734342~60741828:+
BRCA	cis	rs2030746	0.899	rs2030745	ENSG00000237614.1	AC073257.2	-5.54	3.85e-08	5.07e-06	-0.21	-0.17	LDL cholesterol;Total cholesterol levels;LDL cholesterol levels;	chr2:120551706	chr2:120542909~120544326:-
BRCA	cis	rs17301013	0.606	rs1417186	ENSG00000227373.4	RP11-160H22.5	-5.54	3.85e-08	5.07e-06	-0.25	-0.17	Systemic lupus erythematosus;	chr1:174171090	chr1:174115300~174160004:-
BRCA	cis	rs1707322	1	rs11211190	ENSG00000281133.1	AL355480.3	-5.54	3.85e-08	5.07e-06	-0.21	-0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45800583	chr1:45580892~45580996:-
BRCA	cis	rs7927771	0.725	rs11570094	ENSG00000280615.1	Y_RNA	5.54	3.85e-08	5.07e-06	0.22	0.17	Subjective well-being;	chr11:47338155	chr11:47614898~47614994:-
BRCA	cis	rs11955398	0.502	rs158938	ENSG00000215032.2	GNL3LP1	5.54	3.85e-08	5.07e-06	0.22	0.17	Intelligence (multi-trait analysis);	chr5:60939413	chr5:60891935~60893577:-
BRCA	cis	rs1005277	0.579	rs1740742	ENSG00000263064.2	RP11-291L22.7	5.54	3.85e-08	5.08e-06	0.21	0.17	Extrinsic epigenetic age acceleration;	chr10:38229932	chr10:38448689~38448949:+
BRCA	cis	rs1005277	0.602	rs1740743	ENSG00000263064.2	RP11-291L22.7	5.54	3.85e-08	5.08e-06	0.21	0.17	Extrinsic epigenetic age acceleration;	chr10:38230294	chr10:38448689~38448949:+
BRCA	cis	rs1005277	0.579	rs1740745	ENSG00000263064.2	RP11-291L22.7	5.54	3.85e-08	5.08e-06	0.21	0.17	Extrinsic epigenetic age acceleration;	chr10:38231128	chr10:38448689~38448949:+
BRCA	cis	rs1005277	0.579	rs1740747	ENSG00000263064.2	RP11-291L22.7	5.54	3.85e-08	5.08e-06	0.21	0.17	Extrinsic epigenetic age acceleration;	chr10:38231537	chr10:38448689~38448949:+
BRCA	cis	rs1005277	0.579	rs1740749	ENSG00000263064.2	RP11-291L22.7	5.54	3.85e-08	5.08e-06	0.21	0.17	Extrinsic epigenetic age acceleration;	chr10:38232718	chr10:38448689~38448949:+
BRCA	cis	rs1005277	0.579	rs1780115	ENSG00000263064.2	RP11-291L22.7	5.54	3.85e-08	5.08e-06	0.21	0.17	Extrinsic epigenetic age acceleration;	chr10:38235845	chr10:38448689~38448949:+
BRCA	cis	rs910316	0.763	rs175036	ENSG00000279594.1	RP11-950C14.10	-5.54	3.85e-08	5.08e-06	-0.19	-0.17	Height;	chr14:74997592	chr14:75011269~75012851:-
BRCA	cis	rs910316	0.712	rs175037	ENSG00000279594.1	RP11-950C14.10	-5.54	3.85e-08	5.08e-06	-0.19	-0.17	Height;	chr14:74998335	chr14:75011269~75012851:-
BRCA	cis	rs6570726	0.791	rs4896820	ENSG00000270638.1	RP3-466P17.1	5.54	3.85e-08	5.08e-06	0.19	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145573821	chr6:145735570~145737218:+
BRCA	cis	rs1552244	1	rs67569278	ENSG00000180385.7	EMC3-AS1	5.54	3.86e-08	5.08e-06	0.21	0.17	Alzheimer's disease;	chr3:10108209	chr3:9986893~10006990:+
BRCA	cis	rs9300255	0.602	rs2695478	ENSG00000235423.7	RP11-282O18.3	5.54	3.86e-08	5.09e-06	0.24	0.17	Neutrophil percentage of white cells;	chr12:123204974	chr12:123252030~123261483:-
BRCA	cis	rs66887589	0.592	rs2175383	ENSG00000249244.1	RP11-548H18.2	5.54	3.86e-08	5.09e-06	0.19	0.17	Diastolic blood pressure;	chr4:119294681	chr4:119391831~119395335:-
BRCA	cis	rs1722141	0.67	rs788768	ENSG00000237471.1	AC073115.6	5.54	3.86e-08	5.09e-06	0.25	0.17	Sitting height ratio;	chr7:45960955	chr7:45969657~45980191:+
BRCA	cis	rs61160187	0.51	rs6876335	ENSG00000272308.1	RP11-231G3.1	-5.54	3.87e-08	5.09e-06	-0.19	-0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:60795991	chr5:60866457~60866935:-
BRCA	cis	rs61160187	0.51	rs6449501	ENSG00000272308.1	RP11-231G3.1	-5.54	3.87e-08	5.09e-06	-0.19	-0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:60796860	chr5:60866457~60866935:-
BRCA	cis	rs61160187	0.51	rs4235481	ENSG00000272308.1	RP11-231G3.1	-5.54	3.87e-08	5.09e-06	-0.19	-0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:60797560	chr5:60866457~60866935:-
BRCA	cis	rs7308116	0.546	rs61938610	ENSG00000274395.1	RP11-554D14.8	-5.54	3.87e-08	5.09e-06	-0.2	-0.17	Pelvic organ prolapse (moderate/severe);	chr12:107817213	chr12:107835541~107836555:-
BRCA	cis	rs1387259	0.79	rs2732445	ENSG00000240399.1	RP1-228P16.1	5.54	3.87e-08	5.09e-06	0.2	0.17	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48251750	chr12:48054813~48055591:-
BRCA	cis	rs2243480	1	rs316330	ENSG00000164669.11	INTS4P1	5.54	3.87e-08	5.09e-06	0.33	0.17	Diabetic kidney disease;	chr7:66140385	chr7:65141225~65234216:+
BRCA	cis	rs2243480	1	rs1499614	ENSG00000228409.4	CCT6P1	5.54	3.87e-08	5.1e-06	0.23	0.17	Diabetic kidney disease;	chr7:66265811	chr7:65751142~65763354:+
BRCA	cis	rs6847067	0.683	rs12500519	ENSG00000180769.7	WDFY3-AS2	5.54	3.87e-08	5.1e-06	0.18	0.17	Oropharynx cancer;	chr4:84834877	chr4:84965682~85011277:+
BRCA	cis	rs8054556	0.74	rs12716974	ENSG00000273724.1	RP11-347C12.12	-5.54	3.87e-08	5.1e-06	-0.19	-0.17	Autism spectrum disorder or schizophrenia;	chr16:29933511	chr16:30336400~30343336:+
BRCA	cis	rs9309473	0.607	rs4641966	ENSG00000163016.8	ALMS1P	5.54	3.87e-08	5.1e-06	0.2	0.17	Metabolite levels;	chr2:73363678	chr2:73644919~73685576:+
BRCA	cis	rs10129255	0.536	rs17113249	ENSG00000224373.3	IGHV4-59	5.54	3.87e-08	5.1e-06	0.1	0.17	Kawasaki disease;	chr14:106678273	chr14:106627249~106627825:-
BRCA	cis	rs1552244	0.935	rs7649243	ENSG00000232901.1	CYCSP10	5.54	3.87e-08	5.1e-06	0.24	0.17	Alzheimer's disease;	chr3:10047786	chr3:10000647~10000940:-
BRCA	cis	rs1552244	1	rs7615646	ENSG00000232901.1	CYCSP10	5.54	3.87e-08	5.1e-06	0.24	0.17	Alzheimer's disease;	chr3:10048089	chr3:10000647~10000940:-
BRCA	cis	rs1552244	1	rs6793396	ENSG00000232901.1	CYCSP10	5.54	3.87e-08	5.1e-06	0.24	0.17	Alzheimer's disease;	chr3:10069243	chr3:10000647~10000940:-
BRCA	cis	rs1552244	0.935	rs7621551	ENSG00000232901.1	CYCSP10	5.54	3.87e-08	5.1e-06	0.24	0.17	Alzheimer's disease;	chr3:10072521	chr3:10000647~10000940:-
BRCA	cis	rs4713118	0.824	rs9468223	ENSG00000216901.1	AL022393.7	5.54	3.87e-08	5.1e-06	0.23	0.17	Parkinson's disease;	chr6:27772887	chr6:28176188~28176674:+
BRCA	cis	rs4713118	0.866	rs2179094	ENSG00000216901.1	AL022393.7	5.54	3.87e-08	5.1e-06	0.23	0.17	Parkinson's disease;	chr6:27774046	chr6:28176188~28176674:+
BRCA	cis	rs7819412	0.875	rs6981523	ENSG00000255046.1	RP11-297N6.4	5.54	3.87e-08	5.1e-06	0.2	0.17	Triglycerides;	chr8:11204283	chr8:11797928~11802568:-
BRCA	cis	rs597539	0.615	rs629426	ENSG00000261625.1	RP11-554A11.4	-5.54	3.87e-08	5.1e-06	-0.16	-0.17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68903636	chr11:69000765~69002048:-
BRCA	cis	rs10740039	0.516	rs1442549	ENSG00000254271.1	RP11-131N11.4	5.54	3.87e-08	5.1e-06	0.22	0.17	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60574542	chr10:60734342~60741828:+
BRCA	cis	rs6840258	1	rs17701999	ENSG00000251411.1	RP11-397E7.4	-5.54	3.88e-08	5.11e-06	-0.22	-0.17	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87034392	chr4:86913266~86914817:-
BRCA	cis	rs6490294	0.571	rs7970397	ENSG00000226469.1	ADAM1B	5.54	3.88e-08	5.11e-06	0.26	0.17	Mean platelet volume;	chr12:112142267	chr12:111927018~111929017:+
BRCA	cis	rs2153535	0.585	rs9405403	ENSG00000230939.1	RP11-314C16.1	-5.54	3.88e-08	5.11e-06	-0.2	-0.17	Motion sickness;	chr6:8636061	chr6:8784178~8785445:+
BRCA	cis	rs6479901	0.512	rs7082090	ENSG00000232075.1	MRPL35P2	5.54	3.88e-08	5.11e-06	0.3	0.17	Intelligence (multi-trait analysis);	chr10:63239252	chr10:63634317~63634827:-
BRCA	cis	rs13126694	0.659	rs28514324	ENSG00000251429.1	RP11-597D13.7	5.54	3.88e-08	5.11e-06	0.17	0.17	Blood osmolality (transformed sodium);	chr4:158092778	chr4:158270378~158278676:+
BRCA	cis	rs7916697	0.628	rs10998036	ENSG00000233590.1	RP11-153K11.3	5.54	3.88e-08	5.11e-06	0.22	0.17	Optic disc area;	chr10:68256921	chr10:68233251~68242379:-
BRCA	cis	rs919433	0.713	rs10178946	ENSG00000231621.1	AC013264.2	-5.54	3.88e-08	5.11e-06	-0.16	-0.17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197598366	chr2:197197991~197199273:+
BRCA	cis	rs2638953	0.962	rs10843150	ENSG00000278733.1	RP11-425D17.1	5.54	3.88e-08	5.11e-06	0.23	0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28304869	chr12:28185625~28186190:-
BRCA	cis	rs754466	0.58	rs10762765	ENSG00000204049.1	RP11-126H7.4	5.54	3.88e-08	5.11e-06	0.2	0.17	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77806649	chr10:77866875~77869610:+
BRCA	cis	rs9287719	0.967	rs12464817	ENSG00000243819.4	RN7SL832P	5.54	3.88e-08	5.11e-06	0.16	0.17	Prostate cancer;	chr2:10567086	chr2:10690344~10692099:+
BRCA	cis	rs2243480	0.522	rs73150635	ENSG00000273142.1	RP11-458F8.4	-5.54	3.88e-08	5.11e-06	-0.29	-0.17	Diabetic kidney disease;	chr7:66507503	chr7:66902857~66906297:+
BRCA	cis	rs7923609	0.811	rs10822181	ENSG00000232075.1	MRPL35P2	5.54	3.89e-08	5.12e-06	0.21	0.17	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63565366	chr10:63634317~63634827:-
BRCA	cis	rs7620503	0.921	rs6768291	ENSG00000228221.4	LINC00578	5.54	3.89e-08	5.12e-06	0.19	0.17	Corneal structure;	chr3:177572395	chr3:177441921~177752305:+
BRCA	cis	rs7620503	0.917	rs1970861	ENSG00000228221.4	LINC00578	5.54	3.89e-08	5.12e-06	0.19	0.17	Corneal structure;	chr3:177573425	chr3:177441921~177752305:+
BRCA	cis	rs7620503	0.959	rs4241483	ENSG00000228221.4	LINC00578	5.54	3.89e-08	5.12e-06	0.19	0.17	Corneal structure;	chr3:177573530	chr3:177441921~177752305:+
BRCA	cis	rs7772486	0.686	rs702314	ENSG00000270638.1	RP3-466P17.1	-5.54	3.89e-08	5.12e-06	-0.19	-0.17	Lobe attachment (rater-scored or self-reported);	chr6:145682374	chr6:145735570~145737218:+
BRCA	cis	rs1707322	0.717	rs2275086	ENSG00000234329.1	RP11-767N6.2	-5.54	3.89e-08	5.12e-06	-0.18	-0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45620207	chr1:45651039~45651826:-
BRCA	cis	rs873549	1	rs1348270	ENSG00000232679.1	RP11-400N13.3	5.54	3.89e-08	5.13e-06	0.2	0.17	Keloid;	chr1:222096919	chr1:222041705~222064763:-
BRCA	cis	rs1707322	0.721	rs11211149	ENSG00000234329.1	RP11-767N6.2	5.54	3.89e-08	5.13e-06	0.18	0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45646546	chr1:45651039~45651826:-
BRCA	cis	rs9659323	0.67	rs10157346	ENSG00000231365.4	RP11-418J17.1	-5.54	3.89e-08	5.13e-06	-0.2	-0.17	Body mass index;	chr1:119090924	chr1:119140396~119275973:+
BRCA	cis	rs17711722	0.701	rs781143	ENSG00000273024.4	INTS4P2	-5.54	3.9e-08	5.13e-06	-0.19	-0.17	Calcium levels;	chr7:65974892	chr7:65647864~65715661:+
BRCA	cis	rs6490294	0.571	rs73421065	ENSG00000226469.1	ADAM1B	5.54	3.9e-08	5.13e-06	0.26	0.17	Mean platelet volume;	chr12:112121575	chr12:111927018~111929017:+
BRCA	cis	rs6490294	0.528	rs58047810	ENSG00000226469.1	ADAM1B	5.54	3.9e-08	5.13e-06	0.26	0.17	Mean platelet volume;	chr12:112124682	chr12:111927018~111929017:+
BRCA	cis	rs9638182	1	rs35659126	ENSG00000274080.1	CTA-315H11.2	5.54	3.9e-08	5.14e-06	0.3	0.17	Triglycerides;	chr7:73573739	chr7:73609262~73611502:-
BRCA	cis	rs6570726	0.967	rs365515	ENSG00000270638.1	RP3-466P17.1	-5.54	3.91e-08	5.15e-06	-0.19	-0.17	Lobe attachment (rater-scored or self-reported);	chr6:145481697	chr6:145735570~145737218:+
BRCA	cis	rs9307551	0.584	rs2867671	ENSG00000250334.4	LINC00989	-5.54	3.91e-08	5.15e-06	-0.23	-0.17	Refractive error;	chr4:79542000	chr4:79492416~79576460:+
BRCA	cis	rs62388641	0.547	rs9391923	ENSG00000272279.1	RP11-157J24.2	-5.54	3.91e-08	5.15e-06	-0.21	-0.17	Daytime sleep phenotypes;	chr6:1554089	chr6:1528364~1528911:-
BRCA	cis	rs2638953	0.888	rs1871152	ENSG00000247934.4	RP11-967K21.1	5.54	3.91e-08	5.15e-06	0.22	0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28226893	chr12:28163298~28190738:-
BRCA	cis	rs7674212	0.541	rs2045746	ENSG00000251288.2	RP11-10L12.2	5.54	3.91e-08	5.15e-06	0.2	0.17	Type 2 diabetes;	chr4:103162421	chr4:102751401~102752641:+
BRCA	cis	rs7617773	0.817	rs6791930	ENSG00000199476.1	Y_RNA	-5.54	3.91e-08	5.15e-06	-0.24	-0.17	Coronary artery disease;	chr3:48288410	chr3:48288587~48288694:+
BRCA	cis	rs7617773	0.817	rs6794644	ENSG00000199476.1	Y_RNA	-5.54	3.91e-08	5.15e-06	-0.24	-0.17	Coronary artery disease;	chr3:48288547	chr3:48288587~48288694:+
BRCA	cis	rs10129255	0.957	rs10138532	ENSG00000280411.1	IGHV1-69-2	-5.54	3.91e-08	5.15e-06	-0.13	-0.17	Kawasaki disease;	chr14:106803901	chr14:106762092~106762588:-
BRCA	cis	rs8054556	0.692	rs4788199	ENSG00000273724.1	RP11-347C12.12	-5.54	3.92e-08	5.15e-06	-0.19	-0.17	Autism spectrum disorder or schizophrenia;	chr16:29959536	chr16:30336400~30343336:+
BRCA	cis	rs1876905	0.597	rs191631	ENSG00000230177.1	RP5-1112D6.4	-5.54	3.92e-08	5.16e-06	-0.25	-0.17	Mean corpuscular hemoglobin;	chr6:111226862	chr6:111277932~111278742:+
BRCA	cis	rs2704588	0.505	rs1513811	ENSG00000270720.1	RP11-84C13.2	-5.54	3.92e-08	5.16e-06	-0.31	-0.17	Longevity;	chr4:89074647	chr4:89119284~89119871:+
BRCA	cis	rs10129255	0.5	rs988134	ENSG00000224373.3	IGHV4-59	5.54	3.92e-08	5.16e-06	0.1	0.17	Kawasaki disease;	chr14:106776698	chr14:106627249~106627825:-
BRCA	cis	rs10129255	0.5	rs988133	ENSG00000224373.3	IGHV4-59	5.54	3.92e-08	5.16e-06	0.1	0.17	Kawasaki disease;	chr14:106776724	chr14:106627249~106627825:-
BRCA	cis	rs4950322	0.57	rs4593887	ENSG00000244371.2	PFN1P8	-5.54	3.92e-08	5.17e-06	-0.23	-0.17	Protein quantitative trait loci;	chr1:147234246	chr1:146957117~146957659:-
BRCA	cis	rs755249	0.565	rs4660846	ENSG00000182109.6	RP11-69E11.4	-5.54	3.93e-08	5.17e-06	-0.19	-0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39583839	chr1:39522280~39546187:-
BRCA	cis	rs919433	0.713	rs2045245	ENSG00000231621.1	AC013264.2	-5.54	3.93e-08	5.17e-06	-0.16	-0.17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197620617	chr2:197197991~197199273:+
BRCA	cis	rs2998286	0.813	rs2790431	ENSG00000254635.4	WAC-AS1	-5.54	3.93e-08	5.17e-06	-0.27	-0.17	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28500266	chr10:28522652~28532743:-
BRCA	cis	rs6728642	1	rs17037402	ENSG00000230606.9	AC159540.1	5.54	3.93e-08	5.17e-06	0.36	0.17	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:97358816	chr2:97416165~97433527:-
BRCA	cis	rs1707322	0.717	rs2253862	ENSG00000234329.1	RP11-767N6.2	-5.54	3.93e-08	5.17e-06	-0.18	-0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45616288	chr1:45651039~45651826:-
BRCA	cis	rs1707322	0.717	rs2991988	ENSG00000234329.1	RP11-767N6.2	-5.54	3.93e-08	5.17e-06	-0.18	-0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45616759	chr1:45651039~45651826:-
BRCA	cis	rs1707322	0.717	rs2991989	ENSG00000234329.1	RP11-767N6.2	-5.54	3.93e-08	5.17e-06	-0.18	-0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45617293	chr1:45651039~45651826:-
BRCA	cis	rs2018683	1	rs2018683	ENSG00000228421.2	AC005013.5	5.54	3.93e-08	5.17e-06	0.21	0.17	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28974579	chr7:28957667~28959345:+
BRCA	cis	rs4835473	0.897	rs7678190	ENSG00000249741.2	RP11-673E1.3	-5.54	3.93e-08	5.18e-06	-0.18	-0.17	Immature fraction of reticulocytes;	chr4:143722421	chr4:143911514~143912053:-
BRCA	cis	rs1552244	0.882	rs13063929	ENSG00000232901.1	CYCSP10	5.54	3.94e-08	5.18e-06	0.23	0.17	Alzheimer's disease;	chr3:9968624	chr3:10000647~10000940:-
BRCA	cis	rs1387259	0.859	rs2054905	ENSG00000240399.1	RP1-228P16.1	5.54	3.94e-08	5.18e-06	0.2	0.17	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48294168	chr12:48054813~48055591:-
BRCA	cis	rs9656709	0.528	rs4948054	ENSG00000226278.1	PSPHP1	5.53	3.94e-08	5.18e-06	0.19	0.17	Behavioural disinhibition (generation interaction);	chr7:55663907	chr7:55764797~55773288:+
BRCA	cis	rs78487399	0.908	rs6715003	ENSG00000234936.1	AC010883.5	5.53	3.94e-08	5.19e-06	0.22	0.17	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43581520	chr2:43229573~43233394:+
BRCA	cis	rs7648466	0.592	rs2087726	ENSG00000223552.1	RP11-24F11.2	5.53	3.94e-08	5.19e-06	0.17	0.17	Eotaxin levels;	chr3:46166818	chr3:46364955~46407059:-
BRCA	cis	rs6832769	0.925	rs3817444	ENSG00000223305.1	RN7SKP30	5.53	3.94e-08	5.19e-06	0.22	0.17	Personality dimensions;	chr4:55509814	chr4:55540502~55540835:-
BRCA	cis	rs1440410	0.83	rs2165301	ENSG00000250326.1	RP11-284M14.1	-5.53	3.95e-08	5.19e-06	-0.19	-0.17	Ischemic stroke;	chr4:143247497	chr4:142933195~143184861:-
BRCA	cis	rs651386	0.506	rs11577602	ENSG00000271811.1	RP1-79C4.4	5.53	3.95e-08	5.19e-06	0.19	0.17	Atrial fibrillation;	chr1:170627404	chr1:170667381~170669425:+
BRCA	cis	rs577676	0.586	rs10800530	ENSG00000271811.1	RP1-79C4.4	5.53	3.95e-08	5.19e-06	0.19	0.17	Prevalent atrial fibrillation;	chr1:170627431	chr1:170667381~170669425:+
BRCA	cis	rs991427	0.643	rs17018656	ENSG00000258100.1	RP11-121E16.1	-5.53	3.95e-08	5.19e-06	-0.26	-0.17	Systolic blood pressure (alcohol consumption interaction);	chr12:91067070	chr12:91362196~91368606:+
BRCA	cis	rs10129255	1	rs8010605	ENSG00000280411.1	IGHV1-69-2	-5.53	3.95e-08	5.19e-06	-0.13	-0.17	Kawasaki disease;	chr14:106678742	chr14:106762092~106762588:-
BRCA	cis	rs4835473	0.808	rs6831401	ENSG00000249741.2	RP11-673E1.3	5.53	3.95e-08	5.19e-06	0.18	0.17	Immature fraction of reticulocytes;	chr4:143801038	chr4:143911514~143912053:-
BRCA	cis	rs78545713	0.502	rs57145038	ENSG00000241549.7	GUSBP2	-5.53	3.95e-08	5.2e-06	-0.24	-0.17	Iron status biomarkers (total iron binding capacity);	chr6:26311282	chr6:26871484~26956554:-
BRCA	cis	rs3805389	0.961	rs62308665	ENSG00000273257.1	RP11-177J6.1	-5.53	3.95e-08	5.2e-06	-0.25	-0.17	Waist-to-hip ratio adjusted for body mass index;	chr4:55611630	chr4:55387949~55388271:+
BRCA	cis	rs300890	0.513	rs10015412	ENSG00000250326.1	RP11-284M14.1	-5.53	3.96e-08	5.2e-06	-0.2	-0.17	Nasopharyngeal carcinoma;	chr4:143241429	chr4:142933195~143184861:-
BRCA	cis	rs300890	0.513	rs1440418	ENSG00000250326.1	RP11-284M14.1	-5.53	3.96e-08	5.2e-06	-0.2	-0.17	Nasopharyngeal carcinoma;	chr4:143241790	chr4:142933195~143184861:-
BRCA	cis	rs300890	0.513	rs11100784	ENSG00000250326.1	RP11-284M14.1	-5.53	3.96e-08	5.2e-06	-0.2	-0.17	Nasopharyngeal carcinoma;	chr4:143242199	chr4:142933195~143184861:-
BRCA	cis	rs300890	0.513	rs6848475	ENSG00000250326.1	RP11-284M14.1	-5.53	3.96e-08	5.2e-06	-0.2	-0.17	Nasopharyngeal carcinoma;	chr4:143242889	chr4:142933195~143184861:-
BRCA	cis	rs2451932	0.507	rs6882768	ENSG00000251050.1	RP11-168A11.4	-5.53	3.96e-08	5.21e-06	-0.18	-0.17	LDL peak particle diameter (total fat intake interaction);	chr5:79996187	chr5:80019609~80019920:+
BRCA	cis	rs7772486	0.806	rs2265477	ENSG00000270638.1	RP3-466P17.1	5.53	3.96e-08	5.21e-06	0.19	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145891202	chr6:145735570~145737218:+
BRCA	cis	rs7826238	0.539	rs2945891	ENSG00000254153.1	CTA-398F10.2	5.53	3.96e-08	5.21e-06	0.21	0.17	Systolic blood pressure;	chr8:8297953	chr8:8456909~8461337:-
BRCA	cis	rs523522	0.962	rs10849757	ENSG00000278344.1	RP11-18C24.8	5.53	3.96e-08	5.21e-06	0.23	0.17	High light scatter reticulocyte count;	chr12:120526211	chr12:120500735~120501090:-
BRCA	cis	rs7308116	0.546	rs2374727	ENSG00000274395.1	RP11-554D14.8	-5.53	3.96e-08	5.21e-06	-0.2	-0.17	Pelvic organ prolapse (moderate/severe);	chr12:107817096	chr12:107835541~107836555:-
BRCA	cis	rs62388641	0.813	rs34114087	ENSG00000218027.2	RP11-157J24.1	-5.53	3.97e-08	5.21e-06	-0.26	-0.17	Daytime sleep phenotypes;	chr6:1553203	chr6:1513698~1515289:-
BRCA	cis	rs10510102	0.748	rs4589226	ENSG00000226864.1	ATE1-AS1	5.53	3.97e-08	5.21e-06	0.31	0.17	Breast cancer;	chr10:121951073	chr10:121928312~121951965:+
BRCA	cis	rs736408	0.608	rs4687657	ENSG00000242142.1	SERBP1P3	5.53	3.97e-08	5.22e-06	0.21	0.17	Bipolar disorder;	chr3:52818522	chr3:53064283~53065091:-
BRCA	cis	rs2638953	0.889	rs10843155	ENSG00000278733.1	RP11-425D17.1	-5.53	3.97e-08	5.22e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28334920	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.889	rs11049538	ENSG00000278733.1	RP11-425D17.1	-5.53	3.97e-08	5.22e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28335801	chr12:28185625~28186190:-
BRCA	cis	rs2898681	0.77	rs10032190	ENSG00000248375.1	RP11-177B4.1	-5.53	3.97e-08	5.22e-06	-0.23	-0.17	Optic nerve measurement (cup area);	chr4:52868773	chr4:52720081~52720831:-
BRCA	cis	rs910316	0.726	rs175040	ENSG00000279594.1	RP11-950C14.10	-5.53	3.97e-08	5.23e-06	-0.19	-0.17	Height;	chr14:75002852	chr14:75011269~75012851:-
BRCA	cis	rs2834288	0.613	rs2834297	ENSG00000273102.1	AP000569.9	-5.53	3.98e-08	5.23e-06	-0.18	-0.17	Gut microbiota (bacterial taxa);	chr21:33910534	chr21:33967101~33968573:-
BRCA	cis	rs9311474	0.629	rs7639267	ENSG00000243224.1	RP5-1157M23.2	-5.53	3.98e-08	5.23e-06	-0.18	-0.17	Electroencephalogram traits;	chr3:52534789	chr3:52239258~52241097:+
BRCA	cis	rs12144309	0.554	rs2476599	ENSG00000232450.1	RP4-730K3.3	5.53	3.98e-08	5.23e-06	0.22	0.17	Coronary artery disease;	chr1:113820837	chr1:113698884~113699631:-
BRCA	cis	rs6832769	0.961	rs28445925	ENSG00000223305.1	RN7SKP30	-5.53	3.98e-08	5.23e-06	-0.22	-0.17	Personality dimensions;	chr4:55569682	chr4:55540502~55540835:-
BRCA	cis	rs8114671	0.545	rs2378335	ENSG00000202150.1	RNU6-407P	-5.53	3.98e-08	5.23e-06	-0.23	-0.17	Height;	chr20:35169027	chr20:35030317~35030420:-
BRCA	cis	rs6840360	0.837	rs13137669	ENSG00000270265.1	RP11-731D1.4	-5.53	3.98e-08	5.23e-06	-0.19	-0.17	Intelligence (multi-trait analysis);	chr4:151789791	chr4:151333775~151353224:-
BRCA	cis	rs9847710	0.967	rs2244552	ENSG00000242142.1	SERBP1P3	5.53	3.98e-08	5.24e-06	0.19	0.17	Ulcerative colitis;	chr3:53021506	chr3:53064283~53065091:-
BRCA	cis	rs910316	0.967	rs4899551	ENSG00000279594.1	RP11-950C14.10	-5.53	3.99e-08	5.24e-06	-0.19	-0.17	Height;	chr14:75193543	chr14:75011269~75012851:-
BRCA	cis	rs9652601	0.622	rs8056098	ENSG00000274038.1	RP11-66H6.4	-5.53	3.99e-08	5.24e-06	-0.19	-0.17	Systemic lupus erythematosus;	chr16:11044955	chr16:11056556~11057034:+
BRCA	cis	rs2562456	0.526	rs950504	ENSG00000268081.1	RP11-678G14.2	5.53	3.99e-08	5.24e-06	0.24	0.17	Pain;	chr19:21601193	chr19:21554640~21569237:-
BRCA	cis	rs1665050	0.571	rs1446238	ENSG00000277144.1	RP11-59H7.4	-5.53	3.99e-08	5.24e-06	-0.21	-0.17	Atopic dermatitis;	chr15:59055558	chr15:59115547~59116089:-
BRCA	cis	rs2732480	0.557	rs2634682	ENSG00000226413.2	OR8T1P	5.53	3.99e-08	5.24e-06	0.23	0.17	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48339160	chr12:48442030~48442947:-
BRCA	cis	rs9341808	0.718	rs2322631	ENSG00000272129.1	RP11-250B2.6	5.53	3.99e-08	5.25e-06	0.21	0.17	Sitting height ratio;	chr6:80134239	chr6:80355424~80356859:+
BRCA	cis	rs853679	0.55	rs1233701	ENSG00000280107.1	AL022393.9	5.53	3.99e-08	5.25e-06	0.24	0.17	Depression;	chr6:28200948	chr6:28170845~28172521:+
BRCA	cis	rs11105298	0.891	rs3741898	ENSG00000270344.2	RP11-734K2.4	5.53	4e-08	5.25e-06	0.2	0.17	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89539986	chr12:89525654~89548005:+
BRCA	cis	rs10266483	0.654	rs6962076	ENSG00000228653.2	HNRNPCP7	5.53	4e-08	5.26e-06	0.2	0.17	Response to statin therapy;	chr7:64559214	chr7:64500825~64501729:+
BRCA	cis	rs2834288	0.618	rs9977699	ENSG00000273102.1	AP000569.9	-5.53	4e-08	5.26e-06	-0.19	-0.17	Gut microbiota (bacterial taxa);	chr21:33978601	chr21:33967101~33968573:-
BRCA	cis	rs7615952	0.688	rs12485622	ENSG00000171084.14	FAM86JP	5.53	4e-08	5.26e-06	0.26	0.17	Blood pressure (smoking interaction);	chr3:125991896	chr3:125916620~125930024:+
BRCA	cis	rs17508449	0.819	rs6678422	ENSG00000232450.1	RP4-730K3.3	-5.53	4.01e-08	5.27e-06	-0.29	-0.17	Leprosy;	chr1:113662078	chr1:113698884~113699631:-
BRCA	cis	rs12681366	0.839	rs3019280	ENSG00000253704.1	RP11-267M23.4	5.53	4.01e-08	5.27e-06	0.19	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94437804	chr8:94553722~94569745:+
BRCA	cis	rs66887589	0.616	rs1052633	ENSG00000249244.1	RP11-548H18.2	5.53	4.01e-08	5.27e-06	0.19	0.17	Diastolic blood pressure;	chr4:119294159	chr4:119391831~119395335:-
BRCA	cis	rs6490294	0.571	rs12423960	ENSG00000226469.1	ADAM1B	5.53	4.01e-08	5.27e-06	0.27	0.17	Mean platelet volume;	chr12:112004612	chr12:111927018~111929017:+
BRCA	cis	rs6490294	0.571	rs10849992	ENSG00000226469.1	ADAM1B	5.53	4.01e-08	5.27e-06	0.27	0.17	Mean platelet volume;	chr12:112005213	chr12:111927018~111929017:+
BRCA	cis	rs6490294	0.571	rs7310545	ENSG00000226469.1	ADAM1B	5.53	4.01e-08	5.27e-06	0.27	0.17	Mean platelet volume;	chr12:112006156	chr12:111927018~111929017:+
BRCA	cis	rs6490294	0.571	rs7296841	ENSG00000226469.1	ADAM1B	5.53	4.01e-08	5.27e-06	0.27	0.17	Mean platelet volume;	chr12:112006305	chr12:111927018~111929017:+
BRCA	cis	rs11105298	0.891	rs10858906	ENSG00000270344.2	RP11-734K2.4	5.53	4.01e-08	5.27e-06	0.2	0.17	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89540697	chr12:89525654~89548005:+
BRCA	cis	rs2638953	0.815	rs11049683	ENSG00000247934.4	RP11-967K21.1	-5.53	4.01e-08	5.27e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28509597	chr12:28163298~28190738:-
BRCA	cis	rs2239557	0.508	rs9646165	ENSG00000259065.1	RP5-1021I20.1	-5.53	4.02e-08	5.28e-06	-0.25	-0.17	Common traits (Other);	chr14:73858104	chr14:73787360~73803270:+
BRCA	cis	rs4907240	1	rs4907240	ENSG00000237510.6	AC008268.2	-5.53	4.02e-08	5.29e-06	-0.25	-0.17	Event-related brain oscillations;	chr2:96562302	chr2:95789654~95800166:+
BRCA	cis	rs17508449	0.819	rs4589108	ENSG00000232450.1	RP4-730K3.3	-5.53	4.03e-08	5.29e-06	-0.31	-0.17	Leprosy;	chr1:113717003	chr1:113698884~113699631:-
BRCA	cis	rs2638953	0.962	rs11049540	ENSG00000278733.1	RP11-425D17.1	-5.53	4.03e-08	5.29e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28337959	chr12:28185625~28186190:-
BRCA	cis	rs10510102	0.935	rs12255859	ENSG00000226864.1	ATE1-AS1	5.53	4.03e-08	5.29e-06	0.32	0.17	Breast cancer;	chr10:121831661	chr10:121928312~121951965:+
BRCA	cis	rs6490294	0.571	rs7316563	ENSG00000226469.1	ADAM1B	5.53	4.03e-08	5.29e-06	0.26	0.17	Mean platelet volume;	chr12:112015831	chr12:111927018~111929017:+
BRCA	cis	rs6969780	1	rs73071550	ENSG00000233429.8	HOTAIRM1	5.53	4.03e-08	5.29e-06	0.21	0.17	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27109480	chr7:27095647~27100265:+
BRCA	cis	rs897984	0.537	rs8045637	ENSG00000260911.2	RP11-196G11.2	5.53	4.03e-08	5.3e-06	0.16	0.17	Dementia with Lewy bodies;	chr16:30807341	chr16:31043150~31049868:+
BRCA	cis	rs10129255	0.957	rs2013423	ENSG00000224373.3	IGHV4-59	5.53	4.03e-08	5.3e-06	0.11	0.17	Kawasaki disease;	chr14:106690675	chr14:106627249~106627825:-
BRCA	cis	rs10129255	0.957	rs56134540	ENSG00000224373.3	IGHV4-59	5.53	4.03e-08	5.3e-06	0.11	0.17	Kawasaki disease;	chr14:106691290	chr14:106627249~106627825:-
BRCA	cis	rs875971	0.545	rs10950025	ENSG00000228409.4	CCT6P1	-5.53	4.03e-08	5.3e-06	-0.17	-0.17	Aortic root size;	chr7:66158946	chr7:65751142~65763354:+
BRCA	cis	rs875971	0.52	rs12666485	ENSG00000228409.4	CCT6P1	-5.53	4.03e-08	5.3e-06	-0.17	-0.17	Aortic root size;	chr7:66160135	chr7:65751142~65763354:+
BRCA	cis	rs875971	0.545	rs67688847	ENSG00000228409.4	CCT6P1	-5.53	4.03e-08	5.3e-06	-0.17	-0.17	Aortic root size;	chr7:66161064	chr7:65751142~65763354:+
BRCA	cis	rs2803122	0.745	rs10123714	ENSG00000273226.1	RP11-513M16.8	-5.53	4.03e-08	5.3e-06	-0.18	-0.17	Pulse pressure;	chr9:19231645	chr9:19375451~19375996:+
BRCA	cis	rs6840360	0.901	rs4696293	ENSG00000270265.1	RP11-731D1.4	5.53	4.03e-08	5.3e-06	0.19	0.17	Intelligence (multi-trait analysis);	chr4:151786228	chr4:151333775~151353224:-
BRCA	cis	rs1722141	0.67	rs1722148	ENSG00000229628.1	AC073115.7	5.53	4.03e-08	5.3e-06	0.25	0.17	Sitting height ratio;	chr7:45953897	chr7:45990905~46000898:+
BRCA	cis	rs4639966	0.836	rs10892282	ENSG00000255422.1	AP002954.4	-5.53	4.04e-08	5.3e-06	-0.23	-0.17	Systemic lupus erythematosus;	chr11:118757069	chr11:118704607~118750263:+
BRCA	cis	rs10129255	0.957	rs12589190	ENSG00000224373.3	IGHV4-59	5.53	4.04e-08	5.3e-06	0.1	0.17	Kawasaki disease;	chr14:106783079	chr14:106627249~106627825:-
BRCA	cis	rs2638953	0.853	rs11049636	ENSG00000278733.1	RP11-425D17.1	-5.53	4.04e-08	5.3e-06	-0.22	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28465728	chr12:28185625~28186190:-
BRCA	cis	rs6479891	0.841	rs7092504	ENSG00000232075.1	MRPL35P2	-5.53	4.04e-08	5.31e-06	-0.31	-0.17	Arthritis (juvenile idiopathic);	chr10:63329679	chr10:63634317~63634827:-
BRCA	cis	rs3760982	0.585	rs68073292	ENSG00000267058.1	RP11-15A1.3	-5.53	4.04e-08	5.31e-06	-0.2	-0.17	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43787249	chr19:43891804~43901805:-
BRCA	cis	rs73198271	0.74	rs10092600	ENSG00000253893.2	FAM85B	5.53	4.05e-08	5.32e-06	0.23	0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8791513	chr8:8167819~8226614:-
BRCA	cis	rs3120667	0.79	rs3753443	ENSG00000237975.5	FLG-AS1	5.53	4.05e-08	5.32e-06	0.26	0.17	Eating disorders;	chr1:152415331	chr1:152168125~152445456:+
BRCA	cis	rs2708977	0.671	rs582014	ENSG00000237510.6	AC008268.2	-5.53	4.05e-08	5.32e-06	-0.23	-0.17	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96410089	chr2:95789654~95800166:+
BRCA	cis	rs7308116	0.51	rs11525611	ENSG00000274395.1	RP11-554D14.8	-5.53	4.06e-08	5.33e-06	-0.2	-0.17	Pelvic organ prolapse (moderate/severe);	chr12:107825003	chr12:107835541~107836555:-
BRCA	cis	rs7308116	0.51	rs11525612	ENSG00000274395.1	RP11-554D14.8	-5.53	4.06e-08	5.33e-06	-0.2	-0.17	Pelvic organ prolapse (moderate/severe);	chr12:107825014	chr12:107835541~107836555:-
BRCA	cis	rs7308116	0.51	rs11525597	ENSG00000274395.1	RP11-554D14.8	-5.53	4.06e-08	5.33e-06	-0.2	-0.17	Pelvic organ prolapse (moderate/severe);	chr12:107825016	chr12:107835541~107836555:-
BRCA	cis	rs10761482	0.515	rs2393642	ENSG00000254271.1	RP11-131N11.4	5.53	4.06e-08	5.33e-06	0.22	0.17	Schizophrenia;	chr10:60522732	chr10:60734342~60741828:+
BRCA	cis	rs9300255	0.602	rs1569068	ENSG00000235423.7	RP11-282O18.3	-5.53	4.06e-08	5.33e-06	-0.22	-0.17	Neutrophil percentage of white cells;	chr12:123147729	chr12:123252030~123261483:-
BRCA	cis	rs2562456	0.833	rs56179986	ENSG00000268535.1	RP11-420K14.3	5.53	4.06e-08	5.33e-06	0.25	0.17	Pain;	chr19:21337882	chr19:21709522~21710191:+
BRCA	cis	rs4218	0.56	rs8039514	ENSG00000277144.1	RP11-59H7.4	-5.53	4.06e-08	5.33e-06	-0.2	-0.17	Social communication problems;	chr15:59114382	chr15:59115547~59116089:-
BRCA	cis	rs2288884	0.779	rs10411428	ENSG00000275055.1	CTC-471J1.11	-5.53	4.06e-08	5.33e-06	-0.24	-0.17	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52104512	chr19:52049007~52049754:+
BRCA	cis	rs9907295	0.818	rs4796112	ENSG00000271013.1	AC015849.15	5.53	4.06e-08	5.34e-06	0.23	0.17	Fibroblast growth factor basic levels;	chr17:35831722	chr17:35912635~35918010:-
BRCA	cis	rs2732480	0.538	rs1387259	ENSG00000226413.2	OR8T1P	-5.53	4.07e-08	5.34e-06	-0.23	-0.17	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48309739	chr12:48442030~48442947:-
BRCA	cis	rs7208859	0.673	rs9889755	ENSG00000265443.1	CTD-2349P21.6	5.53	4.07e-08	5.34e-06	0.25	0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30907487	chr17:30726305~30727564:-
BRCA	cis	rs2243480	0.901	rs778687	ENSG00000228409.4	CCT6P1	5.53	4.07e-08	5.34e-06	0.24	0.17	Diabetic kidney disease;	chr7:66370832	chr7:65751142~65763354:+
BRCA	cis	rs2243480	1	rs778704	ENSG00000228409.4	CCT6P1	5.53	4.07e-08	5.34e-06	0.24	0.17	Diabetic kidney disease;	chr7:66398480	chr7:65751142~65763354:+
BRCA	cis	rs2243480	0.901	rs778693	ENSG00000228409.4	CCT6P1	5.53	4.07e-08	5.34e-06	0.24	0.17	Diabetic kidney disease;	chr7:66407358	chr7:65751142~65763354:+
BRCA	cis	rs2243480	1	rs778691	ENSG00000228409.4	CCT6P1	5.53	4.07e-08	5.34e-06	0.24	0.17	Diabetic kidney disease;	chr7:66408105	chr7:65751142~65763354:+
BRCA	cis	rs2243480	1	rs13235972	ENSG00000228409.4	CCT6P1	5.53	4.07e-08	5.34e-06	0.24	0.17	Diabetic kidney disease;	chr7:66418618	chr7:65751142~65763354:+
BRCA	cis	rs2243480	1	rs34192067	ENSG00000228409.4	CCT6P1	5.53	4.07e-08	5.34e-06	0.24	0.17	Diabetic kidney disease;	chr7:66422670	chr7:65751142~65763354:+
BRCA	cis	rs8103278	1	rs9807819	ENSG00000267395.4	AC074212.6	5.53	4.07e-08	5.34e-06	0.17	0.17	Coronary artery disease;	chr19:45736340	chr19:45767796~45772504:+
BRCA	cis	rs4950322	0.57	rs17356492	ENSG00000244371.2	PFN1P8	-5.53	4.07e-08	5.34e-06	-0.24	-0.17	Protein quantitative trait loci;	chr1:147296089	chr1:146957117~146957659:-
BRCA	cis	rs10510102	0.935	rs11200187	ENSG00000226864.1	ATE1-AS1	5.53	4.07e-08	5.34e-06	0.31	0.17	Breast cancer;	chr10:121843050	chr10:121928312~121951965:+
BRCA	cis	rs12468226	1	rs16839149	ENSG00000226261.1	AC064836.3	5.53	4.07e-08	5.34e-06	0.29	0.17	Urate levels;	chr2:202427621	chr2:202336024~202336727:-
BRCA	cis	rs2153535	0.537	rs9379232	ENSG00000230939.1	RP11-314C16.1	-5.53	4.07e-08	5.34e-06	-0.2	-0.17	Motion sickness;	chr6:8634176	chr6:8784178~8785445:+
BRCA	cis	rs7923609	1	rs1935	ENSG00000232075.1	MRPL35P2	-5.53	4.07e-08	5.35e-06	-0.21	-0.17	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63168063	chr10:63634317~63634827:-
BRCA	cis	rs5758511	0.68	rs5758686	ENSG00000233903.2	Z83851.4	5.53	4.08e-08	5.35e-06	0.26	0.17	Birth weight;	chr22:42259371	chr22:42276355~42277052:+
BRCA	cis	rs7923837	0.683	rs2149632	ENSG00000236493.2	EIF2S2P3	5.53	4.08e-08	5.35e-06	0.24	0.17	Multiple sclerosis;Body mass index;	chr10:92472490	chr10:92668745~92669743:-
BRCA	cis	rs10129255	0.5	rs4774008	ENSG00000224373.3	IGHV4-59	5.53	4.08e-08	5.35e-06	0.1	0.17	Kawasaki disease;	chr14:106681273	chr14:106627249~106627825:-
BRCA	cis	rs7178375	1	rs4779797	ENSG00000270055.1	CTD-3092A11.2	5.53	4.08e-08	5.36e-06	0.24	0.17	Hypertriglyceridemia;	chr15:30916222	chr15:30487963~30490313:+
BRCA	cis	rs4650994	0.525	rs2811295	ENSG00000273384.1	RP5-1098D14.1	-5.53	4.09e-08	5.36e-06	-0.21	-0.17	HDL cholesterol;HDL cholesterol levels;	chr1:178582132	chr1:178651706~178652282:+
BRCA	cis	rs9307551	0.553	rs7673033	ENSG00000250334.4	LINC00989	-5.53	4.09e-08	5.36e-06	-0.24	-0.17	Refractive error;	chr4:79537914	chr4:79492416~79576460:+
BRCA	cis	rs78487399	0.908	rs74501107	ENSG00000234936.1	AC010883.5	5.53	4.09e-08	5.37e-06	0.22	0.17	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43578873	chr2:43229573~43233394:+
BRCA	cis	rs7131987	0.65	rs7301398	ENSG00000275476.1	RP11-996F15.4	-5.53	4.09e-08	5.37e-06	-0.2	-0.17	QT interval;	chr12:29302457	chr12:29277397~29277882:-
BRCA	cis	rs7131987	0.65	rs7301188	ENSG00000275476.1	RP11-996F15.4	-5.53	4.09e-08	5.37e-06	-0.2	-0.17	QT interval;	chr12:29302458	chr12:29277397~29277882:-
BRCA	cis	rs10510102	1	rs10886994	ENSG00000226864.1	ATE1-AS1	5.53	4.09e-08	5.37e-06	0.31	0.17	Breast cancer;	chr10:121841075	chr10:121928312~121951965:+
BRCA	cis	rs9467773	1	rs28558133	ENSG00000124549.13	BTN2A3P	5.53	4.09e-08	5.37e-06	0.17	0.17	Intelligence (multi-trait analysis);	chr6:26531205	chr6:26421391~26432383:+
BRCA	cis	rs875971	0.789	rs28815324	ENSG00000228409.4	CCT6P1	5.53	4.09e-08	5.37e-06	0.17	0.17	Aortic root size;	chr7:66100789	chr7:65751142~65763354:+
BRCA	cis	rs7474896	0.537	rs2749586	ENSG00000120555.12	SEPT7P9	-5.53	4.1e-08	5.37e-06	-0.23	-0.17	Obesity (extreme);	chr10:37981286	chr10:38383069~38402916:-
BRCA	cis	rs11105298	0.891	rs6538190	ENSG00000270344.2	RP11-734K2.4	5.53	4.1e-08	5.38e-06	0.19	0.17	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89492165	chr12:89525654~89548005:+
BRCA	cis	rs26949	0.554	rs11742421	ENSG00000272308.1	RP11-231G3.1	-5.53	4.1e-08	5.38e-06	-0.19	-0.17	Intelligence (multi-trait analysis);	chr5:60681590	chr5:60866457~60866935:-
BRCA	cis	rs9527	0.83	rs3740392	ENSG00000213061.2	PFN1P11	5.53	4.1e-08	5.38e-06	0.25	0.17	Arsenic metabolism;	chr10:102877098	chr10:102838011~102845473:-
BRCA	cis	rs9287719	0.967	rs4669593	ENSG00000243819.4	RN7SL832P	5.53	4.1e-08	5.38e-06	0.16	0.17	Prostate cancer;	chr2:10561782	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.967	rs3814388	ENSG00000243819.4	RN7SL832P	5.53	4.1e-08	5.38e-06	0.16	0.17	Prostate cancer;	chr2:10561973	chr2:10690344~10692099:+
BRCA	cis	rs523522	0.962	rs4767914	ENSG00000278344.1	RP11-18C24.8	5.53	4.11e-08	5.39e-06	0.23	0.17	High light scatter reticulocyte count;	chr12:120556014	chr12:120500735~120501090:-
BRCA	cis	rs7577696	0.568	rs7562653	ENSG00000272716.1	RP11-563N4.1	5.53	4.11e-08	5.39e-06	0.2	0.17	Inflammatory biomarkers;	chr2:32253560	chr2:32165046~32165757:-
BRCA	cis	rs17301013	0.896	rs3118980	ENSG00000227373.4	RP11-160H22.5	-5.53	4.11e-08	5.39e-06	-0.22	-0.17	Systemic lupus erythematosus;	chr1:174793701	chr1:174115300~174160004:-
BRCA	cis	rs7577696	0.671	rs72863940	ENSG00000272716.1	RP11-563N4.1	-5.53	4.11e-08	5.4e-06	-0.18	-0.17	Inflammatory biomarkers;	chr2:32169605	chr2:32165046~32165757:-
BRCA	cis	rs4835473	0.714	rs10013005	ENSG00000249741.2	RP11-673E1.3	-5.53	4.12e-08	5.4e-06	-0.18	-0.17	Immature fraction of reticulocytes;	chr4:143711351	chr4:143911514~143912053:-
BRCA	cis	rs73081554	0.611	rs4681852	ENSG00000272360.1	RP11-359I18.5	-5.53	4.12e-08	5.4e-06	-0.25	-0.17	Rheumatoid arthritis;	chr3:58423446	chr3:58490830~58491291:-
BRCA	cis	rs2692947	0.727	rs2692950	ENSG00000237510.6	AC008268.2	5.53	4.12e-08	5.41e-06	0.23	0.17	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96007776	chr2:95789654~95800166:+
BRCA	cis	rs1552244	1	rs7615764	ENSG00000232901.1	CYCSP10	5.53	4.12e-08	5.41e-06	0.24	0.17	Alzheimer's disease;	chr3:10040908	chr3:10000647~10000940:-
BRCA	cis	rs11722779	0.935	rs11938650	ENSG00000251288.2	RP11-10L12.2	-5.53	4.12e-08	5.41e-06	-0.2	-0.17	Schizophrenia;	chr4:103021639	chr4:102751401~102752641:+
BRCA	cis	rs13126694	0.71	rs4574459	ENSG00000251429.1	RP11-597D13.7	5.53	4.12e-08	5.41e-06	0.16	0.17	Blood osmolality (transformed sodium);	chr4:157991482	chr4:158270378~158278676:+
BRCA	cis	rs6951245	0.554	rs75075857	ENSG00000229043.2	AC091729.9	-5.53	4.12e-08	5.41e-06	-0.25	-0.17	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1100662	chr7:1160374~1165267:+
BRCA	cis	rs6490294	0.571	rs11066120	ENSG00000226469.1	ADAM1B	5.53	4.12e-08	5.41e-06	0.26	0.17	Mean platelet volume;	chr12:111998391	chr12:111927018~111929017:+
BRCA	cis	rs6490294	0.571	rs7312472	ENSG00000226469.1	ADAM1B	5.53	4.12e-08	5.41e-06	0.26	0.17	Mean platelet volume;	chr12:112000966	chr12:111927018~111929017:+
BRCA	cis	rs6490294	0.571	rs57439171	ENSG00000226469.1	ADAM1B	5.53	4.12e-08	5.41e-06	0.26	0.17	Mean platelet volume;	chr12:112001483	chr12:111927018~111929017:+
BRCA	cis	rs6490294	0.571	rs7316650	ENSG00000226469.1	ADAM1B	5.53	4.12e-08	5.41e-06	0.26	0.17	Mean platelet volume;	chr12:112001860	chr12:111927018~111929017:+
BRCA	cis	rs6490294	0.571	rs7313773	ENSG00000226469.1	ADAM1B	5.53	4.12e-08	5.41e-06	0.26	0.17	Mean platelet volume;	chr12:112003884	chr12:111927018~111929017:+
BRCA	cis	rs1722141	0.67	rs788768	ENSG00000229628.1	AC073115.7	5.53	4.13e-08	5.42e-06	0.25	0.17	Sitting height ratio;	chr7:45960955	chr7:45990905~46000898:+
BRCA	cis	rs1345301	1	rs1345302	ENSG00000234389.1	AC007278.3	-5.53	4.13e-08	5.42e-06	-0.16	-0.17	Waist circumference;	chr2:102256909	chr2:102438713~102440475:+
BRCA	cis	rs1345301	1	rs13431601	ENSG00000234389.1	AC007278.3	-5.53	4.13e-08	5.42e-06	-0.16	-0.17	Waist circumference;	chr2:102257253	chr2:102438713~102440475:+
BRCA	cis	rs454217	0.765	rs392929	ENSG00000277851.1	RP11-756G20.1	5.53	4.13e-08	5.42e-06	0.19	0.17	Smoking quantity;	chr12:92338016	chr12:92247756~92363832:-
BRCA	cis	rs962856	0.964	rs13415002	ENSG00000236780.4	AC078941.1	5.53	4.14e-08	5.42e-06	0.22	0.17	Pancreatic cancer;	chr2:67384691	chr2:67123357~67215319:-
BRCA	cis	rs10829156	0.66	rs10764587	ENSG00000240291.1	RP11-499P20.2	5.53	4.14e-08	5.42e-06	0.19	0.17	Sudden cardiac arrest;	chr10:18548901	chr10:18513115~18545651:-
BRCA	cis	rs2562456	0.754	rs11666213	ENSG00000268535.1	RP11-420K14.3	5.53	4.14e-08	5.43e-06	0.25	0.17	Pain;	chr19:21422843	chr19:21709522~21710191:+
BRCA	cis	rs919433	0.713	rs6719729	ENSG00000231621.1	AC013264.2	-5.53	4.14e-08	5.43e-06	-0.16	-0.17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197615348	chr2:197197991~197199273:+
BRCA	cis	rs2613964	0.504	rs4682466	ENSG00000240057.4	RP11-572M11.4	5.53	4.15e-08	5.44e-06	0.17	0.17	Pediatric bone mineral content (spine);Pediatric bone mineral density (spine);	chr3:113130841	chr3:113019532~113183301:+
BRCA	cis	rs848490	0.508	rs6975810	ENSG00000214293.7	APTR	5.53	4.15e-08	5.44e-06	0.19	0.17	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77659701	chr7:77657660~77696265:-
BRCA	cis	rs2179367	0.632	rs9498329	ENSG00000223701.3	RAET1E-AS1	5.53	4.15e-08	5.44e-06	0.24	0.17	Dupuytren's disease;	chr6:149349941	chr6:149884431~149919508:+
BRCA	cis	rs2790457	0.958	rs2532744	ENSG00000254635.4	WAC-AS1	-5.53	4.15e-08	5.44e-06	-0.2	-0.17	Multiple myeloma;	chr10:28613689	chr10:28522652~28532743:-
BRCA	cis	rs9840812	0.592	rs900048	ENSG00000273486.1	RP11-731C17.2	5.53	4.15e-08	5.44e-06	0.2	0.17	Fibrinogen levels;	chr3:136500088	chr3:136837338~136839021:-
BRCA	cis	rs7804306	0.655	rs34746652	ENSG00000233264.2	AC006042.8	5.53	4.16e-08	5.45e-06	0.37	0.17	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8012957	chr7:7980312~7982228:+
BRCA	cis	rs2253762	0.54	rs7358186	ENSG00000276742.1	RP11-500G22.4	5.53	4.16e-08	5.45e-06	0.29	0.17	Breast cancer;	chr10:122000816	chr10:121956782~121957098:+
BRCA	cis	rs11955398	0.502	rs290514	ENSG00000215032.2	GNL3LP1	5.53	4.16e-08	5.45e-06	0.22	0.17	Intelligence (multi-trait analysis);	chr5:60934494	chr5:60891935~60893577:-
BRCA	cis	rs16866061	0.515	rs3738951	ENSG00000228446.2	AC073052.1	5.53	4.16e-08	5.45e-06	0.18	0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr2:224503604	chr2:224499387~224500100:-
BRCA	cis	rs4835473	0.897	rs1450246	ENSG00000249741.2	RP11-673E1.3	-5.52	4.16e-08	5.45e-06	-0.18	-0.17	Immature fraction of reticulocytes;	chr4:143702954	chr4:143911514~143912053:-
BRCA	cis	rs523522	0.962	rs4766968	ENSG00000278344.1	RP11-18C24.8	5.52	4.16e-08	5.46e-06	0.23	0.17	High light scatter reticulocyte count;	chr12:120509985	chr12:120500735~120501090:-
BRCA	cis	rs10129255	0.5	rs6576231	ENSG00000224373.3	IGHV4-59	5.52	4.17e-08	5.46e-06	0.1	0.17	Kawasaki disease;	chr14:106783693	chr14:106627249~106627825:-
BRCA	cis	rs11098499	0.526	rs10026625	ENSG00000249244.1	RP11-548H18.2	5.52	4.17e-08	5.46e-06	0.18	0.17	Corneal astigmatism;	chr4:119358981	chr4:119391831~119395335:-
BRCA	cis	rs11159086	0.793	rs10150696	ENSG00000270000.1	RP3-449M8.9	5.52	4.17e-08	5.46e-06	0.25	0.17	Advanced glycation end-product levels;	chr14:74476723	chr14:74471930~74472360:-
BRCA	cis	rs11105298	0.891	rs4842664	ENSG00000270344.2	RP11-734K2.4	5.52	4.17e-08	5.46e-06	0.2	0.17	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89544253	chr12:89525654~89548005:+
BRCA	cis	rs77204473	0.744	rs2170317	ENSG00000280143.1	AP000892.6	-5.52	4.17e-08	5.46e-06	-0.27	-0.17	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117200024	chr11:117204967~117210292:+
BRCA	cis	rs7923609	1	rs10761742	ENSG00000232075.1	MRPL35P2	-5.52	4.17e-08	5.46e-06	-0.21	-0.17	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63325288	chr10:63634317~63634827:-
BRCA	cis	rs7208859	0.673	rs2433	ENSG00000266490.1	CTD-2349P21.9	5.52	4.17e-08	5.46e-06	0.26	0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30899210	chr17:30792372~30792833:+
BRCA	cis	rs1075265	0.722	rs7596349	ENSG00000235937.1	AC008280.1	5.52	4.17e-08	5.46e-06	0.18	0.17	Chronotype;Morning vs. evening chronotype;	chr2:53709123	chr2:54029552~54030682:-
BRCA	cis	rs7131987	0.65	rs10843384	ENSG00000275476.1	RP11-996F15.4	-5.52	4.17e-08	5.47e-06	-0.2	-0.17	QT interval;	chr12:29319476	chr12:29277397~29277882:-
BRCA	cis	rs7131987	0.65	rs11050188	ENSG00000275476.1	RP11-996F15.4	-5.52	4.17e-08	5.47e-06	-0.2	-0.17	QT interval;	chr12:29320175	chr12:29277397~29277882:-
BRCA	cis	rs7131987	0.683	rs12366505	ENSG00000275476.1	RP11-996F15.4	-5.52	4.17e-08	5.47e-06	-0.2	-0.17	QT interval;	chr12:29321177	chr12:29277397~29277882:-
BRCA	cis	rs7131987	0.65	rs12366527	ENSG00000275476.1	RP11-996F15.4	-5.52	4.17e-08	5.47e-06	-0.2	-0.17	QT interval;	chr12:29321323	chr12:29277397~29277882:-
BRCA	cis	rs7131987	0.65	rs7311912	ENSG00000275476.1	RP11-996F15.4	-5.52	4.17e-08	5.47e-06	-0.2	-0.17	QT interval;	chr12:29322770	chr12:29277397~29277882:-
BRCA	cis	rs30380	0.632	rs149189	ENSG00000272109.1	CTD-2260A17.3	-5.52	4.17e-08	5.47e-06	-0.24	-0.17	Cerebrospinal fluid biomarker levels;	chr5:96802101	chr5:96804353~96806105:+
BRCA	cis	rs30380	0.632	rs26495	ENSG00000272109.1	CTD-2260A17.3	-5.52	4.17e-08	5.47e-06	-0.24	-0.17	Cerebrospinal fluid biomarker levels;	chr5:96802137	chr5:96804353~96806105:+
BRCA	cis	rs10899021	1	rs11236193	ENSG00000279353.1	RP11-864N7.4	5.52	4.18e-08	5.47e-06	0.34	0.17	Response to metformin (IC50);	chr11:74657262	chr11:74698231~74699658:-
BRCA	cis	rs7772486	0.875	rs1960885	ENSG00000270638.1	RP3-466P17.1	5.52	4.18e-08	5.47e-06	0.19	0.17	Lobe attachment (rater-scored or self-reported);	chr6:146004794	chr6:145735570~145737218:+
BRCA	cis	rs9516	0.565	rs7789	ENSG00000254974.1	RP11-702H23.2	5.52	4.18e-08	5.47e-06	0.2	0.17	Facial morphology (factor 15, philtrum width);	chr11:74455275	chr11:74485580~74486051:-
BRCA	cis	rs13113518	0.507	rs11943456	ENSG00000273257.1	RP11-177J6.1	5.52	4.18e-08	5.48e-06	0.22	0.17	Height;	chr4:55410167	chr4:55387949~55388271:+
BRCA	cis	rs7569084	0.687	rs11675538	ENSG00000237979.1	AC007389.1	5.52	4.18e-08	5.48e-06	0.21	0.17	Sum eosinophil basophil counts;	chr2:65459327	chr2:65500993~65502138:-
BRCA	cis	rs1979679	0.918	rs1586868	ENSG00000278733.1	RP11-425D17.1	5.52	4.18e-08	5.48e-06	0.21	0.17	Ossification of the posterior longitudinal ligament of the spine;	chr12:28368176	chr12:28185625~28186190:-
BRCA	cis	rs12539814	1	rs12666210	ENSG00000204959.4	ARHGEF34P	-5.52	4.19e-08	5.48e-06	-0.27	-0.17	Diastolic blood pressure;	chr7:144435635	chr7:144272445~144286966:-
BRCA	cis	rs4650994	0.544	rs4132058	ENSG00000273384.1	RP5-1098D14.1	5.52	4.19e-08	5.49e-06	0.21	0.17	HDL cholesterol;HDL cholesterol levels;	chr1:178536422	chr1:178651706~178652282:+
BRCA	cis	rs8054556	1	rs3814880	ENSG00000273724.1	RP11-347C12.12	-5.52	4.19e-08	5.49e-06	-0.19	-0.17	Autism spectrum disorder or schizophrenia;	chr16:30006574	chr16:30336400~30343336:+
BRCA	cis	rs2638953	0.962	rs10843171	ENSG00000278733.1	RP11-425D17.1	-5.52	4.2e-08	5.5e-06	-0.21	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28435583	chr12:28185625~28186190:-
BRCA	cis	rs4819052	0.851	rs2838848	ENSG00000184274.3	LINC00315	-5.52	4.2e-08	5.5e-06	-0.23	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251102	chr21:45300245~45305257:-
BRCA	cis	rs4819052	0.851	rs2838849	ENSG00000184274.3	LINC00315	-5.52	4.2e-08	5.5e-06	-0.23	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251112	chr21:45300245~45305257:-
BRCA	cis	rs4835473	0.897	rs1553070	ENSG00000249741.2	RP11-673E1.3	-5.52	4.2e-08	5.5e-06	-0.18	-0.17	Immature fraction of reticulocytes;	chr4:143715981	chr4:143911514~143912053:-
BRCA	cis	rs4834770	0.668	rs1397610	ENSG00000178636.7	RP11-455G16.1	5.52	4.2e-08	5.5e-06	0.22	0.17	Blood protein levels;	chr4:119206606	chr4:119192773~119212644:-
BRCA	cis	rs6479891	0.915	rs10740110	ENSG00000232075.1	MRPL35P2	-5.52	4.2e-08	5.51e-06	-0.29	-0.17	Arthritis (juvenile idiopathic);	chr10:63283461	chr10:63634317~63634827:-
BRCA	cis	rs1552244	0.935	rs35148833	ENSG00000232901.1	CYCSP10	5.52	4.21e-08	5.51e-06	0.24	0.17	Alzheimer's disease;	chr3:10075253	chr3:10000647~10000940:-
BRCA	cis	rs6479891	1	rs16918575	ENSG00000232075.1	MRPL35P2	-5.52	4.21e-08	5.52e-06	-0.31	-0.17	Arthritis (juvenile idiopathic);	chr10:63541565	chr10:63634317~63634827:-
BRCA	cis	rs1476670	0.565	rs2428965	ENSG00000230615.5	RP5-1198O20.4	-5.52	4.21e-08	5.52e-06	-0.23	-0.17	Eotaxin levels;	chr1:44037237	chr1:44030443~44115913:+
BRCA	cis	rs7923837	0.651	rs10882092	ENSG00000236493.2	EIF2S2P3	5.52	4.21e-08	5.52e-06	0.24	0.17	Multiple sclerosis;Body mass index;	chr10:92619466	chr10:92668745~92669743:-
BRCA	cis	rs1552244	1	rs111392584	ENSG00000232901.1	CYCSP10	5.52	4.22e-08	5.52e-06	0.24	0.17	Alzheimer's disease;	chr3:10034307	chr3:10000647~10000940:-
BRCA	cis	rs1552244	1	rs17032276	ENSG00000232901.1	CYCSP10	5.52	4.22e-08	5.52e-06	0.24	0.17	Alzheimer's disease;	chr3:10035291	chr3:10000647~10000940:-
BRCA	cis	rs2739330	0.761	rs5760176	ENSG00000228039.3	KB-1125A3.10	-5.52	4.22e-08	5.52e-06	-0.2	-0.17	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23963780~23964374:+
BRCA	cis	rs4819052	0.819	rs13046807	ENSG00000184274.3	LINC00315	-5.52	4.22e-08	5.52e-06	-0.23	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45252371	chr21:45300245~45305257:-
BRCA	cis	rs9341808	0.69	rs2322634	ENSG00000272129.1	RP11-250B2.6	5.52	4.22e-08	5.52e-06	0.21	0.17	Sitting height ratio;	chr6:80164297	chr6:80355424~80356859:+
BRCA	cis	rs2732480	0.577	rs2732481	ENSG00000257735.1	RP11-370I10.6	5.52	4.22e-08	5.52e-06	0.22	0.17	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48343202	chr12:48350945~48442411:+
BRCA	cis	rs2732480	0.557	rs2732484	ENSG00000257735.1	RP11-370I10.6	5.52	4.22e-08	5.52e-06	0.22	0.17	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48343462	chr12:48350945~48442411:+
BRCA	cis	rs2732480	0.577	rs2732486	ENSG00000257735.1	RP11-370I10.6	5.52	4.22e-08	5.52e-06	0.22	0.17	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344051	chr12:48350945~48442411:+
BRCA	cis	rs2732480	0.517	rs2634676	ENSG00000257735.1	RP11-370I10.6	5.52	4.22e-08	5.52e-06	0.22	0.17	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344453	chr12:48350945~48442411:+
BRCA	cis	rs7308116	0.546	rs1895937	ENSG00000274395.1	RP11-554D14.8	-5.52	4.22e-08	5.53e-06	-0.2	-0.17	Pelvic organ prolapse (moderate/severe);	chr12:107821850	chr12:107835541~107836555:-
BRCA	cis	rs2832191	0.511	rs7278227	ENSG00000176054.6	RPL23P2	-5.52	4.22e-08	5.53e-06	-0.18	-0.17	Dental caries;	chr21:29110386	chr21:28997613~28998033:-
BRCA	cis	rs7772486	0.625	rs2050027	ENSG00000270638.1	RP3-466P17.1	-5.52	4.22e-08	5.53e-06	-0.19	-0.17	Lobe attachment (rater-scored or self-reported);	chr6:145794977	chr6:145735570~145737218:+
BRCA	cis	rs4713118	0.824	rs13211701	ENSG00000216901.1	AL022393.7	5.52	4.23e-08	5.53e-06	0.23	0.17	Parkinson's disease;	chr6:27782300	chr6:28176188~28176674:+
BRCA	cis	rs4713118	0.824	rs9468229	ENSG00000216901.1	AL022393.7	5.52	4.23e-08	5.53e-06	0.23	0.17	Parkinson's disease;	chr6:27782307	chr6:28176188~28176674:+
BRCA	cis	rs801193	0.613	rs2016325	ENSG00000229180.5	GS1-124K5.11	-5.52	4.23e-08	5.53e-06	-0.15	-0.17	Aortic root size;	chr7:66858513	chr7:66526088~66542624:-
BRCA	cis	rs10129255	1	rs10141557	ENSG00000224373.3	IGHV4-59	5.52	4.23e-08	5.53e-06	0.11	0.17	Kawasaki disease;	chr14:106767990	chr14:106627249~106627825:-
BRCA	cis	rs7200543	0.961	rs1741	ENSG00000260872.1	RP11-680G24.5	-5.52	4.23e-08	5.54e-06	-0.18	-0.17	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15036494	chr16:15018106~15020488:-
BRCA	cis	rs4819052	0.851	rs9979545	ENSG00000184274.3	LINC00315	-5.52	4.24e-08	5.54e-06	-0.23	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45259890	chr21:45300245~45305257:-
BRCA	cis	rs4819052	0.851	rs7276591	ENSG00000184274.3	LINC00315	-5.52	4.24e-08	5.54e-06	-0.23	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260241	chr21:45300245~45305257:-
BRCA	cis	rs7617773	0.817	rs9819094	ENSG00000199476.1	Y_RNA	-5.52	4.24e-08	5.54e-06	-0.23	-0.17	Coronary artery disease;	chr3:48278068	chr3:48288587~48288694:+
BRCA	cis	rs6969780	0.778	rs79619106	ENSG00000233429.8	HOTAIRM1	5.52	4.24e-08	5.55e-06	0.21	0.17	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27106709	chr7:27095647~27100265:+
BRCA	cis	rs7772486	0.764	rs7745696	ENSG00000270638.1	RP3-466P17.1	5.52	4.24e-08	5.55e-06	0.19	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145841693	chr6:145735570~145737218:+
BRCA	cis	rs2179367	0.632	rs9498335	ENSG00000223701.3	RAET1E-AS1	5.52	4.24e-08	5.55e-06	0.24	0.17	Dupuytren's disease;	chr6:149372648	chr6:149884431~149919508:+
BRCA	cis	rs1124769	0.719	rs1147138	ENSG00000259378.1	DCAF13P3	-5.52	4.24e-08	5.55e-06	-0.24	-0.17	Cognitive performance;	chr15:50885439	chr15:50944663~50945996:+
BRCA	cis	rs7191700	0.673	rs12325495	ENSG00000262703.1	RP11-485G7.6	5.52	4.24e-08	5.55e-06	0.17	0.17	Multiple sclerosis;	chr16:11324471	chr16:11348143~11349321:-
BRCA	cis	rs9341808	0.718	rs9448898	ENSG00000272129.1	RP11-250B2.6	5.52	4.25e-08	5.56e-06	0.21	0.17	Sitting height ratio;	chr6:80135624	chr6:80355424~80356859:+
BRCA	cis	rs9311474	0.597	rs13303	ENSG00000243224.1	RP5-1157M23.2	-5.52	4.25e-08	5.56e-06	-0.18	-0.17	Electroencephalogram traits;	chr3:52523992	chr3:52239258~52241097:+
BRCA	cis	rs1707322	0.721	rs10890346	ENSG00000234329.1	RP11-767N6.2	-5.52	4.26e-08	5.57e-06	-0.18	-0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45758220	chr1:45651039~45651826:-
BRCA	cis	rs9308731	0.966	rs6753785	ENSG00000227992.1	AC108463.2	-5.52	4.26e-08	5.57e-06	-0.19	-0.17	Chronic lymphocytic leukemia;	chr2:111166053	chr2:111203964~111206215:-
BRCA	cis	rs7897654	0.571	rs12764049	ENSG00000236937.2	PTGES3P4	5.52	4.26e-08	5.57e-06	0.25	0.17	Schizophrenia;	chr10:102875199	chr10:102845595~102845950:+
BRCA	cis	rs4691139	0.903	rs13127188	ENSG00000248632.1	RP11-366M4.11	5.52	4.26e-08	5.57e-06	0.17	0.17	Ovarian cancer in BRCA1 mutation carriers;	chr4:164997524	chr4:164968587~164970002:-
BRCA	cis	rs4691139	0.903	rs6812591	ENSG00000248632.1	RP11-366M4.11	5.52	4.26e-08	5.57e-06	0.17	0.17	Ovarian cancer in BRCA1 mutation carriers;	chr4:164999023	chr4:164968587~164970002:-
BRCA	cis	rs4691139	0.903	rs6812776	ENSG00000248632.1	RP11-366M4.11	5.52	4.26e-08	5.57e-06	0.17	0.17	Ovarian cancer in BRCA1 mutation carriers;	chr4:164999097	chr4:164968587~164970002:-
BRCA	cis	rs875971	0.545	rs10950027	ENSG00000228409.4	CCT6P1	-5.52	4.27e-08	5.58e-06	-0.17	-0.17	Aortic root size;	chr7:66169164	chr7:65751142~65763354:+
BRCA	cis	rs2098713	0.502	rs596585	ENSG00000250155.1	CTD-2353F22.1	5.52	4.27e-08	5.58e-06	0.2	0.17	Telomere length;	chr5:37530563	chr5:36666214~36725195:-
BRCA	cis	rs2235642	0.592	rs743963	ENSG00000280231.1	LA16c-380F5.3	-5.52	4.27e-08	5.58e-06	-0.22	-0.17	Coronary artery disease;	chr16:1607349	chr16:1553655~1554130:-
BRCA	cis	rs73222236	0.825	rs9868120	ENSG00000273486.1	RP11-731C17.2	5.52	4.27e-08	5.58e-06	0.19	0.17	Coronary artery disease;	chr3:136446234	chr3:136837338~136839021:-
BRCA	cis	rs2732480	0.538	rs2732462	ENSG00000257763.1	OR5BK1P	5.52	4.27e-08	5.58e-06	0.18	0.17	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48302601	chr12:48355792~48356614:-
BRCA	cis	rs2732480	0.5	rs2732461	ENSG00000240399.1	RP1-228P16.1	5.52	4.27e-08	5.58e-06	0.2	0.17	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48299019	chr12:48054813~48055591:-
BRCA	cis	rs7208859	0.673	rs9911989	ENSG00000266490.1	CTD-2349P21.9	-5.52	4.27e-08	5.58e-06	-0.26	-0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30910684	chr17:30792372~30792833:+
BRCA	cis	rs9341808	0.754	rs9341810	ENSG00000272129.1	RP11-250B2.6	5.52	4.27e-08	5.58e-06	0.21	0.17	Sitting height ratio;	chr6:80265121	chr6:80355424~80356859:+
BRCA	cis	rs9341808	0.7	rs12215236	ENSG00000272129.1	RP11-250B2.6	5.52	4.27e-08	5.58e-06	0.21	0.17	Sitting height ratio;	chr6:80265341	chr6:80355424~80356859:+
BRCA	cis	rs2732480	0.577	rs2732479	ENSG00000226413.2	OR8T1P	5.52	4.27e-08	5.59e-06	0.23	0.17	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48342477	chr12:48442030~48442947:-
BRCA	cis	rs2732480	0.537	rs1061986	ENSG00000226413.2	OR8T1P	5.52	4.27e-08	5.59e-06	0.23	0.17	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48342656	chr12:48442030~48442947:-
BRCA	cis	rs4908760	0.516	rs11121232	ENSG00000270282.1	RP5-1115A15.2	5.52	4.28e-08	5.59e-06	0.18	0.17	Vitiligo;	chr1:8790650	chr1:8512653~8513021:+
BRCA	cis	rs4415084	1	rs2165009	ENSG00000251141.4	RP11-53O19.1	5.52	4.28e-08	5.59e-06	0.16	0.17	Breast cancer;	chr5:44697814	chr5:44744900~44808777:-
BRCA	cis	rs721917	0.506	rs2475756	ENSG00000244733.5	RP11-506M13.3	-5.52	4.28e-08	5.59e-06	-0.2	-0.17	Chronic obstructive pulmonary disease;	chr10:79897010	chr10:79660891~79677996:+
BRCA	cis	rs4908760	0.899	rs61783642	ENSG00000270282.1	RP5-1115A15.2	5.52	4.28e-08	5.59e-06	0.18	0.17	Vitiligo;	chr1:8531338	chr1:8512653~8513021:+
BRCA	cis	rs8113308	0.752	rs73068868	ENSG00000269483.1	AC006272.1	5.52	4.28e-08	5.6e-06	0.31	0.17	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51987748	chr19:51839924~51843324:-
BRCA	cis	rs2098713	0.537	rs2886667	ENSG00000250155.1	CTD-2353F22.1	-5.52	4.28e-08	5.6e-06	-0.2	-0.17	Telomere length;	chr5:37510849	chr5:36666214~36725195:-
BRCA	cis	rs9638182	1	rs1051921	ENSG00000274080.1	CTA-315H11.2	5.52	4.28e-08	5.6e-06	0.31	0.17	Triglycerides;	chr7:73593613	chr7:73609262~73611502:-
BRCA	cis	rs1979679	0.65	rs3963302	ENSG00000278733.1	RP11-425D17.1	5.52	4.28e-08	5.6e-06	0.24	0.17	Ossification of the posterior longitudinal ligament of the spine;	chr12:28367813	chr12:28185625~28186190:-
BRCA	cis	rs1552244	0.81	rs35711405	ENSG00000232901.1	CYCSP10	5.52	4.28e-08	5.6e-06	0.24	0.17	Alzheimer's disease;	chr3:10075255	chr3:10000647~10000940:-
BRCA	cis	rs2688482	0.512	rs3103953	ENSG00000207650.1	MIR570	-5.52	4.28e-08	5.6e-06	-0.26	-0.17	Lung disease severity in cystic fibrosis;	chr3:195793726	chr3:195699401~195699497:+
BRCA	cis	rs9341808	0.718	rs2874829	ENSG00000272129.1	RP11-250B2.6	5.52	4.29e-08	5.6e-06	0.21	0.17	Sitting height ratio;	chr6:80146380	chr6:80355424~80356859:+
BRCA	cis	rs875971	0.502	rs11769702	ENSG00000228409.4	CCT6P1	-5.52	4.29e-08	5.6e-06	-0.17	-0.17	Aortic root size;	chr7:66255529	chr7:65751142~65763354:+
BRCA	cis	rs10129255	0.826	rs7150693	ENSG00000280411.1	IGHV1-69-2	-5.52	4.29e-08	5.61e-06	-0.13	-0.17	Kawasaki disease;	chr14:106705382	chr14:106762092~106762588:-
BRCA	cis	rs10129255	0.869	rs7150549	ENSG00000280411.1	IGHV1-69-2	-5.52	4.29e-08	5.61e-06	-0.13	-0.17	Kawasaki disease;	chr14:106705441	chr14:106762092~106762588:-
BRCA	cis	rs7200543	1	rs1121	ENSG00000275910.1	RP11-680G24.6	-5.52	4.29e-08	5.61e-06	-0.2	-0.17	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15037219	chr16:15015828~15016390:-
BRCA	cis	rs4908768	0.539	rs1934138	ENSG00000270282.1	RP5-1115A15.2	5.52	4.29e-08	5.61e-06	0.18	0.17	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8585757	chr1:8512653~8513021:+
BRCA	cis	rs61160187	0.582	rs13359074	ENSG00000215032.2	GNL3LP1	5.52	4.29e-08	5.61e-06	0.21	0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:60906758	chr5:60891935~60893577:-
BRCA	cis	rs1552244	0.938	rs34750074	ENSG00000232901.1	CYCSP10	5.52	4.29e-08	5.61e-06	0.24	0.17	Alzheimer's disease;	chr3:10050056	chr3:10000647~10000940:-
BRCA	cis	rs9467773	0.901	rs1407045	ENSG00000124549.13	BTN2A3P	5.52	4.29e-08	5.61e-06	0.18	0.17	Intelligence (multi-trait analysis);	chr6:26475927	chr6:26421391~26432383:+
BRCA	cis	rs42490	0.614	rs445172	ENSG00000251136.7	RP11-37B2.1	-5.52	4.3e-08	5.62e-06	-0.16	-0.17	Leprosy;	chr8:89808322	chr8:89609409~89757727:-
BRCA	cis	rs7911264	1	rs10786052	ENSG00000236493.2	EIF2S2P3	5.52	4.3e-08	5.62e-06	0.21	0.17	Inflammatory bowel disease;	chr10:92686878	chr10:92668745~92669743:-
BRCA	cis	rs72615157	0.612	rs7786505	ENSG00000242294.5	STAG3L5P	5.52	4.31e-08	5.63e-06	0.16	0.17	Lung function (FEV1/FVC);	chr7:100219962	chr7:100336079~100351900:+
BRCA	cis	rs6951245	0.554	rs35126802	ENSG00000229043.2	AC091729.9	-5.52	4.31e-08	5.63e-06	-0.26	-0.17	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1095206	chr7:1160374~1165267:+
BRCA	cis	rs10129255	0.956	rs10137268	ENSG00000224373.3	IGHV4-59	5.52	4.31e-08	5.63e-06	0.11	0.17	Kawasaki disease;	chr14:106697402	chr14:106627249~106627825:-
BRCA	cis	rs2303319	1	rs62194493	ENSG00000227403.1	AC009299.3	5.52	4.31e-08	5.63e-06	0.43	0.17	Cognitive function;	chr2:161362103	chr2:161244739~161249050:+
BRCA	cis	rs7772486	0.625	rs9390355	ENSG00000270638.1	RP3-466P17.1	-5.52	4.31e-08	5.63e-06	-0.19	-0.17	Lobe attachment (rater-scored or self-reported);	chr6:145791806	chr6:145735570~145737218:+
BRCA	cis	rs7772486	0.658	rs4895683	ENSG00000270638.1	RP3-466P17.1	-5.52	4.31e-08	5.63e-06	-0.19	-0.17	Lobe attachment (rater-scored or self-reported);	chr6:145792518	chr6:145735570~145737218:+
BRCA	cis	rs597539	0.652	rs513359	ENSG00000261625.1	RP11-554A11.4	5.52	4.31e-08	5.63e-06	0.16	0.17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68902028	chr11:69000765~69002048:-
BRCA	cis	rs6928977	0.675	rs58761508	ENSG00000231028.7	LINC00271	5.52	4.31e-08	5.63e-06	0.18	0.17	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135514763	chr6:135497801~135716055:+
BRCA	cis	rs6928977	0.631	rs9385726	ENSG00000231028.7	LINC00271	5.52	4.31e-08	5.63e-06	0.18	0.17	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135515824	chr6:135497801~135716055:+
BRCA	cis	rs7617773	0.744	rs2125482	ENSG00000199476.1	Y_RNA	-5.52	4.31e-08	5.63e-06	-0.24	-0.17	Coronary artery disease;	chr3:48281643	chr3:48288587~48288694:+
BRCA	cis	rs8031584	0.918	rs1425292	ENSG00000270015.1	RP11-540B6.6	-5.52	4.31e-08	5.64e-06	-0.18	-0.17	Huntington's disease progression;	chr15:30993219	chr15:30926514~30928407:+
BRCA	cis	rs2638953	0.672	rs11049715	ENSG00000278733.1	RP11-425D17.1	-5.52	4.32e-08	5.64e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28561520	chr12:28185625~28186190:-
BRCA	cis	rs9300255	0.722	rs11830103	ENSG00000235423.7	RP11-282O18.3	-5.52	4.32e-08	5.64e-06	-0.21	-0.17	Neutrophil percentage of white cells;	chr12:123338999	chr12:123252030~123261483:-
BRCA	cis	rs4934494	0.677	rs719909	ENSG00000240996.1	RP11-80H5.7	-5.52	4.32e-08	5.64e-06	-0.23	-0.17	Red blood cell count;	chr10:89585939	chr10:89694295~89697928:-
BRCA	cis	rs6832769	0.961	rs6824955	ENSG00000272969.1	RP11-528I4.2	5.52	4.32e-08	5.64e-06	0.21	0.17	Personality dimensions;	chr4:55450969	chr4:55547112~55547889:+
BRCA	cis	rs10129255	0.701	rs2005643	ENSG00000280411.1	IGHV1-69-2	-5.52	4.32e-08	5.64e-06	-0.12	-0.17	Kawasaki disease;	chr14:106676288	chr14:106762092~106762588:-
BRCA	cis	rs1707322	0.717	rs3014246	ENSG00000234329.1	RP11-767N6.2	-5.52	4.32e-08	5.65e-06	-0.18	-0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45620405	chr1:45651039~45651826:-
BRCA	cis	rs1275468	0.954	rs1148002	ENSG00000257497.2	RP11-585P4.5	5.52	4.32e-08	5.65e-06	0.23	0.17	Polycystic ovary syndrome;	chr12:75539244	chr12:75483454~75489820:-
BRCA	cis	rs6700559	0.74	rs4072551	ENSG00000260088.1	RP11-92G12.3	5.52	4.32e-08	5.65e-06	0.21	0.17	Coronary artery disease;	chr1:200679993	chr1:200669507~200694250:+
BRCA	cis	rs6700559	0.74	rs4072554	ENSG00000260088.1	RP11-92G12.3	5.52	4.32e-08	5.65e-06	0.21	0.17	Coronary artery disease;	chr1:200680238	chr1:200669507~200694250:+
BRCA	cis	rs6700559	0.74	rs10919999	ENSG00000260088.1	RP11-92G12.3	5.52	4.32e-08	5.65e-06	0.21	0.17	Coronary artery disease;	chr1:200680631	chr1:200669507~200694250:+
BRCA	cis	rs4927850	1	rs7630875	ENSG00000207650.1	MIR570	5.52	4.33e-08	5.65e-06	0.2	0.17	Pancreatic cancer;	chr3:196026895	chr3:195699401~195699497:+
BRCA	cis	rs2998286	0.723	rs332191	ENSG00000254635.4	WAC-AS1	-5.52	4.33e-08	5.66e-06	-0.24	-0.17	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28632196	chr10:28522652~28532743:-
BRCA	cis	rs61160187	0.51	rs10077663	ENSG00000272308.1	RP11-231G3.1	-5.52	4.33e-08	5.66e-06	-0.19	-0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:60807665	chr5:60866457~60866935:-
BRCA	cis	rs2179367	0.509	rs9485390	ENSG00000223701.3	RAET1E-AS1	5.52	4.33e-08	5.66e-06	0.24	0.17	Dupuytren's disease;	chr6:149421004	chr6:149884431~149919508:+
BRCA	cis	rs2638953	0.853	rs11049678	ENSG00000278733.1	RP11-425D17.1	-5.52	4.33e-08	5.66e-06	-0.22	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28505546	chr12:28185625~28186190:-
BRCA	cis	rs10510102	0.935	rs75339296	ENSG00000226864.1	ATE1-AS1	5.52	4.34e-08	5.67e-06	0.3	0.17	Breast cancer;	chr10:121859895	chr10:121928312~121951965:+
BRCA	cis	rs253959	0.545	rs10072417	ENSG00000272265.1	CTD-2287O16.4	5.52	4.34e-08	5.67e-06	0.21	0.17	Bipolar disorder and schizophrenia;	chr5:116097906	chr5:116078110~116078570:-
BRCA	cis	rs4650994	0.544	rs4075631	ENSG00000273384.1	RP5-1098D14.1	5.52	4.34e-08	5.67e-06	0.21	0.17	HDL cholesterol;HDL cholesterol levels;	chr1:178537459	chr1:178651706~178652282:+
BRCA	cis	rs4819052	0.851	rs8130285	ENSG00000184274.3	LINC00315	-5.52	4.34e-08	5.67e-06	-0.23	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251786	chr21:45300245~45305257:-
BRCA	cis	rs6088813	1	rs6060401	ENSG00000126005.14	MMP24-AS1	5.52	4.35e-08	5.67e-06	0.2	0.17	Height;	chr20:35417411	chr20:35216462~35278131:-
BRCA	cis	rs6095360	0.649	rs34832487	ENSG00000222365.1	SNORD12B	-5.52	4.35e-08	5.68e-06	-0.23	-0.17	Intelligence (multi-trait analysis);	chr20:48930575	chr20:49280319~49280409:+
BRCA	cis	rs4819052	0.851	rs2330011	ENSG00000184274.3	LINC00315	-5.52	4.35e-08	5.68e-06	-0.23	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238583	chr21:45300245~45305257:-
BRCA	cis	rs17301013	0.932	rs1653627	ENSG00000227373.4	RP11-160H22.5	-5.52	4.35e-08	5.68e-06	-0.22	-0.17	Systemic lupus erythematosus;	chr1:174771879	chr1:174115300~174160004:-
BRCA	cis	rs13126694	0.71	rs6848159	ENSG00000251429.1	RP11-597D13.7	-5.52	4.35e-08	5.68e-06	-0.16	-0.17	Blood osmolality (transformed sodium);	chr4:158051130	chr4:158270378~158278676:+
BRCA	cis	rs55702914	0.967	rs61328028	ENSG00000231621.1	AC013264.2	-5.52	4.35e-08	5.68e-06	-0.16	-0.17	Major depression and alcohol dependence;	chr2:197359030	chr2:197197991~197199273:+
BRCA	cis	rs7308116	0.546	rs2303479	ENSG00000274395.1	RP11-554D14.8	-5.52	4.35e-08	5.68e-06	-0.2	-0.17	Pelvic organ prolapse (moderate/severe);	chr12:107832815	chr12:107835541~107836555:-
BRCA	cis	rs875971	0.54	rs1723268	ENSG00000273024.4	INTS4P2	-5.52	4.36e-08	5.69e-06	-0.18	-0.17	Aortic root size;	chr7:66008093	chr7:65647864~65715661:+
BRCA	cis	rs1075265	0.572	rs3770405	ENSG00000235937.1	AC008280.1	5.52	4.36e-08	5.69e-06	0.19	0.17	Chronotype;Morning vs. evening chronotype;	chr2:53694884	chr2:54029552~54030682:-
BRCA	cis	rs7923837	0.651	rs12355158	ENSG00000236493.2	EIF2S2P3	5.52	4.36e-08	5.69e-06	0.24	0.17	Multiple sclerosis;Body mass index;	chr10:92590924	chr10:92668745~92669743:-
BRCA	cis	rs7191700	0.578	rs243327	ENSG00000262703.1	RP11-485G7.6	-5.52	4.36e-08	5.7e-06	-0.17	-0.17	Multiple sclerosis;	chr16:11259447	chr16:11348143~11349321:-
BRCA	cis	rs7608910	0.832	rs10191548	ENSG00000271889.1	RP11-493E12.1	5.52	4.37e-08	5.7e-06	0.22	0.17	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;	chr2:60970260	chr2:61151433~61162105:-
BRCA	cis	rs4950322	0.57	rs72691004	ENSG00000244371.2	PFN1P8	-5.52	4.37e-08	5.7e-06	-0.23	-0.17	Protein quantitative trait loci;	chr1:147234309	chr1:146957117~146957659:-
BRCA	cis	rs55904328	1	rs1939468	ENSG00000255135.3	RP11-111M22.3	5.52	4.37e-08	5.7e-06	0.19	0.17	3-hydroxypropylmercapturic acid levels in smokers;	chr11:76529077	chr11:76441338~76444656:-
BRCA	cis	rs72799341	1	rs35675346	ENSG00000260911.2	RP11-196G11.2	5.52	4.37e-08	5.71e-06	0.17	0.17	Diastolic blood pressure;	chr16:30924760	chr16:31043150~31049868:+
BRCA	cis	rs7674212	0.541	rs2623070	ENSG00000246560.2	RP11-10L12.4	-5.52	4.38e-08	5.71e-06	-0.18	-0.17	Type 2 diabetes;	chr4:103116231	chr4:102828055~102844075:+
BRCA	cis	rs4706831	0.647	rs627240	ENSG00000272129.1	RP11-250B2.6	-5.52	4.38e-08	5.71e-06	-0.2	-0.17	Joint mobility (Beighton score);	chr6:80276168	chr6:80355424~80356859:+
BRCA	cis	rs357618	1	rs357618	ENSG00000260581.1	CTB-113P19.4	5.52	4.38e-08	5.71e-06	0.19	0.17	Basophil percentage of white cells;	chr5:151467051	chr5:151652275~151655449:+
BRCA	cis	rs7772486	0.79	rs6570723	ENSG00000270638.1	RP3-466P17.1	5.52	4.38e-08	5.72e-06	0.19	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145830094	chr6:145735570~145737218:+
BRCA	cis	rs7772486	0.79	rs6570724	ENSG00000270638.1	RP3-466P17.1	5.52	4.38e-08	5.72e-06	0.19	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145830147	chr6:145735570~145737218:+
BRCA	cis	rs7772486	0.79	rs6917135	ENSG00000270638.1	RP3-466P17.1	5.52	4.38e-08	5.72e-06	0.19	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145831290	chr6:145735570~145737218:+
BRCA	cis	rs875971	0.545	rs6950988	ENSG00000228409.4	CCT6P1	-5.52	4.38e-08	5.72e-06	-0.17	-0.17	Aortic root size;	chr7:66511428	chr7:65751142~65763354:+
BRCA	cis	rs1075265	0.633	rs10183655	ENSG00000235937.1	AC008280.1	5.52	4.38e-08	5.72e-06	0.18	0.17	Chronotype;Morning vs. evening chronotype;	chr2:53983644	chr2:54029552~54030682:-
BRCA	cis	rs10740039	0.516	rs2068042	ENSG00000254271.1	RP11-131N11.4	5.52	4.38e-08	5.72e-06	0.23	0.17	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60560535	chr10:60734342~60741828:+
BRCA	cis	rs10740039	0.516	rs10740032	ENSG00000254271.1	RP11-131N11.4	5.52	4.38e-08	5.72e-06	0.23	0.17	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60562627	chr10:60734342~60741828:+
BRCA	cis	rs10740039	0.516	rs958852	ENSG00000254271.1	RP11-131N11.4	5.52	4.38e-08	5.72e-06	0.23	0.17	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60562860	chr10:60734342~60741828:+
BRCA	cis	rs11159086	0.793	rs8015894	ENSG00000270000.1	RP3-449M8.9	5.52	4.39e-08	5.72e-06	0.25	0.17	Advanced glycation end-product levels;	chr14:74491917	chr14:74471930~74472360:-
BRCA	cis	rs55702914	0.904	rs73050839	ENSG00000231621.1	AC013264.2	-5.52	4.39e-08	5.72e-06	-0.16	-0.17	Major depression and alcohol dependence;	chr2:197366494	chr2:197197991~197199273:+
BRCA	cis	rs651386	0.529	rs12072276	ENSG00000271811.1	RP1-79C4.4	5.52	4.39e-08	5.72e-06	0.19	0.17	Atrial fibrillation;	chr1:170624928	chr1:170667381~170669425:+
BRCA	cis	rs2834188	0.669	rs1467845	ENSG00000272659.1	AP000295.10	-5.52	4.39e-08	5.72e-06	-0.24	-0.17	Narcolepsy;	chr21:33294071	chr21:33309491~33310181:+
BRCA	cis	rs10129255	0.912	rs61997792	ENSG00000280411.1	IGHV1-69-2	-5.52	4.39e-08	5.73e-06	-0.13	-0.17	Kawasaki disease;	chr14:106799304	chr14:106762092~106762588:-
BRCA	cis	rs10129255	0.5	rs8022547	ENSG00000224373.3	IGHV4-59	5.52	4.39e-08	5.73e-06	0.1	0.17	Kawasaki disease;	chr14:106781985	chr14:106627249~106627825:-
BRCA	cis	rs4650994	0.525	rs2493848	ENSG00000273384.1	RP5-1098D14.1	-5.52	4.4e-08	5.73e-06	-0.21	-0.17	HDL cholesterol;HDL cholesterol levels;	chr1:178578703	chr1:178651706~178652282:+
BRCA	cis	rs4835473	0.932	rs4835455	ENSG00000249741.2	RP11-673E1.3	-5.52	4.4e-08	5.74e-06	-0.18	-0.17	Immature fraction of reticulocytes;	chr4:143962290	chr4:143911514~143912053:-
BRCA	cis	rs2732480	0.5	rs2450989	ENSG00000226413.2	OR8T1P	-5.51	4.4e-08	5.74e-06	-0.22	-0.17	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48259625	chr12:48442030~48442947:-
BRCA	cis	rs875971	0.545	rs6970498	ENSG00000228409.4	CCT6P1	-5.51	4.4e-08	5.74e-06	-0.17	-0.17	Aortic root size;	chr7:66275908	chr7:65751142~65763354:+
BRCA	cis	rs641862	1	rs641862	ENSG00000277767.1	RP11-365P13.5	5.51	4.4e-08	5.74e-06	0.28	0.17	Obesity-related traits;	chr13:110137885	chr13:110916004~110917827:+
BRCA	cis	rs7267979	0.586	rs6050439	ENSG00000277938.1	RP5-965G21.3	5.51	4.4e-08	5.74e-06	0.2	0.17	Liver enzyme levels (alkaline phosphatase);	chr20:25211695	chr20:25229150~25231933:+
BRCA	cis	rs4781563	0.621	rs7186212	ENSG00000242307.1	RPS26P52	-5.51	4.4e-08	5.74e-06	-0.19	-0.17	Bilirubin levels;	chr16:13914940	chr16:13922332~13922679:-
BRCA	cis	rs3733585	0.699	rs6449179	ENSG00000250413.1	RP11-448G15.1	5.51	4.4e-08	5.74e-06	0.22	0.17	Cleft plate (environmental tobacco smoke interaction);	chr4:9967493	chr4:10006482~10009725:+
BRCA	cis	rs3733585	0.699	rs7677710	ENSG00000250413.1	RP11-448G15.1	5.51	4.4e-08	5.74e-06	0.22	0.17	Cleft plate (environmental tobacco smoke interaction);	chr4:9967893	chr4:10006482~10009725:+
BRCA	cis	rs4763879	0.752	rs10772083	ENSG00000214776.8	RP11-726G1.1	5.51	4.41e-08	5.75e-06	0.19	0.17	Type 1 diabetes;	chr12:9722302	chr12:9467552~9576275:+
BRCA	cis	rs11159086	0.793	rs11850070	ENSG00000270000.1	RP3-449M8.9	5.51	4.41e-08	5.75e-06	0.25	0.17	Advanced glycation end-product levels;	chr14:74487575	chr14:74471930~74472360:-
BRCA	cis	rs9990333	1	rs9990333	ENSG00000207650.1	MIR570	-5.51	4.41e-08	5.75e-06	-0.2	-0.17	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196100334	chr3:195699401~195699497:+
BRCA	cis	rs1707322	0.752	rs4660313	ENSG00000234329.1	RP11-767N6.2	-5.51	4.42e-08	5.76e-06	-0.17	-0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45645169	chr1:45651039~45651826:-
BRCA	cis	rs1043099	0.556	rs5997642	ENSG00000279699.1	RP1-102K2.9	-5.51	4.42e-08	5.76e-06	-0.21	-0.17	Rheumatoid arthritis;	chr22:30416560	chr22:30275215~30276951:-
BRCA	cis	rs7630852	1	rs9852432	ENSG00000272359.1	U4	-5.51	4.42e-08	5.77e-06	-0.2	-0.17	Eosinophil counts;	chr3:196780210	chr3:196747192~196747324:-
BRCA	cis	rs11105298	0.891	rs11105325	ENSG00000270344.2	RP11-734K2.4	5.51	4.42e-08	5.77e-06	0.2	0.17	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89544813	chr12:89525654~89548005:+
BRCA	cis	rs7577696	0.654	rs212703	ENSG00000272716.1	RP11-563N4.1	5.51	4.42e-08	5.77e-06	0.18	0.17	Inflammatory biomarkers;	chr2:32221544	chr2:32165046~32165757:-
BRCA	cis	rs62025270	0.632	rs7177107	ENSG00000202081.1	RNU6-1280P	-5.51	4.43e-08	5.77e-06	-0.26	-0.17	Idiopathic pulmonary fibrosis;	chr15:85580133	chr15:85651522~85651628:-
BRCA	cis	rs7617773	0.817	rs4131361	ENSG00000199476.1	Y_RNA	-5.51	4.43e-08	5.77e-06	-0.24	-0.17	Coronary artery disease;	chr3:48287322	chr3:48288587~48288694:+
BRCA	cis	rs1707322	0.685	rs56177313	ENSG00000234329.1	RP11-767N6.2	5.51	4.43e-08	5.78e-06	0.18	0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45760134	chr1:45651039~45651826:-
BRCA	cis	rs863750	0.721	rs844085	ENSG00000275389.1	RP11-214K3.24	5.51	4.43e-08	5.78e-06	0.21	0.17	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-hip ratio;	chr12:124080711	chr12:124085761~124088598:+
BRCA	cis	rs11673344	0.502	rs62108306	ENSG00000267422.1	CTD-2554C21.1	5.51	4.43e-08	5.78e-06	0.21	0.17	Obesity-related traits;	chr19:37691789	chr19:37779686~37792865:+
BRCA	cis	rs250585	1	rs250585	ENSG00000260136.4	CTD-2270L9.4	-5.51	4.43e-08	5.78e-06	-0.18	-0.17	Egg allergy;	chr16:23389755	chr16:23452758~23457606:+
BRCA	cis	rs10129255	0.5	rs12101190	ENSG00000224373.3	IGHV4-59	5.51	4.44e-08	5.78e-06	0.1	0.17	Kawasaki disease;	chr14:106784149	chr14:106627249~106627825:-
BRCA	cis	rs10129255	0.518	rs8004895	ENSG00000224373.3	IGHV4-59	5.51	4.44e-08	5.78e-06	0.1	0.17	Kawasaki disease;	chr14:106785139	chr14:106627249~106627825:-
BRCA	cis	rs1707322	0.721	rs12043945	ENSG00000234329.1	RP11-767N6.2	5.51	4.44e-08	5.78e-06	0.18	0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45641250	chr1:45651039~45651826:-
BRCA	cis	rs1707322	0.721	rs12091503	ENSG00000234329.1	RP11-767N6.2	5.51	4.44e-08	5.78e-06	0.18	0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45642196	chr1:45651039~45651826:-
BRCA	cis	rs875971	0.651	rs313829	ENSG00000228409.4	CCT6P1	5.51	4.44e-08	5.79e-06	0.16	0.17	Aortic root size;	chr7:66087510	chr7:65751142~65763354:+
BRCA	cis	rs4819052	0.851	rs2838850	ENSG00000184274.3	LINC00315	-5.51	4.44e-08	5.79e-06	-0.23	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251530	chr21:45300245~45305257:-
BRCA	cis	rs9341808	0.718	rs9343978	ENSG00000272129.1	RP11-250B2.6	5.51	4.44e-08	5.79e-06	0.21	0.17	Sitting height ratio;	chr6:80262261	chr6:80355424~80356859:+
BRCA	cis	rs1862618	0.853	rs1833896	ENSG00000271828.1	CTD-2310F14.1	5.51	4.45e-08	5.8e-06	0.23	0.17	Initial pursuit acceleration;	chr5:56801842	chr5:56927874~56929573:+
BRCA	cis	rs1862618	0.853	rs1862619	ENSG00000271828.1	CTD-2310F14.1	5.51	4.45e-08	5.8e-06	0.23	0.17	Initial pursuit acceleration;	chr5:56802429	chr5:56927874~56929573:+
BRCA	cis	rs13108904	0.935	rs1732102	ENSG00000254094.1	AC078852.1	5.51	4.45e-08	5.8e-06	0.18	0.17	Obesity-related traits;	chr4:1284136	chr4:1356581~1358075:+
BRCA	cis	rs4713118	0.869	rs7776351	ENSG00000216901.1	AL022393.7	-5.51	4.45e-08	5.8e-06	-0.23	-0.17	Parkinson's disease;	chr6:27758952	chr6:28176188~28176674:+
BRCA	cis	rs897984	0.568	rs4889651	ENSG00000260911.2	RP11-196G11.2	5.51	4.45e-08	5.81e-06	0.16	0.17	Dementia with Lewy bodies;	chr16:30884224	chr16:31043150~31049868:+
BRCA	cis	rs7923837	0.651	rs11187096	ENSG00000236493.2	EIF2S2P3	5.51	4.45e-08	5.81e-06	0.24	0.17	Multiple sclerosis;Body mass index;	chr10:92609831	chr10:92668745~92669743:-
BRCA	cis	rs2303759	0.918	rs10405465	ENSG00000268686.1	AC010524.2	-5.51	4.46e-08	5.81e-06	-0.25	-0.17	Multiple sclerosis;	chr19:49366041	chr19:49368705~49388081:-
BRCA	cis	rs6688613	0.685	rs10918600	ENSG00000225171.2	DUTP6	5.51	4.46e-08	5.81e-06	0.21	0.17	Refractive astigmatism;	chr1:166950105	chr1:166868748~166869209:+
BRCA	cis	rs6832769	1	rs7670225	ENSG00000223305.1	RN7SKP30	5.51	4.46e-08	5.81e-06	0.22	0.17	Personality dimensions;	chr4:55501851	chr4:55540502~55540835:-
BRCA	cis	rs5758511	0.634	rs1001587	ENSG00000233903.2	Z83851.4	5.51	4.46e-08	5.82e-06	0.26	0.17	Birth weight;	chr22:42274105	chr22:42276355~42277052:+
BRCA	cis	rs6570726	0.967	rs403584	ENSG00000270638.1	RP3-466P17.1	5.51	4.47e-08	5.82e-06	0.19	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145485874	chr6:145735570~145737218:+
BRCA	cis	rs875971	0.522	rs1968127	ENSG00000273024.4	INTS4P2	5.51	4.47e-08	5.82e-06	0.18	0.17	Aortic root size;	chr7:66591816	chr7:65647864~65715661:+
BRCA	cis	rs2179367	0.632	rs9498348	ENSG00000223701.3	RAET1E-AS1	5.51	4.47e-08	5.82e-06	0.24	0.17	Dupuytren's disease;	chr6:149418352	chr6:149884431~149919508:+
BRCA	cis	rs10911232	0.524	rs4487994	ENSG00000224468.3	RP11-181K3.4	-5.51	4.47e-08	5.82e-06	-0.18	-0.17	Hypertriglyceridemia;	chr1:183013038	chr1:183138402~183141282:-
BRCA	cis	rs6688613	0.84	rs6699294	ENSG00000225171.2	DUTP6	-5.51	4.47e-08	5.83e-06	-0.22	-0.17	Refractive astigmatism;	chr1:166985937	chr1:166868748~166869209:+
BRCA	cis	rs6688613	0.84	rs6669886	ENSG00000225171.2	DUTP6	-5.51	4.47e-08	5.83e-06	-0.22	-0.17	Refractive astigmatism;	chr1:166987473	chr1:166868748~166869209:+
BRCA	cis	rs7044106	0.791	rs747819	ENSG00000238181.2	AHCYP2	-5.51	4.47e-08	5.83e-06	-0.22	-0.17	Hip circumference adjusted for BMI;	chr9:120726163	chr9:120720673~120721972:+
BRCA	cis	rs62025270	0.632	rs6496109	ENSG00000202081.1	RNU6-1280P	-5.51	4.47e-08	5.83e-06	-0.25	-0.17	Idiopathic pulmonary fibrosis;	chr15:85588777	chr15:85651522~85651628:-
BRCA	cis	rs2303319	1	rs62188122	ENSG00000227403.1	AC009299.3	5.51	4.47e-08	5.83e-06	0.43	0.17	Cognitive function;	chr2:161383896	chr2:161244739~161249050:+
BRCA	cis	rs2303319	1	rs2194726	ENSG00000227403.1	AC009299.3	5.51	4.47e-08	5.83e-06	0.43	0.17	Cognitive function;	chr2:161389321	chr2:161244739~161249050:+
BRCA	cis	rs2303319	1	rs2194727	ENSG00000227403.1	AC009299.3	5.51	4.47e-08	5.83e-06	0.43	0.17	Cognitive function;	chr2:161389360	chr2:161244739~161249050:+
BRCA	cis	rs2303319	1	rs74733151	ENSG00000227403.1	AC009299.3	5.51	4.47e-08	5.83e-06	0.43	0.17	Cognitive function;	chr2:161395345	chr2:161244739~161249050:+
BRCA	cis	rs2303319	1	rs12463483	ENSG00000227403.1	AC009299.3	5.51	4.47e-08	5.83e-06	0.43	0.17	Cognitive function;	chr2:161396108	chr2:161244739~161249050:+
BRCA	cis	rs2303319	1	rs12463535	ENSG00000227403.1	AC009299.3	5.51	4.47e-08	5.83e-06	0.43	0.17	Cognitive function;	chr2:161396388	chr2:161244739~161249050:+
BRCA	cis	rs2303319	1	rs62188137	ENSG00000227403.1	AC009299.3	5.51	4.47e-08	5.83e-06	0.43	0.17	Cognitive function;	chr2:161401037	chr2:161244739~161249050:+
BRCA	cis	rs2303319	1	rs16845830	ENSG00000227403.1	AC009299.3	5.51	4.47e-08	5.83e-06	0.43	0.17	Cognitive function;	chr2:161401684	chr2:161244739~161249050:+
BRCA	cis	rs1440410	0.798	rs10031363	ENSG00000250326.1	RP11-284M14.1	-5.51	4.48e-08	5.84e-06	-0.19	-0.17	Ischemic stroke;	chr4:143243045	chr4:142933195~143184861:-
BRCA	cis	rs11955398	0.522	rs329624	ENSG00000215032.2	GNL3LP1	5.51	4.48e-08	5.84e-06	0.22	0.17	Intelligence (multi-trait analysis);	chr5:60989310	chr5:60891935~60893577:-
BRCA	cis	rs6832769	1	rs1522106	ENSG00000272969.1	RP11-528I4.2	-5.51	4.48e-08	5.84e-06	-0.21	-0.17	Personality dimensions;	chr4:55441047	chr4:55547112~55547889:+
BRCA	cis	rs4713118	0.824	rs2092075	ENSG00000216901.1	AL022393.7	5.51	4.49e-08	5.85e-06	0.23	0.17	Parkinson's disease;	chr6:27781551	chr6:28176188~28176674:+
BRCA	cis	rs1707322	0.827	rs10890347	ENSG00000234329.1	RP11-767N6.2	-5.51	4.5e-08	5.86e-06	-0.18	-0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45776660	chr1:45651039~45651826:-
BRCA	cis	rs1722141	0.67	rs1722148	ENSG00000237471.1	AC073115.6	5.51	4.5e-08	5.86e-06	0.25	0.17	Sitting height ratio;	chr7:45953897	chr7:45969657~45980191:+
BRCA	cis	rs745109	0.504	rs80252327	ENSG00000273080.1	RP11-301O19.1	5.51	4.5e-08	5.86e-06	0.27	0.17	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86385089	chr2:86195590~86196049:+
BRCA	cis	rs30380	0.632	rs27045	ENSG00000272109.1	CTD-2260A17.3	-5.51	4.51e-08	5.87e-06	-0.23	-0.17	Cerebrospinal fluid biomarker levels;	chr5:96803158	chr5:96804353~96806105:+
BRCA	cis	rs250585	0.92	rs39815	ENSG00000260136.4	CTD-2270L9.4	5.51	4.51e-08	5.87e-06	0.18	0.17	Egg allergy;	chr16:23408685	chr16:23452758~23457606:+
BRCA	cis	rs1387259	0.899	rs7307566	ENSG00000240399.1	RP1-228P16.1	5.51	4.51e-08	5.87e-06	0.2	0.17	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48210899	chr12:48054813~48055591:-
BRCA	cis	rs17711722	0.565	rs4717276	ENSG00000182722.5	SEPHS1P1	-5.51	4.51e-08	5.87e-06	-0.22	-0.17	Calcium levels;	chr7:65829754	chr7:64852397~64853354:-
BRCA	cis	rs7577696	0.671	rs212738	ENSG00000272716.1	RP11-563N4.1	5.51	4.51e-08	5.88e-06	0.18	0.17	Inflammatory biomarkers;	chr2:32178253	chr2:32165046~32165757:-
BRCA	cis	rs7131987	0.65	rs7957339	ENSG00000275476.1	RP11-996F15.4	-5.51	4.51e-08	5.88e-06	-0.2	-0.17	QT interval;	chr12:29303562	chr12:29277397~29277882:-
BRCA	cis	rs934734	0.532	rs2028150	ENSG00000204929.10	AC074391.1	-5.51	4.51e-08	5.88e-06	-0.21	-0.17	Rheumatoid arthritis;	chr2:65427878	chr2:65436711~66084639:+
BRCA	cis	rs7620503	1	rs4857612	ENSG00000228221.4	LINC00578	5.51	4.52e-08	5.88e-06	0.2	0.17	Corneal structure;	chr3:177588833	chr3:177441921~177752305:+
BRCA	cis	rs7044106	0.762	rs10760110	ENSG00000238181.2	AHCYP2	5.51	4.52e-08	5.88e-06	0.22	0.17	Hip circumference adjusted for BMI;	chr9:120650285	chr9:120720673~120721972:+
BRCA	cis	rs10129255	0.5	rs8014529	ENSG00000224373.3	IGHV4-59	5.51	4.52e-08	5.88e-06	0.1	0.17	Kawasaki disease;	chr14:106784065	chr14:106627249~106627825:-
BRCA	cis	rs3213958	0.574	rs11916285	ENSG00000249274.1	PDLIM1P4	-5.51	4.52e-08	5.88e-06	-0.26	-0.17	Blood protein levels;	chr3:98818497	chr3:98782188~98783193:+
BRCA	cis	rs919433	0.68	rs6434934	ENSG00000231621.1	AC013264.2	-5.51	4.52e-08	5.89e-06	-0.16	-0.17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197572662	chr2:197197991~197199273:+
BRCA	cis	rs2638953	0.962	rs10506034	ENSG00000278733.1	RP11-425D17.1	-5.51	4.52e-08	5.89e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28442363	chr12:28185625~28186190:-
BRCA	cis	rs12468226	0.872	rs1061157	ENSG00000226261.1	AC064836.3	5.51	4.52e-08	5.89e-06	0.3	0.17	Urate levels;	chr2:202556476	chr2:202336024~202336727:-
BRCA	cis	rs4761702	0.516	rs7398486	ENSG00000257252.4	RP11-486A14.2	5.51	4.52e-08	5.89e-06	0.22	0.17	Immature fraction of reticulocytes;	chr12:93301372	chr12:93317135~93377736:-
BRCA	cis	rs2562784	0.597	rs2562785	ENSG00000225151.9	GOLGA2P7	-5.51	4.52e-08	5.89e-06	-0.28	-0.17	Height;	chr15:83617269	chr15:84199311~84230136:-
BRCA	cis	rs2638953	0.962	rs11049488	ENSG00000247934.4	RP11-967K21.1	-5.51	4.53e-08	5.89e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28259439	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.962	rs57618147	ENSG00000247934.4	RP11-967K21.1	-5.51	4.53e-08	5.89e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28259902	chr12:28163298~28190738:-
BRCA	cis	rs12439619	0.81	rs28876157	ENSG00000255769.6	GOLGA2P10	-5.51	4.53e-08	5.9e-06	-0.24	-0.17	Intelligence (multi-trait analysis);	chr15:82216708	chr15:82472993~82513950:-
BRCA	cis	rs2905347	0.591	rs12155285	ENSG00000179428.2	AC073072.5	5.51	4.53e-08	5.9e-06	0.18	0.17	Major depression and alcohol dependence;	chr7:22639018	chr7:22725395~22727620:-
BRCA	cis	rs9307551	0.584	rs13113835	ENSG00000250334.4	LINC00989	-5.51	4.53e-08	5.9e-06	-0.23	-0.17	Refractive error;	chr4:79522945	chr4:79492416~79576460:+
BRCA	cis	rs1005277	0.529	rs1780125	ENSG00000263064.2	RP11-291L22.7	5.51	4.53e-08	5.9e-06	0.21	0.17	Extrinsic epigenetic age acceleration;	chr10:38242448	chr10:38448689~38448949:+
BRCA	cis	rs875971	0.522	rs4718285	ENSG00000213640.3	EEF1DP4	-5.51	4.54e-08	5.91e-06	-0.21	-0.17	Aortic root size;	chr7:65827018	chr7:64862999~64864370:+
BRCA	cis	rs1005277	0.502	rs2800484	ENSG00000263064.2	RP11-291L22.7	5.51	4.54e-08	5.91e-06	0.21	0.17	Extrinsic epigenetic age acceleration;	chr10:38253487	chr10:38448689~38448949:+
BRCA	cis	rs7572733	0.537	rs2340688	ENSG00000231621.1	AC013264.2	-5.51	4.54e-08	5.91e-06	-0.16	-0.17	Dermatomyositis;	chr2:197573701	chr2:197197991~197199273:+
BRCA	cis	rs4588572	0.644	rs1159930	ENSG00000245556.2	SCAMP1-AS1	5.51	4.54e-08	5.91e-06	0.19	0.17	Triglycerides;	chr5:78473120	chr5:78342365~78360507:-
BRCA	cis	rs6570726	0.764	rs9403726	ENSG00000270638.1	RP3-466P17.1	5.51	4.54e-08	5.91e-06	0.19	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145580550	chr6:145735570~145737218:+
BRCA	cis	rs3733585	0.762	rs6449217	ENSG00000250413.1	RP11-448G15.1	-5.51	4.54e-08	5.91e-06	-0.22	-0.17	Cleft plate (environmental tobacco smoke interaction);	chr4:10007527	chr4:10006482~10009725:+
BRCA	cis	rs7618501	0.633	rs55751738	ENSG00000228008.1	CTD-2330K9.3	5.51	4.54e-08	5.91e-06	0.16	0.17	Intelligence (multi-trait analysis);	chr3:49934668	chr3:49903845~49916937:+
BRCA	cis	rs7618501	0.633	rs7621026	ENSG00000228008.1	CTD-2330K9.3	5.51	4.54e-08	5.91e-06	0.16	0.17	Intelligence (multi-trait analysis);	chr3:49937901	chr3:49903845~49916937:+
BRCA	cis	rs755249	0.642	rs28788506	ENSG00000182109.6	RP11-69E11.4	5.51	4.55e-08	5.92e-06	0.21	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39611108	chr1:39522280~39546187:-
BRCA	cis	rs8048589	0.948	rs11648228	ENSG00000175604.2	RP11-276H1.3	-5.51	4.55e-08	5.92e-06	-0.25	-0.17	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);	chr16:12087845	chr16:12086746~12090302:-
BRCA	cis	rs2904967	0.929	rs482842	ENSG00000254614.2	AP003068.23	5.51	4.55e-08	5.92e-06	0.31	0.17	Mean corpuscular volume;	chr11:65277807	chr11:65177606~65181834:-
BRCA	cis	rs5758511	0.68	rs1107554	ENSG00000233903.2	Z83851.4	5.51	4.55e-08	5.92e-06	0.26	0.17	Birth weight;	chr22:42271588	chr22:42276355~42277052:+
BRCA	cis	rs67981189	0.896	rs7146591	ENSG00000258571.1	PTTG4P	5.51	4.55e-08	5.92e-06	0.18	0.17	Schizophrenia;	chr14:70971511	chr14:71085482~71085833:-
BRCA	cis	rs1859596	1	rs4727868	ENSG00000234456.6	MAGI2-AS3	5.51	4.56e-08	5.93e-06	0.11	0.17	Reading or mathematical ability;	chr7:79461511	chr7:79452877~79471208:+
BRCA	cis	rs2243480	1	rs313813	ENSG00000232559.3	GS1-124K5.12	5.51	4.56e-08	5.93e-06	0.32	0.17	Diabetic kidney disease;	chr7:66038513	chr7:66554588~66576923:-
BRCA	cis	rs7923609	0.74	rs10761784	ENSG00000232075.1	MRPL35P2	-5.51	4.56e-08	5.93e-06	-0.21	-0.17	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63548990	chr10:63634317~63634827:-
BRCA	cis	rs3760982	0.585	rs62116964	ENSG00000267058.1	RP11-15A1.3	-5.51	4.56e-08	5.93e-06	-0.2	-0.17	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43787834	chr19:43891804~43901805:-
BRCA	cis	rs873549	1	rs11118946	ENSG00000232679.1	RP11-400N13.3	5.51	4.56e-08	5.93e-06	0.2	0.17	Keloid;	chr1:222096451	chr1:222041705~222064763:-
BRCA	cis	rs873549	1	rs11118947	ENSG00000232679.1	RP11-400N13.3	5.51	4.56e-08	5.93e-06	0.2	0.17	Keloid;	chr1:222096463	chr1:222041705~222064763:-
BRCA	cis	rs6490294	0.528	rs11066126	ENSG00000226469.1	ADAM1B	5.51	4.56e-08	5.93e-06	0.26	0.17	Mean platelet volume;	chr12:112007087	chr12:111927018~111929017:+
BRCA	cis	rs1043099	0.556	rs4820847	ENSG00000279699.1	RP1-102K2.9	-5.51	4.56e-08	5.93e-06	-0.21	-0.17	Rheumatoid arthritis;	chr22:30414956	chr22:30275215~30276951:-
BRCA	cis	rs372883	0.509	rs28462110	ENSG00000215533.7	LINC00189	-5.51	4.56e-08	5.94e-06	-0.19	-0.17	Pancreatic cancer;	chr21:29171997	chr21:29193480~29288205:+
BRCA	cis	rs10510102	0.688	rs76573813	ENSG00000226864.1	ATE1-AS1	5.51	4.56e-08	5.94e-06	0.31	0.17	Breast cancer;	chr10:121928955	chr10:121928312~121951965:+
BRCA	cis	rs14027	0.554	rs6998058	ENSG00000279347.1	RP11-85I17.2	-5.51	4.56e-08	5.94e-06	-0.16	-0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119743079	chr8:119838736~119840385:-
BRCA	cis	rs1823913	0.538	rs11892998	ENSG00000280083.1	RP11-317J9.1	-5.51	4.57e-08	5.94e-06	-0.19	-0.17	Obesity-related traits;	chr2:191340159	chr2:191154118~191156070:-
BRCA	cis	rs2732480	0.577	rs2732481	ENSG00000226413.2	OR8T1P	5.51	4.57e-08	5.94e-06	0.23	0.17	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48343202	chr12:48442030~48442947:-
BRCA	cis	rs2732480	0.557	rs2732484	ENSG00000226413.2	OR8T1P	5.51	4.57e-08	5.94e-06	0.23	0.17	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48343462	chr12:48442030~48442947:-
BRCA	cis	rs2732480	0.577	rs2732486	ENSG00000226413.2	OR8T1P	5.51	4.57e-08	5.94e-06	0.23	0.17	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344051	chr12:48442030~48442947:-
BRCA	cis	rs2732480	0.517	rs2634676	ENSG00000226413.2	OR8T1P	5.51	4.57e-08	5.94e-06	0.23	0.17	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344453	chr12:48442030~48442947:-
BRCA	cis	rs4835473	0.9	rs7667544	ENSG00000249741.2	RP11-673E1.3	5.51	4.57e-08	5.95e-06	0.18	0.17	Immature fraction of reticulocytes;	chr4:143793802	chr4:143911514~143912053:-
BRCA	cis	rs2638953	0.925	rs11049597	ENSG00000278733.1	RP11-425D17.1	-5.51	4.58e-08	5.96e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28433584	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.962	rs11049599	ENSG00000278733.1	RP11-425D17.1	-5.51	4.58e-08	5.96e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28437218	chr12:28185625~28186190:-
BRCA	cis	rs6479891	0.822	rs6479892	ENSG00000232075.1	MRPL35P2	-5.51	4.58e-08	5.96e-06	-0.31	-0.17	Arthritis (juvenile idiopathic);	chr10:63292472	chr10:63634317~63634827:-
BRCA	cis	rs950880	1	rs1420101	ENSG00000234389.1	AC007278.3	-5.51	4.58e-08	5.96e-06	-0.16	-0.17	Serum protein levels (sST2);	chr2:102341256	chr2:102438713~102440475:+
BRCA	cis	rs2115630	0.905	rs1975277	ENSG00000259295.5	CSPG4P12	-5.51	4.59e-08	5.96e-06	-0.2	-0.17	P wave terminal force;	chr15:84786327	chr15:85191438~85213905:+
BRCA	cis	rs55702914	0.628	rs55813500	ENSG00000231621.1	AC013264.2	-5.51	4.59e-08	5.97e-06	-0.16	-0.17	Major depression and alcohol dependence;	chr2:197524448	chr2:197197991~197199273:+
BRCA	cis	rs12681366	0.734	rs16916796	ENSG00000253704.1	RP11-267M23.4	5.51	4.59e-08	5.97e-06	0.18	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94390001	chr8:94553722~94569745:+
BRCA	cis	rs516805	0.706	rs1339533	ENSG00000279453.1	RP3-425C14.4	-5.51	4.59e-08	5.97e-06	-0.22	-0.17	Lymphocyte counts;	chr6:122348687	chr6:122436789~122439223:-
BRCA	cis	rs1577330	0.516	rs3861014	ENSG00000254396.1	RP11-56F10.3	5.51	4.59e-08	5.97e-06	0.33	0.17	IgG glycosylation;	chr9:27103334	chr9:27102630~27104728:+
BRCA	cis	rs1972460	0.506	rs62012050	ENSG00000276710.3	CSPG4P8	-5.51	4.59e-08	5.97e-06	-0.19	-0.17	Intelligence (multi-trait analysis);	chr15:82239933	chr15:82459472~82477258:+
BRCA	cis	rs6832769	1	rs6554286	ENSG00000223305.1	RN7SKP30	-5.51	4.6e-08	5.98e-06	-0.22	-0.17	Personality dimensions;	chr4:55534137	chr4:55540502~55540835:-
BRCA	cis	rs1193	1	rs6711700	ENSG00000231259.4	AC125232.1	-5.51	4.6e-08	5.98e-06	-0.21	-0.17	High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;High light scatter reticulocyte count;	chr2:86760864	chr2:87031815~87053069:-
BRCA	cis	rs13108904	0.539	rs13140926	ENSG00000254094.1	AC078852.1	-5.51	4.6e-08	5.98e-06	-0.2	-0.17	Obesity-related traits;	chr4:1347151	chr4:1356581~1358075:+
BRCA	cis	rs12681366	0.839	rs3019281	ENSG00000253704.1	RP11-267M23.4	5.51	4.6e-08	5.98e-06	0.19	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94438061	chr8:94553722~94569745:+
BRCA	cis	rs7131987	0.65	rs7954871	ENSG00000275476.1	RP11-996F15.4	-5.51	4.6e-08	5.98e-06	-0.2	-0.17	QT interval;	chr12:29306799	chr12:29277397~29277882:-
BRCA	cis	rs875971	0.545	rs7787063	ENSG00000228409.4	CCT6P1	-5.51	4.6e-08	5.99e-06	-0.17	-0.17	Aortic root size;	chr7:66164012	chr7:65751142~65763354:+
BRCA	cis	rs875971	0.545	rs12673308	ENSG00000228409.4	CCT6P1	-5.51	4.6e-08	5.99e-06	-0.17	-0.17	Aortic root size;	chr7:66166374	chr7:65751142~65763354:+
BRCA	cis	rs4535700	0.501	rs9642405	ENSG00000226278.1	PSPHP1	5.51	4.6e-08	5.99e-06	0.19	0.17	Macular telangiectasia type 2;	chr7:55910473	chr7:55764797~55773288:+
BRCA	cis	rs227275	0.525	rs7660298	ENSG00000251288.2	RP11-10L12.2	-5.51	4.6e-08	5.99e-06	-0.2	-0.17	Allergic disease (asthma, hay fever or eczema);	chr4:103039611	chr4:102751401~102752641:+
BRCA	cis	rs12571093	0.773	rs3740588	ENSG00000233590.1	RP11-153K11.3	5.51	4.61e-08	5.99e-06	0.27	0.17	Optic nerve measurement (disc area);	chr10:68261079	chr10:68233251~68242379:-
BRCA	cis	rs6832769	1	rs3805152	ENSG00000272969.1	RP11-528I4.2	5.51	4.61e-08	5.99e-06	0.21	0.17	Personality dimensions;	chr4:55493491	chr4:55547112~55547889:+
BRCA	cis	rs7577696	0.597	rs17011801	ENSG00000272716.1	RP11-563N4.1	-5.51	4.61e-08	5.99e-06	-0.2	-0.17	Inflammatory biomarkers;	chr2:32073003	chr2:32165046~32165757:-
BRCA	cis	rs4266144	0.544	rs6805781	ENSG00000241770.1	RP11-555M1.3	5.51	4.61e-08	5.99e-06	0.21	0.17	Coronary artery disease;	chr3:157112780	chr3:157163452~157169133:+
BRCA	cis	rs253959	0.502	rs10478275	ENSG00000272265.1	CTD-2287O16.4	5.51	4.61e-08	6e-06	0.21	0.17	Bipolar disorder and schizophrenia;	chr5:116092399	chr5:116078110~116078570:-
BRCA	cis	rs2638953	0.925	rs10843154	ENSG00000278733.1	RP11-425D17.1	-5.51	4.61e-08	6e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28326824	chr12:28185625~28186190:-
BRCA	cis	rs62025270	0.632	rs8029034	ENSG00000202081.1	RNU6-1280P	-5.51	4.61e-08	6e-06	-0.25	-0.17	Idiopathic pulmonary fibrosis;	chr15:85582497	chr15:85651522~85651628:-
BRCA	cis	rs2502757	1	rs2502757	ENSG00000225756.1	DBH-AS1	-5.51	4.61e-08	6e-06	-0.17	-0.17	Asthma;	chr9:133721832	chr9:133654586~133657313:-
BRCA	cis	rs1707322	1	rs6429580	ENSG00000281133.1	AL355480.3	-5.51	4.61e-08	6e-06	-0.21	-0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45809976	chr1:45580892~45580996:-
BRCA	cis	rs904251	0.772	rs756202	ENSG00000204110.6	RP1-153P14.8	-5.51	4.62e-08	6e-06	-0.2	-0.17	Cognitive performance;	chr6:37492574	chr6:37507348~37535616:+
BRCA	cis	rs2833693	0.572	rs2833711	ENSG00000261610.1	AP000265.1	5.51	4.62e-08	6e-06	0.21	0.17	Temperament;	chr21:32191022	chr21:32259804~32261585:-
BRCA	cis	rs78487399	0.71	rs57696714	ENSG00000234936.1	AC010883.5	5.51	4.62e-08	6e-06	0.27	0.17	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43399382	chr2:43229573~43233394:+
BRCA	cis	rs78487399	0.71	rs57381820	ENSG00000234936.1	AC010883.5	5.51	4.62e-08	6e-06	0.27	0.17	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43399529	chr2:43229573~43233394:+
BRCA	cis	rs78487399	0.71	rs72879276	ENSG00000234936.1	AC010883.5	5.51	4.62e-08	6e-06	0.27	0.17	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43399962	chr2:43229573~43233394:+
BRCA	cis	rs78487399	0.71	rs7607777	ENSG00000234936.1	AC010883.5	5.51	4.62e-08	6e-06	0.27	0.17	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43402792	chr2:43229573~43233394:+
BRCA	cis	rs7897654	0.571	rs12771681	ENSG00000236937.2	PTGES3P4	5.51	4.62e-08	6e-06	0.25	0.17	Schizophrenia;	chr10:102875863	chr10:102845595~102845950:+
BRCA	cis	rs5758511	0.68	rs5758698	ENSG00000205702.9	CYP2D7	5.51	4.62e-08	6.01e-06	0.18	0.17	Birth weight;	chr22:42288812	chr22:42140203~42144577:-
BRCA	cis	rs2898681	0.581	rs730247	ENSG00000248375.1	RP11-177B4.1	-5.51	4.62e-08	6.01e-06	-0.23	-0.17	Optic nerve measurement (cup area);	chr4:52814529	chr4:52720081~52720831:-
BRCA	cis	rs7567389	0.599	rs6430938	ENSG00000236682.1	AC068282.3	5.51	4.62e-08	6.01e-06	0.24	0.17	Self-rated health;	chr2:127405047	chr2:127389130~127400580:+
BRCA	cis	rs4835473	0.897	rs6537172	ENSG00000249741.2	RP11-673E1.3	-5.51	4.63e-08	6.02e-06	-0.18	-0.17	Immature fraction of reticulocytes;	chr4:143710612	chr4:143911514~143912053:-
BRCA	cis	rs783540	0.5	rs783541	ENSG00000278603.1	RP13-608F4.5	-5.51	4.63e-08	6.02e-06	-0.26	-0.17	Schizophrenia;	chr15:82586310	chr15:82472203~82472426:+
BRCA	cis	rs4650994	0.505	rs2811291	ENSG00000273384.1	RP5-1098D14.1	-5.51	4.63e-08	6.02e-06	-0.22	-0.17	HDL cholesterol;HDL cholesterol levels;	chr1:178605082	chr1:178651706~178652282:+
BRCA	cis	rs4713118	0.869	rs6914924	ENSG00000216901.1	AL022393.7	5.51	4.64e-08	6.03e-06	0.23	0.17	Parkinson's disease;	chr6:27743751	chr6:28176188~28176674:+
BRCA	cis	rs7208859	0.573	rs56031503	ENSG00000265443.1	CTD-2349P21.6	-5.51	4.64e-08	6.03e-06	-0.26	-0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748647	chr17:30726305~30727564:-
BRCA	cis	rs17597773	0.638	rs11118609	ENSG00000272823.1	RP11-295M18.6	5.51	4.64e-08	6.03e-06	0.19	0.17	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220815148	chr1:220828676~220829211:-
BRCA	cis	rs73198271	0.74	rs10105690	ENSG00000253893.2	FAM85B	5.51	4.64e-08	6.03e-06	0.23	0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8791722	chr8:8167819~8226614:-
BRCA	cis	rs950169	0.58	rs11634322	ENSG00000259295.5	CSPG4P12	5.51	4.64e-08	6.03e-06	0.23	0.17	Schizophrenia;	chr15:84628978	chr15:85191438~85213905:+
BRCA	cis	rs6700559	0.716	rs12140579	ENSG00000260088.1	RP11-92G12.3	5.51	4.65e-08	6.04e-06	0.21	0.17	Coronary artery disease;	chr1:200655368	chr1:200669507~200694250:+
BRCA	cis	rs755249	0.529	rs3768299	ENSG00000228060.1	RP11-69E11.8	-5.5	4.65e-08	6.04e-06	-0.2	-0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39391520	chr1:39565160~39573203:+
BRCA	cis	rs1552244	1	rs7651058	ENSG00000232901.1	CYCSP10	5.5	4.65e-08	6.04e-06	0.23	0.17	Alzheimer's disease;	chr3:10025280	chr3:10000647~10000940:-
BRCA	cis	rs6832769	0.961	rs13138697	ENSG00000272969.1	RP11-528I4.2	5.5	4.65e-08	6.04e-06	0.21	0.17	Personality dimensions;	chr4:55497142	chr4:55547112~55547889:+
BRCA	cis	rs2732480	0.967	rs2732469	ENSG00000273765.1	RP11-370I10.11	5.5	4.65e-08	6.04e-06	0.19	0.17	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48319149	chr12:48360920~48361377:+
BRCA	cis	rs7923609	0.934	rs10761756	ENSG00000232075.1	MRPL35P2	-5.5	4.65e-08	6.05e-06	-0.21	-0.17	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63412568	chr10:63634317~63634827:-
BRCA	cis	rs7923609	0.967	rs10761758	ENSG00000232075.1	MRPL35P2	-5.5	4.65e-08	6.05e-06	-0.21	-0.17	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63412987	chr10:63634317~63634827:-
BRCA	cis	rs7923609	0.967	rs7909269	ENSG00000232075.1	MRPL35P2	-5.5	4.65e-08	6.05e-06	-0.21	-0.17	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63418006	chr10:63634317~63634827:-
BRCA	cis	rs783540	0.542	rs62009945	ENSG00000278603.1	RP13-608F4.5	-5.5	4.65e-08	6.05e-06	-0.26	-0.17	Schizophrenia;	chr15:82631205	chr15:82472203~82472426:+
BRCA	cis	rs875971	0.545	rs2420456	ENSG00000228409.4	CCT6P1	-5.5	4.65e-08	6.05e-06	-0.17	-0.17	Aortic root size;	chr7:66280619	chr7:65751142~65763354:+
BRCA	cis	rs4671400	0.571	rs4672429	ENSG00000271889.1	RP11-493E12.1	-5.5	4.65e-08	6.05e-06	-0.25	-0.17	3-hydroxypropylmercapturic acid levels in smokers;	chr2:61268334	chr2:61151433~61162105:-
BRCA	cis	rs301901	0.514	rs11954689	ENSG00000250155.1	CTD-2353F22.1	-5.5	4.66e-08	6.05e-06	-0.2	-0.17	Height;	chr5:37269214	chr5:36666214~36725195:-
BRCA	cis	rs793571	0.554	rs8033691	ENSG00000259250.1	RP11-50C13.1	-5.5	4.66e-08	6.05e-06	-0.28	-0.17	Schizophrenia;	chr15:58711112	chr15:58587507~58591676:+
BRCA	cis	rs1014246	0.848	rs758362	ENSG00000232767.1	RP11-498B4.5	-5.5	4.66e-08	6.06e-06	-0.18	-0.17	Age at smoking initiation in chronic obstructive pulmonary disease;	chr10:116698394	chr10:116670103~116672739:+
BRCA	cis	rs7923609	1	rs10822161	ENSG00000232075.1	MRPL35P2	-5.5	4.66e-08	6.06e-06	-0.21	-0.17	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63358443	chr10:63634317~63634827:-
BRCA	cis	rs523522	0.962	rs2393590	ENSG00000278344.1	RP11-18C24.8	5.5	4.67e-08	6.06e-06	0.23	0.17	High light scatter reticulocyte count;	chr12:120476097	chr12:120500735~120501090:-
BRCA	cis	rs6547705	0.777	rs4832307	ENSG00000231259.4	AC125232.1	-5.5	4.67e-08	6.06e-06	-0.26	-0.17	Progressive supranuclear palsy;	chr2:86682915	chr2:87031815~87053069:-
BRCA	cis	rs2239547	0.522	rs2581805	ENSG00000242142.1	SERBP1P3	-5.5	4.67e-08	6.07e-06	-0.2	-0.17	Schizophrenia;	chr3:52945034	chr3:53064283~53065091:-
BRCA	cis	rs617791	0.508	rs1047464	ENSG00000255320.1	RP11-755F10.1	5.5	4.67e-08	6.07e-06	0.23	0.17	Breast cancer;	chr11:66001985	chr11:66244840~66246239:-
BRCA	cis	rs7044106	0.791	rs10984994	ENSG00000238181.2	AHCYP2	5.5	4.68e-08	6.08e-06	0.21	0.17	Hip circumference adjusted for BMI;	chr9:120716491	chr9:120720673~120721972:+
BRCA	cis	rs13126694	0.659	rs28514324	ENSG00000248429.4	RP11-597D13.9	5.5	4.68e-08	6.08e-06	0.15	0.17	Blood osmolality (transformed sodium);	chr4:158092778	chr4:158170752~158202877:+
BRCA	cis	rs875971	0.545	rs17138156	ENSG00000228409.4	CCT6P1	-5.5	4.68e-08	6.08e-06	-0.17	-0.17	Aortic root size;	chr7:66249708	chr7:65751142~65763354:+
BRCA	cis	rs4713118	0.738	rs200465	ENSG00000216901.1	AL022393.7	5.5	4.68e-08	6.08e-06	0.23	0.17	Parkinson's disease;	chr6:27789875	chr6:28176188~28176674:+
BRCA	cis	rs10435719	0.902	rs4840599	ENSG00000255046.1	RP11-297N6.4	5.5	4.68e-08	6.09e-06	0.19	0.17	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11947871	chr8:11797928~11802568:-
BRCA	cis	rs7208859	0.673	rs61348930	ENSG00000266490.1	CTD-2349P21.9	5.5	4.69e-08	6.09e-06	0.26	0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30894745	chr17:30792372~30792833:+
BRCA	cis	rs7208859	0.614	rs28758251	ENSG00000266490.1	CTD-2349P21.9	5.5	4.69e-08	6.09e-06	0.26	0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30896294	chr17:30792372~30792833:+
BRCA	cis	rs7208859	0.673	rs9899943	ENSG00000266490.1	CTD-2349P21.9	5.5	4.69e-08	6.09e-06	0.26	0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30896907	chr17:30792372~30792833:+
BRCA	cis	rs7208859	0.673	rs11080138	ENSG00000266490.1	CTD-2349P21.9	5.5	4.69e-08	6.09e-06	0.26	0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30897524	chr17:30792372~30792833:+
BRCA	cis	rs7208859	0.673	rs73265612	ENSG00000266490.1	CTD-2349P21.9	5.5	4.69e-08	6.09e-06	0.26	0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30898965	chr17:30792372~30792833:+
BRCA	cis	rs7208859	0.673	rs11658435	ENSG00000266490.1	CTD-2349P21.9	5.5	4.69e-08	6.09e-06	0.26	0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30901543	chr17:30792372~30792833:+
BRCA	cis	rs7208859	0.673	rs73265624	ENSG00000266490.1	CTD-2349P21.9	5.5	4.69e-08	6.09e-06	0.26	0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30905048	chr17:30792372~30792833:+
BRCA	cis	rs2179367	0.6	rs9498355	ENSG00000216906.2	RP11-350J20.9	-5.5	4.69e-08	6.09e-06	-0.25	-0.17	Dupuytren's disease;	chr6:149442274	chr6:149904243~149906418:+
BRCA	cis	rs4415084	1	rs6884702	ENSG00000251141.4	RP11-53O19.1	5.5	4.69e-08	6.09e-06	0.16	0.17	Breast cancer;	chr5:44682487	chr5:44744900~44808777:-
BRCA	cis	rs2239557	0.508	rs34774275	ENSG00000259065.1	RP5-1021I20.1	-5.5	4.69e-08	6.1e-06	-0.25	-0.17	Common traits (Other);	chr14:73867013	chr14:73787360~73803270:+
BRCA	cis	rs7789940	0.904	rs6953281	ENSG00000186704.9	DTX2P1	5.5	4.69e-08	6.1e-06	0.21	0.17	Multiple sclerosis;	chr7:76317626	chr7:76978617~77004308:+
BRCA	cis	rs7789940	0.951	rs7787526	ENSG00000186704.9	DTX2P1	5.5	4.69e-08	6.1e-06	0.21	0.17	Multiple sclerosis;	chr7:76318236	chr7:76978617~77004308:+
BRCA	cis	rs9516	1	rs2367995	ENSG00000254974.1	RP11-702H23.2	-5.5	4.69e-08	6.1e-06	-0.2	-0.17	Facial morphology (factor 15, philtrum width);	chr11:74452791	chr11:74485580~74486051:-
BRCA	cis	rs2179367	0.632	rs997682	ENSG00000223701.3	RAET1E-AS1	-5.5	4.7e-08	6.1e-06	-0.24	-0.17	Dupuytren's disease;	chr6:149345484	chr6:149884431~149919508:+
BRCA	cis	rs5758511	0.689	rs5758691	ENSG00000233903.2	Z83851.4	5.5	4.7e-08	6.1e-06	0.26	0.17	Birth weight;	chr22:42272498	chr22:42276355~42277052:+
BRCA	cis	rs7577696	0.597	rs34197800	ENSG00000272716.1	RP11-563N4.1	-5.5	4.7e-08	6.1e-06	-0.2	-0.17	Inflammatory biomarkers;	chr2:32164577	chr2:32165046~32165757:-
BRCA	cis	rs2243480	1	rs6974723	ENSG00000228409.4	CCT6P1	-5.5	4.7e-08	6.11e-06	-0.23	-0.17	Diabetic kidney disease;	chr7:66172952	chr7:65751142~65763354:+
BRCA	cis	rs2243480	1	rs9769882	ENSG00000228409.4	CCT6P1	-5.5	4.7e-08	6.11e-06	-0.23	-0.17	Diabetic kidney disease;	chr7:66177938	chr7:65751142~65763354:+
BRCA	cis	rs2243480	1	rs6966322	ENSG00000228409.4	CCT6P1	-5.5	4.7e-08	6.11e-06	-0.23	-0.17	Diabetic kidney disease;	chr7:66181767	chr7:65751142~65763354:+
BRCA	cis	rs2243480	1	rs4145008	ENSG00000228409.4	CCT6P1	-5.5	4.7e-08	6.11e-06	-0.23	-0.17	Diabetic kidney disease;	chr7:66182524	chr7:65751142~65763354:+
BRCA	cis	rs10946940	0.965	rs6921256	ENSG00000216901.1	AL022393.7	5.5	4.7e-08	6.11e-06	0.21	0.17	Systemic lupus erythematosus;	chr6:27619739	chr6:28176188~28176674:+
BRCA	cis	rs9628987	0.5	rs1443929	ENSG00000232912.4	RP5-1115A15.1	5.5	4.71e-08	6.11e-06	0.22	0.17	Breast cancer;	chr1:8397563	chr1:8424645~8434838:+
BRCA	cis	rs7772486	0.875	rs2207785	ENSG00000270638.1	RP3-466P17.1	5.5	4.71e-08	6.11e-06	0.19	0.17	Lobe attachment (rater-scored or self-reported);	chr6:146011648	chr6:145735570~145737218:+
BRCA	cis	rs7044106	0.791	rs10985009	ENSG00000238181.2	AHCYP2	5.5	4.71e-08	6.11e-06	0.22	0.17	Hip circumference adjusted for BMI;	chr9:120730761	chr9:120720673~120721972:+
BRCA	cis	rs227275	0.556	rs6842179	ENSG00000251288.2	RP11-10L12.2	-5.5	4.71e-08	6.11e-06	-0.2	-0.17	Allergic disease (asthma, hay fever or eczema);	chr4:103018363	chr4:102751401~102752641:+
BRCA	cis	rs1497406	0.59	rs6676143	ENSG00000237276.7	ANO7P1	-5.5	4.71e-08	6.12e-06	-0.19	-0.17	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);	chr1:16201723	chr1:16215909~16228027:-
BRCA	cis	rs4835473	0.864	rs12507633	ENSG00000249741.2	RP11-673E1.3	-5.5	4.71e-08	6.12e-06	-0.18	-0.17	Immature fraction of reticulocytes;	chr4:143962730	chr4:143911514~143912053:-
BRCA	cis	rs1023500	1	rs1023499	ENSG00000205702.9	CYP2D7	-5.5	4.71e-08	6.12e-06	-0.17	-0.17	Schizophrenia;	chr22:41944578	chr22:42140203~42144577:-
BRCA	cis	rs295490	0.748	rs17335312	ENSG00000272656.1	RP11-219D15.3	5.5	4.72e-08	6.12e-06	0.4	0.17	PR interval in Tripanosoma cruzi seropositivity;	chr3:139356544	chr3:139349024~139349371:-
BRCA	cis	rs2554380	0.628	rs6602993	ENSG00000230373.7	GOLGA6L5P	-5.5	4.72e-08	6.12e-06	-0.2	-0.17	Height;	chr15:83813610	chr15:84507885~84516814:-
BRCA	cis	rs4713118	0.662	rs175954	ENSG00000204709.4	LINC01556	5.5	4.72e-08	6.13e-06	0.25	0.17	Parkinson's disease;	chr6:28043807	chr6:28943877~28944537:+
BRCA	cis	rs6163	0.508	rs12776506	ENSG00000236937.2	PTGES3P4	5.5	4.72e-08	6.13e-06	0.24	0.17	Waist circumference;Hip circumference;	chr10:102773071	chr10:102845595~102845950:+
BRCA	cis	rs7474896	0.515	rs662928	ENSG00000120555.12	SEPT7P9	-5.5	4.72e-08	6.13e-06	-0.23	-0.17	Obesity (extreme);	chr10:38027288	chr10:38383069~38402916:-
BRCA	cis	rs6570726	0.791	rs621382	ENSG00000270638.1	RP3-466P17.1	5.5	4.72e-08	6.13e-06	0.2	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145478008	chr6:145735570~145737218:+
BRCA	cis	rs17507216	1	rs17356118	ENSG00000255769.6	GOLGA2P10	-5.5	4.72e-08	6.13e-06	-0.23	-0.17	Excessive daytime sleepiness;	chr15:82569149	chr15:82472993~82513950:-
BRCA	cis	rs9545047	0.604	rs9565497	ENSG00000227354.5	RBM26-AS1	-5.5	4.73e-08	6.13e-06	-0.18	-0.17	Schizophrenia;	chr13:79406330	chr13:79406309~79424328:+
BRCA	cis	rs875971	0.545	rs67397473	ENSG00000228409.4	CCT6P1	-5.5	4.73e-08	6.13e-06	-0.17	-0.17	Aortic root size;	chr7:66168318	chr7:65751142~65763354:+
BRCA	cis	rs7246657	0.551	rs10419174	ENSG00000226686.6	LINC01535	-5.5	4.73e-08	6.14e-06	-0.29	-0.17	Coronary artery calcification;	chr19:37114439	chr19:37251912~37265535:+
BRCA	cis	rs35612822	0.828	rs13389512	ENSG00000232485.2	AC098820.3	-5.5	4.73e-08	6.14e-06	-0.21	-0.17	Kidney disease (early stage) in type 1 diabetes;	chr2:216434612	chr2:216479030~216498761:-
BRCA	cis	rs728616	0.867	rs34870056	ENSG00000225484.5	NUTM2B-AS1	-5.5	4.73e-08	6.14e-06	-0.44	-0.17	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80188299	chr10:79663088~79826594:-
BRCA	cis	rs1552244	0.935	rs41520445	ENSG00000180385.7	EMC3-AS1	-5.5	4.73e-08	6.14e-06	-0.21	-0.17	Alzheimer's disease;	chr3:10111457	chr3:9986893~10006990:+
BRCA	cis	rs2644899	0.75	rs2607424	ENSG00000268529.1	CYP2T3P	5.5	4.73e-08	6.14e-06	0.22	0.17	Post bronchodilator FEV1/FVC ratio;	chr19:40769242	chr19:41134722~41137308:+
BRCA	cis	rs10129255	0.957	rs12590667	ENSG00000224373.3	IGHV4-59	-5.5	4.74e-08	6.15e-06	-0.1	-0.17	Kawasaki disease;	chr14:106779223	chr14:106627249~106627825:-
BRCA	cis	rs6490294	0.571	rs7973898	ENSG00000226469.1	ADAM1B	5.5	4.74e-08	6.15e-06	0.26	0.17	Mean platelet volume;	chr12:112178363	chr12:111927018~111929017:+
BRCA	cis	rs1799810	0.523	rs11683986	ENSG00000236682.1	AC068282.3	5.5	4.74e-08	6.15e-06	0.24	0.17	Self-rated health;	chr2:127438822	chr2:127389130~127400580:+
BRCA	cis	rs16866061	0.515	rs1027340	ENSG00000228446.2	AC073052.1	5.5	4.74e-08	6.15e-06	0.19	0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr2:224505837	chr2:224499387~224500100:-
BRCA	cis	rs2153535	0.58	rs1034272	ENSG00000251164.1	HULC	-5.5	4.74e-08	6.15e-06	-0.21	-0.17	Motion sickness;	chr6:8469102	chr6:8652137~8653846:+
BRCA	cis	rs7246657	0.943	rs2112923	ENSG00000267422.1	CTD-2554C21.1	-5.5	4.75e-08	6.16e-06	-0.24	-0.17	Coronary artery calcification;	chr19:37449425	chr19:37779686~37792865:+
BRCA	cis	rs7246657	0.943	rs3760825	ENSG00000267422.1	CTD-2554C21.1	-5.5	4.75e-08	6.16e-06	-0.24	-0.17	Coronary artery calcification;	chr19:37454699	chr19:37779686~37792865:+
BRCA	cis	rs62388641	0.813	rs55821127	ENSG00000218027.2	RP11-157J24.1	-5.5	4.75e-08	6.16e-06	-0.25	-0.17	Daytime sleep phenotypes;	chr6:1550635	chr6:1513698~1515289:-
BRCA	cis	rs2624839	0.704	rs2624833	ENSG00000228008.1	CTD-2330K9.3	5.5	4.75e-08	6.16e-06	0.18	0.17	Intelligence (multi-trait analysis);	chr3:50175079	chr3:49903845~49916937:+
BRCA	cis	rs17772222	0.74	rs11845147	ENSG00000258789.1	RP11-507K2.3	-5.5	4.76e-08	6.17e-06	-0.19	-0.17	Coronary artery calcification;	chr14:88502804	chr14:88551597~88552493:+
BRCA	cis	rs357618	1	rs357629	ENSG00000260581.1	CTB-113P19.4	-5.5	4.76e-08	6.17e-06	-0.19	-0.17	Basophil percentage of white cells;	chr5:151471385	chr5:151652275~151655449:+
BRCA	cis	rs7824557	0.527	rs2409756	ENSG00000154316.13	TDH	5.5	4.76e-08	6.18e-06	0.21	0.17	Retinal vascular caliber;	chr8:11384516	chr8:11339637~11368452:+
BRCA	cis	rs600231	0.665	rs1784859	ENSG00000173727.10	CMB9-22P13.1	-5.5	4.76e-08	6.18e-06	-0.22	-0.17	Bone mineral density;	chr11:65453278	chr11:65455258~65466720:+
BRCA	cis	rs7189233	0.955	rs16952242	ENSG00000279722.1	RP11-44F14.6	-5.5	4.76e-08	6.18e-06	-0.2	-0.17	Intelligence (multi-trait analysis);	chr16:53440338	chr16:53487607~53489943:-
BRCA	cis	rs7772486	0.686	rs1292334	ENSG00000270638.1	RP3-466P17.1	5.5	4.77e-08	6.19e-06	0.2	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145647152	chr6:145735570~145737218:+
BRCA	cis	rs10946940	0.965	rs6910838	ENSG00000216901.1	AL022393.7	-5.5	4.77e-08	6.19e-06	-0.21	-0.17	Systemic lupus erythematosus;	chr6:27547740	chr6:28176188~28176674:+
BRCA	cis	rs7772486	0.79	rs2249147	ENSG00000270638.1	RP3-466P17.1	5.5	4.77e-08	6.19e-06	0.19	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145863863	chr6:145735570~145737218:+
BRCA	cis	rs7430456	0.638	rs13071694	ENSG00000228221.4	LINC00578	-5.5	4.77e-08	6.19e-06	-0.21	-0.17	Breast cancer;	chr3:177775198	chr3:177441921~177752305:+
BRCA	cis	rs61160187	0.505	rs4235482	ENSG00000272308.1	RP11-231G3.1	-5.5	4.77e-08	6.19e-06	-0.19	-0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:60797785	chr5:60866457~60866935:-
BRCA	cis	rs2562456	0.917	rs2650804	ENSG00000268081.1	RP11-678G14.2	5.5	4.77e-08	6.19e-06	0.25	0.17	Pain;	chr19:21497382	chr19:21554640~21569237:-
BRCA	cis	rs4713118	0.629	rs203889	ENSG00000204709.4	LINC01556	5.5	4.77e-08	6.19e-06	0.24	0.17	Parkinson's disease;	chr6:28053997	chr6:28943877~28944537:+
BRCA	cis	rs6088813	1	rs4911180	ENSG00000126005.14	MMP24-AS1	5.5	4.78e-08	6.2e-06	0.2	0.17	Height;	chr20:35385145	chr20:35216462~35278131:-
BRCA	cis	rs6828666	1	rs6833533	ENSG00000271817.2	U3	5.5	4.78e-08	6.2e-06	0.22	0.17	Depression;	chr4:158855123	chr4:158700691~158700909:+
BRCA	cis	rs12681366	0.801	rs2043988	ENSG00000253704.1	RP11-267M23.4	5.5	4.78e-08	6.2e-06	0.19	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94457327	chr8:94553722~94569745:+
BRCA	cis	rs2243480	1	rs10247526	ENSG00000228409.4	CCT6P1	-5.5	4.78e-08	6.2e-06	-0.24	-0.17	Diabetic kidney disease;	chr7:66315709	chr7:65751142~65763354:+
BRCA	cis	rs30380	0.632	rs26498	ENSG00000272109.1	CTD-2260A17.3	5.5	4.78e-08	6.2e-06	0.23	0.17	Cerebrospinal fluid biomarker levels;	chr5:96803109	chr5:96804353~96806105:+
BRCA	cis	rs62025270	0.688	rs56388190	ENSG00000202081.1	RNU6-1280P	-5.5	4.79e-08	6.21e-06	-0.23	-0.17	Idiopathic pulmonary fibrosis;	chr15:85771665	chr15:85651522~85651628:-
BRCA	cis	rs2834188	1	rs13050445	ENSG00000272659.1	AP000295.10	5.5	4.79e-08	6.21e-06	0.25	0.17	Narcolepsy;	chr21:33331291	chr21:33309491~33310181:+
BRCA	cis	rs2834188	1	rs2252930	ENSG00000272659.1	AP000295.10	5.5	4.79e-08	6.21e-06	0.25	0.17	Narcolepsy;	chr21:33331895	chr21:33309491~33310181:+
BRCA	cis	rs4713118	0.629	rs203890	ENSG00000204709.4	LINC01556	5.5	4.79e-08	6.21e-06	0.24	0.17	Parkinson's disease;	chr6:28054470	chr6:28943877~28944537:+
BRCA	cis	rs1707322	0.717	rs1547925	ENSG00000234329.1	RP11-767N6.2	-5.5	4.79e-08	6.22e-06	-0.18	-0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45619684	chr1:45651039~45651826:-
BRCA	cis	rs2153535	0.585	rs9393052	ENSG00000230939.1	RP11-314C16.1	-5.5	4.8e-08	6.22e-06	-0.19	-0.17	Motion sickness;	chr6:8644832	chr6:8784178~8785445:+
BRCA	cis	rs55702914	0.628	rs2565154	ENSG00000231621.1	AC013264.2	-5.5	4.8e-08	6.22e-06	-0.16	-0.17	Major depression and alcohol dependence;	chr2:197445665	chr2:197197991~197199273:+
BRCA	cis	rs1387259	0.929	rs2634666	ENSG00000240399.1	RP1-228P16.1	5.5	4.8e-08	6.23e-06	0.2	0.17	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48269887	chr12:48054813~48055591:-
BRCA	cis	rs7044106	0.791	rs2416797	ENSG00000238181.2	AHCYP2	-5.5	4.81e-08	6.23e-06	-0.22	-0.17	Hip circumference adjusted for BMI;	chr9:120718322	chr9:120720673~120721972:+
BRCA	cis	rs7044106	0.791	rs2416798	ENSG00000238181.2	AHCYP2	-5.5	4.81e-08	6.23e-06	-0.22	-0.17	Hip circumference adjusted for BMI;	chr9:120718325	chr9:120720673~120721972:+
BRCA	cis	rs6570726	0.967	rs373527	ENSG00000270638.1	RP3-466P17.1	5.5	4.81e-08	6.23e-06	0.19	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145480725	chr6:145735570~145737218:+
BRCA	cis	rs891378	0.959	rs7533825	ENSG00000274245.1	RP11-357P18.2	-5.5	4.81e-08	6.23e-06	-0.22	-0.17	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207248817	chr1:207372559~207373252:+
BRCA	cis	rs7493	0.755	rs17883791	ENSG00000233942.1	AC004012.1	5.5	4.81e-08	6.24e-06	0.21	0.17	Yu-Zhi constitution type in type 2 diabetes;	chr7:95370126	chr7:95471835~95473998:+
BRCA	cis	rs2243480	1	rs4718315	ENSG00000228409.4	CCT6P1	-5.5	4.82e-08	6.24e-06	-0.23	-0.17	Diabetic kidney disease;	chr7:66183554	chr7:65751142~65763354:+
BRCA	cis	rs2243480	1	rs4718316	ENSG00000228409.4	CCT6P1	-5.5	4.82e-08	6.24e-06	-0.23	-0.17	Diabetic kidney disease;	chr7:66183744	chr7:65751142~65763354:+
BRCA	cis	rs13108904	0.517	rs13134568	ENSG00000254094.1	AC078852.1	-5.5	4.82e-08	6.25e-06	-0.2	-0.17	Obesity-related traits;	chr4:1340501	chr4:1356581~1358075:+
BRCA	cis	rs2239557	0.539	rs35864336	ENSG00000259065.1	RP5-1021I20.1	-5.5	4.82e-08	6.25e-06	-0.25	-0.17	Common traits (Other);	chr14:73987492	chr14:73787360~73803270:+
BRCA	cis	rs7567389	0.626	rs11683344	ENSG00000236682.1	AC068282.3	-5.5	4.82e-08	6.25e-06	-0.27	-0.17	Self-rated health;	chr2:127198676	chr2:127389130~127400580:+
BRCA	cis	rs516805	0.561	rs7772659	ENSG00000279453.1	RP3-425C14.4	5.5	4.82e-08	6.25e-06	0.27	0.17	Lymphocyte counts;	chr6:122608055	chr6:122436789~122439223:-
BRCA	cis	rs2834288	0.645	rs2032313	ENSG00000273102.1	AP000569.9	5.5	4.83e-08	6.26e-06	0.19	0.17	Gut microbiota (bacterial taxa);	chr21:33981946	chr21:33967101~33968573:-
BRCA	cis	rs7577696	0.512	rs212691	ENSG00000272716.1	RP11-563N4.1	5.5	4.83e-08	6.26e-06	0.21	0.17	Inflammatory biomarkers;	chr2:32213006	chr2:32165046~32165757:-
BRCA	cis	rs2179367	0.632	rs55836833	ENSG00000223701.3	RAET1E-AS1	5.5	4.83e-08	6.26e-06	0.24	0.17	Dupuytren's disease;	chr6:149403736	chr6:149884431~149919508:+
BRCA	cis	rs9467773	1	rs12526680	ENSG00000241549.7	GUSBP2	5.5	4.83e-08	6.26e-06	0.18	0.17	Intelligence (multi-trait analysis);	chr6:26550726	chr6:26871484~26956554:-
BRCA	cis	rs3126085	0.935	rs11204981	ENSG00000237975.5	FLG-AS1	5.5	4.84e-08	6.27e-06	0.26	0.17	Atopic dermatitis;	chr1:152325736	chr1:152168125~152445456:+
BRCA	cis	rs2153535	0.58	rs2225766	ENSG00000251164.1	HULC	-5.5	4.84e-08	6.27e-06	-0.21	-0.17	Motion sickness;	chr6:8481600	chr6:8652137~8653846:+
BRCA	cis	rs7648466	0.544	rs2172247	ENSG00000223552.1	RP11-24F11.2	5.5	4.85e-08	6.28e-06	0.17	0.17	Eotaxin levels;	chr3:46173178	chr3:46364955~46407059:-
BRCA	cis	rs6832769	0.857	rs28377791	ENSG00000272969.1	RP11-528I4.2	-5.5	4.85e-08	6.28e-06	-0.21	-0.17	Personality dimensions;	chr4:55607014	chr4:55547112~55547889:+
BRCA	cis	rs61160187	0.698	rs12517174	ENSG00000215032.2	GNL3LP1	-5.5	4.85e-08	6.28e-06	-0.21	-0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:60673188	chr5:60891935~60893577:-
BRCA	cis	rs17711722	0.565	rs4275112	ENSG00000237310.1	GS1-124K5.4	-5.5	4.85e-08	6.28e-06	-0.18	-0.17	Calcium levels;	chr7:65733651	chr7:66493706~66495474:+
BRCA	cis	rs10097215	1	rs10097215	ENSG00000253982.1	CTD-2336O2.1	5.5	4.85e-08	6.29e-06	0.26	0.17	Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);	chr8:2649382	chr8:1761990~1764502:-
BRCA	cis	rs2717559	0.542	rs2717586	ENSG00000253741.1	CTD-2292P10.4	-5.5	4.86e-08	6.29e-06	-0.2	-0.17	Urinary tract infection frequency;	chr8:142816466	chr8:142702252~142726973:-
BRCA	cis	rs4835473	0.831	rs4125544	ENSG00000249741.2	RP11-673E1.3	-5.5	4.86e-08	6.3e-06	-0.18	-0.17	Immature fraction of reticulocytes;	chr4:143962542	chr4:143911514~143912053:-
BRCA	cis	rs1193	0.837	rs7596943	ENSG00000231259.4	AC125232.1	-5.5	4.87e-08	6.31e-06	-0.21	-0.17	High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;High light scatter reticulocyte count;	chr2:86752370	chr2:87031815~87053069:-
BRCA	cis	rs4835473	0.9	rs13133239	ENSG00000249741.2	RP11-673E1.3	5.5	4.87e-08	6.31e-06	0.18	0.17	Immature fraction of reticulocytes;	chr4:143818894	chr4:143911514~143912053:-
BRCA	cis	rs4835473	0.9	rs13106488	ENSG00000249741.2	RP11-673E1.3	5.5	4.87e-08	6.31e-06	0.18	0.17	Immature fraction of reticulocytes;	chr4:143818969	chr4:143911514~143912053:-
BRCA	cis	rs4835473	0.932	rs35271123	ENSG00000249741.2	RP11-673E1.3	5.5	4.87e-08	6.31e-06	0.18	0.17	Immature fraction of reticulocytes;	chr4:143819629	chr4:143911514~143912053:-
BRCA	cis	rs4835473	0.932	rs1383443	ENSG00000249741.2	RP11-673E1.3	5.5	4.87e-08	6.31e-06	0.18	0.17	Immature fraction of reticulocytes;	chr4:143819940	chr4:143911514~143912053:-
BRCA	cis	rs875971	0.545	rs73148639	ENSG00000228409.4	CCT6P1	-5.5	4.87e-08	6.31e-06	-0.17	-0.17	Aortic root size;	chr7:66390342	chr7:65751142~65763354:+
BRCA	cis	rs7308116	0.51	rs726771	ENSG00000274395.1	RP11-554D14.8	-5.5	4.88e-08	6.32e-06	-0.2	-0.17	Pelvic organ prolapse (moderate/severe);	chr12:107833077	chr12:107835541~107836555:-
BRCA	cis	rs13108904	0.935	rs1620928	ENSG00000254094.1	AC078852.1	5.5	4.88e-08	6.32e-06	0.18	0.17	Obesity-related traits;	chr4:1285336	chr4:1356581~1358075:+
BRCA	cis	rs1979679	0.918	rs1586867	ENSG00000278733.1	RP11-425D17.1	5.5	4.88e-08	6.32e-06	0.21	0.17	Ossification of the posterior longitudinal ligament of the spine;	chr12:28368345	chr12:28185625~28186190:-
BRCA	cis	rs4835473	0.897	rs6832722	ENSG00000249741.2	RP11-673E1.3	-5.5	4.88e-08	6.32e-06	-0.18	-0.17	Immature fraction of reticulocytes;	chr4:143709430	chr4:143911514~143912053:-
BRCA	cis	rs4908760	0.539	rs6690928	ENSG00000270282.1	RP5-1115A15.2	5.5	4.88e-08	6.33e-06	0.18	0.17	Vitiligo;	chr1:8799432	chr1:8512653~8513021:+
BRCA	cis	rs853679	0.513	rs13437444	ENSG00000280107.1	AL022393.9	-5.5	4.89e-08	6.33e-06	-0.29	-0.17	Depression;	chr6:28103220	chr6:28170845~28172521:+
BRCA	cis	rs763121	0.819	rs5757237	ENSG00000228274.3	RP3-508I15.9	-5.5	4.89e-08	6.33e-06	-0.19	-0.17	Menopause (age at onset);	chr22:38677830	chr22:38667585~38681820:-
BRCA	cis	rs763121	0.853	rs11704021	ENSG00000228274.3	RP3-508I15.9	-5.5	4.89e-08	6.33e-06	-0.19	-0.17	Menopause (age at onset);	chr22:38678711	chr22:38667585~38681820:-
BRCA	cis	rs1722141	0.67	rs788766	ENSG00000237471.1	AC073115.6	5.5	4.89e-08	6.33e-06	0.25	0.17	Sitting height ratio;	chr7:45957944	chr7:45969657~45980191:+
BRCA	cis	rs11105298	0.891	rs4842662	ENSG00000270344.2	RP11-734K2.4	5.5	4.89e-08	6.33e-06	0.2	0.17	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89539669	chr12:89525654~89548005:+
BRCA	cis	rs7617773	0.78	rs11706277	ENSG00000199476.1	Y_RNA	-5.5	4.89e-08	6.33e-06	-0.26	-0.17	Coronary artery disease;	chr3:48318943	chr3:48288587~48288694:+
BRCA	cis	rs2235642	0.717	rs2236269	ENSG00000260989.1	LA16c-395F10.2	-5.5	4.89e-08	6.33e-06	-0.18	-0.17	Coronary artery disease;	chr16:1602613	chr16:1580527~1610328:+
BRCA	cis	rs9300255	0.664	rs7306755	ENSG00000235423.7	RP11-282O18.3	-5.5	4.89e-08	6.33e-06	-0.24	-0.17	Neutrophil percentage of white cells;	chr12:123283382	chr12:123252030~123261483:-
BRCA	cis	rs7772486	0.686	rs9403746	ENSG00000270638.1	RP3-466P17.1	-5.5	4.9e-08	6.34e-06	-0.19	-0.17	Lobe attachment (rater-scored or self-reported);	chr6:145782632	chr6:145735570~145737218:+
BRCA	cis	rs7618501	0.633	rs12496973	ENSG00000228008.1	CTD-2330K9.3	5.5	4.9e-08	6.34e-06	0.16	0.17	Intelligence (multi-trait analysis);	chr3:49964812	chr3:49903845~49916937:+
BRCA	cis	rs7618501	0.633	rs11130228	ENSG00000228008.1	CTD-2330K9.3	5.5	4.9e-08	6.34e-06	0.16	0.17	Intelligence (multi-trait analysis);	chr3:49965813	chr3:49903845~49916937:+
BRCA	cis	rs1552244	0.882	rs67762674	ENSG00000232901.1	CYCSP10	5.5	4.9e-08	6.34e-06	0.23	0.17	Alzheimer's disease;	chr3:9972801	chr3:10000647~10000940:-
BRCA	cis	rs5753037	0.543	rs140126	ENSG00000279159.1	RP3-394A18.1	-5.5	4.9e-08	6.35e-06	-0.13	-0.17	Type 1 diabetes;	chr22:29751049	chr22:29978950~30028236:-
BRCA	cis	rs17508449	0.819	rs75290614	ENSG00000232450.1	RP4-730K3.3	-5.5	4.9e-08	6.35e-06	-0.31	-0.17	Leprosy;	chr1:113700250	chr1:113698884~113699631:-
BRCA	cis	rs4535700	0.501	rs2135116	ENSG00000226278.1	PSPHP1	5.5	4.91e-08	6.35e-06	0.19	0.17	Macular telangiectasia type 2;	chr7:55923451	chr7:55764797~55773288:+
BRCA	cis	rs4535700	0.543	rs2174459	ENSG00000226278.1	PSPHP1	5.5	4.91e-08	6.35e-06	0.19	0.17	Macular telangiectasia type 2;	chr7:55923600	chr7:55764797~55773288:+
BRCA	cis	rs78487399	0.831	rs10495903	ENSG00000234936.1	AC010883.5	5.5	4.91e-08	6.35e-06	0.23	0.17	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43579779	chr2:43229573~43233394:+
BRCA	cis	rs10761482	0.5	rs2393644	ENSG00000254271.1	RP11-131N11.4	5.5	4.91e-08	6.36e-06	0.23	0.17	Schizophrenia;	chr10:60551516	chr10:60734342~60741828:+
BRCA	cis	rs3733585	0.673	rs9993410	ENSG00000250413.1	RP11-448G15.1	5.5	4.91e-08	6.36e-06	0.22	0.17	Cleft plate (environmental tobacco smoke interaction);	chr4:9949640	chr4:10006482~10009725:+
BRCA	cis	rs1707322	0.721	rs10890333	ENSG00000234329.1	RP11-767N6.2	5.49	4.91e-08	6.36e-06	0.17	0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634650	chr1:45651039~45651826:-
BRCA	cis	rs7567389	0.719	rs6733478	ENSG00000236682.1	AC068282.3	5.49	4.92e-08	6.36e-06	0.26	0.17	Self-rated health;	chr2:127238413	chr2:127389130~127400580:+
BRCA	cis	rs6163	0.588	rs3818708	ENSG00000213061.2	PFN1P11	5.49	4.92e-08	6.36e-06	0.21	0.17	Waist circumference;Hip circumference;	chr10:102743827	chr10:102838011~102845473:-
BRCA	cis	rs651386	0.506	rs10919448	ENSG00000271811.1	RP1-79C4.4	5.49	4.92e-08	6.37e-06	0.19	0.17	Atrial fibrillation;	chr1:170630432	chr1:170667381~170669425:+
BRCA	cis	rs35146811	0.807	rs10228764	ENSG00000235713.1	RP4-604G5.3	5.49	4.92e-08	6.37e-06	0.2	0.17	Coronary artery disease;	chr7:100010406	chr7:99992397~99993050:+
BRCA	cis	rs12681366	0.734	rs16916802	ENSG00000253704.1	RP11-267M23.4	5.49	4.93e-08	6.38e-06	0.18	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94397280	chr8:94553722~94569745:+
BRCA	cis	rs4237845	0.844	rs4630335	ENSG00000257159.1	RP11-58A17.3	5.49	4.94e-08	6.39e-06	0.2	0.17	Intelligence (multi-trait analysis);	chr12:57908475	chr12:57967058~57968399:+
BRCA	cis	rs2243480	0.522	rs431168	ENSG00000273142.1	RP11-458F8.4	-5.49	4.94e-08	6.39e-06	-0.28	-0.17	Diabetic kidney disease;	chr7:66046617	chr7:66902857~66906297:+
BRCA	cis	rs2153535	0.58	rs2143357	ENSG00000251164.1	HULC	-5.49	4.94e-08	6.39e-06	-0.21	-0.17	Motion sickness;	chr6:8496963	chr6:8652137~8653846:+
BRCA	cis	rs858239	0.511	rs10256996	ENSG00000230042.1	AK3P3	5.49	4.95e-08	6.4e-06	0.18	0.17	Cerebrospinal fluid biomarker levels;	chr7:23105676	chr7:23129178~23129841:+
BRCA	cis	rs8098244	0.737	rs1154241	ENSG00000264745.1	TTC39C-AS1	-5.49	4.95e-08	6.4e-06	-0.25	-0.17	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23944675	chr18:23994213~24015339:-
BRCA	cis	rs2998286	0.637	rs332113	ENSG00000254635.4	WAC-AS1	-5.49	4.95e-08	6.41e-06	-0.24	-0.17	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28634806	chr10:28522652~28532743:-
BRCA	cis	rs3733585	0.699	rs7694997	ENSG00000250413.1	RP11-448G15.1	5.49	4.95e-08	6.41e-06	0.22	0.17	Cleft plate (environmental tobacco smoke interaction);	chr4:9946187	chr4:10006482~10009725:+
BRCA	cis	rs962856	0.964	rs5022017	ENSG00000236780.4	AC078941.1	5.49	4.95e-08	6.41e-06	0.21	0.17	Pancreatic cancer;	chr2:67392045	chr2:67123357~67215319:-
BRCA	cis	rs6430585	0.583	rs12475516	ENSG00000224043.6	CCNT2-AS1	-5.49	4.96e-08	6.41e-06	-0.25	-0.17	Corneal structure;	chr2:135803191	chr2:134735464~134918710:-
BRCA	cis	rs6430585	0.583	rs2304370	ENSG00000224043.6	CCNT2-AS1	-5.49	4.96e-08	6.41e-06	-0.25	-0.17	Corneal structure;	chr2:135804165	chr2:134735464~134918710:-
BRCA	cis	rs2562456	0.793	rs3853837	ENSG00000268535.1	RP11-420K14.3	5.49	4.96e-08	6.41e-06	0.25	0.17	Pain;	chr19:21419172	chr19:21709522~21710191:+
BRCA	cis	rs2562456	0.793	rs3853838	ENSG00000268535.1	RP11-420K14.3	5.49	4.96e-08	6.41e-06	0.25	0.17	Pain;	chr19:21419192	chr19:21709522~21710191:+
BRCA	cis	rs2562456	0.833	rs62110426	ENSG00000268535.1	RP11-420K14.3	5.49	4.96e-08	6.41e-06	0.25	0.17	Pain;	chr19:21420124	chr19:21709522~21710191:+
BRCA	cis	rs372883	0.53	rs11088110	ENSG00000215533.7	LINC00189	-5.49	4.96e-08	6.41e-06	-0.19	-0.17	Pancreatic cancer;	chr21:29171052	chr21:29193480~29288205:+
BRCA	cis	rs1014246	0.826	rs1900509	ENSG00000232767.1	RP11-498B4.5	5.49	4.96e-08	6.42e-06	0.17	0.17	Age at smoking initiation in chronic obstructive pulmonary disease;	chr10:116711431	chr10:116670103~116672739:+
BRCA	cis	rs1014246	0.796	rs2420331	ENSG00000232767.1	RP11-498B4.5	5.49	4.96e-08	6.42e-06	0.17	0.17	Age at smoking initiation in chronic obstructive pulmonary disease;	chr10:116711686	chr10:116670103~116672739:+
BRCA	cis	rs1014246	0.826	rs11197801	ENSG00000232767.1	RP11-498B4.5	5.49	4.96e-08	6.42e-06	0.17	0.17	Age at smoking initiation in chronic obstructive pulmonary disease;	chr10:116712182	chr10:116670103~116672739:+
BRCA	cis	rs6840360	0.642	rs1470280	ENSG00000278978.1	RP11-164P12.5	-5.49	4.96e-08	6.42e-06	-0.18	-0.17	Intelligence (multi-trait analysis);	chr4:151510618	chr4:151669786~151670503:+
BRCA	cis	rs2708977	0.666	rs17685664	ENSG00000237510.6	AC008268.2	5.49	4.97e-08	6.42e-06	0.22	0.17	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96649833	chr2:95789654~95800166:+
BRCA	cis	rs9739070	1	rs9739070	ENSG00000235423.7	RP11-282O18.3	5.49	4.97e-08	6.43e-06	0.22	0.17	Allergy;	chr12:123286485	chr12:123252030~123261483:-
BRCA	cis	rs7487075	0.558	rs56988021	ENSG00000257261.4	RP11-96H19.1	5.49	4.97e-08	6.43e-06	0.18	0.17	Itch intensity from mosquito bite;	chr12:46243568	chr12:46383679~46876159:+
BRCA	cis	rs227275	0.554	rs223367	ENSG00000251288.2	RP11-10L12.2	-5.49	4.97e-08	6.43e-06	-0.2	-0.17	Allergic disease (asthma, hay fever or eczema);	chr4:102843836	chr4:102751401~102752641:+
BRCA	cis	rs42490	0.614	rs402434	ENSG00000251136.7	RP11-37B2.1	-5.49	4.97e-08	6.43e-06	-0.16	-0.17	Leprosy;	chr8:89808088	chr8:89609409~89757727:-
BRCA	cis	rs4907240	0.961	rs6759099	ENSG00000237510.6	AC008268.2	-5.49	4.98e-08	6.44e-06	-0.24	-0.17	Event-related brain oscillations;	chr2:96601523	chr2:95789654~95800166:+
BRCA	cis	rs4907240	0.961	rs6749159	ENSG00000237510.6	AC008268.2	-5.49	4.98e-08	6.44e-06	-0.24	-0.17	Event-related brain oscillations;	chr2:96601556	chr2:95789654~95800166:+
BRCA	cis	rs4907240	0.961	rs62154845	ENSG00000237510.6	AC008268.2	-5.49	4.98e-08	6.44e-06	-0.24	-0.17	Event-related brain oscillations;	chr2:96601907	chr2:95789654~95800166:+
BRCA	cis	rs7246657	0.882	rs4803539	ENSG00000267422.1	CTD-2554C21.1	-5.49	4.98e-08	6.44e-06	-0.24	-0.17	Coronary artery calcification;	chr19:37406620	chr19:37779686~37792865:+
BRCA	cis	rs2898681	0.519	rs3811781	ENSG00000248375.1	RP11-177B4.1	-5.49	4.98e-08	6.44e-06	-0.27	-0.17	Optic nerve measurement (cup area);	chr4:52862999	chr4:52720081~52720831:-
BRCA	cis	rs7897654	0.571	rs12765002	ENSG00000236937.2	PTGES3P4	5.49	4.98e-08	6.44e-06	0.25	0.17	Schizophrenia;	chr10:102875591	chr10:102845595~102845950:+
BRCA	cis	rs6001482	0.679	rs1894238	ENSG00000211642.2	IGLV10-54	5.49	4.98e-08	6.45e-06	0.16	0.17	Diastolic blood pressure;	chr22:22235704	chr22:22214794~22215270:+
BRCA	cis	rs240993	0.516	rs181294	ENSG00000230177.1	RP5-1112D6.4	-5.49	4.99e-08	6.45e-06	-0.22	-0.17	Inflammatory skin disease;Psoriasis;	chr6:111298999	chr6:111277932~111278742:+
BRCA	cis	rs7613875	0.641	rs6446194	ENSG00000228008.1	CTD-2330K9.3	-5.49	4.99e-08	6.45e-06	-0.16	-0.17	Body mass index;	chr3:50029865	chr3:49903845~49916937:+
BRCA	cis	rs4763879	1	rs917911	ENSG00000256673.1	RP11-599J14.2	5.49	4.99e-08	6.45e-06	0.2	0.17	Type 1 diabetes;	chr12:9753255	chr12:9398355~9414851:-
BRCA	cis	rs875971	0.545	rs35459055	ENSG00000228409.4	CCT6P1	-5.49	4.99e-08	6.46e-06	-0.17	-0.17	Aortic root size;	chr7:66479399	chr7:65751142~65763354:+
BRCA	cis	rs2638953	0.962	rs11049530	ENSG00000278733.1	RP11-425D17.1	-5.49	4.99e-08	6.46e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28322220	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.962	rs11049531	ENSG00000278733.1	RP11-425D17.1	-5.49	4.99e-08	6.46e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28322797	chr12:28185625~28186190:-
BRCA	cis	rs9656709	0.528	rs4320501	ENSG00000226278.1	PSPHP1	5.49	4.99e-08	6.46e-06	0.19	0.17	Behavioural disinhibition (generation interaction);	chr7:55662529	chr7:55764797~55773288:+
BRCA	cis	rs875971	0.638	rs6460305	ENSG00000273024.4	INTS4P2	5.49	5e-08	6.47e-06	0.18	0.17	Aortic root size;	chr7:66595421	chr7:65647864~65715661:+
BRCA	cis	rs3733585	0.699	rs4408959	ENSG00000250413.1	RP11-448G15.1	5.49	5e-08	6.47e-06	0.22	0.17	Cleft plate (environmental tobacco smoke interaction);	chr4:9947244	chr4:10006482~10009725:+
BRCA	cis	rs3733585	0.699	rs4276278	ENSG00000250413.1	RP11-448G15.1	5.49	5e-08	6.47e-06	0.22	0.17	Cleft plate (environmental tobacco smoke interaction);	chr4:9947246	chr4:10006482~10009725:+
BRCA	cis	rs9341808	0.718	rs9448899	ENSG00000272129.1	RP11-250B2.6	5.49	5e-08	6.47e-06	0.21	0.17	Sitting height ratio;	chr6:80136147	chr6:80355424~80356859:+
BRCA	cis	rs467650	0.853	rs316511	ENSG00000248489.1	CTD-2007H13.3	5.49	5.01e-08	6.47e-06	0.19	0.17	Venous thromboembolism (SNP x SNP interaction);	chr5:98673338	chr5:98929171~98995013:+
BRCA	cis	rs12478296	0.792	rs57482298	ENSG00000261186.2	RP11-341N2.1	-5.49	5.01e-08	6.48e-06	-0.28	-0.17	Obesity-related traits;	chr2:242068997	chr2:242087351~242088457:-
BRCA	cis	rs9308731	0.644	rs1439287	ENSG00000227992.1	AC108463.2	-5.49	5.01e-08	6.48e-06	-0.19	-0.17	Chronic lymphocytic leukemia;	chr2:111114320	chr2:111203964~111206215:-
BRCA	cis	rs116175783	1	rs4309587	ENSG00000227403.1	AC009299.3	5.49	5.02e-08	6.48e-06	0.44	0.17	Intelligence (multi-trait analysis);	chr2:161700077	chr2:161244739~161249050:+
BRCA	cis	rs721917	0.506	rs2493722	ENSG00000244733.5	RP11-506M13.3	-5.49	5.02e-08	6.48e-06	-0.2	-0.17	Chronic obstructive pulmonary disease;	chr10:79896989	chr10:79660891~79677996:+
BRCA	cis	rs721917	0.545	rs2758542	ENSG00000244733.5	RP11-506M13.3	-5.49	5.02e-08	6.48e-06	-0.2	-0.17	Chronic obstructive pulmonary disease;	chr10:79897946	chr10:79660891~79677996:+
BRCA	cis	rs721917	0.506	rs7914360	ENSG00000244733.5	RP11-506M13.3	-5.49	5.02e-08	6.48e-06	-0.2	-0.17	Chronic obstructive pulmonary disease;	chr10:79898002	chr10:79660891~79677996:+
BRCA	cis	rs721917	0.506	rs2254025	ENSG00000244733.5	RP11-506M13.3	-5.49	5.02e-08	6.48e-06	-0.2	-0.17	Chronic obstructive pulmonary disease;	chr10:79898457	chr10:79660891~79677996:+
BRCA	cis	rs721917	0.525	rs2254017	ENSG00000244733.5	RP11-506M13.3	-5.49	5.02e-08	6.48e-06	-0.2	-0.17	Chronic obstructive pulmonary disease;	chr10:79898635	chr10:79660891~79677996:+
BRCA	cis	rs721917	0.506	rs2254013	ENSG00000244733.5	RP11-506M13.3	-5.49	5.02e-08	6.48e-06	-0.2	-0.17	Chronic obstructive pulmonary disease;	chr10:79898692	chr10:79660891~79677996:+
BRCA	cis	rs721917	0.506	rs2253875	ENSG00000244733.5	RP11-506M13.3	-5.49	5.02e-08	6.48e-06	-0.2	-0.17	Chronic obstructive pulmonary disease;	chr10:79899446	chr10:79660891~79677996:+
BRCA	cis	rs721917	0.544	rs9325567	ENSG00000244733.5	RP11-506M13.3	-5.49	5.02e-08	6.48e-06	-0.2	-0.17	Chronic obstructive pulmonary disease;	chr10:79899822	chr10:79660891~79677996:+
BRCA	cis	rs1440410	0.56	rs4413361	ENSG00000250326.1	RP11-284M14.1	-5.49	5.02e-08	6.49e-06	-0.2	-0.17	Ischemic stroke;	chr4:143190802	chr4:142933195~143184861:-
BRCA	cis	rs7731783	1	rs7731783	ENSG00000272459.1	RP11-1277A3.3	-5.49	5.02e-08	6.49e-06	-0.2	-0.17	Methadone dose in opioid dependence;	chr5:177633311	chr5:177554824~177555364:+
BRCA	cis	rs10829156	0.699	rs1917209	ENSG00000240291.1	RP11-499P20.2	5.49	5.03e-08	6.49e-06	0.19	0.17	Sudden cardiac arrest;	chr10:18543631	chr10:18513115~18545651:-
BRCA	cis	rs2638953	0.853	rs11049635	ENSG00000278733.1	RP11-425D17.1	-5.49	5.03e-08	6.5e-06	-0.22	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28464293	chr12:28185625~28186190:-
BRCA	cis	rs7824557	0.591	rs2572452	ENSG00000154316.13	TDH	5.49	5.03e-08	6.5e-06	0.21	0.17	Retinal vascular caliber;	chr8:11370745	chr8:11339637~11368452:+
BRCA	cis	rs7674212	0.541	rs2720448	ENSG00000251288.2	RP11-10L12.2	-5.49	5.03e-08	6.5e-06	-0.2	-0.17	Type 2 diabetes;	chr4:103109432	chr4:102751401~102752641:+
BRCA	cis	rs7674212	0.541	rs2623064	ENSG00000251288.2	RP11-10L12.2	-5.49	5.03e-08	6.5e-06	-0.2	-0.17	Type 2 diabetes;	chr4:103109635	chr4:102751401~102752641:+
BRCA	cis	rs34217772	0.68	rs4586337	ENSG00000258636.1	CTD-2298J14.2	5.49	5.03e-08	6.5e-06	0.23	0.17	Myopia;	chr14:41721820	chr14:41587861~41604856:-
BRCA	cis	rs6479901	0.895	rs1904296	ENSG00000232075.1	MRPL35P2	-5.49	5.03e-08	6.5e-06	-0.24	-0.17	Intelligence (multi-trait analysis);	chr10:63173019	chr10:63634317~63634827:-
BRCA	cis	rs2153535	0.518	rs9328473	ENSG00000230939.1	RP11-314C16.1	-5.49	5.03e-08	6.5e-06	-0.2	-0.17	Motion sickness;	chr6:8487092	chr6:8784178~8785445:+
BRCA	cis	rs67311347	1	rs6599094	ENSG00000280739.1	EIF1B-AS1	5.49	5.03e-08	6.5e-06	0.18	0.17	Renal cell carcinoma;	chr3:40358102	chr3:40173145~40309698:-
BRCA	cis	rs4835473	0.778	rs2622380	ENSG00000249741.2	RP11-673E1.3	5.49	5.03e-08	6.5e-06	0.18	0.17	Immature fraction of reticulocytes;	chr4:143814571	chr4:143911514~143912053:-
BRCA	cis	rs4835473	0.932	rs35792820	ENSG00000249741.2	RP11-673E1.3	5.49	5.03e-08	6.5e-06	0.18	0.17	Immature fraction of reticulocytes;	chr4:143814806	chr4:143911514~143912053:-
BRCA	cis	rs4835473	0.864	rs62337300	ENSG00000249741.2	RP11-673E1.3	5.49	5.03e-08	6.5e-06	0.18	0.17	Immature fraction of reticulocytes;	chr4:143815897	chr4:143911514~143912053:-
BRCA	cis	rs4835473	0.932	rs7697498	ENSG00000249741.2	RP11-673E1.3	5.49	5.03e-08	6.5e-06	0.18	0.17	Immature fraction of reticulocytes;	chr4:143816854	chr4:143911514~143912053:-
BRCA	cis	rs4835473	0.932	rs7656455	ENSG00000249741.2	RP11-673E1.3	5.49	5.03e-08	6.5e-06	0.18	0.17	Immature fraction of reticulocytes;	chr4:143817005	chr4:143911514~143912053:-
BRCA	cis	rs4691139	0.658	rs4690798	ENSG00000248632.1	RP11-366M4.11	5.49	5.03e-08	6.5e-06	0.17	0.17	Ovarian cancer in BRCA1 mutation carriers;	chr4:165005434	chr4:164968587~164970002:-
BRCA	cis	rs9291683	0.566	rs13115776	ENSG00000250413.1	RP11-448G15.1	-5.49	5.03e-08	6.5e-06	-0.22	-0.17	Bone mineral density;	chr4:10038565	chr4:10006482~10009725:+
BRCA	cis	rs3764021	0.837	rs7306557	ENSG00000214776.8	RP11-726G1.1	5.49	5.04e-08	6.51e-06	0.18	0.17	Type 1 diabetes;	chr12:9724760	chr12:9467552~9576275:+
BRCA	cis	rs4950322	0.515	rs11239958	ENSG00000244371.2	PFN1P8	-5.49	5.04e-08	6.51e-06	-0.22	-0.17	Protein quantitative trait loci;	chr1:147247454	chr1:146957117~146957659:-
BRCA	cis	rs4908768	0.539	rs1061039	ENSG00000270282.1	RP5-1115A15.2	5.49	5.04e-08	6.51e-06	0.18	0.17	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8582529	chr1:8512653~8513021:+
BRCA	cis	rs6832769	0.961	rs3805147	ENSG00000223305.1	RN7SKP30	5.49	5.04e-08	6.51e-06	0.21	0.17	Personality dimensions;	chr4:55440563	chr4:55540502~55540835:-
BRCA	cis	rs3764021	0.868	rs7306304	ENSG00000214776.8	RP11-726G1.1	5.49	5.04e-08	6.51e-06	0.18	0.17	Type 1 diabetes;	chr12:9724600	chr12:9467552~9576275:+
BRCA	cis	rs9545047	0.604	rs7988784	ENSG00000227354.5	RBM26-AS1	-5.49	5.04e-08	6.52e-06	-0.18	-0.17	Schizophrenia;	chr13:79335337	chr13:79406309~79424328:+
BRCA	cis	rs2243480	1	rs958550	ENSG00000232559.3	GS1-124K5.12	-5.49	5.05e-08	6.52e-06	-0.31	-0.17	Diabetic kidney disease;	chr7:66170692	chr7:66554588~66576923:-
BRCA	cis	rs35146811	0.771	rs1060544	ENSG00000235713.1	RP4-604G5.3	5.49	5.05e-08	6.52e-06	0.2	0.17	Coronary artery disease;	chr7:100015853	chr7:99992397~99993050:+
BRCA	cis	rs2790457	0.874	rs1265840	ENSG00000254635.4	WAC-AS1	-5.49	5.05e-08	6.52e-06	-0.2	-0.17	Multiple myeloma;	chr10:28630712	chr10:28522652~28532743:-
BRCA	cis	rs3764021	0.87	rs7307111	ENSG00000214776.8	RP11-726G1.1	5.49	5.05e-08	6.53e-06	0.18	0.17	Type 1 diabetes;	chr12:9725227	chr12:9467552~9576275:+
BRCA	cis	rs4372836	1	rs7579277	ENSG00000226833.4	AC097724.3	5.49	5.05e-08	6.53e-06	0.21	0.17	Body mass index;	chr2:28773429	chr2:28708953~28736205:-
BRCA	cis	rs7474896	0.537	rs2749588	ENSG00000120555.12	SEPT7P9	5.49	5.05e-08	6.53e-06	0.23	0.17	Obesity (extreme);	chr10:37980529	chr10:38383069~38402916:-
BRCA	cis	rs9859260	0.744	rs3933	ENSG00000242086.7	LINC00969	-5.49	5.05e-08	6.53e-06	-0.18	-0.17	Mean corpuscular volume;	chr3:196058126	chr3:195658062~195739964:+
BRCA	cis	rs10752881	1	rs6673559	ENSG00000224468.3	RP11-181K3.4	-5.49	5.06e-08	6.54e-06	-0.18	-0.17	Colorectal cancer;	chr1:183014062	chr1:183138402~183141282:-
BRCA	cis	rs10752881	1	rs6697739	ENSG00000224468.3	RP11-181K3.4	-5.49	5.06e-08	6.54e-06	-0.18	-0.17	Colorectal cancer;	chr1:183014198	chr1:183138402~183141282:-
BRCA	cis	rs4950322	0.895	rs17356735	ENSG00000278811.3	LINC00624	5.49	5.06e-08	6.54e-06	0.23	0.17	Protein quantitative trait loci;	chr1:147378328	chr1:147258885~147517875:-
BRCA	cis	rs755249	1	rs61779359	ENSG00000182109.6	RP11-69E11.4	5.49	5.06e-08	6.54e-06	0.23	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39544563	chr1:39522280~39546187:-
BRCA	cis	rs755249	0.959	rs61781363	ENSG00000182109.6	RP11-69E11.4	5.49	5.06e-08	6.54e-06	0.23	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39546761	chr1:39522280~39546187:-
BRCA	cis	rs755249	1	rs4660808	ENSG00000182109.6	RP11-69E11.4	5.49	5.06e-08	6.54e-06	0.23	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39552837	chr1:39522280~39546187:-
BRCA	cis	rs755249	1	rs61781364	ENSG00000182109.6	RP11-69E11.4	5.49	5.06e-08	6.54e-06	0.23	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39553919	chr1:39522280~39546187:-
BRCA	cis	rs9287719	0.601	rs10178751	ENSG00000243819.4	RN7SL832P	5.49	5.07e-08	6.54e-06	0.17	0.17	Prostate cancer;	chr2:10594077	chr2:10690344~10692099:+
BRCA	cis	rs9309473	0.95	rs11126412	ENSG00000163016.8	ALMS1P	5.49	5.07e-08	6.54e-06	0.22	0.17	Metabolite levels;	chr2:73660507	chr2:73644919~73685576:+
BRCA	cis	rs10510102	0.935	rs7923634	ENSG00000226864.1	ATE1-AS1	5.49	5.07e-08	6.55e-06	0.31	0.17	Breast cancer;	chr10:121832800	chr10:121928312~121951965:+
BRCA	cis	rs2904967	0.929	rs611910	ENSG00000254614.2	AP003068.23	5.49	5.07e-08	6.55e-06	0.3	0.17	Mean corpuscular volume;	chr11:65281807	chr11:65177606~65181834:-
BRCA	cis	rs2075677	0.506	rs2273101	ENSG00000222365.1	SNORD12B	-5.49	5.07e-08	6.55e-06	-0.23	-0.17	Subjective well-being;	chr20:48921796	chr20:49280319~49280409:+
BRCA	cis	rs6490294	0.571	rs12300496	ENSG00000226469.1	ADAM1B	5.49	5.07e-08	6.55e-06	0.27	0.17	Mean platelet volume;	chr12:112012629	chr12:111927018~111929017:+
BRCA	cis	rs934734	0.532	rs7569257	ENSG00000204929.10	AC074391.1	-5.49	5.08e-08	6.56e-06	-0.2	-0.17	Rheumatoid arthritis;	chr2:65429842	chr2:65436711~66084639:+
BRCA	cis	rs4660214	0.666	rs4660550	ENSG00000228060.1	RP11-69E11.8	5.49	5.08e-08	6.56e-06	0.17	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39222787	chr1:39565160~39573203:+
BRCA	cis	rs7487075	0.502	rs12299843	ENSG00000257261.4	RP11-96H19.1	5.49	5.08e-08	6.56e-06	0.18	0.17	Itch intensity from mosquito bite;	chr12:46242227	chr12:46383679~46876159:+
BRCA	cis	rs9402743	0.634	rs2327647	ENSG00000231028.7	LINC00271	5.49	5.08e-08	6.56e-06	0.17	0.17	Systemic lupus erythematosus;	chr6:135597296	chr6:135497801~135716055:+
BRCA	cis	rs2732480	0.577	rs2732466	ENSG00000226413.2	OR8T1P	5.49	5.08e-08	6.56e-06	0.23	0.17	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48338676	chr12:48442030~48442947:-
BRCA	cis	rs910316	0.737	rs175072	ENSG00000279594.1	RP11-950C14.10	-5.49	5.08e-08	6.56e-06	-0.18	-0.17	Height;	chr14:75036124	chr14:75011269~75012851:-
BRCA	cis	rs2638953	0.672	rs11609619	ENSG00000278733.1	RP11-425D17.1	-5.49	5.09e-08	6.56e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28557876	chr12:28185625~28186190:-
BRCA	cis	rs6754311	0.551	rs6739713	ENSG00000224043.6	CCNT2-AS1	-5.49	5.09e-08	6.57e-06	-0.24	-0.17	Mosquito bite size;	chr2:135731408	chr2:134735464~134918710:-
BRCA	cis	rs7204230	1	rs2042028	ENSG00000261291.1	RP11-295M3.2	-5.49	5.09e-08	6.57e-06	-0.22	-0.17	Fibrinogen;	chr16:53162364	chr16:53168522~53169450:+
BRCA	cis	rs3740713	1	rs73436668	ENSG00000256464.1	YWHABP2	5.49	5.09e-08	6.57e-06	0.29	0.17	Amyotrophic lateral sclerosis (sporadic);	chr11:18421546	chr11:18490243~18490955:-
BRCA	cis	rs7620503	1	rs4273409	ENSG00000228221.4	LINC00578	5.49	5.09e-08	6.57e-06	0.19	0.17	Corneal structure;	chr3:177580997	chr3:177441921~177752305:+
BRCA	cis	rs7620503	1	rs36102700	ENSG00000228221.4	LINC00578	5.49	5.09e-08	6.57e-06	0.19	0.17	Corneal structure;	chr3:177581321	chr3:177441921~177752305:+
BRCA	cis	rs2562456	0.833	rs62110429	ENSG00000268535.1	RP11-420K14.3	5.49	5.09e-08	6.57e-06	0.25	0.17	Pain;	chr19:21430984	chr19:21709522~21710191:+
BRCA	cis	rs5753037	0.653	rs140123	ENSG00000279159.1	RP3-394A18.1	5.49	5.09e-08	6.57e-06	0.13	0.17	Type 1 diabetes;	chr22:29747217	chr22:29978950~30028236:-
BRCA	cis	rs7615952	0.599	rs7652883	ENSG00000171084.14	FAM86JP	5.49	5.1e-08	6.58e-06	0.25	0.17	Blood pressure (smoking interaction);	chr3:125989134	chr3:125916620~125930024:+
BRCA	cis	rs8048589	1	rs12596549	ENSG00000175604.2	RP11-276H1.3	-5.49	5.1e-08	6.59e-06	-0.25	-0.17	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);	chr16:12089643	chr16:12086746~12090302:-
BRCA	cis	rs2624839	0.704	rs13067082	ENSG00000228008.1	CTD-2330K9.3	-5.49	5.1e-08	6.59e-06	-0.18	-0.17	Intelligence (multi-trait analysis);	chr3:50184282	chr3:49903845~49916937:+
BRCA	cis	rs2749097	1	rs4643	ENSG00000244256.3	RN7SL130P	-5.49	5.1e-08	6.59e-06	-0.24	-0.17	Alcohol consumption (transferrin glycosylation);	chr1:63659768	chr1:63655743~63656047:+
BRCA	cis	rs1953600	0.645	rs2573351	ENSG00000226659.1	RP11-137H2.4	-5.49	5.11e-08	6.59e-06	-0.21	-0.17	Sarcoidosis;	chr10:80171685	chr10:80529597~80535942:-
BRCA	cis	rs6441961	0.586	rs7612940	ENSG00000223552.1	RP11-24F11.2	-5.49	5.11e-08	6.59e-06	-0.21	-0.17	Celiac disease;	chr3:46307797	chr3:46364955~46407059:-
BRCA	cis	rs2243480	1	rs11538349	ENSG00000230295.1	RP11-458F8.2	-5.49	5.11e-08	6.59e-06	-0.22	-0.17	Diabetic kidney disease;	chr7:65956884	chr7:66880708~66882981:+
BRCA	cis	rs2239557	0.539	rs2302118	ENSG00000259065.1	RP5-1021I20.1	-5.49	5.11e-08	6.59e-06	-0.24	-0.17	Common traits (Other);	chr14:73955626	chr14:73787360~73803270:+
BRCA	cis	rs875971	0.522	rs7784623	ENSG00000273024.4	INTS4P2	-5.49	5.11e-08	6.59e-06	-0.18	-0.17	Aortic root size;	chr7:65930047	chr7:65647864~65715661:+
BRCA	cis	rs2638953	0.64	rs11049721	ENSG00000278733.1	RP11-425D17.1	-5.49	5.11e-08	6.6e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28573743	chr12:28185625~28186190:-
BRCA	cis	rs7923609	0.902	rs10822158	ENSG00000232075.1	MRPL35P2	-5.49	5.12e-08	6.6e-06	-0.21	-0.17	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63334623	chr10:63634317~63634827:-
BRCA	cis	rs7923609	0.846	rs10740115	ENSG00000232075.1	MRPL35P2	-5.49	5.12e-08	6.6e-06	-0.21	-0.17	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63335230	chr10:63634317~63634827:-
BRCA	cis	rs7923609	0.846	rs10740116	ENSG00000232075.1	MRPL35P2	-5.49	5.12e-08	6.6e-06	-0.21	-0.17	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63335232	chr10:63634317~63634827:-
BRCA	cis	rs2303759	0.709	rs10422677	ENSG00000268686.1	AC010524.2	-5.49	5.12e-08	6.6e-06	-0.27	-0.17	Multiple sclerosis;	chr19:49321033	chr19:49368705~49388081:-
BRCA	cis	rs2303759	0.709	rs7256363	ENSG00000268686.1	AC010524.2	-5.49	5.12e-08	6.6e-06	-0.27	-0.17	Multiple sclerosis;	chr19:49324547	chr19:49368705~49388081:-
BRCA	cis	rs4535700	0.504	rs66528253	ENSG00000226278.1	PSPHP1	5.49	5.12e-08	6.6e-06	0.19	0.17	Macular telangiectasia type 2;	chr7:55929070	chr7:55764797~55773288:+
BRCA	cis	rs4535700	0.501	rs11765577	ENSG00000226278.1	PSPHP1	5.49	5.12e-08	6.6e-06	0.19	0.17	Macular telangiectasia type 2;	chr7:55930245	chr7:55764797~55773288:+
BRCA	cis	rs6832769	0.961	rs7684810	ENSG00000272969.1	RP11-528I4.2	5.49	5.12e-08	6.6e-06	0.21	0.17	Personality dimensions;	chr4:55486627	chr4:55547112~55547889:+
BRCA	cis	rs7923837	0.687	rs1977833	ENSG00000236493.2	EIF2S2P3	5.49	5.12e-08	6.6e-06	0.22	0.17	Multiple sclerosis;Body mass index;	chr10:92704188	chr10:92668745~92669743:-
BRCA	cis	rs4950322	0.947	rs72694723	ENSG00000278811.3	LINC00624	5.49	5.12e-08	6.6e-06	0.23	0.17	Protein quantitative trait loci;	chr1:147373174	chr1:147258885~147517875:-
BRCA	cis	rs7267979	0.586	rs6037057	ENSG00000277938.1	RP5-965G21.3	5.49	5.12e-08	6.61e-06	0.2	0.17	Liver enzyme levels (alkaline phosphatase);	chr20:25201453	chr20:25229150~25231933:+
BRCA	cis	rs9307551	0.596	rs12510204	ENSG00000250334.4	LINC00989	-5.49	5.12e-08	6.61e-06	-0.24	-0.17	Refractive error;	chr4:79551809	chr4:79492416~79576460:+
BRCA	cis	rs34792	0.626	rs153788	ENSG00000207425.1	Y_RNA	-5.49	5.12e-08	6.61e-06	-0.21	-0.17	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15500346	chr16:14915457~14915556:-
BRCA	cis	rs7674212	0.541	rs2720458	ENSG00000248740.4	RP11-328K4.1	5.49	5.13e-08	6.61e-06	0.2	0.17	Type 2 diabetes;	chr4:103131806	chr4:103256159~103453658:+
BRCA	cis	rs763121	0.853	rs5757187	ENSG00000228274.3	RP3-508I15.9	5.49	5.13e-08	6.62e-06	0.18	0.17	Menopause (age at onset);	chr22:38625517	chr22:38667585~38681820:-
BRCA	cis	rs10129255	0.784	rs7147210	ENSG00000280411.1	IGHV1-69-2	-5.49	5.13e-08	6.62e-06	-0.13	-0.17	Kawasaki disease;	chr14:106705271	chr14:106762092~106762588:-
BRCA	cis	rs13108904	0.87	rs1564508	ENSG00000254094.1	AC078852.1	-5.49	5.13e-08	6.62e-06	-0.18	-0.17	Obesity-related traits;	chr4:1251091	chr4:1356581~1358075:+
BRCA	cis	rs2638953	0.962	rs79708115	ENSG00000278733.1	RP11-425D17.1	-5.49	5.13e-08	6.62e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28440784	chr12:28185625~28186190:-
BRCA	cis	rs5758511	0.68	rs5758681	ENSG00000233903.2	Z83851.4	5.49	5.13e-08	6.62e-06	0.25	0.17	Birth weight;	chr22:42249085	chr22:42276355~42277052:+
BRCA	cis	rs7927771	0.524	rs12286721	ENSG00000280615.1	Y_RNA	-5.49	5.14e-08	6.62e-06	-0.19	-0.17	Subjective well-being;	chr11:47679976	chr11:47614898~47614994:-
BRCA	cis	rs2638953	0.67	rs11049701	ENSG00000278733.1	RP11-425D17.1	-5.49	5.14e-08	6.63e-06	-0.2	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28536042	chr12:28185625~28186190:-
BRCA	cis	rs4819052	0.851	rs9974628	ENSG00000184274.3	LINC00315	-5.49	5.14e-08	6.63e-06	-0.23	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45252732	chr21:45300245~45305257:-
BRCA	cis	rs4218	0.638	rs8042516	ENSG00000277144.1	RP11-59H7.4	-5.49	5.14e-08	6.63e-06	-0.22	-0.17	Social communication problems;	chr15:59067525	chr15:59115547~59116089:-
BRCA	cis	rs7577696	0.695	rs212743	ENSG00000272716.1	RP11-563N4.1	5.49	5.14e-08	6.63e-06	0.18	0.17	Inflammatory biomarkers;	chr2:32185125	chr2:32165046~32165757:-
BRCA	cis	rs1440410	0.56	rs1440414	ENSG00000250326.1	RP11-284M14.1	-5.49	5.14e-08	6.63e-06	-0.2	-0.17	Ischemic stroke;	chr4:143240837	chr4:142933195~143184861:-
BRCA	cis	rs4713118	0.824	rs7759217	ENSG00000216901.1	AL022393.7	5.49	5.14e-08	6.64e-06	0.23	0.17	Parkinson's disease;	chr6:27762684	chr6:28176188~28176674:+
BRCA	cis	rs4713118	0.784	rs9468219	ENSG00000216901.1	AL022393.7	5.49	5.14e-08	6.64e-06	0.23	0.17	Parkinson's disease;	chr6:27763976	chr6:28176188~28176674:+
BRCA	cis	rs1387259	0.79	rs2732445	ENSG00000226413.2	OR8T1P	5.49	5.15e-08	6.64e-06	0.23	0.17	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48251750	chr12:48442030~48442947:-
BRCA	cis	rs2638953	0.853	rs11049519	ENSG00000247934.4	RP11-967K21.1	-5.49	5.15e-08	6.64e-06	-0.25	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28307285	chr12:28163298~28190738:-
BRCA	cis	rs8114671	0.562	rs6060064	ENSG00000269202.1	RP4-614O4.12	5.49	5.15e-08	6.65e-06	0.17	0.17	Height;	chr20:34818536	chr20:35201747~35203288:-
BRCA	cis	rs2153535	0.58	rs9378556	ENSG00000251164.1	HULC	-5.49	5.16e-08	6.65e-06	-0.2	-0.17	Motion sickness;	chr6:8514462	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.58	rs9406171	ENSG00000251164.1	HULC	-5.49	5.16e-08	6.65e-06	-0.2	-0.17	Motion sickness;	chr6:8515129	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.54	rs9378557	ENSG00000251164.1	HULC	-5.49	5.16e-08	6.65e-06	-0.2	-0.17	Motion sickness;	chr6:8517148	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.58	rs2143354	ENSG00000251164.1	HULC	-5.49	5.16e-08	6.65e-06	-0.2	-0.17	Motion sickness;	chr6:8517674	chr6:8652137~8653846:+
BRCA	cis	rs4237845	0.761	rs11172378	ENSG00000257159.1	RP11-58A17.3	5.49	5.16e-08	6.65e-06	0.2	0.17	Intelligence (multi-trait analysis);	chr12:57904378	chr12:57967058~57968399:+
BRCA	cis	rs5758511	0.68	rs56111723	ENSG00000233903.2	Z83851.4	5.49	5.16e-08	6.65e-06	0.25	0.17	Birth weight;	chr22:42268877	chr22:42276355~42277052:+
BRCA	cis	rs7487075	0.558	rs12303214	ENSG00000257261.4	RP11-96H19.1	5.49	5.16e-08	6.65e-06	0.18	0.17	Itch intensity from mosquito bite;	chr12:46255745	chr12:46383679~46876159:+
BRCA	cis	rs375066	0.551	rs73052639	ENSG00000267058.1	RP11-15A1.3	5.49	5.16e-08	6.65e-06	0.2	0.17	Breast cancer;	chr19:43830077	chr19:43891804~43901805:-
BRCA	cis	rs7923837	0.713	rs10882099	ENSG00000236493.2	EIF2S2P3	5.49	5.16e-08	6.66e-06	0.22	0.17	Multiple sclerosis;Body mass index;	chr10:92700893	chr10:92668745~92669743:-
BRCA	cis	rs228614	0.51	rs223453	ENSG00000251288.2	RP11-10L12.2	-5.49	5.16e-08	6.66e-06	-0.19	-0.17	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102789895	chr4:102751401~102752641:+
BRCA	cis	rs6500395	0.962	rs9937623	ENSG00000261267.1	RP11-44I10.3	5.49	5.17e-08	6.66e-06	0.2	0.17	Response to tocilizumab in rheumatoid arthritis;	chr16:48537679	chr16:48559661~48587403:+
BRCA	cis	rs2732480	0.577	rs2732479	ENSG00000257735.1	RP11-370I10.6	5.49	5.17e-08	6.67e-06	0.21	0.17	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48342477	chr12:48350945~48442411:+
BRCA	cis	rs2732480	0.537	rs1061986	ENSG00000257735.1	RP11-370I10.6	5.49	5.17e-08	6.67e-06	0.21	0.17	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48342656	chr12:48350945~48442411:+
BRCA	cis	rs2239557	0.539	rs2302117	ENSG00000259065.1	RP5-1021I20.1	-5.49	5.17e-08	6.67e-06	-0.24	-0.17	Common traits (Other);	chr14:73988110	chr14:73787360~73803270:+
BRCA	cis	rs240993	0.715	rs6920798	ENSG00000230177.1	RP5-1112D6.4	5.49	5.18e-08	6.67e-06	0.21	0.17	Inflammatory skin disease;Psoriasis;	chr6:111526074	chr6:111277932~111278742:+
BRCA	cis	rs7772486	0.686	rs9399564	ENSG00000270638.1	RP3-466P17.1	-5.49	5.18e-08	6.67e-06	-0.19	-0.17	Lobe attachment (rater-scored or self-reported);	chr6:145757771	chr6:145735570~145737218:+
BRCA	cis	rs2243480	0.803	rs34804747	ENSG00000230295.1	RP11-458F8.2	-5.49	5.18e-08	6.68e-06	-0.22	-0.17	Diabetic kidney disease;	chr7:65947955	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs59794892	ENSG00000230295.1	RP11-458F8.2	-5.49	5.18e-08	6.68e-06	-0.22	-0.17	Diabetic kidney disease;	chr7:65950886	chr7:66880708~66882981:+
BRCA	cis	rs2243480	0.803	rs36004293	ENSG00000230295.1	RP11-458F8.2	-5.49	5.18e-08	6.68e-06	-0.22	-0.17	Diabetic kidney disease;	chr7:65951525	chr7:66880708~66882981:+
BRCA	cis	rs2243480	0.803	rs35268390	ENSG00000230295.1	RP11-458F8.2	-5.49	5.18e-08	6.68e-06	-0.22	-0.17	Diabetic kidney disease;	chr7:65951549	chr7:66880708~66882981:+
BRCA	cis	rs853679	0.607	rs13208096	ENSG00000204709.4	LINC01556	5.49	5.19e-08	6.69e-06	0.45	0.17	Depression;	chr6:28257533	chr6:28943877~28944537:+
BRCA	cis	rs1075265	0.527	rs10167891	ENSG00000235937.1	AC008280.1	5.49	5.19e-08	6.69e-06	0.18	0.17	Chronotype;Morning vs. evening chronotype;	chr2:54003658	chr2:54029552~54030682:-
BRCA	cis	rs11159086	0.793	rs10139122	ENSG00000270000.1	RP3-449M8.9	5.48	5.19e-08	6.69e-06	0.25	0.17	Advanced glycation end-product levels;	chr14:74492353	chr14:74471930~74472360:-
BRCA	cis	rs7129556	1	rs7129556	ENSG00000254691.1	RP11-91P24.5	-5.48	5.19e-08	6.69e-06	-0.23	-0.17	Weight loss (gastric bypass surgery);	chr11:77589003	chr11:77850604~77851511:+
BRCA	cis	rs17711722	0.565	rs4717276	ENSG00000237310.1	GS1-124K5.4	5.48	5.19e-08	6.69e-06	0.18	0.17	Calcium levels;	chr7:65829754	chr7:66493706~66495474:+
BRCA	cis	rs7208859	0.673	rs11657270	ENSG00000266490.1	CTD-2349P21.9	5.48	5.2e-08	6.7e-06	0.26	0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887369	chr17:30792372~30792833:+
BRCA	cis	rs7493	0.755	rs17166859	ENSG00000233942.1	AC004012.1	5.48	5.2e-08	6.7e-06	0.21	0.17	Yu-Zhi constitution type in type 2 diabetes;	chr7:95366207	chr7:95471835~95473998:+
BRCA	cis	rs516805	0.665	rs225077	ENSG00000279453.1	RP3-425C14.4	-5.48	5.21e-08	6.71e-06	-0.24	-0.17	Lymphocyte counts;	chr6:122269794	chr6:122436789~122439223:-
BRCA	cis	rs2638953	0.821	rs7964793	ENSG00000278733.1	RP11-425D17.1	5.48	5.21e-08	6.71e-06	0.21	0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28298776	chr12:28185625~28186190:-
BRCA	cis	rs12539814	1	rs12539814	ENSG00000204959.4	ARHGEF34P	5.48	5.21e-08	6.72e-06	0.27	0.17	Diastolic blood pressure;	chr7:144433417	chr7:144272445~144286966:-
BRCA	cis	rs10752881	1	rs4233192	ENSG00000224468.3	RP11-181K3.4	5.48	5.22e-08	6.72e-06	0.18	0.17	Colorectal cancer;	chr1:183001702	chr1:183138402~183141282:-
BRCA	cis	rs2153535	0.58	rs2143355	ENSG00000251164.1	HULC	-5.48	5.22e-08	6.72e-06	-0.2	-0.17	Motion sickness;	chr6:8517623	chr6:8652137~8653846:+
BRCA	cis	rs2239557	0.508	rs10483857	ENSG00000259065.1	RP5-1021I20.1	5.48	5.22e-08	6.72e-06	0.25	0.17	Common traits (Other);	chr14:73899508	chr14:73787360~73803270:+
BRCA	cis	rs17685	0.753	rs11972240	ENSG00000280388.1	RP11-229D13.3	-5.48	5.22e-08	6.73e-06	-0.17	-0.17	Coffee consumption (cups per day);Coffee consumption;	chr7:76064761	chr7:76043977~76045963:-
BRCA	cis	rs7824557	0.591	rs2736283	ENSG00000154316.13	TDH	5.48	5.22e-08	6.73e-06	0.22	0.17	Retinal vascular caliber;	chr8:11368401	chr8:11339637~11368452:+
BRCA	cis	rs7246760	0.867	rs8112764	ENSG00000277587.1	CTD-3116E22.8	-5.48	5.22e-08	6.73e-06	-0.33	-0.17	Pursuit maintenance gain;	chr19:9638231	chr19:9721903~9722410:+
BRCA	cis	rs9880211	0.635	rs6775778	ENSG00000239213.4	NCK1-AS1	-5.48	5.23e-08	6.74e-06	-0.22	-0.17	Height;Body mass index;	chr3:136007837	chr3:136841726~136862054:-
BRCA	cis	rs997295	0.535	rs11630854	ENSG00000270964.1	RP11-502I4.3	-5.48	5.23e-08	6.74e-06	-0.18	-0.17	Motion sickness;	chr15:67565778	chr15:67541072~67542604:-
BRCA	cis	rs234043	1	rs234055	ENSG00000223387.5	RP11-408H1.3	5.48	5.23e-08	6.74e-06	0.22	0.17	Renal cell carcinoma;	chr3:172593030	chr3:172560888~172595607:-
BRCA	cis	rs234043	1	rs234051	ENSG00000223387.5	RP11-408H1.3	-5.48	5.23e-08	6.74e-06	-0.22	-0.17	Renal cell carcinoma;	chr3:172593922	chr3:172560888~172595607:-
BRCA	cis	rs42648	0.564	rs11763820	ENSG00000225498.1	AC002064.5	5.48	5.23e-08	6.74e-06	0.16	0.17	Homocysteine levels;	chr7:90189631	chr7:90312496~90322592:+
BRCA	cis	rs9307551	0.901	rs6850999	ENSG00000250334.4	LINC00989	-5.48	5.23e-08	6.74e-06	-0.25	-0.17	Refractive error;	chr4:79580784	chr4:79492416~79576460:+
BRCA	cis	rs2243480	0.522	rs73150635	ENSG00000230295.1	RP11-458F8.2	-5.48	5.23e-08	6.74e-06	-0.28	-0.17	Diabetic kidney disease;	chr7:66507503	chr7:66880708~66882981:+
BRCA	cis	rs7618501	0.699	rs2777888	ENSG00000228008.1	CTD-2330K9.3	5.48	5.23e-08	6.74e-06	0.16	0.17	Intelligence (multi-trait analysis);	chr3:49860567	chr3:49903845~49916937:+
BRCA	cis	rs7577696	0.597	rs6756085	ENSG00000272716.1	RP11-563N4.1	-5.48	5.23e-08	6.74e-06	-0.2	-0.17	Inflammatory biomarkers;	chr2:32111453	chr2:32165046~32165757:-
BRCA	cis	rs10487112	0.56	rs2888796	ENSG00000225498.1	AC002064.5	5.48	5.24e-08	6.74e-06	0.17	0.17	Perceived unattractiveness to mosquitoes;	chr7:90359357	chr7:90312496~90322592:+
BRCA	cis	rs12554020	0.892	rs7025805	ENSG00000227603.1	RP11-165J3.6	-5.48	5.24e-08	6.75e-06	-0.22	-0.17	Schizophrenia;	chr9:93481463	chr9:93435332~93437121:-
BRCA	cis	rs4650994	0.525	rs4993304	ENSG00000273384.1	RP5-1098D14.1	5.48	5.24e-08	6.75e-06	0.22	0.17	HDL cholesterol;HDL cholesterol levels;	chr1:178566009	chr1:178651706~178652282:+
BRCA	cis	rs2098713	0.534	rs482695	ENSG00000250155.1	CTD-2353F22.1	5.48	5.24e-08	6.75e-06	0.19	0.17	Telomere length;	chr5:37551448	chr5:36666214~36725195:-
BRCA	cis	rs2098713	0.501	rs525463	ENSG00000250155.1	CTD-2353F22.1	5.48	5.24e-08	6.75e-06	0.19	0.17	Telomere length;	chr5:37556180	chr5:36666214~36725195:-
BRCA	cis	rs2898681	0.642	rs11538878	ENSG00000248375.1	RP11-177B4.1	-5.48	5.24e-08	6.75e-06	-0.23	-0.17	Optic nerve measurement (cup area);	chr4:52862357	chr4:52720081~52720831:-
BRCA	cis	rs7569084	0.687	rs963539	ENSG00000237979.1	AC007389.1	-5.48	5.24e-08	6.75e-06	-0.21	-0.17	Sum eosinophil basophil counts;	chr2:65421413	chr2:65500993~65502138:-
BRCA	cis	rs1707322	0.682	rs3014241	ENSG00000234329.1	RP11-767N6.2	-5.48	5.24e-08	6.75e-06	-0.18	-0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45622207	chr1:45651039~45651826:-
BRCA	cis	rs2505998	0.833	rs2565204	ENSG00000273008.1	RP11-351D16.3	-5.48	5.24e-08	6.75e-06	-0.2	-0.17	Hirschsprung disease;	chr10:43107725	chr10:43136824~43138334:-
BRCA	cis	rs2243480	0.711	rs2420172	ENSG00000228409.4	CCT6P1	-5.48	5.24e-08	6.75e-06	-0.23	-0.17	Diabetic kidney disease;	chr7:66170354	chr7:65751142~65763354:+
BRCA	cis	rs2303319	1	rs75552514	ENSG00000227403.1	AC009299.3	5.48	5.25e-08	6.76e-06	0.43	0.17	Cognitive function;	chr2:161259812	chr2:161244739~161249050:+
BRCA	cis	rs6674176	0.542	rs803679	ENSG00000237950.1	RP11-7O11.3	5.48	5.25e-08	6.77e-06	0.21	0.17	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43883733	chr1:43944370~43946551:-
BRCA	cis	rs7191700	0.644	rs12149160	ENSG00000262703.1	RP11-485G7.6	-5.48	5.26e-08	6.77e-06	-0.17	-0.17	Multiple sclerosis;	chr16:11345446	chr16:11348143~11349321:-
BRCA	cis	rs2554380	0.628	rs6602990	ENSG00000230373.7	GOLGA6L5P	-5.48	5.26e-08	6.77e-06	-0.2	-0.17	Height;	chr15:83783470	chr15:84507885~84516814:-
BRCA	cis	rs1552244	1	rs68067759	ENSG00000232901.1	CYCSP10	5.48	5.26e-08	6.78e-06	0.23	0.17	Alzheimer's disease;	chr3:10108851	chr3:10000647~10000940:-
BRCA	cis	rs4237845	0.788	rs1962047	ENSG00000257159.1	RP11-58A17.3	5.48	5.27e-08	6.78e-06	0.2	0.17	Intelligence (multi-trait analysis);	chr12:57898924	chr12:57967058~57968399:+
BRCA	cis	rs3733585	0.673	rs4314284	ENSG00000250413.1	RP11-448G15.1	5.48	5.27e-08	6.78e-06	0.22	0.17	Cleft plate (environmental tobacco smoke interaction);	chr4:9954472	chr4:10006482~10009725:+
BRCA	cis	rs4218	0.543	rs12050865	ENSG00000277144.1	RP11-59H7.4	-5.48	5.27e-08	6.79e-06	-0.21	-0.17	Social communication problems;	chr15:59020689	chr15:59115547~59116089:-
BRCA	cis	rs7621025	0.691	rs4678438	ENSG00000273486.1	RP11-731C17.2	5.48	5.28e-08	6.8e-06	0.19	0.17	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136626078	chr3:136837338~136839021:-
BRCA	cis	rs7923837	0.683	rs10882074	ENSG00000236493.2	EIF2S2P3	5.48	5.29e-08	6.8e-06	0.24	0.17	Multiple sclerosis;Body mass index;	chr10:92521928	chr10:92668745~92669743:-
BRCA	cis	rs6840360	1	rs7439465	ENSG00000270265.1	RP11-731D1.4	5.48	5.29e-08	6.81e-06	0.2	0.17	Intelligence (multi-trait analysis);	chr4:151673662	chr4:151333775~151353224:-
BRCA	cis	rs1861628	1	rs13020935	ENSG00000229352.1	AC007563.3	5.48	5.29e-08	6.81e-06	0.21	0.17	Serum thyroid-stimulating hormone levels;Hypothyroidism;	chr2:216760956	chr2:216799608~216805335:+
BRCA	cis	rs7299940	1	rs7299940	ENSG00000256250.1	RP11-989F5.1	-5.48	5.29e-08	6.81e-06	-0.19	-0.17	Panic disorder;	chr12:130906209	chr12:130810606~130812438:+
BRCA	cis	rs13126694	0.744	rs13121497	ENSG00000251429.1	RP11-597D13.7	5.48	5.3e-08	6.82e-06	0.16	0.17	Blood osmolality (transformed sodium);	chr4:158076724	chr4:158270378~158278676:+
BRCA	cis	rs9307551	0.584	rs4975053	ENSG00000250334.4	LINC00989	5.48	5.3e-08	6.82e-06	0.23	0.17	Refractive error;	chr4:79546733	chr4:79492416~79576460:+
BRCA	cis	rs67981189	0.501	rs2810104	ENSG00000258571.1	PTTG4P	-5.48	5.3e-08	6.82e-06	-0.19	-0.17	Schizophrenia;	chr14:70958096	chr14:71085482~71085833:-
BRCA	cis	rs7617773	0.817	rs4131362	ENSG00000199476.1	Y_RNA	-5.48	5.3e-08	6.82e-06	-0.24	-0.17	Coronary artery disease;	chr3:48287546	chr3:48288587~48288694:+
BRCA	cis	rs13126694	0.678	rs4691452	ENSG00000251429.1	RP11-597D13.7	5.48	5.3e-08	6.82e-06	0.16	0.17	Blood osmolality (transformed sodium);	chr4:158080652	chr4:158270378~158278676:+
BRCA	cis	rs1707322	0.691	rs11211175	ENSG00000234329.1	RP11-767N6.2	5.48	5.3e-08	6.83e-06	0.17	0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755212	chr1:45651039~45651826:-
BRCA	cis	rs4950322	0.542	rs28381210	ENSG00000244371.2	PFN1P8	-5.48	5.3e-08	6.83e-06	-0.23	-0.17	Protein quantitative trait loci;	chr1:147201925	chr1:146957117~146957659:-
BRCA	cis	rs910316	1	rs175425	ENSG00000279594.1	RP11-950C14.10	-5.48	5.31e-08	6.83e-06	-0.19	-0.17	Height;	chr14:75159428	chr14:75011269~75012851:-
BRCA	cis	rs910316	0.935	rs175422	ENSG00000279594.1	RP11-950C14.10	-5.48	5.31e-08	6.83e-06	-0.19	-0.17	Height;	chr14:75160616	chr14:75011269~75012851:-
BRCA	cis	rs2732480	0.577	rs1489109	ENSG00000226413.2	OR8T1P	5.48	5.31e-08	6.84e-06	0.23	0.17	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344997	chr12:48442030~48442947:-
BRCA	cis	rs2732480	0.577	rs1489108	ENSG00000226413.2	OR8T1P	5.48	5.31e-08	6.84e-06	0.23	0.17	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344998	chr12:48442030~48442947:-
BRCA	cis	rs11098499	1	rs13435802	ENSG00000249244.1	RP11-548H18.2	-5.48	5.32e-08	6.84e-06	-0.2	-0.17	Corneal astigmatism;	chr4:119256805	chr4:119391831~119395335:-
BRCA	cis	rs1223397	0.938	rs20500	ENSG00000215022.6	RP1-257A7.4	5.48	5.32e-08	6.84e-06	0.21	0.17	Blood pressure;	chr6:13294744	chr6:13264861~13295586:-
BRCA	cis	rs3785574	0.962	rs9944483	ENSG00000240280.5	TCAM1P	5.48	5.32e-08	6.84e-06	0.18	0.17	Height;	chr17:63706193	chr17:63849292~63864379:+
BRCA	cis	rs1440410	0.795	rs11100785	ENSG00000250326.1	RP11-284M14.1	-5.48	5.32e-08	6.85e-06	-0.18	-0.17	Ischemic stroke;	chr4:143274404	chr4:142933195~143184861:-
BRCA	cis	rs4588572	0.688	rs1594055	ENSG00000245556.2	SCAMP1-AS1	-5.48	5.32e-08	6.85e-06	-0.2	-0.17	Triglycerides;	chr5:78399264	chr5:78342365~78360507:-
BRCA	cis	rs863750	0.721	rs1716393	ENSG00000275389.1	RP11-214K3.24	5.48	5.32e-08	6.85e-06	0.21	0.17	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-hip ratio;	chr12:124075909	chr12:124085761~124088598:+
BRCA	cis	rs863750	0.687	rs1716394	ENSG00000275389.1	RP11-214K3.24	5.48	5.32e-08	6.85e-06	0.21	0.17	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-hip ratio;	chr12:124075910	chr12:124085761~124088598:+
BRCA	cis	rs2919009	0.607	rs2303951	ENSG00000271670.1	RP11-95I16.4	5.48	5.32e-08	6.85e-06	0.23	0.17	Obesity-related traits;	chr10:120954568	chr10:120879256~120880667:-
BRCA	cis	rs7208859	0.623	rs7503335	ENSG00000265443.1	CTD-2349P21.6	-5.48	5.32e-08	6.85e-06	-0.26	-0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30746944	chr17:30726305~30727564:-
BRCA	cis	rs7674212	0.57	rs2711898	ENSG00000248740.4	RP11-328K4.1	5.48	5.32e-08	6.85e-06	0.19	0.17	Type 2 diabetes;	chr4:103141914	chr4:103256159~103453658:+
BRCA	cis	rs7621025	0.63	rs1681818	ENSG00000273486.1	RP11-731C17.2	-5.48	5.33e-08	6.85e-06	-0.21	-0.17	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136754831	chr3:136837338~136839021:-
BRCA	cis	rs4835473	0.778	rs6853798	ENSG00000249741.2	RP11-673E1.3	5.48	5.33e-08	6.85e-06	0.18	0.17	Immature fraction of reticulocytes;	chr4:143801153	chr4:143911514~143912053:-
BRCA	cis	rs4835473	0.9	rs12502940	ENSG00000249741.2	RP11-673E1.3	5.48	5.33e-08	6.85e-06	0.18	0.17	Immature fraction of reticulocytes;	chr4:143812117	chr4:143911514~143912053:-
BRCA	cis	rs17597773	0.674	rs984676	ENSG00000272823.1	RP11-295M18.6	5.48	5.33e-08	6.86e-06	0.19	0.17	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220835080	chr1:220828676~220829211:-
BRCA	cis	rs3733585	0.638	rs13145554	ENSG00000250413.1	RP11-448G15.1	-5.48	5.33e-08	6.86e-06	-0.22	-0.17	Cleft plate (environmental tobacco smoke interaction);	chr4:9977965	chr4:10006482~10009725:+
BRCA	cis	rs77972916	0.561	rs13411629	ENSG00000234936.1	AC010883.5	5.48	5.33e-08	6.86e-06	0.22	0.17	Granulocyte percentage of myeloid white cells;	chr2:43339851	chr2:43229573~43233394:+
BRCA	cis	rs11671005	0.735	rs11671591	ENSG00000252334.1	RNU6-1337P	-5.48	5.33e-08	6.86e-06	-0.25	-0.17	Mean platelet volume;	chr19:58406970	chr19:58483749~58483843:-
BRCA	cis	rs9287719	0.967	rs10206225	ENSG00000243819.4	RN7SL832P	5.48	5.34e-08	6.87e-06	0.16	0.17	Prostate cancer;	chr2:10618531	chr2:10690344~10692099:+
BRCA	cis	rs4908768	0.52	rs6681362	ENSG00000270282.1	RP5-1115A15.2	5.48	5.34e-08	6.87e-06	0.18	0.17	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8598468	chr1:8512653~8513021:+
BRCA	cis	rs4908768	0.539	rs1318218	ENSG00000270282.1	RP5-1115A15.2	5.48	5.34e-08	6.87e-06	0.18	0.17	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8598653	chr1:8512653~8513021:+
BRCA	cis	rs6688613	0.84	rs10918607	ENSG00000225171.2	DUTP6	-5.48	5.34e-08	6.87e-06	-0.22	-0.17	Refractive astigmatism;	chr1:166988566	chr1:166868748~166869209:+
BRCA	cis	rs2239547	0.521	rs9682464	ENSG00000242142.1	SERBP1P3	5.48	5.34e-08	6.87e-06	0.21	0.17	Schizophrenia;	chr3:52854469	chr3:53064283~53065091:-
BRCA	cis	rs6496044	0.568	rs2880764	ENSG00000259295.5	CSPG4P12	5.48	5.34e-08	6.87e-06	0.2	0.17	Interstitial lung disease;	chr15:85513177	chr15:85191438~85213905:+
BRCA	cis	rs2832191	0.935	rs11910316	ENSG00000215533.7	LINC00189	5.48	5.35e-08	6.88e-06	0.19	0.17	Dental caries;	chr21:29147408	chr21:29193480~29288205:+
BRCA	cis	rs7618501	0.699	rs2681781	ENSG00000228008.1	CTD-2330K9.3	5.48	5.35e-08	6.88e-06	0.16	0.17	Intelligence (multi-trait analysis);	chr3:49860840	chr3:49903845~49916937:+
BRCA	cis	rs1440410	0.795	rs3967098	ENSG00000250326.1	RP11-284M14.1	-5.48	5.35e-08	6.88e-06	-0.18	-0.17	Ischemic stroke;	chr4:143274628	chr4:142933195~143184861:-
BRCA	cis	rs9393777	0.668	rs72839449	ENSG00000216901.1	AL022393.7	5.48	5.35e-08	6.88e-06	0.26	0.17	Intelligence (multi-trait analysis);	chr6:27293882	chr6:28176188~28176674:+
BRCA	cis	rs2243480	1	rs160643	ENSG00000229886.1	RP5-1132H15.3	5.48	5.35e-08	6.88e-06	0.28	0.17	Diabetic kidney disease;	chr7:66093235	chr7:66025126~66031544:-
BRCA	cis	rs80285556	0.579	rs11883067	ENSG00000204666.3	FLJ26850	5.48	5.35e-08	6.88e-06	0.26	0.17	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50037214	chr19:50050589~50066793:+
BRCA	cis	rs17711722	0.727	rs35850374	ENSG00000273024.4	INTS4P2	-5.48	5.35e-08	6.88e-06	-0.18	-0.17	Calcium levels;	chr7:65892789	chr7:65647864~65715661:+
BRCA	cis	rs9640161	0.83	rs3757425	ENSG00000261305.1	RP4-584D14.7	5.48	5.36e-08	6.89e-06	0.23	0.17	Blood protein levels;Circulating chemerin levels;	chr7:150370551	chr7:150341771~150342607:+
BRCA	cis	rs9640161	0.83	rs3757424	ENSG00000261305.1	RP4-584D14.7	5.48	5.36e-08	6.89e-06	0.23	0.17	Blood protein levels;Circulating chemerin levels;	chr7:150370590	chr7:150341771~150342607:+
BRCA	cis	rs10510102	0.872	rs10887032	ENSG00000226864.1	ATE1-AS1	-5.48	5.36e-08	6.89e-06	-0.3	-0.17	Breast cancer;	chr10:121955887	chr10:121928312~121951965:+
BRCA	cis	rs6832769	1	rs9312662	ENSG00000223305.1	RN7SKP30	-5.48	5.36e-08	6.89e-06	-0.21	-0.17	Personality dimensions;	chr4:55520204	chr4:55540502~55540835:-
BRCA	cis	rs7618501	0.633	rs2353579	ENSG00000228008.1	CTD-2330K9.3	5.48	5.36e-08	6.89e-06	0.16	0.17	Intelligence (multi-trait analysis);	chr3:49990341	chr3:49903845~49916937:+
BRCA	cis	rs4835473	0.932	rs6813011	ENSG00000249741.2	RP11-673E1.3	-5.48	5.36e-08	6.89e-06	-0.18	-0.17	Immature fraction of reticulocytes;	chr4:143914496	chr4:143911514~143912053:-
BRCA	cis	rs7200543	1	rs1136001	ENSG00000275910.1	RP11-680G24.6	-5.48	5.37e-08	6.9e-06	-0.2	-0.17	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15038117	chr16:15015828~15016390:-
BRCA	cis	rs12468226	0.938	rs10166594	ENSG00000226261.1	AC064836.3	5.48	5.37e-08	6.9e-06	0.25	0.17	Urate levels;	chr2:202250262	chr2:202336024~202336727:-
BRCA	cis	rs2732480	0.5	rs2450989	ENSG00000240399.1	RP1-228P16.1	-5.48	5.37e-08	6.9e-06	-0.19	-0.17	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48259625	chr12:48054813~48055591:-
BRCA	cis	rs7569084	0.663	rs10190233	ENSG00000237979.1	AC007389.1	-5.48	5.37e-08	6.9e-06	-0.21	-0.17	Sum eosinophil basophil counts;	chr2:65413095	chr2:65500993~65502138:-
BRCA	cis	rs16846053	0.71	rs11891026	ENSG00000227403.1	AC009299.3	5.48	5.37e-08	6.91e-06	0.28	0.17	Blood osmolality (transformed sodium);	chr2:161735366	chr2:161244739~161249050:+
BRCA	cis	rs78487399	0.908	rs17031116	ENSG00000234936.1	AC010883.5	5.48	5.37e-08	6.91e-06	0.22	0.17	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43605874	chr2:43229573~43233394:+
BRCA	cis	rs793571	0.554	rs28470809	ENSG00000259250.1	RP11-50C13.1	-5.48	5.37e-08	6.91e-06	-0.3	-0.17	Schizophrenia;	chr15:58744059	chr15:58587507~58591676:+
BRCA	cis	rs13126694	0.744	rs6843728	ENSG00000248429.4	RP11-597D13.9	-5.48	5.38e-08	6.91e-06	-0.15	-0.17	Blood osmolality (transformed sodium);	chr4:158093947	chr4:158170752~158202877:+
BRCA	cis	rs4604234	0.803	rs76568328	ENSG00000272129.1	RP11-250B2.6	-5.48	5.38e-08	6.92e-06	-0.4	-0.17	Cancer;	chr6:80267384	chr6:80355424~80356859:+
BRCA	cis	rs7267979	0.668	rs4815398	ENSG00000204556.4	CTD-2514C3.1	5.48	5.38e-08	6.92e-06	0.24	0.17	Liver enzyme levels (alkaline phosphatase);	chr20:25256702	chr20:26018832~26020684:+
BRCA	cis	rs7824557	0.591	rs2736282	ENSG00000154316.13	TDH	-5.48	5.39e-08	6.92e-06	-0.21	-0.17	Retinal vascular caliber;	chr8:11367971	chr8:11339637~11368452:+
BRCA	cis	rs12612619	0.732	rs10432697	ENSG00000229122.1	AGBL5-IT1	5.48	5.39e-08	6.93e-06	0.18	0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27049184	chr2:27061038~27061815:+
BRCA	cis	rs603446	0.967	rs180340	ENSG00000254851.1	RP11-109L13.1	-5.48	5.39e-08	6.93e-06	-0.2	-0.17	Triglycerides;	chr11:116745686	chr11:117135528~117138582:+
BRCA	cis	rs6479891	1	rs11817689	ENSG00000232075.1	MRPL35P2	-5.48	5.39e-08	6.93e-06	-0.3	-0.17	Arthritis (juvenile idiopathic);	chr10:63164457	chr10:63634317~63634827:-
BRCA	cis	rs3213958	0.574	rs7614892	ENSG00000249274.1	PDLIM1P4	-5.48	5.39e-08	6.93e-06	-0.25	-0.17	Blood protein levels;	chr3:98859053	chr3:98782188~98783193:+
BRCA	cis	rs3213958	0.574	rs73138048	ENSG00000249274.1	PDLIM1P4	-5.48	5.39e-08	6.93e-06	-0.25	-0.17	Blood protein levels;	chr3:98871788	chr3:98782188~98783193:+
BRCA	cis	rs3213958	0.621	rs73138055	ENSG00000249274.1	PDLIM1P4	-5.48	5.39e-08	6.93e-06	-0.25	-0.17	Blood protein levels;	chr3:98877161	chr3:98782188~98783193:+
BRCA	cis	rs3213958	0.621	rs73138058	ENSG00000249274.1	PDLIM1P4	-5.48	5.39e-08	6.93e-06	-0.25	-0.17	Blood protein levels;	chr3:98880597	chr3:98782188~98783193:+
BRCA	cis	rs3213958	0.574	rs73138063	ENSG00000249274.1	PDLIM1P4	-5.48	5.39e-08	6.93e-06	-0.25	-0.17	Blood protein levels;	chr3:98885058	chr3:98782188~98783193:+
BRCA	cis	rs3213958	0.574	rs16840260	ENSG00000249274.1	PDLIM1P4	-5.48	5.39e-08	6.93e-06	-0.25	-0.17	Blood protein levels;	chr3:98885752	chr3:98782188~98783193:+
BRCA	cis	rs2179367	0.632	rs10872636	ENSG00000223701.3	RAET1E-AS1	5.48	5.4e-08	6.93e-06	0.24	0.17	Dupuytren's disease;	chr6:149353678	chr6:149884431~149919508:+
BRCA	cis	rs867371	0.929	rs7173852	ENSG00000278603.1	RP13-608F4.5	5.48	5.4e-08	6.94e-06	0.22	0.17	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82169512	chr15:82472203~82472426:+
BRCA	cis	rs10761482	0.5	rs7098650	ENSG00000254271.1	RP11-131N11.4	5.48	5.4e-08	6.94e-06	0.23	0.17	Schizophrenia;	chr10:60517921	chr10:60734342~60741828:+
BRCA	cis	rs875971	0.522	rs34973832	ENSG00000273024.4	INTS4P2	-5.48	5.4e-08	6.94e-06	-0.18	-0.17	Aortic root size;	chr7:65931217	chr7:65647864~65715661:+
BRCA	cis	rs6840360	0.642	rs2724577	ENSG00000278978.1	RP11-164P12.5	-5.48	5.4e-08	6.94e-06	-0.2	-0.17	Intelligence (multi-trait analysis);	chr4:151433753	chr4:151669786~151670503:+
BRCA	cis	rs4723738	0.693	rs6462818	ENSG00000227191.5	TRGC2	-5.48	5.4e-08	6.94e-06	-0.15	-0.17	Treatment response for severe sepsis;	chr7:38211435	chr7:38239580~38368091:-
BRCA	cis	rs1707322	0.686	rs2230659	ENSG00000234329.1	RP11-767N6.2	-5.48	5.41e-08	6.95e-06	-0.18	-0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613212	chr1:45651039~45651826:-
BRCA	cis	rs2179367	0.552	rs11155652	ENSG00000223701.3	RAET1E-AS1	5.48	5.41e-08	6.95e-06	0.24	0.17	Dupuytren's disease;	chr6:149417849	chr6:149884431~149919508:+
BRCA	cis	rs2179367	0.632	rs12209364	ENSG00000223701.3	RAET1E-AS1	5.48	5.41e-08	6.95e-06	0.24	0.17	Dupuytren's disease;	chr6:149418062	chr6:149884431~149919508:+
BRCA	cis	rs7630852	0.965	rs4256169	ENSG00000272359.1	U4	-5.48	5.41e-08	6.95e-06	-0.2	-0.17	Eosinophil counts;	chr3:196785852	chr3:196747192~196747324:-
BRCA	cis	rs10392	0.543	rs4812332	ENSG00000274825.1	RP4-616B8.5	-5.48	5.41e-08	6.95e-06	-0.17	-0.17	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;	chr20:38906022	chr20:38955910~38956547:+
BRCA	cis	rs2554380	0.628	rs919069	ENSG00000230373.7	GOLGA6L5P	-5.48	5.42e-08	6.96e-06	-0.2	-0.17	Height;	chr15:83775776	chr15:84507885~84516814:-
BRCA	cis	rs11009175	0.556	rs1418540	ENSG00000273038.2	RP11-479G22.8	-5.48	5.42e-08	6.96e-06	-0.22	-0.17	Depression (quantitative trait);	chr10:33008739	chr10:32887255~32889311:-
BRCA	cis	rs3892630	0.824	rs12327732	ENSG00000267567.1	CTD-2538C1.3	5.48	5.42e-08	6.96e-06	0.27	0.17	Red blood cell traits;	chr19:32730861	chr19:32718298~32719595:-
BRCA	cis	rs2562456	0.833	rs2650776	ENSG00000268535.1	RP11-420K14.3	5.48	5.42e-08	6.96e-06	0.25	0.17	Pain;	chr19:21430595	chr19:21709522~21710191:+
BRCA	cis	rs6840360	0.582	rs6535796	ENSG00000278978.1	RP11-164P12.5	-5.48	5.42e-08	6.97e-06	-0.19	-0.17	Intelligence (multi-trait analysis);	chr4:151383576	chr4:151669786~151670503:+
BRCA	cis	rs4835473	0.897	rs6832749	ENSG00000249741.2	RP11-673E1.3	-5.48	5.42e-08	6.97e-06	-0.18	-0.17	Immature fraction of reticulocytes;	chr4:143709473	chr4:143911514~143912053:-
BRCA	cis	rs4835473	0.897	rs6831477	ENSG00000249741.2	RP11-673E1.3	-5.48	5.42e-08	6.97e-06	-0.18	-0.17	Immature fraction of reticulocytes;	chr4:143709487	chr4:143911514~143912053:-
BRCA	cis	rs1979679	0.842	rs4931729	ENSG00000278733.1	RP11-425D17.1	5.48	5.42e-08	6.97e-06	0.21	0.17	Ossification of the posterior longitudinal ligament of the spine;	chr12:28146306	chr12:28185625~28186190:-
BRCA	cis	rs7267979	0.714	rs1555329	ENSG00000277938.1	RP5-965G21.3	5.48	5.43e-08	6.97e-06	0.2	0.17	Liver enzyme levels (alkaline phosphatase);	chr20:25251222	chr20:25229150~25231933:+
BRCA	cis	rs710913	0.717	rs1180349	ENSG00000228060.1	RP11-69E11.8	5.48	5.43e-08	6.97e-06	0.16	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39540380	chr1:39565160~39573203:+
BRCA	cis	rs357618	1	rs165351	ENSG00000260581.1	CTB-113P19.4	5.48	5.43e-08	6.98e-06	0.19	0.17	Basophil percentage of white cells;	chr5:151475320	chr5:151652275~151655449:+
BRCA	cis	rs858239	0.536	rs6961109	ENSG00000230042.1	AK3P3	-5.48	5.43e-08	6.98e-06	-0.19	-0.17	Cerebrospinal fluid biomarker levels;	chr7:23212794	chr7:23129178~23129841:+
BRCA	cis	rs4927850	1	rs7627706	ENSG00000207650.1	MIR570	5.48	5.43e-08	6.98e-06	0.2	0.17	Pancreatic cancer;	chr3:196026482	chr3:195699401~195699497:+
BRCA	cis	rs4927850	0.881	rs7630489	ENSG00000207650.1	MIR570	5.48	5.43e-08	6.98e-06	0.2	0.17	Pancreatic cancer;	chr3:196026530	chr3:195699401~195699497:+
BRCA	cis	rs4927850	1	rs7627868	ENSG00000207650.1	MIR570	5.48	5.43e-08	6.98e-06	0.2	0.17	Pancreatic cancer;	chr3:196026602	chr3:195699401~195699497:+
BRCA	cis	rs12612619	0.667	rs11126871	ENSG00000229122.1	AGBL5-IT1	-5.48	5.43e-08	6.98e-06	-0.18	-0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27121589	chr2:27061038~27061815:+
BRCA	cis	rs10129255	0.5	rs59939897	ENSG00000224373.3	IGHV4-59	5.48	5.43e-08	6.98e-06	0.1	0.17	Kawasaki disease;	chr14:106783414	chr14:106627249~106627825:-
BRCA	cis	rs4489787	1	rs10875804	ENSG00000240399.1	RP1-228P16.1	-5.48	5.43e-08	6.98e-06	-0.3	-0.17	Prostate cancer (SNP x SNP interaction);	chr12:48391191	chr12:48054813~48055591:-
BRCA	cis	rs9847710	0.967	rs2581824	ENSG00000242142.1	SERBP1P3	-5.48	5.44e-08	6.98e-06	-0.19	-0.17	Ulcerative colitis;	chr3:52988392	chr3:53064283~53065091:-
BRCA	cis	rs6832769	0.826	rs10462035	ENSG00000223305.1	RN7SKP30	5.48	5.44e-08	6.99e-06	0.21	0.17	Personality dimensions;	chr4:55513011	chr4:55540502~55540835:-
BRCA	cis	rs987360	0.931	rs13117675	ENSG00000248869.4	RP11-138I17.1	5.48	5.45e-08	6.99e-06	0.17	0.17	Temperament;	chr4:137301583	chr4:136796722~137212799:-
BRCA	cis	rs987360	0.931	rs13144732	ENSG00000248869.4	RP11-138I17.1	5.48	5.45e-08	6.99e-06	0.17	0.17	Temperament;	chr4:137301585	chr4:136796722~137212799:-
BRCA	cis	rs7474896	0.515	rs624359	ENSG00000120555.12	SEPT7P9	-5.48	5.45e-08	6.99e-06	-0.23	-0.17	Obesity (extreme);	chr10:38010204	chr10:38383069~38402916:-
BRCA	cis	rs7474896	0.537	rs598857	ENSG00000120555.12	SEPT7P9	-5.48	5.45e-08	6.99e-06	-0.23	-0.17	Obesity (extreme);	chr10:38013998	chr10:38383069~38402916:-
BRCA	cis	rs7474896	0.515	rs2738208	ENSG00000120555.12	SEPT7P9	-5.48	5.45e-08	6.99e-06	-0.23	-0.17	Obesity (extreme);	chr10:38017200	chr10:38383069~38402916:-
BRCA	cis	rs2898681	0.581	rs730246	ENSG00000248375.1	RP11-177B4.1	-5.48	5.45e-08	6.99e-06	-0.23	-0.17	Optic nerve measurement (cup area);	chr4:52814552	chr4:52720081~52720831:-
BRCA	cis	rs253959	0.576	rs1588268	ENSG00000272265.1	CTD-2287O16.4	5.48	5.45e-08	7e-06	0.21	0.17	Bipolar disorder and schizophrenia;	chr5:116101091	chr5:116078110~116078570:-
BRCA	cis	rs12144309	0.608	rs1217408	ENSG00000232450.1	RP4-730K3.3	5.48	5.45e-08	7e-06	0.22	0.17	Coronary artery disease;	chr1:113853658	chr1:113698884~113699631:-
BRCA	cis	rs2348418	0.647	rs10843210	ENSG00000247934.4	RP11-967K21.1	5.48	5.46e-08	7.01e-06	0.19	0.17	Lung function (FEV1);Lung function (FVC);	chr12:28575800	chr12:28163298~28190738:-
BRCA	cis	rs10129255	0.957	rs17113284	ENSG00000224373.3	IGHV4-59	-5.48	5.46e-08	7.01e-06	-0.11	-0.17	Kawasaki disease;	chr14:106684476	chr14:106627249~106627825:-
BRCA	cis	rs2281636	0.66	rs61871318	ENSG00000233690.1	EBAG9P1	5.48	5.46e-08	7.01e-06	0.2	0.17	Obesity-related traits;	chr10:99606784	chr10:99697407~99697949:-
BRCA	cis	rs2898681	0.739	rs8287	ENSG00000248375.1	RP11-177B4.1	-5.48	5.46e-08	7.01e-06	-0.23	-0.17	Optic nerve measurement (cup area);	chr4:52866419	chr4:52720081~52720831:-
BRCA	cis	rs2098713	0.537	rs668889	ENSG00000250155.1	CTD-2353F22.1	5.48	5.46e-08	7.01e-06	0.19	0.17	Telomere length;	chr5:37540023	chr5:36666214~36725195:-
BRCA	cis	rs6490294	0.571	rs58368428	ENSG00000226469.1	ADAM1B	5.48	5.46e-08	7.01e-06	0.26	0.17	Mean platelet volume;	chr12:112024471	chr12:111927018~111929017:+
BRCA	cis	rs7267979	0.714	rs3787082	ENSG00000277938.1	RP5-965G21.3	5.48	5.46e-08	7.02e-06	0.2	0.17	Liver enzyme levels (alkaline phosphatase);	chr20:25255100	chr20:25229150~25231933:+
BRCA	cis	rs12612619	0.704	rs3769139	ENSG00000229122.1	AGBL5-IT1	5.48	5.47e-08	7.02e-06	0.18	0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27092846	chr2:27061038~27061815:+
BRCA	cis	rs1707322	0.686	rs1250	ENSG00000234329.1	RP11-767N6.2	5.48	5.47e-08	7.02e-06	0.18	0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45628355	chr1:45651039~45651826:-
BRCA	cis	rs736408	0.608	rs35004449	ENSG00000242142.1	SERBP1P3	5.48	5.47e-08	7.03e-06	0.2	0.17	Bipolar disorder;	chr3:52818881	chr3:53064283~53065091:-
BRCA	cis	rs9450351	0.744	rs75096179	ENSG00000203875.9	SNHG5	-5.48	5.48e-08	7.03e-06	-0.44	-0.17	Interferon gamma-induced protein 10 levels;	chr6:85580606	chr6:85660950~85678736:-
BRCA	cis	rs2243480	0.706	rs34466769	ENSG00000228409.4	CCT6P1	5.48	5.48e-08	7.03e-06	0.2	0.17	Diabetic kidney disease;	chr7:65988305	chr7:65751142~65763354:+
BRCA	cis	rs7208859	0.573	rs11654035	ENSG00000280069.1	CTD-2349P21.3	-5.48	5.48e-08	7.03e-06	-0.24	-0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809408	chr17:30738182~30740275:+
BRCA	cis	rs17711722	0.522	rs62469933	ENSG00000222364.1	RNU6-96P	-5.48	5.48e-08	7.03e-06	-0.2	-0.17	Calcium levels;	chr7:65800652	chr7:66395191~66395286:+
BRCA	cis	rs1552244	0.832	rs3732968	ENSG00000232901.1	CYCSP10	5.48	5.48e-08	7.04e-06	0.23	0.17	Alzheimer's disease;	chr3:9971589	chr3:10000647~10000940:-
BRCA	cis	rs2243480	0.908	rs1532573	ENSG00000228409.4	CCT6P1	-5.47	5.48e-08	7.04e-06	-0.24	-0.17	Diabetic kidney disease;	chr7:66333815	chr7:65751142~65763354:+
BRCA	cis	rs1552244	1	rs68045038	ENSG00000232901.1	CYCSP10	5.47	5.49e-08	7.04e-06	0.23	0.17	Alzheimer's disease;	chr3:10110144	chr3:10000647~10000940:-
BRCA	cis	rs62025270	0.632	rs16943251	ENSG00000202081.1	RNU6-1280P	-5.47	5.49e-08	7.05e-06	-0.24	-0.17	Idiopathic pulmonary fibrosis;	chr15:85692004	chr15:85651522~85651628:-
BRCA	cis	rs10739663	0.52	rs3122937	ENSG00000232630.1	PRPS1P2	-5.47	5.49e-08	7.05e-06	-0.17	-0.17	Resting heart rate;	chr9:125392529	chr9:125150653~125151589:+
BRCA	cis	rs17301013	0.9	rs1754351	ENSG00000227373.4	RP11-160H22.5	-5.47	5.49e-08	7.05e-06	-0.22	-0.17	Systemic lupus erythematosus;	chr1:174762458	chr1:174115300~174160004:-
BRCA	cis	rs3733585	0.699	rs12498956	ENSG00000250413.1	RP11-448G15.1	5.47	5.49e-08	7.05e-06	0.22	0.17	Cleft plate (environmental tobacco smoke interaction);	chr4:9949081	chr4:10006482~10009725:+
BRCA	cis	rs11098499	0.754	rs1980027	ENSG00000249244.1	RP11-548H18.2	5.47	5.49e-08	7.05e-06	0.19	0.17	Corneal astigmatism;	chr4:119330422	chr4:119391831~119395335:-
BRCA	cis	rs4853525	0.59	rs12619138	ENSG00000235852.1	AC005540.3	5.47	5.5e-08	7.05e-06	0.21	0.17	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190865474	chr2:190880797~190882059:-
BRCA	cis	rs523522	0.962	rs11065154	ENSG00000278344.1	RP11-18C24.8	5.47	5.5e-08	7.05e-06	0.23	0.17	High light scatter reticulocyte count;	chr12:120533614	chr12:120500735~120501090:-
BRCA	cis	rs523522	0.926	rs10774555	ENSG00000278344.1	RP11-18C24.8	5.47	5.5e-08	7.05e-06	0.23	0.17	High light scatter reticulocyte count;	chr12:120534175	chr12:120500735~120501090:-
BRCA	cis	rs6832769	1	rs9998146	ENSG00000223305.1	RN7SKP30	-5.47	5.5e-08	7.05e-06	-0.21	-0.17	Personality dimensions;	chr4:55531810	chr4:55540502~55540835:-
BRCA	cis	rs10129255	0.518	rs10150460	ENSG00000224373.3	IGHV4-59	-5.47	5.5e-08	7.06e-06	-0.1	-0.17	Kawasaki disease;	chr14:106677179	chr14:106627249~106627825:-
BRCA	cis	rs858239	0.536	rs6956974	ENSG00000230042.1	AK3P3	5.47	5.5e-08	7.06e-06	0.19	0.17	Cerebrospinal fluid biomarker levels;	chr7:23212699	chr7:23129178~23129841:+
BRCA	cis	rs4218	0.513	rs17302142	ENSG00000277144.1	RP11-59H7.4	-5.47	5.5e-08	7.06e-06	-0.21	-0.17	Social communication problems;	chr15:59053813	chr15:59115547~59116089:-
BRCA	cis	rs9467773	1	rs11756120	ENSG00000124549.13	BTN2A3P	5.47	5.5e-08	7.06e-06	0.17	0.17	Intelligence (multi-trait analysis);	chr6:26529580	chr6:26421391~26432383:+
BRCA	cis	rs9467773	1	rs9393732	ENSG00000124549.13	BTN2A3P	5.47	5.5e-08	7.06e-06	0.17	0.17	Intelligence (multi-trait analysis);	chr6:26530670	chr6:26421391~26432383:+
BRCA	cis	rs9467773	0.967	rs9358954	ENSG00000124549.13	BTN2A3P	5.47	5.5e-08	7.06e-06	0.17	0.17	Intelligence (multi-trait analysis);	chr6:26530950	chr6:26421391~26432383:+
BRCA	cis	rs9467773	1	rs10946834	ENSG00000124549.13	BTN2A3P	5.47	5.5e-08	7.06e-06	0.17	0.17	Intelligence (multi-trait analysis);	chr6:26533436	chr6:26421391~26432383:+
BRCA	cis	rs9467773	1	rs10946835	ENSG00000124549.13	BTN2A3P	5.47	5.5e-08	7.06e-06	0.17	0.17	Intelligence (multi-trait analysis);	chr6:26533529	chr6:26421391~26432383:+
BRCA	cis	rs9467773	1	rs9467778	ENSG00000124549.13	BTN2A3P	5.47	5.5e-08	7.06e-06	0.17	0.17	Intelligence (multi-trait analysis);	chr6:26534515	chr6:26421391~26432383:+
BRCA	cis	rs4588572	0.57	rs6453389	ENSG00000245556.2	SCAMP1-AS1	-5.47	5.5e-08	7.06e-06	-0.2	-0.17	Triglycerides;	chr5:78431179	chr5:78342365~78360507:-
BRCA	cis	rs9467773	1	rs9393731	ENSG00000124549.13	BTN2A3P	5.47	5.5e-08	7.06e-06	0.17	0.17	Intelligence (multi-trait analysis);	chr6:26529146	chr6:26421391~26432383:+
BRCA	cis	rs6088813	1	rs6142369	ENSG00000126005.14	MMP24-AS1	5.47	5.51e-08	7.07e-06	0.2	0.17	Height;	chr20:35385512	chr20:35216462~35278131:-
BRCA	cis	rs9467773	1	rs2393670	ENSG00000124549.13	BTN2A3P	5.47	5.51e-08	7.07e-06	0.17	0.17	Intelligence (multi-trait analysis);	chr6:26535313	chr6:26421391~26432383:+
BRCA	cis	rs2303319	1	rs62197070	ENSG00000227403.1	AC009299.3	5.47	5.51e-08	7.07e-06	0.43	0.17	Cognitive function;	chr2:161292656	chr2:161244739~161249050:+
BRCA	cis	rs11742741	0.579	rs4701422	ENSG00000248874.4	C5orf17	-5.47	5.51e-08	7.07e-06	-0.22	-0.17	Educational attainment;	chr5:24108058	chr5:23951348~24178263:+
BRCA	cis	rs2638953	1	rs11049532	ENSG00000278733.1	RP11-425D17.1	-5.47	5.51e-08	7.07e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28323979	chr12:28185625~28186190:-
BRCA	cis	rs4604234	0.614	rs11961937	ENSG00000272129.1	RP11-250B2.6	-5.47	5.51e-08	7.08e-06	-0.43	-0.17	Cancer;	chr6:80119518	chr6:80355424~80356859:+
BRCA	cis	rs4604234	0.614	rs73479907	ENSG00000272129.1	RP11-250B2.6	-5.47	5.51e-08	7.08e-06	-0.43	-0.17	Cancer;	chr6:80124706	chr6:80355424~80356859:+
BRCA	cis	rs4604234	0.614	rs73479909	ENSG00000272129.1	RP11-250B2.6	-5.47	5.51e-08	7.08e-06	-0.43	-0.17	Cancer;	chr6:80125477	chr6:80355424~80356859:+
BRCA	cis	rs1476670	0.71	rs753637	ENSG00000230615.5	RP5-1198O20.4	-5.47	5.52e-08	7.08e-06	-0.25	-0.17	Eotaxin levels;	chr1:44043255	chr1:44030443~44115913:+
BRCA	cis	rs8040855	0.794	rs4843024	ENSG00000259774.1	RP11-182J1.13	-5.47	5.53e-08	7.09e-06	-0.22	-0.17	Bulimia nervosa;	chr15:85162669	chr15:84422618~84425882:+
BRCA	cis	rs2638953	0.925	rs61920563	ENSG00000247934.4	RP11-967K21.1	-5.47	5.53e-08	7.1e-06	-0.25	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28332760	chr12:28163298~28190738:-
BRCA	cis	rs7572733	0.592	rs113964240	ENSG00000231621.1	AC013264.2	-5.47	5.53e-08	7.1e-06	-0.16	-0.17	Dermatomyositis;	chr2:197591586	chr2:197197991~197199273:+
BRCA	cis	rs17508449	0.819	rs78874053	ENSG00000232450.1	RP4-730K3.3	-5.47	5.54e-08	7.1e-06	-0.31	-0.17	Leprosy;	chr1:113700251	chr1:113698884~113699631:-
BRCA	cis	rs2638953	0.815	rs11049677	ENSG00000278733.1	RP11-425D17.1	5.47	5.54e-08	7.11e-06	0.22	0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28505106	chr12:28185625~28186190:-
BRCA	cis	rs1707322	1	rs10890370	ENSG00000281133.1	AL355480.3	-5.47	5.54e-08	7.11e-06	-0.21	-0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45923545	chr1:45580892~45580996:-
BRCA	cis	rs597539	0.652	rs660614	ENSG00000261625.1	RP11-554A11.4	-5.47	5.54e-08	7.11e-06	-0.16	-0.17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68892020	chr11:69000765~69002048:-
BRCA	cis	rs10208649	1	rs6751340	ENSG00000233266.1	HMGB1P31	5.47	5.54e-08	7.11e-06	0.36	0.17	Body mass index;	chr2:53960480	chr2:54051334~54051760:+
BRCA	cis	rs2688608	0.839	rs2675662	ENSG00000271816.1	BMS1P4	-5.47	5.55e-08	7.11e-06	-0.17	-0.17	Inflammatory bowel disease;	chr10:73839369	chr10:73699151~73730487:-
BRCA	cis	rs12646107	1	rs12646107	ENSG00000261672.1	RP11-475B2.1	-5.47	5.55e-08	7.12e-06	-0.26	-0.17	Response to amphetamines;	chr4:173594531	chr4:173593672~173594556:+
BRCA	cis	rs1861628	1	rs13015993	ENSG00000229352.1	AC007563.3	-5.47	5.55e-08	7.12e-06	-0.21	-0.17	Serum thyroid-stimulating hormone levels;Hypothyroidism;	chr2:216760800	chr2:216799608~216805335:+
BRCA	cis	rs2898681	0.581	rs936690	ENSG00000248375.1	RP11-177B4.1	-5.47	5.55e-08	7.12e-06	-0.23	-0.17	Optic nerve measurement (cup area);	chr4:52824868	chr4:52720081~52720831:-
BRCA	cis	rs9309473	0.718	rs10175529	ENSG00000163016.8	ALMS1P	5.47	5.56e-08	7.13e-06	0.2	0.17	Metabolite levels;	chr2:73378965	chr2:73644919~73685576:+
BRCA	cis	rs7620503	1	rs1463858	ENSG00000228221.4	LINC00578	5.47	5.56e-08	7.13e-06	0.19	0.17	Corneal structure;	chr3:177580339	chr3:177441921~177752305:+
BRCA	cis	rs2179367	0.632	rs9322179	ENSG00000223701.3	RAET1E-AS1	5.47	5.56e-08	7.13e-06	0.24	0.17	Dupuytren's disease;	chr6:149418664	chr6:149884431~149919508:+
BRCA	cis	rs13126694	0.744	rs11942932	ENSG00000251429.1	RP11-597D13.7	5.47	5.56e-08	7.13e-06	0.16	0.17	Blood osmolality (transformed sodium);	chr4:158081929	chr4:158270378~158278676:+
BRCA	cis	rs10946940	0.965	rs4713112	ENSG00000216901.1	AL022393.7	-5.47	5.56e-08	7.13e-06	-0.21	-0.17	Systemic lupus erythematosus;	chr6:27549054	chr6:28176188~28176674:+
BRCA	cis	rs987710	0.568	rs5750570	ENSG00000211639.2	IGLV4-60	5.47	5.57e-08	7.14e-06	0.23	0.17	Iron status biomarkers;Iron deficiency;	chr22:22130908	chr22:22162199~22162681:+
BRCA	cis	rs4650994	0.525	rs4316329	ENSG00000273384.1	RP5-1098D14.1	5.47	5.57e-08	7.14e-06	0.21	0.17	HDL cholesterol;HDL cholesterol levels;	chr1:178540198	chr1:178651706~178652282:+
BRCA	cis	rs10129255	0.828	rs10140989	ENSG00000280411.1	IGHV1-69-2	-5.47	5.57e-08	7.14e-06	-0.13	-0.17	Kawasaki disease;	chr14:106668657	chr14:106762092~106762588:-
BRCA	cis	rs2239547	0.657	rs6445539	ENSG00000242142.1	SERBP1P3	5.47	5.57e-08	7.15e-06	0.21	0.17	Schizophrenia;	chr3:52840280	chr3:53064283~53065091:-
BRCA	cis	rs2239547	0.657	rs7638524	ENSG00000242142.1	SERBP1P3	5.47	5.57e-08	7.15e-06	0.21	0.17	Schizophrenia;	chr3:52840845	chr3:53064283~53065091:-
BRCA	cis	rs8054556	0.787	rs12935701	ENSG00000273724.1	RP11-347C12.12	-5.47	5.58e-08	7.15e-06	-0.19	-0.17	Autism spectrum disorder or schizophrenia;	chr16:30015427	chr16:30336400~30343336:+
BRCA	cis	rs7131987	0.65	rs6487808	ENSG00000275476.1	RP11-996F15.4	5.47	5.58e-08	7.15e-06	0.2	0.17	QT interval;	chr12:29310426	chr12:29277397~29277882:-
BRCA	cis	rs1014246	0.848	rs2420330	ENSG00000232767.1	RP11-498B4.5	-5.47	5.58e-08	7.15e-06	-0.18	-0.17	Age at smoking initiation in chronic obstructive pulmonary disease;	chr10:116697970	chr10:116670103~116672739:+
BRCA	cis	rs1440410	0.536	rs6845478	ENSG00000250326.1	RP11-284M14.1	-5.47	5.58e-08	7.16e-06	-0.2	-0.17	Ischemic stroke;	chr4:143239491	chr4:142933195~143184861:-
BRCA	cis	rs6723226	0.708	rs2710627	ENSG00000276517.1	AL133243.2	-5.47	5.59e-08	7.16e-06	-0.21	-0.17	Intelligence (multi-trait analysis);	chr2:32533560	chr2:32526504~32529507:+
BRCA	cis	rs10129255	0.5	rs8006888	ENSG00000224373.3	IGHV4-59	5.47	5.59e-08	7.16e-06	0.09	0.17	Kawasaki disease;	chr14:106782219	chr14:106627249~106627825:-
BRCA	cis	rs2403083	0.541	rs3779901	ENSG00000258256.1	RP11-219B4.5	-5.47	5.59e-08	7.17e-06	-0.2	-0.17	Plasma amyloid beta peptide concentrations (ABx-40);	chr8:85206542	chr8:85222446~85245717:-
BRCA	cis	rs2403083	0.541	rs4150962	ENSG00000258256.1	RP11-219B4.5	-5.47	5.59e-08	7.17e-06	-0.2	-0.17	Plasma amyloid beta peptide concentrations (ABx-40);	chr8:85210186	chr8:85222446~85245717:-
BRCA	cis	rs2403083	0.541	rs4150964	ENSG00000258256.1	RP11-219B4.5	-5.47	5.59e-08	7.17e-06	-0.2	-0.17	Plasma amyloid beta peptide concentrations (ABx-40);	chr8:85210290	chr8:85222446~85245717:-
BRCA	cis	rs6832769	0.925	rs2412663	ENSG00000272969.1	RP11-528I4.2	-5.47	5.59e-08	7.17e-06	-0.2	-0.17	Personality dimensions;	chr4:55589649	chr4:55547112~55547889:+
BRCA	cis	rs7246657	0.943	rs10406177	ENSG00000267422.1	CTD-2554C21.1	-5.47	5.59e-08	7.17e-06	-0.24	-0.17	Coronary artery calcification;	chr19:37417045	chr19:37779686~37792865:+
BRCA	cis	rs7246657	0.882	rs28623164	ENSG00000267422.1	CTD-2554C21.1	-5.47	5.59e-08	7.17e-06	-0.24	-0.17	Coronary artery calcification;	chr19:37422551	chr19:37779686~37792865:+
BRCA	cis	rs7246657	0.943	rs7252346	ENSG00000267422.1	CTD-2554C21.1	-5.47	5.59e-08	7.17e-06	-0.24	-0.17	Coronary artery calcification;	chr19:37423780	chr19:37779686~37792865:+
BRCA	cis	rs7246657	0.943	rs2891699	ENSG00000267422.1	CTD-2554C21.1	-5.47	5.59e-08	7.17e-06	-0.24	-0.17	Coronary artery calcification;	chr19:37429335	chr19:37779686~37792865:+
BRCA	cis	rs7246657	0.943	rs9676967	ENSG00000267422.1	CTD-2554C21.1	-5.47	5.59e-08	7.17e-06	-0.24	-0.17	Coronary artery calcification;	chr19:37437187	chr19:37779686~37792865:+
BRCA	cis	rs7246657	0.943	rs8109632	ENSG00000267422.1	CTD-2554C21.1	-5.47	5.59e-08	7.17e-06	-0.24	-0.17	Coronary artery calcification;	chr19:37440223	chr19:37779686~37792865:+
BRCA	cis	rs7246657	0.943	rs7255407	ENSG00000267422.1	CTD-2554C21.1	-5.47	5.59e-08	7.17e-06	-0.24	-0.17	Coronary artery calcification;	chr19:37443034	chr19:37779686~37792865:+
BRCA	cis	rs2303319	1	rs62194492	ENSG00000227403.1	AC009299.3	5.47	5.6e-08	7.18e-06	0.42	0.17	Cognitive function;	chr2:161359052	chr2:161244739~161249050:+
BRCA	cis	rs10911232	0.507	rs4442336	ENSG00000224468.3	RP11-181K3.4	-5.47	5.6e-08	7.18e-06	-0.18	-0.17	Hypertriglyceridemia;	chr1:183013403	chr1:183138402~183141282:-
BRCA	cis	rs56046484	0.75	rs7173332	ENSG00000259295.5	CSPG4P12	5.47	5.6e-08	7.18e-06	0.27	0.17	Testicular germ cell tumor;	chr15:84978503	chr15:85191438~85213905:+
BRCA	cis	rs7772486	0.875	rs10872582	ENSG00000270638.1	RP3-466P17.1	5.47	5.6e-08	7.18e-06	0.19	0.17	Lobe attachment (rater-scored or self-reported);	chr6:146051925	chr6:145735570~145737218:+
BRCA	cis	rs10510102	0.516	rs11200306	ENSG00000276742.1	RP11-500G22.4	5.47	5.61e-08	7.18e-06	0.29	0.17	Breast cancer;	chr10:121980862	chr10:121956782~121957098:+
BRCA	cis	rs997295	0.592	rs8026627	ENSG00000270964.1	RP11-502I4.3	5.47	5.61e-08	7.18e-06	0.18	0.17	Motion sickness;	chr15:67477968	chr15:67541072~67542604:-
BRCA	cis	rs9847710	0.933	rs1529544	ENSG00000242142.1	SERBP1P3	-5.47	5.61e-08	7.19e-06	-0.18	-0.17	Ulcerative colitis;	chr3:53005439	chr3:53064283~53065091:-
BRCA	cis	rs6700559	0.74	rs10919997	ENSG00000260088.1	RP11-92G12.3	5.47	5.61e-08	7.19e-06	0.2	0.17	Coronary artery disease;	chr1:200677522	chr1:200669507~200694250:+
BRCA	cis	rs6430585	0.528	rs3098102	ENSG00000231890.6	DARS-AS1	-5.47	5.61e-08	7.19e-06	-0.24	-0.17	Corneal structure;	chr2:135897263	chr2:135985176~136022593:+
BRCA	cis	rs26528	0.584	rs153103	ENSG00000278665.1	RP11-666O2.4	-5.47	5.62e-08	7.19e-06	-0.17	-0.17	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr16:28517302	chr16:28599241~28601881:-
BRCA	cis	rs7131987	0.621	rs11050181	ENSG00000275476.1	RP11-996F15.4	-5.47	5.62e-08	7.2e-06	-0.2	-0.17	QT interval;	chr12:29314736	chr12:29277397~29277882:-
BRCA	cis	rs910316	0.967	rs35446981	ENSG00000279594.1	RP11-950C14.10	-5.47	5.62e-08	7.2e-06	-0.18	-0.17	Height;	chr14:75170648	chr14:75011269~75012851:-
BRCA	cis	rs6832769	1	rs1522108	ENSG00000272969.1	RP11-528I4.2	5.47	5.62e-08	7.2e-06	0.21	0.17	Personality dimensions;	chr4:55514566	chr4:55547112~55547889:+
BRCA	cis	rs754466	0.606	rs11002306	ENSG00000204049.1	RP11-126H7.4	5.47	5.62e-08	7.2e-06	0.2	0.17	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77831761	chr10:77866875~77869610:+
BRCA	cis	rs2489715	1	rs2801020	ENSG00000185904.10	LINC00839	5.47	5.62e-08	7.2e-06	0.21	0.17	Helix rolling;	chr10:42461882	chr10:42475543~42495336:+
BRCA	cis	rs9784649	0.641	rs72755823	ENSG00000245662.2	RP11-184E9.1	5.47	5.62e-08	7.21e-06	0.26	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr5:25075428	chr5:25190682~25306172:+
BRCA	cis	rs7620503	1	rs4555562	ENSG00000228221.4	LINC00578	5.47	5.63e-08	7.21e-06	0.19	0.17	Corneal structure;	chr3:177580775	chr3:177441921~177752305:+
BRCA	cis	rs7620503	1	rs4257602	ENSG00000228221.4	LINC00578	5.47	5.63e-08	7.21e-06	0.19	0.17	Corneal structure;	chr3:177580907	chr3:177441921~177752305:+
BRCA	cis	rs7620503	1	rs4290846	ENSG00000228221.4	LINC00578	5.47	5.63e-08	7.21e-06	0.19	0.17	Corneal structure;	chr3:177581146	chr3:177441921~177752305:+
BRCA	cis	rs10752881	0.967	rs8179361	ENSG00000224468.3	RP11-181K3.4	-5.47	5.63e-08	7.21e-06	-0.18	-0.17	Colorectal cancer;	chr1:183005437	chr1:183138402~183141282:-
BRCA	cis	rs10752881	1	rs8179282	ENSG00000224468.3	RP11-181K3.4	-5.47	5.63e-08	7.21e-06	-0.18	-0.17	Colorectal cancer;	chr1:183005463	chr1:183138402~183141282:-
BRCA	cis	rs10752881	1	rs8179283	ENSG00000224468.3	RP11-181K3.4	-5.47	5.63e-08	7.21e-06	-0.18	-0.17	Colorectal cancer;	chr1:183005467	chr1:183138402~183141282:-
BRCA	cis	rs9307551	0.948	rs4975056	ENSG00000250334.4	LINC00989	-5.47	5.64e-08	7.22e-06	-0.25	-0.17	Refractive error;	chr4:79563716	chr4:79492416~79576460:+
BRCA	cis	rs7945705	0.818	rs10769948	ENSG00000254860.4	TMEM9B-AS1	5.47	5.64e-08	7.22e-06	0.17	0.17	Hemoglobin concentration;	chr11:8740235	chr11:8964675~8977527:+
BRCA	cis	rs6570726	0.791	rs9373463	ENSG00000270638.1	RP3-466P17.1	5.47	5.65e-08	7.24e-06	0.19	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145573626	chr6:145735570~145737218:+
BRCA	cis	rs6570726	0.791	rs12205752	ENSG00000270638.1	RP3-466P17.1	5.47	5.65e-08	7.24e-06	0.19	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145574982	chr6:145735570~145737218:+
BRCA	cis	rs2905347	0.531	rs2961289	ENSG00000179428.2	AC073072.5	5.47	5.65e-08	7.24e-06	0.18	0.17	Major depression and alcohol dependence;	chr7:22638136	chr7:22725395~22727620:-
BRCA	cis	rs7618501	0.633	rs6771546	ENSG00000228008.1	CTD-2330K9.3	5.47	5.65e-08	7.24e-06	0.16	0.17	Intelligence (multi-trait analysis);	chr3:49931139	chr3:49903845~49916937:+
BRCA	cis	rs9907295	0.579	rs9899866	ENSG00000270977.1	AC015849.16	5.47	5.65e-08	7.24e-06	0.3	0.17	Fibroblast growth factor basic levels;	chr17:35908466	chr17:35893707~35911023:-
BRCA	cis	rs34217772	0.68	rs61990345	ENSG00000258636.1	CTD-2298J14.2	5.47	5.65e-08	7.24e-06	0.23	0.17	Myopia;	chr14:41725446	chr14:41587861~41604856:-
BRCA	cis	rs875971	0.862	rs6952182	ENSG00000236529.1	RP13-254B10.1	-5.47	5.66e-08	7.24e-06	-0.19	-0.17	Aortic root size;	chr7:66218330	chr7:65840212~65840596:+
BRCA	cis	rs12439619	1	rs12439619	ENSG00000276710.3	CSPG4P8	-5.47	5.66e-08	7.24e-06	-0.19	-0.17	Intelligence (multi-trait analysis);	chr15:82254605	chr15:82459472~82477258:+
BRCA	cis	rs6700559	0.74	rs4437908	ENSG00000260088.1	RP11-92G12.3	5.47	5.68e-08	7.27e-06	0.2	0.17	Coronary artery disease;	chr1:200679311	chr1:200669507~200694250:+
BRCA	cis	rs1345301	1	rs1345301	ENSG00000234389.1	AC007278.3	-5.47	5.68e-08	7.27e-06	-0.16	-0.17	Waist circumference;	chr2:102259127	chr2:102438713~102440475:+
BRCA	cis	rs1345301	1	rs11686567	ENSG00000234389.1	AC007278.3	-5.47	5.68e-08	7.27e-06	-0.16	-0.17	Waist circumference;	chr2:102260149	chr2:102438713~102440475:+
BRCA	cis	rs1345301	0.935	rs11691721	ENSG00000234389.1	AC007278.3	-5.47	5.68e-08	7.27e-06	-0.16	-0.17	Waist circumference;	chr2:102260219	chr2:102438713~102440475:+
BRCA	cis	rs875971	0.545	rs66594357	ENSG00000228409.4	CCT6P1	-5.47	5.68e-08	7.27e-06	-0.17	-0.17	Aortic root size;	chr7:66327797	chr7:65751142~65763354:+
BRCA	cis	rs10129255	0.957	rs11846893	ENSG00000224373.3	IGHV4-59	5.47	5.68e-08	7.28e-06	0.1	0.17	Kawasaki disease;	chr14:106779068	chr14:106627249~106627825:-
BRCA	cis	rs9287719	0.649	rs10207885	ENSG00000243819.4	RN7SL832P	5.47	5.69e-08	7.28e-06	0.17	0.17	Prostate cancer;	chr2:10593062	chr2:10690344~10692099:+
BRCA	cis	rs1387259	0.929	rs11168460	ENSG00000240399.1	RP1-228P16.1	5.47	5.69e-08	7.28e-06	0.2	0.17	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48203582	chr12:48054813~48055591:-
BRCA	cis	rs10888838	1	rs1410896	ENSG00000198711.5	SSBP3-AS1	5.47	5.69e-08	7.28e-06	0.23	0.17	Mitochondrial DNA levels;	chr1:54217341	chr1:54236440~54239063:+
BRCA	cis	rs853679	0.517	rs17711344	ENSG00000204709.4	LINC01556	-5.47	5.69e-08	7.29e-06	-0.24	-0.17	Depression;	chr6:28109824	chr6:28943877~28944537:+
BRCA	cis	rs2098713	0.507	rs13175953	ENSG00000250155.1	CTD-2353F22.1	-5.47	5.69e-08	7.29e-06	-0.19	-0.17	Telomere length;	chr5:37509131	chr5:36666214~36725195:-
BRCA	cis	rs62025270	0.632	rs62022924	ENSG00000202081.1	RNU6-1280P	-5.47	5.7e-08	7.29e-06	-0.25	-0.17	Idiopathic pulmonary fibrosis;	chr15:85692276	chr15:85651522~85651628:-
BRCA	cis	rs62025270	0.576	rs62022925	ENSG00000202081.1	RNU6-1280P	-5.47	5.7e-08	7.29e-06	-0.25	-0.17	Idiopathic pulmonary fibrosis;	chr15:85692835	chr15:85651522~85651628:-
BRCA	cis	rs728616	0.867	rs61860043	ENSG00000225484.5	NUTM2B-AS1	-5.47	5.7e-08	7.29e-06	-0.45	-0.17	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80186642	chr10:79663088~79826594:-
BRCA	cis	rs728616	0.867	rs12414521	ENSG00000225484.5	NUTM2B-AS1	-5.47	5.7e-08	7.29e-06	-0.45	-0.17	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80189778	chr10:79663088~79826594:-
BRCA	cis	rs113835537	0.935	rs15969	ENSG00000255517.5	CTD-3074O7.5	-5.47	5.7e-08	7.29e-06	-0.28	-0.17	Airway imaging phenotypes;	chr11:66626916	chr11:66473490~66480233:-
BRCA	cis	rs1707322	0.682	rs28508523	ENSG00000234329.1	RP11-767N6.2	5.47	5.7e-08	7.29e-06	0.17	0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45723953	chr1:45651039~45651826:-
BRCA	cis	rs2115536	1	rs11072871	ENSG00000278600.1	RP11-81A1.6	-5.47	5.7e-08	7.3e-06	-0.14	-0.17	Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Eosinophil counts;Neutrophil percentage of granulocytes;	chr15:79905589	chr15:79920195~79922455:-
BRCA	cis	rs2638953	0.962	rs11049558	ENSG00000278733.1	RP11-425D17.1	-5.47	5.7e-08	7.3e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28371438	chr12:28185625~28186190:-
BRCA	cis	rs6832769	1	rs7667849	ENSG00000223305.1	RN7SKP30	-5.47	5.7e-08	7.3e-06	-0.21	-0.17	Personality dimensions;	chr4:55522032	chr4:55540502~55540835:-
BRCA	cis	rs934734	0.532	rs1437466	ENSG00000204929.10	AC074391.1	-5.47	5.7e-08	7.3e-06	-0.2	-0.17	Rheumatoid arthritis;	chr2:65437216	chr2:65436711~66084639:+
BRCA	cis	rs801193	0.569	rs35070132	ENSG00000224316.1	RP11-479O9.2	5.47	5.7e-08	7.3e-06	0.17	0.17	Aortic root size;	chr7:66773096	chr7:65773620~65802067:+
BRCA	cis	rs10752881	1	rs12403189	ENSG00000224468.3	RP11-181K3.4	-5.47	5.71e-08	7.31e-06	-0.18	-0.17	Colorectal cancer;	chr1:183014697	chr1:183138402~183141282:-
BRCA	cis	rs1707322	0.686	rs3014235	ENSG00000234329.1	RP11-767N6.2	-5.47	5.71e-08	7.31e-06	-0.17	-0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45625840	chr1:45651039~45651826:-
BRCA	cis	rs1707322	0.717	rs1135850	ENSG00000234329.1	RP11-767N6.2	5.47	5.71e-08	7.31e-06	0.17	0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45628020	chr1:45651039~45651826:-
BRCA	cis	rs6543140	0.601	rs6543135	ENSG00000234389.1	AC007278.3	5.47	5.71e-08	7.31e-06	0.19	0.17	Blood protein levels;	chr2:102445946	chr2:102438713~102440475:+
BRCA	cis	rs7613875	0.62	rs7634441	ENSG00000228008.1	CTD-2330K9.3	-5.47	5.71e-08	7.31e-06	-0.16	-0.17	Body mass index;	chr3:50034244	chr3:49903845~49916937:+
BRCA	cis	rs6490294	0.95	rs7313892	ENSG00000226469.1	ADAM1B	5.47	5.72e-08	7.32e-06	0.22	0.17	Mean platelet volume;	chr12:111983548	chr12:111927018~111929017:+
BRCA	cis	rs6490294	0.904	rs73426401	ENSG00000226469.1	ADAM1B	5.47	5.72e-08	7.32e-06	0.22	0.17	Mean platelet volume;	chr12:111985482	chr12:111927018~111929017:+
BRCA	cis	rs6490294	0.904	rs7956483	ENSG00000226469.1	ADAM1B	5.47	5.72e-08	7.32e-06	0.22	0.17	Mean platelet volume;	chr12:111986766	chr12:111927018~111929017:+
BRCA	cis	rs6565180	0.791	rs4247355	ENSG00000183604.13	SMG1P5	5.47	5.72e-08	7.32e-06	0.18	0.17	Tonsillectomy;	chr16:30380778	chr16:30267553~30335374:-
BRCA	cis	rs78487399	0.908	rs6712944	ENSG00000234936.1	AC010883.5	5.47	5.73e-08	7.33e-06	0.22	0.17	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43606979	chr2:43229573~43233394:+
BRCA	cis	rs2717559	0.542	rs2717586	ENSG00000253196.1	RP11-706C16.7	5.47	5.73e-08	7.33e-06	0.17	0.17	Urinary tract infection frequency;	chr8:142816466	chr8:142763116~142766427:+
BRCA	cis	rs17508449	0.819	rs17274627	ENSG00000232450.1	RP4-730K3.3	-5.47	5.73e-08	7.33e-06	-0.31	-0.17	Leprosy;	chr1:113674773	chr1:113698884~113699631:-
BRCA	cis	rs4950322	0.744	rs2353987	ENSG00000278811.3	LINC00624	5.47	5.73e-08	7.33e-06	0.22	0.17	Protein quantitative trait loci;	chr1:147355845	chr1:147258885~147517875:-
BRCA	cis	rs1979679	0.719	rs11049489	ENSG00000278733.1	RP11-425D17.1	5.47	5.74e-08	7.34e-06	0.22	0.17	Ossification of the posterior longitudinal ligament of the spine;	chr12:28259482	chr12:28185625~28186190:-
BRCA	cis	rs6700559	0.654	rs12061556	ENSG00000260088.1	RP11-92G12.3	5.47	5.74e-08	7.34e-06	0.2	0.17	Coronary artery disease;	chr1:200681111	chr1:200669507~200694250:+
BRCA	cis	rs2522056	1	rs6874639	ENSG00000233006.5	AC034220.3	5.47	5.74e-08	7.34e-06	0.14	0.17	Fibrinogen;Lymphocyte counts;	chr5:132443024	chr5:132311285~132369916:-
BRCA	cis	rs4950322	0.515	rs12060046	ENSG00000244371.2	PFN1P8	-5.47	5.74e-08	7.34e-06	-0.22	-0.17	Protein quantitative trait loci;	chr1:147249278	chr1:146957117~146957659:-
BRCA	cis	rs4650994	0.507	rs56229230	ENSG00000273384.1	RP5-1098D14.1	5.47	5.74e-08	7.34e-06	0.22	0.17	HDL cholesterol;HDL cholesterol levels;	chr1:178557428	chr1:178651706~178652282:+
BRCA	cis	rs2732480	0.5	rs11168464	ENSG00000240399.1	RP1-228P16.1	5.47	5.74e-08	7.35e-06	0.2	0.17	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48208332	chr12:48054813~48055591:-
BRCA	cis	rs34286592	1	rs34127220	ENSG00000214725.6	CDIPT-AS1	-5.47	5.74e-08	7.35e-06	-0.28	-0.17	Multiple sclerosis;	chr16:29831570	chr16:29863593~29868053:+
BRCA	cis	rs6163	0.588	rs12763284	ENSG00000236937.2	PTGES3P4	-5.47	5.75e-08	7.35e-06	-0.21	-0.17	Waist circumference;Hip circumference;	chr10:102748445	chr10:102845595~102845950:+
BRCA	cis	rs7620503	1	rs1463857	ENSG00000228221.4	LINC00578	5.47	5.75e-08	7.35e-06	0.19	0.17	Corneal structure;	chr3:177580539	chr3:177441921~177752305:+
BRCA	cis	rs10899021	1	rs10899025	ENSG00000279353.1	RP11-864N7.4	5.47	5.75e-08	7.36e-06	0.33	0.17	Response to metformin (IC50);	chr11:74655995	chr11:74698231~74699658:-
BRCA	cis	rs7824557	0.603	rs2249804	ENSG00000154316.13	TDH	-5.47	5.75e-08	7.36e-06	-0.21	-0.17	Retinal vascular caliber;	chr8:11358108	chr8:11339637~11368452:+
BRCA	cis	rs875971	0.862	rs1612452	ENSG00000236529.1	RP13-254B10.1	-5.47	5.76e-08	7.36e-06	-0.18	-0.17	Aortic root size;	chr7:66108909	chr7:65840212~65840596:+
BRCA	cis	rs7618501	0.633	rs9814664	ENSG00000228008.1	CTD-2330K9.3	-5.47	5.77e-08	7.37e-06	-0.16	-0.17	Intelligence (multi-trait analysis);	chr3:50041108	chr3:49903845~49916937:+
BRCA	cis	rs8054556	1	rs10871451	ENSG00000273724.1	RP11-347C12.12	-5.47	5.77e-08	7.37e-06	-0.18	-0.17	Autism spectrum disorder or schizophrenia;	chr16:29974884	chr16:30336400~30343336:+
BRCA	cis	rs4834770	1	rs6823963	ENSG00000249244.1	RP11-548H18.2	5.47	5.77e-08	7.37e-06	0.18	0.17	Blood protein levels;	chr4:119321009	chr4:119391831~119395335:-
BRCA	cis	rs4834770	1	rs4834771	ENSG00000249244.1	RP11-548H18.2	5.47	5.77e-08	7.37e-06	0.18	0.17	Blood protein levels;	chr4:119321617	chr4:119391831~119395335:-
BRCA	cis	rs4834770	1	rs1397613	ENSG00000249244.1	RP11-548H18.2	5.47	5.77e-08	7.37e-06	0.18	0.17	Blood protein levels;	chr4:119321774	chr4:119391831~119395335:-
BRCA	cis	rs4834770	1	rs6857641	ENSG00000249244.1	RP11-548H18.2	5.47	5.77e-08	7.37e-06	0.18	0.17	Blood protein levels;	chr4:119322356	chr4:119391831~119395335:-
BRCA	cis	rs4834770	1	rs2282688	ENSG00000249244.1	RP11-548H18.2	5.47	5.77e-08	7.37e-06	0.18	0.17	Blood protein levels;	chr4:119322567	chr4:119391831~119395335:-
BRCA	cis	rs7618501	0.571	rs2240329	ENSG00000228008.1	CTD-2330K9.3	-5.47	5.77e-08	7.38e-06	-0.16	-0.17	Intelligence (multi-trait analysis);	chr3:50070079	chr3:49903845~49916937:+
BRCA	cis	rs2638953	0.924	rs11049472	ENSG00000247934.4	RP11-967K21.1	-5.47	5.77e-08	7.38e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28229772	chr12:28163298~28190738:-
BRCA	cis	rs11668609	0.748	rs16982728	ENSG00000268442.1	CTD-2027I19.2	5.47	5.77e-08	7.38e-06	0.24	0.17	Response to taxane treatment (docetaxel);	chr19:24186760	chr19:24162370~24163425:-
BRCA	cis	rs4907240	0.925	rs7575254	ENSG00000237510.6	AC008268.2	-5.47	5.77e-08	7.38e-06	-0.24	-0.17	Event-related brain oscillations;	chr2:96610023	chr2:95789654~95800166:+
BRCA	cis	rs73607972	0.866	rs17803830	ENSG00000275191.1	RP11-36I17.2	5.47	5.77e-08	7.38e-06	0.27	0.17	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53608948	chr16:53628256~53628816:-
BRCA	cis	rs155076	1	rs261431	ENSG00000235438.6	ESRRAP2	-5.46	5.8e-08	7.41e-06	-0.22	-0.17	White matter hyperintensity burden;	chr13:21291599	chr13:21260015~21295003:+
BRCA	cis	rs6479891	1	rs9414788	ENSG00000232075.1	MRPL35P2	-5.46	5.8e-08	7.42e-06	-0.3	-0.17	Arthritis (juvenile idiopathic);	chr10:63296952	chr10:63634317~63634827:-
BRCA	cis	rs7044106	0.791	rs735110	ENSG00000238181.2	AHCYP2	-5.46	5.8e-08	7.42e-06	-0.22	-0.17	Hip circumference adjusted for BMI;	chr9:120726662	chr9:120720673~120721972:+
BRCA	cis	rs7927592	0.956	rs7944870	ENSG00000212093.1	AP000807.1	5.46	5.8e-08	7.42e-06	0.18	0.17	Total body bone mineral density;	chr11:68541640	chr11:68506083~68506166:-
BRCA	cis	rs8133949	0.638	rs871545	ENSG00000237232.6	ZNF295-AS1	5.46	5.8e-08	7.42e-06	0.3	0.17	Hand grip strength;	chr21:41993542	chr21:42009194~42024924:+
BRCA	cis	rs8114671	0.562	rs6120757	ENSG00000269202.1	RP4-614O4.12	-5.46	5.8e-08	7.42e-06	-0.17	-0.17	Height;	chr20:34900968	chr20:35201747~35203288:-
BRCA	cis	rs62025270	0.632	rs74025655	ENSG00000259295.5	CSPG4P12	-5.46	5.8e-08	7.42e-06	-0.24	-0.17	Idiopathic pulmonary fibrosis;	chr15:85674319	chr15:85191438~85213905:+
BRCA	cis	rs10946940	0.965	rs6915266	ENSG00000216901.1	AL022393.7	-5.46	5.81e-08	7.42e-06	-0.21	-0.17	Systemic lupus erythematosus;	chr6:27560864	chr6:28176188~28176674:+
BRCA	cis	rs2153535	0.58	rs4451187	ENSG00000251164.1	HULC	-5.46	5.81e-08	7.42e-06	-0.21	-0.17	Motion sickness;	chr6:8473677	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.504	rs4493781	ENSG00000251164.1	HULC	-5.46	5.81e-08	7.42e-06	-0.21	-0.17	Motion sickness;	chr6:8473708	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.541	rs5026687	ENSG00000251164.1	HULC	-5.46	5.81e-08	7.42e-06	-0.21	-0.17	Motion sickness;	chr6:8473724	chr6:8652137~8653846:+
BRCA	cis	rs442309	0.551	rs7083045	ENSG00000238280.1	RP11-436D10.3	-5.46	5.81e-08	7.42e-06	-0.21	-0.17	Vogt-Koyanagi-Harada syndrome;	chr10:62780204	chr10:62793562~62805887:-
BRCA	cis	rs875971	0.862	rs6460282	ENSG00000236529.1	RP13-254B10.1	-5.46	5.81e-08	7.43e-06	-0.19	-0.17	Aortic root size;	chr7:66226259	chr7:65840212~65840596:+
BRCA	cis	rs6832769	1	rs28670674	ENSG00000272969.1	RP11-528I4.2	-5.46	5.82e-08	7.43e-06	-0.21	-0.17	Personality dimensions;	chr4:55540936	chr4:55547112~55547889:+
BRCA	cis	rs6723226	0.598	rs2710629	ENSG00000276517.1	AL133243.2	-5.46	5.82e-08	7.43e-06	-0.19	-0.17	Intelligence (multi-trait analysis);	chr2:32540777	chr2:32526504~32529507:+
BRCA	cis	rs7577696	0.597	rs212690	ENSG00000272716.1	RP11-563N4.1	5.46	5.82e-08	7.43e-06	0.21	0.17	Inflammatory biomarkers;	chr2:32212562	chr2:32165046~32165757:-
BRCA	cis	rs2153535	0.58	rs2152348	ENSG00000251164.1	HULC	-5.46	5.82e-08	7.43e-06	-0.21	-0.17	Motion sickness;	chr6:8474068	chr6:8652137~8653846:+
BRCA	cis	rs1075265	0.62	rs2542584	ENSG00000235937.1	AC008280.1	5.46	5.82e-08	7.44e-06	0.18	0.17	Chronotype;Morning vs. evening chronotype;	chr2:53782707	chr2:54029552~54030682:-
BRCA	cis	rs2243480	0.803	rs36127118	ENSG00000228409.4	CCT6P1	5.46	5.82e-08	7.44e-06	0.23	0.17	Diabetic kidney disease;	chr7:66100518	chr7:65751142~65763354:+
BRCA	cis	rs875971	0.638	rs3898855	ENSG00000273024.4	INTS4P2	5.46	5.83e-08	7.45e-06	0.18	0.17	Aortic root size;	chr7:66571411	chr7:65647864~65715661:+
BRCA	cis	rs875971	0.638	rs10278816	ENSG00000273024.4	INTS4P2	5.46	5.83e-08	7.45e-06	0.18	0.17	Aortic root size;	chr7:66572000	chr7:65647864~65715661:+
BRCA	cis	rs875971	0.66	rs10281080	ENSG00000273024.4	INTS4P2	5.46	5.83e-08	7.45e-06	0.18	0.17	Aortic root size;	chr7:66577454	chr7:65647864~65715661:+
BRCA	cis	rs875971	0.66	rs10950044	ENSG00000273024.4	INTS4P2	5.46	5.83e-08	7.45e-06	0.18	0.17	Aortic root size;	chr7:66577989	chr7:65647864~65715661:+
BRCA	cis	rs7620503	1	rs6801659	ENSG00000228221.4	LINC00578	5.46	5.83e-08	7.45e-06	0.19	0.17	Corneal structure;	chr3:177580004	chr3:177441921~177752305:+
BRCA	cis	rs7923609	0.934	rs10822153	ENSG00000232075.1	MRPL35P2	-5.46	5.84e-08	7.46e-06	-0.21	-0.17	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63297053	chr10:63634317~63634827:-
BRCA	cis	rs1426063	0.858	rs6837969	ENSG00000260265.1	RP11-44F21.5	5.46	5.84e-08	7.46e-06	0.28	0.17	QT interval;	chr4:75085005	chr4:75081702~75084717:-
BRCA	cis	rs1426063	0.858	rs6843217	ENSG00000260265.1	RP11-44F21.5	5.46	5.84e-08	7.46e-06	0.28	0.17	QT interval;	chr4:75085201	chr4:75081702~75084717:-
BRCA	cis	rs891378	1	rs2564974	ENSG00000274245.1	RP11-357P18.2	5.46	5.84e-08	7.47e-06	0.23	0.17	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207310100	chr1:207372559~207373252:+
BRCA	cis	rs4950322	0.542	rs17159924	ENSG00000278811.3	LINC00624	5.46	5.85e-08	7.47e-06	0.21	0.17	Protein quantitative trait loci;	chr1:147199463	chr1:147258885~147517875:-
BRCA	cis	rs4934494	0.677	rs11185773	ENSG00000240996.1	RP11-80H5.7	-5.46	5.85e-08	7.47e-06	-0.23	-0.17	Red blood cell count;	chr10:89589574	chr10:89694295~89697928:-
BRCA	cis	rs1552244	0.748	rs113890152	ENSG00000232901.1	CYCSP10	5.46	5.85e-08	7.48e-06	0.23	0.17	Alzheimer's disease;	chr3:10044302	chr3:10000647~10000940:-
BRCA	cis	rs2562784	0.638	rs2585054	ENSG00000225151.9	GOLGA2P7	5.46	5.86e-08	7.48e-06	0.26	0.17	Height;	chr15:83604576	chr15:84199311~84230136:-
BRCA	cis	rs7246760	0.867	rs7259075	ENSG00000277587.1	CTD-3116E22.8	-5.46	5.86e-08	7.48e-06	-0.33	-0.17	Pursuit maintenance gain;	chr19:9668100	chr19:9721903~9722410:+
BRCA	cis	rs7246760	0.867	rs35416342	ENSG00000277587.1	CTD-3116E22.8	-5.46	5.86e-08	7.48e-06	-0.33	-0.17	Pursuit maintenance gain;	chr19:9668382	chr19:9721903~9722410:+
BRCA	cis	rs7246760	0.867	rs12461215	ENSG00000277587.1	CTD-3116E22.8	-5.46	5.86e-08	7.48e-06	-0.33	-0.17	Pursuit maintenance gain;	chr19:9671785	chr19:9721903~9722410:+
BRCA	cis	rs7246760	0.867	rs1115825	ENSG00000277587.1	CTD-3116E22.8	-5.46	5.86e-08	7.48e-06	-0.33	-0.17	Pursuit maintenance gain;	chr19:9675445	chr19:9721903~9722410:+
BRCA	cis	rs7246760	0.867	rs59616842	ENSG00000277587.1	CTD-3116E22.8	-5.46	5.86e-08	7.48e-06	-0.33	-0.17	Pursuit maintenance gain;	chr19:9681569	chr19:9721903~9722410:+
BRCA	cis	rs7246760	0.867	rs66464474	ENSG00000277587.1	CTD-3116E22.8	-5.46	5.86e-08	7.48e-06	-0.33	-0.17	Pursuit maintenance gain;	chr19:9684473	chr19:9721903~9722410:+
BRCA	cis	rs7246760	0.737	rs60584926	ENSG00000277587.1	CTD-3116E22.8	-5.46	5.86e-08	7.48e-06	-0.33	-0.17	Pursuit maintenance gain;	chr19:9686338	chr19:9721903~9722410:+
BRCA	cis	rs2898681	0.561	rs6855240	ENSG00000248375.1	RP11-177B4.1	-5.46	5.87e-08	7.5e-06	-0.32	-0.17	Optic nerve measurement (cup area);	chr4:52874620	chr4:52720081~52720831:-
BRCA	cis	rs875971	0.545	rs10950036	ENSG00000228409.4	CCT6P1	-5.46	5.87e-08	7.5e-06	-0.17	-0.17	Aortic root size;	chr7:66353241	chr7:65751142~65763354:+
BRCA	cis	rs2638953	0.924	rs11049410	ENSG00000247934.4	RP11-967K21.1	-5.46	5.87e-08	7.5e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28183438	chr12:28163298~28190738:-
BRCA	cis	rs7221109	0.71	rs4890093	ENSG00000278834.1	RP11-458J1.1	5.46	5.88e-08	7.5e-06	0.18	0.17	Type 1 diabetes;	chr17:40639691	chr17:40648300~40649718:+
BRCA	cis	rs9545047	0.604	rs9545054	ENSG00000227354.5	RBM26-AS1	5.46	5.88e-08	7.51e-06	0.18	0.17	Schizophrenia;	chr13:79298833	chr13:79406309~79424328:+
BRCA	cis	rs9545047	0.547	rs2876739	ENSG00000227354.5	RBM26-AS1	5.46	5.88e-08	7.51e-06	0.18	0.17	Schizophrenia;	chr13:79299057	chr13:79406309~79424328:+
BRCA	cis	rs55702914	0.935	rs56116936	ENSG00000231621.1	AC013264.2	-5.46	5.88e-08	7.51e-06	-0.17	-0.17	Major depression and alcohol dependence;	chr2:197354493	chr2:197197991~197199273:+
BRCA	cis	rs4781563	0.621	rs7202291	ENSG00000242307.1	RPS26P52	-5.46	5.88e-08	7.51e-06	-0.19	-0.17	Bilirubin levels;	chr16:13915052	chr16:13922332~13922679:-
BRCA	cis	rs3740713	1	rs73440614	ENSG00000256464.1	YWHABP2	5.46	5.89e-08	7.52e-06	0.29	0.17	Amyotrophic lateral sclerosis (sporadic);	chr11:18445153	chr11:18490243~18490955:-
BRCA	cis	rs7119	0.717	rs12917175	ENSG00000259362.2	RP11-307C19.1	-5.46	5.89e-08	7.52e-06	-0.23	-0.17	Type 2 diabetes;	chr15:77525851	chr15:77525540~77534110:+
BRCA	cis	rs8098244	0.737	rs1258148	ENSG00000264745.1	TTC39C-AS1	-5.46	5.89e-08	7.52e-06	-0.25	-0.17	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23940216	chr18:23994213~24015339:-
BRCA	cis	rs721917	0.506	rs2493725	ENSG00000244733.5	RP11-506M13.3	-5.46	5.89e-08	7.53e-06	-0.2	-0.17	Chronic obstructive pulmonary disease;	chr10:79898126	chr10:79660891~79677996:+
BRCA	cis	rs4218	0.543	rs35658945	ENSG00000277144.1	RP11-59H7.4	-5.46	5.9e-08	7.53e-06	-0.21	-0.17	Social communication problems;	chr15:59018053	chr15:59115547~59116089:-
BRCA	cis	rs2179367	0.632	rs9498324	ENSG00000223701.3	RAET1E-AS1	5.46	5.9e-08	7.53e-06	0.24	0.17	Dupuytren's disease;	chr6:149338973	chr6:149884431~149919508:+
BRCA	cis	rs2179367	0.632	rs55826712	ENSG00000223701.3	RAET1E-AS1	5.46	5.9e-08	7.53e-06	0.24	0.17	Dupuytren's disease;	chr6:149344716	chr6:149884431~149919508:+
BRCA	cis	rs7613875	0.6	rs2856238	ENSG00000228008.1	CTD-2330K9.3	5.46	5.9e-08	7.54e-06	0.16	0.17	Body mass index;	chr3:50120758	chr3:49903845~49916937:+
BRCA	cis	rs6570726	0.738	rs6925594	ENSG00000270638.1	RP3-466P17.1	5.46	5.9e-08	7.54e-06	0.19	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145577318	chr6:145735570~145737218:+
BRCA	cis	rs6570726	0.791	rs11155432	ENSG00000270638.1	RP3-466P17.1	5.46	5.9e-08	7.54e-06	0.19	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145577625	chr6:145735570~145737218:+
BRCA	cis	rs6570726	0.791	rs6913727	ENSG00000270638.1	RP3-466P17.1	5.46	5.9e-08	7.54e-06	0.19	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145578690	chr6:145735570~145737218:+
BRCA	cis	rs6570726	0.791	rs10872577	ENSG00000270638.1	RP3-466P17.1	5.46	5.9e-08	7.54e-06	0.19	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145579424	chr6:145735570~145737218:+
BRCA	cis	rs6570726	0.755	rs2103633	ENSG00000270638.1	RP3-466P17.1	5.46	5.91e-08	7.54e-06	0.19	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145572885	chr6:145735570~145737218:+
BRCA	cis	rs875971	0.862	rs1167390	ENSG00000236529.1	RP13-254B10.1	-5.46	5.91e-08	7.55e-06	-0.18	-0.17	Aortic root size;	chr7:66110906	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.862	rs35034167	ENSG00000236529.1	RP13-254B10.1	-5.46	5.91e-08	7.55e-06	-0.18	-0.17	Aortic root size;	chr7:66115179	chr7:65840212~65840596:+
BRCA	cis	rs2098713	0.569	rs11957546	ENSG00000250155.1	CTD-2353F22.1	-5.46	5.92e-08	7.55e-06	-0.18	-0.17	Telomere length;	chr5:37506230	chr5:36666214~36725195:-
BRCA	cis	rs2732480	0.5	rs7297824	ENSG00000240399.1	RP1-228P16.1	5.46	5.92e-08	7.56e-06	0.19	0.17	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48204867	chr12:48054813~48055591:-
BRCA	cis	rs8113308	0.752	rs113374423	ENSG00000269483.1	AC006272.1	5.46	5.92e-08	7.56e-06	0.31	0.17	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51987699	chr19:51839924~51843324:-
BRCA	cis	rs41307935	0.908	rs34618114	ENSG00000260063.1	RP5-968P14.2	-5.46	5.92e-08	7.56e-06	-0.38	-0.17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26771828	chr1:26692132~26694131:-
BRCA	cis	rs17711722	0.701	rs781145	ENSG00000273024.4	INTS4P2	-5.46	5.92e-08	7.56e-06	-0.18	-0.17	Calcium levels;	chr7:65975383	chr7:65647864~65715661:+
BRCA	cis	rs7916697	0.593	rs7912895	ENSG00000233590.1	RP11-153K11.3	-5.46	5.94e-08	7.58e-06	-0.21	-0.17	Optic disc area;	chr10:68261741	chr10:68233251~68242379:-
BRCA	cis	rs6832769	1	rs6811520	ENSG00000272969.1	RP11-528I4.2	5.46	5.94e-08	7.58e-06	0.21	0.17	Personality dimensions;	chr4:55449011	chr4:55547112~55547889:+
BRCA	cis	rs11955398	0.716	rs3857236	ENSG00000215032.2	GNL3LP1	5.46	5.94e-08	7.59e-06	0.2	0.17	Intelligence (multi-trait analysis);	chr5:60613702	chr5:60891935~60893577:-
BRCA	cis	rs6802315	1	rs6802315	ENSG00000272247.1	RP11-379F4.9	-5.46	5.95e-08	7.59e-06	-0.19	-0.17	Periodontitis (CDC/AAP);	chr3:158796571	chr3:158801257~158801935:-
BRCA	cis	rs516805	0.667	rs225074	ENSG00000279453.1	RP3-425C14.4	-5.46	5.95e-08	7.59e-06	-0.24	-0.17	Lymphocyte counts;	chr6:122265102	chr6:122436789~122439223:-
BRCA	cis	rs9652601	0.691	rs12924985	ENSG00000274038.1	RP11-66H6.4	-5.46	5.95e-08	7.6e-06	-0.18	-0.17	Systemic lupus erythematosus;	chr16:11114465	chr16:11056556~11057034:+
BRCA	cis	rs9309473	0.606	rs77962988	ENSG00000163016.8	ALMS1P	5.46	5.95e-08	7.6e-06	0.27	0.17	Metabolite levels;	chr2:73658963	chr2:73644919~73685576:+
BRCA	cis	rs10504130	0.696	rs17212214	ENSG00000272024.1	RP11-546K22.3	5.46	5.95e-08	7.6e-06	0.25	0.17	Venous thromboembolism (SNP x SNP interaction);	chr8:51918582	chr8:51950284~51950690:+
BRCA	cis	rs4950322	1	rs1806618	ENSG00000278811.3	LINC00624	5.46	5.96e-08	7.6e-06	0.23	0.17	Protein quantitative trait loci;	chr1:147377075	chr1:147258885~147517875:-
BRCA	cis	rs4950322	1	rs4448568	ENSG00000278811.3	LINC00624	5.46	5.96e-08	7.6e-06	0.23	0.17	Protein quantitative trait loci;	chr1:147377296	chr1:147258885~147517875:-
BRCA	cis	rs7577696	0.693	rs466126	ENSG00000272716.1	RP11-563N4.1	5.46	5.96e-08	7.61e-06	0.19	0.17	Inflammatory biomarkers;	chr2:32237025	chr2:32165046~32165757:-
BRCA	cis	rs9467773	1	rs6922824	ENSG00000124549.13	BTN2A3P	-5.46	5.97e-08	7.61e-06	-0.17	-0.17	Intelligence (multi-trait analysis);	chr6:26553587	chr6:26421391~26432383:+
BRCA	cis	rs9467773	1	rs1321480	ENSG00000124549.13	BTN2A3P	5.46	5.97e-08	7.61e-06	0.17	0.17	Intelligence (multi-trait analysis);	chr6:26532514	chr6:26421391~26432383:+
BRCA	cis	rs2638953	0.962	rs10506032	ENSG00000278733.1	RP11-425D17.1	-5.46	5.97e-08	7.62e-06	-0.22	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28384177	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.815	rs1534340	ENSG00000247934.4	RP11-967K21.1	-5.46	5.97e-08	7.62e-06	-0.22	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28515550	chr12:28163298~28190738:-
BRCA	cis	rs11992162	0.591	rs35657308	ENSG00000255046.1	RP11-297N6.4	5.46	5.98e-08	7.62e-06	0.19	0.17	Monocyte count;	chr8:11946893	chr8:11797928~11802568:-
BRCA	cis	rs6430585	0.528	rs75753154	ENSG00000224043.6	CCNT2-AS1	-5.46	5.98e-08	7.63e-06	-0.29	-0.17	Corneal structure;	chr2:135908141	chr2:134735464~134918710:-
BRCA	cis	rs6430585	0.528	rs7606267	ENSG00000224043.6	CCNT2-AS1	-5.46	5.98e-08	7.63e-06	-0.29	-0.17	Corneal structure;	chr2:135910553	chr2:134735464~134918710:-
BRCA	cis	rs17711722	0.64	rs13237956	ENSG00000213640.3	EEF1DP4	-5.46	5.98e-08	7.63e-06	-0.2	-0.17	Calcium levels;	chr7:65853042	chr7:64862999~64864370:+
BRCA	cis	rs1555322	0.872	rs2425048	ENSG00000126005.14	MMP24-AS1	-5.46	5.99e-08	7.63e-06	-0.29	-0.17	Attention deficit hyperactivity disorder;	chr20:35284920	chr20:35216462~35278131:-
BRCA	cis	rs2018683	0.768	rs10282015	ENSG00000228421.2	AC005013.5	5.46	5.99e-08	7.64e-06	0.21	0.17	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28982522	chr7:28957667~28959345:+
BRCA	cis	rs2018683	0.77	rs10951208	ENSG00000228421.2	AC005013.5	5.46	5.99e-08	7.64e-06	0.21	0.17	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28982888	chr7:28957667~28959345:+
BRCA	cis	rs3102460	0.618	rs3127454	ENSG00000225401.2	TGIF2P1	-5.46	5.99e-08	7.64e-06	-0.25	-0.17	Obesity-related traits;	chr1:244415550	chr1:244394976~244395660:-
BRCA	cis	rs11159086	0.941	rs12434836	ENSG00000270000.1	RP3-449M8.9	5.46	5.99e-08	7.64e-06	0.28	0.17	Advanced glycation end-product levels;	chr14:74468887	chr14:74471930~74472360:-
BRCA	cis	rs13126694	0.744	rs10027000	ENSG00000251429.1	RP11-597D13.7	5.46	5.99e-08	7.64e-06	0.16	0.17	Blood osmolality (transformed sodium);	chr4:158053401	chr4:158270378~158278676:+
BRCA	cis	rs17213965	0.561	rs8048091	ENSG00000207425.1	Y_RNA	-5.46	5.99e-08	7.64e-06	-0.22	-0.17	Waist-hip ratio;	chr16:15787633	chr16:14915457~14915556:-
BRCA	cis	rs600231	0.665	rs2846861	ENSG00000173727.10	CMB9-22P13.1	5.46	5.99e-08	7.64e-06	0.22	0.17	Bone mineral density;	chr11:65454834	chr11:65455258~65466720:+
BRCA	cis	rs1014246	0.826	rs11197802	ENSG00000232767.1	RP11-498B4.5	5.46	6e-08	7.65e-06	0.17	0.17	Age at smoking initiation in chronic obstructive pulmonary disease;	chr10:116712489	chr10:116670103~116672739:+
BRCA	cis	rs1552244	0.935	rs7618815	ENSG00000232901.1	CYCSP10	5.46	6e-08	7.65e-06	0.23	0.17	Alzheimer's disease;	chr3:10109361	chr3:10000647~10000940:-
BRCA	cis	rs1552244	1	rs7652935	ENSG00000232901.1	CYCSP10	5.46	6e-08	7.65e-06	0.23	0.17	Alzheimer's disease;	chr3:10109454	chr3:10000647~10000940:-
BRCA	cis	rs1552244	1	rs67134728	ENSG00000232901.1	CYCSP10	5.46	6e-08	7.65e-06	0.23	0.17	Alzheimer's disease;	chr3:10109747	chr3:10000647~10000940:-
BRCA	cis	rs7178375	1	rs12907055	ENSG00000270015.1	RP11-540B6.6	5.46	6e-08	7.65e-06	0.21	0.17	Hypertriglyceridemia;	chr15:30912091	chr15:30926514~30928407:+
BRCA	cis	rs4908760	0.827	rs6692693	ENSG00000270282.1	RP5-1115A15.2	5.46	6.01e-08	7.66e-06	0.18	0.17	Vitiligo;	chr1:8647057	chr1:8512653~8513021:+
BRCA	cis	rs8031584	0.723	rs11632229	ENSG00000270015.1	RP11-540B6.6	5.46	6.01e-08	7.66e-06	0.17	0.17	Huntington's disease progression;	chr15:30887331	chr15:30926514~30928407:+
BRCA	cis	rs991427	0.643	rs11829219	ENSG00000258100.1	RP11-121E16.1	-5.46	6.01e-08	7.66e-06	-0.27	-0.17	Systolic blood pressure (alcohol consumption interaction);	chr12:91070148	chr12:91362196~91368606:+
BRCA	cis	rs4372836	1	rs6547872	ENSG00000226833.4	AC097724.3	5.46	6.02e-08	7.68e-06	0.2	0.17	Body mass index;	chr2:28755208	chr2:28708953~28736205:-
BRCA	cis	rs7487075	0.619	rs4077707	ENSG00000274723.1	RP11-618L22.1	5.46	6.02e-08	7.68e-06	0.21	0.17	Itch intensity from mosquito bite;	chr12:46464715	chr12:46970504~46972155:+
BRCA	cis	rs732716	0.74	rs78869060	ENSG00000267980.1	AC007292.6	-5.46	6.03e-08	7.68e-06	-0.21	-0.17	Mean corpuscular volume;	chr19:4444745	chr19:4363789~4364640:+
BRCA	cis	rs970548	0.643	rs12765320	ENSG00000230869.1	CTGLF10P	5.46	6.03e-08	7.69e-06	0.22	0.17	Total cholesterol levels;HDL cholesterol;HDL cholesterol levels;Cholesterol, total;	chr10:45435357	chr10:45678692~45700532:+
BRCA	cis	rs1979679	0.801	rs7977538	ENSG00000278733.1	RP11-425D17.1	5.46	6.03e-08	7.69e-06	0.21	0.17	Ossification of the posterior longitudinal ligament of the spine;	chr12:28143503	chr12:28185625~28186190:-
BRCA	cis	rs73193808	0.851	rs2223036	ENSG00000215533.7	LINC00189	5.46	6.03e-08	7.69e-06	0.24	0.17	Coronary artery disease;	chr21:29232461	chr21:29193480~29288205:+
BRCA	cis	rs911555	0.547	rs8006994	ENSG00000244691.1	RPL10AP1	-5.46	6.03e-08	7.69e-06	-0.22	-0.17	Intelligence (multi-trait analysis);	chr14:103374959	chr14:103412119~103412761:-
BRCA	cis	rs7044106	0.5	rs56725168	ENSG00000238181.2	AHCYP2	-5.46	6.04e-08	7.69e-06	-0.22	-0.17	Hip circumference adjusted for BMI;	chr9:120730298	chr9:120720673~120721972:+
BRCA	cis	rs1426063	0.858	rs11931653	ENSG00000260265.1	RP11-44F21.5	5.46	6.04e-08	7.69e-06	0.27	0.17	QT interval;	chr4:75080856	chr4:75081702~75084717:-
BRCA	cis	rs9311474	0.629	rs11709284	ENSG00000243224.1	RP5-1157M23.2	-5.46	6.04e-08	7.7e-06	-0.18	-0.17	Electroencephalogram traits;	chr3:52525689	chr3:52239258~52241097:+
BRCA	cis	rs7246657	0.882	rs8112610	ENSG00000267422.1	CTD-2554C21.1	-5.46	6.05e-08	7.71e-06	-0.24	-0.17	Coronary artery calcification;	chr19:37437828	chr19:37779686~37792865:+
BRCA	cis	rs7487075	0.78	rs10785620	ENSG00000257261.4	RP11-96H19.1	5.46	6.05e-08	7.72e-06	0.18	0.17	Itch intensity from mosquito bite;	chr12:46343469	chr12:46383679~46876159:+
BRCA	cis	rs2638953	0.924	rs11049569	ENSG00000278733.1	RP11-425D17.1	-5.46	6.06e-08	7.72e-06	-0.22	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28386823	chr12:28185625~28186190:-
BRCA	cis	rs13126694	0.744	rs7656059	ENSG00000248429.4	RP11-597D13.9	5.46	6.06e-08	7.72e-06	0.15	0.17	Blood osmolality (transformed sodium);	chr4:158080386	chr4:158170752~158202877:+
BRCA	cis	rs9308731	0.591	rs10439381	ENSG00000227992.1	AC108463.2	-5.46	6.06e-08	7.72e-06	-0.19	-0.17	Chronic lymphocytic leukemia;	chr2:111178882	chr2:111203964~111206215:-
BRCA	cis	rs12681366	0.734	rs1872889	ENSG00000253704.1	RP11-267M23.4	5.46	6.07e-08	7.73e-06	0.17	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94406193	chr8:94553722~94569745:+
BRCA	cis	rs875971	0.522	rs709604	ENSG00000273024.4	INTS4P2	5.46	6.07e-08	7.74e-06	0.18	0.17	Aortic root size;	chr7:66032447	chr7:65647864~65715661:+
BRCA	cis	rs12612619	0.732	rs3754734	ENSG00000229122.1	AGBL5-IT1	5.46	6.07e-08	7.74e-06	0.18	0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27076730	chr2:27061038~27061815:+
BRCA	cis	rs9659323	0.622	rs28653656	ENSG00000231365.4	RP11-418J17.1	-5.46	6.08e-08	7.74e-06	-0.21	-0.17	Body mass index;	chr1:118943807	chr1:119140396~119275973:+
BRCA	cis	rs12364620	1	rs12364620	ENSG00000212093.1	AP000807.1	5.46	6.08e-08	7.75e-06	0.19	0.17	Total body bone mineral density (age 0-15);	chr11:68484655	chr11:68506083~68506166:-
BRCA	cis	rs8031584	0.958	rs11293	ENSG00000270015.1	RP11-540B6.6	-5.46	6.08e-08	7.75e-06	-0.18	-0.17	Huntington's disease progression;	chr15:30942778	chr15:30926514~30928407:+
BRCA	cis	rs4415084	1	rs12515012	ENSG00000251141.4	RP11-53O19.1	5.46	6.08e-08	7.75e-06	0.16	0.17	Breast cancer;	chr5:44694433	chr5:44744900~44808777:-
BRCA	cis	rs6095360	0.7	rs67777906	ENSG00000222365.1	SNORD12B	-5.46	6.08e-08	7.75e-06	-0.23	-0.17	Intelligence (multi-trait analysis);	chr20:48940592	chr20:49280319~49280409:+
BRCA	cis	rs9659323	0.67	rs61808898	ENSG00000231365.4	RP11-418J17.1	-5.46	6.09e-08	7.75e-06	-0.2	-0.17	Body mass index;	chr1:119096232	chr1:119140396~119275973:+
BRCA	cis	rs523522	0.962	rs12814055	ENSG00000278344.1	RP11-18C24.8	5.46	6.09e-08	7.76e-06	0.23	0.17	High light scatter reticulocyte count;	chr12:120549588	chr12:120500735~120501090:-
BRCA	cis	rs523522	0.962	rs12371550	ENSG00000278344.1	RP11-18C24.8	5.46	6.09e-08	7.76e-06	0.23	0.17	High light scatter reticulocyte count;	chr12:120549840	chr12:120500735~120501090:-
BRCA	cis	rs2551802	0.615	rs17395735	ENSG00000226363.3	HAGLROS	-5.46	6.09e-08	7.76e-06	-0.23	-0.17	Motion sickness;	chr2:176203052	chr2:176177717~176179008:+
BRCA	cis	rs9307551	0.619	rs723243	ENSG00000250334.4	LINC00989	-5.46	6.09e-08	7.76e-06	-0.23	-0.17	Refractive error;	chr4:79504189	chr4:79492416~79576460:+
BRCA	cis	rs7620503	0.959	rs4857713	ENSG00000228221.4	LINC00578	5.46	6.09e-08	7.76e-06	0.19	0.17	Corneal structure;	chr3:177588654	chr3:177441921~177752305:+
BRCA	cis	rs875971	0.895	rs6460278	ENSG00000236529.1	RP13-254B10.1	-5.46	6.1e-08	7.77e-06	-0.19	-0.17	Aortic root size;	chr7:66197749	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.862	rs6460279	ENSG00000236529.1	RP13-254B10.1	-5.46	6.1e-08	7.77e-06	-0.19	-0.17	Aortic root size;	chr7:66197774	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.862	rs28491091	ENSG00000236529.1	RP13-254B10.1	-5.46	6.1e-08	7.77e-06	-0.19	-0.17	Aortic root size;	chr7:66204077	chr7:65840212~65840596:+
BRCA	cis	rs922692	0.715	rs11072803	ENSG00000261143.1	ADAMTS7P3	5.46	6.1e-08	7.77e-06	0.21	0.17	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78785536	chr15:77976042~77993057:+
BRCA	cis	rs7772486	0.654	rs1011597	ENSG00000270638.1	RP3-466P17.1	-5.46	6.1e-08	7.77e-06	-0.19	-0.17	Lobe attachment (rater-scored or self-reported);	chr6:145754536	chr6:145735570~145737218:+
BRCA	cis	rs227932	0.571	rs12536173	ENSG00000234286.1	AC006026.13	-5.46	6.1e-08	7.77e-06	-0.28	-0.17	Schizophrenia;	chr7:23834413	chr7:23680195~23680786:-
BRCA	cis	rs7617773	0.963	rs9822496	ENSG00000228638.1	FCF1P2	-5.46	6.1e-08	7.77e-06	-0.16	-0.17	Coronary artery disease;	chr3:48139843	chr3:48290793~48291375:-
BRCA	cis	rs1707322	0.65	rs4553239	ENSG00000234329.1	RP11-767N6.2	5.46	6.1e-08	7.78e-06	0.18	0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45684814	chr1:45651039~45651826:-
BRCA	cis	rs2836950	0.84	rs12482317	ENSG00000238141.2	BRWD1-AS1	-5.46	6.11e-08	7.78e-06	-0.2	-0.17	Menarche (age at onset);	chr21:39216315	chr21:39315707~39323218:+
BRCA	cis	rs3805389	0.961	rs9996936	ENSG00000273257.1	RP11-177J6.1	-5.46	6.11e-08	7.78e-06	-0.25	-0.17	Waist-to-hip ratio adjusted for body mass index;	chr4:55601472	chr4:55387949~55388271:+
BRCA	cis	rs73222236	0.825	rs56040643	ENSG00000273486.1	RP11-731C17.2	5.46	6.11e-08	7.78e-06	0.19	0.17	Coronary artery disease;	chr3:136538621	chr3:136837338~136839021:-
BRCA	cis	rs6570726	0.791	rs9390336	ENSG00000270638.1	RP3-466P17.1	5.46	6.12e-08	7.79e-06	0.19	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145575687	chr6:145735570~145737218:+
BRCA	cis	rs13126694	0.744	rs7656059	ENSG00000251429.1	RP11-597D13.7	5.45	6.12e-08	7.79e-06	0.16	0.17	Blood osmolality (transformed sodium);	chr4:158080386	chr4:158270378~158278676:+
BRCA	cis	rs4650994	0.525	rs4651000	ENSG00000273384.1	RP5-1098D14.1	5.45	6.13e-08	7.8e-06	0.21	0.17	HDL cholesterol;HDL cholesterol levels;	chr1:178563088	chr1:178651706~178652282:+
BRCA	cis	rs4907240	0.961	rs7580048	ENSG00000237510.6	AC008268.2	-5.45	6.13e-08	7.8e-06	-0.24	-0.17	Event-related brain oscillations;	chr2:96638443	chr2:95789654~95800166:+
BRCA	cis	rs4835473	0.897	rs12508285	ENSG00000249741.2	RP11-673E1.3	5.45	6.13e-08	7.81e-06	0.18	0.17	Immature fraction of reticulocytes;	chr4:143792642	chr4:143911514~143912053:-
BRCA	cis	rs11671005	0.693	rs11668757	ENSG00000252334.1	RNU6-1337P	5.45	6.13e-08	7.81e-06	0.25	0.17	Mean platelet volume;	chr19:58416932	chr19:58483749~58483843:-
BRCA	cis	rs6570726	0.791	rs6923074	ENSG00000270638.1	RP3-466P17.1	5.45	6.13e-08	7.81e-06	0.19	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145572196	chr6:145735570~145737218:+
BRCA	cis	rs6570726	0.755	rs2092296	ENSG00000270638.1	RP3-466P17.1	5.45	6.13e-08	7.81e-06	0.19	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145572548	chr6:145735570~145737218:+
BRCA	cis	rs6570726	0.755	rs2092297	ENSG00000270638.1	RP3-466P17.1	5.45	6.13e-08	7.81e-06	0.19	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145572629	chr6:145735570~145737218:+
BRCA	cis	rs17772222	0.682	rs2297129	ENSG00000258789.1	RP11-507K2.3	-5.45	6.13e-08	7.81e-06	-0.19	-0.17	Coronary artery calcification;	chr14:88469581	chr14:88551597~88552493:+
BRCA	cis	rs17772222	0.682	rs7141363	ENSG00000258789.1	RP11-507K2.3	-5.45	6.13e-08	7.81e-06	-0.19	-0.17	Coronary artery calcification;	chr14:88471879	chr14:88551597~88552493:+
BRCA	cis	rs8031584	0.958	rs3512	ENSG00000270015.1	RP11-540B6.6	-5.45	6.14e-08	7.81e-06	-0.18	-0.17	Huntington's disease progression;	chr15:30942802	chr15:30926514~30928407:+
BRCA	cis	rs8114671	0.562	rs6088655	ENSG00000269202.1	RP4-614O4.12	-5.45	6.14e-08	7.82e-06	-0.17	-0.17	Height;	chr20:34940035	chr20:35201747~35203288:-
BRCA	cis	rs4908768	0.539	rs6663123	ENSG00000270282.1	RP5-1115A15.2	5.45	6.14e-08	7.82e-06	0.18	0.17	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8582872	chr1:8512653~8513021:+
BRCA	cis	rs62025270	0.632	rs10520594	ENSG00000202081.1	RNU6-1280P	5.45	6.15e-08	7.83e-06	0.25	0.17	Idiopathic pulmonary fibrosis;	chr15:85585410	chr15:85651522~85651628:-
BRCA	cis	rs3213958	0.574	rs73136048	ENSG00000249274.1	PDLIM1P4	-5.45	6.15e-08	7.83e-06	-0.25	-0.17	Blood protein levels;	chr3:98785923	chr3:98782188~98783193:+
BRCA	cis	rs1552244	0.882	rs3755783	ENSG00000232901.1	CYCSP10	5.45	6.15e-08	7.83e-06	0.25	0.17	Alzheimer's disease;	chr3:9987605	chr3:10000647~10000940:-
BRCA	cis	rs1861628	1	rs1861628	ENSG00000229352.1	AC007563.3	5.45	6.15e-08	7.83e-06	0.21	0.17	Serum thyroid-stimulating hormone levels;Hypothyroidism;	chr2:216763707	chr2:216799608~216805335:+
BRCA	cis	rs6832769	0.961	rs2177127	ENSG00000223305.1	RN7SKP30	5.45	6.16e-08	7.84e-06	0.21	0.17	Personality dimensions;	chr4:55513792	chr4:55540502~55540835:-
BRCA	cis	rs1005277	0.579	rs1740735	ENSG00000263064.2	RP11-291L22.7	5.45	6.16e-08	7.84e-06	0.2	0.17	Extrinsic epigenetic age acceleration;	chr10:38208849	chr10:38448689~38448949:+
BRCA	cis	rs7914558	0.966	rs10450373	ENSG00000236937.2	PTGES3P4	5.45	6.16e-08	7.84e-06	0.21	0.17	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102968859	chr10:102845595~102845950:+
BRCA	cis	rs7914558	0.966	rs2065977	ENSG00000236937.2	PTGES3P4	5.45	6.16e-08	7.84e-06	0.21	0.17	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102969658	chr10:102845595~102845950:+
BRCA	cis	rs7914558	0.966	rs12569617	ENSG00000236937.2	PTGES3P4	5.45	6.16e-08	7.84e-06	0.21	0.17	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102970239	chr10:102845595~102845950:+
BRCA	cis	rs7914558	0.933	rs1538204	ENSG00000236937.2	PTGES3P4	5.45	6.16e-08	7.84e-06	0.21	0.17	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102974136	chr10:102845595~102845950:+
BRCA	cis	rs2638953	0.889	rs11049481	ENSG00000247934.4	RP11-967K21.1	-5.45	6.16e-08	7.84e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28252087	chr12:28163298~28190738:-
BRCA	cis	rs3733585	0.699	rs6449172	ENSG00000250413.1	RP11-448G15.1	5.45	6.17e-08	7.85e-06	0.22	0.17	Cleft plate (environmental tobacco smoke interaction);	chr4:9964412	chr4:10006482~10009725:+
BRCA	cis	rs2274273	0.564	rs10140164	ENSG00000258413.1	RP11-665C16.6	-5.45	6.17e-08	7.85e-06	-0.21	-0.17	Protein biomarker;	chr14:54939405	chr14:55262767~55272075:-
BRCA	cis	rs793571	0.554	rs12441313	ENSG00000259250.1	RP11-50C13.1	-5.45	6.17e-08	7.85e-06	-0.3	-0.17	Schizophrenia;	chr15:58723289	chr15:58587507~58591676:+
BRCA	cis	rs11671005	0.695	rs11673069	ENSG00000252334.1	RNU6-1337P	5.45	6.17e-08	7.85e-06	0.25	0.17	Mean platelet volume;	chr19:58423551	chr19:58483749~58483843:-
BRCA	cis	rs11159086	1	rs58384818	ENSG00000270000.1	RP3-449M8.9	5.45	6.17e-08	7.86e-06	0.27	0.17	Advanced glycation end-product levels;	chr14:74487045	chr14:74471930~74472360:-
BRCA	cis	rs11159086	1	rs17100588	ENSG00000270000.1	RP3-449M8.9	5.45	6.17e-08	7.86e-06	0.27	0.17	Advanced glycation end-product levels;	chr14:74487624	chr14:74471930~74472360:-
BRCA	cis	rs9307551	0.584	rs1371996	ENSG00000250334.4	LINC00989	-5.45	6.17e-08	7.86e-06	-0.23	-0.17	Refractive error;	chr4:79532718	chr4:79492416~79576460:+
BRCA	cis	rs9307551	0.584	rs12502224	ENSG00000250334.4	LINC00989	-5.45	6.18e-08	7.87e-06	-0.23	-0.17	Refractive error;	chr4:79551688	chr4:79492416~79576460:+
BRCA	cis	rs875971	0.502	rs6460311	ENSG00000228409.4	CCT6P1	5.45	6.19e-08	7.88e-06	0.17	0.17	Aortic root size;	chr7:66646886	chr7:65751142~65763354:+
BRCA	cis	rs2153535	0.58	rs1414348	ENSG00000251164.1	HULC	-5.45	6.2e-08	7.89e-06	-0.2	-0.17	Motion sickness;	chr6:8471707	chr6:8652137~8653846:+
BRCA	cis	rs3740713	1	rs60376560	ENSG00000256464.1	YWHABP2	5.45	6.2e-08	7.89e-06	0.29	0.17	Amyotrophic lateral sclerosis (sporadic);	chr11:18432195	chr11:18490243~18490955:-
BRCA	cis	rs7577696	0.695	rs6717209	ENSG00000272716.1	RP11-563N4.1	-5.45	6.2e-08	7.89e-06	-0.18	-0.17	Inflammatory biomarkers;	chr2:32168880	chr2:32165046~32165757:-
BRCA	cis	rs997295	0.57	rs737226	ENSG00000270964.1	RP11-502I4.3	-5.45	6.2e-08	7.89e-06	-0.18	-0.17	Motion sickness;	chr15:67548435	chr15:67541072~67542604:-
BRCA	cis	rs597539	0.652	rs592697	ENSG00000261625.1	RP11-554A11.4	-5.45	6.21e-08	7.9e-06	-0.16	-0.17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68882596	chr11:69000765~69002048:-
BRCA	cis	rs597539	0.652	rs654071	ENSG00000261625.1	RP11-554A11.4	-5.45	6.21e-08	7.9e-06	-0.16	-0.17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68885964	chr11:69000765~69002048:-
BRCA	cis	rs34217772	0.622	rs61990342	ENSG00000258636.1	CTD-2298J14.2	5.45	6.21e-08	7.9e-06	0.23	0.17	Myopia;	chr14:41719148	chr14:41587861~41604856:-
BRCA	cis	rs34217772	0.68	rs17181615	ENSG00000258636.1	CTD-2298J14.2	5.45	6.21e-08	7.9e-06	0.23	0.17	Myopia;	chr14:41719296	chr14:41587861~41604856:-
BRCA	cis	rs34217772	0.68	rs72686528	ENSG00000258636.1	CTD-2298J14.2	5.45	6.21e-08	7.9e-06	0.23	0.17	Myopia;	chr14:41721738	chr14:41587861~41604856:-
BRCA	cis	rs910316	0.967	rs11624893	ENSG00000279594.1	RP11-950C14.10	-5.45	6.21e-08	7.9e-06	-0.18	-0.17	Height;	chr14:75193421	chr14:75011269~75012851:-
BRCA	cis	rs7178375	0.941	rs4779796	ENSG00000270015.1	RP11-540B6.6	5.45	6.21e-08	7.9e-06	0.21	0.17	Hypertriglyceridemia;	chr15:30915847	chr15:30926514~30928407:+
BRCA	cis	rs11098499	0.754	rs17595608	ENSG00000249244.1	RP11-548H18.2	5.45	6.21e-08	7.91e-06	0.19	0.17	Corneal astigmatism;	chr4:119329351	chr4:119391831~119395335:-
BRCA	cis	rs11009175	0.556	rs7072034	ENSG00000273038.2	RP11-479G22.8	-5.45	6.21e-08	7.91e-06	-0.22	-0.17	Depression (quantitative trait);	chr10:33009689	chr10:32887255~32889311:-
BRCA	cis	rs7474896	0.537	rs2472149	ENSG00000120555.12	SEPT7P9	-5.45	6.22e-08	7.91e-06	-0.23	-0.17	Obesity (extreme);	chr10:37973268	chr10:38383069~38402916:-
BRCA	cis	rs10208649	0.808	rs11886366	ENSG00000233266.1	HMGB1P31	5.45	6.22e-08	7.91e-06	0.39	0.17	Body mass index;	chr2:53997126	chr2:54051334~54051760:+
BRCA	cis	rs17685	0.712	rs1859792	ENSG00000280388.1	RP11-229D13.3	-5.45	6.22e-08	7.91e-06	-0.17	-0.17	Coffee consumption (cups per day);Coffee consumption;	chr7:76159946	chr7:76043977~76045963:-
BRCA	cis	rs793571	0.554	rs2414608	ENSG00000259250.1	RP11-50C13.1	-5.45	6.22e-08	7.91e-06	-0.3	-0.17	Schizophrenia;	chr15:58731413	chr15:58587507~58591676:+
BRCA	cis	rs793571	0.554	rs12900343	ENSG00000259250.1	RP11-50C13.1	-5.45	6.22e-08	7.91e-06	-0.3	-0.17	Schizophrenia;	chr15:58731507	chr15:58587507~58591676:+
BRCA	cis	rs12439619	1	rs35152457	ENSG00000276710.3	CSPG4P8	-5.45	6.22e-08	7.92e-06	-0.19	-0.17	Intelligence (multi-trait analysis);	chr15:82254207	chr15:82459472~82477258:+
BRCA	cis	rs2790457	0.958	rs2772432	ENSG00000254635.4	WAC-AS1	-5.45	6.22e-08	7.92e-06	-0.2	-0.17	Multiple myeloma;	chr10:28605366	chr10:28522652~28532743:-
BRCA	cis	rs17772222	0.637	rs879932	ENSG00000258789.1	RP11-507K2.3	-5.45	6.23e-08	7.92e-06	-0.19	-0.17	Coronary artery calcification;	chr14:88479247	chr14:88551597~88552493:+
BRCA	cis	rs9300255	0.77	rs28683528	ENSG00000235423.7	RP11-282O18.3	-5.45	6.23e-08	7.93e-06	-0.21	-0.17	Neutrophil percentage of white cells;	chr12:123360804	chr12:123252030~123261483:-
BRCA	cis	rs11671005	0.57	rs73062110	ENSG00000252334.1	RNU6-1337P	5.45	6.23e-08	7.93e-06	0.25	0.17	Mean platelet volume;	chr19:58425275	chr19:58483749~58483843:-
BRCA	cis	rs6754311	0.773	rs4988183	ENSG00000224043.6	CCNT2-AS1	-5.45	6.24e-08	7.93e-06	-0.23	-0.17	Mosquito bite size;	chr2:135864476	chr2:134735464~134918710:-
BRCA	cis	rs8054556	0.647	rs4788211	ENSG00000273724.1	RP11-347C12.12	-5.45	6.24e-08	7.93e-06	-0.18	-0.17	Autism spectrum disorder or schizophrenia;	chr16:30004244	chr16:30336400~30343336:+
BRCA	cis	rs113835537	0.935	rs11550057	ENSG00000255517.5	CTD-3074O7.5	-5.45	6.24e-08	7.93e-06	-0.28	-0.17	Airway imaging phenotypes;	chr11:66625409	chr11:66473490~66480233:-
BRCA	cis	rs7044106	0.762	rs12003646	ENSG00000238181.2	AHCYP2	-5.45	6.24e-08	7.94e-06	-0.22	-0.17	Hip circumference adjusted for BMI;	chr9:120708343	chr9:120720673~120721972:+
BRCA	cis	rs7618501	0.633	rs2526748	ENSG00000228008.1	CTD-2330K9.3	-5.45	6.24e-08	7.94e-06	-0.16	-0.17	Intelligence (multi-trait analysis);	chr3:50043006	chr3:49903845~49916937:+
BRCA	cis	rs6088580	0.524	rs2889855	ENSG00000269202.1	RP4-614O4.12	5.45	6.24e-08	7.94e-06	0.17	0.17	Glomerular filtration rate (creatinine);	chr20:34689049	chr20:35201747~35203288:-
BRCA	cis	rs7246657	0.722	rs16958863	ENSG00000276846.1	CTD-3220F14.3	5.45	6.24e-08	7.94e-06	0.22	0.17	Coronary artery calcification;	chr19:37633334	chr19:37314868~37315620:-
BRCA	cis	rs3733585	0.673	rs10000983	ENSG00000250413.1	RP11-448G15.1	5.45	6.24e-08	7.94e-06	0.22	0.17	Cleft plate (environmental tobacco smoke interaction);	chr4:9949982	chr4:10006482~10009725:+
BRCA	cis	rs7267979	0.586	rs6050431	ENSG00000277938.1	RP5-965G21.3	5.45	6.24e-08	7.94e-06	0.2	0.17	Liver enzyme levels (alkaline phosphatase);	chr20:25203272	chr20:25229150~25231933:+
BRCA	cis	rs7267979	0.586	rs6050432	ENSG00000277938.1	RP5-965G21.3	5.45	6.24e-08	7.94e-06	0.2	0.17	Liver enzyme levels (alkaline phosphatase);	chr20:25203392	chr20:25229150~25231933:+
BRCA	cis	rs71636778	0.509	rs74825034	ENSG00000260063.1	RP5-968P14.2	-5.45	6.25e-08	7.94e-06	-0.38	-0.17	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26768641	chr1:26692132~26694131:-
BRCA	cis	rs10510102	0.507	rs12244092	ENSG00000276742.1	RP11-500G22.4	5.45	6.25e-08	7.95e-06	0.29	0.17	Breast cancer;	chr10:122005769	chr10:121956782~121957098:+
BRCA	cis	rs17508449	0.819	rs17031795	ENSG00000232450.1	RP4-730K3.3	-5.45	6.25e-08	7.95e-06	-0.31	-0.17	Leprosy;	chr1:113713206	chr1:113698884~113699631:-
BRCA	cis	rs6570726	0.967	rs6903252	ENSG00000270638.1	RP3-466P17.1	5.45	6.26e-08	7.96e-06	0.19	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145601641	chr6:145735570~145737218:+
BRCA	cis	rs73222236	0.825	rs9853387	ENSG00000273486.1	RP11-731C17.2	5.45	6.26e-08	7.96e-06	0.19	0.17	Coronary artery disease;	chr3:136320146	chr3:136837338~136839021:-
BRCA	cis	rs10129255	0.957	rs10132367	ENSG00000224373.3	IGHV4-59	5.45	6.26e-08	7.96e-06	0.11	0.17	Kawasaki disease;	chr14:106690981	chr14:106627249~106627825:-
BRCA	cis	rs875971	0.862	rs7786892	ENSG00000236529.1	RP13-254B10.1	-5.45	6.26e-08	7.96e-06	-0.18	-0.17	Aortic root size;	chr7:66163889	chr7:65840212~65840596:+
BRCA	cis	rs1979679	0.918	rs2348234	ENSG00000278733.1	RP11-425D17.1	5.45	6.27e-08	7.97e-06	0.21	0.17	Ossification of the posterior longitudinal ligament of the spine;	chr12:28354126	chr12:28185625~28186190:-
BRCA	cis	rs442309	0.551	rs1509966	ENSG00000238280.1	RP11-436D10.3	-5.45	6.27e-08	7.97e-06	-0.22	-0.17	Vogt-Koyanagi-Harada syndrome;	chr10:62792847	chr10:62793562~62805887:-
BRCA	cis	rs6832769	1	rs11133399	ENSG00000223305.1	RN7SKP30	-5.45	6.27e-08	7.98e-06	-0.22	-0.17	Personality dimensions;	chr4:55547664	chr4:55540502~55540835:-
BRCA	cis	rs1555322	0.872	rs2425046	ENSG00000126005.14	MMP24-AS1	-5.45	6.28e-08	7.98e-06	-0.29	-0.17	Attention deficit hyperactivity disorder;	chr20:35283858	chr20:35216462~35278131:-
BRCA	cis	rs2179367	0.881	rs2744432	ENSG00000268592.3	RAET1E-AS1	-5.45	6.28e-08	7.99e-06	-0.21	-0.17	Dupuytren's disease;	chr6:149422735	chr6:149863494~149919507:+
BRCA	cis	rs4950322	0.57	rs11800580	ENSG00000278811.3	LINC00624	-5.45	6.29e-08	7.99e-06	-0.22	-0.17	Protein quantitative trait loci;	chr1:147261053	chr1:147258885~147517875:-
BRCA	cis	rs11955398	0.502	rs158914	ENSG00000215032.2	GNL3LP1	-5.45	6.29e-08	7.99e-06	-0.21	-0.17	Intelligence (multi-trait analysis);	chr5:60950582	chr5:60891935~60893577:-
BRCA	cis	rs867371	0.82	rs12443224	ENSG00000278603.1	RP13-608F4.5	5.45	6.29e-08	7.99e-06	0.22	0.17	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82203269	chr15:82472203~82472426:+
BRCA	cis	rs300890	0.513	rs7673827	ENSG00000250326.1	RP11-284M14.1	-5.45	6.29e-08	7.99e-06	-0.2	-0.17	Nasopharyngeal carcinoma;	chr4:143222187	chr4:142933195~143184861:-
BRCA	cis	rs1707322	0.721	rs11211157	ENSG00000234329.1	RP11-767N6.2	5.45	6.29e-08	8e-06	0.17	0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45667172	chr1:45651039~45651826:-
BRCA	cis	rs1707322	0.721	rs11211158	ENSG00000234329.1	RP11-767N6.2	5.45	6.29e-08	8e-06	0.17	0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45667178	chr1:45651039~45651826:-
BRCA	cis	rs1707322	0.721	rs6429575	ENSG00000234329.1	RP11-767N6.2	5.45	6.29e-08	8e-06	0.17	0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45668544	chr1:45651039~45651826:-
BRCA	cis	rs7620503	1	rs6806363	ENSG00000228221.4	LINC00578	5.45	6.29e-08	8e-06	0.19	0.17	Corneal structure;	chr3:177576293	chr3:177441921~177752305:+
BRCA	cis	rs7208859	0.524	rs73988172	ENSG00000280069.1	CTD-2349P21.3	-5.45	6.3e-08	8.01e-06	-0.23	-0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759314	chr17:30738182~30740275:+
BRCA	cis	rs7308116	0.546	rs1895927	ENSG00000274395.1	RP11-554D14.8	-5.45	6.3e-08	8.01e-06	-0.2	-0.17	Pelvic organ prolapse (moderate/severe);	chr12:107833398	chr12:107835541~107836555:-
BRCA	cis	rs7308116	0.565	rs2888907	ENSG00000274395.1	RP11-554D14.8	-5.45	6.3e-08	8.01e-06	-0.2	-0.17	Pelvic organ prolapse (moderate/severe);	chr12:107833452	chr12:107835541~107836555:-
BRCA	cis	rs7927592	0.956	rs7124078	ENSG00000212093.1	AP000807.1	5.45	6.3e-08	8.01e-06	0.19	0.17	Total body bone mineral density;	chr11:68531165	chr11:68506083~68506166:-
BRCA	cis	rs13113518	1	rs4864548	ENSG00000223305.1	RN7SKP30	-5.45	6.31e-08	8.02e-06	-0.2	-0.17	Height;	chr4:55547636	chr4:55540502~55540835:-
BRCA	cis	rs1440410	0.571	rs7675127	ENSG00000250326.1	RP11-284M14.1	5.45	6.31e-08	8.02e-06	0.2	0.17	Ischemic stroke;	chr4:143119916	chr4:142933195~143184861:-
BRCA	cis	rs3213958	0.621	rs73138053	ENSG00000249274.1	PDLIM1P4	-5.45	6.31e-08	8.02e-06	-0.25	-0.17	Blood protein levels;	chr3:98876058	chr3:98782188~98783193:+
BRCA	cis	rs10129255	0.872	rs8015406	ENSG00000280411.1	IGHV1-69-2	-5.45	6.32e-08	8.03e-06	-0.13	-0.17	Kawasaki disease;	chr14:106670611	chr14:106762092~106762588:-
BRCA	cis	rs1167832	0.645	rs1167829	ENSG00000278416.1	PMS2L2	-5.45	6.32e-08	8.03e-06	-0.27	-0.17	Ankle injury;	chr7:75535697	chr7:75344015~75359550:-
BRCA	cis	rs1223397	0.938	rs3817737	ENSG00000215022.6	RP1-257A7.4	-5.45	6.32e-08	8.03e-06	-0.23	-0.17	Blood pressure;	chr6:13278850	chr6:13264861~13295586:-
BRCA	cis	rs9840812	0.645	rs9883916	ENSG00000239213.4	NCK1-AS1	5.45	6.32e-08	8.04e-06	0.22	0.17	Fibrinogen levels;	chr3:136489946	chr3:136841726~136862054:-
BRCA	cis	rs2692947	0.794	rs2692949	ENSG00000237510.6	AC008268.2	5.45	6.33e-08	8.04e-06	0.23	0.17	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96007777	chr2:95789654~95800166:+
BRCA	cis	rs17711722	0.727	rs2658585	ENSG00000273024.4	INTS4P2	-5.45	6.33e-08	8.04e-06	-0.18	-0.17	Calcium levels;	chr7:65996954	chr7:65647864~65715661:+
BRCA	cis	rs4819052	0.851	rs8126930	ENSG00000184274.3	LINC00315	-5.45	6.33e-08	8.04e-06	-0.22	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251800	chr21:45300245~45305257:-
BRCA	cis	rs2638953	0.85	rs10843167	ENSG00000278733.1	RP11-425D17.1	-5.45	6.33e-08	8.05e-06	-0.22	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28429860	chr12:28185625~28186190:-
BRCA	cis	rs2153535	0.58	rs9378551	ENSG00000251164.1	HULC	-5.45	6.33e-08	8.05e-06	-0.2	-0.17	Motion sickness;	chr6:8463511	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.58	rs9378552	ENSG00000251164.1	HULC	-5.45	6.33e-08	8.05e-06	-0.2	-0.17	Motion sickness;	chr6:8463515	chr6:8652137~8653846:+
BRCA	cis	rs7044106	0.537	rs10818474	ENSG00000238181.2	AHCYP2	-5.45	6.34e-08	8.05e-06	-0.22	-0.17	Hip circumference adjusted for BMI;	chr9:120727686	chr9:120720673~120721972:+
BRCA	cis	rs6496044	0.568	rs4842888	ENSG00000259295.5	CSPG4P12	-5.45	6.34e-08	8.05e-06	-0.2	-0.17	Interstitial lung disease;	chr15:85519902	chr15:85191438~85213905:+
BRCA	cis	rs6490294	0.904	rs2339908	ENSG00000226469.1	ADAM1B	5.45	6.34e-08	8.05e-06	0.22	0.17	Mean platelet volume;	chr12:111980692	chr12:111927018~111929017:+
BRCA	cis	rs7246657	0.678	rs2927740	ENSG00000276846.1	CTD-3220F14.3	-5.45	6.34e-08	8.06e-06	-0.22	-0.17	Coronary artery calcification;	chr19:37650065	chr19:37314868~37315620:-
BRCA	cis	rs2367725	1	rs2367725	ENSG00000237950.1	RP11-7O11.3	5.45	6.35e-08	8.06e-06	0.19	0.17	Aging (time to event);	chr1:43750157	chr1:43944370~43946551:-
BRCA	cis	rs2562456	0.839	rs2562411	ENSG00000268535.1	RP11-420K14.3	5.45	6.35e-08	8.07e-06	0.24	0.17	Pain;	chr19:21419181	chr19:21709522~21710191:+
BRCA	cis	rs2562456	0.876	rs2562413	ENSG00000268535.1	RP11-420K14.3	5.45	6.35e-08	8.07e-06	0.24	0.17	Pain;	chr19:21420084	chr19:21709522~21710191:+
BRCA	cis	rs2562456	0.916	rs1967182	ENSG00000268535.1	RP11-420K14.3	5.45	6.35e-08	8.07e-06	0.24	0.17	Pain;	chr19:21420337	chr19:21709522~21710191:+
BRCA	cis	rs13126694	0.744	rs6821252	ENSG00000248429.4	RP11-597D13.9	5.45	6.36e-08	8.08e-06	0.15	0.17	Blood osmolality (transformed sodium);	chr4:158076296	chr4:158170752~158202877:+
BRCA	cis	rs11098499	0.754	rs66900435	ENSG00000249244.1	RP11-548H18.2	5.45	6.36e-08	8.08e-06	0.19	0.17	Corneal astigmatism;	chr4:119328270	chr4:119391831~119395335:-
BRCA	cis	rs12701220	0.847	rs10272002	ENSG00000229043.2	AC091729.9	-5.45	6.36e-08	8.08e-06	-0.26	-0.17	Bronchopulmonary dysplasia;	chr7:1007979	chr7:1160374~1165267:+
BRCA	cis	rs867371	0.656	rs2665103	ENSG00000255769.6	GOLGA2P10	5.45	6.36e-08	8.08e-06	0.18	0.17	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82140374	chr15:82472993~82513950:-
BRCA	cis	rs2018683	1	rs160837	ENSG00000228421.2	AC005013.5	5.45	6.37e-08	8.09e-06	0.2	0.17	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28973116	chr7:28957667~28959345:+
BRCA	cis	rs4713118	0.662	rs156744	ENSG00000280107.1	AL022393.9	-5.45	6.38e-08	8.1e-06	-0.25	-0.17	Parkinson's disease;	chr6:27999496	chr6:28170845~28172521:+
BRCA	cis	rs4713118	0.662	rs149947	ENSG00000280107.1	AL022393.9	-5.45	6.38e-08	8.1e-06	-0.25	-0.17	Parkinson's disease;	chr6:28004655	chr6:28170845~28172521:+
BRCA	cis	rs1823913	0.538	rs13432697	ENSG00000280083.1	RP11-317J9.1	-5.45	6.38e-08	8.1e-06	-0.19	-0.17	Obesity-related traits;	chr2:191345944	chr2:191154118~191156070:-
BRCA	cis	rs6700559	0.74	rs11582610	ENSG00000260088.1	RP11-92G12.3	5.45	6.39e-08	8.11e-06	0.2	0.17	Coronary artery disease;	chr1:200675973	chr1:200669507~200694250:+
BRCA	cis	rs2281558	0.876	rs12625157	ENSG00000230772.1	VN1R108P	-5.45	6.39e-08	8.12e-06	-0.22	-0.17	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25364913	chr20:25734264~25735093:+
BRCA	cis	rs8103278	0.507	rs3745802	ENSG00000267395.4	AC074212.6	-5.45	6.4e-08	8.12e-06	-0.17	-0.17	Coronary artery disease;	chr19:45767919	chr19:45767796~45772504:+
BRCA	cis	rs2243480	1	rs6958289	ENSG00000228409.4	CCT6P1	-5.45	6.4e-08	8.13e-06	-0.23	-0.17	Diabetic kidney disease;	chr7:66192124	chr7:65751142~65763354:+
BRCA	cis	rs2153535	0.58	rs7753192	ENSG00000251164.1	HULC	-5.45	6.41e-08	8.14e-06	-0.2	-0.17	Motion sickness;	chr6:8482404	chr6:8652137~8653846:+
BRCA	cis	rs17253792	0.545	rs12894368	ENSG00000186615.9	KTN1-AS1	-5.45	6.41e-08	8.14e-06	-0.34	-0.17	Putamen volume;	chr14:55558460	chr14:55499278~55580110:-
BRCA	cis	rs7044106	0.791	rs12554440	ENSG00000238181.2	AHCYP2	-5.45	6.41e-08	8.14e-06	-0.22	-0.17	Hip circumference adjusted for BMI;	chr9:120723055	chr9:120720673~120721972:+
BRCA	cis	rs17772222	0.682	rs3783889	ENSG00000258789.1	RP11-507K2.3	-5.45	6.41e-08	8.14e-06	-0.19	-0.17	Coronary artery calcification;	chr14:88475637	chr14:88551597~88552493:+
BRCA	cis	rs4835473	0.864	rs57137521	ENSG00000249741.2	RP11-673E1.3	5.45	6.42e-08	8.15e-06	0.18	0.17	Immature fraction of reticulocytes;	chr4:143704045	chr4:143911514~143912053:-
BRCA	cis	rs9425766	0.679	rs4650990	ENSG00000227373.4	RP11-160H22.5	5.45	6.42e-08	8.15e-06	0.22	0.17	Life satisfaction;	chr1:174289943	chr1:174115300~174160004:-
BRCA	cis	rs7131987	0.65	rs10843382	ENSG00000275476.1	RP11-996F15.4	-5.45	6.42e-08	8.16e-06	-0.2	-0.17	QT interval;	chr12:29298788	chr12:29277397~29277882:-
BRCA	cis	rs4604234	0.614	rs73477975	ENSG00000272129.1	RP11-250B2.6	-5.45	6.43e-08	8.16e-06	-0.43	-0.17	Cancer;	chr6:80108235	chr6:80355424~80356859:+
BRCA	cis	rs4604234	0.614	rs73477985	ENSG00000272129.1	RP11-250B2.6	-5.45	6.43e-08	8.16e-06	-0.43	-0.17	Cancer;	chr6:80111153	chr6:80355424~80356859:+
BRCA	cis	rs910316	0.737	rs175499	ENSG00000279594.1	RP11-950C14.10	-5.45	6.43e-08	8.16e-06	-0.19	-0.17	Height;	chr14:75069224	chr14:75011269~75012851:-
BRCA	cis	rs6832769	0.961	rs11735267	ENSG00000223305.1	RN7SKP30	5.45	6.43e-08	8.16e-06	0.21	0.17	Personality dimensions;	chr4:55481120	chr4:55540502~55540835:-
BRCA	cis	rs42490	0.652	rs374957	ENSG00000251136.7	RP11-37B2.1	-5.45	6.43e-08	8.16e-06	-0.16	-0.17	Leprosy;	chr8:89825402	chr8:89609409~89757727:-
BRCA	cis	rs7200543	1	rs6498540	ENSG00000275910.1	RP11-680G24.6	-5.45	6.43e-08	8.17e-06	-0.2	-0.17	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15036737	chr16:15015828~15016390:-
BRCA	cis	rs4535700	0.501	rs6943341	ENSG00000226278.1	PSPHP1	5.45	6.44e-08	8.18e-06	0.19	0.17	Macular telangiectasia type 2;	chr7:55907489	chr7:55764797~55773288:+
BRCA	cis	rs1440410	0.795	rs724517	ENSG00000250326.1	RP11-284M14.1	-5.45	6.45e-08	8.18e-06	-0.18	-0.17	Ischemic stroke;	chr4:143275383	chr4:142933195~143184861:-
BRCA	cis	rs848490	0.615	rs2428939	ENSG00000214293.7	APTR	-5.45	6.45e-08	8.19e-06	-0.19	-0.17	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77932977	chr7:77657660~77696265:-
BRCA	cis	rs710913	0.717	rs2243761	ENSG00000228060.1	RP11-69E11.8	5.45	6.45e-08	8.19e-06	0.16	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39585944	chr1:39565160~39573203:+
BRCA	cis	rs934734	0.532	rs2028151	ENSG00000204929.10	AC074391.1	-5.45	6.45e-08	8.19e-06	-0.2	-0.17	Rheumatoid arthritis;	chr2:65428479	chr2:65436711~66084639:+
BRCA	cis	rs10911232	0.56	rs6697320	ENSG00000224468.3	RP11-181K3.4	-5.45	6.46e-08	8.19e-06	-0.18	-0.17	Hypertriglyceridemia;	chr1:183068242	chr1:183138402~183141282:-
BRCA	cis	rs4950322	0.518	rs55697094	ENSG00000244371.2	PFN1P8	-5.45	6.46e-08	8.2e-06	-0.22	-0.17	Protein quantitative trait loci;	chr1:147121205	chr1:146957117~146957659:-
BRCA	cis	rs2834188	0.924	rs6517159	ENSG00000272659.1	AP000295.10	-5.44	6.47e-08	8.21e-06	-0.24	-0.17	Narcolepsy;	chr21:33301095	chr21:33309491~33310181:+
BRCA	cis	rs17508449	0.819	rs77042378	ENSG00000232450.1	RP4-730K3.3	-5.44	6.47e-08	8.21e-06	-0.28	-0.17	Leprosy;	chr1:113666479	chr1:113698884~113699631:-
BRCA	cis	rs227932	0.681	rs79586340	ENSG00000234286.1	AC006026.13	-5.44	6.47e-08	8.21e-06	-0.29	-0.17	Schizophrenia;	chr7:23746122	chr7:23680195~23680786:-
BRCA	cis	rs227932	0.681	rs75405201	ENSG00000234286.1	AC006026.13	-5.44	6.47e-08	8.21e-06	-0.29	-0.17	Schizophrenia;	chr7:23746123	chr7:23680195~23680786:-
BRCA	cis	rs7267979	0.586	rs6050429	ENSG00000277938.1	RP5-965G21.3	5.44	6.47e-08	8.21e-06	0.2	0.17	Liver enzyme levels (alkaline phosphatase);	chr20:25202422	chr20:25229150~25231933:+
BRCA	cis	rs507080	0.885	rs533144	ENSG00000278376.1	RP11-158I9.8	-5.44	6.47e-08	8.21e-06	-0.17	-0.17	Serum metabolite levels;	chr11:118688538	chr11:118791254~118793137:+
BRCA	cis	rs2243480	1	rs1546059	ENSG00000228409.4	CCT6P1	-5.44	6.47e-08	8.21e-06	-0.23	-0.17	Diabetic kidney disease;	chr7:66189722	chr7:65751142~65763354:+
BRCA	cis	rs2243480	1	rs2420170	ENSG00000228409.4	CCT6P1	-5.44	6.47e-08	8.21e-06	-0.23	-0.17	Diabetic kidney disease;	chr7:66191066	chr7:65751142~65763354:+
BRCA	cis	rs7131987	0.65	rs67146951	ENSG00000275476.1	RP11-996F15.4	-5.44	6.47e-08	8.21e-06	-0.2	-0.17	QT interval;	chr12:29297620	chr12:29277397~29277882:-
BRCA	cis	rs5758511	0.68	rs739146	ENSG00000233903.2	Z83851.4	5.44	6.47e-08	8.22e-06	0.25	0.17	Birth weight;	chr22:42264408	chr22:42276355~42277052:+
BRCA	cis	rs10510102	1	rs10510102	ENSG00000226864.1	ATE1-AS1	-5.44	6.49e-08	8.24e-06	-0.28	-0.17	Breast cancer;	chr10:121865675	chr10:121928312~121951965:+
BRCA	cis	rs4535700	0.501	rs28828764	ENSG00000226278.1	PSPHP1	5.44	6.5e-08	8.25e-06	0.19	0.17	Macular telangiectasia type 2;	chr7:55920986	chr7:55764797~55773288:+
BRCA	cis	rs4834770	1	rs4834770	ENSG00000249244.1	RP11-548H18.2	5.44	6.5e-08	8.25e-06	0.18	0.17	Blood protein levels;	chr4:119320694	chr4:119391831~119395335:-
BRCA	cis	rs17214007	0.597	rs11649126	ENSG00000263335.1	AF001548.5	-5.44	6.5e-08	8.25e-06	-0.27	-0.17	Cognitive function;	chr16:15626390	chr16:15726674~15732993:+
BRCA	cis	rs9467773	0.935	rs11752946	ENSG00000124549.13	BTN2A3P	5.44	6.5e-08	8.25e-06	0.18	0.17	Intelligence (multi-trait analysis);	chr6:26560136	chr6:26421391~26432383:+
BRCA	cis	rs71636778	0.509	rs12731749	ENSG00000260063.1	RP5-968P14.2	-5.44	6.5e-08	8.25e-06	-0.38	-0.17	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26759071	chr1:26692132~26694131:-
BRCA	cis	rs71636778	0.509	rs34885854	ENSG00000260063.1	RP5-968P14.2	-5.44	6.5e-08	8.25e-06	-0.38	-0.17	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26759758	chr1:26692132~26694131:-
BRCA	cis	rs71636778	0.509	rs71636777	ENSG00000260063.1	RP5-968P14.2	-5.44	6.5e-08	8.25e-06	-0.38	-0.17	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26761777	chr1:26692132~26694131:-
BRCA	cis	rs71636778	0.509	rs34681611	ENSG00000260063.1	RP5-968P14.2	-5.44	6.5e-08	8.25e-06	-0.38	-0.17	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26762955	chr1:26692132~26694131:-
BRCA	cis	rs875971	0.66	rs801192	ENSG00000273024.4	INTS4P2	5.44	6.51e-08	8.25e-06	0.18	0.17	Aortic root size;	chr7:66566965	chr7:65647864~65715661:+
BRCA	cis	rs875971	0.66	rs801190	ENSG00000273024.4	INTS4P2	5.44	6.51e-08	8.25e-06	0.18	0.17	Aortic root size;	chr7:66568046	chr7:65647864~65715661:+
BRCA	cis	rs875971	0.66	rs3857686	ENSG00000273024.4	INTS4P2	5.44	6.51e-08	8.25e-06	0.18	0.17	Aortic root size;	chr7:66571204	chr7:65647864~65715661:+
BRCA	cis	rs2243480	1	rs160634	ENSG00000232559.3	GS1-124K5.12	-5.44	6.51e-08	8.26e-06	-0.3	-0.17	Diabetic kidney disease;	chr7:66063677	chr7:66554588~66576923:-
BRCA	cis	rs2243480	1	rs1979823	ENSG00000228409.4	CCT6P1	-5.44	6.52e-08	8.26e-06	-0.23	-0.17	Diabetic kidney disease;	chr7:66239626	chr7:65751142~65763354:+
BRCA	cis	rs7824557	0.606	rs2736264	ENSG00000154316.13	TDH	-5.44	6.52e-08	8.26e-06	-0.21	-0.17	Retinal vascular caliber;	chr8:11329130	chr8:11339637~11368452:+
BRCA	cis	rs7621025	0.691	rs9845762	ENSG00000273486.1	RP11-731C17.2	5.44	6.52e-08	8.27e-06	0.19	0.17	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136637622	chr3:136837338~136839021:-
BRCA	cis	rs4919687	0.577	rs12765459	ENSG00000213061.2	PFN1P11	5.44	6.52e-08	8.27e-06	0.26	0.17	Colorectal cancer;	chr10:102705930	chr10:102838011~102845473:-
BRCA	cis	rs7927592	0.913	rs7106339	ENSG00000212093.1	AP000807.1	5.44	6.52e-08	8.27e-06	0.19	0.17	Total body bone mineral density;	chr11:68472773	chr11:68506083~68506166:-
BRCA	cis	rs4835473	0.868	rs13105118	ENSG00000249741.2	RP11-673E1.3	5.44	6.52e-08	8.27e-06	0.18	0.17	Immature fraction of reticulocytes;	chr4:143819077	chr4:143911514~143912053:-
BRCA	cis	rs10946940	0.93	rs10807029	ENSG00000216901.1	AL022393.7	-5.44	6.52e-08	8.27e-06	-0.21	-0.17	Systemic lupus erythematosus;	chr6:27605684	chr6:28176188~28176674:+
BRCA	cis	rs4835473	0.932	rs11734290	ENSG00000249741.2	RP11-673E1.3	5.44	6.53e-08	8.28e-06	0.18	0.17	Immature fraction of reticulocytes;	chr4:143823636	chr4:143911514~143912053:-
BRCA	cis	rs4835473	0.932	rs11734383	ENSG00000249741.2	RP11-673E1.3	5.44	6.53e-08	8.28e-06	0.18	0.17	Immature fraction of reticulocytes;	chr4:143824093	chr4:143911514~143912053:-
BRCA	cis	rs4835473	0.868	rs11735295	ENSG00000249741.2	RP11-673E1.3	5.44	6.53e-08	8.28e-06	0.18	0.17	Immature fraction of reticulocytes;	chr4:143824150	chr4:143911514~143912053:-
BRCA	cis	rs9467773	1	rs6456733	ENSG00000124549.13	BTN2A3P	5.44	6.53e-08	8.28e-06	0.17	0.17	Intelligence (multi-trait analysis);	chr6:26566576	chr6:26421391~26432383:+
BRCA	cis	rs16846053	0.642	rs1449637	ENSG00000227403.1	AC009299.3	5.44	6.53e-08	8.28e-06	0.28	0.17	Blood osmolality (transformed sodium);	chr2:161819440	chr2:161244739~161249050:+
BRCA	cis	rs9300255	0.602	rs1106240	ENSG00000235423.7	RP11-282O18.3	5.44	6.54e-08	8.29e-06	0.23	0.17	Neutrophil percentage of white cells;	chr12:123142435	chr12:123252030~123261483:-
BRCA	cis	rs6545883	0.525	rs1729662	ENSG00000212978.6	AC016747.3	5.44	6.54e-08	8.29e-06	0.22	0.17	Tuberculosis;	chr2:61164170	chr2:61141592~61144969:-
BRCA	cis	rs9315786	0.924	rs7323436	ENSG00000239827.7	SUGT1P3	5.44	6.54e-08	8.3e-06	0.19	0.17	Neutrophil percentage of granulocytes;	chr13:40776843	chr13:40908159~40921774:-
BRCA	cis	rs6969780	1	rs6461985	ENSG00000233429.8	HOTAIRM1	5.44	6.55e-08	8.3e-06	0.21	0.17	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27111015	chr7:27095647~27100265:+
BRCA	cis	rs1552244	1	rs6786638	ENSG00000232901.1	CYCSP10	5.44	6.55e-08	8.3e-06	0.23	0.17	Alzheimer's disease;	chr3:10076391	chr3:10000647~10000940:-
BRCA	cis	rs2732480	0.557	rs2732454	ENSG00000240399.1	RP1-228P16.1	5.44	6.55e-08	8.3e-06	0.19	0.17	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48325894	chr12:48054813~48055591:-
BRCA	cis	rs6832769	1	rs10016506	ENSG00000223305.1	RN7SKP30	-5.44	6.55e-08	8.3e-06	-0.21	-0.17	Personality dimensions;	chr4:55530507	chr4:55540502~55540835:-
BRCA	cis	rs7927592	1	rs7927592	ENSG00000212093.1	AP000807.1	5.44	6.55e-08	8.31e-06	0.19	0.17	Total body bone mineral density;	chr11:68602492	chr11:68506083~68506166:-
BRCA	cis	rs673078	0.66	rs16948197	ENSG00000275409.1	RP11-131L12.4	5.44	6.55e-08	8.31e-06	0.25	0.17	Glucose homeostasis traits;	chr12:118239135	chr12:118430147~118430699:+
BRCA	cis	rs7308116	0.546	rs11113528	ENSG00000274395.1	RP11-554D14.8	5.44	6.56e-08	8.31e-06	0.19	0.17	Pelvic organ prolapse (moderate/severe);	chr12:107831117	chr12:107835541~107836555:-
BRCA	cis	rs1707322	0.721	rs61784800	ENSG00000234329.1	RP11-767N6.2	-5.44	6.56e-08	8.32e-06	-0.17	-0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45712440	chr1:45651039~45651826:-
BRCA	cis	rs2790457	0.958	rs1265829	ENSG00000254635.4	WAC-AS1	-5.44	6.56e-08	8.32e-06	-0.2	-0.17	Multiple myeloma;	chr10:28622374	chr10:28522652~28532743:-
BRCA	cis	rs9921338	0.54	rs2868409	ENSG00000263080.1	RP11-485G7.5	5.44	6.56e-08	8.32e-06	0.21	0.17	Vein graft stenosis in coronary artery bypass grafting;	chr16:11323512	chr16:11341809~11345211:-
BRCA	cis	rs11051970	0.527	rs2388989	ENSG00000274964.1	RP11-817I4.1	-5.44	6.57e-08	8.32e-06	-0.22	-0.17	Response to tocilizumab in rheumatoid arthritis;	chr12:32337341	chr12:32339368~32340724:+
BRCA	cis	rs11051970	0.559	rs4604975	ENSG00000274964.1	RP11-817I4.1	-5.44	6.57e-08	8.32e-06	-0.22	-0.17	Response to tocilizumab in rheumatoid arthritis;	chr12:32337441	chr12:32339368~32340724:+
BRCA	cis	rs7824557	0.569	rs35418978	ENSG00000154316.13	TDH	-5.44	6.57e-08	8.33e-06	-0.21	-0.17	Retinal vascular caliber;	chr8:11328944	chr8:11339637~11368452:+
BRCA	cis	rs9545047	0.604	rs7331867	ENSG00000227354.5	RBM26-AS1	-5.44	6.58e-08	8.34e-06	-0.18	-0.17	Schizophrenia;	chr13:79418791	chr13:79406309~79424328:+
BRCA	cis	rs13113518	0.678	rs7663650	ENSG00000223305.1	RN7SKP30	-5.44	6.58e-08	8.34e-06	-0.2	-0.17	Height;	chr4:55364952	chr4:55540502~55540835:-
BRCA	cis	rs7044106	0.791	rs10985008	ENSG00000238181.2	AHCYP2	-5.44	6.59e-08	8.35e-06	-0.22	-0.17	Hip circumference adjusted for BMI;	chr9:120730682	chr9:120720673~120721972:+
BRCA	cis	rs6565180	0.926	rs4787643	ENSG00000183604.13	SMG1P5	5.44	6.59e-08	8.35e-06	0.18	0.17	Tonsillectomy;	chr16:30382339	chr16:30267553~30335374:-
BRCA	cis	rs6565180	0.926	rs4788409	ENSG00000183604.13	SMG1P5	5.44	6.59e-08	8.35e-06	0.18	0.17	Tonsillectomy;	chr16:30382450	chr16:30267553~30335374:-
BRCA	cis	rs2562456	0.793	rs62110424	ENSG00000268535.1	RP11-420K14.3	5.44	6.59e-08	8.35e-06	0.25	0.17	Pain;	chr19:21416835	chr19:21709522~21710191:+
BRCA	cis	rs4588572	0.644	rs10805920	ENSG00000245556.2	SCAMP1-AS1	-5.44	6.59e-08	8.35e-06	-0.19	-0.17	Triglycerides;	chr5:78402398	chr5:78342365~78360507:-
BRCA	cis	rs7646881	0.812	rs59192661	ENSG00000240207.5	RP11-379F4.4	-5.44	6.59e-08	8.35e-06	-0.26	-0.17	Tetralogy of Fallot;	chr3:158741238	chr3:158732263~158784070:+
BRCA	cis	rs3768617	0.51	rs7518957	ENSG00000224468.3	RP11-181K3.4	5.44	6.59e-08	8.35e-06	0.18	0.17	Fuchs's corneal dystrophy;	chr1:183123893	chr1:183138402~183141282:-
BRCA	cis	rs55692411	0.517	rs13095697	ENSG00000228008.1	CTD-2330K9.3	5.44	6.59e-08	8.35e-06	0.19	0.17	Intelligence (multi-trait analysis);	chr3:50099030	chr3:49903845~49916937:+
BRCA	cis	rs13108904	0.87	rs2279281	ENSG00000254094.1	AC078852.1	-5.44	6.59e-08	8.35e-06	-0.18	-0.17	Obesity-related traits;	chr4:1251489	chr4:1356581~1358075:+
BRCA	cis	rs755249	0.669	rs4660311	ENSG00000182109.6	RP11-69E11.4	5.44	6.6e-08	8.36e-06	0.2	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39613442	chr1:39522280~39546187:-
BRCA	cis	rs2732480	0.5	rs7315820	ENSG00000240399.1	RP1-228P16.1	5.44	6.6e-08	8.36e-06	0.19	0.17	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48205155	chr12:48054813~48055591:-
BRCA	cis	rs2153535	0.601	rs9393030	ENSG00000251164.1	HULC	-5.44	6.6e-08	8.36e-06	-0.2	-0.17	Motion sickness;	chr6:8516256	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.58	rs9328479	ENSG00000251164.1	HULC	-5.44	6.6e-08	8.36e-06	-0.2	-0.17	Motion sickness;	chr6:8519413	chr6:8652137~8653846:+
BRCA	cis	rs300890	0.513	rs6820340	ENSG00000250326.1	RP11-284M14.1	-5.44	6.6e-08	8.36e-06	-0.2	-0.17	Nasopharyngeal carcinoma;	chr4:143199051	chr4:142933195~143184861:-
BRCA	cis	rs300890	0.513	rs4690780	ENSG00000250326.1	RP11-284M14.1	-5.44	6.6e-08	8.36e-06	-0.2	-0.17	Nasopharyngeal carcinoma;	chr4:143202414	chr4:142933195~143184861:-
BRCA	cis	rs300890	0.513	rs7435424	ENSG00000250326.1	RP11-284M14.1	-5.44	6.6e-08	8.36e-06	-0.2	-0.17	Nasopharyngeal carcinoma;	chr4:143203125	chr4:142933195~143184861:-
BRCA	cis	rs11955398	0.625	rs6449485	ENSG00000215032.2	GNL3LP1	5.44	6.6e-08	8.36e-06	0.2	0.17	Intelligence (multi-trait analysis);	chr5:60699614	chr5:60891935~60893577:-
BRCA	cis	rs7620503	0.959	rs7627379	ENSG00000228221.4	LINC00578	5.44	6.6e-08	8.36e-06	0.19	0.17	Corneal structure;	chr3:177569158	chr3:177441921~177752305:+
BRCA	cis	rs7487075	0.78	rs12307969	ENSG00000272369.1	RP11-446N19.1	5.44	6.61e-08	8.37e-06	0.18	0.17	Itch intensity from mosquito bite;	chr12:46365274	chr12:46537502~46652550:+
BRCA	cis	rs2834188	0.889	rs8134026	ENSG00000272659.1	AP000295.10	-5.44	6.61e-08	8.38e-06	-0.25	-0.17	Narcolepsy;	chr21:33298793	chr21:33309491~33310181:+
BRCA	cis	rs2179367	0.632	rs11155649	ENSG00000223701.3	RAET1E-AS1	5.44	6.61e-08	8.38e-06	0.24	0.17	Dupuytren's disease;	chr6:149405830	chr6:149884431~149919508:+
BRCA	cis	rs62025270	0.632	rs7163838	ENSG00000202081.1	RNU6-1280P	-5.44	6.61e-08	8.38e-06	-0.24	-0.17	Idiopathic pulmonary fibrosis;	chr15:85664390	chr15:85651522~85651628:-
BRCA	cis	rs875971	0.638	rs10249404	ENSG00000273024.4	INTS4P2	5.44	6.61e-08	8.38e-06	0.18	0.17	Aortic root size;	chr7:66581737	chr7:65647864~65715661:+
BRCA	cis	rs9467773	0.967	rs6932865	ENSG00000124549.13	BTN2A3P	5.44	6.62e-08	8.38e-06	0.17	0.17	Intelligence (multi-trait analysis);	chr6:26539938	chr6:26421391~26432383:+
BRCA	cis	rs9467773	1	rs6933176	ENSG00000124549.13	BTN2A3P	5.44	6.62e-08	8.38e-06	0.17	0.17	Intelligence (multi-trait analysis);	chr6:26539950	chr6:26421391~26432383:+
BRCA	cis	rs9467773	1	rs1321481	ENSG00000124549.13	BTN2A3P	5.44	6.62e-08	8.39e-06	0.17	0.17	Intelligence (multi-trait analysis);	chr6:26537982	chr6:26421391~26432383:+
BRCA	cis	rs9467773	1	rs4713008	ENSG00000124549.13	BTN2A3P	5.44	6.62e-08	8.39e-06	0.17	0.17	Intelligence (multi-trait analysis);	chr6:26538040	chr6:26421391~26432383:+
BRCA	cis	rs6490294	0.571	rs11066127	ENSG00000226469.1	ADAM1B	5.44	6.62e-08	8.39e-06	0.26	0.17	Mean platelet volume;	chr12:112008551	chr12:111927018~111929017:+
BRCA	cis	rs7474896	0.559	rs2738185	ENSG00000120555.12	SEPT7P9	-5.44	6.62e-08	8.39e-06	-0.23	-0.17	Obesity (extreme);	chr10:37958808	chr10:38383069~38402916:-
BRCA	cis	rs732716	0.889	rs11666856	ENSG00000267980.1	AC007292.6	-5.44	6.63e-08	8.4e-06	-0.21	-0.17	Mean corpuscular volume;	chr19:4437453	chr19:4363789~4364640:+
BRCA	cis	rs10208649	1	rs41536750	ENSG00000233266.1	HMGB1P31	-5.44	6.63e-08	8.4e-06	-0.36	-0.17	Body mass index;	chr2:53894823	chr2:54051334~54051760:+
BRCA	cis	rs2638953	0.886	rs11049393	ENSG00000247934.4	RP11-967K21.1	-5.44	6.64e-08	8.41e-06	-0.22	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28170273	chr12:28163298~28190738:-
BRCA	cis	rs2732480	0.577	rs2732466	ENSG00000257735.1	RP11-370I10.6	5.44	6.64e-08	8.41e-06	0.21	0.17	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48338676	chr12:48350945~48442411:+
BRCA	cis	rs2243480	1	rs316321	ENSG00000228409.4	CCT6P1	5.44	6.64e-08	8.41e-06	0.23	0.17	Diabetic kidney disease;	chr7:66146626	chr7:65751142~65763354:+
BRCA	cis	rs2243480	1	rs316318	ENSG00000228409.4	CCT6P1	5.44	6.64e-08	8.41e-06	0.23	0.17	Diabetic kidney disease;	chr7:66147917	chr7:65751142~65763354:+
BRCA	cis	rs2243480	1	rs316317	ENSG00000228409.4	CCT6P1	5.44	6.64e-08	8.41e-06	0.23	0.17	Diabetic kidney disease;	chr7:66148650	chr7:65751142~65763354:+
BRCA	cis	rs2243480	1	rs316304	ENSG00000228409.4	CCT6P1	5.44	6.64e-08	8.41e-06	0.23	0.17	Diabetic kidney disease;	chr7:66151907	chr7:65751142~65763354:+
BRCA	cis	rs875971	0.516	rs6945322	ENSG00000273024.4	INTS4P2	-5.44	6.65e-08	8.42e-06	-0.18	-0.17	Aortic root size;	chr7:65871069	chr7:65647864~65715661:+
BRCA	cis	rs2051773	0.567	rs7929927	ENSG00000184669.7	OR7E14P	-5.44	6.65e-08	8.43e-06	-0.24	-0.17	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);	chr11:17022811	chr11:17013998~17053024:+
BRCA	cis	rs7569084	0.663	rs6546150	ENSG00000237979.1	AC007389.1	-5.44	6.66e-08	8.43e-06	-0.21	-0.17	Sum eosinophil basophil counts;	chr2:65415066	chr2:65500993~65502138:-
BRCA	cis	rs9847710	0.967	rs2581778	ENSG00000242142.1	SERBP1P3	5.44	6.66e-08	8.43e-06	0.18	0.17	Ulcerative colitis;	chr3:53021295	chr3:53064283~53065091:-
BRCA	cis	rs7923609	0.811	rs12245367	ENSG00000232075.1	MRPL35P2	5.44	6.66e-08	8.44e-06	0.21	0.17	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63561704	chr10:63634317~63634827:-
BRCA	cis	rs6750795	0.569	rs1667305	ENSG00000223198.1	RNU2-22P	-5.44	6.66e-08	8.44e-06	-0.2	-0.17	Height;	chr2:231539118	chr2:231501990~231502201:-
BRCA	cis	rs1707322	0.721	rs56255771	ENSG00000234329.1	RP11-767N6.2	5.44	6.66e-08	8.44e-06	0.17	0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45758647	chr1:45651039~45651826:-
BRCA	cis	rs6832769	1	rs1522111	ENSG00000223305.1	RN7SKP30	5.44	6.66e-08	8.44e-06	0.21	0.17	Personality dimensions;	chr4:55463396	chr4:55540502~55540835:-
BRCA	cis	rs9287719	0.624	rs6740245	ENSG00000243819.4	RN7SL832P	5.44	6.66e-08	8.44e-06	0.17	0.17	Prostate cancer;	chr2:10620776	chr2:10690344~10692099:+
BRCA	cis	rs875971	0.825	rs6951503	ENSG00000236529.1	RP13-254B10.1	-5.44	6.67e-08	8.44e-06	-0.19	-0.17	Aortic root size;	chr7:66253949	chr7:65840212~65840596:+
BRCA	cis	rs7772486	0.875	rs9390371	ENSG00000270638.1	RP3-466P17.1	5.44	6.67e-08	8.44e-06	0.19	0.17	Lobe attachment (rater-scored or self-reported);	chr6:146042044	chr6:145735570~145737218:+
BRCA	cis	rs7772486	0.875	rs6909827	ENSG00000270638.1	RP3-466P17.1	5.44	6.67e-08	8.44e-06	0.19	0.17	Lobe attachment (rater-scored or self-reported);	chr6:146044602	chr6:145735570~145737218:+
BRCA	cis	rs10888838	0.756	rs2282332	ENSG00000198711.5	SSBP3-AS1	5.44	6.67e-08	8.44e-06	0.24	0.17	Mitochondrial DNA levels;	chr1:54224364	chr1:54236440~54239063:+
BRCA	cis	rs4713675	0.565	rs942640	ENSG00000224557.6	HLA-DPB2	-5.44	6.67e-08	8.45e-06	-0.19	-0.17	Plateletcrit;	chr6:33718665	chr6:33112451~33129084:+
BRCA	cis	rs910316	0.934	rs8006587	ENSG00000279594.1	RP11-950C14.10	5.44	6.68e-08	8.45e-06	0.18	0.17	Height;	chr14:75198236	chr14:75011269~75012851:-
BRCA	cis	rs7200543	1	rs16966953	ENSG00000258354.1	MIR3180-1	-5.44	6.68e-08	8.45e-06	-0.22	-0.17	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15041997	chr16:14909887~14911345:-
BRCA	cis	rs2018683	1	rs4719962	ENSG00000228421.2	AC005013.5	5.44	6.68e-08	8.46e-06	0.21	0.17	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28959621	chr7:28957667~28959345:+
BRCA	cis	rs2337406	1	rs17113257	ENSG00000223648.3	IGHV3-64	5.44	6.68e-08	8.46e-06	0.17	0.17	Alzheimer's disease (late onset);	chr14:106679574	chr14:106643132~106658258:-
BRCA	cis	rs1075265	0.656	rs2542574	ENSG00000235937.1	AC008280.1	5.44	6.68e-08	8.46e-06	0.18	0.17	Chronotype;Morning vs. evening chronotype;	chr2:53820295	chr2:54029552~54030682:-
BRCA	cis	rs4218	0.543	rs2414618	ENSG00000277144.1	RP11-59H7.4	-5.44	6.68e-08	8.46e-06	-0.21	-0.17	Social communication problems;	chr15:59019684	chr15:59115547~59116089:-
BRCA	cis	rs1440410	0.795	rs34282097	ENSG00000250326.1	RP11-284M14.1	-5.44	6.69e-08	8.47e-06	-0.18	-0.17	Ischemic stroke;	chr4:143270817	chr4:142933195~143184861:-
BRCA	cis	rs13126694	0.744	rs11100148	ENSG00000248429.4	RP11-597D13.9	5.44	6.69e-08	8.47e-06	0.15	0.17	Blood osmolality (transformed sodium);	chr4:158074688	chr4:158170752~158202877:+
BRCA	cis	rs9868809	0.505	rs13434258	ENSG00000270441.1	RP11-694I15.7	5.44	6.7e-08	8.47e-06	0.3	0.17	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48701058	chr3:49140086~49160851:-
BRCA	cis	rs9868809	0.505	rs35064573	ENSG00000270441.1	RP11-694I15.7	5.44	6.7e-08	8.47e-06	0.3	0.17	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48702847	chr3:49140086~49160851:-
BRCA	cis	rs1707322	0.721	rs28501477	ENSG00000234329.1	RP11-767N6.2	5.44	6.7e-08	8.48e-06	0.18	0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45733412	chr1:45651039~45651826:-
BRCA	cis	rs4718428	0.924	rs6971897	ENSG00000232546.1	RP11-458F8.1	-5.44	6.7e-08	8.48e-06	-0.14	-0.17	Corneal structure;	chr7:66947787	chr7:66848496~66858136:+
BRCA	cis	rs6431644	1	rs183331	ENSG00000224287.2	MSL3P1	5.44	6.7e-08	8.48e-06	0.2	0.17	Left atrial antero-posterior diameter;	chr2:233865503	chr2:233865437~233868444:-
BRCA	cis	rs71520386	0.898	rs12536091	ENSG00000228649.7	AC005682.5	-5.44	6.7e-08	8.48e-06	-0.19	-0.17	Fibrinogen levels;	chr7:22788581	chr7:22854178~22861579:+
BRCA	cis	rs1345301	0.905	rs2310243	ENSG00000234389.1	AC007278.3	-5.44	6.71e-08	8.49e-06	-0.16	-0.17	Waist circumference;	chr2:102261100	chr2:102438713~102440475:+
BRCA	cis	rs13126694	0.744	rs10027000	ENSG00000248429.4	RP11-597D13.9	5.44	6.71e-08	8.49e-06	0.15	0.17	Blood osmolality (transformed sodium);	chr4:158053401	chr4:158170752~158202877:+
BRCA	cis	rs507080	0.885	rs693037	ENSG00000278376.1	RP11-158I9.8	-5.44	6.71e-08	8.49e-06	-0.17	-0.17	Serum metabolite levels;	chr11:118682617	chr11:118791254~118793137:+
BRCA	cis	rs523522	0.962	rs7488320	ENSG00000278344.1	RP11-18C24.8	5.44	6.71e-08	8.5e-06	0.23	0.17	High light scatter reticulocyte count;	chr12:120543827	chr12:120500735~120501090:-
BRCA	cis	rs6832769	1	rs28572116	ENSG00000223305.1	RN7SKP30	-5.44	6.72e-08	8.5e-06	-0.21	-0.17	Personality dimensions;	chr4:55558177	chr4:55540502~55540835:-
BRCA	cis	rs10129255	0.536	rs10142951	ENSG00000224373.3	IGHV4-59	5.44	6.72e-08	8.5e-06	0.09	0.17	Kawasaki disease;	chr14:106782337	chr14:106627249~106627825:-
BRCA	cis	rs6479891	1	rs10761730	ENSG00000232075.1	MRPL35P2	-5.44	6.73e-08	8.51e-06	-0.3	-0.17	Arthritis (juvenile idiopathic);	chr10:63257293	chr10:63634317~63634827:-
BRCA	cis	rs6479891	1	rs7916282	ENSG00000232075.1	MRPL35P2	-5.44	6.73e-08	8.51e-06	-0.3	-0.17	Arthritis (juvenile idiopathic);	chr10:63272051	chr10:63634317~63634827:-
BRCA	cis	rs6479891	0.915	rs9415682	ENSG00000232075.1	MRPL35P2	-5.44	6.73e-08	8.51e-06	-0.3	-0.17	Arthritis (juvenile idiopathic);	chr10:63274057	chr10:63634317~63634827:-
BRCA	cis	rs6479891	0.778	rs10761735	ENSG00000232075.1	MRPL35P2	-5.44	6.73e-08	8.51e-06	-0.3	-0.17	Arthritis (juvenile idiopathic);	chr10:63284158	chr10:63634317~63634827:-
BRCA	cis	rs6479891	1	rs9414786	ENSG00000232075.1	MRPL35P2	-5.44	6.73e-08	8.51e-06	-0.3	-0.17	Arthritis (juvenile idiopathic);	chr10:63284562	chr10:63634317~63634827:-
BRCA	cis	rs7617773	0.817	rs13072018	ENSG00000199476.1	Y_RNA	-5.44	6.73e-08	8.51e-06	-0.25	-0.17	Coronary artery disease;	chr3:48278842	chr3:48288587~48288694:+
BRCA	cis	rs875971	0.502	rs1796227	ENSG00000228409.4	CCT6P1	5.44	6.73e-08	8.52e-06	0.17	0.17	Aortic root size;	chr7:66622032	chr7:65751142~65763354:+
BRCA	cis	rs2803122	0.838	rs10757033	ENSG00000273226.1	RP11-513M16.8	-5.44	6.73e-08	8.52e-06	-0.18	-0.17	Pulse pressure;	chr9:19223306	chr9:19375451~19375996:+
BRCA	cis	rs7119	0.717	rs12904348	ENSG00000259362.2	RP11-307C19.1	-5.44	6.74e-08	8.53e-06	-0.22	-0.17	Type 2 diabetes;	chr15:77523396	chr15:77525540~77534110:+
BRCA	cis	rs12439619	0.921	rs4778672	ENSG00000259429.4	UBE2Q2P2	5.44	6.74e-08	8.53e-06	0.18	0.17	Intelligence (multi-trait analysis);	chr15:82245013	chr15:82355142~82420075:+
BRCA	cis	rs2179367	0.632	rs11155650	ENSG00000223701.3	RAET1E-AS1	5.44	6.75e-08	8.54e-06	0.24	0.17	Dupuytren's disease;	chr6:149407613	chr6:149884431~149919508:+
BRCA	cis	rs2179367	0.632	rs11155651	ENSG00000223701.3	RAET1E-AS1	5.44	6.75e-08	8.54e-06	0.24	0.17	Dupuytren's disease;	chr6:149408146	chr6:149884431~149919508:+
BRCA	cis	rs2179367	0.632	rs7896	ENSG00000223701.3	RAET1E-AS1	5.44	6.75e-08	8.54e-06	0.24	0.17	Dupuytren's disease;	chr6:149410340	chr6:149884431~149919508:+
BRCA	cis	rs7674212	0.57	rs2126470	ENSG00000248740.4	RP11-328K4.1	5.44	6.75e-08	8.54e-06	0.19	0.17	Type 2 diabetes;	chr4:103140605	chr4:103256159~103453658:+
BRCA	cis	rs853679	0.55	rs34477097	ENSG00000280107.1	AL022393.9	-5.44	6.76e-08	8.54e-06	-0.24	-0.17	Depression;	chr6:28229408	chr6:28170845~28172521:+
BRCA	cis	rs4919687	0.679	rs12762176	ENSG00000213061.2	PFN1P11	5.44	6.76e-08	8.55e-06	0.24	0.17	Colorectal cancer;	chr10:102739475	chr10:102838011~102845473:-
BRCA	cis	rs7493	0.755	rs740264	ENSG00000233942.1	AC004012.1	5.44	6.76e-08	8.55e-06	0.21	0.17	Yu-Zhi constitution type in type 2 diabetes;	chr7:95392491	chr7:95471835~95473998:+
BRCA	cis	rs12701220	0.522	rs868833	ENSG00000229043.2	AC091729.9	-5.44	6.76e-08	8.55e-06	-0.22	-0.17	Bronchopulmonary dysplasia;	chr7:1015337	chr7:1160374~1165267:+
BRCA	cis	rs2732480	0.5	rs12828309	ENSG00000226413.2	OR8T1P	5.44	6.76e-08	8.55e-06	0.22	0.17	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48247377	chr12:48442030~48442947:-
BRCA	cis	rs66887589	0.616	rs7659403	ENSG00000249244.1	RP11-548H18.2	5.44	6.77e-08	8.56e-06	0.18	0.17	Diastolic blood pressure;	chr4:119286099	chr4:119391831~119395335:-
BRCA	cis	rs7200543	1	rs4985124	ENSG00000258354.1	MIR3180-1	-5.44	6.77e-08	8.56e-06	-0.21	-0.17	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15031584	chr16:14909887~14911345:-
BRCA	cis	rs4787491	0.729	rs4788215	ENSG00000273724.1	RP11-347C12.12	-5.44	6.77e-08	8.57e-06	-0.18	-0.17	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30036609	chr16:30336400~30343336:+
BRCA	cis	rs2638953	0.853	rs1355473	ENSG00000247934.4	RP11-967K21.1	-5.44	6.78e-08	8.57e-06	-0.22	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28463632	chr12:28163298~28190738:-
BRCA	cis	rs1552244	1	rs66838678	ENSG00000232901.1	CYCSP10	5.44	6.78e-08	8.57e-06	0.23	0.17	Alzheimer's disease;	chr3:10108666	chr3:10000647~10000940:-
BRCA	cis	rs2153535	0.58	rs6941771	ENSG00000251164.1	HULC	-5.44	6.78e-08	8.57e-06	-0.2	-0.17	Motion sickness;	chr6:8494219	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.58	rs6937186	ENSG00000251164.1	HULC	-5.44	6.78e-08	8.57e-06	-0.2	-0.17	Motion sickness;	chr6:8494260	chr6:8652137~8653846:+
BRCA	cis	rs2898681	0.561	rs7699960	ENSG00000248375.1	RP11-177B4.1	-5.44	6.78e-08	8.57e-06	-0.27	-0.17	Optic nerve measurement (cup area);	chr4:52869494	chr4:52720081~52720831:-
BRCA	cis	rs2115630	0.875	rs8039472	ENSG00000259728.4	LINC00933	-5.44	6.78e-08	8.57e-06	-0.19	-0.17	P wave terminal force;	chr15:84818413	chr15:84570649~84580175:+
BRCA	cis	rs17214007	0.597	rs4781677	ENSG00000263335.1	AF001548.5	-5.44	6.78e-08	8.57e-06	-0.26	-0.17	Cognitive function;	chr16:15636388	chr16:15726674~15732993:+
BRCA	cis	rs2239547	0.522	rs9842974	ENSG00000242142.1	SERBP1P3	5.44	6.79e-08	8.58e-06	0.2	0.17	Schizophrenia;	chr3:52977034	chr3:53064283~53065091:-
BRCA	cis	rs62025270	0.688	rs62022939	ENSG00000202081.1	RNU6-1280P	-5.44	6.79e-08	8.58e-06	-0.25	-0.17	Idiopathic pulmonary fibrosis;	chr15:85707651	chr15:85651522~85651628:-
BRCA	cis	rs950776	0.518	rs1504545	ENSG00000279373.1	RP11-650L12.4	-5.44	6.79e-08	8.58e-06	-0.21	-0.17	Sudden cardiac arrest;	chr15:78526129	chr15:78537681~78538946:+
BRCA	cis	rs3764021	0.527	rs10844537	ENSG00000214776.8	RP11-726G1.1	5.44	6.79e-08	8.59e-06	0.2	0.17	Type 1 diabetes;	chr12:9709528	chr12:9467552~9576275:+
BRCA	cis	rs1075265	0.575	rs2692531	ENSG00000235937.1	AC008280.1	5.44	6.79e-08	8.59e-06	0.18	0.17	Chronotype;Morning vs. evening chronotype;	chr2:53776640	chr2:54029552~54030682:-
BRCA	cis	rs4835473	0.932	rs13105102	ENSG00000249741.2	RP11-673E1.3	5.44	6.79e-08	8.59e-06	0.18	0.17	Immature fraction of reticulocytes;	chr4:143819046	chr4:143911514~143912053:-
BRCA	cis	rs1440410	0.804	rs4131029	ENSG00000250326.1	RP11-284M14.1	-5.44	6.8e-08	8.59e-06	-0.18	-0.17	Ischemic stroke;	chr4:143222425	chr4:142933195~143184861:-
BRCA	cis	rs6832769	0.961	rs28445925	ENSG00000272969.1	RP11-528I4.2	-5.44	6.8e-08	8.59e-06	-0.2	-0.17	Personality dimensions;	chr4:55569682	chr4:55547112~55547889:+
BRCA	cis	rs4604234	0.614	rs73482029	ENSG00000272129.1	RP11-250B2.6	-5.44	6.8e-08	8.59e-06	-0.42	-0.17	Cancer;	chr6:80218143	chr6:80355424~80356859:+
BRCA	cis	rs2803122	0.807	rs4977289	ENSG00000273226.1	RP11-513M16.8	-5.44	6.8e-08	8.59e-06	-0.18	-0.17	Pulse pressure;	chr9:19225190	chr9:19375451~19375996:+
BRCA	cis	rs2976388	1	rs1045574	ENSG00000253741.1	CTD-2292P10.4	5.44	6.8e-08	8.59e-06	0.18	0.17	Urinary tract infection frequency;	chr8:142682540	chr8:142702252~142726973:-
BRCA	cis	rs13113518	1	rs4864546	ENSG00000273257.1	RP11-177J6.1	5.44	6.8e-08	8.6e-06	0.21	0.17	Height;	chr4:55537960	chr4:55387949~55388271:+
BRCA	cis	rs7246657	0.943	rs3803895	ENSG00000267422.1	CTD-2554C21.1	-5.44	6.8e-08	8.6e-06	-0.24	-0.17	Coronary artery calcification;	chr19:37407767	chr19:37779686~37792865:+
BRCA	cis	rs12144309	0.58	rs1217403	ENSG00000232450.1	RP4-730K3.3	5.44	6.81e-08	8.6e-06	0.22	0.17	Coronary artery disease;	chr1:113846182	chr1:113698884~113699631:-
BRCA	cis	rs2638953	0.541	rs10843209	ENSG00000247934.4	RP11-967K21.1	-5.44	6.81e-08	8.61e-06	-0.21	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28573702	chr12:28163298~28190738:-
BRCA	cis	rs4713118	0.621	rs9295756	ENSG00000204709.4	LINC01556	5.44	6.81e-08	8.61e-06	0.25	0.17	Parkinson's disease;	chr6:28065618	chr6:28943877~28944537:+
BRCA	cis	rs9467773	1	rs6903973	ENSG00000124549.13	BTN2A3P	5.44	6.81e-08	8.61e-06	0.17	0.17	Intelligence (multi-trait analysis);	chr6:26499714	chr6:26421391~26432383:+
BRCA	cis	rs12439619	0.846	rs62012003	ENSG00000255769.6	GOLGA2P10	-5.44	6.81e-08	8.61e-06	-0.24	-0.17	Intelligence (multi-trait analysis);	chr15:82183236	chr15:82472993~82513950:-
BRCA	cis	rs2058059	0.636	rs2960968	ENSG00000225648.4	SBDSP1	-5.44	6.82e-08	8.62e-06	-0.27	-0.17	Subcutaneous adipose tissue;	chr7:72702378	chr7:72829425~72836701:+
BRCA	cis	rs4908760	0.965	rs1884352	ENSG00000270282.1	RP5-1115A15.2	5.44	6.82e-08	8.62e-06	0.18	0.17	Vitiligo;	chr1:8477229	chr1:8512653~8513021:+
BRCA	cis	rs2708977	0.637	rs676007	ENSG00000237510.6	AC008268.2	-5.44	6.82e-08	8.62e-06	-0.22	-0.17	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96409314	chr2:95789654~95800166:+
BRCA	cis	rs2708977	0.637	rs597420	ENSG00000237510.6	AC008268.2	-5.43	6.82e-08	8.62e-06	-0.22	-0.17	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96404615	chr2:95789654~95800166:+
BRCA	cis	rs1979679	0.842	rs4931727	ENSG00000278733.1	RP11-425D17.1	5.43	6.83e-08	8.63e-06	0.21	0.17	Ossification of the posterior longitudinal ligament of the spine;	chr12:28146186	chr12:28185625~28186190:-
BRCA	cis	rs2153535	0.541	rs9505456	ENSG00000251164.1	HULC	-5.43	6.83e-08	8.63e-06	-0.2	-0.17	Motion sickness;	chr6:8478768	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.58	rs9505458	ENSG00000251164.1	HULC	-5.43	6.83e-08	8.63e-06	-0.2	-0.17	Motion sickness;	chr6:8478982	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.58	rs9379215	ENSG00000251164.1	HULC	-5.43	6.83e-08	8.63e-06	-0.2	-0.17	Motion sickness;	chr6:8480992	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.58	rs6597326	ENSG00000251164.1	HULC	-5.43	6.83e-08	8.63e-06	-0.2	-0.17	Motion sickness;	chr6:8481786	chr6:8652137~8653846:+
BRCA	cis	rs6832769	0.961	rs10009593	ENSG00000272969.1	RP11-528I4.2	-5.43	6.83e-08	8.63e-06	-0.2	-0.17	Personality dimensions;	chr4:55570514	chr4:55547112~55547889:+
BRCA	cis	rs10740039	0.516	rs2393645	ENSG00000254271.1	RP11-131N11.4	5.43	6.83e-08	8.63e-06	0.22	0.17	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60555269	chr10:60734342~60741828:+
BRCA	cis	rs9308731	1	rs1980045	ENSG00000227992.1	AC108463.2	-5.43	6.83e-08	8.63e-06	-0.19	-0.17	Chronic lymphocytic leukemia;	chr2:111146964	chr2:111203964~111206215:-
BRCA	cis	rs7577696	0.785	rs7592239	ENSG00000272716.1	RP11-563N4.1	-5.43	6.83e-08	8.63e-06	-0.19	-0.17	Inflammatory biomarkers;	chr2:32145189	chr2:32165046~32165757:-
BRCA	cis	rs1440410	0.571	rs4690768	ENSG00000250326.1	RP11-284M14.1	5.43	6.83e-08	8.64e-06	0.2	0.17	Ischemic stroke;	chr4:143118125	chr4:142933195~143184861:-
BRCA	cis	rs6479901	0.895	rs10822157	ENSG00000232075.1	MRPL35P2	-5.43	6.84e-08	8.64e-06	-0.24	-0.17	Intelligence (multi-trait analysis);	chr10:63329720	chr10:63634317~63634827:-
BRCA	cis	rs453301	0.686	rs6601280	ENSG00000254153.1	CTA-398F10.2	5.43	6.84e-08	8.64e-06	0.21	0.17	Joint mobility (Beighton score);	chr8:9051726	chr8:8456909~8461337:-
BRCA	cis	rs875971	0.522	rs1617484	ENSG00000273024.4	INTS4P2	-5.43	6.84e-08	8.65e-06	-0.18	-0.17	Aortic root size;	chr7:65998108	chr7:65647864~65715661:+
BRCA	cis	rs7182948	0.846	rs1354920	ENSG00000259531.2	RP11-295H24.3	-5.43	6.84e-08	8.65e-06	-0.23	-0.17	Lung adenocarcinoma;	chr15:49533326	chr15:49365124~49366685:-
BRCA	cis	rs6547741	0.935	rs4260197	ENSG00000234072.1	AC074117.10	-5.43	6.84e-08	8.65e-06	-0.15	-0.17	Oral cavity cancer;	chr2:27571283	chr2:27356246~27367622:+
BRCA	cis	rs7613875	0.58	rs2624819	ENSG00000228008.1	CTD-2330K9.3	5.43	6.85e-08	8.65e-06	0.16	0.17	Body mass index;	chr3:49973138	chr3:49903845~49916937:+
BRCA	cis	rs7772486	0.686	rs2328708	ENSG00000270638.1	RP3-466P17.1	-5.43	6.85e-08	8.66e-06	-0.19	-0.17	Lobe attachment (rater-scored or self-reported);	chr6:145774603	chr6:145735570~145737218:+
BRCA	cis	rs3733585	0.699	rs6449177	ENSG00000250413.1	RP11-448G15.1	5.43	6.86e-08	8.66e-06	0.22	0.17	Cleft plate (environmental tobacco smoke interaction);	chr4:9966426	chr4:10006482~10009725:+
BRCA	cis	rs9307551	0.619	rs11098742	ENSG00000250334.4	LINC00989	-5.43	6.86e-08	8.66e-06	-0.23	-0.17	Refractive error;	chr4:79551637	chr4:79492416~79576460:+
BRCA	cis	rs2790457	0.874	rs2790446	ENSG00000254635.4	WAC-AS1	-5.43	6.86e-08	8.67e-06	-0.2	-0.17	Multiple myeloma;	chr10:28512101	chr10:28522652~28532743:-
BRCA	cis	rs8054556	0.967	rs9932702	ENSG00000273724.1	RP11-347C12.12	-5.43	6.86e-08	8.67e-06	-0.18	-0.17	Autism spectrum disorder or schizophrenia;	chr16:29971640	chr16:30336400~30343336:+
BRCA	cis	rs8054556	1	rs9925102	ENSG00000273724.1	RP11-347C12.12	-5.43	6.86e-08	8.67e-06	-0.18	-0.17	Autism spectrum disorder or schizophrenia;	chr16:29971827	chr16:30336400~30343336:+
BRCA	cis	rs597539	0.652	rs559032	ENSG00000261625.1	RP11-554A11.4	-5.43	6.87e-08	8.68e-06	-0.17	-0.17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68943379	chr11:69000765~69002048:-
BRCA	cis	rs9880211	0.583	rs9870122	ENSG00000239213.4	NCK1-AS1	5.43	6.87e-08	8.68e-06	0.2	0.17	Height;Body mass index;	chr3:136101423	chr3:136841726~136862054:-
BRCA	cis	rs2919009	0.607	rs12250320	ENSG00000271670.1	RP11-95I16.4	5.43	6.88e-08	8.68e-06	0.22	0.17	Obesity-related traits;	chr10:120959795	chr10:120879256~120880667:-
BRCA	cis	rs875971	0.66	rs1860468	ENSG00000273024.4	INTS4P2	5.43	6.88e-08	8.69e-06	0.18	0.17	Aortic root size;	chr7:66642265	chr7:65647864~65715661:+
BRCA	cis	rs6840360	0.642	rs2709842	ENSG00000278978.1	RP11-164P12.5	5.43	6.88e-08	8.69e-06	0.18	0.17	Intelligence (multi-trait analysis);	chr4:151449485	chr4:151669786~151670503:+
BRCA	cis	rs4907240	0.925	rs4907242	ENSG00000237510.6	AC008268.2	-5.43	6.88e-08	8.69e-06	-0.24	-0.17	Event-related brain oscillations;	chr2:96607376	chr2:95789654~95800166:+
BRCA	cis	rs1707322	0.721	rs6665808	ENSG00000234329.1	RP11-767N6.2	5.43	6.88e-08	8.69e-06	0.17	0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45696611	chr1:45651039~45651826:-
BRCA	cis	rs2243480	1	rs2462569	ENSG00000232559.3	GS1-124K5.12	-5.43	6.88e-08	8.69e-06	-0.3	-0.17	Diabetic kidney disease;	chr7:66009859	chr7:66554588~66576923:-
BRCA	cis	rs9868809	0.505	rs11706983	ENSG00000270441.1	RP11-694I15.7	5.43	6.88e-08	8.69e-06	0.3	0.17	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48701245	chr3:49140086~49160851:-
BRCA	cis	rs250585	0.92	rs30016	ENSG00000260136.4	CTD-2270L9.4	5.43	6.88e-08	8.7e-06	0.18	0.17	Egg allergy;	chr16:23401576	chr16:23452758~23457606:+
BRCA	cis	rs62025270	0.688	rs62022941	ENSG00000202081.1	RNU6-1280P	-5.43	6.88e-08	8.7e-06	-0.24	-0.17	Idiopathic pulmonary fibrosis;	chr15:85712824	chr15:85651522~85651628:-
BRCA	cis	rs2732480	0.5	rs1387257	ENSG00000240399.1	RP1-228P16.1	5.43	6.88e-08	8.7e-06	0.19	0.17	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48242883	chr12:48054813~48055591:-
BRCA	cis	rs6479891	1	rs9415680	ENSG00000232075.1	MRPL35P2	-5.43	6.89e-08	8.7e-06	-0.3	-0.17	Arthritis (juvenile idiopathic);	chr10:63261130	chr10:63634317~63634827:-
BRCA	cis	rs13126694	0.744	rs9968557	ENSG00000248429.4	RP11-597D13.9	5.43	6.89e-08	8.7e-06	0.15	0.17	Blood osmolality (transformed sodium);	chr4:158098673	chr4:158170752~158202877:+
BRCA	cis	rs4604234	0.614	rs73477981	ENSG00000272129.1	RP11-250B2.6	-5.43	6.89e-08	8.7e-06	-0.43	-0.17	Cancer;	chr6:80109424	chr6:80355424~80356859:+
BRCA	cis	rs1124769	0.654	rs12441919	ENSG00000259378.1	DCAF13P3	5.43	6.89e-08	8.7e-06	0.24	0.17	Cognitive performance;	chr15:51179503	chr15:50944663~50945996:+
BRCA	cis	rs2153535	0.58	rs4140586	ENSG00000251164.1	HULC	-5.43	6.89e-08	8.7e-06	-0.2	-0.17	Motion sickness;	chr6:8502959	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.601	rs4140585	ENSG00000251164.1	HULC	-5.43	6.89e-08	8.7e-06	-0.2	-0.17	Motion sickness;	chr6:8503065	chr6:8652137~8653846:+
BRCA	cis	rs2179367	0.632	rs66672129	ENSG00000223701.3	RAET1E-AS1	5.43	6.89e-08	8.71e-06	0.24	0.17	Dupuytren's disease;	chr6:149334387	chr6:149884431~149919508:+
BRCA	cis	rs2179367	0.632	rs9498322	ENSG00000223701.3	RAET1E-AS1	5.43	6.89e-08	8.71e-06	0.24	0.17	Dupuytren's disease;	chr6:149335950	chr6:149884431~149919508:+
BRCA	cis	rs2179367	0.632	rs9498323	ENSG00000223701.3	RAET1E-AS1	5.43	6.89e-08	8.71e-06	0.24	0.17	Dupuytren's disease;	chr6:149336077	chr6:149884431~149919508:+
BRCA	cis	rs2179367	0.632	rs12204793	ENSG00000223701.3	RAET1E-AS1	5.43	6.89e-08	8.71e-06	0.24	0.17	Dupuytren's disease;	chr6:149340102	chr6:149884431~149919508:+
BRCA	cis	rs2562456	0.833	rs2562416	ENSG00000268535.1	RP11-420K14.3	5.43	6.9e-08	8.71e-06	0.25	0.17	Pain;	chr19:21430609	chr19:21709522~21710191:+
BRCA	cis	rs3733585	0.673	rs7378340	ENSG00000250413.1	RP11-448G15.1	5.43	6.9e-08	8.71e-06	0.22	0.17	Cleft plate (environmental tobacco smoke interaction);	chr4:9953574	chr4:10006482~10009725:+
BRCA	cis	rs2243480	1	rs410128	ENSG00000228409.4	CCT6P1	5.43	6.9e-08	8.71e-06	0.24	0.17	Diabetic kidney disease;	chr7:66138186	chr7:65751142~65763354:+
BRCA	cis	rs754466	0.606	rs7084705	ENSG00000204049.1	RP11-126H7.4	5.43	6.9e-08	8.71e-06	0.19	0.17	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77836917	chr10:77866875~77869610:+
BRCA	cis	rs720475	0.732	rs62483106	ENSG00000170356.8	OR2A20P	5.43	6.9e-08	8.71e-06	0.25	0.17	Breast cancer;	chr7:144439533	chr7:144250045~144252957:-
BRCA	cis	rs2153535	0.518	rs6925765	ENSG00000230939.1	RP11-314C16.1	-5.43	6.9e-08	8.72e-06	-0.2	-0.17	Motion sickness;	chr6:8566471	chr6:8784178~8785445:+
BRCA	cis	rs6832769	1	rs11133399	ENSG00000272969.1	RP11-528I4.2	-5.43	6.9e-08	8.72e-06	-0.21	-0.17	Personality dimensions;	chr4:55547664	chr4:55547112~55547889:+
BRCA	cis	rs1552244	0.882	rs67631672	ENSG00000232901.1	CYCSP10	5.43	6.91e-08	8.72e-06	0.23	0.17	Alzheimer's disease;	chr3:9963084	chr3:10000647~10000940:-
BRCA	cis	rs721917	0.506	rs2254016	ENSG00000244733.5	RP11-506M13.3	-5.43	6.91e-08	8.72e-06	-0.2	-0.17	Chronic obstructive pulmonary disease;	chr10:79898668	chr10:79660891~79677996:+
BRCA	cis	rs7646881	0.812	rs59957986	ENSG00000240207.5	RP11-379F4.4	-5.43	6.91e-08	8.72e-06	-0.26	-0.17	Tetralogy of Fallot;	chr3:158741124	chr3:158732263~158784070:+
BRCA	cis	rs8054556	0.787	rs12325539	ENSG00000273724.1	RP11-347C12.12	-5.43	6.91e-08	8.73e-06	-0.19	-0.17	Autism spectrum disorder or schizophrenia;	chr16:30022312	chr16:30336400~30343336:+
BRCA	cis	rs8054556	0.751	rs11642430	ENSG00000273724.1	RP11-347C12.12	-5.43	6.91e-08	8.73e-06	-0.19	-0.17	Autism spectrum disorder or schizophrenia;	chr16:30034468	chr16:30336400~30343336:+
BRCA	cis	rs8054556	0.76	rs12598856	ENSG00000273724.1	RP11-347C12.12	-5.43	6.91e-08	8.73e-06	-0.2	-0.17	Autism spectrum disorder or schizophrenia;	chr16:30018227	chr16:30336400~30343336:+
BRCA	cis	rs3740713	1	rs75487138	ENSG00000256464.1	YWHABP2	5.43	6.92e-08	8.74e-06	0.29	0.17	Amyotrophic lateral sclerosis (sporadic);	chr11:18440331	chr11:18490243~18490955:-
BRCA	cis	rs12681366	0.734	rs2291439	ENSG00000253704.1	RP11-267M23.4	5.43	6.93e-08	8.74e-06	0.17	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94407470	chr8:94553722~94569745:+
BRCA	cis	rs7615952	0.611	rs35321002	ENSG00000248787.1	RP11-666A20.4	-5.43	6.93e-08	8.74e-06	-0.3	-0.17	Blood pressure (smoking interaction);	chr3:125893222	chr3:125908005~125910272:-
BRCA	cis	rs2708977	0.692	rs17685766	ENSG00000237510.6	AC008268.2	5.43	6.93e-08	8.75e-06	0.22	0.17	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96653797	chr2:95789654~95800166:+
BRCA	cis	rs6088580	0.505	rs6058106	ENSG00000269202.1	RP4-614O4.12	5.43	6.94e-08	8.76e-06	0.17	0.17	Glomerular filtration rate (creatinine);	chr20:34690451	chr20:35201747~35203288:-
BRCA	cis	rs4835473	0.838	rs6838981	ENSG00000249741.2	RP11-673E1.3	5.43	6.94e-08	8.76e-06	0.18	0.17	Immature fraction of reticulocytes;	chr4:143826484	chr4:143911514~143912053:-
BRCA	cis	rs847577	0.515	rs10953238	ENSG00000272950.1	RP11-307C18.1	5.43	6.94e-08	8.76e-06	0.21	0.17	Breast cancer;	chr7:98046947	chr7:98322853~98323430:+
BRCA	cis	rs9467773	1	rs9467782	ENSG00000124549.13	BTN2A3P	5.43	6.94e-08	8.76e-06	0.17	0.17	Intelligence (multi-trait analysis);	chr6:26542545	chr6:26421391~26432383:+
BRCA	cis	rs9818758	0.556	rs9814987	ENSG00000270441.1	RP11-694I15.7	5.43	6.95e-08	8.77e-06	0.31	0.17	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49170416	chr3:49140086~49160851:-
BRCA	cis	rs10946940	0.965	rs62401383	ENSG00000216901.1	AL022393.7	-5.43	6.95e-08	8.77e-06	-0.21	-0.17	Systemic lupus erythematosus;	chr6:27596768	chr6:28176188~28176674:+
BRCA	cis	rs7674212	0.541	rs2720448	ENSG00000248740.4	RP11-328K4.1	5.43	6.95e-08	8.77e-06	0.19	0.17	Type 2 diabetes;	chr4:103109432	chr4:103256159~103453658:+
BRCA	cis	rs7674212	0.541	rs2623064	ENSG00000248740.4	RP11-328K4.1	5.43	6.95e-08	8.77e-06	0.19	0.17	Type 2 diabetes;	chr4:103109635	chr4:103256159~103453658:+
BRCA	cis	rs6832769	1	rs3736544	ENSG00000223305.1	RN7SKP30	5.43	6.96e-08	8.78e-06	0.21	0.17	Personality dimensions;	chr4:55443825	chr4:55540502~55540835:-
BRCA	cis	rs1707322	0.686	rs1541131	ENSG00000234329.1	RP11-767N6.2	-5.43	6.96e-08	8.79e-06	-0.17	-0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45619262	chr1:45651039~45651826:-
BRCA	cis	rs7044106	0.537	rs4434680	ENSG00000238181.2	AHCYP2	-5.43	6.97e-08	8.79e-06	-0.23	-0.17	Hip circumference adjusted for BMI;	chr9:120727410	chr9:120720673~120721972:+
BRCA	cis	rs7008867	0.744	rs17088184	ENSG00000253390.1	CTC-756D1.2	5.43	6.97e-08	8.79e-06	0.25	0.17	Hip circumference adjusted for BMI;	chr8:23517722	chr8:23458601~23484971:+
BRCA	cis	rs2929278	0.736	rs2412823	ENSG00000275601.1	AC011330.13	5.43	6.97e-08	8.8e-06	0.19	0.17	Schizophrenia;	chr15:43935072	chr15:43642389~43643023:-
BRCA	cis	rs2115630	0.967	rs8028490	ENSG00000259295.5	CSPG4P12	-5.43	6.97e-08	8.8e-06	-0.2	-0.17	P wave terminal force;	chr15:84734657	chr15:85191438~85213905:+
BRCA	cis	rs962856	0.964	rs1552359	ENSG00000236780.4	AC078941.1	5.43	6.98e-08	8.8e-06	0.21	0.17	Pancreatic cancer;	chr2:67388297	chr2:67123357~67215319:-
BRCA	cis	rs7617773	0.817	rs936427	ENSG00000199476.1	Y_RNA	5.43	6.98e-08	8.8e-06	0.24	0.17	Coronary artery disease;	chr3:48259584	chr3:48288587~48288694:+
BRCA	cis	rs7131987	0.565	rs2882294	ENSG00000257176.2	RP11-996F15.2	5.43	6.98e-08	8.81e-06	0.19	0.17	QT interval;	chr12:29245019	chr12:29280418~29317848:-
BRCA	cis	rs67766926	0.541	rs10177855	ENSG00000271889.1	RP11-493E12.1	5.43	6.98e-08	8.81e-06	0.25	0.17	Inflammatory skin disease;	chr2:61061198	chr2:61151433~61162105:-
BRCA	cis	rs2554380	0.628	rs963690	ENSG00000230373.7	GOLGA6L5P	-5.43	6.99e-08	8.81e-06	-0.2	-0.17	Height;	chr15:83771068	chr15:84507885~84516814:-
BRCA	cis	rs7615952	0.609	rs13088451	ENSG00000250012.1	RP11-124N2.1	-5.43	6.99e-08	8.82e-06	-0.23	-0.17	Blood pressure (smoking interaction);	chr3:125834656	chr3:126084220~126095349:+
BRCA	cis	rs34217772	0.68	rs17181636	ENSG00000258636.1	CTD-2298J14.2	-5.43	6.99e-08	8.82e-06	-0.23	-0.17	Myopia;	chr14:41727772	chr14:41587861~41604856:-
BRCA	cis	rs7200543	1	rs6498540	ENSG00000258354.1	MIR3180-1	-5.43	6.99e-08	8.82e-06	-0.22	-0.17	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15036737	chr16:14909887~14911345:-
BRCA	cis	rs10510102	0.935	rs12264495	ENSG00000226864.1	ATE1-AS1	5.43	6.99e-08	8.82e-06	0.3	0.17	Breast cancer;	chr10:121919967	chr10:121928312~121951965:+
BRCA	cis	rs2153535	0.541	rs1414353	ENSG00000251164.1	HULC	-5.43	7e-08	8.83e-06	-0.2	-0.17	Motion sickness;	chr6:8485409	chr6:8652137~8653846:+
BRCA	cis	rs875971	0.66	rs12698534	ENSG00000273024.4	INTS4P2	-5.43	7e-08	8.83e-06	-0.18	-0.17	Aortic root size;	chr7:66521858	chr7:65647864~65715661:+
BRCA	cis	rs1707322	0.721	rs10890336	ENSG00000234329.1	RP11-767N6.2	5.43	7.01e-08	8.84e-06	0.17	0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45645384	chr1:45651039~45651826:-
BRCA	cis	rs1707322	0.721	rs11211151	ENSG00000234329.1	RP11-767N6.2	5.43	7.01e-08	8.84e-06	0.17	0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45647080	chr1:45651039~45651826:-
BRCA	cis	rs1707322	0.721	rs12045096	ENSG00000234329.1	RP11-767N6.2	5.43	7.01e-08	8.84e-06	0.17	0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45648756	chr1:45651039~45651826:-
BRCA	cis	rs1707322	0.721	rs4609469	ENSG00000234329.1	RP11-767N6.2	5.43	7.01e-08	8.84e-06	0.17	0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45651513	chr1:45651039~45651826:-
BRCA	cis	rs1707322	0.721	rs12049027	ENSG00000234329.1	RP11-767N6.2	5.43	7.01e-08	8.84e-06	0.17	0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45652512	chr1:45651039~45651826:-
BRCA	cis	rs1707322	0.752	rs10789467	ENSG00000234329.1	RP11-767N6.2	5.43	7.01e-08	8.84e-06	0.17	0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45653073	chr1:45651039~45651826:-
BRCA	cis	rs1707322	0.721	rs10890337	ENSG00000234329.1	RP11-767N6.2	5.43	7.01e-08	8.84e-06	0.17	0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45658855	chr1:45651039~45651826:-
BRCA	cis	rs1707322	0.752	rs3811435	ENSG00000234329.1	RP11-767N6.2	5.43	7.01e-08	8.84e-06	0.17	0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45660118	chr1:45651039~45651826:-
BRCA	cis	rs1707322	0.721	rs9793568	ENSG00000234329.1	RP11-767N6.2	5.43	7.01e-08	8.84e-06	0.17	0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45664701	chr1:45651039~45651826:-
BRCA	cis	rs1707322	0.685	rs6690926	ENSG00000234329.1	RP11-767N6.2	5.43	7.01e-08	8.84e-06	0.17	0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45669306	chr1:45651039~45651826:-
BRCA	cis	rs1707322	0.752	rs8179402	ENSG00000234329.1	RP11-767N6.2	5.43	7.01e-08	8.84e-06	0.17	0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45676794	chr1:45651039~45651826:-
BRCA	cis	rs1707322	0.752	rs8179296	ENSG00000234329.1	RP11-767N6.2	5.43	7.01e-08	8.84e-06	0.17	0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45678119	chr1:45651039~45651826:-
BRCA	cis	rs227275	0.525	rs7698608	ENSG00000251288.2	RP11-10L12.2	-5.43	7.01e-08	8.84e-06	-0.19	-0.17	Allergic disease (asthma, hay fever or eczema);	chr4:103016817	chr4:102751401~102752641:+
BRCA	cis	rs4819052	0.565	rs35776291	ENSG00000184274.3	LINC00315	-5.43	7.01e-08	8.84e-06	-0.21	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45286227	chr21:45300245~45305257:-
BRCA	cis	rs7131987	0.565	rs7968883	ENSG00000275476.1	RP11-996F15.4	5.43	7.02e-08	8.85e-06	0.18	0.17	QT interval;	chr12:29241258	chr12:29277397~29277882:-
BRCA	cis	rs73222236	0.787	rs7621970	ENSG00000273486.1	RP11-731C17.2	5.43	7.02e-08	8.85e-06	0.19	0.17	Coronary artery disease;	chr3:136645500	chr3:136837338~136839021:-
BRCA	cis	rs6832769	0.925	rs2412663	ENSG00000223305.1	RN7SKP30	-5.43	7.02e-08	8.85e-06	-0.21	-0.17	Personality dimensions;	chr4:55589649	chr4:55540502~55540835:-
BRCA	cis	rs2638953	0.924	rs12368745	ENSG00000278733.1	RP11-425D17.1	-5.43	7.03e-08	8.86e-06	-0.22	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28396198	chr12:28185625~28186190:-
BRCA	cis	rs997295	0.57	rs11632574	ENSG00000270964.1	RP11-502I4.3	-5.43	7.03e-08	8.86e-06	-0.18	-0.17	Motion sickness;	chr15:67560067	chr15:67541072~67542604:-
BRCA	cis	rs4722166	0.597	rs2069845	ENSG00000225541.1	AC002480.5	-5.43	7.03e-08	8.86e-06	-0.17	-0.17	Lung cancer;	chr7:22730530	chr7:22571607~22661792:-
BRCA	cis	rs11051970	0.513	rs2892655	ENSG00000274964.1	RP11-817I4.1	-5.43	7.03e-08	8.86e-06	-0.22	-0.17	Response to tocilizumab in rheumatoid arthritis;	chr12:32337295	chr12:32339368~32340724:+
BRCA	cis	rs9545047	0.604	rs7981067	ENSG00000227354.5	RBM26-AS1	5.43	7.03e-08	8.87e-06	0.18	0.17	Schizophrenia;	chr13:79341254	chr13:79406309~79424328:+
BRCA	cis	rs11159086	0.793	rs28378078	ENSG00000270000.1	RP3-449M8.9	5.43	7.04e-08	8.88e-06	0.25	0.17	Advanced glycation end-product levels;	chr14:74487940	chr14:74471930~74472360:-
BRCA	cis	rs8098244	0.737	rs1154243	ENSG00000264745.1	TTC39C-AS1	-5.43	7.04e-08	8.88e-06	-0.25	-0.17	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23963824	chr18:23994213~24015339:-
BRCA	cis	rs8098244	0.708	rs1154245	ENSG00000264745.1	TTC39C-AS1	-5.43	7.04e-08	8.88e-06	-0.25	-0.17	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23964250	chr18:23994213~24015339:-
BRCA	cis	rs2638953	0.962	rs10843158	ENSG00000247934.4	RP11-967K21.1	5.43	7.05e-08	8.88e-06	0.22	0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28354259	chr12:28163298~28190738:-
BRCA	cis	rs9545047	0.604	rs7996652	ENSG00000227354.5	RBM26-AS1	5.43	7.05e-08	8.89e-06	0.18	0.17	Schizophrenia;	chr13:79341474	chr13:79406309~79424328:+
BRCA	cis	rs9545047	0.604	rs9565488	ENSG00000227354.5	RBM26-AS1	5.43	7.05e-08	8.89e-06	0.18	0.17	Schizophrenia;	chr13:79341604	chr13:79406309~79424328:+
BRCA	cis	rs61160187	0.51	rs4482855	ENSG00000215032.2	GNL3LP1	5.43	7.05e-08	8.89e-06	0.2	0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:60800670	chr5:60891935~60893577:-
BRCA	cis	rs34217772	0.68	rs59082466	ENSG00000258636.1	CTD-2298J14.2	5.43	7.06e-08	8.9e-06	0.23	0.17	Myopia;	chr14:41718111	chr14:41587861~41604856:-
BRCA	cis	rs34217772	0.68	rs17181601	ENSG00000258636.1	CTD-2298J14.2	5.43	7.06e-08	8.9e-06	0.23	0.17	Myopia;	chr14:41718729	chr14:41587861~41604856:-
BRCA	cis	rs34217772	0.68	rs17181608	ENSG00000258636.1	CTD-2298J14.2	5.43	7.06e-08	8.9e-06	0.23	0.17	Myopia;	chr14:41719240	chr14:41587861~41604856:-
BRCA	cis	rs34217772	0.68	rs61990343	ENSG00000258636.1	CTD-2298J14.2	5.43	7.06e-08	8.9e-06	0.23	0.17	Myopia;	chr14:41720521	chr14:41587861~41604856:-
BRCA	cis	rs34217772	0.68	rs4603462	ENSG00000258636.1	CTD-2298J14.2	5.43	7.06e-08	8.9e-06	0.23	0.17	Myopia;	chr14:41721758	chr14:41587861~41604856:-
BRCA	cis	rs34217772	0.68	rs4624078	ENSG00000258636.1	CTD-2298J14.2	5.43	7.06e-08	8.9e-06	0.23	0.17	Myopia;	chr14:41721774	chr14:41587861~41604856:-
BRCA	cis	rs34217772	0.68	rs4584739	ENSG00000258636.1	CTD-2298J14.2	5.43	7.06e-08	8.9e-06	0.23	0.17	Myopia;	chr14:41721859	chr14:41587861~41604856:-
BRCA	cis	rs1440410	0.835	rs6818149	ENSG00000250326.1	RP11-284M14.1	-5.43	7.06e-08	8.9e-06	-0.18	-0.17	Ischemic stroke;	chr4:143203932	chr4:142933195~143184861:-
BRCA	cis	rs6570726	0.791	rs6900040	ENSG00000270638.1	RP3-466P17.1	5.43	7.06e-08	8.9e-06	0.19	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145571998	chr6:145735570~145737218:+
BRCA	cis	rs13113518	0.545	rs6810483	ENSG00000249700.7	SRD5A3-AS1	5.43	7.06e-08	8.9e-06	0.21	0.17	Height;	chr4:55424406	chr4:55363971~55395847:-
BRCA	cis	rs14027	0.64	rs7009073	ENSG00000279347.1	RP11-85I17.2	-5.43	7.07e-08	8.91e-06	-0.16	-0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119769677	chr8:119838736~119840385:-
BRCA	cis	rs4650994	0.525	rs10913567	ENSG00000273384.1	RP5-1098D14.1	5.43	7.07e-08	8.91e-06	0.21	0.17	HDL cholesterol;HDL cholesterol levels;	chr1:178542806	chr1:178651706~178652282:+
BRCA	cis	rs11955398	0.625	rs286154	ENSG00000215032.2	GNL3LP1	5.43	7.07e-08	8.92e-06	0.2	0.17	Intelligence (multi-trait analysis);	chr5:60631084	chr5:60891935~60893577:-
BRCA	cis	rs17508449	0.819	rs17359378	ENSG00000232450.1	RP4-730K3.3	-5.43	7.07e-08	8.92e-06	-0.31	-0.17	Leprosy;	chr1:113674087	chr1:113698884~113699631:-
BRCA	cis	rs2638953	0.819	rs10843146	ENSG00000247934.4	RP11-967K21.1	-5.43	7.07e-08	8.92e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28268352	chr12:28163298~28190738:-
BRCA	cis	rs4835473	0.897	rs6835827	ENSG00000249741.2	RP11-673E1.3	-5.43	7.08e-08	8.93e-06	-0.18	-0.17	Immature fraction of reticulocytes;	chr4:143712803	chr4:143911514~143912053:-
BRCA	cis	rs5758511	0.689	rs17478227	ENSG00000233903.2	Z83851.4	-5.43	7.09e-08	8.93e-06	-0.3	-0.17	Birth weight;	chr22:42258321	chr22:42276355~42277052:+
BRCA	cis	rs9341808	0.718	rs9294171	ENSG00000272129.1	RP11-250B2.6	5.43	7.09e-08	8.94e-06	0.21	0.17	Sitting height ratio;	chr6:80130098	chr6:80355424~80356859:+
BRCA	cis	rs7927592	0.956	rs10896334	ENSG00000212093.1	AP000807.1	5.43	7.09e-08	8.94e-06	0.19	0.17	Total body bone mineral density;	chr11:68514026	chr11:68506083~68506166:-
BRCA	cis	rs1707322	0.656	rs2991981	ENSG00000234329.1	RP11-767N6.2	-5.43	7.1e-08	8.95e-06	-0.17	-0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45591472	chr1:45651039~45651826:-
BRCA	cis	rs2179367	0.632	rs12196750	ENSG00000223701.3	RAET1E-AS1	5.43	7.1e-08	8.95e-06	0.24	0.17	Dupuytren's disease;	chr6:149413335	chr6:149884431~149919508:+
BRCA	cis	rs2554380	0.628	rs7179507	ENSG00000230373.7	GOLGA6L5P	-5.43	7.1e-08	8.95e-06	-0.2	-0.17	Height;	chr15:83804779	chr15:84507885~84516814:-
BRCA	cis	rs2919009	0.607	rs12265028	ENSG00000271670.1	RP11-95I16.4	5.43	7.1e-08	8.95e-06	0.22	0.17	Obesity-related traits;	chr10:120959561	chr10:120879256~120880667:-
BRCA	cis	rs950776	0.518	rs3813571	ENSG00000279373.1	RP11-650L12.4	5.43	7.1e-08	8.95e-06	0.21	0.17	Sudden cardiac arrest;	chr15:78540450	chr15:78537681~78538946:+
BRCA	cis	rs6570726	0.791	rs418701	ENSG00000270638.1	RP3-466P17.1	5.43	7.1e-08	8.95e-06	0.19	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145568856	chr6:145735570~145737218:+
BRCA	cis	rs6570726	0.791	rs1280275	ENSG00000270638.1	RP3-466P17.1	5.43	7.1e-08	8.95e-06	0.19	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145571266	chr6:145735570~145737218:+
BRCA	cis	rs9300255	0.722	rs12322888	ENSG00000235423.7	RP11-282O18.3	5.43	7.11e-08	8.96e-06	0.21	0.17	Neutrophil percentage of white cells;	chr12:123341012	chr12:123252030~123261483:-
BRCA	cis	rs9659323	0.65	rs10923705	ENSG00000231365.4	RP11-418J17.1	-5.43	7.11e-08	8.96e-06	-0.21	-0.17	Body mass index;	chr1:118955781	chr1:119140396~119275973:+
BRCA	cis	rs9545047	0.604	rs7986306	ENSG00000227354.5	RBM26-AS1	5.43	7.11e-08	8.96e-06	0.18	0.17	Schizophrenia;	chr13:79392530	chr13:79406309~79424328:+
BRCA	cis	rs9545047	0.604	rs7329331	ENSG00000227354.5	RBM26-AS1	5.43	7.11e-08	8.96e-06	0.18	0.17	Schizophrenia;	chr13:79384986	chr13:79406309~79424328:+
BRCA	cis	rs9545047	0.604	rs7330479	ENSG00000227354.5	RBM26-AS1	5.43	7.11e-08	8.96e-06	0.18	0.17	Schizophrenia;	chr13:79385058	chr13:79406309~79424328:+
BRCA	cis	rs9545047	0.604	rs6563104	ENSG00000227354.5	RBM26-AS1	5.43	7.11e-08	8.96e-06	0.18	0.17	Schizophrenia;	chr13:79389718	chr13:79406309~79424328:+
BRCA	cis	rs9545047	0.604	rs7981500	ENSG00000227354.5	RBM26-AS1	5.43	7.11e-08	8.96e-06	0.18	0.17	Schizophrenia;	chr13:79391461	chr13:79406309~79424328:+
BRCA	cis	rs9545047	0.604	rs57821487	ENSG00000227354.5	RBM26-AS1	5.43	7.11e-08	8.96e-06	0.18	0.17	Schizophrenia;	chr13:79392810	chr13:79406309~79424328:+
BRCA	cis	rs9545047	0.604	rs7323246	ENSG00000227354.5	RBM26-AS1	5.43	7.11e-08	8.96e-06	0.18	0.17	Schizophrenia;	chr13:79392903	chr13:79406309~79424328:+
BRCA	cis	rs9545047	0.604	rs7331766	ENSG00000227354.5	RBM26-AS1	5.43	7.11e-08	8.96e-06	0.18	0.17	Schizophrenia;	chr13:79394076	chr13:79406309~79424328:+
BRCA	cis	rs13178541	0.688	rs10079688	ENSG00000250378.1	RP11-119J18.1	-5.43	7.11e-08	8.96e-06	-0.24	-0.17	IgG glycosylation;	chr5:135858587	chr5:135812667~135826582:+
BRCA	cis	rs6490294	0.571	rs11066119	ENSG00000226469.1	ADAM1B	5.43	7.12e-08	8.97e-06	0.25	0.17	Mean platelet volume;	chr12:111996700	chr12:111927018~111929017:+
BRCA	cis	rs597539	0.652	rs514833	ENSG00000261625.1	RP11-554A11.4	-5.43	7.12e-08	8.97e-06	-0.16	-0.17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68890266	chr11:69000765~69002048:-
BRCA	cis	rs597539	0.652	rs488363	ENSG00000261625.1	RP11-554A11.4	-5.43	7.12e-08	8.97e-06	-0.16	-0.17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68890830	chr11:69000765~69002048:-
BRCA	cis	rs10911251	0.508	rs2296297	ENSG00000224468.3	RP11-181K3.4	-5.43	7.13e-08	8.99e-06	-0.18	-0.17	Colorectal cancer;	chr1:183136189	chr1:183138402~183141282:-
BRCA	cis	rs10129255	0.5	rs34326748	ENSG00000224373.3	IGHV4-59	5.43	7.14e-08	8.99e-06	0.09	0.17	Kawasaki disease;	chr14:106782523	chr14:106627249~106627825:-
BRCA	cis	rs10129255	0.5	rs10143385	ENSG00000224373.3	IGHV4-59	5.43	7.14e-08	8.99e-06	0.09	0.17	Kawasaki disease;	chr14:106782559	chr14:106627249~106627825:-
BRCA	cis	rs1979679	0.918	rs11049529	ENSG00000278733.1	RP11-425D17.1	5.43	7.14e-08	8.99e-06	0.21	0.17	Ossification of the posterior longitudinal ligament of the spine;	chr12:28318571	chr12:28185625~28186190:-
BRCA	cis	rs9287719	0.649	rs12473957	ENSG00000243819.4	RN7SL832P	-5.43	7.14e-08	8.99e-06	-0.17	-0.17	Prostate cancer;	chr2:10577588	chr2:10690344~10692099:+
BRCA	cis	rs7620503	1	rs6801849	ENSG00000228221.4	LINC00578	5.43	7.14e-08	8.99e-06	0.19	0.17	Corneal structure;	chr3:177580036	chr3:177441921~177752305:+
BRCA	cis	rs10946940	0.897	rs6456801	ENSG00000216901.1	AL022393.7	5.43	7.15e-08	9e-06	0.21	0.17	Systemic lupus erythematosus;	chr6:27657753	chr6:28176188~28176674:+
BRCA	cis	rs2836950	0.501	rs62223052	ENSG00000255568.3	BRWD1-AS2	-5.43	7.15e-08	9e-06	-0.16	-0.17	Menarche (age at onset);	chr21:39336776	chr21:39313935~39314962:+
BRCA	cis	rs875971	0.66	rs62465434	ENSG00000273024.4	INTS4P2	-5.43	7.15e-08	9e-06	-0.18	-0.17	Aortic root size;	chr7:66540165	chr7:65647864~65715661:+
BRCA	cis	rs3120667	0.79	rs4285700	ENSG00000237975.5	FLG-AS1	5.43	7.15e-08	9e-06	0.25	0.17	Eating disorders;	chr1:152415152	chr1:152168125~152445456:+
BRCA	cis	rs7208859	0.623	rs3794796	ENSG00000280069.1	CTD-2349P21.3	-5.43	7.15e-08	9e-06	-0.24	-0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30803862	chr17:30738182~30740275:+
BRCA	cis	rs2239547	0.603	rs2276825	ENSG00000242142.1	SERBP1P3	5.43	7.15e-08	9e-06	0.21	0.17	Schizophrenia;	chr3:52852589	chr3:53064283~53065091:-
BRCA	cis	rs3733585	0.699	rs6856127	ENSG00000250413.1	RP11-448G15.1	5.43	7.16e-08	9.02e-06	0.22	0.17	Cleft plate (environmental tobacco smoke interaction);	chr4:9963819	chr4:10006482~10009725:+
BRCA	cis	rs6832769	0.925	rs4865018	ENSG00000223305.1	RN7SKP30	-5.43	7.16e-08	9.02e-06	-0.21	-0.17	Personality dimensions;	chr4:55591024	chr4:55540502~55540835:-
BRCA	cis	rs9341808	0.618	rs6916507	ENSG00000272129.1	RP11-250B2.6	5.43	7.16e-08	9.02e-06	0.21	0.17	Sitting height ratio;	chr6:80152548	chr6:80355424~80356859:+
BRCA	cis	rs2836950	0.772	rs62222988	ENSG00000238141.2	BRWD1-AS1	-5.43	7.17e-08	9.03e-06	-0.2	-0.17	Menarche (age at onset);	chr21:39197582	chr21:39315707~39323218:+
BRCA	cis	rs950776	0.518	rs8025429	ENSG00000279373.1	RP11-650L12.4	-5.43	7.17e-08	9.03e-06	-0.2	-0.17	Sudden cardiac arrest;	chr15:78544020	chr15:78537681~78538946:+
BRCA	cis	rs950776	0.518	rs4886572	ENSG00000279373.1	RP11-650L12.4	-5.43	7.17e-08	9.03e-06	-0.2	-0.17	Sudden cardiac arrest;	chr15:78545110	chr15:78537681~78538946:+
BRCA	cis	rs4950322	0.542	rs4950384	ENSG00000244371.2	PFN1P8	-5.43	7.17e-08	9.03e-06	-0.22	-0.17	Protein quantitative trait loci;	chr1:147177310	chr1:146957117~146957659:-
BRCA	cis	rs1426063	0.858	rs72662426	ENSG00000260265.1	RP11-44F21.5	5.43	7.17e-08	9.03e-06	0.27	0.17	QT interval;	chr4:75084828	chr4:75081702~75084717:-
BRCA	cis	rs8114671	0.551	rs4911162	ENSG00000269202.1	RP4-614O4.12	-5.43	7.18e-08	9.04e-06	-0.17	-0.17	Height;	chr20:34823622	chr20:35201747~35203288:-
BRCA	cis	rs862034	0.509	rs2190876	ENSG00000270000.1	RP3-449M8.9	5.43	7.18e-08	9.04e-06	0.2	0.17	Height;	chr14:74465565	chr14:74471930~74472360:-
BRCA	cis	rs3733585	0.699	rs10001964	ENSG00000250413.1	RP11-448G15.1	5.43	7.18e-08	9.04e-06	0.22	0.17	Cleft plate (environmental tobacco smoke interaction);	chr4:9957651	chr4:10006482~10009725:+
BRCA	cis	rs3733585	0.699	rs6449158	ENSG00000250413.1	RP11-448G15.1	5.43	7.18e-08	9.04e-06	0.22	0.17	Cleft plate (environmental tobacco smoke interaction);	chr4:9958835	chr4:10006482~10009725:+
BRCA	cis	rs3733585	0.637	rs6850684	ENSG00000250413.1	RP11-448G15.1	5.43	7.18e-08	9.04e-06	0.22	0.17	Cleft plate (environmental tobacco smoke interaction);	chr4:9962756	chr4:10006482~10009725:+
BRCA	cis	rs1005277	0.579	rs2103938	ENSG00000263064.2	RP11-291L22.7	5.43	7.18e-08	9.05e-06	0.2	0.17	Extrinsic epigenetic age acceleration;	chr10:38205070	chr10:38448689~38448949:+
BRCA	cis	rs1707322	0.752	rs7541962	ENSG00000234329.1	RP11-767N6.2	5.43	7.19e-08	9.05e-06	0.18	0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45769445	chr1:45651039~45651826:-
BRCA	cis	rs6570726	0.764	rs9322028	ENSG00000270638.1	RP3-466P17.1	5.43	7.19e-08	9.05e-06	0.19	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145574661	chr6:145735570~145737218:+
BRCA	cis	rs1859596	0.966	rs2269992	ENSG00000234456.6	MAGI2-AS3	5.43	7.19e-08	9.05e-06	0.11	0.17	Reading or mathematical ability;	chr7:79461284	chr7:79452877~79471208:+
BRCA	cis	rs757081	0.533	rs56030184	ENSG00000184669.7	OR7E14P	-5.43	7.19e-08	9.06e-06	-0.26	-0.17	Systolic blood pressure;	chr11:17046302	chr11:17013998~17053024:+
BRCA	cis	rs62025270	0.688	rs17575870	ENSG00000202081.1	RNU6-1280P	-5.43	7.19e-08	9.06e-06	-0.25	-0.17	Idiopathic pulmonary fibrosis;	chr15:85713926	chr15:85651522~85651628:-
BRCA	cis	rs7674212	0.51	rs2720468	ENSG00000246560.2	RP11-10L12.4	5.43	7.2e-08	9.06e-06	0.18	0.17	Type 2 diabetes;	chr4:103163996	chr4:102828055~102844075:+
BRCA	cis	rs875971	0.66	rs801217	ENSG00000273024.4	INTS4P2	5.43	7.2e-08	9.06e-06	0.18	0.17	Aortic root size;	chr7:66545590	chr7:65647864~65715661:+
BRCA	cis	rs875971	0.638	rs801216	ENSG00000273024.4	INTS4P2	5.43	7.2e-08	9.06e-06	0.18	0.17	Aortic root size;	chr7:66546680	chr7:65647864~65715661:+
BRCA	cis	rs875971	0.66	rs13224319	ENSG00000273024.4	INTS4P2	-5.43	7.2e-08	9.06e-06	-0.18	-0.17	Aortic root size;	chr7:66542376	chr7:65647864~65715661:+
BRCA	cis	rs2179367	0.586	rs62426088	ENSG00000223701.3	RAET1E-AS1	5.43	7.2e-08	9.07e-06	0.24	0.17	Dupuytren's disease;	chr6:149339301	chr6:149884431~149919508:+
BRCA	cis	rs10851478	0.872	rs12148764	ENSG00000259531.2	RP11-295H24.3	5.43	7.2e-08	9.07e-06	0.24	0.17	Oral cavity cancer;	chr15:49463884	chr15:49365124~49366685:-
BRCA	cis	rs2153535	0.58	rs9505455	ENSG00000251164.1	HULC	-5.43	7.2e-08	9.07e-06	-0.2	-0.17	Motion sickness;	chr6:8478389	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.58	rs9379216	ENSG00000251164.1	HULC	-5.43	7.2e-08	9.07e-06	-0.2	-0.17	Motion sickness;	chr6:8481002	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.58	rs7450817	ENSG00000251164.1	HULC	-5.43	7.2e-08	9.07e-06	-0.2	-0.17	Motion sickness;	chr6:8481188	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.56	rs2210798	ENSG00000251164.1	HULC	-5.43	7.2e-08	9.07e-06	-0.2	-0.17	Motion sickness;	chr6:8481289	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.58	rs6597327	ENSG00000251164.1	HULC	-5.43	7.2e-08	9.07e-06	-0.2	-0.17	Motion sickness;	chr6:8481924	chr6:8652137~8653846:+
BRCA	cis	rs9467773	1	rs1535277	ENSG00000124549.13	BTN2A3P	5.43	7.2e-08	9.07e-06	0.17	0.17	Intelligence (multi-trait analysis);	chr6:26567574	chr6:26421391~26432383:+
BRCA	cis	rs9467773	1	rs1884948	ENSG00000124549.13	BTN2A3P	5.43	7.2e-08	9.07e-06	0.17	0.17	Intelligence (multi-trait analysis);	chr6:26567760	chr6:26421391~26432383:+
BRCA	cis	rs9467773	1	rs1884949	ENSG00000124549.13	BTN2A3P	5.43	7.2e-08	9.07e-06	0.17	0.17	Intelligence (multi-trait analysis);	chr6:26567839	chr6:26421391~26432383:+
BRCA	cis	rs9467773	1	rs9467796	ENSG00000124549.13	BTN2A3P	5.43	7.2e-08	9.07e-06	0.17	0.17	Intelligence (multi-trait analysis);	chr6:26568183	chr6:26421391~26432383:+
BRCA	cis	rs9467773	1	rs9467797	ENSG00000124549.13	BTN2A3P	5.43	7.2e-08	9.07e-06	0.17	0.17	Intelligence (multi-trait analysis);	chr6:26568245	chr6:26421391~26432383:+
BRCA	cis	rs9467773	1	rs1078679	ENSG00000124549.13	BTN2A3P	5.43	7.2e-08	9.07e-06	0.17	0.17	Intelligence (multi-trait analysis);	chr6:26568513	chr6:26421391~26432383:+
BRCA	cis	rs875971	0.862	rs6964437	ENSG00000236529.1	RP13-254B10.1	-5.42	7.21e-08	9.07e-06	-0.19	-0.17	Aortic root size;	chr7:66221457	chr7:65840212~65840596:+
BRCA	cis	rs4671400	0.571	rs12615222	ENSG00000271889.1	RP11-493E12.1	-5.42	7.21e-08	9.07e-06	-0.25	-0.17	3-hydroxypropylmercapturic acid levels in smokers;	chr2:61267760	chr2:61151433~61162105:-
BRCA	cis	rs7727544	0.606	rs200838	ENSG00000233006.5	AC034220.3	-5.42	7.22e-08	9.09e-06	-0.12	-0.17	Blood metabolite levels;	chr5:132374707	chr5:132311285~132369916:-
BRCA	cis	rs6832769	1	rs4865010	ENSG00000272969.1	RP11-528I4.2	-5.42	7.22e-08	9.09e-06	-0.2	-0.17	Personality dimensions;	chr4:55548795	chr4:55547112~55547889:+
BRCA	cis	rs6723226	0.803	rs176415	ENSG00000276517.1	AL133243.2	5.42	7.24e-08	9.11e-06	0.21	0.17	Intelligence (multi-trait analysis);	chr2:32424710	chr2:32526504~32529507:+
BRCA	cis	rs35146811	0.807	rs6465761	ENSG00000235713.1	RP4-604G5.3	5.42	7.24e-08	9.11e-06	0.19	0.17	Coronary artery disease;	chr7:100022654	chr7:99992397~99993050:+
BRCA	cis	rs2179367	0.568	rs62426092	ENSG00000223701.3	RAET1E-AS1	5.42	7.24e-08	9.11e-06	0.24	0.17	Dupuytren's disease;	chr6:149352720	chr6:149884431~149919508:+
BRCA	cis	rs4711336	0.967	rs4713658	ENSG00000224557.6	HLA-DPB2	-5.42	7.24e-08	9.12e-06	-0.2	-0.17	Height;	chr6:33699340	chr6:33112451~33129084:+
BRCA	cis	rs1440410	0.835	rs4407450	ENSG00000250326.1	RP11-284M14.1	-5.42	7.24e-08	9.12e-06	-0.18	-0.17	Ischemic stroke;	chr4:143225854	chr4:142933195~143184861:-
BRCA	cis	rs1440410	0.835	rs6828369	ENSG00000250326.1	RP11-284M14.1	-5.42	7.24e-08	9.12e-06	-0.18	-0.17	Ischemic stroke;	chr4:143226331	chr4:142933195~143184861:-
BRCA	cis	rs1440410	0.835	rs13116414	ENSG00000250326.1	RP11-284M14.1	-5.42	7.24e-08	9.12e-06	-0.18	-0.17	Ischemic stroke;	chr4:143226473	chr4:142933195~143184861:-
BRCA	cis	rs300890	0.536	rs9996072	ENSG00000250326.1	RP11-284M14.1	-5.42	7.25e-08	9.12e-06	-0.2	-0.17	Nasopharyngeal carcinoma;	chr4:143208808	chr4:142933195~143184861:-
BRCA	cis	rs1440410	0.536	rs10009906	ENSG00000250326.1	RP11-284M14.1	-5.42	7.25e-08	9.12e-06	-0.2	-0.17	Ischemic stroke;	chr4:143210204	chr4:142933195~143184861:-
BRCA	cis	rs7618915	0.547	rs4687636	ENSG00000243224.1	RP5-1157M23.2	-5.42	7.25e-08	9.13e-06	-0.18	-0.17	Bipolar disorder;	chr3:52599913	chr3:52239258~52241097:+
BRCA	cis	rs7618915	0.547	rs34173654	ENSG00000243224.1	RP5-1157M23.2	-5.42	7.25e-08	9.13e-06	-0.18	-0.17	Bipolar disorder;	chr3:52600589	chr3:52239258~52241097:+
BRCA	cis	rs8114671	0.562	rs2424999	ENSG00000269202.1	RP4-614O4.12	-5.42	7.25e-08	9.13e-06	-0.17	-0.17	Height;	chr20:34798627	chr20:35201747~35203288:-
BRCA	cis	rs7267979	0.545	rs6050426	ENSG00000277938.1	RP5-965G21.3	5.42	7.25e-08	9.13e-06	0.2	0.17	Liver enzyme levels (alkaline phosphatase);	chr20:25197629	chr20:25229150~25231933:+
BRCA	cis	rs9638182	1	rs11974409	ENSG00000274080.1	CTA-315H11.2	5.42	7.26e-08	9.13e-06	0.29	0.17	Triglycerides;	chr7:73575060	chr7:73609262~73611502:-
BRCA	cis	rs6479901	0.557	rs1009984	ENSG00000232075.1	MRPL35P2	-5.42	7.26e-08	9.13e-06	-0.25	-0.17	Intelligence (multi-trait analysis);	chr10:63156709	chr10:63634317~63634827:-
BRCA	cis	rs9467773	1	rs6932156	ENSG00000124549.13	BTN2A3P	5.42	7.28e-08	9.16e-06	0.17	0.17	Intelligence (multi-trait analysis);	chr6:26571278	chr6:26421391~26432383:+
BRCA	cis	rs9467773	1	rs6924838	ENSG00000124549.13	BTN2A3P	5.42	7.28e-08	9.16e-06	0.17	0.17	Intelligence (multi-trait analysis);	chr6:26571528	chr6:26421391~26432383:+
BRCA	cis	rs875971	0.66	rs801211	ENSG00000273024.4	INTS4P2	5.42	7.28e-08	9.16e-06	0.18	0.17	Aortic root size;	chr7:66550702	chr7:65647864~65715661:+
BRCA	cis	rs875971	0.638	rs801205	ENSG00000273024.4	INTS4P2	5.42	7.28e-08	9.16e-06	0.18	0.17	Aortic root size;	chr7:66557157	chr7:65647864~65715661:+
BRCA	cis	rs875971	0.617	rs810400	ENSG00000273024.4	INTS4P2	5.42	7.28e-08	9.16e-06	0.18	0.17	Aortic root size;	chr7:66557902	chr7:65647864~65715661:+
BRCA	cis	rs6674176	0.551	rs2906596	ENSG00000237950.1	RP11-7O11.3	5.42	7.29e-08	9.17e-06	0.28	0.17	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43961276	chr1:43944370~43946551:-
BRCA	cis	rs9847710	1	rs12488768	ENSG00000242142.1	SERBP1P3	-5.42	7.3e-08	9.18e-06	-0.19	-0.17	Ulcerative colitis;	chr3:53052218	chr3:53064283~53065091:-
BRCA	cis	rs9545047	0.511	rs1624537	ENSG00000227354.5	RBM26-AS1	5.42	7.3e-08	9.19e-06	0.18	0.17	Schizophrenia;	chr13:79411686	chr13:79406309~79424328:+
BRCA	cis	rs3892630	0.824	rs35654350	ENSG00000267567.1	CTD-2538C1.3	5.42	7.31e-08	9.2e-06	0.27	0.17	Red blood cell traits;	chr19:32732860	chr19:32718298~32719595:-
BRCA	cis	rs11822910	0.911	rs11828218	ENSG00000265566.2	RN7SL605P	5.42	7.31e-08	9.2e-06	0.22	0.17	Platelet distribution width;	chr11:57428750	chr11:57528085~57528365:-
BRCA	cis	rs11763147	1	rs11763147	ENSG00000213640.3	EEF1DP4	5.42	7.31e-08	9.2e-06	0.2	0.17	Corneal structure;	chr7:65861834	chr7:64862999~64864370:+
BRCA	cis	rs1555322	0.53	rs6060347	ENSG00000269202.1	RP4-614O4.12	-5.42	7.32e-08	9.21e-06	-0.19	-0.17	Attention deficit hyperactivity disorder;	chr20:35286348	chr20:35201747~35203288:-
BRCA	cis	rs600231	0.665	rs1784858	ENSG00000173727.10	CMB9-22P13.1	5.42	7.32e-08	9.21e-06	0.21	0.17	Bone mineral density;	chr11:65455481	chr11:65455258~65466720:+
BRCA	cis	rs6832769	1	rs4864998	ENSG00000272969.1	RP11-528I4.2	5.42	7.32e-08	9.21e-06	0.21	0.17	Personality dimensions;	chr4:55466439	chr4:55547112~55547889:+
BRCA	cis	rs11051970	0.527	rs7309590	ENSG00000274964.1	RP11-817I4.1	-5.42	7.33e-08	9.22e-06	-0.22	-0.17	Response to tocilizumab in rheumatoid arthritis;	chr12:32337915	chr12:32339368~32340724:+
BRCA	cis	rs9467773	1	rs6925895	ENSG00000124549.13	BTN2A3P	5.42	7.33e-08	9.22e-06	0.17	0.17	Intelligence (multi-trait analysis);	chr6:26571937	chr6:26421391~26432383:+
BRCA	cis	rs5758511	0.68	rs5758692	ENSG00000205702.9	CYP2D7	5.42	7.34e-08	9.23e-06	0.17	0.17	Birth weight;	chr22:42273023	chr22:42140203~42144577:-
BRCA	cis	rs7976269	0.609	rs2349574	ENSG00000275476.1	RP11-996F15.4	-5.42	7.34e-08	9.23e-06	-0.19	-0.17	Male-pattern baldness;	chr12:29053805	chr12:29277397~29277882:-
BRCA	cis	rs8054556	0.787	rs35105141	ENSG00000273724.1	RP11-347C12.12	-5.42	7.35e-08	9.24e-06	-0.19	-0.17	Autism spectrum disorder or schizophrenia;	chr16:30045827	chr16:30336400~30343336:+
BRCA	cis	rs10129255	0.913	rs28861466	ENSG00000280411.1	IGHV1-69-2	-5.42	7.35e-08	9.24e-06	-0.13	-0.17	Kawasaki disease;	chr14:106718572	chr14:106762092~106762588:-
BRCA	cis	rs7772486	0.686	rs6933161	ENSG00000270638.1	RP3-466P17.1	-5.42	7.35e-08	9.25e-06	-0.19	-0.17	Lobe attachment (rater-scored or self-reported);	chr6:145760233	chr6:145735570~145737218:+
BRCA	cis	rs7772486	0.686	rs9399565	ENSG00000270638.1	RP3-466P17.1	-5.42	7.35e-08	9.25e-06	-0.19	-0.17	Lobe attachment (rater-scored or self-reported);	chr6:145760770	chr6:145735570~145737218:+
BRCA	cis	rs7267979	0.586	rs1007708	ENSG00000277938.1	RP5-965G21.3	5.42	7.35e-08	9.25e-06	0.2	0.17	Liver enzyme levels (alkaline phosphatase);	chr20:25210323	chr20:25229150~25231933:+
BRCA	cis	rs2638953	0.85	rs10843111	ENSG00000278733.1	RP11-425D17.1	-5.42	7.35e-08	9.25e-06	-0.22	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28141022	chr12:28185625~28186190:-
BRCA	cis	rs240993	0.715	rs6920798	ENSG00000271789.1	RP5-1112D6.7	5.42	7.36e-08	9.25e-06	0.21	0.17	Inflammatory skin disease;Psoriasis;	chr6:111526074	chr6:111297126~111298510:+
BRCA	cis	rs2030746	0.899	rs940688	ENSG00000237614.1	AC073257.2	5.42	7.36e-08	9.25e-06	0.2	0.17	LDL cholesterol;Total cholesterol levels;LDL cholesterol levels;	chr2:120553424	chr2:120542909~120544326:-
BRCA	cis	rs891378	1	rs10864181	ENSG00000274245.1	RP11-357P18.2	-5.42	7.36e-08	9.25e-06	-0.24	-0.17	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207274706	chr1:207372559~207373252:+
BRCA	cis	rs17711722	0.565	rs73372653	ENSG00000275400.1	RP4-756H11.5	-5.42	7.36e-08	9.25e-06	-0.2	-0.17	Calcium levels;	chr7:65977808	chr7:66553805~66554199:-
BRCA	cis	rs13118159	0.505	rs1250128	ENSG00000254094.1	AC078852.1	5.42	7.37e-08	9.26e-06	0.21	0.17	Longevity;	chr4:1263523	chr4:1356581~1358075:+
BRCA	cis	rs4713118	0.662	rs149901	ENSG00000280107.1	AL022393.9	-5.42	7.37e-08	9.27e-06	-0.24	-0.17	Parkinson's disease;	chr6:27997725	chr6:28170845~28172521:+
BRCA	cis	rs6754311	0.731	rs1470457	ENSG00000224043.6	CCNT2-AS1	-5.42	7.37e-08	9.27e-06	-0.23	-0.17	Mosquito bite size;	chr2:135824278	chr2:134735464~134918710:-
BRCA	cis	rs853679	0.599	rs156743	ENSG00000204709.4	LINC01556	5.42	7.38e-08	9.27e-06	0.34	0.17	Depression;	chr6:27999311	chr6:28943877~28944537:+
BRCA	cis	rs1499614	1	rs1638731	ENSG00000228409.4	CCT6P1	5.42	7.38e-08	9.27e-06	0.23	0.17	Gout;	chr7:66679692	chr7:65751142~65763354:+
BRCA	cis	rs1499614	1	rs1882655	ENSG00000228409.4	CCT6P1	-5.42	7.38e-08	9.27e-06	-0.23	-0.17	Gout;	chr7:66682070	chr7:65751142~65763354:+
BRCA	cis	rs1499614	0.831	rs3800822	ENSG00000228409.4	CCT6P1	-5.42	7.38e-08	9.27e-06	-0.23	-0.17	Gout;	chr7:66682162	chr7:65751142~65763354:+
BRCA	cis	rs1979679	0.918	rs10843176	ENSG00000278733.1	RP11-425D17.1	-5.42	7.38e-08	9.27e-06	-0.21	-0.17	Ossification of the posterior longitudinal ligament of the spine;	chr12:28454984	chr12:28185625~28186190:-
BRCA	cis	rs1223397	0.938	rs17767967	ENSG00000215022.6	RP1-257A7.4	-5.42	7.38e-08	9.27e-06	-0.24	-0.17	Blood pressure;	chr6:13281835	chr6:13264861~13295586:-
BRCA	cis	rs745109	0.504	rs113679164	ENSG00000273080.1	RP11-301O19.1	5.42	7.38e-08	9.28e-06	0.27	0.17	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86411479	chr2:86195590~86196049:+
BRCA	cis	rs5758511	0.68	rs5758687	ENSG00000205702.9	CYP2D7	5.42	7.38e-08	9.28e-06	0.17	0.17	Birth weight;	chr22:42260582	chr22:42140203~42144577:-
BRCA	cis	rs2051773	0.567	rs4255517	ENSG00000184669.7	OR7E14P	-5.42	7.38e-08	9.28e-06	-0.24	-0.17	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);	chr11:17021662	chr11:17013998~17053024:+
BRCA	cis	rs2153535	0.58	rs7763190	ENSG00000251164.1	HULC	-5.42	7.39e-08	9.28e-06	-0.2	-0.17	Motion sickness;	chr6:8483964	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.541	rs1414352	ENSG00000251164.1	HULC	-5.42	7.39e-08	9.28e-06	-0.2	-0.17	Motion sickness;	chr6:8485314	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.58	rs1577471	ENSG00000251164.1	HULC	-5.42	7.39e-08	9.28e-06	-0.2	-0.17	Motion sickness;	chr6:8485672	chr6:8652137~8653846:+
BRCA	cis	rs3770081	1	rs2303340	ENSG00000273080.1	RP11-301O19.1	-5.42	7.4e-08	9.29e-06	-0.38	-0.17	Facial emotion recognition (sad faces);	chr2:86106070	chr2:86195590~86196049:+
BRCA	cis	rs875971	0.522	rs4718286	ENSG00000273024.4	INTS4P2	-5.42	7.4e-08	9.3e-06	-0.18	-0.17	Aortic root size;	chr7:65827777	chr7:65647864~65715661:+
BRCA	cis	rs17711722	0.585	rs6942660	ENSG00000273024.4	INTS4P2	-5.42	7.4e-08	9.3e-06	-0.18	-0.17	Calcium levels;	chr7:65837419	chr7:65647864~65715661:+
BRCA	cis	rs370915	0.578	rs2375939	ENSG00000250971.1	RP11-696F12.1	5.42	7.4e-08	9.3e-06	0.18	0.17	Gout;	chr4:186862572	chr4:187060099~187060930:+
BRCA	cis	rs867371	0.896	rs8033831	ENSG00000278603.1	RP13-608F4.5	5.42	7.4e-08	9.3e-06	0.22	0.17	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82220953	chr15:82472203~82472426:+
BRCA	cis	rs12144309	0.554	rs1217375	ENSG00000232450.1	RP4-730K3.3	5.42	7.4e-08	9.3e-06	0.22	0.17	Coronary artery disease;	chr1:113804282	chr1:113698884~113699631:-
BRCA	cis	rs3733585	0.699	rs12498150	ENSG00000250413.1	RP11-448G15.1	5.42	7.4e-08	9.31e-06	0.21	0.17	Cleft plate (environmental tobacco smoke interaction);	chr4:9948913	chr4:10006482~10009725:+
BRCA	cis	rs7200543	1	rs14347	ENSG00000275910.1	RP11-680G24.6	-5.42	7.41e-08	9.31e-06	-0.19	-0.17	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15040032	chr16:15015828~15016390:-
BRCA	cis	rs7044106	0.791	rs10984997	ENSG00000238181.2	AHCYP2	-5.42	7.41e-08	9.31e-06	-0.21	-0.17	Hip circumference adjusted for BMI;	chr9:120718928	chr9:120720673~120721972:+
BRCA	cis	rs357618	1	rs357620	ENSG00000260581.1	CTB-113P19.4	5.42	7.41e-08	9.32e-06	0.19	0.17	Basophil percentage of white cells;	chr5:151467560	chr5:151652275~151655449:+
BRCA	cis	rs55702914	0.839	rs2059922	ENSG00000231621.1	AC013264.2	5.42	7.41e-08	9.32e-06	0.17	0.17	Major depression and alcohol dependence;	chr2:197324179	chr2:197197991~197199273:+
BRCA	cis	rs9300255	0.739	rs1879380	ENSG00000235423.7	RP11-282O18.3	-5.42	7.42e-08	9.32e-06	-0.24	-0.17	Neutrophil percentage of white cells;	chr12:123254564	chr12:123252030~123261483:-
BRCA	cis	rs875971	0.642	rs35526611	ENSG00000273024.4	INTS4P2	5.42	7.42e-08	9.32e-06	0.18	0.17	Aortic root size;	chr7:66629021	chr7:65647864~65715661:+
BRCA	cis	rs2303319	0.504	rs1551052	ENSG00000227403.1	AC009299.3	5.42	7.42e-08	9.32e-06	0.28	0.17	Cognitive function;	chr2:161736144	chr2:161244739~161249050:+
BRCA	cis	rs867371	0.929	rs1045508	ENSG00000278603.1	RP13-608F4.5	-5.42	7.42e-08	9.32e-06	-0.22	-0.17	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82157565	chr15:82472203~82472426:+
BRCA	cis	rs638893	0.578	rs582200	ENSG00000255239.1	AP002954.6	-5.42	7.42e-08	9.32e-06	-0.28	-0.17	Vitiligo;	chr11:118798199	chr11:118688039~118690600:-
BRCA	cis	rs11220082	0.666	rs12224788	ENSG00000254671.2	STT3A-AS1	-5.42	7.42e-08	9.32e-06	-0.21	-0.17	Schizophrenia;	chr11:125459165	chr11:125570284~125592568:-
BRCA	cis	rs2179367	0.959	rs652807	ENSG00000216906.2	RP11-350J20.9	-5.42	7.42e-08	9.32e-06	-0.21	-0.17	Dupuytren's disease;	chr6:149416359	chr6:149904243~149906418:+
BRCA	cis	rs2153535	0.546	rs1335640	ENSG00000251164.1	HULC	-5.42	7.42e-08	9.33e-06	-0.2	-0.17	Motion sickness;	chr6:8485092	chr6:8652137~8653846:+
BRCA	cis	rs7267979	0.78	rs2500413	ENSG00000277938.1	RP5-965G21.3	5.42	7.42e-08	9.33e-06	0.2	0.17	Liver enzyme levels (alkaline phosphatase);	chr20:25260519	chr20:25229150~25231933:+
BRCA	cis	rs7267979	0.714	rs2474763	ENSG00000277938.1	RP5-965G21.3	5.42	7.42e-08	9.33e-06	0.2	0.17	Liver enzyme levels (alkaline phosphatase);	chr20:25260659	chr20:25229150~25231933:+
BRCA	cis	rs8098244	0.706	rs1154227	ENSG00000264745.1	TTC39C-AS1	-5.42	7.43e-08	9.33e-06	-0.2	-0.17	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23901376	chr18:23994213~24015339:-
BRCA	cis	rs35612822	0.866	rs10207455	ENSG00000232485.2	AC098820.3	5.42	7.43e-08	9.33e-06	0.21	0.17	Kidney disease (early stage) in type 1 diabetes;	chr2:216460888	chr2:216479030~216498761:-
BRCA	cis	rs10129255	0.5	rs1024350	ENSG00000224373.3	IGHV4-59	5.42	7.44e-08	9.34e-06	0.09	0.17	Kawasaki disease;	chr14:106685105	chr14:106627249~106627825:-
BRCA	cis	rs2638953	0.64	rs10843208	ENSG00000278733.1	RP11-425D17.1	-5.42	7.44e-08	9.35e-06	-0.22	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28572171	chr12:28185625~28186190:-
BRCA	cis	rs9840812	0.623	rs6794351	ENSG00000239213.4	NCK1-AS1	5.42	7.44e-08	9.35e-06	0.2	0.17	Fibrinogen levels;	chr3:136573437	chr3:136841726~136862054:-
BRCA	cis	rs4950322	0.58	rs17355419	ENSG00000278811.3	LINC00624	5.42	7.46e-08	9.37e-06	0.21	0.17	Protein quantitative trait loci;	chr1:147110094	chr1:147258885~147517875:-
BRCA	cis	rs4950322	0.58	rs72706428	ENSG00000278811.3	LINC00624	5.42	7.46e-08	9.37e-06	0.21	0.17	Protein quantitative trait loci;	chr1:147110219	chr1:147258885~147517875:-
BRCA	cis	rs4950322	0.563	rs61838944	ENSG00000278811.3	LINC00624	5.42	7.46e-08	9.37e-06	0.21	0.17	Protein quantitative trait loci;	chr1:147110275	chr1:147258885~147517875:-
BRCA	cis	rs17253792	0.598	rs35830444	ENSG00000186615.9	KTN1-AS1	-5.42	7.46e-08	9.37e-06	-0.34	-0.17	Putamen volume;	chr14:55550632	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.659	rs34330219	ENSG00000186615.9	KTN1-AS1	-5.42	7.46e-08	9.37e-06	-0.34	-0.17	Putamen volume;	chr14:55550657	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.545	rs35418987	ENSG00000186615.9	KTN1-AS1	-5.42	7.46e-08	9.37e-06	-0.34	-0.17	Putamen volume;	chr14:55550689	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.545	rs35294669	ENSG00000186615.9	KTN1-AS1	-5.42	7.46e-08	9.37e-06	-0.34	-0.17	Putamen volume;	chr14:55550720	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.545	rs12879705	ENSG00000186615.9	KTN1-AS1	-5.42	7.46e-08	9.37e-06	-0.34	-0.17	Putamen volume;	chr14:55550966	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.598	rs12880362	ENSG00000186615.9	KTN1-AS1	-5.42	7.46e-08	9.37e-06	-0.34	-0.17	Putamen volume;	chr14:55551211	chr14:55499278~55580110:-
BRCA	cis	rs17253792	0.545	rs12883972	ENSG00000186615.9	KTN1-AS1	-5.42	7.46e-08	9.37e-06	-0.34	-0.17	Putamen volume;	chr14:55551302	chr14:55499278~55580110:-
BRCA	cis	rs295490	0.748	rs77016755	ENSG00000272656.1	RP11-219D15.3	5.42	7.46e-08	9.37e-06	0.38	0.17	PR interval in Tripanosoma cruzi seropositivity;	chr3:139392125	chr3:139349024~139349371:-
BRCA	cis	rs295490	0.748	rs61034702	ENSG00000272656.1	RP11-219D15.3	5.42	7.46e-08	9.37e-06	0.38	0.17	PR interval in Tripanosoma cruzi seropositivity;	chr3:139395105	chr3:139349024~139349371:-
BRCA	cis	rs9307551	0.619	rs4975054	ENSG00000250334.4	LINC00989	-5.42	7.47e-08	9.38e-06	-0.23	-0.17	Refractive error;	chr4:79549923	chr4:79492416~79576460:+
BRCA	cis	rs9307551	0.619	rs4975055	ENSG00000250334.4	LINC00989	-5.42	7.47e-08	9.38e-06	-0.23	-0.17	Refractive error;	chr4:79550097	chr4:79492416~79576460:+
BRCA	cis	rs13113518	1	rs7660980	ENSG00000223305.1	RN7SKP30	-5.42	7.47e-08	9.38e-06	-0.2	-0.17	Height;	chr4:55542948	chr4:55540502~55540835:-
BRCA	cis	rs7927592	0.913	rs10896329	ENSG00000212093.1	AP000807.1	5.42	7.48e-08	9.39e-06	0.19	0.17	Total body bone mineral density;	chr11:68482561	chr11:68506083~68506166:-
BRCA	cis	rs7567389	0.719	rs6430936	ENSG00000236682.1	AC068282.3	5.42	7.48e-08	9.39e-06	0.26	0.17	Self-rated health;	chr2:127250110	chr2:127389130~127400580:+
BRCA	cis	rs3733585	0.699	rs17245723	ENSG00000250413.1	RP11-448G15.1	5.42	7.48e-08	9.39e-06	0.22	0.17	Cleft plate (environmental tobacco smoke interaction);	chr4:9960594	chr4:10006482~10009725:+
BRCA	cis	rs6832769	0.961	rs6824955	ENSG00000223305.1	RN7SKP30	5.42	7.48e-08	9.39e-06	0.21	0.17	Personality dimensions;	chr4:55450969	chr4:55540502~55540835:-
BRCA	cis	rs73222236	0.825	rs7612160	ENSG00000273486.1	RP11-731C17.2	5.42	7.49e-08	9.4e-06	0.19	0.17	Coronary artery disease;	chr3:136553963	chr3:136837338~136839021:-
BRCA	cis	rs910316	0.737	rs175065	ENSG00000279594.1	RP11-950C14.10	-5.42	7.49e-08	9.41e-06	-0.18	-0.17	Height;	chr14:75028280	chr14:75011269~75012851:-
BRCA	cis	rs13108904	0.539	rs13145722	ENSG00000254094.1	AC078852.1	-5.42	7.49e-08	9.41e-06	-0.2	-0.17	Obesity-related traits;	chr4:1344634	chr4:1356581~1358075:+
BRCA	cis	rs12291225	0.877	rs11023160	ENSG00000251991.1	RNU7-49P	5.42	7.5e-08	9.41e-06	0.2	0.17	Sense of smell;	chr11:14242679	chr11:14478892~14478953:+
BRCA	cis	rs11051970	0.559	rs11051946	ENSG00000274964.1	RP11-817I4.1	-5.42	7.5e-08	9.41e-06	-0.22	-0.17	Response to tocilizumab in rheumatoid arthritis;	chr12:32336335	chr12:32339368~32340724:+
BRCA	cis	rs17711722	0.565	rs4275112	ENSG00000182722.5	SEPHS1P1	5.42	7.5e-08	9.42e-06	0.21	0.17	Calcium levels;	chr7:65733651	chr7:64852397~64853354:-
BRCA	cis	rs2562456	0.793	rs627522	ENSG00000268081.1	RP11-678G14.2	5.42	7.5e-08	9.42e-06	0.24	0.17	Pain;	chr19:21313002	chr19:21554640~21569237:-
BRCA	cis	rs9847710	1	rs9847710	ENSG00000242142.1	SERBP1P3	5.42	7.51e-08	9.43e-06	0.19	0.17	Ulcerative colitis;	chr3:53028645	chr3:53064283~53065091:-
BRCA	cis	rs2638953	0.962	rs11049482	ENSG00000247934.4	RP11-967K21.1	-5.42	7.51e-08	9.43e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28252088	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.962	rs11049484	ENSG00000247934.4	RP11-967K21.1	-5.42	7.51e-08	9.43e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28252254	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.962	rs11049485	ENSG00000247934.4	RP11-967K21.1	-5.42	7.51e-08	9.43e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28252522	chr12:28163298~28190738:-
BRCA	cis	rs6688613	0.685	rs6427047	ENSG00000225171.2	DUTP6	-5.42	7.52e-08	9.44e-06	-0.22	-0.17	Refractive astigmatism;	chr1:166945021	chr1:166868748~166869209:+
BRCA	cis	rs7246657	0.722	rs3101746	ENSG00000276846.1	CTD-3220F14.3	-5.42	7.52e-08	9.44e-06	-0.23	-0.17	Coronary artery calcification;	chr19:37655499	chr19:37314868~37315620:-
BRCA	cis	rs2153535	0.58	rs2184586	ENSG00000251164.1	HULC	-5.42	7.52e-08	9.44e-06	-0.2	-0.17	Motion sickness;	chr6:8473949	chr6:8652137~8653846:+
BRCA	cis	rs1707322	0.752	rs11211168	ENSG00000234329.1	RP11-767N6.2	5.42	7.53e-08	9.45e-06	0.18	0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45697975	chr1:45651039~45651826:-
BRCA	cis	rs5758511	0.68	rs5758687	ENSG00000233903.2	Z83851.4	5.42	7.53e-08	9.45e-06	0.25	0.17	Birth weight;	chr22:42260582	chr22:42276355~42277052:+
BRCA	cis	rs9309473	1	rs7598419	ENSG00000163016.8	ALMS1P	5.42	7.53e-08	9.45e-06	0.22	0.17	Metabolite levels;	chr2:73571096	chr2:73644919~73685576:+
BRCA	cis	rs4781563	0.621	rs11648436	ENSG00000242307.1	RPS26P52	5.42	7.54e-08	9.46e-06	0.18	0.17	Bilirubin levels;	chr16:13914817	chr16:13922332~13922679:-
BRCA	cis	rs8098244	0.964	rs79685315	ENSG00000264745.1	TTC39C-AS1	-5.42	7.54e-08	9.46e-06	-0.23	-0.17	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23913774	chr18:23994213~24015339:-
BRCA	cis	rs7617773	0.817	rs9837228	ENSG00000199476.1	Y_RNA	5.42	7.54e-08	9.46e-06	0.23	0.17	Coronary artery disease;	chr3:48282976	chr3:48288587~48288694:+
BRCA	cis	rs792448	0.728	rs2252044	ENSG00000226251.4	RP11-15I11.3	-5.42	7.55e-08	9.47e-06	-0.22	-0.17	White blood cell count (basophil);	chr1:212342903	chr1:212225278~212238977:-
BRCA	cis	rs1979679	0.801	rs1965280	ENSG00000278733.1	RP11-425D17.1	5.42	7.55e-08	9.47e-06	0.21	0.17	Ossification of the posterior longitudinal ligament of the spine;	chr12:28143639	chr12:28185625~28186190:-
BRCA	cis	rs6732426	0.548	rs6544650	ENSG00000234936.1	AC010883.5	5.42	7.55e-08	9.48e-06	0.16	0.17	Hair morphology;	chr2:43389673	chr2:43229573~43233394:+
BRCA	cis	rs2554380	0.628	rs2081541	ENSG00000230373.7	GOLGA6L5P	-5.42	7.56e-08	9.48e-06	-0.2	-0.17	Height;	chr15:83774934	chr15:84507885~84516814:-
BRCA	cis	rs17711722	0.64	rs13237956	ENSG00000273024.4	INTS4P2	-5.42	7.56e-08	9.48e-06	-0.18	-0.17	Calcium levels;	chr7:65853042	chr7:65647864~65715661:+
BRCA	cis	rs13325613	0.915	rs17217831	ENSG00000223552.1	RP11-24F11.2	5.42	7.56e-08	9.49e-06	0.33	0.17	Monocyte count;	chr3:46263950	chr3:46364955~46407059:-
BRCA	cis	rs523522	0.962	rs509445	ENSG00000278344.1	RP11-18C24.8	5.42	7.56e-08	9.49e-06	0.22	0.17	High light scatter reticulocyte count;	chr12:120579440	chr12:120500735~120501090:-
BRCA	cis	rs507080	0.922	rs625513	ENSG00000278376.1	RP11-158I9.8	-5.42	7.56e-08	9.49e-06	-0.17	-0.17	Serum metabolite levels;	chr11:118685010	chr11:118791254~118793137:+
BRCA	cis	rs8098244	1	rs1941521	ENSG00000264745.1	TTC39C-AS1	5.42	7.57e-08	9.49e-06	0.21	0.17	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23824370	chr18:23994213~24015339:-
BRCA	cis	rs2179367	0.632	rs59820585	ENSG00000223701.3	RAET1E-AS1	5.42	7.57e-08	9.49e-06	0.24	0.17	Dupuytren's disease;	chr6:149350249	chr6:149884431~149919508:+
BRCA	cis	rs2179367	0.632	rs56924465	ENSG00000223701.3	RAET1E-AS1	5.42	7.57e-08	9.49e-06	0.24	0.17	Dupuytren's disease;	chr6:149350270	chr6:149884431~149919508:+
BRCA	cis	rs2235642	0.75	rs1894649	ENSG00000280231.1	LA16c-380F5.3	-5.42	7.57e-08	9.5e-06	-0.22	-0.17	Coronary artery disease;	chr16:1607283	chr16:1553655~1554130:-
BRCA	cis	rs6095360	0.727	rs11906450	ENSG00000222365.1	SNORD12B	-5.42	7.58e-08	9.5e-06	-0.22	-0.17	Intelligence (multi-trait analysis);	chr20:48938545	chr20:49280319~49280409:+
BRCA	cis	rs67311347	1	rs7628796	ENSG00000280739.1	EIF1B-AS1	-5.42	7.58e-08	9.51e-06	-0.19	-0.17	Renal cell carcinoma;	chr3:40465841	chr3:40173145~40309698:-
BRCA	cis	rs8098244	0.737	rs948432	ENSG00000264745.1	TTC39C-AS1	-5.42	7.59e-08	9.52e-06	-0.25	-0.17	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23959998	chr18:23994213~24015339:-
BRCA	cis	rs763121	0.853	rs9306329	ENSG00000228274.3	RP3-508I15.9	-5.42	7.59e-08	9.52e-06	-0.18	-0.17	Menopause (age at onset);	chr22:38676449	chr22:38667585~38681820:-
BRCA	cis	rs763121	0.853	rs5750662	ENSG00000228274.3	RP3-508I15.9	-5.42	7.59e-08	9.52e-06	-0.18	-0.17	Menopause (age at onset);	chr22:38676467	chr22:38667585~38681820:-
BRCA	cis	rs763121	0.853	rs5750664	ENSG00000228274.3	RP3-508I15.9	-5.42	7.59e-08	9.52e-06	-0.18	-0.17	Menopause (age at onset);	chr22:38676764	chr22:38667585~38681820:-
BRCA	cis	rs763121	0.626	rs5757236	ENSG00000228274.3	RP3-508I15.9	-5.42	7.59e-08	9.52e-06	-0.18	-0.17	Menopause (age at onset);	chr22:38677819	chr22:38667585~38681820:-
BRCA	cis	rs763121	0.853	rs6001191	ENSG00000228274.3	RP3-508I15.9	-5.42	7.59e-08	9.52e-06	-0.18	-0.17	Menopause (age at onset);	chr22:38678447	chr22:38667585~38681820:-
BRCA	cis	rs7119038	0.509	rs11216961	ENSG00000255422.1	AP002954.4	5.42	7.59e-08	9.52e-06	0.23	0.17	Sjögren's syndrome;	chr11:118709629	chr11:118704607~118750263:+
BRCA	cis	rs6832769	0.961	rs2140077	ENSG00000272969.1	RP11-528I4.2	5.42	7.59e-08	9.52e-06	0.21	0.17	Personality dimensions;	chr4:55472786	chr4:55547112~55547889:+
BRCA	cis	rs891378	1	rs1835307	ENSG00000274245.1	RP11-357P18.2	-5.42	7.59e-08	9.52e-06	-0.22	-0.17	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207253220	chr1:207372559~207373252:+
BRCA	cis	rs8031813	1	rs8031813	ENSG00000259531.2	RP11-295H24.3	5.42	7.59e-08	9.52e-06	0.22	0.17	Major depressive disorder;	chr15:48961764	chr15:49365124~49366685:-
BRCA	cis	rs7824557	0.507	rs7010590	ENSG00000255046.1	RP11-297N6.4	-5.42	7.59e-08	9.52e-06	-0.2	-0.17	Retinal vascular caliber;	chr8:11205373	chr8:11797928~11802568:-
BRCA	cis	rs6832769	0.961	rs28790098	ENSG00000223305.1	RN7SKP30	-5.42	7.6e-08	9.53e-06	-0.21	-0.17	Personality dimensions;	chr4:55531942	chr4:55540502~55540835:-
BRCA	cis	rs728616	0.51	rs34817075	ENSG00000225484.5	NUTM2B-AS1	-5.42	7.6e-08	9.53e-06	-0.32	-0.17	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79989984	chr10:79663088~79826594:-
BRCA	cis	rs2243480	0.522	rs1638736	ENSG00000230295.1	RP11-458F8.2	-5.42	7.6e-08	9.53e-06	-0.26	-0.17	Diabetic kidney disease;	chr7:66627321	chr7:66880708~66882981:+
BRCA	cis	rs2732480	0.5	rs12828309	ENSG00000240399.1	RP1-228P16.1	5.42	7.6e-08	9.53e-06	0.19	0.17	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48247377	chr12:48054813~48055591:-
BRCA	cis	rs1979679	0.837	rs2881860	ENSG00000278733.1	RP11-425D17.1	5.42	7.6e-08	9.53e-06	0.21	0.17	Ossification of the posterior longitudinal ligament of the spine;	chr12:28363268	chr12:28185625~28186190:-
BRCA	cis	rs6545883	0.525	rs2049747	ENSG00000212978.6	AC016747.3	-5.42	7.61e-08	9.54e-06	-0.22	-0.17	Tuberculosis;	chr2:61137019	chr2:61141592~61144969:-
BRCA	cis	rs9467773	1	rs4871	ENSG00000124549.13	BTN2A3P	5.41	7.61e-08	9.54e-06	0.17	0.17	Intelligence (multi-trait analysis);	chr6:26545404	chr6:26421391~26432383:+
BRCA	cis	rs863750	0.744	rs902167	ENSG00000275389.1	RP11-214K3.24	5.41	7.61e-08	9.54e-06	0.21	0.17	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-hip ratio;	chr12:124065504	chr12:124085761~124088598:+
BRCA	cis	rs4908760	0.827	rs2401138	ENSG00000270282.1	RP5-1115A15.2	-5.41	7.62e-08	9.55e-06	-0.18	-0.17	Vitiligo;	chr1:8644000	chr1:8512653~8513021:+
BRCA	cis	rs73222236	0.679	rs66810260	ENSG00000273486.1	RP11-731C17.2	5.41	7.62e-08	9.55e-06	0.18	0.17	Coronary artery disease;	chr3:136574215	chr3:136837338~136839021:-
BRCA	cis	rs9309473	1	rs10187192	ENSG00000163016.8	ALMS1P	5.41	7.62e-08	9.55e-06	0.22	0.17	Metabolite levels;	chr2:73486373	chr2:73644919~73685576:+
BRCA	cis	rs7577696	0.539	rs13010405	ENSG00000272716.1	RP11-563N4.1	-5.41	7.63e-08	9.57e-06	-0.2	-0.17	Inflammatory biomarkers;	chr2:32113135	chr2:32165046~32165757:-
BRCA	cis	rs10911232	0.507	rs6660111	ENSG00000224468.3	RP11-181K3.4	-5.41	7.64e-08	9.57e-06	-0.18	-0.17	Hypertriglyceridemia;	chr1:183045154	chr1:183138402~183141282:-
BRCA	cis	rs6671200	0.667	rs113926595	ENSG00000235501.4	RP4-639F20.1	-5.41	7.64e-08	9.58e-06	-0.39	-0.17	Stearic acid (18:0) levels;	chr1:94930060	chr1:94927566~94963270:+
BRCA	cis	rs1395	0.744	rs62130714	ENSG00000234072.1	AC074117.10	-5.41	7.64e-08	9.58e-06	-0.19	-0.17	Blood metabolite levels;	chr2:27310002	chr2:27356246~27367622:+
BRCA	cis	rs2688608	0.592	rs7908825	ENSG00000271816.1	BMS1P4	-5.41	7.64e-08	9.58e-06	-0.16	-0.17	Inflammatory bowel disease;	chr10:73794783	chr10:73699151~73730487:-
BRCA	cis	rs5758511	0.633	rs5758690	ENSG00000233903.2	Z83851.4	5.41	7.64e-08	9.58e-06	0.25	0.17	Birth weight;	chr22:42272289	chr22:42276355~42277052:+
BRCA	cis	rs4908768	0.539	rs7526171	ENSG00000270282.1	RP5-1115A15.2	5.41	7.65e-08	9.58e-06	0.18	0.17	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8590126	chr1:8512653~8513021:+
BRCA	cis	rs8098244	0.928	rs1893289	ENSG00000264745.1	TTC39C-AS1	5.41	7.65e-08	9.58e-06	0.22	0.17	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23908983	chr18:23994213~24015339:-
BRCA	cis	rs7674212	0.541	rs2720460	ENSG00000251288.2	RP11-10L12.2	5.41	7.65e-08	9.59e-06	0.19	0.17	Type 2 diabetes;	chr4:103133529	chr4:102751401~102752641:+
BRCA	cis	rs34286592	1	rs13332078	ENSG00000214725.6	CDIPT-AS1	-5.41	7.65e-08	9.59e-06	-0.28	-0.17	Multiple sclerosis;	chr16:29839384	chr16:29863593~29868053:+
BRCA	cis	rs1023500	1	rs1023500	ENSG00000205702.9	CYP2D7	5.41	7.65e-08	9.59e-06	0.17	0.17	Schizophrenia;	chr22:41944840	chr22:42140203~42144577:-
BRCA	cis	rs2919009	0.607	rs17594946	ENSG00000271670.1	RP11-95I16.4	5.41	7.65e-08	9.59e-06	0.22	0.17	Obesity-related traits;	chr10:120953414	chr10:120879256~120880667:-
BRCA	cis	rs7191700	0.674	rs12597893	ENSG00000262703.1	RP11-485G7.6	5.41	7.66e-08	9.6e-06	0.17	0.17	Multiple sclerosis;	chr16:11332474	chr16:11348143~11349321:-
BRCA	cis	rs17253792	0.545	rs12879564	ENSG00000186615.9	KTN1-AS1	-5.41	7.66e-08	9.6e-06	-0.34	-0.17	Putamen volume;	chr14:55550976	chr14:55499278~55580110:-
BRCA	cis	rs4950322	0.58	rs1813002	ENSG00000278811.3	LINC00624	5.41	7.66e-08	9.6e-06	0.21	0.17	Protein quantitative trait loci;	chr1:147112579	chr1:147258885~147517875:-
BRCA	cis	rs7621025	0.554	rs1471740	ENSG00000239213.4	NCK1-AS1	5.41	7.66e-08	9.6e-06	0.21	0.17	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136609428	chr3:136841726~136862054:-
BRCA	cis	rs34217772	0.64	rs61990347	ENSG00000258636.1	CTD-2298J14.2	5.41	7.66e-08	9.61e-06	0.23	0.17	Myopia;	chr14:41729996	chr14:41587861~41604856:-
BRCA	cis	rs34217772	0.563	rs1597049	ENSG00000258636.1	CTD-2298J14.2	5.41	7.66e-08	9.61e-06	0.23	0.17	Myopia;	chr14:41730116	chr14:41587861~41604856:-
BRCA	cis	rs3768617	0.51	rs10797838	ENSG00000224468.3	RP11-181K3.4	-5.41	7.67e-08	9.61e-06	-0.17	-0.17	Fuchs's corneal dystrophy;	chr1:183107885	chr1:183138402~183141282:-
BRCA	cis	rs4835473	0.9	rs6834494	ENSG00000249741.2	RP11-673E1.3	5.41	7.67e-08	9.61e-06	0.18	0.17	Immature fraction of reticulocytes;	chr4:143822257	chr4:143911514~143912053:-
BRCA	cis	rs9473147	1	rs9473147	ENSG00000270761.1	RP11-385F7.1	-5.41	7.67e-08	9.62e-06	-0.18	-0.17	Platelet distribution width;Mean platelet volume;	chr6:47641856	chr6:47477243~47477572:-
BRCA	cis	rs2153535	0.58	rs1928184	ENSG00000251164.1	HULC	-5.41	7.69e-08	9.63e-06	-0.2	-0.17	Motion sickness;	chr6:8531875	chr6:8652137~8653846:+
BRCA	cis	rs6832769	1	rs28463765	ENSG00000272969.1	RP11-528I4.2	-5.41	7.69e-08	9.63e-06	-0.2	-0.17	Personality dimensions;	chr4:55546267	chr4:55547112~55547889:+
BRCA	cis	rs2638953	0.962	rs716687	ENSG00000247934.4	RP11-967K21.1	-5.41	7.7e-08	9.64e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28261517	chr12:28163298~28190738:-
BRCA	cis	rs9341808	0.718	rs9352803	ENSG00000272129.1	RP11-250B2.6	5.41	7.7e-08	9.65e-06	0.21	0.17	Sitting height ratio;	chr6:80154950	chr6:80355424~80356859:+
BRCA	cis	rs9341808	0.655	rs9350846	ENSG00000272129.1	RP11-250B2.6	5.41	7.7e-08	9.65e-06	0.21	0.17	Sitting height ratio;	chr6:80155764	chr6:80355424~80356859:+
BRCA	cis	rs55702914	0.935	rs17405525	ENSG00000231621.1	AC013264.2	5.41	7.71e-08	9.65e-06	0.16	0.17	Major depression and alcohol dependence;	chr2:197349459	chr2:197197991~197199273:+
BRCA	cis	rs172166	0.694	rs203877	ENSG00000280107.1	AL022393.9	-5.41	7.71e-08	9.65e-06	-0.22	-0.17	Cardiac Troponin-T levels;	chr6:28080846	chr6:28170845~28172521:+
BRCA	cis	rs11955398	0.502	rs169700	ENSG00000215032.2	GNL3LP1	5.41	7.71e-08	9.66e-06	0.21	0.17	Intelligence (multi-trait analysis);	chr5:60969281	chr5:60891935~60893577:-
BRCA	cis	rs3733585	0.699	rs7435196	ENSG00000250413.1	RP11-448G15.1	5.41	7.71e-08	9.66e-06	0.22	0.17	Cleft plate (environmental tobacco smoke interaction);	chr4:9965932	chr4:10006482~10009725:+
BRCA	cis	rs7665090	1	rs2125211	ENSG00000246560.2	RP11-10L12.4	-5.41	7.71e-08	9.66e-06	-0.18	-0.17	Primary biliary cholangitis;	chr4:102638719	chr4:102828055~102844075:+
BRCA	cis	rs11105298	0.891	rs3741899	ENSG00000270344.2	RP11-734K2.4	5.41	7.71e-08	9.66e-06	0.19	0.17	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89540154	chr12:89525654~89548005:+
BRCA	cis	rs2732480	0.557	rs2634682	ENSG00000257735.1	RP11-370I10.6	5.41	7.71e-08	9.66e-06	0.21	0.17	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48339160	chr12:48350945~48442411:+
BRCA	cis	rs2919009	0.607	rs59153085	ENSG00000271670.1	RP11-95I16.4	5.41	7.71e-08	9.66e-06	0.23	0.17	Obesity-related traits;	chr10:120931782	chr10:120879256~120880667:-
BRCA	cis	rs4578769	0.569	rs12605341	ENSG00000273232.1	RP11-370A5.2	-5.41	7.72e-08	9.67e-06	-0.21	-0.17	Eosinophil percentage of white cells;	chr18:22803011	chr18:22882825~22883357:-
BRCA	cis	rs523522	0.673	rs643372	ENSG00000278344.1	RP11-18C24.8	5.41	7.72e-08	9.68e-06	0.22	0.17	High light scatter reticulocyte count;	chr12:120584837	chr12:120500735~120501090:-
BRCA	cis	rs7829975	0.688	rs7827182	ENSG00000253981.4	ALG1L13P	5.41	7.73e-08	9.68e-06	0.19	0.17	Mood instability;	chr8:8522961	chr8:8236003~8244667:-
BRCA	cis	rs7246657	0.525	rs1667357	ENSG00000226686.6	LINC01535	-5.41	7.73e-08	9.68e-06	-0.27	-0.17	Coronary artery calcification;	chr19:36993450	chr19:37251912~37265535:+
BRCA	cis	rs7246657	0.525	rs1667359	ENSG00000226686.6	LINC01535	-5.41	7.73e-08	9.68e-06	-0.27	-0.17	Coronary artery calcification;	chr19:36995270	chr19:37251912~37265535:+
BRCA	cis	rs2638953	0.67	rs11049701	ENSG00000247934.4	RP11-967K21.1	-5.41	7.73e-08	9.68e-06	-0.2	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28536042	chr12:28163298~28190738:-
BRCA	cis	rs17301013	0.932	rs444678	ENSG00000227373.4	RP11-160H22.5	5.41	7.73e-08	9.69e-06	0.22	0.17	Systemic lupus erythematosus;	chr1:174706080	chr1:174115300~174160004:-
BRCA	cis	rs2337406	1	rs4774172	ENSG00000223648.3	IGHV3-64	5.41	7.73e-08	9.69e-06	0.17	0.17	Alzheimer's disease (late onset);	chr14:106681320	chr14:106643132~106658258:-
BRCA	cis	rs4788196	1	rs4788196	ENSG00000273724.1	RP11-347C12.12	-5.41	7.73e-08	9.69e-06	-0.18	-0.17	Pubertal anthropometrics;	chr16:29956113	chr16:30336400~30343336:+
BRCA	cis	rs9545047	0.532	rs9545079	ENSG00000227354.5	RBM26-AS1	5.41	7.73e-08	9.69e-06	0.18	0.17	Schizophrenia;	chr13:79346044	chr13:79406309~79424328:+
BRCA	cis	rs4950322	0.857	rs72693002	ENSG00000244371.2	PFN1P8	-5.41	7.74e-08	9.7e-06	-0.23	-0.17	Protein quantitative trait loci;	chr1:147357593	chr1:146957117~146957659:-
BRCA	cis	rs4950322	0.857	rs72694703	ENSG00000244371.2	PFN1P8	-5.41	7.74e-08	9.7e-06	-0.23	-0.17	Protein quantitative trait loci;	chr1:147358427	chr1:146957117~146957659:-
BRCA	cis	rs1124769	0.502	rs34354799	ENSG00000259378.1	DCAF13P3	5.41	7.75e-08	9.71e-06	0.23	0.17	Cognitive performance;	chr15:50774380	chr15:50944663~50945996:+
BRCA	cis	rs1124769	0.502	rs8042982	ENSG00000259378.1	DCAF13P3	5.41	7.75e-08	9.71e-06	0.23	0.17	Cognitive performance;	chr15:50774816	chr15:50944663~50945996:+
BRCA	cis	rs1124769	0.502	rs737031	ENSG00000259378.1	DCAF13P3	5.41	7.75e-08	9.71e-06	0.23	0.17	Cognitive performance;	chr15:50775340	chr15:50944663~50945996:+
BRCA	cis	rs2179367	0.553	rs7762222	ENSG00000216906.2	RP11-350J20.9	5.41	7.75e-08	9.71e-06	0.24	0.17	Dupuytren's disease;	chr6:149444846	chr6:149904243~149906418:+
BRCA	cis	rs10946940	0.93	rs12215012	ENSG00000216901.1	AL022393.7	-5.41	7.75e-08	9.71e-06	-0.21	-0.17	Systemic lupus erythematosus;	chr6:27539715	chr6:28176188~28176674:+
BRCA	cis	rs2524005	1	rs2524005	ENSG00000261548.1	HLA-P	-5.41	7.76e-08	9.71e-06	-0.24	-0.17	Bipolar disorder and schizophrenia;	chr6:29931900	chr6:29800415~29802425:+
BRCA	cis	rs2115536	1	rs7163338	ENSG00000278600.1	RP11-81A1.6	-5.41	7.76e-08	9.72e-06	-0.14	-0.17	Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Eosinophil counts;Neutrophil percentage of granulocytes;	chr15:79906066	chr15:79920195~79922455:-
BRCA	cis	rs1552244	1	rs67006488	ENSG00000232901.1	CYCSP10	5.41	7.76e-08	9.72e-06	0.23	0.17	Alzheimer's disease;	chr3:10111309	chr3:10000647~10000940:-
BRCA	cis	rs1552244	1	rs6764068	ENSG00000232901.1	CYCSP10	5.41	7.76e-08	9.72e-06	0.23	0.17	Alzheimer's disease;	chr3:10112158	chr3:10000647~10000940:-
BRCA	cis	rs1552244	1	rs113522867	ENSG00000232901.1	CYCSP10	5.41	7.76e-08	9.72e-06	0.23	0.17	Alzheimer's disease;	chr3:10112819	chr3:10000647~10000940:-
BRCA	cis	rs4654783	0.671	rs1474647	ENSG00000228397.1	RP1-224A6.3	5.41	7.76e-08	9.72e-06	0.2	0.17	Endometriosis;	chr1:22115372	chr1:22023994~22024968:-
BRCA	cis	rs4834770	0.668	rs10007409	ENSG00000178636.7	RP11-455G16.1	5.41	7.77e-08	9.72e-06	0.21	0.17	Blood protein levels;	chr4:119221151	chr4:119192773~119212644:-
BRCA	cis	rs875971	0.619	rs12533585	ENSG00000273024.4	INTS4P2	-5.41	7.78e-08	9.74e-06	-0.18	-0.17	Aortic root size;	chr7:66519618	chr7:65647864~65715661:+
BRCA	cis	rs1850744	1	rs2280208	ENSG00000163612.10	FAM86KP	-5.41	7.78e-08	9.74e-06	-0.41	-0.17	Economic and political preferences;	chr4:9798419	chr4:9153296~9165451:+
BRCA	cis	rs12612619	0.64	rs7560633	ENSG00000229122.1	AGBL5-IT1	-5.41	7.78e-08	9.75e-06	-0.18	-0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27119199	chr2:27061038~27061815:+
BRCA	cis	rs507080	0.885	rs7926959	ENSG00000278376.1	RP11-158I9.8	-5.41	7.79e-08	9.75e-06	-0.17	-0.17	Serum metabolite levels;	chr11:118689157	chr11:118791254~118793137:+
BRCA	cis	rs507080	0.663	rs7926970	ENSG00000278376.1	RP11-158I9.8	-5.41	7.79e-08	9.75e-06	-0.17	-0.17	Serum metabolite levels;	chr11:118689172	chr11:118791254~118793137:+
BRCA	cis	rs2153535	0.585	rs7750891	ENSG00000230939.1	RP11-314C16.1	-5.41	7.79e-08	9.75e-06	-0.19	-0.17	Motion sickness;	chr6:8624613	chr6:8784178~8785445:+
BRCA	cis	rs4834770	1	rs878374	ENSG00000249244.1	RP11-548H18.2	5.41	7.79e-08	9.75e-06	0.18	0.17	Blood protein levels;	chr4:119316409	chr4:119391831~119395335:-
BRCA	cis	rs9880211	0.613	rs12695644	ENSG00000239213.4	NCK1-AS1	5.41	7.79e-08	9.75e-06	0.2	0.17	Height;Body mass index;	chr3:136126096	chr3:136841726~136862054:-
BRCA	cis	rs2638953	0.962	rs12366617	ENSG00000278733.1	RP11-425D17.1	-5.41	7.8e-08	9.76e-06	-0.22	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28395726	chr12:28185625~28186190:-
BRCA	cis	rs6772849	0.896	rs35535737	ENSG00000242551.2	POU5F1P6	-5.41	7.8e-08	9.76e-06	-0.21	-0.17	Monocyte percentage of white cells;Monocyte count;	chr3:128664563	chr3:128674735~128677005:-
BRCA	cis	rs1044826	0.642	rs407958	ENSG00000178631.7	ACTG1P1	5.41	7.8e-08	9.76e-06	0.19	0.17	Obesity-related traits;	chr3:139494790	chr3:139493809~139494937:+
BRCA	cis	rs10819861	0.55	rs4743558	ENSG00000175611.10	LINC00476	5.41	7.8e-08	9.76e-06	0.19	0.17	Electrocardiographic traits;	chr9:96122862	chr9:95759231~95875977:-
BRCA	cis	rs4950322	0.57	rs7554833	ENSG00000244371.2	PFN1P8	5.41	7.81e-08	9.77e-06	0.24	0.17	Protein quantitative trait loci;	chr1:147289362	chr1:146957117~146957659:-
BRCA	cis	rs801193	0.569	rs6978178	ENSG00000273448.1	RP11-166O4.6	-5.41	7.81e-08	9.78e-06	-0.15	-0.17	Aortic root size;	chr7:66658097	chr7:67333047~67334383:+
BRCA	cis	rs2732480	0.557	rs2732441	ENSG00000257735.1	RP11-370I10.6	5.41	7.81e-08	9.78e-06	0.21	0.17	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48329541	chr12:48350945~48442411:+
BRCA	cis	rs2732480	0.577	rs2732448	ENSG00000257735.1	RP11-370I10.6	5.41	7.81e-08	9.78e-06	0.21	0.17	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48336817	chr12:48350945~48442411:+
BRCA	cis	rs651386	0.529	rs722597	ENSG00000271811.1	RP1-79C4.4	5.41	7.81e-08	9.78e-06	0.19	0.17	Atrial fibrillation;	chr1:170607914	chr1:170667381~170669425:+
BRCA	cis	rs875971	0.66	rs28698552	ENSG00000273024.4	INTS4P2	-5.41	7.82e-08	9.79e-06	-0.18	-0.17	Aortic root size;	chr7:66540031	chr7:65647864~65715661:+
BRCA	cis	rs875971	0.522	rs4718285	ENSG00000273024.4	INTS4P2	-5.41	7.82e-08	9.79e-06	-0.18	-0.17	Aortic root size;	chr7:65827018	chr7:65647864~65715661:+
BRCA	cis	rs7267979	0.714	rs6115107	ENSG00000277938.1	RP5-965G21.3	5.41	7.82e-08	9.79e-06	0.2	0.17	Liver enzyme levels (alkaline phosphatase);	chr20:25256754	chr20:25229150~25231933:+
BRCA	cis	rs7208859	0.623	rs9914242	ENSG00000280069.1	CTD-2349P21.3	-5.41	7.82e-08	9.79e-06	-0.23	-0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30889227	chr17:30738182~30740275:+
BRCA	cis	rs7430456	1	rs7430456	ENSG00000228561.2	RP11-114M1.1	-5.41	7.83e-08	9.8e-06	-0.21	-0.17	Breast cancer;	chr3:177768082	chr3:177683627~177691250:+
BRCA	cis	rs7246657	0.943	rs10420754	ENSG00000267422.1	CTD-2554C21.1	-5.41	7.83e-08	9.8e-06	-0.24	-0.17	Coronary artery calcification;	chr19:37468470	chr19:37779686~37792865:+
BRCA	cis	rs7246657	0.943	rs7253091	ENSG00000267422.1	CTD-2554C21.1	-5.41	7.84e-08	9.81e-06	-0.24	-0.17	Coronary artery calcification;	chr19:37476312	chr19:37779686~37792865:+
BRCA	cis	rs2638953	0.924	rs12320545	ENSG00000247934.4	RP11-967K21.1	5.41	7.84e-08	9.81e-06	0.21	0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28248047	chr12:28163298~28190738:-
BRCA	cis	rs2253762	0.54	rs10159634	ENSG00000276742.1	RP11-500G22.4	-5.41	7.84e-08	9.81e-06	-0.28	-0.17	Breast cancer;	chr10:121994520	chr10:121956782~121957098:+
BRCA	cis	rs9859260	0.744	rs406271	ENSG00000242086.7	LINC00969	-5.41	7.84e-08	9.81e-06	-0.18	-0.17	Mean corpuscular volume;	chr3:196050105	chr3:195658062~195739964:+
BRCA	cis	rs4927850	1	rs4927850	ENSG00000207650.1	MIR570	-5.41	7.84e-08	9.82e-06	-0.2	-0.17	Pancreatic cancer;	chr3:196024759	chr3:195699401~195699497:+
BRCA	cis	rs9377188	0.843	rs4897074	ENSG00000236591.1	RP11-162J8.3	-5.41	7.85e-08	9.82e-06	-0.21	-0.17	Cancer;	chr6:149018118	chr6:149027700~149032573:-
BRCA	cis	rs2905347	0.56	rs2961293	ENSG00000179428.2	AC073072.5	5.41	7.85e-08	9.82e-06	0.18	0.17	Major depression and alcohol dependence;	chr7:22644465	chr7:22725395~22727620:-
BRCA	cis	rs863750	0.687	rs825484	ENSG00000275389.1	RP11-214K3.24	5.41	7.85e-08	9.83e-06	0.21	0.17	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-hip ratio;	chr12:124091607	chr12:124085761~124088598:+
BRCA	cis	rs2153535	0.58	rs9505454	ENSG00000251164.1	HULC	-5.41	7.86e-08	9.83e-06	-0.2	-0.17	Motion sickness;	chr6:8478299	chr6:8652137~8653846:+
BRCA	cis	rs8098244	0.708	rs1154244	ENSG00000264745.1	TTC39C-AS1	5.41	7.86e-08	9.84e-06	0.24	0.17	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23964052	chr18:23994213~24015339:-
BRCA	cis	rs75422866	0.51	rs75424057	ENSG00000276691.1	RP5-1057I20.5	5.41	7.86e-08	9.84e-06	0.33	0.17	Pneumonia;	chr12:47737294	chr12:47788426~47788971:+
BRCA	cis	rs1707322	0.691	rs61784799	ENSG00000234329.1	RP11-767N6.2	-5.41	7.87e-08	9.85e-06	-0.18	-0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45712076	chr1:45651039~45651826:-
BRCA	cis	rs875971	0.545	rs4718348	ENSG00000228409.4	CCT6P1	-5.41	7.87e-08	9.85e-06	-0.17	-0.17	Aortic root size;	chr7:66441589	chr7:65751142~65763354:+
BRCA	cis	rs9847710	1	rs2564956	ENSG00000242142.1	SERBP1P3	5.41	7.87e-08	9.85e-06	0.19	0.17	Ulcerative colitis;	chr3:53036446	chr3:53064283~53065091:-
BRCA	cis	rs710913	0.717	rs1180352	ENSG00000228060.1	RP11-69E11.8	5.41	7.87e-08	9.85e-06	0.16	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39542157	chr1:39565160~39573203:+
BRCA	cis	rs1707322	0.647	rs6686944	ENSG00000234329.1	RP11-767N6.2	5.41	7.88e-08	9.86e-06	0.17	0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45690636	chr1:45651039~45651826:-
BRCA	cis	rs2153535	0.58	rs1120392	ENSG00000251164.1	HULC	-5.41	7.88e-08	9.86e-06	-0.2	-0.17	Motion sickness;	chr6:8486820	chr6:8652137~8653846:+
BRCA	cis	rs891378	0.848	rs1579484	ENSG00000274245.1	RP11-357P18.2	-5.41	7.88e-08	9.86e-06	-0.22	-0.17	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207262484	chr1:207372559~207373252:+
BRCA	cis	rs2638953	0.962	rs11049539	ENSG00000278733.1	RP11-425D17.1	-5.41	7.88e-08	9.87e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28335953	chr12:28185625~28186190:-
BRCA	cis	rs2483058	0.767	rs2336938	ENSG00000261000.1	RP11-534L20.5	5.41	7.89e-08	9.87e-06	0.18	0.17	Cholesterol and Triglycerides;	chr1:206445453	chr1:206503948~206504456:+
BRCA	cis	rs11105298	0.891	rs3825330	ENSG00000270344.2	RP11-734K2.4	5.41	7.89e-08	9.87e-06	0.19	0.17	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89539933	chr12:89525654~89548005:+
BRCA	cis	rs2153535	0.58	rs1932283	ENSG00000251164.1	HULC	-5.41	7.89e-08	9.87e-06	-0.2	-0.17	Motion sickness;	chr6:8477428	chr6:8652137~8653846:+
BRCA	cis	rs8040855	0.659	rs8037886	ENSG00000259774.1	RP11-182J1.13	-5.41	7.89e-08	9.88e-06	-0.23	-0.17	Bulimia nervosa;	chr15:85143533	chr15:84422618~84425882:+
BRCA	cis	rs9468186	1	rs9468186	ENSG00000216901.1	AL022393.7	5.41	7.9e-08	9.88e-06	0.21	0.17	Neuroticism;	chr6:27658852	chr6:28176188~28176674:+
BRCA	cis	rs523522	0.962	rs4766969	ENSG00000278344.1	RP11-18C24.8	5.41	7.9e-08	9.88e-06	0.23	0.17	High light scatter reticulocyte count;	chr12:120550435	chr12:120500735~120501090:-
BRCA	cis	rs728616	0.867	rs61860034	ENSG00000225484.5	NUTM2B-AS1	-5.41	7.9e-08	9.88e-06	-0.45	-0.17	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80172092	chr10:79663088~79826594:-
BRCA	cis	rs4713118	0.621	rs4713132	ENSG00000204709.4	LINC01556	5.41	7.9e-08	9.89e-06	0.25	0.17	Parkinson's disease;	chr6:28066257	chr6:28943877~28944537:+
BRCA	cis	rs4713118	0.621	rs4713133	ENSG00000204709.4	LINC01556	5.41	7.9e-08	9.89e-06	0.25	0.17	Parkinson's disease;	chr6:28066263	chr6:28943877~28944537:+
BRCA	cis	rs4713118	0.621	rs4713134	ENSG00000204709.4	LINC01556	5.41	7.9e-08	9.89e-06	0.25	0.17	Parkinson's disease;	chr6:28066343	chr6:28943877~28944537:+
BRCA	cis	rs10510102	0.872	rs11200261	ENSG00000226864.1	ATE1-AS1	5.41	7.9e-08	9.89e-06	0.3	0.17	Breast cancer;	chr10:121921133	chr10:121928312~121951965:+
BRCA	cis	rs12681366	0.734	rs2046664	ENSG00000253704.1	RP11-267M23.4	5.41	7.9e-08	9.89e-06	0.17	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94375713	chr8:94553722~94569745:+
BRCA	cis	rs17711722	0.675	rs6947132	ENSG00000213640.3	EEF1DP4	5.41	7.91e-08	9.89e-06	0.2	0.17	Calcium levels;	chr7:65808508	chr7:64862999~64864370:+
BRCA	cis	rs13178541	0.81	rs6879905	ENSG00000250378.1	RP11-119J18.1	-5.41	7.91e-08	9.9e-06	-0.23	-0.17	IgG glycosylation;	chr5:135854608	chr5:135812667~135826582:+
BRCA	cis	rs2638953	0.752	rs11049571	ENSG00000278733.1	RP11-425D17.1	-5.41	7.92e-08	9.9e-06	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28390939	chr12:28185625~28186190:-
BRCA	cis	rs2337406	0.587	rs10129888	ENSG00000211970.3	IGHV4-61	5.41	7.92e-08	9.9e-06	0.14	0.17	Alzheimer's disease (late onset);	chr14:106647421	chr14:106639119~106639657:-
BRCA	cis	rs66887589	0.616	rs11098497	ENSG00000249244.1	RP11-548H18.2	5.41	7.92e-08	9.9e-06	0.18	0.17	Diastolic blood pressure;	chr4:119265913	chr4:119391831~119395335:-
BRCA	cis	rs3126085	0.56	rs12403031	ENSG00000237975.5	FLG-AS1	5.41	7.92e-08	9.91e-06	0.25	0.17	Atopic dermatitis;	chr1:152370918	chr1:152168125~152445456:+
BRCA	cis	rs2235642	0.717	rs9937922	ENSG00000280231.1	LA16c-380F5.3	-5.41	7.92e-08	9.91e-06	-0.21	-0.17	Coronary artery disease;	chr16:1608153	chr16:1553655~1554130:-
BRCA	cis	rs11853189	0.938	rs16969710	ENSG00000259562.2	RP11-762H8.2	-5.41	7.92e-08	9.91e-06	-0.2	-0.17	Red cell distribution width;	chr15:78314020	chr15:78290527~78291221:-
BRCA	cis	rs7620503	0.959	rs937509	ENSG00000228221.4	LINC00578	5.41	7.92e-08	9.91e-06	0.19	0.17	Corneal structure;	chr3:177569913	chr3:177441921~177752305:+
BRCA	cis	rs7620503	0.959	rs2055366	ENSG00000228221.4	LINC00578	5.41	7.92e-08	9.91e-06	0.19	0.17	Corneal structure;	chr3:177572557	chr3:177441921~177752305:+
BRCA	cis	rs10129255	0.912	rs8011090	ENSG00000224373.3	IGHV4-59	5.41	7.93e-08	9.91e-06	0.11	0.17	Kawasaki disease;	chr14:106678896	chr14:106627249~106627825:-
BRCA	cis	rs2790457	0.958	rs2772431	ENSG00000254635.4	WAC-AS1	-5.41	7.93e-08	9.92e-06	-0.2	-0.17	Multiple myeloma;	chr10:28601231	chr10:28522652~28532743:-
BRCA	cis	rs12144309	0.543	rs2185827	ENSG00000232450.1	RP4-730K3.3	5.41	7.93e-08	9.92e-06	0.22	0.17	Coronary artery disease;	chr1:113843461	chr1:113698884~113699631:-
BRCA	cis	rs9341808	0.617	rs9294170	ENSG00000272129.1	RP11-250B2.6	5.41	7.93e-08	9.92e-06	0.21	0.17	Sitting height ratio;	chr6:80104363	chr6:80355424~80356859:+
BRCA	cis	rs11955398	0.502	rs3101879	ENSG00000215032.2	GNL3LP1	5.41	7.93e-08	9.92e-06	0.21	0.17	Intelligence (multi-trait analysis);	chr5:60971048	chr5:60891935~60893577:-
BRCA	cis	rs3213958	0.574	rs73138027	ENSG00000249274.1	PDLIM1P4	-5.41	7.93e-08	9.92e-06	-0.25	-0.17	Blood protein levels;	chr3:98848889	chr3:98782188~98783193:+
BRCA	cis	rs3126085	0.56	rs11204986	ENSG00000237975.5	FLG-AS1	5.41	7.94e-08	9.93e-06	0.25	0.17	Atopic dermatitis;	chr1:152369583	chr1:152168125~152445456:+
BRCA	cis	rs6061231	1	rs11908473	ENSG00000275437.1	RP5-908M14.10	5.41	7.95e-08	9.94e-06	0.18	0.17	Colorectal cancer;	chr20:62382714	chr20:62402236~62405935:-
BRCA	cis	rs919433	0.68	rs11680291	ENSG00000231621.1	AC013264.2	-5.41	7.95e-08	9.94e-06	-0.15	-0.17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197545160	chr2:197197991~197199273:+
BRCA	cis	rs13118159	0.527	rs1250119	ENSG00000254094.1	AC078852.1	5.41	7.96e-08	9.95e-06	0.21	0.17	Longevity;	chr4:1267548	chr4:1356581~1358075:+
BRCA	cis	rs507080	0.922	rs558907	ENSG00000278376.1	RP11-158I9.8	-5.41	7.96e-08	9.95e-06	-0.17	-0.17	Serum metabolite levels;	chr11:118687746	chr11:118791254~118793137:+
BRCA	cis	rs6674176	0.518	rs917294	ENSG00000237950.1	RP11-7O11.3	5.41	7.96e-08	9.96e-06	0.2	0.17	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43783814	chr1:43944370~43946551:-
BRCA	cis	rs7620503	0.959	rs13079175	ENSG00000228221.4	LINC00578	5.41	7.97e-08	9.96e-06	0.19	0.17	Corneal structure;	chr3:177591745	chr3:177441921~177752305:+
BRCA	cis	rs2235642	0.75	rs763152	ENSG00000280231.1	LA16c-380F5.3	-5.41	7.97e-08	9.96e-06	-0.21	-0.17	Coronary artery disease;	chr16:1608055	chr16:1553655~1554130:-
BRCA	cis	rs2153535	0.525	rs1335644	ENSG00000251164.1	HULC	-5.41	7.97e-08	9.97e-06	-0.2	-0.17	Motion sickness;	chr6:8487808	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.58	rs9393025	ENSG00000251164.1	HULC	-5.41	7.97e-08	9.97e-06	-0.2	-0.17	Motion sickness;	chr6:8490385	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.58	rs1414340	ENSG00000251164.1	HULC	-5.41	7.97e-08	9.97e-06	-0.2	-0.17	Motion sickness;	chr6:8490906	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.58	rs1335628	ENSG00000251164.1	HULC	-5.41	7.97e-08	9.97e-06	-0.2	-0.17	Motion sickness;	chr6:8491509	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.58	rs6597330	ENSG00000251164.1	HULC	-5.41	7.97e-08	9.97e-06	-0.2	-0.17	Motion sickness;	chr6:8491843	chr6:8652137~8653846:+
BRCA	cis	rs1075265	0.783	rs718872	ENSG00000235937.1	AC008280.1	5.41	7.98e-08	9.97e-06	0.18	0.17	Chronotype;Morning vs. evening chronotype;	chr2:53946569	chr2:54029552~54030682:-
BRCA	cis	rs1816213	1	rs16859180	ENSG00000273466.1	RP11-548H3.1	5.41	7.98e-08	9.97e-06	0.34	0.17	Diastolic blood pressure;	chr2:218688745	chr2:218633256~218634014:-
BRCA	cis	rs2732480	0.538	rs1387260	ENSG00000257735.1	RP11-370I10.6	5.41	7.98e-08	9.97e-06	0.21	0.17	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48309308	chr12:48350945~48442411:+
BRCA	cis	rs17685	0.702	rs6960598	ENSG00000280388.1	RP11-229D13.3	-5.41	7.98e-08	9.97e-06	-0.17	-0.17	Coffee consumption (cups per day);Coffee consumption;	chr7:76143673	chr7:76043977~76045963:-
BRCA	cis	rs17685	0.712	rs10235738	ENSG00000280388.1	RP11-229D13.3	-5.41	7.98e-08	9.97e-06	-0.17	-0.17	Coffee consumption (cups per day);Coffee consumption;	chr7:76144142	chr7:76043977~76045963:-
BRCA	cis	rs17685	0.712	rs6953342	ENSG00000280388.1	RP11-229D13.3	-5.41	7.98e-08	9.97e-06	-0.17	-0.17	Coffee consumption (cups per day);Coffee consumption;	chr7:76147435	chr7:76043977~76045963:-
BRCA	cis	rs17685	0.712	rs10952842	ENSG00000280388.1	RP11-229D13.3	-5.41	7.98e-08	9.97e-06	-0.17	-0.17	Coffee consumption (cups per day);Coffee consumption;	chr7:76151095	chr7:76043977~76045963:-
BRCA	cis	rs17685	0.712	rs6464994	ENSG00000280388.1	RP11-229D13.3	-5.41	7.98e-08	9.97e-06	-0.17	-0.17	Coffee consumption (cups per day);Coffee consumption;	chr7:76155350	chr7:76043977~76045963:-
BRCA	cis	rs7772486	0.875	rs2777479	ENSG00000270638.1	RP3-466P17.1	5.41	7.98e-08	9.98e-06	0.19	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145988042	chr6:145735570~145737218:+
BRCA	cis	rs12908161	0.959	rs17598603	ENSG00000176700.18	SCAND2P	5.41	7.98e-08	9.98e-06	0.17	0.17	Schizophrenia;	chr15:84656980	chr15:84631451~84647478:+
BRCA	cis	rs77972916	0.609	rs13414381	ENSG00000234936.1	AC010883.5	5.41	7.99e-08	9.98e-06	0.22	0.17	Granulocyte percentage of myeloid white cells;	chr2:43340079	chr2:43229573~43233394:+
BRCA	cis	rs73193808	1	rs2832232	ENSG00000236056.1	GAPDHP14	-5.41	7.99e-08	9.99e-06	-0.23	-0.17	Coronary artery disease;	chr21:29168238	chr21:29222321~29223257:+
BRCA	cis	rs56104184	0.775	rs17272707	ENSG00000235191.1	NUCB1-AS1	5.41	7.99e-08	9.99e-06	0.3	0.17	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr19:48901278	chr19:48910930~48918891:-
BRCA	cis	rs6832769	1	rs28463765	ENSG00000223305.1	RN7SKP30	-5.41	7.99e-08	9.99e-06	-0.21	-0.17	Personality dimensions;	chr4:55546267	chr4:55540502~55540835:-
BRCA	cis	rs2562456	0.754	rs11673234	ENSG00000268535.1	RP11-420K14.3	5.41	8.01e-08	1e-05	0.24	0.17	Pain;	chr19:21324800	chr19:21709522~21710191:+
BRCA	cis	rs2562456	0.754	rs11673320	ENSG00000268535.1	RP11-420K14.3	5.41	8.01e-08	1e-05	0.24	0.17	Pain;	chr19:21324801	chr19:21709522~21710191:+
BRCA	cis	rs7617773	0.817	rs3937	ENSG00000199476.1	Y_RNA	-5.41	8.01e-08	1e-05	-0.23	-0.17	Coronary artery disease;	chr3:48270912	chr3:48288587~48288694:+
BRCA	cis	rs8048589	1	rs11642386	ENSG00000175604.2	RP11-276H1.3	-5.41	8.01e-08	1e-05	-0.24	-0.17	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);	chr16:12090207	chr16:12086746~12090302:-
BRCA	cis	rs7267979	0.873	rs7453	ENSG00000274973.1	RP13-401N8.7	-5.41	8.01e-08	1e-05	-0.19	-0.17	Liver enzyme levels (alkaline phosphatase);	chr20:25226438	chr20:25845497~25845862:+
BRCA	cis	rs11955398	0.665	rs11948543	ENSG00000215032.2	GNL3LP1	5.41	8.01e-08	1e-05	0.2	0.17	Intelligence (multi-trait analysis);	chr5:60623110	chr5:60891935~60893577:-
BRCA	cis	rs1823874	0.581	rs11855419	ENSG00000259363.4	CTD-2054N24.2	5.41	8.01e-08	1e-05	0.2	0.17	IgG glycosylation;	chr15:99787275	chr15:99807023~99877148:+
BRCA	cis	rs4781563	0.719	rs3136202	ENSG00000242307.1	RPS26P52	-5.41	8.01e-08	1e-05	-0.19	-0.17	Bilirubin levels;	chr16:13944317	chr16:13922332~13922679:-
BRCA	cis	rs13325613	0.915	rs71327048	ENSG00000223552.1	RP11-24F11.2	-5.41	8.02e-08	1e-05	-0.36	-0.17	Monocyte count;	chr3:46308565	chr3:46364955~46407059:-
BRCA	cis	rs755249	0.642	rs28788506	ENSG00000228060.1	RP11-69E11.8	-5.41	8.02e-08	1e-05	-0.18	-0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39611108	chr1:39565160~39573203:+
BRCA	cis	rs78487399	0.831	rs12469373	ENSG00000234936.1	AC010883.5	5.41	8.02e-08	1e-05	0.22	0.17	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43602052	chr2:43229573~43233394:+
BRCA	cis	rs7772486	0.869	rs2777473	ENSG00000270638.1	RP3-466P17.1	5.41	8.03e-08	1e-05	0.19	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145980358	chr6:145735570~145737218:+
BRCA	cis	rs67981189	0.529	rs2158996	ENSG00000258571.1	PTTG4P	-5.41	8.03e-08	1e-05	-0.19	-0.17	Schizophrenia;	chr14:71062882	chr14:71085482~71085833:-
BRCA	cis	rs240993	0.516	rs369594	ENSG00000230177.1	RP5-1112D6.4	-5.4	8.05e-08	1.01e-05	-0.22	-0.17	Inflammatory skin disease;Psoriasis;	chr6:111303197	chr6:111277932~111278742:+
BRCA	cis	rs600231	0.665	rs1626021	ENSG00000173727.10	CMB9-22P13.1	5.4	8.05e-08	1.01e-05	0.22	0.17	Bone mineral density;	chr11:65458716	chr11:65455258~65466720:+
BRCA	cis	rs3733585	0.699	rs13328050	ENSG00000250413.1	RP11-448G15.1	5.4	8.05e-08	1.01e-05	0.21	0.17	Cleft plate (environmental tobacco smoke interaction);	chr4:9949496	chr4:10006482~10009725:+
BRCA	cis	rs6832769	0.961	rs2412647	ENSG00000223305.1	RN7SKP30	5.4	8.06e-08	1.01e-05	0.21	0.17	Personality dimensions;	chr4:55452938	chr4:55540502~55540835:-
BRCA	cis	rs13178541	0.81	rs4327594	ENSG00000250378.1	RP11-119J18.1	-5.4	8.06e-08	1.01e-05	-0.23	-0.17	IgG glycosylation;	chr5:135774638	chr5:135812667~135826582:+
BRCA	cis	rs1014246	0.784	rs4751610	ENSG00000232767.1	RP11-498B4.5	5.4	8.06e-08	1.01e-05	0.16	0.17	Age at smoking initiation in chronic obstructive pulmonary disease;	chr10:116714219	chr10:116670103~116672739:+
BRCA	cis	rs950169	0.512	rs4374136	ENSG00000259728.4	LINC00933	5.4	8.06e-08	1.01e-05	0.24	0.17	Schizophrenia;	chr15:83976255	chr15:84570649~84580175:+
BRCA	cis	rs1124769	1	rs1124769	ENSG00000259378.1	DCAF13P3	5.4	8.06e-08	1.01e-05	0.25	0.17	Cognitive performance;	chr15:51060052	chr15:50944663~50945996:+
BRCA	cis	rs11955398	0.647	rs6449483	ENSG00000215032.2	GNL3LP1	5.4	8.06e-08	1.01e-05	0.2	0.17	Intelligence (multi-trait analysis);	chr5:60699566	chr5:60891935~60893577:-
BRCA	cis	rs7772486	0.686	rs4895684	ENSG00000270638.1	RP3-466P17.1	-5.4	8.06e-08	1.01e-05	-0.19	-0.17	Lobe attachment (rater-scored or self-reported);	chr6:145792887	chr6:145735570~145737218:+
BRCA	cis	rs1075265	0.756	rs805367	ENSG00000235937.1	AC008280.1	5.4	8.06e-08	1.01e-05	0.18	0.17	Chronotype;Morning vs. evening chronotype;	chr2:53943956	chr2:54029552~54030682:-
BRCA	cis	rs7824557	0.564	rs2736295	ENSG00000154316.13	TDH	-5.4	8.06e-08	1.01e-05	-0.21	-0.17	Retinal vascular caliber;	chr8:11377271	chr8:11339637~11368452:+
BRCA	cis	rs2243480	1	rs2420171	ENSG00000228409.4	CCT6P1	-5.4	8.07e-08	1.01e-05	-0.23	-0.17	Diabetic kidney disease;	chr7:66172773	chr7:65751142~65763354:+
BRCA	cis	rs17711722	0.522	rs62469933	ENSG00000237310.1	GS1-124K5.4	5.4	8.08e-08	1.01e-05	0.18	0.17	Calcium levels;	chr7:65800652	chr7:66493706~66495474:+
BRCA	cis	rs295490	0.748	rs115177972	ENSG00000272656.1	RP11-219D15.3	5.4	8.08e-08	1.01e-05	0.38	0.17	PR interval in Tripanosoma cruzi seropositivity;	chr3:139410696	chr3:139349024~139349371:-
BRCA	cis	rs7927592	0.956	rs12277225	ENSG00000212093.1	AP000807.1	5.4	8.09e-08	1.01e-05	0.18	0.17	Total body bone mineral density;	chr11:68573499	chr11:68506083~68506166:-
BRCA	cis	rs1979679	0.801	rs2881787	ENSG00000278733.1	RP11-425D17.1	-5.4	8.09e-08	1.01e-05	-0.2	-0.17	Ossification of the posterior longitudinal ligament of the spine;	chr12:28145489	chr12:28185625~28186190:-
BRCA	cis	rs55702914	0.809	rs3097385	ENSG00000231621.1	AC013264.2	5.4	8.09e-08	1.01e-05	0.17	0.17	Major depression and alcohol dependence;	chr2:197334573	chr2:197197991~197199273:+
BRCA	cis	rs2337406	1	rs1961901	ENSG00000223648.3	IGHV3-64	5.4	8.1e-08	1.01e-05	0.17	0.17	Alzheimer's disease (late onset);	chr14:106680856	chr14:106643132~106658258:-
BRCA	cis	rs17711722	0.701	rs55773927	ENSG00000273024.4	INTS4P2	-5.4	8.1e-08	1.01e-05	-0.18	-0.17	Calcium levels;	chr7:65872915	chr7:65647864~65715661:+
BRCA	cis	rs755249	0.669	rs4660311	ENSG00000228060.1	RP11-69E11.8	-5.4	8.11e-08	1.01e-05	-0.18	-0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39613442	chr1:39565160~39573203:+
BRCA	cis	rs59169624	0.699	rs1502987	ENSG00000255160.4	RP11-428C19.5	5.4	8.11e-08	1.01e-05	0.22	0.17	Parental extreme longevity (95 years and older);	chr11:19275793	chr11:19299883~19308358:+
BRCA	cis	rs2832191	0.74	rs2832177	ENSG00000176054.6	RPL23P2	-5.4	8.11e-08	1.01e-05	-0.18	-0.17	Dental caries;	chr21:29106032	chr21:28997613~28998033:-
BRCA	cis	rs4907240	0.961	rs11682934	ENSG00000237510.6	AC008268.2	-5.4	8.11e-08	1.01e-05	-0.24	-0.17	Event-related brain oscillations;	chr2:96571416	chr2:95789654~95800166:+
BRCA	cis	rs4664293	0.667	rs2042782	ENSG00000224152.1	AC009506.1	5.4	8.11e-08	1.01e-05	0.17	0.17	Monocyte percentage of white cells;	chr2:159789781	chr2:159615296~159617082:+
BRCA	cis	rs507080	0.922	rs546890	ENSG00000278376.1	RP11-158I9.8	-5.4	8.11e-08	1.01e-05	-0.17	-0.17	Serum metabolite levels;	chr11:118686489	chr11:118791254~118793137:+
BRCA	cis	rs507080	0.883	rs693306	ENSG00000278376.1	RP11-158I9.8	-5.4	8.11e-08	1.01e-05	-0.17	-0.17	Serum metabolite levels;	chr11:118687624	chr11:118791254~118793137:+
BRCA	cis	rs507080	0.922	rs561845	ENSG00000278376.1	RP11-158I9.8	-5.4	8.11e-08	1.01e-05	-0.17	-0.17	Serum metabolite levels;	chr11:118688118	chr11:118791254~118793137:+
BRCA	cis	rs507080	0.922	rs638805	ENSG00000278376.1	RP11-158I9.8	-5.4	8.11e-08	1.01e-05	-0.17	-0.17	Serum metabolite levels;	chr11:118688180	chr11:118791254~118793137:+
BRCA	cis	rs507080	0.845	rs510408	ENSG00000278376.1	RP11-158I9.8	-5.4	8.11e-08	1.01e-05	-0.17	-0.17	Serum metabolite levels;	chr11:118688192	chr11:118791254~118793137:+
BRCA	cis	rs507080	0.845	rs509641	ENSG00000278376.1	RP11-158I9.8	-5.4	8.11e-08	1.01e-05	-0.17	-0.17	Serum metabolite levels;	chr11:118688243	chr11:118791254~118793137:+
BRCA	cis	rs507080	0.883	rs563549	ENSG00000278376.1	RP11-158I9.8	-5.4	8.11e-08	1.01e-05	-0.17	-0.17	Serum metabolite levels;	chr11:118688244	chr11:118791254~118793137:+
BRCA	cis	rs710913	0.717	rs2068473	ENSG00000228060.1	RP11-69E11.8	5.4	8.12e-08	1.01e-05	0.16	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39572925	chr1:39565160~39573203:+
BRCA	cis	rs875971	0.929	rs4122249	ENSG00000223473.2	GS1-124K5.3	5.4	8.13e-08	1.01e-05	0.13	0.17	Aortic root size;	chr7:66455949	chr7:66491049~66493566:-
BRCA	cis	rs4713118	0.662	rs464312	ENSG00000280107.1	AL022393.9	-5.4	8.13e-08	1.01e-05	-0.24	-0.17	Parkinson's disease;	chr6:27999813	chr6:28170845~28172521:+
BRCA	cis	rs4713118	0.662	rs469228	ENSG00000280107.1	AL022393.9	-5.4	8.13e-08	1.01e-05	-0.24	-0.17	Parkinson's disease;	chr6:28002926	chr6:28170845~28172521:+
BRCA	cis	rs4713118	0.54	rs469227	ENSG00000280107.1	AL022393.9	-5.4	8.13e-08	1.01e-05	-0.24	-0.17	Parkinson's disease;	chr6:28002927	chr6:28170845~28172521:+
BRCA	cis	rs4713118	0.662	rs149948	ENSG00000280107.1	AL022393.9	-5.4	8.13e-08	1.01e-05	-0.24	-0.17	Parkinson's disease;	chr6:28007039	chr6:28170845~28172521:+
BRCA	cis	rs77204473	1	rs35184536	ENSG00000280143.1	AP000892.6	-5.4	8.13e-08	1.01e-05	-0.34	-0.17	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116908097	chr11:117204967~117210292:+
BRCA	cis	rs11758351	0.929	rs6906367	ENSG00000241549.7	GUSBP2	-5.4	8.14e-08	1.02e-05	-0.21	-0.17	Renal underexcretion gout;Gout;	chr6:26186897	chr6:26871484~26956554:-
BRCA	cis	rs9859260	0.744	rs539816	ENSG00000242086.7	LINC00969	-5.4	8.14e-08	1.02e-05	-0.18	-0.17	Mean corpuscular volume;	chr3:196057205	chr3:195658062~195739964:+
BRCA	cis	rs9859260	0.744	rs492349	ENSG00000242086.7	LINC00969	-5.4	8.14e-08	1.02e-05	-0.18	-0.17	Mean corpuscular volume;	chr3:196057321	chr3:195658062~195739964:+
BRCA	cis	rs9859260	0.744	rs492288	ENSG00000242086.7	LINC00969	-5.4	8.14e-08	1.02e-05	-0.18	-0.17	Mean corpuscular volume;	chr3:196057339	chr3:195658062~195739964:+
BRCA	cis	rs2239557	0.539	rs62005063	ENSG00000259065.1	RP5-1021I20.1	-5.4	8.14e-08	1.02e-05	-0.23	-0.17	Common traits (Other);	chr14:73989276	chr14:73787360~73803270:+
BRCA	cis	rs4604234	0.803	rs79048064	ENSG00000272129.1	RP11-250B2.6	-5.4	8.15e-08	1.02e-05	-0.39	-0.17	Cancer;	chr6:80267381	chr6:80355424~80356859:+
BRCA	cis	rs2732480	0.557	rs923397	ENSG00000240399.1	RP1-228P16.1	5.4	8.15e-08	1.02e-05	0.19	0.17	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48326609	chr12:48054813~48055591:-
BRCA	cis	rs11955398	0.716	rs2061250	ENSG00000215032.2	GNL3LP1	5.4	8.15e-08	1.02e-05	0.2	0.17	Intelligence (multi-trait analysis);	chr5:60621851	chr5:60891935~60893577:-
BRCA	cis	rs17711722	0.522	rs6957759	ENSG00000222364.1	RNU6-96P	-5.4	8.16e-08	1.02e-05	-0.2	-0.17	Calcium levels;	chr7:65806798	chr7:66395191~66395286:+
BRCA	cis	rs2058059	0.593	rs2960944	ENSG00000225648.4	SBDSP1	-5.4	8.16e-08	1.02e-05	-0.27	-0.17	Subcutaneous adipose tissue;	chr7:72680285	chr7:72829425~72836701:+
BRCA	cis	rs6832769	0.925	rs4371676	ENSG00000272969.1	RP11-528I4.2	5.4	8.17e-08	1.02e-05	0.2	0.17	Personality dimensions;	chr4:55462841	chr4:55547112~55547889:+
BRCA	cis	rs2638953	0.888	rs2061760	ENSG00000247934.4	RP11-967K21.1	-5.4	8.18e-08	1.02e-05	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28234492	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.886	rs11049474	ENSG00000247934.4	RP11-967K21.1	-5.4	8.18e-08	1.02e-05	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28235512	chr12:28163298~28190738:-
BRCA	cis	rs228614	0.51	rs223362	ENSG00000251288.2	RP11-10L12.2	-5.4	8.18e-08	1.02e-05	-0.19	-0.17	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102848077	chr4:102751401~102752641:+
BRCA	cis	rs6969780	0.841	rs10246712	ENSG00000233429.8	HOTAIRM1	5.4	8.19e-08	1.02e-05	0.18	0.17	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27159241	chr7:27095647~27100265:+
BRCA	cis	rs3733585	0.725	rs6449201	ENSG00000250413.1	RP11-448G15.1	5.4	8.19e-08	1.02e-05	0.21	0.17	Cleft plate (environmental tobacco smoke interaction);	chr4:9972270	chr4:10006482~10009725:+
BRCA	cis	rs9300255	0.602	rs1727313	ENSG00000235423.7	RP11-282O18.3	5.4	8.19e-08	1.02e-05	0.23	0.17	Neutrophil percentage of white cells;	chr12:123156306	chr12:123252030~123261483:-
BRCA	cis	rs9659323	0.67	rs6701378	ENSG00000231365.4	RP11-418J17.1	-5.4	8.2e-08	1.02e-05	-0.19	-0.17	Body mass index;	chr1:119095930	chr1:119140396~119275973:+
BRCA	cis	rs300890	0.513	rs10015751	ENSG00000250326.1	RP11-284M14.1	-5.4	8.2e-08	1.02e-05	-0.2	-0.17	Nasopharyngeal carcinoma;	chr4:143235665	chr4:142933195~143184861:-
BRCA	cis	rs300890	0.56	rs12649219	ENSG00000250326.1	RP11-284M14.1	-5.4	8.2e-08	1.02e-05	-0.2	-0.17	Nasopharyngeal carcinoma;	chr4:143235932	chr4:142933195~143184861:-
BRCA	cis	rs3812762	0.912	rs11042058	ENSG00000254860.4	TMEM9B-AS1	5.4	8.2e-08	1.02e-05	0.16	0.17	Hypospadias;	chr11:8742268	chr11:8964675~8977527:+
BRCA	cis	rs3126085	0.56	rs6693160	ENSG00000237975.5	FLG-AS1	5.4	8.2e-08	1.02e-05	0.25	0.17	Atopic dermatitis;	chr1:152368845	chr1:152168125~152445456:+
BRCA	cis	rs4722166	0.695	rs56061963	ENSG00000225541.1	AC002480.5	-5.4	8.21e-08	1.02e-05	-0.17	-0.17	Lung cancer;	chr7:22760778	chr7:22571607~22661792:-
BRCA	cis	rs559928	0.569	rs7103915	ENSG00000236935.1	AP003774.1	-5.4	8.21e-08	1.02e-05	-0.22	-0.17	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64176898	chr11:64325050~64329504:-
BRCA	cis	rs62025270	0.576	rs62022947	ENSG00000259295.5	CSPG4P12	-5.4	8.21e-08	1.02e-05	-0.25	-0.17	Idiopathic pulmonary fibrosis;	chr15:85728091	chr15:85191438~85213905:+
BRCA	cis	rs7980687	0.55	rs1727324	ENSG00000235423.7	RP11-282O18.3	5.4	8.21e-08	1.02e-05	0.24	0.17	Head circumference (infant);Educational attainment;Height;	chr12:123214056	chr12:123252030~123261483:-
BRCA	cis	rs9300255	0.51	rs1727322	ENSG00000235423.7	RP11-282O18.3	5.4	8.21e-08	1.02e-05	0.24	0.17	Neutrophil percentage of white cells;	chr12:123214973	chr12:123252030~123261483:-
BRCA	cis	rs2638953	0.672	rs10843203	ENSG00000247934.4	RP11-967K21.1	-5.4	8.22e-08	1.02e-05	-0.23	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28563555	chr12:28163298~28190738:-
BRCA	cis	rs4535700	0.501	rs57251705	ENSG00000226278.1	PSPHP1	5.4	8.22e-08	1.03e-05	0.19	0.17	Macular telangiectasia type 2;	chr7:55913390	chr7:55764797~55773288:+
BRCA	cis	rs9341808	0.718	rs10943699	ENSG00000272129.1	RP11-250B2.6	5.4	8.23e-08	1.03e-05	0.21	0.17	Sitting height ratio;	chr6:80230824	chr6:80355424~80356859:+
BRCA	cis	rs73222236	0.75	rs9832572	ENSG00000273486.1	RP11-731C17.2	5.4	8.23e-08	1.03e-05	0.18	0.17	Coronary artery disease;	chr3:136615386	chr3:136837338~136839021:-
BRCA	cis	rs7809950	0.53	rs111865019	ENSG00000238832.1	snoU109	-5.4	8.23e-08	1.03e-05	-0.24	-0.17	Coronary artery disease;	chr7:107171801	chr7:107603363~107603507:+
BRCA	cis	rs860295	0.702	rs12041534	ENSG00000160766.13	GBAP1	5.4	8.23e-08	1.03e-05	0.17	0.17	Body mass index;	chr1:155437305	chr1:155213821~155227422:-
BRCA	cis	rs7620503	1	rs13077994	ENSG00000228221.4	LINC00578	5.4	8.23e-08	1.03e-05	0.19	0.17	Corneal structure;	chr3:177587917	chr3:177441921~177752305:+
BRCA	cis	rs1395	0.848	rs6716850	ENSG00000234072.1	AC074117.10	-5.4	8.23e-08	1.03e-05	-0.17	-0.17	Blood metabolite levels;	chr2:27302482	chr2:27356246~27367622:+
BRCA	cis	rs875971	0.545	rs1796217	ENSG00000228409.4	CCT6P1	5.4	8.24e-08	1.03e-05	0.17	0.17	Aortic root size;	chr7:66620931	chr7:65751142~65763354:+
BRCA	cis	rs2562456	0.755	rs1879234	ENSG00000268658.4	LINC00664	-5.4	8.24e-08	1.03e-05	-0.26	-0.17	Pain;	chr19:21521677	chr19:21483374~21503238:+
BRCA	cis	rs2638953	0.924	rs11049575	ENSG00000278733.1	RP11-425D17.1	-5.4	8.24e-08	1.03e-05	-0.22	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28411328	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.924	rs2348235	ENSG00000278733.1	RP11-425D17.1	-5.4	8.24e-08	1.03e-05	-0.22	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28414019	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.886	rs11049577	ENSG00000278733.1	RP11-425D17.1	-5.4	8.24e-08	1.03e-05	-0.22	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28414437	chr12:28185625~28186190:-
BRCA	cis	rs858239	0.862	rs1728292	ENSG00000230042.1	AK3P3	-5.4	8.24e-08	1.03e-05	-0.19	-0.17	Cerebrospinal fluid biomarker levels;	chr7:23223855	chr7:23129178~23129841:+
BRCA	cis	rs6001482	0.679	rs5995706	ENSG00000211642.2	IGLV10-54	5.4	8.24e-08	1.03e-05	0.16	0.16	Diastolic blood pressure;	chr22:22236371	chr22:22214794~22215270:+
BRCA	cis	rs9341808	0.754	rs1324121	ENSG00000272129.1	RP11-250B2.6	5.4	8.24e-08	1.03e-05	0.21	0.16	Sitting height ratio;	chr6:80236360	chr6:80355424~80356859:+
BRCA	cis	rs7789940	0.81	rs12533978	ENSG00000186704.9	DTX2P1	5.4	8.24e-08	1.03e-05	0.21	0.16	Multiple sclerosis;	chr7:76314035	chr7:76978617~77004308:+
BRCA	cis	rs9545047	0.604	rs7322901	ENSG00000227354.5	RBM26-AS1	5.4	8.25e-08	1.03e-05	0.18	0.16	Schizophrenia;	chr13:79383505	chr13:79406309~79424328:+
BRCA	cis	rs55702914	0.712	rs6730590	ENSG00000231621.1	AC013264.2	5.4	8.25e-08	1.03e-05	0.16	0.16	Major depression and alcohol dependence;	chr2:197283360	chr2:197197991~197199273:+
BRCA	cis	rs6001482	0.702	rs7286018	ENSG00000211642.2	IGLV10-54	5.4	8.25e-08	1.03e-05	0.16	0.16	Diastolic blood pressure;	chr22:22236464	chr22:22214794~22215270:+
BRCA	cis	rs2688608	0.904	rs2675669	ENSG00000271816.1	BMS1P4	5.4	8.25e-08	1.03e-05	0.16	0.16	Inflammatory bowel disease;	chr10:73894114	chr10:73699151~73730487:-
BRCA	cis	rs4908768	0.501	rs6577502	ENSG00000232912.4	RP5-1115A15.1	5.4	8.26e-08	1.03e-05	0.16	0.16	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8555518	chr1:8424645~8434838:+
BRCA	cis	rs12439619	0.768	rs28694364	ENSG00000255769.6	GOLGA2P10	-5.4	8.26e-08	1.03e-05	-0.23	-0.16	Intelligence (multi-trait analysis);	chr15:82208119	chr15:82472993~82513950:-
BRCA	cis	rs2638953	0.924	rs11049403	ENSG00000247934.4	RP11-967K21.1	-5.4	8.26e-08	1.03e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28177105	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.962	rs11049586	ENSG00000278733.1	RP11-425D17.1	-5.4	8.27e-08	1.03e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28418028	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.962	rs11049588	ENSG00000278733.1	RP11-425D17.1	-5.4	8.27e-08	1.03e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28418628	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.925	rs10843166	ENSG00000278733.1	RP11-425D17.1	-5.4	8.27e-08	1.03e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28422811	chr12:28185625~28186190:-
BRCA	cis	rs7914558	0.966	rs10786725	ENSG00000236937.2	PTGES3P4	5.4	8.27e-08	1.03e-05	0.21	0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102922600	chr10:102845595~102845950:+
BRCA	cis	rs7617773	0.817	rs13059037	ENSG00000199476.1	Y_RNA	-5.4	8.28e-08	1.03e-05	-0.24	-0.16	Coronary artery disease;	chr3:48246389	chr3:48288587~48288694:+
BRCA	cis	rs8114671	0.74	rs3761141	ENSG00000269202.1	RP4-614O4.12	-5.4	8.28e-08	1.03e-05	-0.17	-0.16	Height;	chr20:35150021	chr20:35201747~35203288:-
BRCA	cis	rs9393692	0.905	rs6931391	ENSG00000241549.7	GUSBP2	-5.4	8.29e-08	1.03e-05	-0.18	-0.16	Educational attainment;	chr6:26279007	chr6:26871484~26956554:-
BRCA	cis	rs9393692	0.846	rs7771202	ENSG00000241549.7	GUSBP2	-5.4	8.29e-08	1.03e-05	-0.18	-0.16	Educational attainment;	chr6:26279679	chr6:26871484~26956554:-
BRCA	cis	rs9393692	0.905	rs6940237	ENSG00000241549.7	GUSBP2	-5.4	8.29e-08	1.03e-05	-0.18	-0.16	Educational attainment;	chr6:26282094	chr6:26871484~26956554:-
BRCA	cis	rs34792	0.637	rs1684547	ENSG00000207425.1	Y_RNA	-5.4	8.29e-08	1.03e-05	-0.19	-0.16	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15480604	chr16:14915457~14915556:-
BRCA	cis	rs357618	1	rs357622	ENSG00000260581.1	CTB-113P19.4	5.4	8.29e-08	1.03e-05	0.19	0.16	Basophil percentage of white cells;	chr5:151468844	chr5:151652275~151655449:+
BRCA	cis	rs357618	1	rs357623	ENSG00000260581.1	CTB-113P19.4	5.4	8.29e-08	1.03e-05	0.19	0.16	Basophil percentage of white cells;	chr5:151468939	chr5:151652275~151655449:+
BRCA	cis	rs78487399	0.908	rs6726404	ENSG00000234936.1	AC010883.5	-5.4	8.29e-08	1.03e-05	-0.21	-0.16	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43607024	chr2:43229573~43233394:+
BRCA	cis	rs7493	0.755	rs17886036	ENSG00000233942.1	AC004012.1	5.4	8.29e-08	1.03e-05	0.21	0.16	Yu-Zhi constitution type in type 2 diabetes;	chr7:95358415	chr7:95471835~95473998:+
BRCA	cis	rs6095360	0.727	rs35334143	ENSG00000222365.1	SNORD12B	-5.4	8.29e-08	1.03e-05	-0.23	-0.16	Intelligence (multi-trait analysis);	chr20:48914171	chr20:49280319~49280409:+
BRCA	cis	rs6832769	0.961	rs6817663	ENSG00000223305.1	RN7SKP30	-5.4	8.3e-08	1.03e-05	-0.21	-0.16	Personality dimensions;	chr4:55581048	chr4:55540502~55540835:-
BRCA	cis	rs4925386	1	rs4925386	ENSG00000273619.1	RP5-908M14.9	-5.4	8.3e-08	1.03e-05	-0.14	-0.16	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62345988	chr20:62386303~62386970:-
BRCA	cis	rs2153535	0.58	rs1932284	ENSG00000251164.1	HULC	-5.4	8.3e-08	1.03e-05	-0.2	-0.16	Motion sickness;	chr6:8477461	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.58	rs1932285	ENSG00000251164.1	HULC	-5.4	8.3e-08	1.03e-05	-0.2	-0.16	Motion sickness;	chr6:8477486	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.58	rs7775909	ENSG00000251164.1	HULC	-5.4	8.3e-08	1.03e-05	-0.2	-0.16	Motion sickness;	chr6:8477545	chr6:8652137~8653846:+
BRCA	cis	rs293748	0.891	rs56261529	ENSG00000250155.1	CTD-2353F22.1	-5.4	8.31e-08	1.04e-05	-0.22	-0.16	Obesity-related traits;	chr5:37018714	chr5:36666214~36725195:-
BRCA	cis	rs7772486	0.846	rs2892453	ENSG00000270638.1	RP3-466P17.1	5.4	8.31e-08	1.04e-05	0.19	0.16	Lobe attachment (rater-scored or self-reported);	chr6:146056581	chr6:145735570~145737218:+
BRCA	cis	rs2179367	0.613	rs12207261	ENSG00000223701.3	RAET1E-AS1	5.4	8.31e-08	1.04e-05	0.24	0.16	Dupuytren's disease;	chr6:149423722	chr6:149884431~149919508:+
BRCA	cis	rs7246657	0.943	rs1382357	ENSG00000267422.1	CTD-2554C21.1	-5.4	8.32e-08	1.04e-05	-0.24	-0.16	Coronary artery calcification;	chr19:37486707	chr19:37779686~37792865:+
BRCA	cis	rs10899021	1	rs7102084	ENSG00000279353.1	RP11-864N7.4	5.4	8.32e-08	1.04e-05	0.32	0.16	Response to metformin (IC50);	chr11:74647087	chr11:74698231~74699658:-
BRCA	cis	rs62025270	0.593	rs7166540	ENSG00000202081.1	RNU6-1280P	-5.4	8.32e-08	1.04e-05	-0.24	-0.16	Idiopathic pulmonary fibrosis;	chr15:85700854	chr15:85651522~85651628:-
BRCA	cis	rs11123406	0.723	rs4849463	ENSG00000227992.1	AC108463.2	5.4	8.32e-08	1.04e-05	0.2	0.16	Type 2 diabetes;	chr2:111201277	chr2:111203964~111206215:-
BRCA	cis	rs11742741	0.539	rs13189556	ENSG00000248874.4	C5orf17	-5.4	8.32e-08	1.04e-05	-0.21	-0.16	Educational attainment;	chr5:24103701	chr5:23951348~24178263:+
BRCA	cis	rs1387259	0.69	rs1601985	ENSG00000257735.1	RP11-370I10.6	5.4	8.33e-08	1.04e-05	0.21	0.16	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48368131	chr12:48350945~48442411:+
BRCA	cis	rs17711722	0.565	rs4717276	ENSG00000222364.1	RNU6-96P	-5.4	8.34e-08	1.04e-05	-0.2	-0.16	Calcium levels;	chr7:65829754	chr7:66395191~66395286:+
BRCA	cis	rs4819052	0.851	rs1056099	ENSG00000184274.3	LINC00315	-5.4	8.34e-08	1.04e-05	-0.22	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258977	chr21:45300245~45305257:-
BRCA	cis	rs9868809	0.505	rs9811027	ENSG00000270441.1	RP11-694I15.7	5.4	8.35e-08	1.04e-05	0.3	0.16	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48687581	chr3:49140086~49160851:-
BRCA	cis	rs12497850	0.863	rs4858799	ENSG00000270441.1	RP11-694I15.7	5.4	8.35e-08	1.04e-05	0.3	0.16	Parkinson's disease;	chr3:48690771	chr3:49140086~49160851:-
BRCA	cis	rs2179367	0.632	rs9485389	ENSG00000223701.3	RAET1E-AS1	-5.4	8.35e-08	1.04e-05	-0.24	-0.16	Dupuytren's disease;	chr6:149420078	chr6:149884431~149919508:+
BRCA	cis	rs4819052	0.851	rs2236445	ENSG00000184274.3	LINC00315	-5.4	8.35e-08	1.04e-05	-0.22	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258538	chr21:45300245~45305257:-
BRCA	cis	rs7572733	0.565	rs11891750	ENSG00000231621.1	AC013264.2	-5.4	8.35e-08	1.04e-05	-0.15	-0.16	Dermatomyositis;	chr2:197569595	chr2:197197991~197199273:+
BRCA	cis	rs6569038	0.502	rs2051057	ENSG00000253194.1	RP11-351A11.1	5.4	8.35e-08	1.04e-05	0.21	0.16	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr6:118978278	chr6:118934785~119031541:+
BRCA	cis	rs13126694	0.744	rs13121497	ENSG00000248429.4	RP11-597D13.9	5.4	8.35e-08	1.04e-05	0.15	0.16	Blood osmolality (transformed sodium);	chr4:158076724	chr4:158170752~158202877:+
BRCA	cis	rs2638953	0.962	rs61922976	ENSG00000247934.4	RP11-967K21.1	-5.4	8.36e-08	1.04e-05	-0.23	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28283837	chr12:28163298~28190738:-
BRCA	cis	rs9425766	0.679	rs6670617	ENSG00000227373.4	RP11-160H22.5	5.4	8.36e-08	1.04e-05	0.22	0.16	Life satisfaction;	chr1:174277574	chr1:174115300~174160004:-
BRCA	cis	rs357618	0.965	rs357621	ENSG00000260581.1	CTB-113P19.4	5.4	8.37e-08	1.04e-05	0.19	0.16	Basophil percentage of white cells;	chr5:151467993	chr5:151652275~151655449:+
BRCA	cis	rs357618	1	rs193299	ENSG00000260581.1	CTB-113P19.4	5.4	8.37e-08	1.04e-05	0.19	0.16	Basophil percentage of white cells;	chr5:151468094	chr5:151652275~151655449:+
BRCA	cis	rs2153535	0.58	rs1335641	ENSG00000251164.1	HULC	-5.4	8.37e-08	1.04e-05	-0.2	-0.16	Motion sickness;	chr6:8487627	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.58	rs1335643	ENSG00000251164.1	HULC	-5.4	8.37e-08	1.04e-05	-0.2	-0.16	Motion sickness;	chr6:8487788	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.58	rs9378554	ENSG00000251164.1	HULC	-5.4	8.37e-08	1.04e-05	-0.2	-0.16	Motion sickness;	chr6:8488235	chr6:8652137~8653846:+
BRCA	cis	rs13108904	0.521	rs4974609	ENSG00000254094.1	AC078852.1	5.4	8.37e-08	1.04e-05	0.18	0.16	Obesity-related traits;	chr4:1363136	chr4:1356581~1358075:+
BRCA	cis	rs12681366	0.801	rs2919658	ENSG00000253704.1	RP11-267M23.4	5.4	8.37e-08	1.04e-05	0.19	0.16	Nonsyndromic cleft lip with cleft palate;	chr8:94459550	chr8:94553722~94569745:+
BRCA	cis	rs2562456	0.833	rs55790393	ENSG00000268535.1	RP11-420K14.3	5.4	8.38e-08	1.04e-05	0.24	0.16	Pain;	chr19:21323382	chr19:21709522~21710191:+
BRCA	cis	rs2562456	0.793	rs11672341	ENSG00000268535.1	RP11-420K14.3	5.4	8.38e-08	1.04e-05	0.24	0.16	Pain;	chr19:21324502	chr19:21709522~21710191:+
BRCA	cis	rs9425766	0.679	rs4650989	ENSG00000227373.4	RP11-160H22.5	5.4	8.38e-08	1.04e-05	0.22	0.16	Life satisfaction;	chr1:174289739	chr1:174115300~174160004:-
BRCA	cis	rs2638953	0.925	rs11049563	ENSG00000278733.1	RP11-425D17.1	-5.4	8.38e-08	1.04e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28376041	chr12:28185625~28186190:-
BRCA	cis	rs2562456	0.752	rs7258562	ENSG00000268535.1	RP11-420K14.3	5.4	8.38e-08	1.04e-05	0.24	0.16	Pain;	chr19:21331762	chr19:21709522~21710191:+
BRCA	cis	rs6674176	0.542	rs803675	ENSG00000237950.1	RP11-7O11.3	5.4	8.38e-08	1.04e-05	0.2	0.16	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43887565	chr1:43944370~43946551:-
BRCA	cis	rs17767294	0.612	rs12332927	ENSG00000219392.1	RP1-265C24.5	-5.4	8.38e-08	1.04e-05	-0.31	-0.16	Parkinson's disease;	chr6:27987337	chr6:28115628~28116551:+
BRCA	cis	rs1707322	0.686	rs1084086	ENSG00000234329.1	RP11-767N6.2	-5.4	8.39e-08	1.04e-05	-0.17	-0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45575428	chr1:45651039~45651826:-
BRCA	cis	rs7487075	1	rs7487075	ENSG00000257261.4	RP11-96H19.1	5.4	8.39e-08	1.05e-05	0.18	0.16	Itch intensity from mosquito bite;	chr12:46435135	chr12:46383679~46876159:+
BRCA	cis	rs2153535	0.553	rs2984099	ENSG00000230939.1	RP11-314C16.1	-5.4	8.4e-08	1.05e-05	-0.19	-0.16	Motion sickness;	chr6:8637041	chr6:8784178~8785445:+
BRCA	cis	rs1555322	0.53	rs8122819	ENSG00000269202.1	RP4-614O4.12	-5.4	8.4e-08	1.05e-05	-0.19	-0.16	Attention deficit hyperactivity disorder;	chr20:35293783	chr20:35201747~35203288:-
BRCA	cis	rs7618501	0.699	rs6446187	ENSG00000228008.1	CTD-2330K9.3	5.4	8.4e-08	1.05e-05	0.16	0.16	Intelligence (multi-trait analysis);	chr3:49869678	chr3:49903845~49916937:+
BRCA	cis	rs7829975	0.522	rs6601689	ENSG00000254153.1	CTA-398F10.2	5.4	8.41e-08	1.05e-05	0.2	0.16	Mood instability;	chr8:8314761	chr8:8456909~8461337:-
BRCA	cis	rs4908768	0.501	rs1473420	ENSG00000232912.4	RP5-1115A15.1	5.4	8.41e-08	1.05e-05	0.16	0.16	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8556779	chr1:8424645~8434838:+
BRCA	cis	rs4835473	0.932	rs6849896	ENSG00000249741.2	RP11-673E1.3	5.4	8.41e-08	1.05e-05	0.18	0.16	Immature fraction of reticulocytes;	chr4:143794927	chr4:143911514~143912053:-
BRCA	cis	rs4835473	0.838	rs35998817	ENSG00000249741.2	RP11-673E1.3	5.4	8.41e-08	1.05e-05	0.18	0.16	Immature fraction of reticulocytes;	chr4:143795355	chr4:143911514~143912053:-
BRCA	cis	rs9341808	0.621	rs2322627	ENSG00000272129.1	RP11-250B2.6	5.4	8.41e-08	1.05e-05	0.21	0.16	Sitting height ratio;	chr6:80096624	chr6:80355424~80356859:+
BRCA	cis	rs295490	0.748	rs78681436	ENSG00000272656.1	RP11-219D15.3	5.4	8.42e-08	1.05e-05	0.37	0.16	PR interval in Tripanosoma cruzi seropositivity;	chr3:139510715	chr3:139349024~139349371:-
BRCA	cis	rs7238033	0.663	rs17675121	ENSG00000267193.4	RP11-116O18.3	5.4	8.42e-08	1.05e-05	0.18	0.16	Bladder cancer;	chr18:45738220	chr18:45669367~45747215:-
BRCA	cis	rs6545883	0.525	rs1621048	ENSG00000212978.6	AC016747.3	-5.4	8.43e-08	1.05e-05	-0.22	-0.16	Tuberculosis;	chr2:61137081	chr2:61141592~61144969:-
BRCA	cis	rs7617773	0.71	rs36064160	ENSG00000199476.1	Y_RNA	-5.4	8.43e-08	1.05e-05	-0.25	-0.16	Coronary artery disease;	chr3:48201611	chr3:48288587~48288694:+
BRCA	cis	rs2243480	0.711	rs2460426	ENSG00000228409.4	CCT6P1	-5.4	8.43e-08	1.05e-05	-0.23	-0.16	Diabetic kidney disease;	chr7:66158142	chr7:65751142~65763354:+
BRCA	cis	rs62025270	0.688	rs7179917	ENSG00000259295.5	CSPG4P12	-5.4	8.43e-08	1.05e-05	-0.26	-0.16	Idiopathic pulmonary fibrosis;	chr15:85722413	chr15:85191438~85213905:+
BRCA	cis	rs891378	0.959	rs11120586	ENSG00000274245.1	RP11-357P18.2	-5.4	8.44e-08	1.05e-05	-0.22	-0.16	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207268152	chr1:207372559~207373252:+
BRCA	cis	rs9925964	0.967	rs889548	ENSG00000232748.3	RP11-196G11.6	-5.4	8.44e-08	1.05e-05	-0.21	-0.16	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31126391	chr16:31056460~31062803:+
BRCA	cis	rs2179367	0.959	rs9390677	ENSG00000216906.2	RP11-350J20.9	5.4	8.44e-08	1.05e-05	0.21	0.16	Dupuytren's disease;	chr6:149389361	chr6:149904243~149906418:+
BRCA	cis	rs62025270	0.632	rs13379832	ENSG00000202081.1	RNU6-1280P	-5.4	8.45e-08	1.05e-05	-0.24	-0.16	Idiopathic pulmonary fibrosis;	chr15:85572669	chr15:85651522~85651628:-
BRCA	cis	rs300890	0.513	rs13151561	ENSG00000250326.1	RP11-284M14.1	-5.4	8.45e-08	1.05e-05	-0.2	-0.16	Nasopharyngeal carcinoma;	chr4:143215833	chr4:142933195~143184861:-
BRCA	cis	rs10129255	0.518	rs8009594	ENSG00000224373.3	IGHV4-59	5.4	8.45e-08	1.05e-05	0.09	0.16	Kawasaki disease;	chr14:106777494	chr14:106627249~106627825:-
BRCA	cis	rs10899021	1	rs11236186	ENSG00000279353.1	RP11-864N7.4	5.4	8.45e-08	1.05e-05	0.32	0.16	Response to metformin (IC50);	chr11:74651820	chr11:74698231~74699658:-
BRCA	cis	rs10899021	1	rs7935426	ENSG00000279353.1	RP11-864N7.4	5.4	8.45e-08	1.05e-05	0.32	0.16	Response to metformin (IC50);	chr11:74652845	chr11:74698231~74699658:-
BRCA	cis	rs13108904	0.539	rs13135102	ENSG00000254094.1	AC078852.1	-5.4	8.45e-08	1.05e-05	-0.19	-0.16	Obesity-related traits;	chr4:1337195	chr4:1356581~1358075:+
BRCA	cis	rs863750	0.687	rs825483	ENSG00000275389.1	RP11-214K3.24	5.4	8.45e-08	1.05e-05	0.21	0.16	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-hip ratio;	chr12:124091431	chr12:124085761~124088598:+
BRCA	cis	rs2243480	1	rs1618893	ENSG00000229886.1	RP5-1132H15.3	5.4	8.46e-08	1.05e-05	0.28	0.16	Diabetic kidney disease;	chr7:66631132	chr7:66025126~66031544:-
BRCA	cis	rs2665103	0.61	rs56398167	ENSG00000259429.4	UBE2Q2P2	-5.4	8.46e-08	1.05e-05	-0.16	-0.16	Intelligence (multi-trait analysis);	chr15:82237482	chr15:82355142~82420075:+
BRCA	cis	rs4459386	0.509	rs10876020	ENSG00000272368.2	RP4-605O3.4	5.4	8.46e-08	1.05e-05	0.17	0.16	Schizophrenia;	chr12:50342482	chr12:50112197~50165618:+
BRCA	cis	rs2624839	0.602	rs2526398	ENSG00000228008.1	CTD-2330K9.3	5.4	8.47e-08	1.05e-05	0.18	0.16	Intelligence (multi-trait analysis);	chr3:50150163	chr3:49903845~49916937:+
BRCA	cis	rs300890	0.513	rs10434185	ENSG00000250326.1	RP11-284M14.1	-5.4	8.47e-08	1.05e-05	-0.2	-0.16	Nasopharyngeal carcinoma;	chr4:143225242	chr4:142933195~143184861:-
BRCA	cis	rs7474896	0.559	rs1208560	ENSG00000120555.12	SEPT7P9	-5.4	8.48e-08	1.05e-05	-0.23	-0.16	Obesity (extreme);	chr10:37932690	chr10:38383069~38402916:-
BRCA	cis	rs17301013	0.932	rs1754355	ENSG00000227373.4	RP11-160H22.5	-5.39	8.49e-08	1.06e-05	-0.22	-0.16	Systemic lupus erythematosus;	chr1:174807407	chr1:174115300~174160004:-
BRCA	cis	rs875971	0.66	rs10215132	ENSG00000273024.4	INTS4P2	5.39	8.49e-08	1.06e-05	0.18	0.16	Aortic root size;	chr7:66589419	chr7:65647864~65715661:+
BRCA	cis	rs4865169	0.934	rs12650737	ENSG00000269949.1	RP11-738E22.3	-5.39	8.49e-08	1.06e-05	-0.19	-0.16	Breast cancer;	chr4:57026309	chr4:56960927~56961373:-
BRCA	cis	rs4950322	0.518	rs4950304	ENSG00000278811.3	LINC00624	5.39	8.49e-08	1.06e-05	0.21	0.16	Protein quantitative trait loci;	chr1:147116685	chr1:147258885~147517875:-
BRCA	cis	rs2732480	0.577	rs2450994	ENSG00000240399.1	RP1-228P16.1	5.39	8.5e-08	1.06e-05	0.19	0.16	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48328049	chr12:48054813~48055591:-
BRCA	cis	rs2688608	1	rs2675680	ENSG00000271816.1	BMS1P4	5.39	8.5e-08	1.06e-05	0.16	0.16	Inflammatory bowel disease;	chr10:73899106	chr10:73699151~73730487:-
BRCA	cis	rs1440410	0.795	rs10461280	ENSG00000250326.1	RP11-284M14.1	-5.39	8.5e-08	1.06e-05	-0.18	-0.16	Ischemic stroke;	chr4:143263750	chr4:142933195~143184861:-
BRCA	cis	rs357618	1	rs357627	ENSG00000260581.1	CTB-113P19.4	5.39	8.51e-08	1.06e-05	0.19	0.16	Basophil percentage of white cells;	chr5:151470699	chr5:151652275~151655449:+
BRCA	cis	rs357618	1	rs357628	ENSG00000260581.1	CTB-113P19.4	5.39	8.51e-08	1.06e-05	0.19	0.16	Basophil percentage of white cells;	chr5:151470791	chr5:151652275~151655449:+
BRCA	cis	rs13108904	0.87	rs4974541	ENSG00000254094.1	AC078852.1	-5.39	8.51e-08	1.06e-05	-0.18	-0.16	Obesity-related traits;	chr4:1250249	chr4:1356581~1358075:+
BRCA	cis	rs4713118	0.662	rs9357060	ENSG00000280107.1	AL022393.9	-5.39	8.51e-08	1.06e-05	-0.24	-0.16	Parkinson's disease;	chr6:28056708	chr6:28170845~28172521:+
BRCA	cis	rs4713118	0.662	rs9468271	ENSG00000280107.1	AL022393.9	-5.39	8.51e-08	1.06e-05	-0.24	-0.16	Parkinson's disease;	chr6:28056792	chr6:28170845~28172521:+
BRCA	cis	rs4604234	0.614	rs11961506	ENSG00000272129.1	RP11-250B2.6	-5.39	8.52e-08	1.06e-05	-0.41	-0.16	Cancer;	chr6:80224592	chr6:80355424~80356859:+
BRCA	cis	rs3805389	1	rs10026676	ENSG00000273257.1	RP11-177J6.1	-5.39	8.52e-08	1.06e-05	-0.25	-0.16	Waist-to-hip ratio adjusted for body mass index;	chr4:55612585	chr4:55387949~55388271:+
BRCA	cis	rs10129255	0.53	rs11624912	ENSG00000211967.3	IGHV3-53	-5.39	8.53e-08	1.06e-05	-0.11	-0.16	Kawasaki disease;	chr14:106673891	chr14:106592676~106593347:-
BRCA	cis	rs2562456	1	rs2359155	ENSG00000268658.4	LINC00664	-5.39	8.53e-08	1.06e-05	-0.25	-0.16	Pain;	chr19:21489067	chr19:21483374~21503238:+
BRCA	cis	rs8058578	0.832	rs7500719	ENSG00000260911.2	RP11-196G11.2	5.39	8.53e-08	1.06e-05	0.16	0.16	Multiple myeloma;	chr16:30829556	chr16:31043150~31049868:+
BRCA	cis	rs2898681	0.618	rs7677726	ENSG00000248375.1	RP11-177B4.1	5.39	8.56e-08	1.06e-05	0.32	0.16	Optic nerve measurement (cup area);	chr4:52873095	chr4:52720081~52720831:-
BRCA	cis	rs6723226	0.803	rs387780	ENSG00000276334.1	AL133243.1	5.39	8.56e-08	1.06e-05	0.22	0.16	Intelligence (multi-trait analysis);	chr2:32277426	chr2:32521927~32523547:+
BRCA	cis	rs7914558	0.966	rs7096269	ENSG00000236937.2	PTGES3P4	5.39	8.57e-08	1.07e-05	0.21	0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102976964	chr10:102845595~102845950:+
BRCA	cis	rs2153535	0.58	rs1414344	ENSG00000251164.1	HULC	-5.39	8.57e-08	1.07e-05	-0.2	-0.16	Motion sickness;	chr6:8471132	chr6:8652137~8653846:+
BRCA	cis	rs617791	0.508	rs2276132	ENSG00000255320.1	RP11-755F10.1	5.39	8.57e-08	1.07e-05	0.22	0.16	Breast cancer;	chr11:66003074	chr11:66244840~66246239:-
BRCA	cis	rs2243480	1	rs4718317	ENSG00000232559.3	GS1-124K5.12	-5.39	8.58e-08	1.07e-05	-0.3	-0.16	Diabetic kidney disease;	chr7:66183914	chr7:66554588~66576923:-
BRCA	cis	rs10129255	0.957	rs1024349	ENSG00000224373.3	IGHV4-59	5.39	8.58e-08	1.07e-05	0.11	0.16	Kawasaki disease;	chr14:106689997	chr14:106627249~106627825:-
BRCA	cis	rs600231	0.665	rs2105608	ENSG00000173727.10	CMB9-22P13.1	5.39	8.58e-08	1.07e-05	0.22	0.16	Bone mineral density;	chr11:65461147	chr11:65455258~65466720:+
BRCA	cis	rs17685	0.712	rs7794454	ENSG00000280388.1	RP11-229D13.3	5.39	8.58e-08	1.07e-05	0.17	0.16	Coffee consumption (cups per day);Coffee consumption;	chr7:76146692	chr7:76043977~76045963:-
BRCA	cis	rs7800418	0.544	rs11767539	ENSG00000214870.7	AC004540.5	5.39	8.59e-08	1.07e-05	0.2	0.16	Cognitive function;	chr7:26586792	chr7:26398593~26494256:+
BRCA	cis	rs597539	0.652	rs602805	ENSG00000261625.1	RP11-554A11.4	-5.39	8.59e-08	1.07e-05	-0.16	-0.16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68894608	chr11:69000765~69002048:-
BRCA	cis	rs597539	0.652	rs602364	ENSG00000261625.1	RP11-554A11.4	-5.39	8.59e-08	1.07e-05	-0.16	-0.16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68894699	chr11:69000765~69002048:-
BRCA	cis	rs2638953	0.962	rs11049495	ENSG00000247934.4	RP11-967K21.1	-5.39	8.59e-08	1.07e-05	-0.23	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28264795	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.962	rs11049496	ENSG00000247934.4	RP11-967K21.1	-5.39	8.59e-08	1.07e-05	-0.23	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28267327	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.889	rs2045887	ENSG00000247934.4	RP11-967K21.1	-5.39	8.59e-08	1.07e-05	-0.23	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28270825	chr12:28163298~28190738:-
BRCA	cis	rs2732480	0.557	rs2409004	ENSG00000240399.1	RP1-228P16.1	5.39	8.59e-08	1.07e-05	0.19	0.16	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48327668	chr12:48054813~48055591:-
BRCA	cis	rs2638953	0.925	rs11049491	ENSG00000247934.4	RP11-967K21.1	-5.39	8.59e-08	1.07e-05	-0.23	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28262340	chr12:28163298~28190738:-
BRCA	cis	rs9652601	0.748	rs12924112	ENSG00000274038.1	RP11-66H6.4	-5.39	8.6e-08	1.07e-05	-0.19	-0.16	Systemic lupus erythematosus;	chr16:11125863	chr16:11056556~11057034:+
BRCA	cis	rs991427	0.643	rs76555379	ENSG00000258100.1	RP11-121E16.1	-5.39	8.6e-08	1.07e-05	-0.33	-0.16	Systolic blood pressure (alcohol consumption interaction);	chr12:91047313	chr12:91362196~91368606:+
BRCA	cis	rs2179367	0.959	rs544947	ENSG00000216906.2	RP11-350J20.9	5.39	8.61e-08	1.07e-05	0.21	0.16	Dupuytren's disease;	chr6:149402412	chr6:149904243~149906418:+
BRCA	cis	rs8114671	0.562	rs2425005	ENSG00000279253.1	RP4-614O4.13	5.39	8.61e-08	1.07e-05	0.21	0.16	Height;	chr20:34819912	chr20:35262727~35264187:-
BRCA	cis	rs72615157	0.539	rs2261360	ENSG00000214313.7	AZGP1P1	-5.39	8.61e-08	1.07e-05	-0.19	-0.16	Lung function (FEV1/FVC);	chr7:100095370	chr7:99980762~99987535:+
BRCA	cis	rs2836950	0.501	rs2070865	ENSG00000238141.2	BRWD1-AS1	-5.39	8.61e-08	1.07e-05	-0.19	-0.16	Menarche (age at onset);	chr21:39343593	chr21:39315707~39323218:+
BRCA	cis	rs11009175	0.556	rs11009173	ENSG00000273038.2	RP11-479G22.8	5.39	8.62e-08	1.07e-05	0.2	0.16	Depression (quantitative trait);	chr10:33003397	chr10:32887255~32889311:-
BRCA	cis	rs3733585	0.699	rs6449178	ENSG00000250413.1	RP11-448G15.1	-5.39	8.62e-08	1.07e-05	-0.21	-0.16	Cleft plate (environmental tobacco smoke interaction);	chr4:9967060	chr4:10006482~10009725:+
BRCA	cis	rs516805	0.748	rs155458	ENSG00000279453.1	RP3-425C14.4	5.39	8.63e-08	1.07e-05	0.23	0.16	Lymphocyte counts;	chr6:122493636	chr6:122436789~122439223:-
BRCA	cis	rs7246657	0.525	rs10405238	ENSG00000276846.1	CTD-3220F14.3	5.39	8.64e-08	1.07e-05	0.25	0.16	Coronary artery calcification;	chr19:36997153	chr19:37314868~37315620:-
BRCA	cis	rs9467773	0.873	rs9295698	ENSG00000124549.13	BTN2A3P	5.39	8.64e-08	1.07e-05	0.17	0.16	Intelligence (multi-trait analysis);	chr6:26565871	chr6:26421391~26432383:+
BRCA	cis	rs9847710	1	rs6770152	ENSG00000242142.1	SERBP1P3	5.39	8.65e-08	1.07e-05	0.19	0.16	Ulcerative colitis;	chr3:53066198	chr3:53064283~53065091:-
BRCA	cis	rs6802315	0.712	rs7615751	ENSG00000272247.1	RP11-379F4.9	-5.39	8.66e-08	1.08e-05	-0.18	-0.16	Periodontitis (CDC/AAP);	chr3:158792041	chr3:158801257~158801935:-
BRCA	cis	rs4664293	0.642	rs6732598	ENSG00000224152.1	AC009506.1	5.39	8.66e-08	1.08e-05	0.17	0.16	Monocyte percentage of white cells;	chr2:159790370	chr2:159615296~159617082:+
BRCA	cis	rs73193808	1	rs2832249	ENSG00000236056.1	GAPDHP14	-5.39	8.66e-08	1.08e-05	-0.23	-0.16	Coronary artery disease;	chr21:29185330	chr21:29222321~29223257:+
BRCA	cis	rs755249	1	rs4660293	ENSG00000182109.6	RP11-69E11.4	-5.39	8.67e-08	1.08e-05	-0.22	-0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39562508	chr1:39522280~39546187:-
BRCA	cis	rs10129255	0.957	rs8009948	ENSG00000280411.1	IGHV1-69-2	-5.39	8.68e-08	1.08e-05	-0.13	-0.16	Kawasaki disease;	chr14:106805607	chr14:106762092~106762588:-
BRCA	cis	rs12478296	1	rs59036157	ENSG00000261186.2	RP11-341N2.1	-5.39	8.68e-08	1.08e-05	-0.28	-0.16	Obesity-related traits;	chr2:242098077	chr2:242087351~242088457:-
BRCA	cis	rs12701220	0.894	rs12701348	ENSG00000229043.2	AC091729.9	-5.39	8.69e-08	1.08e-05	-0.26	-0.16	Bronchopulmonary dysplasia;	chr7:999821	chr7:1160374~1165267:+
BRCA	cis	rs2732480	0.5	rs2732461	ENSG00000226413.2	OR8T1P	5.39	8.69e-08	1.08e-05	0.22	0.16	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48299019	chr12:48442030~48442947:-
BRCA	cis	rs1552244	1	rs6764168	ENSG00000232901.1	CYCSP10	5.39	8.69e-08	1.08e-05	0.23	0.16	Alzheimer's disease;	chr3:10082121	chr3:10000647~10000940:-
BRCA	cis	rs7674212	0.51	rs2720468	ENSG00000248740.4	RP11-328K4.1	5.39	8.7e-08	1.08e-05	0.19	0.16	Type 2 diabetes;	chr4:103163996	chr4:103256159~103453658:+
BRCA	cis	rs7246657	0.943	rs7255785	ENSG00000267422.1	CTD-2554C21.1	-5.39	8.7e-08	1.08e-05	-0.24	-0.16	Coronary artery calcification;	chr19:37480781	chr19:37779686~37792865:+
BRCA	cis	rs7246657	0.943	rs7255996	ENSG00000267422.1	CTD-2554C21.1	-5.39	8.7e-08	1.08e-05	-0.24	-0.16	Coronary artery calcification;	chr19:37480797	chr19:37779686~37792865:+
BRCA	cis	rs2257011	1	rs1896797	ENSG00000230373.7	GOLGA6L5P	5.39	8.71e-08	1.08e-05	0.17	0.16	Height;	chr15:83605839	chr15:84507885~84516814:-
BRCA	cis	rs9307551	0.584	rs2903636	ENSG00000250334.4	LINC00989	-5.39	8.72e-08	1.08e-05	-0.23	-0.16	Refractive error;	chr4:79542125	chr4:79492416~79576460:+
BRCA	cis	rs595244	0.803	rs2028109	ENSG00000259705.1	RP11-227D13.1	5.39	8.72e-08	1.08e-05	0.31	0.16	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48626906	chr15:48645951~48652016:+
BRCA	cis	rs875971	0.522	rs4502988	ENSG00000213640.3	EEF1DP4	-5.39	8.72e-08	1.08e-05	-0.2	-0.16	Aortic root size;	chr7:65832759	chr7:64862999~64864370:+
BRCA	cis	rs891378	1	rs2802233	ENSG00000274245.1	RP11-357P18.2	5.39	8.72e-08	1.08e-05	0.22	0.16	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207297879	chr1:207372559~207373252:+
BRCA	cis	rs61160187	0.583	rs6449503	ENSG00000272308.1	RP11-231G3.1	5.39	8.72e-08	1.08e-05	0.18	0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:60799445	chr5:60866457~60866935:-
BRCA	cis	rs10129255	0.518	rs10136903	ENSG00000224373.3	IGHV4-59	5.39	8.73e-08	1.08e-05	0.09	0.16	Kawasaki disease;	chr14:106778866	chr14:106627249~106627825:-
BRCA	cis	rs11159086	0.793	rs9285594	ENSG00000270000.1	RP3-449M8.9	5.39	8.73e-08	1.08e-05	0.25	0.16	Advanced glycation end-product levels;	chr14:74489253	chr14:74471930~74472360:-
BRCA	cis	rs11159086	0.793	rs4903229	ENSG00000270000.1	RP3-449M8.9	5.39	8.73e-08	1.08e-05	0.25	0.16	Advanced glycation end-product levels;	chr14:74489865	chr14:74471930~74472360:-
BRCA	cis	rs11159086	0.793	rs8016972	ENSG00000270000.1	RP3-449M8.9	5.39	8.73e-08	1.08e-05	0.25	0.16	Advanced glycation end-product levels;	chr14:74491833	chr14:74471930~74472360:-
BRCA	cis	rs41369048	0.858	rs2784273	ENSG00000272823.1	RP11-295M18.6	-5.39	8.74e-08	1.09e-05	-0.23	-0.16	Eosinophil counts;Sum eosinophil basophil counts;	chr1:220907744	chr1:220828676~220829211:-
BRCA	cis	rs9287719	0.649	rs11684537	ENSG00000243819.4	RN7SL832P	5.39	8.75e-08	1.09e-05	0.16	0.16	Prostate cancer;	chr2:10594706	chr2:10690344~10692099:+
BRCA	cis	rs66887589	0.592	rs11731571	ENSG00000245958.5	RP11-33B1.1	-5.39	8.75e-08	1.09e-05	-0.15	-0.16	Diastolic blood pressure;	chr4:119300030	chr4:119454791~119552025:+
BRCA	cis	rs4908768	0.539	rs7547411	ENSG00000232912.4	RP5-1115A15.1	5.39	8.75e-08	1.09e-05	0.16	0.16	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8578086	chr1:8424645~8434838:+
BRCA	cis	rs4835473	0.9	rs12503074	ENSG00000249741.2	RP11-673E1.3	5.39	8.76e-08	1.09e-05	0.18	0.16	Immature fraction of reticulocytes;	chr4:143812560	chr4:143911514~143912053:-
BRCA	cis	rs9816784	0.566	rs11720913	ENSG00000231464.1	AC024937.4	5.39	8.76e-08	1.09e-05	0.22	0.16	Mean corpuscular hemoglobin;	chr3:196105689	chr3:195996738~195998233:+
BRCA	cis	rs17767294	0.612	rs9461425	ENSG00000219392.1	RP1-265C24.5	-5.39	8.77e-08	1.09e-05	-0.32	-0.16	Parkinson's disease;	chr6:27951910	chr6:28115628~28116551:+
BRCA	cis	rs11742741	0.523	rs17444026	ENSG00000248874.4	C5orf17	-5.39	8.77e-08	1.09e-05	-0.21	-0.16	Educational attainment;	chr5:24099713	chr5:23951348~24178263:+
BRCA	cis	rs11742741	0.539	rs11955340	ENSG00000248874.4	C5orf17	-5.39	8.77e-08	1.09e-05	-0.21	-0.16	Educational attainment;	chr5:24100036	chr5:23951348~24178263:+
BRCA	cis	rs10510102	0.516	rs79528809	ENSG00000276742.1	RP11-500G22.4	5.39	8.77e-08	1.09e-05	0.3	0.16	Breast cancer;	chr10:121980309	chr10:121956782~121957098:+
BRCA	cis	rs10208649	1	rs6745729	ENSG00000233266.1	HMGB1P31	5.39	8.77e-08	1.09e-05	0.38	0.16	Body mass index;	chr2:53888676	chr2:54051334~54051760:+
BRCA	cis	rs10208649	1	rs13432387	ENSG00000233266.1	HMGB1P31	5.39	8.77e-08	1.09e-05	0.38	0.16	Body mass index;	chr2:53889150	chr2:54051334~54051760:+
BRCA	cis	rs3733585	0.699	rs1079128	ENSG00000250413.1	RP11-448G15.1	5.39	8.78e-08	1.09e-05	0.21	0.16	Cleft plate (environmental tobacco smoke interaction);	chr4:9949597	chr4:10006482~10009725:+
BRCA	cis	rs1707322	0.686	rs2991977	ENSG00000234329.1	RP11-767N6.2	-5.39	8.78e-08	1.09e-05	-0.17	-0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45588011	chr1:45651039~45651826:-
BRCA	cis	rs56114371	0.777	rs200481	ENSG00000220721.1	OR1F12	5.39	8.79e-08	1.09e-05	0.28	0.16	Breast cancer;	chr6:27806054	chr6:28073316~28074233:+
BRCA	cis	rs2239547	0.657	rs12496077	ENSG00000242142.1	SERBP1P3	5.39	8.79e-08	1.09e-05	0.21	0.16	Schizophrenia;	chr3:52852225	chr3:53064283~53065091:-
BRCA	cis	rs2919009	0.607	rs72826623	ENSG00000271670.1	RP11-95I16.4	5.39	8.79e-08	1.09e-05	0.23	0.16	Obesity-related traits;	chr10:120952843	chr10:120879256~120880667:-
BRCA	cis	rs6570726	0.791	rs422099	ENSG00000270638.1	RP3-466P17.1	5.39	8.79e-08	1.09e-05	0.19	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145485800	chr6:145735570~145737218:+
BRCA	cis	rs357618	1	rs357624	ENSG00000260581.1	CTB-113P19.4	5.39	8.79e-08	1.09e-05	0.19	0.16	Basophil percentage of white cells;	chr5:151469140	chr5:151652275~151655449:+
BRCA	cis	rs7923609	1	rs12355784	ENSG00000232075.1	MRPL35P2	-5.39	8.79e-08	1.09e-05	-0.21	-0.16	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63361805	chr10:63634317~63634827:-
BRCA	cis	rs2145598	0.868	rs2348075	ENSG00000279636.2	LINC00216	-5.39	8.79e-08	1.09e-05	-0.16	-0.16	Coronary artery disease;	chr14:58386422	chr14:58288033~58289158:+
BRCA	cis	rs375066	0.516	rs7248807	ENSG00000267058.1	RP11-15A1.3	5.39	8.8e-08	1.09e-05	0.2	0.16	Breast cancer;	chr19:43825930	chr19:43891804~43901805:-
BRCA	cis	rs1387259	0.723	rs2732488	ENSG00000257735.1	RP11-370I10.6	5.39	8.8e-08	1.09e-05	0.21	0.16	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48377661	chr12:48350945~48442411:+
BRCA	cis	rs1387259	0.758	rs2634670	ENSG00000257735.1	RP11-370I10.6	5.39	8.8e-08	1.09e-05	0.21	0.16	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48378094	chr12:48350945~48442411:+
BRCA	cis	rs2732480	0.5	rs11168468	ENSG00000240399.1	RP1-228P16.1	5.39	8.8e-08	1.09e-05	0.19	0.16	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48218682	chr12:48054813~48055591:-
BRCA	cis	rs12681366	0.801	rs1372048	ENSG00000253704.1	RP11-267M23.4	5.39	8.8e-08	1.09e-05	0.19	0.16	Nonsyndromic cleft lip with cleft palate;	chr8:94455013	chr8:94553722~94569745:+
BRCA	cis	rs4713118	0.616	rs9348789	ENSG00000280107.1	AL022393.9	-5.39	8.81e-08	1.09e-05	-0.24	-0.16	Parkinson's disease;	chr6:28057708	chr6:28170845~28172521:+
BRCA	cis	rs1722141	0.6	rs1525819	ENSG00000237471.1	AC073115.6	5.39	8.81e-08	1.09e-05	0.24	0.16	Sitting height ratio;	chr7:45945301	chr7:45969657~45980191:+
BRCA	cis	rs7238033	0.602	rs3819178	ENSG00000267193.4	RP11-116O18.3	5.39	8.81e-08	1.09e-05	0.18	0.16	Bladder cancer;	chr18:45730880	chr18:45669367~45747215:-
BRCA	cis	rs1722141	0.67	rs2965073	ENSG00000237471.1	AC073115.6	5.39	8.81e-08	1.09e-05	0.24	0.16	Sitting height ratio;	chr7:45941524	chr7:45969657~45980191:+
BRCA	cis	rs4853525	0.561	rs11898764	ENSG00000235852.1	AC005540.3	-5.39	8.81e-08	1.09e-05	-0.21	-0.16	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190847844	chr2:190880797~190882059:-
BRCA	cis	rs2239547	0.657	rs7620706	ENSG00000242142.1	SERBP1P3	5.39	8.82e-08	1.09e-05	0.21	0.16	Schizophrenia;	chr3:52857740	chr3:53064283~53065091:-
BRCA	cis	rs7493	0.755	rs13223537	ENSG00000233942.1	AC004012.1	-5.39	8.82e-08	1.09e-05	-0.21	-0.16	Yu-Zhi constitution type in type 2 diabetes;	chr7:95336855	chr7:95471835~95473998:+
BRCA	cis	rs1124769	0.654	rs35373992	ENSG00000259378.1	DCAF13P3	5.39	8.82e-08	1.09e-05	0.24	0.16	Cognitive performance;	chr15:51184090	chr15:50944663~50945996:+
BRCA	cis	rs9545047	0.604	rs9530915	ENSG00000227354.5	RBM26-AS1	5.39	8.82e-08	1.09e-05	0.18	0.16	Schizophrenia;	chr13:79396512	chr13:79406309~79424328:+
BRCA	cis	rs997295	0.592	rs2899724	ENSG00000270964.1	RP11-502I4.3	-5.39	8.83e-08	1.09e-05	-0.18	-0.16	Motion sickness;	chr15:67468470	chr15:67541072~67542604:-
BRCA	cis	rs910316	0.737	rs175080	ENSG00000279594.1	RP11-950C14.10	-5.39	8.83e-08	1.1e-05	-0.18	-0.16	Height;	chr14:75047125	chr14:75011269~75012851:-
BRCA	cis	rs991427	0.643	rs17018648	ENSG00000258100.1	RP11-121E16.1	-5.39	8.83e-08	1.1e-05	-0.26	-0.16	Systolic blood pressure (alcohol consumption interaction);	chr12:91064675	chr12:91362196~91368606:+
BRCA	cis	rs7818688	1	rs7818688	ENSG00000253528.2	RP11-347C18.4	-5.39	8.83e-08	1.1e-05	-0.26	-0.16	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95011854	chr8:94974573~94974853:-
BRCA	cis	rs1707322	0.717	rs3014245	ENSG00000234329.1	RP11-767N6.2	-5.39	8.83e-08	1.1e-05	-0.17	-0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45621241	chr1:45651039~45651826:-
BRCA	cis	rs11158026	0.757	rs8013521	ENSG00000258413.1	RP11-665C16.6	-5.39	8.83e-08	1.1e-05	-0.21	-0.16	Parkinson's disease;	chr14:54947007	chr14:55262767~55272075:-
BRCA	cis	rs1223397	0.938	rs3817742	ENSG00000215022.6	RP1-257A7.4	-5.39	8.85e-08	1.1e-05	-0.23	-0.16	Blood pressure;	chr6:13279320	chr6:13264861~13295586:-
BRCA	cis	rs11123406	0.501	rs3747653	ENSG00000227992.1	AC108463.2	5.39	8.85e-08	1.1e-05	0.23	0.16	Type 2 diabetes;	chr2:111208963	chr2:111203964~111206215:-
BRCA	cis	rs7577696	0.568	rs177082	ENSG00000272716.1	RP11-563N4.1	5.39	8.86e-08	1.1e-05	0.2	0.16	Inflammatory biomarkers;	chr2:32213281	chr2:32165046~32165757:-
BRCA	cis	rs910316	0.763	rs13712	ENSG00000279594.1	RP11-950C14.10	5.39	8.86e-08	1.1e-05	0.18	0.16	Height;	chr14:75017109	chr14:75011269~75012851:-
BRCA	cis	rs9840812	0.591	rs1291921	ENSG00000239213.4	NCK1-AS1	5.39	8.86e-08	1.1e-05	0.19	0.16	Fibrinogen levels;	chr3:136317384	chr3:136841726~136862054:-
BRCA	cis	rs922692	0.696	rs1809420	ENSG00000261143.1	ADAMTS7P3	5.39	8.86e-08	1.1e-05	0.21	0.16	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78764427	chr15:77976042~77993057:+
BRCA	cis	rs4588572	0.615	rs4143070	ENSG00000245556.2	SCAMP1-AS1	-5.39	8.87e-08	1.1e-05	-0.19	-0.16	Triglycerides;	chr5:78473271	chr5:78342365~78360507:-
BRCA	cis	rs3805389	1	rs28564902	ENSG00000273257.1	RP11-177J6.1	-5.39	8.87e-08	1.1e-05	-0.25	-0.16	Waist-to-hip ratio adjusted for body mass index;	chr4:55613324	chr4:55387949~55388271:+
BRCA	cis	rs7923609	0.818	rs10761716	ENSG00000232075.1	MRPL35P2	-5.39	8.87e-08	1.1e-05	-0.21	-0.16	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63122540	chr10:63634317~63634827:-
BRCA	cis	rs6671200	0.667	rs76468062	ENSG00000235501.4	RP4-639F20.1	-5.39	8.87e-08	1.1e-05	-0.39	-0.16	Stearic acid (18:0) levels;	chr1:94932483	chr1:94927566~94963270:+
BRCA	cis	rs3733585	0.699	rs7676733	ENSG00000250413.1	RP11-448G15.1	5.39	8.87e-08	1.1e-05	0.21	0.16	Cleft plate (environmental tobacco smoke interaction);	chr4:9965332	chr4:10006482~10009725:+
BRCA	cis	rs3733585	0.699	rs10017674	ENSG00000250413.1	RP11-448G15.1	5.39	8.87e-08	1.1e-05	0.21	0.16	Cleft plate (environmental tobacco smoke interaction);	chr4:9965429	chr4:10006482~10009725:+
BRCA	cis	rs3733585	0.673	rs7434391	ENSG00000250413.1	RP11-448G15.1	5.39	8.87e-08	1.1e-05	0.21	0.16	Cleft plate (environmental tobacco smoke interaction);	chr4:9966058	chr4:10006482~10009725:+
BRCA	cis	rs3733585	0.699	rs6449176	ENSG00000250413.1	RP11-448G15.1	5.39	8.87e-08	1.1e-05	0.21	0.16	Cleft plate (environmental tobacco smoke interaction);	chr4:9966219	chr4:10006482~10009725:+
BRCA	cis	rs7772486	0.686	rs1569540	ENSG00000270638.1	RP3-466P17.1	-5.39	8.88e-08	1.1e-05	-0.19	-0.16	Lobe attachment (rater-scored or self-reported);	chr6:145747976	chr6:145735570~145737218:+
BRCA	cis	rs7772486	0.686	rs2142983	ENSG00000270638.1	RP3-466P17.1	-5.39	8.88e-08	1.1e-05	-0.19	-0.16	Lobe attachment (rater-scored or self-reported);	chr6:145748565	chr6:145735570~145737218:+
BRCA	cis	rs6723226	0.708	rs2754513	ENSG00000276517.1	AL133243.2	-5.39	8.88e-08	1.1e-05	-0.21	-0.16	Intelligence (multi-trait analysis);	chr2:32557696	chr2:32526504~32529507:+
BRCA	cis	rs370915	0.542	rs28440880	ENSG00000250971.1	RP11-696F12.1	5.39	8.88e-08	1.1e-05	0.18	0.16	Gout;	chr4:186872059	chr4:187060099~187060930:+
BRCA	cis	rs370915	0.542	rs13124558	ENSG00000250971.1	RP11-696F12.1	5.39	8.88e-08	1.1e-05	0.18	0.16	Gout;	chr4:186873021	chr4:187060099~187060930:+
BRCA	cis	rs2235642	0.75	rs2859310	ENSG00000260989.1	LA16c-395F10.2	5.39	8.88e-08	1.1e-05	0.17	0.16	Coronary artery disease;	chr16:1606764	chr16:1580527~1610328:+
BRCA	cis	rs7246657	0.722	rs2927739	ENSG00000276846.1	CTD-3220F14.3	-5.39	8.88e-08	1.1e-05	-0.22	-0.16	Coronary artery calcification;	chr19:37658429	chr19:37314868~37315620:-
BRCA	cis	rs9659323	0.67	rs12096179	ENSG00000231365.4	RP11-418J17.1	-5.39	8.89e-08	1.1e-05	-0.19	-0.16	Body mass index;	chr1:119093100	chr1:119140396~119275973:+
BRCA	cis	rs2243480	0.901	rs778732	ENSG00000232559.3	GS1-124K5.12	5.39	8.89e-08	1.1e-05	0.32	0.16	Diabetic kidney disease;	chr7:66357373	chr7:66554588~66576923:-
BRCA	cis	rs2187895	0.704	rs1476040	ENSG00000271811.1	RP1-79C4.4	5.39	8.89e-08	1.1e-05	0.19	0.16	Tonsillectomy;	chr1:170731617	chr1:170667381~170669425:+
BRCA	cis	rs4948102	0.69	rs35844144	ENSG00000226278.1	PSPHP1	-5.39	8.9e-08	1.1e-05	-0.18	-0.16	Plasma homocysteine levels (post-methionine load test);	chr7:55982832	chr7:55764797~55773288:+
BRCA	cis	rs17253792	0.545	rs75276278	ENSG00000186615.9	KTN1-AS1	-5.39	8.9e-08	1.1e-05	-0.34	-0.16	Putamen volume;	chr14:55557623	chr14:55499278~55580110:-
BRCA	cis	rs6750795	0.641	rs10933375	ENSG00000181798.2	LINC00471	5.39	8.9e-08	1.1e-05	0.23	0.16	Height;	chr2:231502585	chr2:231508426~231514339:-
BRCA	cis	rs17597773	0.638	rs881995	ENSG00000272823.1	RP11-295M18.6	-5.39	8.9e-08	1.1e-05	-0.19	-0.16	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220811152	chr1:220828676~220829211:-
BRCA	cis	rs7772486	0.902	rs2144476	ENSG00000270638.1	RP3-466P17.1	5.39	8.9e-08	1.1e-05	0.19	0.16	Lobe attachment (rater-scored or self-reported);	chr6:146001348	chr6:145735570~145737218:+
BRCA	cis	rs4588572	0.644	rs2241566	ENSG00000245556.2	SCAMP1-AS1	5.39	8.91e-08	1.1e-05	0.2	0.16	Triglycerides;	chr5:78488915	chr5:78342365~78360507:-
BRCA	cis	rs2179367	0.959	rs536203	ENSG00000216906.2	RP11-350J20.9	5.39	8.92e-08	1.11e-05	0.21	0.16	Dupuytren's disease;	chr6:149330128	chr6:149904243~149906418:+
BRCA	cis	rs6586111	0.647	rs76120037	ENSG00000226659.1	RP11-137H2.4	-5.39	8.92e-08	1.11e-05	-0.24	-0.16	Capecitabine sensitivity;	chr10:80612174	chr10:80529597~80535942:-
BRCA	cis	rs17711722	0.727	rs1880555	ENSG00000273024.4	INTS4P2	-5.39	8.92e-08	1.11e-05	-0.18	-0.16	Calcium levels;	chr7:65967580	chr7:65647864~65715661:+
BRCA	cis	rs11051970	0.559	rs11051945	ENSG00000274964.1	RP11-817I4.1	-5.39	8.92e-08	1.11e-05	-0.21	-0.16	Response to tocilizumab in rheumatoid arthritis;	chr12:32336191	chr12:32339368~32340724:+
BRCA	cis	rs863750	0.687	rs825485	ENSG00000275389.1	RP11-214K3.24	5.39	8.93e-08	1.11e-05	0.21	0.16	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-hip ratio;	chr12:124091865	chr12:124085761~124088598:+
BRCA	cis	rs10506328	0.689	rs4759348	ENSG00000248265.1	FLJ12825	5.39	8.93e-08	1.11e-05	0.24	0.16	Mean platelet volume;	chr12:54236733	chr12:54058254~54122234:+
BRCA	cis	rs6671200	0.667	rs76833598	ENSG00000235501.4	RP4-639F20.1	-5.39	8.94e-08	1.11e-05	-0.39	-0.16	Stearic acid (18:0) levels;	chr1:94928425	chr1:94927566~94963270:+
BRCA	cis	rs8098244	0.683	rs10853591	ENSG00000264745.1	TTC39C-AS1	5.39	8.94e-08	1.11e-05	0.2	0.16	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23845888	chr18:23994213~24015339:-
BRCA	cis	rs1552244	0.935	rs41520445	ENSG00000232901.1	CYCSP10	-5.39	8.94e-08	1.11e-05	-0.23	-0.16	Alzheimer's disease;	chr3:10111457	chr3:10000647~10000940:-
BRCA	cis	rs950169	0.58	rs11634320	ENSG00000259295.5	CSPG4P12	-5.39	8.95e-08	1.11e-05	-0.22	-0.16	Schizophrenia;	chr15:84628952	chr15:85191438~85213905:+
BRCA	cis	rs9652601	0.843	rs7204643	ENSG00000274038.1	RP11-66H6.4	5.38	8.96e-08	1.11e-05	0.18	0.16	Systemic lupus erythematosus;	chr16:11073746	chr16:11056556~11057034:+
BRCA	cis	rs55702914	0.746	rs7588530	ENSG00000231621.1	AC013264.2	5.38	8.96e-08	1.11e-05	0.16	0.16	Major depression and alcohol dependence;	chr2:197281974	chr2:197197991~197199273:+
BRCA	cis	rs2243480	1	rs316331	ENSG00000275400.1	RP4-756H11.5	-5.38	8.96e-08	1.11e-05	-0.29	-0.16	Diabetic kidney disease;	chr7:66139635	chr7:66553805~66554199:-
BRCA	cis	rs516805	0.561	rs7754101	ENSG00000279453.1	RP3-425C14.4	5.38	8.96e-08	1.11e-05	0.27	0.16	Lymphocyte counts;	chr6:122607828	chr6:122436789~122439223:-
BRCA	cis	rs1552244	1	rs113153120	ENSG00000232901.1	CYCSP10	5.38	8.97e-08	1.11e-05	0.23	0.16	Alzheimer's disease;	chr3:10114714	chr3:10000647~10000940:-
BRCA	cis	rs1552244	1	rs112509186	ENSG00000232901.1	CYCSP10	5.38	8.97e-08	1.11e-05	0.23	0.16	Alzheimer's disease;	chr3:10114849	chr3:10000647~10000940:-
BRCA	cis	rs62025270	0.632	rs17637411	ENSG00000202081.1	RNU6-1280P	-5.38	8.97e-08	1.11e-05	-0.24	-0.16	Idiopathic pulmonary fibrosis;	chr15:85703216	chr15:85651522~85651628:-
BRCA	cis	rs62025270	0.58	rs62022938	ENSG00000202081.1	RNU6-1280P	-5.38	8.97e-08	1.11e-05	-0.24	-0.16	Idiopathic pulmonary fibrosis;	chr15:85704764	chr15:85651522~85651628:-
BRCA	cis	rs728478	0.845	rs7207830	ENSG00000266992.1	DHX40P1	5.38	8.97e-08	1.11e-05	0.2	0.16	QT interval;	chr17:59402382	chr17:59976009~60002384:-
BRCA	cis	rs2115536	0.967	rs4778734	ENSG00000278600.1	RP11-81A1.6	-5.38	8.97e-08	1.11e-05	-0.14	-0.16	Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Eosinophil counts;Neutrophil percentage of granulocytes;	chr15:79918509	chr15:79920195~79922455:-
BRCA	cis	rs75422866	0.51	rs73105829	ENSG00000276691.1	RP5-1057I20.5	5.38	8.97e-08	1.11e-05	0.33	0.16	Pneumonia;	chr12:47734162	chr12:47788426~47788971:+
BRCA	cis	rs12285276	0.636	rs7120031	ENSG00000205106.4	DKFZp779M0652	5.38	8.98e-08	1.11e-05	0.25	0.16	Visceral fat;	chr11:45794469	chr11:45771432~45772358:+
BRCA	cis	rs950776	0.518	rs2869544	ENSG00000279373.1	RP11-650L12.4	-5.38	8.98e-08	1.11e-05	-0.2	-0.16	Sudden cardiac arrest;	chr15:78547058	chr15:78537681~78538946:+
BRCA	cis	rs6543140	0.572	rs17027173	ENSG00000234389.1	AC007278.3	5.38	8.98e-08	1.11e-05	0.18	0.16	Blood protein levels;	chr2:102440583	chr2:102438713~102440475:+
BRCA	cis	rs4713675	0.584	rs9380375	ENSG00000224557.6	HLA-DPB2	-5.38	8.99e-08	1.11e-05	-0.19	-0.16	Plateletcrit;	chr6:33714614	chr6:33112451~33129084:+
BRCA	cis	rs7577696	0.568	rs410469	ENSG00000272716.1	RP11-563N4.1	-5.38	8.99e-08	1.11e-05	-0.19	-0.16	Inflammatory biomarkers;	chr2:32251923	chr2:32165046~32165757:-
BRCA	cis	rs2179367	0.613	rs12207047	ENSG00000223701.3	RAET1E-AS1	5.38	9e-08	1.11e-05	0.24	0.16	Dupuytren's disease;	chr6:149423496	chr6:149884431~149919508:+
BRCA	cis	rs7772486	0.875	rs7739418	ENSG00000270638.1	RP3-466P17.1	5.38	9e-08	1.11e-05	0.18	0.16	Lobe attachment (rater-scored or self-reported);	chr6:146038052	chr6:145735570~145737218:+
BRCA	cis	rs2153535	0.562	rs9379211	ENSG00000251164.1	HULC	-5.38	9e-08	1.11e-05	-0.2	-0.16	Motion sickness;	chr6:8463694	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.58	rs965706	ENSG00000251164.1	HULC	-5.38	9e-08	1.11e-05	-0.2	-0.16	Motion sickness;	chr6:8464475	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.58	rs6938071	ENSG00000251164.1	HULC	-5.38	9e-08	1.11e-05	-0.2	-0.16	Motion sickness;	chr6:8464612	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.601	rs9406160	ENSG00000251164.1	HULC	-5.38	9e-08	1.11e-05	-0.2	-0.16	Motion sickness;	chr6:8464674	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.58	rs1335636	ENSG00000251164.1	HULC	-5.38	9e-08	1.11e-05	-0.2	-0.16	Motion sickness;	chr6:8464814	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.58	rs986060	ENSG00000251164.1	HULC	-5.38	9e-08	1.11e-05	-0.2	-0.16	Motion sickness;	chr6:8465195	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.58	rs9393021	ENSG00000251164.1	HULC	-5.38	9e-08	1.11e-05	-0.2	-0.16	Motion sickness;	chr6:8465890	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.58	rs9406161	ENSG00000251164.1	HULC	-5.38	9e-08	1.11e-05	-0.2	-0.16	Motion sickness;	chr6:8465911	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.58	rs9405390	ENSG00000251164.1	HULC	-5.38	9e-08	1.11e-05	-0.2	-0.16	Motion sickness;	chr6:8465976	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.58	rs9406163	ENSG00000251164.1	HULC	-5.38	9e-08	1.11e-05	-0.2	-0.16	Motion sickness;	chr6:8466409	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.504	rs9405393	ENSG00000251164.1	HULC	-5.38	9e-08	1.11e-05	-0.2	-0.16	Motion sickness;	chr6:8467199	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.58	rs2184584	ENSG00000251164.1	HULC	-5.38	9e-08	1.11e-05	-0.2	-0.16	Motion sickness;	chr6:8468174	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.541	rs7774752	ENSG00000251164.1	HULC	-5.38	9e-08	1.11e-05	-0.2	-0.16	Motion sickness;	chr6:8468745	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.58	rs9505450	ENSG00000251164.1	HULC	-5.38	9e-08	1.11e-05	-0.2	-0.16	Motion sickness;	chr6:8469669	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.58	rs9406164	ENSG00000251164.1	HULC	-5.38	9e-08	1.11e-05	-0.2	-0.16	Motion sickness;	chr6:8469815	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.58	rs7341201	ENSG00000251164.1	HULC	-5.38	9e-08	1.11e-05	-0.2	-0.16	Motion sickness;	chr6:8470037	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.58	rs7341206	ENSG00000251164.1	HULC	-5.38	9e-08	1.11e-05	-0.2	-0.16	Motion sickness;	chr6:8470256	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.58	rs7341383	ENSG00000251164.1	HULC	-5.38	9e-08	1.11e-05	-0.2	-0.16	Motion sickness;	chr6:8470401	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.504	rs9328472	ENSG00000251164.1	HULC	-5.38	9e-08	1.11e-05	-0.2	-0.16	Motion sickness;	chr6:8470615	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.58	rs1414345	ENSG00000251164.1	HULC	-5.38	9e-08	1.11e-05	-0.2	-0.16	Motion sickness;	chr6:8471304	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.58	rs1414349	ENSG00000251164.1	HULC	-5.38	9e-08	1.11e-05	-0.2	-0.16	Motion sickness;	chr6:8472057	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.58	rs1414350	ENSG00000251164.1	HULC	-5.38	9e-08	1.11e-05	-0.2	-0.16	Motion sickness;	chr6:8472098	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.58	rs9392224	ENSG00000251164.1	HULC	-5.38	9e-08	1.11e-05	-0.2	-0.16	Motion sickness;	chr6:8472381	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.542	rs9378553	ENSG00000251164.1	HULC	-5.38	9e-08	1.11e-05	-0.2	-0.16	Motion sickness;	chr6:8472399	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.601	rs1855768	ENSG00000251164.1	HULC	-5.38	9e-08	1.11e-05	-0.2	-0.16	Motion sickness;	chr6:8472736	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.58	rs1932281	ENSG00000251164.1	HULC	-5.38	9e-08	1.11e-05	-0.2	-0.16	Motion sickness;	chr6:8473532	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.58	rs6900007	ENSG00000251164.1	HULC	-5.38	9e-08	1.11e-05	-0.2	-0.16	Motion sickness;	chr6:8473802	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.58	rs2184585	ENSG00000251164.1	HULC	-5.38	9e-08	1.11e-05	-0.2	-0.16	Motion sickness;	chr6:8473935	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.58	rs6902001	ENSG00000251164.1	HULC	-5.38	9e-08	1.11e-05	-0.2	-0.16	Motion sickness;	chr6:8476822	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.58	rs4960423	ENSG00000251164.1	HULC	-5.38	9e-08	1.11e-05	-0.2	-0.16	Motion sickness;	chr6:8476977	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.58	rs1932282	ENSG00000251164.1	HULC	-5.38	9e-08	1.11e-05	-0.2	-0.16	Motion sickness;	chr6:8477097	chr6:8652137~8653846:+
BRCA	cis	rs2638953	0.962	rs11049518	ENSG00000247934.4	RP11-967K21.1	-5.38	9e-08	1.12e-05	-0.23	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28303728	chr12:28163298~28190738:-
BRCA	cis	rs9859260	0.614	rs493661	ENSG00000242086.7	LINC00969	-5.38	9.01e-08	1.12e-05	-0.18	-0.16	Mean corpuscular volume;	chr3:196059618	chr3:195658062~195739964:+
BRCA	cis	rs2554380	0.628	rs4843156	ENSG00000230373.7	GOLGA6L5P	-5.38	9.01e-08	1.12e-05	-0.2	-0.16	Height;	chr15:83788593	chr15:84507885~84516814:-
BRCA	cis	rs7618501	0.633	rs2624843	ENSG00000228008.1	CTD-2330K9.3	5.38	9.02e-08	1.12e-05	0.16	0.16	Intelligence (multi-trait analysis);	chr3:49960530	chr3:49903845~49916937:+
BRCA	cis	rs2277027	0.552	rs5023028	ENSG00000248544.2	CTB-47B11.3	5.38	9.03e-08	1.12e-05	0.19	0.16	Pulmonary function;Pulmonary function (smoking interaction);	chr5:157530428	chr5:157375741~157384950:-
BRCA	cis	rs10510102	0.935	rs11200257	ENSG00000226864.1	ATE1-AS1	5.38	9.03e-08	1.12e-05	0.29	0.16	Breast cancer;	chr10:121917232	chr10:121928312~121951965:+
BRCA	cis	rs7044106	0.537	rs10739573	ENSG00000238181.2	AHCYP2	-5.38	9.03e-08	1.12e-05	-0.23	-0.16	Hip circumference adjusted for BMI;	chr9:120727540	chr9:120720673~120721972:+
BRCA	cis	rs8114671	0.647	rs6060267	ENSG00000269202.1	RP4-614O4.12	-5.38	9.03e-08	1.12e-05	-0.17	-0.16	Height;	chr20:35146209	chr20:35201747~35203288:-
BRCA	cis	rs8114671	0.647	rs6060268	ENSG00000269202.1	RP4-614O4.12	-5.38	9.03e-08	1.12e-05	-0.17	-0.16	Height;	chr20:35146490	chr20:35201747~35203288:-
BRCA	cis	rs8114671	0.647	rs1415771	ENSG00000269202.1	RP4-614O4.12	-5.38	9.03e-08	1.12e-05	-0.17	-0.16	Height;	chr20:35146690	chr20:35201747~35203288:-
BRCA	cis	rs4908768	0.539	rs6675443	ENSG00000270282.1	RP5-1115A15.2	5.38	9.03e-08	1.12e-05	0.18	0.16	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8591523	chr1:8512653~8513021:+
BRCA	cis	rs891378	0.883	rs6540888	ENSG00000274245.1	RP11-357P18.2	-5.38	9.04e-08	1.12e-05	-0.22	-0.16	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207247514	chr1:207372559~207373252:+
BRCA	cis	rs2638953	0.853	rs10843179	ENSG00000247934.4	RP11-967K21.1	5.38	9.04e-08	1.12e-05	0.22	0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28462125	chr12:28163298~28190738:-
BRCA	cis	rs370915	0.524	rs28826385	ENSG00000250971.1	RP11-696F12.1	5.38	9.04e-08	1.12e-05	0.18	0.16	Gout;	chr4:186848298	chr4:187060099~187060930:+
BRCA	cis	rs2732480	0.577	rs2732457	ENSG00000226413.2	OR8T1P	-5.38	9.05e-08	1.12e-05	-0.22	-0.16	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48364596	chr12:48442030~48442947:-
BRCA	cis	rs910316	0.737	rs28687415	ENSG00000279594.1	RP11-950C14.10	5.38	9.05e-08	1.12e-05	0.18	0.16	Height;	chr14:75028779	chr14:75011269~75012851:-
BRCA	cis	rs673078	0.66	rs7136216	ENSG00000275409.1	RP11-131L12.4	-5.38	9.05e-08	1.12e-05	-0.21	-0.16	Glucose homeostasis traits;	chr12:118170475	chr12:118430147~118430699:+
BRCA	cis	rs2243480	1	rs34703416	ENSG00000232559.3	GS1-124K5.12	5.38	9.05e-08	1.12e-05	0.31	0.16	Diabetic kidney disease;	chr7:65835655	chr7:66554588~66576923:-
BRCA	cis	rs4588572	0.57	rs2115433	ENSG00000245556.2	SCAMP1-AS1	-5.38	9.05e-08	1.12e-05	-0.19	-0.16	Triglycerides;	chr5:78404539	chr5:78342365~78360507:-
BRCA	cis	rs11722779	0.844	rs7694724	ENSG00000251288.2	RP11-10L12.2	-5.38	9.05e-08	1.12e-05	-0.2	-0.16	Schizophrenia;	chr4:103041375	chr4:102751401~102752641:+
BRCA	cis	rs10504130	1	rs12678639	ENSG00000272024.1	RP11-546K22.3	-5.38	9.06e-08	1.12e-05	-0.3	-0.16	Venous thromboembolism (SNP x SNP interaction);	chr8:51918088	chr8:51950284~51950690:+
BRCA	cis	rs10129255	0.912	rs67410411	ENSG00000224373.3	IGHV4-59	5.38	9.06e-08	1.12e-05	0.11	0.16	Kawasaki disease;	chr14:106680324	chr14:106627249~106627825:-
BRCA	cis	rs17660992	0.928	rs12460840	ENSG00000273837.1	LLNLR-470E3.1	-5.38	9.06e-08	1.12e-05	-0.18	-0.16	Blood protein levels;	chr19:51662141	chr19:51639478~51639931:-
BRCA	cis	rs9834975	0.875	rs4678191	ENSG00000272758.4	RP11-299J3.8	-5.38	9.06e-08	1.12e-05	-0.17	-0.16	Diastolic blood pressure;	chr3:122402391	chr3:122416207~122443180:+
BRCA	cis	rs863750	0.687	rs825481	ENSG00000275389.1	RP11-214K3.24	5.38	9.07e-08	1.12e-05	0.21	0.16	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-hip ratio;	chr12:124091012	chr12:124085761~124088598:+
BRCA	cis	rs7772486	0.686	rs7744014	ENSG00000270638.1	RP3-466P17.1	5.38	9.07e-08	1.12e-05	0.19	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145802682	chr6:145735570~145737218:+
BRCA	cis	rs2638953	0.962	rs11049621	ENSG00000247934.4	RP11-967K21.1	-5.38	9.07e-08	1.12e-05	-0.21	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28456074	chr12:28163298~28190738:-
BRCA	cis	rs202072	0.872	rs202044	ENSG00000272379.1	RP1-257A7.5	5.38	9.07e-08	1.12e-05	0.23	0.16	HIV-1 viral setpoint;	chr6:13275718	chr6:13290018~13290490:-
BRCA	cis	rs12681366	0.734	rs10102496	ENSG00000253704.1	RP11-267M23.4	5.38	9.07e-08	1.12e-05	0.17	0.16	Nonsyndromic cleft lip with cleft palate;	chr8:94385953	chr8:94553722~94569745:+
BRCA	cis	rs12681366	0.734	rs16916788	ENSG00000253704.1	RP11-267M23.4	5.38	9.07e-08	1.12e-05	0.17	0.16	Nonsyndromic cleft lip with cleft palate;	chr8:94387390	chr8:94553722~94569745:+
BRCA	cis	rs2243480	1	rs160634	ENSG00000232546.1	RP11-458F8.1	5.38	9.08e-08	1.12e-05	0.21	0.16	Diabetic kidney disease;	chr7:66063677	chr7:66848496~66858136:+
BRCA	cis	rs295490	0.748	rs74636199	ENSG00000272656.1	RP11-219D15.3	5.38	9.08e-08	1.12e-05	0.37	0.16	PR interval in Tripanosoma cruzi seropositivity;	chr3:139493679	chr3:139349024~139349371:-
BRCA	cis	rs7119	0.689	rs12907630	ENSG00000259362.2	RP11-307C19.1	-5.38	9.08e-08	1.12e-05	-0.22	-0.16	Type 2 diabetes;	chr15:77520564	chr15:77525540~77534110:+
BRCA	cis	rs9307551	0.619	rs10022309	ENSG00000250334.4	LINC00989	-5.38	9.08e-08	1.12e-05	-0.23	-0.16	Refractive error;	chr4:79550491	chr4:79492416~79576460:+
BRCA	cis	rs13126694	0.744	rs6821252	ENSG00000251429.1	RP11-597D13.7	5.38	9.08e-08	1.12e-05	0.16	0.16	Blood osmolality (transformed sodium);	chr4:158076296	chr4:158270378~158278676:+
BRCA	cis	rs9925964	0.869	rs2288004	ENSG00000232748.3	RP11-196G11.6	5.38	9.08e-08	1.12e-05	0.2	0.16	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31042719	chr16:31056460~31062803:+
BRCA	cis	rs2638953	0.962	rs61922975	ENSG00000247934.4	RP11-967K21.1	-5.38	9.09e-08	1.12e-05	-0.23	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28283705	chr12:28163298~28190738:-
BRCA	cis	rs6751744	0.824	rs10205689	ENSG00000226266.5	AC009961.3	-5.38	9.09e-08	1.12e-05	-0.22	-0.16	Dysphagia;	chr2:159507158	chr2:159670708~159712435:-
BRCA	cis	rs7914558	0.966	rs2297786	ENSG00000236937.2	PTGES3P4	5.38	9.09e-08	1.12e-05	0.21	0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102920221	chr10:102845595~102845950:+
BRCA	cis	rs875971	0.619	rs2302918	ENSG00000273024.4	INTS4P2	-5.38	9.09e-08	1.13e-05	-0.18	-0.16	Aortic root size;	chr7:66535945	chr7:65647864~65715661:+
BRCA	cis	rs9545047	0.625	rs9565489	ENSG00000227354.5	RBM26-AS1	5.38	9.1e-08	1.13e-05	0.18	0.16	Schizophrenia;	chr13:79342106	chr13:79406309~79424328:+
BRCA	cis	rs4831760	0.555	rs3988420	ENSG00000250483.1	PPM1AP1	-5.38	9.11e-08	1.13e-05	-0.19	-0.16	Pulmonary function decline;	chr8:15690865	chr8:15806149~15807283:-
BRCA	cis	rs1426063	0.858	rs6823982	ENSG00000260265.1	RP11-44F21.5	5.38	9.12e-08	1.13e-05	0.27	0.16	QT interval;	chr4:75084961	chr4:75081702~75084717:-
BRCA	cis	rs7577696	0.886	rs443609	ENSG00000272716.1	RP11-563N4.1	5.38	9.12e-08	1.13e-05	0.18	0.16	Inflammatory biomarkers;	chr2:32258524	chr2:32165046~32165757:-
BRCA	cis	rs227275	0.554	rs223381	ENSG00000251288.2	RP11-10L12.2	-5.38	9.12e-08	1.13e-05	-0.19	-0.16	Allergic disease (asthma, hay fever or eczema);	chr4:102832578	chr4:102751401~102752641:+
BRCA	cis	rs755249	0.565	rs722357	ENSG00000237624.1	OXCT2P1	-5.38	9.12e-08	1.13e-05	-0.2	-0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39479096	chr1:39514956~39516490:+
BRCA	cis	rs7111546	1	rs3763947	ENSG00000246225.5	RP11-17A1.3	-5.38	9.12e-08	1.13e-05	-0.25	-0.16	Dialysis-related mortality;	chr11:22813523	chr11:22829380~22945393:+
BRCA	cis	rs357618	0.965	rs187180	ENSG00000260581.1	CTB-113P19.4	5.38	9.12e-08	1.13e-05	0.19	0.16	Basophil percentage of white cells;	chr5:151468434	chr5:151652275~151655449:+
BRCA	cis	rs6840258	0.891	rs3755983	ENSG00000251411.1	RP11-397E7.4	-5.38	9.12e-08	1.13e-05	-0.23	-0.16	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87116640	chr4:86913266~86914817:-
BRCA	cis	rs9545047	0.625	rs7319320	ENSG00000227354.5	RBM26-AS1	5.38	9.13e-08	1.13e-05	0.18	0.16	Schizophrenia;	chr13:79343072	chr13:79406309~79424328:+
BRCA	cis	rs7777677	0.925	rs4726540	ENSG00000211750.2	TRBV24-1	-5.38	9.13e-08	1.13e-05	-0.15	-0.16	Alcoholic chronic pancreatitis;	chr7:142658771	chr7:142656701~142657213:+
BRCA	cis	rs3760982	0.585	rs8109812	ENSG00000267058.1	RP11-15A1.3	-5.38	9.13e-08	1.13e-05	-0.19	-0.16	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43794342	chr19:43891804~43901805:-
BRCA	cis	rs8133949	0.638	rs2839432	ENSG00000237232.6	ZNF295-AS1	-5.38	9.13e-08	1.13e-05	-0.29	-0.16	Hand grip strength;	chr21:41989963	chr21:42009194~42024924:+
BRCA	cis	rs2098713	0.569	rs12523333	ENSG00000250155.1	CTD-2353F22.1	5.38	9.13e-08	1.13e-05	0.18	0.16	Telomere length;	chr5:37498871	chr5:36666214~36725195:-
BRCA	cis	rs1426063	0.858	rs11936768	ENSG00000260265.1	RP11-44F21.5	5.38	9.13e-08	1.13e-05	0.27	0.16	QT interval;	chr4:75084506	chr4:75081702~75084717:-
BRCA	cis	rs2098713	0.537	rs562154	ENSG00000250155.1	CTD-2353F22.1	5.38	9.14e-08	1.13e-05	0.19	0.16	Telomere length;	chr5:37540947	chr5:36666214~36725195:-
BRCA	cis	rs9307551	0.584	rs7697359	ENSG00000250334.4	LINC00989	-5.38	9.14e-08	1.13e-05	-0.22	-0.16	Refractive error;	chr4:79546982	chr4:79492416~79576460:+
BRCA	cis	rs600231	0.706	rs3782091	ENSG00000245532.5	NEAT1	-5.38	9.15e-08	1.13e-05	-0.16	-0.16	Bone mineral density;	chr11:65569012	chr11:65422774~65445540:+
BRCA	cis	rs720475	0.732	rs73159066	ENSG00000170356.8	OR2A20P	5.38	9.15e-08	1.13e-05	0.25	0.16	Breast cancer;	chr7:144426495	chr7:144250045~144252957:-
BRCA	cis	rs11673344	0.536	rs62108291	ENSG00000267422.1	CTD-2554C21.1	5.38	9.15e-08	1.13e-05	0.21	0.16	Obesity-related traits;	chr19:37659457	chr19:37779686~37792865:+
BRCA	cis	rs7577696	0.695	rs12465351	ENSG00000272716.1	RP11-563N4.1	-5.38	9.15e-08	1.13e-05	-0.18	-0.16	Inflammatory biomarkers;	chr2:32169836	chr2:32165046~32165757:-
BRCA	cis	rs7178909	0.872	rs3931863	ENSG00000259677.1	RP11-493E3.1	5.38	9.15e-08	1.13e-05	0.19	0.16	Common traits (Other);	chr15:89890681	chr15:89876540~89877285:+
BRCA	cis	rs9545047	0.604	rs3752994	ENSG00000227354.5	RBM26-AS1	5.38	9.15e-08	1.13e-05	0.17	0.16	Schizophrenia;	chr13:79345076	chr13:79406309~79424328:+
BRCA	cis	rs7577696	0.554	rs3769605	ENSG00000272716.1	RP11-563N4.1	-5.38	9.16e-08	1.13e-05	-0.19	-0.16	Inflammatory biomarkers;	chr2:32097387	chr2:32165046~32165757:-
BRCA	cis	rs9467773	1	rs6456734	ENSG00000124549.13	BTN2A3P	5.38	9.16e-08	1.13e-05	0.17	0.16	Intelligence (multi-trait analysis);	chr6:26566737	chr6:26421391~26432383:+
BRCA	cis	rs997295	0.556	rs10468041	ENSG00000270964.1	RP11-502I4.3	-5.38	9.17e-08	1.13e-05	-0.18	-0.16	Motion sickness;	chr15:67480865	chr15:67541072~67542604:-
BRCA	cis	rs2839186	0.656	rs8128380	ENSG00000228137.1	AP001469.7	5.38	9.18e-08	1.13e-05	0.18	0.16	Testicular germ cell tumor;	chr21:46245779	chr21:46246890~46247682:+
BRCA	cis	rs9659323	0.596	rs11589179	ENSG00000231365.4	RP11-418J17.1	-5.38	9.18e-08	1.13e-05	-0.21	-0.16	Body mass index;	chr1:118954962	chr1:119140396~119275973:+
BRCA	cis	rs3126085	0.56	rs6587668	ENSG00000237975.5	FLG-AS1	5.38	9.18e-08	1.13e-05	0.25	0.16	Atopic dermatitis;	chr1:152361482	chr1:152168125~152445456:+
BRCA	cis	rs4671400	0.543	rs62152274	ENSG00000271889.1	RP11-493E12.1	-5.38	9.18e-08	1.14e-05	-0.25	-0.16	3-hydroxypropylmercapturic acid levels in smokers;	chr2:61272453	chr2:61151433~61162105:-
BRCA	cis	rs17301013	0.861	rs332770	ENSG00000227373.4	RP11-160H22.5	5.38	9.18e-08	1.14e-05	0.22	0.16	Systemic lupus erythematosus;	chr1:174681511	chr1:174115300~174160004:-
BRCA	cis	rs4835473	0.932	rs7693772	ENSG00000249741.2	RP11-673E1.3	-5.38	9.19e-08	1.14e-05	-0.17	-0.16	Immature fraction of reticulocytes;	chr4:143965614	chr4:143911514~143912053:-
BRCA	cis	rs6723108	0.654	rs669759	ENSG00000224043.6	CCNT2-AS1	-5.38	9.19e-08	1.14e-05	-0.24	-0.16	Type 2 diabetes;	chr2:134533564	chr2:134735464~134918710:-
BRCA	cis	rs9923856	0.519	rs7197754	ENSG00000274038.1	RP11-66H6.4	-5.38	9.2e-08	1.14e-05	-0.18	-0.16	Atopic dermatitis;Adult asthma;	chr16:11036522	chr16:11056556~11057034:+
BRCA	cis	rs2832191	0.716	rs7284006	ENSG00000176054.6	RPL23P2	5.38	9.21e-08	1.14e-05	0.18	0.16	Dental caries;	chr21:29102865	chr21:28997613~28998033:-
BRCA	cis	rs113835537	0.935	rs117480267	ENSG00000255517.5	CTD-3074O7.5	-5.38	9.22e-08	1.14e-05	-0.28	-0.16	Airway imaging phenotypes;	chr11:66631125	chr11:66473490~66480233:-
BRCA	cis	rs7772486	0.837	rs2474354	ENSG00000270638.1	RP3-466P17.1	5.38	9.22e-08	1.14e-05	0.19	0.16	Lobe attachment (rater-scored or self-reported);	chr6:146002659	chr6:145735570~145737218:+
BRCA	cis	rs17301013	0.612	rs56199565	ENSG00000227373.4	RP11-160H22.5	5.38	9.23e-08	1.14e-05	0.22	0.16	Systemic lupus erythematosus;	chr1:174640992	chr1:174115300~174160004:-
BRCA	cis	rs5742933	0.557	rs1233276	ENSG00000253559.1	OSGEPL1-AS1	-5.38	9.23e-08	1.14e-05	-0.23	-0.16	Ferritin levels;	chr2:189820056	chr2:189762704~189765556:+
BRCA	cis	rs962856	0.964	rs6546303	ENSG00000236780.4	AC078941.1	5.38	9.23e-08	1.14e-05	0.21	0.16	Pancreatic cancer;	chr2:67385986	chr2:67123357~67215319:-
BRCA	cis	rs62025270	0.688	rs76902341	ENSG00000259295.5	CSPG4P12	-5.38	9.23e-08	1.14e-05	-0.25	-0.16	Idiopathic pulmonary fibrosis;	chr15:85737059	chr15:85191438~85213905:+
BRCA	cis	rs8133949	0.953	rs7278166	ENSG00000237232.6	ZNF295-AS1	5.38	9.23e-08	1.14e-05	0.26	0.16	Hand grip strength;	chr21:42007431	chr21:42009194~42024924:+
BRCA	cis	rs2051773	0.567	rs7934608	ENSG00000184669.7	OR7E14P	-5.38	9.24e-08	1.14e-05	-0.24	-0.16	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);	chr11:17017370	chr11:17013998~17053024:+
BRCA	cis	rs9300255	0.602	rs2695479	ENSG00000235423.7	RP11-282O18.3	5.38	9.25e-08	1.14e-05	0.23	0.16	Neutrophil percentage of white cells;	chr12:123204839	chr12:123252030~123261483:-
BRCA	cis	rs7572733	0.534	rs6760891	ENSG00000231621.1	AC013264.2	-5.38	9.25e-08	1.14e-05	-0.16	-0.16	Dermatomyositis;	chr2:197903442	chr2:197197991~197199273:+
BRCA	cis	rs7572733	0.534	rs7572123	ENSG00000231621.1	AC013264.2	-5.38	9.25e-08	1.14e-05	-0.16	-0.16	Dermatomyositis;	chr2:197904913	chr2:197197991~197199273:+
BRCA	cis	rs2638953	0.777	rs11049681	ENSG00000247934.4	RP11-967K21.1	-5.38	9.26e-08	1.14e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28508722	chr12:28163298~28190738:-
BRCA	cis	rs7976269	0.515	rs9300183	ENSG00000275476.1	RP11-996F15.4	-5.38	9.26e-08	1.14e-05	-0.19	-0.16	Male-pattern baldness;	chr12:29002316	chr12:29277397~29277882:-
BRCA	cis	rs7178375	1	rs1474382	ENSG00000270055.1	CTD-3092A11.2	-5.38	9.27e-08	1.14e-05	-0.24	-0.16	Hypertriglyceridemia;	chr15:30922446	chr15:30487963~30490313:+
BRCA	cis	rs2904967	0.929	rs2904980	ENSG00000255200.1	AP003068.18	-5.38	9.27e-08	1.15e-05	-0.26	-0.16	Mean corpuscular volume;	chr11:65234208	chr11:65174117~65176470:-
BRCA	cis	rs10829156	0.625	rs7082235	ENSG00000240291.1	RP11-499P20.2	5.38	9.27e-08	1.15e-05	0.19	0.16	Sudden cardiac arrest;	chr10:18536765	chr10:18513115~18545651:-
BRCA	cis	rs17711722	0.522	rs4642526	ENSG00000182722.5	SEPHS1P1	-5.38	9.27e-08	1.15e-05	-0.21	-0.16	Calcium levels;	chr7:65751755	chr7:64852397~64853354:-
BRCA	cis	rs8098244	0.706	rs6508004	ENSG00000264745.1	TTC39C-AS1	5.38	9.28e-08	1.15e-05	0.2	0.16	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23884153	chr18:23994213~24015339:-
BRCA	cis	rs7111546	0.625	rs17570703	ENSG00000246225.5	RP11-17A1.3	-5.38	9.28e-08	1.15e-05	-0.27	-0.16	Dialysis-related mortality;	chr11:22889074	chr11:22829380~22945393:+
BRCA	cis	rs7617773	0.746	rs6796343	ENSG00000199476.1	Y_RNA	-5.38	9.29e-08	1.15e-05	-0.24	-0.16	Coronary artery disease;	chr3:48240531	chr3:48288587~48288694:+
BRCA	cis	rs3733585	0.673	rs6843873	ENSG00000250413.1	RP11-448G15.1	5.38	9.29e-08	1.15e-05	0.21	0.16	Cleft plate (environmental tobacco smoke interaction);	chr4:9957164	chr4:10006482~10009725:+
BRCA	cis	rs3805389	1	rs3805389	ENSG00000273257.1	RP11-177J6.1	-5.38	9.3e-08	1.15e-05	-0.25	-0.16	Waist-to-hip ratio adjusted for body mass index;	chr4:55616583	chr4:55387949~55388271:+
BRCA	cis	rs78487399	0.71	rs79165612	ENSG00000234936.1	AC010883.5	5.38	9.31e-08	1.15e-05	0.29	0.16	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43397113	chr2:43229573~43233394:+
BRCA	cis	rs2638953	0.853	rs3926041	ENSG00000247934.4	RP11-967K21.1	-5.38	9.31e-08	1.15e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28461776	chr12:28163298~28190738:-
BRCA	cis	rs9341808	0.65	rs6909546	ENSG00000272129.1	RP11-250B2.6	5.38	9.31e-08	1.15e-05	0.21	0.16	Sitting height ratio;	chr6:80160206	chr6:80355424~80356859:+
BRCA	cis	rs4819052	0.655	rs2330102	ENSG00000184274.3	LINC00315	-5.38	9.32e-08	1.15e-05	-0.21	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45271053	chr21:45300245~45305257:-
BRCA	cis	rs9868809	0.772	rs9812200	ENSG00000270441.1	RP11-694I15.7	-5.38	9.32e-08	1.15e-05	-0.26	-0.16	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48658234	chr3:49140086~49160851:-
BRCA	cis	rs4266144	0.558	rs34696078	ENSG00000241770.1	RP11-555M1.3	-5.38	9.33e-08	1.15e-05	-0.21	-0.16	Coronary artery disease;	chr3:157114875	chr3:157163452~157169133:+
BRCA	cis	rs2904967	0.852	rs560097	ENSG00000254614.2	AP003068.23	5.38	9.33e-08	1.15e-05	0.3	0.16	Mean corpuscular volume;	chr11:65275059	chr11:65177606~65181834:-
BRCA	cis	rs7246657	0.722	rs958305	ENSG00000276846.1	CTD-3220F14.3	-5.38	9.33e-08	1.15e-05	-0.22	-0.16	Coronary artery calcification;	chr19:37698539	chr19:37314868~37315620:-
BRCA	cis	rs1707322	0.721	rs12069121	ENSG00000234329.1	RP11-767N6.2	5.38	9.34e-08	1.15e-05	0.17	0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45766312	chr1:45651039~45651826:-
BRCA	cis	rs7615952	0.576	rs2276726	ENSG00000171084.14	FAM86JP	5.38	9.34e-08	1.15e-05	0.24	0.16	Blood pressure (smoking interaction);	chr3:126107444	chr3:125916620~125930024:+
BRCA	cis	rs34217772	0.68	rs72686527	ENSG00000258636.1	CTD-2298J14.2	5.38	9.34e-08	1.15e-05	0.22	0.16	Myopia;	chr14:41721651	chr14:41587861~41604856:-
BRCA	cis	rs2905347	0.696	rs2905319	ENSG00000179428.2	AC073072.5	5.38	9.35e-08	1.15e-05	0.18	0.16	Major depression and alcohol dependence;	chr7:22657522	chr7:22725395~22727620:-
BRCA	cis	rs62025270	0.632	rs1807309	ENSG00000259295.5	CSPG4P12	-5.38	9.36e-08	1.16e-05	-0.26	-0.16	Idiopathic pulmonary fibrosis;	chr15:85668526	chr15:85191438~85213905:+
BRCA	cis	rs7914558	0.966	rs3902934	ENSG00000236937.2	PTGES3P4	5.38	9.36e-08	1.16e-05	0.21	0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102986892	chr10:102845595~102845950:+
BRCA	cis	rs2153535	0.58	rs9405391	ENSG00000251164.1	HULC	-5.38	9.36e-08	1.16e-05	-0.2	-0.16	Motion sickness;	chr6:8466315	chr6:8652137~8653846:+
BRCA	cis	rs3760982	0.565	rs8104300	ENSG00000267058.1	RP11-15A1.3	-5.38	9.36e-08	1.16e-05	-0.19	-0.16	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43788992	chr19:43891804~43901805:-
BRCA	cis	rs7772486	0.686	rs9386131	ENSG00000270638.1	RP3-466P17.1	5.38	9.37e-08	1.16e-05	0.19	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145800472	chr6:145735570~145737218:+
BRCA	cis	rs7772486	0.686	rs7739735	ENSG00000270638.1	RP3-466P17.1	5.38	9.37e-08	1.16e-05	0.19	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145802400	chr6:145735570~145737218:+
BRCA	cis	rs227275	0.554	rs223371	ENSG00000251288.2	RP11-10L12.2	-5.38	9.37e-08	1.16e-05	-0.19	-0.16	Allergic disease (asthma, hay fever or eczema);	chr4:102838032	chr4:102751401~102752641:+
BRCA	cis	rs9307551	1	rs1371989	ENSG00000250334.4	LINC00989	5.38	9.37e-08	1.16e-05	0.25	0.16	Refractive error;	chr4:79600692	chr4:79492416~79576460:+
BRCA	cis	rs9425766	0.679	rs4652234	ENSG00000227373.4	RP11-160H22.5	5.38	9.38e-08	1.16e-05	0.22	0.16	Life satisfaction;	chr1:174181712	chr1:174115300~174160004:-
BRCA	cis	rs875971	0.893	rs62465470	ENSG00000236529.1	RP13-254B10.1	-5.38	9.38e-08	1.16e-05	-0.18	-0.16	Aortic root size;	chr7:66136231	chr7:65840212~65840596:+
BRCA	cis	rs8114671	0.647	rs945959	ENSG00000269202.1	RP4-614O4.12	-5.38	9.38e-08	1.16e-05	-0.17	-0.16	Height;	chr20:35147102	chr20:35201747~35203288:-
BRCA	cis	rs2638953	0.815	rs11049684	ENSG00000247934.4	RP11-967K21.1	-5.38	9.38e-08	1.16e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28512426	chr12:28163298~28190738:-
BRCA	cis	rs11955398	0.502	rs34638	ENSG00000215032.2	GNL3LP1	-5.38	9.38e-08	1.16e-05	-0.21	-0.16	Intelligence (multi-trait analysis);	chr5:61054660	chr5:60891935~60893577:-
BRCA	cis	rs875971	0.638	rs35986979	ENSG00000273024.4	INTS4P2	5.38	9.39e-08	1.16e-05	0.18	0.16	Aortic root size;	chr7:66624003	chr7:65647864~65715661:+
BRCA	cis	rs78487399	0.908	rs60735069	ENSG00000234936.1	AC010883.5	5.38	9.39e-08	1.16e-05	0.24	0.16	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43619088	chr2:43229573~43233394:+
BRCA	cis	rs155076	0.711	rs9550724	ENSG00000235438.6	ESRRAP2	-5.38	9.39e-08	1.16e-05	-0.22	-0.16	White matter hyperintensity burden;	chr13:21310891	chr13:21260015~21295003:+
BRCA	cis	rs5758511	0.689	rs56906457	ENSG00000233903.2	Z83851.4	5.38	9.4e-08	1.16e-05	0.28	0.16	Birth weight;	chr22:42232329	chr22:42276355~42277052:+
BRCA	cis	rs11123406	0.501	rs10864954	ENSG00000227992.1	AC108463.2	-5.38	9.4e-08	1.16e-05	-0.23	-0.16	Type 2 diabetes;	chr2:111209370	chr2:111203964~111206215:-
BRCA	cis	rs6832769	1	rs28448438	ENSG00000223305.1	RN7SKP30	-5.38	9.4e-08	1.16e-05	-0.21	-0.16	Personality dimensions;	chr4:55550498	chr4:55540502~55540835:-
BRCA	cis	rs987724	0.515	rs1320011	ENSG00000240875.4	LINC00886	-5.38	9.4e-08	1.16e-05	-0.24	-0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156899993	chr3:156747346~156817062:-
BRCA	cis	rs4819052	0.679	rs2838860	ENSG00000184274.3	LINC00315	-5.38	9.4e-08	1.16e-05	-0.21	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45264989	chr21:45300245~45305257:-
BRCA	cis	rs2904967	0.866	rs676573	ENSG00000254614.2	AP003068.23	-5.38	9.4e-08	1.16e-05	-0.3	-0.16	Mean corpuscular volume;	chr11:65258991	chr11:65177606~65181834:-
BRCA	cis	rs73222236	0.825	rs9850383	ENSG00000273486.1	RP11-731C17.2	5.38	9.41e-08	1.16e-05	0.18	0.16	Coronary artery disease;	chr3:136462601	chr3:136837338~136839021:-
BRCA	cis	rs66887589	0.807	rs7694483	ENSG00000245958.5	RP11-33B1.1	-5.38	9.41e-08	1.16e-05	-0.15	-0.16	Diastolic blood pressure;	chr4:119484774	chr4:119454791~119552025:+
BRCA	cis	rs9393692	0.905	rs9379838	ENSG00000241549.7	GUSBP2	-5.38	9.41e-08	1.16e-05	-0.18	-0.16	Educational attainment;	chr6:26276905	chr6:26871484~26956554:-
BRCA	cis	rs9393692	0.84	rs9358915	ENSG00000241549.7	GUSBP2	-5.38	9.41e-08	1.16e-05	-0.18	-0.16	Educational attainment;	chr6:26277040	chr6:26871484~26956554:-
BRCA	cis	rs9393692	0.905	rs9393693	ENSG00000241549.7	GUSBP2	-5.38	9.41e-08	1.16e-05	-0.18	-0.16	Educational attainment;	chr6:26277180	chr6:26871484~26956554:-
BRCA	cis	rs9393692	0.905	rs7761298	ENSG00000241549.7	GUSBP2	-5.38	9.41e-08	1.16e-05	-0.18	-0.16	Educational attainment;	chr6:26278208	chr6:26871484~26956554:-
BRCA	cis	rs875971	0.66	rs1860470	ENSG00000273024.4	INTS4P2	5.38	9.41e-08	1.16e-05	0.18	0.16	Aortic root size;	chr7:66638707	chr7:65647864~65715661:+
BRCA	cis	rs10504130	1	rs60304457	ENSG00000272024.1	RP11-546K22.3	-5.38	9.41e-08	1.16e-05	-0.3	-0.16	Venous thromboembolism (SNP x SNP interaction);	chr8:51923541	chr8:51950284~51950690:+
BRCA	cis	rs2638953	0.79	rs11049653	ENSG00000247934.4	RP11-967K21.1	-5.38	9.41e-08	1.16e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28479882	chr12:28163298~28190738:-
BRCA	cis	rs8002861	0.87	rs1348671	ENSG00000274001.1	RP11-5G9.5	5.38	9.41e-08	1.16e-05	0.18	0.16	Leprosy;	chr13:43875369	chr13:43877715~43878163:-
BRCA	cis	rs2638953	0.853	rs10506036	ENSG00000247934.4	RP11-967K21.1	5.38	9.42e-08	1.16e-05	0.22	0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28497632	chr12:28163298~28190738:-
BRCA	cis	rs9880211	0.613	rs6799056	ENSG00000239213.4	NCK1-AS1	5.38	9.43e-08	1.16e-05	0.2	0.16	Height;Body mass index;	chr3:136083508	chr3:136841726~136862054:-
BRCA	cis	rs2638953	0.606	rs10843213	ENSG00000278733.1	RP11-425D17.1	-5.38	9.43e-08	1.16e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28582853	chr12:28185625~28186190:-
BRCA	cis	rs17711722	0.522	rs62469933	ENSG00000182722.5	SEPHS1P1	-5.38	9.43e-08	1.16e-05	-0.21	-0.16	Calcium levels;	chr7:65800652	chr7:64852397~64853354:-
BRCA	cis	rs17597773	0.638	rs12129004	ENSG00000272823.1	RP11-295M18.6	-5.38	9.43e-08	1.16e-05	-0.19	-0.16	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220812173	chr1:220828676~220829211:-
BRCA	cis	rs300890	0.513	rs13138084	ENSG00000250326.1	RP11-284M14.1	-5.38	9.44e-08	1.16e-05	-0.2	-0.16	Nasopharyngeal carcinoma;	chr4:143233086	chr4:142933195~143184861:-
BRCA	cis	rs7119	0.717	rs12916822	ENSG00000259362.2	RP11-307C19.1	-5.37	9.45e-08	1.17e-05	-0.23	-0.16	Type 2 diabetes;	chr15:77526206	chr15:77525540~77534110:+
BRCA	cis	rs520525	0.963	rs663887	ENSG00000271811.1	RP1-79C4.4	5.37	9.45e-08	1.17e-05	0.19	0.16	Atrial fibrillation;	chr1:170657812	chr1:170667381~170669425:+
BRCA	cis	rs8180040	0.966	rs11705957	ENSG00000276925.1	RP11-708J19.3	5.37	9.45e-08	1.17e-05	0.19	0.16	Colorectal cancer;	chr3:47401772	chr3:47469777~47469987:+
BRCA	cis	rs9393777	0.841	rs13191474	ENSG00000220721.1	OR1F12	5.37	9.45e-08	1.17e-05	0.36	0.16	Intelligence (multi-trait analysis);	chr6:27445566	chr6:28073316~28074233:+
BRCA	cis	rs7772486	0.79	rs7753833	ENSG00000270638.1	RP3-466P17.1	5.37	9.45e-08	1.17e-05	0.19	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145840296	chr6:145735570~145737218:+
BRCA	cis	rs2153535	0.58	rs7341381	ENSG00000251164.1	HULC	-5.37	9.46e-08	1.17e-05	-0.2	-0.16	Motion sickness;	chr6:8470304	chr6:8652137~8653846:+
BRCA	cis	rs7572733	0.534	rs58374969	ENSG00000231621.1	AC013264.2	-5.37	9.46e-08	1.17e-05	-0.17	-0.16	Dermatomyositis;	chr2:197899639	chr2:197197991~197199273:+
BRCA	cis	rs10129255	1	rs8012033	ENSG00000224373.3	IGHV4-59	5.37	9.46e-08	1.17e-05	0.11	0.16	Kawasaki disease;	chr14:106678854	chr14:106627249~106627825:-
BRCA	cis	rs12681366	0.801	rs2930956	ENSG00000253704.1	RP11-267M23.4	5.37	9.46e-08	1.17e-05	0.19	0.16	Nonsyndromic cleft lip with cleft palate;	chr8:94460840	chr8:94553722~94569745:+
BRCA	cis	rs2613964	0.504	rs9288972	ENSG00000240057.4	RP11-572M11.4	-5.37	9.46e-08	1.17e-05	-0.16	-0.16	Pediatric bone mineral content (spine);Pediatric bone mineral density (spine);	chr3:113131422	chr3:113019532~113183301:+
BRCA	cis	rs3758911	0.713	rs1991200	ENSG00000255353.1	RP11-382M14.1	-5.37	9.47e-08	1.17e-05	-0.21	-0.16	Coronary artery disease;	chr11:107254623	chr11:107176286~107177530:+
BRCA	cis	rs2638953	0.962	rs11049493	ENSG00000247934.4	RP11-967K21.1	-5.37	9.47e-08	1.17e-05	-0.23	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28263115	chr12:28163298~28190738:-
BRCA	cis	rs7577696	0.524	rs805831	ENSG00000272716.1	RP11-563N4.1	5.37	9.47e-08	1.17e-05	0.19	0.16	Inflammatory biomarkers;	chr2:32259159	chr2:32165046~32165757:-
BRCA	cis	rs7923837	0.651	rs11187107	ENSG00000236493.2	EIF2S2P3	5.37	9.47e-08	1.17e-05	0.23	0.16	Multiple sclerosis;Body mass index;	chr10:92631940	chr10:92668745~92669743:-
BRCA	cis	rs853679	0.607	rs34661125	ENSG00000204709.4	LINC01556	5.37	9.47e-08	1.17e-05	0.42	0.16	Depression;	chr6:28314117	chr6:28943877~28944537:+
BRCA	cis	rs853679	0.607	rs13190888	ENSG00000204709.4	LINC01556	5.37	9.47e-08	1.17e-05	0.42	0.16	Depression;	chr6:28318208	chr6:28943877~28944537:+
BRCA	cis	rs7474896	0.515	rs2505233	ENSG00000120555.12	SEPT7P9	5.37	9.48e-08	1.17e-05	0.22	0.16	Obesity (extreme);	chr10:38051337	chr10:38383069~38402916:-
BRCA	cis	rs4908769	0.659	rs12144098	ENSG00000270282.1	RP5-1115A15.2	5.37	9.49e-08	1.17e-05	0.19	0.16	Allergy;	chr1:8756114	chr1:8512653~8513021:+
BRCA	cis	rs997295	0.57	rs17241808	ENSG00000270964.1	RP11-502I4.3	-5.37	9.49e-08	1.17e-05	-0.18	-0.16	Motion sickness;	chr15:67600454	chr15:67541072~67542604:-
BRCA	cis	rs13113518	0.513	rs13147861	ENSG00000272969.1	RP11-528I4.2	5.37	9.49e-08	1.17e-05	0.2	0.16	Height;	chr4:55611014	chr4:55547112~55547889:+
BRCA	cis	rs11051970	0.592	rs11052002	ENSG00000274964.1	RP11-817I4.1	-5.37	9.5e-08	1.17e-05	-0.23	-0.16	Response to tocilizumab in rheumatoid arthritis;	chr12:32437920	chr12:32339368~32340724:+
BRCA	cis	rs2281636	0.894	rs7077070	ENSG00000233690.1	EBAG9P1	5.37	9.51e-08	1.17e-05	0.17	0.16	Obesity-related traits;	chr10:99692220	chr10:99697407~99697949:-
BRCA	cis	rs8031584	0.679	rs34017474	ENSG00000260382.1	RP11-540B6.2	5.37	9.51e-08	1.17e-05	0.18	0.16	Huntington's disease progression;	chr15:30938408	chr15:30882267~30883231:-
BRCA	cis	rs1707322	0.682	rs28490344	ENSG00000234329.1	RP11-767N6.2	5.37	9.52e-08	1.17e-05	0.17	0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45732276	chr1:45651039~45651826:-
BRCA	cis	rs1707322	0.721	rs28641748	ENSG00000234329.1	RP11-767N6.2	5.37	9.52e-08	1.17e-05	0.17	0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45747164	chr1:45651039~45651826:-
BRCA	cis	rs1707322	0.721	rs4330955	ENSG00000234329.1	RP11-767N6.2	5.37	9.52e-08	1.17e-05	0.17	0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45751813	chr1:45651039~45651826:-
BRCA	cis	rs1707322	0.691	rs12031182	ENSG00000234329.1	RP11-767N6.2	5.37	9.52e-08	1.17e-05	0.17	0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755327	chr1:45651039~45651826:-
BRCA	cis	rs1707322	0.721	rs10430123	ENSG00000234329.1	RP11-767N6.2	5.37	9.52e-08	1.17e-05	0.17	0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755768	chr1:45651039~45651826:-
BRCA	cis	rs17711722	0.565	rs73372653	ENSG00000237310.1	GS1-124K5.4	5.37	9.52e-08	1.17e-05	0.18	0.16	Calcium levels;	chr7:65977808	chr7:66493706~66495474:+
BRCA	cis	rs2337406	1	rs4774173	ENSG00000223648.3	IGHV3-64	5.37	9.52e-08	1.17e-05	0.17	0.16	Alzheimer's disease (late onset);	chr14:106682029	chr14:106643132~106658258:-
BRCA	cis	rs10911251	0.509	rs4652780	ENSG00000224468.3	RP11-181K3.4	-5.37	9.52e-08	1.17e-05	-0.17	-0.16	Colorectal cancer;	chr1:183136788	chr1:183138402~183141282:-
BRCA	cis	rs875971	0.66	rs3764903	ENSG00000273024.4	INTS4P2	5.37	9.53e-08	1.17e-05	0.18	0.16	Aortic root size;	chr7:66633495	chr7:65647864~65715661:+
BRCA	cis	rs6840258	0.843	rs3755985	ENSG00000251411.1	RP11-397E7.4	-5.37	9.53e-08	1.17e-05	-0.23	-0.16	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87103586	chr4:86913266~86914817:-
BRCA	cis	rs875971	0.522	rs2949690	ENSG00000273024.4	INTS4P2	5.37	9.53e-08	1.17e-05	0.18	0.16	Aortic root size;	chr7:66018255	chr7:65647864~65715661:+
BRCA	cis	rs9307551	0.619	rs10033410	ENSG00000250334.4	LINC00989	-5.37	9.53e-08	1.18e-05	-0.23	-0.16	Refractive error;	chr4:79550314	chr4:79492416~79576460:+
BRCA	cis	rs875971	0.545	rs1547529	ENSG00000228409.4	CCT6P1	-5.37	9.53e-08	1.18e-05	-0.16	-0.16	Aortic root size;	chr7:66258859	chr7:65751142~65763354:+
BRCA	cis	rs763121	0.853	rs5750673	ENSG00000228274.3	RP3-508I15.9	-5.37	9.54e-08	1.18e-05	-0.19	-0.16	Menopause (age at onset);	chr22:38714119	chr22:38667585~38681820:-
BRCA	cis	rs2179367	0.959	rs237034	ENSG00000216906.2	RP11-350J20.9	5.37	9.54e-08	1.18e-05	0.21	0.16	Dupuytren's disease;	chr6:149390726	chr6:149904243~149906418:+
BRCA	cis	rs9990333	0.862	rs6806599	ENSG00000207650.1	MIR570	-5.37	9.55e-08	1.18e-05	-0.19	-0.16	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196089280	chr3:195699401~195699497:+
BRCA	cis	rs6832769	1	rs10002541	ENSG00000223305.1	RN7SKP30	-5.37	9.55e-08	1.18e-05	-0.21	-0.16	Personality dimensions;	chr4:55528844	chr4:55540502~55540835:-
BRCA	cis	rs9287719	0.967	rs7355649	ENSG00000243819.4	RN7SL832P	5.37	9.55e-08	1.18e-05	0.16	0.16	Prostate cancer;	chr2:10607968	chr2:10690344~10692099:+
BRCA	cis	rs2638953	0.886	rs7957503	ENSG00000247934.4	RP11-967K21.1	-5.37	9.55e-08	1.18e-05	-0.21	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28203762	chr12:28163298~28190738:-
BRCA	cis	rs13178541	0.81	rs9327731	ENSG00000250378.1	RP11-119J18.1	-5.37	9.55e-08	1.18e-05	-0.23	-0.16	IgG glycosylation;	chr5:135861438	chr5:135812667~135826582:+
BRCA	cis	rs7646881	0.812	rs61387735	ENSG00000240207.5	RP11-379F4.4	-5.37	9.56e-08	1.18e-05	-0.26	-0.16	Tetralogy of Fallot;	chr3:158738372	chr3:158732263~158784070:+
BRCA	cis	rs7646881	0.767	rs73015669	ENSG00000240207.5	RP11-379F4.4	-5.37	9.56e-08	1.18e-05	-0.26	-0.16	Tetralogy of Fallot;	chr3:158738529	chr3:158732263~158784070:+
BRCA	cis	rs1555322	0.53	rs2250205	ENSG00000269202.1	RP4-614O4.12	-5.37	9.56e-08	1.18e-05	-0.19	-0.16	Attention deficit hyperactivity disorder;	chr20:35280121	chr20:35201747~35203288:-
BRCA	cis	rs12681366	0.801	rs2919657	ENSG00000253704.1	RP11-267M23.4	5.37	9.57e-08	1.18e-05	0.19	0.16	Nonsyndromic cleft lip with cleft palate;	chr8:94460724	chr8:94553722~94569745:+
BRCA	cis	rs35146811	0.844	rs10281368	ENSG00000235713.1	RP4-604G5.3	5.37	9.57e-08	1.18e-05	0.2	0.16	Coronary artery disease;	chr7:100058274	chr7:99992397~99993050:+
BRCA	cis	rs9595908	0.746	rs9596075	ENSG00000212293.1	SNORA16	5.37	9.57e-08	1.18e-05	0.18	0.16	Body mass index;	chr13:32692147	chr13:32420390~32420516:-
BRCA	cis	rs867371	0.826	rs2047678	ENSG00000255769.6	GOLGA2P10	-5.37	9.58e-08	1.18e-05	-0.19	-0.16	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82205857	chr15:82472993~82513950:-
BRCA	cis	rs2243480	0.522	rs431168	ENSG00000232559.3	GS1-124K5.12	5.37	9.59e-08	1.18e-05	0.38	0.16	Diabetic kidney disease;	chr7:66046617	chr7:66554588~66576923:-
BRCA	cis	rs7577696	0.889	rs212735	ENSG00000272716.1	RP11-563N4.1	5.37	9.59e-08	1.18e-05	0.18	0.16	Inflammatory biomarkers;	chr2:32248019	chr2:32165046~32165757:-
BRCA	cis	rs2239547	0.657	rs4687672	ENSG00000242142.1	SERBP1P3	5.37	9.59e-08	1.18e-05	0.2	0.16	Schizophrenia;	chr3:52846527	chr3:53064283~53065091:-
BRCA	cis	rs523522	0.962	rs3213565	ENSG00000278344.1	RP11-18C24.8	5.37	9.6e-08	1.18e-05	0.23	0.16	High light scatter reticulocyte count;	chr12:120554598	chr12:120500735~120501090:-
BRCA	cis	rs10492201	0.529	rs10878724	ENSG00000236946.2	HNRNPA1P70	5.37	9.6e-08	1.18e-05	0.15	0.16	Itch intensity from mosquito bite adjusted by bite size;	chr12:68006091	chr12:68035767~68036853:+
BRCA	cis	rs11955398	0.625	rs34395679	ENSG00000215032.2	GNL3LP1	5.37	9.6e-08	1.18e-05	0.2	0.16	Intelligence (multi-trait analysis);	chr5:60658889	chr5:60891935~60893577:-
BRCA	cis	rs11955398	0.625	rs11739209	ENSG00000215032.2	GNL3LP1	5.37	9.6e-08	1.18e-05	0.2	0.16	Intelligence (multi-trait analysis);	chr5:60663940	chr5:60891935~60893577:-
BRCA	cis	rs4218	0.689	rs11853828	ENSG00000277144.1	RP11-59H7.4	-5.37	9.6e-08	1.18e-05	-0.22	-0.16	Social communication problems;	chr15:59136031	chr15:59115547~59116089:-
BRCA	cis	rs13108904	0.934	rs13149952	ENSG00000254094.1	AC078852.1	-5.37	9.61e-08	1.18e-05	-0.18	-0.16	Obesity-related traits;	chr4:1314649	chr4:1356581~1358075:+
BRCA	cis	rs6430585	0.591	rs309170	ENSG00000231890.6	DARS-AS1	-5.37	9.62e-08	1.18e-05	-0.24	-0.16	Corneal structure;	chr2:135915205	chr2:135985176~136022593:+
BRCA	cis	rs4713118	0.662	rs9380046	ENSG00000280107.1	AL022393.9	-5.37	9.62e-08	1.19e-05	-0.24	-0.16	Parkinson's disease;	chr6:28062721	chr6:28170845~28172521:+
BRCA	cis	rs11976020	1	rs11976020	ENSG00000225648.4	SBDSP1	-5.37	9.62e-08	1.19e-05	-0.23	-0.16	Educational attainment (years of education);	chr7:72782785	chr7:72829425~72836701:+
BRCA	cis	rs755249	0.565	rs12138051	ENSG00000237624.1	OXCT2P1	-5.37	9.63e-08	1.19e-05	-0.2	-0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39482552	chr1:39514956~39516490:+
BRCA	cis	rs755249	0.564	rs6691194	ENSG00000237624.1	OXCT2P1	-5.37	9.63e-08	1.19e-05	-0.2	-0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39483069	chr1:39514956~39516490:+
BRCA	cis	rs4218	0.593	rs8040456	ENSG00000277144.1	RP11-59H7.4	-5.37	9.63e-08	1.19e-05	-0.21	-0.16	Social communication problems;	chr15:59063904	chr15:59115547~59116089:-
BRCA	cis	rs13126694	0.71	rs4631100	ENSG00000248429.4	RP11-597D13.9	5.37	9.63e-08	1.19e-05	0.15	0.16	Blood osmolality (transformed sodium);	chr4:157991162	chr4:158170752~158202877:+
BRCA	cis	rs1979679	0.879	rs980920	ENSG00000278733.1	RP11-425D17.1	5.37	9.63e-08	1.19e-05	0.21	0.16	Ossification of the posterior longitudinal ligament of the spine;	chr12:28316178	chr12:28185625~28186190:-
BRCA	cis	rs62025270	0.632	rs7181796	ENSG00000202081.1	RNU6-1280P	-5.37	9.64e-08	1.19e-05	-0.25	-0.16	Idiopathic pulmonary fibrosis;	chr15:85689778	chr15:85651522~85651628:-
BRCA	cis	rs9307551	0.584	rs6819333	ENSG00000250334.4	LINC00989	-5.37	9.64e-08	1.19e-05	-0.23	-0.16	Refractive error;	chr4:79540995	chr4:79492416~79576460:+
BRCA	cis	rs4650994	0.525	rs17361286	ENSG00000273384.1	RP5-1098D14.1	5.37	9.64e-08	1.19e-05	0.21	0.16	HDL cholesterol;HDL cholesterol levels;	chr1:178552781	chr1:178651706~178652282:+
BRCA	cis	rs6570726	0.811	rs375873	ENSG00000270638.1	RP3-466P17.1	5.37	9.65e-08	1.19e-05	0.18	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145491235	chr6:145735570~145737218:+
BRCA	cis	rs753307	0.676	rs753308	ENSG00000268655.1	CTB-60B18.10	-5.37	9.65e-08	1.19e-05	-0.21	-0.16	Blood protein levels;	chr19:49015318	chr19:49018247~49019484:-
BRCA	cis	rs11955398	0.625	rs11745077	ENSG00000215032.2	GNL3LP1	5.37	9.65e-08	1.19e-05	0.2	0.16	Intelligence (multi-trait analysis);	chr5:60659889	chr5:60891935~60893577:-
BRCA	cis	rs910316	0.737	rs175077	ENSG00000279594.1	RP11-950C14.10	-5.37	9.66e-08	1.19e-05	-0.18	-0.16	Height;	chr14:75040172	chr14:75011269~75012851:-
BRCA	cis	rs4588572	0.606	rs2362828	ENSG00000245556.2	SCAMP1-AS1	-5.37	9.66e-08	1.19e-05	-0.19	-0.16	Triglycerides;	chr5:78423011	chr5:78342365~78360507:-
BRCA	cis	rs7487075	0.93	rs7308910	ENSG00000257261.4	RP11-96H19.1	5.37	9.66e-08	1.19e-05	0.18	0.16	Itch intensity from mosquito bite;	chr12:46444459	chr12:46383679~46876159:+
BRCA	cis	rs9467773	1	rs6925703	ENSG00000124549.13	BTN2A3P	5.37	9.66e-08	1.19e-05	0.16	0.16	Intelligence (multi-trait analysis);	chr6:26521361	chr6:26421391~26432383:+
BRCA	cis	rs2098713	0.534	rs10941338	ENSG00000250155.1	CTD-2353F22.1	5.37	9.66e-08	1.19e-05	0.18	0.16	Telomere length;	chr5:37488313	chr5:36666214~36725195:-
BRCA	cis	rs2098713	0.534	rs12522043	ENSG00000250155.1	CTD-2353F22.1	5.37	9.66e-08	1.19e-05	0.18	0.16	Telomere length;	chr5:37488317	chr5:36666214~36725195:-
BRCA	cis	rs9308731	0.644	rs10189015	ENSG00000227992.1	AC108463.2	-5.37	9.66e-08	1.19e-05	-0.19	-0.16	Chronic lymphocytic leukemia;	chr2:111160895	chr2:111203964~111206215:-
BRCA	cis	rs11051970	0.559	rs2388988	ENSG00000274964.1	RP11-817I4.1	-5.37	9.66e-08	1.19e-05	-0.21	-0.16	Response to tocilizumab in rheumatoid arthritis;	chr12:32337414	chr12:32339368~32340724:+
BRCA	cis	rs10752881	1	rs4233193	ENSG00000224468.3	RP11-181K3.4	-5.37	9.67e-08	1.19e-05	-0.17	-0.16	Colorectal cancer;	chr1:183001730	chr1:183138402~183141282:-
BRCA	cis	rs7617773	0.743	rs11715876	ENSG00000199476.1	Y_RNA	-5.37	9.68e-08	1.19e-05	-0.25	-0.16	Coronary artery disease;	chr3:48336432	chr3:48288587~48288694:+
BRCA	cis	rs2337406	0.587	rs10150642	ENSG00000211970.3	IGHV4-61	-5.37	9.68e-08	1.19e-05	-0.13	-0.16	Alzheimer's disease (late onset);	chr14:106647269	chr14:106639119~106639657:-
BRCA	cis	rs67981189	0.529	rs17093738	ENSG00000258571.1	PTTG4P	-5.37	9.68e-08	1.19e-05	-0.19	-0.16	Schizophrenia;	chr14:71119931	chr14:71085482~71085833:-
BRCA	cis	rs1707322	0.721	rs4660314	ENSG00000234329.1	RP11-767N6.2	5.37	9.69e-08	1.19e-05	0.17	0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45764213	chr1:45651039~45651826:-
BRCA	cis	rs2638953	0.64	rs11049726	ENSG00000278733.1	RP11-425D17.1	-5.37	9.69e-08	1.19e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28582703	chr12:28185625~28186190:-
BRCA	cis	rs7617773	0.817	rs6796490	ENSG00000199476.1	Y_RNA	-5.37	9.69e-08	1.19e-05	-0.21	-0.16	Coronary artery disease;	chr3:48195614	chr3:48288587~48288694:+
BRCA	cis	rs1979679	0.918	rs786712	ENSG00000278733.1	RP11-425D17.1	5.37	9.7e-08	1.19e-05	0.21	0.16	Ossification of the posterior longitudinal ligament of the spine;	chr12:28399664	chr12:28185625~28186190:-
BRCA	cis	rs11124272	0.625	rs2208158	ENSG00000272716.1	RP11-563N4.1	5.37	9.71e-08	1.2e-05	0.2	0.16	Interleukin-18 levels;	chr2:31517792	chr2:32165046~32165757:-
BRCA	cis	rs5758511	0.689	rs55906806	ENSG00000233903.2	Z83851.4	5.37	9.72e-08	1.2e-05	0.29	0.16	Birth weight;	chr22:42248465	chr22:42276355~42277052:+
BRCA	cis	rs12681366	0.762	rs3019148	ENSG00000253704.1	RP11-267M23.4	5.37	9.72e-08	1.2e-05	0.17	0.16	Nonsyndromic cleft lip with cleft palate;	chr8:94417407	chr8:94553722~94569745:+
BRCA	cis	rs6832769	0.922	rs11133376	ENSG00000223305.1	RN7SKP30	5.37	9.72e-08	1.2e-05	0.21	0.16	Personality dimensions;	chr4:55386866	chr4:55540502~55540835:-
BRCA	cis	rs7726839	0.794	rs11739663	ENSG00000271781.1	CTD-2589H19.6	-5.37	9.72e-08	1.2e-05	-0.2	-0.16	Obesity-related traits;	chr5:593968	chr5:675826~676616:+
BRCA	cis	rs11955398	0.625	rs10939857	ENSG00000215032.2	GNL3LP1	5.37	9.73e-08	1.2e-05	0.2	0.16	Intelligence (multi-trait analysis);	chr5:60660974	chr5:60891935~60893577:-
BRCA	cis	rs1124769	0.778	rs2614787	ENSG00000259378.1	DCAF13P3	-5.37	9.73e-08	1.2e-05	-0.24	-0.16	Cognitive performance;	chr15:50908021	chr15:50944663~50945996:+
BRCA	cis	rs1124769	0.871	rs2614793	ENSG00000259378.1	DCAF13P3	-5.37	9.73e-08	1.2e-05	-0.24	-0.16	Cognitive performance;	chr15:50917477	chr15:50944663~50945996:+
BRCA	cis	rs6163	0.588	rs10786706	ENSG00000213061.2	PFN1P11	5.37	9.73e-08	1.2e-05	0.21	0.16	Waist circumference;Hip circumference;	chr10:102740902	chr10:102838011~102845473:-
BRCA	cis	rs3764021	0.87	rs7956831	ENSG00000214776.8	RP11-726G1.1	-5.37	9.73e-08	1.2e-05	-0.17	-0.16	Type 1 diabetes;	chr12:9736561	chr12:9467552~9576275:+
BRCA	cis	rs801193	0.548	rs6975044	ENSG00000273448.1	RP11-166O4.6	5.37	9.75e-08	1.2e-05	0.15	0.16	Aortic root size;	chr7:66762495	chr7:67333047~67334383:+
BRCA	cis	rs2638953	0.85	rs61920210	ENSG00000278733.1	RP11-425D17.1	-5.37	9.75e-08	1.2e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28144951	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.962	rs11494780	ENSG00000278733.1	RP11-425D17.1	-5.37	9.75e-08	1.2e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28402269	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.962	rs11049574	ENSG00000278733.1	RP11-425D17.1	-5.37	9.75e-08	1.2e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28406130	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.962	rs10506033	ENSG00000278733.1	RP11-425D17.1	-5.37	9.75e-08	1.2e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28415032	chr12:28185625~28186190:-
BRCA	cis	rs2803122	0.871	rs10481512	ENSG00000273226.1	RP11-513M16.8	-5.37	9.77e-08	1.2e-05	-0.18	-0.16	Pulse pressure;	chr9:19230741	chr9:19375451~19375996:+
BRCA	cis	rs35612822	0.866	rs755625	ENSG00000232485.2	AC098820.3	-5.37	9.77e-08	1.2e-05	-0.21	-0.16	Kidney disease (early stage) in type 1 diabetes;	chr2:216454080	chr2:216479030~216498761:-
BRCA	cis	rs66782572	1	rs66782572	ENSG00000243224.1	RP5-1157M23.2	-5.37	9.77e-08	1.2e-05	-0.17	-0.16	Hemoglobin concentration;	chr3:52533601	chr3:52239258~52241097:+
BRCA	cis	rs1979679	0.842	rs4931730	ENSG00000278733.1	RP11-425D17.1	5.37	9.78e-08	1.2e-05	0.2	0.16	Ossification of the posterior longitudinal ligament of the spine;	chr12:28146343	chr12:28185625~28186190:-
BRCA	cis	rs559555	0.778	rs765138	ENSG00000272716.1	RP11-563N4.1	5.37	9.79e-08	1.2e-05	0.18	0.16	Blood metabolite ratios;Blood metabolite levels;	chr2:31578869	chr2:32165046~32165757:-
BRCA	cis	rs59169624	0.699	rs4757778	ENSG00000255160.4	RP11-428C19.5	-5.37	9.79e-08	1.2e-05	-0.22	-0.16	Parental extreme longevity (95 years and older);	chr11:19255375	chr11:19299883~19308358:+
BRCA	cis	rs4907240	0.925	rs11164109	ENSG00000237510.6	AC008268.2	-5.37	9.79e-08	1.2e-05	-0.23	-0.16	Event-related brain oscillations;	chr2:96635096	chr2:95789654~95800166:+
BRCA	cis	rs3760982	0.585	rs8109478	ENSG00000267058.1	RP11-15A1.3	-5.37	9.79e-08	1.21e-05	-0.19	-0.16	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43794104	chr19:43891804~43901805:-
BRCA	cis	rs2638953	0.853	rs3911810	ENSG00000247934.4	RP11-967K21.1	-5.37	9.8e-08	1.21e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28461669	chr12:28163298~28190738:-
BRCA	cis	rs7246657	0.882	rs10412043	ENSG00000267422.1	CTD-2554C21.1	-5.37	9.8e-08	1.21e-05	-0.24	-0.16	Coronary artery calcification;	chr19:37335724	chr19:37779686~37792865:+
BRCA	cis	rs893363	0.623	rs877483	ENSG00000271916.1	RP11-884K10.6	5.37	9.8e-08	1.21e-05	0.15	0.16	Axial length;	chr3:53812714	chr3:53797764~53798019:-
BRCA	cis	rs7772486	0.714	rs1883365	ENSG00000270638.1	RP3-466P17.1	-5.37	9.81e-08	1.21e-05	-0.19	-0.16	Lobe attachment (rater-scored or self-reported);	chr6:145755613	chr6:145735570~145737218:+
BRCA	cis	rs2638953	0.814	rs10843164	ENSG00000278733.1	RP11-425D17.1	-5.37	9.81e-08	1.21e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28416781	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.924	rs11049583	ENSG00000278733.1	RP11-425D17.1	-5.37	9.81e-08	1.21e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28417238	chr12:28185625~28186190:-
BRCA	cis	rs863750	0.744	rs2451321	ENSG00000275389.1	RP11-214K3.24	5.37	9.81e-08	1.21e-05	0.21	0.16	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-hip ratio;	chr12:124060888	chr12:124085761~124088598:+
BRCA	cis	rs73222236	0.825	rs9843801	ENSG00000273486.1	RP11-731C17.2	5.37	9.82e-08	1.21e-05	0.18	0.16	Coronary artery disease;	chr3:136281904	chr3:136837338~136839021:-
BRCA	cis	rs2115630	0.691	rs2292462	ENSG00000259728.4	LINC00933	-5.37	9.82e-08	1.21e-05	-0.19	-0.16	P wave terminal force;	chr15:84657523	chr15:84570649~84580175:+
BRCA	cis	rs4835473	0.932	rs4305468	ENSG00000249741.2	RP11-673E1.3	5.37	9.83e-08	1.21e-05	0.17	0.16	Immature fraction of reticulocytes;	chr4:143987315	chr4:143911514~143912053:-
BRCA	cis	rs7246657	0.882	rs59224125	ENSG00000267422.1	CTD-2554C21.1	-5.37	9.83e-08	1.21e-05	-0.24	-0.16	Coronary artery calcification;	chr19:37472303	chr19:37779686~37792865:+
BRCA	cis	rs17685	0.753	rs8200	ENSG00000280388.1	RP11-229D13.3	5.37	9.83e-08	1.21e-05	0.17	0.16	Coffee consumption (cups per day);Coffee consumption;	chr7:76067288	chr7:76043977~76045963:-
BRCA	cis	rs801193	0.548	rs2109297	ENSG00000273448.1	RP11-166O4.6	-5.37	9.83e-08	1.21e-05	-0.15	-0.16	Aortic root size;	chr7:66657397	chr7:67333047~67334383:+
BRCA	cis	rs2803122	0.967	rs4977519	ENSG00000273226.1	RP11-513M16.8	-5.37	9.83e-08	1.21e-05	-0.18	-0.16	Pulse pressure;	chr9:19241204	chr9:19375451~19375996:+
BRCA	cis	rs1075265	0.633	rs28653587	ENSG00000235937.1	AC008280.1	5.37	9.84e-08	1.21e-05	0.18	0.16	Chronotype;Morning vs. evening chronotype;	chr2:53992435	chr2:54029552~54030682:-
BRCA	cis	rs997295	0.57	rs72747462	ENSG00000270964.1	RP11-502I4.3	-5.37	9.84e-08	1.21e-05	-0.18	-0.16	Motion sickness;	chr15:67526200	chr15:67541072~67542604:-
BRCA	cis	rs1387259	0.929	rs2956703	ENSG00000240399.1	RP1-228P16.1	5.37	9.84e-08	1.21e-05	0.19	0.16	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48276511	chr12:48054813~48055591:-
BRCA	cis	rs9545047	0.604	rs4573813	ENSG00000227354.5	RBM26-AS1	5.37	9.84e-08	1.21e-05	0.18	0.16	Schizophrenia;	chr13:79293357	chr13:79406309~79424328:+
BRCA	cis	rs673078	0.66	rs2280711	ENSG00000275409.1	RP11-131L12.4	-5.37	9.85e-08	1.21e-05	-0.22	-0.16	Glucose homeostasis traits;	chr12:118212149	chr12:118430147~118430699:+
BRCA	cis	rs934734	0.673	rs6742215	ENSG00000281920.1	RP11-418H16.1	5.37	9.85e-08	1.21e-05	0.19	0.16	Rheumatoid arthritis;	chr2:65463362	chr2:65623272~65628424:+
BRCA	cis	rs67981189	0.647	rs36555	ENSG00000258571.1	PTTG4P	5.37	9.85e-08	1.21e-05	0.19	0.16	Schizophrenia;	chr14:70897844	chr14:71085482~71085833:-
BRCA	cis	rs7181230	0.885	rs9919974	ENSG00000275636.1	RP11-521C20.5	5.37	9.85e-08	1.21e-05	0.22	0.16	Dehydroepiandrosterone sulphate levels;	chr15:40045261	chr15:40078892~40079347:+
BRCA	cis	rs7493	0.853	rs6973380	ENSG00000233942.1	AC004012.1	5.37	9.86e-08	1.21e-05	0.21	0.16	Yu-Zhi constitution type in type 2 diabetes;	chr7:95414211	chr7:95471835~95473998:+
BRCA	cis	rs910316	0.737	rs175084	ENSG00000279594.1	RP11-950C14.10	-5.37	9.86e-08	1.21e-05	-0.18	-0.16	Height;	chr14:75052472	chr14:75011269~75012851:-
BRCA	cis	rs2337406	0.587	rs10139664	ENSG00000211970.3	IGHV4-61	5.37	9.86e-08	1.21e-05	0.14	0.16	Alzheimer's disease (late onset);	chr14:106647254	chr14:106639119~106639657:-
BRCA	cis	rs61160187	0.503	rs248911	ENSG00000215032.2	GNL3LP1	5.37	9.87e-08	1.21e-05	0.19	0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:60551711	chr5:60891935~60893577:-
BRCA	cis	rs4713118	0.662	rs9468274	ENSG00000280107.1	AL022393.9	-5.37	9.87e-08	1.21e-05	-0.24	-0.16	Parkinson's disease;	chr6:28058299	chr6:28170845~28172521:+
BRCA	cis	rs4713118	0.662	rs9468275	ENSG00000280107.1	AL022393.9	-5.37	9.87e-08	1.21e-05	-0.24	-0.16	Parkinson's disease;	chr6:28058358	chr6:28170845~28172521:+
BRCA	cis	rs4713118	0.662	rs9468276	ENSG00000280107.1	AL022393.9	-5.37	9.87e-08	1.21e-05	-0.24	-0.16	Parkinson's disease;	chr6:28059910	chr6:28170845~28172521:+
BRCA	cis	rs4713118	0.662	rs9468277	ENSG00000280107.1	AL022393.9	-5.37	9.87e-08	1.21e-05	-0.24	-0.16	Parkinson's disease;	chr6:28060612	chr6:28170845~28172521:+
BRCA	cis	rs4713118	0.662	rs9468278	ENSG00000280107.1	AL022393.9	-5.37	9.87e-08	1.21e-05	-0.24	-0.16	Parkinson's disease;	chr6:28060704	chr6:28170845~28172521:+
BRCA	cis	rs4713118	0.662	rs13218430	ENSG00000280107.1	AL022393.9	-5.37	9.87e-08	1.21e-05	-0.24	-0.16	Parkinson's disease;	chr6:28062059	chr6:28170845~28172521:+
BRCA	cis	rs2281636	0.755	rs2111324	ENSG00000233690.1	EBAG9P1	5.37	9.88e-08	1.21e-05	0.17	0.16	Obesity-related traits;	chr10:99636807	chr10:99697407~99697949:-
BRCA	cis	rs9545047	0.604	rs4885625	ENSG00000227354.5	RBM26-AS1	5.37	9.88e-08	1.21e-05	0.18	0.16	Schizophrenia;	chr13:79290355	chr13:79406309~79424328:+
BRCA	cis	rs9545047	0.604	rs1324873	ENSG00000227354.5	RBM26-AS1	5.37	9.88e-08	1.21e-05	0.18	0.16	Schizophrenia;	chr13:79292246	chr13:79406309~79424328:+
BRCA	cis	rs4713118	0.869	rs9283883	ENSG00000216901.1	AL022393.7	5.37	9.88e-08	1.22e-05	0.22	0.16	Parkinson's disease;	chr6:27747691	chr6:28176188~28176674:+
BRCA	cis	rs2834188	1	rs2843994	ENSG00000272659.1	AP000295.10	-5.37	9.88e-08	1.22e-05	-0.25	-0.16	Narcolepsy;	chr21:33334564	chr21:33309491~33310181:+
BRCA	cis	rs7646881	0.812	rs61696028	ENSG00000240207.5	RP11-379F4.4	-5.37	9.89e-08	1.22e-05	-0.26	-0.16	Tetralogy of Fallot;	chr3:158737914	chr3:158732263~158784070:+
BRCA	cis	rs10129255	0.518	rs2006284	ENSG00000211967.3	IGHV3-53	-5.37	9.89e-08	1.22e-05	-0.11	-0.16	Kawasaki disease;	chr14:106676185	chr14:106592676~106593347:-
BRCA	cis	rs2898681	0.614	rs6839900	ENSG00000248375.1	RP11-177B4.1	-5.37	9.89e-08	1.22e-05	-0.23	-0.16	Optic nerve measurement (cup area);	chr4:52809167	chr4:52720081~52720831:-
BRCA	cis	rs9393692	0.905	rs7747133	ENSG00000241549.7	GUSBP2	-5.37	9.9e-08	1.22e-05	-0.18	-0.16	Educational attainment;	chr6:26293242	chr6:26871484~26956554:-
BRCA	cis	rs853679	0.599	rs149990	ENSG00000204709.4	LINC01556	5.37	9.9e-08	1.22e-05	0.33	0.16	Depression;	chr6:28030480	chr6:28943877~28944537:+
BRCA	cis	rs3733585	0.699	rs4339211	ENSG00000250413.1	RP11-448G15.1	5.37	9.91e-08	1.22e-05	0.21	0.16	Cleft plate (environmental tobacco smoke interaction);	chr4:9946034	chr4:10006482~10009725:+
BRCA	cis	rs1707322	0.686	rs61784833	ENSG00000234329.1	RP11-767N6.2	5.37	9.91e-08	1.22e-05	0.17	0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45768100	chr1:45651039~45651826:-
BRCA	cis	rs13126694	0.678	rs4691452	ENSG00000248429.4	RP11-597D13.9	5.37	9.91e-08	1.22e-05	0.15	0.16	Blood osmolality (transformed sodium);	chr4:158080652	chr4:158170752~158202877:+
BRCA	cis	rs6570726	0.791	rs6914203	ENSG00000270638.1	RP3-466P17.1	5.37	9.92e-08	1.22e-05	0.19	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145578839	chr6:145735570~145737218:+
BRCA	cis	rs3733585	0.648	rs35954357	ENSG00000250413.1	RP11-448G15.1	-5.37	9.92e-08	1.22e-05	-0.21	-0.16	Cleft plate (environmental tobacco smoke interaction);	chr4:9977134	chr4:10006482~10009725:+
BRCA	cis	rs17507216	1	rs17507216	ENSG00000255769.6	GOLGA2P10	5.37	9.92e-08	1.22e-05	0.22	0.16	Excessive daytime sleepiness;	chr15:82558175	chr15:82472993~82513950:-
BRCA	cis	rs10129255	1	rs8010605	ENSG00000211974.3	IGHV2-70	5.37	9.93e-08	1.22e-05	0.17	0.16	Kawasaki disease;	chr14:106678742	chr14:106723574~106724093:-
BRCA	cis	rs73222236	0.825	rs7622833	ENSG00000273486.1	RP11-731C17.2	5.37	9.93e-08	1.22e-05	0.18	0.16	Coronary artery disease;	chr3:136323079	chr3:136837338~136839021:-
BRCA	cis	rs4835473	0.932	rs13134808	ENSG00000249741.2	RP11-673E1.3	5.37	9.94e-08	1.22e-05	0.18	0.16	Immature fraction of reticulocytes;	chr4:143798339	chr4:143911514~143912053:-
BRCA	cis	rs6570726	0.905	rs442435	ENSG00000270638.1	RP3-466P17.1	5.37	9.95e-08	1.22e-05	0.18	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145494423	chr6:145735570~145737218:+
BRCA	cis	rs6570726	0.905	rs396492	ENSG00000270638.1	RP3-466P17.1	5.37	9.95e-08	1.22e-05	0.18	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145495044	chr6:145735570~145737218:+
BRCA	cis	rs6570726	0.935	rs7757387	ENSG00000270638.1	RP3-466P17.1	5.37	9.95e-08	1.22e-05	0.18	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145495590	chr6:145735570~145737218:+
BRCA	cis	rs9925964	0.933	rs9929899	ENSG00000232748.3	RP11-196G11.6	5.37	9.95e-08	1.22e-05	0.2	0.16	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31051380	chr16:31056460~31062803:+
BRCA	cis	rs6832769	1	rs4580704	ENSG00000223305.1	RN7SKP30	-5.37	9.96e-08	1.22e-05	-0.21	-0.16	Personality dimensions;	chr4:55460540	chr4:55540502~55540835:-
BRCA	cis	rs7647973	0.58	rs7652746	ENSG00000225399.4	RP11-3B7.1	-5.37	9.96e-08	1.22e-05	-0.15	-0.16	Menarche (age at onset);	chr3:49224874	chr3:49260085~49261316:+
BRCA	cis	rs1440410	0.795	rs9308169	ENSG00000250326.1	RP11-284M14.1	5.37	9.97e-08	1.22e-05	0.18	0.16	Ischemic stroke;	chr4:143263590	chr4:142933195~143184861:-
BRCA	cis	rs9393692	0.905	rs9393694	ENSG00000241549.7	GUSBP2	-5.37	9.97e-08	1.22e-05	-0.18	-0.16	Educational attainment;	chr6:26279068	chr6:26871484~26956554:-
BRCA	cis	rs9393692	0.875	rs9358917	ENSG00000241549.7	GUSBP2	-5.37	9.97e-08	1.22e-05	-0.18	-0.16	Educational attainment;	chr6:26284189	chr6:26871484~26956554:-
BRCA	cis	rs300890	0.513	rs2323076	ENSG00000250326.1	RP11-284M14.1	-5.37	9.97e-08	1.22e-05	-0.2	-0.16	Nasopharyngeal carcinoma;	chr4:143230758	chr4:142933195~143184861:-
BRCA	cis	rs59169624	0.699	rs813795	ENSG00000255160.4	RP11-428C19.5	5.37	9.97e-08	1.22e-05	0.23	0.16	Parental extreme longevity (95 years and older);	chr11:19253381	chr11:19299883~19308358:+
BRCA	cis	rs2153535	0.58	rs7341382	ENSG00000251164.1	HULC	-5.37	9.97e-08	1.22e-05	-0.2	-0.16	Motion sickness;	chr6:8470316	chr6:8652137~8653846:+
BRCA	cis	rs78487399	0.908	rs12467420	ENSG00000234936.1	AC010883.5	5.37	9.97e-08	1.23e-05	0.22	0.16	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43604011	chr2:43229573~43233394:+
BRCA	cis	rs78487399	0.908	rs12475503	ENSG00000234936.1	AC010883.5	5.37	9.97e-08	1.23e-05	0.22	0.16	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43604180	chr2:43229573~43233394:+
BRCA	cis	rs1707322	1	rs7532204	ENSG00000234329.1	RP11-767N6.2	-5.36	9.98e-08	1.23e-05	-0.17	-0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46019403	chr1:45651039~45651826:-
BRCA	cis	rs13126694	0.744	rs7673290	ENSG00000251429.1	RP11-597D13.7	5.36	9.98e-08	1.23e-05	0.16	0.16	Blood osmolality (transformed sodium);	chr4:157998335	chr4:158270378~158278676:+
BRCA	cis	rs2243480	1	rs410128	ENSG00000164669.11	INTS4P1	5.36	9.99e-08	1.23e-05	0.34	0.16	Diabetic kidney disease;	chr7:66138186	chr7:65141225~65234216:+
BRCA	cis	rs1387259	0.931	rs11168474	ENSG00000240399.1	RP1-228P16.1	5.36	9.99e-08	1.23e-05	0.19	0.16	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48227601	chr12:48054813~48055591:-
BRCA	cis	rs73222236	0.857	rs28396702	ENSG00000273486.1	RP11-731C17.2	5.36	9.99e-08	1.23e-05	0.18	0.16	Coronary artery disease;	chr3:136448539	chr3:136837338~136839021:-
BRCA	cis	rs507080	0.922	rs555356	ENSG00000278376.1	RP11-158I9.8	-5.36	9.99e-08	1.23e-05	-0.17	-0.16	Serum metabolite levels;	chr11:118687369	chr11:118791254~118793137:+
BRCA	cis	rs7200543	1	rs2740	ENSG00000258354.1	MIR3180-1	-5.36	9.99e-08	1.23e-05	-0.22	-0.16	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15038251	chr16:14909887~14911345:-
BRCA	cis	rs4372836	0.964	rs4665431	ENSG00000226833.4	AC097724.3	-5.36	9.99e-08	1.23e-05	-0.2	-0.16	Body mass index;	chr2:28715302	chr2:28708953~28736205:-
BRCA	cis	rs17674580	0.582	rs473429	ENSG00000267193.4	RP11-116O18.3	-5.36	9.99e-08	1.23e-05	-0.17	-0.16	Bladder cancer;	chr18:45739095	chr18:45669367~45747215:-
BRCA	cis	rs875971	0.522	rs9530	ENSG00000273024.4	INTS4P2	-5.36	1e-07	1.23e-05	-0.18	-0.16	Aortic root size;	chr7:65960907	chr7:65647864~65715661:+
BRCA	cis	rs7674212	0.541	rs2720448	ENSG00000246560.2	RP11-10L12.4	5.36	1e-07	1.23e-05	0.17	0.16	Type 2 diabetes;	chr4:103109432	chr4:102828055~102844075:+
BRCA	cis	rs7674212	0.541	rs2623064	ENSG00000246560.2	RP11-10L12.4	5.36	1e-07	1.23e-05	0.17	0.16	Type 2 diabetes;	chr4:103109635	chr4:102828055~102844075:+
BRCA	cis	rs17253792	0.545	rs35536987	ENSG00000186615.9	KTN1-AS1	-5.36	1e-07	1.23e-05	-0.34	-0.16	Putamen volume;	chr14:55557303	chr14:55499278~55580110:-
BRCA	cis	rs2179367	0.632	rs9485384	ENSG00000223701.3	RAET1E-AS1	5.36	1e-07	1.23e-05	0.24	0.16	Dupuytren's disease;	chr6:149328808	chr6:149884431~149919508:+
BRCA	cis	rs2638953	0.815	rs11049634	ENSG00000278733.1	RP11-425D17.1	5.36	1e-07	1.23e-05	0.22	0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28461296	chr12:28185625~28186190:-
BRCA	cis	rs3805389	0.924	rs10029142	ENSG00000273257.1	RP11-177J6.1	-5.36	1e-07	1.23e-05	-0.24	-0.16	Waist-to-hip ratio adjusted for body mass index;	chr4:55612967	chr4:55387949~55388271:+
BRCA	cis	rs6480314	0.542	rs17297383	ENSG00000233590.1	RP11-153K11.3	-5.36	1e-07	1.23e-05	-0.27	-0.16	Optic nerve measurement (disc area);	chr10:68269106	chr10:68233251~68242379:-
BRCA	cis	rs4853525	0.59	rs12619017	ENSG00000235852.1	AC005540.3	5.36	1e-07	1.23e-05	0.21	0.16	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190865167	chr2:190880797~190882059:-
BRCA	cis	rs11992162	0.967	rs10088415	ENSG00000254866.2	DEFB109P3	5.36	1e-07	1.23e-05	0.21	0.16	Monocyte count;	chr8:11973316	chr8:12150895~12151134:-
BRCA	cis	rs9545047	0.604	rs9545048	ENSG00000227354.5	RBM26-AS1	5.36	1e-07	1.23e-05	0.18	0.16	Schizophrenia;	chr13:79285593	chr13:79406309~79424328:+
BRCA	cis	rs7267979	0.586	rs1007707	ENSG00000277938.1	RP5-965G21.3	5.36	1e-07	1.23e-05	0.19	0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25209962	chr20:25229150~25231933:+
BRCA	cis	rs7674212	0.541	rs2251322	ENSG00000248740.4	RP11-328K4.1	5.36	1e-07	1.23e-05	0.19	0.16	Type 2 diabetes;	chr4:103158267	chr4:103256159~103453658:+
BRCA	cis	rs7674212	0.57	rs2251634	ENSG00000248740.4	RP11-328K4.1	5.36	1e-07	1.23e-05	0.19	0.16	Type 2 diabetes;	chr4:103161192	chr4:103256159~103453658:+
BRCA	cis	rs516805	0.63	rs696650	ENSG00000279453.1	RP3-425C14.4	-5.36	1e-07	1.23e-05	-0.23	-0.16	Lymphocyte counts;	chr6:122261316	chr6:122436789~122439223:-
BRCA	cis	rs3758911	0.713	rs10890674	ENSG00000255353.1	RP11-382M14.1	-5.36	1e-07	1.23e-05	-0.21	-0.16	Coronary artery disease;	chr11:107254177	chr11:107176286~107177530:+
BRCA	cis	rs2562456	0.833	rs1781867	ENSG00000268081.1	RP11-678G14.2	5.36	1e-07	1.23e-05	0.26	0.16	Pain;	chr19:21304368	chr19:21554640~21569237:-
BRCA	cis	rs910316	0.737	rs175055	ENSG00000279594.1	RP11-950C14.10	-5.36	1e-07	1.23e-05	-0.18	-0.16	Height;	chr14:75022243	chr14:75011269~75012851:-
BRCA	cis	rs8054556	1	rs11150580	ENSG00000273724.1	RP11-347C12.12	-5.36	1e-07	1.23e-05	-0.19	-0.16	Autism spectrum disorder or schizophrenia;	chr16:30003243	chr16:30336400~30343336:+
BRCA	cis	rs17711722	1	rs17711722	ENSG00000273024.4	INTS4P2	5.36	1e-07	1.23e-05	0.18	0.16	Calcium levels;	chr7:65806210	chr7:65647864~65715661:+
BRCA	cis	rs7246657	0.551	rs28462002	ENSG00000226686.6	LINC01535	-5.36	1e-07	1.23e-05	-0.28	-0.16	Coronary artery calcification;	chr19:37143560	chr19:37251912~37265535:+
BRCA	cis	rs2337406	1	rs3858878	ENSG00000223648.3	IGHV3-64	5.36	1e-07	1.23e-05	0.17	0.16	Alzheimer's disease (late onset);	chr14:106688061	chr14:106643132~106658258:-
BRCA	cis	rs62025270	0.632	rs62022919	ENSG00000259295.5	CSPG4P12	-5.36	1e-07	1.23e-05	-0.26	-0.16	Idiopathic pulmonary fibrosis;	chr15:85675079	chr15:85191438~85213905:+
BRCA	cis	rs4950322	0.518	rs4950305	ENSG00000278811.3	LINC00624	5.36	1e-07	1.23e-05	0.2	0.16	Protein quantitative trait loci;	chr1:147117711	chr1:147258885~147517875:-
BRCA	cis	rs35146811	0.52	rs1015538	ENSG00000214313.7	AZGP1P1	-5.36	1e-07	1.23e-05	-0.17	-0.16	Coronary artery disease;	chr7:100028412	chr7:99980762~99987535:+
BRCA	cis	rs10129255	0.957	rs4387509	ENSG00000280411.1	IGHV1-69-2	-5.36	1e-07	1.23e-05	-0.13	-0.16	Kawasaki disease;	chr14:106704386	chr14:106762092~106762588:-
BRCA	cis	rs2732480	0.538	rs2468943	ENSG00000240399.1	RP1-228P16.1	-5.36	1.01e-07	1.24e-05	-0.19	-0.16	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48353466	chr12:48054813~48055591:-
BRCA	cis	rs6570726	0.791	rs6918814	ENSG00000270638.1	RP3-466P17.1	5.36	1.01e-07	1.24e-05	0.18	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145584892	chr6:145735570~145737218:+
BRCA	cis	rs4713118	0.662	rs9380045	ENSG00000280107.1	AL022393.9	-5.36	1.01e-07	1.24e-05	-0.24	-0.16	Parkinson's disease;	chr6:28057501	chr6:28170845~28172521:+
BRCA	cis	rs6832769	1	rs59804446	ENSG00000272969.1	RP11-528I4.2	-5.36	1.01e-07	1.24e-05	-0.2	-0.16	Personality dimensions;	chr4:55563374	chr4:55547112~55547889:+
BRCA	cis	rs728616	0.51	rs12416084	ENSG00000225484.5	NUTM2B-AS1	-5.36	1.01e-07	1.24e-05	-0.31	-0.16	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79989459	chr10:79663088~79826594:-
BRCA	cis	rs17301013	0.861	rs34819375	ENSG00000227373.4	RP11-160H22.5	5.36	1.01e-07	1.24e-05	0.22	0.16	Systemic lupus erythematosus;	chr1:174654958	chr1:174115300~174160004:-
BRCA	cis	rs59169624	0.699	rs7933531	ENSG00000255160.4	RP11-428C19.5	-5.36	1.01e-07	1.24e-05	-0.21	-0.16	Parental extreme longevity (95 years and older);	chr11:19252050	chr11:19299883~19308358:+
BRCA	cis	rs6439153	0.967	rs61480393	ENSG00000231305.3	RP11-723O4.2	5.36	1.01e-07	1.24e-05	0.19	0.16	Pneumococcal bacteremia;	chr3:128980916	chr3:128861313~128871540:-
BRCA	cis	rs9341808	0.754	rs9361591	ENSG00000272129.1	RP11-250B2.6	5.36	1.01e-07	1.24e-05	0.21	0.16	Sitting height ratio;	chr6:80243538	chr6:80355424~80356859:+
BRCA	cis	rs10911232	0.507	rs4266836	ENSG00000224468.3	RP11-181K3.4	-5.36	1.01e-07	1.24e-05	-0.18	-0.16	Hypertriglyceridemia;	chr1:183059935	chr1:183138402~183141282:-
BRCA	cis	rs13108904	0.517	rs4974551	ENSG00000254094.1	AC078852.1	-5.36	1.01e-07	1.24e-05	-0.19	-0.16	Obesity-related traits;	chr4:1342622	chr4:1356581~1358075:+
BRCA	cis	rs9840812	0.69	rs7628146	ENSG00000239213.4	NCK1-AS1	5.36	1.01e-07	1.24e-05	0.2	0.16	Fibrinogen levels;	chr3:136279611	chr3:136841726~136862054:-
BRCA	cis	rs11098499	0.754	rs9999724	ENSG00000249244.1	RP11-548H18.2	5.36	1.01e-07	1.24e-05	0.19	0.16	Corneal astigmatism;	chr4:119318789	chr4:119391831~119395335:-
BRCA	cis	rs3764021	0.527	rs12227655	ENSG00000214776.8	RP11-726G1.1	5.36	1.01e-07	1.24e-05	0.2	0.16	Type 1 diabetes;	chr12:9715652	chr12:9467552~9576275:+
BRCA	cis	rs3764021	0.506	rs12228641	ENSG00000214776.8	RP11-726G1.1	5.36	1.01e-07	1.24e-05	0.2	0.16	Type 1 diabetes;	chr12:9715680	chr12:9467552~9576275:+
BRCA	cis	rs9868809	0.881	rs3821876	ENSG00000270441.1	RP11-694I15.7	5.36	1.01e-07	1.24e-05	0.32	0.16	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48630961	chr3:49140086~49160851:-
BRCA	cis	rs523522	0.962	rs4767912	ENSG00000278344.1	RP11-18C24.8	5.36	1.01e-07	1.24e-05	0.22	0.16	High light scatter reticulocyte count;	chr12:120543399	chr12:120500735~120501090:-
BRCA	cis	rs7618501	0.699	rs2681780	ENSG00000228008.1	CTD-2330K9.3	5.36	1.01e-07	1.24e-05	0.16	0.16	Intelligence (multi-trait analysis);	chr3:49860397	chr3:49903845~49916937:+
BRCA	cis	rs2638953	0.853	rs17433981	ENSG00000278733.1	RP11-425D17.1	-5.36	1.01e-07	1.24e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28393634	chr12:28185625~28186190:-
BRCA	cis	rs6952407	1	rs6952407	ENSG00000273024.4	INTS4P2	5.36	1.01e-07	1.24e-05	0.18	0.16	Cotinine glucuronidation;	chr7:66580525	chr7:65647864~65715661:+
BRCA	cis	rs2562456	0.833	rs55920089	ENSG00000268535.1	RP11-420K14.3	5.36	1.01e-07	1.24e-05	0.23	0.16	Pain;	chr19:21337891	chr19:21709522~21710191:+
BRCA	cis	rs8114671	0.562	rs2889861	ENSG00000269202.1	RP4-614O4.12	-5.36	1.01e-07	1.24e-05	-0.16	-0.16	Height;	chr20:34817861	chr20:35201747~35203288:-
BRCA	cis	rs1979679	0.766	rs11049365	ENSG00000278733.1	RP11-425D17.1	5.36	1.01e-07	1.24e-05	0.21	0.16	Ossification of the posterior longitudinal ligament of the spine;	chr12:28138401	chr12:28185625~28186190:-
BRCA	cis	rs9545047	0.604	rs1626333	ENSG00000227354.5	RBM26-AS1	5.36	1.01e-07	1.24e-05	0.18	0.16	Schizophrenia;	chr13:79286932	chr13:79406309~79424328:+
BRCA	cis	rs9545047	0.567	rs1856996	ENSG00000227354.5	RBM26-AS1	5.36	1.01e-07	1.24e-05	0.18	0.16	Schizophrenia;	chr13:79287453	chr13:79406309~79424328:+
BRCA	cis	rs2638953	0.962	rs2172299	ENSG00000247934.4	RP11-967K21.1	-5.36	1.01e-07	1.24e-05	-0.23	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28280180	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.962	rs11049503	ENSG00000247934.4	RP11-967K21.1	-5.36	1.01e-07	1.24e-05	-0.23	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28282714	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.962	rs61922974	ENSG00000247934.4	RP11-967K21.1	-5.36	1.01e-07	1.24e-05	-0.23	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28283302	chr12:28163298~28190738:-
BRCA	cis	rs507080	0.922	rs514143	ENSG00000278376.1	RP11-158I9.8	-5.36	1.01e-07	1.24e-05	-0.16	-0.16	Serum metabolite levels;	chr11:118687740	chr11:118791254~118793137:+
BRCA	cis	rs4781563	0.81	rs3136166	ENSG00000242307.1	RPS26P52	-5.36	1.01e-07	1.24e-05	-0.19	-0.16	Bilirubin levels;	chr16:13938236	chr16:13922332~13922679:-
BRCA	cis	rs7617773	0.78	rs11720026	ENSG00000199476.1	Y_RNA	-5.36	1.01e-07	1.24e-05	-0.25	-0.16	Coronary artery disease;	chr3:48336431	chr3:48288587~48288694:+
BRCA	cis	rs4650994	0.525	rs2761463	ENSG00000273384.1	RP5-1098D14.1	-5.36	1.01e-07	1.25e-05	-0.21	-0.16	HDL cholesterol;HDL cholesterol levels;	chr1:178588002	chr1:178651706~178652282:+
BRCA	cis	rs62025270	0.649	rs12148610	ENSG00000202081.1	RNU6-1280P	-5.36	1.02e-07	1.25e-05	-0.25	-0.16	Idiopathic pulmonary fibrosis;	chr15:85702697	chr15:85651522~85651628:-
BRCA	cis	rs6832769	1	rs6812042	ENSG00000272969.1	RP11-528I4.2	5.36	1.02e-07	1.25e-05	0.2	0.16	Personality dimensions;	chr4:55529912	chr4:55547112~55547889:+
BRCA	cis	rs73193808	1	rs73193808	ENSG00000236056.1	GAPDHP14	-5.36	1.02e-07	1.25e-05	-0.23	-0.16	Coronary artery disease;	chr21:29162981	chr21:29222321~29223257:+
BRCA	cis	rs7201929	1	rs12920514	ENSG00000251417.2	RP11-1348G14.4	5.36	1.02e-07	1.25e-05	0.21	0.16	QT interval;	chr16:28824579	chr16:28802743~28817828:+
BRCA	cis	rs78487399	0.908	rs17031092	ENSG00000234936.1	AC010883.5	5.36	1.02e-07	1.25e-05	0.21	0.16	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43582109	chr2:43229573~43233394:+
BRCA	cis	rs17301013	0.896	rs332773	ENSG00000227373.4	RP11-160H22.5	5.36	1.02e-07	1.25e-05	0.22	0.16	Systemic lupus erythematosus;	chr1:174695711	chr1:174115300~174160004:-
BRCA	cis	rs17301013	0.896	rs332791	ENSG00000227373.4	RP11-160H22.5	5.36	1.02e-07	1.25e-05	0.22	0.16	Systemic lupus erythematosus;	chr1:174709784	chr1:174115300~174160004:-
BRCA	cis	rs7617773	0.817	rs13094727	ENSG00000199476.1	Y_RNA	-5.36	1.02e-07	1.25e-05	-0.24	-0.16	Coronary artery disease;	chr3:48281999	chr3:48288587~48288694:+
BRCA	cis	rs9467773	1	rs1884946	ENSG00000124549.13	BTN2A3P	5.36	1.02e-07	1.25e-05	0.16	0.16	Intelligence (multi-trait analysis);	chr6:26545080	chr6:26421391~26432383:+
BRCA	cis	rs35740288	0.857	rs11630274	ENSG00000259407.1	RP11-158M2.3	-5.36	1.02e-07	1.25e-05	-0.22	-0.16	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85745156	chr15:85744109~85750281:-
BRCA	cis	rs13113518	0.783	rs12510400	ENSG00000272969.1	RP11-528I4.2	5.36	1.02e-07	1.25e-05	0.19	0.16	Height;	chr4:55577294	chr4:55547112~55547889:+
BRCA	cis	rs7208859	0.623	rs609063	ENSG00000280069.1	CTD-2349P21.3	-5.36	1.02e-07	1.25e-05	-0.25	-0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30624495	chr17:30738182~30740275:+
BRCA	cis	rs9467773	0.935	rs9461270	ENSG00000124549.13	BTN2A3P	5.36	1.02e-07	1.25e-05	0.16	0.16	Intelligence (multi-trait analysis);	chr6:26543882	chr6:26421391~26432383:+
BRCA	cis	rs847577	0.54	rs3847055	ENSG00000272950.1	RP11-307C18.1	-5.36	1.02e-07	1.25e-05	-0.23	-0.16	Breast cancer;	chr7:98051333	chr7:98322853~98323430:+
BRCA	cis	rs2708977	0.637	rs583705	ENSG00000237510.6	AC008268.2	-5.36	1.02e-07	1.25e-05	-0.22	-0.16	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96403016	chr2:95789654~95800166:+
BRCA	cis	rs875971	0.862	rs4718330	ENSG00000236529.1	RP13-254B10.1	-5.36	1.02e-07	1.25e-05	-0.18	-0.16	Aortic root size;	chr7:66250256	chr7:65840212~65840596:+
BRCA	cis	rs891378	1	rs877049	ENSG00000274245.1	RP11-357P18.2	-5.36	1.02e-07	1.25e-05	-0.21	-0.16	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207249651	chr1:207372559~207373252:+
BRCA	cis	rs2239547	0.522	rs6792578	ENSG00000242142.1	SERBP1P3	5.36	1.02e-07	1.25e-05	0.2	0.16	Schizophrenia;	chr3:52970588	chr3:53064283~53065091:-
BRCA	cis	rs1979679	0.744	rs2348236	ENSG00000278733.1	RP11-425D17.1	-5.36	1.02e-07	1.25e-05	-0.21	-0.16	Ossification of the posterior longitudinal ligament of the spine;	chr12:28441640	chr12:28185625~28186190:-
BRCA	cis	rs7577696	0.72	rs212753	ENSG00000272716.1	RP11-563N4.1	5.36	1.02e-07	1.25e-05	0.18	0.16	Inflammatory biomarkers;	chr2:32196286	chr2:32165046~32165757:-
BRCA	cis	rs6546886	0.536	rs828868	ENSG00000217702.2	RP11-287D1.4	5.36	1.02e-07	1.25e-05	0.2	0.16	Dialysis-related mortality;	chr2:74097377	chr2:74130583~74135395:+
BRCA	cis	rs2832191	0.765	rs2832162	ENSG00000176054.6	RPL23P2	5.36	1.02e-07	1.25e-05	0.17	0.16	Dental caries;	chr21:29089487	chr21:28997613~28998033:-
BRCA	cis	rs7598759	0.966	rs6754426	ENSG00000181798.2	LINC00471	-5.36	1.02e-07	1.25e-05	-0.2	-0.16	Noise-induced hearing loss;	chr2:231458068	chr2:231508426~231514339:-
BRCA	cis	rs13423976	0.6	rs35776111	ENSG00000231367.4	AC016995.3	5.36	1.02e-07	1.25e-05	0.18	0.16	Gut microbiome composition (summer);	chr2:38515087	chr2:38406719~38515740:-
BRCA	cis	rs41369048	0.858	rs2807866	ENSG00000272823.1	RP11-295M18.6	-5.36	1.02e-07	1.25e-05	-0.22	-0.16	Eosinophil counts;Sum eosinophil basophil counts;	chr1:220907587	chr1:220828676~220829211:-
BRCA	cis	rs12908161	0.96	rs17599989	ENSG00000259295.5	CSPG4P12	5.36	1.02e-07	1.25e-05	0.23	0.16	Schizophrenia;	chr15:84742305	chr15:85191438~85213905:+
BRCA	cis	rs2153535	0.58	rs1319169	ENSG00000251164.1	HULC	-5.36	1.02e-07	1.25e-05	-0.2	-0.16	Motion sickness;	chr6:8464223	chr6:8652137~8653846:+
BRCA	cis	rs792448	0.743	rs7415843	ENSG00000226251.4	RP11-15I11.3	-5.36	1.02e-07	1.25e-05	-0.21	-0.16	White blood cell count (basophil);	chr1:212336420	chr1:212225278~212238977:-
BRCA	cis	rs2834288	0.7	rs2834298	ENSG00000273102.1	AP000569.9	-5.36	1.02e-07	1.25e-05	-0.19	-0.16	Gut microbiota (bacterial taxa);	chr21:33911251	chr21:33967101~33968573:-
BRCA	cis	rs1859596	1	rs4388396	ENSG00000234456.6	MAGI2-AS3	5.36	1.02e-07	1.26e-05	0.11	0.16	Reading or mathematical ability;	chr7:79486399	chr7:79452877~79471208:+
BRCA	cis	rs1859596	0.966	rs2214806	ENSG00000234456.6	MAGI2-AS3	5.36	1.02e-07	1.26e-05	0.11	0.16	Reading or mathematical ability;	chr7:79487151	chr7:79452877~79471208:+
BRCA	cis	rs8180040	0.654	rs9837343	ENSG00000276925.1	RP11-708J19.3	-5.36	1.02e-07	1.26e-05	-0.19	-0.16	Colorectal cancer;	chr3:47135898	chr3:47469777~47469987:+
BRCA	cis	rs35146811	0.961	rs1880949	ENSG00000235713.1	RP4-604G5.3	-5.36	1.02e-07	1.26e-05	-0.19	-0.16	Coronary artery disease;	chr7:100124643	chr7:99992397~99993050:+
BRCA	cis	rs2288884	0.79	rs7253849	ENSG00000275055.1	CTC-471J1.11	-5.36	1.02e-07	1.26e-05	-0.21	-0.16	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52056992	chr19:52049007~52049754:+
BRCA	cis	rs6840360	0.681	rs4519779	ENSG00000278978.1	RP11-164P12.5	-5.36	1.02e-07	1.26e-05	-0.18	-0.16	Intelligence (multi-trait analysis);	chr4:151380033	chr4:151669786~151670503:+
BRCA	cis	rs721917	0.525	rs2250652	ENSG00000244733.5	RP11-506M13.3	-5.36	1.03e-07	1.26e-05	-0.19	-0.16	Chronic obstructive pulmonary disease;	chr10:79902893	chr10:79660891~79677996:+
BRCA	cis	rs9307551	0.584	rs10022314	ENSG00000250334.4	LINC00989	-5.36	1.03e-07	1.26e-05	-0.23	-0.16	Refractive error;	chr4:79550505	chr4:79492416~79576460:+
BRCA	cis	rs7914558	0.966	rs1971589	ENSG00000236937.2	PTGES3P4	5.36	1.03e-07	1.26e-05	0.21	0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102984649	chr10:102845595~102845950:+
BRCA	cis	rs6840360	1	rs6535819	ENSG00000270265.1	RP11-731D1.4	-5.36	1.03e-07	1.26e-05	-0.19	-0.16	Intelligence (multi-trait analysis);	chr4:151730351	chr4:151333775~151353224:-
BRCA	cis	rs2732480	0.538	rs1387259	ENSG00000257735.1	RP11-370I10.6	-5.36	1.03e-07	1.26e-05	-0.21	-0.16	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48309739	chr12:48350945~48442411:+
BRCA	cis	rs62025270	0.632	rs62022915	ENSG00000259295.5	CSPG4P12	-5.36	1.03e-07	1.26e-05	-0.26	-0.16	Idiopathic pulmonary fibrosis;	chr15:85670365	chr15:85191438~85213905:+
BRCA	cis	rs7914558	0.933	rs10883814	ENSG00000236937.2	PTGES3P4	5.36	1.03e-07	1.26e-05	0.21	0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102977647	chr10:102845595~102845950:+
BRCA	cis	rs7572733	0.555	rs6729473	ENSG00000231621.1	AC013264.2	-5.36	1.03e-07	1.26e-05	-0.16	-0.16	Dermatomyositis;	chr2:197899204	chr2:197197991~197199273:+
BRCA	cis	rs2638953	0.853	rs11049622	ENSG00000247934.4	RP11-967K21.1	-5.36	1.03e-07	1.26e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28457637	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.888	rs10843177	ENSG00000247934.4	RP11-967K21.1	-5.36	1.03e-07	1.26e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28457737	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.853	rs10771428	ENSG00000247934.4	RP11-967K21.1	-5.36	1.03e-07	1.26e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28458070	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.853	rs10506035	ENSG00000247934.4	RP11-967K21.1	-5.36	1.03e-07	1.26e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28458159	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.815	rs11049627	ENSG00000247934.4	RP11-967K21.1	-5.36	1.03e-07	1.26e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28459389	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.853	rs11049628	ENSG00000247934.4	RP11-967K21.1	-5.36	1.03e-07	1.26e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28459781	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.853	rs11049629	ENSG00000247934.4	RP11-967K21.1	-5.36	1.03e-07	1.26e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28459856	chr12:28163298~28190738:-
BRCA	cis	rs6832769	1	rs3805152	ENSG00000223305.1	RN7SKP30	5.36	1.03e-07	1.26e-05	0.21	0.16	Personality dimensions;	chr4:55493491	chr4:55540502~55540835:-
BRCA	cis	rs6569038	0.502	rs2051056	ENSG00000253194.1	RP11-351A11.1	-5.36	1.03e-07	1.26e-05	-0.21	-0.16	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr6:118978418	chr6:118934785~119031541:+
BRCA	cis	rs3760982	0.546	rs73048681	ENSG00000267058.1	RP11-15A1.3	-5.36	1.03e-07	1.26e-05	-0.21	-0.16	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43785793	chr19:43891804~43901805:-
BRCA	cis	rs2303319	0.901	rs62194249	ENSG00000227403.1	AC009299.3	5.36	1.03e-07	1.26e-05	0.42	0.16	Cognitive function;	chr2:161266450	chr2:161244739~161249050:+
BRCA	cis	rs10504130	0.569	rs11775611	ENSG00000272024.1	RP11-546K22.3	-5.36	1.03e-07	1.26e-05	-0.24	-0.16	Venous thromboembolism (SNP x SNP interaction);	chr8:51907714	chr8:51950284~51950690:+
BRCA	cis	rs7617773	0.78	rs7653152	ENSG00000199476.1	Y_RNA	-5.36	1.03e-07	1.26e-05	-0.25	-0.16	Coronary artery disease;	chr3:48320607	chr3:48288587~48288694:+
BRCA	cis	rs10911232	0.56	rs10911221	ENSG00000224468.3	RP11-181K3.4	-5.36	1.03e-07	1.27e-05	-0.18	-0.16	Hypertriglyceridemia;	chr1:183077602	chr1:183138402~183141282:-
BRCA	cis	rs875971	0.545	rs1267814	ENSG00000228409.4	CCT6P1	5.36	1.03e-07	1.27e-05	0.16	0.16	Aortic root size;	chr7:66579422	chr7:65751142~65763354:+
BRCA	cis	rs73222236	0.75	rs35375192	ENSG00000273486.1	RP11-731C17.2	5.36	1.03e-07	1.27e-05	0.18	0.16	Coronary artery disease;	chr3:136456683	chr3:136837338~136839021:-
BRCA	cis	rs7618501	0.602	rs2013208	ENSG00000228008.1	CTD-2330K9.3	-5.36	1.03e-07	1.27e-05	-0.16	-0.16	Intelligence (multi-trait analysis);	chr3:50091966	chr3:49903845~49916937:+
BRCA	cis	rs250585	0.79	rs7204714	ENSG00000260136.4	CTD-2270L9.4	5.36	1.03e-07	1.27e-05	0.18	0.16	Egg allergy;	chr16:23472032	chr16:23452758~23457606:+
BRCA	cis	rs9545047	0.625	rs9318621	ENSG00000227354.5	RBM26-AS1	5.36	1.03e-07	1.27e-05	0.18	0.16	Schizophrenia;	chr13:79325662	chr13:79406309~79424328:+
BRCA	cis	rs9516	0.565	rs3867278	ENSG00000254974.1	RP11-702H23.2	-5.36	1.04e-07	1.27e-05	-0.2	-0.16	Facial morphology (factor 15, philtrum width);	chr11:74454376	chr11:74485580~74486051:-
BRCA	cis	rs2179367	0.632	rs62426068	ENSG00000223701.3	RAET1E-AS1	5.36	1.04e-07	1.27e-05	0.24	0.16	Dupuytren's disease;	chr6:149325795	chr6:149884431~149919508:+
BRCA	cis	rs2179367	0.632	rs62426069	ENSG00000223701.3	RAET1E-AS1	5.36	1.04e-07	1.27e-05	0.24	0.16	Dupuytren's disease;	chr6:149325804	chr6:149884431~149919508:+
BRCA	cis	rs9425766	0.54	rs2294492	ENSG00000227373.4	RP11-160H22.5	5.36	1.04e-07	1.27e-05	0.22	0.16	Life satisfaction;	chr1:174157884	chr1:174115300~174160004:-
BRCA	cis	rs7487075	0.504	rs1000405	ENSG00000257261.4	RP11-96H19.1	5.36	1.04e-07	1.27e-05	0.19	0.16	Itch intensity from mosquito bite;	chr12:46262739	chr12:46383679~46876159:+
BRCA	cis	rs539096	0.872	rs10890261	ENSG00000236200.4	KDM4A-AS1	5.36	1.04e-07	1.27e-05	0.2	0.16	Intelligence (multi-trait analysis);	chr1:43586706	chr1:43699765~43708138:-
BRCA	cis	rs2098713	0.569	rs16903666	ENSG00000250155.1	CTD-2353F22.1	5.36	1.04e-07	1.27e-05	0.18	0.16	Telomere length;	chr5:37557648	chr5:36666214~36725195:-
BRCA	cis	rs4722166	0.695	rs7787893	ENSG00000225541.1	AC002480.5	-5.36	1.04e-07	1.27e-05	-0.17	-0.16	Lung cancer;	chr7:22734818	chr7:22571607~22661792:-
BRCA	cis	rs293748	0.891	rs292180	ENSG00000250155.1	CTD-2353F22.1	-5.36	1.04e-07	1.27e-05	-0.22	-0.16	Obesity-related traits;	chr5:36950157	chr5:36666214~36725195:-
BRCA	cis	rs4650994	0.525	rs2224811	ENSG00000273384.1	RP5-1098D14.1	-5.36	1.04e-07	1.27e-05	-0.21	-0.16	HDL cholesterol;HDL cholesterol levels;	chr1:178575188	chr1:178651706~178652282:+
BRCA	cis	rs4787491	0.765	rs4788216	ENSG00000273724.1	RP11-347C12.12	-5.36	1.04e-07	1.27e-05	-0.18	-0.16	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30036756	chr16:30336400~30343336:+
BRCA	cis	rs9659323	0.65	rs17013645	ENSG00000231365.4	RP11-418J17.1	-5.36	1.04e-07	1.27e-05	-0.21	-0.16	Body mass index;	chr1:118942226	chr1:119140396~119275973:+
BRCA	cis	rs10129255	0.957	rs10137980	ENSG00000211974.3	IGHV2-70	5.36	1.04e-07	1.27e-05	0.16	0.16	Kawasaki disease;	chr14:106775735	chr14:106723574~106724093:-
BRCA	cis	rs9545047	0.588	rs9530913	ENSG00000227354.5	RBM26-AS1	5.36	1.04e-07	1.27e-05	0.18	0.16	Schizophrenia;	chr13:79384539	chr13:79406309~79424328:+
BRCA	cis	rs9467773	0.804	rs2073526	ENSG00000124549.13	BTN2A3P	-5.36	1.04e-07	1.27e-05	-0.17	-0.16	Intelligence (multi-trait analysis);	chr6:26374430	chr6:26421391~26432383:+
BRCA	cis	rs12681366	0.734	rs13281619	ENSG00000253704.1	RP11-267M23.4	5.36	1.04e-07	1.27e-05	0.17	0.16	Nonsyndromic cleft lip with cleft palate;	chr8:94384658	chr8:94553722~94569745:+
BRCA	cis	rs12681366	0.708	rs13280849	ENSG00000253704.1	RP11-267M23.4	5.36	1.04e-07	1.27e-05	0.17	0.16	Nonsyndromic cleft lip with cleft palate;	chr8:94384731	chr8:94553722~94569745:+
BRCA	cis	rs9816784	0.901	rs12490036	ENSG00000242086.7	LINC00969	-5.36	1.04e-07	1.27e-05	-0.17	-0.16	Mean corpuscular hemoglobin;	chr3:196089324	chr3:195658062~195739964:+
BRCA	cis	rs7246657	0.722	rs958305	ENSG00000226686.6	LINC01535	5.36	1.04e-07	1.27e-05	0.24	0.16	Coronary artery calcification;	chr19:37698539	chr19:37251912~37265535:+
BRCA	cis	rs6430585	0.583	rs4988163	ENSG00000231890.6	DARS-AS1	-5.36	1.04e-07	1.28e-05	-0.25	-0.16	Corneal structure;	chr2:135870551	chr2:135985176~136022593:+
BRCA	cis	rs8054556	1	rs4788209	ENSG00000273724.1	RP11-347C12.12	-5.36	1.04e-07	1.28e-05	-0.19	-0.16	Autism spectrum disorder or schizophrenia;	chr16:30001945	chr16:30336400~30343336:+
BRCA	cis	rs8054556	1	rs4788210	ENSG00000273724.1	RP11-347C12.12	-5.36	1.04e-07	1.28e-05	-0.19	-0.16	Autism spectrum disorder or schizophrenia;	chr16:30002353	chr16:30336400~30343336:+
BRCA	cis	rs1440410	0.835	rs4234887	ENSG00000250326.1	RP11-284M14.1	-5.36	1.04e-07	1.28e-05	-0.18	-0.16	Ischemic stroke;	chr4:143213124	chr4:142933195~143184861:-
BRCA	cis	rs1075265	0.61	rs6746965	ENSG00000235937.1	AC008280.1	5.36	1.04e-07	1.28e-05	0.18	0.16	Chronotype;Morning vs. evening chronotype;	chr2:53996388	chr2:54029552~54030682:-
BRCA	cis	rs2919009	0.551	rs61872771	ENSG00000271670.1	RP11-95I16.4	5.36	1.04e-07	1.28e-05	0.23	0.16	Obesity-related traits;	chr10:120939465	chr10:120879256~120880667:-
BRCA	cis	rs1322639	0.531	rs11751421	ENSG00000261039.2	RP11-417E7.2	5.36	1.04e-07	1.28e-05	0.15	0.16	Pulse pressure;	chr6:169174898	chr6:169175304~169182740:-
BRCA	cis	rs4722166	0.63	rs12537614	ENSG00000225541.1	AC002480.5	-5.36	1.04e-07	1.28e-05	-0.18	-0.16	Lung cancer;	chr7:22749932	chr7:22571607~22661792:-
BRCA	cis	rs9309473	0.948	rs10183818	ENSG00000163016.8	ALMS1P	5.36	1.04e-07	1.28e-05	0.22	0.16	Metabolite levels;	chr2:73487429	chr2:73644919~73685576:+
BRCA	cis	rs2243480	1	rs67728539	ENSG00000230295.1	RP11-458F8.2	-5.36	1.04e-07	1.28e-05	-0.21	-0.16	Diabetic kidney disease;	chr7:65913137	chr7:66880708~66882981:+
BRCA	cis	rs12135996	0.691	rs12130871	ENSG00000232879.2	RP11-544M22.3	-5.36	1.04e-07	1.28e-05	-0.19	-0.16	Night sleep phenotypes;	chr1:161056700	chr1:161034834~161035006:+
BRCA	cis	rs11098499	0.863	rs10004484	ENSG00000249244.1	RP11-548H18.2	5.36	1.05e-07	1.28e-05	0.19	0.16	Corneal astigmatism;	chr4:119521273	chr4:119391831~119395335:-
BRCA	cis	rs2284219	0.565	rs2284217	ENSG00000196295.10	AC005154.6	-5.36	1.05e-07	1.28e-05	-0.16	-0.16	Type 2 diabetes;	chr7:30673992	chr7:30516309~30594809:-
BRCA	cis	rs9309473	0.687	rs6748040	ENSG00000163016.8	ALMS1P	-5.36	1.05e-07	1.28e-05	-0.2	-0.16	Metabolite levels;	chr2:73382800	chr2:73644919~73685576:+
BRCA	cis	rs6600671	1	rs1986111	ENSG00000275538.1	RNVU1-19	5.36	1.05e-07	1.28e-05	0.19	0.16	Hip geometry;	chr1:121462934	chr1:120850819~120850985:-
BRCA	cis	rs62025270	0.631	rs55968154	ENSG00000259295.5	CSPG4P12	-5.36	1.05e-07	1.28e-05	-0.26	-0.16	Idiopathic pulmonary fibrosis;	chr15:85725399	chr15:85191438~85213905:+
BRCA	cis	rs62025270	0.688	rs55851385	ENSG00000259295.5	CSPG4P12	-5.36	1.05e-07	1.28e-05	-0.26	-0.16	Idiopathic pulmonary fibrosis;	chr15:85725400	chr15:85191438~85213905:+
BRCA	cis	rs295490	0.667	rs78684868	ENSG00000272656.1	RP11-219D15.3	5.36	1.05e-07	1.28e-05	0.37	0.16	PR interval in Tripanosoma cruzi seropositivity;	chr3:139485651	chr3:139349024~139349371:-
BRCA	cis	rs10829156	0.699	rs10828879	ENSG00000240291.1	RP11-499P20.2	5.36	1.05e-07	1.28e-05	0.17	0.16	Sudden cardiac arrest;	chr10:18546425	chr10:18513115~18545651:-
BRCA	cis	rs9402743	0.634	rs9321512	ENSG00000231028.7	LINC00271	5.36	1.05e-07	1.28e-05	0.17	0.16	Systemic lupus erythematosus;	chr6:135603299	chr6:135497801~135716055:+
BRCA	cis	rs300890	0.513	rs10000911	ENSG00000250326.1	RP11-284M14.1	-5.36	1.05e-07	1.28e-05	-0.2	-0.16	Nasopharyngeal carcinoma;	chr4:143215040	chr4:142933195~143184861:-
BRCA	cis	rs6479901	0.793	rs7070693	ENSG00000232075.1	MRPL35P2	-5.36	1.05e-07	1.28e-05	-0.24	-0.16	Intelligence (multi-trait analysis);	chr10:63256402	chr10:63634317~63634827:-
BRCA	cis	rs3733585	0.673	rs7672947	ENSG00000250413.1	RP11-448G15.1	5.36	1.05e-07	1.28e-05	0.21	0.16	Cleft plate (environmental tobacco smoke interaction);	chr4:9959744	chr4:10006482~10009725:+
BRCA	cis	rs6540731	1	rs11119884	ENSG00000229983.1	RP11-15I11.2	5.36	1.05e-07	1.28e-05	0.19	0.16	Intelligence (childhood);	chr1:212226804	chr1:212168207~212190259:+
BRCA	cis	rs7829975	0.742	rs12547493	ENSG00000253981.4	ALG1L13P	-5.36	1.05e-07	1.28e-05	-0.19	-0.16	Mood instability;	chr8:8804024	chr8:8236003~8244667:-
BRCA	cis	rs7246657	0.551	rs12972146	ENSG00000226686.6	LINC01535	-5.36	1.05e-07	1.29e-05	-0.28	-0.16	Coronary artery calcification;	chr19:37135193	chr19:37251912~37265535:+
BRCA	cis	rs7246657	0.509	rs10426093	ENSG00000226686.6	LINC01535	-5.36	1.05e-07	1.29e-05	-0.28	-0.16	Coronary artery calcification;	chr19:37124727	chr19:37251912~37265535:+
BRCA	cis	rs7487075	0.554	rs7960819	ENSG00000257261.4	RP11-96H19.1	5.36	1.05e-07	1.29e-05	0.17	0.16	Itch intensity from mosquito bite;	chr12:46234999	chr12:46383679~46876159:+
BRCA	cis	rs7487075	0.554	rs7957777	ENSG00000257261.4	RP11-96H19.1	5.36	1.05e-07	1.29e-05	0.17	0.16	Itch intensity from mosquito bite;	chr12:46235006	chr12:46383679~46876159:+
BRCA	cis	rs17807624	0.78	rs11250152	ENSG00000270154.1	RP11-419I17.1	-5.36	1.05e-07	1.29e-05	-0.2	-0.16	Systemic lupus erythematosus;	chr8:11596691	chr8:12476462~12477122:+
BRCA	cis	rs2098713	0.569	rs7700431	ENSG00000250155.1	CTD-2353F22.1	5.36	1.05e-07	1.29e-05	0.18	0.16	Telomere length;	chr5:37552750	chr5:36666214~36725195:-
BRCA	cis	rs7620503	1	rs1463859	ENSG00000228221.4	LINC00578	5.36	1.05e-07	1.29e-05	0.19	0.16	Corneal structure;	chr3:177580283	chr3:177441921~177752305:+
BRCA	cis	rs10946940	1	rs10946940	ENSG00000216901.1	AL022393.7	-5.35	1.05e-07	1.29e-05	-0.2	-0.16	Systemic lupus erythematosus;	chr6:27592808	chr6:28176188~28176674:+
BRCA	cis	rs7914558	0.966	rs3977751	ENSG00000236937.2	PTGES3P4	5.35	1.05e-07	1.29e-05	0.21	0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103160475	chr10:102845595~102845950:+
BRCA	cis	rs10510102	0.872	rs28586586	ENSG00000226864.1	ATE1-AS1	5.35	1.05e-07	1.29e-05	0.3	0.16	Breast cancer;	chr10:121950228	chr10:121928312~121951965:+
BRCA	cis	rs1559040	1	rs7571660	ENSG00000272156.1	RP11-477N3.1	-5.35	1.05e-07	1.29e-05	-0.26	-0.16	Sudden cardiac arrest;	chr2:54120247	chr2:54082554~54085066:+
BRCA	cis	rs4713118	0.662	rs149970	ENSG00000280107.1	AL022393.9	-5.35	1.05e-07	1.29e-05	-0.24	-0.16	Parkinson's disease;	chr6:28012442	chr6:28170845~28172521:+
BRCA	cis	rs7200543	1	rs16966952	ENSG00000260872.1	RP11-680G24.5	-5.35	1.05e-07	1.29e-05	-0.17	-0.16	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15042086	chr16:15018106~15020488:-
BRCA	cis	rs9628987	0.53	rs301793	ENSG00000232912.4	RP5-1115A15.1	5.35	1.06e-07	1.29e-05	0.21	0.16	Breast cancer;	chr1:8407474	chr1:8424645~8434838:+
BRCA	cis	rs2243480	0.522	rs1638736	ENSG00000273142.1	RP11-458F8.4	-5.35	1.06e-07	1.29e-05	-0.27	-0.16	Diabetic kidney disease;	chr7:66627321	chr7:66902857~66906297:+
BRCA	cis	rs1707322	0.685	rs28617418	ENSG00000234329.1	RP11-767N6.2	5.35	1.06e-07	1.29e-05	0.17	0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45723854	chr1:45651039~45651826:-
BRCA	cis	rs875971	0.862	rs6944374	ENSG00000236529.1	RP13-254B10.1	-5.35	1.06e-07	1.29e-05	-0.18	-0.16	Aortic root size;	chr7:66221942	chr7:65840212~65840596:+
BRCA	cis	rs7200543	1	rs1121	ENSG00000258354.1	MIR3180-1	-5.35	1.06e-07	1.29e-05	-0.22	-0.16	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15037219	chr16:14909887~14911345:-
BRCA	cis	rs6439153	0.933	rs2630262	ENSG00000231305.3	RP11-723O4.2	-5.35	1.06e-07	1.29e-05	-0.18	-0.16	Pneumococcal bacteremia;	chr3:128958255	chr3:128861313~128871540:-
BRCA	cis	rs7577696	0.538	rs2366736	ENSG00000272716.1	RP11-563N4.1	-5.35	1.06e-07	1.29e-05	-0.18	-0.16	Inflammatory biomarkers;	chr2:32167379	chr2:32165046~32165757:-
BRCA	cis	rs7914558	0.899	rs7913682	ENSG00000236937.2	PTGES3P4	5.35	1.06e-07	1.29e-05	0.21	0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102924635	chr10:102845595~102845950:+
BRCA	cis	rs7119	0.717	rs7181283	ENSG00000259362.2	RP11-307C19.1	-5.35	1.06e-07	1.3e-05	-0.23	-0.16	Type 2 diabetes;	chr15:77522202	chr15:77525540~77534110:+
BRCA	cis	rs7119	0.717	rs12901100	ENSG00000259362.2	RP11-307C19.1	-5.35	1.06e-07	1.3e-05	-0.23	-0.16	Type 2 diabetes;	chr15:77523216	chr15:77525540~77534110:+
BRCA	cis	rs7119	0.717	rs12904212	ENSG00000259362.2	RP11-307C19.1	-5.35	1.06e-07	1.3e-05	-0.23	-0.16	Type 2 diabetes;	chr15:77523491	chr15:77525540~77534110:+
BRCA	cis	rs919433	0.68	rs8539	ENSG00000231621.1	AC013264.2	-5.35	1.06e-07	1.3e-05	-0.15	-0.16	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197497294	chr2:197197991~197199273:+
BRCA	cis	rs11105298	0.891	rs10858902	ENSG00000270344.2	RP11-734K2.4	5.35	1.06e-07	1.3e-05	0.19	0.16	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89534012	chr12:89525654~89548005:+
BRCA	cis	rs11105298	0.891	rs10858903	ENSG00000270344.2	RP11-734K2.4	5.35	1.06e-07	1.3e-05	0.19	0.16	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89534195	chr12:89525654~89548005:+
BRCA	cis	rs6802315	0.74	rs9822005	ENSG00000272247.1	RP11-379F4.9	-5.35	1.06e-07	1.3e-05	-0.18	-0.16	Periodontitis (CDC/AAP);	chr3:158794592	chr3:158801257~158801935:-
BRCA	cis	rs7577696	0.695	rs11124278	ENSG00000272716.1	RP11-563N4.1	-5.35	1.06e-07	1.3e-05	-0.18	-0.16	Inflammatory biomarkers;	chr2:32173443	chr2:32165046~32165757:-
BRCA	cis	rs13126694	0.744	rs7673290	ENSG00000248429.4	RP11-597D13.9	5.35	1.06e-07	1.3e-05	0.15	0.16	Blood osmolality (transformed sodium);	chr4:157998335	chr4:158170752~158202877:+
BRCA	cis	rs7617773	0.817	rs13068265	ENSG00000199476.1	Y_RNA	-5.35	1.06e-07	1.3e-05	-0.24	-0.16	Coronary artery disease;	chr3:48260124	chr3:48288587~48288694:+
BRCA	cis	rs365302	1	rs294918	ENSG00000235086.1	FNDC1-IT1	5.35	1.06e-07	1.3e-05	0.19	0.16	Coronary heart disease;	chr6:159205040	chr6:159240786~159243329:+
BRCA	cis	rs4950322	1	rs72694720	ENSG00000278811.3	LINC00624	5.35	1.06e-07	1.3e-05	0.23	0.16	Protein quantitative trait loci;	chr1:147371939	chr1:147258885~147517875:-
BRCA	cis	rs7430456	0.839	rs9824506	ENSG00000228561.2	RP11-114M1.1	-5.35	1.06e-07	1.3e-05	-0.21	-0.16	Breast cancer;	chr3:177751431	chr3:177683627~177691250:+
BRCA	cis	rs858239	0.676	rs3807459	ENSG00000230042.1	AK3P3	-5.35	1.06e-07	1.3e-05	-0.19	-0.16	Cerebrospinal fluid biomarker levels;	chr7:23350132	chr7:23129178~23129841:+
BRCA	cis	rs9545047	0.604	rs7331872	ENSG00000227354.5	RBM26-AS1	-5.35	1.06e-07	1.3e-05	-0.18	-0.16	Schizophrenia;	chr13:79388717	chr13:79406309~79424328:+
BRCA	cis	rs2638953	0.927	rs11049630	ENSG00000278733.1	RP11-425D17.1	-5.35	1.06e-07	1.3e-05	-0.21	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28460240	chr12:28185625~28186190:-
BRCA	cis	rs6442522	0.671	rs2305615	ENSG00000249786.6	EAF1-AS1	5.35	1.07e-07	1.3e-05	0.17	0.16	Uric acid levels;	chr3:15475518	chr3:15436171~15455940:-
BRCA	cis	rs2281636	0.894	rs1332103	ENSG00000233690.1	EBAG9P1	5.35	1.07e-07	1.3e-05	0.17	0.16	Obesity-related traits;	chr10:99616139	chr10:99697407~99697949:-
BRCA	cis	rs853679	0.607	rs67340775	ENSG00000204709.4	LINC01556	5.35	1.07e-07	1.3e-05	0.42	0.16	Depression;	chr6:28336607	chr6:28943877~28944537:+
BRCA	cis	rs1552244	1	rs6442150	ENSG00000232901.1	CYCSP10	5.35	1.07e-07	1.3e-05	0.23	0.16	Alzheimer's disease;	chr3:10080891	chr3:10000647~10000940:-
BRCA	cis	rs9467773	0.967	rs1056347	ENSG00000124549.13	BTN2A3P	5.35	1.07e-07	1.3e-05	0.16	0.16	Intelligence (multi-trait analysis);	chr6:26527296	chr6:26421391~26432383:+
BRCA	cis	rs7131987	0.507	rs3782507	ENSG00000257176.2	RP11-996F15.2	5.35	1.07e-07	1.3e-05	0.19	0.16	QT interval;	chr12:29292597	chr12:29280418~29317848:-
BRCA	cis	rs9341808	0.754	rs3805907	ENSG00000272129.1	RP11-250B2.6	-5.35	1.07e-07	1.3e-05	-0.2	-0.16	Sitting height ratio;	chr6:80263948	chr6:80355424~80356859:+
BRCA	cis	rs60695258	0.55	rs388401	ENSG00000251411.1	RP11-397E7.4	5.35	1.07e-07	1.3e-05	0.18	0.16	Hematocrit;	chr4:87053263	chr4:86913266~86914817:-
BRCA	cis	rs4819052	0.851	rs2838855	ENSG00000184274.3	LINC00315	5.35	1.07e-07	1.3e-05	0.22	0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260651	chr21:45300245~45305257:-
BRCA	cis	rs12701220	0.725	rs13242971	ENSG00000229043.2	AC091729.9	-5.35	1.07e-07	1.3e-05	-0.26	-0.16	Bronchopulmonary dysplasia;	chr7:1015879	chr7:1160374~1165267:+
BRCA	cis	rs34217772	0.68	rs61990339	ENSG00000258636.1	CTD-2298J14.2	5.35	1.07e-07	1.3e-05	0.23	0.16	Myopia;	chr14:41716441	chr14:41587861~41604856:-
BRCA	cis	rs1426063	0.858	rs10026994	ENSG00000260265.1	RP11-44F21.5	5.35	1.07e-07	1.31e-05	0.27	0.16	QT interval;	chr4:75081551	chr4:75081702~75084717:-
BRCA	cis	rs1426063	0.858	rs6830936	ENSG00000260265.1	RP11-44F21.5	5.35	1.07e-07	1.31e-05	0.27	0.16	QT interval;	chr4:75083952	chr4:75081702~75084717:-
BRCA	cis	rs2303759	0.918	rs4802597	ENSG00000268686.1	AC010524.2	-5.35	1.07e-07	1.31e-05	-0.24	-0.16	Multiple sclerosis;	chr19:49368828	chr19:49368705~49388081:-
BRCA	cis	rs4691139	0.903	rs13127378	ENSG00000248632.1	RP11-366M4.11	5.35	1.07e-07	1.31e-05	0.17	0.16	Ovarian cancer in BRCA1 mutation carriers;	chr4:164997485	chr4:164968587~164970002:-
BRCA	cis	rs4713118	0.629	rs149899	ENSG00000204709.4	LINC01556	5.35	1.07e-07	1.31e-05	0.24	0.16	Parkinson's disease;	chr6:28052201	chr6:28943877~28944537:+
BRCA	cis	rs4713118	0.629	rs172165	ENSG00000204709.4	LINC01556	5.35	1.07e-07	1.31e-05	0.24	0.16	Parkinson's disease;	chr6:28053036	chr6:28943877~28944537:+
BRCA	cis	rs2243480	0.901	rs778732	ENSG00000228409.4	CCT6P1	5.35	1.07e-07	1.31e-05	0.23	0.16	Diabetic kidney disease;	chr7:66357373	chr7:65751142~65763354:+
BRCA	cis	rs3733585	0.699	rs11724510	ENSG00000250413.1	RP11-448G15.1	5.35	1.07e-07	1.31e-05	0.21	0.16	Cleft plate (environmental tobacco smoke interaction);	chr4:9956959	chr4:10006482~10009725:+
BRCA	cis	rs3733585	0.699	rs28837683	ENSG00000250413.1	RP11-448G15.1	5.35	1.07e-07	1.31e-05	0.21	0.16	Cleft plate (environmental tobacco smoke interaction);	chr4:9958184	chr4:10006482~10009725:+
BRCA	cis	rs3733585	0.699	rs6449157	ENSG00000250413.1	RP11-448G15.1	5.35	1.07e-07	1.31e-05	0.21	0.16	Cleft plate (environmental tobacco smoke interaction);	chr4:9958818	chr4:10006482~10009725:+
BRCA	cis	rs3733585	0.699	rs6823361	ENSG00000250413.1	RP11-448G15.1	5.35	1.07e-07	1.31e-05	0.21	0.16	Cleft plate (environmental tobacco smoke interaction);	chr4:9961503	chr4:10006482~10009725:+
BRCA	cis	rs1979679	0.879	rs55996833	ENSG00000278733.1	RP11-425D17.1	5.35	1.07e-07	1.31e-05	0.21	0.16	Ossification of the posterior longitudinal ligament of the spine;	chr12:28313303	chr12:28185625~28186190:-
BRCA	cis	rs2898681	0.642	rs62336790	ENSG00000248375.1	RP11-177B4.1	-5.35	1.07e-07	1.31e-05	-0.23	-0.16	Optic nerve measurement (cup area);	chr4:52861833	chr4:52720081~52720831:-
BRCA	cis	rs2613964	0.504	rs9838215	ENSG00000240057.4	RP11-572M11.4	-5.35	1.07e-07	1.31e-05	-0.16	-0.16	Pediatric bone mineral content (spine);Pediatric bone mineral density (spine);	chr3:113131616	chr3:113019532~113183301:+
BRCA	cis	rs2613964	0.504	rs9838253	ENSG00000240057.4	RP11-572M11.4	-5.35	1.07e-07	1.31e-05	-0.16	-0.16	Pediatric bone mineral content (spine);Pediatric bone mineral density (spine);	chr3:113131678	chr3:113019532~113183301:+
BRCA	cis	rs2613964	0.504	rs17317945	ENSG00000240057.4	RP11-572M11.4	-5.35	1.07e-07	1.31e-05	-0.16	-0.16	Pediatric bone mineral content (spine);Pediatric bone mineral density (spine);	chr3:113131934	chr3:113019532~113183301:+
BRCA	cis	rs2613964	0.504	rs12695288	ENSG00000240057.4	RP11-572M11.4	-5.35	1.07e-07	1.31e-05	-0.16	-0.16	Pediatric bone mineral content (spine);Pediatric bone mineral density (spine);	chr3:113132668	chr3:113019532~113183301:+
BRCA	cis	rs7674212	0.512	rs2720462	ENSG00000248740.4	RP11-328K4.1	5.35	1.07e-07	1.31e-05	0.19	0.16	Type 2 diabetes;	chr4:103135053	chr4:103256159~103453658:+
BRCA	cis	rs1559040	1	rs2112125	ENSG00000272156.1	RP11-477N3.1	-5.35	1.07e-07	1.31e-05	-0.26	-0.16	Sudden cardiac arrest;	chr2:54120893	chr2:54082554~54085066:+
BRCA	cis	rs7824557	0.872	rs2572417	ENSG00000154316.13	TDH	5.35	1.07e-07	1.31e-05	0.2	0.16	Retinal vascular caliber;	chr8:11253953	chr8:11339637~11368452:+
BRCA	cis	rs962856	0.897	rs7579304	ENSG00000236780.4	AC078941.1	5.35	1.07e-07	1.31e-05	0.21	0.16	Pancreatic cancer;	chr2:67384118	chr2:67123357~67215319:-
BRCA	cis	rs3758911	0.713	rs10890675	ENSG00000255353.1	RP11-382M14.1	5.35	1.07e-07	1.31e-05	0.21	0.16	Coronary artery disease;	chr11:107254199	chr11:107176286~107177530:+
BRCA	cis	rs2638953	0.707	rs11049711	ENSG00000278733.1	RP11-425D17.1	-5.35	1.07e-07	1.31e-05	-0.21	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28553171	chr12:28185625~28186190:-
BRCA	cis	rs7739264	0.583	rs6456264	ENSG00000228412.5	RP4-625H18.2	-5.35	1.07e-07	1.31e-05	-0.21	-0.16	Endometriosis;	chr6:19786451	chr6:19802164~19804752:-
BRCA	cis	rs2562456	0.833	rs4334427	ENSG00000268535.1	RP11-420K14.3	5.35	1.07e-07	1.31e-05	0.23	0.16	Pain;	chr19:21338090	chr19:21709522~21710191:+
BRCA	cis	rs6498068	0.594	rs1875928	ENSG00000260468.1	LINC01290	-5.35	1.08e-07	1.31e-05	-0.23	-0.16	Metabolite levels (MHPG);	chr16:10528028	chr16:10514842~10528202:-
BRCA	cis	rs6832769	1	rs6824057	ENSG00000223305.1	RN7SKP30	5.35	1.08e-07	1.31e-05	0.21	0.16	Personality dimensions;	chr4:55501111	chr4:55540502~55540835:-
BRCA	cis	rs6832769	1	rs12646078	ENSG00000223305.1	RN7SKP30	5.35	1.08e-07	1.31e-05	0.21	0.16	Personality dimensions;	chr4:55502037	chr4:55540502~55540835:-
BRCA	cis	rs9859260	0.71	rs41298097	ENSG00000242086.7	LINC00969	-5.35	1.08e-07	1.32e-05	-0.18	-0.16	Mean corpuscular volume;	chr3:196052284	chr3:195658062~195739964:+
BRCA	cis	rs9859260	0.71	rs34906439	ENSG00000242086.7	LINC00969	-5.35	1.08e-07	1.32e-05	-0.18	-0.16	Mean corpuscular volume;	chr3:196052835	chr3:195658062~195739964:+
BRCA	cis	rs9840812	0.769	rs534944	ENSG00000239213.4	NCK1-AS1	5.35	1.08e-07	1.32e-05	0.2	0.16	Fibrinogen levels;	chr3:136242189	chr3:136841726~136862054:-
BRCA	cis	rs4787491	0.704	rs67218159	ENSG00000273724.1	RP11-347C12.12	-5.35	1.08e-07	1.32e-05	-0.18	-0.16	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30039184	chr16:30336400~30343336:+
BRCA	cis	rs7911264	1	rs10882100	ENSG00000236493.2	EIF2S2P3	5.35	1.08e-07	1.32e-05	0.21	0.16	Inflammatory bowel disease;	chr10:92700930	chr10:92668745~92669743:-
BRCA	cis	rs7200543	0.848	rs62039480	ENSG00000260735.1	RP11-72I8.1	-5.35	1.08e-07	1.32e-05	-0.19	-0.16	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15043593	chr16:15094411~15109197:+
BRCA	cis	rs1707322	0.686	rs3014242	ENSG00000234329.1	RP11-767N6.2	-5.35	1.08e-07	1.32e-05	-0.17	-0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45621905	chr1:45651039~45651826:-
BRCA	cis	rs2898681	0.521	rs6833350	ENSG00000248375.1	RP11-177B4.1	-5.35	1.08e-07	1.32e-05	-0.32	-0.16	Optic nerve measurement (cup area);	chr4:52874701	chr4:52720081~52720831:-
BRCA	cis	rs1030877	0.557	rs2576752	ENSG00000235319.1	AC012360.4	-5.35	1.08e-07	1.32e-05	-0.2	-0.16	Obesity-related traits;	chr2:105362304	chr2:105324210~105330529:+
BRCA	cis	rs875971	0.545	rs12670811	ENSG00000228409.4	CCT6P1	-5.35	1.08e-07	1.32e-05	-0.16	-0.16	Aortic root size;	chr7:66358032	chr7:65751142~65763354:+
BRCA	cis	rs2638953	0.962	rs11049585	ENSG00000278733.1	RP11-425D17.1	-5.35	1.08e-07	1.32e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28417957	chr12:28185625~28186190:-
BRCA	cis	rs8002861	0.967	rs2325071	ENSG00000274001.1	RP11-5G9.5	5.35	1.08e-07	1.32e-05	0.18	0.16	Leprosy;	chr13:43902657	chr13:43877715~43878163:-
BRCA	cis	rs365302	1	rs371023	ENSG00000235086.1	FNDC1-IT1	5.35	1.08e-07	1.32e-05	0.19	0.16	Coronary heart disease;	chr6:159197365	chr6:159240786~159243329:+
BRCA	cis	rs9467773	1	rs6922824	ENSG00000241549.7	GUSBP2	-5.35	1.08e-07	1.32e-05	-0.17	-0.16	Intelligence (multi-trait analysis);	chr6:26553587	chr6:26871484~26956554:-
BRCA	cis	rs6840360	0.642	rs2709819	ENSG00000278978.1	RP11-164P12.5	-5.35	1.08e-07	1.32e-05	-0.18	-0.16	Intelligence (multi-trait analysis);	chr4:151462680	chr4:151669786~151670503:+
BRCA	cis	rs7618915	0.547	rs35211965	ENSG00000243224.1	RP5-1157M23.2	-5.35	1.08e-07	1.32e-05	-0.18	-0.16	Bipolar disorder;	chr3:52651289	chr3:52239258~52241097:+
BRCA	cis	rs4535700	0.501	rs60517461	ENSG00000226278.1	PSPHP1	5.35	1.08e-07	1.32e-05	0.19	0.16	Macular telangiectasia type 2;	chr7:55949952	chr7:55764797~55773288:+
BRCA	cis	rs2708977	0.609	rs611943	ENSG00000237510.6	AC008268.2	-5.35	1.08e-07	1.32e-05	-0.22	-0.16	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96401336	chr2:95789654~95800166:+
BRCA	cis	rs35612822	0.828	rs2738281	ENSG00000232485.2	AC098820.3	-5.35	1.08e-07	1.32e-05	-0.21	-0.16	Kidney disease (early stage) in type 1 diabetes;	chr2:216427639	chr2:216479030~216498761:-
BRCA	cis	rs7618915	0.547	rs6976	ENSG00000243224.1	RP5-1157M23.2	-5.35	1.08e-07	1.32e-05	-0.18	-0.16	Bipolar disorder;	chr3:52694788	chr3:52239258~52241097:+
BRCA	cis	rs61160187	0.51	rs6872863	ENSG00000215032.2	GNL3LP1	5.35	1.08e-07	1.32e-05	0.2	0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:60792321	chr5:60891935~60893577:-
BRCA	cis	rs61160187	0.527	rs6873181	ENSG00000215032.2	GNL3LP1	5.35	1.08e-07	1.32e-05	0.2	0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:60792423	chr5:60891935~60893577:-
BRCA	cis	rs61160187	0.527	rs6894672	ENSG00000215032.2	GNL3LP1	5.35	1.08e-07	1.32e-05	0.2	0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:60792428	chr5:60891935~60893577:-
BRCA	cis	rs66887589	0.87	rs10518336	ENSG00000245958.5	RP11-33B1.1	-5.35	1.08e-07	1.32e-05	-0.15	-0.16	Diastolic blood pressure;	chr4:119601779	chr4:119454791~119552025:+
BRCA	cis	rs2834188	1	rs2834190	ENSG00000272659.1	AP000295.10	5.35	1.08e-07	1.32e-05	0.24	0.16	Narcolepsy;	chr21:33320706	chr21:33309491~33310181:+
BRCA	cis	rs4950322	0.802	rs72694705	ENSG00000244371.2	PFN1P8	-5.35	1.08e-07	1.32e-05	-0.23	-0.16	Protein quantitative trait loci;	chr1:147362313	chr1:146957117~146957659:-
BRCA	cis	rs3733585	0.673	rs4580649	ENSG00000250413.1	RP11-448G15.1	5.35	1.08e-07	1.32e-05	0.21	0.16	Cleft plate (environmental tobacco smoke interaction);	chr4:9946837	chr4:10006482~10009725:+
BRCA	cis	rs2708977	0.933	rs6576972	ENSG00000237510.6	AC008268.2	-5.35	1.08e-07	1.32e-05	-0.21	-0.16	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96486709	chr2:95789654~95800166:+
BRCA	cis	rs9659323	0.65	rs12086486	ENSG00000231365.4	RP11-418J17.1	-5.35	1.08e-07	1.32e-05	-0.21	-0.16	Body mass index;	chr1:118946419	chr1:119140396~119275973:+
BRCA	cis	rs9467773	1	rs10214634	ENSG00000124549.13	BTN2A3P	5.35	1.09e-07	1.33e-05	0.16	0.16	Intelligence (multi-trait analysis);	chr6:26564354	chr6:26421391~26432383:+
BRCA	cis	rs26949	0.511	rs11740327	ENSG00000215032.2	GNL3LP1	5.35	1.09e-07	1.33e-05	0.2	0.16	Intelligence (multi-trait analysis);	chr5:60603586	chr5:60891935~60893577:-
BRCA	cis	rs17711722	1	rs17711722	ENSG00000213640.3	EEF1DP4	5.35	1.09e-07	1.33e-05	0.2	0.16	Calcium levels;	chr7:65806210	chr7:64862999~64864370:+
BRCA	cis	rs9393777	0.623	rs13211166	ENSG00000216901.1	AL022393.7	5.35	1.09e-07	1.33e-05	0.26	0.16	Intelligence (multi-trait analysis);	chr6:27298161	chr6:28176188~28176674:+
BRCA	cis	rs12144309	0.554	rs2476602	ENSG00000232450.1	RP4-730K3.3	5.35	1.09e-07	1.33e-05	0.21	0.16	Coronary artery disease;	chr1:113854333	chr1:113698884~113699631:-
BRCA	cis	rs6723108	0.678	rs512375	ENSG00000224043.6	CCNT2-AS1	-5.35	1.09e-07	1.33e-05	-0.22	-0.16	Type 2 diabetes;	chr2:134527708	chr2:134735464~134918710:-
BRCA	cis	rs516805	0.748	rs155463	ENSG00000279114.1	RP3-425C14.5	-5.35	1.09e-07	1.33e-05	-0.2	-0.16	Lymphocyte counts;	chr6:122501474	chr6:122471923~122484161:+
BRCA	cis	rs8113308	0.752	rs11879758	ENSG00000269483.1	AC006272.1	5.35	1.09e-07	1.33e-05	0.31	0.16	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51986911	chr19:51839924~51843324:-
BRCA	cis	rs10752881	1	rs10911185	ENSG00000224468.3	RP11-181K3.4	-5.35	1.09e-07	1.33e-05	-0.17	-0.16	Colorectal cancer;	chr1:183002612	chr1:183138402~183141282:-
BRCA	cis	rs10752881	1	rs10737235	ENSG00000224468.3	RP11-181K3.4	-5.35	1.09e-07	1.33e-05	-0.17	-0.16	Colorectal cancer;	chr1:183002681	chr1:183138402~183141282:-
BRCA	cis	rs7131987	0.65	rs4331146	ENSG00000275476.1	RP11-996F15.4	-5.35	1.09e-07	1.33e-05	-0.19	-0.16	QT interval;	chr12:29287150	chr12:29277397~29277882:-
BRCA	cis	rs4691139	0.566	rs60664011	ENSG00000248632.1	RP11-366M4.11	5.35	1.09e-07	1.33e-05	0.17	0.16	Ovarian cancer in BRCA1 mutation carriers;	chr4:165000370	chr4:164968587~164970002:-
BRCA	cis	rs73222236	0.787	rs6782151	ENSG00000273486.1	RP11-731C17.2	5.35	1.09e-07	1.33e-05	0.18	0.16	Coronary artery disease;	chr3:136616953	chr3:136837338~136839021:-
BRCA	cis	rs9287719	0.967	rs4669596	ENSG00000243819.4	RN7SL832P	5.35	1.09e-07	1.33e-05	0.16	0.16	Prostate cancer;	chr2:10580446	chr2:10690344~10692099:+
BRCA	cis	rs2732480	0.5	rs1552550	ENSG00000240399.1	RP1-228P16.1	5.35	1.09e-07	1.33e-05	0.19	0.16	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48249568	chr12:48054813~48055591:-
BRCA	cis	rs2732480	0.5	rs2450991	ENSG00000240399.1	RP1-228P16.1	5.35	1.09e-07	1.33e-05	0.19	0.16	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48257838	chr12:48054813~48055591:-
BRCA	cis	rs1861628	0.927	rs6724363	ENSG00000229352.1	AC007563.3	5.35	1.09e-07	1.34e-05	0.21	0.16	Serum thyroid-stimulating hormone levels;Hypothyroidism;	chr2:216761868	chr2:216799608~216805335:+
BRCA	cis	rs1075265	0.749	rs10203095	ENSG00000235937.1	AC008280.1	5.35	1.09e-07	1.34e-05	0.18	0.16	Chronotype;Morning vs. evening chronotype;	chr2:53737150	chr2:54029552~54030682:-
BRCA	cis	rs3733585	0.673	rs116046986	ENSG00000250413.1	RP11-448G15.1	5.35	1.09e-07	1.34e-05	0.21	0.16	Cleft plate (environmental tobacco smoke interaction);	chr4:9956170	chr4:10006482~10009725:+
BRCA	cis	rs17301013	0.606	rs17350956	ENSG00000227373.4	RP11-160H22.5	5.35	1.09e-07	1.34e-05	0.25	0.16	Systemic lupus erythematosus;	chr1:174093863	chr1:174115300~174160004:-
BRCA	cis	rs9828933	0.752	rs13434089	ENSG00000280620.1	SCAANT1	-5.35	1.1e-07	1.34e-05	-0.28	-0.16	Type 2 diabetes;	chr3:63962890	chr3:63911518~63911772:-
BRCA	cis	rs4950322	0.515	rs76327075	ENSG00000244371.2	PFN1P8	-5.35	1.1e-07	1.34e-05	-0.21	-0.16	Protein quantitative trait loci;	chr1:147246319	chr1:146957117~146957659:-
BRCA	cis	rs34792	0.688	rs153786	ENSG00000207425.1	Y_RNA	-5.35	1.1e-07	1.34e-05	-0.2	-0.16	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15499857	chr16:14915457~14915556:-
BRCA	cis	rs6498068	0.594	rs12996	ENSG00000260468.1	LINC01290	-5.35	1.1e-07	1.34e-05	-0.23	-0.16	Metabolite levels (MHPG);	chr16:10529447	chr16:10514842~10528202:-
BRCA	cis	rs11098499	0.754	rs10518300	ENSG00000249244.1	RP11-548H18.2	-5.35	1.1e-07	1.34e-05	-0.19	-0.16	Corneal astigmatism;	chr4:119328344	chr4:119391831~119395335:-
BRCA	cis	rs7620503	1	rs6777561	ENSG00000228221.4	LINC00578	5.35	1.1e-07	1.34e-05	0.19	0.16	Corneal structure;	chr3:177587410	chr3:177441921~177752305:+
BRCA	cis	rs2638953	0.924	rs11049582	ENSG00000278733.1	RP11-425D17.1	-5.35	1.1e-07	1.34e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28416392	chr12:28185625~28186190:-
BRCA	cis	rs6600671	0.899	rs6674392	ENSG00000275538.1	RNVU1-19	5.35	1.1e-07	1.34e-05	0.19	0.16	Hip geometry;	chr1:121518864	chr1:120850819~120850985:-
BRCA	cis	rs9309473	0.632	rs6546825	ENSG00000163016.8	ALMS1P	5.35	1.1e-07	1.34e-05	0.2	0.16	Metabolite levels;	chr2:73365125	chr2:73644919~73685576:+
BRCA	cis	rs77972916	0.561	rs13411485	ENSG00000234936.1	AC010883.5	-5.35	1.1e-07	1.34e-05	-0.25	-0.16	Granulocyte percentage of myeloid white cells;	chr2:43348845	chr2:43229573~43233394:+
BRCA	cis	rs8072100	0.581	rs4267364	ENSG00000228782.6	CTD-2026D20.3	5.35	1.1e-07	1.34e-05	0.18	0.16	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47703898	chr17:47450568~47492492:-
BRCA	cis	rs6832769	1	rs4865008	ENSG00000223305.1	RN7SKP30	-5.35	1.1e-07	1.34e-05	-0.21	-0.16	Personality dimensions;	chr4:55544688	chr4:55540502~55540835:-
BRCA	cis	rs2832191	0.633	rs2832166	ENSG00000176054.6	RPL23P2	5.35	1.1e-07	1.34e-05	0.18	0.16	Dental caries;	chr21:29090074	chr21:28997613~28998033:-
BRCA	cis	rs6498068	0.594	rs3087620	ENSG00000260468.1	LINC01290	-5.35	1.1e-07	1.34e-05	-0.23	-0.16	Metabolite levels (MHPG);	chr16:10529475	chr16:10514842~10528202:-
BRCA	cis	rs2051773	0.539	rs6486345	ENSG00000184669.7	OR7E14P	-5.35	1.1e-07	1.35e-05	-0.24	-0.16	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);	chr11:17017230	chr11:17013998~17053024:+
BRCA	cis	rs4819052	0.819	rs34818688	ENSG00000184274.3	LINC00315	-5.35	1.1e-07	1.35e-05	-0.22	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45252501	chr21:45300245~45305257:-
BRCA	cis	rs875971	0.522	rs1701760	ENSG00000273024.4	INTS4P2	-5.35	1.1e-07	1.35e-05	-0.18	-0.16	Aortic root size;	chr7:66008701	chr7:65647864~65715661:+
BRCA	cis	rs7208859	0.673	rs2433	ENSG00000280069.1	CTD-2349P21.3	-5.35	1.1e-07	1.35e-05	-0.24	-0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30899210	chr17:30738182~30740275:+
BRCA	cis	rs10129255	0.518	rs12590732	ENSG00000224373.3	IGHV4-59	-5.35	1.11e-07	1.35e-05	-0.09	-0.16	Kawasaki disease;	chr14:106779612	chr14:106627249~106627825:-
BRCA	cis	rs9545047	0.604	rs2147566	ENSG00000227354.5	RBM26-AS1	5.35	1.11e-07	1.35e-05	0.18	0.16	Schizophrenia;	chr13:79296580	chr13:79406309~79424328:+
BRCA	cis	rs2239547	0.522	rs9844736	ENSG00000242142.1	SERBP1P3	-5.35	1.11e-07	1.35e-05	-0.2	-0.16	Schizophrenia;	chr3:52897955	chr3:53064283~53065091:-
BRCA	cis	rs950880	0.767	rs2287037	ENSG00000234389.1	AC007278.3	-5.35	1.11e-07	1.35e-05	-0.15	-0.16	Serum protein levels (sST2);	chr2:102362568	chr2:102438713~102440475:+
BRCA	cis	rs9393692	0.905	rs9358919	ENSG00000241549.7	GUSBP2	-5.35	1.11e-07	1.35e-05	-0.18	-0.16	Educational attainment;	chr6:26287634	chr6:26871484~26956554:-
BRCA	cis	rs2898681	0.614	rs58260946	ENSG00000248375.1	RP11-177B4.1	-5.35	1.11e-07	1.35e-05	-0.23	-0.16	Optic nerve measurement (cup area);	chr4:52809253	chr4:52720081~52720831:-
BRCA	cis	rs7615952	0.575	rs35949599	ENSG00000250012.1	RP11-124N2.1	-5.35	1.11e-07	1.35e-05	-0.23	-0.16	Blood pressure (smoking interaction);	chr3:125825359	chr3:126084220~126095349:+
BRCA	cis	rs4865169	0.934	rs3796531	ENSG00000269949.1	RP11-738E22.3	-5.35	1.11e-07	1.35e-05	-0.19	-0.16	Breast cancer;	chr4:56984680	chr4:56960927~56961373:-
BRCA	cis	rs9545047	0.519	rs8001281	ENSG00000227354.5	RBM26-AS1	5.35	1.11e-07	1.35e-05	0.18	0.16	Schizophrenia;	chr13:79410707	chr13:79406309~79424328:+
BRCA	cis	rs9545047	0.604	rs9545052	ENSG00000227354.5	RBM26-AS1	5.35	1.11e-07	1.35e-05	0.18	0.16	Schizophrenia;	chr13:79294875	chr13:79406309~79424328:+
BRCA	cis	rs4218	0.573	rs16940998	ENSG00000277144.1	RP11-59H7.4	5.35	1.11e-07	1.35e-05	0.2	0.16	Social communication problems;	chr15:59086095	chr15:59115547~59116089:-
BRCA	cis	rs9291683	0.679	rs3756225	ENSG00000250413.1	RP11-448G15.1	5.35	1.11e-07	1.35e-05	0.21	0.16	Bone mineral density;	chr4:10092509	chr4:10006482~10009725:+
BRCA	cis	rs11971779	0.625	rs10260850	ENSG00000273391.1	RP11-634H22.1	5.34	1.11e-07	1.35e-05	0.16	0.16	Diisocyanate-induced asthma;	chr7:139318856	chr7:139359032~139359566:-
BRCA	cis	rs9467773	1	rs9467773	ENSG00000124549.13	BTN2A3P	5.34	1.11e-07	1.36e-05	0.16	0.16	Intelligence (multi-trait analysis);	chr6:26498198	chr6:26421391~26432383:+
BRCA	cis	rs600231	0.706	rs4244811	ENSG00000173727.10	CMB9-22P13.1	-5.34	1.11e-07	1.36e-05	-0.23	-0.16	Bone mineral density;	chr11:65553309	chr11:65455258~65466720:+
BRCA	cis	rs9467773	1	rs6926629	ENSG00000124549.13	BTN2A3P	5.34	1.11e-07	1.36e-05	0.16	0.16	Intelligence (multi-trait analysis);	chr6:26499675	chr6:26421391~26432383:+
BRCA	cis	rs17711722	0.675	rs6947132	ENSG00000273024.4	INTS4P2	5.34	1.11e-07	1.36e-05	0.18	0.16	Calcium levels;	chr7:65808508	chr7:65647864~65715661:+
BRCA	cis	rs10752881	0.901	rs10911201	ENSG00000224468.3	RP11-181K3.4	-5.34	1.11e-07	1.36e-05	-0.18	-0.16	Colorectal cancer;	chr1:183032487	chr1:183138402~183141282:-
BRCA	cis	rs17772222	0.682	rs61542857	ENSG00000258789.1	RP11-507K2.3	-5.34	1.11e-07	1.36e-05	-0.18	-0.16	Coronary artery calcification;	chr14:88470358	chr14:88551597~88552493:+
BRCA	cis	rs17772222	0.637	rs7161660	ENSG00000258789.1	RP11-507K2.3	-5.34	1.11e-07	1.36e-05	-0.18	-0.16	Coronary artery calcification;	chr14:88471832	chr14:88551597~88552493:+
BRCA	cis	rs2235642	0.75	rs2974845	ENSG00000280231.1	LA16c-380F5.3	-5.34	1.11e-07	1.36e-05	-0.21	-0.16	Coronary artery disease;	chr16:1598161	chr16:1553655~1554130:-
BRCA	cis	rs8098244	0.964	rs1268716	ENSG00000264745.1	TTC39C-AS1	-5.34	1.11e-07	1.36e-05	-0.22	-0.16	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23894863	chr18:23994213~24015339:-
BRCA	cis	rs8098244	0.964	rs1262341	ENSG00000264745.1	TTC39C-AS1	-5.34	1.11e-07	1.36e-05	-0.22	-0.16	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23895595	chr18:23994213~24015339:-
BRCA	cis	rs8098244	0.964	rs1258113	ENSG00000264745.1	TTC39C-AS1	-5.34	1.11e-07	1.36e-05	-0.22	-0.16	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23895680	chr18:23994213~24015339:-
BRCA	cis	rs8098244	0.964	rs1154226	ENSG00000264745.1	TTC39C-AS1	-5.34	1.11e-07	1.36e-05	-0.22	-0.16	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23901269	chr18:23994213~24015339:-
BRCA	cis	rs8098244	0.964	rs9961718	ENSG00000264745.1	TTC39C-AS1	5.34	1.11e-07	1.36e-05	0.22	0.16	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23893803	chr18:23994213~24015339:-
BRCA	cis	rs721917	0.506	rs2758539	ENSG00000244733.5	RP11-506M13.3	-5.34	1.11e-07	1.36e-05	-0.19	-0.16	Chronic obstructive pulmonary disease;	chr10:79894680	chr10:79660891~79677996:+
BRCA	cis	rs737008	0.5	rs7189239	ENSG00000262703.1	RP11-485G7.6	5.34	1.11e-07	1.36e-05	0.17	0.16	Obesity-related traits;	chr16:11308658	chr16:11348143~11349321:-
BRCA	cis	rs73222236	0.825	rs9831321	ENSG00000273486.1	RP11-731C17.2	-5.34	1.11e-07	1.36e-05	-0.18	-0.16	Coronary artery disease;	chr3:136423750	chr3:136837338~136839021:-
BRCA	cis	rs16949788	1	rs75532475	ENSG00000261351.2	CTD-3185P2.1	-5.34	1.11e-07	1.36e-05	-0.34	-0.16	Spherical equivalent (joint analysis main effects and education interaction);	chr15:66540128	chr15:66488658~66492109:-
BRCA	cis	rs10129255	0.789	rs61997796	ENSG00000280411.1	IGHV1-69-2	-5.34	1.11e-07	1.36e-05	-0.13	-0.16	Kawasaki disease;	chr14:106813798	chr14:106762092~106762588:-
BRCA	cis	rs13113518	0.783	rs13111128	ENSG00000272969.1	RP11-528I4.2	5.34	1.12e-07	1.36e-05	0.19	0.16	Height;	chr4:55578154	chr4:55547112~55547889:+
BRCA	cis	rs3733585	0.699	rs1122142	ENSG00000250413.1	RP11-448G15.1	5.34	1.12e-07	1.36e-05	0.21	0.16	Cleft plate (environmental tobacco smoke interaction);	chr4:9945924	chr4:10006482~10009725:+
BRCA	cis	rs6840360	0.642	rs2709825	ENSG00000278978.1	RP11-164P12.5	-5.34	1.12e-07	1.36e-05	-0.18	-0.16	Intelligence (multi-trait analysis);	chr4:151444411	chr4:151669786~151670503:+
BRCA	cis	rs6840360	0.607	rs2724547	ENSG00000278978.1	RP11-164P12.5	-5.34	1.12e-07	1.36e-05	-0.18	-0.16	Intelligence (multi-trait analysis);	chr4:151444424	chr4:151669786~151670503:+
BRCA	cis	rs853679	0.607	rs34950484	ENSG00000204709.4	LINC01556	5.34	1.12e-07	1.36e-05	0.42	0.16	Depression;	chr6:28310911	chr6:28943877~28944537:+
BRCA	cis	rs62025270	0.632	rs17636096	ENSG00000259295.5	CSPG4P12	-5.34	1.12e-07	1.36e-05	-0.26	-0.16	Idiopathic pulmonary fibrosis;	chr15:85675503	chr15:85191438~85213905:+
BRCA	cis	rs4713675	0.565	rs4713659	ENSG00000224557.6	HLA-DPB2	-5.34	1.12e-07	1.36e-05	-0.19	-0.16	Plateletcrit;	chr6:33700062	chr6:33112451~33129084:+
BRCA	cis	rs8054556	1	rs12921996	ENSG00000273724.1	RP11-347C12.12	-5.34	1.12e-07	1.36e-05	-0.19	-0.16	Autism spectrum disorder or schizophrenia;	chr16:30000297	chr16:30336400~30343336:+
BRCA	cis	rs2834188	1	rs2834188	ENSG00000272659.1	AP000295.10	-5.34	1.12e-07	1.36e-05	-0.24	-0.16	Narcolepsy;	chr21:33316948	chr21:33309491~33310181:+
BRCA	cis	rs16866061	0.515	rs13020268	ENSG00000228446.2	AC073052.1	5.34	1.12e-07	1.36e-05	0.18	0.16	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr2:224573206	chr2:224499387~224500100:-
BRCA	cis	rs9907295	0.71	rs4796113	ENSG00000270977.1	AC015849.16	-5.34	1.12e-07	1.36e-05	-0.3	-0.16	Fibroblast growth factor basic levels;	chr17:35832562	chr17:35893707~35911023:-
BRCA	cis	rs295490	0.748	rs77347345	ENSG00000272656.1	RP11-219D15.3	5.34	1.12e-07	1.36e-05	0.37	0.16	PR interval in Tripanosoma cruzi seropositivity;	chr3:139459863	chr3:139349024~139349371:-
BRCA	cis	rs9341808	0.718	rs2322630	ENSG00000272129.1	RP11-250B2.6	5.34	1.12e-07	1.36e-05	0.21	0.16	Sitting height ratio;	chr6:80131316	chr6:80355424~80356859:+
BRCA	cis	rs7577696	0.695	rs7581432	ENSG00000272716.1	RP11-563N4.1	-5.34	1.12e-07	1.37e-05	-0.18	-0.16	Inflammatory biomarkers;	chr2:32170246	chr2:32165046~32165757:-
BRCA	cis	rs2288884	1	rs17779301	ENSG00000275055.1	CTC-471J1.11	5.34	1.12e-07	1.37e-05	0.24	0.16	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52035990	chr19:52049007~52049754:+
BRCA	cis	rs375066	0.551	rs11880651	ENSG00000267058.1	RP11-15A1.3	5.34	1.12e-07	1.37e-05	0.2	0.16	Breast cancer;	chr19:43827646	chr19:43891804~43901805:-
BRCA	cis	rs8098244	0.929	rs34963231	ENSG00000264745.1	TTC39C-AS1	-5.34	1.12e-07	1.37e-05	-0.22	-0.16	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23916890	chr18:23994213~24015339:-
BRCA	cis	rs2562456	0.874	rs2562408	ENSG00000268658.4	LINC00664	-5.34	1.12e-07	1.37e-05	-0.26	-0.16	Pain;	chr19:21527079	chr19:21483374~21503238:+
BRCA	cis	rs2051773	0.567	rs12794156	ENSG00000184669.7	OR7E14P	-5.34	1.12e-07	1.37e-05	-0.25	-0.16	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);	chr11:17041458	chr11:17013998~17053024:+
BRCA	cis	rs1559040	1	rs1559040	ENSG00000272156.1	RP11-477N3.1	-5.34	1.12e-07	1.37e-05	-0.26	-0.16	Sudden cardiac arrest;	chr2:54120613	chr2:54082554~54085066:+
BRCA	cis	rs597539	0.652	rs674654	ENSG00000261625.1	RP11-554A11.4	-5.34	1.13e-07	1.37e-05	-0.16	-0.16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68931294	chr11:69000765~69002048:-
BRCA	cis	rs597539	0.616	rs513476	ENSG00000261625.1	RP11-554A11.4	-5.34	1.13e-07	1.37e-05	-0.16	-0.16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68931528	chr11:69000765~69002048:-
BRCA	cis	rs2243480	0.522	rs73150635	ENSG00000232559.3	GS1-124K5.12	5.34	1.13e-07	1.37e-05	0.38	0.16	Diabetic kidney disease;	chr7:66507503	chr7:66554588~66576923:-
BRCA	cis	rs78487399	0.614	rs10166376	ENSG00000234936.1	AC010883.5	5.34	1.13e-07	1.37e-05	0.24	0.16	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43395333	chr2:43229573~43233394:+
BRCA	cis	rs2645424	0.602	rs3779663	ENSG00000255046.1	RP11-297N6.4	-5.34	1.13e-07	1.37e-05	-0.18	-0.16	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);	chr8:11813853	chr8:11797928~11802568:-
BRCA	cis	rs647097	0.694	rs564629	ENSG00000272788.1	RP11-674N23.4	5.34	1.13e-07	1.37e-05	0.24	0.16	Chronic obstructive pulmonary disease;	chr18:8799450	chr18:8801656~8802305:+
BRCA	cis	rs2708977	0.637	rs687950	ENSG00000237510.6	AC008268.2	5.34	1.13e-07	1.37e-05	0.22	0.16	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96403874	chr2:95789654~95800166:+
BRCA	cis	rs7577696	0.924	rs7566162	ENSG00000272716.1	RP11-563N4.1	-5.34	1.13e-07	1.37e-05	-0.18	-0.16	Inflammatory biomarkers;	chr2:32099003	chr2:32165046~32165757:-
BRCA	cis	rs2880765	0.566	rs17553249	ENSG00000230373.7	GOLGA6L5P	5.34	1.13e-07	1.37e-05	0.19	0.16	Coronary artery disease;	chr15:85463463	chr15:84507885~84516814:-
BRCA	cis	rs9307551	0.522	rs13111877	ENSG00000250334.4	LINC00989	-5.34	1.13e-07	1.37e-05	-0.22	-0.16	Refractive error;	chr4:79506745	chr4:79492416~79576460:+
BRCA	cis	rs9307551	0.656	rs11098741	ENSG00000250334.4	LINC00989	-5.34	1.13e-07	1.37e-05	-0.23	-0.16	Refractive error;	chr4:79551480	chr4:79492416~79576460:+
BRCA	cis	rs7674212	0.541	rs4699051	ENSG00000248740.4	RP11-328K4.1	5.34	1.13e-07	1.37e-05	0.19	0.16	Type 2 diabetes;	chr4:103193237	chr4:103256159~103453658:+
BRCA	cis	rs7577696	0.539	rs2280972	ENSG00000272716.1	RP11-563N4.1	-5.34	1.13e-07	1.38e-05	-0.21	-0.16	Inflammatory biomarkers;	chr2:32152892	chr2:32165046~32165757:-
BRCA	cis	rs8180040	0.62	rs2278963	ENSG00000276925.1	RP11-708J19.3	5.34	1.13e-07	1.38e-05	0.19	0.16	Colorectal cancer;	chr3:47013379	chr3:47469777~47469987:+
BRCA	cis	rs6832769	1	rs35767091	ENSG00000223305.1	RN7SKP30	5.34	1.13e-07	1.38e-05	0.21	0.16	Personality dimensions;	chr4:55480556	chr4:55540502~55540835:-
BRCA	cis	rs2524005	1	rs2524005	ENSG00000281831.1	HCP5B	5.34	1.13e-07	1.38e-05	0.25	0.16	Bipolar disorder and schizophrenia;	chr6:29931900	chr6:29871895~29873783:-
BRCA	cis	rs2403083	0.541	rs4150974	ENSG00000258256.1	RP11-219B4.5	-5.34	1.13e-07	1.38e-05	-0.2	-0.16	Plasma amyloid beta peptide concentrations (ABx-40);	chr8:85215235	chr8:85222446~85245717:-
BRCA	cis	rs991427	0.643	rs73197021	ENSG00000258100.1	RP11-121E16.1	-5.34	1.13e-07	1.38e-05	-0.27	-0.16	Systolic blood pressure (alcohol consumption interaction);	chr12:91065893	chr12:91362196~91368606:+
BRCA	cis	rs2562456	0.754	rs11673234	ENSG00000268081.1	RP11-678G14.2	5.34	1.13e-07	1.38e-05	0.26	0.16	Pain;	chr19:21324800	chr19:21554640~21569237:-
BRCA	cis	rs2562456	0.754	rs11673320	ENSG00000268081.1	RP11-678G14.2	5.34	1.13e-07	1.38e-05	0.26	0.16	Pain;	chr19:21324801	chr19:21554640~21569237:-
BRCA	cis	rs10510102	0.872	rs7906271	ENSG00000226864.1	ATE1-AS1	-5.34	1.13e-07	1.38e-05	-0.29	-0.16	Breast cancer;	chr10:121948207	chr10:121928312~121951965:+
BRCA	cis	rs7577696	0.924	rs11124277	ENSG00000272716.1	RP11-563N4.1	-5.34	1.13e-07	1.38e-05	-0.18	-0.16	Inflammatory biomarkers;	chr2:32095301	chr2:32165046~32165757:-
BRCA	cis	rs73193808	1	rs66716206	ENSG00000236056.1	GAPDHP14	-5.34	1.13e-07	1.38e-05	-0.23	-0.16	Coronary artery disease;	chr21:29183333	chr21:29222321~29223257:+
BRCA	cis	rs3733585	0.673	rs9994937	ENSG00000250413.1	RP11-448G15.1	5.34	1.13e-07	1.38e-05	0.21	0.16	Cleft plate (environmental tobacco smoke interaction);	chr4:9963175	chr4:10006482~10009725:+
BRCA	cis	rs4784934	0.513	rs2042400	ENSG00000260186.4	RP11-481J2.2	5.34	1.13e-07	1.38e-05	0.19	0.16	QT interval;	chr16:58430436	chr16:58421326~58462470:+
BRCA	cis	rs4713118	0.662	rs149900	ENSG00000204709.4	LINC01556	5.34	1.13e-07	1.38e-05	0.24	0.16	Parkinson's disease;	chr6:28046819	chr6:28943877~28944537:+
BRCA	cis	rs6430585	0.528	rs309119	ENSG00000231890.6	DARS-AS1	-5.34	1.13e-07	1.38e-05	-0.24	-0.16	Corneal structure;	chr2:135952802	chr2:135985176~136022593:+
BRCA	cis	rs2665103	0.61	rs1972460	ENSG00000259429.4	UBE2Q2P2	-5.34	1.14e-07	1.38e-05	-0.16	-0.16	Intelligence (multi-trait analysis);	chr15:82238289	chr15:82355142~82420075:+
BRCA	cis	rs9467773	0.844	rs2393669	ENSG00000124549.13	BTN2A3P	5.34	1.14e-07	1.38e-05	0.16	0.16	Intelligence (multi-trait analysis);	chr6:26503645	chr6:26421391~26432383:+
BRCA	cis	rs9467773	1	rs9461259	ENSG00000124549.13	BTN2A3P	5.34	1.14e-07	1.38e-05	0.16	0.16	Intelligence (multi-trait analysis);	chr6:26504607	chr6:26421391~26432383:+
BRCA	cis	rs9467773	1	rs3736781	ENSG00000124549.13	BTN2A3P	5.34	1.14e-07	1.38e-05	0.16	0.16	Intelligence (multi-trait analysis);	chr6:26505134	chr6:26421391~26432383:+
BRCA	cis	rs9467773	1	rs3736782	ENSG00000124549.13	BTN2A3P	5.34	1.14e-07	1.38e-05	0.16	0.16	Intelligence (multi-trait analysis);	chr6:26505175	chr6:26421391~26432383:+
BRCA	cis	rs2179367	0.959	rs628488	ENSG00000216906.2	RP11-350J20.9	5.34	1.14e-07	1.38e-05	0.21	0.16	Dupuytren's disease;	chr6:149398264	chr6:149904243~149906418:+
BRCA	cis	rs35612822	0.866	rs1033085	ENSG00000232485.2	AC098820.3	-5.34	1.14e-07	1.38e-05	-0.21	-0.16	Kidney disease (early stage) in type 1 diabetes;	chr2:216449018	chr2:216479030~216498761:-
BRCA	cis	rs2839186	0.814	rs12482209	ENSG00000228137.1	AP001469.7	-5.34	1.14e-07	1.38e-05	-0.17	-0.16	Testicular germ cell tumor;	chr21:46244361	chr21:46246890~46247682:+
BRCA	cis	rs9545047	0.589	rs9545090	ENSG00000227354.5	RBM26-AS1	5.34	1.14e-07	1.39e-05	0.18	0.16	Schizophrenia;	chr13:79367276	chr13:79406309~79424328:+
BRCA	cis	rs9545047	0.604	rs9530902	ENSG00000227354.5	RBM26-AS1	5.34	1.14e-07	1.39e-05	0.18	0.16	Schizophrenia;	chr13:79367748	chr13:79406309~79424328:+
BRCA	cis	rs9545047	0.604	rs9545092	ENSG00000227354.5	RBM26-AS1	5.34	1.14e-07	1.39e-05	0.18	0.16	Schizophrenia;	chr13:79369809	chr13:79406309~79424328:+
BRCA	cis	rs9545047	0.611	rs9545093	ENSG00000227354.5	RBM26-AS1	5.34	1.14e-07	1.39e-05	0.18	0.16	Schizophrenia;	chr13:79371969	chr13:79406309~79424328:+
BRCA	cis	rs9545047	0.604	rs8001392	ENSG00000227354.5	RBM26-AS1	5.34	1.14e-07	1.39e-05	0.18	0.16	Schizophrenia;	chr13:79374211	chr13:79406309~79424328:+
BRCA	cis	rs9545047	0.604	rs4146473	ENSG00000227354.5	RBM26-AS1	5.34	1.14e-07	1.39e-05	0.18	0.16	Schizophrenia;	chr13:79374548	chr13:79406309~79424328:+
BRCA	cis	rs9545047	0.584	rs1619669	ENSG00000227354.5	RBM26-AS1	5.34	1.14e-07	1.39e-05	0.18	0.16	Schizophrenia;	chr13:79378363	chr13:79406309~79424328:+
BRCA	cis	rs6545883	0.708	rs2518936	ENSG00000270820.4	RP11-355B11.2	5.34	1.14e-07	1.39e-05	0.19	0.16	Tuberculosis;	chr2:61565207	chr2:61471188~61484130:+
BRCA	cis	rs875971	0.862	rs28470208	ENSG00000236529.1	RP13-254B10.1	-5.34	1.14e-07	1.39e-05	-0.18	-0.16	Aortic root size;	chr7:66119713	chr7:65840212~65840596:+
BRCA	cis	rs559928	0.606	rs11600628	ENSG00000236935.1	AP003774.1	5.34	1.14e-07	1.39e-05	0.22	0.16	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64208555	chr11:64325050~64329504:-
BRCA	cis	rs6832769	1	rs7670225	ENSG00000272969.1	RP11-528I4.2	5.34	1.14e-07	1.39e-05	0.2	0.16	Personality dimensions;	chr4:55501851	chr4:55547112~55547889:+
BRCA	cis	rs9545047	0.567	rs4884129	ENSG00000227354.5	RBM26-AS1	5.34	1.14e-07	1.39e-05	0.17	0.16	Schizophrenia;	chr13:79346448	chr13:79406309~79424328:+
BRCA	cis	rs9545047	0.567	rs1410336	ENSG00000227354.5	RBM26-AS1	5.34	1.14e-07	1.39e-05	0.17	0.16	Schizophrenia;	chr13:79347598	chr13:79406309~79424328:+
BRCA	cis	rs9545047	0.604	rs9565492	ENSG00000227354.5	RBM26-AS1	5.34	1.14e-07	1.39e-05	0.17	0.16	Schizophrenia;	chr13:79348554	chr13:79406309~79424328:+
BRCA	cis	rs9545047	0.604	rs9318625	ENSG00000227354.5	RBM26-AS1	5.34	1.14e-07	1.39e-05	0.17	0.16	Schizophrenia;	chr13:79351429	chr13:79406309~79424328:+
BRCA	cis	rs9545047	0.604	rs9530899	ENSG00000227354.5	RBM26-AS1	5.34	1.14e-07	1.39e-05	0.17	0.16	Schizophrenia;	chr13:79352461	chr13:79406309~79424328:+
BRCA	cis	rs9545047	0.604	rs7338677	ENSG00000227354.5	RBM26-AS1	5.34	1.14e-07	1.39e-05	0.17	0.16	Schizophrenia;	chr13:79352580	chr13:79406309~79424328:+
BRCA	cis	rs9545047	0.604	rs7322744	ENSG00000227354.5	RBM26-AS1	5.34	1.14e-07	1.39e-05	0.17	0.16	Schizophrenia;	chr13:79354070	chr13:79406309~79424328:+
BRCA	cis	rs17818399	0.712	rs13008088	ENSG00000279254.1	RP11-536C12.1	-5.34	1.14e-07	1.39e-05	-0.21	-0.16	Height;	chr2:46554441	chr2:46668870~46670778:+
BRCA	cis	rs2562456	0.833	rs4321312	ENSG00000268535.1	RP11-420K14.3	5.34	1.14e-07	1.39e-05	0.23	0.16	Pain;	chr19:21336614	chr19:21709522~21710191:+
BRCA	cis	rs4711336	1	rs764752	ENSG00000224557.6	HLA-DPB2	-5.34	1.14e-07	1.39e-05	-0.19	-0.16	Height;	chr6:33690289	chr6:33112451~33129084:+
BRCA	cis	rs4711336	1	rs764754	ENSG00000224557.6	HLA-DPB2	-5.34	1.14e-07	1.39e-05	-0.19	-0.16	Height;	chr6:33690533	chr6:33112451~33129084:+
BRCA	cis	rs1395	0.634	rs72817542	ENSG00000234072.1	AC074117.10	-5.34	1.14e-07	1.39e-05	-0.19	-0.16	Blood metabolite levels;	chr2:27303813	chr2:27356246~27367622:+
BRCA	cis	rs763121	0.853	rs5750659	ENSG00000228274.3	RP3-508I15.9	-5.34	1.15e-07	1.39e-05	-0.18	-0.16	Menopause (age at onset);	chr22:38672784	chr22:38667585~38681820:-
BRCA	cis	rs763121	0.819	rs3747173	ENSG00000228274.3	RP3-508I15.9	-5.34	1.15e-07	1.39e-05	-0.18	-0.16	Menopause (age at onset);	chr22:38673040	chr22:38667585~38681820:-
BRCA	cis	rs763121	0.853	rs3747174	ENSG00000228274.3	RP3-508I15.9	-5.34	1.15e-07	1.39e-05	-0.18	-0.16	Menopause (age at onset);	chr22:38673176	chr22:38667585~38681820:-
BRCA	cis	rs763121	0.853	rs5757226	ENSG00000228274.3	RP3-508I15.9	-5.34	1.15e-07	1.39e-05	-0.18	-0.16	Menopause (age at onset);	chr22:38674545	chr22:38667585~38681820:-
BRCA	cis	rs26949	0.547	rs248909	ENSG00000215032.2	GNL3LP1	5.34	1.15e-07	1.39e-05	0.2	0.16	Intelligence (multi-trait analysis);	chr5:60554367	chr5:60891935~60893577:-
BRCA	cis	rs10129255	0.518	rs7143784	ENSG00000224373.3	IGHV4-59	5.34	1.15e-07	1.39e-05	0.09	0.16	Kawasaki disease;	chr14:106687277	chr14:106627249~106627825:-
BRCA	cis	rs4835473	0.932	rs6826665	ENSG00000249741.2	RP11-673E1.3	5.34	1.15e-07	1.39e-05	0.18	0.16	Immature fraction of reticulocytes;	chr4:143795140	chr4:143911514~143912053:-
BRCA	cis	rs1552244	0.882	rs28366039	ENSG00000232901.1	CYCSP10	5.34	1.15e-07	1.4e-05	0.24	0.16	Alzheimer's disease;	chr3:9987304	chr3:10000647~10000940:-
BRCA	cis	rs4266144	0.558	rs7623382	ENSG00000241770.1	RP11-555M1.3	-5.34	1.15e-07	1.4e-05	-0.21	-0.16	Coronary artery disease;	chr3:157115105	chr3:157163452~157169133:+
BRCA	cis	rs13126694	0.744	rs11942932	ENSG00000248429.4	RP11-597D13.9	5.34	1.15e-07	1.4e-05	0.15	0.16	Blood osmolality (transformed sodium);	chr4:158081929	chr4:158170752~158202877:+
BRCA	cis	rs12468226	1	rs79919139	ENSG00000226261.1	AC064836.3	5.34	1.15e-07	1.4e-05	0.28	0.16	Urate levels;	chr2:202382786	chr2:202336024~202336727:-
BRCA	cis	rs2243480	1	rs316332	ENSG00000228409.4	CCT6P1	5.34	1.15e-07	1.4e-05	0.22	0.16	Diabetic kidney disease;	chr7:66139312	chr7:65751142~65763354:+
BRCA	cis	rs1559040	1	rs72800751	ENSG00000272156.1	RP11-477N3.1	-5.34	1.15e-07	1.4e-05	-0.26	-0.16	Sudden cardiac arrest;	chr2:54121871	chr2:54082554~54085066:+
BRCA	cis	rs2803122	0.967	rs10757040	ENSG00000273226.1	RP11-513M16.8	-5.34	1.15e-07	1.4e-05	-0.18	-0.16	Pulse pressure;	chr9:19241849	chr9:19375451~19375996:+
BRCA	cis	rs2803122	0.934	rs2175378	ENSG00000273226.1	RP11-513M16.8	-5.34	1.15e-07	1.4e-05	-0.18	-0.16	Pulse pressure;	chr9:19241965	chr9:19375451~19375996:+
BRCA	cis	rs910316	0.967	rs4903293	ENSG00000279594.1	RP11-950C14.10	-5.34	1.15e-07	1.4e-05	-0.18	-0.16	Height;	chr14:75189865	chr14:75011269~75012851:-
BRCA	cis	rs9840812	0.773	rs1154988	ENSG00000239213.4	NCK1-AS1	-5.34	1.15e-07	1.4e-05	-0.2	-0.16	Fibrinogen levels;	chr3:136206349	chr3:136841726~136862054:-
BRCA	cis	rs57221529	0.766	rs17563576	ENSG00000271781.1	CTD-2589H19.6	-5.34	1.15e-07	1.4e-05	-0.23	-0.16	Lung disease severity in cystic fibrosis;	chr5:560361	chr5:675826~676616:+
BRCA	cis	rs7772486	0.806	rs4243478	ENSG00000270638.1	RP3-466P17.1	-5.34	1.15e-07	1.4e-05	-0.19	-0.16	Lobe attachment (rater-scored or self-reported);	chr6:145963424	chr6:145735570~145737218:+
BRCA	cis	rs7577696	0.597	rs212689	ENSG00000272716.1	RP11-563N4.1	5.34	1.15e-07	1.4e-05	0.2	0.16	Inflammatory biomarkers;	chr2:32212269	chr2:32165046~32165757:-
BRCA	cis	rs7577696	0.568	rs462878	ENSG00000272716.1	RP11-563N4.1	5.34	1.15e-07	1.4e-05	0.2	0.16	Inflammatory biomarkers;	chr2:32213586	chr2:32165046~32165757:-
BRCA	cis	rs34286592	1	rs13331733	ENSG00000214725.6	CDIPT-AS1	-5.34	1.15e-07	1.4e-05	-0.27	-0.16	Multiple sclerosis;	chr16:29837096	chr16:29863593~29868053:+
BRCA	cis	rs1075265	0.783	rs805359	ENSG00000235937.1	AC008280.1	5.34	1.15e-07	1.4e-05	0.18	0.16	Chronotype;Morning vs. evening chronotype;	chr2:53935317	chr2:54029552~54030682:-
BRCA	cis	rs7119	0.717	rs12917314	ENSG00000259362.2	RP11-307C19.1	-5.34	1.15e-07	1.4e-05	-0.23	-0.16	Type 2 diabetes;	chr15:77525943	chr15:77525540~77534110:+
BRCA	cis	rs1044826	0.642	rs186103	ENSG00000178631.7	ACTG1P1	5.34	1.15e-07	1.4e-05	0.18	0.16	Obesity-related traits;	chr3:139493100	chr3:139493809~139494937:+
BRCA	cis	rs6479901	0.895	rs7082066	ENSG00000232075.1	MRPL35P2	-5.34	1.15e-07	1.4e-05	-0.23	-0.16	Intelligence (multi-trait analysis);	chr10:63239211	chr10:63634317~63634827:-
BRCA	cis	rs13113518	0.812	rs6830409	ENSG00000272969.1	RP11-528I4.2	5.34	1.15e-07	1.4e-05	0.19	0.16	Height;	chr4:55522229	chr4:55547112~55547889:+
BRCA	cis	rs12439619	0.883	rs62012045	ENSG00000259429.4	UBE2Q2P2	-5.34	1.15e-07	1.4e-05	-0.18	-0.16	Intelligence (multi-trait analysis);	chr15:82229366	chr15:82355142~82420075:+
BRCA	cis	rs6570726	0.791	rs398408	ENSG00000270638.1	RP3-466P17.1	5.34	1.15e-07	1.4e-05	0.19	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145479884	chr6:145735570~145737218:+
BRCA	cis	rs7914558	1	rs3740387	ENSG00000236937.2	PTGES3P4	5.34	1.15e-07	1.4e-05	0.21	0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103089711	chr10:102845595~102845950:+
BRCA	cis	rs7617773	0.778	rs11707997	ENSG00000199476.1	Y_RNA	-5.34	1.15e-07	1.4e-05	-0.25	-0.16	Coronary artery disease;	chr3:48336385	chr3:48288587~48288694:+
BRCA	cis	rs801193	0.569	rs35070132	ENSG00000273448.1	RP11-166O4.6	5.34	1.15e-07	1.4e-05	0.15	0.16	Aortic root size;	chr7:66773096	chr7:67333047~67334383:+
BRCA	cis	rs7302981	0.667	rs7308692	ENSG00000272368.2	RP4-605O3.4	-5.34	1.16e-07	1.4e-05	-0.17	-0.16	Systolic blood pressure;	chr12:50233871	chr12:50112197~50165618:+
BRCA	cis	rs867371	0.929	rs7173852	ENSG00000255769.6	GOLGA2P10	-5.34	1.16e-07	1.41e-05	-0.18	-0.16	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82169512	chr15:82472993~82513950:-
BRCA	cis	rs11009175	0.615	rs7901543	ENSG00000273038.2	RP11-479G22.8	-5.34	1.16e-07	1.41e-05	-0.22	-0.16	Depression (quantitative trait);	chr10:33010385	chr10:32887255~32889311:-
BRCA	cis	rs11009175	0.615	rs6481818	ENSG00000273038.2	RP11-479G22.8	-5.34	1.16e-07	1.41e-05	-0.22	-0.16	Depression (quantitative trait);	chr10:33010428	chr10:32887255~32889311:-
BRCA	cis	rs11009175	0.615	rs6481819	ENSG00000273038.2	RP11-479G22.8	-5.34	1.16e-07	1.41e-05	-0.22	-0.16	Depression (quantitative trait);	chr10:33010531	chr10:32887255~32889311:-
BRCA	cis	rs2834188	1	rs2026254	ENSG00000272659.1	AP000295.10	-5.34	1.16e-07	1.41e-05	-0.24	-0.16	Narcolepsy;	chr21:33315727	chr21:33309491~33310181:+
BRCA	cis	rs9545047	0.567	rs7988331	ENSG00000227354.5	RBM26-AS1	5.34	1.16e-07	1.41e-05	0.17	0.16	Schizophrenia;	chr13:79299745	chr13:79406309~79424328:+
BRCA	cis	rs295490	0.748	rs79854429	ENSG00000272656.1	RP11-219D15.3	5.34	1.16e-07	1.41e-05	0.37	0.16	PR interval in Tripanosoma cruzi seropositivity;	chr3:139512550	chr3:139349024~139349371:-
BRCA	cis	rs2235642	0.75	rs2755185	ENSG00000280231.1	LA16c-380F5.3	-5.34	1.16e-07	1.41e-05	-0.21	-0.16	Coronary artery disease;	chr16:1595826	chr16:1553655~1554130:-
BRCA	cis	rs9545047	0.567	rs2296287	ENSG00000227354.5	RBM26-AS1	5.34	1.16e-07	1.41e-05	0.18	0.16	Schizophrenia;	chr13:79407045	chr13:79406309~79424328:+
BRCA	cis	rs4819052	0.851	rs2236443	ENSG00000184274.3	LINC00315	-5.34	1.16e-07	1.41e-05	-0.22	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258259	chr21:45300245~45305257:-
BRCA	cis	rs8054556	0.669	rs12931955	ENSG00000273724.1	RP11-347C12.12	-5.34	1.16e-07	1.41e-05	-0.18	-0.16	Autism spectrum disorder or schizophrenia;	chr16:30001745	chr16:30336400~30343336:+
BRCA	cis	rs6840360	0.642	rs2709838	ENSG00000278978.1	RP11-164P12.5	-5.34	1.16e-07	1.41e-05	-0.18	-0.16	Intelligence (multi-trait analysis);	chr4:151450212	chr4:151669786~151670503:+
BRCA	cis	rs9880211	0.644	rs35352346	ENSG00000239213.4	NCK1-AS1	5.34	1.16e-07	1.41e-05	0.19	0.16	Height;Body mass index;	chr3:136162646	chr3:136841726~136862054:-
BRCA	cis	rs11159086	0.793	rs28612392	ENSG00000270000.1	RP3-449M8.9	5.34	1.16e-07	1.41e-05	0.25	0.16	Advanced glycation end-product levels;	chr14:74467894	chr14:74471930~74472360:-
BRCA	cis	rs60695258	0.572	rs375795	ENSG00000251411.1	RP11-397E7.4	-5.34	1.16e-07	1.41e-05	-0.18	-0.16	Hematocrit;	chr4:87051313	chr4:86913266~86914817:-
BRCA	cis	rs60695258	0.55	rs2007132	ENSG00000251411.1	RP11-397E7.4	-5.34	1.16e-07	1.41e-05	-0.18	-0.16	Hematocrit;	chr4:87051433	chr4:86913266~86914817:-
BRCA	cis	rs7615952	0.688	rs17334074	ENSG00000171084.14	FAM86JP	-5.34	1.16e-07	1.41e-05	-0.25	-0.16	Blood pressure (smoking interaction);	chr3:125821617	chr3:125916620~125930024:+
BRCA	cis	rs6570726	0.846	rs453834	ENSG00000270638.1	RP3-466P17.1	5.34	1.16e-07	1.41e-05	0.18	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145565125	chr6:145735570~145737218:+
BRCA	cis	rs9545047	0.604	rs6563100	ENSG00000227354.5	RBM26-AS1	5.34	1.16e-07	1.41e-05	0.18	0.16	Schizophrenia;	chr13:79382978	chr13:79406309~79424328:+
BRCA	cis	rs6828666	1	rs6828666	ENSG00000271817.2	U3	-5.34	1.16e-07	1.42e-05	-0.2	-0.16	Depression;	chr4:158858089	chr4:158700691~158700909:+
BRCA	cis	rs6001482	0.679	rs5750786	ENSG00000211642.2	IGLV10-54	5.34	1.17e-07	1.42e-05	0.15	0.16	Diastolic blood pressure;	chr22:22235358	chr22:22214794~22215270:+
BRCA	cis	rs7208859	0.673	rs3816780	ENSG00000265443.1	CTD-2349P21.6	-5.34	1.17e-07	1.42e-05	-0.26	-0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30834340	chr17:30726305~30727564:-
BRCA	cis	rs2562456	0.917	rs2681392	ENSG00000268658.4	LINC00664	-5.34	1.17e-07	1.42e-05	-0.26	-0.16	Pain;	chr19:21513185	chr19:21483374~21503238:+
BRCA	cis	rs7818688	0.653	rs11783522	ENSG00000253528.2	RP11-347C18.4	-5.34	1.17e-07	1.42e-05	-0.23	-0.16	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94874396	chr8:94974573~94974853:-
BRCA	cis	rs8048589	1	rs16958964	ENSG00000175604.2	RP11-276H1.3	-5.34	1.17e-07	1.42e-05	-0.25	-0.16	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);	chr16:12092729	chr16:12086746~12090302:-
BRCA	cis	rs2098713	0.534	rs6867424	ENSG00000250155.1	CTD-2353F22.1	5.34	1.17e-07	1.42e-05	0.18	0.16	Telomere length;	chr5:37534771	chr5:36666214~36725195:-
BRCA	cis	rs13096142	0.516	rs9877860	ENSG00000223552.1	RP11-24F11.2	-5.34	1.17e-07	1.42e-05	-0.21	-0.16	Celiac disease;	chr3:46282580	chr3:46364955~46407059:-
BRCA	cis	rs1075265	0.553	rs2692532	ENSG00000235937.1	AC008280.1	5.34	1.17e-07	1.42e-05	0.18	0.16	Chronotype;Morning vs. evening chronotype;	chr2:53778962	chr2:54029552~54030682:-
BRCA	cis	rs7845219	0.544	rs2123647	ENSG00000253528.2	RP11-347C18.4	-5.34	1.17e-07	1.42e-05	-0.18	-0.16	Type 2 diabetes;	chr8:94919554	chr8:94974573~94974853:-
BRCA	cis	rs7119	0.717	rs11634174	ENSG00000259362.2	RP11-307C19.1	-5.34	1.17e-07	1.42e-05	-0.22	-0.16	Type 2 diabetes;	chr15:77518890	chr15:77525540~77534110:+
BRCA	cis	rs12612619	0.704	rs2119026	ENSG00000229122.1	AGBL5-IT1	-5.33	1.17e-07	1.42e-05	-0.18	-0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27087525	chr2:27061038~27061815:+
BRCA	cis	rs757081	0.636	rs664382	ENSG00000184669.7	OR7E14P	-5.33	1.17e-07	1.42e-05	-0.23	-0.16	Systolic blood pressure;	chr11:17184972	chr11:17013998~17053024:+
BRCA	cis	rs6570726	0.846	rs439035	ENSG00000270638.1	RP3-466P17.1	5.33	1.17e-07	1.42e-05	0.18	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145566854	chr6:145735570~145737218:+
BRCA	cis	rs2732480	0.5	rs1552550	ENSG00000226413.2	OR8T1P	5.33	1.17e-07	1.42e-05	0.22	0.16	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48249568	chr12:48442030~48442947:-
BRCA	cis	rs2732480	0.5	rs2450991	ENSG00000226413.2	OR8T1P	5.33	1.17e-07	1.42e-05	0.22	0.16	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48257838	chr12:48442030~48442947:-
BRCA	cis	rs2303319	0.786	rs62194491	ENSG00000227403.1	AC009299.3	5.33	1.17e-07	1.43e-05	0.4	0.16	Cognitive function;	chr2:161348550	chr2:161244739~161249050:+
BRCA	cis	rs4713118	0.513	rs149942	ENSG00000280107.1	AL022393.9	-5.33	1.17e-07	1.43e-05	-0.22	-0.16	Parkinson's disease;	chr6:28033832	chr6:28170845~28172521:+
BRCA	cis	rs4713118	0.513	rs149944	ENSG00000280107.1	AL022393.9	-5.33	1.17e-07	1.43e-05	-0.22	-0.16	Parkinson's disease;	chr6:28035040	chr6:28170845~28172521:+
BRCA	cis	rs4713118	0.513	rs149945	ENSG00000280107.1	AL022393.9	-5.33	1.17e-07	1.43e-05	-0.22	-0.16	Parkinson's disease;	chr6:28035075	chr6:28170845~28172521:+
BRCA	cis	rs60695258	0.55	rs6531948	ENSG00000251411.1	RP11-397E7.4	-5.33	1.17e-07	1.43e-05	-0.18	-0.16	Hematocrit;	chr4:87051816	chr4:86913266~86914817:-
BRCA	cis	rs7615952	0.515	rs7637246	ENSG00000250012.1	RP11-124N2.1	-5.33	1.17e-07	1.43e-05	-0.22	-0.16	Blood pressure (smoking interaction);	chr3:125959863	chr3:126084220~126095349:+
BRCA	cis	rs16846053	0.71	rs7581747	ENSG00000227403.1	AC009299.3	-5.33	1.18e-07	1.43e-05	-0.26	-0.16	Blood osmolality (transformed sodium);	chr2:161758605	chr2:161244739~161249050:+
BRCA	cis	rs10392	0.571	rs4812335	ENSG00000274825.1	RP4-616B8.5	-5.33	1.18e-07	1.43e-05	-0.16	-0.16	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;	chr20:38908969	chr20:38955910~38956547:+
BRCA	cis	rs9784649	0.76	rs17343923	ENSG00000245662.2	RP11-184E9.1	5.33	1.18e-07	1.43e-05	0.25	0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr5:25052305	chr5:25190682~25306172:+
BRCA	cis	rs7119	0.717	rs12904584	ENSG00000259362.2	RP11-307C19.1	-5.33	1.18e-07	1.43e-05	-0.23	-0.16	Type 2 diabetes;	chr15:77523649	chr15:77525540~77534110:+
BRCA	cis	rs7119	0.717	rs11636529	ENSG00000259362.2	RP11-307C19.1	-5.33	1.18e-07	1.43e-05	-0.23	-0.16	Type 2 diabetes;	chr15:77523878	chr15:77525540~77534110:+
BRCA	cis	rs7119	0.717	rs11631274	ENSG00000259362.2	RP11-307C19.1	-5.33	1.18e-07	1.43e-05	-0.23	-0.16	Type 2 diabetes;	chr15:77524089	chr15:77525540~77534110:+
BRCA	cis	rs7119	0.717	rs7176307	ENSG00000259362.2	RP11-307C19.1	-5.33	1.18e-07	1.43e-05	-0.23	-0.16	Type 2 diabetes;	chr15:77524342	chr15:77525540~77534110:+
BRCA	cis	rs7119	0.717	rs12909645	ENSG00000259362.2	RP11-307C19.1	-5.33	1.18e-07	1.43e-05	-0.23	-0.16	Type 2 diabetes;	chr15:77524477	chr15:77525540~77534110:+
BRCA	cis	rs7119	0.679	rs12909808	ENSG00000259362.2	RP11-307C19.1	-5.33	1.18e-07	1.43e-05	-0.23	-0.16	Type 2 diabetes;	chr15:77524602	chr15:77525540~77534110:+
BRCA	cis	rs7119	0.717	rs12910594	ENSG00000259362.2	RP11-307C19.1	-5.33	1.18e-07	1.43e-05	-0.23	-0.16	Type 2 diabetes;	chr15:77524761	chr15:77525540~77534110:+
BRCA	cis	rs7119	0.717	rs12910513	ENSG00000259362.2	RP11-307C19.1	-5.33	1.18e-07	1.43e-05	-0.23	-0.16	Type 2 diabetes;	chr15:77524916	chr15:77525540~77534110:+
BRCA	cis	rs7119	0.717	rs12910975	ENSG00000259362.2	RP11-307C19.1	-5.33	1.18e-07	1.43e-05	-0.23	-0.16	Type 2 diabetes;	chr15:77525145	chr15:77525540~77534110:+
BRCA	cis	rs7119	0.717	rs12912386	ENSG00000259362.2	RP11-307C19.1	-5.33	1.18e-07	1.43e-05	-0.23	-0.16	Type 2 diabetes;	chr15:77525298	chr15:77525540~77534110:+
BRCA	cis	rs7119	0.717	rs62009069	ENSG00000259362.2	RP11-307C19.1	-5.33	1.18e-07	1.43e-05	-0.23	-0.16	Type 2 diabetes;	chr15:77525535	chr15:77525540~77534110:+
BRCA	cis	rs7119	0.717	rs62009070	ENSG00000259362.2	RP11-307C19.1	-5.33	1.18e-07	1.43e-05	-0.23	-0.16	Type 2 diabetes;	chr15:77525542	chr15:77525540~77534110:+
BRCA	cis	rs7119	0.717	rs62009071	ENSG00000259362.2	RP11-307C19.1	-5.33	1.18e-07	1.43e-05	-0.23	-0.16	Type 2 diabetes;	chr15:77525544	chr15:77525540~77534110:+
BRCA	cis	rs11098499	0.754	rs714899	ENSG00000249244.1	RP11-548H18.2	5.33	1.18e-07	1.43e-05	0.19	0.16	Corneal astigmatism;	chr4:119321880	chr4:119391831~119395335:-
BRCA	cis	rs1707322	0.656	rs9429172	ENSG00000234329.1	RP11-767N6.2	-5.33	1.18e-07	1.43e-05	-0.17	-0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45626804	chr1:45651039~45651826:-
BRCA	cis	rs8030379	0.667	rs4842921	ENSG00000230373.7	GOLGA6L5P	-5.33	1.18e-07	1.43e-05	-0.17	-0.16	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83887871	chr15:84507885~84516814:-
BRCA	cis	rs7923837	0.651	rs1573051	ENSG00000236493.2	EIF2S2P3	5.33	1.18e-07	1.43e-05	0.23	0.16	Multiple sclerosis;Body mass index;	chr10:92627577	chr10:92668745~92669743:-
BRCA	cis	rs6439153	1	rs6439153	ENSG00000231305.3	RP11-723O4.2	5.33	1.18e-07	1.43e-05	0.19	0.16	Pneumococcal bacteremia;	chr3:128982287	chr3:128861313~128871540:-
BRCA	cis	rs2790457	0.958	rs2790455	ENSG00000254635.4	WAC-AS1	-5.33	1.18e-07	1.43e-05	-0.2	-0.16	Multiple myeloma;	chr10:28558148	chr10:28522652~28532743:-
BRCA	cis	rs1387259	0.859	rs2054905	ENSG00000226413.2	OR8T1P	5.33	1.18e-07	1.43e-05	0.22	0.16	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48294168	chr12:48442030~48442947:-
BRCA	cis	rs1193	0.837	rs4832311	ENSG00000231259.4	AC125232.1	-5.33	1.18e-07	1.43e-05	-0.2	-0.16	High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;High light scatter reticulocyte count;	chr2:86751772	chr2:87031815~87053069:-
BRCA	cis	rs2098713	0.569	rs477420	ENSG00000250155.1	CTD-2353F22.1	5.33	1.18e-07	1.43e-05	0.19	0.16	Telomere length;	chr5:37541476	chr5:36666214~36725195:-
BRCA	cis	rs2638953	0.925	rs7312201	ENSG00000278733.1	RP11-425D17.1	-5.33	1.18e-07	1.43e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28417885	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.962	rs12372172	ENSG00000278733.1	RP11-425D17.1	-5.33	1.18e-07	1.43e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28419945	chr12:28185625~28186190:-
BRCA	cis	rs62025270	0.688	rs7164373	ENSG00000259295.5	CSPG4P12	-5.33	1.18e-07	1.43e-05	-0.25	-0.16	Idiopathic pulmonary fibrosis;	chr15:85722432	chr15:85191438~85213905:+
BRCA	cis	rs7617773	0.78	rs13079728	ENSG00000199476.1	Y_RNA	-5.33	1.18e-07	1.43e-05	-0.25	-0.16	Coronary artery disease;	chr3:48297870	chr3:48288587~48288694:+
BRCA	cis	rs3758911	0.713	rs10890678	ENSG00000255353.1	RP11-382M14.1	-5.33	1.18e-07	1.43e-05	-0.21	-0.16	Coronary artery disease;	chr11:107255043	chr11:107176286~107177530:+
BRCA	cis	rs6832769	0.961	rs2177127	ENSG00000272969.1	RP11-528I4.2	5.33	1.18e-07	1.43e-05	0.2	0.16	Personality dimensions;	chr4:55513792	chr4:55547112~55547889:+
BRCA	cis	rs4604234	0.803	rs3812124	ENSG00000272129.1	RP11-250B2.6	-5.33	1.18e-07	1.43e-05	-0.4	-0.16	Cancer;	chr6:80248451	chr6:80355424~80356859:+
BRCA	cis	rs467650	0.683	rs251534	ENSG00000248489.1	CTD-2007H13.3	5.33	1.18e-07	1.43e-05	0.18	0.16	Venous thromboembolism (SNP x SNP interaction);	chr5:98598221	chr5:98929171~98995013:+
BRCA	cis	rs2834188	1	rs2096464	ENSG00000272659.1	AP000295.10	5.33	1.18e-07	1.44e-05	0.24	0.16	Narcolepsy;	chr21:33313744	chr21:33309491~33310181:+
BRCA	cis	rs11955398	0.502	rs290513	ENSG00000215032.2	GNL3LP1	5.33	1.18e-07	1.44e-05	0.21	0.16	Intelligence (multi-trait analysis);	chr5:61014936	chr5:60891935~60893577:-
BRCA	cis	rs11955398	0.502	rs248688	ENSG00000215032.2	GNL3LP1	5.33	1.18e-07	1.44e-05	0.21	0.16	Intelligence (multi-trait analysis);	chr5:61021606	chr5:60891935~60893577:-
BRCA	cis	rs6832769	0.922	rs28665088	ENSG00000223305.1	RN7SKP30	5.33	1.19e-07	1.44e-05	0.21	0.16	Personality dimensions;	chr4:55384913	chr4:55540502~55540835:-
BRCA	cis	rs748404	0.55	rs12912505	ENSG00000205771.5	CATSPER2P1	-5.33	1.19e-07	1.44e-05	-0.25	-0.16	Lung cancer;	chr15:43525206	chr15:43726918~43747094:-
BRCA	cis	rs893971	0.508	rs1440581	ENSG00000246375.2	RP11-10L7.1	5.33	1.19e-07	1.44e-05	0.2	0.16	Conduct disorder (maternal expressed emotions interaction);	chr4:88305270	chr4:88284942~88331421:+
BRCA	cis	rs3733585	0.699	rs2018643	ENSG00000250413.1	RP11-448G15.1	-5.33	1.19e-07	1.44e-05	-0.21	-0.16	Cleft plate (environmental tobacco smoke interaction);	chr4:9945497	chr4:10006482~10009725:+
BRCA	cis	rs7208859	0.623	rs9914242	ENSG00000266490.1	CTD-2349P21.9	5.33	1.19e-07	1.44e-05	0.24	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30889227	chr17:30792372~30792833:+
BRCA	cis	rs7246657	0.525	rs10401417	ENSG00000226686.6	LINC01535	-5.33	1.19e-07	1.44e-05	-0.27	-0.16	Coronary artery calcification;	chr19:36976638	chr19:37251912~37265535:+
BRCA	cis	rs78545713	0.502	rs3823157	ENSG00000241549.7	GUSBP2	-5.33	1.19e-07	1.44e-05	-0.22	-0.16	Iron status biomarkers (total iron binding capacity);	chr6:26271811	chr6:26871484~26956554:-
BRCA	cis	rs4713118	0.869	rs9468214	ENSG00000216901.1	AL022393.7	5.33	1.19e-07	1.44e-05	0.22	0.16	Parkinson's disease;	chr6:27745520	chr6:28176188~28176674:+
BRCA	cis	rs4819052	0.851	rs875621	ENSG00000184274.3	LINC00315	-5.33	1.19e-07	1.44e-05	-0.22	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45262380	chr21:45300245~45305257:-
BRCA	cis	rs2403083	0.522	rs28377260	ENSG00000258256.1	RP11-219B4.5	-5.33	1.19e-07	1.44e-05	-0.2	-0.16	Plasma amyloid beta peptide concentrations (ABx-40);	chr8:85216055	chr8:85222446~85245717:-
BRCA	cis	rs2834188	1	rs4408796	ENSG00000272659.1	AP000295.10	5.33	1.19e-07	1.44e-05	0.24	0.16	Narcolepsy;	chr21:33326436	chr21:33309491~33310181:+
BRCA	cis	rs7200543	1	rs6498540	ENSG00000260735.1	RP11-72I8.1	-5.33	1.19e-07	1.44e-05	-0.19	-0.16	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15036737	chr16:15094411~15109197:+
BRCA	cis	rs7200543	1	rs16966953	ENSG00000260872.1	RP11-680G24.5	-5.33	1.19e-07	1.44e-05	-0.17	-0.16	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15041997	chr16:15018106~15020488:-
BRCA	cis	rs1075265	0.621	rs2542593	ENSG00000235937.1	AC008280.1	5.33	1.19e-07	1.44e-05	0.18	0.16	Chronotype;Morning vs. evening chronotype;	chr2:53804299	chr2:54029552~54030682:-
BRCA	cis	rs4713118	0.597	rs172166	ENSG00000204709.4	LINC01556	5.33	1.19e-07	1.44e-05	0.24	0.16	Parkinson's disease;	chr6:28053042	chr6:28943877~28944537:+
BRCA	cis	rs4908768	0.52	rs6681362	ENSG00000232912.4	RP5-1115A15.1	5.33	1.19e-07	1.44e-05	0.16	0.16	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8598468	chr1:8424645~8434838:+
BRCA	cis	rs4908768	0.539	rs1318218	ENSG00000232912.4	RP5-1115A15.1	5.33	1.19e-07	1.44e-05	0.16	0.16	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8598653	chr1:8424645~8434838:+
BRCA	cis	rs9307551	0.584	rs6534429	ENSG00000250334.4	LINC00989	-5.33	1.19e-07	1.44e-05	-0.22	-0.16	Refractive error;	chr4:79543006	chr4:79492416~79576460:+
BRCA	cis	rs7945705	0.782	rs3763918	ENSG00000254860.4	TMEM9B-AS1	-5.33	1.19e-07	1.44e-05	-0.15	-0.16	Hemoglobin concentration;	chr11:8798136	chr11:8964675~8977527:+
BRCA	cis	rs13118159	0.55	rs28733902	ENSG00000254094.1	AC078852.1	-5.33	1.19e-07	1.44e-05	-0.2	-0.16	Longevity;	chr4:1381001	chr4:1356581~1358075:+
BRCA	cis	rs60695258	0.517	rs867196	ENSG00000251411.1	RP11-397E7.4	-5.33	1.19e-07	1.45e-05	-0.18	-0.16	Hematocrit;	chr4:87050448	chr4:86913266~86914817:-
BRCA	cis	rs2919009	0.551	rs7080781	ENSG00000271670.1	RP11-95I16.4	5.33	1.19e-07	1.45e-05	0.21	0.16	Obesity-related traits;	chr10:120962171	chr10:120879256~120880667:-
BRCA	cis	rs7665090	0.517	rs1585214	ENSG00000246560.2	RP11-10L12.4	5.33	1.19e-07	1.45e-05	0.18	0.16	Primary biliary cholangitis;	chr4:102523376	chr4:102828055~102844075:+
BRCA	cis	rs8002861	0.967	rs9525871	ENSG00000274001.1	RP11-5G9.5	5.33	1.19e-07	1.45e-05	0.18	0.16	Leprosy;	chr13:43903576	chr13:43877715~43878163:-
BRCA	cis	rs828999	0.654	rs9325363	ENSG00000280186.1	RP11-483I13.6	5.33	1.19e-07	1.45e-05	0.18	0.16	Monocyte percentage of white cells;	chr1:108170935	chr1:108200413~108202743:+
BRCA	cis	rs2638953	0.853	rs10843185	ENSG00000247934.4	RP11-967K21.1	-5.33	1.19e-07	1.45e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28473778	chr12:28163298~28190738:-
BRCA	cis	rs7577696	0.752	rs12995952	ENSG00000272716.1	RP11-563N4.1	-5.33	1.19e-07	1.45e-05	-0.19	-0.16	Inflammatory biomarkers;	chr2:32148229	chr2:32165046~32165757:-
BRCA	cis	rs6832769	1	rs28572116	ENSG00000272969.1	RP11-528I4.2	-5.33	1.2e-07	1.45e-05	-0.2	-0.16	Personality dimensions;	chr4:55558177	chr4:55547112~55547889:+
BRCA	cis	rs2732480	0.5	rs7966829	ENSG00000226413.2	OR8T1P	5.33	1.2e-07	1.45e-05	0.22	0.16	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48221820	chr12:48442030~48442947:-
BRCA	cis	rs2834188	0.883	rs16997869	ENSG00000272659.1	AP000295.10	5.33	1.2e-07	1.45e-05	0.24	0.16	Narcolepsy;	chr21:33324562	chr21:33309491~33310181:+
BRCA	cis	rs2803122	0.807	rs10757035	ENSG00000273226.1	RP11-513M16.8	-5.33	1.2e-07	1.45e-05	-0.17	-0.16	Pulse pressure;	chr9:19230274	chr9:19375451~19375996:+
BRCA	cis	rs1075265	0.633	rs7564912	ENSG00000235937.1	AC008280.1	5.33	1.2e-07	1.45e-05	0.18	0.16	Chronotype;Morning vs. evening chronotype;	chr2:53995048	chr2:54029552~54030682:-
BRCA	cis	rs6832769	0.857	rs61072181	ENSG00000272969.1	RP11-528I4.2	-5.33	1.2e-07	1.45e-05	-0.2	-0.16	Personality dimensions;	chr4:55617210	chr4:55547112~55547889:+
BRCA	cis	rs11009175	0.615	rs6481817	ENSG00000273038.2	RP11-479G22.8	-5.33	1.2e-07	1.45e-05	-0.22	-0.16	Depression (quantitative trait);	chr10:33010319	chr10:32887255~32889311:-
BRCA	cis	rs1426063	0.858	rs55775471	ENSG00000260265.1	RP11-44F21.5	5.33	1.2e-07	1.45e-05	0.27	0.16	QT interval;	chr4:75081074	chr4:75081702~75084717:-
BRCA	cis	rs7577696	0.962	rs212739	ENSG00000272716.1	RP11-563N4.1	5.33	1.2e-07	1.45e-05	0.18	0.16	Inflammatory biomarkers;	chr2:32179634	chr2:32165046~32165757:-
BRCA	cis	rs7620503	0.917	rs6443469	ENSG00000228221.4	LINC00578	5.33	1.2e-07	1.45e-05	0.19	0.16	Corneal structure;	chr3:177568667	chr3:177441921~177752305:+
BRCA	cis	rs7208859	0.623	rs11658022	ENSG00000280069.1	CTD-2349P21.3	-5.33	1.2e-07	1.45e-05	-0.25	-0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30758341	chr17:30738182~30740275:+
BRCA	cis	rs950880	0.767	rs12712142	ENSG00000234389.1	AC007278.3	5.33	1.2e-07	1.45e-05	0.15	0.16	Serum protein levels (sST2);	chr2:102344124	chr2:102438713~102440475:+
BRCA	cis	rs875971	0.898	rs6977501	ENSG00000223473.2	GS1-124K5.3	-5.33	1.2e-07	1.45e-05	-0.13	-0.16	Aortic root size;	chr7:66228355	chr7:66491049~66493566:-
BRCA	cis	rs6840360	0.642	rs7682837	ENSG00000278978.1	RP11-164P12.5	-5.33	1.2e-07	1.45e-05	-0.18	-0.16	Intelligence (multi-trait analysis);	chr4:151506534	chr4:151669786~151670503:+
BRCA	cis	rs7045881	0.825	rs10967625	ENSG00000254396.1	RP11-56F10.3	5.33	1.2e-07	1.45e-05	0.26	0.16	Schizophrenia;	chr9:26962490	chr9:27102630~27104728:+
BRCA	cis	rs7045881	0.799	rs12352441	ENSG00000254396.1	RP11-56F10.3	5.33	1.2e-07	1.45e-05	0.26	0.16	Schizophrenia;	chr9:26962771	chr9:27102630~27104728:+
BRCA	cis	rs863750	0.744	rs825459	ENSG00000275389.1	RP11-214K3.24	5.33	1.2e-07	1.45e-05	0.21	0.16	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-hip ratio;	chr12:124056537	chr12:124085761~124088598:+
BRCA	cis	rs1322639	0.614	rs9689800	ENSG00000261039.2	RP11-417E7.2	5.33	1.2e-07	1.45e-05	0.15	0.16	Pulse pressure;	chr6:169172850	chr6:169175304~169182740:-
BRCA	cis	rs10510102	0.935	rs7907871	ENSG00000226864.1	ATE1-AS1	5.33	1.2e-07	1.46e-05	0.29	0.16	Breast cancer;	chr10:121878185	chr10:121928312~121951965:+
BRCA	cis	rs55702914	0.712	rs12619296	ENSG00000231621.1	AC013264.2	5.33	1.2e-07	1.46e-05	0.15	0.16	Major depression and alcohol dependence;	chr2:197284043	chr2:197197991~197199273:+
BRCA	cis	rs2904967	1	rs2904967	ENSG00000254614.2	AP003068.23	5.33	1.2e-07	1.46e-05	0.3	0.16	Mean corpuscular volume;	chr11:65324138	chr11:65177606~65181834:-
BRCA	cis	rs7617773	0.817	rs11707606	ENSG00000199476.1	Y_RNA	-5.33	1.2e-07	1.46e-05	-0.24	-0.16	Coronary artery disease;	chr3:48195597	chr3:48288587~48288694:+
BRCA	cis	rs1722141	0.634	rs2453850	ENSG00000237471.1	AC073115.6	5.33	1.2e-07	1.46e-05	0.24	0.16	Sitting height ratio;	chr7:45941135	chr7:45969657~45980191:+
BRCA	cis	rs2638953	0.853	rs11049636	ENSG00000247934.4	RP11-967K21.1	-5.33	1.2e-07	1.46e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28465728	chr12:28163298~28190738:-
BRCA	cis	rs6441961	0.55	rs3918361	ENSG00000223552.1	RP11-24F11.2	5.33	1.2e-07	1.46e-05	0.2	0.16	Celiac disease;	chr3:46354295	chr3:46364955~46407059:-
BRCA	cis	rs6496044	0.568	rs12708554	ENSG00000259295.5	CSPG4P12	5.33	1.2e-07	1.46e-05	0.2	0.16	Interstitial lung disease;	chr15:85531066	chr15:85191438~85213905:+
BRCA	cis	rs7119	0.717	rs12911854	ENSG00000259362.2	RP11-307C19.1	-5.33	1.2e-07	1.46e-05	-0.23	-0.16	Type 2 diabetes;	chr15:77524946	chr15:77525540~77534110:+
BRCA	cis	rs6840360	0.642	rs2724580	ENSG00000278978.1	RP11-164P12.5	-5.33	1.2e-07	1.46e-05	-0.18	-0.16	Intelligence (multi-trait analysis);	chr4:151451353	chr4:151669786~151670503:+
BRCA	cis	rs10129255	0.957	rs10142918	ENSG00000280411.1	IGHV1-69-2	-5.33	1.2e-07	1.46e-05	-0.12	-0.16	Kawasaki disease;	chr14:106782206	chr14:106762092~106762588:-
BRCA	cis	rs9545047	0.604	rs1748761	ENSG00000227354.5	RBM26-AS1	5.33	1.2e-07	1.46e-05	0.18	0.16	Schizophrenia;	chr13:79407491	chr13:79406309~79424328:+
BRCA	cis	rs9545047	0.604	rs2763809	ENSG00000227354.5	RBM26-AS1	5.33	1.2e-07	1.46e-05	0.18	0.16	Schizophrenia;	chr13:79407544	chr13:79406309~79424328:+
BRCA	cis	rs9545047	0.604	rs1748762	ENSG00000227354.5	RBM26-AS1	5.33	1.2e-07	1.46e-05	0.18	0.16	Schizophrenia;	chr13:79407914	chr13:79406309~79424328:+
BRCA	cis	rs9545047	0.604	rs1748763	ENSG00000227354.5	RBM26-AS1	5.33	1.2e-07	1.46e-05	0.18	0.16	Schizophrenia;	chr13:79407965	chr13:79406309~79424328:+
BRCA	cis	rs11159086	1	rs8006958	ENSG00000270000.1	RP3-449M8.9	5.33	1.21e-07	1.46e-05	0.26	0.16	Advanced glycation end-product levels;	chr14:74478148	chr14:74471930~74472360:-
BRCA	cis	rs7927771	0.524	rs1056387	ENSG00000280615.1	Y_RNA	5.33	1.21e-07	1.46e-05	0.19	0.16	Subjective well-being;	chr11:47659818	chr11:47614898~47614994:-
BRCA	cis	rs1707322	1	rs10890365	ENSG00000234329.1	RP11-767N6.2	5.33	1.21e-07	1.46e-05	0.17	0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45893676	chr1:45651039~45651826:-
BRCA	cis	rs3760982	0.585	rs10422108	ENSG00000267058.1	RP11-15A1.3	-5.33	1.21e-07	1.46e-05	-0.19	-0.16	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43790716	chr19:43891804~43901805:-
BRCA	cis	rs763121	0.853	rs5757232	ENSG00000228274.3	RP3-508I15.9	-5.33	1.21e-07	1.46e-05	-0.18	-0.16	Menopause (age at onset);	chr22:38675672	chr22:38667585~38681820:-
BRCA	cis	rs1555322	0.932	rs1205411	ENSG00000126005.14	MMP24-AS1	-5.33	1.21e-07	1.46e-05	-0.27	-0.16	Attention deficit hyperactivity disorder;	chr20:35269439	chr20:35216462~35278131:-
BRCA	cis	rs2638953	0.924	rs7955118	ENSG00000247934.4	RP11-967K21.1	-5.33	1.21e-07	1.46e-05	-0.23	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28157159	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.924	rs7955237	ENSG00000247934.4	RP11-967K21.1	-5.33	1.21e-07	1.46e-05	-0.23	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28157272	chr12:28163298~28190738:-
BRCA	cis	rs2562456	0.876	rs11085465	ENSG00000268535.1	RP11-420K14.3	-5.33	1.21e-07	1.46e-05	-0.22	-0.16	Pain;	chr19:21568988	chr19:21709522~21710191:+
BRCA	cis	rs4781563	0.843	rs3136168	ENSG00000242307.1	RPS26P52	-5.33	1.21e-07	1.46e-05	-0.19	-0.16	Bilirubin levels;	chr16:13938597	chr16:13922332~13922679:-
BRCA	cis	rs9467773	1	rs9467779	ENSG00000124549.13	BTN2A3P	-5.33	1.21e-07	1.46e-05	-0.16	-0.16	Intelligence (multi-trait analysis);	chr6:26536459	chr6:26421391~26432383:+
BRCA	cis	rs875971	0.66	rs2013222	ENSG00000273024.4	INTS4P2	5.33	1.21e-07	1.46e-05	0.17	0.16	Aortic root size;	chr7:66570949	chr7:65647864~65715661:+
BRCA	cis	rs7617773	0.778	rs11715776	ENSG00000199476.1	Y_RNA	-5.33	1.21e-07	1.47e-05	-0.25	-0.16	Coronary artery disease;	chr3:48336121	chr3:48288587~48288694:+
BRCA	cis	rs2638953	0.924	rs11049507	ENSG00000247934.4	RP11-967K21.1	-5.33	1.21e-07	1.47e-05	-0.23	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28289554	chr12:28163298~28190738:-
BRCA	cis	rs2790457	0.958	rs2807754	ENSG00000254635.4	WAC-AS1	-5.33	1.21e-07	1.47e-05	-0.2	-0.16	Multiple myeloma;	chr10:28598263	chr10:28522652~28532743:-
BRCA	cis	rs12712135	0.709	rs11465728	ENSG00000234389.1	AC007278.3	-5.33	1.21e-07	1.47e-05	-0.15	-0.16	Blood protein levels;	chr2:102448051	chr2:102438713~102440475:+
BRCA	cis	rs934734	0.673	rs7575614	ENSG00000281920.1	RP11-418H16.1	5.33	1.21e-07	1.47e-05	0.19	0.16	Rheumatoid arthritis;	chr2:65462666	chr2:65623272~65628424:+
BRCA	cis	rs10911232	0.507	rs4575047	ENSG00000224468.3	RP11-181K3.4	-5.33	1.21e-07	1.47e-05	-0.17	-0.16	Hypertriglyceridemia;	chr1:183006893	chr1:183138402~183141282:-
BRCA	cis	rs10911232	0.507	rs4596846	ENSG00000224468.3	RP11-181K3.4	-5.33	1.21e-07	1.47e-05	-0.17	-0.16	Hypertriglyceridemia;	chr1:183006899	chr1:183138402~183141282:-
BRCA	cis	rs7572733	0.534	rs6434943	ENSG00000231621.1	AC013264.2	-5.33	1.21e-07	1.47e-05	-0.16	-0.16	Dermatomyositis;	chr2:197897468	chr2:197197991~197199273:+
BRCA	cis	rs6840360	0.617	rs2724563	ENSG00000278978.1	RP11-164P12.5	-5.33	1.21e-07	1.47e-05	-0.18	-0.16	Intelligence (multi-trait analysis);	chr4:151428807	chr4:151669786~151670503:+
BRCA	cis	rs6840360	0.617	rs2724564	ENSG00000278978.1	RP11-164P12.5	-5.33	1.21e-07	1.47e-05	-0.18	-0.16	Intelligence (multi-trait analysis);	chr4:151428810	chr4:151669786~151670503:+
BRCA	cis	rs559555	0.888	rs10207755	ENSG00000272716.1	RP11-563N4.1	5.33	1.21e-07	1.47e-05	0.18	0.16	Blood metabolite ratios;Blood metabolite levels;	chr2:31571900	chr2:32165046~32165757:-
BRCA	cis	rs4907240	0.961	rs10460601	ENSG00000237510.6	AC008268.2	-5.33	1.21e-07	1.47e-05	-0.23	-0.16	Event-related brain oscillations;	chr2:96586707	chr2:95789654~95800166:+
BRCA	cis	rs3733585	0.598	rs28677023	ENSG00000250413.1	RP11-448G15.1	5.33	1.21e-07	1.47e-05	0.21	0.16	Cleft plate (environmental tobacco smoke interaction);	chr4:9956702	chr4:10006482~10009725:+
BRCA	cis	rs3733585	0.664	rs28602527	ENSG00000250413.1	RP11-448G15.1	5.33	1.21e-07	1.47e-05	0.21	0.16	Cleft plate (environmental tobacco smoke interaction);	chr4:9956703	chr4:10006482~10009725:+
BRCA	cis	rs3733585	0.699	rs6815001	ENSG00000250413.1	RP11-448G15.1	5.33	1.21e-07	1.47e-05	0.21	0.16	Cleft plate (environmental tobacco smoke interaction);	chr4:9957038	chr4:10006482~10009725:+
BRCA	cis	rs3733585	0.673	rs6849729	ENSG00000250413.1	RP11-448G15.1	5.33	1.21e-07	1.47e-05	0.21	0.16	Cleft plate (environmental tobacco smoke interaction);	chr4:9957108	chr4:10006482~10009725:+
BRCA	cis	rs3733585	0.673	rs6850143	ENSG00000250413.1	RP11-448G15.1	5.33	1.21e-07	1.47e-05	0.21	0.16	Cleft plate (environmental tobacco smoke interaction);	chr4:9957300	chr4:10006482~10009725:+
BRCA	cis	rs3733585	0.699	rs6844316	ENSG00000250413.1	RP11-448G15.1	5.33	1.21e-07	1.47e-05	0.21	0.16	Cleft plate (environmental tobacco smoke interaction);	chr4:9957353	chr4:10006482~10009725:+
BRCA	cis	rs3733585	0.699	rs6834893	ENSG00000250413.1	RP11-448G15.1	5.33	1.21e-07	1.47e-05	0.21	0.16	Cleft plate (environmental tobacco smoke interaction);	chr4:9957499	chr4:10006482~10009725:+
BRCA	cis	rs3733585	0.699	rs6844787	ENSG00000250413.1	RP11-448G15.1	5.33	1.21e-07	1.47e-05	0.21	0.16	Cleft plate (environmental tobacco smoke interaction);	chr4:9957609	chr4:10006482~10009725:+
BRCA	cis	rs3733585	0.648	rs28513781	ENSG00000250413.1	RP11-448G15.1	5.33	1.21e-07	1.47e-05	0.21	0.16	Cleft plate (environmental tobacco smoke interaction);	chr4:9957710	chr4:10006482~10009725:+
BRCA	cis	rs3733585	0.699	rs4515163	ENSG00000250413.1	RP11-448G15.1	5.33	1.21e-07	1.47e-05	0.21	0.16	Cleft plate (environmental tobacco smoke interaction);	chr4:9957979	chr4:10006482~10009725:+
BRCA	cis	rs3733585	0.699	rs62294331	ENSG00000250413.1	RP11-448G15.1	5.33	1.21e-07	1.47e-05	0.21	0.16	Cleft plate (environmental tobacco smoke interaction);	chr4:9958265	chr4:10006482~10009725:+
BRCA	cis	rs3733585	0.699	rs62294332	ENSG00000250413.1	RP11-448G15.1	5.33	1.21e-07	1.47e-05	0.21	0.16	Cleft plate (environmental tobacco smoke interaction);	chr4:9958365	chr4:10006482~10009725:+
BRCA	cis	rs3733585	0.699	rs57574512	ENSG00000250413.1	RP11-448G15.1	5.33	1.21e-07	1.47e-05	0.21	0.16	Cleft plate (environmental tobacco smoke interaction);	chr4:9958558	chr4:10006482~10009725:+
BRCA	cis	rs3733585	0.699	rs6449159	ENSG00000250413.1	RP11-448G15.1	5.33	1.21e-07	1.47e-05	0.21	0.16	Cleft plate (environmental tobacco smoke interaction);	chr4:9958874	chr4:10006482~10009725:+
BRCA	cis	rs3733585	0.699	rs4588456	ENSG00000250413.1	RP11-448G15.1	5.33	1.21e-07	1.47e-05	0.21	0.16	Cleft plate (environmental tobacco smoke interaction);	chr4:9962271	chr4:10006482~10009725:+
BRCA	cis	rs3733585	0.673	rs6836706	ENSG00000250413.1	RP11-448G15.1	5.33	1.21e-07	1.47e-05	0.21	0.16	Cleft plate (environmental tobacco smoke interaction);	chr4:9962627	chr4:10006482~10009725:+
BRCA	cis	rs3733585	0.673	rs10018204	ENSG00000250413.1	RP11-448G15.1	5.33	1.21e-07	1.47e-05	0.21	0.16	Cleft plate (environmental tobacco smoke interaction);	chr4:9962946	chr4:10006482~10009725:+
BRCA	cis	rs3733585	0.699	rs28613263	ENSG00000250413.1	RP11-448G15.1	5.33	1.21e-07	1.47e-05	0.21	0.16	Cleft plate (environmental tobacco smoke interaction);	chr4:9963256	chr4:10006482~10009725:+
BRCA	cis	rs4835473	0.9	rs71612420	ENSG00000249741.2	RP11-673E1.3	5.33	1.21e-07	1.47e-05	0.18	0.16	Immature fraction of reticulocytes;	chr4:143779107	chr4:143911514~143912053:-
BRCA	cis	rs4835473	0.9	rs13134869	ENSG00000249741.2	RP11-673E1.3	5.33	1.21e-07	1.47e-05	0.18	0.16	Immature fraction of reticulocytes;	chr4:143782301	chr4:143911514~143912053:-
BRCA	cis	rs7200543	1	rs1136001	ENSG00000258354.1	MIR3180-1	-5.33	1.21e-07	1.47e-05	-0.22	-0.16	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15038117	chr16:14909887~14911345:-
BRCA	cis	rs10129255	0.957	rs10150241	ENSG00000211974.3	IGHV2-70	-5.33	1.22e-07	1.47e-05	-0.16	-0.16	Kawasaki disease;	chr14:106775945	chr14:106723574~106724093:-
BRCA	cis	rs9545047	0.604	rs9545104	ENSG00000227354.5	RBM26-AS1	5.33	1.22e-07	1.47e-05	0.18	0.16	Schizophrenia;	chr13:79404000	chr13:79406309~79424328:+
BRCA	cis	rs9545047	0.604	rs9545106	ENSG00000227354.5	RBM26-AS1	5.33	1.22e-07	1.47e-05	0.18	0.16	Schizophrenia;	chr13:79404130	chr13:79406309~79424328:+
BRCA	cis	rs2243480	1	rs410128	ENSG00000232559.3	GS1-124K5.12	5.33	1.22e-07	1.47e-05	0.32	0.16	Diabetic kidney disease;	chr7:66138186	chr7:66554588~66576923:-
BRCA	cis	rs1552244	1	rs7628448	ENSG00000232901.1	CYCSP10	5.33	1.22e-07	1.47e-05	0.23	0.16	Alzheimer's disease;	chr3:10105144	chr3:10000647~10000940:-
BRCA	cis	rs4713118	0.662	rs149961	ENSG00000204709.4	LINC01556	5.33	1.22e-07	1.47e-05	0.24	0.16	Parkinson's disease;	chr6:28047791	chr6:28943877~28944537:+
BRCA	cis	rs375066	0.586	rs2356401	ENSG00000267058.1	RP11-15A1.3	-5.33	1.22e-07	1.47e-05	-0.19	-0.16	Breast cancer;	chr19:43817697	chr19:43891804~43901805:-
BRCA	cis	rs875971	1	rs6946143	ENSG00000164669.11	INTS4P1	-5.33	1.22e-07	1.47e-05	-0.2	-0.16	Aortic root size;	chr7:66114735	chr7:65141225~65234216:+
BRCA	cis	rs6490294	0.571	rs57929857	ENSG00000226469.1	ADAM1B	5.33	1.22e-07	1.47e-05	0.29	0.16	Mean platelet volume;	chr12:111995752	chr12:111927018~111929017:+
BRCA	cis	rs9307551	0.619	rs723245	ENSG00000250334.4	LINC00989	-5.33	1.22e-07	1.47e-05	-0.22	-0.16	Refractive error;	chr4:79503913	chr4:79492416~79576460:+
BRCA	cis	rs2562456	0.833	rs8106025	ENSG00000268081.1	RP11-678G14.2	-5.33	1.22e-07	1.48e-05	-0.24	-0.16	Pain;	chr19:21451922	chr19:21554640~21569237:-
BRCA	cis	rs12681366	1	rs10956911	ENSG00000253704.1	RP11-267M23.4	5.33	1.22e-07	1.48e-05	0.17	0.16	Nonsyndromic cleft lip with cleft palate;	chr8:94371647	chr8:94553722~94569745:+
BRCA	cis	rs9847710	1	rs2581817	ENSG00000242142.1	SERBP1P3	5.33	1.22e-07	1.48e-05	0.18	0.16	Ulcerative colitis;	chr3:53037781	chr3:53064283~53065091:-
BRCA	cis	rs17772222	0.682	rs28711639	ENSG00000258789.1	RP11-507K2.3	-5.33	1.22e-07	1.48e-05	-0.18	-0.16	Coronary artery calcification;	chr14:88482277	chr14:88551597~88552493:+
BRCA	cis	rs2403083	0.505	rs2006767	ENSG00000258256.1	RP11-219B4.5	-5.33	1.22e-07	1.48e-05	-0.19	-0.16	Plasma amyloid beta peptide concentrations (ABx-40);	chr8:85268715	chr8:85222446~85245717:-
BRCA	cis	rs7119	0.717	rs12916642	ENSG00000259362.2	RP11-307C19.1	-5.33	1.22e-07	1.48e-05	-0.23	-0.16	Type 2 diabetes;	chr15:77526084	chr15:77525540~77534110:+
BRCA	cis	rs2276314	0.512	rs12458709	ENSG00000278986.1	RP11-723J4.3	5.33	1.22e-07	1.48e-05	0.2	0.16	Endometriosis;Drug-induced torsades de pointes;	chr18:35861928	chr18:35972151~35973916:+
BRCA	cis	rs7914558	0.966	rs4532960	ENSG00000236937.2	PTGES3P4	5.33	1.22e-07	1.48e-05	0.21	0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102907649	chr10:102845595~102845950:+
BRCA	cis	rs7914558	0.966	rs10786724	ENSG00000236937.2	PTGES3P4	5.33	1.22e-07	1.48e-05	0.21	0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102909185	chr10:102845595~102845950:+
BRCA	cis	rs950169	0.58	rs2271431	ENSG00000259295.5	CSPG4P12	5.33	1.22e-07	1.48e-05	0.22	0.16	Schizophrenia;	chr15:84646233	chr15:85191438~85213905:+
BRCA	cis	rs2243480	1	rs10807701	ENSG00000228409.4	CCT6P1	-5.33	1.22e-07	1.48e-05	-0.22	-0.16	Diabetic kidney disease;	chr7:66259699	chr7:65751142~65763354:+
BRCA	cis	rs3102460	0.618	rs3102461	ENSG00000225401.2	TGIF2P1	-5.33	1.22e-07	1.48e-05	-0.24	-0.16	Obesity-related traits;	chr1:244413987	chr1:244394976~244395660:-
BRCA	cis	rs10911232	0.507	rs4652769	ENSG00000224468.3	RP11-181K3.4	-5.33	1.22e-07	1.48e-05	-0.18	-0.16	Hypertriglyceridemia;	chr1:183040061	chr1:183138402~183141282:-
BRCA	cis	rs7615952	0.515	rs4267608	ENSG00000250012.1	RP11-124N2.1	-5.33	1.22e-07	1.48e-05	-0.22	-0.16	Blood pressure (smoking interaction);	chr3:125961657	chr3:126084220~126095349:+
BRCA	cis	rs4948102	0.551	rs4275190	ENSG00000273720.1	RP11-613E4.4	-5.33	1.23e-07	1.48e-05	-0.2	-0.16	Plasma homocysteine levels (post-methionine load test);	chr7:56036695	chr7:55743073~55743457:+
BRCA	cis	rs6840360	0.642	rs2724578	ENSG00000278978.1	RP11-164P12.5	-5.33	1.23e-07	1.48e-05	-0.18	-0.16	Intelligence (multi-trait analysis);	chr4:151446152	chr4:151669786~151670503:+
BRCA	cis	rs6840360	0.574	rs2709844	ENSG00000278978.1	RP11-164P12.5	-5.33	1.23e-07	1.48e-05	-0.18	-0.16	Intelligence (multi-trait analysis);	chr4:151447060	chr4:151669786~151670503:+
BRCA	cis	rs783540	0.542	rs62009945	ENSG00000255769.6	GOLGA2P10	5.33	1.23e-07	1.48e-05	0.22	0.16	Schizophrenia;	chr15:82631205	chr15:82472993~82513950:-
BRCA	cis	rs9307551	0.584	rs1371995	ENSG00000250334.4	LINC00989	-5.33	1.23e-07	1.48e-05	-0.22	-0.16	Refractive error;	chr4:79523353	chr4:79492416~79576460:+
BRCA	cis	rs172166	0.694	rs2791332	ENSG00000280107.1	AL022393.9	-5.33	1.23e-07	1.48e-05	-0.22	-0.16	Cardiac Troponin-T levels;	chr6:28141010	chr6:28170845~28172521:+
BRCA	cis	rs253959	0.545	rs10072350	ENSG00000272265.1	CTD-2287O16.4	5.33	1.23e-07	1.49e-05	0.2	0.16	Bipolar disorder and schizophrenia;	chr5:116097829	chr5:116078110~116078570:-
BRCA	cis	rs863750	0.744	rs825458	ENSG00000275389.1	RP11-214K3.24	5.33	1.23e-07	1.49e-05	0.21	0.16	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-hip ratio;	chr12:124055244	chr12:124085761~124088598:+
BRCA	cis	rs7302981	0.741	rs10783342	ENSG00000272368.2	RP4-605O3.4	5.33	1.23e-07	1.49e-05	0.17	0.16	Systolic blood pressure;	chr12:50234683	chr12:50112197~50165618:+
BRCA	cis	rs8031584	0.706	rs798084	ENSG00000259845.1	HERC2P10	5.33	1.23e-07	1.49e-05	0.2	0.16	Huntington's disease progression;	chr15:30834732	chr15:30815271~30844153:+
BRCA	cis	rs13126694	0.744	rs7691516	ENSG00000251429.1	RP11-597D13.7	5.33	1.23e-07	1.49e-05	0.16	0.16	Blood osmolality (transformed sodium);	chr4:158073326	chr4:158270378~158278676:+
BRCA	cis	rs12681366	0.663	rs2921389	ENSG00000253704.1	RP11-267M23.4	5.33	1.23e-07	1.49e-05	0.17	0.16	Nonsyndromic cleft lip with cleft palate;	chr8:94454138	chr8:94553722~94569745:+
BRCA	cis	rs73193808	1	rs2832228	ENSG00000236056.1	GAPDHP14	-5.33	1.23e-07	1.49e-05	-0.23	-0.16	Coronary artery disease;	chr21:29162364	chr21:29222321~29223257:+
BRCA	cis	rs1862618	0.853	rs1559282	ENSG00000271828.1	CTD-2310F14.1	5.33	1.23e-07	1.49e-05	0.22	0.16	Initial pursuit acceleration;	chr5:56803548	chr5:56927874~56929573:+
BRCA	cis	rs78487399	0.71	rs72879290	ENSG00000234936.1	AC010883.5	5.33	1.23e-07	1.49e-05	0.26	0.16	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43406129	chr2:43229573~43233394:+
BRCA	cis	rs997295	0.57	rs72747464	ENSG00000270964.1	RP11-502I4.3	-5.33	1.23e-07	1.49e-05	-0.18	-0.16	Motion sickness;	chr15:67526202	chr15:67541072~67542604:-
BRCA	cis	rs7572733	0.534	rs1401091	ENSG00000231621.1	AC013264.2	5.33	1.23e-07	1.49e-05	0.16	0.16	Dermatomyositis;	chr2:197925699	chr2:197197991~197199273:+
BRCA	cis	rs10829156	0.66	rs7910506	ENSG00000240291.1	RP11-499P20.2	-5.33	1.23e-07	1.49e-05	-0.18	-0.16	Sudden cardiac arrest;	chr10:18518128	chr10:18513115~18545651:-
BRCA	cis	rs6490294	0.571	rs35662477	ENSG00000226469.1	ADAM1B	5.33	1.23e-07	1.49e-05	0.27	0.16	Mean platelet volume;	chr12:111875404	chr12:111927018~111929017:+
BRCA	cis	rs3733585	0.699	rs7437120	ENSG00000250413.1	RP11-448G15.1	5.33	1.23e-07	1.49e-05	0.21	0.16	Cleft plate (environmental tobacco smoke interaction);	chr4:9966059	chr4:10006482~10009725:+
BRCA	cis	rs1223397	0.938	rs3817738	ENSG00000215022.6	RP1-257A7.4	-5.33	1.23e-07	1.49e-05	-0.23	-0.16	Blood pressure;	chr6:13279156	chr6:13264861~13295586:-
BRCA	cis	rs4218	0.587	rs1446237	ENSG00000277144.1	RP11-59H7.4	-5.33	1.23e-07	1.49e-05	-0.2	-0.16	Social communication problems;	chr15:59052603	chr15:59115547~59116089:-
BRCA	cis	rs2732480	0.557	rs2634682	ENSG00000240399.1	RP1-228P16.1	5.33	1.23e-07	1.49e-05	0.19	0.16	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48339160	chr12:48054813~48055591:-
BRCA	cis	rs172166	0.694	rs203893	ENSG00000280107.1	AL022393.9	-5.33	1.23e-07	1.49e-05	-0.22	-0.16	Cardiac Troponin-T levels;	chr6:28094288	chr6:28170845~28172521:+
BRCA	cis	rs6832769	0.826	rs10462035	ENSG00000272969.1	RP11-528I4.2	5.33	1.23e-07	1.49e-05	0.2	0.16	Personality dimensions;	chr4:55513011	chr4:55547112~55547889:+
BRCA	cis	rs9300255	0.543	rs520088	ENSG00000235423.7	RP11-282O18.3	5.33	1.23e-07	1.49e-05	0.2	0.16	Neutrophil percentage of white cells;	chr12:123037603	chr12:123252030~123261483:-
BRCA	cis	rs2522056	1	rs7730247	ENSG00000233006.5	AC034220.3	-5.33	1.23e-07	1.49e-05	-0.14	-0.16	Fibrinogen;Lymphocyte counts;	chr5:132445596	chr5:132311285~132369916:-
BRCA	cis	rs72799341	0.706	rs1060506	ENSG00000260911.2	RP11-196G11.2	5.33	1.23e-07	1.49e-05	0.15	0.16	Diastolic blood pressure;	chr16:31122128	chr16:31043150~31049868:+
BRCA	cis	rs1979679	0.918	rs7977429	ENSG00000278733.1	RP11-425D17.1	5.33	1.23e-07	1.49e-05	0.21	0.16	Ossification of the posterior longitudinal ligament of the spine;	chr12:28370376	chr12:28185625~28186190:-
BRCA	cis	rs6831352	0.819	rs1230158	ENSG00000272777.1	RP11-571L19.8	-5.33	1.24e-07	1.49e-05	-0.17	-0.16	Alcohol dependence;	chr4:99069035	chr4:99067256~99068125:-
BRCA	cis	rs891378	0.92	rs2564975	ENSG00000274245.1	RP11-357P18.2	-5.33	1.24e-07	1.49e-05	-0.22	-0.16	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207310612	chr1:207372559~207373252:+
BRCA	cis	rs12468226	1	rs74766638	ENSG00000226261.1	AC064836.3	5.33	1.24e-07	1.49e-05	0.28	0.16	Urate levels;	chr2:202445168	chr2:202336024~202336727:-
BRCA	cis	rs2281558	0.837	rs56238023	ENSG00000230772.1	VN1R108P	-5.33	1.24e-07	1.49e-05	-0.21	-0.16	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25536311	chr20:25734264~25735093:+
BRCA	cis	rs6723226	0.708	rs2710627	ENSG00000276334.1	AL133243.1	5.33	1.24e-07	1.49e-05	0.21	0.16	Intelligence (multi-trait analysis);	chr2:32533560	chr2:32521927~32523547:+
BRCA	cis	rs3764563	1	rs4371280	ENSG00000267594.5	CYP4F24P	-5.32	1.24e-07	1.49e-05	-0.32	-0.16	Inflammatory biomarkers;	chr19:15604957	chr19:15760241~15779909:-
BRCA	cis	rs875971	0.66	rs10263935	ENSG00000273024.4	INTS4P2	-5.32	1.24e-07	1.5e-05	-0.18	-0.16	Aortic root size;	chr7:66631041	chr7:65647864~65715661:+
BRCA	cis	rs3760982	0.585	rs67773424	ENSG00000267058.1	RP11-15A1.3	-5.32	1.24e-07	1.5e-05	-0.19	-0.16	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43789842	chr19:43891804~43901805:-
BRCA	cis	rs2638953	0.853	rs12367657	ENSG00000247934.4	RP11-967K21.1	-5.32	1.24e-07	1.5e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28475816	chr12:28163298~28190738:-
BRCA	cis	rs7617773	0.817	rs17786132	ENSG00000199476.1	Y_RNA	-5.32	1.24e-07	1.5e-05	-0.24	-0.16	Coronary artery disease;	chr3:48207930	chr3:48288587~48288694:+
BRCA	cis	rs7617773	0.817	rs35456569	ENSG00000199476.1	Y_RNA	-5.32	1.24e-07	1.5e-05	-0.24	-0.16	Coronary artery disease;	chr3:48209409	chr3:48288587~48288694:+
BRCA	cis	rs2235544	0.664	rs55766128	ENSG00000225183.1	RP4-758J24.4	-5.32	1.24e-07	1.5e-05	-0.19	-0.16	Thyroid hormone levels;Multiple myeloma (hyperdiploidy);	chr1:54012053	chr1:54089856~54090093:+
BRCA	cis	rs3764021	0.527	rs11052604	ENSG00000214776.8	RP11-726G1.1	5.32	1.24e-07	1.5e-05	0.2	0.16	Type 1 diabetes;	chr12:9709952	chr12:9467552~9576275:+
BRCA	cis	rs2278170	1	rs10836102	ENSG00000225101.4	OR52K3P	-5.32	1.24e-07	1.5e-05	-0.22	-0.16	Amyotrophic lateral sclerosis;	chr11:4464695	chr11:4474813~4475755:+
BRCA	cis	rs9925964	0.933	rs4889530	ENSG00000232748.3	RP11-196G11.6	5.32	1.24e-07	1.5e-05	0.2	0.16	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31054597	chr16:31056460~31062803:+
BRCA	cis	rs365302	1	rs294917	ENSG00000235086.1	FNDC1-IT1	5.32	1.24e-07	1.5e-05	0.18	0.16	Coronary heart disease;	chr6:159206045	chr6:159240786~159243329:+
BRCA	cis	rs8048589	1	rs13336687	ENSG00000175604.2	RP11-276H1.3	-5.32	1.24e-07	1.5e-05	-0.24	-0.16	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);	chr16:12093208	chr16:12086746~12090302:-
BRCA	cis	rs1124769	0.57	rs1290084	ENSG00000259378.1	DCAF13P3	-5.32	1.24e-07	1.5e-05	-0.22	-0.16	Cognitive performance;	chr15:50861748	chr15:50944663~50945996:+
BRCA	cis	rs2255336	0.608	rs7958658	ENSG00000245648.1	RP11-277P12.20	5.32	1.24e-07	1.5e-05	0.26	0.16	Blood protein levels;	chr12:10366229	chr12:10363769~10398506:+
BRCA	cis	rs597539	0.652	rs673821	ENSG00000261625.1	RP11-554A11.4	-5.32	1.24e-07	1.5e-05	-0.16	-0.16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68911250	chr11:69000765~69002048:-
BRCA	cis	rs2179367	0.959	rs9373592	ENSG00000216906.2	RP11-350J20.9	5.32	1.24e-07	1.5e-05	0.21	0.16	Dupuytren's disease;	chr6:149412119	chr6:149904243~149906418:+
BRCA	cis	rs7914558	1	rs1890184	ENSG00000236937.2	PTGES3P4	5.32	1.24e-07	1.5e-05	0.21	0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102988702	chr10:102845595~102845950:+
BRCA	cis	rs7618915	0.547	rs62253700	ENSG00000243224.1	RP5-1157M23.2	-5.32	1.25e-07	1.5e-05	-0.18	-0.16	Bipolar disorder;	chr3:52591003	chr3:52239258~52241097:+
BRCA	cis	rs7618915	0.57	rs4687633	ENSG00000243224.1	RP5-1157M23.2	-5.32	1.25e-07	1.5e-05	-0.18	-0.16	Bipolar disorder;	chr3:52596532	chr3:52239258~52241097:+
BRCA	cis	rs7618915	0.547	rs62253703	ENSG00000243224.1	RP5-1157M23.2	-5.32	1.25e-07	1.5e-05	-0.18	-0.16	Bipolar disorder;	chr3:52598341	chr3:52239258~52241097:+
BRCA	cis	rs891378	1	rs1572275	ENSG00000274245.1	RP11-357P18.2	5.32	1.25e-07	1.51e-05	0.21	0.16	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207305635	chr1:207372559~207373252:+
BRCA	cis	rs7617773	0.817	rs35414021	ENSG00000199476.1	Y_RNA	-5.32	1.25e-07	1.51e-05	-0.24	-0.16	Coronary artery disease;	chr3:48252034	chr3:48288587~48288694:+
BRCA	cis	rs7617773	0.784	rs11715799	ENSG00000199476.1	Y_RNA	-5.32	1.25e-07	1.51e-05	-0.24	-0.16	Coronary artery disease;	chr3:48213730	chr3:48288587~48288694:+
BRCA	cis	rs2638953	0.924	rs11049385	ENSG00000247934.4	RP11-967K21.1	-5.32	1.25e-07	1.51e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28167559	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.924	rs11049387	ENSG00000247934.4	RP11-967K21.1	-5.32	1.25e-07	1.51e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28167609	chr12:28163298~28190738:-
BRCA	cis	rs365302	1	rs411523	ENSG00000235086.1	FNDC1-IT1	5.32	1.25e-07	1.51e-05	0.19	0.16	Coronary heart disease;	chr6:159197758	chr6:159240786~159243329:+
BRCA	cis	rs17711722	0.522	rs6957759	ENSG00000237310.1	GS1-124K5.4	5.32	1.25e-07	1.51e-05	0.17	0.16	Calcium levels;	chr7:65806798	chr7:66493706~66495474:+
BRCA	cis	rs7208859	0.673	rs61348930	ENSG00000280069.1	CTD-2349P21.3	-5.32	1.25e-07	1.51e-05	-0.24	-0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30894745	chr17:30738182~30740275:+
BRCA	cis	rs7208859	0.614	rs28758251	ENSG00000280069.1	CTD-2349P21.3	-5.32	1.25e-07	1.51e-05	-0.24	-0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30896294	chr17:30738182~30740275:+
BRCA	cis	rs7208859	0.673	rs9899943	ENSG00000280069.1	CTD-2349P21.3	-5.32	1.25e-07	1.51e-05	-0.24	-0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30896907	chr17:30738182~30740275:+
BRCA	cis	rs7208859	0.673	rs11080138	ENSG00000280069.1	CTD-2349P21.3	-5.32	1.25e-07	1.51e-05	-0.24	-0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30897524	chr17:30738182~30740275:+
BRCA	cis	rs7208859	0.673	rs73265612	ENSG00000280069.1	CTD-2349P21.3	-5.32	1.25e-07	1.51e-05	-0.24	-0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30898965	chr17:30738182~30740275:+
BRCA	cis	rs7208859	0.673	rs11658435	ENSG00000280069.1	CTD-2349P21.3	-5.32	1.25e-07	1.51e-05	-0.24	-0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30901543	chr17:30738182~30740275:+
BRCA	cis	rs7208859	0.673	rs73265624	ENSG00000280069.1	CTD-2349P21.3	-5.32	1.25e-07	1.51e-05	-0.24	-0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30905048	chr17:30738182~30740275:+
BRCA	cis	rs11159086	1	rs3759745	ENSG00000270000.1	RP3-449M8.9	5.32	1.25e-07	1.51e-05	0.25	0.16	Advanced glycation end-product levels;	chr14:74495967	chr14:74471930~74472360:-
BRCA	cis	rs9545047	0.604	rs11620233	ENSG00000227354.5	RBM26-AS1	-5.32	1.25e-07	1.51e-05	-0.18	-0.16	Schizophrenia;	chr13:79373871	chr13:79406309~79424328:+
BRCA	cis	rs9545047	0.604	rs6563098	ENSG00000227354.5	RBM26-AS1	5.32	1.25e-07	1.51e-05	0.17	0.16	Schizophrenia;	chr13:79313102	chr13:79406309~79424328:+
BRCA	cis	rs9311474	0.539	rs12489828	ENSG00000243224.1	RP5-1157M23.2	-5.32	1.25e-07	1.51e-05	-0.17	-0.16	Electroencephalogram traits;	chr3:52532998	chr3:52239258~52241097:+
BRCA	cis	rs10861342	1	rs11112398	ENSG00000257999.1	RP11-61E11.2	-5.32	1.25e-07	1.51e-05	-0.32	-0.16	IgG glycosylation;	chr12:105179189	chr12:105102472~105107179:-
BRCA	cis	rs6570726	0.791	rs414297	ENSG00000270638.1	RP3-466P17.1	5.32	1.25e-07	1.51e-05	0.18	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145566420	chr6:145735570~145737218:+
BRCA	cis	rs7141336	1	rs7141336	ENSG00000258884.1	CTD-3035D6.2	-5.32	1.25e-07	1.51e-05	-0.21	-0.16	Anxiety disorder;	chr14:90819884	chr14:90822365~90828128:-
BRCA	cis	rs17685	0.671	rs10274404	ENSG00000280388.1	RP11-229D13.3	-5.32	1.25e-07	1.51e-05	-0.17	-0.16	Coffee consumption (cups per day);Coffee consumption;	chr7:76077316	chr7:76043977~76045963:-
BRCA	cis	rs7617773	0.78	rs13066044	ENSG00000199476.1	Y_RNA	-5.32	1.25e-07	1.51e-05	-0.25	-0.16	Coronary artery disease;	chr3:48335786	chr3:48288587~48288694:+
BRCA	cis	rs7618915	0.57	rs2336145	ENSG00000243224.1	RP5-1157M23.2	-5.32	1.25e-07	1.51e-05	-0.18	-0.16	Bipolar disorder;	chr3:52595734	chr3:52239258~52241097:+
BRCA	cis	rs9419788	0.605	rs7080472	ENSG00000273450.1	RP11-76P2.4	5.32	1.25e-07	1.51e-05	0.21	0.16	Personality traits in bipolar disorder;	chr10:94253193	chr10:94314907~94315327:-
BRCA	cis	rs7789940	0.951	rs73140055	ENSG00000186704.9	DTX2P1	5.32	1.25e-07	1.51e-05	0.2	0.16	Multiple sclerosis;	chr7:76346460	chr7:76978617~77004308:+
BRCA	cis	rs2562456	0.833	rs4644962	ENSG00000268535.1	RP11-420K14.3	5.32	1.25e-07	1.52e-05	0.23	0.16	Pain;	chr19:21338125	chr19:21709522~21710191:+
BRCA	cis	rs6832769	1	rs9684708	ENSG00000223305.1	RN7SKP30	-5.32	1.25e-07	1.52e-05	-0.21	-0.16	Personality dimensions;	chr4:55564214	chr4:55540502~55540835:-
BRCA	cis	rs853679	0.607	rs34878803	ENSG00000204709.4	LINC01556	5.32	1.26e-07	1.52e-05	0.41	0.16	Depression;	chr6:28282402	chr6:28943877~28944537:+
BRCA	cis	rs853679	0.607	rs34396849	ENSG00000204709.4	LINC01556	5.32	1.26e-07	1.52e-05	0.41	0.16	Depression;	chr6:28283178	chr6:28943877~28944537:+
BRCA	cis	rs2834188	1	rs1018741	ENSG00000272659.1	AP000295.10	-5.32	1.26e-07	1.52e-05	-0.24	-0.16	Narcolepsy;	chr21:33314040	chr21:33309491~33310181:+
BRCA	cis	rs2834188	1	rs1018742	ENSG00000272659.1	AP000295.10	-5.32	1.26e-07	1.52e-05	-0.24	-0.16	Narcolepsy;	chr21:33314076	chr21:33309491~33310181:+
BRCA	cis	rs78487399	0.71	rs74616425	ENSG00000234936.1	AC010883.5	5.32	1.26e-07	1.52e-05	0.29	0.16	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43386443	chr2:43229573~43233394:+
BRCA	cis	rs2732480	0.577	rs2732457	ENSG00000257763.1	OR5BK1P	-5.32	1.26e-07	1.52e-05	-0.18	-0.16	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48364596	chr12:48355792~48356614:-
BRCA	cis	rs9300255	0.602	rs6488864	ENSG00000235423.7	RP11-282O18.3	5.32	1.26e-07	1.52e-05	0.23	0.16	Neutrophil percentage of white cells;	chr12:123133815	chr12:123252030~123261483:-
BRCA	cis	rs2562456	0.917	rs10420016	ENSG00000268658.4	LINC00664	-5.32	1.26e-07	1.52e-05	-0.26	-0.16	Pain;	chr19:21505800	chr19:21483374~21503238:+
BRCA	cis	rs875971	0.54	rs4717275	ENSG00000213640.3	EEF1DP4	5.32	1.26e-07	1.52e-05	0.2	0.16	Aortic root size;	chr7:65800193	chr7:64862999~64864370:+
BRCA	cis	rs3126085	0.56	rs12031363	ENSG00000237975.5	FLG-AS1	5.32	1.26e-07	1.52e-05	0.25	0.16	Atopic dermatitis;	chr1:152378169	chr1:152168125~152445456:+
BRCA	cis	rs12478296	1	rs57603292	ENSG00000261186.2	RP11-341N2.1	-5.32	1.26e-07	1.52e-05	-0.27	-0.16	Obesity-related traits;	chr2:242086386	chr2:242087351~242088457:-
BRCA	cis	rs7246657	0.722	rs2972447	ENSG00000276846.1	CTD-3220F14.3	-5.32	1.26e-07	1.52e-05	-0.22	-0.16	Coronary artery calcification;	chr19:37638835	chr19:37314868~37315620:-
BRCA	cis	rs1440410	0.571	rs4333135	ENSG00000250326.1	RP11-284M14.1	5.32	1.26e-07	1.52e-05	0.18	0.16	Ischemic stroke;	chr4:143118436	chr4:142933195~143184861:-
BRCA	cis	rs6832769	0.961	rs1873092	ENSG00000223305.1	RN7SKP30	-5.32	1.26e-07	1.52e-05	-0.21	-0.16	Personality dimensions;	chr4:55578133	chr4:55540502~55540835:-
BRCA	cis	rs2070074	1	rs2070074	ENSG00000230074.1	RP11-195F19.9	-5.32	1.26e-07	1.52e-05	-0.34	-0.16	CTACK levels;	chr9:34649445	chr9:34665665~34681298:+
BRCA	cis	rs6772849	0.93	rs6768344	ENSG00000242551.2	POU5F1P6	-5.32	1.26e-07	1.52e-05	-0.2	-0.16	Monocyte percentage of white cells;Monocyte count;	chr3:128654713	chr3:128674735~128677005:-
BRCA	cis	rs577676	0.533	rs10800529	ENSG00000271811.1	RP1-79C4.4	5.32	1.26e-07	1.52e-05	0.19	0.16	Prevalent atrial fibrillation;	chr1:170600902	chr1:170667381~170669425:+
BRCA	cis	rs7613875	0.578	rs4688753	ENSG00000228008.1	CTD-2330K9.3	-5.32	1.26e-07	1.52e-05	-0.16	-0.16	Body mass index;	chr3:50037340	chr3:49903845~49916937:+
BRCA	cis	rs7613875	0.578	rs2526749	ENSG00000228008.1	CTD-2330K9.3	-5.32	1.26e-07	1.52e-05	-0.16	-0.16	Body mass index;	chr3:50039301	chr3:49903845~49916937:+
BRCA	cis	rs7613875	0.62	rs7430334	ENSG00000228008.1	CTD-2330K9.3	-5.32	1.26e-07	1.52e-05	-0.16	-0.16	Body mass index;	chr3:50040788	chr3:49903845~49916937:+
BRCA	cis	rs7613875	0.641	rs6793528	ENSG00000228008.1	CTD-2330K9.3	-5.32	1.26e-07	1.52e-05	-0.16	-0.16	Body mass index;	chr3:50062755	chr3:49903845~49916937:+
BRCA	cis	rs7613875	0.578	rs2624822	ENSG00000228008.1	CTD-2330K9.3	-5.32	1.26e-07	1.52e-05	-0.16	-0.16	Body mass index;	chr3:50069786	chr3:49903845~49916937:+
BRCA	cis	rs35146811	1	rs35146811	ENSG00000235713.1	RP4-604G5.3	5.32	1.26e-07	1.52e-05	0.19	0.16	Coronary artery disease;	chr7:100123371	chr7:99992397~99993050:+
BRCA	cis	rs595982	0.527	rs56021835	ENSG00000235191.1	NUCB1-AS1	5.32	1.26e-07	1.52e-05	0.28	0.16	Red cell distribution width;	chr19:48866732	chr19:48910930~48918891:-
BRCA	cis	rs416603	0.967	rs7191538	ENSG00000262636.1	CTD-3088G3.4	-5.32	1.26e-07	1.52e-05	-0.22	-0.16	Type 1 diabetes;	chr16:11269532	chr16:11380859~11381118:-
BRCA	cis	rs595244	0.908	rs625034	ENSG00000259705.1	RP11-227D13.1	5.32	1.26e-07	1.52e-05	0.31	0.16	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48634005	chr15:48645951~48652016:+
BRCA	cis	rs2243480	0.901	rs778730	ENSG00000232559.3	GS1-124K5.12	5.32	1.26e-07	1.53e-05	0.31	0.16	Diabetic kidney disease;	chr7:66358338	chr7:66554588~66576923:-
BRCA	cis	rs3758911	0.713	rs10890679	ENSG00000255353.1	RP11-382M14.1	-5.32	1.26e-07	1.53e-05	-0.21	-0.16	Coronary artery disease;	chr11:107255059	chr11:107176286~107177530:+
BRCA	cis	rs66887589	0.616	rs11731675	ENSG00000249244.1	RP11-548H18.2	5.32	1.27e-07	1.53e-05	0.18	0.16	Diastolic blood pressure;	chr4:119291359	chr4:119391831~119395335:-
BRCA	cis	rs7613875	0.6	rs2624826	ENSG00000228008.1	CTD-2330K9.3	-5.32	1.27e-07	1.53e-05	-0.16	-0.16	Body mass index;	chr3:50118035	chr3:49903845~49916937:+
BRCA	cis	rs2732480	0.5	rs2450989	ENSG00000257735.1	RP11-370I10.6	-5.32	1.27e-07	1.53e-05	-0.2	-0.16	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48259625	chr12:48350945~48442411:+
BRCA	cis	rs875971	0.522	rs4502988	ENSG00000273024.4	INTS4P2	-5.32	1.27e-07	1.53e-05	-0.18	-0.16	Aortic root size;	chr7:65832759	chr7:65647864~65715661:+
BRCA	cis	rs13108904	0.87	rs3755924	ENSG00000254094.1	AC078852.1	-5.32	1.27e-07	1.53e-05	-0.18	-0.16	Obesity-related traits;	chr4:1244575	chr4:1356581~1358075:+
BRCA	cis	rs13108904	0.87	rs3775094	ENSG00000254094.1	AC078852.1	-5.32	1.27e-07	1.53e-05	-0.18	-0.16	Obesity-related traits;	chr4:1245071	chr4:1356581~1358075:+
BRCA	cis	rs962856	0.897	rs644055	ENSG00000236780.4	AC078941.1	5.32	1.27e-07	1.53e-05	0.2	0.16	Pancreatic cancer;	chr2:67432539	chr2:67123357~67215319:-
BRCA	cis	rs8048589	1	rs12599090	ENSG00000175604.2	RP11-276H1.3	-5.32	1.27e-07	1.53e-05	-0.25	-0.16	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);	chr16:12093484	chr16:12086746~12090302:-
BRCA	cis	rs4950322	0.563	rs6700783	ENSG00000278811.3	LINC00624	5.32	1.27e-07	1.53e-05	0.21	0.16	Protein quantitative trait loci;	chr1:147111987	chr1:147258885~147517875:-
BRCA	cis	rs1075265	0.783	rs698858	ENSG00000235937.1	AC008280.1	5.32	1.27e-07	1.53e-05	0.18	0.16	Chronotype;Morning vs. evening chronotype;	chr2:53943333	chr2:54029552~54030682:-
BRCA	cis	rs1707322	0.686	rs2275085	ENSG00000234329.1	RP11-767N6.2	-5.32	1.27e-07	1.53e-05	-0.17	-0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45620180	chr1:45651039~45651826:-
BRCA	cis	rs6570726	0.875	rs368744	ENSG00000270638.1	RP3-466P17.1	5.32	1.27e-07	1.53e-05	0.18	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145491486	chr6:145735570~145737218:+
BRCA	cis	rs2638953	0.925	rs7967281	ENSG00000278733.1	RP11-425D17.1	-5.32	1.27e-07	1.53e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28397843	chr12:28185625~28186190:-
BRCA	cis	rs295490	0.748	rs77876369	ENSG00000272656.1	RP11-219D15.3	5.32	1.27e-07	1.53e-05	0.37	0.16	PR interval in Tripanosoma cruzi seropositivity;	chr3:139412070	chr3:139349024~139349371:-
BRCA	cis	rs9308731	0.583	rs7567184	ENSG00000227992.1	AC108463.2	-5.32	1.27e-07	1.53e-05	-0.19	-0.16	Chronic lymphocytic leukemia;	chr2:111173495	chr2:111203964~111206215:-
BRCA	cis	rs300890	0.513	rs72719151	ENSG00000250326.1	RP11-284M14.1	5.32	1.27e-07	1.53e-05	0.2	0.16	Nasopharyngeal carcinoma;	chr4:143122417	chr4:142933195~143184861:-
BRCA	cis	rs2243480	1	rs6964245	ENSG00000228409.4	CCT6P1	-5.32	1.27e-07	1.53e-05	-0.22	-0.16	Diabetic kidney disease;	chr7:66253730	chr7:65751142~65763354:+
BRCA	cis	rs13096142	0.558	rs4682812	ENSG00000223552.1	RP11-24F11.2	-5.32	1.27e-07	1.53e-05	-0.21	-0.16	Celiac disease;	chr3:46288153	chr3:46364955~46407059:-
BRCA	cis	rs2403083	0.505	rs7839129	ENSG00000258256.1	RP11-219B4.5	-5.32	1.27e-07	1.53e-05	-0.19	-0.16	Plasma amyloid beta peptide concentrations (ABx-40);	chr8:85273995	chr8:85222446~85245717:-
BRCA	cis	rs2281636	0.754	rs4919364	ENSG00000233690.1	EBAG9P1	5.32	1.27e-07	1.53e-05	0.17	0.16	Obesity-related traits;	chr10:99604947	chr10:99697407~99697949:-
BRCA	cis	rs4908768	0.501	rs6702060	ENSG00000232912.4	RP5-1115A15.1	5.32	1.27e-07	1.54e-05	0.16	0.16	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8546965	chr1:8424645~8434838:+
BRCA	cis	rs4713118	0.869	rs6902689	ENSG00000216901.1	AL022393.7	5.32	1.27e-07	1.54e-05	0.22	0.16	Parkinson's disease;	chr6:27741662	chr6:28176188~28176674:+
BRCA	cis	rs2638953	0.962	rs61920565	ENSG00000278733.1	RP11-425D17.1	-5.32	1.27e-07	1.54e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28377192	chr12:28185625~28186190:-
BRCA	cis	rs2098713	0.534	rs12515702	ENSG00000250155.1	CTD-2353F22.1	5.32	1.27e-07	1.54e-05	0.18	0.16	Telomere length;	chr5:37520773	chr5:36666214~36725195:-
BRCA	cis	rs875971	0.862	rs1167408	ENSG00000236529.1	RP13-254B10.1	-5.32	1.27e-07	1.54e-05	-0.18	-0.16	Aortic root size;	chr7:66091121	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.83	rs1167406	ENSG00000236529.1	RP13-254B10.1	-5.32	1.27e-07	1.54e-05	-0.18	-0.16	Aortic root size;	chr7:66091949	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.862	rs1167399	ENSG00000236529.1	RP13-254B10.1	-5.32	1.27e-07	1.54e-05	-0.18	-0.16	Aortic root size;	chr7:66096890	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.862	rs57866200	ENSG00000236529.1	RP13-254B10.1	-5.32	1.27e-07	1.54e-05	-0.18	-0.16	Aortic root size;	chr7:66100405	chr7:65840212~65840596:+
BRCA	cis	rs1707322	1	rs4390216	ENSG00000234329.1	RP11-767N6.2	5.32	1.27e-07	1.54e-05	0.17	0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45800784	chr1:45651039~45651826:-
BRCA	cis	rs10752881	0.967	rs10911186	ENSG00000224468.3	RP11-181K3.4	-5.32	1.28e-07	1.54e-05	-0.17	-0.16	Colorectal cancer;	chr1:183003407	chr1:183138402~183141282:-
BRCA	cis	rs7617773	0.746	rs11713476	ENSG00000199476.1	Y_RNA	-5.32	1.28e-07	1.54e-05	-0.23	-0.16	Coronary artery disease;	chr3:48333944	chr3:48288587~48288694:+
BRCA	cis	rs2638953	0.777	rs11049689	ENSG00000247934.4	RP11-967K21.1	-5.32	1.28e-07	1.54e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28519177	chr12:28163298~28190738:-
BRCA	cis	rs62025270	0.688	rs7164373	ENSG00000202081.1	RNU6-1280P	-5.32	1.28e-07	1.54e-05	-0.24	-0.16	Idiopathic pulmonary fibrosis;	chr15:85722432	chr15:85651522~85651628:-
BRCA	cis	rs7487075	0.619	rs7959731	ENSG00000274723.1	RP11-618L22.1	-5.32	1.28e-07	1.54e-05	-0.2	-0.16	Itch intensity from mosquito bite;	chr12:46445874	chr12:46970504~46972155:+
BRCA	cis	rs3808502	0.516	rs6983727	ENSG00000270154.1	RP11-419I17.1	5.32	1.28e-07	1.54e-05	0.19	0.16	Neuroticism;	chr8:11558303	chr8:12476462~12477122:+
BRCA	cis	rs9308731	0.583	rs2165107	ENSG00000227992.1	AC108463.2	-5.32	1.28e-07	1.54e-05	-0.19	-0.16	Chronic lymphocytic leukemia;	chr2:111173773	chr2:111203964~111206215:-
BRCA	cis	rs2243480	1	rs4718334	ENSG00000228409.4	CCT6P1	-5.32	1.28e-07	1.54e-05	-0.23	-0.16	Diabetic kidney disease;	chr7:66324467	chr7:65751142~65763354:+
BRCA	cis	rs7617773	0.817	rs11720622	ENSG00000199476.1	Y_RNA	-5.32	1.28e-07	1.54e-05	-0.21	-0.16	Coronary artery disease;	chr3:48205189	chr3:48288587~48288694:+
BRCA	cis	rs7191700	0.712	rs7187741	ENSG00000262703.1	RP11-485G7.6	-5.32	1.28e-07	1.54e-05	-0.16	-0.16	Multiple sclerosis;	chr16:11339246	chr16:11348143~11349321:-
BRCA	cis	rs2303319	1	rs3769964	ENSG00000227403.1	AC009299.3	5.32	1.28e-07	1.54e-05	0.4	0.16	Cognitive function;	chr2:161350835	chr2:161244739~161249050:+
BRCA	cis	rs2153535	0.58	rs7766852	ENSG00000251164.1	HULC	-5.32	1.28e-07	1.54e-05	-0.2	-0.16	Motion sickness;	chr6:8472184	chr6:8652137~8653846:+
BRCA	cis	rs9545047	0.625	rs1408657	ENSG00000227354.5	RBM26-AS1	5.32	1.28e-07	1.54e-05	0.17	0.16	Schizophrenia;	chr13:79329315	chr13:79406309~79424328:+
BRCA	cis	rs8098244	0.756	rs1154229	ENSG00000264745.1	TTC39C-AS1	-5.32	1.28e-07	1.55e-05	-0.19	-0.16	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23902252	chr18:23994213~24015339:-
BRCA	cis	rs7617773	0.78	rs35411187	ENSG00000199476.1	Y_RNA	-5.32	1.28e-07	1.55e-05	-0.24	-0.16	Coronary artery disease;	chr3:48318527	chr3:48288587~48288694:+
BRCA	cis	rs7617773	0.78	rs11714176	ENSG00000199476.1	Y_RNA	-5.32	1.28e-07	1.55e-05	-0.24	-0.16	Coronary artery disease;	chr3:48319372	chr3:48288587~48288694:+
BRCA	cis	rs9467773	0.967	rs9295694	ENSG00000124549.13	BTN2A3P	5.32	1.28e-07	1.55e-05	0.16	0.16	Intelligence (multi-trait analysis);	chr6:26512766	chr6:26421391~26432383:+
BRCA	cis	rs9467773	0.967	rs9467775	ENSG00000124549.13	BTN2A3P	5.32	1.28e-07	1.55e-05	0.16	0.16	Intelligence (multi-trait analysis);	chr6:26513207	chr6:26421391~26432383:+
BRCA	cis	rs9859260	0.71	rs419068	ENSG00000242086.7	LINC00969	-5.32	1.28e-07	1.55e-05	-0.18	-0.16	Mean corpuscular volume;	chr3:196055305	chr3:195658062~195739964:+
BRCA	cis	rs9859260	0.71	rs366268	ENSG00000242086.7	LINC00969	-5.32	1.28e-07	1.55e-05	-0.18	-0.16	Mean corpuscular volume;	chr3:196055306	chr3:195658062~195739964:+
BRCA	cis	rs9859260	0.744	rs419059	ENSG00000242086.7	LINC00969	-5.32	1.28e-07	1.55e-05	-0.18	-0.16	Mean corpuscular volume;	chr3:196055313	chr3:195658062~195739964:+
BRCA	cis	rs12681366	0.62	rs2930968	ENSG00000253704.1	RP11-267M23.4	5.32	1.28e-07	1.55e-05	0.17	0.16	Nonsyndromic cleft lip with cleft palate;	chr8:94450467	chr8:94553722~94569745:+
BRCA	cis	rs12681366	0.663	rs2930970	ENSG00000253704.1	RP11-267M23.4	5.32	1.28e-07	1.55e-05	0.17	0.16	Nonsyndromic cleft lip with cleft palate;	chr8:94452109	chr8:94553722~94569745:+
BRCA	cis	rs6540731	1	rs951623	ENSG00000229983.1	RP11-15I11.2	5.32	1.28e-07	1.55e-05	0.19	0.16	Intelligence (childhood);	chr1:212225720	chr1:212168207~212190259:+
BRCA	cis	rs1707322	0.721	rs6697821	ENSG00000234329.1	RP11-767N6.2	5.32	1.28e-07	1.55e-05	0.17	0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45751050	chr1:45651039~45651826:-
BRCA	cis	rs2179367	0.6	rs9498356	ENSG00000216906.2	RP11-350J20.9	5.32	1.28e-07	1.55e-05	0.24	0.16	Dupuytren's disease;	chr6:149443337	chr6:149904243~149906418:+
BRCA	cis	rs2803122	0.774	rs10757034	ENSG00000273226.1	RP11-513M16.8	-5.32	1.29e-07	1.55e-05	-0.17	-0.16	Pulse pressure;	chr9:19227805	chr9:19375451~19375996:+
BRCA	cis	rs7674212	0.541	rs11727498	ENSG00000246560.2	RP11-10L12.4	5.32	1.29e-07	1.55e-05	0.18	0.16	Type 2 diabetes;	chr4:103179830	chr4:102828055~102844075:+
BRCA	cis	rs6496044	0.963	rs11853972	ENSG00000202081.1	RNU6-1280P	5.32	1.29e-07	1.55e-05	0.19	0.16	Interstitial lung disease;	chr15:85519209	chr15:85651522~85651628:-
BRCA	cis	rs357618	0.931	rs394736	ENSG00000260581.1	CTB-113P19.4	5.32	1.29e-07	1.55e-05	0.19	0.16	Basophil percentage of white cells;	chr5:151467948	chr5:151652275~151655449:+
BRCA	cis	rs412050	1	rs412050	ENSG00000224086.5	LL22NC03-86G7.1	-5.32	1.29e-07	1.55e-05	-0.22	-0.16	Attention deficit hyperactivity disorder;	chr22:21953147	chr22:21938293~21977632:+
BRCA	cis	rs1075265	0.584	rs1833497	ENSG00000235937.1	AC008280.1	5.32	1.29e-07	1.55e-05	0.18	0.16	Chronotype;Morning vs. evening chronotype;	chr2:54052186	chr2:54029552~54030682:-
BRCA	cis	rs2115630	1	rs58581703	ENSG00000259295.5	CSPG4P12	-5.32	1.29e-07	1.55e-05	-0.19	-0.16	P wave terminal force;	chr15:84733704	chr15:85191438~85213905:+
BRCA	cis	rs7674212	0.541	rs2720464	ENSG00000246560.2	RP11-10L12.4	5.32	1.29e-07	1.55e-05	0.17	0.16	Type 2 diabetes;	chr4:103152044	chr4:102828055~102844075:+
BRCA	cis	rs7818688	1	rs7832570	ENSG00000253528.2	RP11-347C18.4	-5.32	1.29e-07	1.55e-05	-0.25	-0.16	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95011567	chr8:94974573~94974853:-
BRCA	cis	rs17253792	0.598	rs71413578	ENSG00000186615.9	KTN1-AS1	-5.32	1.29e-07	1.55e-05	-0.33	-0.16	Putamen volume;	chr14:55551933	chr14:55499278~55580110:-
BRCA	cis	rs8098244	0.964	rs729814	ENSG00000264745.1	TTC39C-AS1	-5.32	1.29e-07	1.55e-05	-0.22	-0.16	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23903242	chr18:23994213~24015339:-
BRCA	cis	rs9308731	0.583	rs10211562	ENSG00000227992.1	AC108463.2	-5.32	1.29e-07	1.55e-05	-0.19	-0.16	Chronic lymphocytic leukemia;	chr2:111173219	chr2:111203964~111206215:-
BRCA	cis	rs2243480	0.522	rs431168	ENSG00000230295.1	RP11-458F8.2	-5.32	1.29e-07	1.55e-05	-0.27	-0.16	Diabetic kidney disease;	chr7:66046617	chr7:66880708~66882981:+
BRCA	cis	rs7569084	0.687	rs1344891	ENSG00000281920.1	RP11-418H16.1	5.32	1.29e-07	1.56e-05	0.21	0.16	Sum eosinophil basophil counts;	chr2:65458890	chr2:65623272~65628424:+
BRCA	cis	rs11955398	0.625	rs10805370	ENSG00000215032.2	GNL3LP1	5.32	1.29e-07	1.56e-05	0.2	0.16	Intelligence (multi-trait analysis);	chr5:60688417	chr5:60891935~60893577:-
BRCA	cis	rs10510102	0.935	rs10510101	ENSG00000226864.1	ATE1-AS1	5.32	1.29e-07	1.56e-05	0.29	0.16	Breast cancer;	chr10:121898614	chr10:121928312~121951965:+
BRCA	cis	rs16866061	0.515	rs11695326	ENSG00000228446.2	AC073052.1	5.32	1.29e-07	1.56e-05	0.18	0.16	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr2:224550417	chr2:224499387~224500100:-
BRCA	cis	rs13118159	0.556	rs4974615	ENSG00000254094.1	AC078852.1	5.32	1.29e-07	1.56e-05	0.19	0.16	Longevity;	chr4:1379763	chr4:1356581~1358075:+
BRCA	cis	rs6723226	0.767	rs10172308	ENSG00000276517.1	AL133243.2	5.32	1.29e-07	1.56e-05	0.2	0.16	Intelligence (multi-trait analysis);	chr2:32330691	chr2:32526504~32529507:+
BRCA	cis	rs853679	0.527	rs9461443	ENSG00000280107.1	AL022393.9	-5.32	1.29e-07	1.56e-05	-0.24	-0.16	Depression;	chr6:28226851	chr6:28170845~28172521:+
BRCA	cis	rs6570726	0.846	rs372904	ENSG00000270638.1	RP3-466P17.1	5.32	1.3e-07	1.56e-05	0.18	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145566289	chr6:145735570~145737218:+
BRCA	cis	rs2562456	0.793	rs73537884	ENSG00000268535.1	RP11-420K14.3	5.32	1.3e-07	1.56e-05	0.24	0.16	Pain;	chr19:21321908	chr19:21709522~21710191:+
BRCA	cis	rs2562456	0.793	rs78467454	ENSG00000268535.1	RP11-420K14.3	5.32	1.3e-07	1.56e-05	0.24	0.16	Pain;	chr19:21321930	chr19:21709522~21710191:+
BRCA	cis	rs1440410	0.83	rs4290853	ENSG00000250326.1	RP11-284M14.1	-5.32	1.3e-07	1.56e-05	-0.18	-0.16	Ischemic stroke;	chr4:143262016	chr4:142933195~143184861:-
BRCA	cis	rs73222236	0.825	rs9826146	ENSG00000273486.1	RP11-731C17.2	5.32	1.3e-07	1.56e-05	0.18	0.16	Coronary artery disease;	chr3:136264247	chr3:136837338~136839021:-
BRCA	cis	rs2904967	0.929	rs655433	ENSG00000255200.1	AP003068.18	5.32	1.3e-07	1.56e-05	0.28	0.16	Mean corpuscular volume;	chr11:65301804	chr11:65174117~65176470:-
BRCA	cis	rs853679	0.607	rs13211507	ENSG00000204709.4	LINC01556	5.32	1.3e-07	1.56e-05	0.41	0.16	Depression;	chr6:28289600	chr6:28943877~28944537:+
BRCA	cis	rs853679	0.607	rs34691223	ENSG00000204709.4	LINC01556	5.32	1.3e-07	1.56e-05	0.41	0.16	Depression;	chr6:28290431	chr6:28943877~28944537:+
BRCA	cis	rs202072	1	rs202053	ENSG00000272379.1	RP1-257A7.5	5.32	1.3e-07	1.56e-05	0.23	0.16	HIV-1 viral setpoint;	chr6:13273411	chr6:13290018~13290490:-
BRCA	cis	rs6479901	0.843	rs9414802	ENSG00000232075.1	MRPL35P2	5.32	1.3e-07	1.56e-05	0.24	0.16	Intelligence (multi-trait analysis);	chr10:63391622	chr10:63634317~63634827:-
BRCA	cis	rs1707322	0.691	rs61784803	ENSG00000234329.1	RP11-767N6.2	-5.32	1.3e-07	1.56e-05	-0.17	-0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45713599	chr1:45651039~45651826:-
BRCA	cis	rs1707322	0.663	rs3935296	ENSG00000234329.1	RP11-767N6.2	-5.32	1.3e-07	1.56e-05	-0.17	-0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45714798	chr1:45651039~45651826:-
BRCA	cis	rs1707322	0.721	rs28817701	ENSG00000234329.1	RP11-767N6.2	5.32	1.3e-07	1.56e-05	0.17	0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45720378	chr1:45651039~45651826:-
BRCA	cis	rs1707322	0.691	rs28495425	ENSG00000234329.1	RP11-767N6.2	5.32	1.3e-07	1.56e-05	0.17	0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45721648	chr1:45651039~45651826:-
BRCA	cis	rs7208859	0.623	rs7503335	ENSG00000280069.1	CTD-2349P21.3	-5.32	1.3e-07	1.56e-05	-0.22	-0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30746944	chr17:30738182~30740275:+
BRCA	cis	rs4950322	0.857	rs55790545	ENSG00000244371.2	PFN1P8	-5.32	1.3e-07	1.56e-05	-0.23	-0.16	Protein quantitative trait loci;	chr1:147366649	chr1:146957117~146957659:-
BRCA	cis	rs4950322	0.857	rs7522219	ENSG00000244371.2	PFN1P8	-5.32	1.3e-07	1.56e-05	-0.23	-0.16	Protein quantitative trait loci;	chr1:147366904	chr1:146957117~146957659:-
BRCA	cis	rs3733585	0.699	rs7663079	ENSG00000250413.1	RP11-448G15.1	5.32	1.3e-07	1.56e-05	0.21	0.16	Cleft plate (environmental tobacco smoke interaction);	chr4:9965147	chr4:10006482~10009725:+
BRCA	cis	rs3733585	0.699	rs7657340	ENSG00000250413.1	RP11-448G15.1	5.32	1.3e-07	1.56e-05	0.21	0.16	Cleft plate (environmental tobacco smoke interaction);	chr4:9965148	chr4:10006482~10009725:+
BRCA	cis	rs3733585	0.699	rs7663097	ENSG00000250413.1	RP11-448G15.1	5.32	1.3e-07	1.56e-05	0.21	0.16	Cleft plate (environmental tobacco smoke interaction);	chr4:9965167	chr4:10006482~10009725:+
BRCA	cis	rs17301013	0.761	rs332805	ENSG00000227373.4	RP11-160H22.5	5.32	1.3e-07	1.56e-05	0.22	0.16	Systemic lupus erythematosus;	chr1:174652487	chr1:174115300~174160004:-
BRCA	cis	rs763567	0.585	rs651386	ENSG00000271811.1	RP1-79C4.4	5.32	1.3e-07	1.56e-05	0.17	0.16	Tonsillectomy;	chr1:170622169	chr1:170667381~170669425:+
BRCA	cis	rs6847067	0.8	rs6847811	ENSG00000180769.7	WDFY3-AS2	-5.32	1.3e-07	1.56e-05	-0.15	-0.16	Oropharynx cancer;	chr4:84946160	chr4:84965682~85011277:+
BRCA	cis	rs2179367	0.919	rs577001	ENSG00000216906.2	RP11-350J20.9	5.32	1.3e-07	1.56e-05	0.21	0.16	Dupuytren's disease;	chr6:149325172	chr6:149904243~149906418:+
BRCA	cis	rs7617773	0.817	rs11928691	ENSG00000199476.1	Y_RNA	-5.32	1.3e-07	1.56e-05	-0.22	-0.16	Coronary artery disease;	chr3:48245275	chr3:48288587~48288694:+
BRCA	cis	rs11955398	0.502	rs6869073	ENSG00000215032.2	GNL3LP1	5.32	1.3e-07	1.56e-05	0.2	0.16	Intelligence (multi-trait analysis);	chr5:61117301	chr5:60891935~60893577:-
BRCA	cis	rs11955398	0.542	rs295578	ENSG00000215032.2	GNL3LP1	5.32	1.3e-07	1.56e-05	0.2	0.16	Intelligence (multi-trait analysis);	chr5:61124955	chr5:60891935~60893577:-
BRCA	cis	rs7772486	0.875	rs2777481	ENSG00000270638.1	RP3-466P17.1	5.32	1.3e-07	1.57e-05	0.19	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145988900	chr6:145735570~145737218:+
BRCA	cis	rs9308731	0.842	rs56173510	ENSG00000227992.1	AC108463.2	-5.32	1.3e-07	1.57e-05	-0.19	-0.16	Chronic lymphocytic leukemia;	chr2:111170859	chr2:111203964~111206215:-
BRCA	cis	rs2834188	1	rs2834187	ENSG00000272659.1	AP000295.10	-5.32	1.3e-07	1.57e-05	-0.24	-0.16	Narcolepsy;	chr21:33315105	chr21:33309491~33310181:+
BRCA	cis	rs2297363	0.502	rs4709393	ENSG00000213073.4	RP11-288H12.3	-5.31	1.3e-07	1.57e-05	-0.16	-0.16	Total cholesterol levels;Blood protein levels;	chr6:160051000	chr6:160093082~160096212:+
BRCA	cis	rs7200543	1	rs14347	ENSG00000258354.1	MIR3180-1	-5.31	1.31e-07	1.57e-05	-0.21	-0.16	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15040032	chr16:14909887~14911345:-
BRCA	cis	rs12534093	0.562	rs6461714	ENSG00000234286.1	AC006026.13	-5.31	1.31e-07	1.57e-05	-0.2	-0.16	Infant length;Height;	chr7:23536633	chr7:23680195~23680786:-
BRCA	cis	rs3764563	0.935	rs10408443	ENSG00000267594.5	CYP4F24P	-5.31	1.31e-07	1.57e-05	-0.31	-0.16	Inflammatory biomarkers;	chr19:15605162	chr19:15760241~15779909:-
BRCA	cis	rs9300255	0.679	rs12829456	ENSG00000235423.7	RP11-282O18.3	-5.31	1.31e-07	1.57e-05	-0.24	-0.16	Neutrophil percentage of white cells;	chr12:123240848	chr12:123252030~123261483:-
BRCA	cis	rs793571	0.554	rs28818840	ENSG00000259250.1	RP11-50C13.1	-5.31	1.31e-07	1.57e-05	-0.29	-0.16	Schizophrenia;	chr15:58727115	chr15:58587507~58591676:+
BRCA	cis	rs10392	0.543	rs4300896	ENSG00000274825.1	RP4-616B8.5	-5.31	1.31e-07	1.57e-05	-0.16	-0.16	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;	chr20:38951487	chr20:38955910~38956547:+
BRCA	cis	rs6044112	0.56	rs6080314	ENSG00000273998.1	RP4-777L9.2	5.31	1.31e-07	1.57e-05	0.34	0.16	Response to taxane treatment (docetaxel);	chr20:16597541	chr20:16576068~16579615:+
BRCA	cis	rs910316	0.934	rs8016330	ENSG00000279594.1	RP11-950C14.10	-5.31	1.31e-07	1.57e-05	-0.18	-0.16	Height;	chr14:75190804	chr14:75011269~75012851:-
BRCA	cis	rs295490	0.748	rs61680644	ENSG00000272656.1	RP11-219D15.3	5.31	1.31e-07	1.57e-05	0.37	0.16	PR interval in Tripanosoma cruzi seropositivity;	chr3:139455729	chr3:139349024~139349371:-
BRCA	cis	rs295490	0.667	rs79829464	ENSG00000272656.1	RP11-219D15.3	5.31	1.31e-07	1.57e-05	0.37	0.16	PR interval in Tripanosoma cruzi seropositivity;	chr3:139456842	chr3:139349024~139349371:-
BRCA	cis	rs11668609	0.81	rs17000162	ENSG00000268442.1	CTD-2027I19.2	5.31	1.31e-07	1.57e-05	0.24	0.16	Response to taxane treatment (docetaxel);	chr19:24185347	chr19:24162370~24163425:-
BRCA	cis	rs6951245	0.832	rs10266519	ENSG00000229043.2	AC091729.9	-5.31	1.31e-07	1.58e-05	-0.28	-0.16	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1103341	chr7:1160374~1165267:+
BRCA	cis	rs9545047	0.604	rs9530906	ENSG00000227354.5	RBM26-AS1	5.31	1.31e-07	1.58e-05	0.17	0.16	Schizophrenia;	chr13:79372401	chr13:79406309~79424328:+
BRCA	cis	rs2638953	0.924	rs11049613	ENSG00000247934.4	RP11-967K21.1	-5.31	1.31e-07	1.58e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28449859	chr12:28163298~28190738:-
BRCA	cis	rs2243480	1	rs709607	ENSG00000228409.4	CCT6P1	-5.31	1.31e-07	1.58e-05	-0.22	-0.16	Diabetic kidney disease;	chr7:65984554	chr7:65751142~65763354:+
BRCA	cis	rs950776	0.518	rs12902493	ENSG00000279373.1	RP11-650L12.4	5.31	1.31e-07	1.58e-05	0.2	0.16	Sudden cardiac arrest;	chr15:78526933	chr15:78537681~78538946:+
BRCA	cis	rs62025270	0.688	rs62025272	ENSG00000259295.5	CSPG4P12	-5.31	1.31e-07	1.58e-05	-0.23	-0.16	Idiopathic pulmonary fibrosis;	chr15:85770391	chr15:85191438~85213905:+
BRCA	cis	rs617791	0.53	rs735942	ENSG00000255320.1	RP11-755F10.1	5.31	1.31e-07	1.58e-05	0.22	0.16	Breast cancer;	chr11:65981866	chr11:66244840~66246239:-
BRCA	cis	rs6832769	1	rs6837710	ENSG00000223305.1	RN7SKP30	5.31	1.31e-07	1.58e-05	0.21	0.16	Personality dimensions;	chr4:55508288	chr4:55540502~55540835:-
BRCA	cis	rs7119	0.717	rs12915548	ENSG00000259362.2	RP11-307C19.1	-5.31	1.31e-07	1.58e-05	-0.23	-0.16	Type 2 diabetes;	chr15:77525700	chr15:77525540~77534110:+
BRCA	cis	rs3126085	0.56	rs45541239	ENSG00000237975.5	FLG-AS1	5.31	1.31e-07	1.58e-05	0.25	0.16	Atopic dermatitis;	chr1:152373915	chr1:152168125~152445456:+
BRCA	cis	rs4535700	0.501	rs10227764	ENSG00000226278.1	PSPHP1	5.31	1.31e-07	1.58e-05	0.19	0.16	Macular telangiectasia type 2;	chr7:55944729	chr7:55764797~55773288:+
BRCA	cis	rs7617773	0.78	rs11716848	ENSG00000199476.1	Y_RNA	-5.31	1.31e-07	1.58e-05	-0.24	-0.16	Coronary artery disease;	chr3:48337010	chr3:48288587~48288694:+
BRCA	cis	rs4853525	0.59	rs7587672	ENSG00000235852.1	AC005540.3	5.31	1.31e-07	1.58e-05	0.21	0.16	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190858549	chr2:190880797~190882059:-
BRCA	cis	rs4853525	0.59	rs1860168	ENSG00000235852.1	AC005540.3	5.31	1.31e-07	1.58e-05	0.21	0.16	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190859774	chr2:190880797~190882059:-
BRCA	cis	rs4853525	0.59	rs9973507	ENSG00000235852.1	AC005540.3	5.31	1.31e-07	1.58e-05	0.21	0.16	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190860922	chr2:190880797~190882059:-
BRCA	cis	rs7674212	0.541	rs2623070	ENSG00000248740.4	RP11-328K4.1	-5.31	1.31e-07	1.58e-05	-0.19	-0.16	Type 2 diabetes;	chr4:103116231	chr4:103256159~103453658:+
BRCA	cis	rs795484	0.507	rs1726407	ENSG00000275759.1	RP11-131L12.3	5.31	1.31e-07	1.58e-05	0.18	0.16	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;	chr12:118145921	chr12:118428281~118428870:+
BRCA	cis	rs597539	0.652	rs667989	ENSG00000261625.1	RP11-554A11.4	-5.31	1.32e-07	1.58e-05	-0.16	-0.16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68918308	chr11:69000765~69002048:-
BRCA	cis	rs4713675	0.565	rs9469566	ENSG00000224557.6	HLA-DPB2	-5.31	1.32e-07	1.58e-05	-0.19	-0.16	Plateletcrit;	chr6:33699828	chr6:33112451~33129084:+
BRCA	cis	rs28472312	0.862	rs11150623	ENSG00000251417.2	RP11-1348G14.4	-5.31	1.32e-07	1.59e-05	-0.2	-0.16	Intelligence (multi-trait analysis);	chr16:28869680	chr16:28802743~28817828:+
BRCA	cis	rs2348418	0.832	rs2100924	ENSG00000247934.4	RP11-967K21.1	-5.31	1.32e-07	1.59e-05	-0.19	-0.16	Lung function (FEV1);Lung function (FVC);	chr12:28340798	chr12:28163298~28190738:-
BRCA	cis	rs12439619	0.774	rs2867649	ENSG00000255769.6	GOLGA2P10	-5.31	1.32e-07	1.59e-05	-0.23	-0.16	Intelligence (multi-trait analysis);	chr15:82262331	chr15:82472993~82513950:-
BRCA	cis	rs7267979	0.873	rs7453	ENSG00000277938.1	RP5-965G21.3	5.31	1.32e-07	1.59e-05	0.2	0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25226438	chr20:25229150~25231933:+
BRCA	cis	rs8098244	0.737	rs1154232	ENSG00000264745.1	TTC39C-AS1	-5.31	1.32e-07	1.59e-05	-0.24	-0.16	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23931070	chr18:23994213~24015339:-
BRCA	cis	rs10899021	0.92	rs11236181	ENSG00000279353.1	RP11-864N7.4	5.31	1.32e-07	1.59e-05	0.3	0.16	Response to metformin (IC50);	chr11:74634778	chr11:74698231~74699658:-
BRCA	cis	rs7246657	0.678	rs2972446	ENSG00000276846.1	CTD-3220F14.3	-5.31	1.32e-07	1.59e-05	-0.22	-0.16	Coronary artery calcification;	chr19:37638992	chr19:37314868~37315620:-
BRCA	cis	rs8054556	1	rs7190185	ENSG00000273724.1	RP11-347C12.12	-5.31	1.32e-07	1.59e-05	-0.18	-0.16	Autism spectrum disorder or schizophrenia;	chr16:29951031	chr16:30336400~30343336:+
BRCA	cis	rs8103033	0.676	rs993983	ENSG00000268088.1	AC093063.2	-5.31	1.32e-07	1.59e-05	-0.18	-0.16	Obesity-related traits;	chr19:39660840	chr19:39693925~39696258:+
BRCA	cis	rs720475	0.695	rs62483108	ENSG00000170356.8	OR2A20P	5.31	1.32e-07	1.59e-05	0.25	0.16	Breast cancer;	chr7:144442326	chr7:144250045~144252957:-
BRCA	cis	rs4660456	0.556	rs823674	ENSG00000237899.1	RP4-739H11.3	-5.31	1.32e-07	1.59e-05	-0.2	-0.16	Platelet count;	chr1:40774799	chr1:40669089~40687588:-
BRCA	cis	rs10911232	0.507	rs10797832	ENSG00000224468.3	RP11-181K3.4	-5.31	1.32e-07	1.59e-05	-0.18	-0.16	Hypertriglyceridemia;	chr1:183074899	chr1:183138402~183141282:-
BRCA	cis	rs2638953	0.815	rs117066882	ENSG00000247934.4	RP11-967K21.1	-5.31	1.32e-07	1.59e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28477287	chr12:28163298~28190738:-
BRCA	cis	rs7246657	0.943	rs1373991	ENSG00000267422.1	CTD-2554C21.1	-5.31	1.33e-07	1.59e-05	-0.23	-0.16	Coronary artery calcification;	chr19:37348009	chr19:37779686~37792865:+
BRCA	cis	rs7246657	0.943	rs10405407	ENSG00000267422.1	CTD-2554C21.1	-5.31	1.33e-07	1.59e-05	-0.23	-0.16	Coronary artery calcification;	chr19:37348262	chr19:37779686~37792865:+
BRCA	cis	rs7246657	0.943	rs12709813	ENSG00000267422.1	CTD-2554C21.1	-5.31	1.33e-07	1.59e-05	-0.23	-0.16	Coronary artery calcification;	chr19:37354081	chr19:37779686~37792865:+
BRCA	cis	rs7246657	0.943	rs13345116	ENSG00000267422.1	CTD-2554C21.1	-5.31	1.33e-07	1.59e-05	-0.23	-0.16	Coronary artery calcification;	chr19:37356196	chr19:37779686~37792865:+
BRCA	cis	rs7246657	0.765	rs7247259	ENSG00000267422.1	CTD-2554C21.1	-5.31	1.33e-07	1.59e-05	-0.23	-0.16	Coronary artery calcification;	chr19:37360188	chr19:37779686~37792865:+
BRCA	cis	rs7246657	0.943	rs3745765	ENSG00000267422.1	CTD-2554C21.1	-5.31	1.33e-07	1.59e-05	-0.23	-0.16	Coronary artery calcification;	chr19:37363333	chr19:37779686~37792865:+
BRCA	cis	rs10740039	0.516	rs10740034	ENSG00000254271.1	RP11-131N11.4	5.31	1.33e-07	1.59e-05	0.22	0.16	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60592624	chr10:60734342~60741828:+
BRCA	cis	rs6840360	0.809	rs6847303	ENSG00000270265.1	RP11-731D1.4	5.31	1.33e-07	1.59e-05	0.19	0.16	Intelligence (multi-trait analysis);	chr4:151809069	chr4:151333775~151353224:-
BRCA	cis	rs2638953	0.853	rs11614463	ENSG00000247934.4	RP11-967K21.1	-5.31	1.33e-07	1.6e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28467278	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.853	rs10843183	ENSG00000247934.4	RP11-967K21.1	-5.31	1.33e-07	1.6e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28467775	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.853	rs11494781	ENSG00000247934.4	RP11-967K21.1	-5.31	1.33e-07	1.6e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28469166	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.853	rs11049638	ENSG00000247934.4	RP11-967K21.1	-5.31	1.33e-07	1.6e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28469687	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.853	rs11049639	ENSG00000247934.4	RP11-967K21.1	-5.31	1.33e-07	1.6e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28469868	chr12:28163298~28190738:-
BRCA	cis	rs2562456	0.754	rs58338799	ENSG00000268535.1	RP11-420K14.3	5.31	1.33e-07	1.6e-05	0.23	0.16	Pain;	chr19:21339009	chr19:21709522~21710191:+
BRCA	cis	rs4950322	0.547	rs56864370	ENSG00000278811.3	LINC00624	5.31	1.33e-07	1.6e-05	0.2	0.16	Protein quantitative trait loci;	chr1:147111847	chr1:147258885~147517875:-
BRCA	cis	rs2562456	0.793	rs2650819	ENSG00000268081.1	RP11-678G14.2	-5.31	1.33e-07	1.6e-05	-0.24	-0.16	Pain;	chr19:21456071	chr19:21554640~21569237:-
BRCA	cis	rs2898681	0.614	rs4864680	ENSG00000248375.1	RP11-177B4.1	-5.31	1.33e-07	1.6e-05	-0.22	-0.16	Optic nerve measurement (cup area);	chr4:52842254	chr4:52720081~52720831:-
BRCA	cis	rs2732480	0.5	rs12828309	ENSG00000257735.1	RP11-370I10.6	5.31	1.33e-07	1.6e-05	0.2	0.16	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48247377	chr12:48350945~48442411:+
BRCA	cis	rs9467773	0.967	rs6941022	ENSG00000124549.13	BTN2A3P	5.31	1.33e-07	1.6e-05	0.16	0.16	Intelligence (multi-trait analysis);	chr6:26553303	chr6:26421391~26432383:+
BRCA	cis	rs9467773	1	rs2224380	ENSG00000124549.13	BTN2A3P	5.31	1.33e-07	1.6e-05	0.16	0.16	Intelligence (multi-trait analysis);	chr6:26553715	chr6:26421391~26432383:+
BRCA	cis	rs9467773	1	rs6930120	ENSG00000124549.13	BTN2A3P	5.31	1.33e-07	1.6e-05	0.16	0.16	Intelligence (multi-trait analysis);	chr6:26555256	chr6:26421391~26432383:+
BRCA	cis	rs6479891	1	rs10761745	ENSG00000232075.1	MRPL35P2	-5.31	1.33e-07	1.6e-05	-0.29	-0.16	Arthritis (juvenile idiopathic);	chr10:63341311	chr10:63634317~63634827:-
BRCA	cis	rs6441961	0.501	rs6810232	ENSG00000223552.1	RP11-24F11.2	-5.31	1.33e-07	1.6e-05	-0.21	-0.16	Celiac disease;	chr3:46285113	chr3:46364955~46407059:-
BRCA	cis	rs7613875	0.62	rs11721204	ENSG00000228008.1	CTD-2330K9.3	5.31	1.33e-07	1.6e-05	0.16	0.16	Body mass index;	chr3:49945332	chr3:49903845~49916937:+
BRCA	cis	rs4950322	0.748	rs17360812	ENSG00000244371.2	PFN1P8	5.31	1.33e-07	1.6e-05	0.23	0.16	Protein quantitative trait loci;	chr1:147355010	chr1:146957117~146957659:-
BRCA	cis	rs7617773	0.747	rs34076262	ENSG00000199476.1	Y_RNA	-5.31	1.33e-07	1.6e-05	-0.24	-0.16	Coronary artery disease;	chr3:48328926	chr3:48288587~48288694:+
BRCA	cis	rs2638953	0.924	rs11049418	ENSG00000247934.4	RP11-967K21.1	-5.31	1.33e-07	1.6e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28192154	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.924	rs12367188	ENSG00000247934.4	RP11-967K21.1	-5.31	1.33e-07	1.6e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28192511	chr12:28163298~28190738:-
BRCA	cis	rs12477438	0.501	rs12613624	ENSG00000231822.1	AC019097.7	-5.31	1.33e-07	1.6e-05	-0.17	-0.16	Chronic sinus infection;	chr2:99116278	chr2:99102018~99102752:+
BRCA	cis	rs295490	0.748	rs41356949	ENSG00000272656.1	RP11-219D15.3	5.31	1.33e-07	1.6e-05	0.36	0.16	PR interval in Tripanosoma cruzi seropositivity;	chr3:139469580	chr3:139349024~139349371:-
BRCA	cis	rs2153535	0.526	rs7748404	ENSG00000251164.1	HULC	-5.31	1.33e-07	1.6e-05	-0.2	-0.16	Motion sickness;	chr6:8472267	chr6:8652137~8653846:+
BRCA	cis	rs2251381	0.75	rs2251186	ENSG00000176054.6	RPL23P2	5.31	1.33e-07	1.6e-05	0.19	0.16	Selective IgA deficiency;	chr21:29156559	chr21:28997613~28998033:-
BRCA	cis	rs9868809	0.505	rs9882549	ENSG00000270441.1	RP11-694I15.7	5.31	1.34e-07	1.61e-05	0.28	0.16	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48711925	chr3:49140086~49160851:-
BRCA	cis	rs6840360	0.607	rs2724565	ENSG00000278978.1	RP11-164P12.5	-5.31	1.34e-07	1.61e-05	-0.18	-0.16	Intelligence (multi-trait analysis);	chr4:151429153	chr4:151669786~151670503:+
BRCA	cis	rs7618501	0.538	rs9856572	ENSG00000228008.1	CTD-2330K9.3	-5.31	1.34e-07	1.61e-05	-0.16	-0.16	Intelligence (multi-trait analysis);	chr3:50071640	chr3:49903845~49916937:+
BRCA	cis	rs8002861	0.967	rs7994883	ENSG00000274001.1	RP11-5G9.5	-5.31	1.34e-07	1.61e-05	-0.18	-0.16	Leprosy;	chr13:43904669	chr13:43877715~43878163:-
BRCA	cis	rs8098244	0.894	rs9304391	ENSG00000264745.1	TTC39C-AS1	5.31	1.34e-07	1.61e-05	0.21	0.16	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23829811	chr18:23994213~24015339:-
BRCA	cis	rs950880	1	rs13001325	ENSG00000234389.1	AC007278.3	-5.31	1.34e-07	1.61e-05	-0.15	-0.16	Serum protein levels (sST2);	chr2:102322576	chr2:102438713~102440475:+
BRCA	cis	rs11822910	0.654	rs2439450	ENSG00000265566.2	RN7SL605P	5.31	1.34e-07	1.61e-05	0.22	0.16	Platelet distribution width;	chr11:57445588	chr11:57528085~57528365:-
BRCA	cis	rs9308731	0.623	rs6708784	ENSG00000227992.1	AC108463.2	-5.31	1.34e-07	1.61e-05	-0.19	-0.16	Chronic lymphocytic leukemia;	chr2:111169802	chr2:111203964~111206215:-
BRCA	cis	rs7119	0.717	rs12902925	ENSG00000259362.2	RP11-307C19.1	-5.31	1.34e-07	1.61e-05	-0.23	-0.16	Type 2 diabetes;	chr15:77526799	chr15:77525540~77534110:+
BRCA	cis	rs42490	0.868	rs12675281	ENSG00000251136.7	RP11-37B2.1	5.31	1.34e-07	1.61e-05	0.16	0.16	Leprosy;	chr8:89681561	chr8:89609409~89757727:-
BRCA	cis	rs9467773	0.967	rs6456732	ENSG00000124549.13	BTN2A3P	5.31	1.34e-07	1.61e-05	0.16	0.16	Intelligence (multi-trait analysis);	chr6:26514217	chr6:26421391~26432383:+
BRCA	cis	rs6570726	0.967	rs9497316	ENSG00000270638.1	RP3-466P17.1	-5.31	1.34e-07	1.61e-05	-0.18	-0.16	Lobe attachment (rater-scored or self-reported);	chr6:145471251	chr6:145735570~145737218:+
BRCA	cis	rs4950322	0.58	rs7515160	ENSG00000278811.3	LINC00624	5.31	1.34e-07	1.61e-05	0.21	0.16	Protein quantitative trait loci;	chr1:147120714	chr1:147258885~147517875:-
BRCA	cis	rs6840360	0.809	rs6846809	ENSG00000270265.1	RP11-731D1.4	5.31	1.34e-07	1.61e-05	0.19	0.16	Intelligence (multi-trait analysis);	chr4:151809049	chr4:151333775~151353224:-
BRCA	cis	rs2179367	0.632	rs6920383	ENSG00000268592.3	RAET1E-AS1	5.31	1.34e-07	1.61e-05	0.23	0.16	Dupuytren's disease;	chr6:149356361	chr6:149863494~149919507:+
BRCA	cis	rs7200543	1	rs4985154	ENSG00000258354.1	MIR3180-1	-5.31	1.34e-07	1.61e-05	-0.21	-0.16	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15037785	chr16:14909887~14911345:-
BRCA	cis	rs2255336	0.608	rs7957681	ENSG00000245648.1	RP11-277P12.20	5.31	1.34e-07	1.61e-05	0.26	0.16	Blood protein levels;	chr12:10366223	chr12:10363769~10398506:+
BRCA	cis	rs2919009	0.607	rs12257287	ENSG00000271670.1	RP11-95I16.4	5.31	1.34e-07	1.61e-05	0.22	0.16	Obesity-related traits;	chr10:120950653	chr10:120879256~120880667:-
BRCA	cis	rs11671005	0.504	rs3794963	ENSG00000252334.1	RNU6-1337P	-5.31	1.34e-07	1.61e-05	-0.22	-0.16	Mean platelet volume;	chr19:58559684	chr19:58483749~58483843:-
BRCA	cis	rs9652601	0.691	rs9941107	ENSG00000274038.1	RP11-66H6.4	-5.31	1.34e-07	1.61e-05	-0.18	-0.16	Systemic lupus erythematosus;	chr16:11102184	chr16:11056556~11057034:+
BRCA	cis	rs73222236	0.825	rs7621017	ENSG00000273486.1	RP11-731C17.2	5.31	1.34e-07	1.61e-05	0.18	0.16	Coronary artery disease;	chr3:136553387	chr3:136837338~136839021:-
BRCA	cis	rs7119	0.717	rs11639293	ENSG00000259362.2	RP11-307C19.1	-5.31	1.35e-07	1.62e-05	-0.23	-0.16	Type 2 diabetes;	chr15:77518503	chr15:77525540~77534110:+
BRCA	cis	rs3743162	0.553	rs12915656	ENSG00000259728.4	LINC00933	5.31	1.35e-07	1.62e-05	0.23	0.16	Alzheimer's disease (age of onset);	chr15:84872349	chr15:84570649~84580175:+
BRCA	cis	rs62025270	0.688	rs62022940	ENSG00000259295.5	CSPG4P12	-5.31	1.35e-07	1.62e-05	-0.24	-0.16	Idiopathic pulmonary fibrosis;	chr15:85709289	chr15:85191438~85213905:+
BRCA	cis	rs10129255	0.912	rs67410411	ENSG00000211974.3	IGHV2-70	5.31	1.35e-07	1.62e-05	0.17	0.16	Kawasaki disease;	chr14:106680324	chr14:106723574~106724093:-
BRCA	cis	rs1707322	0.721	rs10789470	ENSG00000234329.1	RP11-767N6.2	5.31	1.35e-07	1.62e-05	0.17	0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692659	chr1:45651039~45651826:-
BRCA	cis	rs7617773	0.78	rs11718350	ENSG00000199476.1	Y_RNA	-5.31	1.35e-07	1.62e-05	-0.25	-0.16	Coronary artery disease;	chr3:48319502	chr3:48288587~48288694:+
BRCA	cis	rs7618501	0.602	rs2071207	ENSG00000228008.1	CTD-2330K9.3	-5.31	1.35e-07	1.62e-05	-0.16	-0.16	Intelligence (multi-trait analysis);	chr3:50122411	chr3:49903845~49916937:+
BRCA	cis	rs2243480	1	rs6964530	ENSG00000228409.4	CCT6P1	-5.31	1.35e-07	1.62e-05	-0.22	-0.16	Diabetic kidney disease;	chr7:66253864	chr7:65751142~65763354:+
BRCA	cis	rs321358	0.945	rs17458235	ENSG00000271390.1	RP11-89C3.3	-5.31	1.35e-07	1.62e-05	-0.26	-0.16	Body mass index;	chr11:111106114	chr11:111089870~111090368:-
BRCA	cis	rs2239557	0.508	rs12587320	ENSG00000259065.1	RP5-1021I20.1	5.31	1.35e-07	1.62e-05	0.24	0.16	Common traits (Other);	chr14:73901591	chr14:73787360~73803270:+
BRCA	cis	rs3733585	0.699	rs7658170	ENSG00000250413.1	RP11-448G15.1	-5.31	1.35e-07	1.62e-05	-0.21	-0.16	Cleft plate (environmental tobacco smoke interaction);	chr4:9964969	chr4:10006482~10009725:+
BRCA	cis	rs7976269	0.537	rs4471475	ENSG00000275476.1	RP11-996F15.4	-5.31	1.35e-07	1.62e-05	-0.19	-0.16	Male-pattern baldness;	chr12:29022461	chr12:29277397~29277882:-
BRCA	cis	rs7845219	0.544	rs7016078	ENSG00000253528.2	RP11-347C18.4	5.31	1.35e-07	1.62e-05	0.17	0.16	Type 2 diabetes;	chr8:94910387	chr8:94974573~94974853:-
BRCA	cis	rs7178909	0.872	rs57715404	ENSG00000259677.1	RP11-493E3.1	5.31	1.35e-07	1.62e-05	0.19	0.16	Common traits (Other);	chr15:89890726	chr15:89876540~89877285:+
BRCA	cis	rs9467773	1	rs6910899	ENSG00000124549.13	BTN2A3P	5.31	1.35e-07	1.62e-05	0.16	0.16	Intelligence (multi-trait analysis);	chr6:26524111	chr6:26421391~26432383:+
BRCA	cis	rs9467773	1	rs4713006	ENSG00000124549.13	BTN2A3P	5.31	1.35e-07	1.62e-05	0.16	0.16	Intelligence (multi-trait analysis);	chr6:26519644	chr6:26421391~26432383:+
BRCA	cis	rs7131987	0.565	rs6487787	ENSG00000257176.2	RP11-996F15.2	5.31	1.35e-07	1.62e-05	0.19	0.16	QT interval;	chr12:29248353	chr12:29280418~29317848:-
BRCA	cis	rs7131987	0.565	rs6487791	ENSG00000257176.2	RP11-996F15.2	5.31	1.35e-07	1.62e-05	0.19	0.16	QT interval;	chr12:29250989	chr12:29280418~29317848:-
BRCA	cis	rs2179367	0.959	rs9373589	ENSG00000216906.2	RP11-350J20.9	5.31	1.35e-07	1.62e-05	0.2	0.16	Dupuytren's disease;	chr6:149386152	chr6:149904243~149906418:+
BRCA	cis	rs7618501	0.633	rs4688755	ENSG00000228008.1	CTD-2330K9.3	-5.31	1.35e-07	1.62e-05	-0.16	-0.16	Intelligence (multi-trait analysis);	chr3:50026991	chr3:49903845~49916937:+
BRCA	cis	rs9907295	0.818	rs3785764	ENSG00000270977.1	AC015849.16	-5.31	1.35e-07	1.62e-05	-0.3	-0.16	Fibroblast growth factor basic levels;	chr17:35833760	chr17:35893707~35911023:-
BRCA	cis	rs875971	0.756	rs4718328	ENSG00000236529.1	RP13-254B10.1	-5.31	1.35e-07	1.62e-05	-0.18	-0.16	Aortic root size;	chr7:66228350	chr7:65840212~65840596:+
BRCA	cis	rs2562456	0.72	rs6511250	ENSG00000268535.1	RP11-420K14.3	-5.31	1.35e-07	1.62e-05	-0.22	-0.16	Pain;	chr19:21473244	chr19:21709522~21710191:+
BRCA	cis	rs10559647	1	rs10559647	ENSG00000273038.2	RP11-479G22.8	-5.31	1.35e-07	1.62e-05	-0.23	-0.16	Platelet distribution width;	chr10:32380146	chr10:32887255~32889311:-
BRCA	cis	rs78487399	0.908	rs75664918	ENSG00000234936.1	AC010883.5	5.31	1.35e-07	1.62e-05	0.22	0.16	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43611951	chr2:43229573~43233394:+
BRCA	cis	rs9473147	0.543	rs9296558	ENSG00000270761.1	RP11-385F7.1	-5.31	1.35e-07	1.62e-05	-0.17	-0.16	Platelet distribution width;Mean platelet volume;	chr6:47484147	chr6:47477243~47477572:-
BRCA	cis	rs1979679	0.918	rs10843187	ENSG00000278733.1	RP11-425D17.1	-5.31	1.35e-07	1.63e-05	-0.21	-0.16	Ossification of the posterior longitudinal ligament of the spine;	chr12:28483586	chr12:28185625~28186190:-
BRCA	cis	rs7772486	0.748	rs2748484	ENSG00000270638.1	RP3-466P17.1	5.31	1.35e-07	1.63e-05	0.18	0.16	Lobe attachment (rater-scored or self-reported);	chr6:146012517	chr6:145735570~145737218:+
BRCA	cis	rs12468226	0.817	rs6722588	ENSG00000226261.1	AC064836.3	-5.31	1.35e-07	1.63e-05	-0.28	-0.16	Urate levels;	chr2:202187163	chr2:202336024~202336727:-
BRCA	cis	rs7119	0.717	rs12899390	ENSG00000259362.2	RP11-307C19.1	-5.31	1.36e-07	1.63e-05	-0.23	-0.16	Type 2 diabetes;	chr15:77522896	chr15:77525540~77534110:+
BRCA	cis	rs1707322	0.686	rs3014239	ENSG00000234329.1	RP11-767N6.2	-5.31	1.36e-07	1.63e-05	-0.17	-0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45624129	chr1:45651039~45651826:-
BRCA	cis	rs8048589	1	rs11648816	ENSG00000175604.2	RP11-276H1.3	-5.31	1.36e-07	1.63e-05	-0.24	-0.16	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);	chr16:12090250	chr16:12086746~12090302:-
BRCA	cis	rs9423406	0.752	rs34390260	ENSG00000224034.1	RP11-445P17.8	-5.31	1.36e-07	1.63e-05	-0.32	-0.16	Intelligence;	chr10:5262995	chr10:5266033~5271236:-
BRCA	cis	rs9423406	0.752	rs35426646	ENSG00000224034.1	RP11-445P17.8	-5.31	1.36e-07	1.63e-05	-0.32	-0.16	Intelligence;	chr10:5264082	chr10:5266033~5271236:-
BRCA	cis	rs9545047	0.604	rs2763810	ENSG00000227354.5	RBM26-AS1	5.31	1.36e-07	1.63e-05	0.18	0.16	Schizophrenia;	chr13:79405544	chr13:79406309~79424328:+
BRCA	cis	rs9308731	0.644	rs3789061	ENSG00000227992.1	AC108463.2	-5.31	1.36e-07	1.63e-05	-0.19	-0.16	Chronic lymphocytic leukemia;	chr2:111160653	chr2:111203964~111206215:-
BRCA	cis	rs2179367	0.632	rs2143075	ENSG00000268592.3	RAET1E-AS1	5.31	1.36e-07	1.63e-05	0.23	0.16	Dupuytren's disease;	chr6:149425507	chr6:149863494~149919507:+
BRCA	cis	rs10888838	0.938	rs12033727	ENSG00000198711.5	SSBP3-AS1	5.31	1.36e-07	1.63e-05	0.22	0.16	Mitochondrial DNA levels;	chr1:54214083	chr1:54236440~54239063:+
BRCA	cis	rs1167827	0.68	rs1167796	ENSG00000223705.8	NSUN5P1	-5.31	1.36e-07	1.63e-05	-0.12	-0.16	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75543861	chr7:75410322~75416787:+
BRCA	cis	rs1426063	0.858	rs9990627	ENSG00000260265.1	RP11-44F21.5	5.31	1.36e-07	1.63e-05	0.27	0.16	QT interval;	chr4:75081244	chr4:75081702~75084717:-
BRCA	cis	rs11124272	0.625	rs56175176	ENSG00000272716.1	RP11-563N4.1	5.31	1.36e-07	1.63e-05	0.2	0.16	Interleukin-18 levels;	chr2:31516496	chr2:32165046~32165757:-
BRCA	cis	rs2638953	0.853	rs3782515	ENSG00000247934.4	RP11-967K21.1	-5.31	1.36e-07	1.64e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28310511	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.962	rs11049521	ENSG00000247934.4	RP11-967K21.1	-5.31	1.36e-07	1.64e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28310976	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.962	rs10843151	ENSG00000247934.4	RP11-967K21.1	-5.31	1.36e-07	1.64e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28318386	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.962	rs10506029	ENSG00000247934.4	RP11-967K21.1	-5.31	1.36e-07	1.64e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28320302	chr12:28163298~28190738:-
BRCA	cis	rs6490294	0.851	rs1016079	ENSG00000226469.1	ADAM1B	-5.31	1.36e-07	1.64e-05	-0.21	-0.16	Mean platelet volume;	chr12:111972382	chr12:111927018~111929017:+
BRCA	cis	rs11009175	0.615	rs6481820	ENSG00000273038.2	RP11-479G22.8	-5.31	1.36e-07	1.64e-05	-0.22	-0.16	Depression (quantitative trait);	chr10:33011009	chr10:32887255~32889311:-
BRCA	cis	rs6480314	0.542	rs1007848	ENSG00000233590.1	RP11-153K11.3	-5.31	1.36e-07	1.64e-05	-0.27	-0.16	Optic nerve measurement (disc area);	chr10:68258549	chr10:68233251~68242379:-
BRCA	cis	rs6480314	0.542	rs61854807	ENSG00000233590.1	RP11-153K11.3	-5.31	1.36e-07	1.64e-05	-0.27	-0.16	Optic nerve measurement (disc area);	chr10:68258948	chr10:68233251~68242379:-
BRCA	cis	rs6480314	0.616	rs12571093	ENSG00000233590.1	RP11-153K11.3	-5.31	1.36e-07	1.64e-05	-0.27	-0.16	Optic nerve measurement (disc area);	chr10:68259614	chr10:68233251~68242379:-
BRCA	cis	rs7617773	0.78	rs7645425	ENSG00000199476.1	Y_RNA	-5.31	1.37e-07	1.64e-05	-0.24	-0.16	Coronary artery disease;	chr3:48320879	chr3:48288587~48288694:+
BRCA	cis	rs7617773	0.743	rs11716371	ENSG00000199476.1	Y_RNA	-5.31	1.37e-07	1.64e-05	-0.24	-0.16	Coronary artery disease;	chr3:48321260	chr3:48288587~48288694:+
BRCA	cis	rs7617773	0.78	rs6793223	ENSG00000199476.1	Y_RNA	-5.31	1.37e-07	1.64e-05	-0.24	-0.16	Coronary artery disease;	chr3:48322611	chr3:48288587~48288694:+
BRCA	cis	rs7617773	0.78	rs11714944	ENSG00000199476.1	Y_RNA	-5.31	1.37e-07	1.64e-05	-0.24	-0.16	Coronary artery disease;	chr3:48325481	chr3:48288587~48288694:+
BRCA	cis	rs7617773	0.78	rs7653336	ENSG00000199476.1	Y_RNA	-5.31	1.37e-07	1.64e-05	-0.24	-0.16	Coronary artery disease;	chr3:48327974	chr3:48288587~48288694:+
BRCA	cis	rs2638953	0.962	rs61922977	ENSG00000247934.4	RP11-967K21.1	-5.31	1.37e-07	1.64e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28286889	chr12:28163298~28190738:-
BRCA	cis	rs9341808	0.754	rs1015158	ENSG00000272129.1	RP11-250B2.6	5.31	1.37e-07	1.64e-05	0.2	0.16	Sitting height ratio;	chr6:80236028	chr6:80355424~80356859:+
BRCA	cis	rs9341808	0.791	rs1324122	ENSG00000272129.1	RP11-250B2.6	5.31	1.37e-07	1.64e-05	0.2	0.16	Sitting height ratio;	chr6:80236344	chr6:80355424~80356859:+
BRCA	cis	rs2051773	0.567	rs4456241	ENSG00000184669.7	OR7E14P	-5.31	1.37e-07	1.64e-05	-0.24	-0.16	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);	chr11:17021494	chr11:17013998~17053024:+
BRCA	cis	rs2051773	0.567	rs4517490	ENSG00000184669.7	OR7E14P	-5.31	1.37e-07	1.64e-05	-0.24	-0.16	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);	chr11:17021507	chr11:17013998~17053024:+
BRCA	cis	rs28472312	0.832	rs28433345	ENSG00000251417.2	RP11-1348G14.4	-5.31	1.37e-07	1.64e-05	-0.19	-0.16	Intelligence (multi-trait analysis);	chr16:28872006	chr16:28802743~28817828:+
BRCA	cis	rs6452524	0.508	rs40214	ENSG00000281327.1	LINC01338	-5.31	1.37e-07	1.64e-05	-0.19	-0.16	Hypertension (SNP x SNP interaction);	chr5:83000359	chr5:82850864~82859836:-
BRCA	cis	rs4925386	0.84	rs6142738	ENSG00000273619.1	RP5-908M14.9	5.31	1.37e-07	1.64e-05	0.15	0.16	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62344904	chr20:62386303~62386970:-
BRCA	cis	rs4803480	1	rs7255679	ENSG00000270164.1	LINC01480	-5.31	1.37e-07	1.64e-05	-0.2	-0.16	Schizophrenia;	chr19:41557611	chr19:41535183~41536904:+
BRCA	cis	rs7267979	0.789	rs6083841	ENSG00000231081.1	RP4-760C5.3	5.31	1.37e-07	1.64e-05	0.21	0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25403928	chr20:26008791~26010531:-
BRCA	cis	rs7267979	0.586	rs11087505	ENSG00000277938.1	RP5-965G21.3	5.31	1.37e-07	1.64e-05	0.19	0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25215884	chr20:25229150~25231933:+
BRCA	cis	rs516805	0.706	rs9490427	ENSG00000279453.1	RP3-425C14.4	5.31	1.37e-07	1.64e-05	0.23	0.16	Lymphocyte counts;	chr6:122353084	chr6:122436789~122439223:-
BRCA	cis	rs6545883	0.894	rs778148	ENSG00000270820.4	RP11-355B11.2	-5.31	1.37e-07	1.64e-05	-0.19	-0.16	Tuberculosis;	chr2:61379731	chr2:61471188~61484130:+
BRCA	cis	rs2638953	0.924	rs11049608	ENSG00000247934.4	RP11-967K21.1	-5.31	1.37e-07	1.64e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28445528	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.924	rs11049609	ENSG00000247934.4	RP11-967K21.1	-5.31	1.37e-07	1.64e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28445732	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.924	rs11049612	ENSG00000247934.4	RP11-967K21.1	-5.31	1.37e-07	1.64e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28449160	chr12:28163298~28190738:-
BRCA	cis	rs962856	1	rs1032157	ENSG00000236780.4	AC078941.1	5.31	1.37e-07	1.64e-05	0.21	0.16	Pancreatic cancer;	chr2:67374684	chr2:67123357~67215319:-
BRCA	cis	rs9287719	0.649	rs6721857	ENSG00000243819.4	RN7SL832P	-5.31	1.37e-07	1.64e-05	-0.16	-0.16	Prostate cancer;	chr2:10581084	chr2:10690344~10692099:+
BRCA	cis	rs2179367	0.632	rs9498335	ENSG00000268592.3	RAET1E-AS1	5.31	1.37e-07	1.65e-05	0.23	0.16	Dupuytren's disease;	chr6:149372648	chr6:149863494~149919507:+
BRCA	cis	rs10510102	0.935	rs12240893	ENSG00000226864.1	ATE1-AS1	5.31	1.37e-07	1.65e-05	0.3	0.16	Breast cancer;	chr10:121870572	chr10:121928312~121951965:+
BRCA	cis	rs12681366	1	rs7825731	ENSG00000253704.1	RP11-267M23.4	5.31	1.37e-07	1.65e-05	0.17	0.16	Nonsyndromic cleft lip with cleft palate;	chr8:94362147	chr8:94553722~94569745:+
BRCA	cis	rs7617773	0.743	rs4632568	ENSG00000199476.1	Y_RNA	-5.31	1.37e-07	1.65e-05	-0.24	-0.16	Coronary artery disease;	chr3:48326329	chr3:48288587~48288694:+
BRCA	cis	rs3733585	0.673	rs4455410	ENSG00000250413.1	RP11-448G15.1	-5.31	1.37e-07	1.65e-05	-0.21	-0.16	Cleft plate (environmental tobacco smoke interaction);	chr4:9951673	chr4:10006482~10009725:+
BRCA	cis	rs7617773	0.817	rs11130163	ENSG00000199476.1	Y_RNA	-5.31	1.37e-07	1.65e-05	-0.21	-0.16	Coronary artery disease;	chr3:48271168	chr3:48288587~48288694:+
BRCA	cis	rs7267979	0.586	rs6050445	ENSG00000277938.1	RP5-965G21.3	5.31	1.37e-07	1.65e-05	0.19	0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25214758	chr20:25229150~25231933:+
BRCA	cis	rs1218582	0.741	rs883718	ENSG00000270361.1	RP11-307C12.13	-5.31	1.38e-07	1.65e-05	-0.19	-0.16	Prostate cancer;	chr1:154873798	chr1:154937370~154938059:+
BRCA	cis	rs58785573	1	rs58785573	ENSG00000231160.8	KLF3-AS1	-5.31	1.38e-07	1.65e-05	-0.16	-0.16	Lymphocyte percentage of white cells;	chr4:38652152	chr4:38612701~38664883:-
BRCA	cis	rs7824557	0.505	rs2736313	ENSG00000154316.13	TDH	-5.3	1.38e-07	1.65e-05	-0.21	-0.16	Retinal vascular caliber;	chr8:11229433	chr8:11339637~11368452:+
BRCA	cis	rs9545047	0.604	rs9545085	ENSG00000227354.5	RBM26-AS1	5.3	1.38e-07	1.65e-05	0.18	0.16	Schizophrenia;	chr13:79363969	chr13:79406309~79424328:+
BRCA	cis	rs597539	0.652	rs627731	ENSG00000261625.1	RP11-554A11.4	-5.3	1.38e-07	1.65e-05	-0.17	-0.16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68931195	chr11:69000765~69002048:-
BRCA	cis	rs7617773	0.78	rs71323395	ENSG00000199476.1	Y_RNA	-5.3	1.38e-07	1.65e-05	-0.24	-0.16	Coronary artery disease;	chr3:48332587	chr3:48288587~48288694:+
BRCA	cis	rs7617773	0.743	rs71323397	ENSG00000199476.1	Y_RNA	-5.3	1.38e-07	1.65e-05	-0.24	-0.16	Coronary artery disease;	chr3:48333384	chr3:48288587~48288694:+
BRCA	cis	rs9307551	0.553	rs12639996	ENSG00000250334.4	LINC00989	-5.3	1.38e-07	1.65e-05	-0.23	-0.16	Refractive error;	chr4:79551326	chr4:79492416~79576460:+
BRCA	cis	rs1707322	0.662	rs11211160	ENSG00000234329.1	RP11-767N6.2	5.3	1.38e-07	1.65e-05	0.17	0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45680557	chr1:45651039~45651826:-
BRCA	cis	rs919433	0.68	rs3792159	ENSG00000231621.1	AC013264.2	5.3	1.38e-07	1.65e-05	0.16	0.16	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197538973	chr2:197197991~197199273:+
BRCA	cis	rs6452524	0.618	rs6452501	ENSG00000281327.1	LINC01338	5.3	1.38e-07	1.65e-05	0.18	0.16	Hypertension (SNP x SNP interaction);	chr5:83068681	chr5:82850864~82859836:-
BRCA	cis	rs5167	0.566	rs60876330	ENSG00000280087.1	CTB-129P6.7	5.3	1.38e-07	1.65e-05	0.22	0.16	Blood protein levels;	chr19:44984875	chr19:44909375~44914968:+
BRCA	cis	rs2732480	0.5	rs2932093	ENSG00000226413.2	OR8T1P	5.3	1.38e-07	1.65e-05	0.22	0.16	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48254488	chr12:48442030~48442947:-
BRCA	cis	rs7818688	1	rs73276406	ENSG00000253528.2	RP11-347C18.4	-5.3	1.38e-07	1.65e-05	-0.25	-0.16	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95009532	chr8:94974573~94974853:-
BRCA	cis	rs7818688	1	rs9297950	ENSG00000253528.2	RP11-347C18.4	-5.3	1.38e-07	1.65e-05	-0.25	-0.16	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95013431	chr8:94974573~94974853:-
BRCA	cis	rs2239557	0.508	rs11159044	ENSG00000259065.1	RP5-1021I20.1	-5.3	1.38e-07	1.65e-05	-0.24	-0.16	Common traits (Other);	chr14:73901158	chr14:73787360~73803270:+
BRCA	cis	rs3198697	0.663	rs12928099	ENSG00000207425.1	Y_RNA	5.3	1.38e-07	1.66e-05	0.22	0.16	Triglycerides;	chr16:15056648	chr16:14915457~14915556:-
BRCA	cis	rs2638953	0.924	rs11049619	ENSG00000247934.4	RP11-967K21.1	-5.3	1.38e-07	1.66e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28453495	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.924	rs60703205	ENSG00000247934.4	RP11-967K21.1	-5.3	1.38e-07	1.66e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28454371	chr12:28163298~28190738:-
BRCA	cis	rs6832769	1	rs4865008	ENSG00000272969.1	RP11-528I4.2	-5.3	1.38e-07	1.66e-05	-0.2	-0.16	Personality dimensions;	chr4:55544688	chr4:55547112~55547889:+
BRCA	cis	rs10510102	0.935	rs11200258	ENSG00000226864.1	ATE1-AS1	5.3	1.38e-07	1.66e-05	0.3	0.16	Breast cancer;	chr10:121918392	chr10:121928312~121951965:+
BRCA	cis	rs5167	0.534	rs56803710	ENSG00000280087.1	CTB-129P6.7	5.3	1.39e-07	1.66e-05	0.22	0.16	Blood protein levels;	chr19:44978627	chr19:44909375~44914968:+
BRCA	cis	rs5167	0.566	rs7253458	ENSG00000280087.1	CTB-129P6.7	5.3	1.39e-07	1.66e-05	0.22	0.16	Blood protein levels;	chr19:44979313	chr19:44909375~44914968:+
BRCA	cis	rs5167	0.533	rs55778858	ENSG00000280087.1	CTB-129P6.7	5.3	1.39e-07	1.66e-05	0.22	0.16	Blood protein levels;	chr19:44982208	chr19:44909375~44914968:+
BRCA	cis	rs5167	0.533	rs11083755	ENSG00000280087.1	CTB-129P6.7	5.3	1.39e-07	1.66e-05	0.22	0.16	Blood protein levels;	chr19:44986807	chr19:44909375~44914968:+
BRCA	cis	rs9473147	0.543	rs4715019	ENSG00000270761.1	RP11-385F7.1	-5.3	1.39e-07	1.66e-05	-0.18	-0.16	Platelet distribution width;Mean platelet volume;	chr6:47479305	chr6:47477243~47477572:-
BRCA	cis	rs2562456	0.833	rs2968076	ENSG00000268081.1	RP11-678G14.2	-5.3	1.39e-07	1.66e-05	-0.24	-0.16	Pain;	chr19:21454299	chr19:21554640~21569237:-
BRCA	cis	rs7617773	0.707	rs13061269	ENSG00000199476.1	Y_RNA	-5.3	1.39e-07	1.66e-05	-0.24	-0.16	Coronary artery disease;	chr3:48331853	chr3:48288587~48288694:+
BRCA	cis	rs2179367	0.92	rs638407	ENSG00000216906.2	RP11-350J20.9	5.3	1.39e-07	1.66e-05	0.2	0.16	Dupuytren's disease;	chr6:149417214	chr6:149904243~149906418:+
BRCA	cis	rs7618501	0.574	rs6765484	ENSG00000228008.1	CTD-2330K9.3	-5.3	1.39e-07	1.66e-05	-0.16	-0.16	Intelligence (multi-trait analysis);	chr3:50003880	chr3:49903845~49916937:+
BRCA	cis	rs10504130	0.569	rs11784869	ENSG00000272024.1	RP11-546K22.3	-5.3	1.39e-07	1.66e-05	-0.24	-0.16	Venous thromboembolism (SNP x SNP interaction);	chr8:51906951	chr8:51950284~51950690:+
BRCA	cis	rs67981189	0.529	rs8181986	ENSG00000258571.1	PTTG4P	-5.3	1.39e-07	1.66e-05	-0.19	-0.16	Schizophrenia;	chr14:71115527	chr14:71085482~71085833:-
BRCA	cis	rs10752881	0.967	rs4652758	ENSG00000224468.3	RP11-181K3.4	-5.3	1.39e-07	1.66e-05	-0.17	-0.16	Colorectal cancer;	chr1:183005965	chr1:183138402~183141282:-
BRCA	cis	rs4664293	0.867	rs6740910	ENSG00000226266.5	AC009961.3	-5.3	1.39e-07	1.66e-05	-0.21	-0.16	Monocyte percentage of white cells;	chr2:159792709	chr2:159670708~159712435:-
BRCA	cis	rs2403083	0.505	rs11261469	ENSG00000258256.1	RP11-219B4.5	-5.3	1.39e-07	1.66e-05	-0.19	-0.16	Plasma amyloid beta peptide concentrations (ABx-40);	chr8:85277470	chr8:85222446~85245717:-
BRCA	cis	rs7617773	0.817	rs13100815	ENSG00000199476.1	Y_RNA	-5.3	1.39e-07	1.67e-05	-0.24	-0.16	Coronary artery disease;	chr3:48245959	chr3:48288587~48288694:+
BRCA	cis	rs7674212	0.541	rs2720458	ENSG00000251288.2	RP11-10L12.2	-5.3	1.39e-07	1.67e-05	-0.19	-0.16	Type 2 diabetes;	chr4:103131806	chr4:102751401~102752641:+
BRCA	cis	rs10946940	0.896	rs12208078	ENSG00000216901.1	AL022393.7	-5.3	1.39e-07	1.67e-05	-0.2	-0.16	Systemic lupus erythematosus;	chr6:27530802	chr6:28176188~28176674:+
BRCA	cis	rs12999373	1	rs12999373	ENSG00000223751.1	AC116609.2	5.3	1.39e-07	1.67e-05	0.23	0.16	Response to fenofibrate (adiponectin levels);Uric acid levels;	chr2:663483	chr2:742488~747767:+
BRCA	cis	rs9393692	0.875	rs9393690	ENSG00000241549.7	GUSBP2	-5.3	1.39e-07	1.67e-05	-0.18	-0.16	Educational attainment;	chr6:26271485	chr6:26871484~26956554:-
BRCA	cis	rs7772486	0.727	rs12190966	ENSG00000270638.1	RP3-466P17.1	5.3	1.39e-07	1.67e-05	0.18	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145825684	chr6:145735570~145737218:+
BRCA	cis	rs7617773	0.817	rs9847953	ENSG00000199476.1	Y_RNA	-5.3	1.39e-07	1.67e-05	-0.22	-0.16	Coronary artery disease;	chr3:48241205	chr3:48288587~48288694:+
BRCA	cis	rs13113518	0.783	rs1586555	ENSG00000272969.1	RP11-528I4.2	5.3	1.39e-07	1.67e-05	0.19	0.16	Height;	chr4:55587104	chr4:55547112~55547889:+
BRCA	cis	rs7617773	0.779	rs77957078	ENSG00000199476.1	Y_RNA	-5.3	1.39e-07	1.67e-05	-0.24	-0.16	Coronary artery disease;	chr3:48289796	chr3:48288587~48288694:+
BRCA	cis	rs4237845	0.844	rs4628718	ENSG00000257159.1	RP11-58A17.3	5.3	1.4e-07	1.67e-05	0.2	0.16	Intelligence (multi-trait analysis);	chr12:57907817	chr12:57967058~57968399:+
BRCA	cis	rs2235544	0.579	rs1537321	ENSG00000225183.1	RP4-758J24.4	-5.3	1.4e-07	1.67e-05	-0.19	-0.16	Thyroid hormone levels;Multiple myeloma (hyperdiploidy);	chr1:54016563	chr1:54089856~54090093:+
BRCA	cis	rs62025270	0.632	rs62022942	ENSG00000202081.1	RNU6-1280P	-5.3	1.4e-07	1.67e-05	-0.24	-0.16	Idiopathic pulmonary fibrosis;	chr15:85715337	chr15:85651522~85651628:-
BRCA	cis	rs6570726	0.846	rs409553	ENSG00000270638.1	RP3-466P17.1	5.3	1.4e-07	1.67e-05	0.18	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145565827	chr6:145735570~145737218:+
BRCA	cis	rs6570726	0.846	rs371186	ENSG00000270638.1	RP3-466P17.1	5.3	1.4e-07	1.67e-05	0.18	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145565835	chr6:145735570~145737218:+
BRCA	cis	rs2638953	0.853	rs10506038	ENSG00000247934.4	RP11-967K21.1	5.3	1.4e-07	1.67e-05	0.22	0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28506239	chr12:28163298~28190738:-
BRCA	cis	rs875971	0.545	rs1796219	ENSG00000228409.4	CCT6P1	5.3	1.4e-07	1.67e-05	0.17	0.16	Aortic root size;	chr7:66645977	chr7:65751142~65763354:+
BRCA	cis	rs2299587	0.662	rs7816769	ENSG00000253671.1	RP11-806O11.1	5.3	1.4e-07	1.67e-05	0.2	0.16	Economic and political preferences;	chr8:17911039	chr8:17808941~17820868:+
BRCA	cis	rs7772486	0.686	rs1011596	ENSG00000270638.1	RP3-466P17.1	5.3	1.4e-07	1.67e-05	0.18	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145755297	chr6:145735570~145737218:+
BRCA	cis	rs1383484	0.958	rs5006997	ENSG00000230373.7	GOLGA6L5P	-5.3	1.4e-07	1.67e-05	-0.18	-0.16	Height;	chr15:83849268	chr15:84507885~84516814:-
BRCA	cis	rs2562456	0.92	rs2650784	ENSG00000268535.1	RP11-420K14.3	-5.3	1.4e-07	1.67e-05	-0.21	-0.16	Pain;	chr19:21483795	chr19:21709522~21710191:+
BRCA	cis	rs4713118	0.513	rs149950	ENSG00000280107.1	AL022393.9	-5.3	1.4e-07	1.67e-05	-0.22	-0.16	Parkinson's disease;	chr6:28065261	chr6:28170845~28172521:+
BRCA	cis	rs4713118	0.513	rs149951	ENSG00000280107.1	AL022393.9	-5.3	1.4e-07	1.67e-05	-0.22	-0.16	Parkinson's disease;	chr6:28065309	chr6:28170845~28172521:+
BRCA	cis	rs4237845	0.735	rs11172375	ENSG00000257159.1	RP11-58A17.3	5.3	1.4e-07	1.67e-05	0.19	0.16	Intelligence (multi-trait analysis);	chr12:57897791	chr12:57967058~57968399:+
BRCA	cis	rs7572733	0.534	rs10211202	ENSG00000231621.1	AC013264.2	-5.3	1.4e-07	1.67e-05	-0.16	-0.16	Dermatomyositis;	chr2:197907217	chr2:197197991~197199273:+
BRCA	cis	rs2704588	0.505	rs28718401	ENSG00000270720.1	RP11-84C13.2	-5.3	1.4e-07	1.67e-05	-0.3	-0.16	Longevity;	chr4:89051438	chr4:89119284~89119871:+
BRCA	cis	rs4908768	0.539	rs6666191	ENSG00000232912.4	RP5-1115A15.1	5.3	1.4e-07	1.68e-05	0.16	0.16	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8598383	chr1:8424645~8434838:+
BRCA	cis	rs1692120	0.545	rs1812458	ENSG00000243742.4	RPLP0P2	-5.3	1.4e-07	1.68e-05	-0.21	-0.16	Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid);	chr11:61640977	chr11:61615036~61639449:+
BRCA	cis	rs7577696	0.962	rs4952249	ENSG00000272716.1	RP11-563N4.1	-5.3	1.4e-07	1.68e-05	-0.18	-0.16	Inflammatory biomarkers;	chr2:32118604	chr2:32165046~32165757:-
BRCA	cis	rs9828933	0.577	rs704374	ENSG00000280620.1	SCAANT1	-5.3	1.4e-07	1.68e-05	-0.27	-0.16	Type 2 diabetes;	chr3:63880271	chr3:63911518~63911772:-
BRCA	cis	rs6772849	0.83	rs7633674	ENSG00000242551.2	POU5F1P6	-5.3	1.4e-07	1.68e-05	-0.2	-0.16	Monocyte percentage of white cells;Monocyte count;	chr3:128636183	chr3:128674735~128677005:-
BRCA	cis	rs9393777	0.668	rs3800318	ENSG00000216901.1	AL022393.7	5.3	1.4e-07	1.68e-05	0.25	0.16	Intelligence (multi-trait analysis);	chr6:27295862	chr6:28176188~28176674:+
BRCA	cis	rs9307551	0.619	rs12513177	ENSG00000250334.4	LINC00989	-5.3	1.4e-07	1.68e-05	-0.22	-0.16	Refractive error;	chr4:79547660	chr4:79492416~79576460:+
BRCA	cis	rs2179367	0.632	rs9498321	ENSG00000223701.3	RAET1E-AS1	5.3	1.4e-07	1.68e-05	0.24	0.16	Dupuytren's disease;	chr6:149322573	chr6:149884431~149919508:+
BRCA	cis	rs2562456	0.752	rs7258562	ENSG00000268081.1	RP11-678G14.2	5.3	1.4e-07	1.68e-05	0.26	0.16	Pain;	chr19:21331762	chr19:21554640~21569237:-
BRCA	cis	rs962856	0.891	rs638190	ENSG00000236780.4	AC078941.1	5.3	1.4e-07	1.68e-05	0.21	0.16	Pancreatic cancer;	chr2:67434958	chr2:67123357~67215319:-
BRCA	cis	rs4907240	0.922	rs4907246	ENSG00000237510.6	AC008268.2	-5.3	1.4e-07	1.68e-05	-0.23	-0.16	Event-related brain oscillations;	chr2:96660549	chr2:95789654~95800166:+
BRCA	cis	rs1823913	0.503	rs6706578	ENSG00000280083.1	RP11-317J9.1	-5.3	1.4e-07	1.68e-05	-0.19	-0.16	Obesity-related traits;	chr2:191346992	chr2:191154118~191156070:-
BRCA	cis	rs12497850	0.765	rs12487580	ENSG00000225399.4	RP11-3B7.1	5.3	1.4e-07	1.68e-05	0.16	0.16	Parkinson's disease;	chr3:49145499	chr3:49260085~49261316:+
BRCA	cis	rs12497850	0.797	rs61583136	ENSG00000225399.4	RP11-3B7.1	5.3	1.4e-07	1.68e-05	0.16	0.16	Parkinson's disease;	chr3:49151762	chr3:49260085~49261316:+
BRCA	cis	rs2624839	0.629	rs2526397	ENSG00000228008.1	CTD-2330K9.3	-5.3	1.4e-07	1.68e-05	-0.17	-0.16	Intelligence (multi-trait analysis);	chr3:50150357	chr3:49903845~49916937:+
BRCA	cis	rs651386	0.505	rs10919441	ENSG00000271811.1	RP1-79C4.4	5.3	1.4e-07	1.68e-05	0.19	0.16	Atrial fibrillation;	chr1:170609948	chr1:170667381~170669425:+
BRCA	cis	rs3102460	0.618	rs3123697	ENSG00000225401.2	TGIF2P1	-5.3	1.4e-07	1.68e-05	-0.24	-0.16	Obesity-related traits;	chr1:244417046	chr1:244394976~244395660:-
BRCA	cis	rs2638953	0.853	rs1355474	ENSG00000247934.4	RP11-967K21.1	-5.3	1.4e-07	1.68e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28463599	chr12:28163298~28190738:-
BRCA	cis	rs7674212	0.54	rs2711897	ENSG00000246560.2	RP11-10L12.4	5.3	1.41e-07	1.68e-05	0.17	0.16	Type 2 diabetes;	chr4:103102410	chr4:102828055~102844075:+
BRCA	cis	rs3892630	0.878	rs11878394	ENSG00000267567.1	CTD-2538C1.3	5.3	1.41e-07	1.68e-05	0.26	0.16	Red blood cell traits;	chr19:32714938	chr19:32718298~32719595:-
BRCA	cis	rs10129255	0.957	rs8014696	ENSG00000280411.1	IGHV1-69-2	5.3	1.41e-07	1.68e-05	0.12	0.16	Kawasaki disease;	chr14:106769752	chr14:106762092~106762588:-
BRCA	cis	rs875971	0.66	rs79009421	ENSG00000273024.4	INTS4P2	5.3	1.41e-07	1.68e-05	0.18	0.16	Aortic root size;	chr7:66603522	chr7:65647864~65715661:+
BRCA	cis	rs8114671	0.562	rs6120758	ENSG00000269202.1	RP4-614O4.12	-5.3	1.41e-07	1.68e-05	-0.16	-0.16	Height;	chr20:34904720	chr20:35201747~35203288:-
BRCA	cis	rs4713118	0.869	rs9348775	ENSG00000216901.1	AL022393.7	5.3	1.41e-07	1.68e-05	0.22	0.16	Parkinson's disease;	chr6:27727550	chr6:28176188~28176674:+
BRCA	cis	rs728616	0.614	rs61860413	ENSG00000225484.5	NUTM2B-AS1	-5.3	1.41e-07	1.68e-05	-0.32	-0.16	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79970363	chr10:79663088~79826594:-
BRCA	cis	rs728616	0.614	rs61860414	ENSG00000225484.5	NUTM2B-AS1	-5.3	1.41e-07	1.68e-05	-0.32	-0.16	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79970424	chr10:79663088~79826594:-
BRCA	cis	rs6545883	0.965	rs6734830	ENSG00000270820.4	RP11-355B11.2	5.3	1.41e-07	1.68e-05	0.18	0.16	Tuberculosis;	chr2:61503977	chr2:61471188~61484130:+
BRCA	cis	rs7620503	0.959	rs2863014	ENSG00000228221.4	LINC00578	5.3	1.41e-07	1.69e-05	0.19	0.16	Corneal structure;	chr3:177585404	chr3:177441921~177752305:+
BRCA	cis	rs4713118	0.513	rs149941	ENSG00000280107.1	AL022393.9	-5.3	1.41e-07	1.69e-05	-0.22	-0.16	Parkinson's disease;	chr6:28033255	chr6:28170845~28172521:+
BRCA	cis	rs7976269	0.583	rs4931131	ENSG00000275476.1	RP11-996F15.4	-5.3	1.41e-07	1.69e-05	-0.19	-0.16	Male-pattern baldness;	chr12:29015898	chr12:29277397~29277882:-
BRCA	cis	rs6847067	0.711	rs6847564	ENSG00000180769.7	WDFY3-AS2	5.3	1.41e-07	1.69e-05	0.17	0.16	Oropharynx cancer;	chr4:84811051	chr4:84965682~85011277:+
BRCA	cis	rs6847067	0.683	rs6829807	ENSG00000180769.7	WDFY3-AS2	5.3	1.41e-07	1.69e-05	0.17	0.16	Oropharynx cancer;	chr4:84811382	chr4:84965682~85011277:+
BRCA	cis	rs10129255	1	rs10134517	ENSG00000274576.2	IGHV2-70	5.3	1.41e-07	1.69e-05	0.15	0.16	Kawasaki disease;	chr14:106718498	chr14:106770577~106771020:-
BRCA	cis	rs875971	0.638	rs6960778	ENSG00000273024.4	INTS4P2	5.3	1.41e-07	1.69e-05	0.18	0.16	Aortic root size;	chr7:66606610	chr7:65647864~65715661:+
BRCA	cis	rs516805	0.63	rs2315816	ENSG00000279453.1	RP3-425C14.4	-5.3	1.41e-07	1.69e-05	-0.22	-0.16	Lymphocyte counts;	chr6:122102793	chr6:122436789~122439223:-
BRCA	cis	rs7577696	0.695	rs6716179	ENSG00000272716.1	RP11-563N4.1	-5.3	1.41e-07	1.69e-05	-0.17	-0.16	Inflammatory biomarkers;	chr2:32168007	chr2:32165046~32165757:-
BRCA	cis	rs9467773	1	rs9295695	ENSG00000124549.13	BTN2A3P	-5.3	1.41e-07	1.69e-05	-0.16	-0.16	Intelligence (multi-trait analysis);	chr6:26528022	chr6:26421391~26432383:+
BRCA	cis	rs9847710	1	rs13088455	ENSG00000242142.1	SERBP1P3	-5.3	1.41e-07	1.69e-05	-0.18	-0.16	Ulcerative colitis;	chr3:53053466	chr3:53064283~53065091:-
BRCA	cis	rs7208859	0.573	rs55661352	ENSG00000280069.1	CTD-2349P21.3	-5.3	1.41e-07	1.69e-05	-0.25	-0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30718610	chr17:30738182~30740275:+
BRCA	cis	rs9545047	0.604	rs1007569	ENSG00000227354.5	RBM26-AS1	5.3	1.41e-07	1.69e-05	0.17	0.16	Schizophrenia;	chr13:79306752	chr13:79406309~79424328:+
BRCA	cis	rs9545047	0.584	rs4885626	ENSG00000227354.5	RBM26-AS1	5.3	1.41e-07	1.69e-05	0.17	0.16	Schizophrenia;	chr13:79309765	chr13:79406309~79424328:+
BRCA	cis	rs9545047	0.604	rs4885627	ENSG00000227354.5	RBM26-AS1	5.3	1.41e-07	1.69e-05	0.17	0.16	Schizophrenia;	chr13:79309786	chr13:79406309~79424328:+
BRCA	cis	rs9545047	0.604	rs4885628	ENSG00000227354.5	RBM26-AS1	5.3	1.41e-07	1.69e-05	0.17	0.16	Schizophrenia;	chr13:79309830	chr13:79406309~79424328:+
BRCA	cis	rs9545047	0.554	rs4885629	ENSG00000227354.5	RBM26-AS1	5.3	1.41e-07	1.69e-05	0.17	0.16	Schizophrenia;	chr13:79309855	chr13:79406309~79424328:+
BRCA	cis	rs9545047	0.604	rs1927506	ENSG00000227354.5	RBM26-AS1	5.3	1.41e-07	1.69e-05	0.17	0.16	Schizophrenia;	chr13:79311350	chr13:79406309~79424328:+
BRCA	cis	rs9545047	0.604	rs1409019	ENSG00000227354.5	RBM26-AS1	5.3	1.41e-07	1.69e-05	0.17	0.16	Schizophrenia;	chr13:79312431	chr13:79406309~79424328:+
BRCA	cis	rs9545047	0.604	rs7317343	ENSG00000227354.5	RBM26-AS1	5.3	1.41e-07	1.69e-05	0.17	0.16	Schizophrenia;	chr13:79312542	chr13:79406309~79424328:+
BRCA	cis	rs7246760	0.867	rs55846005	ENSG00000277587.1	CTD-3116E22.8	-5.3	1.41e-07	1.69e-05	-0.32	-0.16	Pursuit maintenance gain;	chr19:9686033	chr19:9721903~9722410:+
BRCA	cis	rs7742369	0.586	rs6918981	ENSG00000276404.1	MIR6835	-5.3	1.41e-07	1.69e-05	-0.2	-0.16	Birth weight;Height;	chr6:34270737	chr6:34240673~34240736:+
BRCA	cis	rs7914558	1	rs943036	ENSG00000236937.2	PTGES3P4	5.3	1.42e-07	1.69e-05	0.21	0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103076290	chr10:102845595~102845950:+
BRCA	cis	rs1707322	0.686	rs2991987	ENSG00000234329.1	RP11-767N6.2	-5.3	1.42e-07	1.69e-05	-0.17	-0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45615750	chr1:45651039~45651826:-
BRCA	cis	rs2638953	0.962	rs11049515	ENSG00000247934.4	RP11-967K21.1	-5.3	1.42e-07	1.69e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28299564	chr12:28163298~28190738:-
BRCA	cis	rs2638953	1	rs11049516	ENSG00000247934.4	RP11-967K21.1	-5.3	1.42e-07	1.69e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28299649	chr12:28163298~28190738:-
BRCA	cis	rs9467773	1	rs9986382	ENSG00000124549.13	BTN2A3P	5.3	1.42e-07	1.7e-05	0.16	0.16	Intelligence (multi-trait analysis);	chr6:26550391	chr6:26421391~26432383:+
BRCA	cis	rs7119	0.717	rs12916515	ENSG00000259362.2	RP11-307C19.1	-5.3	1.42e-07	1.7e-05	-0.22	-0.16	Type 2 diabetes;	chr15:77526176	chr15:77525540~77534110:+
BRCA	cis	rs9393692	0.905	rs9379843	ENSG00000241549.7	GUSBP2	-5.3	1.42e-07	1.7e-05	-0.18	-0.16	Educational attainment;	chr6:26289207	chr6:26871484~26956554:-
BRCA	cis	rs9467773	0.967	rs1535276	ENSG00000124549.13	BTN2A3P	5.3	1.42e-07	1.7e-05	0.16	0.16	Intelligence (multi-trait analysis);	chr6:26520713	chr6:26421391~26432383:+
BRCA	cis	rs2281636	0.894	rs12782208	ENSG00000233690.1	EBAG9P1	5.3	1.42e-07	1.7e-05	0.17	0.16	Obesity-related traits;	chr10:99617219	chr10:99697407~99697949:-
BRCA	cis	rs875971	0.545	rs7783889	ENSG00000228409.4	CCT6P1	-5.3	1.42e-07	1.7e-05	-0.16	-0.16	Aortic root size;	chr7:66283366	chr7:65751142~65763354:+
BRCA	cis	rs539096	0.872	rs3791138	ENSG00000236200.4	KDM4A-AS1	-5.3	1.42e-07	1.7e-05	-0.2	-0.16	Intelligence (multi-trait analysis);	chr1:43584356	chr1:43699765~43708138:-
BRCA	cis	rs2243480	1	rs160639	ENSG00000228409.4	CCT6P1	5.3	1.42e-07	1.7e-05	0.23	0.16	Diabetic kidney disease;	chr7:66115000	chr7:65751142~65763354:+
BRCA	cis	rs875971	0.66	rs6460308	ENSG00000273024.4	INTS4P2	5.3	1.42e-07	1.7e-05	0.18	0.16	Aortic root size;	chr7:66619753	chr7:65647864~65715661:+
BRCA	cis	rs7577696	0.752	rs12614686	ENSG00000272716.1	RP11-563N4.1	-5.3	1.42e-07	1.7e-05	-0.18	-0.16	Inflammatory biomarkers;	chr2:32138102	chr2:32165046~32165757:-
BRCA	cis	rs11124272	0.571	rs28383003	ENSG00000272716.1	RP11-563N4.1	5.3	1.42e-07	1.7e-05	0.19	0.16	Interleukin-18 levels;	chr2:31578363	chr2:32165046~32165757:-
BRCA	cis	rs6490294	0.528	rs57502306	ENSG00000226469.1	ADAM1B	5.3	1.42e-07	1.7e-05	0.27	0.16	Mean platelet volume;	chr12:111852639	chr12:111927018~111929017:+
BRCA	cis	rs2732480	0.557	rs2732441	ENSG00000240399.1	RP1-228P16.1	5.3	1.42e-07	1.7e-05	0.19	0.16	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48329541	chr12:48054813~48055591:-
BRCA	cis	rs2732480	0.577	rs2732448	ENSG00000240399.1	RP1-228P16.1	5.3	1.42e-07	1.7e-05	0.19	0.16	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48336817	chr12:48054813~48055591:-
BRCA	cis	rs34217772	0.68	rs17181622	ENSG00000258636.1	CTD-2298J14.2	-5.3	1.42e-07	1.7e-05	-0.22	-0.16	Myopia;	chr14:41724366	chr14:41587861~41604856:-
BRCA	cis	rs4218	0.635	rs10431792	ENSG00000277144.1	RP11-59H7.4	-5.3	1.42e-07	1.7e-05	-0.21	-0.16	Social communication problems;	chr15:59066181	chr15:59115547~59116089:-
BRCA	cis	rs11098499	0.863	rs1155576	ENSG00000249244.1	RP11-548H18.2	5.3	1.42e-07	1.7e-05	0.19	0.16	Corneal astigmatism;	chr4:119529004	chr4:119391831~119395335:-
BRCA	cis	rs1979679	0.918	rs10771429	ENSG00000278733.1	RP11-425D17.1	-5.3	1.42e-07	1.7e-05	-0.21	-0.16	Ossification of the posterior longitudinal ligament of the spine;	chr12:28468573	chr12:28185625~28186190:-
BRCA	cis	rs2905347	0.757	rs2961295	ENSG00000179428.2	AC073072.5	-5.3	1.42e-07	1.7e-05	-0.17	-0.16	Major depression and alcohol dependence;	chr7:22656653	chr7:22725395~22727620:-
BRCA	cis	rs9311474	0.629	rs4282054	ENSG00000243224.1	RP5-1157M23.2	-5.3	1.42e-07	1.7e-05	-0.17	-0.16	Electroencephalogram traits;	chr3:52532049	chr3:52239258~52241097:+
BRCA	cis	rs2834188	0.814	rs2843996	ENSG00000272659.1	AP000295.10	-5.3	1.42e-07	1.7e-05	-0.25	-0.16	Narcolepsy;	chr21:33339142	chr21:33309491~33310181:+
BRCA	cis	rs1499614	0.522	rs13247442	ENSG00000228409.4	CCT6P1	5.3	1.42e-07	1.7e-05	0.29	0.16	Gout;	chr7:66723871	chr7:65751142~65763354:+
BRCA	cis	rs9419788	0.605	rs3891783	ENSG00000273450.1	RP11-76P2.4	5.3	1.43e-07	1.7e-05	0.2	0.16	Personality traits in bipolar disorder;	chr10:94256036	chr10:94314907~94315327:-
BRCA	cis	rs9473147	0.543	rs1004173	ENSG00000270761.1	RP11-385F7.1	-5.3	1.43e-07	1.7e-05	-0.18	-0.16	Platelet distribution width;Mean platelet volume;	chr6:47477281	chr6:47477243~47477572:-
BRCA	cis	rs1707322	0.721	rs11211163	ENSG00000234329.1	RP11-767N6.2	5.3	1.43e-07	1.7e-05	0.17	0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45687876	chr1:45651039~45651826:-
BRCA	cis	rs1707322	0.721	rs12037803	ENSG00000234329.1	RP11-767N6.2	5.3	1.43e-07	1.7e-05	0.17	0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45690820	chr1:45651039~45651826:-
BRCA	cis	rs1707322	0.721	rs61784796	ENSG00000234329.1	RP11-767N6.2	5.3	1.43e-07	1.7e-05	0.17	0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45697584	chr1:45651039~45651826:-
BRCA	cis	rs1707322	0.721	rs10749856	ENSG00000234329.1	RP11-767N6.2	5.3	1.43e-07	1.7e-05	0.17	0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45699174	chr1:45651039~45651826:-
BRCA	cis	rs1707322	0.721	rs10890344	ENSG00000234329.1	RP11-767N6.2	5.3	1.43e-07	1.7e-05	0.17	0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45700418	chr1:45651039~45651826:-
BRCA	cis	rs1707322	0.721	rs4564187	ENSG00000234329.1	RP11-767N6.2	5.3	1.43e-07	1.7e-05	0.17	0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45701189	chr1:45651039~45651826:-
BRCA	cis	rs1707322	0.752	rs28438704	ENSG00000234329.1	RP11-767N6.2	5.3	1.43e-07	1.7e-05	0.17	0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45704872	chr1:45651039~45651826:-
BRCA	cis	rs1707322	0.721	rs28442079	ENSG00000234329.1	RP11-767N6.2	5.3	1.43e-07	1.7e-05	0.17	0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45706329	chr1:45651039~45651826:-
BRCA	cis	rs9393692	0.905	rs9366649	ENSG00000241549.7	GUSBP2	5.3	1.43e-07	1.71e-05	0.18	0.16	Educational attainment;	chr6:26328875	chr6:26871484~26956554:-
BRCA	cis	rs1990950	0.933	rs11747685	ENSG00000248544.2	CTB-47B11.3	-5.3	1.43e-07	1.71e-05	-0.19	-0.16	Lung function (FEV1/FVC);	chr5:157476582	chr5:157375741~157384950:-
BRCA	cis	rs6441961	0.501	rs6441950	ENSG00000223552.1	RP11-24F11.2	-5.3	1.43e-07	1.71e-05	-0.21	-0.16	Celiac disease;	chr3:46277485	chr3:46364955~46407059:-
BRCA	cis	rs2274273	0.712	rs7144652	ENSG00000258413.1	RP11-665C16.6	-5.3	1.43e-07	1.71e-05	-0.21	-0.16	Protein biomarker;	chr14:55071000	chr14:55262767~55272075:-
BRCA	cis	rs8054556	1	rs4788204	ENSG00000273724.1	RP11-347C12.12	-5.3	1.43e-07	1.71e-05	-0.18	-0.16	Autism spectrum disorder or schizophrenia;	chr16:29983897	chr16:30336400~30343336:+
BRCA	cis	rs2337406	0.925	rs11851094	ENSG00000223648.3	IGHV3-64	5.3	1.43e-07	1.71e-05	0.17	0.16	Alzheimer's disease (late onset);	chr14:106688967	chr14:106643132~106658258:-
BRCA	cis	rs115769866	0.609	rs2191037	ENSG00000204709.4	LINC01556	5.3	1.43e-07	1.71e-05	0.24	0.16	Bipolar disorder;	chr6:28499211	chr6:28943877~28944537:+
BRCA	cis	rs2115630	0.645	rs1107179	ENSG00000259295.5	CSPG4P12	5.3	1.43e-07	1.71e-05	0.2	0.16	P wave terminal force;	chr15:84655131	chr15:85191438~85213905:+
BRCA	cis	rs7617773	0.78	rs4541431	ENSG00000199476.1	Y_RNA	-5.3	1.43e-07	1.71e-05	-0.24	-0.16	Coronary artery disease;	chr3:48323728	chr3:48288587~48288694:+
BRCA	cis	rs7617773	0.743	rs13071960	ENSG00000199476.1	Y_RNA	-5.3	1.43e-07	1.71e-05	-0.24	-0.16	Coronary artery disease;	chr3:48326047	chr3:48288587~48288694:+
BRCA	cis	rs7617773	0.78	rs11130164	ENSG00000199476.1	Y_RNA	-5.3	1.43e-07	1.71e-05	-0.24	-0.16	Coronary artery disease;	chr3:48327544	chr3:48288587~48288694:+
BRCA	cis	rs4908760	0.965	rs301814	ENSG00000232912.4	RP5-1115A15.1	5.3	1.43e-07	1.71e-05	0.16	0.16	Vitiligo;	chr1:8450517	chr1:8424645~8434838:+
BRCA	cis	rs8031584	0.958	rs7168641	ENSG00000270015.1	RP11-540B6.6	-5.3	1.43e-07	1.71e-05	-0.17	-0.16	Huntington's disease progression;	chr15:30943249	chr15:30926514~30928407:+
BRCA	cis	rs9393777	0.547	rs2893910	ENSG00000216901.1	AL022393.7	5.3	1.43e-07	1.71e-05	0.26	0.16	Intelligence (multi-trait analysis);	chr6:27315475	chr6:28176188~28176674:+
BRCA	cis	rs2179367	0.959	rs562428	ENSG00000216906.2	RP11-350J20.9	5.3	1.43e-07	1.71e-05	0.2	0.16	Dupuytren's disease;	chr6:149326389	chr6:149904243~149906418:+
BRCA	cis	rs9467773	0.967	rs7753565	ENSG00000124549.13	BTN2A3P	5.3	1.43e-07	1.71e-05	0.16	0.16	Intelligence (multi-trait analysis);	chr6:26559784	chr6:26421391~26432383:+
BRCA	cis	rs9638182	0.666	rs14415	ENSG00000274080.1	CTA-315H11.2	5.3	1.43e-07	1.71e-05	0.23	0.16	Triglycerides;	chr7:73570450	chr7:73609262~73611502:-
BRCA	cis	rs6847067	0.672	rs3747680	ENSG00000180769.7	WDFY3-AS2	5.3	1.43e-07	1.71e-05	0.16	0.16	Oropharynx cancer;	chr4:84691584	chr4:84965682~85011277:+
BRCA	cis	rs6565180	0.632	rs8050812	ENSG00000183604.13	SMG1P5	-5.3	1.43e-07	1.71e-05	-0.18	-0.16	Tonsillectomy;	chr16:30374516	chr16:30267553~30335374:-
BRCA	cis	rs4588572	0.688	rs2362829	ENSG00000245556.2	SCAMP1-AS1	-5.3	1.43e-07	1.71e-05	-0.19	-0.16	Triglycerides;	chr5:78428212	chr5:78342365~78360507:-
BRCA	cis	rs8054556	0.967	rs12918652	ENSG00000273724.1	RP11-347C12.12	-5.3	1.43e-07	1.71e-05	-0.18	-0.16	Autism spectrum disorder or schizophrenia;	chr16:29953036	chr16:30336400~30343336:+
BRCA	cis	rs4835473	0.932	rs4092718	ENSG00000249741.2	RP11-673E1.3	5.3	1.43e-07	1.71e-05	0.18	0.16	Immature fraction of reticulocytes;	chr4:143799637	chr4:143911514~143912053:-
BRCA	cis	rs7487075	0.619	rs4768725	ENSG00000274723.1	RP11-618L22.1	5.3	1.43e-07	1.71e-05	0.2	0.16	Itch intensity from mosquito bite;	chr12:46454695	chr12:46970504~46972155:+
BRCA	cis	rs61160187	0.505	rs4235482	ENSG00000215032.2	GNL3LP1	5.3	1.43e-07	1.71e-05	0.2	0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:60797785	chr5:60891935~60893577:-
BRCA	cis	rs1707322	0.964	rs7546237	ENSG00000234329.1	RP11-767N6.2	5.3	1.44e-07	1.71e-05	0.16	0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45819938	chr1:45651039~45651826:-
BRCA	cis	rs9467773	1	rs9467791	ENSG00000241549.7	GUSBP2	-5.3	1.44e-07	1.72e-05	-0.18	-0.16	Intelligence (multi-trait analysis);	chr6:26562258	chr6:26871484~26956554:-
BRCA	cis	rs1387259	0.929	rs11168484	ENSG00000240399.1	RP1-228P16.1	5.3	1.44e-07	1.72e-05	0.19	0.16	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48239806	chr12:48054813~48055591:-
BRCA	cis	rs1223397	0.938	rs35511719	ENSG00000215022.6	RP1-257A7.4	-5.3	1.44e-07	1.72e-05	-0.23	-0.16	Blood pressure;	chr6:13282210	chr6:13264861~13295586:-
BRCA	cis	rs17685	0.632	rs1859793	ENSG00000280388.1	RP11-229D13.3	-5.3	1.44e-07	1.72e-05	-0.17	-0.16	Coffee consumption (cups per day);Coffee consumption;	chr7:76191965	chr7:76043977~76045963:-
BRCA	cis	rs9308731	0.644	rs3789064	ENSG00000227992.1	AC108463.2	-5.3	1.44e-07	1.72e-05	-0.18	-0.16	Chronic lymphocytic leukemia;	chr2:111157745	chr2:111203964~111206215:-
BRCA	cis	rs9992667	0.577	rs10021686	ENSG00000231160.8	KLF3-AS1	5.3	1.44e-07	1.72e-05	0.22	0.16	Eosinophil percentage of granulocytes;	chr4:38703636	chr4:38612701~38664883:-
BRCA	cis	rs7577696	0.853	rs212734	ENSG00000272716.1	RP11-563N4.1	5.3	1.44e-07	1.72e-05	0.18	0.16	Inflammatory biomarkers;	chr2:32247684	chr2:32165046~32165757:-
BRCA	cis	rs9467773	1	rs767471	ENSG00000124549.13	BTN2A3P	5.3	1.44e-07	1.72e-05	0.16	0.16	Intelligence (multi-trait analysis);	chr6:26557626	chr6:26421391~26432383:+
BRCA	cis	rs7617773	0.78	rs13082158	ENSG00000199476.1	Y_RNA	-5.3	1.44e-07	1.72e-05	-0.24	-0.16	Coronary artery disease;	chr3:48330980	chr3:48288587~48288694:+
BRCA	cis	rs7617773	0.78	rs11710257	ENSG00000199476.1	Y_RNA	-5.3	1.44e-07	1.72e-05	-0.24	-0.16	Coronary artery disease;	chr3:48331724	chr3:48288587~48288694:+
BRCA	cis	rs4372836	0.681	rs13025377	ENSG00000226833.4	AC097724.3	5.3	1.44e-07	1.72e-05	0.19	0.16	Body mass index;	chr2:28730690	chr2:28708953~28736205:-
BRCA	cis	rs72717009	0.825	rs12746613	ENSG00000225217.1	HSPA7	5.3	1.44e-07	1.72e-05	0.28	0.16	Rheumatoid arthritis;	chr1:161497252	chr1:161606291~161608217:+
BRCA	cis	rs4535700	0.501	rs10245725	ENSG00000226278.1	PSPHP1	-5.3	1.44e-07	1.72e-05	-0.18	-0.16	Macular telangiectasia type 2;	chr7:55908855	chr7:55764797~55773288:+
BRCA	cis	rs2562456	1	rs2562456	ENSG00000268658.4	LINC00664	5.3	1.45e-07	1.73e-05	0.24	0.16	Pain;	chr19:21483408	chr19:21483374~21503238:+
BRCA	cis	rs10129255	0.744	rs28517388	ENSG00000280411.1	IGHV1-69-2	-5.3	1.45e-07	1.73e-05	-0.13	-0.16	Kawasaki disease;	chr14:106704323	chr14:106762092~106762588:-
BRCA	cis	rs2073316	0.592	rs6543631	ENSG00000272716.1	RP11-563N4.1	5.3	1.45e-07	1.73e-05	0.17	0.16	Interleukin-18 levels;	chr2:31517917	chr2:32165046~32165757:-
BRCA	cis	rs4819052	0.851	rs2838857	ENSG00000184274.3	LINC00315	-5.3	1.45e-07	1.73e-05	-0.22	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45261085	chr21:45300245~45305257:-
BRCA	cis	rs2239557	0.508	rs1974582	ENSG00000259065.1	RP5-1021I20.1	-5.3	1.45e-07	1.73e-05	-0.24	-0.16	Common traits (Other);	chr14:73900601	chr14:73787360~73803270:+
BRCA	cis	rs7618501	0.633	rs4688757	ENSG00000228008.1	CTD-2330K9.3	5.3	1.45e-07	1.73e-05	0.16	0.16	Intelligence (multi-trait analysis);	chr3:49997890	chr3:49903845~49916937:+
BRCA	cis	rs3764563	1	rs2031061	ENSG00000267594.5	CYP4F24P	-5.3	1.45e-07	1.73e-05	-0.31	-0.16	Inflammatory biomarkers;	chr19:15611150	chr19:15760241~15779909:-
BRCA	cis	rs919433	0.713	rs6719483	ENSG00000231621.1	AC013264.2	-5.29	1.45e-07	1.73e-05	-0.15	-0.16	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197608162	chr2:197197991~197199273:+
BRCA	cis	rs17428076	0.633	rs705870	ENSG00000228389.1	AC068039.4	-5.29	1.45e-07	1.73e-05	-0.22	-0.16	Myopia;	chr2:172067555	chr2:171773482~171775844:+
BRCA	cis	rs172166	0.611	rs203882	ENSG00000280107.1	AL022393.9	-5.29	1.45e-07	1.73e-05	-0.22	-0.16	Cardiac Troponin-T levels;	chr6:28110724	chr6:28170845~28172521:+
BRCA	cis	rs2732480	0.577	rs2732466	ENSG00000240399.1	RP1-228P16.1	5.29	1.45e-07	1.73e-05	0.19	0.16	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48338676	chr12:48054813~48055591:-
BRCA	cis	rs13126694	0.933	rs6830475	ENSG00000251429.1	RP11-597D13.7	5.29	1.45e-07	1.74e-05	0.15	0.16	Blood osmolality (transformed sodium);	chr4:158155527	chr4:158270378~158278676:+
BRCA	cis	rs2638953	0.962	rs11049505	ENSG00000247934.4	RP11-967K21.1	-5.29	1.45e-07	1.74e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28288087	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.962	rs11049509	ENSG00000247934.4	RP11-967K21.1	-5.29	1.45e-07	1.74e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28290055	chr12:28163298~28190738:-
BRCA	cis	rs7200543	1	rs16966952	ENSG00000258354.1	MIR3180-1	-5.29	1.46e-07	1.74e-05	-0.21	-0.16	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15042086	chr16:14909887~14911345:-
BRCA	cis	rs2403083	0.505	rs4617148	ENSG00000258256.1	RP11-219B4.5	-5.29	1.46e-07	1.74e-05	-0.19	-0.16	Plasma amyloid beta peptide concentrations (ABx-40);	chr8:85282132	chr8:85222446~85245717:-
BRCA	cis	rs11239930	0.517	rs2477568	ENSG00000230832.3	RP11-325P15.2	5.29	1.46e-07	1.74e-05	0.24	0.16	AIDS progression;	chr1:147076244	chr1:147082338~147083578:-
BRCA	cis	rs718433	1	rs718433	ENSG00000256379.1	TRAV8-5	-5.29	1.46e-07	1.74e-05	-0.19	-0.16	Intraocular pressure;	chr14:21767650	chr14:21903077~21903598:+
BRCA	cis	rs6847067	0.683	rs7695054	ENSG00000180769.7	WDFY3-AS2	5.29	1.46e-07	1.74e-05	0.16	0.16	Oropharynx cancer;	chr4:84841867	chr4:84965682~85011277:+
BRCA	cis	rs2638953	0.925	rs11049510	ENSG00000247934.4	RP11-967K21.1	-5.29	1.46e-07	1.74e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28290839	chr12:28163298~28190738:-
BRCA	cis	rs7620503	1	rs7645281	ENSG00000228221.4	LINC00578	5.29	1.46e-07	1.74e-05	0.19	0.16	Corneal structure;	chr3:177587048	chr3:177441921~177752305:+
BRCA	cis	rs62025270	0.688	rs62022940	ENSG00000202081.1	RNU6-1280P	-5.29	1.46e-07	1.74e-05	-0.23	-0.16	Idiopathic pulmonary fibrosis;	chr15:85709289	chr15:85651522~85651628:-
BRCA	cis	rs2562456	0.917	rs2681389	ENSG00000268658.4	LINC00664	-5.29	1.46e-07	1.74e-05	-0.26	-0.16	Pain;	chr19:21509773	chr19:21483374~21503238:+
BRCA	cis	rs41307935	0.908	rs17162313	ENSG00000260063.1	RP5-968P14.2	5.29	1.46e-07	1.74e-05	0.35	0.16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26849628	chr1:26692132~26694131:-
BRCA	cis	rs904251	0.704	rs2776873	ENSG00000204110.6	RP1-153P14.8	-5.29	1.46e-07	1.74e-05	-0.2	-0.16	Cognitive performance;	chr6:37515366	chr6:37507348~37535616:+
BRCA	cis	rs2098713	0.534	rs57424532	ENSG00000250155.1	CTD-2353F22.1	5.29	1.46e-07	1.74e-05	0.18	0.16	Telomere length;	chr5:37497184	chr5:36666214~36725195:-
BRCA	cis	rs2098713	0.569	rs2102828	ENSG00000250155.1	CTD-2353F22.1	5.29	1.46e-07	1.74e-05	0.18	0.16	Telomere length;	chr5:37498313	chr5:36666214~36725195:-
BRCA	cis	rs301901	0.501	rs10805626	ENSG00000250155.1	CTD-2353F22.1	5.29	1.46e-07	1.74e-05	0.18	0.16	Height;	chr5:37499115	chr5:36666214~36725195:-
BRCA	cis	rs2098713	0.569	rs58038848	ENSG00000250155.1	CTD-2353F22.1	5.29	1.46e-07	1.74e-05	0.18	0.16	Telomere length;	chr5:37502860	chr5:36666214~36725195:-
BRCA	cis	rs2098713	0.535	rs4541679	ENSG00000250155.1	CTD-2353F22.1	5.29	1.46e-07	1.74e-05	0.18	0.16	Telomere length;	chr5:37503120	chr5:36666214~36725195:-
BRCA	cis	rs2098713	0.569	rs7707460	ENSG00000250155.1	CTD-2353F22.1	5.29	1.46e-07	1.74e-05	0.18	0.16	Telomere length;	chr5:37504164	chr5:36666214~36725195:-
BRCA	cis	rs2732480	0.538	rs1387259	ENSG00000240399.1	RP1-228P16.1	-5.29	1.46e-07	1.74e-05	-0.19	-0.16	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48309739	chr12:48054813~48055591:-
BRCA	cis	rs4713118	0.869	rs9461405	ENSG00000216901.1	AL022393.7	5.29	1.46e-07	1.74e-05	0.22	0.16	Parkinson's disease;	chr6:27751596	chr6:28176188~28176674:+
BRCA	cis	rs8114671	0.647	rs1124511	ENSG00000269202.1	RP4-614O4.12	-5.29	1.46e-07	1.74e-05	-0.16	-0.16	Height;	chr20:35148894	chr20:35201747~35203288:-
BRCA	cis	rs10266483	0.562	rs10949887	ENSG00000228653.2	HNRNPCP7	-5.29	1.46e-07	1.75e-05	-0.21	-0.16	Response to statin therapy;	chr7:64291702	chr7:64500825~64501729:+
BRCA	cis	rs7200543	1	rs7200543	ENSG00000258354.1	MIR3180-1	5.29	1.46e-07	1.75e-05	0.21	0.16	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15036113	chr16:14909887~14911345:-
BRCA	cis	rs9473147	0.516	rs4715018	ENSG00000270761.1	RP11-385F7.1	-5.29	1.46e-07	1.75e-05	-0.18	-0.16	Platelet distribution width;Mean platelet volume;	chr6:47474135	chr6:47477243~47477572:-
BRCA	cis	rs2613964	0.504	rs1903431	ENSG00000240057.4	RP11-572M11.4	-5.29	1.46e-07	1.75e-05	-0.16	-0.16	Pediatric bone mineral content (spine);Pediatric bone mineral density (spine);	chr3:113133810	chr3:113019532~113183301:+
BRCA	cis	rs2638953	0.962	rs10843152	ENSG00000247934.4	RP11-967K21.1	-5.29	1.47e-07	1.75e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28319090	chr12:28163298~28190738:-
BRCA	cis	rs9840812	0.577	rs503973	ENSG00000273486.1	RP11-731C17.2	-5.29	1.47e-07	1.75e-05	-0.21	-0.16	Fibrinogen levels;	chr3:136340695	chr3:136837338~136839021:-
BRCA	cis	rs6756513	0.5	rs2278932	ENSG00000231024.1	AC092431.3	-5.29	1.47e-07	1.75e-05	-0.23	-0.16	Breast cancer;Platelet count;	chr2:69828984	chr2:69700192~69713847:-
BRCA	cis	rs10788972	0.683	rs4927055	ENSG00000225183.1	RP4-758J24.4	-5.29	1.47e-07	1.75e-05	-0.21	-0.16	Parkinson disease and lewy body pathology;	chr1:54110073	chr1:54089856~54090093:+
BRCA	cis	rs910316	0.737	rs175071	ENSG00000279594.1	RP11-950C14.10	-5.29	1.47e-07	1.75e-05	-0.18	-0.16	Height;	chr14:75031474	chr14:75011269~75012851:-
BRCA	cis	rs9467773	1	rs2255070	ENSG00000124549.13	BTN2A3P	5.29	1.47e-07	1.75e-05	0.16	0.16	Intelligence (multi-trait analysis);	chr6:26501549	chr6:26421391~26432383:+
BRCA	cis	rs11955398	0.625	rs286153	ENSG00000215032.2	GNL3LP1	5.29	1.47e-07	1.75e-05	0.19	0.16	Intelligence (multi-trait analysis);	chr5:60633121	chr5:60891935~60893577:-
BRCA	cis	rs13108904	0.65	rs3796618	ENSG00000253399.1	AC078852.2	-5.29	1.47e-07	1.75e-05	-0.19	-0.16	Obesity-related traits;	chr4:1355814	chr4:1358479~1359461:+
BRCA	cis	rs34792	0.554	rs12929694	ENSG00000207425.1	Y_RNA	-5.29	1.47e-07	1.75e-05	-0.21	-0.16	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15519840	chr16:14915457~14915556:-
BRCA	cis	rs801193	0.591	rs721717	ENSG00000273448.1	RP11-166O4.6	-5.29	1.47e-07	1.75e-05	-0.15	-0.16	Aortic root size;	chr7:66665305	chr7:67333047~67334383:+
BRCA	cis	rs6840360	0.642	rs2709834	ENSG00000278978.1	RP11-164P12.5	-5.29	1.47e-07	1.75e-05	-0.18	-0.16	Intelligence (multi-trait analysis);	chr4:151454272	chr4:151669786~151670503:+
BRCA	cis	rs9307551	0.619	rs7670107	ENSG00000250334.4	LINC00989	-5.29	1.47e-07	1.75e-05	-0.22	-0.16	Refractive error;	chr4:79502861	chr4:79492416~79576460:+
BRCA	cis	rs13108904	0.87	rs3755927	ENSG00000254094.1	AC078852.1	-5.29	1.47e-07	1.75e-05	-0.18	-0.16	Obesity-related traits;	chr4:1244458	chr4:1356581~1358075:+
BRCA	cis	rs7914558	0.966	rs1890185	ENSG00000236937.2	PTGES3P4	5.29	1.47e-07	1.75e-05	0.21	0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102988961	chr10:102845595~102845950:+
BRCA	cis	rs6723226	0.638	rs6543657	ENSG00000276334.1	AL133243.1	5.29	1.47e-07	1.75e-05	0.2	0.16	Intelligence (multi-trait analysis);	chr2:32480017	chr2:32521927~32523547:+
BRCA	cis	rs7617773	0.78	rs34630841	ENSG00000199476.1	Y_RNA	-5.29	1.47e-07	1.75e-05	-0.24	-0.16	Coronary artery disease;	chr3:48301771	chr3:48288587~48288694:+
BRCA	cis	rs4819052	0.679	rs8132135	ENSG00000184274.3	LINC00315	-5.29	1.47e-07	1.75e-05	-0.21	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45274867	chr21:45300245~45305257:-
BRCA	cis	rs17767294	0.614	rs72850302	ENSG00000204709.4	LINC01556	5.29	1.47e-07	1.76e-05	0.43	0.16	Parkinson's disease;	chr6:28273621	chr6:28943877~28944537:+
BRCA	cis	rs7246657	0.551	rs12978093	ENSG00000226686.6	LINC01535	-5.29	1.47e-07	1.76e-05	-0.28	-0.16	Coronary artery calcification;	chr19:37093514	chr19:37251912~37265535:+
BRCA	cis	rs9287719	0.967	rs7570118	ENSG00000243819.4	RN7SL832P	5.29	1.47e-07	1.76e-05	0.16	0.16	Prostate cancer;	chr2:10577881	chr2:10690344~10692099:+
BRCA	cis	rs875971	0.862	rs10274883	ENSG00000273448.1	RP11-166O4.6	-5.29	1.47e-07	1.76e-05	-0.15	-0.16	Aortic root size;	chr7:66651104	chr7:67333047~67334383:+
BRCA	cis	rs3733585	0.648	rs13103497	ENSG00000250413.1	RP11-448G15.1	-5.29	1.47e-07	1.76e-05	-0.21	-0.16	Cleft plate (environmental tobacco smoke interaction);	chr4:9977638	chr4:10006482~10009725:+
BRCA	cis	rs9291683	0.546	rs4575994	ENSG00000250413.1	RP11-448G15.1	-5.29	1.47e-07	1.76e-05	-0.21	-0.16	Bone mineral density;	chr4:9996355	chr4:10006482~10009725:+
BRCA	cis	rs9287719	0.967	rs12622765	ENSG00000243819.4	RN7SL832P	5.29	1.47e-07	1.76e-05	0.16	0.16	Prostate cancer;	chr2:10588205	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.967	rs759402	ENSG00000243819.4	RN7SL832P	5.29	1.47e-07	1.76e-05	0.16	0.16	Prostate cancer;	chr2:10589428	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.967	rs759403	ENSG00000243819.4	RN7SL832P	5.29	1.47e-07	1.76e-05	0.16	0.16	Prostate cancer;	chr2:10589771	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.967	rs11674433	ENSG00000243819.4	RN7SL832P	5.29	1.47e-07	1.76e-05	0.16	0.16	Prostate cancer;	chr2:10590713	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.967	rs2024431	ENSG00000243819.4	RN7SL832P	5.29	1.47e-07	1.76e-05	0.16	0.16	Prostate cancer;	chr2:10591201	chr2:10690344~10692099:+
BRCA	cis	rs13113518	0.545	rs6810483	ENSG00000273257.1	RP11-177J6.1	5.29	1.48e-07	1.76e-05	0.21	0.16	Height;	chr4:55424406	chr4:55387949~55388271:+
BRCA	cis	rs6840360	0.642	rs2724574	ENSG00000278978.1	RP11-164P12.5	5.29	1.48e-07	1.76e-05	0.18	0.16	Intelligence (multi-trait analysis);	chr4:151460648	chr4:151669786~151670503:+
BRCA	cis	rs9545047	0.604	rs1028770	ENSG00000227354.5	RBM26-AS1	-5.29	1.48e-07	1.76e-05	-0.17	-0.16	Schizophrenia;	chr13:79297346	chr13:79406309~79424328:+
BRCA	cis	rs4650994	0.507	rs12405456	ENSG00000273384.1	RP5-1098D14.1	5.29	1.48e-07	1.76e-05	0.21	0.16	HDL cholesterol;HDL cholesterol levels;	chr1:178543196	chr1:178651706~178652282:+
BRCA	cis	rs8103033	0.676	rs1988274	ENSG00000268088.1	AC093063.2	-5.29	1.48e-07	1.76e-05	-0.18	-0.16	Obesity-related traits;	chr19:39664258	chr19:39693925~39696258:+
BRCA	cis	rs6547705	0.858	rs12714202	ENSG00000231259.4	AC125232.1	5.29	1.48e-07	1.76e-05	0.25	0.16	Progressive supranuclear palsy;	chr2:86672815	chr2:87031815~87053069:-
BRCA	cis	rs9300255	0.679	rs12817892	ENSG00000235423.7	RP11-282O18.3	-5.29	1.48e-07	1.76e-05	-0.23	-0.16	Neutrophil percentage of white cells;	chr12:123244155	chr12:123252030~123261483:-
BRCA	cis	rs35264875	0.851	rs72930631	ENSG00000259799.1	RP11-554A11.9	5.29	1.48e-07	1.76e-05	0.22	0.16	Blond vs. brown hair color;	chr11:69100367	chr11:69155910~69159752:+
BRCA	cis	rs1198872	0.892	rs1198869	ENSG00000272275.1	RP11-791G15.2	-5.29	1.48e-07	1.76e-05	-0.2	-0.16	Cardiac Troponin-T levels;	chr2:10762319	chr2:10767875~10770058:-
BRCA	cis	rs7191700	0.583	rs243314	ENSG00000262636.1	CTD-3088G3.4	5.29	1.48e-07	1.76e-05	0.22	0.16	Multiple sclerosis;	chr16:11291247	chr16:11380859~11381118:-
BRCA	cis	rs875971	0.862	rs880166	ENSG00000236529.1	RP13-254B10.1	-5.29	1.48e-07	1.76e-05	-0.18	-0.16	Aortic root size;	chr7:66205775	chr7:65840212~65840596:+
BRCA	cis	rs55702914	0.809	rs2914982	ENSG00000231621.1	AC013264.2	5.29	1.48e-07	1.76e-05	0.16	0.16	Major depression and alcohol dependence;	chr2:197338069	chr2:197197991~197199273:+
BRCA	cis	rs9287719	0.967	rs9679581	ENSG00000243819.4	RN7SL832P	5.29	1.48e-07	1.77e-05	0.16	0.16	Prostate cancer;	chr2:10611610	chr2:10690344~10692099:+
BRCA	cis	rs2638953	0.924	rs11049579	ENSG00000278733.1	RP11-425D17.1	-5.29	1.48e-07	1.77e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28414693	chr12:28185625~28186190:-
BRCA	cis	rs2638953	0.924	rs10843163	ENSG00000278733.1	RP11-425D17.1	-5.29	1.48e-07	1.77e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28415541	chr12:28185625~28186190:-
BRCA	cis	rs1707322	0.963	rs11211202	ENSG00000234329.1	RP11-767N6.2	5.29	1.48e-07	1.77e-05	0.16	0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45826710	chr1:45651039~45651826:-
BRCA	cis	rs7617773	0.817	rs34728236	ENSG00000199476.1	Y_RNA	-5.29	1.48e-07	1.77e-05	-0.24	-0.16	Coronary artery disease;	chr3:48217618	chr3:48288587~48288694:+
BRCA	cis	rs7617773	0.817	rs79310258	ENSG00000199476.1	Y_RNA	-5.29	1.48e-07	1.77e-05	-0.24	-0.16	Coronary artery disease;	chr3:48218177	chr3:48288587~48288694:+
BRCA	cis	rs12468226	1	rs76284304	ENSG00000226261.1	AC064836.3	5.29	1.48e-07	1.77e-05	0.28	0.16	Urate levels;	chr2:202427116	chr2:202336024~202336727:-
BRCA	cis	rs12701220	0.894	rs12539012	ENSG00000229043.2	AC091729.9	-5.29	1.48e-07	1.77e-05	-0.25	-0.16	Bronchopulmonary dysplasia;	chr7:1012497	chr7:1160374~1165267:+
BRCA	cis	rs10129255	1	rs8010605	ENSG00000224373.3	IGHV4-59	5.29	1.48e-07	1.77e-05	0.1	0.16	Kawasaki disease;	chr14:106678742	chr14:106627249~106627825:-
BRCA	cis	rs9545047	0.604	rs9545082	ENSG00000227354.5	RBM26-AS1	5.29	1.48e-07	1.77e-05	0.17	0.16	Schizophrenia;	chr13:79358994	chr13:79406309~79424328:+
BRCA	cis	rs9545047	0.604	rs7332913	ENSG00000227354.5	RBM26-AS1	5.29	1.48e-07	1.77e-05	0.17	0.16	Schizophrenia;	chr13:79359149	chr13:79406309~79424328:+
BRCA	cis	rs9545047	0.604	rs9545083	ENSG00000227354.5	RBM26-AS1	5.29	1.48e-07	1.77e-05	0.17	0.16	Schizophrenia;	chr13:79360695	chr13:79406309~79424328:+
BRCA	cis	rs9545047	0.604	rs7322756	ENSG00000227354.5	RBM26-AS1	5.29	1.48e-07	1.77e-05	0.17	0.16	Schizophrenia;	chr13:79361120	chr13:79406309~79424328:+
BRCA	cis	rs9545047	0.604	rs7324006	ENSG00000227354.5	RBM26-AS1	5.29	1.48e-07	1.77e-05	0.17	0.16	Schizophrenia;	chr13:79361225	chr13:79406309~79424328:+
BRCA	cis	rs9545047	0.604	rs7322673	ENSG00000227354.5	RBM26-AS1	5.29	1.48e-07	1.77e-05	0.17	0.16	Schizophrenia;	chr13:79361266	chr13:79406309~79424328:+
BRCA	cis	rs9545047	0.604	rs2025913	ENSG00000227354.5	RBM26-AS1	5.29	1.48e-07	1.77e-05	0.17	0.16	Schizophrenia;	chr13:79357315	chr13:79406309~79424328:+
BRCA	cis	rs2098713	0.534	rs4086257	ENSG00000250155.1	CTD-2353F22.1	5.29	1.48e-07	1.77e-05	0.18	0.16	Telomere length;	chr5:37504695	chr5:36666214~36725195:-
BRCA	cis	rs2098713	0.501	rs1829293	ENSG00000250155.1	CTD-2353F22.1	5.29	1.48e-07	1.77e-05	0.18	0.16	Telomere length;	chr5:37505469	chr5:36666214~36725195:-
BRCA	cis	rs4713118	0.513	rs149989	ENSG00000280107.1	AL022393.9	-5.29	1.49e-07	1.77e-05	-0.22	-0.16	Parkinson's disease;	chr6:28030406	chr6:28170845~28172521:+
BRCA	cis	rs4713118	0.621	rs9368548	ENSG00000204709.4	LINC01556	5.29	1.49e-07	1.77e-05	0.24	0.16	Parkinson's disease;	chr6:28066959	chr6:28943877~28944537:+
BRCA	cis	rs7246657	0.943	rs10415937	ENSG00000267422.1	CTD-2554C21.1	-5.29	1.49e-07	1.77e-05	-0.23	-0.16	Coronary artery calcification;	chr19:37339162	chr19:37779686~37792865:+
BRCA	cis	rs7246657	0.943	rs10414904	ENSG00000267422.1	CTD-2554C21.1	-5.29	1.49e-07	1.77e-05	-0.23	-0.16	Coronary artery calcification;	chr19:37339186	chr19:37779686~37792865:+
BRCA	cis	rs55702914	0.712	rs12616329	ENSG00000231621.1	AC013264.2	5.29	1.49e-07	1.77e-05	0.15	0.16	Major depression and alcohol dependence;	chr2:197283905	chr2:197197991~197199273:+
BRCA	cis	rs62025270	0.688	rs17638180	ENSG00000202081.1	RNU6-1280P	-5.29	1.49e-07	1.77e-05	-0.25	-0.16	Idiopathic pulmonary fibrosis;	chr15:85735164	chr15:85651522~85651628:-
BRCA	cis	rs73222236	0.825	rs55797013	ENSG00000273486.1	RP11-731C17.2	5.29	1.49e-07	1.77e-05	0.18	0.16	Coronary artery disease;	chr3:136300362	chr3:136837338~136839021:-
BRCA	cis	rs2739330	0.587	rs4820571	ENSG00000228039.3	KB-1125A3.10	5.29	1.49e-07	1.77e-05	0.19	0.16	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23963780~23964374:+
BRCA	cis	rs720475	0.732	rs17172978	ENSG00000170356.8	OR2A20P	5.29	1.49e-07	1.77e-05	0.25	0.16	Breast cancer;	chr7:144429551	chr7:144250045~144252957:-
BRCA	cis	rs7617773	0.817	rs3731555	ENSG00000199476.1	Y_RNA	-5.29	1.49e-07	1.77e-05	-0.24	-0.16	Coronary artery disease;	chr3:48164612	chr3:48288587~48288694:+
BRCA	cis	rs7246657	0.551	rs10404069	ENSG00000226686.6	LINC01535	-5.29	1.49e-07	1.77e-05	-0.27	-0.16	Coronary artery calcification;	chr19:37147502	chr19:37251912~37265535:+
BRCA	cis	rs2732480	0.5	rs12829841	ENSG00000240399.1	RP1-228P16.1	5.29	1.49e-07	1.77e-05	0.19	0.16	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48234956	chr12:48054813~48055591:-
BRCA	cis	rs2732480	0.523	rs34286639	ENSG00000240399.1	RP1-228P16.1	5.29	1.49e-07	1.77e-05	0.19	0.16	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48235261	chr12:48054813~48055591:-
BRCA	cis	rs4713118	0.824	rs9468225	ENSG00000216901.1	AL022393.7	5.29	1.49e-07	1.77e-05	0.22	0.16	Parkinson's disease;	chr6:27777940	chr6:28176188~28176674:+
BRCA	cis	rs728616	0.614	rs58606426	ENSG00000225484.5	NUTM2B-AS1	-5.29	1.49e-07	1.78e-05	-0.32	-0.16	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79968556	chr10:79663088~79826594:-
BRCA	cis	rs62025270	0.632	rs62022942	ENSG00000259295.5	CSPG4P12	-5.29	1.49e-07	1.78e-05	-0.25	-0.16	Idiopathic pulmonary fibrosis;	chr15:85715337	chr15:85191438~85213905:+
BRCA	cis	rs875971	0.522	rs781144	ENSG00000273024.4	INTS4P2	-5.29	1.49e-07	1.78e-05	-0.18	-0.16	Aortic root size;	chr7:65975357	chr7:65647864~65715661:+
BRCA	cis	rs10911232	0.507	rs11582514	ENSG00000224468.3	RP11-181K3.4	-5.29	1.49e-07	1.78e-05	-0.17	-0.16	Hypertriglyceridemia;	chr1:183023026	chr1:183138402~183141282:-
BRCA	cis	rs1979679	0.801	rs1463571	ENSG00000278733.1	RP11-425D17.1	5.29	1.49e-07	1.78e-05	0.2	0.16	Ossification of the posterior longitudinal ligament of the spine;	chr12:28144514	chr12:28185625~28186190:-
BRCA	cis	rs9880192	0.516	rs2713575	ENSG00000242551.2	POU5F1P6	-5.29	1.49e-07	1.78e-05	-0.19	-0.16	White blood cell count;Eosinophil percentage of white cells;Monocyte count;Neutrophil percentage of granulocytes;Monocyte-lymphocyte ratio;Eosinophil percentage of granulocytes;Eosinophil counts;	chr3:128575512	chr3:128674735~128677005:-
BRCA	cis	rs690037	0.551	rs690522	ENSG00000271964.1	RP11-415F23.2	-5.29	1.49e-07	1.78e-05	-0.17	-0.16	Optic nerve measurement (cup-to-disc ratio);Optic nerve measurement (cup area);	chr3:16335560	chr3:16314439~16314987:+
BRCA	cis	rs13113518	1	rs13113518	ENSG00000223305.1	RN7SKP30	5.29	1.49e-07	1.78e-05	0.2	0.16	Height;	chr4:55533481	chr4:55540502~55540835:-
BRCA	cis	rs172166	0.694	rs1770131	ENSG00000280107.1	AL022393.9	-5.29	1.49e-07	1.78e-05	-0.22	-0.16	Cardiac Troponin-T levels;	chr6:28118635	chr6:28170845~28172521:+
BRCA	cis	rs4535700	0.501	rs28678267	ENSG00000226278.1	PSPHP1	5.29	1.49e-07	1.78e-05	0.18	0.16	Macular telangiectasia type 2;	chr7:55941797	chr7:55764797~55773288:+
BRCA	cis	rs4535700	0.501	rs11765531	ENSG00000226278.1	PSPHP1	5.29	1.49e-07	1.78e-05	0.18	0.16	Macular telangiectasia type 2;	chr7:55942594	chr7:55764797~55773288:+
BRCA	cis	rs7674212	0.541	rs2720458	ENSG00000246560.2	RP11-10L12.4	5.29	1.49e-07	1.78e-05	0.17	0.16	Type 2 diabetes;	chr4:103131806	chr4:102828055~102844075:+
BRCA	cis	rs9393692	0.875	rs2142703	ENSG00000241549.7	GUSBP2	-5.29	1.49e-07	1.78e-05	-0.18	-0.16	Educational attainment;	chr6:26289377	chr6:26871484~26956554:-
BRCA	cis	rs1707322	1	rs11211200	ENSG00000234329.1	RP11-767N6.2	5.29	1.5e-07	1.78e-05	0.16	0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45822680	chr1:45651039~45651826:-
BRCA	cis	rs12681366	0.663	rs2043987	ENSG00000253704.1	RP11-267M23.4	5.29	1.5e-07	1.78e-05	0.17	0.16	Nonsyndromic cleft lip with cleft palate;	chr8:94457465	chr8:94553722~94569745:+
BRCA	cis	rs8114671	0.528	rs6119542	ENSG00000269202.1	RP4-614O4.12	-5.29	1.5e-07	1.78e-05	-0.16	-0.16	Height;	chr20:34896742	chr20:35201747~35203288:-
BRCA	cis	rs2562456	0.793	rs7259396	ENSG00000268535.1	RP11-420K14.3	5.29	1.5e-07	1.78e-05	0.23	0.16	Pain;	chr19:21340661	chr19:21709522~21710191:+
BRCA	cis	rs2562456	0.678	rs7260140	ENSG00000268535.1	RP11-420K14.3	5.29	1.5e-07	1.78e-05	0.23	0.16	Pain;	chr19:21340723	chr19:21709522~21710191:+
BRCA	cis	rs2562456	0.833	rs11880624	ENSG00000268535.1	RP11-420K14.3	5.29	1.5e-07	1.78e-05	0.23	0.16	Pain;	chr19:21341028	chr19:21709522~21710191:+
BRCA	cis	rs12681366	1	rs66787185	ENSG00000253704.1	RP11-267M23.4	5.29	1.5e-07	1.79e-05	0.17	0.16	Nonsyndromic cleft lip with cleft palate;	chr8:94365254	chr8:94553722~94569745:+
BRCA	cis	rs11159086	1	rs11626856	ENSG00000270000.1	RP3-449M8.9	5.29	1.5e-07	1.79e-05	0.27	0.16	Advanced glycation end-product levels;	chr14:74469665	chr14:74471930~74472360:-
BRCA	cis	rs10129255	0.956	rs10137268	ENSG00000280411.1	IGHV1-69-2	-5.29	1.5e-07	1.79e-05	-0.12	-0.16	Kawasaki disease;	chr14:106697402	chr14:106762092~106762588:-
BRCA	cis	rs9650657	0.504	rs10109167	ENSG00000255046.1	RP11-297N6.4	5.29	1.5e-07	1.79e-05	0.19	0.16	Neuroticism;	chr8:11176016	chr8:11797928~11802568:-
BRCA	cis	rs3770081	1	rs12620810	ENSG00000273080.1	RP11-301O19.1	-5.29	1.5e-07	1.79e-05	-0.38	-0.16	Facial emotion recognition (sad faces);	chr2:86164358	chr2:86195590~86196049:+
BRCA	cis	rs153852	0.59	rs36733	ENSG00000243806.1	RPL7P18	5.29	1.5e-07	1.79e-05	0.22	0.16	Cancer;	chr5:94832585	chr5:94825961~94826694:-
BRCA	cis	rs7474896	0.515	rs2738203	ENSG00000120555.12	SEPT7P9	-5.29	1.5e-07	1.79e-05	-0.24	-0.16	Obesity (extreme);	chr10:37988668	chr10:38383069~38402916:-
BRCA	cis	rs8054556	1	rs4787489	ENSG00000273724.1	RP11-347C12.12	-5.29	1.5e-07	1.79e-05	-0.18	-0.16	Autism spectrum disorder or schizophrenia;	chr16:29984559	chr16:30336400~30343336:+
BRCA	cis	rs9308731	0.966	rs1877331	ENSG00000230499.1	AC108463.1	-5.29	1.5e-07	1.79e-05	-0.19	-0.16	Chronic lymphocytic leukemia;	chr2:111148933	chr2:111195963~111206494:+
BRCA	cis	rs14165	0.67	rs2359133	ENSG00000271916.1	RP11-884K10.6	5.29	1.5e-07	1.79e-05	0.16	0.16	Refractive error;	chr3:53802715	chr3:53797764~53798019:-
BRCA	cis	rs997295	0.592	rs7162320	ENSG00000270964.1	RP11-502I4.3	-5.29	1.5e-07	1.79e-05	-0.18	-0.16	Motion sickness;	chr15:67473700	chr15:67541072~67542604:-
BRCA	cis	rs62025270	0.688	rs12148571	ENSG00000202081.1	RNU6-1280P	-5.29	1.5e-07	1.79e-05	-0.25	-0.16	Idiopathic pulmonary fibrosis;	chr15:85724162	chr15:85651522~85651628:-
BRCA	cis	rs3733585	0.699	rs6449174	ENSG00000250413.1	RP11-448G15.1	5.29	1.51e-07	1.79e-05	0.21	0.16	Cleft plate (environmental tobacco smoke interaction);	chr4:9964798	chr4:10006482~10009725:+
BRCA	cis	rs71636778	0.509	rs41303629	ENSG00000260063.1	RP5-968P14.2	-5.29	1.51e-07	1.79e-05	-0.37	-0.16	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26731130	chr1:26692132~26694131:-
BRCA	cis	rs7674212	0.541	rs4699050	ENSG00000248740.4	RP11-328K4.1	5.29	1.51e-07	1.79e-05	0.19	0.16	Type 2 diabetes;	chr4:103193140	chr4:103256159~103453658:+
BRCA	cis	rs7674212	0.541	rs17217473	ENSG00000248740.4	RP11-328K4.1	5.29	1.51e-07	1.79e-05	0.19	0.16	Type 2 diabetes;	chr4:103193585	chr4:103256159~103453658:+
BRCA	cis	rs9650657	0.504	rs10108347	ENSG00000255046.1	RP11-297N6.4	5.29	1.51e-07	1.79e-05	0.19	0.16	Neuroticism;	chr8:11176008	chr8:11797928~11802568:-
BRCA	cis	rs6754311	0.608	rs3739020	ENSG00000224043.6	CCNT2-AS1	-5.29	1.51e-07	1.79e-05	-0.23	-0.16	Mosquito bite size;	chr2:135844921	chr2:134735464~134918710:-
BRCA	cis	rs62103177	0.81	rs62096745	ENSG00000261126.6	RP11-795F19.1	5.29	1.51e-07	1.79e-05	0.26	0.16	Opioid sensitivity;	chr18:79859135	chr18:80046900~80095482:+
BRCA	cis	rs7617773	0.674	rs13069029	ENSG00000199476.1	Y_RNA	-5.29	1.51e-07	1.79e-05	-0.24	-0.16	Coronary artery disease;	chr3:48313534	chr3:48288587~48288694:+
BRCA	cis	rs4925386	0.84	rs6143036	ENSG00000273619.1	RP5-908M14.9	-5.29	1.51e-07	1.79e-05	-0.15	-0.16	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62346665	chr20:62386303~62386970:-
BRCA	cis	rs7119	0.717	rs12901471	ENSG00000259362.2	RP11-307C19.1	-5.29	1.51e-07	1.8e-05	-0.23	-0.16	Type 2 diabetes;	chr15:77526650	chr15:77525540~77534110:+
BRCA	cis	rs9287719	0.967	rs4284804	ENSG00000243819.4	RN7SL832P	5.29	1.51e-07	1.8e-05	0.16	0.16	Prostate cancer;	chr2:10581998	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.935	rs10803723	ENSG00000243819.4	RN7SL832P	5.29	1.51e-07	1.8e-05	0.16	0.16	Prostate cancer;	chr2:10582751	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.935	rs6751075	ENSG00000243819.4	RN7SL832P	5.29	1.51e-07	1.8e-05	0.16	0.16	Prostate cancer;	chr2:10583420	chr2:10690344~10692099:+
BRCA	cis	rs2638953	0.676	rs11049727	ENSG00000278733.1	RP11-425D17.1	-5.29	1.51e-07	1.8e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28584864	chr12:28185625~28186190:-
BRCA	cis	rs9638182	1	rs34594435	ENSG00000274080.1	CTA-315H11.2	5.29	1.51e-07	1.8e-05	0.29	0.16	Triglycerides;	chr7:73562919	chr7:73609262~73611502:-
BRCA	cis	rs6832769	0.925	rs3817444	ENSG00000272969.1	RP11-528I4.2	5.29	1.51e-07	1.8e-05	0.2	0.16	Personality dimensions;	chr4:55509814	chr4:55547112~55547889:+
BRCA	cis	rs9467773	1	rs9467787	ENSG00000124549.13	BTN2A3P	5.29	1.51e-07	1.8e-05	0.16	0.16	Intelligence (multi-trait analysis);	chr6:26556541	chr6:26421391~26432383:+
BRCA	cis	rs8002861	0.967	rs7321596	ENSG00000274001.1	RP11-5G9.5	5.29	1.51e-07	1.8e-05	0.18	0.16	Leprosy;	chr13:43898119	chr13:43877715~43878163:-
BRCA	cis	rs78487399	0.908	rs72868625	ENSG00000234936.1	AC010883.5	5.29	1.51e-07	1.8e-05	0.22	0.16	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43604047	chr2:43229573~43233394:+
BRCA	cis	rs7618501	0.602	rs2240327	ENSG00000228008.1	CTD-2330K9.3	5.29	1.51e-07	1.8e-05	0.15	0.16	Intelligence (multi-trait analysis);	chr3:50075601	chr3:49903845~49916937:+
BRCA	cis	rs13113518	0.812	rs11939580	ENSG00000272969.1	RP11-528I4.2	5.29	1.51e-07	1.8e-05	0.19	0.16	Height;	chr4:55517185	chr4:55547112~55547889:+
BRCA	cis	rs9467773	1	rs9393728	ENSG00000124549.13	BTN2A3P	5.29	1.51e-07	1.8e-05	0.16	0.16	Intelligence (multi-trait analysis);	chr6:26509102	chr6:26421391~26432383:+
BRCA	cis	rs9467773	1	rs1056667	ENSG00000124549.13	BTN2A3P	5.29	1.51e-07	1.8e-05	0.16	0.16	Intelligence (multi-trait analysis);	chr6:26510336	chr6:26421391~26432383:+
BRCA	cis	rs1023500	1	rs1023497	ENSG00000205702.9	CYP2D7	-5.29	1.51e-07	1.8e-05	-0.16	-0.16	Schizophrenia;	chr22:41944504	chr22:42140203~42144577:-
BRCA	cis	rs10510102	0.935	rs11200260	ENSG00000226864.1	ATE1-AS1	5.29	1.51e-07	1.8e-05	0.29	0.16	Breast cancer;	chr10:121920169	chr10:121928312~121951965:+
BRCA	cis	rs7927592	0.913	rs4316515	ENSG00000212093.1	AP000807.1	-5.29	1.51e-07	1.8e-05	-0.18	-0.16	Total body bone mineral density;	chr11:68541372	chr11:68506083~68506166:-
BRCA	cis	rs7674212	0.541	rs2720464	ENSG00000251288.2	RP11-10L12.2	-5.29	1.51e-07	1.8e-05	-0.19	-0.16	Type 2 diabetes;	chr4:103152044	chr4:102751401~102752641:+
BRCA	cis	rs9287719	0.649	rs6732429	ENSG00000243819.4	RN7SL832P	-5.29	1.51e-07	1.8e-05	-0.16	-0.16	Prostate cancer;	chr2:10618846	chr2:10690344~10692099:+
BRCA	cis	rs7620503	0.921	rs7620560	ENSG00000228221.4	LINC00578	5.29	1.51e-07	1.8e-05	0.19	0.16	Corneal structure;	chr3:177586388	chr3:177441921~177752305:+
BRCA	cis	rs7818688	1	rs28616734	ENSG00000253528.2	RP11-347C18.4	-5.29	1.51e-07	1.8e-05	-0.25	-0.16	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95009215	chr8:94974573~94974853:-
BRCA	cis	rs78487399	0.808	rs78886764	ENSG00000234936.1	AC010883.5	5.29	1.51e-07	1.8e-05	0.26	0.16	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43426360	chr2:43229573~43233394:+
BRCA	cis	rs4671400	0.571	rs62152275	ENSG00000271889.1	RP11-493E12.1	-5.29	1.51e-07	1.8e-05	-0.24	-0.16	3-hydroxypropylmercapturic acid levels in smokers;	chr2:61275103	chr2:61151433~61162105:-
BRCA	cis	rs9467773	1	rs9357010	ENSG00000124549.13	BTN2A3P	5.29	1.51e-07	1.8e-05	0.16	0.16	Intelligence (multi-trait analysis);	chr6:26527717	chr6:26421391~26432383:+
BRCA	cis	rs13108904	0.87	rs2291199	ENSG00000254094.1	AC078852.1	-5.29	1.51e-07	1.8e-05	-0.18	-0.16	Obesity-related traits;	chr4:1250479	chr4:1356581~1358075:+
BRCA	cis	rs4713118	0.513	rs9368547	ENSG00000280107.1	AL022393.9	-5.29	1.51e-07	1.8e-05	-0.22	-0.16	Parkinson's disease;	chr6:28060289	chr6:28170845~28172521:+
BRCA	cis	rs4713118	0.513	rs183244	ENSG00000280107.1	AL022393.9	-5.29	1.51e-07	1.8e-05	-0.22	-0.16	Parkinson's disease;	chr6:28064060	chr6:28170845~28172521:+
BRCA	cis	rs1707322	0.927	rs11211194	ENSG00000234329.1	RP11-767N6.2	5.29	1.51e-07	1.8e-05	0.17	0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45816412	chr1:45651039~45651826:-
BRCA	cis	rs8180040	0.587	rs1466741	ENSG00000276925.1	RP11-708J19.3	5.29	1.51e-07	1.8e-05	0.18	0.16	Colorectal cancer;	chr3:47205724	chr3:47469777~47469987:+
BRCA	cis	rs10129255	0.828	rs10140989	ENSG00000211974.3	IGHV2-70	5.29	1.52e-07	1.8e-05	0.17	0.16	Kawasaki disease;	chr14:106668657	chr14:106723574~106724093:-
BRCA	cis	rs4934494	0.677	rs72818709	ENSG00000240996.1	RP11-80H5.7	-5.29	1.52e-07	1.8e-05	-0.22	-0.16	Red blood cell count;	chr10:89611689	chr10:89694295~89697928:-
BRCA	cis	rs2239547	0.522	rs6773040	ENSG00000242142.1	SERBP1P3	-5.29	1.52e-07	1.8e-05	-0.2	-0.16	Schizophrenia;	chr3:52901412	chr3:53064283~53065091:-
BRCA	cis	rs8180040	0.577	rs12493425	ENSG00000276925.1	RP11-708J19.3	-5.29	1.52e-07	1.8e-05	-0.18	-0.16	Colorectal cancer;	chr3:47135456	chr3:47469777~47469987:+
BRCA	cis	rs7760535	0.656	rs1883136	ENSG00000255389.1	C6orf3	-5.29	1.52e-07	1.81e-05	-0.15	-0.16	Metabolic traits;	chr6:111585820	chr6:111599875~111602295:+
BRCA	cis	rs16949788	1	rs74894249	ENSG00000261351.2	CTD-3185P2.1	-5.29	1.52e-07	1.81e-05	-0.33	-0.16	Spherical equivalent (joint analysis main effects and education interaction);	chr15:66526309	chr15:66488658~66492109:-
BRCA	cis	rs9341808	0.718	rs3828754	ENSG00000272129.1	RP11-250B2.6	5.29	1.52e-07	1.81e-05	0.21	0.16	Sitting height ratio;	chr6:80190923	chr6:80355424~80356859:+
BRCA	cis	rs9341808	0.718	rs10943696	ENSG00000272129.1	RP11-250B2.6	5.29	1.52e-07	1.81e-05	0.21	0.16	Sitting height ratio;	chr6:80191555	chr6:80355424~80356859:+
BRCA	cis	rs9341808	0.718	rs6910201	ENSG00000272129.1	RP11-250B2.6	5.29	1.52e-07	1.81e-05	0.21	0.16	Sitting height ratio;	chr6:80195221	chr6:80355424~80356859:+
BRCA	cis	rs7772486	0.79	rs2253764	ENSG00000270638.1	RP3-466P17.1	5.29	1.52e-07	1.81e-05	0.18	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145878745	chr6:145735570~145737218:+
BRCA	cis	rs1707322	0.964	rs10437063	ENSG00000234329.1	RP11-767N6.2	5.29	1.52e-07	1.81e-05	0.17	0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45807994	chr1:45651039~45651826:-
BRCA	cis	rs1707322	1	rs6676982	ENSG00000234329.1	RP11-767N6.2	5.29	1.52e-07	1.81e-05	0.17	0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45809729	chr1:45651039~45651826:-
BRCA	cis	rs4699052	0.963	rs11943325	ENSG00000248740.4	RP11-328K4.1	5.29	1.52e-07	1.81e-05	0.18	0.16	Testicular germ cell tumor;	chr4:103257236	chr4:103256159~103453658:+
BRCA	cis	rs9545047	0.604	rs3187338	ENSG00000227354.5	RBM26-AS1	5.29	1.52e-07	1.81e-05	0.17	0.16	Schizophrenia;	chr13:79320601	chr13:79406309~79424328:+
BRCA	cis	rs9545047	0.604	rs9545068	ENSG00000227354.5	RBM26-AS1	5.29	1.52e-07	1.81e-05	0.17	0.16	Schizophrenia;	chr13:79324101	chr13:79406309~79424328:+
BRCA	cis	rs9545047	0.604	rs7322167	ENSG00000227354.5	RBM26-AS1	5.29	1.52e-07	1.81e-05	0.17	0.16	Schizophrenia;	chr13:79325931	chr13:79406309~79424328:+
BRCA	cis	rs9545047	0.604	rs9285309	ENSG00000227354.5	RBM26-AS1	5.29	1.52e-07	1.81e-05	0.17	0.16	Schizophrenia;	chr13:79326707	chr13:79406309~79424328:+
BRCA	cis	rs9545047	0.584	rs9545069	ENSG00000227354.5	RBM26-AS1	5.29	1.52e-07	1.81e-05	0.17	0.16	Schizophrenia;	chr13:79328065	chr13:79406309~79424328:+
BRCA	cis	rs9545047	0.647	rs7317416	ENSG00000227354.5	RBM26-AS1	5.29	1.52e-07	1.81e-05	0.17	0.16	Schizophrenia;	chr13:79328400	chr13:79406309~79424328:+
BRCA	cis	rs9545047	0.588	rs1408658	ENSG00000227354.5	RBM26-AS1	5.29	1.52e-07	1.81e-05	0.17	0.16	Schizophrenia;	chr13:79329294	chr13:79406309~79424328:+
BRCA	cis	rs295490	0.748	rs17560106	ENSG00000272656.1	RP11-219D15.3	5.29	1.52e-07	1.81e-05	0.37	0.16	PR interval in Tripanosoma cruzi seropositivity;	chr3:139461388	chr3:139349024~139349371:-
BRCA	cis	rs4713118	0.629	rs203889	ENSG00000280107.1	AL022393.9	-5.29	1.52e-07	1.81e-05	-0.24	-0.16	Parkinson's disease;	chr6:28053997	chr6:28170845~28172521:+
BRCA	cis	rs2483058	0.767	rs963894	ENSG00000261000.1	RP11-534L20.5	5.29	1.52e-07	1.81e-05	0.18	0.16	Cholesterol and Triglycerides;	chr1:206452085	chr1:206503948~206504456:+
BRCA	cis	rs8002861	0.87	rs9567293	ENSG00000274001.1	RP11-5G9.5	5.29	1.52e-07	1.81e-05	0.19	0.16	Leprosy;	chr13:43873107	chr13:43877715~43878163:-
BRCA	cis	rs6832769	0.961	rs13152650	ENSG00000223305.1	RN7SKP30	5.29	1.52e-07	1.81e-05	0.2	0.16	Personality dimensions;	chr4:55491691	chr4:55540502~55540835:-
BRCA	cis	rs10510102	0.872	rs3862129	ENSG00000226864.1	ATE1-AS1	5.29	1.52e-07	1.81e-05	0.29	0.16	Breast cancer;	chr10:121824460	chr10:121928312~121951965:+
BRCA	cis	rs7772486	0.79	rs2253880	ENSG00000270638.1	RP3-466P17.1	5.29	1.52e-07	1.81e-05	0.18	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145879638	chr6:145735570~145737218:+
BRCA	cis	rs7772486	0.79	rs2814879	ENSG00000270638.1	RP3-466P17.1	5.29	1.52e-07	1.81e-05	0.18	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145880607	chr6:145735570~145737218:+
BRCA	cis	rs9545047	0.604	rs7327603	ENSG00000227354.5	RBM26-AS1	5.29	1.52e-07	1.81e-05	0.17	0.16	Schizophrenia;	chr13:79366676	chr13:79406309~79424328:+
BRCA	cis	rs2179367	0.959	rs540538	ENSG00000216906.2	RP11-350J20.9	5.29	1.52e-07	1.81e-05	0.2	0.16	Dupuytren's disease;	chr6:149326808	chr6:149904243~149906418:+
BRCA	cis	rs597539	0.652	rs646586	ENSG00000261625.1	RP11-554A11.4	5.29	1.52e-07	1.81e-05	0.16	0.16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68914185	chr11:69000765~69002048:-
BRCA	cis	rs6498068	0.594	rs1875929	ENSG00000260468.1	LINC01290	-5.29	1.52e-07	1.81e-05	-0.23	-0.16	Metabolite levels (MHPG);	chr16:10528202	chr16:10514842~10528202:-
BRCA	cis	rs1387259	0.931	rs1107654	ENSG00000226413.2	OR8T1P	5.29	1.52e-07	1.81e-05	0.22	0.16	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48287314	chr12:48442030~48442947:-
BRCA	cis	rs7620503	0.516	rs1566409	ENSG00000228221.4	LINC00578	5.29	1.52e-07	1.81e-05	0.21	0.16	Corneal structure;	chr3:177616400	chr3:177441921~177752305:+
BRCA	cis	rs367615	0.501	rs447849	ENSG00000249476.1	CTD-2587M2.1	-5.29	1.52e-07	1.81e-05	-0.18	-0.16	Colorectal cancer (SNP x SNP interaction);	chr5:109615489	chr5:109237120~109326369:-
BRCA	cis	rs1124769	0.748	rs7170455	ENSG00000259378.1	DCAF13P3	-5.29	1.52e-07	1.81e-05	-0.23	-0.16	Cognitive performance;	chr15:51077543	chr15:50944663~50945996:+
BRCA	cis	rs8098244	0.928	rs1893290	ENSG00000264745.1	TTC39C-AS1	5.29	1.52e-07	1.81e-05	0.22	0.16	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23862657	chr18:23994213~24015339:-
BRCA	cis	rs35146811	0.883	rs4134903	ENSG00000235713.1	RP4-604G5.3	5.29	1.52e-07	1.81e-05	0.19	0.16	Coronary artery disease;	chr7:100113417	chr7:99992397~99993050:+
BRCA	cis	rs875971	0.862	rs709609	ENSG00000236529.1	RP13-254B10.1	-5.29	1.53e-07	1.81e-05	-0.18	-0.16	Aortic root size;	chr7:66095574	chr7:65840212~65840596:+
BRCA	cis	rs1499614	0.522	rs13247442	ENSG00000230295.1	RP11-458F8.2	-5.29	1.53e-07	1.81e-05	-0.27	-0.16	Gout;	chr7:66723871	chr7:66880708~66882981:+
BRCA	cis	rs9291683	0.527	rs73212848	ENSG00000250413.1	RP11-448G15.1	5.29	1.53e-07	1.81e-05	0.22	0.16	Bone mineral density;	chr4:10091675	chr4:10006482~10009725:+
BRCA	cis	rs9545047	0.604	rs2182873	ENSG00000227354.5	RBM26-AS1	5.29	1.53e-07	1.82e-05	0.17	0.16	Schizophrenia;	chr13:79356846	chr13:79406309~79424328:+
BRCA	cis	rs10788972	0.683	rs12046178	ENSG00000225183.1	RP4-758J24.4	-5.29	1.53e-07	1.82e-05	-0.21	-0.16	Parkinson disease and lewy body pathology;	chr1:54106502	chr1:54089856~54090093:+
BRCA	cis	rs7923609	0.841	rs10740131	ENSG00000232075.1	MRPL35P2	-5.29	1.53e-07	1.82e-05	-0.2	-0.16	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63511728	chr10:63634317~63634827:-
BRCA	cis	rs17214007	0.597	rs11649126	ENSG00000279866.1	CTB-193M12.4	5.29	1.53e-07	1.82e-05	0.26	0.16	Cognitive function;	chr16:15626390	chr16:15704410~15705984:+
BRCA	cis	rs2303759	0.515	rs2334867	ENSG00000268686.1	AC010524.2	5.28	1.53e-07	1.82e-05	0.25	0.16	Multiple sclerosis;	chr19:49284948	chr19:49368705~49388081:-
BRCA	cis	rs34217772	0.68	rs17781361	ENSG00000258636.1	CTD-2298J14.2	5.28	1.53e-07	1.82e-05	0.22	0.16	Myopia;	chr14:41726320	chr14:41587861~41604856:-
BRCA	cis	rs4908768	0.501	rs6577499	ENSG00000232912.4	RP5-1115A15.1	-5.28	1.53e-07	1.82e-05	-0.16	-0.16	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8552045	chr1:8424645~8434838:+
BRCA	cis	rs2638953	0.853	rs11049642	ENSG00000247934.4	RP11-967K21.1	-5.28	1.54e-07	1.82e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28471325	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.853	rs11049643	ENSG00000247934.4	RP11-967K21.1	-5.28	1.54e-07	1.82e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28471581	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.777	rs11049644	ENSG00000247934.4	RP11-967K21.1	-5.28	1.54e-07	1.82e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28471724	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.853	rs11049645	ENSG00000247934.4	RP11-967K21.1	-5.28	1.54e-07	1.82e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28472615	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.853	rs10843184	ENSG00000247934.4	RP11-967K21.1	-5.28	1.54e-07	1.82e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28473339	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.815	rs61920658	ENSG00000247934.4	RP11-967K21.1	-5.28	1.54e-07	1.82e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28475519	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.853	rs11049646	ENSG00000247934.4	RP11-967K21.1	-5.28	1.54e-07	1.82e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28476139	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.815	rs11049654	ENSG00000247934.4	RP11-967K21.1	-5.28	1.54e-07	1.82e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28480502	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.853	rs11049657	ENSG00000247934.4	RP11-967K21.1	-5.28	1.54e-07	1.82e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28481746	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.853	rs11049659	ENSG00000247934.4	RP11-967K21.1	-5.28	1.54e-07	1.82e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28482147	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.853	rs1355475	ENSG00000247934.4	RP11-967K21.1	-5.28	1.54e-07	1.82e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28482398	chr12:28163298~28190738:-
BRCA	cis	rs7204230	1	rs11075783	ENSG00000261291.1	RP11-295M3.2	5.28	1.54e-07	1.83e-05	0.2	0.16	Fibrinogen;	chr16:53198229	chr16:53168522~53169450:+
BRCA	cis	rs962856	0.964	rs1486135	ENSG00000236780.4	AC078941.1	5.28	1.54e-07	1.83e-05	0.21	0.16	Pancreatic cancer;	chr2:67369133	chr2:67123357~67215319:-
BRCA	cis	rs853679	0.599	rs149943	ENSG00000204709.4	LINC01556	5.28	1.54e-07	1.83e-05	0.33	0.16	Depression;	chr6:28034610	chr6:28943877~28944537:+
BRCA	cis	rs7789940	0.904	rs12531348	ENSG00000186704.9	DTX2P1	5.28	1.54e-07	1.83e-05	0.2	0.16	Multiple sclerosis;	chr7:76307874	chr7:76978617~77004308:+
BRCA	cis	rs7789940	0.904	rs61294900	ENSG00000186704.9	DTX2P1	5.28	1.54e-07	1.83e-05	0.2	0.16	Multiple sclerosis;	chr7:76307895	chr7:76978617~77004308:+
BRCA	cis	rs7246657	0.551	rs4806413	ENSG00000226686.6	LINC01535	-5.28	1.54e-07	1.83e-05	-0.28	-0.16	Coronary artery calcification;	chr19:37126814	chr19:37251912~37265535:+
BRCA	cis	rs7615952	0.546	rs2979307	ENSG00000171084.14	FAM86JP	-5.28	1.54e-07	1.83e-05	-0.26	-0.16	Blood pressure (smoking interaction);	chr3:125590730	chr3:125916620~125930024:+
BRCA	cis	rs1198872	0.812	rs1198867	ENSG00000272275.1	RP11-791G15.2	-5.28	1.54e-07	1.83e-05	-0.2	-0.16	Cardiac Troponin-T levels;	chr2:10762281	chr2:10767875~10770058:-
BRCA	cis	rs73222236	0.825	rs9812513	ENSG00000273486.1	RP11-731C17.2	5.28	1.54e-07	1.83e-05	0.18	0.16	Coronary artery disease;	chr3:136335316	chr3:136837338~136839021:-
BRCA	cis	rs9868809	0.772	rs2286651	ENSG00000270441.1	RP11-694I15.7	5.28	1.54e-07	1.83e-05	0.3	0.16	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48656714	chr3:49140086~49160851:-
BRCA	cis	rs6545883	0.931	rs9807965	ENSG00000270820.4	RP11-355B11.2	5.28	1.54e-07	1.83e-05	0.18	0.16	Tuberculosis;	chr2:61505024	chr2:61471188~61484130:+
BRCA	cis	rs11159086	0.793	rs10139029	ENSG00000270000.1	RP3-449M8.9	5.28	1.54e-07	1.83e-05	0.25	0.16	Advanced glycation end-product levels;	chr14:74492284	chr14:74471930~74472360:-
BRCA	cis	rs7572733	0.555	rs7561950	ENSG00000231621.1	AC013264.2	-5.28	1.54e-07	1.83e-05	-0.16	-0.16	Dermatomyositis;	chr2:197889520	chr2:197197991~197199273:+
BRCA	cis	rs9287719	0.967	rs6748036	ENSG00000243819.4	RN7SL832P	5.28	1.54e-07	1.83e-05	0.16	0.16	Prostate cancer;	chr2:10577363	chr2:10690344~10692099:+
BRCA	cis	rs6723226	0.699	rs805830	ENSG00000276334.1	AL133243.1	5.28	1.54e-07	1.83e-05	0.21	0.16	Intelligence (multi-trait analysis);	chr2:32276406	chr2:32521927~32523547:+
BRCA	cis	rs2732480	0.577	rs2634684	ENSG00000257735.1	RP11-370I10.6	-5.28	1.54e-07	1.83e-05	-0.2	-0.16	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48337092	chr12:48350945~48442411:+
BRCA	cis	rs9545047	0.604	rs3742117	ENSG00000227354.5	RBM26-AS1	5.28	1.54e-07	1.83e-05	0.17	0.16	Schizophrenia;	chr13:79342498	chr13:79406309~79424328:+
BRCA	cis	rs9545047	0.647	rs3742118	ENSG00000227354.5	RBM26-AS1	5.28	1.54e-07	1.83e-05	0.17	0.16	Schizophrenia;	chr13:79342838	chr13:79406309~79424328:+
BRCA	cis	rs11159086	0.793	rs11625502	ENSG00000270000.1	RP3-449M8.9	5.28	1.54e-07	1.83e-05	0.25	0.16	Advanced glycation end-product levels;	chr14:74468309	chr14:74471930~74472360:-
BRCA	cis	rs875971	0.545	rs10950029	ENSG00000232546.1	RP11-458F8.1	5.28	1.54e-07	1.83e-05	0.15	0.16	Aortic root size;	chr7:66169334	chr7:66848496~66858136:+
BRCA	cis	rs10946940	0.864	rs13201411	ENSG00000216901.1	AL022393.7	-5.28	1.54e-07	1.83e-05	-0.2	-0.16	Systemic lupus erythematosus;	chr6:27530438	chr6:28176188~28176674:+
BRCA	cis	rs818427	0.927	rs153546	ENSG00000279522.1	CTC-487M23.6	5.28	1.54e-07	1.83e-05	0.18	0.16	Total body bone mineral density;	chr5:112902342	chr5:112894933~112896531:+
BRCA	cis	rs13113518	0.812	rs13140590	ENSG00000272969.1	RP11-528I4.2	5.28	1.54e-07	1.83e-05	0.19	0.16	Height;	chr4:55548666	chr4:55547112~55547889:+
BRCA	cis	rs7246657	0.722	rs2927742	ENSG00000276846.1	CTD-3220F14.3	-5.28	1.54e-07	1.83e-05	-0.22	-0.16	Coronary artery calcification;	chr19:37642717	chr19:37314868~37315620:-
BRCA	cis	rs17508449	0.819	rs17359468	ENSG00000232450.1	RP4-730K3.3	-5.28	1.54e-07	1.84e-05	-0.32	-0.16	Leprosy;	chr1:113700084	chr1:113698884~113699631:-
BRCA	cis	rs62025270	0.632	rs80036674	ENSG00000202081.1	RNU6-1280P	-5.28	1.55e-07	1.84e-05	-0.23	-0.16	Idiopathic pulmonary fibrosis;	chr15:85571217	chr15:85651522~85651628:-
BRCA	cis	rs523522	0.962	rs10744752	ENSG00000278344.1	RP11-18C24.8	5.28	1.55e-07	1.84e-05	0.22	0.16	High light scatter reticulocyte count;	chr12:120462751	chr12:120500735~120501090:-
BRCA	cis	rs539096	0.872	rs3791137	ENSG00000236200.4	KDM4A-AS1	-5.28	1.55e-07	1.84e-05	-0.2	-0.16	Intelligence (multi-trait analysis);	chr1:43584333	chr1:43699765~43708138:-
BRCA	cis	rs357618	1	rs165352	ENSG00000260581.1	CTB-113P19.4	5.28	1.55e-07	1.84e-05	0.18	0.16	Basophil percentage of white cells;	chr5:151476546	chr5:151652275~151655449:+
BRCA	cis	rs13096142	0.558	rs9840204	ENSG00000223552.1	RP11-24F11.2	-5.28	1.55e-07	1.84e-05	-0.21	-0.16	Celiac disease;	chr3:46296328	chr3:46364955~46407059:-
BRCA	cis	rs2638953	0.886	rs10843168	ENSG00000247934.4	RP11-967K21.1	-5.28	1.55e-07	1.84e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28430038	chr12:28163298~28190738:-
BRCA	cis	rs7674212	0.541	rs2720471	ENSG00000246560.2	RP11-10L12.4	5.28	1.55e-07	1.84e-05	0.17	0.16	Type 2 diabetes;	chr4:103102683	chr4:102828055~102844075:+
BRCA	cis	rs9393692	0.905	rs1125000	ENSG00000241549.7	GUSBP2	-5.28	1.55e-07	1.84e-05	-0.18	-0.16	Educational attainment;	chr6:26287028	chr6:26871484~26956554:-
BRCA	cis	rs12144309	0.608	rs1217417	ENSG00000232450.1	RP4-730K3.3	5.28	1.55e-07	1.84e-05	0.22	0.16	Coronary artery disease;	chr1:113858282	chr1:113698884~113699631:-
BRCA	cis	rs2692947	0.667	rs4144055	ENSG00000237510.6	AC008268.2	5.28	1.55e-07	1.84e-05	0.22	0.16	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95982108	chr2:95789654~95800166:+
BRCA	cis	rs2638953	0.853	rs11049641	ENSG00000247934.4	RP11-967K21.1	-5.28	1.55e-07	1.84e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28471160	chr12:28163298~28190738:-
BRCA	cis	rs9467773	1	rs6940188	ENSG00000124549.13	BTN2A3P	5.28	1.55e-07	1.85e-05	0.16	0.16	Intelligence (multi-trait analysis);	chr6:26561801	chr6:26421391~26432383:+
BRCA	cis	rs6840360	0.642	rs7678823	ENSG00000278978.1	RP11-164P12.5	-5.28	1.55e-07	1.85e-05	-0.18	-0.16	Intelligence (multi-trait analysis);	chr4:151435967	chr4:151669786~151670503:+
BRCA	cis	rs2153535	0.58	rs6905237	ENSG00000251164.1	HULC	-5.28	1.56e-07	1.85e-05	-0.2	-0.16	Motion sickness;	chr6:8471557	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.542	rs4440510	ENSG00000251164.1	HULC	-5.28	1.56e-07	1.85e-05	-0.2	-0.16	Motion sickness;	chr6:8471585	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.541	rs1414347	ENSG00000251164.1	HULC	-5.28	1.56e-07	1.85e-05	-0.2	-0.16	Motion sickness;	chr6:8471598	chr6:8652137~8653846:+
BRCA	cis	rs9467773	1	rs6940053	ENSG00000124549.13	BTN2A3P	5.28	1.56e-07	1.85e-05	0.16	0.16	Intelligence (multi-trait analysis);	chr6:26561894	chr6:26421391~26432383:+
BRCA	cis	rs10129255	0.912	rs8011090	ENSG00000211974.3	IGHV2-70	5.28	1.56e-07	1.85e-05	0.17	0.16	Kawasaki disease;	chr14:106678896	chr14:106723574~106724093:-
BRCA	cis	rs67311347	1	rs9332450	ENSG00000280739.1	EIF1B-AS1	-5.28	1.56e-07	1.85e-05	-0.18	-0.16	Renal cell carcinoma;	chr3:40416550	chr3:40173145~40309698:-
BRCA	cis	rs4950322	0.563	rs6686480	ENSG00000278811.3	LINC00624	5.28	1.56e-07	1.85e-05	0.21	0.16	Protein quantitative trait loci;	chr1:147111986	chr1:147258885~147517875:-
BRCA	cis	rs7674212	0.57	rs2711899	ENSG00000251288.2	RP11-10L12.2	-5.28	1.56e-07	1.85e-05	-0.19	-0.16	Type 2 diabetes;	chr4:103141257	chr4:102751401~102752641:+
BRCA	cis	rs17711722	0.653	rs2460421	ENSG00000234585.5	CCT6P3	-5.28	1.56e-07	1.85e-05	-0.16	-0.16	Calcium levels;	chr7:66026136	chr7:65038354~65074713:+
BRCA	cis	rs4925386	1	rs4925389	ENSG00000273619.1	RP5-908M14.9	5.28	1.56e-07	1.85e-05	0.14	0.16	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62347456	chr20:62386303~62386970:-
BRCA	cis	rs13113518	1	rs3805149	ENSG00000223305.1	RN7SKP30	5.28	1.56e-07	1.85e-05	0.2	0.16	Height;	chr4:55442184	chr4:55540502~55540835:-
BRCA	cis	rs13113518	1	rs11945370	ENSG00000223305.1	RN7SKP30	5.28	1.56e-07	1.85e-05	0.2	0.16	Height;	chr4:55442875	chr4:55540502~55540835:-
BRCA	cis	rs13423976	0.631	rs11888984	ENSG00000231367.4	AC016995.3	-5.28	1.56e-07	1.85e-05	-0.18	-0.16	Gut microbiome composition (summer);	chr2:38517250	chr2:38406719~38515740:-
BRCA	cis	rs2898681	0.614	rs11947787	ENSG00000248375.1	RP11-177B4.1	-5.28	1.56e-07	1.85e-05	-0.22	-0.16	Optic nerve measurement (cup area);	chr4:52839058	chr4:52720081~52720831:-
BRCA	cis	rs4650994	0.525	rs2493858	ENSG00000273384.1	RP5-1098D14.1	5.28	1.56e-07	1.85e-05	0.21	0.16	HDL cholesterol;HDL cholesterol levels;	chr1:178572075	chr1:178651706~178652282:+
BRCA	cis	rs4650994	0.525	rs2493860	ENSG00000273384.1	RP5-1098D14.1	5.28	1.56e-07	1.85e-05	0.21	0.16	HDL cholesterol;HDL cholesterol levels;	chr1:178572357	chr1:178651706~178652282:+
BRCA	cis	rs2904967	1	rs487989	ENSG00000255200.1	AP003068.18	5.28	1.56e-07	1.86e-05	0.28	0.16	Mean corpuscular volume;	chr11:65297219	chr11:65174117~65176470:-
BRCA	cis	rs7617773	0.676	rs13060020	ENSG00000199476.1	Y_RNA	-5.28	1.56e-07	1.86e-05	-0.24	-0.16	Coronary artery disease;	chr3:48331156	chr3:48288587~48288694:+
BRCA	cis	rs9450351	0.744	rs76569085	ENSG00000203875.9	SNHG5	-5.28	1.56e-07	1.86e-05	-0.42	-0.16	Interferon gamma-induced protein 10 levels;	chr6:85971523	chr6:85660950~85678736:-
BRCA	cis	rs2115630	0.967	rs10438428	ENSG00000259295.5	CSPG4P12	-5.28	1.56e-07	1.86e-05	-0.19	-0.16	P wave terminal force;	chr15:84787514	chr15:85191438~85213905:+
BRCA	cis	rs357618	1	rs357625	ENSG00000260581.1	CTB-113P19.4	5.28	1.57e-07	1.86e-05	0.18	0.16	Basophil percentage of white cells;	chr5:151469313	chr5:151652275~151655449:+
BRCA	cis	rs9287719	0.699	rs4669602	ENSG00000234818.1	AC092687.5	5.28	1.57e-07	1.86e-05	0.19	0.16	Prostate cancer;	chr2:10647841	chr2:10589166~10604830:+
BRCA	cis	rs2708977	0.588	rs11164062	ENSG00000237510.6	AC008268.2	-5.28	1.57e-07	1.86e-05	-0.26	-0.16	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96185381	chr2:95789654~95800166:+
BRCA	cis	rs35934224	0.831	rs8141610	ENSG00000232926.1	AC000078.5	-5.28	1.57e-07	1.86e-05	-0.21	-0.16	Glaucoma (primary open-angle);	chr22:19882624	chr22:19887289~19887970:+
BRCA	cis	rs804280	0.525	rs1004712	ENSG00000255046.1	RP11-297N6.4	-5.28	1.57e-07	1.86e-05	-0.19	-0.16	Myopia (pathological);	chr8:11764784	chr8:11797928~11802568:-
BRCA	cis	rs7617773	0.78	rs13067450	ENSG00000199476.1	Y_RNA	-5.28	1.57e-07	1.86e-05	-0.24	-0.16	Coronary artery disease;	chr3:48295716	chr3:48288587~48288694:+
BRCA	cis	rs7617773	0.78	rs4479622	ENSG00000199476.1	Y_RNA	-5.28	1.57e-07	1.86e-05	-0.24	-0.16	Coronary artery disease;	chr3:48296683	chr3:48288587~48288694:+
BRCA	cis	rs7617773	0.78	rs34946886	ENSG00000199476.1	Y_RNA	-5.28	1.57e-07	1.86e-05	-0.24	-0.16	Coronary artery disease;	chr3:48296997	chr3:48288587~48288694:+
BRCA	cis	rs7617773	0.78	rs34589064	ENSG00000199476.1	Y_RNA	-5.28	1.57e-07	1.86e-05	-0.24	-0.16	Coronary artery disease;	chr3:48298059	chr3:48288587~48288694:+
BRCA	cis	rs7617773	0.78	rs2541	ENSG00000199476.1	Y_RNA	-5.28	1.57e-07	1.86e-05	-0.24	-0.16	Coronary artery disease;	chr3:48298128	chr3:48288587~48288694:+
BRCA	cis	rs7617773	0.78	rs13085251	ENSG00000199476.1	Y_RNA	-5.28	1.57e-07	1.86e-05	-0.24	-0.16	Coronary artery disease;	chr3:48298555	chr3:48288587~48288694:+
BRCA	cis	rs9300255	0.679	rs28583837	ENSG00000235423.7	RP11-282O18.3	-5.28	1.57e-07	1.86e-05	-0.23	-0.16	Neutrophil percentage of white cells;	chr12:123379073	chr12:123252030~123261483:-
BRCA	cis	rs1075265	0.597	rs10490471	ENSG00000235937.1	AC008280.1	5.28	1.57e-07	1.87e-05	0.18	0.16	Chronotype;Morning vs. evening chronotype;	chr2:53769446	chr2:54029552~54030682:-
BRCA	cis	rs4780355	0.918	rs1646019	ENSG00000262636.1	CTD-3088G3.4	5.28	1.57e-07	1.87e-05	0.23	0.16	Crohn's disease and psoriasis;	chr16:11265823	chr16:11380859~11381118:-
BRCA	cis	rs4372836	0.681	rs13394863	ENSG00000226833.4	AC097724.3	5.28	1.57e-07	1.87e-05	0.19	0.16	Body mass index;	chr2:28733818	chr2:28708953~28736205:-
BRCA	cis	rs8114671	0.527	rs2253484	ENSG00000269202.1	RP4-614O4.12	5.28	1.57e-07	1.87e-05	0.16	0.16	Height;	chr20:34817460	chr20:35201747~35203288:-
BRCA	cis	rs7246657	0.551	rs11084873	ENSG00000226686.6	LINC01535	-5.28	1.57e-07	1.87e-05	-0.28	-0.16	Coronary artery calcification;	chr19:37093008	chr19:37251912~37265535:+
BRCA	cis	rs10946940	0.965	rs10946935	ENSG00000216901.1	AL022393.7	-5.28	1.57e-07	1.87e-05	-0.2	-0.16	Systemic lupus erythematosus;	chr6:27533566	chr6:28176188~28176674:+
BRCA	cis	rs7572733	0.651	rs55852341	ENSG00000231621.1	AC013264.2	-5.28	1.57e-07	1.87e-05	-0.15	-0.16	Dermatomyositis;	chr2:197626456	chr2:197197991~197199273:+
BRCA	cis	rs4664293	0.867	rs3764968	ENSG00000226266.5	AC009961.3	-5.28	1.57e-07	1.87e-05	-0.21	-0.16	Monocyte percentage of white cells;	chr2:159790579	chr2:159670708~159712435:-
BRCA	cis	rs7818688	0.929	rs28419772	ENSG00000253528.2	RP11-347C18.4	-5.28	1.57e-07	1.87e-05	-0.25	-0.16	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95009208	chr8:94974573~94974853:-
BRCA	cis	rs2303319	1	rs62194247	ENSG00000227403.1	AC009299.3	5.28	1.58e-07	1.87e-05	0.41	0.16	Cognitive function;	chr2:161256895	chr2:161244739~161249050:+
BRCA	cis	rs2638953	0.924	rs11049467	ENSG00000247934.4	RP11-967K21.1	-5.28	1.58e-07	1.87e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28215602	chr12:28163298~28190738:-
BRCA	cis	rs6772849	0.93	rs9813197	ENSG00000242551.2	POU5F1P6	-5.28	1.58e-07	1.87e-05	-0.2	-0.16	Monocyte percentage of white cells;Monocyte count;	chr3:128650261	chr3:128674735~128677005:-
BRCA	cis	rs6840360	0.693	rs28622593	ENSG00000278978.1	RP11-164P12.5	-5.28	1.58e-07	1.87e-05	-0.18	-0.16	Intelligence (multi-trait analysis);	chr4:151452928	chr4:151669786~151670503:+
BRCA	cis	rs6442522	0.64	rs28632773	ENSG00000249786.6	EAF1-AS1	5.28	1.58e-07	1.87e-05	0.16	0.16	Uric acid levels;	chr3:15474411	chr3:15436171~15455940:-
BRCA	cis	rs7777677	0.925	rs4726542	ENSG00000211750.2	TRBV24-1	-5.28	1.58e-07	1.87e-05	-0.14	-0.16	Alcoholic chronic pancreatitis;	chr7:142659516	chr7:142656701~142657213:+
BRCA	cis	rs4835473	0.897	rs4835333	ENSG00000249741.2	RP11-673E1.3	5.28	1.58e-07	1.87e-05	0.17	0.16	Immature fraction of reticulocytes;	chr4:143703174	chr4:143911514~143912053:-
BRCA	cis	rs71444571	1	rs71444571	ENSG00000235423.7	RP11-282O18.3	-5.28	1.58e-07	1.87e-05	-0.23	-0.16	Lymphocyte percentage of white cells;	chr12:123286468	chr12:123252030~123261483:-
BRCA	cis	rs783540	0.5	rs783541	ENSG00000276710.3	CSPG4P8	5.28	1.58e-07	1.87e-05	0.2	0.16	Schizophrenia;	chr15:82586310	chr15:82459472~82477258:+
BRCA	cis	rs72843506	0.722	rs9908418	ENSG00000261033.1	RP11-209D14.2	5.28	1.58e-07	1.87e-05	0.3	0.16	Schizophrenia;	chr17:20311252	chr17:20008051~20009234:-
BRCA	cis	rs9545047	0.604	rs9530901	ENSG00000227354.5	RBM26-AS1	5.28	1.58e-07	1.88e-05	0.17	0.16	Schizophrenia;	chr13:79355191	chr13:79406309~79424328:+
BRCA	cis	rs9545047	0.604	rs4328330	ENSG00000227354.5	RBM26-AS1	5.28	1.58e-07	1.88e-05	0.17	0.16	Schizophrenia;	chr13:79355503	chr13:79406309~79424328:+
BRCA	cis	rs9545047	0.567	rs4497554	ENSG00000227354.5	RBM26-AS1	5.28	1.58e-07	1.88e-05	0.17	0.16	Schizophrenia;	chr13:79355651	chr13:79406309~79424328:+
BRCA	cis	rs4664293	0.632	rs7588230	ENSG00000224152.1	AC009506.1	5.28	1.58e-07	1.88e-05	0.17	0.16	Monocyte percentage of white cells;	chr2:159797209	chr2:159615296~159617082:+
BRCA	cis	rs523522	0.962	rs12309824	ENSG00000278344.1	RP11-18C24.8	5.28	1.58e-07	1.88e-05	0.22	0.16	High light scatter reticulocyte count;	chr12:120552779	chr12:120500735~120501090:-
BRCA	cis	rs9467773	1	rs9467774	ENSG00000124549.13	BTN2A3P	5.28	1.58e-07	1.88e-05	0.16	0.16	Intelligence (multi-trait analysis);	chr6:26504808	chr6:26421391~26432383:+
BRCA	cis	rs9467773	1	rs2208331	ENSG00000124549.13	BTN2A3P	5.28	1.58e-07	1.88e-05	0.16	0.16	Intelligence (multi-trait analysis);	chr6:26507091	chr6:26421391~26432383:+
BRCA	cis	rs9907295	1	rs9901195	ENSG00000270977.1	AC015849.16	-5.28	1.58e-07	1.88e-05	-0.28	-0.16	Fibroblast growth factor basic levels;	chr17:35915576	chr17:35893707~35911023:-
BRCA	cis	rs1729951	0.575	rs361237	ENSG00000239213.4	NCK1-AS1	5.28	1.59e-07	1.88e-05	0.17	0.16	Neuroticism;	chr3:136983572	chr3:136841726~136862054:-
BRCA	cis	rs8002861	0.967	rs9533689	ENSG00000274001.1	RP11-5G9.5	5.28	1.59e-07	1.88e-05	0.18	0.16	Leprosy;	chr13:43906277	chr13:43877715~43878163:-
BRCA	cis	rs8002861	0.967	rs9533690	ENSG00000274001.1	RP11-5G9.5	5.28	1.59e-07	1.88e-05	0.18	0.16	Leprosy;	chr13:43906462	chr13:43877715~43878163:-
BRCA	cis	rs8002861	0.967	rs7999434	ENSG00000274001.1	RP11-5G9.5	5.28	1.59e-07	1.88e-05	0.18	0.16	Leprosy;	chr13:43908825	chr13:43877715~43878163:-
BRCA	cis	rs867371	0.82	rs7164362	ENSG00000255769.6	GOLGA2P10	-5.28	1.59e-07	1.88e-05	-0.19	-0.16	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82194401	chr15:82472993~82513950:-
BRCA	cis	rs9907295	1	rs9904675	ENSG00000271013.1	AC015849.15	-5.28	1.59e-07	1.88e-05	-0.27	-0.16	Fibroblast growth factor basic levels;	chr17:35921435	chr17:35912635~35918010:-
BRCA	cis	rs7246657	0.722	rs2927747	ENSG00000276846.1	CTD-3220F14.3	-5.28	1.59e-07	1.88e-05	-0.22	-0.16	Coronary artery calcification;	chr19:37668629	chr19:37314868~37315620:-
BRCA	cis	rs10752881	1	rs10797810	ENSG00000224468.3	RP11-181K3.4	-5.28	1.59e-07	1.88e-05	-0.17	-0.16	Colorectal cancer;	chr1:183011815	chr1:183138402~183141282:-
BRCA	cis	rs10752881	1	rs10752883	ENSG00000224468.3	RP11-181K3.4	-5.28	1.59e-07	1.88e-05	-0.17	-0.16	Colorectal cancer;	chr1:183011828	chr1:183138402~183141282:-
BRCA	cis	rs4787491	0.704	rs66467443	ENSG00000273724.1	RP11-347C12.12	-5.28	1.59e-07	1.88e-05	-0.18	-0.16	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30039173	chr16:30336400~30343336:+
BRCA	cis	rs6545883	0.868	rs778755	ENSG00000270820.4	RP11-355B11.2	-5.28	1.59e-07	1.88e-05	-0.18	-0.16	Tuberculosis;	chr2:61553902	chr2:61471188~61484130:+
BRCA	cis	rs7918232	0.83	rs10764672	ENSG00000262412.1	RP11-85G18.6	-5.28	1.59e-07	1.88e-05	-0.25	-0.16	Breast cancer;	chr10:27103612	chr10:27243130~27250804:+
BRCA	cis	rs875971	0.545	rs2707851	ENSG00000228409.4	CCT6P1	5.28	1.59e-07	1.88e-05	0.16	0.16	Aortic root size;	chr7:66624178	chr7:65751142~65763354:+
BRCA	cis	rs7178375	1	rs7178375	ENSG00000270055.1	CTD-3092A11.2	-5.28	1.59e-07	1.88e-05	-0.24	-0.16	Hypertriglyceridemia;	chr15:30923732	chr15:30487963~30490313:+
BRCA	cis	rs10752881	0.967	rs8179284	ENSG00000224468.3	RP11-181K3.4	-5.28	1.59e-07	1.88e-05	-0.17	-0.16	Colorectal cancer;	chr1:183005572	chr1:183138402~183141282:-
BRCA	cis	rs10752881	0.967	rs4652757	ENSG00000224468.3	RP11-181K3.4	-5.28	1.59e-07	1.88e-05	-0.17	-0.16	Colorectal cancer;	chr1:183005615	chr1:183138402~183141282:-
BRCA	cis	rs10752881	1	rs4420053	ENSG00000224468.3	RP11-181K3.4	-5.28	1.59e-07	1.88e-05	-0.17	-0.16	Colorectal cancer;	chr1:183006998	chr1:183138402~183141282:-
BRCA	cis	rs10752881	1	rs6701400	ENSG00000224468.3	RP11-181K3.4	-5.28	1.59e-07	1.88e-05	-0.17	-0.16	Colorectal cancer;	chr1:183008062	chr1:183138402~183141282:-
BRCA	cis	rs10911232	0.507	rs9787327	ENSG00000224468.3	RP11-181K3.4	-5.28	1.59e-07	1.88e-05	-0.17	-0.16	Hypertriglyceridemia;	chr1:183009324	chr1:183138402~183141282:-
BRCA	cis	rs10752881	1	rs10797807	ENSG00000224468.3	RP11-181K3.4	-5.28	1.59e-07	1.88e-05	-0.17	-0.16	Colorectal cancer;	chr1:183009738	chr1:183138402~183141282:-
BRCA	cis	rs10752881	1	rs10911190	ENSG00000224468.3	RP11-181K3.4	-5.28	1.59e-07	1.88e-05	-0.17	-0.16	Colorectal cancer;	chr1:183009945	chr1:183138402~183141282:-
BRCA	cis	rs10752881	1	rs10797808	ENSG00000224468.3	RP11-181K3.4	-5.28	1.59e-07	1.88e-05	-0.17	-0.16	Colorectal cancer;	chr1:183010488	chr1:183138402~183141282:-
BRCA	cis	rs2562456	0.917	rs6511253	ENSG00000268658.4	LINC00664	-5.28	1.59e-07	1.88e-05	-0.25	-0.16	Pain;	chr19:21495996	chr19:21483374~21503238:+
BRCA	cis	rs13113518	0.934	rs11133397	ENSG00000223305.1	RN7SKP30	5.28	1.59e-07	1.88e-05	0.2	0.16	Height;	chr4:55534166	chr4:55540502~55540835:-
BRCA	cis	rs13113518	0.934	rs11133398	ENSG00000223305.1	RN7SKP30	5.28	1.59e-07	1.88e-05	0.2	0.16	Height;	chr4:55534180	chr4:55540502~55540835:-
BRCA	cis	rs7246657	0.525	rs1667351	ENSG00000226686.6	LINC01535	-5.28	1.59e-07	1.88e-05	-0.24	-0.16	Coronary artery calcification;	chr19:36987125	chr19:37251912~37265535:+
BRCA	cis	rs10938353	0.68	rs12645110	ENSG00000273369.1	RP11-700J17.1	5.28	1.59e-07	1.88e-05	0.2	0.16	Body mass index;	chr4:44667706	chr4:44693946~44694386:-
BRCA	cis	rs12439619	0.846	rs62012056	ENSG00000255769.6	GOLGA2P10	-5.28	1.59e-07	1.88e-05	-0.23	-0.16	Intelligence (multi-trait analysis);	chr15:82247278	chr15:82472993~82513950:-
BRCA	cis	rs6163	0.508	rs11191381	ENSG00000236937.2	PTGES3P4	5.28	1.59e-07	1.88e-05	0.23	0.16	Waist circumference;Hip circumference;	chr10:102733687	chr10:102845595~102845950:+
BRCA	cis	rs2919009	0.509	rs17100858	ENSG00000271670.1	RP11-95I16.4	5.28	1.59e-07	1.89e-05	0.2	0.16	Obesity-related traits;	chr10:120783858	chr10:120879256~120880667:-
BRCA	cis	rs2638953	0.962	rs3782517	ENSG00000247934.4	RP11-967K21.1	-5.28	1.59e-07	1.89e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28310254	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.962	rs11049524	ENSG00000247934.4	RP11-967K21.1	-5.28	1.59e-07	1.89e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28311956	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.962	rs11049525	ENSG00000247934.4	RP11-967K21.1	-5.28	1.59e-07	1.89e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28313227	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.962	rs12371974	ENSG00000247934.4	RP11-967K21.1	-5.28	1.59e-07	1.89e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28313969	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.962	rs11049526	ENSG00000247934.4	RP11-967K21.1	-5.28	1.59e-07	1.89e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28314751	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.962	rs11049527	ENSG00000247934.4	RP11-967K21.1	-5.28	1.59e-07	1.89e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28317667	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.925	rs11049528	ENSG00000247934.4	RP11-967K21.1	-5.28	1.59e-07	1.89e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28317914	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.962	rs10843153	ENSG00000247934.4	RP11-967K21.1	-5.28	1.59e-07	1.89e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28319168	chr12:28163298~28190738:-
BRCA	cis	rs7646881	0.812	rs73017541	ENSG00000240207.5	RP11-379F4.4	-5.28	1.59e-07	1.89e-05	-0.26	-0.16	Tetralogy of Fallot;	chr3:158743007	chr3:158732263~158784070:+
BRCA	cis	rs13126694	0.839	rs66490968	ENSG00000251429.1	RP11-597D13.7	5.28	1.59e-07	1.89e-05	0.16	0.16	Blood osmolality (transformed sodium);	chr4:157994770	chr4:158270378~158278676:+
BRCA	cis	rs950776	0.518	rs8053	ENSG00000279373.1	RP11-650L12.4	-5.28	1.59e-07	1.89e-05	-0.2	-0.16	Sudden cardiac arrest;	chr15:78548878	chr15:78537681~78538946:+
BRCA	cis	rs6832769	1	rs3805154	ENSG00000272969.1	RP11-528I4.2	5.28	1.59e-07	1.89e-05	0.2	0.16	Personality dimensions;	chr4:55497760	chr4:55547112~55547889:+
BRCA	cis	rs4588572	0.537	rs7705718	ENSG00000245556.2	SCAMP1-AS1	-5.28	1.59e-07	1.89e-05	-0.19	-0.16	Triglycerides;	chr5:78434525	chr5:78342365~78360507:-
BRCA	cis	rs4588572	0.537	rs7719228	ENSG00000245556.2	SCAMP1-AS1	-5.28	1.59e-07	1.89e-05	-0.19	-0.16	Triglycerides;	chr5:78434752	chr5:78342365~78360507:-
BRCA	cis	rs4650994	0.544	rs6675811	ENSG00000273384.1	RP5-1098D14.1	5.28	1.59e-07	1.89e-05	0.2	0.16	HDL cholesterol;HDL cholesterol levels;	chr1:178529933	chr1:178651706~178652282:+
BRCA	cis	rs9473147	0.543	rs9367279	ENSG00000270761.1	RP11-385F7.1	-5.28	1.59e-07	1.89e-05	-0.17	-0.16	Platelet distribution width;Mean platelet volume;	chr6:47480600	chr6:47477243~47477572:-
BRCA	cis	rs9473147	0.543	rs9473119	ENSG00000270761.1	RP11-385F7.1	-5.28	1.59e-07	1.89e-05	-0.17	-0.16	Platelet distribution width;Mean platelet volume;	chr6:47482882	chr6:47477243~47477572:-
BRCA	cis	rs2904967	0.929	rs673147	ENSG00000255200.1	AP003068.18	5.28	1.59e-07	1.89e-05	0.27	0.16	Mean corpuscular volume;	chr11:65292956	chr11:65174117~65176470:-
BRCA	cis	rs9907295	1	rs9904675	ENSG00000270977.1	AC015849.16	-5.28	1.6e-07	1.89e-05	-0.3	-0.16	Fibroblast growth factor basic levels;	chr17:35921435	chr17:35893707~35911023:-
BRCA	cis	rs2179367	0.632	rs11155640	ENSG00000223701.3	RAET1E-AS1	5.28	1.6e-07	1.89e-05	0.23	0.16	Dupuytren's disease;	chr6:149323648	chr6:149884431~149919508:+
BRCA	cis	rs9329221	0.868	rs7831557	ENSG00000154316.13	TDH	5.28	1.6e-07	1.89e-05	0.22	0.16	Neuroticism;	chr8:10422718	chr8:11339637~11368452:+
BRCA	cis	rs10487112	0.61	rs6945128	ENSG00000225498.1	AC002064.5	5.28	1.6e-07	1.89e-05	0.16	0.16	Perceived unattractiveness to mosquitoes;	chr7:90393765	chr7:90312496~90322592:+
BRCA	cis	rs7577696	0.695	rs212744	ENSG00000272716.1	RP11-563N4.1	5.28	1.6e-07	1.89e-05	0.18	0.16	Inflammatory biomarkers;	chr2:32186719	chr2:32165046~32165757:-
BRCA	cis	rs7200543	0.666	rs34955778	ENSG00000260735.1	RP11-72I8.1	-5.28	1.6e-07	1.89e-05	-0.18	-0.16	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15045737	chr16:15094411~15109197:+
BRCA	cis	rs863750	0.744	rs1387669	ENSG00000275389.1	RP11-214K3.24	5.28	1.6e-07	1.89e-05	0.2	0.16	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-hip ratio;	chr12:124073248	chr12:124085761~124088598:+
BRCA	cis	rs4372836	0.681	rs9309664	ENSG00000226833.4	AC097724.3	-5.28	1.6e-07	1.89e-05	-0.19	-0.16	Body mass index;	chr2:28716760	chr2:28708953~28736205:-
BRCA	cis	rs62025270	0.688	rs79083718	ENSG00000202081.1	RNU6-1280P	-5.28	1.6e-07	1.89e-05	-0.25	-0.16	Idiopathic pulmonary fibrosis;	chr15:85720298	chr15:85651522~85651628:-
BRCA	cis	rs10492201	1	rs11609077	ENSG00000255733.4	IFNG-AS1	-5.28	1.6e-07	1.9e-05	-0.2	-0.16	Itch intensity from mosquito bite adjusted by bite size;	chr12:67994904	chr12:67989445~68234686:+
BRCA	cis	rs365302	1	rs294923	ENSG00000235086.1	FNDC1-IT1	5.28	1.6e-07	1.9e-05	0.19	0.16	Coronary heart disease;	chr6:159199893	chr6:159240786~159243329:+
BRCA	cis	rs12681366	0.683	rs56285115	ENSG00000253704.1	RP11-267M23.4	5.28	1.6e-07	1.9e-05	0.17	0.16	Nonsyndromic cleft lip with cleft palate;	chr8:94389244	chr8:94553722~94569745:+
BRCA	cis	rs597539	0.652	rs478647	ENSG00000261625.1	RP11-554A11.4	-5.28	1.6e-07	1.9e-05	-0.16	-0.16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68932956	chr11:69000765~69002048:-
BRCA	cis	rs6570726	0.791	rs379040	ENSG00000270638.1	RP3-466P17.1	5.28	1.6e-07	1.9e-05	0.18	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145567899	chr6:145735570~145737218:+
BRCA	cis	rs8002861	0.967	rs7983109	ENSG00000274001.1	RP11-5G9.5	5.28	1.6e-07	1.9e-05	0.18	0.16	Leprosy;	chr13:43910215	chr13:43877715~43878163:-
BRCA	cis	rs8002861	0.967	rs7984393	ENSG00000274001.1	RP11-5G9.5	5.28	1.6e-07	1.9e-05	0.18	0.16	Leprosy;	chr13:43910225	chr13:43877715~43878163:-
BRCA	cis	rs7200543	1	rs34614532	ENSG00000258354.1	MIR3180-1	-5.28	1.6e-07	1.9e-05	-0.21	-0.16	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15039051	chr16:14909887~14911345:-
BRCA	cis	rs10829156	0.699	rs7911922	ENSG00000240291.1	RP11-499P20.2	5.28	1.6e-07	1.9e-05	0.18	0.16	Sudden cardiac arrest;	chr10:18542768	chr10:18513115~18545651:-
BRCA	cis	rs1559040	1	rs11675345	ENSG00000272156.1	RP11-477N3.1	-5.28	1.6e-07	1.9e-05	-0.26	-0.16	Sudden cardiac arrest;	chr2:54121713	chr2:54082554~54085066:+
BRCA	cis	rs728616	0.614	rs57966752	ENSG00000225484.5	NUTM2B-AS1	-5.28	1.6e-07	1.9e-05	-0.31	-0.16	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79968557	chr10:79663088~79826594:-
BRCA	cis	rs3814244	0.751	rs12832728	ENSG00000236946.2	HNRNPA1P70	5.28	1.61e-07	1.9e-05	0.13	0.16	Itch intensity from mosquito bite adjusted by bite size;	chr12:68026623	chr12:68035767~68036853:+
BRCA	cis	rs6840360	0.582	rs2709812	ENSG00000278978.1	RP11-164P12.5	5.28	1.61e-07	1.9e-05	0.18	0.16	Intelligence (multi-trait analysis);	chr4:151414597	chr4:151669786~151670503:+
BRCA	cis	rs17711722	0.522	rs6957759	ENSG00000182722.5	SEPHS1P1	-5.28	1.61e-07	1.9e-05	-0.21	-0.16	Calcium levels;	chr7:65806798	chr7:64852397~64853354:-
BRCA	cis	rs2179367	0.632	rs10872636	ENSG00000268592.3	RAET1E-AS1	5.28	1.61e-07	1.91e-05	0.23	0.16	Dupuytren's disease;	chr6:149353678	chr6:149863494~149919507:+
BRCA	cis	rs13118159	0.509	rs9683830	ENSG00000254094.1	AC078852.1	-5.28	1.61e-07	1.91e-05	-0.2	-0.16	Longevity;	chr4:1384085	chr4:1356581~1358075:+
BRCA	cis	rs7324557	0.717	rs7330646	ENSG00000205861.10	C1QTNF9B-AS1	5.28	1.61e-07	1.91e-05	0.21	0.16	Visceral adipose tissue adjusted for BMI;	chr13:23828025	chr13:23888889~23897263:+
BRCA	cis	rs6832769	1	rs1522110	ENSG00000223305.1	RN7SKP30	5.28	1.61e-07	1.91e-05	0.2	0.16	Personality dimensions;	chr4:55514116	chr4:55540502~55540835:-
BRCA	cis	rs853679	0.607	rs67998226	ENSG00000204709.4	LINC01556	5.28	1.61e-07	1.91e-05	0.41	0.16	Depression;	chr6:28270281	chr6:28943877~28944537:+
BRCA	cis	rs9890032	1	rs9890032	ENSG00000266490.1	CTD-2349P21.9	-5.28	1.61e-07	1.91e-05	-0.16	-0.16	Hip circumference adjusted for BMI;	chr17:30838916	chr17:30792372~30792833:+
BRCA	cis	rs7577696	0.962	rs12617289	ENSG00000272716.1	RP11-563N4.1	-5.28	1.61e-07	1.91e-05	-0.18	-0.16	Inflammatory biomarkers;	chr2:32116330	chr2:32165046~32165757:-
BRCA	cis	rs10266483	0.545	rs116760071	ENSG00000228653.2	HNRNPCP7	5.28	1.61e-07	1.91e-05	0.21	0.16	Response to statin therapy;	chr7:64289082	chr7:64500825~64501729:+
BRCA	cis	rs9393692	0.846	rs9366651	ENSG00000241549.7	GUSBP2	-5.28	1.61e-07	1.91e-05	-0.18	-0.16	Educational attainment;	chr6:26336468	chr6:26871484~26956554:-
BRCA	cis	rs7246657	0.943	rs4803460	ENSG00000267422.1	CTD-2554C21.1	-5.28	1.61e-07	1.91e-05	-0.23	-0.16	Coronary artery calcification;	chr19:37394326	chr19:37779686~37792865:+
BRCA	cis	rs1707322	0.721	rs11211165	ENSG00000234329.1	RP11-767N6.2	5.28	1.61e-07	1.91e-05	0.17	0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692234	chr1:45651039~45651826:-
BRCA	cis	rs1707322	0.721	rs11211166	ENSG00000234329.1	RP11-767N6.2	5.28	1.61e-07	1.91e-05	0.17	0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692270	chr1:45651039~45651826:-
BRCA	cis	rs9659323	0.65	rs12066653	ENSG00000231365.4	RP11-418J17.1	-5.28	1.61e-07	1.91e-05	-0.2	-0.16	Body mass index;	chr1:118939885	chr1:119140396~119275973:+
BRCA	cis	rs4763879	0.865	rs4763839	ENSG00000256673.1	RP11-599J14.2	5.28	1.61e-07	1.91e-05	0.19	0.16	Type 1 diabetes;	chr12:9730104	chr12:9398355~9414851:-
BRCA	cis	rs7178909	0.831	rs1910587	ENSG00000259677.1	RP11-493E3.1	5.28	1.61e-07	1.91e-05	0.19	0.16	Common traits (Other);	chr15:89897255	chr15:89876540~89877285:+
BRCA	cis	rs7178909	0.797	rs1910586	ENSG00000259677.1	RP11-493E3.1	5.28	1.61e-07	1.91e-05	0.19	0.16	Common traits (Other);	chr15:89897257	chr15:89876540~89877285:+
BRCA	cis	rs911555	0.511	rs2296483	ENSG00000244691.1	RPL10AP1	-5.28	1.61e-07	1.91e-05	-0.19	-0.16	Intelligence (multi-trait analysis);	chr14:103563455	chr14:103412119~103412761:-
BRCA	cis	rs9308731	0.623	rs11674517	ENSG00000227992.1	AC108463.2	-5.28	1.61e-07	1.91e-05	-0.19	-0.16	Chronic lymphocytic leukemia;	chr2:111146255	chr2:111203964~111206215:-
BRCA	cis	rs41369048	0.858	rs1572384	ENSG00000272823.1	RP11-295M18.6	-5.28	1.61e-07	1.91e-05	-0.23	-0.16	Eosinophil counts;Sum eosinophil basophil counts;	chr1:220907383	chr1:220828676~220829211:-
BRCA	cis	rs72615157	0.664	rs6953580	ENSG00000242294.5	STAG3L5P	5.27	1.62e-07	1.91e-05	0.15	0.16	Lung function (FEV1/FVC);	chr7:100227652	chr7:100336079~100351900:+
BRCA	cis	rs2790457	0.792	rs1265830	ENSG00000254635.4	WAC-AS1	5.27	1.62e-07	1.91e-05	0.19	0.16	Multiple myeloma;	chr10:28623294	chr10:28522652~28532743:-
BRCA	cis	rs1713985	0.508	rs1713951	ENSG00000269949.1	RP11-738E22.3	-5.27	1.62e-07	1.91e-05	-0.3	-0.16	Age-related macular degeneration;	chr4:56994951	chr4:56960927~56961373:-
BRCA	cis	rs2638953	0.925	rs17432330	ENSG00000247934.4	RP11-967K21.1	-5.27	1.62e-07	1.91e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28292336	chr12:28163298~28190738:-
BRCA	cis	rs62025270	0.632	rs62022920	ENSG00000259295.5	CSPG4P12	-5.27	1.62e-07	1.92e-05	-0.25	-0.16	Idiopathic pulmonary fibrosis;	chr15:85680159	chr15:85191438~85213905:+
BRCA	cis	rs950880	1	rs12479210	ENSG00000234389.1	AC007278.3	-5.27	1.62e-07	1.92e-05	-0.15	-0.16	Serum protein levels (sST2);	chr2:102332701	chr2:102438713~102440475:+
BRCA	cis	rs6832769	1	rs726967	ENSG00000272969.1	RP11-528I4.2	-5.27	1.62e-07	1.92e-05	-0.2	-0.16	Personality dimensions;	chr4:55555546	chr4:55547112~55547889:+
BRCA	cis	rs62025270	0.632	rs3169119	ENSG00000202081.1	RNU6-1280P	-5.27	1.62e-07	1.92e-05	-0.24	-0.16	Idiopathic pulmonary fibrosis;	chr15:85748038	chr15:85651522~85651628:-
BRCA	cis	rs1707322	1	rs785478	ENSG00000234329.1	RP11-767N6.2	-5.27	1.62e-07	1.92e-05	-0.16	-0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46025963	chr1:45651039~45651826:-
BRCA	cis	rs2179367	0.537	rs6911411	ENSG00000223701.3	RAET1E-AS1	5.27	1.62e-07	1.92e-05	0.25	0.16	Dupuytren's disease;	chr6:149366954	chr6:149884431~149919508:+
BRCA	cis	rs559928	0.606	rs11231726	ENSG00000236935.1	AP003774.1	5.27	1.62e-07	1.92e-05	0.22	0.16	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64219867	chr11:64325050~64329504:-
BRCA	cis	rs256438	0.731	rs12332694	ENSG00000251050.1	RP11-168A11.4	-5.27	1.62e-07	1.92e-05	-0.19	-0.16	Serum thyroid-stimulating hormone levels;	chr5:80046166	chr5:80019609~80019920:+
BRCA	cis	rs6442522	0.61	rs6808644	ENSG00000249786.6	EAF1-AS1	5.27	1.62e-07	1.92e-05	0.16	0.16	Uric acid levels;	chr3:15485540	chr3:15436171~15455940:-
BRCA	cis	rs2115630	1	rs6496441	ENSG00000259295.5	CSPG4P12	-5.27	1.62e-07	1.92e-05	-0.19	-0.16	P wave terminal force;	chr15:84820117	chr15:85191438~85213905:+
BRCA	cis	rs8054556	0.647	rs11863174	ENSG00000273724.1	RP11-347C12.12	-5.27	1.62e-07	1.92e-05	-0.17	-0.16	Autism spectrum disorder or schizophrenia;	chr16:30008054	chr16:30336400~30343336:+
BRCA	cis	rs7824557	0.564	rs13260727	ENSG00000154316.13	TDH	-5.27	1.63e-07	1.92e-05	-0.21	-0.16	Retinal vascular caliber;	chr8:11375351	chr8:11339637~11368452:+
BRCA	cis	rs7617773	0.78	rs3197223	ENSG00000199476.1	Y_RNA	-5.27	1.63e-07	1.92e-05	-0.24	-0.16	Coronary artery disease;	chr3:48294367	chr3:48288587~48288694:+
BRCA	cis	rs2732480	0.577	rs2732479	ENSG00000240399.1	RP1-228P16.1	5.27	1.63e-07	1.93e-05	0.19	0.16	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48342477	chr12:48054813~48055591:-
BRCA	cis	rs2732480	0.537	rs1061986	ENSG00000240399.1	RP1-228P16.1	5.27	1.63e-07	1.93e-05	0.19	0.16	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48342656	chr12:48054813~48055591:-
BRCA	cis	rs1075265	0.756	rs2160931	ENSG00000235937.1	AC008280.1	5.27	1.63e-07	1.93e-05	0.18	0.16	Chronotype;Morning vs. evening chronotype;	chr2:53712411	chr2:54029552~54030682:-
BRCA	cis	rs516805	0.63	rs720205	ENSG00000279453.1	RP3-425C14.4	-5.27	1.63e-07	1.93e-05	-0.22	-0.16	Lymphocyte counts;	chr6:122107329	chr6:122436789~122439223:-
BRCA	cis	rs1707322	0.691	rs11211174	ENSG00000234329.1	RP11-767N6.2	5.27	1.63e-07	1.93e-05	0.17	0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755144	chr1:45651039~45651826:-
BRCA	cis	rs12712135	0.709	rs11465730	ENSG00000234389.1	AC007278.3	-5.27	1.63e-07	1.93e-05	-0.14	-0.16	Blood protein levels;	chr2:102450398	chr2:102438713~102440475:+
BRCA	cis	rs2638953	0.815	rs61922546	ENSG00000247934.4	RP11-967K21.1	-5.27	1.63e-07	1.93e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28524632	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.924	rs11049454	ENSG00000247934.4	RP11-967K21.1	-5.27	1.63e-07	1.93e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28204755	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.924	rs10843134	ENSG00000247934.4	RP11-967K21.1	-5.27	1.63e-07	1.93e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28205710	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.924	rs1824768	ENSG00000247934.4	RP11-967K21.1	-5.27	1.63e-07	1.93e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28206530	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.886	rs11049465	ENSG00000247934.4	RP11-967K21.1	-5.27	1.63e-07	1.93e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28212086	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.924	rs7980441	ENSG00000247934.4	RP11-967K21.1	-5.27	1.63e-07	1.93e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28214748	chr12:28163298~28190738:-
BRCA	cis	rs1979679	0.918	rs11049513	ENSG00000278733.1	RP11-425D17.1	5.27	1.63e-07	1.93e-05	0.21	0.16	Ossification of the posterior longitudinal ligament of the spine;	chr12:28297218	chr12:28185625~28186190:-
BRCA	cis	rs10851478	0.872	rs17479589	ENSG00000259531.2	RP11-295H24.3	-5.27	1.63e-07	1.93e-05	-0.23	-0.16	Oral cavity cancer;	chr15:49461335	chr15:49365124~49366685:-
BRCA	cis	rs10851478	0.872	rs7174135	ENSG00000259531.2	RP11-295H24.3	-5.27	1.63e-07	1.93e-05	-0.23	-0.16	Oral cavity cancer;	chr15:49463245	chr15:49365124~49366685:-
BRCA	cis	rs11159086	1	rs12433848	ENSG00000270000.1	RP3-449M8.9	5.27	1.63e-07	1.93e-05	0.26	0.16	Advanced glycation end-product levels;	chr14:74497570	chr14:74471930~74472360:-
BRCA	cis	rs13113518	1	rs10462032	ENSG00000223305.1	RN7SKP30	5.27	1.63e-07	1.93e-05	0.2	0.16	Height;	chr4:55479069	chr4:55540502~55540835:-
BRCA	cis	rs2638953	0.853	rs1918418	ENSG00000247934.4	RP11-967K21.1	-5.27	1.63e-07	1.93e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28483789	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.853	rs1511550	ENSG00000247934.4	RP11-967K21.1	-5.27	1.63e-07	1.93e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28484182	chr12:28163298~28190738:-
BRCA	cis	rs12468226	0.606	rs79092351	ENSG00000226261.1	AC064836.3	5.27	1.64e-07	1.93e-05	0.24	0.16	Urate levels;	chr2:202204388	chr2:202336024~202336727:-
BRCA	cis	rs357618	1	rs165353	ENSG00000260581.1	CTB-113P19.4	5.27	1.64e-07	1.93e-05	0.18	0.16	Basophil percentage of white cells;	chr5:151477196	chr5:151652275~151655449:+
BRCA	cis	rs17508449	0.547	rs3765598	ENSG00000232450.1	RP4-730K3.3	-5.27	1.64e-07	1.93e-05	-0.26	-0.16	Leprosy;	chr1:113851841	chr1:113698884~113699631:-
BRCA	cis	rs2732480	0.577	rs2732481	ENSG00000240399.1	RP1-228P16.1	5.27	1.64e-07	1.94e-05	0.19	0.16	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48343202	chr12:48054813~48055591:-
BRCA	cis	rs2732480	0.557	rs2732484	ENSG00000240399.1	RP1-228P16.1	5.27	1.64e-07	1.94e-05	0.19	0.16	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48343462	chr12:48054813~48055591:-
BRCA	cis	rs2732480	0.577	rs2732486	ENSG00000240399.1	RP1-228P16.1	5.27	1.64e-07	1.94e-05	0.19	0.16	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344051	chr12:48054813~48055591:-
BRCA	cis	rs2732480	0.517	rs2634676	ENSG00000240399.1	RP1-228P16.1	5.27	1.64e-07	1.94e-05	0.19	0.16	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344453	chr12:48054813~48055591:-
BRCA	cis	rs9341808	0.754	rs3812126	ENSG00000272129.1	RP11-250B2.6	-5.27	1.64e-07	1.94e-05	-0.2	-0.16	Sitting height ratio;	chr6:80242984	chr6:80355424~80356859:+
BRCA	cis	rs13113518	0.966	rs12647677	ENSG00000223305.1	RN7SKP30	5.27	1.64e-07	1.94e-05	0.19	0.16	Height;	chr4:55444253	chr4:55540502~55540835:-
BRCA	cis	rs13113518	0.902	rs3805150	ENSG00000223305.1	RN7SKP30	5.27	1.64e-07	1.94e-05	0.19	0.16	Height;	chr4:55446869	chr4:55540502~55540835:-
BRCA	cis	rs13113518	1	rs4864990	ENSG00000223305.1	RN7SKP30	5.27	1.64e-07	1.94e-05	0.19	0.16	Height;	chr4:55447523	chr4:55540502~55540835:-
BRCA	cis	rs8002861	0.935	rs1373903	ENSG00000274001.1	RP11-5G9.5	5.27	1.64e-07	1.94e-05	0.18	0.16	Leprosy;	chr13:43901378	chr13:43877715~43878163:-
BRCA	cis	rs6095360	0.727	rs111235329	ENSG00000222365.1	SNORD12B	-5.27	1.64e-07	1.94e-05	-0.22	-0.16	Intelligence (multi-trait analysis);	chr20:48891540	chr20:49280319~49280409:+
BRCA	cis	rs295490	0.667	rs2289350	ENSG00000272656.1	RP11-219D15.3	5.27	1.64e-07	1.94e-05	0.37	0.16	PR interval in Tripanosoma cruzi seropositivity;	chr3:139462436	chr3:139349024~139349371:-
BRCA	cis	rs295490	0.748	rs80323892	ENSG00000272656.1	RP11-219D15.3	5.27	1.64e-07	1.94e-05	0.37	0.16	PR interval in Tripanosoma cruzi seropositivity;	chr3:139464658	chr3:139349024~139349371:-
BRCA	cis	rs7520050	0.966	rs10789481	ENSG00000280836.1	AL355480.1	5.27	1.64e-07	1.94e-05	0.19	0.16	Reticulocyte count;Red blood cell count;	chr1:45917911	chr1:45581219~45581321:-
BRCA	cis	rs2732480	1	rs2732480	ENSG00000273765.1	RP11-370I10.11	-5.27	1.64e-07	1.94e-05	-0.18	-0.16	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48342520	chr12:48360920~48361377:+
BRCA	cis	rs7200543	1	rs1135999	ENSG00000258354.1	MIR3180-1	-5.27	1.64e-07	1.94e-05	-0.21	-0.16	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15038105	chr16:14909887~14911345:-
BRCA	cis	rs3213958	0.574	rs56075614	ENSG00000249274.1	PDLIM1P4	-5.27	1.64e-07	1.94e-05	-0.25	-0.16	Blood protein levels;	chr3:98819973	chr3:98782188~98783193:+
BRCA	cis	rs9545047	0.604	rs9530900	ENSG00000227354.5	RBM26-AS1	5.27	1.64e-07	1.94e-05	0.17	0.16	Schizophrenia;	chr13:79355048	chr13:79406309~79424328:+
BRCA	cis	rs7569084	0.687	rs35839762	ENSG00000281920.1	RP11-418H16.1	5.27	1.64e-07	1.94e-05	0.21	0.16	Sum eosinophil basophil counts;	chr2:65441318	chr2:65623272~65628424:+
BRCA	cis	rs4925386	0.84	rs6143024	ENSG00000273619.1	RP5-908M14.9	-5.27	1.64e-07	1.94e-05	-0.15	-0.16	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62339173	chr20:62386303~62386970:-
BRCA	cis	rs2638953	0.815	rs11049658	ENSG00000278733.1	RP11-425D17.1	-5.27	1.65e-07	1.95e-05	-0.21	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28481930	chr12:28185625~28186190:-
BRCA	cis	rs9467773	0.967	rs9461267	ENSG00000124549.13	BTN2A3P	5.27	1.65e-07	1.95e-05	0.16	0.16	Intelligence (multi-trait analysis);	chr6:26525227	chr6:26421391~26432383:+
BRCA	cis	rs9859260	0.744	rs557527	ENSG00000242086.7	LINC00969	-5.27	1.65e-07	1.95e-05	-0.18	-0.16	Mean corpuscular volume;	chr3:196053838	chr3:195658062~195739964:+
BRCA	cis	rs4907240	0.961	rs11691670	ENSG00000237510.6	AC008268.2	-5.27	1.65e-07	1.95e-05	-0.23	-0.16	Event-related brain oscillations;	chr2:96573033	chr2:95789654~95800166:+
BRCA	cis	rs3770081	1	rs2303339	ENSG00000273080.1	RP11-301O19.1	5.27	1.65e-07	1.95e-05	0.39	0.16	Facial emotion recognition (sad faces);	chr2:86119057	chr2:86195590~86196049:+
BRCA	cis	rs6504622	0.818	rs3851784	ENSG00000262879.4	RP11-156P1.3	5.27	1.65e-07	1.95e-05	0.16	0.16	Orofacial clefts;	chr17:46962751	chr17:46984045~47100323:-
BRCA	cis	rs2255336	0.578	rs7965744	ENSG00000245648.1	RP11-277P12.20	-5.27	1.65e-07	1.95e-05	-0.24	-0.16	Blood protein levels;	chr12:10367580	chr12:10363769~10398506:+
BRCA	cis	rs875971	0.66	rs7807930	ENSG00000273024.4	INTS4P2	5.27	1.65e-07	1.95e-05	0.18	0.16	Aortic root size;	chr7:66622178	chr7:65647864~65715661:+
BRCA	cis	rs4653663	0.785	rs4653662	ENSG00000226349.1	RP11-145A3.2	5.27	1.65e-07	1.95e-05	0.2	0.16	Neuroticism;	chr1:225733953	chr1:225710968~225736274:-
BRCA	cis	rs250585	0.92	rs631022	ENSG00000260136.4	CTD-2270L9.4	5.27	1.65e-07	1.95e-05	0.17	0.16	Egg allergy;	chr16:23399077	chr16:23452758~23457606:+
BRCA	cis	rs3892630	0.824	rs7247264	ENSG00000267567.1	CTD-2538C1.3	5.27	1.65e-07	1.95e-05	0.26	0.16	Red blood cell traits;	chr19:32748940	chr19:32718298~32719595:-
BRCA	cis	rs3892630	0.824	rs34748593	ENSG00000267567.1	CTD-2538C1.3	5.27	1.65e-07	1.95e-05	0.26	0.16	Red blood cell traits;	chr19:32749541	chr19:32718298~32719595:-
BRCA	cis	rs9473147	0.516	rs1931837	ENSG00000270761.1	RP11-385F7.1	-5.27	1.65e-07	1.95e-05	-0.18	-0.16	Platelet distribution width;Mean platelet volume;	chr6:47474641	chr6:47477243~47477572:-
BRCA	cis	rs9659323	0.706	rs1409160	ENSG00000231365.4	RP11-418J17.1	-5.27	1.65e-07	1.95e-05	-0.19	-0.16	Body mass index;	chr1:119041231	chr1:119140396~119275973:+
BRCA	cis	rs7829975	0.56	rs17154599	ENSG00000253981.4	ALG1L13P	-5.27	1.65e-07	1.95e-05	-0.19	-0.16	Mood instability;	chr8:8693908	chr8:8236003~8244667:-
BRCA	cis	rs4907240	0.961	rs4907241	ENSG00000237510.6	AC008268.2	5.27	1.65e-07	1.95e-05	0.23	0.16	Event-related brain oscillations;	chr2:96576191	chr2:95789654~95800166:+
BRCA	cis	rs17767294	0.708	rs72848784	ENSG00000204709.4	LINC01556	5.27	1.65e-07	1.95e-05	0.44	0.16	Parkinson's disease;	chr6:28003005	chr6:28943877~28944537:+
BRCA	cis	rs7572733	0.534	rs13026569	ENSG00000231621.1	AC013264.2	5.27	1.66e-07	1.96e-05	0.16	0.16	Dermatomyositis;	chr2:197918606	chr2:197197991~197199273:+
BRCA	cis	rs7572733	0.534	rs4850815	ENSG00000231621.1	AC013264.2	5.27	1.66e-07	1.96e-05	0.16	0.16	Dermatomyositis;	chr2:197921443	chr2:197197991~197199273:+
BRCA	cis	rs7572733	0.515	rs12619300	ENSG00000231621.1	AC013264.2	5.27	1.66e-07	1.96e-05	0.16	0.16	Dermatomyositis;	chr2:197921766	chr2:197197991~197199273:+
BRCA	cis	rs7572733	0.534	rs1401092	ENSG00000231621.1	AC013264.2	5.27	1.66e-07	1.96e-05	0.16	0.16	Dermatomyositis;	chr2:197927596	chr2:197197991~197199273:+
BRCA	cis	rs2638953	0.886	rs11049617	ENSG00000247934.4	RP11-967K21.1	-5.27	1.66e-07	1.96e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28453344	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.924	rs11049618	ENSG00000247934.4	RP11-967K21.1	-5.27	1.66e-07	1.96e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28453371	chr12:28163298~28190738:-
BRCA	cis	rs17772222	0.682	rs10132554	ENSG00000258789.1	RP11-507K2.3	-5.27	1.66e-07	1.96e-05	-0.18	-0.16	Coronary artery calcification;	chr14:88473090	chr14:88551597~88552493:+
BRCA	cis	rs2638953	0.924	rs10843162	ENSG00000278733.1	RP11-425D17.1	-5.27	1.66e-07	1.96e-05	-0.21	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28410985	chr12:28185625~28186190:-
BRCA	cis	rs2274273	0.745	rs748017	ENSG00000258413.1	RP11-665C16.6	-5.27	1.66e-07	1.96e-05	-0.2	-0.16	Protein biomarker;	chr14:55075582	chr14:55262767~55272075:-
BRCA	cis	rs12439619	0.846	rs28697264	ENSG00000255769.6	GOLGA2P10	-5.27	1.66e-07	1.96e-05	-0.23	-0.16	Intelligence (multi-trait analysis);	chr15:82265559	chr15:82472993~82513950:-
BRCA	cis	rs4819052	0.851	rs2838844	ENSG00000184274.3	LINC00315	-5.27	1.66e-07	1.96e-05	-0.22	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250818	chr21:45300245~45305257:-
BRCA	cis	rs2403083	0.505	rs4609189	ENSG00000258256.1	RP11-219B4.5	-5.27	1.66e-07	1.96e-05	-0.19	-0.16	Plasma amyloid beta peptide concentrations (ABx-40);	chr8:85277940	chr8:85222446~85245717:-
BRCA	cis	rs2179367	0.568	rs62426092	ENSG00000268592.3	RAET1E-AS1	5.27	1.66e-07	1.96e-05	0.23	0.16	Dupuytren's disease;	chr6:149352720	chr6:149863494~149919507:+
BRCA	cis	rs295490	0.748	rs76522909	ENSG00000272656.1	RP11-219D15.3	5.27	1.66e-07	1.96e-05	0.37	0.16	PR interval in Tripanosoma cruzi seropositivity;	chr3:139444006	chr3:139349024~139349371:-
BRCA	cis	rs12571093	0.803	rs36103935	ENSG00000233590.1	RP11-153K11.3	-5.27	1.66e-07	1.96e-05	-0.27	-0.16	Optic nerve measurement (disc area);	chr10:68273171	chr10:68233251~68242379:-
BRCA	cis	rs9307551	0.584	rs1440865	ENSG00000250334.4	LINC00989	-5.27	1.66e-07	1.96e-05	-0.22	-0.16	Refractive error;	chr4:79548747	chr4:79492416~79576460:+
BRCA	cis	rs172166	0.694	rs203876	ENSG00000280107.1	AL022393.9	-5.27	1.66e-07	1.96e-05	-0.22	-0.16	Cardiac Troponin-T levels;	chr6:28078895	chr6:28170845~28172521:+
BRCA	cis	rs9393692	0.905	rs7769028	ENSG00000241549.7	GUSBP2	-5.27	1.66e-07	1.96e-05	-0.18	-0.16	Educational attainment;	chr6:26267340	chr6:26871484~26956554:-
BRCA	cis	rs10504130	1	rs75527521	ENSG00000253844.1	RP11-546K22.1	-5.27	1.66e-07	1.97e-05	-0.28	-0.16	Venous thromboembolism (SNP x SNP interaction);	chr8:51769788	chr8:51961458~52022974:+
BRCA	cis	rs875971	0.545	rs13311962	ENSG00000228409.4	CCT6P1	5.27	1.66e-07	1.97e-05	0.16	0.16	Aortic root size;	chr7:66603142	chr7:65751142~65763354:+
BRCA	cis	rs591584	0.802	rs7946385	ENSG00000255893.1	RP11-685N10.1	5.27	1.66e-07	1.97e-05	0.17	0.16	Macrophage Migration Inhibitory Factor levels;	chr11:94557283	chr11:94472908~94473570:-
BRCA	cis	rs9545047	0.532	rs1748768	ENSG00000227354.5	RBM26-AS1	5.27	1.67e-07	1.97e-05	0.17	0.16	Schizophrenia;	chr13:79313276	chr13:79406309~79424328:+
BRCA	cis	rs62025270	0.632	rs62022943	ENSG00000202081.1	RNU6-1280P	-5.27	1.67e-07	1.97e-05	-0.23	-0.16	Idiopathic pulmonary fibrosis;	chr15:85716239	chr15:85651522~85651628:-
BRCA	cis	rs4950322	0.58	rs2083720	ENSG00000244371.2	PFN1P8	-5.27	1.67e-07	1.97e-05	-0.22	-0.16	Protein quantitative trait loci;	chr1:147122296	chr1:146957117~146957659:-
BRCA	cis	rs9545047	0.604	rs1748767	ENSG00000227354.5	RBM26-AS1	5.27	1.67e-07	1.97e-05	0.17	0.16	Schizophrenia;	chr13:79313381	chr13:79406309~79424328:+
BRCA	cis	rs9545047	0.567	rs1409018	ENSG00000227354.5	RBM26-AS1	5.27	1.67e-07	1.97e-05	0.17	0.16	Schizophrenia;	chr13:79313403	chr13:79406309~79424328:+
BRCA	cis	rs8054556	0.647	rs11649149	ENSG00000273724.1	RP11-347C12.12	-5.27	1.67e-07	1.97e-05	-0.18	-0.16	Autism spectrum disorder or schizophrenia;	chr16:29997323	chr16:30336400~30343336:+
BRCA	cis	rs6832769	1	rs3736544	ENSG00000272969.1	RP11-528I4.2	5.27	1.67e-07	1.97e-05	0.2	0.16	Personality dimensions;	chr4:55443825	chr4:55547112~55547889:+
BRCA	cis	rs7131987	0.565	rs7974254	ENSG00000257176.2	RP11-996F15.2	5.27	1.67e-07	1.97e-05	0.18	0.16	QT interval;	chr12:29246592	chr12:29280418~29317848:-
BRCA	cis	rs7772486	0.806	rs2247317	ENSG00000270638.1	RP3-466P17.1	5.27	1.67e-07	1.97e-05	0.18	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145896434	chr6:145735570~145737218:+
BRCA	cis	rs9545047	0.604	rs1410332	ENSG00000227354.5	RBM26-AS1	5.27	1.67e-07	1.97e-05	0.17	0.16	Schizophrenia;	chr13:79315171	chr13:79406309~79424328:+
BRCA	cis	rs9545047	0.604	rs9545065	ENSG00000227354.5	RBM26-AS1	5.27	1.67e-07	1.97e-05	0.17	0.16	Schizophrenia;	chr13:79317034	chr13:79406309~79424328:+
BRCA	cis	rs9545047	0.604	rs3818563	ENSG00000227354.5	RBM26-AS1	5.27	1.67e-07	1.97e-05	0.17	0.16	Schizophrenia;	chr13:79318587	chr13:79406309~79424328:+
BRCA	cis	rs597539	0.652	rs516425	ENSG00000261625.1	RP11-554A11.4	-5.27	1.67e-07	1.97e-05	-0.16	-0.16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68948206	chr11:69000765~69002048:-
BRCA	cis	rs1707322	1	rs4660889	ENSG00000234329.1	RP11-767N6.2	5.27	1.67e-07	1.97e-05	0.16	0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45831659	chr1:45651039~45651826:-
BRCA	cis	rs8103033	0.786	rs6508898	ENSG00000268088.1	AC093063.2	-5.27	1.67e-07	1.97e-05	-0.18	-0.16	Obesity-related traits;	chr19:39661841	chr19:39693925~39696258:+
BRCA	cis	rs3733585	0.664	rs17245436	ENSG00000250413.1	RP11-448G15.1	5.27	1.67e-07	1.97e-05	0.21	0.16	Cleft plate (environmental tobacco smoke interaction);	chr4:9956545	chr4:10006482~10009725:+
BRCA	cis	rs2522056	1	rs2522047	ENSG00000233006.5	AC034220.3	-5.27	1.67e-07	1.97e-05	-0.13	-0.16	Fibrinogen;Lymphocyte counts;	chr5:132460190	chr5:132311285~132369916:-
BRCA	cis	rs523522	0.923	rs1048830	ENSG00000278344.1	RP11-18C24.8	5.27	1.67e-07	1.97e-05	0.22	0.16	High light scatter reticulocyte count;	chr12:120444414	chr12:120500735~120501090:-
BRCA	cis	rs13113518	1	rs34648901	ENSG00000223305.1	RN7SKP30	5.27	1.67e-07	1.98e-05	0.19	0.16	Height;	chr4:55541259	chr4:55540502~55540835:-
BRCA	cis	rs7618915	0.571	rs17264436	ENSG00000243224.1	RP5-1157M23.2	-5.27	1.67e-07	1.98e-05	-0.18	-0.16	Bipolar disorder;	chr3:52576635	chr3:52239258~52241097:+
BRCA	cis	rs7618915	0.571	rs34115864	ENSG00000243224.1	RP5-1157M23.2	-5.27	1.67e-07	1.98e-05	-0.18	-0.16	Bipolar disorder;	chr3:52578162	chr3:52239258~52241097:+
BRCA	cis	rs4713118	0.869	rs6922574	ENSG00000216901.1	AL022393.7	5.27	1.67e-07	1.98e-05	0.22	0.16	Parkinson's disease;	chr6:27725224	chr6:28176188~28176674:+
BRCA	cis	rs6772849	0.93	rs13434160	ENSG00000242551.2	POU5F1P6	-5.27	1.67e-07	1.98e-05	-0.2	-0.16	Monocyte percentage of white cells;Monocyte count;	chr3:128655927	chr3:128674735~128677005:-
BRCA	cis	rs6772849	0.93	rs4857916	ENSG00000242551.2	POU5F1P6	-5.27	1.67e-07	1.98e-05	-0.2	-0.16	Monocyte percentage of white cells;Monocyte count;	chr3:128657171	chr3:128674735~128677005:-
BRCA	cis	rs11790994	0.524	rs10979552	ENSG00000175611.10	LINC00476	-5.27	1.68e-07	1.98e-05	-0.24	-0.16	Inattentive symptoms;	chr9:95708930	chr9:95759231~95875977:-
BRCA	cis	rs7577696	0.924	rs3769604	ENSG00000272716.1	RP11-563N4.1	-5.27	1.68e-07	1.98e-05	-0.18	-0.16	Inflammatory biomarkers;	chr2:32097426	chr2:32165046~32165757:-
BRCA	cis	rs17301013	0.932	rs10912813	ENSG00000227373.4	RP11-160H22.5	5.27	1.68e-07	1.98e-05	0.21	0.16	Systemic lupus erythematosus;	chr1:174607342	chr1:174115300~174160004:-
BRCA	cis	rs7613875	0.6	rs1061474	ENSG00000228008.1	CTD-2330K9.3	-5.27	1.68e-07	1.98e-05	-0.16	-0.16	Body mass index;	chr3:50107518	chr3:49903845~49916937:+
BRCA	cis	rs71636778	0.57	rs12728091	ENSG00000260063.1	RP5-968P14.2	-5.27	1.68e-07	1.98e-05	-0.37	-0.16	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26817022	chr1:26692132~26694131:-
BRCA	cis	rs41307935	0.73	rs34716450	ENSG00000260063.1	RP5-968P14.2	-5.27	1.68e-07	1.98e-05	-0.37	-0.16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26817084	chr1:26692132~26694131:-
BRCA	cis	rs7246657	0.722	rs2927746	ENSG00000276846.1	CTD-3220F14.3	-5.27	1.68e-07	1.98e-05	-0.22	-0.16	Coronary artery calcification;	chr19:37665669	chr19:37314868~37315620:-
BRCA	cis	rs61160187	0.51	rs10072745	ENSG00000215032.2	GNL3LP1	5.27	1.68e-07	1.98e-05	0.2	0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:60787448	chr5:60891935~60893577:-
BRCA	cis	rs1555322	1	rs2425032	ENSG00000126005.14	MMP24-AS1	-5.27	1.68e-07	1.98e-05	-0.26	-0.16	Attention deficit hyperactivity disorder;	chr20:35267651	chr20:35216462~35278131:-
BRCA	cis	rs35146811	0.806	rs1534310	ENSG00000235713.1	RP4-604G5.3	5.27	1.68e-07	1.98e-05	0.19	0.16	Coronary artery disease;	chr7:100101546	chr7:99992397~99993050:+
BRCA	cis	rs991427	0.643	rs67973615	ENSG00000258100.1	RP11-121E16.1	-5.27	1.68e-07	1.98e-05	-0.26	-0.16	Systolic blood pressure (alcohol consumption interaction);	chr12:91073173	chr12:91362196~91368606:+
BRCA	cis	rs10510102	0.516	rs2420976	ENSG00000276742.1	RP11-500G22.4	-5.27	1.68e-07	1.99e-05	-0.28	-0.16	Breast cancer;	chr10:121986932	chr10:121956782~121957098:+
BRCA	cis	rs9341808	0.683	rs7771449	ENSG00000272129.1	RP11-250B2.6	5.27	1.68e-07	1.99e-05	0.2	0.16	Sitting height ratio;	chr6:80210260	chr6:80355424~80356859:+
BRCA	cis	rs10911232	0.507	rs7515822	ENSG00000224468.3	RP11-181K3.4	-5.27	1.68e-07	1.99e-05	-0.17	-0.16	Hypertriglyceridemia;	chr1:183068668	chr1:183138402~183141282:-
BRCA	cis	rs16846053	0.681	rs62187563	ENSG00000227403.1	AC009299.3	5.27	1.69e-07	1.99e-05	0.38	0.16	Blood osmolality (transformed sodium);	chr2:161498142	chr2:161244739~161249050:+
BRCA	cis	rs962856	1	rs962856	ENSG00000236780.4	AC078941.1	5.27	1.69e-07	1.99e-05	0.2	0.16	Pancreatic cancer;	chr2:67366671	chr2:67123357~67215319:-
BRCA	cis	rs7620503	1	rs6808260	ENSG00000228221.4	LINC00578	5.27	1.69e-07	1.99e-05	0.19	0.16	Corneal structure;	chr3:177582044	chr3:177441921~177752305:+
BRCA	cis	rs516805	0.748	rs155460	ENSG00000279114.1	RP3-425C14.5	-5.27	1.69e-07	1.99e-05	-0.2	-0.16	Lymphocyte counts;	chr6:122499180	chr6:122471923~122484161:+
BRCA	cis	rs6840360	0.642	rs2709828	ENSG00000278978.1	RP11-164P12.5	-5.27	1.69e-07	1.99e-05	-0.18	-0.16	Intelligence (multi-trait analysis);	chr4:151434116	chr4:151669786~151670503:+
BRCA	cis	rs6840360	0.642	rs2724551	ENSG00000278978.1	RP11-164P12.5	-5.27	1.69e-07	1.99e-05	-0.18	-0.16	Intelligence (multi-trait analysis);	chr4:151434231	chr4:151669786~151670503:+
BRCA	cis	rs6840360	0.667	rs2709829	ENSG00000278978.1	RP11-164P12.5	-5.27	1.69e-07	1.99e-05	-0.18	-0.16	Intelligence (multi-trait analysis);	chr4:151434238	chr4:151669786~151670503:+
BRCA	cis	rs6840360	0.606	rs2709813	ENSG00000278978.1	RP11-164P12.5	-5.27	1.69e-07	1.99e-05	-0.18	-0.16	Intelligence (multi-trait analysis);	chr4:151436292	chr4:151669786~151670503:+
BRCA	cis	rs6840360	0.606	rs2724550	ENSG00000278978.1	RP11-164P12.5	-5.27	1.69e-07	1.99e-05	-0.18	-0.16	Intelligence (multi-trait analysis);	chr4:151437834	chr4:151669786~151670503:+
BRCA	cis	rs6840360	0.642	rs2709815	ENSG00000278978.1	RP11-164P12.5	-5.27	1.69e-07	1.99e-05	-0.18	-0.16	Intelligence (multi-trait analysis);	chr4:151442620	chr4:151669786~151670503:+
BRCA	cis	rs962856	1	rs1601531	ENSG00000236780.4	AC078941.1	5.27	1.69e-07	1.99e-05	0.21	0.16	Pancreatic cancer;	chr2:67370972	chr2:67123357~67215319:-
BRCA	cis	rs7674212	0.541	rs2615539	ENSG00000248740.4	RP11-328K4.1	5.27	1.69e-07	1.99e-05	0.18	0.16	Type 2 diabetes;	chr4:103159949	chr4:103256159~103453658:+
BRCA	cis	rs2098713	0.537	rs36190855	ENSG00000250155.1	CTD-2353F22.1	5.27	1.69e-07	1.99e-05	0.18	0.16	Telomere length;	chr5:37528407	chr5:36666214~36725195:-
BRCA	cis	rs2562456	0.876	rs2650844	ENSG00000268535.1	RP11-420K14.3	5.27	1.69e-07	1.99e-05	0.23	0.16	Pain;	chr19:21419288	chr19:21709522~21710191:+
BRCA	cis	rs2638953	0.924	rs11049468	ENSG00000247934.4	RP11-967K21.1	-5.27	1.69e-07	1.99e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28215684	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.924	rs11049469	ENSG00000247934.4	RP11-967K21.1	-5.27	1.69e-07	1.99e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28216729	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.886	rs11049470	ENSG00000247934.4	RP11-967K21.1	-5.27	1.69e-07	1.99e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28221449	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.924	rs10843140	ENSG00000247934.4	RP11-967K21.1	-5.27	1.69e-07	1.99e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28227273	chr12:28163298~28190738:-
BRCA	cis	rs910316	0.737	rs2098251	ENSG00000279594.1	RP11-950C14.10	5.27	1.69e-07	2e-05	0.18	0.16	Height;	chr14:75025993	chr14:75011269~75012851:-
BRCA	cis	rs910316	0.664	rs2098252	ENSG00000279594.1	RP11-950C14.10	5.27	1.69e-07	2e-05	0.18	0.16	Height;	chr14:75026029	chr14:75011269~75012851:-
BRCA	cis	rs7772486	0.623	rs9485021	ENSG00000270638.1	RP3-466P17.1	-5.27	1.69e-07	2e-05	-0.18	-0.16	Lobe attachment (rater-scored or self-reported);	chr6:145747661	chr6:145735570~145737218:+
BRCA	cis	rs7772486	0.654	rs6928007	ENSG00000270638.1	RP3-466P17.1	-5.27	1.69e-07	2e-05	-0.18	-0.16	Lobe attachment (rater-scored or self-reported);	chr6:145753805	chr6:145735570~145737218:+
BRCA	cis	rs603446	0.901	rs180344	ENSG00000254851.1	RP11-109L13.1	-5.27	1.69e-07	2e-05	-0.19	-0.16	Triglycerides;	chr11:116742468	chr11:117135528~117138582:+
BRCA	cis	rs61160187	0.51	rs10077663	ENSG00000215032.2	GNL3LP1	5.27	1.69e-07	2e-05	0.2	0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:60807665	chr5:60891935~60893577:-
BRCA	cis	rs10504130	1	rs58583070	ENSG00000253844.1	RP11-546K22.1	-5.27	1.69e-07	2e-05	-0.28	-0.16	Venous thromboembolism (SNP x SNP interaction);	chr8:51775492	chr8:51961458~52022974:+
BRCA	cis	rs2708977	0.637	rs675239	ENSG00000237510.6	AC008268.2	-5.27	1.69e-07	2e-05	-0.21	-0.16	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96410819	chr2:95789654~95800166:+
BRCA	cis	rs8133949	1	rs871546	ENSG00000237232.6	ZNF295-AS1	5.27	1.7e-07	2e-05	0.24	0.16	Hand grip strength;	chr21:41993444	chr21:42009194~42024924:+
BRCA	cis	rs1707322	0.896	rs946528	ENSG00000234329.1	RP11-767N6.2	-5.27	1.7e-07	2e-05	-0.16	-0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46019890	chr1:45651039~45651826:-
BRCA	cis	rs2638953	0.853	rs11049666	ENSG00000247934.4	RP11-967K21.1	-5.27	1.7e-07	2e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28496138	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.853	rs11049667	ENSG00000247934.4	RP11-967K21.1	-5.27	1.7e-07	2e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28496942	chr12:28163298~28190738:-
BRCA	cis	rs6732426	0.524	rs10166054	ENSG00000234936.1	AC010883.5	5.27	1.7e-07	2e-05	0.15	0.16	Hair morphology;	chr2:43391901	chr2:43229573~43233394:+
BRCA	cis	rs1075265	0.587	rs2949812	ENSG00000235937.1	AC008280.1	5.27	1.7e-07	2e-05	0.17	0.16	Chronotype;Morning vs. evening chronotype;	chr2:53797190	chr2:54029552~54030682:-
BRCA	cis	rs9659323	0.596	rs6656528	ENSG00000231365.4	RP11-418J17.1	-5.27	1.7e-07	2e-05	-0.2	-0.16	Body mass index;	chr1:118934971	chr1:119140396~119275973:+
BRCA	cis	rs11073619	0.803	rs7180895	ENSG00000230373.7	GOLGA6L5P	5.27	1.7e-07	2.01e-05	0.28	0.16	Positive affect;	chr15:84614489	chr15:84507885~84516814:-
BRCA	cis	rs6028335	0.502	rs8114962	ENSG00000274825.1	RP4-616B8.5	-5.27	1.7e-07	2.01e-05	-0.16	-0.16	Alcohol and nicotine co-dependence;	chr20:39007336	chr20:38955910~38956547:+
BRCA	cis	rs55702914	0.628	rs3849362	ENSG00000231621.1	AC013264.2	5.27	1.7e-07	2.01e-05	0.15	0.16	Major depression and alcohol dependence;	chr2:197443536	chr2:197197991~197199273:+
BRCA	cis	rs7208859	0.573	rs56031503	ENSG00000280069.1	CTD-2349P21.3	-5.27	1.7e-07	2.01e-05	-0.22	-0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748647	chr17:30738182~30740275:+
BRCA	cis	rs13113518	0.783	rs6843997	ENSG00000272969.1	RP11-528I4.2	5.27	1.7e-07	2.01e-05	0.19	0.16	Height;	chr4:55508982	chr4:55547112~55547889:+
BRCA	cis	rs962856	0.633	rs6755775	ENSG00000236780.4	AC078941.1	5.26	1.7e-07	2.01e-05	0.21	0.16	Pancreatic cancer;	chr2:67371451	chr2:67123357~67215319:-
BRCA	cis	rs962856	1	rs6755797	ENSG00000236780.4	AC078941.1	5.26	1.7e-07	2.01e-05	0.21	0.16	Pancreatic cancer;	chr2:67371501	chr2:67123357~67215319:-
BRCA	cis	rs1005277	0.579	rs1740732	ENSG00000263064.2	RP11-291L22.7	5.26	1.7e-07	2.01e-05	0.2	0.16	Extrinsic epigenetic age acceleration;	chr10:38202457	chr10:38448689~38448949:+
BRCA	cis	rs7474896	0.507	rs2474555	ENSG00000120555.12	SEPT7P9	5.26	1.7e-07	2.01e-05	0.24	0.16	Obesity (extreme);	chr10:38176292	chr10:38383069~38402916:-
BRCA	cis	rs12468226	0.873	rs3181153	ENSG00000226261.1	AC064836.3	-5.26	1.7e-07	2.01e-05	-0.27	-0.16	Urate levels;	chr2:202205155	chr2:202336024~202336727:-
BRCA	cis	rs2303319	1	rs16845734	ENSG00000227403.1	AC009299.3	5.26	1.7e-07	2.01e-05	0.41	0.16	Cognitive function;	chr2:161268079	chr2:161244739~161249050:+
BRCA	cis	rs7618501	0.633	rs6772095	ENSG00000228008.1	CTD-2330K9.3	5.26	1.7e-07	2.01e-05	0.16	0.16	Intelligence (multi-trait analysis);	chr3:49940636	chr3:49903845~49916937:+
BRCA	cis	rs7618501	0.603	rs72942333	ENSG00000228008.1	CTD-2330K9.3	5.26	1.7e-07	2.01e-05	0.16	0.16	Intelligence (multi-trait analysis);	chr3:49948685	chr3:49903845~49916937:+
BRCA	cis	rs7618501	0.633	rs6792892	ENSG00000228008.1	CTD-2330K9.3	5.26	1.7e-07	2.01e-05	0.16	0.16	Intelligence (multi-trait analysis);	chr3:49958085	chr3:49903845~49916937:+
BRCA	cis	rs6441961	0.501	rs41276529	ENSG00000223552.1	RP11-24F11.2	5.26	1.7e-07	2.01e-05	0.21	0.16	Celiac disease;	chr3:46263186	chr3:46364955~46407059:-
BRCA	cis	rs2289700	0.518	rs77362013	ENSG00000252061.1	RNU6-415P	-5.26	1.71e-07	2.01e-05	-0.3	-0.16	Bipolar disorder;	chr15:78874918	chr15:78898840~78898936:-
BRCA	cis	rs1552244	0.882	rs13084194	ENSG00000232901.1	CYCSP10	5.26	1.71e-07	2.01e-05	0.24	0.16	Alzheimer's disease;	chr3:9989808	chr3:10000647~10000940:-
BRCA	cis	rs1552244	0.882	rs13099507	ENSG00000232901.1	CYCSP10	5.26	1.71e-07	2.01e-05	0.24	0.16	Alzheimer's disease;	chr3:9989919	chr3:10000647~10000940:-
BRCA	cis	rs4691139	0.658	rs4691141	ENSG00000248632.1	RP11-366M4.11	5.26	1.71e-07	2.01e-05	0.16	0.16	Ovarian cancer in BRCA1 mutation carriers;	chr4:165005070	chr4:164968587~164970002:-
BRCA	cis	rs12571093	0.803	rs61854829	ENSG00000233590.1	RP11-153K11.3	-5.26	1.71e-07	2.01e-05	-0.27	-0.16	Optic nerve measurement (disc area);	chr10:68273286	chr10:68233251~68242379:-
BRCA	cis	rs1707322	1	rs10890370	ENSG00000234329.1	RP11-767N6.2	5.26	1.71e-07	2.01e-05	0.17	0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45923545	chr1:45651039~45651826:-
BRCA	cis	rs13178541	0.688	rs4246802	ENSG00000250378.1	RP11-119J18.1	-5.26	1.71e-07	2.01e-05	-0.24	-0.16	IgG glycosylation;	chr5:135864020	chr5:135812667~135826582:+
BRCA	cis	rs4908768	0.539	rs2100888	ENSG00000232912.4	RP5-1115A15.1	5.26	1.71e-07	2.02e-05	0.16	0.16	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8599223	chr1:8424645~8434838:+
BRCA	cis	rs7829975	0.659	rs4382480	ENSG00000254153.1	CTA-398F10.2	5.26	1.71e-07	2.02e-05	0.19	0.16	Mood instability;	chr8:8863963	chr8:8456909~8461337:-
BRCA	cis	rs2638953	0.924	rs17801436	ENSG00000247934.4	RP11-967K21.1	-5.26	1.71e-07	2.02e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28165421	chr12:28163298~28190738:-
BRCA	cis	rs950880	1	rs13019081	ENSG00000234389.1	AC007278.3	5.26	1.71e-07	2.02e-05	0.15	0.16	Serum protein levels (sST2);	chr2:102334362	chr2:102438713~102440475:+
BRCA	cis	rs6570726	0.967	rs450973	ENSG00000270638.1	RP3-466P17.1	5.26	1.71e-07	2.02e-05	0.18	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145541929	chr6:145735570~145737218:+
BRCA	cis	rs6600671	0.934	rs11249429	ENSG00000275538.1	RNVU1-19	-5.26	1.71e-07	2.02e-05	-0.19	-0.16	Hip geometry;	chr1:121549282	chr1:120850819~120850985:-
BRCA	cis	rs4671400	0.516	rs1809028	ENSG00000271889.1	RP11-493E12.1	5.26	1.71e-07	2.02e-05	0.26	0.16	3-hydroxypropylmercapturic acid levels in smokers;	chr2:61186588	chr2:61151433~61162105:-
BRCA	cis	rs1979679	0.686	rs4348940	ENSG00000278733.1	RP11-425D17.1	-5.26	1.71e-07	2.02e-05	-0.22	-0.16	Ossification of the posterior longitudinal ligament of the spine;	chr12:28437804	chr12:28185625~28186190:-
BRCA	cis	rs61160187	0.51	rs4700393	ENSG00000215032.2	GNL3LP1	5.26	1.72e-07	2.02e-05	0.19	0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:60802440	chr5:60891935~60893577:-
BRCA	cis	rs1953600	0.668	rs3122586	ENSG00000226659.1	RP11-137H2.4	5.26	1.72e-07	2.02e-05	0.2	0.16	Sarcoidosis;	chr10:80190570	chr10:80529597~80535942:-
BRCA	cis	rs1953600	0.645	rs2819945	ENSG00000226659.1	RP11-137H2.4	5.26	1.72e-07	2.02e-05	0.2	0.16	Sarcoidosis;	chr10:80193200	chr10:80529597~80535942:-
BRCA	cis	rs991427	0.643	rs17018653	ENSG00000258100.1	RP11-121E16.1	-5.26	1.72e-07	2.02e-05	-0.26	-0.16	Systolic blood pressure (alcohol consumption interaction);	chr12:91065056	chr12:91362196~91368606:+
BRCA	cis	rs863750	0.744	rs2460761	ENSG00000275389.1	RP11-214K3.24	5.26	1.72e-07	2.02e-05	0.2	0.16	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-hip ratio;	chr12:124060053	chr12:124085761~124088598:+
BRCA	cis	rs7608910	0.896	rs1962449	ENSG00000271889.1	RP11-493E12.1	5.26	1.72e-07	2.02e-05	0.21	0.16	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;	chr2:60975414	chr2:61151433~61162105:-
BRCA	cis	rs794185	0.652	rs2819584	ENSG00000231249.1	ITPR1-AS1	-5.26	1.72e-07	2.02e-05	-0.18	-0.16	Multiple sclerosis--Brain Glutamate Levels;	chr3:4470566	chr3:4490891~4493163:-
BRCA	cis	rs35740288	0.857	rs3803506	ENSG00000259407.1	RP11-158M2.3	-5.26	1.72e-07	2.02e-05	-0.22	-0.16	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85747709	chr15:85744109~85750281:-
BRCA	cis	rs6480314	0.542	rs17231630	ENSG00000233590.1	RP11-153K11.3	-5.26	1.72e-07	2.02e-05	-0.27	-0.16	Optic nerve measurement (disc area);	chr10:68268960	chr10:68233251~68242379:-
BRCA	cis	rs2834288	0.7	rs731060	ENSG00000273102.1	AP000569.9	-5.26	1.72e-07	2.02e-05	-0.18	-0.16	Gut microbiota (bacterial taxa);	chr21:33902624	chr21:33967101~33968573:-
BRCA	cis	rs7617773	0.817	rs6787500	ENSG00000199476.1	Y_RNA	-5.26	1.72e-07	2.02e-05	-0.21	-0.16	Coronary artery disease;	chr3:48257949	chr3:48288587~48288694:+
BRCA	cis	rs4604234	0.614	rs73482038	ENSG00000272129.1	RP11-250B2.6	-5.26	1.72e-07	2.03e-05	-0.4	-0.16	Cancer;	chr6:80236540	chr6:80355424~80356859:+
BRCA	cis	rs6840258	0.831	rs3736668	ENSG00000251411.1	RP11-397E7.4	-5.26	1.72e-07	2.03e-05	-0.23	-0.16	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87071058	chr4:86913266~86914817:-
BRCA	cis	rs365302	1	rs433308	ENSG00000235086.1	FNDC1-IT1	-5.26	1.72e-07	2.03e-05	-0.19	-0.16	Coronary heart disease;	chr6:159198834	chr6:159240786~159243329:+
BRCA	cis	rs172166	0.652	rs476167	ENSG00000280107.1	AL022393.9	-5.26	1.72e-07	2.03e-05	-0.22	-0.16	Cardiac Troponin-T levels;	chr6:28098110	chr6:28170845~28172521:+
BRCA	cis	rs9300255	0.664	rs12316131	ENSG00000235423.7	RP11-282O18.3	-5.26	1.72e-07	2.03e-05	-0.21	-0.16	Neutrophil percentage of white cells;	chr12:123333249	chr12:123252030~123261483:-
BRCA	cis	rs6840258	0.891	rs75921854	ENSG00000251411.1	RP11-397E7.4	-5.26	1.72e-07	2.03e-05	-0.22	-0.16	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87110944	chr4:86913266~86914817:-
BRCA	cis	rs2522056	0.932	rs2522064	ENSG00000233006.5	AC034220.3	-5.26	1.72e-07	2.03e-05	-0.13	-0.16	Fibrinogen;Lymphocyte counts;	chr5:132470796	chr5:132311285~132369916:-
BRCA	cis	rs3733585	0.624	rs76574510	ENSG00000250413.1	RP11-448G15.1	5.26	1.72e-07	2.03e-05	0.21	0.16	Cleft plate (environmental tobacco smoke interaction);	chr4:9951628	chr4:10006482~10009725:+
BRCA	cis	rs3733585	0.577	rs5014939	ENSG00000250413.1	RP11-448G15.1	5.26	1.72e-07	2.03e-05	0.21	0.16	Cleft plate (environmental tobacco smoke interaction);	chr4:9951629	chr4:10006482~10009725:+
BRCA	cis	rs3733585	0.673	rs4560411	ENSG00000250413.1	RP11-448G15.1	5.26	1.72e-07	2.03e-05	0.21	0.16	Cleft plate (environmental tobacco smoke interaction);	chr4:9951737	chr4:10006482~10009725:+
BRCA	cis	rs3733585	0.673	rs4407505	ENSG00000250413.1	RP11-448G15.1	5.26	1.72e-07	2.03e-05	0.21	0.16	Cleft plate (environmental tobacco smoke interaction);	chr4:9951743	chr4:10006482~10009725:+
BRCA	cis	rs2032366	0.606	rs6567225	ENSG00000267279.1	RP11-879F14.2	5.26	1.72e-07	2.03e-05	0.22	0.16	Obesity-related traits;	chr18:61607418	chr18:61585746~61606916:-
BRCA	cis	rs295490	0.748	rs2289348	ENSG00000272656.1	RP11-219D15.3	5.26	1.72e-07	2.03e-05	0.36	0.16	PR interval in Tripanosoma cruzi seropositivity;	chr3:139445424	chr3:139349024~139349371:-
BRCA	cis	rs7487075	0.567	rs4768712	ENSG00000274723.1	RP11-618L22.1	5.26	1.72e-07	2.03e-05	0.2	0.16	Itch intensity from mosquito bite;	chr12:46417738	chr12:46970504~46972155:+
BRCA	cis	rs71636778	0.509	rs34201939	ENSG00000260063.1	RP5-968P14.2	-5.26	1.72e-07	2.03e-05	-0.35	-0.16	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26767220	chr1:26692132~26694131:-
BRCA	cis	rs7577696	0.853	rs212758	ENSG00000272716.1	RP11-563N4.1	-5.26	1.72e-07	2.03e-05	-0.18	-0.16	Inflammatory biomarkers;	chr2:32200913	chr2:32165046~32165757:-
BRCA	cis	rs12534093	0.562	rs66797912	ENSG00000234286.1	AC006026.13	-5.26	1.72e-07	2.03e-05	-0.2	-0.16	Infant length;Height;	chr7:23537569	chr7:23680195~23680786:-
BRCA	cis	rs2179367	0.632	rs12211357	ENSG00000223701.3	RAET1E-AS1	5.26	1.73e-07	2.03e-05	0.23	0.16	Dupuytren's disease;	chr6:149331148	chr6:149884431~149919508:+
BRCA	cis	rs2179367	0.632	rs9498338	ENSG00000268592.3	RAET1E-AS1	5.26	1.73e-07	2.03e-05	0.23	0.16	Dupuytren's disease;	chr6:149376428	chr6:149863494~149919507:+
BRCA	cis	rs3764021	0.87	rs11052710	ENSG00000256673.1	RP11-599J14.2	-5.26	1.73e-07	2.03e-05	-0.18	-0.16	Type 1 diabetes;	chr12:9723754	chr12:9398355~9414851:-
BRCA	cis	rs7617773	0.78	rs4511916	ENSG00000199476.1	Y_RNA	-5.26	1.73e-07	2.03e-05	-0.24	-0.16	Coronary artery disease;	chr3:48308876	chr3:48288587~48288694:+
BRCA	cis	rs7617773	0.815	rs6793150	ENSG00000199476.1	Y_RNA	-5.26	1.73e-07	2.03e-05	-0.24	-0.16	Coronary artery disease;	chr3:48310070	chr3:48288587~48288694:+
BRCA	cis	rs7617773	0.78	rs6793239	ENSG00000199476.1	Y_RNA	-5.26	1.73e-07	2.03e-05	-0.24	-0.16	Coronary artery disease;	chr3:48310128	chr3:48288587~48288694:+
BRCA	cis	rs7617773	0.78	rs6782166	ENSG00000199476.1	Y_RNA	-5.26	1.73e-07	2.03e-05	-0.24	-0.16	Coronary artery disease;	chr3:48310193	chr3:48288587~48288694:+
BRCA	cis	rs7617773	0.78	rs4130522	ENSG00000199476.1	Y_RNA	-5.26	1.73e-07	2.03e-05	-0.24	-0.16	Coronary artery disease;	chr3:48310823	chr3:48288587~48288694:+
BRCA	cis	rs7617773	0.78	rs13081169	ENSG00000199476.1	Y_RNA	-5.26	1.73e-07	2.03e-05	-0.24	-0.16	Coronary artery disease;	chr3:48315307	chr3:48288587~48288694:+
BRCA	cis	rs7246657	0.722	rs2972458	ENSG00000276846.1	CTD-3220F14.3	-5.26	1.73e-07	2.03e-05	-0.22	-0.16	Coronary artery calcification;	chr19:37644502	chr19:37314868~37315620:-
BRCA	cis	rs12681366	0.734	rs10102233	ENSG00000253704.1	RP11-267M23.4	5.26	1.73e-07	2.03e-05	0.17	0.16	Nonsyndromic cleft lip with cleft palate;	chr8:94389429	chr8:94553722~94569745:+
BRCA	cis	rs7618501	0.635	rs7635002	ENSG00000228008.1	CTD-2330K9.3	5.26	1.73e-07	2.03e-05	0.16	0.16	Intelligence (multi-trait analysis);	chr3:49951722	chr3:49903845~49916937:+
BRCA	cis	rs2638953	0.924	rs11049478	ENSG00000247934.4	RP11-967K21.1	-5.26	1.73e-07	2.04e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28244827	chr12:28163298~28190738:-
BRCA	cis	rs9300255	0.77	rs7980687	ENSG00000235423.7	RP11-282O18.3	-5.26	1.73e-07	2.04e-05	-0.22	-0.16	Neutrophil percentage of white cells;	chr12:123338164	chr12:123252030~123261483:-
BRCA	cis	rs1044573	0.526	rs6050422	ENSG00000277938.1	RP5-965G21.3	5.26	1.73e-07	2.04e-05	0.19	0.16	Allergic rhinitis;	chr20:25197284	chr20:25229150~25231933:+
BRCA	cis	rs3120667	0.789	rs11204993	ENSG00000237975.5	FLG-AS1	5.26	1.73e-07	2.04e-05	0.24	0.16	Eating disorders;	chr1:152383857	chr1:152168125~152445456:+
BRCA	cis	rs875971	0.66	rs7807944	ENSG00000273024.4	INTS4P2	5.26	1.73e-07	2.04e-05	0.18	0.16	Aortic root size;	chr7:66622208	chr7:65647864~65715661:+
BRCA	cis	rs2179367	0.632	rs11155645	ENSG00000268592.3	RAET1E-AS1	5.26	1.73e-07	2.04e-05	0.23	0.16	Dupuytren's disease;	chr6:149360056	chr6:149863494~149919507:+
BRCA	cis	rs2179367	0.632	rs9498332	ENSG00000268592.3	RAET1E-AS1	5.26	1.73e-07	2.04e-05	0.23	0.16	Dupuytren's disease;	chr6:149367490	chr6:149863494~149919507:+
BRCA	cis	rs2179367	0.632	rs9498333	ENSG00000268592.3	RAET1E-AS1	5.26	1.73e-07	2.04e-05	0.23	0.16	Dupuytren's disease;	chr6:149368196	chr6:149863494~149919507:+
BRCA	cis	rs7200786	0.557	rs8057040	ENSG00000274038.1	RP11-66H6.4	-5.26	1.73e-07	2.04e-05	-0.18	-0.16	Systemic lupus erythematosus;Multiple sclerosis;	chr16:10997502	chr16:11056556~11057034:+
BRCA	cis	rs1552244	0.938	rs67667957	ENSG00000232901.1	CYCSP10	5.26	1.73e-07	2.04e-05	0.22	0.16	Alzheimer's disease;	chr3:10125580	chr3:10000647~10000940:-
BRCA	cis	rs17685	0.725	rs7795291	ENSG00000280388.1	RP11-229D13.3	-5.26	1.73e-07	2.04e-05	-0.17	-0.16	Coffee consumption (cups per day);Coffee consumption;	chr7:76095888	chr7:76043977~76045963:-
BRCA	cis	rs7620503	1	rs6443474	ENSG00000228221.4	LINC00578	5.26	1.73e-07	2.04e-05	0.19	0.16	Corneal structure;	chr3:177587336	chr3:177441921~177752305:+
BRCA	cis	rs6832769	1	rs6811520	ENSG00000223305.1	RN7SKP30	5.26	1.73e-07	2.04e-05	0.21	0.16	Personality dimensions;	chr4:55449011	chr4:55540502~55540835:-
BRCA	cis	rs4700393	0.967	rs921897	ENSG00000215032.2	GNL3LP1	5.26	1.73e-07	2.04e-05	0.2	0.16	Intelligence (multi-trait analysis);	chr5:60793310	chr5:60891935~60893577:-
BRCA	cis	rs1440410	0.835	rs11100782	ENSG00000250326.1	RP11-284M14.1	-5.26	1.73e-07	2.04e-05	-0.18	-0.16	Ischemic stroke;	chr4:143231744	chr4:142933195~143184861:-
BRCA	cis	rs3213958	0.574	rs6440159	ENSG00000249274.1	PDLIM1P4	-5.26	1.73e-07	2.04e-05	-0.25	-0.16	Blood protein levels;	chr3:98823350	chr3:98782188~98783193:+
BRCA	cis	rs7618501	0.633	rs6446189	ENSG00000228008.1	CTD-2330K9.3	5.26	1.73e-07	2.04e-05	0.16	0.16	Intelligence (multi-trait analysis);	chr3:49971133	chr3:49903845~49916937:+
BRCA	cis	rs13113518	1	rs1522112	ENSG00000223305.1	RN7SKP30	5.26	1.73e-07	2.04e-05	0.19	0.16	Height;	chr4:55463606	chr4:55540502~55540835:-
BRCA	cis	rs13113518	1	rs4864997	ENSG00000223305.1	RN7SKP30	5.26	1.73e-07	2.04e-05	0.19	0.16	Height;	chr4:55466010	chr4:55540502~55540835:-
BRCA	cis	rs13113518	1	rs960152	ENSG00000223305.1	RN7SKP30	5.26	1.73e-07	2.04e-05	0.19	0.16	Height;	chr4:55467308	chr4:55540502~55540835:-
BRCA	cis	rs13113518	0.967	rs12644948	ENSG00000223305.1	RN7SKP30	5.26	1.73e-07	2.04e-05	0.19	0.16	Height;	chr4:55470266	chr4:55540502~55540835:-
BRCA	cis	rs13113518	1	rs3805151	ENSG00000223305.1	RN7SKP30	5.26	1.73e-07	2.04e-05	0.19	0.16	Height;	chr4:55470874	chr4:55540502~55540835:-
BRCA	cis	rs12681366	0.663	rs2919662	ENSG00000253704.1	RP11-267M23.4	5.26	1.73e-07	2.04e-05	0.17	0.16	Nonsyndromic cleft lip with cleft palate;	chr8:94458044	chr8:94553722~94569745:+
BRCA	cis	rs12681366	0.663	rs2919660	ENSG00000253704.1	RP11-267M23.4	5.26	1.73e-07	2.04e-05	0.17	0.16	Nonsyndromic cleft lip with cleft palate;	chr8:94458469	chr8:94553722~94569745:+
BRCA	cis	rs12681366	0.663	rs1561648	ENSG00000253704.1	RP11-267M23.4	5.26	1.73e-07	2.04e-05	0.17	0.16	Nonsyndromic cleft lip with cleft palate;	chr8:94462209	chr8:94553722~94569745:+
BRCA	cis	rs2708977	0.637	rs618454	ENSG00000237510.6	AC008268.2	-5.26	1.73e-07	2.04e-05	-0.21	-0.16	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96414356	chr2:95789654~95800166:+
BRCA	cis	rs6893782	0.83	rs274553	ENSG00000233006.5	AC034220.3	-5.26	1.73e-07	2.04e-05	-0.14	-0.16	Acylcarnitine levels;	chr5:132390140	chr5:132311285~132369916:-
BRCA	cis	rs6430585	0.591	rs77096272	ENSG00000224043.6	CCNT2-AS1	-5.26	1.73e-07	2.04e-05	-0.28	-0.16	Corneal structure;	chr2:135906035	chr2:134735464~134918710:-
BRCA	cis	rs7618915	0.571	rs6798246	ENSG00000243224.1	RP5-1157M23.2	-5.26	1.74e-07	2.05e-05	-0.18	-0.16	Bipolar disorder;	chr3:52565906	chr3:52239258~52241097:+
BRCA	cis	rs7618915	0.571	rs7623199	ENSG00000243224.1	RP5-1157M23.2	-5.26	1.74e-07	2.05e-05	-0.18	-0.16	Bipolar disorder;	chr3:52571958	chr3:52239258~52241097:+
BRCA	cis	rs73222236	0.825	rs9872326	ENSG00000273486.1	RP11-731C17.2	5.26	1.74e-07	2.05e-05	0.18	0.16	Coronary artery disease;	chr3:136267702	chr3:136837338~136839021:-
BRCA	cis	rs4908768	0.539	rs4480384	ENSG00000232912.4	RP5-1115A15.1	5.26	1.74e-07	2.05e-05	0.16	0.16	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8599655	chr1:8424645~8434838:+
BRCA	cis	rs9545047	0.604	rs7336581	ENSG00000227354.5	RBM26-AS1	5.26	1.74e-07	2.05e-05	0.17	0.16	Schizophrenia;	chr13:79385739	chr13:79406309~79424328:+
BRCA	cis	rs3733585	0.673	rs4235347	ENSG00000250413.1	RP11-448G15.1	5.26	1.74e-07	2.05e-05	0.21	0.16	Cleft plate (environmental tobacco smoke interaction);	chr4:9950332	chr4:10006482~10009725:+
BRCA	cis	rs3733585	0.673	rs4235348	ENSG00000250413.1	RP11-448G15.1	5.26	1.74e-07	2.05e-05	0.21	0.16	Cleft plate (environmental tobacco smoke interaction);	chr4:9950344	chr4:10006482~10009725:+
BRCA	cis	rs3733585	0.673	rs4697914	ENSG00000250413.1	RP11-448G15.1	5.26	1.74e-07	2.05e-05	0.21	0.16	Cleft plate (environmental tobacco smoke interaction);	chr4:9950642	chr4:10006482~10009725:+
BRCA	cis	rs3733585	0.624	rs7376154	ENSG00000250413.1	RP11-448G15.1	5.26	1.74e-07	2.05e-05	0.21	0.16	Cleft plate (environmental tobacco smoke interaction);	chr4:9950963	chr4:10006482~10009725:+
BRCA	cis	rs3733585	0.648	rs7376155	ENSG00000250413.1	RP11-448G15.1	5.26	1.74e-07	2.05e-05	0.21	0.16	Cleft plate (environmental tobacco smoke interaction);	chr4:9950964	chr4:10006482~10009725:+
BRCA	cis	rs7617773	0.78	rs3731550	ENSG00000199476.1	Y_RNA	-5.26	1.74e-07	2.05e-05	-0.24	-0.16	Coronary artery disease;	chr3:48165093	chr3:48288587~48288694:+
BRCA	cis	rs7617773	0.817	rs3731534	ENSG00000199476.1	Y_RNA	-5.26	1.74e-07	2.05e-05	-0.24	-0.16	Coronary artery disease;	chr3:48170287	chr3:48288587~48288694:+
BRCA	cis	rs7577696	0.695	rs212713	ENSG00000272716.1	RP11-563N4.1	5.26	1.74e-07	2.05e-05	0.18	0.16	Inflammatory biomarkers;	chr2:32232468	chr2:32165046~32165757:-
BRCA	cis	rs1681630	0.545	rs1228001	ENSG00000280615.1	Y_RNA	-5.26	1.74e-07	2.05e-05	-0.18	-0.16	Height;	chr11:47965442	chr11:47614898~47614994:-
BRCA	cis	rs2562456	0.641	rs62107468	ENSG00000268535.1	RP11-420K14.3	5.26	1.74e-07	2.05e-05	0.23	0.16	Pain;	chr19:21307177	chr19:21709522~21710191:+
BRCA	cis	rs1075265	0.73	rs4413193	ENSG00000235937.1	AC008280.1	5.26	1.74e-07	2.05e-05	0.18	0.16	Chronotype;Morning vs. evening chronotype;	chr2:53710901	chr2:54029552~54030682:-
BRCA	cis	rs1979679	0.918	rs7135922	ENSG00000278733.1	RP11-425D17.1	-5.26	1.74e-07	2.05e-05	-0.21	-0.16	Ossification of the posterior longitudinal ligament of the spine;	chr12:28469148	chr12:28185625~28186190:-
BRCA	cis	rs34097030	1	rs34097030	ENSG00000207217.1	SNORA42	-5.26	1.74e-07	2.05e-05	-0.22	-0.16	Reticulocyte fraction of red cells;	chr7:6014758	chr7:6016877~6017011:+
BRCA	cis	rs6163	0.54	rs11191385	ENSG00000236937.2	PTGES3P4	5.26	1.74e-07	2.05e-05	0.23	0.16	Waist circumference;Hip circumference;	chr10:102753292	chr10:102845595~102845950:+
BRCA	cis	rs13113518	0.812	rs11932712	ENSG00000272969.1	RP11-528I4.2	5.26	1.74e-07	2.05e-05	0.19	0.16	Height;	chr4:55436423	chr4:55547112~55547889:+
BRCA	cis	rs9311474	0.632	rs6445528	ENSG00000243224.1	RP5-1157M23.2	5.26	1.74e-07	2.05e-05	0.17	0.16	Electroencephalogram traits;	chr3:52538431	chr3:52239258~52241097:+
BRCA	cis	rs4588572	0.688	rs2115436	ENSG00000245556.2	SCAMP1-AS1	-5.26	1.74e-07	2.05e-05	-0.18	-0.16	Triglycerides;	chr5:78396793	chr5:78342365~78360507:-
BRCA	cis	rs6430585	0.528	rs12464050	ENSG00000224043.6	CCNT2-AS1	-5.26	1.75e-07	2.05e-05	-0.28	-0.16	Corneal structure;	chr2:135905540	chr2:134735464~134918710:-
BRCA	cis	rs1823913	0.526	rs35340557	ENSG00000280083.1	RP11-317J9.1	-5.26	1.75e-07	2.05e-05	-0.19	-0.16	Obesity-related traits;	chr2:191338688	chr2:191154118~191156070:-
BRCA	cis	rs1823913	0.503	rs35562914	ENSG00000280083.1	RP11-317J9.1	-5.26	1.75e-07	2.05e-05	-0.19	-0.16	Obesity-related traits;	chr2:191338969	chr2:191154118~191156070:-
BRCA	cis	rs7577696	0.85	rs2566483	ENSG00000272716.1	RP11-563N4.1	5.26	1.75e-07	2.06e-05	0.18	0.16	Inflammatory biomarkers;	chr2:32259398	chr2:32165046~32165757:-
BRCA	cis	rs1552244	0.882	rs55962400	ENSG00000232901.1	CYCSP10	5.26	1.75e-07	2.06e-05	0.24	0.16	Alzheimer's disease;	chr3:10002773	chr3:10000647~10000940:-
BRCA	cis	rs595982	0.559	rs117227130	ENSG00000235191.1	NUCB1-AS1	5.26	1.75e-07	2.06e-05	0.27	0.16	Red cell distribution width;	chr19:48864702	chr19:48910930~48918891:-
BRCA	cis	rs595982	0.559	rs73061643	ENSG00000235191.1	NUCB1-AS1	5.26	1.75e-07	2.06e-05	0.27	0.16	Red cell distribution width;	chr19:48864894	chr19:48910930~48918891:-
BRCA	cis	rs595982	0.527	rs12151238	ENSG00000235191.1	NUCB1-AS1	5.26	1.75e-07	2.06e-05	0.27	0.16	Red cell distribution width;	chr19:48865356	chr19:48910930~48918891:-
BRCA	cis	rs795484	0.507	rs2249624	ENSG00000275759.1	RP11-131L12.3	5.26	1.75e-07	2.06e-05	0.18	0.16	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;	chr12:118151264	chr12:118428281~118428870:+
BRCA	cis	rs3733585	0.673	rs7376505	ENSG00000250413.1	RP11-448G15.1	5.26	1.75e-07	2.06e-05	0.21	0.16	Cleft plate (environmental tobacco smoke interaction);	chr4:9951120	chr4:10006482~10009725:+
BRCA	cis	rs3733585	0.673	rs7377578	ENSG00000250413.1	RP11-448G15.1	5.26	1.75e-07	2.06e-05	0.21	0.16	Cleft plate (environmental tobacco smoke interaction);	chr4:9951151	chr4:10006482~10009725:+
BRCA	cis	rs3733585	0.699	rs7699609	ENSG00000250413.1	RP11-448G15.1	5.26	1.75e-07	2.06e-05	0.21	0.16	Cleft plate (environmental tobacco smoke interaction);	chr4:9959435	chr4:10006482~10009725:+
BRCA	cis	rs6479891	1	rs6479891	ENSG00000232075.1	MRPL35P2	5.26	1.75e-07	2.06e-05	0.29	0.16	Arthritis (juvenile idiopathic);	chr10:63246696	chr10:63634317~63634827:-
BRCA	cis	rs6832769	1	rs9312662	ENSG00000272969.1	RP11-528I4.2	-5.26	1.75e-07	2.06e-05	-0.2	-0.16	Personality dimensions;	chr4:55520204	chr4:55547112~55547889:+
BRCA	cis	rs61160187	0.51	rs10076679	ENSG00000215032.2	GNL3LP1	5.26	1.75e-07	2.06e-05	0.19	0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:60795124	chr5:60891935~60893577:-
BRCA	cis	rs61160187	0.527	rs10076742	ENSG00000215032.2	GNL3LP1	5.26	1.75e-07	2.06e-05	0.19	0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:60795219	chr5:60891935~60893577:-
BRCA	cis	rs61160187	0.527	rs6890201	ENSG00000215032.2	GNL3LP1	5.26	1.75e-07	2.06e-05	0.19	0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:60795365	chr5:60891935~60893577:-
BRCA	cis	rs61160187	0.51	rs6875456	ENSG00000215032.2	GNL3LP1	5.26	1.75e-07	2.06e-05	0.19	0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:60795503	chr5:60891935~60893577:-
BRCA	cis	rs61160187	0.51	rs6894750	ENSG00000215032.2	GNL3LP1	5.26	1.75e-07	2.06e-05	0.19	0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:60795729	chr5:60891935~60893577:-
BRCA	cis	rs3764563	1	rs2031062	ENSG00000267594.5	CYP4F24P	-5.26	1.75e-07	2.06e-05	-0.31	-0.16	Inflammatory biomarkers;	chr19:15606762	chr19:15760241~15779909:-
BRCA	cis	rs3764563	0.935	rs4807958	ENSG00000267594.5	CYP4F24P	-5.26	1.75e-07	2.06e-05	-0.31	-0.16	Inflammatory biomarkers;	chr19:15607231	chr19:15760241~15779909:-
BRCA	cis	rs6832769	1	rs1522111	ENSG00000272969.1	RP11-528I4.2	5.26	1.75e-07	2.06e-05	0.2	0.16	Personality dimensions;	chr4:55463396	chr4:55547112~55547889:+
BRCA	cis	rs728616	0.541	rs61860401	ENSG00000225484.5	NUTM2B-AS1	-5.26	1.75e-07	2.06e-05	-0.31	-0.16	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79963766	chr10:79663088~79826594:-
BRCA	cis	rs875971	0.862	rs1875057	ENSG00000236529.1	RP13-254B10.1	-5.26	1.75e-07	2.06e-05	-0.18	-0.16	Aortic root size;	chr7:66266868	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.862	rs6960446	ENSG00000236529.1	RP13-254B10.1	-5.26	1.75e-07	2.06e-05	-0.18	-0.16	Aortic root size;	chr7:66268272	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.789	rs10260426	ENSG00000236529.1	RP13-254B10.1	-5.26	1.75e-07	2.06e-05	-0.18	-0.16	Aortic root size;	chr7:66271055	chr7:65840212~65840596:+
BRCA	cis	rs1030877	0.521	rs2576747	ENSG00000235319.1	AC012360.4	-5.26	1.75e-07	2.06e-05	-0.2	-0.16	Obesity-related traits;	chr2:105362219	chr2:105324210~105330529:+
BRCA	cis	rs4908768	0.539	rs7537982	ENSG00000232912.4	RP5-1115A15.1	5.26	1.75e-07	2.06e-05	0.16	0.16	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8583948	chr1:8424645~8434838:+
BRCA	cis	rs6545883	0.826	rs2694651	ENSG00000270820.4	RP11-355B11.2	-5.26	1.75e-07	2.06e-05	-0.19	-0.16	Tuberculosis;	chr2:61361507	chr2:61471188~61484130:+
BRCA	cis	rs4266144	0.544	rs7340627	ENSG00000241770.1	RP11-555M1.3	-5.26	1.75e-07	2.06e-05	-0.21	-0.16	Coronary artery disease;	chr3:157114604	chr3:157163452~157169133:+
BRCA	cis	rs13108904	0.901	rs2293634	ENSG00000196810.4	CTBP1-AS2	5.26	1.75e-07	2.06e-05	0.17	0.16	Obesity-related traits;	chr4:1297923	chr4:1249300~1288291:+
BRCA	cis	rs295490	0.748	rs3772876	ENSG00000272656.1	RP11-219D15.3	5.26	1.75e-07	2.06e-05	0.37	0.16	PR interval in Tripanosoma cruzi seropositivity;	chr3:139469035	chr3:139349024~139349371:-
BRCA	cis	rs4713118	0.513	rs149955	ENSG00000280107.1	AL022393.9	-5.26	1.75e-07	2.07e-05	-0.22	-0.16	Parkinson's disease;	chr6:28068447	chr6:28170845~28172521:+
BRCA	cis	rs9907295	0.786	rs9901418	ENSG00000270977.1	AC015849.16	-5.26	1.76e-07	2.07e-05	-0.28	-0.16	Fibroblast growth factor basic levels;	chr17:35915699	chr17:35893707~35911023:-
BRCA	cis	rs10504130	0.569	rs10958305	ENSG00000272024.1	RP11-546K22.3	-5.26	1.76e-07	2.07e-05	-0.24	-0.16	Venous thromboembolism (SNP x SNP interaction);	chr8:51906464	chr8:51950284~51950690:+
BRCA	cis	rs2562456	0.833	rs2650776	ENSG00000268081.1	RP11-678G14.2	5.26	1.76e-07	2.07e-05	0.26	0.16	Pain;	chr19:21430595	chr19:21554640~21569237:-
BRCA	cis	rs9291683	0.645	rs11557743	ENSG00000250413.1	RP11-448G15.1	5.26	1.76e-07	2.07e-05	0.21	0.16	Bone mineral density;	chr4:10116753	chr4:10006482~10009725:+
BRCA	cis	rs516805	0.561	rs9320881	ENSG00000279453.1	RP3-425C14.4	5.26	1.76e-07	2.07e-05	0.26	0.16	Lymphocyte counts;	chr6:122613577	chr6:122436789~122439223:-
BRCA	cis	rs6480314	0.542	rs2120902	ENSG00000233590.1	RP11-153K11.3	-5.26	1.76e-07	2.07e-05	-0.27	-0.16	Optic nerve measurement (disc area);	chr10:68260465	chr10:68233251~68242379:-
BRCA	cis	rs6496044	0.611	rs6496055	ENSG00000259295.5	CSPG4P12	5.26	1.76e-07	2.07e-05	0.19	0.16	Interstitial lung disease;	chr15:85527457	chr15:85191438~85213905:+
BRCA	cis	rs4819052	0.851	rs2838842	ENSG00000184274.3	LINC00315	-5.26	1.76e-07	2.07e-05	-0.22	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45249302	chr21:45300245~45305257:-
BRCA	cis	rs8114671	0.562	rs4911161	ENSG00000269202.1	RP4-614O4.12	-5.26	1.76e-07	2.07e-05	-0.16	-0.16	Height;	chr20:34814428	chr20:35201747~35203288:-
BRCA	cis	rs763121	0.853	rs138702	ENSG00000228274.3	RP3-508I15.9	5.26	1.76e-07	2.07e-05	0.18	0.16	Menopause (age at onset);	chr22:38736596	chr22:38667585~38681820:-
BRCA	cis	rs2303319	0.892	rs16845742	ENSG00000227403.1	AC009299.3	5.26	1.76e-07	2.07e-05	0.41	0.16	Cognitive function;	chr2:161270523	chr2:161244739~161249050:+
BRCA	cis	rs595982	0.559	rs17206714	ENSG00000235191.1	NUCB1-AS1	5.26	1.76e-07	2.07e-05	0.28	0.16	Red cell distribution width;	chr19:48858744	chr19:48910930~48918891:-
BRCA	cis	rs728616	0.867	rs61860041	ENSG00000225484.5	NUTM2B-AS1	-5.26	1.76e-07	2.07e-05	-0.43	-0.16	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80184575	chr10:79663088~79826594:-
BRCA	cis	rs728616	0.867	rs61860042	ENSG00000225484.5	NUTM2B-AS1	-5.26	1.76e-07	2.07e-05	-0.43	-0.16	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80186482	chr10:79663088~79826594:-
BRCA	cis	rs728616	0.867	rs12415870	ENSG00000225484.5	NUTM2B-AS1	-5.26	1.76e-07	2.07e-05	-0.43	-0.16	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80189714	chr10:79663088~79826594:-
BRCA	cis	rs1979679	0.918	rs10771430	ENSG00000278733.1	RP11-425D17.1	-5.26	1.76e-07	2.07e-05	-0.21	-0.16	Ossification of the posterior longitudinal ligament of the spine;	chr12:28470505	chr12:28185625~28186190:-
BRCA	cis	rs950776	0.518	rs2292117	ENSG00000279373.1	RP11-650L12.4	5.26	1.76e-07	2.07e-05	0.2	0.16	Sudden cardiac arrest;	chr15:78542347	chr15:78537681~78538946:+
BRCA	cis	rs300890	0.513	rs11100781	ENSG00000250326.1	RP11-284M14.1	-5.26	1.76e-07	2.07e-05	-0.19	-0.16	Nasopharyngeal carcinoma;	chr4:143211469	chr4:142933195~143184861:-
BRCA	cis	rs2015599	0.549	rs9738165	ENSG00000257176.2	RP11-996F15.2	5.26	1.76e-07	2.08e-05	0.18	0.16	Platelet count;Mean platelet volume;	chr12:29290263	chr12:29280418~29317848:-
BRCA	cis	rs9880211	0.613	rs67109185	ENSG00000239213.4	NCK1-AS1	5.26	1.76e-07	2.08e-05	0.19	0.16	Height;Body mass index;	chr3:136108550	chr3:136841726~136862054:-
BRCA	cis	rs2904967	0.929	rs1783486	ENSG00000254614.2	AP003068.23	-5.26	1.76e-07	2.08e-05	-0.3	-0.16	Mean corpuscular volume;	chr11:65241446	chr11:65177606~65181834:-
BRCA	cis	rs7620503	1	rs1875096	ENSG00000228221.4	LINC00578	5.26	1.76e-07	2.08e-05	0.19	0.16	Corneal structure;	chr3:177586076	chr3:177441921~177752305:+
BRCA	cis	rs7620503	1	rs1875097	ENSG00000228221.4	LINC00578	5.26	1.76e-07	2.08e-05	0.19	0.16	Corneal structure;	chr3:177586244	chr3:177441921~177752305:+
BRCA	cis	rs7620503	1	rs7620503	ENSG00000228221.4	LINC00578	5.26	1.76e-07	2.08e-05	0.19	0.16	Corneal structure;	chr3:177586510	chr3:177441921~177752305:+
BRCA	cis	rs875971	1	rs2420820	ENSG00000223473.2	GS1-124K5.3	-5.26	1.76e-07	2.08e-05	-0.13	-0.16	Aortic root size;	chr7:66626920	chr7:66491049~66493566:-
BRCA	cis	rs11955398	0.502	rs159375	ENSG00000215032.2	GNL3LP1	5.26	1.77e-07	2.08e-05	0.2	0.16	Intelligence (multi-trait analysis);	chr5:61137440	chr5:60891935~60893577:-
BRCA	cis	rs11955398	0.502	rs159374	ENSG00000215032.2	GNL3LP1	5.26	1.77e-07	2.08e-05	0.2	0.16	Intelligence (multi-trait analysis);	chr5:61139117	chr5:60891935~60893577:-
BRCA	cis	rs2638953	0.924	rs11049607	ENSG00000247934.4	RP11-967K21.1	-5.26	1.77e-07	2.08e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28444574	chr12:28163298~28190738:-
BRCA	cis	rs9467773	1	rs9467791	ENSG00000124549.13	BTN2A3P	-5.26	1.77e-07	2.08e-05	-0.16	-0.16	Intelligence (multi-trait analysis);	chr6:26562258	chr6:26421391~26432383:+
BRCA	cis	rs7577696	0.889	rs212733	ENSG00000272716.1	RP11-563N4.1	5.26	1.77e-07	2.08e-05	0.18	0.16	Inflammatory biomarkers;	chr2:32247571	chr2:32165046~32165757:-
BRCA	cis	rs2235544	0.664	rs12036530	ENSG00000225183.1	RP4-758J24.4	-5.26	1.77e-07	2.08e-05	-0.19	-0.16	Thyroid hormone levels;Multiple myeloma (hyperdiploidy);	chr1:54010650	chr1:54089856~54090093:+
BRCA	cis	rs2235544	0.664	rs41366847	ENSG00000225183.1	RP4-758J24.4	-5.26	1.77e-07	2.08e-05	-0.19	-0.16	Thyroid hormone levels;Multiple myeloma (hyperdiploidy);	chr1:54011294	chr1:54089856~54090093:+
BRCA	cis	rs867371	0.502	rs28610286	ENSG00000259429.4	UBE2Q2P2	-5.26	1.77e-07	2.08e-05	-0.15	-0.16	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82233314	chr15:82355142~82420075:+
BRCA	cis	rs8180040	0.966	rs6792461	ENSG00000276925.1	RP11-708J19.3	5.26	1.77e-07	2.08e-05	0.19	0.16	Colorectal cancer;	chr3:47431678	chr3:47469777~47469987:+
BRCA	cis	rs17767294	0.614	rs116420641	ENSG00000204709.4	LINC01556	5.26	1.77e-07	2.08e-05	0.44	0.16	Parkinson's disease;	chr6:28307681	chr6:28943877~28944537:+
BRCA	cis	rs17767294	0.614	rs78521938	ENSG00000204709.4	LINC01556	5.26	1.77e-07	2.08e-05	0.44	0.16	Parkinson's disease;	chr6:28312046	chr6:28943877~28944537:+
BRCA	cis	rs17767294	0.614	rs72854521	ENSG00000204709.4	LINC01556	5.26	1.77e-07	2.08e-05	0.44	0.16	Parkinson's disease;	chr6:28317021	chr6:28943877~28944537:+
BRCA	cis	rs4819052	0.851	rs8127834	ENSG00000184274.3	LINC00315	-5.26	1.77e-07	2.08e-05	-0.22	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45276194	chr21:45300245~45305257:-
BRCA	cis	rs10946940	0.965	rs6456799	ENSG00000216901.1	AL022393.7	-5.26	1.77e-07	2.08e-05	-0.2	-0.16	Systemic lupus erythematosus;	chr6:27605757	chr6:28176188~28176674:+
BRCA	cis	rs2638953	0.924	rs10843169	ENSG00000247934.4	RP11-967K21.1	5.26	1.77e-07	2.08e-05	0.22	0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28430051	chr12:28163298~28190738:-
BRCA	cis	rs6496044	0.963	rs7165300	ENSG00000259295.5	CSPG4P12	5.26	1.77e-07	2.08e-05	0.2	0.16	Interstitial lung disease;	chr15:85526838	chr15:85191438~85213905:+
BRCA	cis	rs2638953	0.814	rs60960895	ENSG00000247934.4	RP11-967K21.1	-5.26	1.77e-07	2.08e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28454499	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.853	rs10843178	ENSG00000247934.4	RP11-967K21.1	-5.26	1.77e-07	2.08e-05	-0.21	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28460501	chr12:28163298~28190738:-
BRCA	cis	rs1707322	1	rs10890355	ENSG00000234329.1	RP11-767N6.2	5.26	1.77e-07	2.08e-05	0.16	0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45851676	chr1:45651039~45651826:-
BRCA	cis	rs1707322	1	rs11211204	ENSG00000234329.1	RP11-767N6.2	5.26	1.77e-07	2.08e-05	0.16	0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45852192	chr1:45651039~45651826:-
BRCA	cis	rs4664293	0.669	rs1863219	ENSG00000226266.5	AC009961.3	5.26	1.77e-07	2.08e-05	0.19	0.16	Monocyte percentage of white cells;	chr2:159561660	chr2:159670708~159712435:-
BRCA	cis	rs1193	0.616	rs12613610	ENSG00000231259.4	AC125232.1	-5.26	1.77e-07	2.08e-05	-0.19	-0.16	High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;High light scatter reticulocyte count;	chr2:86670378	chr2:87031815~87053069:-
BRCA	cis	rs2898290	0.5	rs11998678	ENSG00000255052.4	FAM66D	5.26	1.77e-07	2.08e-05	0.2	0.16	Systolic blood pressure;	chr8:11972641	chr8:12115782~12177550:+
BRCA	cis	rs67981189	0.634	rs221898	ENSG00000269927.1	RP6-91H8.3	5.26	1.77e-07	2.09e-05	0.2	0.16	Schizophrenia;	chr14:71138799	chr14:71141125~71143253:-
BRCA	cis	rs651907	0.557	rs59596156	ENSG00000256628.3	ZBTB11-AS1	5.26	1.77e-07	2.09e-05	0.2	0.16	Colorectal cancer;	chr3:101675373	chr3:101676475~101679217:+
BRCA	cis	rs35612822	0.723	rs12694389	ENSG00000232485.2	AC098820.3	-5.26	1.77e-07	2.09e-05	-0.21	-0.16	Kidney disease (early stage) in type 1 diabetes;	chr2:216462836	chr2:216479030~216498761:-
BRCA	cis	rs2241024	0.509	rs12985675	ENSG00000281468.1	CTC-459F4.9	5.26	1.77e-07	2.09e-05	0.25	0.16	Testicular germ cell tumor;	chr19:27531795	chr19:27802838~27803472:+
BRCA	cis	rs2638953	0.962	rs61922978	ENSG00000247934.4	RP11-967K21.1	-5.26	1.78e-07	2.09e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28292075	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.962	rs12372448	ENSG00000247934.4	RP11-967K21.1	-5.26	1.78e-07	2.09e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28293956	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.925	rs11049511	ENSG00000247934.4	RP11-967K21.1	-5.26	1.78e-07	2.09e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28294393	chr12:28163298~28190738:-
BRCA	cis	rs9402743	0.634	rs9494294	ENSG00000231028.7	LINC00271	-5.26	1.78e-07	2.09e-05	-0.16	-0.16	Systemic lupus erythematosus;	chr6:135603460	chr6:135497801~135716055:+
BRCA	cis	rs8098244	0.708	rs1131521	ENSG00000264745.1	TTC39C-AS1	-5.26	1.78e-07	2.09e-05	-0.24	-0.16	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23933804	chr18:23994213~24015339:-
BRCA	cis	rs6430585	0.528	rs309122	ENSG00000231890.6	DARS-AS1	-5.26	1.78e-07	2.09e-05	-0.23	-0.16	Corneal structure;	chr2:136004283	chr2:135985176~136022593:+
BRCA	cis	rs13108904	0.901	rs7668661	ENSG00000196810.4	CTBP1-AS2	5.26	1.78e-07	2.09e-05	0.17	0.16	Obesity-related traits;	chr4:1306384	chr4:1249300~1288291:+
BRCA	cis	rs61160187	0.51	rs6876335	ENSG00000215032.2	GNL3LP1	5.26	1.78e-07	2.09e-05	0.19	0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:60795991	chr5:60891935~60893577:-
BRCA	cis	rs61160187	0.51	rs6449501	ENSG00000215032.2	GNL3LP1	5.26	1.78e-07	2.09e-05	0.19	0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:60796860	chr5:60891935~60893577:-
BRCA	cis	rs61160187	0.51	rs4235481	ENSG00000215032.2	GNL3LP1	5.26	1.78e-07	2.09e-05	0.19	0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:60797560	chr5:60891935~60893577:-
BRCA	cis	rs4835473	0.932	rs3872	ENSG00000249741.2	RP11-673E1.3	-5.26	1.78e-07	2.09e-05	-0.17	-0.16	Immature fraction of reticulocytes;	chr4:143968788	chr4:143911514~143912053:-
BRCA	cis	rs5758511	0.773	rs8140869	ENSG00000205702.9	CYP2D7	-5.26	1.78e-07	2.09e-05	-0.16	-0.16	Birth weight;	chr22:41948293	chr22:42140203~42144577:-
BRCA	cis	rs4761702	0.551	rs11106987	ENSG00000257252.4	RP11-486A14.2	-5.26	1.78e-07	2.1e-05	-0.21	-0.16	Immature fraction of reticulocytes;	chr12:93339760	chr12:93317135~93377736:-
BRCA	cis	rs7617773	0.817	rs11709691	ENSG00000199476.1	Y_RNA	-5.26	1.78e-07	2.1e-05	-0.24	-0.16	Coronary artery disease;	chr3:48262179	chr3:48288587~48288694:+
BRCA	cis	rs3765524	0.574	rs12766693	ENSG00000273450.1	RP11-76P2.4	5.26	1.78e-07	2.1e-05	0.26	0.16	Esophageal cancer and gastric cancer;Dengue shock syndrome;	chr10:94298973	chr10:94314907~94315327:-
BRCA	cis	rs9467773	1	rs9393729	ENSG00000124549.13	BTN2A3P	5.26	1.79e-07	2.1e-05	0.16	0.16	Intelligence (multi-trait analysis);	chr6:26513938	chr6:26421391~26432383:+
BRCA	cis	rs7618501	0.633	rs9853222	ENSG00000228008.1	CTD-2330K9.3	5.26	1.79e-07	2.1e-05	0.16	0.16	Intelligence (multi-trait analysis);	chr3:49985493	chr3:49903845~49916937:+
BRCA	cis	rs73193808	0.851	rs12482584	ENSG00000236056.1	GAPDHP14	-5.26	1.79e-07	2.1e-05	-0.23	-0.16	Coronary artery disease;	chr21:29233532	chr21:29222321~29223257:+
BRCA	cis	rs7178909	0.872	rs7179633	ENSG00000259677.1	RP11-493E3.1	5.26	1.79e-07	2.1e-05	0.19	0.16	Common traits (Other);	chr15:89891645	chr15:89876540~89877285:+
BRCA	cis	rs7178909	0.872	rs28865973	ENSG00000259677.1	RP11-493E3.1	5.26	1.79e-07	2.1e-05	0.19	0.16	Common traits (Other);	chr15:89891946	chr15:89876540~89877285:+
BRCA	cis	rs801193	0.548	rs6975044	ENSG00000224316.1	RP11-479O9.2	5.26	1.79e-07	2.1e-05	0.16	0.16	Aortic root size;	chr7:66762495	chr7:65773620~65802067:+
BRCA	cis	rs2638953	0.79	rs4357727	ENSG00000278733.1	RP11-425D17.1	5.26	1.79e-07	2.1e-05	0.2	0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28291989	chr12:28185625~28186190:-
BRCA	cis	rs3764021	0.87	rs10772085	ENSG00000256673.1	RP11-599J14.2	-5.26	1.79e-07	2.1e-05	-0.18	-0.16	Type 1 diabetes;	chr12:9724281	chr12:9398355~9414851:-
BRCA	cis	rs10851478	0.872	rs12595692	ENSG00000259531.2	RP11-295H24.3	-5.26	1.79e-07	2.1e-05	-0.23	-0.16	Oral cavity cancer;	chr15:49464911	chr15:49365124~49366685:-
BRCA	cis	rs10851478	0.872	rs11854671	ENSG00000259531.2	RP11-295H24.3	-5.26	1.79e-07	2.1e-05	-0.23	-0.16	Oral cavity cancer;	chr15:49473229	chr15:49365124~49366685:-
BRCA	cis	rs10851478	0.872	rs2899434	ENSG00000259531.2	RP11-295H24.3	-5.26	1.79e-07	2.1e-05	-0.23	-0.16	Oral cavity cancer;	chr15:49474771	chr15:49365124~49366685:-
BRCA	cis	rs2243480	0.803	rs160649	ENSG00000232559.3	GS1-124K5.12	5.26	1.79e-07	2.1e-05	0.31	0.16	Diabetic kidney disease;	chr7:66078212	chr7:66554588~66576923:-
BRCA	cis	rs2243480	1	rs160648	ENSG00000232559.3	GS1-124K5.12	5.26	1.79e-07	2.1e-05	0.31	0.16	Diabetic kidney disease;	chr7:66078397	chr7:66554588~66576923:-
BRCA	cis	rs6832769	1	rs6834676	ENSG00000272969.1	RP11-528I4.2	5.26	1.79e-07	2.1e-05	0.2	0.16	Personality dimensions;	chr4:55432247	chr4:55547112~55547889:+
BRCA	cis	rs7178909	0.902	rs2043882	ENSG00000259677.1	RP11-493E3.1	5.26	1.79e-07	2.1e-05	0.19	0.16	Common traits (Other);	chr15:89896521	chr15:89876540~89877285:+
BRCA	cis	rs1552244	0.882	rs113268531	ENSG00000232901.1	CYCSP10	5.26	1.79e-07	2.1e-05	0.22	0.16	Alzheimer's disease;	chr3:10125385	chr3:10000647~10000940:-
BRCA	cis	rs1552244	0.938	rs56274701	ENSG00000232901.1	CYCSP10	5.26	1.79e-07	2.1e-05	0.22	0.16	Alzheimer's disease;	chr3:10126106	chr3:10000647~10000940:-
BRCA	cis	rs10899021	0.92	rs7112384	ENSG00000279353.1	RP11-864N7.4	5.26	1.79e-07	2.11e-05	0.31	0.16	Response to metformin (IC50);	chr11:74637160	chr11:74698231~74699658:-
BRCA	cis	rs2227564	0.62	rs10740418	ENSG00000271816.1	BMS1P4	5.26	1.79e-07	2.11e-05	0.17	0.16	Crohn's disease;Inflammatory bowel disease;	chr10:73759564	chr10:73699151~73730487:-
BRCA	cis	rs12571093	0.773	rs4142047	ENSG00000233590.1	RP11-153K11.3	-5.26	1.79e-07	2.11e-05	-0.27	-0.16	Optic nerve measurement (disc area);	chr10:68261498	chr10:68233251~68242379:-
BRCA	cis	rs7577696	0.785	rs2886393	ENSG00000272716.1	RP11-563N4.1	-5.26	1.79e-07	2.11e-05	-0.18	-0.16	Inflammatory biomarkers;	chr2:32146493	chr2:32165046~32165757:-
BRCA	cis	rs9341808	0.754	rs10806185	ENSG00000272129.1	RP11-250B2.6	5.26	1.79e-07	2.11e-05	0.2	0.16	Sitting height ratio;	chr6:80244794	chr6:80355424~80356859:+
BRCA	cis	rs7914558	1	rs8139	ENSG00000236937.2	PTGES3P4	5.26	1.79e-07	2.11e-05	0.21	0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103088366	chr10:102845595~102845950:+
BRCA	cis	rs6840360	0.606	rs2709814	ENSG00000278978.1	RP11-164P12.5	-5.26	1.79e-07	2.11e-05	-0.18	-0.16	Intelligence (multi-trait analysis);	chr4:151439718	chr4:151669786~151670503:+
BRCA	cis	rs875971	0.54	rs4717275	ENSG00000273024.4	INTS4P2	5.26	1.79e-07	2.11e-05	0.18	0.16	Aortic root size;	chr7:65800193	chr7:65647864~65715661:+
BRCA	cis	rs67981189	0.558	rs56043821	ENSG00000258571.1	PTTG4P	-5.25	1.79e-07	2.11e-05	-0.19	-0.16	Schizophrenia;	chr14:71103835	chr14:71085482~71085833:-
BRCA	cis	rs9549328	0.8	rs1317507	ENSG00000267868.1	RP11-120K24.3	5.25	1.8e-07	2.11e-05	0.22	0.16	Systolic blood pressure;	chr13:112977466	chr13:112964835~112966131:-
BRCA	cis	rs7208859	0.623	rs609063	ENSG00000265443.1	CTD-2349P21.6	-5.25	1.8e-07	2.11e-05	-0.27	-0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30624495	chr17:30726305~30727564:-
BRCA	cis	rs4578769	0.569	rs9951157	ENSG00000265939.1	UBE2CP2	5.25	1.8e-07	2.11e-05	0.18	0.16	Eosinophil percentage of white cells;	chr18:22974173	chr18:22900486~22900995:-
BRCA	cis	rs9287719	0.901	rs10210859	ENSG00000243819.4	RN7SL832P	5.25	1.8e-07	2.11e-05	0.16	0.16	Prostate cancer;	chr2:10593803	chr2:10690344~10692099:+
BRCA	cis	rs12701220	0.894	rs12701406	ENSG00000229043.2	AC091729.9	-5.25	1.8e-07	2.11e-05	-0.25	-0.16	Bronchopulmonary dysplasia;	chr7:1010647	chr7:1160374~1165267:+
BRCA	cis	rs2638953	0.541	rs10843209	ENSG00000278733.1	RP11-425D17.1	-5.25	1.8e-07	2.11e-05	-0.2	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28573702	chr12:28185625~28186190:-
BRCA	cis	rs9402743	0.634	rs6570018	ENSG00000231028.7	LINC00271	-5.25	1.8e-07	2.11e-05	-0.16	-0.16	Systemic lupus erythematosus;	chr6:135602218	chr6:135497801~135716055:+
BRCA	cis	rs71636778	0.509	rs35021342	ENSG00000260063.1	RP5-968P14.2	-5.25	1.8e-07	2.11e-05	-0.35	-0.16	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26759736	chr1:26692132~26694131:-
BRCA	cis	rs10752881	1	rs8179262	ENSG00000224468.3	RP11-181K3.4	-5.25	1.8e-07	2.11e-05	-0.17	-0.16	Colorectal cancer;	chr1:183004051	chr1:183138402~183141282:-
BRCA	cis	rs3765524	0.574	rs12781422	ENSG00000273450.1	RP11-76P2.4	5.25	1.8e-07	2.11e-05	0.26	0.16	Esophageal cancer and gastric cancer;Dengue shock syndrome;	chr10:94294032	chr10:94314907~94315327:-
BRCA	cis	rs8054556	0.669	rs9972866	ENSG00000273724.1	RP11-347C12.12	-5.25	1.8e-07	2.11e-05	-0.18	-0.16	Autism spectrum disorder or schizophrenia;	chr16:30007661	chr16:30336400~30343336:+
BRCA	cis	rs2638953	0.853	rs2141203	ENSG00000247934.4	RP11-967K21.1	-5.25	1.8e-07	2.11e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28461928	chr12:28163298~28190738:-
BRCA	cis	rs8002861	0.967	rs9533691	ENSG00000274001.1	RP11-5G9.5	5.25	1.8e-07	2.12e-05	0.18	0.16	Leprosy;	chr13:43908072	chr13:43877715~43878163:-
BRCA	cis	rs6840360	0.642	rs6845648	ENSG00000278978.1	RP11-164P12.5	-5.25	1.8e-07	2.12e-05	-0.18	-0.16	Intelligence (multi-trait analysis);	chr4:151454898	chr4:151669786~151670503:+
BRCA	cis	rs6840360	0.642	rs2724571	ENSG00000278978.1	RP11-164P12.5	-5.25	1.8e-07	2.12e-05	-0.18	-0.16	Intelligence (multi-trait analysis);	chr4:151455643	chr4:151669786~151670503:+
BRCA	cis	rs6840360	0.642	rs2709833	ENSG00000278978.1	RP11-164P12.5	-5.25	1.8e-07	2.12e-05	-0.18	-0.16	Intelligence (multi-trait analysis);	chr4:151456470	chr4:151669786~151670503:+
BRCA	cis	rs595982	0.559	rs4802516	ENSG00000235191.1	NUCB1-AS1	5.25	1.8e-07	2.12e-05	0.27	0.16	Red cell distribution width;	chr19:48862913	chr19:48910930~48918891:-
BRCA	cis	rs7618915	0.547	rs68021750	ENSG00000243224.1	RP5-1157M23.2	-5.25	1.8e-07	2.12e-05	-0.18	-0.16	Bipolar disorder;	chr3:52590753	chr3:52239258~52241097:+
BRCA	cis	rs7618915	0.547	rs13085331	ENSG00000243224.1	RP5-1157M23.2	-5.25	1.8e-07	2.12e-05	-0.18	-0.16	Bipolar disorder;	chr3:52593470	chr3:52239258~52241097:+
BRCA	cis	rs7618915	0.508	rs12498066	ENSG00000243224.1	RP5-1157M23.2	-5.25	1.8e-07	2.12e-05	-0.18	-0.16	Bipolar disorder;	chr3:52593644	chr3:52239258~52241097:+
BRCA	cis	rs7618915	0.547	rs2164884	ENSG00000243224.1	RP5-1157M23.2	-5.25	1.8e-07	2.12e-05	-0.18	-0.16	Bipolar disorder;	chr3:52595617	chr3:52239258~52241097:+
BRCA	cis	rs7618915	0.524	rs10433615	ENSG00000243224.1	RP5-1157M23.2	-5.25	1.8e-07	2.12e-05	-0.18	-0.16	Bipolar disorder;	chr3:52604466	chr3:52239258~52241097:+
BRCA	cis	rs5758511	0.68	rs5758681	ENSG00000205702.9	CYP2D7	5.25	1.8e-07	2.12e-05	0.17	0.16	Birth weight;	chr22:42249085	chr22:42140203~42144577:-
BRCA	cis	rs13113518	0.812	rs12500601	ENSG00000272969.1	RP11-528I4.2	5.25	1.8e-07	2.12e-05	0.19	0.16	Height;	chr4:55451489	chr4:55547112~55547889:+
BRCA	cis	rs9308731	1	rs6542334	ENSG00000230499.1	AC108463.1	-5.25	1.8e-07	2.12e-05	-0.19	-0.16	Chronic lymphocytic leukemia;	chr2:111149637	chr2:111195963~111206494:+
BRCA	cis	rs13108904	0.901	rs7673398	ENSG00000196810.4	CTBP1-AS2	5.25	1.8e-07	2.12e-05	0.17	0.16	Obesity-related traits;	chr4:1306289	chr4:1249300~1288291:+
BRCA	cis	rs9419788	0.585	rs11187838	ENSG00000273450.1	RP11-76P2.4	5.25	1.8e-07	2.12e-05	0.2	0.16	Personality traits in bipolar disorder;	chr10:94278929	chr10:94314907~94315327:-
BRCA	cis	rs10938353	0.68	rs72624165	ENSG00000273369.1	RP11-700J17.1	5.25	1.8e-07	2.12e-05	0.21	0.16	Body mass index;	chr4:44662457	chr4:44693946~44694386:-
BRCA	cis	rs7621025	0.675	rs34602896	ENSG00000273486.1	RP11-731C17.2	-5.25	1.81e-07	2.12e-05	-0.21	-0.16	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136627543	chr3:136837338~136839021:-
BRCA	cis	rs4950322	0.58	rs72706441	ENSG00000244371.2	PFN1P8	-5.25	1.81e-07	2.12e-05	-0.22	-0.16	Protein quantitative trait loci;	chr1:147122601	chr1:146957117~146957659:-
BRCA	cis	rs7617773	0.746	rs4371540	ENSG00000199476.1	Y_RNA	-5.25	1.81e-07	2.12e-05	-0.24	-0.16	Coronary artery disease;	chr3:48312053	chr3:48288587~48288694:+
BRCA	cis	rs2403083	0.505	rs12546106	ENSG00000258256.1	RP11-219B4.5	-5.25	1.81e-07	2.12e-05	-0.19	-0.16	Plasma amyloid beta peptide concentrations (ABx-40);	chr8:85249308	chr8:85222446~85245717:-
BRCA	cis	rs9393777	0.92	rs34071253	ENSG00000220721.1	OR1F12	5.25	1.81e-07	2.12e-05	0.33	0.16	Intelligence (multi-trait analysis);	chr6:27424023	chr6:28073316~28074233:+
BRCA	cis	rs4835473	0.863	rs7696828	ENSG00000249741.2	RP11-673E1.3	-5.25	1.81e-07	2.13e-05	-0.17	-0.16	Immature fraction of reticulocytes;	chr4:143700846	chr4:143911514~143912053:-
BRCA	cis	rs2403083	0.505	rs6994113	ENSG00000258256.1	RP11-219B4.5	-5.25	1.81e-07	2.13e-05	-0.19	-0.16	Plasma amyloid beta peptide concentrations (ABx-40);	chr8:85254403	chr8:85222446~85245717:-
BRCA	cis	rs523522	0.962	rs2235218	ENSG00000278344.1	RP11-18C24.8	5.25	1.81e-07	2.13e-05	0.22	0.16	High light scatter reticulocyte count;	chr12:120450816	chr12:120500735~120501090:-
BRCA	cis	rs795484	0.507	rs795482	ENSG00000275759.1	RP11-131L12.3	5.25	1.81e-07	2.13e-05	0.18	0.16	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;	chr12:118153011	chr12:118428281~118428870:+
BRCA	cis	rs78487399	0.908	rs6544675	ENSG00000234936.1	AC010883.5	5.25	1.81e-07	2.13e-05	0.22	0.16	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43608813	chr2:43229573~43233394:+
BRCA	cis	rs295490	0.667	rs76728176	ENSG00000272656.1	RP11-219D15.3	5.25	1.81e-07	2.13e-05	0.36	0.16	PR interval in Tripanosoma cruzi seropositivity;	chr3:139441574	chr3:139349024~139349371:-
BRCA	cis	rs2243480	0.522	rs12698511	ENSG00000230295.1	RP11-458F8.2	-5.25	1.82e-07	2.13e-05	-0.26	-0.16	Diabetic kidney disease;	chr7:66009932	chr7:66880708~66882981:+
BRCA	cis	rs6081541	0.622	rs6035257	ENSG00000179447.2	RP5-1027G4.3	5.25	1.82e-07	2.13e-05	0.2	0.16	Psychosis (atypical);	chr20:19224067	chr20:19242302~19284596:-
BRCA	cis	rs17301013	0.932	rs11804941	ENSG00000227373.4	RP11-160H22.5	-5.25	1.82e-07	2.13e-05	-0.21	-0.16	Systemic lupus erythematosus;	chr1:174624074	chr1:174115300~174160004:-
BRCA	cis	rs4835473	0.932	rs10025527	ENSG00000249741.2	RP11-673E1.3	-5.25	1.82e-07	2.13e-05	-0.17	-0.16	Immature fraction of reticulocytes;	chr4:143968391	chr4:143911514~143912053:-
BRCA	cis	rs4819052	0.851	rs8131143	ENSG00000184274.3	LINC00315	5.25	1.82e-07	2.13e-05	0.22	0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251731	chr21:45300245~45305257:-
BRCA	cis	rs2115630	1	rs58581703	ENSG00000259728.4	LINC00933	-5.25	1.82e-07	2.13e-05	-0.18	-0.16	P wave terminal force;	chr15:84733704	chr15:84570649~84580175:+
BRCA	cis	rs9308731	1	rs13396983	ENSG00000230499.1	AC108463.1	-5.25	1.82e-07	2.13e-05	-0.19	-0.16	Chronic lymphocytic leukemia;	chr2:111143021	chr2:111195963~111206494:+
BRCA	cis	rs875971	0.597	rs11763224	ENSG00000228409.4	CCT6P1	-5.25	1.82e-07	2.14e-05	-0.16	-0.16	Aortic root size;	chr7:66518628	chr7:65751142~65763354:+
BRCA	cis	rs755249	0.753	rs72663529	ENSG00000228060.1	RP11-69E11.8	-5.25	1.82e-07	2.14e-05	-0.16	-0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39557684	chr1:39565160~39573203:+
BRCA	cis	rs2638953	0.85	rs59879751	ENSG00000247934.4	RP11-967K21.1	-5.25	1.82e-07	2.14e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28454490	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.924	rs59193275	ENSG00000247934.4	RP11-967K21.1	-5.25	1.82e-07	2.14e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28454560	chr12:28163298~28190738:-
BRCA	cis	rs1707322	1	rs11211248	ENSG00000234329.1	RP11-767N6.2	5.25	1.82e-07	2.14e-05	0.16	0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46011172	chr1:45651039~45651826:-
BRCA	cis	rs6832769	0.922	rs28665088	ENSG00000272969.1	RP11-528I4.2	5.25	1.82e-07	2.14e-05	0.2	0.16	Personality dimensions;	chr4:55384913	chr4:55547112~55547889:+
BRCA	cis	rs2179367	0.632	rs10155766	ENSG00000268592.3	RAET1E-AS1	5.25	1.82e-07	2.14e-05	0.23	0.16	Dupuytren's disease;	chr6:149364577	chr6:149863494~149919507:+
BRCA	cis	rs6545883	0.826	rs1186697	ENSG00000270820.4	RP11-355B11.2	5.25	1.83e-07	2.14e-05	0.19	0.16	Tuberculosis;	chr2:61434282	chr2:61471188~61484130:+
BRCA	cis	rs6832769	1	rs59804446	ENSG00000223305.1	RN7SKP30	-5.25	1.83e-07	2.14e-05	-0.21	-0.16	Personality dimensions;	chr4:55563374	chr4:55540502~55540835:-
BRCA	cis	rs5167	0.566	rs35080293	ENSG00000280087.1	CTB-129P6.7	5.25	1.83e-07	2.14e-05	0.22	0.16	Blood protein levels;	chr19:44993366	chr19:44909375~44914968:+
BRCA	cis	rs7617773	0.78	rs77044321	ENSG00000199476.1	Y_RNA	-5.25	1.83e-07	2.14e-05	-0.24	-0.16	Coronary artery disease;	chr3:48307824	chr3:48288587~48288694:+
BRCA	cis	rs7617773	0.743	rs13081633	ENSG00000199476.1	Y_RNA	-5.25	1.83e-07	2.14e-05	-0.24	-0.16	Coronary artery disease;	chr3:48315791	chr3:48288587~48288694:+
BRCA	cis	rs5167	0.566	rs2075618	ENSG00000280087.1	CTB-129P6.7	5.25	1.83e-07	2.14e-05	0.22	0.16	Blood protein levels;	chr19:44992410	chr19:44909375~44914968:+
BRCA	cis	rs78487399	0.908	rs12471686	ENSG00000234936.1	AC010883.5	5.25	1.83e-07	2.14e-05	0.22	0.16	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43603944	chr2:43229573~43233394:+
BRCA	cis	rs4578769	0.55	rs9953702	ENSG00000265939.1	UBE2CP2	5.25	1.83e-07	2.14e-05	0.18	0.16	Eosinophil percentage of white cells;	chr18:22971001	chr18:22900486~22900995:-
BRCA	cis	rs172166	0.694	rs203892	ENSG00000280107.1	AL022393.9	-5.25	1.83e-07	2.14e-05	-0.22	-0.16	Cardiac Troponin-T levels;	chr6:28099418	chr6:28170845~28172521:+
BRCA	cis	rs172166	0.694	rs188105	ENSG00000280107.1	AL022393.9	-5.25	1.83e-07	2.14e-05	-0.22	-0.16	Cardiac Troponin-T levels;	chr6:28103615	chr6:28170845~28172521:+
BRCA	cis	rs3733585	0.638	rs28715627	ENSG00000250413.1	RP11-448G15.1	5.25	1.83e-07	2.15e-05	0.21	0.16	Cleft plate (environmental tobacco smoke interaction);	chr4:9956516	chr4:10006482~10009725:+
BRCA	cis	rs3733585	0.638	rs17185835	ENSG00000250413.1	RP11-448G15.1	5.25	1.83e-07	2.15e-05	0.21	0.16	Cleft plate (environmental tobacco smoke interaction);	chr4:9956556	chr4:10006482~10009725:+
BRCA	cis	rs3733585	0.664	rs17185870	ENSG00000250413.1	RP11-448G15.1	5.25	1.83e-07	2.15e-05	0.21	0.16	Cleft plate (environmental tobacco smoke interaction);	chr4:9956590	chr4:10006482~10009725:+
BRCA	cis	rs6832769	0.961	rs11735267	ENSG00000272969.1	RP11-528I4.2	5.25	1.83e-07	2.15e-05	0.2	0.16	Personality dimensions;	chr4:55481120	chr4:55547112~55547889:+
BRCA	cis	rs4908768	0.501	rs1463050	ENSG00000232912.4	RP5-1115A15.1	5.25	1.83e-07	2.15e-05	0.15	0.16	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8536983	chr1:8424645~8434838:+
BRCA	cis	rs6832769	1	rs28448438	ENSG00000272969.1	RP11-528I4.2	-5.25	1.83e-07	2.15e-05	-0.2	-0.16	Personality dimensions;	chr4:55550498	chr4:55547112~55547889:+
BRCA	cis	rs4711336	0.935	rs754404	ENSG00000224557.6	HLA-DPB2	-5.25	1.83e-07	2.15e-05	-0.19	-0.16	Height;	chr6:33696953	chr6:33112451~33129084:+
BRCA	cis	rs7804306	1	rs34156160	ENSG00000233264.2	AC006042.8	5.25	1.83e-07	2.15e-05	0.34	0.16	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8043155	chr7:7980312~7982228:+
BRCA	cis	rs2562456	0.793	rs627522	ENSG00000213976.4	CTD-2561J22.2	-5.25	1.83e-07	2.15e-05	-0.19	-0.16	Pain;	chr19:21313002	chr19:21382865~21387177:+
BRCA	cis	rs6480314	0.542	rs17231637	ENSG00000233590.1	RP11-153K11.3	5.25	1.83e-07	2.15e-05	0.26	0.16	Optic nerve measurement (disc area);	chr10:68270137	chr10:68233251~68242379:-
BRCA	cis	rs10938353	0.638	rs6813425	ENSG00000273369.1	RP11-700J17.1	5.25	1.83e-07	2.15e-05	0.21	0.16	Body mass index;	chr4:44659503	chr4:44693946~44694386:-
BRCA	cis	rs4763879	1	rs4763879	ENSG00000256673.1	RP11-599J14.2	-5.25	1.83e-07	2.15e-05	-0.19	-0.16	Type 1 diabetes;	chr12:9757568	chr12:9398355~9414851:-
BRCA	cis	rs9545047	0.604	rs9530897	ENSG00000227354.5	RBM26-AS1	5.25	1.83e-07	2.15e-05	0.17	0.16	Schizophrenia;	chr13:79336420	chr13:79406309~79424328:+
BRCA	cis	rs1859596	1	rs7802883	ENSG00000234456.6	MAGI2-AS3	5.25	1.84e-07	2.15e-05	0.11	0.16	Reading or mathematical ability;	chr7:79455947	chr7:79452877~79471208:+
BRCA	cis	rs7246657	0.943	rs10417844	ENSG00000267422.1	CTD-2554C21.1	-5.25	1.84e-07	2.15e-05	-0.23	-0.16	Coronary artery calcification;	chr19:37346685	chr19:37779686~37792865:+
BRCA	cis	rs9308731	0.644	rs3789065	ENSG00000227992.1	AC108463.2	-5.25	1.84e-07	2.15e-05	-0.18	-0.16	Chronic lymphocytic leukemia;	chr2:111157445	chr2:111203964~111206215:-
BRCA	cis	rs4950322	1	rs72694715	ENSG00000278811.3	LINC00624	5.25	1.84e-07	2.15e-05	0.22	0.16	Protein quantitative trait loci;	chr1:147368468	chr1:147258885~147517875:-
BRCA	cis	rs11955398	0.502	rs34591	ENSG00000215032.2	GNL3LP1	5.25	1.84e-07	2.15e-05	0.2	0.16	Intelligence (multi-trait analysis);	chr5:61034039	chr5:60891935~60893577:-
BRCA	cis	rs4699052	0.787	rs2169508	ENSG00000251288.2	RP11-10L12.2	-5.25	1.84e-07	2.15e-05	-0.19	-0.16	Testicular germ cell tumor;	chr4:103145733	chr4:102751401~102752641:+
BRCA	cis	rs8133949	0.768	rs2839436	ENSG00000237232.6	ZNF295-AS1	-5.25	1.84e-07	2.16e-05	-0.23	-0.16	Hand grip strength;	chr21:42014492	chr21:42009194~42024924:+
BRCA	cis	rs1124769	0.5	rs79722088	ENSG00000259378.1	DCAF13P3	-5.25	1.84e-07	2.16e-05	-0.22	-0.16	Cognitive performance;	chr15:50853702	chr15:50944663~50945996:+
BRCA	cis	rs9307551	0.741	rs12640638	ENSG00000250334.4	LINC00989	-5.25	1.84e-07	2.16e-05	-0.23	-0.16	Refractive error;	chr4:79551314	chr4:79492416~79576460:+
BRCA	cis	rs13178541	0.81	rs2304075	ENSG00000250378.1	RP11-119J18.1	-5.25	1.84e-07	2.16e-05	-0.22	-0.16	IgG glycosylation;	chr5:135842435	chr5:135812667~135826582:+
BRCA	cis	rs2732480	0.577	rs2634684	ENSG00000226413.2	OR8T1P	-5.25	1.84e-07	2.16e-05	-0.22	-0.16	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48337092	chr12:48442030~48442947:-
BRCA	cis	rs11159086	1	rs17100451	ENSG00000270000.1	RP3-449M8.9	5.25	1.84e-07	2.16e-05	0.26	0.16	Advanced glycation end-product levels;	chr14:74476210	chr14:74471930~74472360:-
BRCA	cis	rs2665103	0.632	rs3902959	ENSG00000259429.4	UBE2Q2P2	-5.25	1.84e-07	2.16e-05	-0.15	-0.16	Intelligence (multi-trait analysis);	chr15:82252586	chr15:82355142~82420075:+
BRCA	cis	rs8113308	0.752	rs11882377	ENSG00000269483.1	AC006272.1	5.25	1.85e-07	2.16e-05	0.28	0.16	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:52000877	chr19:51839924~51843324:-
BRCA	cis	rs2732480	0.577	rs2634680	ENSG00000240399.1	RP1-228P16.1	5.25	1.85e-07	2.17e-05	0.19	0.16	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48340781	chr12:48054813~48055591:-
BRCA	cis	rs2732480	0.577	rs2634678	ENSG00000240399.1	RP1-228P16.1	5.25	1.85e-07	2.17e-05	0.19	0.16	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48341755	chr12:48054813~48055591:-
BRCA	cis	rs6569038	0.502	rs4946383	ENSG00000253194.1	RP11-351A11.1	5.25	1.85e-07	2.17e-05	0.2	0.16	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr6:118983460	chr6:118934785~119031541:+
BRCA	cis	rs728616	0.702	rs78734698	ENSG00000225484.5	NUTM2B-AS1	-5.25	1.85e-07	2.17e-05	-0.44	-0.16	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79996693	chr10:79663088~79826594:-
BRCA	cis	rs375066	0.539	rs7249057	ENSG00000267058.1	RP11-15A1.3	5.25	1.85e-07	2.17e-05	0.19	0.16	Breast cancer;	chr19:43826074	chr19:43891804~43901805:-
BRCA	cis	rs597539	0.652	rs569777	ENSG00000261625.1	RP11-554A11.4	-5.25	1.85e-07	2.17e-05	-0.16	-0.16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68939380	chr11:69000765~69002048:-
BRCA	cis	rs62025270	0.688	rs56388190	ENSG00000259295.5	CSPG4P12	-5.25	1.85e-07	2.17e-05	-0.23	-0.16	Idiopathic pulmonary fibrosis;	chr15:85771665	chr15:85191438~85213905:+
BRCA	cis	rs9467773	1	rs9461271	ENSG00000124549.13	BTN2A3P	5.25	1.85e-07	2.17e-05	0.16	0.16	Intelligence (multi-trait analysis);	chr6:26554740	chr6:26421391~26432383:+
BRCA	cis	rs2153535	0.58	rs7747306	ENSG00000251164.1	HULC	5.25	1.85e-07	2.17e-05	0.2	0.16	Motion sickness;	chr6:8453430	chr6:8652137~8653846:+
BRCA	cis	rs7577696	0.752	rs212721	ENSG00000272716.1	RP11-563N4.1	5.25	1.85e-07	2.17e-05	0.18	0.16	Inflammatory biomarkers;	chr2:32240960	chr2:32165046~32165757:-
BRCA	cis	rs10129255	0.957	rs11846893	ENSG00000211974.3	IGHV2-70	5.25	1.85e-07	2.17e-05	0.16	0.16	Kawasaki disease;	chr14:106779068	chr14:106723574~106724093:-
BRCA	cis	rs7617773	0.817	rs6801801	ENSG00000199476.1	Y_RNA	-5.25	1.85e-07	2.17e-05	-0.22	-0.16	Coronary artery disease;	chr3:48284943	chr3:48288587~48288694:+
BRCA	cis	rs2562152	0.744	rs1045001	ENSG00000226942.2	IL9RP3	5.25	1.85e-07	2.17e-05	0.23	0.16	Glioblastoma;	chr16:57275	chr16:29336~38321:-
BRCA	cis	rs6431644	0.899	rs12987473	ENSG00000224287.2	MSL3P1	5.25	1.86e-07	2.17e-05	0.19	0.16	Left atrial antero-posterior diameter;	chr2:233880613	chr2:233865437~233868444:-
BRCA	cis	rs7577696	0.962	rs212746	ENSG00000272716.1	RP11-563N4.1	5.25	1.86e-07	2.18e-05	0.18	0.16	Inflammatory biomarkers;	chr2:32187998	chr2:32165046~32165757:-
BRCA	cis	rs12468226	1	rs12472408	ENSG00000226261.1	AC064836.3	5.25	1.86e-07	2.18e-05	0.28	0.16	Urate levels;	chr2:202413973	chr2:202336024~202336727:-
BRCA	cis	rs2153535	0.546	rs9378559	ENSG00000251164.1	HULC	-5.25	1.86e-07	2.18e-05	-0.2	-0.16	Motion sickness;	chr6:8538825	chr6:8652137~8653846:+
BRCA	cis	rs2348418	0.932	rs12305750	ENSG00000247934.4	RP11-967K21.1	-5.25	1.86e-07	2.18e-05	-0.18	-0.16	Lung function (FEV1);Lung function (FVC);	chr12:28535758	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.962	rs10843150	ENSG00000247934.4	RP11-967K21.1	5.25	1.86e-07	2.18e-05	0.22	0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28304869	chr12:28163298~28190738:-
BRCA	cis	rs11159086	1	rs8006909	ENSG00000270000.1	RP3-449M8.9	5.25	1.86e-07	2.18e-05	0.26	0.16	Advanced glycation end-product levels;	chr14:74478085	chr14:74471930~74472360:-
BRCA	cis	rs597539	0.652	rs622082	ENSG00000261625.1	RP11-554A11.4	-5.25	1.86e-07	2.18e-05	-0.16	-0.16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68936491	chr11:69000765~69002048:-
BRCA	cis	rs597539	0.652	rs546382	ENSG00000261625.1	RP11-554A11.4	-5.25	1.86e-07	2.18e-05	-0.16	-0.16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68936796	chr11:69000765~69002048:-
BRCA	cis	rs2115630	0.755	rs7169629	ENSG00000229212.6	RP11-561C5.4	-5.25	1.86e-07	2.18e-05	-0.17	-0.16	P wave terminal force;	chr15:84648043	chr15:85205440~85234795:-
BRCA	cis	rs6840258	0.891	rs17012512	ENSG00000251411.1	RP11-397E7.4	-5.25	1.86e-07	2.18e-05	-0.22	-0.16	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87146352	chr4:86913266~86914817:-
BRCA	cis	rs516805	0.63	rs2816077	ENSG00000279453.1	RP3-425C14.4	-5.25	1.86e-07	2.18e-05	-0.22	-0.16	Lymphocyte counts;	chr6:122105669	chr6:122436789~122439223:-
BRCA	cis	rs4660214	0.666	rs636083	ENSG00000228060.1	RP11-69E11.8	-5.25	1.86e-07	2.18e-05	-0.16	-0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39356009	chr1:39565160~39573203:+
BRCA	cis	rs7487075	0.619	rs10880968	ENSG00000274723.1	RP11-618L22.1	5.25	1.86e-07	2.18e-05	0.19	0.16	Itch intensity from mosquito bite;	chr12:46429177	chr12:46970504~46972155:+
BRCA	cis	rs11098499	0.754	rs878376	ENSG00000249244.1	RP11-548H18.2	5.25	1.86e-07	2.18e-05	0.18	0.16	Corneal astigmatism;	chr4:119316547	chr4:119391831~119395335:-
BRCA	cis	rs2919009	0.825	rs7099949	ENSG00000271670.1	RP11-95I16.4	5.25	1.86e-07	2.18e-05	0.23	0.16	Obesity-related traits;	chr10:120839119	chr10:120879256~120880667:-
BRCA	cis	rs7487075	0.619	rs7134289	ENSG00000274723.1	RP11-618L22.1	5.25	1.86e-07	2.18e-05	0.2	0.16	Itch intensity from mosquito bite;	chr12:46444553	chr12:46970504~46972155:+
BRCA	cis	rs7618501	0.573	rs2624824	ENSG00000228008.1	CTD-2330K9.3	-5.25	1.87e-07	2.19e-05	-0.15	-0.16	Intelligence (multi-trait analysis);	chr3:50050833	chr3:49903845~49916937:+
BRCA	cis	rs1387259	0.79	rs2732445	ENSG00000257735.1	RP11-370I10.6	5.25	1.87e-07	2.19e-05	0.21	0.16	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48251750	chr12:48350945~48442411:+
BRCA	cis	rs4713118	0.869	rs10214440	ENSG00000216901.1	AL022393.7	5.25	1.87e-07	2.19e-05	0.22	0.16	Parkinson's disease;	chr6:27734661	chr6:28176188~28176674:+
BRCA	cis	rs829883	0.664	rs829864	ENSG00000227825.4	SLC9A7P1	5.25	1.87e-07	2.19e-05	0.19	0.16	Colorectal adenoma (advanced);	chr12:98456417	chr12:98453835~98457145:-
BRCA	cis	rs6545883	0.929	rs6707830	ENSG00000270820.4	RP11-355B11.2	5.25	1.87e-07	2.19e-05	0.18	0.16	Tuberculosis;	chr2:61522337	chr2:61471188~61484130:+
BRCA	cis	rs6088580	0.634	rs6087580	ENSG00000276073.1	RP5-1125A11.7	5.25	1.87e-07	2.19e-05	0.18	0.16	Glomerular filtration rate (creatinine);	chr20:34404786	chr20:33985617~33988989:-
BRCA	cis	rs9311474	0.629	rs13081028	ENSG00000243224.1	RP5-1157M23.2	-5.25	1.87e-07	2.19e-05	-0.17	-0.16	Electroencephalogram traits;	chr3:52521300	chr3:52239258~52241097:+
BRCA	cis	rs4835473	0.932	rs11100824	ENSG00000249741.2	RP11-673E1.3	-5.25	1.87e-07	2.19e-05	-0.17	-0.16	Immature fraction of reticulocytes;	chr4:143964845	chr4:143911514~143912053:-
BRCA	cis	rs4835473	0.592	rs11100825	ENSG00000249741.2	RP11-673E1.3	-5.25	1.87e-07	2.19e-05	-0.17	-0.16	Immature fraction of reticulocytes;	chr4:143964903	chr4:143911514~143912053:-
BRCA	cis	rs7772486	0.806	rs4075696	ENSG00000270638.1	RP3-466P17.1	-5.25	1.87e-07	2.19e-05	-0.18	-0.16	Lobe attachment (rater-scored or self-reported);	chr6:145929811	chr6:145735570~145737218:+
BRCA	cis	rs3758911	0.74	rs11212103	ENSG00000255353.1	RP11-382M14.1	-5.25	1.87e-07	2.19e-05	-0.21	-0.16	Coronary artery disease;	chr11:107253962	chr11:107176286~107177530:+
BRCA	cis	rs3758911	0.701	rs10890672	ENSG00000255353.1	RP11-382M14.1	-5.25	1.87e-07	2.19e-05	-0.21	-0.16	Coronary artery disease;	chr11:107253998	chr11:107176286~107177530:+
BRCA	cis	rs62025270	0.688	rs62025272	ENSG00000202081.1	RNU6-1280P	-5.25	1.87e-07	2.19e-05	-0.22	-0.16	Idiopathic pulmonary fibrosis;	chr15:85770391	chr15:85651522~85651628:-
BRCA	cis	rs9473147	0.516	rs6904764	ENSG00000270761.1	RP11-385F7.1	-5.25	1.87e-07	2.19e-05	-0.17	-0.16	Platelet distribution width;Mean platelet volume;	chr6:47535761	chr6:47477243~47477572:-
BRCA	cis	rs9369695	0.883	rs9473128	ENSG00000270761.1	RP11-385F7.1	-5.25	1.87e-07	2.19e-05	-0.17	-0.16	Reticulocyte count;	chr6:47537274	chr6:47477243~47477572:-
BRCA	cis	rs385076	0.536	rs13017027	ENSG00000272716.1	RP11-563N4.1	-5.25	1.87e-07	2.19e-05	-0.21	-0.16	Interleukin-18 levels;	chr2:32066834	chr2:32165046~32165757:-
BRCA	cis	rs1979679	0.625	rs10843148	ENSG00000278733.1	RP11-425D17.1	5.25	1.88e-07	2.2e-05	0.23	0.16	Ossification of the posterior longitudinal ligament of the spine;	chr12:28288131	chr12:28185625~28186190:-
BRCA	cis	rs7577696	0.925	rs12474443	ENSG00000272716.1	RP11-563N4.1	-5.25	1.88e-07	2.2e-05	-0.18	-0.16	Inflammatory biomarkers;	chr2:32112803	chr2:32165046~32165757:-
BRCA	cis	rs700651	0.821	rs4850812	ENSG00000231621.1	AC013264.2	5.25	1.88e-07	2.2e-05	0.16	0.16	Intracranial aneurysm;	chr2:197878931	chr2:197197991~197199273:+
BRCA	cis	rs12497850	0.931	rs7623023	ENSG00000225399.4	RP11-3B7.1	5.25	1.88e-07	2.2e-05	0.15	0.16	Parkinson's disease;	chr3:48876805	chr3:49260085~49261316:+
BRCA	cis	rs7267979	0.764	rs2474767	ENSG00000277938.1	RP5-965G21.3	5.25	1.88e-07	2.2e-05	0.19	0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25266097	chr20:25229150~25231933:+
BRCA	cis	rs17301013	0.932	rs12074753	ENSG00000227373.4	RP11-160H22.5	5.25	1.88e-07	2.2e-05	0.21	0.16	Systemic lupus erythematosus;	chr1:174565768	chr1:174115300~174160004:-
BRCA	cis	rs17301013	0.932	rs1016466	ENSG00000227373.4	RP11-160H22.5	5.25	1.88e-07	2.2e-05	0.21	0.16	Systemic lupus erythematosus;	chr1:174570652	chr1:174115300~174160004:-
BRCA	cis	rs17301013	0.932	rs10753086	ENSG00000227373.4	RP11-160H22.5	5.25	1.88e-07	2.2e-05	0.21	0.16	Systemic lupus erythematosus;	chr1:174580802	chr1:174115300~174160004:-
BRCA	cis	rs4803480	1	rs3745937	ENSG00000270164.1	LINC01480	-5.25	1.88e-07	2.2e-05	-0.2	-0.16	Schizophrenia;	chr19:41564935	chr19:41535183~41536904:+
BRCA	cis	rs1823913	0.525	rs7424440	ENSG00000280083.1	RP11-317J9.1	-5.25	1.88e-07	2.2e-05	-0.19	-0.16	Obesity-related traits;	chr2:191337919	chr2:191154118~191156070:-
BRCA	cis	rs4650994	0.524	rs2761465	ENSG00000273384.1	RP5-1098D14.1	-5.25	1.88e-07	2.2e-05	-0.21	-0.16	HDL cholesterol;HDL cholesterol levels;	chr1:178610269	chr1:178651706~178652282:+
BRCA	cis	rs6832769	0.961	rs3805147	ENSG00000272969.1	RP11-528I4.2	5.25	1.88e-07	2.2e-05	0.2	0.16	Personality dimensions;	chr4:55440563	chr4:55547112~55547889:+
BRCA	cis	rs6452524	0.618	rs255561	ENSG00000281327.1	LINC01338	5.25	1.88e-07	2.2e-05	0.18	0.16	Hypertension (SNP x SNP interaction);	chr5:83054991	chr5:82850864~82859836:-
BRCA	cis	rs728616	0.558	rs55803802	ENSG00000225484.5	NUTM2B-AS1	-5.25	1.88e-07	2.2e-05	-0.31	-0.16	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79992908	chr10:79663088~79826594:-
BRCA	cis	rs250585	0.92	rs30019	ENSG00000260136.4	CTD-2270L9.4	5.25	1.88e-07	2.2e-05	0.17	0.16	Egg allergy;	chr16:23397106	chr16:23452758~23457606:+
BRCA	cis	rs250585	0.833	rs30018	ENSG00000260136.4	CTD-2270L9.4	5.25	1.88e-07	2.2e-05	0.17	0.16	Egg allergy;	chr16:23397270	chr16:23452758~23457606:+
BRCA	cis	rs2281636	0.894	rs10883396	ENSG00000233690.1	EBAG9P1	5.25	1.88e-07	2.21e-05	0.17	0.16	Obesity-related traits;	chr10:99647135	chr10:99697407~99697949:-
BRCA	cis	rs2281636	0.894	rs12771048	ENSG00000233690.1	EBAG9P1	5.25	1.88e-07	2.21e-05	0.17	0.16	Obesity-related traits;	chr10:99649691	chr10:99697407~99697949:-
BRCA	cis	rs1387259	0.839	rs7486941	ENSG00000273765.1	RP11-370I10.11	-5.25	1.89e-07	2.21e-05	-0.18	-0.16	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48184848	chr12:48360920~48361377:+
BRCA	cis	rs7119	0.689	rs12901765	ENSG00000259362.2	RP11-307C19.1	-5.25	1.89e-07	2.21e-05	-0.22	-0.16	Type 2 diabetes;	chr15:77526761	chr15:77525540~77534110:+
BRCA	cis	rs7800418	0.578	rs2286183	ENSG00000214870.7	AC004540.5	5.25	1.89e-07	2.21e-05	0.2	0.16	Cognitive function;	chr7:26585246	chr7:26398593~26494256:+
BRCA	cis	rs7772486	0.686	rs857880	ENSG00000270638.1	RP3-466P17.1	-5.25	1.89e-07	2.21e-05	-0.18	-0.16	Lobe attachment (rater-scored or self-reported);	chr6:145649979	chr6:145735570~145737218:+
BRCA	cis	rs3733585	0.673	rs6449156	ENSG00000250413.1	RP11-448G15.1	5.25	1.89e-07	2.21e-05	0.21	0.16	Cleft plate (environmental tobacco smoke interaction);	chr4:9955088	chr4:10006482~10009725:+
BRCA	cis	rs6071166	0.903	rs6071174	ENSG00000224635.1	RP4-564F22.5	5.25	1.89e-07	2.21e-05	0.19	0.16	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38707898	chr20:38406011~38416797:-
BRCA	cis	rs72482608	0.865	rs10800541	ENSG00000271811.1	RP1-79C4.4	5.25	1.89e-07	2.21e-05	0.18	0.16	Emphysema imaging phenotypes;	chr1:170795766	chr1:170667381~170669425:+
BRCA	cis	rs9309473	1	rs13384952	ENSG00000163016.8	ALMS1P	-5.25	1.89e-07	2.21e-05	-0.23	-0.16	Metabolite levels;	chr2:73496832	chr2:73644919~73685576:+
BRCA	cis	rs2251666	0.533	rs73517042	ENSG00000267077.1	RP11-127I20.5	5.25	1.89e-07	2.21e-05	0.19	0.16	Cancer;	chr16:4851687	chr16:4795265~4796532:-
BRCA	cis	rs3743162	0.553	rs12900463	ENSG00000259728.4	LINC00933	5.25	1.89e-07	2.21e-05	0.23	0.16	Alzheimer's disease (age of onset);	chr15:84872155	chr15:84570649~84580175:+
BRCA	cis	rs1555322	1	rs2425036	ENSG00000126005.14	MMP24-AS1	-5.25	1.89e-07	2.21e-05	-0.26	-0.16	Attention deficit hyperactivity disorder;	chr20:35268178	chr20:35216462~35278131:-
BRCA	cis	rs7674212	0.541	rs11727498	ENSG00000248740.4	RP11-328K4.1	5.24	1.89e-07	2.22e-05	0.19	0.16	Type 2 diabetes;	chr4:103179830	chr4:103256159~103453658:+
BRCA	cis	rs11955398	0.647	rs57521726	ENSG00000215032.2	GNL3LP1	5.24	1.89e-07	2.22e-05	0.2	0.16	Intelligence (multi-trait analysis);	chr5:60689070	chr5:60891935~60893577:-
BRCA	cis	rs416603	0.967	rs11640138	ENSG00000262636.1	CTD-3088G3.4	5.24	1.89e-07	2.22e-05	0.22	0.16	Type 1 diabetes;	chr16:11268872	chr16:11380859~11381118:-
BRCA	cis	rs8180040	0.654	rs6791062	ENSG00000276925.1	RP11-708J19.3	-5.24	1.89e-07	2.22e-05	-0.18	-0.16	Colorectal cancer;	chr3:47132853	chr3:47469777~47469987:+
BRCA	cis	rs2274273	0.623	rs1187877	ENSG00000258413.1	RP11-665C16.6	5.24	1.9e-07	2.22e-05	0.2	0.16	Protein biomarker;	chr14:55028443	chr14:55262767~55272075:-
BRCA	cis	rs9652601	0.779	rs7203793	ENSG00000274038.1	RP11-66H6.4	-5.24	1.9e-07	2.22e-05	-0.18	-0.16	Systemic lupus erythematosus;	chr16:11088277	chr16:11056556~11057034:+
BRCA	cis	rs13096142	0.547	rs6788849	ENSG00000223552.1	RP11-24F11.2	5.24	1.9e-07	2.22e-05	0.21	0.16	Celiac disease;	chr3:46269109	chr3:46364955~46407059:-
BRCA	cis	rs17301013	0.73	rs12060177	ENSG00000227373.4	RP11-160H22.5	5.24	1.9e-07	2.22e-05	0.21	0.16	Systemic lupus erythematosus;	chr1:174618545	chr1:174115300~174160004:-
BRCA	cis	rs11672691	0.627	rs6508981	ENSG00000270164.1	LINC01480	-5.24	1.9e-07	2.22e-05	-0.19	-0.16	Prostate cancer;	chr19:41483668	chr19:41535183~41536904:+
BRCA	cis	rs2255336	0.616	rs6488285	ENSG00000245648.1	RP11-277P12.20	5.24	1.9e-07	2.22e-05	0.25	0.16	Blood protein levels;	chr12:10366107	chr12:10363769~10398506:+
BRCA	cis	rs61160187	0.51	rs6893642	ENSG00000215032.2	GNL3LP1	5.24	1.9e-07	2.22e-05	0.19	0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:60821896	chr5:60891935~60893577:-
BRCA	cis	rs61160187	0.51	rs3936423	ENSG00000215032.2	GNL3LP1	5.24	1.9e-07	2.22e-05	0.19	0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:60823134	chr5:60891935~60893577:-
BRCA	cis	rs61160187	0.51	rs1445293	ENSG00000215032.2	GNL3LP1	5.24	1.9e-07	2.22e-05	0.19	0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:60823910	chr5:60891935~60893577:-
BRCA	cis	rs11955398	0.502	rs4700406	ENSG00000215032.2	GNL3LP1	5.24	1.9e-07	2.22e-05	0.2	0.16	Intelligence (multi-trait analysis);	chr5:61070048	chr5:60891935~60893577:-
BRCA	cis	rs73193808	0.804	rs2832276	ENSG00000215533.7	LINC00189	-5.24	1.9e-07	2.22e-05	-0.23	-0.16	Coronary artery disease;	chr21:29236463	chr21:29193480~29288205:+
BRCA	cis	rs728616	0.85	rs3889823	ENSG00000225484.5	NUTM2B-AS1	-5.24	1.9e-07	2.23e-05	-0.44	-0.16	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80158606	chr10:79663088~79826594:-
BRCA	cis	rs7119038	0.818	rs7942535	ENSG00000255239.1	AP002954.6	5.24	1.9e-07	2.23e-05	0.21	0.16	Sjögren's syndrome;	chr11:118810755	chr11:118688039~118690600:-
BRCA	cis	rs6430585	0.528	rs660002	ENSG00000231890.6	DARS-AS1	-5.24	1.9e-07	2.23e-05	-0.23	-0.16	Corneal structure;	chr2:135965934	chr2:135985176~136022593:+
BRCA	cis	rs4819052	0.765	rs2838854	ENSG00000184274.3	LINC00315	-5.24	1.9e-07	2.23e-05	-0.22	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260449	chr21:45300245~45305257:-
BRCA	cis	rs875971	0.619	rs10278371	ENSG00000273024.4	INTS4P2	5.24	1.91e-07	2.23e-05	0.18	0.16	Aortic root size;	chr7:66586553	chr7:65647864~65715661:+
BRCA	cis	rs10740039	0.516	rs7477771	ENSG00000254271.1	RP11-131N11.4	5.24	1.91e-07	2.23e-05	0.21	0.16	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60595970	chr10:60734342~60741828:+
BRCA	cis	rs12497850	0.931	rs9311434	ENSG00000225399.4	RP11-3B7.1	5.24	1.91e-07	2.23e-05	0.15	0.16	Parkinson's disease;	chr3:48846714	chr3:49260085~49261316:+
BRCA	cis	rs35740288	0.857	rs11632034	ENSG00000259407.1	RP11-158M2.3	-5.24	1.91e-07	2.23e-05	-0.22	-0.16	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85740841	chr15:85744109~85750281:-
BRCA	cis	rs2403083	0.505	rs7821629	ENSG00000258256.1	RP11-219B4.5	-5.24	1.91e-07	2.23e-05	-0.19	-0.16	Plasma amyloid beta peptide concentrations (ABx-40);	chr8:85237736	chr8:85222446~85245717:-
BRCA	cis	rs1440410	0.598	rs9308167	ENSG00000250326.1	RP11-284M14.1	-5.24	1.91e-07	2.23e-05	-0.18	-0.16	Ischemic stroke;	chr4:143111081	chr4:142933195~143184861:-
BRCA	cis	rs1440410	0.571	rs10471103	ENSG00000250326.1	RP11-284M14.1	-5.24	1.91e-07	2.23e-05	-0.18	-0.16	Ischemic stroke;	chr4:143112503	chr4:142933195~143184861:-
BRCA	cis	rs4650994	0.525	rs4650991	ENSG00000273384.1	RP5-1098D14.1	5.24	1.91e-07	2.23e-05	0.2	0.16	HDL cholesterol;HDL cholesterol levels;	chr1:178542030	chr1:178651706~178652282:+
BRCA	cis	rs860818	0.793	rs2091491	ENSG00000230658.1	KLHL7-AS1	5.24	1.91e-07	2.23e-05	0.41	0.16	Initial pursuit acceleration;	chr7:23153930	chr7:23101228~23105703:-
BRCA	cis	rs8054556	1	rs9925915	ENSG00000273724.1	RP11-347C12.12	-5.24	1.91e-07	2.23e-05	-0.18	-0.16	Autism spectrum disorder or schizophrenia;	chr16:29982365	chr16:30336400~30343336:+
BRCA	cis	rs8048589	1	rs9925009	ENSG00000175604.2	RP11-276H1.3	-5.24	1.91e-07	2.23e-05	-0.24	-0.16	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);	chr16:12092495	chr16:12086746~12090302:-
BRCA	cis	rs2638953	0.962	rs11049570	ENSG00000247934.4	RP11-967K21.1	-5.24	1.91e-07	2.23e-05	-0.23	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28390218	chr12:28163298~28190738:-
BRCA	cis	rs2562456	0.833	rs55790393	ENSG00000268081.1	RP11-678G14.2	5.24	1.91e-07	2.23e-05	0.26	0.16	Pain;	chr19:21323382	chr19:21554640~21569237:-
BRCA	cis	rs2562456	0.793	rs11672341	ENSG00000268081.1	RP11-678G14.2	5.24	1.91e-07	2.23e-05	0.26	0.16	Pain;	chr19:21324502	chr19:21554640~21569237:-
BRCA	cis	rs7200543	0.961	rs1741	ENSG00000258354.1	MIR3180-1	-5.24	1.91e-07	2.24e-05	-0.21	-0.16	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15036494	chr16:14909887~14911345:-
BRCA	cis	rs8002861	0.87	rs4942254	ENSG00000274001.1	RP11-5G9.5	5.24	1.91e-07	2.24e-05	0.18	0.16	Leprosy;	chr13:43877684	chr13:43877715~43878163:-
BRCA	cis	rs2638953	0.886	rs12371462	ENSG00000247934.4	RP11-967K21.1	-5.24	1.91e-07	2.24e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28168770	chr12:28163298~28190738:-
BRCA	cis	rs4853525	0.59	rs1921911	ENSG00000235852.1	AC005540.3	5.24	1.91e-07	2.24e-05	0.2	0.16	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190855644	chr2:190880797~190882059:-
BRCA	cis	rs7618915	0.571	rs1961959	ENSG00000243224.1	RP5-1157M23.2	-5.24	1.91e-07	2.24e-05	-0.18	-0.16	Bipolar disorder;	chr3:52551744	chr3:52239258~52241097:+
BRCA	cis	rs7968440	0.715	rs7967954	ENSG00000272368.2	RP4-605O3.4	-5.24	1.91e-07	2.24e-05	-0.17	-0.16	Fibrinogen;	chr12:50279701	chr12:50112197~50165618:+
BRCA	cis	rs875971	0.528	rs801213	ENSG00000228409.4	CCT6P1	5.24	1.92e-07	2.24e-05	0.16	0.16	Aortic root size;	chr7:66549931	chr7:65751142~65763354:+
BRCA	cis	rs875971	0.545	rs801212	ENSG00000228409.4	CCT6P1	5.24	1.92e-07	2.24e-05	0.16	0.16	Aortic root size;	chr7:66550643	chr7:65751142~65763354:+
BRCA	cis	rs6430585	0.528	rs309120	ENSG00000231890.6	DARS-AS1	-5.24	1.92e-07	2.24e-05	-0.23	-0.16	Corneal structure;	chr2:135951217	chr2:135985176~136022593:+
BRCA	cis	rs6430585	0.528	rs3112496	ENSG00000231890.6	DARS-AS1	-5.24	1.92e-07	2.24e-05	-0.23	-0.16	Corneal structure;	chr2:135953494	chr2:135985176~136022593:+
BRCA	cis	rs2153535	0.505	rs9405395	ENSG00000251164.1	HULC	-5.24	1.92e-07	2.24e-05	-0.2	-0.16	Motion sickness;	chr6:8468389	chr6:8652137~8653846:+
BRCA	cis	rs4908760	0.539	rs7513880	ENSG00000270282.1	RP5-1115A15.2	5.24	1.92e-07	2.24e-05	0.17	0.16	Vitiligo;	chr1:8779241	chr1:8512653~8513021:+
BRCA	cis	rs11858210	1	rs11858210	ENSG00000261143.1	ADAMTS7P3	5.24	1.92e-07	2.24e-05	0.2	0.16	Post bronchodilator FEV1/FVC ratio;	chr15:78786016	chr15:77976042~77993057:+
BRCA	cis	rs11159086	1	rs4903232	ENSG00000270000.1	RP3-449M8.9	5.24	1.92e-07	2.24e-05	0.25	0.16	Advanced glycation end-product levels;	chr14:74496585	chr14:74471930~74472360:-
BRCA	cis	rs8054556	1	rs11642046	ENSG00000273724.1	RP11-347C12.12	-5.24	1.92e-07	2.24e-05	-0.18	-0.16	Autism spectrum disorder or schizophrenia;	chr16:29981787	chr16:30336400~30343336:+
BRCA	cis	rs2153535	0.585	rs9406185	ENSG00000230939.1	RP11-314C16.1	-5.24	1.92e-07	2.25e-05	-0.19	-0.16	Motion sickness;	chr6:8644491	chr6:8784178~8785445:+
BRCA	cis	rs2562456	0.833	rs2154302	ENSG00000268535.1	RP11-420K14.3	5.24	1.92e-07	2.25e-05	0.23	0.16	Pain;	chr19:21307609	chr19:21709522~21710191:+
BRCA	cis	rs4713118	0.513	rs202908	ENSG00000280107.1	AL022393.9	-5.24	1.92e-07	2.25e-05	-0.22	-0.16	Parkinson's disease;	chr6:28043773	chr6:28170845~28172521:+
BRCA	cis	rs9300255	0.739	rs6633	ENSG00000235423.7	RP11-282O18.3	-5.24	1.93e-07	2.25e-05	-0.23	-0.16	Neutrophil percentage of white cells;	chr12:123261262	chr12:123252030~123261483:-
BRCA	cis	rs59169624	0.699	rs793263	ENSG00000255160.4	RP11-428C19.5	-5.24	1.93e-07	2.25e-05	-0.21	-0.16	Parental extreme longevity (95 years and older);	chr11:19276282	chr11:19299883~19308358:+
BRCA	cis	rs2638953	0.853	rs11049632	ENSG00000247934.4	RP11-967K21.1	-5.24	1.93e-07	2.25e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28461130	chr12:28163298~28190738:-
BRCA	cis	rs6600671	0.899	rs11249432	ENSG00000275538.1	RNVU1-19	5.24	1.93e-07	2.25e-05	0.19	0.16	Hip geometry;	chr1:121541678	chr1:120850819~120850985:-
BRCA	cis	rs9880211	0.58	rs56308637	ENSG00000239213.4	NCK1-AS1	5.24	1.93e-07	2.25e-05	0.21	0.16	Height;Body mass index;	chr3:135920806	chr3:136841726~136862054:-
BRCA	cis	rs10504130	1	rs61326367	ENSG00000253844.1	RP11-546K22.1	-5.24	1.93e-07	2.25e-05	-0.28	-0.16	Venous thromboembolism (SNP x SNP interaction);	chr8:51775466	chr8:51961458~52022974:+
BRCA	cis	rs66887589	0.967	rs3775842	ENSG00000245958.5	RP11-33B1.1	-5.24	1.93e-07	2.25e-05	-0.14	-0.16	Diastolic blood pressure;	chr4:119506577	chr4:119454791~119552025:+
BRCA	cis	rs13326165	0.585	rs11711974	ENSG00000243224.1	RP5-1157M23.2	-5.24	1.93e-07	2.25e-05	-0.25	-0.16	HDL cholesterol levels;HDL cholesterol;	chr3:52398198	chr3:52239258~52241097:+
BRCA	cis	rs2624839	0.602	rs2526390	ENSG00000228008.1	CTD-2330K9.3	5.24	1.93e-07	2.25e-05	0.17	0.16	Intelligence (multi-trait analysis);	chr3:50155327	chr3:49903845~49916937:+
BRCA	cis	rs9376098	0.624	rs10872428	ENSG00000232876.1	CTA-212D2.2	5.24	1.93e-07	2.26e-05	0.25	0.16	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr6:135170734	chr6:135055033~135060550:+
BRCA	cis	rs4713118	0.512	rs2622319	ENSG00000280107.1	AL022393.9	-5.24	1.93e-07	2.26e-05	-0.22	-0.16	Parkinson's disease;	chr6:28152623	chr6:28170845~28172521:+
BRCA	cis	rs172166	0.694	rs1150666	ENSG00000280107.1	AL022393.9	-5.24	1.93e-07	2.26e-05	-0.22	-0.16	Cardiac Troponin-T levels;	chr6:28156150	chr6:28170845~28172521:+
BRCA	cis	rs5758511	0.633	rs5758690	ENSG00000205702.9	CYP2D7	5.24	1.93e-07	2.26e-05	0.16	0.16	Birth weight;	chr22:42272289	chr22:42140203~42144577:-
BRCA	cis	rs295490	0.748	rs77131232	ENSG00000272656.1	RP11-219D15.3	5.24	1.93e-07	2.26e-05	0.36	0.16	PR interval in Tripanosoma cruzi seropositivity;	chr3:139415468	chr3:139349024~139349371:-
BRCA	cis	rs295490	0.588	rs75694829	ENSG00000272656.1	RP11-219D15.3	5.24	1.93e-07	2.26e-05	0.36	0.16	PR interval in Tripanosoma cruzi seropositivity;	chr3:139416582	chr3:139349024~139349371:-
BRCA	cis	rs295490	0.748	rs76520271	ENSG00000272656.1	RP11-219D15.3	5.24	1.93e-07	2.26e-05	0.36	0.16	PR interval in Tripanosoma cruzi seropositivity;	chr3:139422441	chr3:139349024~139349371:-
BRCA	cis	rs295490	0.748	rs77343695	ENSG00000272656.1	RP11-219D15.3	5.24	1.93e-07	2.26e-05	0.36	0.16	PR interval in Tripanosoma cruzi seropositivity;	chr3:139430617	chr3:139349024~139349371:-
BRCA	cis	rs2227564	0.678	rs2242256	ENSG00000271816.1	BMS1P4	-5.24	1.93e-07	2.26e-05	-0.17	-0.16	Crohn's disease;Inflammatory bowel disease;	chr10:73837788	chr10:73699151~73730487:-
BRCA	cis	rs2227564	0.678	rs2242257	ENSG00000271816.1	BMS1P4	-5.24	1.93e-07	2.26e-05	-0.17	-0.16	Crohn's disease;Inflammatory bowel disease;	chr10:73837847	chr10:73699151~73730487:-
BRCA	cis	rs28472312	0.862	rs11150623	ENSG00000278665.1	RP11-666O2.4	5.24	1.93e-07	2.26e-05	0.18	0.16	Intelligence (multi-trait analysis);	chr16:28869680	chr16:28599241~28601881:-
BRCA	cis	rs6832769	1	rs9684708	ENSG00000272969.1	RP11-528I4.2	-5.24	1.93e-07	2.26e-05	-0.2	-0.16	Personality dimensions;	chr4:55564214	chr4:55547112~55547889:+
BRCA	cis	rs7871764	0.552	rs13290822	ENSG00000260947.1	RP11-384P7.7	5.24	1.93e-07	2.26e-05	0.24	0.16	Height;	chr9:33803044	chr9:33697459~33700986:+
BRCA	cis	rs6545883	0.965	rs6718887	ENSG00000270820.4	RP11-355B11.2	5.24	1.93e-07	2.26e-05	0.18	0.16	Tuberculosis;	chr2:61500080	chr2:61471188~61484130:+
BRCA	cis	rs860818	0.793	rs1406080	ENSG00000230658.1	KLHL7-AS1	5.24	1.93e-07	2.26e-05	0.41	0.16	Initial pursuit acceleration;	chr7:23153985	chr7:23101228~23105703:-
BRCA	cis	rs9545047	0.604	rs9545076	ENSG00000227354.5	RBM26-AS1	-5.24	1.94e-07	2.26e-05	-0.17	-0.16	Schizophrenia;	chr13:79335983	chr13:79406309~79424328:+
BRCA	cis	rs180730	1	rs1376109	ENSG00000251609.2	SETP12	-5.24	1.94e-07	2.26e-05	-0.23	-0.16	Fasting plasma glucose;	chr4:120917160	chr4:120895494~120897083:-
BRCA	cis	rs516805	0.561	rs9490494	ENSG00000279453.1	RP3-425C14.4	5.24	1.94e-07	2.26e-05	0.26	0.16	Lymphocyte counts;	chr6:122612860	chr6:122436789~122439223:-
BRCA	cis	rs516805	0.561	rs9490495	ENSG00000279453.1	RP3-425C14.4	5.24	1.94e-07	2.26e-05	0.26	0.16	Lymphocyte counts;	chr6:122613043	chr6:122436789~122439223:-
BRCA	cis	rs6723226	0.765	rs12612824	ENSG00000276334.1	AL133243.1	-5.24	1.94e-07	2.26e-05	-0.21	-0.16	Intelligence (multi-trait analysis);	chr2:32354691	chr2:32521927~32523547:+
BRCA	cis	rs10788972	0.683	rs6694397	ENSG00000225183.1	RP4-758J24.4	-5.24	1.94e-07	2.26e-05	-0.21	-0.16	Parkinson disease and lewy body pathology;	chr1:54100637	chr1:54089856~54090093:+
BRCA	cis	rs7493	0.755	rs62467350	ENSG00000233942.1	AC004012.1	5.24	1.94e-07	2.26e-05	0.2	0.16	Yu-Zhi constitution type in type 2 diabetes;	chr7:95340802	chr7:95471835~95473998:+
BRCA	cis	rs1707322	0.963	rs10789484	ENSG00000234329.1	RP11-767N6.2	5.24	1.94e-07	2.26e-05	0.16	0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45941306	chr1:45651039~45651826:-
BRCA	cis	rs9307551	0.584	rs1595966	ENSG00000250334.4	LINC00989	-5.24	1.94e-07	2.27e-05	-0.23	-0.16	Refractive error;	chr4:79549502	chr4:79492416~79576460:+
BRCA	cis	rs854765	0.565	rs4072738	ENSG00000281749.1	Y_RNA	5.24	1.94e-07	2.27e-05	0.19	0.16	Total body bone mineral density;	chr17:17981233	chr17:18001101~18001195:-
BRCA	cis	rs7772486	0.875	rs969694	ENSG00000270638.1	RP3-466P17.1	5.24	1.94e-07	2.27e-05	0.18	0.16	Lobe attachment (rater-scored or self-reported);	chr6:146073519	chr6:145735570~145737218:+
BRCA	cis	rs57221529	0.709	rs72706611	ENSG00000271781.1	CTD-2589H19.6	-5.24	1.94e-07	2.27e-05	-0.23	-0.16	Lung disease severity in cystic fibrosis;	chr5:561031	chr5:675826~676616:+
BRCA	cis	rs57221529	0.709	rs72706612	ENSG00000271781.1	CTD-2589H19.6	-5.24	1.94e-07	2.27e-05	-0.23	-0.16	Lung disease severity in cystic fibrosis;	chr5:561083	chr5:675826~676616:+
BRCA	cis	rs17253792	0.545	rs71412688	ENSG00000186615.9	KTN1-AS1	-5.24	1.94e-07	2.27e-05	-0.33	-0.16	Putamen volume;	chr14:55554821	chr14:55499278~55580110:-
BRCA	cis	rs13126694	0.901	rs4691460	ENSG00000248429.4	RP11-597D13.9	-5.24	1.94e-07	2.27e-05	-0.14	-0.16	Blood osmolality (transformed sodium);	chr4:158138279	chr4:158170752~158202877:+
BRCA	cis	rs62025270	0.688	rs7179917	ENSG00000202081.1	RNU6-1280P	-5.24	1.95e-07	2.27e-05	-0.24	-0.16	Idiopathic pulmonary fibrosis;	chr15:85722413	chr15:85651522~85651628:-
BRCA	cis	rs6479891	0.915	rs10761744	ENSG00000232075.1	MRPL35P2	-5.24	1.95e-07	2.27e-05	-0.28	-0.16	Arthritis (juvenile idiopathic);	chr10:63341266	chr10:63634317~63634827:-
BRCA	cis	rs2638953	0.672	rs11049713	ENSG00000278733.1	RP11-425D17.1	-5.24	1.95e-07	2.27e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28558612	chr12:28185625~28186190:-
BRCA	cis	rs13113518	0.967	rs7696832	ENSG00000223305.1	RN7SKP30	5.24	1.95e-07	2.27e-05	0.19	0.16	Height;	chr4:55537080	chr4:55540502~55540835:-
BRCA	cis	rs875971	0.965	rs6971509	ENSG00000223473.2	GS1-124K5.3	-5.24	1.95e-07	2.27e-05	-0.12	-0.16	Aortic root size;	chr7:66249983	chr7:66491049~66493566:-
BRCA	cis	rs9868809	0.881	rs7620853	ENSG00000270441.1	RP11-694I15.7	5.24	1.95e-07	2.28e-05	0.3	0.16	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48629070	chr3:49140086~49160851:-
BRCA	cis	rs8103033	0.786	rs2270028	ENSG00000268088.1	AC093063.2	-5.24	1.95e-07	2.28e-05	-0.18	-0.16	Obesity-related traits;	chr19:39642185	chr19:39693925~39696258:+
BRCA	cis	rs8103033	0.786	rs2270029	ENSG00000268088.1	AC093063.2	-5.24	1.95e-07	2.28e-05	-0.18	-0.16	Obesity-related traits;	chr19:39642360	chr19:39693925~39696258:+
BRCA	cis	rs7324557	0.651	rs9510875	ENSG00000205861.10	C1QTNF9B-AS1	-5.24	1.95e-07	2.28e-05	-0.21	-0.16	Visceral adipose tissue adjusted for BMI;	chr13:23820351	chr13:23888889~23897263:+
BRCA	cis	rs7914558	0.901	rs35525740	ENSG00000236937.2	PTGES3P4	5.24	1.95e-07	2.28e-05	0.21	0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103181355	chr10:102845595~102845950:+
BRCA	cis	rs7914558	0.869	rs10883842	ENSG00000236937.2	PTGES3P4	5.24	1.95e-07	2.28e-05	0.21	0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103181832	chr10:102845595~102845950:+
BRCA	cis	rs10028773	0.7	rs7671797	ENSG00000260404.2	RP11-384K6.6	5.24	1.95e-07	2.28e-05	0.15	0.16	Educational attainment;	chr4:119327002	chr4:118591773~118633729:+
BRCA	cis	rs801193	0.569	rs4717315	ENSG00000273448.1	RP11-166O4.6	5.24	1.95e-07	2.28e-05	0.15	0.16	Aortic root size;	chr7:66713338	chr7:67333047~67334383:+
BRCA	cis	rs9652601	0.779	rs725613	ENSG00000274038.1	RP11-66H6.4	-5.24	1.95e-07	2.28e-05	-0.18	-0.16	Systemic lupus erythematosus;	chr16:11075826	chr16:11056556~11057034:+
BRCA	cis	rs2153535	0.58	rs9406169	ENSG00000251164.1	HULC	-5.24	1.96e-07	2.28e-05	-0.19	-0.16	Motion sickness;	chr6:8509237	chr6:8652137~8653846:+
BRCA	cis	rs1030877	0.557	rs2278501	ENSG00000235319.1	AC012360.4	5.24	1.96e-07	2.28e-05	0.19	0.16	Obesity-related traits;	chr2:105363049	chr2:105324210~105330529:+
BRCA	cis	rs6545883	0.801	rs778142	ENSG00000270820.4	RP11-355B11.2	5.24	1.96e-07	2.28e-05	0.19	0.16	Tuberculosis;	chr2:61454293	chr2:61471188~61484130:+
BRCA	cis	rs718433	0.556	rs2075477	ENSG00000256379.1	TRAV8-5	5.24	1.96e-07	2.28e-05	0.18	0.16	Intraocular pressure;	chr14:21749072	chr14:21903077~21903598:+
BRCA	cis	rs1329650	1	rs1329650	ENSG00000228701.1	TNKS2-AS1	5.24	1.96e-07	2.28e-05	0.21	0.16	Smoking behavior;	chr10:91588363	chr10:91782839~91798291:-
BRCA	cis	rs13113518	1	rs3805148	ENSG00000223305.1	RN7SKP30	5.24	1.96e-07	2.28e-05	0.19	0.16	Height;	chr4:55440643	chr4:55540502~55540835:-
BRCA	cis	rs13113518	1	rs11133380	ENSG00000223305.1	RN7SKP30	5.24	1.96e-07	2.28e-05	0.19	0.16	Height;	chr4:55441110	chr4:55540502~55540835:-
BRCA	cis	rs13113518	1	rs12510110	ENSG00000223305.1	RN7SKP30	5.24	1.96e-07	2.28e-05	0.19	0.16	Height;	chr4:55441567	chr4:55540502~55540835:-
BRCA	cis	rs13113518	0.966	rs12510990	ENSG00000223305.1	RN7SKP30	5.24	1.96e-07	2.28e-05	0.19	0.16	Height;	chr4:55441907	chr4:55540502~55540835:-
BRCA	cis	rs9341808	0.69	rs9448909	ENSG00000272129.1	RP11-250B2.6	5.24	1.96e-07	2.28e-05	0.2	0.16	Sitting height ratio;	chr6:80199314	chr6:80355424~80356859:+
BRCA	cis	rs2638953	0.924	rs11049620	ENSG00000247934.4	RP11-967K21.1	-5.24	1.96e-07	2.29e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28454698	chr12:28163298~28190738:-
BRCA	cis	rs4925386	1	rs1889201	ENSG00000275437.1	RP5-908M14.10	-5.24	1.96e-07	2.29e-05	-0.16	-0.16	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62348019	chr20:62402236~62405935:-
BRCA	cis	rs7487075	0.619	rs4768718	ENSG00000274723.1	RP11-618L22.1	5.24	1.96e-07	2.29e-05	0.2	0.16	Itch intensity from mosquito bite;	chr12:46440553	chr12:46970504~46972155:+
BRCA	cis	rs875971	0.545	rs6460281	ENSG00000230295.1	RP11-458F8.2	5.24	1.96e-07	2.29e-05	0.15	0.16	Aortic root size;	chr7:66216128	chr7:66880708~66882981:+
BRCA	cis	rs2732480	0.577	rs2634684	ENSG00000240399.1	RP1-228P16.1	-5.24	1.96e-07	2.29e-05	-0.19	-0.16	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48337092	chr12:48054813~48055591:-
BRCA	cis	rs10946940	0.897	rs6456801	ENSG00000220721.1	OR1F12	5.24	1.96e-07	2.29e-05	0.18	0.16	Systemic lupus erythematosus;	chr6:27657753	chr6:28073316~28074233:+
BRCA	cis	rs875971	0.522	rs1880556	ENSG00000273024.4	INTS4P2	-5.24	1.96e-07	2.29e-05	-0.17	-0.16	Aortic root size;	chr7:65967557	chr7:65647864~65715661:+
BRCA	cis	rs66887589	0.934	rs12648182	ENSG00000245958.5	RP11-33B1.1	5.24	1.96e-07	2.29e-05	0.14	0.16	Diastolic blood pressure;	chr4:119582736	chr4:119454791~119552025:+
BRCA	cis	rs1729407	0.814	rs2542051	ENSG00000280143.1	AP000892.6	-5.24	1.96e-07	2.29e-05	-0.15	-0.16	Apolipoprotein A-IV levels;	chr11:116827022	chr11:117204967~117210292:+
BRCA	cis	rs2281558	0.876	rs2281562	ENSG00000230772.1	VN1R108P	-5.24	1.96e-07	2.29e-05	-0.21	-0.16	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25292726	chr20:25734264~25735093:+
BRCA	cis	rs7618501	0.602	rs34831713	ENSG00000228008.1	CTD-2330K9.3	-5.24	1.96e-07	2.29e-05	-0.16	-0.16	Intelligence (multi-trait analysis);	chr3:50081315	chr3:49903845~49916937:+
BRCA	cis	rs2638953	0.853	rs12370338	ENSG00000247934.4	RP11-967K21.1	-5.24	1.96e-07	2.29e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28486787	chr12:28163298~28190738:-
BRCA	cis	rs13113518	1	rs4864547	ENSG00000223305.1	RN7SKP30	5.24	1.96e-07	2.29e-05	0.19	0.16	Height;	chr4:55538228	chr4:55540502~55540835:-
BRCA	cis	rs755249	0.509	rs11206378	ENSG00000182109.6	RP11-69E11.4	-5.24	1.96e-07	2.29e-05	-0.18	-0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39583512	chr1:39522280~39546187:-
BRCA	cis	rs8180040	1	rs4858888	ENSG00000276925.1	RP11-708J19.3	5.24	1.97e-07	2.29e-05	0.19	0.16	Colorectal cancer;	chr3:47363815	chr3:47469777~47469987:+
BRCA	cis	rs4763879	0.739	rs7310460	ENSG00000214776.8	RP11-726G1.1	-5.24	1.97e-07	2.29e-05	-0.18	-0.16	Type 1 diabetes;	chr12:9688177	chr12:9467552~9576275:+
BRCA	cis	rs6840258	0.831	rs3775226	ENSG00000251411.1	RP11-397E7.4	-5.24	1.97e-07	2.29e-05	-0.23	-0.16	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87068313	chr4:86913266~86914817:-
BRCA	cis	rs7618501	0.633	rs4688690	ENSG00000228008.1	CTD-2330K9.3	5.24	1.97e-07	2.3e-05	0.16	0.16	Intelligence (multi-trait analysis);	chr3:49984859	chr3:49903845~49916937:+
BRCA	cis	rs7618501	0.633	rs11130234	ENSG00000228008.1	CTD-2330K9.3	5.24	1.97e-07	2.3e-05	0.16	0.16	Intelligence (multi-trait analysis);	chr3:49987325	chr3:49903845~49916937:+
BRCA	cis	rs1979679	0.918	rs1257741	ENSG00000278733.1	RP11-425D17.1	5.24	1.97e-07	2.3e-05	0.2	0.16	Ossification of the posterior longitudinal ligament of the spine;	chr12:28381636	chr12:28185625~28186190:-
BRCA	cis	rs11124272	0.672	rs4952197	ENSG00000272716.1	RP11-563N4.1	5.24	1.97e-07	2.3e-05	0.21	0.16	Interleukin-18 levels;	chr2:31542061	chr2:32165046~32165757:-
BRCA	cis	rs7772486	0.806	rs7740785	ENSG00000270638.1	RP3-466P17.1	5.24	1.97e-07	2.3e-05	0.18	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145850163	chr6:145735570~145737218:+
BRCA	cis	rs7772486	0.658	rs9403737	ENSG00000270638.1	RP3-466P17.1	5.24	1.97e-07	2.3e-05	0.19	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145641057	chr6:145735570~145737218:+
BRCA	cis	rs7772486	0.754	rs4896832	ENSG00000270638.1	RP3-466P17.1	5.24	1.97e-07	2.3e-05	0.19	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145643015	chr6:145735570~145737218:+
BRCA	cis	rs12612619	0.667	rs7605526	ENSG00000229122.1	AGBL5-IT1	5.24	1.97e-07	2.3e-05	0.17	0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27122616	chr2:27061038~27061815:+
BRCA	cis	rs13113518	1	rs13152173	ENSG00000223305.1	RN7SKP30	5.24	1.97e-07	2.3e-05	0.19	0.16	Height;	chr4:55534788	chr4:55540502~55540835:-
BRCA	cis	rs13113518	1	rs13141049	ENSG00000223305.1	RN7SKP30	5.24	1.97e-07	2.3e-05	0.19	0.16	Height;	chr4:55535489	chr4:55540502~55540835:-
BRCA	cis	rs13113518	0.967	rs12507722	ENSG00000223305.1	RN7SKP30	5.24	1.97e-07	2.3e-05	0.19	0.16	Height;	chr4:55536421	chr4:55540502~55540835:-
BRCA	cis	rs4819052	0.851	rs2236446	ENSG00000184274.3	LINC00315	-5.24	1.97e-07	2.3e-05	-0.21	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45259070	chr21:45300245~45305257:-
BRCA	cis	rs673078	0.66	rs17586342	ENSG00000275409.1	RP11-131L12.4	-5.24	1.97e-07	2.3e-05	-0.21	-0.16	Glucose homeostasis traits;	chr12:118162399	chr12:118430147~118430699:+
BRCA	cis	rs2235642	0.785	rs1057983	ENSG00000260989.1	LA16c-395F10.2	-5.24	1.97e-07	2.3e-05	-0.16	-0.16	Coronary artery disease;	chr16:1610273	chr16:1580527~1610328:+
BRCA	cis	rs919433	0.68	rs2124317	ENSG00000231621.1	AC013264.2	-5.24	1.97e-07	2.3e-05	-0.15	-0.16	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197612882	chr2:197197991~197199273:+
BRCA	cis	rs7772486	0.743	rs9376955	ENSG00000270638.1	RP3-466P17.1	5.24	1.98e-07	2.3e-05	0.18	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145628268	chr6:145735570~145737218:+
BRCA	cis	rs7772486	0.805	rs4896831	ENSG00000270638.1	RP3-466P17.1	5.24	1.98e-07	2.3e-05	0.18	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145638345	chr6:145735570~145737218:+
BRCA	cis	rs3770081	1	rs56104203	ENSG00000273080.1	RP11-301O19.1	-5.24	1.98e-07	2.3e-05	-0.37	-0.16	Facial emotion recognition (sad faces);	chr2:86109133	chr2:86195590~86196049:+
BRCA	cis	rs7577696	0.814	rs435572	ENSG00000272716.1	RP11-563N4.1	5.24	1.98e-07	2.3e-05	0.18	0.16	Inflammatory biomarkers;	chr2:32263012	chr2:32165046~32165757:-
BRCA	cis	rs7819412	0.595	rs4841500	ENSG00000255046.1	RP11-297N6.4	5.24	1.98e-07	2.31e-05	0.19	0.16	Triglycerides;	chr8:11130765	chr8:11797928~11802568:-
BRCA	cis	rs7577696	0.889	rs212726	ENSG00000272716.1	RP11-563N4.1	5.24	1.98e-07	2.31e-05	0.18	0.16	Inflammatory biomarkers;	chr2:32244316	chr2:32165046~32165757:-
BRCA	cis	rs7577696	0.889	rs212727	ENSG00000272716.1	RP11-563N4.1	5.24	1.98e-07	2.31e-05	0.18	0.16	Inflammatory biomarkers;	chr2:32244659	chr2:32165046~32165757:-
BRCA	cis	rs172166	0.694	rs1631552	ENSG00000280107.1	AL022393.9	-5.24	1.98e-07	2.31e-05	-0.22	-0.16	Cardiac Troponin-T levels;	chr6:28121921	chr6:28170845~28172521:+
BRCA	cis	rs7572733	0.534	rs10931794	ENSG00000231621.1	AC013264.2	5.24	1.98e-07	2.31e-05	0.16	0.16	Dermatomyositis;	chr2:197911416	chr2:197197991~197199273:+
BRCA	cis	rs7572733	0.555	rs2341778	ENSG00000231621.1	AC013264.2	5.24	1.98e-07	2.31e-05	0.16	0.16	Dermatomyositis;	chr2:197911822	chr2:197197991~197199273:+
BRCA	cis	rs7572733	0.534	rs1401095	ENSG00000231621.1	AC013264.2	5.24	1.98e-07	2.31e-05	0.16	0.16	Dermatomyositis;	chr2:197915143	chr2:197197991~197199273:+
BRCA	cis	rs2179367	0.632	rs9498336	ENSG00000268592.3	RAET1E-AS1	5.24	1.98e-07	2.31e-05	0.23	0.16	Dupuytren's disease;	chr6:149374208	chr6:149863494~149919507:+
BRCA	cis	rs2179367	0.632	rs1980774	ENSG00000268592.3	RAET1E-AS1	5.24	1.98e-07	2.31e-05	0.23	0.16	Dupuytren's disease;	chr6:149375030	chr6:149863494~149919507:+
BRCA	cis	rs2179367	0.632	rs9498337	ENSG00000268592.3	RAET1E-AS1	5.24	1.98e-07	2.31e-05	0.23	0.16	Dupuytren's disease;	chr6:149375970	chr6:149863494~149919507:+
BRCA	cis	rs34792	0.554	rs2067063	ENSG00000207425.1	Y_RNA	-5.24	1.98e-07	2.31e-05	-0.21	-0.16	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15515106	chr16:14915457~14915556:-
BRCA	cis	rs6430585	0.528	rs309161	ENSG00000231890.6	DARS-AS1	5.24	1.98e-07	2.31e-05	0.23	0.16	Corneal structure;	chr2:135931179	chr2:135985176~136022593:+
BRCA	cis	rs1552244	1	rs17032396	ENSG00000232901.1	CYCSP10	-5.24	1.98e-07	2.31e-05	-0.22	-0.16	Alzheimer's disease;	chr3:10111875	chr3:10000647~10000940:-
BRCA	cis	rs2153535	0.58	rs7741403	ENSG00000251164.1	HULC	5.24	1.98e-07	2.31e-05	0.19	0.16	Motion sickness;	chr6:8530345	chr6:8652137~8653846:+
BRCA	cis	rs710913	0.717	rs11206377	ENSG00000228060.1	RP11-69E11.8	-5.24	1.98e-07	2.31e-05	-0.16	-0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39583432	chr1:39565160~39573203:+
BRCA	cis	rs950776	0.518	rs1979907	ENSG00000279373.1	RP11-650L12.4	-5.24	1.98e-07	2.31e-05	-0.19	-0.16	Sudden cardiac arrest;	chr15:78549897	chr15:78537681~78538946:+
BRCA	cis	rs7267979	1	rs2424713	ENSG00000125804.12	FAM182A	-5.24	1.99e-07	2.32e-05	-0.21	-0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25437846	chr20:26054655~26086917:+
BRCA	cis	rs7267979	0.966	rs2387885	ENSG00000125804.12	FAM182A	5.24	1.99e-07	2.32e-05	0.21	0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25434588	chr20:26054655~26086917:+
BRCA	cis	rs9300255	0.722	rs67624109	ENSG00000235423.7	RP11-282O18.3	-5.24	1.99e-07	2.32e-05	-0.22	-0.16	Neutrophil percentage of white cells;	chr12:123340088	chr12:123252030~123261483:-
BRCA	cis	rs867371	0.896	rs8033831	ENSG00000255769.6	GOLGA2P10	-5.24	1.99e-07	2.32e-05	-0.18	-0.16	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82220953	chr15:82472993~82513950:-
BRCA	cis	rs7621025	0.675	rs34602896	ENSG00000239213.4	NCK1-AS1	-5.24	1.99e-07	2.32e-05	-0.21	-0.16	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136627543	chr3:136841726~136862054:-
BRCA	cis	rs2243480	0.803	rs35480979	ENSG00000230295.1	RP11-458F8.2	-5.24	1.99e-07	2.32e-05	-0.21	-0.16	Diabetic kidney disease;	chr7:65892097	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs35391607	ENSG00000230295.1	RP11-458F8.2	-5.24	1.99e-07	2.32e-05	-0.21	-0.16	Diabetic kidney disease;	chr7:65895842	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs13220979	ENSG00000230295.1	RP11-458F8.2	-5.24	1.99e-07	2.32e-05	-0.21	-0.16	Diabetic kidney disease;	chr7:65898217	chr7:66880708~66882981:+
BRCA	cis	rs2243480	1	rs34974928	ENSG00000230295.1	RP11-458F8.2	-5.24	1.99e-07	2.32e-05	-0.21	-0.16	Diabetic kidney disease;	chr7:65899019	chr7:66880708~66882981:+
BRCA	cis	rs10510102	0.935	rs11200252	ENSG00000226864.1	ATE1-AS1	5.24	1.99e-07	2.32e-05	0.29	0.16	Breast cancer;	chr10:121914728	chr10:121928312~121951965:+
BRCA	cis	rs10510102	0.935	rs12254184	ENSG00000226864.1	ATE1-AS1	5.24	1.99e-07	2.32e-05	0.29	0.16	Breast cancer;	chr10:121914971	chr10:121928312~121951965:+
BRCA	cis	rs10510102	0.935	rs11200203	ENSG00000226864.1	ATE1-AS1	5.24	1.99e-07	2.32e-05	0.3	0.16	Breast cancer;	chr10:121874014	chr10:121928312~121951965:+
BRCA	cis	rs10504130	1	rs12675907	ENSG00000253844.1	RP11-546K22.1	-5.24	1.99e-07	2.32e-05	-0.28	-0.16	Venous thromboembolism (SNP x SNP interaction);	chr8:51773102	chr8:51961458~52022974:+
BRCA	cis	rs12712135	0.709	rs11676236	ENSG00000234389.1	AC007278.3	-5.24	1.99e-07	2.32e-05	-0.14	-0.16	Blood protein levels;	chr2:102465235	chr2:102438713~102440475:+
BRCA	cis	rs12712135	0.677	rs11687013	ENSG00000234389.1	AC007278.3	-5.24	1.99e-07	2.32e-05	-0.14	-0.16	Blood protein levels;	chr2:102465261	chr2:102438713~102440475:+
BRCA	cis	rs7577696	0.785	rs6723154	ENSG00000272716.1	RP11-563N4.1	-5.24	1.99e-07	2.32e-05	-0.18	-0.16	Inflammatory biomarkers;	chr2:32140092	chr2:32165046~32165757:-
BRCA	cis	rs2562456	0.917	rs9304987	ENSG00000268658.4	LINC00664	-5.24	1.99e-07	2.32e-05	-0.24	-0.16	Pain;	chr19:21499472	chr19:21483374~21503238:+
BRCA	cis	rs6840360	0.642	rs2724567	ENSG00000278978.1	RP11-164P12.5	5.24	1.99e-07	2.32e-05	0.17	0.16	Intelligence (multi-trait analysis);	chr4:151430008	chr4:151669786~151670503:+
BRCA	cis	rs718433	0.866	rs4982498	ENSG00000256379.1	TRAV8-5	5.24	1.99e-07	2.32e-05	0.19	0.16	Intraocular pressure;	chr14:21760486	chr14:21903077~21903598:+
BRCA	cis	rs9376098	0.651	rs9402691	ENSG00000232876.1	CTA-212D2.2	-5.24	1.99e-07	2.32e-05	-0.24	-0.16	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr6:135166364	chr6:135055033~135060550:+
BRCA	cis	rs6832769	0.922	rs819271	ENSG00000272969.1	RP11-528I4.2	5.23	2e-07	2.33e-05	0.2	0.16	Personality dimensions;	chr4:55372680	chr4:55547112~55547889:+
BRCA	cis	rs10504130	1	rs58561048	ENSG00000253844.1	RP11-546K22.1	-5.23	2e-07	2.33e-05	-0.28	-0.16	Venous thromboembolism (SNP x SNP interaction);	chr8:51789982	chr8:51961458~52022974:+
BRCA	cis	rs10504130	1	rs11778849	ENSG00000253844.1	RP11-546K22.1	-5.23	2e-07	2.33e-05	-0.28	-0.16	Venous thromboembolism (SNP x SNP interaction);	chr8:51795694	chr8:51961458~52022974:+
BRCA	cis	rs11955398	0.502	rs159371	ENSG00000215032.2	GNL3LP1	5.23	2e-07	2.33e-05	0.2	0.16	Intelligence (multi-trait analysis);	chr5:61148449	chr5:60891935~60893577:-
BRCA	cis	rs11955398	0.502	rs810884	ENSG00000215032.2	GNL3LP1	5.23	2e-07	2.33e-05	0.2	0.16	Intelligence (multi-trait analysis);	chr5:61152449	chr5:60891935~60893577:-
BRCA	cis	rs10504130	1	rs16916820	ENSG00000253844.1	RP11-546K22.1	-5.23	2e-07	2.33e-05	-0.28	-0.16	Venous thromboembolism (SNP x SNP interaction);	chr8:51800156	chr8:51961458~52022974:+
BRCA	cis	rs7246657	0.943	rs4803229	ENSG00000267422.1	CTD-2554C21.1	-5.23	2e-07	2.33e-05	-0.23	-0.16	Coronary artery calcification;	chr19:37373780	chr19:37779686~37792865:+
BRCA	cis	rs9549328	0.7	rs4907568	ENSG00000235280.2	MCF2L-AS1	5.23	2e-07	2.33e-05	0.21	0.16	Systolic blood pressure;	chr13:112963260	chr13:112967484~112968824:-
BRCA	cis	rs6772849	0.93	rs9868579	ENSG00000242551.2	POU5F1P6	5.23	2e-07	2.33e-05	0.2	0.16	Monocyte percentage of white cells;Monocyte count;	chr3:128632211	chr3:128674735~128677005:-
BRCA	cis	rs2638953	0.815	rs11049682	ENSG00000247934.4	RP11-967K21.1	-5.23	2e-07	2.33e-05	-0.21	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28509062	chr12:28163298~28190738:-
BRCA	cis	rs910316	0.687	rs175059	ENSG00000279594.1	RP11-950C14.10	-5.23	2e-07	2.33e-05	-0.18	-0.16	Height;	chr14:75023964	chr14:75011269~75012851:-
BRCA	cis	rs4761702	0.527	rs12824664	ENSG00000257252.4	RP11-486A14.2	-5.23	2e-07	2.33e-05	-0.21	-0.16	Immature fraction of reticulocytes;	chr12:93343125	chr12:93317135~93377736:-
BRCA	cis	rs4950322	0.57	rs72691012	ENSG00000244371.2	PFN1P8	-5.23	2e-07	2.33e-05	-0.22	-0.16	Protein quantitative trait loci;	chr1:147239751	chr1:146957117~146957659:-
BRCA	cis	rs7577696	0.695	rs212748	ENSG00000272716.1	RP11-563N4.1	5.23	2e-07	2.33e-05	0.17	0.16	Inflammatory biomarkers;	chr2:32190677	chr2:32165046~32165757:-
BRCA	cis	rs8103278	0.507	rs7246377	ENSG00000267395.4	AC074212.6	-5.23	2e-07	2.33e-05	-0.16	-0.16	Coronary artery disease;	chr19:45789001	chr19:45767796~45772504:+
BRCA	cis	rs2243480	0.901	rs778730	ENSG00000228409.4	CCT6P1	5.23	2e-07	2.34e-05	0.23	0.16	Diabetic kidney disease;	chr7:66358338	chr7:65751142~65763354:+
BRCA	cis	rs10129255	0.785	rs10150044	ENSG00000211974.3	IGHV2-70	5.23	2.01e-07	2.34e-05	0.16	0.16	Kawasaki disease;	chr14:106775695	chr14:106723574~106724093:-
BRCA	cis	rs7246657	0.525	rs10410594	ENSG00000276846.1	CTD-3220F14.3	5.23	2.01e-07	2.34e-05	0.24	0.16	Coronary artery calcification;	chr19:36986856	chr19:37314868~37315620:-
BRCA	cis	rs78487399	0.908	rs73925553	ENSG00000234936.1	AC010883.5	5.23	2.01e-07	2.34e-05	0.21	0.16	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43583507	chr2:43229573~43233394:+
BRCA	cis	rs2790457	0.958	rs2790454	ENSG00000254635.4	WAC-AS1	-5.23	2.01e-07	2.34e-05	-0.19	-0.16	Multiple myeloma;	chr10:28553103	chr10:28522652~28532743:-
BRCA	cis	rs6480314	0.542	rs4592311	ENSG00000233590.1	RP11-153K11.3	-5.23	2.01e-07	2.34e-05	-0.26	-0.16	Optic nerve measurement (disc area);	chr10:68268492	chr10:68233251~68242379:-
BRCA	cis	rs6480314	0.542	rs79081413	ENSG00000233590.1	RP11-153K11.3	-5.23	2.01e-07	2.34e-05	-0.26	-0.16	Optic nerve measurement (disc area);	chr10:68268746	chr10:68233251~68242379:-
BRCA	cis	rs2243480	1	rs160655	ENSG00000232559.3	GS1-124K5.12	5.23	2.01e-07	2.34e-05	0.31	0.16	Diabetic kidney disease;	chr7:66068227	chr7:66554588~66576923:-
BRCA	cis	rs9419788	0.626	rs10786156	ENSG00000273450.1	RP11-76P2.4	-5.23	2.01e-07	2.34e-05	-0.2	-0.16	Personality traits in bipolar disorder;	chr10:94254865	chr10:94314907~94315327:-
BRCA	cis	rs7572733	0.534	rs4850813	ENSG00000231621.1	AC013264.2	5.23	2.01e-07	2.34e-05	0.16	0.16	Dermatomyositis;	chr2:197911258	chr2:197197991~197199273:+
BRCA	cis	rs7646881	0.812	rs6788069	ENSG00000240207.5	RP11-379F4.4	5.23	2.01e-07	2.34e-05	0.25	0.16	Tetralogy of Fallot;	chr3:158741670	chr3:158732263~158784070:+
BRCA	cis	rs7914558	0.966	rs943035	ENSG00000236937.2	PTGES3P4	5.23	2.01e-07	2.34e-05	0.21	0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103079395	chr10:102845595~102845950:+
BRCA	cis	rs7914558	0.966	rs7921574	ENSG00000236937.2	PTGES3P4	5.23	2.01e-07	2.34e-05	0.21	0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103081213	chr10:102845595~102845950:+
BRCA	cis	rs4683346	0.584	rs339731	ENSG00000173811.9	CCDC13-AS1	-5.23	2.01e-07	2.34e-05	-0.23	-0.16	Granulocyte percentage of myeloid white cells;	chr3:42725867	chr3:42732575~42746768:+
BRCA	cis	rs2732480	0.577	rs2450994	ENSG00000257735.1	RP11-370I10.6	5.23	2.01e-07	2.34e-05	0.2	0.16	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48328049	chr12:48350945~48442411:+
BRCA	cis	rs17660992	0.603	rs2167422	ENSG00000273837.1	LLNLR-470E3.1	-5.23	2.01e-07	2.34e-05	-0.19	-0.16	Blood protein levels;	chr19:51661130	chr19:51639478~51639931:-
BRCA	cis	rs2303319	1	rs34731727	ENSG00000227403.1	AC009299.3	5.23	2.01e-07	2.34e-05	0.4	0.16	Cognitive function;	chr2:161300769	chr2:161244739~161249050:+
BRCA	cis	rs2303319	1	rs62197073	ENSG00000227403.1	AC009299.3	5.23	2.01e-07	2.34e-05	0.4	0.16	Cognitive function;	chr2:161304877	chr2:161244739~161249050:+
BRCA	cis	rs6480314	0.542	rs12570281	ENSG00000233590.1	RP11-153K11.3	-5.23	2.01e-07	2.34e-05	-0.27	-0.16	Optic nerve measurement (disc area);	chr10:68267237	chr10:68233251~68242379:-
BRCA	cis	rs6480314	0.542	rs61854813	ENSG00000233590.1	RP11-153K11.3	-5.23	2.01e-07	2.34e-05	-0.27	-0.16	Optic nerve measurement (disc area);	chr10:68267464	chr10:68233251~68242379:-
BRCA	cis	rs12571093	0.803	rs61854814	ENSG00000233590.1	RP11-153K11.3	-5.23	2.01e-07	2.34e-05	-0.27	-0.16	Optic nerve measurement (disc area);	chr10:68267639	chr10:68233251~68242379:-
BRCA	cis	rs8114671	0.562	rs6087641	ENSG00000269202.1	RP4-614O4.12	-5.23	2.01e-07	2.35e-05	-0.16	-0.16	Height;	chr20:34879914	chr20:35201747~35203288:-
BRCA	cis	rs2832191	0.755	rs2832192	ENSG00000215533.7	LINC00189	5.23	2.01e-07	2.35e-05	0.18	0.16	Dental caries;	chr21:29118852	chr21:29193480~29288205:+
BRCA	cis	rs2098713	0.534	rs11746259	ENSG00000250155.1	CTD-2353F22.1	5.23	2.01e-07	2.35e-05	0.18	0.16	Telomere length;	chr5:37488801	chr5:36666214~36725195:-
BRCA	cis	rs2098713	0.502	rs55872839	ENSG00000250155.1	CTD-2353F22.1	5.23	2.01e-07	2.35e-05	0.18	0.16	Telomere length;	chr5:37488967	chr5:36666214~36725195:-
BRCA	cis	rs2098713	0.501	rs12652895	ENSG00000250155.1	CTD-2353F22.1	5.23	2.01e-07	2.35e-05	0.18	0.16	Telomere length;	chr5:37489269	chr5:36666214~36725195:-
BRCA	cis	rs2098713	0.569	rs12657090	ENSG00000250155.1	CTD-2353F22.1	5.23	2.01e-07	2.35e-05	0.18	0.16	Telomere length;	chr5:37489340	chr5:36666214~36725195:-
BRCA	cis	rs2098713	0.501	rs55758219	ENSG00000250155.1	CTD-2353F22.1	5.23	2.01e-07	2.35e-05	0.18	0.16	Telomere length;	chr5:37489681	chr5:36666214~36725195:-
BRCA	cis	rs2098713	0.534	rs56307385	ENSG00000250155.1	CTD-2353F22.1	5.23	2.01e-07	2.35e-05	0.18	0.16	Telomere length;	chr5:37490062	chr5:36666214~36725195:-
BRCA	cis	rs2098713	0.569	rs7727005	ENSG00000250155.1	CTD-2353F22.1	5.23	2.01e-07	2.35e-05	0.18	0.16	Telomere length;	chr5:37490325	chr5:36666214~36725195:-
BRCA	cis	rs2098713	0.569	rs7727685	ENSG00000250155.1	CTD-2353F22.1	5.23	2.01e-07	2.35e-05	0.18	0.16	Telomere length;	chr5:37490694	chr5:36666214~36725195:-
BRCA	cis	rs2098713	0.569	rs11958226	ENSG00000250155.1	CTD-2353F22.1	5.23	2.01e-07	2.35e-05	0.18	0.16	Telomere length;	chr5:37491418	chr5:36666214~36725195:-
BRCA	cis	rs2098713	0.569	rs7733244	ENSG00000250155.1	CTD-2353F22.1	5.23	2.01e-07	2.35e-05	0.18	0.16	Telomere length;	chr5:37491825	chr5:36666214~36725195:-
BRCA	cis	rs35612822	0.828	rs2738276	ENSG00000232485.2	AC098820.3	-5.23	2.01e-07	2.35e-05	-0.2	-0.16	Kidney disease (early stage) in type 1 diabetes;	chr2:216437441	chr2:216479030~216498761:-
BRCA	cis	rs700651	0.754	rs1518367	ENSG00000231621.1	AC013264.2	-5.23	2.01e-07	2.35e-05	-0.16	-0.16	Intracranial aneurysm;	chr2:197942291	chr2:197197991~197199273:+
BRCA	cis	rs7191700	0.578	rs243327	ENSG00000262636.1	CTD-3088G3.4	-5.23	2.01e-07	2.35e-05	-0.21	-0.16	Multiple sclerosis;	chr16:11259447	chr16:11380859~11381118:-
BRCA	cis	rs1387259	0.839	rs7487682	ENSG00000257735.1	RP11-370I10.6	-5.23	2.01e-07	2.35e-05	-0.2	-0.16	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48185882	chr12:48350945~48442411:+
BRCA	cis	rs12468226	1	rs115170232	ENSG00000226261.1	AC064836.3	5.23	2.02e-07	2.35e-05	0.27	0.16	Urate levels;	chr2:202416790	chr2:202336024~202336727:-
BRCA	cis	rs2839186	0.872	rs2250213	ENSG00000228137.1	AP001469.7	5.23	2.02e-07	2.35e-05	0.16	0.16	Testicular germ cell tumor;	chr21:46254361	chr21:46246890~46247682:+
BRCA	cis	rs4604234	0.803	rs3828750	ENSG00000272129.1	RP11-250B2.6	-5.23	2.02e-07	2.35e-05	-0.39	-0.16	Cancer;	chr6:80253567	chr6:80355424~80356859:+
BRCA	cis	rs3733585	0.673	rs4519796	ENSG00000250413.1	RP11-448G15.1	5.23	2.02e-07	2.35e-05	0.21	0.16	Cleft plate (environmental tobacco smoke interaction);	chr4:9954312	chr4:10006482~10009725:+
BRCA	cis	rs7226408	0.857	rs11664002	ENSG00000267707.2	RP11-95O2.5	5.23	2.02e-07	2.35e-05	0.24	0.16	Obesity-related traits;	chr18:36946414	chr18:37243776~37247506:+
BRCA	cis	rs6840360	0.642	rs7698816	ENSG00000278978.1	RP11-164P12.5	-5.23	2.02e-07	2.35e-05	-0.18	-0.16	Intelligence (multi-trait analysis);	chr4:151431820	chr4:151669786~151670503:+
BRCA	cis	rs5758659	0.716	rs86669	ENSG00000182057.4	OGFRP1	5.23	2.02e-07	2.35e-05	0.18	0.16	Cognitive function;	chr22:42284794	chr22:42269753~42275196:+
BRCA	cis	rs7178375	1	rs9806159	ENSG00000270015.1	RP11-540B6.6	5.23	2.02e-07	2.35e-05	0.19	0.16	Hypertriglyceridemia;	chr15:30917451	chr15:30926514~30928407:+
BRCA	cis	rs8048589	0.898	rs8063329	ENSG00000175604.2	RP11-276H1.3	-5.23	2.02e-07	2.36e-05	-0.23	-0.16	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);	chr16:12092190	chr16:12086746~12090302:-
BRCA	cis	rs4908769	0.66	rs10779702	ENSG00000270282.1	RP5-1115A15.2	-5.23	2.03e-07	2.36e-05	-0.19	-0.16	Allergy;	chr1:8363450	chr1:8512653~8513021:+
BRCA	cis	rs6044112	0.701	rs12481403	ENSG00000273998.1	RP4-777L9.2	5.23	2.03e-07	2.36e-05	0.3	0.16	Response to taxane treatment (docetaxel);	chr20:16570306	chr20:16576068~16579615:+
BRCA	cis	rs2562456	0.917	rs2562466	ENSG00000268658.4	LINC00664	-5.23	2.03e-07	2.36e-05	-0.25	-0.16	Pain;	chr19:21531402	chr19:21483374~21503238:+
BRCA	cis	rs4781563	0.879	rs2276465	ENSG00000242307.1	RPS26P52	-5.23	2.03e-07	2.36e-05	-0.19	-0.16	Bilirubin levels;	chr16:13949157	chr16:13922332~13922679:-
BRCA	cis	rs9473147	0.516	rs9369695	ENSG00000270761.1	RP11-385F7.1	-5.23	2.03e-07	2.36e-05	-0.17	-0.16	Platelet distribution width;Mean platelet volume;	chr6:47472829	chr6:47477243~47477572:-
BRCA	cis	rs2243480	1	rs383402	ENSG00000232559.3	GS1-124K5.12	-5.23	2.03e-07	2.36e-05	-0.3	-0.16	Diabetic kidney disease;	chr7:66121666	chr7:66554588~66576923:-
BRCA	cis	rs9467773	0.967	rs6924865	ENSG00000124549.13	BTN2A3P	5.23	2.03e-07	2.36e-05	0.16	0.16	Intelligence (multi-trait analysis);	chr6:26521125	chr6:26421391~26432383:+
BRCA	cis	rs73198271	0.74	rs10105920	ENSG00000253893.2	FAM85B	-5.23	2.03e-07	2.36e-05	-0.21	-0.16	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8791227	chr8:8167819~8226614:-
BRCA	cis	rs891378	1	rs10864167	ENSG00000274245.1	RP11-357P18.2	-5.23	2.03e-07	2.36e-05	-0.21	-0.16	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207248227	chr1:207372559~207373252:+
BRCA	cis	rs7428	0.847	rs1969260	ENSG00000273196.1	RP11-717A5.2	5.23	2.03e-07	2.37e-05	0.19	0.16	Ear protrusion;	chr2:85341687	chr2:85387074~85387146:-
BRCA	cis	rs4835473	0.932	rs28377887	ENSG00000249741.2	RP11-673E1.3	-5.23	2.03e-07	2.37e-05	-0.17	-0.16	Immature fraction of reticulocytes;	chr4:143977075	chr4:143911514~143912053:-
BRCA	cis	rs7772486	0.846	rs2144478	ENSG00000270638.1	RP3-466P17.1	5.23	2.03e-07	2.37e-05	0.18	0.16	Lobe attachment (rater-scored or self-reported);	chr6:146060309	chr6:145735570~145737218:+
BRCA	cis	rs17685	0.712	rs6954569	ENSG00000280388.1	RP11-229D13.3	-5.23	2.03e-07	2.37e-05	-0.17	-0.16	Coffee consumption (cups per day);Coffee consumption;	chr7:76109567	chr7:76043977~76045963:-
BRCA	cis	rs7772486	0.875	rs2814869	ENSG00000270638.1	RP3-466P17.1	5.23	2.03e-07	2.37e-05	0.19	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145994373	chr6:145735570~145737218:+
BRCA	cis	rs17767294	0.614	rs72850298	ENSG00000204709.4	LINC01556	5.23	2.03e-07	2.37e-05	0.43	0.16	Parkinson's disease;	chr6:28254778	chr6:28943877~28944537:+
BRCA	cis	rs41307935	0.908	rs111707709	ENSG00000260063.1	RP5-968P14.2	-5.23	2.03e-07	2.37e-05	-0.35	-0.16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26848285	chr1:26692132~26694131:-
BRCA	cis	rs3760982	0.585	rs4803659	ENSG00000267058.1	RP11-15A1.3	-5.23	2.03e-07	2.37e-05	-0.19	-0.16	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43786083	chr19:43891804~43901805:-
BRCA	cis	rs77972916	0.536	rs7562101	ENSG00000234936.1	AC010883.5	5.23	2.03e-07	2.37e-05	0.18	0.16	Granulocyte percentage of myeloid white cells;	chr2:43365617	chr2:43229573~43233394:+
BRCA	cis	rs6545883	0.894	rs4672436	ENSG00000270820.4	RP11-355B11.2	-5.23	2.03e-07	2.37e-05	-0.18	-0.16	Tuberculosis;	chr2:61376222	chr2:61471188~61484130:+
BRCA	cis	rs6545883	0.859	rs35760550	ENSG00000270820.4	RP11-355B11.2	-5.23	2.03e-07	2.37e-05	-0.18	-0.16	Tuberculosis;	chr2:61376730	chr2:61471188~61484130:+
BRCA	cis	rs6545883	0.859	rs62149714	ENSG00000270820.4	RP11-355B11.2	-5.23	2.03e-07	2.37e-05	-0.18	-0.16	Tuberculosis;	chr2:61376734	chr2:61471188~61484130:+
BRCA	cis	rs4763879	0.865	rs4763840	ENSG00000256673.1	RP11-599J14.2	5.23	2.03e-07	2.37e-05	0.18	0.16	Type 1 diabetes;	chr12:9731814	chr12:9398355~9414851:-
BRCA	cis	rs11039131	0.629	rs67871383	ENSG00000280615.1	Y_RNA	-5.23	2.04e-07	2.37e-05	-0.2	-0.16	Schizophrenia;	chr11:47314287	chr11:47614898~47614994:-
BRCA	cis	rs7916697	0.54	rs4551651	ENSG00000233590.1	RP11-153K11.3	-5.23	2.04e-07	2.37e-05	-0.2	-0.16	Optic disc area;	chr10:68264772	chr10:68233251~68242379:-
BRCA	cis	rs7968440	0.651	rs7309519	ENSG00000272368.2	RP4-605O3.4	-5.23	2.04e-07	2.37e-05	-0.17	-0.16	Fibrinogen;	chr12:50258497	chr12:50112197~50165618:+
BRCA	cis	rs2904967	0.537	rs7116674	ENSG00000255200.1	AP003068.18	5.23	2.04e-07	2.37e-05	0.3	0.16	Mean corpuscular volume;	chr11:65195487	chr11:65174117~65176470:-
BRCA	cis	rs7613875	0.6	rs7061	ENSG00000228008.1	CTD-2330K9.3	-5.23	2.04e-07	2.37e-05	-0.16	-0.16	Body mass index;	chr3:50077082	chr3:49903845~49916937:+
BRCA	cis	rs7620503	0.959	rs2863015	ENSG00000228221.4	LINC00578	5.23	2.04e-07	2.37e-05	0.18	0.16	Corneal structure;	chr3:177585391	chr3:177441921~177752305:+
BRCA	cis	rs9868809	0.881	rs57334642	ENSG00000270441.1	RP11-694I15.7	5.23	2.04e-07	2.37e-05	0.31	0.16	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48629362	chr3:49140086~49160851:-
BRCA	cis	rs6840360	0.642	rs2709816	ENSG00000278978.1	RP11-164P12.5	-5.23	2.04e-07	2.38e-05	-0.17	-0.16	Intelligence (multi-trait analysis);	chr4:151459117	chr4:151669786~151670503:+
BRCA	cis	rs12571093	0.803	rs61854826	ENSG00000233590.1	RP11-153K11.3	-5.23	2.04e-07	2.38e-05	-0.26	-0.16	Optic nerve measurement (disc area);	chr10:68271801	chr10:68233251~68242379:-
BRCA	cis	rs12497850	0.863	rs4974084	ENSG00000225399.4	RP11-3B7.1	5.23	2.04e-07	2.38e-05	0.16	0.16	Parkinson's disease;	chr3:48901647	chr3:49260085~49261316:+
BRCA	cis	rs3733585	0.673	rs9994266	ENSG00000250413.1	RP11-448G15.1	5.23	2.05e-07	2.38e-05	0.21	0.16	Cleft plate (environmental tobacco smoke interaction);	chr4:9952826	chr4:10006482~10009725:+
BRCA	cis	rs6832769	1	rs7667849	ENSG00000272969.1	RP11-528I4.2	-5.23	2.05e-07	2.38e-05	-0.2	-0.16	Personality dimensions;	chr4:55522032	chr4:55547112~55547889:+
BRCA	cis	rs34792	0.554	rs12918517	ENSG00000207425.1	Y_RNA	-5.23	2.05e-07	2.38e-05	-0.21	-0.16	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15532974	chr16:14915457~14915556:-
BRCA	cis	rs875971	1	rs6963646	ENSG00000223473.2	GS1-124K5.3	-5.23	2.05e-07	2.38e-05	-0.12	-0.16	Aortic root size;	chr7:66220780	chr7:66491049~66493566:-
BRCA	cis	rs2243480	0.522	rs1638736	ENSG00000232559.3	GS1-124K5.12	5.23	2.05e-07	2.38e-05	0.36	0.16	Diabetic kidney disease;	chr7:66627321	chr7:66554588~66576923:-
BRCA	cis	rs2562456	0.516	rs56072098	ENSG00000268535.1	RP11-420K14.3	-5.23	2.05e-07	2.38e-05	-0.22	-0.16	Pain;	chr19:21469158	chr19:21709522~21710191:+
BRCA	cis	rs875971	0.862	rs7809814	ENSG00000236529.1	RP13-254B10.1	-5.23	2.05e-07	2.39e-05	-0.18	-0.16	Aortic root size;	chr7:66150410	chr7:65840212~65840596:+
BRCA	cis	rs2522056	1	rs2522054	ENSG00000233006.5	AC034220.3	-5.23	2.05e-07	2.39e-05	-0.13	-0.16	Fibrinogen;Lymphocyte counts;	chr5:132463834	chr5:132311285~132369916:-
BRCA	cis	rs7200543	0.961	rs1741	ENSG00000275910.1	RP11-680G24.6	-5.23	2.05e-07	2.39e-05	-0.19	-0.16	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15036494	chr16:15015828~15016390:-
BRCA	cis	rs35612822	0.866	rs2738277	ENSG00000232485.2	AC098820.3	-5.23	2.05e-07	2.39e-05	-0.2	-0.16	Kidney disease (early stage) in type 1 diabetes;	chr2:216437510	chr2:216479030~216498761:-
BRCA	cis	rs9784649	0.76	rs17403440	ENSG00000245662.2	RP11-184E9.1	5.23	2.05e-07	2.39e-05	0.24	0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr5:25053895	chr5:25190682~25306172:+
BRCA	cis	rs17301013	0.932	rs7555533	ENSG00000227373.4	RP11-160H22.5	5.23	2.05e-07	2.39e-05	0.21	0.16	Systemic lupus erythematosus;	chr1:174589983	chr1:174115300~174160004:-
BRCA	cis	rs17301013	0.932	rs6671824	ENSG00000227373.4	RP11-160H22.5	5.23	2.05e-07	2.39e-05	0.21	0.16	Systemic lupus erythematosus;	chr1:174603721	chr1:174115300~174160004:-
BRCA	cis	rs17301013	0.861	rs6672148	ENSG00000227373.4	RP11-160H22.5	5.23	2.05e-07	2.39e-05	0.21	0.16	Systemic lupus erythematosus;	chr1:174604016	chr1:174115300~174160004:-
BRCA	cis	rs3820068	0.603	rs6695903	ENSG00000237301.1	RP4-680D5.2	-5.23	2.05e-07	2.39e-05	-0.2	-0.16	Systolic blood pressure;	chr1:15659445	chr1:15586136~15603626:-
BRCA	cis	rs559555	0.553	rs522638	ENSG00000272716.1	RP11-563N4.1	5.23	2.06e-07	2.39e-05	0.19	0.16	Blood metabolite ratios;Blood metabolite levels;	chr2:31580605	chr2:32165046~32165757:-
BRCA	cis	rs6847067	0.965	rs2046402	ENSG00000180769.7	WDFY3-AS2	5.23	2.06e-07	2.39e-05	0.14	0.16	Oropharynx cancer;	chr4:84841232	chr4:84965682~85011277:+
BRCA	cis	rs12497850	0.931	rs7431710	ENSG00000225399.4	RP11-3B7.1	5.23	2.06e-07	2.39e-05	0.15	0.16	Parkinson's disease;	chr3:48898150	chr3:49260085~49261316:+
BRCA	cis	rs516805	0.63	rs2816075	ENSG00000279453.1	RP3-425C14.4	-5.23	2.06e-07	2.4e-05	-0.22	-0.16	Lymphocyte counts;	chr6:122106110	chr6:122436789~122439223:-
BRCA	cis	rs516805	0.667	rs7752093	ENSG00000279453.1	RP3-425C14.4	5.23	2.06e-07	2.4e-05	0.23	0.16	Lymphocyte counts;	chr6:122301265	chr6:122436789~122439223:-
BRCA	cis	rs863750	0.687	rs825476	ENSG00000275389.1	RP11-214K3.24	5.23	2.06e-07	2.4e-05	0.2	0.16	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-hip ratio;	chr12:124083909	chr12:124085761~124088598:+
BRCA	cis	rs9473147	0.516	rs9381564	ENSG00000270761.1	RP11-385F7.1	-5.23	2.06e-07	2.4e-05	-0.17	-0.16	Platelet distribution width;Mean platelet volume;	chr6:47476070	chr6:47477243~47477572:-
BRCA	cis	rs61160187	0.527	rs6449500	ENSG00000215032.2	GNL3LP1	5.23	2.06e-07	2.4e-05	0.19	0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:60788076	chr5:60891935~60893577:-
BRCA	cis	rs1707322	0.686	rs3014236	ENSG00000234329.1	RP11-767N6.2	-5.23	2.06e-07	2.4e-05	-0.17	-0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45625633	chr1:45651039~45651826:-
BRCA	cis	rs9868809	0.649	rs3733086	ENSG00000270441.1	RP11-694I15.7	5.23	2.06e-07	2.4e-05	0.3	0.16	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48662086	chr3:49140086~49160851:-
BRCA	cis	rs9393777	0.92	rs35716472	ENSG00000220721.1	OR1F12	5.23	2.06e-07	2.4e-05	0.34	0.16	Intelligence (multi-trait analysis);	chr6:27438828	chr6:28073316~28074233:+
BRCA	cis	rs7617773	0.817	rs3731513	ENSG00000199476.1	Y_RNA	-5.23	2.06e-07	2.4e-05	-0.24	-0.16	Coronary artery disease;	chr3:48178047	chr3:48288587~48288694:+
BRCA	cis	rs172166	0.694	rs536704	ENSG00000280107.1	AL022393.9	-5.23	2.07e-07	2.4e-05	-0.22	-0.16	Cardiac Troponin-T levels;	chr6:28124825	chr6:28170845~28172521:+
BRCA	cis	rs2408955	0.522	rs973398	ENSG00000273765.1	RP11-370I10.11	-5.23	2.07e-07	2.4e-05	-0.19	-0.16	Glycated hemoglobin levels;	chr12:48097265	chr12:48360920~48361377:+
BRCA	cis	rs7267979	0.789	rs6083810	ENSG00000231081.1	RP4-760C5.3	5.23	2.07e-07	2.4e-05	0.21	0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25349123	chr20:26008791~26010531:-
BRCA	cis	rs6545883	0.525	rs1177274	ENSG00000212978.6	AC016747.3	5.23	2.07e-07	2.4e-05	0.21	0.16	Tuberculosis;	chr2:61141397	chr2:61141592~61144969:-
BRCA	cis	rs1707322	1	rs7519181	ENSG00000234329.1	RP11-767N6.2	5.23	2.07e-07	2.4e-05	0.16	0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45922157	chr1:45651039~45651826:-
BRCA	cis	rs4711890	1	rs4711890	ENSG00000270761.1	RP11-385F7.1	-5.23	2.07e-07	2.4e-05	-0.17	-0.16	Platelet count;	chr6:47638976	chr6:47477243~47477572:-
BRCA	cis	rs10129255	0.872	rs1858683	ENSG00000280411.1	IGHV1-69-2	-5.23	2.07e-07	2.4e-05	-0.12	-0.16	Kawasaki disease;	chr14:106670217	chr14:106762092~106762588:-
BRCA	cis	rs7487075	0.93	rs6582656	ENSG00000257261.4	RP11-96H19.1	5.23	2.07e-07	2.41e-05	0.17	0.16	Itch intensity from mosquito bite;	chr12:46449633	chr12:46383679~46876159:+
BRCA	cis	rs10492201	0.529	rs11177004	ENSG00000236946.2	HNRNPA1P70	5.23	2.07e-07	2.41e-05	0.15	0.16	Itch intensity from mosquito bite adjusted by bite size;	chr12:68015229	chr12:68035767~68036853:+
BRCA	cis	rs42490	0.934	rs218947	ENSG00000251136.7	RP11-37B2.1	5.23	2.07e-07	2.41e-05	0.16	0.16	Leprosy;	chr8:89705148	chr8:89609409~89757727:-
BRCA	cis	rs2115630	1	rs7183401	ENSG00000259295.5	CSPG4P12	-5.23	2.07e-07	2.41e-05	-0.19	-0.16	P wave terminal force;	chr15:84828713	chr15:85191438~85213905:+
BRCA	cis	rs8180040	0.966	rs11130129	ENSG00000276925.1	RP11-708J19.3	5.23	2.07e-07	2.41e-05	0.18	0.16	Colorectal cancer;	chr3:47448395	chr3:47469777~47469987:+
BRCA	cis	rs847577	0.722	rs1013887	ENSG00000272950.1	RP11-307C18.1	5.23	2.07e-07	2.41e-05	0.2	0.16	Breast cancer;	chr7:98080033	chr7:98322853~98323430:+
BRCA	cis	rs7119	0.717	rs12901732	ENSG00000259362.2	RP11-307C19.1	-5.23	2.07e-07	2.41e-05	-0.22	-0.16	Type 2 diabetes;	chr15:77526591	chr15:77525540~77534110:+
BRCA	cis	rs9287719	0.837	rs4233883	ENSG00000243819.4	RN7SL832P	5.23	2.07e-07	2.41e-05	0.16	0.16	Prostate cancer;	chr2:10615470	chr2:10690344~10692099:+
BRCA	cis	rs2403083	0.505	rs7827175	ENSG00000258256.1	RP11-219B4.5	-5.23	2.08e-07	2.41e-05	-0.19	-0.16	Plasma amyloid beta peptide concentrations (ABx-40);	chr8:85236182	chr8:85222446~85245717:-
BRCA	cis	rs4908760	0.965	rs1884352	ENSG00000232912.4	RP5-1115A15.1	5.23	2.08e-07	2.41e-05	0.15	0.16	Vitiligo;	chr1:8477229	chr1:8424645~8434838:+
BRCA	cis	rs4660214	0.666	rs598415	ENSG00000228060.1	RP11-69E11.8	-5.23	2.08e-07	2.41e-05	-0.16	-0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39366735	chr1:39565160~39573203:+
BRCA	cis	rs875971	0.965	rs28682868	ENSG00000223473.2	GS1-124K5.3	-5.23	2.08e-07	2.42e-05	-0.12	-0.16	Aortic root size;	chr7:66224822	chr7:66491049~66493566:-
BRCA	cis	rs6431644	0.931	rs169922	ENSG00000224287.2	MSL3P1	5.23	2.08e-07	2.42e-05	0.19	0.16	Left atrial antero-posterior diameter;	chr2:233869604	chr2:233865437~233868444:-
BRCA	cis	rs987360	0.835	rs4863978	ENSG00000248869.4	RP11-138I17.1	5.23	2.08e-07	2.42e-05	0.16	0.16	Temperament;	chr4:137276580	chr4:136796722~137212799:-
BRCA	cis	rs720475	0.732	rs62483107	ENSG00000170356.8	OR2A20P	5.23	2.08e-07	2.42e-05	0.24	0.16	Breast cancer;	chr7:144442144	chr7:144250045~144252957:-
BRCA	cis	rs2574985	0.739	rs2221	ENSG00000231345.3	BEND3P1	5.23	2.08e-07	2.42e-05	0.26	0.16	Subjective well-being;	chr10:50531612	chr10:50655967~50660472:+
BRCA	cis	rs910316	0.763	rs175044	ENSG00000279594.1	RP11-950C14.10	-5.23	2.08e-07	2.42e-05	-0.18	-0.16	Height;	chr14:75005406	chr14:75011269~75012851:-
BRCA	cis	rs875971	0.862	rs1983372	ENSG00000236529.1	RP13-254B10.1	-5.23	2.08e-07	2.42e-05	-0.17	-0.16	Aortic root size;	chr7:66146364	chr7:65840212~65840596:+
BRCA	cis	rs12681366	0.959	rs58826082	ENSG00000253704.1	RP11-267M23.4	5.23	2.08e-07	2.42e-05	0.17	0.16	Nonsyndromic cleft lip with cleft palate;	chr8:94351487	chr8:94553722~94569745:+
BRCA	cis	rs755249	0.51	rs599892	ENSG00000228060.1	RP11-69E11.8	-5.23	2.08e-07	2.42e-05	-0.17	-0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39457212	chr1:39565160~39573203:+
BRCA	cis	rs801193	0.548	rs2659891	ENSG00000273448.1	RP11-166O4.6	5.23	2.08e-07	2.42e-05	0.15	0.16	Aortic root size;	chr7:66736127	chr7:67333047~67334383:+
BRCA	cis	rs801193	0.548	rs7805152	ENSG00000273448.1	RP11-166O4.6	5.23	2.08e-07	2.42e-05	0.15	0.16	Aortic root size;	chr7:66744266	chr7:67333047~67334383:+
BRCA	cis	rs9473147	0.503	rs2171086	ENSG00000270761.1	RP11-385F7.1	-5.23	2.08e-07	2.42e-05	-0.17	-0.16	Platelet distribution width;Mean platelet volume;	chr6:47622368	chr6:47477243~47477572:-
BRCA	cis	rs2638953	0.849	rs10843172	ENSG00000247934.4	RP11-967K21.1	-5.23	2.08e-07	2.42e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28452300	chr12:28163298~28190738:-
BRCA	cis	rs9425766	0.679	rs4650945	ENSG00000227373.4	RP11-160H22.5	-5.23	2.09e-07	2.42e-05	-0.21	-0.16	Life satisfaction;	chr1:174114966	chr1:174115300~174160004:-
BRCA	cis	rs7567389	0.719	rs1504135	ENSG00000236682.1	AC068282.3	5.23	2.09e-07	2.42e-05	0.25	0.16	Self-rated health;	chr2:127245675	chr2:127389130~127400580:+
BRCA	cis	rs62103177	0.525	rs4799116	ENSG00000278000.1	AC139100.4	-5.23	2.09e-07	2.42e-05	-0.22	-0.16	Opioid sensitivity;	chr18:79976735	chr18:80161752~80162413:+
BRCA	cis	rs7577696	0.925	rs408813	ENSG00000272716.1	RP11-563N4.1	5.23	2.09e-07	2.42e-05	0.18	0.16	Inflammatory biomarkers;	chr2:32251321	chr2:32165046~32165757:-
BRCA	cis	rs11673344	0.542	rs826331	ENSG00000226686.6	LINC01535	5.23	2.09e-07	2.42e-05	0.2	0.16	Obesity-related traits;	chr19:37007360	chr19:37251912~37265535:+
BRCA	cis	rs2688608	1	rs2688608	ENSG00000271816.1	BMS1P4	5.23	2.09e-07	2.43e-05	0.16	0.16	Inflammatory bowel disease;	chr10:73898591	chr10:73699151~73730487:-
BRCA	cis	rs12701220	0.894	rs10257744	ENSG00000229043.2	AC091729.9	-5.23	2.09e-07	2.43e-05	-0.25	-0.16	Bronchopulmonary dysplasia;	chr7:1005976	chr7:1160374~1165267:+
BRCA	cis	rs875971	1	rs2220626	ENSG00000164669.11	INTS4P1	5.23	2.09e-07	2.43e-05	0.2	0.16	Aortic root size;	chr7:66081075	chr7:65141225~65234216:+
BRCA	cis	rs2638953	0.893	rs10771432	ENSG00000247934.4	RP11-967K21.1	-5.23	2.09e-07	2.43e-05	-0.2	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28507798	chr12:28163298~28190738:-
BRCA	cis	rs11719291	0.504	rs34571182	ENSG00000270441.1	RP11-694I15.7	5.23	2.09e-07	2.43e-05	0.31	0.16	Cognitive function;	chr3:49171624	chr3:49140086~49160851:-
BRCA	cis	rs7618915	0.571	rs11130307	ENSG00000243224.1	RP5-1157M23.2	-5.23	2.09e-07	2.43e-05	-0.18	-0.16	Bipolar disorder;	chr3:52573666	chr3:52239258~52241097:+
BRCA	cis	rs7618915	0.571	rs12632381	ENSG00000243224.1	RP5-1157M23.2	-5.23	2.09e-07	2.43e-05	-0.18	-0.16	Bipolar disorder;	chr3:52573669	chr3:52239258~52241097:+
BRCA	cis	rs10911232	0.507	rs10797819	ENSG00000224468.3	RP11-181K3.4	-5.23	2.09e-07	2.43e-05	-0.17	-0.16	Hypertriglyceridemia;	chr1:183037776	chr1:183138402~183141282:-
BRCA	cis	rs6832769	1	rs10002541	ENSG00000272969.1	RP11-528I4.2	-5.23	2.09e-07	2.43e-05	-0.19	-0.16	Personality dimensions;	chr4:55528844	chr4:55547112~55547889:+
BRCA	cis	rs7178909	0.732	rs57163265	ENSG00000259677.1	RP11-493E3.1	5.23	2.09e-07	2.43e-05	0.19	0.16	Common traits (Other);	chr15:89857418	chr15:89876540~89877285:+
BRCA	cis	rs12534093	0.522	rs11768826	ENSG00000234286.1	AC006026.13	-5.23	2.09e-07	2.43e-05	-0.19	-0.16	Infant length;Height;	chr7:23534595	chr7:23680195~23680786:-
BRCA	cis	rs10129255	1	rs4612959	ENSG00000224373.3	IGHV4-59	5.23	2.09e-07	2.43e-05	0.1	0.16	Kawasaki disease;	chr14:106767055	chr14:106627249~106627825:-
BRCA	cis	rs62025270	0.631	rs55968154	ENSG00000202081.1	RNU6-1280P	-5.23	2.09e-07	2.43e-05	-0.24	-0.16	Idiopathic pulmonary fibrosis;	chr15:85725399	chr15:85651522~85651628:-
BRCA	cis	rs62025270	0.688	rs55851385	ENSG00000202081.1	RNU6-1280P	-5.23	2.09e-07	2.43e-05	-0.24	-0.16	Idiopathic pulmonary fibrosis;	chr15:85725400	chr15:85651522~85651628:-
BRCA	cis	rs6545883	0.862	rs778141	ENSG00000270820.4	RP11-355B11.2	5.23	2.1e-07	2.43e-05	0.19	0.16	Tuberculosis;	chr2:61455043	chr2:61471188~61484130:+
BRCA	cis	rs13113518	1	rs13122619	ENSG00000223305.1	RN7SKP30	5.23	2.1e-07	2.44e-05	0.19	0.16	Height;	chr4:55479339	chr4:55540502~55540835:-
BRCA	cis	rs10938353	0.638	rs61549581	ENSG00000273369.1	RP11-700J17.1	5.23	2.1e-07	2.44e-05	0.2	0.16	Body mass index;	chr4:44692702	chr4:44693946~44694386:-
BRCA	cis	rs2898681	0.618	rs79471207	ENSG00000248375.1	RP11-177B4.1	-5.23	2.1e-07	2.44e-05	-0.31	-0.16	Optic nerve measurement (cup area);	chr4:52872357	chr4:52720081~52720831:-
BRCA	cis	rs507080	0.922	rs525485	ENSG00000278376.1	RP11-158I9.8	-5.23	2.1e-07	2.44e-05	-0.16	-0.16	Serum metabolite levels;	chr11:118685045	chr11:118791254~118793137:+
BRCA	cis	rs67981189	0.727	rs221903	ENSG00000258571.1	PTTG4P	5.23	2.1e-07	2.44e-05	0.17	0.16	Schizophrenia;	chr14:71133491	chr14:71085482~71085833:-
BRCA	cis	rs1722141	0.633	rs2132572	ENSG00000229628.1	AC073115.7	5.23	2.1e-07	2.44e-05	0.22	0.16	Sitting height ratio;	chr7:45921946	chr7:45990905~46000898:+
BRCA	cis	rs7819412	0.691	rs73198970	ENSG00000255046.1	RP11-297N6.4	5.23	2.1e-07	2.44e-05	0.19	0.16	Triglycerides;	chr8:11182707	chr8:11797928~11802568:-
BRCA	cis	rs6907340	0.513	rs6938418	ENSG00000228412.5	RP4-625H18.2	-5.23	2.1e-07	2.44e-05	-0.21	-0.16	Endometriosis;	chr6:19808802	chr6:19802164~19804752:-
BRCA	cis	rs2251381	0.778	rs2471947	ENSG00000176054.6	RPL23P2	5.23	2.1e-07	2.44e-05	0.18	0.16	Selective IgA deficiency;	chr21:29161898	chr21:28997613~28998033:-
BRCA	cis	rs2638953	0.962	rs9645730	ENSG00000247934.4	RP11-967K21.1	-5.23	2.1e-07	2.44e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28317151	chr12:28163298~28190738:-
BRCA	cis	rs4691139	0.658	rs6839773	ENSG00000248632.1	RP11-366M4.11	5.23	2.1e-07	2.44e-05	0.16	0.16	Ovarian cancer in BRCA1 mutation carriers;	chr4:165004694	chr4:164968587~164970002:-
BRCA	cis	rs172166	0.611	rs203883	ENSG00000280107.1	AL022393.9	-5.22	2.1e-07	2.44e-05	-0.22	-0.16	Cardiac Troponin-T levels;	chr6:28110578	chr6:28170845~28172521:+
BRCA	cis	rs7617773	0.817	rs936426	ENSG00000199476.1	Y_RNA	-5.22	2.1e-07	2.44e-05	-0.22	-0.16	Coronary artery disease;	chr3:48173763	chr3:48288587~48288694:+
BRCA	cis	rs9307551	0.619	rs13118924	ENSG00000250334.4	LINC00989	-5.22	2.1e-07	2.44e-05	-0.22	-0.16	Refractive error;	chr4:79502369	chr4:79492416~79576460:+
BRCA	cis	rs13108904	0.901	rs4974594	ENSG00000196810.4	CTBP1-AS2	-5.22	2.11e-07	2.45e-05	-0.17	-0.16	Obesity-related traits;	chr4:1306692	chr4:1249300~1288291:+
BRCA	cis	rs7131987	0.565	rs1991113	ENSG00000275476.1	RP11-996F15.4	-5.22	2.11e-07	2.45e-05	-0.18	-0.16	QT interval;	chr12:29239070	chr12:29277397~29277882:-
BRCA	cis	rs4660214	0.614	rs6688708	ENSG00000228060.1	RP11-69E11.8	5.22	2.11e-07	2.45e-05	0.16	0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39293321	chr1:39565160~39573203:+
BRCA	cis	rs7914558	1	rs7920251	ENSG00000236937.2	PTGES3P4	5.22	2.11e-07	2.45e-05	0.21	0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103190440	chr10:102845595~102845950:+
BRCA	cis	rs6832769	0.89	rs1522107	ENSG00000272969.1	RP11-528I4.2	5.22	2.11e-07	2.45e-05	0.19	0.16	Personality dimensions;	chr4:55514606	chr4:55547112~55547889:+
BRCA	cis	rs7617773	0.851	rs7647817	ENSG00000199476.1	Y_RNA	-5.22	2.11e-07	2.45e-05	-0.24	-0.16	Coronary artery disease;	chr3:48195017	chr3:48288587~48288694:+
BRCA	cis	rs28472312	0.832	rs28433345	ENSG00000278665.1	RP11-666O2.4	5.22	2.11e-07	2.45e-05	0.17	0.16	Intelligence (multi-trait analysis);	chr16:28872006	chr16:28599241~28601881:-
BRCA	cis	rs8180040	0.654	rs6766230	ENSG00000276925.1	RP11-708J19.3	-5.22	2.11e-07	2.45e-05	-0.18	-0.16	Colorectal cancer;	chr3:47154719	chr3:47469777~47469987:+
BRCA	cis	rs8180040	0.627	rs9821119	ENSG00000276925.1	RP11-708J19.3	-5.22	2.11e-07	2.45e-05	-0.18	-0.16	Colorectal cancer;	chr3:47156947	chr3:47469777~47469987:+
BRCA	cis	rs13113518	0.812	rs4865001	ENSG00000272969.1	RP11-528I4.2	5.22	2.11e-07	2.45e-05	0.19	0.16	Height;	chr4:55490176	chr4:55547112~55547889:+
BRCA	cis	rs13113518	0.756	rs7658446	ENSG00000272969.1	RP11-528I4.2	5.22	2.11e-07	2.45e-05	0.19	0.16	Height;	chr4:55495262	chr4:55547112~55547889:+
BRCA	cis	rs78487399	0.908	rs10186307	ENSG00000234936.1	AC010883.5	5.22	2.11e-07	2.45e-05	0.22	0.16	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43612757	chr2:43229573~43233394:+
BRCA	cis	rs78487399	0.908	rs7602701	ENSG00000234936.1	AC010883.5	5.22	2.11e-07	2.45e-05	0.22	0.16	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43613980	chr2:43229573~43233394:+
BRCA	cis	rs7618501	0.633	rs3774733	ENSG00000228008.1	CTD-2330K9.3	5.22	2.11e-07	2.45e-05	0.15	0.16	Intelligence (multi-trait analysis);	chr3:49999690	chr3:49903845~49916937:+
BRCA	cis	rs7208859	0.673	rs3816780	ENSG00000266490.1	CTD-2349P21.9	5.22	2.11e-07	2.45e-05	0.23	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30834340	chr17:30792372~30792833:+
BRCA	cis	rs9840812	0.69	rs1618069	ENSG00000239213.4	NCK1-AS1	5.22	2.11e-07	2.45e-05	0.19	0.16	Fibrinogen levels;	chr3:136308303	chr3:136841726~136862054:-
BRCA	cis	rs3733585	0.638	rs7377625	ENSG00000250413.1	RP11-448G15.1	5.22	2.11e-07	2.45e-05	0.21	0.16	Cleft plate (environmental tobacco smoke interaction);	chr4:9951475	chr4:10006482~10009725:+
BRCA	cis	rs321358	0.945	rs73015196	ENSG00000271390.1	RP11-89C3.3	5.22	2.11e-07	2.45e-05	0.27	0.16	Body mass index;	chr11:111104608	chr11:111089870~111090368:-
BRCA	cis	rs2179367	0.959	rs579789	ENSG00000216906.2	RP11-350J20.9	5.22	2.12e-07	2.46e-05	0.2	0.16	Dupuytren's disease;	chr6:149358235	chr6:149904243~149906418:+
BRCA	cis	rs2179367	0.959	rs489551	ENSG00000216906.2	RP11-350J20.9	5.22	2.12e-07	2.46e-05	0.2	0.16	Dupuytren's disease;	chr6:149368321	chr6:149904243~149906418:+
BRCA	cis	rs10129255	0.957	rs2007467	ENSG00000280411.1	IGHV1-69-2	5.22	2.12e-07	2.46e-05	0.12	0.16	Kawasaki disease;	chr14:106771605	chr14:106762092~106762588:-
BRCA	cis	rs10504130	0.569	rs12681734	ENSG00000272024.1	RP11-546K22.3	-5.22	2.12e-07	2.46e-05	-0.23	-0.16	Venous thromboembolism (SNP x SNP interaction);	chr8:51893635	chr8:51950284~51950690:+
BRCA	cis	rs61160187	0.522	rs2045356	ENSG00000215032.2	GNL3LP1	5.22	2.12e-07	2.46e-05	0.2	0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:60651527	chr5:60891935~60893577:-
BRCA	cis	rs11220082	0.666	rs2241514	ENSG00000254671.2	STT3A-AS1	-5.22	2.12e-07	2.46e-05	-0.2	-0.16	Schizophrenia;	chr11:125456130	chr11:125570284~125592568:-
BRCA	cis	rs7208859	0.673	rs2269915	ENSG00000280069.1	CTD-2349P21.3	-5.22	2.12e-07	2.46e-05	-0.24	-0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30906326	chr17:30738182~30740275:+
BRCA	cis	rs7208859	0.673	rs2269916	ENSG00000280069.1	CTD-2349P21.3	-5.22	2.12e-07	2.46e-05	-0.24	-0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30906745	chr17:30738182~30740275:+
BRCA	cis	rs7208859	0.673	rs11649765	ENSG00000280069.1	CTD-2349P21.3	-5.22	2.12e-07	2.46e-05	-0.24	-0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30906870	chr17:30738182~30740275:+
BRCA	cis	rs7617773	0.815	rs7624450	ENSG00000199476.1	Y_RNA	-5.22	2.12e-07	2.46e-05	-0.24	-0.16	Coronary artery disease;	chr3:48308885	chr3:48288587~48288694:+
BRCA	cis	rs6832769	1	rs1522108	ENSG00000223305.1	RN7SKP30	5.22	2.12e-07	2.46e-05	0.21	0.16	Personality dimensions;	chr4:55514566	chr4:55540502~55540835:-
BRCA	cis	rs11976180	1	rs6464574	ENSG00000244479.5	OR2A1-AS1	5.22	2.12e-07	2.46e-05	0.22	0.16	Obesity-related traits;	chr7:144051164	chr7:144251264~144356181:-
BRCA	cis	rs12612619	0.579	rs41448746	ENSG00000272148.1	RP11-195B17.1	-5.22	2.12e-07	2.46e-05	-0.18	-0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:26857838	chr2:27062428~27062907:-
BRCA	cis	rs4713675	0.584	rs3818527	ENSG00000224557.6	HLA-DPB2	5.22	2.12e-07	2.46e-05	0.19	0.16	Plateletcrit;	chr6:33693258	chr6:33112451~33129084:+
BRCA	cis	rs4713118	0.629	rs203890	ENSG00000280107.1	AL022393.9	-5.22	2.12e-07	2.46e-05	-0.23	-0.16	Parkinson's disease;	chr6:28054470	chr6:28170845~28172521:+
BRCA	cis	rs6832769	0.922	rs11133376	ENSG00000272969.1	RP11-528I4.2	5.22	2.12e-07	2.47e-05	0.19	0.16	Personality dimensions;	chr4:55386866	chr4:55547112~55547889:+
BRCA	cis	rs7191700	0.511	rs8058983	ENSG00000262636.1	CTD-3088G3.4	-5.22	2.13e-07	2.47e-05	-0.21	-0.16	Multiple sclerosis;	chr16:11266992	chr16:11380859~11381118:-
BRCA	cis	rs75422866	0.541	rs12425816	ENSG00000276691.1	RP5-1057I20.5	5.22	2.13e-07	2.47e-05	0.32	0.16	Pneumonia;	chr12:47731419	chr12:47788426~47788971:+
BRCA	cis	rs10752881	1	rs10797811	ENSG00000224468.3	RP11-181K3.4	-5.22	2.13e-07	2.47e-05	-0.17	-0.16	Colorectal cancer;	chr1:183015297	chr1:183138402~183141282:-
BRCA	cis	rs2638953	0.924	rs9669509	ENSG00000247934.4	RP11-967K21.1	-5.22	2.13e-07	2.47e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28443507	chr12:28163298~28190738:-
BRCA	cis	rs2732480	0.557	rs2409004	ENSG00000226413.2	OR8T1P	5.22	2.13e-07	2.47e-05	0.21	0.16	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48327668	chr12:48442030~48442947:-
BRCA	cis	rs9287719	0.934	rs6721510	ENSG00000243819.4	RN7SL832P	5.22	2.13e-07	2.47e-05	0.16	0.16	Prostate cancer;	chr2:10610920	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.967	rs6721514	ENSG00000243819.4	RN7SL832P	5.22	2.13e-07	2.47e-05	0.16	0.16	Prostate cancer;	chr2:10610936	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.934	rs6706763	ENSG00000243819.4	RN7SL832P	5.22	2.13e-07	2.47e-05	0.16	0.16	Prostate cancer;	chr2:10611281	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.967	rs6709466	ENSG00000243819.4	RN7SL832P	5.22	2.13e-07	2.47e-05	0.16	0.16	Prostate cancer;	chr2:10608131	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.967	rs6719701	ENSG00000243819.4	RN7SL832P	5.22	2.13e-07	2.47e-05	0.16	0.16	Prostate cancer;	chr2:10608157	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.934	rs6432115	ENSG00000243819.4	RN7SL832P	5.22	2.13e-07	2.47e-05	0.16	0.16	Prostate cancer;	chr2:10608217	chr2:10690344~10692099:+
BRCA	cis	rs4578769	0.55	rs4473296	ENSG00000265939.1	UBE2CP2	-5.22	2.13e-07	2.47e-05	-0.18	-0.16	Eosinophil percentage of white cells;	chr18:22986421	chr18:22900486~22900995:-
BRCA	cis	rs10911232	0.524	rs4652773	ENSG00000224468.3	RP11-181K3.4	-5.22	2.13e-07	2.47e-05	-0.17	-0.16	Hypertriglyceridemia;	chr1:183085692	chr1:183138402~183141282:-
BRCA	cis	rs17301013	0.932	rs67967476	ENSG00000227373.4	RP11-160H22.5	5.22	2.13e-07	2.47e-05	0.21	0.16	Systemic lupus erythematosus;	chr1:174616119	chr1:174115300~174160004:-
BRCA	cis	rs2624839	0.704	rs12637671	ENSG00000228008.1	CTD-2330K9.3	-5.22	2.13e-07	2.47e-05	-0.17	-0.16	Intelligence (multi-trait analysis);	chr3:50187129	chr3:49903845~49916937:+
BRCA	cis	rs13113518	0.841	rs7699867	ENSG00000272969.1	RP11-528I4.2	5.22	2.13e-07	2.47e-05	0.19	0.16	Height;	chr4:55483718	chr4:55547112~55547889:+
BRCA	cis	rs950776	0.518	rs952215	ENSG00000279373.1	RP11-650L12.4	-5.22	2.13e-07	2.47e-05	-0.2	-0.16	Sudden cardiac arrest;	chr15:78526811	chr15:78537681~78538946:+
BRCA	cis	rs4671400	0.543	rs2290324	ENSG00000271889.1	RP11-493E12.1	-5.22	2.13e-07	2.47e-05	-0.24	-0.16	3-hydroxypropylmercapturic acid levels in smokers;	chr2:61221641	chr2:61151433~61162105:-
BRCA	cis	rs7618915	0.547	rs12487591	ENSG00000243224.1	RP5-1157M23.2	-5.22	2.13e-07	2.47e-05	-0.18	-0.16	Bipolar disorder;	chr3:52608920	chr3:52239258~52241097:+
BRCA	cis	rs2638953	0.853	rs11049668	ENSG00000247934.4	RP11-967K21.1	-5.22	2.13e-07	2.47e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28497680	chr12:28163298~28190738:-
BRCA	cis	rs9402743	0.634	rs66513771	ENSG00000231028.7	LINC00271	-5.22	2.13e-07	2.47e-05	-0.16	-0.16	Systemic lupus erythematosus;	chr6:135603885	chr6:135497801~135716055:+
BRCA	cis	rs9402743	0.634	rs7774974	ENSG00000231028.7	LINC00271	-5.22	2.13e-07	2.47e-05	-0.16	-0.16	Systemic lupus erythematosus;	chr6:135604248	chr6:135497801~135716055:+
BRCA	cis	rs6928977	0.538	rs6570019	ENSG00000231028.7	LINC00271	-5.22	2.13e-07	2.47e-05	-0.16	-0.16	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135604595	chr6:135497801~135716055:+
BRCA	cis	rs9402743	0.564	rs6570020	ENSG00000231028.7	LINC00271	-5.22	2.13e-07	2.47e-05	-0.16	-0.16	Systemic lupus erythematosus;	chr6:135604607	chr6:135497801~135716055:+
BRCA	cis	rs867371	0.929	rs1045508	ENSG00000255769.6	GOLGA2P10	5.22	2.13e-07	2.48e-05	0.18	0.16	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82157565	chr15:82472993~82513950:-
BRCA	cis	rs6840258	0.943	rs10029915	ENSG00000251411.1	RP11-397E7.4	-5.22	2.14e-07	2.48e-05	-0.22	-0.16	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87138465	chr4:86913266~86914817:-
BRCA	cis	rs6840258	0.891	rs66477840	ENSG00000251411.1	RP11-397E7.4	-5.22	2.14e-07	2.48e-05	-0.22	-0.16	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87142207	chr4:86913266~86914817:-
BRCA	cis	rs9652601	0.691	rs998592	ENSG00000274038.1	RP11-66H6.4	5.22	2.14e-07	2.48e-05	0.17	0.16	Systemic lupus erythematosus;	chr16:11105821	chr16:11056556~11057034:+
BRCA	cis	rs4604234	0.803	rs11961345	ENSG00000272129.1	RP11-250B2.6	-5.22	2.14e-07	2.48e-05	-0.4	-0.16	Cancer;	chr6:80294807	chr6:80355424~80356859:+
BRCA	cis	rs7618501	0.633	rs12485600	ENSG00000228008.1	CTD-2330K9.3	5.22	2.14e-07	2.48e-05	0.16	0.16	Intelligence (multi-trait analysis);	chr3:49988097	chr3:49903845~49916937:+
BRCA	cis	rs919433	0.713	rs1455653	ENSG00000231621.1	AC013264.2	-5.22	2.14e-07	2.48e-05	-0.15	-0.16	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197613596	chr2:197197991~197199273:+
BRCA	cis	rs9341808	0.718	rs3812121	ENSG00000272129.1	RP11-250B2.6	5.22	2.14e-07	2.48e-05	0.2	0.16	Sitting height ratio;	chr6:80259010	chr6:80355424~80356859:+
BRCA	cis	rs17801127	0.579	rs61198982	ENSG00000231969.1	AC144449.1	5.22	2.14e-07	2.48e-05	0.31	0.16	Liver enzyme levels (alanine transaminase);	chr2:149756549	chr2:149587196~149848233:+
BRCA	cis	rs7577696	0.924	rs7605242	ENSG00000272716.1	RP11-563N4.1	-5.22	2.14e-07	2.48e-05	-0.18	-0.16	Inflammatory biomarkers;	chr2:32099066	chr2:32165046~32165757:-
BRCA	cis	rs17660992	0.525	rs10421946	ENSG00000273837.1	LLNLR-470E3.1	-5.22	2.14e-07	2.48e-05	-0.19	-0.16	Blood protein levels;	chr19:51661797	chr19:51639478~51639931:-
BRCA	cis	rs17660992	0.716	rs8111426	ENSG00000273837.1	LLNLR-470E3.1	-5.22	2.14e-07	2.48e-05	-0.19	-0.16	Blood protein levels;	chr19:51662110	chr19:51639478~51639931:-
BRCA	cis	rs763121	0.853	rs5750668	ENSG00000228274.3	RP3-508I15.9	-5.22	2.14e-07	2.48e-05	-0.18	-0.16	Menopause (age at onset);	chr22:38683959	chr22:38667585~38681820:-
BRCA	cis	rs4835473	0.932	rs4260486	ENSG00000249741.2	RP11-673E1.3	-5.22	2.14e-07	2.48e-05	-0.17	-0.16	Immature fraction of reticulocytes;	chr4:143987556	chr4:143911514~143912053:-
BRCA	cis	rs14027	0.512	rs13253139	ENSG00000279347.1	RP11-85I17.2	5.22	2.14e-07	2.48e-05	0.16	0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119718225	chr8:119838736~119840385:-
BRCA	cis	rs1707322	0.835	rs946525	ENSG00000234329.1	RP11-767N6.2	-5.22	2.14e-07	2.48e-05	-0.16	-0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46021605	chr1:45651039~45651826:-
BRCA	cis	rs1707322	1	rs946524	ENSG00000234329.1	RP11-767N6.2	-5.22	2.14e-07	2.48e-05	-0.16	-0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46021888	chr1:45651039~45651826:-
BRCA	cis	rs529866	0.519	rs4451969	ENSG00000262636.1	CTD-3088G3.4	-5.22	2.14e-07	2.48e-05	-0.22	-0.16	Inflammatory bowel disease;Crohn's disease;	chr16:11289662	chr16:11380859~11381118:-
BRCA	cis	rs13113518	1	rs12501636	ENSG00000223305.1	RN7SKP30	5.22	2.14e-07	2.48e-05	0.19	0.16	Height;	chr4:55482317	chr4:55540502~55540835:-
BRCA	cis	rs7577696	0.785	rs660393	ENSG00000272716.1	RP11-563N4.1	-5.22	2.14e-07	2.48e-05	-0.18	-0.16	Inflammatory biomarkers;	chr2:32056440	chr2:32165046~32165757:-
BRCA	cis	rs793571	0.554	rs7163939	ENSG00000259250.1	RP11-50C13.1	-5.22	2.14e-07	2.48e-05	-0.26	-0.16	Schizophrenia;	chr15:58707956	chr15:58587507~58591676:+
BRCA	cis	rs17711722	0.565	rs4717276	ENSG00000275400.1	RP4-756H11.5	-5.22	2.14e-07	2.49e-05	-0.19	-0.16	Calcium levels;	chr7:65829754	chr7:66553805~66554199:-
BRCA	cis	rs2638953	0.925	rs11049604	ENSG00000247934.4	RP11-967K21.1	-5.22	2.14e-07	2.49e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28443092	chr12:28163298~28190738:-
BRCA	cis	rs2403083	0.505	rs4740045	ENSG00000258256.1	RP11-219B4.5	-5.22	2.15e-07	2.49e-05	-0.19	-0.16	Plasma amyloid beta peptide concentrations (ABx-40);	chr8:85244478	chr8:85222446~85245717:-
BRCA	cis	rs10129255	1	rs10134517	ENSG00000224373.3	IGHV4-59	5.22	2.15e-07	2.49e-05	0.1	0.16	Kawasaki disease;	chr14:106718498	chr14:106627249~106627825:-
BRCA	cis	rs7914558	1	rs10786733	ENSG00000236937.2	PTGES3P4	5.22	2.15e-07	2.49e-05	0.2	0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103035190	chr10:102845595~102845950:+
BRCA	cis	rs1075265	0.584	rs4671178	ENSG00000235937.1	AC008280.1	-5.22	2.15e-07	2.49e-05	-0.18	-0.16	Chronotype;Morning vs. evening chronotype;	chr2:54056356	chr2:54029552~54030682:-
BRCA	cis	rs10833905	0.938	rs2195030	ENSG00000246225.5	RP11-17A1.3	-5.22	2.15e-07	2.49e-05	-0.23	-0.16	Sudden cardiac arrest;	chr11:23074325	chr11:22829380~22945393:+
BRCA	cis	rs6832769	0.961	rs28790098	ENSG00000272969.1	RP11-528I4.2	-5.22	2.15e-07	2.49e-05	-0.19	-0.16	Personality dimensions;	chr4:55531942	chr4:55547112~55547889:+
BRCA	cis	rs848490	0.723	rs62462685	ENSG00000214293.7	APTR	5.22	2.15e-07	2.49e-05	0.19	0.16	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77879316	chr7:77657660~77696265:-
BRCA	cis	rs4908768	0.539	rs1934138	ENSG00000232912.4	RP5-1115A15.1	5.22	2.15e-07	2.5e-05	0.16	0.16	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8585757	chr1:8424645~8434838:+
BRCA	cis	rs35612822	0.798	rs2666290	ENSG00000232485.2	AC098820.3	-5.22	2.15e-07	2.5e-05	-0.2	-0.16	Kidney disease (early stage) in type 1 diabetes;	chr2:216424792	chr2:216479030~216498761:-
BRCA	cis	rs1440410	0.571	rs13116507	ENSG00000250326.1	RP11-284M14.1	-5.22	2.15e-07	2.5e-05	-0.18	-0.16	Ischemic stroke;	chr4:143118285	chr4:142933195~143184861:-
BRCA	cis	rs9788721	0.868	rs17486278	ENSG00000261762.1	RP11-650L12.2	-5.22	2.15e-07	2.5e-05	-0.18	-0.16	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78575140	chr15:78589123~78591276:-
BRCA	cis	rs9300255	0.782	rs12809602	ENSG00000235423.7	RP11-282O18.3	-5.22	2.16e-07	2.5e-05	-0.22	-0.16	Neutrophil percentage of white cells;	chr12:123284369	chr12:123252030~123261483:-
BRCA	cis	rs9393692	0.905	rs9357004	ENSG00000241549.7	GUSBP2	-5.22	2.16e-07	2.5e-05	-0.17	-0.16	Educational attainment;	chr6:26303091	chr6:26871484~26956554:-
BRCA	cis	rs559555	0.523	rs523349	ENSG00000272716.1	RP11-563N4.1	5.22	2.16e-07	2.5e-05	0.19	0.16	Blood metabolite ratios;Blood metabolite levels;	chr2:31580636	chr2:32165046~32165757:-
BRCA	cis	rs4356203	0.87	rs7937176	ENSG00000272034.1	SNORD14A	-5.22	2.16e-07	2.5e-05	-0.16	-0.16	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17258198	chr11:17074654~17074744:-
BRCA	cis	rs10392	0.543	rs12626105	ENSG00000274825.1	RP4-616B8.5	-5.22	2.16e-07	2.5e-05	-0.16	-0.16	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;	chr20:38905939	chr20:38955910~38956547:+
BRCA	cis	rs10392	0.543	rs4812333	ENSG00000274825.1	RP4-616B8.5	-5.22	2.16e-07	2.5e-05	-0.16	-0.16	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;	chr20:38907476	chr20:38955910~38956547:+
BRCA	cis	rs8180040	0.627	rs6442059	ENSG00000276925.1	RP11-708J19.3	-5.22	2.16e-07	2.5e-05	-0.18	-0.16	Colorectal cancer;	chr3:47145585	chr3:47469777~47469987:+
BRCA	cis	rs3733585	0.638	rs6414766	ENSG00000250413.1	RP11-448G15.1	5.22	2.16e-07	2.5e-05	0.21	0.16	Cleft plate (environmental tobacco smoke interaction);	chr4:9954850	chr4:10006482~10009725:+
BRCA	cis	rs2522056	0.932	rs1012793	ENSG00000233006.5	AC034220.3	-5.22	2.16e-07	2.5e-05	-0.13	-0.16	Fibrinogen;Lymphocyte counts;	chr5:132445653	chr5:132311285~132369916:-
BRCA	cis	rs838147	0.844	rs8104897	ENSG00000232871.7	SEC1P	-5.22	2.16e-07	2.5e-05	-0.18	-0.16	Dietary macronutrient intake;	chr19:48746557	chr19:48638071~48682245:+
BRCA	cis	rs2638953	0.64	rs11049723	ENSG00000247934.4	RP11-967K21.1	5.22	2.16e-07	2.5e-05	0.22	0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28575903	chr12:28163298~28190738:-
BRCA	cis	rs8054556	1	rs7204797	ENSG00000273724.1	RP11-347C12.12	-5.22	2.16e-07	2.5e-05	-0.17	-0.16	Autism spectrum disorder or schizophrenia;	chr16:29956694	chr16:30336400~30343336:+
BRCA	cis	rs12571093	0.803	rs61854825	ENSG00000233590.1	RP11-153K11.3	-5.22	2.16e-07	2.51e-05	-0.26	-0.16	Optic nerve measurement (disc area);	chr10:68271535	chr10:68233251~68242379:-
BRCA	cis	rs1979679	0.918	rs78500430	ENSG00000278733.1	RP11-425D17.1	5.22	2.16e-07	2.51e-05	0.2	0.16	Ossification of the posterior longitudinal ligament of the spine;	chr12:28369828	chr12:28185625~28186190:-
BRCA	cis	rs2243480	1	rs1618893	ENSG00000222364.1	RNU6-96P	-5.22	2.16e-07	2.51e-05	-0.28	-0.16	Diabetic kidney disease;	chr7:66631132	chr7:66395191~66395286:+
BRCA	cis	rs10129255	1	rs8012033	ENSG00000211974.3	IGHV2-70	5.22	2.17e-07	2.51e-05	0.17	0.16	Kawasaki disease;	chr14:106678854	chr14:106723574~106724093:-
BRCA	cis	rs4671400	0.571	rs62152270	ENSG00000271889.1	RP11-493E12.1	-5.22	2.17e-07	2.51e-05	-0.24	-0.16	3-hydroxypropylmercapturic acid levels in smokers;	chr2:61267125	chr2:61151433~61162105:-
BRCA	cis	rs13113518	1	rs4865007	ENSG00000223305.1	RN7SKP30	-5.22	2.17e-07	2.51e-05	-0.19	-0.16	Height;	chr4:55537550	chr4:55540502~55540835:-
BRCA	cis	rs357894	1	rs357894	ENSG00000266696.1	RP11-30L3.2	5.22	2.17e-07	2.52e-05	0.17	0.16	Dental caries;	chr18:49053600	chr18:49205912~49208781:+
BRCA	cis	rs7618501	0.633	rs2526751	ENSG00000228008.1	CTD-2330K9.3	-5.22	2.17e-07	2.52e-05	-0.15	-0.16	Intelligence (multi-trait analysis);	chr3:50027434	chr3:49903845~49916937:+
BRCA	cis	rs9308731	0.644	rs3789068	ENSG00000227992.1	AC108463.2	-5.22	2.17e-07	2.52e-05	-0.18	-0.16	Chronic lymphocytic leukemia;	chr2:111151670	chr2:111203964~111206215:-
BRCA	cis	rs2522056	0.808	rs2706373	ENSG00000233006.5	AC034220.3	-5.22	2.17e-07	2.52e-05	-0.13	-0.16	Fibrinogen;Lymphocyte counts;	chr5:132468564	chr5:132311285~132369916:-
BRCA	cis	rs2522056	1	rs2522063	ENSG00000233006.5	AC034220.3	-5.22	2.17e-07	2.52e-05	-0.13	-0.16	Fibrinogen;Lymphocyte counts;	chr5:132469899	chr5:132311285~132369916:-
BRCA	cis	rs2522056	1	rs2706379	ENSG00000233006.5	AC034220.3	-5.22	2.17e-07	2.52e-05	-0.13	-0.16	Fibrinogen;Lymphocyte counts;	chr5:132470043	chr5:132311285~132369916:-
BRCA	cis	rs9287719	0.967	rs4668691	ENSG00000243819.4	RN7SL832P	5.22	2.17e-07	2.52e-05	0.15	0.16	Prostate cancer;	chr2:10600368	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.934	rs10181806	ENSG00000243819.4	RN7SL832P	5.22	2.17e-07	2.52e-05	0.15	0.16	Prostate cancer;	chr2:10601015	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.967	rs11687023	ENSG00000243819.4	RN7SL832P	5.22	2.17e-07	2.52e-05	0.15	0.16	Prostate cancer;	chr2:10601286	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.967	rs10454738	ENSG00000243819.4	RN7SL832P	5.22	2.17e-07	2.52e-05	0.15	0.16	Prostate cancer;	chr2:10601923	chr2:10690344~10692099:+
BRCA	cis	rs1075265	0.73	rs7601692	ENSG00000235937.1	AC008280.1	5.22	2.17e-07	2.52e-05	0.18	0.16	Chronotype;Morning vs. evening chronotype;	chr2:53705532	chr2:54029552~54030682:-
BRCA	cis	rs516805	0.63	rs2816073	ENSG00000279453.1	RP3-425C14.4	-5.22	2.17e-07	2.52e-05	-0.22	-0.16	Lymphocyte counts;	chr6:122106794	chr6:122436789~122439223:-
BRCA	cis	rs516805	0.666	rs2816071	ENSG00000279453.1	RP3-425C14.4	-5.22	2.17e-07	2.52e-05	-0.22	-0.16	Lymphocyte counts;	chr6:122106995	chr6:122436789~122439223:-
BRCA	cis	rs957448	0.554	rs12541408	ENSG00000253175.1	RP11-267M23.6	5.22	2.18e-07	2.52e-05	0.18	0.16	Nonsyndromic cleft lip with cleft palate;	chr8:94573579	chr8:94565036~94565715:+
BRCA	cis	rs8098244	0.928	rs11082828	ENSG00000264745.1	TTC39C-AS1	5.22	2.18e-07	2.52e-05	0.22	0.16	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23881681	chr18:23994213~24015339:-
BRCA	cis	rs6832769	1	rs10016506	ENSG00000272969.1	RP11-528I4.2	-5.22	2.18e-07	2.52e-05	-0.19	-0.16	Personality dimensions;	chr4:55530507	chr4:55547112~55547889:+
BRCA	cis	rs1707322	1	rs4660903	ENSG00000234329.1	RP11-767N6.2	5.22	2.18e-07	2.52e-05	0.16	0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45991929	chr1:45651039~45651826:-
BRCA	cis	rs8114671	0.562	rs2076667	ENSG00000269202.1	RP4-614O4.12	-5.22	2.18e-07	2.52e-05	-0.16	-0.16	Height;	chr20:34919161	chr20:35201747~35203288:-
BRCA	cis	rs10833905	0.938	rs10833927	ENSG00000246225.5	RP11-17A1.3	-5.22	2.18e-07	2.52e-05	-0.23	-0.16	Sudden cardiac arrest;	chr11:23067190	chr11:22829380~22945393:+
BRCA	cis	rs6545883	0.929	rs1186700	ENSG00000270820.4	RP11-355B11.2	5.22	2.18e-07	2.52e-05	0.19	0.16	Tuberculosis;	chr2:61436237	chr2:61471188~61484130:+
BRCA	cis	rs4835473	0.868	rs62337303	ENSG00000249741.2	RP11-673E1.3	5.22	2.18e-07	2.52e-05	0.17	0.16	Immature fraction of reticulocytes;	chr4:143824967	chr4:143911514~143912053:-
BRCA	cis	rs1876905	0.68	rs193281	ENSG00000255389.1	C6orf3	-5.22	2.18e-07	2.53e-05	-0.2	-0.16	Mean corpuscular hemoglobin;	chr6:111166487	chr6:111599875~111602295:+
BRCA	cis	rs7569084	0.64	rs11126039	ENSG00000281920.1	RP11-418H16.1	5.22	2.18e-07	2.53e-05	0.2	0.16	Sum eosinophil basophil counts;	chr2:65457953	chr2:65623272~65628424:+
BRCA	cis	rs1075265	0.783	rs6708095	ENSG00000235937.1	AC008280.1	5.22	2.18e-07	2.53e-05	0.18	0.16	Chronotype;Morning vs. evening chronotype;	chr2:53710365	chr2:54029552~54030682:-
BRCA	cis	rs7487075	0.619	rs10748450	ENSG00000274723.1	RP11-618L22.1	5.22	2.19e-07	2.53e-05	0.2	0.16	Itch intensity from mosquito bite;	chr12:46463319	chr12:46970504~46972155:+
BRCA	cis	rs7772486	0.875	rs2748498	ENSG00000270638.1	RP3-466P17.1	5.22	2.19e-07	2.53e-05	0.19	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145998030	chr6:145735570~145737218:+
BRCA	cis	rs7772486	0.875	rs9322046	ENSG00000270638.1	RP3-466P17.1	5.22	2.19e-07	2.53e-05	0.18	0.16	Lobe attachment (rater-scored or self-reported);	chr6:146072489	chr6:145735570~145737218:+
BRCA	cis	rs11159086	1	rs11159086	ENSG00000270000.1	RP3-449M8.9	5.22	2.19e-07	2.53e-05	0.24	0.16	Advanced glycation end-product levels;	chr14:74495572	chr14:74471930~74472360:-
BRCA	cis	rs1950326	0.515	rs12884221	ENSG00000258526.4	RP11-111A21.1	-5.22	2.19e-07	2.53e-05	-0.21	-0.16	Verbal memory performance (residualized delayed recall level);	chr14:39571372	chr14:39474840~39513780:+
BRCA	cis	rs17508449	0.736	rs76038270	ENSG00000232450.1	RP4-730K3.3	-5.22	2.19e-07	2.53e-05	-0.3	-0.16	Leprosy;	chr1:113696298	chr1:113698884~113699631:-
BRCA	cis	rs10129255	1	rs10129407	ENSG00000280411.1	IGHV1-69-2	-5.22	2.19e-07	2.53e-05	-0.12	-0.16	Kawasaki disease;	chr14:106767956	chr14:106762092~106762588:-
BRCA	cis	rs7618501	0.635	rs34080578	ENSG00000228008.1	CTD-2330K9.3	5.22	2.19e-07	2.53e-05	0.16	0.16	Intelligence (multi-trait analysis);	chr3:49988596	chr3:49903845~49916937:+
BRCA	cis	rs6479891	1	rs9415705	ENSG00000232075.1	MRPL35P2	5.22	2.19e-07	2.54e-05	0.28	0.16	Arthritis (juvenile idiopathic);	chr10:63401790	chr10:63634317~63634827:-
BRCA	cis	rs7674212	0.541	rs2720460	ENSG00000246560.2	RP11-10L12.4	-5.22	2.19e-07	2.54e-05	-0.17	-0.16	Type 2 diabetes;	chr4:103133529	chr4:102828055~102844075:+
BRCA	cis	rs13113518	1	rs13116194	ENSG00000223305.1	RN7SKP30	5.22	2.19e-07	2.54e-05	0.19	0.16	Height;	chr4:55531150	chr4:55540502~55540835:-
BRCA	cis	rs13113518	1	rs13117836	ENSG00000223305.1	RN7SKP30	5.22	2.19e-07	2.54e-05	0.19	0.16	Height;	chr4:55531218	chr4:55540502~55540835:-
BRCA	cis	rs13113518	0.966	rs7668429	ENSG00000223305.1	RN7SKP30	5.22	2.19e-07	2.54e-05	0.19	0.16	Height;	chr4:55531811	chr4:55540502~55540835:-
BRCA	cis	rs7618915	0.547	rs2118540	ENSG00000243224.1	RP5-1157M23.2	-5.22	2.19e-07	2.54e-05	-0.18	-0.16	Bipolar disorder;	chr3:52595370	chr3:52239258~52241097:+
BRCA	cis	rs10504130	0.569	rs4534123	ENSG00000272024.1	RP11-546K22.3	5.22	2.19e-07	2.54e-05	0.23	0.16	Venous thromboembolism (SNP x SNP interaction);	chr8:51765297	chr8:51950284~51950690:+
BRCA	cis	rs13113518	0.812	rs1522114	ENSG00000272969.1	RP11-528I4.2	5.22	2.19e-07	2.54e-05	0.19	0.16	Height;	chr4:55489895	chr4:55547112~55547889:+
BRCA	cis	rs11696845	0.787	rs6031771	ENSG00000276223.1	RP4-781B1.5	-5.22	2.19e-07	2.54e-05	-0.16	-0.16	Obesity-related traits;	chr20:44734949	chr20:44746642~44747201:+
BRCA	cis	rs2051773	0.567	rs7130826	ENSG00000184669.7	OR7E14P	-5.22	2.19e-07	2.54e-05	-0.24	-0.16	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);	chr11:17016246	chr11:17013998~17053024:+
BRCA	cis	rs6439153	0.839	rs2624901	ENSG00000231305.3	RP11-723O4.2	-5.22	2.2e-07	2.54e-05	-0.17	-0.16	Pneumococcal bacteremia;	chr3:128958345	chr3:128861313~128871540:-
BRCA	cis	rs7914558	1	rs7077097	ENSG00000236937.2	PTGES3P4	5.22	2.2e-07	2.54e-05	0.21	0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103185706	chr10:102845595~102845950:+
BRCA	cis	rs9652601	0.719	rs2867880	ENSG00000274038.1	RP11-66H6.4	-5.22	2.2e-07	2.54e-05	-0.17	-0.16	Systemic lupus erythematosus;	chr16:11138000	chr16:11056556~11057034:+
BRCA	cis	rs7577696	0.654	rs212757	ENSG00000272716.1	RP11-563N4.1	5.22	2.2e-07	2.54e-05	0.17	0.16	Inflammatory biomarkers;	chr2:32200009	chr2:32165046~32165757:-
BRCA	cis	rs10510102	0.935	rs10466217	ENSG00000226864.1	ATE1-AS1	5.22	2.2e-07	2.54e-05	0.29	0.16	Breast cancer;	chr10:121860362	chr10:121928312~121951965:+
BRCA	cis	rs2638953	0.924	rs11049610	ENSG00000247934.4	RP11-967K21.1	-5.22	2.2e-07	2.55e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28446674	chr12:28163298~28190738:-
BRCA	cis	rs9311474	0.569	rs7614981	ENSG00000243224.1	RP5-1157M23.2	-5.22	2.2e-07	2.55e-05	-0.17	-0.16	Electroencephalogram traits;	chr3:52532898	chr3:52239258~52241097:+
BRCA	cis	rs7818688	0.929	rs7812312	ENSG00000253528.2	RP11-347C18.4	-5.22	2.2e-07	2.55e-05	-0.24	-0.16	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95008172	chr8:94974573~94974853:-
BRCA	cis	rs10861342	1	rs11112359	ENSG00000257999.1	RP11-61E11.2	-5.22	2.2e-07	2.55e-05	-0.35	-0.16	IgG glycosylation;	chr12:105077883	chr12:105102472~105107179:-
BRCA	cis	rs7617773	0.78	rs36121690	ENSG00000199476.1	Y_RNA	-5.22	2.2e-07	2.55e-05	-0.24	-0.16	Coronary artery disease;	chr3:48304021	chr3:48288587~48288694:+
BRCA	cis	rs1707322	1	rs6657720	ENSG00000234329.1	RP11-767N6.2	5.22	2.2e-07	2.55e-05	0.16	0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45920597	chr1:45651039~45651826:-
BRCA	cis	rs1707322	1	rs7526369	ENSG00000234329.1	RP11-767N6.2	5.22	2.2e-07	2.55e-05	0.16	0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45924888	chr1:45651039~45651826:-
BRCA	cis	rs293748	0.891	rs6861906	ENSG00000250155.1	CTD-2353F22.1	-5.22	2.2e-07	2.55e-05	-0.2	-0.16	Obesity-related traits;	chr5:37075834	chr5:36666214~36725195:-
BRCA	cis	rs1707322	0.721	rs4559551	ENSG00000234329.1	RP11-767N6.2	5.22	2.2e-07	2.55e-05	0.17	0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45701861	chr1:45651039~45651826:-
BRCA	cis	rs8180040	0.966	rs922957	ENSG00000276925.1	RP11-708J19.3	5.22	2.2e-07	2.55e-05	0.18	0.16	Colorectal cancer;	chr3:47380662	chr3:47469777~47469987:+
BRCA	cis	rs5167	0.601	rs73047694	ENSG00000280087.1	CTB-129P6.7	5.22	2.21e-07	2.55e-05	0.22	0.16	Blood protein levels;	chr19:44994594	chr19:44909375~44914968:+
BRCA	cis	rs8054556	1	rs4788195	ENSG00000273724.1	RP11-347C12.12	-5.22	2.21e-07	2.55e-05	-0.18	-0.16	Autism spectrum disorder or schizophrenia;	chr16:29949272	chr16:30336400~30343336:+
BRCA	cis	rs2562456	0.917	rs2562468	ENSG00000268658.4	LINC00664	-5.22	2.21e-07	2.55e-05	-0.25	-0.16	Pain;	chr19:21532048	chr19:21483374~21503238:+
BRCA	cis	rs2562456	0.917	rs2562471	ENSG00000268658.4	LINC00664	-5.22	2.21e-07	2.55e-05	-0.25	-0.16	Pain;	chr19:21533017	chr19:21483374~21503238:+
BRCA	cis	rs12701220	0.894	rs13224488	ENSG00000229043.2	AC091729.9	-5.22	2.21e-07	2.55e-05	-0.25	-0.16	Bronchopulmonary dysplasia;	chr7:1012717	chr7:1160374~1165267:+
BRCA	cis	rs7914558	0.966	rs10883817	ENSG00000236937.2	PTGES3P4	5.22	2.21e-07	2.55e-05	0.2	0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102995674	chr10:102845595~102845950:+
BRCA	cis	rs4907240	0.961	rs12469420	ENSG00000237510.6	AC008268.2	5.22	2.21e-07	2.55e-05	0.23	0.16	Event-related brain oscillations;	chr2:96577568	chr2:95789654~95800166:+
BRCA	cis	rs7301826	1	rs4759787	ENSG00000256250.1	RP11-989F5.1	-5.22	2.21e-07	2.56e-05	-0.34	-0.16	Plasma plasminogen activator levels;	chr12:130805635	chr12:130810606~130812438:+
BRCA	cis	rs875971	0.862	rs4368860	ENSG00000236529.1	RP13-254B10.1	-5.22	2.21e-07	2.56e-05	-0.17	-0.16	Aortic root size;	chr7:66143495	chr7:65840212~65840596:+
BRCA	cis	rs1124769	0.598	rs1438921	ENSG00000259378.1	DCAF13P3	-5.22	2.21e-07	2.56e-05	-0.23	-0.16	Cognitive performance;	chr15:51165905	chr15:50944663~50945996:+
BRCA	cis	rs3822625	0.541	rs112793966	ENSG00000271828.1	CTD-2310F14.1	5.22	2.21e-07	2.56e-05	0.3	0.16	Breast cancer (early onset);	chr5:56908291	chr5:56927874~56929573:+
BRCA	cis	rs853679	0.628	rs9368560	ENSG00000280107.1	AL022393.9	-5.22	2.21e-07	2.56e-05	-0.24	-0.16	Depression;	chr6:28192182	chr6:28170845~28172521:+
BRCA	cis	rs8103033	0.786	rs6508899	ENSG00000268088.1	AC093063.2	5.22	2.21e-07	2.56e-05	0.17	0.16	Obesity-related traits;	chr19:39661982	chr19:39693925~39696258:+
BRCA	cis	rs4950322	1	rs4950429	ENSG00000278811.3	LINC00624	5.22	2.21e-07	2.56e-05	0.22	0.16	Protein quantitative trait loci;	chr1:147400227	chr1:147258885~147517875:-
BRCA	cis	rs4950322	1	rs59498179	ENSG00000278811.3	LINC00624	5.22	2.21e-07	2.56e-05	0.22	0.16	Protein quantitative trait loci;	chr1:147400417	chr1:147258885~147517875:-
BRCA	cis	rs2790457	0.917	rs1265831	ENSG00000254635.4	WAC-AS1	-5.22	2.21e-07	2.56e-05	-0.19	-0.16	Multiple myeloma;	chr10:28623921	chr10:28522652~28532743:-
BRCA	cis	rs2919009	0.607	rs11199682	ENSG00000271670.1	RP11-95I16.4	5.22	2.21e-07	2.56e-05	0.21	0.16	Obesity-related traits;	chr10:120958339	chr10:120879256~120880667:-
BRCA	cis	rs2153535	0.563	rs1737584	ENSG00000251164.1	HULC	-5.22	2.22e-07	2.56e-05	-0.2	-0.16	Motion sickness;	chr6:8536509	chr6:8652137~8653846:+
BRCA	cis	rs2638953	0.924	rs79712894	ENSG00000247934.4	RP11-967K21.1	-5.22	2.22e-07	2.56e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28239400	chr12:28163298~28190738:-
BRCA	cis	rs115769866	0.609	rs2191037	ENSG00000216901.1	AL022393.7	5.21	2.22e-07	2.56e-05	0.23	0.16	Bipolar disorder;	chr6:28499211	chr6:28176188~28176674:+
BRCA	cis	rs4713118	0.513	rs149897	ENSG00000280107.1	AL022393.9	-5.21	2.22e-07	2.56e-05	-0.22	-0.16	Parkinson's disease;	chr6:28038872	chr6:28170845~28172521:+
BRCA	cis	rs4713118	0.513	rs156734	ENSG00000280107.1	AL022393.9	-5.21	2.22e-07	2.56e-05	-0.22	-0.16	Parkinson's disease;	chr6:28039579	chr6:28170845~28172521:+
BRCA	cis	rs13113518	1	rs7660980	ENSG00000249700.7	SRD5A3-AS1	-5.21	2.22e-07	2.56e-05	-0.2	-0.16	Height;	chr4:55542948	chr4:55363971~55395847:-
BRCA	cis	rs4660214	0.756	rs11205823	ENSG00000237624.1	OXCT2P1	-5.21	2.22e-07	2.56e-05	-0.19	-0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39248566	chr1:39514956~39516490:+
BRCA	cis	rs9287719	0.967	rs6432116	ENSG00000243819.4	RN7SL832P	5.21	2.22e-07	2.56e-05	0.15	0.16	Prostate cancer;	chr2:10608489	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.967	rs2110776	ENSG00000243819.4	RN7SL832P	5.21	2.22e-07	2.56e-05	0.15	0.16	Prostate cancer;	chr2:10608684	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.967	rs2110778	ENSG00000243819.4	RN7SL832P	5.21	2.22e-07	2.56e-05	0.15	0.16	Prostate cancer;	chr2:10608844	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.967	rs6432117	ENSG00000243819.4	RN7SL832P	5.21	2.22e-07	2.56e-05	0.15	0.16	Prostate cancer;	chr2:10609233	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.967	rs6432118	ENSG00000243819.4	RN7SL832P	5.21	2.22e-07	2.56e-05	0.15	0.16	Prostate cancer;	chr2:10609315	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.935	rs728283	ENSG00000243819.4	RN7SL832P	5.21	2.22e-07	2.56e-05	0.15	0.16	Prostate cancer;	chr2:10609964	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.967	rs728282	ENSG00000243819.4	RN7SL832P	5.21	2.22e-07	2.56e-05	0.15	0.16	Prostate cancer;	chr2:10610177	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.967	rs728281	ENSG00000243819.4	RN7SL832P	5.21	2.22e-07	2.56e-05	0.15	0.16	Prostate cancer;	chr2:10610229	chr2:10690344~10692099:+
BRCA	cis	rs734999	0.967	rs6667605	ENSG00000238164.5	RP3-395M20.8	-5.21	2.22e-07	2.57e-05	-0.12	-0.16	Ulcerative colitis;	chr1:2571341	chr1:2549920~2557031:-
BRCA	cis	rs734999	0.967	rs6672381	ENSG00000238164.5	RP3-395M20.8	-5.21	2.22e-07	2.57e-05	-0.12	-0.16	Ulcerative colitis;	chr1:2571395	chr1:2549920~2557031:-
BRCA	cis	rs7577696	0.649	rs212762	ENSG00000272716.1	RP11-563N4.1	5.21	2.22e-07	2.57e-05	0.17	0.16	Inflammatory biomarkers;	chr2:32204428	chr2:32165046~32165757:-
BRCA	cis	rs897984	0.568	rs8050107	ENSG00000260911.2	RP11-196G11.2	-5.21	2.22e-07	2.57e-05	-0.16	-0.16	Dementia with Lewy bodies;	chr16:30882130	chr16:31043150~31049868:+
BRCA	cis	rs2921036	0.503	rs7817832	ENSG00000253893.2	FAM85B	-5.21	2.22e-07	2.57e-05	-0.23	-0.16	Neuroticism;	chr8:8523311	chr8:8167819~8226614:-
BRCA	cis	rs9659323	0.613	rs72705339	ENSG00000231365.4	RP11-418J17.1	-5.21	2.22e-07	2.57e-05	-0.2	-0.16	Body mass index;	chr1:118929246	chr1:119140396~119275973:+
BRCA	cis	rs2179367	0.568	rs6932778	ENSG00000216906.2	RP11-350J20.9	5.21	2.22e-07	2.57e-05	0.24	0.16	Dupuytren's disease;	chr6:149328293	chr6:149904243~149906418:+
BRCA	cis	rs10899021	0.92	rs7112664	ENSG00000279353.1	RP11-864N7.4	5.21	2.22e-07	2.57e-05	0.31	0.16	Response to metformin (IC50);	chr11:74637381	chr11:74698231~74699658:-
BRCA	cis	rs4781563	0.81	rs3136160	ENSG00000242307.1	RPS26P52	-5.21	2.22e-07	2.57e-05	-0.18	-0.16	Bilirubin levels;	chr16:13937206	chr16:13922332~13922679:-
BRCA	cis	rs7635879	0.716	rs1078814	ENSG00000230102.6	RP11-407B7.1	5.21	2.22e-07	2.57e-05	0.19	0.16	Breastfeeding duration;	chr3:194015242	chr3:194005259~194070970:-
BRCA	cis	rs7577696	0.962	rs212745	ENSG00000272716.1	RP11-563N4.1	5.21	2.23e-07	2.57e-05	0.18	0.16	Inflammatory biomarkers;	chr2:32187763	chr2:32165046~32165757:-
BRCA	cis	rs10129255	0.957	rs10142859	ENSG00000280411.1	IGHV1-69-2	-5.21	2.23e-07	2.57e-05	-0.11	-0.16	Kawasaki disease;	chr14:106782238	chr14:106762092~106762588:-
BRCA	cis	rs2562456	0.833	rs62109229	ENSG00000268535.1	RP11-420K14.3	5.21	2.23e-07	2.57e-05	0.23	0.16	Pain;	chr19:21354380	chr19:21709522~21710191:+
BRCA	cis	rs2562456	0.833	rs11670815	ENSG00000268535.1	RP11-420K14.3	5.21	2.23e-07	2.57e-05	0.23	0.16	Pain;	chr19:21356515	chr19:21709522~21710191:+
BRCA	cis	rs2562456	0.833	rs11666540	ENSG00000268535.1	RP11-420K14.3	5.21	2.23e-07	2.57e-05	0.23	0.16	Pain;	chr19:21356550	chr19:21709522~21710191:+
BRCA	cis	rs2562456	0.833	rs11667361	ENSG00000268535.1	RP11-420K14.3	5.21	2.23e-07	2.57e-05	0.23	0.16	Pain;	chr19:21356580	chr19:21709522~21710191:+
BRCA	cis	rs7191700	0.601	rs243329	ENSG00000262703.1	RP11-485G7.6	5.21	2.23e-07	2.57e-05	0.16	0.16	Multiple sclerosis;	chr16:11258456	chr16:11348143~11349321:-
BRCA	cis	rs7674212	0.833	rs61075040	ENSG00000251288.2	RP11-10L12.2	-5.21	2.23e-07	2.58e-05	-0.19	-0.16	Type 2 diabetes;	chr4:103052804	chr4:102751401~102752641:+
BRCA	cis	rs12468226	0.935	rs75597391	ENSG00000226261.1	AC064836.3	5.21	2.23e-07	2.58e-05	0.27	0.16	Urate levels;	chr2:202398850	chr2:202336024~202336727:-
BRCA	cis	rs12477438	0.52	rs4347885	ENSG00000231822.1	AC019097.7	5.21	2.23e-07	2.58e-05	0.16	0.16	Chronic sinus infection;	chr2:99187544	chr2:99102018~99102752:+
BRCA	cis	rs1707322	1	rs11211243	ENSG00000234329.1	RP11-767N6.2	5.21	2.23e-07	2.58e-05	0.16	0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45989761	chr1:45651039~45651826:-
BRCA	cis	rs1707322	1	rs11211244	ENSG00000234329.1	RP11-767N6.2	5.21	2.23e-07	2.58e-05	0.16	0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45991001	chr1:45651039~45651826:-
BRCA	cis	rs793571	0.504	rs6494034	ENSG00000259250.1	RP11-50C13.1	-5.21	2.23e-07	2.58e-05	-0.27	-0.16	Schizophrenia;	chr15:58717912	chr15:58587507~58591676:+
BRCA	cis	rs13113518	0.812	rs4865003	ENSG00000272969.1	RP11-528I4.2	5.21	2.23e-07	2.58e-05	0.19	0.16	Height;	chr4:55514802	chr4:55547112~55547889:+
BRCA	cis	rs13113518	0.756	rs12510275	ENSG00000272969.1	RP11-528I4.2	5.21	2.23e-07	2.58e-05	0.19	0.16	Height;	chr4:55516548	chr4:55547112~55547889:+
BRCA	cis	rs13113518	0.812	rs12510327	ENSG00000272969.1	RP11-528I4.2	5.21	2.23e-07	2.58e-05	0.19	0.16	Height;	chr4:55516744	chr4:55547112~55547889:+
BRCA	cis	rs801193	0.569	rs7782587	ENSG00000273448.1	RP11-166O4.6	5.21	2.23e-07	2.58e-05	0.15	0.16	Aortic root size;	chr7:66701485	chr7:67333047~67334383:+
BRCA	cis	rs9907295	0.901	rs78905197	ENSG00000270977.1	AC015849.16	-5.21	2.24e-07	2.58e-05	-0.29	-0.16	Fibroblast growth factor basic levels;	chr17:35850189	chr17:35893707~35911023:-
BRCA	cis	rs11098499	0.863	rs3775858	ENSG00000249244.1	RP11-548H18.2	5.21	2.24e-07	2.58e-05	0.19	0.16	Corneal astigmatism;	chr4:119564873	chr4:119391831~119395335:-
BRCA	cis	rs9309473	0.606	rs78941213	ENSG00000163016.8	ALMS1P	5.21	2.24e-07	2.58e-05	0.27	0.16	Metabolite levels;	chr2:73658010	chr2:73644919~73685576:+
BRCA	cis	rs6832769	0.925	rs4865018	ENSG00000272969.1	RP11-528I4.2	-5.21	2.24e-07	2.58e-05	-0.19	-0.16	Personality dimensions;	chr4:55591024	chr4:55547112~55547889:+
BRCA	cis	rs6772849	0.896	rs9816260	ENSG00000242551.2	POU5F1P6	-5.21	2.24e-07	2.59e-05	-0.2	-0.16	Monocyte percentage of white cells;Monocyte count;	chr3:128633240	chr3:128674735~128677005:-
BRCA	cis	rs4908768	0.539	rs4480384	ENSG00000270282.1	RP5-1115A15.2	5.21	2.24e-07	2.59e-05	0.17	0.16	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8599655	chr1:8512653~8513021:+
BRCA	cis	rs1075265	0.584	rs7558126	ENSG00000235937.1	AC008280.1	5.21	2.24e-07	2.59e-05	0.18	0.16	Chronotype;Morning vs. evening chronotype;	chr2:54053847	chr2:54029552~54030682:-
BRCA	cis	rs6840360	0.642	rs1596290	ENSG00000278978.1	RP11-164P12.5	-5.21	2.24e-07	2.59e-05	-0.18	-0.16	Intelligence (multi-trait analysis);	chr4:151489388	chr4:151669786~151670503:+
BRCA	cis	rs35740288	0.929	rs11636821	ENSG00000259407.1	RP11-158M2.3	-5.21	2.24e-07	2.59e-05	-0.21	-0.16	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85762774	chr15:85744109~85750281:-
BRCA	cis	rs35740288	0.929	rs11630684	ENSG00000259407.1	RP11-158M2.3	-5.21	2.24e-07	2.59e-05	-0.21	-0.16	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85763025	chr15:85744109~85750281:-
BRCA	cis	rs7772486	0.754	rs9497419	ENSG00000270638.1	RP3-466P17.1	5.21	2.24e-07	2.59e-05	0.18	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145821473	chr6:145735570~145737218:+
BRCA	cis	rs10861342	1	rs703683	ENSG00000257999.1	RP11-61E11.2	-5.21	2.24e-07	2.59e-05	-0.32	-0.16	IgG glycosylation;	chr12:105173357	chr12:105102472~105107179:-
BRCA	cis	rs7914558	0.966	rs4917997	ENSG00000236937.2	PTGES3P4	5.21	2.24e-07	2.59e-05	0.21	0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103185456	chr10:102845595~102845950:+
BRCA	cis	rs875971	0.862	rs4718319	ENSG00000236529.1	RP13-254B10.1	-5.21	2.24e-07	2.59e-05	-0.18	-0.16	Aortic root size;	chr7:66187797	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.723	rs28391294	ENSG00000236529.1	RP13-254B10.1	-5.21	2.24e-07	2.59e-05	-0.18	-0.16	Aortic root size;	chr7:66189328	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.83	rs6967708	ENSG00000236529.1	RP13-254B10.1	-5.21	2.24e-07	2.59e-05	-0.18	-0.16	Aortic root size;	chr7:66192326	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.895	rs7782806	ENSG00000236529.1	RP13-254B10.1	-5.21	2.24e-07	2.59e-05	-0.18	-0.16	Aortic root size;	chr7:66192910	chr7:65840212~65840596:+
BRCA	cis	rs6430585	0.528	rs114760827	ENSG00000224043.6	CCNT2-AS1	-5.21	2.24e-07	2.59e-05	-0.28	-0.16	Corneal structure;	chr2:135903540	chr2:134735464~134918710:-
BRCA	cis	rs2638953	0.886	rs11049594	ENSG00000247934.4	RP11-967K21.1	5.21	2.24e-07	2.59e-05	0.22	0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28430368	chr12:28163298~28190738:-
BRCA	cis	rs9341808	0.718	rs2179842	ENSG00000272129.1	RP11-250B2.6	5.21	2.25e-07	2.59e-05	0.2	0.16	Sitting height ratio;	chr6:80269336	chr6:80355424~80356859:+
BRCA	cis	rs13113518	0.812	rs12501746	ENSG00000272969.1	RP11-528I4.2	5.21	2.25e-07	2.59e-05	0.19	0.16	Height;	chr4:55437438	chr4:55547112~55547889:+
BRCA	cis	rs2562456	0.833	rs56187954	ENSG00000268535.1	RP11-420K14.3	5.21	2.25e-07	2.59e-05	0.23	0.16	Pain;	chr19:21345258	chr19:21709522~21710191:+
BRCA	cis	rs9291683	0.597	rs11722989	ENSG00000250413.1	RP11-448G15.1	5.21	2.25e-07	2.59e-05	0.21	0.16	Bone mineral density;	chr4:10124515	chr4:10006482~10009725:+
BRCA	cis	rs7617773	0.851	rs6775179	ENSG00000199476.1	Y_RNA	-5.21	2.25e-07	2.6e-05	-0.22	-0.16	Coronary artery disease;	chr3:48271928	chr3:48288587~48288694:+
BRCA	cis	rs2522056	1	rs2706395	ENSG00000233006.5	AC034220.3	-5.21	2.26e-07	2.6e-05	-0.13	-0.16	Fibrinogen;Lymphocyte counts;	chr5:132461111	chr5:132311285~132369916:-
BRCA	cis	rs11159086	0.793	rs1029701	ENSG00000270000.1	RP3-449M8.9	5.21	2.26e-07	2.61e-05	0.24	0.16	Advanced glycation end-product levels;	chr14:74474112	chr14:74471930~74472360:-
BRCA	cis	rs950880	0.767	rs6543119	ENSG00000234389.1	AC007278.3	-5.21	2.26e-07	2.61e-05	-0.15	-0.16	Serum protein levels (sST2);	chr2:102346612	chr2:102438713~102440475:+
BRCA	cis	rs950880	0.767	rs13017455	ENSG00000234389.1	AC007278.3	-5.21	2.26e-07	2.61e-05	-0.15	-0.16	Serum protein levels (sST2);	chr2:102348282	chr2:102438713~102440475:+
BRCA	cis	rs2898681	0.65	rs6840325	ENSG00000248375.1	RP11-177B4.1	-5.21	2.26e-07	2.61e-05	-0.23	-0.16	Optic nerve measurement (cup area);	chr4:52809382	chr4:52720081~52720831:-
BRCA	cis	rs1383484	1	rs4465575	ENSG00000230373.7	GOLGA6L5P	-5.21	2.26e-07	2.61e-05	-0.18	-0.16	Height;	chr15:83844160	chr15:84507885~84516814:-
BRCA	cis	rs2243480	1	rs160643	ENSG00000232559.3	GS1-124K5.12	5.21	2.26e-07	2.61e-05	0.28	0.16	Diabetic kidney disease;	chr7:66093235	chr7:66554588~66576923:-
BRCA	cis	rs7247513	0.701	rs8107642	ENSG00000213290.4	PGK1P2	-5.21	2.26e-07	2.61e-05	-0.21	-0.16	Bipolar disorder;	chr19:12655556	chr19:12559571~12561105:+
BRCA	cis	rs2562456	0.833	rs2562487	ENSG00000268535.1	RP11-420K14.3	5.21	2.26e-07	2.61e-05	0.23	0.16	Pain;	chr19:21468580	chr19:21709522~21710191:+
BRCA	cis	rs859767	0.54	rs17789633	ENSG00000224043.6	CCNT2-AS1	-5.21	2.26e-07	2.61e-05	-0.22	-0.16	Neuroticism;	chr2:134628904	chr2:134735464~134918710:-
BRCA	cis	rs73193808	0.951	rs1999323	ENSG00000236056.1	GAPDHP14	-5.21	2.26e-07	2.61e-05	-0.23	-0.16	Coronary artery disease;	chr21:29161807	chr21:29222321~29223257:+
BRCA	cis	rs7772486	0.905	rs9373486	ENSG00000270638.1	RP3-466P17.1	-5.21	2.26e-07	2.61e-05	-0.18	-0.16	Lobe attachment (rater-scored or self-reported);	chr6:146124888	chr6:145735570~145737218:+
BRCA	cis	rs12571093	0.803	rs2241969	ENSG00000233590.1	RP11-153K11.3	-5.21	2.26e-07	2.61e-05	-0.26	-0.16	Optic nerve measurement (disc area);	chr10:68271253	chr10:68233251~68242379:-
BRCA	cis	rs7246657	0.525	rs10405238	ENSG00000267422.1	CTD-2554C21.1	-5.21	2.26e-07	2.61e-05	-0.26	-0.16	Coronary artery calcification;	chr19:36997153	chr19:37779686~37792865:+
BRCA	cis	rs4388249	0.687	rs10038829	ENSG00000271849.1	CTC-332L22.1	5.21	2.26e-07	2.61e-05	0.2	0.16	Schizophrenia;	chr5:109769002	chr5:109687802~109688329:-
BRCA	cis	rs7200543	1	rs4985154	ENSG00000260735.1	RP11-72I8.1	-5.21	2.26e-07	2.61e-05	-0.19	-0.16	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15037785	chr16:15094411~15109197:+
BRCA	cis	rs4908768	0.501	rs1463051	ENSG00000232912.4	RP5-1115A15.1	-5.21	2.26e-07	2.61e-05	-0.15	-0.16	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8536834	chr1:8424645~8434838:+
BRCA	cis	rs7577696	0.889	rs212730	ENSG00000272716.1	RP11-563N4.1	5.21	2.26e-07	2.61e-05	0.18	0.16	Inflammatory biomarkers;	chr2:32246604	chr2:32165046~32165757:-
BRCA	cis	rs2638953	0.64	rs10843208	ENSG00000247934.4	RP11-967K21.1	-5.21	2.27e-07	2.62e-05	-0.21	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28572171	chr12:28163298~28190738:-
BRCA	cis	rs910316	0.763	rs175042	ENSG00000279594.1	RP11-950C14.10	-5.21	2.27e-07	2.62e-05	-0.18	-0.16	Height;	chr14:75004130	chr14:75011269~75012851:-
BRCA	cis	rs4356203	0.87	rs10832751	ENSG00000272034.1	SNORD14A	-5.21	2.27e-07	2.62e-05	-0.16	-0.16	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17252469	chr11:17074654~17074744:-
BRCA	cis	rs11955398	0.625	rs6874072	ENSG00000215032.2	GNL3LP1	5.21	2.27e-07	2.62e-05	0.2	0.16	Intelligence (multi-trait analysis);	chr5:60691855	chr5:60891935~60893577:-
BRCA	cis	rs2251381	0.722	rs2251278	ENSG00000176054.6	RPL23P2	5.21	2.27e-07	2.62e-05	0.19	0.16	Selective IgA deficiency;	chr21:29156913	chr21:28997613~28998033:-
BRCA	cis	rs9287719	0.967	rs715247	ENSG00000243819.4	RN7SL832P	5.21	2.27e-07	2.62e-05	0.15	0.16	Prostate cancer;	chr2:10596165	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.967	rs715246	ENSG00000243819.4	RN7SL832P	5.21	2.27e-07	2.62e-05	0.15	0.16	Prostate cancer;	chr2:10596229	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.967	rs2010073	ENSG00000243819.4	RN7SL832P	5.21	2.27e-07	2.62e-05	0.15	0.16	Prostate cancer;	chr2:10596352	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.967	rs2010080	ENSG00000243819.4	RN7SL832P	5.21	2.27e-07	2.62e-05	0.15	0.16	Prostate cancer;	chr2:10596426	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.901	rs6432109	ENSG00000243819.4	RN7SL832P	5.21	2.27e-07	2.62e-05	0.15	0.16	Prostate cancer;	chr2:10596695	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.934	rs6432110	ENSG00000243819.4	RN7SL832P	5.21	2.27e-07	2.62e-05	0.15	0.16	Prostate cancer;	chr2:10597892	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.967	rs7605461	ENSG00000243819.4	RN7SL832P	5.21	2.27e-07	2.62e-05	0.15	0.16	Prostate cancer;	chr2:10598008	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.967	rs7593496	ENSG00000243819.4	RN7SL832P	5.21	2.27e-07	2.62e-05	0.15	0.16	Prostate cancer;	chr2:10598050	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.967	rs7608498	ENSG00000243819.4	RN7SL832P	5.21	2.27e-07	2.62e-05	0.15	0.16	Prostate cancer;	chr2:10598302	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.967	rs7582775	ENSG00000243819.4	RN7SL832P	5.21	2.27e-07	2.62e-05	0.15	0.16	Prostate cancer;	chr2:10598323	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.967	rs6750891	ENSG00000243819.4	RN7SL832P	5.21	2.27e-07	2.62e-05	0.15	0.16	Prostate cancer;	chr2:10598437	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.967	rs6733416	ENSG00000243819.4	RN7SL832P	5.21	2.27e-07	2.62e-05	0.15	0.16	Prostate cancer;	chr2:10598558	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.967	rs6751398	ENSG00000243819.4	RN7SL832P	5.21	2.27e-07	2.62e-05	0.15	0.16	Prostate cancer;	chr2:10598846	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.901	rs13034017	ENSG00000243819.4	RN7SL832P	5.21	2.27e-07	2.62e-05	0.15	0.16	Prostate cancer;	chr2:10599466	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.967	rs13034061	ENSG00000243819.4	RN7SL832P	5.21	2.27e-07	2.62e-05	0.15	0.16	Prostate cancer;	chr2:10599525	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.935	rs7600495	ENSG00000243819.4	RN7SL832P	5.21	2.27e-07	2.62e-05	0.15	0.16	Prostate cancer;	chr2:10599674	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.967	rs7600587	ENSG00000243819.4	RN7SL832P	5.21	2.27e-07	2.62e-05	0.15	0.16	Prostate cancer;	chr2:10599725	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.839	rs7600695	ENSG00000243819.4	RN7SL832P	5.21	2.27e-07	2.62e-05	0.15	0.16	Prostate cancer;	chr2:10599819	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.967	rs7587114	ENSG00000243819.4	RN7SL832P	5.21	2.27e-07	2.62e-05	0.15	0.16	Prostate cancer;	chr2:10599837	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.967	rs7600728	ENSG00000243819.4	RN7SL832P	5.21	2.27e-07	2.62e-05	0.15	0.16	Prostate cancer;	chr2:10599873	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.967	rs7600820	ENSG00000243819.4	RN7SL832P	5.21	2.27e-07	2.62e-05	0.15	0.16	Prostate cancer;	chr2:10599918	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.967	rs7587231	ENSG00000243819.4	RN7SL832P	5.21	2.27e-07	2.62e-05	0.15	0.16	Prostate cancer;	chr2:10599967	chr2:10690344~10692099:+
BRCA	cis	rs7246657	0.525	rs10410594	ENSG00000267422.1	CTD-2554C21.1	-5.21	2.27e-07	2.62e-05	-0.26	-0.16	Coronary artery calcification;	chr19:36986856	chr19:37779686~37792865:+
BRCA	cis	rs9291683	0.679	rs2241483	ENSG00000250413.1	RP11-448G15.1	5.21	2.27e-07	2.62e-05	0.2	0.16	Bone mineral density;	chr4:10098207	chr4:10006482~10009725:+
BRCA	cis	rs987360	0.835	rs4262034	ENSG00000248869.4	RP11-138I17.1	5.21	2.28e-07	2.63e-05	0.16	0.16	Temperament;	chr4:137273195	chr4:136796722~137212799:-
BRCA	cis	rs987360	0.745	rs1946359	ENSG00000248869.4	RP11-138I17.1	5.21	2.28e-07	2.63e-05	0.16	0.16	Temperament;	chr4:137273622	chr4:136796722~137212799:-
BRCA	cis	rs295490	0.748	rs77036655	ENSG00000272656.1	RP11-219D15.3	5.21	2.28e-07	2.63e-05	0.36	0.16	PR interval in Tripanosoma cruzi seropositivity;	chr3:139436231	chr3:139349024~139349371:-
BRCA	cis	rs2732480	0.577	rs2450994	ENSG00000226413.2	OR8T1P	5.21	2.28e-07	2.63e-05	0.21	0.16	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48328049	chr12:48442030~48442947:-
BRCA	cis	rs66887589	0.72	rs2036858	ENSG00000245958.5	RP11-33B1.1	-5.21	2.28e-07	2.63e-05	-0.14	-0.16	Diastolic blood pressure;	chr4:119328082	chr4:119454791~119552025:+
BRCA	cis	rs5758511	0.68	rs739146	ENSG00000205702.9	CYP2D7	5.21	2.28e-07	2.63e-05	0.16	0.16	Birth weight;	chr22:42264408	chr22:42140203~42144577:-
BRCA	cis	rs7577696	0.886	rs659239	ENSG00000272716.1	RP11-563N4.1	5.21	2.28e-07	2.63e-05	0.18	0.16	Inflammatory biomarkers;	chr2:32259500	chr2:32165046~32165757:-
BRCA	cis	rs11168351	0.833	rs6580652	ENSG00000273765.1	RP11-370I10.11	-5.21	2.28e-07	2.63e-05	-0.19	-0.16	Bipolar disorder and schizophrenia;	chr12:48053322	chr12:48360920~48361377:+
BRCA	cis	rs9307551	0.584	rs13118848	ENSG00000250334.4	LINC00989	-5.21	2.28e-07	2.63e-05	-0.22	-0.16	Refractive error;	chr4:79525215	chr4:79492416~79576460:+
BRCA	cis	rs62025270	0.632	rs62022918	ENSG00000259295.5	CSPG4P12	-5.21	2.28e-07	2.63e-05	-0.24	-0.16	Idiopathic pulmonary fibrosis;	chr15:85675053	chr15:85191438~85213905:+
BRCA	cis	rs2998286	0.723	rs332189	ENSG00000254635.4	WAC-AS1	-5.21	2.28e-07	2.63e-05	-0.23	-0.16	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28628292	chr10:28522652~28532743:-
BRCA	cis	rs3733585	0.673	rs4467563	ENSG00000250413.1	RP11-448G15.1	5.21	2.28e-07	2.63e-05	0.21	0.16	Cleft plate (environmental tobacco smoke interaction);	chr4:9951836	chr4:10006482~10009725:+
BRCA	cis	rs3733585	0.673	rs4467564	ENSG00000250413.1	RP11-448G15.1	5.21	2.28e-07	2.63e-05	0.21	0.16	Cleft plate (environmental tobacco smoke interaction);	chr4:9951848	chr4:10006482~10009725:+
BRCA	cis	rs3733585	0.605	rs7656624	ENSG00000250413.1	RP11-448G15.1	5.21	2.28e-07	2.63e-05	0.21	0.16	Cleft plate (environmental tobacco smoke interaction);	chr4:10119473	chr4:10006482~10009725:+
BRCA	cis	rs516805	0.63	rs2816072	ENSG00000279453.1	RP3-425C14.4	-5.21	2.29e-07	2.64e-05	-0.22	-0.16	Lymphocyte counts;	chr6:122106871	chr6:122436789~122439223:-
BRCA	cis	rs13113518	0.966	rs11133387	ENSG00000223305.1	RN7SKP30	5.21	2.29e-07	2.64e-05	0.19	0.16	Height;	chr4:55475130	chr4:55540502~55540835:-
BRCA	cis	rs13113518	1	rs4864999	ENSG00000223305.1	RN7SKP30	5.21	2.29e-07	2.64e-05	0.19	0.16	Height;	chr4:55476736	chr4:55540502~55540835:-
BRCA	cis	rs13113518	0.966	rs10517344	ENSG00000223305.1	RN7SKP30	5.21	2.29e-07	2.64e-05	0.19	0.16	Height;	chr4:55477545	chr4:55540502~55540835:-
BRCA	cis	rs7923609	0.875	rs6479877	ENSG00000232075.1	MRPL35P2	-5.21	2.29e-07	2.64e-05	-0.2	-0.16	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63118358	chr10:63634317~63634827:-
BRCA	cis	rs523522	0.962	rs2168319	ENSG00000278344.1	RP11-18C24.8	5.21	2.29e-07	2.64e-05	0.21	0.16	High light scatter reticulocyte count;	chr12:120495414	chr12:120500735~120501090:-
BRCA	cis	rs7226408	0.857	rs17652483	ENSG00000267707.2	RP11-95O2.5	5.21	2.29e-07	2.64e-05	0.24	0.16	Obesity-related traits;	chr18:36902307	chr18:37243776~37247506:+
BRCA	cis	rs250585	0.736	rs250578	ENSG00000260136.4	CTD-2270L9.4	5.21	2.29e-07	2.64e-05	0.16	0.16	Egg allergy;	chr16:23415789	chr16:23452758~23457606:+
BRCA	cis	rs9287719	0.967	rs4519489	ENSG00000243819.4	RN7SL832P	5.21	2.29e-07	2.64e-05	0.15	0.16	Prostate cancer;	chr2:10598961	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.967	rs4453662	ENSG00000243819.4	RN7SL832P	5.21	2.29e-07	2.64e-05	0.15	0.16	Prostate cancer;	chr2:10599002	chr2:10690344~10692099:+
BRCA	cis	rs9840812	0.728	rs665200	ENSG00000239213.4	NCK1-AS1	5.21	2.29e-07	2.64e-05	0.19	0.16	Fibrinogen levels;	chr3:136276174	chr3:136841726~136862054:-
BRCA	cis	rs1707322	1	rs4660336	ENSG00000234329.1	RP11-767N6.2	-5.21	2.29e-07	2.64e-05	-0.16	-0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46022304	chr1:45651039~45651826:-
BRCA	cis	rs9868809	0.881	rs13063312	ENSG00000270441.1	RP11-694I15.7	5.21	2.29e-07	2.64e-05	0.31	0.16	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48624552	chr3:49140086~49160851:-
BRCA	cis	rs2834188	0.961	rs8130807	ENSG00000272659.1	AP000295.10	-5.21	2.29e-07	2.64e-05	-0.24	-0.16	Narcolepsy;	chr21:33317708	chr21:33309491~33310181:+
BRCA	cis	rs7577696	0.889	rs212737	ENSG00000272716.1	RP11-563N4.1	5.21	2.3e-07	2.65e-05	0.18	0.16	Inflammatory biomarkers;	chr2:32249222	chr2:32165046~32165757:-
BRCA	cis	rs12712135	0.677	rs11678721	ENSG00000234389.1	AC007278.3	-5.21	2.3e-07	2.65e-05	-0.14	-0.16	Blood protein levels;	chr2:102456778	chr2:102438713~102440475:+
BRCA	cis	rs12712135	0.709	rs11677555	ENSG00000234389.1	AC007278.3	-5.21	2.3e-07	2.65e-05	-0.14	-0.16	Blood protein levels;	chr2:102456833	chr2:102438713~102440475:+
BRCA	cis	rs12712135	0.709	rs6705498	ENSG00000234389.1	AC007278.3	-5.21	2.3e-07	2.65e-05	-0.14	-0.16	Blood protein levels;	chr2:102460210	chr2:102438713~102440475:+
BRCA	cis	rs12712135	0.709	rs6719196	ENSG00000234389.1	AC007278.3	-5.21	2.3e-07	2.65e-05	-0.14	-0.16	Blood protein levels;	chr2:102460428	chr2:102438713~102440475:+
BRCA	cis	rs6840258	0.891	rs3733377	ENSG00000251411.1	RP11-397E7.4	5.21	2.3e-07	2.65e-05	0.22	0.16	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87108330	chr4:86913266~86914817:-
BRCA	cis	rs1440410	0.571	rs10471101	ENSG00000250326.1	RP11-284M14.1	-5.21	2.3e-07	2.65e-05	-0.18	-0.16	Ischemic stroke;	chr4:143110775	chr4:142933195~143184861:-
BRCA	cis	rs4671400	0.571	rs4672428	ENSG00000271889.1	RP11-493E12.1	-5.21	2.3e-07	2.65e-05	-0.25	-0.16	3-hydroxypropylmercapturic acid levels in smokers;	chr2:61251362	chr2:61151433~61162105:-
BRCA	cis	rs2749097	0.609	rs2269239	ENSG00000244256.3	RN7SL130P	5.21	2.3e-07	2.65e-05	0.21	0.16	Alcohol consumption (transferrin glycosylation);	chr1:63643688	chr1:63655743~63656047:+
BRCA	cis	rs2562456	0.917	rs2681376	ENSG00000268658.4	LINC00664	-5.21	2.3e-07	2.65e-05	-0.25	-0.16	Pain;	chr19:21532723	chr19:21483374~21503238:+
BRCA	cis	rs7620503	1	rs2173608	ENSG00000228221.4	LINC00578	5.21	2.3e-07	2.65e-05	0.18	0.16	Corneal structure;	chr3:177584550	chr3:177441921~177752305:+
BRCA	cis	rs10911251	0.546	rs1062044	ENSG00000224468.3	RP11-181K3.4	-5.21	2.3e-07	2.65e-05	-0.17	-0.16	Colorectal cancer;	chr1:183143277	chr1:183138402~183141282:-
BRCA	cis	rs10911251	0.546	rs944971	ENSG00000224468.3	RP11-181K3.4	-5.21	2.3e-07	2.65e-05	-0.17	-0.16	Colorectal cancer;	chr1:183143370	chr1:183138402~183141282:-
BRCA	cis	rs10911251	0.508	rs944970	ENSG00000224468.3	RP11-181K3.4	-5.21	2.3e-07	2.65e-05	-0.17	-0.16	Colorectal cancer;	chr1:183143431	chr1:183138402~183141282:-
BRCA	cis	rs10911251	0.508	rs6424890	ENSG00000224468.3	RP11-181K3.4	-5.21	2.3e-07	2.65e-05	-0.17	-0.16	Colorectal cancer;	chr1:183143629	chr1:183138402~183141282:-
BRCA	cis	rs10752881	0.809	rs3738829	ENSG00000224468.3	RP11-181K3.4	-5.21	2.3e-07	2.65e-05	-0.17	-0.16	Colorectal cancer;	chr1:183144727	chr1:183138402~183141282:-
BRCA	cis	rs10911251	0.546	rs1547715	ENSG00000224468.3	RP11-181K3.4	-5.21	2.3e-07	2.65e-05	-0.17	-0.16	Colorectal cancer;	chr1:183144817	chr1:183138402~183141282:-
BRCA	cis	rs10911251	0.546	rs1547714	ENSG00000224468.3	RP11-181K3.4	-5.21	2.3e-07	2.65e-05	-0.17	-0.16	Colorectal cancer;	chr1:183144984	chr1:183138402~183141282:-
BRCA	cis	rs8114671	0.562	rs4911163	ENSG00000269202.1	RP4-614O4.12	-5.21	2.3e-07	2.65e-05	-0.16	-0.16	Height;	chr20:34882891	chr20:35201747~35203288:-
BRCA	cis	rs763121	0.853	rs3827357	ENSG00000228274.3	RP3-508I15.9	-5.21	2.3e-07	2.65e-05	-0.18	-0.16	Menopause (age at onset);	chr22:38683408	chr22:38667585~38681820:-
BRCA	cis	rs7618915	0.547	rs2590846	ENSG00000243224.1	RP5-1157M23.2	-5.21	2.3e-07	2.65e-05	-0.18	-0.16	Bipolar disorder;	chr3:52658343	chr3:52239258~52241097:+
BRCA	cis	rs2251381	0.75	rs2251087	ENSG00000176054.6	RPL23P2	5.21	2.3e-07	2.65e-05	0.18	0.16	Selective IgA deficiency;	chr21:29155678	chr21:28997613~28998033:-
BRCA	cis	rs2251381	0.75	rs2776250	ENSG00000176054.6	RPL23P2	5.21	2.3e-07	2.65e-05	0.18	0.16	Selective IgA deficiency;	chr21:29155773	chr21:28997613~28998033:-
BRCA	cis	rs13113518	0.902	rs11133386	ENSG00000223305.1	RN7SKP30	5.21	2.3e-07	2.65e-05	0.19	0.16	Height;	chr4:55461320	chr4:55540502~55540835:-
BRCA	cis	rs13113518	0.967	rs4340844	ENSG00000223305.1	RN7SKP30	5.21	2.3e-07	2.65e-05	0.19	0.16	Height;	chr4:55462689	chr4:55540502~55540835:-
BRCA	cis	rs7617773	0.78	rs7632297	ENSG00000199476.1	Y_RNA	-5.21	2.3e-07	2.65e-05	-0.24	-0.16	Coronary artery disease;	chr3:48306673	chr3:48288587~48288694:+
BRCA	cis	rs2732480	0.557	rs923397	ENSG00000226413.2	OR8T1P	5.21	2.3e-07	2.66e-05	0.21	0.16	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48326609	chr12:48442030~48442947:-
BRCA	cis	rs17772222	0.74	rs61984675	ENSG00000258789.1	RP11-507K2.3	-5.21	2.31e-07	2.66e-05	-0.18	-0.16	Coronary artery calcification;	chr14:88511236	chr14:88551597~88552493:+
BRCA	cis	rs3760982	0.585	rs61013802	ENSG00000267058.1	RP11-15A1.3	-5.21	2.31e-07	2.66e-05	-0.18	-0.16	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43787990	chr19:43891804~43901805:-
BRCA	cis	rs6840258	0.891	rs10023056	ENSG00000251411.1	RP11-397E7.4	-5.21	2.31e-07	2.66e-05	-0.22	-0.16	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87143314	chr4:86913266~86914817:-
BRCA	cis	rs523522	0.962	rs4766966	ENSG00000278344.1	RP11-18C24.8	5.21	2.31e-07	2.66e-05	0.21	0.16	High light scatter reticulocyte count;	chr12:120505108	chr12:120500735~120501090:-
BRCA	cis	rs10911251	0.508	rs2245784	ENSG00000224468.3	RP11-181K3.4	-5.21	2.31e-07	2.66e-05	-0.17	-0.16	Colorectal cancer;	chr1:183138530	chr1:183138402~183141282:-
BRCA	cis	rs10911251	0.546	rs2147578	ENSG00000224468.3	RP11-181K3.4	-5.21	2.31e-07	2.66e-05	-0.17	-0.16	Colorectal cancer;	chr1:183138564	chr1:183138402~183141282:-
BRCA	cis	rs13108904	0.652	rs2878539	ENSG00000254094.1	AC078852.1	-5.21	2.31e-07	2.66e-05	-0.17	-0.16	Obesity-related traits;	chr4:1250089	chr4:1356581~1358075:+
BRCA	cis	rs7577696	0.962	rs7581340	ENSG00000272716.1	RP11-563N4.1	-5.21	2.31e-07	2.66e-05	-0.17	-0.16	Inflammatory biomarkers;	chr2:32112322	chr2:32165046~32165757:-
BRCA	cis	rs2624839	0.704	rs1046956	ENSG00000228008.1	CTD-2330K9.3	-5.21	2.31e-07	2.66e-05	-0.17	-0.16	Intelligence (multi-trait analysis);	chr3:50185493	chr3:49903845~49916937:+
BRCA	cis	rs5167	0.504	rs3760629	ENSG00000280087.1	CTB-129P6.7	5.21	2.31e-07	2.66e-05	0.19	0.16	Blood protein levels;	chr19:44954889	chr19:44909375~44914968:+
BRCA	cis	rs9516	0.565	rs11600483	ENSG00000254974.1	RP11-702H23.2	-5.21	2.31e-07	2.66e-05	-0.2	-0.16	Facial morphology (factor 15, philtrum width);	chr11:74453455	chr11:74485580~74486051:-
BRCA	cis	rs2179367	0.959	rs9322178	ENSG00000216906.2	RP11-350J20.9	5.21	2.31e-07	2.66e-05	0.2	0.16	Dupuytren's disease;	chr6:149372131	chr6:149904243~149906418:+
BRCA	cis	rs6840360	0.598	rs11944921	ENSG00000270265.1	RP11-731D1.4	5.21	2.31e-07	2.66e-05	0.18	0.16	Intelligence (multi-trait analysis);	chr4:151809957	chr4:151333775~151353224:-
BRCA	cis	rs875971	1	rs1167612	ENSG00000164669.11	INTS4P1	5.21	2.31e-07	2.66e-05	0.2	0.16	Aortic root size;	chr7:66102989	chr7:65141225~65234216:+
BRCA	cis	rs2665103	0.589	rs3858953	ENSG00000259429.4	UBE2Q2P2	-5.21	2.31e-07	2.67e-05	-0.15	-0.16	Intelligence (multi-trait analysis);	chr15:82238049	chr15:82355142~82420075:+
BRCA	cis	rs1075265	0.567	rs66773232	ENSG00000235937.1	AC008280.1	5.21	2.31e-07	2.67e-05	0.17	0.16	Chronotype;Morning vs. evening chronotype;	chr2:53973970	chr2:54029552~54030682:-
BRCA	cis	rs4218	0.689	rs12440692	ENSG00000259732.1	RP11-59H7.3	-5.21	2.31e-07	2.67e-05	-0.2	-0.16	Social communication problems;	chr15:59090671	chr15:59121034~59133250:+
BRCA	cis	rs2153535	0.542	rs9505465	ENSG00000251164.1	HULC	-5.21	2.31e-07	2.67e-05	-0.19	-0.16	Motion sickness;	chr6:8510613	chr6:8652137~8653846:+
BRCA	cis	rs7772486	0.776	rs2265467	ENSG00000270638.1	RP3-466P17.1	5.21	2.32e-07	2.67e-05	0.18	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145897203	chr6:145735570~145737218:+
BRCA	cis	rs13113518	0.966	rs12506788	ENSG00000223305.1	RN7SKP30	5.21	2.32e-07	2.67e-05	0.19	0.16	Height;	chr4:55477426	chr4:55540502~55540835:-
BRCA	cis	rs9840812	0.769	rs3755636	ENSG00000239213.4	NCK1-AS1	5.21	2.32e-07	2.67e-05	0.2	0.16	Fibrinogen levels;	chr3:136249986	chr3:136841726~136862054:-
BRCA	cis	rs7577696	0.962	rs17767988	ENSG00000272716.1	RP11-563N4.1	-5.21	2.32e-07	2.67e-05	-0.18	-0.16	Inflammatory biomarkers;	chr2:32061757	chr2:32165046~32165757:-
BRCA	cis	rs8002861	0.905	rs80209017	ENSG00000274001.1	RP11-5G9.5	5.21	2.32e-07	2.67e-05	0.18	0.16	Leprosy;	chr13:43899046	chr13:43877715~43878163:-
BRCA	cis	rs7824557	0.614	rs2736277	ENSG00000154316.13	TDH	5.21	2.32e-07	2.67e-05	0.2	0.16	Retinal vascular caliber;	chr8:11361384	chr8:11339637~11368452:+
BRCA	cis	rs6714710	0.603	rs17489454	ENSG00000230606.9	AC159540.1	-5.21	2.32e-07	2.67e-05	-0.19	-0.16	Posterior cortical atrophy and Alzheimer's disease;	chr2:97790887	chr2:97416165~97433527:-
BRCA	cis	rs5167	0.566	rs2075620	ENSG00000280087.1	CTB-129P6.7	-5.21	2.32e-07	2.67e-05	-0.21	-0.16	Blood protein levels;	chr19:44976780	chr19:44909375~44914968:+
BRCA	cis	rs9847710	1	rs4687697	ENSG00000242142.1	SERBP1P3	-5.21	2.32e-07	2.67e-05	-0.18	-0.16	Ulcerative colitis;	chr3:53056474	chr3:53064283~53065091:-
BRCA	cis	rs12477438	0.765	rs6740054	ENSG00000231822.1	AC019097.7	-5.21	2.32e-07	2.67e-05	-0.17	-0.16	Chronic sinus infection;	chr2:98960168	chr2:99102018~99102752:+
BRCA	cis	rs270601	0.633	rs733300	ENSG00000233006.5	AC034220.3	5.21	2.32e-07	2.67e-05	0.12	0.16	Acylcarnitine levels;	chr5:132236550	chr5:132311285~132369916:-
BRCA	cis	rs2274273	0.682	rs7141975	ENSG00000258413.1	RP11-665C16.6	-5.21	2.32e-07	2.67e-05	-0.2	-0.16	Protein biomarker;	chr14:55075498	chr14:55262767~55272075:-
BRCA	cis	rs919433	0.713	rs6714697	ENSG00000231621.1	AC013264.2	-5.21	2.32e-07	2.68e-05	-0.15	-0.16	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197619762	chr2:197197991~197199273:+
BRCA	cis	rs17213965	0.925	rs62030569	ENSG00000275910.1	RP11-680G24.6	-5.21	2.33e-07	2.68e-05	-0.24	-0.16	Waist-hip ratio;	chr16:15786892	chr16:15015828~15016390:-
BRCA	cis	rs1440410	0.535	rs4561881	ENSG00000250326.1	RP11-284M14.1	-5.21	2.33e-07	2.68e-05	-0.18	-0.16	Ischemic stroke;	chr4:143118988	chr4:142933195~143184861:-
BRCA	cis	rs1440410	0.535	rs10015279	ENSG00000250326.1	RP11-284M14.1	-5.21	2.33e-07	2.68e-05	-0.18	-0.16	Ischemic stroke;	chr4:143119872	chr4:142933195~143184861:-
BRCA	cis	rs8054556	1	rs4787486	ENSG00000273724.1	RP11-347C12.12	-5.21	2.33e-07	2.68e-05	-0.18	-0.16	Autism spectrum disorder or schizophrenia;	chr16:29966241	chr16:30336400~30343336:+
BRCA	cis	rs4604234	0.803	rs3812123	ENSG00000272129.1	RP11-250B2.6	-5.21	2.33e-07	2.68e-05	-0.39	-0.16	Cancer;	chr6:80253240	chr6:80355424~80356859:+
BRCA	cis	rs6480314	0.542	rs12572967	ENSG00000233590.1	RP11-153K11.3	-5.21	2.33e-07	2.68e-05	-0.26	-0.16	Optic nerve measurement (disc area);	chr10:68270873	chr10:68233251~68242379:-
BRCA	cis	rs9311474	0.629	rs9853056	ENSG00000243224.1	RP5-1157M23.2	-5.21	2.33e-07	2.68e-05	-0.17	-0.16	Electroencephalogram traits;	chr3:52521941	chr3:52239258~52241097:+
BRCA	cis	rs8054556	1	rs9924686	ENSG00000273724.1	RP11-347C12.12	-5.21	2.33e-07	2.68e-05	-0.18	-0.16	Autism spectrum disorder or schizophrenia;	chr16:29991755	chr16:30336400~30343336:+
BRCA	cis	rs12439619	0.846	rs62013464	ENSG00000255769.6	GOLGA2P10	-5.21	2.33e-07	2.68e-05	-0.23	-0.16	Intelligence (multi-trait analysis);	chr15:82288250	chr15:82472993~82513950:-
BRCA	cis	rs10752881	1	rs12028732	ENSG00000224468.3	RP11-181K3.4	-5.21	2.33e-07	2.68e-05	-0.17	-0.16	Colorectal cancer;	chr1:183016390	chr1:183138402~183141282:-
BRCA	cis	rs10129255	0.5	rs10143242	ENSG00000211967.3	IGHV3-53	-5.21	2.33e-07	2.68e-05	-0.11	-0.16	Kawasaki disease;	chr14:106681814	chr14:106592676~106593347:-
BRCA	cis	rs875971	0.862	rs7796162	ENSG00000236529.1	RP13-254B10.1	-5.21	2.33e-07	2.69e-05	-0.18	-0.16	Aortic root size;	chr7:66280771	chr7:65840212~65840596:+
BRCA	cis	rs7617773	0.78	rs35190747	ENSG00000199476.1	Y_RNA	-5.21	2.33e-07	2.69e-05	-0.24	-0.16	Coronary artery disease;	chr3:48301800	chr3:48288587~48288694:+
BRCA	cis	rs7617773	0.78	rs4511915	ENSG00000199476.1	Y_RNA	-5.21	2.33e-07	2.69e-05	-0.24	-0.16	Coronary artery disease;	chr3:48302368	chr3:48288587~48288694:+
BRCA	cis	rs7617773	0.78	rs13066758	ENSG00000199476.1	Y_RNA	-5.21	2.33e-07	2.69e-05	-0.24	-0.16	Coronary artery disease;	chr3:48302387	chr3:48288587~48288694:+
BRCA	cis	rs7617773	0.78	rs4392440	ENSG00000199476.1	Y_RNA	-5.21	2.33e-07	2.69e-05	-0.24	-0.16	Coronary artery disease;	chr3:48302430	chr3:48288587~48288694:+
BRCA	cis	rs4713118	0.662	rs175954	ENSG00000280107.1	AL022393.9	-5.21	2.33e-07	2.69e-05	-0.24	-0.16	Parkinson's disease;	chr6:28043807	chr6:28170845~28172521:+
BRCA	cis	rs11098499	0.863	rs6858592	ENSG00000249244.1	RP11-548H18.2	5.21	2.33e-07	2.69e-05	0.19	0.16	Corneal astigmatism;	chr4:119537537	chr4:119391831~119395335:-
BRCA	cis	rs66887589	0.87	rs2389875	ENSG00000245958.5	RP11-33B1.1	5.2	2.34e-07	2.69e-05	0.14	0.16	Diastolic blood pressure;	chr4:119635859	chr4:119454791~119552025:+
BRCA	cis	rs875971	0.862	rs2420174	ENSG00000236529.1	RP13-254B10.1	-5.2	2.34e-07	2.69e-05	-0.17	-0.16	Aortic root size;	chr7:66180374	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.862	rs2420173	ENSG00000236529.1	RP13-254B10.1	-5.2	2.34e-07	2.69e-05	-0.17	-0.16	Aortic root size;	chr7:66180412	chr7:65840212~65840596:+
BRCA	cis	rs7134599	0.561	rs4913396	ENSG00000255733.4	IFNG-AS1	-5.2	2.34e-07	2.69e-05	-0.14	-0.16	Inflammatory bowel disease;Ulcerative colitis;	chr12:68079555	chr12:67989445~68234686:+
BRCA	cis	rs11955398	0.502	rs34592	ENSG00000215032.2	GNL3LP1	5.2	2.34e-07	2.69e-05	0.2	0.16	Intelligence (multi-trait analysis);	chr5:61033797	chr5:60891935~60893577:-
BRCA	cis	rs2839186	0.708	rs17183123	ENSG00000239415.1	AP001469.9	5.2	2.34e-07	2.69e-05	0.17	0.16	Testicular germ cell tumor;	chr21:46252047	chr21:46251549~46254133:-
BRCA	cis	rs3764021	0.87	rs10743819	ENSG00000256673.1	RP11-599J14.2	-5.2	2.34e-07	2.7e-05	-0.18	-0.16	Type 1 diabetes;	chr12:9724172	chr12:9398355~9414851:-
BRCA	cis	rs7178909	0.902	rs3784386	ENSG00000259677.1	RP11-493E3.1	5.2	2.34e-07	2.7e-05	0.19	0.16	Common traits (Other);	chr15:89894194	chr15:89876540~89877285:+
BRCA	cis	rs4372836	0.636	rs4665434	ENSG00000226833.4	AC097724.3	5.2	2.34e-07	2.7e-05	0.18	0.16	Body mass index;	chr2:28753537	chr2:28708953~28736205:-
BRCA	cis	rs1867631	0.959	rs11208914	ENSG00000248458.2	RP4-598P13.1	5.2	2.34e-07	2.7e-05	0.17	0.16	Menopause (age at onset);	chr1:66584045	chr1:66665864~66677027:-
BRCA	cis	rs35612822	0.866	rs2627046	ENSG00000232485.2	AC098820.3	-5.2	2.35e-07	2.7e-05	-0.2	-0.16	Kidney disease (early stage) in type 1 diabetes;	chr2:216440757	chr2:216479030~216498761:-
BRCA	cis	rs4664293	0.51	rs2113861	ENSG00000226266.5	AC009961.3	5.2	2.35e-07	2.7e-05	0.2	0.16	Monocyte percentage of white cells;	chr2:159585233	chr2:159670708~159712435:-
BRCA	cis	rs8064024	0.65	rs3813749	ENSG00000267077.1	RP11-127I20.5	5.2	2.35e-07	2.7e-05	0.16	0.16	Cancer;	chr16:4869126	chr16:4795265~4796532:-
BRCA	cis	rs10504130	1	rs16916820	ENSG00000272024.1	RP11-546K22.3	-5.2	2.35e-07	2.7e-05	-0.28	-0.16	Venous thromboembolism (SNP x SNP interaction);	chr8:51800156	chr8:51950284~51950690:+
BRCA	cis	rs2688482	0.557	rs2550236	ENSG00000185485.13	SDHAP1	5.2	2.35e-07	2.7e-05	0.21	0.16	Lung disease severity in cystic fibrosis;	chr3:195795450	chr3:195959748~195990318:-
BRCA	cis	rs8016982	0.698	rs12590764	ENSG00000258999.1	RP11-114N19.3	5.2	2.35e-07	2.7e-05	0.19	0.16	Schizophrenia;	chr14:81238073	chr14:81107033~81170414:-
BRCA	cis	rs6480314	0.542	rs61854809	ENSG00000233590.1	RP11-153K11.3	-5.2	2.35e-07	2.7e-05	-0.27	-0.16	Optic nerve measurement (disc area);	chr10:68262847	chr10:68233251~68242379:-
BRCA	cis	rs2732480	0.557	rs2732454	ENSG00000257735.1	RP11-370I10.6	5.2	2.35e-07	2.7e-05	0.2	0.16	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48325894	chr12:48350945~48442411:+
BRCA	cis	rs1707322	1	rs6695421	ENSG00000234329.1	RP11-767N6.2	5.2	2.35e-07	2.71e-05	0.16	0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45914535	chr1:45651039~45651826:-
BRCA	cis	rs6442522	0.64	rs13095087	ENSG00000249786.6	EAF1-AS1	-5.2	2.35e-07	2.71e-05	-0.16	-0.16	Uric acid levels;	chr3:15477334	chr3:15436171~15455940:-
BRCA	cis	rs3733585	0.673	rs6840802	ENSG00000250413.1	RP11-448G15.1	-5.2	2.35e-07	2.71e-05	-0.21	-0.16	Cleft plate (environmental tobacco smoke interaction);	chr4:9964009	chr4:10006482~10009725:+
BRCA	cis	rs7674212	0.54	rs2720469	ENSG00000248740.4	RP11-328K4.1	5.2	2.36e-07	2.71e-05	0.18	0.16	Type 2 diabetes;	chr4:103165327	chr4:103256159~103453658:+
BRCA	cis	rs7246657	0.525	rs10401417	ENSG00000267422.1	CTD-2554C21.1	-5.2	2.36e-07	2.71e-05	-0.26	-0.16	Coronary artery calcification;	chr19:36976638	chr19:37779686~37792865:+
BRCA	cis	rs10992471	0.566	rs5003738	ENSG00000187984.11	ANKRD19P	-5.2	2.36e-07	2.71e-05	-0.15	-0.16	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr9:92875646	chr9:92809388~92888693:+
BRCA	cis	rs9652601	0.779	rs9929994	ENSG00000274038.1	RP11-66H6.4	-5.2	2.36e-07	2.71e-05	-0.18	-0.16	Systemic lupus erythematosus;	chr16:11084388	chr16:11056556~11057034:+
BRCA	cis	rs987360	0.835	rs7664552	ENSG00000248869.4	RP11-138I17.1	-5.2	2.36e-07	2.71e-05	-0.16	-0.16	Temperament;	chr4:137291472	chr4:136796722~137212799:-
BRCA	cis	rs2905347	0.529	rs2961292	ENSG00000179428.2	AC073072.5	5.2	2.36e-07	2.72e-05	0.17	0.16	Major depression and alcohol dependence;	chr7:22643518	chr7:22725395~22727620:-
BRCA	cis	rs8103033	0.781	rs7248699	ENSG00000268088.1	AC093063.2	-5.2	2.36e-07	2.72e-05	-0.18	-0.16	Obesity-related traits;	chr19:39649338	chr19:39693925~39696258:+
BRCA	cis	rs8103033	0.781	rs7248784	ENSG00000268088.1	AC093063.2	-5.2	2.36e-07	2.72e-05	-0.18	-0.16	Obesity-related traits;	chr19:39649347	chr19:39693925~39696258:+
BRCA	cis	rs875971	1	rs697970	ENSG00000164669.11	INTS4P1	5.2	2.36e-07	2.72e-05	0.2	0.16	Aortic root size;	chr7:66095065	chr7:65141225~65234216:+
BRCA	cis	rs6569038	0.502	rs2357020	ENSG00000253194.1	RP11-351A11.1	5.2	2.36e-07	2.72e-05	0.2	0.16	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr6:118986644	chr6:118934785~119031541:+
BRCA	cis	rs8114671	0.562	rs6087651	ENSG00000269202.1	RP4-614O4.12	-5.2	2.36e-07	2.72e-05	-0.16	-0.16	Height;	chr20:34930550	chr20:35201747~35203288:-
BRCA	cis	rs8114671	0.562	rs6119545	ENSG00000269202.1	RP4-614O4.12	-5.2	2.36e-07	2.72e-05	-0.16	-0.16	Height;	chr20:34935066	chr20:35201747~35203288:-
BRCA	cis	rs6490294	0.904	rs11066111	ENSG00000226469.1	ADAM1B	5.2	2.36e-07	2.72e-05	0.21	0.16	Mean platelet volume;	chr12:111977375	chr12:111927018~111929017:+
BRCA	cis	rs6430585	0.591	rs309118	ENSG00000231890.6	DARS-AS1	-5.2	2.37e-07	2.72e-05	-0.23	-0.16	Corneal structure;	chr2:135988654	chr2:135985176~136022593:+
BRCA	cis	rs11124272	0.544	rs725631	ENSG00000272716.1	RP11-563N4.1	5.2	2.37e-07	2.72e-05	0.19	0.16	Interleukin-18 levels;	chr2:31555956	chr2:32165046~32165757:-
BRCA	cis	rs755249	0.565	rs7539279	ENSG00000182109.6	RP11-69E11.4	-5.2	2.37e-07	2.72e-05	-0.18	-0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39584896	chr1:39522280~39546187:-
BRCA	cis	rs721917	0.565	rs2255601	ENSG00000244733.5	RP11-506M13.3	-5.2	2.37e-07	2.73e-05	-0.19	-0.16	Chronic obstructive pulmonary disease;	chr10:79944803	chr10:79660891~79677996:+
BRCA	cis	rs17772222	0.74	rs4390529	ENSG00000258789.1	RP11-507K2.3	-5.2	2.37e-07	2.73e-05	-0.18	-0.16	Coronary artery calcification;	chr14:88510853	chr14:88551597~88552493:+
BRCA	cis	rs17772222	0.771	rs4516145	ENSG00000258789.1	RP11-507K2.3	-5.2	2.37e-07	2.73e-05	-0.18	-0.16	Coronary artery calcification;	chr14:88510953	chr14:88551597~88552493:+
BRCA	cis	rs2638953	0.925	rs7967281	ENSG00000247934.4	RP11-967K21.1	-5.2	2.37e-07	2.73e-05	-0.21	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28397843	chr12:28163298~28190738:-
BRCA	cis	rs9287719	0.967	rs10929682	ENSG00000243819.4	RN7SL832P	5.2	2.37e-07	2.73e-05	0.15	0.16	Prostate cancer;	chr2:10592063	chr2:10690344~10692099:+
BRCA	cis	rs6480314	0.542	rs10998046	ENSG00000233590.1	RP11-153K11.3	-5.2	2.37e-07	2.73e-05	-0.26	-0.16	Optic nerve measurement (disc area);	chr10:68269641	chr10:68233251~68242379:-
BRCA	cis	rs2839186	0.5	rs13052701	ENSG00000228137.1	AP001469.7	5.2	2.37e-07	2.73e-05	0.18	0.16	Testicular germ cell tumor;	chr21:46240131	chr21:46246890~46247682:+
BRCA	cis	rs10504130	0.867	rs11786167	ENSG00000253844.1	RP11-546K22.1	-5.2	2.37e-07	2.73e-05	-0.28	-0.16	Venous thromboembolism (SNP x SNP interaction);	chr8:51763097	chr8:51961458~52022974:+
BRCA	cis	rs10029851	0.56	rs3910459	ENSG00000234492.4	RPL34-AS1	5.2	2.37e-07	2.73e-05	0.18	0.16	Amyotrophic lateral sclerosis (sporadic);	chr4:108691132	chr4:108538190~108620460:-
BRCA	cis	rs7617773	0.963	rs12495221	ENSG00000228638.1	FCF1P2	5.2	2.38e-07	2.73e-05	0.16	0.16	Coronary artery disease;	chr3:48137688	chr3:48290793~48291375:-
BRCA	cis	rs7914558	1	rs10509757	ENSG00000236937.2	PTGES3P4	5.2	2.38e-07	2.73e-05	0.2	0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102993203	chr10:102845595~102845950:+
BRCA	cis	rs8103033	0.786	rs7245574	ENSG00000268088.1	AC093063.2	-5.2	2.38e-07	2.73e-05	-0.17	-0.16	Obesity-related traits;	chr19:39657462	chr19:39693925~39696258:+
BRCA	cis	rs6840360	0.642	rs7684462	ENSG00000278978.1	RP11-164P12.5	-5.2	2.38e-07	2.73e-05	-0.18	-0.16	Intelligence (multi-trait analysis);	chr4:151427270	chr4:151669786~151670503:+
BRCA	cis	rs7618501	0.633	rs4688758	ENSG00000228008.1	CTD-2330K9.3	5.2	2.38e-07	2.73e-05	0.15	0.16	Intelligence (multi-trait analysis);	chr3:49990952	chr3:49903845~49916937:+
BRCA	cis	rs6430585	0.528	rs79826902	ENSG00000224043.6	CCNT2-AS1	-5.2	2.38e-07	2.73e-05	-0.28	-0.16	Corneal structure;	chr2:135912849	chr2:134735464~134918710:-
BRCA	cis	rs2179367	0.632	rs2341774	ENSG00000268592.3	RAET1E-AS1	5.2	2.38e-07	2.74e-05	0.23	0.16	Dupuytren's disease;	chr6:149425014	chr6:149863494~149919507:+
BRCA	cis	rs1867631	0.876	rs10889637	ENSG00000248458.2	RP4-598P13.1	5.2	2.38e-07	2.74e-05	0.17	0.16	Menopause (age at onset);	chr1:66631782	chr1:66665864~66677027:-
BRCA	cis	rs9308731	0.583	rs7596789	ENSG00000227992.1	AC108463.2	-5.2	2.38e-07	2.74e-05	-0.19	-0.16	Chronic lymphocytic leukemia;	chr2:111175039	chr2:111203964~111206215:-
BRCA	cis	rs9308731	0.563	rs11899831	ENSG00000227992.1	AC108463.2	-5.2	2.38e-07	2.74e-05	-0.19	-0.16	Chronic lymphocytic leukemia;	chr2:111175117	chr2:111203964~111206215:-
BRCA	cis	rs4835473	0.831	rs10428468	ENSG00000249741.2	RP11-673E1.3	-5.2	2.38e-07	2.74e-05	-0.17	-0.16	Immature fraction of reticulocytes;	chr4:143974104	chr4:143911514~143912053:-
BRCA	cis	rs7119	0.717	rs8032405	ENSG00000259362.2	RP11-307C19.1	-5.2	2.38e-07	2.74e-05	-0.22	-0.16	Type 2 diabetes;	chr15:77533002	chr15:77525540~77534110:+
BRCA	cis	rs2638953	0.924	rs11049600	ENSG00000247934.4	RP11-967K21.1	-5.2	2.39e-07	2.74e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28439061	chr12:28163298~28190738:-
BRCA	cis	rs4308124	1	rs4308124	ENSG00000230499.1	AC108463.1	-5.2	2.39e-07	2.74e-05	-0.18	-0.16	Vitiligo;	chr2:111252909	chr2:111195963~111206494:+
BRCA	cis	rs11955398	0.625	rs12655515	ENSG00000215032.2	GNL3LP1	5.2	2.39e-07	2.74e-05	0.2	0.16	Intelligence (multi-trait analysis);	chr5:60678271	chr5:60891935~60893577:-
BRCA	cis	rs12712135	0.709	rs4140786	ENSG00000234389.1	AC007278.3	-5.2	2.39e-07	2.74e-05	-0.14	-0.16	Blood protein levels;	chr2:102471716	chr2:102438713~102440475:+
BRCA	cis	rs17508449	0.547	rs17463292	ENSG00000232450.1	RP4-730K3.3	-5.2	2.39e-07	2.74e-05	-0.25	-0.16	Leprosy;	chr1:113828618	chr1:113698884~113699631:-
BRCA	cis	rs17508449	0.547	rs3761935	ENSG00000232450.1	RP4-730K3.3	-5.2	2.39e-07	2.74e-05	-0.25	-0.16	Leprosy;	chr1:113829906	chr1:113698884~113699631:-
BRCA	cis	rs17508449	0.504	rs17509844	ENSG00000232450.1	RP4-730K3.3	-5.2	2.39e-07	2.74e-05	-0.25	-0.16	Leprosy;	chr1:113835147	chr1:113698884~113699631:-
BRCA	cis	rs6442522	0.606	rs3773462	ENSG00000249786.6	EAF1-AS1	5.2	2.39e-07	2.75e-05	0.17	0.16	Uric acid levels;	chr3:15452772	chr3:15436171~15455940:-
BRCA	cis	rs6490294	0.904	rs11066112	ENSG00000226469.1	ADAM1B	5.2	2.39e-07	2.75e-05	0.21	0.16	Mean platelet volume;	chr12:111978782	chr12:111927018~111929017:+
BRCA	cis	rs8054556	1	rs3814881	ENSG00000273724.1	RP11-347C12.12	-5.2	2.39e-07	2.75e-05	-0.18	-0.16	Autism spectrum disorder or schizophrenia;	chr16:29989580	chr16:30336400~30343336:+
BRCA	cis	rs7246657	0.525	rs997516	ENSG00000276846.1	CTD-3220F14.3	5.2	2.4e-07	2.75e-05	0.24	0.16	Coronary artery calcification;	chr19:36983362	chr19:37314868~37315620:-
BRCA	cis	rs17508449	0.547	rs6658523	ENSG00000232450.1	RP4-730K3.3	-5.2	2.4e-07	2.75e-05	-0.25	-0.16	Leprosy;	chr1:113843437	chr1:113698884~113699631:-
BRCA	cis	rs10129255	0.536	rs6576201	ENSG00000254174.1	IGHV1-12	-5.2	2.4e-07	2.75e-05	-0.12	-0.16	Kawasaki disease;	chr14:106683696	chr14:106122420~106122709:-
BRCA	cis	rs1707322	0.963	rs10890371	ENSG00000234329.1	RP11-767N6.2	5.2	2.4e-07	2.75e-05	0.16	0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45925225	chr1:45651039~45651826:-
BRCA	cis	rs1707322	1	rs10890372	ENSG00000234329.1	RP11-767N6.2	5.2	2.4e-07	2.75e-05	0.16	0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45925348	chr1:45651039~45651826:-
BRCA	cis	rs2153535	0.58	rs9392223	ENSG00000251164.1	HULC	-5.2	2.4e-07	2.75e-05	-0.2	-0.16	Motion sickness;	chr6:8468417	chr6:8652137~8653846:+
BRCA	cis	rs7923837	0.687	rs10882101	ENSG00000236493.2	EIF2S2P3	5.2	2.4e-07	2.76e-05	0.2	0.16	Multiple sclerosis;Body mass index;	chr10:92702670	chr10:92668745~92669743:-
BRCA	cis	rs10851478	0.872	rs6493372	ENSG00000259531.2	RP11-295H24.3	-5.2	2.4e-07	2.76e-05	-0.23	-0.16	Oral cavity cancer;	chr15:49466532	chr15:49365124~49366685:-
BRCA	cis	rs6840360	0.642	rs2709820	ENSG00000278978.1	RP11-164P12.5	-5.2	2.4e-07	2.76e-05	-0.17	-0.16	Intelligence (multi-trait analysis);	chr4:151462887	chr4:151669786~151670503:+
BRCA	cis	rs6840360	0.642	rs4235219	ENSG00000278978.1	RP11-164P12.5	-5.2	2.4e-07	2.76e-05	-0.18	-0.16	Intelligence (multi-trait analysis);	chr4:151424951	chr4:151669786~151670503:+
BRCA	cis	rs6840360	0.642	rs6851814	ENSG00000278978.1	RP11-164P12.5	-5.2	2.4e-07	2.76e-05	-0.18	-0.16	Intelligence (multi-trait analysis);	chr4:151425285	chr4:151669786~151670503:+
BRCA	cis	rs6840360	0.606	rs10028035	ENSG00000278978.1	RP11-164P12.5	-5.2	2.4e-07	2.76e-05	-0.18	-0.16	Intelligence (multi-trait analysis);	chr4:151426673	chr4:151669786~151670503:+
BRCA	cis	rs6840360	0.667	rs4266275	ENSG00000278978.1	RP11-164P12.5	-5.2	2.4e-07	2.76e-05	-0.18	-0.16	Intelligence (multi-trait analysis);	chr4:151426912	chr4:151669786~151670503:+
BRCA	cis	rs755249	0.565	rs4660846	ENSG00000237624.1	OXCT2P1	-5.2	2.4e-07	2.76e-05	-0.19	-0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39583839	chr1:39514956~39516490:+
BRCA	cis	rs2638953	0.815	rs11049696	ENSG00000247934.4	RP11-967K21.1	-5.2	2.4e-07	2.76e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28528922	chr12:28163298~28190738:-
BRCA	cis	rs728616	0.614	rs1885552	ENSG00000225484.5	NUTM2B-AS1	-5.2	2.4e-07	2.76e-05	-0.31	-0.16	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79952336	chr10:79663088~79826594:-
BRCA	cis	rs728616	0.614	rs1885551	ENSG00000225484.5	NUTM2B-AS1	-5.2	2.4e-07	2.76e-05	-0.31	-0.16	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79952597	chr10:79663088~79826594:-
BRCA	cis	rs728616	0.614	rs12253608	ENSG00000225484.5	NUTM2B-AS1	-5.2	2.4e-07	2.76e-05	-0.31	-0.16	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79952727	chr10:79663088~79826594:-
BRCA	cis	rs728616	0.764	rs1885549	ENSG00000225484.5	NUTM2B-AS1	-5.2	2.4e-07	2.76e-05	-0.31	-0.16	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79952794	chr10:79663088~79826594:-
BRCA	cis	rs728616	0.614	rs12245076	ENSG00000225484.5	NUTM2B-AS1	-5.2	2.4e-07	2.76e-05	-0.31	-0.16	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79953675	chr10:79663088~79826594:-
BRCA	cis	rs728616	0.614	rs10788319	ENSG00000225484.5	NUTM2B-AS1	-5.2	2.4e-07	2.76e-05	-0.31	-0.16	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79953754	chr10:79663088~79826594:-
BRCA	cis	rs728616	0.614	rs11200859	ENSG00000225484.5	NUTM2B-AS1	-5.2	2.4e-07	2.76e-05	-0.31	-0.16	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79953805	chr10:79663088~79826594:-
BRCA	cis	rs728616	0.614	rs10887229	ENSG00000225484.5	NUTM2B-AS1	-5.2	2.4e-07	2.76e-05	-0.31	-0.16	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79954018	chr10:79663088~79826594:-
BRCA	cis	rs728616	0.614	rs10788321	ENSG00000225484.5	NUTM2B-AS1	-5.2	2.4e-07	2.76e-05	-0.31	-0.16	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79954039	chr10:79663088~79826594:-
BRCA	cis	rs728616	0.614	rs61858839	ENSG00000225484.5	NUTM2B-AS1	-5.2	2.4e-07	2.76e-05	-0.31	-0.16	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79954162	chr10:79663088~79826594:-
BRCA	cis	rs728616	0.614	rs61858841	ENSG00000225484.5	NUTM2B-AS1	-5.2	2.4e-07	2.76e-05	-0.31	-0.16	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79954420	chr10:79663088~79826594:-
BRCA	cis	rs728616	0.614	rs61858842	ENSG00000225484.5	NUTM2B-AS1	-5.2	2.4e-07	2.76e-05	-0.31	-0.16	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79955283	chr10:79663088~79826594:-
BRCA	cis	rs728616	0.614	rs10887233	ENSG00000225484.5	NUTM2B-AS1	-5.2	2.4e-07	2.76e-05	-0.31	-0.16	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79955596	chr10:79663088~79826594:-
BRCA	cis	rs728616	0.614	rs10887234	ENSG00000225484.5	NUTM2B-AS1	-5.2	2.4e-07	2.76e-05	-0.31	-0.16	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79955666	chr10:79663088~79826594:-
BRCA	cis	rs728616	0.614	rs10887235	ENSG00000225484.5	NUTM2B-AS1	-5.2	2.4e-07	2.76e-05	-0.31	-0.16	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79955890	chr10:79663088~79826594:-
BRCA	cis	rs728616	0.614	rs2146192	ENSG00000225484.5	NUTM2B-AS1	-5.2	2.4e-07	2.76e-05	-0.31	-0.16	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79955982	chr10:79663088~79826594:-
BRCA	cis	rs728616	0.614	rs2146191	ENSG00000225484.5	NUTM2B-AS1	-5.2	2.4e-07	2.76e-05	-0.31	-0.16	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79955998	chr10:79663088~79826594:-
BRCA	cis	rs7927592	0.956	rs12271290	ENSG00000212093.1	AP000807.1	-5.2	2.4e-07	2.76e-05	-0.18	-0.16	Total body bone mineral density;	chr11:68558768	chr11:68506083~68506166:-
BRCA	cis	rs8180040	0.654	rs6773521	ENSG00000276925.1	RP11-708J19.3	5.2	2.41e-07	2.76e-05	0.18	0.16	Colorectal cancer;	chr3:47192929	chr3:47469777~47469987:+
BRCA	cis	rs17772222	0.682	rs28482235	ENSG00000258789.1	RP11-507K2.3	-5.2	2.41e-07	2.76e-05	-0.18	-0.16	Coronary artery calcification;	chr14:88472857	chr14:88551597~88552493:+
BRCA	cis	rs854765	0.547	rs4072739	ENSG00000281749.1	Y_RNA	5.2	2.41e-07	2.76e-05	0.18	0.16	Total body bone mineral density;	chr17:17981346	chr17:18001101~18001195:-
BRCA	cis	rs9545047	0.604	rs12865187	ENSG00000227354.5	RBM26-AS1	-5.2	2.41e-07	2.76e-05	-0.17	-0.16	Schizophrenia;	chr13:79316469	chr13:79406309~79424328:+
BRCA	cis	rs7789940	0.904	rs56919252	ENSG00000186704.9	DTX2P1	5.2	2.41e-07	2.76e-05	0.2	0.16	Multiple sclerosis;	chr7:76308203	chr7:76978617~77004308:+
BRCA	cis	rs6071166	0.935	rs6071146	ENSG00000224635.1	RP4-564F22.5	5.2	2.41e-07	2.77e-05	0.19	0.16	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38699962	chr20:38406011~38416797:-
BRCA	cis	rs12477438	0.784	rs13407840	ENSG00000231822.1	AC019097.7	-5.2	2.41e-07	2.77e-05	-0.17	-0.16	Chronic sinus infection;	chr2:98953465	chr2:99102018~99102752:+
BRCA	cis	rs7617773	0.78	rs13082859	ENSG00000199476.1	Y_RNA	-5.2	2.41e-07	2.77e-05	-0.24	-0.16	Coronary artery disease;	chr3:48303185	chr3:48288587~48288694:+
BRCA	cis	rs7617773	0.78	rs35778847	ENSG00000199476.1	Y_RNA	-5.2	2.41e-07	2.77e-05	-0.24	-0.16	Coronary artery disease;	chr3:48305495	chr3:48288587~48288694:+
BRCA	cis	rs7617773	0.78	rs34749846	ENSG00000199476.1	Y_RNA	-5.2	2.41e-07	2.77e-05	-0.24	-0.16	Coronary artery disease;	chr3:48305678	chr3:48288587~48288694:+
BRCA	cis	rs7617773	0.78	rs79089926	ENSG00000199476.1	Y_RNA	-5.2	2.41e-07	2.77e-05	-0.24	-0.16	Coronary artery disease;	chr3:48307074	chr3:48288587~48288694:+
BRCA	cis	rs9907295	1	rs11653016	ENSG00000271013.1	AC015849.15	-5.2	2.41e-07	2.77e-05	-0.24	-0.16	Fibroblast growth factor basic levels;	chr17:35909756	chr17:35912635~35918010:-
BRCA	cis	rs9907295	1	rs9889977	ENSG00000271013.1	AC015849.15	-5.2	2.41e-07	2.77e-05	-0.24	-0.16	Fibroblast growth factor basic levels;	chr17:35910691	chr17:35912635~35918010:-
BRCA	cis	rs9907295	1	rs9894799	ENSG00000271013.1	AC015849.15	-5.2	2.41e-07	2.77e-05	-0.24	-0.16	Fibroblast growth factor basic levels;	chr17:35911085	chr17:35912635~35918010:-
BRCA	cis	rs9907295	1	rs9903590	ENSG00000271013.1	AC015849.15	-5.2	2.41e-07	2.77e-05	-0.24	-0.16	Fibroblast growth factor basic levels;	chr17:35911286	chr17:35912635~35918010:-
BRCA	cis	rs9907295	1	rs9897665	ENSG00000271013.1	AC015849.15	-5.2	2.41e-07	2.77e-05	-0.24	-0.16	Fibroblast growth factor basic levels;	chr17:35911595	chr17:35912635~35918010:-
BRCA	cis	rs9907295	1	rs9912049	ENSG00000271013.1	AC015849.15	-5.2	2.41e-07	2.77e-05	-0.24	-0.16	Fibroblast growth factor basic levels;	chr17:35912530	chr17:35912635~35918010:-
BRCA	cis	rs9907295	1	rs9911016	ENSG00000271013.1	AC015849.15	-5.2	2.41e-07	2.77e-05	-0.24	-0.16	Fibroblast growth factor basic levels;	chr17:35913349	chr17:35912635~35918010:-
BRCA	cis	rs9907295	1	rs9912894	ENSG00000271013.1	AC015849.15	-5.2	2.41e-07	2.77e-05	-0.24	-0.16	Fibroblast growth factor basic levels;	chr17:35913452	chr17:35912635~35918010:-
BRCA	cis	rs9907295	1	rs9914468	ENSG00000271013.1	AC015849.15	-5.2	2.41e-07	2.77e-05	-0.24	-0.16	Fibroblast growth factor basic levels;	chr17:35913727	chr17:35912635~35918010:-
BRCA	cis	rs9907295	1	rs9893004	ENSG00000271013.1	AC015849.15	-5.2	2.41e-07	2.77e-05	-0.24	-0.16	Fibroblast growth factor basic levels;	chr17:35913855	chr17:35912635~35918010:-
BRCA	cis	rs9907295	1	rs9899215	ENSG00000271013.1	AC015849.15	-5.2	2.41e-07	2.77e-05	-0.24	-0.16	Fibroblast growth factor basic levels;	chr17:35914215	chr17:35912635~35918010:-
BRCA	cis	rs9907295	1	rs9907145	ENSG00000271013.1	AC015849.15	-5.2	2.41e-07	2.77e-05	-0.24	-0.16	Fibroblast growth factor basic levels;	chr17:35915237	chr17:35912635~35918010:-
BRCA	cis	rs1387259	0.839	rs7487682	ENSG00000257763.1	OR5BK1P	-5.2	2.41e-07	2.77e-05	-0.17	-0.16	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48185882	chr12:48355792~48356614:-
BRCA	cis	rs9907295	1	rs9303693	ENSG00000271013.1	AC015849.15	-5.2	2.41e-07	2.77e-05	-0.24	-0.16	Fibroblast growth factor basic levels;	chr17:35913595	chr17:35912635~35918010:-
BRCA	cis	rs7772486	0.846	rs2748499	ENSG00000270638.1	RP3-466P17.1	5.2	2.41e-07	2.77e-05	0.19	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145993866	chr6:145735570~145737218:+
BRCA	cis	rs4948275	0.773	rs2787736	ENSG00000237233.2	TMEM26-AS1	-5.2	2.41e-07	2.77e-05	-0.19	-0.16	Night sleep phenotypes;	chr10:61490694	chr10:61452639~61481956:+
BRCA	cis	rs10492201	1	rs10492201	ENSG00000255733.4	IFNG-AS1	5.2	2.41e-07	2.77e-05	0.19	0.16	Itch intensity from mosquito bite adjusted by bite size;	chr12:67992086	chr12:67989445~68234686:+
BRCA	cis	rs1552244	0.882	rs17050672	ENSG00000232901.1	CYCSP10	5.2	2.41e-07	2.77e-05	0.24	0.16	Alzheimer's disease;	chr3:9983779	chr3:10000647~10000940:-
BRCA	cis	rs62025270	0.649	rs12148610	ENSG00000259762.1	RP11-158M2.4	-5.2	2.41e-07	2.77e-05	-0.24	-0.16	Idiopathic pulmonary fibrosis;	chr15:85702697	chr15:85750336~85752901:-
BRCA	cis	rs2251381	0.778	rs2245021	ENSG00000176054.6	RPL23P2	5.2	2.41e-07	2.77e-05	0.18	0.16	Selective IgA deficiency;	chr21:29174520	chr21:28997613~28998033:-
BRCA	cis	rs7592578	0.771	rs62181034	ENSG00000272979.1	RP11-647K16.1	-5.2	2.41e-07	2.77e-05	-0.27	-0.16	Diastolic blood pressure;	chr2:190490237	chr2:190454092~190454521:-
BRCA	cis	rs9840812	0.637	rs667920	ENSG00000239213.4	NCK1-AS1	5.2	2.42e-07	2.77e-05	0.2	0.16	Fibrinogen levels;	chr3:136350630	chr3:136841726~136862054:-
BRCA	cis	rs10510102	0.935	rs7906667	ENSG00000226864.1	ATE1-AS1	5.2	2.42e-07	2.77e-05	0.29	0.16	Breast cancer;	chr10:121909142	chr10:121928312~121951965:+
BRCA	cis	rs875971	1	rs1544549	ENSG00000223473.2	GS1-124K5.3	-5.2	2.42e-07	2.78e-05	-0.12	-0.16	Aortic root size;	chr7:66625676	chr7:66491049~66493566:-
BRCA	cis	rs10911232	0.507	rs10911195	ENSG00000224468.3	RP11-181K3.4	-5.2	2.42e-07	2.78e-05	-0.17	-0.16	Hypertriglyceridemia;	chr1:183024303	chr1:183138402~183141282:-
BRCA	cis	rs10129255	1	rs61997605	ENSG00000224373.3	IGHV4-59	5.2	2.42e-07	2.78e-05	0.1	0.16	Kawasaki disease;	chr14:106678368	chr14:106627249~106627825:-
BRCA	cis	rs6431644	1	rs4663339	ENSG00000224287.2	MSL3P1	5.2	2.42e-07	2.78e-05	0.19	0.16	Left atrial antero-posterior diameter;	chr2:233863389	chr2:233865437~233868444:-
BRCA	cis	rs7617773	0.78	rs36075665	ENSG00000199476.1	Y_RNA	-5.2	2.42e-07	2.78e-05	-0.24	-0.16	Coronary artery disease;	chr3:48301597	chr3:48288587~48288694:+
BRCA	cis	rs7577696	0.785	rs2294179	ENSG00000272716.1	RP11-563N4.1	-5.2	2.42e-07	2.78e-05	-0.18	-0.16	Inflammatory biomarkers;	chr2:32128936	chr2:32165046~32165757:-
BRCA	cis	rs10911232	0.507	rs10911194	ENSG00000224468.3	RP11-181K3.4	-5.2	2.42e-07	2.78e-05	-0.17	-0.16	Hypertriglyceridemia;	chr1:183023890	chr1:183138402~183141282:-
BRCA	cis	rs875971	0.545	rs1638735	ENSG00000228409.4	CCT6P1	-5.2	2.42e-07	2.78e-05	-0.16	-0.16	Aortic root size;	chr7:66630751	chr7:65751142~65763354:+
BRCA	cis	rs4664293	0.667	rs10169681	ENSG00000224152.1	AC009506.1	5.2	2.42e-07	2.78e-05	0.17	0.16	Monocyte percentage of white cells;	chr2:159782065	chr2:159615296~159617082:+
BRCA	cis	rs13113518	1	rs4864542	ENSG00000223305.1	RN7SKP30	-5.2	2.42e-07	2.78e-05	-0.19	-0.16	Height;	chr4:55487920	chr4:55540502~55540835:-
BRCA	cis	rs2408955	0.522	rs7139330	ENSG00000273765.1	RP11-370I10.11	-5.2	2.43e-07	2.78e-05	-0.19	-0.16	Glycated hemoglobin levels;	chr12:48089701	chr12:48360920~48361377:+
BRCA	cis	rs2562456	0.876	rs2650844	ENSG00000268081.1	RP11-678G14.2	5.2	2.43e-07	2.78e-05	0.25	0.16	Pain;	chr19:21419288	chr19:21554640~21569237:-
BRCA	cis	rs5167	0.601	rs892131	ENSG00000280087.1	CTB-129P6.7	5.2	2.43e-07	2.79e-05	0.22	0.16	Blood protein levels;	chr19:44993738	chr19:44909375~44914968:+
BRCA	cis	rs7246657	0.525	rs10401417	ENSG00000276846.1	CTD-3220F14.3	5.2	2.43e-07	2.79e-05	0.24	0.16	Coronary artery calcification;	chr19:36976638	chr19:37314868~37315620:-
BRCA	cis	rs2562456	0.833	rs62107547	ENSG00000268535.1	RP11-420K14.3	5.2	2.43e-07	2.79e-05	0.23	0.16	Pain;	chr19:21341245	chr19:21709522~21710191:+
BRCA	cis	rs2153535	0.585	rs9379234	ENSG00000230939.1	RP11-314C16.1	-5.2	2.43e-07	2.79e-05	-0.19	-0.16	Motion sickness;	chr6:8643520	chr6:8784178~8785445:+
BRCA	cis	rs4713118	0.615	rs9348772	ENSG00000220721.1	OR1F12	5.2	2.43e-07	2.79e-05	0.18	0.16	Parkinson's disease;	chr6:27688311	chr6:28073316~28074233:+
BRCA	cis	rs6441961	0.501	rs6441958	ENSG00000223552.1	RP11-24F11.2	5.2	2.43e-07	2.79e-05	0.2	0.16	Celiac disease;	chr3:46299844	chr3:46364955~46407059:-
BRCA	cis	rs4835473	0.897	rs7657088	ENSG00000249741.2	RP11-673E1.3	5.2	2.43e-07	2.79e-05	0.17	0.16	Immature fraction of reticulocytes;	chr4:143701877	chr4:143911514~143912053:-
BRCA	cis	rs755249	0.545	rs12037073	ENSG00000237624.1	OXCT2P1	-5.2	2.44e-07	2.8e-05	-0.19	-0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39581225	chr1:39514956~39516490:+
BRCA	cis	rs10504130	0.932	rs79067987	ENSG00000272024.1	RP11-546K22.3	-5.2	2.44e-07	2.8e-05	-0.29	-0.16	Venous thromboembolism (SNP x SNP interaction);	chr8:51935697	chr8:51950284~51950690:+
BRCA	cis	rs7620503	1	rs7630147	ENSG00000228221.4	LINC00578	5.2	2.44e-07	2.8e-05	0.18	0.16	Corneal structure;	chr3:177582603	chr3:177441921~177752305:+
BRCA	cis	rs7620503	0.959	rs4857709	ENSG00000228221.4	LINC00578	5.2	2.44e-07	2.8e-05	0.18	0.16	Corneal structure;	chr3:177583167	chr3:177441921~177752305:+
BRCA	cis	rs7620503	1	rs4857710	ENSG00000228221.4	LINC00578	5.2	2.44e-07	2.8e-05	0.18	0.16	Corneal structure;	chr3:177583177	chr3:177441921~177752305:+
BRCA	cis	rs7620503	1	rs6763782	ENSG00000228221.4	LINC00578	5.2	2.44e-07	2.8e-05	0.18	0.16	Corneal structure;	chr3:177583492	chr3:177441921~177752305:+
BRCA	cis	rs7620503	0.729	rs2863018	ENSG00000228221.4	LINC00578	5.2	2.44e-07	2.8e-05	0.18	0.16	Corneal structure;	chr3:177584123	chr3:177441921~177752305:+
BRCA	cis	rs2133593	1	rs2133593	ENSG00000228221.4	LINC00578	5.2	2.44e-07	2.8e-05	0.18	0.16	Chin dimples;	chr3:177584204	chr3:177441921~177752305:+
BRCA	cis	rs7824557	0.675	rs2736265	ENSG00000154316.13	TDH	-5.2	2.44e-07	2.8e-05	-0.2	-0.16	Retinal vascular caliber;	chr8:11329165	chr8:11339637~11368452:+
BRCA	cis	rs8180040	0.62	rs1811652	ENSG00000276925.1	RP11-708J19.3	5.2	2.44e-07	2.8e-05	0.18	0.16	Colorectal cancer;	chr3:47167208	chr3:47469777~47469987:+
BRCA	cis	rs7630852	0.965	rs6774504	ENSG00000272359.1	U4	5.2	2.45e-07	2.8e-05	0.19	0.16	Eosinophil counts;	chr3:196784021	chr3:196747192~196747324:-
BRCA	cis	rs6840258	0.831	rs3775211	ENSG00000251411.1	RP11-397E7.4	-5.2	2.45e-07	2.81e-05	-0.22	-0.16	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87117939	chr4:86913266~86914817:-
BRCA	cis	rs7577696	0.785	rs7592356	ENSG00000272716.1	RP11-563N4.1	-5.2	2.45e-07	2.81e-05	-0.18	-0.16	Inflammatory biomarkers;	chr2:32145275	chr2:32165046~32165757:-
BRCA	cis	rs7577696	0.785	rs11694630	ENSG00000272716.1	RP11-563N4.1	-5.2	2.45e-07	2.81e-05	-0.18	-0.16	Inflammatory biomarkers;	chr2:32151132	chr2:32165046~32165757:-
BRCA	cis	rs7620503	1	rs6783033	ENSG00000228221.4	LINC00578	5.2	2.45e-07	2.81e-05	0.18	0.16	Corneal structure;	chr3:177584963	chr3:177441921~177752305:+
BRCA	cis	rs7620503	0.959	rs6770216	ENSG00000228221.4	LINC00578	5.2	2.45e-07	2.81e-05	0.18	0.16	Corneal structure;	chr3:177585139	chr3:177441921~177752305:+
BRCA	cis	rs7620503	0.959	rs2863016	ENSG00000228221.4	LINC00578	5.2	2.45e-07	2.81e-05	0.18	0.16	Corneal structure;	chr3:177585192	chr3:177441921~177752305:+
BRCA	cis	rs6840360	0.642	rs2709817	ENSG00000278978.1	RP11-164P12.5	-5.2	2.45e-07	2.81e-05	-0.17	-0.16	Intelligence (multi-trait analysis);	chr4:151460898	chr4:151669786~151670503:+
BRCA	cis	rs6840360	0.642	rs2709818	ENSG00000278978.1	RP11-164P12.5	-5.2	2.45e-07	2.81e-05	-0.17	-0.16	Intelligence (multi-trait analysis);	chr4:151461482	chr4:151669786~151670503:+
BRCA	cis	rs2015599	0.549	rs9738165	ENSG00000275476.1	RP11-996F15.4	5.2	2.45e-07	2.81e-05	0.18	0.16	Platelet count;Mean platelet volume;	chr12:29290263	chr12:29277397~29277882:-
BRCA	cis	rs9308731	0.966	rs3827536	ENSG00000230499.1	AC108463.1	-5.2	2.45e-07	2.81e-05	-0.19	-0.16	Chronic lymphocytic leukemia;	chr2:111163164	chr2:111195963~111206494:+
BRCA	cis	rs763121	0.853	rs5750669	ENSG00000228274.3	RP3-508I15.9	-5.2	2.45e-07	2.81e-05	-0.18	-0.16	Menopause (age at onset);	chr22:38684633	chr22:38667585~38681820:-
BRCA	cis	rs1075265	0.62	rs10192626	ENSG00000235937.1	AC008280.1	5.2	2.45e-07	2.81e-05	0.17	0.16	Chronotype;Morning vs. evening chronotype;	chr2:53760885	chr2:54029552~54030682:-
BRCA	cis	rs9659323	0.65	rs1155949	ENSG00000231365.4	RP11-418J17.1	-5.2	2.45e-07	2.81e-05	-0.2	-0.16	Body mass index;	chr1:118953956	chr1:119140396~119275973:+
BRCA	cis	rs3758911	0.673	rs1991199	ENSG00000255353.1	RP11-382M14.1	-5.2	2.45e-07	2.81e-05	-0.21	-0.16	Coronary artery disease;	chr11:107254235	chr11:107176286~107177530:+
BRCA	cis	rs2236295	0.503	rs10822064	ENSG00000238280.1	RP11-436D10.3	5.2	2.45e-07	2.81e-05	0.21	0.16	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks);	chr10:62849964	chr10:62793562~62805887:-
BRCA	cis	rs2839186	0.721	rs3788252	ENSG00000228137.1	AP001469.7	5.2	2.45e-07	2.81e-05	0.16	0.16	Testicular germ cell tumor;	chr21:46241321	chr21:46246890~46247682:+
BRCA	cis	rs4650994	0.525	rs11806608	ENSG00000273384.1	RP5-1098D14.1	5.2	2.45e-07	2.81e-05	0.2	0.16	HDL cholesterol;HDL cholesterol levels;	chr1:178542240	chr1:178651706~178652282:+
BRCA	cis	rs848490	0.656	rs55714086	ENSG00000214293.7	APTR	5.2	2.45e-07	2.81e-05	0.18	0.16	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77807168	chr7:77657660~77696265:-
BRCA	cis	rs4835473	0.897	rs36083752	ENSG00000249741.2	RP11-673E1.3	5.2	2.46e-07	2.82e-05	0.17	0.16	Immature fraction of reticulocytes;	chr4:143693377	chr4:143911514~143912053:-
BRCA	cis	rs4835473	0.897	rs35162238	ENSG00000249741.2	RP11-673E1.3	5.2	2.46e-07	2.82e-05	0.17	0.16	Immature fraction of reticulocytes;	chr4:143693518	chr4:143911514~143912053:-
BRCA	cis	rs4713118	0.513	rs156739	ENSG00000280107.1	AL022393.9	-5.2	2.46e-07	2.82e-05	-0.22	-0.16	Parkinson's disease;	chr6:28045632	chr6:28170845~28172521:+
BRCA	cis	rs7613875	0.58	rs12634780	ENSG00000228008.1	CTD-2330K9.3	-5.2	2.46e-07	2.82e-05	-0.16	-0.16	Body mass index;	chr3:50005908	chr3:49903845~49916937:+
BRCA	cis	rs4671400	0.571	rs2421116	ENSG00000271889.1	RP11-493E12.1	-5.2	2.46e-07	2.82e-05	-0.23	-0.16	3-hydroxypropylmercapturic acid levels in smokers;	chr2:61261276	chr2:61151433~61162105:-
BRCA	cis	rs1707322	1	rs12060274	ENSG00000234329.1	RP11-767N6.2	5.2	2.46e-07	2.82e-05	0.16	0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45825390	chr1:45651039~45651826:-
BRCA	cis	rs7569084	0.687	rs11675538	ENSG00000281920.1	RP11-418H16.1	5.2	2.46e-07	2.82e-05	0.2	0.16	Sum eosinophil basophil counts;	chr2:65459327	chr2:65623272~65628424:+
BRCA	cis	rs4713118	0.621	rs10484403	ENSG00000204709.4	LINC01556	5.2	2.46e-07	2.82e-05	0.24	0.16	Parkinson's disease;	chr6:28065745	chr6:28943877~28944537:+
BRCA	cis	rs2408955	0.561	rs9971924	ENSG00000273765.1	RP11-370I10.11	-5.2	2.46e-07	2.82e-05	-0.19	-0.16	Glycated hemoglobin levels;	chr12:48086049	chr12:48360920~48361377:+
BRCA	cis	rs6545883	0.811	rs778753	ENSG00000271889.1	RP11-493E12.1	5.2	2.46e-07	2.82e-05	0.2	0.16	Tuberculosis;	chr2:61553065	chr2:61151433~61162105:-
BRCA	cis	rs4908768	0.539	rs6663123	ENSG00000232912.4	RP5-1115A15.1	5.2	2.46e-07	2.82e-05	0.15	0.16	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8582872	chr1:8424645~8434838:+
BRCA	cis	rs2708977	0.637	rs654224	ENSG00000237510.6	AC008268.2	-5.2	2.46e-07	2.82e-05	-0.21	-0.16	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96414386	chr2:95789654~95800166:+
BRCA	cis	rs1387259	0.929	rs2634666	ENSG00000226413.2	OR8T1P	5.19	2.46e-07	2.82e-05	0.21	0.16	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48269887	chr12:48442030~48442947:-
BRCA	cis	rs7246657	0.765	rs10402455	ENSG00000267422.1	CTD-2554C21.1	-5.19	2.46e-07	2.82e-05	-0.26	-0.16	Coronary artery calcification;	chr19:37237805	chr19:37779686~37792865:+
BRCA	cis	rs10752881	0.967	rs6695746	ENSG00000224468.3	RP11-181K3.4	-5.19	2.46e-07	2.83e-05	-0.17	-0.16	Colorectal cancer;	chr1:183022220	chr1:183138402~183141282:-
BRCA	cis	rs10752881	0.967	rs6695837	ENSG00000224468.3	RP11-181K3.4	-5.19	2.46e-07	2.83e-05	-0.17	-0.16	Colorectal cancer;	chr1:183022327	chr1:183138402~183141282:-
BRCA	cis	rs7618915	0.547	rs13065019	ENSG00000243224.1	RP5-1157M23.2	-5.19	2.46e-07	2.83e-05	-0.18	-0.16	Bipolar disorder;	chr3:52651228	chr3:52239258~52241097:+
BRCA	cis	rs7621025	0.586	rs12330725	ENSG00000239213.4	NCK1-AS1	-5.19	2.46e-07	2.83e-05	-0.19	-0.16	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136693738	chr3:136841726~136862054:-
BRCA	cis	rs10752881	1	rs10737237	ENSG00000224468.3	RP11-181K3.4	-5.19	2.47e-07	2.83e-05	-0.17	-0.16	Colorectal cancer;	chr1:183020134	chr1:183138402~183141282:-
BRCA	cis	rs10752881	1	rs10797813	ENSG00000224468.3	RP11-181K3.4	-5.19	2.47e-07	2.83e-05	-0.17	-0.16	Colorectal cancer;	chr1:183020231	chr1:183138402~183141282:-
BRCA	cis	rs10752881	0.905	rs12132262	ENSG00000224468.3	RP11-181K3.4	-5.19	2.47e-07	2.83e-05	-0.17	-0.16	Colorectal cancer;	chr1:183020814	chr1:183138402~183141282:-
BRCA	cis	rs10752881	1	rs10752887	ENSG00000224468.3	RP11-181K3.4	-5.19	2.47e-07	2.83e-05	-0.17	-0.16	Colorectal cancer;	chr1:183021699	chr1:183138402~183141282:-
BRCA	cis	rs10911232	0.507	rs10797814	ENSG00000224468.3	RP11-181K3.4	-5.19	2.47e-07	2.83e-05	-0.17	-0.16	Hypertriglyceridemia;	chr1:183021794	chr1:183138402~183141282:-
BRCA	cis	rs794185	0.625	rs1844123	ENSG00000231249.1	ITPR1-AS1	-5.19	2.47e-07	2.83e-05	-0.18	-0.16	Multiple sclerosis--Brain Glutamate Levels;	chr3:4471177	chr3:4490891~4493163:-
BRCA	cis	rs2408955	0.522	rs4760679	ENSG00000273765.1	RP11-370I10.11	-5.19	2.47e-07	2.83e-05	-0.19	-0.16	Glycated hemoglobin levels;	chr12:48067852	chr12:48360920~48361377:+
BRCA	cis	rs1075265	0.589	rs2542571	ENSG00000235937.1	AC008280.1	5.19	2.47e-07	2.83e-05	0.17	0.16	Chronotype;Morning vs. evening chronotype;	chr2:53814846	chr2:54029552~54030682:-
BRCA	cis	rs904251	0.772	rs1812186	ENSG00000204110.6	RP1-153P14.8	-5.19	2.47e-07	2.83e-05	-0.19	-0.16	Cognitive performance;	chr6:37498140	chr6:37507348~37535616:+
BRCA	cis	rs2153535	0.521	rs6939827	ENSG00000251164.1	HULC	-5.19	2.47e-07	2.83e-05	-0.2	-0.16	Motion sickness;	chr6:8461127	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.58	rs9393019	ENSG00000251164.1	HULC	-5.19	2.47e-07	2.83e-05	-0.2	-0.16	Motion sickness;	chr6:8461858	chr6:8652137~8653846:+
BRCA	cis	rs4660214	0.666	rs625384	ENSG00000228060.1	RP11-69E11.8	-5.19	2.47e-07	2.83e-05	-0.16	-0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39427421	chr1:39565160~39573203:+
BRCA	cis	rs250585	0.92	rs250553	ENSG00000260136.4	CTD-2270L9.4	5.19	2.47e-07	2.83e-05	0.17	0.16	Egg allergy;	chr16:23430144	chr16:23452758~23457606:+
BRCA	cis	rs6430585	0.528	rs6711493	ENSG00000231890.6	DARS-AS1	-5.19	2.47e-07	2.83e-05	-0.23	-0.16	Corneal structure;	chr2:135934983	chr2:135985176~136022593:+
BRCA	cis	rs9341808	0.718	rs2143887	ENSG00000272129.1	RP11-250B2.6	5.19	2.47e-07	2.83e-05	0.2	0.16	Sitting height ratio;	chr6:80207570	chr6:80355424~80356859:+
BRCA	cis	rs4908760	0.539	rs6698830	ENSG00000270282.1	RP5-1115A15.2	5.19	2.47e-07	2.84e-05	0.17	0.16	Vitiligo;	chr1:8794486	chr1:8512653~8513021:+
BRCA	cis	rs7134599	0.561	rs7134731	ENSG00000255733.4	IFNG-AS1	5.19	2.47e-07	2.84e-05	0.13	0.16	Inflammatory bowel disease;Ulcerative colitis;	chr12:68076278	chr12:67989445~68234686:+
BRCA	cis	rs7914558	1	rs10748838	ENSG00000236937.2	PTGES3P4	5.19	2.47e-07	2.84e-05	0.2	0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103184229	chr10:102845595~102845950:+
BRCA	cis	rs7914558	0.966	rs3758543	ENSG00000236937.2	PTGES3P4	5.19	2.47e-07	2.84e-05	0.2	0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103184987	chr10:102845595~102845950:+
BRCA	cis	rs910316	0.699	rs175039	ENSG00000279594.1	RP11-950C14.10	-5.19	2.48e-07	2.84e-05	-0.18	-0.16	Height;	chr14:75002247	chr14:75011269~75012851:-
BRCA	cis	rs7620503	0.506	rs2242401	ENSG00000228221.4	LINC00578	5.19	2.48e-07	2.84e-05	0.2	0.16	Corneal structure;	chr3:177620492	chr3:177441921~177752305:+
BRCA	cis	rs910316	0.967	rs12147532	ENSG00000279594.1	RP11-950C14.10	-5.19	2.48e-07	2.84e-05	-0.18	-0.16	Height;	chr14:75185155	chr14:75011269~75012851:-
BRCA	cis	rs6496044	0.591	rs979825	ENSG00000259295.5	CSPG4P12	5.19	2.48e-07	2.84e-05	0.19	0.16	Interstitial lung disease;	chr15:85537394	chr15:85191438~85213905:+
BRCA	cis	rs7267979	0.789	rs6050472	ENSG00000277938.1	RP5-965G21.3	5.19	2.48e-07	2.84e-05	0.2	0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25239216	chr20:25229150~25231933:+
BRCA	cis	rs4819052	0.679	rs4819053	ENSG00000184274.3	LINC00315	5.19	2.48e-07	2.84e-05	0.2	0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45291442	chr21:45300245~45305257:-
BRCA	cis	rs7577696	0.695	rs212687	ENSG00000272716.1	RP11-563N4.1	5.19	2.48e-07	2.85e-05	0.17	0.16	Inflammatory biomarkers;	chr2:32210107	chr2:32165046~32165757:-
BRCA	cis	rs2638953	0.962	rs11049611	ENSG00000247934.4	RP11-967K21.1	-5.19	2.48e-07	2.85e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28447311	chr12:28163298~28190738:-
BRCA	cis	rs1075265	0.783	rs805438	ENSG00000235937.1	AC008280.1	5.19	2.48e-07	2.85e-05	0.17	0.16	Chronotype;Morning vs. evening chronotype;	chr2:53829051	chr2:54029552~54030682:-
BRCA	cis	rs4713675	0.584	rs7739505	ENSG00000224557.6	HLA-DPB2	-5.19	2.49e-07	2.85e-05	-0.19	-0.16	Plateletcrit;	chr6:33702593	chr6:33112451~33129084:+
BRCA	cis	rs507080	0.769	rs745663	ENSG00000278376.1	RP11-158I9.8	-5.19	2.49e-07	2.85e-05	-0.16	-0.16	Serum metabolite levels;	chr11:118658886	chr11:118791254~118793137:+
BRCA	cis	rs9393777	0.92	rs34953377	ENSG00000220721.1	OR1F12	5.19	2.49e-07	2.85e-05	0.34	0.16	Intelligence (multi-trait analysis);	chr6:27413881	chr6:28073316~28074233:+
BRCA	cis	rs9393777	0.778	rs66841633	ENSG00000220721.1	OR1F12	5.19	2.49e-07	2.85e-05	0.34	0.16	Intelligence (multi-trait analysis);	chr6:27414607	chr6:28073316~28074233:+
BRCA	cis	rs494453	0.883	rs1099800	ENSG00000227811.2	FAM212B-AS1	-5.19	2.49e-07	2.85e-05	-0.2	-0.16	Osteoporosis-related phenotypes;	chr1:111682961	chr1:111739841~111747798:+
BRCA	cis	rs875971	0.964	rs697969	ENSG00000164669.11	INTS4P1	5.19	2.49e-07	2.85e-05	0.2	0.16	Aortic root size;	chr7:66093491	chr7:65141225~65234216:+
BRCA	cis	rs875971	1	rs1182882	ENSG00000164669.11	INTS4P1	5.19	2.49e-07	2.85e-05	0.2	0.16	Aortic root size;	chr7:66097076	chr7:65141225~65234216:+
BRCA	cis	rs6439153	0.933	rs9822511	ENSG00000231305.3	RP11-723O4.2	5.19	2.49e-07	2.85e-05	0.18	0.16	Pneumococcal bacteremia;	chr3:128986724	chr3:128861313~128871540:-
BRCA	cis	rs860295	0.702	rs12081067	ENSG00000160766.13	GBAP1	-5.19	2.49e-07	2.85e-05	-0.17	-0.16	Body mass index;	chr1:155389191	chr1:155213821~155227422:-
BRCA	cis	rs9656709	0.528	rs4948054	ENSG00000273720.1	RP11-613E4.4	5.19	2.49e-07	2.85e-05	0.2	0.16	Behavioural disinhibition (generation interaction);	chr7:55663907	chr7:55743073~55743457:+
BRCA	cis	rs7577696	0.962	rs13000753	ENSG00000272716.1	RP11-563N4.1	-5.19	2.49e-07	2.85e-05	-0.17	-0.16	Inflammatory biomarkers;	chr2:32057228	chr2:32165046~32165757:-
BRCA	cis	rs2522056	0.935	rs1981524	ENSG00000233006.5	AC034220.3	-5.19	2.49e-07	2.86e-05	-0.14	-0.16	Fibrinogen;Lymphocyte counts;	chr5:132420814	chr5:132311285~132369916:-
BRCA	cis	rs875971	1	rs1540651	ENSG00000223473.2	GS1-124K5.3	-5.19	2.49e-07	2.86e-05	-0.12	-0.16	Aortic root size;	chr7:66185134	chr7:66491049~66493566:-
BRCA	cis	rs6840360	0.642	rs7677131	ENSG00000278978.1	RP11-164P12.5	-5.19	2.49e-07	2.86e-05	-0.18	-0.16	Intelligence (multi-trait analysis);	chr4:151431863	chr4:151669786~151670503:+
BRCA	cis	rs17685	0.753	rs10476	ENSG00000280388.1	RP11-229D13.3	5.19	2.5e-07	2.86e-05	0.17	0.16	Coffee consumption (cups per day);Coffee consumption;	chr7:76067102	chr7:76043977~76045963:-
BRCA	cis	rs7430456	0.874	rs7428501	ENSG00000228561.2	RP11-114M1.1	5.19	2.5e-07	2.86e-05	0.2	0.16	Breast cancer;	chr3:177751974	chr3:177683627~177691250:+
BRCA	cis	rs7193541	0.859	rs12598791	ENSG00000262904.1	TMPOP2	-5.19	2.5e-07	2.86e-05	-0.16	-0.16	Multiple myeloma;	chr16:74466847	chr16:74667506~74668706:+
BRCA	cis	rs1552244	1	rs56394721	ENSG00000232901.1	CYCSP10	5.19	2.5e-07	2.86e-05	0.22	0.16	Alzheimer's disease;	chr3:10109111	chr3:10000647~10000940:-
BRCA	cis	rs7267979	1	rs6138572	ENSG00000125804.12	FAM182A	-5.19	2.5e-07	2.87e-05	-0.21	-0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25455298	chr20:26054655~26086917:+
BRCA	cis	rs7267979	1	rs6138575	ENSG00000125804.12	FAM182A	-5.19	2.5e-07	2.87e-05	-0.21	-0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25458316	chr20:26054655~26086917:+
BRCA	cis	rs875971	0.79	rs10257911	ENSG00000236529.1	RP13-254B10.1	-5.19	2.5e-07	2.87e-05	-0.18	-0.16	Aortic root size;	chr7:66278783	chr7:65840212~65840596:+
BRCA	cis	rs35740288	0.929	rs11556865	ENSG00000259407.1	RP11-158M2.3	-5.19	2.5e-07	2.87e-05	-0.21	-0.16	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85759949	chr15:85744109~85750281:-
BRCA	cis	rs2638953	0.711	rs11049605	ENSG00000247934.4	RP11-967K21.1	-5.19	2.51e-07	2.87e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28443132	chr12:28163298~28190738:-
BRCA	cis	rs1124769	0.654	rs55712458	ENSG00000259378.1	DCAF13P3	5.19	2.51e-07	2.87e-05	0.23	0.16	Cognitive performance;	chr15:51191799	chr15:50944663~50945996:+
BRCA	cis	rs1075265	0.633	rs3731967	ENSG00000235937.1	AC008280.1	-5.19	2.51e-07	2.87e-05	-0.17	-0.16	Chronotype;Morning vs. evening chronotype;	chr2:53975311	chr2:54029552~54030682:-
BRCA	cis	rs7111546	0.625	rs78747550	ENSG00000246225.5	RP11-17A1.3	5.19	2.51e-07	2.87e-05	0.27	0.16	Dialysis-related mortality;	chr11:22899990	chr11:22829380~22945393:+
BRCA	cis	rs763121	0.853	rs6519120	ENSG00000228274.3	RP3-508I15.9	5.19	2.51e-07	2.87e-05	0.18	0.16	Menopause (age at onset);	chr22:38595388	chr22:38667585~38681820:-
BRCA	cis	rs12612619	0.579	rs6722906	ENSG00000272148.1	RP11-195B17.1	-5.19	2.51e-07	2.87e-05	-0.18	-0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:26857167	chr2:27062428~27062907:-
BRCA	cis	rs804280	0.56	rs10503426	ENSG00000255046.1	RP11-297N6.4	-5.19	2.51e-07	2.87e-05	-0.2	-0.16	Myopia (pathological);	chr8:11731874	chr8:11797928~11802568:-
BRCA	cis	rs8002861	0.901	rs9525867	ENSG00000274001.1	RP11-5G9.5	5.19	2.51e-07	2.88e-05	0.18	0.16	Leprosy;	chr13:43889421	chr13:43877715~43878163:-
BRCA	cis	rs3733585	0.673	rs4292332	ENSG00000250413.1	RP11-448G15.1	5.19	2.51e-07	2.88e-05	0.21	0.16	Cleft plate (environmental tobacco smoke interaction);	chr4:9952206	chr4:10006482~10009725:+
BRCA	cis	rs3733585	0.673	rs4292333	ENSG00000250413.1	RP11-448G15.1	5.19	2.51e-07	2.88e-05	0.21	0.16	Cleft plate (environmental tobacco smoke interaction);	chr4:9952247	chr4:10006482~10009725:+
BRCA	cis	rs3733585	0.673	rs4447861	ENSG00000250413.1	RP11-448G15.1	5.19	2.51e-07	2.88e-05	0.21	0.16	Cleft plate (environmental tobacco smoke interaction);	chr4:9952316	chr4:10006482~10009725:+
BRCA	cis	rs3733585	0.673	rs4459990	ENSG00000250413.1	RP11-448G15.1	5.19	2.51e-07	2.88e-05	0.21	0.16	Cleft plate (environmental tobacco smoke interaction);	chr4:9952381	chr4:10006482~10009725:+
BRCA	cis	rs3733585	0.673	rs4495037	ENSG00000250413.1	RP11-448G15.1	5.19	2.51e-07	2.88e-05	0.21	0.16	Cleft plate (environmental tobacco smoke interaction);	chr4:9952426	chr4:10006482~10009725:+
BRCA	cis	rs3733585	0.673	rs4627861	ENSG00000250413.1	RP11-448G15.1	5.19	2.51e-07	2.88e-05	0.21	0.16	Cleft plate (environmental tobacco smoke interaction);	chr4:9952614	chr4:10006482~10009725:+
BRCA	cis	rs17767294	0.614	rs41269291	ENSG00000204709.4	LINC01556	5.19	2.51e-07	2.88e-05	0.43	0.16	Parkinson's disease;	chr6:28283762	chr6:28943877~28944537:+
BRCA	cis	rs17767294	0.614	rs72854506	ENSG00000204709.4	LINC01556	5.19	2.51e-07	2.88e-05	0.43	0.16	Parkinson's disease;	chr6:28284720	chr6:28943877~28944537:+
BRCA	cis	rs7487075	0.619	rs2220727	ENSG00000274723.1	RP11-618L22.1	5.19	2.51e-07	2.88e-05	0.19	0.16	Itch intensity from mosquito bite;	chr12:46411286	chr12:46970504~46972155:+
BRCA	cis	rs3764021	0.87	rs10844597	ENSG00000256673.1	RP11-599J14.2	-5.19	2.51e-07	2.88e-05	-0.18	-0.16	Type 1 diabetes;	chr12:9722303	chr12:9398355~9414851:-
BRCA	cis	rs8103033	0.786	rs2190912	ENSG00000268088.1	AC093063.2	-5.19	2.52e-07	2.88e-05	-0.17	-0.16	Obesity-related traits;	chr19:39656982	chr19:39693925~39696258:+
BRCA	cis	rs8103033	0.786	rs2190913	ENSG00000268088.1	AC093063.2	-5.19	2.52e-07	2.88e-05	-0.17	-0.16	Obesity-related traits;	chr19:39656984	chr19:39693925~39696258:+
BRCA	cis	rs9921338	0.961	rs4780357	ENSG00000262703.1	RP11-485G7.6	-5.19	2.52e-07	2.88e-05	-0.2	-0.16	Vein graft stenosis in coronary artery bypass grafting;	chr16:11277114	chr16:11348143~11349321:-
BRCA	cis	rs799165	0.54	rs17145813	ENSG00000274080.1	CTA-315H11.2	-5.19	2.52e-07	2.88e-05	-0.23	-0.16	Age-related diseases, mortality and associated endophenotypes;Age-related disease endophenotypes;	chr7:73632428	chr7:73609262~73611502:-
BRCA	cis	rs559555	0.574	rs632148	ENSG00000272716.1	RP11-563N4.1	5.19	2.52e-07	2.88e-05	0.19	0.16	Blood metabolite ratios;Blood metabolite levels;	chr2:31580962	chr2:32165046~32165757:-
BRCA	cis	rs6480314	0.542	rs12572960	ENSG00000233590.1	RP11-153K11.3	-5.19	2.52e-07	2.88e-05	-0.26	-0.16	Optic nerve measurement (disc area);	chr10:68270966	chr10:68233251~68242379:-
BRCA	cis	rs7200543	1	rs1121	ENSG00000260735.1	RP11-72I8.1	-5.19	2.52e-07	2.88e-05	-0.19	-0.16	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15037219	chr16:15094411~15109197:+
BRCA	cis	rs7208859	0.623	rs9895785	ENSG00000280069.1	CTD-2349P21.3	5.19	2.52e-07	2.88e-05	0.22	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780690	chr17:30738182~30740275:+
BRCA	cis	rs7772486	0.875	rs6930975	ENSG00000270638.1	RP3-466P17.1	5.19	2.52e-07	2.88e-05	0.18	0.16	Lobe attachment (rater-scored or self-reported);	chr6:146065975	chr6:145735570~145737218:+
BRCA	cis	rs77972916	0.536	rs59362315	ENSG00000234936.1	AC010883.5	5.19	2.52e-07	2.89e-05	0.18	0.16	Granulocyte percentage of myeloid white cells;	chr2:43367792	chr2:43229573~43233394:+
BRCA	cis	rs9300255	0.722	rs12304248	ENSG00000235423.7	RP11-282O18.3	-5.19	2.52e-07	2.89e-05	-0.2	-0.16	Neutrophil percentage of white cells;	chr12:123325878	chr12:123252030~123261483:-
BRCA	cis	rs1075265	0.54	rs2542587	ENSG00000235937.1	AC008280.1	5.19	2.52e-07	2.89e-05	0.17	0.16	Chronotype;Morning vs. evening chronotype;	chr2:53788839	chr2:54029552~54030682:-
BRCA	cis	rs1075265	0.563	rs2692537	ENSG00000235937.1	AC008280.1	5.19	2.52e-07	2.89e-05	0.17	0.16	Chronotype;Morning vs. evening chronotype;	chr2:53788840	chr2:54029552~54030682:-
BRCA	cis	rs7845219	0.544	rs7017487	ENSG00000253528.2	RP11-347C18.4	-5.19	2.52e-07	2.89e-05	-0.17	-0.16	Type 2 diabetes;	chr8:94910524	chr8:94974573~94974853:-
BRCA	cis	rs6600671	1	rs10794671	ENSG00000275538.1	RNVU1-19	5.19	2.52e-07	2.89e-05	0.19	0.16	Hip geometry;	chr1:121426382	chr1:120850819~120850985:-
BRCA	cis	rs6430585	0.528	rs309152	ENSG00000231890.6	DARS-AS1	5.19	2.52e-07	2.89e-05	0.23	0.16	Corneal structure;	chr2:135899682	chr2:135985176~136022593:+
BRCA	cis	rs6081541	0.622	rs6035259	ENSG00000179447.2	RP5-1027G4.3	5.19	2.52e-07	2.89e-05	0.2	0.16	Psychosis (atypical);	chr20:19225349	chr20:19242302~19284596:-
BRCA	cis	rs6756513	0.5	rs4420721	ENSG00000231024.1	AC092431.3	5.19	2.52e-07	2.89e-05	0.22	0.16	Breast cancer;Platelet count;	chr2:69836395	chr2:69700192~69713847:-
BRCA	cis	rs7181230	0.885	rs8026641	ENSG00000275636.1	RP11-521C20.5	-5.19	2.53e-07	2.89e-05	-0.2	-0.16	Dehydroepiandrosterone sulphate levels;	chr15:40046660	chr15:40078892~40079347:+
BRCA	cis	rs4950322	0.547	rs17355509	ENSG00000244371.2	PFN1P8	-5.19	2.53e-07	2.89e-05	-0.22	-0.16	Protein quantitative trait loci;	chr1:147123139	chr1:146957117~146957659:-
BRCA	cis	rs728616	0.867	rs12412226	ENSG00000225484.5	NUTM2B-AS1	-5.19	2.53e-07	2.89e-05	-0.43	-0.16	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79975532	chr10:79663088~79826594:-
BRCA	cis	rs728616	0.867	rs4387301	ENSG00000225484.5	NUTM2B-AS1	-5.19	2.53e-07	2.89e-05	-0.43	-0.16	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79976643	chr10:79663088~79826594:-
BRCA	cis	rs728616	0.867	rs61860420	ENSG00000225484.5	NUTM2B-AS1	-5.19	2.53e-07	2.89e-05	-0.43	-0.16	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79979623	chr10:79663088~79826594:-
BRCA	cis	rs728616	0.867	rs75447386	ENSG00000225484.5	NUTM2B-AS1	-5.19	2.53e-07	2.89e-05	-0.43	-0.16	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79979891	chr10:79663088~79826594:-
BRCA	cis	rs728616	0.867	rs4520539	ENSG00000225484.5	NUTM2B-AS1	-5.19	2.53e-07	2.89e-05	-0.43	-0.16	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79980773	chr10:79663088~79826594:-
BRCA	cis	rs728616	0.867	rs61860421	ENSG00000225484.5	NUTM2B-AS1	-5.19	2.53e-07	2.89e-05	-0.43	-0.16	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79983643	chr10:79663088~79826594:-
BRCA	cis	rs7188861	0.626	rs7193871	ENSG00000262636.1	CTD-3088G3.4	5.19	2.53e-07	2.89e-05	0.22	0.16	HDL cholesterol;	chr16:11361749	chr16:11380859~11381118:-
BRCA	cis	rs9287719	0.87	rs728135	ENSG00000243819.4	RN7SL832P	5.19	2.53e-07	2.89e-05	0.15	0.16	Prostate cancer;	chr2:10605006	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.967	rs2884233	ENSG00000243819.4	RN7SL832P	5.19	2.53e-07	2.89e-05	0.15	0.16	Prostate cancer;	chr2:10605177	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.839	rs12692415	ENSG00000243819.4	RN7SL832P	5.19	2.53e-07	2.89e-05	0.15	0.16	Prostate cancer;	chr2:10605348	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.934	rs12692416	ENSG00000243819.4	RN7SL832P	5.19	2.53e-07	2.89e-05	0.15	0.16	Prostate cancer;	chr2:10605501	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.967	rs12692417	ENSG00000243819.4	RN7SL832P	5.19	2.53e-07	2.89e-05	0.15	0.16	Prostate cancer;	chr2:10605592	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.934	rs12692418	ENSG00000243819.4	RN7SL832P	5.19	2.53e-07	2.89e-05	0.15	0.16	Prostate cancer;	chr2:10605744	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.967	rs6755548	ENSG00000243819.4	RN7SL832P	5.19	2.53e-07	2.89e-05	0.15	0.16	Prostate cancer;	chr2:10606000	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.967	rs6761678	ENSG00000243819.4	RN7SL832P	5.19	2.53e-07	2.89e-05	0.15	0.16	Prostate cancer;	chr2:10606215	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.967	rs6759100	ENSG00000243819.4	RN7SL832P	5.19	2.53e-07	2.89e-05	0.15	0.16	Prostate cancer;	chr2:10606584	chr2:10690344~10692099:+
BRCA	cis	rs4835473	0.897	rs1545437	ENSG00000249741.2	RP11-673E1.3	5.19	2.53e-07	2.89e-05	0.17	0.16	Immature fraction of reticulocytes;	chr4:143696689	chr4:143911514~143912053:-
BRCA	cis	rs7772486	0.686	rs857883	ENSG00000270638.1	RP3-466P17.1	-5.19	2.53e-07	2.89e-05	-0.18	-0.16	Lobe attachment (rater-scored or self-reported);	chr6:145648078	chr6:145735570~145737218:+
BRCA	cis	rs7772486	0.686	rs857882	ENSG00000270638.1	RP3-466P17.1	-5.19	2.53e-07	2.89e-05	-0.18	-0.16	Lobe attachment (rater-scored or self-reported);	chr6:145648580	chr6:145735570~145737218:+
BRCA	cis	rs7772486	0.686	rs857877	ENSG00000270638.1	RP3-466P17.1	-5.19	2.53e-07	2.89e-05	-0.18	-0.16	Lobe attachment (rater-scored or self-reported);	chr6:145655094	chr6:145735570~145737218:+
BRCA	cis	rs16846053	0.786	rs72873645	ENSG00000227403.1	AC009299.3	5.19	2.53e-07	2.89e-05	0.38	0.16	Blood osmolality (transformed sodium);	chr2:161638537	chr2:161244739~161249050:+
BRCA	cis	rs2303319	0.504	rs55925603	ENSG00000227403.1	AC009299.3	5.19	2.53e-07	2.89e-05	0.38	0.16	Cognitive function;	chr2:161640700	chr2:161244739~161249050:+
BRCA	cis	rs2303319	0.504	rs56260047	ENSG00000227403.1	AC009299.3	5.19	2.53e-07	2.89e-05	0.38	0.16	Cognitive function;	chr2:161640715	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.792	rs62188983	ENSG00000227403.1	AC009299.3	5.19	2.53e-07	2.89e-05	0.38	0.16	Blood osmolality (transformed sodium);	chr2:161657449	chr2:161244739~161249050:+
BRCA	cis	rs2303319	0.504	rs62188987	ENSG00000227403.1	AC009299.3	5.19	2.53e-07	2.89e-05	0.38	0.16	Cognitive function;	chr2:161669176	chr2:161244739~161249050:+
BRCA	cis	rs2303319	0.504	rs12467042	ENSG00000227403.1	AC009299.3	5.19	2.53e-07	2.89e-05	0.38	0.16	Cognitive function;	chr2:161670461	chr2:161244739~161249050:+
BRCA	cis	rs641862	1	rs641862	ENSG00000275880.1	RP11-90L1.8	5.19	2.53e-07	2.9e-05	0.35	0.16	Obesity-related traits;	chr13:110137885	chr13:110613082~110616353:-
BRCA	cis	rs7617773	0.78	rs35297395	ENSG00000199476.1	Y_RNA	-5.19	2.53e-07	2.9e-05	-0.24	-0.16	Coronary artery disease;	chr3:48301392	chr3:48288587~48288694:+
BRCA	cis	rs7577696	0.785	rs7572964	ENSG00000272716.1	RP11-563N4.1	-5.19	2.53e-07	2.9e-05	-0.18	-0.16	Inflammatory biomarkers;	chr2:32147027	chr2:32165046~32165757:-
BRCA	cis	rs10761482	0.5	rs1938535	ENSG00000254271.1	RP11-131N11.4	5.19	2.53e-07	2.9e-05	0.21	0.16	Schizophrenia;	chr10:60514142	chr10:60734342~60741828:+
BRCA	cis	rs6840360	0.642	rs2709831	ENSG00000278978.1	RP11-164P12.5	-5.19	2.54e-07	2.9e-05	-0.17	-0.16	Intelligence (multi-trait analysis);	chr4:151458499	chr4:151669786~151670503:+
BRCA	cis	rs875971	0.545	rs73152714	ENSG00000228409.4	CCT6P1	-5.19	2.54e-07	2.9e-05	-0.16	-0.16	Aortic root size;	chr7:66534641	chr7:65751142~65763354:+
BRCA	cis	rs875971	0.545	rs4718364	ENSG00000228409.4	CCT6P1	-5.19	2.54e-07	2.9e-05	-0.16	-0.16	Aortic root size;	chr7:66536353	chr7:65751142~65763354:+
BRCA	cis	rs875971	0.545	rs801199	ENSG00000228409.4	CCT6P1	5.19	2.54e-07	2.9e-05	0.16	0.16	Aortic root size;	chr7:66560286	chr7:65751142~65763354:+
BRCA	cis	rs539096	0.872	rs3828150	ENSG00000236200.4	KDM4A-AS1	-5.19	2.54e-07	2.9e-05	-0.2	-0.16	Intelligence (multi-trait analysis);	chr1:43585185	chr1:43699765~43708138:-
BRCA	cis	rs8048589	0.948	rs11648468	ENSG00000175604.2	RP11-276H1.3	5.19	2.54e-07	2.9e-05	0.24	0.16	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);	chr16:12087653	chr16:12086746~12090302:-
BRCA	cis	rs12477438	0.52	rs1453563	ENSG00000231822.1	AC019097.7	5.19	2.54e-07	2.9e-05	0.16	0.16	Chronic sinus infection;	chr2:99103804	chr2:99102018~99102752:+
BRCA	cis	rs12477438	0.501	rs11683188	ENSG00000231822.1	AC019097.7	5.19	2.54e-07	2.9e-05	0.16	0.16	Chronic sinus infection;	chr2:99108049	chr2:99102018~99102752:+
BRCA	cis	rs6430585	0.528	rs309165	ENSG00000231890.6	DARS-AS1	-5.19	2.54e-07	2.9e-05	-0.23	-0.16	Corneal structure;	chr2:135909731	chr2:135985176~136022593:+
BRCA	cis	rs6430585	0.528	rs309158	ENSG00000231890.6	DARS-AS1	-5.19	2.54e-07	2.9e-05	-0.23	-0.16	Corneal structure;	chr2:135922964	chr2:135985176~136022593:+
BRCA	cis	rs2274273	0.713	rs56725788	ENSG00000258413.1	RP11-665C16.6	-5.19	2.54e-07	2.9e-05	-0.2	-0.16	Protein biomarker;	chr14:55073383	chr14:55262767~55272075:-
BRCA	cis	rs2274273	0.743	rs13379159	ENSG00000258413.1	RP11-665C16.6	-5.19	2.54e-07	2.9e-05	-0.2	-0.16	Protein biomarker;	chr14:55074083	chr14:55262767~55272075:-
BRCA	cis	rs2153535	0.563	rs1796688	ENSG00000251164.1	HULC	-5.19	2.54e-07	2.9e-05	-0.2	-0.16	Motion sickness;	chr6:8536190	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.526	rs1796689	ENSG00000251164.1	HULC	-5.19	2.54e-07	2.9e-05	-0.2	-0.16	Motion sickness;	chr6:8536200	chr6:8652137~8653846:+
BRCA	cis	rs7208859	0.623	rs11657662	ENSG00000280069.1	CTD-2349P21.3	5.19	2.54e-07	2.9e-05	0.23	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30749329	chr17:30738182~30740275:+
BRCA	cis	rs793571	0.58	rs12913383	ENSG00000259250.1	RP11-50C13.1	5.19	2.54e-07	2.9e-05	0.24	0.16	Schizophrenia;	chr15:58751587	chr15:58587507~58591676:+
BRCA	cis	rs442309	0.551	rs10822056	ENSG00000238280.1	RP11-436D10.3	-5.19	2.54e-07	2.9e-05	-0.2	-0.16	Vogt-Koyanagi-Harada syndrome;	chr10:62754351	chr10:62793562~62805887:-
BRCA	cis	rs3733585	0.577	rs28558552	ENSG00000250413.1	RP11-448G15.1	5.19	2.54e-07	2.91e-05	0.21	0.16	Cleft plate (environmental tobacco smoke interaction);	chr4:9963289	chr4:10006482~10009725:+
BRCA	cis	rs6543140	0.601	rs7558013	ENSG00000234389.1	AC007278.3	5.19	2.54e-07	2.91e-05	0.18	0.16	Blood protein levels;	chr2:102376346	chr2:102438713~102440475:+
BRCA	cis	rs9341808	0.754	rs9343973	ENSG00000272129.1	RP11-250B2.6	5.19	2.54e-07	2.91e-05	0.2	0.16	Sitting height ratio;	chr6:80203499	chr6:80355424~80356859:+
BRCA	cis	rs4835473	0.864	rs2089837	ENSG00000249741.2	RP11-673E1.3	-5.19	2.54e-07	2.91e-05	-0.17	-0.16	Immature fraction of reticulocytes;	chr4:143965038	chr4:143911514~143912053:-
BRCA	cis	rs10752881	0.809	rs3768613	ENSG00000224468.3	RP11-181K3.4	-5.19	2.54e-07	2.91e-05	-0.17	-0.16	Colorectal cancer;	chr1:183137161	chr1:183138402~183141282:-
BRCA	cis	rs60843830	0.928	rs62114494	ENSG00000272342.1	RP13-539J13.1	5.19	2.54e-07	2.91e-05	0.21	0.16	Spherical equivalent (joint analysis main effects and education interaction);	chr2:211317	chr2:739588~740164:-
BRCA	cis	rs559928	1	rs559928	ENSG00000236935.1	AP003774.1	-5.19	2.55e-07	2.91e-05	-0.18	-0.16	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64382898	chr11:64325050~64329504:-
BRCA	cis	rs17685	0.753	rs869804	ENSG00000280388.1	RP11-229D13.3	-5.19	2.55e-07	2.91e-05	-0.17	-0.16	Coffee consumption (cups per day);Coffee consumption;	chr7:76059636	chr7:76043977~76045963:-
BRCA	cis	rs8048589	1	rs8048589	ENSG00000175604.2	RP11-276H1.3	-5.19	2.55e-07	2.91e-05	-0.23	-0.16	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);	chr16:12091953	chr16:12086746~12090302:-
BRCA	cis	rs12612619	0.732	rs7560144	ENSG00000229122.1	AGBL5-IT1	5.19	2.55e-07	2.91e-05	0.17	0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27057592	chr2:27061038~27061815:+
BRCA	cis	rs8180040	0.681	rs9818382	ENSG00000276925.1	RP11-708J19.3	-5.19	2.55e-07	2.91e-05	-0.18	-0.16	Colorectal cancer;	chr3:47151544	chr3:47469777~47469987:+
BRCA	cis	rs4835473	0.864	rs61427459	ENSG00000249741.2	RP11-673E1.3	5.19	2.55e-07	2.91e-05	0.17	0.16	Immature fraction of reticulocytes;	chr4:143699605	chr4:143911514~143912053:-
BRCA	cis	rs10844706	0.699	rs10844610	ENSG00000214776.8	RP11-726G1.1	5.19	2.55e-07	2.91e-05	0.19	0.16	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9724016	chr12:9467552~9576275:+
BRCA	cis	rs2790457	0.958	rs2772433	ENSG00000254635.4	WAC-AS1	5.19	2.55e-07	2.91e-05	0.19	0.16	Multiple myeloma;	chr10:28607017	chr10:28522652~28532743:-
BRCA	cis	rs11098499	0.754	rs938056	ENSG00000249244.1	RP11-548H18.2	5.19	2.55e-07	2.91e-05	0.18	0.16	Corneal astigmatism;	chr4:119316298	chr4:119391831~119395335:-
BRCA	cis	rs617791	0.53	rs7934543	ENSG00000255320.1	RP11-755F10.1	5.19	2.55e-07	2.91e-05	0.22	0.16	Breast cancer;	chr11:65985037	chr11:66244840~66246239:-
BRCA	cis	rs617791	0.53	rs55947178	ENSG00000255320.1	RP11-755F10.1	5.19	2.55e-07	2.91e-05	0.22	0.16	Breast cancer;	chr11:65986759	chr11:66244840~66246239:-
BRCA	cis	rs6832769	1	rs6832769	ENSG00000272969.1	RP11-528I4.2	5.19	2.55e-07	2.91e-05	0.19	0.16	Personality dimensions;	chr4:55432027	chr4:55547112~55547889:+
BRCA	cis	rs7577696	0.925	rs212717	ENSG00000272716.1	RP11-563N4.1	5.19	2.55e-07	2.91e-05	0.18	0.16	Inflammatory biomarkers;	chr2:32236571	chr2:32165046~32165757:-
BRCA	cis	rs2638953	0.85	rs10843167	ENSG00000247934.4	RP11-967K21.1	-5.19	2.55e-07	2.91e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28429860	chr12:28163298~28190738:-
BRCA	cis	rs2179367	0.632	rs12197598	ENSG00000268592.3	RAET1E-AS1	5.19	2.55e-07	2.92e-05	0.23	0.16	Dupuytren's disease;	chr6:149385418	chr6:149863494~149919507:+
BRCA	cis	rs13108904	0.936	rs4974540	ENSG00000254094.1	AC078852.1	-5.19	2.55e-07	2.92e-05	-0.17	-0.16	Obesity-related traits;	chr4:1219675	chr4:1356581~1358075:+
BRCA	cis	rs9907295	0.579	rs9899866	ENSG00000271013.1	AC015849.15	5.19	2.55e-07	2.92e-05	0.25	0.16	Fibroblast growth factor basic levels;	chr17:35908466	chr17:35912635~35918010:-
BRCA	cis	rs9393777	0.841	rs34332556	ENSG00000220721.1	OR1F12	5.19	2.55e-07	2.92e-05	0.34	0.16	Intelligence (multi-trait analysis);	chr6:27389635	chr6:28073316~28074233:+
BRCA	cis	rs13113518	0.783	rs12508367	ENSG00000272969.1	RP11-528I4.2	5.19	2.56e-07	2.92e-05	0.19	0.16	Height;	chr4:55509442	chr4:55547112~55547889:+
BRCA	cis	rs13113518	0.812	rs2272073	ENSG00000272969.1	RP11-528I4.2	5.19	2.56e-07	2.92e-05	0.19	0.16	Height;	chr4:55510177	chr4:55547112~55547889:+
BRCA	cis	rs6832769	0.961	rs2412647	ENSG00000272969.1	RP11-528I4.2	5.19	2.56e-07	2.92e-05	0.19	0.16	Personality dimensions;	chr4:55452938	chr4:55547112~55547889:+
BRCA	cis	rs12477438	0.559	rs6733285	ENSG00000231822.1	AC019097.7	5.19	2.56e-07	2.92e-05	0.16	0.16	Chronic sinus infection;	chr2:99109112	chr2:99102018~99102752:+
BRCA	cis	rs763121	0.962	rs138703	ENSG00000273076.1	RP3-508I15.22	5.19	2.56e-07	2.92e-05	0.17	0.16	Menopause (age at onset);	chr22:38736743	chr22:38743495~38743910:+
BRCA	cis	rs10911232	0.507	rs6664995	ENSG00000224468.3	RP11-181K3.4	-5.19	2.56e-07	2.92e-05	-0.17	-0.16	Hypertriglyceridemia;	chr1:183048210	chr1:183138402~183141282:-
BRCA	cis	rs7592578	0.771	rs12052514	ENSG00000272979.1	RP11-647K16.1	-5.19	2.56e-07	2.92e-05	-0.26	-0.16	Diastolic blood pressure;	chr2:190513444	chr2:190454092~190454521:-
BRCA	cis	rs13113518	1	rs7662966	ENSG00000223305.1	RN7SKP30	5.19	2.56e-07	2.92e-05	0.19	0.16	Height;	chr4:55548261	chr4:55540502~55540835:-
BRCA	cis	rs17772222	0.696	rs28666030	ENSG00000258789.1	RP11-507K2.3	-5.19	2.56e-07	2.93e-05	-0.18	-0.16	Coronary artery calcification;	chr14:88511463	chr14:88551597~88552493:+
BRCA	cis	rs17772222	0.74	rs28493481	ENSG00000258789.1	RP11-507K2.3	-5.19	2.56e-07	2.93e-05	-0.18	-0.16	Coronary artery calcification;	chr14:88511491	chr14:88551597~88552493:+
BRCA	cis	rs6430585	0.583	rs7581814	ENSG00000231890.6	DARS-AS1	5.19	2.56e-07	2.93e-05	0.24	0.16	Corneal structure;	chr2:135884023	chr2:135985176~136022593:+
BRCA	cis	rs7577696	0.962	rs13024004	ENSG00000272716.1	RP11-563N4.1	-5.19	2.56e-07	2.93e-05	-0.17	-0.16	Inflammatory biomarkers;	chr2:32057293	chr2:32165046~32165757:-
BRCA	cis	rs8016982	0.674	rs8004096	ENSG00000258999.1	RP11-114N19.3	5.19	2.56e-07	2.93e-05	0.19	0.16	Schizophrenia;	chr14:81234738	chr14:81107033~81170414:-
BRCA	cis	rs1707322	0.721	rs7519900	ENSG00000234329.1	RP11-767N6.2	5.19	2.56e-07	2.93e-05	0.17	0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45769275	chr1:45651039~45651826:-
BRCA	cis	rs950169	0.519	rs7237	ENSG00000259295.5	CSPG4P12	5.19	2.56e-07	2.93e-05	0.22	0.16	Schizophrenia;	chr15:84643346	chr15:85191438~85213905:+
BRCA	cis	rs8098244	0.964	rs17203003	ENSG00000264745.1	TTC39C-AS1	-5.19	2.56e-07	2.93e-05	-0.22	-0.16	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23913926	chr18:23994213~24015339:-
BRCA	cis	rs875971	0.545	rs6460281	ENSG00000232546.1	RP11-458F8.1	5.19	2.57e-07	2.93e-05	0.15	0.16	Aortic root size;	chr7:66216128	chr7:66848496~66858136:+
BRCA	cis	rs2115630	0.967	rs8028490	ENSG00000259728.4	LINC00933	-5.19	2.57e-07	2.93e-05	-0.18	-0.16	P wave terminal force;	chr15:84734657	chr15:84570649~84580175:+
BRCA	cis	rs11051970	0.559	rs11051938	ENSG00000274964.1	RP11-817I4.1	-5.19	2.57e-07	2.93e-05	-0.21	-0.16	Response to tocilizumab in rheumatoid arthritis;	chr12:32329882	chr12:32339368~32340724:+
BRCA	cis	rs10761482	0.5	rs10821779	ENSG00000254271.1	RP11-131N11.4	5.19	2.57e-07	2.93e-05	0.21	0.16	Schizophrenia;	chr10:60514767	chr10:60734342~60741828:+
BRCA	cis	rs7487075	0.619	rs67249026	ENSG00000274723.1	RP11-618L22.1	5.19	2.57e-07	2.93e-05	0.19	0.16	Itch intensity from mosquito bite;	chr12:46441985	chr12:46970504~46972155:+
BRCA	cis	rs9652601	0.677	rs35732840	ENSG00000274038.1	RP11-66H6.4	-5.19	2.57e-07	2.93e-05	-0.18	-0.16	Systemic lupus erythematosus;	chr16:11134498	chr16:11056556~11057034:+
BRCA	cis	rs2732480	0.557	rs2409004	ENSG00000257735.1	RP11-370I10.6	5.19	2.57e-07	2.93e-05	0.2	0.16	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48327668	chr12:48350945~48442411:+
BRCA	cis	rs10911232	0.507	rs28477876	ENSG00000224468.3	RP11-181K3.4	-5.19	2.57e-07	2.93e-05	-0.17	-0.16	Hypertriglyceridemia;	chr1:183050747	chr1:183138402~183141282:-
BRCA	cis	rs8002861	0.87	rs2121030	ENSG00000274001.1	RP11-5G9.5	-5.19	2.57e-07	2.94e-05	-0.18	-0.16	Leprosy;	chr13:43870438	chr13:43877715~43878163:-
BRCA	cis	rs1707322	1	rs10890350	ENSG00000234329.1	RP11-767N6.2	5.19	2.57e-07	2.94e-05	0.16	0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45796706	chr1:45651039~45651826:-
BRCA	cis	rs13113518	1	rs12651640	ENSG00000223305.1	RN7SKP30	5.19	2.57e-07	2.94e-05	0.19	0.16	Height;	chr4:55454154	chr4:55540502~55540835:-
BRCA	cis	rs13113518	1	rs1554483	ENSG00000223305.1	RN7SKP30	5.19	2.57e-07	2.94e-05	0.19	0.16	Height;	chr4:55455650	chr4:55540502~55540835:-
BRCA	cis	rs13113518	1	rs1464490	ENSG00000223305.1	RN7SKP30	5.19	2.57e-07	2.94e-05	0.19	0.16	Height;	chr4:55456620	chr4:55540502~55540835:-
BRCA	cis	rs13113518	1	rs10517346	ENSG00000223305.1	RN7SKP30	5.19	2.57e-07	2.94e-05	0.19	0.16	Height;	chr4:55457027	chr4:55540502~55540835:-
BRCA	cis	rs13113518	1	rs11133384	ENSG00000223305.1	RN7SKP30	5.19	2.57e-07	2.94e-05	0.19	0.16	Height;	chr4:55457086	chr4:55540502~55540835:-
BRCA	cis	rs1598856	0.932	rs2168803	ENSG00000246560.2	RP11-10L12.4	5.19	2.57e-07	2.94e-05	0.18	0.16	Primary biliary cholangitis;	chr4:102507458	chr4:102828055~102844075:+
BRCA	cis	rs7772486	0.776	rs4316025	ENSG00000270638.1	RP3-466P17.1	-5.19	2.57e-07	2.94e-05	-0.18	-0.16	Lobe attachment (rater-scored or self-reported);	chr6:145916896	chr6:145735570~145737218:+
BRCA	cis	rs9473147	0.747	rs9395288	ENSG00000270761.1	RP11-385F7.1	-5.19	2.57e-07	2.94e-05	-0.18	-0.16	Platelet distribution width;Mean platelet volume;	chr6:47630389	chr6:47477243~47477572:-
BRCA	cis	rs7618501	0.665	rs7621352	ENSG00000228008.1	CTD-2330K9.3	-5.19	2.57e-07	2.94e-05	-0.15	-0.16	Intelligence (multi-trait analysis);	chr3:50033330	chr3:49903845~49916937:+
BRCA	cis	rs7577696	0.785	rs11683842	ENSG00000272716.1	RP11-563N4.1	-5.19	2.58e-07	2.94e-05	-0.18	-0.16	Inflammatory biomarkers;	chr2:32139062	chr2:32165046~32165757:-
BRCA	cis	rs10911232	0.507	rs10797820	ENSG00000224468.3	RP11-181K3.4	-5.19	2.58e-07	2.94e-05	-0.17	-0.16	Hypertriglyceridemia;	chr1:183042231	chr1:183138402~183141282:-
BRCA	cis	rs10911232	0.507	rs10911206	ENSG00000224468.3	RP11-181K3.4	-5.19	2.58e-07	2.94e-05	-0.17	-0.16	Hypertriglyceridemia;	chr1:183043288	chr1:183138402~183141282:-
BRCA	cis	rs10911232	0.507	rs10797821	ENSG00000224468.3	RP11-181K3.4	-5.19	2.58e-07	2.94e-05	-0.17	-0.16	Hypertriglyceridemia;	chr1:183043424	chr1:183138402~183141282:-
BRCA	cis	rs10911232	0.524	rs10911209	ENSG00000224468.3	RP11-181K3.4	-5.19	2.58e-07	2.94e-05	-0.17	-0.16	Hypertriglyceridemia;	chr1:183044853	chr1:183138402~183141282:-
BRCA	cis	rs11124272	0.625	rs6760199	ENSG00000272716.1	RP11-563N4.1	5.19	2.58e-07	2.94e-05	0.19	0.16	Interleukin-18 levels;	chr2:31517208	chr2:32165046~32165757:-
BRCA	cis	rs11992162	1	rs7460395	ENSG00000270154.1	RP11-419I17.1	5.19	2.58e-07	2.94e-05	0.19	0.16	Monocyte count;	chr8:11977866	chr8:12476462~12477122:+
BRCA	cis	rs9818758	0.607	rs34566463	ENSG00000270441.1	RP11-694I15.7	5.19	2.58e-07	2.95e-05	0.29	0.16	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49207644	chr3:49140086~49160851:-
BRCA	cis	rs9545047	0.604	rs9601227	ENSG00000227354.5	RBM26-AS1	-5.19	2.58e-07	2.95e-05	-0.17	-0.16	Schizophrenia;	chr13:79420805	chr13:79406309~79424328:+
BRCA	cis	rs6756513	0.5	rs12613917	ENSG00000231024.1	AC092431.3	-5.19	2.58e-07	2.95e-05	-0.23	-0.16	Breast cancer;Platelet count;	chr2:69838970	chr2:69700192~69713847:-
BRCA	cis	rs6756513	0.5	rs11888098	ENSG00000231024.1	AC092431.3	-5.19	2.58e-07	2.95e-05	-0.23	-0.16	Breast cancer;Platelet count;	chr2:69839759	chr2:69700192~69713847:-
BRCA	cis	rs6756513	0.5	rs11888102	ENSG00000231024.1	AC092431.3	-5.19	2.58e-07	2.95e-05	-0.23	-0.16	Breast cancer;Platelet count;	chr2:69839790	chr2:69700192~69713847:-
BRCA	cis	rs6756513	0.5	rs3771533	ENSG00000231024.1	AC092431.3	-5.19	2.58e-07	2.95e-05	-0.23	-0.16	Breast cancer;Platelet count;	chr2:69840925	chr2:69700192~69713847:-
BRCA	cis	rs6756513	0.5	rs2872076	ENSG00000231024.1	AC092431.3	-5.19	2.58e-07	2.95e-05	-0.23	-0.16	Breast cancer;Platelet count;	chr2:69841623	chr2:69700192~69713847:-
BRCA	cis	rs3768617	0.51	rs3765521	ENSG00000224468.3	RP11-181K3.4	-5.19	2.58e-07	2.95e-05	-0.17	-0.16	Fuchs's corneal dystrophy;	chr1:183108480	chr1:183138402~183141282:-
BRCA	cis	rs17301013	0.932	rs4233195	ENSG00000227373.4	RP11-160H22.5	-5.19	2.58e-07	2.95e-05	-0.21	-0.16	Systemic lupus erythematosus;	chr1:174806736	chr1:174115300~174160004:-
BRCA	cis	rs2179367	0.632	rs12196656	ENSG00000268592.3	RAET1E-AS1	5.19	2.58e-07	2.95e-05	0.23	0.16	Dupuytren's disease;	chr6:149383104	chr6:149863494~149919507:+
BRCA	cis	rs2179367	0.632	rs12211570	ENSG00000268592.3	RAET1E-AS1	5.19	2.58e-07	2.95e-05	0.23	0.16	Dupuytren's disease;	chr6:149383616	chr6:149863494~149919507:+
BRCA	cis	rs2179367	0.568	rs11155647	ENSG00000268592.3	RAET1E-AS1	5.19	2.58e-07	2.95e-05	0.23	0.16	Dupuytren's disease;	chr6:149384499	chr6:149863494~149919507:+
BRCA	cis	rs2522056	1	rs2522050	ENSG00000233006.5	AC034220.3	-5.19	2.58e-07	2.95e-05	-0.13	-0.16	Fibrinogen;Lymphocyte counts;	chr5:132460917	chr5:132311285~132369916:-
BRCA	cis	rs7937890	0.9	rs7118682	ENSG00000251991.1	RNU7-49P	-5.19	2.58e-07	2.95e-05	-0.17	-0.16	Mitochondrial DNA levels;	chr11:14253004	chr11:14478892~14478953:+
BRCA	cis	rs2179367	0.537	rs12192159	ENSG00000223701.3	RAET1E-AS1	5.19	2.58e-07	2.95e-05	0.24	0.16	Dupuytren's disease;	chr6:149445969	chr6:149884431~149919508:+
BRCA	cis	rs7818688	1	rs10098453	ENSG00000253528.2	RP11-347C18.4	5.19	2.58e-07	2.95e-05	0.24	0.16	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95017528	chr8:94974573~94974853:-
BRCA	cis	rs2832191	0.791	rs7282843	ENSG00000215533.7	LINC00189	-5.19	2.59e-07	2.95e-05	-0.17	-0.16	Dental caries;	chr21:29102905	chr21:29193480~29288205:+
BRCA	cis	rs12501370	0.589	rs12507848	ENSG00000201736.1	RNA5SP160	5.19	2.59e-07	2.95e-05	0.19	0.16	Iris color (L* coordinate);	chr4:40982735	chr4:40990154~40990273:+
BRCA	cis	rs7569084	0.687	rs12614851	ENSG00000281920.1	RP11-418H16.1	5.19	2.59e-07	2.95e-05	0.21	0.16	Sum eosinophil basophil counts;	chr2:65458050	chr2:65623272~65628424:+
BRCA	cis	rs2732480	0.577	rs2634681	ENSG00000257763.1	OR5BK1P	-5.19	2.59e-07	2.95e-05	-0.16	-0.16	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48339301	chr12:48355792~48356614:-
BRCA	cis	rs3733585	0.673	rs7376948	ENSG00000250413.1	RP11-448G15.1	5.19	2.59e-07	2.95e-05	0.21	0.16	Cleft plate (environmental tobacco smoke interaction);	chr4:9953084	chr4:10006482~10009725:+
BRCA	cis	rs950776	0.72	rs11633223	ENSG00000261762.1	RP11-650L12.2	5.19	2.59e-07	2.95e-05	0.19	0.16	Sudden cardiac arrest;	chr15:78643134	chr15:78589123~78591276:-
BRCA	cis	rs6480314	0.542	rs61854810	ENSG00000233590.1	RP11-153K11.3	-5.19	2.59e-07	2.95e-05	-0.27	-0.16	Optic nerve measurement (disc area);	chr10:68264139	chr10:68233251~68242379:-
BRCA	cis	rs6480314	0.542	rs61854811	ENSG00000233590.1	RP11-153K11.3	-5.19	2.59e-07	2.95e-05	-0.27	-0.16	Optic nerve measurement (disc area);	chr10:68264474	chr10:68233251~68242379:-
BRCA	cis	rs9652601	0.691	rs9921287	ENSG00000274038.1	RP11-66H6.4	-5.19	2.59e-07	2.96e-05	-0.17	-0.16	Systemic lupus erythematosus;	chr16:11115882	chr16:11056556~11057034:+
BRCA	cis	rs559928	0.606	rs78038516	ENSG00000236935.1	AP003774.1	5.19	2.59e-07	2.96e-05	0.22	0.16	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64210595	chr11:64325050~64329504:-
BRCA	cis	rs270601	0.721	rs162894	ENSG00000233006.5	AC034220.3	5.19	2.59e-07	2.96e-05	0.12	0.16	Acylcarnitine levels;	chr5:132276179	chr5:132311285~132369916:-
BRCA	cis	rs7487075	0.619	rs10880973	ENSG00000274723.1	RP11-618L22.1	5.19	2.59e-07	2.96e-05	0.2	0.16	Itch intensity from mosquito bite;	chr12:46459426	chr12:46970504~46972155:+
BRCA	cis	rs113835537	0.935	rs79106199	ENSG00000255517.5	CTD-3074O7.5	-5.19	2.59e-07	2.96e-05	-0.27	-0.16	Airway imaging phenotypes;	chr11:66653047	chr11:66473490~66480233:-
BRCA	cis	rs2153535	0.58	rs6597325	ENSG00000251164.1	HULC	-5.19	2.59e-07	2.96e-05	-0.19	-0.16	Motion sickness;	chr6:8460820	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.58	rs6918391	ENSG00000251164.1	HULC	-5.19	2.59e-07	2.96e-05	-0.19	-0.16	Motion sickness;	chr6:8460945	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.58	rs9379210	ENSG00000251164.1	HULC	-5.19	2.59e-07	2.96e-05	-0.19	-0.16	Motion sickness;	chr6:8461695	chr6:8652137~8653846:+
BRCA	cis	rs2562456	0.833	rs4334427	ENSG00000268081.1	RP11-678G14.2	5.19	2.59e-07	2.96e-05	0.25	0.16	Pain;	chr19:21338090	chr19:21554640~21569237:-
BRCA	cis	rs10844706	0.699	rs2058560	ENSG00000214776.8	RP11-726G1.1	5.19	2.59e-07	2.96e-05	0.19	0.16	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9721093	chr12:9467552~9576275:+
BRCA	cis	rs4835473	0.615	rs6857432	ENSG00000249741.2	RP11-673E1.3	-5.18	2.59e-07	2.96e-05	-0.17	-0.16	Immature fraction of reticulocytes;	chr4:143971912	chr4:143911514~143912053:-
BRCA	cis	rs10129255	1	rs11627342	ENSG00000224373.3	IGHV4-59	5.18	2.6e-07	2.96e-05	0.1	0.16	Kawasaki disease;	chr14:106675823	chr14:106627249~106627825:-
BRCA	cis	rs4713118	0.662	rs149961	ENSG00000280107.1	AL022393.9	-5.18	2.6e-07	2.96e-05	-0.23	-0.16	Parkinson's disease;	chr6:28047791	chr6:28170845~28172521:+
BRCA	cis	rs6600671	0.966	rs6600664	ENSG00000275538.1	RNVU1-19	5.18	2.6e-07	2.97e-05	0.19	0.16	Hip geometry;	chr1:121480638	chr1:120850819~120850985:-
BRCA	cis	rs6600671	0.932	rs6600663	ENSG00000275538.1	RNVU1-19	5.18	2.6e-07	2.97e-05	0.19	0.16	Hip geometry;	chr1:121480639	chr1:120850819~120850985:-
BRCA	cis	rs4835473	0.932	rs4516663	ENSG00000249741.2	RP11-673E1.3	-5.18	2.6e-07	2.97e-05	-0.17	-0.16	Immature fraction of reticulocytes;	chr4:143980791	chr4:143911514~143912053:-
BRCA	cis	rs10129255	1	rs11627342	ENSG00000211974.3	IGHV2-70	5.18	2.6e-07	2.97e-05	0.17	0.16	Kawasaki disease;	chr14:106675823	chr14:106723574~106724093:-
BRCA	cis	rs7818688	0.745	rs16917117	ENSG00000253528.2	RP11-347C18.4	5.18	2.6e-07	2.97e-05	0.22	0.16	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94897270	chr8:94974573~94974853:-
BRCA	cis	rs1707322	1	rs7547189	ENSG00000234329.1	RP11-767N6.2	5.18	2.6e-07	2.97e-05	0.16	0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45853842	chr1:45651039~45651826:-
BRCA	cis	rs1707322	1	rs7547284	ENSG00000234329.1	RP11-767N6.2	5.18	2.6e-07	2.97e-05	0.16	0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45853893	chr1:45651039~45651826:-
BRCA	cis	rs1707322	1	rs11211205	ENSG00000234329.1	RP11-767N6.2	5.18	2.6e-07	2.97e-05	0.16	0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45856202	chr1:45651039~45651826:-
BRCA	cis	rs7914558	1	rs10883824	ENSG00000236937.2	PTGES3P4	5.18	2.6e-07	2.97e-05	0.2	0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103053140	chr10:102845595~102845950:+
BRCA	cis	rs17301013	0.932	rs6683602	ENSG00000227373.4	RP11-160H22.5	5.18	2.6e-07	2.97e-05	0.21	0.16	Systemic lupus erythematosus;	chr1:174617615	chr1:174115300~174160004:-
BRCA	cis	rs17301013	0.932	rs6696197	ENSG00000227373.4	RP11-160H22.5	5.18	2.6e-07	2.97e-05	0.21	0.16	Systemic lupus erythematosus;	chr1:174617860	chr1:174115300~174160004:-
BRCA	cis	rs67981189	0.529	rs2810097	ENSG00000258571.1	PTTG4P	5.18	2.6e-07	2.97e-05	0.19	0.16	Schizophrenia;	chr14:70967397	chr14:71085482~71085833:-
BRCA	cis	rs10510102	0.935	rs11200253	ENSG00000226864.1	ATE1-AS1	5.18	2.6e-07	2.97e-05	0.29	0.16	Breast cancer;	chr10:121915114	chr10:121928312~121951965:+
BRCA	cis	rs10510102	0.935	rs11200254	ENSG00000226864.1	ATE1-AS1	5.18	2.6e-07	2.97e-05	0.29	0.16	Breast cancer;	chr10:121915241	chr10:121928312~121951965:+
BRCA	cis	rs7267979	1	rs13038834	ENSG00000125804.12	FAM182A	-5.18	2.6e-07	2.97e-05	-0.21	-0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25460797	chr20:26054655~26086917:+
BRCA	cis	rs2274273	0.774	rs9323278	ENSG00000258413.1	RP11-665C16.6	-5.18	2.61e-07	2.97e-05	-0.2	-0.16	Protein biomarker;	chr14:55074856	chr14:55262767~55272075:-
BRCA	cis	rs6095360	0.727	rs13037942	ENSG00000222365.1	SNORD12B	-5.18	2.61e-07	2.97e-05	-0.22	-0.16	Intelligence (multi-trait analysis);	chr20:48909134	chr20:49280319~49280409:+
BRCA	cis	rs7246657	0.525	rs997516	ENSG00000267422.1	CTD-2554C21.1	-5.18	2.61e-07	2.98e-05	-0.26	-0.16	Coronary artery calcification;	chr19:36983362	chr19:37779686~37792865:+
BRCA	cis	rs7620503	1	rs2133595	ENSG00000228221.4	LINC00578	5.18	2.61e-07	2.98e-05	0.18	0.16	Corneal structure;	chr3:177585822	chr3:177441921~177752305:+
BRCA	cis	rs2692947	0.637	rs72492201	ENSG00000237510.6	AC008268.2	5.18	2.61e-07	2.98e-05	0.22	0.16	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95964453	chr2:95789654~95800166:+
BRCA	cis	rs9287719	1	rs9679122	ENSG00000243819.4	RN7SL832P	5.18	2.61e-07	2.98e-05	0.15	0.16	Prostate cancer;	chr2:10611584	chr2:10690344~10692099:+
BRCA	cis	rs17489649	0.826	rs17162179	ENSG00000271849.1	CTC-332L22.1	5.18	2.61e-07	2.98e-05	0.21	0.16	Intelligence (multi-trait analysis);	chr5:109767865	chr5:109687802~109688329:-
BRCA	cis	rs9467773	1	rs9461271	ENSG00000241549.7	GUSBP2	5.18	2.61e-07	2.98e-05	0.17	0.16	Intelligence (multi-trait analysis);	chr6:26554740	chr6:26871484~26956554:-
BRCA	cis	rs10129255	1	rs9324091	ENSG00000224373.3	IGHV4-59	5.18	2.61e-07	2.98e-05	0.1	0.16	Kawasaki disease;	chr14:106676625	chr14:106627249~106627825:-
BRCA	cis	rs597539	0.689	rs596874	ENSG00000261625.1	RP11-554A11.4	5.18	2.61e-07	2.98e-05	0.15	0.16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68863406	chr11:69000765~69002048:-
BRCA	cis	rs6832769	1	rs9998146	ENSG00000272969.1	RP11-528I4.2	-5.18	2.62e-07	2.98e-05	-0.19	-0.16	Personality dimensions;	chr4:55531810	chr4:55547112~55547889:+
BRCA	cis	rs11955398	0.502	rs42437	ENSG00000215032.2	GNL3LP1	5.18	2.62e-07	2.98e-05	0.2	0.16	Intelligence (multi-trait analysis);	chr5:61052219	chr5:60891935~60893577:-
BRCA	cis	rs78487399	0.71	rs78681698	ENSG00000234936.1	AC010883.5	5.18	2.62e-07	2.98e-05	0.27	0.16	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43371021	chr2:43229573~43233394:+
BRCA	cis	rs2834288	0.666	rs2834293	ENSG00000273102.1	AP000569.9	-5.18	2.62e-07	2.98e-05	-0.18	-0.16	Gut microbiota (bacterial taxa);	chr21:33903905	chr21:33967101~33968573:-
BRCA	cis	rs6840360	0.582	rs11732918	ENSG00000278978.1	RP11-164P12.5	-5.18	2.62e-07	2.99e-05	-0.18	-0.16	Intelligence (multi-trait analysis);	chr4:151397893	chr4:151669786~151670503:+
BRCA	cis	rs7577696	0.752	rs212714	ENSG00000272716.1	RP11-563N4.1	5.18	2.62e-07	2.99e-05	0.18	0.16	Inflammatory biomarkers;	chr2:32235279	chr2:32165046~32165757:-
BRCA	cis	rs78487399	0.808	rs76684055	ENSG00000234936.1	AC010883.5	5.18	2.62e-07	2.99e-05	0.28	0.16	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43438804	chr2:43229573~43233394:+
BRCA	cis	rs12439619	0.846	rs62012004	ENSG00000255769.6	GOLGA2P10	-5.18	2.62e-07	2.99e-05	-0.23	-0.16	Intelligence (multi-trait analysis);	chr15:82183924	chr15:82472993~82513950:-
BRCA	cis	rs2732480	0.5	rs1387257	ENSG00000226413.2	OR8T1P	5.18	2.62e-07	2.99e-05	0.21	0.16	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48242883	chr12:48442030~48442947:-
BRCA	cis	rs875971	0.545	rs73376394	ENSG00000228409.4	CCT6P1	-5.18	2.62e-07	2.99e-05	-0.16	-0.16	Aortic root size;	chr7:66172694	chr7:65751142~65763354:+
BRCA	cis	rs6973609	0.962	rs6462612	ENSG00000271122.1	RP11-379H18.1	5.18	2.62e-07	2.99e-05	0.17	0.16	Obesity-related traits;	chr7:35566864	chr7:35695214~35699413:+
BRCA	cis	rs4761702	0.857	rs1135400	ENSG00000257322.4	RP11-511B23.2	5.18	2.62e-07	2.99e-05	0.2	0.16	Immature fraction of reticulocytes;	chr12:93315763	chr12:93003415~93215679:-
BRCA	cis	rs863750	0.634	rs825475	ENSG00000275389.1	RP11-214K3.24	5.18	2.62e-07	2.99e-05	0.2	0.16	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-hip ratio;	chr12:124082761	chr12:124085761~124088598:+
BRCA	cis	rs9341808	0.718	rs7740627	ENSG00000272129.1	RP11-250B2.6	5.18	2.62e-07	2.99e-05	0.2	0.16	Sitting height ratio;	chr6:80206630	chr6:80355424~80356859:+
BRCA	cis	rs9921338	0.923	rs72771877	ENSG00000262703.1	RP11-485G7.6	-5.18	2.63e-07	2.99e-05	-0.2	-0.16	Vein graft stenosis in coronary artery bypass grafting;	chr16:11274759	chr16:11348143~11349321:-
BRCA	cis	rs2749097	1	rs2749096	ENSG00000244256.3	RN7SL130P	-5.18	2.63e-07	2.99e-05	-0.23	-0.16	Alcohol consumption (transferrin glycosylation);	chr1:63661991	chr1:63655743~63656047:+
BRCA	cis	rs6545883	0.862	rs11691734	ENSG00000270820.4	RP11-355B11.2	5.18	2.63e-07	2.99e-05	0.18	0.16	Tuberculosis;	chr2:61475331	chr2:61471188~61484130:+
BRCA	cis	rs6840360	0.642	rs6855845	ENSG00000278978.1	RP11-164P12.5	-5.18	2.63e-07	2.99e-05	-0.18	-0.16	Intelligence (multi-trait analysis);	chr4:151496228	chr4:151669786~151670503:+
BRCA	cis	rs7818688	0.614	rs73271148	ENSG00000253528.2	RP11-347C18.4	-5.18	2.63e-07	3e-05	-0.22	-0.16	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94864317	chr8:94974573~94974853:-
BRCA	cis	rs750460	1	rs12441130	ENSG00000261801.4	LOXL1-AS1	-5.18	2.63e-07	3e-05	-0.18	-0.16	Height;	chr15:73942561	chr15:73908071~73928248:-
BRCA	cis	rs997295	0.513	rs11635495	ENSG00000270964.1	RP11-502I4.3	-5.18	2.63e-07	3e-05	-0.18	-0.16	Motion sickness;	chr15:67512344	chr15:67541072~67542604:-
BRCA	cis	rs7914558	1	rs7077291	ENSG00000236937.2	PTGES3P4	5.18	2.63e-07	3e-05	0.21	0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103185994	chr10:102845595~102845950:+
BRCA	cis	rs2645424	0.635	rs6980952	ENSG00000255046.1	RP11-297N6.4	-5.18	2.63e-07	3e-05	-0.18	-0.16	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);	chr8:11858964	chr8:11797928~11802568:-
BRCA	cis	rs3733585	0.631	rs3822236	ENSG00000250413.1	RP11-448G15.1	5.18	2.63e-07	3e-05	0.21	0.16	Cleft plate (environmental tobacco smoke interaction);	chr4:10118337	chr4:10006482~10009725:+
BRCA	cis	rs9287719	0.967	rs963831	ENSG00000243819.4	RN7SL832P	5.18	2.63e-07	3e-05	0.15	0.16	Prostate cancer;	chr2:10605058	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.967	rs728134	ENSG00000243819.4	RN7SL832P	5.18	2.63e-07	3e-05	0.15	0.16	Prostate cancer;	chr2:10605061	chr2:10690344~10692099:+
BRCA	cis	rs1707322	1	rs946527	ENSG00000234329.1	RP11-767N6.2	5.18	2.63e-07	3e-05	0.16	0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46020298	chr1:45651039~45651826:-
BRCA	cis	rs6832769	0.961	rs13138697	ENSG00000223305.1	RN7SKP30	5.18	2.63e-07	3e-05	0.21	0.16	Personality dimensions;	chr4:55497142	chr4:55540502~55540835:-
BRCA	cis	rs8060686	0.516	rs7193701	ENSG00000280214.1	CTD-2012K14.5	5.18	2.63e-07	3e-05	0.19	0.16	HDL cholesterol;Metabolic syndrome;	chr16:68151257	chr16:67550815~67552935:-
BRCA	cis	rs1198430	1	rs1198430	ENSG00000232482.2	RP4-654C18.1	5.18	2.63e-07	3e-05	0.24	0.16	Total cholesterol levels;	chr1:23429020	chr1:23410832~23412146:+
BRCA	cis	rs829883	0.664	rs1096148	ENSG00000227825.4	SLC9A7P1	5.18	2.63e-07	3e-05	0.19	0.16	Colorectal adenoma (advanced);	chr12:98457227	chr12:98453835~98457145:-
BRCA	cis	rs7577696	0.962	rs11681731	ENSG00000272716.1	RP11-563N4.1	-5.18	2.63e-07	3e-05	-0.17	-0.16	Inflammatory biomarkers;	chr2:32120256	chr2:32165046~32165757:-
BRCA	cis	rs2179367	0.959	rs237034	ENSG00000268592.3	RAET1E-AS1	5.18	2.64e-07	3.01e-05	0.2	0.16	Dupuytren's disease;	chr6:149390726	chr6:149863494~149919507:+
BRCA	cis	rs6452524	0.618	rs1993948	ENSG00000281327.1	LINC01338	5.18	2.64e-07	3.01e-05	0.18	0.16	Hypertension (SNP x SNP interaction);	chr5:83076461	chr5:82850864~82859836:-
BRCA	cis	rs860295	0.702	rs2025669	ENSG00000160766.13	GBAP1	-5.18	2.64e-07	3.01e-05	-0.17	-0.16	Body mass index;	chr1:155387818	chr1:155213821~155227422:-
BRCA	cis	rs13113518	1	rs11133381	ENSG00000223305.1	RN7SKP30	5.18	2.64e-07	3.01e-05	0.19	0.16	Height;	chr4:55450812	chr4:55540502~55540835:-
BRCA	cis	rs13113518	1	rs4864995	ENSG00000223305.1	RN7SKP30	5.18	2.64e-07	3.01e-05	0.19	0.16	Height;	chr4:55452853	chr4:55540502~55540835:-
BRCA	cis	rs7200543	1	rs1135999	ENSG00000260735.1	RP11-72I8.1	-5.18	2.64e-07	3.01e-05	-0.19	-0.16	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15038105	chr16:15094411~15109197:+
BRCA	cis	rs172166	0.694	rs1225716	ENSG00000280107.1	AL022393.9	-5.18	2.64e-07	3.01e-05	-0.22	-0.16	Cardiac Troponin-T levels;	chr6:28145968	chr6:28170845~28172521:+
BRCA	cis	rs8180040	0.966	rs12486969	ENSG00000276925.1	RP11-708J19.3	5.18	2.64e-07	3.01e-05	0.18	0.16	Colorectal cancer;	chr3:47387513	chr3:47469777~47469987:+
BRCA	cis	rs9300255	0.722	rs10846515	ENSG00000235423.7	RP11-282O18.3	5.18	2.64e-07	3.01e-05	0.2	0.16	Neutrophil percentage of white cells;	chr12:123317125	chr12:123252030~123261483:-
BRCA	cis	rs4588572	0.688	rs4590164	ENSG00000245556.2	SCAMP1-AS1	-5.18	2.65e-07	3.02e-05	-0.19	-0.16	Triglycerides;	chr5:78376046	chr5:78342365~78360507:-
BRCA	cis	rs7267979	0.718	rs2983489	ENSG00000277938.1	RP5-965G21.3	5.18	2.65e-07	3.02e-05	0.19	0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25263484	chr20:25229150~25231933:+
BRCA	cis	rs2692947	0.666	rs7566050	ENSG00000237510.6	AC008268.2	5.18	2.65e-07	3.02e-05	0.22	0.16	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95960282	chr2:95789654~95800166:+
BRCA	cis	rs7267979	0.727	rs2474765	ENSG00000277938.1	RP5-965G21.3	5.18	2.65e-07	3.02e-05	0.19	0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25265314	chr20:25229150~25231933:+
BRCA	cis	rs2562456	0.833	rs4321312	ENSG00000268081.1	RP11-678G14.2	5.18	2.65e-07	3.02e-05	0.25	0.16	Pain;	chr19:21336614	chr19:21554640~21569237:-
BRCA	cis	rs9990343	0.543	rs11575815	ENSG00000223552.1	RP11-24F11.2	5.18	2.65e-07	3.02e-05	0.17	0.16	Brain structure;	chr3:46378679	chr3:46364955~46407059:-
BRCA	cis	rs651907	0.557	rs2303474	ENSG00000256628.3	ZBTB11-AS1	5.18	2.65e-07	3.02e-05	0.21	0.16	Colorectal cancer;	chr3:101653055	chr3:101676475~101679217:+
BRCA	cis	rs1440410	0.571	rs4579067	ENSG00000250326.1	RP11-284M14.1	-5.18	2.65e-07	3.02e-05	-0.18	-0.16	Ischemic stroke;	chr4:143120675	chr4:142933195~143184861:-
BRCA	cis	rs8103278	1	rs725660	ENSG00000267395.4	AC074212.6	5.18	2.66e-07	3.03e-05	0.16	0.16	Coronary artery disease;	chr19:45759028	chr19:45767796~45772504:+
BRCA	cis	rs597539	0.652	rs513615	ENSG00000261625.1	RP11-554A11.4	-5.18	2.66e-07	3.03e-05	-0.16	-0.16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68938036	chr11:69000765~69002048:-
BRCA	cis	rs875971	0.825	rs28480509	ENSG00000273448.1	RP11-166O4.6	-5.18	2.66e-07	3.03e-05	-0.15	-0.16	Aortic root size;	chr7:66634237	chr7:67333047~67334383:+
BRCA	cis	rs6431644	1	rs6431643	ENSG00000224287.2	MSL3P1	5.18	2.66e-07	3.03e-05	0.19	0.16	Left atrial antero-posterior diameter;	chr2:233865054	chr2:233865437~233868444:-
BRCA	cis	rs6431644	1	rs6431644	ENSG00000224287.2	MSL3P1	5.18	2.66e-07	3.03e-05	0.19	0.16	Left atrial antero-posterior diameter;	chr2:233865083	chr2:233865437~233868444:-
BRCA	cis	rs7178909	0.902	rs28372736	ENSG00000259677.1	RP11-493E3.1	5.18	2.66e-07	3.03e-05	0.19	0.16	Common traits (Other);	chr15:89894626	chr15:89876540~89877285:+
BRCA	cis	rs7178909	0.902	rs10459674	ENSG00000259677.1	RP11-493E3.1	5.18	2.66e-07	3.03e-05	0.19	0.16	Common traits (Other);	chr15:89895063	chr15:89876540~89877285:+
BRCA	cis	rs2562456	0.833	rs4644962	ENSG00000268081.1	RP11-678G14.2	5.18	2.66e-07	3.03e-05	0.25	0.16	Pain;	chr19:21338125	chr19:21554640~21569237:-
BRCA	cis	rs12478296	1	rs4973685	ENSG00000261186.2	RP11-341N2.1	-5.18	2.66e-07	3.03e-05	-0.26	-0.16	Obesity-related traits;	chr2:242076938	chr2:242087351~242088457:-
BRCA	cis	rs9287719	0.967	rs6706542	ENSG00000243819.4	RN7SL832P	5.18	2.66e-07	3.03e-05	0.15	0.16	Prostate cancer;	chr2:10602365	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.967	rs2287061	ENSG00000243819.4	RN7SL832P	5.18	2.66e-07	3.03e-05	0.15	0.16	Prostate cancer;	chr2:10603027	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.967	rs2287062	ENSG00000243819.4	RN7SL832P	5.18	2.66e-07	3.03e-05	0.15	0.16	Prostate cancer;	chr2:10603065	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.935	rs1309	ENSG00000243819.4	RN7SL832P	5.18	2.66e-07	3.03e-05	0.15	0.16	Prostate cancer;	chr2:10603420	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.967	rs3815521	ENSG00000243819.4	RN7SL832P	5.18	2.66e-07	3.03e-05	0.15	0.16	Prostate cancer;	chr2:10603528	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.967	rs10929686	ENSG00000243819.4	RN7SL832P	5.18	2.66e-07	3.03e-05	0.15	0.16	Prostate cancer;	chr2:10603579	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.967	rs4613248	ENSG00000243819.4	RN7SL832P	5.18	2.66e-07	3.03e-05	0.15	0.16	Prostate cancer;	chr2:10603925	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.967	rs10191883	ENSG00000243819.4	RN7SL832P	5.18	2.66e-07	3.03e-05	0.15	0.16	Prostate cancer;	chr2:10604010	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.934	rs4629131	ENSG00000243819.4	RN7SL832P	5.18	2.66e-07	3.03e-05	0.15	0.16	Prostate cancer;	chr2:10604033	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.901	rs4555317	ENSG00000243819.4	RN7SL832P	5.18	2.66e-07	3.03e-05	0.15	0.16	Prostate cancer;	chr2:10604121	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.967	rs4555318	ENSG00000243819.4	RN7SL832P	5.18	2.66e-07	3.03e-05	0.15	0.16	Prostate cancer;	chr2:10604169	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.934	rs4622695	ENSG00000243819.4	RN7SL832P	5.18	2.66e-07	3.03e-05	0.15	0.16	Prostate cancer;	chr2:10604201	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.934	rs6432111	ENSG00000243819.4	RN7SL832P	5.18	2.66e-07	3.03e-05	0.15	0.16	Prostate cancer;	chr2:10604494	chr2:10690344~10692099:+
BRCA	cis	rs2303319	1	rs16845747	ENSG00000227403.1	AC009299.3	5.18	2.66e-07	3.03e-05	0.4	0.16	Cognitive function;	chr2:161277014	chr2:161244739~161249050:+
BRCA	cis	rs7674212	0.541	rs2045746	ENSG00000246560.2	RP11-10L12.4	-5.18	2.66e-07	3.03e-05	-0.17	-0.16	Type 2 diabetes;	chr4:103162421	chr4:102828055~102844075:+
BRCA	cis	rs7772486	0.754	rs6921073	ENSG00000270638.1	RP3-466P17.1	5.18	2.66e-07	3.03e-05	0.18	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145823241	chr6:145735570~145737218:+
BRCA	cis	rs4835473	0.932	rs13148097	ENSG00000249741.2	RP11-673E1.3	-5.18	2.66e-07	3.03e-05	-0.17	-0.16	Immature fraction of reticulocytes;	chr4:143976238	chr4:143911514~143912053:-
BRCA	cis	rs2303319	0.504	rs62187655	ENSG00000227403.1	AC009299.3	5.18	2.66e-07	3.03e-05	0.38	0.16	Cognitive function;	chr2:161630930	chr2:161244739~161249050:+
BRCA	cis	rs2303319	0.504	rs62187656	ENSG00000227403.1	AC009299.3	5.18	2.66e-07	3.03e-05	0.38	0.16	Cognitive function;	chr2:161631189	chr2:161244739~161249050:+
BRCA	cis	rs10989172	0.714	rs4352973	ENSG00000175611.10	LINC00476	5.18	2.66e-07	3.03e-05	0.17	0.16	Common carotid intima-media thickness in HIV negative individuals;	chr9:96077654	chr9:95759231~95875977:-
BRCA	cis	rs6714710	0.603	rs11684749	ENSG00000230606.9	AC159540.1	-5.18	2.66e-07	3.03e-05	-0.19	-0.16	Posterior cortical atrophy and Alzheimer's disease;	chr2:97803679	chr2:97416165~97433527:-
BRCA	cis	rs1707322	0.964	rs6697830	ENSG00000234329.1	RP11-767N6.2	5.18	2.66e-07	3.03e-05	0.16	0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45824805	chr1:45651039~45651826:-
BRCA	cis	rs6540731	0.87	rs1967114	ENSG00000229983.1	RP11-15I11.2	-5.18	2.66e-07	3.03e-05	-0.18	-0.16	Intelligence (childhood);	chr1:212201994	chr1:212168207~212190259:+
BRCA	cis	rs4908768	0.539	rs7526171	ENSG00000232912.4	RP5-1115A15.1	5.18	2.66e-07	3.03e-05	0.16	0.16	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8590126	chr1:8424645~8434838:+
BRCA	cis	rs4925386	0.84	rs6143035	ENSG00000273619.1	RP5-908M14.9	5.18	2.66e-07	3.03e-05	0.14	0.16	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62345644	chr20:62386303~62386970:-
BRCA	cis	rs6545883	0.929	rs7563678	ENSG00000270820.4	RP11-355B11.2	-5.18	2.67e-07	3.04e-05	-0.18	-0.16	Tuberculosis;	chr2:61514676	chr2:61471188~61484130:+
BRCA	cis	rs11168618	0.935	rs2114322	ENSG00000240399.1	RP1-228P16.1	-5.18	2.67e-07	3.04e-05	-0.18	-0.16	Adiponectin levels;	chr12:48557824	chr12:48054813~48055591:-
BRCA	cis	rs11098499	0.863	rs10018280	ENSG00000249244.1	RP11-548H18.2	5.18	2.67e-07	3.04e-05	0.19	0.16	Corneal astigmatism;	chr4:119556984	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.863	rs6534141	ENSG00000249244.1	RP11-548H18.2	5.18	2.67e-07	3.04e-05	0.19	0.16	Corneal astigmatism;	chr4:119564068	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.863	rs2127823	ENSG00000249244.1	RP11-548H18.2	5.18	2.67e-07	3.04e-05	0.19	0.16	Corneal astigmatism;	chr4:119564515	chr4:119391831~119395335:-
BRCA	cis	rs494453	0.845	rs523650	ENSG00000227811.2	FAM212B-AS1	-5.18	2.67e-07	3.04e-05	-0.2	-0.16	Osteoporosis-related phenotypes;	chr1:111699642	chr1:111739841~111747798:+
BRCA	cis	rs6430538	0.621	rs12471304	ENSG00000224043.6	CCNT2-AS1	-5.18	2.67e-07	3.04e-05	-0.22	-0.16	Parkinson's disease;	chr2:134802950	chr2:134735464~134918710:-
BRCA	cis	rs2281636	0.823	rs11190225	ENSG00000233690.1	EBAG9P1	5.18	2.67e-07	3.04e-05	0.17	0.16	Obesity-related traits;	chr10:99657156	chr10:99697407~99697949:-
BRCA	cis	rs8040855	0.579	rs28521166	ENSG00000259774.1	RP11-182J1.13	-5.18	2.67e-07	3.04e-05	-0.18	-0.16	Bulimia nervosa;	chr15:85184801	chr15:84422618~84425882:+
BRCA	cis	rs801193	0.636	rs10233806	ENSG00000223473.2	GS1-124K5.3	-5.18	2.67e-07	3.04e-05	-0.12	-0.16	Aortic root size;	chr7:66653261	chr7:66491049~66493566:-
BRCA	cis	rs4950322	1	rs72694750	ENSG00000278811.3	LINC00624	5.18	2.67e-07	3.05e-05	0.22	0.16	Protein quantitative trait loci;	chr1:147396856	chr1:147258885~147517875:-
BRCA	cis	rs4950322	1	rs1986987	ENSG00000278811.3	LINC00624	5.18	2.67e-07	3.05e-05	0.22	0.16	Protein quantitative trait loci;	chr1:147397553	chr1:147258885~147517875:-
BRCA	cis	rs4950322	1	rs61230354	ENSG00000278811.3	LINC00624	5.18	2.67e-07	3.05e-05	0.22	0.16	Protein quantitative trait loci;	chr1:147398161	chr1:147258885~147517875:-
BRCA	cis	rs13113518	1	rs11934897	ENSG00000223305.1	RN7SKP30	5.18	2.68e-07	3.05e-05	0.19	0.16	Height;	chr4:55553396	chr4:55540502~55540835:-
BRCA	cis	rs13113518	0.934	rs11932293	ENSG00000223305.1	RN7SKP30	5.18	2.68e-07	3.05e-05	0.19	0.16	Height;	chr4:55554025	chr4:55540502~55540835:-
BRCA	cis	rs7200543	1	rs4985124	ENSG00000275910.1	RP11-680G24.6	-5.18	2.68e-07	3.05e-05	-0.18	-0.16	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15031584	chr16:15015828~15016390:-
BRCA	cis	rs991427	0.554	rs73197036	ENSG00000258100.1	RP11-121E16.1	-5.18	2.68e-07	3.05e-05	-0.26	-0.16	Systolic blood pressure (alcohol consumption interaction);	chr12:91072106	chr12:91362196~91368606:+
BRCA	cis	rs10888838	0.618	rs13571	ENSG00000198711.5	SSBP3-AS1	-5.18	2.68e-07	3.05e-05	-0.17	-0.16	Mitochondrial DNA levels;	chr1:54216247	chr1:54236440~54239063:+
BRCA	cis	rs9840812	0.769	rs548288	ENSG00000239213.4	NCK1-AS1	-5.18	2.68e-07	3.05e-05	-0.19	-0.16	Fibrinogen levels;	chr3:136250913	chr3:136841726~136862054:-
BRCA	cis	rs2562456	0.876	rs11085465	ENSG00000268658.4	LINC00664	-5.18	2.68e-07	3.05e-05	-0.25	-0.16	Pain;	chr19:21568988	chr19:21483374~21503238:+
BRCA	cis	rs133885	0.696	rs133901	ENSG00000100058.11	CRYBB2P1	-5.18	2.68e-07	3.05e-05	-0.17	-0.16	Mathematical ability in children with dyslexia;	chr22:25768029	chr22:25448105~25520854:+
BRCA	cis	rs13108904	0.901	rs7695691	ENSG00000196810.4	CTBP1-AS2	5.18	2.68e-07	3.05e-05	0.17	0.16	Obesity-related traits;	chr4:1310844	chr4:1249300~1288291:+
BRCA	cis	rs2179367	0.586	rs9498341	ENSG00000268592.3	RAET1E-AS1	5.18	2.68e-07	3.05e-05	0.23	0.16	Dupuytren's disease;	chr6:149379737	chr6:149863494~149919507:+
BRCA	cis	rs2179367	0.632	rs9498342	ENSG00000268592.3	RAET1E-AS1	5.18	2.68e-07	3.05e-05	0.23	0.16	Dupuytren's disease;	chr6:149379806	chr6:149863494~149919507:+
BRCA	cis	rs2179367	0.632	rs12191079	ENSG00000268592.3	RAET1E-AS1	5.18	2.68e-07	3.05e-05	0.23	0.16	Dupuytren's disease;	chr6:149380333	chr6:149863494~149919507:+
BRCA	cis	rs2179367	0.632	rs12204461	ENSG00000268592.3	RAET1E-AS1	5.18	2.68e-07	3.05e-05	0.23	0.16	Dupuytren's disease;	chr6:149380399	chr6:149863494~149919507:+
BRCA	cis	rs6832769	0.961	rs7684810	ENSG00000223305.1	RN7SKP30	5.18	2.68e-07	3.05e-05	0.21	0.16	Personality dimensions;	chr4:55486627	chr4:55540502~55540835:-
BRCA	cis	rs8040855	0.756	rs2342118	ENSG00000259774.1	RP11-182J1.13	-5.18	2.68e-07	3.06e-05	-0.21	-0.16	Bulimia nervosa;	chr15:85149785	chr15:84422618~84425882:+
BRCA	cis	rs3758911	0.673	rs2883632	ENSG00000255353.1	RP11-382M14.1	-5.18	2.68e-07	3.06e-05	-0.21	-0.16	Coronary artery disease;	chr11:107254220	chr11:107176286~107177530:+
BRCA	cis	rs2732480	0.557	rs923397	ENSG00000257735.1	RP11-370I10.6	5.18	2.68e-07	3.06e-05	0.2	0.16	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48326609	chr12:48350945~48442411:+
BRCA	cis	rs17685	0.753	rs10233282	ENSG00000280388.1	RP11-229D13.3	-5.18	2.69e-07	3.06e-05	-0.16	-0.16	Coffee consumption (cups per day);Coffee consumption;	chr7:76160763	chr7:76043977~76045963:-
BRCA	cis	rs17685	0.753	rs10251863	ENSG00000280388.1	RP11-229D13.3	-5.18	2.69e-07	3.06e-05	-0.16	-0.16	Coffee consumption (cups per day);Coffee consumption;	chr7:76160874	chr7:76043977~76045963:-
BRCA	cis	rs17685	0.753	rs9691174	ENSG00000280388.1	RP11-229D13.3	-5.18	2.69e-07	3.06e-05	-0.16	-0.16	Coffee consumption (cups per day);Coffee consumption;	chr7:76161087	chr7:76043977~76045963:-
BRCA	cis	rs17685	0.664	rs9801113	ENSG00000280388.1	RP11-229D13.3	-5.18	2.69e-07	3.06e-05	-0.16	-0.16	Coffee consumption (cups per day);Coffee consumption;	chr7:76162713	chr7:76043977~76045963:-
BRCA	cis	rs17685	0.558	rs60787921	ENSG00000280388.1	RP11-229D13.3	-5.18	2.69e-07	3.06e-05	-0.16	-0.16	Coffee consumption (cups per day);Coffee consumption;	chr7:76163526	chr7:76043977~76045963:-
BRCA	cis	rs17685	0.712	rs56965035	ENSG00000280388.1	RP11-229D13.3	-5.18	2.69e-07	3.06e-05	-0.16	-0.16	Coffee consumption (cups per day);Coffee consumption;	chr7:76166352	chr7:76043977~76045963:-
BRCA	cis	rs17685	0.672	rs56343450	ENSG00000280388.1	RP11-229D13.3	-5.18	2.69e-07	3.06e-05	-0.16	-0.16	Coffee consumption (cups per day);Coffee consumption;	chr7:76166917	chr7:76043977~76045963:-
BRCA	cis	rs911555	0.706	rs10129426	ENSG00000244691.1	RPL10AP1	-5.18	2.69e-07	3.06e-05	-0.18	-0.16	Intelligence (multi-trait analysis);	chr14:103552118	chr14:103412119~103412761:-
BRCA	cis	rs4835473	0.864	rs4257604	ENSG00000249741.2	RP11-673E1.3	-5.18	2.69e-07	3.06e-05	-0.17	-0.16	Immature fraction of reticulocytes;	chr4:143980261	chr4:143911514~143912053:-
BRCA	cis	rs7432375	0.641	rs1971397	ENSG00000239213.4	NCK1-AS1	5.18	2.69e-07	3.06e-05	0.17	0.16	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136808458	chr3:136841726~136862054:-
BRCA	cis	rs1707322	0.721	rs7520123	ENSG00000234329.1	RP11-767N6.2	5.18	2.69e-07	3.06e-05	0.16	0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45769547	chr1:45651039~45651826:-
BRCA	cis	rs2562456	0.917	rs2681377	ENSG00000268658.4	LINC00664	-5.18	2.69e-07	3.07e-05	-0.25	-0.16	Pain;	chr19:21533718	chr19:21483374~21503238:+
BRCA	cis	rs950880	0.767	rs13001714	ENSG00000234389.1	AC007278.3	-5.18	2.7e-07	3.07e-05	-0.15	-0.16	Serum protein levels (sST2);	chr2:102344025	chr2:102438713~102440475:+
BRCA	cis	rs17674580	0.582	rs3745006	ENSG00000267193.4	RP11-116O18.3	5.18	2.7e-07	3.07e-05	0.17	0.16	Bladder cancer;	chr18:45749625	chr18:45669367~45747215:-
BRCA	cis	rs1075265	0.563	rs2692536	ENSG00000235937.1	AC008280.1	5.18	2.7e-07	3.07e-05	0.18	0.16	Chronotype;Morning vs. evening chronotype;	chr2:53788266	chr2:54029552~54030682:-
BRCA	cis	rs7577696	0.752	rs12618002	ENSG00000272716.1	RP11-563N4.1	-5.18	2.7e-07	3.07e-05	-0.18	-0.16	Inflammatory biomarkers;	chr2:32122646	chr2:32165046~32165757:-
BRCA	cis	rs9467773	0.572	rs62394558	ENSG00000124549.13	BTN2A3P	5.18	2.7e-07	3.07e-05	0.17	0.16	Intelligence (multi-trait analysis);	chr6:26604422	chr6:26421391~26432383:+
BRCA	cis	rs1488902	1	rs1488902	ENSG00000280367.1	RP11-121L10.2	-5.18	2.7e-07	3.07e-05	-0.18	-0.16	Amyotrophic lateral sclerosis;	chr11:89611857	chr11:90223153~90226538:+
BRCA	cis	rs910316	0.663	rs175034	ENSG00000279594.1	RP11-950C14.10	-5.18	2.7e-07	3.08e-05	-0.17	-0.16	Height;	chr14:74996984	chr14:75011269~75012851:-
BRCA	cis	rs7618501	0.602	rs2624816	ENSG00000228008.1	CTD-2330K9.3	-5.18	2.7e-07	3.08e-05	-0.15	-0.16	Intelligence (multi-trait analysis);	chr3:50079879	chr3:49903845~49916937:+
BRCA	cis	rs17660992	0.603	rs8108345	ENSG00000273837.1	LLNLR-470E3.1	-5.18	2.7e-07	3.08e-05	-0.19	-0.16	Blood protein levels;	chr19:51661033	chr19:51639478~51639931:-
BRCA	cis	rs7487075	0.619	rs10785627	ENSG00000274723.1	RP11-618L22.1	5.18	2.71e-07	3.08e-05	0.19	0.16	Itch intensity from mosquito bite;	chr12:46430446	chr12:46970504~46972155:+
BRCA	cis	rs11072804	1	rs11072804	ENSG00000261143.1	ADAMTS7P3	5.18	2.71e-07	3.08e-05	0.2	0.16	Post bronchodilator FEV1/FVC ratio;	chr15:78786144	chr15:77976042~77993057:+
BRCA	cis	rs7618915	0.547	rs62253733	ENSG00000243224.1	RP5-1157M23.2	-5.18	2.71e-07	3.08e-05	-0.18	-0.16	Bipolar disorder;	chr3:52619398	chr3:52239258~52241097:+
BRCA	cis	rs875971	0.862	rs11765791	ENSG00000273448.1	RP11-166O4.6	5.18	2.71e-07	3.08e-05	0.15	0.16	Aortic root size;	chr7:66471587	chr7:67333047~67334383:+
BRCA	cis	rs922692	0.744	rs11072806	ENSG00000261143.1	ADAMTS7P3	5.18	2.71e-07	3.08e-05	0.2	0.16	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78786732	chr15:77976042~77993057:+
BRCA	cis	rs17747401	0.778	rs1538311	ENSG00000213731.2	RAB5CP1	5.18	2.71e-07	3.08e-05	0.18	0.16	Hypospadias;	chr10:74655751	chr10:74423435~74424014:-
BRCA	cis	rs9307551	0.584	rs9994403	ENSG00000250334.4	LINC00989	-5.18	2.71e-07	3.09e-05	-0.22	-0.16	Refractive error;	chr4:79521324	chr4:79492416~79576460:+
BRCA	cis	rs4588572	0.537	rs7702000	ENSG00000245556.2	SCAMP1-AS1	-5.18	2.71e-07	3.09e-05	-0.19	-0.16	Triglycerides;	chr5:78434732	chr5:78342365~78360507:-
BRCA	cis	rs11098499	0.535	rs7671759	ENSG00000249244.1	RP11-548H18.2	5.18	2.71e-07	3.09e-05	0.19	0.16	Corneal astigmatism;	chr4:119326939	chr4:119391831~119395335:-
BRCA	cis	rs1876905	0.68	rs434034	ENSG00000272356.1	RP5-1112D6.8	-5.18	2.71e-07	3.09e-05	-0.21	-0.16	Mean corpuscular hemoglobin;	chr6:111204180	chr6:111309203~111313517:+
BRCA	cis	rs4699052	0.963	rs4698890	ENSG00000248740.4	RP11-328K4.1	5.18	2.72e-07	3.09e-05	0.18	0.16	Testicular germ cell tumor;	chr4:103260721	chr4:103256159~103453658:+
BRCA	cis	rs270601	0.633	rs4535443	ENSG00000233006.5	AC034220.3	5.18	2.72e-07	3.09e-05	0.12	0.16	Acylcarnitine levels;	chr5:132236868	chr5:132311285~132369916:-
BRCA	cis	rs1979679	0.918	rs11049562	ENSG00000278733.1	RP11-425D17.1	5.18	2.72e-07	3.09e-05	0.2	0.16	Ossification of the posterior longitudinal ligament of the spine;	chr12:28375576	chr12:28185625~28186190:-
BRCA	cis	rs6840360	0.539	rs1443087	ENSG00000278978.1	RP11-164P12.5	-5.18	2.72e-07	3.09e-05	-0.18	-0.16	Intelligence (multi-trait analysis);	chr4:151528943	chr4:151669786~151670503:+
BRCA	cis	rs6840360	0.642	rs1443088	ENSG00000278978.1	RP11-164P12.5	-5.18	2.72e-07	3.09e-05	-0.18	-0.16	Intelligence (multi-trait analysis);	chr4:151528974	chr4:151669786~151670503:+
BRCA	cis	rs13113518	0.812	rs2048564	ENSG00000272969.1	RP11-528I4.2	5.18	2.72e-07	3.09e-05	0.18	0.16	Height;	chr4:55407965	chr4:55547112~55547889:+
BRCA	cis	rs10504130	1	rs11780891	ENSG00000253844.1	RP11-546K22.1	-5.18	2.72e-07	3.09e-05	-0.28	-0.16	Venous thromboembolism (SNP x SNP interaction);	chr8:51762067	chr8:51961458~52022974:+
BRCA	cis	rs13113518	1	rs13115828	ENSG00000223305.1	RN7SKP30	5.18	2.72e-07	3.1e-05	0.19	0.16	Height;	chr4:55551447	chr4:55540502~55540835:-
BRCA	cis	rs13113518	1	rs13136282	ENSG00000223305.1	RN7SKP30	5.18	2.72e-07	3.1e-05	0.19	0.16	Height;	chr4:55551845	chr4:55540502~55540835:-
BRCA	cis	rs1707322	0.928	rs6681068	ENSG00000234329.1	RP11-767N6.2	5.18	2.72e-07	3.1e-05	0.16	0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45932710	chr1:45651039~45651826:-
BRCA	cis	rs17801127	0.688	rs35224448	ENSG00000231969.1	AC144449.1	5.18	2.73e-07	3.1e-05	0.31	0.16	Liver enzyme levels (alanine transaminase);	chr2:149762838	chr2:149587196~149848233:+
BRCA	cis	rs2403083	0.723	rs4150893	ENSG00000258256.1	RP11-219B4.5	5.18	2.73e-07	3.1e-05	0.2	0.16	Plasma amyloid beta peptide concentrations (ABx-40);	chr8:85192519	chr8:85222446~85245717:-
BRCA	cis	rs10833905	0.878	rs875248	ENSG00000246225.5	RP11-17A1.3	-5.18	2.73e-07	3.1e-05	-0.23	-0.16	Sudden cardiac arrest;	chr11:23061279	chr11:22829380~22945393:+
BRCA	cis	rs4308124	1	rs62160391	ENSG00000230499.1	AC108463.1	-5.18	2.73e-07	3.1e-05	-0.18	-0.16	Vitiligo;	chr2:111251258	chr2:111195963~111206494:+
BRCA	cis	rs4908768	0.501	rs11121201	ENSG00000232912.4	RP5-1115A15.1	5.18	2.73e-07	3.1e-05	0.15	0.16	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8572732	chr1:8424645~8434838:+
BRCA	cis	rs57221529	0.766	rs72706610	ENSG00000271781.1	CTD-2589H19.6	-5.18	2.73e-07	3.1e-05	-0.23	-0.16	Lung disease severity in cystic fibrosis;	chr5:560996	chr5:675826~676616:+
BRCA	cis	rs962856	1	rs6739392	ENSG00000236780.4	AC078941.1	5.18	2.73e-07	3.1e-05	0.2	0.16	Pancreatic cancer;	chr2:67374839	chr2:67123357~67215319:-
BRCA	cis	rs6751744	0.855	rs10206214	ENSG00000226266.5	AC009961.3	-5.18	2.73e-07	3.1e-05	-0.21	-0.16	Dysphagia;	chr2:159507781	chr2:159670708~159712435:-
BRCA	cis	rs6751744	0.855	rs1425045	ENSG00000226266.5	AC009961.3	-5.18	2.73e-07	3.1e-05	-0.21	-0.16	Dysphagia;	chr2:159508236	chr2:159670708~159712435:-
BRCA	cis	rs9341808	0.727	rs10943697	ENSG00000272129.1	RP11-250B2.6	5.18	2.73e-07	3.1e-05	0.2	0.16	Sitting height ratio;	chr6:80221789	chr6:80355424~80356859:+
BRCA	cis	rs9341808	0.718	rs1324123	ENSG00000272129.1	RP11-250B2.6	5.18	2.73e-07	3.1e-05	0.2	0.16	Sitting height ratio;	chr6:80223177	chr6:80355424~80356859:+
BRCA	cis	rs1555322	1	rs2425034	ENSG00000126005.14	MMP24-AS1	-5.18	2.73e-07	3.11e-05	-0.26	-0.16	Attention deficit hyperactivity disorder;	chr20:35268011	chr20:35216462~35278131:-
BRCA	cis	rs1555322	0.858	rs2425035	ENSG00000126005.14	MMP24-AS1	-5.18	2.73e-07	3.11e-05	-0.26	-0.16	Attention deficit hyperactivity disorder;	chr20:35268016	chr20:35216462~35278131:-
BRCA	cis	rs4718428	1	rs4718428	ENSG00000229180.5	GS1-124K5.11	5.18	2.73e-07	3.11e-05	0.14	0.16	Corneal structure;	chr7:66956459	chr7:66526088~66542624:-
BRCA	cis	rs17685	0.753	rs1637037	ENSG00000280388.1	RP11-229D13.3	-5.17	2.73e-07	3.11e-05	-0.17	-0.16	Coffee consumption (cups per day);Coffee consumption;	chr7:76063609	chr7:76043977~76045963:-
BRCA	cis	rs7618915	0.533	rs35107891	ENSG00000243224.1	RP5-1157M23.2	-5.17	2.73e-07	3.11e-05	-0.18	-0.16	Bipolar disorder;	chr3:52579640	chr3:52239258~52241097:+
BRCA	cis	rs6840258	0.891	rs3775209	ENSG00000251411.1	RP11-397E7.4	-5.17	2.73e-07	3.11e-05	-0.21	-0.16	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87125794	chr4:86913266~86914817:-
BRCA	cis	rs8180040	0.654	rs1466740	ENSG00000276925.1	RP11-708J19.3	5.17	2.73e-07	3.11e-05	0.18	0.16	Colorectal cancer;	chr3:47204393	chr3:47469777~47469987:+
BRCA	cis	rs17660992	0.603	rs59485321	ENSG00000273837.1	LLNLR-470E3.1	-5.17	2.74e-07	3.11e-05	-0.19	-0.16	Blood protein levels;	chr19:51660710	chr19:51639478~51639931:-
BRCA	cis	rs9656709	0.528	rs4320501	ENSG00000273720.1	RP11-613E4.4	5.17	2.74e-07	3.11e-05	0.2	0.16	Behavioural disinhibition (generation interaction);	chr7:55662529	chr7:55743073~55743457:+
BRCA	cis	rs728616	0.614	rs10887243	ENSG00000225484.5	NUTM2B-AS1	-5.17	2.74e-07	3.11e-05	-0.31	-0.16	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79957339	chr10:79663088~79826594:-
BRCA	cis	rs728616	0.614	rs10887244	ENSG00000225484.5	NUTM2B-AS1	-5.17	2.74e-07	3.11e-05	-0.31	-0.16	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79957352	chr10:79663088~79826594:-
BRCA	cis	rs950776	0.72	rs11637890	ENSG00000261762.1	RP11-650L12.2	-5.17	2.74e-07	3.11e-05	-0.18	-0.16	Sudden cardiac arrest;	chr15:78643077	chr15:78589123~78591276:-
BRCA	cis	rs13113518	0.902	rs12642716	ENSG00000223305.1	RN7SKP30	5.17	2.74e-07	3.11e-05	0.19	0.16	Height;	chr4:55479996	chr4:55540502~55540835:-
BRCA	cis	rs7487075	0.619	rs10785629	ENSG00000274723.1	RP11-618L22.1	5.17	2.74e-07	3.11e-05	0.2	0.16	Itch intensity from mosquito bite;	chr12:46460944	chr12:46970504~46972155:+
BRCA	cis	rs9341808	0.718	rs2322636	ENSG00000272129.1	RP11-250B2.6	5.17	2.74e-07	3.11e-05	0.2	0.16	Sitting height ratio;	chr6:80187719	chr6:80355424~80356859:+
BRCA	cis	rs4713118	0.662	rs149900	ENSG00000280107.1	AL022393.9	-5.17	2.74e-07	3.11e-05	-0.24	-0.16	Parkinson's disease;	chr6:28046819	chr6:28170845~28172521:+
BRCA	cis	rs2638953	0.962	rs61922969	ENSG00000247934.4	RP11-967K21.1	-5.17	2.74e-07	3.12e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28261721	chr12:28163298~28190738:-
BRCA	cis	rs8031584	0.918	rs61997140	ENSG00000270015.1	RP11-540B6.6	-5.17	2.74e-07	3.12e-05	-0.17	-0.16	Huntington's disease progression;	chr15:30985109	chr15:30926514~30928407:+
BRCA	cis	rs2153535	0.58	rs2327051	ENSG00000251164.1	HULC	5.17	2.74e-07	3.12e-05	0.2	0.16	Motion sickness;	chr6:8440917	chr6:8652137~8653846:+
BRCA	cis	rs2562456	0.833	rs1626404	ENSG00000268081.1	RP11-678G14.2	5.17	2.74e-07	3.12e-05	0.25	0.16	Pain;	chr19:21300986	chr19:21554640~21569237:-
BRCA	cis	rs6442522	0.671	rs2305616	ENSG00000249786.6	EAF1-AS1	5.17	2.74e-07	3.12e-05	0.16	0.16	Uric acid levels;	chr3:15474188	chr3:15436171~15455940:-
BRCA	cis	rs2243480	1	rs709607	ENSG00000229886.1	RP5-1132H15.3	-5.17	2.74e-07	3.12e-05	-0.27	-0.16	Diabetic kidney disease;	chr7:65984554	chr7:66025126~66031544:-
BRCA	cis	rs1440410	0.571	rs10034934	ENSG00000250326.1	RP11-284M14.1	-5.17	2.74e-07	3.12e-05	-0.18	-0.16	Ischemic stroke;	chr4:143112368	chr4:142933195~143184861:-
BRCA	cis	rs1440410	0.571	rs11728569	ENSG00000250326.1	RP11-284M14.1	-5.17	2.74e-07	3.12e-05	-0.18	-0.16	Ischemic stroke;	chr4:143115500	chr4:142933195~143184861:-
BRCA	cis	rs783540	0.5	rs7163840	ENSG00000255769.6	GOLGA2P10	5.17	2.75e-07	3.12e-05	0.21	0.16	Schizophrenia;	chr15:82729551	chr15:82472993~82513950:-
BRCA	cis	rs763121	0.853	rs4821812	ENSG00000228274.3	RP3-508I15.9	-5.17	2.75e-07	3.12e-05	-0.18	-0.16	Menopause (age at onset);	chr22:38679230	chr22:38667585~38681820:-
BRCA	cis	rs728616	0.764	rs117833443	ENSG00000225484.5	NUTM2B-AS1	-5.17	2.75e-07	3.12e-05	-0.43	-0.16	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79978380	chr10:79663088~79826594:-
BRCA	cis	rs728616	0.867	rs116994688	ENSG00000225484.5	NUTM2B-AS1	-5.17	2.75e-07	3.12e-05	-0.43	-0.16	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79978381	chr10:79663088~79826594:-
BRCA	cis	rs9393692	0.905	rs6908328	ENSG00000241549.7	GUSBP2	-5.17	2.75e-07	3.13e-05	-0.17	-0.16	Educational attainment;	chr6:26292627	chr6:26871484~26956554:-
BRCA	cis	rs1707322	1	rs4660905	ENSG00000234329.1	RP11-767N6.2	-5.17	2.75e-07	3.13e-05	-0.16	-0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45995915	chr1:45651039~45651826:-
BRCA	cis	rs8114671	0.527	rs6088650	ENSG00000269202.1	RP4-614O4.12	5.17	2.75e-07	3.13e-05	0.16	0.16	Height;	chr20:34926662	chr20:35201747~35203288:-
BRCA	cis	rs801193	0.569	rs2013908	ENSG00000273448.1	RP11-166O4.6	-5.17	2.75e-07	3.13e-05	-0.15	-0.16	Aortic root size;	chr7:66656082	chr7:67333047~67334383:+
BRCA	cis	rs17685	0.753	rs869806	ENSG00000280388.1	RP11-229D13.3	-5.17	2.75e-07	3.13e-05	-0.16	-0.16	Coffee consumption (cups per day);Coffee consumption;	chr7:76059305	chr7:76043977~76045963:-
BRCA	cis	rs829883	0.664	rs865509	ENSG00000227825.4	SLC9A7P1	5.17	2.75e-07	3.13e-05	0.19	0.16	Colorectal adenoma (advanced);	chr12:98460666	chr12:98453835~98457145:-
BRCA	cis	rs1707322	0.827	rs6683274	ENSG00000234329.1	RP11-767N6.2	5.17	2.75e-07	3.13e-05	0.17	0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45775966	chr1:45651039~45651826:-
BRCA	cis	rs442309	0.687	rs10822053	ENSG00000238280.1	RP11-436D10.3	5.17	2.75e-07	3.13e-05	0.22	0.16	Vogt-Koyanagi-Harada syndrome;	chr10:62701075	chr10:62793562~62805887:-
BRCA	cis	rs7976269	0.609	rs10771475	ENSG00000275476.1	RP11-996F15.4	-5.17	2.75e-07	3.13e-05	-0.18	-0.16	Male-pattern baldness;	chr12:29071077	chr12:29277397~29277882:-
BRCA	cis	rs2274273	0.712	rs6572999	ENSG00000258413.1	RP11-665C16.6	-5.17	2.76e-07	3.13e-05	-0.2	-0.16	Protein biomarker;	chr14:55060656	chr14:55262767~55272075:-
BRCA	cis	rs950880	1	rs950880	ENSG00000234389.1	AC007278.3	-5.17	2.76e-07	3.13e-05	-0.15	-0.16	Serum protein levels (sST2);	chr2:102316102	chr2:102438713~102440475:+
BRCA	cis	rs4819052	0.851	rs2838840	ENSG00000184274.3	LINC00315	-5.17	2.76e-07	3.13e-05	-0.22	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45248579	chr21:45300245~45305257:-
BRCA	cis	rs6496044	0.963	rs6496050	ENSG00000202081.1	RNU6-1280P	5.17	2.76e-07	3.13e-05	0.18	0.16	Interstitial lung disease;	chr15:85526019	chr15:85651522~85651628:-
BRCA	cis	rs1979679	0.682	rs4359252	ENSG00000278733.1	RP11-425D17.1	-5.17	2.76e-07	3.13e-05	-0.22	-0.16	Ossification of the posterior longitudinal ligament of the spine;	chr12:28434298	chr12:28185625~28186190:-
BRCA	cis	rs1019173	0.966	rs6971164	ENSG00000261455.1	LINC01003	5.17	2.76e-07	3.13e-05	0.19	0.16	Kidney function decline traits;	chr7:152011217	chr7:152463786~152465549:+
BRCA	cis	rs2281558	0.833	rs12480853	ENSG00000230772.1	VN1R108P	-5.17	2.76e-07	3.13e-05	-0.2	-0.16	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25542323	chr20:25734264~25735093:+
BRCA	cis	rs2638953	0.821	rs76265865	ENSG00000247934.4	RP11-967K21.1	-5.17	2.76e-07	3.14e-05	-0.21	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28504107	chr12:28163298~28190738:-
BRCA	cis	rs2153535	0.58	rs7748455	ENSG00000251164.1	HULC	-5.17	2.76e-07	3.14e-05	-0.19	-0.16	Motion sickness;	chr6:8453392	chr6:8652137~8653846:+
BRCA	cis	rs12701220	0.901	rs12701708	ENSG00000229043.2	AC091729.9	-5.17	2.76e-07	3.14e-05	-0.24	-0.16	Bronchopulmonary dysplasia;	chr7:1050697	chr7:1160374~1165267:+
BRCA	cis	rs11072805	1	rs11072805	ENSG00000261143.1	ADAMTS7P3	5.17	2.76e-07	3.14e-05	0.2	0.16	Post bronchodilator FEV1/FVC ratio;	chr15:78786176	chr15:77976042~77993057:+
BRCA	cis	rs2638953	0.962	rs12370271	ENSG00000247934.4	RP11-967K21.1	-5.17	2.76e-07	3.14e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28313840	chr12:28163298~28190738:-
BRCA	cis	rs7577696	0.962	rs4952248	ENSG00000272716.1	RP11-563N4.1	-5.17	2.77e-07	3.14e-05	-0.17	-0.16	Inflammatory biomarkers;	chr2:32118600	chr2:32165046~32165757:-
BRCA	cis	rs7577696	0.962	rs4952250	ENSG00000272716.1	RP11-563N4.1	-5.17	2.77e-07	3.14e-05	-0.17	-0.16	Inflammatory biomarkers;	chr2:32118630	chr2:32165046~32165757:-
BRCA	cis	rs172166	0.694	rs9295760	ENSG00000280107.1	AL022393.9	-5.17	2.77e-07	3.14e-05	-0.22	-0.16	Cardiac Troponin-T levels;	chr6:28179607	chr6:28170845~28172521:+
BRCA	cis	rs17508449	0.547	rs3789604	ENSG00000232450.1	RP4-730K3.3	-5.17	2.77e-07	3.14e-05	-0.25	-0.16	Leprosy;	chr1:113812320	chr1:113698884~113699631:-
BRCA	cis	rs2613964	0.504	rs3995917	ENSG00000240057.4	RP11-572M11.4	5.17	2.77e-07	3.14e-05	0.16	0.16	Pediatric bone mineral content (spine);Pediatric bone mineral density (spine);	chr3:113133767	chr3:113019532~113183301:+
BRCA	cis	rs7577696	0.962	rs2235134	ENSG00000272716.1	RP11-563N4.1	-5.17	2.77e-07	3.14e-05	-0.17	-0.16	Inflammatory biomarkers;	chr2:32107474	chr2:32165046~32165757:-
BRCA	cis	rs7209700	0.742	rs999323	ENSG00000228782.6	CTD-2026D20.3	-5.17	2.77e-07	3.14e-05	-0.19	-0.16	IgG glycosylation;	chr17:47294237	chr17:47450568~47492492:-
BRCA	cis	rs6832769	0.925	rs4371676	ENSG00000223305.1	RN7SKP30	5.17	2.77e-07	3.14e-05	0.21	0.16	Personality dimensions;	chr4:55462841	chr4:55540502~55540835:-
BRCA	cis	rs8113308	0.752	rs8113758	ENSG00000269483.1	AC006272.1	5.17	2.77e-07	3.15e-05	0.26	0.16	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51990054	chr19:51839924~51843324:-
BRCA	cis	rs9545047	0.604	rs9530895	ENSG00000227354.5	RBM26-AS1	5.17	2.77e-07	3.15e-05	0.17	0.16	Schizophrenia;	chr13:79334877	chr13:79406309~79424328:+
BRCA	cis	rs9545047	0.567	rs9530896	ENSG00000227354.5	RBM26-AS1	5.17	2.77e-07	3.15e-05	0.17	0.16	Schizophrenia;	chr13:79335507	chr13:79406309~79424328:+
BRCA	cis	rs7577696	0.889	rs2365558	ENSG00000272716.1	RP11-563N4.1	-5.17	2.77e-07	3.15e-05	-0.17	-0.16	Inflammatory biomarkers;	chr2:32111588	chr2:32165046~32165757:-
BRCA	cis	rs516805	0.706	rs11752939	ENSG00000279453.1	RP3-425C14.4	5.17	2.77e-07	3.15e-05	0.22	0.16	Lymphocyte counts;	chr6:122350062	chr6:122436789~122439223:-
BRCA	cis	rs11667325	1	rs4802867	ENSG00000268316.1	AC006272.2	-5.17	2.78e-07	3.15e-05	-0.18	-0.16	Neutrophil percentage of granulocytes;	chr19:51796632	chr19:51839771~51840945:-
BRCA	cis	rs6840360	1	rs2278304	ENSG00000270265.1	RP11-731D1.4	5.17	2.78e-07	3.15e-05	0.18	0.16	Intelligence (multi-trait analysis);	chr4:151672257	chr4:151333775~151353224:-
BRCA	cis	rs1030877	0.515	rs17030766	ENSG00000235319.1	AC012360.4	5.17	2.78e-07	3.15e-05	0.22	0.16	Obesity-related traits;	chr2:105295448	chr2:105324210~105330529:+
BRCA	cis	rs2562456	0.833	rs552800	ENSG00000268081.1	RP11-678G14.2	-5.17	2.78e-07	3.15e-05	-0.24	-0.16	Pain;	chr19:21301840	chr19:21554640~21569237:-
BRCA	cis	rs875971	0.862	rs10263690	ENSG00000236529.1	RP13-254B10.1	-5.17	2.78e-07	3.15e-05	-0.18	-0.16	Aortic root size;	chr7:66301466	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.862	rs10250544	ENSG00000236529.1	RP13-254B10.1	-5.17	2.78e-07	3.15e-05	-0.18	-0.16	Aortic root size;	chr7:66301574	chr7:65840212~65840596:+
BRCA	cis	rs7577696	0.853	rs56740303	ENSG00000272716.1	RP11-563N4.1	-5.17	2.78e-07	3.15e-05	-0.17	-0.16	Inflammatory biomarkers;	chr2:32079587	chr2:32165046~32165757:-
BRCA	cis	rs875971	0.767	rs12668005	ENSG00000273448.1	RP11-166O4.6	5.17	2.78e-07	3.15e-05	0.15	0.16	Aortic root size;	chr7:66444034	chr7:67333047~67334383:+
BRCA	cis	rs7914558	1	rs7094843	ENSG00000236937.2	PTGES3P4	5.17	2.78e-07	3.16e-05	0.2	0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103046897	chr10:102845595~102845950:+
BRCA	cis	rs2638953	0.815	rs11049709	ENSG00000247934.4	RP11-967K21.1	-5.17	2.78e-07	3.16e-05	-0.21	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28545099	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.782	rs11049710	ENSG00000247934.4	RP11-967K21.1	-5.17	2.78e-07	3.16e-05	-0.21	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28546231	chr12:28163298~28190738:-
BRCA	cis	rs2408955	0.522	rs2051851	ENSG00000273765.1	RP11-370I10.11	-5.17	2.78e-07	3.16e-05	-0.19	-0.16	Glycated hemoglobin levels;	chr12:48092157	chr12:48360920~48361377:+
BRCA	cis	rs4835473	0.897	rs11931330	ENSG00000249741.2	RP11-673E1.3	-5.17	2.78e-07	3.16e-05	-0.17	-0.16	Immature fraction of reticulocytes;	chr4:143970808	chr4:143911514~143912053:-
BRCA	cis	rs13113518	0.812	rs2035691	ENSG00000272969.1	RP11-528I4.2	5.17	2.78e-07	3.16e-05	0.19	0.16	Height;	chr4:55529786	chr4:55547112~55547889:+
BRCA	cis	rs13113518	0.756	rs11939652	ENSG00000272969.1	RP11-528I4.2	5.17	2.78e-07	3.16e-05	0.19	0.16	Height;	chr4:55532542	chr4:55547112~55547889:+
BRCA	cis	rs7577696	0.785	rs11683760	ENSG00000272716.1	RP11-563N4.1	-5.17	2.79e-07	3.16e-05	-0.18	-0.16	Inflammatory biomarkers;	chr2:32139024	chr2:32165046~32165757:-
BRCA	cis	rs11159086	0.793	rs10136668	ENSG00000270000.1	RP3-449M8.9	5.17	2.79e-07	3.16e-05	0.24	0.16	Advanced glycation end-product levels;	chr14:74492183	chr14:74471930~74472360:-
BRCA	cis	rs516805	0.596	rs2606640	ENSG00000279453.1	RP3-425C14.4	-5.17	2.79e-07	3.16e-05	-0.22	-0.16	Lymphocyte counts;	chr6:122102901	chr6:122436789~122439223:-
BRCA	cis	rs516805	0.63	rs2262318	ENSG00000279453.1	RP3-425C14.4	-5.17	2.79e-07	3.16e-05	-0.22	-0.16	Lymphocyte counts;	chr6:122102980	chr6:122436789~122439223:-
BRCA	cis	rs7191700	0.578	rs243324	ENSG00000262636.1	CTD-3088G3.4	5.17	2.79e-07	3.16e-05	0.21	0.16	Multiple sclerosis;	chr16:11261113	chr16:11380859~11381118:-
BRCA	cis	rs11955398	0.678	rs12522801	ENSG00000215032.2	GNL3LP1	5.17	2.79e-07	3.16e-05	0.19	0.16	Intelligence (multi-trait analysis);	chr5:60682579	chr5:60891935~60893577:-
BRCA	cis	rs1876905	0.597	rs354551	ENSG00000230177.1	RP5-1112D6.4	-5.17	2.79e-07	3.16e-05	-0.24	-0.16	Mean corpuscular hemoglobin;	chr6:111224337	chr6:111277932~111278742:+
BRCA	cis	rs1707322	0.928	rs10732844	ENSG00000234329.1	RP11-767N6.2	5.17	2.79e-07	3.16e-05	0.16	0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45907016	chr1:45651039~45651826:-
BRCA	cis	rs1862618	0.671	rs2591957	ENSG00000271828.1	CTD-2310F14.1	-5.17	2.79e-07	3.17e-05	-0.2	-0.16	Initial pursuit acceleration;	chr5:56947319	chr5:56927874~56929573:+
BRCA	cis	rs801193	0.569	rs6951302	ENSG00000273448.1	RP11-166O4.6	-5.17	2.79e-07	3.17e-05	-0.15	-0.16	Aortic root size;	chr7:66667525	chr7:67333047~67334383:+
BRCA	cis	rs9840812	0.861	rs511154	ENSG00000239213.4	NCK1-AS1	5.17	2.79e-07	3.17e-05	0.19	0.16	Fibrinogen levels;	chr3:136232079	chr3:136841726~136862054:-
BRCA	cis	rs2073316	0.559	rs6732223	ENSG00000272716.1	RP11-563N4.1	-5.17	2.79e-07	3.17e-05	-0.17	-0.16	Interleukin-18 levels;	chr2:31517592	chr2:32165046~32165757:-
BRCA	cis	rs783540	0.656	rs783524	ENSG00000255769.6	GOLGA2P10	5.17	2.79e-07	3.17e-05	0.19	0.16	Schizophrenia;	chr15:82615393	chr15:82472993~82513950:-
BRCA	cis	rs783540	0.592	rs2567632	ENSG00000255769.6	GOLGA2P10	5.17	2.79e-07	3.17e-05	0.19	0.16	Schizophrenia;	chr15:82616053	chr15:82472993~82513950:-
BRCA	cis	rs73222236	0.586	rs6763239	ENSG00000273486.1	RP11-731C17.2	5.17	2.79e-07	3.17e-05	0.18	0.16	Coronary artery disease;	chr3:136660909	chr3:136837338~136839021:-
BRCA	cis	rs12712135	0.651	rs12712150	ENSG00000234389.1	AC007278.3	-5.17	2.79e-07	3.17e-05	-0.14	-0.16	Blood protein levels;	chr2:102458353	chr2:102438713~102440475:+
BRCA	cis	rs9287719	0.967	rs6432114	ENSG00000243819.4	RN7SL832P	5.17	2.79e-07	3.17e-05	0.15	0.16	Prostate cancer;	chr2:10604804	chr2:10690344~10692099:+
BRCA	cis	rs7618501	0.602	rs6780731	ENSG00000228008.1	CTD-2330K9.3	5.17	2.8e-07	3.17e-05	0.15	0.16	Intelligence (multi-trait analysis);	chr3:49980045	chr3:49903845~49916937:+
BRCA	cis	rs801193	0.569	rs3846973	ENSG00000273448.1	RP11-166O4.6	-5.17	2.8e-07	3.17e-05	-0.15	-0.16	Aortic root size;	chr7:66655048	chr7:67333047~67334383:+
BRCA	cis	rs10510102	0.935	rs79360006	ENSG00000226864.1	ATE1-AS1	5.17	2.8e-07	3.17e-05	0.29	0.16	Breast cancer;	chr10:121912856	chr10:121928312~121951965:+
BRCA	cis	rs3733585	0.673	rs4312757	ENSG00000250413.1	RP11-448G15.1	5.17	2.8e-07	3.17e-05	0.21	0.16	Cleft plate (environmental tobacco smoke interaction);	chr4:9954521	chr4:10006482~10009725:+
BRCA	cis	rs3733585	0.673	rs6814664	ENSG00000250413.1	RP11-448G15.1	5.17	2.8e-07	3.17e-05	0.21	0.16	Cleft plate (environmental tobacco smoke interaction);	chr4:9954604	chr4:10006482~10009725:+
BRCA	cis	rs3733585	0.588	rs6449154	ENSG00000250413.1	RP11-448G15.1	5.17	2.8e-07	3.17e-05	0.21	0.16	Cleft plate (environmental tobacco smoke interaction);	chr4:9954780	chr4:10006482~10009725:+
BRCA	cis	rs3733585	0.638	rs6449155	ENSG00000250413.1	RP11-448G15.1	5.17	2.8e-07	3.17e-05	0.21	0.16	Cleft plate (environmental tobacco smoke interaction);	chr4:9954923	chr4:10006482~10009725:+
BRCA	cis	rs4925386	1	rs1889201	ENSG00000273619.1	RP5-908M14.9	5.17	2.8e-07	3.17e-05	0.13	0.16	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62348019	chr20:62386303~62386970:-
BRCA	cis	rs7772486	0.79	rs2243665	ENSG00000270638.1	RP3-466P17.1	5.17	2.8e-07	3.18e-05	0.19	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145886984	chr6:145735570~145737218:+
BRCA	cis	rs35740288	0.895	rs3743332	ENSG00000259407.1	RP11-158M2.3	-5.17	2.8e-07	3.18e-05	-0.21	-0.16	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85760520	chr15:85744109~85750281:-
BRCA	cis	rs338389	0.586	rs338400	ENSG00000260657.2	RP11-315D16.4	-5.17	2.8e-07	3.18e-05	-0.2	-0.16	Survival in rectal cancer;	chr15:67961818	chr15:68267792~68277994:-
BRCA	cis	rs2562456	0.833	rs516519	ENSG00000268081.1	RP11-678G14.2	-5.17	2.8e-07	3.18e-05	-0.24	-0.16	Pain;	chr19:21298730	chr19:21554640~21569237:-
BRCA	cis	rs7618501	0.602	rs9311446	ENSG00000228008.1	CTD-2330K9.3	-5.17	2.8e-07	3.18e-05	-0.15	-0.16	Intelligence (multi-trait analysis);	chr3:50054793	chr3:49903845~49916937:+
BRCA	cis	rs7618501	0.602	rs2245365	ENSG00000228008.1	CTD-2330K9.3	-5.17	2.8e-07	3.18e-05	-0.15	-0.16	Intelligence (multi-trait analysis);	chr3:50059886	chr3:49903845~49916937:+
BRCA	cis	rs2243480	1	rs4718317	ENSG00000228409.4	CCT6P1	-5.17	2.8e-07	3.18e-05	-0.21	-0.16	Diabetic kidney disease;	chr7:66183914	chr7:65751142~65763354:+
BRCA	cis	rs12906542	0.507	rs4395040	ENSG00000259792.1	RP11-114H24.6	-5.17	2.8e-07	3.18e-05	-0.2	-0.16	Breast cancer;	chr15:77990191	chr15:77993405~77995289:+
BRCA	cis	rs875971	1	rs11974264	ENSG00000223473.2	GS1-124K5.3	-5.17	2.8e-07	3.18e-05	-0.12	-0.16	Aortic root size;	chr7:66182595	chr7:66491049~66493566:-
BRCA	cis	rs734999	0.967	rs10752745	ENSG00000238164.5	RP3-395M20.8	-5.17	2.8e-07	3.18e-05	-0.12	-0.16	Ulcerative colitis;	chr1:2576499	chr1:2549920~2557031:-
BRCA	cis	rs8048589	1	rs8059989	ENSG00000175604.2	RP11-276H1.3	-5.17	2.8e-07	3.18e-05	-0.23	-0.16	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);	chr16:12091889	chr16:12086746~12090302:-
BRCA	cis	rs1859596	1	rs7783388	ENSG00000234456.6	MAGI2-AS3	-5.17	2.8e-07	3.18e-05	-0.1	-0.16	Reading or mathematical ability;	chr7:79456027	chr7:79452877~79471208:+
BRCA	cis	rs9818758	0.607	rs11706189	ENSG00000270441.1	RP11-694I15.7	5.17	2.8e-07	3.18e-05	0.31	0.16	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49173400	chr3:49140086~49160851:-
BRCA	cis	rs847577	0.508	rs12538837	ENSG00000272950.1	RP11-307C18.1	5.17	2.8e-07	3.18e-05	0.22	0.16	Breast cancer;	chr7:98055156	chr7:98322853~98323430:+
BRCA	cis	rs4660214	0.666	rs1180376	ENSG00000228060.1	RP11-69E11.8	-5.17	2.8e-07	3.18e-05	-0.16	-0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39418761	chr1:39565160~39573203:+
BRCA	cis	rs1555322	0.53	rs2275275	ENSG00000269202.1	RP4-614O4.12	-5.17	2.8e-07	3.18e-05	-0.19	-0.16	Attention deficit hyperactivity disorder;	chr20:35284508	chr20:35201747~35203288:-
BRCA	cis	rs1075265	0.611	rs3770403	ENSG00000235937.1	AC008280.1	5.17	2.81e-07	3.18e-05	0.18	0.16	Chronotype;Morning vs. evening chronotype;	chr2:53695688	chr2:54029552~54030682:-
BRCA	cis	rs2303759	0.709	rs2278405	ENSG00000268686.1	AC010524.2	5.17	2.81e-07	3.18e-05	0.25	0.16	Multiple sclerosis;	chr19:49309146	chr19:49368705~49388081:-
BRCA	cis	rs9840812	0.769	rs1279425	ENSG00000239213.4	NCK1-AS1	5.17	2.81e-07	3.18e-05	0.19	0.16	Fibrinogen levels;	chr3:136288142	chr3:136841726~136862054:-
BRCA	cis	rs9638182	0.697	rs12539316	ENSG00000274080.1	CTA-315H11.2	-5.17	2.81e-07	3.18e-05	-0.22	-0.16	Triglycerides;	chr7:73563568	chr7:73609262~73611502:-
BRCA	cis	rs595982	0.527	rs17272673	ENSG00000235191.1	NUCB1-AS1	5.17	2.81e-07	3.18e-05	0.27	0.16	Red cell distribution width;	chr19:48859735	chr19:48910930~48918891:-
BRCA	cis	rs2403083	0.505	rs1845892	ENSG00000258256.1	RP11-219B4.5	-5.17	2.81e-07	3.18e-05	-0.18	-0.16	Plasma amyloid beta peptide concentrations (ABx-40);	chr8:85260388	chr8:85222446~85245717:-
BRCA	cis	rs6480314	0.542	rs61854816	ENSG00000233590.1	RP11-153K11.3	-5.17	2.81e-07	3.18e-05	-0.26	-0.16	Optic nerve measurement (disc area);	chr10:68269051	chr10:68233251~68242379:-
BRCA	cis	rs2839186	0.508	rs6518278	ENSG00000228137.1	AP001469.7	-5.17	2.81e-07	3.19e-05	-0.18	-0.16	Testicular germ cell tumor;	chr21:46220657	chr21:46246890~46247682:+
BRCA	cis	rs987724	0.515	rs9876148	ENSG00000240875.4	LINC00886	-5.17	2.81e-07	3.19e-05	-0.22	-0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156894349	chr3:156747346~156817062:-
BRCA	cis	rs13113518	1	rs4864994	ENSG00000223305.1	RN7SKP30	5.17	2.81e-07	3.19e-05	0.19	0.16	Height;	chr4:55451955	chr4:55540502~55540835:-
BRCA	cis	rs17597773	0.527	rs2484698	ENSG00000238078.1	LINC01352	5.17	2.81e-07	3.19e-05	0.17	0.16	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220912723	chr1:220829255~220832429:+
BRCA	cis	rs2638953	0.815	rs11049680	ENSG00000247934.4	RP11-967K21.1	-5.17	2.81e-07	3.19e-05	-0.21	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28508436	chr12:28163298~28190738:-
BRCA	cis	rs9287719	0.674	rs1387566	ENSG00000243819.4	RN7SL832P	-5.17	2.82e-07	3.19e-05	-0.15	-0.16	Prostate cancer;	chr2:10688524	chr2:10690344~10692099:+
BRCA	cis	rs73193808	1	rs73193819	ENSG00000236056.1	GAPDHP14	-5.17	2.82e-07	3.19e-05	-0.23	-0.16	Coronary artery disease;	chr21:29172336	chr21:29222321~29223257:+
BRCA	cis	rs73193808	1	rs73193820	ENSG00000236056.1	GAPDHP14	-5.17	2.82e-07	3.19e-05	-0.23	-0.16	Coronary artery disease;	chr21:29172348	chr21:29222321~29223257:+
BRCA	cis	rs4835473	0.83	rs7692672	ENSG00000249741.2	RP11-673E1.3	-5.17	2.82e-07	3.2e-05	-0.17	-0.16	Immature fraction of reticulocytes;	chr4:143971048	chr4:143911514~143912053:-
BRCA	cis	rs9652601	0.649	rs7403919	ENSG00000274038.1	RP11-66H6.4	5.17	2.82e-07	3.2e-05	0.18	0.16	Systemic lupus erythematosus;	chr16:10992111	chr16:11056556~11057034:+
BRCA	cis	rs7359257	0.576	rs56038097	ENSG00000260657.2	RP11-315D16.4	5.17	2.82e-07	3.2e-05	0.2	0.16	Menarche (age at onset);	chr15:67612231	chr15:68267792~68277994:-
BRCA	cis	rs7569084	0.687	rs6755006	ENSG00000281920.1	RP11-418H16.1	-5.17	2.82e-07	3.2e-05	-0.21	-0.16	Sum eosinophil basophil counts;	chr2:65426008	chr2:65623272~65628424:+
BRCA	cis	rs7569084	0.687	rs6755128	ENSG00000281920.1	RP11-418H16.1	-5.17	2.82e-07	3.2e-05	-0.21	-0.16	Sum eosinophil basophil counts;	chr2:65426065	chr2:65623272~65628424:+
BRCA	cis	rs875971	1	rs10215948	ENSG00000223473.2	GS1-124K5.3	-5.17	2.82e-07	3.2e-05	-0.12	-0.16	Aortic root size;	chr7:66282799	chr7:66491049~66493566:-
BRCA	cis	rs4761702	0.527	rs11106988	ENSG00000257252.4	RP11-486A14.2	-5.17	2.82e-07	3.2e-05	-0.21	-0.16	Immature fraction of reticulocytes;	chr12:93340674	chr12:93317135~93377736:-
BRCA	cis	rs7618501	0.602	rs2526743	ENSG00000228008.1	CTD-2330K9.3	-5.17	2.83e-07	3.2e-05	-0.15	-0.16	Intelligence (multi-trait analysis);	chr3:50077812	chr3:49903845~49916937:+
BRCA	cis	rs9308731	0.583	rs6726007	ENSG00000227992.1	AC108463.2	-5.17	2.83e-07	3.2e-05	-0.19	-0.16	Chronic lymphocytic leukemia;	chr2:111174545	chr2:111203964~111206215:-
BRCA	cis	rs9393692	0.875	rs12526215	ENSG00000241549.7	GUSBP2	-5.17	2.83e-07	3.21e-05	-0.17	-0.16	Educational attainment;	chr6:26262688	chr6:26871484~26956554:-
BRCA	cis	rs4266144	0.558	rs4680339	ENSG00000241770.1	RP11-555M1.3	5.17	2.83e-07	3.21e-05	0.19	0.16	Coronary artery disease;	chr3:157117630	chr3:157163452~157169133:+
BRCA	cis	rs6545883	0.929	rs778140	ENSG00000270820.4	RP11-355B11.2	5.17	2.83e-07	3.21e-05	0.19	0.16	Tuberculosis;	chr2:61455841	chr2:61471188~61484130:+
BRCA	cis	rs987360	0.835	rs34522413	ENSG00000248869.4	RP11-138I17.1	5.17	2.83e-07	3.21e-05	0.16	0.16	Temperament;	chr4:137279474	chr4:136796722~137212799:-
BRCA	cis	rs875971	0.862	rs9791712	ENSG00000273448.1	RP11-166O4.6	-5.17	2.83e-07	3.21e-05	-0.15	-0.16	Aortic root size;	chr7:66640176	chr7:67333047~67334383:+
BRCA	cis	rs875971	0.862	rs9791713	ENSG00000273448.1	RP11-166O4.6	-5.17	2.83e-07	3.21e-05	-0.15	-0.16	Aortic root size;	chr7:66640211	chr7:67333047~67334383:+
BRCA	cis	rs72482608	0.865	rs10919471	ENSG00000271811.1	RP1-79C4.4	5.17	2.83e-07	3.21e-05	0.18	0.16	Emphysema imaging phenotypes;	chr1:170794412	chr1:170667381~170669425:+
BRCA	cis	rs13423976	1	rs13423976	ENSG00000231367.4	AC016995.3	-5.17	2.83e-07	3.21e-05	-0.18	-0.16	Gut microbiome composition (summer);	chr2:38518482	chr2:38406719~38515740:-
BRCA	cis	rs9393692	0.905	rs7746807	ENSG00000241549.7	GUSBP2	-5.17	2.83e-07	3.21e-05	-0.17	-0.16	Educational attainment;	chr6:26293110	chr6:26871484~26956554:-
BRCA	cis	rs957448	0.554	rs10956919	ENSG00000253175.1	RP11-267M23.6	5.17	2.83e-07	3.21e-05	0.19	0.16	Nonsyndromic cleft lip with cleft palate;	chr8:94572945	chr8:94565036~94565715:+
BRCA	cis	rs13113518	1	rs13118237	ENSG00000223305.1	RN7SKP30	5.17	2.83e-07	3.21e-05	0.19	0.16	Height;	chr4:55474259	chr4:55540502~55540835:-
BRCA	cis	rs10492201	0.529	rs4913269	ENSG00000236946.2	HNRNPA1P70	5.17	2.84e-07	3.21e-05	0.15	0.16	Itch intensity from mosquito bite adjusted by bite size;	chr12:68014065	chr12:68035767~68036853:+
BRCA	cis	rs11955398	0.529	rs62373032	ENSG00000215032.2	GNL3LP1	5.17	2.84e-07	3.21e-05	0.19	0.16	Intelligence (multi-trait analysis);	chr5:60660332	chr5:60891935~60893577:-
BRCA	cis	rs11096990	0.613	rs1451821	ENSG00000249685.1	RP11-360F5.3	-5.17	2.84e-07	3.21e-05	-0.2	-0.16	Cognitive function;	chr4:39178797	chr4:39133913~39135608:+
BRCA	cis	rs9341808	0.718	rs910266	ENSG00000272129.1	RP11-250B2.6	5.17	2.84e-07	3.22e-05	0.2	0.16	Sitting height ratio;	chr6:80211453	chr6:80355424~80356859:+
BRCA	cis	rs7617773	0.817	rs11710861	ENSG00000199476.1	Y_RNA	-5.17	2.84e-07	3.22e-05	-0.22	-0.16	Coronary artery disease;	chr3:48256070	chr3:48288587~48288694:+
BRCA	cis	rs4713118	0.621	rs9295755	ENSG00000204709.4	LINC01556	-5.17	2.84e-07	3.22e-05	-0.24	-0.16	Parkinson's disease;	chr6:28065396	chr6:28943877~28944537:+
BRCA	cis	rs1979679	0.918	rs1533142	ENSG00000278733.1	RP11-425D17.1	-5.17	2.84e-07	3.22e-05	-0.21	-0.16	Ossification of the posterior longitudinal ligament of the spine;	chr12:28461206	chr12:28185625~28186190:-
BRCA	cis	rs7178909	0.872	rs28468074	ENSG00000259677.1	RP11-493E3.1	5.17	2.84e-07	3.22e-05	0.19	0.16	Common traits (Other);	chr15:89892368	chr15:89876540~89877285:+
BRCA	cis	rs7178909	0.872	rs61345389	ENSG00000259677.1	RP11-493E3.1	5.17	2.84e-07	3.22e-05	0.19	0.16	Common traits (Other);	chr15:89892653	chr15:89876540~89877285:+
BRCA	cis	rs4819052	0.851	rs1999334	ENSG00000184274.3	LINC00315	-5.17	2.84e-07	3.22e-05	-0.21	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250542	chr21:45300245~45305257:-
BRCA	cis	rs9423406	0.66	rs113394930	ENSG00000224034.1	RP11-445P17.8	-5.17	2.84e-07	3.22e-05	-0.31	-0.16	Intelligence;	chr10:5254040	chr10:5266033~5271236:-
BRCA	cis	rs2832191	0.791	rs9983651	ENSG00000176054.6	RPL23P2	-5.17	2.84e-07	3.22e-05	-0.17	-0.16	Dental caries;	chr21:29118906	chr21:28997613~28998033:-
BRCA	cis	rs2832191	0.755	rs55671430	ENSG00000176054.6	RPL23P2	-5.17	2.84e-07	3.22e-05	-0.17	-0.16	Dental caries;	chr21:29120100	chr21:28997613~28998033:-
BRCA	cis	rs2832191	0.72	rs2832194	ENSG00000176054.6	RPL23P2	-5.17	2.84e-07	3.22e-05	-0.17	-0.16	Dental caries;	chr21:29121929	chr21:28997613~28998033:-
BRCA	cis	rs755249	0.509	rs710913	ENSG00000182109.6	RP11-69E11.4	-5.17	2.84e-07	3.22e-05	-0.18	-0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39524254	chr1:39522280~39546187:-
BRCA	cis	rs9545047	0.604	rs314695	ENSG00000227354.5	RBM26-AS1	-5.17	2.85e-07	3.22e-05	-0.17	-0.16	Schizophrenia;	chr13:79432206	chr13:79406309~79424328:+
BRCA	cis	rs78487399	0.908	rs80144434	ENSG00000234936.1	AC010883.5	5.17	2.85e-07	3.22e-05	0.23	0.16	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43617501	chr2:43229573~43233394:+
BRCA	cis	rs8064024	0.68	rs3747613	ENSG00000267077.1	RP11-127I20.5	-5.17	2.85e-07	3.22e-05	-0.16	-0.16	Cancer;	chr16:4858503	chr16:4795265~4796532:-
BRCA	cis	rs6061231	1	rs6061231	ENSG00000275437.1	RP5-908M14.10	5.17	2.85e-07	3.23e-05	0.17	0.16	Colorectal cancer;	chr20:62381861	chr20:62402236~62405935:-
BRCA	cis	rs7635879	0.905	rs9861931	ENSG00000230102.6	RP11-407B7.1	5.17	2.85e-07	3.23e-05	0.2	0.16	Breastfeeding duration;	chr3:194022716	chr3:194005259~194070970:-
BRCA	cis	rs4713118	0.513	rs149972	ENSG00000280107.1	AL022393.9	-5.17	2.85e-07	3.23e-05	-0.22	-0.16	Parkinson's disease;	chr6:28015449	chr6:28170845~28172521:+
BRCA	cis	rs4713118	0.513	rs149975	ENSG00000280107.1	AL022393.9	-5.17	2.85e-07	3.23e-05	-0.22	-0.16	Parkinson's disease;	chr6:28018562	chr6:28170845~28172521:+
BRCA	cis	rs987724	0.515	rs1574980	ENSG00000240875.4	LINC00886	-5.17	2.85e-07	3.23e-05	-0.23	-0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156917639	chr3:156747346~156817062:-
BRCA	cis	rs2832191	1	rs9984793	ENSG00000215533.7	LINC00189	5.17	2.85e-07	3.23e-05	0.18	0.16	Dental caries;	chr21:29114150	chr21:29193480~29288205:+
BRCA	cis	rs34792	0.525	rs66651392	ENSG00000207425.1	Y_RNA	-5.17	2.85e-07	3.23e-05	-0.21	-0.16	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15517735	chr16:14915457~14915556:-
BRCA	cis	rs16846053	0.786	rs62187567	ENSG00000227403.1	AC009299.3	5.17	2.85e-07	3.23e-05	0.38	0.16	Blood osmolality (transformed sodium);	chr2:161506555	chr2:161244739~161249050:+
BRCA	cis	rs2303319	0.504	rs60824222	ENSG00000227403.1	AC009299.3	5.17	2.85e-07	3.23e-05	0.38	0.16	Cognitive function;	chr2:161512209	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.681	rs62187569	ENSG00000227403.1	AC009299.3	5.17	2.85e-07	3.23e-05	0.38	0.16	Blood osmolality (transformed sodium);	chr2:161517007	chr2:161244739~161249050:+
BRCA	cis	rs2303319	0.504	rs62187570	ENSG00000227403.1	AC009299.3	5.17	2.85e-07	3.23e-05	0.38	0.16	Cognitive function;	chr2:161517389	chr2:161244739~161249050:+
BRCA	cis	rs2303319	0.504	rs62187571	ENSG00000227403.1	AC009299.3	5.17	2.85e-07	3.23e-05	0.38	0.16	Cognitive function;	chr2:161517809	chr2:161244739~161249050:+
BRCA	cis	rs7617773	0.784	rs9850672	ENSG00000199476.1	Y_RNA	-5.17	2.86e-07	3.23e-05	-0.22	-0.16	Coronary artery disease;	chr3:48259682	chr3:48288587~48288694:+
BRCA	cis	rs9473147	0.503	rs9473123	ENSG00000270761.1	RP11-385F7.1	-5.17	2.86e-07	3.23e-05	-0.17	-0.16	Platelet distribution width;Mean platelet volume;	chr6:47507603	chr6:47477243~47477572:-
BRCA	cis	rs7131987	0.507	rs3782507	ENSG00000275476.1	RP11-996F15.4	5.17	2.86e-07	3.23e-05	0.17	0.16	QT interval;	chr12:29292597	chr12:29277397~29277882:-
BRCA	cis	rs4699052	0.963	rs2061646	ENSG00000248740.4	RP11-328K4.1	5.17	2.86e-07	3.23e-05	0.18	0.16	Testicular germ cell tumor;	chr4:103262737	chr4:103256159~103453658:+
BRCA	cis	rs6570726	0.526	rs7755237	ENSG00000235652.6	RP11-545I5.3	-5.17	2.86e-07	3.23e-05	-0.15	-0.16	Lobe attachment (rater-scored or self-reported);	chr6:145410716	chr6:145799409~145886585:+
BRCA	cis	rs270601	0.69	rs162904	ENSG00000233006.5	AC034220.3	-5.17	2.86e-07	3.23e-05	-0.12	-0.16	Acylcarnitine levels;	chr5:132260091	chr5:132311285~132369916:-
BRCA	cis	rs8103033	0.748	rs8101868	ENSG00000268088.1	AC093063.2	-5.17	2.86e-07	3.24e-05	-0.18	-0.16	Obesity-related traits;	chr19:39646090	chr19:39693925~39696258:+
BRCA	cis	rs1007190	0.881	rs12941832	ENSG00000267505.1	CTC-296K1.3	5.17	2.86e-07	3.24e-05	0.29	0.16	DNA methylation (variation);	chr17:44910114	chr17:44793199~44794474:+
BRCA	cis	rs2098713	0.569	rs55758014	ENSG00000250155.1	CTD-2353F22.1	5.17	2.86e-07	3.24e-05	0.17	0.16	Telomere length;	chr5:37565674	chr5:36666214~36725195:-
BRCA	cis	rs78487399	0.908	rs10186441	ENSG00000234936.1	AC010883.5	5.17	2.86e-07	3.24e-05	0.22	0.16	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43612909	chr2:43229573~43233394:+
BRCA	cis	rs7577696	0.925	rs212716	ENSG00000272716.1	RP11-563N4.1	5.17	2.86e-07	3.24e-05	0.17	0.16	Inflammatory biomarkers;	chr2:32235865	chr2:32165046~32165757:-
BRCA	cis	rs17685	0.753	rs1637039	ENSG00000280388.1	RP11-229D13.3	-5.17	2.86e-07	3.24e-05	-0.17	-0.16	Coffee consumption (cups per day);Coffee consumption;	chr7:76063691	chr7:76043977~76045963:-
BRCA	cis	rs6772849	0.796	rs9841521	ENSG00000242551.2	POU5F1P6	-5.17	2.86e-07	3.24e-05	-0.2	-0.16	Monocyte percentage of white cells;Monocyte count;	chr3:128673431	chr3:128674735~128677005:-
BRCA	cis	rs321358	0.945	rs10502129	ENSG00000271390.1	RP11-89C3.3	5.17	2.86e-07	3.24e-05	0.26	0.16	Body mass index;	chr11:111107405	chr11:111089870~111090368:-
BRCA	cis	rs9287719	0.967	rs6759714	ENSG00000243819.4	RN7SL832P	5.17	2.87e-07	3.24e-05	0.15	0.16	Prostate cancer;	chr2:10607081	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.967	rs6744854	ENSG00000243819.4	RN7SL832P	5.17	2.87e-07	3.24e-05	0.15	0.16	Prostate cancer;	chr2:10607120	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.967	rs6759740	ENSG00000243819.4	RN7SL832P	5.17	2.87e-07	3.24e-05	0.15	0.16	Prostate cancer;	chr2:10607145	chr2:10690344~10692099:+
BRCA	cis	rs4819052	0.851	rs12626188	ENSG00000184274.3	LINC00315	-5.17	2.87e-07	3.24e-05	-0.22	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45249343	chr21:45300245~45305257:-
BRCA	cis	rs17674580	0.604	rs9954521	ENSG00000267193.4	RP11-116O18.3	5.17	2.87e-07	3.24e-05	0.17	0.16	Bladder cancer;	chr18:45750931	chr18:45669367~45747215:-
BRCA	cis	rs17253792	0.545	rs3742571	ENSG00000186615.9	KTN1-AS1	-5.17	2.87e-07	3.25e-05	-0.32	-0.16	Putamen volume;	chr14:55549986	chr14:55499278~55580110:-
BRCA	cis	rs10129255	0.912	rs6576227	ENSG00000211974.3	IGHV2-70	5.17	2.87e-07	3.25e-05	0.16	0.16	Kawasaki disease;	chr14:106778202	chr14:106723574~106724093:-
BRCA	cis	rs10129255	0.957	rs6576228	ENSG00000211974.3	IGHV2-70	5.17	2.87e-07	3.25e-05	0.16	0.16	Kawasaki disease;	chr14:106778401	chr14:106723574~106724093:-
BRCA	cis	rs1950326	0.515	rs175677	ENSG00000258526.4	RP11-111A21.1	-5.17	2.87e-07	3.25e-05	-0.2	-0.16	Verbal memory performance (residualized delayed recall level);	chr14:39580491	chr14:39474840~39513780:+
BRCA	cis	rs7617773	0.817	rs6806112	ENSG00000199476.1	Y_RNA	-5.17	2.87e-07	3.25e-05	-0.21	-0.16	Coronary artery disease;	chr3:48234587	chr3:48288587~48288694:+
BRCA	cis	rs10911232	0.507	rs4652767	ENSG00000224468.3	RP11-181K3.4	-5.17	2.87e-07	3.25e-05	-0.17	-0.16	Hypertriglyceridemia;	chr1:183033348	chr1:183138402~183141282:-
BRCA	cis	rs1729951	0.575	rs1654926	ENSG00000239213.4	NCK1-AS1	5.17	2.87e-07	3.25e-05	0.16	0.16	Neuroticism;	chr3:136991082	chr3:136841726~136862054:-
BRCA	cis	rs10911232	0.507	rs4129857	ENSG00000224468.3	RP11-181K3.4	-5.17	2.87e-07	3.25e-05	-0.17	-0.16	Hypertriglyceridemia;	chr1:183035412	chr1:183138402~183141282:-
BRCA	cis	rs7674212	0.512	rs2720462	ENSG00000246560.2	RP11-10L12.4	5.17	2.87e-07	3.25e-05	0.16	0.16	Type 2 diabetes;	chr4:103135053	chr4:102828055~102844075:+
BRCA	cis	rs4781563	0.81	rs3136112	ENSG00000242307.1	RPS26P52	-5.17	2.87e-07	3.25e-05	-0.19	-0.16	Bilirubin levels;	chr16:13930550	chr16:13922332~13922679:-
BRCA	cis	rs1075265	0.563	rs2542588	ENSG00000235937.1	AC008280.1	-5.17	2.87e-07	3.25e-05	-0.17	-0.16	Chronotype;Morning vs. evening chronotype;	chr2:53791787	chr2:54029552~54030682:-
BRCA	cis	rs4356203	0.905	rs214940	ENSG00000272034.1	SNORD14A	-5.17	2.88e-07	3.25e-05	-0.16	-0.16	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17165308	chr11:17074654~17074744:-
BRCA	cis	rs9659323	0.7	rs10923746	ENSG00000231365.4	RP11-418J17.1	-5.17	2.88e-07	3.25e-05	-0.18	-0.16	Body mass index;	chr1:119073655	chr1:119140396~119275973:+
BRCA	cis	rs7572733	0.534	rs1435568	ENSG00000231621.1	AC013264.2	-5.17	2.88e-07	3.25e-05	-0.16	-0.16	Dermatomyositis;	chr2:197898155	chr2:197197991~197199273:+
BRCA	cis	rs62025270	0.632	rs62022924	ENSG00000259295.5	CSPG4P12	-5.17	2.88e-07	3.25e-05	-0.25	-0.16	Idiopathic pulmonary fibrosis;	chr15:85692276	chr15:85191438~85213905:+
BRCA	cis	rs62025270	0.576	rs62022925	ENSG00000259295.5	CSPG4P12	-5.17	2.88e-07	3.25e-05	-0.25	-0.16	Idiopathic pulmonary fibrosis;	chr15:85692835	chr15:85191438~85213905:+
BRCA	cis	rs763121	0.853	rs9607566	ENSG00000228274.3	RP3-508I15.9	-5.17	2.88e-07	3.25e-05	-0.18	-0.16	Menopause (age at onset);	chr22:38679429	chr22:38667585~38681820:-
BRCA	cis	rs2274273	0.712	rs17832311	ENSG00000258413.1	RP11-665C16.6	-5.17	2.88e-07	3.25e-05	-0.2	-0.16	Protein biomarker;	chr14:55067748	chr14:55262767~55272075:-
BRCA	cis	rs5167	0.504	rs4803781	ENSG00000280087.1	CTB-129P6.7	5.17	2.88e-07	3.26e-05	0.18	0.16	Blood protein levels;	chr19:44956414	chr19:44909375~44914968:+
BRCA	cis	rs4780355	0.843	rs243325	ENSG00000262636.1	CTD-3088G3.4	5.17	2.88e-07	3.26e-05	0.21	0.16	Crohn's disease and psoriasis;	chr16:11260640	chr16:11380859~11381118:-
BRCA	cis	rs9425766	0.64	rs2295366	ENSG00000227373.4	RP11-160H22.5	5.17	2.88e-07	3.26e-05	0.23	0.16	Life satisfaction;	chr1:173856554	chr1:174115300~174160004:-
BRCA	cis	rs2832191	0.967	rs2898160	ENSG00000215533.7	LINC00189	5.17	2.88e-07	3.26e-05	0.18	0.16	Dental caries;	chr21:29115175	chr21:29193480~29288205:+
BRCA	cis	rs6840360	0.667	rs2709832	ENSG00000278978.1	RP11-164P12.5	-5.17	2.88e-07	3.26e-05	-0.17	-0.16	Intelligence (multi-trait analysis);	chr4:151458242	chr4:151669786~151670503:+
BRCA	cis	rs6480314	0.542	rs17231644	ENSG00000233590.1	RP11-153K11.3	5.16	2.88e-07	3.26e-05	0.26	0.16	Optic nerve measurement (disc area);	chr10:68270301	chr10:68233251~68242379:-
BRCA	cis	rs4950322	0.547	rs61838945	ENSG00000278811.3	LINC00624	5.16	2.88e-07	3.26e-05	0.2	0.16	Protein quantitative trait loci;	chr1:147111477	chr1:147258885~147517875:-
BRCA	cis	rs7487075	0.619	rs6582645	ENSG00000274723.1	RP11-618L22.1	5.16	2.88e-07	3.26e-05	0.19	0.16	Itch intensity from mosquito bite;	chr12:46411361	chr12:46970504~46972155:+
BRCA	cis	rs919433	0.519	rs700658	ENSG00000231621.1	AC013264.2	-5.16	2.88e-07	3.26e-05	-0.16	-0.16	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197790283	chr2:197197991~197199273:+
BRCA	cis	rs4950322	0.542	rs56080828	ENSG00000244371.2	PFN1P8	-5.16	2.88e-07	3.26e-05	-0.22	-0.16	Protein quantitative trait loci;	chr1:147183447	chr1:146957117~146957659:-
BRCA	cis	rs1075265	0.783	rs805439	ENSG00000235937.1	AC008280.1	5.16	2.88e-07	3.26e-05	0.17	0.16	Chronotype;Morning vs. evening chronotype;	chr2:53829437	chr2:54029552~54030682:-
BRCA	cis	rs2179367	0.959	rs9390677	ENSG00000268592.3	RAET1E-AS1	5.16	2.88e-07	3.26e-05	0.2	0.16	Dupuytren's disease;	chr6:149389361	chr6:149863494~149919507:+
BRCA	cis	rs453301	0.624	rs330049	ENSG00000233609.3	RP11-62H7.2	5.16	2.89e-07	3.26e-05	0.14	0.16	Joint mobility (Beighton score);	chr8:9229789	chr8:8961200~8979025:+
BRCA	cis	rs1862618	0.671	rs2255726	ENSG00000271828.1	CTD-2310F14.1	-5.16	2.89e-07	3.26e-05	-0.2	-0.16	Initial pursuit acceleration;	chr5:56947301	chr5:56927874~56929573:+
BRCA	cis	rs3764021	0.509	rs10772070	ENSG00000214776.8	RP11-726G1.1	5.16	2.89e-07	3.26e-05	0.2	0.16	Type 1 diabetes;	chr12:9717320	chr12:9467552~9576275:+
BRCA	cis	rs17685	0.753	rs2868203	ENSG00000280388.1	RP11-229D13.3	5.16	2.89e-07	3.26e-05	0.16	0.16	Coffee consumption (cups per day);Coffee consumption;	chr7:76050708	chr7:76043977~76045963:-
BRCA	cis	rs79040073	0.911	rs17393193	ENSG00000259531.2	RP11-295H24.3	5.16	2.89e-07	3.26e-05	0.25	0.16	Lung cancer in ever smokers;	chr15:49039882	chr15:49365124~49366685:-
BRCA	cis	rs494453	0.922	rs498787	ENSG00000227811.2	FAM212B-AS1	-5.16	2.89e-07	3.27e-05	-0.2	-0.16	Osteoporosis-related phenotypes;	chr1:111690722	chr1:111739841~111747798:+
BRCA	cis	rs494453	0.922	rs2473843	ENSG00000227811.2	FAM212B-AS1	-5.16	2.89e-07	3.27e-05	-0.2	-0.16	Osteoporosis-related phenotypes;	chr1:111698035	chr1:111739841~111747798:+
BRCA	cis	rs494453	0.845	rs2477427	ENSG00000227811.2	FAM212B-AS1	-5.16	2.89e-07	3.27e-05	-0.2	-0.16	Osteoporosis-related phenotypes;	chr1:111698072	chr1:111739841~111747798:+
BRCA	cis	rs7818688	1	rs10100089	ENSG00000253528.2	RP11-347C18.4	-5.16	2.89e-07	3.27e-05	-0.24	-0.16	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95012865	chr8:94974573~94974853:-
BRCA	cis	rs7818688	1	rs10111300	ENSG00000253528.2	RP11-347C18.4	-5.16	2.89e-07	3.27e-05	-0.24	-0.16	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95013403	chr8:94974573~94974853:-
BRCA	cis	rs7487075	0.78	rs10785624	ENSG00000272369.1	RP11-446N19.1	5.16	2.89e-07	3.27e-05	0.18	0.16	Itch intensity from mosquito bite;	chr12:46373004	chr12:46537502~46652550:+
BRCA	cis	rs7487075	0.78	rs2279559	ENSG00000272369.1	RP11-446N19.1	5.16	2.89e-07	3.27e-05	0.18	0.16	Itch intensity from mosquito bite;	chr12:46373392	chr12:46537502~46652550:+
BRCA	cis	rs2098713	0.534	rs11952015	ENSG00000250155.1	CTD-2353F22.1	5.16	2.89e-07	3.27e-05	0.17	0.16	Telomere length;	chr5:37539402	chr5:36666214~36725195:-
BRCA	cis	rs7577696	0.889	rs455060	ENSG00000272716.1	RP11-563N4.1	5.16	2.9e-07	3.27e-05	0.18	0.16	Inflammatory biomarkers;	chr2:32250040	chr2:32165046~32165757:-
BRCA	cis	rs6832769	1	rs1522106	ENSG00000223305.1	RN7SKP30	-5.16	2.9e-07	3.27e-05	-0.2	-0.16	Personality dimensions;	chr4:55441047	chr4:55540502~55540835:-
BRCA	cis	rs9287719	0.967	rs7592691	ENSG00000243819.4	RN7SL832P	5.16	2.9e-07	3.27e-05	0.15	0.16	Prostate cancer;	chr2:10597300	chr2:10690344~10692099:+
BRCA	cis	rs7487075	0.619	rs6582658	ENSG00000274723.1	RP11-618L22.1	5.16	2.9e-07	3.27e-05	0.2	0.16	Itch intensity from mosquito bite;	chr12:46462312	chr12:46970504~46972155:+
BRCA	cis	rs2098713	0.569	rs35624889	ENSG00000250155.1	CTD-2353F22.1	5.16	2.9e-07	3.28e-05	0.17	0.16	Telomere length;	chr5:37514162	chr5:36666214~36725195:-
BRCA	cis	rs2098713	0.569	rs36186847	ENSG00000250155.1	CTD-2353F22.1	5.16	2.9e-07	3.28e-05	0.17	0.16	Telomere length;	chr5:37514268	chr5:36666214~36725195:-
BRCA	cis	rs67311347	1	rs2276870	ENSG00000280739.1	EIF1B-AS1	-5.16	2.9e-07	3.28e-05	-0.18	-0.16	Renal cell carcinoma;	chr3:40457691	chr3:40173145~40309698:-
BRCA	cis	rs860295	0.702	rs10908465	ENSG00000160766.13	GBAP1	-5.16	2.9e-07	3.28e-05	-0.17	-0.16	Body mass index;	chr1:155419897	chr1:155213821~155227422:-
BRCA	cis	rs7577696	0.813	rs212723	ENSG00000272716.1	RP11-563N4.1	5.16	2.9e-07	3.28e-05	0.18	0.16	Inflammatory biomarkers;	chr2:32242079	chr2:32165046~32165757:-
BRCA	cis	rs1499614	0.522	rs13247442	ENSG00000273142.1	RP11-458F8.4	-5.16	2.9e-07	3.28e-05	-0.28	-0.16	Gout;	chr7:66723871	chr7:66902857~66906297:+
BRCA	cis	rs7577696	0.925	rs212715	ENSG00000272716.1	RP11-563N4.1	5.16	2.9e-07	3.28e-05	0.17	0.16	Inflammatory biomarkers;	chr2:32235817	chr2:32165046~32165757:-
BRCA	cis	rs924712	0.526	rs4712075	ENSG00000261116.1	RP3-523K23.2	-5.16	2.9e-07	3.28e-05	-0.18	-0.16	Breast cancer;	chr6:54844894	chr6:54943167~54945099:+
BRCA	cis	rs7011507	0.537	rs16937171	ENSG00000279881.1	RP11-513O13.1	5.16	2.9e-07	3.28e-05	0.2	0.16	Inflammatory bowel disease;Ulcerative colitis;	chr8:48444175	chr8:48428143~48431041:-
BRCA	cis	rs2790457	0.917	rs2790462	ENSG00000254635.4	WAC-AS1	-5.16	2.9e-07	3.28e-05	-0.19	-0.16	Multiple myeloma;	chr10:28584273	chr10:28522652~28532743:-
BRCA	cis	rs919433	0.713	rs13411968	ENSG00000231621.1	AC013264.2	-5.16	2.9e-07	3.28e-05	-0.15	-0.16	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197602417	chr2:197197991~197199273:+
BRCA	cis	rs2098713	0.569	rs56305849	ENSG00000250155.1	CTD-2353F22.1	5.16	2.9e-07	3.28e-05	0.17	0.16	Telomere length;	chr5:37506445	chr5:36666214~36725195:-
BRCA	cis	rs7651446	0.737	rs62275652	ENSG00000240875.4	LINC00886	-5.16	2.9e-07	3.28e-05	-0.34	-0.16	Ovarian cancer;Epithelial ovarian cancer;	chr3:156654000	chr3:156747346~156817062:-
BRCA	cis	rs7651446	0.737	rs10936033	ENSG00000240875.4	LINC00886	-5.16	2.9e-07	3.28e-05	-0.34	-0.16	Ovarian cancer;Epithelial ovarian cancer;	chr3:156654402	chr3:156747346~156817062:-
BRCA	cis	rs7651446	0.737	rs10936034	ENSG00000240875.4	LINC00886	-5.16	2.9e-07	3.28e-05	-0.34	-0.16	Ovarian cancer;Epithelial ovarian cancer;	chr3:156654444	chr3:156747346~156817062:-
BRCA	cis	rs7651446	0.737	rs10936035	ENSG00000240875.4	LINC00886	-5.16	2.9e-07	3.28e-05	-0.34	-0.16	Ovarian cancer;Epithelial ovarian cancer;	chr3:156654495	chr3:156747346~156817062:-
BRCA	cis	rs4950322	0.57	rs79810882	ENSG00000244371.2	PFN1P8	-5.16	2.9e-07	3.28e-05	-0.22	-0.16	Protein quantitative trait loci;	chr1:147235575	chr1:146957117~146957659:-
BRCA	cis	rs875971	0.545	rs6961853	ENSG00000228409.4	CCT6P1	-5.16	2.9e-07	3.28e-05	-0.16	-0.16	Aortic root size;	chr7:66537035	chr7:65751142~65763354:+
BRCA	cis	rs13113518	0.776	rs13124436	ENSG00000272969.1	RP11-528I4.2	5.16	2.91e-07	3.28e-05	0.19	0.16	Height;	chr4:55502504	chr4:55547112~55547889:+
BRCA	cis	rs7191700	0.644	rs918738	ENSG00000262703.1	RP11-485G7.6	-5.16	2.91e-07	3.28e-05	-0.16	-0.16	Multiple sclerosis;	chr16:11345822	chr16:11348143~11349321:-
BRCA	cis	rs2505998	0.833	rs2505533	ENSG00000273008.1	RP11-351D16.3	-5.16	2.91e-07	3.29e-05	-0.19	-0.16	Hirschsprung disease;	chr10:43099005	chr10:43136824~43138334:-
BRCA	cis	rs7613875	0.6	rs2247510	ENSG00000228008.1	CTD-2330K9.3	5.16	2.91e-07	3.29e-05	0.15	0.16	Body mass index;	chr3:50088782	chr3:49903845~49916937:+
BRCA	cis	rs2153535	0.601	rs9502719	ENSG00000251164.1	HULC	-5.16	2.91e-07	3.29e-05	-0.19	-0.16	Motion sickness;	chr6:8540799	chr6:8652137~8653846:+
BRCA	cis	rs2243480	1	rs7804223	ENSG00000228409.4	CCT6P1	-5.16	2.92e-07	3.3e-05	-0.22	-0.16	Diabetic kidney disease;	chr7:66199572	chr7:65751142~65763354:+
BRCA	cis	rs8016982	0.698	rs8021385	ENSG00000258999.1	RP11-114N19.3	5.16	2.92e-07	3.3e-05	0.19	0.16	Schizophrenia;	chr14:81238338	chr14:81107033~81170414:-
BRCA	cis	rs6600671	0.934	rs12131379	ENSG00000275538.1	RNVU1-19	5.16	2.92e-07	3.3e-05	0.19	0.16	Hip geometry;	chr1:121551639	chr1:120850819~120850985:-
BRCA	cis	rs6840360	0.642	rs7678823	ENSG00000251611.1	RP11-610P16.1	-5.16	2.92e-07	3.3e-05	-0.14	-0.16	Intelligence (multi-trait analysis);	chr4:151435967	chr4:151407551~151408835:-
BRCA	cis	rs13113518	0.902	rs12505266	ENSG00000223305.1	RN7SKP30	5.16	2.92e-07	3.3e-05	0.19	0.16	Height;	chr4:55546002	chr4:55540502~55540835:-
BRCA	cis	rs987360	0.804	rs35208140	ENSG00000248869.4	RP11-138I17.1	5.16	2.92e-07	3.3e-05	0.16	0.16	Temperament;	chr4:137277742	chr4:136796722~137212799:-
BRCA	cis	rs4950322	0.57	rs17360443	ENSG00000244371.2	PFN1P8	-5.16	2.92e-07	3.3e-05	-0.22	-0.16	Protein quantitative trait loci;	chr1:147279737	chr1:146957117~146957659:-
BRCA	cis	rs10510102	0.872	rs78369301	ENSG00000226864.1	ATE1-AS1	5.16	2.92e-07	3.3e-05	0.29	0.16	Breast cancer;	chr10:121858527	chr10:121928312~121951965:+
BRCA	cis	rs4835473	0.897	rs1391189	ENSG00000249741.2	RP11-673E1.3	5.16	2.92e-07	3.3e-05	0.17	0.16	Immature fraction of reticulocytes;	chr4:143690951	chr4:143911514~143912053:-
BRCA	cis	rs9287719	0.967	rs4470306	ENSG00000243819.4	RN7SL832P	5.16	2.92e-07	3.3e-05	0.15	0.16	Prostate cancer;	chr2:10603872	chr2:10690344~10692099:+
BRCA	cis	rs7204230	0.96	rs3803658	ENSG00000261291.1	RP11-295M3.2	-5.16	2.92e-07	3.3e-05	-0.2	-0.16	Fibrinogen;	chr16:53314671	chr16:53168522~53169450:+
BRCA	cis	rs2235642	0.653	rs7197288	ENSG00000260989.1	LA16c-395F10.2	-5.16	2.92e-07	3.3e-05	-0.17	-0.16	Coronary artery disease;	chr16:1604752	chr16:1580527~1610328:+
BRCA	cis	rs4908768	0.539	rs11121204	ENSG00000232912.4	RP5-1115A15.1	-5.16	2.93e-07	3.3e-05	-0.16	-0.16	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8594246	chr1:8424645~8434838:+
BRCA	cis	rs9638182	0.582	rs12539351	ENSG00000274080.1	CTA-315H11.2	5.16	2.93e-07	3.31e-05	0.22	0.16	Triglycerides;	chr7:73563782	chr7:73609262~73611502:-
BRCA	cis	rs6442522	0.606	rs12633820	ENSG00000249786.6	EAF1-AS1	5.16	2.93e-07	3.31e-05	0.17	0.16	Uric acid levels;	chr3:15452495	chr3:15436171~15455940:-
BRCA	cis	rs7818688	1	rs28651964	ENSG00000253528.2	RP11-347C18.4	-5.16	2.93e-07	3.31e-05	-0.25	-0.16	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95014553	chr8:94974573~94974853:-
BRCA	cis	rs6442522	0.772	rs2278961	ENSG00000249786.6	EAF1-AS1	5.16	2.93e-07	3.31e-05	0.16	0.16	Uric acid levels;	chr3:15451300	chr3:15436171~15455940:-
BRCA	cis	rs9532669	0.89	rs4941999	ENSG00000168852.11	TPTE2P5	5.16	2.93e-07	3.31e-05	0.16	0.16	Cervical cancer;	chr13:40859926	chr13:40822296~40921749:-
BRCA	cis	rs4763879	0.752	rs10772083	ENSG00000256673.1	RP11-599J14.2	-5.16	2.93e-07	3.31e-05	-0.18	-0.16	Type 1 diabetes;	chr12:9722302	chr12:9398355~9414851:-
BRCA	cis	rs6847067	0.672	rs6825852	ENSG00000180769.7	WDFY3-AS2	5.16	2.94e-07	3.32e-05	0.16	0.16	Oropharynx cancer;	chr4:84740907	chr4:84965682~85011277:+
BRCA	cis	rs2562456	1	rs2359155	ENSG00000268535.1	RP11-420K14.3	-5.16	2.94e-07	3.32e-05	-0.21	-0.16	Pain;	chr19:21489067	chr19:21709522~21710191:+
BRCA	cis	rs7267979	0.966	rs7270835	ENSG00000125804.12	FAM182A	-5.16	2.94e-07	3.32e-05	-0.21	-0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25454431	chr20:26054655~26086917:+
BRCA	cis	rs7267979	1	rs6115191	ENSG00000125804.12	FAM182A	-5.16	2.94e-07	3.32e-05	-0.21	-0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25459842	chr20:26054655~26086917:+
BRCA	cis	rs7267979	1	rs6107045	ENSG00000125804.12	FAM182A	-5.16	2.94e-07	3.32e-05	-0.21	-0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25461300	chr20:26054655~26086917:+
BRCA	cis	rs7267979	1	rs6107046	ENSG00000125804.12	FAM182A	-5.16	2.94e-07	3.32e-05	-0.21	-0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25461413	chr20:26054655~26086917:+
BRCA	cis	rs7267979	1	rs6107047	ENSG00000125804.12	FAM182A	-5.16	2.94e-07	3.32e-05	-0.21	-0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25461461	chr20:26054655~26086917:+
BRCA	cis	rs6490294	0.528	rs60998439	ENSG00000226469.1	ADAM1B	5.16	2.94e-07	3.32e-05	0.28	0.16	Mean platelet volume;	chr12:112008165	chr12:111927018~111929017:+
BRCA	cis	rs736408	0.688	rs2239551	ENSG00000243224.1	RP5-1157M23.2	5.16	2.94e-07	3.32e-05	0.17	0.16	Bipolar disorder;	chr3:52784563	chr3:52239258~52241097:+
BRCA	cis	rs8031584	0.918	rs34331396	ENSG00000270015.1	RP11-540B6.6	-5.16	2.94e-07	3.32e-05	-0.17	-0.16	Huntington's disease progression;	chr15:30956533	chr15:30926514~30928407:+
BRCA	cis	rs7618915	0.571	rs6778844	ENSG00000243224.1	RP5-1157M23.2	5.16	2.94e-07	3.32e-05	0.18	0.16	Bipolar disorder;	chr3:52562382	chr3:52239258~52241097:+
BRCA	cis	rs7914558	0.966	rs10748836	ENSG00000236937.2	PTGES3P4	5.16	2.94e-07	3.32e-05	0.2	0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102934160	chr10:102845595~102845950:+
BRCA	cis	rs6832769	1	rs4864998	ENSG00000223305.1	RN7SKP30	5.16	2.94e-07	3.32e-05	0.21	0.16	Personality dimensions;	chr4:55466439	chr4:55540502~55540835:-
BRCA	cis	rs8098244	0.737	rs1258131	ENSG00000264745.1	TTC39C-AS1	-5.16	2.94e-07	3.32e-05	-0.24	-0.16	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23959755	chr18:23994213~24015339:-
BRCA	cis	rs875971	0.545	rs1638735	ENSG00000230295.1	RP11-458F8.2	5.16	2.95e-07	3.33e-05	0.15	0.16	Aortic root size;	chr7:66630751	chr7:66880708~66882981:+
BRCA	cis	rs17685	0.633	rs3801471	ENSG00000280388.1	RP11-229D13.3	-5.16	2.95e-07	3.33e-05	-0.17	-0.16	Coffee consumption (cups per day);Coffee consumption;	chr7:76066870	chr7:76043977~76045963:-
BRCA	cis	rs6772849	0.93	rs4467479	ENSG00000242551.2	POU5F1P6	-5.16	2.95e-07	3.33e-05	-0.2	-0.16	Monocyte percentage of white cells;Monocyte count;	chr3:128650212	chr3:128674735~128677005:-
BRCA	cis	rs6772849	0.93	rs12630379	ENSG00000242551.2	POU5F1P6	-5.16	2.95e-07	3.33e-05	-0.2	-0.16	Monocyte percentage of white cells;Monocyte count;	chr3:128651361	chr3:128674735~128677005:-
BRCA	cis	rs4512344	0.509	rs2409784	ENSG00000270154.1	RP11-419I17.1	-5.16	2.95e-07	3.33e-05	-0.18	-0.16	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:11539347	chr8:12476462~12477122:+
BRCA	cis	rs13108904	0.905	rs34490749	ENSG00000254094.1	AC078852.1	-5.16	2.95e-07	3.33e-05	-0.17	-0.16	Obesity-related traits;	chr4:1224193	chr4:1356581~1358075:+
BRCA	cis	rs2274273	0.662	rs4525413	ENSG00000258413.1	RP11-665C16.6	-5.16	2.95e-07	3.33e-05	-0.21	-0.16	Protein biomarker;	chr14:55194420	chr14:55262767~55272075:-
BRCA	cis	rs11719291	0.667	rs9877542	ENSG00000270441.1	RP11-694I15.7	5.16	2.95e-07	3.33e-05	0.27	0.16	Cognitive function;	chr3:48711112	chr3:49140086~49160851:-
BRCA	cis	rs3768617	0.528	rs6672093	ENSG00000224468.3	RP11-181K3.4	-5.16	2.96e-07	3.34e-05	-0.17	-0.16	Fuchs's corneal dystrophy;	chr1:183110718	chr1:183138402~183141282:-
BRCA	cis	rs2408955	0.504	rs11168441	ENSG00000273765.1	RP11-370I10.11	5.16	2.96e-07	3.34e-05	0.19	0.16	Glycated hemoglobin levels;	chr12:48182271	chr12:48360920~48361377:+
BRCA	cis	rs8054556	1	rs11150579	ENSG00000273724.1	RP11-347C12.12	-5.16	2.96e-07	3.34e-05	-0.18	-0.16	Autism spectrum disorder or schizophrenia;	chr16:29989009	chr16:30336400~30343336:+
BRCA	cis	rs7178909	0.902	rs8038480	ENSG00000259677.1	RP11-493E3.1	5.16	2.96e-07	3.34e-05	0.19	0.16	Common traits (Other);	chr15:89898365	chr15:89876540~89877285:+
BRCA	cis	rs2255336	0.817	rs4764430	ENSG00000245648.1	RP11-277P12.20	5.16	2.96e-07	3.34e-05	0.25	0.16	Blood protein levels;	chr12:10365209	chr12:10363769~10398506:+
BRCA	cis	rs2153535	0.601	rs9505472	ENSG00000251164.1	HULC	-5.16	2.96e-07	3.34e-05	-0.19	-0.16	Motion sickness;	chr6:8538532	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.601	rs9505473	ENSG00000251164.1	HULC	-5.16	2.96e-07	3.34e-05	-0.19	-0.16	Motion sickness;	chr6:8538544	chr6:8652137~8653846:+
BRCA	cis	rs9473147	0.543	rs9296559	ENSG00000270761.1	RP11-385F7.1	-5.16	2.96e-07	3.34e-05	-0.17	-0.16	Platelet distribution width;Mean platelet volume;	chr6:47484534	chr6:47477243~47477572:-
BRCA	cis	rs13113518	1	rs13133579	ENSG00000223305.1	RN7SKP30	5.16	2.96e-07	3.35e-05	0.19	0.16	Height;	chr4:55459921	chr4:55540502~55540835:-
BRCA	cis	rs7191700	0.511	rs8043625	ENSG00000262636.1	CTD-3088G3.4	-5.16	2.97e-07	3.35e-05	-0.21	-0.16	Multiple sclerosis;	chr16:11268038	chr16:11380859~11381118:-
BRCA	cis	rs13113518	1	rs4864549	ENSG00000223305.1	RN7SKP30	5.16	2.97e-07	3.35e-05	0.19	0.16	Height;	chr4:55554380	chr4:55540502~55540835:-
BRCA	cis	rs2904967	0.929	rs482842	ENSG00000255200.1	AP003068.18	5.16	2.97e-07	3.35e-05	0.27	0.16	Mean corpuscular volume;	chr11:65277807	chr11:65174117~65176470:-
BRCA	cis	rs35740288	0.929	rs11630585	ENSG00000259407.1	RP11-158M2.3	-5.16	2.97e-07	3.35e-05	-0.21	-0.16	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85762773	chr15:85744109~85750281:-
BRCA	cis	rs10911251	0.546	rs2027084	ENSG00000224468.3	RP11-181K3.4	-5.16	2.97e-07	3.35e-05	-0.17	-0.16	Colorectal cancer;	chr1:183141666	chr1:183138402~183141282:-
BRCA	cis	rs2153535	0.547	rs9502720	ENSG00000251164.1	HULC	-5.16	2.97e-07	3.35e-05	-0.19	-0.16	Motion sickness;	chr6:8541129	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.547	rs9505475	ENSG00000251164.1	HULC	-5.16	2.97e-07	3.35e-05	-0.19	-0.16	Motion sickness;	chr6:8542657	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.601	rs6906170	ENSG00000251164.1	HULC	-5.16	2.97e-07	3.35e-05	-0.19	-0.16	Motion sickness;	chr6:8542895	chr6:8652137~8653846:+
BRCA	cis	rs62025270	0.632	rs56153788	ENSG00000259295.5	CSPG4P12	-5.16	2.97e-07	3.35e-05	-0.25	-0.16	Idiopathic pulmonary fibrosis;	chr15:85627761	chr15:85191438~85213905:+
BRCA	cis	rs2098713	0.569	rs62359006	ENSG00000250155.1	CTD-2353F22.1	5.16	2.97e-07	3.35e-05	0.17	0.16	Telomere length;	chr5:37510947	chr5:36666214~36725195:-
BRCA	cis	rs13113518	1	rs13114841	ENSG00000223305.1	RN7SKP30	5.16	2.97e-07	3.36e-05	0.19	0.16	Height;	chr4:55485974	chr4:55540502~55540835:-
BRCA	cis	rs7200543	1	rs34614532	ENSG00000260735.1	RP11-72I8.1	-5.16	2.97e-07	3.36e-05	-0.19	-0.16	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15039051	chr16:15094411~15109197:+
BRCA	cis	rs6546886	0.536	rs7589197	ENSG00000217702.2	RP11-287D1.4	5.16	2.97e-07	3.36e-05	0.19	0.16	Dialysis-related mortality;	chr2:74095342	chr2:74130583~74135395:+
BRCA	cis	rs7487075	0.619	rs9971879	ENSG00000274723.1	RP11-618L22.1	5.16	2.97e-07	3.36e-05	0.19	0.16	Itch intensity from mosquito bite;	chr12:46412990	chr12:46970504~46972155:+
BRCA	cis	rs7487075	0.619	rs4768710	ENSG00000274723.1	RP11-618L22.1	5.16	2.97e-07	3.36e-05	0.19	0.16	Itch intensity from mosquito bite;	chr12:46414321	chr12:46970504~46972155:+
BRCA	cis	rs7487075	0.578	rs1492895	ENSG00000274723.1	RP11-618L22.1	5.16	2.97e-07	3.36e-05	0.19	0.16	Itch intensity from mosquito bite;	chr12:46414972	chr12:46970504~46972155:+
BRCA	cis	rs7487075	0.578	rs2897951	ENSG00000274723.1	RP11-618L22.1	5.16	2.97e-07	3.36e-05	0.19	0.16	Itch intensity from mosquito bite;	chr12:46415423	chr12:46970504~46972155:+
BRCA	cis	rs7487075	0.578	rs10880967	ENSG00000274723.1	RP11-618L22.1	5.16	2.97e-07	3.36e-05	0.19	0.16	Itch intensity from mosquito bite;	chr12:46418240	chr12:46970504~46972155:+
BRCA	cis	rs7615952	0.546	rs4428131	ENSG00000171084.14	FAM86JP	5.16	2.98e-07	3.36e-05	0.27	0.16	Blood pressure (smoking interaction);	chr3:125627635	chr3:125916620~125930024:+
BRCA	cis	rs875971	0.965	rs10267430	ENSG00000223473.2	GS1-124K5.3	-5.16	2.98e-07	3.36e-05	-0.12	-0.16	Aortic root size;	chr7:66278036	chr7:66491049~66493566:-
BRCA	cis	rs494453	0.922	rs480578	ENSG00000227811.2	FAM212B-AS1	-5.16	2.98e-07	3.36e-05	-0.2	-0.16	Osteoporosis-related phenotypes;	chr1:111709839	chr1:111739841~111747798:+
BRCA	cis	rs4906332	1	rs12879663	ENSG00000244691.1	RPL10AP1	-5.16	2.98e-07	3.36e-05	-0.2	-0.16	Coronary artery disease;	chr14:103407878	chr14:103412119~103412761:-
BRCA	cis	rs1867631	1	rs1867631	ENSG00000248458.2	RP4-598P13.1	5.16	2.98e-07	3.36e-05	0.17	0.16	Menopause (age at onset);	chr1:66580443	chr1:66665864~66677027:-
BRCA	cis	rs13113518	1	rs56154935	ENSG00000223305.1	RN7SKP30	5.16	2.98e-07	3.36e-05	0.19	0.16	Height;	chr4:55546378	chr4:55540502~55540835:-
BRCA	cis	rs3758911	0.713	rs1907404	ENSG00000255353.1	RP11-382M14.1	-5.16	2.98e-07	3.36e-05	-0.2	-0.16	Coronary artery disease;	chr11:107253200	chr11:107176286~107177530:+
BRCA	cis	rs9300255	0.722	rs10773008	ENSG00000235423.7	RP11-282O18.3	5.16	2.98e-07	3.36e-05	0.2	0.16	Neutrophil percentage of white cells;	chr12:123316273	chr12:123252030~123261483:-
BRCA	cis	rs7651778	0.588	rs7638936	ENSG00000243926.1	TIPARP-AS1	-5.16	2.98e-07	3.37e-05	-0.17	-0.16	Corneal astigmatism;	chr3:156621843	chr3:156671862~156674378:-
BRCA	cis	rs11758351	1	rs79868973	ENSG00000241549.7	GUSBP2	-5.16	2.99e-07	3.37e-05	-0.23	-0.16	Renal underexcretion gout;Gout;	chr6:26189084	chr6:26871484~26956554:-
BRCA	cis	rs12477438	0.501	rs13008171	ENSG00000231822.1	AC019097.7	5.16	2.99e-07	3.37e-05	0.16	0.16	Chronic sinus infection;	chr2:99126956	chr2:99102018~99102752:+
BRCA	cis	rs3758911	0.621	rs11212101	ENSG00000255353.1	RP11-382M14.1	-5.16	2.99e-07	3.37e-05	-0.2	-0.16	Coronary artery disease;	chr11:107253495	chr11:107176286~107177530:+
BRCA	cis	rs3758911	0.662	rs11212102	ENSG00000255353.1	RP11-382M14.1	-5.16	2.99e-07	3.37e-05	-0.2	-0.16	Coronary artery disease;	chr11:107253496	chr11:107176286~107177530:+
BRCA	cis	rs6496044	1	rs6496044	ENSG00000202081.1	RNU6-1280P	5.16	2.99e-07	3.37e-05	0.18	0.16	Interstitial lung disease;	chr15:85524075	chr15:85651522~85651628:-
BRCA	cis	rs875971	0.862	rs6460307	ENSG00000273448.1	RP11-166O4.6	5.16	2.99e-07	3.37e-05	0.15	0.16	Aortic root size;	chr7:66595884	chr7:67333047~67334383:+
BRCA	cis	rs7487075	0.619	rs4768724	ENSG00000274723.1	RP11-618L22.1	5.16	2.99e-07	3.37e-05	0.2	0.16	Itch intensity from mosquito bite;	chr12:46454633	chr12:46970504~46972155:+
BRCA	cis	rs2115630	1	rs4633690	ENSG00000259295.5	CSPG4P12	-5.16	2.99e-07	3.37e-05	-0.19	-0.16	P wave terminal force;	chr15:84818729	chr15:85191438~85213905:+
BRCA	cis	rs2905347	0.757	rs1006509	ENSG00000179428.2	AC073072.5	-5.16	3e-07	3.38e-05	-0.17	-0.16	Major depression and alcohol dependence;	chr7:22658847	chr7:22725395~22727620:-
BRCA	cis	rs12477438	0.52	rs4850897	ENSG00000231822.1	AC019097.7	5.16	3e-07	3.38e-05	0.16	0.16	Chronic sinus infection;	chr2:99151956	chr2:99102018~99102752:+
BRCA	cis	rs2179367	0.632	rs59820585	ENSG00000268592.3	RAET1E-AS1	5.16	3e-07	3.38e-05	0.23	0.16	Dupuytren's disease;	chr6:149350249	chr6:149863494~149919507:+
BRCA	cis	rs2179367	0.632	rs56924465	ENSG00000268592.3	RAET1E-AS1	5.16	3e-07	3.38e-05	0.23	0.16	Dupuytren's disease;	chr6:149350270	chr6:149863494~149919507:+
BRCA	cis	rs35612822	0.866	rs2738284	ENSG00000232485.2	AC098820.3	-5.16	3e-07	3.38e-05	-0.2	-0.16	Kidney disease (early stage) in type 1 diabetes;	chr2:216446886	chr2:216479030~216498761:-
BRCA	cis	rs8127691	0.935	rs2876932	ENSG00000237604.1	AP001056.1	5.16	3e-07	3.38e-05	0.18	0.16	Inflammatory bowel disease;	chr21:44198653	chr21:44175489~44176453:+
BRCA	cis	rs6545883	0.894	rs2694643	ENSG00000270820.4	RP11-355B11.2	5.16	3e-07	3.38e-05	0.18	0.16	Tuberculosis;	chr2:61377248	chr2:61471188~61484130:+
BRCA	cis	rs2638953	0.741	rs12184491	ENSG00000247934.4	RP11-967K21.1	-5.16	3e-07	3.38e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28535619	chr12:28163298~28190738:-
BRCA	cis	rs7577696	0.85	rs11124276	ENSG00000272716.1	RP11-563N4.1	-5.16	3e-07	3.39e-05	-0.17	-0.16	Inflammatory biomarkers;	chr2:32093359	chr2:32165046~32165757:-
BRCA	cis	rs1193	0.837	rs9309636	ENSG00000231259.4	AC125232.1	-5.16	3e-07	3.39e-05	-0.19	-0.16	High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;High light scatter reticulocyte count;	chr2:86748847	chr2:87031815~87053069:-
BRCA	cis	rs1193	0.837	rs9309637	ENSG00000231259.4	AC125232.1	-5.16	3e-07	3.39e-05	-0.19	-0.16	High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;High light scatter reticulocyte count;	chr2:86749116	chr2:87031815~87053069:-
BRCA	cis	rs1193	0.837	rs9309638	ENSG00000231259.4	AC125232.1	-5.16	3e-07	3.39e-05	-0.19	-0.16	High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;High light scatter reticulocyte count;	chr2:86749225	chr2:87031815~87053069:-
BRCA	cis	rs4835473	0.897	rs12649594	ENSG00000249741.2	RP11-673E1.3	-5.16	3e-07	3.39e-05	-0.17	-0.16	Immature fraction of reticulocytes;	chr4:143989307	chr4:143911514~143912053:-
BRCA	cis	rs4835473	0.864	rs13101482	ENSG00000249741.2	RP11-673E1.3	-5.16	3e-07	3.39e-05	-0.17	-0.16	Immature fraction of reticulocytes;	chr4:143989463	chr4:143911514~143912053:-
BRCA	cis	rs4835473	0.864	rs13135472	ENSG00000249741.2	RP11-673E1.3	-5.16	3e-07	3.39e-05	-0.17	-0.16	Immature fraction of reticulocytes;	chr4:143989465	chr4:143911514~143912053:-
BRCA	cis	rs2179367	0.632	rs9498348	ENSG00000268592.3	RAET1E-AS1	5.16	3.01e-07	3.39e-05	0.23	0.16	Dupuytren's disease;	chr6:149418352	chr6:149863494~149919507:+
BRCA	cis	rs516805	0.63	rs2816082	ENSG00000279453.1	RP3-425C14.4	-5.16	3.01e-07	3.39e-05	-0.22	-0.16	Lymphocyte counts;	chr6:122102489	chr6:122436789~122439223:-
BRCA	cis	rs516805	0.63	rs2315814	ENSG00000279453.1	RP3-425C14.4	-5.16	3.01e-07	3.39e-05	-0.22	-0.16	Lymphocyte counts;	chr6:122102712	chr6:122436789~122439223:-
BRCA	cis	rs4934494	0.677	rs11185804	ENSG00000240996.1	RP11-80H5.7	5.16	3.01e-07	3.39e-05	0.22	0.16	Red blood cell count;	chr10:89619336	chr10:89694295~89697928:-
BRCA	cis	rs11955398	0.583	rs7719726	ENSG00000215032.2	GNL3LP1	5.16	3.01e-07	3.4e-05	0.2	0.16	Intelligence (multi-trait analysis);	chr5:60653710	chr5:60891935~60893577:-
BRCA	cis	rs2732480	0.5	rs2450986	ENSG00000226413.2	OR8T1P	5.16	3.01e-07	3.4e-05	0.21	0.16	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48267905	chr12:48442030~48442947:-
BRCA	cis	rs7267979	0.844	rs6115188	ENSG00000125804.12	FAM182A	-5.16	3.01e-07	3.4e-05	-0.2	-0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25451534	chr20:26054655~26086917:+
BRCA	cis	rs2153535	0.584	rs9502723	ENSG00000251164.1	HULC	-5.16	3.02e-07	3.4e-05	-0.19	-0.16	Motion sickness;	chr6:8541271	chr6:8652137~8653846:+
BRCA	cis	rs597539	0.652	rs636049	ENSG00000261625.1	RP11-554A11.4	-5.16	3.02e-07	3.4e-05	-0.15	-0.16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68899730	chr11:69000765~69002048:-
BRCA	cis	rs7191700	0.578	rs243324	ENSG00000262703.1	RP11-485G7.6	5.16	3.02e-07	3.4e-05	0.16	0.16	Multiple sclerosis;	chr16:11261113	chr16:11348143~11349321:-
BRCA	cis	rs2505998	0.833	rs1864405	ENSG00000273008.1	RP11-351D16.3	-5.16	3.02e-07	3.4e-05	-0.19	-0.16	Hirschsprung disease;	chr10:43108700	chr10:43136824~43138334:-
BRCA	cis	rs2505998	0.833	rs1864404	ENSG00000273008.1	RP11-351D16.3	-5.16	3.02e-07	3.4e-05	-0.19	-0.16	Hirschsprung disease;	chr10:43108942	chr10:43136824~43138334:-
BRCA	cis	rs6480314	0.542	rs10998045	ENSG00000233590.1	RP11-153K11.3	-5.16	3.02e-07	3.4e-05	-0.26	-0.16	Optic nerve measurement (disc area);	chr10:68269626	chr10:68233251~68242379:-
BRCA	cis	rs11955398	0.502	rs295573	ENSG00000215032.2	GNL3LP1	5.16	3.02e-07	3.4e-05	0.2	0.16	Intelligence (multi-trait analysis);	chr5:61130433	chr5:60891935~60893577:-
BRCA	cis	rs922692	0.744	rs2277545	ENSG00000261143.1	ADAMTS7P3	5.16	3.02e-07	3.4e-05	0.2	0.16	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78791249	chr15:77976042~77993057:+
BRCA	cis	rs9393692	0.537	rs2393594	ENSG00000241549.7	GUSBP2	-5.16	3.02e-07	3.41e-05	-0.21	-0.16	Educational attainment;	chr6:26316061	chr6:26871484~26956554:-
BRCA	cis	rs4713118	0.614	rs9468209	ENSG00000220721.1	OR1F12	5.16	3.02e-07	3.41e-05	0.18	0.16	Parkinson's disease;	chr6:27726642	chr6:28073316~28074233:+
BRCA	cis	rs1707322	1	rs10890375	ENSG00000234329.1	RP11-767N6.2	5.16	3.02e-07	3.41e-05	0.16	0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45940909	chr1:45651039~45651826:-
BRCA	cis	rs1707322	1	rs10890377	ENSG00000234329.1	RP11-767N6.2	5.16	3.02e-07	3.41e-05	0.16	0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45940922	chr1:45651039~45651826:-
BRCA	cis	rs6570726	0.967	rs7772286	ENSG00000270638.1	RP3-466P17.1	-5.16	3.03e-07	3.41e-05	-0.18	-0.16	Lobe attachment (rater-scored or self-reported);	chr6:145609287	chr6:145735570~145737218:+
BRCA	cis	rs10510102	0.935	rs11200243	ENSG00000226864.1	ATE1-AS1	5.16	3.03e-07	3.41e-05	0.29	0.16	Breast cancer;	chr10:121906888	chr10:121928312~121951965:+
BRCA	cis	rs10510102	0.935	rs11200244	ENSG00000226864.1	ATE1-AS1	5.16	3.03e-07	3.41e-05	0.29	0.16	Breast cancer;	chr10:121906944	chr10:121928312~121951965:+
BRCA	cis	rs1075265	0.584	rs1862121	ENSG00000235937.1	AC008280.1	5.16	3.03e-07	3.41e-05	0.18	0.16	Chronotype;Morning vs. evening chronotype;	chr2:54058102	chr2:54029552~54030682:-
BRCA	cis	rs2836950	0.501	rs2070865	ENSG00000255568.3	BRWD1-AS2	-5.16	3.03e-07	3.41e-05	-0.15	-0.16	Menarche (age at onset);	chr21:39343593	chr21:39313935~39314962:+
BRCA	cis	rs9287719	0.674	rs11691060	ENSG00000243819.4	RN7SL832P	-5.16	3.03e-07	3.41e-05	-0.15	-0.16	Prostate cancer;	chr2:10686935	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.674	rs11684157	ENSG00000243819.4	RN7SL832P	-5.16	3.03e-07	3.41e-05	-0.15	-0.16	Prostate cancer;	chr2:10687031	chr2:10690344~10692099:+
BRCA	cis	rs9311474	0.508	rs17052256	ENSG00000243224.1	RP5-1157M23.2	-5.16	3.03e-07	3.41e-05	-0.17	-0.16	Electroencephalogram traits;	chr3:52559103	chr3:52239258~52241097:+
BRCA	cis	rs9311474	0.508	rs17052259	ENSG00000243224.1	RP5-1157M23.2	-5.16	3.03e-07	3.41e-05	-0.17	-0.16	Electroencephalogram traits;	chr3:52559122	chr3:52239258~52241097:+
BRCA	cis	rs9311474	0.508	rs3796353	ENSG00000243224.1	RP5-1157M23.2	-5.16	3.03e-07	3.41e-05	-0.17	-0.16	Electroencephalogram traits;	chr3:52559214	chr3:52239258~52241097:+
BRCA	cis	rs234043	1	rs234043	ENSG00000223387.5	RP11-408H1.3	5.16	3.03e-07	3.41e-05	0.21	0.16	Renal cell carcinoma;	chr3:172595577	chr3:172560888~172595607:-
BRCA	cis	rs270601	0.721	rs270621	ENSG00000233006.5	AC034220.3	5.16	3.03e-07	3.41e-05	0.12	0.16	Acylcarnitine levels;	chr5:132270128	chr5:132311285~132369916:-
BRCA	cis	rs34792	0.524	rs34629185	ENSG00000207425.1	Y_RNA	-5.16	3.03e-07	3.41e-05	-0.21	-0.16	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15517597	chr16:14915457~14915556:-
BRCA	cis	rs56804039	0.524	rs7003826	ENSG00000253893.2	FAM85B	-5.16	3.03e-07	3.41e-05	-0.27	-0.16	Cervical cancer;	chr8:8548680	chr8:8167819~8226614:-
BRCA	cis	rs7267979	0.789	rs62213729	ENSG00000231081.1	RP4-760C5.3	5.16	3.03e-07	3.41e-05	0.21	0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25382790	chr20:26008791~26010531:-
BRCA	cis	rs4819052	0.679	rs2838859	ENSG00000184274.3	LINC00315	-5.16	3.03e-07	3.42e-05	-0.2	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45264602	chr21:45300245~45305257:-
BRCA	cis	rs75920871	0.66	rs12271161	ENSG00000254851.1	RP11-109L13.1	5.16	3.03e-07	3.42e-05	0.21	0.16	Subjective well-being;	chr11:117109195	chr11:117135528~117138582:+
BRCA	cis	rs875971	0.545	rs1909508	ENSG00000230295.1	RP11-458F8.2	5.15	3.03e-07	3.42e-05	0.15	0.16	Aortic root size;	chr7:66301366	chr7:66880708~66882981:+
BRCA	cis	rs7572733	0.534	rs4550664	ENSG00000231621.1	AC013264.2	-5.15	3.03e-07	3.42e-05	-0.16	-0.16	Dermatomyositis;	chr2:197826681	chr2:197197991~197199273:+
BRCA	cis	rs919433	0.68	rs1961558	ENSG00000231621.1	AC013264.2	-5.15	3.04e-07	3.42e-05	-0.15	-0.16	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197622554	chr2:197197991~197199273:+
BRCA	cis	rs1707322	1	rs785480	ENSG00000234329.1	RP11-767N6.2	5.15	3.04e-07	3.42e-05	0.16	0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46026492	chr1:45651039~45651826:-
BRCA	cis	rs7923837	0.651	rs10882095	ENSG00000236493.2	EIF2S2P3	5.15	3.04e-07	3.42e-05	0.22	0.16	Multiple sclerosis;Body mass index;	chr10:92634645	chr10:92668745~92669743:-
BRCA	cis	rs2303759	0.551	rs7249040	ENSG00000268686.1	AC010524.2	-5.15	3.04e-07	3.42e-05	-0.25	-0.16	Multiple sclerosis;	chr19:49287345	chr19:49368705~49388081:-
BRCA	cis	rs1707322	1	rs12077974	ENSG00000234329.1	RP11-767N6.2	5.15	3.04e-07	3.43e-05	0.17	0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45918469	chr1:45651039~45651826:-
BRCA	cis	rs10504130	1	rs60304457	ENSG00000253844.1	RP11-546K22.1	-5.15	3.04e-07	3.43e-05	-0.28	-0.16	Venous thromboembolism (SNP x SNP interaction);	chr8:51923541	chr8:51961458~52022974:+
BRCA	cis	rs7246657	0.654	rs10407568	ENSG00000276846.1	CTD-3220F14.3	5.15	3.04e-07	3.43e-05	0.21	0.16	Coronary artery calcification;	chr19:37632108	chr19:37314868~37315620:-
BRCA	cis	rs6772849	0.93	rs4857914	ENSG00000242551.2	POU5F1P6	-5.15	3.04e-07	3.43e-05	-0.2	-0.16	Monocyte percentage of white cells;Monocyte count;	chr3:128631841	chr3:128674735~128677005:-
BRCA	cis	rs12786942	0.502	rs2513176	ENSG00000254506.1	RP11-748H22.1	5.15	3.04e-07	3.43e-05	0.18	0.16	Facial depth;	chr11:101397935	chr11:101584295~101595156:+
BRCA	cis	rs804280	0.509	rs12719915	ENSG00000255495.1	AC145124.2	-5.15	3.04e-07	3.43e-05	-0.18	-0.16	Myopia (pathological);	chr8:11928746	chr8:12194467~12196280:+
BRCA	cis	rs11098499	0.754	rs10213554	ENSG00000249244.1	RP11-548H18.2	-5.15	3.05e-07	3.43e-05	-0.18	-0.16	Corneal astigmatism;	chr4:119339630	chr4:119391831~119395335:-
BRCA	cis	rs11051970	0.559	rs3748275	ENSG00000274964.1	RP11-817I4.1	-5.15	3.05e-07	3.43e-05	-0.21	-0.16	Response to tocilizumab in rheumatoid arthritis;	chr12:32328159	chr12:32339368~32340724:+
BRCA	cis	rs7818688	1	rs10100842	ENSG00000253528.2	RP11-347C18.4	-5.15	3.05e-07	3.43e-05	-0.24	-0.16	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95013675	chr8:94974573~94974853:-
BRCA	cis	rs7818688	1	rs10103841	ENSG00000253528.2	RP11-347C18.4	-5.15	3.05e-07	3.43e-05	-0.24	-0.16	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95013676	chr8:94974573~94974853:-
BRCA	cis	rs875971	0.798	rs12698522	ENSG00000273448.1	RP11-166O4.6	5.15	3.05e-07	3.43e-05	0.15	0.16	Aortic root size;	chr7:66502354	chr7:67333047~67334383:+
BRCA	cis	rs875971	0.83	rs28714531	ENSG00000273448.1	RP11-166O4.6	5.15	3.05e-07	3.43e-05	0.15	0.16	Aortic root size;	chr7:66503250	chr7:67333047~67334383:+
BRCA	cis	rs875971	0.862	rs12698526	ENSG00000273448.1	RP11-166O4.6	5.15	3.05e-07	3.43e-05	0.15	0.16	Aortic root size;	chr7:66504118	chr7:67333047~67334383:+
BRCA	cis	rs2638953	0.853	rs11049635	ENSG00000247934.4	RP11-967K21.1	-5.15	3.05e-07	3.43e-05	-0.21	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28464293	chr12:28163298~28190738:-
BRCA	cis	rs375066	0.586	rs59503823	ENSG00000267058.1	RP11-15A1.3	5.15	3.05e-07	3.43e-05	0.19	0.16	Breast cancer;	chr19:43822266	chr19:43891804~43901805:-
BRCA	cis	rs17508449	0.547	rs55940960	ENSG00000232450.1	RP4-730K3.3	-5.15	3.05e-07	3.43e-05	-0.25	-0.16	Leprosy;	chr1:113813474	chr1:113698884~113699631:-
BRCA	cis	rs17508449	0.547	rs3811021	ENSG00000232450.1	RP4-730K3.3	-5.15	3.05e-07	3.43e-05	-0.25	-0.16	Leprosy;	chr1:113814041	chr1:113698884~113699631:-
BRCA	cis	rs2554380	0.628	rs12914377	ENSG00000230373.7	GOLGA6L5P	-5.15	3.05e-07	3.43e-05	-0.19	-0.16	Height;	chr15:83791941	chr15:84507885~84516814:-
BRCA	cis	rs741668	1	rs741668	ENSG00000235903.6	CPB2-AS1	-5.15	3.05e-07	3.43e-05	-0.2	-0.16	Cerebrospinal fluid clusterin levels;	chr13:45942333	chr13:46052806~46113332:+
BRCA	cis	rs2243480	1	rs6958420	ENSG00000228409.4	CCT6P1	-5.15	3.05e-07	3.44e-05	-0.22	-0.16	Diabetic kidney disease;	chr7:66286184	chr7:65751142~65763354:+
BRCA	cis	rs2243480	1	rs1392104	ENSG00000228409.4	CCT6P1	-5.15	3.05e-07	3.44e-05	-0.22	-0.16	Diabetic kidney disease;	chr7:66294120	chr7:65751142~65763354:+
BRCA	cis	rs9813712	0.595	rs6439226	ENSG00000228252.7	COL6A4P2	5.15	3.05e-07	3.44e-05	0.19	0.16	Response to amphetamines;	chr3:130283686	chr3:130212823~130273806:+
BRCA	cis	rs6452524	0.648	rs27364	ENSG00000281327.1	LINC01338	5.15	3.05e-07	3.44e-05	0.18	0.16	Hypertension (SNP x SNP interaction);	chr5:83052137	chr5:82850864~82859836:-
BRCA	cis	rs7474896	0.515	rs688608	ENSG00000120555.12	SEPT7P9	-5.15	3.06e-07	3.44e-05	-0.23	-0.16	Obesity (extreme);	chr10:38042696	chr10:38383069~38402916:-
BRCA	cis	rs8048589	0.898	rs3851011	ENSG00000175604.2	RP11-276H1.3	-5.15	3.06e-07	3.44e-05	-0.25	-0.16	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);	chr16:12098615	chr16:12086746~12090302:-
BRCA	cis	rs7487075	0.578	rs4768713	ENSG00000274723.1	RP11-618L22.1	5.15	3.06e-07	3.44e-05	0.19	0.16	Itch intensity from mosquito bite;	chr12:46420264	chr12:46970504~46972155:+
BRCA	cis	rs7577696	0.695	rs212755	ENSG00000272716.1	RP11-563N4.1	5.15	3.06e-07	3.44e-05	0.17	0.16	Inflammatory biomarkers;	chr2:32198950	chr2:32165046~32165757:-
BRCA	cis	rs7572733	0.592	rs4389332	ENSG00000231621.1	AC013264.2	-5.15	3.06e-07	3.44e-05	-0.14	-0.16	Dermatomyositis;	chr2:197612896	chr2:197197991~197199273:+
BRCA	cis	rs6723108	0.678	rs578384	ENSG00000224043.6	CCNT2-AS1	-5.15	3.06e-07	3.44e-05	-0.23	-0.16	Type 2 diabetes;	chr2:134530343	chr2:134735464~134918710:-
BRCA	cis	rs7772486	0.79	rs7742333	ENSG00000270638.1	RP3-466P17.1	-5.15	3.06e-07	3.44e-05	-0.18	-0.16	Lobe attachment (rater-scored or self-reported);	chr6:145837893	chr6:145735570~145737218:+
BRCA	cis	rs12497850	0.931	rs7628719	ENSG00000225399.4	RP11-3B7.1	5.15	3.06e-07	3.44e-05	0.15	0.16	Parkinson's disease;	chr3:48958054	chr3:49260085~49261316:+
BRCA	cis	rs8114671	0.562	rs6088640	ENSG00000269202.1	RP4-614O4.12	-5.15	3.06e-07	3.44e-05	-0.16	-0.16	Height;	chr20:34884706	chr20:35201747~35203288:-
BRCA	cis	rs997295	0.57	rs60066681	ENSG00000270964.1	RP11-502I4.3	-5.15	3.06e-07	3.44e-05	-0.18	-0.16	Motion sickness;	chr15:67515738	chr15:67541072~67542604:-
BRCA	cis	rs1707322	1	rs10890353	ENSG00000234329.1	RP11-767N6.2	5.15	3.06e-07	3.45e-05	0.16	0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45832711	chr1:45651039~45651826:-
BRCA	cis	rs7819412	0.595	rs10106914	ENSG00000255046.1	RP11-297N6.4	5.15	3.06e-07	3.45e-05	0.19	0.16	Triglycerides;	chr8:11130141	chr8:11797928~11802568:-
BRCA	cis	rs7178909	0.902	rs2043881	ENSG00000259677.1	RP11-493E3.1	5.15	3.06e-07	3.45e-05	0.19	0.16	Common traits (Other);	chr15:89896728	chr15:89876540~89877285:+
BRCA	cis	rs9467773	0.967	rs7753565	ENSG00000241549.7	GUSBP2	5.15	3.06e-07	3.45e-05	0.17	0.16	Intelligence (multi-trait analysis);	chr6:26559784	chr6:26871484~26956554:-
BRCA	cis	rs11051970	0.592	rs7132235	ENSG00000274964.1	RP11-817I4.1	-5.15	3.06e-07	3.45e-05	-0.22	-0.16	Response to tocilizumab in rheumatoid arthritis;	chr12:32383369	chr12:32339368~32340724:+
BRCA	cis	rs7487075	0.619	rs7311504	ENSG00000274723.1	RP11-618L22.1	5.15	3.06e-07	3.45e-05	0.19	0.16	Itch intensity from mosquito bite;	chr12:46436993	chr12:46970504~46972155:+
BRCA	cis	rs9467773	1	rs10484442	ENSG00000124549.13	BTN2A3P	5.15	3.06e-07	3.45e-05	0.16	0.16	Intelligence (multi-trait analysis);	chr6:26555651	chr6:26421391~26432383:+
BRCA	cis	rs4819052	0.851	rs10470246	ENSG00000184274.3	LINC00315	-5.15	3.07e-07	3.45e-05	-0.22	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239102	chr21:45300245~45305257:-
BRCA	cis	rs4819052	0.851	rs10470247	ENSG00000184274.3	LINC00315	-5.15	3.07e-07	3.45e-05	-0.22	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239103	chr21:45300245~45305257:-
BRCA	cis	rs4819052	0.851	rs4819043	ENSG00000184274.3	LINC00315	-5.15	3.07e-07	3.45e-05	-0.22	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240163	chr21:45300245~45305257:-
BRCA	cis	rs4819052	0.851	rs4819044	ENSG00000184274.3	LINC00315	-5.15	3.07e-07	3.45e-05	-0.22	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240203	chr21:45300245~45305257:-
BRCA	cis	rs17772222	0.682	rs2274736	ENSG00000258789.1	RP11-507K2.3	-5.15	3.07e-07	3.45e-05	-0.18	-0.16	Coronary artery calcification;	chr14:88472308	chr14:88551597~88552493:+
BRCA	cis	rs1555322	0.53	rs932562	ENSG00000269202.1	RP4-614O4.12	-5.15	3.07e-07	3.45e-05	-0.19	-0.16	Attention deficit hyperactivity disorder;	chr20:35283507	chr20:35201747~35203288:-
BRCA	cis	rs6847067	0.894	rs72664926	ENSG00000180769.7	WDFY3-AS2	5.15	3.07e-07	3.45e-05	0.14	0.16	Oropharynx cancer;	chr4:84827743	chr4:84965682~85011277:+
BRCA	cis	rs13113518	1	rs4865004	ENSG00000223305.1	RN7SKP30	5.15	3.07e-07	3.45e-05	0.19	0.16	Height;	chr4:55515118	chr4:55540502~55540835:-
BRCA	cis	rs9923856	0.519	rs2867168	ENSG00000274038.1	RP11-66H6.4	-5.15	3.07e-07	3.45e-05	-0.17	-0.16	Atopic dermatitis;Adult asthma;	chr16:11029932	chr16:11056556~11057034:+
BRCA	cis	rs7178909	0.872	rs10852124	ENSG00000259677.1	RP11-493E3.1	5.15	3.07e-07	3.45e-05	0.19	0.16	Common traits (Other);	chr15:89887232	chr15:89876540~89877285:+
BRCA	cis	rs4835473	0.549	rs11940719	ENSG00000249741.2	RP11-673E1.3	-5.15	3.07e-07	3.46e-05	-0.17	-0.16	Immature fraction of reticulocytes;	chr4:143970855	chr4:143911514~143912053:-
BRCA	cis	rs4835473	0.9	rs6537223	ENSG00000249741.2	RP11-673E1.3	-5.15	3.07e-07	3.46e-05	-0.17	-0.16	Immature fraction of reticulocytes;	chr4:143971541	chr4:143911514~143912053:-
BRCA	cis	rs7618501	0.573	rs7634917	ENSG00000228008.1	CTD-2330K9.3	-5.15	3.07e-07	3.46e-05	-0.15	-0.16	Intelligence (multi-trait analysis);	chr3:50011866	chr3:49903845~49916937:+
BRCA	cis	rs6723226	0.698	rs13409142	ENSG00000276517.1	AL133243.2	-5.15	3.07e-07	3.46e-05	-0.2	-0.16	Intelligence (multi-trait analysis);	chr2:32441069	chr2:32526504~32529507:+
BRCA	cis	rs801193	0.591	rs4506088	ENSG00000273448.1	RP11-166O4.6	-5.15	3.07e-07	3.46e-05	-0.15	-0.16	Aortic root size;	chr7:66670470	chr7:67333047~67334383:+
BRCA	cis	rs6095360	0.727	rs13037063	ENSG00000222365.1	SNORD12B	-5.15	3.07e-07	3.46e-05	-0.22	-0.16	Intelligence (multi-trait analysis);	chr20:48909128	chr20:49280319~49280409:+
BRCA	cis	rs7914558	1	rs11191542	ENSG00000236937.2	PTGES3P4	5.15	3.08e-07	3.46e-05	0.2	0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103064567	chr10:102845595~102845950:+
BRCA	cis	rs6674176	0.551	rs2486006	ENSG00000237950.1	RP11-7O11.3	5.15	3.08e-07	3.46e-05	0.26	0.16	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43980962	chr1:43944370~43946551:-
BRCA	cis	rs8180040	0.966	rs2101247	ENSG00000276925.1	RP11-708J19.3	5.15	3.08e-07	3.46e-05	0.18	0.16	Colorectal cancer;	chr3:47452813	chr3:47469777~47469987:+
BRCA	cis	rs338389	0.586	rs338402	ENSG00000260657.2	RP11-315D16.4	-5.15	3.08e-07	3.46e-05	-0.2	-0.16	Survival in rectal cancer;	chr15:67961613	chr15:68267792~68277994:-
BRCA	cis	rs4713118	0.662	rs149969	ENSG00000280107.1	AL022393.9	-5.15	3.08e-07	3.46e-05	-0.23	-0.16	Parkinson's disease;	chr6:28009959	chr6:28170845~28172521:+
BRCA	cis	rs9473147	0.516	rs2151975	ENSG00000270761.1	RP11-385F7.1	-5.15	3.08e-07	3.46e-05	-0.17	-0.16	Platelet distribution width;Mean platelet volume;	chr6:47547927	chr6:47477243~47477572:-
BRCA	cis	rs7302981	0.746	rs836177	ENSG00000272368.2	RP4-605O3.4	5.15	3.08e-07	3.46e-05	0.17	0.16	Systolic blood pressure;	chr12:50098038	chr12:50112197~50165618:+
BRCA	cis	rs13126694	0.901	rs4691460	ENSG00000251429.1	RP11-597D13.7	-5.15	3.08e-07	3.46e-05	-0.15	-0.16	Blood osmolality (transformed sodium);	chr4:158138279	chr4:158270378~158278676:+
BRCA	cis	rs6832769	0.961	rs2140077	ENSG00000223305.1	RN7SKP30	5.15	3.08e-07	3.46e-05	0.21	0.16	Personality dimensions;	chr4:55472786	chr4:55540502~55540835:-
BRCA	cis	rs2153535	0.58	rs4365970	ENSG00000251164.1	HULC	5.15	3.08e-07	3.46e-05	0.19	0.16	Motion sickness;	chr6:8453580	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.58	rs7743686	ENSG00000251164.1	HULC	-5.15	3.08e-07	3.47e-05	-0.19	-0.16	Motion sickness;	chr6:8525878	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.601	rs718504	ENSG00000251164.1	HULC	-5.15	3.08e-07	3.47e-05	-0.19	-0.16	Motion sickness;	chr6:8527279	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.601	rs9328487	ENSG00000251164.1	HULC	-5.15	3.08e-07	3.47e-05	-0.19	-0.16	Motion sickness;	chr6:8529145	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.58	rs9328488	ENSG00000251164.1	HULC	-5.15	3.08e-07	3.47e-05	-0.19	-0.16	Motion sickness;	chr6:8529178	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.601	rs7775274	ENSG00000251164.1	HULC	-5.15	3.08e-07	3.47e-05	-0.19	-0.16	Motion sickness;	chr6:8530070	chr6:8652137~8653846:+
BRCA	cis	rs922692	0.715	rs2277546	ENSG00000261143.1	ADAMTS7P3	5.15	3.08e-07	3.47e-05	0.2	0.16	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78791034	chr15:77976042~77993057:+
BRCA	cis	rs6840360	0.642	rs2724577	ENSG00000251611.1	RP11-610P16.1	-5.15	3.08e-07	3.47e-05	-0.15	-0.16	Intelligence (multi-trait analysis);	chr4:151433753	chr4:151407551~151408835:-
BRCA	cis	rs3768617	0.546	rs2296296	ENSG00000224468.3	RP11-181K3.4	-5.15	3.08e-07	3.47e-05	-0.17	-0.16	Fuchs's corneal dystrophy;	chr1:183136264	chr1:183138402~183141282:-
BRCA	cis	rs924712	0.545	rs72954815	ENSG00000261116.1	RP3-523K23.2	5.15	3.08e-07	3.47e-05	0.18	0.16	Breast cancer;	chr6:54843291	chr6:54943167~54945099:+
BRCA	cis	rs924712	0.545	rs12205222	ENSG00000261116.1	RP3-523K23.2	5.15	3.08e-07	3.47e-05	0.18	0.16	Breast cancer;	chr6:54843292	chr6:54943167~54945099:+
BRCA	cis	rs4713118	0.513	rs149958	ENSG00000280107.1	AL022393.9	-5.15	3.08e-07	3.47e-05	-0.22	-0.16	Parkinson's disease;	chr6:28045839	chr6:28170845~28172521:+
BRCA	cis	rs7819412	0.594	rs7460507	ENSG00000255046.1	RP11-297N6.4	5.15	3.09e-07	3.47e-05	0.19	0.16	Triglycerides;	chr8:11111565	chr8:11797928~11802568:-
BRCA	cis	rs1850744	1	rs938556	ENSG00000163612.10	FAM86KP	-5.15	3.09e-07	3.47e-05	-0.4	-0.16	Economic and political preferences;	chr4:9800742	chr4:9153296~9165451:+
BRCA	cis	rs7577696	0.695	rs212686	ENSG00000272716.1	RP11-563N4.1	5.15	3.09e-07	3.47e-05	0.17	0.16	Inflammatory biomarkers;	chr2:32209800	chr2:32165046~32165757:-
BRCA	cis	rs7978895	1	rs4565964	ENSG00000258331.1	RP11-118A3.1	-5.15	3.09e-07	3.47e-05	-0.16	-0.16	Type 2 diabetes;	chr12:43181199	chr12:43155315~43163110:+
BRCA	cis	rs1075265	0.611	rs11684084	ENSG00000235937.1	AC008280.1	5.15	3.09e-07	3.47e-05	0.18	0.16	Chronotype;Morning vs. evening chronotype;	chr2:53695806	chr2:54029552~54030682:-
BRCA	cis	rs6840360	0.642	rs7657670	ENSG00000278978.1	RP11-164P12.5	-5.15	3.09e-07	3.47e-05	-0.17	-0.16	Intelligence (multi-trait analysis);	chr4:151432223	chr4:151669786~151670503:+
BRCA	cis	rs4604234	0.803	rs112533182	ENSG00000272129.1	RP11-250B2.6	-5.15	3.09e-07	3.48e-05	-0.38	-0.16	Cancer;	chr6:80295792	chr6:80355424~80356859:+
BRCA	cis	rs2904967	0.852	rs1633466	ENSG00000254614.2	AP003068.23	-5.15	3.09e-07	3.48e-05	-0.29	-0.16	Mean corpuscular volume;	chr11:65248702	chr11:65177606~65181834:-
BRCA	cis	rs295490	0.748	rs10513063	ENSG00000272656.1	RP11-219D15.3	5.15	3.09e-07	3.48e-05	0.36	0.16	PR interval in Tripanosoma cruzi seropositivity;	chr3:139341586	chr3:139349024~139349371:-
BRCA	cis	rs7618501	0.633	rs9866695	ENSG00000228008.1	CTD-2330K9.3	-5.15	3.09e-07	3.48e-05	-0.15	-0.16	Intelligence (multi-trait analysis);	chr3:50032019	chr3:49903845~49916937:+
BRCA	cis	rs10911232	0.507	rs10732271	ENSG00000224468.3	RP11-181K3.4	-5.15	3.09e-07	3.48e-05	-0.17	-0.16	Hypertriglyceridemia;	chr1:183056763	chr1:183138402~183141282:-
BRCA	cis	rs9868809	0.881	rs2276850	ENSG00000270441.1	RP11-694I15.7	5.15	3.09e-07	3.48e-05	0.3	0.16	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48632215	chr3:49140086~49160851:-
BRCA	cis	rs9868809	0.881	rs34368826	ENSG00000270441.1	RP11-694I15.7	5.15	3.09e-07	3.48e-05	0.3	0.16	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48633394	chr3:49140086~49160851:-
BRCA	cis	rs2904967	0.929	rs611910	ENSG00000255200.1	AP003068.18	5.15	3.09e-07	3.48e-05	0.27	0.16	Mean corpuscular volume;	chr11:65281807	chr11:65174117~65176470:-
BRCA	cis	rs523522	0.962	rs7136951	ENSG00000278344.1	RP11-18C24.8	5.15	3.09e-07	3.48e-05	0.21	0.16	High light scatter reticulocyte count;	chr12:120504124	chr12:120500735~120501090:-
BRCA	cis	rs2638953	0.893	rs10843192	ENSG00000247934.4	RP11-967K21.1	-5.15	3.1e-07	3.48e-05	-0.19	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28508756	chr12:28163298~28190738:-
BRCA	cis	rs9473147	0.516	rs6931478	ENSG00000270761.1	RP11-385F7.1	-5.15	3.1e-07	3.48e-05	-0.17	-0.16	Platelet distribution width;Mean platelet volume;	chr6:47494177	chr6:47477243~47477572:-
BRCA	cis	rs9369695	0.881	rs9349409	ENSG00000270761.1	RP11-385F7.1	-5.15	3.1e-07	3.48e-05	-0.17	-0.16	Reticulocyte count;	chr6:47495390	chr6:47477243~47477572:-
BRCA	cis	rs4835473	0.766	rs6537222	ENSG00000249741.2	RP11-673E1.3	-5.15	3.1e-07	3.48e-05	-0.17	-0.16	Immature fraction of reticulocytes;	chr4:143971459	chr4:143911514~143912053:-
BRCA	cis	rs9341808	0.69	rs6930534	ENSG00000272129.1	RP11-250B2.6	5.15	3.1e-07	3.48e-05	0.2	0.16	Sitting height ratio;	chr6:80186333	chr6:80355424~80356859:+
BRCA	cis	rs2688608	1	rs2688610	ENSG00000271816.1	BMS1P4	-5.15	3.1e-07	3.48e-05	-0.16	-0.16	Inflammatory bowel disease;	chr10:73895173	chr10:73699151~73730487:-
BRCA	cis	rs7226408	0.857	rs72887051	ENSG00000267707.2	RP11-95O2.5	5.15	3.1e-07	3.48e-05	0.24	0.16	Obesity-related traits;	chr18:36907030	chr18:37243776~37247506:+
BRCA	cis	rs7226408	0.857	rs72887063	ENSG00000267707.2	RP11-95O2.5	5.15	3.1e-07	3.48e-05	0.24	0.16	Obesity-related traits;	chr18:36913158	chr18:37243776~37247506:+
BRCA	cis	rs9287719	0.649	rs10186984	ENSG00000243819.4	RN7SL832P	-5.15	3.1e-07	3.49e-05	-0.16	-0.16	Prostate cancer;	chr2:10594066	chr2:10690344~10692099:+
BRCA	cis	rs2832191	0.791	rs2251517	ENSG00000176054.6	RPL23P2	5.15	3.1e-07	3.49e-05	0.17	0.16	Dental caries;	chr21:29159630	chr21:28997613~28998033:-
BRCA	cis	rs4718428	0.705	rs2901311	ENSG00000230295.1	RP11-458F8.2	-5.15	3.1e-07	3.49e-05	-0.15	-0.16	Corneal structure;	chr7:66950082	chr7:66880708~66882981:+
BRCA	cis	rs9868809	0.881	rs3806694	ENSG00000270441.1	RP11-694I15.7	5.15	3.1e-07	3.49e-05	0.3	0.16	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48634901	chr3:49140086~49160851:-
BRCA	cis	rs7267979	0.789	rs6083820	ENSG00000231081.1	RP4-760C5.3	5.15	3.11e-07	3.49e-05	0.21	0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25373542	chr20:26008791~26010531:-
BRCA	cis	rs2303319	0.504	rs62188988	ENSG00000227403.1	AC009299.3	5.15	3.11e-07	3.49e-05	0.38	0.16	Cognitive function;	chr2:161674558	chr2:161244739~161249050:+
BRCA	cis	rs7617773	0.78	rs35297486	ENSG00000199476.1	Y_RNA	-5.15	3.11e-07	3.49e-05	-0.24	-0.16	Coronary artery disease;	chr3:48336657	chr3:48288587~48288694:+
BRCA	cis	rs17772222	0.74	rs61975278	ENSG00000258789.1	RP11-507K2.3	-5.15	3.11e-07	3.49e-05	-0.18	-0.16	Coronary artery calcification;	chr14:88511223	chr14:88551597~88552493:+
BRCA	cis	rs10504130	0.778	rs74866791	ENSG00000272024.1	RP11-546K22.3	-5.15	3.11e-07	3.49e-05	-0.27	-0.16	Venous thromboembolism (SNP x SNP interaction);	chr8:51909787	chr8:51950284~51950690:+
BRCA	cis	rs11051970	0.659	rs73088096	ENSG00000274964.1	RP11-817I4.1	-5.15	3.11e-07	3.5e-05	-0.22	-0.16	Response to tocilizumab in rheumatoid arthritis;	chr12:32431469	chr12:32339368~32340724:+
BRCA	cis	rs8180040	0.966	rs11130128	ENSG00000276925.1	RP11-708J19.3	5.15	3.11e-07	3.5e-05	0.18	0.16	Colorectal cancer;	chr3:47445142	chr3:47469777~47469987:+
BRCA	cis	rs8098244	0.603	rs1711460	ENSG00000264745.1	TTC39C-AS1	5.15	3.11e-07	3.5e-05	0.18	0.16	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23711441	chr18:23994213~24015339:-
BRCA	cis	rs9640161	0.83	rs3757423	ENSG00000261305.1	RP4-584D14.7	-5.15	3.11e-07	3.5e-05	-0.21	-0.16	Blood protein levels;Circulating chemerin levels;	chr7:150370625	chr7:150341771~150342607:+
BRCA	cis	rs7044106	0.69	rs10739569	ENSG00000238181.2	AHCYP2	-5.15	3.11e-07	3.5e-05	-0.2	-0.16	Hip circumference adjusted for BMI;	chr9:120598749	chr9:120720673~120721972:+
BRCA	cis	rs12612619	0.579	rs11887277	ENSG00000272148.1	RP11-195B17.1	-5.15	3.12e-07	3.5e-05	-0.18	-0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:26860401	chr2:27062428~27062907:-
BRCA	cis	rs7226408	0.857	rs72887052	ENSG00000267707.2	RP11-95O2.5	5.15	3.12e-07	3.5e-05	0.24	0.16	Obesity-related traits;	chr18:36907333	chr18:37243776~37247506:+
BRCA	cis	rs13113518	1	rs4865013	ENSG00000223305.1	RN7SKP30	5.15	3.12e-07	3.5e-05	0.19	0.16	Height;	chr4:55559957	chr4:55540502~55540835:-
BRCA	cis	rs2179367	0.632	rs7349921	ENSG00000268592.3	RAET1E-AS1	5.15	3.12e-07	3.5e-05	0.23	0.16	Dupuytren's disease;	chr6:149392727	chr6:149863494~149919507:+
BRCA	cis	rs2179367	0.632	rs60153446	ENSG00000268592.3	RAET1E-AS1	5.15	3.12e-07	3.5e-05	0.23	0.16	Dupuytren's disease;	chr6:149393186	chr6:149863494~149919507:+
BRCA	cis	rs2179367	0.632	rs61259243	ENSG00000268592.3	RAET1E-AS1	5.15	3.12e-07	3.5e-05	0.23	0.16	Dupuytren's disease;	chr6:149393457	chr6:149863494~149919507:+
BRCA	cis	rs2179367	0.632	rs62426115	ENSG00000268592.3	RAET1E-AS1	5.15	3.12e-07	3.5e-05	0.23	0.16	Dupuytren's disease;	chr6:149393718	chr6:149863494~149919507:+
BRCA	cis	rs2179367	0.632	rs68080376	ENSG00000268592.3	RAET1E-AS1	5.15	3.12e-07	3.5e-05	0.23	0.16	Dupuytren's disease;	chr6:149393873	chr6:149863494~149919507:+
BRCA	cis	rs853679	0.546	rs13213986	ENSG00000204709.4	LINC01556	5.15	3.12e-07	3.5e-05	0.43	0.16	Depression;	chr6:28390232	chr6:28943877~28944537:+
BRCA	cis	rs853679	0.546	rs34546986	ENSG00000204709.4	LINC01556	5.15	3.12e-07	3.5e-05	0.43	0.16	Depression;	chr6:28394532	chr6:28943877~28944537:+
BRCA	cis	rs853679	0.546	rs34871267	ENSG00000204709.4	LINC01556	5.15	3.12e-07	3.5e-05	0.43	0.16	Depression;	chr6:28396455	chr6:28943877~28944537:+
BRCA	cis	rs853679	0.546	rs35883476	ENSG00000204709.4	LINC01556	5.15	3.12e-07	3.5e-05	0.43	0.16	Depression;	chr6:28400731	chr6:28943877~28944537:+
BRCA	cis	rs17685	0.753	rs10085567	ENSG00000280388.1	RP11-229D13.3	-5.15	3.12e-07	3.5e-05	-0.16	-0.16	Coffee consumption (cups per day);Coffee consumption;	chr7:76104888	chr7:76043977~76045963:-
BRCA	cis	rs494453	0.922	rs486982	ENSG00000227811.2	FAM212B-AS1	-5.15	3.12e-07	3.5e-05	-0.2	-0.16	Osteoporosis-related phenotypes;	chr1:111710492	chr1:111739841~111747798:+
BRCA	cis	rs875971	0.862	rs908915	ENSG00000236529.1	RP13-254B10.1	-5.15	3.12e-07	3.5e-05	-0.17	-0.16	Aortic root size;	chr7:66149664	chr7:65840212~65840596:+
BRCA	cis	rs78487399	0.71	rs17334919	ENSG00000234936.1	AC010883.5	-5.15	3.12e-07	3.5e-05	-0.27	-0.16	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43480246	chr2:43229573~43233394:+
BRCA	cis	rs13236243	0.559	rs7810862	ENSG00000237773.4	AC003075.4	-5.15	3.12e-07	3.51e-05	-0.23	-0.16	Sensory disturbances after bilateral sagittal split ramus osteotomy;	chr7:17283975	chr7:17279834~17299357:-
BRCA	cis	rs4819052	0.634	rs8128636	ENSG00000184274.3	LINC00315	-5.15	3.13e-07	3.51e-05	-0.2	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45270718	chr21:45300245~45305257:-
BRCA	cis	rs6831352	0.819	rs13832	ENSG00000272777.1	RP11-571L19.8	-5.15	3.13e-07	3.51e-05	-0.17	-0.16	Alcohol dependence;	chr4:99071924	chr4:99067256~99068125:-
BRCA	cis	rs792448	0.743	rs12033246	ENSG00000226251.4	RP11-15I11.3	-5.15	3.13e-07	3.51e-05	-0.21	-0.16	White blood cell count (basophil);	chr1:212339906	chr1:212225278~212238977:-
BRCA	cis	rs2638953	0.962	rs61922979	ENSG00000247934.4	RP11-967K21.1	-5.15	3.13e-07	3.51e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28301218	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.962	rs11049517	ENSG00000247934.4	RP11-967K21.1	-5.15	3.13e-07	3.51e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28301627	chr12:28163298~28190738:-
BRCA	cis	rs1707322	1	rs11211222	ENSG00000234329.1	RP11-767N6.2	5.15	3.13e-07	3.51e-05	0.16	0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45902085	chr1:45651039~45651826:-
BRCA	cis	rs1707322	0.963	rs9787412	ENSG00000234329.1	RP11-767N6.2	5.15	3.13e-07	3.51e-05	0.16	0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45905924	chr1:45651039~45651826:-
BRCA	cis	rs1707322	1	rs4660896	ENSG00000234329.1	RP11-767N6.2	5.15	3.13e-07	3.51e-05	0.16	0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45906744	chr1:45651039~45651826:-
BRCA	cis	rs1707322	1	rs12133129	ENSG00000234329.1	RP11-767N6.2	5.15	3.13e-07	3.51e-05	0.16	0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45907676	chr1:45651039~45651826:-
BRCA	cis	rs1707322	0.963	rs4553121	ENSG00000234329.1	RP11-767N6.2	5.15	3.13e-07	3.51e-05	0.16	0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45909581	chr1:45651039~45651826:-
BRCA	cis	rs1707322	0.963	rs6690652	ENSG00000234329.1	RP11-767N6.2	5.15	3.13e-07	3.51e-05	0.16	0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45911020	chr1:45651039~45651826:-
BRCA	cis	rs1979679	0.766	rs10843197	ENSG00000278733.1	RP11-425D17.1	-5.15	3.13e-07	3.51e-05	-0.2	-0.16	Ossification of the posterior longitudinal ligament of the spine;	chr12:28518308	chr12:28185625~28186190:-
BRCA	cis	rs7618915	0.547	rs12486847	ENSG00000243224.1	RP5-1157M23.2	-5.15	3.13e-07	3.51e-05	-0.18	-0.16	Bipolar disorder;	chr3:52657096	chr3:52239258~52241097:+
BRCA	cis	rs10129255	0.872	rs8015406	ENSG00000211974.3	IGHV2-70	5.15	3.13e-07	3.51e-05	0.17	0.16	Kawasaki disease;	chr14:106670611	chr14:106723574~106724093:-
BRCA	cis	rs2153535	0.601	rs330105	ENSG00000251164.1	HULC	-5.15	3.13e-07	3.51e-05	-0.19	-0.16	Motion sickness;	chr6:8543748	chr6:8652137~8653846:+
BRCA	cis	rs597539	0.652	rs1249474	ENSG00000261625.1	RP11-554A11.4	-5.15	3.13e-07	3.52e-05	-0.15	-0.16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68887306	chr11:69000765~69002048:-
BRCA	cis	rs115344852	0.557	rs2859351	ENSG00000216901.1	AL022393.7	5.15	3.13e-07	3.52e-05	0.22	0.16	Epithelial ovarian cancer;	chr6:28488418	chr6:28176188~28176674:+
BRCA	cis	rs115344852	0.575	rs2531820	ENSG00000216901.1	AL022393.7	5.15	3.13e-07	3.52e-05	0.22	0.16	Epithelial ovarian cancer;	chr6:28488942	chr6:28176188~28176674:+
BRCA	cis	rs4699052	0.928	rs2169511	ENSG00000248740.4	RP11-328K4.1	5.15	3.13e-07	3.52e-05	0.18	0.16	Testicular germ cell tumor;	chr4:103271423	chr4:103256159~103453658:+
BRCA	cis	rs4699052	0.963	rs6849319	ENSG00000248740.4	RP11-328K4.1	5.15	3.13e-07	3.52e-05	0.18	0.16	Testicular germ cell tumor;	chr4:103271585	chr4:103256159~103453658:+
BRCA	cis	rs728616	0.867	rs118134654	ENSG00000225484.5	NUTM2B-AS1	-5.15	3.14e-07	3.52e-05	-0.43	-0.16	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79984625	chr10:79663088~79826594:-
BRCA	cis	rs875971	0.862	rs801195	ENSG00000273448.1	RP11-166O4.6	-5.15	3.14e-07	3.52e-05	-0.15	-0.16	Aortic root size;	chr7:66561128	chr7:67333047~67334383:+
BRCA	cis	rs7690839	0.803	rs1795736	ENSG00000270720.1	RP11-84C13.2	-5.15	3.14e-07	3.52e-05	-0.18	-0.16	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr4:89011122	chr4:89119284~89119871:+
BRCA	cis	rs875971	1	rs10257427	ENSG00000223473.2	GS1-124K5.3	-5.15	3.14e-07	3.52e-05	-0.12	-0.16	Aortic root size;	chr7:66278221	chr7:66491049~66493566:-
BRCA	cis	rs9847710	0.818	rs6445558	ENSG00000242142.1	SERBP1P3	-5.15	3.14e-07	3.52e-05	-0.18	-0.16	Ulcerative colitis;	chr3:53063644	chr3:53064283~53065091:-
BRCA	cis	rs962856	0.866	rs13387185	ENSG00000236780.4	AC078941.1	5.15	3.14e-07	3.52e-05	0.2	0.16	Pancreatic cancer;	chr2:67401517	chr2:67123357~67215319:-
BRCA	cis	rs9545047	0.588	rs9530894	ENSG00000227354.5	RBM26-AS1	5.15	3.14e-07	3.52e-05	0.17	0.16	Schizophrenia;	chr13:79334020	chr13:79406309~79424328:+
BRCA	cis	rs7674212	0.541	rs2623070	ENSG00000251288.2	RP11-10L12.2	5.15	3.14e-07	3.52e-05	0.19	0.16	Type 2 diabetes;	chr4:103116231	chr4:102751401~102752641:+
BRCA	cis	rs321358	0.945	rs12420595	ENSG00000271390.1	RP11-89C3.3	5.15	3.14e-07	3.52e-05	0.26	0.16	Body mass index;	chr11:111115871	chr11:111089870~111090368:-
BRCA	cis	rs7927592	0.913	rs12363722	ENSG00000212093.1	AP000807.1	5.15	3.14e-07	3.52e-05	0.18	0.16	Total body bone mineral density;	chr11:68468823	chr11:68506083~68506166:-
BRCA	cis	rs7927592	0.871	rs12360903	ENSG00000212093.1	AP000807.1	5.15	3.14e-07	3.52e-05	0.18	0.16	Total body bone mineral density;	chr11:68468846	chr11:68506083~68506166:-
BRCA	cis	rs9307551	0.619	rs998437	ENSG00000250334.4	LINC00989	-5.15	3.14e-07	3.52e-05	-0.21	-0.16	Refractive error;	chr4:79508616	chr4:79492416~79576460:+
BRCA	cis	rs1075265	0.633	rs7591431	ENSG00000235937.1	AC008280.1	5.15	3.14e-07	3.53e-05	0.18	0.16	Chronotype;Morning vs. evening chronotype;	chr2:53995028	chr2:54029552~54030682:-
BRCA	cis	rs9308731	0.563	rs6760053	ENSG00000227992.1	AC108463.2	-5.15	3.15e-07	3.53e-05	-0.18	-0.16	Chronic lymphocytic leukemia;	chr2:111175420	chr2:111203964~111206215:-
BRCA	cis	rs2115630	1	rs8037423	ENSG00000259295.5	CSPG4P12	-5.15	3.15e-07	3.53e-05	-0.19	-0.16	P wave terminal force;	chr15:84812263	chr15:85191438~85213905:+
BRCA	cis	rs11955398	0.502	rs10471502	ENSG00000215032.2	GNL3LP1	5.15	3.15e-07	3.53e-05	0.2	0.16	Intelligence (multi-trait analysis);	chr5:61073256	chr5:60891935~60893577:-
BRCA	cis	rs1552244	1	rs13319597	ENSG00000232901.1	CYCSP10	-5.15	3.15e-07	3.53e-05	-0.22	-0.16	Alzheimer's disease;	chr3:10084628	chr3:10000647~10000940:-
BRCA	cis	rs7226408	0.857	rs72887045	ENSG00000267707.2	RP11-95O2.5	5.15	3.15e-07	3.53e-05	0.24	0.16	Obesity-related traits;	chr18:36901774	chr18:37243776~37247506:+
BRCA	cis	rs4388249	0.578	rs427691	ENSG00000271849.1	CTC-332L22.1	-5.15	3.15e-07	3.53e-05	-0.23	-0.16	Schizophrenia;	chr5:109678809	chr5:109687802~109688329:-
BRCA	cis	rs9369695	0.842	rs9395262	ENSG00000270761.1	RP11-385F7.1	-5.15	3.15e-07	3.53e-05	-0.17	-0.16	Reticulocyte count;	chr6:47497531	chr6:47477243~47477572:-
BRCA	cis	rs4218	0.619	rs10851643	ENSG00000277144.1	RP11-59H7.4	-5.15	3.15e-07	3.54e-05	-0.2	-0.16	Social communication problems;	chr15:59102985	chr15:59115547~59116089:-
BRCA	cis	rs4835473	0.831	rs4452380	ENSG00000249741.2	RP11-673E1.3	-5.15	3.15e-07	3.54e-05	-0.17	-0.16	Immature fraction of reticulocytes;	chr4:143972856	chr4:143911514~143912053:-
BRCA	cis	rs9341808	0.718	rs3805920	ENSG00000272129.1	RP11-250B2.6	5.15	3.15e-07	3.54e-05	0.2	0.16	Sitting height ratio;	chr6:80183028	chr6:80355424~80356859:+
BRCA	cis	rs9287719	0.967	rs10929688	ENSG00000243819.4	RN7SL832P	5.15	3.16e-07	3.54e-05	0.15	0.16	Prostate cancer;	chr2:10616524	chr2:10690344~10692099:+
BRCA	cis	rs2562456	0.92	rs2650784	ENSG00000268658.4	LINC00664	-5.15	3.16e-07	3.54e-05	-0.23	-0.16	Pain;	chr19:21483795	chr19:21483374~21503238:+
BRCA	cis	rs4713118	0.513	rs156738	ENSG00000280107.1	AL022393.9	-5.15	3.16e-07	3.54e-05	-0.22	-0.16	Parkinson's disease;	chr6:28046247	chr6:28170845~28172521:+
BRCA	cis	rs2638953	0.925	rs11049520	ENSG00000278733.1	RP11-425D17.1	-5.15	3.16e-07	3.54e-05	-0.21	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28310656	chr12:28185625~28186190:-
BRCA	cis	rs1555322	1	rs2425037	ENSG00000126005.14	MMP24-AS1	5.15	3.16e-07	3.54e-05	0.26	0.16	Attention deficit hyperactivity disorder;	chr20:35268626	chr20:35216462~35278131:-
BRCA	cis	rs8098244	0.557	rs11082712	ENSG00000264745.1	TTC39C-AS1	5.15	3.16e-07	3.54e-05	0.18	0.16	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23718286	chr18:23994213~24015339:-
BRCA	cis	rs2115630	1	rs6496452	ENSG00000259295.5	CSPG4P12	-5.15	3.16e-07	3.54e-05	-0.19	-0.16	P wave terminal force;	chr15:84829414	chr15:85191438~85213905:+
BRCA	cis	rs13113518	0.812	rs4864543	ENSG00000272969.1	RP11-528I4.2	5.15	3.16e-07	3.54e-05	0.19	0.16	Height;	chr4:55490228	chr4:55547112~55547889:+
BRCA	cis	rs13113518	0.812	rs6825774	ENSG00000272969.1	RP11-528I4.2	5.15	3.16e-07	3.54e-05	0.19	0.16	Height;	chr4:55491150	chr4:55547112~55547889:+
BRCA	cis	rs13113518	0.812	rs3805153	ENSG00000272969.1	RP11-528I4.2	5.15	3.16e-07	3.54e-05	0.19	0.16	Height;	chr4:55493557	chr4:55547112~55547889:+
BRCA	cis	rs10752881	1	rs4593781	ENSG00000224468.3	RP11-181K3.4	-5.15	3.16e-07	3.55e-05	-0.17	-0.16	Colorectal cancer;	chr1:183015848	chr1:183138402~183141282:-
BRCA	cis	rs6847067	1	rs6847067	ENSG00000180769.7	WDFY3-AS2	5.15	3.16e-07	3.55e-05	0.14	0.16	Oropharynx cancer;	chr4:84811016	chr4:84965682~85011277:+
BRCA	cis	rs4713118	0.662	rs9393881	ENSG00000280107.1	AL022393.9	-5.15	3.16e-07	3.55e-05	-0.23	-0.16	Parkinson's disease;	chr6:28055973	chr6:28170845~28172521:+
BRCA	cis	rs1075265	0.744	rs2909460	ENSG00000235937.1	AC008280.1	5.15	3.16e-07	3.55e-05	0.17	0.16	Chronotype;Morning vs. evening chronotype;	chr2:53967611	chr2:54029552~54030682:-
BRCA	cis	rs13113518	1	rs4865011	ENSG00000223305.1	RN7SKP30	5.15	3.16e-07	3.55e-05	0.19	0.16	Height;	chr4:55554456	chr4:55540502~55540835:-
BRCA	cis	rs13108904	0.901	rs6851528	ENSG00000196810.4	CTBP1-AS2	5.15	3.16e-07	3.55e-05	0.17	0.16	Obesity-related traits;	chr4:1302221	chr4:1249300~1288291:+
BRCA	cis	rs11098499	0.754	rs7672372	ENSG00000260404.2	RP11-384K6.6	5.15	3.16e-07	3.55e-05	0.14	0.16	Corneal astigmatism;	chr4:119327251	chr4:118591773~118633729:+
BRCA	cis	rs4934494	0.677	rs11185792	ENSG00000240996.1	RP11-80H5.7	-5.15	3.16e-07	3.55e-05	-0.22	-0.16	Red blood cell count;	chr10:89615210	chr10:89694295~89697928:-
BRCA	cis	rs8177876	0.642	rs12445303	ENSG00000261061.1	RP11-303E16.2	5.15	3.16e-07	3.55e-05	0.19	0.16	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081968	chr16:81030770~81031485:+
BRCA	cis	rs853679	0.546	rs13213152	ENSG00000204709.4	LINC01556	5.15	3.17e-07	3.55e-05	0.43	0.16	Depression;	chr6:28381921	chr6:28943877~28944537:+
BRCA	cis	rs12477438	0.501	rs34272114	ENSG00000231822.1	AC019097.7	5.15	3.17e-07	3.55e-05	0.16	0.16	Chronic sinus infection;	chr2:99120980	chr2:99102018~99102752:+
BRCA	cis	rs2098713	0.569	rs7715951	ENSG00000250155.1	CTD-2353F22.1	5.15	3.17e-07	3.55e-05	0.17	0.16	Telomere length;	chr5:37492108	chr5:36666214~36725195:-
BRCA	cis	rs7914558	1	rs7911789	ENSG00000236937.2	PTGES3P4	5.15	3.17e-07	3.55e-05	0.2	0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102996617	chr10:102845595~102845950:+
BRCA	cis	rs16846053	0.584	rs57840078	ENSG00000227403.1	AC009299.3	5.15	3.17e-07	3.55e-05	0.38	0.16	Blood osmolality (transformed sodium);	chr2:161545949	chr2:161244739~161249050:+
BRCA	cis	rs7226408	0.857	rs10502667	ENSG00000267707.2	RP11-95O2.5	5.15	3.17e-07	3.55e-05	0.24	0.16	Obesity-related traits;	chr18:36902486	chr18:37243776~37247506:+
BRCA	cis	rs2832191	0.791	rs2832197	ENSG00000215533.7	LINC00189	5.15	3.17e-07	3.55e-05	0.18	0.16	Dental caries;	chr21:29125469	chr21:29193480~29288205:+
BRCA	cis	rs2832191	0.791	rs57721945	ENSG00000215533.7	LINC00189	5.15	3.17e-07	3.55e-05	0.18	0.16	Dental caries;	chr21:29126423	chr21:29193480~29288205:+
BRCA	cis	rs7914558	0.966	rs10786727	ENSG00000236937.2	PTGES3P4	5.15	3.17e-07	3.55e-05	0.2	0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102938766	chr10:102845595~102845950:+
BRCA	cis	rs3764021	0.527	rs10772062	ENSG00000214776.8	RP11-726G1.1	5.15	3.17e-07	3.55e-05	0.19	0.16	Type 1 diabetes;	chr12:9712561	chr12:9467552~9576275:+
BRCA	cis	rs115769866	0.609	rs2859356	ENSG00000204709.4	LINC01556	5.15	3.17e-07	3.55e-05	0.23	0.16	Bipolar disorder;	chr6:28497578	chr6:28943877~28944537:+
BRCA	cis	rs2179367	0.959	rs9373589	ENSG00000268592.3	RAET1E-AS1	5.15	3.17e-07	3.56e-05	0.2	0.16	Dupuytren's disease;	chr6:149386152	chr6:149863494~149919507:+
BRCA	cis	rs7577696	0.85	rs428002	ENSG00000272716.1	RP11-563N4.1	5.15	3.17e-07	3.56e-05	0.17	0.16	Inflammatory biomarkers;	chr2:32262705	chr2:32165046~32165757:-
BRCA	cis	rs4819052	0.851	rs2838843	ENSG00000184274.3	LINC00315	-5.15	3.17e-07	3.56e-05	-0.21	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45249369	chr21:45300245~45305257:-
BRCA	cis	rs17213965	0.852	rs4781691	ENSG00000275910.1	RP11-680G24.6	-5.15	3.17e-07	3.56e-05	-0.25	-0.16	Waist-hip ratio;	chr16:15783798	chr16:15015828~15016390:-
BRCA	cis	rs12701220	0.894	rs34712249	ENSG00000229043.2	AC091729.9	-5.15	3.17e-07	3.56e-05	-0.25	-0.16	Bronchopulmonary dysplasia;	chr7:996998	chr7:1160374~1165267:+
BRCA	cis	rs9300255	0.722	rs1060105	ENSG00000235423.7	RP11-282O18.3	-5.15	3.17e-07	3.56e-05	-0.22	-0.16	Neutrophil percentage of white cells;	chr12:123321672	chr12:123252030~123261483:-
BRCA	cis	rs6928977	0.675	rs9399148	ENSG00000234084.1	RP3-388E23.2	5.15	3.17e-07	3.56e-05	0.16	0.16	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135523221	chr6:135301568~135307158:+
BRCA	cis	rs2803122	0.905	rs10123360	ENSG00000273226.1	RP11-513M16.8	-5.15	3.17e-07	3.56e-05	-0.17	-0.16	Pulse pressure;	chr9:19303664	chr9:19375451~19375996:+
BRCA	cis	rs8133949	0.768	rs11701229	ENSG00000237232.6	ZNF295-AS1	5.15	3.17e-07	3.56e-05	0.24	0.16	Hand grip strength;	chr21:42013022	chr21:42009194~42024924:+
BRCA	cis	rs875971	0.964	rs55748098	ENSG00000223473.2	GS1-124K5.3	-5.15	3.17e-07	3.56e-05	-0.12	-0.16	Aortic root size;	chr7:66298631	chr7:66491049~66493566:-
BRCA	cis	rs2832191	0.72	rs2832200	ENSG00000215533.7	LINC00189	5.15	3.18e-07	3.56e-05	0.18	0.16	Dental caries;	chr21:29126844	chr21:29193480~29288205:+
BRCA	cis	rs2832191	0.791	rs28633762	ENSG00000215533.7	LINC00189	5.15	3.18e-07	3.56e-05	0.18	0.16	Dental caries;	chr21:29127749	chr21:29193480~29288205:+
BRCA	cis	rs9545047	0.604	rs1752649	ENSG00000227354.5	RBM26-AS1	5.15	3.18e-07	3.56e-05	0.17	0.16	Schizophrenia;	chr13:79331980	chr13:79406309~79424328:+
BRCA	cis	rs9545047	0.604	rs1749983	ENSG00000227354.5	RBM26-AS1	5.15	3.18e-07	3.56e-05	0.17	0.16	Schizophrenia;	chr13:79332077	chr13:79406309~79424328:+
BRCA	cis	rs9545047	0.567	rs1752648	ENSG00000227354.5	RBM26-AS1	5.15	3.18e-07	3.56e-05	0.17	0.16	Schizophrenia;	chr13:79332124	chr13:79406309~79424328:+
BRCA	cis	rs9545047	0.604	rs1752647	ENSG00000227354.5	RBM26-AS1	5.15	3.18e-07	3.56e-05	0.17	0.16	Schizophrenia;	chr13:79332741	chr13:79406309~79424328:+
BRCA	cis	rs9545047	0.532	rs1752646	ENSG00000227354.5	RBM26-AS1	5.15	3.18e-07	3.56e-05	0.17	0.16	Schizophrenia;	chr13:79332752	chr13:79406309~79424328:+
BRCA	cis	rs9545047	0.604	rs1749988	ENSG00000227354.5	RBM26-AS1	5.15	3.18e-07	3.56e-05	0.17	0.16	Schizophrenia;	chr13:79333103	chr13:79406309~79424328:+
BRCA	cis	rs4835473	0.663	rs1511423	ENSG00000249741.2	RP11-673E1.3	-5.15	3.18e-07	3.56e-05	-0.17	-0.16	Immature fraction of reticulocytes;	chr4:143990136	chr4:143911514~143912053:-
BRCA	cis	rs7204230	1	rs17302707	ENSG00000261291.1	RP11-295M3.2	-5.15	3.18e-07	3.56e-05	-0.2	-0.16	Fibrinogen;	chr16:53177940	chr16:53168522~53169450:+
BRCA	cis	rs7592578	0.771	rs1128723	ENSG00000272979.1	RP11-647K16.1	-5.15	3.18e-07	3.56e-05	-0.27	-0.16	Diastolic blood pressure;	chr2:190501981	chr2:190454092~190454521:-
BRCA	cis	rs1005277	0.579	rs1740737	ENSG00000263064.2	RP11-291L22.7	5.15	3.18e-07	3.56e-05	0.19	0.16	Extrinsic epigenetic age acceleration;	chr10:38210437	chr10:38448689~38448949:+
BRCA	cis	rs3742264	1	rs9316179	ENSG00000235903.6	CPB2-AS1	5.15	3.18e-07	3.57e-05	0.19	0.16	Blood protein levels;	chr13:46067331	chr13:46052806~46113332:+
BRCA	cis	rs7618501	0.633	rs2252833	ENSG00000228008.1	CTD-2330K9.3	5.15	3.18e-07	3.57e-05	0.15	0.16	Intelligence (multi-trait analysis);	chr3:49966776	chr3:49903845~49916937:+
BRCA	cis	rs7474896	0.616	rs2505239	ENSG00000120555.12	SEPT7P9	5.15	3.18e-07	3.57e-05	0.23	0.16	Obesity (extreme);	chr10:38151837	chr10:38383069~38402916:-
BRCA	cis	rs6452524	0.618	rs6452506	ENSG00000281327.1	LINC01338	5.15	3.18e-07	3.57e-05	0.18	0.16	Hypertension (SNP x SNP interaction);	chr5:83075844	chr5:82850864~82859836:-
BRCA	cis	rs4700393	0.542	rs4370226	ENSG00000215032.2	GNL3LP1	5.15	3.18e-07	3.57e-05	0.21	0.16	Intelligence (multi-trait analysis);	chr5:60705295	chr5:60891935~60893577:-
BRCA	cis	rs8040855	0.69	rs8041189	ENSG00000259774.1	RP11-182J1.13	-5.15	3.19e-07	3.57e-05	-0.22	-0.16	Bulimia nervosa;	chr15:85143096	chr15:84422618~84425882:+
BRCA	cis	rs73607972	0.866	rs111763946	ENSG00000275191.1	RP11-36I17.2	-5.15	3.19e-07	3.57e-05	-0.26	-0.16	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53602740	chr16:53628256~53628816:-
BRCA	cis	rs9393692	0.905	rs7450556	ENSG00000241549.7	GUSBP2	-5.15	3.19e-07	3.57e-05	-0.17	-0.16	Educational attainment;	chr6:26299672	chr6:26871484~26956554:-
BRCA	cis	rs300890	0.513	rs4269133	ENSG00000250326.1	RP11-284M14.1	-5.15	3.19e-07	3.57e-05	-0.18	-0.16	Nasopharyngeal carcinoma;	chr4:143125692	chr4:142933195~143184861:-
BRCA	cis	rs1440410	0.52	rs4629391	ENSG00000250326.1	RP11-284M14.1	-5.15	3.19e-07	3.57e-05	-0.18	-0.16	Ischemic stroke;	chr4:143125721	chr4:142933195~143184861:-
BRCA	cis	rs300890	0.513	rs4286475	ENSG00000250326.1	RP11-284M14.1	-5.15	3.19e-07	3.57e-05	-0.18	-0.16	Nasopharyngeal carcinoma;	chr4:143125758	chr4:142933195~143184861:-
BRCA	cis	rs10504130	1	rs12678639	ENSG00000253844.1	RP11-546K22.1	-5.15	3.19e-07	3.57e-05	-0.28	-0.16	Venous thromboembolism (SNP x SNP interaction);	chr8:51918088	chr8:51961458~52022974:+
BRCA	cis	rs3743162	1	rs12917429	ENSG00000259728.4	LINC00933	-5.15	3.19e-07	3.57e-05	-0.23	-0.16	Alzheimer's disease (age of onset);	chr15:84881866	chr15:84570649~84580175:+
BRCA	cis	rs13108904	0.901	rs12509700	ENSG00000196810.4	CTBP1-AS2	5.15	3.19e-07	3.58e-05	0.17	0.16	Obesity-related traits;	chr4:1302533	chr4:1249300~1288291:+
BRCA	cis	rs4218	0.648	rs8042896	ENSG00000277144.1	RP11-59H7.4	-5.15	3.19e-07	3.58e-05	-0.21	-0.16	Social communication problems;	chr15:59067727	chr15:59115547~59116089:-
BRCA	cis	rs6991838	0.806	rs17302392	ENSG00000272010.1	CTD-3025N20.3	5.15	3.19e-07	3.58e-05	0.17	0.16	Intelligence (multi-trait analysis);	chr8:65551073	chr8:65591850~65592472:-
BRCA	cis	rs11105298	0.891	rs8181784	ENSG00000270344.2	RP11-734K2.4	5.15	3.19e-07	3.58e-05	0.17	0.16	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89434814	chr12:89525654~89548005:+
BRCA	cis	rs4908768	0.539	rs11121205	ENSG00000232912.4	RP5-1115A15.1	5.15	3.19e-07	3.58e-05	0.15	0.16	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8598026	chr1:8424645~8434838:+
BRCA	cis	rs5758511	0.68	rs5758692	ENSG00000233903.2	Z83851.4	5.15	3.19e-07	3.58e-05	0.24	0.16	Birth weight;	chr22:42273023	chr22:42276355~42277052:+
BRCA	cis	rs62025270	0.593	rs62022926	ENSG00000259762.1	RP11-158M2.4	-5.15	3.2e-07	3.58e-05	-0.24	-0.16	Idiopathic pulmonary fibrosis;	chr15:85696261	chr15:85750336~85752901:-
BRCA	cis	rs1387259	0.929	rs2956703	ENSG00000226413.2	OR8T1P	5.14	3.2e-07	3.58e-05	0.21	0.16	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48276511	chr12:48442030~48442947:-
BRCA	cis	rs7226408	0.857	rs10502666	ENSG00000267707.2	RP11-95O2.5	5.14	3.2e-07	3.58e-05	0.24	0.16	Obesity-related traits;	chr18:36843430	chr18:37243776~37247506:+
BRCA	cis	rs523522	0.962	rs4767904	ENSG00000278344.1	RP11-18C24.8	5.14	3.2e-07	3.58e-05	0.21	0.16	High light scatter reticulocyte count;	chr12:120492995	chr12:120500735~120501090:-
BRCA	cis	rs2115630	0.967	rs11073731	ENSG00000259295.5	CSPG4P12	-5.14	3.2e-07	3.58e-05	-0.19	-0.16	P wave terminal force;	chr15:84811882	chr15:85191438~85213905:+
BRCA	cis	rs7200543	1	rs14347	ENSG00000260735.1	RP11-72I8.1	-5.14	3.2e-07	3.59e-05	-0.19	-0.16	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15040032	chr16:15094411~15109197:+
BRCA	cis	rs2732480	0.5	rs7966829	ENSG00000240399.1	RP1-228P16.1	5.14	3.2e-07	3.59e-05	0.18	0.16	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48221820	chr12:48054813~48055591:-
BRCA	cis	rs2115536	0.73	rs4573897	ENSG00000278600.1	RP11-81A1.6	-5.14	3.2e-07	3.59e-05	-0.14	-0.16	Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Eosinophil counts;Neutrophil percentage of granulocytes;	chr15:79894883	chr15:79920195~79922455:-
BRCA	cis	rs7487075	0.578	rs11183486	ENSG00000274723.1	RP11-618L22.1	5.14	3.2e-07	3.59e-05	0.19	0.16	Itch intensity from mosquito bite;	chr12:46443921	chr12:46970504~46972155:+
BRCA	cis	rs9287719	0.967	rs6744599	ENSG00000243819.4	RN7SL832P	-5.14	3.21e-07	3.59e-05	-0.15	-0.16	Prostate cancer;	chr2:10606887	chr2:10690344~10692099:+
BRCA	cis	rs922692	0.744	rs12899147	ENSG00000261143.1	ADAMTS7P3	5.14	3.21e-07	3.59e-05	0.2	0.16	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78787170	chr15:77976042~77993057:+
BRCA	cis	rs6832769	1	rs6834676	ENSG00000223305.1	RN7SKP30	5.14	3.21e-07	3.59e-05	0.2	0.16	Personality dimensions;	chr4:55432247	chr4:55540502~55540835:-
BRCA	cis	rs853679	0.517	rs9283884	ENSG00000204709.4	LINC01556	-5.14	3.21e-07	3.59e-05	-0.23	-0.16	Depression;	chr6:28167882	chr6:28943877~28944537:+
BRCA	cis	rs950880	0.699	rs1882348	ENSG00000234389.1	AC007278.3	-5.14	3.21e-07	3.59e-05	-0.15	-0.16	Serum protein levels (sST2);	chr2:102368211	chr2:102438713~102440475:+
BRCA	cis	rs4835473	0.932	rs1849118	ENSG00000249741.2	RP11-673E1.3	-5.14	3.21e-07	3.59e-05	-0.17	-0.16	Immature fraction of reticulocytes;	chr4:143989822	chr4:143911514~143912053:-
BRCA	cis	rs13326165	0.585	rs56322342	ENSG00000243224.1	RP5-1157M23.2	-5.14	3.21e-07	3.59e-05	-0.25	-0.16	HDL cholesterol levels;HDL cholesterol;	chr3:52398594	chr3:52239258~52241097:+
BRCA	cis	rs55966801	0.68	rs6541	ENSG00000277290.1	RP11-326C3.16	-5.14	3.21e-07	3.6e-05	-0.19	-0.16	Plateletcrit;	chr11:252851	chr11:243099~243483:-
BRCA	cis	rs3733585	0.699	rs7686538	ENSG00000250413.1	RP11-448G15.1	5.14	3.21e-07	3.6e-05	0.2	0.16	Cleft plate (environmental tobacco smoke interaction);	chr4:9946453	chr4:10006482~10009725:+
BRCA	cis	rs6044112	0.56	rs112026770	ENSG00000273998.1	RP4-777L9.2	5.14	3.21e-07	3.6e-05	0.33	0.16	Response to taxane treatment (docetaxel);	chr20:16581461	chr20:16576068~16579615:+
BRCA	cis	rs7618501	0.633	rs2883057	ENSG00000228008.1	CTD-2330K9.3	5.14	3.22e-07	3.6e-05	0.15	0.16	Intelligence (multi-trait analysis);	chr3:49960849	chr3:49903845~49916937:+
BRCA	cis	rs9311474	0.508	rs4687546	ENSG00000243224.1	RP5-1157M23.2	-5.14	3.22e-07	3.6e-05	-0.17	-0.16	Electroencephalogram traits;	chr3:52571927	chr3:52239258~52241097:+
BRCA	cis	rs9311474	0.508	rs11718420	ENSG00000243224.1	RP5-1157M23.2	-5.14	3.22e-07	3.6e-05	-0.17	-0.16	Electroencephalogram traits;	chr3:52577397	chr3:52239258~52241097:+
BRCA	cis	rs2281636	0.792	rs10883385	ENSG00000233690.1	EBAG9P1	5.14	3.22e-07	3.6e-05	0.17	0.16	Obesity-related traits;	chr10:99621956	chr10:99697407~99697949:-
BRCA	cis	rs9311474	0.508	rs6788887	ENSG00000243224.1	RP5-1157M23.2	-5.14	3.22e-07	3.6e-05	-0.17	-0.16	Electroencephalogram traits;	chr3:52570989	chr3:52239258~52241097:+
BRCA	cis	rs523522	1	rs1563333	ENSG00000278344.1	RP11-18C24.8	5.14	3.22e-07	3.6e-05	0.21	0.16	High light scatter reticulocyte count;	chr12:120496604	chr12:120500735~120501090:-
BRCA	cis	rs6832769	1	rs726967	ENSG00000223305.1	RN7SKP30	-5.14	3.22e-07	3.61e-05	-0.2	-0.16	Personality dimensions;	chr4:55555546	chr4:55540502~55540835:-
BRCA	cis	rs6545883	0.503	rs1665272	ENSG00000212978.6	AC016747.3	5.14	3.22e-07	3.61e-05	0.2	0.16	Tuberculosis;	chr2:61152151	chr2:61141592~61144969:-
BRCA	cis	rs17508449	0.602	rs3789608	ENSG00000232450.1	RP4-730K3.3	-5.14	3.22e-07	3.61e-05	-0.25	-0.16	Leprosy;	chr1:113855166	chr1:113698884~113699631:-
BRCA	cis	rs17508449	0.547	rs55646484	ENSG00000232450.1	RP4-730K3.3	-5.14	3.22e-07	3.61e-05	-0.25	-0.16	Leprosy;	chr1:113856152	chr1:113698884~113699631:-
BRCA	cis	rs17508449	0.547	rs35173468	ENSG00000232450.1	RP4-730K3.3	-5.14	3.22e-07	3.61e-05	-0.25	-0.16	Leprosy;	chr1:113856199	chr1:113698884~113699631:-
BRCA	cis	rs7845219	0.506	rs12548999	ENSG00000253528.2	RP11-347C18.4	5.14	3.22e-07	3.61e-05	0.17	0.16	Type 2 diabetes;	chr8:94917615	chr8:94974573~94974853:-
BRCA	cis	rs1075265	0.84	rs805309	ENSG00000235937.1	AC008280.1	5.14	3.23e-07	3.61e-05	0.17	0.16	Chronotype;Morning vs. evening chronotype;	chr2:53968877	chr2:54029552~54030682:-
BRCA	cis	rs35740288	1	rs11637212	ENSG00000259407.1	RP11-158M2.3	5.14	3.23e-07	3.61e-05	0.21	0.16	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85749866	chr15:85744109~85750281:-
BRCA	cis	rs2562456	0.833	rs55920089	ENSG00000268081.1	RP11-678G14.2	5.14	3.23e-07	3.61e-05	0.25	0.16	Pain;	chr19:21337891	chr19:21554640~21569237:-
BRCA	cis	rs12497850	0.864	rs4513485	ENSG00000225399.4	RP11-3B7.1	5.14	3.23e-07	3.61e-05	0.15	0.16	Parkinson's disease;	chr3:49102533	chr3:49260085~49261316:+
BRCA	cis	rs12612619	0.579	rs4552148	ENSG00000272148.1	RP11-195B17.1	-5.14	3.23e-07	3.61e-05	-0.18	-0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:26857645	chr2:27062428~27062907:-
BRCA	cis	rs919433	0.713	rs11900232	ENSG00000231621.1	AC013264.2	-5.14	3.23e-07	3.62e-05	-0.15	-0.16	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197601549	chr2:197197991~197199273:+
BRCA	cis	rs6832769	1	rs35767091	ENSG00000272969.1	RP11-528I4.2	5.14	3.23e-07	3.62e-05	0.19	0.16	Personality dimensions;	chr4:55480556	chr4:55547112~55547889:+
BRCA	cis	rs6840360	0.642	rs2724568	ENSG00000278978.1	RP11-164P12.5	-5.14	3.23e-07	3.62e-05	-0.17	-0.16	Intelligence (multi-trait analysis);	chr4:151431071	chr4:151669786~151670503:+
BRCA	cis	rs617791	0.569	rs11227370	ENSG00000255320.1	RP11-755F10.1	5.14	3.23e-07	3.62e-05	0.21	0.16	Breast cancer;	chr11:65980222	chr11:66244840~66246239:-
BRCA	cis	rs962856	0.964	rs12473253	ENSG00000236780.4	AC078941.1	5.14	3.23e-07	3.62e-05	0.2	0.16	Pancreatic cancer;	chr2:67419189	chr2:67123357~67215319:-
BRCA	cis	rs2032366	0.606	rs7226896	ENSG00000267279.1	RP11-879F14.2	-5.14	3.23e-07	3.62e-05	-0.21	-0.16	Obesity-related traits;	chr18:61608946	chr18:61585746~61606916:-
BRCA	cis	rs10752881	1	rs10797800	ENSG00000224468.3	RP11-181K3.4	-5.14	3.24e-07	3.62e-05	-0.17	-0.16	Colorectal cancer;	chr1:183000693	chr1:183138402~183141282:-
BRCA	cis	rs2562456	0.833	rs56187954	ENSG00000268081.1	RP11-678G14.2	5.14	3.24e-07	3.62e-05	0.25	0.16	Pain;	chr19:21345258	chr19:21554640~21569237:-
BRCA	cis	rs1005277	0.579	rs1780130	ENSG00000263064.2	RP11-291L22.7	5.14	3.24e-07	3.62e-05	0.19	0.16	Extrinsic epigenetic age acceleration;	chr10:38196450	chr10:38448689~38448949:+
BRCA	cis	rs8133949	0.768	rs7278794	ENSG00000237232.6	ZNF295-AS1	5.14	3.24e-07	3.62e-05	0.24	0.16	Hand grip strength;	chr21:42012145	chr21:42009194~42024924:+
BRCA	cis	rs17495987	0.75	rs73061256	ENSG00000219545.8	UMAD1	5.14	3.24e-07	3.63e-05	0.22	0.16	Tonsillectomy;	chr7:7867012	chr7:7640711~8004059:+
BRCA	cis	rs1075265	0.636	rs2193683	ENSG00000235937.1	AC008280.1	5.14	3.24e-07	3.63e-05	0.18	0.16	Chronotype;Morning vs. evening chronotype;	chr2:53695319	chr2:54029552~54030682:-
BRCA	cis	rs9880211	0.563	rs6793835	ENSG00000239213.4	NCK1-AS1	-5.14	3.24e-07	3.63e-05	-0.2	-0.16	Height;Body mass index;	chr3:136101092	chr3:136841726~136862054:-
BRCA	cis	rs10752881	1	rs4304541	ENSG00000224468.3	RP11-181K3.4	-5.14	3.24e-07	3.63e-05	-0.17	-0.16	Colorectal cancer;	chr1:183001103	chr1:183138402~183141282:-
BRCA	cis	rs13113518	0.966	rs4864544	ENSG00000223305.1	RN7SKP30	5.14	3.24e-07	3.63e-05	0.19	0.16	Height;	chr4:55515292	chr4:55540502~55540835:-
BRCA	cis	rs12612619	0.579	rs13029206	ENSG00000272148.1	RP11-195B17.1	-5.14	3.24e-07	3.63e-05	-0.18	-0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:26854742	chr2:27062428~27062907:-
BRCA	cis	rs7914558	0.966	rs10883805	ENSG00000236937.2	PTGES3P4	5.14	3.24e-07	3.63e-05	0.2	0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102948494	chr10:102845595~102845950:+
BRCA	cis	rs7914558	0.933	rs10786729	ENSG00000236937.2	PTGES3P4	5.14	3.24e-07	3.63e-05	0.2	0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102959621	chr10:102845595~102845950:+
BRCA	cis	rs3733585	0.631	rs4697707	ENSG00000250413.1	RP11-448G15.1	5.14	3.25e-07	3.63e-05	0.21	0.16	Cleft plate (environmental tobacco smoke interaction);	chr4:10118163	chr4:10006482~10009725:+
BRCA	cis	rs2708977	0.73	rs674920	ENSG00000237510.6	AC008268.2	-5.14	3.25e-07	3.63e-05	-0.21	-0.16	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96404418	chr2:95789654~95800166:+
BRCA	cis	rs1193	0.77	rs6731890	ENSG00000231259.4	AC125232.1	-5.14	3.25e-07	3.63e-05	-0.19	-0.16	High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;High light scatter reticulocyte count;	chr2:86748042	chr2:87031815~87053069:-
BRCA	cis	rs9467773	1	rs6932156	ENSG00000241549.7	GUSBP2	5.14	3.25e-07	3.63e-05	0.17	0.16	Intelligence (multi-trait analysis);	chr6:26571278	chr6:26871484~26956554:-
BRCA	cis	rs9467773	1	rs6924838	ENSG00000241549.7	GUSBP2	5.14	3.25e-07	3.63e-05	0.17	0.16	Intelligence (multi-trait analysis);	chr6:26571528	chr6:26871484~26956554:-
BRCA	cis	rs6479901	0.895	rs907	ENSG00000232075.1	MRPL35P2	-5.14	3.25e-07	3.63e-05	-0.22	-0.16	Intelligence (multi-trait analysis);	chr10:63176919	chr10:63634317~63634827:-
BRCA	cis	rs2235642	0.653	rs7197288	ENSG00000280231.1	LA16c-380F5.3	-5.14	3.25e-07	3.63e-05	-0.21	-0.16	Coronary artery disease;	chr16:1604752	chr16:1553655~1554130:-
BRCA	cis	rs8040855	0.657	rs6496733	ENSG00000259774.1	RP11-182J1.13	-5.14	3.25e-07	3.63e-05	-0.21	-0.16	Bulimia nervosa;	chr15:85129945	chr15:84422618~84425882:+
BRCA	cis	rs11098499	0.535	rs7671759	ENSG00000260404.2	RP11-384K6.6	5.14	3.25e-07	3.63e-05	0.15	0.16	Corneal astigmatism;	chr4:119326939	chr4:118591773~118633729:+
BRCA	cis	rs9467773	1	rs6925895	ENSG00000241549.7	GUSBP2	5.14	3.25e-07	3.63e-05	0.17	0.16	Intelligence (multi-trait analysis);	chr6:26571937	chr6:26871484~26956554:-
BRCA	cis	rs6490294	0.904	rs12423126	ENSG00000226469.1	ADAM1B	5.14	3.25e-07	3.63e-05	0.21	0.16	Mean platelet volume;	chr12:111991665	chr12:111927018~111929017:+
BRCA	cis	rs9311474	0.508	rs11714565	ENSG00000243224.1	RP5-1157M23.2	-5.14	3.25e-07	3.63e-05	-0.17	-0.16	Electroencephalogram traits;	chr3:52572276	chr3:52239258~52241097:+
BRCA	cis	rs875971	0.862	rs10276077	ENSG00000236529.1	RP13-254B10.1	-5.14	3.25e-07	3.64e-05	-0.17	-0.16	Aortic root size;	chr7:66263424	chr7:65840212~65840596:+
BRCA	cis	rs6480314	0.542	rs4403687	ENSG00000233590.1	RP11-153K11.3	-5.14	3.25e-07	3.64e-05	-0.26	-0.16	Optic nerve measurement (disc area);	chr10:68268295	chr10:68233251~68242379:-
BRCA	cis	rs4218	0.573	rs4775115	ENSG00000277144.1	RP11-59H7.4	-5.14	3.25e-07	3.64e-05	-0.2	-0.16	Social communication problems;	chr15:59076311	chr15:59115547~59116089:-
BRCA	cis	rs2073316	0.592	rs11679875	ENSG00000272716.1	RP11-563N4.1	5.14	3.25e-07	3.64e-05	0.17	0.16	Interleukin-18 levels;	chr2:31484188	chr2:32165046~32165757:-
BRCA	cis	rs6442522	0.606	rs2345105	ENSG00000249786.6	EAF1-AS1	5.14	3.25e-07	3.64e-05	0.16	0.16	Uric acid levels;	chr3:15454257	chr3:15436171~15455940:-
BRCA	cis	rs801193	0.569	rs881285	ENSG00000273448.1	RP11-166O4.6	-5.14	3.25e-07	3.64e-05	-0.15	-0.16	Aortic root size;	chr7:66654433	chr7:67333047~67334383:+
BRCA	cis	rs9467773	1	rs1535277	ENSG00000241549.7	GUSBP2	5.14	3.25e-07	3.64e-05	0.17	0.16	Intelligence (multi-trait analysis);	chr6:26567574	chr6:26871484~26956554:-
BRCA	cis	rs9467773	1	rs1884948	ENSG00000241549.7	GUSBP2	5.14	3.25e-07	3.64e-05	0.17	0.16	Intelligence (multi-trait analysis);	chr6:26567760	chr6:26871484~26956554:-
BRCA	cis	rs9467773	1	rs1884949	ENSG00000241549.7	GUSBP2	5.14	3.25e-07	3.64e-05	0.17	0.16	Intelligence (multi-trait analysis);	chr6:26567839	chr6:26871484~26956554:-
BRCA	cis	rs9467773	1	rs9467796	ENSG00000241549.7	GUSBP2	5.14	3.25e-07	3.64e-05	0.17	0.16	Intelligence (multi-trait analysis);	chr6:26568183	chr6:26871484~26956554:-
BRCA	cis	rs9467773	1	rs9467797	ENSG00000241549.7	GUSBP2	5.14	3.25e-07	3.64e-05	0.17	0.16	Intelligence (multi-trait analysis);	chr6:26568245	chr6:26871484~26956554:-
BRCA	cis	rs9467773	1	rs1078679	ENSG00000241549.7	GUSBP2	5.14	3.25e-07	3.64e-05	0.17	0.16	Intelligence (multi-trait analysis);	chr6:26568513	chr6:26871484~26956554:-
BRCA	cis	rs710913	0.738	rs755247	ENSG00000228060.1	RP11-69E11.8	5.14	3.26e-07	3.64e-05	0.15	0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39528873	chr1:39565160~39573203:+
BRCA	cis	rs17685	0.753	rs10245584	ENSG00000280388.1	RP11-229D13.3	-5.14	3.26e-07	3.64e-05	-0.16	-0.16	Coffee consumption (cups per day);Coffee consumption;	chr7:76116548	chr7:76043977~76045963:-
BRCA	cis	rs1707322	1	rs11211228	ENSG00000234329.1	RP11-767N6.2	5.14	3.26e-07	3.64e-05	0.16	0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45934168	chr1:45651039~45651826:-
BRCA	cis	rs1707322	0.963	rs11211229	ENSG00000234329.1	RP11-767N6.2	5.14	3.26e-07	3.64e-05	0.16	0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45934845	chr1:45651039~45651826:-
BRCA	cis	rs1707322	1	rs9803784	ENSG00000234329.1	RP11-767N6.2	5.14	3.26e-07	3.64e-05	0.16	0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45936235	chr1:45651039~45651826:-
BRCA	cis	rs6088813	0.845	rs2378349	ENSG00000126005.14	MMP24-AS1	-5.14	3.26e-07	3.64e-05	-0.19	-0.16	Height;	chr20:35338040	chr20:35216462~35278131:-
BRCA	cis	rs736408	0.54	rs4687637	ENSG00000243224.1	RP5-1157M23.2	-5.14	3.26e-07	3.64e-05	-0.17	-0.16	Bipolar disorder;	chr3:52600076	chr3:52239258~52241097:+
BRCA	cis	rs78487399	0.908	rs72868636	ENSG00000234936.1	AC010883.5	5.14	3.26e-07	3.65e-05	0.21	0.16	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43611377	chr2:43229573~43233394:+
BRCA	cis	rs2522056	1	rs886286	ENSG00000233006.5	AC034220.3	-5.14	3.26e-07	3.65e-05	-0.13	-0.16	Fibrinogen;Lymphocyte counts;	chr5:132459905	chr5:132311285~132369916:-
BRCA	cis	rs2522056	1	rs757105	ENSG00000233006.5	AC034220.3	-5.14	3.26e-07	3.65e-05	-0.13	-0.16	Fibrinogen;Lymphocyte counts;	chr5:132459971	chr5:132311285~132369916:-
BRCA	cis	rs2522056	1	rs2706393	ENSG00000233006.5	AC034220.3	-5.14	3.26e-07	3.65e-05	-0.13	-0.16	Fibrinogen;Lymphocyte counts;	chr5:132460375	chr5:132311285~132369916:-
BRCA	cis	rs8180040	0.966	rs56351005	ENSG00000276925.1	RP11-708J19.3	5.14	3.26e-07	3.65e-05	0.18	0.16	Colorectal cancer;	chr3:47388696	chr3:47469777~47469987:+
BRCA	cis	rs2179367	0.919	rs577001	ENSG00000268592.3	RAET1E-AS1	5.14	3.26e-07	3.65e-05	0.2	0.16	Dupuytren's disease;	chr6:149325172	chr6:149863494~149919507:+
BRCA	cis	rs17772222	0.74	rs3783885	ENSG00000258789.1	RP11-507K2.3	-5.14	3.27e-07	3.65e-05	-0.18	-0.16	Coronary artery calcification;	chr14:88510714	chr14:88551597~88552493:+
BRCA	cis	rs17772222	0.74	rs11159857	ENSG00000258789.1	RP11-507K2.3	-5.14	3.27e-07	3.65e-05	-0.18	-0.16	Coronary artery calcification;	chr14:88510796	chr14:88551597~88552493:+
BRCA	cis	rs17772222	0.74	rs4594187	ENSG00000258789.1	RP11-507K2.3	-5.14	3.27e-07	3.65e-05	-0.18	-0.16	Coronary artery calcification;	chr14:88511071	chr14:88551597~88552493:+
BRCA	cis	rs17772222	0.74	rs4514599	ENSG00000258789.1	RP11-507K2.3	-5.14	3.27e-07	3.65e-05	-0.18	-0.16	Coronary artery calcification;	chr14:88511083	chr14:88551597~88552493:+
BRCA	cis	rs17772222	0.74	rs61975276	ENSG00000258789.1	RP11-507K2.3	-5.14	3.27e-07	3.65e-05	-0.18	-0.16	Coronary artery calcification;	chr14:88511193	chr14:88551597~88552493:+
BRCA	cis	rs17772222	0.74	rs61975277	ENSG00000258789.1	RP11-507K2.3	-5.14	3.27e-07	3.65e-05	-0.18	-0.16	Coronary artery calcification;	chr14:88511202	chr14:88551597~88552493:+
BRCA	cis	rs10510102	0.872	rs12264046	ENSG00000226864.1	ATE1-AS1	5.14	3.27e-07	3.65e-05	0.29	0.16	Breast cancer;	chr10:121894996	chr10:121928312~121951965:+
BRCA	cis	rs370915	0.549	rs1367933	ENSG00000250971.1	RP11-696F12.1	5.14	3.27e-07	3.65e-05	0.17	0.16	Gout;	chr4:186855437	chr4:187060099~187060930:+
BRCA	cis	rs7209700	0.742	rs7217710	ENSG00000228782.6	CTD-2026D20.3	5.14	3.27e-07	3.65e-05	0.19	0.16	IgG glycosylation;	chr17:47293216	chr17:47450568~47492492:-
BRCA	cis	rs893818	0.832	rs893817	ENSG00000261801.4	LOXL1-AS1	-5.14	3.27e-07	3.66e-05	-0.19	-0.16	Exfoliation glaucoma or exfoliation syndrome;	chr15:73936724	chr15:73908071~73928248:-
BRCA	cis	rs9473147	0.843	rs12202615	ENSG00000270761.1	RP11-385F7.1	-5.14	3.27e-07	3.66e-05	-0.17	-0.16	Platelet distribution width;Mean platelet volume;	chr6:47650435	chr6:47477243~47477572:-
BRCA	cis	rs6772849	0.896	rs61112519	ENSG00000242551.2	POU5F1P6	-5.14	3.27e-07	3.66e-05	-0.2	-0.16	Monocyte percentage of white cells;Monocyte count;	chr3:128619333	chr3:128674735~128677005:-
BRCA	cis	rs8180040	0.966	rs1872164	ENSG00000276925.1	RP11-708J19.3	5.14	3.28e-07	3.66e-05	0.18	0.16	Colorectal cancer;	chr3:47373610	chr3:47469777~47469987:+
BRCA	cis	rs9307551	0.619	rs1074134	ENSG00000250334.4	LINC00989	-5.14	3.28e-07	3.66e-05	-0.21	-0.16	Refractive error;	chr4:79503752	chr4:79492416~79576460:+
BRCA	cis	rs7818688	1	rs10110635	ENSG00000253528.2	RP11-347C18.4	-5.14	3.28e-07	3.66e-05	-0.24	-0.16	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95012841	chr8:94974573~94974853:-
BRCA	cis	rs10924970	0.601	rs2803847	ENSG00000230026.2	RP11-382D8.5	-5.14	3.28e-07	3.66e-05	-0.18	-0.16	Asthma;	chr1:235340296	chr1:235361153~235362540:+
BRCA	cis	rs4713118	0.588	rs200994	ENSG00000216901.1	AL022393.7	-5.14	3.28e-07	3.67e-05	-0.22	-0.16	Parkinson's disease;	chr6:27846035	chr6:28176188~28176674:+
BRCA	cis	rs2243480	1	rs4718269	ENSG00000232559.3	GS1-124K5.12	-5.14	3.28e-07	3.67e-05	-0.29	-0.16	Diabetic kidney disease;	chr7:65735810	chr7:66554588~66576923:-
BRCA	cis	rs8098244	0.964	rs8086359	ENSG00000264745.1	TTC39C-AS1	5.14	3.28e-07	3.67e-05	0.22	0.16	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23849607	chr18:23994213~24015339:-
BRCA	cis	rs2115630	0.691	rs2292462	ENSG00000259295.5	CSPG4P12	-5.14	3.29e-07	3.67e-05	-0.19	-0.16	P wave terminal force;	chr15:84657523	chr15:85191438~85213905:+
BRCA	cis	rs3758911	0.713	rs11212100	ENSG00000255353.1	RP11-382M14.1	-5.14	3.29e-07	3.67e-05	-0.2	-0.16	Coronary artery disease;	chr11:107253418	chr11:107176286~107177530:+
BRCA	cis	rs2179367	0.586	rs62426088	ENSG00000268592.3	RAET1E-AS1	5.14	3.29e-07	3.67e-05	0.23	0.16	Dupuytren's disease;	chr6:149339301	chr6:149863494~149919507:+
BRCA	cis	rs875971	0.862	rs6955837	ENSG00000273448.1	RP11-166O4.6	-5.14	3.29e-07	3.67e-05	-0.15	-0.16	Aortic root size;	chr7:66578155	chr7:67333047~67334383:+
BRCA	cis	rs6832769	0.89	rs564762	ENSG00000223305.1	RN7SKP30	5.14	3.29e-07	3.67e-05	0.19	0.16	Personality dimensions;	chr4:55418464	chr4:55540502~55540835:-
BRCA	cis	rs10911232	0.507	rs4651138	ENSG00000224468.3	RP11-181K3.4	-5.14	3.29e-07	3.68e-05	-0.17	-0.16	Hypertriglyceridemia;	chr1:183032177	chr1:183138402~183141282:-
BRCA	cis	rs957448	0.554	rs72674877	ENSG00000253175.1	RP11-267M23.6	5.14	3.29e-07	3.68e-05	0.18	0.16	Nonsyndromic cleft lip with cleft palate;	chr8:94580479	chr8:94565036~94565715:+
BRCA	cis	rs7618915	0.524	rs2028216	ENSG00000243224.1	RP5-1157M23.2	-5.14	3.29e-07	3.68e-05	-0.18	-0.16	Bipolar disorder;	chr3:52646807	chr3:52239258~52241097:+
BRCA	cis	rs10129255	0.872	rs8015406	ENSG00000224373.3	IGHV4-59	5.14	3.3e-07	3.68e-05	0.1	0.16	Kawasaki disease;	chr14:106670611	chr14:106627249~106627825:-
BRCA	cis	rs9425766	0.64	rs9425756	ENSG00000200674.1	RN7SKP160	5.14	3.3e-07	3.68e-05	0.23	0.16	Life satisfaction;	chr1:173847448	chr1:173791548~173791887:+
BRCA	cis	rs2179367	0.632	rs9498334	ENSG00000268592.3	RAET1E-AS1	5.14	3.3e-07	3.68e-05	0.23	0.16	Dupuytren's disease;	chr6:149370902	chr6:149863494~149919507:+
BRCA	cis	rs6496044	0.547	rs8039929	ENSG00000259295.5	CSPG4P12	5.14	3.3e-07	3.68e-05	0.19	0.16	Interstitial lung disease;	chr15:85537731	chr15:85191438~85213905:+
BRCA	cis	rs9473147	0.516	rs7754971	ENSG00000270761.1	RP11-385F7.1	-5.14	3.3e-07	3.69e-05	-0.17	-0.16	Platelet distribution width;Mean platelet volume;	chr6:47622740	chr6:47477243~47477572:-
BRCA	cis	rs603446	1	rs1145208	ENSG00000254851.1	RP11-109L13.1	-5.14	3.3e-07	3.69e-05	-0.19	-0.16	Triglycerides;	chr11:116767269	chr11:117135528~117138582:+
BRCA	cis	rs875971	0.54	rs736270	ENSG00000273024.4	INTS4P2	-5.14	3.3e-07	3.69e-05	-0.17	-0.16	Aortic root size;	chr7:65963835	chr7:65647864~65715661:+
BRCA	cis	rs10844706	0.699	rs10844632	ENSG00000214776.8	RP11-726G1.1	5.14	3.3e-07	3.69e-05	0.19	0.16	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9734309	chr12:9467552~9576275:+
BRCA	cis	rs7221109	1	rs7221109	ENSG00000278834.1	RP11-458J1.1	5.14	3.3e-07	3.69e-05	0.17	0.16	Type 1 diabetes;	chr17:40614034	chr17:40648300~40649718:+
BRCA	cis	rs9308731	0.505	rs10169613	ENSG00000227992.1	AC108463.2	-5.14	3.31e-07	3.69e-05	-0.18	-0.16	Chronic lymphocytic leukemia;	chr2:111177400	chr2:111203964~111206215:-
BRCA	cis	rs860295	0.557	rs11264371	ENSG00000160766.13	GBAP1	-5.14	3.31e-07	3.69e-05	-0.17	-0.16	Body mass index;	chr1:155442246	chr1:155213821~155227422:-
BRCA	cis	rs2803122	0.905	rs2772401	ENSG00000273226.1	RP11-513M16.8	5.14	3.31e-07	3.7e-05	0.17	0.16	Pulse pressure;	chr9:19322933	chr9:19375451~19375996:+
BRCA	cis	rs13113518	1	rs6838882	ENSG00000223305.1	RN7SKP30	5.14	3.31e-07	3.7e-05	0.19	0.16	Height;	chr4:55489310	chr4:55540502~55540835:-
BRCA	cis	rs755249	0.565	rs7539279	ENSG00000237624.1	OXCT2P1	-5.14	3.31e-07	3.7e-05	-0.19	-0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39584896	chr1:39514956~39516490:+
BRCA	cis	rs2832191	1	rs8131214	ENSG00000215533.7	LINC00189	5.14	3.31e-07	3.7e-05	0.18	0.16	Dental caries;	chr21:29111065	chr21:29193480~29288205:+
BRCA	cis	rs416603	0.901	rs149597	ENSG00000262636.1	CTD-3088G3.4	-5.14	3.31e-07	3.7e-05	-0.21	-0.16	Type 1 diabetes;	chr16:11250085	chr16:11380859~11381118:-
BRCA	cis	rs2412819	0.571	rs12443084	ENSG00000166763.7	STRCP1	-5.14	3.31e-07	3.7e-05	-0.22	-0.16	Lung cancer;	chr15:43748767	chr15:43699488~43718184:-
BRCA	cis	rs7569084	0.687	rs934731	ENSG00000281920.1	RP11-418H16.1	5.14	3.31e-07	3.7e-05	0.2	0.16	Sum eosinophil basophil counts;	chr2:65456353	chr2:65623272~65628424:+
BRCA	cis	rs13126694	0.744	rs6843728	ENSG00000251429.1	RP11-597D13.7	-5.14	3.31e-07	3.7e-05	-0.15	-0.16	Blood osmolality (transformed sodium);	chr4:158093947	chr4:158270378~158278676:+
BRCA	cis	rs7572733	0.534	rs734037	ENSG00000231621.1	AC013264.2	-5.14	3.32e-07	3.7e-05	-0.16	-0.16	Dermatomyositis;	chr2:197884545	chr2:197197991~197199273:+
BRCA	cis	rs7572733	0.555	rs13395030	ENSG00000231621.1	AC013264.2	-5.14	3.32e-07	3.7e-05	-0.16	-0.16	Dermatomyositis;	chr2:197886082	chr2:197197991~197199273:+
BRCA	cis	rs7572733	0.534	rs2060488	ENSG00000231621.1	AC013264.2	-5.14	3.32e-07	3.7e-05	-0.16	-0.16	Dermatomyositis;	chr2:197886913	chr2:197197991~197199273:+
BRCA	cis	rs10911232	0.507	rs7547953	ENSG00000224468.3	RP11-181K3.4	-5.14	3.32e-07	3.7e-05	-0.17	-0.16	Hypertriglyceridemia;	chr1:183062506	chr1:183138402~183141282:-
BRCA	cis	rs2562456	1	rs2562456	ENSG00000268535.1	RP11-420K14.3	5.14	3.32e-07	3.7e-05	0.2	0.16	Pain;	chr19:21483408	chr19:21709522~21710191:+
BRCA	cis	rs10911251	0.546	rs3359	ENSG00000224468.3	RP11-181K3.4	-5.14	3.32e-07	3.7e-05	-0.17	-0.16	Colorectal cancer;	chr1:183142906	chr1:183138402~183141282:-
BRCA	cis	rs494453	0.885	rs496296	ENSG00000227811.2	FAM212B-AS1	-5.14	3.32e-07	3.7e-05	-0.2	-0.16	Osteoporosis-related phenotypes;	chr1:111682034	chr1:111739841~111747798:+
BRCA	cis	rs867371	0.502	rs7176926	ENSG00000259429.4	UBE2Q2P2	-5.14	3.32e-07	3.71e-05	-0.15	-0.16	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82245753	chr15:82355142~82420075:+
BRCA	cis	rs6772849	0.93	rs9873888	ENSG00000242551.2	POU5F1P6	-5.14	3.32e-07	3.71e-05	-0.2	-0.16	Monocyte percentage of white cells;Monocyte count;	chr3:128642144	chr3:128674735~128677005:-
BRCA	cis	rs4835473	0.742	rs1838519	ENSG00000249741.2	RP11-673E1.3	-5.14	3.32e-07	3.71e-05	-0.17	-0.16	Immature fraction of reticulocytes;	chr4:143972242	chr4:143911514~143912053:-
BRCA	cis	rs4072705	0.615	rs6478666	ENSG00000224020.1	MIR181A2HG	5.14	3.32e-07	3.71e-05	0.18	0.16	Menarche (age at onset);	chr9:124487064	chr9:124658467~124698631:+
BRCA	cis	rs6480314	0.542	rs7079054	ENSG00000233590.1	RP11-153K11.3	-5.14	3.32e-07	3.71e-05	-0.26	-0.16	Optic nerve measurement (disc area);	chr10:68266404	chr10:68233251~68242379:-
BRCA	cis	rs950880	1	rs12470864	ENSG00000234389.1	AC007278.3	-5.14	3.32e-07	3.71e-05	-0.15	-0.16	Serum protein levels (sST2);	chr2:102309902	chr2:102438713~102440475:+
BRCA	cis	rs7246657	0.943	rs1559229	ENSG00000267422.1	CTD-2554C21.1	-5.14	3.32e-07	3.71e-05	-0.23	-0.16	Coronary artery calcification;	chr19:37385295	chr19:37779686~37792865:+
BRCA	cis	rs7246657	0.882	rs6508719	ENSG00000267422.1	CTD-2554C21.1	-5.14	3.32e-07	3.71e-05	-0.23	-0.16	Coronary artery calcification;	chr19:37386517	chr19:37779686~37792865:+
BRCA	cis	rs13113518	1	rs11133392	ENSG00000223305.1	RN7SKP30	5.14	3.32e-07	3.71e-05	0.19	0.16	Height;	chr4:55507729	chr4:55540502~55540835:-
BRCA	cis	rs13113518	1	rs6838305	ENSG00000223305.1	RN7SKP30	5.14	3.32e-07	3.71e-05	0.19	0.16	Height;	chr4:55508587	chr4:55540502~55540835:-
BRCA	cis	rs13113518	0.902	rs12503578	ENSG00000223305.1	RN7SKP30	5.14	3.32e-07	3.71e-05	0.19	0.16	Height;	chr4:55509367	chr4:55540502~55540835:-
BRCA	cis	rs13113518	0.966	rs3828480	ENSG00000223305.1	RN7SKP30	5.14	3.32e-07	3.71e-05	0.19	0.16	Height;	chr4:55510352	chr4:55540502~55540835:-
BRCA	cis	rs13113518	1	rs3762837	ENSG00000223305.1	RN7SKP30	5.14	3.32e-07	3.71e-05	0.19	0.16	Height;	chr4:55511198	chr4:55540502~55540835:-
BRCA	cis	rs13113518	0.812	rs13116035	ENSG00000272969.1	RP11-528I4.2	5.14	3.32e-07	3.71e-05	0.19	0.16	Height;	chr4:55561218	chr4:55547112~55547889:+
BRCA	cis	rs4907240	0.883	rs11678174	ENSG00000237510.6	AC008268.2	-5.14	3.33e-07	3.71e-05	-0.22	-0.16	Event-related brain oscillations;	chr2:96583366	chr2:95789654~95800166:+
BRCA	cis	rs2303319	1	rs62197078	ENSG00000227403.1	AC009299.3	5.14	3.33e-07	3.71e-05	0.39	0.16	Cognitive function;	chr2:161326443	chr2:161244739~161249050:+
BRCA	cis	rs2303319	1	rs60767767	ENSG00000227403.1	AC009299.3	5.14	3.33e-07	3.71e-05	0.39	0.16	Cognitive function;	chr2:161329047	chr2:161244739~161249050:+
BRCA	cis	rs17685	0.796	rs3757594	ENSG00000280388.1	RP11-229D13.3	5.14	3.33e-07	3.71e-05	0.16	0.16	Coffee consumption (cups per day);Coffee consumption;	chr7:76049326	chr7:76043977~76045963:-
BRCA	cis	rs1707322	1	rs11211190	ENSG00000234329.1	RP11-767N6.2	5.14	3.33e-07	3.71e-05	0.16	0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45800583	chr1:45651039~45651826:-
BRCA	cis	rs950169	0.545	rs4842841	ENSG00000259728.4	LINC00933	5.14	3.33e-07	3.71e-05	0.23	0.16	Schizophrenia;	chr15:83972373	chr15:84570649~84580175:+
BRCA	cis	rs7618915	0.547	rs11720432	ENSG00000243224.1	RP5-1157M23.2	-5.14	3.33e-07	3.71e-05	-0.18	-0.16	Bipolar disorder;	chr3:52638726	chr3:52239258~52241097:+
BRCA	cis	rs1075265	0.73	rs11893270	ENSG00000235937.1	AC008280.1	5.14	3.33e-07	3.71e-05	0.17	0.16	Chronotype;Morning vs. evening chronotype;	chr2:54019828	chr2:54029552~54030682:-
BRCA	cis	rs2179367	0.632	rs9498329	ENSG00000268592.3	RAET1E-AS1	5.14	3.33e-07	3.71e-05	0.23	0.16	Dupuytren's disease;	chr6:149349941	chr6:149863494~149919507:+
BRCA	cis	rs73193808	1	rs8127464	ENSG00000236056.1	GAPDHP14	-5.14	3.33e-07	3.71e-05	-0.22	-0.16	Coronary artery disease;	chr21:29187381	chr21:29222321~29223257:+
BRCA	cis	rs2562456	0.793	rs73537884	ENSG00000268081.1	RP11-678G14.2	5.14	3.33e-07	3.71e-05	0.25	0.16	Pain;	chr19:21321908	chr19:21554640~21569237:-
BRCA	cis	rs2562456	0.793	rs78467454	ENSG00000268081.1	RP11-678G14.2	5.14	3.33e-07	3.71e-05	0.25	0.16	Pain;	chr19:21321930	chr19:21554640~21569237:-
BRCA	cis	rs801193	0.613	rs2659900	ENSG00000223473.2	GS1-124K5.3	5.14	3.33e-07	3.71e-05	0.12	0.16	Aortic root size;	chr7:66719456	chr7:66491049~66493566:-
BRCA	cis	rs1707322	1	rs11211223	ENSG00000234329.1	RP11-767N6.2	5.14	3.33e-07	3.72e-05	0.16	0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45914933	chr1:45651039~45651826:-
BRCA	cis	rs860295	0.702	rs56675301	ENSG00000160766.13	GBAP1	-5.14	3.33e-07	3.72e-05	-0.17	-0.16	Body mass index;	chr1:155394536	chr1:155213821~155227422:-
BRCA	cis	rs9921338	0.668	rs55870745	ENSG00000262703.1	RP11-485G7.6	-5.14	3.33e-07	3.72e-05	-0.19	-0.16	Vein graft stenosis in coronary artery bypass grafting;	chr16:11261245	chr16:11348143~11349321:-
BRCA	cis	rs9921338	0.636	rs56350515	ENSG00000262703.1	RP11-485G7.6	-5.14	3.33e-07	3.72e-05	-0.19	-0.16	Vein graft stenosis in coronary artery bypass grafting;	chr16:11261247	chr16:11348143~11349321:-
BRCA	cis	rs4908760	0.539	rs10864367	ENSG00000270282.1	RP5-1115A15.2	5.14	3.34e-07	3.72e-05	0.17	0.16	Vitiligo;	chr1:8787321	chr1:8512653~8513021:+
BRCA	cis	rs2235642	0.685	rs2667681	ENSG00000280231.1	LA16c-380F5.3	-5.14	3.34e-07	3.72e-05	-0.21	-0.16	Coronary artery disease;	chr16:1603205	chr16:1553655~1554130:-
BRCA	cis	rs597539	0.617	rs686348	ENSG00000261625.1	RP11-554A11.4	-5.14	3.34e-07	3.73e-05	-0.16	-0.16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68869528	chr11:69000765~69002048:-
BRCA	cis	rs3892630	0.878	rs114224536	ENSG00000267567.1	CTD-2538C1.3	5.14	3.34e-07	3.73e-05	0.25	0.16	Red blood cell traits;	chr19:32720326	chr19:32718298~32719595:-
BRCA	cis	rs875971	0.862	rs11984115	ENSG00000236529.1	RP13-254B10.1	-5.14	3.34e-07	3.73e-05	-0.18	-0.16	Aortic root size;	chr7:66308872	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.895	rs12531677	ENSG00000236529.1	RP13-254B10.1	-5.14	3.34e-07	3.73e-05	-0.18	-0.16	Aortic root size;	chr7:66304099	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.862	rs7798630	ENSG00000236529.1	RP13-254B10.1	-5.14	3.34e-07	3.73e-05	-0.18	-0.16	Aortic root size;	chr7:66306492	chr7:65840212~65840596:+
BRCA	cis	rs7617773	0.643	rs78159520	ENSG00000199476.1	Y_RNA	-5.14	3.34e-07	3.73e-05	-0.24	-0.16	Coronary artery disease;	chr3:48307533	chr3:48288587~48288694:+
BRCA	cis	rs1440410	0.571	rs62331619	ENSG00000250326.1	RP11-284M14.1	5.14	3.35e-07	3.73e-05	0.19	0.16	Ischemic stroke;	chr4:143107299	chr4:142933195~143184861:-
BRCA	cis	rs2562456	0.617	rs34203148	ENSG00000268081.1	RP11-678G14.2	5.14	3.35e-07	3.74e-05	0.24	0.16	Pain;	chr19:21590743	chr19:21554640~21569237:-
BRCA	cis	rs848490	0.762	rs7796089	ENSG00000214293.7	APTR	5.14	3.35e-07	3.74e-05	0.18	0.16	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77882781	chr7:77657660~77696265:-
BRCA	cis	rs13113518	1	rs939823	ENSG00000223305.1	RN7SKP30	5.14	3.35e-07	3.74e-05	0.19	0.16	Height;	chr4:55487368	chr4:55540502~55540835:-
BRCA	cis	rs10911232	0.507	rs10737239	ENSG00000224468.3	RP11-181K3.4	-5.14	3.35e-07	3.74e-05	-0.17	-0.16	Hypertriglyceridemia;	chr1:183061035	chr1:183138402~183141282:-
BRCA	cis	rs7299940	0.967	rs9738957	ENSG00000256250.1	RP11-989F5.1	5.14	3.35e-07	3.74e-05	0.18	0.16	Panic disorder;	chr12:130904256	chr12:130810606~130812438:+
BRCA	cis	rs10510102	0.935	rs12246704	ENSG00000226864.1	ATE1-AS1	5.14	3.35e-07	3.74e-05	0.28	0.16	Breast cancer;	chr10:121906165	chr10:121928312~121951965:+
BRCA	cis	rs4650994	0.544	rs11579513	ENSG00000273384.1	RP5-1098D14.1	5.14	3.35e-07	3.74e-05	0.2	0.16	HDL cholesterol;HDL cholesterol levels;	chr1:178526957	chr1:178651706~178652282:+
BRCA	cis	rs10788972	0.683	rs6694292	ENSG00000225183.1	RP4-758J24.4	5.14	3.35e-07	3.74e-05	0.2	0.16	Parkinson disease and lewy body pathology;	chr1:54100517	chr1:54089856~54090093:+
BRCA	cis	rs1440410	0.571	rs7673171	ENSG00000250326.1	RP11-284M14.1	-5.14	3.35e-07	3.74e-05	-0.18	-0.16	Ischemic stroke;	chr4:143109945	chr4:142933195~143184861:-
BRCA	cis	rs9840812	0.769	rs1279840	ENSG00000239213.4	NCK1-AS1	5.14	3.35e-07	3.74e-05	0.19	0.16	Fibrinogen levels;	chr3:136287734	chr3:136841726~136862054:-
BRCA	cis	rs4835473	0.932	rs2323417	ENSG00000249741.2	RP11-673E1.3	-5.14	3.35e-07	3.74e-05	-0.17	-0.16	Immature fraction of reticulocytes;	chr4:143969108	chr4:143911514~143912053:-
BRCA	cis	rs10844706	0.699	rs1008610	ENSG00000214776.8	RP11-726G1.1	5.14	3.35e-07	3.74e-05	0.19	0.16	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9731264	chr12:9467552~9576275:+
BRCA	cis	rs1665050	0.842	rs1665049	ENSG00000259732.1	RP11-59H7.3	5.14	3.35e-07	3.74e-05	0.19	0.16	Atopic dermatitis;	chr15:58998453	chr15:59121034~59133250:+
BRCA	cis	rs7267979	1	rs11087521	ENSG00000125804.12	FAM182A	-5.14	3.36e-07	3.74e-05	-0.21	-0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25460012	chr20:26054655~26086917:+
BRCA	cis	rs2562456	0.754	rs58338799	ENSG00000268081.1	RP11-678G14.2	5.14	3.36e-07	3.74e-05	0.25	0.16	Pain;	chr19:21339009	chr19:21554640~21569237:-
BRCA	cis	rs7674212	0.57	rs12501621	ENSG00000248740.4	RP11-328K4.1	5.14	3.36e-07	3.74e-05	0.18	0.16	Type 2 diabetes;	chr4:103174348	chr4:103256159~103453658:+
BRCA	cis	rs10888838	0.617	rs4927071	ENSG00000198711.5	SSBP3-AS1	5.14	3.36e-07	3.74e-05	0.17	0.16	Mitochondrial DNA levels;	chr1:54214239	chr1:54236440~54239063:+
BRCA	cis	rs9847710	0.791	rs6808387	ENSG00000242142.1	SERBP1P3	-5.14	3.36e-07	3.75e-05	-0.18	-0.16	Ulcerative colitis;	chr3:53045716	chr3:53064283~53065091:-
BRCA	cis	rs72681920	0.881	rs7692358	ENSG00000246090.5	RP11-696N14.1	-5.14	3.36e-07	3.75e-05	-0.22	-0.16	Alcohol dependence;	chr4:99217579	chr4:99088857~99301356:+
BRCA	cis	rs1729951	0.575	rs361248	ENSG00000239213.4	NCK1-AS1	5.14	3.36e-07	3.75e-05	0.16	0.16	Neuroticism;	chr3:136990224	chr3:136841726~136862054:-
BRCA	cis	rs2243480	1	rs10807702	ENSG00000222364.1	RNU6-96P	-5.14	3.36e-07	3.75e-05	-0.29	-0.16	Diabetic kidney disease;	chr7:66302856	chr7:66395191~66395286:+
BRCA	cis	rs7200543	1	rs1136001	ENSG00000260735.1	RP11-72I8.1	-5.14	3.36e-07	3.75e-05	-0.19	-0.16	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15038117	chr16:15094411~15109197:+
BRCA	cis	rs13113518	0.783	rs11133389	ENSG00000272969.1	RP11-528I4.2	5.14	3.36e-07	3.75e-05	0.19	0.16	Height;	chr4:55486718	chr4:55547112~55547889:+
BRCA	cis	rs597539	0.617	rs598353	ENSG00000261625.1	RP11-554A11.4	-5.14	3.36e-07	3.75e-05	-0.16	-0.16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68868302	chr11:69000765~69002048:-
BRCA	cis	rs718433	0.816	rs11621221	ENSG00000256379.1	TRAV8-5	5.14	3.36e-07	3.75e-05	0.18	0.16	Intraocular pressure;	chr14:21754101	chr14:21903077~21903598:+
BRCA	cis	rs7772486	0.79	rs9403756	ENSG00000270638.1	RP3-466P17.1	-5.14	3.36e-07	3.75e-05	-0.18	-0.16	Lobe attachment (rater-scored or self-reported);	chr6:145936625	chr6:145735570~145737218:+
BRCA	cis	rs3764021	0.509	rs10844569	ENSG00000256673.1	RP11-599J14.2	-5.13	3.37e-07	3.75e-05	-0.2	-0.16	Type 1 diabetes;	chr12:9717756	chr12:9398355~9414851:-
BRCA	cis	rs4604234	0.803	rs11961389	ENSG00000272129.1	RP11-250B2.6	-5.13	3.37e-07	3.75e-05	-0.4	-0.16	Cancer;	chr6:80254174	chr6:80355424~80356859:+
BRCA	cis	rs7119038	0.509	rs10892256	ENSG00000255422.1	AP002954.4	5.13	3.37e-07	3.75e-05	0.23	0.16	Sjögren's syndrome;	chr11:118707996	chr11:118704607~118750263:+
BRCA	cis	rs7119038	0.509	rs10892257	ENSG00000255422.1	AP002954.4	5.13	3.37e-07	3.75e-05	0.23	0.16	Sjögren's syndrome;	chr11:118708618	chr11:118704607~118750263:+
BRCA	cis	rs9311474	0.508	rs1570	ENSG00000243224.1	RP5-1157M23.2	-5.13	3.37e-07	3.75e-05	-0.17	-0.16	Electroencephalogram traits;	chr3:52552666	chr3:52239258~52241097:+
BRCA	cis	rs17711722	0.565	rs73372653	ENSG00000222364.1	RNU6-96P	-5.13	3.37e-07	3.75e-05	-0.19	-0.16	Calcium levels;	chr7:65977808	chr7:66395191~66395286:+
BRCA	cis	rs9393692	0.905	rs989134	ENSG00000241549.7	GUSBP2	-5.13	3.37e-07	3.75e-05	-0.17	-0.16	Educational attainment;	chr6:26335996	chr6:26871484~26956554:-
BRCA	cis	rs7914558	1	rs4917994	ENSG00000236937.2	PTGES3P4	5.13	3.37e-07	3.75e-05	0.2	0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103051942	chr10:102845595~102845950:+
BRCA	cis	rs7914558	1	rs2275271	ENSG00000236937.2	PTGES3P4	5.13	3.37e-07	3.75e-05	0.2	0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103054405	chr10:102845595~102845950:+
BRCA	cis	rs7914558	1	rs11191539	ENSG00000236937.2	PTGES3P4	5.13	3.37e-07	3.75e-05	0.2	0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103060013	chr10:102845595~102845950:+
BRCA	cis	rs2919009	0.664	rs57078496	ENSG00000271670.1	RP11-95I16.4	5.13	3.37e-07	3.75e-05	0.23	0.16	Obesity-related traits;	chr10:120881877	chr10:120879256~120880667:-
BRCA	cis	rs2638953	0.962	rs10506032	ENSG00000247934.4	RP11-967K21.1	-5.13	3.37e-07	3.76e-05	-0.21	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28384177	chr12:28163298~28190738:-
BRCA	cis	rs75422866	0.867	rs73102125	ENSG00000280054.1	RP1-197B17.7	5.13	3.37e-07	3.76e-05	0.38	0.16	Pneumonia;	chr12:47637869	chr12:47728151~47730598:-
BRCA	cis	rs75422866	0.867	rs12426849	ENSG00000280054.1	RP1-197B17.7	5.13	3.37e-07	3.76e-05	0.38	0.16	Pneumonia;	chr12:47638975	chr12:47728151~47730598:-
BRCA	cis	rs75422866	0.867	rs117950951	ENSG00000280054.1	RP1-197B17.7	5.13	3.37e-07	3.76e-05	0.38	0.16	Pneumonia;	chr12:47639794	chr12:47728151~47730598:-
BRCA	cis	rs75422866	0.867	rs7954764	ENSG00000280054.1	RP1-197B17.7	5.13	3.37e-07	3.76e-05	0.38	0.16	Pneumonia;	chr12:47641136	chr12:47728151~47730598:-
BRCA	cis	rs6772849	0.93	rs55987729	ENSG00000242551.2	POU5F1P6	-5.13	3.38e-07	3.76e-05	-0.2	-0.16	Monocyte percentage of white cells;Monocyte count;	chr3:128621267	chr3:128674735~128677005:-
BRCA	cis	rs3768617	0.51	rs10911247	ENSG00000224468.3	RP11-181K3.4	-5.13	3.38e-07	3.76e-05	-0.17	-0.16	Fuchs's corneal dystrophy;	chr1:183107858	chr1:183138402~183141282:-
BRCA	cis	rs10911232	0.507	rs4072709	ENSG00000224468.3	RP11-181K3.4	-5.13	3.38e-07	3.77e-05	-0.17	-0.16	Hypertriglyceridemia;	chr1:183059720	chr1:183138402~183141282:-
BRCA	cis	rs4835473	0.808	rs11725413	ENSG00000249741.2	RP11-673E1.3	5.13	3.38e-07	3.77e-05	0.18	0.16	Immature fraction of reticulocytes;	chr4:143943366	chr4:143911514~143912053:-
BRCA	cis	rs2638953	0.853	rs11049670	ENSG00000247934.4	RP11-967K21.1	5.13	3.38e-07	3.77e-05	0.21	0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28499342	chr12:28163298~28190738:-
BRCA	cis	rs10911232	0.507	rs3934578	ENSG00000224468.3	RP11-181K3.4	-5.13	3.38e-07	3.77e-05	-0.17	-0.16	Hypertriglyceridemia;	chr1:183058081	chr1:183138402~183141282:-
BRCA	cis	rs10911232	0.507	rs3934579	ENSG00000224468.3	RP11-181K3.4	-5.13	3.38e-07	3.77e-05	-0.17	-0.16	Hypertriglyceridemia;	chr1:183058297	chr1:183138402~183141282:-
BRCA	cis	rs10911232	0.507	rs3934697	ENSG00000224468.3	RP11-181K3.4	-5.13	3.38e-07	3.77e-05	-0.17	-0.16	Hypertriglyceridemia;	chr1:183058377	chr1:183138402~183141282:-
BRCA	cis	rs66887589	1	rs66887589	ENSG00000245958.5	RP11-33B1.1	5.13	3.38e-07	3.77e-05	0.14	0.16	Diastolic blood pressure;	chr4:119588124	chr4:119454791~119552025:+
BRCA	cis	rs2153535	0.58	rs7745043	ENSG00000251164.1	HULC	-5.13	3.39e-07	3.77e-05	-0.19	-0.16	Motion sickness;	chr6:8513274	chr6:8652137~8653846:+
BRCA	cis	rs66887589	0.616	rs11098498	ENSG00000249244.1	RP11-548H18.2	5.13	3.39e-07	3.77e-05	0.17	0.16	Diastolic blood pressure;	chr4:119265964	chr4:119391831~119395335:-
BRCA	cis	rs4718428	0.924	rs6971897	ENSG00000229180.5	GS1-124K5.11	5.13	3.39e-07	3.77e-05	0.14	0.16	Corneal structure;	chr7:66947787	chr7:66526088~66542624:-
BRCA	cis	rs2898681	1	rs2046364	ENSG00000248375.1	RP11-177B4.1	-5.13	3.39e-07	3.77e-05	-0.24	-0.16	Optic nerve measurement (cup area);	chr4:52877051	chr4:52720081~52720831:-
BRCA	cis	rs2522056	1	rs2522056	ENSG00000233006.5	AC034220.3	-5.13	3.39e-07	3.77e-05	-0.13	-0.16	Fibrinogen;Lymphocyte counts;	chr5:132466034	chr5:132311285~132369916:-
BRCA	cis	rs3758911	0.713	rs1907402	ENSG00000255353.1	RP11-382M14.1	-5.13	3.39e-07	3.77e-05	-0.2	-0.16	Coronary artery disease;	chr11:107253176	chr11:107176286~107177530:+
BRCA	cis	rs10911251	0.546	rs1051473	ENSG00000224468.3	RP11-181K3.4	-5.13	3.39e-07	3.78e-05	-0.17	-0.16	Colorectal cancer;	chr1:183145011	chr1:183138402~183141282:-
BRCA	cis	rs950880	0.961	rs13020553	ENSG00000234389.1	AC007278.3	-5.13	3.39e-07	3.78e-05	-0.15	-0.16	Serum protein levels (sST2);	chr2:102315366	chr2:102438713~102440475:+
BRCA	cis	rs997295	0.57	rs28730805	ENSG00000270964.1	RP11-502I4.3	-5.13	3.39e-07	3.78e-05	-0.17	-0.16	Motion sickness;	chr15:67587080	chr15:67541072~67542604:-
BRCA	cis	rs794185	0.657	rs2633846	ENSG00000231249.1	ITPR1-AS1	-5.13	3.4e-07	3.78e-05	-0.18	-0.16	Multiple sclerosis--Brain Glutamate Levels;	chr3:4471781	chr3:4490891~4493163:-
BRCA	cis	rs8098244	0.964	rs7243993	ENSG00000264745.1	TTC39C-AS1	5.13	3.4e-07	3.78e-05	0.22	0.16	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23869438	chr18:23994213~24015339:-
BRCA	cis	rs8098244	0.964	rs7229663	ENSG00000264745.1	TTC39C-AS1	5.13	3.4e-07	3.78e-05	0.22	0.16	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23869480	chr18:23994213~24015339:-
BRCA	cis	rs516805	0.63	rs2606641	ENSG00000279453.1	RP3-425C14.4	-5.13	3.4e-07	3.78e-05	-0.21	-0.16	Lymphocyte counts;	chr6:122103704	chr6:122436789~122439223:-
BRCA	cis	rs516805	0.63	rs2606643	ENSG00000279453.1	RP3-425C14.4	-5.13	3.4e-07	3.78e-05	-0.21	-0.16	Lymphocyte counts;	chr6:122104352	chr6:122436789~122439223:-
BRCA	cis	rs1707322	1	rs785506	ENSG00000234329.1	RP11-767N6.2	-5.13	3.4e-07	3.78e-05	-0.16	-0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46074980	chr1:45651039~45651826:-
BRCA	cis	rs2562456	0.793	rs7259396	ENSG00000268081.1	RP11-678G14.2	5.13	3.4e-07	3.79e-05	0.25	0.16	Pain;	chr19:21340661	chr19:21554640~21569237:-
BRCA	cis	rs2562456	0.678	rs7260140	ENSG00000268081.1	RP11-678G14.2	5.13	3.4e-07	3.79e-05	0.25	0.16	Pain;	chr19:21340723	chr19:21554640~21569237:-
BRCA	cis	rs2562456	0.833	rs11880624	ENSG00000268081.1	RP11-678G14.2	5.13	3.4e-07	3.79e-05	0.25	0.16	Pain;	chr19:21341028	chr19:21554640~21569237:-
BRCA	cis	rs875971	0.564	rs313804	ENSG00000236529.1	RP13-254B10.1	5.13	3.4e-07	3.79e-05	0.17	0.16	Aortic root size;	chr7:66049635	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.662	rs448725	ENSG00000236529.1	RP13-254B10.1	5.13	3.4e-07	3.79e-05	0.17	0.16	Aortic root size;	chr7:66049641	chr7:65840212~65840596:+
BRCA	cis	rs10844706	0.699	rs7296241	ENSG00000214776.8	RP11-726G1.1	5.13	3.4e-07	3.79e-05	0.19	0.16	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9725044	chr12:9467552~9576275:+
BRCA	cis	rs7968440	1	rs10747586	ENSG00000272368.2	RP4-605O3.4	-5.13	3.4e-07	3.79e-05	-0.17	-0.16	Fibrinogen;	chr12:50589782	chr12:50112197~50165618:+
BRCA	cis	rs27434	0.51	rs27038	ENSG00000272109.1	CTD-2260A17.3	-5.13	3.4e-07	3.79e-05	-0.25	-0.16	Ankylosing spondylitis;	chr5:96777250	chr5:96804353~96806105:+
BRCA	cis	rs7914558	0.966	rs11191471	ENSG00000236937.2	PTGES3P4	5.13	3.4e-07	3.79e-05	0.2	0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102942293	chr10:102845595~102845950:+
BRCA	cis	rs7208859	0.673	rs73263776	ENSG00000280069.1	CTD-2349P21.3	-5.13	3.4e-07	3.79e-05	-0.23	-0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30884313	chr17:30738182~30740275:+
BRCA	cis	rs7208859	0.623	rs11650271	ENSG00000280069.1	CTD-2349P21.3	-5.13	3.4e-07	3.79e-05	-0.23	-0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30886925	chr17:30738182~30740275:+
BRCA	cis	rs10492201	0.554	rs2870962	ENSG00000236946.2	HNRNPA1P70	5.13	3.41e-07	3.79e-05	0.15	0.16	Itch intensity from mosquito bite adjusted by bite size;	chr12:68008143	chr12:68035767~68036853:+
BRCA	cis	rs1075265	0.749	rs805436	ENSG00000235937.1	AC008280.1	5.13	3.41e-07	3.8e-05	0.17	0.16	Chronotype;Morning vs. evening chronotype;	chr2:53837843	chr2:54029552~54030682:-
BRCA	cis	rs9467773	1	rs9467787	ENSG00000241549.7	GUSBP2	5.13	3.41e-07	3.8e-05	0.17	0.16	Intelligence (multi-trait analysis);	chr6:26556541	chr6:26871484~26956554:-
BRCA	cis	rs801193	0.569	rs11772819	ENSG00000273448.1	RP11-166O4.6	5.13	3.41e-07	3.8e-05	0.14	0.16	Aortic root size;	chr7:66752983	chr7:67333047~67334383:+
BRCA	cis	rs801193	0.569	rs7800620	ENSG00000273448.1	RP11-166O4.6	5.13	3.41e-07	3.8e-05	0.14	0.16	Aortic root size;	chr7:66758701	chr7:67333047~67334383:+
BRCA	cis	rs6600671	1	rs1856572	ENSG00000275538.1	RNVU1-19	5.13	3.41e-07	3.8e-05	0.18	0.16	Hip geometry;	chr1:121427719	chr1:120850819~120850985:-
BRCA	cis	rs4218	0.597	rs12438208	ENSG00000277144.1	RP11-59H7.4	-5.13	3.41e-07	3.8e-05	-0.21	-0.16	Social communication problems;	chr15:59057715	chr15:59115547~59116089:-
BRCA	cis	rs7618915	0.571	rs1961958	ENSG00000243224.1	RP5-1157M23.2	-5.13	3.41e-07	3.8e-05	-0.18	-0.16	Bipolar disorder;	chr3:52551974	chr3:52239258~52241097:+
BRCA	cis	rs2832191	0.72	rs7277028	ENSG00000176054.6	RPL23P2	-5.13	3.41e-07	3.8e-05	-0.16	-0.16	Dental caries;	chr21:29122283	chr21:28997613~28998033:-
BRCA	cis	rs9907295	0.71	rs9894083	ENSG00000270977.1	AC015849.16	-5.13	3.41e-07	3.8e-05	-0.28	-0.16	Fibroblast growth factor basic levels;	chr17:35842151	chr17:35893707~35911023:-
BRCA	cis	rs17772222	0.74	rs73317739	ENSG00000258789.1	RP11-507K2.3	-5.13	3.42e-07	3.8e-05	-0.18	-0.16	Coronary artery calcification;	chr14:88511400	chr14:88551597~88552493:+
BRCA	cis	rs2832191	0.791	rs2065270	ENSG00000215533.7	LINC00189	5.13	3.42e-07	3.81e-05	0.17	0.16	Dental caries;	chr21:29113099	chr21:29193480~29288205:+
BRCA	cis	rs9659323	0.65	rs12093893	ENSG00000231365.4	RP11-418J17.1	-5.13	3.42e-07	3.81e-05	-0.2	-0.16	Body mass index;	chr1:118948196	chr1:119140396~119275973:+
BRCA	cis	rs7674212	0.51	rs2720468	ENSG00000251288.2	RP11-10L12.2	-5.13	3.42e-07	3.81e-05	-0.19	-0.16	Type 2 diabetes;	chr4:103163996	chr4:102751401~102752641:+
BRCA	cis	rs7618915	0.547	rs10865973	ENSG00000243224.1	RP5-1157M23.2	-5.13	3.42e-07	3.81e-05	-0.18	-0.16	Bipolar disorder;	chr3:52684138	chr3:52239258~52241097:+
BRCA	cis	rs7618915	0.547	rs34537256	ENSG00000243224.1	RP5-1157M23.2	-5.13	3.42e-07	3.81e-05	-0.18	-0.16	Bipolar disorder;	chr3:52623456	chr3:52239258~52241097:+
BRCA	cis	rs4218	0.588	rs9788719	ENSG00000277144.1	RP11-59H7.4	-5.13	3.43e-07	3.81e-05	-0.19	-0.16	Social communication problems;	chr15:59028920	chr15:59115547~59116089:-
BRCA	cis	rs4218	0.681	rs34977427	ENSG00000277144.1	RP11-59H7.4	-5.13	3.43e-07	3.81e-05	-0.21	-0.16	Social communication problems;	chr15:59098172	chr15:59115547~59116089:-
BRCA	cis	rs7246657	0.943	rs4452075	ENSG00000267422.1	CTD-2554C21.1	-5.13	3.43e-07	3.81e-05	-0.23	-0.16	Coronary artery calcification;	chr19:37388687	chr19:37779686~37792865:+
BRCA	cis	rs2153535	0.601	rs2015281	ENSG00000251164.1	HULC	-5.13	3.43e-07	3.81e-05	-0.19	-0.16	Motion sickness;	chr6:8539440	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.601	rs9505474	ENSG00000251164.1	HULC	-5.13	3.43e-07	3.81e-05	-0.19	-0.16	Motion sickness;	chr6:8539561	chr6:8652137~8653846:+
BRCA	cis	rs6840360	0.642	rs1470281	ENSG00000278978.1	RP11-164P12.5	-5.13	3.43e-07	3.81e-05	-0.17	-0.16	Intelligence (multi-trait analysis);	chr4:151510400	chr4:151669786~151670503:+
BRCA	cis	rs6772849	0.896	rs4557179	ENSG00000242551.2	POU5F1P6	-5.13	3.43e-07	3.81e-05	-0.2	-0.16	Monocyte percentage of white cells;Monocyte count;	chr3:128647883	chr3:128674735~128677005:-
BRCA	cis	rs9311474	0.508	rs2878628	ENSG00000243224.1	RP5-1157M23.2	5.13	3.43e-07	3.82e-05	0.17	0.16	Electroencephalogram traits;	chr3:52550699	chr3:52239258~52241097:+
BRCA	cis	rs987724	0.515	rs6762708	ENSG00000240875.4	LINC00886	5.13	3.43e-07	3.82e-05	0.24	0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156973815	chr3:156747346~156817062:-
BRCA	cis	rs516805	0.748	rs155467	ENSG00000279114.1	RP3-425C14.5	-5.13	3.43e-07	3.82e-05	-0.19	-0.16	Lymphocyte counts;	chr6:122512451	chr6:122471923~122484161:+
BRCA	cis	rs6479901	0.512	rs4746244	ENSG00000232075.1	MRPL35P2	-5.13	3.43e-07	3.82e-05	-0.28	-0.16	Intelligence (multi-trait analysis);	chr10:63599941	chr10:63634317~63634827:-
BRCA	cis	rs10911232	0.524	rs10737238	ENSG00000224468.3	RP11-181K3.4	-5.13	3.43e-07	3.82e-05	-0.17	-0.16	Hypertriglyceridemia;	chr1:183056168	chr1:183138402~183141282:-
BRCA	cis	rs7617773	0.746	rs7619865	ENSG00000199476.1	Y_RNA	-5.13	3.44e-07	3.82e-05	-0.21	-0.16	Coronary artery disease;	chr3:48329090	chr3:48288587~48288694:+
BRCA	cis	rs4908768	0.501	rs2016084	ENSG00000232912.4	RP5-1115A15.1	5.13	3.44e-07	3.83e-05	0.15	0.16	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8553359	chr1:8424645~8434838:+
BRCA	cis	rs7674212	0.54	rs2711897	ENSG00000248740.4	RP11-328K4.1	5.13	3.44e-07	3.83e-05	0.18	0.16	Type 2 diabetes;	chr4:103102410	chr4:103256159~103453658:+
BRCA	cis	rs1953600	0.645	rs2819950	ENSG00000226659.1	RP11-137H2.4	5.13	3.44e-07	3.83e-05	0.2	0.16	Sarcoidosis;	chr10:80175523	chr10:80529597~80535942:-
BRCA	cis	rs875971	0.545	rs10950027	ENSG00000232546.1	RP11-458F8.1	5.13	3.45e-07	3.83e-05	0.15	0.16	Aortic root size;	chr7:66169164	chr7:66848496~66858136:+
BRCA	cis	rs2980439	0.818	rs2948294	ENSG00000233609.3	RP11-62H7.2	5.13	3.45e-07	3.83e-05	0.15	0.16	Neuroticism;	chr8:8237439	chr8:8961200~8979025:+
BRCA	cis	rs10510102	0.935	rs10887014	ENSG00000226864.1	ATE1-AS1	5.13	3.45e-07	3.83e-05	0.29	0.16	Breast cancer;	chr10:121892322	chr10:121928312~121951965:+
BRCA	cis	rs10510102	0.872	rs11818735	ENSG00000226864.1	ATE1-AS1	5.13	3.45e-07	3.83e-05	0.29	0.16	Breast cancer;	chr10:121892472	chr10:121928312~121951965:+
BRCA	cis	rs10510102	0.81	rs12259902	ENSG00000226864.1	ATE1-AS1	5.13	3.45e-07	3.83e-05	0.29	0.16	Breast cancer;	chr10:121893017	chr10:121928312~121951965:+
BRCA	cis	rs10510102	0.935	rs11200228	ENSG00000226864.1	ATE1-AS1	5.13	3.45e-07	3.83e-05	0.29	0.16	Breast cancer;	chr10:121893358	chr10:121928312~121951965:+
BRCA	cis	rs10510102	0.935	rs11200229	ENSG00000226864.1	ATE1-AS1	5.13	3.45e-07	3.83e-05	0.29	0.16	Breast cancer;	chr10:121893519	chr10:121928312~121951965:+
BRCA	cis	rs10510102	0.935	rs10887016	ENSG00000226864.1	ATE1-AS1	5.13	3.45e-07	3.83e-05	0.29	0.16	Breast cancer;	chr10:121893830	chr10:121928312~121951965:+
BRCA	cis	rs10510102	0.935	rs10887018	ENSG00000226864.1	ATE1-AS1	5.13	3.45e-07	3.83e-05	0.29	0.16	Breast cancer;	chr10:121894457	chr10:121928312~121951965:+
BRCA	cis	rs10510102	0.935	rs11200230	ENSG00000226864.1	ATE1-AS1	5.13	3.45e-07	3.83e-05	0.29	0.16	Breast cancer;	chr10:121895117	chr10:121928312~121951965:+
BRCA	cis	rs10510102	0.935	rs11200234	ENSG00000226864.1	ATE1-AS1	5.13	3.45e-07	3.83e-05	0.29	0.16	Breast cancer;	chr10:121895851	chr10:121928312~121951965:+
BRCA	cis	rs11051970	0.592	rs12227991	ENSG00000274964.1	RP11-817I4.1	-5.13	3.45e-07	3.84e-05	-0.22	-0.16	Response to tocilizumab in rheumatoid arthritis;	chr12:32387111	chr12:32339368~32340724:+
BRCA	cis	rs11051970	0.559	rs11051973	ENSG00000274964.1	RP11-817I4.1	-5.13	3.45e-07	3.84e-05	-0.22	-0.16	Response to tocilizumab in rheumatoid arthritis;	chr12:32388978	chr12:32339368~32340724:+
BRCA	cis	rs2562456	0.833	rs62107547	ENSG00000268081.1	RP11-678G14.2	5.13	3.45e-07	3.84e-05	0.25	0.16	Pain;	chr19:21341245	chr19:21554640~21569237:-
BRCA	cis	rs7119038	0.509	rs11216960	ENSG00000255422.1	AP002954.4	5.13	3.45e-07	3.84e-05	0.23	0.16	Sjögren's syndrome;	chr11:118707164	chr11:118704607~118750263:+
BRCA	cis	rs13113518	0.812	rs11945371	ENSG00000272969.1	RP11-528I4.2	5.13	3.45e-07	3.84e-05	0.18	0.16	Height;	chr4:55409063	chr4:55547112~55547889:+
BRCA	cis	rs8031584	0.958	rs1043742	ENSG00000270015.1	RP11-540B6.6	-5.13	3.45e-07	3.84e-05	-0.16	-0.16	Huntington's disease progression;	chr15:30940378	chr15:30926514~30928407:+
BRCA	cis	rs7487075	0.606	rs4768714	ENSG00000274723.1	RP11-618L22.1	5.13	3.45e-07	3.84e-05	0.19	0.16	Itch intensity from mosquito bite;	chr12:46420462	chr12:46970504~46972155:+
BRCA	cis	rs875971	0.825	rs10281499	ENSG00000273448.1	RP11-166O4.6	-5.13	3.45e-07	3.84e-05	-0.15	-0.16	Aortic root size;	chr7:66583979	chr7:67333047~67334383:+
BRCA	cis	rs1979679	1	rs11049506	ENSG00000278733.1	RP11-425D17.1	-5.13	3.45e-07	3.84e-05	-0.19	-0.16	Ossification of the posterior longitudinal ligament of the spine;	chr12:28289141	chr12:28185625~28186190:-
BRCA	cis	rs7617773	0.815	rs9825637	ENSG00000199476.1	Y_RNA	-5.13	3.45e-07	3.84e-05	-0.23	-0.16	Coronary artery disease;	chr3:48330792	chr3:48288587~48288694:+
BRCA	cis	rs73193808	0.851	rs66903141	ENSG00000236056.1	GAPDHP14	-5.13	3.45e-07	3.84e-05	-0.23	-0.16	Coronary artery disease;	chr21:29229214	chr21:29222321~29223257:+
BRCA	cis	rs12550612	0.83	rs10111172	ENSG00000253616.4	RP11-875O11.3	-5.13	3.46e-07	3.84e-05	-0.24	-0.16	Myeloid white cell count;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;White blood cell count;Sum neutrophil eosinophil counts;	chr8:23111578	chr8:23071377~23074488:-
BRCA	cis	rs6756513	0.5	rs58819073	ENSG00000231024.1	AC092431.3	-5.13	3.46e-07	3.84e-05	-0.22	-0.16	Breast cancer;Platelet count;	chr2:69822090	chr2:69700192~69713847:-
BRCA	cis	rs9467773	0.62	rs2494696	ENSG00000124549.13	BTN2A3P	5.13	3.46e-07	3.85e-05	0.16	0.16	Intelligence (multi-trait analysis);	chr6:26620666	chr6:26421391~26432383:+
BRCA	cis	rs6496044	0.548	rs7163032	ENSG00000259295.5	CSPG4P12	5.13	3.46e-07	3.85e-05	0.19	0.16	Interstitial lung disease;	chr15:85529188	chr15:85191438~85213905:+
BRCA	cis	rs7968440	1	rs2731443	ENSG00000272368.2	RP4-605O3.4	5.13	3.46e-07	3.85e-05	0.17	0.16	Fibrinogen;	chr12:50700355	chr12:50112197~50165618:+
BRCA	cis	rs11955398	0.502	rs6868884	ENSG00000215032.2	GNL3LP1	5.13	3.47e-07	3.85e-05	0.2	0.16	Intelligence (multi-trait analysis);	chr5:61087133	chr5:60891935~60893577:-
BRCA	cis	rs9473147	0.516	rs2151974	ENSG00000270761.1	RP11-385F7.1	-5.13	3.47e-07	3.85e-05	-0.17	-0.16	Platelet distribution width;Mean platelet volume;	chr6:47547894	chr6:47477243~47477572:-
BRCA	cis	rs6071166	0.935	rs1358899	ENSG00000224635.1	RP4-564F22.5	-5.13	3.47e-07	3.86e-05	-0.19	-0.16	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38701050	chr20:38406011~38416797:-
BRCA	cis	rs3781264	0.55	rs12781628	ENSG00000273450.1	RP11-76P2.4	5.13	3.47e-07	3.86e-05	0.27	0.16	Esophageal cancer and gastric cancer;	chr10:94361032	chr10:94314907~94315327:-
BRCA	cis	rs2732480	0.538	rs2732462	ENSG00000226413.2	OR8T1P	5.13	3.47e-07	3.86e-05	0.21	0.16	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48302601	chr12:48442030~48442947:-
BRCA	cis	rs8031584	0.958	rs61997079	ENSG00000270015.1	RP11-540B6.6	-5.13	3.47e-07	3.86e-05	-0.17	-0.16	Huntington's disease progression;	chr15:30946068	chr15:30926514~30928407:+
BRCA	cis	rs8031584	0.958	rs11637469	ENSG00000270015.1	RP11-540B6.6	-5.13	3.47e-07	3.86e-05	-0.17	-0.16	Huntington's disease progression;	chr15:30946580	chr15:30926514~30928407:+
BRCA	cis	rs465969	0.793	rs34288099	ENSG00000272356.1	RP5-1112D6.8	5.13	3.47e-07	3.86e-05	0.27	0.16	Psoriasis;	chr6:111424034	chr6:111309203~111313517:+
BRCA	cis	rs2153535	0.623	rs6597338	ENSG00000251164.1	HULC	-5.13	3.47e-07	3.86e-05	-0.19	-0.16	Motion sickness;	chr6:8533275	chr6:8652137~8653846:+
BRCA	cis	rs7618501	0.633	rs4688689	ENSG00000228008.1	CTD-2330K9.3	5.13	3.48e-07	3.87e-05	0.15	0.16	Intelligence (multi-trait analysis);	chr3:49998109	chr3:49903845~49916937:+
BRCA	cis	rs9341808	0.718	rs3805922	ENSG00000272129.1	RP11-250B2.6	5.13	3.48e-07	3.87e-05	0.2	0.16	Sitting height ratio;	chr6:80182272	chr6:80355424~80356859:+
BRCA	cis	rs11955398	0.585	rs10063407	ENSG00000215032.2	GNL3LP1	-5.13	3.48e-07	3.87e-05	-0.19	-0.16	Intelligence (multi-trait analysis);	chr5:60713236	chr5:60891935~60893577:-
BRCA	cis	rs2403083	0.626	rs4150867	ENSG00000258256.1	RP11-219B4.5	-5.13	3.48e-07	3.87e-05	-0.19	-0.16	Plasma amyloid beta peptide concentrations (ABx-40);	chr8:85187307	chr8:85222446~85245717:-
BRCA	cis	rs2403083	0.515	rs4150869	ENSG00000258256.1	RP11-219B4.5	-5.13	3.48e-07	3.87e-05	-0.19	-0.16	Plasma amyloid beta peptide concentrations (ABx-40);	chr8:85187466	chr8:85222446~85245717:-
BRCA	cis	rs950880	0.767	rs1420098	ENSG00000234389.1	AC007278.3	-5.13	3.48e-07	3.87e-05	-0.14	-0.16	Serum protein levels (sST2);	chr2:102367819	chr2:102438713~102440475:+
BRCA	cis	rs8098244	0.737	rs1786046	ENSG00000264745.1	TTC39C-AS1	-5.13	3.48e-07	3.87e-05	-0.24	-0.16	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23955801	chr18:23994213~24015339:-
BRCA	cis	rs2153535	0.601	rs2327091	ENSG00000251164.1	HULC	-5.13	3.48e-07	3.87e-05	-0.19	-0.16	Motion sickness;	chr6:8540136	chr6:8652137~8653846:+
BRCA	cis	rs13113518	1	rs9312661	ENSG00000223305.1	RN7SKP30	5.13	3.48e-07	3.87e-05	0.19	0.16	Height;	chr4:55476159	chr4:55540502~55540835:-
BRCA	cis	rs2281558	0.754	rs73597824	ENSG00000230772.1	VN1R108P	-5.13	3.48e-07	3.87e-05	-0.2	-0.16	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25610841	chr20:25734264~25735093:+
BRCA	cis	rs9473147	0.516	rs9395279	ENSG00000270761.1	RP11-385F7.1	-5.13	3.48e-07	3.87e-05	-0.17	-0.16	Platelet distribution width;Mean platelet volume;	chr6:47575128	chr6:47477243~47477572:-
BRCA	cis	rs7727544	0.606	rs2631360	ENSG00000233006.5	AC034220.3	5.13	3.48e-07	3.87e-05	0.12	0.16	Blood metabolite levels;	chr5:132371737	chr5:132311285~132369916:-
BRCA	cis	rs2522056	0.935	rs757104	ENSG00000233006.5	AC034220.3	-5.13	3.48e-07	3.87e-05	-0.13	-0.16	Fibrinogen;Lymphocyte counts;	chr5:132459537	chr5:132311285~132369916:-
BRCA	cis	rs300890	0.585	rs542555	ENSG00000250326.1	RP11-284M14.1	5.13	3.49e-07	3.87e-05	0.19	0.16	Nasopharyngeal carcinoma;	chr4:143264803	chr4:142933195~143184861:-
BRCA	cis	rs957448	0.554	rs10956919	ENSG00000261437.1	RP11-22C11.2	5.13	3.49e-07	3.87e-05	0.15	0.16	Nonsyndromic cleft lip with cleft palate;	chr8:94572945	chr8:94637285~94639467:-
BRCA	cis	rs7818688	1	rs28406132	ENSG00000253528.2	RP11-347C18.4	-5.13	3.49e-07	3.88e-05	-0.24	-0.16	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95018149	chr8:94974573~94974853:-
BRCA	cis	rs1862618	0.671	rs2591956	ENSG00000271828.1	CTD-2310F14.1	-5.13	3.49e-07	3.88e-05	-0.2	-0.16	Initial pursuit acceleration;	chr5:56948777	chr5:56927874~56929573:+
BRCA	cis	rs300890	0.583	rs2012599	ENSG00000250326.1	RP11-284M14.1	-5.13	3.49e-07	3.88e-05	-0.17	-0.16	Nasopharyngeal carcinoma;	chr4:143275707	chr4:142933195~143184861:-
BRCA	cis	rs2153535	0.601	rs1737581	ENSG00000251164.1	HULC	-5.13	3.49e-07	3.88e-05	-0.19	-0.16	Motion sickness;	chr6:8538905	chr6:8652137~8653846:+
BRCA	cis	rs1707322	1	rs785486	ENSG00000234329.1	RP11-767N6.2	-5.13	3.49e-07	3.88e-05	-0.16	-0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46109476	chr1:45651039~45651826:-
BRCA	cis	rs4722166	0.597	rs1554606	ENSG00000225541.1	AC002480.5	-5.13	3.49e-07	3.88e-05	-0.16	-0.16	Lung cancer;	chr7:22729088	chr7:22571607~22661792:-
BRCA	cis	rs8177876	0.597	rs1048194	ENSG00000261838.4	RP11-303E16.6	-5.13	3.49e-07	3.88e-05	-0.36	-0.16	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81031097	chr16:81069854~81076598:+
BRCA	cis	rs6714710	0.58	rs13032265	ENSG00000230606.9	AC159540.1	-5.13	3.49e-07	3.88e-05	-0.18	-0.16	Posterior cortical atrophy and Alzheimer's disease;	chr2:97793102	chr2:97416165~97433527:-
BRCA	cis	rs2832191	0.755	rs2832193	ENSG00000176054.6	RPL23P2	-5.13	3.49e-07	3.88e-05	-0.17	-0.16	Dental caries;	chr21:29121268	chr21:28997613~28998033:-
BRCA	cis	rs4700393	0.967	rs4700394	ENSG00000215032.2	GNL3LP1	-5.13	3.49e-07	3.88e-05	-0.19	-0.16	Intelligence (multi-trait analysis);	chr5:60821375	chr5:60891935~60893577:-
BRCA	cis	rs7772486	0.875	rs9322048	ENSG00000270638.1	RP3-466P17.1	5.13	3.5e-07	3.88e-05	0.18	0.16	Lobe attachment (rater-scored or self-reported);	chr6:146079303	chr6:145735570~145737218:+
BRCA	cis	rs12477438	0.52	rs2516830	ENSG00000231822.1	AC019097.7	5.13	3.5e-07	3.88e-05	0.16	0.16	Chronic sinus infection;	chr2:99157239	chr2:99102018~99102752:+
BRCA	cis	rs12477438	0.52	rs2632283	ENSG00000231822.1	AC019097.7	5.13	3.5e-07	3.88e-05	0.16	0.16	Chronic sinus infection;	chr2:99159537	chr2:99102018~99102752:+
BRCA	cis	rs12477438	0.501	rs2516833	ENSG00000231822.1	AC019097.7	5.13	3.5e-07	3.88e-05	0.16	0.16	Chronic sinus infection;	chr2:99160942	chr2:99102018~99102752:+
BRCA	cis	rs12477438	0.52	rs2516835	ENSG00000231822.1	AC019097.7	5.13	3.5e-07	3.88e-05	0.16	0.16	Chronic sinus infection;	chr2:99162668	chr2:99102018~99102752:+
BRCA	cis	rs12477438	0.501	rs7608938	ENSG00000231822.1	AC019097.7	5.13	3.5e-07	3.88e-05	0.16	0.16	Chronic sinus infection;	chr2:99165763	chr2:99102018~99102752:+
BRCA	cis	rs12477438	0.501	rs6542868	ENSG00000231822.1	AC019097.7	5.13	3.5e-07	3.88e-05	0.16	0.16	Chronic sinus infection;	chr2:99166385	chr2:99102018~99102752:+
BRCA	cis	rs12477438	0.501	rs6727749	ENSG00000231822.1	AC019097.7	5.13	3.5e-07	3.88e-05	0.16	0.16	Chronic sinus infection;	chr2:99177127	chr2:99102018~99102752:+
BRCA	cis	rs12477438	0.501	rs13033012	ENSG00000231822.1	AC019097.7	5.13	3.5e-07	3.88e-05	0.16	0.16	Chronic sinus infection;	chr2:99178686	chr2:99102018~99102752:+
BRCA	cis	rs12477438	0.501	rs13000731	ENSG00000231822.1	AC019097.7	5.13	3.5e-07	3.88e-05	0.16	0.16	Chronic sinus infection;	chr2:99178768	chr2:99102018~99102752:+
BRCA	cis	rs875971	0.545	rs17138156	ENSG00000232546.1	RP11-458F8.1	5.13	3.5e-07	3.88e-05	0.15	0.16	Aortic root size;	chr7:66249708	chr7:66848496~66858136:+
BRCA	cis	rs6847067	0.672	rs6838727	ENSG00000180769.7	WDFY3-AS2	5.13	3.5e-07	3.88e-05	0.16	0.16	Oropharynx cancer;	chr4:84735197	chr4:84965682~85011277:+
BRCA	cis	rs7914558	0.966	rs7908280	ENSG00000236937.2	PTGES3P4	5.13	3.5e-07	3.89e-05	0.2	0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103057190	chr10:102845595~102845950:+
BRCA	cis	rs847577	0.572	rs847573	ENSG00000272950.1	RP11-307C18.1	-5.13	3.5e-07	3.89e-05	-0.22	-0.16	Breast cancer;	chr7:98052449	chr7:98322853~98323430:+
BRCA	cis	rs321358	0.945	rs10502130	ENSG00000271390.1	RP11-89C3.3	5.13	3.5e-07	3.89e-05	0.26	0.16	Body mass index;	chr11:111107437	chr11:111089870~111090368:-
BRCA	cis	rs321358	0.945	rs73017109	ENSG00000271390.1	RP11-89C3.3	5.13	3.5e-07	3.89e-05	0.26	0.16	Body mass index;	chr11:111108484	chr11:111089870~111090368:-
BRCA	cis	rs321358	0.887	rs1470537	ENSG00000271390.1	RP11-89C3.3	5.13	3.5e-07	3.89e-05	0.26	0.16	Body mass index;	chr11:111109328	chr11:111089870~111090368:-
BRCA	cis	rs321358	0.945	rs12421769	ENSG00000271390.1	RP11-89C3.3	5.13	3.5e-07	3.89e-05	0.26	0.16	Body mass index;	chr11:111109500	chr11:111089870~111090368:-
BRCA	cis	rs321358	0.945	rs73017114	ENSG00000271390.1	RP11-89C3.3	5.13	3.5e-07	3.89e-05	0.26	0.16	Body mass index;	chr11:111111582	chr11:111089870~111090368:-
BRCA	cis	rs321358	0.945	rs17458493	ENSG00000271390.1	RP11-89C3.3	5.13	3.5e-07	3.89e-05	0.26	0.16	Body mass index;	chr11:111112156	chr11:111089870~111090368:-
BRCA	cis	rs321358	0.945	rs17458541	ENSG00000271390.1	RP11-89C3.3	5.13	3.5e-07	3.89e-05	0.26	0.16	Body mass index;	chr11:111113182	chr11:111089870~111090368:-
BRCA	cis	rs321358	0.836	rs17458597	ENSG00000271390.1	RP11-89C3.3	5.13	3.5e-07	3.89e-05	0.26	0.16	Body mass index;	chr11:111113599	chr11:111089870~111090368:-
BRCA	cis	rs321358	0.945	rs73017176	ENSG00000271390.1	RP11-89C3.3	5.13	3.5e-07	3.89e-05	0.26	0.16	Body mass index;	chr11:111113879	chr11:111089870~111090368:-
BRCA	cis	rs321358	0.887	rs80221187	ENSG00000271390.1	RP11-89C3.3	5.13	3.5e-07	3.89e-05	0.26	0.16	Body mass index;	chr11:111113977	chr11:111089870~111090368:-
BRCA	cis	rs321358	0.945	rs73017177	ENSG00000271390.1	RP11-89C3.3	5.13	3.5e-07	3.89e-05	0.26	0.16	Body mass index;	chr11:111114034	chr11:111089870~111090368:-
BRCA	cis	rs321358	0.895	rs73017179	ENSG00000271390.1	RP11-89C3.3	5.13	3.5e-07	3.89e-05	0.26	0.16	Body mass index;	chr11:111114037	chr11:111089870~111090368:-
BRCA	cis	rs321358	0.945	rs1356411	ENSG00000271390.1	RP11-89C3.3	5.13	3.5e-07	3.89e-05	0.26	0.16	Body mass index;	chr11:111115371	chr11:111089870~111090368:-
BRCA	cis	rs1552244	0.882	rs34706481	ENSG00000232901.1	CYCSP10	5.13	3.5e-07	3.89e-05	0.23	0.16	Alzheimer's disease;	chr3:9962439	chr3:10000647~10000940:-
BRCA	cis	rs7914558	0.966	rs10748835	ENSG00000236937.2	PTGES3P4	5.13	3.5e-07	3.89e-05	0.2	0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102900499	chr10:102845595~102845950:+
BRCA	cis	rs10504130	0.932	rs11787229	ENSG00000272024.1	RP11-546K22.3	-5.13	3.5e-07	3.89e-05	-0.29	-0.16	Venous thromboembolism (SNP x SNP interaction);	chr8:51935311	chr8:51950284~51950690:+
BRCA	cis	rs4835473	0.897	rs2089835	ENSG00000249741.2	RP11-673E1.3	-5.13	3.5e-07	3.89e-05	-0.17	-0.16	Immature fraction of reticulocytes;	chr4:143965127	chr4:143911514~143912053:-
BRCA	cis	rs8002861	0.905	rs9525869	ENSG00000274001.1	RP11-5G9.5	5.13	3.51e-07	3.89e-05	0.18	0.16	Leprosy;	chr13:43893074	chr13:43877715~43878163:-
BRCA	cis	rs8002861	0.934	rs9533685	ENSG00000274001.1	RP11-5G9.5	5.13	3.51e-07	3.89e-05	0.18	0.16	Leprosy;	chr13:43894195	chr13:43877715~43878163:-
BRCA	cis	rs8180040	0.647	rs57756484	ENSG00000276925.1	RP11-708J19.3	5.13	3.51e-07	3.89e-05	0.18	0.16	Colorectal cancer;	chr3:47197843	chr3:47469777~47469987:+
BRCA	cis	rs11673344	0.504	rs2595555	ENSG00000226686.6	LINC01535	5.13	3.51e-07	3.9e-05	0.2	0.16	Obesity-related traits;	chr19:37000219	chr19:37251912~37265535:+
BRCA	cis	rs11673344	0.504	rs1667377	ENSG00000226686.6	LINC01535	5.13	3.51e-07	3.9e-05	0.2	0.16	Obesity-related traits;	chr19:37000966	chr19:37251912~37265535:+
BRCA	cis	rs11673344	0.523	rs1667379	ENSG00000226686.6	LINC01535	5.13	3.51e-07	3.9e-05	0.2	0.16	Obesity-related traits;	chr19:37001192	chr19:37251912~37265535:+
BRCA	cis	rs1075265	0.729	rs10201364	ENSG00000235937.1	AC008280.1	5.13	3.51e-07	3.9e-05	0.17	0.16	Chronotype;Morning vs. evening chronotype;	chr2:53990220	chr2:54029552~54030682:-
BRCA	cis	rs6445975	0.726	rs7639532	ENSG00000272360.1	RP11-359I18.5	5.13	3.51e-07	3.9e-05	0.17	0.16	Systemic lupus erythematosus;	chr3:58481929	chr3:58490830~58491291:-
BRCA	cis	rs962856	0.822	rs6546307	ENSG00000236780.4	AC078941.1	5.13	3.51e-07	3.9e-05	0.2	0.16	Pancreatic cancer;	chr2:67416921	chr2:67123357~67215319:-
BRCA	cis	rs12285276	0.636	rs7114337	ENSG00000205106.4	DKFZp779M0652	5.13	3.52e-07	3.91e-05	0.24	0.16	Visceral fat;	chr11:45779608	chr11:45771432~45772358:+
BRCA	cis	rs10129255	1	rs9324091	ENSG00000211974.3	IGHV2-70	5.13	3.52e-07	3.91e-05	0.17	0.16	Kawasaki disease;	chr14:106676625	chr14:106723574~106724093:-
BRCA	cis	rs4908768	0.501	rs12756257	ENSG00000232912.4	RP5-1115A15.1	5.13	3.52e-07	3.91e-05	0.15	0.16	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8556874	chr1:8424645~8434838:+
BRCA	cis	rs11783469	0.522	rs11781871	ENSG00000253390.1	CTC-756D1.2	-5.13	3.52e-07	3.91e-05	-0.24	-0.16	Reticulocyte count;	chr8:23399577	chr8:23458601~23484971:+
BRCA	cis	rs2832191	0.74	rs6516890	ENSG00000215533.7	LINC00189	-5.13	3.52e-07	3.91e-05	-0.17	-0.16	Dental caries;	chr21:29104491	chr21:29193480~29288205:+
BRCA	cis	rs1520333	0.54	rs61334537	ENSG00000254352.1	RP11-578O24.2	-5.13	3.52e-07	3.91e-05	-0.24	-0.16	Multiple sclerosis;	chr8:78451390	chr8:78723796~78724136:-
BRCA	cis	rs1520333	0.54	rs59995609	ENSG00000254352.1	RP11-578O24.2	-5.13	3.52e-07	3.91e-05	-0.24	-0.16	Multiple sclerosis;	chr8:78451391	chr8:78723796~78724136:-
BRCA	cis	rs7829975	0.623	rs10087493	ENSG00000233609.3	RP11-62H7.2	-5.13	3.52e-07	3.91e-05	-0.15	-0.16	Mood instability;	chr8:8516047	chr8:8961200~8979025:+
BRCA	cis	rs9816784	0.901	rs56253832	ENSG00000242086.7	LINC00969	5.13	3.52e-07	3.91e-05	0.17	0.16	Mean corpuscular hemoglobin;	chr3:196090304	chr3:195658062~195739964:+
BRCA	cis	rs2243480	1	rs160634	ENSG00000230295.1	RP11-458F8.2	5.13	3.52e-07	3.91e-05	0.2	0.16	Diabetic kidney disease;	chr7:66063677	chr7:66880708~66882981:+
BRCA	cis	rs2303319	1	rs57090160	ENSG00000227403.1	AC009299.3	5.13	3.52e-07	3.91e-05	0.39	0.16	Cognitive function;	chr2:161322686	chr2:161244739~161249050:+
BRCA	cis	rs1005277	0.579	rs1614236	ENSG00000263064.2	RP11-291L22.7	5.13	3.53e-07	3.92e-05	0.19	0.16	Extrinsic epigenetic age acceleration;	chr10:38214068	chr10:38448689~38448949:+
BRCA	cis	rs1005277	0.579	rs2749616	ENSG00000263064.2	RP11-291L22.7	5.13	3.53e-07	3.92e-05	0.19	0.16	Extrinsic epigenetic age acceleration;	chr10:38222065	chr10:38448689~38448949:+
BRCA	cis	rs7474896	0.561	rs2474603	ENSG00000120555.12	SEPT7P9	5.13	3.53e-07	3.92e-05	0.23	0.16	Obesity (extreme);	chr10:38156754	chr10:38383069~38402916:-
BRCA	cis	rs6751744	0.855	rs35019796	ENSG00000226266.5	AC009961.3	-5.13	3.53e-07	3.92e-05	-0.21	-0.16	Dysphagia;	chr2:159510644	chr2:159670708~159712435:-
BRCA	cis	rs4819052	0.679	rs2255761	ENSG00000184274.3	LINC00315	-5.13	3.53e-07	3.92e-05	-0.2	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45263707	chr21:45300245~45305257:-
BRCA	cis	rs2638953	0.924	rs2272361	ENSG00000247934.4	RP11-967K21.1	-5.13	3.53e-07	3.92e-05	-0.2	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28450037	chr12:28163298~28190738:-
BRCA	cis	rs9907295	0.605	rs11652192	ENSG00000270977.1	AC015849.16	-5.13	3.53e-07	3.92e-05	-0.28	-0.16	Fibroblast growth factor basic levels;	chr17:35833174	chr17:35893707~35911023:-
BRCA	cis	rs7620503	1	rs1875095	ENSG00000228221.4	LINC00578	5.13	3.53e-07	3.92e-05	0.18	0.16	Corneal structure;	chr3:177585935	chr3:177441921~177752305:+
BRCA	cis	rs12477438	0.501	rs11692336	ENSG00000231822.1	AC019097.7	5.13	3.53e-07	3.92e-05	0.16	0.16	Chronic sinus infection;	chr2:99124143	chr2:99102018~99102752:+
BRCA	cis	rs12477438	0.52	rs1133978	ENSG00000231822.1	AC019097.7	5.13	3.53e-07	3.92e-05	0.16	0.16	Chronic sinus infection;	chr2:99125501	chr2:99102018~99102752:+
BRCA	cis	rs8002861	0.935	rs1811464	ENSG00000274001.1	RP11-5G9.5	5.13	3.53e-07	3.92e-05	0.18	0.16	Leprosy;	chr13:43895154	chr13:43877715~43878163:-
BRCA	cis	rs875971	0.767	rs61348003	ENSG00000273448.1	RP11-166O4.6	5.13	3.53e-07	3.92e-05	0.15	0.16	Aortic root size;	chr7:66540947	chr7:67333047~67334383:+
BRCA	cis	rs875971	0.825	rs801202	ENSG00000273448.1	RP11-166O4.6	-5.13	3.53e-07	3.92e-05	-0.15	-0.16	Aortic root size;	chr7:66558942	chr7:67333047~67334383:+
BRCA	cis	rs10504130	0.932	rs11777016	ENSG00000253844.1	RP11-546K22.1	-5.13	3.53e-07	3.92e-05	-0.27	-0.16	Venous thromboembolism (SNP x SNP interaction);	chr8:51874258	chr8:51961458~52022974:+
BRCA	cis	rs4835473	0.524	rs4404495	ENSG00000249741.2	RP11-673E1.3	-5.13	3.53e-07	3.92e-05	-0.17	-0.16	Immature fraction of reticulocytes;	chr4:143979791	chr4:143911514~143912053:-
BRCA	cis	rs2839186	0.77	rs2839984	ENSG00000228137.1	AP001469.7	5.13	3.54e-07	3.92e-05	0.16	0.16	Testicular germ cell tumor;	chr21:46251776	chr21:46246890~46247682:+
BRCA	cis	rs7267979	0.844	rs2257649	ENSG00000274973.1	RP13-401N8.7	-5.13	3.54e-07	3.92e-05	-0.18	-0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25282821	chr20:25845497~25845862:+
BRCA	cis	rs2281558	0.833	rs55792313	ENSG00000230772.1	VN1R108P	-5.13	3.54e-07	3.92e-05	-0.2	-0.16	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25540619	chr20:25734264~25735093:+
BRCA	cis	rs7267979	0.789	rs2260197	ENSG00000231081.1	RP4-760C5.3	-5.13	3.54e-07	3.92e-05	-0.21	-0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25303707	chr20:26008791~26010531:-
BRCA	cis	rs3733585	0.578	rs4466042	ENSG00000250413.1	RP11-448G15.1	5.13	3.54e-07	3.93e-05	0.2	0.16	Cleft plate (environmental tobacco smoke interaction);	chr4:9953743	chr4:10006482~10009725:+
BRCA	cis	rs3733585	0.726	rs4306953	ENSG00000250413.1	RP11-448G15.1	5.13	3.54e-07	3.93e-05	0.2	0.16	Cleft plate (environmental tobacco smoke interaction);	chr4:9954152	chr4:10006482~10009725:+
BRCA	cis	rs13113518	0.783	rs34534635	ENSG00000272969.1	RP11-528I4.2	5.13	3.54e-07	3.93e-05	0.19	0.16	Height;	chr4:55573424	chr4:55547112~55547889:+
BRCA	cis	rs13113518	0.783	rs7690837	ENSG00000272969.1	RP11-528I4.2	5.13	3.54e-07	3.93e-05	0.19	0.16	Height;	chr4:55575856	chr4:55547112~55547889:+
BRCA	cis	rs10739663	0.52	rs2819624	ENSG00000232630.1	PRPS1P2	-5.13	3.54e-07	3.93e-05	-0.16	-0.16	Resting heart rate;	chr9:125394240	chr9:125150653~125151589:+
BRCA	cis	rs987360	0.775	rs10012725	ENSG00000248869.4	RP11-138I17.1	5.13	3.54e-07	3.93e-05	0.16	0.16	Temperament;	chr4:137270770	chr4:136796722~137212799:-
BRCA	cis	rs4835473	1	rs4835473	ENSG00000249741.2	RP11-673E1.3	-5.13	3.54e-07	3.93e-05	-0.17	-0.16	Immature fraction of reticulocytes;	chr4:143982419	chr4:143911514~143912053:-
BRCA	cis	rs10752881	0.905	rs10797830	ENSG00000224468.3	RP11-181K3.4	-5.13	3.54e-07	3.93e-05	-0.17	-0.16	Colorectal cancer;	chr1:183067139	chr1:183138402~183141282:-
BRCA	cis	rs10911232	0.52	rs10797831	ENSG00000224468.3	RP11-181K3.4	-5.13	3.54e-07	3.93e-05	-0.17	-0.16	Hypertriglyceridemia;	chr1:183067681	chr1:183138402~183141282:-
BRCA	cis	rs10861342	1	rs1345095	ENSG00000257999.1	RP11-61E11.2	-5.12	3.55e-07	3.93e-05	-0.35	-0.16	IgG glycosylation;	chr12:105077799	chr12:105102472~105107179:-
BRCA	cis	rs11955398	0.502	rs295531	ENSG00000215032.2	GNL3LP1	5.12	3.55e-07	3.94e-05	0.2	0.16	Intelligence (multi-trait analysis);	chr5:61099916	chr5:60891935~60893577:-
BRCA	cis	rs1555322	0.53	rs2425047	ENSG00000269202.1	RP4-614O4.12	5.12	3.55e-07	3.94e-05	0.18	0.16	Attention deficit hyperactivity disorder;	chr20:35283872	chr20:35201747~35203288:-
BRCA	cis	rs9921338	0.961	rs8060767	ENSG00000262703.1	RP11-485G7.6	-5.12	3.55e-07	3.94e-05	-0.2	-0.16	Vein graft stenosis in coronary artery bypass grafting;	chr16:11276741	chr16:11348143~11349321:-
BRCA	cis	rs7914558	0.902	rs7092200	ENSG00000236937.2	PTGES3P4	5.12	3.55e-07	3.94e-05	0.2	0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103085115	chr10:102845595~102845950:+
BRCA	cis	rs2303319	0.504	rs56371522	ENSG00000227403.1	AC009299.3	5.12	3.55e-07	3.94e-05	0.37	0.16	Cognitive function;	chr2:161634599	chr2:161244739~161249050:+
BRCA	cis	rs2303319	0.504	rs62188960	ENSG00000227403.1	AC009299.3	5.12	3.55e-07	3.94e-05	0.37	0.16	Cognitive function;	chr2:161636068	chr2:161244739~161249050:+
BRCA	cis	rs2303319	0.504	rs12470590	ENSG00000227403.1	AC009299.3	5.12	3.55e-07	3.94e-05	0.37	0.16	Cognitive function;	chr2:161636592	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.786	rs115562071	ENSG00000227403.1	AC009299.3	5.12	3.55e-07	3.94e-05	0.37	0.16	Blood osmolality (transformed sodium);	chr2:161636731	chr2:161244739~161249050:+
BRCA	cis	rs5167	0.566	rs934427	ENSG00000280087.1	CTB-129P6.7	5.12	3.55e-07	3.94e-05	0.21	0.16	Blood protein levels;	chr19:44975559	chr19:44909375~44914968:+
BRCA	cis	rs6480314	0.542	rs10998044	ENSG00000233590.1	RP11-153K11.3	-5.12	3.55e-07	3.94e-05	-0.25	-0.16	Optic nerve measurement (disc area);	chr10:68269508	chr10:68233251~68242379:-
BRCA	cis	rs6568686	0.627	rs174374	ENSG00000255389.1	C6orf3	5.12	3.56e-07	3.94e-05	0.22	0.16	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr6:111584852	chr6:111599875~111602295:+
BRCA	cis	rs9287719	0.839	rs11683335	ENSG00000243819.4	RN7SL832P	5.12	3.56e-07	3.94e-05	0.15	0.16	Prostate cancer;	chr2:10616539	chr2:10690344~10692099:+
BRCA	cis	rs1218582	0.741	rs6656494	ENSG00000270361.1	RP11-307C12.13	-5.12	3.56e-07	3.95e-05	-0.18	-0.16	Prostate cancer;	chr1:154867323	chr1:154937370~154938059:+
BRCA	cis	rs7617773	0.78	rs6442111	ENSG00000199476.1	Y_RNA	-5.12	3.56e-07	3.95e-05	-0.22	-0.16	Coronary artery disease;	chr3:48270570	chr3:48288587~48288694:+
BRCA	cis	rs7577696	0.525	rs2366547	ENSG00000272716.1	RP11-563N4.1	-5.12	3.56e-07	3.95e-05	-0.19	-0.16	Inflammatory biomarkers;	chr2:32026040	chr2:32165046~32165757:-
BRCA	cis	rs801193	0.569	rs2707824	ENSG00000273448.1	RP11-166O4.6	5.12	3.56e-07	3.95e-05	0.14	0.16	Aortic root size;	chr7:66724256	chr7:67333047~67334383:+
BRCA	cis	rs12680842	0.883	rs13265241	ENSG00000253175.1	RP11-267M23.6	5.12	3.57e-07	3.95e-05	0.18	0.16	Body mass index;	chr8:94575129	chr8:94565036~94565715:+
BRCA	cis	rs77204473	1	rs12279433	ENSG00000280143.1	AP000892.6	-5.12	3.57e-07	3.96e-05	-0.28	-0.16	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116877505	chr11:117204967~117210292:+
BRCA	cis	rs1075265	0.87	rs7569214	ENSG00000235937.1	AC008280.1	5.12	3.57e-07	3.96e-05	0.17	0.16	Chronotype;Morning vs. evening chronotype;	chr2:53989049	chr2:54029552~54030682:-
BRCA	cis	rs8040855	0.756	rs12909477	ENSG00000259774.1	RP11-182J1.13	-5.12	3.57e-07	3.96e-05	-0.22	-0.16	Bulimia nervosa;	chr15:85146644	chr15:84422618~84425882:+
BRCA	cis	rs2574985	0.739	rs3011794	ENSG00000231345.3	BEND3P1	-5.12	3.57e-07	3.96e-05	-0.26	-0.16	Subjective well-being;	chr10:50556830	chr10:50655967~50660472:+
BRCA	cis	rs2098713	0.535	rs10941358	ENSG00000250155.1	CTD-2353F22.1	5.12	3.57e-07	3.96e-05	0.17	0.16	Telomere length;	chr5:37637276	chr5:36666214~36725195:-
BRCA	cis	rs6490294	0.528	rs79761579	ENSG00000226469.1	ADAM1B	5.12	3.57e-07	3.96e-05	0.28	0.16	Mean platelet volume;	chr12:112021081	chr12:111927018~111929017:+
BRCA	cis	rs13113518	1	rs13146987	ENSG00000223305.1	RN7SKP30	5.12	3.57e-07	3.96e-05	0.19	0.16	Height;	chr4:55491628	chr4:55540502~55540835:-
BRCA	cis	rs13113518	1	rs7677085	ENSG00000223305.1	RN7SKP30	5.12	3.57e-07	3.96e-05	0.19	0.16	Height;	chr4:55495801	chr4:55540502~55540835:-
BRCA	cis	rs13113518	0.966	rs12510681	ENSG00000223305.1	RN7SKP30	5.12	3.57e-07	3.96e-05	0.19	0.16	Height;	chr4:55496737	chr4:55540502~55540835:-
BRCA	cis	rs13113518	1	rs12500162	ENSG00000223305.1	RN7SKP30	5.12	3.57e-07	3.96e-05	0.19	0.16	Height;	chr4:55496933	chr4:55540502~55540835:-
BRCA	cis	rs13113518	1	rs7686261	ENSG00000223305.1	RN7SKP30	5.12	3.57e-07	3.96e-05	0.19	0.16	Height;	chr4:55500224	chr4:55540502~55540835:-
BRCA	cis	rs13113518	1	rs11729220	ENSG00000223305.1	RN7SKP30	5.12	3.57e-07	3.96e-05	0.19	0.16	Height;	chr4:55501629	chr4:55540502~55540835:-
BRCA	cis	rs13113518	1	rs11133390	ENSG00000223305.1	RN7SKP30	5.12	3.57e-07	3.96e-05	0.19	0.16	Height;	chr4:55501726	chr4:55540502~55540835:-
BRCA	cis	rs13113518	1	rs11133391	ENSG00000223305.1	RN7SKP30	5.12	3.57e-07	3.96e-05	0.19	0.16	Height;	chr4:55501788	chr4:55540502~55540835:-
BRCA	cis	rs13113518	0.966	rs13133484	ENSG00000223305.1	RN7SKP30	5.12	3.57e-07	3.96e-05	0.19	0.16	Height;	chr4:55504176	chr4:55540502~55540835:-
BRCA	cis	rs13113518	0.934	rs13127906	ENSG00000223305.1	RN7SKP30	5.12	3.57e-07	3.96e-05	0.19	0.16	Height;	chr4:55504201	chr4:55540502~55540835:-
BRCA	cis	rs370915	0.578	rs1367932	ENSG00000250971.1	RP11-696F12.1	5.12	3.57e-07	3.96e-05	0.17	0.16	Gout;	chr4:186855500	chr4:187060099~187060930:+
BRCA	cis	rs13325613	0.915	rs34414382	ENSG00000223552.1	RP11-24F11.2	-5.12	3.57e-07	3.96e-05	-0.33	-0.16	Monocyte count;	chr3:46223699	chr3:46364955~46407059:-
BRCA	cis	rs13325613	0.915	rs35613615	ENSG00000223552.1	RP11-24F11.2	-5.12	3.57e-07	3.96e-05	-0.33	-0.16	Monocyte count;	chr3:46223752	chr3:46364955~46407059:-
BRCA	cis	rs914615	0.508	rs4971079	ENSG00000160766.13	GBAP1	-5.12	3.57e-07	3.96e-05	-0.15	-0.16	Urinary albumin-to-creatinine ratio;	chr1:155157915	chr1:155213821~155227422:-
BRCA	cis	rs11758351	0.66	rs11753655	ENSG00000241549.7	GUSBP2	-5.12	3.58e-07	3.96e-05	-0.22	-0.16	Renal underexcretion gout;Gout;	chr6:26219881	chr6:26871484~26956554:-
BRCA	cis	rs2638953	0.815	rs10843186	ENSG00000247934.4	RP11-967K21.1	-5.12	3.58e-07	3.96e-05	-0.21	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28482921	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.815	rs1511551	ENSG00000247934.4	RP11-967K21.1	-5.12	3.58e-07	3.96e-05	-0.21	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28483897	chr12:28163298~28190738:-
BRCA	cis	rs7617773	0.743	rs6804986	ENSG00000199476.1	Y_RNA	-5.12	3.58e-07	3.97e-05	-0.22	-0.16	Coronary artery disease;	chr3:48322105	chr3:48288587~48288694:+
BRCA	cis	rs2839186	0.708	rs17183123	ENSG00000228137.1	AP001469.7	5.12	3.58e-07	3.97e-05	0.16	0.16	Testicular germ cell tumor;	chr21:46252047	chr21:46246890~46247682:+
BRCA	cis	rs2638953	0.893	rs7313862	ENSG00000247934.4	RP11-967K21.1	-5.12	3.58e-07	3.97e-05	-0.19	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28458846	chr12:28163298~28190738:-
BRCA	cis	rs202072	0.527	rs366904	ENSG00000272379.1	RP1-257A7.5	5.12	3.58e-07	3.97e-05	0.25	0.16	HIV-1 viral setpoint;	chr6:13267449	chr6:13290018~13290490:-
BRCA	cis	rs7613875	0.58	rs6808044	ENSG00000228008.1	CTD-2330K9.3	-5.12	3.58e-07	3.97e-05	-0.16	-0.16	Body mass index;	chr3:50098732	chr3:49903845~49916937:+
BRCA	cis	rs7178909	0.866	rs3784388	ENSG00000259677.1	RP11-493E3.1	5.12	3.58e-07	3.97e-05	0.18	0.16	Common traits (Other);	chr15:89894069	chr15:89876540~89877285:+
BRCA	cis	rs7178909	0.872	rs3784387	ENSG00000259677.1	RP11-493E3.1	5.12	3.58e-07	3.97e-05	0.18	0.16	Common traits (Other);	chr15:89894138	chr15:89876540~89877285:+
BRCA	cis	rs7178909	0.8	rs3825866	ENSG00000259677.1	RP11-493E3.1	5.12	3.58e-07	3.97e-05	0.18	0.16	Common traits (Other);	chr15:89894406	chr15:89876540~89877285:+
BRCA	cis	rs11051970	0.559	rs3748276	ENSG00000274964.1	RP11-817I4.1	-5.12	3.58e-07	3.97e-05	-0.21	-0.16	Response to tocilizumab in rheumatoid arthritis;	chr12:32328643	chr12:32339368~32340724:+
BRCA	cis	rs4950322	0.947	rs58671552	ENSG00000278811.3	LINC00624	5.12	3.58e-07	3.97e-05	0.22	0.16	Protein quantitative trait loci;	chr1:147409534	chr1:147258885~147517875:-
BRCA	cis	rs11051970	0.559	rs11536026	ENSG00000274964.1	RP11-817I4.1	-5.12	3.58e-07	3.97e-05	-0.22	-0.16	Response to tocilizumab in rheumatoid arthritis;	chr12:32316593	chr12:32339368~32340724:+
BRCA	cis	rs7674212	0.541	rs11727498	ENSG00000251288.2	RP11-10L12.2	-5.12	3.58e-07	3.97e-05	-0.19	-0.16	Type 2 diabetes;	chr4:103179830	chr4:102751401~102752641:+
BRCA	cis	rs2361701	0.929	rs1467979	ENSG00000279259.1	RP11-334C17.3	-5.12	3.59e-07	3.97e-05	-0.2	-0.16	IgG glycosylation;	chr17:80086944	chr17:80147250~80148596:+
BRCA	cis	rs2832191	0.903	rs11700687	ENSG00000215533.7	LINC00189	5.12	3.59e-07	3.98e-05	0.18	0.16	Dental caries;	chr21:29114446	chr21:29193480~29288205:+
BRCA	cis	rs2832191	1	rs2832190	ENSG00000215533.7	LINC00189	5.12	3.59e-07	3.98e-05	0.18	0.16	Dental caries;	chr21:29115905	chr21:29193480~29288205:+
BRCA	cis	rs9652601	0.748	rs9927527	ENSG00000274038.1	RP11-66H6.4	-5.12	3.59e-07	3.98e-05	-0.18	-0.16	Systemic lupus erythematosus;	chr16:11118824	chr16:11056556~11057034:+
BRCA	cis	rs13113518	0.812	rs4864996	ENSG00000272969.1	RP11-528I4.2	5.12	3.59e-07	3.98e-05	0.18	0.16	Height;	chr4:55452921	chr4:55547112~55547889:+
BRCA	cis	rs7615952	0.546	rs2922194	ENSG00000171084.14	FAM86JP	5.12	3.59e-07	3.98e-05	0.27	0.16	Blood pressure (smoking interaction);	chr3:125613419	chr3:125916620~125930024:+
BRCA	cis	rs12468226	1	rs7597156	ENSG00000226261.1	AC064836.3	5.12	3.59e-07	3.98e-05	0.25	0.16	Urate levels;	chr2:202329339	chr2:202336024~202336727:-
BRCA	cis	rs1950326	0.515	rs8010499	ENSG00000258526.4	RP11-111A21.1	-5.12	3.59e-07	3.98e-05	-0.2	-0.16	Verbal memory performance (residualized delayed recall level);	chr14:39565767	chr14:39474840~39513780:+
BRCA	cis	rs62025270	0.632	rs111906684	ENSG00000259295.5	CSPG4P12	-5.12	3.59e-07	3.98e-05	-0.24	-0.16	Idiopathic pulmonary fibrosis;	chr15:85678705	chr15:85191438~85213905:+
BRCA	cis	rs4835473	0.897	rs6537170	ENSG00000249741.2	RP11-673E1.3	-5.12	3.59e-07	3.98e-05	-0.17	-0.16	Immature fraction of reticulocytes;	chr4:143691747	chr4:143911514~143912053:-
BRCA	cis	rs6723226	0.842	rs2754522	ENSG00000276334.1	AL133243.1	5.12	3.59e-07	3.98e-05	0.2	0.16	Intelligence (multi-trait analysis);	chr2:32576190	chr2:32521927~32523547:+
BRCA	cis	rs4650994	0.525	rs4457535	ENSG00000273384.1	RP5-1098D14.1	-5.12	3.59e-07	3.98e-05	-0.19	-0.16	HDL cholesterol;HDL cholesterol levels;	chr1:178528051	chr1:178651706~178652282:+
BRCA	cis	rs7178909	0.902	rs8034116	ENSG00000259677.1	RP11-493E3.1	5.12	3.59e-07	3.98e-05	0.19	0.16	Common traits (Other);	chr15:89898336	chr15:89876540~89877285:+
BRCA	cis	rs9473147	0.516	rs9367284	ENSG00000270761.1	RP11-385F7.1	-5.12	3.59e-07	3.98e-05	-0.17	-0.16	Platelet distribution width;Mean platelet volume;	chr6:47548633	chr6:47477243~47477572:-
BRCA	cis	rs6754311	0.517	rs1469996	ENSG00000224043.6	CCNT2-AS1	-5.12	3.6e-07	3.99e-05	-0.25	-0.16	Mosquito bite size;	chr2:135784990	chr2:134735464~134918710:-
BRCA	cis	rs11098499	0.863	rs9997631	ENSG00000249244.1	RP11-548H18.2	5.12	3.6e-07	3.99e-05	0.18	0.16	Corneal astigmatism;	chr4:119548840	chr4:119391831~119395335:-
BRCA	cis	rs17301013	0.869	rs3133270	ENSG00000227373.4	RP11-160H22.5	-5.12	3.6e-07	3.99e-05	-0.21	-0.16	Systemic lupus erythematosus;	chr1:174819547	chr1:174115300~174160004:-
BRCA	cis	rs1387259	0.931	rs1107654	ENSG00000257735.1	RP11-370I10.6	5.12	3.6e-07	3.99e-05	0.2	0.16	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48287314	chr12:48350945~48442411:+
BRCA	cis	rs9532669	0.926	rs2039119	ENSG00000239827.7	SUGT1P3	5.12	3.6e-07	3.99e-05	0.18	0.16	Cervical cancer;	chr13:40872432	chr13:40908159~40921774:-
BRCA	cis	rs12571093	0.803	rs61854839	ENSG00000233590.1	RP11-153K11.3	-5.12	3.6e-07	3.99e-05	-0.27	-0.16	Optic nerve measurement (disc area);	chr10:68284859	chr10:68233251~68242379:-
BRCA	cis	rs2286503	0.533	rs1880239	ENSG00000228649.7	AC005682.5	5.12	3.61e-07	3.99e-05	0.16	0.16	Fibrinogen;	chr7:22832065	chr7:22854178~22861579:+
BRCA	cis	rs3733585	0.534	rs7375642	ENSG00000250413.1	RP11-448G15.1	5.12	3.61e-07	4e-05	0.2	0.16	Cleft plate (environmental tobacco smoke interaction);	chr4:9953612	chr4:10006482~10009725:+
BRCA	cis	rs3733585	0.578	rs6837224	ENSG00000250413.1	RP11-448G15.1	5.12	3.61e-07	4e-05	0.2	0.16	Cleft plate (environmental tobacco smoke interaction);	chr4:9953631	chr4:10006482~10009725:+
BRCA	cis	rs7226408	0.857	rs72887048	ENSG00000267707.2	RP11-95O2.5	5.12	3.61e-07	4e-05	0.24	0.16	Obesity-related traits;	chr18:36903457	chr18:37243776~37247506:+
BRCA	cis	rs7226408	0.857	rs11081970	ENSG00000267707.2	RP11-95O2.5	5.12	3.61e-07	4e-05	0.24	0.16	Obesity-related traits;	chr18:36904803	chr18:37243776~37247506:+
BRCA	cis	rs7226408	0.802	rs11664299	ENSG00000267707.2	RP11-95O2.5	5.12	3.61e-07	4e-05	0.24	0.16	Obesity-related traits;	chr18:36906006	chr18:37243776~37247506:+
BRCA	cis	rs6940638	0.688	rs9393795	ENSG00000216901.1	AL022393.7	5.12	3.61e-07	4e-05	0.2	0.16	Intelligence (multi-trait analysis);	chr6:27249940	chr6:28176188~28176674:+
BRCA	cis	rs10492201	0.529	rs740420	ENSG00000236946.2	HNRNPA1P70	5.12	3.61e-07	4e-05	0.15	0.16	Itch intensity from mosquito bite adjusted by bite size;	chr12:68007862	chr12:68035767~68036853:+
BRCA	cis	rs539096	0.831	rs650729	ENSG00000236200.4	KDM4A-AS1	-5.12	3.61e-07	4e-05	-0.2	-0.16	Intelligence (multi-trait analysis);	chr1:43576868	chr1:43699765~43708138:-
BRCA	cis	rs516805	0.673	rs12201010	ENSG00000279453.1	RP3-425C14.4	5.12	3.62e-07	4.01e-05	0.22	0.16	Lymphocyte counts;	chr6:122345675	chr6:122436789~122439223:-
BRCA	cis	rs516805	0.64	rs12208084	ENSG00000279453.1	RP3-425C14.4	5.12	3.62e-07	4.01e-05	0.22	0.16	Lymphocyte counts;	chr6:122345745	chr6:122436789~122439223:-
BRCA	cis	rs516805	0.706	rs17662514	ENSG00000279453.1	RP3-425C14.4	5.12	3.62e-07	4.01e-05	0.22	0.16	Lymphocyte counts;	chr6:122346013	chr6:122436789~122439223:-
BRCA	cis	rs516805	0.706	rs9320863	ENSG00000279453.1	RP3-425C14.4	5.12	3.62e-07	4.01e-05	0.22	0.16	Lymphocyte counts;	chr6:122347086	chr6:122436789~122439223:-
BRCA	cis	rs1440410	0.83	rs12499485	ENSG00000250326.1	RP11-284M14.1	-5.12	3.62e-07	4.01e-05	-0.17	-0.16	Ischemic stroke;	chr4:143253707	chr4:142933195~143184861:-
BRCA	cis	rs4713118	0.824	rs742046	ENSG00000216901.1	AL022393.7	5.12	3.62e-07	4.01e-05	0.21	0.16	Parkinson's disease;	chr6:27771475	chr6:28176188~28176674:+
BRCA	cis	rs7772486	0.727	rs10447449	ENSG00000270638.1	RP3-466P17.1	5.12	3.62e-07	4.01e-05	0.18	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145817571	chr6:145735570~145737218:+
BRCA	cis	rs17685	0.753	rs2302438	ENSG00000280388.1	RP11-229D13.3	-5.12	3.63e-07	4.02e-05	-0.16	-0.16	Coffee consumption (cups per day);Coffee consumption;	chr7:76047747	chr7:76043977~76045963:-
BRCA	cis	rs2153535	0.58	rs7761937	ENSG00000251164.1	HULC	-5.12	3.63e-07	4.02e-05	-0.19	-0.16	Motion sickness;	chr6:8459201	chr6:8652137~8653846:+
BRCA	cis	rs6452524	0.618	rs6452502	ENSG00000281327.1	LINC01338	5.12	3.63e-07	4.02e-05	0.18	0.16	Hypertension (SNP x SNP interaction);	chr5:83074578	chr5:82850864~82859836:-
BRCA	cis	rs6452524	0.618	rs6452503	ENSG00000281327.1	LINC01338	5.12	3.63e-07	4.02e-05	0.18	0.16	Hypertension (SNP x SNP interaction);	chr5:83074596	chr5:82850864~82859836:-
BRCA	cis	rs516805	0.667	rs9482234	ENSG00000279453.1	RP3-425C14.4	5.12	3.63e-07	4.02e-05	0.22	0.16	Lymphocyte counts;	chr6:122313998	chr6:122436789~122439223:-
BRCA	cis	rs2832191	0.791	rs2832196	ENSG00000215533.7	LINC00189	5.12	3.63e-07	4.02e-05	0.18	0.16	Dental caries;	chr21:29125091	chr21:29193480~29288205:+
BRCA	cis	rs4780355	1	rs1111186	ENSG00000262636.1	CTD-3088G3.4	5.12	3.63e-07	4.02e-05	0.22	0.16	Crohn's disease and psoriasis;	chr16:11253191	chr16:11380859~11381118:-
BRCA	cis	rs11098499	0.954	rs1546505	ENSG00000250412.1	KLHL2P1	5.12	3.63e-07	4.02e-05	0.19	0.16	Corneal astigmatism;	chr4:119320069	chr4:119334329~119378233:+
BRCA	cis	rs17674580	0.604	rs3087560	ENSG00000267193.4	RP11-116O18.3	5.12	3.64e-07	4.03e-05	0.17	0.16	Bladder cancer;	chr18:45752290	chr18:45669367~45747215:-
BRCA	cis	rs17674580	0.582	rs3178156	ENSG00000267193.4	RP11-116O18.3	5.12	3.64e-07	4.03e-05	0.17	0.16	Bladder cancer;	chr18:45752515	chr18:45669367~45747215:-
BRCA	cis	rs13108904	0.935	rs2293633	ENSG00000196810.4	CTBP1-AS2	5.12	3.64e-07	4.03e-05	0.16	0.16	Obesity-related traits;	chr4:1297852	chr4:1249300~1288291:+
BRCA	cis	rs2411233	0.674	rs7175659	ENSG00000259278.1	RP11-62C7.2	-5.12	3.64e-07	4.03e-05	-0.19	-0.16	Platelet count;	chr15:39023696	chr15:39019233~39024918:+
BRCA	cis	rs17685	0.712	rs6976236	ENSG00000280388.1	RP11-229D13.3	-5.12	3.64e-07	4.03e-05	-0.16	-0.16	Coffee consumption (cups per day);Coffee consumption;	chr7:76111769	chr7:76043977~76045963:-
BRCA	cis	rs8054556	0.935	rs4788203	ENSG00000273724.1	RP11-347C12.12	-5.12	3.64e-07	4.03e-05	-0.18	-0.16	Autism spectrum disorder or schizophrenia;	chr16:29967506	chr16:30336400~30343336:+
BRCA	cis	rs1552244	0.515	rs67626468	ENSG00000232901.1	CYCSP10	5.12	3.65e-07	4.04e-05	0.24	0.16	Alzheimer's disease;	chr3:10119834	chr3:10000647~10000940:-
BRCA	cis	rs12439619	0.846	rs62012059	ENSG00000255769.6	GOLGA2P10	-5.12	3.65e-07	4.04e-05	-0.23	-0.16	Intelligence (multi-trait analysis);	chr15:82251669	chr15:82472993~82513950:-
BRCA	cis	rs6545883	0.894	rs778143	ENSG00000270820.4	RP11-355B11.2	5.12	3.65e-07	4.04e-05	0.18	0.16	Tuberculosis;	chr2:61354755	chr2:61471188~61484130:+
BRCA	cis	rs2179367	0.543	rs9498328	ENSG00000268592.3	RAET1E-AS1	5.12	3.65e-07	4.04e-05	0.23	0.16	Dupuytren's disease;	chr6:149348715	chr6:149863494~149919507:+
BRCA	cis	rs7577696	0.524	rs12991444	ENSG00000272716.1	RP11-563N4.1	-5.12	3.65e-07	4.04e-05	-0.19	-0.16	Inflammatory biomarkers;	chr2:32040056	chr2:32165046~32165757:-
BRCA	cis	rs1387259	0.929	rs11168484	ENSG00000226413.2	OR8T1P	5.12	3.65e-07	4.04e-05	0.22	0.16	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48239806	chr12:48442030~48442947:-
BRCA	cis	rs1707322	1	rs4298677	ENSG00000234329.1	RP11-767N6.2	5.12	3.65e-07	4.04e-05	0.16	0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45840947	chr1:45651039~45651826:-
BRCA	cis	rs13113518	1	rs56362210	ENSG00000223305.1	RN7SKP30	5.12	3.65e-07	4.04e-05	0.19	0.16	Height;	chr4:55540972	chr4:55540502~55540835:-
BRCA	cis	rs10129255	0.957	rs10141052	ENSG00000211974.3	IGHV2-70	5.12	3.65e-07	4.04e-05	0.15	0.16	Kawasaki disease;	chr14:106776528	chr14:106723574~106724093:-
BRCA	cis	rs2803122	0.967	rs10811148	ENSG00000273226.1	RP11-513M16.8	-5.12	3.65e-07	4.04e-05	-0.17	-0.16	Pulse pressure;	chr9:19246469	chr9:19375451~19375996:+
BRCA	cis	rs7474896	0.537	rs1208587	ENSG00000120555.12	SEPT7P9	-5.12	3.65e-07	4.04e-05	-0.21	-0.16	Obesity (extreme);	chr10:37918831	chr10:38383069~38402916:-
BRCA	cis	rs13325613	0.915	rs34005848	ENSG00000223552.1	RP11-24F11.2	-5.12	3.66e-07	4.05e-05	-0.33	-0.16	Monocyte count;	chr3:46222254	chr3:46364955~46407059:-
BRCA	cis	rs7246657	0.943	rs2081096	ENSG00000267422.1	CTD-2554C21.1	-5.12	3.66e-07	4.05e-05	-0.23	-0.16	Coronary artery calcification;	chr19:37473798	chr19:37779686~37792865:+
BRCA	cis	rs9307551	0.894	rs6812760	ENSG00000250334.4	LINC00989	-5.12	3.66e-07	4.05e-05	-0.24	-0.16	Refractive error;	chr4:79560702	chr4:79492416~79576460:+
BRCA	cis	rs1707322	0.964	rs785483	ENSG00000234329.1	RP11-767N6.2	-5.12	3.66e-07	4.05e-05	-0.16	-0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46093499	chr1:45651039~45651826:-
BRCA	cis	rs801193	0.569	rs2659908	ENSG00000273448.1	RP11-166O4.6	5.12	3.66e-07	4.05e-05	0.14	0.16	Aortic root size;	chr7:66695835	chr7:67333047~67334383:+
BRCA	cis	rs10129255	0.957	rs10141009	ENSG00000211974.3	IGHV2-70	5.12	3.66e-07	4.05e-05	0.15	0.16	Kawasaki disease;	chr14:106776695	chr14:106723574~106724093:-
BRCA	cis	rs35146811	0.844	rs12705070	ENSG00000235713.1	RP4-604G5.3	5.12	3.66e-07	4.05e-05	0.18	0.16	Coronary artery disease;	chr7:100059304	chr7:99992397~99993050:+
BRCA	cis	rs1862618	0.671	rs2591955	ENSG00000271828.1	CTD-2310F14.1	-5.12	3.67e-07	4.06e-05	-0.2	-0.16	Initial pursuit acceleration;	chr5:56949121	chr5:56927874~56929573:+
BRCA	cis	rs1862618	0.671	rs906631	ENSG00000271828.1	CTD-2310F14.1	-5.12	3.67e-07	4.06e-05	-0.2	-0.16	Initial pursuit acceleration;	chr5:56949976	chr5:56927874~56929573:+
BRCA	cis	rs595244	1	rs2455925	ENSG00000259705.1	RP11-227D13.1	5.12	3.67e-07	4.06e-05	0.27	0.16	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48601452	chr15:48645951~48652016:+
BRCA	cis	rs11159086	1	rs4899514	ENSG00000270000.1	RP3-449M8.9	-5.12	3.67e-07	4.06e-05	-0.26	-0.16	Advanced glycation end-product levels;	chr14:74473467	chr14:74471930~74472360:-
BRCA	cis	rs1707322	1	rs11211219	ENSG00000234329.1	RP11-767N6.2	5.12	3.67e-07	4.06e-05	0.16	0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45893806	chr1:45651039~45651826:-
BRCA	cis	rs4819052	0.679	rs28623526	ENSG00000184274.3	LINC00315	-5.12	3.67e-07	4.06e-05	-0.2	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45292409	chr21:45300245~45305257:-
BRCA	cis	rs9863	0.828	rs4765541	ENSG00000270028.1	RP11-380L11.4	5.12	3.67e-07	4.06e-05	0.19	0.16	White blood cell count;	chr12:123981448	chr12:123925461~123926083:-
BRCA	cis	rs11758351	0.518	rs78871852	ENSG00000241549.7	GUSBP2	-5.12	3.67e-07	4.06e-05	-0.22	-0.16	Renal underexcretion gout;Gout;	chr6:26221338	chr6:26871484~26956554:-
BRCA	cis	rs6071166	0.935	rs6015693	ENSG00000224635.1	RP4-564F22.5	-5.12	3.67e-07	4.06e-05	-0.19	-0.16	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38702166	chr20:38406011~38416797:-
BRCA	cis	rs13113518	1	rs6849433	ENSG00000223305.1	RN7SKP30	5.12	3.67e-07	4.06e-05	0.19	0.16	Height;	chr4:55506498	chr4:55540502~55540835:-
BRCA	cis	rs13113518	0.966	rs12501327	ENSG00000223305.1	RN7SKP30	5.12	3.67e-07	4.06e-05	0.19	0.16	Height;	chr4:55507248	chr4:55540502~55540835:-
BRCA	cis	rs10129255	1	rs10129319	ENSG00000224373.3	IGHV4-59	5.12	3.67e-07	4.06e-05	0.1	0.16	Kawasaki disease;	chr14:106767996	chr14:106627249~106627825:-
BRCA	cis	rs11295209	1	rs11295209	ENSG00000245958.5	RP11-33B1.1	5.12	3.67e-07	4.06e-05	0.14	0.16	Plateletcrit;	chr4:119559079	chr4:119454791~119552025:+
BRCA	cis	rs4934494	0.677	rs56160723	ENSG00000240996.1	RP11-80H5.7	-5.12	3.67e-07	4.06e-05	-0.22	-0.16	Red blood cell count;	chr10:89613874	chr10:89694295~89697928:-
BRCA	cis	rs4934494	0.677	rs10881608	ENSG00000240996.1	RP11-80H5.7	-5.12	3.67e-07	4.06e-05	-0.22	-0.16	Red blood cell count;	chr10:89614892	chr10:89694295~89697928:-
BRCA	cis	rs4934494	0.677	rs10881610	ENSG00000240996.1	RP11-80H5.7	-5.12	3.67e-07	4.06e-05	-0.22	-0.16	Red blood cell count;	chr10:89615076	chr10:89694295~89697928:-
BRCA	cis	rs4934494	0.677	rs11185793	ENSG00000240996.1	RP11-80H5.7	-5.12	3.67e-07	4.06e-05	-0.22	-0.16	Red blood cell count;	chr10:89615467	chr10:89694295~89697928:-
BRCA	cis	rs4934494	0.677	rs11185794	ENSG00000240996.1	RP11-80H5.7	-5.12	3.67e-07	4.06e-05	-0.22	-0.16	Red blood cell count;	chr10:89615662	chr10:89694295~89697928:-
BRCA	cis	rs4934494	0.677	rs11185795	ENSG00000240996.1	RP11-80H5.7	-5.12	3.67e-07	4.06e-05	-0.22	-0.16	Red blood cell count;	chr10:89615672	chr10:89694295~89697928:-
BRCA	cis	rs4934494	0.677	rs11185796	ENSG00000240996.1	RP11-80H5.7	-5.12	3.67e-07	4.06e-05	-0.22	-0.16	Red blood cell count;	chr10:89615725	chr10:89694295~89697928:-
BRCA	cis	rs4934494	0.677	rs12219790	ENSG00000240996.1	RP11-80H5.7	-5.12	3.67e-07	4.06e-05	-0.22	-0.16	Red blood cell count;	chr10:89615734	chr10:89694295~89697928:-
BRCA	cis	rs4934494	0.677	rs11185797	ENSG00000240996.1	RP11-80H5.7	-5.12	3.67e-07	4.06e-05	-0.22	-0.16	Red blood cell count;	chr10:89616041	chr10:89694295~89697928:-
BRCA	cis	rs4934494	0.677	rs11185798	ENSG00000240996.1	RP11-80H5.7	-5.12	3.67e-07	4.06e-05	-0.22	-0.16	Red blood cell count;	chr10:89616211	chr10:89694295~89697928:-
BRCA	cis	rs4781563	0.81	rs2238463	ENSG00000242307.1	RPS26P52	-5.12	3.68e-07	4.07e-05	-0.18	-0.16	Bilirubin levels;	chr16:13924045	chr16:13922332~13922679:-
BRCA	cis	rs3770081	1	rs12617717	ENSG00000273080.1	RP11-301O19.1	-5.12	3.68e-07	4.07e-05	-0.38	-0.16	Facial emotion recognition (sad faces);	chr2:86115180	chr2:86195590~86196049:+
BRCA	cis	rs9307551	0.948	rs1866835	ENSG00000250334.4	LINC00989	-5.12	3.68e-07	4.07e-05	-0.24	-0.16	Refractive error;	chr4:79626099	chr4:79492416~79576460:+
BRCA	cis	rs62025270	0.688	rs55957626	ENSG00000202081.1	RNU6-1280P	-5.12	3.68e-07	4.07e-05	-0.23	-0.16	Idiopathic pulmonary fibrosis;	chr15:85773486	chr15:85651522~85651628:-
BRCA	cis	rs494453	0.922	rs531692	ENSG00000227811.2	FAM212B-AS1	-5.12	3.68e-07	4.07e-05	-0.2	-0.16	Osteoporosis-related phenotypes;	chr1:111691954	chr1:111739841~111747798:+
BRCA	cis	rs924712	0.545	rs12216039	ENSG00000261116.1	RP3-523K23.2	5.12	3.68e-07	4.07e-05	0.18	0.16	Breast cancer;	chr6:54845124	chr6:54943167~54945099:+
BRCA	cis	rs924712	0.545	rs12216049	ENSG00000261116.1	RP3-523K23.2	5.12	3.68e-07	4.07e-05	0.18	0.16	Breast cancer;	chr6:54845171	chr6:54943167~54945099:+
BRCA	cis	rs17772222	0.74	rs7151164	ENSG00000258789.1	RP11-507K2.3	-5.12	3.68e-07	4.07e-05	-0.18	-0.16	Coronary artery calcification;	chr14:88509329	chr14:88551597~88552493:+
BRCA	cis	rs17772222	0.74	rs12433026	ENSG00000258789.1	RP11-507K2.3	-5.12	3.68e-07	4.07e-05	-0.18	-0.16	Coronary artery calcification;	chr14:88509495	chr14:88551597~88552493:+
BRCA	cis	rs17772222	0.74	rs10138139	ENSG00000258789.1	RP11-507K2.3	-5.12	3.68e-07	4.07e-05	-0.18	-0.16	Coronary artery calcification;	chr14:88510027	chr14:88551597~88552493:+
BRCA	cis	rs2832191	1	rs2832189	ENSG00000215533.7	LINC00189	5.12	3.68e-07	4.07e-05	0.18	0.16	Dental caries;	chr21:29115093	chr21:29193480~29288205:+
BRCA	cis	rs7577696	0.962	rs7575139	ENSG00000272716.1	RP11-563N4.1	-5.12	3.69e-07	4.08e-05	-0.17	-0.16	Inflammatory biomarkers;	chr2:32066265	chr2:32165046~32165757:-
BRCA	cis	rs7577696	0.962	rs10490360	ENSG00000272716.1	RP11-563N4.1	-5.12	3.69e-07	4.08e-05	-0.17	-0.16	Inflammatory biomarkers;	chr2:32071199	chr2:32165046~32165757:-
BRCA	cis	rs7577696	1	rs7577696	ENSG00000272716.1	RP11-563N4.1	-5.12	3.69e-07	4.08e-05	-0.17	-0.16	Inflammatory biomarkers;	chr2:32053713	chr2:32165046~32165757:-
BRCA	cis	rs10911232	0.507	rs10797833	ENSG00000224468.3	RP11-181K3.4	-5.12	3.69e-07	4.08e-05	-0.17	-0.16	Hypertriglyceridemia;	chr1:183074932	chr1:183138402~183141282:-
BRCA	cis	rs14027	0.64	rs16893104	ENSG00000279347.1	RP11-85I17.2	-5.12	3.69e-07	4.08e-05	-0.15	-0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119754778	chr8:119838736~119840385:-
BRCA	cis	rs987724	0.501	rs2321293	ENSG00000240875.4	LINC00886	-5.12	3.69e-07	4.08e-05	-0.23	-0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156931311	chr3:156747346~156817062:-
BRCA	cis	rs17301013	0.932	rs7542389	ENSG00000227373.4	RP11-160H22.5	5.12	3.69e-07	4.08e-05	0.21	0.16	Systemic lupus erythematosus;	chr1:174565104	chr1:174115300~174160004:-
BRCA	cis	rs11098499	0.754	rs938056	ENSG00000260404.2	RP11-384K6.6	5.12	3.69e-07	4.08e-05	0.14	0.16	Corneal astigmatism;	chr4:119316298	chr4:118591773~118633729:+
BRCA	cis	rs8098244	0.557	rs11662720	ENSG00000264745.1	TTC39C-AS1	-5.12	3.69e-07	4.08e-05	-0.18	-0.16	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23722127	chr18:23994213~24015339:-
BRCA	cis	rs1876905	0.68	rs373526	ENSG00000255389.1	C6orf3	-5.12	3.69e-07	4.08e-05	-0.19	-0.16	Mean corpuscular hemoglobin;	chr6:111190261	chr6:111599875~111602295:+
BRCA	cis	rs13113518	1	rs11724094	ENSG00000223305.1	RN7SKP30	5.12	3.69e-07	4.08e-05	0.19	0.16	Height;	chr4:55501479	chr4:55540502~55540835:-
BRCA	cis	rs4835473	0.932	rs4125545	ENSG00000249741.2	RP11-673E1.3	-5.12	3.7e-07	4.09e-05	-0.17	-0.16	Immature fraction of reticulocytes;	chr4:143988650	chr4:143911514~143912053:-
BRCA	cis	rs295490	0.667	rs79661321	ENSG00000272656.1	RP11-219D15.3	5.12	3.7e-07	4.09e-05	0.36	0.16	PR interval in Tripanosoma cruzi seropositivity;	chr3:139434762	chr3:139349024~139349371:-
BRCA	cis	rs7617773	0.779	rs3731487	ENSG00000199476.1	Y_RNA	-5.12	3.7e-07	4.09e-05	-0.23	-0.16	Coronary artery disease;	chr3:48188134	chr3:48288587~48288694:+
BRCA	cis	rs2179367	0.632	rs9498344	ENSG00000268592.3	RAET1E-AS1	5.12	3.7e-07	4.09e-05	0.23	0.16	Dupuytren's disease;	chr6:149401053	chr6:149863494~149919507:+
BRCA	cis	rs7618501	0.602	rs2301166	ENSG00000228008.1	CTD-2330K9.3	-5.12	3.7e-07	4.09e-05	-0.15	-0.16	Intelligence (multi-trait analysis);	chr3:50110872	chr3:49903845~49916937:+
BRCA	cis	rs8133949	0.768	rs7280167	ENSG00000237232.6	ZNF295-AS1	5.12	3.7e-07	4.09e-05	0.23	0.16	Hand grip strength;	chr21:42012188	chr21:42009194~42024924:+
BRCA	cis	rs55702914	0.65	rs6715690	ENSG00000231621.1	AC013264.2	5.12	3.71e-07	4.1e-05	0.15	0.16	Major depression and alcohol dependence;	chr2:197283647	chr2:197197991~197199273:+
BRCA	cis	rs67981189	0.679	rs221901	ENSG00000269927.1	RP6-91H8.3	-5.12	3.71e-07	4.1e-05	-0.19	-0.16	Schizophrenia;	chr14:71135509	chr14:71141125~71143253:-
BRCA	cis	rs2832191	0.791	rs7283853	ENSG00000215533.7	LINC00189	5.12	3.71e-07	4.1e-05	0.17	0.16	Dental caries;	chr21:29126194	chr21:29193480~29288205:+
BRCA	cis	rs2562456	0.874	rs2562417	ENSG00000268658.4	LINC00664	-5.12	3.71e-07	4.1e-05	-0.25	-0.16	Pain;	chr19:21528400	chr19:21483374~21503238:+
BRCA	cis	rs7618915	0.524	rs12488461	ENSG00000243224.1	RP5-1157M23.2	-5.12	3.71e-07	4.1e-05	-0.18	-0.16	Bipolar disorder;	chr3:52664401	chr3:52239258~52241097:+
BRCA	cis	rs2562456	0.833	rs62109229	ENSG00000268081.1	RP11-678G14.2	5.12	3.71e-07	4.1e-05	0.25	0.16	Pain;	chr19:21354380	chr19:21554640~21569237:-
BRCA	cis	rs2562456	0.833	rs11670815	ENSG00000268081.1	RP11-678G14.2	5.12	3.71e-07	4.1e-05	0.25	0.16	Pain;	chr19:21356515	chr19:21554640~21569237:-
BRCA	cis	rs2562456	0.833	rs11666540	ENSG00000268081.1	RP11-678G14.2	5.12	3.71e-07	4.1e-05	0.25	0.16	Pain;	chr19:21356550	chr19:21554640~21569237:-
BRCA	cis	rs2562456	0.833	rs11667361	ENSG00000268081.1	RP11-678G14.2	5.12	3.71e-07	4.1e-05	0.25	0.16	Pain;	chr19:21356580	chr19:21554640~21569237:-
BRCA	cis	rs2337406	0.587	rs10150642	ENSG00000211974.3	IGHV2-70	5.12	3.71e-07	4.1e-05	0.18	0.16	Alzheimer's disease (late onset);	chr14:106647269	chr14:106723574~106724093:-
BRCA	cis	rs13126694	0.744	rs11100148	ENSG00000251429.1	RP11-597D13.7	5.12	3.71e-07	4.1e-05	0.15	0.16	Blood osmolality (transformed sodium);	chr4:158074688	chr4:158270378~158278676:+
BRCA	cis	rs2115630	0.967	rs10438428	ENSG00000259728.4	LINC00933	-5.12	3.71e-07	4.1e-05	-0.18	-0.16	P wave terminal force;	chr15:84787514	chr15:84570649~84580175:+
BRCA	cis	rs453301	0.653	rs7016139	ENSG00000254153.1	CTA-398F10.2	-5.12	3.72e-07	4.11e-05	-0.19	-0.16	Joint mobility (Beighton score);	chr8:9037960	chr8:8456909~8461337:-
BRCA	cis	rs9473147	0.543	rs4711878	ENSG00000270761.1	RP11-385F7.1	-5.12	3.72e-07	4.11e-05	-0.17	-0.16	Platelet distribution width;Mean platelet volume;	chr6:47488382	chr6:47477243~47477572:-
BRCA	cis	rs2638953	0.64	rs11049718	ENSG00000247934.4	RP11-967K21.1	-5.12	3.72e-07	4.11e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28565739	chr12:28163298~28190738:-
BRCA	cis	rs9473147	0.543	rs9349417	ENSG00000270761.1	RP11-385F7.1	-5.12	3.72e-07	4.11e-05	-0.17	-0.16	Platelet distribution width;Mean platelet volume;	chr6:47612921	chr6:47477243~47477572:-
BRCA	cis	rs9369695	0.883	rs9381581	ENSG00000270761.1	RP11-385F7.1	-5.12	3.72e-07	4.11e-05	-0.17	-0.16	Reticulocyte count;	chr6:47612959	chr6:47477243~47477572:-
BRCA	cis	rs9473147	0.516	rs9463342	ENSG00000270761.1	RP11-385F7.1	-5.12	3.72e-07	4.11e-05	-0.17	-0.16	Platelet distribution width;Mean platelet volume;	chr6:47617370	chr6:47477243~47477572:-
BRCA	cis	rs922692	0.744	rs4886592	ENSG00000261143.1	ADAMTS7P3	5.12	3.72e-07	4.11e-05	0.2	0.16	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78790205	chr15:77976042~77993057:+
BRCA	cis	rs7818688	1	rs16917224	ENSG00000253528.2	RP11-347C18.4	-5.12	3.72e-07	4.11e-05	-0.24	-0.16	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95017882	chr8:94974573~94974853:-
BRCA	cis	rs8114671	0.562	rs3818273	ENSG00000269202.1	RP4-614O4.12	-5.12	3.72e-07	4.11e-05	-0.16	-0.16	Height;	chr20:34921472	chr20:35201747~35203288:-
BRCA	cis	rs600231	0.623	rs587080	ENSG00000173727.10	CMB9-22P13.1	5.12	3.72e-07	4.11e-05	0.21	0.16	Bone mineral density;	chr11:65486329	chr11:65455258~65466720:+
BRCA	cis	rs1729951	0.546	rs835632	ENSG00000239213.4	NCK1-AS1	5.12	3.72e-07	4.12e-05	0.16	0.16	Neuroticism;	chr3:136957683	chr3:136841726~136862054:-
BRCA	cis	rs2638953	0.924	rs10843170	ENSG00000247934.4	RP11-967K21.1	-5.12	3.73e-07	4.12e-05	-0.21	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28430118	chr12:28163298~28190738:-
BRCA	cis	rs6840360	0.642	rs2709828	ENSG00000251611.1	RP11-610P16.1	-5.12	3.73e-07	4.12e-05	-0.14	-0.16	Intelligence (multi-trait analysis);	chr4:151434116	chr4:151407551~151408835:-
BRCA	cis	rs6840360	0.642	rs2724551	ENSG00000251611.1	RP11-610P16.1	-5.12	3.73e-07	4.12e-05	-0.14	-0.16	Intelligence (multi-trait analysis);	chr4:151434231	chr4:151407551~151408835:-
BRCA	cis	rs6840360	0.667	rs2709829	ENSG00000251611.1	RP11-610P16.1	-5.12	3.73e-07	4.12e-05	-0.14	-0.16	Intelligence (multi-trait analysis);	chr4:151434238	chr4:151407551~151408835:-
BRCA	cis	rs6840360	0.606	rs2709813	ENSG00000251611.1	RP11-610P16.1	-5.12	3.73e-07	4.12e-05	-0.14	-0.16	Intelligence (multi-trait analysis);	chr4:151436292	chr4:151407551~151408835:-
BRCA	cis	rs6840360	0.606	rs2724550	ENSG00000251611.1	RP11-610P16.1	-5.12	3.73e-07	4.12e-05	-0.14	-0.16	Intelligence (multi-trait analysis);	chr4:151437834	chr4:151407551~151408835:-
BRCA	cis	rs6840360	0.642	rs2709815	ENSG00000251611.1	RP11-610P16.1	-5.12	3.73e-07	4.12e-05	-0.14	-0.16	Intelligence (multi-trait analysis);	chr4:151442620	chr4:151407551~151408835:-
BRCA	cis	rs5167	0.539	rs4803783	ENSG00000214855.8	APOC1P1	-5.12	3.73e-07	4.12e-05	-0.2	-0.16	Blood protein levels;	chr19:44967201	chr19:44926804~44931386:+
BRCA	cis	rs12477438	0.501	rs6708878	ENSG00000231822.1	AC019097.7	5.12	3.73e-07	4.12e-05	0.16	0.16	Chronic sinus infection;	chr2:99185101	chr2:99102018~99102752:+
BRCA	cis	rs13108904	0.901	rs4974594	ENSG00000254094.1	AC078852.1	5.12	3.73e-07	4.12e-05	0.17	0.16	Obesity-related traits;	chr4:1306692	chr4:1356581~1358075:+
BRCA	cis	rs1124769	0.619	rs28637301	ENSG00000259378.1	DCAF13P3	5.12	3.73e-07	4.12e-05	0.21	0.16	Cognitive performance;	chr15:51095051	chr15:50944663~50945996:+
BRCA	cis	rs2153535	0.58	rs1832100	ENSG00000251164.1	HULC	-5.12	3.73e-07	4.12e-05	-0.19	-0.16	Motion sickness;	chr6:8446723	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.58	rs2327058	ENSG00000251164.1	HULC	-5.12	3.73e-07	4.12e-05	-0.19	-0.16	Motion sickness;	chr6:8446785	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.601	rs2327059	ENSG00000251164.1	HULC	-5.12	3.73e-07	4.12e-05	-0.19	-0.16	Motion sickness;	chr6:8446838	chr6:8652137~8653846:+
BRCA	cis	rs4650994	0.544	rs4652301	ENSG00000273384.1	RP5-1098D14.1	5.12	3.73e-07	4.12e-05	0.2	0.16	HDL cholesterol;HDL cholesterol levels;	chr1:178530664	chr1:178651706~178652282:+
BRCA	cis	rs4650994	0.544	rs10798613	ENSG00000273384.1	RP5-1098D14.1	5.12	3.73e-07	4.12e-05	0.2	0.16	HDL cholesterol;HDL cholesterol levels;	chr1:178530887	chr1:178651706~178652282:+
BRCA	cis	rs17674580	0.582	rs7359740	ENSG00000267193.4	RP11-116O18.3	5.12	3.73e-07	4.12e-05	0.17	0.16	Bladder cancer;	chr18:45753948	chr18:45669367~45747215:-
BRCA	cis	rs7577696	0.688	rs9677104	ENSG00000272716.1	RP11-563N4.1	-5.12	3.73e-07	4.12e-05	-0.18	-0.16	Inflammatory biomarkers;	chr2:32110030	chr2:32165046~32165757:-
BRCA	cis	rs2839186	0.77	rs2330353	ENSG00000239415.1	AP001469.9	5.12	3.73e-07	4.12e-05	0.16	0.16	Testicular germ cell tumor;	chr21:46249734	chr21:46251549~46254133:-
BRCA	cis	rs2153535	0.58	rs2327061	ENSG00000251164.1	HULC	-5.12	3.73e-07	4.12e-05	-0.19	-0.16	Motion sickness;	chr6:8446998	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.58	rs7453115	ENSG00000251164.1	HULC	-5.12	3.73e-07	4.12e-05	-0.19	-0.16	Motion sickness;	chr6:8447028	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.58	rs6910742	ENSG00000251164.1	HULC	-5.12	3.73e-07	4.12e-05	-0.19	-0.16	Motion sickness;	chr6:8448095	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.58	rs7767780	ENSG00000251164.1	HULC	-5.12	3.73e-07	4.12e-05	-0.19	-0.16	Motion sickness;	chr6:8453229	chr6:8652137~8653846:+
BRCA	cis	rs13113518	0.812	rs11133385	ENSG00000272969.1	RP11-528I4.2	5.12	3.73e-07	4.12e-05	0.18	0.16	Height;	chr4:55460485	chr4:55547112~55547889:+
BRCA	cis	rs62025270	0.632	rs7163838	ENSG00000259295.5	CSPG4P12	-5.11	3.74e-07	4.13e-05	-0.24	-0.16	Idiopathic pulmonary fibrosis;	chr15:85664390	chr15:85191438~85213905:+
BRCA	cis	rs12144309	1	rs12144309	ENSG00000232450.1	RP4-730K3.3	5.11	3.74e-07	4.13e-05	0.24	0.16	Coronary artery disease;	chr1:113772871	chr1:113698884~113699631:-
BRCA	cis	rs9308731	0.863	rs616582	ENSG00000227992.1	AC108463.2	-5.11	3.74e-07	4.13e-05	-0.18	-0.16	Chronic lymphocytic leukemia;	chr2:111184418	chr2:111203964~111206215:-
BRCA	cis	rs11051970	0.559	rs16919727	ENSG00000274964.1	RP11-817I4.1	-5.11	3.74e-07	4.13e-05	-0.21	-0.16	Response to tocilizumab in rheumatoid arthritis;	chr12:32329976	chr12:32339368~32340724:+
BRCA	cis	rs11051970	0.559	rs11051940	ENSG00000274964.1	RP11-817I4.1	-5.11	3.74e-07	4.13e-05	-0.21	-0.16	Response to tocilizumab in rheumatoid arthritis;	chr12:32330187	chr12:32339368~32340724:+
BRCA	cis	rs9467773	1	rs6940188	ENSG00000241549.7	GUSBP2	5.11	3.75e-07	4.14e-05	0.17	0.16	Intelligence (multi-trait analysis);	chr6:26561801	chr6:26871484~26956554:-
BRCA	cis	rs9467773	1	rs6940053	ENSG00000241549.7	GUSBP2	5.11	3.75e-07	4.14e-05	0.17	0.16	Intelligence (multi-trait analysis);	chr6:26561894	chr6:26871484~26956554:-
BRCA	cis	rs9595908	0.832	rs2032495	ENSG00000212293.1	SNORA16	5.11	3.75e-07	4.14e-05	0.17	0.16	Body mass index;	chr13:32630605	chr13:32420390~32420516:-
BRCA	cis	rs8040855	0.557	rs9744503	ENSG00000259774.1	RP11-182J1.13	-5.11	3.75e-07	4.14e-05	-0.18	-0.16	Bulimia nervosa;	chr15:85180986	chr15:84422618~84425882:+
BRCA	cis	rs17685	0.743	rs10277259	ENSG00000280388.1	RP11-229D13.3	-5.11	3.75e-07	4.14e-05	-0.16	-0.16	Coffee consumption (cups per day);Coffee consumption;	chr7:76173356	chr7:76043977~76045963:-
BRCA	cis	rs2749097	1	rs2749097	ENSG00000244256.3	RN7SL130P	-5.11	3.75e-07	4.14e-05	-0.22	-0.16	Alcohol consumption (transferrin glycosylation);	chr1:63661797	chr1:63655743~63656047:+
BRCA	cis	rs7141336	1	rs8019191	ENSG00000258884.1	CTD-3035D6.2	5.11	3.76e-07	4.15e-05	0.2	0.16	Anxiety disorder;	chr14:90819163	chr14:90822365~90828128:-
BRCA	cis	rs4664293	0.867	rs13432	ENSG00000226266.5	AC009961.3	-5.11	3.76e-07	4.15e-05	-0.2	-0.16	Monocyte percentage of white cells;	chr2:159769216	chr2:159670708~159712435:-
BRCA	cis	rs2562456	0.55	rs4809143	ENSG00000268081.1	RP11-678G14.2	5.11	3.76e-07	4.15e-05	0.26	0.16	Pain;	chr19:21589926	chr19:21554640~21569237:-
BRCA	cis	rs2562456	0.583	rs4809144	ENSG00000268081.1	RP11-678G14.2	5.11	3.76e-07	4.15e-05	0.26	0.16	Pain;	chr19:21589928	chr19:21554640~21569237:-
BRCA	cis	rs6596100	0.91	rs62375234	ENSG00000248648.1	RP11-485M7.1	-5.11	3.76e-07	4.15e-05	-0.2	-0.16	Breast cancer;	chr5:133073958	chr5:133003119~133003365:+
BRCA	cis	rs2919009	0.563	rs55761976	ENSG00000271670.1	RP11-95I16.4	5.11	3.76e-07	4.15e-05	0.22	0.16	Obesity-related traits;	chr10:120935030	chr10:120879256~120880667:-
BRCA	cis	rs10129255	1	rs10129319	ENSG00000211974.3	IGHV2-70	5.11	3.76e-07	4.15e-05	0.16	0.16	Kawasaki disease;	chr14:106767996	chr14:106723574~106724093:-
BRCA	cis	rs11051970	0.527	rs7313432	ENSG00000274964.1	RP11-817I4.1	-5.11	3.76e-07	4.15e-05	-0.22	-0.16	Response to tocilizumab in rheumatoid arthritis;	chr12:32419335	chr12:32339368~32340724:+
BRCA	cis	rs10833905	0.938	rs3909701	ENSG00000246225.5	RP11-17A1.3	-5.11	3.76e-07	4.16e-05	-0.23	-0.16	Sudden cardiac arrest;	chr11:23068738	chr11:22829380~22945393:+
BRCA	cis	rs17508449	0.547	rs11582409	ENSG00000232450.1	RP4-730K3.3	-5.11	3.76e-07	4.16e-05	-0.25	-0.16	Leprosy;	chr1:113856811	chr1:113698884~113699631:-
BRCA	cis	rs7577696	0.889	rs212731	ENSG00000272716.1	RP11-563N4.1	5.11	3.76e-07	4.16e-05	0.18	0.16	Inflammatory biomarkers;	chr2:32247081	chr2:32165046~32165757:-
BRCA	cis	rs2574985	0.739	rs3011790	ENSG00000231345.3	BEND3P1	5.11	3.77e-07	4.16e-05	0.26	0.16	Subjective well-being;	chr10:50549943	chr10:50655967~50660472:+
BRCA	cis	rs11672691	0.67	rs4802119	ENSG00000270164.1	LINC01480	-5.11	3.77e-07	4.16e-05	-0.19	-0.16	Prostate cancer;	chr19:41484417	chr19:41535183~41536904:+
BRCA	cis	rs1075265	0.87	rs1421617	ENSG00000235937.1	AC008280.1	5.11	3.77e-07	4.16e-05	0.17	0.16	Chronotype;Morning vs. evening chronotype;	chr2:54032995	chr2:54029552~54030682:-
BRCA	cis	rs801193	0.527	rs2707837	ENSG00000273448.1	RP11-166O4.6	5.11	3.77e-07	4.16e-05	0.14	0.16	Aortic root size;	chr7:66716086	chr7:67333047~67334383:+
BRCA	cis	rs12571093	0.803	rs17297418	ENSG00000233590.1	RP11-153K11.3	5.11	3.77e-07	4.16e-05	0.26	0.16	Optic nerve measurement (disc area);	chr10:68271894	chr10:68233251~68242379:-
BRCA	cis	rs11992162	0.613	rs56094399	ENSG00000255046.1	RP11-297N6.4	5.11	3.77e-07	4.16e-05	0.18	0.16	Monocyte count;	chr8:11939961	chr8:11797928~11802568:-
BRCA	cis	rs2919009	0.607	rs56004902	ENSG00000271670.1	RP11-95I16.4	5.11	3.77e-07	4.16e-05	0.22	0.16	Obesity-related traits;	chr10:120938378	chr10:120879256~120880667:-
BRCA	cis	rs2522056	1	rs2522062	ENSG00000233006.5	AC034220.3	-5.11	3.77e-07	4.16e-05	-0.13	-0.16	Fibrinogen;Lymphocyte counts;	chr5:132469724	chr5:132311285~132369916:-
BRCA	cis	rs2919009	0.607	rs61872773	ENSG00000271670.1	RP11-95I16.4	5.11	3.77e-07	4.17e-05	0.22	0.16	Obesity-related traits;	chr10:120946998	chr10:120879256~120880667:-
BRCA	cis	rs7618915	0.501	rs13060048	ENSG00000243224.1	RP5-1157M23.2	-5.11	3.78e-07	4.17e-05	-0.17	-0.16	Bipolar disorder;	chr3:52564592	chr3:52239258~52241097:+
BRCA	cis	rs9311474	0.508	rs6786919	ENSG00000243224.1	RP5-1157M23.2	-5.11	3.78e-07	4.17e-05	-0.17	-0.16	Electroencephalogram traits;	chr3:52565773	chr3:52239258~52241097:+
BRCA	cis	rs7789940	0.904	rs7459185	ENSG00000186704.9	DTX2P1	-5.11	3.78e-07	4.17e-05	-0.19	-0.16	Multiple sclerosis;	chr7:76305323	chr7:76978617~77004308:+
BRCA	cis	rs7267979	0.932	rs424487	ENSG00000277938.1	RP5-965G21.3	5.11	3.78e-07	4.18e-05	0.19	0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25487495	chr20:25229150~25231933:+
BRCA	cis	rs2179367	0.632	rs763590	ENSG00000268592.3	RAET1E-AS1	5.11	3.78e-07	4.18e-05	0.23	0.16	Dupuytren's disease;	chr6:149398831	chr6:149863494~149919507:+
BRCA	cis	rs2179367	0.632	rs17506789	ENSG00000268592.3	RAET1E-AS1	5.11	3.78e-07	4.18e-05	0.23	0.16	Dupuytren's disease;	chr6:149399710	chr6:149863494~149919507:+
BRCA	cis	rs2179367	0.586	rs34097428	ENSG00000268592.3	RAET1E-AS1	5.11	3.78e-07	4.18e-05	0.23	0.16	Dupuytren's disease;	chr6:149399822	chr6:149863494~149919507:+
BRCA	cis	rs2179367	0.632	rs12154153	ENSG00000268592.3	RAET1E-AS1	5.11	3.78e-07	4.18e-05	0.23	0.16	Dupuytren's disease;	chr6:149401686	chr6:149863494~149919507:+
BRCA	cis	rs10924970	0.625	rs12730441	ENSG00000230026.2	RP11-382D8.5	-5.11	3.79e-07	4.18e-05	-0.18	-0.16	Asthma;	chr1:235334744	chr1:235361153~235362540:+
BRCA	cis	rs10129255	0.536	rs3944157	ENSG00000254174.1	IGHV1-12	5.11	3.79e-07	4.18e-05	0.12	0.16	Kawasaki disease;	chr14:106682286	chr14:106122420~106122709:-
BRCA	cis	rs11051970	0.559	rs7300646	ENSG00000274964.1	RP11-817I4.1	-5.11	3.79e-07	4.18e-05	-0.2	-0.16	Response to tocilizumab in rheumatoid arthritis;	chr12:32335695	chr12:32339368~32340724:+
BRCA	cis	rs9467773	0.967	rs6941022	ENSG00000241549.7	GUSBP2	5.11	3.79e-07	4.18e-05	0.17	0.16	Intelligence (multi-trait analysis);	chr6:26553303	chr6:26871484~26956554:-
BRCA	cis	rs9467773	1	rs2224380	ENSG00000241549.7	GUSBP2	5.11	3.79e-07	4.18e-05	0.17	0.16	Intelligence (multi-trait analysis);	chr6:26553715	chr6:26871484~26956554:-
BRCA	cis	rs9467773	1	rs6930120	ENSG00000241549.7	GUSBP2	5.11	3.79e-07	4.18e-05	0.17	0.16	Intelligence (multi-trait analysis);	chr6:26555256	chr6:26871484~26956554:-
BRCA	cis	rs7618915	0.547	rs3774365	ENSG00000243224.1	RP5-1157M23.2	-5.11	3.79e-07	4.18e-05	-0.18	-0.16	Bipolar disorder;	chr3:52608471	chr3:52239258~52241097:+
BRCA	cis	rs7617773	0.817	rs745116	ENSG00000199476.1	Y_RNA	-5.11	3.79e-07	4.18e-05	-0.22	-0.16	Coronary artery disease;	chr3:48231046	chr3:48288587~48288694:+
BRCA	cis	rs4718428	0.705	rs28648401	ENSG00000229180.5	GS1-124K5.11	5.11	3.79e-07	4.18e-05	0.15	0.16	Corneal structure;	chr7:66902145	chr7:66526088~66542624:-
BRCA	cis	rs17428076	0.715	rs788164	ENSG00000228389.1	AC068039.4	5.11	3.79e-07	4.18e-05	0.21	0.16	Myopia;	chr2:172048662	chr2:171773482~171775844:+
BRCA	cis	rs2251381	0.808	rs7364112	ENSG00000176054.6	RPL23P2	5.11	3.79e-07	4.18e-05	0.18	0.16	Selective IgA deficiency;	chr21:29176647	chr21:28997613~28998033:-
BRCA	cis	rs2115630	0.967	rs7171167	ENSG00000259295.5	CSPG4P12	-5.11	3.79e-07	4.18e-05	-0.19	-0.16	P wave terminal force;	chr15:84695892	chr15:85191438~85213905:+
BRCA	cis	rs17772222	0.74	rs10138309	ENSG00000258789.1	RP11-507K2.3	-5.11	3.79e-07	4.19e-05	-0.18	-0.16	Coronary artery calcification;	chr14:88510352	chr14:88551597~88552493:+
BRCA	cis	rs9990343	0.967	rs6803980	ENSG00000223552.1	RP11-24F11.2	-5.11	3.79e-07	4.19e-05	-0.15	-0.16	Brain structure;	chr3:46301144	chr3:46364955~46407059:-
BRCA	cis	rs10861342	1	rs10861342	ENSG00000257999.1	RP11-61E11.2	5.11	3.79e-07	4.19e-05	0.34	0.16	IgG glycosylation;	chr12:105065019	chr12:105102472~105107179:-
BRCA	cis	rs2255336	0.938	rs1478310	ENSG00000245648.1	RP11-277P12.20	5.11	3.8e-07	4.19e-05	0.23	0.16	Blood protein levels;	chr12:10382279	chr12:10363769~10398506:+
BRCA	cis	rs7772486	0.84	rs2474355	ENSG00000270638.1	RP3-466P17.1	5.11	3.8e-07	4.19e-05	0.18	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145991404	chr6:145735570~145737218:+
BRCA	cis	rs2522056	1	rs2405528	ENSG00000233006.5	AC034220.3	-5.11	3.8e-07	4.19e-05	-0.13	-0.16	Fibrinogen;Lymphocyte counts;	chr5:132458606	chr5:132311285~132369916:-
BRCA	cis	rs10504130	0.932	rs76877865	ENSG00000253844.1	RP11-546K22.1	-5.11	3.8e-07	4.19e-05	-0.27	-0.16	Venous thromboembolism (SNP x SNP interaction);	chr8:51803967	chr8:51961458~52022974:+
BRCA	cis	rs11955398	0.716	rs1379117	ENSG00000215032.2	GNL3LP1	5.11	3.8e-07	4.19e-05	0.19	0.16	Intelligence (multi-trait analysis);	chr5:60646482	chr5:60891935~60893577:-
BRCA	cis	rs987360	0.689	rs10024495	ENSG00000248869.4	RP11-138I17.1	5.11	3.8e-07	4.19e-05	0.16	0.16	Temperament;	chr4:137270922	chr4:136796722~137212799:-
BRCA	cis	rs2243480	0.522	rs1638736	ENSG00000228409.4	CCT6P1	5.11	3.8e-07	4.19e-05	0.26	0.16	Diabetic kidney disease;	chr7:66627321	chr7:65751142~65763354:+
BRCA	cis	rs10540	1	rs12794284	ENSG00000279672.1	CMB9-55F22.1	5.11	3.8e-07	4.19e-05	0.28	0.16	Body mass index;	chr11:477623	chr11:779617~780755:+
BRCA	cis	rs2239547	0.607	rs9836178	ENSG00000242142.1	SERBP1P3	-5.11	3.8e-07	4.19e-05	-0.19	-0.16	Schizophrenia;	chr3:52891387	chr3:53064283~53065091:-
BRCA	cis	rs875971	1	rs11971949	ENSG00000223473.2	GS1-124K5.3	-5.11	3.8e-07	4.19e-05	-0.12	-0.16	Aortic root size;	chr7:66161027	chr7:66491049~66493566:-
BRCA	cis	rs6847067	1	rs13145705	ENSG00000180769.7	WDFY3-AS2	5.11	3.8e-07	4.19e-05	0.14	0.16	Oropharynx cancer;	chr4:84799214	chr4:84965682~85011277:+
BRCA	cis	rs867371	0.717	rs3858954	ENSG00000276710.3	CSPG4P8	-5.11	3.8e-07	4.2e-05	-0.17	-0.16	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82265693	chr15:82459472~82477258:+
BRCA	cis	rs875971	0.862	rs801194	ENSG00000273448.1	RP11-166O4.6	-5.11	3.8e-07	4.2e-05	-0.15	-0.16	Aortic root size;	chr7:66563508	chr7:67333047~67334383:+
BRCA	cis	rs2281558	0.793	rs6115227	ENSG00000230772.1	VN1R108P	-5.11	3.8e-07	4.2e-05	-0.2	-0.16	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25610741	chr20:25734264~25735093:+
BRCA	cis	rs4835473	0.639	rs5029916	ENSG00000249741.2	RP11-673E1.3	-5.11	3.81e-07	4.2e-05	-0.17	-0.16	Immature fraction of reticulocytes;	chr4:143990684	chr4:143911514~143912053:-
BRCA	cis	rs1950832	0.689	rs12880770	ENSG00000258636.1	CTD-2298J14.2	-5.11	3.81e-07	4.2e-05	-0.18	-0.16	Urate levels in obese individuals;	chr14:41693207	chr14:41587861~41604856:-
BRCA	cis	rs9638182	0.638	rs6946689	ENSG00000274080.1	CTA-315H11.2	5.11	3.81e-07	4.2e-05	0.22	0.16	Triglycerides;	chr7:73563307	chr7:73609262~73611502:-
BRCA	cis	rs736408	0.609	rs13061423	ENSG00000243224.1	RP5-1157M23.2	-5.11	3.81e-07	4.2e-05	-0.18	-0.16	Bipolar disorder;	chr3:52756197	chr3:52239258~52241097:+
BRCA	cis	rs9840812	0.861	rs1153871	ENSG00000239213.4	NCK1-AS1	5.11	3.81e-07	4.2e-05	0.19	0.16	Fibrinogen levels;	chr3:136235757	chr3:136841726~136862054:-
BRCA	cis	rs9287719	0.967	rs6432126	ENSG00000243819.4	RN7SL832P	5.11	3.81e-07	4.2e-05	0.15	0.16	Prostate cancer;	chr2:10616975	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.904	rs55738250	ENSG00000243819.4	RN7SL832P	5.11	3.81e-07	4.2e-05	0.15	0.16	Prostate cancer;	chr2:10617006	chr2:10690344~10692099:+
BRCA	cis	rs2235642	0.685	rs2667681	ENSG00000260989.1	LA16c-395F10.2	-5.11	3.81e-07	4.2e-05	-0.16	-0.16	Coronary artery disease;	chr16:1603205	chr16:1580527~1610328:+
BRCA	cis	rs17801127	0.748	rs12990176	ENSG00000231969.1	AC144449.1	-5.11	3.81e-07	4.2e-05	-0.3	-0.16	Liver enzyme levels (alanine transaminase);	chr2:149820562	chr2:149587196~149848233:+
BRCA	cis	rs8103033	0.786	rs4802053	ENSG00000268088.1	AC093063.2	-5.11	3.81e-07	4.2e-05	-0.17	-0.16	Obesity-related traits;	chr19:39656599	chr19:39693925~39696258:+
BRCA	cis	rs2153535	0.58	rs1119690	ENSG00000251164.1	HULC	-5.11	3.81e-07	4.2e-05	-0.19	-0.16	Motion sickness;	chr6:8460427	chr6:8652137~8653846:+
BRCA	cis	rs7577696	0.785	rs3769602	ENSG00000272716.1	RP11-563N4.1	-5.11	3.81e-07	4.2e-05	-0.18	-0.16	Inflammatory biomarkers;	chr2:32156760	chr2:32165046~32165757:-
BRCA	cis	rs6480314	0.542	rs7476012	ENSG00000233590.1	RP11-153K11.3	-5.11	3.81e-07	4.2e-05	-0.26	-0.16	Optic nerve measurement (disc area);	chr10:68259950	chr10:68233251~68242379:-
BRCA	cis	rs4218	0.541	rs8030323	ENSG00000277144.1	RP11-59H7.4	-5.11	3.81e-07	4.21e-05	-0.2	-0.16	Social communication problems;	chr15:59048048	chr15:59115547~59116089:-
BRCA	cis	rs2281636	1	rs2804418	ENSG00000233690.1	EBAG9P1	-5.11	3.82e-07	4.21e-05	-0.17	-0.16	Obesity-related traits;	chr10:99752337	chr10:99697407~99697949:-
BRCA	cis	rs7246657	0.722	rs10409605	ENSG00000276846.1	CTD-3220F14.3	5.11	3.82e-07	4.21e-05	0.21	0.16	Coronary artery calcification;	chr19:37632236	chr19:37314868~37315620:-
BRCA	cis	rs7302981	0.967	rs7972842	ENSG00000272368.2	RP4-605O3.4	-5.11	3.82e-07	4.21e-05	-0.17	-0.16	Systolic blood pressure;	chr12:50122540	chr12:50112197~50165618:+
BRCA	cis	rs728616	0.867	rs61860412	ENSG00000225484.5	NUTM2B-AS1	-5.11	3.82e-07	4.21e-05	-0.42	-0.16	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79968730	chr10:79663088~79826594:-
BRCA	cis	rs4713118	0.513	rs149962	ENSG00000280107.1	AL022393.9	-5.11	3.82e-07	4.21e-05	-0.21	-0.16	Parkinson's disease;	chr6:28048140	chr6:28170845~28172521:+
BRCA	cis	rs172166	0.769	rs149965	ENSG00000280107.1	AL022393.9	-5.11	3.82e-07	4.21e-05	-0.21	-0.16	Cardiac Troponin-T levels;	chr6:28050911	chr6:28170845~28172521:+
BRCA	cis	rs10504130	1	rs76649221	ENSG00000253844.1	RP11-546K22.1	-5.11	3.82e-07	4.21e-05	-0.27	-0.16	Venous thromboembolism (SNP x SNP interaction);	chr8:51884175	chr8:51961458~52022974:+
BRCA	cis	rs7772486	0.754	rs4896839	ENSG00000270638.1	RP3-466P17.1	-5.11	3.82e-07	4.21e-05	-0.18	-0.16	Lobe attachment (rater-scored or self-reported);	chr6:145698553	chr6:145735570~145737218:+
BRCA	cis	rs4835473	0.897	rs11727223	ENSG00000249741.2	RP11-673E1.3	-5.11	3.82e-07	4.21e-05	-0.17	-0.16	Immature fraction of reticulocytes;	chr4:143707090	chr4:143911514~143912053:-
BRCA	cis	rs9473147	0.516	rs9381575	ENSG00000270761.1	RP11-385F7.1	-5.11	3.82e-07	4.21e-05	-0.17	-0.16	Platelet distribution width;Mean platelet volume;	chr6:47561028	chr6:47477243~47477572:-
BRCA	cis	rs6714710	0.603	rs34502870	ENSG00000230606.9	AC159540.1	-5.11	3.82e-07	4.21e-05	-0.18	-0.16	Posterior cortical atrophy and Alzheimer's disease;	chr2:97789466	chr2:97416165~97433527:-
BRCA	cis	rs66887589	0.748	rs28439855	ENSG00000245958.5	RP11-33B1.1	-5.11	3.82e-07	4.21e-05	-0.14	-0.16	Diastolic blood pressure;	chr4:119341101	chr4:119454791~119552025:+
BRCA	cis	rs10504130	0.696	rs76522329	ENSG00000253844.1	RP11-546K22.1	-5.11	3.82e-07	4.21e-05	-0.24	-0.16	Venous thromboembolism (SNP x SNP interaction);	chr8:51928822	chr8:51961458~52022974:+
BRCA	cis	rs2832191	0.791	rs2832182	ENSG00000215533.7	LINC00189	5.11	3.83e-07	4.22e-05	0.17	0.16	Dental caries;	chr21:29109291	chr21:29193480~29288205:+
BRCA	cis	rs13113518	0.934	rs3805155	ENSG00000223305.1	RN7SKP30	5.11	3.83e-07	4.22e-05	0.19	0.16	Height;	chr4:55497842	chr4:55540502~55540835:-
BRCA	cis	rs17685	0.523	rs10246583	ENSG00000280388.1	RP11-229D13.3	-5.11	3.83e-07	4.22e-05	-0.16	-0.16	Coffee consumption (cups per day);Coffee consumption;	chr7:76117349	chr7:76043977~76045963:-
BRCA	cis	rs2153535	0.58	rs1832101	ENSG00000251164.1	HULC	-5.11	3.83e-07	4.22e-05	-0.19	-0.16	Motion sickness;	chr6:8459944	chr6:8652137~8653846:+
BRCA	cis	rs10129255	1	rs4612959	ENSG00000280411.1	IGHV1-69-2	-5.11	3.83e-07	4.22e-05	-0.11	-0.16	Kawasaki disease;	chr14:106767055	chr14:106762092~106762588:-
BRCA	cis	rs13113518	1	rs6858803	ENSG00000223305.1	RN7SKP30	5.11	3.83e-07	4.22e-05	0.19	0.16	Height;	chr4:55484534	chr4:55540502~55540835:-
BRCA	cis	rs13113518	1	rs55699500	ENSG00000223305.1	RN7SKP30	5.11	3.83e-07	4.22e-05	0.19	0.16	Height;	chr4:55540912	chr4:55540502~55540835:-
BRCA	cis	rs4908768	0.539	rs11121205	ENSG00000270282.1	RP5-1115A15.2	5.11	3.83e-07	4.22e-05	0.17	0.16	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8598026	chr1:8512653~8513021:+
BRCA	cis	rs321358	0.945	rs17537360	ENSG00000271390.1	RP11-89C3.3	5.11	3.83e-07	4.22e-05	0.26	0.16	Body mass index;	chr11:111116921	chr11:111089870~111090368:-
BRCA	cis	rs78487399	0.908	rs77613902	ENSG00000234936.1	AC010883.5	5.11	3.83e-07	4.22e-05	0.23	0.16	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43616852	chr2:43229573~43233394:+
BRCA	cis	rs1707322	0.865	rs785501	ENSG00000234329.1	RP11-767N6.2	-5.11	3.83e-07	4.23e-05	-0.16	-0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46113939	chr1:45651039~45651826:-
BRCA	cis	rs718433	0.782	rs4246993	ENSG00000256379.1	TRAV8-5	5.11	3.83e-07	4.23e-05	0.19	0.16	Intraocular pressure;	chr14:21774136	chr14:21903077~21903598:+
BRCA	cis	rs4706831	0.647	rs627240	ENSG00000233967.5	RP11-250B2.3	-5.11	3.83e-07	4.23e-05	-0.15	-0.16	Joint mobility (Beighton score);	chr6:80276168	chr6:80443344~80465927:+
BRCA	cis	rs867371	0.502	rs3759800	ENSG00000259429.4	UBE2Q2P2	5.11	3.83e-07	4.23e-05	0.15	0.16	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82240622	chr15:82355142~82420075:+
BRCA	cis	rs6840360	0.642	rs2709825	ENSG00000251611.1	RP11-610P16.1	-5.11	3.83e-07	4.23e-05	-0.14	-0.16	Intelligence (multi-trait analysis);	chr4:151444411	chr4:151407551~151408835:-
BRCA	cis	rs6840360	0.607	rs2724547	ENSG00000251611.1	RP11-610P16.1	-5.11	3.83e-07	4.23e-05	-0.14	-0.16	Intelligence (multi-trait analysis);	chr4:151444424	chr4:151407551~151408835:-
BRCA	cis	rs7937890	0.874	rs2303972	ENSG00000251991.1	RNU7-49P	-5.11	3.84e-07	4.23e-05	-0.17	-0.16	Mitochondrial DNA levels;	chr11:14281736	chr11:14478892~14478953:+
BRCA	cis	rs10510102	0.935	rs74362676	ENSG00000226864.1	ATE1-AS1	5.11	3.84e-07	4.23e-05	0.28	0.16	Breast cancer;	chr10:121898216	chr10:121928312~121951965:+
BRCA	cis	rs8054556	1	rs3814884	ENSG00000273724.1	RP11-347C12.12	-5.11	3.84e-07	4.23e-05	-0.18	-0.16	Autism spectrum disorder or schizophrenia;	chr16:29983415	chr16:30336400~30343336:+
BRCA	cis	rs4650994	0.525	rs4650997	ENSG00000273384.1	RP5-1098D14.1	5.11	3.84e-07	4.23e-05	0.2	0.16	HDL cholesterol;HDL cholesterol levels;	chr1:178561609	chr1:178651706~178652282:+
BRCA	cis	rs6500602	0.927	rs7200817	ENSG00000280063.1	RP11-295D4.3	5.11	3.84e-07	4.23e-05	0.12	0.16	Schizophrenia;	chr16:4430597	chr16:4346694~4348648:-
BRCA	cis	rs7246657	0.508	rs10419845	ENSG00000276846.1	CTD-3220F14.3	5.11	3.84e-07	4.24e-05	0.26	0.16	Coronary artery calcification;	chr19:37000290	chr19:37314868~37315620:-
BRCA	cis	rs12501370	0.569	rs6839964	ENSG00000201736.1	RNA5SP160	5.11	3.85e-07	4.24e-05	0.18	0.16	Iris color (L* coordinate);	chr4:40972925	chr4:40990154~40990273:+
BRCA	cis	rs2919009	0.607	rs61088531	ENSG00000271670.1	RP11-95I16.4	5.11	3.85e-07	4.24e-05	0.22	0.16	Obesity-related traits;	chr10:120946696	chr10:120879256~120880667:-
BRCA	cis	rs8054556	0.647	rs4077410	ENSG00000273724.1	RP11-347C12.12	-5.11	3.85e-07	4.24e-05	-0.17	-0.16	Autism spectrum disorder or schizophrenia;	chr16:29986879	chr16:30336400~30343336:+
BRCA	cis	rs2179367	0.959	rs480034	ENSG00000216906.2	RP11-350J20.9	-5.11	3.85e-07	4.24e-05	-0.2	-0.16	Dupuytren's disease;	chr6:149414294	chr6:149904243~149906418:+
BRCA	cis	rs338389	0.542	rs338342	ENSG00000260657.2	RP11-315D16.4	5.11	3.85e-07	4.25e-05	0.2	0.16	Survival in rectal cancer;	chr15:67979714	chr15:68267792~68277994:-
BRCA	cis	rs11124272	0.582	rs1475054	ENSG00000272716.1	RP11-563N4.1	5.11	3.85e-07	4.25e-05	0.19	0.16	Interleukin-18 levels;	chr2:31516895	chr2:32165046~32165757:-
BRCA	cis	rs10129255	0.957	rs10137980	ENSG00000274576.2	IGHV2-70	5.11	3.85e-07	4.25e-05	0.13	0.16	Kawasaki disease;	chr14:106775735	chr14:106770577~106771020:-
BRCA	cis	rs14027	0.64	rs28421406	ENSG00000279347.1	RP11-85I17.2	-5.11	3.85e-07	4.25e-05	-0.15	-0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119752249	chr8:119838736~119840385:-
BRCA	cis	rs1876905	0.68	rs434034	ENSG00000271789.1	RP5-1112D6.7	-5.11	3.85e-07	4.25e-05	-0.23	-0.16	Mean corpuscular hemoglobin;	chr6:111204180	chr6:111297126~111298510:+
BRCA	cis	rs754466	0.51	rs55893027	ENSG00000204049.1	RP11-126H7.4	5.11	3.86e-07	4.25e-05	0.18	0.16	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77828451	chr10:77866875~77869610:+
BRCA	cis	rs4948275	0.806	rs1953748	ENSG00000237233.2	TMEM26-AS1	-5.11	3.86e-07	4.25e-05	-0.19	-0.16	Night sleep phenotypes;	chr10:61494529	chr10:61452639~61481956:+
BRCA	cis	rs755249	0.565	rs9729677	ENSG00000237624.1	OXCT2P1	-5.11	3.86e-07	4.25e-05	-0.19	-0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39587137	chr1:39514956~39516490:+
BRCA	cis	rs1707322	1	rs6687301	ENSG00000234329.1	RP11-767N6.2	5.11	3.86e-07	4.25e-05	0.16	0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45917180	chr1:45651039~45651826:-
BRCA	cis	rs2522056	1	rs2706339	ENSG00000233006.5	AC034220.3	-5.11	3.86e-07	4.25e-05	-0.13	-0.16	Fibrinogen;Lymphocyte counts;	chr5:132464413	chr5:132311285~132369916:-
BRCA	cis	rs10911232	0.507	rs10797822	ENSG00000224468.3	RP11-181K3.4	-5.11	3.86e-07	4.25e-05	-0.17	-0.16	Hypertriglyceridemia;	chr1:183048634	chr1:183138402~183141282:-
BRCA	cis	rs2839186	0.807	rs2032226	ENSG00000228137.1	AP001469.7	5.11	3.86e-07	4.25e-05	0.16	0.16	Testicular germ cell tumor;	chr21:46260438	chr21:46246890~46247682:+
BRCA	cis	rs8114671	0.562	rs6087653	ENSG00000269202.1	RP4-614O4.12	-5.11	3.86e-07	4.25e-05	-0.16	-0.16	Height;	chr20:34934251	chr20:35201747~35203288:-
BRCA	cis	rs62025270	0.632	rs62022943	ENSG00000259762.1	RP11-158M2.4	-5.11	3.86e-07	4.25e-05	-0.23	-0.16	Idiopathic pulmonary fibrosis;	chr15:85716239	chr15:85750336~85752901:-
BRCA	cis	rs9659323	0.623	rs12091291	ENSG00000231365.4	RP11-418J17.1	5.11	3.86e-07	4.25e-05	0.2	0.16	Body mass index;	chr1:118936205	chr1:119140396~119275973:+
BRCA	cis	rs2638953	0.853	rs3898068	ENSG00000247934.4	RP11-967K21.1	-5.11	3.86e-07	4.25e-05	-0.21	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28457084	chr12:28163298~28190738:-
BRCA	cis	rs4835473	0.897	rs3874	ENSG00000249741.2	RP11-673E1.3	-5.11	3.86e-07	4.26e-05	-0.17	-0.16	Immature fraction of reticulocytes;	chr4:143968795	chr4:143911514~143912053:-
BRCA	cis	rs2832191	0.791	rs2832186	ENSG00000215533.7	LINC00189	5.11	3.87e-07	4.26e-05	0.17	0.16	Dental caries;	chr21:29111830	chr21:29193480~29288205:+
BRCA	cis	rs4713118	0.513	rs149959	ENSG00000280107.1	AL022393.9	-5.11	3.87e-07	4.26e-05	-0.22	-0.16	Parkinson's disease;	chr6:28046076	chr6:28170845~28172521:+
BRCA	cis	rs4835473	0.8	rs2089839	ENSG00000249741.2	RP11-673E1.3	-5.11	3.87e-07	4.26e-05	-0.17	-0.16	Immature fraction of reticulocytes;	chr4:143980955	chr4:143911514~143912053:-
BRCA	cis	rs6569038	0.502	rs2797352	ENSG00000253194.1	RP11-351A11.1	5.11	3.87e-07	4.26e-05	0.2	0.16	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr6:118996678	chr6:118934785~119031541:+
BRCA	cis	rs4819052	0.851	rs2255766	ENSG00000184274.3	LINC00315	-5.11	3.87e-07	4.26e-05	-0.21	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45263862	chr21:45300245~45305257:-
BRCA	cis	rs7617773	0.817	rs9311421	ENSG00000199476.1	Y_RNA	-5.11	3.87e-07	4.27e-05	-0.21	-0.16	Coronary artery disease;	chr3:48251588	chr3:48288587~48288694:+
BRCA	cis	rs10752881	0.935	rs3935221	ENSG00000224468.3	RP11-181K3.4	-5.11	3.87e-07	4.27e-05	-0.17	-0.16	Colorectal cancer;	chr1:182999875	chr1:183138402~183141282:-
BRCA	cis	rs77972916	0.536	rs7589361	ENSG00000234936.1	AC010883.5	5.11	3.87e-07	4.27e-05	0.18	0.16	Granulocyte percentage of myeloid white cells;	chr2:43362189	chr2:43229573~43233394:+
BRCA	cis	rs9863	0.828	rs12303671	ENSG00000270028.1	RP11-380L11.4	5.11	3.88e-07	4.27e-05	0.19	0.16	White blood cell count;	chr12:124008063	chr12:123925461~123926083:-
BRCA	cis	rs10911232	0.507	rs4483371	ENSG00000224468.3	RP11-181K3.4	-5.11	3.88e-07	4.27e-05	-0.17	-0.16	Hypertriglyceridemia;	chr1:183019217	chr1:183138402~183141282:-
BRCA	cis	rs10752881	1	rs12133714	ENSG00000224468.3	RP11-181K3.4	-5.11	3.88e-07	4.27e-05	-0.17	-0.16	Colorectal cancer;	chr1:183019117	chr1:183138402~183141282:-
BRCA	cis	rs10752881	1	rs12028740	ENSG00000224468.3	RP11-181K3.4	-5.11	3.88e-07	4.27e-05	-0.17	-0.16	Colorectal cancer;	chr1:183016446	chr1:183138402~183141282:-
BRCA	cis	rs10752881	1	rs12035773	ENSG00000224468.3	RP11-181K3.4	-5.11	3.88e-07	4.27e-05	-0.17	-0.16	Colorectal cancer;	chr1:183016581	chr1:183138402~183141282:-
BRCA	cis	rs10752881	1	rs4402094	ENSG00000224468.3	RP11-181K3.4	-5.11	3.88e-07	4.27e-05	-0.17	-0.16	Colorectal cancer;	chr1:183017306	chr1:183138402~183141282:-
BRCA	cis	rs10752881	1	rs6424879	ENSG00000224468.3	RP11-181K3.4	-5.11	3.88e-07	4.27e-05	-0.17	-0.16	Colorectal cancer;	chr1:183017457	chr1:183138402~183141282:-
BRCA	cis	rs10752881	1	rs6424880	ENSG00000224468.3	RP11-181K3.4	-5.11	3.88e-07	4.27e-05	-0.17	-0.16	Colorectal cancer;	chr1:183017544	chr1:183138402~183141282:-
BRCA	cis	rs10752881	1	rs10752886	ENSG00000224468.3	RP11-181K3.4	-5.11	3.88e-07	4.27e-05	-0.17	-0.16	Colorectal cancer;	chr1:183018113	chr1:183138402~183141282:-
BRCA	cis	rs10844706	0.699	rs10844627	ENSG00000214776.8	RP11-726G1.1	5.11	3.88e-07	4.27e-05	0.19	0.16	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9733781	chr12:9467552~9576275:+
BRCA	cis	rs507080	0.769	rs7389	ENSG00000278376.1	RP11-158I9.8	5.11	3.88e-07	4.27e-05	0.15	0.16	Serum metabolite levels;	chr11:118657756	chr11:118791254~118793137:+
BRCA	cis	rs595244	1	rs111297611	ENSG00000259705.1	RP11-227D13.1	5.11	3.88e-07	4.27e-05	0.29	0.16	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48518744	chr15:48645951~48652016:+
BRCA	cis	rs2839186	0.709	rs2156117	ENSG00000239415.1	AP001469.9	5.11	3.88e-07	4.28e-05	0.16	0.16	Testicular germ cell tumor;	chr21:46249386	chr21:46251549~46254133:-
BRCA	cis	rs2243480	0.831	rs57294491	ENSG00000228409.4	CCT6P1	-5.11	3.88e-07	4.28e-05	-0.22	-0.16	Diabetic kidney disease;	chr7:66219914	chr7:65751142~65763354:+
BRCA	cis	rs9907295	0.901	rs4796118	ENSG00000271013.1	AC015849.15	-5.11	3.89e-07	4.28e-05	-0.22	-0.16	Fibroblast growth factor basic levels;	chr17:35858804	chr17:35912635~35918010:-
BRCA	cis	rs1193	0.837	rs2138396	ENSG00000231259.4	AC125232.1	-5.11	3.89e-07	4.28e-05	-0.19	-0.16	High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;High light scatter reticulocyte count;	chr2:86752599	chr2:87031815~87053069:-
BRCA	cis	rs8054556	1	rs8054556	ENSG00000273724.1	RP11-347C12.12	-5.11	3.89e-07	4.28e-05	-0.18	-0.16	Autism spectrum disorder or schizophrenia;	chr16:29946895	chr16:30336400~30343336:+
BRCA	cis	rs829883	0.639	rs829898	ENSG00000227825.4	SLC9A7P1	5.11	3.89e-07	4.28e-05	0.18	0.16	Colorectal adenoma (advanced);	chr12:98463897	chr12:98453835~98457145:-
BRCA	cis	rs4934494	0.677	rs1815338	ENSG00000240996.1	RP11-80H5.7	-5.11	3.89e-07	4.28e-05	-0.22	-0.16	Red blood cell count;	chr10:89616934	chr10:89694295~89697928:-
BRCA	cis	rs4819052	0.851	rs4819041	ENSG00000184274.3	LINC00315	-5.11	3.89e-07	4.28e-05	-0.21	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240040	chr21:45300245~45305257:-
BRCA	cis	rs13113518	0.783	rs6843722	ENSG00000272969.1	RP11-528I4.2	5.11	3.89e-07	4.29e-05	0.18	0.16	Height;	chr4:55465165	chr4:55547112~55547889:+
BRCA	cis	rs793571	0.628	rs7169205	ENSG00000259250.1	RP11-50C13.1	-5.11	3.89e-07	4.29e-05	-0.26	-0.16	Schizophrenia;	chr15:58788004	chr15:58587507~58591676:+
BRCA	cis	rs2562456	0.558	rs62108173	ENSG00000268535.1	RP11-420K14.3	5.11	3.89e-07	4.29e-05	0.24	0.16	Pain;	chr19:21244386	chr19:21709522~21710191:+
BRCA	cis	rs1193	0.837	rs10186663	ENSG00000231259.4	AC125232.1	-5.11	3.89e-07	4.29e-05	-0.19	-0.16	High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;High light scatter reticulocyte count;	chr2:86751970	chr2:87031815~87053069:-
BRCA	cis	rs1193	0.837	rs2887012	ENSG00000231259.4	AC125232.1	-5.11	3.89e-07	4.29e-05	-0.19	-0.16	High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;High light scatter reticulocyte count;	chr2:86752294	chr2:87031815~87053069:-
BRCA	cis	rs9287719	0.967	rs6727768	ENSG00000243819.4	RN7SL832P	5.11	3.89e-07	4.29e-05	0.15	0.16	Prostate cancer;	chr2:10617353	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.967	rs10167129	ENSG00000243819.4	RN7SL832P	5.11	3.89e-07	4.29e-05	0.15	0.16	Prostate cancer;	chr2:10618449	chr2:10690344~10692099:+
BRCA	cis	rs8180040	0.654	rs11714373	ENSG00000276925.1	RP11-708J19.3	5.11	3.89e-07	4.29e-05	0.18	0.16	Colorectal cancer;	chr3:47173327	chr3:47469777~47469987:+
BRCA	cis	rs1707322	0.963	rs12022335	ENSG00000234329.1	RP11-767N6.2	5.11	3.9e-07	4.29e-05	0.16	0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45937060	chr1:45651039~45651826:-
BRCA	cis	rs67311347	1	rs17078813	ENSG00000280739.1	EIF1B-AS1	5.11	3.9e-07	4.3e-05	0.18	0.16	Renal cell carcinoma;	chr3:40392671	chr3:40173145~40309698:-
BRCA	cis	rs10911232	0.507	rs10752888	ENSG00000224468.3	RP11-181K3.4	-5.11	3.9e-07	4.3e-05	-0.17	-0.16	Hypertriglyceridemia;	chr1:183024616	chr1:183138402~183141282:-
BRCA	cis	rs867371	0.502	rs2047679	ENSG00000259429.4	UBE2Q2P2	-5.11	3.91e-07	4.3e-05	-0.15	-0.16	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82239540	chr15:82355142~82420075:+
BRCA	cis	rs8180040	0.629	rs7426969	ENSG00000276925.1	RP11-708J19.3	-5.11	3.91e-07	4.3e-05	-0.18	-0.16	Colorectal cancer;	chr3:47049865	chr3:47469777~47469987:+
BRCA	cis	rs9307551	0.584	rs2119419	ENSG00000250334.4	LINC00989	-5.11	3.91e-07	4.3e-05	-0.21	-0.16	Refractive error;	chr4:79515828	chr4:79492416~79576460:+
BRCA	cis	rs801193	0.569	rs2659893	ENSG00000273448.1	RP11-166O4.6	5.11	3.91e-07	4.3e-05	0.14	0.16	Aortic root size;	chr7:66735006	chr7:67333047~67334383:+
BRCA	cis	rs801193	0.569	rs2659892	ENSG00000273448.1	RP11-166O4.6	5.11	3.91e-07	4.3e-05	0.14	0.16	Aortic root size;	chr7:66735318	chr7:67333047~67334383:+
BRCA	cis	rs801193	0.569	rs2707847	ENSG00000273448.1	RP11-166O4.6	5.11	3.91e-07	4.3e-05	0.14	0.16	Aortic root size;	chr7:66737884	chr7:67333047~67334383:+
BRCA	cis	rs1075265	0.589	rs2253760	ENSG00000235937.1	AC008280.1	5.11	3.91e-07	4.3e-05	0.17	0.16	Chronotype;Morning vs. evening chronotype;	chr2:53806851	chr2:54029552~54030682:-
BRCA	cis	rs7674212	0.57	rs6810571	ENSG00000248740.4	RP11-328K4.1	5.11	3.91e-07	4.3e-05	0.18	0.16	Type 2 diabetes;	chr4:103165630	chr4:103256159~103453658:+
BRCA	cis	rs427691	0.625	rs845738	ENSG00000271849.1	CTC-332L22.1	-5.11	3.91e-07	4.3e-05	-0.25	-0.16	Autism spectrum disorder or schizophrenia;	chr5:109682414	chr5:109687802~109688329:-
BRCA	cis	rs1862618	0.671	rs2591968	ENSG00000271828.1	CTD-2310F14.1	5.11	3.91e-07	4.3e-05	0.19	0.16	Initial pursuit acceleration;	chr5:56937714	chr5:56927874~56929573:+
BRCA	cis	rs1075265	0.554	rs10168293	ENSG00000235937.1	AC008280.1	5.11	3.91e-07	4.3e-05	0.17	0.16	Chronotype;Morning vs. evening chronotype;	chr2:53973793	chr2:54029552~54030682:-
BRCA	cis	rs11955398	0.716	rs56191602	ENSG00000215032.2	GNL3LP1	5.11	3.91e-07	4.3e-05	0.19	0.16	Intelligence (multi-trait analysis);	chr5:60658617	chr5:60891935~60893577:-
BRCA	cis	rs10510102	0.81	rs11200240	ENSG00000226864.1	ATE1-AS1	5.11	3.91e-07	4.3e-05	0.28	0.16	Breast cancer;	chr10:121903265	chr10:121928312~121951965:+
BRCA	cis	rs10510102	0.935	rs74914751	ENSG00000226864.1	ATE1-AS1	5.11	3.91e-07	4.3e-05	0.28	0.16	Breast cancer;	chr10:121904496	chr10:121928312~121951965:+
BRCA	cis	rs10510102	0.935	rs11200242	ENSG00000226864.1	ATE1-AS1	5.11	3.91e-07	4.3e-05	0.28	0.16	Breast cancer;	chr10:121905378	chr10:121928312~121951965:+
BRCA	cis	rs73607972	0.935	rs73605911	ENSG00000275191.1	RP11-36I17.2	-5.11	3.91e-07	4.31e-05	-0.26	-0.16	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53597184	chr16:53628256~53628816:-
BRCA	cis	rs10504130	0.778	rs71513564	ENSG00000272024.1	RP11-546K22.3	-5.11	3.92e-07	4.31e-05	-0.26	-0.16	Venous thromboembolism (SNP x SNP interaction);	chr8:51910177	chr8:51950284~51950690:+
BRCA	cis	rs4699052	0.927	rs1870888	ENSG00000248740.4	RP11-328K4.1	5.11	3.92e-07	4.31e-05	0.18	0.16	Testicular germ cell tumor;	chr4:103248169	chr4:103256159~103453658:+
BRCA	cis	rs6714710	0.603	rs2305143	ENSG00000230606.9	AC159540.1	-5.11	3.92e-07	4.31e-05	-0.18	-0.16	Posterior cortical atrophy and Alzheimer's disease;	chr2:97797318	chr2:97416165~97433527:-
BRCA	cis	rs6714710	0.603	rs11691494	ENSG00000230606.9	AC159540.1	-5.11	3.92e-07	4.31e-05	-0.18	-0.16	Posterior cortical atrophy and Alzheimer's disease;	chr2:97803263	chr2:97416165~97433527:-
BRCA	cis	rs6714710	0.58	rs17489915	ENSG00000230606.9	AC159540.1	-5.11	3.92e-07	4.31e-05	-0.18	-0.16	Posterior cortical atrophy and Alzheimer's disease;	chr2:97803968	chr2:97416165~97433527:-
BRCA	cis	rs6600671	1	rs7532615	ENSG00000275538.1	RNVU1-19	-5.11	3.92e-07	4.31e-05	-0.18	-0.16	Hip geometry;	chr1:121430980	chr1:120850819~120850985:-
BRCA	cis	rs10844706	0.699	rs741199	ENSG00000214776.8	RP11-726G1.1	5.11	3.92e-07	4.31e-05	0.19	0.16	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9720769	chr12:9467552~9576275:+
BRCA	cis	rs4819052	0.851	rs1999333	ENSG00000184274.3	LINC00315	-5.11	3.92e-07	4.31e-05	-0.21	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250486	chr21:45300245~45305257:-
BRCA	cis	rs2348418	0.715	rs1581076	ENSG00000247934.4	RP11-967K21.1	5.11	3.92e-07	4.31e-05	0.17	0.16	Lung function (FEV1);Lung function (FVC);	chr12:28570724	chr12:28163298~28190738:-
BRCA	cis	rs763121	0.853	rs5750630	ENSG00000228274.3	RP3-508I15.9	-5.11	3.92e-07	4.31e-05	-0.18	-0.16	Menopause (age at onset);	chr22:38589813	chr22:38667585~38681820:-
BRCA	cis	rs7618915	0.547	rs3755806	ENSG00000243224.1	RP5-1157M23.2	5.11	3.92e-07	4.32e-05	0.18	0.16	Bipolar disorder;	chr3:52609669	chr3:52239258~52241097:+
BRCA	cis	rs7824557	0.592	rs920044	ENSG00000154316.13	TDH	-5.11	3.92e-07	4.32e-05	-0.2	-0.16	Retinal vascular caliber;	chr8:11366804	chr8:11339637~11368452:+
BRCA	cis	rs9467773	0.595	rs2451736	ENSG00000124549.13	BTN2A3P	5.11	3.92e-07	4.32e-05	0.16	0.16	Intelligence (multi-trait analysis);	chr6:26620316	chr6:26421391~26432383:+
BRCA	cis	rs6570726	0.791	rs12208019	ENSG00000270638.1	RP3-466P17.1	5.11	3.93e-07	4.32e-05	0.18	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145614436	chr6:145735570~145737218:+
BRCA	cis	rs6570726	0.791	rs11155435	ENSG00000270638.1	RP3-466P17.1	5.11	3.93e-07	4.32e-05	0.18	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145617409	chr6:145735570~145737218:+
BRCA	cis	rs8114671	0.562	rs7266550	ENSG00000269202.1	RP4-614O4.12	-5.11	3.93e-07	4.32e-05	-0.16	-0.16	Height;	chr20:34907707	chr20:35201747~35203288:-
BRCA	cis	rs2153535	0.58	rs2184582	ENSG00000251164.1	HULC	-5.11	3.93e-07	4.32e-05	-0.19	-0.16	Motion sickness;	chr6:8447560	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.58	rs2184583	ENSG00000251164.1	HULC	-5.11	3.93e-07	4.32e-05	-0.19	-0.16	Motion sickness;	chr6:8447575	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.58	rs9505446	ENSG00000251164.1	HULC	-5.11	3.93e-07	4.32e-05	-0.19	-0.16	Motion sickness;	chr6:8448458	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.58	rs1335633	ENSG00000251164.1	HULC	-5.11	3.93e-07	4.32e-05	-0.19	-0.16	Motion sickness;	chr6:8448567	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.58	rs1115079	ENSG00000251164.1	HULC	-5.11	3.93e-07	4.32e-05	-0.19	-0.16	Motion sickness;	chr6:8449382	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.58	rs1115078	ENSG00000251164.1	HULC	-5.11	3.93e-07	4.32e-05	-0.19	-0.16	Motion sickness;	chr6:8449405	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.58	rs6597322	ENSG00000251164.1	HULC	-5.11	3.93e-07	4.32e-05	-0.19	-0.16	Motion sickness;	chr6:8449719	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.58	rs962590	ENSG00000251164.1	HULC	-5.11	3.93e-07	4.32e-05	-0.19	-0.16	Motion sickness;	chr6:8450666	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.58	rs5001324	ENSG00000251164.1	HULC	-5.11	3.93e-07	4.32e-05	-0.19	-0.16	Motion sickness;	chr6:8451371	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.58	rs5001322	ENSG00000251164.1	HULC	-5.11	3.93e-07	4.32e-05	-0.19	-0.16	Motion sickness;	chr6:8451375	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.58	rs969422	ENSG00000251164.1	HULC	-5.11	3.93e-07	4.32e-05	-0.19	-0.16	Motion sickness;	chr6:8451547	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.58	rs969421	ENSG00000251164.1	HULC	-5.11	3.93e-07	4.32e-05	-0.19	-0.16	Motion sickness;	chr6:8451716	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.601	rs969420	ENSG00000251164.1	HULC	-5.11	3.93e-07	4.32e-05	-0.19	-0.16	Motion sickness;	chr6:8451733	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.58	rs7741456	ENSG00000251164.1	HULC	-5.11	3.93e-07	4.32e-05	-0.19	-0.16	Motion sickness;	chr6:8452191	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.58	rs7742689	ENSG00000251164.1	HULC	-5.11	3.93e-07	4.32e-05	-0.19	-0.16	Motion sickness;	chr6:8452200	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.58	rs7767756	ENSG00000251164.1	HULC	-5.11	3.93e-07	4.32e-05	-0.19	-0.16	Motion sickness;	chr6:8453195	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.58	rs7767926	ENSG00000251164.1	HULC	-5.11	3.93e-07	4.32e-05	-0.19	-0.16	Motion sickness;	chr6:8453324	chr6:8652137~8653846:+
BRCA	cis	rs9923856	0.542	rs11859698	ENSG00000274038.1	RP11-66H6.4	-5.11	3.93e-07	4.32e-05	-0.17	-0.16	Atopic dermatitis;Adult asthma;	chr16:11032878	chr16:11056556~11057034:+
BRCA	cis	rs4906332	1	rs2065015	ENSG00000244691.1	RPL10AP1	5.11	3.93e-07	4.32e-05	0.2	0.16	Coronary artery disease;	chr14:103437724	chr14:103412119~103412761:-
BRCA	cis	rs2243480	1	rs2465120	ENSG00000228409.4	CCT6P1	5.11	3.93e-07	4.32e-05	0.22	0.16	Diabetic kidney disease;	chr7:66155987	chr7:65751142~65763354:+
BRCA	cis	rs2243480	0.908	rs2460431	ENSG00000228409.4	CCT6P1	-5.11	3.93e-07	4.32e-05	-0.22	-0.16	Diabetic kidney disease;	chr7:66157859	chr7:65751142~65763354:+
BRCA	cis	rs2243480	1	rs4718309	ENSG00000228409.4	CCT6P1	-5.11	3.93e-07	4.32e-05	-0.22	-0.16	Diabetic kidney disease;	chr7:66162777	chr7:65751142~65763354:+
BRCA	cis	rs2243480	1	rs6460274	ENSG00000228409.4	CCT6P1	-5.11	3.93e-07	4.32e-05	-0.22	-0.16	Diabetic kidney disease;	chr7:66163497	chr7:65751142~65763354:+
BRCA	cis	rs2243480	1	rs7787230	ENSG00000228409.4	CCT6P1	-5.11	3.93e-07	4.32e-05	-0.22	-0.16	Diabetic kidney disease;	chr7:66164112	chr7:65751142~65763354:+
BRCA	cis	rs6545883	0.894	rs12622458	ENSG00000270820.4	RP11-355B11.2	-5.1	3.93e-07	4.32e-05	-0.18	-0.16	Tuberculosis;	chr2:61296419	chr2:61471188~61484130:+
BRCA	cis	rs227932	0.681	rs7776862	ENSG00000234286.1	AC006026.13	5.1	3.93e-07	4.33e-05	0.25	0.16	Schizophrenia;	chr7:23736607	chr7:23680195~23680786:-
BRCA	cis	rs12646107	0.891	rs11132998	ENSG00000261672.1	RP11-475B2.1	-5.1	3.93e-07	4.33e-05	-0.25	-0.16	Response to amphetamines;	chr4:173595439	chr4:173593672~173594556:+
BRCA	cis	rs3126085	0.56	rs72698932	ENSG00000237975.5	FLG-AS1	5.1	3.93e-07	4.33e-05	0.23	0.16	Atopic dermatitis;	chr1:152383044	chr1:152168125~152445456:+
BRCA	cis	rs6840360	0.642	rs2034061	ENSG00000278978.1	RP11-164P12.5	-5.1	3.94e-07	4.33e-05	-0.17	-0.16	Intelligence (multi-trait analysis);	chr4:151499604	chr4:151669786~151670503:+
BRCA	cis	rs12135996	0.592	rs11588189	ENSG00000232879.2	RP11-544M22.3	-5.1	3.94e-07	4.33e-05	-0.18	-0.16	Night sleep phenotypes;	chr1:161049831	chr1:161034834~161035006:+
BRCA	cis	rs2303319	0.504	rs2175142	ENSG00000227403.1	AC009299.3	5.1	3.94e-07	4.33e-05	0.37	0.16	Cognitive function;	chr2:161593614	chr2:161244739~161249050:+
BRCA	cis	rs2179367	0.537	rs12192159	ENSG00000268592.3	RAET1E-AS1	5.1	3.94e-07	4.33e-05	0.24	0.16	Dupuytren's disease;	chr6:149445969	chr6:149863494~149919507:+
BRCA	cis	rs6714710	0.603	rs35424768	ENSG00000230606.9	AC159540.1	-5.1	3.94e-07	4.33e-05	-0.18	-0.16	Posterior cortical atrophy and Alzheimer's disease;	chr2:97779190	chr2:97416165~97433527:-
BRCA	cis	rs6714710	0.603	rs13020776	ENSG00000230606.9	AC159540.1	-5.1	3.94e-07	4.33e-05	-0.18	-0.16	Posterior cortical atrophy and Alzheimer's disease;	chr2:97786290	chr2:97416165~97433527:-
BRCA	cis	rs2708977	0.545	rs772177	ENSG00000237510.6	AC008268.2	-5.1	3.94e-07	4.33e-05	-0.24	-0.16	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96294733	chr2:95789654~95800166:+
BRCA	cis	rs875971	0.545	rs10950029	ENSG00000230295.1	RP11-458F8.2	5.1	3.94e-07	4.34e-05	0.15	0.16	Aortic root size;	chr7:66169334	chr7:66880708~66882981:+
BRCA	cis	rs8040855	0.599	rs1964724	ENSG00000259774.1	RP11-182J1.13	-5.1	3.94e-07	4.34e-05	-0.18	-0.16	Bulimia nervosa;	chr15:85183269	chr15:84422618~84425882:+
BRCA	cis	rs597539	0.652	rs544370	ENSG00000261625.1	RP11-554A11.4	-5.1	3.94e-07	4.34e-05	-0.15	-0.16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68885764	chr11:69000765~69002048:-
BRCA	cis	rs6570726	0.791	rs10457788	ENSG00000270638.1	RP3-466P17.1	5.1	3.95e-07	4.34e-05	0.18	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145600000	chr6:145735570~145737218:+
BRCA	cis	rs7178909	0.933	rs7183156	ENSG00000259677.1	RP11-493E3.1	5.1	3.95e-07	4.34e-05	0.19	0.16	Common traits (Other);	chr15:89902214	chr15:89876540~89877285:+
BRCA	cis	rs4948275	0.709	rs2249921	ENSG00000237233.2	TMEM26-AS1	-5.1	3.95e-07	4.34e-05	-0.18	-0.16	Night sleep phenotypes;	chr10:61487354	chr10:61452639~61481956:+
BRCA	cis	rs9287719	0.967	rs6712304	ENSG00000243819.4	RN7SL832P	5.1	3.95e-07	4.34e-05	0.15	0.16	Prostate cancer;	chr2:10614249	chr2:10690344~10692099:+
BRCA	cis	rs2638953	0.853	rs10843180	ENSG00000247934.4	RP11-967K21.1	-5.1	3.95e-07	4.34e-05	-0.21	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28462221	chr12:28163298~28190738:-
BRCA	cis	rs1075265	0.811	rs805308	ENSG00000235937.1	AC008280.1	5.1	3.95e-07	4.34e-05	0.17	0.16	Chronotype;Morning vs. evening chronotype;	chr2:53967797	chr2:54029552~54030682:-
BRCA	cis	rs6442522	0.526	rs13074638	ENSG00000249786.6	EAF1-AS1	5.1	3.95e-07	4.34e-05	0.16	0.16	Uric acid levels;	chr3:15477382	chr3:15436171~15455940:-
BRCA	cis	rs2235544	0.579	rs1537322	ENSG00000225183.1	RP4-758J24.4	-5.1	3.95e-07	4.35e-05	-0.18	-0.16	Thyroid hormone levels;Multiple myeloma (hyperdiploidy);	chr1:54016633	chr1:54089856~54090093:+
BRCA	cis	rs2562456	0.652	rs62110214	ENSG00000268081.1	RP11-678G14.2	5.1	3.95e-07	4.35e-05	0.25	0.16	Pain;	chr19:21592406	chr19:21554640~21569237:-
BRCA	cis	rs7226408	0.842	rs11662247	ENSG00000267707.2	RP11-95O2.5	5.1	3.96e-07	4.35e-05	0.25	0.16	Obesity-related traits;	chr18:36768547	chr18:37243776~37247506:+
BRCA	cis	rs6840360	0.642	rs2709822	ENSG00000251611.1	RP11-610P16.1	-5.1	3.96e-07	4.35e-05	-0.14	-0.16	Intelligence (multi-trait analysis);	chr4:151430348	chr4:151407551~151408835:-
BRCA	cis	rs28735056	0.62	rs12456484	ENSG00000261126.6	RP11-795F19.1	5.1	3.96e-07	4.35e-05	0.15	0.16	Schizophrenia;	chr18:79917315	chr18:80046900~80095482:+
BRCA	cis	rs8114671	0.562	rs725521	ENSG00000269202.1	RP4-614O4.12	-5.1	3.96e-07	4.35e-05	-0.16	-0.16	Height;	chr20:34928268	chr20:35201747~35203288:-
BRCA	cis	rs1707322	1	rs6429580	ENSG00000234329.1	RP11-767N6.2	5.1	3.96e-07	4.35e-05	0.16	0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45809976	chr1:45651039~45651826:-
BRCA	cis	rs8031584	0.958	rs35256769	ENSG00000270015.1	RP11-540B6.6	-5.1	3.96e-07	4.35e-05	-0.16	-0.16	Huntington's disease progression;	chr15:30945573	chr15:30926514~30928407:+
BRCA	cis	rs8031584	0.958	rs11629793	ENSG00000270015.1	RP11-540B6.6	-5.1	3.96e-07	4.35e-05	-0.16	-0.16	Huntington's disease progression;	chr15:30946220	chr15:30926514~30928407:+
BRCA	cis	rs6714710	0.603	rs4311104	ENSG00000230606.9	AC159540.1	-5.1	3.96e-07	4.36e-05	-0.18	-0.16	Posterior cortical atrophy and Alzheimer's disease;	chr2:97808339	chr2:97416165~97433527:-
BRCA	cis	rs8054556	1	rs4583255	ENSG00000273724.1	RP11-347C12.12	-5.1	3.97e-07	4.36e-05	-0.18	-0.16	Autism spectrum disorder or schizophrenia;	chr16:29977620	chr16:30336400~30343336:+
BRCA	cis	rs4713118	0.629	rs203888	ENSG00000280107.1	AL022393.9	-5.1	3.97e-07	4.36e-05	-0.22	-0.16	Parkinson's disease;	chr6:28053811	chr6:28170845~28172521:+
BRCA	cis	rs2179367	0.959	rs514839	ENSG00000216906.2	RP11-350J20.9	5.1	3.97e-07	4.36e-05	0.2	0.16	Dupuytren's disease;	chr6:149327304	chr6:149904243~149906418:+
BRCA	cis	rs1552244	0.572	rs73117481	ENSG00000232901.1	CYCSP10	5.1	3.97e-07	4.36e-05	0.24	0.16	Alzheimer's disease;	chr3:10118448	chr3:10000647~10000940:-
BRCA	cis	rs1552244	0.572	rs59074548	ENSG00000232901.1	CYCSP10	5.1	3.97e-07	4.36e-05	0.24	0.16	Alzheimer's disease;	chr3:10122663	chr3:10000647~10000940:-
BRCA	cis	rs1552244	0.572	rs3774208	ENSG00000232901.1	CYCSP10	5.1	3.97e-07	4.36e-05	0.24	0.16	Alzheimer's disease;	chr3:10123038	chr3:10000647~10000940:-
BRCA	cis	rs1552244	0.572	rs6783705	ENSG00000232901.1	CYCSP10	5.1	3.97e-07	4.36e-05	0.24	0.16	Alzheimer's disease;	chr3:10123099	chr3:10000647~10000940:-
BRCA	cis	rs4835473	0.897	rs35599924	ENSG00000249741.2	RP11-673E1.3	-5.1	3.97e-07	4.36e-05	-0.17	-0.16	Immature fraction of reticulocytes;	chr4:143980602	chr4:143911514~143912053:-
BRCA	cis	rs8098244	0.964	rs1941515	ENSG00000264745.1	TTC39C-AS1	5.1	3.97e-07	4.37e-05	0.22	0.16	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23831968	chr18:23994213~24015339:-
BRCA	cis	rs950880	0.767	rs4851569	ENSG00000234389.1	AC007278.3	-5.1	3.97e-07	4.37e-05	-0.14	-0.16	Serum protein levels (sST2);	chr2:102366787	chr2:102438713~102440475:+
BRCA	cis	rs7487075	0.578	rs12319162	ENSG00000274723.1	RP11-618L22.1	5.1	3.97e-07	4.37e-05	0.19	0.16	Itch intensity from mosquito bite;	chr12:46444131	chr12:46970504~46972155:+
BRCA	cis	rs2638953	0.752	rs11049571	ENSG00000247934.4	RP11-967K21.1	-5.1	3.98e-07	4.37e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28390939	chr12:28163298~28190738:-
BRCA	cis	rs6545883	0.894	rs10496092	ENSG00000270820.4	RP11-355B11.2	-5.1	3.98e-07	4.37e-05	-0.18	-0.16	Tuberculosis;	chr2:61297544	chr2:61471188~61484130:+
BRCA	cis	rs2251381	0.722	rs2776252	ENSG00000176054.6	RPL23P2	5.1	3.98e-07	4.37e-05	0.18	0.16	Selective IgA deficiency;	chr21:29159384	chr21:28997613~28998033:-
BRCA	cis	rs1722141	0.576	rs788755	ENSG00000237471.1	AC073115.6	5.1	3.98e-07	4.37e-05	0.22	0.16	Sitting height ratio;	chr7:46011227	chr7:45969657~45980191:+
BRCA	cis	rs4218	0.551	rs12906212	ENSG00000277144.1	RP11-59H7.4	-5.1	3.98e-07	4.37e-05	-0.21	-0.16	Social communication problems;	chr15:59070556	chr15:59115547~59116089:-
BRCA	cis	rs13113518	1	rs13108499	ENSG00000223305.1	RN7SKP30	5.1	3.98e-07	4.37e-05	0.19	0.16	Height;	chr4:55526514	chr4:55540502~55540835:-
BRCA	cis	rs1707322	0.821	rs11211182	ENSG00000234329.1	RP11-767N6.2	5.1	3.98e-07	4.37e-05	0.16	0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45774498	chr1:45651039~45651826:-
BRCA	cis	rs9650657	0.562	rs10090444	ENSG00000154316.13	TDH	-5.1	3.98e-07	4.37e-05	-0.2	-0.16	Neuroticism;	chr8:10887959	chr8:11339637~11368452:+
BRCA	cis	rs2732480	0.5	rs2732461	ENSG00000257735.1	RP11-370I10.6	5.1	3.99e-07	4.38e-05	0.2	0.16	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48299019	chr12:48350945~48442411:+
BRCA	cis	rs4819052	0.851	rs2255774	ENSG00000184274.3	LINC00315	-5.1	3.99e-07	4.38e-05	-0.2	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45263936	chr21:45300245~45305257:-
BRCA	cis	rs755249	0.565	rs9729677	ENSG00000182109.6	RP11-69E11.4	-5.1	3.99e-07	4.38e-05	-0.18	-0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39587137	chr1:39522280~39546187:-
BRCA	cis	rs9467773	1	rs6456734	ENSG00000241549.7	GUSBP2	5.1	3.99e-07	4.39e-05	0.17	0.16	Intelligence (multi-trait analysis);	chr6:26566737	chr6:26871484~26956554:-
BRCA	cis	rs7914558	0.966	rs10748839	ENSG00000236937.2	PTGES3P4	5.1	4e-07	4.39e-05	0.2	0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103193790	chr10:102845595~102845950:+
BRCA	cis	rs17685	0.753	rs3757593	ENSG00000280388.1	RP11-229D13.3	5.1	4e-07	4.39e-05	0.16	0.16	Coffee consumption (cups per day);Coffee consumption;	chr7:76049417	chr7:76043977~76045963:-
BRCA	cis	rs8180040	0.62	rs9858443	ENSG00000276925.1	RP11-708J19.3	-5.1	4e-07	4.39e-05	-0.18	-0.16	Colorectal cancer;	chr3:47044558	chr3:47469777~47469987:+
BRCA	cis	rs8180040	0.62	rs4683322	ENSG00000276925.1	RP11-708J19.3	-5.1	4e-07	4.39e-05	-0.18	-0.16	Colorectal cancer;	chr3:47051699	chr3:47469777~47469987:+
BRCA	cis	rs17772222	0.74	rs7160471	ENSG00000258789.1	RP11-507K2.3	-5.1	4e-07	4.39e-05	-0.18	-0.16	Coronary artery calcification;	chr14:88507241	chr14:88551597~88552493:+
BRCA	cis	rs17772222	0.74	rs9323830	ENSG00000258789.1	RP11-507K2.3	-5.1	4e-07	4.39e-05	-0.18	-0.16	Coronary artery calcification;	chr14:88507260	chr14:88551597~88552493:+
BRCA	cis	rs17772222	0.74	rs10143744	ENSG00000258789.1	RP11-507K2.3	-5.1	4e-07	4.39e-05	-0.18	-0.16	Coronary artery calcification;	chr14:88508073	chr14:88551597~88552493:+
BRCA	cis	rs17772222	0.74	rs1999177	ENSG00000258789.1	RP11-507K2.3	-5.1	4e-07	4.39e-05	-0.18	-0.16	Coronary artery calcification;	chr14:88508298	chr14:88551597~88552493:+
BRCA	cis	rs17772222	0.74	rs1999176	ENSG00000258789.1	RP11-507K2.3	-5.1	4e-07	4.39e-05	-0.18	-0.16	Coronary artery calcification;	chr14:88508371	chr14:88551597~88552493:+
BRCA	cis	rs17772222	0.74	rs1864746	ENSG00000258789.1	RP11-507K2.3	-5.1	4e-07	4.39e-05	-0.18	-0.16	Coronary artery calcification;	chr14:88508455	chr14:88551597~88552493:+
BRCA	cis	rs17772222	0.74	rs1864747	ENSG00000258789.1	RP11-507K2.3	-5.1	4e-07	4.39e-05	-0.18	-0.16	Coronary artery calcification;	chr14:88508523	chr14:88551597~88552493:+
BRCA	cis	rs1876905	0.539	rs457497	ENSG00000230177.1	RP5-1112D6.4	5.1	4e-07	4.4e-05	0.23	0.16	Mean corpuscular hemoglobin;	chr6:111301346	chr6:111277932~111278742:+
BRCA	cis	rs1671400	1	rs919586	ENSG00000250794.2	ALG1L12P	5.1	4e-07	4.4e-05	0.25	0.16	Obesity-related traits;	chr8:13317162	chr8:12421032~12425000:+
BRCA	cis	rs6496044	0.568	rs11636764	ENSG00000259295.5	CSPG4P12	5.1	4.01e-07	4.4e-05	0.19	0.16	Interstitial lung disease;	chr15:85536520	chr15:85191438~85213905:+
BRCA	cis	rs11955398	0.585	rs4524466	ENSG00000215032.2	GNL3LP1	-5.1	4.01e-07	4.4e-05	-0.19	-0.16	Intelligence (multi-trait analysis);	chr5:60724251	chr5:60891935~60893577:-
BRCA	cis	rs7141336	1	rs6575154	ENSG00000258884.1	CTD-3035D6.2	5.1	4.01e-07	4.4e-05	0.2	0.16	Anxiety disorder;	chr14:90818361	chr14:90822365~90828128:-
BRCA	cis	rs9300255	0.544	rs1727310	ENSG00000235423.7	RP11-282O18.3	5.1	4.01e-07	4.4e-05	0.23	0.16	Neutrophil percentage of white cells;	chr12:123175963	chr12:123252030~123261483:-
BRCA	cis	rs2732480	0.5	rs7315820	ENSG00000257735.1	RP11-370I10.6	5.1	4.01e-07	4.4e-05	0.2	0.16	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48205155	chr12:48350945~48442411:+
BRCA	cis	rs1707322	0.964	rs796773	ENSG00000234329.1	RP11-767N6.2	-5.1	4.01e-07	4.41e-05	-0.16	-0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46098803	chr1:45651039~45651826:-
BRCA	cis	rs1707322	0.896	rs785518	ENSG00000234329.1	RP11-767N6.2	-5.1	4.01e-07	4.41e-05	-0.16	-0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46102750	chr1:45651039~45651826:-
BRCA	cis	rs1707322	1	rs785519	ENSG00000234329.1	RP11-767N6.2	-5.1	4.01e-07	4.41e-05	-0.16	-0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46102890	chr1:45651039~45651826:-
BRCA	cis	rs763121	0.819	rs4560233	ENSG00000228274.3	RP3-508I15.9	-5.1	4.01e-07	4.41e-05	-0.18	-0.16	Menopause (age at onset);	chr22:38586437	chr22:38667585~38681820:-
BRCA	cis	rs2638953	0.962	rs11049530	ENSG00000247934.4	RP11-967K21.1	-5.1	4.01e-07	4.41e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28322220	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.962	rs11049531	ENSG00000247934.4	RP11-967K21.1	-5.1	4.01e-07	4.41e-05	-0.22	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28322797	chr12:28163298~28190738:-
BRCA	cis	rs7226408	0.857	rs72885245	ENSG00000267707.2	RP11-95O2.5	5.1	4.02e-07	4.41e-05	0.24	0.16	Obesity-related traits;	chr18:36845495	chr18:37243776~37247506:+
BRCA	cis	rs4671400	0.543	rs10178135	ENSG00000271889.1	RP11-493E12.1	-5.1	4.02e-07	4.41e-05	-0.23	-0.16	3-hydroxypropylmercapturic acid levels in smokers;	chr2:61258132	chr2:61151433~61162105:-
BRCA	cis	rs9308731	0.842	rs56173510	ENSG00000230499.1	AC108463.1	-5.1	4.02e-07	4.41e-05	-0.18	-0.16	Chronic lymphocytic leukemia;	chr2:111170859	chr2:111195963~111206494:+
BRCA	cis	rs520525	0.963	rs552277	ENSG00000271811.1	RP1-79C4.4	5.1	4.02e-07	4.41e-05	0.18	0.16	Atrial fibrillation;	chr1:170658653	chr1:170667381~170669425:+
BRCA	cis	rs2274273	0.682	rs7151224	ENSG00000258413.1	RP11-665C16.6	-5.1	4.02e-07	4.42e-05	-0.2	-0.16	Protein biomarker;	chr14:55050544	chr14:55262767~55272075:-
BRCA	cis	rs7621025	0.599	rs13063987	ENSG00000273486.1	RP11-731C17.2	-5.1	4.02e-07	4.42e-05	-0.2	-0.16	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136726555	chr3:136837338~136839021:-
BRCA	cis	rs2412819	0.571	rs10163069	ENSG00000166763.7	STRCP1	-5.1	4.02e-07	4.42e-05	-0.21	-0.16	Lung cancer;	chr15:43755372	chr15:43699488~43718184:-
BRCA	cis	rs5758511	0.68	rs56111723	ENSG00000205702.9	CYP2D7	5.1	4.02e-07	4.42e-05	0.16	0.16	Birth weight;	chr22:42268877	chr22:42140203~42144577:-
BRCA	cis	rs7647973	0.516	rs12490393	ENSG00000225399.4	RP11-3B7.1	5.1	4.03e-07	4.42e-05	0.15	0.16	Menarche (age at onset);	chr3:49158699	chr3:49260085~49261316:+
BRCA	cis	rs4578769	0.691	rs28594790	ENSG00000265939.1	UBE2CP2	-5.1	4.03e-07	4.42e-05	-0.17	-0.16	Eosinophil percentage of white cells;	chr18:22985463	chr18:22900486~22900995:-
BRCA	cis	rs728616	0.681	rs3862518	ENSG00000225484.5	NUTM2B-AS1	-5.1	4.03e-07	4.43e-05	-0.35	-0.16	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80158201	chr10:79663088~79826594:-
BRCA	cis	rs9467773	1	rs767471	ENSG00000241549.7	GUSBP2	5.1	4.03e-07	4.43e-05	0.17	0.16	Intelligence (multi-trait analysis);	chr6:26557626	chr6:26871484~26956554:-
BRCA	cis	rs3733585	0.648	rs7378305	ENSG00000250413.1	RP11-448G15.1	5.1	4.03e-07	4.43e-05	0.2	0.16	Cleft plate (environmental tobacco smoke interaction);	chr4:9953269	chr4:10006482~10009725:+
BRCA	cis	rs4671400	0.516	rs62152277	ENSG00000271889.1	RP11-493E12.1	-5.1	4.03e-07	4.43e-05	-0.24	-0.16	3-hydroxypropylmercapturic acid levels in smokers;	chr2:61276269	chr2:61151433~61162105:-
BRCA	cis	rs4908768	0.501	rs35865480	ENSG00000232912.4	RP5-1115A15.1	5.1	4.03e-07	4.43e-05	0.15	0.16	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8543718	chr1:8424645~8434838:+
BRCA	cis	rs10028773	0.7	rs7671797	ENSG00000249244.1	RP11-548H18.2	5.1	4.03e-07	4.43e-05	0.18	0.16	Educational attainment;	chr4:119327002	chr4:119391831~119395335:-
BRCA	cis	rs7914558	0.902	rs3736922	ENSG00000236937.2	PTGES3P4	-5.1	4.04e-07	4.43e-05	-0.2	-0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103090875	chr10:102845595~102845950:+
BRCA	cis	rs2153535	0.58	rs1328862	ENSG00000251164.1	HULC	-5.1	4.04e-07	4.43e-05	-0.19	-0.16	Motion sickness;	chr6:8526448	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.601	rs1928183	ENSG00000251164.1	HULC	-5.1	4.04e-07	4.43e-05	-0.19	-0.16	Motion sickness;	chr6:8529785	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.58	rs6597337	ENSG00000251164.1	HULC	-5.1	4.04e-07	4.43e-05	-0.19	-0.16	Motion sickness;	chr6:8531419	chr6:8652137~8653846:+
BRCA	cis	rs9652601	0.748	rs12930373	ENSG00000274038.1	RP11-66H6.4	-5.1	4.04e-07	4.43e-05	-0.18	-0.16	Systemic lupus erythematosus;	chr16:11145742	chr16:11056556~11057034:+
BRCA	cis	rs12612619	0.557	rs1368888	ENSG00000272148.1	RP11-195B17.1	-5.1	4.04e-07	4.43e-05	-0.18	-0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:26845709	chr2:27062428~27062907:-
BRCA	cis	rs11887277	0.868	rs6717682	ENSG00000272148.1	RP11-195B17.1	-5.1	4.04e-07	4.43e-05	-0.18	-0.16	Obesity-related traits;	chr2:26846343	chr2:27062428~27062907:-
BRCA	cis	rs6840360	0.718	rs2136960	ENSG00000270265.1	RP11-731D1.4	5.1	4.04e-07	4.43e-05	0.18	0.16	Intelligence (multi-trait analysis);	chr4:151825037	chr4:151333775~151353224:-
BRCA	cis	rs494453	0.922	rs484495	ENSG00000227811.2	FAM212B-AS1	-5.1	4.04e-07	4.43e-05	-0.2	-0.16	Osteoporosis-related phenotypes;	chr1:111693680	chr1:111739841~111747798:+
BRCA	cis	rs516805	0.667	rs7767993	ENSG00000279453.1	RP3-425C14.4	5.1	4.04e-07	4.44e-05	0.22	0.16	Lymphocyte counts;	chr6:122343192	chr6:122436789~122439223:-
BRCA	cis	rs516805	0.667	rs10457432	ENSG00000279453.1	RP3-425C14.4	5.1	4.04e-07	4.44e-05	0.22	0.16	Lymphocyte counts;	chr6:122344699	chr6:122436789~122439223:-
BRCA	cis	rs7569084	0.687	rs1370394	ENSG00000281920.1	RP11-418H16.1	5.1	4.05e-07	4.44e-05	0.2	0.16	Sum eosinophil basophil counts;	chr2:65453176	chr2:65623272~65628424:+
BRCA	cis	rs1707322	1	rs7527079	ENSG00000234329.1	RP11-767N6.2	5.1	4.05e-07	4.44e-05	0.16	0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45947778	chr1:45651039~45651826:-
BRCA	cis	rs1707322	1	rs34446427	ENSG00000234329.1	RP11-767N6.2	5.1	4.05e-07	4.44e-05	0.16	0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45951983	chr1:45651039~45651826:-
BRCA	cis	rs1707322	0.963	rs4660900	ENSG00000234329.1	RP11-767N6.2	5.1	4.05e-07	4.44e-05	0.16	0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45953933	chr1:45651039~45651826:-
BRCA	cis	rs4713118	0.629	rs149899	ENSG00000280107.1	AL022393.9	-5.1	4.05e-07	4.44e-05	-0.23	-0.16	Parkinson's disease;	chr6:28052201	chr6:28170845~28172521:+
BRCA	cis	rs4713118	0.629	rs172165	ENSG00000280107.1	AL022393.9	-5.1	4.05e-07	4.44e-05	-0.23	-0.16	Parkinson's disease;	chr6:28053036	chr6:28170845~28172521:+
BRCA	cis	rs10510102	0.935	rs12244951	ENSG00000226864.1	ATE1-AS1	5.1	4.05e-07	4.45e-05	0.28	0.16	Breast cancer;	chr10:121896879	chr10:121928312~121951965:+
BRCA	cis	rs6969780	0.632	rs11762730	ENSG00000233429.8	HOTAIRM1	-5.1	4.05e-07	4.45e-05	-0.17	-0.16	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27150779	chr7:27095647~27100265:+
BRCA	cis	rs7592578	0.771	rs12053190	ENSG00000272979.1	RP11-647K16.1	-5.1	4.05e-07	4.45e-05	-0.26	-0.16	Diastolic blood pressure;	chr2:190518622	chr2:190454092~190454521:-
BRCA	cis	rs1707322	1	rs11211217	ENSG00000234329.1	RP11-767N6.2	5.1	4.05e-07	4.45e-05	0.16	0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45882557	chr1:45651039~45651826:-
BRCA	cis	rs7646881	1	rs73015652	ENSG00000240207.5	RP11-379F4.4	-5.1	4.06e-07	4.45e-05	-0.22	-0.16	Tetralogy of Fallot;	chr3:158733594	chr3:158732263~158784070:+
BRCA	cis	rs1667284	0.846	rs1026123	ENSG00000266521.1	RP11-650P15.1	5.1	4.06e-07	4.45e-05	0.18	0.16	Problematic alcohol use in trauma-exposed individuals;	chr18:31627192	chr18:31496645~31497195:-
BRCA	cis	rs2839186	0.709	rs2156117	ENSG00000228137.1	AP001469.7	5.1	4.06e-07	4.45e-05	0.16	0.16	Testicular germ cell tumor;	chr21:46249386	chr21:46246890~46247682:+
BRCA	cis	rs1707322	0.896	rs809774	ENSG00000234329.1	RP11-767N6.2	-5.1	4.06e-07	4.45e-05	-0.16	-0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46094572	chr1:45651039~45651826:-
BRCA	cis	rs2505998	0.787	rs28502801	ENSG00000273008.1	RP11-351D16.3	-5.1	4.06e-07	4.45e-05	-0.19	-0.16	Hirschsprung disease;	chr10:43088591	chr10:43136824~43138334:-
BRCA	cis	rs6545883	0.859	rs2694644	ENSG00000270820.4	RP11-355B11.2	-5.1	4.06e-07	4.45e-05	-0.18	-0.16	Tuberculosis;	chr2:61377721	chr2:61471188~61484130:+
BRCA	cis	rs6545883	0.929	rs2694625	ENSG00000270820.4	RP11-355B11.2	-5.1	4.06e-07	4.45e-05	-0.18	-0.16	Tuberculosis;	chr2:61388920	chr2:61471188~61484130:+
BRCA	cis	rs7226408	0.857	rs72887044	ENSG00000267707.2	RP11-95O2.5	5.1	4.06e-07	4.46e-05	0.24	0.16	Obesity-related traits;	chr18:36901610	chr18:37243776~37247506:+
BRCA	cis	rs4781563	0.81	rs1646332	ENSG00000242307.1	RPS26P52	-5.1	4.07e-07	4.46e-05	-0.18	-0.16	Bilirubin levels;	chr16:13955870	chr16:13922332~13922679:-
BRCA	cis	rs10510102	0.935	rs7098562	ENSG00000226864.1	ATE1-AS1	5.1	4.07e-07	4.47e-05	0.28	0.16	Breast cancer;	chr10:121902148	chr10:121928312~121951965:+
BRCA	cis	rs10510102	0.935	rs7098822	ENSG00000226864.1	ATE1-AS1	5.1	4.07e-07	4.47e-05	0.28	0.16	Breast cancer;	chr10:121902157	chr10:121928312~121951965:+
BRCA	cis	rs13113518	0.683	rs9761521	ENSG00000223305.1	RN7SKP30	5.1	4.07e-07	4.47e-05	0.2	0.16	Height;	chr4:55363436	chr4:55540502~55540835:-
BRCA	cis	rs8098244	0.603	rs2960580	ENSG00000264745.1	TTC39C-AS1	5.1	4.07e-07	4.47e-05	0.18	0.16	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23712058	chr18:23994213~24015339:-
BRCA	cis	rs9341808	0.69	rs9343970	ENSG00000272129.1	RP11-250B2.6	5.1	4.07e-07	4.47e-05	0.2	0.16	Sitting height ratio;	chr6:80171572	chr6:80355424~80356859:+
BRCA	cis	rs6545883	0.868	rs778755	ENSG00000271889.1	RP11-493E12.1	-5.1	4.07e-07	4.47e-05	-0.2	-0.16	Tuberculosis;	chr2:61553902	chr2:61151433~61162105:-
BRCA	cis	rs8098244	1	rs8098244	ENSG00000264745.1	TTC39C-AS1	5.1	4.07e-07	4.47e-05	0.22	0.16	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23825589	chr18:23994213~24015339:-
BRCA	cis	rs17685	0.753	rs1104878	ENSG00000280388.1	RP11-229D13.3	-5.1	4.08e-07	4.47e-05	-0.16	-0.16	Coffee consumption (cups per day);Coffee consumption;	chr7:76056275	chr7:76043977~76045963:-
BRCA	cis	rs17685	0.712	rs869805	ENSG00000280388.1	RP11-229D13.3	-5.1	4.08e-07	4.47e-05	-0.16	-0.16	Coffee consumption (cups per day);Coffee consumption;	chr7:76059278	chr7:76043977~76045963:-
BRCA	cis	rs7617773	0.743	rs7621785	ENSG00000199476.1	Y_RNA	-5.1	4.08e-07	4.47e-05	-0.23	-0.16	Coronary artery disease;	chr3:48302218	chr3:48288587~48288694:+
BRCA	cis	rs11742741	0.6	rs1428201	ENSG00000248874.4	C5orf17	-5.1	4.08e-07	4.47e-05	-0.21	-0.16	Educational attainment;	chr5:24141009	chr5:23951348~24178263:+
BRCA	cis	rs2153535	0.58	rs2327053	ENSG00000251164.1	HULC	-5.1	4.08e-07	4.47e-05	-0.19	-0.16	Motion sickness;	chr6:8442894	chr6:8652137~8653846:+
BRCA	cis	rs8127691	0.967	rs743478	ENSG00000237604.1	AP001056.1	5.1	4.08e-07	4.47e-05	0.18	0.16	Inflammatory bowel disease;	chr21:44191803	chr21:44175489~44176453:+
BRCA	cis	rs6545883	0.894	rs2694639	ENSG00000270820.4	RP11-355B11.2	-5.1	4.08e-07	4.48e-05	-0.18	-0.16	Tuberculosis;	chr2:61368156	chr2:61471188~61484130:+
BRCA	cis	rs1014246	0.541	rs2011695	ENSG00000232767.1	RP11-498B4.5	5.1	4.09e-07	4.48e-05	0.15	0.16	Age at smoking initiation in chronic obstructive pulmonary disease;	chr10:116747708	chr10:116670103~116672739:+
BRCA	cis	rs10129255	0.719	rs7156660	ENSG00000211967.3	IGHV3-53	-5.1	4.09e-07	4.48e-05	-0.11	-0.16	Kawasaki disease;	chr14:106673171	chr14:106592676~106593347:-
BRCA	cis	rs875971	0.545	rs4718325	ENSG00000230295.1	RP11-458F8.2	5.1	4.09e-07	4.48e-05	0.15	0.16	Aortic root size;	chr7:66215323	chr7:66880708~66882981:+
BRCA	cis	rs13108904	0.846	rs3775100	ENSG00000253399.1	AC078852.2	-5.1	4.09e-07	4.48e-05	-0.17	-0.16	Obesity-related traits;	chr4:1231318	chr4:1358479~1359461:+
BRCA	cis	rs4835473	0.932	rs4287958	ENSG00000249741.2	RP11-673E1.3	-5.1	4.09e-07	4.48e-05	-0.17	-0.16	Immature fraction of reticulocytes;	chr4:143987719	chr4:143911514~143912053:-
BRCA	cis	rs2153535	0.58	rs1119689	ENSG00000251164.1	HULC	-5.1	4.09e-07	4.48e-05	-0.19	-0.16	Motion sickness;	chr6:8460521	chr6:8652137~8653846:+
BRCA	cis	rs7119	0.689	rs11630557	ENSG00000259362.2	RP11-307C19.1	-5.1	4.09e-07	4.49e-05	-0.21	-0.16	Type 2 diabetes;	chr15:77528370	chr15:77525540~77534110:+
BRCA	cis	rs7923609	0.776	rs10761785	ENSG00000232075.1	MRPL35P2	-5.1	4.09e-07	4.49e-05	-0.2	-0.16	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63559006	chr10:63634317~63634827:-
BRCA	cis	rs77972916	0.611	rs11693190	ENSG00000234936.1	AC010883.5	5.1	4.09e-07	4.49e-05	0.18	0.16	Granulocyte percentage of myeloid white cells;	chr2:43375276	chr2:43229573~43233394:+
BRCA	cis	rs6163	0.588	rs67506723	ENSG00000236937.2	PTGES3P4	5.1	4.09e-07	4.49e-05	0.19	0.16	Waist circumference;Hip circumference;	chr10:102749307	chr10:102845595~102845950:+
BRCA	cis	rs1030877	0.515	rs920217	ENSG00000235319.1	AC012360.4	5.1	4.09e-07	4.49e-05	0.22	0.16	Obesity-related traits;	chr2:105288205	chr2:105324210~105330529:+
BRCA	cis	rs4934494	0.677	rs11185802	ENSG00000240996.1	RP11-80H5.7	-5.1	4.1e-07	4.49e-05	-0.22	-0.16	Red blood cell count;	chr10:89618997	chr10:89694295~89697928:-
BRCA	cis	rs6490294	0.571	rs58886972	ENSG00000226469.1	ADAM1B	5.1	4.1e-07	4.49e-05	0.27	0.16	Mean platelet volume;	chr12:112071477	chr12:111927018~111929017:+
BRCA	cis	rs2303319	0.504	rs56407015	ENSG00000227403.1	AC009299.3	5.1	4.1e-07	4.49e-05	0.36	0.16	Cognitive function;	chr2:161599115	chr2:161244739~161249050:+
BRCA	cis	rs8016982	0.651	rs9806027	ENSG00000258999.1	RP11-114N19.3	5.1	4.1e-07	4.49e-05	0.19	0.16	Schizophrenia;	chr14:81202363	chr14:81107033~81170414:-
BRCA	cis	rs7572733	0.534	rs7557203	ENSG00000231621.1	AC013264.2	-5.1	4.1e-07	4.49e-05	-0.15	-0.16	Dermatomyositis;	chr2:197930926	chr2:197197991~197199273:+
BRCA	cis	rs4819052	0.851	rs58644915	ENSG00000184274.3	LINC00315	-5.1	4.1e-07	4.5e-05	-0.21	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45249997	chr21:45300245~45305257:-
BRCA	cis	rs8180040	0.871	rs11716661	ENSG00000271161.1	BOLA2P2	-5.1	4.1e-07	4.5e-05	-0.17	-0.16	Colorectal cancer;	chr3:47476283	chr3:47499841~47500407:+
BRCA	cis	rs801193	0.569	rs13242290	ENSG00000236529.1	RP13-254B10.1	-5.1	4.11e-07	4.5e-05	-0.17	-0.16	Aortic root size;	chr7:66656898	chr7:65840212~65840596:+
BRCA	cis	rs10129255	0.5	rs11627315	ENSG00000211959.2	IGHV4-39	5.1	4.11e-07	4.5e-05	0.1	0.16	Kawasaki disease;	chr14:106802182	chr14:106421711~106422218:-
BRCA	cis	rs4835473	0.75	rs57610804	ENSG00000249741.2	RP11-673E1.3	-5.1	4.11e-07	4.5e-05	-0.17	-0.16	Immature fraction of reticulocytes;	chr4:143974341	chr4:143911514~143912053:-
BRCA	cis	rs559555	0.523	rs12467911	ENSG00000272716.1	RP11-563N4.1	5.1	4.11e-07	4.5e-05	0.18	0.16	Blood metabolite ratios;Blood metabolite levels;	chr2:31557721	chr2:32165046~32165757:-
BRCA	cis	rs7914558	1	rs10786740	ENSG00000236937.2	PTGES3P4	5.1	4.11e-07	4.5e-05	0.2	0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103175836	chr10:102845595~102845950:+
BRCA	cis	rs6751744	0.855	rs7585513	ENSG00000226266.5	AC009961.3	-5.1	4.11e-07	4.5e-05	-0.2	-0.16	Dysphagia;	chr2:159550379	chr2:159670708~159712435:-
BRCA	cis	rs17685	0.753	rs1104879	ENSG00000280388.1	RP11-229D13.3	-5.1	4.11e-07	4.51e-05	-0.16	-0.16	Coffee consumption (cups per day);Coffee consumption;	chr7:76056250	chr7:76043977~76045963:-
BRCA	cis	rs2274273	0.743	rs7161656	ENSG00000258413.1	RP11-665C16.6	-5.1	4.12e-07	4.51e-05	-0.2	-0.16	Protein biomarker;	chr14:55057812	chr14:55262767~55272075:-
BRCA	cis	rs1440410	0.597	rs4690766	ENSG00000250326.1	RP11-284M14.1	-5.1	4.12e-07	4.51e-05	-0.18	-0.16	Ischemic stroke;	chr4:143108887	chr4:142933195~143184861:-
BRCA	cis	rs321358	0.945	rs7931995	ENSG00000271390.1	RP11-89C3.3	5.1	4.12e-07	4.51e-05	0.26	0.16	Body mass index;	chr11:111117691	chr11:111089870~111090368:-
BRCA	cis	rs6596100	0.868	rs66827546	ENSG00000248648.1	RP11-485M7.1	-5.1	4.12e-07	4.51e-05	-0.2	-0.16	Breast cancer;	chr5:133053268	chr5:133003119~133003365:+
BRCA	cis	rs17507216	0.958	rs72751643	ENSG00000255769.6	GOLGA2P10	-5.1	4.12e-07	4.52e-05	-0.21	-0.16	Excessive daytime sleepiness;	chr15:82559444	chr15:82472993~82513950:-
BRCA	cis	rs7226408	0.901	rs72885252	ENSG00000267707.2	RP11-95O2.5	5.1	4.12e-07	4.52e-05	0.24	0.16	Obesity-related traits;	chr18:36849435	chr18:37243776~37247506:+
BRCA	cis	rs7226408	0.857	rs56049218	ENSG00000267707.2	RP11-95O2.5	5.1	4.12e-07	4.52e-05	0.24	0.16	Obesity-related traits;	chr18:36849722	chr18:37243776~37247506:+
BRCA	cis	rs7226408	0.857	rs56364983	ENSG00000267707.2	RP11-95O2.5	5.1	4.12e-07	4.52e-05	0.24	0.16	Obesity-related traits;	chr18:36850312	chr18:37243776~37247506:+
BRCA	cis	rs7226408	0.857	rs72885256	ENSG00000267707.2	RP11-95O2.5	5.1	4.12e-07	4.52e-05	0.24	0.16	Obesity-related traits;	chr18:36850503	chr18:37243776~37247506:+
BRCA	cis	rs7226408	0.857	rs72885260	ENSG00000267707.2	RP11-95O2.5	5.1	4.12e-07	4.52e-05	0.24	0.16	Obesity-related traits;	chr18:36851041	chr18:37243776~37247506:+
BRCA	cis	rs875971	0.862	rs2909688	ENSG00000236529.1	RP13-254B10.1	5.1	4.12e-07	4.52e-05	0.17	0.16	Aortic root size;	chr7:66376625	chr7:65840212~65840596:+
BRCA	cis	rs17507216	0.718	rs7165690	ENSG00000255769.6	GOLGA2P10	-5.1	4.13e-07	4.52e-05	-0.23	-0.16	Excessive daytime sleepiness;	chr15:82654804	chr15:82472993~82513950:-
BRCA	cis	rs10911232	0.507	rs4651137	ENSG00000224468.3	RP11-181K3.4	-5.1	4.13e-07	4.52e-05	-0.17	-0.16	Hypertriglyceridemia;	chr1:183025165	chr1:183138402~183141282:-
BRCA	cis	rs10911232	0.507	rs4652766	ENSG00000224468.3	RP11-181K3.4	-5.1	4.13e-07	4.52e-05	-0.17	-0.16	Hypertriglyceridemia;	chr1:183025201	chr1:183138402~183141282:-
BRCA	cis	rs10911232	0.507	rs10911196	ENSG00000224468.3	RP11-181K3.4	-5.1	4.13e-07	4.52e-05	-0.17	-0.16	Hypertriglyceridemia;	chr1:183026098	chr1:183138402~183141282:-
BRCA	cis	rs10752881	0.935	rs10911197	ENSG00000224468.3	RP11-181K3.4	-5.1	4.13e-07	4.52e-05	-0.17	-0.16	Colorectal cancer;	chr1:183026264	chr1:183138402~183141282:-
BRCA	cis	rs10911232	0.507	rs61081633	ENSG00000224468.3	RP11-181K3.4	-5.1	4.13e-07	4.52e-05	-0.17	-0.16	Hypertriglyceridemia;	chr1:183026473	chr1:183138402~183141282:-
BRCA	cis	rs10911232	0.507	rs4652762	ENSG00000224468.3	RP11-181K3.4	-5.1	4.13e-07	4.52e-05	-0.17	-0.16	Hypertriglyceridemia;	chr1:183024825	chr1:183138402~183141282:-
BRCA	cis	rs10911232	0.507	rs4652765	ENSG00000224468.3	RP11-181K3.4	-5.1	4.13e-07	4.52e-05	-0.17	-0.16	Hypertriglyceridemia;	chr1:183025012	chr1:183138402~183141282:-
BRCA	cis	rs10911232	0.507	rs10797815	ENSG00000224468.3	RP11-181K3.4	-5.1	4.13e-07	4.52e-05	-0.17	-0.16	Hypertriglyceridemia;	chr1:183027692	chr1:183138402~183141282:-
BRCA	cis	rs10911232	0.507	rs5022057	ENSG00000224468.3	RP11-181K3.4	-5.1	4.13e-07	4.52e-05	-0.17	-0.16	Hypertriglyceridemia;	chr1:183028626	chr1:183138402~183141282:-
BRCA	cis	rs10911232	0.507	rs10911199	ENSG00000224468.3	RP11-181K3.4	-5.1	4.13e-07	4.52e-05	-0.17	-0.16	Hypertriglyceridemia;	chr1:183028901	chr1:183138402~183141282:-
BRCA	cis	rs10911232	0.507	rs12037585	ENSG00000224468.3	RP11-181K3.4	-5.1	4.13e-07	4.52e-05	-0.17	-0.16	Hypertriglyceridemia;	chr1:183030906	chr1:183138402~183141282:-
BRCA	cis	rs10911232	0.507	rs12037623	ENSG00000224468.3	RP11-181K3.4	-5.1	4.13e-07	4.52e-05	-0.17	-0.16	Hypertriglyceridemia;	chr1:183031013	chr1:183138402~183141282:-
BRCA	cis	rs2098713	0.537	rs682825	ENSG00000250155.1	CTD-2353F22.1	5.1	4.13e-07	4.52e-05	0.18	0.16	Telomere length;	chr5:37580716	chr5:36666214~36725195:-
BRCA	cis	rs6723226	0.65	rs6729952	ENSG00000276334.1	AL133243.1	5.1	4.13e-07	4.53e-05	0.19	0.16	Intelligence (multi-trait analysis);	chr2:32539855	chr2:32521927~32523547:+
BRCA	cis	rs10911232	0.507	rs4652763	ENSG00000224468.3	RP11-181K3.4	-5.1	4.13e-07	4.53e-05	-0.17	-0.16	Hypertriglyceridemia;	chr1:183024949	chr1:183138402~183141282:-
BRCA	cis	rs2929278	0.617	rs3986209	ENSG00000166763.7	STRCP1	-5.1	4.13e-07	4.53e-05	-0.21	-0.16	Schizophrenia;	chr15:43758675	chr15:43699488~43718184:-
BRCA	cis	rs2832191	1	rs2832185	ENSG00000215533.7	LINC00189	5.1	4.13e-07	4.53e-05	0.18	0.16	Dental caries;	chr21:29111440	chr21:29193480~29288205:+
BRCA	cis	rs14027	0.512	rs6997976	ENSG00000279347.1	RP11-85I17.2	5.1	4.13e-07	4.53e-05	0.15	0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119722044	chr8:119838736~119840385:-
BRCA	cis	rs7181230	0.885	rs17723133	ENSG00000275636.1	RP11-521C20.5	-5.1	4.14e-07	4.53e-05	-0.2	-0.16	Dehydroepiandrosterone sulphate levels;	chr15:40073217	chr15:40078892~40079347:+
BRCA	cis	rs9291683	0.655	rs3822242	ENSG00000250413.1	RP11-448G15.1	5.1	4.14e-07	4.53e-05	0.2	0.16	Bone mineral density;	chr4:10093280	chr4:10006482~10009725:+
BRCA	cis	rs2832191	1	rs6516891	ENSG00000215533.7	LINC00189	5.1	4.14e-07	4.53e-05	0.18	0.16	Dental caries;	chr21:29110749	chr21:29193480~29288205:+
BRCA	cis	rs2832191	1	rs2832184	ENSG00000215533.7	LINC00189	5.1	4.14e-07	4.53e-05	0.18	0.16	Dental caries;	chr21:29110944	chr21:29193480~29288205:+
BRCA	cis	rs2638953	0.962	rs10843159	ENSG00000247934.4	RP11-967K21.1	-5.1	4.14e-07	4.53e-05	-0.21	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28354597	chr12:28163298~28190738:-
BRCA	cis	rs4266144	0.581	rs1806867	ENSG00000241770.1	RP11-555M1.3	-5.1	4.14e-07	4.53e-05	-0.2	-0.16	Coronary artery disease;	chr3:157110513	chr3:157163452~157169133:+
BRCA	cis	rs62025270	0.688	rs17576534	ENSG00000202081.1	RNU6-1280P	-5.09	4.14e-07	4.53e-05	-0.24	-0.16	Idiopathic pulmonary fibrosis;	chr15:85742509	chr15:85651522~85651628:-
BRCA	cis	rs17406451	0.587	rs6544646	ENSG00000234936.1	AC010883.5	5.09	4.14e-07	4.53e-05	0.15	0.16	Mitochondrial DNA levels;	chr2:43349858	chr2:43229573~43233394:+
BRCA	cis	rs2834288	0.666	rs762188	ENSG00000273102.1	AP000569.9	-5.09	4.14e-07	4.53e-05	-0.18	-0.16	Gut microbiota (bacterial taxa);	chr21:33902206	chr21:33967101~33968573:-
BRCA	cis	rs9921338	0.961	rs4781055	ENSG00000262703.1	RP11-485G7.6	-5.09	4.14e-07	4.53e-05	-0.2	-0.16	Vein graft stenosis in coronary artery bypass grafting;	chr16:11275571	chr16:11348143~11349321:-
BRCA	cis	rs370915	0.607	rs28548850	ENSG00000250971.1	RP11-696F12.1	5.09	4.14e-07	4.54e-05	0.17	0.16	Gout;	chr4:186865562	chr4:187060099~187060930:+
BRCA	cis	rs2638953	0.853	rs11049693	ENSG00000247934.4	RP11-967K21.1	-5.09	4.14e-07	4.54e-05	-0.19	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28525011	chr12:28163298~28190738:-
BRCA	cis	rs2839186	0.77	rs2330353	ENSG00000228137.1	AP001469.7	5.09	4.14e-07	4.54e-05	0.16	0.16	Testicular germ cell tumor;	chr21:46249734	chr21:46246890~46247682:+
BRCA	cis	rs2179367	0.632	rs9498321	ENSG00000268592.3	RAET1E-AS1	5.09	4.15e-07	4.54e-05	0.23	0.16	Dupuytren's disease;	chr6:149322573	chr6:149863494~149919507:+
BRCA	cis	rs875971	0.545	rs17138156	ENSG00000230295.1	RP11-458F8.2	5.09	4.15e-07	4.54e-05	0.15	0.16	Aortic root size;	chr7:66249708	chr7:66880708~66882981:+
BRCA	cis	rs27434	0.66	rs26493	ENSG00000272109.1	CTD-2260A17.3	-5.09	4.15e-07	4.54e-05	-0.25	-0.16	Ankylosing spondylitis;	chr5:96819615	chr5:96804353~96806105:+
BRCA	cis	rs6001482	0.702	rs5757581	ENSG00000211642.2	IGLV10-54	-5.09	4.15e-07	4.54e-05	-0.15	-0.16	Diastolic blood pressure;	chr22:22234220	chr22:22214794~22215270:+
BRCA	cis	rs4713118	0.597	rs172166	ENSG00000280107.1	AL022393.9	-5.09	4.15e-07	4.54e-05	-0.23	-0.16	Parkinson's disease;	chr6:28053042	chr6:28170845~28172521:+
BRCA	cis	rs2665103	0.589	rs2134046	ENSG00000259429.4	UBE2Q2P2	-5.09	4.15e-07	4.54e-05	-0.15	-0.16	Intelligence (multi-trait analysis);	chr15:82232203	chr15:82355142~82420075:+
BRCA	cis	rs4908760	0.931	rs1463049	ENSG00000232912.4	RP5-1115A15.1	5.09	4.15e-07	4.55e-05	0.15	0.16	Vitiligo;	chr1:8537049	chr1:8424645~8434838:+
BRCA	cis	rs1395	0.744	rs4665962	ENSG00000234072.1	AC074117.10	-5.09	4.15e-07	4.55e-05	-0.17	-0.16	Blood metabolite levels;	chr2:27292237	chr2:27356246~27367622:+
BRCA	cis	rs7226408	0.857	rs17567674	ENSG00000267707.2	RP11-95O2.5	5.09	4.15e-07	4.55e-05	0.24	0.16	Obesity-related traits;	chr18:36900053	chr18:37243776~37247506:+
BRCA	cis	rs4908768	0.539	rs2100888	ENSG00000270282.1	RP5-1115A15.2	5.09	4.15e-07	4.55e-05	0.17	0.16	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8599223	chr1:8512653~8513021:+
BRCA	cis	rs2153535	0.58	rs6912374	ENSG00000251164.1	HULC	-5.09	4.15e-07	4.55e-05	-0.19	-0.16	Motion sickness;	chr6:8456190	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.541	rs6908504	ENSG00000251164.1	HULC	-5.09	4.15e-07	4.55e-05	-0.19	-0.16	Motion sickness;	chr6:8456545	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.58	rs7755284	ENSG00000251164.1	HULC	-5.09	4.15e-07	4.55e-05	-0.19	-0.16	Motion sickness;	chr6:8457246	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.58	rs7769020	ENSG00000251164.1	HULC	-5.09	4.15e-07	4.55e-05	-0.19	-0.16	Motion sickness;	chr6:8457491	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.58	rs9379206	ENSG00000251164.1	HULC	-5.09	4.15e-07	4.55e-05	-0.19	-0.16	Motion sickness;	chr6:8457788	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.541	rs9379207	ENSG00000251164.1	HULC	-5.09	4.15e-07	4.55e-05	-0.19	-0.16	Motion sickness;	chr6:8457953	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.58	rs9393016	ENSG00000251164.1	HULC	-5.09	4.15e-07	4.55e-05	-0.19	-0.16	Motion sickness;	chr6:8458340	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.58	rs4960421	ENSG00000251164.1	HULC	-5.09	4.15e-07	4.55e-05	-0.19	-0.16	Motion sickness;	chr6:8459059	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.58	rs4960422	ENSG00000251164.1	HULC	-5.09	4.15e-07	4.55e-05	-0.19	-0.16	Motion sickness;	chr6:8459076	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.58	rs7742794	ENSG00000251164.1	HULC	-5.09	4.15e-07	4.55e-05	-0.19	-0.16	Motion sickness;	chr6:8459490	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.58	rs9505448	ENSG00000251164.1	HULC	-5.09	4.15e-07	4.55e-05	-0.19	-0.16	Motion sickness;	chr6:8459571	chr6:8652137~8653846:+
BRCA	cis	rs858239	0.831	rs7796541	ENSG00000230042.1	AK3P3	-5.09	4.15e-07	4.55e-05	-0.18	-0.16	Cerebrospinal fluid biomarker levels;	chr7:23349454	chr7:23129178~23129841:+
BRCA	cis	rs9473147	0.516	rs1485780	ENSG00000270761.1	RP11-385F7.1	-5.09	4.16e-07	4.55e-05	-0.16	-0.16	Platelet distribution width;Mean platelet volume;	chr6:47588894	chr6:47477243~47477572:-
BRCA	cis	rs9473147	0.543	rs9381578	ENSG00000270761.1	RP11-385F7.1	-5.09	4.16e-07	4.55e-05	-0.16	-0.16	Platelet distribution width;Mean platelet volume;	chr6:47588898	chr6:47477243~47477572:-
BRCA	cis	rs9473147	0.516	rs9381579	ENSG00000270761.1	RP11-385F7.1	-5.09	4.16e-07	4.55e-05	-0.16	-0.16	Platelet distribution width;Mean platelet volume;	chr6:47588944	chr6:47477243~47477572:-
BRCA	cis	rs9473147	0.516	rs10456570	ENSG00000270761.1	RP11-385F7.1	-5.09	4.16e-07	4.55e-05	-0.16	-0.16	Platelet distribution width;Mean platelet volume;	chr6:47591715	chr6:47477243~47477572:-
BRCA	cis	rs797680	0.576	rs55838267	ENSG00000223745.6	RP4-717I23.3	5.09	4.16e-07	4.55e-05	0.18	0.16	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93338159	chr1:93262186~93346025:-
BRCA	cis	rs9287719	0.934	rs6710033	ENSG00000243819.4	RN7SL832P	5.09	4.16e-07	4.55e-05	0.15	0.16	Prostate cancer;	chr2:10617551	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.967	rs4669598	ENSG00000243819.4	RN7SL832P	5.09	4.16e-07	4.55e-05	0.15	0.16	Prostate cancer;	chr2:10617712	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.967	rs4669599	ENSG00000243819.4	RN7SL832P	5.09	4.16e-07	4.55e-05	0.15	0.16	Prostate cancer;	chr2:10617903	chr2:10690344~10692099:+
BRCA	cis	rs9545047	0.604	rs2477397	ENSG00000227354.5	RBM26-AS1	-5.09	4.16e-07	4.55e-05	-0.17	-0.16	Schizophrenia;	chr13:79428211	chr13:79406309~79424328:+
BRCA	cis	rs17507216	0.958	rs28648832	ENSG00000255769.6	GOLGA2P10	-5.09	4.16e-07	4.56e-05	-0.21	-0.16	Excessive daytime sleepiness;	chr15:82567642	chr15:82472993~82513950:-
BRCA	cis	rs8180040	0.654	rs62246451	ENSG00000276925.1	RP11-708J19.3	5.09	4.16e-07	4.56e-05	0.18	0.16	Colorectal cancer;	chr3:47170142	chr3:47469777~47469987:+
BRCA	cis	rs8180040	0.627	rs58956475	ENSG00000276925.1	RP11-708J19.3	5.09	4.16e-07	4.56e-05	0.18	0.16	Colorectal cancer;	chr3:47183125	chr3:47469777~47469987:+
BRCA	cis	rs10129255	0.872	rs1858683	ENSG00000211974.3	IGHV2-70	5.09	4.16e-07	4.56e-05	0.16	0.16	Kawasaki disease;	chr14:106670217	chr14:106723574~106724093:-
BRCA	cis	rs4356203	0.87	rs1979603	ENSG00000272034.1	SNORD14A	-5.09	4.17e-07	4.56e-05	-0.16	-0.16	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17261839	chr11:17074654~17074744:-
BRCA	cis	rs7914558	0.966	rs1591915	ENSG00000236937.2	PTGES3P4	5.09	4.17e-07	4.56e-05	0.2	0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102887092	chr10:102845595~102845950:+
BRCA	cis	rs7914558	0.966	rs56946876	ENSG00000236937.2	PTGES3P4	5.09	4.17e-07	4.56e-05	0.2	0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102893788	chr10:102845595~102845950:+
BRCA	cis	rs7914558	0.933	rs12763665	ENSG00000236937.2	PTGES3P4	5.09	4.17e-07	4.56e-05	0.2	0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102893960	chr10:102845595~102845950:+
BRCA	cis	rs7914558	0.966	rs10786721	ENSG00000236937.2	PTGES3P4	5.09	4.17e-07	4.56e-05	0.2	0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102894626	chr10:102845595~102845950:+
BRCA	cis	rs9584850	0.834	rs3783005	ENSG00000231194.1	FARP1-AS1	-5.09	4.17e-07	4.56e-05	-0.2	-0.16	Neuroticism;	chr13:98459083	chr13:98435405~98435840:-
BRCA	cis	rs7618501	0.602	rs2526754	ENSG00000228008.1	CTD-2330K9.3	-5.09	4.17e-07	4.56e-05	-0.15	-0.16	Intelligence (multi-trait analysis);	chr3:50088563	chr3:49903845~49916937:+
BRCA	cis	rs12612619	0.579	rs6753540	ENSG00000272148.1	RP11-195B17.1	-5.09	4.17e-07	4.57e-05	-0.17	-0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:26857266	chr2:27062428~27062907:-
BRCA	cis	rs875971	1	rs6961717	ENSG00000223473.2	GS1-124K5.3	-5.09	4.17e-07	4.57e-05	-0.12	-0.16	Aortic root size;	chr7:66122550	chr7:66491049~66493566:-
BRCA	cis	rs2153535	0.58	rs6920779	ENSG00000251164.1	HULC	-5.09	4.17e-07	4.57e-05	-0.19	-0.16	Motion sickness;	chr6:8437391	chr6:8652137~8653846:+
BRCA	cis	rs987724	0.515	rs9870137	ENSG00000240875.4	LINC00886	-5.09	4.17e-07	4.57e-05	-0.23	-0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156898867	chr3:156747346~156817062:-
BRCA	cis	rs2179367	0.959	rs9322178	ENSG00000268592.3	RAET1E-AS1	5.09	4.18e-07	4.57e-05	0.2	0.16	Dupuytren's disease;	chr6:149372131	chr6:149863494~149919507:+
BRCA	cis	rs736408	0.609	rs2336545	ENSG00000243224.1	RP5-1157M23.2	5.09	4.18e-07	4.57e-05	0.17	0.16	Bipolar disorder;	chr3:52753587	chr3:52239258~52241097:+
BRCA	cis	rs7618915	0.571	rs6762457	ENSG00000243224.1	RP5-1157M23.2	-5.09	4.18e-07	4.57e-05	-0.18	-0.16	Bipolar disorder;	chr3:52575141	chr3:52239258~52241097:+
BRCA	cis	rs7618915	0.571	rs34954168	ENSG00000243224.1	RP5-1157M23.2	-5.09	4.18e-07	4.57e-05	-0.18	-0.16	Bipolar disorder;	chr3:52578143	chr3:52239258~52241097:+
BRCA	cis	rs3758911	0.713	rs10890673	ENSG00000255353.1	RP11-382M14.1	-5.09	4.18e-07	4.57e-05	-0.2	-0.16	Coronary artery disease;	chr11:107254089	chr11:107176286~107177530:+
BRCA	cis	rs78487399	0.908	rs73925552	ENSG00000234936.1	AC010883.5	5.09	4.18e-07	4.57e-05	0.21	0.16	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43583425	chr2:43229573~43233394:+
BRCA	cis	rs78487399	0.908	rs75597324	ENSG00000234936.1	AC010883.5	5.09	4.18e-07	4.57e-05	0.21	0.16	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43584100	chr2:43229573~43233394:+
BRCA	cis	rs2574985	0.702	rs3011793	ENSG00000231345.3	BEND3P1	-5.09	4.18e-07	4.57e-05	-0.25	-0.16	Subjective well-being;	chr10:50556712	chr10:50655967~50660472:+
BRCA	cis	rs4780355	0.843	rs243325	ENSG00000262703.1	RP11-485G7.6	5.09	4.18e-07	4.57e-05	0.16	0.16	Crohn's disease and psoriasis;	chr16:11260640	chr16:11348143~11349321:-
BRCA	cis	rs9425766	0.546	rs6691001	ENSG00000200674.1	RN7SKP160	5.09	4.18e-07	4.57e-05	0.23	0.16	Life satisfaction;	chr1:173849938	chr1:173791548~173791887:+
BRCA	cis	rs7572733	0.534	rs11899188	ENSG00000231621.1	AC013264.2	-5.09	4.18e-07	4.58e-05	-0.16	-0.16	Dermatomyositis;	chr2:197875397	chr2:197197991~197199273:+
BRCA	cis	rs7577696	0.626	rs3769603	ENSG00000272716.1	RP11-563N4.1	-5.09	4.18e-07	4.58e-05	-0.18	-0.16	Inflammatory biomarkers;	chr2:32135818	chr2:32165046~32165757:-
BRCA	cis	rs597539	0.652	rs514296	ENSG00000261625.1	RP11-554A11.4	-5.09	4.18e-07	4.58e-05	-0.15	-0.16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68886714	chr11:69000765~69002048:-
BRCA	cis	rs9307551	0.619	rs1440862	ENSG00000250334.4	LINC00989	-5.09	4.18e-07	4.58e-05	-0.21	-0.16	Refractive error;	chr4:79503116	chr4:79492416~79576460:+
BRCA	cis	rs17685	0.625	rs1639630	ENSG00000280388.1	RP11-229D13.3	-5.09	4.19e-07	4.58e-05	-0.16	-0.16	Coffee consumption (cups per day);Coffee consumption;	chr7:76101181	chr7:76043977~76045963:-
BRCA	cis	rs17685	0.784	rs1613890	ENSG00000280388.1	RP11-229D13.3	-5.09	4.19e-07	4.58e-05	-0.16	-0.16	Coffee consumption (cups per day);Coffee consumption;	chr7:76105719	chr7:76043977~76045963:-
BRCA	cis	rs875971	0.756	rs2901210	ENSG00000273448.1	RP11-166O4.6	-5.09	4.19e-07	4.58e-05	-0.14	-0.16	Aortic root size;	chr7:66552518	chr7:67333047~67334383:+
BRCA	cis	rs11667325	0.92	rs12610825	ENSG00000268316.1	AC006272.2	5.09	4.19e-07	4.58e-05	0.19	0.16	Neutrophil percentage of granulocytes;	chr19:51795323	chr19:51839771~51840945:-
BRCA	cis	rs7651446	0.737	rs62275654	ENSG00000240875.4	LINC00886	-5.09	4.19e-07	4.58e-05	-0.33	-0.16	Ovarian cancer;Epithelial ovarian cancer;	chr3:156656782	chr3:156747346~156817062:-
BRCA	cis	rs6951245	0.507	rs11763865	ENSG00000229043.2	AC091729.9	-5.09	4.19e-07	4.58e-05	-0.22	-0.16	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1154638	chr7:1160374~1165267:+
BRCA	cis	rs4654783	1	rs4654783	ENSG00000228397.1	RP1-224A6.3	5.09	4.19e-07	4.58e-05	0.21	0.16	Endometriosis;	chr1:22113027	chr1:22023994~22024968:-
BRCA	cis	rs7487075	0.567	rs7486580	ENSG00000274723.1	RP11-618L22.1	5.09	4.19e-07	4.58e-05	0.19	0.16	Itch intensity from mosquito bite;	chr12:46434565	chr12:46970504~46972155:+
BRCA	cis	rs1707322	0.717	rs1972410	ENSG00000234329.1	RP11-767N6.2	5.09	4.19e-07	4.58e-05	0.16	0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45615275	chr1:45651039~45651826:-
BRCA	cis	rs7577696	0.785	rs3851310	ENSG00000272716.1	RP11-563N4.1	-5.09	4.19e-07	4.58e-05	-0.18	-0.16	Inflammatory biomarkers;	chr2:32142917	chr2:32165046~32165757:-
BRCA	cis	rs4948275	0.773	rs2650726	ENSG00000237233.2	TMEM26-AS1	-5.09	4.19e-07	4.58e-05	-0.19	-0.16	Night sleep phenotypes;	chr10:61511113	chr10:61452639~61481956:+
BRCA	cis	rs6496044	0.963	rs11853972	ENSG00000259295.5	CSPG4P12	5.09	4.19e-07	4.58e-05	0.19	0.16	Interstitial lung disease;	chr15:85519209	chr15:85191438~85213905:+
BRCA	cis	rs7141336	0.965	rs8017072	ENSG00000258884.1	CTD-3035D6.2	-5.09	4.19e-07	4.58e-05	-0.2	-0.16	Anxiety disorder;	chr14:90814615	chr14:90822365~90828128:-
BRCA	cis	rs7918232	1	rs6482595	ENSG00000262412.1	RP11-85G18.6	-5.09	4.19e-07	4.58e-05	-0.23	-0.16	Breast cancer;	chr10:27091332	chr10:27243130~27250804:+
BRCA	cis	rs6840360	0.642	rs7682770	ENSG00000278978.1	RP11-164P12.5	-5.09	4.19e-07	4.58e-05	-0.17	-0.16	Intelligence (multi-trait analysis);	chr4:151469261	chr4:151669786~151670503:+
BRCA	cis	rs6840360	0.667	rs9994482	ENSG00000278978.1	RP11-164P12.5	-5.09	4.19e-07	4.58e-05	-0.17	-0.16	Intelligence (multi-trait analysis);	chr4:151470078	chr4:151669786~151670503:+
BRCA	cis	rs6840360	0.642	rs11729923	ENSG00000278978.1	RP11-164P12.5	-5.09	4.19e-07	4.58e-05	-0.17	-0.16	Intelligence (multi-trait analysis);	chr4:151470884	chr4:151669786~151670503:+
BRCA	cis	rs6840360	0.642	rs7676059	ENSG00000278978.1	RP11-164P12.5	-5.09	4.19e-07	4.58e-05	-0.17	-0.16	Intelligence (multi-trait analysis);	chr4:151472115	chr4:151669786~151670503:+
BRCA	cis	rs6840360	0.642	rs7657747	ENSG00000278978.1	RP11-164P12.5	-5.09	4.19e-07	4.58e-05	-0.17	-0.16	Intelligence (multi-trait analysis);	chr4:151473102	chr4:151669786~151670503:+
BRCA	cis	rs10752881	0.875	rs10797825	ENSG00000224468.3	RP11-181K3.4	-5.09	4.19e-07	4.59e-05	-0.17	-0.16	Colorectal cancer;	chr1:183055446	chr1:183138402~183141282:-
BRCA	cis	rs6847067	1	rs1385263	ENSG00000180769.7	WDFY3-AS2	5.09	4.2e-07	4.59e-05	0.14	0.16	Oropharynx cancer;	chr4:84783821	chr4:84965682~85011277:+
BRCA	cis	rs7267979	0.966	rs2482918	ENSG00000125804.12	FAM182A	5.09	4.2e-07	4.59e-05	0.2	0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25431499	chr20:26054655~26086917:+
BRCA	cis	rs7618915	0.571	rs12487445	ENSG00000243224.1	RP5-1157M23.2	-5.09	4.2e-07	4.59e-05	-0.18	-0.16	Bipolar disorder;	chr3:52584303	chr3:52239258~52241097:+
BRCA	cis	rs7617773	0.694	rs13099560	ENSG00000199476.1	Y_RNA	5.09	4.2e-07	4.6e-05	0.2	0.16	Coronary artery disease;	chr3:48163278	chr3:48288587~48288694:+
BRCA	cis	rs7621025	0.69	rs11715257	ENSG00000273486.1	RP11-731C17.2	5.09	4.2e-07	4.6e-05	0.19	0.16	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136463211	chr3:136837338~136839021:-
BRCA	cis	rs13113518	1	rs4864546	ENSG00000223305.1	RN7SKP30	5.09	4.21e-07	4.6e-05	0.19	0.16	Height;	chr4:55537960	chr4:55540502~55540835:-
BRCA	cis	rs4218	0.597	rs4775114	ENSG00000277144.1	RP11-59H7.4	-5.09	4.21e-07	4.6e-05	-0.21	-0.16	Social communication problems;	chr15:59059635	chr15:59115547~59116089:-
BRCA	cis	rs7914558	1	rs11191541	ENSG00000236937.2	PTGES3P4	5.09	4.21e-07	4.6e-05	0.2	0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103064442	chr10:102845595~102845950:+
BRCA	cis	rs467650	0.747	rs461409	ENSG00000248489.1	CTD-2007H13.3	-5.09	4.21e-07	4.6e-05	-0.17	-0.16	Venous thromboembolism (SNP x SNP interaction);	chr5:98594262	chr5:98929171~98995013:+
BRCA	cis	rs7618501	0.602	rs2624853	ENSG00000228008.1	CTD-2330K9.3	-5.09	4.21e-07	4.6e-05	-0.15	-0.16	Intelligence (multi-trait analysis);	chr3:50091460	chr3:49903845~49916937:+
BRCA	cis	rs62025270	0.688	rs10163064	ENSG00000202081.1	RNU6-1280P	-5.09	4.21e-07	4.6e-05	-0.23	-0.16	Idiopathic pulmonary fibrosis;	chr15:85734289	chr15:85651522~85651628:-
BRCA	cis	rs801193	0.569	rs13242290	ENSG00000273448.1	RP11-166O4.6	-5.09	4.22e-07	4.61e-05	-0.14	-0.16	Aortic root size;	chr7:66656898	chr7:67333047~67334383:+
BRCA	cis	rs2268667	0.509	rs7521189	ENSG00000223653.4	RP11-131L23.1	-5.09	4.22e-07	4.61e-05	-0.17	-0.16	Asymmetrical dimethylarginine levels;	chr1:85423913	chr1:85276715~85448124:+
BRCA	cis	rs7617773	0.817	rs11130162	ENSG00000199476.1	Y_RNA	-5.09	4.22e-07	4.62e-05	-0.2	-0.16	Coronary artery disease;	chr3:48256121	chr3:48288587~48288694:+
BRCA	cis	rs6756513	0.5	rs2054046	ENSG00000231024.1	AC092431.3	5.09	4.22e-07	4.62e-05	0.22	0.16	Breast cancer;Platelet count;	chr2:69889942	chr2:69700192~69713847:-
BRCA	cis	rs710913	0.816	rs1727098	ENSG00000228060.1	RP11-69E11.8	5.09	4.22e-07	4.62e-05	0.15	0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39523655	chr1:39565160~39573203:+
BRCA	cis	rs516805	0.596	rs2606644	ENSG00000279453.1	RP3-425C14.4	-5.09	4.22e-07	4.62e-05	-0.21	-0.16	Lymphocyte counts;	chr6:122104734	chr6:122436789~122439223:-
BRCA	cis	rs4934494	0.677	rs11185800	ENSG00000240996.1	RP11-80H5.7	-5.09	4.23e-07	4.62e-05	-0.22	-0.16	Red blood cell count;	chr10:89618323	chr10:89694295~89697928:-
BRCA	cis	rs875971	1	rs6957199	ENSG00000223473.2	GS1-124K5.3	5.09	4.23e-07	4.62e-05	0.12	0.16	Aortic root size;	chr7:66513532	chr7:66491049~66493566:-
BRCA	cis	rs1669338	0.588	rs3864049	ENSG00000271870.1	RP11-97C16.1	5.09	4.23e-07	4.62e-05	0.2	0.16	White matter integrity;	chr3:3145035	chr3:3152942~3153435:+
BRCA	cis	rs2179367	0.632	rs9498325	ENSG00000268592.3	RAET1E-AS1	5.09	4.23e-07	4.62e-05	0.22	0.16	Dupuytren's disease;	chr6:149345993	chr6:149863494~149919507:+
BRCA	cis	rs2179367	0.632	rs9498326	ENSG00000268592.3	RAET1E-AS1	5.09	4.23e-07	4.62e-05	0.22	0.16	Dupuytren's disease;	chr6:149346112	chr6:149863494~149919507:+
BRCA	cis	rs11955398	0.502	rs248683	ENSG00000215032.2	GNL3LP1	5.09	4.23e-07	4.62e-05	0.2	0.16	Intelligence (multi-trait analysis);	chr5:61064331	chr5:60891935~60893577:-
BRCA	cis	rs2243480	1	rs160634	ENSG00000164669.11	INTS4P1	-5.09	4.23e-07	4.62e-05	-0.29	-0.16	Diabetic kidney disease;	chr7:66063677	chr7:65141225~65234216:+
BRCA	cis	rs62025270	0.688	rs76902341	ENSG00000202081.1	RNU6-1280P	-5.09	4.23e-07	4.63e-05	-0.23	-0.16	Idiopathic pulmonary fibrosis;	chr15:85737059	chr15:85651522~85651628:-
BRCA	cis	rs12468226	1	rs6739198	ENSG00000226261.1	AC064836.3	5.09	4.23e-07	4.63e-05	0.25	0.16	Urate levels;	chr2:202492273	chr2:202336024~202336727:-
BRCA	cis	rs7618915	0.547	rs34215106	ENSG00000243224.1	RP5-1157M23.2	-5.09	4.23e-07	4.63e-05	-0.17	-0.16	Bipolar disorder;	chr3:52625108	chr3:52239258~52241097:+
BRCA	cis	rs801193	0.548	rs2659904	ENSG00000223473.2	GS1-124K5.3	5.09	4.24e-07	4.63e-05	0.12	0.16	Aortic root size;	chr7:66713615	chr7:66491049~66493566:-
BRCA	cis	rs5758511	0.596	rs55644935	ENSG00000205702.9	CYP2D7	5.09	4.24e-07	4.63e-05	0.16	0.16	Birth weight;	chr22:42270063	chr22:42140203~42144577:-
BRCA	cis	rs11098499	0.754	rs9999724	ENSG00000260404.2	RP11-384K6.6	5.09	4.24e-07	4.63e-05	0.14	0.16	Corneal astigmatism;	chr4:119318789	chr4:118591773~118633729:+
BRCA	cis	rs1707322	1	rs4524994	ENSG00000234329.1	RP11-767N6.2	5.09	4.24e-07	4.63e-05	0.16	0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45904591	chr1:45651039~45651826:-
BRCA	cis	rs17685	0.753	rs7804598	ENSG00000280388.1	RP11-229D13.3	-5.09	4.24e-07	4.64e-05	-0.16	-0.16	Coffee consumption (cups per day);Coffee consumption;	chr7:76073260	chr7:76043977~76045963:-
BRCA	cis	rs7923609	0.875	rs10822143	ENSG00000232075.1	MRPL35P2	-5.09	4.24e-07	4.64e-05	-0.19	-0.16	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63128096	chr10:63634317~63634827:-
BRCA	cis	rs7647973	0.621	rs3774800	ENSG00000225399.4	RP11-3B7.1	-5.09	4.25e-07	4.64e-05	-0.15	-0.16	Menarche (age at onset);	chr3:49297335	chr3:49260085~49261316:+
BRCA	cis	rs1707322	1	rs1707303	ENSG00000234329.1	RP11-767N6.2	-5.09	4.25e-07	4.64e-05	-0.17	-0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46132601	chr1:45651039~45651826:-
BRCA	cis	rs8054556	1	rs11901	ENSG00000273724.1	RP11-347C12.12	-5.09	4.25e-07	4.65e-05	-0.17	-0.16	Autism spectrum disorder or schizophrenia;	chr16:29972749	chr16:30336400~30343336:+
BRCA	cis	rs2179367	0.959	rs579789	ENSG00000268592.3	RAET1E-AS1	5.09	4.25e-07	4.65e-05	0.2	0.16	Dupuytren's disease;	chr6:149358235	chr6:149863494~149919507:+
BRCA	cis	rs2179367	0.959	rs489551	ENSG00000268592.3	RAET1E-AS1	5.09	4.25e-07	4.65e-05	0.2	0.16	Dupuytren's disease;	chr6:149368321	chr6:149863494~149919507:+
BRCA	cis	rs7811142	1	rs1000215	ENSG00000078319.8	PMS2P1	-5.09	4.25e-07	4.65e-05	-0.24	-0.16	Platelet count;	chr7:100406920	chr7:100320992~100341908:-
BRCA	cis	rs12900463	0.813	rs186266	ENSG00000225151.9	GOLGA2P7	-5.09	4.25e-07	4.65e-05	-0.21	-0.16	Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine);	chr15:84859564	chr15:84199311~84230136:-
BRCA	cis	rs10910092	1	rs10910092	ENSG00000238164.5	RP3-395M20.8	-5.09	4.26e-07	4.65e-05	-0.12	-0.16	Ulcerative colitis;	chr1:2570077	chr1:2549920~2557031:-
BRCA	cis	rs6583826	0.538	rs11187076	ENSG00000236493.2	EIF2S2P3	5.09	4.26e-07	4.65e-05	0.2	0.16	Type 2 diabetes;	chr10:92577206	chr10:92668745~92669743:-
BRCA	cis	rs73193808	0.95	rs12627426	ENSG00000215533.7	LINC00189	-5.09	4.26e-07	4.65e-05	-0.21	-0.16	Coronary artery disease;	chr21:29147136	chr21:29193480~29288205:+
BRCA	cis	rs7617773	0.78	rs3731489	ENSG00000199476.1	Y_RNA	-5.09	4.26e-07	4.65e-05	-0.23	-0.16	Coronary artery disease;	chr3:48187416	chr3:48288587~48288694:+
BRCA	cis	rs703842	1	rs8181644	ENSG00000270039.1	RP11-571M6.17	-5.09	4.26e-07	4.65e-05	-0.22	-0.16	Multiple sclerosis;	chr12:57779683	chr12:57803838~57804415:+
BRCA	cis	rs12681366	0.801	rs12549544	ENSG00000253175.1	RP11-267M23.6	5.09	4.26e-07	4.65e-05	0.19	0.16	Nonsyndromic cleft lip with cleft palate;	chr8:94471329	chr8:94565036~94565715:+
BRCA	cis	rs6480314	0.542	rs61854805	ENSG00000233590.1	RP11-153K11.3	-5.09	4.26e-07	4.66e-05	-0.26	-0.16	Optic nerve measurement (disc area);	chr10:68255826	chr10:68233251~68242379:-
BRCA	cis	rs9307551	0.584	rs1978916	ENSG00000250334.4	LINC00989	-5.09	4.26e-07	4.66e-05	-0.21	-0.16	Refractive error;	chr4:79526106	chr4:79492416~79576460:+
BRCA	cis	rs875971	1	rs1167612	ENSG00000223473.2	GS1-124K5.3	-5.09	4.27e-07	4.66e-05	-0.12	-0.16	Aortic root size;	chr7:66102989	chr7:66491049~66493566:-
BRCA	cis	rs13326165	0.585	rs11708811	ENSG00000243224.1	RP5-1157M23.2	-5.09	4.27e-07	4.66e-05	-0.29	-0.16	HDL cholesterol levels;HDL cholesterol;	chr3:52294591	chr3:52239258~52241097:+
BRCA	cis	rs7829975	0.582	rs448231	ENSG00000233609.3	RP11-62H7.2	-5.09	4.27e-07	4.66e-05	-0.14	-0.16	Mood instability;	chr8:8932549	chr8:8961200~8979025:+
BRCA	cis	rs6545883	0.894	rs10177303	ENSG00000270820.4	RP11-355B11.2	-5.09	4.27e-07	4.66e-05	-0.18	-0.16	Tuberculosis;	chr2:61367324	chr2:61471188~61484130:+
BRCA	cis	rs6738627	1	rs6738627	ENSG00000223318.1	RNA5SP111	5.09	4.27e-07	4.66e-05	0.18	0.16	circulating leptin levels adjusted for BMI;Body fat percentage;circulating leptin levels;	chr2:164687940	chr2:164895677~164895777:-
BRCA	cis	rs6496044	0.568	rs11632326	ENSG00000259295.5	CSPG4P12	5.09	4.27e-07	4.67e-05	0.19	0.16	Interstitial lung disease;	chr15:85536603	chr15:85191438~85213905:+
BRCA	cis	rs1440410	0.571	rs72719141	ENSG00000250326.1	RP11-284M14.1	5.09	4.28e-07	4.67e-05	0.19	0.16	Ischemic stroke;	chr4:143107415	chr4:142933195~143184861:-
BRCA	cis	rs843532	0.925	rs1718414	ENSG00000272359.1	U4	-5.09	4.28e-07	4.67e-05	-0.3	-0.16	Glucose homeostasis traits;	chr3:196787765	chr3:196747192~196747324:-
BRCA	cis	rs7914558	1	rs7067970	ENSG00000236937.2	PTGES3P4	5.09	4.28e-07	4.67e-05	0.2	0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103154113	chr10:102845595~102845950:+
BRCA	cis	rs875971	1	rs6958484	ENSG00000223473.2	GS1-124K5.3	-5.09	4.28e-07	4.67e-05	-0.12	-0.16	Aortic root size;	chr7:66134459	chr7:66491049~66493566:-
BRCA	cis	rs2562456	0.839	rs2562411	ENSG00000268081.1	RP11-678G14.2	5.09	4.28e-07	4.67e-05	0.24	0.16	Pain;	chr19:21419181	chr19:21554640~21569237:-
BRCA	cis	rs2562456	0.876	rs2562413	ENSG00000268081.1	RP11-678G14.2	5.09	4.28e-07	4.67e-05	0.24	0.16	Pain;	chr19:21420084	chr19:21554640~21569237:-
BRCA	cis	rs2562456	0.916	rs1967182	ENSG00000268081.1	RP11-678G14.2	5.09	4.28e-07	4.67e-05	0.24	0.16	Pain;	chr19:21420337	chr19:21554640~21569237:-
BRCA	cis	rs7618915	0.547	rs6768697	ENSG00000243224.1	RP5-1157M23.2	-5.09	4.28e-07	4.67e-05	-0.17	-0.16	Bipolar disorder;	chr3:52669599	chr3:52239258~52241097:+
BRCA	cis	rs7618915	0.547	rs34610142	ENSG00000243224.1	RP5-1157M23.2	-5.09	4.28e-07	4.67e-05	-0.17	-0.16	Bipolar disorder;	chr3:52674413	chr3:52239258~52241097:+
BRCA	cis	rs7618915	0.547	rs12496476	ENSG00000243224.1	RP5-1157M23.2	-5.09	4.28e-07	4.67e-05	-0.17	-0.16	Bipolar disorder;	chr3:52674721	chr3:52239258~52241097:+
BRCA	cis	rs6088813	1	rs6142360	ENSG00000126005.14	MMP24-AS1	5.09	4.28e-07	4.68e-05	0.19	0.16	Height;	chr20:35372683	chr20:35216462~35278131:-
BRCA	cis	rs60843830	1	rs3791223	ENSG00000272342.1	RP13-539J13.1	5.09	4.28e-07	4.68e-05	0.2	0.16	Spherical equivalent (joint analysis main effects and education interaction);	chr2:222336	chr2:739588~740164:-
BRCA	cis	rs9308731	1	rs2015454	ENSG00000230499.1	AC108463.1	-5.09	4.28e-07	4.68e-05	-0.19	-0.16	Chronic lymphocytic leukemia;	chr2:111114571	chr2:111195963~111206494:+
BRCA	cis	rs62184315	0.52	rs62184268	ENSG00000253559.1	OSGEPL1-AS1	-5.09	4.29e-07	4.68e-05	-0.27	-0.16	Alcohol dependence (age at onset);	chr2:189767451	chr2:189762704~189765556:+
BRCA	cis	rs1005277	0.579	rs1780146	ENSG00000263064.2	RP11-291L22.7	5.09	4.29e-07	4.68e-05	0.19	0.16	Extrinsic epigenetic age acceleration;	chr10:38228946	chr10:38448689~38448949:+
BRCA	cis	rs9341808	0.718	rs9448908	ENSG00000272129.1	RP11-250B2.6	5.09	4.29e-07	4.68e-05	0.2	0.16	Sitting height ratio;	chr6:80188352	chr6:80355424~80356859:+
BRCA	cis	rs6586111	0.647	rs2880655	ENSG00000226659.1	RP11-137H2.4	-5.09	4.29e-07	4.68e-05	-0.22	-0.16	Capecitabine sensitivity;	chr10:80610060	chr10:80529597~80535942:-
BRCA	cis	rs8031584	0.958	rs35256769	ENSG00000259845.1	HERC2P10	5.09	4.29e-07	4.68e-05	0.18	0.16	Huntington's disease progression;	chr15:30945573	chr15:30815271~30844153:+
BRCA	cis	rs8031584	0.958	rs11629793	ENSG00000259845.1	HERC2P10	5.09	4.29e-07	4.68e-05	0.18	0.16	Huntington's disease progression;	chr15:30946220	chr15:30815271~30844153:+
BRCA	cis	rs9308731	0.583	rs4848406	ENSG00000227992.1	AC108463.2	-5.09	4.29e-07	4.69e-05	-0.18	-0.16	Chronic lymphocytic leukemia;	chr2:111176181	chr2:111203964~111206215:-
BRCA	cis	rs17674580	0.582	rs9955503	ENSG00000267193.4	RP11-116O18.3	5.09	4.29e-07	4.69e-05	0.16	0.16	Bladder cancer;	chr18:45738729	chr18:45669367~45747215:-
BRCA	cis	rs6671200	0.667	rs79658099	ENSG00000235501.4	RP4-639F20.1	-5.09	4.29e-07	4.69e-05	-0.35	-0.16	Stearic acid (18:0) levels;	chr1:94951833	chr1:94927566~94963270:+
BRCA	cis	rs4908768	0.539	rs1809332	ENSG00000270282.1	RP5-1115A15.2	5.09	4.3e-07	4.7e-05	0.17	0.16	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8596375	chr1:8512653~8513021:+
BRCA	cis	rs875971	0.545	rs67397473	ENSG00000232546.1	RP11-458F8.1	5.09	4.31e-07	4.7e-05	0.15	0.16	Aortic root size;	chr7:66168318	chr7:66848496~66858136:+
BRCA	cis	rs7674212	0.539	rs6821617	ENSG00000248740.4	RP11-328K4.1	5.09	4.31e-07	4.7e-05	0.18	0.16	Type 2 diabetes;	chr4:103207253	chr4:103256159~103453658:+
BRCA	cis	rs12612619	0.579	rs6756245	ENSG00000272148.1	RP11-195B17.1	5.09	4.31e-07	4.7e-05	0.17	0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:26860621	chr2:27062428~27062907:-
BRCA	cis	rs7176527	1	rs3762169	ENSG00000225151.9	GOLGA2P7	5.09	4.31e-07	4.7e-05	0.23	0.16	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84598728	chr15:84199311~84230136:-
BRCA	cis	rs7618915	0.571	rs2289249	ENSG00000243224.1	RP5-1157M23.2	-5.09	4.31e-07	4.7e-05	-0.18	-0.16	Bipolar disorder;	chr3:52563648	chr3:52239258~52241097:+
BRCA	cis	rs7200543	0.848	rs62039480	ENSG00000207425.1	Y_RNA	-5.09	4.31e-07	4.7e-05	-0.18	-0.16	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15043593	chr16:14915457~14915556:-
BRCA	cis	rs7577696	0.925	rs12617290	ENSG00000272716.1	RP11-563N4.1	-5.09	4.31e-07	4.7e-05	-0.17	-0.16	Inflammatory biomarkers;	chr2:32116339	chr2:32165046~32165757:-
BRCA	cis	rs7577696	0.925	rs7573543	ENSG00000272716.1	RP11-563N4.1	-5.09	4.31e-07	4.7e-05	-0.17	-0.16	Inflammatory biomarkers;	chr2:32117439	chr2:32165046~32165757:-
BRCA	cis	rs73193808	0.901	rs1997568	ENSG00000236056.1	GAPDHP14	-5.09	4.31e-07	4.71e-05	-0.22	-0.16	Coronary artery disease;	chr21:29213260	chr21:29222321~29223257:+
BRCA	cis	rs11098499	0.754	rs878376	ENSG00000260404.2	RP11-384K6.6	5.09	4.31e-07	4.71e-05	0.14	0.16	Corneal astigmatism;	chr4:119316547	chr4:118591773~118633729:+
BRCA	cis	rs2115630	1	rs11854291	ENSG00000259295.5	CSPG4P12	-5.09	4.31e-07	4.71e-05	-0.19	-0.16	P wave terminal force;	chr15:84820477	chr15:85191438~85213905:+
BRCA	cis	rs2980439	0.846	rs2980437	ENSG00000233609.3	RP11-62H7.2	-5.09	4.31e-07	4.71e-05	-0.15	-0.16	Neuroticism;	chr8:8237241	chr8:8961200~8979025:+
BRCA	cis	rs2562456	0.793	rs7259708	ENSG00000268535.1	RP11-420K14.3	5.09	4.31e-07	4.71e-05	0.21	0.16	Pain;	chr19:21567846	chr19:21709522~21710191:+
BRCA	cis	rs1729951	0.546	rs835634	ENSG00000239213.4	NCK1-AS1	5.09	4.32e-07	4.71e-05	0.16	0.16	Neuroticism;	chr3:136957461	chr3:136841726~136862054:-
BRCA	cis	rs9467773	0.572	rs13213953	ENSG00000124549.13	BTN2A3P	5.09	4.32e-07	4.71e-05	0.17	0.16	Intelligence (multi-trait analysis);	chr6:26594306	chr6:26421391~26432383:+
BRCA	cis	rs2153535	0.541	rs9405386	ENSG00000251164.1	HULC	-5.09	4.32e-07	4.71e-05	-0.19	-0.16	Motion sickness;	chr6:8457834	chr6:8652137~8653846:+
BRCA	cis	rs875971	1	rs2087647	ENSG00000223473.2	GS1-124K5.3	-5.09	4.32e-07	4.71e-05	-0.12	-0.16	Aortic root size;	chr7:66128201	chr7:66491049~66493566:-
BRCA	cis	rs1223397	0.938	rs17700321	ENSG00000215022.6	RP1-257A7.4	-5.09	4.32e-07	4.71e-05	-0.22	-0.16	Blood pressure;	chr6:13280434	chr6:13264861~13295586:-
BRCA	cis	rs7682317	0.797	rs6849143	ENSG00000270720.1	RP11-84C13.2	-5.09	4.32e-07	4.71e-05	-0.17	-0.16	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr4:89007338	chr4:89119284~89119871:+
BRCA	cis	rs9308731	0.931	rs616130	ENSG00000230499.1	AC108463.1	-5.09	4.32e-07	4.71e-05	-0.18	-0.16	Chronic lymphocytic leukemia;	chr2:111155104	chr2:111195963~111206494:+
BRCA	cis	rs7577696	0.962	rs6758024	ENSG00000272716.1	RP11-563N4.1	-5.09	4.32e-07	4.72e-05	-0.17	-0.16	Inflammatory biomarkers;	chr2:32069417	chr2:32165046~32165757:-
BRCA	cis	rs6728642	0.519	rs7589232	ENSG00000230606.9	AC159540.1	5.09	4.32e-07	4.72e-05	0.24	0.16	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:96900411	chr2:97416165~97433527:-
BRCA	cis	rs2562456	0.874	rs9304986	ENSG00000268658.4	LINC00664	-5.09	4.32e-07	4.72e-05	-0.25	-0.16	Pain;	chr19:21499260	chr19:21483374~21503238:+
BRCA	cis	rs1075265	0.756	rs3821081	ENSG00000235937.1	AC008280.1	-5.09	4.32e-07	4.72e-05	-0.17	-0.16	Chronotype;Morning vs. evening chronotype;	chr2:53738252	chr2:54029552~54030682:-
BRCA	cis	rs2562456	0.876	rs62110202	ENSG00000268658.4	LINC00664	5.09	4.32e-07	4.72e-05	0.24	0.16	Pain;	chr19:21571799	chr19:21483374~21503238:+
BRCA	cis	rs793571	0.628	rs12917083	ENSG00000259250.1	RP11-50C13.1	-5.09	4.32e-07	4.72e-05	-0.25	-0.16	Schizophrenia;	chr15:58752341	chr15:58587507~58591676:+
BRCA	cis	rs838147	0.815	rs28400015	ENSG00000232871.7	SEC1P	-5.09	4.33e-07	4.72e-05	-0.17	-0.16	Dietary macronutrient intake;	chr19:48747376	chr19:48638071~48682245:+
BRCA	cis	rs4660214	0.666	rs11205839	ENSG00000228060.1	RP11-69E11.8	5.09	4.33e-07	4.72e-05	0.16	0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39268061	chr1:39565160~39573203:+
BRCA	cis	rs3768617	0.51	rs35968946	ENSG00000224468.3	RP11-181K3.4	-5.09	4.33e-07	4.72e-05	-0.17	-0.16	Fuchs's corneal dystrophy;	chr1:183145736	chr1:183138402~183141282:-
BRCA	cis	rs4660214	0.756	rs11205823	ENSG00000228060.1	RP11-69E11.8	5.09	4.33e-07	4.73e-05	0.16	0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39248566	chr1:39565160~39573203:+
BRCA	cis	rs1075265	0.818	rs12713253	ENSG00000235937.1	AC008280.1	5.09	4.33e-07	4.73e-05	0.17	0.16	Chronotype;Morning vs. evening chronotype;	chr2:54037323	chr2:54029552~54030682:-
BRCA	cis	rs7615952	0.604	rs9837847	ENSG00000250012.1	RP11-124N2.1	-5.09	4.33e-07	4.73e-05	-0.27	-0.16	Blood pressure (smoking interaction);	chr3:125905076	chr3:126084220~126095349:+
BRCA	cis	rs73193808	0.804	rs2832276	ENSG00000236056.1	GAPDHP14	-5.09	4.33e-07	4.73e-05	-0.21	-0.16	Coronary artery disease;	chr21:29236463	chr21:29222321~29223257:+
BRCA	cis	rs2790457	0.958	rs2532742	ENSG00000254635.4	WAC-AS1	-5.09	4.33e-07	4.73e-05	-0.19	-0.16	Multiple myeloma;	chr10:28578291	chr10:28522652~28532743:-
BRCA	cis	rs957448	0.554	rs12540967	ENSG00000253175.1	RP11-267M23.6	5.09	4.34e-07	4.73e-05	0.18	0.16	Nonsyndromic cleft lip with cleft palate;	chr8:94576862	chr8:94565036~94565715:+
BRCA	cis	rs957448	0.554	rs4735297	ENSG00000253175.1	RP11-267M23.6	5.09	4.34e-07	4.73e-05	0.18	0.16	Nonsyndromic cleft lip with cleft palate;	chr8:94577112	chr8:94565036~94565715:+
BRCA	cis	rs2732480	0.538	rs2468943	ENSG00000226413.2	OR8T1P	-5.09	4.34e-07	4.73e-05	-0.21	-0.16	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48353466	chr12:48442030~48442947:-
BRCA	cis	rs6600671	1	rs6600669	ENSG00000275538.1	RNVU1-19	5.09	4.34e-07	4.73e-05	0.19	0.16	Hip geometry;	chr1:121471785	chr1:120850819~120850985:-
BRCA	cis	rs10129255	0.957	rs10136560	ENSG00000280411.1	IGHV1-69-2	-5.09	4.34e-07	4.74e-05	-0.12	-0.16	Kawasaki disease;	chr14:106787630	chr14:106762092~106762588:-
BRCA	cis	rs1075265	0.548	rs2542575	ENSG00000235937.1	AC008280.1	5.09	4.34e-07	4.74e-05	0.17	0.16	Chronotype;Morning vs. evening chronotype;	chr2:53821221	chr2:54029552~54030682:-
BRCA	cis	rs6071166	0.967	rs6027419	ENSG00000224635.1	RP4-564F22.5	-5.09	4.34e-07	4.74e-05	-0.18	-0.16	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38703562	chr20:38406011~38416797:-
BRCA	cis	rs987360	0.804	rs13136583	ENSG00000248869.4	RP11-138I17.1	5.09	4.34e-07	4.74e-05	0.15	0.16	Temperament;	chr4:137281359	chr4:136796722~137212799:-
BRCA	cis	rs2638953	0.886	rs11049572	ENSG00000247934.4	RP11-967K21.1	-5.09	4.35e-07	4.74e-05	-0.21	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28397268	chr12:28163298~28190738:-
BRCA	cis	rs8054556	1	rs4788197	ENSG00000273724.1	RP11-347C12.12	-5.09	4.35e-07	4.74e-05	-0.17	-0.16	Autism spectrum disorder or schizophrenia;	chr16:29959513	chr16:30336400~30343336:+
BRCA	cis	rs8054556	1	rs4788198	ENSG00000273724.1	RP11-347C12.12	-5.09	4.35e-07	4.74e-05	-0.17	-0.16	Autism spectrum disorder or schizophrenia;	chr16:29959514	chr16:30336400~30343336:+
BRCA	cis	rs595244	1	rs1018148	ENSG00000259705.1	RP11-227D13.1	-5.09	4.35e-07	4.74e-05	-0.29	-0.16	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48610929	chr15:48645951~48652016:+
BRCA	cis	rs2638953	0.925	rs11049597	ENSG00000247934.4	RP11-967K21.1	-5.09	4.35e-07	4.74e-05	-0.21	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28433584	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.962	rs11049599	ENSG00000247934.4	RP11-967K21.1	-5.09	4.35e-07	4.74e-05	-0.21	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28437218	chr12:28163298~28190738:-
BRCA	cis	rs9308731	0.966	rs6753785	ENSG00000230499.1	AC108463.1	-5.09	4.35e-07	4.74e-05	-0.18	-0.16	Chronic lymphocytic leukemia;	chr2:111166053	chr2:111195963~111206494:+
BRCA	cis	rs7569084	0.687	rs7577452	ENSG00000281920.1	RP11-418H16.1	5.09	4.36e-07	4.75e-05	0.2	0.16	Sum eosinophil basophil counts;	chr2:65456694	chr2:65623272~65628424:+
BRCA	cis	rs1707322	1	rs4539075	ENSG00000234329.1	RP11-767N6.2	5.09	4.36e-07	4.75e-05	0.16	0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45892338	chr1:45651039~45651826:-
BRCA	cis	rs17801127	0.688	rs13000594	ENSG00000231969.1	AC144449.1	5.09	4.36e-07	4.75e-05	0.3	0.16	Liver enzyme levels (alanine transaminase);	chr2:149810533	chr2:149587196~149848233:+
BRCA	cis	rs2839186	0.605	rs2839170	ENSG00000228137.1	AP001469.7	5.08	4.36e-07	4.75e-05	0.16	0.16	Testicular germ cell tumor;	chr21:46251391	chr21:46246890~46247682:+
BRCA	cis	rs10504130	0.569	rs13265006	ENSG00000272024.1	RP11-546K22.3	-5.08	4.36e-07	4.75e-05	-0.23	-0.16	Venous thromboembolism (SNP x SNP interaction);	chr8:51877963	chr8:51950284~51950690:+
BRCA	cis	rs10504130	0.597	rs34058697	ENSG00000272024.1	RP11-546K22.3	-5.08	4.36e-07	4.75e-05	-0.23	-0.16	Venous thromboembolism (SNP x SNP interaction);	chr8:51882392	chr8:51950284~51950690:+
BRCA	cis	rs3822625	0.541	rs76679228	ENSG00000271828.1	CTD-2310F14.1	5.08	4.36e-07	4.76e-05	0.29	0.16	Breast cancer (early onset);	chr5:56903684	chr5:56927874~56929573:+
BRCA	cis	rs7646881	0.951	rs6441222	ENSG00000240207.5	RP11-379F4.4	-5.08	4.36e-07	4.76e-05	-0.22	-0.16	Tetralogy of Fallot;	chr3:158731978	chr3:158732263~158784070:+
BRCA	cis	rs1707322	0.928	rs7527244	ENSG00000234329.1	RP11-767N6.2	5.08	4.36e-07	4.76e-05	0.16	0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45903100	chr1:45651039~45651826:-
BRCA	cis	rs2638953	0.853	rs11049678	ENSG00000247934.4	RP11-967K21.1	-5.08	4.37e-07	4.77e-05	-0.21	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28505546	chr12:28163298~28190738:-
BRCA	cis	rs801193	0.569	rs10950050	ENSG00000236529.1	RP13-254B10.1	5.08	4.37e-07	4.77e-05	0.17	0.16	Aortic root size;	chr7:66774601	chr7:65840212~65840596:+
BRCA	cis	rs6840360	0.557	rs4696261	ENSG00000278978.1	RP11-164P12.5	-5.08	4.37e-07	4.77e-05	-0.17	-0.16	Intelligence (multi-trait analysis);	chr4:151401507	chr4:151669786~151670503:+
BRCA	cis	rs891378	0.959	rs77542432	ENSG00000274245.1	RP11-357P18.2	-5.08	4.37e-07	4.77e-05	-0.21	-0.16	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207301020	chr1:207372559~207373252:+
BRCA	cis	rs10129255	0.957	rs12590667	ENSG00000211974.3	IGHV2-70	-5.08	4.37e-07	4.77e-05	-0.15	-0.16	Kawasaki disease;	chr14:106779223	chr14:106723574~106724093:-
BRCA	cis	rs1009647	0.592	rs1045004	ENSG00000258413.1	RP11-665C16.6	-5.08	4.37e-07	4.77e-05	-0.25	-0.16	Testicular germ cell tumor;	chr14:55353073	chr14:55262767~55272075:-
BRCA	cis	rs6452524	0.618	rs6452504	ENSG00000281327.1	LINC01338	5.08	4.37e-07	4.77e-05	0.18	0.16	Hypertension (SNP x SNP interaction);	chr5:83074625	chr5:82850864~82859836:-
BRCA	cis	rs1005277	0.579	rs1780116	ENSG00000263064.2	RP11-291L22.7	5.08	4.37e-07	4.77e-05	0.19	0.16	Extrinsic epigenetic age acceleration;	chr10:38237693	chr10:38448689~38448949:+
BRCA	cis	rs1005277	0.579	rs1780121	ENSG00000263064.2	RP11-291L22.7	5.08	4.37e-07	4.77e-05	0.19	0.16	Extrinsic epigenetic age acceleration;	chr10:38240509	chr10:38448689~38448949:+
BRCA	cis	rs4835473	0.932	rs1849115	ENSG00000249741.2	RP11-673E1.3	-5.08	4.38e-07	4.77e-05	-0.17	-0.16	Immature fraction of reticulocytes;	chr4:143989687	chr4:143911514~143912053:-
BRCA	cis	rs1005277	0.579	rs1780145	ENSG00000263064.2	RP11-291L22.7	5.08	4.38e-07	4.77e-05	0.19	0.16	Extrinsic epigenetic age acceleration;	chr10:38248142	chr10:38448689~38448949:+
BRCA	cis	rs10129255	0.872	rs1858683	ENSG00000224373.3	IGHV4-59	5.08	4.38e-07	4.77e-05	0.1	0.16	Kawasaki disease;	chr14:106670217	chr14:106627249~106627825:-
BRCA	cis	rs4950322	0.58	rs4950308	ENSG00000278811.3	LINC00624	5.08	4.38e-07	4.77e-05	0.2	0.16	Protein quantitative trait loci;	chr1:147120092	chr1:147258885~147517875:-
BRCA	cis	rs7688540	0.723	rs17521834	ENSG00000211553.1	AC253576.2	5.08	4.38e-07	4.78e-05	0.25	0.16	Facial morphology (factor 6, height of vermillion lower lip);	chr4:231660	chr4:136461~136568:+
BRCA	cis	rs1075265	0.87	rs7569370	ENSG00000235937.1	AC008280.1	5.08	4.38e-07	4.78e-05	0.17	0.16	Chronotype;Morning vs. evening chronotype;	chr2:53989212	chr2:54029552~54030682:-
BRCA	cis	rs3764563	1	rs623675	ENSG00000267594.5	CYP4F24P	5.08	4.38e-07	4.78e-05	0.3	0.16	Inflammatory biomarkers;	chr19:15594304	chr19:15760241~15779909:-
BRCA	cis	rs27434	0.605	rs12659825	ENSG00000272109.1	CTD-2260A17.3	5.08	4.38e-07	4.78e-05	0.25	0.16	Ankylosing spondylitis;	chr5:96852380	chr5:96804353~96806105:+
BRCA	cis	rs9287719	0.967	rs10203664	ENSG00000243819.4	RN7SL832P	5.08	4.38e-07	4.78e-05	0.15	0.16	Prostate cancer;	chr2:10612251	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.934	rs10201077	ENSG00000243819.4	RN7SL832P	5.08	4.38e-07	4.78e-05	0.15	0.16	Prostate cancer;	chr2:10612300	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.967	rs9287720	ENSG00000243819.4	RN7SL832P	5.08	4.38e-07	4.78e-05	0.15	0.16	Prostate cancer;	chr2:10612538	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.87	rs10167676	ENSG00000243819.4	RN7SL832P	5.08	4.38e-07	4.78e-05	0.15	0.16	Prostate cancer;	chr2:10613014	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.967	rs12995159	ENSG00000243819.4	RN7SL832P	5.08	4.38e-07	4.78e-05	0.15	0.16	Prostate cancer;	chr2:10613197	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.967	rs12995602	ENSG00000243819.4	RN7SL832P	5.08	4.38e-07	4.78e-05	0.15	0.16	Prostate cancer;	chr2:10613416	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.967	rs6432119	ENSG00000243819.4	RN7SL832P	5.08	4.38e-07	4.78e-05	0.15	0.16	Prostate cancer;	chr2:10613561	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.967	rs6432120	ENSG00000243819.4	RN7SL832P	5.08	4.38e-07	4.78e-05	0.15	0.16	Prostate cancer;	chr2:10613645	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.967	rs6432122	ENSG00000243819.4	RN7SL832P	5.08	4.38e-07	4.78e-05	0.15	0.16	Prostate cancer;	chr2:10613718	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.967	rs6712406	ENSG00000243819.4	RN7SL832P	5.08	4.38e-07	4.78e-05	0.15	0.16	Prostate cancer;	chr2:10614294	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.967	rs10195802	ENSG00000243819.4	RN7SL832P	5.08	4.38e-07	4.78e-05	0.15	0.16	Prostate cancer;	chr2:10614406	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.967	rs7566875	ENSG00000243819.4	RN7SL832P	5.08	4.38e-07	4.78e-05	0.15	0.16	Prostate cancer;	chr2:10614666	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.934	rs4371336	ENSG00000243819.4	RN7SL832P	5.08	4.38e-07	4.78e-05	0.15	0.16	Prostate cancer;	chr2:10615597	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.967	rs4405729	ENSG00000243819.4	RN7SL832P	5.08	4.38e-07	4.78e-05	0.15	0.16	Prostate cancer;	chr2:10615653	chr2:10690344~10692099:+
BRCA	cis	rs2281636	0.823	rs4917877	ENSG00000233690.1	EBAG9P1	5.08	4.38e-07	4.78e-05	0.16	0.16	Obesity-related traits;	chr10:99670281	chr10:99697407~99697949:-
BRCA	cis	rs4819052	0.851	rs1006779	ENSG00000184274.3	LINC00315	-5.08	4.38e-07	4.78e-05	-0.21	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250837	chr21:45300245~45305257:-
BRCA	cis	rs321358	0.945	rs17537367	ENSG00000271390.1	RP11-89C3.3	5.08	4.38e-07	4.78e-05	0.26	0.16	Body mass index;	chr11:111117008	chr11:111089870~111090368:-
BRCA	cis	rs66887589	0.967	rs6844263	ENSG00000245958.5	RP11-33B1.1	-5.08	4.39e-07	4.78e-05	-0.14	-0.16	Diastolic blood pressure;	chr4:119512652	chr4:119454791~119552025:+
BRCA	cis	rs17495987	0.75	rs17562267	ENSG00000219545.8	UMAD1	5.08	4.39e-07	4.78e-05	0.22	0.16	Tonsillectomy;	chr7:7865782	chr7:7640711~8004059:+
BRCA	cis	rs6723226	0.739	rs2069213	ENSG00000276334.1	AL133243.1	5.08	4.39e-07	4.78e-05	0.2	0.16	Intelligence (multi-trait analysis);	chr2:32518017	chr2:32521927~32523547:+
BRCA	cis	rs9300255	0.602	rs2695476	ENSG00000235423.7	RP11-282O18.3	5.08	4.39e-07	4.78e-05	0.22	0.16	Neutrophil percentage of white cells;	chr12:123209659	chr12:123252030~123261483:-
BRCA	cis	rs4494364	0.502	rs2293754	ENSG00000258100.1	RP11-121E16.1	5.08	4.39e-07	4.78e-05	0.23	0.16	Systolic blood pressure (alcohol consumption interaction);	chr12:91004857	chr12:91362196~91368606:+
BRCA	cis	rs10777288	0.561	rs10777279	ENSG00000258100.1	RP11-121E16.1	5.08	4.39e-07	4.78e-05	0.23	0.16	Pulmonary function (smoking interaction);	chr12:91005023	chr12:91362196~91368606:+
BRCA	cis	rs4494364	0.502	rs10777280	ENSG00000258100.1	RP11-121E16.1	5.08	4.39e-07	4.78e-05	0.23	0.16	Systolic blood pressure (alcohol consumption interaction);	chr12:91005087	chr12:91362196~91368606:+
BRCA	cis	rs4494364	0.502	rs1920748	ENSG00000258100.1	RP11-121E16.1	5.08	4.39e-07	4.78e-05	0.23	0.16	Systolic blood pressure (alcohol consumption interaction);	chr12:91005279	chr12:91362196~91368606:+
BRCA	cis	rs4494364	0.502	rs10745544	ENSG00000258100.1	RP11-121E16.1	5.08	4.39e-07	4.78e-05	0.23	0.16	Systolic blood pressure (alcohol consumption interaction);	chr12:91005928	chr12:91362196~91368606:+
BRCA	cis	rs4494364	0.502	rs10745545	ENSG00000258100.1	RP11-121E16.1	5.08	4.39e-07	4.78e-05	0.23	0.16	Systolic blood pressure (alcohol consumption interaction);	chr12:91005974	chr12:91362196~91368606:+
BRCA	cis	rs4494364	0.502	rs10745546	ENSG00000258100.1	RP11-121E16.1	5.08	4.39e-07	4.78e-05	0.23	0.16	Systolic blood pressure (alcohol consumption interaction);	chr12:91006105	chr12:91362196~91368606:+
BRCA	cis	rs4494364	0.502	rs7958085	ENSG00000258100.1	RP11-121E16.1	5.08	4.39e-07	4.78e-05	0.23	0.16	Systolic blood pressure (alcohol consumption interaction);	chr12:91006328	chr12:91362196~91368606:+
BRCA	cis	rs4494364	0.502	rs6538255	ENSG00000258100.1	RP11-121E16.1	5.08	4.39e-07	4.78e-05	0.23	0.16	Systolic blood pressure (alcohol consumption interaction);	chr12:91006444	chr12:91362196~91368606:+
BRCA	cis	rs736408	0.609	rs13095332	ENSG00000243224.1	RP5-1157M23.2	-5.08	4.39e-07	4.78e-05	-0.17	-0.16	Bipolar disorder;	chr3:52753226	chr3:52239258~52241097:+
BRCA	cis	rs7674212	0.541	rs2720460	ENSG00000248740.4	RP11-328K4.1	-5.08	4.39e-07	4.78e-05	-0.18	-0.16	Type 2 diabetes;	chr4:103133529	chr4:103256159~103453658:+
BRCA	cis	rs875971	0.545	rs73142245	ENSG00000230295.1	RP11-458F8.2	5.08	4.39e-07	4.79e-05	0.15	0.16	Aortic root size;	chr7:66226662	chr7:66880708~66882981:+
BRCA	cis	rs859767	0.501	rs6745983	ENSG00000224043.6	CCNT2-AS1	5.08	4.39e-07	4.79e-05	0.21	0.16	Neuroticism;	chr2:134673139	chr2:134735464~134918710:-
BRCA	cis	rs1707322	1	rs6675222	ENSG00000234329.1	RP11-767N6.2	5.08	4.4e-07	4.79e-05	0.16	0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45860904	chr1:45651039~45651826:-
BRCA	cis	rs1707322	1	rs4660895	ENSG00000234329.1	RP11-767N6.2	5.08	4.4e-07	4.79e-05	0.16	0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45864067	chr1:45651039~45651826:-
BRCA	cis	rs1707322	1	rs4660318	ENSG00000234329.1	RP11-767N6.2	5.08	4.4e-07	4.79e-05	0.16	0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45869204	chr1:45651039~45651826:-
BRCA	cis	rs1707322	1	rs10890360	ENSG00000234329.1	RP11-767N6.2	5.08	4.4e-07	4.79e-05	0.16	0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45872772	chr1:45651039~45651826:-
BRCA	cis	rs4713118	0.525	rs9357042	ENSG00000216901.1	AL022393.7	5.08	4.4e-07	4.79e-05	0.19	0.16	Parkinson's disease;	chr6:27615016	chr6:28176188~28176674:+
BRCA	cis	rs12477438	0.765	rs2309520	ENSG00000231822.1	AC019097.7	5.08	4.4e-07	4.79e-05	0.17	0.16	Chronic sinus infection;	chr2:98954014	chr2:99102018~99102752:+
BRCA	cis	rs9287719	0.967	rs6432113	ENSG00000243819.4	RN7SL832P	-5.08	4.4e-07	4.79e-05	-0.15	-0.16	Prostate cancer;	chr2:10604763	chr2:10690344~10692099:+
BRCA	cis	rs1193	0.837	rs2138397	ENSG00000231259.4	AC125232.1	-5.08	4.4e-07	4.79e-05	-0.19	-0.16	High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;High light scatter reticulocyte count;	chr2:86746926	chr2:87031815~87053069:-
BRCA	cis	rs891378	1	rs1507761	ENSG00000274245.1	RP11-357P18.2	5.08	4.4e-07	4.79e-05	0.21	0.16	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207336454	chr1:207372559~207373252:+
BRCA	cis	rs13113518	1	rs7691799	ENSG00000223305.1	RN7SKP30	5.08	4.4e-07	4.8e-05	0.19	0.16	Height;	chr4:55545574	chr4:55540502~55540835:-
BRCA	cis	rs12681366	0.839	rs3019278	ENSG00000253175.1	RP11-267M23.6	5.08	4.4e-07	4.8e-05	0.19	0.16	Nonsyndromic cleft lip with cleft palate;	chr8:94434339	chr8:94565036~94565715:+
BRCA	cis	rs4919694	0.536	rs12414777	ENSG00000236937.2	PTGES3P4	5.08	4.41e-07	4.8e-05	0.24	0.16	Arsenic metabolism;	chr10:102938024	chr10:102845595~102845950:+
BRCA	cis	rs10844706	0.699	rs10772087	ENSG00000214776.8	RP11-726G1.1	5.08	4.41e-07	4.81e-05	0.19	0.16	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9730515	chr12:9467552~9576275:+
BRCA	cis	rs2153535	0.58	rs7743995	ENSG00000251164.1	HULC	-5.08	4.42e-07	4.81e-05	-0.19	-0.16	Motion sickness;	chr6:8495979	chr6:8652137~8653846:+
BRCA	cis	rs442309	0.687	rs10822052	ENSG00000238280.1	RP11-436D10.3	5.08	4.42e-07	4.81e-05	0.22	0.16	Vogt-Koyanagi-Harada syndrome;	chr10:62696010	chr10:62793562~62805887:-
BRCA	cis	rs11051970	0.592	rs11051985	ENSG00000274964.1	RP11-817I4.1	-5.08	4.42e-07	4.81e-05	-0.22	-0.16	Response to tocilizumab in rheumatoid arthritis;	chr12:32402156	chr12:32339368~32340724:+
BRCA	cis	rs11051970	0.559	rs11051986	ENSG00000274964.1	RP11-817I4.1	-5.08	4.42e-07	4.81e-05	-0.22	-0.16	Response to tocilizumab in rheumatoid arthritis;	chr12:32402339	chr12:32339368~32340724:+
BRCA	cis	rs6163	0.588	rs11191392	ENSG00000213061.2	PFN1P11	5.08	4.42e-07	4.82e-05	0.19	0.16	Waist circumference;Hip circumference;	chr10:102767194	chr10:102838011~102845473:-
BRCA	cis	rs957448	0.554	rs12540967	ENSG00000261437.1	RP11-22C11.2	5.08	4.42e-07	4.82e-05	0.15	0.16	Nonsyndromic cleft lip with cleft palate;	chr8:94576862	chr8:94637285~94639467:-
BRCA	cis	rs957448	0.554	rs4735297	ENSG00000261437.1	RP11-22C11.2	5.08	4.42e-07	4.82e-05	0.15	0.16	Nonsyndromic cleft lip with cleft palate;	chr8:94577112	chr8:94637285~94639467:-
BRCA	cis	rs459482	0.501	rs148214	ENSG00000228318.3	AP001610.5	5.08	4.42e-07	4.82e-05	0.18	0.16	IgG glycosylation;	chr21:41442291	chr21:41441056~41445708:-
BRCA	cis	rs17772222	0.74	rs10150986	ENSG00000258789.1	RP11-507K2.3	-5.08	4.43e-07	4.82e-05	-0.17	-0.16	Coronary artery calcification;	chr14:88517326	chr14:88551597~88552493:+
BRCA	cis	rs7618915	0.524	rs35249778	ENSG00000243224.1	RP5-1157M23.2	-5.08	4.43e-07	4.82e-05	-0.17	-0.16	Bipolar disorder;	chr3:52627624	chr3:52239258~52241097:+
BRCA	cis	rs172166	0.637	rs1071893	ENSG00000219392.1	RP1-265C24.5	-5.08	4.43e-07	4.82e-05	-0.21	-0.16	Cardiac Troponin-T levels;	chr6:28199857	chr6:28115628~28116551:+
BRCA	cis	rs4660214	0.666	rs1537818	ENSG00000228060.1	RP11-69E11.8	5.08	4.43e-07	4.82e-05	0.16	0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39181366	chr1:39565160~39573203:+
BRCA	cis	rs8031584	0.958	rs8034856	ENSG00000270015.1	RP11-540B6.6	-5.08	4.43e-07	4.82e-05	-0.16	-0.16	Huntington's disease progression;	chr15:30948754	chr15:30926514~30928407:+
BRCA	cis	rs1609391	0.567	rs835633	ENSG00000239213.4	NCK1-AS1	5.08	4.43e-07	4.82e-05	0.16	0.16	Neuroticism;	chr3:136957654	chr3:136841726~136862054:-
BRCA	cis	rs9650657	0.537	rs7016385	ENSG00000154316.13	TDH	-5.08	4.43e-07	4.82e-05	-0.2	-0.16	Neuroticism;	chr8:10921962	chr8:11339637~11368452:+
BRCA	cis	rs7119	0.717	rs12910512	ENSG00000259362.2	RP11-307C19.1	-5.08	4.43e-07	4.82e-05	-0.21	-0.16	Type 2 diabetes;	chr15:77524911	chr15:77525540~77534110:+
BRCA	cis	rs4835473	0.932	rs6826862	ENSG00000249741.2	RP11-673E1.3	-5.08	4.43e-07	4.83e-05	-0.17	-0.16	Immature fraction of reticulocytes;	chr4:143978180	chr4:143911514~143912053:-
BRCA	cis	rs17507216	0.718	rs7161977	ENSG00000255769.6	GOLGA2P10	-5.08	4.44e-07	4.83e-05	-0.24	-0.16	Excessive daytime sleepiness;	chr15:82646782	chr15:82472993~82513950:-
BRCA	cis	rs4718428	0.672	rs12530806	ENSG00000229180.5	GS1-124K5.11	5.08	4.44e-07	4.83e-05	0.15	0.16	Corneal structure;	chr7:66925737	chr7:66526088~66542624:-
BRCA	cis	rs1223397	0.524	rs2496151	ENSG00000215022.6	RP1-257A7.4	-5.08	4.44e-07	4.83e-05	-0.18	-0.16	Blood pressure;	chr6:13314309	chr6:13264861~13295586:-
BRCA	cis	rs1223397	0.524	rs2496152	ENSG00000215022.6	RP1-257A7.4	-5.08	4.44e-07	4.83e-05	-0.18	-0.16	Blood pressure;	chr6:13314315	chr6:13264861~13295586:-
BRCA	cis	rs14027	0.64	rs2043431	ENSG00000279347.1	RP11-85I17.2	-5.08	4.44e-07	4.83e-05	-0.15	-0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119736214	chr8:119838736~119840385:-
BRCA	cis	rs6061231	1	rs67941642	ENSG00000275437.1	RP5-908M14.10	5.08	4.44e-07	4.84e-05	0.17	0.16	Colorectal cancer;	chr20:62383052	chr20:62402236~62405935:-
BRCA	cis	rs2839186	0.77	rs2839984	ENSG00000239415.1	AP001469.9	5.08	4.44e-07	4.84e-05	0.16	0.16	Testicular germ cell tumor;	chr21:46251776	chr21:46251549~46254133:-
BRCA	cis	rs957448	0.554	rs12680855	ENSG00000253175.1	RP11-267M23.6	5.08	4.45e-07	4.84e-05	0.18	0.16	Nonsyndromic cleft lip with cleft palate;	chr8:94570427	chr8:94565036~94565715:+
BRCA	cis	rs4835473	0.932	rs6852502	ENSG00000249741.2	RP11-673E1.3	-5.08	4.45e-07	4.84e-05	-0.17	-0.16	Immature fraction of reticulocytes;	chr4:143987174	chr4:143911514~143912053:-
BRCA	cis	rs4934494	0.677	rs730287	ENSG00000240996.1	RP11-80H5.7	-5.08	4.45e-07	4.85e-05	-0.21	-0.16	Red blood cell count;	chr10:89616589	chr10:89694295~89697928:-
BRCA	cis	rs4934494	0.677	rs1075374	ENSG00000240996.1	RP11-80H5.7	-5.08	4.45e-07	4.85e-05	-0.21	-0.16	Red blood cell count;	chr10:89617218	chr10:89694295~89697928:-
BRCA	cis	rs987724	0.515	rs344079	ENSG00000240875.4	LINC00886	-5.08	4.45e-07	4.85e-05	-0.23	-0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156837783	chr3:156747346~156817062:-
BRCA	cis	rs987724	0.515	rs344080	ENSG00000240875.4	LINC00886	-5.08	4.45e-07	4.85e-05	-0.23	-0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156837996	chr3:156747346~156817062:-
BRCA	cis	rs987724	0.515	rs344082	ENSG00000240875.4	LINC00886	-5.08	4.45e-07	4.85e-05	-0.23	-0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156838290	chr3:156747346~156817062:-
BRCA	cis	rs987724	0.515	rs344084	ENSG00000240875.4	LINC00886	-5.08	4.45e-07	4.85e-05	-0.23	-0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156838591	chr3:156747346~156817062:-
BRCA	cis	rs4781563	0.81	rs11075223	ENSG00000242307.1	RPS26P52	-5.08	4.45e-07	4.85e-05	-0.18	-0.16	Bilirubin levels;	chr16:13950860	chr16:13922332~13922679:-
BRCA	cis	rs17508449	0.505	rs78491726	ENSG00000232450.1	RP4-730K3.3	-5.08	4.46e-07	4.85e-05	-0.25	-0.16	Leprosy;	chr1:113784847	chr1:113698884~113699631:-
BRCA	cis	rs6570726	1	rs1935617	ENSG00000270638.1	RP3-466P17.1	5.08	4.46e-07	4.85e-05	0.18	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145622190	chr6:145735570~145737218:+
BRCA	cis	rs10788972	0.634	rs66746724	ENSG00000225183.1	RP4-758J24.4	-5.08	4.46e-07	4.85e-05	-0.2	-0.16	Parkinson disease and lewy body pathology;	chr1:54094999	chr1:54089856~54090093:+
BRCA	cis	rs2732480	0.557	rs2732454	ENSG00000226413.2	OR8T1P	5.08	4.46e-07	4.86e-05	0.21	0.16	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48325894	chr12:48442030~48442947:-
BRCA	cis	rs2274273	0.745	rs8005399	ENSG00000258413.1	RP11-665C16.6	-5.08	4.46e-07	4.86e-05	-0.2	-0.16	Protein biomarker;	chr14:55076127	chr14:55262767~55272075:-
BRCA	cis	rs6832769	0.922	rs28726308	ENSG00000272969.1	RP11-528I4.2	5.08	4.46e-07	4.86e-05	0.19	0.16	Personality dimensions;	chr4:55368239	chr4:55547112~55547889:+
BRCA	cis	rs9341808	0.69	rs3805926	ENSG00000272129.1	RP11-250B2.6	5.08	4.46e-07	4.86e-05	0.2	0.16	Sitting height ratio;	chr6:80169563	chr6:80355424~80356859:+
BRCA	cis	rs7246657	0.551	rs10407224	ENSG00000267422.1	CTD-2554C21.1	-5.08	4.46e-07	4.86e-05	-0.26	-0.16	Coronary artery calcification;	chr19:37160568	chr19:37779686~37792865:+
BRCA	cis	rs6600671	0.934	rs12060031	ENSG00000275538.1	RNVU1-19	-5.08	4.47e-07	4.86e-05	-0.19	-0.16	Hip geometry;	chr1:121501652	chr1:120850819~120850985:-
BRCA	cis	rs73222236	0.817	rs7629905	ENSG00000273486.1	RP11-731C17.2	5.08	4.47e-07	4.86e-05	0.17	0.16	Coronary artery disease;	chr3:136620847	chr3:136837338~136839021:-
BRCA	cis	rs73222236	0.817	rs9828068	ENSG00000273486.1	RP11-731C17.2	5.08	4.47e-07	4.86e-05	0.17	0.16	Coronary artery disease;	chr3:136623860	chr3:136837338~136839021:-
BRCA	cis	rs11051970	0.592	rs11051987	ENSG00000274964.1	RP11-817I4.1	-5.08	4.47e-07	4.86e-05	-0.22	-0.16	Response to tocilizumab in rheumatoid arthritis;	chr12:32402472	chr12:32339368~32340724:+
BRCA	cis	rs9467773	0.62	rs2504571	ENSG00000124549.13	BTN2A3P	5.08	4.47e-07	4.87e-05	0.15	0.16	Intelligence (multi-trait analysis);	chr6:26643207	chr6:26421391~26432383:+
BRCA	cis	rs1707322	1	rs4660331	ENSG00000234329.1	RP11-767N6.2	5.08	4.48e-07	4.88e-05	0.16	0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45993111	chr1:45651039~45651826:-
BRCA	cis	rs1707322	1	rs12097799	ENSG00000234329.1	RP11-767N6.2	5.08	4.48e-07	4.88e-05	0.16	0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45994214	chr1:45651039~45651826:-
BRCA	cis	rs6840360	0.642	rs2724574	ENSG00000251611.1	RP11-610P16.1	5.08	4.48e-07	4.88e-05	0.14	0.16	Intelligence (multi-trait analysis);	chr4:151460648	chr4:151407551~151408835:-
BRCA	cis	rs13325613	0.915	rs17284138	ENSG00000223552.1	RP11-24F11.2	-5.08	4.48e-07	4.88e-05	-0.35	-0.16	Monocyte count;	chr3:46290361	chr3:46364955~46407059:-
BRCA	cis	rs4835473	0.831	rs7689328	ENSG00000249741.2	RP11-673E1.3	-5.08	4.48e-07	4.88e-05	-0.17	-0.16	Immature fraction of reticulocytes;	chr4:143973768	chr4:143911514~143912053:-
BRCA	cis	rs4835473	0.831	rs7694353	ENSG00000249741.2	RP11-673E1.3	-5.08	4.48e-07	4.88e-05	-0.17	-0.16	Immature fraction of reticulocytes;	chr4:143973787	chr4:143911514~143912053:-
BRCA	cis	rs4072980	0.545	rs7528185	ENSG00000212541.1	RNU6-510P	5.08	4.48e-07	4.88e-05	0.21	0.16	Coronary artery disease;	chr1:37986387	chr1:37991462~37991569:+
BRCA	cis	rs8031584	0.918	rs34693097	ENSG00000270015.1	RP11-540B6.6	-5.08	4.49e-07	4.88e-05	-0.16	-0.16	Huntington's disease progression;	chr15:30961781	chr15:30926514~30928407:+
BRCA	cis	rs7119	0.717	rs11635567	ENSG00000259362.2	RP11-307C19.1	-5.08	4.49e-07	4.88e-05	-0.22	-0.16	Type 2 diabetes;	chr15:77527173	chr15:77525540~77534110:+
BRCA	cis	rs10844706	0.666	rs10844609	ENSG00000214776.8	RP11-726G1.1	5.08	4.49e-07	4.88e-05	0.19	0.16	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9723909	chr12:9467552~9576275:+
BRCA	cis	rs9650657	0.504	rs7813802	ENSG00000255046.1	RP11-297N6.4	-5.08	4.49e-07	4.89e-05	-0.18	-0.16	Neuroticism;	chr8:11176467	chr8:11797928~11802568:-
BRCA	cis	rs987724	0.515	rs453219	ENSG00000240875.4	LINC00886	-5.08	4.49e-07	4.89e-05	-0.23	-0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156856463	chr3:156747346~156817062:-
BRCA	cis	rs270601	0.661	rs10036208	ENSG00000233006.5	AC034220.3	5.08	4.49e-07	4.89e-05	0.12	0.16	Acylcarnitine levels;	chr5:132235630	chr5:132311285~132369916:-
BRCA	cis	rs2153535	0.58	rs9406170	ENSG00000251164.1	HULC	-5.08	4.49e-07	4.89e-05	-0.19	-0.16	Motion sickness;	chr6:8513920	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.58	rs9379222	ENSG00000251164.1	HULC	-5.08	4.49e-07	4.89e-05	-0.19	-0.16	Motion sickness;	chr6:8514555	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.58	rs9406172	ENSG00000251164.1	HULC	-5.08	4.49e-07	4.89e-05	-0.19	-0.16	Motion sickness;	chr6:8515231	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.58	rs9406174	ENSG00000251164.1	HULC	-5.08	4.49e-07	4.89e-05	-0.19	-0.16	Motion sickness;	chr6:8516531	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.58	rs2143356	ENSG00000251164.1	HULC	-5.08	4.49e-07	4.89e-05	-0.19	-0.16	Motion sickness;	chr6:8517442	chr6:8652137~8653846:+
BRCA	cis	rs6847067	0.644	rs12502409	ENSG00000180769.7	WDFY3-AS2	5.08	4.49e-07	4.89e-05	0.16	0.16	Oropharynx cancer;	chr4:84778426	chr4:84965682~85011277:+
BRCA	cis	rs1395	0.744	rs1975384	ENSG00000234072.1	AC074117.10	-5.08	4.49e-07	4.89e-05	-0.18	-0.16	Blood metabolite levels;	chr2:27319174	chr2:27356246~27367622:+
BRCA	cis	rs2277027	1	rs4579242	ENSG00000248544.2	CTB-47B11.3	5.08	4.49e-07	4.89e-05	0.19	0.16	Pulmonary function;Pulmonary function (smoking interaction);	chr5:157512490	chr5:157375741~157384950:-
BRCA	cis	rs807029	0.533	rs67692077	ENSG00000236662.1	RP11-108L7.4	5.08	4.5e-07	4.89e-05	0.2	0.16	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100980514	chr10:100980507~100985614:-
BRCA	cis	rs807029	0.533	rs12571302	ENSG00000236662.1	RP11-108L7.4	5.08	4.5e-07	4.89e-05	0.2	0.16	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100983006	chr10:100980507~100985614:-
BRCA	cis	rs807029	0.533	rs2863095	ENSG00000236662.1	RP11-108L7.4	5.08	4.5e-07	4.89e-05	0.2	0.16	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100986746	chr10:100980507~100985614:-
BRCA	cis	rs1707322	1	rs7553924	ENSG00000234329.1	RP11-767N6.2	5.08	4.5e-07	4.9e-05	0.16	0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45886952	chr1:45651039~45651826:-
BRCA	cis	rs1707322	1	rs4641257	ENSG00000234329.1	RP11-767N6.2	5.08	4.5e-07	4.9e-05	0.16	0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45887917	chr1:45651039~45651826:-
BRCA	cis	rs1707322	1	rs6693336	ENSG00000234329.1	RP11-767N6.2	5.08	4.5e-07	4.9e-05	0.16	0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45888923	chr1:45651039~45651826:-
BRCA	cis	rs2153535	0.58	rs9392220	ENSG00000251164.1	HULC	-5.08	4.5e-07	4.9e-05	-0.19	-0.16	Motion sickness;	chr6:8457713	chr6:8652137~8653846:+
BRCA	cis	rs62025270	0.593	rs7166540	ENSG00000259295.5	CSPG4P12	-5.08	4.5e-07	4.9e-05	-0.24	-0.16	Idiopathic pulmonary fibrosis;	chr15:85700854	chr15:85191438~85213905:+
BRCA	cis	rs1950832	0.689	rs11627839	ENSG00000258636.1	CTD-2298J14.2	-5.08	4.5e-07	4.9e-05	-0.17	-0.16	Urate levels in obese individuals;	chr14:41695101	chr14:41587861~41604856:-
BRCA	cis	rs115769866	0.569	rs2859358	ENSG00000204709.4	LINC01556	5.08	4.5e-07	4.9e-05	0.23	0.16	Bipolar disorder;	chr6:28505044	chr6:28943877~28944537:+
BRCA	cis	rs4671400	0.571	rs6738482	ENSG00000271889.1	RP11-493E12.1	-5.08	4.5e-07	4.9e-05	-0.23	-0.16	3-hydroxypropylmercapturic acid levels in smokers;	chr2:61267766	chr2:61151433~61162105:-
BRCA	cis	rs8114671	0.562	rs6088642	ENSG00000269202.1	RP4-614O4.12	-5.08	4.5e-07	4.9e-05	-0.16	-0.16	Height;	chr20:34895383	chr20:35201747~35203288:-
BRCA	cis	rs34286592	0.929	rs11863748	ENSG00000214725.6	CDIPT-AS1	-5.08	4.5e-07	4.9e-05	-0.26	-0.16	Multiple sclerosis;	chr16:29824267	chr16:29863593~29868053:+
BRCA	cis	rs4072980	0.545	rs7519947	ENSG00000212541.1	RNU6-510P	5.08	4.5e-07	4.9e-05	0.22	0.16	Coronary artery disease;	chr1:37982053	chr1:37991462~37991569:+
BRCA	cis	rs962856	0.964	rs2171175	ENSG00000236780.4	AC078941.1	5.08	4.51e-07	4.9e-05	0.19	0.16	Pancreatic cancer;	chr2:67413595	chr2:67123357~67215319:-
BRCA	cis	rs7178909	0.902	rs8033554	ENSG00000259677.1	RP11-493E3.1	5.08	4.51e-07	4.9e-05	0.18	0.16	Common traits (Other);	chr15:89898337	chr15:89876540~89877285:+
BRCA	cis	rs78487399	0.808	rs17406646	ENSG00000234936.1	AC010883.5	5.08	4.51e-07	4.91e-05	0.27	0.16	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43451478	chr2:43229573~43233394:+
BRCA	cis	rs13108904	0.875	rs1732099	ENSG00000196810.4	CTBP1-AS2	-5.08	4.51e-07	4.91e-05	-0.16	-0.16	Obesity-related traits;	chr4:1288908	chr4:1249300~1288291:+
BRCA	cis	rs2562456	0.833	rs2928211	ENSG00000268081.1	RP11-678G14.2	-5.08	4.51e-07	4.91e-05	-0.24	-0.16	Pain;	chr19:21358495	chr19:21554640~21569237:-
BRCA	cis	rs4718428	0.705	rs13220977	ENSG00000229180.5	GS1-124K5.11	-5.08	4.51e-07	4.91e-05	-0.15	-0.16	Corneal structure;	chr7:66872661	chr7:66526088~66542624:-
BRCA	cis	rs9473147	0.516	rs9296564	ENSG00000270761.1	RP11-385F7.1	-5.08	4.51e-07	4.91e-05	-0.16	-0.16	Platelet distribution width;Mean platelet volume;	chr6:47527023	chr6:47477243~47477572:-
BRCA	cis	rs7119	0.717	rs11630916	ENSG00000259362.2	RP11-307C19.1	-5.08	4.51e-07	4.91e-05	-0.21	-0.16	Type 2 diabetes;	chr15:77528989	chr15:77525540~77534110:+
BRCA	cis	rs6452524	0.618	rs1871203	ENSG00000281327.1	LINC01338	5.08	4.52e-07	4.91e-05	0.18	0.16	Hypertension (SNP x SNP interaction);	chr5:83059567	chr5:82850864~82859836:-
BRCA	cis	rs962856	1	rs6710832	ENSG00000236780.4	AC078941.1	5.08	4.52e-07	4.91e-05	0.2	0.16	Pancreatic cancer;	chr2:67374810	chr2:67123357~67215319:-
BRCA	cis	rs11955398	0.669	rs11952735	ENSG00000215032.2	GNL3LP1	5.08	4.52e-07	4.91e-05	0.19	0.16	Intelligence (multi-trait analysis);	chr5:60643319	chr5:60891935~60893577:-
BRCA	cis	rs1862618	0.641	rs2591954	ENSG00000271828.1	CTD-2310F14.1	-5.08	4.52e-07	4.91e-05	-0.19	-0.16	Initial pursuit acceleration;	chr5:56949217	chr5:56927874~56929573:+
BRCA	cis	rs6957923	0.655	rs10232644	ENSG00000234286.1	AC006026.13	-5.08	4.52e-07	4.91e-05	-0.18	-0.16	Height;	chr7:23552301	chr7:23680195~23680786:-
BRCA	cis	rs875971	0.862	rs2901152	ENSG00000236529.1	RP13-254B10.1	-5.08	4.52e-07	4.91e-05	-0.17	-0.16	Aortic root size;	chr7:66300017	chr7:65840212~65840596:+
BRCA	cis	rs11673344	0.542	rs1667380	ENSG00000226686.6	LINC01535	5.08	4.52e-07	4.91e-05	0.2	0.16	Obesity-related traits;	chr19:37001848	chr19:37251912~37265535:+
BRCA	cis	rs7577696	0.695	rs212749	ENSG00000272716.1	RP11-563N4.1	5.08	4.52e-07	4.91e-05	0.17	0.16	Inflammatory biomarkers;	chr2:32190908	chr2:32165046~32165757:-
BRCA	cis	rs6490294	0.528	rs78745958	ENSG00000226469.1	ADAM1B	5.08	4.52e-07	4.91e-05	0.28	0.16	Mean platelet volume;	chr12:111990367	chr12:111927018~111929017:+
BRCA	cis	rs4835473	0.663	rs4835115	ENSG00000249741.2	RP11-673E1.3	-5.08	4.52e-07	4.92e-05	-0.17	-0.16	Immature fraction of reticulocytes;	chr4:143979308	chr4:143911514~143912053:-
BRCA	cis	rs12477438	0.765	rs12470471	ENSG00000231822.1	AC019097.7	5.08	4.52e-07	4.92e-05	0.17	0.16	Chronic sinus infection;	chr2:99072678	chr2:99102018~99102752:+
BRCA	cis	rs9652601	0.676	rs9926615	ENSG00000274038.1	RP11-66H6.4	-5.08	4.52e-07	4.92e-05	-0.17	-0.16	Systemic lupus erythematosus;	chr16:11009303	chr16:11056556~11057034:+
BRCA	cis	rs875971	0.83	rs4718358	ENSG00000223473.2	GS1-124K5.3	5.08	4.52e-07	4.92e-05	0.12	0.16	Aortic root size;	chr7:66508681	chr7:66491049~66493566:-
BRCA	cis	rs801193	0.569	rs13226966	ENSG00000273448.1	RP11-166O4.6	5.08	4.53e-07	4.92e-05	0.14	0.16	Aortic root size;	chr7:66768636	chr7:67333047~67334383:+
BRCA	cis	rs1005277	0.579	rs1780122	ENSG00000263064.2	RP11-291L22.7	5.08	4.53e-07	4.92e-05	0.19	0.16	Extrinsic epigenetic age acceleration;	chr10:38240581	chr10:38448689~38448949:+
BRCA	cis	rs875971	0.789	rs7808013	ENSG00000273448.1	RP11-166O4.6	-5.08	4.53e-07	4.92e-05	-0.14	-0.16	Aortic root size;	chr7:66606209	chr7:67333047~67334383:+
BRCA	cis	rs2115630	0.875	rs8039472	ENSG00000259295.5	CSPG4P12	-5.08	4.53e-07	4.92e-05	-0.19	-0.16	P wave terminal force;	chr15:84818413	chr15:85191438~85213905:+
BRCA	cis	rs8098244	0.861	rs9962023	ENSG00000264745.1	TTC39C-AS1	-5.08	4.53e-07	4.92e-05	-0.2	-0.16	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23833905	chr18:23994213~24015339:-
BRCA	cis	rs1722141	0.598	rs2453849	ENSG00000229628.1	AC073115.7	5.08	4.53e-07	4.92e-05	0.21	0.16	Sitting height ratio;	chr7:45935066	chr7:45990905~46000898:+
BRCA	cis	rs7824557	0.583	rs2736306	ENSG00000154316.13	TDH	-5.08	4.53e-07	4.93e-05	-0.21	-0.16	Retinal vascular caliber;	chr8:11382253	chr8:11339637~11368452:+
BRCA	cis	rs8040855	0.599	rs8037195	ENSG00000259774.1	RP11-182J1.13	-5.08	4.53e-07	4.93e-05	-0.18	-0.16	Bulimia nervosa;	chr15:85181455	chr15:84422618~84425882:+
BRCA	cis	rs2243480	1	rs313832	ENSG00000275400.1	RP4-756H11.5	5.08	4.54e-07	4.93e-05	0.29	0.16	Diabetic kidney disease;	chr7:66085904	chr7:66553805~66554199:-
BRCA	cis	rs733592	0.723	rs10875766	ENSG00000273765.1	RP11-370I10.11	5.08	4.54e-07	4.93e-05	0.18	0.16	Plateletcrit;	chr12:48199797	chr12:48360920~48361377:+
BRCA	cis	rs4699052	0.662	rs1400363	ENSG00000248740.4	RP11-328K4.1	5.08	4.54e-07	4.93e-05	0.17	0.16	Testicular germ cell tumor;	chr4:103329565	chr4:103256159~103453658:+
BRCA	cis	rs1729951	0.575	rs75976	ENSG00000239213.4	NCK1-AS1	5.08	4.54e-07	4.94e-05	0.16	0.16	Neuroticism;	chr3:136981613	chr3:136841726~136862054:-
BRCA	cis	rs7914558	1	rs4917996	ENSG00000236937.2	PTGES3P4	5.08	4.54e-07	4.94e-05	0.2	0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103166072	chr10:102845595~102845950:+
BRCA	cis	rs7914558	1	rs6584540	ENSG00000236937.2	PTGES3P4	5.08	4.54e-07	4.94e-05	0.2	0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103167877	chr10:102845595~102845950:+
BRCA	cis	rs7914558	1	rs7081075	ENSG00000236937.2	PTGES3P4	5.08	4.54e-07	4.94e-05	0.2	0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103169434	chr10:102845595~102845950:+
BRCA	cis	rs7141336	1	rs7141114	ENSG00000258884.1	CTD-3035D6.2	5.08	4.55e-07	4.94e-05	0.2	0.16	Anxiety disorder;	chr14:90819690	chr14:90822365~90828128:-
BRCA	cis	rs7487075	0.554	rs7967629	ENSG00000257261.4	RP11-96H19.1	5.08	4.55e-07	4.94e-05	0.16	0.16	Itch intensity from mosquito bite;	chr12:46234824	chr12:46383679~46876159:+
BRCA	cis	rs4934494	0.677	rs11185801	ENSG00000240996.1	RP11-80H5.7	-5.08	4.55e-07	4.94e-05	-0.22	-0.16	Red blood cell count;	chr10:89618959	chr10:89694295~89697928:-
BRCA	cis	rs8180040	0.62	rs11917361	ENSG00000276925.1	RP11-708J19.3	5.08	4.55e-07	4.95e-05	0.18	0.16	Colorectal cancer;	chr3:47029007	chr3:47469777~47469987:+
BRCA	cis	rs10888838	0.938	rs11206304	ENSG00000198711.5	SSBP3-AS1	-5.08	4.55e-07	4.95e-05	-0.22	-0.16	Mitochondrial DNA levels;	chr1:54213646	chr1:54236440~54239063:+
BRCA	cis	rs10946940	0.632	rs9366698	ENSG00000220721.1	OR1F12	5.08	4.55e-07	4.95e-05	0.19	0.16	Systemic lupus erythematosus;	chr6:27704256	chr6:28073316~28074233:+
BRCA	cis	rs832187	0.629	rs6798742	ENSG00000280620.1	SCAANT1	5.08	4.56e-07	4.95e-05	0.2	0.16	Schizophrenia;	chr3:63918083	chr3:63911518~63911772:-
BRCA	cis	rs9467773	0.534	rs34453863	ENSG00000124549.13	BTN2A3P	5.08	4.56e-07	4.95e-05	0.16	0.16	Intelligence (multi-trait analysis);	chr6:26627777	chr6:26421391~26432383:+
BRCA	cis	rs4706831	0.625	rs638056	ENSG00000272129.1	RP11-250B2.6	-5.08	4.56e-07	4.95e-05	-0.19	-0.16	Joint mobility (Beighton score);	chr6:80271091	chr6:80355424~80356859:+
BRCA	cis	rs1669338	0.588	rs3864050	ENSG00000271870.1	RP11-97C16.1	5.08	4.56e-07	4.96e-05	0.2	0.16	White matter integrity;	chr3:3145085	chr3:3152942~3153435:+
BRCA	cis	rs7608910	0.93	rs4560096	ENSG00000271889.1	RP11-493E12.1	5.08	4.56e-07	4.96e-05	0.2	0.16	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;	chr2:60977782	chr2:61151433~61162105:-
BRCA	cis	rs12701220	0.894	rs8591	ENSG00000229043.2	AC091729.9	-5.08	4.56e-07	4.96e-05	-0.24	-0.16	Bronchopulmonary dysplasia;	chr7:997163	chr7:1160374~1165267:+
BRCA	cis	rs7923609	0.871	rs12245149	ENSG00000232075.1	MRPL35P2	5.08	4.56e-07	4.96e-05	0.19	0.16	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63561387	chr10:63634317~63634827:-
BRCA	cis	rs4780355	1	rs4780355	ENSG00000262636.1	CTD-3088G3.4	5.08	4.57e-07	4.96e-05	0.22	0.16	Crohn's disease and psoriasis;	chr16:11254001	chr16:11380859~11381118:-
BRCA	cis	rs8098244	0.964	rs1109950	ENSG00000264745.1	TTC39C-AS1	5.08	4.57e-07	4.96e-05	0.22	0.16	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23834146	chr18:23994213~24015339:-
BRCA	cis	rs2531992	0.858	rs2230742	ENSG00000262888.1	RP11-462G12.2	5.08	4.57e-07	4.96e-05	0.23	0.16	Waist circumference;	chr16:3966675	chr16:3931217~3946305:-
BRCA	cis	rs8098244	0.52	rs12955607	ENSG00000264745.1	TTC39C-AS1	-5.08	4.57e-07	4.96e-05	-0.18	-0.16	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23677671	chr18:23994213~24015339:-
BRCA	cis	rs7976269	0.609	rs10771474	ENSG00000275476.1	RP11-996F15.4	5.08	4.57e-07	4.97e-05	0.18	0.16	Male-pattern baldness;	chr12:29068776	chr12:29277397~29277882:-
BRCA	cis	rs3764021	0.527	rs10772062	ENSG00000256673.1	RP11-599J14.2	-5.08	4.57e-07	4.97e-05	-0.19	-0.16	Type 1 diabetes;	chr12:9712561	chr12:9398355~9414851:-
BRCA	cis	rs2562456	0.561	rs12610883	ENSG00000268535.1	RP11-420K14.3	5.08	4.58e-07	4.97e-05	0.21	0.16	Pain;	chr19:21567257	chr19:21709522~21710191:+
BRCA	cis	rs2562456	0.837	rs11085462	ENSG00000268535.1	RP11-420K14.3	5.08	4.58e-07	4.97e-05	0.21	0.16	Pain;	chr19:21567449	chr19:21709522~21710191:+
BRCA	cis	rs10911232	0.507	rs10911212	ENSG00000224468.3	RP11-181K3.4	-5.08	4.58e-07	4.97e-05	-0.17	-0.16	Hypertriglyceridemia;	chr1:183055334	chr1:183138402~183141282:-
BRCA	cis	rs875971	0.929	rs10950041	ENSG00000223473.2	GS1-124K5.3	5.08	4.58e-07	4.98e-05	0.12	0.16	Aortic root size;	chr7:66508888	chr7:66491049~66493566:-
BRCA	cis	rs73222236	0.782	rs9820513	ENSG00000273486.1	RP11-731C17.2	5.08	4.58e-07	4.98e-05	0.17	0.16	Coronary artery disease;	chr3:136627450	chr3:136837338~136839021:-
BRCA	cis	rs13325613	0.915	rs9882616	ENSG00000223552.1	RP11-24F11.2	-5.08	4.58e-07	4.98e-05	-0.32	-0.16	Monocyte count;	chr3:46276060	chr3:46364955~46407059:-
BRCA	cis	rs2251381	0.778	rs722013	ENSG00000176054.6	RPL23P2	5.08	4.58e-07	4.98e-05	0.18	0.16	Selective IgA deficiency;	chr21:29176924	chr21:28997613~28998033:-
BRCA	cis	rs12681366	0.839	rs2930964	ENSG00000253175.1	RP11-267M23.6	5.08	4.58e-07	4.98e-05	0.19	0.16	Nonsyndromic cleft lip with cleft palate;	chr8:94435906	chr8:94565036~94565715:+
BRCA	cis	rs2839186	0.77	rs2839171	ENSG00000228137.1	AP001469.7	-5.08	4.59e-07	4.98e-05	-0.16	-0.16	Testicular germ cell tumor;	chr21:46253333	chr21:46246890~46247682:+
BRCA	cis	rs6772849	0.93	rs7639400	ENSG00000242551.2	POU5F1P6	-5.07	4.59e-07	4.98e-05	-0.2	-0.16	Monocyte percentage of white cells;Monocyte count;	chr3:128604513	chr3:128674735~128677005:-
BRCA	cis	rs801193	0.569	rs11761542	ENSG00000273448.1	RP11-166O4.6	5.07	4.6e-07	4.99e-05	0.14	0.16	Aortic root size;	chr7:66753209	chr7:67333047~67334383:+
BRCA	cis	rs17685	0.672	rs1639618	ENSG00000280388.1	RP11-229D13.3	-5.07	4.6e-07	4.99e-05	-0.16	-0.16	Coffee consumption (cups per day);Coffee consumption;	chr7:76072669	chr7:76043977~76045963:-
BRCA	cis	rs17685	0.753	rs1637044	ENSG00000280388.1	RP11-229D13.3	-5.07	4.6e-07	4.99e-05	-0.16	-0.16	Coffee consumption (cups per day);Coffee consumption;	chr7:76074426	chr7:76043977~76045963:-
BRCA	cis	rs17685	0.712	rs1639620	ENSG00000280388.1	RP11-229D13.3	-5.07	4.6e-07	4.99e-05	-0.16	-0.16	Coffee consumption (cups per day);Coffee consumption;	chr7:76074772	chr7:76043977~76045963:-
BRCA	cis	rs875971	0.825	rs7384021	ENSG00000273448.1	RP11-166O4.6	-5.07	4.6e-07	4.99e-05	-0.14	-0.16	Aortic root size;	chr7:66612917	chr7:67333047~67334383:+
BRCA	cis	rs12477438	0.765	rs1453564	ENSG00000231822.1	AC019097.7	-5.07	4.6e-07	4.99e-05	-0.17	-0.16	Chronic sinus infection;	chr2:98947965	chr2:99102018~99102752:+
BRCA	cis	rs6430585	0.583	rs4988163	ENSG00000224043.6	CCNT2-AS1	-5.07	4.6e-07	5e-05	-0.26	-0.16	Corneal structure;	chr2:135870551	chr2:134735464~134918710:-
BRCA	cis	rs8048589	0.527	rs9939383	ENSG00000175604.2	RP11-276H1.3	-5.07	4.6e-07	5e-05	-0.23	-0.16	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);	chr16:12082263	chr16:12086746~12090302:-
BRCA	cis	rs2303319	0.504	rs56384808	ENSG00000227403.1	AC009299.3	5.07	4.6e-07	5e-05	0.37	0.16	Cognitive function;	chr2:161491244	chr2:161244739~161249050:+
BRCA	cis	rs2303319	0.504	rs12463509	ENSG00000227403.1	AC009299.3	5.07	4.6e-07	5e-05	0.37	0.16	Cognitive function;	chr2:161491437	chr2:161244739~161249050:+
BRCA	cis	rs2562456	0.876	rs11085467	ENSG00000268535.1	RP11-420K14.3	5.07	4.61e-07	5e-05	0.21	0.16	Pain;	chr19:21569041	chr19:21709522~21710191:+
BRCA	cis	rs9287719	0.967	rs7563894	ENSG00000243819.4	RN7SL832P	5.07	4.61e-07	5e-05	0.15	0.16	Prostate cancer;	chr2:10614523	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.967	rs7566767	ENSG00000243819.4	RN7SL832P	5.07	4.61e-07	5e-05	0.15	0.16	Prostate cancer;	chr2:10614537	chr2:10690344~10692099:+
BRCA	cis	rs748404	0.666	rs12906017	ENSG00000205771.5	CATSPER2P1	-5.07	4.61e-07	5.01e-05	-0.24	-0.16	Lung cancer;	chr15:43504710	chr15:43726918~43747094:-
BRCA	cis	rs13113518	1	rs11133388	ENSG00000223305.1	RN7SKP30	-5.07	4.61e-07	5.01e-05	-0.19	-0.16	Height;	chr4:55477866	chr4:55540502~55540835:-
BRCA	cis	rs1387259	0.929	rs11168460	ENSG00000257735.1	RP11-370I10.6	5.07	4.61e-07	5.01e-05	0.2	0.16	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48203582	chr12:48350945~48442411:+
BRCA	cis	rs6441961	0.501	rs4683199	ENSG00000223552.1	RP11-24F11.2	-5.07	4.62e-07	5.01e-05	-0.19	-0.16	Celiac disease;	chr3:46287886	chr3:46364955~46407059:-
BRCA	cis	rs73193808	0.901	rs2832271	ENSG00000236056.1	GAPDHP14	-5.07	4.62e-07	5.01e-05	-0.22	-0.16	Coronary artery disease;	chr21:29223865	chr21:29222321~29223257:+
BRCA	cis	rs10844706	0.699	rs10844620	ENSG00000214776.8	RP11-726G1.1	5.07	4.62e-07	5.01e-05	0.19	0.16	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9729910	chr12:9467552~9576275:+
BRCA	cis	rs2179367	0.632	rs9285520	ENSG00000223701.3	RAET1E-AS1	-5.07	4.62e-07	5.02e-05	-0.22	-0.16	Dupuytren's disease;	chr6:149372001	chr6:149884431~149919508:+
BRCA	cis	rs2179367	0.632	rs9322179	ENSG00000268592.3	RAET1E-AS1	5.07	4.62e-07	5.02e-05	0.22	0.16	Dupuytren's disease;	chr6:149418664	chr6:149863494~149919507:+
BRCA	cis	rs6832769	1	rs4580704	ENSG00000272969.1	RP11-528I4.2	-5.07	4.62e-07	5.02e-05	-0.19	-0.16	Personality dimensions;	chr4:55460540	chr4:55547112~55547889:+
BRCA	cis	rs6163	0.588	rs10786706	ENSG00000236937.2	PTGES3P4	5.07	4.62e-07	5.02e-05	0.19	0.16	Waist circumference;Hip circumference;	chr10:102740902	chr10:102845595~102845950:+
BRCA	cis	rs4819052	0.851	rs2838864	ENSG00000184274.3	LINC00315	5.07	4.62e-07	5.02e-05	0.21	0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45291559	chr21:45300245~45305257:-
BRCA	cis	rs62025270	0.632	rs10520594	ENSG00000259295.5	CSPG4P12	5.07	4.63e-07	5.02e-05	0.25	0.16	Idiopathic pulmonary fibrosis;	chr15:85585410	chr15:85191438~85213905:+
BRCA	cis	rs250585	1	rs488131	ENSG00000260136.4	CTD-2270L9.4	-5.07	4.63e-07	5.02e-05	-0.18	-0.16	Egg allergy;	chr16:23463819	chr16:23452758~23457606:+
BRCA	cis	rs12468226	1	rs7565875	ENSG00000226261.1	AC064836.3	5.07	4.63e-07	5.02e-05	0.25	0.16	Urate levels;	chr2:202516412	chr2:202336024~202336727:-
BRCA	cis	rs2562456	0.917	rs2650825	ENSG00000268535.1	RP11-420K14.3	5.07	4.63e-07	5.02e-05	0.23	0.16	Pain;	chr19:21516423	chr19:21709522~21710191:+
BRCA	cis	rs9840812	0.769	rs483465	ENSG00000239213.4	NCK1-AS1	5.07	4.63e-07	5.02e-05	0.19	0.16	Fibrinogen levels;	chr3:136329135	chr3:136841726~136862054:-
BRCA	cis	rs9308731	0.863	rs17558117	ENSG00000227992.1	AC108463.2	-5.07	4.63e-07	5.03e-05	-0.18	-0.16	Chronic lymphocytic leukemia;	chr2:111183419	chr2:111203964~111206215:-
BRCA	cis	rs7200543	0.961	rs1741	ENSG00000260735.1	RP11-72I8.1	-5.07	4.63e-07	5.03e-05	-0.18	-0.16	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15036494	chr16:15094411~15109197:+
BRCA	cis	rs2638953	0.925	rs11049567	ENSG00000247934.4	RP11-967K21.1	5.07	4.64e-07	5.03e-05	0.21	0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28385502	chr12:28163298~28190738:-
BRCA	cis	rs3768617	0.51	rs2027078	ENSG00000224468.3	RP11-181K3.4	-5.07	4.64e-07	5.03e-05	-0.17	-0.16	Fuchs's corneal dystrophy;	chr1:183104343	chr1:183138402~183141282:-
BRCA	cis	rs3768617	0.565	rs2027080	ENSG00000224468.3	RP11-181K3.4	-5.07	4.64e-07	5.03e-05	-0.17	-0.16	Fuchs's corneal dystrophy;	chr1:183105280	chr1:183138402~183141282:-
BRCA	cis	rs875971	0.545	rs6460276	ENSG00000232546.1	RP11-458F8.1	5.07	4.64e-07	5.03e-05	0.15	0.16	Aortic root size;	chr7:66182290	chr7:66848496~66858136:+
BRCA	cis	rs7617773	0.817	rs3731497	ENSG00000199476.1	Y_RNA	-5.07	4.64e-07	5.03e-05	-0.23	-0.16	Coronary artery disease;	chr3:48185063	chr3:48288587~48288694:+
BRCA	cis	rs2834288	0.7	rs731059	ENSG00000273102.1	AP000569.9	-5.07	4.64e-07	5.04e-05	-0.18	-0.16	Gut microbiota (bacterial taxa);	chr21:33902813	chr21:33967101~33968573:-
BRCA	cis	rs2834288	0.7	rs731061	ENSG00000273102.1	AP000569.9	-5.07	4.64e-07	5.04e-05	-0.18	-0.16	Gut microbiota (bacterial taxa);	chr21:33902937	chr21:33967101~33968573:-
BRCA	cis	rs2904967	0.852	rs667341	ENSG00000255200.1	AP003068.18	5.07	4.64e-07	5.04e-05	0.26	0.16	Mean corpuscular volume;	chr11:65282711	chr11:65174117~65176470:-
BRCA	cis	rs1075265	0.572	rs2193682	ENSG00000235937.1	AC008280.1	5.07	4.65e-07	5.04e-05	0.18	0.16	Chronotype;Morning vs. evening chronotype;	chr2:53695119	chr2:54029552~54030682:-
BRCA	cis	rs736408	0.527	rs2336147	ENSG00000243224.1	RP5-1157M23.2	-5.07	4.65e-07	5.04e-05	-0.16	-0.16	Bipolar disorder;	chr3:52592427	chr3:52239258~52241097:+
BRCA	cis	rs875971	0.862	rs6460307	ENSG00000236529.1	RP13-254B10.1	5.07	4.65e-07	5.04e-05	0.17	0.16	Aortic root size;	chr7:66595884	chr7:65840212~65840596:+
BRCA	cis	rs2562456	0.917	rs6511256	ENSG00000268658.4	LINC00664	-5.07	4.65e-07	5.05e-05	-0.25	-0.16	Pain;	chr19:21510513	chr19:21483374~21503238:+
BRCA	cis	rs1707322	0.929	rs785500	ENSG00000234329.1	RP11-767N6.2	-5.07	4.65e-07	5.05e-05	-0.16	-0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46127372	chr1:45651039~45651826:-
BRCA	cis	rs7818688	1	rs34700722	ENSG00000253528.2	RP11-347C18.4	-5.07	4.66e-07	5.05e-05	-0.23	-0.16	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95009648	chr8:94974573~94974853:-
BRCA	cis	rs7818688	1	rs4323442	ENSG00000253528.2	RP11-347C18.4	-5.07	4.66e-07	5.05e-05	-0.23	-0.16	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95010758	chr8:94974573~94974853:-
BRCA	cis	rs600231	0.719	rs7114809	ENSG00000173727.10	CMB9-22P13.1	5.07	4.66e-07	5.05e-05	0.2	0.16	Bone mineral density;	chr11:65483973	chr11:65455258~65466720:+
BRCA	cis	rs11051970	0.559	rs4316592	ENSG00000274964.1	RP11-817I4.1	-5.07	4.66e-07	5.05e-05	-0.21	-0.16	Response to tocilizumab in rheumatoid arthritis;	chr12:32331076	chr12:32339368~32340724:+
BRCA	cis	rs13108904	0.901	rs12642410	ENSG00000254094.1	AC078852.1	-5.07	4.66e-07	5.05e-05	-0.18	-0.16	Obesity-related traits;	chr4:1314621	chr4:1356581~1358075:+
BRCA	cis	rs875971	0.929	rs6970860	ENSG00000223473.2	GS1-124K5.3	5.07	4.66e-07	5.06e-05	0.12	0.16	Aortic root size;	chr7:66511647	chr7:66491049~66493566:-
BRCA	cis	rs5742933	0.948	rs5743063	ENSG00000253559.1	OSGEPL1-AS1	5.07	4.66e-07	5.06e-05	0.2	0.16	Ferritin levels;	chr2:189829723	chr2:189762704~189765556:+
BRCA	cis	rs6840360	0.642	rs1470280	ENSG00000251611.1	RP11-610P16.1	-5.07	4.66e-07	5.06e-05	-0.14	-0.16	Intelligence (multi-trait analysis);	chr4:151510618	chr4:151407551~151408835:-
BRCA	cis	rs4604234	0.522	rs79603875	ENSG00000272129.1	RP11-250B2.6	-5.07	4.66e-07	5.06e-05	-0.39	-0.16	Cancer;	chr6:80243177	chr6:80355424~80356859:+
BRCA	cis	rs7914558	1	rs67908413	ENSG00000236937.2	PTGES3P4	5.07	4.66e-07	5.06e-05	0.2	0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103005232	chr10:102845595~102845950:+
BRCA	cis	rs3760982	0.565	rs3786956	ENSG00000267058.1	RP11-15A1.3	-5.07	4.67e-07	5.06e-05	-0.19	-0.16	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43782677	chr19:43891804~43901805:-
BRCA	cis	rs2153535	0.58	rs6597334	ENSG00000251164.1	HULC	-5.07	4.67e-07	5.06e-05	-0.19	-0.16	Motion sickness;	chr6:8504546	chr6:8652137~8653846:+
BRCA	cis	rs34286592	0.929	rs1045968	ENSG00000214725.6	CDIPT-AS1	-5.07	4.67e-07	5.06e-05	-0.27	-0.16	Multiple sclerosis;	chr16:29815044	chr16:29863593~29868053:+
BRCA	cis	rs13126694	0.71	rs4631100	ENSG00000251429.1	RP11-597D13.7	5.07	4.67e-07	5.06e-05	0.15	0.16	Blood osmolality (transformed sodium);	chr4:157991162	chr4:158270378~158278676:+
BRCA	cis	rs7200543	0.883	rs4985148	ENSG00000260735.1	RP11-72I8.1	-5.07	4.67e-07	5.06e-05	-0.18	-0.16	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15053931	chr16:15094411~15109197:+
BRCA	cis	rs62025270	0.688	rs62025297	ENSG00000202081.1	RNU6-1280P	-5.07	4.67e-07	5.06e-05	-0.23	-0.16	Idiopathic pulmonary fibrosis;	chr15:85773708	chr15:85651522~85651628:-
BRCA	cis	rs1552244	0.572	rs17032426	ENSG00000232901.1	CYCSP10	5.07	4.67e-07	5.06e-05	0.24	0.16	Alzheimer's disease;	chr3:10125428	chr3:10000647~10000940:-
BRCA	cis	rs11955398	0.521	rs4298206	ENSG00000215032.2	GNL3LP1	-5.07	4.67e-07	5.07e-05	-0.19	-0.16	Intelligence (multi-trait analysis);	chr5:60716408	chr5:60891935~60893577:-
BRCA	cis	rs2243480	1	rs160643	ENSG00000228409.4	CCT6P1	5.07	4.67e-07	5.07e-05	0.2	0.16	Diabetic kidney disease;	chr7:66093235	chr7:65751142~65763354:+
BRCA	cis	rs2574985	0.739	rs3011788	ENSG00000231345.3	BEND3P1	-5.07	4.67e-07	5.07e-05	-0.26	-0.16	Subjective well-being;	chr10:50539093	chr10:50655967~50660472:+
BRCA	cis	rs4908768	0.539	rs6675443	ENSG00000232912.4	RP5-1115A15.1	5.07	4.68e-07	5.07e-05	0.15	0.16	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8591523	chr1:8424645~8434838:+
BRCA	cis	rs73222236	0.825	rs59931907	ENSG00000273486.1	RP11-731C17.2	5.07	4.68e-07	5.07e-05	0.17	0.16	Coronary artery disease;	chr3:136646255	chr3:136837338~136839021:-
BRCA	cis	rs13113518	1	rs3805146	ENSG00000223305.1	RN7SKP30	5.07	4.68e-07	5.07e-05	0.19	0.16	Height;	chr4:55436985	chr4:55540502~55540835:-
BRCA	cis	rs13113518	1	rs11133378	ENSG00000223305.1	RN7SKP30	5.07	4.68e-07	5.07e-05	0.19	0.16	Height;	chr4:55439472	chr4:55540502~55540835:-
BRCA	cis	rs13113518	1	rs11942279	ENSG00000223305.1	RN7SKP30	5.07	4.68e-07	5.07e-05	0.19	0.16	Height;	chr4:55439652	chr4:55540502~55540835:-
BRCA	cis	rs2708977	0.73	rs596069	ENSG00000237510.6	AC008268.2	5.07	4.68e-07	5.07e-05	0.2	0.16	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96410905	chr2:95789654~95800166:+
BRCA	cis	rs7772486	0.686	rs9390357	ENSG00000270638.1	RP3-466P17.1	5.07	4.68e-07	5.07e-05	0.18	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145808211	chr6:145735570~145737218:+
BRCA	cis	rs4700393	0.52	rs6449484	ENSG00000215032.2	GNL3LP1	-5.07	4.68e-07	5.07e-05	-0.21	-0.16	Intelligence (multi-trait analysis);	chr5:60699603	chr5:60891935~60893577:-
BRCA	cis	rs9467773	0.62	rs2101581	ENSG00000124549.13	BTN2A3P	5.07	4.68e-07	5.07e-05	0.15	0.16	Intelligence (multi-trait analysis);	chr6:26622541	chr6:26421391~26432383:+
BRCA	cis	rs6490294	0.528	rs77030808	ENSG00000226469.1	ADAM1B	5.07	4.68e-07	5.07e-05	0.27	0.16	Mean platelet volume;	chr12:111891224	chr12:111927018~111929017:+
BRCA	cis	rs12893668	0.543	rs1799796	ENSG00000269958.1	RP11-73M18.8	5.07	4.68e-07	5.07e-05	0.18	0.16	Reticulocyte count;	chr14:103699590	chr14:103696353~103697163:+
BRCA	cis	rs2638953	0.925	rs11049545	ENSG00000247934.4	RP11-967K21.1	-5.07	4.69e-07	5.08e-05	-0.21	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28344965	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.962	rs11049547	ENSG00000247934.4	RP11-967K21.1	-5.07	4.69e-07	5.08e-05	-0.21	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28346945	chr12:28163298~28190738:-
BRCA	cis	rs9545047	0.604	rs9565487	ENSG00000227354.5	RBM26-AS1	-5.07	4.69e-07	5.08e-05	-0.17	-0.16	Schizophrenia;	chr13:79332742	chr13:79406309~79424328:+
BRCA	cis	rs1552244	0.572	rs57268864	ENSG00000232901.1	CYCSP10	5.07	4.69e-07	5.08e-05	0.24	0.16	Alzheimer's disease;	chr3:10122549	chr3:10000647~10000940:-
BRCA	cis	rs7674212	0.865	rs13149311	ENSG00000251288.2	RP11-10L12.2	-5.07	4.69e-07	5.08e-05	-0.19	-0.16	Type 2 diabetes;	chr4:103056543	chr4:102751401~102752641:+
BRCA	cis	rs2051773	0.567	rs58047221	ENSG00000184669.7	OR7E14P	-5.07	4.69e-07	5.09e-05	-0.24	-0.16	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);	chr11:17035087	chr11:17013998~17053024:+
BRCA	cis	rs2732480	0.5	rs1552550	ENSG00000257735.1	RP11-370I10.6	5.07	4.69e-07	5.09e-05	0.19	0.16	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48249568	chr12:48350945~48442411:+
BRCA	cis	rs2732480	0.5	rs2450991	ENSG00000257735.1	RP11-370I10.6	5.07	4.69e-07	5.09e-05	0.19	0.16	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48257838	chr12:48350945~48442411:+
BRCA	cis	rs11051970	0.885	rs7309692	ENSG00000274964.1	RP11-817I4.1	-5.07	4.69e-07	5.09e-05	-0.18	-0.16	Response to tocilizumab in rheumatoid arthritis;	chr12:32385246	chr12:32339368~32340724:+
BRCA	cis	rs2235642	0.717	rs2236269	ENSG00000280231.1	LA16c-380F5.3	-5.07	4.69e-07	5.09e-05	-0.2	-0.16	Coronary artery disease;	chr16:1602613	chr16:1553655~1554130:-
BRCA	cis	rs2732480	0.5	rs11168468	ENSG00000226413.2	OR8T1P	5.07	4.7e-07	5.09e-05	0.21	0.16	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48218682	chr12:48442030~48442947:-
BRCA	cis	rs13113518	0.812	rs7667741	ENSG00000272969.1	RP11-528I4.2	5.07	4.7e-07	5.09e-05	0.18	0.16	Height;	chr4:55544621	chr4:55547112~55547889:+
BRCA	cis	rs12681366	0.801	rs12682524	ENSG00000253175.1	RP11-267M23.6	5.07	4.7e-07	5.09e-05	0.19	0.16	Nonsyndromic cleft lip with cleft palate;	chr8:94472071	chr8:94565036~94565715:+
BRCA	cis	rs2732480	0.577	rs2634681	ENSG00000257735.1	RP11-370I10.6	-5.07	4.7e-07	5.09e-05	-0.18	-0.16	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48339301	chr12:48350945~48442411:+
BRCA	cis	rs17772222	0.653	rs1346996	ENSG00000258789.1	RP11-507K2.3	-5.07	4.7e-07	5.1e-05	-0.17	-0.16	Coronary artery calcification;	chr14:88507174	chr14:88551597~88552493:+
BRCA	cis	rs699371	0.525	rs7156302	ENSG00000270000.1	RP3-449M8.9	5.07	4.7e-07	5.1e-05	0.18	0.16	Height;	chr14:74428260	chr14:74471930~74472360:-
BRCA	cis	rs7577696	0.962	rs12992743	ENSG00000272716.1	RP11-563N4.1	-5.07	4.7e-07	5.1e-05	-0.17	-0.16	Inflammatory biomarkers;	chr2:32075500	chr2:32165046~32165757:-
BRCA	cis	rs7308116	0.546	rs60908257	ENSG00000274395.1	RP11-554D14.8	-5.07	4.71e-07	5.1e-05	-0.19	-0.16	Pelvic organ prolapse (moderate/severe);	chr12:107813431	chr12:107835541~107836555:-
BRCA	cis	rs875971	0.862	rs6947339	ENSG00000273448.1	RP11-166O4.6	5.07	4.71e-07	5.1e-05	0.15	0.16	Aortic root size;	chr7:66423483	chr7:67333047~67334383:+
BRCA	cis	rs957448	0.554	rs72674877	ENSG00000261437.1	RP11-22C11.2	5.07	4.71e-07	5.1e-05	0.15	0.16	Nonsyndromic cleft lip with cleft palate;	chr8:94580479	chr8:94637285~94639467:-
BRCA	cis	rs10911251	0.546	rs10911267	ENSG00000224468.3	RP11-181K3.4	-5.07	4.71e-07	5.1e-05	-0.17	-0.16	Colorectal cancer;	chr1:183146188	chr1:183138402~183141282:-
BRCA	cis	rs17507216	1	rs17158413	ENSG00000255769.6	GOLGA2P10	-5.07	4.71e-07	5.1e-05	-0.21	-0.16	Excessive daytime sleepiness;	chr15:82566658	chr15:82472993~82513950:-
BRCA	cis	rs7267979	0.844	rs6115188	ENSG00000204556.4	CTD-2514C3.1	-5.07	4.71e-07	5.11e-05	-0.21	-0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25451534	chr20:26018832~26020684:+
BRCA	cis	rs7646881	1	rs73015655	ENSG00000240207.5	RP11-379F4.4	-5.07	4.72e-07	5.11e-05	-0.22	-0.16	Tetralogy of Fallot;	chr3:158734093	chr3:158732263~158784070:+
BRCA	cis	rs10510102	0.935	rs78525391	ENSG00000226864.1	ATE1-AS1	5.07	4.72e-07	5.11e-05	0.28	0.16	Breast cancer;	chr10:121901102	chr10:121928312~121951965:+
BRCA	cis	rs10911232	0.507	rs4422969	ENSG00000224468.3	RP11-181K3.4	-5.07	4.72e-07	5.11e-05	-0.17	-0.16	Hypertriglyceridemia;	chr1:183051627	chr1:183138402~183141282:-
BRCA	cis	rs8114671	0.562	rs1018447	ENSG00000269202.1	RP4-614O4.12	5.07	4.72e-07	5.11e-05	0.15	0.16	Height;	chr20:34813904	chr20:35201747~35203288:-
BRCA	cis	rs1707322	1	rs4660334	ENSG00000234329.1	RP11-767N6.2	5.07	4.72e-07	5.11e-05	0.16	0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45996454	chr1:45651039~45651826:-
BRCA	cis	rs2153535	0.623	rs2152346	ENSG00000251164.1	HULC	-5.07	4.72e-07	5.12e-05	-0.19	-0.16	Motion sickness;	chr6:8454419	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.562	rs6901765	ENSG00000251164.1	HULC	-5.07	4.72e-07	5.12e-05	-0.19	-0.16	Motion sickness;	chr6:8455203	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.601	rs9502715	ENSG00000251164.1	HULC	-5.07	4.72e-07	5.12e-05	-0.19	-0.16	Motion sickness;	chr6:8455476	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.58	rs6912193	ENSG00000251164.1	HULC	-5.07	4.72e-07	5.12e-05	-0.19	-0.16	Motion sickness;	chr6:8456073	chr6:8652137~8653846:+
BRCA	cis	rs6570726	0.791	rs11155426	ENSG00000270638.1	RP3-466P17.1	5.07	4.72e-07	5.12e-05	0.18	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145495994	chr6:145735570~145737218:+
BRCA	cis	rs7225151	0.71	rs16954552	ENSG00000234327.6	AC012146.7	5.07	4.72e-07	5.12e-05	0.25	0.16	Alzheimer's disease (late onset);	chr17:5349219	chr17:5111468~5115004:+
BRCA	cis	rs7119038	0.509	rs10790261	ENSG00000255422.1	AP002954.4	-5.07	4.72e-07	5.12e-05	-0.23	-0.16	Sjögren's syndrome;	chr11:118709038	chr11:118704607~118750263:+
BRCA	cis	rs9287719	0.901	rs55861579	ENSG00000243819.4	RN7SL832P	5.07	4.73e-07	5.12e-05	0.15	0.16	Prostate cancer;	chr2:10623214	chr2:10690344~10692099:+
BRCA	cis	rs7267979	0.844	rs4423675	ENSG00000204556.4	CTD-2514C3.1	5.07	4.73e-07	5.12e-05	0.21	0.16	Liver enzyme levels (alkaline phosphatase);	chr20:25422142	chr20:26018832~26020684:+
BRCA	cis	rs13325613	0.915	rs13096905	ENSG00000223552.1	RP11-24F11.2	-5.07	4.73e-07	5.12e-05	-0.34	-0.16	Monocyte count;	chr3:46233275	chr3:46364955~46407059:-
BRCA	cis	rs13325613	0.915	rs13096808	ENSG00000223552.1	RP11-24F11.2	-5.07	4.73e-07	5.12e-05	-0.34	-0.16	Monocyte count;	chr3:46233415	chr3:46364955~46407059:-
BRCA	cis	rs9548119	0.696	rs4943544	ENSG00000223685.4	LINC00571	5.07	4.73e-07	5.13e-05	0.23	0.16	Self-rated health;	chr13:37900316	chr13:38050817~38143232:-
BRCA	cis	rs1707322	1	rs6682683	ENSG00000234329.1	RP11-767N6.2	5.07	4.73e-07	5.13e-05	0.16	0.16	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45876665	chr1:45651039~45651826:-
BRCA	cis	rs2179367	0.959	rs562428	ENSG00000268592.3	RAET1E-AS1	5.07	4.74e-07	5.13e-05	0.2	0.16	Dupuytren's disease;	chr6:149326389	chr6:149863494~149919507:+
BRCA	cis	rs4718428	0.607	rs66954441	ENSG00000229180.5	GS1-124K5.11	5.07	4.74e-07	5.13e-05	0.15	0.16	Corneal structure;	chr7:66904222	chr7:66526088~66542624:-
BRCA	cis	rs62103177	0.564	rs7228971	ENSG00000278000.1	AC139100.4	-5.07	4.74e-07	5.13e-05	-0.24	-0.16	Opioid sensitivity;	chr18:79978025	chr18:80161752~80162413:+
BRCA	cis	rs9840812	0.773	rs1154988	ENSG00000273486.1	RP11-731C17.2	-5.07	4.74e-07	5.14e-05	-0.19	-0.16	Fibrinogen levels;	chr3:136206349	chr3:136837338~136839021:-
BRCA	cis	rs9907295	1	rs11657908	ENSG00000271013.1	AC015849.15	-5.07	4.74e-07	5.14e-05	-0.23	-0.16	Fibroblast growth factor basic levels;	chr17:35908993	chr17:35912635~35918010:-
BRCA	cis	rs17711722	0.528	rs73138179	ENSG00000222364.1	RNU6-96P	-5.07	4.75e-07	5.14e-05	-0.19	-0.16	Calcium levels;	chr7:65829495	chr7:66395191~66395286:+
BRCA	cis	rs1075265	0.587	rs2949811	ENSG00000235937.1	AC008280.1	5.07	4.75e-07	5.14e-05	0.17	0.16	Chronotype;Morning vs. evening chronotype;	chr2:53797028	chr2:54029552~54030682:-
BRCA	cis	rs4713118	0.868	rs7756968	ENSG00000216901.1	AL022393.7	5.07	4.75e-07	5.15e-05	0.22	0.16	Parkinson's disease;	chr6:27767175	chr6:28176188~28176674:+
BRCA	cis	rs8180040	0.62	rs6767907	ENSG00000276925.1	RP11-708J19.3	5.07	4.75e-07	5.15e-05	0.18	0.16	Colorectal cancer;	chr3:47121171	chr3:47469777~47469987:+
BRCA	cis	rs897984	0.806	rs1046276	ENSG00000260911.2	RP11-196G11.2	-5.07	4.76e-07	5.15e-05	-0.14	-0.16	Dementia with Lewy bodies;	chr16:30903305	chr16:31043150~31049868:+
BRCA	cis	rs7772486	0.743	rs62433835	ENSG00000270638.1	RP3-466P17.1	-5.07	4.76e-07	5.16e-05	-0.18	-0.16	Lobe attachment (rater-scored or self-reported);	chr6:145711552	chr6:145735570~145737218:+
BRCA	cis	rs7772486	0.743	rs2092262	ENSG00000270638.1	RP3-466P17.1	-5.07	4.76e-07	5.16e-05	-0.18	-0.16	Lobe attachment (rater-scored or self-reported);	chr6:145715969	chr6:145735570~145737218:+
BRCA	cis	rs7772486	0.682	rs1337840	ENSG00000270638.1	RP3-466P17.1	-5.07	4.76e-07	5.16e-05	-0.18	-0.16	Lobe attachment (rater-scored or self-reported);	chr6:145721422	chr6:145735570~145737218:+
BRCA	cis	rs597539	0.652	rs10792001	ENSG00000261625.1	RP11-554A11.4	-5.07	4.76e-07	5.16e-05	-0.15	-0.16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68870269	chr11:69000765~69002048:-
BRCA	cis	rs597539	0.652	rs613128	ENSG00000261625.1	RP11-554A11.4	-5.07	4.76e-07	5.16e-05	-0.15	-0.16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68870590	chr11:69000765~69002048:-
BRCA	cis	rs1124769	0.57	rs1903588	ENSG00000259378.1	DCAF13P3	-5.07	4.76e-07	5.16e-05	-0.2	-0.16	Cognitive performance;	chr15:50851849	chr15:50944663~50945996:+
BRCA	cis	rs950880	0.767	rs6710885	ENSG00000234389.1	AC007278.3	5.07	4.77e-07	5.16e-05	0.14	0.16	Serum protein levels (sST2);	chr2:102361077	chr2:102438713~102440475:+
BRCA	cis	rs2708977	0.933	rs2708976	ENSG00000237510.6	AC008268.2	-5.07	4.77e-07	5.16e-05	-0.2	-0.16	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96518795	chr2:95789654~95800166:+
BRCA	cis	rs1075265	0.783	rs6545376	ENSG00000235937.1	AC008280.1	5.07	4.77e-07	5.17e-05	0.17	0.16	Chronotype;Morning vs. evening chronotype;	chr2:53987685	chr2:54029552~54030682:-
BRCA	cis	rs17674580	0.582	rs9947769	ENSG00000267193.4	RP11-116O18.3	5.07	4.78e-07	5.17e-05	0.17	0.16	Bladder cancer;	chr18:45757602	chr18:45669367~45747215:-
BRCA	cis	rs2179367	0.632	rs11155640	ENSG00000268592.3	RAET1E-AS1	5.07	4.78e-07	5.17e-05	0.23	0.16	Dupuytren's disease;	chr6:149323648	chr6:149863494~149919507:+
BRCA	cis	rs4650994	0.544	rs2811306	ENSG00000273384.1	RP5-1098D14.1	-5.07	4.78e-07	5.18e-05	-0.2	-0.16	HDL cholesterol;HDL cholesterol levels;	chr1:178630113	chr1:178651706~178652282:+
BRCA	cis	rs3733585	0.699	rs4621431	ENSG00000250413.1	RP11-448G15.1	5.07	4.79e-07	5.18e-05	0.21	0.16	Cleft plate (environmental tobacco smoke interaction);	chr4:9945966	chr4:10006482~10009725:+
BRCA	cis	rs4781563	0.667	rs12926685	ENSG00000242307.1	RPS26P52	-5.07	4.79e-07	5.18e-05	-0.18	-0.16	Bilirubin levels;	chr16:13915962	chr16:13922332~13922679:-
BRCA	cis	rs867371	0.502	rs1846908	ENSG00000259429.4	UBE2Q2P2	-5.07	4.79e-07	5.18e-05	-0.15	-0.16	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82230185	chr15:82355142~82420075:+
BRCA	cis	rs2665103	0.655	rs1501367	ENSG00000259429.4	UBE2Q2P2	-5.07	4.79e-07	5.18e-05	-0.15	-0.16	Intelligence (multi-trait analysis);	chr15:82230475	chr15:82355142~82420075:+
BRCA	cis	rs875971	0.862	rs7783779	ENSG00000236529.1	RP13-254B10.1	-5.07	4.79e-07	5.18e-05	-0.17	-0.16	Aortic root size;	chr7:66331639	chr7:65840212~65840596:+
BRCA	cis	rs58785573	0.624	rs2126526	ENSG00000231160.8	KLF3-AS1	-5.07	4.79e-07	5.18e-05	-0.15	-0.16	Lymphocyte percentage of white cells;	chr4:38617068	chr4:38612701~38664883:-
BRCA	cis	rs4835473	0.932	rs6847869	ENSG00000249741.2	RP11-673E1.3	-5.07	4.79e-07	5.19e-05	-0.17	-0.16	Immature fraction of reticulocytes;	chr4:143982881	chr4:143911514~143912053:-
BRCA	cis	rs4835473	0.897	rs6846984	ENSG00000249741.2	RP11-673E1.3	-5.07	4.79e-07	5.19e-05	-0.17	-0.16	Immature fraction of reticulocytes;	chr4:143983098	chr4:143911514~143912053:-
BRCA	cis	rs7618915	0.571	rs6805539	ENSG00000243224.1	RP5-1157M23.2	-5.07	4.79e-07	5.19e-05	-0.17	-0.16	Bipolar disorder;	chr3:52575694	chr3:52239258~52241097:+
BRCA	cis	rs62025270	0.688	rs62022939	ENSG00000259762.1	RP11-158M2.4	-5.07	4.79e-07	5.19e-05	-0.24	-0.16	Idiopathic pulmonary fibrosis;	chr15:85707651	chr15:85750336~85752901:-
BRCA	cis	rs6452524	0.618	rs3899556	ENSG00000281327.1	LINC01338	5.07	4.79e-07	5.19e-05	0.18	0.16	Hypertension (SNP x SNP interaction);	chr5:83067862	chr5:82850864~82859836:-
BRCA	cis	rs6840360	0.642	rs2724578	ENSG00000251611.1	RP11-610P16.1	-5.07	4.8e-07	5.19e-05	-0.14	-0.16	Intelligence (multi-trait analysis);	chr4:151446152	chr4:151407551~151408835:-
BRCA	cis	rs6840360	0.574	rs2709844	ENSG00000251611.1	RP11-610P16.1	-5.07	4.8e-07	5.19e-05	-0.14	-0.16	Intelligence (multi-trait analysis);	chr4:151447060	chr4:151407551~151408835:-
BRCA	cis	rs9473147	0.516	rs13212790	ENSG00000270761.1	RP11-385F7.1	-5.07	4.8e-07	5.19e-05	-0.16	-0.16	Platelet distribution width;Mean platelet volume;	chr6:47608631	chr6:47477243~47477572:-
BRCA	cis	rs7577696	0.554	rs34835885	ENSG00000272716.1	RP11-563N4.1	-5.07	4.8e-07	5.19e-05	-0.19	-0.16	Inflammatory biomarkers;	chr2:32100345	chr2:32165046~32165757:-
BRCA	cis	rs7772486	0.902	rs2777480	ENSG00000270638.1	RP3-466P17.1	5.07	4.8e-07	5.2e-05	0.18	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145988847	chr6:145735570~145737218:+
BRCA	cis	rs28472312	0.855	rs12448482	ENSG00000251417.2	RP11-1348G14.4	5.07	4.8e-07	5.2e-05	0.19	0.16	Intelligence (multi-trait analysis);	chr16:28826752	chr16:28802743~28817828:+
BRCA	cis	rs10411936	1	rs1870071	ENSG00000280332.1	CTD-2013N17.6	-5.07	4.81e-07	5.2e-05	-0.13	-0.16	Multiple sclerosis;White blood cell count;	chr19:16394295	chr19:16356329~16358327:-
BRCA	cis	rs62025270	0.632	rs1807309	ENSG00000259762.1	RP11-158M2.4	-5.07	4.81e-07	5.2e-05	-0.23	-0.16	Idiopathic pulmonary fibrosis;	chr15:85668526	chr15:85750336~85752901:-
BRCA	cis	rs11955398	0.502	rs295561	ENSG00000215032.2	GNL3LP1	5.07	4.81e-07	5.2e-05	0.19	0.16	Intelligence (multi-trait analysis);	chr5:61104390	chr5:60891935~60893577:-
BRCA	cis	rs1371614	0.569	rs486582	ENSG00000272148.1	RP11-195B17.1	5.07	4.81e-07	5.2e-05	0.17	0.16	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26881263	chr2:27062428~27062907:-
BRCA	cis	rs9307551	0.948	rs894055	ENSG00000250334.4	LINC00989	-5.07	4.81e-07	5.2e-05	-0.23	-0.16	Refractive error;	chr4:79621498	chr4:79492416~79576460:+
BRCA	cis	rs9907295	0.901	rs9907121	ENSG00000271013.1	AC015849.15	-5.07	4.81e-07	5.21e-05	-0.22	-0.16	Fibroblast growth factor basic levels;	chr17:35849074	chr17:35912635~35918010:-
BRCA	cis	rs61869271	0.805	rs7086663	ENSG00000236799.1	RP11-383C6.2	-5.07	4.81e-07	5.21e-05	-0.19	-0.16	Tonsillectomy;	chr10:115006577	chr10:114994657~114996593:+
BRCA	cis	rs9545047	0.625	rs9545109	ENSG00000227354.5	RBM26-AS1	5.07	4.82e-07	5.21e-05	0.17	0.16	Schizophrenia;	chr13:79413480	chr13:79406309~79424328:+
BRCA	cis	rs9545047	0.518	rs7328494	ENSG00000227354.5	RBM26-AS1	5.07	4.82e-07	5.21e-05	0.17	0.16	Schizophrenia;	chr13:79414673	chr13:79406309~79424328:+
BRCA	cis	rs9545047	0.604	rs2147568	ENSG00000227354.5	RBM26-AS1	5.07	4.82e-07	5.21e-05	0.17	0.16	Schizophrenia;	chr13:79417091	chr13:79406309~79424328:+
BRCA	cis	rs9545047	0.604	rs9530917	ENSG00000227354.5	RBM26-AS1	5.07	4.82e-07	5.21e-05	0.17	0.16	Schizophrenia;	chr13:79417719	chr13:79406309~79424328:+
BRCA	cis	rs9545047	0.604	rs7990321	ENSG00000227354.5	RBM26-AS1	5.07	4.82e-07	5.21e-05	0.17	0.16	Schizophrenia;	chr13:79418066	chr13:79406309~79424328:+
BRCA	cis	rs6928977	0.5	rs6925161	ENSG00000234084.1	RP3-388E23.2	-5.07	4.82e-07	5.21e-05	-0.16	-0.16	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135615496	chr6:135301568~135307158:+
BRCA	cis	rs7487075	0.619	rs7485580	ENSG00000274723.1	RP11-618L22.1	5.07	4.82e-07	5.22e-05	0.19	0.16	Itch intensity from mosquito bite;	chr12:46436591	chr12:46970504~46972155:+
BRCA	cis	rs7487075	0.619	rs4768717	ENSG00000274723.1	RP11-618L22.1	5.07	4.82e-07	5.22e-05	0.19	0.16	Itch intensity from mosquito bite;	chr12:46437778	chr12:46970504~46972155:+
BRCA	cis	rs7246967	0.611	rs56944174	ENSG00000198153.8	ZNF849P	-5.07	4.82e-07	5.22e-05	-0.3	-0.16	Bronchopulmonary dysplasia;	chr19:22738872	chr19:22685167~22686732:+
BRCA	cis	rs1223397	0.651	rs2496142	ENSG00000215022.6	RP1-257A7.4	5.07	4.83e-07	5.22e-05	0.18	0.16	Blood pressure;	chr6:13311562	chr6:13264861~13295586:-
BRCA	cis	rs957448	0.607	rs12680842	ENSG00000253175.1	RP11-267M23.6	5.06	4.83e-07	5.22e-05	0.18	0.16	Nonsyndromic cleft lip with cleft palate;	chr8:94570378	chr8:94565036~94565715:+
BRCA	cis	rs2562456	0.917	rs9304987	ENSG00000268535.1	RP11-420K14.3	-5.06	4.83e-07	5.22e-05	-0.21	-0.16	Pain;	chr19:21499472	chr19:21709522~21710191:+
BRCA	cis	rs8059260	0.524	rs1122185	ENSG00000274038.1	RP11-66H6.4	-5.06	4.83e-07	5.22e-05	-0.19	-0.16	Alcohol consumption over the past year;	chr16:11104119	chr16:11056556~11057034:+
BRCA	cis	rs11159086	1	rs4903233	ENSG00000270000.1	RP3-449M8.9	5.06	4.83e-07	5.22e-05	0.24	0.16	Advanced glycation end-product levels;	chr14:74497291	chr14:74471930~74472360:-
BRCA	cis	rs6025590	1	rs6025590	ENSG00000124097.7	HMGB1P1	-5.06	4.83e-07	5.23e-05	-0.19	-0.16	Obesity-related traits;	chr20:57495449	chr20:57488392~57489027:-
BRCA	cis	rs8098244	0.964	rs11662907	ENSG00000264745.1	TTC39C-AS1	5.06	4.83e-07	5.23e-05	0.22	0.16	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23875595	chr18:23994213~24015339:-
BRCA	cis	rs7618915	0.532	rs13060675	ENSG00000243224.1	RP5-1157M23.2	-5.06	4.83e-07	5.23e-05	-0.17	-0.16	Bipolar disorder;	chr3:52640284	chr3:52239258~52241097:+
BRCA	cis	rs12477438	0.765	rs1115756	ENSG00000231822.1	AC019097.7	-5.06	4.83e-07	5.23e-05	-0.17	-0.16	Chronic sinus infection;	chr2:99043382	chr2:99102018~99102752:+
BRCA	cis	rs2380205	0.651	rs12357094	ENSG00000232807.2	RP11-536K7.3	5.06	4.84e-07	5.23e-05	0.15	0.15	Breast cancer;	chr10:5884340	chr10:5934270~5945900:-
BRCA	cis	rs1552244	0.515	rs111560858	ENSG00000232901.1	CYCSP10	5.06	4.84e-07	5.23e-05	0.24	0.15	Alzheimer's disease;	chr3:10125161	chr3:10000647~10000940:-
BRCA	cis	rs710865	0.527	rs2275403	ENSG00000270728.1	RP4-657E11.10	5.06	4.84e-07	5.23e-05	0.15	0.15	Brain structure;	chr1:19231219	chr1:19297080~19297903:+
BRCA	cis	rs962856	1	rs11888062	ENSG00000236780.4	AC078941.1	5.06	4.84e-07	5.24e-05	0.2	0.15	Pancreatic cancer;	chr2:67378226	chr2:67123357~67215319:-
BRCA	cis	rs1387259	0.859	rs2054905	ENSG00000257735.1	RP11-370I10.6	5.06	4.84e-07	5.24e-05	0.19	0.15	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48294168	chr12:48350945~48442411:+
BRCA	cis	rs1440410	0.835	rs11725565	ENSG00000250326.1	RP11-284M14.1	5.06	4.85e-07	5.24e-05	0.18	0.15	Ischemic stroke;	chr4:143216206	chr4:142933195~143184861:-
BRCA	cis	rs10506328	0.689	rs4759348	ENSG00000257534.1	RP11-834C11.10	5.06	4.85e-07	5.24e-05	0.2	0.15	Mean platelet volume;	chr12:54236733	chr12:54162065~54164452:-
BRCA	cis	rs7914558	1	rs943038	ENSG00000236937.2	PTGES3P4	5.06	4.85e-07	5.24e-05	0.2	0.15	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103066504	chr10:102845595~102845950:+
BRCA	cis	rs4713675	0.565	rs4713674	ENSG00000224557.6	HLA-DPB2	5.06	4.85e-07	5.24e-05	0.18	0.15	Plateletcrit;	chr6:33740392	chr6:33112451~33129084:+
BRCA	cis	rs61864810	1	rs61864810	ENSG00000257261.4	RP11-96H19.1	5.06	4.85e-07	5.25e-05	0.17	0.15	Itch intensity from mosquito bite;	chr12:46288226	chr12:46383679~46876159:+
BRCA	cis	rs1322639	0.614	rs4708414	ENSG00000261039.2	RP11-417E7.2	-5.06	4.85e-07	5.25e-05	-0.15	-0.15	Pulse pressure;	chr6:169174049	chr6:169175304~169182740:-
BRCA	cis	rs10924970	0.625	rs10925482	ENSG00000230026.2	RP11-382D8.5	-5.06	4.85e-07	5.25e-05	-0.18	-0.15	Asthma;	chr1:235335948	chr1:235361153~235362540:+
BRCA	cis	rs4908768	0.52	rs7520025	ENSG00000232912.4	RP5-1115A15.1	5.06	4.86e-07	5.25e-05	0.15	0.15	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8638218	chr1:8424645~8434838:+
BRCA	cis	rs1043099	0.528	rs1046199	ENSG00000279699.1	RP1-102K2.9	-5.06	4.86e-07	5.25e-05	-0.21	-0.15	Rheumatoid arthritis;	chr22:30424562	chr22:30275215~30276951:-
BRCA	cis	rs1383484	1	rs28612730	ENSG00000230373.7	GOLGA6L5P	-5.06	4.86e-07	5.25e-05	-0.18	-0.15	Height;	chr15:83842454	chr15:84507885~84516814:-
BRCA	cis	rs3743162	0.609	rs12906879	ENSG00000225151.9	GOLGA2P7	5.06	4.86e-07	5.26e-05	0.18	0.15	Alzheimer's disease (age of onset);	chr15:84882237	chr15:84199311~84230136:-
BRCA	cis	rs6840360	0.681	rs9968292	ENSG00000278978.1	RP11-164P12.5	-5.06	4.86e-07	5.26e-05	-0.17	-0.15	Intelligence (multi-trait analysis);	chr4:151376216	chr4:151669786~151670503:+
BRCA	cis	rs2638953	1	rs11049532	ENSG00000247934.4	RP11-967K21.1	-5.06	4.87e-07	5.26e-05	-0.21	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28323979	chr12:28163298~28190738:-
BRCA	cis	rs4819052	0.851	rs1999335	ENSG00000184274.3	LINC00315	-5.06	4.87e-07	5.26e-05	-0.21	-0.15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250698	chr21:45300245~45305257:-
BRCA	cis	rs1707322	0.963	rs10890373	ENSG00000234329.1	RP11-767N6.2	5.06	4.87e-07	5.26e-05	0.16	0.15	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45928083	chr1:45651039~45651826:-
BRCA	cis	rs4388249	0.651	rs31607	ENSG00000249476.1	CTD-2587M2.1	-5.06	4.87e-07	5.26e-05	-0.23	-0.15	Schizophrenia;	chr5:109663965	chr5:109237120~109326369:-
BRCA	cis	rs2644899	1	rs2644899	ENSG00000268529.1	CYP2T3P	5.06	4.87e-07	5.26e-05	0.2	0.15	Post bronchodilator FEV1/FVC ratio;	chr19:40797044	chr19:41134722~41137308:+
BRCA	cis	rs6545883	0.708	rs2518936	ENSG00000271889.1	RP11-493E12.1	5.06	4.87e-07	5.26e-05	0.2	0.15	Tuberculosis;	chr2:61565207	chr2:61151433~61162105:-
BRCA	cis	rs10844706	0.699	rs11052752	ENSG00000214776.8	RP11-726G1.1	5.06	4.87e-07	5.26e-05	0.19	0.15	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9735222	chr12:9467552~9576275:+
BRCA	cis	rs875971	1	rs1565531	ENSG00000223473.2	GS1-124K5.3	-5.06	4.87e-07	5.27e-05	-0.12	-0.15	Aortic root size;	chr7:66198126	chr7:66491049~66493566:-
BRCA	cis	rs9652601	0.748	rs35294447	ENSG00000274038.1	RP11-66H6.4	-5.06	4.87e-07	5.27e-05	-0.18	-0.15	Systemic lupus erythematosus;	chr16:11146997	chr16:11056556~11057034:+
BRCA	cis	rs4835473	0.897	rs11100802	ENSG00000249741.2	RP11-673E1.3	5.06	4.87e-07	5.27e-05	0.17	0.15	Immature fraction of reticulocytes;	chr4:143700046	chr4:143911514~143912053:-
BRCA	cis	rs9840812	0.769	rs576771	ENSG00000239213.4	NCK1-AS1	5.06	4.87e-07	5.27e-05	0.19	0.15	Fibrinogen levels;	chr3:136270450	chr3:136841726~136862054:-
BRCA	cis	rs2732480	0.577	rs1489109	ENSG00000240399.1	RP1-228P16.1	5.06	4.87e-07	5.27e-05	0.19	0.15	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344997	chr12:48054813~48055591:-
BRCA	cis	rs2732480	0.577	rs1489108	ENSG00000240399.1	RP1-228P16.1	5.06	4.87e-07	5.27e-05	0.19	0.15	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344998	chr12:48054813~48055591:-
BRCA	cis	rs6490294	0.898	rs57646770	ENSG00000226469.1	ADAM1B	5.06	4.88e-07	5.27e-05	0.2	0.15	Mean platelet volume;	chr12:111993408	chr12:111927018~111929017:+
BRCA	cis	rs13113518	1	rs4864993	ENSG00000223305.1	RN7SKP30	5.06	4.88e-07	5.27e-05	0.19	0.15	Height;	chr4:55450662	chr4:55540502~55540835:-
BRCA	cis	rs4711336	1	rs2296740	ENSG00000224557.6	HLA-DPB2	-5.06	4.88e-07	5.27e-05	-0.18	-0.15	Height;	chr6:33691759	chr6:33112451~33129084:+
BRCA	cis	rs60695258	0.594	rs6531946	ENSG00000251411.1	RP11-397E7.4	-5.06	4.88e-07	5.28e-05	-0.17	-0.15	Hematocrit;	chr4:87044239	chr4:86913266~86914817:-
BRCA	cis	rs6772849	0.83	rs4857917	ENSG00000242551.2	POU5F1P6	-5.06	4.88e-07	5.28e-05	-0.2	-0.15	Monocyte percentage of white cells;Monocyte count;	chr3:128657335	chr3:128674735~128677005:-
BRCA	cis	rs1552244	1	rs35993975	ENSG00000232901.1	CYCSP10	5.06	4.88e-07	5.28e-05	0.24	0.15	Alzheimer's disease;	chr3:10026110	chr3:10000647~10000940:-
BRCA	cis	rs4835473	0.932	rs4835118	ENSG00000249741.2	RP11-673E1.3	-5.06	4.89e-07	5.28e-05	-0.17	-0.15	Immature fraction of reticulocytes;	chr4:143981994	chr4:143911514~143912053:-
BRCA	cis	rs9393777	0.668	rs16897515	ENSG00000216901.1	AL022393.7	-5.06	4.89e-07	5.28e-05	-0.24	-0.15	Intelligence (multi-trait analysis);	chr6:27310241	chr6:28176188~28176674:+
BRCA	cis	rs2574985	0.739	rs2983361	ENSG00000231345.3	BEND3P1	-5.06	4.89e-07	5.28e-05	-0.26	-0.15	Subjective well-being;	chr10:50556120	chr10:50655967~50660472:+
BRCA	cis	rs987724	0.515	rs4315647	ENSG00000240875.4	LINC00886	-5.06	4.89e-07	5.28e-05	-0.23	-0.15	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156941199	chr3:156747346~156817062:-
BRCA	cis	rs17685	0.753	rs1639609	ENSG00000280388.1	RP11-229D13.3	-5.06	4.89e-07	5.28e-05	-0.16	-0.15	Coffee consumption (cups per day);Coffee consumption;	chr7:76054263	chr7:76043977~76045963:-
BRCA	cis	rs710913	0.745	rs67563067	ENSG00000228060.1	RP11-69E11.8	5.06	4.89e-07	5.28e-05	0.15	0.15	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39581323	chr1:39565160~39573203:+
BRCA	cis	rs2562456	0.682	rs11085464	ENSG00000268535.1	RP11-420K14.3	5.06	4.89e-07	5.29e-05	0.21	0.15	Pain;	chr19:21568976	chr19:21709522~21710191:+
BRCA	cis	rs7134599	0.508	rs1861488	ENSG00000255733.4	IFNG-AS1	5.06	4.89e-07	5.29e-05	0.13	0.15	Inflammatory bowel disease;Ulcerative colitis;	chr12:68075499	chr12:67989445~68234686:+
BRCA	cis	rs4443100	0.535	rs13055979	ENSG00000230701.2	FBXW4P1	5.06	4.89e-07	5.29e-05	0.2	0.15	Serum parathyroid hormone levels;	chr22:23131898	chr22:23262767~23265005:+
BRCA	cis	rs6840360	0.607	rs2724565	ENSG00000251611.1	RP11-610P16.1	-5.06	4.89e-07	5.29e-05	-0.14	-0.15	Intelligence (multi-trait analysis);	chr4:151429153	chr4:151407551~151408835:-
BRCA	cis	rs728616	0.614	rs55768100	ENSG00000225484.5	NUTM2B-AS1	-5.06	4.9e-07	5.29e-05	-0.3	-0.15	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79964721	chr10:79663088~79826594:-
BRCA	cis	rs13113518	1	rs2279458	ENSG00000223305.1	RN7SKP30	5.06	4.9e-07	5.3e-05	0.19	0.15	Height;	chr4:55562653	chr4:55540502~55540835:-
BRCA	cis	rs9341808	0.754	rs3805925	ENSG00000272129.1	RP11-250B2.6	5.06	4.91e-07	5.3e-05	0.2	0.15	Sitting height ratio;	chr6:80174116	chr6:80355424~80356859:+
BRCA	cis	rs9473147	0.516	rs9349413	ENSG00000270761.1	RP11-385F7.1	-5.06	4.91e-07	5.31e-05	-0.18	-0.15	Platelet distribution width;Mean platelet volume;	chr6:47543755	chr6:47477243~47477572:-
BRCA	cis	rs13113518	1	rs6847529	ENSG00000223305.1	RN7SKP30	5.06	4.91e-07	5.31e-05	0.19	0.15	Height;	chr4:55518776	chr4:55540502~55540835:-
BRCA	cis	rs13113518	1	rs6822740	ENSG00000223305.1	RN7SKP30	5.06	4.91e-07	5.31e-05	0.19	0.15	Height;	chr4:55518922	chr4:55540502~55540835:-
BRCA	cis	rs6840360	1	rs3749561	ENSG00000270265.1	RP11-731D1.4	5.06	4.92e-07	5.31e-05	0.17	0.15	Intelligence (multi-trait analysis);	chr4:151688965	chr4:151333775~151353224:-
BRCA	cis	rs73193808	1	rs2832230	ENSG00000236056.1	GAPDHP14	5.06	4.92e-07	5.31e-05	0.22	0.15	Coronary artery disease;	chr21:29164391	chr21:29222321~29223257:+
BRCA	cis	rs2281636	0.824	rs2160620	ENSG00000233690.1	EBAG9P1	5.06	4.92e-07	5.32e-05	0.16	0.15	Obesity-related traits;	chr10:99627261	chr10:99697407~99697949:-
BRCA	cis	rs957448	0.554	rs12541408	ENSG00000261437.1	RP11-22C11.2	5.06	4.93e-07	5.32e-05	0.15	0.15	Nonsyndromic cleft lip with cleft palate;	chr8:94573579	chr8:94637285~94639467:-
BRCA	cis	rs2153535	0.58	rs2327062	ENSG00000251164.1	HULC	-5.06	4.93e-07	5.32e-05	-0.19	-0.15	Motion sickness;	chr6:8453625	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.58	rs4587214	ENSG00000251164.1	HULC	-5.06	4.93e-07	5.32e-05	-0.19	-0.15	Motion sickness;	chr6:8453886	chr6:8652137~8653846:+
BRCA	cis	rs6088590	0.561	rs3891369	ENSG00000276073.1	RP5-1125A11.7	-5.06	4.93e-07	5.32e-05	-0.17	-0.15	Coronary artery disease;	chr20:34573323	chr20:33985617~33988989:-
BRCA	cis	rs7674212	0.541	rs2045746	ENSG00000248740.4	RP11-328K4.1	-5.06	4.93e-07	5.33e-05	-0.18	-0.15	Type 2 diabetes;	chr4:103162421	chr4:103256159~103453658:+
BRCA	cis	rs8133949	1	rs8133949	ENSG00000237232.6	ZNF295-AS1	5.06	4.93e-07	5.33e-05	0.25	0.15	Hand grip strength;	chr21:42001005	chr21:42009194~42024924:+
BRCA	cis	rs13108904	0.901	rs12641735	ENSG00000196810.4	CTBP1-AS2	5.06	4.94e-07	5.33e-05	0.17	0.15	Obesity-related traits;	chr4:1310646	chr4:1249300~1288291:+
BRCA	cis	rs13108904	0.557	rs1680030	ENSG00000254094.1	AC078852.1	5.06	4.94e-07	5.33e-05	0.18	0.15	Obesity-related traits;	chr4:1251712	chr4:1356581~1358075:+
BRCA	cis	rs7613875	0.6	rs2624848	ENSG00000228008.1	CTD-2330K9.3	-5.06	4.94e-07	5.34e-05	-0.15	-0.15	Body mass index;	chr3:50127668	chr3:49903845~49916937:+
BRCA	cis	rs8133949	0.904	rs11701177	ENSG00000237232.6	ZNF295-AS1	5.06	4.94e-07	5.34e-05	0.24	0.15	Hand grip strength;	chr21:42012779	chr21:42009194~42024924:+
BRCA	cis	rs4908768	0.539	rs1061039	ENSG00000232912.4	RP5-1115A15.1	5.06	4.94e-07	5.34e-05	0.15	0.15	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8582529	chr1:8424645~8434838:+
BRCA	cis	rs78487399	0.71	rs74382177	ENSG00000234936.1	AC010883.5	5.06	4.95e-07	5.34e-05	0.28	0.15	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43300918	chr2:43229573~43233394:+
BRCA	cis	rs2243480	1	rs316330	ENSG00000275400.1	RP4-756H11.5	5.06	4.95e-07	5.34e-05	0.28	0.15	Diabetic kidney disease;	chr7:66140385	chr7:66553805~66554199:-
BRCA	cis	rs2505998	0.833	rs2565203	ENSG00000273008.1	RP11-351D16.3	-5.06	4.95e-07	5.34e-05	-0.19	-0.15	Hirschsprung disease;	chr10:43108287	chr10:43136824~43138334:-
BRCA	cis	rs12744310	0.887	rs12028244	ENSG00000235358.1	RP11-399E6.1	5.06	4.95e-07	5.35e-05	0.23	0.15	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41343490	chr1:41242373~41284861:+
BRCA	cis	rs1440410	0.83	rs985619	ENSG00000250326.1	RP11-284M14.1	-5.06	4.95e-07	5.35e-05	-0.17	-0.15	Ischemic stroke;	chr4:143253423	chr4:142933195~143184861:-
BRCA	cis	rs2153535	0.58	rs2152347	ENSG00000251164.1	HULC	-5.06	4.95e-07	5.35e-05	-0.19	-0.15	Motion sickness;	chr6:8474048	chr6:8652137~8653846:+
BRCA	cis	rs9628987	0.5	rs11121179	ENSG00000232912.4	RP5-1115A15.1	-5.06	4.96e-07	5.35e-05	-0.21	-0.15	Breast cancer;	chr1:8395652	chr1:8424645~8434838:+
BRCA	cis	rs7267979	0.844	rs2424703	ENSG00000274973.1	RP13-401N8.7	-5.06	4.96e-07	5.35e-05	-0.18	-0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25289488	chr20:25845497~25845862:+
BRCA	cis	rs7243790	0.807	rs13380938	ENSG00000277324.1	RP11-850A17.1	-5.06	4.96e-07	5.35e-05	-0.17	-0.15	Diastolic blood pressure;	chr18:54369177	chr18:54268346~54270028:-
BRCA	cis	rs595982	0.559	rs73061632	ENSG00000235191.1	NUCB1-AS1	5.06	4.96e-07	5.35e-05	0.27	0.15	Red cell distribution width;	chr19:48858406	chr19:48910930~48918891:-
BRCA	cis	rs7267979	0.753	rs400357	ENSG00000204556.4	CTD-2514C3.1	-5.06	4.96e-07	5.36e-05	-0.21	-0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25498422	chr20:26018832~26020684:+
BRCA	cis	rs875971	0.658	rs432667	ENSG00000236529.1	RP13-254B10.1	5.06	4.96e-07	5.36e-05	0.17	0.15	Aortic root size;	chr7:66049646	chr7:65840212~65840596:+
BRCA	cis	rs10510102	0.935	rs4627017	ENSG00000226864.1	ATE1-AS1	5.06	4.96e-07	5.36e-05	0.28	0.15	Breast cancer;	chr10:121901878	chr10:121928312~121951965:+
BRCA	cis	rs8002861	0.935	rs9533678	ENSG00000274001.1	RP11-5G9.5	5.06	4.97e-07	5.36e-05	0.17	0.15	Leprosy;	chr13:43889273	chr13:43877715~43878163:-
BRCA	cis	rs11696739	0.536	rs3761268	ENSG00000242324.1	RP4-576H24.2	5.06	4.97e-07	5.36e-05	0.22	0.15	Mean platelet volume;	chr20:1620521	chr20:1516759~1557653:-
BRCA	cis	rs8002861	0.869	rs7989857	ENSG00000274001.1	RP11-5G9.5	5.06	4.97e-07	5.36e-05	0.17	0.15	Leprosy;	chr13:43889954	chr13:43877715~43878163:-
BRCA	cis	rs7617773	0.817	rs34225441	ENSG00000199476.1	Y_RNA	-5.06	4.97e-07	5.36e-05	-0.23	-0.15	Coronary artery disease;	chr3:48267401	chr3:48288587~48288694:+
BRCA	cis	rs1223397	0.651	rs2496148	ENSG00000215022.6	RP1-257A7.4	-5.06	4.97e-07	5.36e-05	-0.18	-0.15	Blood pressure;	chr6:13313321	chr6:13264861~13295586:-
BRCA	cis	rs875971	1	rs6958271	ENSG00000223473.2	GS1-124K5.3	5.06	4.97e-07	5.36e-05	0.12	0.15	Aortic root size;	chr7:66514344	chr7:66491049~66493566:-
BRCA	cis	rs875971	1	rs6958277	ENSG00000223473.2	GS1-124K5.3	5.06	4.97e-07	5.36e-05	0.12	0.15	Aortic root size;	chr7:66514362	chr7:66491049~66493566:-
BRCA	cis	rs2839186	0.77	rs2839171	ENSG00000239415.1	AP001469.9	-5.06	4.97e-07	5.37e-05	-0.16	-0.15	Testicular germ cell tumor;	chr21:46253333	chr21:46251549~46254133:-
BRCA	cis	rs7119	0.689	rs12916833	ENSG00000259362.2	RP11-307C19.1	-5.06	4.97e-07	5.37e-05	-0.22	-0.15	Type 2 diabetes;	chr15:77527436	chr15:77525540~77534110:+
BRCA	cis	rs7923837	0.963	rs11187141	ENSG00000236493.2	EIF2S2P3	5.06	4.97e-07	5.37e-05	0.21	0.15	Multiple sclerosis;Body mass index;	chr10:92707388	chr10:92668745~92669743:-
BRCA	cis	rs875971	1	rs11974219	ENSG00000223473.2	GS1-124K5.3	-5.06	4.97e-07	5.37e-05	-0.12	-0.15	Aortic root size;	chr7:66182423	chr7:66491049~66493566:-
BRCA	cis	rs860295	1	rs822490	ENSG00000160766.13	GBAP1	-5.06	4.98e-07	5.37e-05	-0.15	-0.15	Body mass index;	chr1:155853180	chr1:155213821~155227422:-
BRCA	cis	rs2562456	0.917	rs2650805	ENSG00000268658.4	LINC00664	-5.06	4.98e-07	5.37e-05	-0.24	-0.15	Pain;	chr19:21505137	chr19:21483374~21503238:+
BRCA	cis	rs2303319	0.504	rs62188729	ENSG00000227403.1	AC009299.3	5.06	4.98e-07	5.37e-05	0.37	0.15	Cognitive function;	chr2:161480541	chr2:161244739~161249050:+
BRCA	cis	rs2303319	0.504	rs62188731	ENSG00000227403.1	AC009299.3	5.06	4.98e-07	5.37e-05	0.37	0.15	Cognitive function;	chr2:161488265	chr2:161244739~161249050:+
BRCA	cis	rs7226408	0.857	rs12185461	ENSG00000267707.2	RP11-95O2.5	-5.06	4.98e-07	5.37e-05	-0.24	-0.15	Obesity-related traits;	chr18:36912073	chr18:37243776~37247506:+
BRCA	cis	rs35740288	0.929	rs3858927	ENSG00000259407.1	RP11-158M2.3	-5.06	4.98e-07	5.37e-05	-0.21	-0.15	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85758385	chr15:85744109~85750281:-
BRCA	cis	rs1722141	0.633	rs2471552	ENSG00000229628.1	AC073115.7	5.06	4.98e-07	5.37e-05	0.21	0.15	Sitting height ratio;	chr7:45937574	chr7:45990905~46000898:+
BRCA	cis	rs673078	0.66	rs17440364	ENSG00000275409.1	RP11-131L12.4	-5.06	4.98e-07	5.38e-05	-0.23	-0.15	Glucose homeostasis traits;	chr12:118186613	chr12:118430147~118430699:+
BRCA	cis	rs10911232	0.507	rs10911198	ENSG00000224468.3	RP11-181K3.4	-5.06	4.98e-07	5.38e-05	-0.17	-0.15	Hypertriglyceridemia;	chr1:183028183	chr1:183138402~183141282:-
BRCA	cis	rs11051970	0.559	rs11051939	ENSG00000274964.1	RP11-817I4.1	5.06	4.98e-07	5.38e-05	0.2	0.15	Response to tocilizumab in rheumatoid arthritis;	chr12:32330107	chr12:32339368~32340724:+
BRCA	cis	rs1707322	0.964	rs1768802	ENSG00000234329.1	RP11-767N6.2	-5.06	4.99e-07	5.38e-05	-0.16	-0.15	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46082196	chr1:45651039~45651826:-
BRCA	cis	rs1707322	1	rs1588663	ENSG00000234329.1	RP11-767N6.2	-5.06	4.99e-07	5.38e-05	-0.16	-0.15	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46083153	chr1:45651039~45651826:-
BRCA	cis	rs1707322	1	rs1768801	ENSG00000234329.1	RP11-767N6.2	-5.06	4.99e-07	5.38e-05	-0.16	-0.15	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46083465	chr1:45651039~45651826:-
BRCA	cis	rs1707322	1	rs1768800	ENSG00000234329.1	RP11-767N6.2	-5.06	4.99e-07	5.38e-05	-0.16	-0.15	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46083516	chr1:45651039~45651826:-
BRCA	cis	rs7829975	0.688	rs7827182	ENSG00000233609.3	RP11-62H7.2	5.06	4.99e-07	5.38e-05	0.14	0.15	Mood instability;	chr8:8522961	chr8:8961200~8979025:+
BRCA	cis	rs7200543	1	rs2740	ENSG00000260735.1	RP11-72I8.1	-5.06	4.99e-07	5.38e-05	-0.18	-0.15	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15038251	chr16:15094411~15109197:+
BRCA	cis	rs7246657	1	rs1529957	ENSG00000267422.1	CTD-2554C21.1	-5.06	4.99e-07	5.38e-05	-0.23	-0.15	Coronary artery calcification;	chr19:37248899	chr19:37779686~37792865:+
BRCA	cis	rs11098499	0.954	rs9993199	ENSG00000260091.1	RP11-33B1.4	5.06	4.99e-07	5.39e-05	0.14	0.15	Corneal astigmatism;	chr4:119471718	chr4:119409333~119410233:+
BRCA	cis	rs9287719	0.967	rs6432121	ENSG00000243819.4	RN7SL832P	5.06	4.99e-07	5.39e-05	0.15	0.15	Prostate cancer;	chr2:10613678	chr2:10690344~10692099:+
BRCA	cis	rs11719291	0.915	rs11557629	ENSG00000270441.1	RP11-694I15.7	5.06	5e-07	5.39e-05	0.26	0.15	Cognitive function;	chr3:48694790	chr3:49140086~49160851:-
BRCA	cis	rs13113518	1	rs10462032	ENSG00000249700.7	SRD5A3-AS1	5.06	5e-07	5.39e-05	0.19	0.15	Height;	chr4:55479069	chr4:55363971~55395847:-
BRCA	cis	rs2281558	0.876	rs6115135	ENSG00000230772.1	VN1R108P	-5.06	5e-07	5.39e-05	-0.2	-0.15	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25299242	chr20:25734264~25735093:+
BRCA	cis	rs12497850	1	rs10865952	ENSG00000225399.4	RP11-3B7.1	5.06	5e-07	5.39e-05	0.15	0.15	Parkinson's disease;	chr3:48707051	chr3:49260085~49261316:+
BRCA	cis	rs1707322	1	rs4454479	ENSG00000234329.1	RP11-767N6.2	5.06	5e-07	5.39e-05	0.16	0.15	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45957883	chr1:45651039~45651826:-
BRCA	cis	rs2638953	0.889	rs10843157	ENSG00000247934.4	RP11-967K21.1	-5.06	5e-07	5.39e-05	-0.21	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28346417	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.962	rs11049548	ENSG00000247934.4	RP11-967K21.1	-5.06	5e-07	5.39e-05	-0.21	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28350789	chr12:28163298~28190738:-
BRCA	cis	rs17495987	0.711	rs2348765	ENSG00000219545.8	UMAD1	5.06	5e-07	5.39e-05	0.22	0.15	Tonsillectomy;	chr7:7863677	chr7:7640711~8004059:+
BRCA	cis	rs3764021	0.509	rs10844569	ENSG00000214776.8	RP11-726G1.1	5.06	5.01e-07	5.4e-05	0.19	0.15	Type 1 diabetes;	chr12:9717756	chr12:9467552~9576275:+
BRCA	cis	rs6832769	1	rs9997288	ENSG00000272969.1	RP11-528I4.2	5.06	5.01e-07	5.4e-05	0.19	0.15	Personality dimensions;	chr4:55481060	chr4:55547112~55547889:+
BRCA	cis	rs2239547	0.522	rs6768844	ENSG00000242142.1	SERBP1P3	-5.06	5.01e-07	5.4e-05	-0.19	-0.15	Schizophrenia;	chr3:52970604	chr3:53064283~53065091:-
BRCA	cis	rs321358	0.945	rs17458885	ENSG00000271390.1	RP11-89C3.3	5.06	5.01e-07	5.41e-05	0.26	0.15	Body mass index;	chr11:111117222	chr11:111089870~111090368:-
BRCA	cis	rs595244	0.901	rs2466790	ENSG00000259705.1	RP11-227D13.1	5.06	5.01e-07	5.41e-05	0.29	0.15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48607202	chr15:48645951~48652016:+
BRCA	cis	rs2562456	0.833	rs1781872	ENSG00000268535.1	RP11-420K14.3	5.06	5.01e-07	5.41e-05	0.23	0.15	Pain;	chr19:21294601	chr19:21709522~21710191:+
BRCA	cis	rs4948275	0.773	rs2650709	ENSG00000237233.2	TMEM26-AS1	-5.06	5.01e-07	5.41e-05	-0.18	-0.15	Night sleep phenotypes;	chr10:61483034	chr10:61452639~61481956:+
BRCA	cis	rs172166	0.694	rs203884	ENSG00000280107.1	AL022393.9	-5.06	5.02e-07	5.41e-05	-0.21	-0.15	Cardiac Troponin-T levels;	chr6:28109596	chr6:28170845~28172521:+
BRCA	cis	rs73193808	0.901	rs67137684	ENSG00000236056.1	GAPDHP14	-5.06	5.02e-07	5.41e-05	-0.22	-0.15	Coronary artery disease;	chr21:29195373	chr21:29222321~29223257:+
BRCA	cis	rs9473147	0.543	rs7738044	ENSG00000270761.1	RP11-385F7.1	-5.06	5.02e-07	5.41e-05	-0.16	-0.15	Platelet distribution width;Mean platelet volume;	chr6:47501537	chr6:47477243~47477572:-
BRCA	cis	rs9473147	0.543	rs9473122	ENSG00000270761.1	RP11-385F7.1	-5.06	5.02e-07	5.41e-05	-0.16	-0.15	Platelet distribution width;Mean platelet volume;	chr6:47507226	chr6:47477243~47477572:-
BRCA	cis	rs9473147	0.543	rs1872505	ENSG00000270761.1	RP11-385F7.1	-5.06	5.02e-07	5.41e-05	-0.16	-0.15	Platelet distribution width;Mean platelet volume;	chr6:47513239	chr6:47477243~47477572:-
BRCA	cis	rs9473147	0.516	rs9296561	ENSG00000270761.1	RP11-385F7.1	-5.06	5.02e-07	5.41e-05	-0.16	-0.15	Platelet distribution width;Mean platelet volume;	chr6:47521202	chr6:47477243~47477572:-
BRCA	cis	rs9473147	0.516	rs7749167	ENSG00000270761.1	RP11-385F7.1	-5.06	5.02e-07	5.41e-05	-0.16	-0.15	Platelet distribution width;Mean platelet volume;	chr6:47526204	chr6:47477243~47477572:-
BRCA	cis	rs6688613	0.685	rs11579987	ENSG00000225171.2	DUTP6	5.06	5.02e-07	5.42e-05	0.21	0.15	Refractive astigmatism;	chr1:166920127	chr1:166868748~166869209:+
BRCA	cis	rs926392	0.896	rs742276	ENSG00000274825.1	RP4-616B8.5	-5.06	5.02e-07	5.42e-05	-0.15	-0.15	Dialysis-related mortality;	chr20:39051206	chr20:38955910~38956547:+
BRCA	cis	rs957448	0.554	rs12680855	ENSG00000261437.1	RP11-22C11.2	5.06	5.03e-07	5.42e-05	0.15	0.15	Nonsyndromic cleft lip with cleft palate;	chr8:94570427	chr8:94637285~94639467:-
BRCA	cis	rs1345301	0.587	rs10186746	ENSG00000234389.1	AC007278.3	-5.06	5.03e-07	5.42e-05	-0.14	-0.15	Waist circumference;	chr2:102249917	chr2:102438713~102440475:+
BRCA	cis	rs911555	0.511	rs8007489	ENSG00000269958.1	RP11-73M18.8	-5.06	5.03e-07	5.43e-05	-0.16	-0.15	Intelligence (multi-trait analysis);	chr14:103588235	chr14:103696353~103697163:+
BRCA	cis	rs7829975	0.623	rs10087493	ENSG00000253981.4	ALG1L13P	-5.06	5.04e-07	5.43e-05	-0.18	-0.15	Mood instability;	chr8:8516047	chr8:8236003~8244667:-
BRCA	cis	rs2574985	0.739	rs2983354	ENSG00000231345.3	BEND3P1	-5.06	5.04e-07	5.43e-05	-0.26	-0.15	Subjective well-being;	chr10:50532887	chr10:50655967~50660472:+
BRCA	cis	rs442309	0.875	rs224064	ENSG00000238280.1	RP11-436D10.3	-5.06	5.04e-07	5.43e-05	-0.21	-0.15	Vogt-Koyanagi-Harada syndrome;	chr10:62744452	chr10:62793562~62805887:-
BRCA	cis	rs7246657	0.722	rs2291002	ENSG00000276846.1	CTD-3220F14.3	5.06	5.04e-07	5.43e-05	0.21	0.15	Coronary artery calcification;	chr19:37543024	chr19:37314868~37315620:-
BRCA	cis	rs7246657	0.722	rs10404031	ENSG00000276846.1	CTD-3220F14.3	5.06	5.04e-07	5.43e-05	0.21	0.15	Coronary artery calcification;	chr19:37545052	chr19:37314868~37315620:-
BRCA	cis	rs7246657	0.722	rs10406379	ENSG00000276846.1	CTD-3220F14.3	5.06	5.04e-07	5.43e-05	0.21	0.15	Coronary artery calcification;	chr19:37545823	chr19:37314868~37315620:-
BRCA	cis	rs875971	1	rs709595	ENSG00000223473.2	GS1-124K5.3	5.06	5.04e-07	5.43e-05	0.12	0.15	Aortic root size;	chr7:66352346	chr7:66491049~66493566:-
BRCA	cis	rs875971	1	rs811880	ENSG00000223473.2	GS1-124K5.3	5.06	5.04e-07	5.43e-05	0.12	0.15	Aortic root size;	chr7:66353659	chr7:66491049~66493566:-
BRCA	cis	rs7937890	0.904	rs67623158	ENSG00000251991.1	RNU7-49P	-5.06	5.04e-07	5.43e-05	-0.17	-0.15	Mitochondrial DNA levels;	chr11:14273650	chr11:14478892~14478953:+
BRCA	cis	rs8114671	0.562	rs6058120	ENSG00000269202.1	RP4-614O4.12	-5.06	5.04e-07	5.43e-05	-0.15	-0.15	Height;	chr20:34815026	chr20:35201747~35203288:-
BRCA	cis	rs10788972	0.658	rs12046885	ENSG00000225183.1	RP4-758J24.4	-5.06	5.04e-07	5.44e-05	-0.2	-0.15	Parkinson disease and lewy body pathology;	chr1:54091617	chr1:54089856~54090093:+
BRCA	cis	rs763121	0.853	rs1043441	ENSG00000228274.3	RP3-508I15.9	-5.06	5.04e-07	5.44e-05	-0.18	-0.15	Menopause (age at onset);	chr22:38734959	chr22:38667585~38681820:-
BRCA	cis	rs2153535	0.58	rs4639392	ENSG00000251164.1	HULC	-5.06	5.04e-07	5.44e-05	-0.19	-0.15	Motion sickness;	chr6:8446314	chr6:8652137~8653846:+
BRCA	cis	rs4781563	0.667	rs12921111	ENSG00000242307.1	RPS26P52	-5.06	5.05e-07	5.44e-05	-0.18	-0.15	Bilirubin levels;	chr16:13915966	chr16:13922332~13922679:-
BRCA	cis	rs7617773	0.817	rs3729577	ENSG00000199476.1	Y_RNA	-5.06	5.05e-07	5.44e-05	-0.23	-0.15	Coronary artery disease;	chr3:48187504	chr3:48288587~48288694:+
BRCA	cis	rs875971	0.83	rs778711	ENSG00000236529.1	RP13-254B10.1	5.06	5.05e-07	5.44e-05	0.17	0.15	Aortic root size;	chr7:66386670	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.862	rs1083554	ENSG00000236529.1	RP13-254B10.1	5.06	5.05e-07	5.44e-05	0.17	0.15	Aortic root size;	chr7:66387354	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.862	rs778707	ENSG00000236529.1	RP13-254B10.1	5.06	5.05e-07	5.44e-05	0.17	0.15	Aortic root size;	chr7:66392040	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.862	rs778705	ENSG00000236529.1	RP13-254B10.1	5.06	5.05e-07	5.44e-05	0.17	0.15	Aortic root size;	chr7:66396128	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.862	rs778697	ENSG00000236529.1	RP13-254B10.1	5.06	5.05e-07	5.44e-05	0.17	0.15	Aortic root size;	chr7:66405439	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.798	rs7789615	ENSG00000236529.1	RP13-254B10.1	5.06	5.05e-07	5.44e-05	0.17	0.15	Aortic root size;	chr7:66413674	chr7:65840212~65840596:+
BRCA	cis	rs4713118	0.629	rs203887	ENSG00000204709.4	LINC01556	5.06	5.06e-07	5.45e-05	0.23	0.15	Parkinson's disease;	chr6:28053491	chr6:28943877~28944537:+
BRCA	cis	rs875971	0.862	rs10282433	ENSG00000236529.1	RP13-254B10.1	-5.06	5.06e-07	5.45e-05	-0.17	-0.15	Aortic root size;	chr7:66256452	chr7:65840212~65840596:+
BRCA	cis	rs10504130	0.696	rs78238505	ENSG00000253844.1	RP11-546K22.1	-5.06	5.06e-07	5.45e-05	-0.24	-0.15	Venous thromboembolism (SNP x SNP interaction);	chr8:51915578	chr8:51961458~52022974:+
BRCA	cis	rs854765	0.547	rs9896837	ENSG00000281749.1	Y_RNA	5.06	5.06e-07	5.46e-05	0.18	0.15	Total body bone mineral density;	chr17:18021554	chr17:18001101~18001195:-
BRCA	cis	rs8054556	1	rs4318227	ENSG00000273724.1	RP11-347C12.12	-5.06	5.06e-07	5.46e-05	-0.17	-0.15	Autism spectrum disorder or schizophrenia;	chr16:29973518	chr16:30336400~30343336:+
BRCA	cis	rs7618915	0.57	rs11130312	ENSG00000243224.1	RP5-1157M23.2	-5.06	5.06e-07	5.46e-05	-0.17	-0.15	Bipolar disorder;	chr3:52641039	chr3:52239258~52241097:+
BRCA	cis	rs427691	0.625	rs845739	ENSG00000271849.1	CTC-332L22.1	-5.06	5.06e-07	5.46e-05	-0.25	-0.15	Autism spectrum disorder or schizophrenia;	chr5:109682839	chr5:109687802~109688329:-
BRCA	cis	rs7267979	1	rs6083856	ENSG00000125804.12	FAM182A	5.06	5.06e-07	5.46e-05	0.2	0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25426949	chr20:26054655~26086917:+
BRCA	cis	rs7493	0.901	rs17883318	ENSG00000233942.1	AC004012.1	5.06	5.06e-07	5.46e-05	0.19	0.15	Yu-Zhi constitution type in type 2 diabetes;	chr7:95329000	chr7:95471835~95473998:+
BRCA	cis	rs4835473	0.9	rs10027246	ENSG00000249741.2	RP11-673E1.3	5.06	5.07e-07	5.46e-05	0.17	0.15	Immature fraction of reticulocytes;	chr4:143935069	chr4:143911514~143912053:-
BRCA	cis	rs8064024	0.87	rs6500635	ENSG00000267077.1	RP11-127I20.5	5.06	5.07e-07	5.46e-05	0.15	0.15	Cancer;	chr16:4817564	chr16:4795265~4796532:-
BRCA	cis	rs2281558	0.876	rs2274890	ENSG00000230772.1	VN1R108P	-5.06	5.07e-07	5.46e-05	-0.2	-0.15	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25320386	chr20:25734264~25735093:+
BRCA	cis	rs1707322	0.963	rs1768815	ENSG00000234329.1	RP11-767N6.2	-5.06	5.07e-07	5.47e-05	-0.16	-0.15	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46062931	chr1:45651039~45651826:-
BRCA	cis	rs4072705	0.586	rs7855247	ENSG00000224020.1	MIR181A2HG	5.06	5.07e-07	5.47e-05	0.18	0.15	Menarche (age at onset);	chr9:124484365	chr9:124658467~124698631:+
BRCA	cis	rs11098499	0.754	rs714899	ENSG00000260404.2	RP11-384K6.6	5.06	5.07e-07	5.47e-05	0.14	0.15	Corneal astigmatism;	chr4:119321880	chr4:118591773~118633729:+
BRCA	cis	rs1913185	0.787	rs67671074	ENSG00000240032.1	RP11-274H2.3	-5.06	5.08e-07	5.47e-05	-0.24	-0.15	Obesity-related traits;	chr3:146085476	chr3:146066344~146069185:-
BRCA	cis	rs962856	1	rs6722203	ENSG00000236780.4	AC078941.1	5.06	5.08e-07	5.47e-05	0.2	0.15	Pancreatic cancer;	chr2:67342061	chr2:67123357~67215319:-
BRCA	cis	rs79349575	0.716	rs46522	ENSG00000270781.1	RP11-501C14.9	-5.06	5.08e-07	5.47e-05	-0.18	-0.15	Type 2 diabetes;	chr17:48911235	chr17:48899131~48899748:+
BRCA	cis	rs62025270	0.688	rs17577869	ENSG00000202081.1	RNU6-1280P	-5.06	5.08e-07	5.47e-05	-0.23	-0.15	Idiopathic pulmonary fibrosis;	chr15:85771142	chr15:85651522~85651628:-
BRCA	cis	rs10861342	0.892	rs3829297	ENSG00000257999.1	RP11-61E11.2	-5.06	5.08e-07	5.47e-05	-0.31	-0.15	IgG glycosylation;	chr12:105199045	chr12:105102472~105107179:-
BRCA	cis	rs1707322	1	rs7517560	ENSG00000234329.1	RP11-767N6.2	5.05	5.08e-07	5.48e-05	0.16	0.15	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45960271	chr1:45651039~45651826:-
BRCA	cis	rs2745572	0.538	rs4587210	ENSG00000272279.1	RP11-157J24.2	5.05	5.08e-07	5.48e-05	0.18	0.15	Intraocular pressure;Glaucoma (primary open-angle);Glaucoma (high intraocular pressure);	chr6:1542956	chr6:1528364~1528911:-
BRCA	cis	rs4718428	0.96	rs6460317	ENSG00000229180.5	GS1-124K5.11	5.05	5.08e-07	5.48e-05	0.14	0.15	Corneal structure;	chr7:66925268	chr7:66526088~66542624:-
BRCA	cis	rs8114671	0.562	rs4911447	ENSG00000269202.1	RP4-614O4.12	-5.05	5.08e-07	5.48e-05	-0.16	-0.15	Height;	chr20:34891642	chr20:35201747~35203288:-
BRCA	cis	rs10911902	0.643	rs3766702	ENSG00000229739.2	RP11-295K2.3	-5.05	5.09e-07	5.48e-05	-0.24	-0.15	Schizophrenia;	chr1:186346832	chr1:186435161~186470291:+
BRCA	cis	rs4713118	0.513	rs149954	ENSG00000280107.1	AL022393.9	-5.05	5.09e-07	5.48e-05	-0.21	-0.15	Parkinson's disease;	chr6:28067468	chr6:28170845~28172521:+
BRCA	cis	rs8114671	0.562	rs6087643	ENSG00000269202.1	RP4-614O4.12	-5.05	5.09e-07	5.48e-05	-0.16	-0.15	Height;	chr20:34886659	chr20:35201747~35203288:-
BRCA	cis	rs2098713	0.534	rs12188314	ENSG00000250155.1	CTD-2353F22.1	5.05	5.09e-07	5.48e-05	0.17	0.15	Telomere length;	chr5:37578577	chr5:36666214~36725195:-
BRCA	cis	rs4660214	0.666	rs7554206	ENSG00000228060.1	RP11-69E11.8	5.05	5.09e-07	5.48e-05	0.16	0.15	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39463568	chr1:39565160~39573203:+
BRCA	cis	rs867186	1	rs80277764	ENSG00000126005.14	MMP24-AS1	-5.05	5.09e-07	5.48e-05	-0.31	-0.15	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35151653	chr20:35216462~35278131:-
BRCA	cis	rs10911232	0.507	rs4642853	ENSG00000224468.3	RP11-181K3.4	-5.05	5.09e-07	5.49e-05	-0.17	-0.15	Hypertriglyceridemia;	chr1:183027107	chr1:183138402~183141282:-
BRCA	cis	rs10911232	0.507	rs4369195	ENSG00000224468.3	RP11-181K3.4	-5.05	5.09e-07	5.49e-05	-0.17	-0.15	Hypertriglyceridemia;	chr1:183027156	chr1:183138402~183141282:-
BRCA	cis	rs2179367	0.632	rs66672129	ENSG00000268592.3	RAET1E-AS1	5.05	5.09e-07	5.49e-05	0.22	0.15	Dupuytren's disease;	chr6:149334387	chr6:149863494~149919507:+
BRCA	cis	rs2179367	0.632	rs9498322	ENSG00000268592.3	RAET1E-AS1	5.05	5.09e-07	5.49e-05	0.22	0.15	Dupuytren's disease;	chr6:149335950	chr6:149863494~149919507:+
BRCA	cis	rs2179367	0.632	rs9498323	ENSG00000268592.3	RAET1E-AS1	5.05	5.09e-07	5.49e-05	0.22	0.15	Dupuytren's disease;	chr6:149336077	chr6:149863494~149919507:+
BRCA	cis	rs2179367	0.632	rs12204793	ENSG00000268592.3	RAET1E-AS1	5.05	5.09e-07	5.49e-05	0.22	0.15	Dupuytren's disease;	chr6:149340102	chr6:149863494~149919507:+
BRCA	cis	rs1075265	0.87	rs6749817	ENSG00000235937.1	AC008280.1	5.05	5.09e-07	5.49e-05	0.17	0.15	Chronotype;Morning vs. evening chronotype;	chr2:54032396	chr2:54029552~54030682:-
BRCA	cis	rs7119	0.651	rs8041398	ENSG00000259362.2	RP11-307C19.1	-5.05	5.09e-07	5.49e-05	-0.21	-0.15	Type 2 diabetes;	chr15:77546831	chr15:77525540~77534110:+
BRCA	cis	rs1707322	0.963	rs34907901	ENSG00000234329.1	RP11-767N6.2	5.05	5.1e-07	5.49e-05	0.16	0.15	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45939542	chr1:45651039~45651826:-
BRCA	cis	rs9638182	0.666	rs2286276	ENSG00000274080.1	CTA-315H11.2	5.05	5.1e-07	5.49e-05	0.22	0.15	Triglycerides;	chr7:73573024	chr7:73609262~73611502:-
BRCA	cis	rs2574985	0.739	rs3011789	ENSG00000231345.3	BEND3P1	-5.05	5.1e-07	5.5e-05	-0.26	-0.15	Subjective well-being;	chr10:50549644	chr10:50655967~50660472:+
BRCA	cis	rs6832769	0.89	rs1522107	ENSG00000223305.1	RN7SKP30	5.05	5.1e-07	5.5e-05	0.19	0.15	Personality dimensions;	chr4:55514606	chr4:55540502~55540835:-
BRCA	cis	rs1043099	0.571	rs4820844	ENSG00000279699.1	RP1-102K2.9	-5.05	5.1e-07	5.5e-05	-0.2	-0.15	Rheumatoid arthritis;	chr22:30399226	chr22:30275215~30276951:-
BRCA	cis	rs1707322	1	rs10789486	ENSG00000234329.1	RP11-767N6.2	5.05	5.11e-07	5.5e-05	0.16	0.15	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45942995	chr1:45651039~45651826:-
BRCA	cis	rs924712	0.545	rs10948862	ENSG00000261116.1	RP3-523K23.2	5.05	5.11e-07	5.5e-05	0.18	0.15	Breast cancer;	chr6:54846673	chr6:54943167~54945099:+
BRCA	cis	rs924712	0.506	rs62412647	ENSG00000261116.1	RP3-523K23.2	5.05	5.11e-07	5.5e-05	0.18	0.15	Breast cancer;	chr6:54846906	chr6:54943167~54945099:+
BRCA	cis	rs924712	0.526	rs12664732	ENSG00000261116.1	RP3-523K23.2	5.05	5.11e-07	5.5e-05	0.18	0.15	Breast cancer;	chr6:54846916	chr6:54943167~54945099:+
BRCA	cis	rs6688613	0.685	rs61815130	ENSG00000225171.2	DUTP6	-5.05	5.11e-07	5.5e-05	-0.21	-0.15	Refractive astigmatism;	chr1:166941228	chr1:166868748~166869209:+
BRCA	cis	rs7577696	0.962	rs11124275	ENSG00000272716.1	RP11-563N4.1	-5.05	5.11e-07	5.5e-05	-0.17	-0.15	Inflammatory biomarkers;	chr2:32078693	chr2:32165046~32165757:-
BRCA	cis	rs7577696	0.925	rs11683931	ENSG00000272716.1	RP11-563N4.1	-5.05	5.11e-07	5.5e-05	-0.17	-0.15	Inflammatory biomarkers;	chr2:32078999	chr2:32165046~32165757:-
BRCA	cis	rs875971	0.862	rs12537823	ENSG00000236529.1	RP13-254B10.1	5.05	5.11e-07	5.5e-05	0.17	0.15	Aortic root size;	chr7:66255897	chr7:65840212~65840596:+
BRCA	cis	rs12439619	0.81	rs62012049	ENSG00000255769.6	GOLGA2P10	-5.05	5.11e-07	5.51e-05	-0.22	-0.15	Intelligence (multi-trait analysis);	chr15:82237722	chr15:82472993~82513950:-
BRCA	cis	rs7246657	0.722	rs11083432	ENSG00000226686.6	LINC01535	5.05	5.12e-07	5.51e-05	0.23	0.15	Coronary artery calcification;	chr19:37691732	chr19:37251912~37265535:+
BRCA	cis	rs6545883	0.894	rs7602859	ENSG00000270820.4	RP11-355B11.2	-5.05	5.12e-07	5.51e-05	-0.18	-0.15	Tuberculosis;	chr2:61231071	chr2:61471188~61484130:+
BRCA	cis	rs17772222	0.561	rs8020376	ENSG00000258983.2	RP11-507K2.2	5.05	5.12e-07	5.51e-05	0.16	0.15	Coronary artery calcification;	chr14:88349823	chr14:88499334~88515502:+
BRCA	cis	rs8127691	0.967	rs2070551	ENSG00000237604.1	AP001056.1	5.05	5.12e-07	5.51e-05	0.17	0.15	Inflammatory bowel disease;	chr21:44196789	chr21:44175489~44176453:+
BRCA	cis	rs2638953	0.962	rs79708115	ENSG00000247934.4	RP11-967K21.1	-5.05	5.12e-07	5.51e-05	-0.21	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28440784	chr12:28163298~28190738:-
BRCA	cis	rs10129255	0.5	rs1024350	ENSG00000211967.3	IGHV3-53	-5.05	5.12e-07	5.51e-05	-0.1	-0.15	Kawasaki disease;	chr14:106685105	chr14:106592676~106593347:-
BRCA	cis	rs7617773	0.963	rs12494304	ENSG00000228638.1	FCF1P2	5.05	5.12e-07	5.52e-05	0.15	0.15	Coronary artery disease;	chr3:48136539	chr3:48290793~48291375:-
BRCA	cis	rs116139393	0.634	rs17789828	ENSG00000187953.9	PMS2CL	-5.05	5.12e-07	5.52e-05	-0.29	-0.15	Alzheimer's disease (APOE e4 interaction);	chr7:6699006	chr7:6710128~6753862:+
BRCA	cis	rs6772849	0.931	rs60825080	ENSG00000242551.2	POU5F1P6	-5.05	5.13e-07	5.52e-05	-0.2	-0.15	Monocyte percentage of white cells;Monocyte count;	chr3:128665991	chr3:128674735~128677005:-
BRCA	cis	rs1707322	1	rs12077546	ENSG00000234329.1	RP11-767N6.2	5.05	5.13e-07	5.52e-05	0.16	0.15	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45966134	chr1:45651039~45651826:-
BRCA	cis	rs1707322	1	rs12124291	ENSG00000234329.1	RP11-767N6.2	5.05	5.13e-07	5.52e-05	0.16	0.15	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45966460	chr1:45651039~45651826:-
BRCA	cis	rs4934494	0.634	rs11185791	ENSG00000240996.1	RP11-80H5.7	-5.05	5.13e-07	5.52e-05	-0.22	-0.15	Red blood cell count;	chr10:89615198	chr10:89694295~89697928:-
BRCA	cis	rs7246967	0.673	rs62122382	ENSG00000198153.8	ZNF849P	-5.05	5.13e-07	5.52e-05	-0.28	-0.15	Bronchopulmonary dysplasia;	chr19:22798046	chr19:22685167~22686732:+
BRCA	cis	rs3845817	0.832	rs702950	ENSG00000237979.1	AC007389.1	5.05	5.13e-07	5.52e-05	0.19	0.15	Bipolar disorder;	chr2:65537776	chr2:65500993~65502138:-
BRCA	cis	rs867371	0.762	rs12905578	ENSG00000276710.3	CSPG4P8	5.05	5.13e-07	5.52e-05	0.17	0.15	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82288923	chr15:82459472~82477258:+
BRCA	cis	rs10911251	0.546	rs7473	ENSG00000224468.3	RP11-181K3.4	-5.05	5.14e-07	5.53e-05	-0.17	-0.15	Colorectal cancer;	chr1:183145499	chr1:183138402~183141282:-
BRCA	cis	rs66887589	0.616	rs10032299	ENSG00000249244.1	RP11-548H18.2	5.05	5.14e-07	5.53e-05	0.17	0.15	Diastolic blood pressure;	chr4:119285264	chr4:119391831~119395335:-
BRCA	cis	rs7267979	0.844	rs4423675	ENSG00000125804.12	FAM182A	5.05	5.14e-07	5.53e-05	0.2	0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25422142	chr20:26054655~26086917:+
BRCA	cis	rs10504130	0.696	rs12676780	ENSG00000253844.1	RP11-546K22.1	-5.05	5.14e-07	5.54e-05	-0.24	-0.15	Venous thromboembolism (SNP x SNP interaction);	chr8:51919420	chr8:51961458~52022974:+
BRCA	cis	rs8098244	0.557	rs4347707	ENSG00000264745.1	TTC39C-AS1	5.05	5.14e-07	5.54e-05	0.18	0.15	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23710362	chr18:23994213~24015339:-
BRCA	cis	rs7246657	0.606	rs2972439	ENSG00000276846.1	CTD-3220F14.3	-5.05	5.15e-07	5.54e-05	-0.21	-0.15	Coronary artery calcification;	chr19:37721680	chr19:37314868~37315620:-
BRCA	cis	rs7246657	0.722	rs2909100	ENSG00000276846.1	CTD-3220F14.3	-5.05	5.15e-07	5.54e-05	-0.21	-0.15	Coronary artery calcification;	chr19:37721779	chr19:37314868~37315620:-
BRCA	cis	rs739496	0.579	rs9971746	ENSG00000226469.1	ADAM1B	-5.05	5.15e-07	5.54e-05	-0.2	-0.15	Platelet count;	chr12:111899558	chr12:111927018~111929017:+
BRCA	cis	rs17711722	0.503	rs453835	ENSG00000222364.1	RNU6-96P	5.05	5.15e-07	5.55e-05	0.19	0.15	Calcium levels;	chr7:66046172	chr7:66395191~66395286:+
BRCA	cis	rs7577696	0.722	rs466125	ENSG00000272716.1	RP11-563N4.1	5.05	5.15e-07	5.55e-05	0.17	0.15	Inflammatory biomarkers;	chr2:32237023	chr2:32165046~32165757:-
BRCA	cis	rs2638953	0.814	rs10843164	ENSG00000247934.4	RP11-967K21.1	-5.05	5.16e-07	5.55e-05	-0.21	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28416781	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.924	rs11049583	ENSG00000247934.4	RP11-967K21.1	-5.05	5.16e-07	5.55e-05	-0.21	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28417238	chr12:28163298~28190738:-
BRCA	cis	rs3808502	0.525	rs9650661	ENSG00000270154.1	RP11-419I17.1	-5.05	5.16e-07	5.55e-05	-0.18	-0.15	Neuroticism;	chr8:11569624	chr8:12476462~12477122:+
BRCA	cis	rs2281636	0.931	rs2804419	ENSG00000233690.1	EBAG9P1	-5.05	5.16e-07	5.55e-05	-0.16	-0.15	Obesity-related traits;	chr10:99749356	chr10:99697407~99697949:-
BRCA	cis	rs6756513	0.5	rs1048130	ENSG00000231024.1	AC092431.3	-5.05	5.16e-07	5.55e-05	-0.23	-0.15	Breast cancer;Platelet count;	chr2:69904452	chr2:69700192~69713847:-
BRCA	cis	rs6001482	0.686	rs9623125	ENSG00000211642.2	IGLV10-54	5.05	5.16e-07	5.55e-05	0.15	0.15	Diastolic blood pressure;	chr22:22234600	chr22:22214794~22215270:+
BRCA	cis	rs6001482	0.702	rs9623126	ENSG00000211642.2	IGLV10-54	5.05	5.16e-07	5.55e-05	0.15	0.15	Diastolic blood pressure;	chr22:22234624	chr22:22214794~22215270:+
BRCA	cis	rs9311474	0.713	rs352170	ENSG00000243224.1	RP5-1157M23.2	-5.05	5.17e-07	5.56e-05	-0.17	-0.15	Electroencephalogram traits;	chr3:52202061	chr3:52239258~52241097:+
BRCA	cis	rs4948275	0.773	rs2256066	ENSG00000237233.2	TMEM26-AS1	-5.05	5.17e-07	5.56e-05	-0.19	-0.15	Night sleep phenotypes;	chr10:61507370	chr10:61452639~61481956:+
BRCA	cis	rs9473147	0.516	rs9357546	ENSG00000270761.1	RP11-385F7.1	-5.05	5.17e-07	5.56e-05	-0.16	-0.15	Platelet distribution width;Mean platelet volume;	chr6:47581759	chr6:47477243~47477572:-
BRCA	cis	rs8180040	0.593	rs12715421	ENSG00000276925.1	RP11-708J19.3	-5.05	5.17e-07	5.56e-05	-0.18	-0.15	Colorectal cancer;	chr3:47043369	chr3:47469777~47469987:+
BRCA	cis	rs1861628	1	rs2712172	ENSG00000229352.1	AC007563.3	-5.05	5.17e-07	5.57e-05	-0.21	-0.15	Serum thyroid-stimulating hormone levels;Hypothyroidism;	chr2:216756010	chr2:216799608~216805335:+
BRCA	cis	rs12900463	0.813	rs306198	ENSG00000225151.9	GOLGA2P7	5.05	5.18e-07	5.57e-05	0.2	0.15	Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine);	chr15:84862138	chr15:84199311~84230136:-
BRCA	cis	rs2274223	0.62	rs7914997	ENSG00000273450.1	RP11-76P2.4	5.05	5.18e-07	5.57e-05	0.24	0.15	Esophageal cancer;Esophageal squamous cell carcinoma;	chr10:94301366	chr10:94314907~94315327:-
BRCA	cis	rs11098499	0.754	rs11732087	ENSG00000260404.2	RP11-384K6.6	5.05	5.18e-07	5.57e-05	0.14	0.15	Corneal astigmatism;	chr4:119318676	chr4:118591773~118633729:+
BRCA	cis	rs10129255	0.957	rs8009464	ENSG00000211974.3	IGHV2-70	5.05	5.18e-07	5.57e-05	0.15	0.15	Kawasaki disease;	chr14:106777611	chr14:106723574~106724093:-
BRCA	cis	rs875971	0.545	rs6460276	ENSG00000230295.1	RP11-458F8.2	5.05	5.18e-07	5.57e-05	0.15	0.15	Aortic root size;	chr7:66182290	chr7:66880708~66882981:+
BRCA	cis	rs875971	0.862	rs6978028	ENSG00000236529.1	RP13-254B10.1	5.05	5.18e-07	5.58e-05	0.17	0.15	Aortic root size;	chr7:66421313	chr7:65840212~65840596:+
BRCA	cis	rs210138	0.706	rs3916279	ENSG00000197251.3	LINC00336	5.05	5.19e-07	5.58e-05	0.21	0.15	Testicular germ cell tumor;	chr6:33607173	chr6:33586106~33593338:-
BRCA	cis	rs35099186	0.583	rs12280645	ENSG00000254905.1	RP11-712L6.7	5.05	5.19e-07	5.58e-05	0.2	0.15	Coronary artery disease;	chr11:126393990	chr11:126292922~126294254:-
BRCA	cis	rs7200543	1	rs3803575	ENSG00000260872.1	RP11-680G24.5	-5.05	5.2e-07	5.59e-05	-0.16	-0.15	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15044590	chr16:15018106~15020488:-
BRCA	cis	rs728616	0.867	rs117139504	ENSG00000225484.5	NUTM2B-AS1	-5.05	5.2e-07	5.59e-05	-0.43	-0.15	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79974451	chr10:79663088~79826594:-
BRCA	cis	rs7267979	0.789	rs6076347	ENSG00000231081.1	RP4-760C5.3	5.05	5.2e-07	5.59e-05	0.2	0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25418154	chr20:26008791~26010531:-
BRCA	cis	rs12893668	0.572	rs1606	ENSG00000269958.1	RP11-73M18.8	5.05	5.2e-07	5.59e-05	0.17	0.15	Reticulocyte count;	chr14:103694944	chr14:103696353~103697163:+
BRCA	cis	rs734999	0.967	rs10797433	ENSG00000238164.5	RP3-395M20.8	-5.05	5.2e-07	5.59e-05	-0.12	-0.15	Ulcerative colitis;	chr1:2570571	chr1:2549920~2557031:-
BRCA	cis	rs2505998	0.833	rs1864403	ENSG00000273008.1	RP11-351D16.3	5.05	5.2e-07	5.59e-05	0.18	0.15	Hirschsprung disease;	chr10:43109502	chr10:43136824~43138334:-
BRCA	cis	rs4604234	0.803	rs28888768	ENSG00000272129.1	RP11-250B2.6	-5.05	5.2e-07	5.59e-05	-0.38	-0.15	Cancer;	chr6:80311913	chr6:80355424~80356859:+
BRCA	cis	rs1713985	0.92	rs1002285	ENSG00000269949.1	RP11-738E22.3	-5.05	5.2e-07	5.59e-05	-0.31	-0.15	Age-related macular degeneration;	chr4:56906546	chr4:56960927~56961373:-
BRCA	cis	rs8054556	0.669	rs4787491	ENSG00000261367.1	RP11-455F5.4	-5.05	5.2e-07	5.59e-05	-0.17	-0.15	Autism spectrum disorder or schizophrenia;	chr16:30004016	chr16:30107675~30110541:+
BRCA	cis	rs60843830	1	rs3791224	ENSG00000272342.1	RP13-539J13.1	5.05	5.2e-07	5.59e-05	0.19	0.15	Spherical equivalent (joint analysis main effects and education interaction);	chr2:221981	chr2:739588~740164:-
BRCA	cis	rs8180040	0.966	rs57346147	ENSG00000276925.1	RP11-708J19.3	5.05	5.21e-07	5.61e-05	0.18	0.15	Colorectal cancer;	chr3:47369074	chr3:47469777~47469987:+
BRCA	cis	rs2638953	0.925	rs11049598	ENSG00000247934.4	RP11-967K21.1	-5.05	5.22e-07	5.61e-05	-0.21	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28436160	chr12:28163298~28190738:-
BRCA	cis	rs2153535	0.58	rs915350	ENSG00000251164.1	HULC	-5.05	5.22e-07	5.61e-05	-0.19	-0.15	Motion sickness;	chr6:8443253	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.58	rs6941670	ENSG00000251164.1	HULC	-5.05	5.22e-07	5.61e-05	-0.19	-0.15	Motion sickness;	chr6:8446113	chr6:8652137~8653846:+
BRCA	cis	rs889312	0.961	rs961847	ENSG00000271828.1	CTD-2310F14.1	-5.05	5.22e-07	5.62e-05	-0.19	-0.15	Breast cancer (early onset);Breast cancer;	chr5:56745237	chr5:56927874~56929573:+
BRCA	cis	rs13108904	0.901	rs13119532	ENSG00000254094.1	AC078852.1	-5.05	5.22e-07	5.62e-05	-0.17	-0.15	Obesity-related traits;	chr4:1310717	chr4:1356581~1358075:+
BRCA	cis	rs1876905	0.68	rs373526	ENSG00000271789.1	RP5-1112D6.7	5.05	5.22e-07	5.62e-05	0.22	0.15	Mean corpuscular hemoglobin;	chr6:111190261	chr6:111297126~111298510:+
BRCA	cis	rs9473147	0.543	rs13211285	ENSG00000270761.1	RP11-385F7.1	-5.05	5.23e-07	5.62e-05	-0.16	-0.15	Platelet distribution width;Mean platelet volume;	chr6:47511882	chr6:47477243~47477572:-
BRCA	cis	rs2919009	0.607	rs41287984	ENSG00000271670.1	RP11-95I16.4	5.05	5.23e-07	5.62e-05	0.22	0.15	Obesity-related traits;	chr10:120852958	chr10:120879256~120880667:-
BRCA	cis	rs6480314	0.542	rs61854824	ENSG00000233590.1	RP11-153K11.3	-5.05	5.23e-07	5.62e-05	-0.26	-0.15	Optic nerve measurement (disc area);	chr10:68270438	chr10:68233251~68242379:-
BRCA	cis	rs6480314	0.542	rs12572954	ENSG00000233590.1	RP11-153K11.3	-5.05	5.23e-07	5.62e-05	-0.26	-0.15	Optic nerve measurement (disc area);	chr10:68270766	chr10:68233251~68242379:-
BRCA	cis	rs10504130	1	rs12678680	ENSG00000253844.1	RP11-546K22.1	-5.05	5.23e-07	5.62e-05	-0.28	-0.15	Venous thromboembolism (SNP x SNP interaction);	chr8:51755889	chr8:51961458~52022974:+
BRCA	cis	rs75422866	0.51	rs35784744	ENSG00000276691.1	RP5-1057I20.5	5.05	5.23e-07	5.62e-05	0.31	0.15	Pneumonia;	chr12:47729646	chr12:47788426~47788971:+
BRCA	cis	rs1552244	0.572	rs68013239	ENSG00000232901.1	CYCSP10	5.05	5.23e-07	5.62e-05	0.24	0.15	Alzheimer's disease;	chr3:10124027	chr3:10000647~10000940:-
BRCA	cis	rs1552244	0.572	rs68121641	ENSG00000232901.1	CYCSP10	5.05	5.23e-07	5.62e-05	0.24	0.15	Alzheimer's disease;	chr3:10124161	chr3:10000647~10000940:-
BRCA	cis	rs1552244	0.515	rs67342818	ENSG00000232901.1	CYCSP10	5.05	5.23e-07	5.62e-05	0.24	0.15	Alzheimer's disease;	chr3:10124722	chr3:10000647~10000940:-
BRCA	cis	rs1552244	0.572	rs66514627	ENSG00000232901.1	CYCSP10	5.05	5.23e-07	5.62e-05	0.24	0.15	Alzheimer's disease;	chr3:10124948	chr3:10000647~10000940:-
BRCA	cis	rs2562456	0.833	rs2562416	ENSG00000268081.1	RP11-678G14.2	5.05	5.23e-07	5.63e-05	0.25	0.15	Pain;	chr19:21430609	chr19:21554640~21569237:-
BRCA	cis	rs6001482	0.702	rs5757586	ENSG00000211642.2	IGLV10-54	5.05	5.24e-07	5.63e-05	0.15	0.15	Diastolic blood pressure;	chr22:22234458	chr22:22214794~22215270:+
BRCA	cis	rs62025270	0.688	rs62025298	ENSG00000202081.1	RNU6-1280P	-5.05	5.24e-07	5.63e-05	-0.23	-0.15	Idiopathic pulmonary fibrosis;	chr15:85773921	chr15:85651522~85651628:-
BRCA	cis	rs6840360	0.642	rs7658169	ENSG00000278978.1	RP11-164P12.5	-5.05	5.24e-07	5.63e-05	-0.17	-0.15	Intelligence (multi-trait analysis);	chr4:151432262	chr4:151669786~151670503:+
BRCA	cis	rs4934494	0.677	rs11185799	ENSG00000240996.1	RP11-80H5.7	-5.05	5.24e-07	5.63e-05	-0.21	-0.15	Red blood cell count;	chr10:89617709	chr10:89694295~89697928:-
BRCA	cis	rs9652601	0.845	rs7184615	ENSG00000274038.1	RP11-66H6.4	-5.05	5.24e-07	5.63e-05	-0.18	-0.15	Systemic lupus erythematosus;	chr16:11071685	chr16:11056556~11057034:+
BRCA	cis	rs8114671	0.562	rs6087642	ENSG00000269202.1	RP4-614O4.12	-5.05	5.25e-07	5.64e-05	-0.15	-0.15	Height;	chr20:34880503	chr20:35201747~35203288:-
BRCA	cis	rs2839186	0.814	rs2839167	ENSG00000228137.1	AP001469.7	5.05	5.25e-07	5.64e-05	0.16	0.15	Testicular germ cell tumor;	chr21:46241673	chr21:46246890~46247682:+
BRCA	cis	rs1979679	1	rs6487672	ENSG00000278733.1	RP11-425D17.1	5.05	5.25e-07	5.64e-05	0.2	0.15	Ossification of the posterior longitudinal ligament of the spine;	chr12:28270413	chr12:28185625~28186190:-
BRCA	cis	rs6496044	0.568	rs10468112	ENSG00000259295.5	CSPG4P12	5.05	5.25e-07	5.65e-05	0.18	0.15	Interstitial lung disease;	chr15:85530193	chr15:85191438~85213905:+
BRCA	cis	rs6496044	0.568	rs2344436	ENSG00000259295.5	CSPG4P12	5.05	5.25e-07	5.65e-05	0.18	0.15	Interstitial lung disease;	chr15:85531675	chr15:85191438~85213905:+
BRCA	cis	rs6496044	0.568	rs6496065	ENSG00000259295.5	CSPG4P12	5.05	5.25e-07	5.65e-05	0.18	0.15	Interstitial lung disease;	chr15:85532141	chr15:85191438~85213905:+
BRCA	cis	rs6496044	0.568	rs6496066	ENSG00000259295.5	CSPG4P12	5.05	5.25e-07	5.65e-05	0.18	0.15	Interstitial lung disease;	chr15:85532231	chr15:85191438~85213905:+
BRCA	cis	rs8048589	0.612	rs2869808	ENSG00000175604.2	RP11-276H1.3	-5.05	5.26e-07	5.65e-05	-0.23	-0.15	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);	chr16:12083007	chr16:12086746~12090302:-
BRCA	cis	rs8048589	0.642	rs8062015	ENSG00000175604.2	RP11-276H1.3	-5.05	5.26e-07	5.65e-05	-0.23	-0.15	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);	chr16:12083022	chr16:12086746~12090302:-
BRCA	cis	rs875971	0.545	rs73142233	ENSG00000230295.1	RP11-458F8.2	5.05	5.26e-07	5.65e-05	0.15	0.15	Aortic root size;	chr7:66221293	chr7:66880708~66882981:+
BRCA	cis	rs7487075	0.619	rs10880970	ENSG00000274723.1	RP11-618L22.1	5.05	5.26e-07	5.65e-05	0.19	0.15	Itch intensity from mosquito bite;	chr12:46436637	chr12:46970504~46972155:+
BRCA	cis	rs7487075	0.619	rs4076247	ENSG00000274723.1	RP11-618L22.1	5.05	5.26e-07	5.65e-05	0.19	0.15	Itch intensity from mosquito bite;	chr12:46439667	chr12:46970504~46972155:+
BRCA	cis	rs4713118	0.826	rs2893929	ENSG00000216901.1	AL022393.7	5.05	5.26e-07	5.65e-05	0.22	0.15	Parkinson's disease;	chr6:27770953	chr6:28176188~28176674:+
BRCA	cis	rs4713118	0.666	rs4140646	ENSG00000216901.1	AL022393.7	5.05	5.26e-07	5.65e-05	0.22	0.15	Parkinson's disease;	chr6:27771022	chr6:28176188~28176674:+
BRCA	cis	rs4713118	0.666	rs2893930	ENSG00000216901.1	AL022393.7	5.05	5.26e-07	5.65e-05	0.22	0.15	Parkinson's disease;	chr6:27771027	chr6:28176188~28176674:+
BRCA	cis	rs6840360	0.642	rs4696089	ENSG00000278978.1	RP11-164P12.5	-5.05	5.26e-07	5.65e-05	-0.17	-0.15	Intelligence (multi-trait analysis);	chr4:151474581	chr4:151669786~151670503:+
BRCA	cis	rs6840360	0.642	rs11932398	ENSG00000278978.1	RP11-164P12.5	-5.05	5.26e-07	5.65e-05	-0.17	-0.15	Intelligence (multi-trait analysis);	chr4:151476402	chr4:151669786~151670503:+
BRCA	cis	rs6840360	0.642	rs4263379	ENSG00000278978.1	RP11-164P12.5	-5.05	5.26e-07	5.65e-05	-0.17	-0.15	Intelligence (multi-trait analysis);	chr4:151477979	chr4:151669786~151670503:+
BRCA	cis	rs7665090	0.846	rs4496586	ENSG00000251288.2	RP11-10L12.2	-5.05	5.26e-07	5.65e-05	-0.18	-0.15	Primary biliary cholangitis;	chr4:102636154	chr4:102751401~102752641:+
BRCA	cis	rs1552244	0.572	rs41464050	ENSG00000232901.1	CYCSP10	5.05	5.26e-07	5.65e-05	0.24	0.15	Alzheimer's disease;	chr3:10116709	chr3:10000647~10000940:-
BRCA	cis	rs2839627	0.598	rs2246573	ENSG00000225218.1	AP001628.6	-5.05	5.26e-07	5.65e-05	-0.2	-0.15	Information processing speed;	chr21:42832906	chr21:42831040~42836477:-
BRCA	cis	rs7772486	0.743	rs9390344	ENSG00000270638.1	RP3-466P17.1	-5.05	5.27e-07	5.66e-05	-0.18	-0.15	Lobe attachment (rater-scored or self-reported);	chr6:145691619	chr6:145735570~145737218:+
BRCA	cis	rs9921338	0.961	rs9937269	ENSG00000262703.1	RP11-485G7.6	5.05	5.27e-07	5.66e-05	0.19	0.15	Vein graft stenosis in coronary artery bypass grafting;	chr16:11322822	chr16:11348143~11349321:-
BRCA	cis	rs7103648	0.603	rs3740688	ENSG00000280615.1	Y_RNA	5.05	5.27e-07	5.66e-05	0.17	0.15	Systolic blood pressure;Diastolic blood pressure;	chr11:47358789	chr11:47614898~47614994:-
BRCA	cis	rs17685	0.712	rs59659102	ENSG00000280388.1	RP11-229D13.3	-5.05	5.27e-07	5.66e-05	-0.16	-0.15	Coffee consumption (cups per day);Coffee consumption;	chr7:76080796	chr7:76043977~76045963:-
BRCA	cis	rs6088590	0.61	rs6120663	ENSG00000276073.1	RP5-1125A11.7	5.05	5.27e-07	5.67e-05	0.18	0.15	Coronary artery disease;	chr20:34494101	chr20:33985617~33988989:-
BRCA	cis	rs7267979	1	rs2500436	ENSG00000125804.12	FAM182A	5.05	5.28e-07	5.67e-05	0.2	0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25425730	chr20:26054655~26086917:+
BRCA	cis	rs11637445	0.626	rs1878699	ENSG00000260657.2	RP11-315D16.4	5.05	5.28e-07	5.67e-05	0.2	0.15	Posterior cortical atrophy and Alzheimer's disease;	chr15:67608545	chr15:68267792~68277994:-
BRCA	cis	rs9868809	0.505	rs11706203	ENSG00000270441.1	RP11-694I15.7	5.05	5.28e-07	5.67e-05	0.27	0.15	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48708806	chr3:49140086~49160851:-
BRCA	cis	rs11955398	0.563	rs7730342	ENSG00000215032.2	GNL3LP1	-5.05	5.28e-07	5.67e-05	-0.19	-0.15	Intelligence (multi-trait analysis);	chr5:60724818	chr5:60891935~60893577:-
BRCA	cis	rs10510102	0.688	rs56094144	ENSG00000226864.1	ATE1-AS1	5.05	5.28e-07	5.67e-05	0.28	0.15	Breast cancer;	chr10:121903941	chr10:121928312~121951965:+
BRCA	cis	rs17685	0.753	rs4728586	ENSG00000280388.1	RP11-229D13.3	-5.05	5.28e-07	5.67e-05	-0.16	-0.15	Coffee consumption (cups per day);Coffee consumption;	chr7:76173551	chr7:76043977~76045963:-
BRCA	cis	rs7267979	0.74	rs2259961	ENSG00000274973.1	RP13-401N8.7	-5.05	5.28e-07	5.67e-05	-0.18	-0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25301990	chr20:25845497~25845862:+
BRCA	cis	rs2153535	0.585	rs7765238	ENSG00000230939.1	RP11-314C16.1	5.05	5.29e-07	5.68e-05	0.18	0.15	Motion sickness;	chr6:8632560	chr6:8784178~8785445:+
BRCA	cis	rs9467773	0.62	rs2451741	ENSG00000124549.13	BTN2A3P	5.05	5.29e-07	5.68e-05	0.15	0.15	Intelligence (multi-trait analysis);	chr6:26629176	chr6:26421391~26432383:+
BRCA	cis	rs2638953	0.64	rs10843211	ENSG00000278733.1	RP11-425D17.1	-5.05	5.29e-07	5.68e-05	-0.21	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28577717	chr12:28185625~28186190:-
BRCA	cis	rs6547741	0.904	rs1528403	ENSG00000234072.1	AC074117.10	5.05	5.29e-07	5.68e-05	0.14	0.15	Oral cavity cancer;	chr2:27623778	chr2:27356246~27367622:+
BRCA	cis	rs2274273	0.712	rs1002054	ENSG00000258413.1	RP11-665C16.6	-5.05	5.29e-07	5.68e-05	-0.2	-0.15	Protein biomarker;	chr14:55062195	chr14:55262767~55272075:-
BRCA	cis	rs2153535	0.541	rs945304	ENSG00000251164.1	HULC	-5.05	5.29e-07	5.68e-05	-0.19	-0.15	Motion sickness;	chr6:8442659	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.58	rs1889715	ENSG00000251164.1	HULC	-5.05	5.29e-07	5.68e-05	-0.19	-0.15	Motion sickness;	chr6:8443242	chr6:8652137~8653846:+
BRCA	cis	rs7569084	0.663	rs11126037	ENSG00000281920.1	RP11-418H16.1	5.05	5.29e-07	5.69e-05	0.2	0.15	Sum eosinophil basophil counts;	chr2:65436024	chr2:65623272~65628424:+
BRCA	cis	rs17685	0.736	rs4732594	ENSG00000280388.1	RP11-229D13.3	-5.05	5.3e-07	5.69e-05	-0.16	-0.15	Coffee consumption (cups per day);Coffee consumption;	chr7:76123955	chr7:76043977~76045963:-
BRCA	cis	rs17685	0.671	rs60303271	ENSG00000280388.1	RP11-229D13.3	-5.05	5.3e-07	5.69e-05	-0.16	-0.15	Coffee consumption (cups per day);Coffee consumption;	chr7:76130690	chr7:76043977~76045963:-
BRCA	cis	rs17685	0.735	rs11763339	ENSG00000280388.1	RP11-229D13.3	-5.05	5.3e-07	5.69e-05	-0.16	-0.15	Coffee consumption (cups per day);Coffee consumption;	chr7:76132223	chr7:76043977~76045963:-
BRCA	cis	rs17685	0.775	rs11761172	ENSG00000280388.1	RP11-229D13.3	-5.05	5.3e-07	5.69e-05	-0.16	-0.15	Coffee consumption (cups per day);Coffee consumption;	chr7:76132229	chr7:76043977~76045963:-
BRCA	cis	rs17685	0.753	rs11764129	ENSG00000280388.1	RP11-229D13.3	-5.05	5.3e-07	5.69e-05	-0.16	-0.15	Coffee consumption (cups per day);Coffee consumption;	chr7:76132572	chr7:76043977~76045963:-
BRCA	cis	rs17685	0.623	rs7782808	ENSG00000280388.1	RP11-229D13.3	-5.05	5.3e-07	5.69e-05	-0.16	-0.15	Coffee consumption (cups per day);Coffee consumption;	chr7:76139327	chr7:76043977~76045963:-
BRCA	cis	rs17685	0.753	rs6953665	ENSG00000280388.1	RP11-229D13.3	-5.05	5.3e-07	5.69e-05	-0.16	-0.15	Coffee consumption (cups per day);Coffee consumption;	chr7:76139731	chr7:76043977~76045963:-
BRCA	cis	rs17685	0.712	rs7778735	ENSG00000280388.1	RP11-229D13.3	-5.05	5.3e-07	5.69e-05	-0.16	-0.15	Coffee consumption (cups per day);Coffee consumption;	chr7:76140919	chr7:76043977~76045963:-
BRCA	cis	rs17685	0.712	rs10275521	ENSG00000280388.1	RP11-229D13.3	-5.05	5.3e-07	5.69e-05	-0.16	-0.15	Coffee consumption (cups per day);Coffee consumption;	chr7:76141654	chr7:76043977~76045963:-
BRCA	cis	rs35740288	0.822	rs11629690	ENSG00000202081.1	RNU6-1280P	5.05	5.3e-07	5.69e-05	0.21	0.15	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85744493	chr15:85651522~85651628:-
BRCA	cis	rs10833905	0.938	rs2468560	ENSG00000246225.5	RP11-17A1.3	5.05	5.3e-07	5.69e-05	0.22	0.15	Sudden cardiac arrest;	chr11:23067083	chr11:22829380~22945393:+
BRCA	cis	rs6714710	0.603	rs11692010	ENSG00000230606.9	AC159540.1	-5.05	5.3e-07	5.69e-05	-0.18	-0.15	Posterior cortical atrophy and Alzheimer's disease;	chr2:97780838	chr2:97416165~97433527:-
BRCA	cis	rs8031584	0.958	rs34294266	ENSG00000270015.1	RP11-540B6.6	-5.05	5.31e-07	5.7e-05	-0.16	-0.15	Huntington's disease progression;	chr15:30954637	chr15:30926514~30928407:+
BRCA	cis	rs6452524	0.967	rs2731844	ENSG00000281327.1	LINC01338	5.05	5.31e-07	5.7e-05	0.18	0.15	Hypertension (SNP x SNP interaction);	chr5:83192627	chr5:82850864~82859836:-
BRCA	cis	rs6452524	0.901	rs2940540	ENSG00000281327.1	LINC01338	5.05	5.31e-07	5.7e-05	0.18	0.15	Hypertension (SNP x SNP interaction);	chr5:83193004	chr5:82850864~82859836:-
BRCA	cis	rs4372836	0.681	rs6547875	ENSG00000226833.4	AC097724.3	5.05	5.31e-07	5.7e-05	0.18	0.15	Body mass index;	chr2:28774274	chr2:28708953~28736205:-
BRCA	cis	rs4372836	0.658	rs10178852	ENSG00000226833.4	AC097724.3	5.05	5.31e-07	5.7e-05	0.18	0.15	Body mass index;	chr2:28774969	chr2:28708953~28736205:-
BRCA	cis	rs7267979	0.714	rs6132825	ENSG00000125804.12	FAM182A	-5.05	5.31e-07	5.7e-05	-0.2	-0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25257673	chr20:26054655~26086917:+
BRCA	cis	rs6840360	0.642	rs2724567	ENSG00000251611.1	RP11-610P16.1	5.05	5.31e-07	5.7e-05	0.13	0.15	Intelligence (multi-trait analysis);	chr4:151430008	chr4:151407551~151408835:-
BRCA	cis	rs2832191	0.791	rs2832182	ENSG00000176054.6	RPL23P2	-5.05	5.32e-07	5.71e-05	-0.16	-0.15	Dental caries;	chr21:29109291	chr21:28997613~28998033:-
BRCA	cis	rs1552244	0.572	rs59132826	ENSG00000232901.1	CYCSP10	5.05	5.32e-07	5.71e-05	0.24	0.15	Alzheimer's disease;	chr3:10128041	chr3:10000647~10000940:-
BRCA	cis	rs1552244	0.572	rs58223482	ENSG00000232901.1	CYCSP10	5.05	5.32e-07	5.71e-05	0.24	0.15	Alzheimer's disease;	chr3:10128062	chr3:10000647~10000940:-
BRCA	cis	rs1552244	0.572	rs113406084	ENSG00000232901.1	CYCSP10	5.05	5.32e-07	5.71e-05	0.24	0.15	Alzheimer's disease;	chr3:10128506	chr3:10000647~10000940:-
BRCA	cis	rs116139393	0.571	rs3801035	ENSG00000187953.9	PMS2CL	-5.05	5.32e-07	5.72e-05	-0.28	-0.15	Alzheimer's disease (APOE e4 interaction);	chr7:6695903	chr7:6710128~6753862:+
BRCA	cis	rs78487399	0.808	rs75321787	ENSG00000234936.1	AC010883.5	5.05	5.32e-07	5.72e-05	0.22	0.15	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43615932	chr2:43229573~43233394:+
BRCA	cis	rs8180040	0.902	rs73081205	ENSG00000276925.1	RP11-708J19.3	5.05	5.33e-07	5.72e-05	0.18	0.15	Colorectal cancer;	chr3:47476180	chr3:47469777~47469987:+
BRCA	cis	rs9818758	0.607	rs11710247	ENSG00000270441.1	RP11-694I15.7	5.05	5.33e-07	5.72e-05	0.29	0.15	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49212367	chr3:49140086~49160851:-
BRCA	cis	rs9467773	1	rs10484442	ENSG00000241549.7	GUSBP2	5.05	5.33e-07	5.72e-05	0.17	0.15	Intelligence (multi-trait analysis);	chr6:26555651	chr6:26871484~26956554:-
BRCA	cis	rs1707322	1	rs10158032	ENSG00000234329.1	RP11-767N6.2	5.05	5.33e-07	5.72e-05	0.16	0.15	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45867029	chr1:45651039~45651826:-
BRCA	cis	rs3764021	0.87	rs10492166	ENSG00000256673.1	RP11-599J14.2	-5.05	5.33e-07	5.72e-05	-0.17	-0.15	Type 1 diabetes;	chr12:9733403	chr12:9398355~9414851:-
BRCA	cis	rs4908768	0.501	rs11121199	ENSG00000232912.4	RP5-1115A15.1	5.05	5.33e-07	5.72e-05	0.15	0.15	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8540133	chr1:8424645~8434838:+
BRCA	cis	rs12497850	0.864	rs4521268	ENSG00000225399.4	RP11-3B7.1	5.05	5.33e-07	5.72e-05	0.15	0.15	Parkinson's disease;	chr3:49100471	chr3:49260085~49261316:+
BRCA	cis	rs13113518	0.513	rs13132085	ENSG00000272969.1	RP11-528I4.2	-5.05	5.33e-07	5.72e-05	-0.18	-0.15	Height;	chr4:55593918	chr4:55547112~55547889:+
BRCA	cis	rs559928	0.947	rs12417275	ENSG00000236935.1	AP003774.1	5.05	5.33e-07	5.73e-05	0.2	0.15	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64376302	chr11:64325050~64329504:-
BRCA	cis	rs7819412	0.645	rs10156356	ENSG00000255046.1	RP11-297N6.4	5.05	5.34e-07	5.73e-05	0.19	0.15	Triglycerides;	chr8:11188700	chr8:11797928~11802568:-
BRCA	cis	rs9287719	0.967	rs10203785	ENSG00000243819.4	RN7SL832P	5.05	5.34e-07	5.73e-05	0.15	0.15	Prostate cancer;	chr2:10612382	chr2:10690344~10692099:+
BRCA	cis	rs9907295	0.748	rs4251719	ENSG00000271013.1	AC015849.15	-5.05	5.34e-07	5.73e-05	-0.2	-0.15	Fibroblast growth factor basic levels;	chr17:35815358	chr17:35912635~35918010:-
BRCA	cis	rs1499614	0.522	rs13247442	ENSG00000232559.3	GS1-124K5.12	5.05	5.35e-07	5.74e-05	0.37	0.15	Gout;	chr7:66723871	chr7:66554588~66576923:-
BRCA	cis	rs2624839	0.704	rs2526384	ENSG00000228008.1	CTD-2330K9.3	5.05	5.35e-07	5.74e-05	0.17	0.15	Intelligence (multi-trait analysis);	chr3:50143703	chr3:49903845~49916937:+
BRCA	cis	rs13096357	0.52	rs17080319	ENSG00000270441.1	RP11-694I15.7	5.04	5.35e-07	5.74e-05	0.27	0.15	Cognitive ability (multi-trait analysis);	chr3:48695047	chr3:49140086~49160851:-
BRCA	cis	rs11158026	0.575	rs8008150	ENSG00000258413.1	RP11-665C16.6	-5.04	5.35e-07	5.74e-05	-0.21	-0.15	Parkinson's disease;	chr14:54954718	chr14:55262767~55272075:-
BRCA	cis	rs730566	1	rs4858819	ENSG00000229759.1	MRPS18AP1	-5.04	5.35e-07	5.74e-05	-0.2	-0.15	Prion diseases;	chr3:48436678	chr3:48256350~48256938:-
BRCA	cis	rs6723226	0.764	rs176403	ENSG00000276517.1	AL133243.2	5.04	5.35e-07	5.74e-05	0.19	0.15	Intelligence (multi-trait analysis);	chr2:32412796	chr2:32526504~32529507:+
BRCA	cis	rs7119	0.717	rs8042307	ENSG00000259362.2	RP11-307C19.1	-5.04	5.35e-07	5.75e-05	-0.21	-0.15	Type 2 diabetes;	chr15:77511671	chr15:77525540~77534110:+
BRCA	cis	rs4835473	0.932	rs1511425	ENSG00000249741.2	RP11-673E1.3	-5.04	5.36e-07	5.75e-05	-0.16	-0.15	Immature fraction of reticulocytes;	chr4:143985122	chr4:143911514~143912053:-
BRCA	cis	rs4835473	0.932	rs1849120	ENSG00000249741.2	RP11-673E1.3	-5.04	5.36e-07	5.75e-05	-0.16	-0.15	Immature fraction of reticulocytes;	chr4:143985337	chr4:143911514~143912053:-
BRCA	cis	rs4835473	0.932	rs4835476	ENSG00000249741.2	RP11-673E1.3	-5.04	5.36e-07	5.75e-05	-0.16	-0.15	Immature fraction of reticulocytes;	chr4:143985517	chr4:143911514~143912053:-
BRCA	cis	rs4835473	0.932	rs1828502	ENSG00000249741.2	RP11-673E1.3	-5.04	5.36e-07	5.75e-05	-0.16	-0.15	Immature fraction of reticulocytes;	chr4:143985797	chr4:143911514~143912053:-
BRCA	cis	rs4835473	0.932	rs7668698	ENSG00000249741.2	RP11-673E1.3	-5.04	5.36e-07	5.75e-05	-0.16	-0.15	Immature fraction of reticulocytes;	chr4:143986333	chr4:143911514~143912053:-
BRCA	cis	rs4835473	0.932	rs6537231	ENSG00000249741.2	RP11-673E1.3	-5.04	5.36e-07	5.75e-05	-0.16	-0.15	Immature fraction of reticulocytes;	chr4:143986489	chr4:143911514~143912053:-
BRCA	cis	rs4835473	0.932	rs1877234	ENSG00000249741.2	RP11-673E1.3	-5.04	5.36e-07	5.75e-05	-0.16	-0.15	Immature fraction of reticulocytes;	chr4:143986774	chr4:143911514~143912053:-
BRCA	cis	rs2638953	0.815	rs11049677	ENSG00000247934.4	RP11-967K21.1	5.04	5.36e-07	5.75e-05	0.21	0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28505106	chr12:28163298~28190738:-
BRCA	cis	rs2179367	0.632	rs9498324	ENSG00000268592.3	RAET1E-AS1	5.04	5.36e-07	5.75e-05	0.22	0.15	Dupuytren's disease;	chr6:149338973	chr6:149863494~149919507:+
BRCA	cis	rs2179367	0.632	rs55826712	ENSG00000268592.3	RAET1E-AS1	5.04	5.36e-07	5.75e-05	0.22	0.15	Dupuytren's disease;	chr6:149344716	chr6:149863494~149919507:+
BRCA	cis	rs9300255	0.602	rs10744147	ENSG00000235423.7	RP11-282O18.3	5.04	5.36e-07	5.76e-05	0.2	0.15	Neutrophil percentage of white cells;	chr12:123159182	chr12:123252030~123261483:-
BRCA	cis	rs4925386	0.765	rs6142737	ENSG00000273619.1	RP5-908M14.9	-5.04	5.37e-07	5.76e-05	-0.14	-0.15	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62344744	chr20:62386303~62386970:-
BRCA	cis	rs1979679	0.918	rs7314502	ENSG00000278733.1	RP11-425D17.1	-5.04	5.37e-07	5.76e-05	-0.2	-0.15	Ossification of the posterior longitudinal ligament of the spine;	chr12:28462300	chr12:28185625~28186190:-
BRCA	cis	rs2574985	0.739	rs3011791	ENSG00000231345.3	BEND3P1	-5.04	5.37e-07	5.77e-05	-0.26	-0.15	Subjective well-being;	chr10:50550661	chr10:50655967~50660472:+
BRCA	cis	rs17685	0.753	rs10264760	ENSG00000280388.1	RP11-229D13.3	-5.04	5.38e-07	5.77e-05	-0.16	-0.15	Coffee consumption (cups per day);Coffee consumption;	chr7:76120376	chr7:76043977~76045963:-
BRCA	cis	rs2243480	1	rs313831	ENSG00000275400.1	RP4-756H11.5	5.04	5.38e-07	5.77e-05	0.29	0.15	Diabetic kidney disease;	chr7:66086239	chr7:66553805~66554199:-
BRCA	cis	rs2251381	0.741	rs2735966	ENSG00000176054.6	RPL23P2	5.04	5.38e-07	5.77e-05	0.18	0.15	Selective IgA deficiency;	chr21:29165853	chr21:28997613~28998033:-
BRCA	cis	rs11098499	0.731	rs6846966	ENSG00000249244.1	RP11-548H18.2	5.04	5.38e-07	5.77e-05	0.18	0.15	Corneal astigmatism;	chr4:119372053	chr4:119391831~119395335:-
BRCA	cis	rs7119	0.745	rs11632602	ENSG00000259362.2	RP11-307C19.1	-5.04	5.38e-07	5.77e-05	-0.21	-0.15	Type 2 diabetes;	chr15:77517422	chr15:77525540~77534110:+
BRCA	cis	rs4356203	0.875	rs11024136	ENSG00000272034.1	SNORD14A	-5.04	5.38e-07	5.77e-05	-0.16	-0.15	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17042850	chr11:17074654~17074744:-
BRCA	cis	rs6442522	0.933	rs7622657	ENSG00000249786.6	EAF1-AS1	-5.04	5.38e-07	5.77e-05	-0.16	-0.15	Uric acid levels;	chr3:15370385	chr3:15436171~15455940:-
BRCA	cis	rs7914558	1	rs7914558	ENSG00000236937.2	PTGES3P4	5.04	5.39e-07	5.77e-05	0.2	0.15	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103016151	chr10:102845595~102845950:+
BRCA	cis	rs6596100	0.915	rs55914434	ENSG00000248648.1	RP11-485M7.1	-5.04	5.39e-07	5.78e-05	-0.2	-0.15	Breast cancer;	chr5:133059845	chr5:133003119~133003365:+
BRCA	cis	rs6596100	0.915	rs58821592	ENSG00000248648.1	RP11-485M7.1	-5.04	5.39e-07	5.78e-05	-0.2	-0.15	Breast cancer;	chr5:133064252	chr5:133003119~133003365:+
BRCA	cis	rs6756513	0.5	rs36081078	ENSG00000231024.1	AC092431.3	-5.04	5.39e-07	5.78e-05	-0.23	-0.15	Breast cancer;Platelet count;	chr2:69859231	chr2:69700192~69713847:-
BRCA	cis	rs7572733	0.534	rs1435570	ENSG00000231621.1	AC013264.2	-5.04	5.39e-07	5.78e-05	-0.15	-0.15	Dermatomyositis;	chr2:197866647	chr2:197197991~197199273:+
BRCA	cis	rs9369695	0.842	rs2396825	ENSG00000270761.1	RP11-385F7.1	-5.04	5.39e-07	5.78e-05	-0.16	-0.15	Reticulocyte count;	chr6:47600960	chr6:47477243~47477572:-
BRCA	cis	rs9473147	0.516	rs9395286	ENSG00000270761.1	RP11-385F7.1	-5.04	5.39e-07	5.78e-05	-0.16	-0.15	Platelet distribution width;Mean platelet volume;	chr6:47607596	chr6:47477243~47477572:-
BRCA	cis	rs2911132	0.564	rs731827	ENSG00000248734.2	CTD-2260A17.1	5.04	5.39e-07	5.78e-05	0.18	0.15	Urate levels (BMI interaction);	chr5:96751311	chr5:96784777~96785999:+
BRCA	cis	rs2243480	0.706	rs6460257	ENSG00000229886.1	RP5-1132H15.3	5.04	5.39e-07	5.78e-05	0.23	0.15	Diabetic kidney disease;	chr7:65731813	chr7:66025126~66031544:-
BRCA	cis	rs2638953	0.815	rs58416107	ENSG00000247934.4	RP11-967K21.1	-5.04	5.39e-07	5.78e-05	-0.21	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28543645	chr12:28163298~28190738:-
BRCA	cis	rs11955398	0.716	rs1379114	ENSG00000215032.2	GNL3LP1	5.04	5.39e-07	5.78e-05	0.19	0.15	Intelligence (multi-trait analysis);	chr5:60701971	chr5:60891935~60893577:-
BRCA	cis	rs11955398	0.716	rs1379115	ENSG00000215032.2	GNL3LP1	5.04	5.39e-07	5.78e-05	0.19	0.15	Intelligence (multi-trait analysis);	chr5:60702059	chr5:60891935~60893577:-
BRCA	cis	rs11955398	0.678	rs1824120	ENSG00000215032.2	GNL3LP1	5.04	5.39e-07	5.78e-05	0.19	0.15	Intelligence (multi-trait analysis);	chr5:60702102	chr5:60891935~60893577:-
BRCA	cis	rs11955398	0.716	rs10939860	ENSG00000215032.2	GNL3LP1	5.04	5.39e-07	5.78e-05	0.19	0.15	Intelligence (multi-trait analysis);	chr5:60703533	chr5:60891935~60893577:-
BRCA	cis	rs11955398	0.716	rs12515025	ENSG00000215032.2	GNL3LP1	5.04	5.39e-07	5.78e-05	0.19	0.15	Intelligence (multi-trait analysis);	chr5:60703610	chr5:60891935~60893577:-
BRCA	cis	rs2624839	0.704	rs13064381	ENSG00000228008.1	CTD-2330K9.3	5.04	5.39e-07	5.78e-05	0.16	0.15	Intelligence (multi-trait analysis);	chr3:50195884	chr3:49903845~49916937:+
BRCA	cis	rs2522056	1	rs2106854	ENSG00000233006.5	AC034220.3	-5.04	5.39e-07	5.78e-05	-0.13	-0.15	Fibrinogen;Lymphocyte counts;	chr5:132433482	chr5:132311285~132369916:-
BRCA	cis	rs595244	1	rs2437947	ENSG00000259705.1	RP11-227D13.1	5.04	5.4e-07	5.79e-05	0.28	0.15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48584684	chr15:48645951~48652016:+
BRCA	cis	rs13113518	1	rs11937487	ENSG00000223305.1	RN7SKP30	5.04	5.4e-07	5.79e-05	0.19	0.15	Height;	chr4:55436576	chr4:55540502~55540835:-
BRCA	cis	rs1499614	0.901	rs3936	ENSG00000275400.1	RP4-756H11.5	5.04	5.4e-07	5.79e-05	0.28	0.15	Gout;	chr7:66661502	chr7:66553805~66554199:-
BRCA	cis	rs597539	0.652	rs686877	ENSG00000261625.1	RP11-554A11.4	-5.04	5.41e-07	5.8e-05	-0.15	-0.15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68869701	chr11:69000765~69002048:-
BRCA	cis	rs597539	0.652	rs579136	ENSG00000261625.1	RP11-554A11.4	-5.04	5.41e-07	5.8e-05	-0.15	-0.15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68870008	chr11:69000765~69002048:-
BRCA	cis	rs6442522	0.606	rs13093164	ENSG00000249786.6	EAF1-AS1	5.04	5.41e-07	5.8e-05	0.16	0.15	Uric acid levels;	chr3:15452311	chr3:15436171~15455940:-
BRCA	cis	rs11098499	0.619	rs28502463	ENSG00000249244.1	RP11-548H18.2	5.04	5.41e-07	5.8e-05	0.18	0.15	Corneal astigmatism;	chr4:119335868	chr4:119391831~119395335:-
BRCA	cis	rs9425766	0.546	rs6691001	ENSG00000227373.4	RP11-160H22.5	5.04	5.41e-07	5.8e-05	0.22	0.15	Life satisfaction;	chr1:173849938	chr1:174115300~174160004:-
BRCA	cis	rs3120667	0.79	rs3753444	ENSG00000237975.5	FLG-AS1	5.04	5.41e-07	5.8e-05	0.21	0.15	Eating disorders;	chr1:152415391	chr1:152168125~152445456:+
BRCA	cis	rs9467773	0.62	rs2451737	ENSG00000124549.13	BTN2A3P	5.04	5.41e-07	5.8e-05	0.15	0.15	Intelligence (multi-trait analysis);	chr6:26618813	chr6:26421391~26432383:+
BRCA	cis	rs9467773	0.596	rs2494693	ENSG00000124549.13	BTN2A3P	5.04	5.41e-07	5.8e-05	0.15	0.15	Intelligence (multi-trait analysis);	chr6:26618998	chr6:26421391~26432383:+
BRCA	cis	rs9467773	0.62	rs2494694	ENSG00000124549.13	BTN2A3P	5.04	5.41e-07	5.8e-05	0.15	0.15	Intelligence (multi-trait analysis);	chr6:26619100	chr6:26421391~26432383:+
BRCA	cis	rs10504130	0.666	rs7819892	ENSG00000253844.1	RP11-546K22.1	5.04	5.41e-07	5.8e-05	0.2	0.15	Venous thromboembolism (SNP x SNP interaction);	chr8:51932916	chr8:51961458~52022974:+
BRCA	cis	rs875971	0.895	rs4145009	ENSG00000236529.1	RP13-254B10.1	-5.04	5.41e-07	5.8e-05	-0.17	-0.15	Aortic root size;	chr7:66261628	chr7:65840212~65840596:+
BRCA	cis	rs9473147	0.516	rs6903331	ENSG00000270761.1	RP11-385F7.1	-5.04	5.42e-07	5.81e-05	-0.16	-0.15	Platelet distribution width;Mean platelet volume;	chr6:47595179	chr6:47477243~47477572:-
BRCA	cis	rs1707322	1	rs2458400	ENSG00000234329.1	RP11-767N6.2	-5.04	5.42e-07	5.81e-05	-0.16	-0.15	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46065126	chr1:45651039~45651826:-
BRCA	cis	rs7246657	0.722	rs10402671	ENSG00000276846.1	CTD-3220F14.3	5.04	5.42e-07	5.81e-05	0.21	0.15	Coronary artery calcification;	chr19:37626185	chr19:37314868~37315620:-
BRCA	cis	rs7246657	0.722	rs10417576	ENSG00000276846.1	CTD-3220F14.3	5.04	5.42e-07	5.81e-05	0.21	0.15	Coronary artery calcification;	chr19:37628311	chr19:37314868~37315620:-
BRCA	cis	rs8180040	0.603	rs9854790	ENSG00000276925.1	RP11-708J19.3	-5.04	5.42e-07	5.81e-05	-0.18	-0.15	Colorectal cancer;	chr3:47059816	chr3:47469777~47469987:+
BRCA	cis	rs7267979	0.816	rs443009	ENSG00000125804.12	FAM182A	5.04	5.42e-07	5.81e-05	0.2	0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25519181	chr20:26054655~26086917:+
BRCA	cis	rs10129255	0.913	rs10140943	ENSG00000211974.3	IGHV2-70	5.04	5.43e-07	5.82e-05	0.17	0.15	Kawasaki disease;	chr14:106767441	chr14:106723574~106724093:-
BRCA	cis	rs7569084	0.687	rs11126038	ENSG00000281920.1	RP11-418H16.1	5.04	5.43e-07	5.82e-05	0.2	0.15	Sum eosinophil basophil counts;	chr2:65436100	chr2:65623272~65628424:+
BRCA	cis	rs7569084	0.663	rs11694714	ENSG00000281920.1	RP11-418H16.1	5.04	5.43e-07	5.82e-05	0.2	0.15	Sum eosinophil basophil counts;	chr2:65436802	chr2:65623272~65628424:+
BRCA	cis	rs35146811	0.844	rs4424195	ENSG00000235713.1	RP4-604G5.3	5.04	5.43e-07	5.82e-05	0.18	0.15	Coronary artery disease;	chr7:100045122	chr7:99992397~99993050:+
BRCA	cis	rs1552244	1	rs12374115	ENSG00000180385.7	EMC3-AS1	-5.04	5.44e-07	5.83e-05	-0.19	-0.15	Alzheimer's disease;	chr3:10093082	chr3:9986893~10006990:+
BRCA	cis	rs8031584	0.918	rs35784593	ENSG00000270015.1	RP11-540B6.6	-5.04	5.44e-07	5.83e-05	-0.16	-0.15	Huntington's disease progression;	chr15:30962385	chr15:30926514~30928407:+
BRCA	cis	rs8054556	1	rs6565173	ENSG00000273724.1	RP11-347C12.12	-5.04	5.44e-07	5.83e-05	-0.17	-0.15	Autism spectrum disorder or schizophrenia;	chr16:29962846	chr16:30336400~30343336:+
BRCA	cis	rs2286503	0.901	rs2286505	ENSG00000226329.2	AC005682.6	5.04	5.44e-07	5.83e-05	0.14	0.15	Fibrinogen;	chr7:22815221	chr7:22863874~22881350:-
BRCA	cis	rs10129255	0.509	rs756583	ENSG00000254174.1	IGHV1-12	5.04	5.44e-07	5.83e-05	0.12	0.15	Kawasaki disease;	chr14:106680002	chr14:106122420~106122709:-
BRCA	cis	rs10888838	0.756	rs11589005	ENSG00000198711.5	SSBP3-AS1	5.04	5.44e-07	5.83e-05	0.23	0.15	Mitochondrial DNA levels;	chr1:54227752	chr1:54236440~54239063:+
BRCA	cis	rs12497850	0.897	rs9884022	ENSG00000225399.4	RP11-3B7.1	5.04	5.44e-07	5.83e-05	0.15	0.15	Parkinson's disease;	chr3:48919429	chr3:49260085~49261316:+
BRCA	cis	rs7577696	0.785	rs11689817	ENSG00000272716.1	RP11-563N4.1	-5.04	5.45e-07	5.84e-05	-0.17	-0.15	Inflammatory biomarkers;	chr2:32139172	chr2:32165046~32165757:-
BRCA	cis	rs11955398	0.501	rs4235480	ENSG00000215032.2	GNL3LP1	-5.04	5.45e-07	5.84e-05	-0.19	-0.15	Intelligence (multi-trait analysis);	chr5:60736544	chr5:60891935~60893577:-
BRCA	cis	rs11955398	0.563	rs4700385	ENSG00000215032.2	GNL3LP1	-5.04	5.45e-07	5.84e-05	-0.19	-0.15	Intelligence (multi-trait analysis);	chr5:60736772	chr5:60891935~60893577:-
BRCA	cis	rs1075265	0.811	rs805322	ENSG00000235937.1	AC008280.1	-5.04	5.45e-07	5.84e-05	-0.17	-0.15	Chronotype;Morning vs. evening chronotype;	chr2:53912758	chr2:54029552~54030682:-
BRCA	cis	rs801193	0.66	rs2659914	ENSG00000223473.2	GS1-124K5.3	5.04	5.45e-07	5.84e-05	0.12	0.15	Aortic root size;	chr7:66691927	chr7:66491049~66493566:-
BRCA	cis	rs801193	0.591	rs2707839	ENSG00000223473.2	GS1-124K5.3	5.04	5.45e-07	5.84e-05	0.12	0.15	Aortic root size;	chr7:66728097	chr7:66491049~66493566:-
BRCA	cis	rs7572733	0.515	rs6752458	ENSG00000231621.1	AC013264.2	-5.04	5.45e-07	5.84e-05	-0.15	-0.15	Dermatomyositis;	chr2:197970382	chr2:197197991~197199273:+
BRCA	cis	rs10911232	0.507	rs4652764	ENSG00000224468.3	RP11-181K3.4	-5.04	5.45e-07	5.84e-05	-0.17	-0.15	Hypertriglyceridemia;	chr1:183024980	chr1:183138402~183141282:-
BRCA	cis	rs7226408	0.857	rs17652513	ENSG00000267707.2	RP11-95O2.5	5.04	5.45e-07	5.84e-05	0.23	0.15	Obesity-related traits;	chr18:36903356	chr18:37243776~37247506:+
BRCA	cis	rs1124769	0.619	rs28637301	ENSG00000273674.3	CTD-2378E12.1	5.04	5.45e-07	5.84e-05	0.19	0.15	Cognitive performance;	chr15:51095051	chr15:50839875~50908599:-
BRCA	cis	rs3764021	0.87	rs10466829	ENSG00000256673.1	RP11-599J14.2	-5.04	5.46e-07	5.85e-05	-0.17	-0.15	Type 1 diabetes;	chr12:9723495	chr12:9398355~9414851:-
BRCA	cis	rs2638953	0.925	rs11049549	ENSG00000247934.4	RP11-967K21.1	-5.04	5.46e-07	5.85e-05	-0.21	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28357808	chr12:28163298~28190738:-
BRCA	cis	rs78487399	0.808	rs76282560	ENSG00000234936.1	AC010883.5	5.04	5.46e-07	5.85e-05	0.25	0.15	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43455496	chr2:43229573~43233394:+
BRCA	cis	rs1043099	0.556	rs737723	ENSG00000279699.1	RP1-102K2.9	-5.04	5.46e-07	5.85e-05	-0.2	-0.15	Rheumatoid arthritis;	chr22:30406040	chr22:30275215~30276951:-
BRCA	cis	rs1729951	0.575	rs747843	ENSG00000239213.4	NCK1-AS1	5.04	5.46e-07	5.85e-05	0.16	0.15	Neuroticism;	chr3:136984288	chr3:136841726~136862054:-
BRCA	cis	rs10844706	0.699	rs10844615	ENSG00000214776.8	RP11-726G1.1	5.04	5.47e-07	5.86e-05	0.19	0.15	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9725646	chr12:9467552~9576275:+
BRCA	cis	rs4835473	0.932	rs34617134	ENSG00000249741.2	RP11-673E1.3	-5.04	5.47e-07	5.86e-05	-0.17	-0.15	Immature fraction of reticulocytes;	chr4:143983606	chr4:143911514~143912053:-
BRCA	cis	rs10911232	0.507	rs10797817	ENSG00000224468.3	RP11-181K3.4	-5.04	5.47e-07	5.86e-05	-0.17	-0.15	Hypertriglyceridemia;	chr1:183030001	chr1:183138402~183141282:-
BRCA	cis	rs7267979	0.816	rs422148	ENSG00000125804.12	FAM182A	-5.04	5.47e-07	5.86e-05	-0.2	-0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25531968	chr20:26054655~26086917:+
BRCA	cis	rs962856	0.964	rs601827	ENSG00000236780.4	AC078941.1	5.04	5.47e-07	5.86e-05	0.19	0.15	Pancreatic cancer;	chr2:67435398	chr2:67123357~67215319:-
BRCA	cis	rs867371	0.502	rs8025964	ENSG00000259429.4	UBE2Q2P2	-5.04	5.47e-07	5.87e-05	-0.15	-0.15	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82229429	chr15:82355142~82420075:+
BRCA	cis	rs1979679	0.581	rs1405812	ENSG00000278733.1	RP11-425D17.1	-5.04	5.48e-07	5.87e-05	-0.22	-0.15	Ossification of the posterior longitudinal ligament of the spine;	chr12:28476043	chr12:28185625~28186190:-
BRCA	cis	rs7592578	0.771	rs75579212	ENSG00000272979.1	RP11-647K16.1	-5.04	5.48e-07	5.87e-05	-0.26	-0.15	Diastolic blood pressure;	chr2:190511849	chr2:190454092~190454521:-
BRCA	cis	rs11158026	0.603	rs12147796	ENSG00000258413.1	RP11-665C16.6	-5.04	5.49e-07	5.88e-05	-0.2	-0.15	Parkinson's disease;	chr14:54941978	chr14:55262767~55272075:-
BRCA	cis	rs2303319	0.504	rs55821334	ENSG00000227403.1	AC009299.3	5.04	5.49e-07	5.88e-05	0.36	0.15	Cognitive function;	chr2:161595504	chr2:161244739~161249050:+
BRCA	cis	rs11955398	0.501	rs10067618	ENSG00000215032.2	GNL3LP1	-5.04	5.49e-07	5.88e-05	-0.19	-0.15	Intelligence (multi-trait analysis);	chr5:60715168	chr5:60891935~60893577:-
BRCA	cis	rs8054556	1	rs4788200	ENSG00000273724.1	RP11-347C12.12	-5.04	5.49e-07	5.88e-05	-0.17	-0.15	Autism spectrum disorder or schizophrenia;	chr16:29959944	chr16:30336400~30343336:+
BRCA	cis	rs4218	0.689	rs34338282	ENSG00000277144.1	RP11-59H7.4	-5.04	5.49e-07	5.88e-05	-0.21	-0.15	Social communication problems;	chr15:59096897	chr15:59115547~59116089:-
BRCA	cis	rs73193808	0.95	rs12627426	ENSG00000236056.1	GAPDHP14	-5.04	5.49e-07	5.88e-05	-0.21	-0.15	Coronary artery disease;	chr21:29147136	chr21:29222321~29223257:+
BRCA	cis	rs454217	0.846	rs337663	ENSG00000277851.1	RP11-756G20.1	-5.04	5.49e-07	5.88e-05	-0.17	-0.15	Smoking quantity;	chr12:92311428	chr12:92247756~92363832:-
BRCA	cis	rs2153535	0.58	rs4960411	ENSG00000251164.1	HULC	-5.04	5.49e-07	5.88e-05	-0.19	-0.15	Motion sickness;	chr6:8437998	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.58	rs4960412	ENSG00000251164.1	HULC	-5.04	5.49e-07	5.88e-05	-0.19	-0.15	Motion sickness;	chr6:8438028	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.58	rs4960413	ENSG00000251164.1	HULC	-5.04	5.49e-07	5.88e-05	-0.19	-0.15	Motion sickness;	chr6:8438233	chr6:8652137~8653846:+
BRCA	cis	rs7618915	0.571	rs33964154	ENSG00000243224.1	RP5-1157M23.2	-5.04	5.49e-07	5.88e-05	-0.17	-0.15	Bipolar disorder;	chr3:52562898	chr3:52239258~52241097:+
BRCA	cis	rs71520386	0.846	rs13243243	ENSG00000228649.7	AC005682.5	5.04	5.49e-07	5.88e-05	0.17	0.15	Fibrinogen levels;	chr7:22781400	chr7:22854178~22861579:+
BRCA	cis	rs13113518	0.812	rs2412648	ENSG00000272969.1	RP11-528I4.2	5.04	5.49e-07	5.88e-05	0.18	0.15	Height;	chr4:55454900	chr4:55547112~55547889:+
BRCA	cis	rs13113518	0.812	rs12512737	ENSG00000272969.1	RP11-528I4.2	5.04	5.49e-07	5.88e-05	0.18	0.15	Height;	chr4:55454938	chr4:55547112~55547889:+
BRCA	cis	rs13113518	0.812	rs13125984	ENSG00000272969.1	RP11-528I4.2	5.04	5.49e-07	5.88e-05	0.18	0.15	Height;	chr4:55455102	chr4:55547112~55547889:+
BRCA	cis	rs2408955	0.501	rs8716	ENSG00000273765.1	RP11-370I10.11	5.04	5.5e-07	5.89e-05	0.18	0.15	Glycated hemoglobin levels;	chr12:48145699	chr12:48360920~48361377:+
BRCA	cis	rs7577696	0.962	rs7608127	ENSG00000272716.1	RP11-563N4.1	-5.04	5.5e-07	5.89e-05	-0.17	-0.15	Inflammatory biomarkers;	chr2:32054854	chr2:32165046~32165757:-
BRCA	cis	rs160451	0.739	rs218904	ENSG00000251136.7	RP11-37B2.1	-5.04	5.5e-07	5.89e-05	-0.16	-0.15	Leprosy;	chr8:89722278	chr8:89609409~89757727:-
BRCA	cis	rs34286592	0.929	rs11864180	ENSG00000214725.6	CDIPT-AS1	-5.04	5.51e-07	5.9e-05	-0.26	-0.15	Multiple sclerosis;	chr16:29819508	chr16:29863593~29868053:+
BRCA	cis	rs34286592	0.929	rs9923649	ENSG00000214725.6	CDIPT-AS1	-5.04	5.51e-07	5.9e-05	-0.26	-0.15	Multiple sclerosis;	chr16:29820817	chr16:29863593~29868053:+
BRCA	cis	rs4787491	0.658	rs11647753	ENSG00000183604.13	SMG1P5	5.04	5.51e-07	5.9e-05	0.15	0.15	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:29916794	chr16:30267553~30335374:-
BRCA	cis	rs2834288	0.7	rs6517196	ENSG00000273102.1	AP000569.9	-5.04	5.51e-07	5.9e-05	-0.18	-0.15	Gut microbiota (bacterial taxa);	chr21:33905116	chr21:33967101~33968573:-
BRCA	cis	rs739496	0.579	rs16941759	ENSG00000226469.1	ADAM1B	-5.04	5.51e-07	5.9e-05	-0.2	-0.15	Platelet count;	chr12:111930117	chr12:111927018~111929017:+
BRCA	cis	rs10392	0.543	rs4812336	ENSG00000274825.1	RP4-616B8.5	-5.04	5.51e-07	5.9e-05	-0.16	-0.15	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;	chr20:38918731	chr20:38955910~38956547:+
BRCA	cis	rs4780355	0.918	rs243323	ENSG00000262636.1	CTD-3088G3.4	5.04	5.52e-07	5.91e-05	0.22	0.15	Crohn's disease and psoriasis;	chr16:11267345	chr16:11380859~11381118:-
BRCA	cis	rs2153535	0.58	rs4404802	ENSG00000251164.1	HULC	-5.04	5.52e-07	5.91e-05	-0.19	-0.15	Motion sickness;	chr6:8441819	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.58	rs1932275	ENSG00000251164.1	HULC	-5.04	5.52e-07	5.91e-05	-0.19	-0.15	Motion sickness;	chr6:8442100	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.58	rs1932276	ENSG00000251164.1	HULC	-5.04	5.52e-07	5.91e-05	-0.19	-0.15	Motion sickness;	chr6:8442360	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.58	rs915352	ENSG00000251164.1	HULC	-5.04	5.52e-07	5.91e-05	-0.19	-0.15	Motion sickness;	chr6:8442533	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.58	rs915351	ENSG00000251164.1	HULC	-5.04	5.52e-07	5.91e-05	-0.19	-0.15	Motion sickness;	chr6:8442560	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.601	rs1855765	ENSG00000251164.1	HULC	-5.04	5.52e-07	5.91e-05	-0.19	-0.15	Motion sickness;	chr6:8444092	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.58	rs9406143	ENSG00000251164.1	HULC	-5.04	5.52e-07	5.91e-05	-0.19	-0.15	Motion sickness;	chr6:8444350	chr6:8652137~8653846:+
BRCA	cis	rs597539	0.552	rs10896384	ENSG00000261625.1	RP11-554A11.4	5.04	5.52e-07	5.91e-05	0.15	0.15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68952542	chr11:69000765~69002048:-
BRCA	cis	rs17685	0.753	rs4728550	ENSG00000280388.1	RP11-229D13.3	5.04	5.52e-07	5.91e-05	0.16	0.15	Coffee consumption (cups per day);Coffee consumption;	chr7:76041670	chr7:76043977~76045963:-
BRCA	cis	rs17685	0.753	rs13240404	ENSG00000280388.1	RP11-229D13.3	5.04	5.52e-07	5.91e-05	0.16	0.15	Coffee consumption (cups per day);Coffee consumption;	chr7:76046401	chr7:76043977~76045963:-
BRCA	cis	rs17685	0.697	rs2302437	ENSG00000280388.1	RP11-229D13.3	5.04	5.52e-07	5.91e-05	0.16	0.15	Coffee consumption (cups per day);Coffee consumption;	chr7:76047698	chr7:76043977~76045963:-
BRCA	cis	rs8054556	1	rs4788201	ENSG00000273724.1	RP11-347C12.12	-5.04	5.52e-07	5.91e-05	-0.17	-0.15	Autism spectrum disorder or schizophrenia;	chr16:29961369	chr16:30336400~30343336:+
BRCA	cis	rs2790457	1	rs2790457	ENSG00000254635.4	WAC-AS1	-5.04	5.53e-07	5.92e-05	-0.19	-0.15	Multiple myeloma;	chr10:28567890	chr10:28522652~28532743:-
BRCA	cis	rs2638953	0.962	rs10506034	ENSG00000247934.4	RP11-967K21.1	-5.04	5.53e-07	5.92e-05	-0.21	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28442363	chr12:28163298~28190738:-
BRCA	cis	rs10739663	0.52	rs13294786	ENSG00000232630.1	PRPS1P2	-5.04	5.53e-07	5.92e-05	-0.16	-0.15	Resting heart rate;	chr9:125394682	chr9:125150653~125151589:+
BRCA	cis	rs7569084	0.687	rs12993075	ENSG00000281920.1	RP11-418H16.1	5.04	5.53e-07	5.92e-05	0.2	0.15	Sum eosinophil basophil counts;	chr2:65431010	chr2:65623272~65628424:+
BRCA	cis	rs34286592	0.929	rs35901559	ENSG00000214725.6	CDIPT-AS1	-5.04	5.53e-07	5.92e-05	-0.26	-0.15	Multiple sclerosis;	chr16:29818294	chr16:29863593~29868053:+
BRCA	cis	rs2732480	0.577	rs2634681	ENSG00000226413.2	OR8T1P	-5.04	5.53e-07	5.92e-05	-0.2	-0.15	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48339301	chr12:48442030~48442947:-
BRCA	cis	rs919433	0.679	rs7564924	ENSG00000231621.1	AC013264.2	-5.04	5.54e-07	5.93e-05	-0.15	-0.15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197649153	chr2:197197991~197199273:+
BRCA	cis	rs4664293	0.867	rs6720304	ENSG00000226266.5	AC009961.3	-5.04	5.54e-07	5.93e-05	-0.2	-0.15	Monocyte percentage of white cells;	chr2:159787321	chr2:159670708~159712435:-
BRCA	cis	rs78487399	0.808	rs12105626	ENSG00000234936.1	AC010883.5	5.04	5.54e-07	5.93e-05	0.25	0.15	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43451620	chr2:43229573~43233394:+
BRCA	cis	rs1223397	0.651	rs2496149	ENSG00000215022.6	RP1-257A7.4	-5.04	5.54e-07	5.93e-05	-0.18	-0.15	Blood pressure;	chr6:13313661	chr6:13264861~13295586:-
BRCA	cis	rs1552244	0.572	rs67439440	ENSG00000232901.1	CYCSP10	5.04	5.54e-07	5.93e-05	0.23	0.15	Alzheimer's disease;	chr3:10127819	chr3:10000647~10000940:-
BRCA	cis	rs7572733	0.515	rs1356542	ENSG00000231621.1	AC013264.2	-5.04	5.54e-07	5.93e-05	-0.15	-0.15	Dermatomyositis;	chr2:197970978	chr2:197197991~197199273:+
BRCA	cis	rs10911232	0.507	rs6668980	ENSG00000224468.3	RP11-181K3.4	-5.04	5.54e-07	5.93e-05	-0.17	-0.15	Hypertriglyceridemia;	chr1:183049722	chr1:183138402~183141282:-
BRCA	cis	rs6847067	0.672	rs16995920	ENSG00000180769.7	WDFY3-AS2	5.04	5.54e-07	5.93e-05	0.16	0.15	Oropharynx cancer;	chr4:84721898	chr4:84965682~85011277:+
BRCA	cis	rs10911232	0.507	rs10911222	ENSG00000224468.3	RP11-181K3.4	-5.04	5.55e-07	5.94e-05	-0.17	-0.15	Hypertriglyceridemia;	chr1:183078228	chr1:183138402~183141282:-
BRCA	cis	rs9921338	0.961	rs17605444	ENSG00000262703.1	RP11-485G7.6	-5.04	5.55e-07	5.94e-05	-0.19	-0.15	Vein graft stenosis in coronary artery bypass grafting;	chr16:11319732	chr16:11348143~11349321:-
BRCA	cis	rs919433	0.679	rs6719832	ENSG00000231621.1	AC013264.2	5.04	5.55e-07	5.94e-05	0.15	0.15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197668645	chr2:197197991~197199273:+
BRCA	cis	rs1075265	0.704	rs13417926	ENSG00000235937.1	AC008280.1	5.04	5.55e-07	5.94e-05	0.17	0.15	Chronotype;Morning vs. evening chronotype;	chr2:53825520	chr2:54029552~54030682:-
BRCA	cis	rs801193	0.569	rs2659907	ENSG00000273448.1	RP11-166O4.6	5.04	5.55e-07	5.94e-05	0.14	0.15	Aortic root size;	chr7:66699045	chr7:67333047~67334383:+
BRCA	cis	rs7923609	0.841	rs2163188	ENSG00000232075.1	MRPL35P2	5.04	5.56e-07	5.95e-05	0.19	0.15	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63554951	chr10:63634317~63634827:-
BRCA	cis	rs9300255	0.739	rs12824957	ENSG00000235423.7	RP11-282O18.3	-5.04	5.56e-07	5.95e-05	-0.23	-0.15	Neutrophil percentage of white cells;	chr12:123265681	chr12:123252030~123261483:-
BRCA	cis	rs10938353	0.911	rs13138228	ENSG00000273369.1	RP11-700J17.1	5.04	5.56e-07	5.95e-05	0.17	0.15	Body mass index;	chr4:44590043	chr4:44693946~44694386:-
BRCA	cis	rs7772486	0.875	rs2073287	ENSG00000270638.1	RP3-466P17.1	5.04	5.57e-07	5.95e-05	0.17	0.15	Lobe attachment (rater-scored or self-reported);	chr6:146029128	chr6:145735570~145737218:+
BRCA	cis	rs8002861	0.87	rs4942255	ENSG00000274001.1	RP11-5G9.5	-5.04	5.57e-07	5.95e-05	-0.18	-0.15	Leprosy;	chr13:43877708	chr13:43877715~43878163:-
BRCA	cis	rs6714710	0.58	rs57804205	ENSG00000230606.9	AC159540.1	-5.04	5.57e-07	5.96e-05	-0.18	-0.15	Posterior cortical atrophy and Alzheimer's disease;	chr2:97838009	chr2:97416165~97433527:-
BRCA	cis	rs7267979	0.844	rs2474780	ENSG00000274973.1	RP13-401N8.7	-5.04	5.57e-07	5.96e-05	-0.18	-0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25305199	chr20:25845497~25845862:+
BRCA	cis	rs739496	0.542	rs10219736	ENSG00000257595.2	RP3-473L9.4	5.04	5.57e-07	5.96e-05	0.2	0.15	Platelet count;	chr12:111350598	chr12:111369282~111403310:+
BRCA	cis	rs2790457	0.76	rs1265834	ENSG00000254635.4	WAC-AS1	5.04	5.57e-07	5.96e-05	0.19	0.15	Multiple myeloma;	chr10:28652932	chr10:28522652~28532743:-
BRCA	cis	rs2179367	0.632	rs9485389	ENSG00000268592.3	RAET1E-AS1	-5.04	5.57e-07	5.96e-05	-0.22	-0.15	Dupuytren's disease;	chr6:149420078	chr6:149863494~149919507:+
BRCA	cis	rs7923609	0.871	rs7898861	ENSG00000232075.1	MRPL35P2	5.04	5.57e-07	5.96e-05	0.19	0.15	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63559918	chr10:63634317~63634827:-
BRCA	cis	rs12439619	0.739	rs62012046	ENSG00000255769.6	GOLGA2P10	-5.04	5.58e-07	5.97e-05	-0.22	-0.15	Intelligence (multi-trait analysis);	chr15:82236824	chr15:82472993~82513950:-
BRCA	cis	rs12439619	0.774	rs62012047	ENSG00000255769.6	GOLGA2P10	-5.04	5.58e-07	5.97e-05	-0.22	-0.15	Intelligence (multi-trait analysis);	chr15:82236852	chr15:82472993~82513950:-
BRCA	cis	rs11051970	0.559	rs11051941	ENSG00000274964.1	RP11-817I4.1	-5.04	5.58e-07	5.97e-05	-0.21	-0.15	Response to tocilizumab in rheumatoid arthritis;	chr12:32330338	chr12:32339368~32340724:+
BRCA	cis	rs11051970	0.559	rs11051942	ENSG00000274964.1	RP11-817I4.1	-5.04	5.58e-07	5.97e-05	-0.21	-0.15	Response to tocilizumab in rheumatoid arthritis;	chr12:32330344	chr12:32339368~32340724:+
BRCA	cis	rs62388641	0.539	rs56016631	ENSG00000218027.2	RP11-157J24.1	-5.04	5.58e-07	5.97e-05	-0.19	-0.15	Daytime sleep phenotypes;	chr6:1542340	chr6:1513698~1515289:-
BRCA	cis	rs9818758	0.607	rs9880088	ENSG00000270441.1	RP11-694I15.7	5.04	5.58e-07	5.97e-05	0.31	0.15	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49141557	chr3:49140086~49160851:-
BRCA	cis	rs2179367	0.552	rs11155652	ENSG00000268592.3	RAET1E-AS1	5.04	5.58e-07	5.97e-05	0.22	0.15	Dupuytren's disease;	chr6:149417849	chr6:149863494~149919507:+
BRCA	cis	rs2179367	0.632	rs12209364	ENSG00000268592.3	RAET1E-AS1	5.04	5.58e-07	5.97e-05	0.22	0.15	Dupuytren's disease;	chr6:149418062	chr6:149863494~149919507:+
BRCA	cis	rs4660456	0.504	rs542214	ENSG00000237899.1	RP4-739H11.3	5.04	5.58e-07	5.97e-05	0.23	0.15	Platelet count;	chr1:40632806	chr1:40669089~40687588:-
BRCA	cis	rs7267979	0.753	rs400357	ENSG00000125804.12	FAM182A	-5.04	5.58e-07	5.97e-05	-0.2	-0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25498422	chr20:26054655~26086917:+
BRCA	cis	rs1075265	0.572	rs62139835	ENSG00000235937.1	AC008280.1	5.04	5.58e-07	5.97e-05	0.17	0.15	Chronotype;Morning vs. evening chronotype;	chr2:53682307	chr2:54029552~54030682:-
BRCA	cis	rs11955398	0.522	rs34643	ENSG00000215032.2	GNL3LP1	5.04	5.58e-07	5.97e-05	0.2	0.15	Intelligence (multi-trait analysis);	chr5:61048750	chr5:60891935~60893577:-
BRCA	cis	rs801193	0.636	rs2659895	ENSG00000223473.2	GS1-124K5.3	5.04	5.58e-07	5.97e-05	0.12	0.15	Aortic root size;	chr7:66731484	chr7:66491049~66493566:-
BRCA	cis	rs828999	0.688	rs10881508	ENSG00000280186.1	RP11-483I13.6	5.04	5.58e-07	5.97e-05	0.17	0.15	Monocyte percentage of white cells;	chr1:108155476	chr1:108200413~108202743:+
BRCA	cis	rs4713118	0.955	rs9468206	ENSG00000216901.1	AL022393.7	5.04	5.58e-07	5.97e-05	0.21	0.15	Parkinson's disease;	chr6:27722674	chr6:28176188~28176674:+
BRCA	cis	rs62184315	0.536	rs62184265	ENSG00000253559.1	OSGEPL1-AS1	-5.04	5.59e-07	5.98e-05	-0.27	-0.15	Alcohol dependence (age at onset);	chr2:189756231	chr2:189762704~189765556:+
BRCA	cis	rs57221529	0.766	rs4081846	ENSG00000271781.1	CTD-2589H19.6	-5.04	5.59e-07	5.98e-05	-0.22	-0.15	Lung disease severity in cystic fibrosis;	chr5:573904	chr5:675826~676616:+
BRCA	cis	rs10129255	0.957	rs11847726	ENSG00000211974.3	IGHV2-70	5.04	5.59e-07	5.98e-05	0.16	0.15	Kawasaki disease;	chr14:106779116	chr14:106723574~106724093:-
BRCA	cis	rs7617773	0.963	rs12493256	ENSG00000228638.1	FCF1P2	5.04	5.59e-07	5.98e-05	0.15	0.15	Coronary artery disease;	chr3:48135257	chr3:48290793~48291375:-
BRCA	cis	rs10938353	0.68	rs66829609	ENSG00000273369.1	RP11-700J17.1	5.04	5.59e-07	5.98e-05	0.19	0.15	Body mass index;	chr4:44769814	chr4:44693946~44694386:-
BRCA	cis	rs6840360	0.582	rs2709823	ENSG00000278978.1	RP11-164P12.5	-5.04	5.59e-07	5.98e-05	-0.17	-0.15	Intelligence (multi-trait analysis);	chr4:151419294	chr4:151669786~151670503:+
BRCA	cis	rs7324557	1	rs7324557	ENSG00000205861.10	C1QTNF9B-AS1	5.04	5.59e-07	5.98e-05	0.2	0.15	Visceral adipose tissue adjusted for BMI;	chr13:23722723	chr13:23888889~23897263:+
BRCA	cis	rs4356203	0.87	rs7925692	ENSG00000272034.1	SNORD14A	5.04	5.6e-07	5.98e-05	0.16	0.15	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17249575	chr11:17074654~17074744:-
BRCA	cis	rs13325613	0.748	rs114115904	ENSG00000223552.1	RP11-24F11.2	-5.04	5.6e-07	5.99e-05	-0.32	-0.15	Monocyte count;	chr3:46227173	chr3:46364955~46407059:-
BRCA	cis	rs875971	0.862	rs6978028	ENSG00000273448.1	RP11-166O4.6	5.04	5.6e-07	5.99e-05	0.14	0.15	Aortic root size;	chr7:66421313	chr7:67333047~67334383:+
BRCA	cis	rs6840360	0.693	rs28622593	ENSG00000251611.1	RP11-610P16.1	-5.04	5.6e-07	5.99e-05	-0.13	-0.15	Intelligence (multi-trait analysis);	chr4:151452928	chr4:151407551~151408835:-
BRCA	cis	rs9868809	0.881	rs6773261	ENSG00000270441.1	RP11-694I15.7	5.04	5.6e-07	5.99e-05	0.28	0.15	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48637631	chr3:49140086~49160851:-
BRCA	cis	rs2574985	0.739	rs3011792	ENSG00000231345.3	BEND3P1	-5.04	5.6e-07	5.99e-05	-0.26	-0.15	Subjective well-being;	chr10:50552381	chr10:50655967~50660472:+
BRCA	cis	rs62025270	0.632	rs16943251	ENSG00000259295.5	CSPG4P12	-5.04	5.61e-07	5.99e-05	-0.23	-0.15	Idiopathic pulmonary fibrosis;	chr15:85692004	chr15:85191438~85213905:+
BRCA	cis	rs7569084	0.687	rs4671663	ENSG00000281920.1	RP11-418H16.1	5.04	5.61e-07	6e-05	0.2	0.15	Sum eosinophil basophil counts;	chr2:65434400	chr2:65623272~65628424:+
BRCA	cis	rs8180040	0.593	rs4018905	ENSG00000276925.1	RP11-708J19.3	-5.04	5.61e-07	6e-05	-0.18	-0.15	Colorectal cancer;	chr3:47096680	chr3:47469777~47469987:+
BRCA	cis	rs2562456	0.833	rs1626404	ENSG00000268535.1	RP11-420K14.3	5.04	5.61e-07	6e-05	0.22	0.15	Pain;	chr19:21300986	chr19:21709522~21710191:+
BRCA	cis	rs6453278	1	rs6453279	ENSG00000250802.5	ZBED3-AS1	-5.04	5.62e-07	6e-05	-0.2	-0.15	Autism;	chr5:77121249	chr5:77086740~77166909:+
BRCA	cis	rs2274273	0.682	rs8008134	ENSG00000258413.1	RP11-665C16.6	-5.04	5.62e-07	6.01e-05	-0.19	-0.15	Protein biomarker;	chr14:55040802	chr14:55262767~55272075:-
BRCA	cis	rs35146811	0.961	rs35991721	ENSG00000235713.1	RP4-604G5.3	5.04	5.62e-07	6.01e-05	0.19	0.15	Coronary artery disease;	chr7:100131167	chr7:99992397~99993050:+
BRCA	cis	rs2839186	0.814	rs12482209	ENSG00000239415.1	AP001469.9	-5.04	5.62e-07	6.01e-05	-0.16	-0.15	Testicular germ cell tumor;	chr21:46244361	chr21:46251549~46254133:-
BRCA	cis	rs2408955	0.541	rs11168428	ENSG00000273765.1	RP11-370I10.11	-5.04	5.62e-07	6.01e-05	-0.18	-0.15	Glycated hemoglobin levels;	chr12:48153345	chr12:48360920~48361377:+
BRCA	cis	rs6430585	0.528	rs309154	ENSG00000231890.6	DARS-AS1	-5.03	5.63e-07	6.02e-05	-0.24	-0.15	Corneal structure;	chr2:135968997	chr2:135985176~136022593:+
BRCA	cis	rs10504130	1	rs763550	ENSG00000253844.1	RP11-546K22.1	5.03	5.63e-07	6.02e-05	0.27	0.15	Venous thromboembolism (SNP x SNP interaction);	chr8:51802905	chr8:51961458~52022974:+
BRCA	cis	rs160451	0.934	rs160453	ENSG00000251136.7	RP11-37B2.1	5.03	5.63e-07	6.02e-05	0.15	0.15	Leprosy;	chr8:89652326	chr8:89609409~89757727:-
BRCA	cis	rs7621025	0.599	rs13063987	ENSG00000239213.4	NCK1-AS1	-5.03	5.63e-07	6.02e-05	-0.2	-0.15	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136726555	chr3:136841726~136862054:-
BRCA	cis	rs3845817	0.808	rs702895	ENSG00000237979.1	AC007389.1	5.03	5.63e-07	6.02e-05	0.18	0.15	Bipolar disorder;	chr2:65534933	chr2:65500993~65502138:-
BRCA	cis	rs6840360	0.582	rs2709812	ENSG00000251611.1	RP11-610P16.1	5.03	5.64e-07	6.03e-05	0.14	0.15	Intelligence (multi-trait analysis);	chr4:151414597	chr4:151407551~151408835:-
BRCA	cis	rs9402743	0.634	rs2327646	ENSG00000231028.7	LINC00271	-5.03	5.64e-07	6.03e-05	-0.16	-0.15	Systemic lupus erythematosus;	chr6:135597186	chr6:135497801~135716055:+
BRCA	cis	rs9473147	0.516	rs7749271	ENSG00000270761.1	RP11-385F7.1	-5.03	5.64e-07	6.03e-05	-0.16	-0.15	Platelet distribution width;Mean platelet volume;	chr6:47517266	chr6:47477243~47477572:-
BRCA	cis	rs2745572	0.557	rs2745569	ENSG00000272279.1	RP11-157J24.2	-5.03	5.64e-07	6.03e-05	-0.18	-0.15	Intraocular pressure;Glaucoma (primary open-angle);Glaucoma (high intraocular pressure);	chr6:1547396	chr6:1528364~1528911:-
BRCA	cis	rs9652601	0.748	rs12917893	ENSG00000274038.1	RP11-66H6.4	-5.03	5.65e-07	6.03e-05	-0.18	-0.15	Systemic lupus erythematosus;	chr16:11146121	chr16:11056556~11057034:+
BRCA	cis	rs62244186	0.516	rs11922470	ENSG00000214820.3	MPRIPP1	5.03	5.65e-07	6.03e-05	0.18	0.15	Depressive symptoms;	chr3:44736303	chr3:44579938~44581026:-
BRCA	cis	rs9473147	0.543	rs9349407	ENSG00000270761.1	RP11-385F7.1	-5.03	5.65e-07	6.03e-05	-0.17	-0.15	Platelet distribution width;Mean platelet volume;	chr6:47485642	chr6:47477243~47477572:-
BRCA	cis	rs71227278	1	rs71227278	ENSG00000228630.4	HOTAIR	5.03	5.65e-07	6.03e-05	0.18	0.15	Urinary tract infection frequency;	chr12:53964263	chr12:53962308~53974956:-
BRCA	cis	rs7914558	1	rs12255047	ENSG00000236937.2	PTGES3P4	5.03	5.65e-07	6.03e-05	0.2	0.15	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103000995	chr10:102845595~102845950:+
BRCA	cis	rs494453	0.922	rs476515	ENSG00000227811.2	FAM212B-AS1	-5.03	5.65e-07	6.04e-05	-0.2	-0.15	Osteoporosis-related phenotypes;	chr1:111672454	chr1:111739841~111747798:+
BRCA	cis	rs9287719	0.674	rs759399	ENSG00000243819.4	RN7SL832P	-5.03	5.65e-07	6.04e-05	-0.15	-0.15	Prostate cancer;	chr2:10656757	chr2:10690344~10692099:+
BRCA	cis	rs6723226	0.764	rs176403	ENSG00000276334.1	AL133243.1	-5.03	5.65e-07	6.04e-05	-0.2	-0.15	Intelligence (multi-trait analysis);	chr2:32412796	chr2:32521927~32523547:+
BRCA	cis	rs13113518	0.812	rs12500686	ENSG00000272969.1	RP11-528I4.2	5.03	5.65e-07	6.04e-05	0.19	0.15	Height;	chr4:55457922	chr4:55547112~55547889:+
BRCA	cis	rs4664293	0.867	rs7579206	ENSG00000224152.1	AC009506.1	-5.03	5.65e-07	6.04e-05	-0.17	-0.15	Monocyte percentage of white cells;	chr2:159715992	chr2:159615296~159617082:+
BRCA	cis	rs7572733	0.515	rs35730302	ENSG00000231621.1	AC013264.2	5.03	5.66e-07	6.04e-05	0.15	0.15	Dermatomyositis;	chr2:197953902	chr2:197197991~197199273:+
BRCA	cis	rs35146811	0.844	rs13223792	ENSG00000235713.1	RP4-604G5.3	5.03	5.66e-07	6.05e-05	0.18	0.15	Coronary artery disease;	chr7:100078036	chr7:99992397~99993050:+
BRCA	cis	rs2638953	0.925	rs10843154	ENSG00000247934.4	RP11-967K21.1	-5.03	5.66e-07	6.05e-05	-0.21	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28326824	chr12:28163298~28190738:-
BRCA	cis	rs4908768	0.539	rs922366	ENSG00000270282.1	RP5-1115A15.2	5.03	5.66e-07	6.05e-05	0.17	0.15	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8593674	chr1:8512653~8513021:+
BRCA	cis	rs4713118	0.866	rs9468217	ENSG00000216901.1	AL022393.7	5.03	5.67e-07	6.05e-05	0.21	0.15	Parkinson's disease;	chr6:27758688	chr6:28176188~28176674:+
BRCA	cis	rs4713118	0.911	rs9295746	ENSG00000216901.1	AL022393.7	5.03	5.67e-07	6.05e-05	0.21	0.15	Parkinson's disease;	chr6:27762285	chr6:28176188~28176674:+
BRCA	cis	rs2288884	0.505	rs75919042	ENSG00000275055.1	CTC-471J1.11	-5.03	5.67e-07	6.05e-05	-0.25	-0.15	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:51973246	chr19:52049007~52049754:+
BRCA	cis	rs6723226	0.806	rs2710606	ENSG00000276334.1	AL133243.1	5.03	5.67e-07	6.05e-05	0.2	0.15	Intelligence (multi-trait analysis);	chr2:32586842	chr2:32521927~32523547:+
BRCA	cis	rs1030877	0.515	rs1020064	ENSG00000235319.1	AC012360.4	-5.03	5.67e-07	6.06e-05	-0.22	-0.15	Obesity-related traits;	chr2:105281283	chr2:105324210~105330529:+
BRCA	cis	rs1030877	0.515	rs2576741	ENSG00000235319.1	AC012360.4	-5.03	5.67e-07	6.06e-05	-0.22	-0.15	Obesity-related traits;	chr2:105281507	chr2:105324210~105330529:+
BRCA	cis	rs7615952	0.611	rs9681518	ENSG00000250012.1	RP11-124N2.1	-5.03	5.67e-07	6.06e-05	-0.27	-0.15	Blood pressure (smoking interaction);	chr3:125896287	chr3:126084220~126095349:+
BRCA	cis	rs2015599	0.549	rs10771512	ENSG00000275476.1	RP11-996F15.4	5.03	5.68e-07	6.06e-05	0.17	0.15	Platelet count;Mean platelet volume;	chr12:29287303	chr12:29277397~29277882:-
BRCA	cis	rs2625529	0.73	rs4777485	ENSG00000260037.4	CTD-2524L6.3	-5.03	5.68e-07	6.06e-05	-0.21	-0.15	Red blood cell count;	chr15:72097043	chr15:71818396~71823384:+
BRCA	cis	rs62103177	0.81	rs62103194	ENSG00000261126.6	RP11-795F19.1	5.03	5.68e-07	6.06e-05	0.24	0.15	Opioid sensitivity;	chr18:79869482	chr18:80046900~80095482:+
BRCA	cis	rs12591650	0.556	rs12591848	ENSG00000259591.1	RP11-554D20.1	-5.03	5.69e-07	6.07e-05	-0.25	-0.15	Subcutaneous adipose tissue;	chr15:60793494	chr15:60763906~60765625:+
BRCA	cis	rs2303319	0.504	rs13417851	ENSG00000227403.1	AC009299.3	5.03	5.69e-07	6.07e-05	0.34	0.15	Cognitive function;	chr2:161703409	chr2:161244739~161249050:+
BRCA	cis	rs9287719	0.967	rs6432112	ENSG00000243819.4	RN7SL832P	-5.03	5.69e-07	6.07e-05	-0.15	-0.15	Prostate cancer;	chr2:10604748	chr2:10690344~10692099:+
BRCA	cis	rs12497850	0.864	rs4279134	ENSG00000225399.4	RP11-3B7.1	5.03	5.69e-07	6.08e-05	0.15	0.15	Parkinson's disease;	chr3:49119243	chr3:49260085~49261316:+
BRCA	cis	rs2179367	0.632	rs12196750	ENSG00000268592.3	RAET1E-AS1	5.03	5.69e-07	6.08e-05	0.22	0.15	Dupuytren's disease;	chr6:149413335	chr6:149863494~149919507:+
BRCA	cis	rs1075265	0.749	rs805375	ENSG00000235937.1	AC008280.1	5.03	5.69e-07	6.08e-05	0.17	0.15	Chronotype;Morning vs. evening chronotype;	chr2:53863268	chr2:54029552~54030682:-
BRCA	cis	rs2153535	0.58	rs2327067	ENSG00000251164.1	HULC	-5.03	5.69e-07	6.08e-05	-0.19	-0.15	Motion sickness;	chr6:8518249	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.541	rs9328477	ENSG00000251164.1	HULC	-5.03	5.69e-07	6.08e-05	-0.19	-0.15	Motion sickness;	chr6:8518876	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.58	rs9328478	ENSG00000251164.1	HULC	-5.03	5.69e-07	6.08e-05	-0.19	-0.15	Motion sickness;	chr6:8518950	chr6:8652137~8653846:+
BRCA	cis	rs1124769	0.57	rs1903589	ENSG00000259378.1	DCAF13P3	-5.03	5.69e-07	6.08e-05	-0.2	-0.15	Cognitive performance;	chr15:50852087	chr15:50944663~50945996:+
BRCA	cis	rs2179367	0.632	rs62426068	ENSG00000268592.3	RAET1E-AS1	5.03	5.7e-07	6.08e-05	0.23	0.15	Dupuytren's disease;	chr6:149325795	chr6:149863494~149919507:+
BRCA	cis	rs2179367	0.632	rs62426069	ENSG00000268592.3	RAET1E-AS1	5.03	5.7e-07	6.08e-05	0.23	0.15	Dupuytren's disease;	chr6:149325804	chr6:149863494~149919507:+
BRCA	cis	rs9300255	0.602	rs1617434	ENSG00000235423.7	RP11-282O18.3	5.03	5.7e-07	6.08e-05	0.2	0.15	Neutrophil percentage of white cells;	chr12:123164939	chr12:123252030~123261483:-
BRCA	cis	rs2625529	0.689	rs10851847	ENSG00000260037.4	CTD-2524L6.3	-5.03	5.7e-07	6.09e-05	-0.19	-0.15	Red blood cell count;	chr15:71819419	chr15:71818396~71823384:+
BRCA	cis	rs2562456	0.516	rs56072098	ENSG00000268658.4	LINC00664	-5.03	5.71e-07	6.09e-05	-0.24	-0.15	Pain;	chr19:21469158	chr19:21483374~21503238:+
BRCA	cis	rs4415084	0.87	rs66996829	ENSG00000251141.4	RP11-53O19.1	5.03	5.71e-07	6.09e-05	0.15	0.15	Breast cancer;	chr5:44649295	chr5:44744900~44808777:-
BRCA	cis	rs1979679	0.879	rs1581630	ENSG00000278733.1	RP11-425D17.1	-5.03	5.71e-07	6.09e-05	-0.19	-0.15	Ossification of the posterior longitudinal ligament of the spine;	chr12:28466378	chr12:28185625~28186190:-
BRCA	cis	rs1979679	0.573	rs4931087	ENSG00000278733.1	RP11-425D17.1	5.03	5.71e-07	6.1e-05	0.2	0.15	Ossification of the posterior longitudinal ligament of the spine;	chr12:28582158	chr12:28185625~28186190:-
BRCA	cis	rs6498068	0.633	rs7194566	ENSG00000260468.1	LINC01290	-5.03	5.72e-07	6.1e-05	-0.22	-0.15	Metabolite levels (MHPG);	chr16:10532140	chr16:10514842~10528202:-
BRCA	cis	rs1729951	0.546	rs12054219	ENSG00000239213.4	NCK1-AS1	5.03	5.72e-07	6.1e-05	0.16	0.15	Neuroticism;	chr3:136958630	chr3:136841726~136862054:-
BRCA	cis	rs7267979	0.866	rs2424698	ENSG00000276952.1	RP5-965G21.6	5.03	5.72e-07	6.1e-05	0.19	0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25275470	chr20:25284915~25285588:-
BRCA	cis	rs4781563	0.81	rs3743538	ENSG00000242307.1	RPS26P52	5.03	5.72e-07	6.1e-05	0.17	0.15	Bilirubin levels;	chr16:13948831	chr16:13922332~13922679:-
BRCA	cis	rs12497850	0.931	rs9311430	ENSG00000225399.4	RP11-3B7.1	5.03	5.72e-07	6.11e-05	0.15	0.15	Parkinson's disease;	chr3:48807818	chr3:49260085~49261316:+
BRCA	cis	rs1707322	1	rs785498	ENSG00000234329.1	RP11-767N6.2	-5.03	5.72e-07	6.11e-05	-0.16	-0.15	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46126742	chr1:45651039~45651826:-
BRCA	cis	rs6756513	0.5	rs72839877	ENSG00000231024.1	AC092431.3	-5.03	5.73e-07	6.11e-05	-0.22	-0.15	Breast cancer;Platelet count;	chr2:69832475	chr2:69700192~69713847:-
BRCA	cis	rs7976269	0.609	rs10843305	ENSG00000275476.1	RP11-996F15.4	-5.03	5.73e-07	6.11e-05	-0.18	-0.15	Male-pattern baldness;	chr12:29073147	chr12:29277397~29277882:-
BRCA	cis	rs6847067	0.929	rs12511112	ENSG00000180769.7	WDFY3-AS2	-5.03	5.73e-07	6.11e-05	-0.14	-0.15	Oropharynx cancer;	chr4:84754946	chr4:84965682~85011277:+
BRCA	cis	rs12497850	0.864	rs3212	ENSG00000225399.4	RP11-3B7.1	5.03	5.73e-07	6.12e-05	0.15	0.15	Parkinson's disease;	chr3:49108308	chr3:49260085~49261316:+
BRCA	cis	rs2408955	0.521	rs7301003	ENSG00000273765.1	RP11-370I10.11	5.03	5.73e-07	6.12e-05	0.18	0.15	Glycated hemoglobin levels;	chr12:48156444	chr12:48360920~48361377:+
BRCA	cis	rs6847067	0.683	rs17009334	ENSG00000180769.7	WDFY3-AS2	5.03	5.74e-07	6.12e-05	0.16	0.15	Oropharynx cancer;	chr4:84868291	chr4:84965682~85011277:+
BRCA	cis	rs38055	0.519	rs10069631	ENSG00000247796.2	CTD-2366F13.1	5.03	5.74e-07	6.12e-05	0.22	0.15	Acne (severe);	chr5:53126169	chr5:53109842~53115126:+
BRCA	cis	rs9467773	1	rs6456733	ENSG00000241549.7	GUSBP2	5.03	5.74e-07	6.13e-05	0.17	0.15	Intelligence (multi-trait analysis);	chr6:26566576	chr6:26871484~26956554:-
BRCA	cis	rs4494364	0.502	rs1073962	ENSG00000258100.1	RP11-121E16.1	5.03	5.74e-07	6.13e-05	0.23	0.15	Systolic blood pressure (alcohol consumption interaction);	chr12:91027495	chr12:91362196~91368606:+
BRCA	cis	rs2624839	0.704	rs14321	ENSG00000228008.1	CTD-2330K9.3	-5.03	5.74e-07	6.13e-05	-0.16	-0.15	Intelligence (multi-trait analysis);	chr3:50188718	chr3:49903845~49916937:+
BRCA	cis	rs12712135	0.709	rs12463588	ENSG00000234389.1	AC007278.3	-5.03	5.74e-07	6.13e-05	-0.14	-0.15	Blood protein levels;	chr2:102468797	chr2:102438713~102440475:+
BRCA	cis	rs4664293	0.836	rs2556102	ENSG00000226266.5	AC009961.3	-5.03	5.75e-07	6.13e-05	-0.2	-0.15	Monocyte percentage of white cells;	chr2:159798611	chr2:159670708~159712435:-
BRCA	cis	rs7165170	0.678	rs12593759	ENSG00000245479.2	LINC01585	5.03	5.75e-07	6.13e-05	0.19	0.15	Crohn's disease;Inflammatory bowel disease;	chr15:90659370	chr15:90660234~90664967:+
BRCA	cis	rs6545883	0.862	rs1880866	ENSG00000270820.4	RP11-355B11.2	5.03	5.75e-07	6.13e-05	0.18	0.15	Tuberculosis;	chr2:61471837	chr2:61471188~61484130:+
BRCA	cis	rs1707322	0.686	rs1547924	ENSG00000234329.1	RP11-767N6.2	5.03	5.75e-07	6.13e-05	0.16	0.15	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45619440	chr1:45651039~45651826:-
BRCA	cis	rs7615952	0.673	rs35001498	ENSG00000250012.1	RP11-124N2.1	-5.03	5.75e-07	6.13e-05	-0.27	-0.15	Blood pressure (smoking interaction);	chr3:125909801	chr3:126084220~126095349:+
BRCA	cis	rs763121	0.853	rs5757193	ENSG00000228274.3	RP3-508I15.9	5.03	5.75e-07	6.13e-05	0.18	0.15	Menopause (age at onset);	chr22:38638862	chr22:38667585~38681820:-
BRCA	cis	rs7267979	0.789	rs4815400	ENSG00000274973.1	RP13-401N8.7	5.03	5.75e-07	6.13e-05	0.17	0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25311924	chr20:25845497~25845862:+
BRCA	cis	rs1124769	0.619	rs7177664	ENSG00000259378.1	DCAF13P3	-5.03	5.75e-07	6.14e-05	-0.2	-0.15	Cognitive performance;	chr15:51093137	chr15:50944663~50945996:+
BRCA	cis	rs1910358	0.664	rs6881059	ENSG00000248874.4	C5orf17	-5.03	5.75e-07	6.14e-05	-0.2	-0.15	Venous thromboembolism (SNP x SNP interaction);	chr5:23882024	chr5:23951348~24178263:+
BRCA	cis	rs6738627	1	rs6753142	ENSG00000223318.1	RNA5SP111	5.03	5.76e-07	6.15e-05	0.17	0.15	circulating leptin levels adjusted for BMI;Body fat percentage;circulating leptin levels;	chr2:164687561	chr2:164895677~164895777:-
BRCA	cis	rs7617773	0.78	rs34523942	ENSG00000199476.1	Y_RNA	-5.03	5.76e-07	6.15e-05	-0.22	-0.15	Coronary artery disease;	chr3:48301179	chr3:48288587~48288694:+
BRCA	cis	rs3733585	0.673	rs4311316	ENSG00000250413.1	RP11-448G15.1	-5.03	5.77e-07	6.15e-05	-0.2	-0.15	Cleft plate (environmental tobacco smoke interaction);	chr4:9954347	chr4:10006482~10009725:+
BRCA	cis	rs1823913	0.503	rs35868016	ENSG00000280083.1	RP11-317J9.1	-5.03	5.77e-07	6.15e-05	-0.18	-0.15	Obesity-related traits;	chr2:191344082	chr2:191154118~191156070:-
BRCA	cis	rs11159086	1	rs4899516	ENSG00000270000.1	RP3-449M8.9	5.03	5.77e-07	6.15e-05	0.25	0.15	Advanced glycation end-product levels;	chr14:74492825	chr14:74471930~74472360:-
BRCA	cis	rs734999	0.933	rs4648648	ENSG00000238164.5	RP3-395M20.8	-5.03	5.77e-07	6.15e-05	-0.12	-0.15	Ulcerative colitis;	chr1:2581013	chr1:2549920~2557031:-
BRCA	cis	rs2834288	0.7	rs2409502	ENSG00000273102.1	AP000569.9	-5.03	5.77e-07	6.15e-05	-0.18	-0.15	Gut microbiota (bacterial taxa);	chr21:33902431	chr21:33967101~33968573:-
BRCA	cis	rs919433	0.713	rs55642934	ENSG00000231621.1	AC013264.2	-5.03	5.77e-07	6.16e-05	-0.15	-0.15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197626386	chr2:197197991~197199273:+
BRCA	cis	rs62025270	0.688	rs7182210	ENSG00000259295.5	CSPG4P12	-5.03	5.77e-07	6.16e-05	-0.24	-0.15	Idiopathic pulmonary fibrosis;	chr15:85722551	chr15:85191438~85213905:+
BRCA	cis	rs2243480	1	rs6958289	ENSG00000222364.1	RNU6-96P	5.03	5.77e-07	6.16e-05	0.28	0.15	Diabetic kidney disease;	chr7:66192124	chr7:66395191~66395286:+
BRCA	cis	rs6951245	0.507	rs11976805	ENSG00000229043.2	AC091729.9	-5.03	5.78e-07	6.16e-05	-0.22	-0.15	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1099080	chr7:1160374~1165267:+
BRCA	cis	rs2905347	0.895	rs2961283	ENSG00000179428.2	AC073072.5	-5.03	5.78e-07	6.16e-05	-0.16	-0.15	Major depression and alcohol dependence;	chr7:22600879	chr7:22725395~22727620:-
BRCA	cis	rs4834770	1	rs10034579	ENSG00000248280.1	RP11-33B1.2	5.03	5.78e-07	6.16e-05	0.14	0.15	Blood protein levels;	chr4:119322874	chr4:119440561~119450157:-
BRCA	cis	rs7615952	0.605	rs11708269	ENSG00000171084.14	FAM86JP	5.03	5.78e-07	6.16e-05	0.33	0.15	Blood pressure (smoking interaction);	chr3:125613306	chr3:125916620~125930024:+
BRCA	cis	rs950169	0.58	rs17532346	ENSG00000275120.1	RP11-182J1.17	5.03	5.78e-07	6.17e-05	0.21	0.15	Schizophrenia;	chr15:84628264	chr15:84599434~84606463:-
BRCA	cis	rs2303319	0.582	rs12464282	ENSG00000227403.1	AC009299.3	5.03	5.79e-07	6.17e-05	0.36	0.15	Cognitive function;	chr2:161592345	chr2:161244739~161249050:+
BRCA	cis	rs875971	0.895	rs3857684	ENSG00000223473.2	GS1-124K5.3	5.03	5.79e-07	6.17e-05	0.12	0.15	Aortic root size;	chr7:66473171	chr7:66491049~66493566:-
BRCA	cis	rs4908760	0.864	rs1463052	ENSG00000232912.4	RP5-1115A15.1	5.03	5.79e-07	6.17e-05	0.15	0.15	Vitiligo;	chr1:8641172	chr1:8424645~8434838:+
BRCA	cis	rs7267979	0.816	rs404775	ENSG00000204556.4	CTD-2514C3.1	-5.03	5.79e-07	6.17e-05	-0.21	-0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25500481	chr20:26018832~26020684:+
BRCA	cis	rs7267979	0.816	rs374701	ENSG00000204556.4	CTD-2514C3.1	-5.03	5.79e-07	6.17e-05	-0.21	-0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25502980	chr20:26018832~26020684:+
BRCA	cis	rs4578769	0.569	rs12605341	ENSG00000265939.1	UBE2CP2	-5.03	5.79e-07	6.17e-05	-0.17	-0.15	Eosinophil percentage of white cells;	chr18:22803011	chr18:22900486~22900995:-
BRCA	cis	rs7267979	0.844	rs2257649	ENSG00000277938.1	RP5-965G21.3	5.03	5.79e-07	6.18e-05	0.18	0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25282821	chr20:25229150~25231933:+
BRCA	cis	rs991427	1	rs11105988	ENSG00000258100.1	RP11-121E16.1	-5.03	5.8e-07	6.18e-05	-0.21	-0.15	Systolic blood pressure (alcohol consumption interaction);	chr12:91104522	chr12:91362196~91368606:+
BRCA	cis	rs12744310	0.887	rs12046670	ENSG00000235358.1	RP11-399E6.1	5.03	5.8e-07	6.18e-05	0.23	0.15	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41343640	chr1:41242373~41284861:+
BRCA	cis	rs6430585	0.583	rs6728946	ENSG00000231890.6	DARS-AS1	-5.03	5.8e-07	6.18e-05	-0.24	-0.15	Corneal structure;	chr2:135877773	chr2:135985176~136022593:+
BRCA	cis	rs12744310	0.887	rs12032040	ENSG00000235358.1	RP11-399E6.1	5.03	5.8e-07	6.18e-05	0.23	0.15	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41352635	chr1:41242373~41284861:+
BRCA	cis	rs442309	0.812	rs448355	ENSG00000238280.1	RP11-436D10.3	-5.03	5.8e-07	6.18e-05	-0.21	-0.15	Vogt-Koyanagi-Harada syndrome;	chr10:62772835	chr10:62793562~62805887:-
BRCA	cis	rs11089937	0.585	rs6001229	ENSG00000211638.2	IGLV8-61	5.03	5.8e-07	6.18e-05	0.16	0.15	Periodontitis (PAL4Q3);	chr22:22187693	chr22:22098700~22099212:+
BRCA	cis	rs2832191	0.791	rs2832181	ENSG00000176054.6	RPL23P2	-5.03	5.8e-07	6.18e-05	-0.16	-0.15	Dental caries;	chr21:29109050	chr21:28997613~28998033:-
BRCA	cis	rs10861342	1	rs12316054	ENSG00000257999.1	RP11-61E11.2	-5.03	5.8e-07	6.19e-05	-0.33	-0.15	IgG glycosylation;	chr12:105175365	chr12:105102472~105107179:-
BRCA	cis	rs2153535	0.58	rs1932280	ENSG00000251164.1	HULC	-5.03	5.8e-07	6.19e-05	-0.19	-0.15	Motion sickness;	chr6:8473421	chr6:8652137~8653846:+
BRCA	cis	rs2832191	0.791	rs2832179	ENSG00000215533.7	LINC00189	5.03	5.8e-07	6.19e-05	0.17	0.15	Dental caries;	chr21:29108045	chr21:29193480~29288205:+
BRCA	cis	rs2832191	0.791	rs4817270	ENSG00000215533.7	LINC00189	5.03	5.8e-07	6.19e-05	0.17	0.15	Dental caries;	chr21:29108047	chr21:29193480~29288205:+
BRCA	cis	rs13326165	0.585	rs11715391	ENSG00000243224.1	RP5-1157M23.2	-5.03	5.8e-07	6.19e-05	-0.25	-0.15	HDL cholesterol levels;HDL cholesterol;	chr3:52246362	chr3:52239258~52241097:+
BRCA	cis	rs370915	0.578	rs1367934	ENSG00000250971.1	RP11-696F12.1	5.03	5.8e-07	6.19e-05	0.17	0.15	Gout;	chr4:186855242	chr4:187060099~187060930:+
BRCA	cis	rs7267979	0.816	rs390123	ENSG00000204556.4	CTD-2514C3.1	-5.03	5.81e-07	6.19e-05	-0.21	-0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25499469	chr20:26018832~26020684:+
BRCA	cis	rs12612619	0.732	rs11677841	ENSG00000229122.1	AGBL5-IT1	5.03	5.81e-07	6.19e-05	0.16	0.15	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27017081	chr2:27061038~27061815:+
BRCA	cis	rs7200543	1	rs16966952	ENSG00000260735.1	RP11-72I8.1	-5.03	5.81e-07	6.19e-05	-0.18	-0.15	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15042086	chr16:15094411~15109197:+
BRCA	cis	rs8127691	0.874	rs2838516	ENSG00000237604.1	AP001056.1	5.03	5.81e-07	6.19e-05	0.17	0.15	Inflammatory bowel disease;	chr21:44192592	chr21:44175489~44176453:+
BRCA	cis	rs875971	1	rs2220626	ENSG00000223473.2	GS1-124K5.3	-5.03	5.81e-07	6.19e-05	-0.12	-0.15	Aortic root size;	chr7:66081075	chr7:66491049~66493566:-
BRCA	cis	rs8005677	0.611	rs11624528	ENSG00000257285.4	RP11-298I3.1	5.03	5.81e-07	6.19e-05	0.17	0.15	Cognitive ability (multi-trait analysis);	chr14:22989947	chr14:22929609~22955562:+
BRCA	cis	rs10129255	0.957	rs17113284	ENSG00000211974.3	IGHV2-70	-5.03	5.81e-07	6.2e-05	-0.16	-0.15	Kawasaki disease;	chr14:106684476	chr14:106723574~106724093:-
BRCA	cis	rs2790457	0.793	rs2153302	ENSG00000254635.4	WAC-AS1	-5.03	5.82e-07	6.2e-05	-0.19	-0.15	Multiple myeloma;	chr10:28529607	chr10:28522652~28532743:-
BRCA	cis	rs2832191	0.791	rs8134407	ENSG00000215533.7	LINC00189	-5.03	5.82e-07	6.2e-05	-0.17	-0.15	Dental caries;	chr21:29104265	chr21:29193480~29288205:+
BRCA	cis	rs180730	0.561	rs3106314	ENSG00000251609.2	SETP12	-5.03	5.82e-07	6.2e-05	-0.2	-0.15	Fasting plasma glucose;	chr4:120895637	chr4:120895494~120897083:-
BRCA	cis	rs7200543	1	rs16966952	ENSG00000275910.1	RP11-680G24.6	-5.03	5.82e-07	6.2e-05	-0.18	-0.15	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15042086	chr16:15015828~15016390:-
BRCA	cis	rs10504130	0.696	rs76649327	ENSG00000253844.1	RP11-546K22.1	-5.03	5.83e-07	6.21e-05	-0.24	-0.15	Venous thromboembolism (SNP x SNP interaction);	chr8:51917219	chr8:51961458~52022974:+
BRCA	cis	rs9308731	0.765	rs6738028	ENSG00000227992.1	AC108463.2	-5.03	5.83e-07	6.21e-05	-0.18	-0.15	Chronic lymphocytic leukemia;	chr2:111191750	chr2:111203964~111206215:-
BRCA	cis	rs7267979	0.873	rs6083853	ENSG00000125804.12	FAM182A	5.03	5.83e-07	6.21e-05	0.2	0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25423905	chr20:26054655~26086917:+
BRCA	cis	rs7267979	0.934	rs2482913	ENSG00000125804.12	FAM182A	5.03	5.83e-07	6.21e-05	0.2	0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25424450	chr20:26054655~26086917:+
BRCA	cis	rs9473147	0.516	rs9395283	ENSG00000270761.1	RP11-385F7.1	-5.03	5.83e-07	6.21e-05	-0.16	-0.15	Platelet distribution width;Mean platelet volume;	chr6:47583708	chr6:47477243~47477572:-
BRCA	cis	rs9473147	0.516	rs9349415	ENSG00000270761.1	RP11-385F7.1	-5.03	5.83e-07	6.21e-05	-0.16	-0.15	Platelet distribution width;Mean platelet volume;	chr6:47584125	chr6:47477243~47477572:-
BRCA	cis	rs9473147	0.516	rs9349416	ENSG00000270761.1	RP11-385F7.1	-5.03	5.83e-07	6.21e-05	-0.16	-0.15	Platelet distribution width;Mean platelet volume;	chr6:47584202	chr6:47477243~47477572:-
BRCA	cis	rs2253762	0.54	rs11200324	ENSG00000276742.1	RP11-500G22.4	-5.03	5.83e-07	6.21e-05	-0.26	-0.15	Breast cancer;	chr10:122009999	chr10:121956782~121957098:+
BRCA	cis	rs57221529	0.713	rs12521091	ENSG00000271781.1	CTD-2589H19.6	-5.03	5.83e-07	6.22e-05	-0.23	-0.15	Lung disease severity in cystic fibrosis;	chr5:590595	chr5:675826~676616:+
BRCA	cis	rs9308731	1	rs9308731	ENSG00000230499.1	AC108463.1	-5.03	5.83e-07	6.22e-05	-0.18	-0.15	Chronic lymphocytic leukemia;	chr2:111150685	chr2:111195963~111206494:+
BRCA	cis	rs4819052	0.851	rs3673	ENSG00000184274.3	LINC00315	-5.03	5.84e-07	6.22e-05	-0.21	-0.15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45261860	chr21:45300245~45305257:-
BRCA	cis	rs12591650	0.556	rs12593925	ENSG00000259591.1	RP11-554D20.1	-5.03	5.84e-07	6.22e-05	-0.26	-0.15	Subcutaneous adipose tissue;	chr15:60789537	chr15:60763906~60765625:+
BRCA	cis	rs3764021	1	rs7977720	ENSG00000256582.1	RP11-75L1.1	5.03	5.84e-07	6.22e-05	0.15	0.15	Type 1 diabetes;	chr12:9713753	chr12:9704077~9709350:+
BRCA	cis	rs2574985	0.739	rs3011797	ENSG00000231345.3	BEND3P1	-5.03	5.84e-07	6.22e-05	-0.26	-0.15	Subjective well-being;	chr10:50558612	chr10:50655967~50660472:+
BRCA	cis	rs78487399	0.908	rs72868628	ENSG00000234936.1	AC010883.5	5.03	5.85e-07	6.23e-05	0.21	0.15	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43605900	chr2:43229573~43233394:+
BRCA	cis	rs10504130	0.696	rs79069311	ENSG00000253844.1	RP11-546K22.1	-5.03	5.85e-07	6.23e-05	-0.24	-0.15	Venous thromboembolism (SNP x SNP interaction);	chr8:51926891	chr8:51961458~52022974:+
BRCA	cis	rs10504130	0.696	rs60796336	ENSG00000253844.1	RP11-546K22.1	-5.03	5.85e-07	6.23e-05	-0.24	-0.15	Venous thromboembolism (SNP x SNP interaction);	chr8:51928310	chr8:51961458~52022974:+
BRCA	cis	rs875971	0.83	rs778711	ENSG00000273448.1	RP11-166O4.6	5.03	5.85e-07	6.23e-05	0.14	0.15	Aortic root size;	chr7:66386670	chr7:67333047~67334383:+
BRCA	cis	rs875971	0.862	rs1083554	ENSG00000273448.1	RP11-166O4.6	5.03	5.85e-07	6.23e-05	0.14	0.15	Aortic root size;	chr7:66387354	chr7:67333047~67334383:+
BRCA	cis	rs875971	0.862	rs778707	ENSG00000273448.1	RP11-166O4.6	5.03	5.85e-07	6.23e-05	0.14	0.15	Aortic root size;	chr7:66392040	chr7:67333047~67334383:+
BRCA	cis	rs875971	0.862	rs778705	ENSG00000273448.1	RP11-166O4.6	5.03	5.85e-07	6.23e-05	0.14	0.15	Aortic root size;	chr7:66396128	chr7:67333047~67334383:+
BRCA	cis	rs875971	0.862	rs778697	ENSG00000273448.1	RP11-166O4.6	5.03	5.85e-07	6.23e-05	0.14	0.15	Aortic root size;	chr7:66405439	chr7:67333047~67334383:+
BRCA	cis	rs875971	0.798	rs7789615	ENSG00000273448.1	RP11-166O4.6	5.03	5.85e-07	6.23e-05	0.14	0.15	Aortic root size;	chr7:66413674	chr7:67333047~67334383:+
BRCA	cis	rs7577696	0.785	rs12611678	ENSG00000272716.1	RP11-563N4.1	-5.03	5.85e-07	6.23e-05	-0.17	-0.15	Inflammatory biomarkers;	chr2:32122716	chr2:32165046~32165757:-
BRCA	cis	rs7577696	0.785	rs11683110	ENSG00000272716.1	RP11-563N4.1	-5.03	5.85e-07	6.23e-05	-0.17	-0.15	Inflammatory biomarkers;	chr2:32124744	chr2:32165046~32165757:-
BRCA	cis	rs4835473	0.8	rs1849122	ENSG00000249741.2	RP11-673E1.3	-5.03	5.85e-07	6.23e-05	-0.17	-0.15	Immature fraction of reticulocytes;	chr4:143978699	chr4:143911514~143912053:-
BRCA	cis	rs7914558	0.966	rs11191518	ENSG00000236937.2	PTGES3P4	5.03	5.85e-07	6.23e-05	0.2	0.15	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103023096	chr10:102845595~102845950:+
BRCA	cis	rs8031584	0.958	rs7168641	ENSG00000259845.1	HERC2P10	5.03	5.85e-07	6.23e-05	0.18	0.15	Huntington's disease progression;	chr15:30943249	chr15:30815271~30844153:+
BRCA	cis	rs5769707	0.521	rs739244	ENSG00000235111.1	RP1-29C18.8	-5.03	5.85e-07	6.23e-05	-0.17	-0.15	Monocyte percentage of white cells;Monocyte count;	chr22:49666510	chr22:49612657~49615716:-
BRCA	cis	rs13113518	0.812	rs12649507	ENSG00000272969.1	RP11-528I4.2	-5.03	5.85e-07	6.24e-05	-0.18	-0.15	Height;	chr4:55514317	chr4:55547112~55547889:+
BRCA	cis	rs12681366	0.761	rs2930963	ENSG00000253175.1	RP11-267M23.6	5.03	5.86e-07	6.24e-05	0.19	0.15	Nonsyndromic cleft lip with cleft palate;	chr8:94434892	chr8:94565036~94565715:+
BRCA	cis	rs202072	0.585	rs3817735	ENSG00000272379.1	RP1-257A7.5	5.03	5.86e-07	6.24e-05	0.2	0.15	HIV-1 viral setpoint;	chr6:13278416	chr6:13290018~13290490:-
BRCA	cis	rs2638953	0.671	rs11049352	ENSG00000278733.1	RP11-425D17.1	-5.03	5.86e-07	6.24e-05	-0.22	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28113832	chr12:28185625~28186190:-
BRCA	cis	rs6496044	0.634	rs4843066	ENSG00000259295.5	CSPG4P12	5.03	5.86e-07	6.24e-05	0.18	0.15	Interstitial lung disease;	chr15:85519680	chr15:85191438~85213905:+
BRCA	cis	rs700651	0.821	rs770661	ENSG00000231621.1	AC013264.2	-5.03	5.86e-07	6.24e-05	-0.15	-0.15	Intracranial aneurysm;	chr2:197860720	chr2:197197991~197199273:+
BRCA	cis	rs700651	0.821	rs700690	ENSG00000231621.1	AC013264.2	-5.03	5.86e-07	6.24e-05	-0.15	-0.15	Intracranial aneurysm;	chr2:197862902	chr2:197197991~197199273:+
BRCA	cis	rs7572733	0.534	rs700692	ENSG00000231621.1	AC013264.2	-5.03	5.86e-07	6.24e-05	-0.15	-0.15	Dermatomyositis;	chr2:197863776	chr2:197197991~197199273:+
BRCA	cis	rs7572733	0.534	rs770662	ENSG00000231621.1	AC013264.2	-5.03	5.86e-07	6.24e-05	-0.15	-0.15	Dermatomyositis;	chr2:197864559	chr2:197197991~197199273:+
BRCA	cis	rs2562456	0.641	rs62107468	ENSG00000268081.1	RP11-678G14.2	5.03	5.86e-07	6.24e-05	0.25	0.15	Pain;	chr19:21307177	chr19:21554640~21569237:-
BRCA	cis	rs10129255	0.5	rs2105991	ENSG00000211967.3	IGHV3-53	-5.03	5.86e-07	6.24e-05	-0.1	-0.15	Kawasaki disease;	chr14:106682022	chr14:106592676~106593347:-
BRCA	cis	rs17685	0.753	rs1637045	ENSG00000280388.1	RP11-229D13.3	-5.03	5.86e-07	6.24e-05	-0.16	-0.15	Coffee consumption (cups per day);Coffee consumption;	chr7:76074577	chr7:76043977~76045963:-
BRCA	cis	rs12478296	0.792	rs6738361	ENSG00000261186.2	RP11-341N2.1	-5.03	5.86e-07	6.24e-05	-0.25	-0.15	Obesity-related traits;	chr2:242072106	chr2:242087351~242088457:-
BRCA	cis	rs12680842	0.883	rs13265241	ENSG00000261437.1	RP11-22C11.2	5.03	5.86e-07	6.24e-05	0.15	0.15	Body mass index;	chr8:94575129	chr8:94637285~94639467:-
BRCA	cis	rs2638953	0.962	rs3825246	ENSG00000247934.4	RP11-967K21.1	-5.03	5.86e-07	6.25e-05	-0.21	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28310186	chr12:28163298~28190738:-
BRCA	cis	rs4722166	0.541	rs1800795	ENSG00000225541.1	AC002480.5	-5.03	5.87e-07	6.25e-05	-0.17	-0.15	Lung cancer;	chr7:22727026	chr7:22571607~22661792:-
BRCA	cis	rs559928	1	rs72926046	ENSG00000236935.1	AP003774.1	5.03	5.87e-07	6.25e-05	0.2	0.15	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64375915	chr11:64325050~64329504:-
BRCA	cis	rs559928	1	rs72926050	ENSG00000236935.1	AP003774.1	5.03	5.87e-07	6.25e-05	0.2	0.15	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64376102	chr11:64325050~64329504:-
BRCA	cis	rs9291683	0.597	rs11723016	ENSG00000250413.1	RP11-448G15.1	5.03	5.87e-07	6.25e-05	0.2	0.15	Bone mineral density;	chr4:10124565	chr4:10006482~10009725:+
BRCA	cis	rs1722141	0.542	rs1723917	ENSG00000229628.1	AC073115.7	5.03	5.87e-07	6.25e-05	0.22	0.15	Sitting height ratio;	chr7:46006030	chr7:45990905~46000898:+
BRCA	cis	rs6832769	1	rs28670674	ENSG00000223305.1	RN7SKP30	-5.03	5.87e-07	6.25e-05	-0.2	-0.15	Personality dimensions;	chr4:55540936	chr4:55540502~55540835:-
BRCA	cis	rs3845817	0.832	rs702883	ENSG00000237979.1	AC007389.1	5.03	5.87e-07	6.26e-05	0.19	0.15	Bipolar disorder;	chr2:65524951	chr2:65500993~65502138:-
BRCA	cis	rs721917	0.506	rs2254016	ENSG00000242600.5	MBL1P	5.03	5.87e-07	6.26e-05	0.18	0.15	Chronic obstructive pulmonary disease;	chr10:79898668	chr10:79904898~79950336:+
BRCA	cis	rs10788972	0.683	rs6672905	ENSG00000225183.1	RP4-758J24.4	-5.03	5.88e-07	6.26e-05	-0.2	-0.15	Parkinson disease and lewy body pathology;	chr1:54097566	chr1:54089856~54090093:+
BRCA	cis	rs10752881	0.935	rs10797834	ENSG00000224468.3	RP11-181K3.4	-5.03	5.88e-07	6.26e-05	-0.17	-0.15	Colorectal cancer;	chr1:183079614	chr1:183138402~183141282:-
BRCA	cis	rs1823913	0.503	rs34716486	ENSG00000280083.1	RP11-317J9.1	-5.03	5.88e-07	6.26e-05	-0.18	-0.15	Obesity-related traits;	chr2:191343335	chr2:191154118~191156070:-
BRCA	cis	rs2179367	0.959	rs628488	ENSG00000268592.3	RAET1E-AS1	5.03	5.88e-07	6.26e-05	0.2	0.15	Dupuytren's disease;	chr6:149398264	chr6:149863494~149919507:+
BRCA	cis	rs3102460	0.618	rs3101469	ENSG00000225401.2	TGIF2P1	-5.03	5.88e-07	6.26e-05	-0.23	-0.15	Obesity-related traits;	chr1:244410343	chr1:244394976~244395660:-
BRCA	cis	rs5758659	0.729	rs134866	ENSG00000182057.4	OGFRP1	5.03	5.88e-07	6.26e-05	0.17	0.15	Cognitive function;	chr22:42254657	chr22:42269753~42275196:+
BRCA	cis	rs4664293	0.836	rs13016015	ENSG00000224152.1	AC009506.1	-5.03	5.88e-07	6.26e-05	-0.17	-0.15	Monocyte percentage of white cells;	chr2:159790018	chr2:159615296~159617082:+
BRCA	cis	rs4718428	0.705	rs12698547	ENSG00000229180.5	GS1-124K5.11	5.03	5.89e-07	6.27e-05	0.15	0.15	Corneal structure;	chr7:66813271	chr7:66526088~66542624:-
BRCA	cis	rs2278170	1	rs2566264	ENSG00000225101.4	OR52K3P	-5.03	5.89e-07	6.27e-05	-0.22	-0.15	Amyotrophic lateral sclerosis;	chr11:4460913	chr11:4474813~4475755:+
BRCA	cis	rs7200543	1	rs3803575	ENSG00000275910.1	RP11-680G24.6	-5.03	5.9e-07	6.28e-05	-0.18	-0.15	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15044590	chr16:15015828~15016390:-
BRCA	cis	rs2153535	0.58	rs9505457	ENSG00000251164.1	HULC	-5.03	5.9e-07	6.28e-05	-0.19	-0.15	Motion sickness;	chr6:8478909	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.56	rs9379214	ENSG00000251164.1	HULC	-5.03	5.9e-07	6.28e-05	-0.19	-0.15	Motion sickness;	chr6:8480637	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.58	rs2225765	ENSG00000251164.1	HULC	-5.03	5.9e-07	6.28e-05	-0.19	-0.15	Motion sickness;	chr6:8481552	chr6:8652137~8653846:+
BRCA	cis	rs4218	0.517	rs71480503	ENSG00000277144.1	RP11-59H7.4	-5.03	5.9e-07	6.28e-05	-0.21	-0.15	Social communication problems;	chr15:59098246	chr15:59115547~59116089:-
BRCA	cis	rs2153535	0.58	rs6927589	ENSG00000251164.1	HULC	5.03	5.9e-07	6.28e-05	0.19	0.15	Motion sickness;	chr6:8456399	chr6:8652137~8653846:+
BRCA	cis	rs10191773	0.535	rs12477879	ENSG00000243389.1	AC012442.5	5.03	5.9e-07	6.28e-05	0.29	0.15	Yeast infection;	chr2:112212288	chr2:112589040~112614431:+
BRCA	cis	rs10911232	0.507	rs10752891	ENSG00000224468.3	RP11-181K3.4	-5.03	5.9e-07	6.28e-05	-0.17	-0.15	Hypertriglyceridemia;	chr1:183054148	chr1:183138402~183141282:-
BRCA	cis	rs10752881	0.935	rs4652771	ENSG00000224468.3	RP11-181K3.4	-5.03	5.9e-07	6.28e-05	-0.17	-0.15	Colorectal cancer;	chr1:183054368	chr1:183138402~183141282:-
BRCA	cis	rs957448	0.607	rs12680842	ENSG00000261437.1	RP11-22C11.2	5.03	5.9e-07	6.28e-05	0.15	0.15	Nonsyndromic cleft lip with cleft palate;	chr8:94570378	chr8:94637285~94639467:-
BRCA	cis	rs9393692	1	rs9393692	ENSG00000241549.7	GUSBP2	-5.03	5.9e-07	6.28e-05	-0.17	-0.15	Educational attainment;	chr6:26276422	chr6:26871484~26956554:-
BRCA	cis	rs78487399	0.808	rs12105394	ENSG00000234936.1	AC010883.5	5.03	5.9e-07	6.28e-05	0.25	0.15	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43449651	chr2:43229573~43233394:+
BRCA	cis	rs78487399	0.808	rs76171330	ENSG00000234936.1	AC010883.5	5.03	5.9e-07	6.28e-05	0.25	0.15	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43450301	chr2:43229573~43233394:+
BRCA	cis	rs8031584	0.56	rs7171208	ENSG00000259845.1	HERC2P10	-5.03	5.9e-07	6.28e-05	-0.17	-0.15	Huntington's disease progression;	chr15:30906726	chr15:30815271~30844153:+
BRCA	cis	rs6840360	0.642	rs7657670	ENSG00000251611.1	RP11-610P16.1	-5.03	5.9e-07	6.28e-05	-0.13	-0.15	Intelligence (multi-trait analysis);	chr4:151432223	chr4:151407551~151408835:-
BRCA	cis	rs4834770	1	rs6823963	ENSG00000248280.1	RP11-33B1.2	5.03	5.91e-07	6.29e-05	0.14	0.15	Blood protein levels;	chr4:119321009	chr4:119440561~119450157:-
BRCA	cis	rs4834770	1	rs4834771	ENSG00000248280.1	RP11-33B1.2	5.03	5.91e-07	6.29e-05	0.14	0.15	Blood protein levels;	chr4:119321617	chr4:119440561~119450157:-
BRCA	cis	rs4834770	1	rs1397613	ENSG00000248280.1	RP11-33B1.2	5.03	5.91e-07	6.29e-05	0.14	0.15	Blood protein levels;	chr4:119321774	chr4:119440561~119450157:-
BRCA	cis	rs4834770	1	rs6857641	ENSG00000248280.1	RP11-33B1.2	5.03	5.91e-07	6.29e-05	0.14	0.15	Blood protein levels;	chr4:119322356	chr4:119440561~119450157:-
BRCA	cis	rs4834770	1	rs2282688	ENSG00000248280.1	RP11-33B1.2	5.03	5.91e-07	6.29e-05	0.14	0.15	Blood protein levels;	chr4:119322567	chr4:119440561~119450157:-
BRCA	cis	rs595244	1	rs2456475	ENSG00000259705.1	RP11-227D13.1	5.03	5.91e-07	6.29e-05	0.28	0.15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48593680	chr15:48645951~48652016:+
BRCA	cis	rs2638953	0.962	rs61920564	ENSG00000247934.4	RP11-967K21.1	-5.03	5.91e-07	6.29e-05	-0.21	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28357000	chr12:28163298~28190738:-
BRCA	cis	rs4835473	0.831	rs4323050	ENSG00000249741.2	RP11-673E1.3	-5.03	5.91e-07	6.29e-05	-0.17	-0.15	Immature fraction of reticulocytes;	chr4:143992106	chr4:143911514~143912053:-
BRCA	cis	rs4908760	0.827	rs7513420	ENSG00000232912.4	RP5-1115A15.1	5.03	5.92e-07	6.3e-05	0.15	0.15	Vitiligo;	chr1:8620985	chr1:8424645~8434838:+
BRCA	cis	rs2153535	0.58	rs6921964	ENSG00000251164.1	HULC	-5.03	5.92e-07	6.3e-05	-0.19	-0.15	Motion sickness;	chr6:8446162	chr6:8652137~8653846:+
BRCA	cis	rs11955398	0.502	rs159357	ENSG00000215032.2	GNL3LP1	5.03	5.92e-07	6.3e-05	0.2	0.15	Intelligence (multi-trait analysis);	chr5:61174363	chr5:60891935~60893577:-
BRCA	cis	rs10181042	0.514	rs1177288	ENSG00000273302.1	RP11-493E12.2	5.03	5.92e-07	6.3e-05	0.14	0.15	Crohn's disease;	chr2:61125850	chr2:61199979~61200769:+
BRCA	cis	rs113835537	0.935	rs3867133	ENSG00000255517.5	CTD-3074O7.5	5.02	5.92e-07	6.3e-05	0.24	0.15	Airway imaging phenotypes;	chr11:66684491	chr11:66473490~66480233:-
BRCA	cis	rs2115630	0.967	rs11073702	ENSG00000259295.5	CSPG4P12	-5.02	5.93e-07	6.3e-05	-0.18	-0.15	P wave terminal force;	chr15:84766840	chr15:85191438~85213905:+
BRCA	cis	rs8002861	0.935	rs4101376	ENSG00000274001.1	RP11-5G9.5	-5.02	5.93e-07	6.3e-05	-0.17	-0.15	Leprosy;	chr13:43895699	chr13:43877715~43878163:-
BRCA	cis	rs10129255	0.957	rs2013423	ENSG00000211974.3	IGHV2-70	5.02	5.93e-07	6.31e-05	0.16	0.15	Kawasaki disease;	chr14:106690675	chr14:106723574~106724093:-
BRCA	cis	rs10129255	0.957	rs56134540	ENSG00000211974.3	IGHV2-70	5.02	5.93e-07	6.31e-05	0.16	0.15	Kawasaki disease;	chr14:106691290	chr14:106723574~106724093:-
BRCA	cis	rs2531992	1	rs2531992	ENSG00000262185.1	RP11-462G12.1	-5.02	5.93e-07	6.31e-05	-0.24	-0.15	Waist circumference;	chr16:3971733	chr16:3947609~3950444:-
BRCA	cis	rs7618915	0.508	rs13065851	ENSG00000243224.1	RP5-1157M23.2	-5.02	5.93e-07	6.31e-05	-0.17	-0.15	Bipolar disorder;	chr3:52610820	chr3:52239258~52241097:+
BRCA	cis	rs2255336	0.938	rs2255353	ENSG00000245648.1	RP11-277P12.20	5.02	5.93e-07	6.31e-05	0.22	0.15	Blood protein levels;	chr12:10379512	chr12:10363769~10398506:+
BRCA	cis	rs794185	0.625	rs2819582	ENSG00000231249.1	ITPR1-AS1	-5.02	5.93e-07	6.31e-05	-0.17	-0.15	Multiple sclerosis--Brain Glutamate Levels;	chr3:4470643	chr3:4490891~4493163:-
BRCA	cis	rs7923609	0.871	rs2393984	ENSG00000232075.1	MRPL35P2	5.02	5.93e-07	6.31e-05	0.19	0.15	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63555211	chr10:63634317~63634827:-
BRCA	cis	rs7923609	0.871	rs6479905	ENSG00000232075.1	MRPL35P2	5.02	5.93e-07	6.31e-05	0.19	0.15	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63555471	chr10:63634317~63634827:-
BRCA	cis	rs4925386	1	rs4925389	ENSG00000275437.1	RP5-908M14.10	-5.02	5.93e-07	6.31e-05	-0.16	-0.15	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62347456	chr20:62402236~62405935:-
BRCA	cis	rs7487075	0.619	rs7486495	ENSG00000274723.1	RP11-618L22.1	5.02	5.93e-07	6.31e-05	0.19	0.15	Itch intensity from mosquito bite;	chr12:46432553	chr12:46970504~46972155:+
BRCA	cis	rs2638953	0.815	rs7139060	ENSG00000247934.4	RP11-967K21.1	-5.02	5.93e-07	6.31e-05	-0.19	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28540211	chr12:28163298~28190738:-
BRCA	cis	rs2153535	0.58	rs9406167	ENSG00000251164.1	HULC	-5.02	5.93e-07	6.31e-05	-0.19	-0.15	Motion sickness;	chr6:8502619	chr6:8652137~8653846:+
BRCA	cis	rs875971	1	rs10244498	ENSG00000223473.2	GS1-124K5.3	5.02	5.93e-07	6.31e-05	0.12	0.15	Aortic root size;	chr7:66651069	chr7:66491049~66493566:-
BRCA	cis	rs321358	0.945	rs73015199	ENSG00000271390.1	RP11-89C3.3	5.02	5.94e-07	6.31e-05	0.25	0.15	Body mass index;	chr11:111104952	chr11:111089870~111090368:-
BRCA	cis	rs9868809	0.505	rs28657585	ENSG00000270441.1	RP11-694I15.7	5.02	5.94e-07	6.32e-05	0.27	0.15	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48698783	chr3:49140086~49160851:-
BRCA	cis	rs6928977	0.5	rs6570022	ENSG00000231028.7	LINC00271	-5.02	5.94e-07	6.32e-05	-0.16	-0.15	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135627683	chr6:135497801~135716055:+
BRCA	cis	rs875971	0.964	rs12668936	ENSG00000223473.2	GS1-124K5.3	5.02	5.94e-07	6.32e-05	0.12	0.15	Aortic root size;	chr7:66449417	chr7:66491049~66493566:-
BRCA	cis	rs595244	1	rs636178	ENSG00000259705.1	RP11-227D13.1	5.02	5.94e-07	6.32e-05	0.28	0.15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48605085	chr15:48645951~48652016:+
BRCA	cis	rs4713118	0.868	rs2893928	ENSG00000216901.1	AL022393.7	5.02	5.95e-07	6.32e-05	0.22	0.15	Parkinson's disease;	chr6:27770651	chr6:28176188~28176674:+
BRCA	cis	rs7267979	0.844	rs6083851	ENSG00000204556.4	CTD-2514C3.1	5.02	5.95e-07	6.32e-05	0.21	0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25420599	chr20:26018832~26020684:+
BRCA	cis	rs4934494	0.677	rs11185808	ENSG00000240996.1	RP11-80H5.7	-5.02	5.95e-07	6.33e-05	-0.21	-0.15	Red blood cell count;	chr10:89621353	chr10:89694295~89697928:-
BRCA	cis	rs11051970	0.559	rs113700251	ENSG00000274964.1	RP11-817I4.1	-5.02	5.95e-07	6.33e-05	-0.22	-0.15	Response to tocilizumab in rheumatoid arthritis;	chr12:32409337	chr12:32339368~32340724:+
BRCA	cis	rs7923609	0.811	rs7919685	ENSG00000232075.1	MRPL35P2	5.02	5.95e-07	6.33e-05	0.19	0.15	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63556040	chr10:63634317~63634827:-
BRCA	cis	rs7923609	0.749	rs12247907	ENSG00000232075.1	MRPL35P2	5.02	5.95e-07	6.33e-05	0.19	0.15	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63557285	chr10:63634317~63634827:-
BRCA	cis	rs7923609	0.746	rs7070761	ENSG00000232075.1	MRPL35P2	5.02	5.95e-07	6.33e-05	0.19	0.15	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63557296	chr10:63634317~63634827:-
BRCA	cis	rs7246657	0.663	rs4803287	ENSG00000276846.1	CTD-3220F14.3	5.02	5.95e-07	6.33e-05	0.21	0.15	Coronary artery calcification;	chr19:37588534	chr19:37314868~37315620:-
BRCA	cis	rs10266483	0.654	rs6962076	ENSG00000271550.1	BNIP3P11	-5.02	5.95e-07	6.33e-05	-0.21	-0.15	Response to statin therapy;	chr7:64559214	chr7:64678954~64687393:-
BRCA	cis	rs6490294	0.528	rs74187049	ENSG00000226469.1	ADAM1B	5.02	5.96e-07	6.33e-05	0.27	0.15	Mean platelet volume;	chr12:112180114	chr12:111927018~111929017:+
BRCA	cis	rs6490294	0.528	rs16941909	ENSG00000226469.1	ADAM1B	5.02	5.96e-07	6.33e-05	0.27	0.15	Mean platelet volume;	chr12:112188420	chr12:111927018~111929017:+
BRCA	cis	rs2098713	0.569	rs56264101	ENSG00000250155.1	CTD-2353F22.1	5.02	5.96e-07	6.33e-05	0.17	0.15	Telomere length;	chr5:37540792	chr5:36666214~36725195:-
BRCA	cis	rs2098713	0.569	rs55716037	ENSG00000250155.1	CTD-2353F22.1	5.02	5.96e-07	6.33e-05	0.17	0.15	Telomere length;	chr5:37540805	chr5:36666214~36725195:-
BRCA	cis	rs2562456	0.793	rs627522	ENSG00000268658.4	LINC00664	5.02	5.96e-07	6.34e-05	0.23	0.15	Pain;	chr19:21313002	chr19:21483374~21503238:+
BRCA	cis	rs4715166	0.773	rs6458720	ENSG00000272379.1	RP1-257A7.5	-5.02	5.96e-07	6.34e-05	-0.18	-0.15	Hip geometry;	chr6:13224845	chr6:13290018~13290490:-
BRCA	cis	rs9393692	1	rs3999544	ENSG00000241549.7	GUSBP2	-5.02	5.96e-07	6.34e-05	-0.18	-0.15	Educational attainment;	chr6:26285639	chr6:26871484~26956554:-
BRCA	cis	rs2904967	0.852	rs560097	ENSG00000255200.1	AP003068.18	5.02	5.96e-07	6.34e-05	0.26	0.15	Mean corpuscular volume;	chr11:65275059	chr11:65174117~65176470:-
BRCA	cis	rs7569084	0.687	rs11692813	ENSG00000281920.1	RP11-418H16.1	5.02	5.96e-07	6.34e-05	0.2	0.15	Sum eosinophil basophil counts;	chr2:65435172	chr2:65623272~65628424:+
BRCA	cis	rs1198872	0.892	rs1198866	ENSG00000272275.1	RP11-791G15.2	-5.02	5.96e-07	6.34e-05	-0.19	-0.15	Cardiac Troponin-T levels;	chr2:10761664	chr2:10767875~10770058:-
BRCA	cis	rs4835473	0.932	rs7667092	ENSG00000249741.2	RP11-673E1.3	-5.02	5.97e-07	6.34e-05	-0.16	-0.15	Immature fraction of reticulocytes;	chr4:143968604	chr4:143911514~143912053:-
BRCA	cis	rs370915	1	rs370915	ENSG00000250971.1	RP11-696F12.1	5.02	5.97e-07	6.35e-05	0.16	0.15	Gout;	chr4:186897102	chr4:187060099~187060930:+
BRCA	cis	rs4711336	0.967	rs4711338	ENSG00000224557.6	HLA-DPB2	-5.02	5.97e-07	6.35e-05	-0.18	-0.15	Height;	chr6:33692411	chr6:33112451~33129084:+
BRCA	cis	rs77204473	0.744	rs17120293	ENSG00000280143.1	AP000892.6	-5.02	5.98e-07	6.35e-05	-0.28	-0.15	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117074130	chr11:117204967~117210292:+
BRCA	cis	rs8114671	0.562	rs6088636	ENSG00000269202.1	RP4-614O4.12	-5.02	5.98e-07	6.36e-05	-0.15	-0.15	Height;	chr20:34881943	chr20:35201747~35203288:-
BRCA	cis	rs9659323	0.65	rs61528304	ENSG00000231365.4	RP11-418J17.1	-5.02	5.98e-07	6.36e-05	-0.19	-0.15	Body mass index;	chr1:118920976	chr1:119140396~119275973:+
BRCA	cis	rs6570726	0.791	rs407887	ENSG00000270638.1	RP3-466P17.1	5.02	5.99e-07	6.36e-05	0.18	0.15	Lobe attachment (rater-scored or self-reported);	chr6:145522623	chr6:145735570~145737218:+
BRCA	cis	rs6569038	0.502	rs794261	ENSG00000253194.1	RP11-351A11.1	5.02	5.99e-07	6.36e-05	0.19	0.15	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr6:119007434	chr6:118934785~119031541:+
BRCA	cis	rs7621331	0.963	rs9808979	ENSG00000273486.1	RP11-731C17.2	5.02	5.99e-07	6.36e-05	0.18	0.15	Waist circumference adjusted for body mass index;	chr3:136000456	chr3:136837338~136839021:-
BRCA	cis	rs7621331	1	rs9872542	ENSG00000273486.1	RP11-731C17.2	5.02	5.99e-07	6.36e-05	0.18	0.15	Waist circumference adjusted for body mass index;	chr3:136001831	chr3:136837338~136839021:-
BRCA	cis	rs5742933	0.696	rs17271246	ENSG00000253559.1	OSGEPL1-AS1	-5.02	5.99e-07	6.36e-05	-0.27	-0.15	Ferritin levels;	chr2:189781481	chr2:189762704~189765556:+
BRCA	cis	rs2153535	0.58	rs1414342	ENSG00000251164.1	HULC	-5.02	5.99e-07	6.37e-05	-0.19	-0.15	Motion sickness;	chr6:8462319	chr6:8652137~8653846:+
BRCA	cis	rs8016982	0.633	rs4363794	ENSG00000258999.1	RP11-114N19.3	5.02	5.99e-07	6.37e-05	0.18	0.15	Schizophrenia;	chr14:81207983	chr14:81107033~81170414:-
BRCA	cis	rs2153535	0.601	rs9379224	ENSG00000251164.1	HULC	-5.02	5.99e-07	6.37e-05	-0.19	-0.15	Motion sickness;	chr6:8538180	chr6:8652137~8653846:+
BRCA	cis	rs9818758	0.607	rs9862483	ENSG00000270441.1	RP11-694I15.7	5.02	5.99e-07	6.37e-05	0.3	0.15	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49158008	chr3:49140086~49160851:-
BRCA	cis	rs728616	0.867	rs61860039	ENSG00000225484.5	NUTM2B-AS1	-5.02	5.99e-07	6.37e-05	-0.42	-0.15	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80180150	chr10:79663088~79826594:-
BRCA	cis	rs2638953	0.64	rs11049721	ENSG00000247934.4	RP11-967K21.1	-5.02	6e-07	6.37e-05	-0.21	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28573743	chr12:28163298~28190738:-
BRCA	cis	rs1729951	0.575	rs361239	ENSG00000239213.4	NCK1-AS1	5.02	6e-07	6.38e-05	0.16	0.15	Neuroticism;	chr3:136982453	chr3:136841726~136862054:-
BRCA	cis	rs7980687	0.662	rs585522	ENSG00000235423.7	RP11-282O18.3	5.02	6.01e-07	6.39e-05	0.19	0.15	Head circumference (infant);Educational attainment;Height;	chr12:123066266	chr12:123252030~123261483:-
BRCA	cis	rs2732480	0.5	rs1387257	ENSG00000257735.1	RP11-370I10.6	5.02	6.01e-07	6.39e-05	0.19	0.15	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48242883	chr12:48350945~48442411:+
BRCA	cis	rs1913185	0.787	rs59384952	ENSG00000240032.1	RP11-274H2.3	-5.02	6.01e-07	6.39e-05	-0.24	-0.15	Obesity-related traits;	chr3:146060012	chr3:146066344~146069185:-
BRCA	cis	rs10752881	0.875	rs10752894	ENSG00000224468.3	RP11-181K3.4	-5.02	6.01e-07	6.39e-05	-0.17	-0.15	Colorectal cancer;	chr1:183081475	chr1:183138402~183141282:-
BRCA	cis	rs10911232	0.507	rs10911234	ENSG00000224468.3	RP11-181K3.4	-5.02	6.01e-07	6.39e-05	-0.17	-0.15	Hypertriglyceridemia;	chr1:183083866	chr1:183138402~183141282:-
BRCA	cis	rs9307551	0.619	rs1899232	ENSG00000250334.4	LINC00989	-5.02	6.03e-07	6.4e-05	-0.21	-0.15	Refractive error;	chr4:79501789	chr4:79492416~79576460:+
BRCA	cis	rs9307551	0.619	rs7684683	ENSG00000250334.4	LINC00989	-5.02	6.03e-07	6.4e-05	-0.21	-0.15	Refractive error;	chr4:79501867	chr4:79492416~79576460:+
BRCA	cis	rs9307551	0.584	rs7663844	ENSG00000250334.4	LINC00989	-5.02	6.03e-07	6.4e-05	-0.21	-0.15	Refractive error;	chr4:79502053	chr4:79492416~79576460:+
BRCA	cis	rs2153535	0.58	rs2327056	ENSG00000251164.1	HULC	-5.02	6.03e-07	6.4e-05	-0.19	-0.15	Motion sickness;	chr6:8443072	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.58	rs3938660	ENSG00000251164.1	HULC	-5.02	6.03e-07	6.4e-05	-0.19	-0.15	Motion sickness;	chr6:8443102	chr6:8652137~8653846:+
BRCA	cis	rs6831352	0.819	rs1230155	ENSG00000272777.1	RP11-571L19.8	-5.02	6.03e-07	6.4e-05	-0.17	-0.15	Alcohol dependence;	chr4:99068108	chr4:99067256~99068125:-
BRCA	cis	rs11955398	0.502	rs34610	ENSG00000215032.2	GNL3LP1	5.02	6.03e-07	6.4e-05	0.2	0.15	Intelligence (multi-trait analysis);	chr5:61183854	chr5:60891935~60893577:-
BRCA	cis	rs7577696	0.962	rs34856365	ENSG00000272716.1	RP11-563N4.1	-5.02	6.03e-07	6.4e-05	-0.17	-0.15	Inflammatory biomarkers;	chr2:32079931	chr2:32165046~32165757:-
BRCA	cis	rs7577696	0.962	rs6760105	ENSG00000272716.1	RP11-563N4.1	-5.02	6.03e-07	6.4e-05	-0.17	-0.15	Inflammatory biomarkers;	chr2:32082317	chr2:32165046~32165757:-
BRCA	cis	rs7577696	0.924	rs6747488	ENSG00000272716.1	RP11-563N4.1	-5.02	6.03e-07	6.4e-05	-0.17	-0.15	Inflammatory biomarkers;	chr2:32086215	chr2:32165046~32165757:-
BRCA	cis	rs7577696	0.924	rs7561519	ENSG00000272716.1	RP11-563N4.1	-5.02	6.03e-07	6.4e-05	-0.17	-0.15	Inflammatory biomarkers;	chr2:32087631	chr2:32165046~32165757:-
BRCA	cis	rs9840812	0.861	rs511154	ENSG00000273486.1	RP11-731C17.2	5.02	6.03e-07	6.41e-05	0.19	0.15	Fibrinogen levels;	chr3:136232079	chr3:136837338~136839021:-
BRCA	cis	rs6847067	0.965	rs17009249	ENSG00000180769.7	WDFY3-AS2	-5.02	6.03e-07	6.41e-05	-0.14	-0.15	Oropharynx cancer;	chr4:84746674	chr4:84965682~85011277:+
BRCA	cis	rs13113518	0.966	rs1474271	ENSG00000223305.1	RN7SKP30	5.02	6.03e-07	6.41e-05	0.19	0.15	Height;	chr4:55435912	chr4:55540502~55540835:-
BRCA	cis	rs6756513	0.5	rs72839879	ENSG00000231024.1	AC092431.3	-5.02	6.03e-07	6.41e-05	-0.22	-0.15	Breast cancer;Platelet count;	chr2:69835144	chr2:69700192~69713847:-
BRCA	cis	rs7618915	0.547	rs11709448	ENSG00000243224.1	RP5-1157M23.2	-5.02	6.03e-07	6.41e-05	-0.17	-0.15	Bipolar disorder;	chr3:52613433	chr3:52239258~52241097:+
BRCA	cis	rs11696845	0.787	rs13043441	ENSG00000276223.1	RP4-781B1.5	-5.02	6.03e-07	6.41e-05	-0.15	-0.15	Obesity-related traits;	chr20:44735667	chr20:44746642~44747201:+
BRCA	cis	rs1910358	0.664	rs7708664	ENSG00000248874.4	C5orf17	-5.02	6.03e-07	6.41e-05	-0.2	-0.15	Venous thromboembolism (SNP x SNP interaction);	chr5:23885088	chr5:23951348~24178263:+
BRCA	cis	rs17660992	0.716	rs8111426	ENSG00000273837.1	LLNLR-470E3.1	5.02	6.04e-07	6.42e-05	0.21	0.15	Blood protein levels;	chr19:51662110	chr19:51639478~51639931:-
BRCA	cis	rs7978895	1	rs1849781	ENSG00000258331.1	RP11-118A3.1	5.02	6.04e-07	6.42e-05	0.16	0.15	Type 2 diabetes;	chr12:43180163	chr12:43155315~43163110:+
BRCA	cis	rs7800418	0.578	rs6945012	ENSG00000214870.7	AC004540.5	5.02	6.04e-07	6.42e-05	0.19	0.15	Cognitive function;	chr7:26572514	chr7:26398593~26494256:+
BRCA	cis	rs7647973	0.516	rs4536858	ENSG00000225399.4	RP11-3B7.1	5.02	6.04e-07	6.42e-05	0.15	0.15	Menarche (age at onset);	chr3:49155648	chr3:49260085~49261316:+
BRCA	cis	rs2153535	0.58	rs1577472	ENSG00000251164.1	HULC	-5.02	6.05e-07	6.42e-05	-0.19	-0.15	Motion sickness;	chr6:8485982	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.542	rs1120393	ENSG00000251164.1	HULC	-5.02	6.05e-07	6.42e-05	-0.19	-0.15	Motion sickness;	chr6:8486657	chr6:8652137~8653846:+
BRCA	cis	rs2638953	0.924	rs10843139	ENSG00000247934.4	RP11-967K21.1	-5.02	6.05e-07	6.43e-05	-0.21	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28227160	chr12:28163298~28190738:-
BRCA	cis	rs12497850	0.897	rs9850134	ENSG00000225399.4	RP11-3B7.1	5.02	6.05e-07	6.43e-05	0.15	0.15	Parkinson's disease;	chr3:48919714	chr3:49260085~49261316:+
BRCA	cis	rs12497850	0.931	rs9867373	ENSG00000225399.4	RP11-3B7.1	5.02	6.05e-07	6.43e-05	0.15	0.15	Parkinson's disease;	chr3:48923505	chr3:49260085~49261316:+
BRCA	cis	rs35740288	0.685	rs12899481	ENSG00000259407.1	RP11-158M2.3	-5.02	6.05e-07	6.43e-05	-0.21	-0.15	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85765739	chr15:85744109~85750281:-
BRCA	cis	rs6847067	0.578	rs72664928	ENSG00000180769.7	WDFY3-AS2	5.02	6.06e-07	6.43e-05	0.15	0.15	Oropharynx cancer;	chr4:84827863	chr4:84965682~85011277:+
BRCA	cis	rs8098244	0.964	rs8097662	ENSG00000264745.1	TTC39C-AS1	5.02	6.06e-07	6.44e-05	0.21	0.15	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23790151	chr18:23994213~24015339:-
BRCA	cis	rs1552244	1	rs9849434	ENSG00000232901.1	CYCSP10	-5.02	6.06e-07	6.44e-05	-0.21	-0.15	Alzheimer's disease;	chr3:10092026	chr3:10000647~10000940:-
BRCA	cis	rs9510787	0.649	rs7992255	ENSG00000205861.10	C1QTNF9B-AS1	-5.02	6.06e-07	6.44e-05	-0.2	-0.15	Nasopharyngeal carcinoma;	chr13:23640674	chr13:23888889~23897263:+
BRCA	cis	rs6019512	0.525	rs6125554	ENSG00000222365.1	SNORD12B	5.02	6.07e-07	6.44e-05	0.16	0.15	Intelligence (multi-trait analysis);	chr20:49111570	chr20:49280319~49280409:+
BRCA	cis	rs11758351	1	rs75921373	ENSG00000241549.7	GUSBP2	-5.02	6.07e-07	6.44e-05	-0.22	-0.15	Renal underexcretion gout;Gout;	chr6:26191615	chr6:26871484~26956554:-
BRCA	cis	rs7308116	0.546	rs1895934	ENSG00000274395.1	RP11-554D14.8	-5.02	6.07e-07	6.45e-05	-0.18	-0.15	Pelvic organ prolapse (moderate/severe);	chr12:107822624	chr12:107835541~107836555:-
BRCA	cis	rs7308116	0.546	rs1895933	ENSG00000274395.1	RP11-554D14.8	-5.02	6.07e-07	6.45e-05	-0.18	-0.15	Pelvic organ prolapse (moderate/severe);	chr12:107822640	chr12:107835541~107836555:-
BRCA	cis	rs7308116	0.546	rs1895932	ENSG00000274395.1	RP11-554D14.8	-5.02	6.07e-07	6.45e-05	-0.18	-0.15	Pelvic organ prolapse (moderate/severe);	chr12:107822702	chr12:107835541~107836555:-
BRCA	cis	rs2243480	1	rs6958420	ENSG00000222364.1	RNU6-96P	5.02	6.07e-07	6.45e-05	0.28	0.15	Diabetic kidney disease;	chr7:66286184	chr7:66395191~66395286:+
BRCA	cis	rs2243480	1	rs1392104	ENSG00000222364.1	RNU6-96P	5.02	6.07e-07	6.45e-05	0.28	0.15	Diabetic kidney disease;	chr7:66294120	chr7:66395191~66395286:+
BRCA	cis	rs10510102	0.935	rs11818001	ENSG00000226864.1	ATE1-AS1	-5.02	6.08e-07	6.45e-05	-0.27	-0.15	Breast cancer;	chr10:121884830	chr10:121928312~121951965:+
BRCA	cis	rs2638953	0.924	rs11049582	ENSG00000247934.4	RP11-967K21.1	-5.02	6.08e-07	6.45e-05	-0.21	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28416392	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.815	rs11049708	ENSG00000247934.4	RP11-967K21.1	-5.02	6.08e-07	6.46e-05	-0.21	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28544881	chr12:28163298~28190738:-
BRCA	cis	rs11098499	0.908	rs2017057	ENSG00000250412.1	KLHL2P1	5.02	6.08e-07	6.46e-05	0.18	0.15	Corneal astigmatism;	chr4:119336556	chr4:119334329~119378233:+
BRCA	cis	rs1722141	0.669	rs788735	ENSG00000237471.1	AC073115.6	5.02	6.09e-07	6.46e-05	0.21	0.15	Sitting height ratio;	chr7:45990801	chr7:45969657~45980191:+
BRCA	cis	rs2638953	0.962	rs9300176	ENSG00000247934.4	RP11-967K21.1	5.02	6.09e-07	6.46e-05	0.19	0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28368584	chr12:28163298~28190738:-
BRCA	cis	rs35740288	0.929	rs11073537	ENSG00000259407.1	RP11-158M2.3	-5.02	6.09e-07	6.46e-05	-0.21	-0.15	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85769450	chr15:85744109~85750281:-
BRCA	cis	rs8040855	0.599	rs4577058	ENSG00000259774.1	RP11-182J1.13	-5.02	6.09e-07	6.46e-05	-0.18	-0.15	Bulimia nervosa;	chr15:85183227	chr15:84422618~84425882:+
BRCA	cis	rs17508449	0.504	rs3827733	ENSG00000232450.1	RP4-730K3.3	-5.02	6.1e-07	6.47e-05	-0.25	-0.15	Leprosy;	chr1:113795967	chr1:113698884~113699631:-
BRCA	cis	rs2255336	1	rs2255336	ENSG00000245648.1	RP11-277P12.20	5.02	6.1e-07	6.47e-05	0.22	0.15	Blood protein levels;	chr12:10379727	chr12:10363769~10398506:+
BRCA	cis	rs10129255	0.785	rs10150044	ENSG00000274576.2	IGHV2-70	5.02	6.1e-07	6.47e-05	0.13	0.15	Kawasaki disease;	chr14:106775695	chr14:106770577~106771020:-
BRCA	cis	rs7618915	0.531	rs77146033	ENSG00000243224.1	RP5-1157M23.2	-5.02	6.1e-07	6.47e-05	-0.17	-0.15	Bipolar disorder;	chr3:52667485	chr3:52239258~52241097:+
BRCA	cis	rs4434138	0.664	rs62255364	ENSG00000243224.1	RP5-1157M23.2	-5.02	6.1e-07	6.47e-05	-0.17	-0.15	Intelligence (multi-trait analysis);	chr3:52667486	chr3:52239258~52241097:+
BRCA	cis	rs26949	0.511	rs1562235	ENSG00000215032.2	GNL3LP1	5.02	6.1e-07	6.47e-05	0.18	0.15	Intelligence (multi-trait analysis);	chr5:60581711	chr5:60891935~60893577:-
BRCA	cis	rs62025270	0.688	rs7182210	ENSG00000202081.1	RNU6-1280P	-5.02	6.1e-07	6.47e-05	-0.23	-0.15	Idiopathic pulmonary fibrosis;	chr15:85722551	chr15:85651522~85651628:-
BRCA	cis	rs6840360	0.642	rs6843639	ENSG00000278978.1	RP11-164P12.5	-5.02	6.1e-07	6.48e-05	-0.17	-0.15	Intelligence (multi-trait analysis);	chr4:151494863	chr4:151669786~151670503:+
BRCA	cis	rs9393692	1	rs2393593	ENSG00000241549.7	GUSBP2	-5.02	6.11e-07	6.48e-05	-0.18	-0.15	Educational attainment;	chr6:26285455	chr6:26871484~26956554:-
BRCA	cis	rs10946940	0.965	rs6921256	ENSG00000220721.1	OR1F12	5.02	6.11e-07	6.48e-05	0.18	0.15	Systemic lupus erythematosus;	chr6:27619739	chr6:28073316~28074233:+
BRCA	cis	rs8016982	0.698	rs8011097	ENSG00000258999.1	RP11-114N19.3	5.02	6.11e-07	6.48e-05	0.18	0.15	Schizophrenia;	chr14:81236392	chr14:81107033~81170414:-
BRCA	cis	rs4834770	1	rs4834770	ENSG00000248280.1	RP11-33B1.2	5.02	6.11e-07	6.48e-05	0.14	0.15	Blood protein levels;	chr4:119320694	chr4:119440561~119450157:-
BRCA	cis	rs7818688	1	rs73276417	ENSG00000253528.2	RP11-347C18.4	-5.02	6.11e-07	6.48e-05	-0.23	-0.15	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95014084	chr8:94974573~94974853:-
BRCA	cis	rs7818688	1	rs28440026	ENSG00000253528.2	RP11-347C18.4	-5.02	6.11e-07	6.48e-05	-0.23	-0.15	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95014516	chr8:94974573~94974853:-
BRCA	cis	rs7818688	1	rs28712702	ENSG00000253528.2	RP11-347C18.4	-5.02	6.11e-07	6.48e-05	-0.23	-0.15	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95014752	chr8:94974573~94974853:-
BRCA	cis	rs7818688	1	rs28363725	ENSG00000253528.2	RP11-347C18.4	-5.02	6.11e-07	6.48e-05	-0.23	-0.15	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95014880	chr8:94974573~94974853:-
BRCA	cis	rs7818688	1	rs28378156	ENSG00000253528.2	RP11-347C18.4	-5.02	6.11e-07	6.48e-05	-0.23	-0.15	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95014899	chr8:94974573~94974853:-
BRCA	cis	rs7818688	1	rs6989862	ENSG00000253528.2	RP11-347C18.4	-5.02	6.11e-07	6.48e-05	-0.23	-0.15	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95015340	chr8:94974573~94974853:-
BRCA	cis	rs7818688	1	rs6985880	ENSG00000253528.2	RP11-347C18.4	-5.02	6.11e-07	6.48e-05	-0.23	-0.15	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95015371	chr8:94974573~94974853:-
BRCA	cis	rs7818688	1	rs7008542	ENSG00000253528.2	RP11-347C18.4	-5.02	6.11e-07	6.48e-05	-0.23	-0.15	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95015635	chr8:94974573~94974853:-
BRCA	cis	rs7818688	0.932	rs6471505	ENSG00000253528.2	RP11-347C18.4	-5.02	6.11e-07	6.48e-05	-0.23	-0.15	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95016397	chr8:94974573~94974853:-
BRCA	cis	rs7818688	0.932	rs6471506	ENSG00000253528.2	RP11-347C18.4	-5.02	6.11e-07	6.48e-05	-0.23	-0.15	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95016472	chr8:94974573~94974853:-
BRCA	cis	rs7818688	0.858	rs7826196	ENSG00000253528.2	RP11-347C18.4	-5.02	6.11e-07	6.48e-05	-0.23	-0.15	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95016774	chr8:94974573~94974853:-
BRCA	cis	rs7829975	0.682	rs7013471	ENSG00000254153.1	CTA-398F10.2	-5.02	6.11e-07	6.48e-05	-0.18	-0.15	Mood instability;	chr8:8829815	chr8:8456909~8461337:-
BRCA	cis	rs7246657	0.722	rs1564208	ENSG00000276846.1	CTD-3220F14.3	5.02	6.11e-07	6.48e-05	0.21	0.15	Coronary artery calcification;	chr19:37550319	chr19:37314868~37315620:-
BRCA	cis	rs9921338	0.668	rs193779	ENSG00000262703.1	RP11-485G7.6	-5.02	6.11e-07	6.48e-05	-0.19	-0.15	Vein graft stenosis in coronary artery bypass grafting;	chr16:11257108	chr16:11348143~11349321:-
BRCA	cis	rs17711722	0.522	rs62469933	ENSG00000275400.1	RP4-756H11.5	-5.02	6.12e-07	6.49e-05	-0.18	-0.15	Calcium levels;	chr7:65800652	chr7:66553805~66554199:-
BRCA	cis	rs17277546	0.588	rs13242458	ENSG00000214313.7	AZGP1P1	5.02	6.12e-07	6.49e-05	0.25	0.15	Dehydroepiandrosterone sulphate levels;Metabolic traits;	chr7:100097508	chr7:99980762~99987535:+
BRCA	cis	rs4835473	0.897	rs7682204	ENSG00000249741.2	RP11-673E1.3	-5.02	6.12e-07	6.49e-05	-0.16	-0.15	Immature fraction of reticulocytes;	chr4:143966306	chr4:143911514~143912053:-
BRCA	cis	rs10911251	0.528	rs10911248	ENSG00000224468.3	RP11-181K3.4	-5.02	6.12e-07	6.49e-05	-0.17	-0.15	Colorectal cancer;	chr1:183111429	chr1:183138402~183141282:-
BRCA	cis	rs7569084	0.663	rs4671128	ENSG00000281920.1	RP11-418H16.1	5.02	6.12e-07	6.49e-05	0.19	0.15	Sum eosinophil basophil counts;	chr2:65438130	chr2:65623272~65628424:+
BRCA	cis	rs7618915	0.547	rs4687638	ENSG00000243224.1	RP5-1157M23.2	-5.02	6.13e-07	6.5e-05	-0.17	-0.15	Bipolar disorder;	chr3:52617950	chr3:52239258~52241097:+
BRCA	cis	rs7976269	0.559	rs9651838	ENSG00000275476.1	RP11-996F15.4	5.02	6.13e-07	6.5e-05	0.17	0.15	Male-pattern baldness;	chr12:28999700	chr12:29277397~29277882:-
BRCA	cis	rs875971	0.895	rs4718349	ENSG00000223473.2	GS1-124K5.3	5.02	6.14e-07	6.51e-05	0.12	0.15	Aortic root size;	chr7:66444024	chr7:66491049~66493566:-
BRCA	cis	rs875971	1	rs2042133	ENSG00000223473.2	GS1-124K5.3	5.02	6.14e-07	6.51e-05	0.12	0.15	Aortic root size;	chr7:66466935	chr7:66491049~66493566:-
BRCA	cis	rs875971	0.964	rs2161065	ENSG00000223473.2	GS1-124K5.3	5.02	6.14e-07	6.51e-05	0.12	0.15	Aortic root size;	chr7:66467918	chr7:66491049~66493566:-
BRCA	cis	rs875971	0.862	rs12698521	ENSG00000223473.2	GS1-124K5.3	5.02	6.14e-07	6.51e-05	0.12	0.15	Aortic root size;	chr7:66474502	chr7:66491049~66493566:-
BRCA	cis	rs1440410	0.571	rs4410482	ENSG00000250326.1	RP11-284M14.1	-5.02	6.14e-07	6.51e-05	-0.17	-0.15	Ischemic stroke;	chr4:143116498	chr4:142933195~143184861:-
BRCA	cis	rs539096	0.872	rs2842186	ENSG00000236200.4	KDM4A-AS1	5.02	6.14e-07	6.51e-05	0.2	0.15	Intelligence (multi-trait analysis);	chr1:43569422	chr1:43699765~43708138:-
BRCA	cis	rs8054556	0.76	rs12598856	ENSG00000261367.1	RP11-455F5.4	-5.02	6.14e-07	6.51e-05	-0.18	-0.15	Autism spectrum disorder or schizophrenia;	chr16:30018227	chr16:30107675~30110541:+
BRCA	cis	rs7829975	0.714	rs11784052	ENSG00000254153.1	CTA-398F10.2	5.02	6.14e-07	6.52e-05	0.18	0.15	Mood instability;	chr8:8814452	chr8:8456909~8461337:-
BRCA	cis	rs2153535	0.541	rs4637688	ENSG00000251164.1	HULC	-5.02	6.15e-07	6.52e-05	-0.19	-0.15	Motion sickness;	chr6:8446268	chr6:8652137~8653846:+
BRCA	cis	rs8040855	0.599	rs6496800	ENSG00000259774.1	RP11-182J1.13	-5.02	6.15e-07	6.52e-05	-0.17	-0.15	Bulimia nervosa;	chr15:85185055	chr15:84422618~84425882:+
BRCA	cis	rs4650994	0.544	rs2476560	ENSG00000273384.1	RP5-1098D14.1	-5.02	6.15e-07	6.52e-05	-0.2	-0.15	HDL cholesterol;HDL cholesterol levels;	chr1:178625784	chr1:178651706~178652282:+
BRCA	cis	rs13113518	0.812	rs13107810	ENSG00000272969.1	RP11-528I4.2	5.02	6.15e-07	6.52e-05	0.18	0.15	Height;	chr4:55542243	chr4:55547112~55547889:+
BRCA	cis	rs4835473	0.771	rs4261935	ENSG00000249741.2	RP11-673E1.3	-5.02	6.15e-07	6.52e-05	-0.17	-0.15	Immature fraction of reticulocytes;	chr4:143979751	chr4:143911514~143912053:-
BRCA	cis	rs2255336	0.938	rs2255364	ENSG00000245648.1	RP11-277P12.20	5.02	6.15e-07	6.52e-05	0.22	0.15	Blood protein levels;	chr12:10379297	chr12:10363769~10398506:+
BRCA	cis	rs16958440	0.867	rs12326221	ENSG00000280212.1	RP11-49K24.3	5.02	6.15e-07	6.52e-05	0.36	0.15	Sitting height ratio;	chr18:47156522	chr18:47076117~47076594:+
BRCA	cis	rs7615952	0.673	rs35955861	ENSG00000250012.1	RP11-124N2.1	-5.02	6.15e-07	6.52e-05	-0.27	-0.15	Blood pressure (smoking interaction);	chr3:125907358	chr3:126084220~126095349:+
BRCA	cis	rs2898681	0.77	rs62336795	ENSG00000248375.1	RP11-177B4.1	-5.02	6.15e-07	6.53e-05	-0.21	-0.15	Optic nerve measurement (cup area);	chr4:52871605	chr4:52720081~52720831:-
BRCA	cis	rs78487399	0.71	rs77620935	ENSG00000234936.1	AC010883.5	5.02	6.15e-07	6.53e-05	0.25	0.15	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43446626	chr2:43229573~43233394:+
BRCA	cis	rs6439153	0.933	rs34193129	ENSG00000231305.3	RP11-723O4.2	5.02	6.15e-07	6.53e-05	0.17	0.15	Pneumococcal bacteremia;	chr3:128972564	chr3:128861313~128871540:-
BRCA	cis	rs597539	0.616	rs72945243	ENSG00000261625.1	RP11-554A11.4	-5.02	6.15e-07	6.53e-05	-0.15	-0.15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68865890	chr11:69000765~69002048:-
BRCA	cis	rs7308116	0.546	rs6539371	ENSG00000274395.1	RP11-554D14.8	5.02	6.16e-07	6.53e-05	0.19	0.15	Pelvic organ prolapse (moderate/severe);	chr12:107838946	chr12:107835541~107836555:-
BRCA	cis	rs7621025	0.662	rs3856637	ENSG00000273486.1	RP11-731C17.2	5.02	6.16e-07	6.53e-05	0.18	0.15	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136672353	chr3:136837338~136839021:-
BRCA	cis	rs6714710	0.603	rs2278700	ENSG00000230606.9	AC159540.1	-5.02	6.16e-07	6.53e-05	-0.18	-0.15	Posterior cortical atrophy and Alzheimer's disease;	chr2:97810919	chr2:97416165~97433527:-
BRCA	cis	rs6714710	0.603	rs78006955	ENSG00000230606.9	AC159540.1	-5.02	6.16e-07	6.53e-05	-0.18	-0.15	Posterior cortical atrophy and Alzheimer's disease;	chr2:97839047	chr2:97416165~97433527:-
BRCA	cis	rs8064024	0.68	rs2063101	ENSG00000267077.1	RP11-127I20.5	5.02	6.16e-07	6.54e-05	0.15	0.15	Cancer;	chr16:4866347	chr16:4795265~4796532:-
BRCA	cis	rs559555	0.888	rs2300697	ENSG00000272716.1	RP11-563N4.1	5.02	6.17e-07	6.54e-05	0.17	0.15	Blood metabolite ratios;Blood metabolite levels;	chr2:31561567	chr2:32165046~32165757:-
BRCA	cis	rs78487399	0.808	rs77787499	ENSG00000234936.1	AC010883.5	5.02	6.17e-07	6.54e-05	0.26	0.15	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43536670	chr2:43229573~43233394:+
BRCA	cis	rs62388641	0.547	rs9391923	ENSG00000218027.2	RP11-157J24.1	5.02	6.17e-07	6.54e-05	0.18	0.15	Daytime sleep phenotypes;	chr6:1554089	chr6:1513698~1515289:-
BRCA	cis	rs7772486	0.754	rs4896838	ENSG00000270638.1	RP3-466P17.1	-5.02	6.17e-07	6.54e-05	-0.18	-0.15	Lobe attachment (rater-scored or self-reported);	chr6:145694315	chr6:145735570~145737218:+
BRCA	cis	rs7608910	1	rs7608910	ENSG00000271889.1	RP11-493E12.1	-5.02	6.17e-07	6.54e-05	-0.19	-0.15	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;	chr2:60977721	chr2:61151433~61162105:-
BRCA	cis	rs2898681	0.874	rs4864691	ENSG00000248375.1	RP11-177B4.1	-5.02	6.17e-07	6.54e-05	-0.22	-0.15	Optic nerve measurement (cup area);	chr4:52889805	chr4:52720081~52720831:-
BRCA	cis	rs987360	0.835	rs1946360	ENSG00000248869.4	RP11-138I17.1	5.02	6.18e-07	6.55e-05	0.15	0.15	Temperament;	chr4:137288375	chr4:136796722~137212799:-
BRCA	cis	rs17685	0.784	rs1637043	ENSG00000280388.1	RP11-229D13.3	-5.02	6.18e-07	6.55e-05	-0.16	-0.15	Coffee consumption (cups per day);Coffee consumption;	chr7:76069781	chr7:76043977~76045963:-
BRCA	cis	rs57221529	0.766	rs4081847	ENSG00000271781.1	CTD-2589H19.6	-5.02	6.18e-07	6.55e-05	-0.22	-0.15	Lung disease severity in cystic fibrosis;	chr5:573957	chr5:675826~676616:+
BRCA	cis	rs875971	0.862	rs2088653	ENSG00000236529.1	RP13-254B10.1	-5.02	6.18e-07	6.55e-05	-0.17	-0.15	Aortic root size;	chr7:66343621	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.862	rs6460293	ENSG00000236529.1	RP13-254B10.1	-5.02	6.18e-07	6.55e-05	-0.17	-0.15	Aortic root size;	chr7:66345205	chr7:65840212~65840596:+
BRCA	cis	rs10504130	0.666	rs7819892	ENSG00000272024.1	RP11-546K22.3	5.02	6.18e-07	6.55e-05	0.2	0.15	Venous thromboembolism (SNP x SNP interaction);	chr8:51932916	chr8:51950284~51950690:+
BRCA	cis	rs7481584	0.624	rs438384	ENSG00000247473.2	CARS-AS1	-5.02	6.18e-07	6.55e-05	-0.18	-0.15	Calcium levels;	chr11:3024421	chr11:3029009~3041260:+
BRCA	cis	rs2574985	0.703	rs2983357	ENSG00000231345.3	BEND3P1	5.02	6.18e-07	6.55e-05	0.25	0.15	Subjective well-being;	chr10:50541662	chr10:50655967~50660472:+
BRCA	cis	rs875971	0.895	rs7788984	ENSG00000223473.2	GS1-124K5.3	5.02	6.19e-07	6.56e-05	0.12	0.15	Aortic root size;	chr7:66450629	chr7:66491049~66493566:-
BRCA	cis	rs6480314	0.522	rs80326649	ENSG00000233590.1	RP11-153K11.3	-5.02	6.19e-07	6.56e-05	-0.28	-0.15	Optic nerve measurement (disc area);	chr10:68285667	chr10:68233251~68242379:-
BRCA	cis	rs1707322	1	rs785504	ENSG00000234329.1	RP11-767N6.2	-5.02	6.19e-07	6.56e-05	-0.16	-0.15	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46130024	chr1:45651039~45651826:-
BRCA	cis	rs9659323	0.622	rs11582744	ENSG00000231365.4	RP11-418J17.1	-5.02	6.19e-07	6.56e-05	-0.19	-0.15	Body mass index;	chr1:118914781	chr1:119140396~119275973:+
BRCA	cis	rs10504130	0.735	rs12681203	ENSG00000253844.1	RP11-546K22.1	-5.02	6.19e-07	6.56e-05	-0.24	-0.15	Venous thromboembolism (SNP x SNP interaction);	chr8:51925292	chr8:51961458~52022974:+
BRCA	cis	rs4763879	0.739	rs12582584	ENSG00000278635.1	CTD-2318O12.1	5.02	6.19e-07	6.56e-05	0.16	0.15	Type 1 diabetes;	chr12:9671542	chr12:9415641~9416718:+
BRCA	cis	rs2732480	0.5	rs7297824	ENSG00000257735.1	RP11-370I10.6	5.02	6.19e-07	6.56e-05	0.19	0.15	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48204867	chr12:48350945~48442411:+
BRCA	cis	rs2153535	0.601	rs2327054	ENSG00000251164.1	HULC	-5.02	6.2e-07	6.56e-05	-0.19	-0.15	Motion sickness;	chr6:8442897	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.623	rs2327055	ENSG00000251164.1	HULC	-5.02	6.2e-07	6.56e-05	-0.19	-0.15	Motion sickness;	chr6:8442912	chr6:8652137~8653846:+
BRCA	cis	rs7267979	0.816	rs6138593	ENSG00000125804.12	FAM182A	-5.02	6.2e-07	6.56e-05	-0.2	-0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25523856	chr20:26054655~26086917:+
BRCA	cis	rs62025270	0.576	rs62022947	ENSG00000202081.1	RNU6-1280P	-5.02	6.2e-07	6.57e-05	-0.22	-0.15	Idiopathic pulmonary fibrosis;	chr15:85728091	chr15:85651522~85651628:-
BRCA	cis	rs4908768	0.539	rs11121204	ENSG00000270282.1	RP5-1115A15.2	-5.02	6.2e-07	6.57e-05	-0.17	-0.15	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8594246	chr1:8512653~8513021:+
BRCA	cis	rs17767294	0.708	rs78094982	ENSG00000204709.4	LINC01556	5.02	6.2e-07	6.57e-05	0.41	0.15	Parkinson's disease;	chr6:28000572	chr6:28943877~28944537:+
BRCA	cis	rs17767294	0.708	rs72848785	ENSG00000204709.4	LINC01556	5.02	6.2e-07	6.57e-05	0.41	0.15	Parkinson's disease;	chr6:28009825	chr6:28943877~28944537:+
BRCA	cis	rs2281558	0.833	rs6115202	ENSG00000230772.1	VN1R108P	5.02	6.21e-07	6.58e-05	0.19	0.15	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25516902	chr20:25734264~25735093:+
BRCA	cis	rs875971	0.862	rs1860469	ENSG00000273448.1	RP11-166O4.6	-5.02	6.21e-07	6.58e-05	-0.14	-0.15	Aortic root size;	chr7:66641888	chr7:67333047~67334383:+
BRCA	cis	rs7818688	1	rs11786878	ENSG00000253528.2	RP11-347C18.4	-5.02	6.21e-07	6.58e-05	-0.25	-0.15	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95021064	chr8:94974573~94974853:-
BRCA	cis	rs7914558	0.966	rs10748837	ENSG00000236937.2	PTGES3P4	5.02	6.21e-07	6.58e-05	0.2	0.15	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103120479	chr10:102845595~102845950:+
BRCA	cis	rs6545883	0.894	rs12997538	ENSG00000270820.4	RP11-355B11.2	-5.02	6.22e-07	6.58e-05	-0.18	-0.15	Tuberculosis;	chr2:61337114	chr2:61471188~61484130:+
BRCA	cis	rs962856	0.964	rs1486133	ENSG00000236780.4	AC078941.1	-5.02	6.22e-07	6.58e-05	-0.19	-0.15	Pancreatic cancer;	chr2:67414889	chr2:67123357~67215319:-
BRCA	cis	rs6570726	0.791	rs11759979	ENSG00000270638.1	RP3-466P17.1	5.02	6.22e-07	6.59e-05	0.18	0.15	Lobe attachment (rater-scored or self-reported);	chr6:145597745	chr6:145735570~145737218:+
BRCA	cis	rs6545883	0.501	rs935860	ENSG00000273302.1	RP11-493E12.2	5.02	6.22e-07	6.59e-05	0.13	0.15	Tuberculosis;	chr2:61179426	chr2:61199979~61200769:+
BRCA	cis	rs11700536	1	rs4919965	ENSG00000236663.1	AP001631.9	-5.02	6.22e-07	6.59e-05	-0.17	-0.15	Interleukin-18 levels;	chr21:43137961	chr21:43140523~43141092:-
BRCA	cis	rs5752326	1	rs2157586	ENSG00000261188.1	CTA-445C9.14	-5.02	6.22e-07	6.59e-05	-0.31	-0.15	Ischemic stroke;	chr22:26499095	chr22:26512537~26514568:+
BRCA	cis	rs2734839	0.507	rs4648318	ENSG00000270179.1	RP11-159N11.4	-5.02	6.22e-07	6.59e-05	-0.16	-0.15	Information processing speed;	chr11:113442667	chr11:113368478~113369117:+
BRCA	cis	rs2288884	0.505	rs11666461	ENSG00000275055.1	CTC-471J1.11	-5.02	6.23e-07	6.6e-05	-0.25	-0.15	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:51934234	chr19:52049007~52049754:+
BRCA	cis	rs4908768	0.501	rs6677736	ENSG00000232912.4	RP5-1115A15.1	5.01	6.23e-07	6.6e-05	0.15	0.15	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8492744	chr1:8424645~8434838:+
BRCA	cis	rs1395	0.778	rs60631624	ENSG00000234072.1	AC074117.10	-5.01	6.23e-07	6.6e-05	-0.17	-0.15	Blood metabolite levels;	chr2:27274947	chr2:27356246~27367622:+
BRCA	cis	rs10504130	0.696	rs12676835	ENSG00000253844.1	RP11-546K22.1	-5.01	6.23e-07	6.6e-05	-0.24	-0.15	Venous thromboembolism (SNP x SNP interaction);	chr8:51919770	chr8:51961458~52022974:+
BRCA	cis	rs10504130	0.696	rs12677407	ENSG00000253844.1	RP11-546K22.1	-5.01	6.23e-07	6.6e-05	-0.24	-0.15	Venous thromboembolism (SNP x SNP interaction);	chr8:51920718	chr8:51961458~52022974:+
BRCA	cis	rs10504130	0.696	rs59602923	ENSG00000253844.1	RP11-546K22.1	-5.01	6.23e-07	6.6e-05	-0.24	-0.15	Venous thromboembolism (SNP x SNP interaction);	chr8:51923565	chr8:51961458~52022974:+
BRCA	cis	rs10504130	0.696	rs113096282	ENSG00000253844.1	RP11-546K22.1	-5.01	6.23e-07	6.6e-05	-0.24	-0.15	Venous thromboembolism (SNP x SNP interaction);	chr8:51924206	chr8:51961458~52022974:+
BRCA	cis	rs10504130	0.735	rs77362085	ENSG00000253844.1	RP11-546K22.1	-5.01	6.23e-07	6.6e-05	-0.24	-0.15	Venous thromboembolism (SNP x SNP interaction);	chr8:51924398	chr8:51961458~52022974:+
BRCA	cis	rs12497850	0.805	rs11130176	ENSG00000225399.4	RP11-3B7.1	5.01	6.23e-07	6.6e-05	0.15	0.15	Parkinson's disease;	chr3:48806644	chr3:49260085~49261316:+
BRCA	cis	rs4660214	0.666	rs587404	ENSG00000228060.1	RP11-69E11.8	-5.01	6.23e-07	6.6e-05	-0.16	-0.15	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39442834	chr1:39565160~39573203:+
BRCA	cis	rs875971	0.838	rs2173570	ENSG00000223473.2	GS1-124K5.3	-5.01	6.24e-07	6.61e-05	-0.12	-0.15	Aortic root size;	chr7:66297976	chr7:66491049~66493566:-
BRCA	cis	rs6840360	0.642	rs7676493	ENSG00000278978.1	RP11-164P12.5	-5.01	6.24e-07	6.61e-05	-0.17	-0.15	Intelligence (multi-trait analysis);	chr4:151505613	chr4:151669786~151670503:+
BRCA	cis	rs6840360	0.642	rs11735957	ENSG00000278978.1	RP11-164P12.5	-5.01	6.24e-07	6.61e-05	-0.17	-0.15	Intelligence (multi-trait analysis);	chr4:151506354	chr4:151669786~151670503:+
BRCA	cis	rs6840360	0.642	rs2053566	ENSG00000278978.1	RP11-164P12.5	-5.01	6.24e-07	6.61e-05	-0.17	-0.15	Intelligence (multi-trait analysis);	chr4:151524679	chr4:151669786~151670503:+
BRCA	cis	rs6840360	0.607	rs1561918	ENSG00000278978.1	RP11-164P12.5	-5.01	6.24e-07	6.61e-05	-0.17	-0.15	Intelligence (multi-trait analysis);	chr4:151525680	chr4:151669786~151670503:+
BRCA	cis	rs4908768	0.501	rs6577488	ENSG00000232912.4	RP5-1115A15.1	5.01	6.24e-07	6.61e-05	0.15	0.15	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8474469	chr1:8424645~8434838:+
BRCA	cis	rs4908768	0.501	rs4351668	ENSG00000232912.4	RP5-1115A15.1	5.01	6.24e-07	6.61e-05	0.15	0.15	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8475758	chr1:8424645~8434838:+
BRCA	cis	rs7246657	0.598	rs10417545	ENSG00000267422.1	CTD-2554C21.1	-5.01	6.24e-07	6.61e-05	-0.26	-0.15	Coronary artery calcification;	chr19:37163361	chr19:37779686~37792865:+
BRCA	cis	rs10510102	0.935	rs11200237	ENSG00000226864.1	ATE1-AS1	5.01	6.25e-07	6.61e-05	0.28	0.15	Breast cancer;	chr10:121900715	chr10:121928312~121951965:+
BRCA	cis	rs2213770	0.528	rs7284543	ENSG00000223704.1	LINC01422	5.01	6.25e-07	6.62e-05	0.16	0.15	Gastroesophageal reflux disease;	chr22:26844493	chr22:26858634~26865786:+
BRCA	cis	rs13113518	0.812	rs6849474	ENSG00000272969.1	RP11-528I4.2	5.01	6.25e-07	6.62e-05	0.18	0.15	Height;	chr4:55452295	chr4:55547112~55547889:+
BRCA	cis	rs875971	0.862	rs35378740	ENSG00000273448.1	RP11-166O4.6	5.01	6.25e-07	6.62e-05	0.14	0.15	Aortic root size;	chr7:66522725	chr7:67333047~67334383:+
BRCA	cis	rs875971	0.895	rs10755833	ENSG00000223473.2	GS1-124K5.3	5.01	6.25e-07	6.62e-05	0.12	0.15	Aortic root size;	chr7:66448930	chr7:66491049~66493566:-
BRCA	cis	rs875971	0.895	rs1833495	ENSG00000223473.2	GS1-124K5.3	5.01	6.25e-07	6.62e-05	0.12	0.15	Aortic root size;	chr7:66456608	chr7:66491049~66493566:-
BRCA	cis	rs875971	0.964	rs6945032	ENSG00000223473.2	GS1-124K5.3	5.01	6.25e-07	6.62e-05	0.12	0.15	Aortic root size;	chr7:66457499	chr7:66491049~66493566:-
BRCA	cis	rs875971	0.929	rs12673810	ENSG00000223473.2	GS1-124K5.3	5.01	6.25e-07	6.62e-05	0.12	0.15	Aortic root size;	chr7:66458866	chr7:66491049~66493566:-
BRCA	cis	rs875971	1	rs6961155	ENSG00000223473.2	GS1-124K5.3	5.01	6.25e-07	6.62e-05	0.12	0.15	Aortic root size;	chr7:66468308	chr7:66491049~66493566:-
BRCA	cis	rs875971	1	rs7789768	ENSG00000223473.2	GS1-124K5.3	5.01	6.25e-07	6.62e-05	0.12	0.15	Aortic root size;	chr7:66473993	chr7:66491049~66493566:-
BRCA	cis	rs875971	1	rs1363055	ENSG00000223473.2	GS1-124K5.3	5.01	6.25e-07	6.62e-05	0.12	0.15	Aortic root size;	chr7:66478288	chr7:66491049~66493566:-
BRCA	cis	rs875971	0.964	rs9691480	ENSG00000223473.2	GS1-124K5.3	5.01	6.25e-07	6.62e-05	0.12	0.15	Aortic root size;	chr7:66479319	chr7:66491049~66493566:-
BRCA	cis	rs10129255	1	rs10129319	ENSG00000274576.2	IGHV2-70	5.01	6.25e-07	6.62e-05	0.14	0.15	Kawasaki disease;	chr14:106767996	chr14:106770577~106771020:-
BRCA	cis	rs7577696	0.719	rs3752916	ENSG00000272716.1	RP11-563N4.1	-5.01	6.26e-07	6.62e-05	-0.17	-0.15	Inflammatory biomarkers;	chr2:32129489	chr2:32165046~32165757:-
BRCA	cis	rs9545047	0.604	rs9530891	ENSG00000227354.5	RBM26-AS1	5.01	6.26e-07	6.62e-05	0.17	0.15	Schizophrenia;	chr13:79284750	chr13:79406309~79424328:+
BRCA	cis	rs875971	0.545	rs7787063	ENSG00000232546.1	RP11-458F8.1	5.01	6.26e-07	6.62e-05	0.14	0.15	Aortic root size;	chr7:66164012	chr7:66848496~66858136:+
BRCA	cis	rs875971	0.545	rs12673308	ENSG00000232546.1	RP11-458F8.1	5.01	6.26e-07	6.62e-05	0.14	0.15	Aortic root size;	chr7:66166374	chr7:66848496~66858136:+
BRCA	cis	rs875971	0.862	rs6947339	ENSG00000236529.1	RP13-254B10.1	5.01	6.26e-07	6.63e-05	0.17	0.15	Aortic root size;	chr7:66423483	chr7:65840212~65840596:+
BRCA	cis	rs11098499	0.738	rs28687057	ENSG00000249244.1	RP11-548H18.2	5.01	6.26e-07	6.63e-05	0.18	0.15	Corneal astigmatism;	chr4:119359657	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.775	rs67281037	ENSG00000249244.1	RP11-548H18.2	5.01	6.26e-07	6.63e-05	0.18	0.15	Corneal astigmatism;	chr4:119360002	chr4:119391831~119395335:-
BRCA	cis	rs10028773	0.506	rs12374346	ENSG00000249244.1	RP11-548H18.2	5.01	6.26e-07	6.63e-05	0.18	0.15	Educational attainment;	chr4:119360550	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.866	rs12374244	ENSG00000249244.1	RP11-548H18.2	5.01	6.26e-07	6.63e-05	0.18	0.15	Corneal astigmatism;	chr4:119360817	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.866	rs12374352	ENSG00000249244.1	RP11-548H18.2	5.01	6.26e-07	6.63e-05	0.18	0.15	Corneal astigmatism;	chr4:119360822	chr4:119391831~119395335:-
BRCA	cis	rs523522	0.962	rs4767903	ENSG00000278344.1	RP11-18C24.8	5.01	6.27e-07	6.63e-05	0.2	0.15	High light scatter reticulocyte count;	chr12:120492243	chr12:120500735~120501090:-
BRCA	cis	rs11089937	0.555	rs6001226	ENSG00000211638.2	IGLV8-61	-5.01	6.27e-07	6.63e-05	-0.15	-0.15	Periodontitis (PAL4Q3);	chr22:22186888	chr22:22098700~22099212:+
BRCA	cis	rs11955398	0.501	rs10057004	ENSG00000215032.2	GNL3LP1	-5.01	6.27e-07	6.64e-05	-0.19	-0.15	Intelligence (multi-trait analysis);	chr5:60745207	chr5:60891935~60893577:-
BRCA	cis	rs2708977	0.901	rs6753667	ENSG00000237510.6	AC008268.2	-5.01	6.27e-07	6.64e-05	-0.2	-0.15	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96494645	chr2:95789654~95800166:+
BRCA	cis	rs7226408	0.857	rs56391099	ENSG00000267707.2	RP11-95O2.5	5.01	6.27e-07	6.64e-05	0.23	0.15	Obesity-related traits;	chr18:36898664	chr18:37243776~37247506:+
BRCA	cis	rs7226408	0.857	rs55895201	ENSG00000267707.2	RP11-95O2.5	5.01	6.27e-07	6.64e-05	0.23	0.15	Obesity-related traits;	chr18:36898667	chr18:37243776~37247506:+
BRCA	cis	rs7031325	0.819	rs10758801	ENSG00000229611.1	RP11-390F4.10	5.01	6.27e-07	6.64e-05	0.17	0.15	Systemic lupus erythematosus;	chr9:6657192	chr9:6704471~6707780:+
BRCA	cis	rs4819052	0.851	rs2838832	ENSG00000184274.3	LINC00315	5.01	6.27e-07	6.64e-05	0.21	0.15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244989	chr21:45300245~45305257:-
BRCA	cis	rs6893782	0.83	rs274549	ENSG00000233006.5	AC034220.3	5.01	6.28e-07	6.64e-05	0.13	0.15	Acylcarnitine levels;	chr5:132393426	chr5:132311285~132369916:-
BRCA	cis	rs2179367	0.632	rs11155650	ENSG00000268592.3	RAET1E-AS1	5.01	6.28e-07	6.64e-05	0.22	0.15	Dupuytren's disease;	chr6:149407613	chr6:149863494~149919507:+
BRCA	cis	rs2179367	0.632	rs11155651	ENSG00000268592.3	RAET1E-AS1	5.01	6.28e-07	6.64e-05	0.22	0.15	Dupuytren's disease;	chr6:149408146	chr6:149863494~149919507:+
BRCA	cis	rs2179367	0.632	rs7896	ENSG00000268592.3	RAET1E-AS1	5.01	6.28e-07	6.64e-05	0.22	0.15	Dupuytren's disease;	chr6:149410340	chr6:149863494~149919507:+
BRCA	cis	rs875971	0.862	rs4718383	ENSG00000236529.1	RP13-254B10.1	-5.01	6.28e-07	6.65e-05	-0.17	-0.15	Aortic root size;	chr7:66643422	chr7:65840212~65840596:+
BRCA	cis	rs17685	0.587	rs1623759	ENSG00000280388.1	RP11-229D13.3	-5.01	6.28e-07	6.65e-05	-0.16	-0.15	Coffee consumption (cups per day);Coffee consumption;	chr7:76095361	chr7:76043977~76045963:-
BRCA	cis	rs17685	0.753	rs1637051	ENSG00000280388.1	RP11-229D13.3	-5.01	6.28e-07	6.65e-05	-0.16	-0.15	Coffee consumption (cups per day);Coffee consumption;	chr7:76101341	chr7:76043977~76045963:-
BRCA	cis	rs17685	0.753	rs4573217	ENSG00000280388.1	RP11-229D13.3	-5.01	6.28e-07	6.65e-05	-0.16	-0.15	Coffee consumption (cups per day);Coffee consumption;	chr7:76104628	chr7:76043977~76045963:-
BRCA	cis	rs11098499	0.866	rs6847778	ENSG00000249244.1	RP11-548H18.2	5.01	6.28e-07	6.65e-05	0.18	0.15	Corneal astigmatism;	chr4:119372427	chr4:119391831~119395335:-
BRCA	cis	rs7178909	0.872	rs7174330	ENSG00000259677.1	RP11-493E3.1	-5.01	6.28e-07	6.65e-05	-0.18	-0.15	Common traits (Other);	chr15:89891347	chr15:89876540~89877285:+
BRCA	cis	rs2638953	0.962	rs11049550	ENSG00000247934.4	RP11-967K21.1	-5.01	6.28e-07	6.65e-05	-0.21	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28358591	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.962	rs11049552	ENSG00000247934.4	RP11-967K21.1	-5.01	6.28e-07	6.65e-05	-0.21	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28361466	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.962	rs11049553	ENSG00000247934.4	RP11-967K21.1	-5.01	6.28e-07	6.65e-05	-0.21	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28361611	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.962	rs11049554	ENSG00000247934.4	RP11-967K21.1	-5.01	6.28e-07	6.65e-05	-0.21	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28362819	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.962	rs12371222	ENSG00000247934.4	RP11-967K21.1	-5.01	6.28e-07	6.65e-05	-0.21	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28363245	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.962	rs11049555	ENSG00000247934.4	RP11-967K21.1	-5.01	6.28e-07	6.65e-05	-0.21	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28364919	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.962	rs11049556	ENSG00000247934.4	RP11-967K21.1	-5.01	6.28e-07	6.65e-05	-0.21	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28365626	chr12:28163298~28190738:-
BRCA	cis	rs910316	0.726	rs61979167	ENSG00000279594.1	RP11-950C14.10	-5.01	6.28e-07	6.65e-05	-0.17	-0.15	Height;	chr14:75196907	chr14:75011269~75012851:-
BRCA	cis	rs6452524	0.618	rs2075685	ENSG00000281327.1	LINC01338	5.01	6.28e-07	6.65e-05	0.18	0.15	Hypertension (SNP x SNP interaction);	chr5:83076846	chr5:82850864~82859836:-
BRCA	cis	rs62025270	0.632	rs62022915	ENSG00000259762.1	RP11-158M2.4	-5.01	6.28e-07	6.65e-05	-0.23	-0.15	Idiopathic pulmonary fibrosis;	chr15:85670365	chr15:85750336~85752901:-
BRCA	cis	rs7772486	0.846	rs1474871	ENSG00000270638.1	RP3-466P17.1	5.01	6.28e-07	6.65e-05	0.17	0.15	Lobe attachment (rater-scored or self-reported);	chr6:146085158	chr6:145735570~145737218:+
BRCA	cis	rs6540731	0.805	rs7530375	ENSG00000229983.1	RP11-15I11.2	5.01	6.29e-07	6.65e-05	0.18	0.15	Intelligence (childhood);	chr1:212197963	chr1:212168207~212190259:+
BRCA	cis	rs6540731	0.84	rs10863954	ENSG00000229983.1	RP11-15I11.2	5.01	6.29e-07	6.65e-05	0.18	0.15	Intelligence (childhood);	chr1:212199944	chr1:212168207~212190259:+
BRCA	cis	rs2638953	0.924	rs11049579	ENSG00000247934.4	RP11-967K21.1	-5.01	6.29e-07	6.66e-05	-0.21	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28414693	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.924	rs10843163	ENSG00000247934.4	RP11-967K21.1	-5.01	6.29e-07	6.66e-05	-0.21	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28415541	chr12:28163298~28190738:-
BRCA	cis	rs6723108	0.702	rs55920206	ENSG00000224043.6	CCNT2-AS1	5.01	6.29e-07	6.66e-05	0.2	0.15	Type 2 diabetes;	chr2:134674496	chr2:134735464~134918710:-
BRCA	cis	rs12712135	0.709	rs10195075	ENSG00000234389.1	AC007278.3	-5.01	6.3e-07	6.66e-05	-0.14	-0.15	Blood protein levels;	chr2:102471192	chr2:102438713~102440475:+
BRCA	cis	rs12712135	0.709	rs1403553	ENSG00000234389.1	AC007278.3	-5.01	6.3e-07	6.66e-05	-0.14	-0.15	Blood protein levels;	chr2:102471202	chr2:102438713~102440475:+
BRCA	cis	rs10129255	0.957	rs12590667	ENSG00000274576.2	IGHV2-70	-5.01	6.3e-07	6.67e-05	-0.13	-0.15	Kawasaki disease;	chr14:106779223	chr14:106770577~106771020:-
BRCA	cis	rs897984	0.568	rs4889653	ENSG00000260911.2	RP11-196G11.2	-5.01	6.3e-07	6.67e-05	-0.15	-0.15	Dementia with Lewy bodies;	chr16:30884392	chr16:31043150~31049868:+
BRCA	cis	rs4718428	0.705	rs4718424	ENSG00000229180.5	GS1-124K5.11	5.01	6.31e-07	6.67e-05	0.15	0.15	Corneal structure;	chr7:66911108	chr7:66526088~66542624:-
BRCA	cis	rs2562456	0.837	rs62110205	ENSG00000268535.1	RP11-420K14.3	5.01	6.31e-07	6.67e-05	0.21	0.15	Pain;	chr19:21577269	chr19:21709522~21710191:+
BRCA	cis	rs2749097	0.609	rs2269242	ENSG00000244256.3	RN7SL130P	-5.01	6.31e-07	6.67e-05	-0.21	-0.15	Alcohol consumption (transferrin glycosylation);	chr1:63643011	chr1:63655743~63656047:+
BRCA	cis	rs2179367	0.632	rs55836833	ENSG00000268592.3	RAET1E-AS1	5.01	6.31e-07	6.68e-05	0.22	0.15	Dupuytren's disease;	chr6:149403736	chr6:149863494~149919507:+
BRCA	cis	rs6860540	0.796	rs57229403	ENSG00000248544.2	CTB-47B11.3	-5.01	6.32e-07	6.68e-05	-0.2	-0.15	Inflammatory skin disease;	chr5:157489634	chr5:157375741~157384950:-
BRCA	cis	rs2688482	0.512	rs3103953	ENSG00000185485.13	SDHAP1	-5.01	6.32e-07	6.68e-05	-0.21	-0.15	Lung disease severity in cystic fibrosis;	chr3:195793726	chr3:195959748~195990318:-
BRCA	cis	rs4835473	0.715	rs4538428	ENSG00000249741.2	RP11-673E1.3	-5.01	6.32e-07	6.68e-05	-0.17	-0.15	Immature fraction of reticulocytes;	chr4:143992751	chr4:143911514~143912053:-
BRCA	cis	rs1075265	0.756	rs698854	ENSG00000235937.1	AC008280.1	5.01	6.32e-07	6.68e-05	0.17	0.15	Chronotype;Morning vs. evening chronotype;	chr2:53826784	chr2:54029552~54030682:-
BRCA	cis	rs2638953	0.893	rs7969086	ENSG00000247934.4	RP11-967K21.1	5.01	6.32e-07	6.68e-05	0.19	0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28507273	chr12:28163298~28190738:-
BRCA	cis	rs17508449	0.547	rs79100402	ENSG00000232450.1	RP4-730K3.3	-5.01	6.32e-07	6.69e-05	-0.24	-0.15	Leprosy;	chr1:113803538	chr1:113698884~113699631:-
BRCA	cis	rs6545883	0.894	rs2177962	ENSG00000270820.4	RP11-355B11.2	-5.01	6.32e-07	6.69e-05	-0.18	-0.15	Tuberculosis;	chr2:61360935	chr2:61471188~61484130:+
BRCA	cis	rs34217772	0.57	rs113771571	ENSG00000258636.1	CTD-2298J14.2	5.01	6.32e-07	6.69e-05	0.2	0.15	Myopia;	chr14:41722561	chr14:41587861~41604856:-
BRCA	cis	rs12477438	0.748	rs10200974	ENSG00000231822.1	AC019097.7	-5.01	6.33e-07	6.69e-05	-0.17	-0.15	Chronic sinus infection;	chr2:99058764	chr2:99102018~99102752:+
BRCA	cis	rs6714710	0.603	rs12104810	ENSG00000230606.9	AC159540.1	-5.01	6.33e-07	6.69e-05	-0.18	-0.15	Posterior cortical atrophy and Alzheimer's disease;	chr2:97827195	chr2:97416165~97433527:-
BRCA	cis	rs710913	0.816	rs1180341	ENSG00000228060.1	RP11-69E11.8	5.01	6.33e-07	6.7e-05	0.15	0.15	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39527136	chr1:39565160~39573203:+
BRCA	cis	rs10911232	0.507	rs6672306	ENSG00000224468.3	RP11-181K3.4	-5.01	6.34e-07	6.7e-05	-0.16	-0.15	Hypertriglyceridemia;	chr1:183089763	chr1:183138402~183141282:-
BRCA	cis	rs7246657	0.663	rs4803287	ENSG00000226686.6	LINC01535	-5.01	6.34e-07	6.7e-05	-0.23	-0.15	Coronary artery calcification;	chr19:37588534	chr19:37251912~37265535:+
BRCA	cis	rs71520386	0.53	rs10256628	ENSG00000226329.2	AC005682.6	-5.01	6.34e-07	6.7e-05	-0.16	-0.15	Fibrinogen levels;	chr7:22843640	chr7:22863874~22881350:-
BRCA	cis	rs6570726	1	rs386678	ENSG00000270638.1	RP3-466P17.1	5.01	6.34e-07	6.7e-05	0.17	0.15	Lobe attachment (rater-scored or self-reported);	chr6:145547874	chr6:145735570~145737218:+
BRCA	cis	rs34929064	0.536	rs2905306	ENSG00000179428.2	AC073072.5	-5.01	6.34e-07	6.7e-05	-0.17	-0.15	Major depression and alcohol dependence;	chr7:22599199	chr7:22725395~22727620:-
BRCA	cis	rs2243480	1	rs4718334	ENSG00000222364.1	RNU6-96P	5.01	6.34e-07	6.71e-05	0.28	0.15	Diabetic kidney disease;	chr7:66324467	chr7:66395191~66395286:+
BRCA	cis	rs7829975	0.533	rs1039917	ENSG00000253981.4	ALG1L13P	5.01	6.35e-07	6.71e-05	0.18	0.15	Mood instability;	chr8:8861340	chr8:8236003~8244667:-
BRCA	cis	rs7226408	0.802	rs55889065	ENSG00000267707.2	RP11-95O2.5	5.01	6.35e-07	6.71e-05	0.24	0.15	Obesity-related traits;	chr18:36845344	chr18:37243776~37247506:+
BRCA	cis	rs2562456	0.876	rs2359144	ENSG00000268081.1	RP11-678G14.2	5.01	6.35e-07	6.71e-05	0.24	0.15	Pain;	chr19:21407834	chr19:21554640~21569237:-
BRCA	cis	rs2562456	0.876	rs4638726	ENSG00000268081.1	RP11-678G14.2	5.01	6.35e-07	6.71e-05	0.24	0.15	Pain;	chr19:21409710	chr19:21554640~21569237:-
BRCA	cis	rs6714710	0.603	rs11681535	ENSG00000230606.9	AC159540.1	-5.01	6.35e-07	6.71e-05	-0.18	-0.15	Posterior cortical atrophy and Alzheimer's disease;	chr2:97872486	chr2:97416165~97433527:-
BRCA	cis	rs6714710	0.58	rs55886305	ENSG00000230606.9	AC159540.1	-5.01	6.35e-07	6.72e-05	-0.18	-0.15	Posterior cortical atrophy and Alzheimer's disease;	chr2:97879198	chr2:97416165~97433527:-
BRCA	cis	rs1861628	1	rs737310	ENSG00000229352.1	AC007563.3	5.01	6.35e-07	6.72e-05	0.19	0.15	Serum thyroid-stimulating hormone levels;Hypothyroidism;	chr2:216758503	chr2:216799608~216805335:+
BRCA	cis	rs67311347	1	rs2276871	ENSG00000280739.1	EIF1B-AS1	5.01	6.36e-07	6.72e-05	0.17	0.15	Renal cell carcinoma;	chr3:40457782	chr3:40173145~40309698:-
BRCA	cis	rs3845817	0.832	rs702945	ENSG00000237979.1	AC007389.1	5.01	6.36e-07	6.72e-05	0.18	0.15	Bipolar disorder;	chr2:65534098	chr2:65500993~65502138:-
BRCA	cis	rs3845817	0.868	rs702896	ENSG00000237979.1	AC007389.1	5.01	6.36e-07	6.72e-05	0.18	0.15	Bipolar disorder;	chr2:65535089	chr2:65500993~65502138:-
BRCA	cis	rs2412819	0.545	rs3862143	ENSG00000166763.7	STRCP1	-5.01	6.36e-07	6.72e-05	-0.21	-0.15	Lung cancer;	chr15:43779282	chr15:43699488~43718184:-
BRCA	cis	rs2638953	0.924	rs11049569	ENSG00000247934.4	RP11-967K21.1	-5.01	6.36e-07	6.72e-05	-0.21	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28386823	chr12:28163298~28190738:-
BRCA	cis	rs14027	0.64	rs16893071	ENSG00000279347.1	RP11-85I17.2	-5.01	6.36e-07	6.72e-05	-0.15	-0.15	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119738183	chr8:119838736~119840385:-
BRCA	cis	rs4819052	0.851	rs9977178	ENSG00000184274.3	LINC00315	-5.01	6.36e-07	6.73e-05	-0.21	-0.15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244616	chr21:45300245~45305257:-
BRCA	cis	rs875971	0.862	rs2909688	ENSG00000273448.1	RP11-166O4.6	5.01	6.36e-07	6.73e-05	0.14	0.15	Aortic root size;	chr7:66376625	chr7:67333047~67334383:+
BRCA	cis	rs3764021	0.87	rs7976584	ENSG00000256673.1	RP11-599J14.2	-5.01	6.37e-07	6.73e-05	-0.17	-0.15	Type 1 diabetes;	chr12:9726059	chr12:9398355~9414851:-
BRCA	cis	rs9307551	0.948	rs1371993	ENSG00000250334.4	LINC00989	-5.01	6.37e-07	6.73e-05	-0.24	-0.15	Refractive error;	chr4:79560662	chr4:79492416~79576460:+
BRCA	cis	rs875971	0.825	rs4587224	ENSG00000236529.1	RP13-254B10.1	-5.01	6.37e-07	6.74e-05	-0.17	-0.15	Aortic root size;	chr7:66271195	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.792	rs6971752	ENSG00000236529.1	RP13-254B10.1	-5.01	6.37e-07	6.74e-05	-0.17	-0.15	Aortic root size;	chr7:66272999	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.862	rs10950033	ENSG00000236529.1	RP13-254B10.1	-5.01	6.37e-07	6.74e-05	-0.17	-0.15	Aortic root size;	chr7:66274686	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.862	rs11760844	ENSG00000236529.1	RP13-254B10.1	-5.01	6.37e-07	6.74e-05	-0.17	-0.15	Aortic root size;	chr7:66274896	chr7:65840212~65840596:+
BRCA	cis	rs7131987	0.65	rs11050208	ENSG00000275476.1	RP11-996F15.4	-5.01	6.38e-07	6.74e-05	-0.2	-0.15	QT interval;	chr12:29357436	chr12:29277397~29277882:-
BRCA	cis	rs10844706	0.73	rs12317499	ENSG00000214776.8	RP11-726G1.1	5.01	6.38e-07	6.74e-05	0.19	0.15	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9732764	chr12:9467552~9576275:+
BRCA	cis	rs7267979	0.873	rs7453	ENSG00000274414.1	RP5-965G21.4	-5.01	6.38e-07	6.74e-05	-0.19	-0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25226438	chr20:25239007~25245229:-
BRCA	cis	rs2562456	0.834	rs2173727	ENSG00000268658.4	LINC00664	-5.01	6.38e-07	6.74e-05	-0.24	-0.15	Pain;	chr19:21491155	chr19:21483374~21503238:+
BRCA	cis	rs2832191	1	rs2832183	ENSG00000176054.6	RPL23P2	-5.01	6.38e-07	6.74e-05	-0.16	-0.15	Dental caries;	chr21:29109829	chr21:28997613~28998033:-
BRCA	cis	rs860295	0.665	rs12028416	ENSG00000160766.13	GBAP1	-5.01	6.38e-07	6.74e-05	-0.17	-0.15	Body mass index;	chr1:155431370	chr1:155213821~155227422:-
BRCA	cis	rs860295	0.629	rs12026638	ENSG00000160766.13	GBAP1	-5.01	6.38e-07	6.74e-05	-0.17	-0.15	Body mass index;	chr1:155431469	chr1:155213821~155227422:-
BRCA	cis	rs6840360	0.617	rs2724563	ENSG00000251611.1	RP11-610P16.1	-5.01	6.38e-07	6.74e-05	-0.13	-0.15	Intelligence (multi-trait analysis);	chr4:151428807	chr4:151407551~151408835:-
BRCA	cis	rs6840360	0.617	rs2724564	ENSG00000251611.1	RP11-610P16.1	-5.01	6.38e-07	6.74e-05	-0.13	-0.15	Intelligence (multi-trait analysis);	chr4:151428810	chr4:151407551~151408835:-
BRCA	cis	rs875971	0.755	rs10228885	ENSG00000236529.1	RP13-254B10.1	-5.01	6.38e-07	6.75e-05	-0.17	-0.15	Aortic root size;	chr7:66315542	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.862	rs4718383	ENSG00000273448.1	RP11-166O4.6	-5.01	6.39e-07	6.75e-05	-0.14	-0.15	Aortic root size;	chr7:66643422	chr7:67333047~67334383:+
BRCA	cis	rs7829975	0.659	rs4382480	ENSG00000173295.6	FAM86B3P	5.01	6.39e-07	6.75e-05	0.16	0.15	Mood instability;	chr8:8863963	chr8:8228595~8244865:+
BRCA	cis	rs4908768	0.501	rs12046643	ENSG00000232912.4	RP5-1115A15.1	5.01	6.39e-07	6.75e-05	0.15	0.15	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8487806	chr1:8424645~8434838:+
BRCA	cis	rs2255336	0.817	rs7310643	ENSG00000245648.1	RP11-277P12.20	5.01	6.39e-07	6.75e-05	0.24	0.15	Blood protein levels;	chr12:10365501	chr12:10363769~10398506:+
BRCA	cis	rs1552244	1	rs67852463	ENSG00000232901.1	CYCSP10	5.01	6.39e-07	6.75e-05	0.22	0.15	Alzheimer's disease;	chr3:10115521	chr3:10000647~10000940:-
BRCA	cis	rs6847067	1	rs6858666	ENSG00000180769.7	WDFY3-AS2	5.01	6.39e-07	6.75e-05	0.14	0.15	Oropharynx cancer;	chr4:84808783	chr4:84965682~85011277:+
BRCA	cis	rs4835473	0.932	rs4835472	ENSG00000249741.2	RP11-673E1.3	-5.01	6.39e-07	6.75e-05	-0.16	-0.15	Immature fraction of reticulocytes;	chr4:143982398	chr4:143911514~143912053:-
BRCA	cis	rs7226408	0.857	rs72885278	ENSG00000267707.2	RP11-95O2.5	5.01	6.39e-07	6.75e-05	0.23	0.15	Obesity-related traits;	chr18:36861191	chr18:37243776~37247506:+
BRCA	cis	rs6490294	0.528	rs57866673	ENSG00000226469.1	ADAM1B	5.01	6.39e-07	6.75e-05	0.27	0.15	Mean platelet volume;	chr12:112195500	chr12:111927018~111929017:+
BRCA	cis	rs7226408	0.857	rs55917307	ENSG00000267707.2	RP11-95O2.5	5.01	6.39e-07	6.76e-05	0.23	0.15	Obesity-related traits;	chr18:36923701	chr18:37243776~37247506:+
BRCA	cis	rs7226408	0.857	rs72887084	ENSG00000267707.2	RP11-95O2.5	5.01	6.39e-07	6.76e-05	0.23	0.15	Obesity-related traits;	chr18:36924019	chr18:37243776~37247506:+
BRCA	cis	rs9863	0.861	rs11835839	ENSG00000270028.1	RP11-380L11.4	5.01	6.4e-07	6.76e-05	0.19	0.15	White blood cell count;	chr12:123946502	chr12:123925461~123926083:-
BRCA	cis	rs2153535	0.58	rs6597318	ENSG00000251164.1	HULC	-5.01	6.4e-07	6.76e-05	-0.19	-0.15	Motion sickness;	chr6:8437056	chr6:8652137~8653846:+
BRCA	cis	rs2832191	0.791	rs2065270	ENSG00000176054.6	RPL23P2	-5.01	6.4e-07	6.76e-05	-0.16	-0.15	Dental caries;	chr21:29113099	chr21:28997613~28998033:-
BRCA	cis	rs4713118	0.513	rs149955	ENSG00000219392.1	RP1-265C24.5	-5.01	6.4e-07	6.76e-05	-0.21	-0.15	Parkinson's disease;	chr6:28068447	chr6:28115628~28116551:+
BRCA	cis	rs7976269	0.609	rs10843306	ENSG00000275476.1	RP11-996F15.4	-5.01	6.4e-07	6.76e-05	-0.18	-0.15	Male-pattern baldness;	chr12:29073417	chr12:29277397~29277882:-
BRCA	cis	rs10129255	0.83	rs61997609	ENSG00000211974.3	IGHV2-70	5.01	6.4e-07	6.77e-05	0.16	0.15	Kawasaki disease;	chr14:106692376	chr14:106723574~106724093:-
BRCA	cis	rs559555	0.568	rs569320	ENSG00000272716.1	RP11-563N4.1	5.01	6.41e-07	6.77e-05	0.18	0.15	Blood metabolite ratios;Blood metabolite levels;	chr2:31642978	chr2:32165046~32165757:-
BRCA	cis	rs1850744	0.826	rs7685513	ENSG00000163612.10	FAM86KP	5.01	6.41e-07	6.77e-05	0.35	0.15	Economic and political preferences;	chr4:9726975	chr4:9153296~9165451:+
BRCA	cis	rs300890	0.56	rs300929	ENSG00000250326.1	RP11-284M14.1	-5.01	6.41e-07	6.77e-05	-0.18	-0.15	Nasopharyngeal carcinoma;	chr4:143272388	chr4:142933195~143184861:-
BRCA	cis	rs7267979	0.844	rs4423675	ENSG00000274973.1	RP13-401N8.7	5.01	6.41e-07	6.77e-05	0.17	0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25422142	chr20:25845497~25845862:+
BRCA	cis	rs2255336	0.938	rs1600127	ENSG00000245648.1	RP11-277P12.20	5.01	6.41e-07	6.78e-05	0.23	0.15	Blood protein levels;	chr12:10383648	chr12:10363769~10398506:+
BRCA	cis	rs227932	0.764	rs73084758	ENSG00000234286.1	AC006026.13	-5.01	6.41e-07	6.78e-05	-0.26	-0.15	Schizophrenia;	chr7:23804816	chr7:23680195~23680786:-
BRCA	cis	rs13325613	0.915	rs3091310	ENSG00000223552.1	RP11-24F11.2	-5.01	6.42e-07	6.78e-05	-0.33	-0.15	Monocyte count;	chr3:46262206	chr3:46364955~46407059:-
BRCA	cis	rs13325613	0.915	rs17283712	ENSG00000223552.1	RP11-24F11.2	-5.01	6.42e-07	6.78e-05	-0.33	-0.15	Monocyte count;	chr3:46262573	chr3:46364955~46407059:-
BRCA	cis	rs27434	0.615	rs61112531	ENSG00000272109.1	CTD-2260A17.3	5.01	6.42e-07	6.78e-05	0.25	0.15	Ankylosing spondylitis;	chr5:96856117	chr5:96804353~96806105:+
BRCA	cis	rs6545883	0.839	rs778764	ENSG00000271889.1	RP11-493E12.1	5.01	6.42e-07	6.78e-05	0.19	0.15	Tuberculosis;	chr2:61558545	chr2:61151433~61162105:-
BRCA	cis	rs111326718	1	rs111326718	ENSG00000236937.2	PTGES3P4	5.01	6.42e-07	6.78e-05	0.2	0.15	Reticulocyte count;	chr10:103011454	chr10:102845595~102845950:+
BRCA	cis	rs7914558	1	rs7071373	ENSG00000236937.2	PTGES3P4	5.01	6.42e-07	6.78e-05	0.2	0.15	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103012165	chr10:102845595~102845950:+
BRCA	cis	rs10129255	0.957	rs10140904	ENSG00000280411.1	IGHV1-69-2	-5.01	6.42e-07	6.78e-05	-0.11	-0.15	Kawasaki disease;	chr14:106776558	chr14:106762092~106762588:-
BRCA	cis	rs7914558	1	rs12780843	ENSG00000236937.2	PTGES3P4	5.01	6.42e-07	6.78e-05	0.2	0.15	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103009578	chr10:102845595~102845950:+
BRCA	cis	rs4415084	1	rs13155752	ENSG00000251141.4	RP11-53O19.1	5.01	6.42e-07	6.79e-05	0.14	0.15	Breast cancer;	chr5:44680585	chr5:44744900~44808777:-
BRCA	cis	rs8114671	0.562	rs3746450	ENSG00000269202.1	RP4-614O4.12	-5.01	6.43e-07	6.79e-05	-0.15	-0.15	Height;	chr20:34920785	chr20:35201747~35203288:-
BRCA	cis	rs8114671	0.562	rs6087649	ENSG00000269202.1	RP4-614O4.12	-5.01	6.43e-07	6.79e-05	-0.15	-0.15	Height;	chr20:34922859	chr20:35201747~35203288:-
BRCA	cis	rs8114671	0.562	rs4911449	ENSG00000269202.1	RP4-614O4.12	-5.01	6.43e-07	6.79e-05	-0.15	-0.15	Height;	chr20:34924433	chr20:35201747~35203288:-
BRCA	cis	rs7577696	0.962	rs6738349	ENSG00000272716.1	RP11-563N4.1	-5.01	6.43e-07	6.79e-05	-0.17	-0.15	Inflammatory biomarkers;	chr2:32089062	chr2:32165046~32165757:-
BRCA	cis	rs6756513	0.5	rs6546552	ENSG00000231024.1	AC092431.3	-5.01	6.44e-07	6.8e-05	-0.22	-0.15	Breast cancer;Platelet count;	chr2:69849518	chr2:69700192~69713847:-
BRCA	cis	rs6756513	0.5	rs7577662	ENSG00000231024.1	AC092431.3	-5.01	6.44e-07	6.8e-05	-0.22	-0.15	Breast cancer;Platelet count;	chr2:69850290	chr2:69700192~69713847:-
BRCA	cis	rs6756513	0.5	rs7565230	ENSG00000231024.1	AC092431.3	-5.01	6.44e-07	6.8e-05	-0.22	-0.15	Breast cancer;Platelet count;	chr2:69850301	chr2:69700192~69713847:-
BRCA	cis	rs728616	0.614	rs2181204	ENSG00000225484.5	NUTM2B-AS1	-5.01	6.44e-07	6.8e-05	-0.28	-0.15	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79944756	chr10:79663088~79826594:-
BRCA	cis	rs1440410	0.83	rs12501994	ENSG00000250326.1	RP11-284M14.1	-5.01	6.44e-07	6.8e-05	-0.17	-0.15	Ischemic stroke;	chr4:143259802	chr4:142933195~143184861:-
BRCA	cis	rs875971	0.862	rs4718377	ENSG00000273448.1	RP11-166O4.6	-5.01	6.45e-07	6.81e-05	-0.14	-0.15	Aortic root size;	chr7:66584691	chr7:67333047~67334383:+
BRCA	cis	rs875971	0.862	rs10278014	ENSG00000273448.1	RP11-166O4.6	-5.01	6.45e-07	6.81e-05	-0.14	-0.15	Aortic root size;	chr7:66586277	chr7:67333047~67334383:+
BRCA	cis	rs1198872	0.892	rs10427170	ENSG00000272275.1	RP11-791G15.2	5.01	6.45e-07	6.81e-05	0.19	0.15	Cardiac Troponin-T levels;	chr2:10762044	chr2:10767875~10770058:-
BRCA	cis	rs1729951	0.575	rs835642	ENSG00000239213.4	NCK1-AS1	5.01	6.45e-07	6.81e-05	0.16	0.15	Neuroticism;	chr3:136984523	chr3:136841726~136862054:-
BRCA	cis	rs7246657	0.507	rs8107654	ENSG00000226686.6	LINC01535	-5.01	6.45e-07	6.81e-05	-0.28	-0.15	Coronary artery calcification;	chr19:36962632	chr19:37251912~37265535:+
BRCA	cis	rs4819052	0.851	rs7276103	ENSG00000184274.3	LINC00315	-5.01	6.45e-07	6.81e-05	-0.2	-0.15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45246163	chr21:45300245~45305257:-
BRCA	cis	rs17356983	1	rs17356983	ENSG00000233325.3	MIPEPP3	5.01	6.45e-07	6.81e-05	0.21	0.15	Obesity-related traits;	chr13:21340975	chr13:21298139~21306373:+
BRCA	cis	rs11098499	0.754	rs2036857	ENSG00000260404.2	RP11-384K6.6	5.01	6.45e-07	6.81e-05	0.14	0.15	Corneal astigmatism;	chr4:119328085	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.754	rs2036856	ENSG00000260404.2	RP11-384K6.6	5.01	6.45e-07	6.81e-05	0.14	0.15	Corneal astigmatism;	chr4:119328133	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.754	rs4443261	ENSG00000260404.2	RP11-384K6.6	5.01	6.45e-07	6.81e-05	0.14	0.15	Corneal astigmatism;	chr4:119328146	chr4:118591773~118633729:+
BRCA	cis	rs6088590	0.561	rs6059934	ENSG00000276073.1	RP5-1125A11.7	-5.01	6.46e-07	6.82e-05	-0.17	-0.15	Coronary artery disease;	chr20:34590520	chr20:33985617~33988989:-
BRCA	cis	rs6600671	1	rs1591882	ENSG00000275538.1	RNVU1-19	5.01	6.46e-07	6.82e-05	0.18	0.15	Hip geometry;	chr1:121441455	chr1:120850819~120850985:-
BRCA	cis	rs7646881	0.812	rs73015665	ENSG00000240207.5	RP11-379F4.4	-5.01	6.46e-07	6.82e-05	-0.24	-0.15	Tetralogy of Fallot;	chr3:158736145	chr3:158732263~158784070:+
BRCA	cis	rs11758351	1	rs80259160	ENSG00000241549.7	GUSBP2	-5.01	6.46e-07	6.82e-05	-0.22	-0.15	Renal underexcretion gout;Gout;	chr6:26189971	chr6:26871484~26956554:-
BRCA	cis	rs11758351	0.929	rs75475698	ENSG00000241549.7	GUSBP2	-5.01	6.46e-07	6.82e-05	-0.22	-0.15	Renal underexcretion gout;Gout;	chr6:26190381	chr6:26871484~26956554:-
BRCA	cis	rs891378	0.958	rs1354942	ENSG00000274245.1	RP11-357P18.2	5.01	6.46e-07	6.82e-05	0.21	0.15	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207335147	chr1:207372559~207373252:+
BRCA	cis	rs1950832	0.689	rs13379153	ENSG00000258636.1	CTD-2298J14.2	5.01	6.46e-07	6.82e-05	0.17	0.15	Urate levels in obese individuals;	chr14:41691433	chr14:41587861~41604856:-
BRCA	cis	rs13096142	0.558	rs9839623	ENSG00000223552.1	RP11-24F11.2	-5.01	6.46e-07	6.82e-05	-0.2	-0.15	Celiac disease;	chr3:46282368	chr3:46364955~46407059:-
BRCA	cis	rs6921919	0.515	rs1339898	ENSG00000220721.1	OR1F12	5.01	6.47e-07	6.83e-05	0.18	0.15	Autism spectrum disorder or schizophrenia;	chr6:28427729	chr6:28073316~28074233:+
BRCA	cis	rs8114671	0.545	rs2378335	ENSG00000269202.1	RP4-614O4.12	-5.01	6.47e-07	6.83e-05	-0.19	-0.15	Height;	chr20:35169027	chr20:35201747~35203288:-
BRCA	cis	rs6570726	0.818	rs437147	ENSG00000270638.1	RP3-466P17.1	5.01	6.47e-07	6.83e-05	0.18	0.15	Lobe attachment (rater-scored or self-reported);	chr6:145554287	chr6:145735570~145737218:+
BRCA	cis	rs11955398	0.585	rs1456743	ENSG00000215032.2	GNL3LP1	-5.01	6.47e-07	6.83e-05	-0.18	-0.15	Intelligence (multi-trait analysis);	chr5:60711594	chr5:60891935~60893577:-
BRCA	cis	rs11955398	0.585	rs10063166	ENSG00000215032.2	GNL3LP1	-5.01	6.47e-07	6.83e-05	-0.18	-0.15	Intelligence (multi-trait analysis);	chr5:60713017	chr5:60891935~60893577:-
BRCA	cis	rs11955398	0.585	rs10041431	ENSG00000215032.2	GNL3LP1	-5.01	6.47e-07	6.83e-05	-0.18	-0.15	Intelligence (multi-trait analysis);	chr5:60715090	chr5:60891935~60893577:-
BRCA	cis	rs4908760	0.827	rs6692693	ENSG00000232912.4	RP5-1115A15.1	5.01	6.47e-07	6.83e-05	0.15	0.15	Vitiligo;	chr1:8647057	chr1:8424645~8434838:+
BRCA	cis	rs2274273	0.682	rs1187876	ENSG00000258413.1	RP11-665C16.6	5.01	6.47e-07	6.83e-05	0.19	0.15	Protein biomarker;	chr14:55028481	chr14:55262767~55272075:-
BRCA	cis	rs1729951	0.514	rs75977	ENSG00000239213.4	NCK1-AS1	5.01	6.48e-07	6.83e-05	0.16	0.15	Neuroticism;	chr3:136981707	chr3:136841726~136862054:-
BRCA	cis	rs6723226	0.765	rs12612824	ENSG00000276517.1	AL133243.2	5.01	6.48e-07	6.84e-05	0.19	0.15	Intelligence (multi-trait analysis);	chr2:32354691	chr2:32526504~32529507:+
BRCA	cis	rs10861342	0.892	rs11112378	ENSG00000257999.1	RP11-61E11.2	-5.01	6.48e-07	6.84e-05	-0.33	-0.15	IgG glycosylation;	chr12:105120255	chr12:105102472~105107179:-
BRCA	cis	rs10861342	1	rs10861353	ENSG00000257999.1	RP11-61E11.2	-5.01	6.48e-07	6.84e-05	-0.33	-0.15	IgG glycosylation;	chr12:105121512	chr12:105102472~105107179:-
BRCA	cis	rs10861342	0.892	rs77479670	ENSG00000257999.1	RP11-61E11.2	-5.01	6.48e-07	6.84e-05	-0.33	-0.15	IgG glycosylation;	chr12:105122853	chr12:105102472~105107179:-
BRCA	cis	rs3892630	1	rs3892630	ENSG00000267475.1	CTD-2538C1.2	5.01	6.48e-07	6.84e-05	0.23	0.15	Red blood cell traits;	chr19:32690578	chr19:32687089~32691750:-
BRCA	cis	rs11955398	0.563	rs1816864	ENSG00000215032.2	GNL3LP1	-5.01	6.48e-07	6.84e-05	-0.18	-0.15	Intelligence (multi-trait analysis);	chr5:60715446	chr5:60891935~60893577:-
BRCA	cis	rs11955398	0.585	rs1816861	ENSG00000215032.2	GNL3LP1	-5.01	6.48e-07	6.84e-05	-0.18	-0.15	Intelligence (multi-trait analysis);	chr5:60715849	chr5:60891935~60893577:-
BRCA	cis	rs10129255	0.957	rs10150241	ENSG00000274576.2	IGHV2-70	-5.01	6.49e-07	6.84e-05	-0.13	-0.15	Kawasaki disease;	chr14:106775945	chr14:106770577~106771020:-
BRCA	cis	rs6569038	0.502	rs11967399	ENSG00000253194.1	RP11-351A11.1	5.01	6.49e-07	6.85e-05	0.19	0.15	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr6:118992352	chr6:118934785~119031541:+
BRCA	cis	rs6714710	0.603	rs13008968	ENSG00000230606.9	AC159540.1	-5.01	6.5e-07	6.86e-05	-0.18	-0.15	Posterior cortical atrophy and Alzheimer's disease;	chr2:97819519	chr2:97416165~97433527:-
BRCA	cis	rs11955398	0.585	rs2085409	ENSG00000215032.2	GNL3LP1	-5.01	6.5e-07	6.86e-05	-0.18	-0.15	Intelligence (multi-trait analysis);	chr5:60725356	chr5:60891935~60893577:-
BRCA	cis	rs11955398	0.585	rs2100584	ENSG00000215032.2	GNL3LP1	-5.01	6.5e-07	6.86e-05	-0.18	-0.15	Intelligence (multi-trait analysis);	chr5:60725660	chr5:60891935~60893577:-
BRCA	cis	rs11955398	0.585	rs930864	ENSG00000215032.2	GNL3LP1	-5.01	6.5e-07	6.86e-05	-0.18	-0.15	Intelligence (multi-trait analysis);	chr5:60725861	chr5:60891935~60893577:-
BRCA	cis	rs11955398	0.585	rs4447941	ENSG00000215032.2	GNL3LP1	-5.01	6.5e-07	6.86e-05	-0.18	-0.15	Intelligence (multi-trait analysis);	chr5:60726384	chr5:60891935~60893577:-
BRCA	cis	rs59972978	0.562	rs6099653	ENSG00000124097.7	HMGB1P1	5.01	6.5e-07	6.86e-05	0.2	0.15	Alcohol consumption;	chr20:57487747	chr20:57488392~57489027:-
BRCA	cis	rs4835473	0.798	rs34353812	ENSG00000249741.2	RP11-673E1.3	-5.01	6.5e-07	6.86e-05	-0.16	-0.15	Immature fraction of reticulocytes;	chr4:143973949	chr4:143911514~143912053:-
BRCA	cis	rs1075265	0.704	rs805410	ENSG00000235937.1	AC008280.1	5.01	6.51e-07	6.86e-05	0.17	0.15	Chronotype;Morning vs. evening chronotype;	chr2:53893360	chr2:54029552~54030682:-
BRCA	cis	rs728616	0.867	rs4633405	ENSG00000225484.5	NUTM2B-AS1	-5.01	6.51e-07	6.87e-05	-0.41	-0.15	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80167690	chr10:79663088~79826594:-
BRCA	cis	rs673078	0.66	rs17440336	ENSG00000275409.1	RP11-131L12.4	5.01	6.51e-07	6.87e-05	0.23	0.15	Glucose homeostasis traits;	chr12:118163305	chr12:118430147~118430699:+
BRCA	cis	rs6600671	1	rs4844616	ENSG00000275538.1	RNVU1-19	5.01	6.51e-07	6.87e-05	0.18	0.15	Hip geometry;	chr1:121429348	chr1:120850819~120850985:-
BRCA	cis	rs4908769	0.627	rs2252865	ENSG00000270282.1	RP5-1115A15.2	-5.01	6.51e-07	6.87e-05	-0.18	-0.15	Allergy;	chr1:8362616	chr1:8512653~8513021:+
BRCA	cis	rs2832191	1	rs2832183	ENSG00000215533.7	LINC00189	5.01	6.51e-07	6.87e-05	0.17	0.15	Dental caries;	chr21:29109829	chr21:29193480~29288205:+
BRCA	cis	rs6600671	1	rs4844381	ENSG00000275538.1	RNVU1-19	5.01	6.52e-07	6.87e-05	0.18	0.15	Hip geometry;	chr1:121443040	chr1:120850819~120850985:-
BRCA	cis	rs7577696	0.575	rs177083	ENSG00000272716.1	RP11-563N4.1	5.01	6.52e-07	6.87e-05	0.16	0.15	Inflammatory biomarkers;	chr2:32222649	chr2:32165046~32165757:-
BRCA	cis	rs728616	0.867	rs726289	ENSG00000225484.5	NUTM2B-AS1	-5.01	6.52e-07	6.88e-05	-0.37	-0.15	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79947195	chr10:79663088~79826594:-
BRCA	cis	rs2243480	0.901	rs778730	ENSG00000222364.1	RNU6-96P	-5.01	6.52e-07	6.88e-05	-0.29	-0.15	Diabetic kidney disease;	chr7:66358338	chr7:66395191~66395286:+
BRCA	cis	rs13287066	0.716	rs4744239	ENSG00000227603.1	RP11-165J3.6	5.01	6.52e-07	6.88e-05	0.16	0.15	Intelligence (multi-trait analysis);	chr9:93404100	chr9:93435332~93437121:-
BRCA	cis	rs3176789	0.914	rs10844750	ENSG00000256673.1	RP11-599J14.2	5.01	6.52e-07	6.88e-05	0.19	0.15	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9774279	chr12:9398355~9414851:-
BRCA	cis	rs62025270	0.688	rs11073516	ENSG00000202081.1	RNU6-1280P	-5.01	6.53e-07	6.88e-05	-0.23	-0.15	Idiopathic pulmonary fibrosis;	chr15:85741996	chr15:85651522~85651628:-
BRCA	cis	rs7267979	0.844	rs869358	ENSG00000277938.1	RP5-965G21.3	-5.01	6.53e-07	6.88e-05	-0.18	-0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25394038	chr20:25229150~25231933:+
BRCA	cis	rs4266144	0.544	rs13080798	ENSG00000241770.1	RP11-555M1.3	-5.01	6.53e-07	6.89e-05	-0.2	-0.15	Coronary artery disease;	chr3:157114612	chr3:157163452~157169133:+
BRCA	cis	rs12744310	0.887	rs6660265	ENSG00000235358.1	RP11-399E6.1	-5.01	6.53e-07	6.89e-05	-0.22	-0.15	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41353004	chr1:41242373~41284861:+
BRCA	cis	rs6441961	0.501	rs7371987	ENSG00000223552.1	RP11-24F11.2	5.01	6.53e-07	6.89e-05	0.2	0.15	Celiac disease;	chr3:46277017	chr3:46364955~46407059:-
BRCA	cis	rs1910358	0.566	rs320572	ENSG00000248874.4	C5orf17	-5.01	6.53e-07	6.89e-05	-0.24	-0.15	Venous thromboembolism (SNP x SNP interaction);	chr5:23848157	chr5:23951348~24178263:+
BRCA	cis	rs62388641	0.539	rs56304710	ENSG00000218027.2	RP11-157J24.1	-5.01	6.53e-07	6.89e-05	-0.18	-0.15	Daytime sleep phenotypes;	chr6:1542341	chr6:1513698~1515289:-
BRCA	cis	rs7246657	0.722	rs8100646	ENSG00000276846.1	CTD-3220F14.3	5.01	6.53e-07	6.89e-05	0.21	0.15	Coronary artery calcification;	chr19:37617042	chr19:37314868~37315620:-
BRCA	cis	rs875971	0.862	rs778686	ENSG00000236529.1	RP13-254B10.1	5.01	6.53e-07	6.89e-05	0.17	0.15	Aortic root size;	chr7:66370923	chr7:65840212~65840596:+
BRCA	cis	rs10911251	0.528	rs10911266	ENSG00000224468.3	RP11-181K3.4	-5.01	6.53e-07	6.89e-05	-0.17	-0.15	Colorectal cancer;	chr1:183145962	chr1:183138402~183141282:-
BRCA	cis	rs6540731	0.84	rs11119879	ENSG00000229983.1	RP11-15I11.2	5.01	6.54e-07	6.89e-05	0.18	0.15	Intelligence (childhood);	chr1:212199006	chr1:212168207~212190259:+
BRCA	cis	rs4388249	0.687	rs2269204	ENSG00000271849.1	CTC-332L22.1	-5.01	6.54e-07	6.89e-05	-0.2	-0.15	Schizophrenia;	chr5:109763402	chr5:109687802~109688329:-
BRCA	cis	rs13108904	0.901	rs1680073	ENSG00000196810.4	CTBP1-AS2	-5.01	6.54e-07	6.89e-05	-0.16	-0.15	Obesity-related traits;	chr4:1286549	chr4:1249300~1288291:+
BRCA	cis	rs801193	0.569	rs6951302	ENSG00000236529.1	RP13-254B10.1	-5.01	6.54e-07	6.89e-05	-0.17	-0.15	Aortic root size;	chr7:66667525	chr7:65840212~65840596:+
BRCA	cis	rs7772486	0.754	rs697053	ENSG00000270638.1	RP3-466P17.1	-5.01	6.54e-07	6.9e-05	-0.18	-0.15	Lobe attachment (rater-scored or self-reported);	chr6:145668671	chr6:145735570~145737218:+
BRCA	cis	rs7772486	0.875	rs2474353	ENSG00000270638.1	RP3-466P17.1	5.01	6.54e-07	6.9e-05	0.18	0.15	Lobe attachment (rater-scored or self-reported);	chr6:146002747	chr6:145735570~145737218:+
BRCA	cis	rs801193	0.591	rs4506088	ENSG00000236529.1	RP13-254B10.1	-5.01	6.54e-07	6.9e-05	-0.17	-0.15	Aortic root size;	chr7:66670470	chr7:65840212~65840596:+
BRCA	cis	rs4535700	0.501	rs57153841	ENSG00000226278.1	PSPHP1	5.01	6.54e-07	6.9e-05	0.18	0.15	Macular telangiectasia type 2;	chr7:55927400	chr7:55764797~55773288:+
BRCA	cis	rs516805	0.665	rs517427	ENSG00000279453.1	RP3-425C14.4	-5.01	6.55e-07	6.91e-05	-0.22	-0.15	Lymphocyte counts;	chr6:122291180	chr6:122436789~122439223:-
BRCA	cis	rs875971	0.861	rs801215	ENSG00000273448.1	RP11-166O4.6	-5.01	6.55e-07	6.91e-05	-0.14	-0.15	Aortic root size;	chr7:66546951	chr7:67333047~67334383:+
BRCA	cis	rs1014246	0.541	rs887195	ENSG00000232767.1	RP11-498B4.5	5	6.56e-07	6.91e-05	0.16	0.15	Age at smoking initiation in chronic obstructive pulmonary disease;	chr10:116748465	chr10:116670103~116672739:+
BRCA	cis	rs728616	0.867	rs12412257	ENSG00000225484.5	NUTM2B-AS1	-5	6.56e-07	6.91e-05	-0.41	-0.15	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79969847	chr10:79663088~79826594:-
BRCA	cis	rs6570726	0.643	rs9403735	ENSG00000270638.1	RP3-466P17.1	5	6.56e-07	6.91e-05	0.18	0.15	Lobe attachment (rater-scored or self-reported);	chr6:145615455	chr6:145735570~145737218:+
BRCA	cis	rs11955398	0.542	rs2085413	ENSG00000215032.2	GNL3LP1	-5	6.56e-07	6.91e-05	-0.19	-0.15	Intelligence (multi-trait analysis);	chr5:60729552	chr5:60891935~60893577:-
BRCA	cis	rs2153535	0.58	rs2327064	ENSG00000251164.1	HULC	-5	6.56e-07	6.92e-05	-0.19	-0.15	Motion sickness;	chr6:8453819	chr6:8652137~8653846:+
BRCA	cis	rs6431644	0.931	rs655525	ENSG00000224287.2	MSL3P1	-5	6.56e-07	6.92e-05	-0.18	-0.15	Left atrial antero-posterior diameter;	chr2:233885305	chr2:233865437~233868444:-
BRCA	cis	rs12712135	0.677	rs6705385	ENSG00000234389.1	AC007278.3	-5	6.56e-07	6.92e-05	-0.14	-0.15	Blood protein levels;	chr2:102460109	chr2:102438713~102440475:+
BRCA	cis	rs78487399	0.908	rs74854268	ENSG00000234936.1	AC010883.5	5	6.56e-07	6.92e-05	0.22	0.15	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43616940	chr2:43229573~43233394:+
BRCA	cis	rs1075265	0.84	rs10084355	ENSG00000235937.1	AC008280.1	5	6.56e-07	6.92e-05	0.17	0.15	Chronotype;Morning vs. evening chronotype;	chr2:54021711	chr2:54029552~54030682:-
BRCA	cis	rs11098499	0.789	rs9991166	ENSG00000260404.2	RP11-384K6.6	5	6.57e-07	6.92e-05	0.14	0.15	Corneal astigmatism;	chr4:119316696	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.708	rs10005237	ENSG00000260404.2	RP11-384K6.6	5	6.57e-07	6.92e-05	0.14	0.15	Corneal astigmatism;	chr4:119316742	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.754	rs10213267	ENSG00000260404.2	RP11-384K6.6	5	6.57e-07	6.92e-05	0.14	0.15	Corneal astigmatism;	chr4:119317919	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.754	rs10212775	ENSG00000260404.2	RP11-384K6.6	5	6.57e-07	6.92e-05	0.14	0.15	Corneal astigmatism;	chr4:119318089	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.754	rs2964	ENSG00000260404.2	RP11-384K6.6	5	6.57e-07	6.92e-05	0.14	0.15	Corneal astigmatism;	chr4:119318976	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.754	rs1511025	ENSG00000260404.2	RP11-384K6.6	5	6.57e-07	6.92e-05	0.14	0.15	Corneal astigmatism;	chr4:119319083	chr4:118591773~118633729:+
BRCA	cis	rs1707322	0.686	rs2991986	ENSG00000234329.1	RP11-767N6.2	-5	6.57e-07	6.92e-05	-0.16	-0.15	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45615610	chr1:45651039~45651826:-
BRCA	cis	rs67311347	1	rs1119179	ENSG00000280739.1	EIF1B-AS1	-5	6.57e-07	6.93e-05	-0.17	-0.15	Renal cell carcinoma;	chr3:40383438	chr3:40173145~40309698:-
BRCA	cis	rs7246657	0.663	rs10408619	ENSG00000276846.1	CTD-3220F14.3	5	6.58e-07	6.93e-05	0.21	0.15	Coronary artery calcification;	chr19:37579573	chr19:37314868~37315620:-
BRCA	cis	rs875971	0.862	rs13536	ENSG00000273448.1	RP11-166O4.6	-5	6.58e-07	6.93e-05	-0.14	-0.15	Aortic root size;	chr7:66554203	chr7:67333047~67334383:+
BRCA	cis	rs875971	0.862	rs801209	ENSG00000273448.1	RP11-166O4.6	-5	6.58e-07	6.93e-05	-0.14	-0.15	Aortic root size;	chr7:66554403	chr7:67333047~67334383:+
BRCA	cis	rs875971	0.862	rs801206	ENSG00000273448.1	RP11-166O4.6	-5	6.58e-07	6.93e-05	-0.14	-0.15	Aortic root size;	chr7:66556979	chr7:67333047~67334383:+
BRCA	cis	rs875971	0.862	rs801204	ENSG00000273448.1	RP11-166O4.6	-5	6.58e-07	6.93e-05	-0.14	-0.15	Aortic root size;	chr7:66557934	chr7:67333047~67334383:+
BRCA	cis	rs875971	0.862	rs801203	ENSG00000273448.1	RP11-166O4.6	-5	6.58e-07	6.93e-05	-0.14	-0.15	Aortic root size;	chr7:66558025	chr7:67333047~67334383:+
BRCA	cis	rs875971	0.862	rs13232191	ENSG00000273448.1	RP11-166O4.6	5	6.58e-07	6.93e-05	0.14	0.15	Aortic root size;	chr7:66521661	chr7:67333047~67334383:+
BRCA	cis	rs875971	0.862	rs10950043	ENSG00000273448.1	RP11-166O4.6	5	6.58e-07	6.93e-05	0.14	0.15	Aortic root size;	chr7:66523623	chr7:67333047~67334383:+
BRCA	cis	rs875971	0.862	rs17747530	ENSG00000273448.1	RP11-166O4.6	5	6.58e-07	6.93e-05	0.14	0.15	Aortic root size;	chr7:66529742	chr7:67333047~67334383:+
BRCA	cis	rs7267979	1	rs2500448	ENSG00000125804.12	FAM182A	5	6.58e-07	6.93e-05	0.2	0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25423391	chr20:26054655~26086917:+
BRCA	cis	rs9467773	1	rs9986382	ENSG00000241549.7	GUSBP2	5	6.58e-07	6.94e-05	0.16	0.15	Intelligence (multi-trait analysis);	chr6:26550391	chr6:26871484~26956554:-
BRCA	cis	rs416603	0.967	rs11640138	ENSG00000262703.1	RP11-485G7.6	5	6.58e-07	6.94e-05	0.16	0.15	Type 1 diabetes;	chr16:11268872	chr16:11348143~11349321:-
BRCA	cis	rs2832191	0.791	rs2832198	ENSG00000176054.6	RPL23P2	5	6.58e-07	6.94e-05	0.16	0.15	Dental caries;	chr21:29125919	chr21:28997613~28998033:-
BRCA	cis	rs2288884	0.505	rs57637334	ENSG00000275055.1	CTC-471J1.11	-5	6.59e-07	6.94e-05	-0.26	-0.15	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:51977572	chr19:52049007~52049754:+
BRCA	cis	rs11758351	1	rs41266807	ENSG00000241549.7	GUSBP2	-5	6.59e-07	6.94e-05	-0.22	-0.15	Renal underexcretion gout;Gout;	chr6:26199594	chr6:26871484~26956554:-
BRCA	cis	rs875971	0.862	rs778724	ENSG00000236529.1	RP13-254B10.1	5	6.59e-07	6.94e-05	0.17	0.15	Aortic root size;	chr7:66364304	chr7:65840212~65840596:+
BRCA	cis	rs6596100	0.915	rs6596102	ENSG00000248648.1	RP11-485M7.1	-5	6.59e-07	6.94e-05	-0.2	-0.15	Breast cancer;	chr5:133079877	chr5:133003119~133003365:+
BRCA	cis	rs10504130	0.696	rs76717135	ENSG00000253844.1	RP11-546K22.1	-5	6.59e-07	6.94e-05	-0.24	-0.15	Venous thromboembolism (SNP x SNP interaction);	chr8:51917672	chr8:51961458~52022974:+
BRCA	cis	rs10504130	0.696	rs17212256	ENSG00000253844.1	RP11-546K22.1	-5	6.59e-07	6.94e-05	-0.24	-0.15	Venous thromboembolism (SNP x SNP interaction);	chr8:51919058	chr8:51961458~52022974:+
BRCA	cis	rs1552244	0.872	rs115331527	ENSG00000232901.1	CYCSP10	5	6.59e-07	6.95e-05	0.21	0.15	Alzheimer's disease;	chr3:10112820	chr3:10000647~10000940:-
BRCA	cis	rs2749097	0.609	rs2269246	ENSG00000244256.3	RN7SL130P	-5	6.6e-07	6.95e-05	-0.21	-0.15	Alcohol consumption (transferrin glycosylation);	chr1:63641820	chr1:63655743~63656047:+
BRCA	cis	rs2832191	0.967	rs2251377	ENSG00000236056.1	GAPDHP14	-5	6.6e-07	6.95e-05	-0.17	-0.15	Dental caries;	chr21:29158278	chr21:29222321~29223257:+
BRCA	cis	rs2834288	0.7	rs2834292	ENSG00000273102.1	AP000569.9	-5	6.6e-07	6.95e-05	-0.18	-0.15	Gut microbiota (bacterial taxa);	chr21:33901909	chr21:33967101~33968573:-
BRCA	cis	rs6596100	0.91	rs62375215	ENSG00000248648.1	RP11-485M7.1	-5	6.6e-07	6.95e-05	-0.2	-0.15	Breast cancer;	chr5:133069945	chr5:133003119~133003365:+
BRCA	cis	rs13108904	0.846	rs12643212	ENSG00000253399.1	AC078852.2	-5	6.6e-07	6.95e-05	-0.18	-0.15	Obesity-related traits;	chr4:1231160	chr4:1358479~1359461:+
BRCA	cis	rs12477438	0.765	rs4374423	ENSG00000231822.1	AC019097.7	-5	6.6e-07	6.95e-05	-0.17	-0.15	Chronic sinus infection;	chr2:99045885	chr2:99102018~99102752:+
BRCA	cis	rs12477438	0.748	rs4851185	ENSG00000231822.1	AC019097.7	-5	6.6e-07	6.95e-05	-0.17	-0.15	Chronic sinus infection;	chr2:99050034	chr2:99102018~99102752:+
BRCA	cis	rs12477438	0.765	rs7607578	ENSG00000231822.1	AC019097.7	-5	6.6e-07	6.95e-05	-0.17	-0.15	Chronic sinus infection;	chr2:99053308	chr2:99102018~99102752:+
BRCA	cis	rs12477438	0.765	rs9710648	ENSG00000231822.1	AC019097.7	-5	6.6e-07	6.95e-05	-0.17	-0.15	Chronic sinus infection;	chr2:99056666	chr2:99102018~99102752:+
BRCA	cis	rs12477438	0.798	rs2123686	ENSG00000231822.1	AC019097.7	-5	6.6e-07	6.95e-05	-0.17	-0.15	Chronic sinus infection;	chr2:99073672	chr2:99102018~99102752:+
BRCA	cis	rs12477438	0.765	rs10181344	ENSG00000231822.1	AC019097.7	-5	6.6e-07	6.95e-05	-0.17	-0.15	Chronic sinus infection;	chr2:99076366	chr2:99102018~99102752:+
BRCA	cis	rs12477438	0.765	rs62156363	ENSG00000231822.1	AC019097.7	-5	6.6e-07	6.95e-05	-0.17	-0.15	Chronic sinus infection;	chr2:99076861	chr2:99102018~99102752:+
BRCA	cis	rs7914558	1	rs4917380	ENSG00000236937.2	PTGES3P4	5	6.6e-07	6.96e-05	0.2	0.15	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103015578	chr10:102845595~102845950:+
BRCA	cis	rs4781563	0.81	rs3136155	ENSG00000242307.1	RPS26P52	-5	6.6e-07	6.96e-05	-0.18	-0.15	Bilirubin levels;	chr16:13936503	chr16:13922332~13922679:-
BRCA	cis	rs875971	0.545	rs17138149	ENSG00000230295.1	RP11-458F8.2	5	6.6e-07	6.96e-05	0.14	0.15	Aortic root size;	chr7:66228193	chr7:66880708~66882981:+
BRCA	cis	rs919433	0.617	rs4850436	ENSG00000231621.1	AC013264.2	5	6.61e-07	6.96e-05	0.15	0.15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197676674	chr2:197197991~197199273:+
BRCA	cis	rs7546	0.529	rs966062	ENSG00000267077.1	RP11-127I20.5	5	6.61e-07	6.96e-05	0.18	0.15	Cancer;	chr16:4857429	chr16:4795265~4796532:-
BRCA	cis	rs516805	0.63	rs170422	ENSG00000279453.1	RP3-425C14.4	-5	6.61e-07	6.96e-05	-0.21	-0.15	Lymphocyte counts;	chr6:122261422	chr6:122436789~122439223:-
BRCA	cis	rs875971	0.651	rs313829	ENSG00000273024.4	INTS4P2	5	6.61e-07	6.96e-05	0.18	0.15	Aortic root size;	chr7:66087510	chr7:65647864~65715661:+
BRCA	cis	rs1850744	1	rs2867388	ENSG00000163612.10	FAM86KP	-5	6.61e-07	6.96e-05	-0.37	-0.15	Economic and political preferences;	chr4:9794871	chr4:9153296~9165451:+
BRCA	cis	rs7226408	0.857	rs72887089	ENSG00000267707.2	RP11-95O2.5	5	6.61e-07	6.97e-05	0.23	0.15	Obesity-related traits;	chr18:36926873	chr18:37243776~37247506:+
BRCA	cis	rs7569084	0.663	rs1437461	ENSG00000281920.1	RP11-418H16.1	5	6.61e-07	6.97e-05	0.2	0.15	Sum eosinophil basophil counts;	chr2:65452578	chr2:65623272~65628424:+
BRCA	cis	rs7569084	0.687	rs7562559	ENSG00000281920.1	RP11-418H16.1	5	6.61e-07	6.97e-05	0.2	0.15	Sum eosinophil basophil counts;	chr2:65452719	chr2:65623272~65628424:+
BRCA	cis	rs10911251	0.508	rs10797854	ENSG00000224468.3	RP11-181K3.4	-5	6.61e-07	6.97e-05	-0.16	-0.15	Colorectal cancer;	chr1:183137604	chr1:183138402~183141282:-
BRCA	cis	rs7772486	0.681	rs9390343	ENSG00000270638.1	RP3-466P17.1	-5	6.62e-07	6.97e-05	-0.18	-0.15	Lobe attachment (rater-scored or self-reported);	chr6:145689391	chr6:145735570~145737218:+
BRCA	cis	rs2562456	0.682	rs11085464	ENSG00000268658.4	LINC00664	5	6.62e-07	6.97e-05	0.24	0.15	Pain;	chr19:21568976	chr19:21483374~21503238:+
BRCA	cis	rs4835473	0.9	rs3856989	ENSG00000249741.2	RP11-673E1.3	-5	6.62e-07	6.97e-05	-0.17	-0.15	Immature fraction of reticulocytes;	chr4:143921752	chr4:143911514~143912053:-
BRCA	cis	rs1722141	0.669	rs1722120	ENSG00000237471.1	AC073115.6	5	6.62e-07	6.97e-05	0.21	0.15	Sitting height ratio;	chr7:45993346	chr7:45969657~45980191:+
BRCA	cis	rs6570726	0.791	rs2096201	ENSG00000270638.1	RP3-466P17.1	5	6.62e-07	6.97e-05	0.18	0.15	Lobe attachment (rater-scored or self-reported);	chr6:145613137	chr6:145735570~145737218:+
BRCA	cis	rs7674212	0.537	rs2623060	ENSG00000251288.2	RP11-10L12.2	-5	6.62e-07	6.97e-05	-0.18	-0.15	Type 2 diabetes;	chr4:103126347	chr4:102751401~102752641:+
BRCA	cis	rs12646107	0.843	rs17262212	ENSG00000261672.1	RP11-475B2.1	-5	6.62e-07	6.97e-05	-0.22	-0.15	Response to amphetamines;	chr4:173588447	chr4:173593672~173594556:+
BRCA	cis	rs6840360	0.642	rs28666858	ENSG00000278978.1	RP11-164P12.5	-5	6.63e-07	6.98e-05	-0.17	-0.15	Intelligence (multi-trait analysis);	chr4:151495230	chr4:151669786~151670503:+
BRCA	cis	rs793571	0.784	rs12915713	ENSG00000259250.1	RP11-50C13.1	-5	6.63e-07	6.98e-05	-0.24	-0.15	Schizophrenia;	chr15:58815663	chr15:58587507~58591676:+
BRCA	cis	rs2562456	0.724	rs58001930	ENSG00000268535.1	RP11-420K14.3	5	6.63e-07	6.98e-05	0.21	0.15	Pain;	chr19:21560061	chr19:21709522~21710191:+
BRCA	cis	rs7914558	1	rs10883826	ENSG00000236937.2	PTGES3P4	5	6.63e-07	6.98e-05	0.2	0.15	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103071062	chr10:102845595~102845950:+
BRCA	cis	rs6570726	0.764	rs366673	ENSG00000270638.1	RP3-466P17.1	5	6.63e-07	6.98e-05	0.18	0.15	Lobe attachment (rater-scored or self-reported);	chr6:145493492	chr6:145735570~145737218:+
BRCA	cis	rs6545883	0.929	rs1838978	ENSG00000270820.4	RP11-355B11.2	-5	6.63e-07	6.98e-05	-0.18	-0.15	Tuberculosis;	chr2:61313788	chr2:61471188~61484130:+
BRCA	cis	rs60843830	0.508	rs300750	ENSG00000223751.1	AC116609.2	5	6.63e-07	6.98e-05	0.19	0.15	Spherical equivalent (joint analysis main effects and education interaction);	chr2:208794	chr2:742488~747767:+
BRCA	cis	rs4588572	0.688	rs11743511	ENSG00000245556.2	SCAMP1-AS1	-5	6.63e-07	6.98e-05	-0.18	-0.15	Triglycerides;	chr5:78396995	chr5:78342365~78360507:-
BRCA	cis	rs6674176	0.551	rs2428955	ENSG00000237950.1	RP11-7O11.3	5	6.63e-07	6.98e-05	0.26	0.15	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43948751	chr1:43944370~43946551:-
BRCA	cis	rs7332672	0.962	rs2182885	ENSG00000280710.1	RP11-214F16.8	-5	6.64e-07	6.99e-05	-0.17	-0.15	Eosinophil counts;	chr13:99202870	chr13:99498524~99501315:+
BRCA	cis	rs7119	0.678	rs12914098	ENSG00000259362.2	RP11-307C19.1	-5	6.64e-07	6.99e-05	-0.21	-0.15	Type 2 diabetes;	chr15:77530671	chr15:77525540~77534110:+
BRCA	cis	rs12893668	0.514	rs3212090	ENSG00000269958.1	RP11-73M18.8	5	6.64e-07	6.99e-05	0.17	0.15	Reticulocyte count;	chr14:103702526	chr14:103696353~103697163:+
BRCA	cis	rs17685	0.712	rs1637049	ENSG00000280388.1	RP11-229D13.3	-5	6.64e-07	6.99e-05	-0.16	-0.15	Coffee consumption (cups per day);Coffee consumption;	chr7:76100657	chr7:76043977~76045963:-
BRCA	cis	rs2243480	1	rs1546059	ENSG00000222364.1	RNU6-96P	5	6.64e-07	6.99e-05	0.28	0.15	Diabetic kidney disease;	chr7:66189722	chr7:66395191~66395286:+
BRCA	cis	rs2243480	1	rs2420170	ENSG00000222364.1	RNU6-96P	5	6.64e-07	6.99e-05	0.28	0.15	Diabetic kidney disease;	chr7:66191066	chr7:66395191~66395286:+
BRCA	cis	rs8048589	0.604	rs62038898	ENSG00000175604.2	RP11-276H1.3	-5	6.64e-07	6.99e-05	-0.28	-0.15	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);	chr16:12129780	chr16:12086746~12090302:-
BRCA	cis	rs2243480	1	rs958550	ENSG00000222364.1	RNU6-96P	5	6.64e-07	6.99e-05	0.27	0.15	Diabetic kidney disease;	chr7:66170692	chr7:66395191~66395286:+
BRCA	cis	rs5167	0.536	rs1882752	ENSG00000280087.1	CTB-129P6.7	5	6.64e-07	7e-05	0.21	0.15	Blood protein levels;	chr19:44958085	chr19:44909375~44914968:+
BRCA	cis	rs6452524	0.56	rs6895174	ENSG00000281327.1	LINC01338	5	6.65e-07	7e-05	0.17	0.15	Hypertension (SNP x SNP interaction);	chr5:83071606	chr5:82850864~82859836:-
BRCA	cis	rs2255336	0.882	rs2617156	ENSG00000245648.1	RP11-277P12.20	5	6.65e-07	7e-05	0.22	0.15	Blood protein levels;	chr12:10384280	chr12:10363769~10398506:+
BRCA	cis	rs2255336	0.938	rs2617157	ENSG00000245648.1	RP11-277P12.20	5	6.65e-07	7e-05	0.22	0.15	Blood protein levels;	chr12:10384299	chr12:10363769~10398506:+
BRCA	cis	rs2255336	0.938	rs2927561	ENSG00000245648.1	RP11-277P12.20	5	6.65e-07	7e-05	0.22	0.15	Blood protein levels;	chr12:10384974	chr12:10363769~10398506:+
BRCA	cis	rs2255336	0.882	rs2126889	ENSG00000245648.1	RP11-277P12.20	5	6.65e-07	7e-05	0.22	0.15	Blood protein levels;	chr12:10385280	chr12:10363769~10398506:+
BRCA	cis	rs17674580	0.541	rs9951207	ENSG00000267193.4	RP11-116O18.3	5	6.65e-07	7e-05	0.17	0.15	Bladder cancer;	chr18:45758661	chr18:45669367~45747215:-
BRCA	cis	rs6430585	0.528	rs6743537	ENSG00000231890.6	DARS-AS1	-5	6.65e-07	7e-05	-0.23	-0.15	Corneal structure;	chr2:135945031	chr2:135985176~136022593:+
BRCA	cis	rs7267979	1	rs2482943	ENSG00000276952.1	RP5-965G21.6	-5	6.65e-07	7e-05	-0.19	-0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25399957	chr20:25284915~25285588:-
BRCA	cis	rs4218	0.681	rs1867757	ENSG00000277144.1	RP11-59H7.4	-5	6.65e-07	7e-05	-0.2	-0.15	Social communication problems;	chr15:59072315	chr15:59115547~59116089:-
BRCA	cis	rs17767294	0.708	rs72846802	ENSG00000204709.4	LINC01556	5	6.66e-07	7.01e-05	0.4	0.15	Parkinson's disease;	chr6:28197064	chr6:28943877~28944537:+
BRCA	cis	rs6714710	0.603	rs13023980	ENSG00000230606.9	AC159540.1	-5	6.66e-07	7.01e-05	-0.18	-0.15	Posterior cortical atrophy and Alzheimer's disease;	chr2:97886524	chr2:97416165~97433527:-
BRCA	cis	rs34217772	0.68	rs60030517	ENSG00000258636.1	CTD-2298J14.2	5	6.66e-07	7.01e-05	0.21	0.15	Myopia;	chr14:41733863	chr14:41587861~41604856:-
BRCA	cis	rs7572733	0.534	rs700678	ENSG00000231621.1	AC013264.2	-5	6.66e-07	7.01e-05	-0.15	-0.15	Dermatomyositis;	chr2:197841096	chr2:197197991~197199273:+
BRCA	cis	rs7572733	0.515	rs11887138	ENSG00000231621.1	AC013264.2	-5	6.66e-07	7.01e-05	-0.15	-0.15	Dermatomyositis;	chr2:197941114	chr2:197197991~197199273:+
BRCA	cis	rs1707322	1	rs4660906	ENSG00000234329.1	RP11-767N6.2	5	6.66e-07	7.01e-05	0.16	0.15	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46005188	chr1:45651039~45651826:-
BRCA	cis	rs7577696	0.72	rs12465124	ENSG00000272716.1	RP11-563N4.1	5	6.66e-07	7.01e-05	0.17	0.15	Inflammatory biomarkers;	chr2:32111610	chr2:32165046~32165757:-
BRCA	cis	rs6772849	0.896	rs4857859	ENSG00000242551.2	POU5F1P6	-5	6.66e-07	7.01e-05	-0.19	-0.15	Monocyte percentage of white cells;Monocyte count;	chr3:128629171	chr3:128674735~128677005:-
BRCA	cis	rs17685	0.816	rs11763076	ENSG00000280388.1	RP11-229D13.3	-5	6.66e-07	7.01e-05	-0.16	-0.15	Coffee consumption (cups per day);Coffee consumption;	chr7:76136645	chr7:76043977~76045963:-
BRCA	cis	rs7474896	0.806	rs1779150	ENSG00000272983.1	RP11-508N22.12	-5	6.67e-07	7.02e-05	-0.32	-0.15	Obesity (extreme);	chr10:37749759	chr10:38137337~38144399:+
BRCA	cis	rs12744310	0.887	rs12047161	ENSG00000235358.1	RP11-399E6.1	5	6.67e-07	7.02e-05	0.23	0.15	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41341856	chr1:41242373~41284861:+
BRCA	cis	rs78487399	0.808	rs17030855	ENSG00000234936.1	AC010883.5	5	6.67e-07	7.02e-05	0.25	0.15	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43462225	chr2:43229573~43233394:+
BRCA	cis	rs78487399	0.808	rs17030859	ENSG00000234936.1	AC010883.5	5	6.67e-07	7.02e-05	0.25	0.15	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43462765	chr2:43229573~43233394:+
BRCA	cis	rs1218582	0.772	rs6669791	ENSG00000270361.1	RP11-307C12.13	-5	6.67e-07	7.02e-05	-0.18	-0.15	Prostate cancer;	chr1:154873008	chr1:154937370~154938059:+
BRCA	cis	rs7246657	1	rs6508710	ENSG00000267422.1	CTD-2554C21.1	-5	6.67e-07	7.02e-05	-0.23	-0.15	Coronary artery calcification;	chr19:37258984	chr19:37779686~37792865:+
BRCA	cis	rs875971	1	rs697970	ENSG00000223473.2	GS1-124K5.3	-5	6.67e-07	7.02e-05	-0.12	-0.15	Aortic root size;	chr7:66095065	chr7:66491049~66493566:-
BRCA	cis	rs6598266	1	rs6598266	ENSG00000259363.4	CTD-2054N24.2	5	6.67e-07	7.02e-05	0.22	0.15	Major depressive disorder;	chr15:99759034	chr15:99807023~99877148:+
BRCA	cis	rs73222236	0.817	rs6772759	ENSG00000273486.1	RP11-731C17.2	5	6.68e-07	7.03e-05	0.17	0.15	Coronary artery disease;	chr3:136652645	chr3:136837338~136839021:-
BRCA	cis	rs73222236	0.817	rs9869361	ENSG00000273486.1	RP11-731C17.2	5	6.68e-07	7.03e-05	0.17	0.15	Coronary artery disease;	chr3:136654174	chr3:136837338~136839021:-
BRCA	cis	rs1729951	0.546	rs12054218	ENSG00000239213.4	NCK1-AS1	5	6.69e-07	7.04e-05	0.16	0.15	Neuroticism;	chr3:136958654	chr3:136841726~136862054:-
BRCA	cis	rs8048589	0.604	rs2175020	ENSG00000175604.2	RP11-276H1.3	-5	6.7e-07	7.05e-05	-0.26	-0.15	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);	chr16:12125333	chr16:12086746~12090302:-
BRCA	cis	rs4819052	0.851	rs2838834	ENSG00000184274.3	LINC00315	-5	6.7e-07	7.05e-05	-0.21	-0.15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245293	chr21:45300245~45305257:-
BRCA	cis	rs10861342	1	rs34705618	ENSG00000257999.1	RP11-61E11.2	-5	6.7e-07	7.05e-05	-0.33	-0.15	IgG glycosylation;	chr12:105124833	chr12:105102472~105107179:-
BRCA	cis	rs6001482	0.702	rs5757581	ENSG00000279278.1	CH17-264L24.1	-5	6.7e-07	7.05e-05	-0.13	-0.15	Diastolic blood pressure;	chr22:22234220	chr22:22264601~22273020:+
BRCA	cis	rs2839186	0.709	rs2839176	ENSG00000239415.1	AP001469.9	5	6.71e-07	7.06e-05	0.16	0.15	Testicular germ cell tumor;	chr21:46258259	chr21:46251549~46254133:-
BRCA	cis	rs2562456	0.52	rs250001	ENSG00000268535.1	RP11-420K14.3	5	6.71e-07	7.06e-05	0.24	0.15	Pain;	chr19:21225387	chr19:21709522~21710191:+
BRCA	cis	rs11124272	0.761	rs4952244	ENSG00000272716.1	RP11-563N4.1	-5	6.71e-07	7.06e-05	-0.18	-0.15	Interleukin-18 levels;	chr2:31811556	chr2:32165046~32165757:-
BRCA	cis	rs2153535	0.58	rs9406165	ENSG00000251164.1	HULC	-5	6.72e-07	7.07e-05	-0.19	-0.15	Motion sickness;	chr6:8488604	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.563	rs4428546	ENSG00000251164.1	HULC	-5	6.72e-07	7.07e-05	-0.19	-0.15	Motion sickness;	chr6:8490143	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.505	rs1335629	ENSG00000251164.1	HULC	-5	6.72e-07	7.07e-05	-0.19	-0.15	Motion sickness;	chr6:8491630	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.58	rs763376	ENSG00000251164.1	HULC	-5	6.72e-07	7.07e-05	-0.19	-0.15	Motion sickness;	chr6:8492543	chr6:8652137~8653846:+
BRCA	cis	rs6714710	0.58	rs57681139	ENSG00000230606.9	AC159540.1	-5	6.72e-07	7.07e-05	-0.18	-0.15	Posterior cortical atrophy and Alzheimer's disease;	chr2:97838010	chr2:97416165~97433527:-
BRCA	cis	rs6714710	0.58	rs1838797	ENSG00000230606.9	AC159540.1	-5	6.72e-07	7.07e-05	-0.18	-0.15	Posterior cortical atrophy and Alzheimer's disease;	chr2:97838109	chr2:97416165~97433527:-
BRCA	cis	rs10911232	0.507	rs10797816	ENSG00000224468.3	RP11-181K3.4	-5	6.72e-07	7.07e-05	-0.16	-0.15	Hypertriglyceridemia;	chr1:183029351	chr1:183138402~183141282:-
BRCA	cis	rs6921919	0.583	rs740621	ENSG00000220721.1	OR1F12	5	6.72e-07	7.07e-05	0.19	0.15	Autism spectrum disorder or schizophrenia;	chr6:28430010	chr6:28073316~28074233:+
BRCA	cis	rs5167	0.583	rs7252480	ENSG00000280087.1	CTB-129P6.7	5	6.72e-07	7.07e-05	0.21	0.15	Blood protein levels;	chr19:44955668	chr19:44909375~44914968:+
BRCA	cis	rs4948275	0.742	rs2937153	ENSG00000237233.2	TMEM26-AS1	-5	6.72e-07	7.07e-05	-0.18	-0.15	Night sleep phenotypes;	chr10:61478029	chr10:61452639~61481956:+
BRCA	cis	rs2803122	0.756	rs1129101	ENSG00000273226.1	RP11-513M16.8	5	6.73e-07	7.07e-05	0.16	0.15	Pulse pressure;	chr9:19372992	chr9:19375451~19375996:+
BRCA	cis	rs6714710	0.603	rs6757357	ENSG00000230606.9	AC159540.1	-5	6.73e-07	7.07e-05	-0.18	-0.15	Posterior cortical atrophy and Alzheimer's disease;	chr2:97875287	chr2:97416165~97433527:-
BRCA	cis	rs7818688	1	rs11786380	ENSG00000253528.2	RP11-347C18.4	-5	6.73e-07	7.08e-05	-0.23	-0.15	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95015908	chr8:94974573~94974853:-
BRCA	cis	rs516805	0.63	rs699405	ENSG00000279453.1	RP3-425C14.4	-5	6.73e-07	7.08e-05	-0.21	-0.15	Lymphocyte counts;	chr6:122274145	chr6:122436789~122439223:-
BRCA	cis	rs516805	0.596	rs225088	ENSG00000279453.1	RP3-425C14.4	-5	6.73e-07	7.08e-05	-0.21	-0.15	Lymphocyte counts;	chr6:122277898	chr6:122436789~122439223:-
BRCA	cis	rs2905347	0.726	rs2905321	ENSG00000179428.2	AC073072.5	-5	6.73e-07	7.08e-05	-0.16	-0.15	Major depression and alcohol dependence;	chr7:22664968	chr7:22725395~22727620:-
BRCA	cis	rs11098499	0.775	rs10021601	ENSG00000249244.1	RP11-548H18.2	5	6.73e-07	7.08e-05	0.18	0.15	Corneal astigmatism;	chr4:119361408	chr4:119391831~119395335:-
BRCA	cis	rs2153535	0.58	rs6597332	ENSG00000251164.1	HULC	-5	6.73e-07	7.08e-05	-0.19	-0.15	Motion sickness;	chr6:8504515	chr6:8652137~8653846:+
BRCA	cis	rs2832191	0.755	rs2832193	ENSG00000215533.7	LINC00189	5	6.74e-07	7.09e-05	0.17	0.15	Dental caries;	chr21:29121268	chr21:29193480~29288205:+
BRCA	cis	rs875971	0.964	rs778735	ENSG00000223473.2	GS1-124K5.3	5	6.74e-07	7.09e-05	0.12	0.15	Aortic root size;	chr7:66349822	chr7:66491049~66493566:-
BRCA	cis	rs6840360	0.642	rs1443089	ENSG00000278978.1	RP11-164P12.5	-5	6.74e-07	7.09e-05	-0.17	-0.15	Intelligence (multi-trait analysis);	chr4:151529148	chr4:151669786~151670503:+
BRCA	cis	rs875971	1	rs6460296	ENSG00000223473.2	GS1-124K5.3	5	6.74e-07	7.09e-05	0.12	0.15	Aortic root size;	chr7:66430152	chr7:66491049~66493566:-
BRCA	cis	rs6728642	0.908	rs9973669	ENSG00000230606.9	AC159540.1	5	6.74e-07	7.09e-05	0.27	0.15	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:97013357	chr2:97416165~97433527:-
BRCA	cis	rs7577696	0.962	rs67157050	ENSG00000272716.1	RP11-563N4.1	-5	6.74e-07	7.09e-05	-0.17	-0.15	Inflammatory biomarkers;	chr2:32046295	chr2:32165046~32165757:-
BRCA	cis	rs1979679	0.573	rs2348417	ENSG00000278733.1	RP11-425D17.1	-5	6.75e-07	7.1e-05	-0.2	-0.15	Ossification of the posterior longitudinal ligament of the spine;	chr12:28582663	chr12:28185625~28186190:-
BRCA	cis	rs2522056	1	rs62385693	ENSG00000233006.5	AC034220.3	-5	6.75e-07	7.1e-05	-0.13	-0.15	Fibrinogen;Lymphocyte counts;	chr5:132437982	chr5:132311285~132369916:-
BRCA	cis	rs2489715	0.67	rs2801015	ENSG00000185904.10	LINC00839	-5	6.75e-07	7.1e-05	-0.2	-0.15	Helix rolling;	chr10:42444496	chr10:42475543~42495336:+
BRCA	cis	rs6439153	0.933	rs11711812	ENSG00000231305.3	RP11-723O4.2	5	6.75e-07	7.1e-05	0.17	0.15	Pneumococcal bacteremia;	chr3:128989711	chr3:128861313~128871540:-
BRCA	cis	rs1075265	0.568	rs2542577	ENSG00000235937.1	AC008280.1	5	6.76e-07	7.11e-05	0.16	0.15	Chronotype;Morning vs. evening chronotype;	chr2:53822111	chr2:54029552~54030682:-
BRCA	cis	rs78487399	0.71	rs17030798	ENSG00000234936.1	AC010883.5	-5	6.76e-07	7.11e-05	-0.24	-0.15	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43443044	chr2:43229573~43233394:+
BRCA	cis	rs370915	0.542	rs6838849	ENSG00000250971.1	RP11-696F12.1	5	6.76e-07	7.11e-05	0.16	0.15	Gout;	chr4:186869530	chr4:187060099~187060930:+
BRCA	cis	rs11124272	0.625	rs2224310	ENSG00000272716.1	RP11-563N4.1	5	6.76e-07	7.11e-05	0.18	0.15	Interleukin-18 levels;	chr2:31517397	chr2:32165046~32165757:-
BRCA	cis	rs2243480	1	rs2243480	ENSG00000275400.1	RP4-756H11.5	5	6.76e-07	7.11e-05	0.28	0.15	Diabetic kidney disease;	chr7:66134209	chr7:66553805~66554199:-
BRCA	cis	rs3845817	0.838	rs702886	ENSG00000237979.1	AC007389.1	5	6.76e-07	7.11e-05	0.19	0.15	Bipolar disorder;	chr2:65526176	chr2:65500993~65502138:-
BRCA	cis	rs11758351	1	rs78012445	ENSG00000241549.7	GUSBP2	-5	6.77e-07	7.12e-05	-0.22	-0.15	Renal underexcretion gout;Gout;	chr6:26194852	chr6:26871484~26956554:-
BRCA	cis	rs6772849	0.805	rs13325747	ENSG00000242551.2	POU5F1P6	-5	6.77e-07	7.12e-05	-0.19	-0.15	Monocyte percentage of white cells;Monocyte count;	chr3:128617180	chr3:128674735~128677005:-
BRCA	cis	rs2638953	0.962	rs11049537	ENSG00000247934.4	RP11-967K21.1	-5	6.78e-07	7.12e-05	-0.21	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28331239	chr12:28163298~28190738:-
BRCA	cis	rs7818688	1	rs7002940	ENSG00000253528.2	RP11-347C18.4	-5	6.78e-07	7.13e-05	-0.23	-0.15	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95015164	chr8:94974573~94974853:-
BRCA	cis	rs7923837	0.687	rs2185756	ENSG00000236493.2	EIF2S2P3	5	6.79e-07	7.14e-05	0.2	0.15	Multiple sclerosis;Body mass index;	chr10:92670740	chr10:92668745~92669743:-
BRCA	cis	rs1223397	0.651	rs2496153	ENSG00000215022.6	RP1-257A7.4	-5	6.79e-07	7.14e-05	-0.18	-0.15	Blood pressure;	chr6:13314642	chr6:13264861~13295586:-
BRCA	cis	rs875971	1	rs55962648	ENSG00000223473.2	GS1-124K5.3	-5	6.8e-07	7.14e-05	-0.12	-0.15	Aortic root size;	chr7:66160764	chr7:66491049~66493566:-
BRCA	cis	rs8114671	0.562	rs6088646	ENSG00000269202.1	RP4-614O4.12	-5	6.8e-07	7.15e-05	-0.15	-0.15	Height;	chr20:34918134	chr20:35201747~35203288:-
BRCA	cis	rs8114671	0.562	rs6120763	ENSG00000269202.1	RP4-614O4.12	-5	6.8e-07	7.15e-05	-0.15	-0.15	Height;	chr20:34918597	chr20:35201747~35203288:-
BRCA	cis	rs875971	0.895	rs12698520	ENSG00000223473.2	GS1-124K5.3	5	6.8e-07	7.15e-05	0.12	0.15	Aortic root size;	chr7:66453720	chr7:66491049~66493566:-
BRCA	cis	rs7618915	0.57	rs13068293	ENSG00000243224.1	RP5-1157M23.2	-5	6.8e-07	7.15e-05	-0.17	-0.15	Bipolar disorder;	chr3:52638151	chr3:52239258~52241097:+
BRCA	cis	rs7618915	0.547	rs11130311	ENSG00000243224.1	RP5-1157M23.2	-5	6.8e-07	7.15e-05	-0.17	-0.15	Bipolar disorder;	chr3:52640989	chr3:52239258~52241097:+
BRCA	cis	rs7618915	0.547	rs7642198	ENSG00000243224.1	RP5-1157M23.2	-5	6.8e-07	7.15e-05	-0.17	-0.15	Bipolar disorder;	chr3:52643944	chr3:52239258~52241097:+
BRCA	cis	rs7618915	0.547	rs13085895	ENSG00000243224.1	RP5-1157M23.2	-5	6.8e-07	7.15e-05	-0.17	-0.15	Bipolar disorder;	chr3:52644254	chr3:52239258~52241097:+
BRCA	cis	rs1861628	0.927	rs737308	ENSG00000229352.1	AC007563.3	5	6.8e-07	7.15e-05	0.19	0.15	Serum thyroid-stimulating hormone levels;Hypothyroidism;	chr2:216758526	chr2:216799608~216805335:+
BRCA	cis	rs7572733	0.534	rs700673	ENSG00000231621.1	AC013264.2	-5	6.8e-07	7.15e-05	-0.15	-0.15	Dermatomyositis;	chr2:197828205	chr2:197197991~197199273:+
BRCA	cis	rs35740288	0.929	rs11635081	ENSG00000259407.1	RP11-158M2.3	-5	6.8e-07	7.15e-05	-0.21	-0.15	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85761029	chr15:85744109~85750281:-
BRCA	cis	rs7914558	1	rs7899084	ENSG00000236937.2	PTGES3P4	5	6.81e-07	7.15e-05	0.2	0.15	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103112790	chr10:102845595~102845950:+
BRCA	cis	rs9287719	0.967	rs12467642	ENSG00000243819.4	RN7SL832P	5	6.81e-07	7.16e-05	0.15	0.15	Prostate cancer;	chr2:10621358	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.967	rs12464908	ENSG00000243819.4	RN7SL832P	5	6.81e-07	7.16e-05	0.15	0.15	Prostate cancer;	chr2:10621370	chr2:10690344~10692099:+
BRCA	cis	rs6570726	0.738	rs6917199	ENSG00000270638.1	RP3-466P17.1	5	6.81e-07	7.16e-05	0.18	0.15	Lobe attachment (rater-scored or self-reported);	chr6:145597184	chr6:145735570~145737218:+
BRCA	cis	rs78487399	0.808	rs76856054	ENSG00000234936.1	AC010883.5	5	6.81e-07	7.16e-05	0.26	0.15	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43537045	chr2:43229573~43233394:+
BRCA	cis	rs1075265	0.783	rs805424	ENSG00000235937.1	AC008280.1	5	6.81e-07	7.16e-05	0.17	0.15	Chronotype;Morning vs. evening chronotype;	chr2:53901098	chr2:54029552~54030682:-
BRCA	cis	rs8180040	0.545	rs9311403	ENSG00000276925.1	RP11-708J19.3	-5	6.82e-07	7.16e-05	-0.17	-0.15	Colorectal cancer;	chr3:47097388	chr3:47469777~47469987:+
BRCA	cis	rs9818758	0.607	rs34784192	ENSG00000270441.1	RP11-694I15.7	5	6.82e-07	7.16e-05	0.28	0.15	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49237390	chr3:49140086~49160851:-
BRCA	cis	rs12612619	0.542	rs6710065	ENSG00000272148.1	RP11-195B17.1	-5	6.82e-07	7.16e-05	-0.17	-0.15	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:26853689	chr2:27062428~27062907:-
BRCA	cis	rs17767294	0.708	rs72851105	ENSG00000204709.4	LINC01556	5	6.82e-07	7.16e-05	0.42	0.15	Parkinson's disease;	chr6:28068630	chr6:28943877~28944537:+
BRCA	cis	rs12477438	0.765	rs4851183	ENSG00000231822.1	AC019097.7	-5	6.82e-07	7.17e-05	-0.17	-0.15	Chronic sinus infection;	chr2:99012686	chr2:99102018~99102752:+
BRCA	cis	rs12477438	0.765	rs62154638	ENSG00000231822.1	AC019097.7	-5	6.82e-07	7.17e-05	-0.17	-0.15	Chronic sinus infection;	chr2:99023121	chr2:99102018~99102752:+
BRCA	cis	rs12477438	0.765	rs7605734	ENSG00000231822.1	AC019097.7	-5	6.82e-07	7.17e-05	-0.17	-0.15	Chronic sinus infection;	chr2:99027605	chr2:99102018~99102752:+
BRCA	cis	rs12477438	0.798	rs7606635	ENSG00000231822.1	AC019097.7	-5	6.82e-07	7.17e-05	-0.17	-0.15	Chronic sinus infection;	chr2:99028319	chr2:99102018~99102752:+
BRCA	cis	rs8031584	0.872	rs11634761	ENSG00000270015.1	RP11-540B6.6	-5	6.82e-07	7.17e-05	-0.16	-0.15	Huntington's disease progression;	chr15:30950970	chr15:30926514~30928407:+
BRCA	cis	rs6442522	0.526	rs3773448	ENSG00000249786.6	EAF1-AS1	5	6.82e-07	7.17e-05	0.16	0.15	Uric acid levels;	chr3:15477755	chr3:15436171~15455940:-
BRCA	cis	rs4781563	0.913	rs4781562	ENSG00000242307.1	RPS26P52	-5	6.82e-07	7.17e-05	-0.18	-0.15	Bilirubin levels;	chr16:13951379	chr16:13922332~13922679:-
BRCA	cis	rs5167	0.677	rs2238682	ENSG00000280087.1	CTB-129P6.7	5	6.82e-07	7.17e-05	0.21	0.15	Blood protein levels;	chr19:44955336	chr19:44909375~44914968:+
BRCA	cis	rs17685	0.753	rs1639617	ENSG00000280388.1	RP11-229D13.3	-5	6.83e-07	7.17e-05	-0.16	-0.15	Coffee consumption (cups per day);Coffee consumption;	chr7:76072410	chr7:76043977~76045963:-
BRCA	cis	rs17685	0.753	rs11982200	ENSG00000280388.1	RP11-229D13.3	-5	6.83e-07	7.17e-05	-0.16	-0.15	Coffee consumption (cups per day);Coffee consumption;	chr7:76085565	chr7:76043977~76045963:-
BRCA	cis	rs9921338	0.636	rs72771866	ENSG00000262703.1	RP11-485G7.6	-5	6.83e-07	7.17e-05	-0.19	-0.15	Vein graft stenosis in coronary artery bypass grafting;	chr16:11261365	chr16:11348143~11349321:-
BRCA	cis	rs4934494	0.677	rs943125	ENSG00000240996.1	RP11-80H5.7	-5	6.83e-07	7.17e-05	-0.21	-0.15	Red blood cell count;	chr10:89619789	chr10:89694295~89697928:-
BRCA	cis	rs300890	0.513	rs10005340	ENSG00000250326.1	RP11-284M14.1	-5	6.83e-07	7.18e-05	-0.18	-0.15	Nasopharyngeal carcinoma;	chr4:143122478	chr4:142933195~143184861:-
BRCA	cis	rs934734	0.532	rs2860773	ENSG00000204929.10	AC074391.1	-5	6.84e-07	7.18e-05	-0.19	-0.15	Rheumatoid arthritis;	chr2:65438507	chr2:65436711~66084639:+
BRCA	cis	rs6545883	0.931	rs12713438	ENSG00000270820.4	RP11-355B11.2	5	6.84e-07	7.18e-05	0.17	0.15	Tuberculosis;	chr2:61498366	chr2:61471188~61484130:+
BRCA	cis	rs6569038	0.502	rs9401113	ENSG00000253194.1	RP11-351A11.1	5	6.84e-07	7.18e-05	0.19	0.15	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr6:118993959	chr6:118934785~119031541:+
BRCA	cis	rs9393692	0.902	rs6456711	ENSG00000241549.7	GUSBP2	-5	6.84e-07	7.18e-05	-0.17	-0.15	Educational attainment;	chr6:26302344	chr6:26871484~26956554:-
BRCA	cis	rs9393692	0.967	rs6456712	ENSG00000241549.7	GUSBP2	-5	6.84e-07	7.18e-05	-0.17	-0.15	Educational attainment;	chr6:26302345	chr6:26871484~26956554:-
BRCA	cis	rs2153535	0.58	rs1577467	ENSG00000251164.1	HULC	-5	6.84e-07	7.19e-05	-0.19	-0.15	Motion sickness;	chr6:8444008	chr6:8652137~8653846:+
BRCA	cis	rs7572733	0.534	rs1983359	ENSG00000231621.1	AC013264.2	-5	6.84e-07	7.19e-05	-0.15	-0.15	Dermatomyositis;	chr2:197940374	chr2:197197991~197199273:+
BRCA	cis	rs801193	0.569	rs2013908	ENSG00000236529.1	RP13-254B10.1	-5	6.84e-07	7.19e-05	-0.17	-0.15	Aortic root size;	chr7:66656082	chr7:65840212~65840596:+
BRCA	cis	rs12291225	0.883	rs1864658	ENSG00000251991.1	RNU7-49P	-5	6.85e-07	7.19e-05	-0.18	-0.15	Sense of smell;	chr11:14234898	chr11:14478892~14478953:+
BRCA	cis	rs2638953	0.64	rs1511548	ENSG00000247934.4	RP11-967K21.1	-5	6.85e-07	7.19e-05	-0.19	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28579057	chr12:28163298~28190738:-
BRCA	cis	rs11168351	0.864	rs12228750	ENSG00000273765.1	RP11-370I10.11	-5	6.85e-07	7.19e-05	-0.18	-0.15	Bipolar disorder and schizophrenia;	chr12:48103214	chr12:48360920~48361377:+
BRCA	cis	rs1499614	1	rs2707832	ENSG00000275400.1	RP4-756H11.5	5	6.85e-07	7.2e-05	0.27	0.15	Gout;	chr7:66671562	chr7:66553805~66554199:-
BRCA	cis	rs12712135	0.709	rs2310302	ENSG00000234389.1	AC007278.3	-5	6.85e-07	7.2e-05	-0.14	-0.15	Blood protein levels;	chr2:102469589	chr2:102438713~102440475:+
BRCA	cis	rs12712135	0.709	rs12469887	ENSG00000234389.1	AC007278.3	-5	6.85e-07	7.2e-05	-0.14	-0.15	Blood protein levels;	chr2:102470298	chr2:102438713~102440475:+
BRCA	cis	rs2562456	0.833	rs1781872	ENSG00000268081.1	RP11-678G14.2	5	6.86e-07	7.2e-05	0.25	0.15	Pain;	chr19:21294601	chr19:21554640~21569237:-
BRCA	cis	rs78487399	0.908	rs17031106	ENSG00000234936.1	AC010883.5	5	6.86e-07	7.2e-05	0.21	0.15	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43601917	chr2:43229573~43233394:+
BRCA	cis	rs2153535	0.58	rs1410766	ENSG00000251164.1	HULC	-5	6.86e-07	7.2e-05	-0.19	-0.15	Motion sickness;	chr6:8525127	chr6:8652137~8653846:+
BRCA	cis	rs6723226	0.804	rs17428810	ENSG00000276334.1	AL133243.1	-5	6.86e-07	7.2e-05	-0.21	-0.15	Intelligence (multi-trait analysis);	chr2:32510976	chr2:32521927~32523547:+
BRCA	cis	rs875971	1	rs4717292	ENSG00000223473.2	GS1-124K5.3	5	6.86e-07	7.21e-05	0.12	0.15	Aortic root size;	chr7:66430611	chr7:66491049~66493566:-
BRCA	cis	rs875971	1	rs35149210	ENSG00000223473.2	GS1-124K5.3	5	6.86e-07	7.21e-05	0.12	0.15	Aortic root size;	chr7:66464938	chr7:66491049~66493566:-
BRCA	cis	rs539096	0.872	rs663618	ENSG00000236200.4	KDM4A-AS1	-5	6.86e-07	7.21e-05	-0.19	-0.15	Intelligence (multi-trait analysis);	chr1:43577434	chr1:43699765~43708138:-
BRCA	cis	rs66887589	0.66	rs4833613	ENSG00000248280.1	RP11-33B1.2	-5	6.87e-07	7.21e-05	-0.14	-0.15	Diastolic blood pressure;	chr4:119229001	chr4:119440561~119450157:-
BRCA	cis	rs6570726	0.818	rs437978	ENSG00000270638.1	RP3-466P17.1	5	6.87e-07	7.21e-05	0.17	0.15	Lobe attachment (rater-scored or self-reported);	chr6:145487998	chr6:145735570~145737218:+
BRCA	cis	rs7226408	0.857	rs9675466	ENSG00000267707.2	RP11-95O2.5	5	6.87e-07	7.22e-05	0.23	0.15	Obesity-related traits;	chr18:36922829	chr18:37243776~37247506:+
BRCA	cis	rs12612619	0.732	rs11897106	ENSG00000229122.1	AGBL5-IT1	-5	6.87e-07	7.22e-05	-0.16	-0.15	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:26973431	chr2:27061038~27061815:+
BRCA	cis	rs6847067	0.965	rs67045782	ENSG00000180769.7	WDFY3-AS2	5	6.88e-07	7.22e-05	0.14	0.15	Oropharynx cancer;	chr4:84859429	chr4:84965682~85011277:+
BRCA	cis	rs7914558	0.966	rs10786745	ENSG00000236937.2	PTGES3P4	5	6.88e-07	7.22e-05	0.2	0.15	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103197070	chr10:102845595~102845950:+
BRCA	cis	rs17685	0.753	rs2286830	ENSG00000280388.1	RP11-229D13.3	5	6.88e-07	7.22e-05	0.16	0.15	Coffee consumption (cups per day);Coffee consumption;	chr7:76064645	chr7:76043977~76045963:-
BRCA	cis	rs62184315	0.536	rs5742985	ENSG00000253559.1	OSGEPL1-AS1	-5	6.88e-07	7.23e-05	-0.27	-0.15	Alcohol dependence (age at onset);	chr2:189796383	chr2:189762704~189765556:+
BRCA	cis	rs2732480	0.5	rs7315820	ENSG00000226413.2	OR8T1P	5	6.89e-07	7.23e-05	0.21	0.15	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48205155	chr12:48442030~48442947:-
BRCA	cis	rs9473147	0.843	rs7772202	ENSG00000270761.1	RP11-385F7.1	-5	6.89e-07	7.23e-05	-0.16	-0.15	Platelet distribution width;Mean platelet volume;	chr6:47653843	chr6:47477243~47477572:-
BRCA	cis	rs801193	0.569	rs3846973	ENSG00000236529.1	RP13-254B10.1	-5	6.89e-07	7.23e-05	-0.17	-0.15	Aortic root size;	chr7:66655048	chr7:65840212~65840596:+
BRCA	cis	rs11009175	0.725	rs10827170	ENSG00000273038.2	RP11-479G22.8	5	6.89e-07	7.23e-05	0.22	0.15	Depression (quantitative trait);	chr10:33001415	chr10:32887255~32889311:-
BRCA	cis	rs7267979	0.844	rs6083851	ENSG00000125804.12	FAM182A	5	6.89e-07	7.23e-05	0.2	0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25420599	chr20:26054655~26086917:+
BRCA	cis	rs6442522	0.772	rs2278962	ENSG00000249786.6	EAF1-AS1	5	6.89e-07	7.23e-05	0.15	0.15	Uric acid levels;	chr3:15451279	chr3:15436171~15455940:-
BRCA	cis	rs3733585	0.579	rs4235356	ENSG00000250413.1	RP11-448G15.1	5	6.89e-07	7.23e-05	0.21	0.15	Cleft plate (environmental tobacco smoke interaction);	chr4:10121482	chr4:10006482~10009725:+
BRCA	cis	rs4718428	0.705	rs13231140	ENSG00000229180.5	GS1-124K5.11	5	6.89e-07	7.23e-05	0.15	0.15	Corneal structure;	chr7:66896631	chr7:66526088~66542624:-
BRCA	cis	rs4908769	0.66	rs13596	ENSG00000270282.1	RP5-1115A15.2	-5	6.89e-07	7.23e-05	-0.18	-0.15	Allergy;	chr1:8361143	chr1:8512653~8513021:+
BRCA	cis	rs6490294	0.528	rs12423268	ENSG00000226469.1	ADAM1B	5	6.89e-07	7.24e-05	0.27	0.15	Mean platelet volume;	chr12:112203903	chr12:111927018~111929017:+
BRCA	cis	rs9467773	0.62	rs9467810	ENSG00000124549.13	BTN2A3P	5	6.89e-07	7.24e-05	0.15	0.15	Intelligence (multi-trait analysis);	chr6:26608033	chr6:26421391~26432383:+
BRCA	cis	rs1722141	0.669	rs788736	ENSG00000237471.1	AC073115.6	-4.99	6.9e-07	7.24e-05	-0.2	-0.15	Sitting height ratio;	chr7:45990601	chr7:45969657~45980191:+
BRCA	cis	rs6545883	0.895	rs2256617	ENSG00000270820.4	RP11-355B11.2	4.99	6.9e-07	7.24e-05	0.18	0.15	Tuberculosis;	chr2:61452789	chr2:61471188~61484130:+
BRCA	cis	rs9840812	0.577	rs503973	ENSG00000239213.4	NCK1-AS1	-4.99	6.9e-07	7.24e-05	-0.2	-0.15	Fibrinogen levels;	chr3:136340695	chr3:136841726~136862054:-
BRCA	cis	rs1009647	1	rs1890256	ENSG00000258413.1	RP11-665C16.6	-4.99	6.91e-07	7.25e-05	-0.21	-0.15	Testicular germ cell tumor;	chr14:55414558	chr14:55262767~55272075:-
BRCA	cis	rs6840360	0.557	rs1143036	ENSG00000278978.1	RP11-164P12.5	-4.99	6.91e-07	7.25e-05	-0.17	-0.15	Intelligence (multi-trait analysis);	chr4:151408252	chr4:151669786~151670503:+
BRCA	cis	rs2562456	0.917	rs6511253	ENSG00000268535.1	RP11-420K14.3	-4.99	6.91e-07	7.25e-05	-0.21	-0.15	Pain;	chr19:21495996	chr19:21709522~21710191:+
BRCA	cis	rs1005277	0.579	rs2749612	ENSG00000263064.2	RP11-291L22.7	4.99	6.91e-07	7.25e-05	0.19	0.15	Extrinsic epigenetic age acceleration;	chr10:38199682	chr10:38448689~38448949:+
BRCA	cis	rs12477438	0.765	rs1115757	ENSG00000231822.1	AC019097.7	-4.99	6.91e-07	7.25e-05	-0.17	-0.15	Chronic sinus infection;	chr2:99043683	chr2:99102018~99102752:+
BRCA	cis	rs12477438	0.765	rs7340412	ENSG00000231822.1	AC019097.7	-4.99	6.91e-07	7.25e-05	-0.17	-0.15	Chronic sinus infection;	chr2:99044685	chr2:99102018~99102752:+
BRCA	cis	rs12477438	0.684	rs6756880	ENSG00000231822.1	AC019097.7	-4.99	6.91e-07	7.25e-05	-0.17	-0.15	Chronic sinus infection;	chr2:99060528	chr2:99102018~99102752:+
BRCA	cis	rs12477438	0.765	rs6750876	ENSG00000231822.1	AC019097.7	-4.99	6.91e-07	7.25e-05	-0.17	-0.15	Chronic sinus infection;	chr2:99063210	chr2:99102018~99102752:+
BRCA	cis	rs12477438	0.765	rs6754843	ENSG00000231822.1	AC019097.7	-4.99	6.91e-07	7.25e-05	-0.17	-0.15	Chronic sinus infection;	chr2:99064022	chr2:99102018~99102752:+
BRCA	cis	rs12477438	0.765	rs6737257	ENSG00000231822.1	AC019097.7	-4.99	6.91e-07	7.25e-05	-0.17	-0.15	Chronic sinus infection;	chr2:99066867	chr2:99102018~99102752:+
BRCA	cis	rs1043099	0.536	rs9620979	ENSG00000279699.1	RP1-102K2.9	-4.99	6.91e-07	7.26e-05	-0.2	-0.15	Rheumatoid arthritis;	chr22:30412763	chr22:30275215~30276951:-
BRCA	cis	rs42490	0.51	rs13278061	ENSG00000251136.7	RP11-37B2.1	-4.99	6.91e-07	7.26e-05	-0.15	-0.15	Leprosy;	chr8:89686032	chr8:89609409~89757727:-
BRCA	cis	rs875971	0.965	rs9969301	ENSG00000223473.2	GS1-124K5.3	-4.99	6.92e-07	7.26e-05	-0.12	-0.15	Aortic root size;	chr7:66316668	chr7:66491049~66493566:-
BRCA	cis	rs1167827	0.71	rs1167836	ENSG00000223705.8	NSUN5P1	4.99	6.92e-07	7.26e-05	0.12	0.15	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75539580	chr7:75410322~75416787:+
BRCA	cis	rs1223397	0.651	rs59639740	ENSG00000215022.6	RP1-257A7.4	-4.99	6.92e-07	7.26e-05	-0.18	-0.15	Blood pressure;	chr6:13310663	chr6:13264861~13295586:-
BRCA	cis	rs1223397	0.651	rs957175	ENSG00000215022.6	RP1-257A7.4	-4.99	6.92e-07	7.26e-05	-0.18	-0.15	Blood pressure;	chr6:13311011	chr6:13264861~13295586:-
BRCA	cis	rs1223397	0.617	rs957176	ENSG00000215022.6	RP1-257A7.4	-4.99	6.92e-07	7.26e-05	-0.18	-0.15	Blood pressure;	chr6:13311294	chr6:13264861~13295586:-
BRCA	cis	rs2732480	0.5	rs11168464	ENSG00000226413.2	OR8T1P	4.99	6.92e-07	7.26e-05	0.21	0.15	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48208332	chr12:48442030~48442947:-
BRCA	cis	rs12744310	0.887	rs12045979	ENSG00000235358.1	RP11-399E6.1	4.99	6.92e-07	7.27e-05	0.23	0.15	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41343805	chr1:41242373~41284861:+
BRCA	cis	rs4072980	0.545	rs10890285	ENSG00000212541.1	RNU6-510P	4.99	6.93e-07	7.27e-05	0.2	0.15	Coronary artery disease;	chr1:37987904	chr1:37991462~37991569:+
BRCA	cis	rs74233809	0.636	rs284861	ENSG00000213277.3	MARCKSL1P1	-4.99	6.93e-07	7.27e-05	-0.23	-0.15	Birth weight;	chr10:102812519	chr10:103175554~103176094:+
BRCA	cis	rs2562456	0.876	rs62110163	ENSG00000268535.1	RP11-420K14.3	4.99	6.93e-07	7.27e-05	0.21	0.15	Pain;	chr19:21546020	chr19:21709522~21710191:+
BRCA	cis	rs2562456	0.761	rs35008138	ENSG00000268535.1	RP11-420K14.3	4.99	6.93e-07	7.27e-05	0.21	0.15	Pain;	chr19:21548822	chr19:21709522~21710191:+
BRCA	cis	rs2562456	0.833	rs2681388	ENSG00000268535.1	RP11-420K14.3	4.99	6.93e-07	7.27e-05	0.21	0.15	Pain;	chr19:21549451	chr19:21709522~21710191:+
BRCA	cis	rs2562456	0.876	rs2681370	ENSG00000268535.1	RP11-420K14.3	4.99	6.93e-07	7.27e-05	0.21	0.15	Pain;	chr19:21554036	chr19:21709522~21710191:+
BRCA	cis	rs2562456	0.876	rs11668606	ENSG00000268535.1	RP11-420K14.3	4.99	6.93e-07	7.27e-05	0.21	0.15	Pain;	chr19:21554618	chr19:21709522~21710191:+
BRCA	cis	rs2562456	0.876	rs2681395	ENSG00000268535.1	RP11-420K14.3	4.99	6.93e-07	7.27e-05	0.21	0.15	Pain;	chr19:21555338	chr19:21709522~21710191:+
BRCA	cis	rs2638953	0.85	rs61920210	ENSG00000247934.4	RP11-967K21.1	-4.99	6.93e-07	7.27e-05	-0.21	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28144951	chr12:28163298~28190738:-
BRCA	cis	rs1075265	0.87	rs17268179	ENSG00000235937.1	AC008280.1	4.99	6.93e-07	7.27e-05	0.17	0.15	Chronotype;Morning vs. evening chronotype;	chr2:54036876	chr2:54029552~54030682:-
BRCA	cis	rs9907295	0.71	rs4796113	ENSG00000271013.1	AC015849.15	-4.99	6.93e-07	7.27e-05	-0.25	-0.15	Fibroblast growth factor basic levels;	chr17:35832562	chr17:35912635~35918010:-
BRCA	cis	rs7111546	0.584	rs7950255	ENSG00000246225.5	RP11-17A1.3	4.99	6.93e-07	7.27e-05	0.26	0.15	Dialysis-related mortality;	chr11:22894368	chr11:22829380~22945393:+
BRCA	cis	rs12477438	0.572	rs10170063	ENSG00000231822.1	AC019097.7	-4.99	6.93e-07	7.27e-05	-0.17	-0.15	Chronic sinus infection;	chr2:99039176	chr2:99102018~99102752:+
BRCA	cis	rs12477438	0.561	rs2084988	ENSG00000231822.1	AC019097.7	-4.99	6.93e-07	7.27e-05	-0.17	-0.15	Chronic sinus infection;	chr2:99039292	chr2:99102018~99102752:+
BRCA	cis	rs12477438	0.765	rs6735801	ENSG00000231822.1	AC019097.7	-4.99	6.93e-07	7.27e-05	-0.17	-0.15	Chronic sinus infection;	chr2:99041532	chr2:99102018~99102752:+
BRCA	cis	rs6840360	0.642	rs11099819	ENSG00000278978.1	RP11-164P12.5	-4.99	6.94e-07	7.28e-05	-0.17	-0.15	Intelligence (multi-trait analysis);	chr4:151509026	chr4:151669786~151670503:+
BRCA	cis	rs6840360	0.607	rs6815320	ENSG00000278978.1	RP11-164P12.5	-4.99	6.94e-07	7.28e-05	-0.17	-0.15	Intelligence (multi-trait analysis);	chr4:151511348	chr4:151669786~151670503:+
BRCA	cis	rs6840360	0.642	rs11726254	ENSG00000278978.1	RP11-164P12.5	-4.99	6.94e-07	7.28e-05	-0.17	-0.15	Intelligence (multi-trait analysis);	chr4:151517698	chr4:151669786~151670503:+
BRCA	cis	rs848490	0.546	rs7384722	ENSG00000214293.7	APTR	4.99	6.94e-07	7.28e-05	0.17	0.15	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77646106	chr7:77657660~77696265:-
BRCA	cis	rs6756513	0.5	rs2278933	ENSG00000231024.1	AC092431.3	-4.99	6.94e-07	7.28e-05	-0.22	-0.15	Breast cancer;Platelet count;	chr2:69829233	chr2:69700192~69713847:-
BRCA	cis	rs10129255	1	rs61997605	ENSG00000211974.3	IGHV2-70	4.99	6.94e-07	7.28e-05	0.16	0.15	Kawasaki disease;	chr14:106678368	chr14:106723574~106724093:-
BRCA	cis	rs2832191	0.791	rs2832179	ENSG00000176054.6	RPL23P2	-4.99	6.94e-07	7.28e-05	-0.16	-0.15	Dental caries;	chr21:29108045	chr21:28997613~28998033:-
BRCA	cis	rs2832191	0.791	rs4817270	ENSG00000176054.6	RPL23P2	-4.99	6.94e-07	7.28e-05	-0.16	-0.15	Dental caries;	chr21:29108047	chr21:28997613~28998033:-
BRCA	cis	rs66887589	0.616	rs6822808	ENSG00000249244.1	RP11-548H18.2	4.99	6.94e-07	7.28e-05	0.17	0.15	Diastolic blood pressure;	chr4:119296210	chr4:119391831~119395335:-
BRCA	cis	rs2638953	0.962	rs12371059	ENSG00000247934.4	RP11-967K21.1	-4.99	6.94e-07	7.28e-05	-0.22	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28375375	chr12:28163298~28190738:-
BRCA	cis	rs7914558	0.933	rs2066323	ENSG00000236937.2	PTGES3P4	4.99	6.94e-07	7.28e-05	0.2	0.15	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103111604	chr10:102845595~102845950:+
BRCA	cis	rs11168618	1	rs11168621	ENSG00000240399.1	RP1-228P16.1	4.99	6.94e-07	7.28e-05	0.17	0.15	Adiponectin levels;	chr12:48545188	chr12:48054813~48055591:-
BRCA	cis	rs7818688	0.653	rs16893774	ENSG00000253528.2	RP11-347C18.4	4.99	6.94e-07	7.28e-05	0.21	0.15	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94883748	chr8:94974573~94974853:-
BRCA	cis	rs1862618	0.671	rs2591958	ENSG00000271828.1	CTD-2310F14.1	-4.99	6.94e-07	7.28e-05	-0.19	-0.15	Initial pursuit acceleration;	chr5:56943542	chr5:56927874~56929573:+
BRCA	cis	rs7914558	0.932	rs4307650	ENSG00000236937.2	PTGES3P4	4.99	6.95e-07	7.28e-05	0.2	0.15	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103200095	chr10:102845595~102845950:+
BRCA	cis	rs13113518	1	rs4864546	ENSG00000249700.7	SRD5A3-AS1	4.99	6.95e-07	7.29e-05	0.19	0.15	Height;	chr4:55537960	chr4:55363971~55395847:-
BRCA	cis	rs2638953	0.889	rs10843155	ENSG00000247934.4	RP11-967K21.1	-4.99	6.95e-07	7.29e-05	-0.21	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28334920	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.889	rs11049538	ENSG00000247934.4	RP11-967K21.1	-4.99	6.95e-07	7.29e-05	-0.21	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28335801	chr12:28163298~28190738:-
BRCA	cis	rs9307551	0.584	rs1115518	ENSG00000250334.4	LINC00989	-4.99	6.95e-07	7.29e-05	-0.21	-0.15	Refractive error;	chr4:79491423	chr4:79492416~79576460:+
BRCA	cis	rs4763879	0.634	rs2012643	ENSG00000278635.1	CTD-2318O12.1	4.99	6.95e-07	7.29e-05	0.15	0.15	Type 1 diabetes;	chr12:9707128	chr12:9415641~9416718:+
BRCA	cis	rs78487399	0.908	rs4339008	ENSG00000234936.1	AC010883.5	4.99	6.96e-07	7.3e-05	0.19	0.15	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43607213	chr2:43229573~43233394:+
BRCA	cis	rs7839435	1	rs11780592	ENSG00000234770.1	GULOP	-4.99	6.96e-07	7.3e-05	-0.21	-0.15	Lung adenocarcinoma;	chr8:27561230	chr8:27560274~27589073:+
BRCA	cis	rs4683346	0.523	rs12491179	ENSG00000173811.9	CCDC13-AS1	-4.99	6.96e-07	7.3e-05	-0.23	-0.15	Granulocyte percentage of myeloid white cells;	chr3:42732470	chr3:42732575~42746768:+
BRCA	cis	rs17818399	0.781	rs12105006	ENSG00000279254.1	RP11-536C12.1	4.99	6.96e-07	7.3e-05	0.2	0.15	Height;	chr2:46635447	chr2:46668870~46670778:+
BRCA	cis	rs77972916	0.611	rs6709988	ENSG00000234936.1	AC010883.5	4.99	6.96e-07	7.3e-05	0.18	0.15	Granulocyte percentage of myeloid white cells;	chr2:43374178	chr2:43229573~43233394:+
BRCA	cis	rs897984	0.568	rs72799330	ENSG00000260911.2	RP11-196G11.2	4.99	6.96e-07	7.3e-05	0.16	0.15	Dementia with Lewy bodies;	chr16:30882234	chr16:31043150~31049868:+
BRCA	cis	rs6569038	0.502	rs57285368	ENSG00000253194.1	RP11-351A11.1	4.99	6.96e-07	7.3e-05	0.19	0.15	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr6:118993517	chr6:118934785~119031541:+
BRCA	cis	rs6840360	0.642	rs2724568	ENSG00000251611.1	RP11-610P16.1	-4.99	6.96e-07	7.3e-05	-0.13	-0.15	Intelligence (multi-trait analysis);	chr4:151431071	chr4:151407551~151408835:-
BRCA	cis	rs7809950	0.637	rs2701685	ENSG00000238832.1	snoU109	4.99	6.97e-07	7.31e-05	0.2	0.15	Coronary artery disease;	chr7:107659139	chr7:107603363~107603507:+
BRCA	cis	rs10540	1	rs35898083	ENSG00000279672.1	CMB9-55F22.1	4.99	6.97e-07	7.31e-05	0.27	0.15	Body mass index;	chr11:484469	chr11:779617~780755:+
BRCA	cis	rs10844706	0.699	rs11052717	ENSG00000214776.8	RP11-726G1.1	4.99	6.97e-07	7.31e-05	0.19	0.15	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9726217	chr12:9467552~9576275:+
BRCA	cis	rs6452524	0.618	rs6867727	ENSG00000281327.1	LINC01338	4.99	6.98e-07	7.31e-05	0.17	0.15	Hypertension (SNP x SNP interaction);	chr5:83061333	chr5:82850864~82859836:-
BRCA	cis	rs6452524	0.618	rs7723639	ENSG00000281327.1	LINC01338	4.99	6.98e-07	7.31e-05	0.17	0.15	Hypertension (SNP x SNP interaction);	chr5:83062610	chr5:82850864~82859836:-
BRCA	cis	rs6452524	0.618	rs2306336	ENSG00000281327.1	LINC01338	4.99	6.98e-07	7.31e-05	0.17	0.15	Hypertension (SNP x SNP interaction);	chr5:83064964	chr5:82850864~82859836:-
BRCA	cis	rs6570726	0.526	rs9376928	ENSG00000235652.6	RP11-545I5.3	-4.99	6.98e-07	7.32e-05	-0.15	-0.15	Lobe attachment (rater-scored or self-reported);	chr6:145403267	chr6:145799409~145886585:+
BRCA	cis	rs4835473	0.932	rs1988206	ENSG00000249741.2	RP11-673E1.3	-4.99	6.98e-07	7.32e-05	-0.16	-0.15	Immature fraction of reticulocytes;	chr4:143991344	chr4:143911514~143912053:-
BRCA	cis	rs10129255	0.957	rs7493713	ENSG00000211974.3	IGHV2-70	4.99	6.98e-07	7.32e-05	0.15	0.15	Kawasaki disease;	chr14:106783685	chr14:106723574~106724093:-
BRCA	cis	rs10129255	0.912	rs35468694	ENSG00000211974.3	IGHV2-70	4.99	6.98e-07	7.32e-05	0.15	0.15	Kawasaki disease;	chr14:106784199	chr14:106723574~106724093:-
BRCA	cis	rs6723226	0.721	rs3769600	ENSG00000276517.1	AL133243.2	4.99	6.98e-07	7.32e-05	0.18	0.15	Intelligence (multi-trait analysis);	chr2:32391811	chr2:32526504~32529507:+
BRCA	cis	rs7811142	0.943	rs3900792	ENSG00000078319.8	PMS2P1	-4.99	6.98e-07	7.32e-05	-0.24	-0.15	Platelet count;	chr7:100406954	chr7:100320992~100341908:-
BRCA	cis	rs7923837	0.687	rs10882102	ENSG00000236493.2	EIF2S2P3	4.99	6.99e-07	7.32e-05	0.19	0.15	Multiple sclerosis;Body mass index;	chr10:92706738	chr10:92668745~92669743:-
BRCA	cis	rs2255336	0.938	rs1382265	ENSG00000245648.1	RP11-277P12.20	4.99	6.99e-07	7.33e-05	0.22	0.15	Blood protein levels;	chr12:10381206	chr12:10363769~10398506:+
BRCA	cis	rs7772486	0.875	rs9403765	ENSG00000270638.1	RP3-466P17.1	-4.99	6.99e-07	7.33e-05	-0.17	-0.15	Lobe attachment (rater-scored or self-reported);	chr6:146046905	chr6:145735570~145737218:+
BRCA	cis	rs12817211	0.549	rs6580728	ENSG00000272368.2	RP4-605O3.4	-4.99	6.99e-07	7.33e-05	-0.15	-0.15	Colorectal or endometrial cancer;	chr12:50147344	chr12:50112197~50165618:+
BRCA	cis	rs2243480	1	rs4149468	ENSG00000222364.1	RNU6-96P	-4.99	7e-07	7.33e-05	-0.28	-0.15	Diabetic kidney disease;	chr7:66360703	chr7:66395191~66395286:+
BRCA	cis	rs7572733	0.534	rs700674	ENSG00000231621.1	AC013264.2	-4.99	7e-07	7.34e-05	-0.15	-0.15	Dermatomyositis;	chr2:197828979	chr2:197197991~197199273:+
BRCA	cis	rs6569038	0.502	rs794264	ENSG00000253194.1	RP11-351A11.1	4.99	7e-07	7.34e-05	0.19	0.15	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr6:119001257	chr6:118934785~119031541:+
BRCA	cis	rs6569038	0.502	rs794263	ENSG00000253194.1	RP11-351A11.1	4.99	7e-07	7.34e-05	0.19	0.15	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr6:119001303	chr6:118934785~119031541:+
BRCA	cis	rs7572733	0.515	rs700675	ENSG00000231621.1	AC013264.2	-4.99	7e-07	7.34e-05	-0.15	-0.15	Dermatomyositis;	chr2:197835492	chr2:197197991~197199273:+
BRCA	cis	rs801193	0.569	rs2659907	ENSG00000236529.1	RP13-254B10.1	4.99	7e-07	7.34e-05	0.17	0.15	Aortic root size;	chr7:66699045	chr7:65840212~65840596:+
BRCA	cis	rs7191700	0.601	rs243329	ENSG00000262636.1	CTD-3088G3.4	4.99	7.01e-07	7.34e-05	0.2	0.15	Multiple sclerosis;	chr16:11258456	chr16:11380859~11381118:-
BRCA	cis	rs875971	0.862	rs949930	ENSG00000236529.1	RP13-254B10.1	-4.99	7.01e-07	7.34e-05	-0.17	-0.15	Aortic root size;	chr7:66301835	chr7:65840212~65840596:+
BRCA	cis	rs1707322	1	rs6671754	ENSG00000234329.1	RP11-767N6.2	4.99	7.01e-07	7.35e-05	0.16	0.15	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45968318	chr1:45651039~45651826:-
BRCA	cis	rs1707322	0.963	rs6666763	ENSG00000234329.1	RP11-767N6.2	4.99	7.01e-07	7.35e-05	0.16	0.15	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45970779	chr1:45651039~45651826:-
BRCA	cis	rs1707322	1	rs4489497	ENSG00000234329.1	RP11-767N6.2	4.99	7.01e-07	7.35e-05	0.16	0.15	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45973026	chr1:45651039~45651826:-
BRCA	cis	rs1707322	1	rs11211235	ENSG00000234329.1	RP11-767N6.2	4.99	7.01e-07	7.35e-05	0.16	0.15	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45974703	chr1:45651039~45651826:-
BRCA	cis	rs1707322	0.893	rs9919275	ENSG00000234329.1	RP11-767N6.2	4.99	7.01e-07	7.35e-05	0.16	0.15	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45975688	chr1:45651039~45651826:-
BRCA	cis	rs1707322	1	rs11211236	ENSG00000234329.1	RP11-767N6.2	4.99	7.01e-07	7.35e-05	0.16	0.15	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45978095	chr1:45651039~45651826:-
BRCA	cis	rs1707322	1	rs4660328	ENSG00000234329.1	RP11-767N6.2	4.99	7.01e-07	7.35e-05	0.16	0.15	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45979159	chr1:45651039~45651826:-
BRCA	cis	rs1707322	0.928	rs61785614	ENSG00000234329.1	RP11-767N6.2	4.99	7.01e-07	7.35e-05	0.16	0.15	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45980375	chr1:45651039~45651826:-
BRCA	cis	rs1707322	1	rs9793167	ENSG00000234329.1	RP11-767N6.2	4.99	7.01e-07	7.35e-05	0.16	0.15	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45981128	chr1:45651039~45651826:-
BRCA	cis	rs1707322	1	rs11211237	ENSG00000234329.1	RP11-767N6.2	4.99	7.01e-07	7.35e-05	0.16	0.15	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45981657	chr1:45651039~45651826:-
BRCA	cis	rs1707322	0.963	rs11211238	ENSG00000234329.1	RP11-767N6.2	4.99	7.01e-07	7.35e-05	0.16	0.15	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45983743	chr1:45651039~45651826:-
BRCA	cis	rs1707322	1	rs4460583	ENSG00000234329.1	RP11-767N6.2	4.99	7.01e-07	7.35e-05	0.16	0.15	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45984246	chr1:45651039~45651826:-
BRCA	cis	rs1707322	0.963	rs4459051	ENSG00000234329.1	RP11-767N6.2	4.99	7.01e-07	7.35e-05	0.16	0.15	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45985531	chr1:45651039~45651826:-
BRCA	cis	rs1707322	1	rs11211239	ENSG00000234329.1	RP11-767N6.2	4.99	7.01e-07	7.35e-05	0.16	0.15	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45986275	chr1:45651039~45651826:-
BRCA	cis	rs11098499	0.754	rs1546503	ENSG00000260404.2	RP11-384K6.6	4.99	7.01e-07	7.35e-05	0.14	0.15	Corneal astigmatism;	chr4:119320012	chr4:118591773~118633729:+
BRCA	cis	rs9907295	0.818	rs3785764	ENSG00000271013.1	AC015849.15	-4.99	7.01e-07	7.35e-05	-0.25	-0.15	Fibroblast growth factor basic levels;	chr17:35833760	chr17:35912635~35918010:-
BRCA	cis	rs9287719	0.674	rs10929690	ENSG00000243819.4	RN7SL832P	-4.99	7.01e-07	7.35e-05	-0.15	-0.15	Prostate cancer;	chr2:10665848	chr2:10690344~10692099:+
BRCA	cis	rs1910358	0.664	rs10036373	ENSG00000248874.4	C5orf17	-4.99	7.01e-07	7.35e-05	-0.2	-0.15	Venous thromboembolism (SNP x SNP interaction);	chr5:23909810	chr5:23951348~24178263:+
BRCA	cis	rs2274273	0.682	rs1201378	ENSG00000258413.1	RP11-665C16.6	4.99	7.01e-07	7.35e-05	0.19	0.15	Protein biomarker;	chr14:55026690	chr14:55262767~55272075:-
BRCA	cis	rs6452524	0.589	rs6882386	ENSG00000281327.1	LINC01338	4.99	7.01e-07	7.35e-05	0.17	0.15	Hypertension (SNP x SNP interaction);	chr5:83065555	chr5:82850864~82859836:-
BRCA	cis	rs6452524	0.618	rs6860752	ENSG00000281327.1	LINC01338	4.99	7.01e-07	7.35e-05	0.17	0.15	Hypertension (SNP x SNP interaction);	chr5:83065587	chr5:82850864~82859836:-
BRCA	cis	rs1864585	0.806	rs17778223	ENSG00000248896.2	CTD-2135J3.3	4.99	7.01e-07	7.35e-05	0.2	0.15	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr8:10872182	chr8:10729314~10771392:+
BRCA	cis	rs7200543	0.961	rs3803573	ENSG00000258354.1	MIR3180-1	-4.99	7.01e-07	7.35e-05	-0.2	-0.15	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15044556	chr16:14909887~14911345:-
BRCA	cis	rs2832191	0.933	rs2832236	ENSG00000236056.1	GAPDHP14	4.99	7.01e-07	7.35e-05	0.17	0.15	Dental caries;	chr21:29175281	chr21:29222321~29223257:+
BRCA	cis	rs17507216	1	rs3850610	ENSG00000255769.6	GOLGA2P10	4.99	7.02e-07	7.35e-05	0.19	0.15	Excessive daytime sleepiness;	chr15:82552642	chr15:82472993~82513950:-
BRCA	cis	rs11089937	0.616	rs6001227	ENSG00000211638.2	IGLV8-61	-4.99	7.02e-07	7.35e-05	-0.15	-0.15	Periodontitis (PAL4Q3);	chr22:22187099	chr22:22098700~22099212:+
BRCA	cis	rs721917	0.506	rs2758539	ENSG00000242600.5	MBL1P	4.99	7.02e-07	7.35e-05	0.18	0.15	Chronic obstructive pulmonary disease;	chr10:79894680	chr10:79904898~79950336:+
BRCA	cis	rs4237845	0.78	rs3751331	ENSG00000257159.1	RP11-58A17.3	4.99	7.02e-07	7.35e-05	0.18	0.15	Intelligence (multi-trait analysis);	chr12:57896495	chr12:57967058~57968399:+
BRCA	cis	rs2278702	0.622	rs3848200	ENSG00000259495.2	RP11-210M15.2	-4.99	7.02e-07	7.35e-05	-0.25	-0.15	Bipolar disorder;	chr15:80350581	chr15:80344853~80403575:-
BRCA	cis	rs2790457	0.795	rs7903703	ENSG00000254635.4	WAC-AS1	-4.99	7.02e-07	7.35e-05	-0.19	-0.15	Multiple myeloma;	chr10:28646220	chr10:28522652~28532743:-
BRCA	cis	rs8114671	0.562	rs2378294	ENSG00000269202.1	RP4-614O4.12	-4.99	7.02e-07	7.36e-05	-0.15	-0.15	Height;	chr20:34912575	chr20:35201747~35203288:-
BRCA	cis	rs1707322	1	rs785465	ENSG00000234329.1	RP11-767N6.2	4.99	7.03e-07	7.36e-05	0.16	0.15	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46056905	chr1:45651039~45651826:-
BRCA	cis	rs8098244	0.557	rs12954712	ENSG00000264745.1	TTC39C-AS1	4.99	7.03e-07	7.36e-05	0.18	0.15	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23707144	chr18:23994213~24015339:-
BRCA	cis	rs2179367	0.632	rs11155649	ENSG00000268592.3	RAET1E-AS1	4.99	7.03e-07	7.37e-05	0.22	0.15	Dupuytren's disease;	chr6:149405830	chr6:149863494~149919507:+
BRCA	cis	rs875971	0.862	rs778736	ENSG00000273448.1	RP11-166O4.6	4.99	7.03e-07	7.37e-05	0.14	0.15	Aortic root size;	chr7:66348861	chr7:67333047~67334383:+
BRCA	cis	rs11124272	0.67	rs206843	ENSG00000272716.1	RP11-563N4.1	4.99	7.04e-07	7.37e-05	0.18	0.15	Interleukin-18 levels;	chr2:31496262	chr2:32165046~32165757:-
BRCA	cis	rs1322639	1	rs1322639	ENSG00000223485.1	RP11-417E7.1	4.99	7.04e-07	7.37e-05	0.18	0.15	Pulse pressure;	chr6:169187008	chr6:169158092~169162924:-
BRCA	cis	rs4835473	0.639	rs28674022	ENSG00000249741.2	RP11-673E1.3	-4.99	7.04e-07	7.37e-05	-0.16	-0.15	Immature fraction of reticulocytes;	chr4:143966409	chr4:143911514~143912053:-
BRCA	cis	rs4835473	0.864	rs28423022	ENSG00000249741.2	RP11-673E1.3	-4.99	7.04e-07	7.37e-05	-0.16	-0.15	Immature fraction of reticulocytes;	chr4:143966416	chr4:143911514~143912053:-
BRCA	cis	rs4835473	0.864	rs35888177	ENSG00000249741.2	RP11-673E1.3	-4.99	7.04e-07	7.37e-05	-0.16	-0.15	Immature fraction of reticulocytes;	chr4:143966863	chr4:143911514~143912053:-
BRCA	cis	rs4835473	0.932	rs10033382	ENSG00000249741.2	RP11-673E1.3	-4.99	7.04e-07	7.37e-05	-0.16	-0.15	Immature fraction of reticulocytes;	chr4:143967103	chr4:143911514~143912053:-
BRCA	cis	rs9287719	0.967	rs7563816	ENSG00000243819.4	RN7SL832P	4.99	7.04e-07	7.37e-05	0.15	0.15	Prostate cancer;	chr2:10623274	chr2:10690344~10692099:+
BRCA	cis	rs7246657	0.722	rs1531549	ENSG00000276846.1	CTD-3220F14.3	4.99	7.04e-07	7.38e-05	0.21	0.15	Coronary artery calcification;	chr19:37597108	chr19:37314868~37315620:-
BRCA	cis	rs783540	0.5	rs7178459	ENSG00000255769.6	GOLGA2P10	-4.99	7.04e-07	7.38e-05	-0.2	-0.15	Schizophrenia;	chr15:82729632	chr15:82472993~82513950:-
BRCA	cis	rs9921338	1	rs9921338	ENSG00000262703.1	RP11-485G7.6	4.99	7.04e-07	7.38e-05	0.18	0.15	Vein graft stenosis in coronary artery bypass grafting;	chr16:11322982	chr16:11348143~11349321:-
BRCA	cis	rs17495987	0.75	rs2348766	ENSG00000219545.8	UMAD1	4.99	7.05e-07	7.38e-05	0.21	0.15	Tonsillectomy;	chr7:7863972	chr7:7640711~8004059:+
BRCA	cis	rs6840360	0.642	rs2709838	ENSG00000251611.1	RP11-610P16.1	-4.99	7.05e-07	7.38e-05	-0.13	-0.15	Intelligence (multi-trait analysis);	chr4:151450212	chr4:151407551~151408835:-
BRCA	cis	rs77972916	0.536	rs6751209	ENSG00000234936.1	AC010883.5	4.99	7.05e-07	7.38e-05	0.17	0.15	Granulocyte percentage of myeloid white cells;	chr2:43361163	chr2:43229573~43233394:+
BRCA	cis	rs7772486	0.713	rs2328704	ENSG00000270638.1	RP3-466P17.1	-4.99	7.05e-07	7.39e-05	-0.17	-0.15	Lobe attachment (rater-scored or self-reported);	chr6:145699358	chr6:145735570~145737218:+
BRCA	cis	rs2179367	0.959	rs9373592	ENSG00000268592.3	RAET1E-AS1	4.99	7.05e-07	7.39e-05	0.2	0.15	Dupuytren's disease;	chr6:149412119	chr6:149863494~149919507:+
BRCA	cis	rs5742933	0.597	rs6756913	ENSG00000253559.1	OSGEPL1-AS1	4.99	7.05e-07	7.39e-05	0.19	0.15	Ferritin levels;	chr2:189641040	chr2:189762704~189765556:+
BRCA	cis	rs1707322	0.964	rs10890358	ENSG00000234329.1	RP11-767N6.2	4.99	7.05e-07	7.39e-05	0.16	0.15	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45853353	chr1:45651039~45651826:-
BRCA	cis	rs7267979	0.789	rs6050472	ENSG00000204556.4	CTD-2514C3.1	-4.99	7.06e-07	7.39e-05	-0.21	-0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25239216	chr20:26018832~26020684:+
BRCA	cis	rs357618	0.897	rs357630	ENSG00000260581.1	CTB-113P19.4	4.99	7.06e-07	7.39e-05	0.17	0.15	Basophil percentage of white cells;	chr5:151471697	chr5:151652275~151655449:+
BRCA	cis	rs875971	1	rs2420168	ENSG00000223473.2	GS1-124K5.3	-4.99	7.06e-07	7.4e-05	-0.12	-0.15	Aortic root size;	chr7:66165644	chr7:66491049~66493566:-
BRCA	cis	rs7200543	1	rs35574015	ENSG00000260735.1	RP11-72I8.1	-4.99	7.07e-07	7.4e-05	-0.18	-0.15	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15052204	chr16:15094411~15109197:+
BRCA	cis	rs875971	0.862	rs2024192	ENSG00000273448.1	RP11-166O4.6	-4.99	7.07e-07	7.4e-05	-0.14	-0.15	Aortic root size;	chr7:66576460	chr7:67333047~67334383:+
BRCA	cis	rs11098499	0.754	rs7672372	ENSG00000249244.1	RP11-548H18.2	4.99	7.07e-07	7.4e-05	0.18	0.15	Corneal astigmatism;	chr4:119327251	chr4:119391831~119395335:-
BRCA	cis	rs801193	0.66	rs10950049	ENSG00000223473.2	GS1-124K5.3	4.99	7.07e-07	7.4e-05	0.12	0.15	Aortic root size;	chr7:66765873	chr7:66491049~66493566:-
BRCA	cis	rs7267979	0.844	rs6083845	ENSG00000277938.1	RP5-965G21.3	-4.99	7.07e-07	7.4e-05	-0.18	-0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25407454	chr20:25229150~25231933:+
BRCA	cis	rs999943	0.81	rs62407648	ENSG00000224557.6	HLA-DPB2	-4.99	7.07e-07	7.41e-05	-0.22	-0.15	Obesity (extreme);	chr6:33654659	chr6:33112451~33129084:+
BRCA	cis	rs6480314	0.542	rs7078967	ENSG00000233590.1	RP11-153K11.3	-4.99	7.07e-07	7.41e-05	-0.25	-0.15	Optic nerve measurement (disc area);	chr10:68266564	chr10:68233251~68242379:-
BRCA	cis	rs1387259	0.929	rs2634666	ENSG00000257735.1	RP11-370I10.6	4.99	7.07e-07	7.41e-05	0.19	0.15	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48269887	chr12:48350945~48442411:+
BRCA	cis	rs1862618	0.671	rs72644088	ENSG00000271828.1	CTD-2310F14.1	-4.99	7.08e-07	7.41e-05	-0.19	-0.15	Initial pursuit acceleration;	chr5:56945192	chr5:56927874~56929573:+
BRCA	cis	rs12477438	0.765	rs7571390	ENSG00000231822.1	AC019097.7	-4.99	7.08e-07	7.41e-05	-0.17	-0.15	Chronic sinus infection;	chr2:99010130	chr2:99102018~99102752:+
BRCA	cis	rs4072705	0.615	rs7028021	ENSG00000224020.1	MIR181A2HG	-4.99	7.08e-07	7.41e-05	-0.18	-0.15	Menarche (age at onset);	chr9:124486743	chr9:124658467~124698631:+
BRCA	cis	rs7577696	0.925	rs212718	ENSG00000272716.1	RP11-563N4.1	4.99	7.08e-07	7.42e-05	0.17	0.15	Inflammatory biomarkers;	chr2:32236764	chr2:32165046~32165757:-
BRCA	cis	rs7615952	0.546	rs11711150	ENSG00000171084.14	FAM86JP	4.99	7.08e-07	7.42e-05	0.26	0.15	Blood pressure (smoking interaction);	chr3:125596819	chr3:125916620~125930024:+
BRCA	cis	rs12497850	0.931	rs7626445	ENSG00000225399.4	RP11-3B7.1	4.99	7.08e-07	7.42e-05	0.15	0.15	Parkinson's disease;	chr3:49077111	chr3:49260085~49261316:+
BRCA	cis	rs8002861	0.902	rs1445557	ENSG00000274001.1	RP11-5G9.5	4.99	7.08e-07	7.42e-05	0.17	0.15	Leprosy;	chr13:43890691	chr13:43877715~43878163:-
BRCA	cis	rs2179367	0.92	rs638407	ENSG00000268592.3	RAET1E-AS1	4.99	7.09e-07	7.42e-05	0.2	0.15	Dupuytren's disease;	chr6:149417214	chr6:149863494~149919507:+
BRCA	cis	rs11051970	0.559	rs11051992	ENSG00000274964.1	RP11-817I4.1	-4.99	7.09e-07	7.42e-05	-0.21	-0.15	Response to tocilizumab in rheumatoid arthritis;	chr12:32411733	chr12:32339368~32340724:+
BRCA	cis	rs6570726	0.791	rs401331	ENSG00000270638.1	RP3-466P17.1	4.99	7.09e-07	7.42e-05	0.18	0.15	Lobe attachment (rater-scored or self-reported);	chr6:145510272	chr6:145735570~145737218:+
BRCA	cis	rs2562456	0.833	rs2968078	ENSG00000268535.1	RP11-420K14.3	-4.99	7.09e-07	7.42e-05	-0.21	-0.15	Pain;	chr19:21458942	chr19:21709522~21710191:+
BRCA	cis	rs2153535	0.526	rs9406179	ENSG00000251164.1	HULC	-4.99	7.09e-07	7.43e-05	-0.19	-0.15	Motion sickness;	chr6:8537991	chr6:8652137~8653846:+
BRCA	cis	rs7267979	0.816	rs405822	ENSG00000125804.12	FAM182A	-4.99	7.1e-07	7.43e-05	-0.2	-0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25520678	chr20:26054655~26086917:+
BRCA	cis	rs7267979	0.816	rs409853	ENSG00000125804.12	FAM182A	-4.99	7.1e-07	7.43e-05	-0.2	-0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25525431	chr20:26054655~26086917:+
BRCA	cis	rs6589563	0.609	rs12280724	ENSG00000278768.1	BACE1-AS	4.99	7.1e-07	7.43e-05	0.22	0.15	Eosinophil counts;	chr11:116742707	chr11:117290874~117293571:+
BRCA	cis	rs875971	0.862	rs709596	ENSG00000236529.1	RP13-254B10.1	4.99	7.1e-07	7.43e-05	0.17	0.15	Aortic root size;	chr7:66360926	chr7:65840212~65840596:+
BRCA	cis	rs2243480	1	rs1873494	ENSG00000222364.1	RNU6-96P	4.99	7.11e-07	7.44e-05	0.28	0.15	Diabetic kidney disease;	chr7:66184912	chr7:66395191~66395286:+
BRCA	cis	rs2243480	1	rs6959002	ENSG00000222364.1	RNU6-96P	4.99	7.11e-07	7.44e-05	0.28	0.15	Diabetic kidney disease;	chr7:66185509	chr7:66395191~66395286:+
BRCA	cis	rs1552244	0.572	rs3894322	ENSG00000232901.1	CYCSP10	4.99	7.11e-07	7.44e-05	0.23	0.15	Alzheimer's disease;	chr3:10127281	chr3:10000647~10000940:-
BRCA	cis	rs1552244	0.572	rs3894323	ENSG00000232901.1	CYCSP10	4.99	7.11e-07	7.44e-05	0.23	0.15	Alzheimer's disease;	chr3:10127283	chr3:10000647~10000940:-
BRCA	cis	rs8127691	1	rs8127691	ENSG00000237604.1	AP001056.1	4.99	7.11e-07	7.44e-05	0.17	0.15	Inflammatory bowel disease;	chr21:44194977	chr21:44175489~44176453:+
BRCA	cis	rs910316	0.763	rs175490	ENSG00000279594.1	RP11-950C14.10	4.99	7.11e-07	7.44e-05	0.17	0.15	Height;	chr14:75078982	chr14:75011269~75012851:-
BRCA	cis	rs17685	0.753	rs10262501	ENSG00000280388.1	RP11-229D13.3	4.99	7.11e-07	7.44e-05	0.16	0.15	Coffee consumption (cups per day);Coffee consumption;	chr7:76038854	chr7:76043977~76045963:-
BRCA	cis	rs2832191	1	rs2832185	ENSG00000176054.6	RPL23P2	-4.99	7.11e-07	7.44e-05	-0.16	-0.15	Dental caries;	chr21:29111440	chr21:28997613~28998033:-
BRCA	cis	rs4218	0.648	rs12442134	ENSG00000277144.1	RP11-59H7.4	-4.99	7.12e-07	7.45e-05	-0.2	-0.15	Social communication problems;	chr15:59074478	chr15:59115547~59116089:-
BRCA	cis	rs13113518	0.812	rs12505880	ENSG00000272969.1	RP11-528I4.2	4.99	7.12e-07	7.45e-05	0.18	0.15	Height;	chr4:55440988	chr4:55547112~55547889:+
BRCA	cis	rs4906332	1	rs4900574	ENSG00000244691.1	RPL10AP1	4.99	7.12e-07	7.45e-05	0.19	0.15	Coronary artery disease;	chr14:103412687	chr14:103412119~103412761:-
BRCA	cis	rs6723226	0.806	rs2249109	ENSG00000276517.1	AL133243.2	-4.99	7.12e-07	7.45e-05	-0.19	-0.15	Intelligence (multi-trait analysis);	chr2:32525812	chr2:32526504~32529507:+
BRCA	cis	rs7577696	0.924	rs212760	ENSG00000272716.1	RP11-563N4.1	4.99	7.13e-07	7.46e-05	0.17	0.15	Inflammatory biomarkers;	chr2:32204153	chr2:32165046~32165757:-
BRCA	cis	rs7200543	1	rs3803575	ENSG00000258354.1	MIR3180-1	-4.99	7.13e-07	7.46e-05	-0.2	-0.15	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15044590	chr16:14909887~14911345:-
BRCA	cis	rs6445975	1	rs4076852	ENSG00000272182.1	RP11-802O23.3	4.99	7.13e-07	7.46e-05	0.17	0.15	Systemic lupus erythematosus;	chr3:58389559	chr3:58428255~58428815:+
BRCA	cis	rs6570726	0.818	rs399516	ENSG00000270638.1	RP3-466P17.1	4.99	7.13e-07	7.46e-05	0.17	0.15	Lobe attachment (rater-scored or self-reported);	chr6:145489713	chr6:145735570~145737218:+
BRCA	cis	rs721917	0.525	rs10788338	ENSG00000244733.5	RP11-506M13.3	-4.99	7.13e-07	7.46e-05	-0.18	-0.15	Chronic obstructive pulmonary disease;	chr10:79973266	chr10:79660891~79677996:+
BRCA	cis	rs4494364	0.502	rs1920783	ENSG00000258100.1	RP11-121E16.1	4.99	7.13e-07	7.46e-05	0.23	0.15	Systolic blood pressure (alcohol consumption interaction);	chr12:90979844	chr12:91362196~91368606:+
BRCA	cis	rs4494364	0.502	rs1920777	ENSG00000258100.1	RP11-121E16.1	4.99	7.13e-07	7.46e-05	0.23	0.15	Systolic blood pressure (alcohol consumption interaction);	chr12:90980701	chr12:91362196~91368606:+
BRCA	cis	rs3743772	0.5	rs8045574	ENSG00000279344.1	RP11-44F14.7	-4.99	7.14e-07	7.46e-05	-0.21	-0.15	Depressive symptoms (SSRI exposure interaction);	chr16:53395293	chr16:53478957~53481550:-
BRCA	cis	rs12744310	0.83	rs12045184	ENSG00000235358.1	RP11-399E6.1	4.99	7.14e-07	7.47e-05	0.23	0.15	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41333939	chr1:41242373~41284861:+
BRCA	cis	rs7267979	0.706	rs6037069	ENSG00000274973.1	RP13-401N8.7	-4.99	7.14e-07	7.47e-05	-0.18	-0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25253530	chr20:25845497~25845862:+
BRCA	cis	rs12477438	0.715	rs6724476	ENSG00000231822.1	AC019097.7	-4.99	7.14e-07	7.47e-05	-0.17	-0.15	Chronic sinus infection;	chr2:99010853	chr2:99102018~99102752:+
BRCA	cis	rs10861342	1	rs11112403	ENSG00000257999.1	RP11-61E11.2	-4.99	7.14e-07	7.47e-05	-0.31	-0.15	IgG glycosylation;	chr12:105192871	chr12:105102472~105107179:-
BRCA	cis	rs6439153	0.967	rs9821769	ENSG00000231305.3	RP11-723O4.2	4.99	7.14e-07	7.47e-05	0.18	0.15	Pneumococcal bacteremia;	chr3:129007423	chr3:128861313~128871540:-
BRCA	cis	rs7829975	0.658	rs907181	ENSG00000254153.1	CTA-398F10.2	4.99	7.15e-07	7.48e-05	0.18	0.15	Mood instability;	chr8:8845365	chr8:8456909~8461337:-
BRCA	cis	rs72772090	0.522	rs75688868	ENSG00000248734.2	CTD-2260A17.1	-4.99	7.15e-07	7.48e-05	-0.32	-0.15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96653573	chr5:96784777~96785999:+
BRCA	cis	rs2179367	0.959	rs514839	ENSG00000268592.3	RAET1E-AS1	4.99	7.15e-07	7.48e-05	0.19	0.15	Dupuytren's disease;	chr6:149327304	chr6:149863494~149919507:+
BRCA	cis	rs12497850	1	rs4858828	ENSG00000225399.4	RP11-3B7.1	4.99	7.15e-07	7.48e-05	0.15	0.15	Parkinson's disease;	chr3:48687378	chr3:49260085~49261316:+
BRCA	cis	rs202072	1	rs202074	ENSG00000272379.1	RP1-257A7.5	4.99	7.16e-07	7.49e-05	0.22	0.15	HIV-1 viral setpoint;	chr6:13269131	chr6:13290018~13290490:-
BRCA	cis	rs7923837	1	rs4933736	ENSG00000236493.2	EIF2S2P3	4.99	7.16e-07	7.49e-05	0.21	0.15	Multiple sclerosis;Body mass index;	chr10:92711838	chr10:92668745~92669743:-
BRCA	cis	rs6840360	0.642	rs4235219	ENSG00000251611.1	RP11-610P16.1	-4.99	7.17e-07	7.5e-05	-0.13	-0.15	Intelligence (multi-trait analysis);	chr4:151424951	chr4:151407551~151408835:-
BRCA	cis	rs6840360	0.642	rs6851814	ENSG00000251611.1	RP11-610P16.1	-4.99	7.17e-07	7.5e-05	-0.13	-0.15	Intelligence (multi-trait analysis);	chr4:151425285	chr4:151407551~151408835:-
BRCA	cis	rs6840360	0.606	rs10028035	ENSG00000251611.1	RP11-610P16.1	-4.99	7.17e-07	7.5e-05	-0.13	-0.15	Intelligence (multi-trait analysis);	chr4:151426673	chr4:151407551~151408835:-
BRCA	cis	rs6840360	0.667	rs4266275	ENSG00000251611.1	RP11-610P16.1	-4.99	7.17e-07	7.5e-05	-0.13	-0.15	Intelligence (multi-trait analysis);	chr4:151426912	chr4:151407551~151408835:-
BRCA	cis	rs7608910	1	rs67927699	ENSG00000271889.1	RP11-493E12.1	4.99	7.17e-07	7.5e-05	0.19	0.15	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;	chr2:60960280	chr2:61151433~61162105:-
BRCA	cis	rs7572733	0.534	rs7604700	ENSG00000231621.1	AC013264.2	-4.99	7.17e-07	7.5e-05	-0.15	-0.15	Dermatomyositis;	chr2:197853906	chr2:197197991~197199273:+
BRCA	cis	rs7572733	0.555	rs1435569	ENSG00000231621.1	AC013264.2	-4.99	7.17e-07	7.5e-05	-0.15	-0.15	Dermatomyositis;	chr2:197853943	chr2:197197991~197199273:+
BRCA	cis	rs7572733	0.514	rs700686	ENSG00000231621.1	AC013264.2	-4.99	7.17e-07	7.5e-05	-0.15	-0.15	Dermatomyositis;	chr2:197856330	chr2:197197991~197199273:+
BRCA	cis	rs7572733	0.534	rs700687	ENSG00000231621.1	AC013264.2	-4.99	7.17e-07	7.5e-05	-0.15	-0.15	Dermatomyositis;	chr2:197856836	chr2:197197991~197199273:+
BRCA	cis	rs7572733	0.534	rs696817	ENSG00000231621.1	AC013264.2	-4.99	7.17e-07	7.5e-05	-0.15	-0.15	Dermatomyositis;	chr2:197857501	chr2:197197991~197199273:+
BRCA	cis	rs10504130	0.569	rs13275967	ENSG00000272024.1	RP11-546K22.3	-4.99	7.17e-07	7.5e-05	-0.23	-0.15	Venous thromboembolism (SNP x SNP interaction);	chr8:51761316	chr8:51950284~51950690:+
BRCA	cis	rs10504130	0.569	rs13274159	ENSG00000272024.1	RP11-546K22.3	-4.99	7.17e-07	7.5e-05	-0.23	-0.15	Venous thromboembolism (SNP x SNP interaction);	chr8:51761450	chr8:51950284~51950690:+
BRCA	cis	rs10504130	0.569	rs4436115	ENSG00000272024.1	RP11-546K22.3	-4.99	7.17e-07	7.5e-05	-0.23	-0.15	Venous thromboembolism (SNP x SNP interaction);	chr8:51761932	chr8:51950284~51950690:+
BRCA	cis	rs10504130	0.569	rs4573262	ENSG00000272024.1	RP11-546K22.3	-4.99	7.17e-07	7.5e-05	-0.23	-0.15	Venous thromboembolism (SNP x SNP interaction);	chr8:51762249	chr8:51950284~51950690:+
BRCA	cis	rs7613875	0.6	rs1138536	ENSG00000228008.1	CTD-2330K9.3	4.99	7.17e-07	7.5e-05	0.15	0.15	Body mass index;	chr3:50115923	chr3:49903845~49916937:+
BRCA	cis	rs7923837	0.687	rs11187139	ENSG00000236493.2	EIF2S2P3	4.99	7.17e-07	7.5e-05	0.19	0.15	Multiple sclerosis;Body mass index;	chr10:92706670	chr10:92668745~92669743:-
BRCA	cis	rs6570726	0.791	rs447992	ENSG00000270638.1	RP3-466P17.1	4.99	7.17e-07	7.5e-05	0.18	0.15	Lobe attachment (rater-scored or self-reported);	chr6:145496048	chr6:145735570~145737218:+
BRCA	cis	rs6570726	0.791	rs425999	ENSG00000270638.1	RP3-466P17.1	4.99	7.17e-07	7.5e-05	0.18	0.15	Lobe attachment (rater-scored or self-reported);	chr6:145498234	chr6:145735570~145737218:+
BRCA	cis	rs6570726	0.791	rs387376	ENSG00000270638.1	RP3-466P17.1	4.99	7.17e-07	7.5e-05	0.18	0.15	Lobe attachment (rater-scored or self-reported);	chr6:145501429	chr6:145735570~145737218:+
BRCA	cis	rs6570726	0.764	rs1912023	ENSG00000270638.1	RP3-466P17.1	4.99	7.17e-07	7.5e-05	0.18	0.15	Lobe attachment (rater-scored or self-reported);	chr6:145503142	chr6:145735570~145737218:+
BRCA	cis	rs6445975	0.726	rs4330265	ENSG00000272360.1	RP11-359I18.5	-4.99	7.18e-07	7.5e-05	-0.16	-0.15	Systemic lupus erythematosus;	chr3:58482301	chr3:58490830~58491291:-
BRCA	cis	rs10129255	1	rs10129407	ENSG00000211974.3	IGHV2-70	4.99	7.18e-07	7.5e-05	0.16	0.15	Kawasaki disease;	chr14:106767956	chr14:106723574~106724093:-
BRCA	cis	rs3743162	1	rs12917429	ENSG00000225151.9	GOLGA2P7	4.99	7.18e-07	7.51e-05	0.21	0.15	Alzheimer's disease (age of onset);	chr15:84881866	chr15:84199311~84230136:-
BRCA	cis	rs7914558	1	rs11191577	ENSG00000236937.2	PTGES3P4	4.99	7.18e-07	7.51e-05	0.2	0.15	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103142408	chr10:102845595~102845950:+
BRCA	cis	rs7246657	0.653	rs10425441	ENSG00000267422.1	CTD-2554C21.1	-4.99	7.19e-07	7.51e-05	-0.26	-0.15	Coronary artery calcification;	chr19:37179746	chr19:37779686~37792865:+
BRCA	cis	rs2243480	0.706	rs34466769	ENSG00000229180.5	GS1-124K5.11	4.99	7.19e-07	7.51e-05	0.18	0.15	Diabetic kidney disease;	chr7:65988305	chr7:66526088~66542624:-
BRCA	cis	rs11722228	0.508	rs3756227	ENSG00000261490.1	RP11-448G15.3	4.99	7.19e-07	7.52e-05	0.17	0.15	Urate levels;Serum uric acid levels;Gout;	chr4:10086371	chr4:10068089~10073019:-
BRCA	cis	rs6081541	1	rs6081541	ENSG00000179447.2	RP5-1027G4.3	4.99	7.19e-07	7.52e-05	0.21	0.15	Psychosis (atypical);	chr20:19232246	chr20:19242302~19284596:-
BRCA	cis	rs6570726	0.791	rs427128	ENSG00000270638.1	RP3-466P17.1	4.99	7.19e-07	7.52e-05	0.18	0.15	Lobe attachment (rater-scored or self-reported);	chr6:145544781	chr6:145735570~145737218:+
BRCA	cis	rs2836974	0.583	rs9981884	ENSG00000238141.2	BRWD1-AS1	4.99	7.2e-07	7.52e-05	0.18	0.15	Cognitive function;	chr21:39213707	chr21:39315707~39323218:+
BRCA	cis	rs1075265	0.729	rs7571086	ENSG00000235937.1	AC008280.1	4.99	7.2e-07	7.53e-05	0.17	0.15	Chronotype;Morning vs. evening chronotype;	chr2:54007899	chr2:54029552~54030682:-
BRCA	cis	rs7829975	0.688	rs13270194	ENSG00000233609.3	RP11-62H7.2	4.99	7.2e-07	7.53e-05	0.14	0.15	Mood instability;	chr8:8520592	chr8:8961200~8979025:+
BRCA	cis	rs4356203	0.905	rs11024158	ENSG00000272034.1	SNORD14A	4.99	7.2e-07	7.53e-05	0.16	0.15	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17103621	chr11:17074654~17074744:-
BRCA	cis	rs4908760	0.827	rs1463053	ENSG00000232912.4	RP5-1115A15.1	4.99	7.21e-07	7.54e-05	0.15	0.15	Vitiligo;	chr1:8644978	chr1:8424645~8434838:+
BRCA	cis	rs1707322	1	rs10890378	ENSG00000234329.1	RP11-767N6.2	-4.99	7.21e-07	7.54e-05	-0.16	-0.15	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45944985	chr1:45651039~45651826:-
BRCA	cis	rs1707322	1	rs9429186	ENSG00000234329.1	RP11-767N6.2	-4.99	7.21e-07	7.54e-05	-0.16	-0.15	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46074015	chr1:45651039~45651826:-
BRCA	cis	rs2153535	0.58	rs9406158	ENSG00000251164.1	HULC	-4.99	7.21e-07	7.54e-05	-0.19	-0.15	Motion sickness;	chr6:8463919	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.58	rs9406159	ENSG00000251164.1	HULC	-4.99	7.21e-07	7.54e-05	-0.19	-0.15	Motion sickness;	chr6:8464626	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.58	rs1335637	ENSG00000251164.1	HULC	-4.99	7.21e-07	7.54e-05	-0.19	-0.15	Motion sickness;	chr6:8464868	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.58	rs9406162	ENSG00000251164.1	HULC	-4.99	7.21e-07	7.54e-05	-0.19	-0.15	Motion sickness;	chr6:8465963	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.541	rs9392222	ENSG00000251164.1	HULC	-4.99	7.21e-07	7.54e-05	-0.19	-0.15	Motion sickness;	chr6:8467416	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.541	rs6932434	ENSG00000251164.1	HULC	-4.99	7.21e-07	7.54e-05	-0.19	-0.15	Motion sickness;	chr6:8467446	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.58	rs1034273	ENSG00000251164.1	HULC	-4.99	7.21e-07	7.54e-05	-0.19	-0.15	Motion sickness;	chr6:8467912	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.541	rs9328471	ENSG00000251164.1	HULC	-4.99	7.21e-07	7.54e-05	-0.19	-0.15	Motion sickness;	chr6:8468609	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.601	rs9505451	ENSG00000251164.1	HULC	-4.99	7.21e-07	7.54e-05	-0.19	-0.15	Motion sickness;	chr6:8469717	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.58	rs9393023	ENSG00000251164.1	HULC	-4.99	7.21e-07	7.54e-05	-0.19	-0.15	Motion sickness;	chr6:8469761	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.58	rs1414346	ENSG00000251164.1	HULC	-4.99	7.21e-07	7.54e-05	-0.19	-0.15	Motion sickness;	chr6:8471341	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.58	rs1932279	ENSG00000251164.1	HULC	-4.99	7.21e-07	7.54e-05	-0.19	-0.15	Motion sickness;	chr6:8473420	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.58	rs9379213	ENSG00000251164.1	HULC	-4.99	7.21e-07	7.54e-05	-0.19	-0.15	Motion sickness;	chr6:8474712	chr6:8652137~8653846:+
BRCA	cis	rs11673344	0.542	rs826325	ENSG00000226686.6	LINC01535	4.99	7.21e-07	7.54e-05	0.2	0.15	Obesity-related traits;	chr19:37003580	chr19:37251912~37265535:+
BRCA	cis	rs2562456	0.876	rs11085467	ENSG00000268658.4	LINC00664	4.99	7.22e-07	7.54e-05	0.24	0.15	Pain;	chr19:21569041	chr19:21483374~21503238:+
BRCA	cis	rs919433	0.617	rs10460394	ENSG00000231621.1	AC013264.2	4.99	7.22e-07	7.54e-05	0.15	0.15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197684017	chr2:197197991~197199273:+
BRCA	cis	rs6570726	0.791	rs9403729	ENSG00000270638.1	RP3-466P17.1	4.99	7.22e-07	7.54e-05	0.18	0.15	Lobe attachment (rater-scored or self-reported);	chr6:145585871	chr6:145735570~145737218:+
BRCA	cis	rs4664293	0.667	rs3815876	ENSG00000224152.1	AC009506.1	-4.99	7.22e-07	7.54e-05	-0.16	-0.15	Monocyte percentage of white cells;	chr2:159783640	chr2:159615296~159617082:+
BRCA	cis	rs875971	0.83	rs12673450	ENSG00000273448.1	RP11-166O4.6	4.99	7.22e-07	7.54e-05	0.14	0.15	Aortic root size;	chr7:66544233	chr7:67333047~67334383:+
BRCA	cis	rs875971	0.83	rs12673450	ENSG00000236529.1	RP13-254B10.1	4.99	7.22e-07	7.55e-05	0.17	0.15	Aortic root size;	chr7:66544233	chr7:65840212~65840596:+
BRCA	cis	rs2243480	1	rs160643	ENSG00000164669.11	INTS4P1	4.99	7.22e-07	7.55e-05	0.28	0.15	Diabetic kidney disease;	chr7:66093235	chr7:65141225~65234216:+
BRCA	cis	rs60695258	0.529	rs340630	ENSG00000251411.1	RP11-397E7.4	4.99	7.22e-07	7.55e-05	0.17	0.15	Hematocrit;	chr4:87037243	chr4:86913266~86914817:-
BRCA	cis	rs8127691	0.967	rs762422	ENSG00000237604.1	AP001056.1	-4.99	7.22e-07	7.55e-05	-0.17	-0.15	Inflammatory bowel disease;	chr21:44195755	chr21:44175489~44176453:+
BRCA	cis	rs7200543	1	rs16966953	ENSG00000275910.1	RP11-680G24.6	-4.99	7.23e-07	7.55e-05	-0.18	-0.15	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15041997	chr16:15015828~15016390:-
BRCA	cis	rs73193808	0.901	rs1997570	ENSG00000236056.1	GAPDHP14	-4.99	7.23e-07	7.55e-05	-0.22	-0.15	Coronary artery disease;	chr21:29212989	chr21:29222321~29223257:+
BRCA	cis	rs7914558	1	rs10883837	ENSG00000236937.2	PTGES3P4	4.99	7.23e-07	7.55e-05	0.2	0.15	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103136729	chr10:102845595~102845950:+
BRCA	cis	rs7914558	0.966	rs746293	ENSG00000236937.2	PTGES3P4	4.99	7.23e-07	7.55e-05	0.2	0.15	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103137497	chr10:102845595~102845950:+
BRCA	cis	rs7772486	0.875	rs2180192	ENSG00000270638.1	RP3-466P17.1	4.99	7.23e-07	7.56e-05	0.18	0.15	Lobe attachment (rater-scored or self-reported);	chr6:146001148	chr6:145735570~145737218:+
BRCA	cis	rs2274273	0.522	rs2251366	ENSG00000258413.1	RP11-665C16.6	-4.99	7.23e-07	7.56e-05	-0.19	-0.15	Protein biomarker;	chr14:55051438	chr14:55262767~55272075:-
BRCA	cis	rs7914558	0.966	rs12571568	ENSG00000236937.2	PTGES3P4	4.99	7.24e-07	7.56e-05	0.2	0.15	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103131639	chr10:102845595~102845950:+
BRCA	cis	rs7914558	0.966	rs12766205	ENSG00000236937.2	PTGES3P4	4.99	7.24e-07	7.56e-05	0.2	0.15	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103133811	chr10:102845595~102845950:+
BRCA	cis	rs4835473	0.932	rs4835471	ENSG00000249741.2	RP11-673E1.3	-4.99	7.24e-07	7.56e-05	-0.16	-0.15	Immature fraction of reticulocytes;	chr4:143982153	chr4:143911514~143912053:-
BRCA	cis	rs4835473	0.897	rs4835119	ENSG00000249741.2	RP11-673E1.3	-4.99	7.24e-07	7.56e-05	-0.16	-0.15	Immature fraction of reticulocytes;	chr4:143982210	chr4:143911514~143912053:-
BRCA	cis	rs6600671	1	rs4844607	ENSG00000275538.1	RNVU1-19	-4.99	7.24e-07	7.57e-05	-0.18	-0.15	Hip geometry;	chr1:121442201	chr1:120850819~120850985:-
BRCA	cis	rs9341808	0.754	rs978814	ENSG00000272129.1	RP11-250B2.6	4.99	7.24e-07	7.57e-05	0.19	0.15	Sitting height ratio;	chr6:80250195	chr6:80355424~80356859:+
BRCA	cis	rs8127691	1	rs743479	ENSG00000237604.1	AP001056.1	4.99	7.24e-07	7.57e-05	0.17	0.15	Inflammatory bowel disease;	chr21:44192067	chr21:44175489~44176453:+
BRCA	cis	rs8064024	0.68	rs8056320	ENSG00000267077.1	RP11-127I20.5	4.99	7.25e-07	7.57e-05	0.15	0.15	Cancer;	chr16:4868016	chr16:4795265~4796532:-
BRCA	cis	rs2255336	0.882	rs2733853	ENSG00000245648.1	RP11-277P12.20	4.99	7.25e-07	7.57e-05	0.22	0.15	Blood protein levels;	chr12:10381483	chr12:10363769~10398506:+
BRCA	cis	rs115769866	0.609	rs2859356	ENSG00000216901.1	AL022393.7	4.99	7.25e-07	7.57e-05	0.21	0.15	Bipolar disorder;	chr6:28497578	chr6:28176188~28176674:+
BRCA	cis	rs11051970	0.559	rs73086036	ENSG00000274964.1	RP11-817I4.1	-4.99	7.25e-07	7.57e-05	-0.21	-0.15	Response to tocilizumab in rheumatoid arthritis;	chr12:32411651	chr12:32339368~32340724:+
BRCA	cis	rs7226408	0.846	rs2121024	ENSG00000267707.2	RP11-95O2.5	4.98	7.25e-07	7.58e-05	0.23	0.15	Obesity-related traits;	chr18:36908243	chr18:37243776~37247506:+
BRCA	cis	rs7226408	0.857	rs2121023	ENSG00000267707.2	RP11-95O2.5	4.98	7.25e-07	7.58e-05	0.23	0.15	Obesity-related traits;	chr18:36908451	chr18:37243776~37247506:+
BRCA	cis	rs7226408	0.857	rs2166295	ENSG00000267707.2	RP11-95O2.5	4.98	7.25e-07	7.58e-05	0.23	0.15	Obesity-related traits;	chr18:36908518	chr18:37243776~37247506:+
BRCA	cis	rs7226408	0.857	rs2166294	ENSG00000267707.2	RP11-95O2.5	4.98	7.25e-07	7.58e-05	0.23	0.15	Obesity-related traits;	chr18:36908571	chr18:37243776~37247506:+
BRCA	cis	rs7226408	0.857	rs56133445	ENSG00000267707.2	RP11-95O2.5	4.98	7.25e-07	7.58e-05	0.23	0.15	Obesity-related traits;	chr18:36911429	chr18:37243776~37247506:+
BRCA	cis	rs7226408	0.857	rs72887066	ENSG00000267707.2	RP11-95O2.5	4.98	7.25e-07	7.58e-05	0.23	0.15	Obesity-related traits;	chr18:36916408	chr18:37243776~37247506:+
BRCA	cis	rs7226408	0.857	rs72887072	ENSG00000267707.2	RP11-95O2.5	4.98	7.25e-07	7.58e-05	0.23	0.15	Obesity-related traits;	chr18:36919490	chr18:37243776~37247506:+
BRCA	cis	rs2839186	0.721	rs3788252	ENSG00000239415.1	AP001469.9	4.98	7.26e-07	7.58e-05	0.16	0.15	Testicular germ cell tumor;	chr21:46241321	chr21:46251549~46254133:-
BRCA	cis	rs4664293	0.899	rs7588710	ENSG00000226266.5	AC009961.3	-4.98	7.26e-07	7.58e-05	-0.2	-0.15	Monocyte percentage of white cells;	chr2:159673011	chr2:159670708~159712435:-
BRCA	cis	rs12497850	0.931	rs4974085	ENSG00000225399.4	RP11-3B7.1	4.98	7.26e-07	7.58e-05	0.15	0.15	Parkinson's disease;	chr3:48887467	chr3:49260085~49261316:+
BRCA	cis	rs4664293	0.805	rs7593273	ENSG00000224152.1	AC009506.1	-4.98	7.26e-07	7.59e-05	-0.17	-0.15	Monocyte percentage of white cells;	chr2:159749349	chr2:159615296~159617082:+
BRCA	cis	rs2243480	1	rs316329	ENSG00000275400.1	RP4-756H11.5	4.98	7.26e-07	7.59e-05	0.27	0.15	Diabetic kidney disease;	chr7:66143429	chr7:66553805~66554199:-
BRCA	cis	rs7572733	0.534	rs1518365	ENSG00000231621.1	AC013264.2	-4.98	7.26e-07	7.59e-05	-0.15	-0.15	Dermatomyositis;	chr2:197944686	chr2:197197991~197199273:+
BRCA	cis	rs7572733	0.534	rs1518363	ENSG00000231621.1	AC013264.2	-4.98	7.26e-07	7.59e-05	-0.15	-0.15	Dermatomyositis;	chr2:197945407	chr2:197197991~197199273:+
BRCA	cis	rs7572733	0.534	rs1518361	ENSG00000231621.1	AC013264.2	-4.98	7.26e-07	7.59e-05	-0.15	-0.15	Dermatomyositis;	chr2:197948150	chr2:197197991~197199273:+
BRCA	cis	rs7923609	1	rs2393969	ENSG00000232075.1	MRPL35P2	-4.98	7.26e-07	7.59e-05	-0.19	-0.15	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63380680	chr10:63634317~63634827:-
BRCA	cis	rs1223397	0.651	rs2919685	ENSG00000215022.6	RP1-257A7.4	-4.98	7.27e-07	7.59e-05	-0.18	-0.15	Blood pressure;	chr6:13311436	chr6:13264861~13295586:-
BRCA	cis	rs11159086	1	rs72730186	ENSG00000270000.1	RP3-449M8.9	4.98	7.27e-07	7.59e-05	0.29	0.15	Advanced glycation end-product levels;	chr14:74475610	chr14:74471930~74472360:-
BRCA	cis	rs4925386	0.802	rs6142735	ENSG00000273619.1	RP5-908M14.9	-4.98	7.27e-07	7.59e-05	-0.14	-0.15	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62343031	chr20:62386303~62386970:-
BRCA	cis	rs4934494	0.677	rs11185806	ENSG00000240996.1	RP11-80H5.7	-4.98	7.27e-07	7.59e-05	-0.21	-0.15	Red blood cell count;	chr10:89620458	chr10:89694295~89697928:-
BRCA	cis	rs4934494	0.591	rs7476027	ENSG00000240996.1	RP11-80H5.7	-4.98	7.27e-07	7.59e-05	-0.21	-0.15	Red blood cell count;	chr10:89621164	chr10:89694295~89697928:-
BRCA	cis	rs4934494	0.677	rs11185809	ENSG00000240996.1	RP11-80H5.7	-4.98	7.27e-07	7.59e-05	-0.21	-0.15	Red blood cell count;	chr10:89621474	chr10:89694295~89697928:-
BRCA	cis	rs6723226	0.842	rs2754522	ENSG00000276517.1	AL133243.2	-4.98	7.27e-07	7.6e-05	-0.19	-0.15	Intelligence (multi-trait analysis);	chr2:32576190	chr2:32526504~32529507:+
BRCA	cis	rs4218	0.648	rs2289895	ENSG00000277144.1	RP11-59H7.4	-4.98	7.28e-07	7.61e-05	-0.2	-0.15	Social communication problems;	chr15:59089570	chr15:59115547~59116089:-
BRCA	cis	rs7487075	0.619	rs12822345	ENSG00000274723.1	RP11-618L22.1	4.98	7.28e-07	7.61e-05	0.19	0.15	Itch intensity from mosquito bite;	chr12:46440894	chr12:46970504~46972155:+
BRCA	cis	rs7487075	0.619	rs12824565	ENSG00000274723.1	RP11-618L22.1	4.98	7.28e-07	7.61e-05	0.19	0.15	Itch intensity from mosquito bite;	chr12:46440910	chr12:46970504~46972155:+
BRCA	cis	rs10888838	0.567	rs3766453	ENSG00000198711.5	SSBP3-AS1	4.98	7.28e-07	7.61e-05	0.18	0.15	Mitochondrial DNA levels;	chr1:54237196	chr1:54236440~54239063:+
BRCA	cis	rs1858037	0.867	rs876933	ENSG00000237979.1	AC007389.1	4.98	7.28e-07	7.61e-05	0.2	0.15	Rheumatoid arthritis;	chr2:65382303	chr2:65500993~65502138:-
BRCA	cis	rs17685	0.725	rs6467993	ENSG00000280388.1	RP11-229D13.3	-4.98	7.28e-07	7.61e-05	-0.16	-0.15	Coffee consumption (cups per day);Coffee consumption;	chr7:76090032	chr7:76043977~76045963:-
BRCA	cis	rs2562456	0.876	rs10424079	ENSG00000268081.1	RP11-678G14.2	4.98	7.29e-07	7.61e-05	0.24	0.15	Pain;	chr19:21406377	chr19:21554640~21569237:-
BRCA	cis	rs9309473	0.607	rs6546826	ENSG00000163016.8	ALMS1P	-4.98	7.29e-07	7.61e-05	-0.18	-0.15	Metabolite levels;	chr2:73372680	chr2:73644919~73685576:+
BRCA	cis	rs3120667	0.72	rs72698964	ENSG00000237975.5	FLG-AS1	4.98	7.29e-07	7.62e-05	0.23	0.15	Eating disorders;	chr1:152444140	chr1:152168125~152445456:+
BRCA	cis	rs4713118	0.868	rs742047	ENSG00000216901.1	AL022393.7	4.98	7.29e-07	7.62e-05	0.22	0.15	Parkinson's disease;	chr6:27771601	chr6:28176188~28176674:+
BRCA	cis	rs7618915	0.547	rs11130313	ENSG00000243224.1	RP5-1157M23.2	-4.98	7.3e-07	7.62e-05	-0.17	-0.15	Bipolar disorder;	chr3:52642174	chr3:52239258~52241097:+
BRCA	cis	rs10911251	0.546	rs3768625	ENSG00000224468.3	RP11-181K3.4	-4.98	7.3e-07	7.62e-05	-0.17	-0.15	Colorectal cancer;	chr1:183109577	chr1:183138402~183141282:-
BRCA	cis	rs867371	0.614	rs7183805	ENSG00000255769.6	GOLGA2P10	-4.98	7.3e-07	7.62e-05	-0.19	-0.15	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82247090	chr15:82472993~82513950:-
BRCA	cis	rs853679	0.599	rs149949	ENSG00000204709.4	LINC01556	4.98	7.3e-07	7.63e-05	0.31	0.15	Depression;	chr6:28043738	chr6:28943877~28944537:+
BRCA	cis	rs9311474	0.508	rs12629701	ENSG00000243224.1	RP5-1157M23.2	-4.98	7.31e-07	7.63e-05	-0.16	-0.15	Electroencephalogram traits;	chr3:52585820	chr3:52239258~52241097:+
BRCA	cis	rs6860540	0.796	rs10404	ENSG00000248544.2	CTB-47B11.3	-4.98	7.31e-07	7.63e-05	-0.2	-0.15	Inflammatory skin disease;	chr5:157477625	chr5:157375741~157384950:-
BRCA	cis	rs7833986	0.501	rs2719227	ENSG00000253603.1	CTA-397H3.3	4.98	7.31e-07	7.63e-05	0.22	0.15	Height;	chr8:56131235	chr8:56074592~56075274:+
BRCA	cis	rs2562456	0.833	rs2154302	ENSG00000268081.1	RP11-678G14.2	4.98	7.31e-07	7.63e-05	0.24	0.15	Pain;	chr19:21307609	chr19:21554640~21569237:-
BRCA	cis	rs997295	0.57	rs7172298	ENSG00000270964.1	RP11-502I4.3	-4.98	7.31e-07	7.63e-05	-0.17	-0.15	Motion sickness;	chr15:67580645	chr15:67541072~67542604:-
BRCA	cis	rs799165	1	rs799166	ENSG00000274080.1	CTA-315H11.2	4.98	7.31e-07	7.63e-05	0.27	0.15	Age-related diseases, mortality and associated endophenotypes;Age-related disease endophenotypes;	chr7:73637602	chr7:73609262~73611502:-
BRCA	cis	rs17772222	0.74	rs7160647	ENSG00000258789.1	RP11-507K2.3	-4.98	7.31e-07	7.64e-05	-0.17	-0.15	Coronary artery calcification;	chr14:88507340	chr14:88551597~88552493:+
BRCA	cis	rs1552244	0.572	rs6442154	ENSG00000232901.1	CYCSP10	4.98	7.32e-07	7.64e-05	0.23	0.15	Alzheimer's disease;	chr3:10127101	chr3:10000647~10000940:-
BRCA	cis	rs2732480	0.5	rs2932093	ENSG00000257735.1	RP11-370I10.6	4.98	7.32e-07	7.64e-05	0.19	0.15	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48254488	chr12:48350945~48442411:+
BRCA	cis	rs4718428	0.705	rs68168107	ENSG00000229180.5	GS1-124K5.11	4.98	7.32e-07	7.64e-05	0.15	0.15	Corneal structure;	chr7:66790251	chr7:66526088~66542624:-
BRCA	cis	rs2839186	0.709	rs2839176	ENSG00000228137.1	AP001469.7	4.98	7.32e-07	7.64e-05	0.15	0.15	Testicular germ cell tumor;	chr21:46258259	chr21:46246890~46247682:+
BRCA	cis	rs6840360	0.642	rs7684462	ENSG00000251611.1	RP11-610P16.1	-4.98	7.32e-07	7.64e-05	-0.13	-0.15	Intelligence (multi-trait analysis);	chr4:151427270	chr4:151407551~151408835:-
BRCA	cis	rs7200543	0.848	rs62039480	ENSG00000188599.16	NPIPP1	-4.98	7.32e-07	7.64e-05	-0.13	-0.15	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15043593	chr16:15104312~15123498:-
BRCA	cis	rs8180040	0.934	rs4858811	ENSG00000276925.1	RP11-708J19.3	4.98	7.32e-07	7.65e-05	0.18	0.15	Colorectal cancer;	chr3:47439034	chr3:47469777~47469987:+
BRCA	cis	rs6668534	1	rs6668534	ENSG00000225217.1	HSPA7	-4.98	7.33e-07	7.65e-05	-0.18	-0.15	Blood protein levels;	chr1:161702205	chr1:161606291~161608217:+
BRCA	cis	rs454217	0.846	rs1661024	ENSG00000277851.1	RP11-756G20.1	4.98	7.33e-07	7.65e-05	0.17	0.15	Smoking quantity;	chr12:92330771	chr12:92247756~92363832:-
BRCA	cis	rs516805	0.706	rs1034060	ENSG00000279453.1	RP3-425C14.4	4.98	7.33e-07	7.65e-05	0.21	0.15	Lymphocyte counts;	chr6:122319181	chr6:122436789~122439223:-
BRCA	cis	rs62025270	0.688	rs55738258	ENSG00000202081.1	RNU6-1280P	-4.98	7.33e-07	7.65e-05	-0.22	-0.15	Idiopathic pulmonary fibrosis;	chr15:85773000	chr15:85651522~85651628:-
BRCA	cis	rs7618915	0.508	rs11717043	ENSG00000243224.1	RP5-1157M23.2	-4.98	7.33e-07	7.65e-05	-0.17	-0.15	Bipolar disorder;	chr3:52622076	chr3:52239258~52241097:+
BRCA	cis	rs7618915	0.547	rs13064064	ENSG00000243224.1	RP5-1157M23.2	-4.98	7.33e-07	7.65e-05	-0.17	-0.15	Bipolar disorder;	chr3:52622986	chr3:52239258~52241097:+
BRCA	cis	rs11098499	0.754	rs17595608	ENSG00000260404.2	RP11-384K6.6	4.98	7.33e-07	7.66e-05	0.14	0.15	Corneal astigmatism;	chr4:119329351	chr4:118591773~118633729:+
BRCA	cis	rs5751614	0.557	rs5759666	ENSG00000240160.3	RN7SL263P	4.98	7.34e-07	7.66e-05	0.2	0.15	Height;	chr22:23260155	chr22:23261782~23262071:-
BRCA	cis	rs9467773	0.583	rs2498380	ENSG00000124549.13	BTN2A3P	-4.98	7.34e-07	7.66e-05	-0.15	-0.15	Intelligence (multi-trait analysis);	chr6:26643768	chr6:26421391~26432383:+
BRCA	cis	rs4835473	0.771	rs4443231	ENSG00000249741.2	RP11-673E1.3	-4.98	7.35e-07	7.67e-05	-0.16	-0.15	Immature fraction of reticulocytes;	chr4:143979501	chr4:143911514~143912053:-
BRCA	cis	rs7647973	0.925	rs9881860	ENSG00000244380.1	RP11-24C3.2	4.98	7.35e-07	7.67e-05	0.2	0.15	Menarche (age at onset);	chr3:49315089	chr3:48440352~48446656:-
BRCA	cis	rs6832769	1	rs6832769	ENSG00000223305.1	RN7SKP30	4.98	7.35e-07	7.67e-05	0.2	0.15	Personality dimensions;	chr4:55432027	chr4:55540502~55540835:-
BRCA	cis	rs1667284	0.846	rs1667279	ENSG00000266521.1	RP11-650P15.1	4.98	7.35e-07	7.67e-05	0.18	0.15	Problematic alcohol use in trauma-exposed individuals;	chr18:31638910	chr18:31496645~31497195:-
BRCA	cis	rs6496044	0.527	rs7163068	ENSG00000259295.5	CSPG4P12	4.98	7.35e-07	7.67e-05	0.18	0.15	Interstitial lung disease;	chr15:85529235	chr15:85191438~85213905:+
BRCA	cis	rs7577696	0.962	rs36014814	ENSG00000272716.1	RP11-563N4.1	-4.98	7.35e-07	7.67e-05	-0.17	-0.15	Inflammatory biomarkers;	chr2:32079890	chr2:32165046~32165757:-
BRCA	cis	rs1440410	0.83	rs2010767	ENSG00000250326.1	RP11-284M14.1	-4.98	7.36e-07	7.68e-05	-0.17	-0.15	Ischemic stroke;	chr4:143255393	chr4:142933195~143184861:-
BRCA	cis	rs10129255	0.957	rs12589190	ENSG00000211974.3	IGHV2-70	4.98	7.36e-07	7.68e-05	0.15	0.15	Kawasaki disease;	chr14:106783079	chr14:106723574~106724093:-
BRCA	cis	rs2278170	1	rs331527	ENSG00000225101.4	OR52K3P	-4.98	7.36e-07	7.68e-05	-0.2	-0.15	Amyotrophic lateral sclerosis;	chr11:4457736	chr11:4474813~4475755:+
BRCA	cis	rs4780355	0.918	rs243318	ENSG00000262636.1	CTD-3088G3.4	4.98	7.36e-07	7.68e-05	0.21	0.15	Crohn's disease and psoriasis;	chr16:11264161	chr16:11380859~11381118:-
BRCA	cis	rs8040855	0.579	rs6496797	ENSG00000259774.1	RP11-182J1.13	-4.98	7.36e-07	7.68e-05	-0.17	-0.15	Bulimia nervosa;	chr15:85183624	chr15:84422618~84425882:+
BRCA	cis	rs2833693	0.574	rs2211675	ENSG00000261610.1	AP000265.1	-4.98	7.36e-07	7.68e-05	-0.18	-0.15	Temperament;	chr21:32180793	chr21:32259804~32261585:-
BRCA	cis	rs1193	0.837	rs1878109	ENSG00000231259.4	AC125232.1	-4.98	7.36e-07	7.69e-05	-0.19	-0.15	High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;High light scatter reticulocyte count;	chr2:86755753	chr2:87031815~87053069:-
BRCA	cis	rs8114671	0.562	rs6088653	ENSG00000269202.1	RP4-614O4.12	-4.98	7.36e-07	7.69e-05	-0.15	-0.15	Height;	chr20:34932518	chr20:35201747~35203288:-
BRCA	cis	rs1729951	0.575	rs835641	ENSG00000239213.4	NCK1-AS1	4.98	7.37e-07	7.69e-05	0.16	0.15	Neuroticism;	chr3:136984632	chr3:136841726~136862054:-
BRCA	cis	rs1729951	0.575	rs16844362	ENSG00000239213.4	NCK1-AS1	4.98	7.37e-07	7.69e-05	0.16	0.15	Neuroticism;	chr3:136985166	chr3:136841726~136862054:-
BRCA	cis	rs4853525	0.59	rs2203715	ENSG00000235852.1	AC005540.3	4.98	7.37e-07	7.69e-05	0.19	0.15	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190944157	chr2:190880797~190882059:-
BRCA	cis	rs1729951	0.546	rs12054408	ENSG00000239213.4	NCK1-AS1	4.98	7.37e-07	7.69e-05	0.16	0.15	Neuroticism;	chr3:136958803	chr3:136841726~136862054:-
BRCA	cis	rs66887589	0.777	rs1814815	ENSG00000245958.5	RP11-33B1.1	-4.98	7.37e-07	7.69e-05	-0.13	-0.15	Diastolic blood pressure;	chr4:119336936	chr4:119454791~119552025:+
BRCA	cis	rs7226408	0.857	rs72888926	ENSG00000267707.2	RP11-95O2.5	4.98	7.37e-07	7.69e-05	0.23	0.15	Obesity-related traits;	chr18:36950994	chr18:37243776~37247506:+
BRCA	cis	rs4950322	0.542	rs115179956	ENSG00000244371.2	PFN1P8	-4.98	7.37e-07	7.69e-05	-0.18	-0.15	Protein quantitative trait loci;	chr1:147172620	chr1:146957117~146957659:-
BRCA	cis	rs11098499	0.754	rs1511017	ENSG00000249244.1	RP11-548H18.2	4.98	7.37e-07	7.69e-05	0.17	0.15	Corneal astigmatism;	chr4:119329650	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.789	rs12498994	ENSG00000249244.1	RP11-548H18.2	4.98	7.37e-07	7.69e-05	0.17	0.15	Corneal astigmatism;	chr4:119329663	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.754	rs12507565	ENSG00000249244.1	RP11-548H18.2	4.98	7.37e-07	7.69e-05	0.17	0.15	Corneal astigmatism;	chr4:119329966	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.826	rs12511640	ENSG00000249244.1	RP11-548H18.2	4.98	7.37e-07	7.69e-05	0.17	0.15	Corneal astigmatism;	chr4:119330093	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.754	rs1980026	ENSG00000249244.1	RP11-548H18.2	4.98	7.37e-07	7.69e-05	0.17	0.15	Corneal astigmatism;	chr4:119330488	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.743	rs11098501	ENSG00000249244.1	RP11-548H18.2	4.98	7.37e-07	7.69e-05	0.17	0.15	Corneal astigmatism;	chr4:119330862	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.754	rs11098502	ENSG00000249244.1	RP11-548H18.2	4.98	7.37e-07	7.69e-05	0.17	0.15	Corneal astigmatism;	chr4:119330908	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.708	rs11732686	ENSG00000249244.1	RP11-548H18.2	4.98	7.37e-07	7.69e-05	0.17	0.15	Corneal astigmatism;	chr4:119331175	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.754	rs11724409	ENSG00000249244.1	RP11-548H18.2	4.98	7.37e-07	7.69e-05	0.17	0.15	Corneal astigmatism;	chr4:119331206	chr4:119391831~119395335:-
BRCA	cis	rs2562456	0.793	rs7259708	ENSG00000268658.4	LINC00664	4.98	7.37e-07	7.69e-05	0.24	0.15	Pain;	chr19:21567846	chr19:21483374~21503238:+
BRCA	cis	rs12682352	0.652	rs1567398	ENSG00000233609.3	RP11-62H7.2	-4.98	7.37e-07	7.69e-05	-0.14	-0.15	Neuroticism;	chr8:8869294	chr8:8961200~8979025:+
BRCA	cis	rs6439153	0.743	rs71331685	ENSG00000231305.3	RP11-723O4.2	4.98	7.37e-07	7.69e-05	0.18	0.15	Pneumococcal bacteremia;	chr3:128992582	chr3:128861313~128871540:-
BRCA	cis	rs9868809	0.505	rs11708786	ENSG00000270441.1	RP11-694I15.7	4.98	7.38e-07	7.69e-05	0.26	0.15	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48715221	chr3:49140086~49160851:-
BRCA	cis	rs6840360	0.642	rs7677131	ENSG00000251611.1	RP11-610P16.1	-4.98	7.38e-07	7.69e-05	-0.13	-0.15	Intelligence (multi-trait analysis);	chr4:151431863	chr4:151407551~151408835:-
BRCA	cis	rs6452524	0.967	rs965674	ENSG00000281327.1	LINC01338	4.98	7.38e-07	7.7e-05	0.18	0.15	Hypertension (SNP x SNP interaction);	chr5:83186765	chr5:82850864~82859836:-
BRCA	cis	rs6452524	0.967	rs2662242	ENSG00000281327.1	LINC01338	4.98	7.38e-07	7.7e-05	0.18	0.15	Hypertension (SNP x SNP interaction);	chr5:83189066	chr5:82850864~82859836:-
BRCA	cis	rs8064024	0.625	rs960006	ENSG00000267077.1	RP11-127I20.5	4.98	7.38e-07	7.7e-05	0.16	0.15	Cancer;	chr16:4861194	chr16:4795265~4796532:-
BRCA	cis	rs6840360	0.642	rs2724580	ENSG00000251611.1	RP11-610P16.1	-4.98	7.38e-07	7.7e-05	-0.13	-0.15	Intelligence (multi-trait analysis);	chr4:151451353	chr4:151407551~151408835:-
BRCA	cis	rs595244	1	rs627634	ENSG00000259705.1	RP11-227D13.1	4.98	7.38e-07	7.7e-05	0.28	0.15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48587094	chr15:48645951~48652016:+
BRCA	cis	rs1345301	0.587	rs12464251	ENSG00000234389.1	AC007278.3	-4.98	7.38e-07	7.7e-05	-0.14	-0.15	Waist circumference;	chr2:102250748	chr2:102438713~102440475:+
BRCA	cis	rs1345301	0.609	rs56389410	ENSG00000234389.1	AC007278.3	-4.98	7.38e-07	7.7e-05	-0.14	-0.15	Waist circumference;	chr2:102251203	chr2:102438713~102440475:+
BRCA	cis	rs4713118	0.513	rs1225591	ENSG00000280107.1	AL022393.9	-4.98	7.39e-07	7.71e-05	-0.21	-0.15	Parkinson's disease;	chr6:28180974	chr6:28170845~28172521:+
BRCA	cis	rs13113518	1	rs7660980	ENSG00000272969.1	RP11-528I4.2	-4.98	7.39e-07	7.71e-05	-0.18	-0.15	Height;	chr4:55542948	chr4:55547112~55547889:+
BRCA	cis	rs4218	0.681	rs10518996	ENSG00000277144.1	RP11-59H7.4	-4.98	7.39e-07	7.71e-05	-0.19	-0.15	Social communication problems;	chr15:59085247	chr15:59115547~59116089:-
BRCA	cis	rs875971	1	rs6460292	ENSG00000223473.2	GS1-124K5.3	-4.98	7.4e-07	7.72e-05	-0.12	-0.15	Aortic root size;	chr7:66345088	chr7:66491049~66493566:-
BRCA	cis	rs13108904	0.934	rs13149952	ENSG00000253399.1	AC078852.2	-4.98	7.4e-07	7.72e-05	-0.17	-0.15	Obesity-related traits;	chr4:1314649	chr4:1358479~1359461:+
BRCA	cis	rs8098244	0.964	rs6507956	ENSG00000264745.1	TTC39C-AS1	4.98	7.4e-07	7.72e-05	0.21	0.15	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23820064	chr18:23994213~24015339:-
BRCA	cis	rs6847067	0.711	rs12502294	ENSG00000180769.7	WDFY3-AS2	4.98	7.4e-07	7.72e-05	0.15	0.15	Oropharynx cancer;	chr4:84782035	chr4:84965682~85011277:+
BRCA	cis	rs7818688	1	rs10113545	ENSG00000253528.2	RP11-347C18.4	-4.98	7.4e-07	7.72e-05	-0.23	-0.15	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95017479	chr8:94974573~94974853:-
BRCA	cis	rs9341808	0.527	rs7453746	ENSG00000272129.1	RP11-250B2.6	4.98	7.41e-07	7.72e-05	0.19	0.15	Sitting height ratio;	chr6:80100296	chr6:80355424~80356859:+
BRCA	cis	rs950169	0.579	rs11633088	ENSG00000275120.1	RP11-182J1.17	-4.98	7.41e-07	7.72e-05	-0.22	-0.15	Schizophrenia;	chr15:84003429	chr15:84599434~84606463:-
BRCA	cis	rs8098244	0.603	rs2337186	ENSG00000264745.1	TTC39C-AS1	4.98	7.41e-07	7.73e-05	0.18	0.15	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23732088	chr18:23994213~24015339:-
BRCA	cis	rs2638953	0.924	rs10843162	ENSG00000247934.4	RP11-967K21.1	-4.98	7.41e-07	7.73e-05	-0.21	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28410985	chr12:28163298~28190738:-
BRCA	cis	rs4666002	0.957	rs1919128	ENSG00000234072.1	AC074117.10	4.98	7.41e-07	7.73e-05	0.16	0.15	Phospholipid levels (plasma);	chr2:27578892	chr2:27356246~27367622:+
BRCA	cis	rs7141336	1	rs6575155	ENSG00000258884.1	CTD-3035D6.2	4.98	7.41e-07	7.73e-05	0.2	0.15	Anxiety disorder;	chr14:90818596	chr14:90822365~90828128:-
BRCA	cis	rs62025270	0.806	rs62025266	ENSG00000259295.5	CSPG4P12	-4.98	7.42e-07	7.73e-05	-0.23	-0.15	Idiopathic pulmonary fibrosis;	chr15:85755217	chr15:85191438~85213905:+
BRCA	cis	rs11168351	0.864	rs10875743	ENSG00000273765.1	RP11-370I10.11	-4.98	7.42e-07	7.73e-05	-0.18	-0.15	Bipolar disorder and schizophrenia;	chr12:48104630	chr12:48360920~48361377:+
BRCA	cis	rs875971	0.545	rs10950025	ENSG00000232546.1	RP11-458F8.1	4.98	7.42e-07	7.73e-05	0.14	0.15	Aortic root size;	chr7:66158946	chr7:66848496~66858136:+
BRCA	cis	rs875971	0.52	rs12666485	ENSG00000232546.1	RP11-458F8.1	4.98	7.42e-07	7.73e-05	0.14	0.15	Aortic root size;	chr7:66160135	chr7:66848496~66858136:+
BRCA	cis	rs875971	0.545	rs67688847	ENSG00000232546.1	RP11-458F8.1	4.98	7.42e-07	7.73e-05	0.14	0.15	Aortic root size;	chr7:66161064	chr7:66848496~66858136:+
BRCA	cis	rs2408955	0.568	rs12099462	ENSG00000273765.1	RP11-370I10.11	-4.98	7.42e-07	7.74e-05	-0.18	-0.15	Glycated hemoglobin levels;	chr12:48109321	chr12:48360920~48361377:+
BRCA	cis	rs7246657	0.722	rs2909098	ENSG00000276846.1	CTD-3220F14.3	-4.98	7.42e-07	7.74e-05	-0.21	-0.15	Coronary artery calcification;	chr19:37713347	chr19:37314868~37315620:-
BRCA	cis	rs2243480	1	rs2533288	ENSG00000222364.1	RNU6-96P	-4.98	7.42e-07	7.74e-05	-0.28	-0.15	Diabetic kidney disease;	chr7:66591724	chr7:66395191~66395286:+
BRCA	cis	rs2255336	0.938	rs2617152	ENSG00000245648.1	RP11-277P12.20	4.98	7.43e-07	7.75e-05	0.22	0.15	Blood protein levels;	chr12:10380507	chr12:10363769~10398506:+
BRCA	cis	rs597539	0.615	rs583182	ENSG00000261625.1	RP11-554A11.4	-4.98	7.43e-07	7.75e-05	-0.15	-0.15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68911166	chr11:69000765~69002048:-
BRCA	cis	rs7577696	0.85	rs3769606	ENSG00000272716.1	RP11-563N4.1	-4.98	7.43e-07	7.75e-05	-0.17	-0.15	Inflammatory biomarkers;	chr2:32092481	chr2:32165046~32165757:-
BRCA	cis	rs6490294	0.528	rs77211491	ENSG00000226469.1	ADAM1B	4.98	7.43e-07	7.75e-05	0.26	0.15	Mean platelet volume;	chr12:111884974	chr12:111927018~111929017:+
BRCA	cis	rs2235544	0.554	rs7540270	ENSG00000225183.1	RP4-758J24.4	-4.98	7.43e-07	7.75e-05	-0.18	-0.15	Thyroid hormone levels;Multiple myeloma (hyperdiploidy);	chr1:54019009	chr1:54089856~54090093:+
BRCA	cis	rs10129255	1	rs4612959	ENSG00000211974.3	IGHV2-70	4.98	7.44e-07	7.76e-05	0.16	0.15	Kawasaki disease;	chr14:106767055	chr14:106723574~106724093:-
BRCA	cis	rs7200543	1	rs16966947	ENSG00000258354.1	MIR3180-1	-4.98	7.44e-07	7.76e-05	-0.2	-0.15	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15047188	chr16:14909887~14911345:-
BRCA	cis	rs7772486	0.754	rs702306	ENSG00000270638.1	RP3-466P17.1	-4.98	7.45e-07	7.76e-05	-0.18	-0.15	Lobe attachment (rater-scored or self-reported);	chr6:145669893	chr6:145735570~145737218:+
BRCA	cis	rs4218	0.689	rs60262196	ENSG00000277144.1	RP11-59H7.4	-4.98	7.45e-07	7.76e-05	-0.21	-0.15	Social communication problems;	chr15:59088853	chr15:59115547~59116089:-
BRCA	cis	rs34787248	1	rs34787248	ENSG00000216901.1	AL022393.7	4.98	7.45e-07	7.77e-05	0.24	0.15	Autism spectrum disorder or schizophrenia;	chr6:28230108	chr6:28176188~28176674:+
BRCA	cis	rs801193	0.591	rs721717	ENSG00000236529.1	RP13-254B10.1	-4.98	7.45e-07	7.77e-05	-0.17	-0.15	Aortic root size;	chr7:66665305	chr7:65840212~65840596:+
BRCA	cis	rs6496044	0.568	rs7166642	ENSG00000259295.5	CSPG4P12	4.98	7.45e-07	7.77e-05	0.18	0.15	Interstitial lung disease;	chr15:85518040	chr15:85191438~85213905:+
BRCA	cis	rs9467773	0.62	rs2101582	ENSG00000124549.13	BTN2A3P	4.98	7.45e-07	7.77e-05	0.15	0.15	Intelligence (multi-trait analysis);	chr6:26622506	chr6:26421391~26432383:+
BRCA	cis	rs875971	0.798	rs12698522	ENSG00000236529.1	RP13-254B10.1	4.98	7.46e-07	7.78e-05	0.17	0.15	Aortic root size;	chr7:66502354	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.83	rs28714531	ENSG00000236529.1	RP13-254B10.1	4.98	7.46e-07	7.78e-05	0.17	0.15	Aortic root size;	chr7:66503250	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.862	rs12698526	ENSG00000236529.1	RP13-254B10.1	4.98	7.46e-07	7.78e-05	0.17	0.15	Aortic root size;	chr7:66504118	chr7:65840212~65840596:+
BRCA	cis	rs4718428	0.705	rs10267335	ENSG00000229180.5	GS1-124K5.11	4.98	7.46e-07	7.78e-05	0.15	0.15	Corneal structure;	chr7:66938233	chr7:66526088~66542624:-
BRCA	cis	rs7617773	1	rs12496784	ENSG00000228638.1	FCF1P2	4.98	7.47e-07	7.78e-05	0.15	0.15	Coronary artery disease;	chr3:48144777	chr3:48290793~48291375:-
BRCA	cis	rs2505998	0.833	rs2251674	ENSG00000273008.1	RP11-351D16.3	4.98	7.47e-07	7.78e-05	0.18	0.15	Hirschsprung disease;	chr10:43109944	chr10:43136824~43138334:-
BRCA	cis	rs3845817	0.801	rs2438102	ENSG00000237979.1	AC007389.1	4.98	7.47e-07	7.79e-05	0.19	0.15	Bipolar disorder;	chr2:65530223	chr2:65500993~65502138:-
BRCA	cis	rs4886920	0.638	rs4886919	ENSG00000260776.4	RP11-114H24.2	-4.98	7.48e-07	7.79e-05	-0.18	-0.15	Neuroticism;	chr15:77814822	chr15:77914217~77926846:-
BRCA	cis	rs9868809	0.881	rs13324142	ENSG00000270441.1	RP11-694I15.7	4.98	7.48e-07	7.79e-05	0.28	0.15	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48632014	chr3:49140086~49160851:-
BRCA	cis	rs2408955	0.521	rs10875749	ENSG00000273765.1	RP11-370I10.11	-4.98	7.48e-07	7.79e-05	-0.18	-0.15	Glycated hemoglobin levels;	chr12:48138134	chr12:48360920~48361377:+
BRCA	cis	rs6569038	0.502	rs57100274	ENSG00000253194.1	RP11-351A11.1	4.98	7.48e-07	7.8e-05	0.19	0.15	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr6:118993610	chr6:118934785~119031541:+
BRCA	cis	rs7226408	0.857	rs3747896	ENSG00000267707.2	RP11-95O2.5	4.98	7.49e-07	7.8e-05	0.23	0.15	Obesity-related traits;	chr18:37067360	chr18:37243776~37247506:+
BRCA	cis	rs7246657	0.551	rs4806414	ENSG00000267422.1	CTD-2554C21.1	-4.98	7.49e-07	7.81e-05	-0.26	-0.15	Coronary artery calcification;	chr19:37147886	chr19:37779686~37792865:+
BRCA	cis	rs62025270	0.806	rs62025262	ENSG00000259762.1	RP11-158M2.4	-4.98	7.49e-07	7.81e-05	-0.23	-0.15	Idiopathic pulmonary fibrosis;	chr15:85750002	chr15:85750336~85752901:-
BRCA	cis	rs1850744	0.536	rs6843869	ENSG00000163612.10	FAM86KP	-4.98	7.5e-07	7.81e-05	-0.34	-0.15	Economic and political preferences;	chr4:9632827	chr4:9153296~9165451:+
BRCA	cis	rs2243480	1	rs13310597	ENSG00000275400.1	RP4-756H11.5	4.98	7.5e-07	7.81e-05	0.28	0.15	Diabetic kidney disease;	chr7:66133553	chr7:66553805~66554199:-
BRCA	cis	rs4713118	0.868	rs760587	ENSG00000216901.1	AL022393.7	4.98	7.5e-07	7.81e-05	0.22	0.15	Parkinson's disease;	chr6:27772521	chr6:28176188~28176674:+
BRCA	cis	rs10911232	0.507	rs10752890	ENSG00000224468.3	RP11-181K3.4	-4.98	7.5e-07	7.81e-05	-0.16	-0.15	Hypertriglyceridemia;	chr1:183052775	chr1:183138402~183141282:-
BRCA	cis	rs4072705	0.646	rs10120967	ENSG00000224020.1	MIR181A2HG	-4.98	7.5e-07	7.82e-05	-0.18	-0.15	Menarche (age at onset);	chr9:124481855	chr9:124658467~124698631:+
BRCA	cis	rs7615952	0.546	rs2979340	ENSG00000171084.14	FAM86JP	4.98	7.5e-07	7.82e-05	0.26	0.15	Blood pressure (smoking interaction);	chr3:125622540	chr3:125916620~125930024:+
BRCA	cis	rs7615952	0.546	rs2979338	ENSG00000171084.14	FAM86JP	4.98	7.5e-07	7.82e-05	0.26	0.15	Blood pressure (smoking interaction);	chr3:125624282	chr3:125916620~125930024:+
BRCA	cis	rs7615952	0.546	rs2922171	ENSG00000171084.14	FAM86JP	4.98	7.5e-07	7.82e-05	0.26	0.15	Blood pressure (smoking interaction);	chr3:125624349	chr3:125916620~125930024:+
BRCA	cis	rs7615952	0.546	rs112919177	ENSG00000171084.14	FAM86JP	4.98	7.5e-07	7.82e-05	0.26	0.15	Blood pressure (smoking interaction);	chr3:125627226	chr3:125916620~125930024:+
BRCA	cis	rs6163	0.588	rs3818708	ENSG00000236937.2	PTGES3P4	4.98	7.51e-07	7.83e-05	0.19	0.15	Waist circumference;Hip circumference;	chr10:102743827	chr10:102845595~102845950:+
BRCA	cis	rs13113518	0.966	rs13108409	ENSG00000223305.1	RN7SKP30	4.98	7.51e-07	7.83e-05	0.18	0.15	Height;	chr4:55520278	chr4:55540502~55540835:-
BRCA	cis	rs11098499	0.826	rs4472123	ENSG00000249244.1	RP11-548H18.2	4.98	7.51e-07	7.83e-05	0.18	0.15	Corneal astigmatism;	chr4:119315475	chr4:119391831~119395335:-
BRCA	cis	rs897984	0.806	rs12924903	ENSG00000275263.1	RP11-1072A3.4	-4.98	7.52e-07	7.83e-05	-0.18	-0.15	Dementia with Lewy bodies;	chr16:30917649	chr16:30956872~30957199:-
BRCA	cis	rs1876905	0.597	rs354538	ENSG00000272356.1	RP5-1112D6.8	-4.98	7.52e-07	7.83e-05	-0.2	-0.15	Mean corpuscular hemoglobin;	chr6:111196863	chr6:111309203~111313517:+
BRCA	cis	rs17767294	0.708	rs72848786	ENSG00000204709.4	LINC01556	4.98	7.52e-07	7.84e-05	0.4	0.15	Parkinson's disease;	chr6:28012239	chr6:28943877~28944537:+
BRCA	cis	rs16846053	0.792	rs55893794	ENSG00000227403.1	AC009299.3	4.98	7.52e-07	7.84e-05	0.36	0.15	Blood osmolality (transformed sodium);	chr2:161562241	chr2:161244739~161249050:+
BRCA	cis	rs2303319	0.504	rs57464189	ENSG00000227403.1	AC009299.3	4.98	7.52e-07	7.84e-05	0.36	0.15	Cognitive function;	chr2:161562802	chr2:161244739~161249050:+
BRCA	cis	rs2303319	0.504	rs72870226	ENSG00000227403.1	AC009299.3	4.98	7.52e-07	7.84e-05	0.36	0.15	Cognitive function;	chr2:161563919	chr2:161244739~161249050:+
BRCA	cis	rs3764021	0.509	rs10772071	ENSG00000214776.8	RP11-726G1.1	4.98	7.52e-07	7.84e-05	0.19	0.15	Type 1 diabetes;	chr12:9717324	chr12:9467552~9576275:+
BRCA	cis	rs2274223	0.62	rs35658839	ENSG00000273450.1	RP11-76P2.4	4.98	7.52e-07	7.84e-05	0.24	0.15	Esophageal cancer;Esophageal squamous cell carcinoma;	chr10:94302642	chr10:94314907~94315327:-
BRCA	cis	rs10129255	0.957	rs8019272	ENSG00000211974.3	IGHV2-70	4.98	7.53e-07	7.84e-05	0.15	0.15	Kawasaki disease;	chr14:106784709	chr14:106723574~106724093:-
BRCA	cis	rs8180040	0.966	rs12636851	ENSG00000271161.1	BOLA2P2	4.98	7.53e-07	7.84e-05	0.16	0.15	Colorectal cancer;	chr3:47422077	chr3:47499841~47500407:+
BRCA	cis	rs9545047	0.604	rs2765078	ENSG00000227354.5	RBM26-AS1	4.98	7.53e-07	7.84e-05	0.17	0.15	Schizophrenia;	chr13:79420604	chr13:79406309~79424328:+
BRCA	cis	rs7267979	0.844	rs2474780	ENSG00000204556.4	CTD-2514C3.1	-4.98	7.53e-07	7.84e-05	-0.21	-0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25305199	chr20:26018832~26020684:+
BRCA	cis	rs115769866	0.569	rs2859358	ENSG00000216901.1	AL022393.7	4.98	7.53e-07	7.84e-05	0.21	0.15	Bipolar disorder;	chr6:28505044	chr6:28176188~28176674:+
BRCA	cis	rs11758351	0.66	rs55643278	ENSG00000241549.7	GUSBP2	-4.98	7.53e-07	7.84e-05	-0.22	-0.15	Renal underexcretion gout;Gout;	chr6:26222660	chr6:26871484~26956554:-
BRCA	cis	rs2562456	0.754	rs55771551	ENSG00000268535.1	RP11-420K14.3	4.98	7.53e-07	7.84e-05	0.21	0.15	Pain;	chr19:21563578	chr19:21709522~21710191:+
BRCA	cis	rs12893668	0.703	rs729438	ENSG00000269940.1	RP11-73M18.7	-4.98	7.53e-07	7.84e-05	-0.17	-0.15	Reticulocyte count;	chr14:103626452	chr14:103694560~103695170:+
BRCA	cis	rs9907295	0.818	rs4251702	ENSG00000271013.1	AC015849.15	4.98	7.54e-07	7.85e-05	0.24	0.15	Fibroblast growth factor basic levels;	chr17:35807933	chr17:35912635~35918010:-
BRCA	cis	rs6596100	0.915	rs76836760	ENSG00000248648.1	RP11-485M7.1	-4.98	7.54e-07	7.85e-05	-0.19	-0.15	Breast cancer;	chr5:133052376	chr5:133003119~133003365:+
BRCA	cis	rs875971	0.545	rs17138149	ENSG00000232546.1	RP11-458F8.1	4.98	7.54e-07	7.85e-05	0.14	0.15	Aortic root size;	chr7:66228193	chr7:66848496~66858136:+
BRCA	cis	rs13118159	0.55	rs28522910	ENSG00000254094.1	AC078852.1	-4.98	7.54e-07	7.85e-05	-0.18	-0.15	Longevity;	chr4:1380986	chr4:1356581~1358075:+
BRCA	cis	rs4934494	0.677	rs11185810	ENSG00000240996.1	RP11-80H5.7	-4.98	7.54e-07	7.85e-05	-0.21	-0.15	Red blood cell count;	chr10:89621724	chr10:89694295~89697928:-
BRCA	cis	rs875971	0.862	rs11765791	ENSG00000236529.1	RP13-254B10.1	4.98	7.54e-07	7.86e-05	0.17	0.15	Aortic root size;	chr7:66471587	chr7:65840212~65840596:+
BRCA	cis	rs172166	0.694	rs203877	ENSG00000219392.1	RP1-265C24.5	-4.98	7.54e-07	7.86e-05	-0.21	-0.15	Cardiac Troponin-T levels;	chr6:28080846	chr6:28115628~28116551:+
BRCA	cis	rs4218	0.517	rs2899640	ENSG00000277144.1	RP11-59H7.4	-4.98	7.55e-07	7.86e-05	-0.2	-0.15	Social communication problems;	chr15:59060281	chr15:59115547~59116089:-
BRCA	cis	rs3768617	0.51	rs3765522	ENSG00000224468.3	RP11-181K3.4	-4.98	7.55e-07	7.86e-05	-0.17	-0.15	Fuchs's corneal dystrophy;	chr1:183108483	chr1:183138402~183141282:-
BRCA	cis	rs7824557	1	rs7824557	ENSG00000154316.13	TDH	4.98	7.55e-07	7.86e-05	0.2	0.15	Retinal vascular caliber;	chr8:11246602	chr8:11339637~11368452:+
BRCA	cis	rs8098244	1	rs938602	ENSG00000264745.1	TTC39C-AS1	-4.98	7.56e-07	7.87e-05	-0.21	-0.15	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23812714	chr18:23994213~24015339:-
BRCA	cis	rs66887589	0.777	rs2017058	ENSG00000245958.5	RP11-33B1.1	-4.98	7.56e-07	7.87e-05	-0.13	-0.15	Diastolic blood pressure;	chr4:119336584	chr4:119454791~119552025:+
BRCA	cis	rs9311474	0.713	rs352168	ENSG00000243224.1	RP5-1157M23.2	-4.98	7.56e-07	7.87e-05	-0.16	-0.15	Electroencephalogram traits;	chr3:52203954	chr3:52239258~52241097:+
BRCA	cis	rs736408	0.609	rs2268025	ENSG00000243224.1	RP5-1157M23.2	-4.98	7.56e-07	7.87e-05	-0.17	-0.15	Bipolar disorder;	chr3:52761208	chr3:52239258~52241097:+
BRCA	cis	rs7267979	0.844	rs6083851	ENSG00000274973.1	RP13-401N8.7	4.98	7.57e-07	7.87e-05	0.17	0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25420599	chr20:25845497~25845862:+
BRCA	cis	rs10989172	0.714	rs4559354	ENSG00000175611.10	LINC00476	4.98	7.57e-07	7.88e-05	0.16	0.15	Common carotid intima-media thickness in HIV negative individuals;	chr9:96077165	chr9:95759231~95875977:-
BRCA	cis	rs2665103	0.589	rs2134046	ENSG00000276710.3	CSPG4P8	-4.98	7.57e-07	7.88e-05	-0.16	-0.15	Intelligence (multi-trait analysis);	chr15:82232203	chr15:82459472~82477258:+
BRCA	cis	rs1005277	0.563	rs2505216	ENSG00000263064.2	RP11-291L22.7	4.98	7.57e-07	7.88e-05	0.19	0.15	Extrinsic epigenetic age acceleration;	chr10:38193902	chr10:38448689~38448949:+
BRCA	cis	rs7572733	0.534	rs11890137	ENSG00000231621.1	AC013264.2	-4.98	7.57e-07	7.88e-05	-0.15	-0.15	Dermatomyositis;	chr2:197951938	chr2:197197991~197199273:+
BRCA	cis	rs6893782	0.887	rs274554	ENSG00000233006.5	AC034220.3	-4.98	7.57e-07	7.88e-05	-0.13	-0.15	Acylcarnitine levels;	chr5:132389258	chr5:132311285~132369916:-
BRCA	cis	rs1722141	0.6	rs788738	ENSG00000237471.1	AC073115.6	4.98	7.58e-07	7.89e-05	0.21	0.15	Sitting height ratio;	chr7:46001766	chr7:45969657~45980191:+
BRCA	cis	rs3764021	0.509	rs10772070	ENSG00000256673.1	RP11-599J14.2	-4.98	7.58e-07	7.89e-05	-0.19	-0.15	Type 1 diabetes;	chr12:9717320	chr12:9398355~9414851:-
BRCA	cis	rs9921338	0.961	rs72773825	ENSG00000262703.1	RP11-485G7.6	-4.98	7.58e-07	7.89e-05	-0.19	-0.15	Vein graft stenosis in coronary artery bypass grafting;	chr16:11318591	chr16:11348143~11349321:-
BRCA	cis	rs875971	0.545	rs67775320	ENSG00000232546.1	RP11-458F8.1	4.98	7.58e-07	7.89e-05	0.14	0.15	Aortic root size;	chr7:66193792	chr7:66848496~66858136:+
BRCA	cis	rs8127691	0.967	rs4317019	ENSG00000237604.1	AP001056.1	4.98	7.59e-07	7.9e-05	0.17	0.15	Inflammatory bowel disease;	chr21:44196392	chr21:44175489~44176453:+
BRCA	cis	rs2562456	0.917	rs2650804	ENSG00000268535.1	RP11-420K14.3	4.98	7.59e-07	7.9e-05	0.2	0.15	Pain;	chr19:21497382	chr19:21709522~21710191:+
BRCA	cis	rs4819052	0.851	rs2838856	ENSG00000184274.3	LINC00315	-4.98	7.59e-07	7.9e-05	-0.2	-0.15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260851	chr21:45300245~45305257:-
BRCA	cis	rs4819052	0.851	rs9974891	ENSG00000184274.3	LINC00315	-4.98	7.59e-07	7.9e-05	-0.2	-0.15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260852	chr21:45300245~45305257:-
BRCA	cis	rs8064024	0.681	rs1395602	ENSG00000267077.1	RP11-127I20.5	4.98	7.59e-07	7.9e-05	0.16	0.15	Cancer;	chr16:4861238	chr16:4795265~4796532:-
BRCA	cis	rs7226408	0.842	rs62083203	ENSG00000267707.2	RP11-95O2.5	4.98	7.59e-07	7.9e-05	0.26	0.15	Obesity-related traits;	chr18:36772544	chr18:37243776~37247506:+
BRCA	cis	rs7577696	0.962	rs2280967	ENSG00000272716.1	RP11-563N4.1	-4.98	7.59e-07	7.9e-05	-0.17	-0.15	Inflammatory biomarkers;	chr2:32064677	chr2:32165046~32165757:-
BRCA	cis	rs10752881	0.967	rs12404594	ENSG00000224468.3	RP11-181K3.4	-4.98	7.6e-07	7.9e-05	-0.16	-0.15	Colorectal cancer;	chr1:183018892	chr1:183138402~183141282:-
BRCA	cis	rs559555	0.849	rs2208532	ENSG00000272716.1	RP11-563N4.1	-4.98	7.6e-07	7.91e-05	-0.16	-0.15	Blood metabolite ratios;Blood metabolite levels;	chr2:31563919	chr2:32165046~32165757:-
BRCA	cis	rs9863	0.861	rs4930726	ENSG00000270028.1	RP11-380L11.4	4.98	7.6e-07	7.91e-05	0.19	0.15	White blood cell count;	chr12:123943784	chr12:123925461~123926083:-
BRCA	cis	rs7572733	0.515	rs1401096	ENSG00000231621.1	AC013264.2	-4.98	7.61e-07	7.91e-05	-0.15	-0.15	Dermatomyositis;	chr2:197959104	chr2:197197991~197199273:+
BRCA	cis	rs62025270	0.522	rs16943120	ENSG00000259295.5	CSPG4P12	-4.98	7.61e-07	7.92e-05	-0.23	-0.15	Idiopathic pulmonary fibrosis;	chr15:85683066	chr15:85191438~85213905:+
BRCA	cis	rs875971	0.862	rs1860469	ENSG00000236529.1	RP13-254B10.1	-4.98	7.61e-07	7.92e-05	-0.17	-0.15	Aortic root size;	chr7:66641888	chr7:65840212~65840596:+
BRCA	cis	rs10911251	0.508	rs729672	ENSG00000224468.3	RP11-181K3.4	-4.98	7.61e-07	7.92e-05	-0.16	-0.15	Colorectal cancer;	chr1:183140101	chr1:183138402~183141282:-
BRCA	cis	rs7246657	0.722	rs2909102	ENSG00000276846.1	CTD-3220F14.3	-4.98	7.62e-07	7.92e-05	-0.21	-0.15	Coronary artery calcification;	chr19:37676463	chr19:37314868~37315620:-
BRCA	cis	rs875971	1	rs4718307	ENSG00000223473.2	GS1-124K5.3	-4.98	7.62e-07	7.93e-05	-0.12	-0.15	Aortic root size;	chr7:66146001	chr7:66491049~66493566:-
BRCA	cis	rs875971	1	rs7801282	ENSG00000223473.2	GS1-124K5.3	-4.98	7.62e-07	7.93e-05	-0.12	-0.15	Aortic root size;	chr7:66148700	chr7:66491049~66493566:-
BRCA	cis	rs4718428	0.705	rs4718422	ENSG00000229180.5	GS1-124K5.11	4.98	7.62e-07	7.93e-05	0.15	0.15	Corneal structure;	chr7:66894282	chr7:66526088~66542624:-
BRCA	cis	rs1075265	0.704	rs805402	ENSG00000235937.1	AC008280.1	4.98	7.62e-07	7.93e-05	0.17	0.15	Chronotype;Morning vs. evening chronotype;	chr2:53889212	chr2:54029552~54030682:-
BRCA	cis	rs7572733	0.534	rs1607375	ENSG00000231621.1	AC013264.2	-4.98	7.62e-07	7.93e-05	-0.15	-0.15	Dermatomyositis;	chr2:197935663	chr2:197197991~197199273:+
BRCA	cis	rs7572733	0.534	rs4369854	ENSG00000231621.1	AC013264.2	-4.98	7.62e-07	7.93e-05	-0.15	-0.15	Dermatomyositis;	chr2:197935906	chr2:197197991~197199273:+
BRCA	cis	rs1499614	0.803	rs1796229	ENSG00000275400.1	RP4-756H11.5	4.98	7.63e-07	7.93e-05	0.28	0.15	Gout;	chr7:66654674	chr7:66553805~66554199:-
BRCA	cis	rs13434995	0.513	rs6851971	ENSG00000249700.7	SRD5A3-AS1	4.97	7.63e-07	7.94e-05	0.22	0.15	Adiponectin levels;	chr4:55561897	chr4:55363971~55395847:-
BRCA	cis	rs375066	0.551	rs2099356	ENSG00000267058.1	RP11-15A1.3	4.97	7.63e-07	7.94e-05	0.19	0.15	Breast cancer;	chr19:43811044	chr19:43891804~43901805:-
BRCA	cis	rs3176789	0.914	rs724667	ENSG00000256673.1	RP11-599J14.2	4.97	7.64e-07	7.94e-05	0.19	0.15	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9770255	chr12:9398355~9414851:-
BRCA	cis	rs2153535	0.585	rs7753781	ENSG00000230939.1	RP11-314C16.1	-4.97	7.65e-07	7.95e-05	-0.17	-0.15	Motion sickness;	chr6:8637268	chr6:8784178~8785445:+
BRCA	cis	rs11673344	0.542	rs826328	ENSG00000226686.6	LINC01535	4.97	7.65e-07	7.96e-05	0.2	0.15	Obesity-related traits;	chr19:37004479	chr19:37251912~37265535:+
BRCA	cis	rs66887589	0.967	rs56173225	ENSG00000245958.5	RP11-33B1.1	4.97	7.65e-07	7.96e-05	0.13	0.15	Diastolic blood pressure;	chr4:119588817	chr4:119454791~119552025:+
BRCA	cis	rs3845817	0.868	rs702938	ENSG00000237979.1	AC007389.1	-4.97	7.66e-07	7.96e-05	-0.19	-0.15	Bipolar disorder;	chr2:65520308	chr2:65500993~65502138:-
BRCA	cis	rs867371	0.762	rs1846910	ENSG00000276710.3	CSPG4P8	-4.97	7.66e-07	7.96e-05	-0.17	-0.15	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82279439	chr15:82459472~82477258:+
BRCA	cis	rs6928977	0.5	rs719885	ENSG00000231028.7	LINC00271	-4.97	7.66e-07	7.96e-05	-0.16	-0.15	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135618217	chr6:135497801~135716055:+
BRCA	cis	rs1552244	1	rs58275763	ENSG00000232901.1	CYCSP10	4.97	7.66e-07	7.97e-05	0.21	0.15	Alzheimer's disease;	chr3:10101590	chr3:10000647~10000940:-
BRCA	cis	rs6570726	0.791	rs9376945	ENSG00000270638.1	RP3-466P17.1	4.97	7.67e-07	7.97e-05	0.18	0.15	Lobe attachment (rater-scored or self-reported);	chr6:145506944	chr6:145735570~145737218:+
BRCA	cis	rs6570726	0.755	rs451699	ENSG00000270638.1	RP3-466P17.1	4.97	7.67e-07	7.97e-05	0.18	0.15	Lobe attachment (rater-scored or self-reported);	chr6:145509458	chr6:145735570~145737218:+
BRCA	cis	rs6570726	0.791	rs401561	ENSG00000270638.1	RP3-466P17.1	4.97	7.67e-07	7.97e-05	0.18	0.15	Lobe attachment (rater-scored or self-reported);	chr6:145514781	chr6:145735570~145737218:+
BRCA	cis	rs6570726	0.791	rs405206	ENSG00000270638.1	RP3-466P17.1	4.97	7.67e-07	7.97e-05	0.18	0.15	Lobe attachment (rater-scored or self-reported);	chr6:145515737	chr6:145735570~145737218:+
BRCA	cis	rs6570726	0.791	rs374478	ENSG00000270638.1	RP3-466P17.1	4.97	7.67e-07	7.97e-05	0.18	0.15	Lobe attachment (rater-scored or self-reported);	chr6:145518886	chr6:145735570~145737218:+
BRCA	cis	rs2274273	0.686	rs66842809	ENSG00000258413.1	RP11-665C16.6	-4.97	7.67e-07	7.97e-05	-0.2	-0.15	Protein biomarker;	chr14:55163853	chr14:55262767~55272075:-
BRCA	cis	rs2638953	0.962	rs11049585	ENSG00000247934.4	RP11-967K21.1	-4.97	7.67e-07	7.97e-05	-0.21	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28417957	chr12:28163298~28190738:-
BRCA	cis	rs600231	0.708	rs2957268	ENSG00000173727.10	CMB9-22P13.1	4.97	7.68e-07	7.98e-05	0.2	0.15	Bone mineral density;	chr11:65478345	chr11:65455258~65466720:+
BRCA	cis	rs35264875	0.808	rs2305498	ENSG00000259799.1	RP11-554A11.9	4.97	7.68e-07	7.98e-05	0.21	0.15	Blond vs. brown hair color;	chr11:69099446	chr11:69155910~69159752:+
BRCA	cis	rs2904967	0.866	rs676573	ENSG00000255200.1	AP003068.18	-4.97	7.68e-07	7.99e-05	-0.26	-0.15	Mean corpuscular volume;	chr11:65258991	chr11:65174117~65176470:-
BRCA	cis	rs5751614	0.537	rs3788358	ENSG00000240160.3	RN7SL263P	4.97	7.68e-07	7.99e-05	0.2	0.15	Height;	chr22:23274168	chr22:23261782~23262071:-
BRCA	cis	rs783540	0.632	rs17356528	ENSG00000255769.6	GOLGA2P10	4.97	7.68e-07	7.99e-05	0.19	0.15	Schizophrenia;	chr15:82636799	chr15:82472993~82513950:-
BRCA	cis	rs7945705	0.837	rs10769966	ENSG00000254860.4	TMEM9B-AS1	-4.97	7.68e-07	7.99e-05	-0.14	-0.15	Hemoglobin concentration;	chr11:8825494	chr11:8964675~8977527:+
BRCA	cis	rs7572733	0.534	rs1464209	ENSG00000231621.1	AC013264.2	-4.97	7.69e-07	7.99e-05	-0.15	-0.15	Dermatomyositis;	chr2:197949672	chr2:197197991~197199273:+
BRCA	cis	rs700651	0.786	rs58224025	ENSG00000231621.1	AC013264.2	-4.97	7.69e-07	7.99e-05	-0.15	-0.15	Intracranial aneurysm;	chr2:197957264	chr2:197197991~197199273:+
BRCA	cis	rs7572733	0.515	rs13408411	ENSG00000231621.1	AC013264.2	-4.97	7.69e-07	7.99e-05	-0.15	-0.15	Dermatomyositis;	chr2:197960738	chr2:197197991~197199273:+
BRCA	cis	rs700651	0.752	rs1850631	ENSG00000231621.1	AC013264.2	-4.97	7.69e-07	7.99e-05	-0.15	-0.15	Intracranial aneurysm;	chr2:197964744	chr2:197197991~197199273:+
BRCA	cis	rs2403083	0.578	rs7823218	ENSG00000258256.1	RP11-219B4.5	-4.97	7.69e-07	8e-05	-0.19	-0.15	Plasma amyloid beta peptide concentrations (ABx-40);	chr8:85173662	chr8:85222446~85245717:-
BRCA	cis	rs12612619	0.732	rs1866654	ENSG00000272148.1	RP11-195B17.1	4.97	7.7e-07	8e-05	0.17	0.15	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27040254	chr2:27062428~27062907:-
BRCA	cis	rs997295	0.57	rs7170299	ENSG00000270964.1	RP11-502I4.3	-4.97	7.7e-07	8.01e-05	-0.17	-0.15	Motion sickness;	chr15:67580380	chr15:67541072~67542604:-
BRCA	cis	rs2403083	0.723	rs4150897	ENSG00000258256.1	RP11-219B4.5	-4.97	7.7e-07	8.01e-05	-0.19	-0.15	Plasma amyloid beta peptide concentrations (ABx-40);	chr8:85193033	chr8:85222446~85245717:-
BRCA	cis	rs1387259	0.899	rs7307566	ENSG00000226413.2	OR8T1P	4.97	7.7e-07	8.01e-05	0.2	0.15	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48210899	chr12:48442030~48442947:-
BRCA	cis	rs11098499	0.754	rs66900435	ENSG00000260404.2	RP11-384K6.6	4.97	7.71e-07	8.01e-05	0.14	0.15	Corneal astigmatism;	chr4:119328270	chr4:118591773~118633729:+
BRCA	cis	rs7914558	1	rs7896547	ENSG00000236937.2	PTGES3P4	4.97	7.71e-07	8.02e-05	0.2	0.15	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103107201	chr10:102845595~102845950:+
BRCA	cis	rs11098499	0.954	rs12505469	ENSG00000250412.1	KLHL2P1	4.97	7.72e-07	8.02e-05	0.18	0.15	Corneal astigmatism;	chr4:119328430	chr4:119334329~119378233:+
BRCA	cis	rs7226408	0.802	rs72887095	ENSG00000267707.2	RP11-95O2.5	4.97	7.72e-07	8.02e-05	0.23	0.15	Obesity-related traits;	chr18:36928986	chr18:37243776~37247506:+
BRCA	cis	rs7226408	0.802	rs72887098	ENSG00000267707.2	RP11-95O2.5	4.97	7.72e-07	8.02e-05	0.23	0.15	Obesity-related traits;	chr18:36931110	chr18:37243776~37247506:+
BRCA	cis	rs7226408	0.802	rs1445529	ENSG00000267707.2	RP11-95O2.5	4.97	7.72e-07	8.02e-05	0.23	0.15	Obesity-related traits;	chr18:36932794	chr18:37243776~37247506:+
BRCA	cis	rs7226408	0.901	rs72887101	ENSG00000267707.2	RP11-95O2.5	4.97	7.72e-07	8.02e-05	0.23	0.15	Obesity-related traits;	chr18:36933811	chr18:37243776~37247506:+
BRCA	cis	rs7226408	0.857	rs72888908	ENSG00000267707.2	RP11-95O2.5	4.97	7.72e-07	8.02e-05	0.23	0.15	Obesity-related traits;	chr18:36937826	chr18:37243776~37247506:+
BRCA	cis	rs7226408	0.857	rs11661504	ENSG00000267707.2	RP11-95O2.5	4.97	7.72e-07	8.02e-05	0.23	0.15	Obesity-related traits;	chr18:36938761	chr18:37243776~37247506:+
BRCA	cis	rs7226408	0.857	rs55992510	ENSG00000267707.2	RP11-95O2.5	4.97	7.72e-07	8.02e-05	0.23	0.15	Obesity-related traits;	chr18:36939167	chr18:37243776~37247506:+
BRCA	cis	rs7226408	0.817	rs72888915	ENSG00000267707.2	RP11-95O2.5	4.97	7.72e-07	8.02e-05	0.23	0.15	Obesity-related traits;	chr18:36941298	chr18:37243776~37247506:+
BRCA	cis	rs7226408	0.857	rs72888916	ENSG00000267707.2	RP11-95O2.5	4.97	7.72e-07	8.02e-05	0.23	0.15	Obesity-related traits;	chr18:36941373	chr18:37243776~37247506:+
BRCA	cis	rs7200543	0.961	rs3803573	ENSG00000260735.1	RP11-72I8.1	-4.97	7.72e-07	8.02e-05	-0.18	-0.15	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15044556	chr16:15094411~15109197:+
BRCA	cis	rs7226408	0.749	rs72892525	ENSG00000267707.2	RP11-95O2.5	4.97	7.72e-07	8.02e-05	0.23	0.15	Obesity-related traits;	chr18:37090778	chr18:37243776~37247506:+
BRCA	cis	rs17213965	0.561	rs9929522	ENSG00000260872.1	RP11-680G24.5	-4.97	7.72e-07	8.02e-05	-0.18	-0.15	Waist-hip ratio;	chr16:15785903	chr16:15018106~15020488:-
BRCA	cis	rs17685	0.712	rs4732578	ENSG00000280388.1	RP11-229D13.3	-4.97	7.72e-07	8.02e-05	-0.16	-0.15	Coffee consumption (cups per day);Coffee consumption;	chr7:76092214	chr7:76043977~76045963:-
BRCA	cis	rs10510102	0.935	rs12262776	ENSG00000226864.1	ATE1-AS1	4.97	7.72e-07	8.02e-05	0.27	0.15	Breast cancer;	chr10:121884532	chr10:121928312~121951965:+
BRCA	cis	rs10510102	0.935	rs12244866	ENSG00000226864.1	ATE1-AS1	4.97	7.72e-07	8.02e-05	0.27	0.15	Breast cancer;	chr10:121886013	chr10:121928312~121951965:+
BRCA	cis	rs10510102	0.935	rs12266597	ENSG00000226864.1	ATE1-AS1	4.97	7.72e-07	8.02e-05	0.27	0.15	Breast cancer;	chr10:121886062	chr10:121928312~121951965:+
BRCA	cis	rs10510102	0.935	rs12245018	ENSG00000226864.1	ATE1-AS1	4.97	7.72e-07	8.02e-05	0.27	0.15	Breast cancer;	chr10:121886195	chr10:121928312~121951965:+
BRCA	cis	rs10510102	0.935	rs11200217	ENSG00000226864.1	ATE1-AS1	4.97	7.72e-07	8.02e-05	0.27	0.15	Breast cancer;	chr10:121886372	chr10:121928312~121951965:+
BRCA	cis	rs10510102	0.935	rs11200218	ENSG00000226864.1	ATE1-AS1	4.97	7.72e-07	8.02e-05	0.27	0.15	Breast cancer;	chr10:121886410	chr10:121928312~121951965:+
BRCA	cis	rs10510102	0.935	rs10887008	ENSG00000226864.1	ATE1-AS1	4.97	7.72e-07	8.02e-05	0.27	0.15	Breast cancer;	chr10:121886714	chr10:121928312~121951965:+
BRCA	cis	rs10510102	0.935	rs12268872	ENSG00000226864.1	ATE1-AS1	4.97	7.72e-07	8.02e-05	0.27	0.15	Breast cancer;	chr10:121887426	chr10:121928312~121951965:+
BRCA	cis	rs10510102	0.935	rs9630107	ENSG00000226864.1	ATE1-AS1	4.97	7.72e-07	8.02e-05	0.27	0.15	Breast cancer;	chr10:121887713	chr10:121928312~121951965:+
BRCA	cis	rs10510102	0.935	rs10887010	ENSG00000226864.1	ATE1-AS1	4.97	7.72e-07	8.02e-05	0.27	0.15	Breast cancer;	chr10:121888542	chr10:121928312~121951965:+
BRCA	cis	rs10510102	0.935	rs12251175	ENSG00000226864.1	ATE1-AS1	4.97	7.72e-07	8.02e-05	0.27	0.15	Breast cancer;	chr10:121889015	chr10:121928312~121951965:+
BRCA	cis	rs10510102	0.872	rs11200220	ENSG00000226864.1	ATE1-AS1	4.97	7.72e-07	8.02e-05	0.27	0.15	Breast cancer;	chr10:121889949	chr10:121928312~121951965:+
BRCA	cis	rs10510102	0.935	rs11200221	ENSG00000226864.1	ATE1-AS1	4.97	7.72e-07	8.02e-05	0.27	0.15	Breast cancer;	chr10:121890134	chr10:121928312~121951965:+
BRCA	cis	rs10510102	0.935	rs10887011	ENSG00000226864.1	ATE1-AS1	4.97	7.72e-07	8.02e-05	0.27	0.15	Breast cancer;	chr10:121890203	chr10:121928312~121951965:+
BRCA	cis	rs10510102	0.935	rs10887012	ENSG00000226864.1	ATE1-AS1	4.97	7.72e-07	8.02e-05	0.27	0.15	Breast cancer;	chr10:121890454	chr10:121928312~121951965:+
BRCA	cis	rs10510102	0.872	rs11200222	ENSG00000226864.1	ATE1-AS1	4.97	7.72e-07	8.02e-05	0.27	0.15	Breast cancer;	chr10:121891177	chr10:121928312~121951965:+
BRCA	cis	rs10510102	0.935	rs11200223	ENSG00000226864.1	ATE1-AS1	4.97	7.72e-07	8.02e-05	0.27	0.15	Breast cancer;	chr10:121891416	chr10:121928312~121951965:+
BRCA	cis	rs10510102	0.935	rs10887013	ENSG00000226864.1	ATE1-AS1	4.97	7.72e-07	8.02e-05	0.27	0.15	Breast cancer;	chr10:121891546	chr10:121928312~121951965:+
BRCA	cis	rs10510102	0.872	rs11200225	ENSG00000226864.1	ATE1-AS1	4.97	7.72e-07	8.02e-05	0.27	0.15	Breast cancer;	chr10:121891948	chr10:121928312~121951965:+
BRCA	cis	rs10510102	0.935	rs11200226	ENSG00000226864.1	ATE1-AS1	4.97	7.72e-07	8.02e-05	0.27	0.15	Breast cancer;	chr10:121891988	chr10:121928312~121951965:+
BRCA	cis	rs7772486	0.79	rs4280983	ENSG00000270638.1	RP3-466P17.1	-4.97	7.72e-07	8.03e-05	-0.18	-0.15	Lobe attachment (rater-scored or self-reported);	chr6:145959654	chr6:145735570~145737218:+
BRCA	cis	rs4072705	0.617	rs10283445	ENSG00000224020.1	MIR181A2HG	-4.97	7.73e-07	8.03e-05	-0.18	-0.15	Menarche (age at onset);	chr9:124481358	chr9:124658467~124698631:+
BRCA	cis	rs1729951	0.575	rs16844326	ENSG00000239213.4	NCK1-AS1	4.97	7.73e-07	8.03e-05	0.16	0.15	Neuroticism;	chr3:136959543	chr3:136841726~136862054:-
BRCA	cis	rs7246657	0.722	rs1564206	ENSG00000276846.1	CTD-3220F14.3	4.97	7.73e-07	8.03e-05	0.21	0.15	Coronary artery calcification;	chr19:37549174	chr19:37314868~37315620:-
BRCA	cis	rs4415084	1	rs6890556	ENSG00000251141.4	RP11-53O19.1	4.97	7.73e-07	8.03e-05	0.14	0.15	Breast cancer;	chr5:44648564	chr5:44744900~44808777:-
BRCA	cis	rs4919687	0.577	rs12765459	ENSG00000236937.2	PTGES3P4	4.97	7.74e-07	8.04e-05	0.23	0.15	Colorectal cancer;	chr10:102705930	chr10:102845595~102845950:+
BRCA	cis	rs875971	0.964	rs60193905	ENSG00000223473.2	GS1-124K5.3	4.97	7.74e-07	8.04e-05	0.12	0.15	Aortic root size;	chr7:66506273	chr7:66491049~66493566:-
BRCA	cis	rs78487399	0.71	rs28470852	ENSG00000234936.1	AC010883.5	4.97	7.75e-07	8.05e-05	0.24	0.15	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43365861	chr2:43229573~43233394:+
BRCA	cis	rs9840812	0.769	rs632016	ENSG00000239213.4	NCK1-AS1	4.97	7.75e-07	8.05e-05	0.18	0.15	Fibrinogen levels;	chr3:136258198	chr3:136841726~136862054:-
BRCA	cis	rs2638953	0.962	rs11049514	ENSG00000247934.4	RP11-967K21.1	-4.97	7.75e-07	8.05e-05	-0.21	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28299461	chr12:28163298~28190738:-
BRCA	cis	rs6442522	0.56	rs924812	ENSG00000249786.6	EAF1-AS1	4.97	7.75e-07	8.05e-05	0.16	0.15	Uric acid levels;	chr3:15474974	chr3:15436171~15455940:-
BRCA	cis	rs6442522	0.56	rs3816526	ENSG00000249786.6	EAF1-AS1	4.97	7.75e-07	8.05e-05	0.16	0.15	Uric acid levels;	chr3:15475403	chr3:15436171~15455940:-
BRCA	cis	rs2273156	0.706	rs7144617	ENSG00000226677.3	IGBP1P1	-4.97	7.75e-07	8.05e-05	-0.24	-0.15	Immunoglobulin light chain (AL) amyloidosis;	chr14:35028853	chr14:34939324~34940332:+
BRCA	cis	rs2273156	0.706	rs7155696	ENSG00000226677.3	IGBP1P1	-4.97	7.75e-07	8.05e-05	-0.24	-0.15	Immunoglobulin light chain (AL) amyloidosis;	chr14:35027548	chr14:34939324~34940332:+
BRCA	cis	rs4578769	0.836	rs3936488	ENSG00000265939.1	UBE2CP2	4.97	7.76e-07	8.06e-05	0.18	0.15	Eosinophil percentage of white cells;	chr18:22874459	chr18:22900486~22900995:-
BRCA	cis	rs6490294	0.528	rs12423689	ENSG00000226469.1	ADAM1B	4.97	7.76e-07	8.06e-05	0.27	0.15	Mean platelet volume;	chr12:111965331	chr12:111927018~111929017:+
BRCA	cis	rs6490294	0.528	rs12423699	ENSG00000226469.1	ADAM1B	4.97	7.76e-07	8.06e-05	0.27	0.15	Mean platelet volume;	chr12:111965357	chr12:111927018~111929017:+
BRCA	cis	rs4415084	0.966	rs4463188	ENSG00000251141.4	RP11-53O19.1	4.97	7.76e-07	8.06e-05	0.14	0.15	Breast cancer;	chr5:44642568	chr5:44744900~44808777:-
BRCA	cis	rs7833790	0.963	rs1451997	ENSG00000254689.1	RP11-354A14.1	-4.97	7.76e-07	8.06e-05	-0.21	-0.15	Diastolic blood pressure;	chr8:81861818	chr8:81885377~81923193:+
BRCA	cis	rs7226408	0.857	rs11665258	ENSG00000267707.2	RP11-95O2.5	4.97	7.77e-07	8.07e-05	0.23	0.15	Obesity-related traits;	chr18:36928149	chr18:37243776~37247506:+
BRCA	cis	rs7772486	0.72	rs4896837	ENSG00000270638.1	RP3-466P17.1	-4.97	7.77e-07	8.07e-05	-0.18	-0.15	Lobe attachment (rater-scored or self-reported);	chr6:145693032	chr6:145735570~145737218:+
BRCA	cis	rs4948275	0.773	rs2650724	ENSG00000237233.2	TMEM26-AS1	-4.97	7.77e-07	8.07e-05	-0.18	-0.15	Night sleep phenotypes;	chr10:61513024	chr10:61452639~61481956:+
BRCA	cis	rs2574985	0.667	rs3011782	ENSG00000231345.3	BEND3P1	-4.97	7.77e-07	8.07e-05	-0.26	-0.15	Subjective well-being;	chr10:50530242	chr10:50655967~50660472:+
BRCA	cis	rs7617773	0.925	rs7374376	ENSG00000228638.1	FCF1P2	4.97	7.78e-07	8.07e-05	0.15	0.15	Coronary artery disease;	chr3:48131197	chr3:48290793~48291375:-
BRCA	cis	rs11098499	0.754	rs12506610	ENSG00000260404.2	RP11-384K6.6	4.97	7.78e-07	8.07e-05	0.14	0.15	Corneal astigmatism;	chr4:119320504	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.743	rs10003567	ENSG00000260404.2	RP11-384K6.6	4.97	7.78e-07	8.07e-05	0.14	0.15	Corneal astigmatism;	chr4:119320519	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.754	rs10006259	ENSG00000260404.2	RP11-384K6.6	4.97	7.78e-07	8.07e-05	0.14	0.15	Corneal astigmatism;	chr4:119320990	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.754	rs28652763	ENSG00000260404.2	RP11-384K6.6	4.97	7.78e-07	8.07e-05	0.14	0.15	Corneal astigmatism;	chr4:119321157	chr4:118591773~118633729:+
BRCA	cis	rs2243480	0.706	rs34466769	ENSG00000229886.1	RP5-1132H15.3	4.97	7.78e-07	8.08e-05	0.23	0.15	Diabetic kidney disease;	chr7:65988305	chr7:66025126~66031544:-
BRCA	cis	rs875971	0.545	rs1909508	ENSG00000232546.1	RP11-458F8.1	4.97	7.78e-07	8.08e-05	0.14	0.15	Aortic root size;	chr7:66301366	chr7:66848496~66858136:+
BRCA	cis	rs9818758	0.607	rs9850917	ENSG00000270441.1	RP11-694I15.7	4.97	7.78e-07	8.08e-05	0.28	0.15	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49249550	chr3:49140086~49160851:-
BRCA	cis	rs9818758	0.607	rs9847839	ENSG00000270441.1	RP11-694I15.7	4.97	7.78e-07	8.08e-05	0.28	0.15	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49251570	chr3:49140086~49160851:-
BRCA	cis	rs7772486	0.875	rs10872583	ENSG00000270638.1	RP3-466P17.1	-4.97	7.78e-07	8.08e-05	-0.17	-0.15	Lobe attachment (rater-scored or self-reported);	chr6:146075563	chr6:145735570~145737218:+
BRCA	cis	rs10504130	0.932	rs16916856	ENSG00000272024.1	RP11-546K22.3	-4.97	7.79e-07	8.09e-05	-0.27	-0.15	Venous thromboembolism (SNP x SNP interaction);	chr8:51826590	chr8:51950284~51950690:+
BRCA	cis	rs875971	0.8	rs427557	ENSG00000236529.1	RP13-254B10.1	4.97	7.79e-07	8.09e-05	0.17	0.15	Aortic root size;	chr7:66054263	chr7:65840212~65840596:+
BRCA	cis	rs2243480	1	rs316322	ENSG00000275400.1	RP4-756H11.5	4.97	7.79e-07	8.09e-05	0.27	0.15	Diabetic kidney disease;	chr7:66146246	chr7:66553805~66554199:-
BRCA	cis	rs875971	0.545	rs1547529	ENSG00000232546.1	RP11-458F8.1	4.97	7.8e-07	8.09e-05	0.14	0.15	Aortic root size;	chr7:66258859	chr7:66848496~66858136:+
BRCA	cis	rs17772222	0.74	rs7143642	ENSG00000258789.1	RP11-507K2.3	-4.97	7.8e-07	8.09e-05	-0.17	-0.15	Coronary artery calcification;	chr14:88507616	chr14:88551597~88552493:+
BRCA	cis	rs9467773	0.62	rs1490488	ENSG00000124549.13	BTN2A3P	4.97	7.8e-07	8.1e-05	0.15	0.15	Intelligence (multi-trait analysis);	chr6:26614580	chr6:26421391~26432383:+
BRCA	cis	rs9467773	0.62	rs2494692	ENSG00000124549.13	BTN2A3P	4.97	7.8e-07	8.1e-05	0.15	0.15	Intelligence (multi-trait analysis);	chr6:26614995	chr6:26421391~26432383:+
BRCA	cis	rs10911232	0.507	rs10797829	ENSG00000224468.3	RP11-181K3.4	4.97	7.81e-07	8.1e-05	0.17	0.15	Hypertriglyceridemia;	chr1:183064093	chr1:183138402~183141282:-
BRCA	cis	rs9840812	0.623	rs6794351	ENSG00000273486.1	RP11-731C17.2	4.97	7.81e-07	8.11e-05	0.19	0.15	Fibrinogen levels;	chr3:136573437	chr3:136837338~136839021:-
BRCA	cis	rs4948275	0.742	rs2650694	ENSG00000237233.2	TMEM26-AS1	-4.97	7.82e-07	8.11e-05	-0.19	-0.15	Night sleep phenotypes;	chr10:61527069	chr10:61452639~61481956:+
BRCA	cis	rs1707322	1	rs6661500	ENSG00000234329.1	RP11-767N6.2	4.97	7.82e-07	8.12e-05	0.16	0.15	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45999990	chr1:45651039~45651826:-
BRCA	cis	rs7572733	0.534	rs1464211	ENSG00000231621.1	AC013264.2	-4.97	7.83e-07	8.12e-05	-0.15	-0.15	Dermatomyositis;	chr2:197933906	chr2:197197991~197199273:+
BRCA	cis	rs62025270	0.848	rs62025269	ENSG00000259295.5	CSPG4P12	-4.97	7.83e-07	8.13e-05	-0.23	-0.15	Idiopathic pulmonary fibrosis;	chr15:85756859	chr15:85191438~85213905:+
BRCA	cis	rs6442522	0.533	rs2100544	ENSG00000249786.6	EAF1-AS1	4.97	7.84e-07	8.13e-05	0.16	0.15	Uric acid levels;	chr3:15480158	chr3:15436171~15455940:-
BRCA	cis	rs10129255	0.957	rs8022165	ENSG00000211974.3	IGHV2-70	4.97	7.84e-07	8.13e-05	0.15	0.15	Kawasaki disease;	chr14:106781682	chr14:106723574~106724093:-
BRCA	cis	rs4908768	0.501	rs7551849	ENSG00000232912.4	RP5-1115A15.1	4.97	7.84e-07	8.14e-05	0.15	0.15	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8479403	chr1:8424645~8434838:+
BRCA	cis	rs875971	0.964	rs6945019	ENSG00000223473.2	GS1-124K5.3	4.97	7.84e-07	8.14e-05	0.12	0.15	Aortic root size;	chr7:66457471	chr7:66491049~66493566:-
BRCA	cis	rs828999	0.688	rs10881507	ENSG00000280186.1	RP11-483I13.6	-4.97	7.85e-07	8.14e-05	-0.17	-0.15	Monocyte percentage of white cells;	chr1:108152515	chr1:108200413~108202743:+
BRCA	cis	rs875971	0.862	rs10274883	ENSG00000236529.1	RP13-254B10.1	-4.97	7.85e-07	8.14e-05	-0.17	-0.15	Aortic root size;	chr7:66651104	chr7:65840212~65840596:+
BRCA	cis	rs12819124	0.502	rs10875718	ENSG00000240399.1	RP1-228P16.1	4.97	7.86e-07	8.15e-05	0.18	0.15	Glycated hemoglobin levels;	chr12:48017319	chr12:48054813~48055591:-
BRCA	cis	rs4218	0.681	rs35204615	ENSG00000277144.1	RP11-59H7.4	-4.97	7.86e-07	8.15e-05	-0.2	-0.15	Social communication problems;	chr15:59099637	chr15:59115547~59116089:-
BRCA	cis	rs4835473	0.897	rs4835474	ENSG00000249741.2	RP11-673E1.3	-4.97	7.86e-07	8.15e-05	-0.16	-0.15	Immature fraction of reticulocytes;	chr4:143982444	chr4:143911514~143912053:-
BRCA	cis	rs4415084	0.966	rs12516900	ENSG00000251141.4	RP11-53O19.1	4.97	7.86e-07	8.15e-05	0.14	0.15	Breast cancer;	chr5:44644393	chr5:44744900~44808777:-
BRCA	cis	rs4415084	0.932	rs4321755	ENSG00000251141.4	RP11-53O19.1	4.97	7.86e-07	8.15e-05	0.14	0.15	Breast cancer;	chr5:44646093	chr5:44744900~44808777:-
BRCA	cis	rs34421088	0.603	rs10086064	ENSG00000255046.1	RP11-297N6.4	-4.97	7.86e-07	8.15e-05	-0.18	-0.15	Neuroticism;	chr8:11726332	chr8:11797928~11802568:-
BRCA	cis	rs6840360	0.642	rs1899550	ENSG00000278978.1	RP11-164P12.5	-4.97	7.86e-07	8.16e-05	-0.17	-0.15	Intelligence (multi-trait analysis);	chr4:151486084	chr4:151669786~151670503:+
BRCA	cis	rs1910358	0.664	rs1566726	ENSG00000248874.4	C5orf17	-4.97	7.86e-07	8.16e-05	-0.2	-0.15	Venous thromboembolism (SNP x SNP interaction);	chr5:23913763	chr5:23951348~24178263:+
BRCA	cis	rs1910358	0.664	rs1566727	ENSG00000248874.4	C5orf17	-4.97	7.86e-07	8.16e-05	-0.2	-0.15	Venous thromboembolism (SNP x SNP interaction);	chr5:23913794	chr5:23951348~24178263:+
BRCA	cis	rs7267979	0.844	rs2424703	ENSG00000204556.4	CTD-2514C3.1	-4.97	7.87e-07	8.16e-05	-0.21	-0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25289488	chr20:26018832~26020684:+
BRCA	cis	rs60843830	1	rs6709534	ENSG00000272342.1	RP13-539J13.1	4.97	7.87e-07	8.16e-05	0.19	0.15	Spherical equivalent (joint analysis main effects and education interaction);	chr2:217334	chr2:739588~740164:-
BRCA	cis	rs8127691	0.967	rs762423	ENSG00000237604.1	AP001056.1	4.97	7.87e-07	8.16e-05	0.17	0.15	Inflammatory bowel disease;	chr21:44195803	chr21:44175489~44176453:+
BRCA	cis	rs10861342	1	rs115224406	ENSG00000257999.1	RP11-61E11.2	-4.97	7.87e-07	8.17e-05	-0.33	-0.15	IgG glycosylation;	chr12:105184282	chr12:105102472~105107179:-
BRCA	cis	rs4835473	0.868	rs1822841	ENSG00000249741.2	RP11-673E1.3	-4.97	7.87e-07	8.17e-05	-0.17	-0.15	Immature fraction of reticulocytes;	chr4:143921485	chr4:143911514~143912053:-
BRCA	cis	rs6714710	0.603	rs35505530	ENSG00000230606.9	AC159540.1	-4.97	7.88e-07	8.17e-05	-0.18	-0.15	Posterior cortical atrophy and Alzheimer's disease;	chr2:97890447	chr2:97416165~97433527:-
BRCA	cis	rs11673344	0.598	rs826326	ENSG00000226686.6	LINC01535	4.97	7.88e-07	8.17e-05	0.2	0.15	Obesity-related traits;	chr19:37003863	chr19:37251912~37265535:+
BRCA	cis	rs4711336	1	rs2229642	ENSG00000224557.6	HLA-DPB2	-4.97	7.88e-07	8.17e-05	-0.18	-0.15	Height;	chr6:33691695	chr6:33112451~33129084:+
BRCA	cis	rs6430585	0.583	rs3769012	ENSG00000231890.6	DARS-AS1	-4.97	7.88e-07	8.17e-05	-0.24	-0.15	Corneal structure;	chr2:135798910	chr2:135985176~136022593:+
BRCA	cis	rs1707322	1	rs1707337	ENSG00000234329.1	RP11-767N6.2	-4.97	7.89e-07	8.18e-05	-0.15	-0.15	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46043097	chr1:45651039~45651826:-
BRCA	cis	rs1707322	1	rs1768807	ENSG00000234329.1	RP11-767N6.2	-4.97	7.89e-07	8.18e-05	-0.15	-0.15	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46044898	chr1:45651039~45651826:-
BRCA	cis	rs9907295	0.605	rs11652192	ENSG00000271013.1	AC015849.15	-4.97	7.89e-07	8.18e-05	-0.24	-0.15	Fibroblast growth factor basic levels;	chr17:35833174	chr17:35912635~35918010:-
BRCA	cis	rs12497850	0.764	rs6784111	ENSG00000225399.4	RP11-3B7.1	4.97	7.89e-07	8.18e-05	0.15	0.15	Parkinson's disease;	chr3:49141413	chr3:49260085~49261316:+
BRCA	cis	rs7226408	0.857	rs2034215	ENSG00000267707.2	RP11-95O2.5	4.97	7.89e-07	8.18e-05	0.23	0.15	Obesity-related traits;	chr18:36949200	chr18:37243776~37247506:+
BRCA	cis	rs7226408	0.857	rs7233017	ENSG00000267707.2	RP11-95O2.5	4.97	7.89e-07	8.18e-05	0.23	0.15	Obesity-related traits;	chr18:36949747	chr18:37243776~37247506:+
BRCA	cis	rs2153535	0.563	rs1737585	ENSG00000251164.1	HULC	4.97	7.89e-07	8.18e-05	0.19	0.15	Motion sickness;	chr6:8536361	chr6:8652137~8653846:+
BRCA	cis	rs4711336	1	rs2296742	ENSG00000224557.6	HLA-DPB2	-4.97	7.89e-07	8.19e-05	-0.18	-0.15	Height;	chr6:33692016	chr6:33112451~33129084:+
BRCA	cis	rs7937890	0.904	rs11023169	ENSG00000254418.1	RP11-21L19.1	-4.97	7.9e-07	8.19e-05	-0.18	-0.15	Mitochondrial DNA levels;	chr11:14269439	chr11:14262846~14273691:-
BRCA	cis	rs597539	0.652	rs584108	ENSG00000261625.1	RP11-554A11.4	4.97	7.9e-07	8.19e-05	0.15	0.15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68862814	chr11:69000765~69002048:-
BRCA	cis	rs412050	0.502	rs17759796	ENSG00000224086.5	LL22NC03-86G7.1	4.97	7.9e-07	8.19e-05	0.24	0.15	Attention deficit hyperactivity disorder;	chr22:21835874	chr22:21938293~21977632:+
BRCA	cis	rs6570726	0.764	rs451108	ENSG00000270638.1	RP3-466P17.1	4.97	7.9e-07	8.19e-05	0.18	0.15	Lobe attachment (rater-scored or self-reported);	chr6:145523173	chr6:145735570~145737218:+
BRCA	cis	rs6847067	0.588	rs2044161	ENSG00000180769.7	WDFY3-AS2	4.97	7.91e-07	8.2e-05	0.16	0.15	Oropharynx cancer;	chr4:84700267	chr4:84965682~85011277:+
BRCA	cis	rs2243480	1	rs1553174	ENSG00000222364.1	RNU6-96P	4.97	7.91e-07	8.2e-05	0.28	0.15	Diabetic kidney disease;	chr7:66266207	chr7:66395191~66395286:+
BRCA	cis	rs2243480	1	rs10950032	ENSG00000222364.1	RNU6-96P	4.97	7.91e-07	8.2e-05	0.28	0.15	Diabetic kidney disease;	chr7:66273604	chr7:66395191~66395286:+
BRCA	cis	rs7618915	0.547	rs11130314	ENSG00000243224.1	RP5-1157M23.2	-4.97	7.91e-07	8.2e-05	-0.17	-0.15	Bipolar disorder;	chr3:52663066	chr3:52239258~52241097:+
BRCA	cis	rs7618915	0.547	rs11130315	ENSG00000243224.1	RP5-1157M23.2	-4.97	7.91e-07	8.2e-05	-0.17	-0.15	Bipolar disorder;	chr3:52663147	chr3:52239258~52241097:+
BRCA	cis	rs7618915	0.547	rs62255362	ENSG00000243224.1	RP5-1157M23.2	-4.97	7.91e-07	8.2e-05	-0.17	-0.15	Bipolar disorder;	chr3:52665725	chr3:52239258~52241097:+
BRCA	cis	rs7618915	0.547	rs12496634	ENSG00000243224.1	RP5-1157M23.2	-4.97	7.91e-07	8.2e-05	-0.17	-0.15	Bipolar disorder;	chr3:52675243	chr3:52239258~52241097:+
BRCA	cis	rs7618915	0.547	rs2336542	ENSG00000243224.1	RP5-1157M23.2	-4.97	7.91e-07	8.2e-05	-0.17	-0.15	Bipolar disorder;	chr3:52676620	chr3:52239258~52241097:+
BRCA	cis	rs7618915	0.571	rs67539070	ENSG00000243224.1	RP5-1157M23.2	-4.97	7.91e-07	8.2e-05	-0.17	-0.15	Bipolar disorder;	chr3:52677958	chr3:52239258~52241097:+
BRCA	cis	rs4711336	1	rs4711337	ENSG00000224557.6	HLA-DPB2	-4.97	7.91e-07	8.21e-05	-0.18	-0.15	Height;	chr6:33692210	chr6:33112451~33129084:+
BRCA	cis	rs250585	0.92	rs250555	ENSG00000260136.4	CTD-2270L9.4	4.97	7.91e-07	8.21e-05	0.18	0.15	Egg allergy;	chr16:23432947	chr16:23452758~23457606:+
BRCA	cis	rs11051970	0.592	rs73086040	ENSG00000274964.1	RP11-817I4.1	-4.97	7.92e-07	8.21e-05	-0.21	-0.15	Response to tocilizumab in rheumatoid arthritis;	chr12:32414501	chr12:32339368~32340724:+
BRCA	cis	rs10419113	0.701	rs10403317	ENSG00000268545.1	VN1R107P	4.97	7.92e-07	8.21e-05	0.18	0.15	Pediatric bone mineral density (spine);	chr19:57680115	chr19:57459912~57460120:+
BRCA	cis	rs7246657	0.653	rs10401525	ENSG00000267422.1	CTD-2554C21.1	-4.97	7.93e-07	8.22e-05	-0.26	-0.15	Coronary artery calcification;	chr19:37168077	chr19:37779686~37792865:+
BRCA	cis	rs11955398	0.501	rs4700387	ENSG00000215032.2	GNL3LP1	-4.97	7.94e-07	8.23e-05	-0.19	-0.15	Intelligence (multi-trait analysis);	chr5:60740924	chr5:60891935~60893577:-
BRCA	cis	rs2153535	0.601	rs4960414	ENSG00000251164.1	HULC	-4.97	7.94e-07	8.23e-05	-0.19	-0.15	Motion sickness;	chr6:8438308	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.542	rs9393012	ENSG00000251164.1	HULC	-4.97	7.94e-07	8.23e-05	-0.19	-0.15	Motion sickness;	chr6:8439576	chr6:8652137~8653846:+
BRCA	cis	rs9652601	0.691	rs9926078	ENSG00000274038.1	RP11-66H6.4	-4.97	7.94e-07	8.23e-05	-0.17	-0.15	Systemic lupus erythematosus;	chr16:11109708	chr16:11056556~11057034:+
BRCA	cis	rs1707322	0.785	rs10890348	ENSG00000234329.1	RP11-767N6.2	4.97	7.94e-07	8.23e-05	0.16	0.15	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45776751	chr1:45651039~45651826:-
BRCA	cis	rs11098499	0.866	rs6857892	ENSG00000249244.1	RP11-548H18.2	4.97	7.94e-07	8.23e-05	0.18	0.15	Corneal astigmatism;	chr4:119361541	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.909	rs28581362	ENSG00000249244.1	RP11-548H18.2	4.97	7.94e-07	8.23e-05	0.18	0.15	Corneal astigmatism;	chr4:119362393	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.82	rs12503082	ENSG00000249244.1	RP11-548H18.2	4.97	7.94e-07	8.23e-05	0.18	0.15	Corneal astigmatism;	chr4:119363162	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.866	rs12499602	ENSG00000249244.1	RP11-548H18.2	4.97	7.94e-07	8.23e-05	0.18	0.15	Corneal astigmatism;	chr4:119363232	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.774	rs11098505	ENSG00000249244.1	RP11-548H18.2	4.97	7.94e-07	8.23e-05	0.18	0.15	Corneal astigmatism;	chr4:119363472	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.866	rs13105020	ENSG00000249244.1	RP11-548H18.2	4.97	7.94e-07	8.23e-05	0.18	0.15	Corneal astigmatism;	chr4:119364533	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.866	rs6824111	ENSG00000249244.1	RP11-548H18.2	4.97	7.94e-07	8.23e-05	0.18	0.15	Corneal astigmatism;	chr4:119364813	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.775	rs10029303	ENSG00000249244.1	RP11-548H18.2	4.97	7.94e-07	8.23e-05	0.18	0.15	Corneal astigmatism;	chr4:119365600	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.866	rs9995136	ENSG00000249244.1	RP11-548H18.2	4.97	7.94e-07	8.23e-05	0.18	0.15	Corneal astigmatism;	chr4:119365690	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.866	rs13125526	ENSG00000249244.1	RP11-548H18.2	4.97	7.94e-07	8.23e-05	0.18	0.15	Corneal astigmatism;	chr4:119366864	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.866	rs12513310	ENSG00000249244.1	RP11-548H18.2	4.97	7.94e-07	8.23e-05	0.18	0.15	Corneal astigmatism;	chr4:119366884	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.866	rs12510451	ENSG00000249244.1	RP11-548H18.2	4.97	7.94e-07	8.23e-05	0.18	0.15	Corneal astigmatism;	chr4:119367988	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.774	rs73842616	ENSG00000249244.1	RP11-548H18.2	4.97	7.94e-07	8.23e-05	0.18	0.15	Corneal astigmatism;	chr4:119369528	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.645	rs72676059	ENSG00000249244.1	RP11-548H18.2	4.97	7.94e-07	8.23e-05	0.18	0.15	Corneal astigmatism;	chr4:119369673	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.569	rs55845118	ENSG00000249244.1	RP11-548H18.2	4.97	7.94e-07	8.23e-05	0.18	0.15	Corneal astigmatism;	chr4:119369758	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.866	rs7677068	ENSG00000249244.1	RP11-548H18.2	4.97	7.94e-07	8.23e-05	0.18	0.15	Corneal astigmatism;	chr4:119370549	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.866	rs9991221	ENSG00000249244.1	RP11-548H18.2	4.97	7.94e-07	8.23e-05	0.18	0.15	Corneal astigmatism;	chr4:119370952	chr4:119391831~119395335:-
BRCA	cis	rs6840360	0.642	rs2709834	ENSG00000251611.1	RP11-610P16.1	-4.97	7.94e-07	8.23e-05	-0.13	-0.15	Intelligence (multi-trait analysis);	chr4:151454272	chr4:151407551~151408835:-
BRCA	cis	rs35740288	0.822	rs2241268	ENSG00000259407.1	RP11-158M2.3	-4.97	7.95e-07	8.24e-05	-0.21	-0.15	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85735078	chr15:85744109~85750281:-
BRCA	cis	rs2243480	0.901	rs778732	ENSG00000222364.1	RNU6-96P	-4.97	7.95e-07	8.24e-05	-0.29	-0.15	Diabetic kidney disease;	chr7:66357373	chr7:66395191~66395286:+
BRCA	cis	rs9402743	0.634	rs7767072	ENSG00000231028.7	LINC00271	-4.97	7.95e-07	8.24e-05	-0.16	-0.15	Systemic lupus erythematosus;	chr6:135593899	chr6:135497801~135716055:+
BRCA	cis	rs494453	1	rs494453	ENSG00000227811.2	FAM212B-AS1	-4.97	7.95e-07	8.24e-05	-0.19	-0.15	Osteoporosis-related phenotypes;	chr1:111649500	chr1:111739841~111747798:+
BRCA	cis	rs6545883	0.859	rs13004855	ENSG00000270820.4	RP11-355B11.2	-4.97	7.95e-07	8.24e-05	-0.18	-0.15	Tuberculosis;	chr2:61277937	chr2:61471188~61484130:+
BRCA	cis	rs962856	1	rs979043	ENSG00000236780.4	AC078941.1	4.97	7.95e-07	8.24e-05	0.19	0.15	Pancreatic cancer;	chr2:67339149	chr2:67123357~67215319:-
BRCA	cis	rs6772849	0.805	rs61159406	ENSG00000242551.2	POU5F1P6	-4.97	7.96e-07	8.25e-05	-0.18	-0.15	Monocyte percentage of white cells;Monocyte count;	chr3:128617166	chr3:128674735~128677005:-
BRCA	cis	rs2243480	1	rs4718317	ENSG00000222364.1	RNU6-96P	4.97	7.96e-07	8.25e-05	0.27	0.15	Diabetic kidney disease;	chr7:66183914	chr7:66395191~66395286:+
BRCA	cis	rs2898681	0.614	rs962416	ENSG00000248375.1	RP11-177B4.1	4.97	7.96e-07	8.25e-05	0.21	0.15	Optic nerve measurement (cup area);	chr4:52829490	chr4:52720081~52720831:-
BRCA	cis	rs62025270	0.632	rs62023935	ENSG00000259295.5	CSPG4P12	-4.97	7.96e-07	8.25e-05	-0.23	-0.15	Idiopathic pulmonary fibrosis;	chr15:85605604	chr15:85191438~85213905:+
BRCA	cis	rs10751647	0.804	rs3809112	ENSG00000254910.1	RP11-326C3.7	4.97	7.97e-07	8.25e-05	0.16	0.15	Monocyte count;	chr11:307036	chr11:310139~311141:-
BRCA	cis	rs7267979	0.844	rs6083845	ENSG00000204556.4	CTD-2514C3.1	4.97	7.97e-07	8.25e-05	0.2	0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25407454	chr20:26018832~26020684:+
BRCA	cis	rs8054556	0.787	rs11642612	ENSG00000261367.1	RP11-455F5.4	-4.97	7.97e-07	8.26e-05	-0.18	-0.15	Autism spectrum disorder or schizophrenia;	chr16:30018874	chr16:30107675~30110541:+
BRCA	cis	rs8054556	0.787	rs11150581	ENSG00000261367.1	RP11-455F5.4	-4.97	7.97e-07	8.26e-05	-0.18	-0.15	Autism spectrum disorder or schizophrenia;	chr16:30019378	chr16:30107675~30110541:+
BRCA	cis	rs1075265	0.749	rs805380	ENSG00000235937.1	AC008280.1	4.97	7.97e-07	8.26e-05	0.17	0.15	Chronotype;Morning vs. evening chronotype;	chr2:53867284	chr2:54029552~54030682:-
BRCA	cis	rs1950832	0.689	rs712407	ENSG00000258636.1	CTD-2298J14.2	4.97	7.97e-07	8.26e-05	0.17	0.15	Urate levels in obese individuals;	chr14:41648171	chr14:41587861~41604856:-
BRCA	cis	rs2243480	1	rs2707844	ENSG00000222364.1	RNU6-96P	-4.97	7.97e-07	8.26e-05	-0.28	-0.15	Diabetic kidney disease;	chr7:66594522	chr7:66395191~66395286:+
BRCA	cis	rs2243480	1	rs1796220	ENSG00000222364.1	RNU6-96P	-4.97	7.97e-07	8.26e-05	-0.28	-0.15	Diabetic kidney disease;	chr7:66597113	chr7:66395191~66395286:+
BRCA	cis	rs2243480	1	rs2707831	ENSG00000222364.1	RNU6-96P	-4.97	7.97e-07	8.26e-05	-0.28	-0.15	Diabetic kidney disease;	chr7:66597524	chr7:66395191~66395286:+
BRCA	cis	rs2278170	1	rs1864498	ENSG00000225101.4	OR52K3P	-4.97	7.97e-07	8.26e-05	-0.2	-0.15	Amyotrophic lateral sclerosis;	chr11:4457986	chr11:4474813~4475755:+
BRCA	cis	rs2153535	0.542	rs6912740	ENSG00000251164.1	HULC	-4.97	7.97e-07	8.26e-05	-0.19	-0.15	Motion sickness;	chr6:8439726	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.542	rs6905925	ENSG00000251164.1	HULC	-4.97	7.97e-07	8.26e-05	-0.19	-0.15	Motion sickness;	chr6:8439797	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.541	rs6905934	ENSG00000251164.1	HULC	-4.97	7.97e-07	8.26e-05	-0.19	-0.15	Motion sickness;	chr6:8439810	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.58	rs2327050	ENSG00000251164.1	HULC	-4.97	7.97e-07	8.26e-05	-0.19	-0.15	Motion sickness;	chr6:8440397	chr6:8652137~8653846:+
BRCA	cis	rs875971	0.545	rs10950027	ENSG00000230295.1	RP11-458F8.2	4.97	7.97e-07	8.26e-05	0.14	0.15	Aortic root size;	chr7:66169164	chr7:66880708~66882981:+
BRCA	cis	rs2408955	0.5	rs12816820	ENSG00000273765.1	RP11-370I10.11	4.97	7.98e-07	8.27e-05	0.18	0.15	Glycated hemoglobin levels;	chr12:48164542	chr12:48360920~48361377:+
BRCA	cis	rs13030978	0.505	rs72916554	ENSG00000280083.1	RP11-317J9.1	-4.97	7.98e-07	8.27e-05	-0.18	-0.15	Liver enzyme levels (gamma-glutamyl transferase);	chr2:191330532	chr2:191154118~191156070:-
BRCA	cis	rs8180040	0.62	rs11707736	ENSG00000276925.1	RP11-708J19.3	4.97	7.98e-07	8.27e-05	0.17	0.15	Colorectal cancer;	chr3:47028014	chr3:47469777~47469987:+
BRCA	cis	rs838147	0.76	rs281408	ENSG00000232871.7	SEC1P	4.97	7.98e-07	8.27e-05	0.17	0.15	Dietary macronutrient intake;	chr19:48730149	chr19:48638071~48682245:+
BRCA	cis	rs12497850	0.931	rs9311432	ENSG00000225399.4	RP11-3B7.1	4.97	7.99e-07	8.28e-05	0.15	0.15	Parkinson's disease;	chr3:48813010	chr3:49260085~49261316:+
BRCA	cis	rs2153535	0.58	rs9393022	ENSG00000251164.1	HULC	-4.97	7.99e-07	8.28e-05	-0.19	-0.15	Motion sickness;	chr6:8466355	chr6:8652137~8653846:+
BRCA	cis	rs7302981	0.719	rs844347	ENSG00000272368.2	RP4-605O3.4	4.97	7.99e-07	8.28e-05	0.16	0.15	Systolic blood pressure;	chr12:50067893	chr12:50112197~50165618:+
BRCA	cis	rs4388249	0.659	rs10078710	ENSG00000271849.1	CTC-332L22.1	4.97	7.99e-07	8.28e-05	0.2	0.15	Schizophrenia;	chr5:109748057	chr5:109687802~109688329:-
BRCA	cis	rs2227564	0.597	rs2633305	ENSG00000271816.1	BMS1P4	4.97	7.99e-07	8.28e-05	0.16	0.15	Crohn's disease;Inflammatory bowel disease;	chr10:73892365	chr10:73699151~73730487:-
BRCA	cis	rs875971	0.825	rs28480509	ENSG00000236529.1	RP13-254B10.1	-4.97	7.99e-07	8.28e-05	-0.17	-0.15	Aortic root size;	chr7:66634237	chr7:65840212~65840596:+
BRCA	cis	rs7267979	0.844	rs6083845	ENSG00000274973.1	RP13-401N8.7	4.97	8e-07	8.28e-05	0.17	0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25407454	chr20:25845497~25845862:+
BRCA	cis	rs2638953	0.886	rs11049576	ENSG00000247934.4	RP11-967K21.1	-4.97	8e-07	8.29e-05	-0.21	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28412347	chr12:28163298~28190738:-
BRCA	cis	rs17684571	0.7	rs4299824	ENSG00000231441.1	RP11-472M19.2	4.97	8e-07	8.29e-05	0.23	0.15	Schizophrenia;	chr6:56815697	chr6:56844002~56864078:+
BRCA	cis	rs7569084	0.687	rs1437462	ENSG00000281920.1	RP11-418H16.1	4.97	8e-07	8.29e-05	0.2	0.15	Sum eosinophil basophil counts;	chr2:65449559	chr2:65623272~65628424:+
BRCA	cis	rs8180040	0.966	rs60369822	ENSG00000276925.1	RP11-708J19.3	4.97	8e-07	8.29e-05	0.18	0.15	Colorectal cancer;	chr3:47438245	chr3:47469777~47469987:+
BRCA	cis	rs2919009	0.581	rs61872768	ENSG00000271670.1	RP11-95I16.4	4.97	8.01e-07	8.29e-05	0.2	0.15	Obesity-related traits;	chr10:120934409	chr10:120879256~120880667:-
BRCA	cis	rs6441961	0.628	rs7635588	ENSG00000223552.1	RP11-24F11.2	-4.97	8.01e-07	8.29e-05	-0.19	-0.15	Celiac disease;	chr3:46303996	chr3:46364955~46407059:-
BRCA	cis	rs875971	0.862	rs778684	ENSG00000236529.1	RP13-254B10.1	4.97	8.01e-07	8.3e-05	0.17	0.15	Aortic root size;	chr7:66371416	chr7:65840212~65840596:+
BRCA	cis	rs7246657	0.722	rs35863684	ENSG00000276846.1	CTD-3220F14.3	4.97	8.01e-07	8.3e-05	0.2	0.15	Coronary artery calcification;	chr19:37618876	chr19:37314868~37315620:-
BRCA	cis	rs2179367	0.632	rs9485384	ENSG00000268592.3	RAET1E-AS1	4.97	8.01e-07	8.3e-05	0.22	0.15	Dupuytren's disease;	chr6:149328808	chr6:149863494~149919507:+
BRCA	cis	rs11098499	0.754	rs878372	ENSG00000260404.2	RP11-384K6.6	4.97	8.02e-07	8.3e-05	0.14	0.15	Corneal astigmatism;	chr4:119317625	chr4:118591773~118633729:+
BRCA	cis	rs10938353	0.68	rs2173108	ENSG00000273369.1	RP11-700J17.1	4.97	8.02e-07	8.31e-05	0.19	0.15	Body mass index;	chr4:44838785	chr4:44693946~44694386:-
BRCA	cis	rs7818688	0.546	rs13250762	ENSG00000253528.2	RP11-347C18.4	-4.97	8.02e-07	8.31e-05	-0.23	-0.15	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94975342	chr8:94974573~94974853:-
BRCA	cis	rs2842346	0.568	rs1476586	ENSG00000258623.1	CTD-2325P2.3	-4.97	8.02e-07	8.31e-05	-0.19	-0.15	Breast cancer;	chr14:68536787	chr14:68683411~68685565:-
BRCA	cis	rs6832769	1	rs11726609	ENSG00000272969.1	RP11-528I4.2	4.97	8.02e-07	8.31e-05	0.19	0.15	Personality dimensions;	chr4:55534702	chr4:55547112~55547889:+
BRCA	cis	rs2839627	0.561	rs4148970	ENSG00000225218.1	AP001628.6	4.97	8.02e-07	8.31e-05	0.21	0.15	Information processing speed;	chr21:42893183	chr21:42831040~42836477:-
BRCA	cis	rs10504130	0.932	rs76877865	ENSG00000272024.1	RP11-546K22.3	-4.96	8.03e-07	8.31e-05	-0.27	-0.15	Venous thromboembolism (SNP x SNP interaction);	chr8:51803967	chr8:51950284~51950690:+
BRCA	cis	rs4865762	1	rs13171110	ENSG00000247796.2	CTD-2366F13.1	-4.96	8.03e-07	8.31e-05	-0.16	-0.15	Intraocular pressure;	chr5:53285980	chr5:53109842~53115126:+
BRCA	cis	rs853679	0.599	rs202906	ENSG00000204709.4	LINC01556	-4.96	8.03e-07	8.32e-05	-0.29	-0.15	Depression;	chr6:28043874	chr6:28943877~28944537:+
BRCA	cis	rs2832191	0.967	rs1999321	ENSG00000236056.1	GAPDHP14	-4.96	8.03e-07	8.32e-05	-0.17	-0.15	Dental caries;	chr21:29157912	chr21:29222321~29223257:+
BRCA	cis	rs17495987	0.75	rs2109972	ENSG00000219545.8	UMAD1	-4.96	8.03e-07	8.32e-05	-0.21	-0.15	Tonsillectomy;	chr7:7866705	chr7:7640711~8004059:+
BRCA	cis	rs9818758	0.607	rs113186424	ENSG00000270441.1	RP11-694I15.7	4.96	8.04e-07	8.32e-05	0.28	0.15	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49235293	chr3:49140086~49160851:-
BRCA	cis	rs1005277	0.563	rs2800550	ENSG00000263064.2	RP11-291L22.7	4.96	8.04e-07	8.32e-05	0.19	0.15	Extrinsic epigenetic age acceleration;	chr10:38194001	chr10:38448689~38448949:+
BRCA	cis	rs2243480	0.908	rs1532573	ENSG00000222364.1	RNU6-96P	4.96	8.04e-07	8.32e-05	0.28	0.15	Diabetic kidney disease;	chr7:66333815	chr7:66395191~66395286:+
BRCA	cis	rs13118159	0.573	rs4974618	ENSG00000254094.1	AC078852.1	-4.96	8.04e-07	8.33e-05	-0.18	-0.15	Longevity;	chr4:1379875	chr4:1356581~1358075:+
BRCA	cis	rs7726839	0.54	rs4957080	ENSG00000225138.6	CTD-2228K2.7	-4.96	8.04e-07	8.33e-05	-0.22	-0.15	Obesity-related traits;	chr5:644437	chr5:473236~480884:+
BRCA	cis	rs3768617	0.565	rs7542277	ENSG00000224468.3	RP11-181K3.4	-4.96	8.04e-07	8.33e-05	-0.16	-0.15	Fuchs's corneal dystrophy;	chr1:183094392	chr1:183138402~183141282:-
BRCA	cis	rs1555322	1	rs2425040	ENSG00000126005.14	MMP24-AS1	-4.96	8.05e-07	8.33e-05	-0.25	-0.15	Attention deficit hyperactivity disorder;	chr20:35271075	chr20:35216462~35278131:-
BRCA	cis	rs3768617	0.565	rs4652775	ENSG00000224468.3	RP11-181K3.4	-4.96	8.05e-07	8.33e-05	-0.16	-0.15	Fuchs's corneal dystrophy;	chr1:183092690	chr1:183138402~183141282:-
BRCA	cis	rs642858	0.615	rs1856757	ENSG00000234147.1	RP3-460G2.2	-4.96	8.05e-07	8.34e-05	-0.19	-0.15	Type 2 diabetes;	chr6:140412718	chr6:140845958~140852924:-
BRCA	cis	rs10129255	0.957	rs1024349	ENSG00000211974.3	IGHV2-70	4.96	8.06e-07	8.34e-05	0.16	0.15	Kawasaki disease;	chr14:106689997	chr14:106723574~106724093:-
BRCA	cis	rs739496	0.579	rs7975437	ENSG00000226469.1	ADAM1B	4.96	8.06e-07	8.34e-05	0.19	0.15	Platelet count;	chr12:111939145	chr12:111927018~111929017:+
BRCA	cis	rs77972916	0.611	rs10495899	ENSG00000234936.1	AC010883.5	4.96	8.06e-07	8.34e-05	0.18	0.15	Granulocyte percentage of myeloid white cells;	chr2:43375165	chr2:43229573~43233394:+
BRCA	cis	rs4835473	0.932	rs4835120	ENSG00000249741.2	RP11-673E1.3	-4.96	8.06e-07	8.34e-05	-0.16	-0.15	Immature fraction of reticulocytes;	chr4:143982370	chr4:143911514~143912053:-
BRCA	cis	rs62025270	0.632	rs56153788	ENSG00000259762.1	RP11-158M2.4	-4.96	8.06e-07	8.35e-05	-0.23	-0.15	Idiopathic pulmonary fibrosis;	chr15:85627761	chr15:85750336~85752901:-
BRCA	cis	rs763121	0.853	rs2235230	ENSG00000228274.3	RP3-508I15.9	4.96	8.07e-07	8.35e-05	0.18	0.15	Menopause (age at onset);	chr22:38728462	chr22:38667585~38681820:-
BRCA	cis	rs1124609	1	rs1124609	ENSG00000244879.4	GABPB1-AS1	4.96	8.07e-07	8.36e-05	0.31	0.15	Subjective well-being;	chr15:50193820	chr15:50354959~50372202:+
BRCA	cis	rs12571093	0.541	rs7893837	ENSG00000233590.1	RP11-153K11.3	-4.96	8.07e-07	8.36e-05	-0.27	-0.15	Optic nerve measurement (disc area);	chr10:68295578	chr10:68233251~68242379:-
BRCA	cis	rs6756513	0.5	rs33992437	ENSG00000231024.1	AC092431.3	-4.96	8.07e-07	8.36e-05	-0.22	-0.15	Breast cancer;Platelet count;	chr2:69828039	chr2:69700192~69713847:-
BRCA	cis	rs4664293	0.867	rs2303550	ENSG00000224152.1	AC009506.1	-4.96	8.07e-07	8.36e-05	-0.17	-0.15	Monocyte percentage of white cells;	chr2:159781110	chr2:159615296~159617082:+
BRCA	cis	rs9402743	0.634	rs9483853	ENSG00000231028.7	LINC00271	-4.96	8.08e-07	8.37e-05	-0.16	-0.15	Systemic lupus erythematosus;	chr6:135595767	chr6:135497801~135716055:+
BRCA	cis	rs9402743	0.634	rs4394233	ENSG00000231028.7	LINC00271	-4.96	8.08e-07	8.37e-05	-0.16	-0.15	Systemic lupus erythematosus;	chr6:135596752	chr6:135497801~135716055:+
BRCA	cis	rs12893668	0.572	rs4900591	ENSG00000269958.1	RP11-73M18.8	4.96	8.08e-07	8.37e-05	0.17	0.15	Reticulocyte count;	chr14:103688541	chr14:103696353~103697163:+
BRCA	cis	rs1552244	1	rs17032414	ENSG00000232901.1	CYCSP10	4.96	8.09e-07	8.37e-05	0.2	0.15	Alzheimer's disease;	chr3:10116618	chr3:10000647~10000940:-
BRCA	cis	rs2562456	0.833	rs56179986	ENSG00000268081.1	RP11-678G14.2	4.96	8.09e-07	8.38e-05	0.25	0.15	Pain;	chr19:21337882	chr19:21554640~21569237:-
BRCA	cis	rs6540731	0.595	rs61828662	ENSG00000229983.1	RP11-15I11.2	4.96	8.09e-07	8.38e-05	0.17	0.15	Intelligence (childhood);	chr1:212198822	chr1:212168207~212190259:+
BRCA	cis	rs6540731	0.536	rs61828663	ENSG00000229983.1	RP11-15I11.2	4.96	8.09e-07	8.38e-05	0.17	0.15	Intelligence (childhood);	chr1:212198823	chr1:212168207~212190259:+
BRCA	cis	rs2638953	0.962	rs11049541	ENSG00000247934.4	RP11-967K21.1	-4.96	8.1e-07	8.38e-05	-0.21	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28341781	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.889	rs11049543	ENSG00000247934.4	RP11-967K21.1	-4.96	8.1e-07	8.38e-05	-0.21	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28342124	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.962	rs11049544	ENSG00000247934.4	RP11-967K21.1	-4.96	8.1e-07	8.38e-05	-0.21	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28342348	chr12:28163298~28190738:-
BRCA	cis	rs8177876	0.822	rs8177959	ENSG00000261061.1	RP11-303E16.2	-4.96	8.1e-07	8.38e-05	-0.19	-0.15	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81082082	chr16:81030770~81031485:+
BRCA	cis	rs13043901	0.95	rs2766664	ENSG00000197670.6	RP4-724E16.2	4.96	8.1e-07	8.38e-05	0.15	0.15	Type 2 diabetes (age of onset);	chr20:53554702	chr20:53552770~53575863:+
BRCA	cis	rs4699052	0.787	rs2169508	ENSG00000246560.2	RP11-10L12.4	4.96	8.11e-07	8.39e-05	0.16	0.15	Testicular germ cell tumor;	chr4:103145733	chr4:102828055~102844075:+
BRCA	cis	rs17711722	0.522	rs6957759	ENSG00000275400.1	RP4-756H11.5	-4.96	8.11e-07	8.39e-05	-0.18	-0.15	Calcium levels;	chr7:65806798	chr7:66553805~66554199:-
BRCA	cis	rs4948275	0.773	rs2650738	ENSG00000237233.2	TMEM26-AS1	-4.96	8.11e-07	8.39e-05	-0.18	-0.15	Night sleep phenotypes;	chr10:61492554	chr10:61452639~61481956:+
BRCA	cis	rs7937890	0.904	rs7484197	ENSG00000251991.1	RNU7-49P	4.96	8.11e-07	8.4e-05	0.17	0.15	Mitochondrial DNA levels;	chr11:14262108	chr11:14478892~14478953:+
BRCA	cis	rs17508449	0.547	rs3195954	ENSG00000232450.1	RP4-730K3.3	-4.96	8.11e-07	8.4e-05	-0.25	-0.15	Leprosy;	chr1:113812032	chr1:113698884~113699631:-
BRCA	cis	rs11758351	1	rs16891405	ENSG00000241549.7	GUSBP2	-4.96	8.12e-07	8.4e-05	-0.22	-0.15	Renal underexcretion gout;Gout;	chr6:26204278	chr6:26871484~26956554:-
BRCA	cis	rs642803	0.551	rs1308020	ENSG00000255557.1	RP11-770G2.2	-4.96	8.12e-07	8.4e-05	-0.19	-0.15	Urate levels;	chr11:65730087	chr11:65745729~65771585:+
BRCA	cis	rs6570726	0.791	rs370112	ENSG00000270638.1	RP3-466P17.1	4.96	8.12e-07	8.41e-05	0.18	0.15	Lobe attachment (rater-scored or self-reported);	chr6:145538717	chr6:145735570~145737218:+
BRCA	cis	rs875971	0.767	rs12668005	ENSG00000236529.1	RP13-254B10.1	4.96	8.12e-07	8.41e-05	0.17	0.15	Aortic root size;	chr7:66444034	chr7:65840212~65840596:+
BRCA	cis	rs793571	0.628	rs1426652	ENSG00000259250.1	RP11-50C13.1	-4.96	8.12e-07	8.41e-05	-0.25	-0.15	Schizophrenia;	chr15:58764513	chr15:58587507~58591676:+
BRCA	cis	rs875971	0.545	rs73142265	ENSG00000230295.1	RP11-458F8.2	4.96	8.13e-07	8.41e-05	0.15	0.15	Aortic root size;	chr7:66234510	chr7:66880708~66882981:+
BRCA	cis	rs10761482	0.6	rs1572843	ENSG00000254271.1	RP11-131N11.4	4.96	8.13e-07	8.41e-05	0.21	0.15	Schizophrenia;	chr10:60467222	chr10:60734342~60741828:+
BRCA	cis	rs3742264	1	rs9534312	ENSG00000235903.6	CPB2-AS1	-4.96	8.13e-07	8.41e-05	-0.2	-0.15	Blood protein levels;	chr13:46076084	chr13:46052806~46113332:+
BRCA	cis	rs9525927	0.817	rs6561169	ENSG00000227258.4	SMIM2-AS1	-4.96	8.13e-07	8.41e-05	-0.22	-0.15	Dupuytren's disease;	chr13:44270102	chr13:44110451~44240517:+
BRCA	cis	rs13108904	0.905	rs1680074	ENSG00000196810.4	CTBP1-AS2	-4.96	8.13e-07	8.41e-05	-0.16	-0.15	Obesity-related traits;	chr4:1285833	chr4:1249300~1288291:+
BRCA	cis	rs10861342	1	rs73395802	ENSG00000257999.1	RP11-61E11.2	-4.96	8.13e-07	8.41e-05	-0.3	-0.15	IgG glycosylation;	chr12:105194940	chr12:105102472~105107179:-
BRCA	cis	rs420259	0.549	rs40076	ENSG00000260136.4	CTD-2270L9.4	4.96	8.13e-07	8.42e-05	0.14	0.15	Bipolar disorder;	chr16:23681084	chr16:23452758~23457606:+
BRCA	cis	rs4819052	0.851	rs2838831	ENSG00000184274.3	LINC00315	-4.96	8.13e-07	8.42e-05	-0.21	-0.15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244860	chr21:45300245~45305257:-
BRCA	cis	rs875971	0.862	rs13226170	ENSG00000236529.1	RP13-254B10.1	4.96	8.14e-07	8.42e-05	0.17	0.15	Aortic root size;	chr7:66534311	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.862	rs2420611	ENSG00000236529.1	RP13-254B10.1	4.96	8.14e-07	8.42e-05	0.17	0.15	Aortic root size;	chr7:66534333	chr7:65840212~65840596:+
BRCA	cis	rs34286592	0.929	rs8058824	ENSG00000214725.6	CDIPT-AS1	-4.96	8.14e-07	8.42e-05	-0.26	-0.15	Multiple sclerosis;	chr16:29817389	chr16:29863593~29868053:+
BRCA	cis	rs1713985	1	rs1713985	ENSG00000269949.1	RP11-738E22.3	-4.96	8.14e-07	8.43e-05	-0.3	-0.15	Age-related macular degeneration;	chr4:56920284	chr4:56960927~56961373:-
BRCA	cis	rs2239547	0.618	rs4687663	ENSG00000242142.1	SERBP1P3	4.96	8.14e-07	8.43e-05	0.19	0.15	Schizophrenia;	chr3:52836602	chr3:53064283~53065091:-
BRCA	cis	rs17685	0.672	rs1639623	ENSG00000280388.1	RP11-229D13.3	-4.96	8.15e-07	8.43e-05	-0.16	-0.15	Coffee consumption (cups per day);Coffee consumption;	chr7:76078633	chr7:76043977~76045963:-
BRCA	cis	rs17685	0.712	rs4552844	ENSG00000280388.1	RP11-229D13.3	-4.96	8.15e-07	8.43e-05	-0.16	-0.15	Coffee consumption (cups per day);Coffee consumption;	chr7:76088777	chr7:76043977~76045963:-
BRCA	cis	rs875971	1	rs6956179	ENSG00000223473.2	GS1-124K5.3	-4.96	8.15e-07	8.43e-05	-0.11	-0.15	Aortic root size;	chr7:66341672	chr7:66491049~66493566:-
BRCA	cis	rs7617773	0.709	rs4404473	ENSG00000199476.1	Y_RNA	-4.96	8.15e-07	8.43e-05	-0.23	-0.15	Coronary artery disease;	chr3:48312136	chr3:48288587~48288694:+
BRCA	cis	rs2408955	0.504	rs11168441	ENSG00000257763.1	OR5BK1P	4.96	8.15e-07	8.44e-05	0.16	0.15	Glycated hemoglobin levels;	chr12:48182271	chr12:48355792~48356614:-
BRCA	cis	rs12497850	0.931	rs13315711	ENSG00000225399.4	RP11-3B7.1	4.96	8.16e-07	8.44e-05	0.15	0.15	Parkinson's disease;	chr3:48948966	chr3:49260085~49261316:+
BRCA	cis	rs12497850	0.931	rs7636057	ENSG00000225399.4	RP11-3B7.1	4.96	8.16e-07	8.44e-05	0.15	0.15	Parkinson's disease;	chr3:48955149	chr3:49260085~49261316:+
BRCA	cis	rs12497850	0.931	rs7643368	ENSG00000225399.4	RP11-3B7.1	4.96	8.16e-07	8.44e-05	0.15	0.15	Parkinson's disease;	chr3:48955422	chr3:49260085~49261316:+
BRCA	cis	rs9923856	0.519	rs720130	ENSG00000274038.1	RP11-66H6.4	4.96	8.16e-07	8.44e-05	0.17	0.15	Atopic dermatitis;Adult asthma;	chr16:11038776	chr16:11056556~11057034:+
BRCA	cis	rs9473147	0.543	rs4711880	ENSG00000270761.1	RP11-385F7.1	-4.96	8.16e-07	8.44e-05	-0.16	-0.15	Platelet distribution width;Mean platelet volume;	chr6:47512940	chr6:47477243~47477572:-
BRCA	cis	rs9473147	0.543	rs9473126	ENSG00000270761.1	RP11-385F7.1	-4.96	8.16e-07	8.44e-05	-0.16	-0.15	Platelet distribution width;Mean platelet volume;	chr6:47514097	chr6:47477243~47477572:-
BRCA	cis	rs9473147	0.543	rs4715025	ENSG00000270761.1	RP11-385F7.1	-4.96	8.16e-07	8.44e-05	-0.16	-0.15	Platelet distribution width;Mean platelet volume;	chr6:47515917	chr6:47477243~47477572:-
BRCA	cis	rs9473147	0.516	rs10948363	ENSG00000270761.1	RP11-385F7.1	-4.96	8.16e-07	8.44e-05	-0.16	-0.15	Platelet distribution width;Mean platelet volume;	chr6:47520026	chr6:47477243~47477572:-
BRCA	cis	rs6714710	0.603	rs6746768	ENSG00000230606.9	AC159540.1	-4.96	8.16e-07	8.44e-05	-0.18	-0.15	Posterior cortical atrophy and Alzheimer's disease;	chr2:97850184	chr2:97416165~97433527:-
BRCA	cis	rs6840360	0.642	rs12647555	ENSG00000278978.1	RP11-164P12.5	-4.96	8.16e-07	8.44e-05	-0.17	-0.15	Intelligence (multi-trait analysis);	chr4:151479946	chr4:151669786~151670503:+
BRCA	cis	rs2562456	0.958	rs2562508	ENSG00000268535.1	RP11-420K14.3	-4.96	8.16e-07	8.45e-05	-0.21	-0.15	Pain;	chr19:21543479	chr19:21709522~21710191:+
BRCA	cis	rs4787491	0.729	rs7191849	ENSG00000261367.1	RP11-455F5.4	-4.96	8.17e-07	8.45e-05	-0.17	-0.15	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30011836	chr16:30107675~30110541:+
BRCA	cis	rs1707322	0.964	rs785508	ENSG00000234329.1	RP11-767N6.2	-4.96	8.17e-07	8.45e-05	-0.16	-0.15	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46061487	chr1:45651039~45651826:-
BRCA	cis	rs1707322	0.964	rs785509	ENSG00000234329.1	RP11-767N6.2	-4.96	8.17e-07	8.45e-05	-0.16	-0.15	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46061628	chr1:45651039~45651826:-
BRCA	cis	rs2880765	0.566	rs17553790	ENSG00000230373.7	GOLGA6L5P	-4.96	8.17e-07	8.45e-05	-0.17	-0.15	Coronary artery disease;	chr15:85470434	chr15:84507885~84516814:-
BRCA	cis	rs4763879	0.778	rs7977940	ENSG00000278635.1	CTD-2318O12.1	4.96	8.17e-07	8.45e-05	0.15	0.15	Type 1 diabetes;	chr12:9686320	chr12:9415641~9416718:+
BRCA	cis	rs1823913	0.503	rs35282329	ENSG00000280083.1	RP11-317J9.1	-4.96	8.18e-07	8.46e-05	-0.18	-0.15	Obesity-related traits;	chr2:191343925	chr2:191154118~191156070:-
BRCA	cis	rs11098499	0.722	rs28713555	ENSG00000249244.1	RP11-548H18.2	4.96	8.18e-07	8.46e-05	0.17	0.15	Corneal astigmatism;	chr4:119330840	chr4:119391831~119395335:-
BRCA	cis	rs9307551	1	rs2582681	ENSG00000250334.4	LINC00989	-4.96	8.18e-07	8.46e-05	-0.23	-0.15	Refractive error;	chr4:79623064	chr4:79492416~79576460:+
BRCA	cis	rs10911251	0.546	rs12034436	ENSG00000224468.3	RP11-181K3.4	-4.96	8.18e-07	8.46e-05	-0.16	-0.15	Colorectal cancer;	chr1:183145662	chr1:183138402~183141282:-
BRCA	cis	rs11700536	1	rs11700536	ENSG00000236663.1	AP001631.9	-4.96	8.18e-07	8.46e-05	-0.17	-0.15	Interleukin-18 levels;	chr21:43138577	chr21:43140523~43141092:-
BRCA	cis	rs875971	1	rs2420591	ENSG00000223473.2	GS1-124K5.3	4.96	8.19e-07	8.47e-05	0.12	0.15	Aortic root size;	chr7:66447394	chr7:66491049~66493566:-
BRCA	cis	rs2115630	1	rs55646601	ENSG00000259295.5	CSPG4P12	-4.96	8.19e-07	8.47e-05	-0.18	-0.15	P wave terminal force;	chr15:84780337	chr15:85191438~85213905:+
BRCA	cis	rs7246657	0.653	rs10414983	ENSG00000267422.1	CTD-2554C21.1	-4.96	8.19e-07	8.47e-05	-0.26	-0.15	Coronary artery calcification;	chr19:37174830	chr19:37779686~37792865:+
BRCA	cis	rs7246657	0.598	rs10405372	ENSG00000267422.1	CTD-2554C21.1	-4.96	8.19e-07	8.47e-05	-0.26	-0.15	Coronary artery calcification;	chr19:37177873	chr19:37779686~37792865:+
BRCA	cis	rs7246657	0.653	rs4805207	ENSG00000267422.1	CTD-2554C21.1	-4.96	8.19e-07	8.47e-05	-0.26	-0.15	Coronary artery calcification;	chr19:37182831	chr19:37779686~37792865:+
BRCA	cis	rs890448	0.726	rs2583397	ENSG00000254531.1	FLJ20021	-4.96	8.19e-07	8.47e-05	-0.18	-0.15	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101308565	chr4:101347780~101348883:+
BRCA	cis	rs754466	0.51	rs10824579	ENSG00000204049.1	RP11-126H7.4	4.96	8.19e-07	8.47e-05	0.17	0.15	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77830927	chr10:77866875~77869610:+
BRCA	cis	rs4711336	0.809	rs749338	ENSG00000224557.6	HLA-DPB2	4.96	8.19e-07	8.47e-05	0.18	0.15	Height;	chr6:33685671	chr6:33112451~33129084:+
BRCA	cis	rs763121	0.776	rs4820346	ENSG00000228274.3	RP3-508I15.9	4.96	8.2e-07	8.48e-05	0.17	0.15	Menopause (age at onset);	chr22:38729069	chr22:38667585~38681820:-
BRCA	cis	rs189798	0.738	rs330908	ENSG00000254340.1	RP11-10A14.3	4.96	8.21e-07	8.49e-05	0.19	0.15	Myopia (pathological);	chr8:9137656	chr8:9141424~9145435:+
BRCA	cis	rs10129255	0.917	rs8022493	ENSG00000211974.3	IGHV2-70	4.96	8.21e-07	8.49e-05	0.15	0.15	Kawasaki disease;	chr14:106781820	chr14:106723574~106724093:-
BRCA	cis	rs60843830	0.55	rs300751	ENSG00000223751.1	AC116609.2	4.96	8.21e-07	8.49e-05	0.19	0.15	Spherical equivalent (joint analysis main effects and education interaction);	chr2:209063	chr2:742488~747767:+
BRCA	cis	rs8114671	0.967	rs2069945	ENSG00000269202.1	RP4-614O4.12	-4.96	8.21e-07	8.49e-05	-0.16	-0.15	Height;	chr20:35174034	chr20:35201747~35203288:-
BRCA	cis	rs559555	0.512	rs481344	ENSG00000272716.1	RP11-563N4.1	4.96	8.22e-07	8.49e-05	0.18	0.15	Blood metabolite ratios;Blood metabolite levels;	chr2:31634850	chr2:32165046~32165757:-
BRCA	cis	rs10419113	0.668	rs3746208	ENSG00000268545.1	VN1R107P	4.96	8.22e-07	8.49e-05	0.18	0.15	Pediatric bone mineral density (spine);	chr19:57688731	chr19:57459912~57460120:+
BRCA	cis	rs2832191	0.791	rs2832181	ENSG00000215533.7	LINC00189	4.96	8.22e-07	8.5e-05	0.17	0.15	Dental caries;	chr21:29109050	chr21:29193480~29288205:+
BRCA	cis	rs7577696	0.924	rs7586448	ENSG00000272716.1	RP11-563N4.1	-4.96	8.22e-07	8.5e-05	-0.17	-0.15	Inflammatory biomarkers;	chr2:32043571	chr2:32165046~32165757:-
BRCA	cis	rs9287719	0.967	rs6735074	ENSG00000243819.4	RN7SL832P	-4.96	8.22e-07	8.5e-05	-0.15	-0.15	Prostate cancer;	chr2:10594640	chr2:10690344~10692099:+
BRCA	cis	rs13118159	0.55	rs28614045	ENSG00000254094.1	AC078852.1	-4.96	8.22e-07	8.5e-05	-0.18	-0.15	Longevity;	chr4:1380907	chr4:1356581~1358075:+
BRCA	cis	rs7682317	0.797	rs1795720	ENSG00000270720.1	RP11-84C13.2	-4.96	8.23e-07	8.5e-05	-0.17	-0.15	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr4:89008103	chr4:89119284~89119871:+
BRCA	cis	rs7045881	0.877	rs111723654	ENSG00000254396.1	RP11-56F10.3	4.96	8.23e-07	8.51e-05	0.29	0.15	Schizophrenia;	chr9:26789776	chr9:27102630~27104728:+
BRCA	cis	rs2179367	0.959	rs544947	ENSG00000268592.3	RAET1E-AS1	4.96	8.23e-07	8.51e-05	0.19	0.15	Dupuytren's disease;	chr6:149402412	chr6:149863494~149919507:+
BRCA	cis	rs11098499	0.754	rs1980027	ENSG00000260404.2	RP11-384K6.6	4.96	8.24e-07	8.51e-05	0.14	0.15	Corneal astigmatism;	chr4:119330422	chr4:118591773~118633729:+
BRCA	cis	rs11758351	0.517	rs79958315	ENSG00000241549.7	GUSBP2	-4.96	8.24e-07	8.51e-05	-0.21	-0.15	Renal underexcretion gout;Gout;	chr6:26221598	chr6:26871484~26956554:-
BRCA	cis	rs875971	0.545	rs73376401	ENSG00000232546.1	RP11-458F8.1	4.96	8.24e-07	8.52e-05	0.14	0.15	Aortic root size;	chr7:66174841	chr7:66848496~66858136:+
BRCA	cis	rs7246657	0.653	rs28701616	ENSG00000267422.1	CTD-2554C21.1	-4.96	8.24e-07	8.52e-05	-0.26	-0.15	Coronary artery calcification;	chr19:37190196	chr19:37779686~37792865:+
BRCA	cis	rs13113518	1	rs3749474	ENSG00000223305.1	RN7SKP30	4.96	8.24e-07	8.52e-05	0.18	0.15	Height;	chr4:55434518	chr4:55540502~55540835:-
BRCA	cis	rs7246657	0.722	rs954504	ENSG00000276846.1	CTD-3220F14.3	4.96	8.25e-07	8.52e-05	0.21	0.15	Coronary artery calcification;	chr19:37554492	chr19:37314868~37315620:-
BRCA	cis	rs7246657	0.722	rs8110865	ENSG00000276846.1	CTD-3220F14.3	4.96	8.25e-07	8.52e-05	0.21	0.15	Coronary artery calcification;	chr19:37556485	chr19:37314868~37315620:-
BRCA	cis	rs7246657	0.678	rs4802024	ENSG00000276846.1	CTD-3220F14.3	4.96	8.25e-07	8.52e-05	0.21	0.15	Coronary artery calcification;	chr19:37561291	chr19:37314868~37315620:-
BRCA	cis	rs7246657	0.722	rs4802029	ENSG00000276846.1	CTD-3220F14.3	4.96	8.25e-07	8.52e-05	0.21	0.15	Coronary artery calcification;	chr19:37564710	chr19:37314868~37315620:-
BRCA	cis	rs7246657	0.722	rs28512414	ENSG00000276846.1	CTD-3220F14.3	4.96	8.25e-07	8.52e-05	0.21	0.15	Coronary artery calcification;	chr19:37565672	chr19:37314868~37315620:-
BRCA	cis	rs7246657	0.722	rs6508736	ENSG00000276846.1	CTD-3220F14.3	4.96	8.25e-07	8.52e-05	0.21	0.15	Coronary artery calcification;	chr19:37570855	chr19:37314868~37315620:-
BRCA	cis	rs3845817	0.798	rs702952	ENSG00000237979.1	AC007389.1	4.96	8.25e-07	8.52e-05	0.18	0.15	Bipolar disorder;	chr2:65537915	chr2:65500993~65502138:-
BRCA	cis	rs7226408	0.857	rs72887029	ENSG00000267707.2	RP11-95O2.5	4.96	8.25e-07	8.52e-05	0.23	0.15	Obesity-related traits;	chr18:36892006	chr18:37243776~37247506:+
BRCA	cis	rs7226408	0.857	rs72887031	ENSG00000267707.2	RP11-95O2.5	4.96	8.25e-07	8.52e-05	0.23	0.15	Obesity-related traits;	chr18:36892120	chr18:37243776~37247506:+
BRCA	cis	rs7226408	0.857	rs72887032	ENSG00000267707.2	RP11-95O2.5	4.96	8.25e-07	8.52e-05	0.23	0.15	Obesity-related traits;	chr18:36893270	chr18:37243776~37247506:+
BRCA	cis	rs7226408	0.857	rs17652450	ENSG00000267707.2	RP11-95O2.5	4.96	8.25e-07	8.52e-05	0.23	0.15	Obesity-related traits;	chr18:36893620	chr18:37243776~37247506:+
BRCA	cis	rs7226408	0.857	rs72887034	ENSG00000267707.2	RP11-95O2.5	4.96	8.25e-07	8.52e-05	0.23	0.15	Obesity-related traits;	chr18:36894224	chr18:37243776~37247506:+
BRCA	cis	rs7226408	0.857	rs72887035	ENSG00000267707.2	RP11-95O2.5	4.96	8.25e-07	8.52e-05	0.23	0.15	Obesity-related traits;	chr18:36894498	chr18:37243776~37247506:+
BRCA	cis	rs7226408	0.857	rs3967207	ENSG00000267707.2	RP11-95O2.5	4.96	8.25e-07	8.52e-05	0.23	0.15	Obesity-related traits;	chr18:36894779	chr18:37243776~37247506:+
BRCA	cis	rs7226408	0.857	rs72887036	ENSG00000267707.2	RP11-95O2.5	4.96	8.25e-07	8.52e-05	0.23	0.15	Obesity-related traits;	chr18:36895774	chr18:37243776~37247506:+
BRCA	cis	rs7226408	0.857	rs17652454	ENSG00000267707.2	RP11-95O2.5	4.96	8.25e-07	8.52e-05	0.23	0.15	Obesity-related traits;	chr18:36896145	chr18:37243776~37247506:+
BRCA	cis	rs7226408	0.857	rs11660125	ENSG00000267707.2	RP11-95O2.5	4.96	8.25e-07	8.52e-05	0.23	0.15	Obesity-related traits;	chr18:36896659	chr18:37243776~37247506:+
BRCA	cis	rs2153535	0.585	rs9502734	ENSG00000230939.1	RP11-314C16.1	-4.96	8.25e-07	8.53e-05	-0.18	-0.15	Motion sickness;	chr6:8631618	chr6:8784178~8785445:+
BRCA	cis	rs2153535	0.56	rs7750064	ENSG00000230939.1	RP11-314C16.1	-4.96	8.25e-07	8.53e-05	-0.18	-0.15	Motion sickness;	chr6:8632012	chr6:8784178~8785445:+
BRCA	cis	rs12497850	0.931	rs7430501	ENSG00000225399.4	RP11-3B7.1	4.96	8.25e-07	8.53e-05	0.15	0.15	Parkinson's disease;	chr3:48852686	chr3:49260085~49261316:+
BRCA	cis	rs12497850	0.931	rs10780033	ENSG00000225399.4	RP11-3B7.1	4.96	8.25e-07	8.53e-05	0.15	0.15	Parkinson's disease;	chr3:48853842	chr3:49260085~49261316:+
BRCA	cis	rs11976180	1	rs1540894	ENSG00000244479.5	OR2A1-AS1	4.96	8.25e-07	8.53e-05	0.2	0.15	Obesity-related traits;	chr7:144070583	chr7:144251264~144356181:-
BRCA	cis	rs2842992	0.724	rs9347340	ENSG00000237927.1	RP3-393E18.2	4.96	8.25e-07	8.53e-05	0.2	0.15	Age-related macular degeneration (geographic atrophy);	chr6:159767859	chr6:159586955~159589169:-
BRCA	cis	rs1015362	0.581	rs4911373	ENSG00000276073.1	RP5-1125A11.7	-4.96	8.26e-07	8.53e-05	-0.22	-0.15	Freckles;Red vs. non-red hair color;Skin sensitivity to sun;Burning and freckling;	chr20:33920952	chr20:33985617~33988989:-
BRCA	cis	rs60843830	1	rs3828165	ENSG00000272342.1	RP13-539J13.1	4.96	8.26e-07	8.53e-05	0.19	0.15	Spherical equivalent (joint analysis main effects and education interaction);	chr2:220889	chr2:739588~740164:-
BRCA	cis	rs10504130	0.696	rs113323463	ENSG00000253844.1	RP11-546K22.1	-4.96	8.26e-07	8.53e-05	-0.23	-0.15	Venous thromboembolism (SNP x SNP interaction);	chr8:51912737	chr8:51961458~52022974:+
BRCA	cis	rs10504130	0.696	rs111926180	ENSG00000253844.1	RP11-546K22.1	-4.96	8.26e-07	8.53e-05	-0.23	-0.15	Venous thromboembolism (SNP x SNP interaction);	chr8:51913101	chr8:51961458~52022974:+
BRCA	cis	rs7246657	0.663	rs9304568	ENSG00000276846.1	CTD-3220F14.3	4.96	8.26e-07	8.53e-05	0.2	0.15	Coronary artery calcification;	chr19:37563606	chr19:37314868~37315620:-
BRCA	cis	rs7615952	0.546	rs11717632	ENSG00000171084.14	FAM86JP	4.96	8.26e-07	8.54e-05	0.26	0.15	Blood pressure (smoking interaction);	chr3:125602286	chr3:125916620~125930024:+
BRCA	cis	rs7615952	0.546	rs2922197	ENSG00000171084.14	FAM86JP	4.96	8.26e-07	8.54e-05	0.26	0.15	Blood pressure (smoking interaction);	chr3:125603188	chr3:125916620~125930024:+
BRCA	cis	rs11992162	0.967	rs10088415	ENSG00000255046.1	RP11-297N6.4	4.96	8.26e-07	8.54e-05	0.18	0.15	Monocyte count;	chr8:11973316	chr8:11797928~11802568:-
BRCA	cis	rs801193	0.548	rs2109297	ENSG00000236529.1	RP13-254B10.1	-4.96	8.26e-07	8.54e-05	-0.17	-0.15	Aortic root size;	chr7:66657397	chr7:65840212~65840596:+
BRCA	cis	rs7267979	0.844	rs6076343	ENSG00000274414.1	RP5-965G21.4	4.96	8.27e-07	8.55e-05	0.18	0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25396027	chr20:25239007~25245229:-
BRCA	cis	rs875971	0.767	rs1643394	ENSG00000236529.1	RP13-254B10.1	4.96	8.28e-07	8.55e-05	0.17	0.15	Aortic root size;	chr7:66371107	chr7:65840212~65840596:+
BRCA	cis	rs10129255	1	rs10129319	ENSG00000280411.1	IGHV1-69-2	-4.96	8.28e-07	8.55e-05	-0.11	-0.15	Kawasaki disease;	chr14:106767996	chr14:106762092~106762588:-
BRCA	cis	rs6964587	0.967	rs10953065	ENSG00000188693.7	CYP51A1-AS1	4.96	8.28e-07	8.55e-05	0.17	0.15	Breast cancer;	chr7:92179601	chr7:92134604~92180725:+
BRCA	cis	rs793571	0.504	rs28549001	ENSG00000259250.1	RP11-50C13.1	-4.96	8.28e-07	8.55e-05	-0.25	-0.15	Schizophrenia;	chr15:58721969	chr15:58587507~58591676:+
BRCA	cis	rs11239930	0.517	rs685741	ENSG00000230832.3	RP11-325P15.2	-4.96	8.28e-07	8.55e-05	-0.22	-0.15	AIDS progression;	chr1:147074503	chr1:147082338~147083578:-
BRCA	cis	rs11051970	0.559	rs2291420	ENSG00000274964.1	RP11-817I4.1	-4.96	8.29e-07	8.56e-05	-0.2	-0.15	Response to tocilizumab in rheumatoid arthritis;	chr12:32334816	chr12:32339368~32340724:+
BRCA	cis	rs4718428	0.705	rs4717328	ENSG00000229180.5	GS1-124K5.11	4.96	8.29e-07	8.56e-05	0.15	0.15	Corneal structure;	chr7:66887678	chr7:66526088~66542624:-
BRCA	cis	rs35740288	0.752	rs11635956	ENSG00000202081.1	RNU6-1280P	4.96	8.29e-07	8.56e-05	0.21	0.15	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85736697	chr15:85651522~85651628:-
BRCA	cis	rs6714710	0.627	rs6748124	ENSG00000230606.9	AC159540.1	-4.96	8.29e-07	8.56e-05	-0.18	-0.15	Posterior cortical atrophy and Alzheimer's disease;	chr2:97902551	chr2:97416165~97433527:-
BRCA	cis	rs6714710	0.603	rs58546246	ENSG00000230606.9	AC159540.1	-4.96	8.29e-07	8.56e-05	-0.18	-0.15	Posterior cortical atrophy and Alzheimer's disease;	chr2:97905360	chr2:97416165~97433527:-
BRCA	cis	rs78487399	1	rs79611878	ENSG00000234936.1	AC010883.5	4.96	8.29e-07	8.56e-05	0.22	0.15	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43617664	chr2:43229573~43233394:+
BRCA	cis	rs7613875	0.6	rs2856237	ENSG00000228008.1	CTD-2330K9.3	-4.96	8.29e-07	8.57e-05	-0.15	-0.15	Body mass index;	chr3:50121341	chr3:49903845~49916937:+
BRCA	cis	rs1395	0.778	rs17005956	ENSG00000234072.1	AC074117.10	-4.96	8.3e-07	8.57e-05	-0.17	-0.15	Blood metabolite levels;	chr2:27228231	chr2:27356246~27367622:+
BRCA	cis	rs6439153	0.933	rs900381	ENSG00000231305.3	RP11-723O4.2	4.96	8.3e-07	8.57e-05	0.17	0.15	Pneumococcal bacteremia;	chr3:128994612	chr3:128861313~128871540:-
BRCA	cis	rs1005277	0.579	rs1780137	ENSG00000263064.2	RP11-291L22.7	4.96	8.3e-07	8.58e-05	0.19	0.15	Extrinsic epigenetic age acceleration;	chr10:38212547	chr10:38448689~38448949:+
BRCA	cis	rs35146811	0.844	rs34031156	ENSG00000235713.1	RP4-604G5.3	4.96	8.31e-07	8.58e-05	0.18	0.15	Coronary artery disease;	chr7:100080294	chr7:99992397~99993050:+
BRCA	cis	rs891378	1	rs2802234	ENSG00000274245.1	RP11-357P18.2	-4.96	8.31e-07	8.58e-05	-0.2	-0.15	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207298244	chr1:207372559~207373252:+
BRCA	cis	rs1669338	0.588	rs55959448	ENSG00000271870.1	RP11-97C16.1	4.96	8.31e-07	8.58e-05	0.2	0.15	White matter integrity;	chr3:3162316	chr3:3152942~3153435:+
BRCA	cis	rs1005277	0.563	rs2505215	ENSG00000263064.2	RP11-291L22.7	4.96	8.31e-07	8.58e-05	0.19	0.15	Extrinsic epigenetic age acceleration;	chr10:38192345	chr10:38448689~38448949:+
BRCA	cis	rs7246657	0.55	rs9941475	ENSG00000276846.1	CTD-3220F14.3	4.96	8.31e-07	8.58e-05	0.21	0.15	Coronary artery calcification;	chr19:37573615	chr19:37314868~37315620:-
BRCA	cis	rs7246657	0.765	rs4803262	ENSG00000276846.1	CTD-3220F14.3	4.96	8.31e-07	8.58e-05	0.21	0.15	Coronary artery calcification;	chr19:37575858	chr19:37314868~37315620:-
BRCA	cis	rs7246657	0.712	rs4803263	ENSG00000276846.1	CTD-3220F14.3	4.96	8.31e-07	8.58e-05	0.21	0.15	Coronary artery calcification;	chr19:37575880	chr19:37314868~37315620:-
BRCA	cis	rs7246657	0.722	rs10412510	ENSG00000276846.1	CTD-3220F14.3	4.96	8.31e-07	8.58e-05	0.21	0.15	Coronary artery calcification;	chr19:37585043	chr19:37314868~37315620:-
BRCA	cis	rs7246657	0.722	rs3829688	ENSG00000276846.1	CTD-3220F14.3	4.96	8.31e-07	8.58e-05	0.21	0.15	Coronary artery calcification;	chr19:37586199	chr19:37314868~37315620:-
BRCA	cis	rs7246657	0.722	rs13744	ENSG00000276846.1	CTD-3220F14.3	4.96	8.31e-07	8.58e-05	0.21	0.15	Coronary artery calcification;	chr19:37587011	chr19:37314868~37315620:-
BRCA	cis	rs7246657	0.722	rs10403173	ENSG00000276846.1	CTD-3220F14.3	4.96	8.31e-07	8.58e-05	0.21	0.15	Coronary artery calcification;	chr19:37587779	chr19:37314868~37315620:-
BRCA	cis	rs7246657	0.679	rs12461113	ENSG00000276846.1	CTD-3220F14.3	4.96	8.31e-07	8.58e-05	0.21	0.15	Coronary artery calcification;	chr19:37592287	chr19:37314868~37315620:-
BRCA	cis	rs7246657	0.639	rs12459015	ENSG00000276846.1	CTD-3220F14.3	4.96	8.31e-07	8.58e-05	0.21	0.15	Coronary artery calcification;	chr19:37592288	chr19:37314868~37315620:-
BRCA	cis	rs6840360	0.642	rs2709822	ENSG00000251603.1	RP11-164P12.4	-4.96	8.31e-07	8.59e-05	-0.14	-0.15	Intelligence (multi-trait analysis);	chr4:151430348	chr4:151667224~151670502:+
BRCA	cis	rs6439153	0.933	rs810952	ENSG00000231305.3	RP11-723O4.2	4.96	8.32e-07	8.59e-05	0.17	0.15	Pneumococcal bacteremia;	chr3:128967062	chr3:128861313~128871540:-
BRCA	cis	rs300890	0.585	rs1440412	ENSG00000250326.1	RP11-284M14.1	-4.96	8.32e-07	8.59e-05	-0.18	-0.15	Nasopharyngeal carcinoma;	chr4:143237122	chr4:142933195~143184861:-
BRCA	cis	rs1440410	0.56	rs4299537	ENSG00000250326.1	RP11-284M14.1	-4.96	8.33e-07	8.6e-05	-0.18	-0.15	Ischemic stroke;	chr4:143127155	chr4:142933195~143184861:-
BRCA	cis	rs7131987	0.621	rs3782506	ENSG00000275476.1	RP11-996F15.4	4.96	8.33e-07	8.6e-05	0.18	0.15	QT interval;	chr12:29292489	chr12:29277397~29277882:-
BRCA	cis	rs1371614	0.61	rs12615509	ENSG00000272148.1	RP11-195B17.1	-4.96	8.33e-07	8.6e-05	-0.17	-0.15	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26875898	chr2:27062428~27062907:-
BRCA	cis	rs4948275	0.773	rs2787732	ENSG00000237233.2	TMEM26-AS1	4.96	8.33e-07	8.6e-05	0.18	0.15	Night sleep phenotypes;	chr10:61487841	chr10:61452639~61481956:+
BRCA	cis	rs7226408	0.857	rs74682538	ENSG00000267707.2	RP11-95O2.5	4.96	8.33e-07	8.61e-05	0.23	0.15	Obesity-related traits;	chr18:36893609	chr18:37243776~37247506:+
BRCA	cis	rs1387259	0.929	rs2956703	ENSG00000257735.1	RP11-370I10.6	4.96	8.34e-07	8.61e-05	0.19	0.15	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48276511	chr12:48350945~48442411:+
BRCA	cis	rs11098499	0.866	rs10518329	ENSG00000249244.1	RP11-548H18.2	4.96	8.34e-07	8.61e-05	0.17	0.15	Corneal astigmatism;	chr4:119480680	chr4:119391831~119395335:-
BRCA	cis	rs2736345	0.788	rs2618476	ENSG00000255046.1	RP11-297N6.4	-4.96	8.34e-07	8.61e-05	-0.19	-0.15	Systemic lupus erythematosus;Sjögren's syndrome;	chr8:11495032	chr8:11797928~11802568:-
BRCA	cis	rs4664293	0.967	rs4665103	ENSG00000226266.5	AC009961.3	-4.96	8.34e-07	8.61e-05	-0.2	-0.15	Monocyte percentage of white cells;	chr2:159675801	chr2:159670708~159712435:-
BRCA	cis	rs4908768	0.539	rs1809332	ENSG00000232912.4	RP5-1115A15.1	4.96	8.35e-07	8.62e-05	0.15	0.15	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8596375	chr1:8424645~8434838:+
BRCA	cis	rs6921919	0.583	rs2071965	ENSG00000220721.1	OR1F12	4.96	8.35e-07	8.62e-05	0.18	0.15	Autism spectrum disorder or schizophrenia;	chr6:28435448	chr6:28073316~28074233:+
BRCA	cis	rs75422866	0.51	rs73105803	ENSG00000276691.1	RP5-1057I20.5	4.96	8.35e-07	8.62e-05	0.3	0.15	Pneumonia;	chr12:47722135	chr12:47788426~47788971:+
BRCA	cis	rs75422866	0.51	rs73105812	ENSG00000276691.1	RP5-1057I20.5	4.96	8.35e-07	8.62e-05	0.3	0.15	Pneumonia;	chr12:47724404	chr12:47788426~47788971:+
BRCA	cis	rs75422866	0.51	rs74733564	ENSG00000276691.1	RP5-1057I20.5	4.96	8.35e-07	8.62e-05	0.3	0.15	Pneumonia;	chr12:47724644	chr12:47788426~47788971:+
BRCA	cis	rs75422866	0.51	rs73105814	ENSG00000276691.1	RP5-1057I20.5	4.96	8.35e-07	8.62e-05	0.3	0.15	Pneumonia;	chr12:47725817	chr12:47788426~47788971:+
BRCA	cis	rs2574985	0.739	rs2983359	ENSG00000231345.3	BEND3P1	-4.96	8.35e-07	8.62e-05	-0.25	-0.15	Subjective well-being;	chr10:50541899	chr10:50655967~50660472:+
BRCA	cis	rs875971	0.755	rs76288834	ENSG00000273448.1	RP11-166O4.6	-4.96	8.35e-07	8.62e-05	-0.14	-0.15	Aortic root size;	chr7:66604815	chr7:67333047~67334383:+
BRCA	cis	rs10129255	1	rs10141557	ENSG00000211974.3	IGHV2-70	4.96	8.36e-07	8.63e-05	0.16	0.15	Kawasaki disease;	chr14:106767990	chr14:106723574~106724093:-
BRCA	cis	rs2243480	1	rs316313	ENSG00000275400.1	RP4-756H11.5	4.96	8.36e-07	8.63e-05	0.28	0.15	Diabetic kidney disease;	chr7:66128561	chr7:66553805~66554199:-
BRCA	cis	rs2243480	1	rs316312	ENSG00000275400.1	RP4-756H11.5	4.96	8.36e-07	8.63e-05	0.28	0.15	Diabetic kidney disease;	chr7:66131504	chr7:66553805~66554199:-
BRCA	cis	rs2243480	1	rs419603	ENSG00000275400.1	RP4-756H11.5	4.96	8.36e-07	8.63e-05	0.28	0.15	Diabetic kidney disease;	chr7:66132354	chr7:66553805~66554199:-
BRCA	cis	rs1124769	0.57	rs4142324	ENSG00000259378.1	DCAF13P3	4.96	8.36e-07	8.63e-05	0.2	0.15	Cognitive performance;	chr15:50871860	chr15:50944663~50945996:+
BRCA	cis	rs4664293	0.867	rs3771718	ENSG00000224152.1	AC009506.1	-4.96	8.37e-07	8.64e-05	-0.17	-0.15	Monocyte percentage of white cells;	chr2:159780397	chr2:159615296~159617082:+
BRCA	cis	rs10911232	0.542	rs12128323	ENSG00000224468.3	RP11-181K3.4	-4.96	8.37e-07	8.64e-05	-0.16	-0.15	Hypertriglyceridemia;	chr1:183080952	chr1:183138402~183141282:-
BRCA	cis	rs4666002	0.75	rs13021208	ENSG00000234072.1	AC074117.10	4.96	8.37e-07	8.64e-05	0.18	0.15	Phospholipid levels (plasma);	chr2:27678861	chr2:27356246~27367622:+
BRCA	cis	rs10504130	0.569	rs11785467	ENSG00000272024.1	RP11-546K22.3	-4.96	8.37e-07	8.64e-05	-0.22	-0.15	Venous thromboembolism (SNP x SNP interaction);	chr8:51763108	chr8:51950284~51950690:+
BRCA	cis	rs6095360	1	rs2426125	ENSG00000222365.1	SNORD12B	-4.96	8.37e-07	8.64e-05	-0.17	-0.15	Intelligence (multi-trait analysis);	chr20:49084445	chr20:49280319~49280409:+
BRCA	cis	rs734999	0.967	rs4486391	ENSG00000238164.5	RP3-395M20.8	-4.96	8.37e-07	8.64e-05	-0.12	-0.15	Ulcerative colitis;	chr1:2581616	chr1:2549920~2557031:-
BRCA	cis	rs370915	0.578	rs28627789	ENSG00000250971.1	RP11-696F12.1	4.96	8.38e-07	8.65e-05	0.16	0.15	Gout;	chr4:186867620	chr4:187060099~187060930:+
BRCA	cis	rs7196129	0.966	rs12598978	ENSG00000273724.1	RP11-347C12.12	4.96	8.38e-07	8.65e-05	0.17	0.15	Monocyte count;	chr16:30471219	chr16:30336400~30343336:+
BRCA	cis	rs2732480	0.577	rs2732457	ENSG00000240399.1	RP1-228P16.1	-4.96	8.38e-07	8.65e-05	-0.18	-0.15	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48364596	chr12:48054813~48055591:-
BRCA	cis	rs7577696	0.515	rs2300699	ENSG00000272716.1	RP11-563N4.1	4.96	8.38e-07	8.65e-05	0.18	0.15	Inflammatory biomarkers;	chr2:31561897	chr2:32165046~32165757:-
BRCA	cis	rs9616064	0.74	rs6520049	ENSG00000234869.1	RP3-439F8.1	-4.96	8.38e-07	8.65e-05	-0.18	-0.15	Urate levels in obese individuals;	chr22:46600412	chr22:46541495~46548196:+
BRCA	cis	rs12468226	0.873	rs1474267	ENSG00000226261.1	AC064836.3	-4.96	8.39e-07	8.66e-05	-0.25	-0.15	Urate levels;	chr2:202178596	chr2:202336024~202336727:-
BRCA	cis	rs3845817	1	rs11126042	ENSG00000237979.1	AC007389.1	-4.96	8.4e-07	8.67e-05	-0.18	-0.15	Bipolar disorder;	chr2:65536511	chr2:65500993~65502138:-
BRCA	cis	rs250585	1	rs250587	ENSG00000260136.4	CTD-2270L9.4	-4.96	8.41e-07	8.68e-05	-0.16	-0.15	Egg allergy;	chr16:23388873	chr16:23452758~23457606:+
BRCA	cis	rs2562456	0.792	rs2562398	ENSG00000268535.1	RP11-420K14.3	-4.96	8.41e-07	8.68e-05	-0.21	-0.15	Pain;	chr19:21540147	chr19:21709522~21710191:+
BRCA	cis	rs7618915	0.547	rs1561337	ENSG00000243224.1	RP5-1157M23.2	-4.96	8.41e-07	8.68e-05	-0.17	-0.15	Bipolar disorder;	chr3:52625947	chr3:52239258~52241097:+
BRCA	cis	rs924712	0.545	rs9475040	ENSG00000261116.1	RP3-523K23.2	4.96	8.42e-07	8.69e-05	0.18	0.15	Breast cancer;	chr6:54847760	chr6:54943167~54945099:+
BRCA	cis	rs11098499	0.754	rs12513083	ENSG00000249244.1	RP11-548H18.2	4.96	8.42e-07	8.69e-05	0.17	0.15	Corneal astigmatism;	chr4:119328457	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.754	rs12509621	ENSG00000249244.1	RP11-548H18.2	4.96	8.42e-07	8.69e-05	0.17	0.15	Corneal astigmatism;	chr4:119328505	chr4:119391831~119395335:-
BRCA	cis	rs875971	0.862	rs4149461	ENSG00000236529.1	RP13-254B10.1	-4.96	8.42e-07	8.69e-05	-0.17	-0.15	Aortic root size;	chr7:66279745	chr7:65840212~65840596:+
BRCA	cis	rs10504130	0.597	rs4598243	ENSG00000272024.1	RP11-546K22.3	-4.96	8.42e-07	8.69e-05	-0.22	-0.15	Venous thromboembolism (SNP x SNP interaction);	chr8:51797158	chr8:51950284~51950690:+
BRCA	cis	rs6452524	0.618	rs10051445	ENSG00000281327.1	LINC01338	4.96	8.42e-07	8.69e-05	0.17	0.15	Hypertension (SNP x SNP interaction);	chr5:83060280	chr5:82850864~82859836:-
BRCA	cis	rs11955398	0.716	rs2409792	ENSG00000215032.2	GNL3LP1	4.96	8.43e-07	8.69e-05	0.18	0.15	Intelligence (multi-trait analysis);	chr5:60702409	chr5:60891935~60893577:-
BRCA	cis	rs11955398	0.716	rs12514253	ENSG00000215032.2	GNL3LP1	4.96	8.43e-07	8.69e-05	0.18	0.15	Intelligence (multi-trait analysis);	chr5:60702474	chr5:60891935~60893577:-
BRCA	cis	rs1387259	0.698	rs4579969	ENSG00000226413.2	OR8T1P	-4.96	8.43e-07	8.7e-05	-0.19	-0.15	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48385779	chr12:48442030~48442947:-
BRCA	cis	rs13113518	0.702	rs78829811	ENSG00000223305.1	RN7SKP30	4.96	8.44e-07	8.7e-05	0.19	0.15	Height;	chr4:55558258	chr4:55540502~55540835:-
BRCA	cis	rs13113518	0.702	rs75801206	ENSG00000223305.1	RN7SKP30	4.96	8.44e-07	8.7e-05	0.19	0.15	Height;	chr4:55558259	chr4:55540502~55540835:-
BRCA	cis	rs13113518	0.702	rs34658078	ENSG00000223305.1	RN7SKP30	4.96	8.44e-07	8.7e-05	0.19	0.15	Height;	chr4:55558261	chr4:55540502~55540835:-
BRCA	cis	rs6545883	0.929	rs2252662	ENSG00000270820.4	RP11-355B11.2	4.95	8.44e-07	8.7e-05	0.17	0.15	Tuberculosis;	chr2:61443596	chr2:61471188~61484130:+
BRCA	cis	rs4700393	0.52	rs4515250	ENSG00000215032.2	GNL3LP1	4.95	8.44e-07	8.7e-05	0.21	0.15	Intelligence (multi-trait analysis);	chr5:60646302	chr5:60891935~60893577:-
BRCA	cis	rs9300255	0.543	rs655293	ENSG00000235423.7	RP11-282O18.3	4.95	8.44e-07	8.7e-05	0.19	0.15	Neutrophil percentage of white cells;	chr12:123043858	chr12:123252030~123261483:-
BRCA	cis	rs853679	0.769	rs7752608	ENSG00000204709.4	LINC01556	4.95	8.44e-07	8.71e-05	0.32	0.15	Depression;	chr6:28333418	chr6:28943877~28944537:+
BRCA	cis	rs9467773	0.595	rs7767847	ENSG00000124549.13	BTN2A3P	4.95	8.45e-07	8.71e-05	0.15	0.15	Intelligence (multi-trait analysis);	chr6:26597665	chr6:26421391~26432383:+
BRCA	cis	rs4781563	1	rs4781563	ENSG00000242307.1	RPS26P52	-4.95	8.45e-07	8.71e-05	-0.19	-0.15	Bilirubin levels;	chr16:13951542	chr16:13922332~13922679:-
BRCA	cis	rs7302981	0.845	rs56709084	ENSG00000272368.2	RP4-605O3.4	4.95	8.45e-07	8.71e-05	0.15	0.15	Systolic blood pressure;	chr12:50170107	chr12:50112197~50165618:+
BRCA	cis	rs7474896	0.616	rs1985260	ENSG00000120555.12	SEPT7P9	4.95	8.45e-07	8.71e-05	0.23	0.15	Obesity (extreme);	chr10:38145162	chr10:38383069~38402916:-
BRCA	cis	rs6439153	0.901	rs2630263	ENSG00000231305.3	RP11-723O4.2	4.95	8.45e-07	8.71e-05	0.17	0.15	Pneumococcal bacteremia;	chr3:128969475	chr3:128861313~128871540:-
BRCA	cis	rs1876905	0.68	rs434034	ENSG00000230177.1	RP5-1112D6.4	-4.95	8.45e-07	8.72e-05	-0.22	-0.15	Mean corpuscular hemoglobin;	chr6:111204180	chr6:111277932~111278742:+
BRCA	cis	rs61160187	0.51	rs4400080	ENSG00000215032.2	GNL3LP1	-4.95	8.45e-07	8.72e-05	-0.19	-0.15	Educational attainment (years of education);Educational attainment (college completion);	chr5:60744809	chr5:60891935~60893577:-
BRCA	cis	rs3808502	0.605	rs11784572	ENSG00000154316.13	TDH	4.95	8.46e-07	8.72e-05	0.2	0.15	Neuroticism;	chr8:11316975	chr8:11339637~11368452:+
BRCA	cis	rs3020264	0.586	rs3020265	ENSG00000271743.1	CTD-2541M15.3	4.95	8.46e-07	8.72e-05	0.19	0.15	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 24 weeks);	chr8:6631400	chr8:6615604~6617198:-
BRCA	cis	rs875971	0.862	rs3893216	ENSG00000236529.1	RP13-254B10.1	-4.95	8.46e-07	8.73e-05	-0.17	-0.15	Aortic root size;	chr7:66325720	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.862	rs6958294	ENSG00000236529.1	RP13-254B10.1	-4.95	8.46e-07	8.73e-05	-0.17	-0.15	Aortic root size;	chr7:66329809	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.862	rs2088655	ENSG00000236529.1	RP13-254B10.1	-4.95	8.46e-07	8.73e-05	-0.17	-0.15	Aortic root size;	chr7:66330724	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.895	rs10447522	ENSG00000236529.1	RP13-254B10.1	-4.95	8.46e-07	8.73e-05	-0.17	-0.15	Aortic root size;	chr7:66331087	chr7:65840212~65840596:+
BRCA	cis	rs253959	0.607	rs1396497	ENSG00000271918.1	CTD-2287O16.5	4.95	8.47e-07	8.73e-05	0.13	0.15	Bipolar disorder and schizophrenia;	chr5:116091719	chr5:116083807~116085416:-
BRCA	cis	rs17685	0.753	rs55812043	ENSG00000280388.1	RP11-229D13.3	-4.95	8.47e-07	8.73e-05	-0.16	-0.15	Coffee consumption (cups per day);Coffee consumption;	chr7:76117923	chr7:76043977~76045963:-
BRCA	cis	rs6756513	0.5	rs17037193	ENSG00000231024.1	AC092431.3	-4.95	8.47e-07	8.74e-05	-0.22	-0.15	Breast cancer;Platelet count;	chr2:69876372	chr2:69700192~69713847:-
BRCA	cis	rs57221529	0.713	rs56328416	ENSG00000225138.6	CTD-2228K2.7	4.95	8.47e-07	8.74e-05	0.23	0.15	Lung disease severity in cystic fibrosis;	chr5:591023	chr5:473236~480884:+
BRCA	cis	rs7927592	0.913	rs7118897	ENSG00000212093.1	AP000807.1	4.95	8.48e-07	8.74e-05	0.17	0.15	Total body bone mineral density;	chr11:68593212	chr11:68506083~68506166:-
BRCA	cis	rs4237845	0.816	rs61935769	ENSG00000257159.1	RP11-58A17.3	4.95	8.48e-07	8.74e-05	0.18	0.15	Intelligence (multi-trait analysis);	chr12:57900561	chr12:57967058~57968399:+
BRCA	cis	rs4763879	0.502	rs11052552	ENSG00000256582.1	RP11-75L1.1	4.95	8.48e-07	8.74e-05	0.15	0.15	Type 1 diabetes;	chr12:9703362	chr12:9704077~9709350:+
BRCA	cis	rs718433	0.717	rs12893255	ENSG00000256379.1	TRAV8-5	4.95	8.48e-07	8.74e-05	0.17	0.15	Intraocular pressure;	chr14:21773162	chr14:21903077~21903598:+
BRCA	cis	rs7618915	0.501	rs62253740	ENSG00000243224.1	RP5-1157M23.2	-4.95	8.48e-07	8.74e-05	-0.16	-0.15	Bipolar disorder;	chr3:52650112	chr3:52239258~52241097:+
BRCA	cis	rs6570726	0.526	rs72994723	ENSG00000235652.6	RP11-545I5.3	-4.95	8.48e-07	8.75e-05	-0.15	-0.15	Lobe attachment (rater-scored or self-reported);	chr6:145401812	chr6:145799409~145886585:+
BRCA	cis	rs3768617	0.51	rs12091137	ENSG00000224468.3	RP11-181K3.4	-4.95	8.49e-07	8.75e-05	-0.16	-0.15	Fuchs's corneal dystrophy;	chr1:183106597	chr1:183138402~183141282:-
BRCA	cis	rs4372836	0.675	rs72782280	ENSG00000226833.4	AC097724.3	-4.95	8.49e-07	8.75e-05	-0.21	-0.15	Body mass index;	chr2:28688483	chr2:28708953~28736205:-
BRCA	cis	rs3176789	0.914	rs1540356	ENSG00000256673.1	RP11-599J14.2	4.95	8.49e-07	8.76e-05	0.19	0.15	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9774188	chr12:9398355~9414851:-
BRCA	cis	rs3176789	0.914	rs1540355	ENSG00000256673.1	RP11-599J14.2	4.95	8.49e-07	8.76e-05	0.19	0.15	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9774272	chr12:9398355~9414851:-
BRCA	cis	rs6570726	0.764	rs4263604	ENSG00000270638.1	RP3-466P17.1	4.95	8.49e-07	8.76e-05	0.17	0.15	Lobe attachment (rater-scored or self-reported);	chr6:145595561	chr6:145735570~145737218:+
BRCA	cis	rs6723226	0.732	rs390480	ENSG00000276517.1	AL133243.2	4.95	8.5e-07	8.76e-05	0.19	0.15	Intelligence (multi-trait analysis);	chr2:32285003	chr2:32526504~32529507:+
BRCA	cis	rs2153535	0.585	rs1328870	ENSG00000230939.1	RP11-314C16.1	-4.95	8.5e-07	8.76e-05	-0.18	-0.15	Motion sickness;	chr6:8637803	chr6:8784178~8785445:+
BRCA	cis	rs2638953	0.924	rs11049386	ENSG00000247934.4	RP11-967K21.1	-4.95	8.5e-07	8.76e-05	-0.21	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28167603	chr12:28163298~28190738:-
BRCA	cis	rs9659323	0.804	rs10923722	ENSG00000231365.4	RP11-418J17.1	-4.95	8.51e-07	8.77e-05	-0.19	-0.15	Body mass index;	chr1:119000863	chr1:119140396~119275973:+
BRCA	cis	rs17685	0.753	rs6976532	ENSG00000280388.1	RP11-229D13.3	-4.95	8.51e-07	8.77e-05	-0.16	-0.15	Coffee consumption (cups per day);Coffee consumption;	chr7:76051776	chr7:76043977~76045963:-
BRCA	cis	rs9473147	0.516	rs10948367	ENSG00000270761.1	RP11-385F7.1	-4.95	8.51e-07	8.77e-05	-0.16	-0.15	Platelet distribution width;Mean platelet volume;	chr6:47617879	chr6:47477243~47477572:-
BRCA	cis	rs4787491	0.704	rs66467443	ENSG00000261367.1	RP11-455F5.4	-4.95	8.52e-07	8.78e-05	-0.17	-0.15	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30039173	chr16:30107675~30110541:+
BRCA	cis	rs4356203	0.87	rs214901	ENSG00000272034.1	SNORD14A	4.95	8.52e-07	8.78e-05	0.15	0.15	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17206181	chr11:17074654~17074744:-
BRCA	cis	rs7577696	0.853	rs430759	ENSG00000272716.1	RP11-563N4.1	-4.95	8.52e-07	8.78e-05	-0.17	-0.15	Inflammatory biomarkers;	chr2:32222799	chr2:32165046~32165757:-
BRCA	cis	rs7674212	0.57	rs6841136	ENSG00000248740.4	RP11-328K4.1	4.95	8.53e-07	8.79e-05	0.17	0.15	Type 2 diabetes;	chr4:103182352	chr4:103256159~103453658:+
BRCA	cis	rs1910358	0.664	rs10069580	ENSG00000248874.4	C5orf17	-4.95	8.53e-07	8.79e-05	-0.2	-0.15	Venous thromboembolism (SNP x SNP interaction);	chr5:23925192	chr5:23951348~24178263:+
BRCA	cis	rs12571093	0.803	rs2241970	ENSG00000233590.1	RP11-153K11.3	4.95	8.54e-07	8.79e-05	0.25	0.15	Optic nerve measurement (disc area);	chr10:68271310	chr10:68233251~68242379:-
BRCA	cis	rs8180040	0.966	rs6792488	ENSG00000276925.1	RP11-708J19.3	4.95	8.54e-07	8.8e-05	0.17	0.15	Colorectal cancer;	chr3:47461859	chr3:47469777~47469987:+
BRCA	cis	rs11098499	0.779	rs10857066	ENSG00000249244.1	RP11-548H18.2	4.95	8.54e-07	8.8e-05	0.18	0.15	Corneal astigmatism;	chr4:119365441	chr4:119391831~119395335:-
BRCA	cis	rs6545883	0.894	rs7566035	ENSG00000270820.4	RP11-355B11.2	-4.95	8.54e-07	8.8e-05	-0.18	-0.15	Tuberculosis;	chr2:61293680	chr2:61471188~61484130:+
BRCA	cis	rs4713118	0.513	rs149954	ENSG00000219392.1	RP1-265C24.5	-4.95	8.54e-07	8.8e-05	-0.21	-0.15	Parkinson's disease;	chr6:28067468	chr6:28115628~28116551:+
BRCA	cis	rs10129255	0.957	rs8005468	ENSG00000224373.3	IGHV4-59	4.95	8.55e-07	8.81e-05	0.1	0.15	Kawasaki disease;	chr14:106686431	chr14:106627249~106627825:-
BRCA	cis	rs11887277	0.708	rs12470698	ENSG00000272148.1	RP11-195B17.1	-4.95	8.55e-07	8.81e-05	-0.17	-0.15	Obesity-related traits;	chr2:26840393	chr2:27062428~27062907:-
BRCA	cis	rs12497850	0.931	rs7621015	ENSG00000225399.4	RP11-3B7.1	4.95	8.55e-07	8.81e-05	0.15	0.15	Parkinson's disease;	chr3:48978623	chr3:49260085~49261316:+
BRCA	cis	rs17711722	0.565	rs4275112	ENSG00000275400.1	RP4-756H11.5	4.95	8.55e-07	8.81e-05	0.18	0.15	Calcium levels;	chr7:65733651	chr7:66553805~66554199:-
BRCA	cis	rs2098713	0.569	rs55822509	ENSG00000250155.1	CTD-2353F22.1	4.95	8.55e-07	8.81e-05	0.17	0.15	Telomere length;	chr5:37571908	chr5:36666214~36725195:-
BRCA	cis	rs3764021	0.87	rs2401391	ENSG00000256673.1	RP11-599J14.2	-4.95	8.56e-07	8.81e-05	-0.17	-0.15	Type 1 diabetes;	chr12:9725987	chr12:9398355~9414851:-
BRCA	cis	rs2403083	0.697	rs2403085	ENSG00000258256.1	RP11-219B4.5	-4.95	8.56e-07	8.81e-05	-0.18	-0.15	Plasma amyloid beta peptide concentrations (ABx-40);	chr8:85200925	chr8:85222446~85245717:-
BRCA	cis	rs2403083	0.697	rs2403086	ENSG00000258256.1	RP11-219B4.5	-4.95	8.56e-07	8.81e-05	-0.18	-0.15	Plasma amyloid beta peptide concentrations (ABx-40);	chr8:85200969	chr8:85222446~85245717:-
BRCA	cis	rs12497850	0.931	rs9311433	ENSG00000225399.4	RP11-3B7.1	4.95	8.56e-07	8.82e-05	0.15	0.15	Parkinson's disease;	chr3:48826402	chr3:49260085~49261316:+
BRCA	cis	rs6598266	1	rs6598268	ENSG00000259363.4	CTD-2054N24.2	-4.95	8.56e-07	8.82e-05	-0.22	-0.15	Major depressive disorder;	chr15:99759095	chr15:99807023~99877148:+
BRCA	cis	rs736408	0.609	rs1029871	ENSG00000243224.1	RP5-1157M23.2	-4.95	8.56e-07	8.82e-05	-0.17	-0.15	Bipolar disorder;	chr3:52763618	chr3:52239258~52241097:+
BRCA	cis	rs4718428	0.705	rs11028	ENSG00000229180.5	GS1-124K5.11	4.95	8.56e-07	8.82e-05	0.14	0.15	Corneal structure;	chr7:66811230	chr7:66526088~66542624:-
BRCA	cis	rs875971	0.862	rs6460306	ENSG00000273448.1	RP11-166O4.6	-4.95	8.57e-07	8.82e-05	-0.14	-0.15	Aortic root size;	chr7:66595806	chr7:67333047~67334383:+
BRCA	cis	rs1015362	0.54	rs2378026	ENSG00000276073.1	RP5-1125A11.7	-4.95	8.57e-07	8.83e-05	-0.22	-0.15	Freckles;Red vs. non-red hair color;Skin sensitivity to sun;Burning and freckling;	chr20:33921845	chr20:33985617~33988989:-
BRCA	cis	rs1722141	0.567	rs2960427	ENSG00000237471.1	AC073115.6	4.95	8.57e-07	8.83e-05	0.21	0.15	Sitting height ratio;	chr7:46003093	chr7:45969657~45980191:+
BRCA	cis	rs4787491	0.729	rs11150584	ENSG00000261367.1	RP11-455F5.4	-4.95	8.57e-07	8.83e-05	-0.17	-0.15	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30028357	chr16:30107675~30110541:+
BRCA	cis	rs4218	0.681	rs17302163	ENSG00000277144.1	RP11-59H7.4	-4.95	8.57e-07	8.83e-05	-0.19	-0.15	Social communication problems;	chr15:59076773	chr15:59115547~59116089:-
BRCA	cis	rs10129255	0.957	rs12590799	ENSG00000211974.3	IGHV2-70	4.95	8.58e-07	8.83e-05	0.15	0.15	Kawasaki disease;	chr14:106779713	chr14:106723574~106724093:-
BRCA	cis	rs867371	0.519	rs1566560	ENSG00000259429.4	UBE2Q2P2	-4.95	8.58e-07	8.84e-05	-0.14	-0.15	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82232116	chr15:82355142~82420075:+
BRCA	cis	rs867371	0.519	rs1566559	ENSG00000259429.4	UBE2Q2P2	-4.95	8.58e-07	8.84e-05	-0.14	-0.15	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82232120	chr15:82355142~82420075:+
BRCA	cis	rs829883	0.664	rs829876	ENSG00000227825.4	SLC9A7P1	4.95	8.58e-07	8.84e-05	0.17	0.15	Colorectal adenoma (advanced);	chr12:98448360	chr12:98453835~98457145:-
BRCA	cis	rs8002861	0.935	rs9525865	ENSG00000274001.1	RP11-5G9.5	4.95	8.58e-07	8.84e-05	0.17	0.15	Leprosy;	chr13:43885511	chr13:43877715~43878163:-
BRCA	cis	rs10028773	0.7	rs7690338	ENSG00000249244.1	RP11-548H18.2	4.95	8.59e-07	8.84e-05	0.17	0.15	Educational attainment;	chr4:119335313	chr4:119391831~119395335:-
BRCA	cis	rs6088580	0.567	rs6088520	ENSG00000276073.1	RP5-1125A11.7	4.95	8.59e-07	8.84e-05	0.17	0.15	Glomerular filtration rate (creatinine);	chr20:34544560	chr20:33985617~33988989:-
BRCA	cis	rs1223397	0.651	rs2496140	ENSG00000215022.6	RP1-257A7.4	-4.95	8.59e-07	8.84e-05	-0.18	-0.15	Blood pressure;	chr6:13309663	chr6:13264861~13295586:-
BRCA	cis	rs1223397	0.651	rs2458311	ENSG00000215022.6	RP1-257A7.4	-4.95	8.59e-07	8.84e-05	-0.18	-0.15	Blood pressure;	chr6:13309780	chr6:13264861~13295586:-
BRCA	cis	rs1223397	0.651	rs2458310	ENSG00000215022.6	RP1-257A7.4	-4.95	8.59e-07	8.84e-05	-0.18	-0.15	Blood pressure;	chr6:13310076	chr6:13264861~13295586:-
BRCA	cis	rs1223397	0.651	rs2439541	ENSG00000215022.6	RP1-257A7.4	-4.95	8.59e-07	8.84e-05	-0.18	-0.15	Blood pressure;	chr6:13310335	chr6:13264861~13295586:-
BRCA	cis	rs9921338	0.961	rs7198849	ENSG00000262703.1	RP11-485G7.6	-4.95	8.59e-07	8.85e-05	-0.18	-0.15	Vein graft stenosis in coronary artery bypass grafting;	chr16:11279444	chr16:11348143~11349321:-
BRCA	cis	rs600231	0.683	rs588298	ENSG00000173727.10	CMB9-22P13.1	4.95	8.59e-07	8.85e-05	0.2	0.15	Bone mineral density;	chr11:65486103	chr11:65455258~65466720:+
BRCA	cis	rs875971	0.862	rs6971059	ENSG00000273448.1	RP11-166O4.6	-4.95	8.6e-07	8.85e-05	-0.14	-0.15	Aortic root size;	chr7:66602045	chr7:67333047~67334383:+
BRCA	cis	rs11098499	0.697	rs35280960	ENSG00000260404.2	RP11-384K6.6	4.95	8.6e-07	8.85e-05	0.14	0.15	Corneal astigmatism;	chr4:119335904	chr4:118591773~118633729:+
BRCA	cis	rs7267979	0.816	rs390123	ENSG00000125804.12	FAM182A	-4.95	8.6e-07	8.85e-05	-0.2	-0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25499469	chr20:26054655~26086917:+
BRCA	cis	rs7572733	0.576	rs6734781	ENSG00000231621.1	AC013264.2	-4.95	8.6e-07	8.86e-05	-0.15	-0.15	Dermatomyositis;	chr2:197895249	chr2:197197991~197199273:+
BRCA	cis	rs875971	0.862	rs4236208	ENSG00000236529.1	RP13-254B10.1	-4.95	8.6e-07	8.86e-05	-0.17	-0.15	Aortic root size;	chr7:66284091	chr7:65840212~65840596:+
BRCA	cis	rs9545047	0.604	rs2265381	ENSG00000227354.5	RBM26-AS1	-4.95	8.6e-07	8.86e-05	-0.16	-0.15	Schizophrenia;	chr13:79425903	chr13:79406309~79424328:+
BRCA	cis	rs2179367	0.959	rs540538	ENSG00000268592.3	RAET1E-AS1	4.95	8.6e-07	8.86e-05	0.19	0.15	Dupuytren's disease;	chr6:149326808	chr6:149863494~149919507:+
BRCA	cis	rs728616	0.614	rs726014	ENSG00000225484.5	NUTM2B-AS1	-4.95	8.61e-07	8.86e-05	-0.29	-0.15	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79948988	chr10:79663088~79826594:-
BRCA	cis	rs2153535	0.504	rs5001323	ENSG00000251164.1	HULC	-4.95	8.61e-07	8.87e-05	-0.19	-0.15	Motion sickness;	chr6:8451372	chr6:8652137~8653846:+
BRCA	cis	rs375066	0.544	rs12462507	ENSG00000267058.1	RP11-15A1.3	4.95	8.61e-07	8.87e-05	0.19	0.15	Breast cancer;	chr19:43806239	chr19:43891804~43901805:-
BRCA	cis	rs12497850	0.864	rs12493001	ENSG00000225399.4	RP11-3B7.1	4.95	8.62e-07	8.87e-05	0.15	0.15	Parkinson's disease;	chr3:49144452	chr3:49260085~49261316:+
BRCA	cis	rs12497850	0.829	rs12636030	ENSG00000225399.4	RP11-3B7.1	4.95	8.62e-07	8.87e-05	0.15	0.15	Parkinson's disease;	chr3:49144804	chr3:49260085~49261316:+
BRCA	cis	rs12497850	0.931	rs6791542	ENSG00000225399.4	RP11-3B7.1	4.95	8.62e-07	8.87e-05	0.14	0.15	Parkinson's disease;	chr3:48749786	chr3:49260085~49261316:+
BRCA	cis	rs4835473	0.864	rs2323418	ENSG00000249741.2	RP11-673E1.3	-4.95	8.62e-07	8.87e-05	-0.16	-0.15	Immature fraction of reticulocytes;	chr4:143969141	chr4:143911514~143912053:-
BRCA	cis	rs7927592	0.956	rs2155730	ENSG00000212093.1	AP000807.1	4.95	8.62e-07	8.88e-05	0.17	0.15	Total body bone mineral density;	chr11:68562006	chr11:68506083~68506166:-
BRCA	cis	rs7811142	1	rs76913697	ENSG00000078319.8	PMS2P1	-4.95	8.63e-07	8.88e-05	-0.24	-0.15	Platelet count;	chr7:100405149	chr7:100320992~100341908:-
BRCA	cis	rs10833905	1	rs28591594	ENSG00000246225.5	RP11-17A1.3	-4.95	8.63e-07	8.88e-05	-0.22	-0.15	Sudden cardiac arrest;	chr11:23022338	chr11:22829380~22945393:+
BRCA	cis	rs9467773	0.873	rs9295698	ENSG00000241549.7	GUSBP2	4.95	8.63e-07	8.88e-05	0.16	0.15	Intelligence (multi-trait analysis);	chr6:26565871	chr6:26871484~26956554:-
BRCA	cis	rs202072	1	rs202077	ENSG00000272379.1	RP1-257A7.5	4.95	8.63e-07	8.88e-05	0.22	0.15	HIV-1 viral setpoint;	chr6:13271206	chr6:13290018~13290490:-
BRCA	cis	rs71520386	0.846	rs17778126	ENSG00000228649.7	AC005682.5	-4.95	8.63e-07	8.89e-05	-0.17	-0.15	Fibrinogen levels;	chr7:22779340	chr7:22854178~22861579:+
BRCA	cis	rs9287719	0.967	rs1541573	ENSG00000243819.4	RN7SL832P	4.95	8.63e-07	8.89e-05	0.15	0.15	Prostate cancer;	chr2:10633259	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.967	rs1541574	ENSG00000243819.4	RN7SL832P	4.95	8.63e-07	8.89e-05	0.15	0.15	Prostate cancer;	chr2:10633382	chr2:10690344~10692099:+
BRCA	cis	rs7246657	0.598	rs28660259	ENSG00000267422.1	CTD-2554C21.1	-4.95	8.63e-07	8.89e-05	-0.26	-0.15	Coronary artery calcification;	chr19:37167779	chr19:37779686~37792865:+
BRCA	cis	rs2153535	0.58	rs1577468	ENSG00000251164.1	HULC	-4.95	8.64e-07	8.9e-05	-0.19	-0.15	Motion sickness;	chr6:8444033	chr6:8652137~8653846:+
BRCA	cis	rs10510102	1	rs6585764	ENSG00000226864.1	ATE1-AS1	4.95	8.65e-07	8.91e-05	0.26	0.15	Breast cancer;	chr10:121837308	chr10:121928312~121951965:+
BRCA	cis	rs6452524	0.618	rs10462394	ENSG00000281327.1	LINC01338	4.95	8.66e-07	8.91e-05	0.17	0.15	Hypertension (SNP x SNP interaction);	chr5:83058735	chr5:82850864~82859836:-
BRCA	cis	rs7587476	0.505	rs777323	ENSG00000229267.2	AC072062.1	4.95	8.66e-07	8.91e-05	0.2	0.15	Neuroblastoma;	chr2:214873761	chr2:214810229~214963274:+
BRCA	cis	rs60843830	1	rs57542652	ENSG00000272342.1	RP13-539J13.1	4.95	8.66e-07	8.92e-05	0.19	0.15	Spherical equivalent (joint analysis main effects and education interaction);	chr2:228088	chr2:739588~740164:-
BRCA	cis	rs13113518	0.966	rs13144598	ENSG00000223305.1	RN7SKP30	4.95	8.67e-07	8.92e-05	0.18	0.15	Height;	chr4:55570311	chr4:55540502~55540835:-
BRCA	cis	rs2574985	0.739	rs3011783	ENSG00000231345.3	BEND3P1	-4.95	8.67e-07	8.93e-05	-0.25	-0.15	Subjective well-being;	chr10:50530595	chr10:50655967~50660472:+
BRCA	cis	rs10129255	1	rs10129255	ENSG00000280411.1	IGHV1-69-2	4.95	8.68e-07	8.94e-05	0.11	0.15	Kawasaki disease;	chr14:106767970	chr14:106762092~106762588:-
BRCA	cis	rs2898681	1	rs6833096	ENSG00000248375.1	RP11-177B4.1	-4.95	8.69e-07	8.94e-05	-0.24	-0.15	Optic nerve measurement (cup area);	chr4:52878108	chr4:52720081~52720831:-
BRCA	cis	rs2832191	0.72	rs7277028	ENSG00000215533.7	LINC00189	4.95	8.69e-07	8.94e-05	0.17	0.15	Dental caries;	chr21:29122283	chr21:29193480~29288205:+
BRCA	cis	rs67311347	1	rs13073003	ENSG00000280739.1	EIF1B-AS1	-4.95	8.69e-07	8.95e-05	-0.17	-0.15	Renal cell carcinoma;	chr3:40462835	chr3:40173145~40309698:-
BRCA	cis	rs67311347	1	rs6801185	ENSG00000280739.1	EIF1B-AS1	-4.95	8.69e-07	8.95e-05	-0.17	-0.15	Renal cell carcinoma;	chr3:40463569	chr3:40173145~40309698:-
BRCA	cis	rs828999	0.703	rs11185287	ENSG00000280186.1	RP11-483I13.6	-4.95	8.7e-07	8.95e-05	-0.17	-0.15	Monocyte percentage of white cells;	chr1:108155983	chr1:108200413~108202743:+
BRCA	cis	rs9468186	1	rs9468186	ENSG00000220721.1	OR1F12	4.95	8.71e-07	8.96e-05	0.18	0.15	Neuroticism;	chr6:27658852	chr6:28073316~28074233:+
BRCA	cis	rs8180040	0.966	rs59586735	ENSG00000276925.1	RP11-708J19.3	4.95	8.71e-07	8.96e-05	0.17	0.15	Colorectal cancer;	chr3:47476835	chr3:47469777~47469987:+
BRCA	cis	rs73193808	0.851	rs2018158	ENSG00000236056.1	GAPDHP14	-4.95	8.71e-07	8.96e-05	-0.22	-0.15	Coronary artery disease;	chr21:29216482	chr21:29222321~29223257:+
BRCA	cis	rs2243480	1	rs313813	ENSG00000222364.1	RNU6-96P	-4.95	8.71e-07	8.96e-05	-0.28	-0.15	Diabetic kidney disease;	chr7:66038513	chr7:66395191~66395286:+
BRCA	cis	rs4072705	0.646	rs4838187	ENSG00000224020.1	MIR181A2HG	-4.95	8.71e-07	8.96e-05	-0.17	-0.15	Menarche (age at onset);	chr9:124479797	chr9:124658467~124698631:+
BRCA	cis	rs7267979	0.844	rs4815413	ENSG00000277938.1	RP5-965G21.3	-4.95	8.72e-07	8.97e-05	-0.18	-0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25378593	chr20:25229150~25231933:+
BRCA	cis	rs7267979	0.844	rs6083824	ENSG00000277938.1	RP5-965G21.3	-4.95	8.72e-07	8.97e-05	-0.18	-0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25382421	chr20:25229150~25231933:+
BRCA	cis	rs559928	1	rs7105178	ENSG00000236935.1	AP003774.1	-4.95	8.72e-07	8.97e-05	-0.19	-0.15	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64377637	chr11:64325050~64329504:-
BRCA	cis	rs875971	0.825	rs66981195	ENSG00000273448.1	RP11-166O4.6	-4.95	8.73e-07	8.97e-05	-0.14	-0.15	Aortic root size;	chr7:66614048	chr7:67333047~67334383:+
BRCA	cis	rs875971	0.862	rs3926380	ENSG00000273448.1	RP11-166O4.6	-4.95	8.73e-07	8.97e-05	-0.14	-0.15	Aortic root size;	chr7:66615658	chr7:67333047~67334383:+
BRCA	cis	rs875971	0.825	rs1860472	ENSG00000273448.1	RP11-166O4.6	-4.95	8.73e-07	8.97e-05	-0.14	-0.15	Aortic root size;	chr7:66617736	chr7:67333047~67334383:+
BRCA	cis	rs17767294	0.708	rs72849204	ENSG00000204709.4	LINC01556	4.95	8.73e-07	8.98e-05	0.4	0.15	Parkinson's disease;	chr6:28203165	chr6:28943877~28944537:+
BRCA	cis	rs17767294	0.708	rs72849205	ENSG00000204709.4	LINC01556	4.95	8.73e-07	8.98e-05	0.4	0.15	Parkinson's disease;	chr6:28203751	chr6:28943877~28944537:+
BRCA	cis	rs17767294	0.708	rs72849206	ENSG00000204709.4	LINC01556	4.95	8.73e-07	8.98e-05	0.4	0.15	Parkinson's disease;	chr6:28204926	chr6:28943877~28944537:+
BRCA	cis	rs6490294	0.528	rs12578195	ENSG00000226469.1	ADAM1B	4.95	8.73e-07	8.98e-05	0.27	0.15	Mean platelet volume;	chr12:111956130	chr12:111927018~111929017:+
BRCA	cis	rs17345786	0.628	rs11718446	ENSG00000244119.1	PDCL3P4	4.95	8.73e-07	8.98e-05	0.13	0.15	Colonoscopy-negative controls vs population controls;	chr3:101833709	chr3:101712472~101713191:+
BRCA	cis	rs2243480	1	rs316326	ENSG00000275400.1	RP4-756H11.5	4.95	8.73e-07	8.98e-05	0.27	0.15	Diabetic kidney disease;	chr7:66144466	chr7:66553805~66554199:-
BRCA	cis	rs2243480	1	rs316325	ENSG00000275400.1	RP4-756H11.5	4.95	8.73e-07	8.98e-05	0.27	0.15	Diabetic kidney disease;	chr7:66144531	chr7:66553805~66554199:-
BRCA	cis	rs11098499	0.687	rs71610270	ENSG00000249244.1	RP11-548H18.2	4.95	8.74e-07	8.98e-05	0.17	0.15	Corneal astigmatism;	chr4:119366281	chr4:119391831~119395335:-
BRCA	cis	rs829883	0.738	rs249854	ENSG00000227825.4	SLC9A7P1	4.95	8.74e-07	8.99e-05	0.18	0.15	Colorectal adenoma (advanced);	chr12:98468994	chr12:98453835~98457145:-
BRCA	cis	rs11512640	1	rs11512640	ENSG00000254671.2	STT3A-AS1	-4.95	8.74e-07	8.99e-05	-0.33	-0.15	Peripheral arterial disease (traffic-related air pollution interaction);	chr11:125556427	chr11:125570284~125592568:-
BRCA	cis	rs875971	0.862	rs13226170	ENSG00000273448.1	RP11-166O4.6	4.95	8.75e-07	9e-05	0.14	0.15	Aortic root size;	chr7:66534311	chr7:67333047~67334383:+
BRCA	cis	rs875971	0.862	rs2420611	ENSG00000273448.1	RP11-166O4.6	4.95	8.75e-07	9e-05	0.14	0.15	Aortic root size;	chr7:66534333	chr7:67333047~67334383:+
BRCA	cis	rs7267979	0.903	rs6107015	ENSG00000276952.1	RP5-965G21.6	4.95	8.75e-07	9e-05	0.19	0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25236128	chr20:25284915~25285588:-
BRCA	cis	rs1876905	0.539	rs457497	ENSG00000272356.1	RP5-1112D6.8	4.95	8.75e-07	9e-05	0.21	0.15	Mean corpuscular hemoglobin;	chr6:111301346	chr6:111309203~111313517:+
BRCA	cis	rs9393777	0.668	rs7746199	ENSG00000216901.1	AL022393.7	-4.95	8.75e-07	9e-05	-0.23	-0.15	Intelligence (multi-trait analysis);	chr6:27293545	chr6:28176188~28176674:+
BRCA	cis	rs2732480	0.5	rs12829841	ENSG00000226413.2	OR8T1P	4.95	8.76e-07	9e-05	0.21	0.15	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48234956	chr12:48442030~48442947:-
BRCA	cis	rs2732480	0.523	rs34286639	ENSG00000226413.2	OR8T1P	4.95	8.76e-07	9e-05	0.21	0.15	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48235261	chr12:48442030~48442947:-
BRCA	cis	rs12497850	0.931	rs7647813	ENSG00000225399.4	RP11-3B7.1	4.95	8.76e-07	9e-05	0.15	0.15	Parkinson's disease;	chr3:48795915	chr3:49260085~49261316:+
BRCA	cis	rs7772486	0.719	rs702307	ENSG00000270638.1	RP3-466P17.1	-4.95	8.76e-07	9.01e-05	-0.18	-0.15	Lobe attachment (rater-scored or self-reported);	chr6:145672318	chr6:145735570~145737218:+
BRCA	cis	rs10129255	0.957	rs10136781	ENSG00000211974.3	IGHV2-70	4.95	8.76e-07	9.01e-05	0.15	0.15	Kawasaki disease;	chr14:106780451	chr14:106723574~106724093:-
BRCA	cis	rs595244	1	rs682737	ENSG00000259705.1	RP11-227D13.1	4.95	8.76e-07	9.01e-05	0.28	0.15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48599574	chr15:48645951~48652016:+
BRCA	cis	rs1823913	0.503	rs35672076	ENSG00000280083.1	RP11-317J9.1	-4.95	8.77e-07	9.01e-05	-0.18	-0.15	Obesity-related traits;	chr2:191343907	chr2:191154118~191156070:-
BRCA	cis	rs6840360	0.642	rs10857260	ENSG00000278978.1	RP11-164P12.5	-4.95	8.77e-07	9.01e-05	-0.17	-0.15	Intelligence (multi-trait analysis);	chr4:151502904	chr4:151669786~151670503:+
BRCA	cis	rs875971	1	rs937495	ENSG00000223473.2	GS1-124K5.3	-4.95	8.77e-07	9.02e-05	-0.12	-0.15	Aortic root size;	chr7:66314811	chr7:66491049~66493566:-
BRCA	cis	rs875971	1	rs2036264	ENSG00000223473.2	GS1-124K5.3	-4.95	8.77e-07	9.02e-05	-0.12	-0.15	Aortic root size;	chr7:66334917	chr7:66491049~66493566:-
BRCA	cis	rs875971	1	rs7783613	ENSG00000223473.2	GS1-124K5.3	-4.95	8.77e-07	9.02e-05	-0.12	-0.15	Aortic root size;	chr7:66340274	chr7:66491049~66493566:-
BRCA	cis	rs8040855	0.599	rs6496792	ENSG00000259774.1	RP11-182J1.13	-4.95	8.77e-07	9.02e-05	-0.17	-0.15	Bulimia nervosa;	chr15:85182514	chr15:84422618~84425882:+
BRCA	cis	rs8040855	0.599	rs6496793	ENSG00000259774.1	RP11-182J1.13	-4.95	8.77e-07	9.02e-05	-0.17	-0.15	Bulimia nervosa;	chr15:85182515	chr15:84422618~84425882:+
BRCA	cis	rs8040855	0.599	rs6496795	ENSG00000259774.1	RP11-182J1.13	-4.95	8.77e-07	9.02e-05	-0.17	-0.15	Bulimia nervosa;	chr15:85182622	chr15:84422618~84425882:+
BRCA	cis	rs4819052	0.851	rs2838829	ENSG00000184274.3	LINC00315	-4.95	8.77e-07	9.02e-05	-0.21	-0.15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244125	chr21:45300245~45305257:-
BRCA	cis	rs7176527	1	rs3762169	ENSG00000230373.7	GOLGA6L5P	4.95	8.77e-07	9.02e-05	0.21	0.15	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84598728	chr15:84507885~84516814:-
BRCA	cis	rs1161098	0.68	rs1152880	ENSG00000256037.1	MRPL40P1	4.95	8.77e-07	9.02e-05	0.25	0.15	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr12:67441881	chr12:67351436~67352039:+
BRCA	cis	rs4781563	1	rs2276466	ENSG00000242307.1	RPS26P52	-4.95	8.78e-07	9.02e-05	-0.19	-0.15	Bilirubin levels;	chr16:13949318	chr16:13922332~13922679:-
BRCA	cis	rs7618915	0.547	rs11177	ENSG00000243224.1	RP5-1157M23.2	-4.95	8.78e-07	9.02e-05	-0.17	-0.15	Bipolar disorder;	chr3:52687289	chr3:52239258~52241097:+
BRCA	cis	rs6840360	0.606	rs2709814	ENSG00000251611.1	RP11-610P16.1	-4.95	8.78e-07	9.02e-05	-0.13	-0.15	Intelligence (multi-trait analysis);	chr4:151439718	chr4:151407551~151408835:-
BRCA	cis	rs4819052	0.851	rs2838839	ENSG00000184274.3	LINC00315	4.95	8.78e-07	9.02e-05	0.21	0.15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45247943	chr21:45300245~45305257:-
BRCA	cis	rs7618915	0.547	rs11130317	ENSG00000243224.1	RP5-1157M23.2	-4.95	8.78e-07	9.03e-05	-0.17	-0.15	Bipolar disorder;	chr3:52697467	chr3:52239258~52241097:+
BRCA	cis	rs875971	0.862	rs778734	ENSG00000236529.1	RP13-254B10.1	4.95	8.78e-07	9.03e-05	0.17	0.15	Aortic root size;	chr7:66349862	chr7:65840212~65840596:+
BRCA	cis	rs13043901	0.904	rs2766667	ENSG00000197670.6	RP4-724E16.2	-4.95	8.79e-07	9.03e-05	-0.15	-0.15	Type 2 diabetes (age of onset);	chr20:53555865	chr20:53552770~53575863:+
BRCA	cis	rs3812762	0.871	rs11042068	ENSG00000254860.4	TMEM9B-AS1	4.95	8.79e-07	9.03e-05	0.15	0.15	Hypospadias;	chr11:8794052	chr11:8964675~8977527:+
BRCA	cis	rs180730	0.519	rs1901135	ENSG00000251609.2	SETP12	4.95	8.79e-07	9.03e-05	0.2	0.15	Fasting plasma glucose;	chr4:120907364	chr4:120895494~120897083:-
BRCA	cis	rs180730	0.539	rs3804178	ENSG00000251609.2	SETP12	4.95	8.79e-07	9.03e-05	0.2	0.15	Fasting plasma glucose;	chr4:120907911	chr4:120895494~120897083:-
BRCA	cis	rs4664293	1	rs6753181	ENSG00000226266.5	AC009961.3	-4.95	8.79e-07	9.03e-05	-0.19	-0.15	Monocyte percentage of white cells;	chr2:159635927	chr2:159670708~159712435:-
BRCA	cis	rs12612619	0.732	rs11126857	ENSG00000229122.1	AGBL5-IT1	-4.95	8.79e-07	9.03e-05	-0.16	-0.15	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27074889	chr2:27061038~27061815:+
BRCA	cis	rs2243480	1	rs7804223	ENSG00000222364.1	RNU6-96P	4.95	8.79e-07	9.04e-05	0.28	0.15	Diabetic kidney disease;	chr7:66199572	chr7:66395191~66395286:+
BRCA	cis	rs6570726	0.764	rs376257	ENSG00000270638.1	RP3-466P17.1	4.95	8.79e-07	9.04e-05	0.18	0.15	Lobe attachment (rater-scored or self-reported);	chr6:145541813	chr6:145735570~145737218:+
BRCA	cis	rs6570726	0.693	rs450921	ENSG00000270638.1	RP3-466P17.1	4.95	8.79e-07	9.04e-05	0.18	0.15	Lobe attachment (rater-scored or self-reported);	chr6:145543124	chr6:145735570~145737218:+
BRCA	cis	rs2905347	0.895	rs2905308	ENSG00000179428.2	AC073072.5	4.95	8.8e-07	9.04e-05	0.16	0.15	Major depression and alcohol dependence;	chr7:22608575	chr7:22725395~22727620:-
BRCA	cis	rs12646107	0.891	rs17328110	ENSG00000261672.1	RP11-475B2.1	-4.95	8.8e-07	9.04e-05	-0.23	-0.15	Response to amphetamines;	chr4:173588509	chr4:173593672~173594556:+
BRCA	cis	rs6570726	0.791	rs9403734	ENSG00000270638.1	RP3-466P17.1	4.95	8.81e-07	9.05e-05	0.18	0.15	Lobe attachment (rater-scored or self-reported);	chr6:145610323	chr6:145735570~145737218:+
BRCA	cis	rs6430538	0.621	rs749017	ENSG00000224043.6	CCNT2-AS1	-4.95	8.81e-07	9.05e-05	-0.21	-0.15	Parkinson's disease;	chr2:134816089	chr2:134735464~134918710:-
BRCA	cis	rs2337406	0.539	rs2583292	ENSG00000223648.3	IGHV3-64	4.95	8.81e-07	9.05e-05	0.15	0.15	Alzheimer's disease (late onset);	chr14:106649040	chr14:106643132~106658258:-
BRCA	cis	rs793571	0.628	rs12437952	ENSG00000259250.1	RP11-50C13.1	-4.95	8.81e-07	9.05e-05	-0.27	-0.15	Schizophrenia;	chr15:58757147	chr15:58587507~58591676:+
BRCA	cis	rs2179367	0.553	rs7762222	ENSG00000223701.3	RAET1E-AS1	4.95	8.82e-07	9.06e-05	0.22	0.15	Dupuytren's disease;	chr6:149444846	chr6:149884431~149919508:+
BRCA	cis	rs1440410	0.83	rs4690715	ENSG00000250326.1	RP11-284M14.1	-4.95	8.82e-07	9.06e-05	-0.16	-0.15	Ischemic stroke;	chr4:143259186	chr4:142933195~143184861:-
BRCA	cis	rs4578769	0.959	rs7226652	ENSG00000265939.1	UBE2CP2	4.95	8.82e-07	9.06e-05	0.18	0.15	Eosinophil percentage of white cells;	chr18:22904043	chr18:22900486~22900995:-
BRCA	cis	rs7267979	0.966	rs6050611	ENSG00000125804.12	FAM182A	-4.95	8.82e-07	9.06e-05	-0.2	-0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25433783	chr20:26054655~26086917:+
BRCA	cis	rs703842	0.964	rs10431552	ENSG00000270039.1	RP11-571M6.17	-4.95	8.82e-07	9.06e-05	-0.21	-0.15	Multiple sclerosis;	chr12:57784365	chr12:57803838~57804415:+
BRCA	cis	rs2243480	1	rs387676	ENSG00000275400.1	RP4-756H11.5	4.95	8.82e-07	9.07e-05	0.28	0.15	Diabetic kidney disease;	chr7:66133233	chr7:66553805~66554199:-
BRCA	cis	rs7829975	0.623	rs10092965	ENSG00000233609.3	RP11-62H7.2	4.95	8.82e-07	9.07e-05	0.14	0.15	Mood instability;	chr8:8515975	chr8:8961200~8979025:+
BRCA	cis	rs1371614	0.523	rs11904656	ENSG00000229122.1	AGBL5-IT1	4.95	8.82e-07	9.07e-05	0.16	0.15	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26950381	chr2:27061038~27061815:+
BRCA	cis	rs11089937	0.616	rs7291684	ENSG00000211638.2	IGLV8-61	-4.95	8.83e-07	9.07e-05	-0.15	-0.15	Periodontitis (PAL4Q3);	chr22:22183834	chr22:22098700~22099212:+
BRCA	cis	rs11089937	0.616	rs6001219	ENSG00000211638.2	IGLV8-61	-4.95	8.83e-07	9.07e-05	-0.15	-0.15	Periodontitis (PAL4Q3);	chr22:22184348	chr22:22098700~22099212:+
BRCA	cis	rs10510102	1	rs11200181	ENSG00000226864.1	ATE1-AS1	4.95	8.83e-07	9.07e-05	0.27	0.15	Breast cancer;	chr10:121828528	chr10:121928312~121951965:+
BRCA	cis	rs4763879	0.634	rs917913	ENSG00000278635.1	CTD-2318O12.1	4.95	8.83e-07	9.07e-05	0.15	0.15	Type 1 diabetes;	chr12:9707040	chr12:9415641~9416718:+
BRCA	cis	rs919433	0.617	rs12619333	ENSG00000231621.1	AC013264.2	4.95	8.83e-07	9.07e-05	0.15	0.15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197702914	chr2:197197991~197199273:+
BRCA	cis	rs3764021	0.87	rs2401395	ENSG00000256673.1	RP11-599J14.2	-4.95	8.83e-07	9.07e-05	-0.17	-0.15	Type 1 diabetes;	chr12:9726944	chr12:9398355~9414851:-
BRCA	cis	rs12571093	0.773	rs61854802	ENSG00000233590.1	RP11-153K11.3	-4.95	8.83e-07	9.07e-05	-0.26	-0.15	Optic nerve measurement (disc area);	chr10:68249815	chr10:68233251~68242379:-
BRCA	cis	rs11887277	0.708	rs12474330	ENSG00000272148.1	RP11-195B17.1	-4.95	8.83e-07	9.07e-05	-0.17	-0.15	Obesity-related traits;	chr2:26840392	chr2:27062428~27062907:-
BRCA	cis	rs9423406	0.706	rs4881427	ENSG00000224034.1	RP11-445P17.8	-4.95	8.84e-07	9.08e-05	-0.3	-0.15	Intelligence;	chr10:5280034	chr10:5266033~5271236:-
BRCA	cis	rs8127691	0.904	rs2070552	ENSG00000237604.1	AP001056.1	4.95	8.84e-07	9.08e-05	0.17	0.15	Inflammatory bowel disease;	chr21:44197186	chr21:44175489~44176453:+
BRCA	cis	rs6570726	1	rs951143	ENSG00000270638.1	RP3-466P17.1	4.95	8.84e-07	9.08e-05	0.17	0.15	Lobe attachment (rater-scored or self-reported);	chr6:145611440	chr6:145735570~145737218:+
BRCA	cis	rs11051970	0.559	rs11051944	ENSG00000274964.1	RP11-817I4.1	-4.95	8.84e-07	9.08e-05	-0.2	-0.15	Response to tocilizumab in rheumatoid arthritis;	chr12:32332984	chr12:32339368~32340724:+
BRCA	cis	rs2832191	0.791	rs9983651	ENSG00000215533.7	LINC00189	4.95	8.84e-07	9.08e-05	0.17	0.15	Dental caries;	chr21:29118906	chr21:29193480~29288205:+
BRCA	cis	rs2832191	0.755	rs55671430	ENSG00000215533.7	LINC00189	4.95	8.84e-07	9.08e-05	0.17	0.15	Dental caries;	chr21:29120100	chr21:29193480~29288205:+
BRCA	cis	rs2832191	0.72	rs2832194	ENSG00000215533.7	LINC00189	4.95	8.84e-07	9.08e-05	0.17	0.15	Dental caries;	chr21:29121929	chr21:29193480~29288205:+
BRCA	cis	rs3733585	0.604	rs73215003	ENSG00000250413.1	RP11-448G15.1	4.95	8.85e-07	9.09e-05	0.2	0.15	Cleft plate (environmental tobacco smoke interaction);	chr4:10124693	chr4:10006482~10009725:+
BRCA	cis	rs6840360	0.642	rs1596290	ENSG00000251611.1	RP11-610P16.1	-4.95	8.85e-07	9.09e-05	-0.13	-0.15	Intelligence (multi-trait analysis);	chr4:151489388	chr4:151407551~151408835:-
BRCA	cis	rs2227564	0.649	rs2243610	ENSG00000271816.1	BMS1P4	4.95	8.85e-07	9.09e-05	0.16	0.15	Crohn's disease;Inflammatory bowel disease;	chr10:73841895	chr10:73699151~73730487:-
BRCA	cis	rs1729951	0.575	rs16844325	ENSG00000239213.4	NCK1-AS1	4.95	8.85e-07	9.09e-05	0.16	0.15	Neuroticism;	chr3:136959319	chr3:136841726~136862054:-
BRCA	cis	rs6573604	0.681	rs12436299	ENSG00000276116.2	FUT8-AS1	4.95	8.86e-07	9.1e-05	0.22	0.15	N-glycan levels;	chr14:65318476	chr14:65411170~65412690:-
BRCA	cis	rs8127691	1	rs762421	ENSG00000237604.1	AP001056.1	-4.95	8.86e-07	9.1e-05	-0.17	-0.15	Inflammatory bowel disease;	chr21:44195678	chr21:44175489~44176453:+
BRCA	cis	rs2274273	0.682	rs10145268	ENSG00000258413.1	RP11-665C16.6	-4.95	8.86e-07	9.1e-05	-0.19	-0.15	Protein biomarker;	chr14:55037796	chr14:55262767~55272075:-
BRCA	cis	rs2562456	0.876	rs11085468	ENSG00000268658.4	LINC00664	4.95	8.86e-07	9.1e-05	0.23	0.15	Pain;	chr19:21569087	chr19:21483374~21503238:+
BRCA	cis	rs10510102	0.872	rs3750837	ENSG00000226864.1	ATE1-AS1	4.95	8.86e-07	9.1e-05	0.27	0.15	Breast cancer;	chr10:121899080	chr10:121928312~121951965:+
BRCA	cis	rs10510102	0.872	rs3750836	ENSG00000226864.1	ATE1-AS1	4.95	8.86e-07	9.1e-05	0.27	0.15	Breast cancer;	chr10:121899087	chr10:121928312~121951965:+
BRCA	cis	rs375066	0.539	rs11878787	ENSG00000267058.1	RP11-15A1.3	4.95	8.86e-07	9.1e-05	0.19	0.15	Breast cancer;	chr19:43826088	chr19:43891804~43901805:-
BRCA	cis	rs2303319	0.504	rs1515182	ENSG00000227403.1	AC009299.3	4.95	8.87e-07	9.11e-05	0.36	0.15	Cognitive function;	chr2:161580424	chr2:161244739~161249050:+
BRCA	cis	rs2303319	0.504	rs12465645	ENSG00000227403.1	AC009299.3	4.95	8.87e-07	9.11e-05	0.36	0.15	Cognitive function;	chr2:161581129	chr2:161244739~161249050:+
BRCA	cis	rs2303319	0.504	rs12465734	ENSG00000227403.1	AC009299.3	4.95	8.87e-07	9.11e-05	0.36	0.15	Cognitive function;	chr2:161581349	chr2:161244739~161249050:+
BRCA	cis	rs2179367	0.959	rs521845	ENSG00000216906.2	RP11-350J20.9	-4.94	8.87e-07	9.11e-05	-0.18	-0.15	Dupuytren's disease;	chr6:149350562	chr6:149904243~149906418:+
BRCA	cis	rs7267979	0.816	rs404775	ENSG00000125804.12	FAM182A	-4.94	8.88e-07	9.12e-05	-0.2	-0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25500481	chr20:26054655~26086917:+
BRCA	cis	rs7267979	0.816	rs374701	ENSG00000125804.12	FAM182A	-4.94	8.88e-07	9.12e-05	-0.2	-0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25502980	chr20:26054655~26086917:+
BRCA	cis	rs2153535	0.58	rs6913100	ENSG00000251164.1	HULC	-4.94	8.88e-07	9.12e-05	-0.19	-0.15	Motion sickness;	chr6:8456622	chr6:8652137~8653846:+
BRCA	cis	rs987360	0.835	rs58968273	ENSG00000248869.4	RP11-138I17.1	4.94	8.88e-07	9.12e-05	0.15	0.15	Temperament;	chr4:137279316	chr4:136796722~137212799:-
BRCA	cis	rs987360	0.835	rs59417815	ENSG00000248869.4	RP11-138I17.1	4.94	8.88e-07	9.12e-05	0.15	0.15	Temperament;	chr4:137279381	chr4:136796722~137212799:-
BRCA	cis	rs7267979	1	rs2500424	ENSG00000276952.1	RP5-965G21.6	-4.94	8.89e-07	9.12e-05	-0.19	-0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25411333	chr20:25284915~25285588:-
BRCA	cis	rs4711336	1	rs3818523	ENSG00000224557.6	HLA-DPB2	-4.94	8.89e-07	9.13e-05	-0.18	-0.15	Height;	chr6:33692594	chr6:33112451~33129084:+
BRCA	cis	rs922692	0.744	rs12903203	ENSG00000261143.1	ADAMTS7P3	4.94	8.89e-07	9.13e-05	0.19	0.15	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78792591	chr15:77976042~77993057:+
BRCA	cis	rs875971	0.862	rs778736	ENSG00000236529.1	RP13-254B10.1	4.94	8.89e-07	9.13e-05	0.17	0.15	Aortic root size;	chr7:66348861	chr7:65840212~65840596:+
BRCA	cis	rs2281636	0.894	rs11190196	ENSG00000233690.1	EBAG9P1	4.94	8.9e-07	9.14e-05	0.16	0.15	Obesity-related traits;	chr10:99626757	chr10:99697407~99697949:-
BRCA	cis	rs6452524	0.967	rs4290995	ENSG00000281327.1	LINC01338	4.94	8.9e-07	9.14e-05	0.18	0.15	Hypertension (SNP x SNP interaction);	chr5:83182177	chr5:82850864~82859836:-
BRCA	cis	rs5167	0.504	rs8100120	ENSG00000280087.1	CTB-129P6.7	4.94	8.9e-07	9.14e-05	0.18	0.15	Blood protein levels;	chr19:44962801	chr19:44909375~44914968:+
BRCA	cis	rs4718428	0.705	rs12536410	ENSG00000229180.5	GS1-124K5.11	4.94	8.9e-07	9.14e-05	0.15	0.15	Corneal structure;	chr7:66789303	chr7:66526088~66542624:-
BRCA	cis	rs7954584	0.813	rs1523261	ENSG00000272849.1	RP11-347I19.8	-4.94	8.9e-07	9.14e-05	-0.12	-0.15	Mean corpuscular volume;	chr12:122024971	chr12:121797511~121801972:+
BRCA	cis	rs4218	0.648	rs60285686	ENSG00000277144.1	RP11-59H7.4	-4.94	8.91e-07	9.14e-05	-0.2	-0.15	Social communication problems;	chr15:59079829	chr15:59115547~59116089:-
BRCA	cis	rs4218	0.648	rs60741546	ENSG00000277144.1	RP11-59H7.4	-4.94	8.91e-07	9.14e-05	-0.2	-0.15	Social communication problems;	chr15:59079831	chr15:59115547~59116089:-
BRCA	cis	rs1387259	0.929	rs11168460	ENSG00000226413.2	OR8T1P	4.94	8.91e-07	9.15e-05	0.2	0.15	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48203582	chr12:48442030~48442947:-
BRCA	cis	rs10504130	0.866	rs74738864	ENSG00000253844.1	RP11-546K22.1	-4.94	8.91e-07	9.15e-05	-0.26	-0.15	Venous thromboembolism (SNP x SNP interaction);	chr8:51878654	chr8:51961458~52022974:+
BRCA	cis	rs853679	0.513	rs13437444	ENSG00000219392.1	RP1-265C24.5	-4.94	8.93e-07	9.16e-05	-0.26	-0.15	Depression;	chr6:28103220	chr6:28115628~28116551:+
BRCA	cis	rs11098499	0.754	rs4107728	ENSG00000249244.1	RP11-548H18.2	4.94	8.93e-07	9.17e-05	0.17	0.15	Corneal astigmatism;	chr4:119332755	chr4:119391831~119395335:-
BRCA	cis	rs17772222	0.74	rs11847417	ENSG00000258789.1	RP11-507K2.3	4.94	8.93e-07	9.17e-05	0.17	0.15	Coronary artery calcification;	chr14:88510606	chr14:88551597~88552493:+
BRCA	cis	rs9549367	0.577	rs3024718	ENSG00000269125.1	RP11-98F14.11	4.94	8.94e-07	9.17e-05	0.22	0.15	Platelet distribution width;	chr13:113159539	chr13:113165002~113165183:-
BRCA	cis	rs748404	0.666	rs12906481	ENSG00000205771.5	CATSPER2P1	-4.94	8.94e-07	9.18e-05	-0.23	-0.15	Lung cancer;	chr15:43467356	chr15:43726918~43747094:-
BRCA	cis	rs748404	0.666	rs35958032	ENSG00000205771.5	CATSPER2P1	-4.94	8.94e-07	9.18e-05	-0.23	-0.15	Lung cancer;	chr15:43494397	chr15:43726918~43747094:-
BRCA	cis	rs9473147	0.516	rs2171089	ENSG00000270761.1	RP11-385F7.1	-4.94	8.95e-07	9.18e-05	-0.16	-0.15	Platelet distribution width;Mean platelet volume;	chr6:47548075	chr6:47477243~47477572:-
BRCA	cis	rs875971	0.862	rs9791712	ENSG00000236529.1	RP13-254B10.1	-4.94	8.95e-07	9.18e-05	-0.17	-0.15	Aortic root size;	chr7:66640176	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.862	rs9791713	ENSG00000236529.1	RP13-254B10.1	-4.94	8.95e-07	9.18e-05	-0.17	-0.15	Aortic root size;	chr7:66640211	chr7:65840212~65840596:+
BRCA	cis	rs10504130	0.696	rs79740712	ENSG00000253844.1	RP11-546K22.1	-4.94	8.95e-07	9.18e-05	-0.23	-0.15	Venous thromboembolism (SNP x SNP interaction);	chr8:51925750	chr8:51961458~52022974:+
BRCA	cis	rs10504130	0.696	rs77958054	ENSG00000253844.1	RP11-546K22.1	-4.94	8.95e-07	9.18e-05	-0.23	-0.15	Venous thromboembolism (SNP x SNP interaction);	chr8:51926157	chr8:51961458~52022974:+
BRCA	cis	rs4218	0.597	rs12438111	ENSG00000277144.1	RP11-59H7.4	-4.94	8.95e-07	9.19e-05	-0.2	-0.15	Social communication problems;	chr15:59057540	chr15:59115547~59116089:-
BRCA	cis	rs987360	0.835	rs2059563	ENSG00000248869.4	RP11-138I17.1	4.94	8.95e-07	9.19e-05	0.15	0.15	Temperament;	chr4:137283323	chr4:136796722~137212799:-
BRCA	cis	rs987360	0.835	rs10010861	ENSG00000248869.4	RP11-138I17.1	4.94	8.95e-07	9.19e-05	0.15	0.15	Temperament;	chr4:137285806	chr4:136796722~137212799:-
BRCA	cis	rs987360	0.835	rs10033132	ENSG00000248869.4	RP11-138I17.1	4.94	8.95e-07	9.19e-05	0.15	0.15	Temperament;	chr4:137285928	chr4:136796722~137212799:-
BRCA	cis	rs987360	0.835	rs12507234	ENSG00000248869.4	RP11-138I17.1	4.94	8.95e-07	9.19e-05	0.15	0.15	Temperament;	chr4:137287730	chr4:136796722~137212799:-
BRCA	cis	rs4819052	0.851	rs10470258	ENSG00000184274.3	LINC00315	-4.94	8.96e-07	9.19e-05	-0.21	-0.15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239074	chr21:45300245~45305257:-
BRCA	cis	rs4819052	0.851	rs4819038	ENSG00000184274.3	LINC00315	-4.94	8.96e-07	9.19e-05	-0.21	-0.15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239478	chr21:45300245~45305257:-
BRCA	cis	rs4819052	0.851	rs4819039	ENSG00000184274.3	LINC00315	-4.94	8.96e-07	9.19e-05	-0.21	-0.15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239543	chr21:45300245~45305257:-
BRCA	cis	rs4819052	0.851	rs4818768	ENSG00000184274.3	LINC00315	-4.94	8.96e-07	9.19e-05	-0.21	-0.15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239903	chr21:45300245~45305257:-
BRCA	cis	rs4819052	0.851	rs4819042	ENSG00000184274.3	LINC00315	-4.94	8.96e-07	9.19e-05	-0.21	-0.15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240157	chr21:45300245~45305257:-
BRCA	cis	rs4819052	0.8	rs4819045	ENSG00000184274.3	LINC00315	-4.94	8.96e-07	9.19e-05	-0.21	-0.15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240223	chr21:45300245~45305257:-
BRCA	cis	rs4819052	0.851	rs13047598	ENSG00000184274.3	LINC00315	-4.94	8.96e-07	9.19e-05	-0.21	-0.15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240862	chr21:45300245~45305257:-
BRCA	cis	rs4819052	0.724	rs9753962	ENSG00000184274.3	LINC00315	-4.94	8.96e-07	9.19e-05	-0.21	-0.15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45241469	chr21:45300245~45305257:-
BRCA	cis	rs4819052	0.724	rs9753987	ENSG00000184274.3	LINC00315	-4.94	8.96e-07	9.19e-05	-0.21	-0.15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45241474	chr21:45300245~45305257:-
BRCA	cis	rs4819052	0.851	rs9753963	ENSG00000184274.3	LINC00315	-4.94	8.96e-07	9.19e-05	-0.21	-0.15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45241522	chr21:45300245~45305257:-
BRCA	cis	rs875971	0.862	rs35378740	ENSG00000236529.1	RP13-254B10.1	4.94	8.96e-07	9.19e-05	0.17	0.15	Aortic root size;	chr7:66522725	chr7:65840212~65840596:+
BRCA	cis	rs2562456	0.793	rs3853837	ENSG00000268081.1	RP11-678G14.2	4.94	8.96e-07	9.19e-05	0.25	0.15	Pain;	chr19:21419172	chr19:21554640~21569237:-
BRCA	cis	rs2562456	0.793	rs3853838	ENSG00000268081.1	RP11-678G14.2	4.94	8.96e-07	9.19e-05	0.25	0.15	Pain;	chr19:21419192	chr19:21554640~21569237:-
BRCA	cis	rs2562456	0.833	rs62110426	ENSG00000268081.1	RP11-678G14.2	4.94	8.96e-07	9.19e-05	0.25	0.15	Pain;	chr19:21420124	chr19:21554640~21569237:-
BRCA	cis	rs12477438	0.52	rs4851188	ENSG00000231822.1	AC019097.7	4.94	8.97e-07	9.2e-05	0.16	0.15	Chronic sinus infection;	chr2:99129435	chr2:99102018~99102752:+
BRCA	cis	rs12477438	0.501	rs11683107	ENSG00000231822.1	AC019097.7	4.94	8.97e-07	9.2e-05	0.16	0.15	Chronic sinus infection;	chr2:99142772	chr2:99102018~99102752:+
BRCA	cis	rs12477438	0.52	rs6542866	ENSG00000231822.1	AC019097.7	4.94	8.97e-07	9.2e-05	0.16	0.15	Chronic sinus infection;	chr2:99148129	chr2:99102018~99102752:+
BRCA	cis	rs17801127	0.748	rs34247742	ENSG00000231969.1	AC144449.1	4.94	8.97e-07	9.2e-05	0.3	0.15	Liver enzyme levels (alanine transaminase);	chr2:149771152	chr2:149587196~149848233:+
BRCA	cis	rs17801127	0.748	rs72992402	ENSG00000231969.1	AC144449.1	4.94	8.97e-07	9.2e-05	0.3	0.15	Liver enzyme levels (alanine transaminase);	chr2:149771773	chr2:149587196~149848233:+
BRCA	cis	rs539096	0.872	rs573350	ENSG00000236200.4	KDM4A-AS1	-4.94	8.97e-07	9.21e-05	-0.19	-0.15	Intelligence (multi-trait analysis);	chr1:43592279	chr1:43699765~43708138:-
BRCA	cis	rs6714710	0.603	rs7583868	ENSG00000230606.9	AC159540.1	-4.94	8.98e-07	9.21e-05	-0.18	-0.15	Posterior cortical atrophy and Alzheimer's disease;	chr2:97971909	chr2:97416165~97433527:-
BRCA	cis	rs2562456	0.833	rs11666447	ENSG00000268081.1	RP11-678G14.2	4.94	8.98e-07	9.21e-05	0.25	0.15	Pain;	chr19:21416270	chr19:21554640~21569237:-
BRCA	cis	rs875971	0.545	rs67775320	ENSG00000230295.1	RP11-458F8.2	4.94	8.98e-07	9.21e-05	0.14	0.15	Aortic root size;	chr7:66193792	chr7:66880708~66882981:+
BRCA	cis	rs801193	0.569	rs881285	ENSG00000236529.1	RP13-254B10.1	-4.94	8.98e-07	9.21e-05	-0.17	-0.15	Aortic root size;	chr7:66654433	chr7:65840212~65840596:+
BRCA	cis	rs794185	0.625	rs2259801	ENSG00000231249.1	ITPR1-AS1	-4.94	8.98e-07	9.21e-05	-0.17	-0.15	Multiple sclerosis--Brain Glutamate Levels;	chr3:4471859	chr3:4490891~4493163:-
BRCA	cis	rs4494364	0.502	rs7314350	ENSG00000258100.1	RP11-121E16.1	4.94	8.99e-07	9.22e-05	0.22	0.15	Systolic blood pressure (alcohol consumption interaction);	chr12:90974514	chr12:91362196~91368606:+
BRCA	cis	rs7131987	0.565	rs7976667	ENSG00000257176.2	RP11-996F15.2	4.94	8.99e-07	9.22e-05	0.17	0.15	QT interval;	chr12:29273098	chr12:29280418~29317848:-
BRCA	cis	rs13113518	0.966	rs7677952	ENSG00000223305.1	RN7SKP30	4.94	8.99e-07	9.22e-05	0.18	0.15	Height;	chr4:55425312	chr4:55540502~55540835:-
BRCA	cis	rs13113518	1	rs1047354	ENSG00000223305.1	RN7SKP30	4.94	8.99e-07	9.22e-05	0.18	0.15	Height;	chr4:55429416	chr4:55540502~55540835:-
BRCA	cis	rs13113518	1	rs1056547	ENSG00000223305.1	RN7SKP30	4.94	8.99e-07	9.22e-05	0.18	0.15	Height;	chr4:55430596	chr4:55540502~55540835:-
BRCA	cis	rs13113518	1	rs1056545	ENSG00000223305.1	RN7SKP30	4.94	8.99e-07	9.22e-05	0.18	0.15	Height;	chr4:55430730	chr4:55540502~55540835:-
BRCA	cis	rs13113518	1	rs5863	ENSG00000223305.1	RN7SKP30	4.94	8.99e-07	9.22e-05	0.18	0.15	Height;	chr4:55430740	chr4:55540502~55540835:-
BRCA	cis	rs13113518	0.966	rs6828570	ENSG00000223305.1	RN7SKP30	4.94	8.99e-07	9.22e-05	0.18	0.15	Height;	chr4:55431595	chr4:55540502~55540835:-
BRCA	cis	rs11098499	0.754	rs7672594	ENSG00000249244.1	RP11-548H18.2	4.94	8.99e-07	9.22e-05	0.17	0.15	Corneal astigmatism;	chr4:119327388	chr4:119391831~119395335:-
BRCA	cis	rs890448	0.726	rs1031034	ENSG00000254531.1	FLJ20021	-4.94	8.99e-07	9.22e-05	-0.18	-0.15	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101302229	chr4:101347780~101348883:+
BRCA	cis	rs4218	0.638	rs12437587	ENSG00000277144.1	RP11-59H7.4	-4.94	9e-07	9.22e-05	-0.19	-0.15	Social communication problems;	chr15:59072785	chr15:59115547~59116089:-
BRCA	cis	rs2255336	0.938	rs2417734	ENSG00000245648.1	RP11-277P12.20	4.94	9e-07	9.23e-05	0.22	0.15	Blood protein levels;	chr12:10380807	chr12:10363769~10398506:+
BRCA	cis	rs4819052	0.851	rs8133045	ENSG00000184274.3	LINC00315	-4.94	9e-07	9.23e-05	-0.21	-0.15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238222	chr21:45300245~45305257:-
BRCA	cis	rs6723226	0.75	rs10182170	ENSG00000276517.1	AL133243.2	-4.94	9e-07	9.23e-05	-0.19	-0.15	Intelligence (multi-trait analysis);	chr2:32479118	chr2:32526504~32529507:+
BRCA	cis	rs10833905	1	rs11026880	ENSG00000246225.5	RP11-17A1.3	-4.94	9.01e-07	9.23e-05	-0.21	-0.15	Sudden cardiac arrest;	chr11:22994273	chr11:22829380~22945393:+
BRCA	cis	rs17685	0.753	rs1574107	ENSG00000280388.1	RP11-229D13.3	-4.94	9.01e-07	9.24e-05	-0.16	-0.15	Coffee consumption (cups per day);Coffee consumption;	chr7:76055729	chr7:76043977~76045963:-
BRCA	cis	rs1552244	0.572	rs7645759	ENSG00000232901.1	CYCSP10	4.94	9.01e-07	9.24e-05	0.23	0.15	Alzheimer's disease;	chr3:10115684	chr3:10000647~10000940:-
BRCA	cis	rs4578769	0.765	rs1609464	ENSG00000265939.1	UBE2CP2	-4.94	9.01e-07	9.24e-05	-0.19	-0.15	Eosinophil percentage of white cells;	chr18:22844191	chr18:22900486~22900995:-
BRCA	cis	rs62025270	0.632	rs62022942	ENSG00000259762.1	RP11-158M2.4	-4.94	9.01e-07	9.24e-05	-0.22	-0.15	Idiopathic pulmonary fibrosis;	chr15:85715337	chr15:85750336~85752901:-
BRCA	cis	rs7226408	0.802	rs72892528	ENSG00000267707.2	RP11-95O2.5	4.94	9.02e-07	9.25e-05	0.23	0.15	Obesity-related traits;	chr18:37093051	chr18:37243776~37247506:+
BRCA	cis	rs6832769	1	rs9997288	ENSG00000223305.1	RN7SKP30	4.94	9.02e-07	9.25e-05	0.2	0.15	Personality dimensions;	chr4:55481060	chr4:55540502~55540835:-
BRCA	cis	rs7267979	0.903	rs6050482	ENSG00000274973.1	RP13-401N8.7	-4.94	9.02e-07	9.25e-05	-0.17	-0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25245691	chr20:25845497~25845862:+
BRCA	cis	rs6598266	1	rs6598267	ENSG00000259363.4	CTD-2054N24.2	-4.94	9.02e-07	9.25e-05	-0.22	-0.15	Major depressive disorder;	chr15:99759090	chr15:99807023~99877148:+
BRCA	cis	rs9868809	0.505	rs13316551	ENSG00000270441.1	RP11-694I15.7	4.94	9.02e-07	9.25e-05	0.26	0.15	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48707734	chr3:49140086~49160851:-
BRCA	cis	rs10504130	1	rs74953260	ENSG00000253844.1	RP11-546K22.1	-4.94	9.02e-07	9.25e-05	-0.26	-0.15	Venous thromboembolism (SNP x SNP interaction);	chr8:51863087	chr8:51961458~52022974:+
BRCA	cis	rs10504130	1	rs75826750	ENSG00000253844.1	RP11-546K22.1	-4.94	9.02e-07	9.25e-05	-0.26	-0.15	Venous thromboembolism (SNP x SNP interaction);	chr8:51863133	chr8:51961458~52022974:+
BRCA	cis	rs780094	0.5	rs12464616	ENSG00000234072.1	AC074117.10	4.94	9.03e-07	9.26e-05	0.16	0.15	Urate levels in overweight individuals;C-reactive protein;Metabolic syndrome;Red blood cell count;Renal underexcretion gout;Nonalcoholic fatty liver disease;Age-related diseases, mortality and associated endophenotypes;Crohn's disease;Calcium levels;Fasting plasma glucose;Metabolic traits;Fasting blood glucose;Fasting blood insulin;Urate levels in obese individuals;Alcohol consumption (drinks per week);Height;Urate levels;Gondoic acid (20:1n-9) levels;Uric acid levels;Age-related disease endophenotypes;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Homeostasis model assessment of insulin resistance;Alcohol consumption;Fasting blood insulin (BMI interaction);Triglycerides;Fasting blood glucose (BMI interaction);Hypertriglyceridemia;LDL cholesterol;Type 2 diabetes;Triglyceride levels;	chr2:27604225	chr2:27356246~27367622:+
BRCA	cis	rs6545883	0.894	rs10177303	ENSG00000212978.6	AC016747.3	-4.94	9.04e-07	9.26e-05	-0.21	-0.15	Tuberculosis;	chr2:61367324	chr2:61141592~61144969:-
BRCA	cis	rs6991838	0.806	rs11777025	ENSG00000272010.1	CTD-3025N20.3	-4.94	9.04e-07	9.27e-05	-0.16	-0.15	Intelligence (multi-trait analysis);	chr8:65551438	chr8:65591850~65592472:-
BRCA	cis	rs2562456	0.754	rs11666213	ENSG00000268081.1	RP11-678G14.2	4.94	9.05e-07	9.27e-05	0.25	0.15	Pain;	chr19:21422843	chr19:21554640~21569237:-
BRCA	cis	rs7978895	0.647	rs7305366	ENSG00000258331.1	RP11-118A3.1	-4.94	9.05e-07	9.28e-05	-0.16	-0.15	Type 2 diabetes;	chr12:43183910	chr12:43155315~43163110:+
BRCA	cis	rs1656368	0.726	rs17628958	ENSG00000279311.1	RP11-170K4.2	4.94	9.05e-07	9.28e-05	0.19	0.15	Lobe attachment (rater-scored or self-reported);	chr3:158538778	chr3:158869898~158871821:+
BRCA	cis	rs6598266	1	rs6598272	ENSG00000259363.4	CTD-2054N24.2	-4.94	9.06e-07	9.28e-05	-0.22	-0.15	Major depressive disorder;	chr15:99759468	chr15:99807023~99877148:+
BRCA	cis	rs6546324	0.514	rs2861639	ENSG00000236780.4	AC078941.1	4.94	9.06e-07	9.28e-05	0.26	0.15	Endometriosis;	chr2:67552787	chr2:67123357~67215319:-
BRCA	cis	rs2255336	0.938	rs2045876	ENSG00000245648.1	RP11-277P12.20	4.94	9.06e-07	9.28e-05	0.23	0.15	Blood protein levels;	chr12:10389233	chr12:10363769~10398506:+
BRCA	cis	rs6756513	0.5	rs56168154	ENSG00000231024.1	AC092431.3	-4.94	9.06e-07	9.29e-05	-0.22	-0.15	Breast cancer;Platelet count;	chr2:69863781	chr2:69700192~69713847:-
BRCA	cis	rs11098499	0.78	rs10013652	ENSG00000249244.1	RP11-548H18.2	4.94	9.07e-07	9.29e-05	0.17	0.15	Corneal astigmatism;	chr4:119371101	chr4:119391831~119395335:-
BRCA	cis	rs10989172	0.714	rs3925103	ENSG00000175611.10	LINC00476	4.94	9.07e-07	9.29e-05	0.16	0.15	Common carotid intima-media thickness in HIV negative individuals;	chr9:96081052	chr9:95759231~95875977:-
BRCA	cis	rs780094	0.5	rs4665991	ENSG00000234072.1	AC074117.10	4.94	9.07e-07	9.29e-05	0.16	0.15	Urate levels in overweight individuals;C-reactive protein;Metabolic syndrome;Red blood cell count;Renal underexcretion gout;Nonalcoholic fatty liver disease;Age-related diseases, mortality and associated endophenotypes;Crohn's disease;Calcium levels;Fasting plasma glucose;Metabolic traits;Fasting blood glucose;Fasting blood insulin;Urate levels in obese individuals;Alcohol consumption (drinks per week);Height;Urate levels;Gondoic acid (20:1n-9) levels;Uric acid levels;Age-related disease endophenotypes;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Homeostasis model assessment of insulin resistance;Alcohol consumption;Fasting blood insulin (BMI interaction);Triglycerides;Fasting blood glucose (BMI interaction);Hypertriglyceridemia;LDL cholesterol;Type 2 diabetes;Triglyceride levels;	chr2:27543417	chr2:27356246~27367622:+
BRCA	cis	rs4834770	0.746	rs2389747	ENSG00000248280.1	RP11-33B1.2	4.94	9.07e-07	9.29e-05	0.14	0.15	Blood protein levels;	chr4:119314947	chr4:119440561~119450157:-
BRCA	cis	rs4834770	0.717	rs1022146	ENSG00000248280.1	RP11-33B1.2	4.94	9.07e-07	9.29e-05	0.14	0.15	Blood protein levels;	chr4:119314948	chr4:119440561~119450157:-
BRCA	cis	rs3768617	0.51	rs2093985	ENSG00000224468.3	RP11-181K3.4	-4.94	9.07e-07	9.29e-05	-0.16	-0.15	Fuchs's corneal dystrophy;	chr1:183125187	chr1:183138402~183141282:-
BRCA	cis	rs6044112	0.56	rs17681978	ENSG00000273998.1	RP4-777L9.2	4.94	9.07e-07	9.3e-05	0.31	0.15	Response to taxane treatment (docetaxel);	chr20:16607929	chr20:16576068~16579615:+
BRCA	cis	rs17772222	0.516	rs1006259	ENSG00000258983.2	RP11-507K2.2	4.94	9.07e-07	9.3e-05	0.17	0.15	Coronary artery calcification;	chr14:88339759	chr14:88499334~88515502:+
BRCA	cis	rs2665103	0.61	rs1972460	ENSG00000276710.3	CSPG4P8	-4.94	9.07e-07	9.3e-05	-0.16	-0.15	Intelligence (multi-trait analysis);	chr15:82238289	chr15:82459472~82477258:+
BRCA	cis	rs1850744	1	rs7664572	ENSG00000163612.10	FAM86KP	4.94	9.07e-07	9.3e-05	0.38	0.15	Economic and political preferences;	chr4:9807085	chr4:9153296~9165451:+
BRCA	cis	rs6686842	0.965	rs10157966	ENSG00000235358.1	RP11-399E6.1	-4.94	9.07e-07	9.3e-05	-0.19	-0.15	Height;	chr1:41256904	chr1:41242373~41284861:+
BRCA	cis	rs919433	0.617	rs13018267	ENSG00000231621.1	AC013264.2	4.94	9.08e-07	9.31e-05	0.15	0.15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197680868	chr2:197197991~197199273:+
BRCA	cis	rs12893668	0.572	rs35011804	ENSG00000269958.1	RP11-73M18.8	4.94	9.08e-07	9.31e-05	0.17	0.15	Reticulocyte count;	chr14:103685063	chr14:103696353~103697163:+
BRCA	cis	rs2732480	0.538	rs2732462	ENSG00000257735.1	RP11-370I10.6	4.94	9.09e-07	9.32e-05	0.19	0.15	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48302601	chr12:48350945~48442411:+
BRCA	cis	rs2439831	1	rs9920763	ENSG00000205771.5	CATSPER2P1	-4.94	9.1e-07	9.32e-05	-0.28	-0.15	Lung cancer in ever smokers;	chr15:43468310	chr15:43726918~43747094:-
BRCA	cis	rs494453	0.922	rs2477428	ENSG00000227811.2	FAM212B-AS1	-4.94	9.1e-07	9.32e-05	-0.19	-0.15	Osteoporosis-related phenotypes;	chr1:111671634	chr1:111739841~111747798:+
BRCA	cis	rs4763879	0.778	rs9332411	ENSG00000278635.1	CTD-2318O12.1	4.94	9.1e-07	9.32e-05	0.15	0.15	Type 1 diabetes;	chr12:9681749	chr12:9415641~9416718:+
BRCA	cis	rs7226408	0.857	rs72892509	ENSG00000267707.2	RP11-95O2.5	4.94	9.1e-07	9.32e-05	0.23	0.15	Obesity-related traits;	chr18:37081834	chr18:37243776~37247506:+
BRCA	cis	rs8058578	0.887	rs28421305	ENSG00000260911.2	RP11-196G11.2	4.94	9.1e-07	9.32e-05	0.15	0.15	Multiple myeloma;	chr16:30826807	chr16:31043150~31049868:+
BRCA	cis	rs6723226	0.803	rs176415	ENSG00000276334.1	AL133243.1	-4.94	9.1e-07	9.33e-05	-0.19	-0.15	Intelligence (multi-trait analysis);	chr2:32424710	chr2:32521927~32523547:+
BRCA	cis	rs4415084	1	rs7735881	ENSG00000251141.4	RP11-53O19.1	4.94	9.1e-07	9.33e-05	0.14	0.15	Breast cancer;	chr5:44650074	chr5:44744900~44808777:-
BRCA	cis	rs2880765	0.566	rs55899824	ENSG00000202081.1	RNU6-1280P	4.94	9.11e-07	9.33e-05	0.19	0.15	Coronary artery disease;	chr15:85460860	chr15:85651522~85651628:-
BRCA	cis	rs9467773	1	rs10214634	ENSG00000241549.7	GUSBP2	4.94	9.11e-07	9.33e-05	0.16	0.15	Intelligence (multi-trait analysis);	chr6:26564354	chr6:26871484~26956554:-
BRCA	cis	rs875971	0.862	rs4718377	ENSG00000236529.1	RP13-254B10.1	-4.94	9.11e-07	9.33e-05	-0.17	-0.15	Aortic root size;	chr7:66584691	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.862	rs10278014	ENSG00000236529.1	RP13-254B10.1	-4.94	9.11e-07	9.33e-05	-0.17	-0.15	Aortic root size;	chr7:66586277	chr7:65840212~65840596:+
BRCA	cis	rs9545047	0.604	rs2265382	ENSG00000227354.5	RBM26-AS1	-4.94	9.11e-07	9.33e-05	-0.16	-0.15	Schizophrenia;	chr13:79426196	chr13:79406309~79424328:+
BRCA	cis	rs875971	0.756	rs2901210	ENSG00000236529.1	RP13-254B10.1	-4.94	9.11e-07	9.33e-05	-0.17	-0.15	Aortic root size;	chr7:66552518	chr7:65840212~65840596:+
BRCA	cis	rs9545047	0.604	rs2477395	ENSG00000227354.5	RBM26-AS1	-4.94	9.11e-07	9.33e-05	-0.16	-0.15	Schizophrenia;	chr13:79427679	chr13:79406309~79424328:+
BRCA	cis	rs10129255	0.828	rs10140989	ENSG00000224373.3	IGHV4-59	4.94	9.11e-07	9.33e-05	0.1	0.15	Kawasaki disease;	chr14:106668657	chr14:106627249~106627825:-
BRCA	cis	rs9423406	0.615	rs117529926	ENSG00000224034.1	RP11-445P17.8	-4.94	9.11e-07	9.33e-05	-0.29	-0.15	Intelligence;	chr10:5273908	chr10:5266033~5271236:-
BRCA	cis	rs9423406	0.615	rs114602781	ENSG00000224034.1	RP11-445P17.8	-4.94	9.11e-07	9.33e-05	-0.29	-0.15	Intelligence;	chr10:5273909	chr10:5266033~5271236:-
BRCA	cis	rs7246657	0.639	rs3112434	ENSG00000226686.6	LINC01535	4.94	9.12e-07	9.34e-05	0.23	0.15	Coronary artery calcification;	chr19:37707247	chr19:37251912~37265535:+
BRCA	cis	rs2243480	1	rs10247526	ENSG00000222364.1	RNU6-96P	4.94	9.12e-07	9.34e-05	0.28	0.15	Diabetic kidney disease;	chr7:66315709	chr7:66395191~66395286:+
BRCA	cis	rs7246657	0.524	rs28542490	ENSG00000267422.1	CTD-2554C21.1	-4.94	9.12e-07	9.34e-05	-0.25	-0.15	Coronary artery calcification;	chr19:36965682	chr19:37779686~37792865:+
BRCA	cis	rs2243480	1	rs2707844	ENSG00000275400.1	RP4-756H11.5	4.94	9.12e-07	9.34e-05	0.28	0.15	Diabetic kidney disease;	chr7:66594522	chr7:66553805~66554199:-
BRCA	cis	rs2243480	1	rs1796220	ENSG00000275400.1	RP4-756H11.5	4.94	9.12e-07	9.34e-05	0.28	0.15	Diabetic kidney disease;	chr7:66597113	chr7:66553805~66554199:-
BRCA	cis	rs2243480	1	rs2707831	ENSG00000275400.1	RP4-756H11.5	4.94	9.12e-07	9.34e-05	0.28	0.15	Diabetic kidney disease;	chr7:66597524	chr7:66553805~66554199:-
BRCA	cis	rs3764021	0.87	rs10492166	ENSG00000278635.1	CTD-2318O12.1	-4.94	9.12e-07	9.34e-05	-0.15	-0.15	Type 1 diabetes;	chr12:9733403	chr12:9415641~9416718:+
BRCA	cis	rs160451	0.966	rs160423	ENSG00000251136.7	RP11-37B2.1	4.94	9.12e-07	9.34e-05	0.15	0.15	Leprosy;	chr8:89658395	chr8:89609409~89757727:-
BRCA	cis	rs6545883	0.895	rs796597	ENSG00000270820.4	RP11-355B11.2	4.94	9.12e-07	9.34e-05	0.18	0.15	Tuberculosis;	chr2:61453925	chr2:61471188~61484130:+
BRCA	cis	rs6772849	0.93	rs1962040	ENSG00000242551.2	POU5F1P6	-4.94	9.12e-07	9.35e-05	-0.19	-0.15	Monocyte percentage of white cells;Monocyte count;	chr3:128605318	chr3:128674735~128677005:-
BRCA	cis	rs867371	0.929	rs1501371	ENSG00000278603.1	RP13-608F4.5	4.94	9.13e-07	9.35e-05	0.2	0.15	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82168099	chr15:82472203~82472426:+
BRCA	cis	rs11673344	0.503	rs1667370	ENSG00000226686.6	LINC01535	4.94	9.14e-07	9.36e-05	0.19	0.15	Obesity-related traits;	chr19:36999318	chr19:37251912~37265535:+
BRCA	cis	rs2243480	1	rs2257790	ENSG00000275400.1	RP4-756H11.5	4.94	9.14e-07	9.36e-05	0.27	0.15	Diabetic kidney disease;	chr7:66135463	chr7:66553805~66554199:-
BRCA	cis	rs7226408	0.901	rs11081986	ENSG00000267707.2	RP11-95O2.5	4.94	9.14e-07	9.36e-05	0.23	0.15	Obesity-related traits;	chr18:37103344	chr18:37243776~37247506:+
BRCA	cis	rs7226408	0.857	rs11081988	ENSG00000267707.2	RP11-95O2.5	4.94	9.14e-07	9.36e-05	0.23	0.15	Obesity-related traits;	chr18:37117870	chr18:37243776~37247506:+
BRCA	cis	rs7226408	0.857	rs997661	ENSG00000267707.2	RP11-95O2.5	4.94	9.14e-07	9.36e-05	0.23	0.15	Obesity-related traits;	chr18:37123764	chr18:37243776~37247506:+
BRCA	cis	rs7226408	0.857	rs72894317	ENSG00000267707.2	RP11-95O2.5	4.94	9.14e-07	9.36e-05	0.23	0.15	Obesity-related traits;	chr18:37126278	chr18:37243776~37247506:+
BRCA	cis	rs7226408	0.857	rs11081989	ENSG00000267707.2	RP11-95O2.5	4.94	9.14e-07	9.36e-05	0.23	0.15	Obesity-related traits;	chr18:37133404	chr18:37243776~37247506:+
BRCA	cis	rs7226408	0.802	rs72894332	ENSG00000267707.2	RP11-95O2.5	4.94	9.14e-07	9.36e-05	0.23	0.15	Obesity-related traits;	chr18:37137758	chr18:37243776~37247506:+
BRCA	cis	rs848490	0.674	rs6971555	ENSG00000214293.7	APTR	4.94	9.14e-07	9.36e-05	0.18	0.15	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77777422	chr7:77657660~77696265:-
BRCA	cis	rs17027633	1	rs80017784	ENSG00000260948.1	RP11-552M11.8	-4.94	9.14e-07	9.36e-05	-0.29	-0.15	Cerebrospinal fluid t-tau:AB1-42 ratio;	chr1:111405657	chr1:111431046~111433068:-
BRCA	cis	rs17027633	1	rs74935221	ENSG00000260948.1	RP11-552M11.8	-4.94	9.14e-07	9.36e-05	-0.29	-0.15	Cerebrospinal fluid t-tau:AB1-42 ratio;	chr1:111405676	chr1:111431046~111433068:-
BRCA	cis	rs17027633	1	rs74226038	ENSG00000260948.1	RP11-552M11.8	-4.94	9.14e-07	9.36e-05	-0.29	-0.15	Cerebrospinal fluid t-tau:AB1-42 ratio;	chr1:111405985	chr1:111431046~111433068:-
BRCA	cis	rs2255336	0.882	rs2733847	ENSG00000245648.1	RP11-277P12.20	4.94	9.14e-07	9.36e-05	0.22	0.15	Blood protein levels;	chr12:10380608	chr12:10363769~10398506:+
BRCA	cis	rs3892630	0.757	rs8109823	ENSG00000267475.1	CTD-2538C1.2	-4.94	9.15e-07	9.37e-05	-0.23	-0.15	Red blood cell traits;	chr19:32692410	chr19:32687089~32691750:-
BRCA	cis	rs7572733	0.534	rs1436131	ENSG00000231621.1	AC013264.2	-4.94	9.15e-07	9.37e-05	-0.15	-0.15	Dermatomyositis;	chr2:197866506	chr2:197197991~197199273:+
BRCA	cis	rs875971	0.964	rs1643388	ENSG00000223473.2	GS1-124K5.3	4.94	9.15e-07	9.37e-05	0.12	0.15	Aortic root size;	chr7:66379575	chr7:66491049~66493566:-
BRCA	cis	rs875971	1	rs778722	ENSG00000223473.2	GS1-124K5.3	4.94	9.15e-07	9.37e-05	0.12	0.15	Aortic root size;	chr7:66379841	chr7:66491049~66493566:-
BRCA	cis	rs9859260	0.689	rs3817672	ENSG00000231464.1	AC024937.4	4.94	9.16e-07	9.38e-05	0.19	0.15	Mean corpuscular volume;	chr3:196073940	chr3:195996738~195998233:+
BRCA	cis	rs2832191	1	rs6516891	ENSG00000176054.6	RPL23P2	-4.94	9.16e-07	9.38e-05	-0.16	-0.15	Dental caries;	chr21:29110749	chr21:28997613~28998033:-
BRCA	cis	rs2832191	1	rs2832184	ENSG00000176054.6	RPL23P2	-4.94	9.16e-07	9.38e-05	-0.16	-0.15	Dental caries;	chr21:29110944	chr21:28997613~28998033:-
BRCA	cis	rs1950326	0.515	rs1955711	ENSG00000258526.4	RP11-111A21.1	-4.94	9.16e-07	9.38e-05	-0.19	-0.15	Verbal memory performance (residualized delayed recall level);	chr14:39563985	chr14:39474840~39513780:+
BRCA	cis	rs7267979	0.816	rs6037158	ENSG00000277938.1	RP5-965G21.3	4.94	9.16e-07	9.38e-05	0.18	0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25614830	chr20:25229150~25231933:+
BRCA	cis	rs9300255	0.663	rs7953929	ENSG00000235423.7	RP11-282O18.3	4.94	9.16e-07	9.38e-05	0.21	0.15	Neutrophil percentage of white cells;	chr12:123273688	chr12:123252030~123261483:-
BRCA	cis	rs73193808	0.901	rs67463471	ENSG00000236056.1	GAPDHP14	-4.94	9.17e-07	9.39e-05	-0.21	-0.15	Coronary artery disease;	chr21:29195488	chr21:29222321~29223257:+
BRCA	cis	rs718433	0.584	rs4982496	ENSG00000256379.1	TRAV8-5	4.94	9.18e-07	9.4e-05	0.17	0.15	Intraocular pressure;	chr14:21752353	chr14:21903077~21903598:+
BRCA	cis	rs4671400	0.602	rs2694623	ENSG00000271889.1	RP11-493E12.1	-4.94	9.18e-07	9.4e-05	-0.24	-0.15	3-hydroxypropylmercapturic acid levels in smokers;	chr2:61326331	chr2:61151433~61162105:-
BRCA	cis	rs7577696	0.85	rs11124274	ENSG00000272716.1	RP11-563N4.1	-4.94	9.19e-07	9.41e-05	-0.17	-0.15	Inflammatory biomarkers;	chr2:32040848	chr2:32165046~32165757:-
BRCA	cis	rs987724	0.515	rs344087	ENSG00000240875.4	LINC00886	-4.94	9.19e-07	9.41e-05	-0.23	-0.15	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156842608	chr3:156747346~156817062:-
BRCA	cis	rs442309	0.846	rs224145	ENSG00000238280.1	RP11-436D10.3	-4.94	9.19e-07	9.41e-05	-0.21	-0.15	Vogt-Koyanagi-Harada syndrome;	chr10:62718695	chr10:62793562~62805887:-
BRCA	cis	rs2243480	0.764	rs2460423	ENSG00000275400.1	RP4-756H11.5	4.94	9.19e-07	9.41e-05	0.28	0.15	Diabetic kidney disease;	chr7:66136229	chr7:66553805~66554199:-
BRCA	cis	rs7772486	0.754	rs857881	ENSG00000270638.1	RP3-466P17.1	-4.94	9.2e-07	9.41e-05	-0.18	-0.15	Lobe attachment (rater-scored or self-reported);	chr6:145649657	chr6:145735570~145737218:+
BRCA	cis	rs9921338	0.961	rs56136462	ENSG00000262703.1	RP11-485G7.6	-4.94	9.2e-07	9.41e-05	-0.19	-0.15	Vein graft stenosis in coronary artery bypass grafting;	chr16:11321738	chr16:11348143~11349321:-
BRCA	cis	rs1223397	0.53	rs2458313	ENSG00000215022.6	RP1-257A7.4	-4.94	9.2e-07	9.41e-05	-0.18	-0.15	Blood pressure;	chr6:13309557	chr6:13264861~13295586:-
BRCA	cis	rs807029	0.577	rs701834	ENSG00000236662.1	RP11-108L7.4	4.94	9.2e-07	9.42e-05	0.19	0.15	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:101002044	chr10:100980507~100985614:-
BRCA	cis	rs7572733	0.534	rs700672	ENSG00000231621.1	AC013264.2	-4.94	9.2e-07	9.42e-05	-0.15	-0.15	Dermatomyositis;	chr2:197826731	chr2:197197991~197199273:+
BRCA	cis	rs2839627	0.561	rs2839601	ENSG00000225218.1	AP001628.6	4.94	9.2e-07	9.42e-05	0.2	0.15	Information processing speed;	chr21:42897271	chr21:42831040~42836477:-
BRCA	cis	rs2277027	1	rs3734030	ENSG00000248544.2	CTB-47B11.3	4.94	9.21e-07	9.43e-05	0.18	0.15	Pulmonary function;Pulmonary function (smoking interaction);	chr5:157512872	chr5:157375741~157384950:-
BRCA	cis	rs7598759	1	rs7598759	ENSG00000181798.2	LINC00471	-4.94	9.22e-07	9.43e-05	-0.18	-0.15	Noise-induced hearing loss;	chr2:231457245	chr2:231508426~231514339:-
BRCA	cis	rs7572733	0.534	rs2574832	ENSG00000231621.1	AC013264.2	-4.94	9.22e-07	9.43e-05	-0.15	-0.15	Dermatomyositis;	chr2:197840094	chr2:197197991~197199273:+
BRCA	cis	rs11955398	0.563	rs10471493	ENSG00000215032.2	GNL3LP1	-4.94	9.22e-07	9.44e-05	-0.18	-0.15	Intelligence (multi-trait analysis);	chr5:60739395	chr5:60891935~60893577:-
BRCA	cis	rs8054556	0.669	rs4787491	ENSG00000273724.1	RP11-347C12.12	-4.94	9.23e-07	9.44e-05	-0.17	-0.15	Autism spectrum disorder or schizophrenia;	chr16:30004016	chr16:30336400~30343336:+
BRCA	cis	rs7430456	0.638	rs13071694	ENSG00000228561.2	RP11-114M1.1	-4.94	9.23e-07	9.44e-05	-0.19	-0.15	Breast cancer;	chr3:177775198	chr3:177683627~177691250:+
BRCA	cis	rs11158026	0.603	rs3783646	ENSG00000258413.1	RP11-665C16.6	-4.94	9.23e-07	9.44e-05	-0.2	-0.15	Parkinson's disease;	chr14:55005169	chr14:55262767~55272075:-
BRCA	cis	rs300890	0.56	rs300925	ENSG00000250326.1	RP11-284M14.1	-4.94	9.23e-07	9.45e-05	-0.18	-0.15	Nasopharyngeal carcinoma;	chr4:143263040	chr4:142933195~143184861:-
BRCA	cis	rs9287719	0.753	rs1990613	ENSG00000243819.4	RN7SL832P	-4.94	9.23e-07	9.45e-05	-0.14	-0.15	Prostate cancer;	chr2:10641849	chr2:10690344~10692099:+
BRCA	cis	rs2562456	0.833	rs2562507	ENSG00000268535.1	RP11-420K14.3	-4.94	9.23e-07	9.45e-05	-0.21	-0.15	Pain;	chr19:21543535	chr19:21709522~21710191:+
BRCA	cis	rs9863	0.828	rs1187415	ENSG00000270028.1	RP11-380L11.4	-4.94	9.24e-07	9.45e-05	-0.18	-0.15	White blood cell count;	chr12:124006982	chr12:123925461~123926083:-
BRCA	cis	rs7772486	0.875	rs2814863	ENSG00000270638.1	RP3-466P17.1	-4.94	9.24e-07	9.45e-05	-0.17	-0.15	Lobe attachment (rater-scored or self-reported);	chr6:146026163	chr6:145735570~145737218:+
BRCA	cis	rs919433	0.617	rs10931791	ENSG00000231621.1	AC013264.2	4.94	9.24e-07	9.45e-05	0.15	0.15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197708888	chr2:197197991~197199273:+
BRCA	cis	rs11051970	0.559	rs3816819	ENSG00000274964.1	RP11-817I4.1	-4.94	9.24e-07	9.45e-05	-0.2	-0.15	Response to tocilizumab in rheumatoid arthritis;	chr12:32334123	chr12:32339368~32340724:+
BRCA	cis	rs801193	0.569	rs11761542	ENSG00000236529.1	RP13-254B10.1	4.94	9.24e-07	9.46e-05	0.17	0.15	Aortic root size;	chr7:66753209	chr7:65840212~65840596:+
BRCA	cis	rs12612619	0.732	rs920433	ENSG00000229122.1	AGBL5-IT1	4.94	9.24e-07	9.46e-05	0.16	0.15	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:26989658	chr2:27061038~27061815:+
BRCA	cis	rs1161098	0.767	rs1152883	ENSG00000203585.3	RP11-542B15.1	-4.94	9.24e-07	9.46e-05	-0.23	-0.15	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr12:67436034	chr12:67519829~67567126:+
BRCA	cis	rs7572733	0.534	rs700680	ENSG00000231621.1	AC013264.2	4.94	9.25e-07	9.46e-05	0.15	0.15	Dermatomyositis;	chr2:197843226	chr2:197197991~197199273:+
BRCA	cis	rs875971	0.862	rs801195	ENSG00000236529.1	RP13-254B10.1	-4.94	9.25e-07	9.46e-05	-0.17	-0.15	Aortic root size;	chr7:66561128	chr7:65840212~65840596:+
BRCA	cis	rs7226408	0.857	rs72894323	ENSG00000267707.2	RP11-95O2.5	4.94	9.25e-07	9.46e-05	0.23	0.15	Obesity-related traits;	chr18:37130162	chr18:37243776~37247506:+
BRCA	cis	rs7226408	0.857	rs7228810	ENSG00000267707.2	RP11-95O2.5	4.94	9.25e-07	9.46e-05	0.23	0.15	Obesity-related traits;	chr18:37142087	chr18:37243776~37247506:+
BRCA	cis	rs7572733	0.534	rs771009	ENSG00000231621.1	AC013264.2	-4.94	9.25e-07	9.47e-05	-0.15	-0.15	Dermatomyositis;	chr2:197826358	chr2:197197991~197199273:+
BRCA	cis	rs12744310	0.836	rs12048808	ENSG00000235358.1	RP11-399E6.1	4.94	9.25e-07	9.47e-05	0.23	0.15	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41348636	chr1:41242373~41284861:+
BRCA	cis	rs250585	1	rs250577	ENSG00000260136.4	CTD-2270L9.4	4.94	9.26e-07	9.47e-05	0.17	0.15	Egg allergy;	chr16:23416737	chr16:23452758~23457606:+
BRCA	cis	rs250585	0.92	rs250556	ENSG00000260136.4	CTD-2270L9.4	4.94	9.26e-07	9.47e-05	0.17	0.15	Egg allergy;	chr16:23435075	chr16:23452758~23457606:+
BRCA	cis	rs6545883	0.894	rs2694639	ENSG00000212978.6	AC016747.3	-4.94	9.26e-07	9.47e-05	-0.21	-0.15	Tuberculosis;	chr2:61368156	chr2:61141592~61144969:-
BRCA	cis	rs338389	0.516	rs4777016	ENSG00000260657.2	RP11-315D16.4	-4.94	9.26e-07	9.47e-05	-0.18	-0.15	Survival in rectal cancer;	chr15:68022581	chr15:68267792~68277994:-
BRCA	cis	rs801193	0.66	rs974239	ENSG00000223473.2	GS1-124K5.3	4.94	9.26e-07	9.47e-05	0.12	0.15	Aortic root size;	chr7:66748504	chr7:66491049~66493566:-
BRCA	cis	rs17711722	0.51	rs11767457	ENSG00000222364.1	RNU6-96P	-4.94	9.26e-07	9.48e-05	-0.18	-0.15	Calcium levels;	chr7:65825628	chr7:66395191~66395286:+
BRCA	cis	rs11098499	0.691	rs9996644	ENSG00000249244.1	RP11-548H18.2	4.94	9.26e-07	9.48e-05	0.17	0.15	Corneal astigmatism;	chr4:119317722	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.691	rs9996494	ENSG00000249244.1	RP11-548H18.2	4.94	9.26e-07	9.48e-05	0.17	0.15	Corneal astigmatism;	chr4:119317725	chr4:119391831~119395335:-
BRCA	cis	rs2243480	0.831	rs57294491	ENSG00000222364.1	RNU6-96P	4.94	9.27e-07	9.48e-05	0.28	0.15	Diabetic kidney disease;	chr7:66219914	chr7:66395191~66395286:+
BRCA	cis	rs11098499	0.863	rs6534139	ENSG00000250412.1	KLHL2P1	-4.94	9.27e-07	9.49e-05	-0.19	-0.15	Corneal astigmatism;	chr4:119528301	chr4:119334329~119378233:+
BRCA	cis	rs780094	0.5	rs12467476	ENSG00000234072.1	AC074117.10	4.94	9.27e-07	9.49e-05	0.16	0.15	Urate levels in overweight individuals;C-reactive protein;Metabolic syndrome;Red blood cell count;Renal underexcretion gout;Nonalcoholic fatty liver disease;Age-related diseases, mortality and associated endophenotypes;Crohn's disease;Calcium levels;Fasting plasma glucose;Metabolic traits;Fasting blood glucose;Fasting blood insulin;Urate levels in obese individuals;Alcohol consumption (drinks per week);Height;Urate levels;Gondoic acid (20:1n-9) levels;Uric acid levels;Age-related disease endophenotypes;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Homeostasis model assessment of insulin resistance;Alcohol consumption;Fasting blood insulin (BMI interaction);Triglycerides;Fasting blood glucose (BMI interaction);Hypertriglyceridemia;LDL cholesterol;Type 2 diabetes;Triglyceride levels;	chr2:27602848	chr2:27356246~27367622:+
BRCA	cis	rs17597773	1	rs17597773	ENSG00000272823.1	RP11-295M18.6	-4.94	9.28e-07	9.49e-05	-0.18	-0.15	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220881419	chr1:220828676~220829211:-
BRCA	cis	rs9467773	0.62	rs2451731	ENSG00000124549.13	BTN2A3P	4.94	9.28e-07	9.49e-05	0.15	0.15	Intelligence (multi-trait analysis);	chr6:26624594	chr6:26421391~26432383:+
BRCA	cis	rs7618501	0.633	rs7628058	ENSG00000228008.1	CTD-2330K9.3	4.94	9.28e-07	9.49e-05	0.15	0.15	Intelligence (multi-trait analysis);	chr3:50002041	chr3:49903845~49916937:+
BRCA	cis	rs66887589	0.967	rs2892869	ENSG00000245958.5	RP11-33B1.1	4.94	9.28e-07	9.5e-05	0.13	0.15	Diastolic blood pressure;	chr4:119600142	chr4:119454791~119552025:+
BRCA	cis	rs854765	0.547	rs4584886	ENSG00000197815.4	RP1-253P7.4	-4.94	9.29e-07	9.5e-05	-0.11	-0.15	Total body bone mineral density;	chr17:17992891	chr17:17858227~17860041:+
BRCA	cis	rs12497850	0.931	rs11924597	ENSG00000225399.4	RP11-3B7.1	4.94	9.29e-07	9.5e-05	0.15	0.15	Parkinson's disease;	chr3:48900357	chr3:49260085~49261316:+
BRCA	cis	rs1950832	0.689	rs8009481	ENSG00000258636.1	CTD-2298J14.2	-4.94	9.29e-07	9.5e-05	-0.17	-0.15	Urate levels in obese individuals;	chr14:41667567	chr14:41587861~41604856:-
BRCA	cis	rs1707322	1	rs34444543	ENSG00000234329.1	RP11-767N6.2	4.94	9.29e-07	9.5e-05	0.15	0.15	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45893190	chr1:45651039~45651826:-
BRCA	cis	rs2412819	0.597	rs7181912	ENSG00000166763.7	STRCP1	-4.94	9.29e-07	9.5e-05	-0.21	-0.15	Lung cancer;	chr15:43770676	chr15:43699488~43718184:-
BRCA	cis	rs11098499	0.754	rs2036860	ENSG00000260404.2	RP11-384K6.6	4.94	9.29e-07	9.51e-05	0.14	0.15	Corneal astigmatism;	chr4:119327779	chr4:118591773~118633729:+
BRCA	cis	rs875971	0.545	rs1547529	ENSG00000230295.1	RP11-458F8.2	4.94	9.29e-07	9.51e-05	0.14	0.15	Aortic root size;	chr7:66258859	chr7:66880708~66882981:+
BRCA	cis	rs987360	0.835	rs28427118	ENSG00000248869.4	RP11-138I17.1	4.94	9.29e-07	9.51e-05	0.15	0.15	Temperament;	chr4:137280205	chr4:136796722~137212799:-
BRCA	cis	rs12435908	1	rs17826820	ENSG00000276116.2	FUT8-AS1	-4.94	9.3e-07	9.51e-05	-0.23	-0.15	Ischemic stroke;	chr14:65647119	chr14:65411170~65412690:-
BRCA	cis	rs4713118	0.699	rs200969	ENSG00000219392.1	RP1-265C24.5	-4.94	9.3e-07	9.51e-05	-0.23	-0.15	Parkinson's disease;	chr6:27891675	chr6:28115628~28116551:+
BRCA	cis	rs2408955	0.542	rs7975632	ENSG00000273765.1	RP11-370I10.11	4.94	9.3e-07	9.51e-05	0.19	0.15	Glycated hemoglobin levels;	chr12:48049265	chr12:48360920~48361377:+
BRCA	cis	rs11098499	0.754	rs2036860	ENSG00000249244.1	RP11-548H18.2	4.94	9.3e-07	9.51e-05	0.17	0.15	Corneal astigmatism;	chr4:119327779	chr4:119391831~119395335:-
BRCA	cis	rs7246657	0.653	rs4805208	ENSG00000267422.1	CTD-2554C21.1	-4.94	9.31e-07	9.52e-05	-0.26	-0.15	Coronary artery calcification;	chr19:37183357	chr19:37779686~37792865:+
BRCA	cis	rs4948275	0.679	rs10994772	ENSG00000237233.2	TMEM26-AS1	-4.94	9.31e-07	9.52e-05	-0.18	-0.15	Night sleep phenotypes;	chr10:61456117	chr10:61452639~61481956:+
BRCA	cis	rs2179367	0.632	rs11155642	ENSG00000268592.3	RAET1E-AS1	4.94	9.31e-07	9.52e-05	0.22	0.15	Dupuytren's disease;	chr6:149332984	chr6:149863494~149919507:+
BRCA	cis	rs7918232	1	rs7918232	ENSG00000262412.1	RP11-85G18.6	4.94	9.31e-07	9.52e-05	0.24	0.15	Breast cancer;	chr10:27080233	chr10:27243130~27250804:+
BRCA	cis	rs62025270	0.632	rs62022924	ENSG00000259762.1	RP11-158M2.4	-4.94	9.31e-07	9.52e-05	-0.22	-0.15	Idiopathic pulmonary fibrosis;	chr15:85692276	chr15:85750336~85752901:-
BRCA	cis	rs62025270	0.576	rs62022925	ENSG00000259762.1	RP11-158M2.4	-4.94	9.31e-07	9.52e-05	-0.22	-0.15	Idiopathic pulmonary fibrosis;	chr15:85692835	chr15:85750336~85752901:-
BRCA	cis	rs1555322	1	rs2425027	ENSG00000126005.14	MMP24-AS1	-4.94	9.32e-07	9.53e-05	-0.25	-0.15	Attention deficit hyperactivity disorder;	chr20:35261587	chr20:35216462~35278131:-
BRCA	cis	rs2833693	0.574	rs4143359	ENSG00000261610.1	AP000265.1	4.94	9.32e-07	9.53e-05	0.18	0.15	Temperament;	chr21:32179062	chr21:32259804~32261585:-
BRCA	cis	rs7226408	0.842	rs9958203	ENSG00000267707.2	RP11-95O2.5	4.94	9.32e-07	9.53e-05	0.25	0.15	Obesity-related traits;	chr18:36768995	chr18:37243776~37247506:+
BRCA	cis	rs2278170	1	rs2081575	ENSG00000225101.4	OR52K3P	-4.94	9.32e-07	9.53e-05	-0.2	-0.15	Amyotrophic lateral sclerosis;	chr11:4457238	chr11:4474813~4475755:+
BRCA	cis	rs736408	0.634	rs11717836	ENSG00000243224.1	RP5-1157M23.2	-4.94	9.32e-07	9.53e-05	-0.17	-0.15	Bipolar disorder;	chr3:52773720	chr3:52239258~52241097:+
BRCA	cis	rs2708977	0.842	rs10209780	ENSG00000237510.6	AC008268.2	-4.93	9.33e-07	9.54e-05	-0.2	-0.15	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96474405	chr2:95789654~95800166:+
BRCA	cis	rs2833693	0.574	rs9653707	ENSG00000261610.1	AP000265.1	4.93	9.33e-07	9.54e-05	0.18	0.15	Temperament;	chr21:32179462	chr21:32259804~32261585:-
BRCA	cis	rs4835473	0.8	rs1849117	ENSG00000249741.2	RP11-673E1.3	-4.93	9.33e-07	9.54e-05	-0.16	-0.15	Immature fraction of reticulocytes;	chr4:143989791	chr4:143911514~143912053:-
BRCA	cis	rs4948275	0.773	rs2787739	ENSG00000237233.2	TMEM26-AS1	-4.93	9.33e-07	9.54e-05	-0.18	-0.15	Night sleep phenotypes;	chr10:61503040	chr10:61452639~61481956:+
BRCA	cis	rs9291683	0.704	rs11726271	ENSG00000250413.1	RP11-448G15.1	4.93	9.33e-07	9.54e-05	0.19	0.15	Bone mineral density;	chr4:10096568	chr4:10006482~10009725:+
BRCA	cis	rs875971	1	rs6956179	ENSG00000229180.5	GS1-124K5.11	-4.93	9.33e-07	9.54e-05	-0.13	-0.15	Aortic root size;	chr7:66341672	chr7:66526088~66542624:-
BRCA	cis	rs2303319	0.582	rs62187608	ENSG00000227403.1	AC009299.3	4.93	9.34e-07	9.55e-05	0.36	0.15	Cognitive function;	chr2:161574628	chr2:161244739~161249050:+
BRCA	cis	rs4218	0.648	rs34407560	ENSG00000277144.1	RP11-59H7.4	-4.93	9.35e-07	9.55e-05	-0.2	-0.15	Social communication problems;	chr15:59073397	chr15:59115547~59116089:-
BRCA	cis	rs875971	0.862	rs13536	ENSG00000236529.1	RP13-254B10.1	-4.93	9.35e-07	9.56e-05	-0.17	-0.15	Aortic root size;	chr7:66554203	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.862	rs801209	ENSG00000236529.1	RP13-254B10.1	-4.93	9.35e-07	9.56e-05	-0.17	-0.15	Aortic root size;	chr7:66554403	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.862	rs801206	ENSG00000236529.1	RP13-254B10.1	-4.93	9.35e-07	9.56e-05	-0.17	-0.15	Aortic root size;	chr7:66556979	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.862	rs801204	ENSG00000236529.1	RP13-254B10.1	-4.93	9.35e-07	9.56e-05	-0.17	-0.15	Aortic root size;	chr7:66557934	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.862	rs801203	ENSG00000236529.1	RP13-254B10.1	-4.93	9.35e-07	9.56e-05	-0.17	-0.15	Aortic root size;	chr7:66558025	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.862	rs13232191	ENSG00000236529.1	RP13-254B10.1	4.93	9.35e-07	9.56e-05	0.17	0.15	Aortic root size;	chr7:66521661	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.862	rs10950043	ENSG00000236529.1	RP13-254B10.1	4.93	9.35e-07	9.56e-05	0.17	0.15	Aortic root size;	chr7:66523623	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.862	rs17747530	ENSG00000236529.1	RP13-254B10.1	4.93	9.35e-07	9.56e-05	0.17	0.15	Aortic root size;	chr7:66529742	chr7:65840212~65840596:+
BRCA	cis	rs4835473	0.798	rs11100829	ENSG00000249741.2	RP11-673E1.3	-4.93	9.36e-07	9.56e-05	-0.16	-0.15	Immature fraction of reticulocytes;	chr4:143984761	chr4:143911514~143912053:-
BRCA	cis	rs875971	0.862	rs6955837	ENSG00000236529.1	RP13-254B10.1	-4.93	9.36e-07	9.56e-05	-0.17	-0.15	Aortic root size;	chr7:66578155	chr7:65840212~65840596:+
BRCA	cis	rs7674212	0.537	rs2623060	ENSG00000246560.2	RP11-10L12.4	4.93	9.36e-07	9.57e-05	0.16	0.15	Type 2 diabetes;	chr4:103126347	chr4:102828055~102844075:+
BRCA	cis	rs5167	0.645	rs1130742	ENSG00000280087.1	CTB-129P6.7	4.93	9.36e-07	9.57e-05	0.21	0.15	Blood protein levels;	chr19:44949555	chr19:44909375~44914968:+
BRCA	cis	rs180730	1	rs1450479	ENSG00000251609.2	SETP12	4.93	9.36e-07	9.57e-05	0.22	0.15	Fasting plasma glucose;	chr4:120916718	chr4:120895494~120897083:-
BRCA	cis	rs7914558	0.901	rs1926034	ENSG00000236937.2	PTGES3P4	4.93	9.37e-07	9.57e-05	0.2	0.15	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103069345	chr10:102845595~102845950:+
BRCA	cis	rs7577696	0.512	rs212736	ENSG00000272716.1	RP11-563N4.1	4.93	9.37e-07	9.57e-05	0.18	0.15	Inflammatory biomarkers;	chr2:32248057	chr2:32165046~32165757:-
BRCA	cis	rs11098499	0.865	rs4001305	ENSG00000260091.1	RP11-33B1.4	-4.93	9.37e-07	9.58e-05	-0.13	-0.15	Corneal astigmatism;	chr4:119438081	chr4:119409333~119410233:+
BRCA	cis	rs7829975	0.593	rs2921077	ENSG00000233609.3	RP11-62H7.2	4.93	9.37e-07	9.58e-05	0.14	0.15	Mood instability;	chr8:8446992	chr8:8961200~8979025:+
BRCA	cis	rs7572733	0.534	rs700684	ENSG00000231621.1	AC013264.2	-4.93	9.37e-07	9.58e-05	-0.15	-0.15	Dermatomyositis;	chr2:197848375	chr2:197197991~197199273:+
BRCA	cis	rs9659323	0.539	rs1750331	ENSG00000231365.4	RP11-418J17.1	-4.93	9.37e-07	9.58e-05	-0.18	-0.15	Body mass index;	chr1:118952350	chr1:119140396~119275973:+
BRCA	cis	rs6452524	0.934	rs2940543	ENSG00000281327.1	LINC01338	4.93	9.37e-07	9.58e-05	0.18	0.15	Hypertension (SNP x SNP interaction);	chr5:83187297	chr5:82850864~82859836:-
BRCA	cis	rs6452524	0.967	rs2974450	ENSG00000281327.1	LINC01338	4.93	9.37e-07	9.58e-05	0.18	0.15	Hypertension (SNP x SNP interaction);	chr5:83187323	chr5:82850864~82859836:-
BRCA	cis	rs6452524	0.967	rs2974449	ENSG00000281327.1	LINC01338	4.93	9.37e-07	9.58e-05	0.18	0.15	Hypertension (SNP x SNP interaction);	chr5:83187465	chr5:82850864~82859836:-
BRCA	cis	rs6452524	0.967	rs2662241	ENSG00000281327.1	LINC01338	4.93	9.37e-07	9.58e-05	0.18	0.15	Hypertension (SNP x SNP interaction);	chr5:83188774	chr5:82850864~82859836:-
BRCA	cis	rs6452524	0.935	rs2940544	ENSG00000281327.1	LINC01338	4.93	9.37e-07	9.58e-05	0.18	0.15	Hypertension (SNP x SNP interaction);	chr5:83189785	chr5:82850864~82859836:-
BRCA	cis	rs6452524	0.967	rs2731865	ENSG00000281327.1	LINC01338	4.93	9.37e-07	9.58e-05	0.18	0.15	Hypertension (SNP x SNP interaction);	chr5:83190570	chr5:82850864~82859836:-
BRCA	cis	rs2286503	0.966	rs2286507	ENSG00000226329.2	AC005682.6	4.93	9.38e-07	9.58e-05	0.14	0.15	Fibrinogen;	chr7:22815141	chr7:22863874~22881350:-
BRCA	cis	rs6598266	1	rs8026166	ENSG00000259363.4	CTD-2054N24.2	-4.93	9.38e-07	9.58e-05	-0.22	-0.15	Major depressive disorder;	chr15:99759209	chr15:99807023~99877148:+
BRCA	cis	rs6598266	0.908	rs8040391	ENSG00000259363.4	CTD-2054N24.2	-4.93	9.38e-07	9.58e-05	-0.22	-0.15	Major depressive disorder;	chr15:99759243	chr15:99807023~99877148:+
BRCA	cis	rs6598266	1	rs6598271	ENSG00000259363.4	CTD-2054N24.2	-4.93	9.38e-07	9.58e-05	-0.22	-0.15	Major depressive disorder;	chr15:99759428	chr15:99807023~99877148:+
BRCA	cis	rs62184315	0.536	rs5742926	ENSG00000253559.1	OSGEPL1-AS1	-4.93	9.38e-07	9.59e-05	-0.26	-0.15	Alcohol dependence (age at onset);	chr2:189784079	chr2:189762704~189765556:+
BRCA	cis	rs17685	0.753	rs4732595	ENSG00000280388.1	RP11-229D13.3	-4.93	9.38e-07	9.59e-05	-0.16	-0.15	Coffee consumption (cups per day);Coffee consumption;	chr7:76125821	chr7:76043977~76045963:-
BRCA	cis	rs13160562	0.522	rs26502	ENSG00000272109.1	CTD-2260A17.3	-4.93	9.39e-07	9.59e-05	-0.19	-0.15	Alcohol dependence;	chr5:96764254	chr5:96804353~96806105:+
BRCA	cis	rs755249	0.565	rs7539261	ENSG00000182109.6	RP11-69E11.4	-4.93	9.39e-07	9.59e-05	-0.17	-0.15	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39584831	chr1:39522280~39546187:-
BRCA	cis	rs12681366	0.801	rs6981551	ENSG00000253175.1	RP11-267M23.6	4.93	9.4e-07	9.6e-05	0.19	0.15	Nonsyndromic cleft lip with cleft palate;	chr8:94466421	chr8:94565036~94565715:+
BRCA	cis	rs7577696	0.528	rs160801	ENSG00000272716.1	RP11-563N4.1	-4.93	9.4e-07	9.6e-05	-0.16	-0.15	Inflammatory biomarkers;	chr2:31879685	chr2:32165046~32165757:-
BRCA	cis	rs66887589	0.967	rs7678973	ENSG00000245958.5	RP11-33B1.1	4.93	9.4e-07	9.61e-05	0.13	0.15	Diastolic blood pressure;	chr4:119590662	chr4:119454791~119552025:+
BRCA	cis	rs6840360	0.642	rs1899550	ENSG00000251611.1	RP11-610P16.1	-4.93	9.4e-07	9.61e-05	-0.13	-0.15	Intelligence (multi-trait analysis);	chr4:151486084	chr4:151407551~151408835:-
BRCA	cis	rs2625529	0.73	rs2957725	ENSG00000260037.4	CTD-2524L6.3	4.93	9.4e-07	9.61e-05	0.19	0.15	Red blood cell count;	chr15:71955864	chr15:71818396~71823384:+
BRCA	cis	rs3213958	0.574	rs56290036	ENSG00000249274.1	PDLIM1P4	-4.93	9.41e-07	9.61e-05	-0.24	-0.15	Blood protein levels;	chr3:98845479	chr3:98782188~98783193:+
BRCA	cis	rs1722141	0.669	rs1722124	ENSG00000237471.1	AC073115.6	4.93	9.41e-07	9.61e-05	0.21	0.15	Sitting height ratio;	chr7:45987446	chr7:45969657~45980191:+
BRCA	cis	rs875971	0.825	rs1000464	ENSG00000236529.1	RP13-254B10.1	-4.93	9.41e-07	9.61e-05	-0.17	-0.15	Aortic root size;	chr7:66312922	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.862	rs2024192	ENSG00000236529.1	RP13-254B10.1	-4.93	9.41e-07	9.61e-05	-0.17	-0.15	Aortic root size;	chr7:66576460	chr7:65840212~65840596:+
BRCA	cis	rs74233809	0.591	rs284853	ENSG00000213277.3	MARCKSL1P1	-4.93	9.41e-07	9.62e-05	-0.23	-0.15	Birth weight;	chr10:102814885	chr10:103175554~103176094:+
BRCA	cis	rs801193	0.569	rs7782587	ENSG00000236529.1	RP13-254B10.1	4.93	9.41e-07	9.62e-05	0.17	0.15	Aortic root size;	chr7:66701485	chr7:65840212~65840596:+
BRCA	cis	rs5167	0.677	rs73047643	ENSG00000280087.1	CTB-129P6.7	4.93	9.41e-07	9.62e-05	0.21	0.15	Blood protein levels;	chr19:44954136	chr19:44909375~44914968:+
BRCA	cis	rs6596100	0.868	rs7715447	ENSG00000248648.1	RP11-485M7.1	-4.93	9.42e-07	9.62e-05	-0.19	-0.15	Breast cancer;	chr5:133045039	chr5:133003119~133003365:+
BRCA	cis	rs3768617	0.51	rs10797842	ENSG00000224468.3	RP11-181K3.4	-4.93	9.42e-07	9.62e-05	-0.16	-0.15	Fuchs's corneal dystrophy;	chr1:183112732	chr1:183138402~183141282:-
BRCA	cis	rs6065	0.529	rs1056626	ENSG00000234203.1	RP5-1050D4.2	4.93	9.42e-07	9.62e-05	0.28	0.15	Platelet count;	chr17:5028258	chr17:4972851~4974681:+
BRCA	cis	rs1876905	0.597	rs354538	ENSG00000271789.1	RP5-1112D6.7	-4.93	9.42e-07	9.62e-05	-0.22	-0.15	Mean corpuscular hemoglobin;	chr6:111196863	chr6:111297126~111298510:+
BRCA	cis	rs17213965	0.561	rs8048091	ENSG00000260872.1	RP11-680G24.5	-4.93	9.42e-07	9.62e-05	-0.18	-0.15	Waist-hip ratio;	chr16:15787633	chr16:15018106~15020488:-
BRCA	cis	rs539096	0.872	rs631248	ENSG00000236200.4	KDM4A-AS1	-4.93	9.42e-07	9.62e-05	-0.18	-0.15	Intelligence (multi-trait analysis);	chr1:43605550	chr1:43699765~43708138:-
BRCA	cis	rs60695258	0.726	rs1471251	ENSG00000251411.1	RP11-397E7.4	4.93	9.42e-07	9.62e-05	0.16	0.15	Hematocrit;	chr4:87055207	chr4:86913266~86914817:-
BRCA	cis	rs11098499	0.564	rs11098507	ENSG00000249244.1	RP11-548H18.2	4.93	9.42e-07	9.62e-05	0.17	0.15	Corneal astigmatism;	chr4:119367131	chr4:119391831~119395335:-
BRCA	cis	rs854765	0.547	rs9896837	ENSG00000197815.4	RP1-253P7.4	-4.93	9.42e-07	9.62e-05	-0.11	-0.15	Total body bone mineral density;	chr17:18021554	chr17:17858227~17860041:+
BRCA	cis	rs10504130	0.735	rs12679287	ENSG00000253844.1	RP11-546K22.1	-4.93	9.42e-07	9.63e-05	-0.23	-0.15	Venous thromboembolism (SNP x SNP interaction);	chr8:51925568	chr8:51961458~52022974:+
BRCA	cis	rs3764021	0.87	rs2192437	ENSG00000256673.1	RP11-599J14.2	-4.93	9.43e-07	9.63e-05	-0.17	-0.15	Type 1 diabetes;	chr12:9726639	chr12:9398355~9414851:-
BRCA	cis	rs3764021	0.87	rs10844617	ENSG00000256673.1	RP11-599J14.2	-4.93	9.43e-07	9.63e-05	-0.17	-0.15	Type 1 diabetes;	chr12:9726772	chr12:9398355~9414851:-
BRCA	cis	rs2273156	0.706	rs7153331	ENSG00000226677.3	IGBP1P1	-4.93	9.43e-07	9.63e-05	-0.24	-0.15	Immunoglobulin light chain (AL) amyloidosis;	chr14:35032464	chr14:34939324~34940332:+
BRCA	cis	rs7246657	0.722	rs1975937	ENSG00000276846.1	CTD-3220F14.3	4.93	9.44e-07	9.64e-05	0.2	0.15	Coronary artery calcification;	chr19:37601031	chr19:37314868~37315620:-
BRCA	cis	rs780094	0.5	rs13002853	ENSG00000234072.1	AC074117.10	4.93	9.44e-07	9.64e-05	0.17	0.15	Urate levels in overweight individuals;C-reactive protein;Metabolic syndrome;Red blood cell count;Renal underexcretion gout;Nonalcoholic fatty liver disease;Age-related diseases, mortality and associated endophenotypes;Crohn's disease;Calcium levels;Fasting plasma glucose;Metabolic traits;Fasting blood glucose;Fasting blood insulin;Urate levels in obese individuals;Alcohol consumption (drinks per week);Height;Urate levels;Gondoic acid (20:1n-9) levels;Uric acid levels;Age-related disease endophenotypes;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Homeostasis model assessment of insulin resistance;Alcohol consumption;Fasting blood insulin (BMI interaction);Triglycerides;Fasting blood glucose (BMI interaction);Hypertriglyceridemia;LDL cholesterol;Type 2 diabetes;Triglyceride levels;	chr2:27630378	chr2:27356246~27367622:+
BRCA	cis	rs7267979	1	rs2500418	ENSG00000276952.1	RP5-965G21.6	-4.93	9.45e-07	9.65e-05	-0.19	-0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25401632	chr20:25284915~25285588:-
BRCA	cis	rs4218	0.681	rs1074701	ENSG00000277144.1	RP11-59H7.4	-4.93	9.45e-07	9.65e-05	-0.19	-0.15	Social communication problems;	chr15:59073862	chr15:59115547~59116089:-
BRCA	cis	rs2638953	0.924	rs12368745	ENSG00000247934.4	RP11-967K21.1	-4.93	9.45e-07	9.65e-05	-0.21	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28396198	chr12:28163298~28190738:-
BRCA	cis	rs2115630	1	rs2879828	ENSG00000259295.5	CSPG4P12	-4.93	9.46e-07	9.66e-05	-0.18	-0.15	P wave terminal force;	chr15:84818746	chr15:85191438~85213905:+
BRCA	cis	rs7246657	0.722	rs2972437	ENSG00000276846.1	CTD-3220F14.3	4.93	9.46e-07	9.66e-05	0.2	0.15	Coronary artery calcification;	chr19:37719610	chr19:37314868~37315620:-
BRCA	cis	rs4908760	0.965	rs10864353	ENSG00000232912.4	RP5-1115A15.1	4.93	9.47e-07	9.67e-05	0.15	0.15	Vitiligo;	chr1:8489656	chr1:8424645~8434838:+
BRCA	cis	rs9840812	0.861	rs1153871	ENSG00000273486.1	RP11-731C17.2	4.93	9.47e-07	9.67e-05	0.19	0.15	Fibrinogen levels;	chr3:136235757	chr3:136837338~136839021:-
BRCA	cis	rs10504130	1	rs58561048	ENSG00000272024.1	RP11-546K22.3	-4.93	9.47e-07	9.67e-05	-0.27	-0.15	Venous thromboembolism (SNP x SNP interaction);	chr8:51789982	chr8:51950284~51950690:+
BRCA	cis	rs10504130	1	rs11778849	ENSG00000272024.1	RP11-546K22.3	-4.93	9.47e-07	9.67e-05	-0.27	-0.15	Venous thromboembolism (SNP x SNP interaction);	chr8:51795694	chr8:51950284~51950690:+
BRCA	cis	rs7246657	0.525	rs1667357	ENSG00000267422.1	CTD-2554C21.1	-4.93	9.47e-07	9.67e-05	-0.24	-0.15	Coronary artery calcification;	chr19:36993450	chr19:37779686~37792865:+
BRCA	cis	rs7246657	0.525	rs1667359	ENSG00000267422.1	CTD-2554C21.1	-4.93	9.47e-07	9.67e-05	-0.24	-0.15	Coronary artery calcification;	chr19:36995270	chr19:37779686~37792865:+
BRCA	cis	rs2243480	0.706	rs34466769	ENSG00000232559.3	GS1-124K5.12	4.93	9.47e-07	9.67e-05	0.24	0.15	Diabetic kidney disease;	chr7:65988305	chr7:66554588~66576923:-
BRCA	cis	rs13325613	0.915	rs36078103	ENSG00000223552.1	RP11-24F11.2	-4.93	9.47e-07	9.67e-05	-0.32	-0.15	Monocyte count;	chr3:46270291	chr3:46364955~46407059:-
BRCA	cis	rs13325613	0.915	rs35373513	ENSG00000223552.1	RP11-24F11.2	-4.93	9.47e-07	9.67e-05	-0.32	-0.15	Monocyte count;	chr3:46271462	chr3:46364955~46407059:-
BRCA	cis	rs2073316	0.559	rs7602067	ENSG00000272716.1	RP11-563N4.1	4.93	9.48e-07	9.68e-05	0.16	0.15	Interleukin-18 levels;	chr2:31475574	chr2:32165046~32165757:-
BRCA	cis	rs1440410	0.56	rs300941	ENSG00000250326.1	RP11-284M14.1	-4.93	9.48e-07	9.68e-05	-0.18	-0.15	Ischemic stroke;	chr4:143252387	chr4:142933195~143184861:-
BRCA	cis	rs1707322	1	rs785469	ENSG00000234329.1	RP11-767N6.2	-4.93	9.48e-07	9.68e-05	-0.15	-0.15	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46055419	chr1:45651039~45651826:-
BRCA	cis	rs1707322	1	rs785468	ENSG00000234329.1	RP11-767N6.2	-4.93	9.48e-07	9.68e-05	-0.15	-0.15	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46055845	chr1:45651039~45651826:-
BRCA	cis	rs1440410	0.804	rs12647238	ENSG00000250326.1	RP11-284M14.1	-4.93	9.49e-07	9.68e-05	-0.17	-0.15	Ischemic stroke;	chr4:143141504	chr4:142933195~143184861:-
BRCA	cis	rs1440410	0.804	rs13146326	ENSG00000250326.1	RP11-284M14.1	-4.93	9.49e-07	9.68e-05	-0.17	-0.15	Ischemic stroke;	chr4:143155588	chr4:142933195~143184861:-
BRCA	cis	rs1440410	0.748	rs4690774	ENSG00000250326.1	RP11-284M14.1	-4.93	9.49e-07	9.68e-05	-0.17	-0.15	Ischemic stroke;	chr4:143164174	chr4:142933195~143184861:-
BRCA	cis	rs9868809	0.505	rs28567949	ENSG00000270441.1	RP11-694I15.7	4.93	9.49e-07	9.69e-05	0.26	0.15	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48707127	chr3:49140086~49160851:-
BRCA	cis	rs6832769	0.696	rs7660054	ENSG00000272969.1	RP11-528I4.2	4.93	9.5e-07	9.7e-05	0.18	0.15	Personality dimensions;	chr4:55402340	chr4:55547112~55547889:+
BRCA	cis	rs7572733	0.514	rs770659	ENSG00000231621.1	AC013264.2	-4.93	9.5e-07	9.7e-05	-0.15	-0.15	Dermatomyositis;	chr2:197805030	chr2:197197991~197199273:+
BRCA	cis	rs700651	0.821	rs700663	ENSG00000231621.1	AC013264.2	-4.93	9.5e-07	9.7e-05	-0.15	-0.15	Intracranial aneurysm;	chr2:197805754	chr2:197197991~197199273:+
BRCA	cis	rs7572733	0.534	rs700664	ENSG00000231621.1	AC013264.2	-4.93	9.5e-07	9.7e-05	-0.15	-0.15	Dermatomyositis;	chr2:197806421	chr2:197197991~197199273:+
BRCA	cis	rs1124769	0.57	rs7181593	ENSG00000259378.1	DCAF13P3	-4.93	9.5e-07	9.7e-05	-0.2	-0.15	Cognitive performance;	chr15:50853917	chr15:50944663~50945996:+
BRCA	cis	rs801193	0.569	rs11772819	ENSG00000236529.1	RP13-254B10.1	4.93	9.5e-07	9.7e-05	0.17	0.15	Aortic root size;	chr7:66752983	chr7:65840212~65840596:+
BRCA	cis	rs801193	0.569	rs7800620	ENSG00000236529.1	RP13-254B10.1	4.93	9.5e-07	9.7e-05	0.17	0.15	Aortic root size;	chr7:66758701	chr7:65840212~65840596:+
BRCA	cis	rs8031584	0.918	rs61997138	ENSG00000270015.1	RP11-540B6.6	-4.93	9.51e-07	9.7e-05	-0.16	-0.15	Huntington's disease progression;	chr15:30978573	chr15:30926514~30928407:+
BRCA	cis	rs4218	0.608	rs59282449	ENSG00000277144.1	RP11-59H7.4	-4.93	9.51e-07	9.7e-05	-0.2	-0.15	Social communication problems;	chr15:59078881	chr15:59115547~59116089:-
BRCA	cis	rs17772222	0.682	rs2401751	ENSG00000258789.1	RP11-507K2.3	4.93	9.51e-07	9.71e-05	0.17	0.15	Coronary artery calcification;	chr14:88480278	chr14:88551597~88552493:+
BRCA	cis	rs4218	0.681	rs7178935	ENSG00000277144.1	RP11-59H7.4	-4.93	9.51e-07	9.71e-05	-0.19	-0.15	Social communication problems;	chr15:59075968	chr15:59115547~59116089:-
BRCA	cis	rs13326165	0.585	rs7638204	ENSG00000243224.1	RP5-1157M23.2	-4.93	9.52e-07	9.71e-05	-0.25	-0.15	HDL cholesterol levels;HDL cholesterol;	chr3:52244225	chr3:52239258~52241097:+
BRCA	cis	rs1030877	0.515	rs3828300	ENSG00000235319.1	AC012360.4	4.93	9.52e-07	9.71e-05	0.22	0.15	Obesity-related traits;	chr2:105284650	chr2:105324210~105330529:+
BRCA	cis	rs6596100	0.956	rs67476324	ENSG00000248648.1	RP11-485M7.1	-4.93	9.52e-07	9.72e-05	-0.19	-0.15	Breast cancer;	chr5:133046088	chr5:133003119~133003365:+
BRCA	cis	rs4356203	0.818	rs214927	ENSG00000272034.1	SNORD14A	-4.93	9.52e-07	9.72e-05	-0.15	-0.15	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17209698	chr11:17074654~17074744:-
BRCA	cis	rs7246967	0.551	rs62121805	ENSG00000198153.8	ZNF849P	-4.93	9.52e-07	9.72e-05	-0.29	-0.15	Bronchopulmonary dysplasia;	chr19:22726178	chr19:22685167~22686732:+
BRCA	cis	rs17685	0.712	rs10271413	ENSG00000280388.1	RP11-229D13.3	-4.93	9.53e-07	9.72e-05	-0.16	-0.15	Coffee consumption (cups per day);Coffee consumption;	chr7:76125540	chr7:76043977~76045963:-
BRCA	cis	rs35740288	0.822	rs11629690	ENSG00000259407.1	RP11-158M2.3	-4.93	9.53e-07	9.72e-05	-0.2	-0.15	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85744493	chr15:85744109~85750281:-
BRCA	cis	rs7976269	0.559	rs10843313	ENSG00000275476.1	RP11-996F15.4	-4.93	9.53e-07	9.72e-05	-0.18	-0.15	Male-pattern baldness;	chr12:29078317	chr12:29277397~29277882:-
BRCA	cis	rs2704588	0.505	rs9999793	ENSG00000270720.1	RP11-84C13.2	-4.93	9.54e-07	9.73e-05	-0.31	-0.15	Longevity;	chr4:89005389	chr4:89119284~89119871:+
BRCA	cis	rs8031584	0.958	rs7176569	ENSG00000270015.1	RP11-540B6.6	4.93	9.54e-07	9.73e-05	0.16	0.15	Huntington's disease progression;	chr15:30952292	chr15:30926514~30928407:+
BRCA	cis	rs3176789	1	rs3176789	ENSG00000256673.1	RP11-599J14.2	4.93	9.54e-07	9.73e-05	0.19	0.15	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9760134	chr12:9398355~9414851:-
BRCA	cis	rs13325613	0.915	rs13065351	ENSG00000223552.1	RP11-24F11.2	-4.93	9.54e-07	9.73e-05	-0.32	-0.15	Monocyte count;	chr3:46286021	chr3:46364955~46407059:-
BRCA	cis	rs13325613	0.915	rs13071469	ENSG00000223552.1	RP11-24F11.2	-4.93	9.54e-07	9.73e-05	-0.32	-0.15	Monocyte count;	chr3:46287136	chr3:46364955~46407059:-
BRCA	cis	rs13325613	0.915	rs35218998	ENSG00000223552.1	RP11-24F11.2	-4.93	9.54e-07	9.73e-05	-0.32	-0.15	Monocyte count;	chr3:46287224	chr3:46364955~46407059:-
BRCA	cis	rs13325613	0.915	rs13093063	ENSG00000223552.1	RP11-24F11.2	-4.93	9.54e-07	9.73e-05	-0.32	-0.15	Monocyte count;	chr3:46287877	chr3:46364955~46407059:-
BRCA	cis	rs13325613	0.915	rs13077302	ENSG00000223552.1	RP11-24F11.2	-4.93	9.54e-07	9.73e-05	-0.32	-0.15	Monocyte count;	chr3:46287984	chr3:46364955~46407059:-
BRCA	cis	rs13325613	0.915	rs13078564	ENSG00000223552.1	RP11-24F11.2	-4.93	9.54e-07	9.73e-05	-0.32	-0.15	Monocyte count;	chr3:46288714	chr3:46364955~46407059:-
BRCA	cis	rs7577696	0.925	rs212695	ENSG00000272716.1	RP11-563N4.1	4.93	9.54e-07	9.74e-05	0.17	0.15	Inflammatory biomarkers;	chr2:32215799	chr2:32165046~32165757:-
BRCA	cis	rs372883	0.53	rs55921835	ENSG00000215533.7	LINC00189	-4.93	9.54e-07	9.74e-05	-0.18	-0.15	Pancreatic cancer;	chr21:29172302	chr21:29193480~29288205:+
BRCA	cis	rs78487399	0.71	rs76215753	ENSG00000234936.1	AC010883.5	4.93	9.55e-07	9.74e-05	0.27	0.15	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43370003	chr2:43229573~43233394:+
BRCA	cis	rs792448	0.701	rs3099112	ENSG00000226251.4	RP11-15I11.3	-4.93	9.55e-07	9.74e-05	-0.2	-0.15	White blood cell count (basophil);	chr1:212369068	chr1:212225278~212238977:-
BRCA	cis	rs2489715	1	rs2489715	ENSG00000185904.10	LINC00839	-4.93	9.55e-07	9.74e-05	-0.2	-0.15	Helix rolling;	chr10:42422028	chr10:42475543~42495336:+
BRCA	cis	rs7829975	0.688	rs7817376	ENSG00000253981.4	ALG1L13P	-4.93	9.56e-07	9.75e-05	-0.17	-0.15	Mood instability;	chr8:8523020	chr8:8236003~8244667:-
BRCA	cis	rs875971	0.825	rs1129531	ENSG00000236529.1	RP13-254B10.1	-4.93	9.56e-07	9.76e-05	-0.17	-0.15	Aortic root size;	chr7:66154117	chr7:65840212~65840596:+
BRCA	cis	rs13325613	0.915	rs34073838	ENSG00000223552.1	RP11-24F11.2	-4.93	9.56e-07	9.76e-05	-0.32	-0.15	Monocyte count;	chr3:46296201	chr3:46364955~46407059:-
BRCA	cis	rs11098499	0.575	rs907204	ENSG00000260404.2	RP11-384K6.6	4.93	9.56e-07	9.76e-05	0.14	0.15	Corneal astigmatism;	chr4:119317499	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.575	rs907205	ENSG00000260404.2	RP11-384K6.6	4.93	9.56e-07	9.76e-05	0.14	0.15	Corneal astigmatism;	chr4:119317509	chr4:118591773~118633729:+
BRCA	cis	rs73193808	0.901	rs2056864	ENSG00000236056.1	GAPDHP14	-4.93	9.57e-07	9.76e-05	-0.22	-0.15	Coronary artery disease;	chr21:29196085	chr21:29222321~29223257:+
BRCA	cis	rs875971	0.964	rs778721	ENSG00000223473.2	GS1-124K5.3	4.93	9.57e-07	9.76e-05	0.12	0.15	Aortic root size;	chr7:66380410	chr7:66491049~66493566:-
BRCA	cis	rs1722141	0.669	rs2462684	ENSG00000237471.1	AC073115.6	-4.93	9.57e-07	9.76e-05	-0.2	-0.15	Sitting height ratio;	chr7:45999922	chr7:45969657~45980191:+
BRCA	cis	rs1722141	0.669	rs700744	ENSG00000237471.1	AC073115.6	4.93	9.57e-07	9.76e-05	0.2	0.15	Sitting height ratio;	chr7:45998408	chr7:45969657~45980191:+
BRCA	cis	rs1722141	0.705	rs1085925	ENSG00000237471.1	AC073115.6	4.93	9.57e-07	9.76e-05	0.2	0.15	Sitting height ratio;	chr7:46002166	chr7:45969657~45980191:+
BRCA	cis	rs6430585	0.583	rs59213715	ENSG00000231890.6	DARS-AS1	-4.93	9.57e-07	9.76e-05	-0.24	-0.15	Corneal structure;	chr2:135889012	chr2:135985176~136022593:+
BRCA	cis	rs2243480	1	rs1638734	ENSG00000275400.1	RP4-756H11.5	4.93	9.57e-07	9.77e-05	0.28	0.15	Diabetic kidney disease;	chr7:66632552	chr7:66553805~66554199:-
BRCA	cis	rs7226408	0.802	rs11665058	ENSG00000267707.2	RP11-95O2.5	4.93	9.57e-07	9.77e-05	0.23	0.15	Obesity-related traits;	chr18:36889589	chr18:37243776~37247506:+
BRCA	cis	rs6441961	0.628	rs6783993	ENSG00000223552.1	RP11-24F11.2	-4.93	9.58e-07	9.77e-05	-0.19	-0.15	Celiac disease;	chr3:46302202	chr3:46364955~46407059:-
BRCA	cis	rs4218	0.648	rs1074702	ENSG00000277144.1	RP11-59H7.4	-4.93	9.58e-07	9.77e-05	-0.2	-0.15	Social communication problems;	chr15:59073900	chr15:59115547~59116089:-
BRCA	cis	rs2638953	0.64	rs1511549	ENSG00000247934.4	RP11-967K21.1	-4.93	9.58e-07	9.77e-05	-0.19	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28578968	chr12:28163298~28190738:-
BRCA	cis	rs78487399	0.71	rs75607314	ENSG00000234936.1	AC010883.5	4.93	9.58e-07	9.77e-05	0.25	0.15	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43492552	chr2:43229573~43233394:+
BRCA	cis	rs78487399	0.808	rs78497923	ENSG00000234936.1	AC010883.5	4.93	9.58e-07	9.77e-05	0.25	0.15	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43495843	chr2:43229573~43233394:+
BRCA	cis	rs12501370	0.569	rs12509038	ENSG00000201736.1	RNA5SP160	-4.93	9.58e-07	9.77e-05	-0.17	-0.15	Iris color (L* coordinate);	chr4:40978720	chr4:40990154~40990273:+
BRCA	cis	rs6496044	0.568	rs3743321	ENSG00000259295.5	CSPG4P12	4.93	9.58e-07	9.78e-05	0.18	0.15	Interstitial lung disease;	chr15:85521737	chr15:85191438~85213905:+
BRCA	cis	rs9473147	0.516	rs7754282	ENSG00000270761.1	RP11-385F7.1	4.93	9.58e-07	9.78e-05	0.16	0.15	Platelet distribution width;Mean platelet volume;	chr6:47534288	chr6:47477243~47477572:-
BRCA	cis	rs1371614	0.501	rs4992933	ENSG00000229122.1	AGBL5-IT1	4.93	9.59e-07	9.78e-05	0.16	0.15	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26956104	chr2:27061038~27061815:+
BRCA	cis	rs12501370	0.569	rs1032984	ENSG00000201736.1	RNA5SP160	-4.93	9.59e-07	9.79e-05	-0.18	-0.15	Iris color (L* coordinate);	chr4:40980727	chr4:40990154~40990273:+
BRCA	cis	rs6840360	0.642	rs7682837	ENSG00000251603.1	RP11-164P12.4	-4.93	9.6e-07	9.79e-05	-0.14	-0.15	Intelligence (multi-trait analysis);	chr4:151506534	chr4:151667224~151670502:+
BRCA	cis	rs11098499	0.708	rs1546506	ENSG00000260404.2	RP11-384K6.6	4.93	9.6e-07	9.79e-05	0.14	0.15	Corneal astigmatism;	chr4:119320085	chr4:118591773~118633729:+
BRCA	cis	rs2278170	1	rs331532	ENSG00000225101.4	OR52K3P	-4.93	9.6e-07	9.79e-05	-0.2	-0.15	Amyotrophic lateral sclerosis;	chr11:4456865	chr11:4474813~4475755:+
BRCA	cis	rs12439619	0.846	rs62010071	ENSG00000255769.6	GOLGA2P10	-4.93	9.6e-07	9.79e-05	-0.22	-0.15	Intelligence (multi-trait analysis);	chr15:82289442	chr15:82472993~82513950:-
BRCA	cis	rs7246657	0.722	rs8103647	ENSG00000276846.1	CTD-3220F14.3	4.93	9.61e-07	9.8e-05	0.2	0.15	Coronary artery calcification;	chr19:37609551	chr19:37314868~37315620:-
BRCA	cis	rs62103177	0.713	rs62103186	ENSG00000261126.6	RP11-795F19.1	4.93	9.61e-07	9.8e-05	0.23	0.15	Opioid sensitivity;	chr18:79867574	chr18:80046900~80095482:+
BRCA	cis	rs62103177	0.81	rs62103187	ENSG00000261126.6	RP11-795F19.1	4.93	9.61e-07	9.8e-05	0.23	0.15	Opioid sensitivity;	chr18:79867633	chr18:80046900~80095482:+
BRCA	cis	rs62103177	0.81	rs62103188	ENSG00000261126.6	RP11-795F19.1	4.93	9.61e-07	9.8e-05	0.23	0.15	Opioid sensitivity;	chr18:79867661	chr18:80046900~80095482:+
BRCA	cis	rs7226408	0.857	rs72888928	ENSG00000267707.2	RP11-95O2.5	4.93	9.61e-07	9.8e-05	0.23	0.15	Obesity-related traits;	chr18:36951110	chr18:37243776~37247506:+
BRCA	cis	rs10752881	1	rs10752881	ENSG00000224468.3	RP11-181K3.4	-4.93	9.61e-07	9.8e-05	-0.16	-0.15	Colorectal cancer;	chr1:183004356	chr1:183138402~183141282:-
BRCA	cis	rs2235544	0.579	rs11804837	ENSG00000225183.1	RP4-758J24.4	-4.93	9.61e-07	9.8e-05	-0.18	-0.15	Thyroid hormone levels;Multiple myeloma (hyperdiploidy);	chr1:54017242	chr1:54089856~54090093:+
BRCA	cis	rs4415084	0.966	rs4492118	ENSG00000251141.4	RP11-53O19.1	4.93	9.61e-07	9.8e-05	0.14	0.15	Breast cancer;	chr5:44646523	chr5:44744900~44808777:-
BRCA	cis	rs16958440	0.867	rs76922914	ENSG00000280212.1	RP11-49K24.3	4.93	9.61e-07	9.8e-05	0.35	0.15	Sitting height ratio;	chr18:47162083	chr18:47076117~47076594:+
BRCA	cis	rs595982	0.559	rs17272680	ENSG00000235191.1	NUCB1-AS1	-4.93	9.61e-07	9.8e-05	-0.25	-0.15	Red cell distribution width;	chr19:48861254	chr19:48910930~48918891:-
BRCA	cis	rs2278170	0.962	rs1864499	ENSG00000225101.4	OR52K3P	-4.93	9.62e-07	9.81e-05	-0.2	-0.15	Amyotrophic lateral sclerosis;	chr11:4458002	chr11:4474813~4475755:+
BRCA	cis	rs12497850	0.864	rs7431857	ENSG00000225399.4	RP11-3B7.1	4.93	9.62e-07	9.81e-05	0.15	0.15	Parkinson's disease;	chr3:48862914	chr3:49260085~49261316:+
BRCA	cis	rs595982	0.559	rs17206700	ENSG00000235191.1	NUCB1-AS1	4.93	9.62e-07	9.81e-05	0.25	0.15	Red cell distribution width;	chr19:48857998	chr19:48910930~48918891:-
BRCA	cis	rs2562456	0.561	rs12610883	ENSG00000268658.4	LINC00664	4.93	9.63e-07	9.82e-05	0.24	0.15	Pain;	chr19:21567257	chr19:21483374~21503238:+
BRCA	cis	rs2562456	0.837	rs11085462	ENSG00000268658.4	LINC00664	4.93	9.63e-07	9.82e-05	0.24	0.15	Pain;	chr19:21567449	chr19:21483374~21503238:+
BRCA	cis	rs6754311	0.517	rs1865452	ENSG00000224043.6	CCNT2-AS1	-4.93	9.63e-07	9.82e-05	-0.24	-0.15	Mosquito bite size;	chr2:135781760	chr2:134735464~134918710:-
BRCA	cis	rs7226408	0.857	rs11662905	ENSG00000267707.2	RP11-95O2.5	4.93	9.63e-07	9.82e-05	0.23	0.15	Obesity-related traits;	chr18:36853307	chr18:37243776~37247506:+
BRCA	cis	rs7226408	0.857	rs7234586	ENSG00000267707.2	RP11-95O2.5	4.93	9.63e-07	9.82e-05	0.23	0.15	Obesity-related traits;	chr18:36854671	chr18:37243776~37247506:+
BRCA	cis	rs7226408	0.749	rs4539671	ENSG00000267707.2	RP11-95O2.5	4.93	9.63e-07	9.82e-05	0.23	0.15	Obesity-related traits;	chr18:36855043	chr18:37243776~37247506:+
BRCA	cis	rs7226408	0.749	rs11664744	ENSG00000267707.2	RP11-95O2.5	4.93	9.63e-07	9.82e-05	0.23	0.15	Obesity-related traits;	chr18:36855148	chr18:37243776~37247506:+
BRCA	cis	rs7226408	0.857	rs59634585	ENSG00000267707.2	RP11-95O2.5	4.93	9.63e-07	9.82e-05	0.23	0.15	Obesity-related traits;	chr18:36857069	chr18:37243776~37247506:+
BRCA	cis	rs7226408	0.857	rs2162389	ENSG00000267707.2	RP11-95O2.5	4.93	9.63e-07	9.82e-05	0.23	0.15	Obesity-related traits;	chr18:36857070	chr18:37243776~37247506:+
BRCA	cis	rs7226408	0.802	rs72885272	ENSG00000267707.2	RP11-95O2.5	4.93	9.63e-07	9.82e-05	0.23	0.15	Obesity-related traits;	chr18:36857693	chr18:37243776~37247506:+
BRCA	cis	rs7226408	0.857	rs72885273	ENSG00000267707.2	RP11-95O2.5	4.93	9.63e-07	9.82e-05	0.23	0.15	Obesity-related traits;	chr18:36858575	chr18:37243776~37247506:+
BRCA	cis	rs7226408	0.857	rs72885275	ENSG00000267707.2	RP11-95O2.5	4.93	9.63e-07	9.82e-05	0.23	0.15	Obesity-related traits;	chr18:36859661	chr18:37243776~37247506:+
BRCA	cis	rs7226408	0.857	rs61044601	ENSG00000267707.2	RP11-95O2.5	4.93	9.63e-07	9.82e-05	0.23	0.15	Obesity-related traits;	chr18:36860216	chr18:37243776~37247506:+
BRCA	cis	rs7226408	0.857	rs72885287	ENSG00000267707.2	RP11-95O2.5	4.93	9.63e-07	9.82e-05	0.23	0.15	Obesity-related traits;	chr18:36866696	chr18:37243776~37247506:+
BRCA	cis	rs7226408	0.857	rs55752284	ENSG00000267707.2	RP11-95O2.5	4.93	9.63e-07	9.82e-05	0.23	0.15	Obesity-related traits;	chr18:36867212	chr18:37243776~37247506:+
BRCA	cis	rs7226408	0.857	rs34250790	ENSG00000267707.2	RP11-95O2.5	4.93	9.63e-07	9.82e-05	0.23	0.15	Obesity-related traits;	chr18:36868017	chr18:37243776~37247506:+
BRCA	cis	rs7226408	0.817	rs55766643	ENSG00000267707.2	RP11-95O2.5	4.93	9.63e-07	9.82e-05	0.23	0.15	Obesity-related traits;	chr18:36868106	chr18:37243776~37247506:+
BRCA	cis	rs7226408	0.857	rs56822468	ENSG00000267707.2	RP11-95O2.5	4.93	9.63e-07	9.82e-05	0.23	0.15	Obesity-related traits;	chr18:36868954	chr18:37243776~37247506:+
BRCA	cis	rs7226408	0.857	rs72885291	ENSG00000267707.2	RP11-95O2.5	4.93	9.63e-07	9.82e-05	0.23	0.15	Obesity-related traits;	chr18:36869381	chr18:37243776~37247506:+
BRCA	cis	rs7226408	0.857	rs2007524	ENSG00000267707.2	RP11-95O2.5	4.93	9.63e-07	9.82e-05	0.23	0.15	Obesity-related traits;	chr18:36870179	chr18:37243776~37247506:+
BRCA	cis	rs7226408	0.802	rs59419623	ENSG00000267707.2	RP11-95O2.5	4.93	9.63e-07	9.82e-05	0.23	0.15	Obesity-related traits;	chr18:36870405	chr18:37243776~37247506:+
BRCA	cis	rs4950322	0.58	rs7514970	ENSG00000244371.2	PFN1P8	-4.93	9.64e-07	9.83e-05	-0.2	-0.15	Protein quantitative trait loci;	chr1:147120516	chr1:146957117~146957659:-
BRCA	cis	rs10504130	1	rs75221577	ENSG00000253844.1	RP11-546K22.1	-4.93	9.64e-07	9.83e-05	-0.26	-0.15	Venous thromboembolism (SNP x SNP interaction);	chr8:51856812	chr8:51961458~52022974:+
BRCA	cis	rs10504130	1	rs74681723	ENSG00000253844.1	RP11-546K22.1	-4.93	9.64e-07	9.83e-05	-0.26	-0.15	Venous thromboembolism (SNP x SNP interaction);	chr8:51857932	chr8:51961458~52022974:+
BRCA	cis	rs919433	0.679	rs1598469	ENSG00000231621.1	AC013264.2	-4.93	9.65e-07	9.84e-05	-0.15	-0.15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197650934	chr2:197197991~197199273:+
BRCA	cis	rs919433	0.679	rs10203581	ENSG00000231621.1	AC013264.2	-4.93	9.65e-07	9.84e-05	-0.15	-0.15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197651176	chr2:197197991~197199273:+
BRCA	cis	rs3781264	0.583	rs4394764	ENSG00000273450.1	RP11-76P2.4	4.93	9.66e-07	9.85e-05	0.24	0.15	Esophageal cancer and gastric cancer;	chr10:94302036	chr10:94314907~94315327:-
BRCA	cis	rs7226408	0.857	rs17652769	ENSG00000267707.2	RP11-95O2.5	4.93	9.66e-07	9.85e-05	0.23	0.15	Obesity-related traits;	chr18:37151865	chr18:37243776~37247506:+
BRCA	cis	rs6442522	0.606	rs3773459	ENSG00000249786.6	EAF1-AS1	4.93	9.66e-07	9.85e-05	0.16	0.15	Uric acid levels;	chr3:15454137	chr3:15436171~15455940:-
BRCA	cis	rs6442522	0.606	rs3773458	ENSG00000249786.6	EAF1-AS1	4.93	9.66e-07	9.85e-05	0.16	0.15	Uric acid levels;	chr3:15454147	chr3:15436171~15455940:-
BRCA	cis	rs12681366	0.537	rs10956914	ENSG00000253704.1	RP11-267M23.4	-4.93	9.66e-07	9.85e-05	-0.16	-0.15	Nonsyndromic cleft lip with cleft palate;	chr8:94471495	chr8:94553722~94569745:+
BRCA	cis	rs7542375	0.507	rs2784270	ENSG00000272823.1	RP11-295M18.6	4.93	9.67e-07	9.85e-05	0.16	0.15	Obesity-related traits;	chr1:220921625	chr1:220828676~220829211:-
BRCA	cis	rs11098499	0.913	rs68128210	ENSG00000249244.1	RP11-548H18.2	4.93	9.67e-07	9.85e-05	0.19	0.15	Corneal astigmatism;	chr4:119216664	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.913	rs13126596	ENSG00000249244.1	RP11-548H18.2	4.93	9.67e-07	9.85e-05	0.19	0.15	Corneal astigmatism;	chr4:119219574	chr4:119391831~119395335:-
BRCA	cis	rs875971	0.964	rs697969	ENSG00000223473.2	GS1-124K5.3	-4.93	9.67e-07	9.86e-05	-0.12	-0.15	Aortic root size;	chr7:66093491	chr7:66491049~66493566:-
BRCA	cis	rs875971	1	rs1182882	ENSG00000223473.2	GS1-124K5.3	-4.93	9.67e-07	9.86e-05	-0.12	-0.15	Aortic root size;	chr7:66097076	chr7:66491049~66493566:-
BRCA	cis	rs6479901	0.557	rs4746125	ENSG00000232075.1	MRPL35P2	4.93	9.67e-07	9.86e-05	0.26	0.15	Intelligence (multi-trait analysis);	chr10:63393125	chr10:63634317~63634827:-
BRCA	cis	rs6840360	0.642	rs2709820	ENSG00000251611.1	RP11-610P16.1	-4.93	9.68e-07	9.86e-05	-0.13	-0.15	Intelligence (multi-trait analysis);	chr4:151462887	chr4:151407551~151408835:-
BRCA	cis	rs4924935	0.781	rs2472694	ENSG00000264885.1	RP11-815I9.4	-4.93	9.68e-07	9.86e-05	-0.19	-0.15	Pancreatic cancer;	chr17:18945185	chr17:18667629~18669461:-
BRCA	cis	rs4664293	0.867	rs6432558	ENSG00000224152.1	AC009506.1	-4.93	9.68e-07	9.86e-05	-0.17	-0.15	Monocyte percentage of white cells;	chr2:159745397	chr2:159615296~159617082:+
BRCA	cis	rs4664293	0.836	rs7567818	ENSG00000224152.1	AC009506.1	-4.93	9.68e-07	9.86e-05	-0.17	-0.15	Monocyte percentage of white cells;	chr2:159746186	chr2:159615296~159617082:+
BRCA	cis	rs4664293	0.867	rs12692563	ENSG00000224152.1	AC009506.1	-4.93	9.68e-07	9.86e-05	-0.17	-0.15	Monocyte percentage of white cells;	chr2:159746300	chr2:159615296~159617082:+
BRCA	cis	rs4664293	0.836	rs13397597	ENSG00000224152.1	AC009506.1	-4.93	9.68e-07	9.86e-05	-0.17	-0.15	Monocyte percentage of white cells;	chr2:159747084	chr2:159615296~159617082:+
BRCA	cis	rs1383484	1	rs4357909	ENSG00000230373.7	GOLGA6L5P	4.93	9.68e-07	9.86e-05	0.17	0.15	Height;	chr15:83846823	chr15:84507885~84516814:-
BRCA	cis	rs3764021	0.509	rs10772073	ENSG00000256673.1	RP11-599J14.2	-4.93	9.69e-07	9.87e-05	-0.19	-0.15	Type 1 diabetes;	chr12:9717428	chr12:9398355~9414851:-
BRCA	cis	rs3764021	0.509	rs10772074	ENSG00000256673.1	RP11-599J14.2	-4.93	9.69e-07	9.87e-05	-0.19	-0.15	Type 1 diabetes;	chr12:9717686	chr12:9398355~9414851:-
BRCA	cis	rs2186369	1	rs17630758	ENSG00000211683.3	KB-1572G7.3	4.93	9.7e-07	9.88e-05	0.23	0.15	IgG N-glycosylation phenotypes (multivariate analysis);IgG digalactosylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG glycosylation;IgG fucosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);	chr22:23794355	chr22:23630618~23638941:-
BRCA	cis	rs3892630	0.818	rs80137870	ENSG00000267475.1	CTD-2538C1.2	-4.93	9.7e-07	9.88e-05	-0.23	-0.15	Red blood cell traits;	chr19:32691844	chr19:32687089~32691750:-
BRCA	cis	rs4218	0.531	rs10431791	ENSG00000259732.1	RP11-59H7.3	-4.93	9.7e-07	9.88e-05	-0.17	-0.15	Social communication problems;	chr15:59055159	chr15:59121034~59133250:+
BRCA	cis	rs10419113	0.645	rs12162230	ENSG00000268545.1	VN1R107P	4.93	9.7e-07	9.89e-05	0.17	0.15	Pediatric bone mineral density (spine);	chr19:57683020	chr19:57459912~57460120:+
BRCA	cis	rs801193	0.66	rs1016265	ENSG00000223473.2	GS1-124K5.3	4.93	9.71e-07	9.89e-05	0.12	0.15	Aortic root size;	chr7:66749580	chr7:66491049~66493566:-
BRCA	cis	rs801193	0.66	rs4610622	ENSG00000223473.2	GS1-124K5.3	4.93	9.71e-07	9.89e-05	0.12	0.15	Aortic root size;	chr7:66759510	chr7:66491049~66493566:-
BRCA	cis	rs2638953	0.815	rs11049669	ENSG00000278733.1	RP11-425D17.1	4.93	9.71e-07	9.89e-05	0.2	0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28498982	chr12:28185625~28186190:-
BRCA	cis	rs6095360	0.901	rs2426120	ENSG00000222365.1	SNORD12B	-4.93	9.71e-07	9.89e-05	-0.16	-0.15	Intelligence (multi-trait analysis);	chr20:49080716	chr20:49280319~49280409:+
BRCA	cis	rs13113518	1	rs11726198	ENSG00000223305.1	RN7SKP30	4.93	9.71e-07	9.89e-05	0.18	0.15	Height;	chr4:55523835	chr4:55540502~55540835:-
BRCA	cis	rs13113518	0.966	rs11133396	ENSG00000223305.1	RN7SKP30	4.93	9.71e-07	9.89e-05	0.18	0.15	Height;	chr4:55524246	chr4:55540502~55540835:-
BRCA	cis	rs13113518	1	rs7675109	ENSG00000223305.1	RN7SKP30	4.93	9.71e-07	9.89e-05	0.18	0.15	Height;	chr4:55525589	chr4:55540502~55540835:-
BRCA	cis	rs13113518	1	rs4865005	ENSG00000223305.1	RN7SKP30	4.93	9.71e-07	9.89e-05	0.18	0.15	Height;	chr4:55525781	chr4:55540502~55540835:-
BRCA	cis	rs2880765	0.566	rs11630381	ENSG00000230373.7	GOLGA6L5P	4.93	9.71e-07	9.89e-05	0.17	0.15	Coronary artery disease;	chr15:85469272	chr15:84507885~84516814:-
BRCA	cis	rs10129255	0.957	rs12590735	ENSG00000211974.3	IGHV2-70	4.93	9.71e-07	9.9e-05	0.15	0.15	Kawasaki disease;	chr14:106779660	chr14:106723574~106724093:-
BRCA	cis	rs2408955	0.521	rs10875753	ENSG00000273765.1	RP11-370I10.11	4.93	9.72e-07	9.9e-05	0.18	0.15	Glycated hemoglobin levels;	chr12:48163358	chr12:48360920~48361377:+
BRCA	cis	rs2278702	0.622	rs3848199	ENSG00000259495.2	RP11-210M15.2	-4.93	9.72e-07	9.9e-05	-0.25	-0.15	Bipolar disorder;	chr15:80350452	chr15:80344853~80403575:-
BRCA	cis	rs7267979	0.764	rs2474767	ENSG00000274973.1	RP13-401N8.7	-4.93	9.72e-07	9.91e-05	-0.17	-0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25266097	chr20:25845497~25845862:+
BRCA	cis	rs62025270	0.688	rs12148571	ENSG00000259295.5	CSPG4P12	-4.93	9.73e-07	9.91e-05	-0.24	-0.15	Idiopathic pulmonary fibrosis;	chr15:85724162	chr15:85191438~85213905:+
BRCA	cis	rs13118159	0.55	rs1137789	ENSG00000254094.1	AC078852.1	-4.93	9.73e-07	9.91e-05	-0.18	-0.15	Longevity;	chr4:1388010	chr4:1356581~1358075:+
BRCA	cis	rs2243480	1	rs10807701	ENSG00000222364.1	RNU6-96P	4.93	9.73e-07	9.91e-05	0.27	0.15	Diabetic kidney disease;	chr7:66259699	chr7:66395191~66395286:+
BRCA	cis	rs2288912	0.838	rs2239375	ENSG00000280087.1	CTB-129P6.7	4.93	9.73e-07	9.91e-05	0.18	0.15	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr19:44956594	chr19:44909375~44914968:+
BRCA	cis	rs62103177	0.608	rs4799115	ENSG00000278000.1	AC139100.4	-4.93	9.74e-07	9.91e-05	-0.22	-0.15	Opioid sensitivity;	chr18:79976365	chr18:80161752~80162413:+
BRCA	cis	rs4950322	0.58	rs2014106	ENSG00000244371.2	PFN1P8	-4.93	9.74e-07	9.92e-05	-0.2	-0.15	Protein quantitative trait loci;	chr1:147118499	chr1:146957117~146957659:-
BRCA	cis	rs2179367	0.568	rs6932778	ENSG00000268592.3	RAET1E-AS1	4.93	9.74e-07	9.92e-05	0.23	0.15	Dupuytren's disease;	chr6:149328293	chr6:149863494~149919507:+
BRCA	cis	rs62025270	0.688	rs55957626	ENSG00000259295.5	CSPG4P12	-4.93	9.75e-07	9.93e-05	-0.24	-0.15	Idiopathic pulmonary fibrosis;	chr15:85773486	chr15:85191438~85213905:+
BRCA	cis	rs6439153	0.933	rs6799008	ENSG00000231305.3	RP11-723O4.2	4.93	9.75e-07	9.93e-05	0.17	0.15	Pneumococcal bacteremia;	chr3:128998544	chr3:128861313~128871540:-
BRCA	cis	rs7226408	0.857	rs11662124	ENSG00000267707.2	RP11-95O2.5	4.93	9.75e-07	9.93e-05	0.23	0.15	Obesity-related traits;	chr18:37148471	chr18:37243776~37247506:+
BRCA	cis	rs7226408	0.857	rs55731927	ENSG00000267707.2	RP11-95O2.5	4.93	9.75e-07	9.93e-05	0.23	0.15	Obesity-related traits;	chr18:37151468	chr18:37243776~37247506:+
BRCA	cis	rs11955398	0.585	rs9654363	ENSG00000215032.2	GNL3LP1	-4.93	9.75e-07	9.93e-05	-0.18	-0.15	Intelligence (multi-trait analysis);	chr5:60737405	chr5:60891935~60893577:-
BRCA	cis	rs7267979	0.74	rs2259961	ENSG00000277938.1	RP5-965G21.3	4.93	9.75e-07	9.93e-05	0.18	0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25301990	chr20:25229150~25231933:+
BRCA	cis	rs2832191	0.967	rs2832216	ENSG00000236056.1	GAPDHP14	-4.93	9.75e-07	9.93e-05	-0.16	-0.15	Dental caries;	chr21:29149600	chr21:29222321~29223257:+
BRCA	cis	rs10504130	1	rs75371481	ENSG00000253844.1	RP11-546K22.1	-4.93	9.75e-07	9.93e-05	-0.26	-0.15	Venous thromboembolism (SNP x SNP interaction);	chr8:51863252	chr8:51961458~52022974:+
BRCA	cis	rs10504130	1	rs77082359	ENSG00000253844.1	RP11-546K22.1	-4.93	9.75e-07	9.93e-05	-0.26	-0.15	Venous thromboembolism (SNP x SNP interaction);	chr8:51866587	chr8:51961458~52022974:+
BRCA	cis	rs10504130	1	rs74769823	ENSG00000253844.1	RP11-546K22.1	-4.93	9.75e-07	9.93e-05	-0.26	-0.15	Venous thromboembolism (SNP x SNP interaction);	chr8:51867608	chr8:51961458~52022974:+
BRCA	cis	rs10504130	1	rs79727212	ENSG00000253844.1	RP11-546K22.1	-4.93	9.75e-07	9.93e-05	-0.26	-0.15	Venous thromboembolism (SNP x SNP interaction);	chr8:51868528	chr8:51961458~52022974:+
BRCA	cis	rs10504130	1	rs77534642	ENSG00000253844.1	RP11-546K22.1	-4.93	9.75e-07	9.93e-05	-0.26	-0.15	Venous thromboembolism (SNP x SNP interaction);	chr8:51868956	chr8:51961458~52022974:+
BRCA	cis	rs10504130	1	rs16916906	ENSG00000253844.1	RP11-546K22.1	-4.93	9.75e-07	9.93e-05	-0.26	-0.15	Venous thromboembolism (SNP x SNP interaction);	chr8:51869133	chr8:51961458~52022974:+
BRCA	cis	rs10504130	0.935	rs112132091	ENSG00000253844.1	RP11-546K22.1	-4.93	9.75e-07	9.93e-05	-0.26	-0.15	Venous thromboembolism (SNP x SNP interaction);	chr8:51869344	chr8:51961458~52022974:+
BRCA	cis	rs10504130	1	rs77532876	ENSG00000253844.1	RP11-546K22.1	-4.93	9.75e-07	9.93e-05	-0.26	-0.15	Venous thromboembolism (SNP x SNP interaction);	chr8:51873542	chr8:51961458~52022974:+
BRCA	cis	rs10504130	1	rs11777714	ENSG00000253844.1	RP11-546K22.1	-4.93	9.75e-07	9.93e-05	-0.26	-0.15	Venous thromboembolism (SNP x SNP interaction);	chr8:51874273	chr8:51961458~52022974:+
BRCA	cis	rs10504130	1	rs10958300	ENSG00000253844.1	RP11-546K22.1	-4.93	9.75e-07	9.93e-05	-0.26	-0.15	Venous thromboembolism (SNP x SNP interaction);	chr8:51875389	chr8:51961458~52022974:+
BRCA	cis	rs10504130	1	rs10958301	ENSG00000253844.1	RP11-546K22.1	-4.93	9.75e-07	9.93e-05	-0.26	-0.15	Venous thromboembolism (SNP x SNP interaction);	chr8:51875676	chr8:51961458~52022974:+
BRCA	cis	rs10504130	0.932	rs77153951	ENSG00000253844.1	RP11-546K22.1	-4.93	9.75e-07	9.93e-05	-0.26	-0.15	Venous thromboembolism (SNP x SNP interaction);	chr8:51878837	chr8:51961458~52022974:+
BRCA	cis	rs10504130	0.932	rs77140083	ENSG00000253844.1	RP11-546K22.1	-4.93	9.75e-07	9.93e-05	-0.26	-0.15	Venous thromboembolism (SNP x SNP interaction);	chr8:51880352	chr8:51961458~52022974:+
BRCA	cis	rs7226408	0.857	rs72885294	ENSG00000267707.2	RP11-95O2.5	4.93	9.76e-07	9.94e-05	0.23	0.15	Obesity-related traits;	chr18:36870978	chr18:37243776~37247506:+
BRCA	cis	rs867371	0.722	rs8033050	ENSG00000276710.3	CSPG4P8	-4.93	9.76e-07	9.94e-05	-0.17	-0.15	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82269648	chr15:82459472~82477258:+
BRCA	cis	rs4664293	0.836	rs13032500	ENSG00000224152.1	AC009506.1	-4.93	9.77e-07	9.94e-05	-0.17	-0.15	Monocyte percentage of white cells;	chr2:159749740	chr2:159615296~159617082:+
BRCA	cis	rs6442522	0.526	rs909354	ENSG00000249786.6	EAF1-AS1	4.93	9.77e-07	9.95e-05	0.16	0.15	Uric acid levels;	chr3:15478737	chr3:15436171~15455940:-
BRCA	cis	rs7226408	0.857	rs72887024	ENSG00000267707.2	RP11-95O2.5	4.93	9.77e-07	9.95e-05	0.23	0.15	Obesity-related traits;	chr18:36888519	chr18:37243776~37247506:+
BRCA	cis	rs2562456	0.833	rs8106025	ENSG00000268535.1	RP11-420K14.3	-4.93	9.77e-07	9.95e-05	-0.2	-0.15	Pain;	chr19:21451922	chr19:21709522~21710191:+
BRCA	cis	rs4819052	0.851	rs34101026	ENSG00000184274.3	LINC00315	-4.93	9.77e-07	9.95e-05	-0.21	-0.15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45242285	chr21:45300245~45305257:-
BRCA	cis	rs4819052	0.851	rs2838828	ENSG00000184274.3	LINC00315	-4.93	9.77e-07	9.95e-05	-0.21	-0.15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45243508	chr21:45300245~45305257:-
BRCA	cis	rs4819052	0.851	rs13049337	ENSG00000184274.3	LINC00315	-4.93	9.77e-07	9.95e-05	-0.21	-0.15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45243545	chr21:45300245~45305257:-
BRCA	cis	rs4218	0.648	rs12441973	ENSG00000277144.1	RP11-59H7.4	-4.93	9.78e-07	9.96e-05	-0.2	-0.15	Social communication problems;	chr15:59057016	chr15:59115547~59116089:-
BRCA	cis	rs711830	0.576	rs1348807	ENSG00000272729.1	RP11-387A1.5	4.93	9.79e-07	9.96e-05	0.17	0.15	Serous invasive ovarian cancer;Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;High-grade serous ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;	chr2:176141029	chr2:176164164~176165716:-
BRCA	cis	rs62025270	0.688	rs62025297	ENSG00000259295.5	CSPG4P12	-4.93	9.79e-07	9.96e-05	-0.24	-0.15	Idiopathic pulmonary fibrosis;	chr15:85773708	chr15:85191438~85213905:+
BRCA	cis	rs7267979	0.844	rs2424703	ENSG00000277938.1	RP5-965G21.3	4.93	9.8e-07	9.97e-05	0.18	0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25289488	chr20:25229150~25231933:+
BRCA	cis	rs11098499	0.754	rs7672594	ENSG00000260404.2	RP11-384K6.6	4.93	9.8e-07	9.97e-05	0.14	0.15	Corneal astigmatism;	chr4:119327388	chr4:118591773~118633729:+
BRCA	cis	rs11955398	0.604	rs4700379	ENSG00000215032.2	GNL3LP1	4.93	9.8e-07	9.98e-05	0.18	0.15	Intelligence (multi-trait analysis);	chr5:60576565	chr5:60891935~60893577:-
BRCA	cis	rs2749097	0.609	rs2269245	ENSG00000244256.3	RN7SL130P	-4.92	9.81e-07	9.98e-05	-0.21	-0.15	Alcohol consumption (transferrin glycosylation);	chr1:63642222	chr1:63655743~63656047:+
BRCA	cis	rs11051970	0.559	rs2291421	ENSG00000274964.1	RP11-817I4.1	-4.92	9.81e-07	9.98e-05	-0.19	-0.15	Response to tocilizumab in rheumatoid arthritis;	chr12:32334173	chr12:32339368~32340724:+
BRCA	cis	rs699371	0.557	rs2286412	ENSG00000270000.1	RP3-449M8.9	4.92	9.81e-07	9.98e-05	0.19	0.15	Height;	chr14:74502464	chr14:74471930~74472360:-
BRCA	cis	rs4948275	0.773	rs1902429	ENSG00000237233.2	TMEM26-AS1	-4.92	9.81e-07	9.99e-05	-0.19	-0.15	Night sleep phenotypes;	chr10:61517317	chr10:61452639~61481956:+
BRCA	cis	rs4948275	0.773	rs2606097	ENSG00000237233.2	TMEM26-AS1	-4.92	9.81e-07	9.99e-05	-0.19	-0.15	Night sleep phenotypes;	chr10:61519195	chr10:61452639~61481956:+
BRCA	cis	rs7308116	0.546	rs11113527	ENSG00000274395.1	RP11-554D14.8	4.92	9.82e-07	9.99e-05	0.17	0.15	Pelvic organ prolapse (moderate/severe);	chr12:107830662	chr12:107835541~107836555:-
BRCA	cis	rs875971	0.964	rs778723	ENSG00000223473.2	GS1-124K5.3	4.92	9.82e-07	9.99e-05	0.11	0.15	Aortic root size;	chr7:66364510	chr7:66491049~66493566:-
BRCA	cis	rs8133949	1	rs2839434	ENSG00000237232.6	ZNF295-AS1	4.92	9.83e-07	1e-04	0.23	0.15	Hand grip strength;	chr21:41998796	chr21:42009194~42024924:+
BRCA	cis	rs2948294	0.588	rs4840913	ENSG00000253981.4	ALG1L13P	4.92	9.83e-07	1e-04	0.19	0.15	Red cell distribution width;	chr8:8259384	chr8:8236003~8244667:-
BRCA	cis	rs4711336	1	rs4711336	ENSG00000224557.6	HLA-DPB2	4.92	9.83e-07	1e-04	0.18	0.15	Height;	chr6:33691269	chr6:33112451~33129084:+
BRCA	cis	rs875971	0.867	rs1002053	ENSG00000223473.2	GS1-124K5.3	-4.92	9.84e-07	1e-04	-0.12	-0.15	Aortic root size;	chr7:66333558	chr7:66491049~66493566:-
BRCA	cis	rs8054556	1	rs3935873	ENSG00000273724.1	RP11-347C12.12	4.92	9.84e-07	1e-04	0.17	0.15	Autism spectrum disorder or schizophrenia;	chr16:30007179	chr16:30336400~30343336:+
BRCA	cis	rs12701220	0.901	rs12701710	ENSG00000229043.2	AC091729.9	4.92	9.84e-07	1e-04	0.22	0.15	Bronchopulmonary dysplasia;	chr7:1050760	chr7:1160374~1165267:+
BRCA	cis	rs4950322	0.58	rs7541393	ENSG00000278811.3	LINC00624	4.92	9.84e-07	1e-04	0.19	0.15	Protein quantitative trait loci;	chr1:147117186	chr1:147258885~147517875:-
BRCA	cis	rs8064024	0.676	rs9926458	ENSG00000267077.1	RP11-127I20.5	4.92	9.84e-07	1e-04	0.15	0.15	Cancer;	chr16:4822627	chr16:4795265~4796532:-
BRCA	cis	rs6071166	0.683	rs6071101	ENSG00000224635.1	RP4-564F22.5	-4.92	9.85e-07	1e-04	-0.18	-0.15	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38689335	chr20:38406011~38416797:-
BRCA	cis	rs6071166	0.683	rs6015637	ENSG00000224635.1	RP4-564F22.5	-4.92	9.85e-07	1e-04	-0.18	-0.15	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38689862	chr20:38406011~38416797:-
BRCA	cis	rs7646881	0.812	rs73015644	ENSG00000240207.5	RP11-379F4.4	-4.92	9.85e-07	1e-04	-0.24	-0.15	Tetralogy of Fallot;	chr3:158729955	chr3:158732263~158784070:+
BRCA	cis	rs16958440	0.867	rs58061761	ENSG00000280212.1	RP11-49K24.3	4.92	9.86e-07	1e-04	0.35	0.15	Sitting height ratio;	chr18:47159794	chr18:47076117~47076594:+
BRCA	cis	rs8098244	0.537	rs11877880	ENSG00000264745.1	TTC39C-AS1	4.92	9.86e-07	1e-04	0.18	0.15	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23716401	chr18:23994213~24015339:-
BRCA	cis	rs1722141	0.633	rs2132570	ENSG00000229628.1	AC073115.7	4.92	9.86e-07	1e-04	0.21	0.15	Sitting height ratio;	chr7:45922864	chr7:45990905~46000898:+
BRCA	cis	rs2638953	0.741	rs10843199	ENSG00000247934.4	RP11-967K21.1	4.92	9.86e-07	1e-04	0.21	0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28535711	chr12:28163298~28190738:-
BRCA	cis	rs7647973	0.516	rs4499638	ENSG00000225399.4	RP11-3B7.1	4.92	9.86e-07	1e-04	0.14	0.15	Menarche (age at onset);	chr3:49165349	chr3:49260085~49261316:+
BRCA	cis	rs2921036	0.503	rs7817832	ENSG00000254153.1	CTA-398F10.2	4.92	9.86e-07	1e-04	0.21	0.15	Neuroticism;	chr8:8523311	chr8:8456909~8461337:-
BRCA	cis	rs72843506	0.591	rs75334890	ENSG00000261033.1	RP11-209D14.2	4.92	9.86e-07	1e-04	0.29	0.15	Schizophrenia;	chr17:20318087	chr17:20008051~20009234:-
BRCA	cis	rs1218582	0.772	rs10796934	ENSG00000270361.1	RP11-307C12.13	-4.92	9.86e-07	1e-04	-0.18	-0.15	Prostate cancer;	chr1:154877003	chr1:154937370~154938059:+
BRCA	cis	rs8064024	0.62	rs8048709	ENSG00000267077.1	RP11-127I20.5	4.92	9.86e-07	1e-04	0.15	0.15	Cancer;	chr16:4863760	chr16:4795265~4796532:-
BRCA	cis	rs6840360	0.642	rs1470280	ENSG00000251603.1	RP11-164P12.4	-4.92	9.86e-07	1e-04	-0.14	-0.15	Intelligence (multi-trait analysis);	chr4:151510618	chr4:151667224~151670502:+
BRCA	cis	rs6480314	0.522	rs11816028	ENSG00000233590.1	RP11-153K11.3	-4.92	9.86e-07	1e-04	-0.27	-0.15	Optic nerve measurement (disc area);	chr10:68296566	chr10:68233251~68242379:-
BRCA	cis	rs8180040	0.871	rs11716661	ENSG00000276925.1	RP11-708J19.3	4.92	9.87e-07	1e-04	0.17	0.15	Colorectal cancer;	chr3:47476283	chr3:47469777~47469987:+
BRCA	cis	rs16944613	0.541	rs7183319	ENSG00000271396.1	RP11-697E2.9	-4.92	9.87e-07	1e-04	-0.23	-0.15	Colorectal cancer;	chr15:90551800	chr15:90284376~90285580:-
BRCA	cis	rs12501370	0.589	rs35944254	ENSG00000201736.1	RNA5SP160	4.92	9.88e-07	1e-04	0.18	0.15	Iris color (L* coordinate);	chr4:40974505	chr4:40990154~40990273:+
BRCA	cis	rs6714710	0.58	rs35564270	ENSG00000230606.9	AC159540.1	-4.92	9.88e-07	1e-04	-0.18	-0.15	Posterior cortical atrophy and Alzheimer's disease;	chr2:97985702	chr2:97416165~97433527:-
BRCA	cis	rs4218	0.648	rs10851642	ENSG00000277144.1	RP11-59H7.4	-4.92	9.88e-07	1e-04	-0.2	-0.15	Social communication problems;	chr15:59077909	chr15:59115547~59116089:-
BRCA	cis	rs893363	0.559	rs3774611	ENSG00000271916.1	RP11-884K10.6	-4.92	9.89e-07	0.000101	-0.14	-0.15	Axial length;	chr3:53806638	chr3:53797764~53798019:-
BRCA	cis	rs875971	0.545	rs73142245	ENSG00000232546.1	RP11-458F8.1	4.92	9.89e-07	0.000101	0.15	0.15	Aortic root size;	chr7:66226662	chr7:66848496~66858136:+
BRCA	cis	rs62025270	0.806	rs62025262	ENSG00000259295.5	CSPG4P12	-4.92	9.9e-07	0.000101	-0.24	-0.15	Idiopathic pulmonary fibrosis;	chr15:85750002	chr15:85191438~85213905:+
BRCA	cis	rs7299940	0.967	rs10848243	ENSG00000256250.1	RP11-989F5.1	-4.92	9.9e-07	0.000101	-0.16	-0.15	Panic disorder;	chr12:130894769	chr12:130810606~130812438:+
BRCA	cis	rs8127691	0.967	rs2838521	ENSG00000237604.1	AP001056.1	-4.92	9.9e-07	0.000101	-0.17	-0.15	Inflammatory bowel disease;	chr21:44196034	chr21:44175489~44176453:+
BRCA	cis	rs72615157	0.716	rs75779608	ENSG00000242294.5	STAG3L5P	4.92	9.91e-07	0.000101	0.15	0.15	Lung function (FEV1/FVC);	chr7:100171334	chr7:100336079~100351900:+
BRCA	cis	rs1161098	0.767	rs1161084	ENSG00000203585.3	RP11-542B15.1	-4.92	9.91e-07	0.000101	-0.23	-0.15	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr12:67435106	chr12:67519829~67567126:+
BRCA	cis	rs897984	0.553	rs2125293	ENSG00000260911.2	RP11-196G11.2	-4.92	9.91e-07	0.000101	-0.15	-0.15	Dementia with Lewy bodies;	chr16:30852554	chr16:31043150~31049868:+
BRCA	cis	rs6545883	0.894	rs6734628	ENSG00000270820.4	RP11-355B11.2	-4.92	9.91e-07	0.000101	-0.18	-0.15	Tuberculosis;	chr2:61224125	chr2:61471188~61484130:+
BRCA	cis	rs875971	0.862	rs10261398	ENSG00000236529.1	RP13-254B10.1	-4.92	9.91e-07	0.000101	-0.16	-0.15	Aortic root size;	chr7:66285177	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.862	rs10224872	ENSG00000236529.1	RP13-254B10.1	-4.92	9.91e-07	0.000101	-0.16	-0.15	Aortic root size;	chr7:66294786	chr7:65840212~65840596:+
BRCA	cis	rs6840360	0.642	rs12647555	ENSG00000251611.1	RP11-610P16.1	-4.92	9.91e-07	0.000101	-0.13	-0.15	Intelligence (multi-trait analysis);	chr4:151479946	chr4:151407551~151408835:-
BRCA	cis	rs793571	0.628	rs12591310	ENSG00000259250.1	RP11-50C13.1	-4.92	9.91e-07	0.000101	-0.25	-0.15	Schizophrenia;	chr15:58792069	chr15:58587507~58591676:+
BRCA	cis	rs6570726	0.791	rs408443	ENSG00000270638.1	RP3-466P17.1	4.92	9.92e-07	0.000101	0.18	0.15	Lobe attachment (rater-scored or self-reported);	chr6:145553507	chr6:145735570~145737218:+
BRCA	cis	rs6570726	0.791	rs436156	ENSG00000270638.1	RP3-466P17.1	4.92	9.92e-07	0.000101	0.18	0.15	Lobe attachment (rater-scored or self-reported);	chr6:145553737	chr6:145735570~145737218:+
BRCA	cis	rs1501911	0.509	rs327786	ENSG00000246763.5	RGMB-AS1	4.92	9.92e-07	0.000101	0.17	0.15	Lung function (FEV1/FVC);	chr5:98878301	chr5:98769618~98773469:-
BRCA	cis	rs6545883	0.894	rs12620105	ENSG00000270820.4	RP11-355B11.2	-4.92	9.92e-07	0.000101	-0.17	-0.15	Tuberculosis;	chr2:61285186	chr2:61471188~61484130:+
BRCA	cis	rs7615952	0.673	rs9821905	ENSG00000250012.1	RP11-124N2.1	4.92	9.92e-07	0.000101	0.26	0.15	Blood pressure (smoking interaction);	chr3:125902007	chr3:126084220~126095349:+
BRCA	cis	rs739496	0.527	rs2269801	ENSG00000226469.1	ADAM1B	4.92	9.93e-07	0.000101	0.19	0.15	Platelet count;	chr12:111888319	chr12:111927018~111929017:+
BRCA	cis	rs6490294	0.748	rs2269802	ENSG00000226469.1	ADAM1B	4.92	9.93e-07	0.000101	0.19	0.15	Mean platelet volume;	chr12:111888334	chr12:111927018~111929017:+
BRCA	cis	rs7572733	0.555	rs700671	ENSG00000231621.1	AC013264.2	-4.92	9.93e-07	0.000101	-0.15	-0.15	Dermatomyositis;	chr2:197825277	chr2:197197991~197199273:+
BRCA	cis	rs454217	0.846	rs381966	ENSG00000277851.1	RP11-756G20.1	4.92	9.93e-07	0.000101	0.17	0.15	Smoking quantity;	chr12:92335913	chr12:92247756~92363832:-
BRCA	cis	rs17801127	0.748	rs67065535	ENSG00000231969.1	AC144449.1	4.92	9.93e-07	0.000101	0.29	0.15	Liver enzyme levels (alanine transaminase);	chr2:149819760	chr2:149587196~149848233:+
BRCA	cis	rs6840360	0.642	rs2709831	ENSG00000251611.1	RP11-610P16.1	-4.92	9.93e-07	0.000101	-0.13	-0.15	Intelligence (multi-trait analysis);	chr4:151458499	chr4:151407551~151408835:-
BRCA	cis	rs4664293	0.867	rs13022404	ENSG00000226266.5	AC009961.3	-4.92	9.93e-07	0.000101	-0.2	-0.15	Monocyte percentage of white cells;	chr2:159732981	chr2:159670708~159712435:-
BRCA	cis	rs875971	0.545	rs4718325	ENSG00000232546.1	RP11-458F8.1	4.92	9.94e-07	0.000101	0.15	0.15	Aortic root size;	chr7:66215323	chr7:66848496~66858136:+
BRCA	cis	rs4072705	0.586	rs7023736	ENSG00000224020.1	MIR181A2HG	-4.92	9.94e-07	0.000101	-0.18	-0.15	Menarche (age at onset);	chr9:124485667	chr9:124658467~124698631:+
BRCA	cis	rs10129255	1	rs10129255	ENSG00000211974.3	IGHV2-70	-4.92	9.94e-07	0.000101	-0.15	-0.15	Kawasaki disease;	chr14:106767970	chr14:106723574~106724093:-
BRCA	cis	rs1707322	1	rs7539800	ENSG00000234329.1	RP11-767N6.2	-4.92	9.94e-07	0.000101	-0.16	-0.15	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45796457	chr1:45651039~45651826:-
BRCA	cis	rs4950322	0.58	rs17355474	ENSG00000244371.2	PFN1P8	-4.92	9.94e-07	0.000101	-0.2	-0.15	Protein quantitative trait loci;	chr1:147120541	chr1:146957117~146957659:-
BRCA	cis	rs8031584	0.505	rs2959036	ENSG00000259845.1	HERC2P10	-4.92	9.94e-07	0.000101	-0.17	-0.15	Huntington's disease progression;	chr15:30927539	chr15:30815271~30844153:+
BRCA	cis	rs4388249	0.687	rs10041575	ENSG00000271849.1	CTC-332L22.1	-4.92	9.94e-07	0.000101	-0.2	-0.15	Schizophrenia;	chr5:109768576	chr5:109687802~109688329:-
BRCA	cis	rs3733585	0.605	rs4235355	ENSG00000250413.1	RP11-448G15.1	4.92	9.95e-07	0.000101	0.2	0.15	Cleft plate (environmental tobacco smoke interaction);	chr4:10121454	chr4:10006482~10009725:+
BRCA	cis	rs1858037	0.867	rs55945621	ENSG00000237979.1	AC007389.1	4.92	9.95e-07	0.000101	0.19	0.15	Rheumatoid arthritis;	chr2:65388220	chr2:65500993~65502138:-
BRCA	cis	rs1722141	0.633	rs788717	ENSG00000229628.1	AC073115.7	4.92	9.95e-07	0.000101	0.21	0.15	Sitting height ratio;	chr7:45964897	chr7:45990905~46000898:+
BRCA	cis	rs919433	0.647	rs2045242	ENSG00000231621.1	AC013264.2	-4.92	9.96e-07	0.000101	-0.15	-0.15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197642925	chr2:197197991~197199273:+
BRCA	cis	rs8180040	0.966	rs11716763	ENSG00000276925.1	RP11-708J19.3	4.92	9.96e-07	0.000101	0.17	0.15	Colorectal cancer;	chr3:47476776	chr3:47469777~47469987:+
BRCA	cis	rs7577696	0.613	rs212752	ENSG00000272716.1	RP11-563N4.1	4.92	9.96e-07	0.000101	0.16	0.15	Inflammatory biomarkers;	chr2:32194834	chr2:32165046~32165757:-
BRCA	cis	rs4664293	0.867	rs12620924	ENSG00000224152.1	AC009506.1	-4.92	9.96e-07	0.000101	-0.17	-0.15	Monocyte percentage of white cells;	chr2:159746452	chr2:159615296~159617082:+
BRCA	cis	rs10752881	0.935	rs10911235	ENSG00000224468.3	RP11-181K3.4	-4.92	9.96e-07	0.000101	-0.16	-0.15	Colorectal cancer;	chr1:183084611	chr1:183138402~183141282:-
BRCA	cis	rs11955398	0.563	rs1117676	ENSG00000215032.2	GNL3LP1	-4.92	9.96e-07	0.000101	-0.18	-0.15	Intelligence (multi-trait analysis);	chr5:60738997	chr5:60891935~60893577:-
BRCA	cis	rs7246657	0.551	rs28462002	ENSG00000267422.1	CTD-2554C21.1	-4.92	9.97e-07	0.000101	-0.26	-0.15	Coronary artery calcification;	chr19:37143560	chr19:37779686~37792865:+
BRCA	cis	rs10911232	0.507	rs2151669	ENSG00000224468.3	RP11-181K3.4	-4.92	9.97e-07	0.000101	-0.16	-0.15	Hypertriglyceridemia;	chr1:183086263	chr1:183138402~183141282:-
BRCA	cis	rs4948275	0.806	rs2256377	ENSG00000237233.2	TMEM26-AS1	-4.92	9.97e-07	0.000101	-0.18	-0.15	Night sleep phenotypes;	chr10:61504725	chr10:61452639~61481956:+
BRCA	cis	rs4948275	0.773	rs2256370	ENSG00000237233.2	TMEM26-AS1	-4.92	9.97e-07	0.000101	-0.18	-0.15	Night sleep phenotypes;	chr10:61504853	chr10:61452639~61481956:+
BRCA	cis	rs2638953	0.924	rs11049575	ENSG00000247934.4	RP11-967K21.1	-4.92	9.97e-07	0.000101	-0.21	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28411328	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.924	rs2348235	ENSG00000247934.4	RP11-967K21.1	-4.92	9.97e-07	0.000101	-0.21	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28414019	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.886	rs11049577	ENSG00000247934.4	RP11-967K21.1	-4.92	9.97e-07	0.000101	-0.21	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28414437	chr12:28163298~28190738:-
BRCA	cis	rs1075265	0.547	rs7557799	ENSG00000235937.1	AC008280.1	-4.92	9.97e-07	0.000101	-0.17	-0.15	Chronotype;Morning vs. evening chronotype;	chr2:53674760	chr2:54029552~54030682:-
BRCA	cis	rs13108904	0.557	rs1680033	ENSG00000254094.1	AC078852.1	4.92	9.97e-07	0.000101	0.18	0.15	Obesity-related traits;	chr4:1249616	chr4:1356581~1358075:+
BRCA	cis	rs12612619	0.732	rs2289360	ENSG00000229122.1	AGBL5-IT1	4.92	9.97e-07	0.000101	0.16	0.15	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27079297	chr2:27061038~27061815:+
BRCA	cis	rs7572733	0.534	rs700681	ENSG00000231621.1	AC013264.2	-4.92	9.97e-07	0.000101	-0.15	-0.15	Dermatomyositis;	chr2:197846778	chr2:197197991~197199273:+
BRCA	cis	rs7572733	0.534	rs700682	ENSG00000231621.1	AC013264.2	-4.92	9.97e-07	0.000101	-0.15	-0.15	Dermatomyositis;	chr2:197847586	chr2:197197991~197199273:+
BRCA	cis	rs7572733	0.534	rs700683	ENSG00000231621.1	AC013264.2	-4.92	9.97e-07	0.000101	-0.15	-0.15	Dermatomyositis;	chr2:197847608	chr2:197197991~197199273:+
BRCA	cis	rs9907295	1	rs9901195	ENSG00000271013.1	AC015849.15	-4.92	9.98e-07	0.000101	-0.23	-0.15	Fibroblast growth factor basic levels;	chr17:35915576	chr17:35912635~35918010:-
BRCA	cis	rs6756513	0.5	rs11126249	ENSG00000231024.1	AC092431.3	-4.92	9.98e-07	0.000101	-0.22	-0.15	Breast cancer;Platelet count;	chr2:69909485	chr2:69700192~69713847:-
BRCA	cis	rs72647484	0.558	rs2807366	ENSG00000228397.1	RP1-224A6.3	-4.92	9.98e-07	0.000101	-0.42	-0.15	Colorectal cancer;	chr1:22157419	chr1:22023994~22024968:-
BRCA	cis	rs9659323	0.689	rs7545737	ENSG00000231365.4	RP11-418J17.1	4.92	9.98e-07	0.000101	0.2	0.15	Body mass index;	chr1:118991200	chr1:119140396~119275973:+
BRCA	cis	rs10911232	0.524	rs10911229	ENSG00000224468.3	RP11-181K3.4	-4.92	9.98e-07	0.000101	-0.16	-0.15	Hypertriglyceridemia;	chr1:183081233	chr1:183138402~183141282:-
BRCA	cis	rs10504130	1	rs75219463	ENSG00000253844.1	RP11-546K22.1	-4.92	9.99e-07	0.000101	-0.26	-0.15	Venous thromboembolism (SNP x SNP interaction);	chr8:51852803	chr8:51961458~52022974:+
BRCA	cis	rs7267979	0.816	rs443009	ENSG00000274414.1	RP5-965G21.4	4.92	9.99e-07	0.000101	0.18	0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25519181	chr20:25239007~25245229:-
BRCA	cis	rs4713118	0.955	rs9468204	ENSG00000216901.1	AL022393.7	4.92	9.99e-07	0.000101	0.21	0.15	Parkinson's disease;	chr6:27721030	chr6:28176188~28176674:+
BRCA	cis	rs875971	0.522	rs4718286	ENSG00000182722.5	SEPHS1P1	-4.92	1e-06	0.000102	-0.19	-0.15	Aortic root size;	chr7:65827777	chr7:64852397~64853354:-
BRCA	cis	rs17711722	0.585	rs6942660	ENSG00000182722.5	SEPHS1P1	-4.92	1e-06	0.000102	-0.19	-0.15	Calcium levels;	chr7:65837419	chr7:64852397~64853354:-
BRCA	cis	rs7674212	0.539	rs2866635	ENSG00000248740.4	RP11-328K4.1	4.92	1e-06	0.000102	0.17	0.15	Type 2 diabetes;	chr4:103200419	chr4:103256159~103453658:+
BRCA	cis	rs10911232	0.507	rs10911230	ENSG00000224468.3	RP11-181K3.4	-4.92	1e-06	0.000102	-0.16	-0.15	Hypertriglyceridemia;	chr1:183081983	chr1:183138402~183141282:-
BRCA	cis	rs10911232	0.507	rs35782443	ENSG00000224468.3	RP11-181K3.4	-4.92	1e-06	0.000102	-0.16	-0.15	Hypertriglyceridemia;	chr1:183082367	chr1:183138402~183141282:-
BRCA	cis	rs10752881	0.935	rs12082051	ENSG00000224468.3	RP11-181K3.4	-4.92	1e-06	0.000102	-0.16	-0.15	Colorectal cancer;	chr1:183082479	chr1:183138402~183141282:-
BRCA	cis	rs10911232	0.507	rs10911231	ENSG00000224468.3	RP11-181K3.4	-4.92	1e-06	0.000102	-0.16	-0.15	Hypertriglyceridemia;	chr1:183082610	chr1:183138402~183141282:-
BRCA	cis	rs10911232	0.507	rs4397624	ENSG00000224468.3	RP11-181K3.4	-4.92	1e-06	0.000102	-0.16	-0.15	Hypertriglyceridemia;	chr1:183083996	chr1:183138402~183141282:-
BRCA	cis	rs7772486	0.743	rs111332144	ENSG00000270638.1	RP3-466P17.1	-4.92	1e-06	0.000102	-0.17	-0.15	Lobe attachment (rater-scored or self-reported);	chr6:145735545	chr6:145735570~145737218:+
BRCA	cis	rs4835473	0.831	rs1912743	ENSG00000249741.2	RP11-673E1.3	-4.92	1e-06	0.000102	-0.16	-0.15	Immature fraction of reticulocytes;	chr4:143993705	chr4:143911514~143912053:-
BRCA	cis	rs4835473	0.614	rs4487293	ENSG00000249741.2	RP11-673E1.3	-4.92	1e-06	0.000102	-0.16	-0.15	Immature fraction of reticulocytes;	chr4:143993880	chr4:143911514~143912053:-
BRCA	cis	rs17772222	0.74	rs10138002	ENSG00000258789.1	RP11-507K2.3	4.92	1e-06	0.000102	0.17	0.15	Coronary artery calcification;	chr14:88510071	chr14:88551597~88552493:+
BRCA	cis	rs6756513	0.5	rs60515724	ENSG00000231024.1	AC092431.3	-4.92	1e-06	0.000102	-0.22	-0.15	Breast cancer;Platelet count;	chr2:69889316	chr2:69700192~69713847:-
BRCA	cis	rs13113518	1	rs4864542	ENSG00000249700.7	SRD5A3-AS1	-4.92	1e-06	0.000102	-0.19	-0.15	Height;	chr4:55487920	chr4:55363971~55395847:-
BRCA	cis	rs35740288	0.752	rs11635956	ENSG00000259407.1	RP11-158M2.3	-4.92	1e-06	0.000102	-0.2	-0.15	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85736697	chr15:85744109~85750281:-
BRCA	cis	rs11098499	0.789	rs1980024	ENSG00000249244.1	RP11-548H18.2	4.92	1e-06	0.000102	0.17	0.15	Corneal astigmatism;	chr4:119331892	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.754	rs34425882	ENSG00000249244.1	RP11-548H18.2	4.92	1e-06	0.000102	0.17	0.15	Corneal astigmatism;	chr4:119332022	chr4:119391831~119395335:-
BRCA	cis	rs6044112	0.56	rs6080322	ENSG00000273998.1	RP4-777L9.2	4.92	1e-06	0.000102	0.31	0.15	Response to taxane treatment (docetaxel);	chr20:16608358	chr20:16576068~16579615:+
BRCA	cis	rs875971	1	rs778726	ENSG00000223473.2	GS1-124K5.3	4.92	1e-06	0.000102	0.11	0.15	Aortic root size;	chr7:66363744	chr7:66491049~66493566:-
BRCA	cis	rs875971	0.767	rs1695815	ENSG00000223473.2	GS1-124K5.3	4.92	1e-06	0.000102	0.11	0.15	Aortic root size;	chr7:66366357	chr7:66491049~66493566:-
BRCA	cis	rs875971	1	rs778685	ENSG00000223473.2	GS1-124K5.3	4.92	1e-06	0.000102	0.11	0.15	Aortic root size;	chr7:66371189	chr7:66491049~66493566:-
BRCA	cis	rs875971	0.929	rs778682	ENSG00000223473.2	GS1-124K5.3	4.92	1e-06	0.000102	0.11	0.15	Aortic root size;	chr7:66372947	chr7:66491049~66493566:-
BRCA	cis	rs875971	0.964	rs11765965	ENSG00000223473.2	GS1-124K5.3	4.92	1e-06	0.000102	0.11	0.15	Aortic root size;	chr7:66377234	chr7:66491049~66493566:-
BRCA	cis	rs8180040	0.966	rs59586735	ENSG00000271161.1	BOLA2P2	-4.92	1e-06	0.000102	-0.16	-0.15	Colorectal cancer;	chr3:47476835	chr3:47499841~47500407:+
BRCA	cis	rs828999	0.688	rs1157390	ENSG00000280186.1	RP11-483I13.6	-4.92	1e-06	0.000102	-0.17	-0.15	Monocyte percentage of white cells;	chr1:108156474	chr1:108200413~108202743:+
BRCA	cis	rs828999	0.653	rs6677101	ENSG00000280186.1	RP11-483I13.6	-4.92	1e-06	0.000102	-0.17	-0.15	Monocyte percentage of white cells;	chr1:108157108	chr1:108200413~108202743:+
BRCA	cis	rs4664293	0.903	rs10185155	ENSG00000226266.5	AC009961.3	-4.92	1e-06	0.000102	-0.19	-0.15	Monocyte percentage of white cells;	chr2:159696717	chr2:159670708~159712435:-
BRCA	cis	rs11098499	0.619	rs28502463	ENSG00000260404.2	RP11-384K6.6	4.92	1e-06	0.000102	0.14	0.15	Corneal astigmatism;	chr4:119335868	chr4:118591773~118633729:+
BRCA	cis	rs6496044	0.568	rs6496039	ENSG00000259295.5	CSPG4P12	4.92	1.01e-06	0.000102	0.18	0.15	Interstitial lung disease;	chr15:85518732	chr15:85191438~85213905:+
BRCA	cis	rs9307551	1	rs2709847	ENSG00000250334.4	LINC00989	-4.92	1.01e-06	0.000102	-0.22	-0.15	Refractive error;	chr4:79621672	chr4:79492416~79576460:+
BRCA	cis	rs11051970	0.559	rs10844188	ENSG00000274964.1	RP11-817I4.1	-4.92	1.01e-06	0.000102	-0.19	-0.15	Response to tocilizumab in rheumatoid arthritis;	chr12:32334710	chr12:32339368~32340724:+
BRCA	cis	rs875971	1	rs9986696	ENSG00000223473.2	GS1-124K5.3	-4.92	1.01e-06	0.000102	-0.12	-0.15	Aortic root size;	chr7:66239589	chr7:66491049~66493566:-
BRCA	cis	rs115769866	0.618	rs7759252	ENSG00000204709.4	LINC01556	4.92	1.01e-06	0.000102	0.22	0.15	Bipolar disorder;	chr6:28501645	chr6:28943877~28944537:+
BRCA	cis	rs9307551	0.948	rs11098779	ENSG00000250334.4	LINC00989	-4.92	1.01e-06	0.000102	-0.23	-0.15	Refractive error;	chr4:79619060	chr4:79492416~79576460:+
BRCA	cis	rs7674212	0.57	rs2069274	ENSG00000246560.2	RP11-10L12.4	4.92	1.01e-06	0.000102	0.15	0.15	Type 2 diabetes;	chr4:103099624	chr4:102828055~102844075:+
BRCA	cis	rs4218	0.648	rs12442086	ENSG00000277144.1	RP11-59H7.4	-4.92	1.01e-06	0.000102	-0.2	-0.15	Social communication problems;	chr15:59074364	chr15:59115547~59116089:-
BRCA	cis	rs16958440	0.867	rs12326412	ENSG00000280212.1	RP11-49K24.3	4.92	1.01e-06	0.000102	0.35	0.15	Sitting height ratio;	chr18:47157223	chr18:47076117~47076594:+
BRCA	cis	rs16958440	0.867	rs77615793	ENSG00000280212.1	RP11-49K24.3	4.92	1.01e-06	0.000102	0.35	0.15	Sitting height ratio;	chr18:47158093	chr18:47076117~47076594:+
BRCA	cis	rs16958440	0.867	rs75287977	ENSG00000280212.1	RP11-49K24.3	4.92	1.01e-06	0.000102	0.35	0.15	Sitting height ratio;	chr18:47160452	chr18:47076117~47076594:+
BRCA	cis	rs16958440	0.867	rs28578518	ENSG00000280212.1	RP11-49K24.3	4.92	1.01e-06	0.000102	0.35	0.15	Sitting height ratio;	chr18:47161177	chr18:47076117~47076594:+
BRCA	cis	rs16958440	0.867	rs28587821	ENSG00000280212.1	RP11-49K24.3	4.92	1.01e-06	0.000102	0.35	0.15	Sitting height ratio;	chr18:47161535	chr18:47076117~47076594:+
BRCA	cis	rs16958440	0.867	rs77599321	ENSG00000280212.1	RP11-49K24.3	4.92	1.01e-06	0.000102	0.35	0.15	Sitting height ratio;	chr18:47163271	chr18:47076117~47076594:+
BRCA	cis	rs16958440	0.867	rs75901436	ENSG00000280212.1	RP11-49K24.3	4.92	1.01e-06	0.000102	0.35	0.15	Sitting height ratio;	chr18:47163273	chr18:47076117~47076594:+
BRCA	cis	rs16958440	0.867	rs74845165	ENSG00000280212.1	RP11-49K24.3	4.92	1.01e-06	0.000102	0.35	0.15	Sitting height ratio;	chr18:47164481	chr18:47076117~47076594:+
BRCA	cis	rs16958440	0.867	rs114475395	ENSG00000280212.1	RP11-49K24.3	4.92	1.01e-06	0.000102	0.35	0.15	Sitting height ratio;	chr18:47164639	chr18:47076117~47076594:+
BRCA	cis	rs16958440	0.867	rs16949157	ENSG00000280212.1	RP11-49K24.3	4.92	1.01e-06	0.000102	0.35	0.15	Sitting height ratio;	chr18:47164953	chr18:47076117~47076594:+
BRCA	cis	rs16958440	0.867	rs75808931	ENSG00000280212.1	RP11-49K24.3	4.92	1.01e-06	0.000102	0.35	0.15	Sitting height ratio;	chr18:47166671	chr18:47076117~47076594:+
BRCA	cis	rs16958440	0.867	rs59217333	ENSG00000280212.1	RP11-49K24.3	4.92	1.01e-06	0.000102	0.35	0.15	Sitting height ratio;	chr18:47168473	chr18:47076117~47076594:+
BRCA	cis	rs16958440	0.867	rs10083937	ENSG00000280212.1	RP11-49K24.3	4.92	1.01e-06	0.000102	0.35	0.15	Sitting height ratio;	chr18:47169231	chr18:47076117~47076594:+
BRCA	cis	rs16958440	0.867	rs80006910	ENSG00000280212.1	RP11-49K24.3	4.92	1.01e-06	0.000102	0.35	0.15	Sitting height ratio;	chr18:47170011	chr18:47076117~47076594:+
BRCA	cis	rs2303319	0.504	rs60495163	ENSG00000227403.1	AC009299.3	4.92	1.01e-06	0.000102	0.36	0.15	Cognitive function;	chr2:161552297	chr2:161244739~161249050:+
BRCA	cis	rs78487399	0.71	rs79629200	ENSG00000234936.1	AC010883.5	4.92	1.01e-06	0.000102	0.27	0.15	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43375793	chr2:43229573~43233394:+
BRCA	cis	rs78487399	0.71	rs78314405	ENSG00000234936.1	AC010883.5	4.92	1.01e-06	0.000102	0.27	0.15	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43377602	chr2:43229573~43233394:+
BRCA	cis	rs10129255	0.957	rs28887506	ENSG00000211974.3	IGHV2-70	4.92	1.01e-06	0.000102	0.16	0.15	Kawasaki disease;	chr14:106785589	chr14:106723574~106724093:-
BRCA	cis	rs1979679	0.877	rs6487684	ENSG00000278733.1	RP11-425D17.1	-4.92	1.01e-06	0.000102	-0.2	-0.15	Ossification of the posterior longitudinal ligament of the spine;	chr12:28490280	chr12:28185625~28186190:-
BRCA	cis	rs10504130	1	rs12675786	ENSG00000253844.1	RP11-546K22.1	-4.92	1.01e-06	0.000102	-0.26	-0.15	Venous thromboembolism (SNP x SNP interaction);	chr8:51852132	chr8:51961458~52022974:+
BRCA	cis	rs10504130	1	rs11781330	ENSG00000253844.1	RP11-546K22.1	-4.92	1.01e-06	0.000102	-0.26	-0.15	Venous thromboembolism (SNP x SNP interaction);	chr8:51853231	chr8:51961458~52022974:+
BRCA	cis	rs9467773	0.62	rs2504567	ENSG00000124549.13	BTN2A3P	4.92	1.01e-06	0.000102	0.15	0.15	Intelligence (multi-trait analysis);	chr6:26662692	chr6:26421391~26432383:+
BRCA	cis	rs875971	0.862	rs6460302	ENSG00000236529.1	RP13-254B10.1	4.92	1.01e-06	0.000102	0.17	0.15	Aortic root size;	chr7:66495270	chr7:65840212~65840596:+
BRCA	cis	rs7572733	0.534	rs700670	ENSG00000231621.1	AC013264.2	-4.92	1.01e-06	0.000102	-0.15	-0.15	Dermatomyositis;	chr2:197822560	chr2:197197991~197199273:+
BRCA	cis	rs9287719	0.81	rs7601748	ENSG00000243819.4	RN7SL832P	4.92	1.01e-06	0.000102	0.15	0.15	Prostate cancer;	chr2:10645320	chr2:10690344~10692099:+
BRCA	cis	rs9425766	0.64	rs1322774	ENSG00000200674.1	RN7SKP160	4.92	1.01e-06	0.000102	0.22	0.15	Life satisfaction;	chr1:173870102	chr1:173791548~173791887:+
BRCA	cis	rs4908768	0.539	rs922366	ENSG00000232912.4	RP5-1115A15.1	4.92	1.01e-06	0.000102	0.15	0.15	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8593674	chr1:8424645~8434838:+
BRCA	cis	rs6430585	0.941	rs60963894	ENSG00000224043.6	CCNT2-AS1	-4.92	1.01e-06	0.000103	-0.24	-0.15	Corneal structure;	chr2:135782100	chr2:134735464~134918710:-
BRCA	cis	rs6430585	0.941	rs10496737	ENSG00000224043.6	CCNT2-AS1	-4.92	1.01e-06	0.000103	-0.24	-0.15	Corneal structure;	chr2:135782513	chr2:134735464~134918710:-
BRCA	cis	rs7772486	0.875	rs2748501	ENSG00000270638.1	RP3-466P17.1	4.92	1.01e-06	0.000103	0.18	0.15	Lobe attachment (rater-scored or self-reported);	chr6:145991122	chr6:145735570~145737218:+
BRCA	cis	rs4323050	0.51	rs4254715	ENSG00000249741.2	RP11-673E1.3	-4.92	1.01e-06	0.000103	-0.16	-0.15	High light scatter reticulocyte percentage of red cells;	chr4:143993140	chr4:143911514~143912053:-
BRCA	cis	rs4323050	0.51	rs4273414	ENSG00000249741.2	RP11-673E1.3	-4.92	1.01e-06	0.000103	-0.16	-0.15	High light scatter reticulocyte percentage of red cells;	chr4:143993142	chr4:143911514~143912053:-
BRCA	cis	rs4835473	0.736	rs11724009	ENSG00000249741.2	RP11-673E1.3	-4.92	1.01e-06	0.000103	-0.16	-0.15	Immature fraction of reticulocytes;	chr4:143984291	chr4:143911514~143912053:-
BRCA	cis	rs4323050	0.514	rs28647406	ENSG00000249741.2	RP11-673E1.3	-4.92	1.01e-06	0.000103	-0.16	-0.15	High light scatter reticulocyte percentage of red cells;	chr4:143984437	chr4:143911514~143912053:-
BRCA	cis	rs4835473	0.604	rs11938387	ENSG00000249741.2	RP11-673E1.3	-4.92	1.01e-06	0.000103	-0.16	-0.15	Immature fraction of reticulocytes;	chr4:143984476	chr4:143911514~143912053:-
BRCA	cis	rs4819052	0.851	rs13052312	ENSG00000184274.3	LINC00315	-4.92	1.01e-06	0.000103	-0.21	-0.15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45242444	chr21:45300245~45305257:-
BRCA	cis	rs7267979	0.844	rs6083845	ENSG00000125804.12	FAM182A	4.92	1.01e-06	0.000103	0.2	0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25407454	chr20:26054655~26086917:+
BRCA	cis	rs7246657	0.722	rs10410588	ENSG00000276846.1	CTD-3220F14.3	4.92	1.01e-06	0.000103	0.2	0.15	Coronary artery calcification;	chr19:37551508	chr19:37314868~37315620:-
BRCA	cis	rs8054556	0.647	rs4787488	ENSG00000273724.1	RP11-347C12.12	4.92	1.01e-06	0.000103	0.16	0.15	Autism spectrum disorder or schizophrenia;	chr16:29984482	chr16:30336400~30343336:+
BRCA	cis	rs6570726	0.791	rs436498	ENSG00000270638.1	RP3-466P17.1	4.92	1.01e-06	0.000103	0.18	0.15	Lobe attachment (rater-scored or self-reported);	chr6:145555211	chr6:145735570~145737218:+
BRCA	cis	rs71636778	0.509	rs41307935	ENSG00000260063.1	RP5-968P14.2	-4.92	1.01e-06	0.000103	-0.34	-0.15	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26854576	chr1:26692132~26694131:-
BRCA	cis	rs13325613	0.915	rs35511592	ENSG00000223552.1	RP11-24F11.2	-4.92	1.01e-06	0.000103	-0.32	-0.15	Monocyte count;	chr3:46293355	chr3:46364955~46407059:-
BRCA	cis	rs1979679	0.673	rs1351266	ENSG00000278733.1	RP11-425D17.1	4.92	1.01e-06	0.000103	0.19	0.15	Ossification of the posterior longitudinal ligament of the spine;	chr12:28124405	chr12:28185625~28186190:-
BRCA	cis	rs1552244	0.572	rs6797536	ENSG00000232901.1	CYCSP10	-4.92	1.01e-06	0.000103	-0.23	-0.15	Alzheimer's disease;	chr3:10127118	chr3:10000647~10000940:-
BRCA	cis	rs7674212	0.539	rs6850461	ENSG00000248740.4	RP11-328K4.1	4.92	1.01e-06	0.000103	0.17	0.15	Type 2 diabetes;	chr4:103198884	chr4:103256159~103453658:+
BRCA	cis	rs10840133	1	rs10840133	ENSG00000254860.4	TMEM9B-AS1	-4.92	1.01e-06	0.000103	-0.14	-0.15	Reticulocyte fraction of red cells;	chr11:8824822	chr11:8964675~8977527:+
BRCA	cis	rs7800944	0.715	rs12540011	ENSG00000274080.1	CTA-315H11.2	4.92	1.01e-06	0.000103	0.21	0.15	Coffee consumption (cups per day);	chr7:73577374	chr7:73609262~73611502:-
BRCA	cis	rs6847067	0.8	rs12498637	ENSG00000180769.7	WDFY3-AS2	4.92	1.01e-06	0.000103	0.14	0.15	Oropharynx cancer;	chr4:84922800	chr4:84965682~85011277:+
BRCA	cis	rs2018683	0.768	rs10282015	ENSG00000233517.1	AC005162.5	-4.92	1.01e-06	0.000103	-0.18	-0.15	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28982522	chr7:28987028~28988899:+
BRCA	cis	rs2018683	0.77	rs10951208	ENSG00000233517.1	AC005162.5	-4.92	1.01e-06	0.000103	-0.18	-0.15	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28982888	chr7:28987028~28988899:+
BRCA	cis	rs867186	1	rs17317888	ENSG00000126005.14	MMP24-AS1	-4.92	1.01e-06	0.000103	-0.29	-0.15	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35007156	chr20:35216462~35278131:-
BRCA	cis	rs12893668	0.572	rs7148857	ENSG00000269958.1	RP11-73M18.8	4.92	1.02e-06	0.000103	0.17	0.15	Reticulocyte count;	chr14:103676900	chr14:103696353~103697163:+
BRCA	cis	rs2487032	0.573	rs2164560	ENSG00000226334.1	RP11-217B7.2	-4.92	1.02e-06	0.000103	-0.22	-0.15	Glaucoma (high intraocular pressure);	chr9:104945072	chr9:104927553~104928892:+
BRCA	cis	rs9425766	0.64	rs2208850	ENSG00000200674.1	RN7SKP160	4.92	1.02e-06	0.000103	0.22	0.15	Life satisfaction;	chr1:173862569	chr1:173791548~173791887:+
BRCA	cis	rs35740288	0.929	rs1978391	ENSG00000259407.1	RP11-158M2.3	4.92	1.02e-06	0.000103	0.2	0.15	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85768464	chr15:85744109~85750281:-
BRCA	cis	rs739496	0.579	rs3177647	ENSG00000226469.1	ADAM1B	4.92	1.02e-06	0.000103	0.19	0.15	Platelet count;	chr12:111839772	chr12:111927018~111929017:+
BRCA	cis	rs35740288	0.822	rs56322219	ENSG00000259407.1	RP11-158M2.3	-4.92	1.02e-06	0.000103	-0.21	-0.15	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85733109	chr15:85744109~85750281:-
BRCA	cis	rs875971	0.545	rs316306	ENSG00000232546.1	RP11-458F8.1	-4.92	1.02e-06	0.000103	-0.14	-0.15	Aortic root size;	chr7:66153687	chr7:66848496~66858136:+
BRCA	cis	rs7772486	0.727	rs6941429	ENSG00000270638.1	RP3-466P17.1	4.92	1.02e-06	0.000103	0.18	0.15	Lobe attachment (rater-scored or self-reported);	chr6:145631147	chr6:145735570~145737218:+
BRCA	cis	rs11098499	0.754	rs28643450	ENSG00000260404.2	RP11-384K6.6	4.92	1.02e-06	0.000103	0.14	0.15	Corneal astigmatism;	chr4:119324087	chr4:118591773~118633729:+
BRCA	cis	rs7931462	0.655	rs6483208	ENSG00000202314.1	SNORD6	-4.92	1.02e-06	0.000103	-0.24	-0.15	DNA methylation (parent-of-origin);	chr11:92972678	chr11:93731502~93731574:-
BRCA	cis	rs7824557	0.628	rs11782706	ENSG00000154316.13	TDH	-4.92	1.02e-06	0.000103	-0.2	-0.15	Retinal vascular caliber;	chr8:11328706	chr8:11339637~11368452:+
BRCA	cis	rs7267979	0.844	rs6115188	ENSG00000274973.1	RP13-401N8.7	-4.92	1.02e-06	0.000103	-0.17	-0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25451534	chr20:25845497~25845862:+
BRCA	cis	rs2625529	0.73	rs8182011	ENSG00000260037.4	CTD-2524L6.3	4.92	1.02e-06	0.000103	0.2	0.15	Red blood cell count;	chr15:72097607	chr15:71818396~71823384:+
BRCA	cis	rs793571	0.628	rs7171482	ENSG00000259250.1	RP11-50C13.1	-4.92	1.02e-06	0.000103	-0.24	-0.15	Schizophrenia;	chr15:58814296	chr15:58587507~58591676:+
BRCA	cis	rs12477438	0.501	rs11688004	ENSG00000231822.1	AC019097.7	4.92	1.02e-06	0.000103	0.15	0.15	Chronic sinus infection;	chr2:99118589	chr2:99102018~99102752:+
BRCA	cis	rs12477438	0.501	rs17759607	ENSG00000231822.1	AC019097.7	4.92	1.02e-06	0.000103	0.15	0.15	Chronic sinus infection;	chr2:99120542	chr2:99102018~99102752:+
BRCA	cis	rs11051970	0.559	rs4931012	ENSG00000274964.1	RP11-817I4.1	-4.92	1.02e-06	0.000103	-0.2	-0.15	Response to tocilizumab in rheumatoid arthritis;	chr12:32328970	chr12:32339368~32340724:+
BRCA	cis	rs9863	0.828	rs34114498	ENSG00000270028.1	RP11-380L11.4	4.92	1.02e-06	0.000103	0.18	0.15	White blood cell count;	chr12:123995826	chr12:123925461~123926083:-
BRCA	cis	rs7267979	0.844	rs6076343	ENSG00000204556.4	CTD-2514C3.1	4.92	1.02e-06	0.000103	0.2	0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25396027	chr20:26018832~26020684:+
BRCA	cis	rs853679	1	rs2799079	ENSG00000280107.1	AL022393.9	-4.92	1.02e-06	0.000104	-0.26	-0.15	Depression;	chr6:28267398	chr6:28170845~28172521:+
BRCA	cis	rs17767294	0.708	rs72848769	ENSG00000204709.4	LINC01556	4.92	1.02e-06	0.000104	0.4	0.15	Parkinson's disease;	chr6:27950601	chr6:28943877~28944537:+
BRCA	cis	rs17767294	0.708	rs72848770	ENSG00000204709.4	LINC01556	4.92	1.02e-06	0.000104	0.4	0.15	Parkinson's disease;	chr6:27951371	chr6:28943877~28944537:+
BRCA	cis	rs17767294	0.708	rs72848772	ENSG00000204709.4	LINC01556	4.92	1.02e-06	0.000104	0.4	0.15	Parkinson's disease;	chr6:27953170	chr6:28943877~28944537:+
BRCA	cis	rs3845817	0.868	rs702890	ENSG00000237979.1	AC007389.1	-4.92	1.02e-06	0.000104	-0.18	-0.15	Bipolar disorder;	chr2:65530517	chr2:65500993~65502138:-
BRCA	cis	rs6545883	0.783	rs6545888	ENSG00000271889.1	RP11-493E12.1	4.92	1.02e-06	0.000104	0.19	0.15	Tuberculosis;	chr2:61618080	chr2:61151433~61162105:-
BRCA	cis	rs7226408	0.857	rs55804703	ENSG00000267707.2	RP11-95O2.5	4.92	1.02e-06	0.000104	0.23	0.15	Obesity-related traits;	chr18:36872740	chr18:37243776~37247506:+
BRCA	cis	rs7226408	0.857	rs57901563	ENSG00000267707.2	RP11-95O2.5	4.92	1.02e-06	0.000104	0.23	0.15	Obesity-related traits;	chr18:36873244	chr18:37243776~37247506:+
BRCA	cis	rs7226408	0.857	rs72885302	ENSG00000267707.2	RP11-95O2.5	4.92	1.02e-06	0.000104	0.23	0.15	Obesity-related traits;	chr18:36873528	chr18:37243776~37247506:+
BRCA	cis	rs7226408	0.901	rs56360477	ENSG00000267707.2	RP11-95O2.5	4.92	1.02e-06	0.000104	0.23	0.15	Obesity-related traits;	chr18:36876870	chr18:37243776~37247506:+
BRCA	cis	rs7226408	0.857	rs11659681	ENSG00000267707.2	RP11-95O2.5	4.92	1.02e-06	0.000104	0.23	0.15	Obesity-related traits;	chr18:36878072	chr18:37243776~37247506:+
BRCA	cis	rs7226408	0.595	rs72887010	ENSG00000267707.2	RP11-95O2.5	4.92	1.02e-06	0.000104	0.23	0.15	Obesity-related traits;	chr18:36880294	chr18:37243776~37247506:+
BRCA	cis	rs7226408	0.857	rs11664211	ENSG00000267707.2	RP11-95O2.5	4.92	1.02e-06	0.000104	0.23	0.15	Obesity-related traits;	chr18:36881533	chr18:37243776~37247506:+
BRCA	cis	rs7226408	0.901	rs1013833	ENSG00000267707.2	RP11-95O2.5	4.92	1.02e-06	0.000104	0.23	0.15	Obesity-related traits;	chr18:36882251	chr18:37243776~37247506:+
BRCA	cis	rs7226408	0.857	rs72887014	ENSG00000267707.2	RP11-95O2.5	4.92	1.02e-06	0.000104	0.23	0.15	Obesity-related traits;	chr18:36883808	chr18:37243776~37247506:+
BRCA	cis	rs7226408	0.857	rs72887016	ENSG00000267707.2	RP11-95O2.5	4.92	1.02e-06	0.000104	0.23	0.15	Obesity-related traits;	chr18:36884127	chr18:37243776~37247506:+
BRCA	cis	rs7226408	0.857	rs72887017	ENSG00000267707.2	RP11-95O2.5	4.92	1.02e-06	0.000104	0.23	0.15	Obesity-related traits;	chr18:36884270	chr18:37243776~37247506:+
BRCA	cis	rs4588572	0.644	rs2115435	ENSG00000245556.2	SCAMP1-AS1	-4.92	1.02e-06	0.000104	-0.17	-0.15	Triglycerides;	chr5:78427876	chr5:78342365~78360507:-
BRCA	cis	rs454217	0.846	rs427600	ENSG00000277851.1	RP11-756G20.1	4.92	1.02e-06	0.000104	0.17	0.15	Smoking quantity;	chr12:92326886	chr12:92247756~92363832:-
BRCA	cis	rs454217	0.818	rs1661031	ENSG00000277851.1	RP11-756G20.1	4.92	1.02e-06	0.000104	0.17	0.15	Smoking quantity;	chr12:92328010	chr12:92247756~92363832:-
BRCA	cis	rs2235642	0.821	rs8051895	ENSG00000260989.1	LA16c-395F10.2	-4.92	1.02e-06	0.000104	-0.16	-0.15	Coronary artery disease;	chr16:1552810	chr16:1580527~1610328:+
BRCA	cis	rs2638953	0.962	rs11049558	ENSG00000247934.4	RP11-967K21.1	-4.92	1.02e-06	0.000104	-0.21	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28371438	chr12:28163298~28190738:-
BRCA	cis	rs34217772	0.68	rs61990349	ENSG00000258636.1	CTD-2298J14.2	4.92	1.03e-06	0.000104	0.21	0.15	Myopia;	chr14:41733468	chr14:41587861~41604856:-
BRCA	cis	rs7246657	0.722	rs2909093	ENSG00000276846.1	CTD-3220F14.3	-4.92	1.03e-06	0.000104	-0.21	-0.15	Coronary artery calcification;	chr19:37708561	chr19:37314868~37315620:-
BRCA	cis	rs3764021	0.87	rs10492166	ENSG00000214776.8	RP11-726G1.1	4.92	1.03e-06	0.000104	0.16	0.15	Type 1 diabetes;	chr12:9733403	chr12:9467552~9576275:+
BRCA	cis	rs7577696	0.85	rs11676938	ENSG00000272716.1	RP11-563N4.1	-4.92	1.03e-06	0.000104	-0.17	-0.15	Inflammatory biomarkers;	chr2:32090954	chr2:32165046~32165757:-
BRCA	cis	rs11098499	0.754	rs17049949	ENSG00000249244.1	RP11-548H18.2	4.92	1.03e-06	0.000104	0.17	0.15	Corneal astigmatism;	chr4:119334135	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.754	rs7689729	ENSG00000249244.1	RP11-548H18.2	4.92	1.03e-06	0.000104	0.17	0.15	Corneal astigmatism;	chr4:119335037	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.865	rs3956464	ENSG00000249244.1	RP11-548H18.2	4.92	1.03e-06	0.000104	0.17	0.15	Corneal astigmatism;	chr4:119335609	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.648	rs2002047	ENSG00000249244.1	RP11-548H18.2	4.92	1.03e-06	0.000104	0.17	0.15	Corneal astigmatism;	chr4:119336073	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.775	rs2002049	ENSG00000249244.1	RP11-548H18.2	4.92	1.03e-06	0.000104	0.17	0.15	Corneal astigmatism;	chr4:119336262	chr4:119391831~119395335:-
BRCA	cis	rs4650994	0.544	rs2811314	ENSG00000273384.1	RP5-1098D14.1	-4.92	1.03e-06	0.000104	-0.19	-0.15	HDL cholesterol;HDL cholesterol levels;	chr1:178650048	chr1:178651706~178652282:+
BRCA	cis	rs6088590	0.561	rs6059926	ENSG00000276073.1	RP5-1125A11.7	-4.92	1.03e-06	0.000104	-0.16	-0.15	Coronary artery disease;	chr20:34577000	chr20:33985617~33988989:-
BRCA	cis	rs35740288	0.822	rs11630179	ENSG00000202081.1	RNU6-1280P	4.92	1.03e-06	0.000104	0.2	0.15	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85739703	chr15:85651522~85651628:-
BRCA	cis	rs11124272	0.67	rs4952218	ENSG00000272716.1	RP11-563N4.1	-4.92	1.03e-06	0.000104	-0.18	-0.15	Interleukin-18 levels;	chr2:31506050	chr2:32165046~32165757:-
BRCA	cis	rs739496	0.542	rs7316698	ENSG00000257595.2	RP3-473L9.4	4.92	1.03e-06	0.000104	0.2	0.15	Platelet count;	chr12:111352707	chr12:111369282~111403310:+
BRCA	cis	rs739496	0.542	rs7399113	ENSG00000257595.2	RP3-473L9.4	4.92	1.03e-06	0.000104	0.2	0.15	Platelet count;	chr12:111355044	chr12:111369282~111403310:+
BRCA	cis	rs739496	0.542	rs7312913	ENSG00000257595.2	RP3-473L9.4	4.92	1.03e-06	0.000104	0.2	0.15	Platelet count;	chr12:111355748	chr12:111369282~111403310:+
BRCA	cis	rs1800795	0.53	rs7805828	ENSG00000179428.2	AC073072.5	4.92	1.03e-06	0.000104	0.16	0.15	Cerebrospinal fluid clusterin levels in APOEe4- carriers;	chr7:22718943	chr7:22725395~22727620:-
BRCA	cis	rs7829975	0.56	rs17154599	ENSG00000173295.6	FAM86B3P	-4.92	1.03e-06	0.000104	-0.16	-0.15	Mood instability;	chr8:8693908	chr8:8228595~8244865:+
BRCA	cis	rs7208859	0.623	rs122898	ENSG00000214719.10	AC005562.1	4.92	1.03e-06	0.000104	0.27	0.15	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30578236	chr17:30576464~30672789:+
BRCA	cis	rs454217	0.846	rs337661	ENSG00000277851.1	RP11-756G20.1	4.92	1.03e-06	0.000104	0.17	0.15	Smoking quantity;	chr12:92310960	chr12:92247756~92363832:-
BRCA	cis	rs848490	0.681	rs12537271	ENSG00000214293.7	APTR	4.92	1.03e-06	0.000104	0.18	0.15	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77671409	chr7:77657660~77696265:-
BRCA	cis	rs2617170	0.922	rs2086098	ENSG00000245648.1	RP11-277P12.20	4.92	1.03e-06	0.000104	0.2	0.15	Behcet's disease;	chr12:10373949	chr12:10363769~10398506:+
BRCA	cis	rs11098499	0.754	rs7672778	ENSG00000249244.1	RP11-548H18.2	4.92	1.03e-06	0.000104	0.17	0.15	Corneal astigmatism;	chr4:119327430	chr4:119391831~119395335:-
BRCA	cis	rs12900463	0.813	rs187316	ENSG00000225151.9	GOLGA2P7	-4.91	1.03e-06	0.000104	-0.2	-0.15	Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine);	chr15:84862764	chr15:84199311~84230136:-
BRCA	cis	rs10946940	0.965	rs9393830	ENSG00000220721.1	OR1F12	4.91	1.03e-06	0.000104	0.17	0.15	Systemic lupus erythematosus;	chr6:27619248	chr6:28073316~28074233:+
BRCA	cis	rs7267979	0.816	rs6138593	ENSG00000277938.1	RP5-965G21.3	4.91	1.03e-06	0.000105	0.18	0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25523856	chr20:25229150~25231933:+
BRCA	cis	rs9652601	0.691	rs7203150	ENSG00000274038.1	RP11-66H6.4	-4.91	1.03e-06	0.000105	-0.16	-0.15	Systemic lupus erythematosus;	chr16:11113865	chr16:11056556~11057034:+
BRCA	cis	rs9868809	1	rs2310997	ENSG00000270441.1	RP11-694I15.7	4.91	1.03e-06	0.000105	0.3	0.15	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48640578	chr3:49140086~49160851:-
BRCA	cis	rs1223397	0.651	rs2439542	ENSG00000215022.6	RP1-257A7.4	-4.91	1.03e-06	0.000105	-0.18	-0.15	Blood pressure;	chr6:13311591	chr6:13264861~13295586:-
BRCA	cis	rs3764021	0.87	rs2401394	ENSG00000256673.1	RP11-599J14.2	-4.91	1.03e-06	0.000105	-0.17	-0.15	Type 1 diabetes;	chr12:9726830	chr12:9398355~9414851:-
BRCA	cis	rs934734	0.563	rs11126034	ENSG00000204929.10	AC074391.1	-4.91	1.03e-06	0.000105	-0.19	-0.15	Rheumatoid arthritis;	chr2:65353087	chr2:65436711~66084639:+
BRCA	cis	rs848490	0.734	rs12531933	ENSG00000214293.7	APTR	4.91	1.03e-06	0.000105	0.18	0.15	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77671171	chr7:77657660~77696265:-
BRCA	cis	rs2732480	0.5	rs7966829	ENSG00000257735.1	RP11-370I10.6	4.91	1.03e-06	0.000105	0.19	0.15	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48221820	chr12:48350945~48442411:+
BRCA	cis	rs2638953	0.925	rs7312201	ENSG00000247934.4	RP11-967K21.1	-4.91	1.03e-06	0.000105	-0.21	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28417885	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.962	rs12372172	ENSG00000247934.4	RP11-967K21.1	-4.91	1.03e-06	0.000105	-0.21	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28419945	chr12:28163298~28190738:-
BRCA	cis	rs3768617	0.51	rs723014	ENSG00000224468.3	RP11-181K3.4	-4.91	1.04e-06	0.000105	-0.16	-0.15	Fuchs's corneal dystrophy;	chr1:183107152	chr1:183138402~183141282:-
BRCA	cis	rs780094	0.5	rs12995461	ENSG00000234072.1	AC074117.10	4.91	1.04e-06	0.000105	0.16	0.15	Urate levels in overweight individuals;C-reactive protein;Metabolic syndrome;Red blood cell count;Renal underexcretion gout;Nonalcoholic fatty liver disease;Age-related diseases, mortality and associated endophenotypes;Crohn's disease;Calcium levels;Fasting plasma glucose;Metabolic traits;Fasting blood glucose;Fasting blood insulin;Urate levels in obese individuals;Alcohol consumption (drinks per week);Height;Urate levels;Gondoic acid (20:1n-9) levels;Uric acid levels;Age-related disease endophenotypes;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Homeostasis model assessment of insulin resistance;Alcohol consumption;Fasting blood insulin (BMI interaction);Triglycerides;Fasting blood glucose (BMI interaction);Hypertriglyceridemia;LDL cholesterol;Type 2 diabetes;Triglyceride levels;	chr2:27555300	chr2:27356246~27367622:+
BRCA	cis	rs2638953	0.671	rs10843097	ENSG00000278733.1	RP11-425D17.1	-4.91	1.04e-06	0.000105	-0.21	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28114106	chr12:28185625~28186190:-
BRCA	cis	rs9287719	0.674	rs6432130	ENSG00000243819.4	RN7SL832P	-4.91	1.04e-06	0.000105	-0.15	-0.15	Prostate cancer;	chr2:10681431	chr2:10690344~10692099:+
BRCA	cis	rs6921919	0.583	rs7740351	ENSG00000220721.1	OR1F12	4.91	1.04e-06	0.000105	0.18	0.15	Autism spectrum disorder or schizophrenia;	chr6:28431635	chr6:28073316~28074233:+
BRCA	cis	rs9425766	0.64	rs9425756	ENSG00000227373.4	RP11-160H22.5	4.91	1.04e-06	0.000105	0.22	0.15	Life satisfaction;	chr1:173847448	chr1:174115300~174160004:-
BRCA	cis	rs7308116	0.546	rs10507218	ENSG00000274395.1	RP11-554D14.8	4.91	1.04e-06	0.000105	0.18	0.15	Pelvic organ prolapse (moderate/severe);	chr12:107813456	chr12:107835541~107836555:-
BRCA	cis	rs828999	0.688	rs2119344	ENSG00000280186.1	RP11-483I13.6	-4.91	1.04e-06	0.000105	-0.17	-0.15	Monocyte percentage of white cells;	chr1:108157916	chr1:108200413~108202743:+
BRCA	cis	rs875971	0.825	rs10281499	ENSG00000236529.1	RP13-254B10.1	-4.91	1.04e-06	0.000105	-0.17	-0.15	Aortic root size;	chr7:66583979	chr7:65840212~65840596:+
BRCA	cis	rs7772486	0.754	rs6932863	ENSG00000270638.1	RP3-466P17.1	-4.91	1.04e-06	0.000105	-0.18	-0.15	Lobe attachment (rater-scored or self-reported);	chr6:145700119	chr6:145735570~145737218:+
BRCA	cis	rs801193	0.527	rs2707837	ENSG00000236529.1	RP13-254B10.1	4.91	1.04e-06	0.000105	0.17	0.15	Aortic root size;	chr7:66716086	chr7:65840212~65840596:+
BRCA	cis	rs7226408	0.857	rs72885296	ENSG00000267707.2	RP11-95O2.5	4.91	1.04e-06	0.000105	0.23	0.15	Obesity-related traits;	chr18:36871928	chr18:37243776~37247506:+
BRCA	cis	rs7226408	0.802	rs72885298	ENSG00000267707.2	RP11-95O2.5	4.91	1.04e-06	0.000105	0.23	0.15	Obesity-related traits;	chr18:36872101	chr18:37243776~37247506:+
BRCA	cis	rs67981189	0.656	rs2810113	ENSG00000258571.1	PTTG4P	4.91	1.04e-06	0.000105	0.16	0.15	Schizophrenia;	chr14:70929053	chr14:71085482~71085833:-
BRCA	cis	rs7160336	1	rs12589973	ENSG00000259065.1	RP5-1021I20.1	-4.91	1.04e-06	0.000105	-0.17	-0.15	Blood protein levels;	chr14:74142716	chr14:73787360~73803270:+
BRCA	cis	rs9307551	0.552	rs12506212	ENSG00000250334.4	LINC00989	-4.91	1.04e-06	0.000105	-0.2	-0.15	Refractive error;	chr4:79512944	chr4:79492416~79576460:+
BRCA	cis	rs60843830	1	rs60484953	ENSG00000272342.1	RP13-539J13.1	4.91	1.04e-06	0.000105	0.19	0.15	Spherical equivalent (joint analysis main effects and education interaction);	chr2:221560	chr2:739588~740164:-
BRCA	cis	rs6088590	0.561	rs2295444	ENSG00000276073.1	RP5-1125A11.7	-4.91	1.04e-06	0.000105	-0.16	-0.15	Coronary artery disease;	chr20:34586079	chr20:33985617~33988989:-
BRCA	cis	rs10510102	1	rs7923678	ENSG00000226864.1	ATE1-AS1	4.91	1.04e-06	0.000105	0.26	0.15	Breast cancer;	chr10:121832546	chr10:121928312~121951965:+
BRCA	cis	rs3176789	1	rs2071647	ENSG00000256673.1	RP11-599J14.2	4.91	1.04e-06	0.000105	0.19	0.15	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9761409	chr12:9398355~9414851:-
BRCA	cis	rs2562456	0.754	rs112195516	ENSG00000268081.1	RP11-678G14.2	4.91	1.04e-06	0.000105	0.25	0.15	Pain;	chr19:21410849	chr19:21554640~21569237:-
BRCA	cis	rs3764021	0.509	rs10772072	ENSG00000214776.8	RP11-726G1.1	4.91	1.04e-06	0.000105	0.18	0.15	Type 1 diabetes;	chr12:9717335	chr12:9467552~9576275:+
BRCA	cis	rs11098499	0.863	rs17050695	ENSG00000249244.1	RP11-548H18.2	4.91	1.04e-06	0.000105	0.17	0.15	Corneal astigmatism;	chr4:119568372	chr4:119391831~119395335:-
BRCA	cis	rs7267979	0.816	rs6138593	ENSG00000204556.4	CTD-2514C3.1	-4.91	1.04e-06	0.000105	-0.2	-0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25523856	chr20:26018832~26020684:+
BRCA	cis	rs2749097	0.557	rs2301055	ENSG00000244256.3	RN7SL130P	-4.91	1.04e-06	0.000105	-0.21	-0.15	Alcohol consumption (transferrin glycosylation);	chr1:63641146	chr1:63655743~63656047:+
BRCA	cis	rs6081541	0.689	rs6081546	ENSG00000179447.2	RP5-1027G4.3	-4.91	1.04e-06	0.000105	-0.18	-0.15	Psychosis (atypical);	chr20:19240785	chr20:19242302~19284596:-
BRCA	cis	rs2303319	0.504	rs56153413	ENSG00000227403.1	AC009299.3	4.91	1.04e-06	0.000105	0.35	0.15	Cognitive function;	chr2:161583569	chr2:161244739~161249050:+
BRCA	cis	rs8002861	0.935	rs4942256	ENSG00000274001.1	RP11-5G9.5	4.91	1.04e-06	0.000105	0.17	0.15	Leprosy;	chr13:43881784	chr13:43877715~43878163:-
BRCA	cis	rs8002861	0.935	rs9567299	ENSG00000274001.1	RP11-5G9.5	4.91	1.04e-06	0.000105	0.17	0.15	Leprosy;	chr13:43882833	chr13:43877715~43878163:-
BRCA	cis	rs7674212	0.539	rs6815783	ENSG00000248740.4	RP11-328K4.1	4.91	1.04e-06	0.000105	0.17	0.15	Type 2 diabetes;	chr4:103200989	chr4:103256159~103453658:+
BRCA	cis	rs6430585	0.528	rs309142	ENSG00000231890.6	DARS-AS1	-4.91	1.04e-06	0.000105	-0.21	-0.15	Corneal structure;	chr2:135957754	chr2:135985176~136022593:+
BRCA	cis	rs754466	0.914	rs4595491	ENSG00000204049.1	RP11-126H7.4	4.91	1.04e-06	0.000105	0.2	0.15	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77926075	chr10:77866875~77869610:+
BRCA	cis	rs10938353	0.911	rs6447356	ENSG00000273369.1	RP11-700J17.1	-4.91	1.04e-06	0.000105	-0.17	-0.15	Body mass index;	chr4:44588558	chr4:44693946~44694386:-
BRCA	cis	rs10938353	0.911	rs6447357	ENSG00000273369.1	RP11-700J17.1	-4.91	1.04e-06	0.000105	-0.17	-0.15	Body mass index;	chr4:44588577	chr4:44693946~44694386:-
BRCA	cis	rs734999	1	rs10797432	ENSG00000238164.5	RP3-395M20.8	-4.91	1.04e-06	0.000106	-0.12	-0.15	Ulcerative colitis;	chr1:2569899	chr1:2549920~2557031:-
BRCA	cis	rs10938353	0.68	rs1371240	ENSG00000273369.1	RP11-700J17.1	4.91	1.04e-06	0.000106	0.19	0.15	Body mass index;	chr4:44621681	chr4:44693946~44694386:-
BRCA	cis	rs1729951	0.575	rs747842	ENSG00000239213.4	NCK1-AS1	4.91	1.04e-06	0.000106	0.15	0.15	Neuroticism;	chr3:136984279	chr3:136841726~136862054:-
BRCA	cis	rs12681366	0.801	rs55963151	ENSG00000253175.1	RP11-267M23.6	4.91	1.04e-06	0.000106	0.19	0.15	Nonsyndromic cleft lip with cleft palate;	chr8:94466198	chr8:94565036~94565715:+
BRCA	cis	rs1722141	0.633	rs903889	ENSG00000229628.1	AC073115.7	-4.91	1.04e-06	0.000106	-0.2	-0.15	Sitting height ratio;	chr7:45925396	chr7:45990905~46000898:+
BRCA	cis	rs3768617	0.51	rs3768624	ENSG00000224468.3	RP11-181K3.4	-4.91	1.04e-06	0.000106	-0.16	-0.15	Fuchs's corneal dystrophy;	chr1:183110117	chr1:183138402~183141282:-
BRCA	cis	rs3768617	0.51	rs3818417	ENSG00000224468.3	RP11-181K3.4	-4.91	1.04e-06	0.000106	-0.16	-0.15	Fuchs's corneal dystrophy;	chr1:183110241	chr1:183138402~183141282:-
BRCA	cis	rs3768617	0.51	rs2296290	ENSG00000224468.3	RP11-181K3.4	-4.91	1.04e-06	0.000106	-0.16	-0.15	Fuchs's corneal dystrophy;	chr1:183110277	chr1:183138402~183141282:-
BRCA	cis	rs3768617	0.51	rs2296291	ENSG00000224468.3	RP11-181K3.4	-4.91	1.04e-06	0.000106	-0.16	-0.15	Fuchs's corneal dystrophy;	chr1:183110374	chr1:183138402~183141282:-
BRCA	cis	rs3768617	0.528	rs6686682	ENSG00000224468.3	RP11-181K3.4	-4.91	1.04e-06	0.000106	-0.16	-0.15	Fuchs's corneal dystrophy;	chr1:183111404	chr1:183138402~183141282:-
BRCA	cis	rs3768617	0.51	rs10911249	ENSG00000224468.3	RP11-181K3.4	-4.91	1.04e-06	0.000106	-0.16	-0.15	Fuchs's corneal dystrophy;	chr1:183111555	chr1:183138402~183141282:-
BRCA	cis	rs3768617	0.51	rs10752899	ENSG00000224468.3	RP11-181K3.4	-4.91	1.04e-06	0.000106	-0.16	-0.15	Fuchs's corneal dystrophy;	chr1:183112106	chr1:183138402~183141282:-
BRCA	cis	rs2638953	0.962	rs11049540	ENSG00000247934.4	RP11-967K21.1	-4.91	1.04e-06	0.000106	-0.21	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28337959	chr12:28163298~28190738:-
BRCA	cis	rs10911251	0.528	rs2333622	ENSG00000224468.3	RP11-181K3.4	-4.91	1.04e-06	0.000106	-0.16	-0.15	Colorectal cancer;	chr1:183106321	chr1:183138402~183141282:-
BRCA	cis	rs62064224	0.589	rs9889607	ENSG00000279781.1	RP11-466A19.7	-4.91	1.04e-06	0.000106	-0.18	-0.15	Schizophrenia;	chr17:32458567	chr17:32518322~32518934:-
BRCA	cis	rs5770917	1	rs5770917	ENSG00000205559.3	CHKB-AS1	-4.91	1.04e-06	0.000106	-0.34	-0.15	Narcolepsy;	chr22:50578924	chr22:50583026~50583877:+
BRCA	cis	rs3733585	0.631	rs7699671	ENSG00000250413.1	RP11-448G15.1	4.91	1.05e-06	0.000106	0.2	0.15	Cleft plate (environmental tobacco smoke interaction);	chr4:10124250	chr4:10006482~10009725:+
BRCA	cis	rs17507216	0.718	rs72751675	ENSG00000255769.6	GOLGA2P10	-4.91	1.05e-06	0.000106	-0.23	-0.15	Excessive daytime sleepiness;	chr15:82630452	chr15:82472993~82513950:-
BRCA	cis	rs4691139	0.658	rs4691142	ENSG00000248632.1	RP11-366M4.11	4.91	1.05e-06	0.000106	0.15	0.15	Ovarian cancer in BRCA1 mutation carriers;	chr4:165005634	chr4:164968587~164970002:-
BRCA	cis	rs783540	0.542	rs62009945	ENSG00000276710.3	CSPG4P8	4.91	1.05e-06	0.000106	0.19	0.15	Schizophrenia;	chr15:82631205	chr15:82459472~82477258:+
BRCA	cis	rs11098499	0.722	rs7673476	ENSG00000249244.1	RP11-548H18.2	4.91	1.05e-06	0.000106	0.17	0.15	Corneal astigmatism;	chr4:119327528	chr4:119391831~119395335:-
BRCA	cis	rs12477438	0.798	rs7570657	ENSG00000231822.1	AC019097.7	-4.91	1.05e-06	0.000106	-0.17	-0.15	Chronic sinus infection;	chr2:99037818	chr2:99102018~99102752:+
BRCA	cis	rs1387259	0.839	rs7486941	ENSG00000257763.1	OR5BK1P	-4.91	1.05e-06	0.000106	-0.15	-0.15	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48184848	chr12:48355792~48356614:-
BRCA	cis	rs6570726	0.764	rs9403733	ENSG00000270638.1	RP3-466P17.1	4.91	1.05e-06	0.000106	0.17	0.15	Lobe attachment (rater-scored or self-reported);	chr6:145591175	chr6:145735570~145737218:+
BRCA	cis	rs10510102	0.935	rs12243529	ENSG00000226864.1	ATE1-AS1	4.91	1.05e-06	0.000106	0.27	0.15	Breast cancer;	chr10:121880321	chr10:121928312~121951965:+
BRCA	cis	rs1223397	0.651	rs2496147	ENSG00000215022.6	RP1-257A7.4	-4.91	1.05e-06	0.000106	-0.18	-0.15	Blood pressure;	chr6:13313001	chr6:13264861~13295586:-
BRCA	cis	rs728616	0.867	rs723191	ENSG00000225484.5	NUTM2B-AS1	-4.91	1.05e-06	0.000106	-0.38	-0.15	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79948164	chr10:79663088~79826594:-
BRCA	cis	rs2638953	0.925	rs11049563	ENSG00000247934.4	RP11-967K21.1	-4.91	1.05e-06	0.000106	-0.21	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28376041	chr12:28163298~28190738:-
BRCA	cis	rs10504130	1	rs75061868	ENSG00000253844.1	RP11-546K22.1	-4.91	1.05e-06	0.000106	-0.26	-0.15	Venous thromboembolism (SNP x SNP interaction);	chr8:51883380	chr8:51961458~52022974:+
BRCA	cis	rs10504130	1	rs2176120	ENSG00000253844.1	RP11-546K22.1	-4.91	1.05e-06	0.000106	-0.26	-0.15	Venous thromboembolism (SNP x SNP interaction);	chr8:51885462	chr8:51961458~52022974:+
BRCA	cis	rs10504130	1	rs80340160	ENSG00000253844.1	RP11-546K22.1	-4.91	1.05e-06	0.000106	-0.26	-0.15	Venous thromboembolism (SNP x SNP interaction);	chr8:51885628	chr8:51961458~52022974:+
BRCA	cis	rs10504130	1	rs9792352	ENSG00000253844.1	RP11-546K22.1	-4.91	1.05e-06	0.000106	-0.26	-0.15	Venous thromboembolism (SNP x SNP interaction);	chr8:51886862	chr8:51961458~52022974:+
BRCA	cis	rs10504130	1	rs2037138	ENSG00000253844.1	RP11-546K22.1	-4.91	1.05e-06	0.000106	-0.26	-0.15	Venous thromboembolism (SNP x SNP interaction);	chr8:51892153	chr8:51961458~52022974:+
BRCA	cis	rs10504130	1	rs2037139	ENSG00000253844.1	RP11-546K22.1	-4.91	1.05e-06	0.000106	-0.26	-0.15	Venous thromboembolism (SNP x SNP interaction);	chr8:51892324	chr8:51961458~52022974:+
BRCA	cis	rs875971	0.83	rs427575	ENSG00000236529.1	RP13-254B10.1	4.91	1.05e-06	0.000106	0.17	0.15	Aortic root size;	chr7:66054232	chr7:65840212~65840596:+
BRCA	cis	rs6095360	0.966	rs6019557	ENSG00000222365.1	SNORD12B	-4.91	1.05e-06	0.000106	-0.17	-0.15	Intelligence (multi-trait analysis);	chr20:48966835	chr20:49280319~49280409:+
BRCA	cis	rs6095360	1	rs6019558	ENSG00000222365.1	SNORD12B	-4.91	1.05e-06	0.000106	-0.17	-0.15	Intelligence (multi-trait analysis);	chr20:48966943	chr20:49280319~49280409:+
BRCA	cis	rs7973683	0.541	rs6488910	ENSG00000270028.1	RP11-380L11.4	4.91	1.05e-06	0.000106	0.18	0.15	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr12:123909150	chr12:123925461~123926083:-
BRCA	cis	rs17767294	0.708	rs115714358	ENSG00000204709.4	LINC01556	4.91	1.05e-06	0.000106	0.4	0.15	Parkinson's disease;	chr6:27996554	chr6:28943877~28944537:+
BRCA	cis	rs739496	0.542	rs7300400	ENSG00000257595.2	RP3-473L9.4	4.91	1.05e-06	0.000106	0.2	0.15	Platelet count;	chr12:111354375	chr12:111369282~111403310:+
BRCA	cis	rs6991838	0.806	rs11777025	ENSG00000200714.1	Y_RNA	-4.91	1.05e-06	0.000106	-0.17	-0.15	Intelligence (multi-trait analysis);	chr8:65551438	chr8:65592731~65592820:+
BRCA	cis	rs4908768	0.539	rs6670508	ENSG00000232912.4	RP5-1115A15.1	4.91	1.05e-06	0.000106	0.15	0.15	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8587858	chr1:8424645~8434838:+
BRCA	cis	rs875971	1	rs709597	ENSG00000223473.2	GS1-124K5.3	-4.91	1.05e-06	0.000106	-0.12	-0.15	Aortic root size;	chr7:66360996	chr7:66491049~66493566:-
BRCA	cis	rs59972978	0.562	rs3810541	ENSG00000124097.7	HMGB1P1	4.91	1.05e-06	0.000107	0.19	0.15	Alcohol consumption;	chr20:57488263	chr20:57488392~57489027:-
BRCA	cis	rs1979679	0.673	rs12229872	ENSG00000278733.1	RP11-425D17.1	4.91	1.05e-06	0.000107	0.19	0.15	Ossification of the posterior longitudinal ligament of the spine;	chr12:28137845	chr12:28185625~28186190:-
BRCA	cis	rs7246967	0.673	rs62119090	ENSG00000198153.8	ZNF849P	-4.91	1.05e-06	0.000107	-0.29	-0.15	Bronchopulmonary dysplasia;	chr19:22741112	chr19:22685167~22686732:+
BRCA	cis	rs2227564	0.729	rs2633306	ENSG00000271816.1	BMS1P4	-4.91	1.05e-06	0.000107	-0.16	-0.15	Crohn's disease;Inflammatory bowel disease;	chr10:73892689	chr10:73699151~73730487:-
BRCA	cis	rs7674212	0.539	rs6533056	ENSG00000248740.4	RP11-328K4.1	4.91	1.05e-06	0.000107	0.17	0.15	Type 2 diabetes;	chr4:103199840	chr4:103256159~103453658:+
BRCA	cis	rs2836974	0.563	rs6517522	ENSG00000255568.3	BRWD1-AS2	4.91	1.05e-06	0.000107	0.14	0.15	Cognitive function;	chr21:39181919	chr21:39313935~39314962:+
BRCA	cis	rs801193	0.569	rs13226966	ENSG00000236529.1	RP13-254B10.1	4.91	1.05e-06	0.000107	0.17	0.15	Aortic root size;	chr7:66768636	chr7:65840212~65840596:+
BRCA	cis	rs11955398	0.585	rs4398599	ENSG00000215032.2	GNL3LP1	-4.91	1.06e-06	0.000107	-0.18	-0.15	Intelligence (multi-trait analysis);	chr5:60736586	chr5:60891935~60893577:-
BRCA	cis	rs11955398	0.585	rs4700384	ENSG00000215032.2	GNL3LP1	-4.91	1.06e-06	0.000107	-0.18	-0.15	Intelligence (multi-trait analysis);	chr5:60736644	chr5:60891935~60893577:-
BRCA	cis	rs8114671	0.805	rs6060168	ENSG00000279253.1	RP4-614O4.13	-4.91	1.06e-06	0.000107	-0.17	-0.15	Height;	chr20:35033214	chr20:35262727~35264187:-
BRCA	cis	rs11098499	0.954	rs878373	ENSG00000250412.1	KLHL2P1	4.91	1.06e-06	0.000107	0.18	0.15	Corneal astigmatism;	chr4:119316329	chr4:119334329~119378233:+
BRCA	cis	rs12501370	0.569	rs13106895	ENSG00000201736.1	RNA5SP160	4.91	1.06e-06	0.000107	0.17	0.15	Iris color (L* coordinate);	chr4:40981262	chr4:40990154~40990273:+
BRCA	cis	rs12501370	0.569	rs6835668	ENSG00000201736.1	RNA5SP160	4.91	1.06e-06	0.000107	0.17	0.15	Iris color (L* coordinate);	chr4:40981774	chr4:40990154~40990273:+
BRCA	cis	rs2638953	0.676	rs11049727	ENSG00000247934.4	RP11-967K21.1	-4.91	1.06e-06	0.000107	-0.21	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28584864	chr12:28163298~28190738:-
BRCA	cis	rs7246657	0.508	rs10419845	ENSG00000267422.1	CTD-2554C21.1	-4.91	1.06e-06	0.000107	-0.27	-0.15	Coronary artery calcification;	chr19:37000290	chr19:37779686~37792865:+
BRCA	cis	rs739496	0.579	rs10849984	ENSG00000226469.1	ADAM1B	4.91	1.06e-06	0.000107	0.19	0.15	Platelet count;	chr12:111909924	chr12:111927018~111929017:+
BRCA	cis	rs739496	0.579	rs10849985	ENSG00000226469.1	ADAM1B	4.91	1.06e-06	0.000107	0.19	0.15	Platelet count;	chr12:111909950	chr12:111927018~111929017:+
BRCA	cis	rs7267979	0.844	rs6083851	ENSG00000277938.1	RP5-965G21.3	-4.91	1.06e-06	0.000107	-0.18	-0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25420599	chr20:25229150~25231933:+
BRCA	cis	rs9652601	0.691	rs12708717	ENSG00000274038.1	RP11-66H6.4	-4.91	1.06e-06	0.000107	-0.16	-0.15	Systemic lupus erythematosus;	chr16:11098522	chr16:11056556~11057034:+
BRCA	cis	rs2832077	0.506	rs2832088	ENSG00000215533.7	LINC00189	4.91	1.06e-06	0.000107	0.19	0.15	Cognitive test performance;	chr21:28786298	chr21:29193480~29288205:+
BRCA	cis	rs180730	0.561	rs2892917	ENSG00000251609.2	SETP12	-4.91	1.06e-06	0.000107	-0.19	-0.15	Fasting plasma glucose;	chr4:120898600	chr4:120895494~120897083:-
BRCA	cis	rs3768617	0.51	rs2027076	ENSG00000224468.3	RP11-181K3.4	-4.91	1.06e-06	0.000107	-0.16	-0.15	Fuchs's corneal dystrophy;	chr1:183104272	chr1:183138402~183141282:-
BRCA	cis	rs10752881	0.775	rs2147585	ENSG00000224468.3	RP11-181K3.4	-4.91	1.06e-06	0.000107	-0.16	-0.15	Colorectal cancer;	chr1:183105740	chr1:183138402~183141282:-
BRCA	cis	rs10911251	0.528	rs2182020	ENSG00000224468.3	RP11-181K3.4	-4.91	1.06e-06	0.000107	-0.16	-0.15	Colorectal cancer;	chr1:183105829	chr1:183138402~183141282:-
BRCA	cis	rs3768617	0.51	rs7414273	ENSG00000224468.3	RP11-181K3.4	-4.91	1.06e-06	0.000107	-0.16	-0.15	Fuchs's corneal dystrophy;	chr1:183105882	chr1:183138402~183141282:-
BRCA	cis	rs3768617	0.51	rs10911243	ENSG00000224468.3	RP11-181K3.4	-4.91	1.06e-06	0.000107	-0.16	-0.15	Fuchs's corneal dystrophy;	chr1:183106280	chr1:183138402~183141282:-
BRCA	cis	rs10129255	0.5	rs4774008	ENSG00000211967.3	IGHV3-53	-4.91	1.06e-06	0.000107	-0.1	-0.15	Kawasaki disease;	chr14:106681273	chr14:106592676~106593347:-
BRCA	cis	rs1707322	1	rs1707338	ENSG00000234329.1	RP11-767N6.2	-4.91	1.06e-06	0.000107	-0.15	-0.15	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46046309	chr1:45651039~45651826:-
BRCA	cis	rs1707322	0.964	rs1707339	ENSG00000234329.1	RP11-767N6.2	-4.91	1.06e-06	0.000107	-0.15	-0.15	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46047507	chr1:45651039~45651826:-
BRCA	cis	rs1707322	1	rs1768818	ENSG00000234329.1	RP11-767N6.2	-4.91	1.06e-06	0.000107	-0.15	-0.15	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46048614	chr1:45651039~45651826:-
BRCA	cis	rs1707322	1	rs1768817	ENSG00000234329.1	RP11-767N6.2	-4.91	1.06e-06	0.000107	-0.15	-0.15	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46048862	chr1:45651039~45651826:-
BRCA	cis	rs4664293	0.867	rs12617546	ENSG00000224152.1	AC009506.1	-4.91	1.06e-06	0.000107	-0.17	-0.15	Monocyte percentage of white cells;	chr2:159767079	chr2:159615296~159617082:+
BRCA	cis	rs7618915	0.547	rs2878726	ENSG00000243224.1	RP5-1157M23.2	-4.91	1.06e-06	0.000107	-0.17	-0.15	Bipolar disorder;	chr3:52714255	chr3:52239258~52241097:+
BRCA	cis	rs7592578	0.771	rs10432434	ENSG00000272979.1	RP11-647K16.1	-4.91	1.06e-06	0.000107	-0.25	-0.15	Diastolic blood pressure;	chr2:190522353	chr2:190454092~190454521:-
BRCA	cis	rs7312933	0.531	rs1796380	ENSG00000257225.1	RP11-328C8.4	4.91	1.06e-06	0.000107	0.18	0.15	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42397741	chr12:42459366~42466128:+
BRCA	cis	rs1383484	0.958	rs5016012	ENSG00000230373.7	GOLGA6L5P	-4.91	1.06e-06	0.000107	-0.17	-0.15	Height;	chr15:83843253	chr15:84507885~84516814:-
BRCA	cis	rs2243480	0.522	rs12698511	ENSG00000228409.4	CCT6P1	4.91	1.06e-06	0.000107	0.25	0.15	Diabetic kidney disease;	chr7:66009932	chr7:65751142~65763354:+
BRCA	cis	rs1520333	0.54	rs12679690	ENSG00000254352.1	RP11-578O24.2	-4.91	1.06e-06	0.000107	-0.23	-0.15	Multiple sclerosis;	chr8:78454599	chr8:78723796~78724136:-
BRCA	cis	rs12477438	0.501	rs11123770	ENSG00000231822.1	AC019097.7	4.91	1.06e-06	0.000107	0.15	0.15	Chronic sinus infection;	chr2:99208639	chr2:99102018~99102752:+
BRCA	cis	rs875971	0.83	rs6950137	ENSG00000273448.1	RP11-166O4.6	4.91	1.06e-06	0.000107	0.14	0.15	Aortic root size;	chr7:66511623	chr7:67333047~67334383:+
BRCA	cis	rs12893668	0.608	rs12889721	ENSG00000244691.1	RPL10AP1	-4.91	1.06e-06	0.000107	-0.2	-0.15	Reticulocyte count;	chr14:103568526	chr14:103412119~103412761:-
BRCA	cis	rs8180040	0.966	rs2062278	ENSG00000271161.1	BOLA2P2	4.91	1.06e-06	0.000107	0.16	0.15	Colorectal cancer;	chr3:47375271	chr3:47499841~47500407:+
BRCA	cis	rs6840360	0.642	rs7680013	ENSG00000278978.1	RP11-164P12.5	-4.91	1.06e-06	0.000107	-0.17	-0.15	Intelligence (multi-trait analysis);	chr4:151488325	chr4:151669786~151670503:+
BRCA	cis	rs6840360	0.642	rs7680236	ENSG00000278978.1	RP11-164P12.5	-4.91	1.06e-06	0.000107	-0.17	-0.15	Intelligence (multi-trait analysis);	chr4:151488449	chr4:151669786~151670503:+
BRCA	cis	rs1862618	0.671	rs252897	ENSG00000271828.1	CTD-2310F14.1	4.91	1.06e-06	0.000107	0.19	0.15	Initial pursuit acceleration;	chr5:56927173	chr5:56927874~56929573:+
BRCA	cis	rs7671261	0.54	rs4325981	ENSG00000270720.1	RP11-84C13.2	4.91	1.06e-06	0.000107	0.18	0.15	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr4:89103170	chr4:89119284~89119871:+
BRCA	cis	rs4718428	0.672	rs4718412	ENSG00000229180.5	GS1-124K5.11	-4.91	1.06e-06	0.000107	-0.14	-0.15	Corneal structure;	chr7:66821880	chr7:66526088~66542624:-
BRCA	cis	rs2380205	0.516	rs7919913	ENSG00000232807.2	RP11-536K7.3	4.91	1.06e-06	0.000107	0.16	0.15	Breast cancer;	chr10:5884253	chr10:5934270~5945900:-
BRCA	cis	rs10989172	0.714	rs4320660	ENSG00000175611.10	LINC00476	4.91	1.06e-06	0.000107	0.16	0.15	Common carotid intima-media thickness in HIV negative individuals;	chr9:96080586	chr9:95759231~95875977:-
BRCA	cis	rs4664293	0.867	rs34392518	ENSG00000224152.1	AC009506.1	-4.91	1.06e-06	0.000107	-0.17	-0.15	Monocyte percentage of white cells;	chr2:159749367	chr2:159615296~159617082:+
BRCA	cis	rs4664293	0.805	rs6432559	ENSG00000224152.1	AC009506.1	-4.91	1.06e-06	0.000107	-0.17	-0.15	Monocyte percentage of white cells;	chr2:159750649	chr2:159615296~159617082:+
BRCA	cis	rs4664293	0.867	rs6432560	ENSG00000224152.1	AC009506.1	-4.91	1.06e-06	0.000107	-0.17	-0.15	Monocyte percentage of white cells;	chr2:159750758	chr2:159615296~159617082:+
BRCA	cis	rs4664293	0.867	rs3863924	ENSG00000224152.1	AC009506.1	-4.91	1.06e-06	0.000107	-0.17	-0.15	Monocyte percentage of white cells;	chr2:159758247	chr2:159615296~159617082:+
BRCA	cis	rs4664293	0.867	rs11681565	ENSG00000224152.1	AC009506.1	-4.91	1.06e-06	0.000107	-0.17	-0.15	Monocyte percentage of white cells;	chr2:159760362	chr2:159615296~159617082:+
BRCA	cis	rs4664293	0.836	rs11687502	ENSG00000224152.1	AC009506.1	-4.91	1.06e-06	0.000107	-0.17	-0.15	Monocyte percentage of white cells;	chr2:159760464	chr2:159615296~159617082:+
BRCA	cis	rs4664293	0.836	rs13401087	ENSG00000224152.1	AC009506.1	-4.91	1.06e-06	0.000107	-0.17	-0.15	Monocyte percentage of white cells;	chr2:159760957	chr2:159615296~159617082:+
BRCA	cis	rs4664293	0.867	rs12692564	ENSG00000224152.1	AC009506.1	-4.91	1.06e-06	0.000107	-0.17	-0.15	Monocyte percentage of white cells;	chr2:159761326	chr2:159615296~159617082:+
BRCA	cis	rs4664293	0.867	rs1427328	ENSG00000224152.1	AC009506.1	-4.91	1.06e-06	0.000107	-0.17	-0.15	Monocyte percentage of white cells;	chr2:159762064	chr2:159615296~159617082:+
BRCA	cis	rs4664293	0.613	rs9784044	ENSG00000224152.1	AC009506.1	-4.91	1.06e-06	0.000107	-0.17	-0.15	Monocyte percentage of white cells;	chr2:159765854	chr2:159615296~159617082:+
BRCA	cis	rs4664293	0.867	rs4664301	ENSG00000224152.1	AC009506.1	-4.91	1.06e-06	0.000107	-0.17	-0.15	Monocyte percentage of white cells;	chr2:159766855	chr2:159615296~159617082:+
BRCA	cis	rs7267979	0.932	rs4280527	ENSG00000125804.12	FAM182A	-4.91	1.06e-06	0.000107	-0.19	-0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25563378	chr20:26054655~26086917:+
BRCA	cis	rs853679	0.76	rs2299029	ENSG00000216901.1	AL022393.7	4.91	1.06e-06	0.000107	0.23	0.15	Depression;	chr6:28231053	chr6:28176188~28176674:+
BRCA	cis	rs1124769	0.57	rs2574757	ENSG00000259378.1	DCAF13P3	4.91	1.06e-06	0.000107	0.2	0.15	Cognitive performance;	chr15:50846263	chr15:50944663~50945996:+
BRCA	cis	rs2790457	0.792	rs1265841	ENSG00000254635.4	WAC-AS1	-4.91	1.06e-06	0.000108	-0.18	-0.15	Multiple myeloma;	chr10:28631772	chr10:28522652~28532743:-
BRCA	cis	rs6723108	0.651	rs35215000	ENSG00000224043.6	CCNT2-AS1	4.91	1.06e-06	0.000108	0.2	0.15	Type 2 diabetes;	chr2:134610086	chr2:134735464~134918710:-
BRCA	cis	rs1722141	0.634	rs2462326	ENSG00000237471.1	AC073115.6	4.91	1.06e-06	0.000108	0.2	0.15	Sitting height ratio;	chr7:46003037	chr7:45969657~45980191:+
BRCA	cis	rs7312933	0.558	rs55702525	ENSG00000257225.1	RP11-328C8.4	4.91	1.06e-06	0.000108	0.18	0.15	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42420507	chr12:42459366~42466128:+
BRCA	cis	rs7312933	0.558	rs1796394	ENSG00000257225.1	RP11-328C8.4	4.91	1.06e-06	0.000108	0.18	0.15	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42432557	chr12:42459366~42466128:+
BRCA	cis	rs5758659	0.652	rs133335	ENSG00000273366.1	CTA-989H11.1	4.91	1.06e-06	0.000108	0.18	0.15	Cognitive function;	chr22:42020052	chr22:42278188~42278846:+
BRCA	cis	rs875971	0.767	rs61348003	ENSG00000236529.1	RP13-254B10.1	4.91	1.06e-06	0.000108	0.17	0.15	Aortic root size;	chr7:66540947	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.825	rs801202	ENSG00000236529.1	RP13-254B10.1	-4.91	1.06e-06	0.000108	-0.17	-0.15	Aortic root size;	chr7:66558942	chr7:65840212~65840596:+
BRCA	cis	rs10844706	0.699	rs2401390	ENSG00000214776.8	RP11-726G1.1	4.91	1.07e-06	0.000108	0.18	0.15	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9719218	chr12:9467552~9576275:+
BRCA	cis	rs2833693	0.574	rs9978000	ENSG00000261610.1	AP000265.1	4.91	1.07e-06	0.000108	0.18	0.15	Temperament;	chr21:32176510	chr21:32259804~32261585:-
BRCA	cis	rs12477438	0.501	rs1133977	ENSG00000231822.1	AC019097.7	-4.91	1.07e-06	0.000108	-0.15	-0.15	Chronic sinus infection;	chr2:99125521	chr2:99102018~99102752:+
BRCA	cis	rs7226408	0.857	rs56217642	ENSG00000267707.2	RP11-95O2.5	4.91	1.07e-06	0.000108	0.22	0.15	Obesity-related traits;	chr18:37107881	chr18:37243776~37247506:+
BRCA	cis	rs6439153	0.933	rs7648877	ENSG00000231305.3	RP11-723O4.2	4.91	1.07e-06	0.000108	0.17	0.15	Pneumococcal bacteremia;	chr3:128991137	chr3:128861313~128871540:-
BRCA	cis	rs4664293	0.967	rs10202187	ENSG00000226266.5	AC009961.3	-4.91	1.07e-06	0.000108	-0.19	-0.15	Monocyte percentage of white cells;	chr2:159571135	chr2:159670708~159712435:-
BRCA	cis	rs2015599	0.549	rs10771512	ENSG00000257176.2	RP11-996F15.2	4.91	1.07e-06	0.000108	0.17	0.15	Platelet count;Mean platelet volume;	chr12:29287303	chr12:29280418~29317848:-
BRCA	cis	rs11714574	0.557	rs6787467	ENSG00000273493.1	RP11-80H18.4	-4.91	1.07e-06	0.000108	-0.19	-0.15	Response to abacavir-containing treatment in HIV-1 infection (virologic failure);	chr3:58392161	chr3:58329965~58330118:+
BRCA	cis	rs2243480	0.908	rs313822	ENSG00000275400.1	RP4-756H11.5	4.91	1.07e-06	0.000108	0.28	0.15	Diabetic kidney disease;	chr7:66108952	chr7:66553805~66554199:-
BRCA	cis	rs10911251	0.528	rs2147584	ENSG00000224468.3	RP11-181K3.4	-4.91	1.07e-06	0.000108	-0.16	-0.15	Colorectal cancer;	chr1:183105629	chr1:183138402~183141282:-
BRCA	cis	rs12893668	0.572	rs2273175	ENSG00000269958.1	RP11-73M18.8	4.91	1.07e-06	0.000108	0.17	0.15	Reticulocyte count;	chr14:103693804	chr14:103696353~103697163:+
BRCA	cis	rs1075265	0.568	rs3095756	ENSG00000235937.1	AC008280.1	4.91	1.07e-06	0.000108	0.16	0.15	Chronotype;Morning vs. evening chronotype;	chr2:53822332	chr2:54029552~54030682:-
BRCA	cis	rs6545883	0.894	rs4672431	ENSG00000270820.4	RP11-355B11.2	-4.91	1.07e-06	0.000108	-0.17	-0.15	Tuberculosis;	chr2:61292787	chr2:61471188~61484130:+
BRCA	cis	rs7772486	0.79	rs9497431	ENSG00000270638.1	RP3-466P17.1	-4.91	1.07e-06	0.000108	-0.18	-0.15	Lobe attachment (rater-scored or self-reported);	chr6:145927041	chr6:145735570~145737218:+
BRCA	cis	rs7772486	0.79	rs7753092	ENSG00000270638.1	RP3-466P17.1	-4.91	1.07e-06	0.000108	-0.18	-0.15	Lobe attachment (rater-scored or self-reported);	chr6:145927727	chr6:145735570~145737218:+
BRCA	cis	rs10899021	1	rs10899021	ENSG00000279353.1	RP11-864N7.4	-4.91	1.07e-06	0.000108	-0.27	-0.15	Response to metformin (IC50);	chr11:74627009	chr11:74698231~74699658:-
BRCA	cis	rs1124769	0.619	rs4598846	ENSG00000259378.1	DCAF13P3	4.91	1.07e-06	0.000108	0.2	0.15	Cognitive performance;	chr15:51095918	chr15:50944663~50945996:+
BRCA	cis	rs11098499	0.754	rs28643450	ENSG00000249244.1	RP11-548H18.2	4.91	1.07e-06	0.000108	0.17	0.15	Corneal astigmatism;	chr4:119324087	chr4:119391831~119395335:-
BRCA	cis	rs875971	0.862	rs801194	ENSG00000236529.1	RP13-254B10.1	-4.91	1.07e-06	0.000108	-0.17	-0.15	Aortic root size;	chr7:66563508	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.651	rs2420596	ENSG00000273448.1	RP11-166O4.6	4.91	1.07e-06	0.000108	0.14	0.15	Aortic root size;	chr7:66450996	chr7:67333047~67334383:+
BRCA	cis	rs875971	0.52	rs2420597	ENSG00000273448.1	RP11-166O4.6	4.91	1.07e-06	0.000108	0.14	0.15	Aortic root size;	chr7:66450999	chr7:67333047~67334383:+
BRCA	cis	rs12497850	0.864	rs6779394	ENSG00000225399.4	RP11-3B7.1	4.91	1.07e-06	0.000108	0.15	0.15	Parkinson's disease;	chr3:49120338	chr3:49260085~49261316:+
BRCA	cis	rs875971	0.862	rs1968126	ENSG00000236529.1	RP13-254B10.1	-4.91	1.07e-06	0.000108	-0.17	-0.15	Aortic root size;	chr7:66592017	chr7:65840212~65840596:+
BRCA	cis	rs7572733	0.773	rs11690491	ENSG00000231621.1	AC013264.2	-4.91	1.07e-06	0.000108	-0.14	-0.15	Dermatomyositis;	chr2:197650200	chr2:197197991~197199273:+
BRCA	cis	rs2524005	1	rs2524005	ENSG00000228022.4	HCG20	-4.91	1.07e-06	0.000108	-0.25	-0.15	Bipolar disorder and schizophrenia;	chr6:29931900	chr6:30766825~30792250:+
BRCA	cis	rs4356203	0.87	rs214918	ENSG00000272034.1	SNORD14A	-4.91	1.07e-06	0.000108	-0.15	-0.15	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17218302	chr11:17074654~17074744:-
BRCA	cis	rs4356203	0.87	rs214915	ENSG00000272034.1	SNORD14A	-4.91	1.07e-06	0.000108	-0.15	-0.15	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17220226	chr11:17074654~17074744:-
BRCA	cis	rs4356203	0.87	rs214914	ENSG00000272034.1	SNORD14A	-4.91	1.07e-06	0.000108	-0.15	-0.15	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17220345	chr11:17074654~17074744:-
BRCA	cis	rs4356203	0.84	rs214911	ENSG00000272034.1	SNORD14A	-4.91	1.07e-06	0.000108	-0.15	-0.15	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17220691	chr11:17074654~17074744:-
BRCA	cis	rs4356203	0.87	rs214910	ENSG00000272034.1	SNORD14A	-4.91	1.07e-06	0.000108	-0.15	-0.15	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17221242	chr11:17074654~17074744:-
BRCA	cis	rs4356203	0.87	rs214909	ENSG00000272034.1	SNORD14A	-4.91	1.07e-06	0.000108	-0.15	-0.15	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17221731	chr11:17074654~17074744:-
BRCA	cis	rs6430585	0.583	rs79176913	ENSG00000231890.6	DARS-AS1	-4.91	1.07e-06	0.000108	-0.23	-0.15	Corneal structure;	chr2:135880543	chr2:135985176~136022593:+
BRCA	cis	rs8040855	0.599	rs6496791	ENSG00000259774.1	RP11-182J1.13	-4.91	1.07e-06	0.000108	-0.17	-0.15	Bulimia nervosa;	chr15:85182428	chr15:84422618~84425882:+
BRCA	cis	rs6545883	0.894	rs9677047	ENSG00000270820.4	RP11-355B11.2	-4.91	1.07e-06	0.000108	-0.17	-0.15	Tuberculosis;	chr2:61358160	chr2:61471188~61484130:+
BRCA	cis	rs2303319	0.504	rs1567421	ENSG00000227403.1	AC009299.3	-4.91	1.07e-06	0.000108	-0.35	-0.15	Cognitive function;	chr2:161619107	chr2:161244739~161249050:+
BRCA	cis	rs2803122	0.501	rs10811140	ENSG00000272842.1	RP11-513M16.7	-4.91	1.07e-06	0.000108	-0.18	-0.15	Pulse pressure;	chr9:19230401	chr9:19371386~19371945:-
BRCA	cis	rs7267979	1	rs6050565	ENSG00000125804.12	FAM182A	4.91	1.07e-06	0.000108	0.19	0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25366927	chr20:26054655~26086917:+
BRCA	cis	rs595244	1	rs77360718	ENSG00000259705.1	RP11-227D13.1	4.91	1.07e-06	0.000108	0.27	0.15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48501418	chr15:48645951~48652016:+
BRCA	cis	rs6723226	0.638	rs6543657	ENSG00000276517.1	AL133243.2	-4.91	1.07e-06	0.000108	-0.18	-0.15	Intelligence (multi-trait analysis);	chr2:32480017	chr2:32526504~32529507:+
BRCA	cis	rs4699052	0.662	rs6825489	ENSG00000248740.4	RP11-328K4.1	4.91	1.07e-06	0.000108	0.17	0.15	Testicular germ cell tumor;	chr4:103329027	chr4:103256159~103453658:+
BRCA	cis	rs13108904	0.901	rs1316394	ENSG00000254094.1	AC078852.1	-4.91	1.07e-06	0.000108	-0.17	-0.15	Obesity-related traits;	chr4:1322032	chr4:1356581~1358075:+
BRCA	cis	rs13108904	0.934	rs13115173	ENSG00000254094.1	AC078852.1	-4.91	1.07e-06	0.000108	-0.17	-0.15	Obesity-related traits;	chr4:1323036	chr4:1356581~1358075:+
BRCA	cis	rs10208649	0.831	rs2287347	ENSG00000233266.1	HMGB1P31	-4.91	1.07e-06	0.000109	-0.28	-0.15	Body mass index;	chr2:53812428	chr2:54051334~54051760:+
BRCA	cis	rs4356203	0.87	rs214916	ENSG00000272034.1	SNORD14A	-4.91	1.08e-06	0.000109	-0.15	-0.15	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17220102	chr11:17074654~17074744:-
BRCA	cis	rs4666002	0.956	rs34502053	ENSG00000234072.1	AC074117.10	4.91	1.08e-06	0.000109	0.16	0.15	Phospholipid levels (plasma);	chr2:27631657	chr2:27356246~27367622:+
BRCA	cis	rs6840360	0.642	rs7698816	ENSG00000251611.1	RP11-610P16.1	-4.91	1.08e-06	0.000109	-0.13	-0.15	Intelligence (multi-trait analysis);	chr4:151431820	chr4:151407551~151408835:-
BRCA	cis	rs6570726	0.738	rs4495284	ENSG00000270638.1	RP3-466P17.1	4.91	1.08e-06	0.000109	0.17	0.15	Lobe attachment (rater-scored or self-reported);	chr6:145595481	chr6:145735570~145737218:+
BRCA	cis	rs10654220	1	rs10654220	ENSG00000235423.7	RP11-282O18.3	4.91	1.08e-06	0.000109	0.22	0.15	Platelet count;	chr12:123218875	chr12:123252030~123261483:-
BRCA	cis	rs12439619	0.846	rs62011975	ENSG00000255769.6	GOLGA2P10	-4.91	1.08e-06	0.000109	-0.22	-0.15	Intelligence (multi-trait analysis);	chr15:82159213	chr15:82472993~82513950:-
BRCA	cis	rs6570726	0.791	rs365747	ENSG00000270638.1	RP3-466P17.1	4.91	1.08e-06	0.000109	0.17	0.15	Lobe attachment (rater-scored or self-reported);	chr6:145545648	chr6:145735570~145737218:+
BRCA	cis	rs6570726	0.764	rs448258	ENSG00000270638.1	RP3-466P17.1	4.91	1.08e-06	0.000109	0.17	0.15	Lobe attachment (rater-scored or self-reported);	chr6:145548009	chr6:145735570~145737218:+
BRCA	cis	rs72482608	0.835	rs7527200	ENSG00000271811.1	RP1-79C4.4	4.91	1.08e-06	0.000109	0.17	0.15	Emphysema imaging phenotypes;	chr1:170771949	chr1:170667381~170669425:+
BRCA	cis	rs4578769	0.959	rs3898593	ENSG00000265939.1	UBE2CP2	4.91	1.08e-06	0.000109	0.18	0.15	Eosinophil percentage of white cells;	chr18:22909074	chr18:22900486~22900995:-
BRCA	cis	rs8180040	0.932	rs62248599	ENSG00000276925.1	RP11-708J19.3	4.91	1.08e-06	0.000109	0.17	0.15	Colorectal cancer;	chr3:47475238	chr3:47469777~47469987:+
BRCA	cis	rs16958440	0.867	rs80106524	ENSG00000280212.1	RP11-49K24.3	4.91	1.08e-06	0.000109	0.35	0.15	Sitting height ratio;	chr18:47150268	chr18:47076117~47076594:+
BRCA	cis	rs16958440	0.867	rs79712753	ENSG00000280212.1	RP11-49K24.3	4.91	1.08e-06	0.000109	0.35	0.15	Sitting height ratio;	chr18:47150356	chr18:47076117~47076594:+
BRCA	cis	rs16958440	0.867	rs3809965	ENSG00000280212.1	RP11-49K24.3	4.91	1.08e-06	0.000109	0.35	0.15	Sitting height ratio;	chr18:47150501	chr18:47076117~47076594:+
BRCA	cis	rs16958440	0.867	rs74411203	ENSG00000280212.1	RP11-49K24.3	4.91	1.08e-06	0.000109	0.35	0.15	Sitting height ratio;	chr18:47151095	chr18:47076117~47076594:+
BRCA	cis	rs16958440	0.867	rs74346439	ENSG00000280212.1	RP11-49K24.3	4.91	1.08e-06	0.000109	0.35	0.15	Sitting height ratio;	chr18:47151096	chr18:47076117~47076594:+
BRCA	cis	rs16958440	0.867	rs3809966	ENSG00000280212.1	RP11-49K24.3	4.91	1.08e-06	0.000109	0.35	0.15	Sitting height ratio;	chr18:47151256	chr18:47076117~47076594:+
BRCA	cis	rs16958440	0.867	rs12326457	ENSG00000280212.1	RP11-49K24.3	4.91	1.08e-06	0.000109	0.35	0.15	Sitting height ratio;	chr18:47152054	chr18:47076117~47076594:+
BRCA	cis	rs16958440	0.867	rs12326465	ENSG00000280212.1	RP11-49K24.3	4.91	1.08e-06	0.000109	0.35	0.15	Sitting height ratio;	chr18:47152274	chr18:47076117~47076594:+
BRCA	cis	rs16958440	0.867	rs75934126	ENSG00000280212.1	RP11-49K24.3	4.91	1.08e-06	0.000109	0.35	0.15	Sitting height ratio;	chr18:47153410	chr18:47076117~47076594:+
BRCA	cis	rs2239547	0.657	rs3755803	ENSG00000242142.1	SERBP1P3	4.91	1.08e-06	0.000109	0.19	0.15	Schizophrenia;	chr3:52832141	chr3:53064283~53065091:-
BRCA	cis	rs3753275	0.568	rs10864359	ENSG00000230679.1	ENO1-AS1	4.91	1.08e-06	0.000109	0.2	0.15	Educational attainment;	chr1:8638551	chr1:8878835~8879894:+
BRCA	cis	rs7246967	0.551	rs62118775	ENSG00000198153.8	ZNF849P	-4.91	1.08e-06	0.000109	-0.3	-0.15	Bronchopulmonary dysplasia;	chr19:22644376	chr19:22685167~22686732:+
BRCA	cis	rs2235642	0.893	rs2076442	ENSG00000260989.1	LA16c-395F10.2	-4.91	1.08e-06	0.000109	-0.16	-0.15	Coronary artery disease;	chr16:1541111	chr16:1580527~1610328:+
BRCA	cis	rs494453	0.807	rs1324889	ENSG00000227811.2	FAM212B-AS1	4.91	1.08e-06	0.000109	0.19	0.15	Osteoporosis-related phenotypes;	chr1:111641018	chr1:111739841~111747798:+
BRCA	cis	rs904251	0.698	rs2646926	ENSG00000204110.6	RP1-153P14.8	-4.91	1.08e-06	0.000109	-0.17	-0.15	Cognitive performance;	chr6:37457212	chr6:37507348~37535616:+
BRCA	cis	rs9652601	0.608	rs8061826	ENSG00000274038.1	RP11-66H6.4	-4.91	1.08e-06	0.000109	-0.16	-0.15	Systemic lupus erythematosus;	chr16:11098930	chr16:11056556~11057034:+
BRCA	cis	rs8133949	1	rs75128809	ENSG00000237232.6	ZNF295-AS1	4.91	1.08e-06	0.000109	0.23	0.15	Hand grip strength;	chr21:41998101	chr21:42009194~42024924:+
BRCA	cis	rs3764021	0.837	rs7306557	ENSG00000256673.1	RP11-599J14.2	-4.91	1.08e-06	0.000109	-0.17	-0.15	Type 1 diabetes;	chr12:9724760	chr12:9398355~9414851:-
BRCA	cis	rs11158026	0.603	rs8020545	ENSG00000258413.1	RP11-665C16.6	-4.91	1.08e-06	0.000109	-0.2	-0.15	Parkinson's disease;	chr14:54942352	chr14:55262767~55272075:-
BRCA	cis	rs11158026	0.574	rs8019390	ENSG00000258413.1	RP11-665C16.6	-4.91	1.08e-06	0.000109	-0.2	-0.15	Parkinson's disease;	chr14:54942366	chr14:55262767~55272075:-
BRCA	cis	rs7577696	0.886	rs6737500	ENSG00000272716.1	RP11-563N4.1	-4.91	1.08e-06	0.000109	-0.17	-0.15	Inflammatory biomarkers;	chr2:32038018	chr2:32165046~32165757:-
BRCA	cis	rs9308731	0.863	rs616582	ENSG00000230499.1	AC108463.1	-4.91	1.08e-06	0.000109	-0.18	-0.15	Chronic lymphocytic leukemia;	chr2:111184418	chr2:111195963~111206494:+
BRCA	cis	rs7985	0.595	rs2032576	ENSG00000244625.4	MIATNB	4.91	1.08e-06	0.000109	0.17	0.15	Electroencephalogram traits;	chr22:26693692	chr22:26672767~26780207:+
BRCA	cis	rs1440410	0.83	rs12505142	ENSG00000250326.1	RP11-284M14.1	-4.91	1.08e-06	0.000109	-0.16	-0.15	Ischemic stroke;	chr4:143259754	chr4:142933195~143184861:-
BRCA	cis	rs7226408	0.847	rs115623155	ENSG00000267707.2	RP11-95O2.5	4.91	1.08e-06	0.000109	0.23	0.15	Obesity-related traits;	chr18:37104749	chr18:37243776~37247506:+
BRCA	cis	rs172166	0.694	rs203876	ENSG00000219392.1	RP1-265C24.5	-4.91	1.08e-06	0.000109	-0.21	-0.15	Cardiac Troponin-T levels;	chr6:28078895	chr6:28115628~28116551:+
BRCA	cis	rs2880765	0.631	rs55767890	ENSG00000202081.1	RNU6-1280P	4.91	1.08e-06	0.000109	0.19	0.15	Coronary artery disease;	chr15:85460911	chr15:85651522~85651628:-
BRCA	cis	rs10129255	0.518	rs7143784	ENSG00000211967.3	IGHV3-53	-4.91	1.08e-06	0.000109	-0.1	-0.15	Kawasaki disease;	chr14:106687277	chr14:106592676~106593347:-
BRCA	cis	rs11955398	0.502	rs295559	ENSG00000215032.2	GNL3LP1	-4.91	1.08e-06	0.000109	-0.19	-0.15	Intelligence (multi-trait analysis);	chr5:61105395	chr5:60891935~60893577:-
BRCA	cis	rs3764021	0.87	rs7307111	ENSG00000256673.1	RP11-599J14.2	-4.91	1.08e-06	0.000109	-0.17	-0.15	Type 1 diabetes;	chr12:9725227	chr12:9398355~9414851:-
BRCA	cis	rs7572733	0.773	rs16866970	ENSG00000231621.1	AC013264.2	-4.91	1.08e-06	0.000109	-0.14	-0.15	Dermatomyositis;	chr2:197646362	chr2:197197991~197199273:+
BRCA	cis	rs559555	0.695	rs12470143	ENSG00000272716.1	RP11-563N4.1	4.91	1.08e-06	0.000109	0.17	0.15	Blood metabolite ratios;Blood metabolite levels;	chr2:31538488	chr2:32165046~32165757:-
BRCA	cis	rs3782123	0.514	rs11246007	ENSG00000277290.1	RP11-326C3.16	-4.91	1.08e-06	0.000109	-0.18	-0.15	Red cell distribution width;Glycated hemoglobin levels;	chr11:221584	chr11:243099~243483:-
BRCA	cis	rs7572733	0.773	rs970551	ENSG00000231621.1	AC013264.2	-4.91	1.08e-06	0.000109	-0.14	-0.15	Dermatomyositis;	chr2:197632985	chr2:197197991~197199273:+
BRCA	cis	rs6754311	0.517	rs1469995	ENSG00000224043.6	CCNT2-AS1	-4.91	1.08e-06	0.000109	-0.24	-0.15	Mosquito bite size;	chr2:135784989	chr2:134735464~134918710:-
BRCA	cis	rs13325613	0.915	rs17284187	ENSG00000223552.1	RP11-24F11.2	-4.91	1.08e-06	0.000109	-0.32	-0.15	Monocyte count;	chr3:46291508	chr3:46364955~46407059:-
BRCA	cis	rs853679	0.76	rs11967137	ENSG00000216901.1	AL022393.7	4.91	1.08e-06	0.000109	0.23	0.15	Depression;	chr6:28231986	chr6:28176188~28176674:+
BRCA	cis	rs11742741	0.539	rs6888764	ENSG00000248874.4	C5orf17	-4.9	1.08e-06	0.000109	-0.2	-0.15	Educational attainment;	chr5:24089299	chr5:23951348~24178263:+
BRCA	cis	rs454217	0.846	rs418571	ENSG00000277851.1	RP11-756G20.1	4.9	1.08e-06	0.000109	0.17	0.15	Smoking quantity;	chr12:92330380	chr12:92247756~92363832:-
BRCA	cis	rs9652601	0.665	rs17805769	ENSG00000274038.1	RP11-66H6.4	-4.9	1.08e-06	0.000109	-0.16	-0.15	Systemic lupus erythematosus;	chr16:11092016	chr16:11056556~11057034:+
BRCA	cis	rs12030196	0.827	rs6699576	ENSG00000230812.4	LINC01358	4.9	1.08e-06	0.000109	0.16	0.15	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr1:58957154	chr1:59020387~59044614:+
BRCA	cis	rs2278170	1	rs12788189	ENSG00000225101.4	OR52K3P	-4.9	1.08e-06	0.000109	-0.21	-0.15	Amyotrophic lateral sclerosis;	chr11:4462401	chr11:4474813~4475755:+
BRCA	cis	rs2179367	0.6	rs1001305	ENSG00000268592.3	RAET1E-AS1	4.9	1.08e-06	0.000109	0.22	0.15	Dupuytren's disease;	chr6:149436808	chr6:149863494~149919507:+
BRCA	cis	rs6545883	0.86	rs6749226	ENSG00000212978.6	AC016747.3	-4.9	1.08e-06	0.000109	-0.2	-0.15	Tuberculosis;	chr2:61282648	chr2:61141592~61144969:-
BRCA	cis	rs2235544	0.513	rs10158824	ENSG00000225183.1	RP4-758J24.4	4.9	1.09e-06	0.000109	0.17	0.15	Thyroid hormone levels;Multiple myeloma (hyperdiploidy);	chr1:54014725	chr1:54089856~54090093:+
BRCA	cis	rs1823913	0.513	rs4334520	ENSG00000280083.1	RP11-317J9.1	-4.9	1.09e-06	0.000109	-0.18	-0.15	Obesity-related traits;	chr2:191329200	chr2:191154118~191156070:-
BRCA	cis	rs6921919	0.583	rs16894060	ENSG00000220721.1	OR1F12	4.9	1.09e-06	0.000109	0.18	0.15	Autism spectrum disorder or schizophrenia;	chr6:28394694	chr6:28073316~28074233:+
BRCA	cis	rs7914558	0.966	rs11191438	ENSG00000236937.2	PTGES3P4	4.9	1.09e-06	0.00011	0.19	0.15	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102878107	chr10:102845595~102845950:+
BRCA	cis	rs2832191	1	rs2832191	ENSG00000215533.7	LINC00189	4.9	1.09e-06	0.00011	0.17	0.15	Dental caries;	chr21:29116979	chr21:29193480~29288205:+
BRCA	cis	rs2898681	1	rs2411281	ENSG00000248375.1	RP11-177B4.1	-4.9	1.09e-06	0.00011	-0.23	-0.15	Optic nerve measurement (cup area);	chr4:52890890	chr4:52720081~52720831:-
BRCA	cis	rs62025270	0.688	rs17577869	ENSG00000259295.5	CSPG4P12	-4.9	1.09e-06	0.00011	-0.23	-0.15	Idiopathic pulmonary fibrosis;	chr15:85771142	chr15:85191438~85213905:+
BRCA	cis	rs1387259	0.57	rs12368659	ENSG00000273765.1	RP11-370I10.11	4.9	1.09e-06	0.00011	0.18	0.15	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48168516	chr12:48360920~48361377:+
BRCA	cis	rs875971	0.862	rs1968126	ENSG00000273448.1	RP11-166O4.6	-4.9	1.09e-06	0.00011	-0.14	-0.15	Aortic root size;	chr7:66592017	chr7:67333047~67334383:+
BRCA	cis	rs11098499	0.691	rs9996644	ENSG00000260404.2	RP11-384K6.6	4.9	1.09e-06	0.00011	0.14	0.15	Corneal astigmatism;	chr4:119317722	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.691	rs9996494	ENSG00000260404.2	RP11-384K6.6	4.9	1.09e-06	0.00011	0.14	0.15	Corneal astigmatism;	chr4:119317725	chr4:118591773~118633729:+
BRCA	cis	rs919433	0.617	rs34632716	ENSG00000231621.1	AC013264.2	4.9	1.09e-06	0.00011	0.15	0.15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197677895	chr2:197197991~197199273:+
BRCA	cis	rs807029	0.577	rs11190787	ENSG00000236662.1	RP11-108L7.4	4.9	1.09e-06	0.00011	0.19	0.15	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100998868	chr10:100980507~100985614:-
BRCA	cis	rs13236243	0.603	rs10250822	ENSG00000237773.4	AC003075.4	-4.9	1.09e-06	0.00011	-0.22	-0.15	Sensory disturbances after bilateral sagittal split ramus osteotomy;	chr7:17293365	chr7:17279834~17299357:-
BRCA	cis	rs6570726	0.526	rs4896805	ENSG00000235652.6	RP11-545I5.3	-4.9	1.09e-06	0.00011	-0.14	-0.15	Lobe attachment (rater-scored or self-reported);	chr6:145414293	chr6:145799409~145886585:+
BRCA	cis	rs7204230	1	rs17303428	ENSG00000261291.1	RP11-295M3.2	4.9	1.09e-06	0.00011	0.19	0.15	Fibrinogen;	chr16:53283844	chr16:53168522~53169450:+
BRCA	cis	rs2186369	1	rs9624326	ENSG00000211683.3	KB-1572G7.3	-4.9	1.09e-06	0.00011	-0.23	-0.15	IgG N-glycosylation phenotypes (multivariate analysis);IgG digalactosylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG glycosylation;IgG fucosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);	chr22:23792856	chr22:23630618~23638941:-
BRCA	cis	rs4699052	0.963	rs4699057	ENSG00000248740.4	RP11-328K4.1	-4.9	1.09e-06	0.00011	-0.17	-0.15	Testicular germ cell tumor;	chr4:103249966	chr4:103256159~103453658:+
BRCA	cis	rs11051970	1	rs1872829	ENSG00000274964.1	RP11-817I4.1	-4.9	1.09e-06	0.00011	-0.18	-0.15	Response to tocilizumab in rheumatoid arthritis;	chr12:32382166	chr12:32339368~32340724:+
BRCA	cis	rs3764021	0.868	rs7306304	ENSG00000256673.1	RP11-599J14.2	-4.9	1.09e-06	0.00011	-0.17	-0.15	Type 1 diabetes;	chr12:9724600	chr12:9398355~9414851:-
BRCA	cis	rs13108904	0.967	rs62293658	ENSG00000196810.4	CTBP1-AS2	-4.9	1.09e-06	0.00011	-0.16	-0.15	Obesity-related traits;	chr4:1282628	chr4:1249300~1288291:+
BRCA	cis	rs11955398	0.502	rs34623	ENSG00000215032.2	GNL3LP1	4.9	1.09e-06	0.00011	0.19	0.15	Intelligence (multi-trait analysis);	chr5:61166012	chr5:60891935~60893577:-
BRCA	cis	rs7572733	0.773	rs7588831	ENSG00000231621.1	AC013264.2	-4.9	1.09e-06	0.00011	-0.14	-0.15	Dermatomyositis;	chr2:197643292	chr2:197197991~197199273:+
BRCA	cis	rs7267979	0.844	rs35735333	ENSG00000204556.4	CTD-2514C3.1	4.9	1.09e-06	0.00011	0.2	0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25356569	chr20:26018832~26020684:+
BRCA	cis	rs6840258	0.831	rs3755980	ENSG00000251411.1	RP11-397E7.4	4.9	1.09e-06	0.00011	0.21	0.15	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87121099	chr4:86913266~86914817:-
BRCA	cis	rs736408	0.609	rs13087772	ENSG00000243224.1	RP5-1157M23.2	-4.9	1.09e-06	0.00011	-0.17	-0.15	Bipolar disorder;	chr3:52748258	chr3:52239258~52241097:+
BRCA	cis	rs2562456	0.958	rs2562508	ENSG00000268658.4	LINC00664	-4.9	1.09e-06	0.00011	-0.24	-0.15	Pain;	chr19:21543479	chr19:21483374~21503238:+
BRCA	cis	rs2708977	1	rs1011040	ENSG00000237510.6	AC008268.2	-4.9	1.09e-06	0.00011	-0.2	-0.15	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96547018	chr2:95789654~95800166:+
BRCA	cis	rs9423406	0.752	rs71479714	ENSG00000224034.1	RP11-445P17.8	-4.9	1.09e-06	0.00011	-0.29	-0.15	Intelligence;	chr10:5277862	chr10:5266033~5271236:-
BRCA	cis	rs891378	1	rs1652333	ENSG00000274245.1	RP11-357P18.2	4.9	1.09e-06	0.00011	0.2	0.15	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207297115	chr1:207372559~207373252:+
BRCA	cis	rs7267979	0.844	rs6076343	ENSG00000274973.1	RP13-401N8.7	4.9	1.09e-06	0.00011	0.17	0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25396027	chr20:25845497~25845862:+
BRCA	cis	rs597539	0.652	rs501799	ENSG00000261625.1	RP11-554A11.4	-4.9	1.09e-06	0.00011	-0.15	-0.15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68863772	chr11:69000765~69002048:-
BRCA	cis	rs10752881	0.933	rs2027086	ENSG00000224468.3	RP11-181K3.4	-4.9	1.09e-06	0.00011	-0.16	-0.15	Colorectal cancer;	chr1:183088798	chr1:183138402~183141282:-
BRCA	cis	rs7487075	0.619	rs12832777	ENSG00000274723.1	RP11-618L22.1	4.9	1.09e-06	0.00011	0.2	0.15	Itch intensity from mosquito bite;	chr12:46437346	chr12:46970504~46972155:+
BRCA	cis	rs875971	0.862	rs778680	ENSG00000236529.1	RP13-254B10.1	4.9	1.09e-06	0.00011	0.17	0.15	Aortic root size;	chr7:66375427	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.862	rs11769079	ENSG00000236529.1	RP13-254B10.1	4.9	1.09e-06	0.00011	0.17	0.15	Aortic root size;	chr7:66377141	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.862	rs1695820	ENSG00000236529.1	RP13-254B10.1	4.9	1.09e-06	0.00011	0.17	0.15	Aortic root size;	chr7:66379576	chr7:65840212~65840596:+
BRCA	cis	rs9473147	0.798	rs4711895	ENSG00000270761.1	RP11-385F7.1	4.9	1.09e-06	0.00011	0.16	0.15	Platelet distribution width;Mean platelet volume;	chr6:47659291	chr6:47477243~47477572:-
BRCA	cis	rs7267979	0.74	rs2259961	ENSG00000204556.4	CTD-2514C3.1	-4.9	1.09e-06	0.00011	-0.2	-0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25301990	chr20:26018832~26020684:+
BRCA	cis	rs1953600	1	rs2789679	ENSG00000226659.1	RP11-137H2.4	-4.9	1.09e-06	0.00011	-0.2	-0.15	Sarcoidosis;	chr10:80148128	chr10:80529597~80535942:-
BRCA	cis	rs829883	0.664	rs829874	ENSG00000227825.4	SLC9A7P1	4.9	1.09e-06	0.00011	0.17	0.15	Colorectal adenoma (advanced);	chr12:98446837	chr12:98453835~98457145:-
BRCA	cis	rs16958440	0.867	rs77149690	ENSG00000280212.1	RP11-49K24.3	4.9	1.09e-06	0.00011	0.35	0.15	Sitting height ratio;	chr18:47170772	chr18:47076117~47076594:+
BRCA	cis	rs16958440	0.867	rs79285649	ENSG00000280212.1	RP11-49K24.3	4.9	1.09e-06	0.00011	0.35	0.15	Sitting height ratio;	chr18:47172648	chr18:47076117~47076594:+
BRCA	cis	rs16958440	0.867	rs57744138	ENSG00000280212.1	RP11-49K24.3	4.9	1.09e-06	0.00011	0.35	0.15	Sitting height ratio;	chr18:47174111	chr18:47076117~47076594:+
BRCA	cis	rs16958440	0.867	rs16949275	ENSG00000280212.1	RP11-49K24.3	4.9	1.09e-06	0.00011	0.35	0.15	Sitting height ratio;	chr18:47174332	chr18:47076117~47076594:+
BRCA	cis	rs2303319	0.504	rs12467662	ENSG00000227403.1	AC009299.3	4.9	1.1e-06	0.00011	0.36	0.15	Cognitive function;	chr2:161530274	chr2:161244739~161249050:+
BRCA	cis	rs2303319	0.504	rs55650699	ENSG00000227403.1	AC009299.3	4.9	1.1e-06	0.00011	0.36	0.15	Cognitive function;	chr2:161532421	chr2:161244739~161249050:+
BRCA	cis	rs2303319	0.504	rs56145818	ENSG00000227403.1	AC009299.3	4.9	1.1e-06	0.00011	0.36	0.15	Cognitive function;	chr2:161547268	chr2:161244739~161249050:+
BRCA	cis	rs60843830	0.928	rs55742348	ENSG00000272342.1	RP13-539J13.1	4.9	1.1e-06	0.00011	0.19	0.15	Spherical equivalent (joint analysis main effects and education interaction);	chr2:217563	chr2:739588~740164:-
BRCA	cis	rs2337406	0.538	rs10141701	ENSG00000254174.1	IGHV1-12	4.9	1.1e-06	0.00011	0.15	0.15	Alzheimer's disease (late onset);	chr14:106633467	chr14:106122420~106122709:-
BRCA	cis	rs875971	0.545	rs2707851	ENSG00000230295.1	RP11-458F8.2	-4.9	1.1e-06	0.000111	-0.14	-0.15	Aortic root size;	chr7:66624178	chr7:66880708~66882981:+
BRCA	cis	rs10911251	0.546	rs2027085	ENSG00000224468.3	RP11-181K3.4	4.9	1.1e-06	0.000111	0.16	0.15	Colorectal cancer;	chr1:183139476	chr1:183138402~183141282:-
BRCA	cis	rs7267979	0.816	rs390123	ENSG00000277938.1	RP5-965G21.3	4.9	1.1e-06	0.000111	0.18	0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25499469	chr20:25229150~25231933:+
BRCA	cis	rs1823874	0.605	rs1840300	ENSG00000182397.13	DNM1P46	-4.9	1.1e-06	0.000111	-0.15	-0.15	IgG glycosylation;	chr15:99826739	chr15:99790156~99806927:-
BRCA	cis	rs9425766	0.678	rs1951625	ENSG00000200674.1	RN7SKP160	4.9	1.1e-06	0.000111	0.22	0.15	Life satisfaction;	chr1:173867464	chr1:173791548~173791887:+
BRCA	cis	rs9907295	0.688	rs2376287	ENSG00000271013.1	AC015849.15	-4.9	1.1e-06	0.000111	-0.19	-0.15	Fibroblast growth factor basic levels;	chr17:35919865	chr17:35912635~35918010:-
BRCA	cis	rs9907295	0.688	rs4796133	ENSG00000271013.1	AC015849.15	-4.9	1.1e-06	0.000111	-0.19	-0.15	Fibroblast growth factor basic levels;	chr17:35920505	chr17:35912635~35918010:-
BRCA	cis	rs9907295	0.688	rs7213636	ENSG00000271013.1	AC015849.15	-4.9	1.1e-06	0.000111	-0.19	-0.15	Fibroblast growth factor basic levels;	chr17:35920944	chr17:35912635~35918010:-
BRCA	cis	rs2880765	0.545	rs11631739	ENSG00000230373.7	GOLGA6L5P	4.9	1.1e-06	0.000111	0.17	0.15	Coronary artery disease;	chr15:85469347	chr15:84507885~84516814:-
BRCA	cis	rs1858037	0.867	rs964505	ENSG00000237979.1	AC007389.1	4.9	1.1e-06	0.000111	0.19	0.15	Rheumatoid arthritis;	chr2:65396055	chr2:65500993~65502138:-
BRCA	cis	rs7576126	1	rs7576126	ENSG00000204929.10	AC074391.1	-4.9	1.1e-06	0.000111	-0.18	-0.15	Severe influenza A (H1N1) infection;	chr2:65431235	chr2:65436711~66084639:+
BRCA	cis	rs385076	0.562	rs1119292	ENSG00000272716.1	RP11-563N4.1	-4.9	1.1e-06	0.000111	-0.18	-0.15	Interleukin-18 levels;	chr2:31820704	chr2:32165046~32165757:-
BRCA	cis	rs2153535	0.542	rs915353	ENSG00000251164.1	HULC	-4.9	1.1e-06	0.000111	-0.19	-0.15	Motion sickness;	chr6:8440137	chr6:8652137~8653846:+
BRCA	cis	rs700651	0.821	rs700666	ENSG00000231621.1	AC013264.2	-4.9	1.1e-06	0.000111	-0.15	-0.15	Intracranial aneurysm;	chr2:197808820	chr2:197197991~197199273:+
BRCA	cis	rs7572733	0.534	rs770657	ENSG00000231621.1	AC013264.2	-4.9	1.1e-06	0.000111	-0.15	-0.15	Dermatomyositis;	chr2:197809460	chr2:197197991~197199273:+
BRCA	cis	rs700651	0.821	rs771005	ENSG00000231621.1	AC013264.2	-4.9	1.1e-06	0.000111	-0.15	-0.15	Intracranial aneurysm;	chr2:197811224	chr2:197197991~197199273:+
BRCA	cis	rs7226408	0.857	rs11664715	ENSG00000267707.2	RP11-95O2.5	4.9	1.1e-06	0.000111	0.23	0.15	Obesity-related traits;	chr18:36855105	chr18:37243776~37247506:+
BRCA	cis	rs10938353	0.871	rs7677605	ENSG00000273369.1	RP11-700J17.1	-4.9	1.1e-06	0.000111	-0.16	-0.15	Body mass index;	chr4:44592074	chr4:44693946~44694386:-
BRCA	cis	rs875971	0.545	rs7783889	ENSG00000230295.1	RP11-458F8.2	4.9	1.1e-06	0.000111	0.14	0.15	Aortic root size;	chr7:66283366	chr7:66880708~66882981:+
BRCA	cis	rs66887589	0.934	rs56843000	ENSG00000245958.5	RP11-33B1.1	4.9	1.1e-06	0.000111	0.13	0.15	Diastolic blood pressure;	chr4:119595442	chr4:119454791~119552025:+
BRCA	cis	rs4835473	0.932	rs1849128	ENSG00000249741.2	RP11-673E1.3	-4.9	1.1e-06	0.000111	-0.16	-0.15	Immature fraction of reticulocytes;	chr4:143992582	chr4:143911514~143912053:-
BRCA	cis	rs4835473	0.771	rs2175452	ENSG00000249741.2	RP11-673E1.3	-4.9	1.1e-06	0.000111	-0.16	-0.15	Immature fraction of reticulocytes;	chr4:143992887	chr4:143911514~143912053:-
BRCA	cis	rs4835473	0.8	rs2175451	ENSG00000249741.2	RP11-673E1.3	-4.9	1.1e-06	0.000111	-0.16	-0.15	Immature fraction of reticulocytes;	chr4:143992964	chr4:143911514~143912053:-
BRCA	cis	rs875971	0.545	rs73376401	ENSG00000230295.1	RP11-458F8.2	4.9	1.1e-06	0.000111	0.14	0.15	Aortic root size;	chr7:66174841	chr7:66880708~66882981:+
BRCA	cis	rs6490294	0.571	rs77176084	ENSG00000226469.1	ADAM1B	4.9	1.1e-06	0.000111	0.26	0.15	Mean platelet volume;	chr12:112077508	chr12:111927018~111929017:+
BRCA	cis	rs6490294	0.528	rs74636821	ENSG00000226469.1	ADAM1B	4.9	1.1e-06	0.000111	0.26	0.15	Mean platelet volume;	chr12:112078108	chr12:111927018~111929017:+
BRCA	cis	rs6081541	1	rs3790167	ENSG00000179447.2	RP5-1027G4.3	-4.9	1.1e-06	0.000111	-0.2	-0.15	Psychosis (atypical);	chr20:19240267	chr20:19242302~19284596:-
BRCA	cis	rs6840360	0.582	rs4473638	ENSG00000278978.1	RP11-164P12.5	-4.9	1.1e-06	0.000111	-0.17	-0.15	Intelligence (multi-trait analysis);	chr4:151400994	chr4:151669786~151670503:+
BRCA	cis	rs6840360	0.548	rs4254751	ENSG00000278978.1	RP11-164P12.5	-4.9	1.1e-06	0.000111	-0.17	-0.15	Intelligence (multi-trait analysis);	chr4:151401419	chr4:151669786~151670503:+
BRCA	cis	rs745109	0.882	rs75084119	ENSG00000273080.1	RP11-301O19.1	4.9	1.1e-06	0.000111	0.25	0.15	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86443077	chr2:86195590~86196049:+
BRCA	cis	rs755249	0.727	rs12028034	ENSG00000182109.6	RP11-69E11.4	-4.9	1.11e-06	0.000111	-0.17	-0.15	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39574035	chr1:39522280~39546187:-
BRCA	cis	rs7618501	0.633	rs2008877	ENSG00000228008.1	CTD-2330K9.3	-4.9	1.11e-06	0.000111	-0.15	-0.15	Intelligence (multi-trait analysis);	chr3:50124858	chr3:49903845~49916937:+
BRCA	cis	rs6490294	0.799	rs73424286	ENSG00000226469.1	ADAM1B	4.9	1.11e-06	0.000111	0.19	0.15	Mean platelet volume;	chr12:111889338	chr12:111927018~111929017:+
BRCA	cis	rs875971	0.545	rs1638735	ENSG00000273142.1	RP11-458F8.4	4.9	1.11e-06	0.000111	0.15	0.15	Aortic root size;	chr7:66630751	chr7:66902857~66906297:+
BRCA	cis	rs854765	0.52	rs7219324	ENSG00000281749.1	Y_RNA	-4.9	1.11e-06	0.000111	-0.17	-0.15	Total body bone mineral density;	chr17:18006461	chr17:18001101~18001195:-
BRCA	cis	rs934734	0.511	rs62141115	ENSG00000204929.10	AC074391.1	-4.9	1.11e-06	0.000111	-0.18	-0.15	Rheumatoid arthritis;	chr2:65445058	chr2:65436711~66084639:+
BRCA	cis	rs801193	0.569	rs2707824	ENSG00000236529.1	RP13-254B10.1	4.9	1.11e-06	0.000111	0.17	0.15	Aortic root size;	chr7:66724256	chr7:65840212~65840596:+
BRCA	cis	rs3102460	0.507	rs3127459	ENSG00000225401.2	TGIF2P1	4.9	1.11e-06	0.000112	0.17	0.15	Obesity-related traits;	chr1:244423764	chr1:244394976~244395660:-
BRCA	cis	rs13113518	1	rs10462032	ENSG00000273257.1	RP11-177J6.1	4.9	1.11e-06	0.000112	0.19	0.15	Height;	chr4:55479069	chr4:55387949~55388271:+
BRCA	cis	rs875971	0.862	rs6460290	ENSG00000236529.1	RP13-254B10.1	-4.9	1.11e-06	0.000112	-0.16	-0.15	Aortic root size;	chr7:66344119	chr7:65840212~65840596:+
BRCA	cis	rs7267979	0.816	rs404775	ENSG00000277938.1	RP5-965G21.3	4.9	1.11e-06	0.000112	0.18	0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25500481	chr20:25229150~25231933:+
BRCA	cis	rs7267979	0.816	rs374701	ENSG00000277938.1	RP5-965G21.3	4.9	1.11e-06	0.000112	0.18	0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25502980	chr20:25229150~25231933:+
BRCA	cis	rs4578769	0.879	rs7235234	ENSG00000265939.1	UBE2CP2	4.9	1.11e-06	0.000112	0.18	0.15	Eosinophil percentage of white cells;	chr18:22864239	chr18:22900486~22900995:-
BRCA	cis	rs4578769	0.879	rs9950650	ENSG00000265939.1	UBE2CP2	4.9	1.11e-06	0.000112	0.18	0.15	Eosinophil percentage of white cells;	chr18:22864537	chr18:22900486~22900995:-
BRCA	cis	rs4578769	0.918	rs1902920	ENSG00000265939.1	UBE2CP2	4.9	1.11e-06	0.000112	0.18	0.15	Eosinophil percentage of white cells;	chr18:22964688	chr18:22900486~22900995:-
BRCA	cis	rs10129255	0.957	rs10132367	ENSG00000211974.3	IGHV2-70	4.9	1.11e-06	0.000112	0.16	0.15	Kawasaki disease;	chr14:106690981	chr14:106723574~106724093:-
BRCA	cis	rs2436845	0.603	rs2679753	ENSG00000253320.4	KB-1507C5.2	-4.9	1.11e-06	0.000112	-0.19	-0.15	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102855232	chr8:102864300~102977876:+
BRCA	cis	rs13113518	1	rs9312661	ENSG00000249700.7	SRD5A3-AS1	4.9	1.11e-06	0.000112	0.19	0.15	Height;	chr4:55476159	chr4:55363971~55395847:-
BRCA	cis	rs9907295	0.688	rs4796135	ENSG00000271013.1	AC015849.15	-4.9	1.11e-06	0.000112	-0.2	-0.15	Fibroblast growth factor basic levels;	chr17:35924236	chr17:35912635~35918010:-
BRCA	cis	rs9907295	0.688	rs4796136	ENSG00000271013.1	AC015849.15	-4.9	1.11e-06	0.000112	-0.2	-0.15	Fibroblast growth factor basic levels;	chr17:35924397	chr17:35912635~35918010:-
BRCA	cis	rs9907295	0.688	rs4796137	ENSG00000271013.1	AC015849.15	-4.9	1.11e-06	0.000112	-0.2	-0.15	Fibroblast growth factor basic levels;	chr17:35924448	chr17:35912635~35918010:-
BRCA	cis	rs1910358	0.664	rs10473666	ENSG00000248874.4	C5orf17	-4.9	1.11e-06	0.000112	-0.2	-0.15	Venous thromboembolism (SNP x SNP interaction);	chr5:23884120	chr5:23951348~24178263:+
BRCA	cis	rs2832191	0.791	rs2832186	ENSG00000176054.6	RPL23P2	-4.9	1.11e-06	0.000112	-0.15	-0.15	Dental caries;	chr21:29111830	chr21:28997613~28998033:-
BRCA	cis	rs4908768	0.501	rs7527389	ENSG00000232912.4	RP5-1115A15.1	4.9	1.11e-06	0.000112	0.15	0.15	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8496485	chr1:8424645~8434838:+
BRCA	cis	rs35740288	0.545	rs11637283	ENSG00000259407.1	RP11-158M2.3	-4.9	1.11e-06	0.000112	-0.22	-0.15	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85772872	chr15:85744109~85750281:-
BRCA	cis	rs10829156	0.732	rs7075678	ENSG00000240291.1	RP11-499P20.2	4.9	1.11e-06	0.000112	0.18	0.15	Sudden cardiac arrest;	chr10:18585174	chr10:18513115~18545651:-
BRCA	cis	rs2905347	0.726	rs2961294	ENSG00000179428.2	AC073072.5	4.9	1.11e-06	0.000112	0.16	0.15	Major depression and alcohol dependence;	chr7:22655412	chr7:22725395~22727620:-
BRCA	cis	rs651907	0.557	rs7651721	ENSG00000256628.3	ZBTB11-AS1	4.9	1.11e-06	0.000112	0.19	0.15	Colorectal cancer;	chr3:101674739	chr3:101676475~101679217:+
BRCA	cis	rs6840360	0.642	rs7680013	ENSG00000251611.1	RP11-610P16.1	-4.9	1.11e-06	0.000112	-0.13	-0.15	Intelligence (multi-trait analysis);	chr4:151488325	chr4:151407551~151408835:-
BRCA	cis	rs6840360	0.642	rs7680236	ENSG00000251611.1	RP11-610P16.1	-4.9	1.11e-06	0.000112	-0.13	-0.15	Intelligence (multi-trait analysis);	chr4:151488449	chr4:151407551~151408835:-
BRCA	cis	rs6545883	0.859	rs7561672	ENSG00000270820.4	RP11-355B11.2	-4.9	1.11e-06	0.000112	-0.17	-0.15	Tuberculosis;	chr2:61291959	chr2:61471188~61484130:+
BRCA	cis	rs6840360	0.642	rs4696092	ENSG00000278978.1	RP11-164P12.5	-4.9	1.11e-06	0.000112	-0.16	-0.15	Intelligence (multi-trait analysis);	chr4:151491451	chr4:151669786~151670503:+
BRCA	cis	rs858267	0.661	rs7786708	ENSG00000226816.2	AC005082.12	4.9	1.11e-06	0.000112	0.31	0.15	Blood protein levels;	chr7:23075797	chr7:23206013~23208045:+
BRCA	cis	rs74781061	0.932	rs11629749	ENSG00000260103.2	RP11-10O17.1	-4.9	1.12e-06	0.000112	-0.17	-0.15	Endometriosis;	chr15:74627252	chr15:74478070~74490286:-
BRCA	cis	rs8177876	0.749	rs10459871	ENSG00000261061.1	RP11-303E16.2	-4.9	1.12e-06	0.000112	-0.21	-0.15	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81059462	chr16:81030770~81031485:+
BRCA	cis	rs4666002	0.956	rs4665383	ENSG00000234072.1	AC074117.10	4.9	1.12e-06	0.000112	0.16	0.15	Phospholipid levels (plasma);	chr2:27568688	chr2:27356246~27367622:+
BRCA	cis	rs745109	0.504	rs76526816	ENSG00000273080.1	RP11-301O19.1	4.9	1.12e-06	0.000112	0.24	0.15	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86370509	chr2:86195590~86196049:+
BRCA	cis	rs7833790	0.963	rs28823280	ENSG00000254689.1	RP11-354A14.1	-4.9	1.12e-06	0.000112	-0.2	-0.15	Diastolic blood pressure;	chr8:81865481	chr8:81885377~81923193:+
BRCA	cis	rs12893668	0.572	rs11846404	ENSG00000269958.1	RP11-73M18.8	4.9	1.12e-06	0.000112	0.17	0.15	Reticulocyte count;	chr14:103689771	chr14:103696353~103697163:+
BRCA	cis	rs6088813	1	rs725908	ENSG00000126005.14	MMP24-AS1	4.9	1.12e-06	0.000112	0.18	0.15	Height;	chr20:35380264	chr20:35216462~35278131:-
BRCA	cis	rs4722166	0.695	rs35779989	ENSG00000225541.1	AC002480.5	-4.9	1.12e-06	0.000112	-0.15	-0.15	Lung cancer;	chr7:22760695	chr7:22571607~22661792:-
BRCA	cis	rs1167827	0.71	rs1167836	ENSG00000205583.12	STAG3L1	4.9	1.12e-06	0.000112	0.18	0.15	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75539580	chr7:75359194~75395383:+
BRCA	cis	rs7818688	1	rs28477467	ENSG00000253528.2	RP11-347C18.4	-4.9	1.12e-06	0.000112	-0.23	-0.15	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95020677	chr8:94974573~94974853:-
BRCA	cis	rs11089937	0.616	rs6001224	ENSG00000211638.2	IGLV8-61	-4.9	1.12e-06	0.000112	-0.15	-0.15	Periodontitis (PAL4Q3);	chr22:22186042	chr22:22098700~22099212:+
BRCA	cis	rs11098499	0.866	rs11098506	ENSG00000249244.1	RP11-548H18.2	4.9	1.12e-06	0.000113	0.17	0.15	Corneal astigmatism;	chr4:119363816	chr4:119391831~119395335:-
BRCA	cis	rs454217	0.846	rs1948656	ENSG00000277851.1	RP11-756G20.1	4.9	1.12e-06	0.000113	0.17	0.15	Smoking quantity;	chr12:92337508	chr12:92247756~92363832:-
BRCA	cis	rs6095360	1	rs6019624	ENSG00000222365.1	SNORD12B	-4.9	1.12e-06	0.000113	-0.16	-0.15	Intelligence (multi-trait analysis);	chr20:49069278	chr20:49280319~49280409:+
BRCA	cis	rs1707322	0.89	rs2297883	ENSG00000234329.1	RP11-767N6.2	-4.9	1.12e-06	0.000113	-0.15	-0.15	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46045815	chr1:45651039~45651826:-
BRCA	cis	rs7829975	0.688	rs7817376	ENSG00000233609.3	RP11-62H7.2	-4.9	1.12e-06	0.000113	-0.14	-0.15	Mood instability;	chr8:8523020	chr8:8961200~8979025:+
BRCA	cis	rs4950322	0.576	rs2353979	ENSG00000244371.2	PFN1P8	4.9	1.12e-06	0.000113	0.18	0.15	Protein quantitative trait loci;	chr1:147368185	chr1:146957117~146957659:-
BRCA	cis	rs4950322	0.576	rs2353980	ENSG00000244371.2	PFN1P8	4.9	1.12e-06	0.000113	0.18	0.15	Protein quantitative trait loci;	chr1:147368274	chr1:146957117~146957659:-
BRCA	cis	rs3768617	0.754	rs6673768	ENSG00000224468.3	RP11-181K3.4	-4.9	1.12e-06	0.000113	-0.17	-0.15	Fuchs's corneal dystrophy;	chr1:183014261	chr1:183138402~183141282:-
BRCA	cis	rs71520386	0.807	rs10263435	ENSG00000230658.1	KLHL7-AS1	4.9	1.12e-06	0.000113	0.25	0.15	Fibrinogen levels;	chr7:22790243	chr7:23101228~23105703:-
BRCA	cis	rs60843830	1	rs3791220	ENSG00000272342.1	RP13-539J13.1	4.9	1.12e-06	0.000113	0.18	0.15	Spherical equivalent (joint analysis main effects and education interaction);	chr2:227066	chr2:739588~740164:-
BRCA	cis	rs7727544	0.716	rs7701414	ENSG00000233006.5	AC034220.3	4.9	1.12e-06	0.000113	0.11	0.15	Blood metabolite levels;	chr5:132250265	chr5:132311285~132369916:-
BRCA	cis	rs4218	0.689	rs12907187	ENSG00000277144.1	RP11-59H7.4	-4.9	1.12e-06	0.000113	-0.2	-0.15	Social communication problems;	chr15:59100607	chr15:59115547~59116089:-
BRCA	cis	rs10419113	0.628	rs12608585	ENSG00000268545.1	VN1R107P	4.9	1.12e-06	0.000113	0.17	0.15	Pediatric bone mineral density (spine);	chr19:57689260	chr19:57459912~57460120:+
BRCA	cis	rs72843506	0.591	rs74319100	ENSG00000261033.1	RP11-209D14.2	4.9	1.12e-06	0.000113	0.29	0.15	Schizophrenia;	chr17:20318079	chr17:20008051~20009234:-
BRCA	cis	rs73193808	0.901	rs2832262	ENSG00000236056.1	GAPDHP14	-4.9	1.12e-06	0.000113	-0.22	-0.15	Coronary artery disease;	chr21:29214771	chr21:29222321~29223257:+
BRCA	cis	rs6840360	0.642	rs4696089	ENSG00000251611.1	RP11-610P16.1	-4.9	1.12e-06	0.000113	-0.13	-0.15	Intelligence (multi-trait analysis);	chr4:151474581	chr4:151407551~151408835:-
BRCA	cis	rs6840360	0.642	rs11932398	ENSG00000251611.1	RP11-610P16.1	-4.9	1.12e-06	0.000113	-0.13	-0.15	Intelligence (multi-trait analysis);	chr4:151476402	chr4:151407551~151408835:-
BRCA	cis	rs6840360	0.642	rs4263379	ENSG00000251611.1	RP11-610P16.1	-4.9	1.12e-06	0.000113	-0.13	-0.15	Intelligence (multi-trait analysis);	chr4:151477979	chr4:151407551~151408835:-
BRCA	cis	rs875971	1	rs7792762	ENSG00000223473.2	GS1-124K5.3	4.9	1.12e-06	0.000113	0.12	0.15	Aortic root size;	chr7:66539151	chr7:66491049~66493566:-
BRCA	cis	rs2153535	0.601	rs4140584	ENSG00000251164.1	HULC	4.9	1.12e-06	0.000113	0.19	0.15	Motion sickness;	chr6:8540381	chr6:8652137~8653846:+
BRCA	cis	rs7267979	0.816	rs405822	ENSG00000204556.4	CTD-2514C3.1	-4.9	1.12e-06	0.000113	-0.2	-0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25520678	chr20:26018832~26020684:+
BRCA	cis	rs7267979	0.816	rs409853	ENSG00000204556.4	CTD-2514C3.1	-4.9	1.12e-06	0.000113	-0.2	-0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25525431	chr20:26018832~26020684:+
BRCA	cis	rs7267979	0.844	rs869358	ENSG00000204556.4	CTD-2514C3.1	4.9	1.12e-06	0.000113	0.2	0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25394038	chr20:26018832~26020684:+
BRCA	cis	rs1707322	0.752	rs4660880	ENSG00000234329.1	RP11-767N6.2	4.9	1.12e-06	0.000113	0.16	0.15	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45645368	chr1:45651039~45651826:-
BRCA	cis	rs3768617	0.51	rs10797839	ENSG00000224468.3	RP11-181K3.4	-4.9	1.12e-06	0.000113	-0.16	-0.15	Fuchs's corneal dystrophy;	chr1:183108662	chr1:183138402~183141282:-
BRCA	cis	rs6570726	0.791	rs440477	ENSG00000270638.1	RP3-466P17.1	4.9	1.12e-06	0.000113	0.17	0.15	Lobe attachment (rater-scored or self-reported);	chr6:145533052	chr6:145735570~145737218:+
BRCA	cis	rs6570726	0.791	rs385729	ENSG00000270638.1	RP3-466P17.1	4.9	1.12e-06	0.000113	0.17	0.15	Lobe attachment (rater-scored or self-reported);	chr6:145534329	chr6:145735570~145737218:+
BRCA	cis	rs7131987	0.683	rs7954278	ENSG00000275476.1	RP11-996F15.4	-4.9	1.12e-06	0.000113	-0.18	-0.15	QT interval;	chr12:29306357	chr12:29277397~29277882:-
BRCA	cis	rs853679	0.76	rs9468317	ENSG00000216901.1	AL022393.7	4.9	1.12e-06	0.000113	0.23	0.15	Depression;	chr6:28230678	chr6:28176188~28176674:+
BRCA	cis	rs17027633	1	rs1361851	ENSG00000260948.1	RP11-552M11.8	4.9	1.13e-06	0.000113	0.27	0.15	Cerebrospinal fluid t-tau:AB1-42 ratio;	chr1:111420201	chr1:111431046~111433068:-
BRCA	cis	rs11758351	1	rs16891401	ENSG00000241549.7	GUSBP2	-4.9	1.13e-06	0.000113	-0.22	-0.15	Renal underexcretion gout;Gout;	chr6:26202109	chr6:26871484~26956554:-
BRCA	cis	rs67981189	0.593	rs2240341	ENSG00000269927.1	RP6-91H8.3	-4.9	1.13e-06	0.000113	-0.18	-0.15	Schizophrenia;	chr14:70906863	chr14:71141125~71143253:-
BRCA	cis	rs1555322	1	rs1555322	ENSG00000126005.14	MMP24-AS1	-4.9	1.13e-06	0.000113	-0.25	-0.15	Attention deficit hyperactivity disorder;	chr20:35261376	chr20:35216462~35278131:-
BRCA	cis	rs1707322	1	rs785470	ENSG00000234329.1	RP11-767N6.2	-4.9	1.13e-06	0.000113	-0.15	-0.15	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46053950	chr1:45651039~45651826:-
BRCA	cis	rs2625529	0.617	rs8557	ENSG00000260037.4	CTD-2524L6.3	-4.9	1.13e-06	0.000113	-0.19	-0.15	Red blood cell count;	chr15:71823392	chr15:71818396~71823384:+
BRCA	cis	rs12744310	0.887	rs17362424	ENSG00000235358.1	RP11-399E6.1	-4.9	1.13e-06	0.000113	-0.23	-0.15	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41328731	chr1:41242373~41284861:+
BRCA	cis	rs11098499	0.954	rs6848389	ENSG00000250412.1	KLHL2P1	4.9	1.13e-06	0.000113	0.18	0.15	Corneal astigmatism;	chr4:119481467	chr4:119334329~119378233:+
BRCA	cis	rs12701220	0.522	rs12334290	ENSG00000229043.2	AC091729.9	-4.9	1.13e-06	0.000113	-0.19	-0.15	Bronchopulmonary dysplasia;	chr7:1014881	chr7:1160374~1165267:+
BRCA	cis	rs2051773	0.567	rs12288579	ENSG00000184669.7	OR7E14P	-4.9	1.13e-06	0.000113	-0.22	-0.15	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);	chr11:17018363	chr11:17013998~17053024:+
BRCA	cis	rs7487075	0.619	rs7488450	ENSG00000274723.1	RP11-618L22.1	4.9	1.13e-06	0.000113	0.2	0.15	Itch intensity from mosquito bite;	chr12:46427255	chr12:46970504~46972155:+
BRCA	cis	rs875971	0.862	rs778702	ENSG00000236529.1	RP13-254B10.1	4.9	1.13e-06	0.000113	0.17	0.15	Aortic root size;	chr7:66399848	chr7:65840212~65840596:+
BRCA	cis	rs9868809	0.772	rs34096717	ENSG00000270441.1	RP11-694I15.7	4.9	1.13e-06	0.000114	0.28	0.15	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48682020	chr3:49140086~49160851:-
BRCA	cis	rs1552244	0.572	rs17032440	ENSG00000232901.1	CYCSP10	-4.9	1.13e-06	0.000114	-0.23	-0.15	Alzheimer's disease;	chr3:10128135	chr3:10000647~10000940:-
BRCA	cis	rs1862618	0.671	rs832531	ENSG00000271828.1	CTD-2310F14.1	4.9	1.13e-06	0.000114	0.18	0.15	Initial pursuit acceleration;	chr5:56932574	chr5:56927874~56929573:+
BRCA	cis	rs67981189	0.656	rs2810113	ENSG00000269927.1	RP6-91H8.3	-4.9	1.13e-06	0.000114	-0.18	-0.15	Schizophrenia;	chr14:70929053	chr14:71141125~71143253:-
BRCA	cis	rs9467773	0.62	rs2451738	ENSG00000124549.13	BTN2A3P	-4.9	1.13e-06	0.000114	-0.15	-0.15	Intelligence (multi-trait analysis);	chr6:26618231	chr6:26421391~26432383:+
BRCA	cis	rs6570726	0.905	rs377143	ENSG00000270638.1	RP3-466P17.1	4.9	1.13e-06	0.000114	0.17	0.15	Lobe attachment (rater-scored or self-reported);	chr6:145513084	chr6:145735570~145737218:+
BRCA	cis	rs7324557	0.93	rs7324545	ENSG00000205861.10	C1QTNF9B-AS1	4.9	1.13e-06	0.000114	0.2	0.15	Visceral adipose tissue adjusted for BMI;	chr13:23722702	chr13:23888889~23897263:+
BRCA	cis	rs62184315	0.536	rs2278591	ENSG00000253559.1	OSGEPL1-AS1	-4.9	1.13e-06	0.000114	-0.26	-0.15	Alcohol dependence (age at onset);	chr2:189755778	chr2:189762704~189765556:+
BRCA	cis	rs62184315	0.536	rs16831972	ENSG00000253559.1	OSGEPL1-AS1	-4.9	1.13e-06	0.000114	-0.26	-0.15	Alcohol dependence (age at onset);	chr2:189756707	chr2:189762704~189765556:+
BRCA	cis	rs7481584	0.624	rs377765	ENSG00000247473.2	CARS-AS1	-4.9	1.13e-06	0.000114	-0.18	-0.15	Calcium levels;	chr11:3025068	chr11:3029009~3041260:+
BRCA	cis	rs875971	0.798	rs57739047	ENSG00000273448.1	RP11-166O4.6	4.9	1.13e-06	0.000114	0.14	0.15	Aortic root size;	chr7:66507579	chr7:67333047~67334383:+
BRCA	cis	rs61160187	0.667	rs7722373	ENSG00000272308.1	RP11-231G3.1	-4.9	1.13e-06	0.000114	-0.17	-0.15	Educational attainment (years of education);Educational attainment (college completion);	chr5:60951988	chr5:60866457~60866935:-
BRCA	cis	rs6452524	0.901	rs4571449	ENSG00000281327.1	LINC01338	4.9	1.13e-06	0.000114	0.18	0.15	Hypertension (SNP x SNP interaction);	chr5:83175392	chr5:82850864~82859836:-
BRCA	cis	rs4763879	0.502	rs11052552	ENSG00000278635.1	CTD-2318O12.1	-4.9	1.13e-06	0.000114	-0.15	-0.15	Type 1 diabetes;	chr12:9703362	chr12:9415641~9416718:+
BRCA	cis	rs2904967	0.929	rs1783486	ENSG00000255200.1	AP003068.18	-4.9	1.13e-06	0.000114	-0.26	-0.15	Mean corpuscular volume;	chr11:65241446	chr11:65174117~65176470:-
BRCA	cis	rs10833905	0.938	rs10833923	ENSG00000246225.5	RP11-17A1.3	-4.9	1.13e-06	0.000114	-0.22	-0.15	Sudden cardiac arrest;	chr11:23050982	chr11:22829380~22945393:+
BRCA	cis	rs2243480	0.803	rs36127118	ENSG00000275400.1	RP4-756H11.5	4.9	1.14e-06	0.000114	0.27	0.15	Diabetic kidney disease;	chr7:66100518	chr7:66553805~66554199:-
BRCA	cis	rs9925964	0.748	rs4889603	ENSG00000232748.3	RP11-196G11.6	-4.9	1.14e-06	0.000114	-0.19	-0.15	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:30970904	chr16:31056460~31062803:+
BRCA	cis	rs1707322	1	rs7531911	ENSG00000234329.1	RP11-767N6.2	4.9	1.14e-06	0.000114	0.15	0.15	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45864751	chr1:45651039~45651826:-
BRCA	cis	rs1707322	1	rs10890359	ENSG00000234329.1	RP11-767N6.2	4.9	1.14e-06	0.000114	0.15	0.15	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45870963	chr1:45651039~45651826:-
BRCA	cis	rs11098499	0.954	rs2389802	ENSG00000260091.1	RP11-33B1.4	-4.9	1.14e-06	0.000114	-0.13	-0.15	Corneal astigmatism;	chr4:119404577	chr4:119409333~119410233:+
BRCA	cis	rs17772222	0.74	rs10150311	ENSG00000258789.1	RP11-507K2.3	-4.9	1.14e-06	0.000114	-0.17	-0.15	Coronary artery calcification;	chr14:88510128	chr14:88551597~88552493:+
BRCA	cis	rs7772486	0.875	rs6570738	ENSG00000270638.1	RP3-466P17.1	4.9	1.14e-06	0.000114	0.17	0.15	Lobe attachment (rater-scored or self-reported);	chr6:146091559	chr6:145735570~145737218:+
BRCA	cis	rs7772486	0.875	rs1412080	ENSG00000270638.1	RP3-466P17.1	4.9	1.14e-06	0.000114	0.17	0.15	Lobe attachment (rater-scored or self-reported);	chr6:146096168	chr6:145735570~145737218:+
BRCA	cis	rs4388249	0.516	rs435494	ENSG00000271849.1	CTC-332L22.1	-4.9	1.14e-06	0.000114	-0.24	-0.15	Schizophrenia;	chr5:109674877	chr5:109687802~109688329:-
BRCA	cis	rs1395	0.744	rs11686131	ENSG00000234072.1	AC074117.10	-4.9	1.14e-06	0.000114	-0.17	-0.15	Blood metabolite levels;	chr2:27285842	chr2:27356246~27367622:+
BRCA	cis	rs2562456	0.876	rs2650844	ENSG00000268658.4	LINC00664	4.9	1.14e-06	0.000114	0.24	0.15	Pain;	chr19:21419288	chr19:21483374~21503238:+
BRCA	cis	rs4664293	0.967	rs13000070	ENSG00000226266.5	AC009961.3	-4.9	1.14e-06	0.000114	-0.19	-0.15	Monocyte percentage of white cells;	chr2:159669263	chr2:159670708~159712435:-
BRCA	cis	rs736408	0.609	rs2230534	ENSG00000243224.1	RP5-1157M23.2	-4.9	1.14e-06	0.000114	-0.17	-0.15	Bipolar disorder;	chr3:52768386	chr3:52239258~52241097:+
BRCA	cis	rs3120667	0.72	rs36061814	ENSG00000237975.5	FLG-AS1	4.89	1.14e-06	0.000114	0.23	0.15	Eating disorders;	chr1:152444388	chr1:152168125~152445456:+
BRCA	cis	rs7914558	1	rs1926030	ENSG00000236937.2	PTGES3P4	4.89	1.14e-06	0.000114	0.19	0.15	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103095899	chr10:102845595~102845950:+
BRCA	cis	rs875971	0.83	rs778715	ENSG00000236529.1	RP13-254B10.1	4.89	1.14e-06	0.000114	0.17	0.15	Aortic root size;	chr7:66384222	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.862	rs2088653	ENSG00000273448.1	RP11-166O4.6	-4.89	1.14e-06	0.000114	-0.14	-0.15	Aortic root size;	chr7:66343621	chr7:67333047~67334383:+
BRCA	cis	rs875971	0.862	rs6460293	ENSG00000273448.1	RP11-166O4.6	-4.89	1.14e-06	0.000114	-0.14	-0.15	Aortic root size;	chr7:66345205	chr7:67333047~67334383:+
BRCA	cis	rs2833693	0.574	rs11088205	ENSG00000261610.1	AP000265.1	4.89	1.14e-06	0.000114	0.18	0.15	Temperament;	chr21:32179989	chr21:32259804~32261585:-
BRCA	cis	rs6832769	0.922	rs28726308	ENSG00000223305.1	RN7SKP30	4.89	1.14e-06	0.000114	0.2	0.15	Personality dimensions;	chr4:55368239	chr4:55540502~55540835:-
BRCA	cis	rs9840812	0.769	rs4678428	ENSG00000239213.4	NCK1-AS1	4.89	1.14e-06	0.000114	0.18	0.15	Fibrinogen levels;	chr3:136269570	chr3:136841726~136862054:-
BRCA	cis	rs57221529	0.766	rs56350081	ENSG00000225138.6	CTD-2228K2.7	4.89	1.14e-06	0.000114	0.23	0.15	Lung disease severity in cystic fibrosis;	chr5:583083	chr5:473236~480884:+
BRCA	cis	rs116095464	0.558	rs10056628	ENSG00000248925.1	CTD-2083E4.6	4.89	1.14e-06	0.000114	0.3	0.15	Breast cancer;	chr5:279397	chr5:269858~271516:-
BRCA	cis	rs875971	1	rs12533997	ENSG00000223473.2	GS1-124K5.3	4.89	1.14e-06	0.000115	0.11	0.15	Aortic root size;	chr7:66500390	chr7:66491049~66493566:-
BRCA	cis	rs4356203	0.87	rs214919	ENSG00000272034.1	SNORD14A	-4.89	1.14e-06	0.000115	-0.15	-0.15	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17217157	chr11:17074654~17074744:-
BRCA	cis	rs62025270	0.688	rs62022940	ENSG00000259762.1	RP11-158M2.4	-4.89	1.14e-06	0.000115	-0.22	-0.15	Idiopathic pulmonary fibrosis;	chr15:85709289	chr15:85750336~85752901:-
BRCA	cis	rs2243480	1	rs316332	ENSG00000275400.1	RP4-756H11.5	4.89	1.14e-06	0.000115	0.27	0.15	Diabetic kidney disease;	chr7:66139312	chr7:66553805~66554199:-
BRCA	cis	rs3176789	0.914	rs4519176	ENSG00000256673.1	RP11-599J14.2	-4.89	1.14e-06	0.000115	-0.19	-0.15	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9772636	chr12:9398355~9414851:-
BRCA	cis	rs57221529	0.766	rs72703070	ENSG00000225138.6	CTD-2228K2.7	4.89	1.14e-06	0.000115	0.23	0.15	Lung disease severity in cystic fibrosis;	chr5:590343	chr5:473236~480884:+
BRCA	cis	rs57221529	0.713	rs72703072	ENSG00000225138.6	CTD-2228K2.7	4.89	1.14e-06	0.000115	0.23	0.15	Lung disease severity in cystic fibrosis;	chr5:590511	chr5:473236~480884:+
BRCA	cis	rs57221529	0.713	rs12522724	ENSG00000225138.6	CTD-2228K2.7	4.89	1.14e-06	0.000115	0.23	0.15	Lung disease severity in cystic fibrosis;	chr5:590627	chr5:473236~480884:+
BRCA	cis	rs7267979	0.816	rs405822	ENSG00000277938.1	RP5-965G21.3	4.89	1.14e-06	0.000115	0.18	0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25520678	chr20:25229150~25231933:+
BRCA	cis	rs7267979	0.816	rs409853	ENSG00000277938.1	RP5-965G21.3	4.89	1.14e-06	0.000115	0.18	0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25525431	chr20:25229150~25231933:+
BRCA	cis	rs721917	0.525	rs2758541	ENSG00000242600.5	MBL1P	4.89	1.14e-06	0.000115	0.18	0.15	Chronic obstructive pulmonary disease;	chr10:79895801	chr10:79904898~79950336:+
BRCA	cis	rs1223397	0.651	rs2496154	ENSG00000215022.6	RP1-257A7.4	-4.89	1.15e-06	0.000115	-0.18	-0.15	Blood pressure;	chr6:13314799	chr6:13264861~13295586:-
BRCA	cis	rs4803480	0.872	rs10420470	ENSG00000270164.1	LINC01480	-4.89	1.15e-06	0.000115	-0.19	-0.15	Schizophrenia;	chr19:41567075	chr19:41535183~41536904:+
BRCA	cis	rs6570726	0.764	rs9399553	ENSG00000270638.1	RP3-466P17.1	4.89	1.15e-06	0.000115	0.17	0.15	Lobe attachment (rater-scored or self-reported);	chr6:145552528	chr6:145735570~145737218:+
BRCA	cis	rs1707322	0.896	rs785512	ENSG00000234329.1	RP11-767N6.2	-4.89	1.15e-06	0.000115	-0.15	-0.15	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46068871	chr1:45651039~45651826:-
BRCA	cis	rs875971	0.545	rs73376394	ENSG00000230295.1	RP11-458F8.2	4.89	1.15e-06	0.000115	0.14	0.15	Aortic root size;	chr7:66172694	chr7:66880708~66882981:+
BRCA	cis	rs2832191	1	rs2832191	ENSG00000176054.6	RPL23P2	-4.89	1.15e-06	0.000115	-0.16	-0.15	Dental caries;	chr21:29116979	chr21:28997613~28998033:-
BRCA	cis	rs2115630	1	rs56074163	ENSG00000259295.5	CSPG4P12	-4.89	1.15e-06	0.000115	-0.18	-0.15	P wave terminal force;	chr15:84808101	chr15:85191438~85213905:+
BRCA	cis	rs7045881	0.877	rs7035755	ENSG00000254396.1	RP11-56F10.3	-4.89	1.15e-06	0.000115	-0.24	-0.15	Schizophrenia;	chr9:26945978	chr9:27102630~27104728:+
BRCA	cis	rs6496044	0.568	rs2880764	ENSG00000202081.1	RNU6-1280P	4.89	1.15e-06	0.000115	0.17	0.15	Interstitial lung disease;	chr15:85513177	chr15:85651522~85651628:-
BRCA	cis	rs2179367	0.632	rs9285520	ENSG00000268592.3	RAET1E-AS1	-4.89	1.15e-06	0.000115	-0.21	-0.15	Dupuytren's disease;	chr6:149372001	chr6:149863494~149919507:+
BRCA	cis	rs2243480	1	rs6964245	ENSG00000222364.1	RNU6-96P	4.89	1.15e-06	0.000115	0.27	0.15	Diabetic kidney disease;	chr7:66253730	chr7:66395191~66395286:+
BRCA	cis	rs8127691	1	rs7276302	ENSG00000237604.1	AP001056.1	4.89	1.15e-06	0.000115	0.17	0.15	Inflammatory bowel disease;	chr21:44194276	chr21:44175489~44176453:+
BRCA	cis	rs4218	0.593	rs8040456	ENSG00000259732.1	RP11-59H7.3	-4.89	1.15e-06	0.000115	-0.18	-0.15	Social communication problems;	chr15:59063904	chr15:59121034~59133250:+
BRCA	cis	rs9341808	0.718	rs9343971	ENSG00000272129.1	RP11-250B2.6	4.89	1.15e-06	0.000115	0.19	0.15	Sitting height ratio;	chr6:80172339	chr6:80355424~80356859:+
BRCA	cis	rs801193	0.569	rs2659908	ENSG00000236529.1	RP13-254B10.1	4.89	1.15e-06	0.000115	0.16	0.15	Aortic root size;	chr7:66695835	chr7:65840212~65840596:+
BRCA	cis	rs2098713	0.536	rs2366419	ENSG00000250155.1	CTD-2353F22.1	4.89	1.15e-06	0.000115	0.17	0.15	Telomere length;	chr5:37529948	chr5:36666214~36725195:-
BRCA	cis	rs427691	0.625	rs372062	ENSG00000271849.1	CTC-332L22.1	-4.89	1.15e-06	0.000115	-0.24	-0.15	Autism spectrum disorder or schizophrenia;	chr5:109674826	chr5:109687802~109688329:-
BRCA	cis	rs2638953	0.671	rs7969830	ENSG00000278733.1	RP11-425D17.1	-4.89	1.15e-06	0.000115	-0.21	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28111770	chr12:28185625~28186190:-
BRCA	cis	rs2279168	1	rs28397760	ENSG00000259407.1	RP11-158M2.3	4.89	1.15e-06	0.000115	0.25	0.15	Response to platinum-based chemotherapy (carboplatin);	chr15:85534321	chr15:85744109~85750281:-
BRCA	cis	rs2179367	0.6	rs9498356	ENSG00000223701.3	RAET1E-AS1	4.89	1.15e-06	0.000115	0.22	0.15	Dupuytren's disease;	chr6:149443337	chr6:149884431~149919508:+
BRCA	cis	rs4700393	0.52	rs6896680	ENSG00000215032.2	GNL3LP1	4.89	1.15e-06	0.000115	0.21	0.15	Intelligence (multi-trait analysis);	chr5:60695704	chr5:60891935~60893577:-
BRCA	cis	rs7267979	0.727	rs2474765	ENSG00000274973.1	RP13-401N8.7	-4.89	1.15e-06	0.000115	-0.17	-0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25265314	chr20:25845497~25845862:+
BRCA	cis	rs10129255	0.913	rs28861466	ENSG00000274576.2	IGHV2-70	4.89	1.15e-06	0.000115	0.14	0.15	Kawasaki disease;	chr14:106718572	chr14:106770577~106771020:-
BRCA	cis	rs198426	0.506	rs11230766	ENSG00000243742.4	RPLP0P2	-4.89	1.15e-06	0.000115	-0.2	-0.15	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr11:61659110	chr11:61615036~61639449:+
BRCA	cis	rs9652601	0.691	rs9888868	ENSG00000274038.1	RP11-66H6.4	-4.89	1.15e-06	0.000115	-0.16	-0.15	Systemic lupus erythematosus;	chr16:11089706	chr16:11056556~11057034:+
BRCA	cis	rs9652601	0.691	rs11861236	ENSG00000274038.1	RP11-66H6.4	-4.89	1.15e-06	0.000115	-0.16	-0.15	Systemic lupus erythematosus;	chr16:11089769	chr16:11056556~11057034:+
BRCA	cis	rs1858037	0.867	rs72621551	ENSG00000237979.1	AC007389.1	4.89	1.15e-06	0.000115	0.19	0.15	Rheumatoid arthritis;	chr2:65388087	chr2:65500993~65502138:-
BRCA	cis	rs11250098	0.567	rs4326350	ENSG00000154316.13	TDH	-4.89	1.15e-06	0.000116	-0.19	-0.15	Morning vs. evening chronotype;	chr8:10906145	chr8:11339637~11368452:+
BRCA	cis	rs4919687	0.679	rs12762176	ENSG00000236937.2	PTGES3P4	4.89	1.15e-06	0.000116	0.21	0.15	Colorectal cancer;	chr10:102739475	chr10:102845595~102845950:+
BRCA	cis	rs739496	0.579	rs1981517	ENSG00000226469.1	ADAM1B	4.89	1.15e-06	0.000116	0.19	0.15	Platelet count;	chr12:111885778	chr12:111927018~111929017:+
BRCA	cis	rs9990333	0.862	rs6806599	ENSG00000231464.1	AC024937.4	-4.89	1.15e-06	0.000116	-0.19	-0.15	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196089280	chr3:195996738~195998233:+
BRCA	cis	rs3768617	0.565	rs10752897	ENSG00000224468.3	RP11-181K3.4	-4.89	1.15e-06	0.000116	-0.16	-0.15	Fuchs's corneal dystrophy;	chr1:183101889	chr1:183138402~183141282:-
BRCA	cis	rs2638953	0.962	rs11049533	ENSG00000247934.4	RP11-967K21.1	-4.89	1.15e-06	0.000116	-0.21	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28327471	chr12:28163298~28190738:-
BRCA	cis	rs6430538	0.671	rs1942050	ENSG00000224043.6	CCNT2-AS1	4.89	1.15e-06	0.000116	0.21	0.15	Parkinson's disease;	chr2:134817013	chr2:134735464~134918710:-
BRCA	cis	rs2562456	0.52	rs660063	ENSG00000268535.1	RP11-420K14.3	-4.89	1.15e-06	0.000116	-0.23	-0.15	Pain;	chr19:21271103	chr19:21709522~21710191:+
BRCA	cis	rs7226408	0.857	rs72888992	ENSG00000267707.2	RP11-95O2.5	4.89	1.15e-06	0.000116	0.23	0.15	Obesity-related traits;	chr18:36992418	chr18:37243776~37247506:+
BRCA	cis	rs9467773	0.62	rs3800303	ENSG00000124549.13	BTN2A3P	4.89	1.15e-06	0.000116	0.15	0.15	Intelligence (multi-trait analysis);	chr6:26597960	chr6:26421391~26432383:+
BRCA	cis	rs922692	1	rs4887077	ENSG00000261143.1	ADAMTS7P3	-4.89	1.15e-06	0.000116	-0.19	-0.15	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78686022	chr15:77976042~77993057:+
BRCA	cis	rs3213958	0.509	rs56322058	ENSG00000249274.1	PDLIM1P4	-4.89	1.15e-06	0.000116	-0.25	-0.15	Blood protein levels;	chr3:98900445	chr3:98782188~98783193:+
BRCA	cis	rs9308731	0.966	rs36018702	ENSG00000230499.1	AC108463.1	4.89	1.16e-06	0.000116	0.17	0.15	Chronic lymphocytic leukemia;	chr2:111170796	chr2:111195963~111206494:+
BRCA	cis	rs2281636	0.894	rs2297446	ENSG00000233690.1	EBAG9P1	4.89	1.16e-06	0.000116	0.16	0.15	Obesity-related traits;	chr10:99610258	chr10:99697407~99697949:-
BRCA	cis	rs801193	0.569	rs6978178	ENSG00000236529.1	RP13-254B10.1	-4.89	1.16e-06	0.000116	-0.17	-0.15	Aortic root size;	chr7:66658097	chr7:65840212~65840596:+
BRCA	cis	rs643177	0.609	rs644340	ENSG00000226004.1	RP11-10J5.1	4.89	1.16e-06	0.000116	0.14	0.15	Psoriasis;Inflammatory skin disease;	chr6:137894437	chr6:137943079~137945802:-
BRCA	cis	rs801193	0.569	rs2659893	ENSG00000236529.1	RP13-254B10.1	4.89	1.16e-06	0.000116	0.17	0.15	Aortic root size;	chr7:66735006	chr7:65840212~65840596:+
BRCA	cis	rs801193	0.569	rs2659892	ENSG00000236529.1	RP13-254B10.1	4.89	1.16e-06	0.000116	0.17	0.15	Aortic root size;	chr7:66735318	chr7:65840212~65840596:+
BRCA	cis	rs801193	0.569	rs2707847	ENSG00000236529.1	RP13-254B10.1	4.89	1.16e-06	0.000116	0.17	0.15	Aortic root size;	chr7:66737884	chr7:65840212~65840596:+
BRCA	cis	rs1322639	0.614	rs9455889	ENSG00000223485.1	RP11-417E7.1	-4.89	1.16e-06	0.000116	-0.21	-0.15	Pulse pressure;	chr6:169165992	chr6:169158092~169162924:-
BRCA	cis	rs4948275	0.773	rs2787731	ENSG00000237233.2	TMEM26-AS1	-4.89	1.16e-06	0.000116	-0.18	-0.15	Night sleep phenotypes;	chr10:61487775	chr10:61452639~61481956:+
BRCA	cis	rs10129255	0.957	rs11846893	ENSG00000274576.2	IGHV2-70	4.89	1.16e-06	0.000116	0.13	0.15	Kawasaki disease;	chr14:106779068	chr14:106770577~106771020:-
BRCA	cis	rs516805	0.561	rs9482260	ENSG00000279453.1	RP3-425C14.4	4.89	1.16e-06	0.000116	0.23	0.15	Lymphocyte counts;	chr6:122606981	chr6:122436789~122439223:-
BRCA	cis	rs2732480	0.5	rs2450986	ENSG00000257735.1	RP11-370I10.6	4.89	1.16e-06	0.000116	0.19	0.15	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48267905	chr12:48350945~48442411:+
BRCA	cis	rs2562456	0.72	rs6511250	ENSG00000268658.4	LINC00664	-4.89	1.16e-06	0.000116	-0.23	-0.15	Pain;	chr19:21473244	chr19:21483374~21503238:+
BRCA	cis	rs9659323	0.745	rs10923723	ENSG00000231365.4	RP11-418J17.1	-4.89	1.16e-06	0.000116	-0.18	-0.15	Body mass index;	chr1:119001379	chr1:119140396~119275973:+
BRCA	cis	rs62064224	0.56	rs12162135	ENSG00000279781.1	RP11-466A19.7	4.89	1.16e-06	0.000116	0.18	0.15	Schizophrenia;	chr17:32478777	chr17:32518322~32518934:-
BRCA	cis	rs1520333	0.54	rs10957891	ENSG00000254352.1	RP11-578O24.2	-4.89	1.16e-06	0.000116	-0.23	-0.15	Multiple sclerosis;	chr8:78456278	chr8:78723796~78724136:-
BRCA	cis	rs2898681	0.874	rs59649036	ENSG00000248375.1	RP11-177B4.1	-4.89	1.16e-06	0.000116	-0.21	-0.15	Optic nerve measurement (cup area);	chr4:52875008	chr4:52720081~52720831:-
BRCA	cis	rs1913185	0.787	rs58874363	ENSG00000240032.1	RP11-274H2.3	-4.89	1.16e-06	0.000116	-0.24	-0.15	Obesity-related traits;	chr3:146126725	chr3:146066344~146069185:-
BRCA	cis	rs11853189	1	rs11856774	ENSG00000259562.2	RP11-762H8.2	4.89	1.16e-06	0.000116	0.19	0.15	Red cell distribution width;	chr15:78273697	chr15:78290527~78291221:-
BRCA	cis	rs9818758	0.607	rs12715434	ENSG00000270441.1	RP11-694I15.7	4.89	1.16e-06	0.000116	0.28	0.15	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49257592	chr3:49140086~49160851:-
BRCA	cis	rs6772849	0.93	rs68090762	ENSG00000242551.2	POU5F1P6	-4.89	1.16e-06	0.000117	-0.19	-0.15	Monocyte percentage of white cells;Monocyte count;	chr3:128625064	chr3:128674735~128677005:-
BRCA	cis	rs721917	0.506	rs2493722	ENSG00000242600.5	MBL1P	4.89	1.16e-06	0.000117	0.18	0.15	Chronic obstructive pulmonary disease;	chr10:79896989	chr10:79904898~79950336:+
BRCA	cis	rs721917	0.545	rs2758542	ENSG00000242600.5	MBL1P	4.89	1.16e-06	0.000117	0.18	0.15	Chronic obstructive pulmonary disease;	chr10:79897946	chr10:79904898~79950336:+
BRCA	cis	rs721917	0.506	rs7914360	ENSG00000242600.5	MBL1P	4.89	1.16e-06	0.000117	0.18	0.15	Chronic obstructive pulmonary disease;	chr10:79898002	chr10:79904898~79950336:+
BRCA	cis	rs721917	0.506	rs2254025	ENSG00000242600.5	MBL1P	4.89	1.16e-06	0.000117	0.18	0.15	Chronic obstructive pulmonary disease;	chr10:79898457	chr10:79904898~79950336:+
BRCA	cis	rs721917	0.525	rs2254017	ENSG00000242600.5	MBL1P	4.89	1.16e-06	0.000117	0.18	0.15	Chronic obstructive pulmonary disease;	chr10:79898635	chr10:79904898~79950336:+
BRCA	cis	rs721917	0.506	rs2254013	ENSG00000242600.5	MBL1P	4.89	1.16e-06	0.000117	0.18	0.15	Chronic obstructive pulmonary disease;	chr10:79898692	chr10:79904898~79950336:+
BRCA	cis	rs721917	0.506	rs2253875	ENSG00000242600.5	MBL1P	4.89	1.16e-06	0.000117	0.18	0.15	Chronic obstructive pulmonary disease;	chr10:79899446	chr10:79904898~79950336:+
BRCA	cis	rs721917	0.544	rs9325567	ENSG00000242600.5	MBL1P	4.89	1.16e-06	0.000117	0.18	0.15	Chronic obstructive pulmonary disease;	chr10:79899822	chr10:79904898~79950336:+
BRCA	cis	rs6747488	0.529	rs665237	ENSG00000272716.1	RP11-563N4.1	-4.89	1.16e-06	0.000117	-0.16	-0.15	Interleukin-18 levels;	chr2:31644874	chr2:32165046~32165757:-
BRCA	cis	rs1910358	0.638	rs7702367	ENSG00000248874.4	C5orf17	-4.89	1.16e-06	0.000117	-0.2	-0.15	Venous thromboembolism (SNP x SNP interaction);	chr5:23881016	chr5:23951348~24178263:+
BRCA	cis	rs1910358	0.614	rs1602373	ENSG00000248874.4	C5orf17	-4.89	1.16e-06	0.000117	-0.2	-0.15	Venous thromboembolism (SNP x SNP interaction);	chr5:23889548	chr5:23951348~24178263:+
BRCA	cis	rs11098499	0.754	rs878372	ENSG00000249244.1	RP11-548H18.2	4.89	1.16e-06	0.000117	0.17	0.15	Corneal astigmatism;	chr4:119317625	chr4:119391831~119395335:-
BRCA	cis	rs494453	0.883	rs474722	ENSG00000227811.2	FAM212B-AS1	-4.89	1.16e-06	0.000117	-0.19	-0.15	Osteoporosis-related phenotypes;	chr1:111674356	chr1:111739841~111747798:+
BRCA	cis	rs2832191	1	rs8131214	ENSG00000176054.6	RPL23P2	-4.89	1.16e-06	0.000117	-0.16	-0.15	Dental caries;	chr21:29111065	chr21:28997613~28998033:-
BRCA	cis	rs793571	0.628	rs28510910	ENSG00000259250.1	RP11-50C13.1	-4.89	1.17e-06	0.000117	-0.25	-0.15	Schizophrenia;	chr15:58790188	chr15:58587507~58591676:+
BRCA	cis	rs793571	0.628	rs28793354	ENSG00000259250.1	RP11-50C13.1	-4.89	1.17e-06	0.000117	-0.25	-0.15	Schizophrenia;	chr15:58792647	chr15:58587507~58591676:+
BRCA	cis	rs600231	0.708	rs2957269	ENSG00000173727.10	CMB9-22P13.1	4.89	1.17e-06	0.000117	0.2	0.15	Bone mineral density;	chr11:65475536	chr11:65455258~65466720:+
BRCA	cis	rs2832191	1	rs2832189	ENSG00000176054.6	RPL23P2	-4.89	1.17e-06	0.000117	-0.16	-0.15	Dental caries;	chr21:29115093	chr21:28997613~28998033:-
BRCA	cis	rs3781264	0.517	rs12780240	ENSG00000273450.1	RP11-76P2.4	4.89	1.17e-06	0.000117	0.24	0.15	Esophageal cancer and gastric cancer;	chr10:94300954	chr10:94314907~94315327:-
BRCA	cis	rs875971	0.929	rs12535036	ENSG00000223473.2	GS1-124K5.3	4.89	1.17e-06	0.000117	0.11	0.15	Aortic root size;	chr7:66499076	chr7:66491049~66493566:-
BRCA	cis	rs875971	1	rs6970030	ENSG00000223473.2	GS1-124K5.3	4.89	1.17e-06	0.000117	0.11	0.15	Aortic root size;	chr7:66503692	chr7:66491049~66493566:-
BRCA	cis	rs875971	0.928	rs6970357	ENSG00000223473.2	GS1-124K5.3	4.89	1.17e-06	0.000117	0.11	0.15	Aortic root size;	chr7:66503891	chr7:66491049~66493566:-
BRCA	cis	rs11976180	1	rs1919951	ENSG00000244479.5	OR2A1-AS1	4.89	1.17e-06	0.000117	0.2	0.15	Obesity-related traits;	chr7:144071798	chr7:144251264~144356181:-
BRCA	cis	rs9341808	0.538	rs615585	ENSG00000233967.5	RP11-250B2.3	-4.89	1.17e-06	0.000117	-0.15	-0.15	Sitting height ratio;	chr6:80276436	chr6:80443344~80465927:+
BRCA	cis	rs8114671	0.562	rs1060615	ENSG00000269202.1	RP4-614O4.12	4.89	1.17e-06	0.000117	0.15	0.15	Height;	chr20:34890578	chr20:35201747~35203288:-
BRCA	cis	rs651907	0.967	rs694936	ENSG00000244119.1	PDCL3P4	4.89	1.17e-06	0.000117	0.12	0.15	Colorectal cancer;	chr3:101868949	chr3:101712472~101713191:+
BRCA	cis	rs56322409	0.865	rs4512761	ENSG00000226688.5	ENTPD1-AS1	4.89	1.17e-06	0.000117	0.18	0.15	Blood metabolite levels;	chr10:95865342	chr10:95753206~96090238:-
BRCA	cis	rs4906332	1	rs8012127	ENSG00000244691.1	RPL10AP1	-4.89	1.17e-06	0.000117	-0.19	-0.15	Coronary artery disease;	chr14:103476425	chr14:103412119~103412761:-
BRCA	cis	rs4906332	1	rs78316803	ENSG00000244691.1	RPL10AP1	-4.89	1.17e-06	0.000117	-0.19	-0.15	Coronary artery disease;	chr14:103476526	chr14:103412119~103412761:-
BRCA	cis	rs4906332	1	rs17617832	ENSG00000244691.1	RPL10AP1	-4.89	1.17e-06	0.000117	-0.19	-0.15	Coronary artery disease;	chr14:103476803	chr14:103412119~103412761:-
BRCA	cis	rs4906332	1	rs11625172	ENSG00000244691.1	RPL10AP1	-4.89	1.17e-06	0.000117	-0.19	-0.15	Coronary artery disease;	chr14:103478575	chr14:103412119~103412761:-
BRCA	cis	rs11098499	0.954	rs12508504	ENSG00000250412.1	KLHL2P1	4.89	1.17e-06	0.000117	0.18	0.15	Corneal astigmatism;	chr4:119489452	chr4:119334329~119378233:+
BRCA	cis	rs7572733	0.742	rs3828317	ENSG00000231621.1	AC013264.2	-4.89	1.17e-06	0.000117	-0.14	-0.15	Dermatomyositis;	chr2:197630707	chr2:197197991~197199273:+
BRCA	cis	rs875971	0.545	rs2460427	ENSG00000232546.1	RP11-458F8.1	-4.89	1.17e-06	0.000117	-0.14	-0.15	Aortic root size;	chr7:66154218	chr7:66848496~66858136:+
BRCA	cis	rs7208859	0.573	rs216443	ENSG00000280069.1	CTD-2349P21.3	-4.89	1.17e-06	0.000117	-0.23	-0.15	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30604853	chr17:30738182~30740275:+
BRCA	cis	rs4356203	0.905	rs10832743	ENSG00000272034.1	SNORD14A	-4.89	1.17e-06	0.000117	-0.15	-0.15	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17194933	chr11:17074654~17074744:-
BRCA	cis	rs2617170	0.883	rs2086099	ENSG00000245648.1	RP11-277P12.20	4.89	1.17e-06	0.000117	0.2	0.15	Behcet's disease;	chr12:10373939	chr12:10363769~10398506:+
BRCA	cis	rs66887589	0.967	rs1155577	ENSG00000245958.5	RP11-33B1.1	4.89	1.17e-06	0.000117	0.13	0.15	Diastolic blood pressure;	chr4:119528655	chr4:119454791~119552025:+
BRCA	cis	rs875971	1	rs12532998	ENSG00000223473.2	GS1-124K5.3	4.89	1.17e-06	0.000117	0.11	0.15	Aortic root size;	chr7:66502472	chr7:66491049~66493566:-
BRCA	cis	rs11098499	0.754	rs4107728	ENSG00000260404.2	RP11-384K6.6	4.89	1.17e-06	0.000118	0.14	0.15	Corneal astigmatism;	chr4:119332755	chr4:118591773~118633729:+
BRCA	cis	rs728616	0.614	rs958865	ENSG00000225484.5	NUTM2B-AS1	-4.89	1.17e-06	0.000118	-0.28	-0.15	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79948273	chr10:79663088~79826594:-
BRCA	cis	rs2303319	0.504	rs62187597	ENSG00000227403.1	AC009299.3	4.89	1.17e-06	0.000118	0.35	0.15	Cognitive function;	chr2:161541753	chr2:161244739~161249050:+
BRCA	cis	rs7572733	0.534	rs700662	ENSG00000231621.1	AC013264.2	-4.89	1.17e-06	0.000118	-0.15	-0.15	Dermatomyositis;	chr2:197804027	chr2:197197991~197199273:+
BRCA	cis	rs7308116	0.546	rs1895928	ENSG00000274395.1	RP11-554D14.8	-4.89	1.18e-06	0.000118	-0.18	-0.15	Pelvic organ prolapse (moderate/severe);	chr12:107833325	chr12:107835541~107836555:-
BRCA	cis	rs62025270	0.632	rs13379832	ENSG00000259295.5	CSPG4P12	-4.89	1.18e-06	0.000118	-0.23	-0.15	Idiopathic pulmonary fibrosis;	chr15:85572669	chr15:85191438~85213905:+
BRCA	cis	rs17597773	0.598	rs11118616	ENSG00000238078.1	LINC01352	-4.89	1.18e-06	0.000118	-0.18	-0.15	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220832314	chr1:220829255~220832429:+
BRCA	cis	rs11073619	0.803	rs7180895	ENSG00000259295.5	CSPG4P12	4.89	1.18e-06	0.000118	0.29	0.15	Positive affect;	chr15:84614489	chr15:85191438~85213905:+
BRCA	cis	rs1122401	0.515	rs2564983	ENSG00000280159.1	CTD-2591A1.1	4.89	1.18e-06	0.000118	0.24	0.15	Smoking initiation;	chr5:54568610	chr5:54643557~54645987:+
BRCA	cis	rs3176789	0.914	rs4385980	ENSG00000256673.1	RP11-599J14.2	4.89	1.18e-06	0.000118	0.19	0.15	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9772596	chr12:9398355~9414851:-
BRCA	cis	rs4494364	0.502	rs10745547	ENSG00000258100.1	RP11-121E16.1	4.89	1.18e-06	0.000118	0.22	0.15	Systolic blood pressure (alcohol consumption interaction);	chr12:91018163	chr12:91362196~91368606:+
BRCA	cis	rs7226408	0.857	rs8098708	ENSG00000267707.2	RP11-95O2.5	4.89	1.18e-06	0.000118	0.23	0.15	Obesity-related traits;	chr18:36983410	chr18:37243776~37247506:+
BRCA	cis	rs2278170	1	rs2554944	ENSG00000225101.4	OR52K3P	-4.89	1.18e-06	0.000118	-0.2	-0.15	Amyotrophic lateral sclerosis;	chr11:4458671	chr11:4474813~4475755:+
BRCA	cis	rs7428	0.527	rs6547612	ENSG00000273196.1	RP11-717A5.2	4.89	1.18e-06	0.000118	0.18	0.15	Ear protrusion;	chr2:85324061	chr2:85387074~85387146:-
BRCA	cis	rs62025270	0.688	rs79083718	ENSG00000259762.1	RP11-158M2.4	-4.89	1.18e-06	0.000118	-0.23	-0.15	Idiopathic pulmonary fibrosis;	chr15:85720298	chr15:85750336~85752901:-
BRCA	cis	rs2051773	0.567	rs7935677	ENSG00000184669.7	OR7E14P	-4.89	1.18e-06	0.000118	-0.22	-0.15	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);	chr11:17018285	chr11:17013998~17053024:+
BRCA	cis	rs9467773	0.596	rs3001369	ENSG00000241549.7	GUSBP2	4.89	1.18e-06	0.000118	0.16	0.15	Intelligence (multi-trait analysis);	chr6:26670741	chr6:26871484~26956554:-
BRCA	cis	rs4908768	0.501	rs12061328	ENSG00000232912.4	RP5-1115A15.1	4.89	1.18e-06	0.000118	0.14	0.15	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8471903	chr1:8424645~8434838:+
BRCA	cis	rs7267979	0.718	rs2983489	ENSG00000274973.1	RP13-401N8.7	-4.89	1.18e-06	0.000118	-0.17	-0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25263484	chr20:25845497~25845862:+
BRCA	cis	rs875971	0.862	rs1643375	ENSG00000236529.1	RP13-254B10.1	4.89	1.18e-06	0.000118	0.17	0.15	Aortic root size;	chr7:66407690	chr7:65840212~65840596:+
BRCA	cis	rs7246657	0.722	rs12979640	ENSG00000276846.1	CTD-3220F14.3	-4.89	1.18e-06	0.000118	-0.2	-0.15	Coronary artery calcification;	chr19:37688255	chr19:37314868~37315620:-
BRCA	cis	rs2562456	0.833	rs2968076	ENSG00000268658.4	LINC00664	-4.89	1.18e-06	0.000118	-0.23	-0.15	Pain;	chr19:21454299	chr19:21483374~21503238:+
BRCA	cis	rs7246657	0.722	rs4802051	ENSG00000276846.1	CTD-3220F14.3	4.89	1.18e-06	0.000118	0.2	0.15	Coronary artery calcification;	chr19:37581427	chr19:37314868~37315620:-
BRCA	cis	rs7246657	0.663	rs4803276	ENSG00000276846.1	CTD-3220F14.3	4.89	1.18e-06	0.000118	0.2	0.15	Coronary artery calcification;	chr19:37581429	chr19:37314868~37315620:-
BRCA	cis	rs7772486	0.79	rs4896852	ENSG00000270638.1	RP3-466P17.1	-4.89	1.18e-06	0.000118	-0.18	-0.15	Lobe attachment (rater-scored or self-reported);	chr6:145963485	chr6:145735570~145737218:+
BRCA	cis	rs2179367	0.6	rs1001305	ENSG00000223701.3	RAET1E-AS1	4.89	1.18e-06	0.000118	0.22	0.15	Dupuytren's disease;	chr6:149436808	chr6:149884431~149919508:+
BRCA	cis	rs2278170	1	rs331502	ENSG00000225101.4	OR52K3P	-4.89	1.18e-06	0.000118	-0.2	-0.15	Amyotrophic lateral sclerosis;	chr11:4470602	chr11:4474813~4475755:+
BRCA	cis	rs1395	0.778	rs1978881	ENSG00000234072.1	AC074117.10	-4.89	1.18e-06	0.000118	-0.16	-0.15	Blood metabolite levels;	chr2:27177982	chr2:27356246~27367622:+
BRCA	cis	rs1395	0.778	rs72810794	ENSG00000234072.1	AC074117.10	-4.89	1.18e-06	0.000118	-0.16	-0.15	Blood metabolite levels;	chr2:27178392	chr2:27356246~27367622:+
BRCA	cis	rs4363385	0.934	rs4240865	ENSG00000272654.1	RP11-422P24.11	-4.89	1.18e-06	0.000118	-0.16	-0.15	Inflammatory skin disease;	chr1:152982363	chr1:153977743~153979160:+
BRCA	cis	rs2486012	1	rs2245439	ENSG00000237950.1	RP11-7O11.3	-4.89	1.18e-06	0.000118	-0.26	-0.15	Intelligence (multi-trait analysis);	chr1:43924287	chr1:43944370~43946551:-
BRCA	cis	rs1722141	0.542	rs1723917	ENSG00000237471.1	AC073115.6	4.89	1.18e-06	0.000119	0.21	0.15	Sitting height ratio;	chr7:46006030	chr7:45969657~45980191:+
BRCA	cis	rs1387259	0.931	rs11168474	ENSG00000257735.1	RP11-370I10.6	4.89	1.18e-06	0.000119	0.19	0.15	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48227601	chr12:48350945~48442411:+
BRCA	cis	rs42490	0.664	rs39516	ENSG00000251136.7	RP11-37B2.1	-4.89	1.18e-06	0.000119	-0.14	-0.15	Leprosy;	chr8:89822157	chr8:89609409~89757727:-
BRCA	cis	rs17685	0.753	rs4732542	ENSG00000280388.1	RP11-229D13.3	-4.89	1.18e-06	0.000119	-0.15	-0.15	Coffee consumption (cups per day);Coffee consumption;	chr7:76033885	chr7:76043977~76045963:-
BRCA	cis	rs11098499	0.754	rs12513083	ENSG00000260404.2	RP11-384K6.6	4.89	1.18e-06	0.000119	0.14	0.15	Corneal astigmatism;	chr4:119328457	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.754	rs12509621	ENSG00000260404.2	RP11-384K6.6	4.89	1.18e-06	0.000119	0.14	0.15	Corneal astigmatism;	chr4:119328505	chr4:118591773~118633729:+
BRCA	cis	rs1371614	0.589	rs502751	ENSG00000272148.1	RP11-195B17.1	-4.89	1.18e-06	0.000119	-0.17	-0.15	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26888782	chr2:27062428~27062907:-
BRCA	cis	rs35740288	0.857	rs11632034	ENSG00000202081.1	RNU6-1280P	4.89	1.19e-06	0.000119	0.2	0.15	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85740841	chr15:85651522~85651628:-
BRCA	cis	rs6545883	0.895	rs2442029	ENSG00000270820.4	RP11-355B11.2	4.89	1.19e-06	0.000119	0.18	0.15	Tuberculosis;	chr2:61452417	chr2:61471188~61484130:+
BRCA	cis	rs6545883	0.929	rs2256615	ENSG00000270820.4	RP11-355B11.2	4.89	1.19e-06	0.000119	0.18	0.15	Tuberculosis;	chr2:61452759	chr2:61471188~61484130:+
BRCA	cis	rs703842	1	rs10747783	ENSG00000270039.1	RP11-571M6.17	-4.89	1.19e-06	0.000119	-0.21	-0.15	Multiple sclerosis;	chr12:57782831	chr12:57803838~57804415:+
BRCA	cis	rs7617773	0.779	rs11718329	ENSG00000199476.1	Y_RNA	-4.89	1.19e-06	0.000119	-0.21	-0.15	Coronary artery disease;	chr3:48268338	chr3:48288587~48288694:+
BRCA	cis	rs875971	0.798	rs6460304	ENSG00000273448.1	RP11-166O4.6	4.89	1.19e-06	0.000119	0.14	0.15	Aortic root size;	chr7:66499741	chr7:67333047~67334383:+
BRCA	cis	rs875971	0.862	rs6945775	ENSG00000273448.1	RP11-166O4.6	4.89	1.19e-06	0.000119	0.14	0.15	Aortic root size;	chr7:66503987	chr7:67333047~67334383:+
BRCA	cis	rs4718428	0.705	rs3800817	ENSG00000229180.5	GS1-124K5.11	4.89	1.19e-06	0.000119	0.14	0.15	Corneal structure;	chr7:66798563	chr7:66526088~66542624:-
BRCA	cis	rs2179367	0.6	rs9498355	ENSG00000223701.3	RAET1E-AS1	-4.89	1.19e-06	0.000119	-0.22	-0.15	Dupuytren's disease;	chr6:149442274	chr6:149884431~149919508:+
BRCA	cis	rs7577696	0.524	rs545303	ENSG00000272716.1	RP11-563N4.1	4.89	1.19e-06	0.000119	0.16	0.15	Inflammatory biomarkers;	chr2:31588929	chr2:32165046~32165757:-
BRCA	cis	rs11051970	0.513	rs4931013	ENSG00000274964.1	RP11-817I4.1	-4.89	1.19e-06	0.000119	-0.21	-0.15	Response to tocilizumab in rheumatoid arthritis;	chr12:32407788	chr12:32339368~32340724:+
BRCA	cis	rs11051970	0.546	rs11051989	ENSG00000274964.1	RP11-817I4.1	-4.89	1.19e-06	0.000119	-0.21	-0.15	Response to tocilizumab in rheumatoid arthritis;	chr12:32407956	chr12:32339368~32340724:+
BRCA	cis	rs8098244	1	rs2155841	ENSG00000264745.1	TTC39C-AS1	4.89	1.19e-06	0.000119	0.21	0.15	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23815394	chr18:23994213~24015339:-
BRCA	cis	rs13113518	1	rs13118237	ENSG00000249700.7	SRD5A3-AS1	4.89	1.19e-06	0.000119	0.19	0.15	Height;	chr4:55474259	chr4:55363971~55395847:-
BRCA	cis	rs7267979	0.789	rs1983974	ENSG00000274973.1	RP13-401N8.7	4.89	1.19e-06	0.000119	0.17	0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25549983	chr20:25845497~25845862:+
BRCA	cis	rs1005277	0.638	rs1005278	ENSG00000226578.1	RP11-258F22.1	4.89	1.19e-06	0.000119	0.17	0.15	Extrinsic epigenetic age acceleration;	chr10:37929820	chr10:37775371~37784131:-
BRCA	cis	rs4287000	0.508	rs17533702	ENSG00000227603.1	RP11-165J3.6	-4.89	1.19e-06	0.000119	-0.16	-0.15	Itch intensity from mosquito bite adjusted by bite size;	chr9:93598946	chr9:93435332~93437121:-
BRCA	cis	rs11098499	0.754	rs7672778	ENSG00000260404.2	RP11-384K6.6	4.89	1.19e-06	0.000119	0.14	0.15	Corneal astigmatism;	chr4:119327430	chr4:118591773~118633729:+
BRCA	cis	rs3781264	0.55	rs77218185	ENSG00000273450.1	RP11-76P2.4	4.89	1.19e-06	0.000119	0.24	0.15	Esophageal cancer and gastric cancer;	chr10:94311455	chr10:94314907~94315327:-
BRCA	cis	rs2732480	0.5	rs11168464	ENSG00000257735.1	RP11-370I10.6	4.89	1.19e-06	0.000119	0.19	0.15	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48208332	chr12:48350945~48442411:+
BRCA	cis	rs10129255	0.536	rs17113249	ENSG00000211967.3	IGHV3-53	-4.89	1.19e-06	0.000119	-0.1	-0.15	Kawasaki disease;	chr14:106678273	chr14:106592676~106593347:-
BRCA	cis	rs7772486	0.72	rs702320	ENSG00000270638.1	RP3-466P17.1	-4.89	1.19e-06	0.000119	-0.17	-0.15	Lobe attachment (rater-scored or self-reported);	chr6:145685518	chr6:145735570~145737218:+
BRCA	cis	rs442309	0.846	rs382412	ENSG00000238280.1	RP11-436D10.3	-4.89	1.19e-06	0.000119	-0.2	-0.15	Vogt-Koyanagi-Harada syndrome;	chr10:62730004	chr10:62793562~62805887:-
BRCA	cis	rs2274273	0.686	rs66782529	ENSG00000258413.1	RP11-665C16.6	-4.89	1.19e-06	0.000119	-0.2	-0.15	Protein biomarker;	chr14:55121149	chr14:55262767~55272075:-
BRCA	cis	rs4711336	0.935	rs3818525	ENSG00000224557.6	HLA-DPB2	-4.89	1.19e-06	0.000119	-0.17	-0.15	Height;	chr6:33693002	chr6:33112451~33129084:+
BRCA	cis	rs7674212	0.57	rs2069274	ENSG00000248740.4	RP11-328K4.1	4.89	1.19e-06	0.000119	0.17	0.15	Type 2 diabetes;	chr4:103099624	chr4:103256159~103453658:+
BRCA	cis	rs2278170	1	rs331524	ENSG00000225101.4	OR52K3P	-4.89	1.19e-06	0.000119	-0.21	-0.15	Amyotrophic lateral sclerosis;	chr11:4458724	chr11:4474813~4475755:+
BRCA	cis	rs11051970	0.625	rs2728709	ENSG00000274964.1	RP11-817I4.1	-4.89	1.19e-06	0.000119	-0.19	-0.15	Response to tocilizumab in rheumatoid arthritis;	chr12:32414782	chr12:32339368~32340724:+
BRCA	cis	rs3892630	0.878	rs66788054	ENSG00000267475.1	CTD-2538C1.2	-4.89	1.19e-06	0.000119	-0.23	-0.15	Red blood cell traits;	chr19:32699240	chr19:32687089~32691750:-
BRCA	cis	rs7618915	0.547	rs4130905	ENSG00000243224.1	RP5-1157M23.2	-4.89	1.19e-06	0.000119	-0.17	-0.15	Bipolar disorder;	chr3:52675815	chr3:52239258~52241097:+
BRCA	cis	rs867371	0.614	rs1814739	ENSG00000255769.6	GOLGA2P10	-4.89	1.19e-06	0.000119	-0.19	-0.15	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82234283	chr15:82472993~82513950:-
BRCA	cis	rs10833905	0.877	rs11026924	ENSG00000246225.5	RP11-17A1.3	-4.89	1.19e-06	0.000119	-0.2	-0.15	Sudden cardiac arrest;	chr11:23034626	chr11:22829380~22945393:+
BRCA	cis	rs1124769	0.57	rs2614768	ENSG00000259378.1	DCAF13P3	-4.89	1.19e-06	0.000119	-0.2	-0.15	Cognitive performance;	chr15:50871261	chr15:50944663~50945996:+
BRCA	cis	rs2562456	0.833	rs1781867	ENSG00000268535.1	RP11-420K14.3	4.89	1.19e-06	0.000119	0.22	0.15	Pain;	chr19:21304368	chr19:21709522~21710191:+
BRCA	cis	rs10504130	0.569	rs34004633	ENSG00000272024.1	RP11-546K22.3	-4.89	1.19e-06	0.000119	-0.22	-0.15	Venous thromboembolism (SNP x SNP interaction);	chr8:51764279	chr8:51950284~51950690:+
BRCA	cis	rs3176789	0.957	rs3136559	ENSG00000256673.1	RP11-599J14.2	4.89	1.19e-06	0.000119	0.19	0.15	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9764044	chr12:9398355~9414851:-
BRCA	cis	rs6840360	0.582	rs4696259	ENSG00000278978.1	RP11-164P12.5	-4.89	1.2e-06	0.00012	-0.16	-0.15	Intelligence (multi-trait analysis);	chr4:151389636	chr4:151669786~151670503:+
BRCA	cis	rs6832769	0.922	rs819271	ENSG00000223305.1	RN7SKP30	4.89	1.2e-06	0.00012	0.2	0.15	Personality dimensions;	chr4:55372680	chr4:55540502~55540835:-
BRCA	cis	rs6714710	0.603	rs11123974	ENSG00000230606.9	AC159540.1	-4.89	1.2e-06	0.00012	-0.18	-0.15	Posterior cortical atrophy and Alzheimer's disease;	chr2:97989519	chr2:97416165~97433527:-
BRCA	cis	rs7811142	0.83	rs11771936	ENSG00000078319.8	PMS2P1	-4.89	1.2e-06	0.00012	-0.25	-0.15	Platelet count;	chr7:100345660	chr7:100320992~100341908:-
BRCA	cis	rs7811142	0.779	rs77370288	ENSG00000078319.8	PMS2P1	-4.89	1.2e-06	0.00012	-0.25	-0.15	Platelet count;	chr7:100350274	chr7:100320992~100341908:-
BRCA	cis	rs11822910	0.737	rs2584858	ENSG00000265566.2	RN7SL605P	4.89	1.2e-06	0.00012	0.2	0.15	Platelet distribution width;	chr11:57439604	chr11:57528085~57528365:-
BRCA	cis	rs2243480	1	rs431076	ENSG00000275400.1	RP4-756H11.5	4.89	1.2e-06	0.00012	0.27	0.15	Diabetic kidney disease;	chr7:66135333	chr7:66553805~66554199:-
BRCA	cis	rs2243480	1	rs2460422	ENSG00000275400.1	RP4-756H11.5	4.89	1.2e-06	0.00012	0.27	0.15	Diabetic kidney disease;	chr7:66136518	chr7:66553805~66554199:-
BRCA	cis	rs2243480	1	rs316334	ENSG00000275400.1	RP4-756H11.5	4.89	1.2e-06	0.00012	0.27	0.15	Diabetic kidney disease;	chr7:66137139	chr7:66553805~66554199:-
BRCA	cis	rs2403083	0.578	rs7015758	ENSG00000258256.1	RP11-219B4.5	-4.89	1.2e-06	0.00012	-0.18	-0.15	Plasma amyloid beta peptide concentrations (ABx-40);	chr8:85145172	chr8:85222446~85245717:-
BRCA	cis	rs862034	0.509	rs12586772	ENSG00000270000.1	RP3-449M8.9	4.89	1.2e-06	0.00012	0.19	0.15	Height;	chr14:74465938	chr14:74471930~74472360:-
BRCA	cis	rs11955398	0.606	rs56137970	ENSG00000215032.2	GNL3LP1	4.88	1.2e-06	0.00012	0.18	0.15	Intelligence (multi-trait analysis);	chr5:60577635	chr5:60891935~60893577:-
BRCA	cis	rs7208859	0.623	rs122898	ENSG00000264538.5	SUZ12P1	4.88	1.2e-06	0.00012	0.22	0.15	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30578236	chr17:30709299~30790908:+
BRCA	cis	rs6545883	0.894	rs2600660	ENSG00000270820.4	RP11-355B11.2	-4.88	1.2e-06	0.00012	-0.17	-0.15	Tuberculosis;	chr2:61322465	chr2:61471188~61484130:+
BRCA	cis	rs853679	0.882	rs3757188	ENSG00000280107.1	AL022393.9	-4.88	1.2e-06	0.00012	-0.31	-0.15	Depression;	chr6:28139579	chr6:28170845~28172521:+
BRCA	cis	rs875971	0.929	rs778712	ENSG00000223473.2	GS1-124K5.3	4.88	1.2e-06	0.00012	0.11	0.15	Aortic root size;	chr7:66384991	chr7:66491049~66493566:-
BRCA	cis	rs4819052	0.851	rs2877018	ENSG00000184274.3	LINC00315	-4.88	1.2e-06	0.00012	-0.21	-0.15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238391	chr21:45300245~45305257:-
BRCA	cis	rs4819052	0.851	rs2330012	ENSG00000184274.3	LINC00315	-4.88	1.2e-06	0.00012	-0.21	-0.15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238677	chr21:45300245~45305257:-
BRCA	cis	rs4819052	0.851	rs2877019	ENSG00000184274.3	LINC00315	-4.88	1.2e-06	0.00012	-0.21	-0.15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238732	chr21:45300245~45305257:-
BRCA	cis	rs4819052	0.851	rs2877020	ENSG00000184274.3	LINC00315	-4.88	1.2e-06	0.00012	-0.21	-0.15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238827	chr21:45300245~45305257:-
BRCA	cis	rs4819052	0.851	rs10470245	ENSG00000184274.3	LINC00315	-4.88	1.2e-06	0.00012	-0.21	-0.15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238997	chr21:45300245~45305257:-
BRCA	cis	rs6671200	0.831	rs35098538	ENSG00000235501.4	RP4-639F20.1	-4.88	1.2e-06	0.00012	-0.33	-0.15	Stearic acid (18:0) levels;	chr1:95139890	chr1:94927566~94963270:+
BRCA	cis	rs6671200	0.831	rs35013306	ENSG00000235501.4	RP4-639F20.1	-4.88	1.2e-06	0.00012	-0.33	-0.15	Stearic acid (18:0) levels;	chr1:95140216	chr1:94927566~94963270:+
BRCA	cis	rs6671200	0.831	rs77817666	ENSG00000235501.4	RP4-639F20.1	-4.88	1.2e-06	0.00012	-0.33	-0.15	Stearic acid (18:0) levels;	chr1:95140496	chr1:94927566~94963270:+
BRCA	cis	rs6671200	0.831	rs78629196	ENSG00000235501.4	RP4-639F20.1	-4.88	1.2e-06	0.00012	-0.33	-0.15	Stearic acid (18:0) levels;	chr1:95140514	chr1:94927566~94963270:+
BRCA	cis	rs6671200	0.831	rs13376185	ENSG00000235501.4	RP4-639F20.1	-4.88	1.2e-06	0.00012	-0.33	-0.15	Stearic acid (18:0) levels;	chr1:95140722	chr1:94927566~94963270:+
BRCA	cis	rs6671200	0.831	rs13376187	ENSG00000235501.4	RP4-639F20.1	-4.88	1.2e-06	0.00012	-0.33	-0.15	Stearic acid (18:0) levels;	chr1:95140814	chr1:94927566~94963270:+
BRCA	cis	rs2638953	0.853	rs11049656	ENSG00000247934.4	RP11-967K21.1	-4.88	1.2e-06	0.00012	-0.19	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28481705	chr12:28163298~28190738:-
BRCA	cis	rs7572733	0.534	rs700667	ENSG00000231621.1	AC013264.2	-4.88	1.2e-06	0.00012	-0.15	-0.15	Dermatomyositis;	chr2:197812784	chr2:197197991~197199273:+
BRCA	cis	rs2562456	0.834	rs2173727	ENSG00000268535.1	RP11-420K14.3	-4.88	1.2e-06	0.00012	-0.2	-0.15	Pain;	chr19:21491155	chr19:21709522~21710191:+
BRCA	cis	rs11955398	0.585	rs1117677	ENSG00000215032.2	GNL3LP1	-4.88	1.2e-06	0.00012	-0.18	-0.15	Intelligence (multi-trait analysis);	chr5:60738848	chr5:60891935~60893577:-
BRCA	cis	rs11955398	0.585	rs1117675	ENSG00000215032.2	GNL3LP1	-4.88	1.2e-06	0.00012	-0.18	-0.15	Intelligence (multi-trait analysis);	chr5:60739059	chr5:60891935~60893577:-
BRCA	cis	rs780094	0.5	rs4665382	ENSG00000234072.1	AC074117.10	4.88	1.2e-06	0.00012	0.16	0.15	Urate levels in overweight individuals;C-reactive protein;Metabolic syndrome;Red blood cell count;Renal underexcretion gout;Nonalcoholic fatty liver disease;Age-related diseases, mortality and associated endophenotypes;Crohn's disease;Calcium levels;Fasting plasma glucose;Metabolic traits;Fasting blood glucose;Fasting blood insulin;Urate levels in obese individuals;Alcohol consumption (drinks per week);Height;Urate levels;Gondoic acid (20:1n-9) levels;Uric acid levels;Age-related disease endophenotypes;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Homeostasis model assessment of insulin resistance;Alcohol consumption;Fasting blood insulin (BMI interaction);Triglycerides;Fasting blood glucose (BMI interaction);Hypertriglyceridemia;LDL cholesterol;Type 2 diabetes;Triglyceride levels;	chr2:27560934	chr2:27356246~27367622:+
BRCA	cis	rs6570726	0.791	rs7755253	ENSG00000270638.1	RP3-466P17.1	4.88	1.2e-06	0.00012	0.17	0.15	Lobe attachment (rater-scored or self-reported);	chr6:145537757	chr6:145735570~145737218:+
BRCA	cis	rs7572733	0.515	rs1518368	ENSG00000231621.1	AC013264.2	-4.88	1.2e-06	0.00012	-0.15	-0.15	Dermatomyositis;	chr2:197974421	chr2:197197991~197199273:+
BRCA	cis	rs13160562	0.527	rs27525	ENSG00000272109.1	CTD-2260A17.3	-4.88	1.2e-06	0.00012	-0.19	-0.15	Alcohol dependence;	chr5:96766255	chr5:96804353~96806105:+
BRCA	cis	rs10510102	0.935	rs7921873	ENSG00000226864.1	ATE1-AS1	4.88	1.2e-06	0.00012	0.27	0.15	Breast cancer;	chr10:121881736	chr10:121928312~121951965:+
BRCA	cis	rs10510102	0.935	rs12258426	ENSG00000226864.1	ATE1-AS1	4.88	1.2e-06	0.00012	0.27	0.15	Breast cancer;	chr10:121882189	chr10:121928312~121951965:+
BRCA	cis	rs10510102	0.935	rs12266380	ENSG00000226864.1	ATE1-AS1	4.88	1.2e-06	0.00012	0.27	0.15	Breast cancer;	chr10:121882559	chr10:121928312~121951965:+
BRCA	cis	rs10510102	0.935	rs11200212	ENSG00000226864.1	ATE1-AS1	4.88	1.2e-06	0.00012	0.27	0.15	Breast cancer;	chr10:121883145	chr10:121928312~121951965:+
BRCA	cis	rs10510102	0.935	rs11200213	ENSG00000226864.1	ATE1-AS1	4.88	1.2e-06	0.00012	0.27	0.15	Breast cancer;	chr10:121883228	chr10:121928312~121951965:+
BRCA	cis	rs1729951	0.575	rs35289288	ENSG00000239213.4	NCK1-AS1	4.88	1.2e-06	0.00012	0.15	0.15	Neuroticism;	chr3:136961726	chr3:136841726~136862054:-
BRCA	cis	rs1729951	0.575	rs1654904	ENSG00000239213.4	NCK1-AS1	4.88	1.2e-06	0.00012	0.15	0.15	Neuroticism;	chr3:136962307	chr3:136841726~136862054:-
BRCA	cis	rs4781563	0.692	rs6498485	ENSG00000242307.1	RPS26P52	-4.88	1.2e-06	0.00012	-0.17	-0.15	Bilirubin levels;	chr16:13917137	chr16:13922332~13922679:-
BRCA	cis	rs7267979	0.844	rs35735333	ENSG00000277938.1	RP5-965G21.3	-4.88	1.2e-06	0.00012	-0.18	-0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25356569	chr20:25229150~25231933:+
BRCA	cis	rs9473147	0.516	rs7767350	ENSG00000270761.1	RP11-385F7.1	-4.88	1.2e-06	0.00012	-0.16	-0.15	Platelet distribution width;Mean platelet volume;	chr6:47517390	chr6:47477243~47477572:-
BRCA	cis	rs1124769	0.619	rs7170036	ENSG00000259378.1	DCAF13P3	4.88	1.2e-06	0.00012	0.19	0.15	Cognitive performance;	chr15:50956106	chr15:50944663~50945996:+
BRCA	cis	rs2227564	0.729	rs2675674	ENSG00000271816.1	BMS1P4	4.88	1.2e-06	0.00012	0.16	0.15	Crohn's disease;Inflammatory bowel disease;	chr10:73892924	chr10:73699151~73730487:-
BRCA	cis	rs828999	0.688	rs10785837	ENSG00000280186.1	RP11-483I13.6	-4.88	1.2e-06	0.00012	-0.17	-0.15	Monocyte percentage of white cells;	chr1:108155511	chr1:108200413~108202743:+
BRCA	cis	rs828999	0.688	rs11185286	ENSG00000280186.1	RP11-483I13.6	-4.88	1.2e-06	0.00012	-0.17	-0.15	Monocyte percentage of white cells;	chr1:108155812	chr1:108200413~108202743:+
BRCA	cis	rs7267979	0.844	rs2474780	ENSG00000277938.1	RP5-965G21.3	4.88	1.2e-06	0.00012	0.18	0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25305199	chr20:25229150~25231933:+
BRCA	cis	rs17685	0.753	rs6951808	ENSG00000280388.1	RP11-229D13.3	-4.88	1.2e-06	0.00012	-0.15	-0.15	Coffee consumption (cups per day);Coffee consumption;	chr7:76143095	chr7:76043977~76045963:-
BRCA	cis	rs17685	0.753	rs10952840	ENSG00000280388.1	RP11-229D13.3	-4.88	1.2e-06	0.00012	-0.15	-0.15	Coffee consumption (cups per day);Coffee consumption;	chr7:76143560	chr7:76043977~76045963:-
BRCA	cis	rs17685	0.672	rs10952841	ENSG00000280388.1	RP11-229D13.3	-4.88	1.2e-06	0.00012	-0.15	-0.15	Coffee consumption (cups per day);Coffee consumption;	chr7:76149308	chr7:76043977~76045963:-
BRCA	cis	rs17685	0.753	rs1806885	ENSG00000280388.1	RP11-229D13.3	-4.88	1.2e-06	0.00012	-0.15	-0.15	Coffee consumption (cups per day);Coffee consumption;	chr7:76156294	chr7:76043977~76045963:-
BRCA	cis	rs17685	0.753	rs1859791	ENSG00000280388.1	RP11-229D13.3	-4.88	1.2e-06	0.00012	-0.15	-0.15	Coffee consumption (cups per day);Coffee consumption;	chr7:76156725	chr7:76043977~76045963:-
BRCA	cis	rs17685	0.753	rs6464999	ENSG00000280388.1	RP11-229D13.3	-4.88	1.2e-06	0.00012	-0.15	-0.15	Coffee consumption (cups per day);Coffee consumption;	chr7:76157997	chr7:76043977~76045963:-
BRCA	cis	rs17685	0.753	rs6465000	ENSG00000280388.1	RP11-229D13.3	-4.88	1.2e-06	0.00012	-0.15	-0.15	Coffee consumption (cups per day);Coffee consumption;	chr7:76158099	chr7:76043977~76045963:-
BRCA	cis	rs4356203	0.87	rs214926	ENSG00000272034.1	SNORD14A	-4.88	1.2e-06	0.00012	-0.15	-0.15	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17210255	chr11:17074654~17074744:-
BRCA	cis	rs2803122	0.846	rs10757032	ENSG00000273226.1	RP11-513M16.8	-4.88	1.2e-06	0.00012	-0.16	-0.15	Pulse pressure;	chr9:19213350	chr9:19375451~19375996:+
BRCA	cis	rs7267979	0.816	rs376742	ENSG00000277938.1	RP5-965G21.3	4.88	1.2e-06	0.00012	0.18	0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25506781	chr20:25229150~25231933:+
BRCA	cis	rs3768617	0.51	rs2027075	ENSG00000224468.3	RP11-181K3.4	-4.88	1.2e-06	0.00012	-0.16	-0.15	Fuchs's corneal dystrophy;	chr1:183104131	chr1:183138402~183141282:-
BRCA	cis	rs875971	0.83	rs809025	ENSG00000236529.1	RP13-254B10.1	4.88	1.21e-06	0.00012	0.17	0.15	Aortic root size;	chr7:66384832	chr7:65840212~65840596:+
BRCA	cis	rs1075265	0.73	rs6711105	ENSG00000235937.1	AC008280.1	4.88	1.21e-06	0.00012	0.16	0.15	Chronotype;Morning vs. evening chronotype;	chr2:54017775	chr2:54029552~54030682:-
BRCA	cis	rs6671200	0.92	rs11165339	ENSG00000235501.4	RP4-639F20.1	4.88	1.21e-06	0.00012	0.3	0.15	Stearic acid (18:0) levels;	chr1:95208508	chr1:94927566~94963270:+
BRCA	cis	rs12435908	1	rs2268957	ENSG00000276116.2	FUT8-AS1	4.88	1.21e-06	0.000121	0.23	0.15	Ischemic stroke;	chr14:65646515	chr14:65411170~65412690:-
BRCA	cis	rs6545883	0.895	rs7588814	ENSG00000270820.4	RP11-355B11.2	4.88	1.21e-06	0.000121	0.17	0.15	Tuberculosis;	chr2:61468454	chr2:61471188~61484130:+
BRCA	cis	rs6570726	0.846	rs397311	ENSG00000270638.1	RP3-466P17.1	-4.88	1.21e-06	0.000121	-0.17	-0.15	Lobe attachment (rater-scored or self-reported);	chr6:145485565	chr6:145735570~145737218:+
BRCA	cis	rs2625529	0.586	rs2306489	ENSG00000260037.4	CTD-2524L6.3	4.88	1.21e-06	0.000121	0.19	0.15	Red blood cell count;	chr15:71935130	chr15:71818396~71823384:+
BRCA	cis	rs2018683	0.649	rs221193	ENSG00000228421.2	AC005013.5	4.88	1.21e-06	0.000121	0.2	0.15	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28976168	chr7:28957667~28959345:+
BRCA	cis	rs875971	0.545	rs67397473	ENSG00000230295.1	RP11-458F8.2	4.88	1.21e-06	0.000121	0.14	0.15	Aortic root size;	chr7:66168318	chr7:66880708~66882981:+
BRCA	cis	rs2303319	0.504	rs62188728	ENSG00000227403.1	AC009299.3	4.88	1.21e-06	0.000121	0.36	0.15	Cognitive function;	chr2:161479190	chr2:161244739~161249050:+
BRCA	cis	rs7674212	0.539	rs7676041	ENSG00000248740.4	RP11-328K4.1	4.88	1.21e-06	0.000121	0.17	0.15	Type 2 diabetes;	chr4:103205264	chr4:103256159~103453658:+
BRCA	cis	rs4356203	0.87	rs7342262	ENSG00000272034.1	SNORD14A	-4.88	1.21e-06	0.000121	-0.15	-0.15	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17264260	chr11:17074654~17074744:-
BRCA	cis	rs1075265	0.547	rs7587217	ENSG00000235937.1	AC008280.1	4.88	1.21e-06	0.000121	0.16	0.15	Chronotype;Morning vs. evening chronotype;	chr2:53675029	chr2:54029552~54030682:-
BRCA	cis	rs875971	0.862	rs6962717	ENSG00000236529.1	RP13-254B10.1	4.88	1.21e-06	0.000121	0.17	0.15	Aortic root size;	chr7:66418748	chr7:65840212~65840596:+
BRCA	cis	rs7772486	0.902	rs1331643	ENSG00000270638.1	RP3-466P17.1	4.88	1.21e-06	0.000121	0.17	0.15	Lobe attachment (rater-scored or self-reported);	chr6:146077737	chr6:145735570~145737218:+
BRCA	cis	rs783540	0.521	rs1259176	ENSG00000255769.6	GOLGA2P10	4.88	1.21e-06	0.000121	0.19	0.15	Schizophrenia;	chr15:82602149	chr15:82472993~82513950:-
BRCA	cis	rs2617170	0.885	rs2617150	ENSG00000245648.1	RP11-277P12.20	4.88	1.21e-06	0.000121	0.2	0.15	Behcet's disease;	chr12:10376435	chr12:10363769~10398506:+
BRCA	cis	rs11098499	0.789	rs10212719	ENSG00000249244.1	RP11-548H18.2	4.88	1.21e-06	0.000121	0.17	0.15	Corneal astigmatism;	chr4:119333282	chr4:119391831~119395335:-
BRCA	cis	rs9818758	0.607	rs66991555	ENSG00000270441.1	RP11-694I15.7	4.88	1.21e-06	0.000121	0.28	0.15	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49191210	chr3:49140086~49160851:-
BRCA	cis	rs2153535	0.58	rs6905242	ENSG00000251164.1	HULC	-4.88	1.21e-06	0.000121	-0.18	-0.15	Motion sickness;	chr6:8471566	chr6:8652137~8653846:+
BRCA	cis	rs7246657	0.722	rs2909093	ENSG00000226686.6	LINC01535	4.88	1.21e-06	0.000121	0.23	0.15	Coronary artery calcification;	chr19:37708561	chr19:37251912~37265535:+
BRCA	cis	rs2638953	0.924	rs11524516	ENSG00000247934.4	RP11-967K21.1	-4.88	1.21e-06	0.000121	-0.21	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28209517	chr12:28163298~28190738:-
BRCA	cis	rs4781563	1	rs1799801	ENSG00000242307.1	RPS26P52	-4.88	1.21e-06	0.000121	-0.18	-0.15	Bilirubin levels;	chr16:13948101	chr16:13922332~13922679:-
BRCA	cis	rs6600671	0.967	rs4844613	ENSG00000275538.1	RNVU1-19	4.88	1.21e-06	0.000121	0.18	0.15	Hip geometry;	chr1:121431913	chr1:120850819~120850985:-
BRCA	cis	rs7487075	0.78	rs1873793	ENSG00000272369.1	RP11-446N19.1	-4.88	1.21e-06	0.000121	-0.16	-0.15	Itch intensity from mosquito bite;	chr12:46367541	chr12:46537502~46652550:+
BRCA	cis	rs8180040	0.593	rs10433549	ENSG00000276925.1	RP11-708J19.3	4.88	1.21e-06	0.000121	0.17	0.15	Colorectal cancer;	chr3:46989943	chr3:47469777~47469987:+
BRCA	cis	rs12817211	0.549	rs7972465	ENSG00000272368.2	RP4-605O3.4	4.88	1.21e-06	0.000121	0.15	0.15	Colorectal or endometrial cancer;	chr12:50152342	chr12:50112197~50165618:+
BRCA	cis	rs6840360	0.642	rs2709816	ENSG00000251611.1	RP11-610P16.1	-4.88	1.21e-06	0.000121	-0.13	-0.15	Intelligence (multi-trait analysis);	chr4:151459117	chr4:151407551~151408835:-
BRCA	cis	rs6674176	0.551	rs2486013	ENSG00000237950.1	RP11-7O11.3	-4.88	1.21e-06	0.000121	-0.25	-0.15	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43954576	chr1:43944370~43946551:-
BRCA	cis	rs7141336	1	rs8005254	ENSG00000258884.1	CTD-3035D6.2	4.88	1.21e-06	0.000121	0.19	0.15	Anxiety disorder;	chr14:90820265	chr14:90822365~90828128:-
BRCA	cis	rs11098499	0.954	rs6849561	ENSG00000250412.1	KLHL2P1	-4.88	1.21e-06	0.000121	-0.18	-0.15	Corneal astigmatism;	chr4:119488539	chr4:119334329~119378233:+
BRCA	cis	rs2833693	0.572	rs2040106	ENSG00000261610.1	AP000265.1	4.88	1.21e-06	0.000121	0.18	0.15	Temperament;	chr21:32242397	chr21:32259804~32261585:-
BRCA	cis	rs2153535	0.563	rs1737586	ENSG00000251164.1	HULC	-4.88	1.21e-06	0.000121	-0.18	-0.15	Motion sickness;	chr6:8535664	chr6:8652137~8653846:+
BRCA	cis	rs1559040	0.685	rs13426329	ENSG00000272156.1	RP11-477N3.1	-4.88	1.22e-06	0.000121	-0.21	-0.15	Sudden cardiac arrest;	chr2:54048054	chr2:54082554~54085066:+
BRCA	cis	rs957448	0.561	rs4735302	ENSG00000253175.1	RP11-267M23.6	-4.88	1.22e-06	0.000121	-0.17	-0.15	Nonsyndromic cleft lip with cleft palate;	chr8:94604752	chr8:94565036~94565715:+
BRCA	cis	rs6480314	0.522	rs61857273	ENSG00000233590.1	RP11-153K11.3	-4.88	1.22e-06	0.000121	-0.27	-0.15	Optic nerve measurement (disc area);	chr10:68307530	chr10:68233251~68242379:-
BRCA	cis	rs6840360	0.642	rs7658169	ENSG00000251611.1	RP11-610P16.1	-4.88	1.22e-06	0.000121	-0.13	-0.15	Intelligence (multi-trait analysis);	chr4:151432262	chr4:151407551~151408835:-
BRCA	cis	rs7246657	0.551	rs10404069	ENSG00000267422.1	CTD-2554C21.1	-4.88	1.22e-06	0.000122	-0.25	-0.15	Coronary artery calcification;	chr19:37147502	chr19:37779686~37792865:+
BRCA	cis	rs2179367	0.632	rs12211357	ENSG00000268592.3	RAET1E-AS1	4.88	1.22e-06	0.000122	0.22	0.15	Dupuytren's disease;	chr6:149331148	chr6:149863494~149919507:+
BRCA	cis	rs4718428	0.705	rs62465692	ENSG00000229180.5	GS1-124K5.11	4.88	1.22e-06	0.000122	0.14	0.15	Corneal structure;	chr7:66830758	chr7:66526088~66542624:-
BRCA	cis	rs2243480	1	rs160639	ENSG00000222364.1	RNU6-96P	-4.88	1.22e-06	0.000122	-0.28	-0.15	Diabetic kidney disease;	chr7:66115000	chr7:66395191~66395286:+
BRCA	cis	rs78487399	0.614	rs74907855	ENSG00000234936.1	AC010883.5	4.88	1.22e-06	0.000122	0.25	0.15	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43529062	chr2:43229573~43233394:+
BRCA	cis	rs62025270	0.632	rs17636096	ENSG00000259762.1	RP11-158M2.4	-4.88	1.22e-06	0.000122	-0.22	-0.15	Idiopathic pulmonary fibrosis;	chr15:85675503	chr15:85750336~85752901:-
BRCA	cis	rs2688482	0.557	rs3103952	ENSG00000185485.13	SDHAP1	4.88	1.22e-06	0.000122	0.2	0.15	Lung disease severity in cystic fibrosis;	chr3:195795819	chr3:195959748~195990318:-
BRCA	cis	rs11158026	0.603	rs57667631	ENSG00000258413.1	RP11-665C16.6	-4.88	1.22e-06	0.000122	-0.2	-0.15	Parkinson's disease;	chr14:54976349	chr14:55262767~55272075:-
BRCA	cis	rs11158026	0.603	rs56335168	ENSG00000258413.1	RP11-665C16.6	-4.88	1.22e-06	0.000122	-0.2	-0.15	Parkinson's disease;	chr14:54978414	chr14:55262767~55272075:-
BRCA	cis	rs1322639	0.806	rs1322640	ENSG00000223485.1	RP11-417E7.1	4.88	1.22e-06	0.000122	0.18	0.15	Pulse pressure;	chr6:169186792	chr6:169158092~169162924:-
BRCA	cis	rs875971	1	rs3735148	ENSG00000223473.2	GS1-124K5.3	4.88	1.22e-06	0.000122	0.11	0.15	Aortic root size;	chr7:66506022	chr7:66491049~66493566:-
BRCA	cis	rs71636778	0.509	rs34556682	ENSG00000260063.1	RP5-968P14.2	-4.88	1.22e-06	0.000122	-0.35	-0.15	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26859658	chr1:26692132~26694131:-
BRCA	cis	rs4648045	0.565	rs62327181	ENSG00000246560.2	RP11-10L12.4	4.88	1.22e-06	0.000122	0.17	0.15	Lymphocyte percentage of white cells;	chr4:102624981	chr4:102828055~102844075:+
BRCA	cis	rs7621025	0.755	rs1017881	ENSG00000239213.4	NCK1-AS1	4.88	1.22e-06	0.000122	0.18	0.15	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136638851	chr3:136841726~136862054:-
BRCA	cis	rs4835473	0.742	rs6537238	ENSG00000249741.2	RP11-673E1.3	-4.88	1.22e-06	0.000122	-0.16	-0.15	Immature fraction of reticulocytes;	chr4:143996463	chr4:143911514~143912053:-
BRCA	cis	rs4835473	0.932	rs1473055	ENSG00000249741.2	RP11-673E1.3	-4.88	1.22e-06	0.000122	-0.16	-0.15	Immature fraction of reticulocytes;	chr4:143997714	chr4:143911514~143912053:-
BRCA	cis	rs6921919	0.609	rs9461455	ENSG00000220721.1	OR1F12	4.88	1.22e-06	0.000122	0.18	0.15	Autism spectrum disorder or schizophrenia;	chr6:28361954	chr6:28073316~28074233:+
BRCA	cis	rs1223397	0.651	rs2439544	ENSG00000215022.6	RP1-257A7.4	-4.88	1.22e-06	0.000122	-0.18	-0.15	Blood pressure;	chr6:13312238	chr6:13264861~13295586:-
BRCA	cis	rs3892630	0.817	rs35408716	ENSG00000267475.1	CTD-2538C1.2	-4.88	1.22e-06	0.000122	-0.23	-0.15	Red blood cell traits;	chr19:32697055	chr19:32687089~32691750:-
BRCA	cis	rs3892630	0.878	rs8112955	ENSG00000267475.1	CTD-2538C1.2	-4.88	1.22e-06	0.000122	-0.23	-0.15	Red blood cell traits;	chr19:32700286	chr19:32687089~32691750:-
BRCA	cis	rs1729951	0.575	rs1654925	ENSG00000239213.4	NCK1-AS1	-4.88	1.22e-06	0.000122	-0.15	-0.15	Neuroticism;	chr3:136971549	chr3:136841726~136862054:-
BRCA	cis	rs4666002	0.636	rs2272406	ENSG00000234072.1	AC074117.10	4.88	1.22e-06	0.000122	0.18	0.15	Phospholipid levels (plasma);	chr2:27669156	chr2:27356246~27367622:+
BRCA	cis	rs3768617	0.51	rs10797843	ENSG00000224468.3	RP11-181K3.4	-4.88	1.22e-06	0.000122	-0.16	-0.15	Fuchs's corneal dystrophy;	chr1:183112860	chr1:183138402~183141282:-
BRCA	cis	rs3768617	0.51	rs10797844	ENSG00000224468.3	RP11-181K3.4	-4.88	1.22e-06	0.000122	-0.16	-0.15	Fuchs's corneal dystrophy;	chr1:183112932	chr1:183138402~183141282:-
BRCA	cis	rs10911251	0.528	rs6669199	ENSG00000224468.3	RP11-181K3.4	-4.88	1.22e-06	0.000122	-0.16	-0.15	Colorectal cancer;	chr1:183113286	chr1:183138402~183141282:-
BRCA	cis	rs2562456	0.833	rs62110429	ENSG00000268081.1	RP11-678G14.2	4.88	1.22e-06	0.000122	0.25	0.15	Pain;	chr19:21430984	chr19:21554640~21569237:-
BRCA	cis	rs62025270	0.632	rs17637411	ENSG00000259762.1	RP11-158M2.4	-4.88	1.22e-06	0.000122	-0.22	-0.15	Idiopathic pulmonary fibrosis;	chr15:85703216	chr15:85750336~85752901:-
BRCA	cis	rs62025270	0.58	rs62022938	ENSG00000259762.1	RP11-158M2.4	-4.88	1.22e-06	0.000122	-0.22	-0.15	Idiopathic pulmonary fibrosis;	chr15:85704764	chr15:85750336~85752901:-
BRCA	cis	rs73198271	0.653	rs3827811	ENSG00000253893.2	FAM85B	4.88	1.22e-06	0.000122	0.19	0.15	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8801528	chr8:8167819~8226614:-
BRCA	cis	rs859767	0.741	rs883964	ENSG00000224043.6	CCNT2-AS1	4.88	1.22e-06	0.000122	0.21	0.15	Neuroticism;	chr2:134678630	chr2:134735464~134918710:-
BRCA	cis	rs893971	0.534	rs7660693	ENSG00000246375.2	RP11-10L7.1	-4.88	1.22e-06	0.000122	-0.18	-0.15	Conduct disorder (maternal expressed emotions interaction);	chr4:88307231	chr4:88284942~88331421:+
BRCA	cis	rs739496	0.579	rs7974772	ENSG00000226469.1	ADAM1B	4.88	1.22e-06	0.000122	0.19	0.15	Platelet count;	chr12:111894479	chr12:111927018~111929017:+
BRCA	cis	rs739496	0.579	rs10849982	ENSG00000226469.1	ADAM1B	4.88	1.22e-06	0.000122	0.19	0.15	Platelet count;	chr12:111897735	chr12:111927018~111929017:+
BRCA	cis	rs1395	0.744	rs62130709	ENSG00000234072.1	AC074117.10	-4.88	1.22e-06	0.000122	-0.17	-0.15	Blood metabolite levels;	chr2:27282914	chr2:27356246~27367622:+
BRCA	cis	rs7618915	0.547	rs10780035	ENSG00000243224.1	RP5-1157M23.2	-4.88	1.22e-06	0.000122	-0.17	-0.15	Bipolar disorder;	chr3:52730608	chr3:52239258~52241097:+
BRCA	cis	rs7618915	0.547	rs2268027	ENSG00000243224.1	RP5-1157M23.2	-4.88	1.22e-06	0.000122	-0.17	-0.15	Bipolar disorder;	chr3:52732590	chr3:52239258~52241097:+
BRCA	cis	rs6840360	0.642	rs6845648	ENSG00000251611.1	RP11-610P16.1	-4.88	1.23e-06	0.000122	-0.13	-0.15	Intelligence (multi-trait analysis);	chr4:151454898	chr4:151407551~151408835:-
BRCA	cis	rs6840360	0.642	rs2724571	ENSG00000251611.1	RP11-610P16.1	-4.88	1.23e-06	0.000122	-0.13	-0.15	Intelligence (multi-trait analysis);	chr4:151455643	chr4:151407551~151408835:-
BRCA	cis	rs6840360	0.642	rs2709833	ENSG00000251611.1	RP11-610P16.1	-4.88	1.23e-06	0.000122	-0.13	-0.15	Intelligence (multi-trait analysis);	chr4:151456470	chr4:151407551~151408835:-
BRCA	cis	rs9291683	0.527	rs11727087	ENSG00000250413.1	RP11-448G15.1	-4.88	1.23e-06	0.000122	-0.2	-0.15	Bone mineral density;	chr4:10094396	chr4:10006482~10009725:+
BRCA	cis	rs4835473	0.932	rs13130345	ENSG00000249741.2	RP11-673E1.3	-4.88	1.23e-06	0.000122	-0.16	-0.15	Immature fraction of reticulocytes;	chr4:143920939	chr4:143911514~143912053:-
BRCA	cis	rs10208649	0.611	rs3929001	ENSG00000272156.1	RP11-477N3.1	-4.88	1.23e-06	0.000122	-0.26	-0.15	Body mass index;	chr2:54055750	chr2:54082554~54085066:+
BRCA	cis	rs17685	0.753	rs6951943	ENSG00000280388.1	RP11-229D13.3	-4.88	1.23e-06	0.000122	-0.15	-0.15	Coffee consumption (cups per day);Coffee consumption;	chr7:76143134	chr7:76043977~76045963:-
BRCA	cis	rs6545883	0.894	rs2694642	ENSG00000270820.4	RP11-355B11.2	-4.88	1.23e-06	0.000122	-0.17	-0.15	Tuberculosis;	chr2:61369045	chr2:61471188~61484130:+
BRCA	cis	rs924712	0.545	rs9296769	ENSG00000261116.1	RP3-523K23.2	4.88	1.23e-06	0.000122	0.17	0.15	Breast cancer;	chr6:54841180	chr6:54943167~54945099:+
BRCA	cis	rs924712	0.545	rs1910357	ENSG00000261116.1	RP3-523K23.2	4.88	1.23e-06	0.000122	0.17	0.15	Breast cancer;	chr6:54841588	chr6:54943167~54945099:+
BRCA	cis	rs10504130	0.935	rs76813841	ENSG00000253844.1	RP11-546K22.1	-4.88	1.23e-06	0.000122	-0.26	-0.15	Venous thromboembolism (SNP x SNP interaction);	chr8:51848253	chr8:51961458~52022974:+
BRCA	cis	rs10129255	0.826	rs7150693	ENSG00000274576.2	IGHV2-70	4.88	1.23e-06	0.000122	0.14	0.15	Kawasaki disease;	chr14:106705382	chr14:106770577~106771020:-
BRCA	cis	rs10129255	0.869	rs7150549	ENSG00000274576.2	IGHV2-70	4.88	1.23e-06	0.000122	0.14	0.15	Kawasaki disease;	chr14:106705441	chr14:106770577~106771020:-
BRCA	cis	rs13113518	0.966	rs11133387	ENSG00000249700.7	SRD5A3-AS1	4.88	1.23e-06	0.000122	0.19	0.15	Height;	chr4:55475130	chr4:55363971~55395847:-
BRCA	cis	rs13113518	1	rs4864999	ENSG00000249700.7	SRD5A3-AS1	4.88	1.23e-06	0.000122	0.19	0.15	Height;	chr4:55476736	chr4:55363971~55395847:-
BRCA	cis	rs13113518	0.966	rs10517344	ENSG00000249700.7	SRD5A3-AS1	4.88	1.23e-06	0.000122	0.19	0.15	Height;	chr4:55477545	chr4:55363971~55395847:-
BRCA	cis	rs6430585	0.646	rs1057031	ENSG00000231890.6	DARS-AS1	-4.88	1.23e-06	0.000123	-0.23	-0.15	Corneal structure;	chr2:135876392	chr2:135985176~136022593:+
BRCA	cis	rs734999	0.967	rs10797434	ENSG00000238164.5	RP3-395M20.8	-4.88	1.23e-06	0.000123	-0.12	-0.15	Ulcerative colitis;	chr1:2579841	chr1:2549920~2557031:-
BRCA	cis	rs10510102	0.935	rs12253283	ENSG00000226864.1	ATE1-AS1	-4.88	1.23e-06	0.000123	-0.26	-0.15	Breast cancer;	chr10:121909740	chr10:121928312~121951965:+
BRCA	cis	rs11955398	0.502	rs295524	ENSG00000215032.2	GNL3LP1	4.88	1.23e-06	0.000123	0.19	0.15	Intelligence (multi-trait analysis);	chr5:61177224	chr5:60891935~60893577:-
BRCA	cis	rs11168618	0.967	rs10875831	ENSG00000240399.1	RP1-228P16.1	4.88	1.23e-06	0.000123	0.16	0.15	Adiponectin levels;	chr12:48544597	chr12:48054813~48055591:-
BRCA	cis	rs11758351	1	rs16891397	ENSG00000241549.7	GUSBP2	-4.88	1.23e-06	0.000123	-0.21	-0.15	Renal underexcretion gout;Gout;	chr6:26200028	chr6:26871484~26956554:-
BRCA	cis	rs11673344	0.523	rs1402468	ENSG00000226686.6	LINC01535	4.88	1.23e-06	0.000123	0.19	0.15	Obesity-related traits;	chr19:37129346	chr19:37251912~37265535:+
BRCA	cis	rs375066	0.577	rs7508701	ENSG00000267058.1	RP11-15A1.3	4.88	1.23e-06	0.000123	0.18	0.15	Breast cancer;	chr19:43808710	chr19:43891804~43901805:-
BRCA	cis	rs17193922	0.876	rs17194040	ENSG00000279344.1	RP11-44F14.7	4.88	1.23e-06	0.000123	0.17	0.15	Hip circumference adjusted for BMI;	chr16:53516986	chr16:53478957~53481550:-
BRCA	cis	rs2303319	0.582	rs62187614	ENSG00000227403.1	AC009299.3	4.88	1.23e-06	0.000123	0.35	0.15	Cognitive function;	chr2:161579775	chr2:161244739~161249050:+
BRCA	cis	rs2281558	0.917	rs3787080	ENSG00000230772.1	VN1R108P	-4.88	1.23e-06	0.000123	-0.19	-0.15	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25251968	chr20:25734264~25735093:+
BRCA	cis	rs875971	0.964	rs6978429	ENSG00000223473.2	GS1-124K5.3	4.88	1.23e-06	0.000123	0.11	0.15	Aortic root size;	chr7:66494889	chr7:66491049~66493566:-
BRCA	cis	rs875971	1	rs4718357	ENSG00000223473.2	GS1-124K5.3	4.88	1.23e-06	0.000123	0.11	0.15	Aortic root size;	chr7:66495891	chr7:66491049~66493566:-
BRCA	cis	rs11098499	0.954	rs10006877	ENSG00000250412.1	KLHL2P1	4.88	1.23e-06	0.000123	0.18	0.15	Corneal astigmatism;	chr4:119321638	chr4:119334329~119378233:+
BRCA	cis	rs4072980	0.545	rs12120737	ENSG00000212541.1	RNU6-510P	-4.88	1.23e-06	0.000123	-0.19	-0.15	Coronary artery disease;	chr1:37956872	chr1:37991462~37991569:+
BRCA	cis	rs875971	0.545	rs73142233	ENSG00000232546.1	RP11-458F8.1	4.88	1.23e-06	0.000123	0.14	0.15	Aortic root size;	chr7:66221293	chr7:66848496~66858136:+
BRCA	cis	rs2243480	1	rs383402	ENSG00000228409.4	CCT6P1	-4.88	1.23e-06	0.000123	-0.2	-0.15	Diabetic kidney disease;	chr7:66121666	chr7:65751142~65763354:+
BRCA	cis	rs8002861	0.81	rs2275252	ENSG00000274001.1	RP11-5G9.5	4.88	1.23e-06	0.000123	0.17	0.15	Leprosy;	chr13:43880238	chr13:43877715~43878163:-
BRCA	cis	rs4819052	0.851	rs9754134	ENSG00000184274.3	LINC00315	-4.88	1.23e-06	0.000123	-0.21	-0.15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45241836	chr21:45300245~45305257:-
BRCA	cis	rs9300255	0.679	rs58809476	ENSG00000235423.7	RP11-282O18.3	-4.88	1.24e-06	0.000123	-0.21	-0.15	Neutrophil percentage of white cells;	chr12:123240333	chr12:123252030~123261483:-
BRCA	cis	rs6570726	0.791	rs9399558	ENSG00000270638.1	RP3-466P17.1	4.88	1.24e-06	0.000123	0.17	0.15	Lobe attachment (rater-scored or self-reported);	chr6:145590594	chr6:145735570~145737218:+
BRCA	cis	rs6570726	0.791	rs9376953	ENSG00000270638.1	RP3-466P17.1	4.88	1.24e-06	0.000123	0.17	0.15	Lobe attachment (rater-scored or self-reported);	chr6:145591090	chr6:145735570~145737218:+
BRCA	cis	rs6570726	0.791	rs13202312	ENSG00000270638.1	RP3-466P17.1	4.88	1.24e-06	0.000123	0.17	0.15	Lobe attachment (rater-scored or self-reported);	chr6:145591957	chr6:145735570~145737218:+
BRCA	cis	rs6570726	0.791	rs7765675	ENSG00000270638.1	RP3-466P17.1	4.88	1.24e-06	0.000123	0.17	0.15	Lobe attachment (rater-scored or self-reported);	chr6:145593941	chr6:145735570~145737218:+
BRCA	cis	rs6088580	0.634	rs6088508	ENSG00000276073.1	RP5-1125A11.7	-4.88	1.24e-06	0.000123	-0.16	-0.15	Glomerular filtration rate (creatinine);	chr20:34472276	chr20:33985617~33988989:-
BRCA	cis	rs6847067	0.683	rs17009317	ENSG00000180769.7	WDFY3-AS2	-4.88	1.24e-06	0.000123	-0.15	-0.15	Oropharynx cancer;	chr4:84848703	chr4:84965682~85011277:+
BRCA	cis	rs2562456	0.833	rs11666525	ENSG00000268081.1	RP11-678G14.2	4.88	1.24e-06	0.000123	0.25	0.15	Pain;	chr19:21416503	chr19:21554640~21569237:-
BRCA	cis	rs7772486	0.719	rs702317	ENSG00000270638.1	RP3-466P17.1	-4.88	1.24e-06	0.000123	-0.17	-0.15	Lobe attachment (rater-scored or self-reported);	chr6:145683874	chr6:145735570~145737218:+
BRCA	cis	rs1440410	0.83	rs4690781	ENSG00000250326.1	RP11-284M14.1	-4.88	1.24e-06	0.000123	-0.16	-0.15	Ischemic stroke;	chr4:143259053	chr4:142933195~143184861:-
BRCA	cis	rs78487399	0.71	rs74469180	ENSG00000234936.1	AC010883.5	4.88	1.24e-06	0.000123	0.26	0.15	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43376228	chr2:43229573~43233394:+
BRCA	cis	rs9784649	1	rs56205870	ENSG00000245662.2	RP11-184E9.1	4.88	1.24e-06	0.000123	0.22	0.15	Peripheral arterial disease (traffic-related air pollution interaction);	chr5:24958761	chr5:25190682~25306172:+
BRCA	cis	rs7809615	0.901	rs10235235	ENSG00000244219.5	GS1-259H13.2	-4.88	1.24e-06	0.000123	-0.26	-0.15	Blood metabolite ratios;	chr7:99478208	chr7:99598066~99610813:+
BRCA	cis	rs11098499	0.866	rs7665125	ENSG00000249244.1	RP11-548H18.2	4.88	1.24e-06	0.000123	0.17	0.15	Corneal astigmatism;	chr4:119480924	chr4:119391831~119395335:-
BRCA	cis	rs11673344	0.548	rs2058852	ENSG00000267422.1	CTD-2554C21.1	4.88	1.24e-06	0.000123	0.19	0.15	Obesity-related traits;	chr19:37673701	chr19:37779686~37792865:+
BRCA	cis	rs16846053	0.786	rs116099394	ENSG00000227403.1	AC009299.3	4.88	1.24e-06	0.000124	0.33	0.15	Blood osmolality (transformed sodium);	chr2:161743572	chr2:161244739~161249050:+
BRCA	cis	rs4908760	0.868	rs12131864	ENSG00000232912.4	RP5-1115A15.1	4.88	1.24e-06	0.000124	0.15	0.15	Vitiligo;	chr1:8531103	chr1:8424645~8434838:+
BRCA	cis	rs793571	0.628	rs28733370	ENSG00000259250.1	RP11-50C13.1	-4.88	1.24e-06	0.000124	-0.25	-0.15	Schizophrenia;	chr15:58779385	chr15:58587507~58591676:+
BRCA	cis	rs793571	0.628	rs7165019	ENSG00000259250.1	RP11-50C13.1	-4.88	1.24e-06	0.000124	-0.25	-0.15	Schizophrenia;	chr15:58780098	chr15:58587507~58591676:+
BRCA	cis	rs2243480	1	rs778729	ENSG00000222364.1	RNU6-96P	-4.88	1.24e-06	0.000124	-0.28	-0.15	Diabetic kidney disease;	chr7:66359432	chr7:66395191~66395286:+
BRCA	cis	rs8180040	0.966	rs11716763	ENSG00000271161.1	BOLA2P2	-4.88	1.24e-06	0.000124	-0.16	-0.15	Colorectal cancer;	chr3:47476776	chr3:47499841~47500407:+
BRCA	cis	rs11696739	0.536	rs11696842	ENSG00000242324.1	RP4-576H24.2	4.88	1.24e-06	0.000124	0.21	0.15	Mean platelet volume;	chr20:1620148	chr20:1516759~1557653:-
BRCA	cis	rs4356203	0.87	rs603618	ENSG00000272034.1	SNORD14A	-4.88	1.24e-06	0.000124	-0.15	-0.15	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17224815	chr11:17074654~17074744:-
BRCA	cis	rs736408	0.57	rs11130327	ENSG00000243224.1	RP5-1157M23.2	-4.88	1.24e-06	0.000124	-0.17	-0.15	Bipolar disorder;	chr3:52759223	chr3:52239258~52241097:+
BRCA	cis	rs828999	0.618	rs11185284	ENSG00000280186.1	RP11-483I13.6	-4.88	1.24e-06	0.000124	-0.17	-0.15	Monocyte percentage of white cells;	chr1:108152378	chr1:108200413~108202743:+
BRCA	cis	rs1387259	0.929	rs11168484	ENSG00000257735.1	RP11-370I10.6	4.88	1.24e-06	0.000124	0.19	0.15	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48239806	chr12:48350945~48442411:+
BRCA	cis	rs8127691	0.967	rs4456788	ENSG00000237604.1	AP001056.1	4.88	1.24e-06	0.000124	0.17	0.15	Inflammatory bowel disease;	chr21:44196441	chr21:44175489~44176453:+
BRCA	cis	rs8127691	0.967	rs8134436	ENSG00000237604.1	AP001056.1	4.88	1.24e-06	0.000124	0.17	0.15	Inflammatory bowel disease;	chr21:44196614	chr21:44175489~44176453:+
BRCA	cis	rs73193808	0.901	rs8132759	ENSG00000236056.1	GAPDHP14	-4.88	1.24e-06	0.000124	-0.21	-0.15	Coronary artery disease;	chr21:29218630	chr21:29222321~29223257:+
BRCA	cis	rs11955398	0.692	rs897672	ENSG00000215032.2	GNL3LP1	4.88	1.24e-06	0.000124	0.18	0.15	Intelligence (multi-trait analysis);	chr5:60700274	chr5:60891935~60893577:-
BRCA	cis	rs736408	0.609	rs2230535	ENSG00000243224.1	RP5-1157M23.2	-4.88	1.24e-06	0.000124	-0.17	-0.15	Bipolar disorder;	chr3:52766268	chr3:52239258~52241097:+
BRCA	cis	rs651907	0.557	rs3094297	ENSG00000256628.3	ZBTB11-AS1	4.88	1.24e-06	0.000124	0.19	0.15	Colorectal cancer;	chr3:101680416	chr3:101676475~101679217:+
BRCA	cis	rs2243480	1	rs10807702	ENSG00000232559.3	GS1-124K5.12	4.88	1.24e-06	0.000124	0.28	0.15	Diabetic kidney disease;	chr7:66302856	chr7:66554588~66576923:-
BRCA	cis	rs7481584	0.581	rs515481	ENSG00000247473.2	CARS-AS1	-4.88	1.24e-06	0.000124	-0.18	-0.15	Calcium levels;	chr11:3025954	chr11:3029009~3041260:+
BRCA	cis	rs7226408	0.857	rs8094856	ENSG00000267707.2	RP11-95O2.5	4.88	1.24e-06	0.000124	0.23	0.15	Obesity-related traits;	chr18:36968336	chr18:37243776~37247506:+
BRCA	cis	rs7226408	0.857	rs117376812	ENSG00000267707.2	RP11-95O2.5	4.88	1.24e-06	0.000124	0.23	0.15	Obesity-related traits;	chr18:36969923	chr18:37243776~37247506:+
BRCA	cis	rs1030877	0.515	rs2576742	ENSG00000235319.1	AC012360.4	-4.88	1.24e-06	0.000124	-0.21	-0.15	Obesity-related traits;	chr2:105282365	chr2:105324210~105330529:+
BRCA	cis	rs7428	0.962	rs3637	ENSG00000273196.1	RP11-717A5.2	4.88	1.24e-06	0.000124	0.18	0.15	Ear protrusion;	chr2:85322751	chr2:85387074~85387146:-
BRCA	cis	rs12497850	0.931	rs11705888	ENSG00000225399.4	RP11-3B7.1	4.88	1.24e-06	0.000124	0.15	0.15	Parkinson's disease;	chr3:48779856	chr3:49260085~49261316:+
BRCA	cis	rs1124769	0.57	rs2663552	ENSG00000259378.1	DCAF13P3	4.88	1.24e-06	0.000124	0.2	0.15	Cognitive performance;	chr15:50839973	chr15:50944663~50945996:+
BRCA	cis	rs6600671	1	rs2185281	ENSG00000275538.1	RNVU1-19	4.88	1.24e-06	0.000124	0.18	0.15	Hip geometry;	chr1:121438132	chr1:120850819~120850985:-
BRCA	cis	rs35740288	0.857	rs11630274	ENSG00000202081.1	RNU6-1280P	4.88	1.25e-06	0.000124	0.2	0.15	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85745156	chr15:85651522~85651628:-
BRCA	cis	rs859767	0.501	rs11898465	ENSG00000224043.6	CCNT2-AS1	4.88	1.25e-06	0.000124	0.2	0.15	Neuroticism;	chr2:134673879	chr2:134735464~134918710:-
BRCA	cis	rs78487399	0.808	rs76993899	ENSG00000234936.1	AC010883.5	4.88	1.25e-06	0.000124	0.24	0.15	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43444018	chr2:43229573~43233394:+
BRCA	cis	rs7487075	0.619	rs7489242	ENSG00000274723.1	RP11-618L22.1	4.88	1.25e-06	0.000124	0.2	0.15	Itch intensity from mosquito bite;	chr12:46434848	chr12:46970504~46972155:+
BRCA	cis	rs62025270	0.632	rs17571078	ENSG00000259295.5	CSPG4P12	-4.88	1.25e-06	0.000124	-0.23	-0.15	Idiopathic pulmonary fibrosis;	chr15:85597248	chr15:85191438~85213905:+
BRCA	cis	rs77204473	0.744	rs17120344	ENSG00000280143.1	AP000892.6	4.88	1.25e-06	0.000124	0.3	0.15	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117125629	chr11:117204967~117210292:+
BRCA	cis	rs7481584	0.624	rs428726	ENSG00000247473.2	CARS-AS1	-4.88	1.25e-06	0.000124	-0.18	-0.15	Calcium levels;	chr11:3024971	chr11:3029009~3041260:+
BRCA	cis	rs7572733	0.773	rs56858593	ENSG00000231621.1	AC013264.2	-4.88	1.25e-06	0.000124	-0.14	-0.15	Dermatomyositis;	chr2:197629744	chr2:197197991~197199273:+
BRCA	cis	rs7267979	0.844	rs6115188	ENSG00000274414.1	RP5-965G21.4	-4.88	1.25e-06	0.000124	-0.17	-0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25451534	chr20:25239007~25245229:-
BRCA	cis	rs1223397	0.651	rs2919686	ENSG00000215022.6	RP1-257A7.4	-4.88	1.25e-06	0.000124	-0.18	-0.15	Blood pressure;	chr6:13312409	chr6:13264861~13295586:-
BRCA	cis	rs1223397	0.651	rs3001966	ENSG00000215022.6	RP1-257A7.4	-4.88	1.25e-06	0.000124	-0.18	-0.15	Blood pressure;	chr6:13312452	chr6:13264861~13295586:-
BRCA	cis	rs442309	0.783	rs224095	ENSG00000238280.1	RP11-436D10.3	-4.88	1.25e-06	0.000124	-0.2	-0.15	Vogt-Koyanagi-Harada syndrome;	chr10:62782299	chr10:62793562~62805887:-
BRCA	cis	rs2411233	0.674	rs12907914	ENSG00000259278.1	RP11-62C7.2	-4.88	1.25e-06	0.000124	-0.18	-0.15	Platelet count;	chr15:39023157	chr15:39019233~39024918:+
BRCA	cis	rs2243480	0.901	rs12530490	ENSG00000222364.1	RNU6-96P	4.88	1.25e-06	0.000124	0.28	0.15	Diabetic kidney disease;	chr7:66226660	chr7:66395191~66395286:+
BRCA	cis	rs2243480	1	rs7778911	ENSG00000222364.1	RNU6-96P	4.88	1.25e-06	0.000124	0.28	0.15	Diabetic kidney disease;	chr7:66229519	chr7:66395191~66395286:+
BRCA	cis	rs4819052	0.851	rs13048789	ENSG00000184274.3	LINC00315	-4.88	1.25e-06	0.000125	-0.21	-0.15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240799	chr21:45300245~45305257:-
BRCA	cis	rs12497850	0.931	rs9846123	ENSG00000225399.4	RP11-3B7.1	-4.88	1.25e-06	0.000125	-0.15	-0.15	Parkinson's disease;	chr3:49050679	chr3:49260085~49261316:+
BRCA	cis	rs1910358	0.664	rs6881440	ENSG00000248874.4	C5orf17	-4.88	1.25e-06	0.000125	-0.19	-0.15	Venous thromboembolism (SNP x SNP interaction);	chr5:23912358	chr5:23951348~24178263:+
BRCA	cis	rs7772486	0.79	rs6924159	ENSG00000270638.1	RP3-466P17.1	-4.88	1.25e-06	0.000125	-0.18	-0.15	Lobe attachment (rater-scored or self-reported);	chr6:145946737	chr6:145735570~145737218:+
BRCA	cis	rs2665103	0.61	rs56398167	ENSG00000276710.3	CSPG4P8	-4.88	1.25e-06	0.000125	-0.16	-0.15	Intelligence (multi-trait analysis);	chr15:82237482	chr15:82459472~82477258:+
BRCA	cis	rs10129255	0.912	rs8009135	ENSG00000211974.3	IGHV2-70	4.88	1.25e-06	0.000125	0.15	0.15	Kawasaki disease;	chr14:106777528	chr14:106723574~106724093:-
BRCA	cis	rs2638953	0.962	rs11049539	ENSG00000247934.4	RP11-967K21.1	-4.88	1.25e-06	0.000125	-0.21	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28335953	chr12:28163298~28190738:-
BRCA	cis	rs1124769	0.506	rs2614766	ENSG00000259378.1	DCAF13P3	-4.88	1.25e-06	0.000125	-0.19	-0.15	Cognitive performance;	chr15:50852394	chr15:50944663~50945996:+
BRCA	cis	rs6095360	1	rs2295027	ENSG00000222365.1	SNORD12B	-4.88	1.25e-06	0.000125	-0.16	-0.15	Intelligence (multi-trait analysis);	chr20:48966347	chr20:49280319~49280409:+
BRCA	cis	rs11148252	0.583	rs9536048	ENSG00000278238.1	RP11-245D16.4	-4.88	1.25e-06	0.000125	-0.18	-0.15	Lewy body disease;	chr13:52384653	chr13:52454775~52455331:-
BRCA	cis	rs2303319	0.504	rs1567420	ENSG00000227403.1	AC009299.3	-4.88	1.25e-06	0.000125	-0.35	-0.15	Cognitive function;	chr2:161619091	chr2:161244739~161249050:+
BRCA	cis	rs801193	0.613	rs2016325	ENSG00000222364.1	RNU6-96P	4.88	1.25e-06	0.000125	0.17	0.15	Aortic root size;	chr7:66858513	chr7:66395191~66395286:+
BRCA	cis	rs1598856	1	rs11934404	ENSG00000246560.2	RP11-10L12.4	4.88	1.26e-06	0.000125	0.16	0.15	Primary biliary cholangitis;	chr4:102516444	chr4:102828055~102844075:+
BRCA	cis	rs14027	0.577	rs12707876	ENSG00000279347.1	RP11-85I17.2	-4.88	1.26e-06	0.000125	-0.15	-0.15	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119730143	chr8:119838736~119840385:-
BRCA	cis	rs595982	0.527	rs17206707	ENSG00000235191.1	NUCB1-AS1	4.87	1.26e-06	0.000125	0.26	0.15	Red cell distribution width;	chr19:48858184	chr19:48910930~48918891:-
BRCA	cis	rs1193	0.789	rs36100635	ENSG00000231259.4	AC125232.1	-4.87	1.26e-06	0.000125	-0.18	-0.15	High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;High light scatter reticulocyte count;	chr2:86707448	chr2:87031815~87053069:-
BRCA	cis	rs4388249	0.687	rs3797692	ENSG00000271849.1	CTC-332L22.1	-4.87	1.26e-06	0.000125	-0.19	-0.15	Schizophrenia;	chr5:109761985	chr5:109687802~109688329:-
BRCA	cis	rs4388249	0.687	rs10059767	ENSG00000271849.1	CTC-332L22.1	-4.87	1.26e-06	0.000125	-0.19	-0.15	Schizophrenia;	chr5:109765049	chr5:109687802~109688329:-
BRCA	cis	rs9659323	0.632	rs10802074	ENSG00000231365.4	RP11-418J17.1	-4.87	1.26e-06	0.000125	-0.17	-0.15	Body mass index;	chr1:119082373	chr1:119140396~119275973:+
BRCA	cis	rs7131987	0.565	rs6487787	ENSG00000275476.1	RP11-996F15.4	4.87	1.26e-06	0.000125	0.16	0.15	QT interval;	chr12:29248353	chr12:29277397~29277882:-
BRCA	cis	rs7131987	0.565	rs6487791	ENSG00000275476.1	RP11-996F15.4	4.87	1.26e-06	0.000125	0.16	0.15	QT interval;	chr12:29250989	chr12:29277397~29277882:-
BRCA	cis	rs7267979	0.816	rs443009	ENSG00000274973.1	RP13-401N8.7	4.87	1.26e-06	0.000125	0.17	0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25519181	chr20:25845497~25845862:+
BRCA	cis	rs9784649	0.882	rs2201296	ENSG00000245662.2	RP11-184E9.1	4.87	1.26e-06	0.000125	0.22	0.15	Peripheral arterial disease (traffic-related air pollution interaction);	chr5:24967010	chr5:25190682~25306172:+
BRCA	cis	rs9784649	1	rs11738315	ENSG00000245662.2	RP11-184E9.1	4.87	1.26e-06	0.000125	0.22	0.15	Peripheral arterial disease (traffic-related air pollution interaction);	chr5:24967782	chr5:25190682~25306172:+
BRCA	cis	rs14027	0.512	rs7012791	ENSG00000279347.1	RP11-85I17.2	4.87	1.26e-06	0.000125	0.15	0.15	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119707451	chr8:119838736~119840385:-
BRCA	cis	rs13325613	0.915	rs4987053	ENSG00000223552.1	RP11-24F11.2	4.87	1.26e-06	0.000125	0.27	0.15	Monocyte count;	chr3:46265209	chr3:46364955~46407059:-
BRCA	cis	rs35740288	0.822	rs11630179	ENSG00000259407.1	RP11-158M2.3	-4.87	1.26e-06	0.000126	-0.2	-0.15	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85739703	chr15:85744109~85750281:-
BRCA	cis	rs7772486	0.686	rs9373473	ENSG00000270638.1	RP3-466P17.1	4.87	1.26e-06	0.000126	0.17	0.15	Lobe attachment (rater-scored or self-reported);	chr6:145761146	chr6:145735570~145737218:+
BRCA	cis	rs2803122	0.967	rs10964066	ENSG00000273226.1	RP11-513M16.8	-4.87	1.26e-06	0.000126	-0.16	-0.15	Pulse pressure;	chr9:19250780	chr9:19375451~19375996:+
BRCA	cis	rs700651	0.789	rs1371663	ENSG00000231621.1	AC013264.2	4.87	1.26e-06	0.000126	0.15	0.15	Intracranial aneurysm;	chr2:198035581	chr2:197197991~197199273:+
BRCA	cis	rs9287719	0.746	rs6742448	ENSG00000243819.4	RN7SL832P	4.87	1.26e-06	0.000126	0.15	0.15	Prostate cancer;	chr2:10619000	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.781	rs6732671	ENSG00000243819.4	RN7SL832P	4.87	1.26e-06	0.000126	0.15	0.15	Prostate cancer;	chr2:10619023	chr2:10690344~10692099:+
BRCA	cis	rs721917	0.525	rs11201011	ENSG00000244733.5	RP11-506M13.3	-4.87	1.26e-06	0.000126	-0.18	-0.15	Chronic obstructive pulmonary disease;	chr10:79980164	chr10:79660891~79677996:+
BRCA	cis	rs3764021	0.509	rs10772073	ENSG00000214776.8	RP11-726G1.1	4.87	1.26e-06	0.000126	0.18	0.15	Type 1 diabetes;	chr12:9717428	chr12:9467552~9576275:+
BRCA	cis	rs3764021	0.509	rs10772074	ENSG00000214776.8	RP11-726G1.1	4.87	1.26e-06	0.000126	0.18	0.15	Type 1 diabetes;	chr12:9717686	chr12:9467552~9576275:+
BRCA	cis	rs6452524	0.967	rs11949474	ENSG00000281327.1	LINC01338	4.87	1.26e-06	0.000126	0.17	0.15	Hypertension (SNP x SNP interaction);	chr5:83179759	chr5:82850864~82859836:-
BRCA	cis	rs3120667	0.72	rs72698963	ENSG00000237975.5	FLG-AS1	4.87	1.26e-06	0.000126	0.23	0.15	Eating disorders;	chr1:152444006	chr1:152168125~152445456:+
BRCA	cis	rs6596100	0.876	rs57079115	ENSG00000248648.1	RP11-485M7.1	-4.87	1.26e-06	0.000126	-0.19	-0.15	Breast cancer;	chr5:133046580	chr5:133003119~133003365:+
BRCA	cis	rs8031584	0.781	rs4779498	ENSG00000259845.1	HERC2P10	4.87	1.26e-06	0.000126	0.18	0.15	Huntington's disease progression;	chr15:30885273	chr15:30815271~30844153:+
BRCA	cis	rs3768617	0.811	rs4350171	ENSG00000224468.3	RP11-181K3.4	-4.87	1.26e-06	0.000126	-0.17	-0.15	Fuchs's corneal dystrophy;	chr1:183013013	chr1:183138402~183141282:-
BRCA	cis	rs300890	0.536	rs300940	ENSG00000250326.1	RP11-284M14.1	-4.87	1.26e-06	0.000126	-0.18	-0.15	Nasopharyngeal carcinoma;	chr4:143252152	chr4:142933195~143184861:-
BRCA	cis	rs6847067	0.931	rs7685537	ENSG00000180769.7	WDFY3-AS2	4.87	1.26e-06	0.000126	0.13	0.15	Oropharynx cancer;	chr4:84757471	chr4:84965682~85011277:+
BRCA	cis	rs17685	0.672	rs55807301	ENSG00000280388.1	RP11-229D13.3	-4.87	1.26e-06	0.000126	-0.15	-0.15	Coffee consumption (cups per day);Coffee consumption;	chr7:76178083	chr7:76043977~76045963:-
BRCA	cis	rs9307551	0.584	rs2119420	ENSG00000250334.4	LINC00989	-4.87	1.27e-06	0.000126	-0.2	-0.15	Refractive error;	chr4:79515963	chr4:79492416~79576460:+
BRCA	cis	rs11098499	0.789	rs9991166	ENSG00000249244.1	RP11-548H18.2	4.87	1.27e-06	0.000126	0.17	0.15	Corneal astigmatism;	chr4:119316696	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.708	rs10005237	ENSG00000249244.1	RP11-548H18.2	4.87	1.27e-06	0.000126	0.17	0.15	Corneal astigmatism;	chr4:119316742	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.754	rs10213267	ENSG00000249244.1	RP11-548H18.2	4.87	1.27e-06	0.000126	0.17	0.15	Corneal astigmatism;	chr4:119317919	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.754	rs10212775	ENSG00000249244.1	RP11-548H18.2	4.87	1.27e-06	0.000126	0.17	0.15	Corneal astigmatism;	chr4:119318089	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.754	rs2964	ENSG00000249244.1	RP11-548H18.2	4.87	1.27e-06	0.000126	0.17	0.15	Corneal astigmatism;	chr4:119318976	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.754	rs1511025	ENSG00000249244.1	RP11-548H18.2	4.87	1.27e-06	0.000126	0.17	0.15	Corneal astigmatism;	chr4:119319083	chr4:119391831~119395335:-
BRCA	cis	rs2905347	0.895	rs2961281	ENSG00000179428.2	AC073072.5	4.87	1.27e-06	0.000126	0.16	0.15	Major depression and alcohol dependence;	chr7:22600673	chr7:22725395~22727620:-
BRCA	cis	rs13113518	0.841	rs11133400	ENSG00000223305.1	RN7SKP30	4.87	1.27e-06	0.000126	0.18	0.15	Height;	chr4:55578787	chr4:55540502~55540835:-
BRCA	cis	rs11098499	0.954	rs13145352	ENSG00000249244.1	RP11-548H18.2	-4.87	1.27e-06	0.000126	-0.18	-0.15	Corneal astigmatism;	chr4:119488808	chr4:119391831~119395335:-
BRCA	cis	rs12744310	0.887	rs12022655	ENSG00000235358.1	RP11-399E6.1	4.87	1.27e-06	0.000126	0.22	0.15	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41350647	chr1:41242373~41284861:+
BRCA	cis	rs1867631	0.565	rs10749764	ENSG00000248458.2	RP4-598P13.1	4.87	1.27e-06	0.000126	0.15	0.15	Menopause (age at onset);	chr1:66684023	chr1:66665864~66677027:-
BRCA	cis	rs57221529	0.766	rs12518859	ENSG00000225138.6	CTD-2228K2.7	4.87	1.27e-06	0.000126	0.23	0.15	Lung disease severity in cystic fibrosis;	chr5:587317	chr5:473236~480884:+
BRCA	cis	rs875971	0.895	rs778700	ENSG00000223473.2	GS1-124K5.3	4.87	1.27e-06	0.000126	0.11	0.15	Aortic root size;	chr7:66401463	chr7:66491049~66493566:-
BRCA	cis	rs875971	1	rs778699	ENSG00000223473.2	GS1-124K5.3	4.87	1.27e-06	0.000126	0.11	0.15	Aortic root size;	chr7:66403303	chr7:66491049~66493566:-
BRCA	cis	rs11098499	0.754	rs1511017	ENSG00000260404.2	RP11-384K6.6	4.87	1.27e-06	0.000126	0.14	0.15	Corneal astigmatism;	chr4:119329650	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.789	rs12498994	ENSG00000260404.2	RP11-384K6.6	4.87	1.27e-06	0.000126	0.14	0.15	Corneal astigmatism;	chr4:119329663	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.754	rs12507565	ENSG00000260404.2	RP11-384K6.6	4.87	1.27e-06	0.000126	0.14	0.15	Corneal astigmatism;	chr4:119329966	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.826	rs12511640	ENSG00000260404.2	RP11-384K6.6	4.87	1.27e-06	0.000126	0.14	0.15	Corneal astigmatism;	chr4:119330093	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.754	rs1980026	ENSG00000260404.2	RP11-384K6.6	4.87	1.27e-06	0.000126	0.14	0.15	Corneal astigmatism;	chr4:119330488	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.743	rs11098501	ENSG00000260404.2	RP11-384K6.6	4.87	1.27e-06	0.000126	0.14	0.15	Corneal astigmatism;	chr4:119330862	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.754	rs11098502	ENSG00000260404.2	RP11-384K6.6	4.87	1.27e-06	0.000126	0.14	0.15	Corneal astigmatism;	chr4:119330908	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.708	rs11732686	ENSG00000260404.2	RP11-384K6.6	4.87	1.27e-06	0.000126	0.14	0.15	Corneal astigmatism;	chr4:119331175	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.754	rs11724409	ENSG00000260404.2	RP11-384K6.6	4.87	1.27e-06	0.000126	0.14	0.15	Corneal astigmatism;	chr4:119331206	chr4:118591773~118633729:+
BRCA	cis	rs875971	0.862	rs6971059	ENSG00000236529.1	RP13-254B10.1	-4.87	1.27e-06	0.000126	-0.17	-0.15	Aortic root size;	chr7:66602045	chr7:65840212~65840596:+
BRCA	cis	rs62025270	0.688	rs62025298	ENSG00000259295.5	CSPG4P12	-4.87	1.27e-06	0.000126	-0.23	-0.15	Idiopathic pulmonary fibrosis;	chr15:85773921	chr15:85191438~85213905:+
BRCA	cis	rs17428076	0.836	rs57775770	ENSG00000228389.1	AC068039.4	-4.87	1.27e-06	0.000126	-0.21	-0.15	Myopia;	chr2:171831221	chr2:171773482~171775844:+
BRCA	cis	rs7267979	0.844	rs4815413	ENSG00000274414.1	RP5-965G21.4	4.87	1.27e-06	0.000126	0.18	0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25378593	chr20:25239007~25245229:-
BRCA	cis	rs7267979	0.844	rs6083824	ENSG00000274414.1	RP5-965G21.4	4.87	1.27e-06	0.000126	0.18	0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25382421	chr20:25239007~25245229:-
BRCA	cis	rs559555	0.553	rs682895	ENSG00000272716.1	RP11-563N4.1	-4.87	1.27e-06	0.000126	-0.18	-0.15	Blood metabolite ratios;Blood metabolite levels;	chr2:31646514	chr2:32165046~32165757:-
BRCA	cis	rs4664293	0.836	rs4516379	ENSG00000224152.1	AC009506.1	-4.87	1.27e-06	0.000126	-0.17	-0.15	Monocyte percentage of white cells;	chr2:159808892	chr2:159615296~159617082:+
BRCA	cis	rs875971	1	rs6979382	ENSG00000223473.2	GS1-124K5.3	4.87	1.27e-06	0.000126	0.11	0.15	Aortic root size;	chr7:66421388	chr7:66491049~66493566:-
BRCA	cis	rs875971	1	rs6961990	ENSG00000223473.2	GS1-124K5.3	4.87	1.27e-06	0.000126	0.11	0.15	Aortic root size;	chr7:66423583	chr7:66491049~66493566:-
BRCA	cis	rs9467773	0.62	rs2504592	ENSG00000124549.13	BTN2A3P	4.87	1.27e-06	0.000126	0.15	0.15	Intelligence (multi-trait analysis);	chr6:26640723	chr6:26421391~26432383:+
BRCA	cis	rs4781563	0.621	rs11639593	ENSG00000242307.1	RPS26P52	-4.87	1.27e-06	0.000126	-0.17	-0.15	Bilirubin levels;	chr16:13915619	chr16:13922332~13922679:-
BRCA	cis	rs12744310	0.887	rs12024263	ENSG00000235358.1	RP11-399E6.1	4.87	1.27e-06	0.000126	0.22	0.15	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41355277	chr1:41242373~41284861:+
BRCA	cis	rs7487075	0.619	rs7485599	ENSG00000274723.1	RP11-618L22.1	4.87	1.27e-06	0.000127	0.2	0.15	Itch intensity from mosquito bite;	chr12:46436696	chr12:46970504~46972155:+
BRCA	cis	rs7487075	0.578	rs4768716	ENSG00000274723.1	RP11-618L22.1	4.87	1.27e-06	0.000127	0.2	0.15	Itch intensity from mosquito bite;	chr12:46437375	chr12:46970504~46972155:+
BRCA	cis	rs7487075	0.578	rs4768122	ENSG00000274723.1	RP11-618L22.1	4.87	1.27e-06	0.000127	0.2	0.15	Itch intensity from mosquito bite;	chr12:46438551	chr12:46970504~46972155:+
BRCA	cis	rs4908760	0.965	rs12080583	ENSG00000232912.4	RP5-1115A15.1	4.87	1.27e-06	0.000127	0.14	0.15	Vitiligo;	chr1:8464817	chr1:8424645~8434838:+
BRCA	cis	rs4664293	0.802	rs7563417	ENSG00000226266.5	AC009961.3	-4.87	1.27e-06	0.000127	-0.2	-0.15	Monocyte percentage of white cells;	chr2:159727762	chr2:159670708~159712435:-
BRCA	cis	rs4908760	0.899	rs6577496	ENSG00000232912.4	RP5-1115A15.1	4.87	1.27e-06	0.000127	0.14	0.15	Vitiligo;	chr1:8521168	chr1:8424645~8434838:+
BRCA	cis	rs957448	0.561	rs58663902	ENSG00000253175.1	RP11-267M23.6	4.87	1.27e-06	0.000127	0.17	0.15	Nonsyndromic cleft lip with cleft palate;	chr8:94610177	chr8:94565036~94565715:+
BRCA	cis	rs9818758	0.607	rs35060561	ENSG00000270441.1	RP11-694I15.7	4.87	1.27e-06	0.000127	0.29	0.15	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49218070	chr3:49140086~49160851:-
BRCA	cis	rs4718428	0.672	rs13241598	ENSG00000229180.5	GS1-124K5.11	4.87	1.27e-06	0.000127	0.14	0.15	Corneal structure;	chr7:66835665	chr7:66526088~66542624:-
BRCA	cis	rs2562456	0.917	rs2681376	ENSG00000268535.1	RP11-420K14.3	-4.87	1.27e-06	0.000127	-0.21	-0.15	Pain;	chr19:21532723	chr19:21709522~21710191:+
BRCA	cis	rs597539	0.654	rs619727	ENSG00000261625.1	RP11-554A11.4	-4.87	1.27e-06	0.000127	-0.15	-0.15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68860067	chr11:69000765~69002048:-
BRCA	cis	rs875971	0.545	rs73142265	ENSG00000232546.1	RP11-458F8.1	4.87	1.27e-06	0.000127	0.14	0.15	Aortic root size;	chr7:66234510	chr7:66848496~66858136:+
BRCA	cis	rs321358	1	rs12419222	ENSG00000271390.1	RP11-89C3.3	4.87	1.27e-06	0.000127	0.25	0.15	Body mass index;	chr11:111128439	chr11:111089870~111090368:-
BRCA	cis	rs1669338	0.588	rs73005226	ENSG00000271870.1	RP11-97C16.1	4.87	1.27e-06	0.000127	0.19	0.15	White matter integrity;	chr3:3153685	chr3:3152942~3153435:+
BRCA	cis	rs1669338	0.588	rs3846135	ENSG00000271870.1	RP11-97C16.1	4.87	1.27e-06	0.000127	0.19	0.15	White matter integrity;	chr3:3153890	chr3:3152942~3153435:+
BRCA	cis	rs875971	0.862	rs6460306	ENSG00000236529.1	RP13-254B10.1	-4.87	1.27e-06	0.000127	-0.17	-0.15	Aortic root size;	chr7:66595806	chr7:65840212~65840596:+
BRCA	cis	rs300890	0.56	rs6812850	ENSG00000250326.1	RP11-284M14.1	-4.87	1.28e-06	0.000127	-0.18	-0.15	Nasopharyngeal carcinoma;	chr4:143264929	chr4:142933195~143184861:-
BRCA	cis	rs13113518	0.729	rs11133377	ENSG00000272969.1	RP11-528I4.2	4.87	1.28e-06	0.000127	0.19	0.15	Height;	chr4:55413708	chr4:55547112~55547889:+
BRCA	cis	rs2638953	0.815	rs11049658	ENSG00000247934.4	RP11-967K21.1	-4.87	1.28e-06	0.000127	-0.2	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28481930	chr12:28163298~28190738:-
BRCA	cis	rs287982	0.611	rs75809337	ENSG00000269973.1	RP11-95D17.1	-4.87	1.28e-06	0.000127	-0.24	-0.15	Nonsyndromic cleft lip with cleft palate;	chr2:9837684	chr2:9936360~9939590:+
BRCA	cis	rs287982	0.611	rs78100109	ENSG00000269973.1	RP11-95D17.1	-4.87	1.28e-06	0.000127	-0.24	-0.15	Nonsyndromic cleft lip with cleft palate;	chr2:9838280	chr2:9936360~9939590:+
BRCA	cis	rs287982	0.611	rs75277217	ENSG00000269973.1	RP11-95D17.1	-4.87	1.28e-06	0.000127	-0.24	-0.15	Nonsyndromic cleft lip with cleft palate;	chr2:9839275	chr2:9936360~9939590:+
BRCA	cis	rs875971	1	rs3981131	ENSG00000223473.2	GS1-124K5.3	4.87	1.28e-06	0.000127	0.11	0.15	Aortic root size;	chr7:66486690	chr7:66491049~66493566:-
BRCA	cis	rs35740288	0.822	rs11630549	ENSG00000259407.1	RP11-158M2.3	-4.87	1.28e-06	0.000127	-0.2	-0.15	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85732565	chr15:85744109~85750281:-
BRCA	cis	rs7200543	0.961	rs3803573	ENSG00000260872.1	RP11-680G24.5	-4.87	1.28e-06	0.000127	-0.16	-0.15	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15044556	chr16:15018106~15020488:-
BRCA	cis	rs2235544	0.579	rs1537323	ENSG00000225183.1	RP4-758J24.4	4.87	1.28e-06	0.000127	0.17	0.15	Thyroid hormone levels;Multiple myeloma (hyperdiploidy);	chr1:54016850	chr1:54089856~54090093:+
BRCA	cis	rs2153535	0.563	rs6942177	ENSG00000251164.1	HULC	4.87	1.28e-06	0.000127	0.18	0.15	Motion sickness;	chr6:8534227	chr6:8652137~8653846:+
BRCA	cis	rs10457838	0.851	rs9322164	ENSG00000236591.1	RP11-162J8.3	-4.87	1.28e-06	0.000127	-0.21	-0.15	Post-traumatic stress disorder;	chr6:149053348	chr6:149027700~149032573:-
BRCA	cis	rs10504130	1	rs76649221	ENSG00000272024.1	RP11-546K22.3	-4.87	1.28e-06	0.000127	-0.26	-0.15	Venous thromboembolism (SNP x SNP interaction);	chr8:51884175	chr8:51950284~51950690:+
BRCA	cis	rs2522056	1	rs2706383	ENSG00000233006.5	AC034220.3	-4.87	1.28e-06	0.000127	-0.13	-0.15	Fibrinogen;Lymphocyte counts;	chr5:132456710	chr5:132311285~132369916:-
BRCA	cis	rs875971	0.83	rs587360	ENSG00000236529.1	RP13-254B10.1	4.87	1.28e-06	0.000127	0.16	0.15	Aortic root size;	chr7:66057711	chr7:65840212~65840596:+
BRCA	cis	rs13325613	1	rs13325613	ENSG00000223552.1	RP11-24F11.2	-4.87	1.28e-06	0.000127	-0.28	-0.15	Monocyte count;	chr3:46256882	chr3:46364955~46407059:-
BRCA	cis	rs875971	0.964	rs778708	ENSG00000223473.2	GS1-124K5.3	4.87	1.28e-06	0.000127	0.11	0.15	Aortic root size;	chr7:66391332	chr7:66491049~66493566:-
BRCA	cis	rs9921338	0.961	rs6498185	ENSG00000262703.1	RP11-485G7.6	-4.87	1.28e-06	0.000127	-0.17	-0.15	Vein graft stenosis in coronary artery bypass grafting;	chr16:11350869	chr16:11348143~11349321:-
BRCA	cis	rs6847067	1	rs2170935	ENSG00000180769.7	WDFY3-AS2	4.87	1.28e-06	0.000127	0.13	0.15	Oropharynx cancer;	chr4:84797795	chr4:84965682~85011277:+
BRCA	cis	rs875971	0.545	rs316316	ENSG00000232546.1	RP11-458F8.1	-4.87	1.28e-06	0.000127	-0.14	-0.15	Aortic root size;	chr7:66149270	chr7:66848496~66858136:+
BRCA	cis	rs67981189	0.542	rs17109053	ENSG00000258571.1	PTTG4P	-4.87	1.28e-06	0.000127	-0.18	-0.15	Schizophrenia;	chr14:71142981	chr14:71085482~71085833:-
BRCA	cis	rs2179367	0.6	rs9498353	ENSG00000223701.3	RAET1E-AS1	4.87	1.28e-06	0.000127	0.22	0.15	Dupuytren's disease;	chr6:149439860	chr6:149884431~149919508:+
BRCA	cis	rs875971	0.861	rs801215	ENSG00000236529.1	RP13-254B10.1	-4.87	1.28e-06	0.000127	-0.17	-0.15	Aortic root size;	chr7:66546951	chr7:65840212~65840596:+
BRCA	cis	rs987360	0.835	rs4864402	ENSG00000248869.4	RP11-138I17.1	4.87	1.28e-06	0.000127	0.15	0.15	Temperament;	chr4:137283583	chr4:136796722~137212799:-
BRCA	cis	rs8180040	0.932	rs62248599	ENSG00000271161.1	BOLA2P2	-4.87	1.28e-06	0.000127	-0.16	-0.15	Colorectal cancer;	chr3:47475238	chr3:47499841~47500407:+
BRCA	cis	rs13113518	0.966	rs12506788	ENSG00000249700.7	SRD5A3-AS1	4.87	1.28e-06	0.000127	0.19	0.15	Height;	chr4:55477426	chr4:55363971~55395847:-
BRCA	cis	rs1910358	0.664	rs10069401	ENSG00000248874.4	C5orf17	-4.87	1.28e-06	0.000127	-0.19	-0.15	Venous thromboembolism (SNP x SNP interaction);	chr5:23924942	chr5:23951348~24178263:+
BRCA	cis	rs3743162	1	rs12909280	ENSG00000259728.4	LINC00933	4.87	1.28e-06	0.000128	0.21	0.15	Alzheimer's disease (age of onset);	chr15:84886125	chr15:84570649~84580175:+
BRCA	cis	rs4835473	0.715	rs1849124	ENSG00000249741.2	RP11-673E1.3	-4.87	1.28e-06	0.000128	-0.16	-0.15	Immature fraction of reticulocytes;	chr4:143978494	chr4:143911514~143912053:-
BRCA	cis	rs4835473	0.689	rs1849123	ENSG00000249741.2	RP11-673E1.3	-4.87	1.28e-06	0.000128	-0.16	-0.15	Immature fraction of reticulocytes;	chr4:143978495	chr4:143911514~143912053:-
BRCA	cis	rs647097	0.551	rs16954164	ENSG00000265962.1	GACAT2	-4.87	1.28e-06	0.000128	-0.21	-0.15	Chronic obstructive pulmonary disease;	chr18:8789383	chr18:8695856~8707621:-
BRCA	cis	rs718433	0.782	rs4982505	ENSG00000256379.1	TRAV8-5	4.87	1.28e-06	0.000128	0.18	0.15	Intraocular pressure;	chr14:21773721	chr14:21903077~21903598:+
BRCA	cis	rs9423406	0.706	rs71479715	ENSG00000224034.1	RP11-445P17.8	-4.87	1.28e-06	0.000128	-0.29	-0.15	Intelligence;	chr10:5281059	chr10:5266033~5271236:-
BRCA	cis	rs17767294	0.708	rs72851182	ENSG00000204709.4	LINC01556	4.87	1.28e-06	0.000128	0.39	0.15	Parkinson's disease;	chr6:28138921	chr6:28943877~28944537:+
BRCA	cis	rs17767294	0.708	rs75543204	ENSG00000204709.4	LINC01556	4.87	1.28e-06	0.000128	0.39	0.15	Parkinson's disease;	chr6:28141038	chr6:28943877~28944537:+
BRCA	cis	rs6840360	0.642	rs7666571	ENSG00000278978.1	RP11-164P12.5	-4.87	1.28e-06	0.000128	-0.16	-0.15	Intelligence (multi-trait analysis);	chr4:151522121	chr4:151669786~151670503:+
BRCA	cis	rs3781264	0.55	rs35247409	ENSG00000273450.1	RP11-76P2.4	4.87	1.29e-06	0.000128	0.24	0.15	Esophageal cancer and gastric cancer;	chr10:94302726	chr10:94314907~94315327:-
BRCA	cis	rs9467773	0.62	rs6925087	ENSG00000124549.13	BTN2A3P	4.87	1.29e-06	0.000128	0.15	0.15	Intelligence (multi-trait analysis);	chr6:26592625	chr6:26421391~26432383:+
BRCA	cis	rs9467773	0.62	rs4368798	ENSG00000124549.13	BTN2A3P	4.87	1.29e-06	0.000128	0.15	0.15	Intelligence (multi-trait analysis);	chr6:26593243	chr6:26421391~26432383:+
BRCA	cis	rs1075265	0.84	rs2884254	ENSG00000235937.1	AC008280.1	4.87	1.29e-06	0.000128	0.16	0.15	Chronotype;Morning vs. evening chronotype;	chr2:53979326	chr2:54029552~54030682:-
BRCA	cis	rs7916697	0.626	rs61854803	ENSG00000233590.1	RP11-153K11.3	-4.87	1.29e-06	0.000128	-0.18	-0.15	Optic disc area;	chr10:68254881	chr10:68233251~68242379:-
BRCA	cis	rs8031584	0.541	rs2955777	ENSG00000259845.1	HERC2P10	-4.87	1.29e-06	0.000128	-0.17	-0.15	Huntington's disease progression;	chr15:30927585	chr15:30815271~30844153:+
BRCA	cis	rs17801127	0.818	rs34131478	ENSG00000231969.1	AC144449.1	4.87	1.29e-06	0.000128	0.29	0.15	Liver enzyme levels (alanine transaminase);	chr2:149802126	chr2:149587196~149848233:+
BRCA	cis	rs9467773	0.62	rs9295701	ENSG00000124549.13	BTN2A3P	4.87	1.29e-06	0.000128	0.15	0.15	Intelligence (multi-trait analysis);	chr6:26627280	chr6:26421391~26432383:+
BRCA	cis	rs4908768	0.501	rs6577494	ENSG00000232912.4	RP5-1115A15.1	4.87	1.29e-06	0.000128	0.14	0.15	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8516866	chr1:8424645~8434838:+
BRCA	cis	rs2235642	0.821	rs2281234	ENSG00000260989.1	LA16c-395F10.2	-4.87	1.29e-06	0.000128	-0.15	-0.15	Coronary artery disease;	chr16:1552937	chr16:1580527~1610328:+
BRCA	cis	rs11098499	0.865	rs10213221	ENSG00000249244.1	RP11-548H18.2	4.87	1.29e-06	0.000128	0.17	0.15	Corneal astigmatism;	chr4:119334771	chr4:119391831~119395335:-
BRCA	cis	rs6452524	0.967	rs4541638	ENSG00000281327.1	LINC01338	4.87	1.29e-06	0.000128	0.17	0.15	Hypertension (SNP x SNP interaction);	chr5:83181325	chr5:82850864~82859836:-
BRCA	cis	rs7267979	0.789	rs4815400	ENSG00000204556.4	CTD-2514C3.1	4.87	1.29e-06	0.000128	0.2	0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25311924	chr20:26018832~26020684:+
BRCA	cis	rs2638953	0.671	rs10843099	ENSG00000278733.1	RP11-425D17.1	-4.87	1.29e-06	0.000128	-0.21	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28116901	chr12:28185625~28186190:-
BRCA	cis	rs600231	0.706	rs1111934	ENSG00000173727.10	CMB9-22P13.1	4.87	1.29e-06	0.000128	0.21	0.15	Bone mineral density;	chr11:65561921	chr11:65455258~65466720:+
BRCA	cis	rs300890	0.662	rs592349	ENSG00000250326.1	RP11-284M14.1	4.87	1.29e-06	0.000128	0.17	0.15	Nasopharyngeal carcinoma;	chr4:143299230	chr4:142933195~143184861:-
BRCA	cis	rs875971	0.83	rs6976714	ENSG00000236529.1	RP13-254B10.1	4.87	1.29e-06	0.000128	0.17	0.15	Aortic root size;	chr7:66426474	chr7:65840212~65840596:+
BRCA	cis	rs2277027	1	rs10866659	ENSG00000248544.2	CTB-47B11.3	-4.87	1.29e-06	0.000128	-0.18	-0.15	Pulmonary function;Pulmonary function (smoking interaction);	chr5:157510035	chr5:157375741~157384950:-
BRCA	cis	rs11758351	0.789	rs4496782	ENSG00000241549.7	GUSBP2	-4.87	1.29e-06	0.000128	-0.19	-0.15	Renal underexcretion gout;Gout;	chr6:26184389	chr6:26871484~26956554:-
BRCA	cis	rs739496	0.527	rs10849981	ENSG00000226469.1	ADAM1B	4.87	1.29e-06	0.000128	0.19	0.15	Platelet count;	chr12:111897413	chr12:111927018~111929017:+
BRCA	cis	rs9652601	0.691	rs12922303	ENSG00000274038.1	RP11-66H6.4	-4.87	1.29e-06	0.000128	-0.16	-0.15	Systemic lupus erythematosus;	chr16:11099608	chr16:11056556~11057034:+
BRCA	cis	rs2732480	0.5	rs7297824	ENSG00000226413.2	OR8T1P	4.87	1.29e-06	0.000128	0.2	0.15	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48204867	chr12:48442030~48442947:-
BRCA	cis	rs2832077	0.506	rs10222093	ENSG00000215533.7	LINC00189	4.87	1.29e-06	0.000128	0.19	0.15	Cognitive test performance;	chr21:28791196	chr21:29193480~29288205:+
BRCA	cis	rs11098499	0.909	rs1546504	ENSG00000250412.1	KLHL2P1	4.87	1.29e-06	0.000128	0.18	0.15	Corneal astigmatism;	chr4:119320024	chr4:119334329~119378233:+
BRCA	cis	rs2276314	0.512	rs9949178	ENSG00000278986.1	RP11-723J4.3	4.87	1.29e-06	0.000128	0.17	0.15	Endometriosis;Drug-induced torsades de pointes;	chr18:35870612	chr18:35972151~35973916:+
BRCA	cis	rs8030379	0.667	rs4842921	ENSG00000225151.9	GOLGA2P7	-4.87	1.29e-06	0.000128	-0.16	-0.15	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83887871	chr15:84199311~84230136:-
BRCA	cis	rs919433	0.679	rs13394214	ENSG00000231621.1	AC013264.2	-4.87	1.29e-06	0.000128	-0.14	-0.15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197662647	chr2:197197991~197199273:+
BRCA	cis	rs11098499	0.532	rs12512646	ENSG00000249244.1	RP11-548H18.2	4.87	1.29e-06	0.000128	0.18	0.15	Corneal astigmatism;	chr4:119664578	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.754	rs17049949	ENSG00000260404.2	RP11-384K6.6	4.87	1.29e-06	0.000128	0.14	0.15	Corneal astigmatism;	chr4:119334135	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.754	rs7689729	ENSG00000260404.2	RP11-384K6.6	4.87	1.29e-06	0.000128	0.14	0.15	Corneal astigmatism;	chr4:119335037	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.865	rs3956464	ENSG00000260404.2	RP11-384K6.6	4.87	1.29e-06	0.000128	0.14	0.15	Corneal astigmatism;	chr4:119335609	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.648	rs2002047	ENSG00000260404.2	RP11-384K6.6	4.87	1.29e-06	0.000128	0.14	0.15	Corneal astigmatism;	chr4:119336073	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.775	rs2002049	ENSG00000260404.2	RP11-384K6.6	4.87	1.29e-06	0.000128	0.14	0.15	Corneal astigmatism;	chr4:119336262	chr4:118591773~118633729:+
BRCA	cis	rs6723108	0.591	rs13399952	ENSG00000224043.6	CCNT2-AS1	4.87	1.29e-06	0.000128	0.2	0.15	Type 2 diabetes;	chr2:134636834	chr2:134735464~134918710:-
BRCA	cis	rs17756712	0.57	rs1122256	ENSG00000271911.1	RP11-532F6.5	4.87	1.29e-06	0.000128	0.21	0.15	Vertical cup-disc ratio;	chr6:611969	chr6:761675~780648:+
BRCA	cis	rs6545883	0.894	rs778143	ENSG00000212978.6	AC016747.3	4.87	1.29e-06	0.000128	0.2	0.15	Tuberculosis;	chr2:61354755	chr2:61141592~61144969:-
BRCA	cis	rs9467773	0.62	rs9461276	ENSG00000124549.13	BTN2A3P	4.87	1.29e-06	0.000128	0.15	0.15	Intelligence (multi-trait analysis);	chr6:26594940	chr6:26421391~26432383:+
BRCA	cis	rs375066	0.577	rs12462476	ENSG00000267058.1	RP11-15A1.3	4.87	1.29e-06	0.000128	0.18	0.15	Breast cancer;	chr19:43806368	chr19:43891804~43901805:-
BRCA	cis	rs4711336	0.935	rs3818529	ENSG00000224557.6	HLA-DPB2	-4.87	1.29e-06	0.000128	-0.17	-0.15	Height;	chr6:33693329	chr6:33112451~33129084:+
BRCA	cis	rs11051970	0.559	rs3789975	ENSG00000274964.1	RP11-817I4.1	-4.87	1.29e-06	0.000128	-0.2	-0.15	Response to tocilizumab in rheumatoid arthritis;	chr12:32331469	chr12:32339368~32340724:+
BRCA	cis	rs4865762	0.967	rs10940307	ENSG00000247796.2	CTD-2366F13.1	-4.87	1.29e-06	0.000129	-0.16	-0.15	Intraocular pressure;	chr5:53274450	chr5:53109842~53115126:+
BRCA	cis	rs2832191	0.903	rs11700687	ENSG00000176054.6	RPL23P2	-4.87	1.29e-06	0.000129	-0.16	-0.15	Dental caries;	chr21:29114446	chr21:28997613~28998033:-
BRCA	cis	rs2832191	1	rs2832190	ENSG00000176054.6	RPL23P2	-4.87	1.29e-06	0.000129	-0.16	-0.15	Dental caries;	chr21:29115905	chr21:28997613~28998033:-
BRCA	cis	rs875971	0.545	rs316305	ENSG00000232546.1	RP11-458F8.1	-4.87	1.29e-06	0.000129	-0.14	-0.15	Aortic root size;	chr7:66152984	chr7:66848496~66858136:+
BRCA	cis	rs7487075	0.619	rs7486532	ENSG00000274723.1	RP11-618L22.1	4.87	1.29e-06	0.000129	0.2	0.15	Itch intensity from mosquito bite;	chr12:46449472	chr12:46970504~46972155:+
BRCA	cis	rs10129255	0.784	rs7147210	ENSG00000274576.2	IGHV2-70	4.87	1.29e-06	0.000129	0.14	0.15	Kawasaki disease;	chr14:106705271	chr14:106770577~106771020:-
BRCA	cis	rs721917	0.506	rs7073842	ENSG00000242600.5	MBL1P	4.87	1.29e-06	0.000129	0.18	0.15	Chronic obstructive pulmonary disease;	chr10:79896644	chr10:79904898~79950336:+
BRCA	cis	rs74233809	0.636	rs284851	ENSG00000213277.3	MARCKSL1P1	4.87	1.3e-06	0.000129	0.22	0.15	Birth weight;	chr10:102818774	chr10:103175554~103176094:+
BRCA	cis	rs7226408	0.857	rs72888996	ENSG00000267707.2	RP11-95O2.5	4.87	1.3e-06	0.000129	0.22	0.15	Obesity-related traits;	chr18:37000092	chr18:37243776~37247506:+
BRCA	cis	rs7226408	0.857	rs72888997	ENSG00000267707.2	RP11-95O2.5	4.87	1.3e-06	0.000129	0.22	0.15	Obesity-related traits;	chr18:37000253	chr18:37243776~37247506:+
BRCA	cis	rs7226408	0.857	rs56308574	ENSG00000267707.2	RP11-95O2.5	4.87	1.3e-06	0.000129	0.22	0.15	Obesity-related traits;	chr18:37006330	chr18:37243776~37247506:+
BRCA	cis	rs7226408	0.857	rs72890514	ENSG00000267707.2	RP11-95O2.5	4.87	1.3e-06	0.000129	0.22	0.15	Obesity-related traits;	chr18:37008065	chr18:37243776~37247506:+
BRCA	cis	rs7226408	0.857	rs72890516	ENSG00000267707.2	RP11-95O2.5	4.87	1.3e-06	0.000129	0.22	0.15	Obesity-related traits;	chr18:37011638	chr18:37243776~37247506:+
BRCA	cis	rs7226408	0.857	rs8099124	ENSG00000267707.2	RP11-95O2.5	4.87	1.3e-06	0.000129	0.22	0.15	Obesity-related traits;	chr18:37013713	chr18:37243776~37247506:+
BRCA	cis	rs7226408	0.857	rs8099118	ENSG00000267707.2	RP11-95O2.5	4.87	1.3e-06	0.000129	0.22	0.15	Obesity-related traits;	chr18:37013736	chr18:37243776~37247506:+
BRCA	cis	rs7226408	0.857	rs8084381	ENSG00000267707.2	RP11-95O2.5	4.87	1.3e-06	0.000129	0.22	0.15	Obesity-related traits;	chr18:37017559	chr18:37243776~37247506:+
BRCA	cis	rs7226408	0.857	rs72890545	ENSG00000267707.2	RP11-95O2.5	4.87	1.3e-06	0.000129	0.22	0.15	Obesity-related traits;	chr18:37023329	chr18:37243776~37247506:+
BRCA	cis	rs7226408	0.857	rs55809464	ENSG00000267707.2	RP11-95O2.5	4.87	1.3e-06	0.000129	0.22	0.15	Obesity-related traits;	chr18:37028353	chr18:37243776~37247506:+
BRCA	cis	rs7226408	0.857	rs4344828	ENSG00000267707.2	RP11-95O2.5	4.87	1.3e-06	0.000129	0.22	0.15	Obesity-related traits;	chr18:37033376	chr18:37243776~37247506:+
BRCA	cis	rs7226408	0.857	rs56331183	ENSG00000267707.2	RP11-95O2.5	4.87	1.3e-06	0.000129	0.22	0.15	Obesity-related traits;	chr18:37041950	chr18:37243776~37247506:+
BRCA	cis	rs7226408	0.857	rs55811995	ENSG00000267707.2	RP11-95O2.5	4.87	1.3e-06	0.000129	0.22	0.15	Obesity-related traits;	chr18:37042378	chr18:37243776~37247506:+
BRCA	cis	rs7572733	0.84	rs4286272	ENSG00000231621.1	AC013264.2	4.87	1.3e-06	0.000129	0.14	0.15	Dermatomyositis;	chr2:197670954	chr2:197197991~197199273:+
BRCA	cis	rs6545883	0.783	rs7355640	ENSG00000271889.1	RP11-493E12.1	4.87	1.3e-06	0.000129	0.19	0.15	Tuberculosis;	chr2:61618350	chr2:61151433~61162105:-
BRCA	cis	rs6756513	0.5	rs58206747	ENSG00000231024.1	AC092431.3	-4.87	1.3e-06	0.000129	-0.22	-0.15	Breast cancer;Platelet count;	chr2:69899534	chr2:69700192~69713847:-
BRCA	cis	rs11955398	0.521	rs6449489	ENSG00000215032.2	GNL3LP1	-4.87	1.3e-06	0.000129	-0.18	-0.15	Intelligence (multi-trait analysis);	chr5:60730409	chr5:60891935~60893577:-
BRCA	cis	rs2505998	0.833	rs2505535	ENSG00000273008.1	RP11-351D16.3	-4.87	1.3e-06	0.000129	-0.18	-0.15	Hirschsprung disease;	chr10:43097595	chr10:43136824~43138334:-
BRCA	cis	rs11696739	0.513	rs34600126	ENSG00000242324.1	RP4-576H24.2	4.87	1.3e-06	0.000129	0.21	0.15	Mean platelet volume;	chr20:1616787	chr20:1516759~1557653:-
BRCA	cis	rs2243480	1	rs1499613	ENSG00000222364.1	RNU6-96P	4.87	1.3e-06	0.000129	0.27	0.15	Diabetic kidney disease;	chr7:66265873	chr7:66395191~66395286:+
BRCA	cis	rs8098244	0.603	rs4800507	ENSG00000264745.1	TTC39C-AS1	4.87	1.3e-06	0.000129	0.17	0.15	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23726168	chr18:23994213~24015339:-
BRCA	cis	rs987724	0.515	rs11914959	ENSG00000240875.4	LINC00886	-4.87	1.3e-06	0.000129	-0.24	-0.15	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156898616	chr3:156747346~156817062:-
BRCA	cis	rs987724	0.501	rs4680313	ENSG00000240875.4	LINC00886	-4.87	1.3e-06	0.000129	-0.24	-0.15	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156901348	chr3:156747346~156817062:-
BRCA	cis	rs860295	0.702	rs10796946	ENSG00000160766.13	GBAP1	-4.87	1.3e-06	0.000129	-0.16	-0.15	Body mass index;	chr1:155459699	chr1:155213821~155227422:-
BRCA	cis	rs860295	0.676	rs10908466	ENSG00000160766.13	GBAP1	-4.87	1.3e-06	0.000129	-0.16	-0.15	Body mass index;	chr1:155459934	chr1:155213821~155227422:-
BRCA	cis	rs10510102	0.935	rs12247749	ENSG00000226864.1	ATE1-AS1	4.87	1.3e-06	0.000129	0.27	0.15	Breast cancer;	chr10:121884196	chr10:121928312~121951965:+
BRCA	cis	rs9287719	0.781	rs6714413	ENSG00000243819.4	RN7SL832P	4.87	1.3e-06	0.000129	0.15	0.15	Prostate cancer;	chr2:10618733	chr2:10690344~10692099:+
BRCA	cis	rs9287719	0.753	rs2018512	ENSG00000243819.4	RN7SL832P	4.87	1.3e-06	0.000129	0.15	0.15	Prostate cancer;	chr2:10619153	chr2:10690344~10692099:+
BRCA	cis	rs11742741	0.765	rs6862766	ENSG00000248874.4	C5orf17	-4.87	1.3e-06	0.000129	-0.19	-0.15	Educational attainment;	chr5:24156823	chr5:23951348~24178263:+
BRCA	cis	rs5167	0.677	rs12709889	ENSG00000280087.1	CTB-129P6.7	-4.87	1.3e-06	0.000129	-0.2	-0.15	Blood protein levels;	chr19:44949982	chr19:44909375~44914968:+
BRCA	cis	rs7772486	0.806	rs2253648	ENSG00000270638.1	RP3-466P17.1	4.87	1.3e-06	0.000129	0.17	0.15	Lobe attachment (rater-scored or self-reported);	chr6:145878160	chr6:145735570~145737218:+
BRCA	cis	rs9308731	0.863	rs17558117	ENSG00000230499.1	AC108463.1	-4.87	1.3e-06	0.000129	-0.17	-0.15	Chronic lymphocytic leukemia;	chr2:111183419	chr2:111195963~111206494:+
BRCA	cis	rs7621025	0.617	rs12637102	ENSG00000273486.1	RP11-731C17.2	4.87	1.3e-06	0.000129	0.19	0.15	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136493118	chr3:136837338~136839021:-
BRCA	cis	rs7267979	0.844	rs4423675	ENSG00000277938.1	RP5-965G21.3	-4.87	1.3e-06	0.000129	-0.18	-0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25422142	chr20:25229150~25231933:+
BRCA	cis	rs442309	0.846	rs224127	ENSG00000238280.1	RP11-436D10.3	-4.87	1.3e-06	0.000129	-0.2	-0.15	Vogt-Koyanagi-Harada syndrome;	chr10:62701513	chr10:62793562~62805887:-
BRCA	cis	rs14027	0.64	rs9297604	ENSG00000279347.1	RP11-85I17.2	4.87	1.3e-06	0.000129	0.15	0.15	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119738772	chr8:119838736~119840385:-
BRCA	cis	rs8054556	0.787	rs12935701	ENSG00000261367.1	RP11-455F5.4	-4.87	1.3e-06	0.000129	-0.17	-0.15	Autism spectrum disorder or schizophrenia;	chr16:30015427	chr16:30107675~30110541:+
BRCA	cis	rs919433	0.679	rs55656916	ENSG00000231621.1	AC013264.2	-4.87	1.3e-06	0.000129	-0.14	-0.15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197654904	chr2:197197991~197199273:+
BRCA	cis	rs6071166	0.869	rs6027422	ENSG00000224635.1	RP4-564F22.5	4.87	1.3e-06	0.000129	0.17	0.15	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38703838	chr20:38406011~38416797:-
BRCA	cis	rs875971	1	rs778706	ENSG00000223473.2	GS1-124K5.3	4.87	1.3e-06	0.000129	0.11	0.15	Aortic root size;	chr7:66395437	chr7:66491049~66493566:-
BRCA	cis	rs7927592	0.913	rs7107622	ENSG00000212093.1	AP000807.1	4.87	1.3e-06	0.000129	0.16	0.15	Total body bone mineral density;	chr11:68606715	chr11:68506083~68506166:-
BRCA	cis	rs2243480	1	rs4718315	ENSG00000222364.1	RNU6-96P	4.87	1.3e-06	0.000129	0.27	0.15	Diabetic kidney disease;	chr7:66183554	chr7:66395191~66395286:+
BRCA	cis	rs2243480	1	rs4718316	ENSG00000222364.1	RNU6-96P	4.87	1.3e-06	0.000129	0.27	0.15	Diabetic kidney disease;	chr7:66183744	chr7:66395191~66395286:+
BRCA	cis	rs1122401	0.576	rs766529	ENSG00000280159.1	CTD-2591A1.1	4.87	1.3e-06	0.000129	0.21	0.15	Smoking initiation;	chr5:54577625	chr5:54643557~54645987:+
BRCA	cis	rs6840360	0.642	rs7682770	ENSG00000251611.1	RP11-610P16.1	-4.87	1.31e-06	0.000129	-0.13	-0.15	Intelligence (multi-trait analysis);	chr4:151469261	chr4:151407551~151408835:-
BRCA	cis	rs6840360	0.667	rs9994482	ENSG00000251611.1	RP11-610P16.1	-4.87	1.31e-06	0.000129	-0.13	-0.15	Intelligence (multi-trait analysis);	chr4:151470078	chr4:151407551~151408835:-
BRCA	cis	rs6840360	0.642	rs11729923	ENSG00000251611.1	RP11-610P16.1	-4.87	1.31e-06	0.000129	-0.13	-0.15	Intelligence (multi-trait analysis);	chr4:151470884	chr4:151407551~151408835:-
BRCA	cis	rs6840360	0.642	rs7676059	ENSG00000251611.1	RP11-610P16.1	-4.87	1.31e-06	0.000129	-0.13	-0.15	Intelligence (multi-trait analysis);	chr4:151472115	chr4:151407551~151408835:-
BRCA	cis	rs6840360	0.642	rs7657747	ENSG00000251611.1	RP11-610P16.1	-4.87	1.31e-06	0.000129	-0.13	-0.15	Intelligence (multi-trait analysis);	chr4:151473102	chr4:151407551~151408835:-
BRCA	cis	rs801193	0.569	rs4717315	ENSG00000236529.1	RP13-254B10.1	4.87	1.31e-06	0.000129	0.16	0.15	Aortic root size;	chr7:66713338	chr7:65840212~65840596:+
BRCA	cis	rs6754311	0.517	rs60453613	ENSG00000224043.6	CCNT2-AS1	-4.87	1.31e-06	0.00013	-0.23	-0.15	Mosquito bite size;	chr2:135769550	chr2:134735464~134918710:-
BRCA	cis	rs1552244	0.572	rs3894321	ENSG00000232901.1	CYCSP10	4.87	1.31e-06	0.00013	0.22	0.15	Alzheimer's disease;	chr3:10127208	chr3:10000647~10000940:-
BRCA	cis	rs7976269	0.583	rs2117997	ENSG00000275476.1	RP11-996F15.4	4.87	1.31e-06	0.00013	0.17	0.15	Male-pattern baldness;	chr12:29143428	chr12:29277397~29277882:-
BRCA	cis	rs7267979	0.844	rs4815413	ENSG00000274973.1	RP13-401N8.7	4.87	1.31e-06	0.00013	0.17	0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25378593	chr20:25845497~25845862:+
BRCA	cis	rs7267979	0.844	rs6083824	ENSG00000274973.1	RP13-401N8.7	4.87	1.31e-06	0.00013	0.17	0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25382421	chr20:25845497~25845862:+
BRCA	cis	rs13126694	1	rs13126694	ENSG00000251429.1	RP11-597D13.7	-4.87	1.31e-06	0.00013	-0.14	-0.15	Blood osmolality (transformed sodium);	chr4:158177632	chr4:158270378~158278676:+
BRCA	cis	rs13108904	0.87	rs2279281	ENSG00000253399.1	AC078852.2	-4.87	1.31e-06	0.00013	-0.16	-0.15	Obesity-related traits;	chr4:1251489	chr4:1358479~1359461:+
BRCA	cis	rs2280018	0.963	rs12928424	ENSG00000188599.16	NPIPP1	-4.87	1.31e-06	0.00013	-0.12	-0.15	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15056916	chr16:15104312~15123498:-
BRCA	cis	rs875971	1	rs12698523	ENSG00000223473.2	GS1-124K5.3	4.87	1.31e-06	0.00013	0.11	0.15	Aortic root size;	chr7:66503126	chr7:66491049~66493566:-
BRCA	cis	rs8180040	0.62	rs6442055	ENSG00000276925.1	RP11-708J19.3	-4.87	1.31e-06	0.00013	-0.17	-0.15	Colorectal cancer;	chr3:47069232	chr3:47469777~47469987:+
BRCA	cis	rs1832007	0.529	rs17306779	ENSG00000224034.1	RP11-445P17.8	4.87	1.31e-06	0.00013	0.24	0.15	Triglyceride levels;Triglycerides;	chr10:5200201	chr10:5266033~5271236:-
BRCA	cis	rs539096	0.831	rs10789436	ENSG00000236200.4	KDM4A-AS1	-4.87	1.31e-06	0.00013	-0.2	-0.15	Intelligence (multi-trait analysis);	chr1:43575295	chr1:43699765~43708138:-
BRCA	cis	rs7141336	0.965	rs12884258	ENSG00000258884.1	CTD-3035D6.2	4.87	1.31e-06	0.00013	0.19	0.15	Anxiety disorder;	chr14:90817368	chr14:90822365~90828128:-
BRCA	cis	rs2905347	0.895	rs2961282	ENSG00000179428.2	AC073072.5	4.87	1.31e-06	0.00013	0.16	0.15	Major depression and alcohol dependence;	chr7:22600770	chr7:22725395~22727620:-
BRCA	cis	rs9467773	0.549	rs9461273	ENSG00000241549.7	GUSBP2	-4.87	1.31e-06	0.00013	-0.16	-0.15	Intelligence (multi-trait analysis);	chr6:26584298	chr6:26871484~26956554:-
BRCA	cis	rs1729951	0.575	rs10935213	ENSG00000239213.4	NCK1-AS1	4.87	1.31e-06	0.00013	0.15	0.15	Neuroticism;	chr3:136974617	chr3:136841726~136862054:-
BRCA	cis	rs9467773	0.62	rs1027203	ENSG00000124549.13	BTN2A3P	4.87	1.31e-06	0.00013	0.15	0.15	Intelligence (multi-trait analysis);	chr6:26639104	chr6:26421391~26432383:+
BRCA	cis	rs9467773	0.595	rs2172007	ENSG00000124549.13	BTN2A3P	4.87	1.31e-06	0.00013	0.15	0.15	Intelligence (multi-trait analysis);	chr6:26639549	chr6:26421391~26432383:+
BRCA	cis	rs924712	0.545	rs9464148	ENSG00000261116.1	RP3-523K23.2	4.87	1.31e-06	0.00013	0.17	0.15	Breast cancer;	chr6:54840286	chr6:54943167~54945099:+
BRCA	cis	rs755249	0.588	rs2275767	ENSG00000182109.6	RP11-69E11.4	-4.87	1.31e-06	0.00013	-0.17	-0.15	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39479625	chr1:39522280~39546187:-
BRCA	cis	rs4718428	0.672	rs36038499	ENSG00000229180.5	GS1-124K5.11	4.87	1.31e-06	0.00013	0.14	0.15	Corneal structure;	chr7:66824628	chr7:66526088~66542624:-
BRCA	cis	rs6921919	0.609	rs67211468	ENSG00000220721.1	OR1F12	4.87	1.31e-06	0.00013	0.18	0.15	Autism spectrum disorder or schizophrenia;	chr6:28424210	chr6:28073316~28074233:+
BRCA	cis	rs600231	0.708	rs602838	ENSG00000173727.10	CMB9-22P13.1	4.87	1.31e-06	0.00013	0.19	0.15	Bone mineral density;	chr11:65485776	chr11:65455258~65466720:+
BRCA	cis	rs73193808	0.901	rs2065274	ENSG00000236056.1	GAPDHP14	-4.87	1.31e-06	0.00013	-0.21	-0.15	Coronary artery disease;	chr21:29197521	chr21:29222321~29223257:+
BRCA	cis	rs2880765	0.545	rs17553734	ENSG00000230373.7	GOLGA6L5P	-4.87	1.31e-06	0.00013	-0.17	-0.15	Coronary artery disease;	chr15:85469828	chr15:84507885~84516814:-
BRCA	cis	rs7267979	0.844	rs6050477	ENSG00000277938.1	RP5-965G21.3	-4.87	1.31e-06	0.00013	-0.18	-0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25240911	chr20:25229150~25231933:+
BRCA	cis	rs11672691	0.67	rs758643	ENSG00000270164.1	LINC01480	4.87	1.31e-06	0.00013	0.18	0.15	Prostate cancer;	chr19:41485616	chr19:41535183~41536904:+
BRCA	cis	rs6714710	0.603	rs1875699	ENSG00000230606.9	AC159540.1	-4.87	1.31e-06	0.00013	-0.17	-0.15	Posterior cortical atrophy and Alzheimer's disease;	chr2:97964261	chr2:97416165~97433527:-
BRCA	cis	rs1223397	0.651	rs2496146	ENSG00000215022.6	RP1-257A7.4	-4.87	1.31e-06	0.00013	-0.18	-0.15	Blood pressure;	chr6:13312242	chr6:13264861~13295586:-
BRCA	cis	rs6430585	0.591	rs3098103	ENSG00000231890.6	DARS-AS1	-4.87	1.31e-06	0.00013	-0.24	-0.15	Corneal structure;	chr2:135898524	chr2:135985176~136022593:+
BRCA	cis	rs6921919	0.583	rs3800328	ENSG00000220721.1	OR1F12	4.87	1.31e-06	0.00013	0.18	0.15	Autism spectrum disorder or schizophrenia;	chr6:28423066	chr6:28073316~28074233:+
BRCA	cis	rs7226408	0.857	rs72890574	ENSG00000267707.2	RP11-95O2.5	4.87	1.31e-06	0.00013	0.23	0.15	Obesity-related traits;	chr18:37043516	chr18:37243776~37247506:+
BRCA	cis	rs7226408	0.857	rs17567920	ENSG00000267707.2	RP11-95O2.5	4.87	1.31e-06	0.00013	0.23	0.15	Obesity-related traits;	chr18:37045850	chr18:37243776~37247506:+
BRCA	cis	rs853679	0.55	rs9295762	ENSG00000216901.1	AL022393.7	-4.87	1.31e-06	0.00013	-0.2	-0.15	Depression;	chr6:28187640	chr6:28176188~28176674:+
BRCA	cis	rs7726839	0.555	rs4541696	ENSG00000271781.1	CTD-2589H19.6	-4.87	1.31e-06	0.00013	-0.17	-0.15	Obesity-related traits;	chr5:580938	chr5:675826~676616:+
BRCA	cis	rs7674212	0.539	rs6854709	ENSG00000251288.2	RP11-10L12.2	-4.87	1.32e-06	0.00013	-0.17	-0.15	Type 2 diabetes;	chr4:103208629	chr4:102751401~102752641:+
BRCA	cis	rs6832769	1	rs473005	ENSG00000223305.1	RN7SKP30	4.87	1.32e-06	0.00013	0.18	0.15	Personality dimensions;	chr4:55421958	chr4:55540502~55540835:-
BRCA	cis	rs8031584	0.958	rs61997079	ENSG00000259845.1	HERC2P10	4.87	1.32e-06	0.00013	0.18	0.15	Huntington's disease progression;	chr15:30946068	chr15:30815271~30844153:+
BRCA	cis	rs8031584	0.958	rs11637469	ENSG00000259845.1	HERC2P10	4.87	1.32e-06	0.00013	0.18	0.15	Huntington's disease progression;	chr15:30946580	chr15:30815271~30844153:+
BRCA	cis	rs6088590	0.561	rs6088527	ENSG00000276073.1	RP5-1125A11.7	-4.87	1.32e-06	0.00013	-0.16	-0.15	Coronary artery disease;	chr20:34568037	chr20:33985617~33988989:-
BRCA	cis	rs1729951	0.575	rs1682357	ENSG00000239213.4	NCK1-AS1	4.87	1.32e-06	0.000131	0.15	0.15	Neuroticism;	chr3:136973167	chr3:136841726~136862054:-
BRCA	cis	rs1729951	0.575	rs1654923	ENSG00000239213.4	NCK1-AS1	4.87	1.32e-06	0.000131	0.15	0.15	Neuroticism;	chr3:136973778	chr3:136841726~136862054:-
BRCA	cis	rs1729951	0.575	rs10935214	ENSG00000239213.4	NCK1-AS1	4.87	1.32e-06	0.000131	0.15	0.15	Neuroticism;	chr3:136974643	chr3:136841726~136862054:-
BRCA	cis	rs1729951	0.545	rs1097288	ENSG00000239213.4	NCK1-AS1	4.87	1.32e-06	0.000131	0.15	0.15	Neuroticism;	chr3:136974879	chr3:136841726~136862054:-
BRCA	cis	rs801193	0.548	rs2659891	ENSG00000236529.1	RP13-254B10.1	4.87	1.32e-06	0.000131	0.16	0.15	Aortic root size;	chr7:66736127	chr7:65840212~65840596:+
BRCA	cis	rs801193	0.548	rs7805152	ENSG00000236529.1	RP13-254B10.1	4.87	1.32e-06	0.000131	0.16	0.15	Aortic root size;	chr7:66744266	chr7:65840212~65840596:+
BRCA	cis	rs9638182	0.56	rs66506038	ENSG00000274080.1	CTA-315H11.2	4.87	1.32e-06	0.000131	0.21	0.15	Triglycerides;	chr7:73581613	chr7:73609262~73611502:-
BRCA	cis	rs9638182	0.56	rs67644909	ENSG00000274080.1	CTA-315H11.2	4.87	1.32e-06	0.000131	0.21	0.15	Triglycerides;	chr7:73581624	chr7:73609262~73611502:-
BRCA	cis	rs2562456	0.917	rs2650805	ENSG00000268535.1	RP11-420K14.3	-4.87	1.32e-06	0.000131	-0.21	-0.15	Pain;	chr19:21505137	chr19:21709522~21710191:+
BRCA	cis	rs4415084	1	rs2218081	ENSG00000251141.4	RP11-53O19.1	4.87	1.32e-06	0.000131	0.14	0.15	Breast cancer;	chr5:44705038	chr5:44744900~44808777:-
BRCA	cis	rs12030196	0.743	rs71646019	ENSG00000230812.4	LINC01358	4.87	1.32e-06	0.000131	0.16	0.15	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr1:58967682	chr1:59020387~59044614:+
BRCA	cis	rs2243480	1	rs316327	ENSG00000275400.1	RP4-756H11.5	-4.87	1.32e-06	0.000131	-0.26	-0.15	Diabetic kidney disease;	chr7:66144214	chr7:66553805~66554199:-
BRCA	cis	rs10911251	0.546	rs2027081	ENSG00000224468.3	RP11-181K3.4	-4.87	1.32e-06	0.000131	-0.16	-0.15	Colorectal cancer;	chr1:183105441	chr1:183138402~183141282:-
BRCA	cis	rs3768617	0.51	rs3768629	ENSG00000224468.3	RP11-181K3.4	-4.87	1.32e-06	0.000131	-0.16	-0.15	Fuchs's corneal dystrophy;	chr1:183105447	chr1:183138402~183141282:-
BRCA	cis	rs7246657	1	rs7246657	ENSG00000267422.1	CTD-2554C21.1	4.87	1.32e-06	0.000131	0.22	0.15	Coronary artery calcification;	chr19:37256206	chr19:37779686~37792865:+
BRCA	cis	rs2505998	0.833	rs1800858	ENSG00000273008.1	RP11-351D16.3	-4.87	1.32e-06	0.000131	-0.18	-0.15	Hirschsprung disease;	chr10:43100520	chr10:43136824~43138334:-
BRCA	cis	rs9840812	0.769	rs3755636	ENSG00000273486.1	RP11-731C17.2	4.87	1.32e-06	0.000131	0.18	0.15	Fibrinogen levels;	chr3:136249986	chr3:136837338~136839021:-
BRCA	cis	rs11955398	0.585	rs1117674	ENSG00000215032.2	GNL3LP1	-4.87	1.32e-06	0.000131	-0.18	-0.15	Intelligence (multi-trait analysis);	chr5:60739180	chr5:60891935~60893577:-
BRCA	cis	rs2833693	0.572	rs2833715	ENSG00000261610.1	AP000265.1	4.87	1.32e-06	0.000131	0.18	0.15	Temperament;	chr21:32192268	chr21:32259804~32261585:-
BRCA	cis	rs919433	0.647	rs1979239	ENSG00000231621.1	AC013264.2	-4.87	1.32e-06	0.000131	-0.14	-0.15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197633592	chr2:197197991~197199273:+
BRCA	cis	rs1656368	0.726	rs73154331	ENSG00000279311.1	RP11-170K4.2	4.87	1.32e-06	0.000131	0.19	0.15	Lobe attachment (rater-scored or self-reported);	chr3:158540873	chr3:158869898~158871821:+
BRCA	cis	rs6442522	0.526	rs2168428	ENSG00000249786.6	EAF1-AS1	4.87	1.32e-06	0.000131	0.15	0.15	Uric acid levels;	chr3:15487797	chr3:15436171~15455940:-
BRCA	cis	rs78487399	0.808	rs75386849	ENSG00000234936.1	AC010883.5	4.87	1.32e-06	0.000131	0.26	0.15	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43496144	chr2:43229573~43233394:+
BRCA	cis	rs2638953	0.672	rs11609619	ENSG00000247934.4	RP11-967K21.1	-4.87	1.32e-06	0.000131	-0.21	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28557876	chr12:28163298~28190738:-
BRCA	cis	rs7829975	0.56	rs17154599	ENSG00000233609.3	RP11-62H7.2	-4.87	1.32e-06	0.000131	-0.14	-0.15	Mood instability;	chr8:8693908	chr8:8961200~8979025:+
BRCA	cis	rs1075265	0.547	rs6743627	ENSG00000235937.1	AC008280.1	-4.87	1.32e-06	0.000131	-0.17	-0.15	Chronotype;Morning vs. evening chronotype;	chr2:53687024	chr2:54029552~54030682:-
BRCA	cis	rs6840360	0.642	rs4696092	ENSG00000251611.1	RP11-610P16.1	-4.87	1.32e-06	0.000131	-0.13	-0.15	Intelligence (multi-trait analysis);	chr4:151491451	chr4:151407551~151408835:-
BRCA	cis	rs66887589	0.967	rs13104219	ENSG00000245958.5	RP11-33B1.1	-4.87	1.32e-06	0.000131	-0.13	-0.15	Diastolic blood pressure;	chr4:119517019	chr4:119454791~119552025:+
BRCA	cis	rs1387259	0.899	rs7307566	ENSG00000257735.1	RP11-370I10.6	4.86	1.32e-06	0.000131	0.19	0.15	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48210899	chr12:48350945~48442411:+
BRCA	cis	rs11098499	0.754	rs10212714	ENSG00000249244.1	RP11-548H18.2	4.86	1.32e-06	0.000131	0.17	0.15	Corneal astigmatism;	chr4:119333147	chr4:119391831~119395335:-
BRCA	cis	rs1707322	1	rs6429588	ENSG00000234329.1	RP11-767N6.2	4.86	1.32e-06	0.000131	0.15	0.15	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45988386	chr1:45651039~45651826:-
BRCA	cis	rs2708977	0.901	rs3731938	ENSG00000237510.6	AC008268.2	-4.86	1.32e-06	0.000131	-0.19	-0.15	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96500467	chr2:95789654~95800166:+
BRCA	cis	rs2562456	0.52	rs279793	ENSG00000268535.1	RP11-420K14.3	4.86	1.32e-06	0.000131	0.23	0.15	Pain;	chr19:21272972	chr19:21709522~21710191:+
BRCA	cis	rs792448	0.798	rs7521853	ENSG00000226251.4	RP11-15I11.3	-4.86	1.32e-06	0.000131	-0.19	-0.15	White blood cell count (basophil);	chr1:212330862	chr1:212225278~212238977:-
BRCA	cis	rs7200543	1	rs16966953	ENSG00000260735.1	RP11-72I8.1	-4.86	1.32e-06	0.000131	-0.17	-0.15	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15041997	chr16:15094411~15109197:+
BRCA	cis	rs4908760	0.827	rs11121210	ENSG00000232912.4	RP5-1115A15.1	4.86	1.32e-06	0.000131	0.14	0.15	Vitiligo;	chr1:8648470	chr1:8424645~8434838:+
BRCA	cis	rs6088580	0.713	rs1884669	ENSG00000276073.1	RP5-1125A11.7	-4.86	1.32e-06	0.000131	-0.16	-0.15	Glomerular filtration rate (creatinine);	chr20:34583483	chr20:33985617~33988989:-
BRCA	cis	rs9907295	0.688	rs28722787	ENSG00000271013.1	AC015849.15	-4.86	1.32e-06	0.000131	-0.19	-0.15	Fibroblast growth factor basic levels;	chr17:35922795	chr17:35912635~35918010:-
BRCA	cis	rs860295	1	rs822490	ENSG00000225082.2	DAP3P1	-4.86	1.32e-06	0.000131	-0.18	-0.15	Body mass index;	chr1:155853180	chr1:155586644~155602197:+
BRCA	cis	rs8031584	0.541	rs2959037	ENSG00000259845.1	HERC2P10	-4.86	1.33e-06	0.000131	-0.17	-0.15	Huntington's disease progression;	chr15:30925961	chr15:30815271~30844153:+
BRCA	cis	rs7487075	0.55	rs1472179	ENSG00000274723.1	RP11-618L22.1	4.86	1.33e-06	0.000131	0.2	0.15	Itch intensity from mosquito bite;	chr12:46416731	chr12:46970504~46972155:+
BRCA	cis	rs67311347	1	rs73080138	ENSG00000280739.1	EIF1B-AS1	4.86	1.33e-06	0.000131	0.17	0.15	Renal cell carcinoma;	chr3:40474926	chr3:40173145~40309698:-
BRCA	cis	rs12477438	0.52	rs720229	ENSG00000231822.1	AC019097.7	4.86	1.33e-06	0.000131	0.15	0.15	Chronic sinus infection;	chr2:99087810	chr2:99102018~99102752:+
BRCA	cis	rs4267450	0.793	rs73017620	ENSG00000261770.1	CTC-459F4.1	4.86	1.33e-06	0.000131	0.28	0.15	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);	chr19:28320420	chr19:27757184~27760849:-
BRCA	cis	rs5758659	0.679	rs134870	ENSG00000273366.1	CTA-989H11.1	-4.86	1.33e-06	0.000131	-0.17	-0.15	Cognitive function;	chr22:42256311	chr22:42278188~42278846:+
BRCA	cis	rs7918232	0.8	rs7907981	ENSG00000262412.1	RP11-85G18.6	4.86	1.33e-06	0.000132	0.21	0.15	Breast cancer;	chr10:27155400	chr10:27243130~27250804:+
BRCA	cis	rs62025270	0.688	rs17576534	ENSG00000259295.5	CSPG4P12	-4.86	1.33e-06	0.000132	-0.24	-0.15	Idiopathic pulmonary fibrosis;	chr15:85742509	chr15:85191438~85213905:+
BRCA	cis	rs9377188	0.778	rs1934224	ENSG00000236591.1	RP11-162J8.3	-4.86	1.33e-06	0.000132	-0.19	-0.15	Cancer;	chr6:148995642	chr6:149027700~149032573:-
BRCA	cis	rs4713118	0.911	rs9461406	ENSG00000216901.1	AL022393.7	-4.86	1.33e-06	0.000132	-0.21	-0.15	Parkinson's disease;	chr6:27751985	chr6:28176188~28176674:+
BRCA	cis	rs739496	0.579	rs12296574	ENSG00000226469.1	ADAM1B	4.86	1.33e-06	0.000132	0.19	0.15	Platelet count;	chr12:111884973	chr12:111927018~111929017:+
BRCA	cis	rs7226408	0.948	rs17652351	ENSG00000267707.2	RP11-95O2.5	4.86	1.33e-06	0.000132	0.23	0.15	Obesity-related traits;	chr18:36813709	chr18:37243776~37247506:+
BRCA	cis	rs2919009	0.62	rs17501806	ENSG00000271670.1	RP11-95I16.4	4.86	1.33e-06	0.000132	0.19	0.15	Obesity-related traits;	chr10:120868905	chr10:120879256~120880667:-
BRCA	cis	rs4664293	0.867	rs1427329	ENSG00000224152.1	AC009506.1	-4.86	1.33e-06	0.000132	-0.17	-0.15	Monocyte percentage of white cells;	chr2:159748301	chr2:159615296~159617082:+
BRCA	cis	rs911555	0.511	rs8007489	ENSG00000244691.1	RPL10AP1	4.86	1.33e-06	0.000132	0.18	0.15	Intelligence (multi-trait analysis);	chr14:103588235	chr14:103412119~103412761:-
BRCA	cis	rs7267979	0.789	rs1983974	ENSG00000125804.12	FAM182A	4.86	1.33e-06	0.000132	0.19	0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25549983	chr20:26054655~26086917:+
BRCA	cis	rs7246657	0.722	rs968073	ENSG00000226686.6	LINC01535	4.86	1.33e-06	0.000132	0.22	0.15	Coronary artery calcification;	chr19:37701120	chr19:37251912~37265535:+
BRCA	cis	rs11098499	0.754	rs2036857	ENSG00000249244.1	RP11-548H18.2	4.86	1.33e-06	0.000132	0.17	0.15	Corneal astigmatism;	chr4:119328085	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.754	rs2036856	ENSG00000249244.1	RP11-548H18.2	4.86	1.33e-06	0.000132	0.17	0.15	Corneal astigmatism;	chr4:119328133	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.754	rs4443261	ENSG00000249244.1	RP11-548H18.2	4.86	1.33e-06	0.000132	0.17	0.15	Corneal astigmatism;	chr4:119328146	chr4:119391831~119395335:-
BRCA	cis	rs4664293	0.867	rs2059698	ENSG00000226266.5	AC009961.3	4.86	1.33e-06	0.000132	0.19	0.15	Monocyte percentage of white cells;	chr2:159785905	chr2:159670708~159712435:-
BRCA	cis	rs6452524	0.618	rs7722924	ENSG00000281327.1	LINC01338	4.86	1.33e-06	0.000132	0.17	0.15	Hypertension (SNP x SNP interaction);	chr5:83060223	chr5:82850864~82859836:-
BRCA	cis	rs2273156	0.706	rs35030792	ENSG00000226677.3	IGBP1P1	-4.86	1.33e-06	0.000132	-0.24	-0.15	Immunoglobulin light chain (AL) amyloidosis;	chr14:35019917	chr14:34939324~34940332:+
BRCA	cis	rs919433	0.679	rs10497806	ENSG00000231621.1	AC013264.2	-4.86	1.33e-06	0.000132	-0.14	-0.15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197644227	chr2:197197991~197199273:+
BRCA	cis	rs919433	0.679	rs10166328	ENSG00000231621.1	AC013264.2	-4.86	1.33e-06	0.000132	-0.14	-0.15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197647193	chr2:197197991~197199273:+
BRCA	cis	rs3781264	0.617	rs34818536	ENSG00000273450.1	RP11-76P2.4	4.86	1.33e-06	0.000132	0.24	0.15	Esophageal cancer and gastric cancer;	chr10:94283136	chr10:94314907~94315327:-
BRCA	cis	rs71636778	0.509	rs17162311	ENSG00000260063.1	RP5-968P14.2	4.86	1.33e-06	0.000132	0.31	0.15	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26848475	chr1:26692132~26694131:-
BRCA	cis	rs13113518	1	rs11133388	ENSG00000249700.7	SRD5A3-AS1	-4.86	1.33e-06	0.000132	-0.19	-0.15	Height;	chr4:55477866	chr4:55363971~55395847:-
BRCA	cis	rs62025270	0.688	rs79083718	ENSG00000259295.5	CSPG4P12	-4.86	1.33e-06	0.000132	-0.24	-0.15	Idiopathic pulmonary fibrosis;	chr15:85720298	chr15:85191438~85213905:+
BRCA	cis	rs2562456	0.793	rs2650819	ENSG00000268658.4	LINC00664	-4.86	1.33e-06	0.000132	-0.23	-0.15	Pain;	chr19:21456071	chr19:21483374~21503238:+
BRCA	cis	rs12554020	1	rs4552973	ENSG00000227603.1	RP11-165J3.6	4.86	1.33e-06	0.000132	0.2	0.15	Schizophrenia;	chr9:93539437	chr9:93435332~93437121:-
BRCA	cis	rs9467773	0.62	rs2504599	ENSG00000124549.13	BTN2A3P	4.86	1.33e-06	0.000132	0.15	0.15	Intelligence (multi-trait analysis);	chr6:26640832	chr6:26421391~26432383:+
BRCA	cis	rs7267979	0.844	rs6076343	ENSG00000277938.1	RP5-965G21.3	-4.86	1.34e-06	0.000132	-0.18	-0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25396027	chr20:25229150~25231933:+
BRCA	cis	rs7772486	0.754	rs1415747	ENSG00000270638.1	RP3-466P17.1	4.86	1.34e-06	0.000132	0.17	0.15	Lobe attachment (rater-scored or self-reported);	chr6:145756113	chr6:145735570~145737218:+
BRCA	cis	rs3764021	0.87	rs7976584	ENSG00000278635.1	CTD-2318O12.1	-4.86	1.34e-06	0.000132	-0.15	-0.15	Type 1 diabetes;	chr12:9726059	chr12:9415641~9416718:+
BRCA	cis	rs14027	0.512	rs6469841	ENSG00000279347.1	RP11-85I17.2	-4.86	1.34e-06	0.000132	-0.14	-0.15	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119721889	chr8:119838736~119840385:-
BRCA	cis	rs7267979	0.844	rs35735333	ENSG00000274973.1	RP13-401N8.7	4.86	1.34e-06	0.000132	0.17	0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25356569	chr20:25845497~25845862:+
BRCA	cis	rs4835473	0.897	rs4423826	ENSG00000249741.2	RP11-673E1.3	-4.86	1.34e-06	0.000132	-0.16	-0.15	Immature fraction of reticulocytes;	chr4:143992165	chr4:143911514~143912053:-
BRCA	cis	rs9650657	0.74	rs7002282	ENSG00000255046.1	RP11-297N6.4	4.86	1.34e-06	0.000132	0.17	0.15	Neuroticism;	chr8:10809483	chr8:11797928~11802568:-
BRCA	cis	rs4664293	0.836	rs4665118	ENSG00000224152.1	AC009506.1	-4.86	1.34e-06	0.000132	-0.17	-0.15	Monocyte percentage of white cells;	chr2:159802938	chr2:159615296~159617082:+
BRCA	cis	rs7267979	1	rs2482943	ENSG00000125804.12	FAM182A	4.86	1.34e-06	0.000132	0.2	0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25399957	chr20:26054655~26086917:+
BRCA	cis	rs17027633	1	rs79696376	ENSG00000260948.1	RP11-552M11.8	-4.86	1.34e-06	0.000132	-0.28	-0.15	Cerebrospinal fluid t-tau:AB1-42 ratio;	chr1:111405708	chr1:111431046~111433068:-
BRCA	cis	rs17027633	1	rs76747944	ENSG00000260948.1	RP11-552M11.8	-4.86	1.34e-06	0.000132	-0.28	-0.15	Cerebrospinal fluid t-tau:AB1-42 ratio;	chr1:111405727	chr1:111431046~111433068:-
BRCA	cis	rs12497850	0.931	rs12493289	ENSG00000225399.4	RP11-3B7.1	4.86	1.34e-06	0.000132	0.14	0.15	Parkinson's disease;	chr3:48867728	chr3:49260085~49261316:+
BRCA	cis	rs4388249	0.687	rs3797689	ENSG00000271849.1	CTC-332L22.1	-4.86	1.34e-06	0.000133	-0.19	-0.15	Schizophrenia;	chr5:109764814	chr5:109687802~109688329:-
BRCA	cis	rs11955398	0.585	rs6887434	ENSG00000215032.2	GNL3LP1	-4.86	1.34e-06	0.000133	-0.18	-0.15	Intelligence (multi-trait analysis);	chr5:60739593	chr5:60891935~60893577:-
BRCA	cis	rs9863	0.828	rs12833624	ENSG00000270028.1	RP11-380L11.4	4.86	1.34e-06	0.000133	0.18	0.15	White blood cell count;	chr12:123992326	chr12:123925461~123926083:-
BRCA	cis	rs875971	0.862	rs11763189	ENSG00000273448.1	RP11-166O4.6	4.86	1.34e-06	0.000133	0.14	0.15	Aortic root size;	chr7:66518542	chr7:67333047~67334383:+
BRCA	cis	rs7111546	0.625	rs74557384	ENSG00000246225.5	RP11-17A1.3	4.86	1.34e-06	0.000133	0.25	0.15	Dialysis-related mortality;	chr11:22885834	chr11:22829380~22945393:+
BRCA	cis	rs6439153	0.839	rs2624901	ENSG00000261159.1	RP11-723O4.9	-4.86	1.34e-06	0.000133	-0.15	-0.15	Pneumococcal bacteremia;	chr3:128958345	chr3:128859716~128860526:-
BRCA	cis	rs6723226	0.806	rs6543658	ENSG00000276334.1	AL133243.1	4.86	1.34e-06	0.000133	0.19	0.15	Intelligence (multi-trait analysis);	chr2:32493782	chr2:32521927~32523547:+
BRCA	cis	rs6840360	0.642	rs2709817	ENSG00000251611.1	RP11-610P16.1	-4.86	1.34e-06	0.000133	-0.13	-0.15	Intelligence (multi-trait analysis);	chr4:151460898	chr4:151407551~151408835:-
BRCA	cis	rs6840360	0.642	rs2709818	ENSG00000251611.1	RP11-610P16.1	-4.86	1.34e-06	0.000133	-0.13	-0.15	Intelligence (multi-trait analysis);	chr4:151461482	chr4:151407551~151408835:-
BRCA	cis	rs7111546	0.618	rs79784202	ENSG00000246225.5	RP11-17A1.3	4.86	1.34e-06	0.000133	0.25	0.15	Dialysis-related mortality;	chr11:22877965	chr11:22829380~22945393:+
BRCA	cis	rs10938353	0.731	rs17600732	ENSG00000273369.1	RP11-700J17.1	-4.86	1.34e-06	0.000133	-0.19	-0.15	Body mass index;	chr4:44619710	chr4:44693946~44694386:-
BRCA	cis	rs7621025	0.586	rs34553037	ENSG00000273486.1	RP11-731C17.2	-4.86	1.34e-06	0.000133	-0.2	-0.15	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136660571	chr3:136837338~136839021:-
BRCA	cis	rs2834288	0.7	rs11088263	ENSG00000273102.1	AP000569.9	-4.86	1.34e-06	0.000133	-0.18	-0.15	Gut microbiota (bacterial taxa);	chr21:33918486	chr21:33967101~33968573:-
BRCA	cis	rs6496044	1	rs6496044	ENSG00000259295.5	CSPG4P12	4.86	1.34e-06	0.000133	0.18	0.15	Interstitial lung disease;	chr15:85524075	chr15:85191438~85213905:+
BRCA	cis	rs2239547	0.618	rs4687658	ENSG00000242142.1	SERBP1P3	4.86	1.34e-06	0.000133	0.19	0.15	Schizophrenia;	chr3:52826350	chr3:53064283~53065091:-
BRCA	cis	rs2239547	0.657	rs2276817	ENSG00000242142.1	SERBP1P3	4.86	1.34e-06	0.000133	0.19	0.15	Schizophrenia;	chr3:52826920	chr3:53064283~53065091:-
BRCA	cis	rs2239547	0.657	rs13072536	ENSG00000242142.1	SERBP1P3	4.86	1.34e-06	0.000133	0.19	0.15	Schizophrenia;	chr3:52827195	chr3:53064283~53065091:-
BRCA	cis	rs2239547	0.657	rs12488303	ENSG00000242142.1	SERBP1P3	4.86	1.34e-06	0.000133	0.19	0.15	Schizophrenia;	chr3:52827987	chr3:53064283~53065091:-
BRCA	cis	rs2239547	0.657	rs2072391	ENSG00000242142.1	SERBP1P3	4.86	1.34e-06	0.000133	0.19	0.15	Schizophrenia;	chr3:52828184	chr3:53064283~53065091:-
BRCA	cis	rs875971	0.789	rs7808013	ENSG00000236529.1	RP13-254B10.1	-4.86	1.34e-06	0.000133	-0.17	-0.15	Aortic root size;	chr7:66606209	chr7:65840212~65840596:+
BRCA	cis	rs9287719	0.781	rs6714795	ENSG00000243819.4	RN7SL832P	4.86	1.34e-06	0.000133	0.15	0.15	Prostate cancer;	chr2:10619008	chr2:10690344~10692099:+
BRCA	cis	rs2832191	0.791	rs7283853	ENSG00000176054.6	RPL23P2	-4.86	1.34e-06	0.000133	-0.16	-0.15	Dental caries;	chr21:29126194	chr21:28997613~28998033:-
BRCA	cis	rs9467773	0.62	rs2494700	ENSG00000124549.13	BTN2A3P	4.86	1.34e-06	0.000133	0.15	0.15	Intelligence (multi-trait analysis);	chr6:26631078	chr6:26421391~26432383:+
BRCA	cis	rs9467773	0.584	rs1021372	ENSG00000124549.13	BTN2A3P	4.86	1.34e-06	0.000133	0.15	0.15	Intelligence (multi-trait analysis);	chr6:26632216	chr6:26421391~26432383:+
BRCA	cis	rs9467773	0.583	rs1021373	ENSG00000124549.13	BTN2A3P	4.86	1.34e-06	0.000133	0.15	0.15	Intelligence (multi-trait analysis);	chr6:26632229	chr6:26421391~26432383:+
BRCA	cis	rs9467773	0.62	rs2451744	ENSG00000124549.13	BTN2A3P	4.86	1.34e-06	0.000133	0.15	0.15	Intelligence (multi-trait analysis);	chr6:26633235	chr6:26421391~26432383:+
BRCA	cis	rs9467773	0.62	rs2494701	ENSG00000124549.13	BTN2A3P	4.86	1.34e-06	0.000133	0.15	0.15	Intelligence (multi-trait analysis);	chr6:26634204	chr6:26421391~26432383:+
BRCA	cis	rs9467773	0.62	rs1027204	ENSG00000124549.13	BTN2A3P	4.86	1.34e-06	0.000133	0.15	0.15	Intelligence (multi-trait analysis);	chr6:26639385	chr6:26421391~26432383:+
BRCA	cis	rs11758351	0.587	rs10484436	ENSG00000241549.7	GUSBP2	-4.86	1.34e-06	0.000133	-0.22	-0.15	Renal underexcretion gout;Gout;	chr6:26236927	chr6:26871484~26956554:-
BRCA	cis	rs10191773	0.589	rs72831641	ENSG00000243389.1	AC012442.5	4.86	1.34e-06	0.000133	0.29	0.15	Yeast infection;	chr2:112198238	chr2:112589040~112614431:+
BRCA	cis	rs651907	0.64	rs771575	ENSG00000244119.1	PDCL3P4	4.86	1.35e-06	0.000133	0.12	0.15	Colorectal cancer;	chr3:101900515	chr3:101712472~101713191:+
BRCA	cis	rs2279168	1	rs16940964	ENSG00000259407.1	RP11-158M2.3	4.86	1.35e-06	0.000133	0.24	0.15	Response to platinum-based chemotherapy (carboplatin);	chr15:85527566	chr15:85744109~85750281:-
BRCA	cis	rs853679	0.55	rs6901017	ENSG00000216901.1	AL022393.7	4.86	1.35e-06	0.000133	0.21	0.15	Depression;	chr6:28184805	chr6:28176188~28176674:+
BRCA	cis	rs6570726	0.791	rs4335004	ENSG00000270638.1	RP3-466P17.1	4.86	1.35e-06	0.000133	0.17	0.15	Lobe attachment (rater-scored or self-reported);	chr6:145583628	chr6:145735570~145737218:+
BRCA	cis	rs453301	0.624	rs330049	ENSG00000254153.1	CTA-398F10.2	4.86	1.35e-06	0.000133	0.17	0.15	Joint mobility (Beighton score);	chr8:9229789	chr8:8456909~8461337:-
BRCA	cis	rs8180040	0.966	rs7651762	ENSG00000276925.1	RP11-708J19.3	4.86	1.35e-06	0.000133	0.17	0.15	Colorectal cancer;	chr3:47428994	chr3:47469777~47469987:+
BRCA	cis	rs4578769	0.879	rs12963622	ENSG00000265939.1	UBE2CP2	4.86	1.35e-06	0.000133	0.18	0.15	Eosinophil percentage of white cells;	chr18:22859594	chr18:22900486~22900995:-
BRCA	cis	rs4578769	0.879	rs7241050	ENSG00000265939.1	UBE2CP2	4.86	1.35e-06	0.000133	0.18	0.15	Eosinophil percentage of white cells;	chr18:22860300	chr18:22900486~22900995:-
BRCA	cis	rs7074356	0.569	rs1832683	ENSG00000225484.5	NUTM2B-AS1	-4.86	1.35e-06	0.000133	-0.25	-0.15	Borderline personality disorder;	chr10:80272575	chr10:79663088~79826594:-
BRCA	cis	rs600231	0.706	rs10896016	ENSG00000173727.10	CMB9-22P13.1	-4.86	1.35e-06	0.000133	-0.2	-0.15	Bone mineral density;	chr11:65568234	chr11:65455258~65466720:+
BRCA	cis	rs11758351	1	rs16891378	ENSG00000241549.7	GUSBP2	-4.86	1.35e-06	0.000133	-0.22	-0.15	Renal underexcretion gout;Gout;	chr6:26188636	chr6:26871484~26956554:-
BRCA	cis	rs17507216	0.588	rs28864981	ENSG00000255769.6	GOLGA2P10	-4.86	1.35e-06	0.000133	-0.22	-0.15	Excessive daytime sleepiness;	chr15:82695420	chr15:82472993~82513950:-
BRCA	cis	rs17507216	0.628	rs8032321	ENSG00000255769.6	GOLGA2P10	-4.86	1.35e-06	0.000133	-0.22	-0.15	Excessive daytime sleepiness;	chr15:82698956	chr15:82472993~82513950:-
BRCA	cis	rs17507216	0.628	rs8040488	ENSG00000255769.6	GOLGA2P10	-4.86	1.35e-06	0.000133	-0.22	-0.15	Excessive daytime sleepiness;	chr15:82699081	chr15:82472993~82513950:-
BRCA	cis	rs4388249	0.651	rs31608	ENSG00000249476.1	CTD-2587M2.1	4.86	1.35e-06	0.000134	0.22	0.15	Schizophrenia;	chr5:109663811	chr5:109237120~109326369:-
BRCA	cis	rs924712	0.509	rs9475038	ENSG00000261116.1	RP3-523K23.2	4.86	1.35e-06	0.000134	0.17	0.15	Breast cancer;	chr6:54840247	chr6:54943167~54945099:+
BRCA	cis	rs287982	0.611	rs111636862	ENSG00000269973.1	RP11-95D17.1	-4.86	1.35e-06	0.000134	-0.24	-0.15	Nonsyndromic cleft lip with cleft palate;	chr2:9840128	chr2:9936360~9939590:+
BRCA	cis	rs7674212	0.57	rs2711899	ENSG00000246560.2	RP11-10L12.4	4.86	1.35e-06	0.000134	0.16	0.15	Type 2 diabetes;	chr4:103141257	chr4:102828055~102844075:+
BRCA	cis	rs6928977	0.5	rs11154810	ENSG00000231028.7	LINC00271	4.86	1.35e-06	0.000134	0.15	0.15	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135629234	chr6:135497801~135716055:+
BRCA	cis	rs7246657	0.606	rs2972439	ENSG00000226686.6	LINC01535	4.86	1.35e-06	0.000134	0.22	0.15	Coronary artery calcification;	chr19:37721680	chr19:37251912~37265535:+
BRCA	cis	rs7246657	0.722	rs2909100	ENSG00000226686.6	LINC01535	4.86	1.35e-06	0.000134	0.22	0.15	Coronary artery calcification;	chr19:37721779	chr19:37251912~37265535:+
BRCA	cis	rs4578769	0.879	rs7244549	ENSG00000265939.1	UBE2CP2	4.86	1.35e-06	0.000134	0.18	0.15	Eosinophil percentage of white cells;	chr18:22866052	chr18:22900486~22900995:-
BRCA	cis	rs10492201	0.529	rs4913390	ENSG00000236946.2	HNRNPA1P70	4.86	1.35e-06	0.000134	0.15	0.15	Itch intensity from mosquito bite adjusted by bite size;	chr12:67993696	chr12:68035767~68036853:+
BRCA	cis	rs10492201	0.529	rs11176998	ENSG00000236946.2	HNRNPA1P70	4.86	1.35e-06	0.000134	0.15	0.15	Itch intensity from mosquito bite adjusted by bite size;	chr12:67993774	chr12:68035767~68036853:+
BRCA	cis	rs454217	0.846	rs413415	ENSG00000277851.1	RP11-756G20.1	4.86	1.35e-06	0.000134	0.17	0.15	Smoking quantity;	chr12:92327115	chr12:92247756~92363832:-
BRCA	cis	rs10916772	0.609	rs12049377	ENSG00000236963.4	LINC01141	-4.86	1.35e-06	0.000134	-0.27	-0.15	Psychosis proneness (perceptual aberration scale);	chr1:20389376	chr1:20360579~20431234:-
BRCA	cis	rs7141336	0.77	rs36039295	ENSG00000258884.1	CTD-3035D6.2	4.86	1.35e-06	0.000134	0.2	0.15	Anxiety disorder;	chr14:90826986	chr14:90822365~90828128:-
BRCA	cis	rs7141336	0.77	rs36118153	ENSG00000258884.1	CTD-3035D6.2	4.86	1.35e-06	0.000134	0.2	0.15	Anxiety disorder;	chr14:90826989	chr14:90822365~90828128:-
BRCA	cis	rs6545883	0.86	rs6749226	ENSG00000270820.4	RP11-355B11.2	-4.86	1.35e-06	0.000134	-0.17	-0.15	Tuberculosis;	chr2:61282648	chr2:61471188~61484130:+
BRCA	cis	rs6496044	0.568	rs6496040	ENSG00000259295.5	CSPG4P12	4.86	1.35e-06	0.000134	0.18	0.15	Interstitial lung disease;	chr15:85520898	chr15:85191438~85213905:+
BRCA	cis	rs10761482	0.564	rs10733765	ENSG00000254271.1	RP11-131N11.4	4.86	1.35e-06	0.000134	0.2	0.15	Schizophrenia;	chr10:60477641	chr10:60734342~60741828:+
BRCA	cis	rs1124769	0.57	rs17702978	ENSG00000259378.1	DCAF13P3	4.86	1.35e-06	0.000134	0.2	0.15	Cognitive performance;	chr15:50868358	chr15:50944663~50945996:+
BRCA	cis	rs465969	0.793	rs34288099	ENSG00000271789.1	RP5-1112D6.7	4.86	1.35e-06	0.000134	0.28	0.15	Psoriasis;	chr6:111424034	chr6:111297126~111298510:+
BRCA	cis	rs3808502	0.605	rs11784572	ENSG00000255046.1	RP11-297N6.4	4.86	1.35e-06	0.000134	0.18	0.15	Neuroticism;	chr8:11316975	chr8:11797928~11802568:-
BRCA	cis	rs1395	0.778	rs62128747	ENSG00000234072.1	AC074117.10	-4.86	1.35e-06	0.000134	-0.16	-0.15	Blood metabolite levels;	chr2:27189737	chr2:27356246~27367622:+
BRCA	cis	rs1395	0.778	rs11693001	ENSG00000234072.1	AC074117.10	-4.86	1.35e-06	0.000134	-0.16	-0.15	Blood metabolite levels;	chr2:27189876	chr2:27356246~27367622:+
BRCA	cis	rs7618915	0.547	rs2286800	ENSG00000243224.1	RP5-1157M23.2	-4.86	1.35e-06	0.000134	-0.17	-0.15	Bipolar disorder;	chr3:52744035	chr3:52239258~52241097:+
BRCA	cis	rs172166	0.694	rs203893	ENSG00000219392.1	RP1-265C24.5	-4.86	1.36e-06	0.000134	-0.2	-0.15	Cardiac Troponin-T levels;	chr6:28094288	chr6:28115628~28116551:+
BRCA	cis	rs4237845	0.788	rs6581157	ENSG00000257159.1	RP11-58A17.3	4.86	1.36e-06	0.000134	0.18	0.15	Intelligence (multi-trait analysis);	chr12:57895010	chr12:57967058~57968399:+
BRCA	cis	rs1707322	1	rs6672115	ENSG00000234329.1	RP11-767N6.2	4.86	1.36e-06	0.000134	0.16	0.15	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45807207	chr1:45651039~45651826:-
BRCA	cis	rs12497850	0.931	rs9840050	ENSG00000225399.4	RP11-3B7.1	4.86	1.36e-06	0.000134	0.15	0.15	Parkinson's disease;	chr3:49095877	chr3:49260085~49261316:+
BRCA	cis	rs13113518	0.966	rs11942472	ENSG00000223305.1	RN7SKP30	4.86	1.36e-06	0.000134	0.18	0.15	Height;	chr4:55574959	chr4:55540502~55540835:-
BRCA	cis	rs17767294	0.708	rs72848791	ENSG00000204709.4	LINC01556	4.86	1.36e-06	0.000134	0.39	0.15	Parkinson's disease;	chr6:28018421	chr6:28943877~28944537:+
BRCA	cis	rs1729951	0.575	rs2163896	ENSG00000239213.4	NCK1-AS1	4.86	1.36e-06	0.000134	0.15	0.15	Neuroticism;	chr3:136972335	chr3:136841726~136862054:-
BRCA	cis	rs7618915	0.547	rs4687548	ENSG00000243224.1	RP5-1157M23.2	-4.86	1.36e-06	0.000134	-0.17	-0.15	Bipolar disorder;	chr3:52632634	chr3:52239258~52241097:+
BRCA	cis	rs7618915	0.547	rs13069481	ENSG00000243224.1	RP5-1157M23.2	-4.86	1.36e-06	0.000134	-0.17	-0.15	Bipolar disorder;	chr3:52632850	chr3:52239258~52241097:+
BRCA	cis	rs7618501	0.602	rs10049087	ENSG00000228008.1	CTD-2330K9.3	-4.86	1.36e-06	0.000134	-0.14	-0.15	Intelligence (multi-trait analysis);	chr3:50085984	chr3:49903845~49916937:+
BRCA	cis	rs4908760	0.864	rs6701331	ENSG00000232912.4	RP5-1115A15.1	4.86	1.36e-06	0.000134	0.15	0.15	Vitiligo;	chr1:8610147	chr1:8424645~8434838:+
BRCA	cis	rs875971	1	rs778696	ENSG00000223473.2	GS1-124K5.3	4.86	1.36e-06	0.000134	0.11	0.15	Aortic root size;	chr7:66405826	chr7:66491049~66493566:-
BRCA	cis	rs875971	1	rs778694	ENSG00000223473.2	GS1-124K5.3	4.86	1.36e-06	0.000134	0.11	0.15	Aortic root size;	chr7:66406571	chr7:66491049~66493566:-
BRCA	cis	rs875971	1	rs4718344	ENSG00000223473.2	GS1-124K5.3	4.86	1.36e-06	0.000134	0.11	0.15	Aortic root size;	chr7:66409394	chr7:66491049~66493566:-
BRCA	cis	rs875971	0.737	rs7803424	ENSG00000223473.2	GS1-124K5.3	4.86	1.36e-06	0.000134	0.11	0.15	Aortic root size;	chr7:66415618	chr7:66491049~66493566:-
BRCA	cis	rs875971	0.83	rs7799834	ENSG00000223473.2	GS1-124K5.3	4.86	1.36e-06	0.000134	0.11	0.15	Aortic root size;	chr7:66415707	chr7:66491049~66493566:-
BRCA	cis	rs2980439	0.818	rs2948294	ENSG00000173295.6	FAM86B3P	4.86	1.36e-06	0.000134	0.16	0.15	Neuroticism;	chr8:8237439	chr8:8228595~8244865:+
BRCA	cis	rs7487075	0.619	rs11183488	ENSG00000274723.1	RP11-618L22.1	4.86	1.36e-06	0.000134	0.2	0.15	Itch intensity from mosquito bite;	chr12:46448053	chr12:46970504~46972155:+
BRCA	cis	rs875971	0.928	rs2036263	ENSG00000236529.1	RP13-254B10.1	-4.86	1.36e-06	0.000134	-0.16	-0.15	Aortic root size;	chr7:66335210	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.862	rs10240949	ENSG00000236529.1	RP13-254B10.1	-4.86	1.36e-06	0.000134	-0.16	-0.15	Aortic root size;	chr7:66339430	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.862	rs7782704	ENSG00000236529.1	RP13-254B10.1	-4.86	1.36e-06	0.000134	-0.16	-0.15	Aortic root size;	chr7:66340379	chr7:65840212~65840596:+
BRCA	cis	rs6832769	1	rs473005	ENSG00000272969.1	RP11-528I4.2	4.86	1.36e-06	0.000134	0.18	0.15	Personality dimensions;	chr4:55421958	chr4:55547112~55547889:+
BRCA	cis	rs11098499	0.754	rs11732087	ENSG00000249244.1	RP11-548H18.2	4.86	1.36e-06	0.000134	0.17	0.15	Corneal astigmatism;	chr4:119318676	chr4:119391831~119395335:-
BRCA	cis	rs6005807	0.843	rs134194	ENSG00000272858.1	CTA-292E10.8	-4.86	1.36e-06	0.000134	-0.27	-0.15	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28257911	chr22:28814914~28815662:+
BRCA	cis	rs2638953	0.962	rs10843171	ENSG00000247934.4	RP11-967K21.1	-4.86	1.36e-06	0.000134	-0.19	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28435583	chr12:28163298~28190738:-
BRCA	cis	rs754466	0.958	rs11002341	ENSG00000204049.1	RP11-126H7.4	4.86	1.36e-06	0.000134	0.2	0.15	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77941605	chr10:77866875~77869610:+
BRCA	cis	rs2243480	1	rs6974723	ENSG00000222364.1	RNU6-96P	4.86	1.36e-06	0.000134	0.27	0.15	Diabetic kidney disease;	chr7:66172952	chr7:66395191~66395286:+
BRCA	cis	rs2243480	1	rs9769882	ENSG00000222364.1	RNU6-96P	4.86	1.36e-06	0.000134	0.27	0.15	Diabetic kidney disease;	chr7:66177938	chr7:66395191~66395286:+
BRCA	cis	rs2243480	1	rs6966322	ENSG00000222364.1	RNU6-96P	4.86	1.36e-06	0.000134	0.27	0.15	Diabetic kidney disease;	chr7:66181767	chr7:66395191~66395286:+
BRCA	cis	rs2243480	1	rs4145008	ENSG00000222364.1	RNU6-96P	4.86	1.36e-06	0.000134	0.27	0.15	Diabetic kidney disease;	chr7:66182524	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.825	rs66981195	ENSG00000236529.1	RP13-254B10.1	-4.86	1.36e-06	0.000135	-0.17	-0.15	Aortic root size;	chr7:66614048	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.862	rs3926380	ENSG00000236529.1	RP13-254B10.1	-4.86	1.36e-06	0.000135	-0.17	-0.15	Aortic root size;	chr7:66615658	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.825	rs1860472	ENSG00000236529.1	RP13-254B10.1	-4.86	1.36e-06	0.000135	-0.17	-0.15	Aortic root size;	chr7:66617736	chr7:65840212~65840596:+
BRCA	cis	rs8054556	0.787	rs12325539	ENSG00000261367.1	RP11-455F5.4	-4.86	1.36e-06	0.000135	-0.17	-0.15	Autism spectrum disorder or schizophrenia;	chr16:30022312	chr16:30107675~30110541:+
BRCA	cis	rs8054556	0.751	rs11642430	ENSG00000261367.1	RP11-455F5.4	-4.86	1.36e-06	0.000135	-0.17	-0.15	Autism spectrum disorder or schizophrenia;	chr16:30034468	chr16:30107675~30110541:+
BRCA	cis	rs10833905	1	rs10833905	ENSG00000246225.5	RP11-17A1.3	4.86	1.36e-06	0.000135	0.2	0.15	Sudden cardiac arrest;	chr11:23023046	chr11:22829380~22945393:+
BRCA	cis	rs9473147	0.843	rs6904933	ENSG00000270761.1	RP11-385F7.1	-4.86	1.36e-06	0.000135	-0.15	-0.15	Platelet distribution width;Mean platelet volume;	chr6:47660822	chr6:47477243~47477572:-
BRCA	cis	rs4781563	0.764	rs3136038	ENSG00000242307.1	RPS26P52	-4.86	1.36e-06	0.000135	-0.17	-0.15	Bilirubin levels;	chr16:13919522	chr16:13922332~13922679:-
BRCA	cis	rs13113518	0.934	rs10866425	ENSG00000223305.1	RN7SKP30	4.86	1.36e-06	0.000135	0.18	0.15	Height;	chr4:55582068	chr4:55540502~55540835:-
BRCA	cis	rs4388249	0.687	rs2300998	ENSG00000271849.1	CTC-332L22.1	-4.86	1.36e-06	0.000135	-0.19	-0.15	Schizophrenia;	chr5:109747421	chr5:109687802~109688329:-
BRCA	cis	rs1124769	0.57	rs2663528	ENSG00000259378.1	DCAF13P3	-4.86	1.36e-06	0.000135	-0.2	-0.15	Cognitive performance;	chr15:50862707	chr15:50944663~50945996:+
BRCA	cis	rs416603	0.967	rs11644184	ENSG00000262636.1	CTD-3088G3.4	-4.86	1.36e-06	0.000135	-0.2	-0.15	Type 1 diabetes;	chr16:11271247	chr16:11380859~11381118:-
BRCA	cis	rs597539	0.652	rs604524	ENSG00000261625.1	RP11-554A11.4	-4.86	1.37e-06	0.000135	-0.15	-0.15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68862461	chr11:69000765~69002048:-
BRCA	cis	rs11098499	0.909	rs78332141	ENSG00000260091.1	RP11-33B1.4	-4.86	1.37e-06	0.000135	-0.13	-0.15	Corneal astigmatism;	chr4:119454627	chr4:119409333~119410233:+
BRCA	cis	rs1832007	0.529	rs7088788	ENSG00000224034.1	RP11-445P17.8	-4.86	1.37e-06	0.000135	-0.24	-0.15	Triglyceride levels;Triglycerides;	chr10:5201130	chr10:5266033~5271236:-
BRCA	cis	rs7267979	0.844	rs4815413	ENSG00000204556.4	CTD-2514C3.1	4.86	1.37e-06	0.000135	0.2	0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25378593	chr20:26018832~26020684:+
BRCA	cis	rs7267979	0.844	rs6083824	ENSG00000204556.4	CTD-2514C3.1	4.86	1.37e-06	0.000135	0.2	0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25382421	chr20:26018832~26020684:+
BRCA	cis	rs6439153	0.933	rs6769662	ENSG00000231305.3	RP11-723O4.2	4.86	1.37e-06	0.000135	0.17	0.15	Pneumococcal bacteremia;	chr3:129002467	chr3:128861313~128871540:-
BRCA	cis	rs9467773	0.62	rs2451741	ENSG00000241549.7	GUSBP2	4.86	1.37e-06	0.000135	0.16	0.15	Intelligence (multi-trait analysis);	chr6:26629176	chr6:26871484~26956554:-
BRCA	cis	rs1075265	0.522	rs7584474	ENSG00000235937.1	AC008280.1	4.86	1.37e-06	0.000135	0.16	0.15	Chronotype;Morning vs. evening chronotype;	chr2:53674874	chr2:54029552~54030682:-
BRCA	cis	rs1322639	1	rs9689079	ENSG00000223485.1	RP11-417E7.1	4.86	1.37e-06	0.000135	0.18	0.15	Pulse pressure;	chr6:169187053	chr6:169158092~169162924:-
BRCA	cis	rs7829975	0.626	rs907183	ENSG00000233609.3	RP11-62H7.2	-4.86	1.37e-06	0.000135	-0.14	-0.15	Mood instability;	chr8:8872251	chr8:8961200~8979025:+
BRCA	cis	rs10833905	0.877	rs11026946	ENSG00000246225.5	RP11-17A1.3	-4.86	1.37e-06	0.000135	-0.21	-0.15	Sudden cardiac arrest;	chr11:23053292	chr11:22829380~22945393:+
BRCA	cis	rs7674212	0.541	rs2720471	ENSG00000251288.2	RP11-10L12.2	-4.86	1.37e-06	0.000135	-0.17	-0.15	Type 2 diabetes;	chr4:103102683	chr4:102751401~102752641:+
BRCA	cis	rs1876905	0.597	rs1150076	ENSG00000255389.1	C6orf3	4.86	1.37e-06	0.000135	0.19	0.15	Mean corpuscular hemoglobin;	chr6:111227227	chr6:111599875~111602295:+
BRCA	cis	rs1223397	0.689	rs2439539	ENSG00000215022.6	RP1-257A7.4	-4.86	1.37e-06	0.000135	-0.18	-0.15	Blood pressure;	chr6:13308601	chr6:13264861~13295586:-
BRCA	cis	rs7226408	0.749	rs17567737	ENSG00000267707.2	RP11-95O2.5	4.86	1.37e-06	0.000135	0.22	0.15	Obesity-related traits;	chr18:36919406	chr18:37243776~37247506:+
BRCA	cis	rs4948275	0.773	rs2650697	ENSG00000237233.2	TMEM26-AS1	-4.86	1.37e-06	0.000135	-0.18	-0.15	Night sleep phenotypes;	chr10:61536585	chr10:61452639~61481956:+
BRCA	cis	rs56104184	0.725	rs4347731	ENSG00000235191.1	NUCB1-AS1	4.86	1.37e-06	0.000136	0.29	0.15	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr19:48881897	chr19:48910930~48918891:-
BRCA	cis	rs6754311	0.731	rs309134	ENSG00000231890.6	DARS-AS1	4.86	1.37e-06	0.000136	0.19	0.15	Mosquito bite size;	chr2:135998114	chr2:135985176~136022593:+
BRCA	cis	rs7918232	0.882	rs10829190	ENSG00000262412.1	RP11-85G18.6	4.86	1.37e-06	0.000136	0.24	0.15	Breast cancer;	chr10:27120626	chr10:27243130~27250804:+
BRCA	cis	rs9834975	1	rs9834975	ENSG00000272758.4	RP11-299J3.8	-4.86	1.37e-06	0.000136	-0.15	-0.15	Diastolic blood pressure;	chr3:122398816	chr3:122416207~122443180:+
BRCA	cis	rs12681366	0.839	rs3019281	ENSG00000253175.1	RP11-267M23.6	4.86	1.37e-06	0.000136	0.18	0.15	Nonsyndromic cleft lip with cleft palate;	chr8:94438061	chr8:94565036~94565715:+
BRCA	cis	rs897984	0.806	rs1046276	ENSG00000275263.1	RP11-1072A3.4	4.86	1.37e-06	0.000136	0.18	0.15	Dementia with Lewy bodies;	chr16:30903305	chr16:30956872~30957199:-
BRCA	cis	rs6832769	1	rs2177129	ENSG00000272969.1	RP11-528I4.2	4.86	1.37e-06	0.000136	0.18	0.15	Personality dimensions;	chr4:55499247	chr4:55547112~55547889:+
BRCA	cis	rs62025270	0.632	rs62022919	ENSG00000259762.1	RP11-158M2.4	-4.86	1.37e-06	0.000136	-0.22	-0.15	Idiopathic pulmonary fibrosis;	chr15:85675079	chr15:85750336~85752901:-
BRCA	cis	rs1707322	1	rs34694458	ENSG00000234329.1	RP11-767N6.2	4.86	1.37e-06	0.000136	0.15	0.15	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45867024	chr1:45651039~45651826:-
BRCA	cis	rs7011507	0.582	rs72637612	ENSG00000279881.1	RP11-513O13.1	-4.86	1.38e-06	0.000136	-0.23	-0.15	Inflammatory bowel disease;Ulcerative colitis;	chr8:48342546	chr8:48428143~48431041:-
BRCA	cis	rs7011507	0.582	rs56214700	ENSG00000279881.1	RP11-513O13.1	-4.86	1.38e-06	0.000136	-0.23	-0.15	Inflammatory bowel disease;Ulcerative colitis;	chr8:48343387	chr8:48428143~48431041:-
BRCA	cis	rs7226408	0.857	rs57233384	ENSG00000267707.2	RP11-95O2.5	4.86	1.38e-06	0.000136	0.22	0.15	Obesity-related traits;	chr18:36966758	chr18:37243776~37247506:+
BRCA	cis	rs287982	0.611	rs78401890	ENSG00000269973.1	RP11-95D17.1	-4.86	1.38e-06	0.000136	-0.24	-0.15	Nonsyndromic cleft lip with cleft palate;	chr2:9838332	chr2:9936360~9939590:+
BRCA	cis	rs4853525	0.504	rs2883582	ENSG00000235852.1	AC005540.3	4.86	1.38e-06	0.000136	0.19	0.15	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190939306	chr2:190880797~190882059:-
BRCA	cis	rs12439619	0.693	rs7165536	ENSG00000255769.6	GOLGA2P10	-4.86	1.38e-06	0.000136	-0.2	-0.15	Intelligence (multi-trait analysis);	chr15:82273743	chr15:82472993~82513950:-
BRCA	cis	rs7937890	0.904	rs11023169	ENSG00000251991.1	RNU7-49P	-4.86	1.38e-06	0.000136	-0.16	-0.15	Mitochondrial DNA levels;	chr11:14269439	chr11:14478892~14478953:+
BRCA	cis	rs10129255	0.912	rs6576227	ENSG00000274576.2	IGHV2-70	4.86	1.38e-06	0.000136	0.13	0.15	Kawasaki disease;	chr14:106778202	chr14:106770577~106771020:-
BRCA	cis	rs10129255	0.957	rs6576228	ENSG00000274576.2	IGHV2-70	4.86	1.38e-06	0.000136	0.13	0.15	Kawasaki disease;	chr14:106778401	chr14:106770577~106771020:-
BRCA	cis	rs7267979	1	rs453329	ENSG00000125804.12	FAM182A	-4.86	1.38e-06	0.000136	-0.19	-0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25459957	chr20:26054655~26086917:+
BRCA	cis	rs763121	0.853	rs5750672	ENSG00000225450.1	RP3-508I15.14	4.86	1.38e-06	0.000136	0.16	0.15	Menopause (age at onset);	chr22:38708163	chr22:38739003~38749041:+
BRCA	cis	rs2562456	0.52	rs582992	ENSG00000240522.1	RPL7AP10	4.86	1.38e-06	0.000136	0.19	0.15	Pain;	chr19:21266744	chr19:21149648~21150438:-
BRCA	cis	rs4660214	0.666	rs11205839	ENSG00000237624.1	OXCT2P1	-4.86	1.38e-06	0.000136	-0.18	-0.15	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39268061	chr1:39514956~39516490:+
BRCA	cis	rs9402743	0.634	rs7765113	ENSG00000231028.7	LINC00271	-4.86	1.38e-06	0.000136	-0.15	-0.15	Systemic lupus erythematosus;	chr6:135598935	chr6:135497801~135716055:+
BRCA	cis	rs3764563	1	rs4808326	ENSG00000267594.5	CYP4F24P	-4.86	1.38e-06	0.000136	-0.29	-0.15	Inflammatory biomarkers;	chr19:15615336	chr19:15760241~15779909:-
BRCA	cis	rs357894	0.802	rs357895	ENSG00000266696.1	RP11-30L3.2	4.86	1.38e-06	0.000136	0.16	0.15	Dental caries;	chr18:49053897	chr18:49205912~49208781:+
BRCA	cis	rs1552244	1	rs2272123	ENSG00000232901.1	CYCSP10	4.86	1.38e-06	0.000136	0.21	0.15	Alzheimer's disease;	chr3:10098431	chr3:10000647~10000940:-
BRCA	cis	rs7727544	0.716	rs4594848	ENSG00000233006.5	AC034220.3	4.86	1.38e-06	0.000136	0.11	0.15	Blood metabolite levels;	chr5:132250905	chr5:132311285~132369916:-
BRCA	cis	rs7246657	0.722	rs2972430	ENSG00000226686.6	LINC01535	4.86	1.38e-06	0.000136	0.22	0.15	Coronary artery calcification;	chr19:37691210	chr19:37251912~37265535:+
BRCA	cis	rs62025270	0.632	rs3169119	ENSG00000259762.1	RP11-158M2.4	-4.86	1.38e-06	0.000136	-0.23	-0.15	Idiopathic pulmonary fibrosis;	chr15:85748038	chr15:85750336~85752901:-
BRCA	cis	rs11603691	1	rs10896598	ENSG00000254662.1	RP11-872D17.4	-4.86	1.38e-06	0.000136	-0.35	-0.15	Low high density lipoprotein cholesterol levels;	chr11:57284533	chr11:57325603~57327958:+
BRCA	cis	rs17711722	0.565	rs73372653	ENSG00000226767.1	RP11-328P23.3	4.86	1.38e-06	0.000136	0.17	0.15	Calcium levels;	chr7:65977808	chr7:65508773~65508944:-
BRCA	cis	rs8098244	0.77	rs62094786	ENSG00000264745.1	TTC39C-AS1	4.86	1.38e-06	0.000136	0.2	0.15	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23795719	chr18:23994213~24015339:-
BRCA	cis	rs62025270	0.576	rs55639123	ENSG00000259762.1	RP11-158M2.4	-4.86	1.38e-06	0.000136	-0.23	-0.15	Idiopathic pulmonary fibrosis;	chr15:85617037	chr15:85750336~85752901:-
BRCA	cis	rs8180040	0.966	rs17784882	ENSG00000276925.1	RP11-708J19.3	4.86	1.38e-06	0.000137	0.17	0.15	Colorectal cancer;	chr3:47502513	chr3:47469777~47469987:+
BRCA	cis	rs57221529	0.766	rs12522140	ENSG00000225138.6	CTD-2228K2.7	4.86	1.38e-06	0.000137	0.23	0.15	Lung disease severity in cystic fibrosis;	chr5:587146	chr5:473236~480884:+
BRCA	cis	rs57221529	0.766	rs72703064	ENSG00000225138.6	CTD-2228K2.7	4.86	1.38e-06	0.000137	0.23	0.15	Lung disease severity in cystic fibrosis;	chr5:587710	chr5:473236~480884:+
BRCA	cis	rs57221529	0.766	rs72703065	ENSG00000225138.6	CTD-2228K2.7	4.86	1.38e-06	0.000137	0.23	0.15	Lung disease severity in cystic fibrosis;	chr5:588008	chr5:473236~480884:+
BRCA	cis	rs57221529	0.766	rs1399381	ENSG00000225138.6	CTD-2228K2.7	4.86	1.38e-06	0.000137	0.23	0.15	Lung disease severity in cystic fibrosis;	chr5:589738	chr5:473236~480884:+
BRCA	cis	rs2255336	0.938	rs1478309	ENSG00000245648.1	RP11-277P12.20	4.86	1.38e-06	0.000137	0.22	0.15	Blood protein levels;	chr12:10389146	chr12:10363769~10398506:+
BRCA	cis	rs9543976	0.623	rs7996884	ENSG00000261105.4	LMO7-AS1	4.86	1.38e-06	0.000137	0.23	0.15	Diabetic retinopathy;	chr13:75598608	chr13:75604700~75635994:-
BRCA	cis	rs7487075	0.619	rs10880971	ENSG00000274723.1	RP11-618L22.1	4.86	1.38e-06	0.000137	0.19	0.15	Itch intensity from mosquito bite;	chr12:46445715	chr12:46970504~46972155:+
BRCA	cis	rs7487075	0.619	rs10467214	ENSG00000274723.1	RP11-618L22.1	4.86	1.38e-06	0.000137	0.19	0.15	Itch intensity from mosquito bite;	chr12:46447427	chr12:46970504~46972155:+
BRCA	cis	rs6088580	0.634	rs6059905	ENSG00000276073.1	RP5-1125A11.7	-4.86	1.38e-06	0.000137	-0.16	-0.15	Glomerular filtration rate (creatinine);	chr20:34539142	chr20:33985617~33988989:-
BRCA	cis	rs4664293	0.667	rs6432562	ENSG00000224152.1	AC009506.1	-4.86	1.38e-06	0.000137	-0.16	-0.15	Monocyte percentage of white cells;	chr2:159791495	chr2:159615296~159617082:+
BRCA	cis	rs860295	0.676	rs11264374	ENSG00000160766.13	GBAP1	-4.86	1.38e-06	0.000137	-0.16	-0.15	Body mass index;	chr1:155451721	chr1:155213821~155227422:-
BRCA	cis	rs7226408	0.857	rs1365511	ENSG00000267707.2	RP11-95O2.5	4.86	1.39e-06	0.000137	0.23	0.15	Obesity-related traits;	chr18:36846035	chr18:37243776~37247506:+
BRCA	cis	rs987724	0.515	rs4680309	ENSG00000240875.4	LINC00886	-4.86	1.39e-06	0.000137	-0.22	-0.15	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156865807	chr3:156747346~156817062:-
BRCA	cis	rs987724	0.515	rs2874488	ENSG00000240875.4	LINC00886	-4.86	1.39e-06	0.000137	-0.22	-0.15	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156868027	chr3:156747346~156817062:-
BRCA	cis	rs987724	0.515	rs6765353	ENSG00000240875.4	LINC00886	-4.86	1.39e-06	0.000137	-0.22	-0.15	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156868755	chr3:156747346~156817062:-
BRCA	cis	rs987724	0.515	rs7638330	ENSG00000240875.4	LINC00886	-4.86	1.39e-06	0.000137	-0.22	-0.15	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156869976	chr3:156747346~156817062:-
BRCA	cis	rs1867631	0.958	rs7536188	ENSG00000248458.2	RP4-598P13.1	-4.86	1.39e-06	0.000137	-0.16	-0.15	Menopause (age at onset);	chr1:66622243	chr1:66665864~66677027:-
BRCA	cis	rs7481584	0.669	rs12421922	ENSG00000247473.2	CARS-AS1	-4.86	1.39e-06	0.000137	-0.18	-0.15	Calcium levels;	chr11:3013840	chr11:3029009~3041260:+
BRCA	cis	rs11239930	0.538	rs604716	ENSG00000230832.3	RP11-325P15.2	-4.86	1.39e-06	0.000137	-0.22	-0.15	AIDS progression;	chr1:147073173	chr1:147082338~147083578:-
BRCA	cis	rs2153535	0.58	rs718502	ENSG00000251164.1	HULC	-4.86	1.39e-06	0.000137	-0.18	-0.15	Motion sickness;	chr6:8527167	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.58	rs718503	ENSG00000251164.1	HULC	-4.86	1.39e-06	0.000137	-0.18	-0.15	Motion sickness;	chr6:8527230	chr6:8652137~8653846:+
BRCA	cis	rs2842992	0.724	rs9365097	ENSG00000237927.1	RP3-393E18.2	-4.86	1.39e-06	0.000137	-0.2	-0.15	Age-related macular degeneration (geographic atrophy);	chr6:159790227	chr6:159586955~159589169:-
BRCA	cis	rs2505998	0.843	rs2435344	ENSG00000273008.1	RP11-351D16.3	-4.86	1.39e-06	0.000137	-0.18	-0.15	Hirschsprung disease;	chr10:43090426	chr10:43136824~43138334:-
BRCA	cis	rs17767294	0.708	rs72846777	ENSG00000204709.4	LINC01556	4.86	1.39e-06	0.000137	0.39	0.15	Parkinson's disease;	chr6:28147032	chr6:28943877~28944537:+
BRCA	cis	rs17767294	0.708	rs62620226	ENSG00000204709.4	LINC01556	4.86	1.39e-06	0.000137	0.39	0.15	Parkinson's disease;	chr6:28153500	chr6:28943877~28944537:+
BRCA	cis	rs17767294	0.708	rs72846788	ENSG00000204709.4	LINC01556	4.86	1.39e-06	0.000137	0.39	0.15	Parkinson's disease;	chr6:28163065	chr6:28943877~28944537:+
BRCA	cis	rs17767294	0.708	rs72846792	ENSG00000204709.4	LINC01556	4.86	1.39e-06	0.000137	0.39	0.15	Parkinson's disease;	chr6:28165533	chr6:28943877~28944537:+
BRCA	cis	rs17767294	0.708	rs74756732	ENSG00000204709.4	LINC01556	4.86	1.39e-06	0.000137	0.39	0.15	Parkinson's disease;	chr6:28184769	chr6:28943877~28944537:+
BRCA	cis	rs10510102	0.516	rs11200301	ENSG00000276742.1	RP11-500G22.4	4.85	1.39e-06	0.000137	0.27	0.15	Breast cancer;	chr10:121977976	chr10:121956782~121957098:+
BRCA	cis	rs10761482	0.531	rs10740029	ENSG00000254271.1	RP11-131N11.4	4.85	1.39e-06	0.000137	0.2	0.15	Schizophrenia;	chr10:60479144	chr10:60734342~60741828:+
BRCA	cis	rs3768617	0.51	rs7525917	ENSG00000224468.3	RP11-181K3.4	-4.85	1.39e-06	0.000137	-0.16	-0.15	Fuchs's corneal dystrophy;	chr1:183096271	chr1:183138402~183141282:-
BRCA	cis	rs4718428	1	rs1830070	ENSG00000229180.5	GS1-124K5.11	4.85	1.39e-06	0.000137	0.13	0.15	Corneal structure;	chr7:66884684	chr7:66526088~66542624:-
BRCA	cis	rs8054556	0.967	rs7193532	ENSG00000273724.1	RP11-347C12.12	-4.85	1.39e-06	0.000137	-0.17	-0.15	Autism spectrum disorder or schizophrenia;	chr16:29951481	chr16:30336400~30343336:+
BRCA	cis	rs875971	0.929	rs778692	ENSG00000223473.2	GS1-124K5.3	4.85	1.39e-06	0.000137	0.11	0.15	Aortic root size;	chr7:66407462	chr7:66491049~66493566:-
BRCA	cis	rs875971	1	rs4718343	ENSG00000223473.2	GS1-124K5.3	4.85	1.39e-06	0.000137	0.11	0.15	Aortic root size;	chr7:66409301	chr7:66491049~66493566:-
BRCA	cis	rs875971	1	rs1968225	ENSG00000223473.2	GS1-124K5.3	4.85	1.39e-06	0.000137	0.11	0.15	Aortic root size;	chr7:66409786	chr7:66491049~66493566:-
BRCA	cis	rs875971	1	rs6460295	ENSG00000223473.2	GS1-124K5.3	4.85	1.39e-06	0.000137	0.11	0.15	Aortic root size;	chr7:66417741	chr7:66491049~66493566:-
BRCA	cis	rs875971	0.964	rs6978721	ENSG00000223473.2	GS1-124K5.3	4.85	1.39e-06	0.000137	0.11	0.15	Aortic root size;	chr7:66418217	chr7:66491049~66493566:-
BRCA	cis	rs7772486	0.79	rs1854900	ENSG00000270638.1	RP3-466P17.1	4.85	1.39e-06	0.000137	0.17	0.15	Lobe attachment (rater-scored or self-reported);	chr6:146010246	chr6:145735570~145737218:+
BRCA	cis	rs7487075	0.619	rs1472178	ENSG00000274723.1	RP11-618L22.1	4.85	1.39e-06	0.000137	0.2	0.15	Itch intensity from mosquito bite;	chr12:46410392	chr12:46970504~46972155:+
BRCA	cis	rs12681366	0.839	rs3019280	ENSG00000253175.1	RP11-267M23.6	4.85	1.39e-06	0.000137	0.18	0.15	Nonsyndromic cleft lip with cleft palate;	chr8:94437804	chr8:94565036~94565715:+
BRCA	cis	rs2832191	0.791	rs8134407	ENSG00000176054.6	RPL23P2	4.85	1.39e-06	0.000137	0.15	0.15	Dental caries;	chr21:29104265	chr21:28997613~28998033:-
BRCA	cis	rs4908760	0.792	rs6577515	ENSG00000232912.4	RP5-1115A15.1	4.85	1.39e-06	0.000137	0.14	0.15	Vitiligo;	chr1:8654143	chr1:8424645~8434838:+
BRCA	cis	rs4415084	1	rs6874055	ENSG00000251141.4	RP11-53O19.1	4.85	1.39e-06	0.000137	0.14	0.15	Breast cancer;	chr5:44666863	chr5:44744900~44808777:-
BRCA	cis	rs7267979	0.844	rs2257649	ENSG00000204556.4	CTD-2514C3.1	-4.85	1.39e-06	0.000137	-0.2	-0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25282821	chr20:26018832~26020684:+
BRCA	cis	rs3892630	0.878	rs6510277	ENSG00000267475.1	CTD-2538C1.2	-4.85	1.39e-06	0.000137	-0.23	-0.15	Red blood cell traits;	chr19:32692763	chr19:32687089~32691750:-
BRCA	cis	rs3892630	0.817	rs12609866	ENSG00000267475.1	CTD-2538C1.2	-4.85	1.39e-06	0.000137	-0.23	-0.15	Red blood cell traits;	chr19:32693506	chr19:32687089~32691750:-
BRCA	cis	rs12922040	0.651	rs35288467	ENSG00000207425.1	Y_RNA	4.85	1.39e-06	0.000138	0.17	0.15	Serum uric acid levels in response to allopurinol in gout;	chr16:15773097	chr16:14915457~14915556:-
BRCA	cis	rs7811142	0.775	rs1636980	ENSG00000078319.8	PMS2P1	4.85	1.39e-06	0.000138	0.24	0.15	Platelet count;	chr7:100341241	chr7:100320992~100341908:-
BRCA	cis	rs6545883	0.894	rs12615783	ENSG00000270820.4	RP11-355B11.2	-4.85	1.4e-06	0.000138	-0.17	-0.15	Tuberculosis;	chr2:61213812	chr2:61471188~61484130:+
BRCA	cis	rs4781563	1	rs2276464	ENSG00000242307.1	RPS26P52	-4.85	1.4e-06	0.000138	-0.18	-0.15	Bilirubin levels;	chr16:13949073	chr16:13922332~13922679:-
BRCA	cis	rs875971	1	rs7789554	ENSG00000223473.2	GS1-124K5.3	4.85	1.4e-06	0.000138	0.11	0.15	Aortic root size;	chr7:66481051	chr7:66491049~66493566:-
BRCA	cis	rs875971	1	rs4717300	ENSG00000223473.2	GS1-124K5.3	4.85	1.4e-06	0.000138	0.11	0.15	Aortic root size;	chr7:66482393	chr7:66491049~66493566:-
BRCA	cis	rs875971	0.895	rs1974769	ENSG00000223473.2	GS1-124K5.3	4.85	1.4e-06	0.000138	0.11	0.15	Aortic root size;	chr7:66485627	chr7:66491049~66493566:-
BRCA	cis	rs875971	0.895	rs6460300	ENSG00000223473.2	GS1-124K5.3	4.85	1.4e-06	0.000138	0.11	0.15	Aortic root size;	chr7:66487937	chr7:66491049~66493566:-
BRCA	cis	rs875971	0.862	rs7803416	ENSG00000223473.2	GS1-124K5.3	4.85	1.4e-06	0.000138	0.11	0.15	Aortic root size;	chr7:66489212	chr7:66491049~66493566:-
BRCA	cis	rs875971	0.964	rs2277911	ENSG00000223473.2	GS1-124K5.3	4.85	1.4e-06	0.000138	0.11	0.15	Aortic root size;	chr7:66493638	chr7:66491049~66493566:-
BRCA	cis	rs647097	0.961	rs633286	ENSG00000272788.1	RP11-674N23.4	4.85	1.4e-06	0.000138	0.2	0.15	Chronic obstructive pulmonary disease;	chr18:8809275	chr18:8801656~8802305:+
BRCA	cis	rs4664293	0.867	rs3771721	ENSG00000224152.1	AC009506.1	-4.85	1.4e-06	0.000138	-0.17	-0.15	Monocyte percentage of white cells;	chr2:159771644	chr2:159615296~159617082:+
BRCA	cis	rs1950832	0.689	rs10150151	ENSG00000258636.1	CTD-2298J14.2	-4.85	1.4e-06	0.000138	-0.17	-0.15	Urate levels in obese individuals;	chr14:41691851	chr14:41587861~41604856:-
BRCA	cis	rs6600671	1	rs11249350	ENSG00000275538.1	RNVU1-19	4.85	1.4e-06	0.000138	0.17	0.15	Hip geometry;	chr1:121436587	chr1:120850819~120850985:-
BRCA	cis	rs1161098	0.723	rs1161178	ENSG00000256037.1	MRPL40P1	4.85	1.4e-06	0.000138	0.24	0.15	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr12:67428952	chr12:67351436~67352039:+
BRCA	cis	rs1598856	1	rs1598856	ENSG00000246560.2	RP11-10L12.4	4.85	1.4e-06	0.000138	0.16	0.15	Primary biliary cholangitis;	chr4:102524958	chr4:102828055~102844075:+
BRCA	cis	rs875971	1	rs1981798	ENSG00000223473.2	GS1-124K5.3	4.85	1.4e-06	0.000138	0.11	0.15	Aortic root size;	chr7:66489916	chr7:66491049~66493566:-
BRCA	cis	rs12612619	0.732	rs1440044	ENSG00000229122.1	AGBL5-IT1	4.85	1.4e-06	0.000138	0.16	0.15	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27004086	chr2:27061038~27061815:+
BRCA	cis	rs2281558	0.876	rs6107025	ENSG00000230772.1	VN1R108P	-4.85	1.4e-06	0.000138	-0.2	-0.15	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25299244	chr20:25734264~25735093:+
BRCA	cis	rs11668609	0.766	rs10414075	ENSG00000268442.1	CTD-2027I19.2	4.85	1.4e-06	0.000138	0.2	0.15	Response to taxane treatment (docetaxel);	chr19:24055649	chr19:24162370~24163425:-
BRCA	cis	rs6921919	0.551	rs13201753	ENSG00000220721.1	OR1F12	4.85	1.4e-06	0.000138	0.18	0.15	Autism spectrum disorder or schizophrenia;	chr6:28363351	chr6:28073316~28074233:+
BRCA	cis	rs13326165	0.543	rs11707056	ENSG00000243224.1	RP5-1157M23.2	-4.85	1.4e-06	0.000138	-0.29	-0.15	HDL cholesterol levels;HDL cholesterol;	chr3:52287960	chr3:52239258~52241097:+
BRCA	cis	rs2834288	0.734	rs9984514	ENSG00000273102.1	AP000569.9	4.85	1.4e-06	0.000138	0.17	0.15	Gut microbiota (bacterial taxa);	chr21:33892370	chr21:33967101~33968573:-
BRCA	cis	rs3126085	0.515	rs12033221	ENSG00000237975.5	FLG-AS1	4.85	1.4e-06	0.000138	0.22	0.15	Atopic dermatitis;	chr1:152383637	chr1:152168125~152445456:+
BRCA	cis	rs875971	1	rs778710	ENSG00000223473.2	GS1-124K5.3	4.85	1.4e-06	0.000138	0.11	0.15	Aortic root size;	chr7:66389847	chr7:66491049~66493566:-
BRCA	cis	rs4218	0.608	rs34859729	ENSG00000277144.1	RP11-59H7.4	-4.85	1.4e-06	0.000138	-0.2	-0.15	Social communication problems;	chr15:59070117	chr15:59115547~59116089:-
BRCA	cis	rs7829975	0.522	rs6601689	ENSG00000233609.3	RP11-62H7.2	4.85	1.4e-06	0.000138	0.14	0.15	Mood instability;	chr8:8314761	chr8:8961200~8979025:+
BRCA	cis	rs859767	0.501	rs4954160	ENSG00000224043.6	CCNT2-AS1	4.85	1.4e-06	0.000138	0.2	0.15	Neuroticism;	chr2:134674122	chr2:134735464~134918710:-
BRCA	cis	rs4512344	0.509	rs2409784	ENSG00000255046.1	RP11-297N6.4	4.85	1.4e-06	0.000138	0.17	0.15	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:11539347	chr8:11797928~11802568:-
BRCA	cis	rs2227564	0.729	rs2688615	ENSG00000271816.1	BMS1P4	4.85	1.4e-06	0.000138	0.16	0.15	Crohn's disease;Inflammatory bowel disease;	chr10:73891741	chr10:73699151~73730487:-
BRCA	cis	rs1729951	0.575	rs12494558	ENSG00000239213.4	NCK1-AS1	4.85	1.4e-06	0.000138	0.15	0.15	Neuroticism;	chr3:136959939	chr3:136841726~136862054:-
BRCA	cis	rs6569038	0.528	rs1762200	ENSG00000253194.1	RP11-351A11.1	4.85	1.4e-06	0.000138	0.19	0.15	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr6:119004753	chr6:118934785~119031541:+
BRCA	cis	rs9907295	0.818	rs4796109	ENSG00000270977.1	AC015849.16	-4.85	1.41e-06	0.000139	-0.26	-0.15	Fibroblast growth factor basic levels;	chr17:35811904	chr17:35893707~35911023:-
BRCA	cis	rs7208859	0.573	rs216443	ENSG00000265443.1	CTD-2349P21.6	-4.85	1.41e-06	0.000139	-0.26	-0.15	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30604853	chr17:30726305~30727564:-
BRCA	cis	rs11673344	0.504	rs7245882	ENSG00000226686.6	LINC01535	-4.85	1.41e-06	0.000139	-0.19	-0.15	Obesity-related traits;	chr19:37089513	chr19:37251912~37265535:+
BRCA	cis	rs4906332	1	rs3783398	ENSG00000244691.1	RPL10AP1	4.85	1.41e-06	0.000139	0.19	0.15	Coronary artery disease;	chr14:103483041	chr14:103412119~103412761:-
BRCA	cis	rs4415084	1	rs10941677	ENSG00000251141.4	RP11-53O19.1	4.85	1.41e-06	0.000139	0.14	0.15	Breast cancer;	chr5:44662297	chr5:44744900~44808777:-
BRCA	cis	rs7119	0.651	rs12917431	ENSG00000259362.2	RP11-307C19.1	-4.85	1.41e-06	0.000139	-0.21	-0.15	Type 2 diabetes;	chr15:77557842	chr15:77525540~77534110:+
BRCA	cis	rs6832769	1	rs576779	ENSG00000272969.1	RP11-528I4.2	4.85	1.41e-06	0.000139	0.18	0.15	Personality dimensions;	chr4:55408140	chr4:55547112~55547889:+
BRCA	cis	rs6832769	0.961	rs480479	ENSG00000272969.1	RP11-528I4.2	4.85	1.41e-06	0.000139	0.18	0.15	Personality dimensions;	chr4:55408163	chr4:55547112~55547889:+
BRCA	cis	rs3176789	0.914	rs1029992	ENSG00000256673.1	RP11-599J14.2	4.85	1.41e-06	0.000139	0.19	0.15	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9773162	chr12:9398355~9414851:-
BRCA	cis	rs3176789	0.914	rs1029990	ENSG00000256673.1	RP11-599J14.2	4.85	1.41e-06	0.000139	0.19	0.15	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9773801	chr12:9398355~9414851:-
BRCA	cis	rs3176789	0.914	rs10844749	ENSG00000256673.1	RP11-599J14.2	4.85	1.41e-06	0.000139	0.19	0.15	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9774028	chr12:9398355~9414851:-
BRCA	cis	rs10510102	0.507	rs12244092	ENSG00000226864.1	ATE1-AS1	4.85	1.41e-06	0.000139	0.28	0.15	Breast cancer;	chr10:122005769	chr10:121928312~121951965:+
BRCA	cis	rs950880	0.767	rs11123923	ENSG00000234389.1	AC007278.3	-4.85	1.41e-06	0.000139	-0.14	-0.15	Serum protein levels (sST2);	chr2:102351384	chr2:102438713~102440475:+
BRCA	cis	rs9402743	0.597	rs9385729	ENSG00000231028.7	LINC00271	-4.85	1.41e-06	0.000139	-0.15	-0.15	Systemic lupus erythematosus;	chr6:135600001	chr6:135497801~135716055:+
BRCA	cis	rs78487399	0.808	rs17030946	ENSG00000234936.1	AC010883.5	4.85	1.41e-06	0.000139	0.24	0.15	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43506370	chr2:43229573~43233394:+
BRCA	cis	rs7789940	0.857	rs12532935	ENSG00000186704.9	DTX2P1	4.85	1.41e-06	0.000139	0.18	0.15	Multiple sclerosis;	chr7:76310381	chr7:76978617~77004308:+
BRCA	cis	rs35740288	0.753	rs4843095	ENSG00000259407.1	RP11-158M2.3	-4.85	1.41e-06	0.000139	-0.2	-0.15	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85731900	chr15:85744109~85750281:-
BRCA	cis	rs11089937	0.616	rs928895	ENSG00000211638.2	IGLV8-61	-4.85	1.41e-06	0.000139	-0.14	-0.15	Periodontitis (PAL4Q3);	chr22:22185915	chr22:22098700~22099212:+
BRCA	cis	rs1950326	0.515	rs4902773	ENSG00000258526.4	RP11-111A21.1	-4.85	1.41e-06	0.000139	-0.19	-0.15	Verbal memory performance (residualized delayed recall level);	chr14:39562784	chr14:39474840~39513780:+
BRCA	cis	rs10504130	0.696	rs75833886	ENSG00000253844.1	RP11-546K22.1	-4.85	1.41e-06	0.000139	-0.23	-0.15	Venous thromboembolism (SNP x SNP interaction);	chr8:51929844	chr8:51961458~52022974:+
BRCA	cis	rs10504130	0.696	rs17284746	ENSG00000253844.1	RP11-546K22.1	-4.85	1.41e-06	0.000139	-0.23	-0.15	Venous thromboembolism (SNP x SNP interaction);	chr8:51930320	chr8:51961458~52022974:+
BRCA	cis	rs6600671	1	rs12047116	ENSG00000275538.1	RNVU1-19	4.85	1.42e-06	0.000139	0.17	0.15	Hip geometry;	chr1:121443912	chr1:120850819~120850985:-
BRCA	cis	rs6600671	0.967	rs11249347	ENSG00000275538.1	RNVU1-19	4.85	1.42e-06	0.000139	0.17	0.15	Hip geometry;	chr1:121446489	chr1:120850819~120850985:-
BRCA	cis	rs783540	0.656	rs783538	ENSG00000255769.6	GOLGA2P10	4.85	1.42e-06	0.000139	0.18	0.15	Schizophrenia;	chr15:82584394	chr15:82472993~82513950:-
BRCA	cis	rs4489787	1	rs12298871	ENSG00000240399.1	RP1-228P16.1	4.85	1.42e-06	0.000139	0.26	0.15	Prostate cancer (SNP x SNP interaction);	chr12:48395194	chr12:48054813~48055591:-
BRCA	cis	rs12497850	0.897	rs7373778	ENSG00000225399.4	RP11-3B7.1	4.85	1.42e-06	0.000139	0.15	0.15	Parkinson's disease;	chr3:48798959	chr3:49260085~49261316:+
BRCA	cis	rs875971	0.862	rs6959268	ENSG00000236529.1	RP13-254B10.1	-4.85	1.42e-06	0.00014	-0.16	-0.15	Aortic root size;	chr7:66347979	chr7:65840212~65840596:+
BRCA	cis	rs2277027	0.955	rs7728609	ENSG00000248544.2	CTB-47B11.3	4.85	1.42e-06	0.00014	0.18	0.15	Pulmonary function;Pulmonary function (smoking interaction);	chr5:157508516	chr5:157375741~157384950:-
BRCA	cis	rs2277027	1	rs7729274	ENSG00000248544.2	CTB-47B11.3	4.85	1.42e-06	0.00014	0.18	0.15	Pulmonary function;Pulmonary function (smoking interaction);	chr5:157508900	chr5:157375741~157384950:-
BRCA	cis	rs780094	0.5	rs4666002	ENSG00000234072.1	AC074117.10	4.85	1.42e-06	0.00014	0.16	0.15	Urate levels in overweight individuals;C-reactive protein;Metabolic syndrome;Red blood cell count;Renal underexcretion gout;Nonalcoholic fatty liver disease;Age-related diseases, mortality and associated endophenotypes;Crohn's disease;Calcium levels;Fasting plasma glucose;Metabolic traits;Fasting blood glucose;Fasting blood insulin;Urate levels in obese individuals;Alcohol consumption (drinks per week);Height;Urate levels;Gondoic acid (20:1n-9) levels;Uric acid levels;Age-related disease endophenotypes;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Homeostasis model assessment of insulin resistance;Alcohol consumption;Fasting blood insulin (BMI interaction);Triglycerides;Fasting blood glucose (BMI interaction);Hypertriglyceridemia;LDL cholesterol;Type 2 diabetes;Triglyceride levels;	chr2:27617773	chr2:27356246~27367622:+
BRCA	cis	rs2835345	0.563	rs12482423	ENSG00000279365.1	KB-176G8.1	4.85	1.42e-06	0.00014	0.2	0.15	Pulmonary function;	chr21:36448662	chr21:36485867~36487760:+
BRCA	cis	rs6490294	0.904	rs60217649	ENSG00000226469.1	ADAM1B	4.85	1.42e-06	0.00014	0.19	0.15	Mean platelet volume;	chr12:111973116	chr12:111927018~111929017:+
BRCA	cis	rs2638953	0.64	rs10843204	ENSG00000247934.4	RP11-967K21.1	-4.85	1.42e-06	0.00014	-0.21	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28568028	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.64	rs10843205	ENSG00000247934.4	RP11-967K21.1	-4.85	1.42e-06	0.00014	-0.21	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28568220	chr12:28163298~28190738:-
BRCA	cis	rs11239930	0.538	rs604716	ENSG00000278811.3	LINC00624	4.85	1.42e-06	0.00014	0.18	0.15	AIDS progression;	chr1:147073173	chr1:147258885~147517875:-
BRCA	cis	rs638893	0.617	rs4938565	ENSG00000278376.1	RP11-158I9.8	4.85	1.42e-06	0.00014	0.16	0.15	Vitiligo;	chr11:118850289	chr11:118791254~118793137:+
BRCA	cis	rs9467773	0.62	rs2451738	ENSG00000241549.7	GUSBP2	-4.85	1.42e-06	0.00014	-0.16	-0.15	Intelligence (multi-trait analysis);	chr6:26618231	chr6:26871484~26956554:-
BRCA	cis	rs11239930	0.538	rs4950362	ENSG00000278811.3	LINC00624	4.85	1.42e-06	0.00014	0.18	0.15	AIDS progression;	chr1:147088336	chr1:147258885~147517875:-
BRCA	cis	rs189798	0.738	rs330908	ENSG00000253893.2	FAM85B	-4.85	1.42e-06	0.00014	-0.19	-0.15	Myopia (pathological);	chr8:9137656	chr8:8167819~8226614:-
BRCA	cis	rs8180040	0.966	rs57346147	ENSG00000271161.1	BOLA2P2	-4.85	1.42e-06	0.00014	-0.16	-0.15	Colorectal cancer;	chr3:47369074	chr3:47499841~47500407:+
BRCA	cis	rs62025270	0.593	rs7166540	ENSG00000259762.1	RP11-158M2.4	-4.85	1.42e-06	0.00014	-0.22	-0.15	Idiopathic pulmonary fibrosis;	chr15:85700854	chr15:85750336~85752901:-
BRCA	cis	rs13113518	1	rs13116194	ENSG00000249700.7	SRD5A3-AS1	4.85	1.42e-06	0.00014	0.18	0.15	Height;	chr4:55531150	chr4:55363971~55395847:-
BRCA	cis	rs13113518	1	rs13117836	ENSG00000249700.7	SRD5A3-AS1	4.85	1.42e-06	0.00014	0.18	0.15	Height;	chr4:55531218	chr4:55363971~55395847:-
BRCA	cis	rs13113518	0.966	rs7668429	ENSG00000249700.7	SRD5A3-AS1	4.85	1.42e-06	0.00014	0.18	0.15	Height;	chr4:55531811	chr4:55363971~55395847:-
BRCA	cis	rs12681366	0.801	rs2011246	ENSG00000253175.1	RP11-267M23.6	4.85	1.42e-06	0.00014	0.18	0.15	Nonsyndromic cleft lip with cleft palate;	chr8:94450846	chr8:94565036~94565715:+
BRCA	cis	rs6570726	0.791	rs370654	ENSG00000270638.1	RP3-466P17.1	4.85	1.42e-06	0.00014	0.17	0.15	Lobe attachment (rater-scored or self-reported);	chr6:145557869	chr6:145735570~145737218:+
BRCA	cis	rs7916697	0.52	rs10762201	ENSG00000233590.1	RP11-153K11.3	4.85	1.42e-06	0.00014	0.19	0.15	Optic disc area;	chr10:68280354	chr10:68233251~68242379:-
BRCA	cis	rs78487399	0.908	rs35478206	ENSG00000234936.1	AC010883.5	4.85	1.42e-06	0.00014	0.2	0.15	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43603893	chr2:43229573~43233394:+
BRCA	cis	rs78487399	0.908	rs7559723	ENSG00000234936.1	AC010883.5	4.85	1.42e-06	0.00014	0.2	0.15	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43604910	chr2:43229573~43233394:+
BRCA	cis	rs4356203	0.905	rs11821773	ENSG00000272034.1	SNORD14A	-4.85	1.42e-06	0.00014	-0.15	-0.15	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17095807	chr11:17074654~17074744:-
BRCA	cis	rs700651	0.789	rs62277902	ENSG00000231621.1	AC013264.2	4.85	1.42e-06	0.00014	0.15	0.15	Intracranial aneurysm;	chr2:198014719	chr2:197197991~197199273:+
BRCA	cis	rs2880765	0.566	rs12911430	ENSG00000230373.7	GOLGA6L5P	4.85	1.42e-06	0.00014	0.17	0.15	Coronary artery disease;	chr15:85468033	chr15:84507885~84516814:-
BRCA	cis	rs62244186	0.535	rs59726036	ENSG00000233509.2	ZNF197-AS1	4.85	1.42e-06	0.00014	0.18	0.15	Depressive symptoms;	chr3:44808582	chr3:44617128~44624797:-
BRCA	cis	rs6847067	0.644	rs6816534	ENSG00000180769.7	WDFY3-AS2	4.85	1.42e-06	0.00014	0.15	0.15	Oropharynx cancer;	chr4:84700619	chr4:84965682~85011277:+
BRCA	cis	rs6671200	1	rs71654419	ENSG00000235501.4	RP4-639F20.1	-4.85	1.43e-06	0.00014	-0.35	-0.15	Stearic acid (18:0) levels;	chr1:95198941	chr1:94927566~94963270:+
BRCA	cis	rs4356203	0.87	rs214900	ENSG00000272034.1	SNORD14A	4.85	1.43e-06	0.00014	0.15	0.15	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17206215	chr11:17074654~17074744:-
BRCA	cis	rs9907295	0.786	rs9901418	ENSG00000271013.1	AC015849.15	-4.85	1.43e-06	0.00014	-0.23	-0.15	Fibroblast growth factor basic levels;	chr17:35915699	chr17:35912635~35918010:-
BRCA	cis	rs7246657	0.722	rs2287229	ENSG00000226686.6	LINC01535	4.85	1.43e-06	0.00014	0.22	0.15	Coronary artery calcification;	chr19:37697751	chr19:37251912~37265535:+
BRCA	cis	rs10833905	1	rs57275726	ENSG00000246225.5	RP11-17A1.3	-4.85	1.43e-06	0.00014	-0.2	-0.15	Sudden cardiac arrest;	chr11:23024166	chr11:22829380~22945393:+
BRCA	cis	rs1707322	1	rs10890380	ENSG00000234329.1	RP11-767N6.2	4.85	1.43e-06	0.00014	0.15	0.15	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45983797	chr1:45651039~45651826:-
BRCA	cis	rs1005277	0.602	rs1831315	ENSG00000263064.2	RP11-291L22.7	4.85	1.43e-06	0.00014	0.18	0.15	Extrinsic epigenetic age acceleration;	chr10:38184425	chr10:38448689~38448949:+
BRCA	cis	rs300890	0.662	rs10012713	ENSG00000250326.1	RP11-284M14.1	-4.85	1.43e-06	0.00014	-0.17	-0.15	Nasopharyngeal carcinoma;	chr4:143303957	chr4:142933195~143184861:-
BRCA	cis	rs7246657	0.722	rs2909105	ENSG00000226686.6	LINC01535	4.85	1.43e-06	0.00014	0.22	0.15	Coronary artery calcification;	chr19:37677005	chr19:37251912~37265535:+
BRCA	cis	rs4787491	0.729	rs3814878	ENSG00000261367.1	RP11-455F5.4	-4.85	1.43e-06	0.00014	-0.17	-0.15	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30030645	chr16:30107675~30110541:+
BRCA	cis	rs12744310	0.887	rs35436312	ENSG00000235358.1	RP11-399E6.1	4.85	1.43e-06	0.00014	0.22	0.15	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41327686	chr1:41242373~41284861:+
BRCA	cis	rs12744310	0.887	rs1316274	ENSG00000235358.1	RP11-399E6.1	4.85	1.43e-06	0.00014	0.22	0.15	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41327986	chr1:41242373~41284861:+
BRCA	cis	rs5742933	0.696	rs6748102	ENSG00000253559.1	OSGEPL1-AS1	-4.85	1.43e-06	0.000141	-0.27	-0.15	Ferritin levels;	chr2:189760786	chr2:189762704~189765556:+
BRCA	cis	rs17507216	0.681	rs28877110	ENSG00000255769.6	GOLGA2P10	-4.85	1.43e-06	0.000141	-0.22	-0.15	Excessive daytime sleepiness;	chr15:82672111	chr15:82472993~82513950:-
BRCA	cis	rs2281558	1	rs2281558	ENSG00000230772.1	VN1R108P	-4.85	1.43e-06	0.000141	-0.19	-0.15	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25259553	chr20:25734264~25735093:+
BRCA	cis	rs754466	1	rs2278218	ENSG00000204049.1	RP11-126H7.4	4.85	1.43e-06	0.000141	0.2	0.15	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77920641	chr10:77866875~77869610:+
BRCA	cis	rs6545883	0.929	rs1209434	ENSG00000270820.4	RP11-355B11.2	4.85	1.43e-06	0.000141	0.17	0.15	Tuberculosis;	chr2:61445823	chr2:61471188~61484130:+
BRCA	cis	rs11638815	0.626	rs1313492	ENSG00000259429.4	UBE2Q2P2	-4.85	1.43e-06	0.000141	-0.14	-0.15	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82604206	chr15:82355142~82420075:+
BRCA	cis	rs7617773	0.78	rs71323396	ENSG00000199476.1	Y_RNA	-4.85	1.43e-06	0.000141	-0.22	-0.15	Coronary artery disease;	chr3:48333244	chr3:48288587~48288694:+
BRCA	cis	rs2638953	0.604	rs10843100	ENSG00000278733.1	RP11-425D17.1	-4.85	1.43e-06	0.000141	-0.21	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28117101	chr12:28185625~28186190:-
BRCA	cis	rs7116495	0.609	rs10501408	ENSG00000248671.6	ALG1L9P	-4.85	1.43e-06	0.000141	-0.36	-0.15	Severe influenza A (H1N1) infection;	chr11:71969544	chr11:71794363~71818238:-
BRCA	cis	rs2179367	0.6	rs11155654	ENSG00000268592.3	RAET1E-AS1	4.85	1.43e-06	0.000141	0.22	0.15	Dupuytren's disease;	chr6:149442001	chr6:149863494~149919507:+
BRCA	cis	rs4664293	1	rs6745766	ENSG00000226266.5	AC009961.3	-4.85	1.43e-06	0.000141	-0.18	-0.15	Monocyte percentage of white cells;	chr2:159598284	chr2:159670708~159712435:-
BRCA	cis	rs6596100	0.868	rs67394705	ENSG00000248648.1	RP11-485M7.1	-4.85	1.43e-06	0.000141	-0.19	-0.15	Breast cancer;	chr5:133107563	chr5:133003119~133003365:+
BRCA	cis	rs4713118	0.525	rs9357042	ENSG00000220721.1	OR1F12	4.85	1.43e-06	0.000141	0.17	0.15	Parkinson's disease;	chr6:27615016	chr6:28073316~28074233:+
BRCA	cis	rs7246657	0.722	rs2909105	ENSG00000276846.1	CTD-3220F14.3	-4.85	1.43e-06	0.000141	-0.2	-0.15	Coronary artery calcification;	chr19:37677005	chr19:37314868~37315620:-
BRCA	cis	rs2562456	0.792	rs2562398	ENSG00000268658.4	LINC00664	-4.85	1.43e-06	0.000141	-0.23	-0.15	Pain;	chr19:21540147	chr19:21483374~21503238:+
BRCA	cis	rs7226408	0.857	rs72890579	ENSG00000267707.2	RP11-95O2.5	4.85	1.43e-06	0.000141	0.22	0.15	Obesity-related traits;	chr18:37046493	chr18:37243776~37247506:+
BRCA	cis	rs977987	0.806	rs1109342	ENSG00000280152.1	RP11-331F4.5	4.85	1.43e-06	0.000141	0.16	0.15	Dupuytren's disease;	chr16:75411777	chr16:75245994~75250077:-
BRCA	cis	rs1124769	0.525	rs8033807	ENSG00000259378.1	DCAF13P3	4.85	1.43e-06	0.000141	0.19	0.15	Cognitive performance;	chr15:50778531	chr15:50944663~50945996:+
BRCA	cis	rs7487075	0.619	rs4768719	ENSG00000274723.1	RP11-618L22.1	4.85	1.44e-06	0.000141	0.2	0.15	Itch intensity from mosquito bite;	chr12:46447055	chr12:46970504~46972155:+
BRCA	cis	rs2235642	0.691	rs2281235	ENSG00000260989.1	LA16c-395F10.2	-4.85	1.44e-06	0.000141	-0.15	-0.15	Coronary artery disease;	chr16:1553534	chr16:1580527~1610328:+
BRCA	cis	rs7200543	1	rs35574015	ENSG00000260872.1	RP11-680G24.5	-4.85	1.44e-06	0.000141	-0.16	-0.15	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15052204	chr16:15018106~15020488:-
BRCA	cis	rs372883	0.53	rs2832226	ENSG00000215533.7	LINC00189	-4.85	1.44e-06	0.000141	-0.17	-0.15	Pancreatic cancer;	chr21:29160665	chr21:29193480~29288205:+
BRCA	cis	rs1707322	1	rs3922887	ENSG00000234329.1	RP11-767N6.2	4.85	1.44e-06	0.000141	0.15	0.15	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46008130	chr1:45651039~45651826:-
BRCA	cis	rs1707322	1	rs3922886	ENSG00000234329.1	RP11-767N6.2	4.85	1.44e-06	0.000141	0.15	0.15	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46008230	chr1:45651039~45651826:-
BRCA	cis	rs8054556	0.967	rs11150576	ENSG00000273724.1	RP11-347C12.12	-4.85	1.44e-06	0.000141	-0.17	-0.15	Autism spectrum disorder or schizophrenia;	chr16:29954175	chr16:30336400~30343336:+
BRCA	cis	rs4356203	0.87	rs214922	ENSG00000272034.1	SNORD14A	-4.85	1.44e-06	0.000142	-0.15	-0.15	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17215576	chr11:17074654~17074744:-
BRCA	cis	rs4356203	0.811	rs214920	ENSG00000272034.1	SNORD14A	-4.85	1.44e-06	0.000142	-0.15	-0.15	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17216402	chr11:17074654~17074744:-
BRCA	cis	rs8054556	0.787	rs12325400	ENSG00000261367.1	RP11-455F5.4	-4.85	1.44e-06	0.000142	-0.17	-0.15	Autism spectrum disorder or schizophrenia;	chr16:30012465	chr16:30107675~30110541:+
BRCA	cis	rs854765	0.583	rs2350977	ENSG00000197815.4	RP1-253P7.4	-4.85	1.44e-06	0.000142	-0.1	-0.15	Total body bone mineral density;	chr17:17899465	chr17:17858227~17860041:+
BRCA	cis	rs4578769	0.733	rs7226388	ENSG00000265939.1	UBE2CP2	4.85	1.44e-06	0.000142	0.18	0.15	Eosinophil percentage of white cells;	chr18:22865371	chr18:22900486~22900995:-
BRCA	cis	rs853679	0.723	rs9366718	ENSG00000280107.1	AL022393.9	-4.85	1.44e-06	0.000142	-0.24	-0.15	Depression;	chr6:28237724	chr6:28170845~28172521:+
BRCA	cis	rs56322409	0.865	rs1935815	ENSG00000226688.5	ENTPD1-AS1	4.85	1.44e-06	0.000142	0.17	0.15	Blood metabolite levels;	chr10:95871735	chr10:95753206~96090238:-
BRCA	cis	rs875971	0.825	rs7384021	ENSG00000236529.1	RP13-254B10.1	-4.85	1.44e-06	0.000142	-0.17	-0.15	Aortic root size;	chr7:66612917	chr7:65840212~65840596:+
BRCA	cis	rs7772486	0.875	rs2814877	ENSG00000270638.1	RP3-466P17.1	4.85	1.44e-06	0.000142	0.18	0.15	Lobe attachment (rater-scored or self-reported);	chr6:145978627	chr6:145735570~145737218:+
BRCA	cis	rs1075265	0.704	rs10084374	ENSG00000235937.1	AC008280.1	4.85	1.44e-06	0.000142	0.16	0.15	Chronotype;Morning vs. evening chronotype;	chr2:54022175	chr2:54029552~54030682:-
BRCA	cis	rs10457838	0.814	rs56358125	ENSG00000236591.1	RP11-162J8.3	-4.85	1.44e-06	0.000142	-0.21	-0.15	Post-traumatic stress disorder;	chr6:149054909	chr6:149027700~149032573:-
BRCA	cis	rs454217	0.846	rs1661029	ENSG00000277851.1	RP11-756G20.1	4.85	1.44e-06	0.000142	0.17	0.15	Smoking quantity;	chr12:92324197	chr12:92247756~92363832:-
BRCA	cis	rs9467773	0.62	rs2504540	ENSG00000124549.13	BTN2A3P	4.85	1.44e-06	0.000142	0.15	0.15	Intelligence (multi-trait analysis);	chr6:26641398	chr6:26421391~26432383:+
BRCA	cis	rs78487399	0.71	rs75330033	ENSG00000234936.1	AC010883.5	4.85	1.44e-06	0.000142	0.26	0.15	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43470584	chr2:43229573~43233394:+
BRCA	cis	rs78487399	0.71	rs80147536	ENSG00000234936.1	AC010883.5	4.85	1.44e-06	0.000142	0.26	0.15	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43470889	chr2:43229573~43233394:+
BRCA	cis	rs78487399	0.808	rs75135247	ENSG00000234936.1	AC010883.5	4.85	1.44e-06	0.000142	0.26	0.15	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43472260	chr2:43229573~43233394:+
BRCA	cis	rs2243480	1	rs160639	ENSG00000275400.1	RP4-756H11.5	4.85	1.44e-06	0.000142	0.27	0.15	Diabetic kidney disease;	chr7:66115000	chr7:66553805~66554199:-
BRCA	cis	rs8098244	0.964	rs8091948	ENSG00000264745.1	TTC39C-AS1	4.85	1.45e-06	0.000142	0.2	0.15	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23793331	chr18:23994213~24015339:-
BRCA	cis	rs875971	1	rs6945843	ENSG00000223473.2	GS1-124K5.3	-4.85	1.45e-06	0.000142	-0.11	-0.15	Aortic root size;	chr7:66269796	chr7:66491049~66493566:-
BRCA	cis	rs11098499	0.754	rs12506610	ENSG00000249244.1	RP11-548H18.2	4.85	1.45e-06	0.000142	0.17	0.15	Corneal astigmatism;	chr4:119320504	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.743	rs10003567	ENSG00000249244.1	RP11-548H18.2	4.85	1.45e-06	0.000142	0.17	0.15	Corneal astigmatism;	chr4:119320519	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.754	rs10006259	ENSG00000249244.1	RP11-548H18.2	4.85	1.45e-06	0.000142	0.17	0.15	Corneal astigmatism;	chr4:119320990	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.754	rs28652763	ENSG00000249244.1	RP11-548H18.2	4.85	1.45e-06	0.000142	0.17	0.15	Corneal astigmatism;	chr4:119321157	chr4:119391831~119395335:-
BRCA	cis	rs651907	0.557	rs2288272	ENSG00000256628.3	ZBTB11-AS1	4.85	1.45e-06	0.000142	0.19	0.15	Colorectal cancer;	chr3:101659632	chr3:101676475~101679217:+
BRCA	cis	rs1832007	0.529	rs7100517	ENSG00000224034.1	RP11-445P17.8	-4.85	1.45e-06	0.000142	-0.24	-0.15	Triglyceride levels;Triglycerides;	chr10:5201007	chr10:5266033~5271236:-
BRCA	cis	rs1832007	0.529	rs7085249	ENSG00000224034.1	RP11-445P17.8	-4.85	1.45e-06	0.000142	-0.24	-0.15	Triglyceride levels;Triglycerides;	chr10:5201054	chr10:5266033~5271236:-
BRCA	cis	rs950880	0.796	rs12987977	ENSG00000234389.1	AC007278.3	-4.85	1.45e-06	0.000142	-0.14	-0.15	Serum protein levels (sST2);	chr2:102358876	chr2:102438713~102440475:+
BRCA	cis	rs2243480	1	rs313802	ENSG00000222364.1	RNU6-96P	-4.85	1.45e-06	0.000142	-0.28	-0.15	Diabetic kidney disease;	chr7:66051386	chr7:66395191~66395286:+
BRCA	cis	rs2243480	0.803	rs403089	ENSG00000222364.1	RNU6-96P	-4.85	1.45e-06	0.000142	-0.28	-0.15	Diabetic kidney disease;	chr7:66052736	chr7:66395191~66395286:+
BRCA	cis	rs2243480	1	rs458291	ENSG00000222364.1	RNU6-96P	-4.85	1.45e-06	0.000142	-0.28	-0.15	Diabetic kidney disease;	chr7:66055492	chr7:66395191~66395286:+
BRCA	cis	rs57221529	0.766	rs58015612	ENSG00000271781.1	CTD-2589H19.6	-4.85	1.45e-06	0.000142	-0.22	-0.15	Lung disease severity in cystic fibrosis;	chr5:580550	chr5:675826~676616:+
BRCA	cis	rs57221529	0.766	rs56216231	ENSG00000271781.1	CTD-2589H19.6	-4.85	1.45e-06	0.000142	-0.22	-0.15	Lung disease severity in cystic fibrosis;	chr5:581078	chr5:675826~676616:+
BRCA	cis	rs2562456	0.833	rs62110428	ENSG00000268081.1	RP11-678G14.2	4.85	1.45e-06	0.000142	0.24	0.15	Pain;	chr19:21430854	chr19:21554640~21569237:-
BRCA	cis	rs2279168	1	rs2279168	ENSG00000259407.1	RP11-158M2.3	4.85	1.45e-06	0.000142	0.24	0.15	Response to platinum-based chemotherapy (carboplatin);	chr15:85533958	chr15:85744109~85750281:-
BRCA	cis	rs78487399	0.908	rs75621188	ENSG00000234936.1	AC010883.5	4.85	1.45e-06	0.000142	0.23	0.15	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43619536	chr2:43229573~43233394:+
BRCA	cis	rs10911251	0.528	rs10911263	ENSG00000224468.3	RP11-181K3.4	-4.85	1.45e-06	0.000142	-0.16	-0.15	Colorectal cancer;	chr1:183145883	chr1:183138402~183141282:-
BRCA	cis	rs10911251	0.528	rs10911264	ENSG00000224468.3	RP11-181K3.4	-4.85	1.45e-06	0.000142	-0.16	-0.15	Colorectal cancer;	chr1:183145905	chr1:183138402~183141282:-
BRCA	cis	rs7481584	0.624	rs2106229	ENSG00000247473.2	CARS-AS1	-4.85	1.45e-06	0.000142	-0.18	-0.15	Calcium levels;	chr11:3019965	chr11:3029009~3041260:+
BRCA	cis	rs9291683	0.527	rs3822241	ENSG00000250413.1	RP11-448G15.1	4.85	1.45e-06	0.000142	0.2	0.15	Bone mineral density;	chr4:10093307	chr4:10006482~10009725:+
BRCA	cis	rs2281636	1	rs2281636	ENSG00000233690.1	EBAG9P1	-4.85	1.45e-06	0.000142	-0.16	-0.15	Obesity-related traits;	chr10:99732646	chr10:99697407~99697949:-
BRCA	cis	rs62025270	0.688	rs7179917	ENSG00000259762.1	RP11-158M2.4	-4.85	1.45e-06	0.000142	-0.22	-0.15	Idiopathic pulmonary fibrosis;	chr15:85722413	chr15:85750336~85752901:-
BRCA	cis	rs7267979	1	rs2856	ENSG00000125804.12	FAM182A	-4.85	1.45e-06	0.000142	-0.19	-0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25452900	chr20:26054655~26086917:+
BRCA	cis	rs3176789	0.914	rs1029991	ENSG00000256673.1	RP11-599J14.2	4.85	1.45e-06	0.000143	0.19	0.15	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9773468	chr12:9398355~9414851:-
BRCA	cis	rs6545883	0.895	rs2421192	ENSG00000270820.4	RP11-355B11.2	-4.85	1.45e-06	0.000143	-0.17	-0.15	Tuberculosis;	chr2:61416496	chr2:61471188~61484130:+
BRCA	cis	rs9818758	0.607	rs11719220	ENSG00000270441.1	RP11-694I15.7	4.85	1.45e-06	0.000143	0.29	0.15	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49207768	chr3:49140086~49160851:-
BRCA	cis	rs7487075	0.619	rs10880969	ENSG00000274723.1	RP11-618L22.1	4.85	1.45e-06	0.000143	0.2	0.15	Itch intensity from mosquito bite;	chr12:46433240	chr12:46970504~46972155:+
BRCA	cis	rs1395	0.778	rs2580761	ENSG00000234072.1	AC074117.10	-4.85	1.45e-06	0.000143	-0.16	-0.15	Blood metabolite levels;	chr2:27203494	chr2:27356246~27367622:+
BRCA	cis	rs1499614	1	rs2141924	ENSG00000222364.1	RNU6-96P	-4.85	1.45e-06	0.000143	-0.28	-0.15	Gout;	chr7:66721259	chr7:66395191~66395286:+
BRCA	cis	rs7208859	0.673	rs9889755	ENSG00000264538.5	SUZ12P1	4.85	1.45e-06	0.000143	0.2	0.15	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30907487	chr17:30709299~30790908:+
BRCA	cis	rs7839435	0.53	rs6558008	ENSG00000234770.1	GULOP	-4.85	1.45e-06	0.000143	-0.19	-0.15	Lung adenocarcinoma;	chr8:27580789	chr8:27560274~27589073:+
BRCA	cis	rs6570726	0.967	rs418662	ENSG00000270638.1	RP3-466P17.1	4.85	1.45e-06	0.000143	0.17	0.15	Lobe attachment (rater-scored or self-reported);	chr6:145527696	chr6:145735570~145737218:+
BRCA	cis	rs465969	0.744	rs3851228	ENSG00000230177.1	RP5-1112D6.4	-4.85	1.45e-06	0.000143	-0.29	-0.15	Psoriasis;	chr6:111526988	chr6:111277932~111278742:+
BRCA	cis	rs600231	0.708	rs1784860	ENSG00000173727.10	CMB9-22P13.1	4.85	1.45e-06	0.000143	0.19	0.15	Bone mineral density;	chr11:65473241	chr11:65455258~65466720:+
BRCA	cis	rs8054556	0.787	rs11649274	ENSG00000261367.1	RP11-455F5.4	-4.85	1.45e-06	0.000143	-0.17	-0.15	Autism spectrum disorder or schizophrenia;	chr16:30015148	chr16:30107675~30110541:+
BRCA	cis	rs4650994	0.524	rs2476558	ENSG00000273384.1	RP5-1098D14.1	-4.85	1.45e-06	0.000143	-0.19	-0.15	HDL cholesterol;HDL cholesterol levels;	chr1:178611818	chr1:178651706~178652282:+
BRCA	cis	rs2243480	1	rs1267820	ENSG00000275400.1	RP4-756H11.5	4.85	1.45e-06	0.000143	0.27	0.15	Diabetic kidney disease;	chr7:66585308	chr7:66553805~66554199:-
BRCA	cis	rs7226408	0.857	rs72890583	ENSG00000267707.2	RP11-95O2.5	4.85	1.45e-06	0.000143	0.22	0.15	Obesity-related traits;	chr18:37047943	chr18:37243776~37247506:+
BRCA	cis	rs4356203	0.875	rs680205	ENSG00000272034.1	SNORD14A	-4.85	1.45e-06	0.000143	-0.15	-0.15	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17186210	chr11:17074654~17074744:-
BRCA	cis	rs8064024	0.62	rs9923349	ENSG00000267077.1	RP11-127I20.5	4.85	1.45e-06	0.000143	0.15	0.15	Cancer;	chr16:4855123	chr16:4795265~4796532:-
BRCA	cis	rs875971	0.545	rs6460281	ENSG00000273142.1	RP11-458F8.4	4.85	1.45e-06	0.000143	0.15	0.15	Aortic root size;	chr7:66216128	chr7:66902857~66906297:+
BRCA	cis	rs1075265	0.704	rs805405	ENSG00000235937.1	AC008280.1	4.85	1.46e-06	0.000143	0.16	0.15	Chronotype;Morning vs. evening chronotype;	chr2:53891014	chr2:54029552~54030682:-
BRCA	cis	rs3768617	0.565	rs4233194	ENSG00000224468.3	RP11-181K3.4	-4.85	1.46e-06	0.000143	-0.16	-0.15	Fuchs's corneal dystrophy;	chr1:183091782	chr1:183138402~183141282:-
BRCA	cis	rs7618915	0.547	rs8906	ENSG00000243224.1	RP5-1157M23.2	-4.85	1.46e-06	0.000143	-0.17	-0.15	Bipolar disorder;	chr3:52705504	chr3:52239258~52241097:+
BRCA	cis	rs6671200	1	rs933107	ENSG00000235501.4	RP4-639F20.1	4.85	1.46e-06	0.000143	0.29	0.15	Stearic acid (18:0) levels;	chr1:95206673	chr1:94927566~94963270:+
BRCA	cis	rs4218	0.689	rs12902628	ENSG00000277144.1	RP11-59H7.4	-4.84	1.46e-06	0.000143	-0.2	-0.15	Social communication problems;	chr15:59100193	chr15:59115547~59116089:-
BRCA	cis	rs9543976	0.623	rs4885323	ENSG00000261105.4	LMO7-AS1	4.84	1.46e-06	0.000143	0.22	0.15	Diabetic retinopathy;	chr13:75598278	chr13:75604700~75635994:-
BRCA	cis	rs7968440	0.966	rs7977742	ENSG00000272368.2	RP4-605O3.4	4.84	1.46e-06	0.000143	0.16	0.15	Fibrinogen;	chr12:50736424	chr12:50112197~50165618:+
BRCA	cis	rs8040855	0.69	rs8041189	ENSG00000230373.7	GOLGA6L5P	-4.84	1.46e-06	0.000143	-0.19	-0.15	Bulimia nervosa;	chr15:85143096	chr15:84507885~84516814:-
BRCA	cis	rs3176789	0.872	rs1029993	ENSG00000256673.1	RP11-599J14.2	4.84	1.46e-06	0.000143	0.19	0.15	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9772843	chr12:9398355~9414851:-
BRCA	cis	rs66887589	0.967	rs59516282	ENSG00000245958.5	RP11-33B1.1	4.84	1.46e-06	0.000143	0.13	0.15	Diastolic blood pressure;	chr4:119580861	chr4:119454791~119552025:+
BRCA	cis	rs2835345	0.563	rs12482140	ENSG00000279365.1	KB-176G8.1	4.84	1.46e-06	0.000143	0.2	0.15	Pulmonary function;	chr21:36451735	chr21:36485867~36487760:+
BRCA	cis	rs2835345	0.528	rs73204243	ENSG00000279365.1	KB-176G8.1	4.84	1.46e-06	0.000143	0.2	0.15	Pulmonary function;	chr21:36451776	chr21:36485867~36487760:+
BRCA	cis	rs2835345	0.595	rs78237434	ENSG00000279365.1	KB-176G8.1	4.84	1.46e-06	0.000143	0.2	0.15	Pulmonary function;	chr21:36451826	chr21:36485867~36487760:+
BRCA	cis	rs9650657	0.529	rs10108618	ENSG00000154316.13	TDH	4.84	1.46e-06	0.000143	0.19	0.15	Neuroticism;	chr8:11095582	chr8:11339637~11368452:+
BRCA	cis	rs3764021	0.837	rs7306557	ENSG00000278635.1	CTD-2318O12.1	-4.84	1.46e-06	0.000143	-0.15	-0.15	Type 1 diabetes;	chr12:9724760	chr12:9415641~9416718:+
BRCA	cis	rs3733585	0.699	rs6839490	ENSG00000250413.1	RP11-448G15.1	-4.84	1.46e-06	0.000143	-0.2	-0.15	Cleft plate (environmental tobacco smoke interaction);	chr4:9963376	chr4:10006482~10009725:+
BRCA	cis	rs6957923	0.655	rs13241000	ENSG00000234286.1	AC006026.13	-4.84	1.46e-06	0.000143	-0.17	-0.15	Height;	chr7:23548516	chr7:23680195~23680786:-
BRCA	cis	rs2839186	0.605	rs2839173	ENSG00000228137.1	AP001469.7	4.84	1.46e-06	0.000143	0.16	0.15	Testicular germ cell tumor;	chr21:46256797	chr21:46246890~46247682:+
BRCA	cis	rs11239930	0.538	rs4950362	ENSG00000230832.3	RP11-325P15.2	-4.84	1.46e-06	0.000143	-0.21	-0.15	AIDS progression;	chr1:147088336	chr1:147082338~147083578:-
BRCA	cis	rs7772486	0.754	rs2328707	ENSG00000270638.1	RP3-466P17.1	-4.84	1.46e-06	0.000143	-0.17	-0.15	Lobe attachment (rater-scored or self-reported);	chr6:145732362	chr6:145735570~145737218:+
BRCA	cis	rs2278702	0.848	rs77593396	ENSG00000259495.2	RP11-210M15.2	-4.84	1.46e-06	0.000143	-0.23	-0.15	Bipolar disorder;	chr15:80387970	chr15:80344853~80403575:-
BRCA	cis	rs4781563	0.81	rs1799799	ENSG00000242307.1	RPS26P52	-4.84	1.46e-06	0.000143	-0.17	-0.15	Bilirubin levels;	chr16:13944688	chr16:13922332~13922679:-
BRCA	cis	rs754466	1	rs12220311	ENSG00000204049.1	RP11-126H7.4	4.84	1.46e-06	0.000144	0.2	0.15	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77921749	chr10:77866875~77869610:+
BRCA	cis	rs67981189	0.579	rs2240533	ENSG00000258571.1	PTTG4P	-4.84	1.46e-06	0.000144	-0.17	-0.15	Schizophrenia;	chr14:71074309	chr14:71085482~71085833:-
BRCA	cis	rs9921338	0.924	rs72773831	ENSG00000262703.1	RP11-485G7.6	-4.84	1.46e-06	0.000144	-0.19	-0.15	Vein graft stenosis in coronary artery bypass grafting;	chr16:11319070	chr16:11348143~11349321:-
BRCA	cis	rs13113518	1	rs1522112	ENSG00000249700.7	SRD5A3-AS1	4.84	1.46e-06	0.000144	0.18	0.15	Height;	chr4:55463606	chr4:55363971~55395847:-
BRCA	cis	rs13113518	1	rs4864997	ENSG00000249700.7	SRD5A3-AS1	4.84	1.46e-06	0.000144	0.18	0.15	Height;	chr4:55466010	chr4:55363971~55395847:-
BRCA	cis	rs13113518	1	rs960152	ENSG00000249700.7	SRD5A3-AS1	4.84	1.46e-06	0.000144	0.18	0.15	Height;	chr4:55467308	chr4:55363971~55395847:-
BRCA	cis	rs13113518	0.967	rs12644948	ENSG00000249700.7	SRD5A3-AS1	4.84	1.46e-06	0.000144	0.18	0.15	Height;	chr4:55470266	chr4:55363971~55395847:-
BRCA	cis	rs13113518	1	rs3805151	ENSG00000249700.7	SRD5A3-AS1	4.84	1.46e-06	0.000144	0.18	0.15	Height;	chr4:55470874	chr4:55363971~55395847:-
BRCA	cis	rs853679	1	rs853685	ENSG00000204709.4	LINC01556	4.84	1.46e-06	0.000144	0.26	0.15	Depression;	chr6:28321008	chr6:28943877~28944537:+
BRCA	cis	rs3176789	0.914	rs1029994	ENSG00000256673.1	RP11-599J14.2	4.84	1.46e-06	0.000144	0.19	0.15	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9772834	chr12:9398355~9414851:-
BRCA	cis	rs736408	0.609	rs13082960	ENSG00000243224.1	RP5-1157M23.2	-4.84	1.46e-06	0.000144	-0.17	-0.15	Bipolar disorder;	chr3:52751152	chr3:52239258~52241097:+
BRCA	cis	rs1669338	0.507	rs4685609	ENSG00000271870.1	RP11-97C16.1	4.84	1.46e-06	0.000144	0.19	0.15	White matter integrity;	chr3:3160595	chr3:3152942~3153435:+
BRCA	cis	rs2243480	0.901	rs13237344	ENSG00000275400.1	RP4-756H11.5	4.84	1.46e-06	0.000144	0.27	0.15	Diabetic kidney disease;	chr7:66557269	chr7:66553805~66554199:-
BRCA	cis	rs1075265	0.73	rs805392	ENSG00000235937.1	AC008280.1	4.84	1.46e-06	0.000144	0.16	0.15	Chronotype;Morning vs. evening chronotype;	chr2:53877594	chr2:54029552~54030682:-
BRCA	cis	rs9628987	0.5	rs56812469	ENSG00000232912.4	RP5-1115A15.1	-4.84	1.46e-06	0.000144	-0.19	-0.15	Breast cancer;	chr1:8384170	chr1:8424645~8434838:+
BRCA	cis	rs10752881	1	rs12126434	ENSG00000224468.3	RP11-181K3.4	4.84	1.46e-06	0.000144	0.16	0.15	Colorectal cancer;	chr1:183019279	chr1:183138402~183141282:-
BRCA	cis	rs860295	0.702	rs10796943	ENSG00000160766.13	GBAP1	-4.84	1.46e-06	0.000144	-0.16	-0.15	Body mass index;	chr1:155444938	chr1:155213821~155227422:-
BRCA	cis	rs8040855	0.599	rs2342123	ENSG00000259774.1	RP11-182J1.13	4.84	1.46e-06	0.000144	0.17	0.15	Bulimia nervosa;	chr15:85181918	chr15:84422618~84425882:+
BRCA	cis	rs2073316	0.592	rs2365772	ENSG00000272716.1	RP11-563N4.1	4.84	1.47e-06	0.000144	0.16	0.15	Interleukin-18 levels;	chr2:31436360	chr2:32165046~32165757:-
BRCA	cis	rs875971	0.545	rs2707851	ENSG00000232546.1	RP11-458F8.1	-4.84	1.47e-06	0.000144	-0.14	-0.15	Aortic root size;	chr7:66624178	chr7:66848496~66858136:+
BRCA	cis	rs4356203	0.905	rs536628	ENSG00000272034.1	SNORD14A	-4.84	1.47e-06	0.000144	-0.15	-0.15	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17186545	chr11:17074654~17074744:-
BRCA	cis	rs7191700	0.511	rs12923756	ENSG00000262636.1	CTD-3088G3.4	-4.84	1.47e-06	0.000144	-0.2	-0.15	Multiple sclerosis;	chr16:11265818	chr16:11380859~11381118:-
BRCA	cis	rs12497850	0.865	rs13072911	ENSG00000225399.4	RP11-3B7.1	4.84	1.47e-06	0.000144	0.14	0.15	Parkinson's disease;	chr3:48924695	chr3:49260085~49261316:+
BRCA	cis	rs9818758	0.607	rs9837625	ENSG00000270441.1	RP11-694I15.7	4.84	1.47e-06	0.000144	0.29	0.15	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49178533	chr3:49140086~49160851:-
BRCA	cis	rs728616	0.867	rs723193	ENSG00000225484.5	NUTM2B-AS1	-4.84	1.47e-06	0.000144	-0.38	-0.15	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79948399	chr10:79663088~79826594:-
BRCA	cis	rs4718428	0.705	rs2901311	ENSG00000229180.5	GS1-124K5.11	4.84	1.47e-06	0.000144	0.14	0.15	Corneal structure;	chr7:66950082	chr7:66526088~66542624:-
BRCA	cis	rs11955398	0.585	rs12655977	ENSG00000215032.2	GNL3LP1	4.84	1.47e-06	0.000144	0.18	0.15	Intelligence (multi-trait analysis);	chr5:60738648	chr5:60891935~60893577:-
BRCA	cis	rs7181230	0.813	rs4924417	ENSG00000275636.1	RP11-521C20.5	4.84	1.47e-06	0.000144	0.19	0.15	Dehydroepiandrosterone sulphate levels;	chr15:40074738	chr15:40078892~40079347:+
BRCA	cis	rs4664293	0.867	rs10194483	ENSG00000224152.1	AC009506.1	-4.84	1.47e-06	0.000144	-0.17	-0.15	Monocyte percentage of white cells;	chr2:159739883	chr2:159615296~159617082:+
BRCA	cis	rs11098499	0.532	rs4504231	ENSG00000249244.1	RP11-548H18.2	4.84	1.47e-06	0.000144	0.17	0.15	Corneal astigmatism;	chr4:119665736	chr4:119391831~119395335:-
BRCA	cis	rs6756513	0.5	rs60248458	ENSG00000231024.1	AC092431.3	-4.84	1.47e-06	0.000144	-0.22	-0.15	Breast cancer;Platelet count;	chr2:69866766	chr2:69700192~69713847:-
BRCA	cis	rs6928977	0.637	rs9647635	ENSG00000234084.1	RP3-388E23.2	4.84	1.47e-06	0.000144	0.15	0.15	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135519918	chr6:135301568~135307158:+
BRCA	cis	rs11976180	1	rs6464573	ENSG00000244479.5	OR2A1-AS1	-4.84	1.47e-06	0.000144	-0.2	-0.15	Obesity-related traits;	chr7:144051005	chr7:144251264~144356181:-
BRCA	cis	rs9921338	0.961	rs72773830	ENSG00000262703.1	RP11-485G7.6	-4.84	1.47e-06	0.000144	-0.18	-0.15	Vein graft stenosis in coronary artery bypass grafting;	chr16:11318966	chr16:11348143~11349321:-
BRCA	cis	rs10739663	0.52	rs1566362	ENSG00000232630.1	PRPS1P2	4.84	1.47e-06	0.000144	0.15	0.15	Resting heart rate;	chr9:125400853	chr9:125150653~125151589:+
BRCA	cis	rs984222	0.62	rs10923763	ENSG00000231365.4	RP11-418J17.1	4.84	1.47e-06	0.000144	0.18	0.15	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119175597	chr1:119140396~119275973:+
BRCA	cis	rs11168618	1	rs10875833	ENSG00000240399.1	RP1-228P16.1	4.84	1.47e-06	0.000144	0.17	0.15	Adiponectin levels;	chr12:48559585	chr12:48054813~48055591:-
BRCA	cis	rs300890	0.76	rs13118846	ENSG00000250326.1	RP11-284M14.1	4.84	1.47e-06	0.000145	0.16	0.15	Nasopharyngeal carcinoma;	chr4:143289009	chr4:142933195~143184861:-
BRCA	cis	rs300890	0.586	rs300897	ENSG00000250326.1	RP11-284M14.1	-4.84	1.47e-06	0.000145	-0.17	-0.15	Nasopharyngeal carcinoma;	chr4:143312198	chr4:142933195~143184861:-
BRCA	cis	rs7267979	0.844	rs869358	ENSG00000274414.1	RP5-965G21.4	4.84	1.47e-06	0.000145	0.17	0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25394038	chr20:25239007~25245229:-
BRCA	cis	rs2638953	0.962	rs11049586	ENSG00000247934.4	RP11-967K21.1	-4.84	1.47e-06	0.000145	-0.2	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28418028	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.962	rs11049588	ENSG00000247934.4	RP11-967K21.1	-4.84	1.47e-06	0.000145	-0.2	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28418628	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.925	rs10843166	ENSG00000247934.4	RP11-967K21.1	-4.84	1.47e-06	0.000145	-0.2	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28422811	chr12:28163298~28190738:-
BRCA	cis	rs755249	0.565	rs12138051	ENSG00000182109.6	RP11-69E11.4	-4.84	1.47e-06	0.000145	-0.17	-0.15	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39482552	chr1:39522280~39546187:-
BRCA	cis	rs755249	0.564	rs6691194	ENSG00000182109.6	RP11-69E11.4	-4.84	1.47e-06	0.000145	-0.17	-0.15	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39483069	chr1:39522280~39546187:-
BRCA	cis	rs7481584	0.624	rs421196	ENSG00000247473.2	CARS-AS1	-4.84	1.47e-06	0.000145	-0.18	-0.15	Calcium levels;	chr11:3027352	chr11:3029009~3041260:+
BRCA	cis	rs7200543	1	rs4985124	ENSG00000260735.1	RP11-72I8.1	-4.84	1.47e-06	0.000145	-0.17	-0.15	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15031584	chr16:15094411~15109197:+
BRCA	cis	rs11089937	0.616	rs4145537	ENSG00000211638.2	IGLV8-61	4.84	1.48e-06	0.000145	0.15	0.15	Periodontitis (PAL4Q3);	chr22:22182550	chr22:22098700~22099212:+
BRCA	cis	rs4356203	0.87	rs10832745	ENSG00000272034.1	SNORD14A	-4.84	1.48e-06	0.000145	-0.15	-0.15	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17228128	chr11:17074654~17074744:-
BRCA	cis	rs4356203	0.87	rs10832747	ENSG00000272034.1	SNORD14A	-4.84	1.48e-06	0.000145	-0.15	-0.15	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17228472	chr11:17074654~17074744:-
BRCA	cis	rs3764021	0.87	rs7307111	ENSG00000278635.1	CTD-2318O12.1	-4.84	1.48e-06	0.000145	-0.15	-0.15	Type 1 diabetes;	chr12:9725227	chr12:9415641~9416718:+
BRCA	cis	rs6596100	0.915	rs7712181	ENSG00000248648.1	RP11-485M7.1	-4.84	1.48e-06	0.000145	-0.19	-0.15	Breast cancer;	chr5:133050549	chr5:133003119~133003365:+
BRCA	cis	rs6596100	0.915	rs7712182	ENSG00000248648.1	RP11-485M7.1	-4.84	1.48e-06	0.000145	-0.19	-0.15	Breast cancer;	chr5:133050550	chr5:133003119~133003365:+
BRCA	cis	rs11089937	0.616	rs928896	ENSG00000211638.2	IGLV8-61	-4.84	1.48e-06	0.000145	-0.14	-0.15	Periodontitis (PAL4Q3);	chr22:22185929	chr22:22098700~22099212:+
BRCA	cis	rs11089937	0.616	rs5995615	ENSG00000211638.2	IGLV8-61	-4.84	1.48e-06	0.000145	-0.14	-0.15	Periodontitis (PAL4Q3);	chr22:22185250	chr22:22098700~22099212:+
BRCA	cis	rs11089937	0.616	rs6001223	ENSG00000211638.2	IGLV8-61	-4.84	1.48e-06	0.000145	-0.14	-0.15	Periodontitis (PAL4Q3);	chr22:22185359	chr22:22098700~22099212:+
BRCA	cis	rs11098499	0.754	rs1546503	ENSG00000249244.1	RP11-548H18.2	4.84	1.48e-06	0.000145	0.17	0.15	Corneal astigmatism;	chr4:119320012	chr4:119391831~119395335:-
BRCA	cis	rs6570726	0.935	rs387965	ENSG00000270638.1	RP3-466P17.1	4.84	1.48e-06	0.000145	0.16	0.15	Lobe attachment (rater-scored or self-reported);	chr6:145548230	chr6:145735570~145737218:+
BRCA	cis	rs9788721	0.592	rs28564957	ENSG00000279373.1	RP11-650L12.4	-4.84	1.48e-06	0.000145	-0.18	-0.15	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78613765	chr15:78537681~78538946:+
BRCA	cis	rs2411233	0.713	rs11853413	ENSG00000259278.1	RP11-62C7.2	4.84	1.48e-06	0.000145	0.18	0.15	Platelet count;	chr15:39027372	chr15:39019233~39024918:+
BRCA	cis	rs2243480	0.522	rs431168	ENSG00000228409.4	CCT6P1	4.84	1.48e-06	0.000145	0.25	0.15	Diabetic kidney disease;	chr7:66046617	chr7:65751142~65763354:+
BRCA	cis	rs12105510	0.501	rs34342984	ENSG00000270696.1	RP11-342K6.1	-4.84	1.48e-06	0.000145	-0.17	-0.15	Response to platinum-based chemotherapy (cisplatin);	chr2:75649385	chr2:75660462~75662208:+
BRCA	cis	rs7397814	0.558	rs4764447	ENSG00000214826.5	DDX12P	-4.84	1.48e-06	0.000145	-0.13	-0.15	IgG glycosylation;	chr12:9426513	chr12:9418673~9448229:-
BRCA	cis	rs4713118	0.955	rs9468203	ENSG00000216901.1	AL022393.7	4.84	1.48e-06	0.000145	0.2	0.15	Parkinson's disease;	chr6:27720888	chr6:28176188~28176674:+
BRCA	cis	rs3126085	0.515	rs9633409	ENSG00000237975.5	FLG-AS1	4.84	1.48e-06	0.000145	0.22	0.15	Atopic dermatitis;	chr1:152389853	chr1:152168125~152445456:+
BRCA	cis	rs10863681	0.664	rs10863680	ENSG00000232679.1	RP11-400N13.3	-4.84	1.48e-06	0.000145	-0.16	-0.15	Metabolite levels (HVA-5-HIAA Factor score);	chr1:222071538	chr1:222041705~222064763:-
BRCA	cis	rs9659323	0.73	rs10923720	ENSG00000231365.4	RP11-418J17.1	-4.84	1.48e-06	0.000145	-0.18	-0.15	Body mass index;	chr1:118999256	chr1:119140396~119275973:+
BRCA	cis	rs3764021	0.868	rs7306304	ENSG00000278635.1	CTD-2318O12.1	-4.84	1.48e-06	0.000145	-0.15	-0.15	Type 1 diabetes;	chr12:9724600	chr12:9415641~9416718:+
BRCA	cis	rs739401	0.595	rs6578304	ENSG00000183562.3	CTC-343N3.1	4.84	1.48e-06	0.000145	0.16	0.15	Longevity;	chr11:2977049	chr11:2989863~2991344:+
BRCA	cis	rs253959	0.545	rs712596	ENSG00000271918.1	CTD-2287O16.5	-4.84	1.48e-06	0.000145	-0.12	-0.15	Bipolar disorder and schizophrenia;	chr5:116322214	chr5:116083807~116085416:-
BRCA	cis	rs860818	0.557	rs2178138	ENSG00000230658.1	KLHL7-AS1	4.84	1.48e-06	0.000145	0.38	0.15	Initial pursuit acceleration;	chr7:23154414	chr7:23101228~23105703:-
BRCA	cis	rs860818	0.793	rs1358441	ENSG00000230658.1	KLHL7-AS1	4.84	1.48e-06	0.000145	0.38	0.15	Initial pursuit acceleration;	chr7:23154850	chr7:23101228~23105703:-
BRCA	cis	rs860818	0.557	rs6961136	ENSG00000230658.1	KLHL7-AS1	4.84	1.48e-06	0.000145	0.38	0.15	Initial pursuit acceleration;	chr7:23155343	chr7:23101228~23105703:-
BRCA	cis	rs860818	0.793	rs12700418	ENSG00000230658.1	KLHL7-AS1	4.84	1.48e-06	0.000145	0.38	0.15	Initial pursuit acceleration;	chr7:23155701	chr7:23101228~23105703:-
BRCA	cis	rs860818	0.793	rs6966420	ENSG00000230658.1	KLHL7-AS1	4.84	1.48e-06	0.000145	0.38	0.15	Initial pursuit acceleration;	chr7:23156346	chr7:23101228~23105703:-
BRCA	cis	rs860818	0.793	rs4722227	ENSG00000230658.1	KLHL7-AS1	4.84	1.48e-06	0.000145	0.38	0.15	Initial pursuit acceleration;	chr7:23156399	chr7:23101228~23105703:-
BRCA	cis	rs860818	0.793	rs6966929	ENSG00000230658.1	KLHL7-AS1	4.84	1.48e-06	0.000145	0.38	0.15	Initial pursuit acceleration;	chr7:23156455	chr7:23101228~23105703:-
BRCA	cis	rs860818	0.546	rs4722228	ENSG00000230658.1	KLHL7-AS1	4.84	1.48e-06	0.000145	0.38	0.15	Initial pursuit acceleration;	chr7:23156479	chr7:23101228~23105703:-
BRCA	cis	rs860818	0.793	rs4722229	ENSG00000230658.1	KLHL7-AS1	4.84	1.48e-06	0.000145	0.38	0.15	Initial pursuit acceleration;	chr7:23156485	chr7:23101228~23105703:-
BRCA	cis	rs860818	0.793	rs4722230	ENSG00000230658.1	KLHL7-AS1	4.84	1.48e-06	0.000145	0.38	0.15	Initial pursuit acceleration;	chr7:23157572	chr7:23101228~23105703:-
BRCA	cis	rs10129255	0.957	rs12589190	ENSG00000280411.1	IGHV1-69-2	-4.84	1.48e-06	0.000145	-0.1	-0.15	Kawasaki disease;	chr14:106783079	chr14:106762092~106762588:-
BRCA	cis	rs4698412	0.561	rs11729955	ENSG00000214846.4	RP11-115L11.1	-4.84	1.48e-06	0.000145	-0.18	-0.15	Parkinson's disease;	chr4:15688009	chr4:15730962~15731627:-
BRCA	cis	rs6496044	0.507	rs62022863	ENSG00000259295.5	CSPG4P12	-4.84	1.48e-06	0.000146	-0.18	-0.15	Interstitial lung disease;	chr15:85618822	chr15:85191438~85213905:+
BRCA	cis	rs2153535	0.601	rs7741024	ENSG00000251164.1	HULC	-4.84	1.49e-06	0.000146	-0.18	-0.15	Motion sickness;	chr6:8530080	chr6:8652137~8653846:+
BRCA	cis	rs11239930	0.517	rs535827	ENSG00000278811.3	LINC00624	4.84	1.49e-06	0.000146	0.17	0.15	AIDS progression;	chr1:147076642	chr1:147258885~147517875:-
BRCA	cis	rs6088590	0.582	rs6059909	ENSG00000276073.1	RP5-1125A11.7	-4.84	1.49e-06	0.000146	-0.16	-0.15	Coronary artery disease;	chr20:34551887	chr20:33985617~33988989:-
BRCA	cis	rs7646881	1	rs61558956	ENSG00000240207.5	RP11-379F4.4	-4.84	1.49e-06	0.000146	-0.21	-0.15	Tetralogy of Fallot;	chr3:158734866	chr3:158732263~158784070:+
BRCA	cis	rs754466	1	rs67059283	ENSG00000204049.1	RP11-126H7.4	4.84	1.49e-06	0.000146	0.2	0.15	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77923477	chr10:77866875~77869610:+
BRCA	cis	rs6676180	0.555	rs871665	ENSG00000231365.4	RP11-418J17.1	-4.84	1.49e-06	0.000146	-0.17	-0.15	Monobrow;	chr1:119230040	chr1:119140396~119275973:+
BRCA	cis	rs7226408	0.948	rs11662126	ENSG00000267707.2	RP11-95O2.5	4.84	1.49e-06	0.000146	0.24	0.15	Obesity-related traits;	chr18:36828355	chr18:37243776~37247506:+
BRCA	cis	rs2277027	1	rs9313617	ENSG00000248544.2	CTB-47B11.3	4.84	1.49e-06	0.000146	0.18	0.15	Pulmonary function;Pulmonary function (smoking interaction);	chr5:157506450	chr5:157375741~157384950:-
BRCA	cis	rs4072980	0.545	rs11210870	ENSG00000212541.1	RNU6-510P	4.84	1.49e-06	0.000146	0.21	0.15	Coronary artery disease;	chr1:37984238	chr1:37991462~37991569:+
BRCA	cis	rs14027	0.512	rs13252708	ENSG00000279347.1	RP11-85I17.2	-4.84	1.49e-06	0.000146	-0.14	-0.15	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119718283	chr8:119838736~119840385:-
BRCA	cis	rs7267979	0.844	rs6083851	ENSG00000274414.1	RP5-965G21.4	4.84	1.49e-06	0.000146	0.17	0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25420599	chr20:25239007~25245229:-
BRCA	cis	rs829883	0.664	rs249833	ENSG00000227825.4	SLC9A7P1	4.84	1.49e-06	0.000146	0.17	0.15	Colorectal adenoma (advanced);	chr12:98438411	chr12:98453835~98457145:-
BRCA	cis	rs829883	0.616	rs249832	ENSG00000227825.4	SLC9A7P1	4.84	1.49e-06	0.000146	0.17	0.15	Colorectal adenoma (advanced);	chr12:98438609	chr12:98453835~98457145:-
BRCA	cis	rs8031584	0.541	rs1983459	ENSG00000259845.1	HERC2P10	4.84	1.49e-06	0.000146	0.17	0.15	Huntington's disease progression;	chr15:30916546	chr15:30815271~30844153:+
BRCA	cis	rs10911251	0.546	rs2274984	ENSG00000224468.3	RP11-181K3.4	4.84	1.49e-06	0.000146	0.16	0.15	Colorectal cancer;	chr1:183138311	chr1:183138402~183141282:-
BRCA	cis	rs494453	0.922	rs500184	ENSG00000227811.2	FAM212B-AS1	4.84	1.49e-06	0.000146	0.19	0.15	Osteoporosis-related phenotypes;	chr1:111620924	chr1:111739841~111747798:+
BRCA	cis	rs5749696	1	rs5749696	ENSG00000224086.5	LL22NC03-86G7.1	-4.84	1.49e-06	0.000146	-0.15	-0.15	Schizophrenia;	chr22:21709048	chr22:21938293~21977632:+
BRCA	cis	rs12468226	0.606	rs10445793	ENSG00000226261.1	AC064836.3	4.84	1.49e-06	0.000146	0.23	0.15	Urate levels;	chr2:202190799	chr2:202336024~202336727:-
BRCA	cis	rs2617170	0.961	rs2734565	ENSG00000245648.1	RP11-277P12.20	4.84	1.49e-06	0.000146	0.19	0.15	Behcet's disease;	chr12:10407992	chr12:10363769~10398506:+
BRCA	cis	rs6921919	0.583	rs35560946	ENSG00000220721.1	OR1F12	4.84	1.5e-06	0.000147	0.18	0.15	Autism spectrum disorder or schizophrenia;	chr6:28427660	chr6:28073316~28074233:+
BRCA	cis	rs10989172	0.714	rs4440728	ENSG00000175611.10	LINC00476	4.84	1.5e-06	0.000147	0.16	0.15	Common carotid intima-media thickness in HIV negative individuals;	chr9:96078350	chr9:95759231~95875977:-
BRCA	cis	rs2562456	0.793	rs2650819	ENSG00000268535.1	RP11-420K14.3	-4.84	1.5e-06	0.000147	-0.2	-0.15	Pain;	chr19:21456071	chr19:21709522~21710191:+
BRCA	cis	rs6723226	0.698	rs13409142	ENSG00000276334.1	AL133243.1	4.84	1.5e-06	0.000147	0.19	0.15	Intelligence (multi-trait analysis);	chr2:32441069	chr2:32521927~32523547:+
BRCA	cis	rs3845817	0.868	rs702891	ENSG00000237979.1	AC007389.1	-4.84	1.5e-06	0.000147	-0.18	-0.15	Bipolar disorder;	chr2:65531316	chr2:65500993~65502138:-
BRCA	cis	rs4763879	0.739	rs2114871	ENSG00000278635.1	CTD-2318O12.1	4.84	1.5e-06	0.000147	0.15	0.15	Type 1 diabetes;	chr12:9676842	chr12:9415641~9416718:+
BRCA	cis	rs1555322	0.872	rs2425033	ENSG00000126005.14	MMP24-AS1	-4.84	1.5e-06	0.000147	-0.23	-0.15	Attention deficit hyperactivity disorder;	chr20:35267823	chr20:35216462~35278131:-
BRCA	cis	rs6095360	0.933	rs6019620	ENSG00000222365.1	SNORD12B	-4.84	1.5e-06	0.000147	-0.16	-0.15	Intelligence (multi-trait analysis);	chr20:49062763	chr20:49280319~49280409:+
BRCA	cis	rs6095360	1	rs6019621	ENSG00000222365.1	SNORD12B	-4.84	1.5e-06	0.000147	-0.16	-0.15	Intelligence (multi-trait analysis);	chr20:49063426	chr20:49280319~49280409:+
BRCA	cis	rs6095360	1	rs2075675	ENSG00000222365.1	SNORD12B	-4.84	1.5e-06	0.000147	-0.16	-0.15	Intelligence (multi-trait analysis);	chr20:49068956	chr20:49280319~49280409:+
BRCA	cis	rs8098244	0.964	rs948435	ENSG00000264745.1	TTC39C-AS1	4.84	1.5e-06	0.000147	0.2	0.15	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23803808	chr18:23994213~24015339:-
BRCA	cis	rs7226408	0.857	rs11665085	ENSG00000267707.2	RP11-95O2.5	4.84	1.5e-06	0.000147	0.22	0.15	Obesity-related traits;	chr18:36889502	chr18:37243776~37247506:+
BRCA	cis	rs875971	0.54	rs781152	ENSG00000273024.4	INTS4P2	-4.84	1.5e-06	0.000147	-0.17	-0.15	Aortic root size;	chr7:66014585	chr7:65647864~65715661:+
BRCA	cis	rs17711722	0.727	rs781151	ENSG00000273024.4	INTS4P2	-4.84	1.5e-06	0.000147	-0.17	-0.15	Calcium levels;	chr7:66014891	chr7:65647864~65715661:+
BRCA	cis	rs3176789	0.872	rs7488011	ENSG00000256673.1	RP11-599J14.2	4.84	1.5e-06	0.000147	0.19	0.15	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9772740	chr12:9398355~9414851:-
BRCA	cis	rs4356203	0.678	rs1125737	ENSG00000272034.1	SNORD14A	-4.84	1.5e-06	0.000147	-0.15	-0.15	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17242386	chr11:17074654~17074744:-
BRCA	cis	rs1440410	0.571	rs9993291	ENSG00000250326.1	RP11-284M14.1	-4.84	1.5e-06	0.000147	-0.17	-0.15	Ischemic stroke;	chr4:143107020	chr4:142933195~143184861:-
BRCA	cis	rs9287719	0.781	rs12472807	ENSG00000243819.4	RN7SL832P	4.84	1.5e-06	0.000147	0.14	0.15	Prostate cancer;	chr2:10641479	chr2:10690344~10692099:+
BRCA	cis	rs7577696	0.924	rs6749336	ENSG00000272716.1	RP11-563N4.1	-4.84	1.5e-06	0.000147	-0.16	-0.15	Inflammatory biomarkers;	chr2:32046641	chr2:32165046~32165757:-
BRCA	cis	rs442309	0.875	rs224062	ENSG00000238280.1	RP11-436D10.3	-4.84	1.5e-06	0.000147	-0.2	-0.15	Vogt-Koyanagi-Harada syndrome;	chr10:62743036	chr10:62793562~62805887:-
BRCA	cis	rs1707322	1	rs785507	ENSG00000234329.1	RP11-767N6.2	-4.84	1.5e-06	0.000147	-0.16	-0.15	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46075886	chr1:45651039~45651826:-
BRCA	cis	rs4650994	0.507	rs2811312	ENSG00000273384.1	RP5-1098D14.1	-4.84	1.5e-06	0.000147	-0.19	-0.15	HDL cholesterol;HDL cholesterol levels;	chr1:178648468	chr1:178651706~178652282:+
BRCA	cis	rs9291683	0.554	rs7668175	ENSG00000250413.1	RP11-448G15.1	4.84	1.5e-06	0.000147	0.19	0.15	Bone mineral density;	chr4:10124158	chr4:10006482~10009725:+
BRCA	cis	rs9291683	0.62	rs7699512	ENSG00000250413.1	RP11-448G15.1	4.84	1.5e-06	0.000147	0.19	0.15	Bone mineral density;	chr4:10124184	chr4:10006482~10009725:+
BRCA	cis	rs1729951	0.575	rs361241	ENSG00000239213.4	NCK1-AS1	4.84	1.5e-06	0.000147	0.15	0.15	Neuroticism;	chr3:136980719	chr3:136841726~136862054:-
BRCA	cis	rs4356203	0.905	rs594034	ENSG00000272034.1	SNORD14A	-4.84	1.5e-06	0.000147	-0.15	-0.15	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17200833	chr11:17074654~17074744:-
BRCA	cis	rs10504130	0.932	rs16916856	ENSG00000253844.1	RP11-546K22.1	-4.84	1.51e-06	0.000147	-0.26	-0.15	Venous thromboembolism (SNP x SNP interaction);	chr8:51826590	chr8:51961458~52022974:+
BRCA	cis	rs7572733	0.534	rs1589162	ENSG00000231621.1	AC013264.2	-4.84	1.51e-06	0.000148	-0.15	-0.15	Dermatomyositis;	chr2:197917968	chr2:197197991~197199273:+
BRCA	cis	rs875971	0.545	rs7787063	ENSG00000230295.1	RP11-458F8.2	4.84	1.51e-06	0.000148	0.14	0.15	Aortic root size;	chr7:66164012	chr7:66880708~66882981:+
BRCA	cis	rs875971	0.545	rs12673308	ENSG00000230295.1	RP11-458F8.2	4.84	1.51e-06	0.000148	0.14	0.15	Aortic root size;	chr7:66166374	chr7:66880708~66882981:+
BRCA	cis	rs2277027	1	rs2277027	ENSG00000248544.2	CTB-47B11.3	4.84	1.51e-06	0.000148	0.18	0.15	Pulmonary function;Pulmonary function (smoking interaction);	chr5:157505368	chr5:157375741~157384950:-
BRCA	cis	rs2277027	0.956	rs10078178	ENSG00000248544.2	CTB-47B11.3	4.84	1.51e-06	0.000148	0.18	0.15	Pulmonary function;Pulmonary function (smoking interaction);	chr5:157505976	chr5:157375741~157384950:-
BRCA	cis	rs6430538	0.582	rs11903701	ENSG00000224043.6	CCNT2-AS1	-4.84	1.51e-06	0.000148	-0.21	-0.15	Parkinson's disease;	chr2:134807680	chr2:134735464~134918710:-
BRCA	cis	rs1075265	0.704	rs6711217	ENSG00000235937.1	AC008280.1	4.84	1.51e-06	0.000148	0.16	0.15	Chronotype;Morning vs. evening chronotype;	chr2:54017892	chr2:54029552~54030682:-
BRCA	cis	rs10510102	0.935	rs12245528	ENSG00000226864.1	ATE1-AS1	-4.84	1.51e-06	0.000148	-0.27	-0.15	Breast cancer;	chr10:121881006	chr10:121928312~121951965:+
BRCA	cis	rs2243480	1	rs313803	ENSG00000222364.1	RNU6-96P	-4.84	1.51e-06	0.000148	-0.28	-0.15	Diabetic kidney disease;	chr7:66049744	chr7:66395191~66395286:+
BRCA	cis	rs3768617	0.565	rs3768626	ENSG00000224468.3	RP11-181K3.4	-4.84	1.51e-06	0.000148	-0.16	-0.15	Fuchs's corneal dystrophy;	chr1:183109327	chr1:183138402~183141282:-
BRCA	cis	rs2115630	0.645	rs1107179	ENSG00000275120.1	RP11-182J1.17	4.84	1.51e-06	0.000148	0.18	0.15	P wave terminal force;	chr15:84655131	chr15:84599434~84606463:-
BRCA	cis	rs57221529	0.709	rs4957056	ENSG00000271781.1	CTD-2589H19.6	-4.84	1.51e-06	0.000148	-0.21	-0.15	Lung disease severity in cystic fibrosis;	chr5:569990	chr5:675826~676616:+
BRCA	cis	rs1167832	0.645	rs1167828	ENSG00000278416.1	PMS2L2	-4.84	1.51e-06	0.000148	-0.24	-0.15	Ankle injury;	chr7:75534076	chr7:75344015~75359550:-
BRCA	cis	rs12497850	1	rs4858798	ENSG00000225399.4	RP11-3B7.1	4.84	1.51e-06	0.000148	0.14	0.15	Parkinson's disease;	chr3:48689679	chr3:49260085~49261316:+
BRCA	cis	rs10833905	1	rs3909702	ENSG00000246225.5	RP11-17A1.3	-4.84	1.51e-06	0.000148	-0.21	-0.15	Sudden cardiac arrest;	chr11:23022607	chr11:22829380~22945393:+
BRCA	cis	rs8064024	0.901	rs930855	ENSG00000267077.1	RP11-127I20.5	4.84	1.51e-06	0.000148	0.15	0.15	Cancer;	chr16:4814178	chr16:4795265~4796532:-
BRCA	cis	rs7487075	0.578	rs4072304	ENSG00000274723.1	RP11-618L22.1	4.84	1.51e-06	0.000148	0.19	0.15	Itch intensity from mosquito bite;	chr12:46432404	chr12:46970504~46972155:+
BRCA	cis	rs12285276	0.504	rs7120278	ENSG00000205106.4	DKFZp779M0652	4.84	1.51e-06	0.000148	0.22	0.15	Visceral fat;	chr11:45796560	chr11:45771432~45772358:+
BRCA	cis	rs2505998	0.796	rs2505537	ENSG00000273008.1	RP11-351D16.3	-4.84	1.51e-06	0.000148	-0.18	-0.15	Hirschsprung disease;	chr10:43096710	chr10:43136824~43138334:-
BRCA	cis	rs6088590	0.561	rs6059918	ENSG00000276073.1	RP5-1125A11.7	-4.84	1.51e-06	0.000148	-0.16	-0.15	Coronary artery disease;	chr20:34562699	chr20:33985617~33988989:-
BRCA	cis	rs9818758	0.556	rs9813813	ENSG00000270441.1	RP11-694I15.7	4.84	1.51e-06	0.000148	0.33	0.15	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49169660	chr3:49140086~49160851:-
BRCA	cis	rs7226408	0.842	rs72885229	ENSG00000267707.2	RP11-95O2.5	4.84	1.51e-06	0.000148	0.24	0.15	Obesity-related traits;	chr18:36826389	chr18:37243776~37247506:+
BRCA	cis	rs7226408	0.948	rs11660471	ENSG00000267707.2	RP11-95O2.5	4.84	1.51e-06	0.000148	0.24	0.15	Obesity-related traits;	chr18:36826873	chr18:37243776~37247506:+
BRCA	cis	rs7226408	0.948	rs11662148	ENSG00000267707.2	RP11-95O2.5	4.84	1.51e-06	0.000148	0.24	0.15	Obesity-related traits;	chr18:36828460	chr18:37243776~37247506:+
BRCA	cis	rs62025270	0.547	rs338520	ENSG00000259295.5	CSPG4P12	4.84	1.51e-06	0.000148	0.19	0.15	Idiopathic pulmonary fibrosis;	chr15:85671567	chr15:85191438~85213905:+
BRCA	cis	rs2732480	0.5	rs12829841	ENSG00000257735.1	RP11-370I10.6	4.84	1.51e-06	0.000148	0.19	0.15	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48234956	chr12:48350945~48442411:+
BRCA	cis	rs2732480	0.523	rs34286639	ENSG00000257735.1	RP11-370I10.6	4.84	1.51e-06	0.000148	0.19	0.15	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48235261	chr12:48350945~48442411:+
BRCA	cis	rs1910358	0.664	rs35319374	ENSG00000248874.4	C5orf17	-4.84	1.51e-06	0.000148	-0.19	-0.15	Venous thromboembolism (SNP x SNP interaction);	chr5:23896969	chr5:23951348~24178263:+
BRCA	cis	rs1910358	0.664	rs35603833	ENSG00000248874.4	C5orf17	-4.84	1.51e-06	0.000148	-0.19	-0.15	Venous thromboembolism (SNP x SNP interaction);	chr5:23897087	chr5:23951348~24178263:+
BRCA	cis	rs1910358	0.664	rs9647547	ENSG00000248874.4	C5orf17	-4.84	1.51e-06	0.000148	-0.19	-0.15	Venous thromboembolism (SNP x SNP interaction);	chr5:23901534	chr5:23951348~24178263:+
BRCA	cis	rs442309	0.812	rs224135	ENSG00000238280.1	RP11-436D10.3	-4.84	1.52e-06	0.000148	-0.2	-0.15	Vogt-Koyanagi-Harada syndrome;	chr10:62707042	chr10:62793562~62805887:-
BRCA	cis	rs6452524	0.967	rs28360104	ENSG00000281327.1	LINC01338	4.84	1.52e-06	0.000149	0.17	0.15	Hypertension (SNP x SNP interaction);	chr5:83181525	chr5:82850864~82859836:-
BRCA	cis	rs3764021	0.509	rs10772072	ENSG00000256673.1	RP11-599J14.2	-4.84	1.52e-06	0.000149	-0.18	-0.15	Type 1 diabetes;	chr12:9717335	chr12:9398355~9414851:-
BRCA	cis	rs11098499	0.663	rs9996501	ENSG00000249244.1	RP11-548H18.2	4.84	1.52e-06	0.000149	0.17	0.15	Corneal astigmatism;	chr4:119317763	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.697	rs28458294	ENSG00000249244.1	RP11-548H18.2	4.84	1.52e-06	0.000149	0.17	0.15	Corneal astigmatism;	chr4:119317769	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.663	rs28369503	ENSG00000249244.1	RP11-548H18.2	4.84	1.52e-06	0.000149	0.17	0.15	Corneal astigmatism;	chr4:119317770	chr4:119391831~119395335:-
BRCA	cis	rs253959	0.532	rs10045890	ENSG00000271918.1	CTD-2287O16.5	4.84	1.52e-06	0.000149	0.13	0.15	Bipolar disorder and schizophrenia;	chr5:116112188	chr5:116083807~116085416:-
BRCA	cis	rs10510102	0.935	rs12250677	ENSG00000226864.1	ATE1-AS1	4.84	1.52e-06	0.000149	0.27	0.15	Breast cancer;	chr10:121880575	chr10:121928312~121951965:+
BRCA	cis	rs10510102	0.872	rs12243874	ENSG00000226864.1	ATE1-AS1	4.84	1.52e-06	0.000149	0.27	0.15	Breast cancer;	chr10:121880788	chr10:121928312~121951965:+
BRCA	cis	rs7772486	0.72	rs991507	ENSG00000270638.1	RP3-466P17.1	-4.84	1.52e-06	0.000149	-0.17	-0.15	Lobe attachment (rater-scored or self-reported);	chr6:145702473	chr6:145735570~145737218:+
BRCA	cis	rs2239547	0.618	rs3733047	ENSG00000242142.1	SERBP1P3	-4.84	1.52e-06	0.000149	-0.19	-0.15	Schizophrenia;	chr3:52837913	chr3:53064283~53065091:-
BRCA	cis	rs957448	0.554	rs12682601	ENSG00000253175.1	RP11-267M23.6	4.84	1.52e-06	0.000149	0.18	0.15	Nonsyndromic cleft lip with cleft palate;	chr8:94582492	chr8:94565036~94565715:+
BRCA	cis	rs897984	0.52	rs4889534	ENSG00000260911.2	RP11-196G11.2	-4.84	1.52e-06	0.000149	-0.15	-0.15	Dementia with Lewy bodies;	chr16:30854119	chr16:31043150~31049868:+
BRCA	cis	rs2278170	1	rs10768026	ENSG00000225101.4	OR52K3P	-4.84	1.52e-06	0.000149	-0.2	-0.15	Amyotrophic lateral sclerosis;	chr11:4468880	chr11:4474813~4475755:+
BRCA	cis	rs4713118	0.513	rs149950	ENSG00000219392.1	RP1-265C24.5	-4.84	1.52e-06	0.000149	-0.2	-0.15	Parkinson's disease;	chr6:28065261	chr6:28115628~28116551:+
BRCA	cis	rs4713118	0.513	rs149951	ENSG00000219392.1	RP1-265C24.5	-4.84	1.52e-06	0.000149	-0.2	-0.15	Parkinson's disease;	chr6:28065309	chr6:28115628~28116551:+
BRCA	cis	rs12149695	0.735	rs28456036	ENSG00000259940.2	CTD-3203P2.1	-4.84	1.52e-06	0.000149	-0.18	-0.15	Gut microbiota (bacterial taxa);	chr16:27233227	chr16:27213308~27214993:-
BRCA	cis	rs11239930	0.56	rs632334	ENSG00000230832.3	RP11-325P15.2	-4.84	1.52e-06	0.000149	-0.21	-0.15	AIDS progression;	chr1:147079972	chr1:147082338~147083578:-
BRCA	cis	rs2179367	0.959	rs536203	ENSG00000268592.3	RAET1E-AS1	4.84	1.52e-06	0.000149	0.19	0.15	Dupuytren's disease;	chr6:149330128	chr6:149863494~149919507:+
BRCA	cis	rs3213958	0.574	rs73138082	ENSG00000249274.1	PDLIM1P4	-4.84	1.52e-06	0.000149	-0.24	-0.15	Blood protein levels;	chr3:98898313	chr3:98782188~98783193:+
BRCA	cis	rs13113518	1	rs55699500	ENSG00000249700.7	SRD5A3-AS1	4.84	1.52e-06	0.000149	0.18	0.15	Height;	chr4:55540912	chr4:55363971~55395847:-
BRCA	cis	rs11098499	0.865	rs10213221	ENSG00000260404.2	RP11-384K6.6	4.84	1.52e-06	0.000149	0.14	0.15	Corneal astigmatism;	chr4:119334771	chr4:118591773~118633729:+
BRCA	cis	rs62025270	0.688	rs55738258	ENSG00000259295.5	CSPG4P12	-4.84	1.52e-06	0.000149	-0.23	-0.15	Idiopathic pulmonary fibrosis;	chr15:85773000	chr15:85191438~85213905:+
BRCA	cis	rs4660214	0.666	rs1537818	ENSG00000237624.1	OXCT2P1	-4.84	1.52e-06	0.000149	-0.18	-0.15	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39181366	chr1:39514956~39516490:+
BRCA	cis	rs7577696	0.962	rs212679	ENSG00000272716.1	RP11-563N4.1	4.84	1.52e-06	0.000149	0.16	0.15	Inflammatory biomarkers;	chr2:32206038	chr2:32165046~32165757:-
BRCA	cis	rs13113518	1	rs13108499	ENSG00000249700.7	SRD5A3-AS1	4.84	1.52e-06	0.000149	0.18	0.15	Height;	chr4:55526514	chr4:55363971~55395847:-
BRCA	cis	rs875971	0.545	rs1267814	ENSG00000230295.1	RP11-458F8.2	-4.84	1.52e-06	0.000149	-0.14	-0.15	Aortic root size;	chr7:66579422	chr7:66880708~66882981:+
BRCA	cis	rs7651446	0.737	rs12486016	ENSG00000240875.4	LINC00886	-4.84	1.52e-06	0.000149	-0.31	-0.15	Ovarian cancer;Epithelial ovarian cancer;	chr3:156657736	chr3:156747346~156817062:-
BRCA	cis	rs1223397	0.651	rs2458312	ENSG00000215022.6	RP1-257A7.4	-4.84	1.52e-06	0.000149	-0.18	-0.15	Blood pressure;	chr6:13309757	chr6:13264861~13295586:-
BRCA	cis	rs7481584	0.624	rs12417389	ENSG00000247473.2	CARS-AS1	-4.84	1.52e-06	0.000149	-0.18	-0.15	Calcium levels;	chr11:3014074	chr11:3029009~3041260:+
BRCA	cis	rs4415084	1	rs4419600	ENSG00000251141.4	RP11-53O19.1	4.84	1.52e-06	0.000149	0.14	0.15	Breast cancer;	chr5:44678432	chr5:44744900~44808777:-
BRCA	cis	rs559555	0.849	rs2300698	ENSG00000272716.1	RP11-563N4.1	4.84	1.52e-06	0.000149	0.16	0.15	Blood metabolite ratios;Blood metabolite levels;	chr2:31561723	chr2:32165046~32165757:-
BRCA	cis	rs11158026	0.574	rs58055971	ENSG00000258413.1	RP11-665C16.6	-4.84	1.52e-06	0.000149	-0.2	-0.15	Parkinson's disease;	chr14:54969606	chr14:55262767~55272075:-
BRCA	cis	rs780094	0.5	rs12987055	ENSG00000234072.1	AC074117.10	4.84	1.53e-06	0.000149	0.15	0.15	Urate levels in overweight individuals;C-reactive protein;Metabolic syndrome;Red blood cell count;Renal underexcretion gout;Nonalcoholic fatty liver disease;Age-related diseases, mortality and associated endophenotypes;Crohn's disease;Calcium levels;Fasting plasma glucose;Metabolic traits;Fasting blood glucose;Fasting blood insulin;Urate levels in obese individuals;Alcohol consumption (drinks per week);Height;Urate levels;Gondoic acid (20:1n-9) levels;Uric acid levels;Age-related disease endophenotypes;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Homeostasis model assessment of insulin resistance;Alcohol consumption;Fasting blood insulin (BMI interaction);Triglycerides;Fasting blood glucose (BMI interaction);Hypertriglyceridemia;LDL cholesterol;Type 2 diabetes;Triglyceride levels;	chr2:27611285	chr2:27356246~27367622:+
BRCA	cis	rs2832191	0.791	rs2832197	ENSG00000176054.6	RPL23P2	-4.84	1.53e-06	0.000149	-0.16	-0.15	Dental caries;	chr21:29125469	chr21:28997613~28998033:-
BRCA	cis	rs2832191	0.791	rs57721945	ENSG00000176054.6	RPL23P2	-4.84	1.53e-06	0.000149	-0.16	-0.15	Dental caries;	chr21:29126423	chr21:28997613~28998033:-
BRCA	cis	rs2562456	0.833	rs8106025	ENSG00000268658.4	LINC00664	-4.84	1.53e-06	0.000149	-0.23	-0.15	Pain;	chr19:21451922	chr19:21483374~21503238:+
BRCA	cis	rs11098499	0.909	rs71614422	ENSG00000260091.1	RP11-33B1.4	-4.84	1.53e-06	0.000149	-0.13	-0.15	Corneal astigmatism;	chr4:119438185	chr4:119409333~119410233:+
BRCA	cis	rs8040855	0.579	rs4843029	ENSG00000259774.1	RP11-182J1.13	-4.84	1.53e-06	0.000149	-0.17	-0.15	Bulimia nervosa;	chr15:85182164	chr15:84422618~84425882:+
BRCA	cis	rs648090	0.914	rs3016694	ENSG00000187686.4	KRT18P59	-4.84	1.53e-06	0.000149	-0.19	-0.15	Testicular germ cell tumor;	chr11:125189794	chr11:125113161~125126781:+
BRCA	cis	rs10788972	0.508	rs6691549	ENSG00000225183.1	RP4-758J24.4	-4.84	1.53e-06	0.000149	-0.18	-0.15	Parkinson disease and lewy body pathology;	chr1:54015230	chr1:54089856~54090093:+
BRCA	cis	rs4925386	0.84	rs6143034	ENSG00000273619.1	RP5-908M14.9	-4.84	1.53e-06	0.000149	-0.13	-0.15	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62345489	chr20:62386303~62386970:-
BRCA	cis	rs745109	0.504	rs77013753	ENSG00000273080.1	RP11-301O19.1	4.84	1.53e-06	0.000149	0.23	0.15	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86371654	chr2:86195590~86196049:+
BRCA	cis	rs7618915	0.501	rs12486554	ENSG00000243224.1	RP5-1157M23.2	-4.84	1.53e-06	0.000149	-0.16	-0.15	Bipolar disorder;	chr3:52708521	chr3:52239258~52241097:+
BRCA	cis	rs370915	0.507	rs6835018	ENSG00000250971.1	RP11-696F12.1	4.84	1.53e-06	0.00015	0.16	0.15	Gout;	chr4:186873174	chr4:187060099~187060930:+
BRCA	cis	rs7772486	0.701	rs7772717	ENSG00000270638.1	RP3-466P17.1	4.84	1.53e-06	0.00015	0.17	0.15	Lobe attachment (rater-scored or self-reported);	chr6:145633718	chr6:145735570~145737218:+
BRCA	cis	rs4218	0.648	rs58087223	ENSG00000277144.1	RP11-59H7.4	-4.84	1.53e-06	0.00015	-0.2	-0.15	Social communication problems;	chr15:59075132	chr15:59115547~59116089:-
BRCA	cis	rs11098499	0.575	rs907204	ENSG00000249244.1	RP11-548H18.2	4.84	1.53e-06	0.00015	0.17	0.15	Corneal astigmatism;	chr4:119317499	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.575	rs907205	ENSG00000249244.1	RP11-548H18.2	4.84	1.53e-06	0.00015	0.17	0.15	Corneal astigmatism;	chr4:119317509	chr4:119391831~119395335:-
BRCA	cis	rs2832191	0.967	rs2898160	ENSG00000176054.6	RPL23P2	-4.84	1.53e-06	0.00015	-0.16	-0.15	Dental caries;	chr21:29115175	chr21:28997613~28998033:-
BRCA	cis	rs875971	0.862	rs1981799	ENSG00000223473.2	GS1-124K5.3	4.84	1.53e-06	0.00015	0.11	0.15	Aortic root size;	chr7:66490572	chr7:66491049~66493566:-
BRCA	cis	rs2905347	0.726	rs2905320	ENSG00000179428.2	AC073072.5	4.84	1.53e-06	0.00015	0.16	0.15	Major depression and alcohol dependence;	chr7:22664624	chr7:22725395~22727620:-
BRCA	cis	rs2832191	0.72	rs2832200	ENSG00000176054.6	RPL23P2	-4.84	1.53e-06	0.00015	-0.16	-0.15	Dental caries;	chr21:29126844	chr21:28997613~28998033:-
BRCA	cis	rs2832191	0.791	rs28633762	ENSG00000176054.6	RPL23P2	-4.84	1.53e-06	0.00015	-0.16	-0.15	Dental caries;	chr21:29127749	chr21:28997613~28998033:-
BRCA	cis	rs198426	0.506	rs11230767	ENSG00000243742.4	RPLP0P2	4.83	1.53e-06	0.00015	0.2	0.15	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr11:61659460	chr11:61615036~61639449:+
BRCA	cis	rs12612619	0.685	rs4665937	ENSG00000229122.1	AGBL5-IT1	-4.83	1.53e-06	0.00015	-0.16	-0.15	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27018927	chr2:27061038~27061815:+
BRCA	cis	rs11758351	0.66	rs2143345	ENSG00000241549.7	GUSBP2	-4.83	1.53e-06	0.00015	-0.21	-0.15	Renal underexcretion gout;Gout;	chr6:26228920	chr6:26871484~26956554:-
BRCA	cis	rs17818399	0.533	rs13420857	ENSG00000279254.1	RP11-536C12.1	4.83	1.53e-06	0.00015	0.18	0.15	Height;	chr2:46570866	chr2:46668870~46670778:+
BRCA	cis	rs924712	0.545	rs12216039	ENSG00000224984.1	RP11-524H19.2	4.83	1.53e-06	0.00015	0.17	0.15	Breast cancer;	chr6:54845124	chr6:54840118~54840855:-
BRCA	cis	rs924712	0.545	rs12216049	ENSG00000224984.1	RP11-524H19.2	4.83	1.53e-06	0.00015	0.17	0.15	Breast cancer;	chr6:54845171	chr6:54840118~54840855:-
BRCA	cis	rs987724	0.515	rs6441101	ENSG00000240875.4	LINC00886	-4.83	1.53e-06	0.00015	-0.22	-0.15	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156875409	chr3:156747346~156817062:-
BRCA	cis	rs6547741	0.935	rs4666004	ENSG00000234072.1	AC074117.10	4.83	1.53e-06	0.00015	0.14	0.15	Oral cavity cancer;	chr2:27632185	chr2:27356246~27367622:+
BRCA	cis	rs950880	0.767	rs12999364	ENSG00000234389.1	AC007278.3	-4.83	1.53e-06	0.00015	-0.14	-0.15	Serum protein levels (sST2);	chr2:102357669	chr2:102438713~102440475:+
BRCA	cis	rs950880	0.767	rs12998521	ENSG00000234389.1	AC007278.3	-4.83	1.53e-06	0.00015	-0.14	-0.15	Serum protein levels (sST2);	chr2:102357957	chr2:102438713~102440475:+
BRCA	cis	rs62025270	0.632	rs6496109	ENSG00000259295.5	CSPG4P12	-4.83	1.53e-06	0.00015	-0.23	-0.15	Idiopathic pulmonary fibrosis;	chr15:85588777	chr15:85191438~85213905:+
BRCA	cis	rs783540	0.521	rs28719490	ENSG00000255769.6	GOLGA2P10	-4.83	1.53e-06	0.00015	-0.19	-0.15	Schizophrenia;	chr15:82720688	chr15:82472993~82513950:-
BRCA	cis	rs454217	0.773	rs518009	ENSG00000277851.1	RP11-756G20.1	4.83	1.53e-06	0.00015	0.17	0.15	Smoking quantity;	chr12:92339730	chr12:92247756~92363832:-
BRCA	cis	rs7918232	0.825	rs4749233	ENSG00000262412.1	RP11-85G18.6	4.83	1.54e-06	0.00015	0.24	0.15	Breast cancer;	chr10:27179038	chr10:27243130~27250804:+
BRCA	cis	rs2278702	0.943	rs77271632	ENSG00000259495.2	RP11-210M15.2	-4.83	1.54e-06	0.00015	-0.23	-0.15	Bipolar disorder;	chr15:80396735	chr15:80344853~80403575:-
BRCA	cis	rs1322639	0.697	rs12661910	ENSG00000223485.1	RP11-417E7.1	-4.83	1.54e-06	0.00015	-0.2	-0.15	Pulse pressure;	chr6:169184293	chr6:169158092~169162924:-
BRCA	cis	rs7246657	0.722	rs16958861	ENSG00000276846.1	CTD-3220F14.3	4.83	1.54e-06	0.00015	0.2	0.15	Coronary artery calcification;	chr19:37633278	chr19:37314868~37315620:-
BRCA	cis	rs6847067	0.683	rs13118671	ENSG00000180769.7	WDFY3-AS2	4.83	1.54e-06	0.00015	0.15	0.15	Oropharynx cancer;	chr4:84850272	chr4:84965682~85011277:+
BRCA	cis	rs7208859	0.673	rs9889755	ENSG00000280069.1	CTD-2349P21.3	4.83	1.54e-06	0.00015	0.19	0.15	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30907487	chr17:30738182~30740275:+
BRCA	cis	rs9652601	0.748	rs4322688	ENSG00000274038.1	RP11-66H6.4	-4.83	1.54e-06	0.00015	-0.17	-0.15	Systemic lupus erythematosus;	chr16:11145134	chr16:11056556~11057034:+
BRCA	cis	rs7923837	1	rs7923837	ENSG00000236493.2	EIF2S2P3	4.83	1.54e-06	0.00015	0.2	0.15	Multiple sclerosis;Body mass index;	chr10:92722160	chr10:92668745~92669743:-
BRCA	cis	rs11168351	0.927	rs7971880	ENSG00000240399.1	RP1-228P16.1	4.83	1.54e-06	0.000151	0.18	0.15	Bipolar disorder and schizophrenia;	chr12:47997272	chr12:48054813~48055591:-
BRCA	cis	rs6545883	0.783	rs12713442	ENSG00000271889.1	RP11-493E12.1	4.83	1.54e-06	0.000151	0.19	0.15	Tuberculosis;	chr2:61620943	chr2:61151433~61162105:-
BRCA	cis	rs10129255	0.957	rs8009073	ENSG00000211974.3	IGHV2-70	4.83	1.54e-06	0.000151	0.15	0.15	Kawasaki disease;	chr14:106777278	chr14:106723574~106724093:-
BRCA	cis	rs13113518	1	rs56362210	ENSG00000249700.7	SRD5A3-AS1	4.83	1.54e-06	0.000151	0.18	0.15	Height;	chr4:55540972	chr4:55363971~55395847:-
BRCA	cis	rs6968419	0.925	rs11764793	ENSG00000279086.1	RP11-667F14.1	-4.83	1.54e-06	0.000151	-0.15	-0.15	Intraocular pressure;	chr7:116191206	chr7:116209234~116211511:-
BRCA	cis	rs172166	0.637	rs1071893	ENSG00000280107.1	AL022393.9	-4.83	1.54e-06	0.000151	-0.2	-0.15	Cardiac Troponin-T levels;	chr6:28199857	chr6:28170845~28172521:+
BRCA	cis	rs4578769	0.569	rs9951157	ENSG00000273232.1	RP11-370A5.2	4.83	1.54e-06	0.000151	0.18	0.15	Eosinophil percentage of white cells;	chr18:22974173	chr18:22882825~22883357:-
BRCA	cis	rs454217	0.846	rs428699	ENSG00000277851.1	RP11-756G20.1	4.83	1.54e-06	0.000151	0.17	0.15	Smoking quantity;	chr12:92334822	chr12:92247756~92363832:-
BRCA	cis	rs8180040	0.966	rs6792488	ENSG00000271161.1	BOLA2P2	-4.83	1.54e-06	0.000151	-0.16	-0.15	Colorectal cancer;	chr3:47461859	chr3:47499841~47500407:+
BRCA	cis	rs3176789	0.914	rs10772132	ENSG00000256673.1	RP11-599J14.2	-4.83	1.54e-06	0.000151	-0.19	-0.15	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9772316	chr12:9398355~9414851:-
BRCA	cis	rs13113518	0.966	rs4864544	ENSG00000249700.7	SRD5A3-AS1	4.83	1.54e-06	0.000151	0.18	0.15	Height;	chr4:55515292	chr4:55363971~55395847:-
BRCA	cis	rs4908768	0.501	rs1922983	ENSG00000232912.4	RP5-1115A15.1	4.83	1.54e-06	0.000151	0.14	0.15	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8471266	chr1:8424645~8434838:+
BRCA	cis	rs1729951	0.575	rs1682356	ENSG00000239213.4	NCK1-AS1	4.83	1.55e-06	0.000151	0.15	0.15	Neuroticism;	chr3:136973195	chr3:136841726~136862054:-
BRCA	cis	rs13326165	0.585	rs11717028	ENSG00000243224.1	RP5-1157M23.2	-4.83	1.55e-06	0.000151	-0.25	-0.15	HDL cholesterol levels;HDL cholesterol;	chr3:52320045	chr3:52239258~52241097:+
BRCA	cis	rs3808502	0.525	rs9650661	ENSG00000154316.13	TDH	4.83	1.55e-06	0.000151	0.19	0.15	Neuroticism;	chr8:11569624	chr8:11339637~11368452:+
BRCA	cis	rs7200543	1	rs3803575	ENSG00000260735.1	RP11-72I8.1	-4.83	1.55e-06	0.000151	-0.17	-0.15	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15044590	chr16:15094411~15109197:+
BRCA	cis	rs6714710	0.603	rs10432626	ENSG00000230606.9	AC159540.1	-4.83	1.55e-06	0.000151	-0.17	-0.15	Posterior cortical atrophy and Alzheimer's disease;	chr2:97944690	chr2:97416165~97433527:-
BRCA	cis	rs8064024	0.649	rs9934930	ENSG00000267077.1	RP11-127I20.5	4.83	1.55e-06	0.000151	0.15	0.15	Cancer;	chr16:4852037	chr16:4795265~4796532:-
BRCA	cis	rs10461617	0.617	rs6874733	ENSG00000271828.1	CTD-2310F14.1	4.83	1.55e-06	0.000151	0.19	0.15	Type 2 diabetes;	chr5:56773773	chr5:56927874~56929573:+
BRCA	cis	rs7178375	1	rs7178533	ENSG00000270055.1	CTD-3092A11.2	-4.83	1.55e-06	0.000151	-0.22	-0.15	Hypertriglyceridemia;	chr15:30923773	chr15:30487963~30490313:+
BRCA	cis	rs6847067	0.8	rs12506456	ENSG00000180769.7	WDFY3-AS2	4.83	1.55e-06	0.000151	0.13	0.15	Oropharynx cancer;	chr4:84937095	chr4:84965682~85011277:+
BRCA	cis	rs2919009	0.581	rs2118962	ENSG00000271670.1	RP11-95I16.4	4.83	1.55e-06	0.000151	0.2	0.15	Obesity-related traits;	chr10:120937721	chr10:120879256~120880667:-
BRCA	cis	rs2919009	0.581	rs56118695	ENSG00000271670.1	RP11-95I16.4	4.83	1.55e-06	0.000151	0.2	0.15	Obesity-related traits;	chr10:120938383	chr10:120879256~120880667:-
BRCA	cis	rs919433	0.617	rs4850807	ENSG00000231621.1	AC013264.2	4.83	1.55e-06	0.000151	0.14	0.15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197711251	chr2:197197991~197199273:+
BRCA	cis	rs7267979	0.789	rs1983974	ENSG00000274414.1	RP5-965G21.4	4.83	1.55e-06	0.000151	0.17	0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25549983	chr20:25239007~25245229:-
BRCA	cis	rs11124272	0.868	rs477517	ENSG00000272716.1	RP11-563N4.1	4.83	1.55e-06	0.000151	0.17	0.15	Interleukin-18 levels;	chr2:31623568	chr2:32165046~32165757:-
BRCA	cis	rs2505998	0.833	rs752977	ENSG00000273008.1	RP11-351D16.3	-4.83	1.55e-06	0.000151	-0.18	-0.15	Hirschsprung disease;	chr10:43092933	chr10:43136824~43138334:-
BRCA	cis	rs2505998	0.833	rs12767776	ENSG00000273008.1	RP11-351D16.3	-4.83	1.55e-06	0.000151	-0.18	-0.15	Hirschsprung disease;	chr10:43094065	chr10:43136824~43138334:-
BRCA	cis	rs2073316	0.592	rs17545760	ENSG00000272716.1	RP11-563N4.1	4.83	1.55e-06	0.000151	0.16	0.15	Interleukin-18 levels;	chr2:31448792	chr2:32165046~32165757:-
BRCA	cis	rs11096990	0.634	rs11096988	ENSG00000249685.1	RP11-360F5.3	4.83	1.55e-06	0.000151	0.19	0.15	Cognitive function;	chr4:39264081	chr4:39133913~39135608:+
BRCA	cis	rs600231	0.598	rs2508712	ENSG00000173727.10	CMB9-22P13.1	4.83	1.55e-06	0.000152	0.19	0.15	Bone mineral density;	chr11:65464790	chr11:65455258~65466720:+
BRCA	cis	rs1223397	0.651	rs2439543	ENSG00000215022.6	RP1-257A7.4	-4.83	1.55e-06	0.000152	-0.17	-0.15	Blood pressure;	chr6:13311921	chr6:13264861~13295586:-
BRCA	cis	rs13113518	1	rs6847529	ENSG00000249700.7	SRD5A3-AS1	4.83	1.55e-06	0.000152	0.18	0.15	Height;	chr4:55518776	chr4:55363971~55395847:-
BRCA	cis	rs13113518	1	rs6822740	ENSG00000249700.7	SRD5A3-AS1	4.83	1.55e-06	0.000152	0.18	0.15	Height;	chr4:55518922	chr4:55363971~55395847:-
BRCA	cis	rs10861342	1	rs10778370	ENSG00000257999.1	RP11-61E11.2	-4.83	1.55e-06	0.000152	-0.32	-0.15	IgG glycosylation;	chr12:105209361	chr12:105102472~105107179:-
BRCA	cis	rs11154801	0.732	rs13202115	ENSG00000231028.7	LINC00271	-4.83	1.55e-06	0.000152	-0.15	-0.15	Multiple sclerosis;	chr6:135604386	chr6:135497801~135716055:+
BRCA	cis	rs6596100	0.915	rs62375246	ENSG00000248648.1	RP11-485M7.1	-4.83	1.55e-06	0.000152	-0.19	-0.15	Breast cancer;	chr5:133103318	chr5:133003119~133003365:+
BRCA	cis	rs79040073	0.911	rs11638981	ENSG00000259531.2	RP11-295H24.3	4.83	1.55e-06	0.000152	0.23	0.15	Lung cancer in ever smokers;	chr15:49029332	chr15:49365124~49366685:-
BRCA	cis	rs9659323	0.65	rs10802064	ENSG00000231365.4	RP11-418J17.1	-4.83	1.55e-06	0.000152	-0.19	-0.15	Body mass index;	chr1:118915514	chr1:119140396~119275973:+
BRCA	cis	rs1707322	1	rs12124847	ENSG00000234329.1	RP11-767N6.2	4.83	1.56e-06	0.000152	0.16	0.15	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45915178	chr1:45651039~45651826:-
BRCA	cis	rs6430585	0.941	rs6708957	ENSG00000224043.6	CCNT2-AS1	-4.83	1.56e-06	0.000152	-0.23	-0.15	Corneal structure;	chr2:135762473	chr2:134735464~134918710:-
BRCA	cis	rs7226408	0.948	rs1426755	ENSG00000267707.2	RP11-95O2.5	4.83	1.56e-06	0.000152	0.24	0.15	Obesity-related traits;	chr18:36830868	chr18:37243776~37247506:+
BRCA	cis	rs4356203	0.87	rs10741724	ENSG00000272034.1	SNORD14A	-4.83	1.56e-06	0.000152	-0.15	-0.15	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17231604	chr11:17074654~17074744:-
BRCA	cis	rs7267979	0.844	rs2424703	ENSG00000125804.12	FAM182A	-4.83	1.56e-06	0.000152	-0.19	-0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25289488	chr20:26054655~26086917:+
BRCA	cis	rs1669338	0.507	rs4685607	ENSG00000271870.1	RP11-97C16.1	-4.83	1.56e-06	0.000152	-0.19	-0.15	White matter integrity;	chr3:3137716	chr3:3152942~3153435:+
BRCA	cis	rs66887589	0.934	rs7681980	ENSG00000245958.5	RP11-33B1.1	4.83	1.56e-06	0.000152	0.13	0.15	Diastolic blood pressure;	chr4:119612068	chr4:119454791~119552025:+
BRCA	cis	rs6570726	0.935	rs398060	ENSG00000235652.6	RP11-545I5.3	-4.83	1.56e-06	0.000152	-0.15	-0.15	Lobe attachment (rater-scored or self-reported);	chr6:145520379	chr6:145799409~145886585:+
BRCA	cis	rs7809615	0.901	rs6947974	ENSG00000244219.5	GS1-259H13.2	-4.83	1.56e-06	0.000152	-0.26	-0.15	Blood metabolite ratios;	chr7:99558883	chr7:99598066~99610813:+
BRCA	cis	rs2638953	0.85	rs10843112	ENSG00000247934.4	RP11-967K21.1	-4.83	1.56e-06	0.000152	-0.2	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28144614	chr12:28163298~28190738:-
BRCA	cis	rs2243480	1	rs2533288	ENSG00000275400.1	RP4-756H11.5	4.83	1.56e-06	0.000152	0.27	0.15	Diabetic kidney disease;	chr7:66591724	chr7:66553805~66554199:-
BRCA	cis	rs875971	0.929	rs34406470	ENSG00000223473.2	GS1-124K5.3	4.83	1.56e-06	0.000152	0.11	0.15	Aortic root size;	chr7:66464969	chr7:66491049~66493566:-
BRCA	cis	rs1395	0.778	rs12465084	ENSG00000234072.1	AC074117.10	-4.83	1.56e-06	0.000152	-0.16	-0.15	Blood metabolite levels;	chr2:27191335	chr2:27356246~27367622:+
BRCA	cis	rs9926296	0.715	rs467035	ENSG00000260259.1	RP11-368I7.4	-4.83	1.56e-06	0.000152	-0.2	-0.15	Vitiligo;	chr16:89673877	chr16:89682620~89686569:-
BRCA	cis	rs1853665	1	rs9383993	ENSG00000216906.2	RP11-350J20.9	-4.83	1.56e-06	0.000152	-0.22	-0.15	Radiation response;	chr6:149978163	chr6:149904243~149906418:+
BRCA	cis	rs4578769	0.55	rs9953702	ENSG00000273232.1	RP11-370A5.2	4.83	1.56e-06	0.000153	0.18	0.15	Eosinophil percentage of white cells;	chr18:22971001	chr18:22882825~22883357:-
BRCA	cis	rs2243480	1	rs4718333	ENSG00000222364.1	RNU6-96P	4.83	1.56e-06	0.000153	0.28	0.15	Diabetic kidney disease;	chr7:66307771	chr7:66395191~66395286:+
BRCA	cis	rs2243480	1	rs7792391	ENSG00000222364.1	RNU6-96P	4.83	1.56e-06	0.000153	0.28	0.15	Diabetic kidney disease;	chr7:66308442	chr7:66395191~66395286:+
BRCA	cis	rs2281636	1	rs2804417	ENSG00000233690.1	EBAG9P1	-4.83	1.56e-06	0.000153	-0.16	-0.15	Obesity-related traits;	chr10:99756458	chr10:99697407~99697949:-
BRCA	cis	rs62244186	0.566	rs2135531	ENSG00000233509.2	ZNF197-AS1	4.83	1.56e-06	0.000153	0.18	0.15	Depressive symptoms;	chr3:44839666	chr3:44617128~44624797:-
BRCA	cis	rs10992797	0.523	rs4744258	ENSG00000227603.1	RP11-165J3.6	-4.83	1.56e-06	0.000153	-0.16	-0.15	Intelligence (multi-trait analysis);	chr9:93599287	chr9:93435332~93437121:-
BRCA	cis	rs4934494	0.677	rs11185790	ENSG00000240996.1	RP11-80H5.7	4.83	1.56e-06	0.000153	0.2	0.15	Red blood cell count;	chr10:89612776	chr10:89694295~89697928:-
BRCA	cis	rs2832191	0.74	rs2832175	ENSG00000176054.6	RPL23P2	-4.83	1.56e-06	0.000153	-0.16	-0.15	Dental caries;	chr21:29103285	chr21:28997613~28998033:-
BRCA	cis	rs4908769	0.55	rs2029706	ENSG00000270282.1	RP5-1115A15.2	4.83	1.56e-06	0.000153	0.18	0.15	Allergy;	chr1:8807242	chr1:8512653~8513021:+
BRCA	cis	rs7481584	0.624	rs516443	ENSG00000247473.2	CARS-AS1	-4.83	1.56e-06	0.000153	-0.18	-0.15	Calcium levels;	chr11:3026064	chr11:3029009~3041260:+
BRCA	cis	rs7481584	0.624	rs412842	ENSG00000247473.2	CARS-AS1	-4.83	1.56e-06	0.000153	-0.18	-0.15	Calcium levels;	chr11:3026218	chr11:3029009~3041260:+
BRCA	cis	rs7481584	0.624	rs449466	ENSG00000247473.2	CARS-AS1	-4.83	1.56e-06	0.000153	-0.18	-0.15	Calcium levels;	chr11:3026373	chr11:3029009~3041260:+
BRCA	cis	rs7481584	0.624	rs413368	ENSG00000247473.2	CARS-AS1	-4.83	1.56e-06	0.000153	-0.18	-0.15	Calcium levels;	chr11:3026416	chr11:3029009~3041260:+
BRCA	cis	rs26949	0.504	rs10054744	ENSG00000215032.2	GNL3LP1	-4.83	1.56e-06	0.000153	-0.18	-0.15	Intelligence (multi-trait analysis);	chr5:60744220	chr5:60891935~60893577:-
BRCA	cis	rs61160187	0.51	rs4577661	ENSG00000215032.2	GNL3LP1	-4.83	1.56e-06	0.000153	-0.18	-0.15	Educational attainment (years of education);Educational attainment (college completion);	chr5:60744640	chr5:60891935~60893577:-
BRCA	cis	rs12539814	1	rs12539814	ENSG00000244198.4	RP4-545C24.1	4.83	1.56e-06	0.000153	0.27	0.15	Diastolic blood pressure;	chr7:144433417	chr7:144194858~144280547:+
BRCA	cis	rs4356203	0.87	rs7949699	ENSG00000272034.1	SNORD14A	-4.83	1.56e-06	0.000153	-0.15	-0.15	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17226161	chr11:17074654~17074744:-
BRCA	cis	rs4356203	0.87	rs11024204	ENSG00000272034.1	SNORD14A	-4.83	1.56e-06	0.000153	-0.15	-0.15	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17228258	chr11:17074654~17074744:-
BRCA	cis	rs703842	1	rs11172335	ENSG00000270039.1	RP11-571M6.17	-4.83	1.56e-06	0.000153	-0.21	-0.15	Multiple sclerosis;	chr12:57781418	chr12:57803838~57804415:+
BRCA	cis	rs703842	0.964	rs2014886	ENSG00000270039.1	RP11-571M6.17	-4.83	1.56e-06	0.000153	-0.21	-0.15	Multiple sclerosis;	chr12:57783654	chr12:57803838~57804415:+
BRCA	cis	rs703842	1	rs1599932	ENSG00000270039.1	RP11-571M6.17	-4.83	1.56e-06	0.000153	-0.21	-0.15	Multiple sclerosis;	chr12:57784160	chr12:57803838~57804415:+
BRCA	cis	rs2832191	0.74	rs6516890	ENSG00000236056.1	GAPDHP14	-4.83	1.56e-06	0.000153	-0.16	-0.15	Dental caries;	chr21:29104491	chr21:29222321~29223257:+
BRCA	cis	rs6723226	0.739	rs2069213	ENSG00000276517.1	AL133243.2	-4.83	1.57e-06	0.000153	-0.18	-0.15	Intelligence (multi-trait analysis);	chr2:32518017	chr2:32526504~32529507:+
BRCA	cis	rs4713118	0.513	rs202908	ENSG00000219392.1	RP1-265C24.5	-4.83	1.57e-06	0.000153	-0.21	-0.15	Parkinson's disease;	chr6:28043773	chr6:28115628~28116551:+
BRCA	cis	rs4787491	0.679	rs12933575	ENSG00000261367.1	RP11-455F5.4	-4.83	1.57e-06	0.000153	-0.16	-0.15	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30011243	chr16:30107675~30110541:+
BRCA	cis	rs11124272	0.859	rs11678843	ENSG00000272716.1	RP11-563N4.1	-4.83	1.57e-06	0.000153	-0.18	-0.15	Interleukin-18 levels;	chr2:31736113	chr2:32165046~32165757:-
BRCA	cis	rs3764021	0.87	rs7970116	ENSG00000278635.1	CTD-2318O12.1	4.83	1.57e-06	0.000153	0.14	0.15	Type 1 diabetes;	chr12:9727518	chr12:9415641~9416718:+
BRCA	cis	rs11098499	0.954	rs13133522	ENSG00000260091.1	RP11-33B1.4	-4.83	1.57e-06	0.000153	-0.13	-0.15	Corneal astigmatism;	chr4:119403269	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.954	rs35091806	ENSG00000260091.1	RP11-33B1.4	-4.83	1.57e-06	0.000153	-0.13	-0.15	Corneal astigmatism;	chr4:119404374	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.909	rs35165976	ENSG00000260091.1	RP11-33B1.4	-4.83	1.57e-06	0.000153	-0.13	-0.15	Corneal astigmatism;	chr4:119404475	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.954	rs6846442	ENSG00000260091.1	RP11-33B1.4	-4.83	1.57e-06	0.000153	-0.13	-0.15	Corneal astigmatism;	chr4:119405168	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.954	rs71614438	ENSG00000260091.1	RP11-33B1.4	-4.83	1.57e-06	0.000153	-0.13	-0.15	Corneal astigmatism;	chr4:119450097	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.954	rs66506550	ENSG00000260091.1	RP11-33B1.4	-4.83	1.57e-06	0.000153	-0.13	-0.15	Corneal astigmatism;	chr4:119450290	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.909	rs7659501	ENSG00000260091.1	RP11-33B1.4	-4.83	1.57e-06	0.000153	-0.13	-0.15	Corneal astigmatism;	chr4:119450397	chr4:119409333~119410233:+
BRCA	cis	rs7976269	0.609	rs1344855	ENSG00000275476.1	RP11-996F15.4	4.83	1.57e-06	0.000153	0.17	0.15	Male-pattern baldness;	chr12:29065605	chr12:29277397~29277882:-
BRCA	cis	rs1707322	0.929	rs785513	ENSG00000234329.1	RP11-767N6.2	-4.83	1.57e-06	0.000153	-0.15	-0.15	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46072648	chr1:45651039~45651826:-
BRCA	cis	rs4948275	0.773	rs2606081	ENSG00000237233.2	TMEM26-AS1	-4.83	1.57e-06	0.000153	-0.18	-0.15	Night sleep phenotypes;	chr10:61532493	chr10:61452639~61481956:+
BRCA	cis	rs13118159	0.509	rs10023473	ENSG00000254094.1	AC078852.1	-4.83	1.57e-06	0.000153	-0.18	-0.15	Longevity;	chr4:1381497	chr4:1356581~1358075:+
BRCA	cis	rs6490294	0.528	rs12580175	ENSG00000226469.1	ADAM1B	4.83	1.57e-06	0.000153	0.26	0.15	Mean platelet volume;	chr12:111926708	chr12:111927018~111929017:+
BRCA	cis	rs6490294	0.528	rs61012856	ENSG00000226469.1	ADAM1B	4.83	1.57e-06	0.000153	0.26	0.15	Mean platelet volume;	chr12:111927687	chr12:111927018~111929017:+
BRCA	cis	rs6490294	0.528	rs59131168	ENSG00000226469.1	ADAM1B	4.83	1.57e-06	0.000153	0.26	0.15	Mean platelet volume;	chr12:111930559	chr12:111927018~111929017:+
BRCA	cis	rs7267979	0.816	rs404775	ENSG00000274414.1	RP5-965G21.4	-4.83	1.57e-06	0.000153	-0.17	-0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25500481	chr20:25239007~25245229:-
BRCA	cis	rs7267979	0.816	rs374701	ENSG00000274414.1	RP5-965G21.4	-4.83	1.57e-06	0.000153	-0.17	-0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25502980	chr20:25239007~25245229:-
BRCA	cis	rs2239547	0.618	rs13083728	ENSG00000242142.1	SERBP1P3	4.83	1.57e-06	0.000153	0.18	0.15	Schizophrenia;	chr3:52834429	chr3:53064283~53065091:-
BRCA	cis	rs12591650	0.556	rs78498480	ENSG00000259591.1	RP11-554D20.1	4.83	1.57e-06	0.000153	0.25	0.15	Subcutaneous adipose tissue;	chr15:60791084	chr15:60763906~60765625:+
BRCA	cis	rs9638182	1	rs17145713	ENSG00000274080.1	CTA-315H11.2	4.83	1.57e-06	0.000153	0.26	0.15	Triglycerides;	chr7:73490480	chr7:73609262~73611502:-
BRCA	cis	rs7772486	0.846	rs866473	ENSG00000270638.1	RP3-466P17.1	4.83	1.57e-06	0.000153	0.17	0.15	Lobe attachment (rater-scored or self-reported);	chr6:146032278	chr6:145735570~145737218:+
BRCA	cis	rs919433	0.679	rs7600862	ENSG00000231621.1	AC013264.2	-4.83	1.57e-06	0.000153	-0.14	-0.15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197669790	chr2:197197991~197199273:+
BRCA	cis	rs875971	0.755	rs76288834	ENSG00000236529.1	RP13-254B10.1	-4.83	1.57e-06	0.000153	-0.16	-0.15	Aortic root size;	chr7:66604815	chr7:65840212~65840596:+
BRCA	cis	rs321358	0.945	rs7111445	ENSG00000271390.1	RP11-89C3.3	-4.83	1.57e-06	0.000153	-0.23	-0.15	Body mass index;	chr11:111105787	chr11:111089870~111090368:-
BRCA	cis	rs2832191	1	rs9984793	ENSG00000176054.6	RPL23P2	-4.83	1.57e-06	0.000153	-0.16	-0.15	Dental caries;	chr21:29114150	chr21:28997613~28998033:-
BRCA	cis	rs6012564	1	rs3092374	ENSG00000227431.4	CSE1L-AS1	-4.83	1.57e-06	0.000153	-0.18	-0.15	Anger;	chr20:49047407	chr20:49040463~49046044:-
BRCA	cis	rs6498068	0.522	rs10775284	ENSG00000260468.1	LINC01290	-4.83	1.57e-06	0.000153	-0.2	-0.15	Metabolite levels (MHPG);	chr16:10535402	chr16:10514842~10528202:-
BRCA	cis	rs2898681	1	rs2898681	ENSG00000248375.1	RP11-177B4.1	-4.83	1.57e-06	0.000153	-0.23	-0.15	Optic nerve measurement (cup area);	chr4:52890833	chr4:52720081~52720831:-
BRCA	cis	rs6671200	0.831	rs35949014	ENSG00000235501.4	RP4-639F20.1	-4.83	1.57e-06	0.000153	-0.32	-0.15	Stearic acid (18:0) levels;	chr1:95139279	chr1:94927566~94963270:+
BRCA	cis	rs2235544	0.565	rs928443	ENSG00000225183.1	RP4-758J24.4	4.83	1.57e-06	0.000153	0.18	0.15	Thyroid hormone levels;Multiple myeloma (hyperdiploidy);	chr1:54007843	chr1:54089856~54090093:+
BRCA	cis	rs7226408	0.857	rs59065432	ENSG00000267707.2	RP11-95O2.5	4.83	1.57e-06	0.000153	0.23	0.15	Obesity-related traits;	chr18:36839382	chr18:37243776~37247506:+
BRCA	cis	rs1499614	0.901	rs2178742	ENSG00000275400.1	RP4-756H11.5	4.83	1.57e-06	0.000153	0.28	0.15	Gout;	chr7:66732812	chr7:66553805~66554199:-
BRCA	cis	rs17428076	0.837	rs62182430	ENSG00000228389.1	AC068039.4	-4.83	1.57e-06	0.000153	-0.22	-0.15	Myopia;	chr2:171916327	chr2:171773482~171775844:+
BRCA	cis	rs7267979	0.844	rs4423675	ENSG00000274414.1	RP5-965G21.4	4.83	1.57e-06	0.000153	0.17	0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25422142	chr20:25239007~25245229:-
BRCA	cis	rs12744310	0.887	rs4453028	ENSG00000235358.1	RP11-399E6.1	4.83	1.57e-06	0.000154	0.22	0.15	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41326851	chr1:41242373~41284861:+
BRCA	cis	rs4388249	0.696	rs31600	ENSG00000271849.1	CTC-332L22.1	4.83	1.57e-06	0.000154	0.22	0.15	Schizophrenia;	chr5:109670675	chr5:109687802~109688329:-
BRCA	cis	rs6832769	1	rs13121235	ENSG00000223305.1	RN7SKP30	4.83	1.57e-06	0.000154	0.18	0.15	Personality dimensions;	chr4:55445780	chr4:55540502~55540835:-
BRCA	cis	rs4356203	0.87	rs10832746	ENSG00000272034.1	SNORD14A	-4.83	1.57e-06	0.000154	-0.15	-0.15	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17228406	chr11:17074654~17074744:-
BRCA	cis	rs4835473	0.8	rs13124170	ENSG00000249741.2	RP11-673E1.3	-4.83	1.57e-06	0.000154	-0.16	-0.15	Immature fraction of reticulocytes;	chr4:143975951	chr4:143911514~143912053:-
BRCA	cis	rs9402743	0.671	rs6934889	ENSG00000231028.7	LINC00271	4.83	1.57e-06	0.000154	0.15	0.15	Systemic lupus erythematosus;	chr6:135629542	chr6:135497801~135716055:+
BRCA	cis	rs6840360	0.582	rs11733820	ENSG00000278978.1	RP11-164P12.5	-4.83	1.57e-06	0.000154	-0.16	-0.15	Intelligence (multi-trait analysis);	chr4:151394987	chr4:151669786~151670503:+
BRCA	cis	rs10989172	0.69	rs4562454	ENSG00000175611.10	LINC00476	4.83	1.57e-06	0.000154	0.16	0.15	Common carotid intima-media thickness in HIV negative individuals;	chr9:96078514	chr9:95759231~95875977:-
BRCA	cis	rs7818688	0.578	rs11786451	ENSG00000253528.2	RP11-347C18.4	-4.83	1.57e-06	0.000154	-0.2	-0.15	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94884803	chr8:94974573~94974853:-
BRCA	cis	rs7487075	0.619	rs10785628	ENSG00000274723.1	RP11-618L22.1	4.83	1.57e-06	0.000154	0.2	0.15	Itch intensity from mosquito bite;	chr12:46460893	chr12:46970504~46972155:+
BRCA	cis	rs11951515	0.509	rs12521249	ENSG00000248240.1	RP11-159F24.5	4.83	1.57e-06	0.000154	0.18	0.15	Metabolite levels  (X-11787);	chr5:43558527	chr5:43515274~43525310:+
BRCA	cis	rs4699052	0.662	rs1516732	ENSG00000248740.4	RP11-328K4.1	4.83	1.58e-06	0.000154	0.16	0.15	Testicular germ cell tumor;	chr4:103329997	chr4:103256159~103453658:+
BRCA	cis	rs6951245	1	rs11770909	ENSG00000229043.2	AC091729.9	-4.83	1.58e-06	0.000154	-0.27	-0.15	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1047080	chr7:1160374~1165267:+
BRCA	cis	rs12501370	0.55	rs6830108	ENSG00000201736.1	RNA5SP160	4.83	1.58e-06	0.000154	0.17	0.15	Iris color (L* coordinate);	chr4:40976497	chr4:40990154~40990273:+
BRCA	cis	rs12501370	0.569	rs4861348	ENSG00000201736.1	RNA5SP160	4.83	1.58e-06	0.000154	0.17	0.15	Iris color (L* coordinate);	chr4:40976748	chr4:40990154~40990273:+
BRCA	cis	rs7428	1	rs7428	ENSG00000273196.1	RP11-717A5.2	-4.83	1.58e-06	0.000154	-0.18	-0.15	Ear protrusion;	chr2:85318367	chr2:85387074~85387146:-
BRCA	cis	rs11671005	0.695	rs8106061	ENSG00000269473.1	CTD-2619J13.19	4.83	1.58e-06	0.000154	0.18	0.15	Mean platelet volume;	chr19:58406623	chr19:58440448~58445849:+
BRCA	cis	rs2832191	0.935	rs11910475	ENSG00000236056.1	GAPDHP14	4.83	1.58e-06	0.000154	0.16	0.15	Dental caries;	chr21:29147381	chr21:29222321~29223257:+
BRCA	cis	rs860818	0.793	rs1881202	ENSG00000230658.1	KLHL7-AS1	4.83	1.58e-06	0.000154	0.38	0.15	Initial pursuit acceleration;	chr7:23153889	chr7:23101228~23105703:-
BRCA	cis	rs10419113	0.668	rs2360530	ENSG00000268545.1	VN1R107P	4.83	1.58e-06	0.000154	0.17	0.15	Pediatric bone mineral density (spine);	chr19:57669785	chr19:57459912~57460120:+
BRCA	cis	rs3764021	0.87	rs2192437	ENSG00000278635.1	CTD-2318O12.1	-4.83	1.58e-06	0.000154	-0.15	-0.15	Type 1 diabetes;	chr12:9726639	chr12:9415641~9416718:+
BRCA	cis	rs3764021	0.87	rs10844617	ENSG00000278635.1	CTD-2318O12.1	-4.83	1.58e-06	0.000154	-0.15	-0.15	Type 1 diabetes;	chr12:9726772	chr12:9415641~9416718:+
BRCA	cis	rs736408	0.609	rs62255396	ENSG00000243224.1	RP5-1157M23.2	-4.83	1.58e-06	0.000154	-0.17	-0.15	Bipolar disorder;	chr3:52748823	chr3:52239258~52241097:+
BRCA	cis	rs7474896	0.583	rs10740950	ENSG00000120555.12	SEPT7P9	4.83	1.58e-06	0.000154	0.21	0.15	Obesity (extreme);	chr10:37714568	chr10:38383069~38402916:-
BRCA	cis	rs7246657	0.722	rs8100646	ENSG00000226686.6	LINC01535	-4.83	1.58e-06	0.000154	-0.22	-0.15	Coronary artery calcification;	chr19:37617042	chr19:37251912~37265535:+
BRCA	cis	rs2281636	0.894	rs1541598	ENSG00000233690.1	EBAG9P1	-4.83	1.58e-06	0.000154	-0.15	-0.15	Obesity-related traits;	chr10:99630733	chr10:99697407~99697949:-
BRCA	cis	rs7267979	0.932	rs6115200	ENSG00000125804.12	FAM182A	-4.83	1.58e-06	0.000154	-0.19	-0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25506741	chr20:26054655~26086917:+
BRCA	cis	rs2562456	0.833	rs2928211	ENSG00000268535.1	RP11-420K14.3	-4.83	1.58e-06	0.000154	-0.2	-0.15	Pain;	chr19:21358495	chr19:21709522~21710191:+
BRCA	cis	rs4908768	0.501	rs7518608	ENSG00000232912.4	RP5-1115A15.1	4.83	1.58e-06	0.000154	0.14	0.15	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8497260	chr1:8424645~8434838:+
BRCA	cis	rs911555	0.511	rs8007489	ENSG00000269940.1	RP11-73M18.7	-4.83	1.58e-06	0.000154	-0.15	-0.15	Intelligence (multi-trait analysis);	chr14:103588235	chr14:103694560~103695170:+
BRCA	cis	rs11158026	0.603	rs68065548	ENSG00000258413.1	RP11-665C16.6	-4.83	1.58e-06	0.000154	-0.2	-0.15	Parkinson's disease;	chr14:54979835	chr14:55262767~55272075:-
BRCA	cis	rs2904967	1	rs636928	ENSG00000255200.1	AP003068.18	4.83	1.58e-06	0.000154	0.26	0.15	Mean corpuscular volume;	chr11:65326013	chr11:65174117~65176470:-
BRCA	cis	rs4218	0.541	rs1374155	ENSG00000277144.1	RP11-59H7.4	-4.83	1.58e-06	0.000154	-0.18	-0.15	Social communication problems;	chr15:59030630	chr15:59115547~59116089:-
BRCA	cis	rs2243480	1	rs313820	ENSG00000222364.1	RNU6-96P	-4.83	1.58e-06	0.000154	-0.28	-0.15	Diabetic kidney disease;	chr7:66109479	chr7:66395191~66395286:+
BRCA	cis	rs1832007	0.554	rs34179396	ENSG00000224034.1	RP11-445P17.8	-4.83	1.58e-06	0.000154	-0.29	-0.15	Triglyceride levels;Triglycerides;	chr10:5278817	chr10:5266033~5271236:-
BRCA	cis	rs7572733	0.935	rs1369512	ENSG00000231621.1	AC013264.2	-4.83	1.58e-06	0.000154	-0.14	-0.15	Dermatomyositis;	chr2:197902408	chr2:197197991~197199273:+
BRCA	cis	rs8054556	0.539	rs12596543	ENSG00000261367.1	RP11-455F5.4	-4.83	1.58e-06	0.000154	-0.16	-0.15	Autism spectrum disorder or schizophrenia;	chr16:30017814	chr16:30107675~30110541:+
BRCA	cis	rs6847067	1	rs6531775	ENSG00000180769.7	WDFY3-AS2	4.83	1.58e-06	0.000154	0.13	0.15	Oropharynx cancer;	chr4:84809761	chr4:84965682~85011277:+
BRCA	cis	rs67311347	1	rs7641495	ENSG00000280739.1	EIF1B-AS1	-4.83	1.58e-06	0.000154	-0.16	-0.15	Renal cell carcinoma;	chr3:40453199	chr3:40173145~40309698:-
BRCA	cis	rs26949	0.526	rs6887637	ENSG00000215032.2	GNL3LP1	-4.83	1.58e-06	0.000154	-0.18	-0.15	Intelligence (multi-trait analysis);	chr5:60739813	chr5:60891935~60893577:-
BRCA	cis	rs427691	0.625	rs845740	ENSG00000271849.1	CTC-332L22.1	-4.83	1.58e-06	0.000154	-0.24	-0.15	Autism spectrum disorder or schizophrenia;	chr5:109683201	chr5:109687802~109688329:-
BRCA	cis	rs7267979	0.899	rs2179459	ENSG00000125804.12	FAM182A	-4.83	1.58e-06	0.000154	-0.19	-0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25475505	chr20:26054655~26086917:+
BRCA	cis	rs370915	1	rs9685837	ENSG00000250971.1	RP11-696F12.1	4.83	1.58e-06	0.000154	0.16	0.15	Gout;	chr4:186897312	chr4:187060099~187060930:+
BRCA	cis	rs6714710	0.603	rs35255677	ENSG00000230606.9	AC159540.1	-4.83	1.58e-06	0.000154	-0.18	-0.15	Posterior cortical atrophy and Alzheimer's disease;	chr2:97951357	chr2:97416165~97433527:-
BRCA	cis	rs1707322	1	rs10789485	ENSG00000234329.1	RP11-767N6.2	4.83	1.58e-06	0.000155	0.16	0.15	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45941636	chr1:45651039~45651826:-
BRCA	cis	rs6490294	0.528	rs12426312	ENSG00000226469.1	ADAM1B	4.83	1.59e-06	0.000155	0.26	0.15	Mean platelet volume;	chr12:111968945	chr12:111927018~111929017:+
BRCA	cis	rs4853525	0.59	rs3771308	ENSG00000235852.1	AC005540.3	4.83	1.59e-06	0.000155	0.19	0.15	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190936179	chr2:190880797~190882059:-
BRCA	cis	rs7160336	1	rs11623625	ENSG00000259065.1	RP5-1021I20.1	-4.83	1.59e-06	0.000155	-0.16	-0.15	Blood protein levels;	chr14:74148327	chr14:73787360~73803270:+
BRCA	cis	rs4356203	0.905	rs618331	ENSG00000272034.1	SNORD14A	-4.83	1.59e-06	0.000155	-0.15	-0.15	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17225789	chr11:17074654~17074744:-
BRCA	cis	rs11686241	0.935	rs284530	ENSG00000241520.1	AC098820.4	4.83	1.59e-06	0.000155	0.22	0.15	Cancer;	chr2:216468816	chr2:216483032~216487196:-
BRCA	cis	rs2832191	0.755	rs2832192	ENSG00000176054.6	RPL23P2	-4.83	1.59e-06	0.000155	-0.16	-0.15	Dental caries;	chr21:29118852	chr21:28997613~28998033:-
BRCA	cis	rs2638953	0.925	rs11049584	ENSG00000247934.4	RP11-967K21.1	-4.83	1.59e-06	0.000155	-0.21	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28417879	chr12:28163298~28190738:-
BRCA	cis	rs26949	1	rs26949	ENSG00000215032.2	GNL3LP1	-4.83	1.59e-06	0.000155	-0.19	-0.15	Intelligence (multi-trait analysis);	chr5:60529473	chr5:60891935~60893577:-
BRCA	cis	rs7923837	0.964	rs10882106	ENSG00000236493.2	EIF2S2P3	4.83	1.59e-06	0.000155	0.2	0.15	Multiple sclerosis;Body mass index;	chr10:92720577	chr10:92668745~92669743:-
BRCA	cis	rs16944613	0.51	rs4476150	ENSG00000245479.2	LINC01585	4.83	1.59e-06	0.000155	0.17	0.15	Colorectal cancer;	chr15:90603982	chr15:90660234~90664967:+
BRCA	cis	rs7267979	0.816	rs443009	ENSG00000204556.4	CTD-2514C3.1	4.83	1.59e-06	0.000155	0.2	0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25519181	chr20:26018832~26020684:+
BRCA	cis	rs10938353	0.68	rs6828324	ENSG00000273369.1	RP11-700J17.1	-4.83	1.59e-06	0.000155	-0.18	-0.15	Body mass index;	chr4:44776331	chr4:44693946~44694386:-
BRCA	cis	rs4666002	0.956	rs13020949	ENSG00000234072.1	AC074117.10	4.83	1.59e-06	0.000155	0.15	0.15	Phospholipid levels (plasma);	chr2:27613738	chr2:27356246~27367622:+
BRCA	cis	rs1850744	0.702	rs6836184	ENSG00000163612.10	FAM86KP	-4.83	1.59e-06	0.000155	-0.33	-0.15	Economic and political preferences;	chr4:9632087	chr4:9153296~9165451:+
BRCA	cis	rs7976269	0.537	rs10843308	ENSG00000275476.1	RP11-996F15.4	-4.83	1.59e-06	0.000155	-0.17	-0.15	Male-pattern baldness;	chr12:29075172	chr12:29277397~29277882:-
BRCA	cis	rs9300255	0.602	rs2851435	ENSG00000235423.7	RP11-282O18.3	4.83	1.59e-06	0.000155	0.2	0.15	Neutrophil percentage of white cells;	chr12:123227869	chr12:123252030~123261483:-
BRCA	cis	rs4489787	1	rs2705142	ENSG00000240399.1	RP1-228P16.1	4.83	1.59e-06	0.000155	0.28	0.15	Prostate cancer (SNP x SNP interaction);	chr12:48529508	chr12:48054813~48055591:-
BRCA	cis	rs11637445	0.677	rs4539549	ENSG00000260657.2	RP11-315D16.4	-4.83	1.59e-06	0.000155	-0.18	-0.15	Posterior cortical atrophy and Alzheimer's disease;	chr15:67778281	chr15:68267792~68277994:-
BRCA	cis	rs11098499	0.954	rs10518331	ENSG00000260091.1	RP11-33B1.4	-4.83	1.59e-06	0.000155	-0.13	-0.15	Corneal astigmatism;	chr4:119402440	chr4:119409333~119410233:+
BRCA	cis	rs11239930	0.56	rs632334	ENSG00000278811.3	LINC00624	4.83	1.59e-06	0.000155	0.18	0.15	AIDS progression;	chr1:147079972	chr1:147258885~147517875:-
BRCA	cis	rs7772486	0.754	rs702318	ENSG00000270638.1	RP3-466P17.1	-4.83	1.59e-06	0.000155	-0.18	-0.15	Lobe attachment (rater-scored or self-reported);	chr6:145684737	chr6:145735570~145737218:+
BRCA	cis	rs2562456	0.833	rs2562507	ENSG00000268658.4	LINC00664	-4.83	1.59e-06	0.000155	-0.23	-0.15	Pain;	chr19:21543535	chr19:21483374~21503238:+
BRCA	cis	rs7572733	0.935	rs2060489	ENSG00000231621.1	AC013264.2	-4.83	1.59e-06	0.000155	-0.14	-0.15	Dermatomyositis;	chr2:197887562	chr2:197197991~197199273:+
BRCA	cis	rs4853525	0.561	rs10931476	ENSG00000235852.1	AC005540.3	4.83	1.59e-06	0.000155	0.19	0.15	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190938082	chr2:190880797~190882059:-
BRCA	cis	rs7119	0.717	rs12902896	ENSG00000259362.2	RP11-307C19.1	4.83	1.59e-06	0.000155	0.2	0.15	Type 2 diabetes;	chr15:77516808	chr15:77525540~77534110:+
BRCA	cis	rs924712	0.526	rs4712075	ENSG00000224984.1	RP11-524H19.2	-4.83	1.6e-06	0.000155	-0.17	-0.15	Breast cancer;	chr6:54844894	chr6:54840118~54840855:-
BRCA	cis	rs783540	0.681	rs1259178	ENSG00000255769.6	GOLGA2P10	4.83	1.6e-06	0.000156	0.18	0.15	Schizophrenia;	chr15:82603127	chr15:82472993~82513950:-
BRCA	cis	rs9287719	0.934	rs6727884	ENSG00000243819.4	RN7SL832P	-4.83	1.6e-06	0.000156	-0.14	-0.15	Prostate cancer;	chr2:10617431	chr2:10690344~10692099:+
BRCA	cis	rs61160187	0.583	rs6449503	ENSG00000215032.2	GNL3LP1	-4.83	1.6e-06	0.000156	-0.18	-0.15	Educational attainment (years of education);Educational attainment (college completion);	chr5:60799445	chr5:60891935~60893577:-
BRCA	cis	rs7267979	0.932	rs6138588	ENSG00000125804.12	FAM182A	-4.83	1.6e-06	0.000156	-0.19	-0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25506887	chr20:26054655~26086917:+
BRCA	cis	rs7621331	1	rs6810223	ENSG00000273486.1	RP11-731C17.2	4.83	1.6e-06	0.000156	0.17	0.15	Waist circumference adjusted for body mass index;	chr3:135975662	chr3:136837338~136839021:-
BRCA	cis	rs7772486	0.738	rs9485039	ENSG00000270638.1	RP3-466P17.1	4.83	1.6e-06	0.000156	0.17	0.15	Lobe attachment (rater-scored or self-reported);	chr6:145998251	chr6:145735570~145737218:+
BRCA	cis	rs897984	0.762	rs1870293	ENSG00000275263.1	RP11-1072A3.4	4.83	1.6e-06	0.000156	0.17	0.15	Dementia with Lewy bodies;	chr16:30959620	chr16:30956872~30957199:-
BRCA	cis	rs2492286	0.673	rs17255991	ENSG00000242551.2	POU5F1P6	4.83	1.6e-06	0.000156	0.31	0.15	Eosinophil counts;	chr3:128637371	chr3:128674735~128677005:-
BRCA	cis	rs651907	0.557	rs3094295	ENSG00000256628.3	ZBTB11-AS1	4.83	1.6e-06	0.000156	0.19	0.15	Colorectal cancer;	chr3:101683151	chr3:101676475~101679217:+
BRCA	cis	rs9473147	0.571	rs9463335	ENSG00000270761.1	RP11-385F7.1	-4.83	1.6e-06	0.000156	-0.16	-0.15	Platelet distribution width;Mean platelet volume;	chr6:47511400	chr6:47477243~47477572:-
BRCA	cis	rs72615157	0.561	rs113844570	ENSG00000242294.5	STAG3L5P	4.83	1.6e-06	0.000156	0.15	0.15	Lung function (FEV1/FVC);	chr7:100276155	chr7:100336079~100351900:+
BRCA	cis	rs7618915	0.547	rs34610878	ENSG00000243224.1	RP5-1157M23.2	-4.83	1.6e-06	0.000156	-0.17	-0.15	Bipolar disorder;	chr3:52725153	chr3:52239258~52241097:+
BRCA	cis	rs7487075	0.619	rs4768123	ENSG00000274723.1	RP11-618L22.1	4.83	1.6e-06	0.000156	0.2	0.15	Itch intensity from mosquito bite;	chr12:46458310	chr12:46970504~46972155:+
BRCA	cis	rs875971	0.965	rs7794930	ENSG00000223473.2	GS1-124K5.3	-4.83	1.6e-06	0.000156	-0.11	-0.15	Aortic root size;	chr7:66313559	chr7:66491049~66493566:-
BRCA	cis	rs2638953	0.64	rs11049726	ENSG00000247934.4	RP11-967K21.1	-4.83	1.6e-06	0.000156	-0.2	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28582703	chr12:28163298~28190738:-
BRCA	cis	rs3768617	0.51	rs10797837	ENSG00000224468.3	RP11-181K3.4	-4.83	1.6e-06	0.000156	-0.16	-0.15	Fuchs's corneal dystrophy;	chr1:183105986	chr1:183138402~183141282:-
BRCA	cis	rs7674212	0.539	rs2866635	ENSG00000251288.2	RP11-10L12.2	-4.83	1.6e-06	0.000156	-0.17	-0.15	Type 2 diabetes;	chr4:103200419	chr4:102751401~102752641:+
BRCA	cis	rs10129255	0.5	rs2105991	ENSG00000254174.1	IGHV1-12	4.83	1.6e-06	0.000156	0.11	0.15	Kawasaki disease;	chr14:106682022	chr14:106122420~106122709:-
BRCA	cis	rs6569038	0.502	rs794266	ENSG00000253194.1	RP11-351A11.1	4.83	1.6e-06	0.000156	0.19	0.15	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr6:118999148	chr6:118934785~119031541:+
BRCA	cis	rs3845817	0.703	rs1673457	ENSG00000237979.1	AC007389.1	4.83	1.6e-06	0.000156	0.17	0.15	Bipolar disorder;	chr2:65544511	chr2:65500993~65502138:-
BRCA	cis	rs875971	0.502	rs2465121	ENSG00000232546.1	RP11-458F8.1	-4.83	1.6e-06	0.000156	-0.14	-0.15	Aortic root size;	chr7:66156017	chr7:66848496~66858136:+
BRCA	cis	rs6840258	0.891	rs1842685	ENSG00000251411.1	RP11-397E7.4	-4.83	1.6e-06	0.000156	-0.19	-0.15	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87139680	chr4:86913266~86914817:-
BRCA	cis	rs6496044	0.568	rs7176291	ENSG00000259295.5	CSPG4P12	4.83	1.61e-06	0.000156	0.18	0.15	Interstitial lung disease;	chr15:85524167	chr15:85191438~85213905:+
BRCA	cis	rs4865762	0.967	rs977576	ENSG00000247796.2	CTD-2366F13.1	-4.83	1.61e-06	0.000156	-0.16	-0.15	Intraocular pressure;	chr5:53261380	chr5:53109842~53115126:+
BRCA	cis	rs13113518	0.966	rs13108409	ENSG00000249700.7	SRD5A3-AS1	4.83	1.61e-06	0.000156	0.18	0.15	Height;	chr4:55520278	chr4:55363971~55395847:-
BRCA	cis	rs11098499	0.663	rs9996501	ENSG00000260404.2	RP11-384K6.6	4.83	1.61e-06	0.000156	0.14	0.15	Corneal astigmatism;	chr4:119317763	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.697	rs28458294	ENSG00000260404.2	RP11-384K6.6	4.83	1.61e-06	0.000156	0.14	0.15	Corneal astigmatism;	chr4:119317769	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.663	rs28369503	ENSG00000260404.2	RP11-384K6.6	4.83	1.61e-06	0.000156	0.14	0.15	Corneal astigmatism;	chr4:119317770	chr4:118591773~118633729:+
BRCA	cis	rs6840360	0.582	rs2709826	ENSG00000278978.1	RP11-164P12.5	-4.83	1.61e-06	0.000156	-0.16	-0.15	Intelligence (multi-trait analysis);	chr4:151410968	chr4:151669786~151670503:+
BRCA	cis	rs6431644	0.931	rs719154	ENSG00000224287.2	MSL3P1	-4.83	1.61e-06	0.000157	-0.18	-0.15	Left atrial antero-posterior diameter;	chr2:233890530	chr2:233865437~233868444:-
BRCA	cis	rs7267979	0.844	rs6107027	ENSG00000274973.1	RP13-401N8.7	-4.83	1.61e-06	0.000157	-0.17	-0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25307996	chr20:25845497~25845862:+
BRCA	cis	rs2832191	0.791	rs2832198	ENSG00000215533.7	LINC00189	-4.83	1.61e-06	0.000157	-0.16	-0.15	Dental caries;	chr21:29125919	chr21:29193480~29288205:+
BRCA	cis	rs4713118	0.955	rs9368529	ENSG00000216901.1	AL022393.7	4.83	1.61e-06	0.000157	0.2	0.15	Parkinson's disease;	chr6:27716852	chr6:28176188~28176674:+
BRCA	cis	rs6430585	0.591	rs3098103	ENSG00000224043.6	CCNT2-AS1	-4.83	1.61e-06	0.000157	-0.26	-0.15	Corneal structure;	chr2:135898524	chr2:134735464~134918710:-
BRCA	cis	rs7829975	0.688	rs7826654	ENSG00000233609.3	RP11-62H7.2	4.83	1.61e-06	0.000157	0.14	0.15	Mood instability;	chr8:8521596	chr8:8961200~8979025:+
BRCA	cis	rs7829975	0.688	rs7826660	ENSG00000233609.3	RP11-62H7.2	4.83	1.61e-06	0.000157	0.14	0.15	Mood instability;	chr8:8521597	chr8:8961200~8979025:+
BRCA	cis	rs703842	1	rs11172342	ENSG00000270039.1	RP11-571M6.17	-4.83	1.61e-06	0.000157	-0.21	-0.15	Multiple sclerosis;	chr12:57793975	chr12:57803838~57804415:+
BRCA	cis	rs703842	1	rs11172343	ENSG00000270039.1	RP11-571M6.17	-4.83	1.61e-06	0.000157	-0.21	-0.15	Multiple sclerosis;	chr12:57794374	chr12:57803838~57804415:+
BRCA	cis	rs9990333	0.87	rs58758084	ENSG00000242086.7	LINC00969	-4.83	1.61e-06	0.000157	-0.16	-0.15	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196086110	chr3:195658062~195739964:+
BRCA	cis	rs2833693	0.572	rs8130652	ENSG00000261610.1	AP000265.1	4.83	1.61e-06	0.000157	0.18	0.15	Temperament;	chr21:32189593	chr21:32259804~32261585:-
BRCA	cis	rs600231	0.708	rs682845	ENSG00000173727.10	CMB9-22P13.1	4.83	1.61e-06	0.000157	0.19	0.15	Bone mineral density;	chr11:65486730	chr11:65455258~65466720:+
BRCA	cis	rs7577696	0.924	rs7601267	ENSG00000272716.1	RP11-563N4.1	-4.83	1.61e-06	0.000157	-0.16	-0.15	Inflammatory biomarkers;	chr2:32047330	chr2:32165046~32165757:-
BRCA	cis	rs7487075	0.619	rs10748448	ENSG00000274723.1	RP11-618L22.1	4.83	1.61e-06	0.000157	0.18	0.15	Itch intensity from mosquito bite;	chr12:46409555	chr12:46970504~46972155:+
BRCA	cis	rs2430307	0.556	rs3905501	ENSG00000242435.1	UPK3BP1	-4.82	1.61e-06	0.000157	-0.21	-0.15	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index;	chr7:76912763	chr7:77004662~77005774:+
BRCA	cis	rs7617773	0.78	rs9846818	ENSG00000199476.1	Y_RNA	-4.82	1.61e-06	0.000157	-0.2	-0.15	Coronary artery disease;	chr3:48334195	chr3:48288587~48288694:+
BRCA	cis	rs7918232	0.782	rs7910168	ENSG00000262412.1	RP11-85G18.6	4.82	1.61e-06	0.000157	0.24	0.15	Breast cancer;	chr10:27176367	chr10:27243130~27250804:+
BRCA	cis	rs1862618	0.671	rs2591964	ENSG00000271828.1	CTD-2310F14.1	-4.82	1.61e-06	0.000157	-0.18	-0.15	Initial pursuit acceleration;	chr5:56941073	chr5:56927874~56929573:+
BRCA	cis	rs12135996	0.592	rs2516838	ENSG00000232879.2	RP11-544M22.3	4.82	1.61e-06	0.000157	0.17	0.15	Night sleep phenotypes;	chr1:161044580	chr1:161034834~161035006:+
BRCA	cis	rs6570726	0.791	rs400329	ENSG00000270638.1	RP3-466P17.1	4.82	1.61e-06	0.000157	0.17	0.15	Lobe attachment (rater-scored or self-reported);	chr6:145558306	chr6:145735570~145737218:+
BRCA	cis	rs6570726	0.764	rs367065	ENSG00000270638.1	RP3-466P17.1	4.82	1.61e-06	0.000157	0.17	0.15	Lobe attachment (rater-scored or self-reported);	chr6:145561173	chr6:145735570~145737218:+
BRCA	cis	rs4356203	0.87	rs10832748	ENSG00000272034.1	SNORD14A	-4.82	1.61e-06	0.000157	-0.15	-0.15	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17230184	chr11:17074654~17074744:-
BRCA	cis	rs7618915	0.547	rs2289250	ENSG00000243224.1	RP5-1157M23.2	4.82	1.61e-06	0.000157	0.16	0.15	Bipolar disorder;	chr3:52648930	chr3:52239258~52241097:+
BRCA	cis	rs10829156	0.898	rs6482565	ENSG00000240291.1	RP11-499P20.2	4.82	1.61e-06	0.000157	0.17	0.15	Sudden cardiac arrest;	chr10:18611664	chr10:18513115~18545651:-
BRCA	cis	rs2998286	1	rs2998286	ENSG00000254635.4	WAC-AS1	-4.82	1.61e-06	0.000157	-0.19	-0.15	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28491444	chr10:28522652~28532743:-
BRCA	cis	rs6430585	0.528	rs78274583	ENSG00000231890.6	DARS-AS1	-4.82	1.61e-06	0.000157	-0.24	-0.15	Corneal structure;	chr2:135976999	chr2:135985176~136022593:+
BRCA	cis	rs897984	0.52	rs4889622	ENSG00000260911.2	RP11-196G11.2	-4.82	1.61e-06	0.000157	-0.15	-0.15	Dementia with Lewy bodies;	chr16:30859636	chr16:31043150~31049868:+
BRCA	cis	rs11185790	0.784	rs10881603	ENSG00000240996.1	RP11-80H5.7	-4.82	1.61e-06	0.000157	-0.18	-0.15	Metabolic traits;	chr10:89573917	chr10:89694295~89697928:-
BRCA	cis	rs3733585	0.673	rs7375587	ENSG00000250413.1	RP11-448G15.1	-4.82	1.61e-06	0.000157	-0.19	-0.15	Cleft plate (environmental tobacco smoke interaction);	chr4:9953134	chr4:10006482~10009725:+
BRCA	cis	rs10419113	0.628	rs9304795	ENSG00000268545.1	VN1R107P	4.82	1.62e-06	0.000157	0.17	0.15	Pediatric bone mineral density (spine);	chr19:57666177	chr19:57459912~57460120:+
BRCA	cis	rs4948275	0.773	rs2787738	ENSG00000237233.2	TMEM26-AS1	4.82	1.62e-06	0.000157	0.17	0.15	Night sleep phenotypes;	chr10:61493601	chr10:61452639~61481956:+
BRCA	cis	rs1030877	0.515	rs1866038	ENSG00000235319.1	AC012360.4	-4.82	1.62e-06	0.000157	-0.21	-0.15	Obesity-related traits;	chr2:105262065	chr2:105324210~105330529:+
BRCA	cis	rs3845817	0.703	rs702909	ENSG00000237979.1	AC007389.1	-4.82	1.62e-06	0.000157	-0.17	-0.15	Bipolar disorder;	chr2:65540113	chr2:65500993~65502138:-
BRCA	cis	rs7923837	1	rs10748582	ENSG00000236493.2	EIF2S2P3	4.82	1.62e-06	0.000157	0.2	0.15	Multiple sclerosis;Body mass index;	chr10:92717462	chr10:92668745~92669743:-
BRCA	cis	rs1395	0.778	rs6709602	ENSG00000234072.1	AC074117.10	-4.82	1.62e-06	0.000157	-0.16	-0.15	Blood metabolite levels;	chr2:27182629	chr2:27356246~27367622:+
BRCA	cis	rs11168618	1	rs11168637	ENSG00000240399.1	RP1-228P16.1	4.82	1.62e-06	0.000157	0.17	0.15	Adiponectin levels;	chr12:48559721	chr12:48054813~48055591:-
BRCA	cis	rs4713118	0.513	rs149972	ENSG00000219392.1	RP1-265C24.5	-4.82	1.62e-06	0.000157	-0.21	-0.15	Parkinson's disease;	chr6:28015449	chr6:28115628~28116551:+
BRCA	cis	rs4713118	0.513	rs149975	ENSG00000219392.1	RP1-265C24.5	-4.82	1.62e-06	0.000157	-0.21	-0.15	Parkinson's disease;	chr6:28018562	chr6:28115628~28116551:+
BRCA	cis	rs10861342	1	rs11112380	ENSG00000257999.1	RP11-61E11.2	-4.82	1.62e-06	0.000157	-0.32	-0.15	IgG glycosylation;	chr12:105132917	chr12:105102472~105107179:-
BRCA	cis	rs1859596	0.691	rs10231884	ENSG00000234456.6	MAGI2-AS3	4.82	1.62e-06	0.000158	0.09	0.15	Reading or mathematical ability;	chr7:79455484	chr7:79452877~79471208:+
BRCA	cis	rs9659323	0.612	rs10923721	ENSG00000231365.4	RP11-418J17.1	-4.82	1.62e-06	0.000158	-0.18	-0.15	Body mass index;	chr1:118999564	chr1:119140396~119275973:+
BRCA	cis	rs4664293	0.631	rs13024749	ENSG00000224152.1	AC009506.1	4.82	1.62e-06	0.000158	0.16	0.15	Monocyte percentage of white cells;	chr2:159799606	chr2:159615296~159617082:+
BRCA	cis	rs1577330	0.516	rs3861015	ENSG00000254396.1	RP11-56F10.3	-4.82	1.62e-06	0.000158	-0.27	-0.15	IgG glycosylation;	chr9:27103416	chr9:27102630~27104728:+
BRCA	cis	rs1075265	0.68	rs6715488	ENSG00000235937.1	AC008280.1	4.82	1.62e-06	0.000158	0.16	0.15	Chronotype;Morning vs. evening chronotype;	chr2:54004130	chr2:54029552~54030682:-
BRCA	cis	rs1800795	0.652	rs7802307	ENSG00000225541.1	AC002480.5	-4.82	1.62e-06	0.000158	-0.16	-0.15	Cerebrospinal fluid clusterin levels in APOEe4- carriers;	chr7:22726814	chr7:22571607~22661792:-
BRCA	cis	rs9925964	0.967	rs12716981	ENSG00000232748.3	RP11-196G11.6	4.82	1.62e-06	0.000158	0.18	0.15	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31106703	chr16:31056460~31062803:+
BRCA	cis	rs6832769	0.961	rs1011095	ENSG00000272969.1	RP11-528I4.2	4.82	1.62e-06	0.000158	0.18	0.15	Personality dimensions;	chr4:55398774	chr4:55547112~55547889:+
BRCA	cis	rs9287719	0.81	rs1990612	ENSG00000243819.4	RN7SL832P	4.82	1.62e-06	0.000158	0.14	0.15	Prostate cancer;	chr2:10641818	chr2:10690344~10692099:+
BRCA	cis	rs7811142	0.943	rs10241492	ENSG00000078319.8	PMS2P1	-4.82	1.62e-06	0.000158	-0.24	-0.15	Platelet count;	chr7:100397190	chr7:100320992~100341908:-
BRCA	cis	rs9545047	0.584	rs12871015	ENSG00000227354.5	RBM26-AS1	-4.82	1.62e-06	0.000158	-0.16	-0.15	Schizophrenia;	chr13:79333564	chr13:79406309~79424328:+
BRCA	cis	rs7577696	0.889	rs6725184	ENSG00000272716.1	RP11-563N4.1	-4.82	1.62e-06	0.000158	-0.17	-0.15	Inflammatory biomarkers;	chr2:32105816	chr2:32165046~32165757:-
BRCA	cis	rs8058578	0.775	rs8046391	ENSG00000260911.2	RP11-196G11.2	4.82	1.62e-06	0.000158	0.14	0.15	Multiple myeloma;	chr16:30825327	chr16:31043150~31049868:+
BRCA	cis	rs9863	0.861	rs7958691	ENSG00000270028.1	RP11-380L11.4	4.82	1.62e-06	0.000158	0.18	0.15	White blood cell count;	chr12:123956196	chr12:123925461~123926083:-
BRCA	cis	rs1656368	0.726	rs4680444	ENSG00000279311.1	RP11-170K4.2	4.82	1.62e-06	0.000158	0.19	0.15	Lobe attachment (rater-scored or self-reported);	chr3:158542725	chr3:158869898~158871821:+
BRCA	cis	rs1075265	0.836	rs1363063	ENSG00000235937.1	AC008280.1	4.82	1.62e-06	0.000158	0.16	0.15	Chronotype;Morning vs. evening chronotype;	chr2:54047433	chr2:54029552~54030682:-
BRCA	cis	rs7621331	1	rs13097946	ENSG00000239213.4	NCK1-AS1	-4.82	1.62e-06	0.000158	-0.17	-0.15	Waist circumference adjusted for body mass index;	chr3:135994780	chr3:136841726~136862054:-
BRCA	cis	rs6847067	0.8	rs13109918	ENSG00000180769.7	WDFY3-AS2	4.82	1.62e-06	0.000158	0.13	0.15	Oropharynx cancer;	chr4:84919619	chr4:84965682~85011277:+
BRCA	cis	rs6570726	0.791	rs6912079	ENSG00000270638.1	RP3-466P17.1	4.82	1.63e-06	0.000158	0.17	0.15	Lobe attachment (rater-scored or self-reported);	chr6:145573813	chr6:145735570~145737218:+
BRCA	cis	rs7682317	0.767	rs6823536	ENSG00000270720.1	RP11-84C13.2	-4.82	1.63e-06	0.000158	-0.16	-0.15	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr4:89007381	chr4:89119284~89119871:+
BRCA	cis	rs10028773	0.7	rs7690338	ENSG00000260404.2	RP11-384K6.6	4.82	1.63e-06	0.000158	0.13	0.15	Educational attainment;	chr4:119335313	chr4:118591773~118633729:+
BRCA	cis	rs9311474	0.713	rs352169	ENSG00000243224.1	RP5-1157M23.2	-4.82	1.63e-06	0.000158	-0.16	-0.15	Electroencephalogram traits;	chr3:52202746	chr3:52239258~52241097:+
BRCA	cis	rs2562456	0.876	rs11085468	ENSG00000268535.1	RP11-420K14.3	4.82	1.63e-06	0.000158	0.2	0.15	Pain;	chr19:21569087	chr19:21709522~21710191:+
BRCA	cis	rs1501911	0.509	rs34487	ENSG00000246763.5	RGMB-AS1	4.82	1.63e-06	0.000158	0.17	0.15	Lung function (FEV1/FVC);	chr5:98872725	chr5:98769618~98773469:-
BRCA	cis	rs12744310	1	rs12030762	ENSG00000235358.1	RP11-399E6.1	4.82	1.63e-06	0.000158	0.22	0.15	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41301089	chr1:41242373~41284861:+
BRCA	cis	rs957448	0.561	rs71532325	ENSG00000253175.1	RP11-267M23.6	4.82	1.63e-06	0.000158	0.18	0.15	Nonsyndromic cleft lip with cleft palate;	chr8:94615738	chr8:94565036~94565715:+
BRCA	cis	rs2243480	1	rs160646	ENSG00000222364.1	RNU6-96P	-4.82	1.63e-06	0.000159	-0.27	-0.15	Diabetic kidney disease;	chr7:66091293	chr7:66395191~66395286:+
BRCA	cis	rs3892630	0.878	rs6510277	ENSG00000267567.1	CTD-2538C1.3	4.82	1.63e-06	0.000159	0.23	0.15	Red blood cell traits;	chr19:32692763	chr19:32718298~32719595:-
BRCA	cis	rs3892630	0.817	rs12609866	ENSG00000267567.1	CTD-2538C1.3	4.82	1.63e-06	0.000159	0.23	0.15	Red blood cell traits;	chr19:32693506	chr19:32718298~32719595:-
BRCA	cis	rs853679	1	rs853679	ENSG00000204709.4	LINC01556	4.82	1.63e-06	0.000159	0.26	0.15	Depression;	chr6:28329086	chr6:28943877~28944537:+
BRCA	cis	rs853679	1	rs853678	ENSG00000204709.4	LINC01556	4.82	1.63e-06	0.000159	0.26	0.15	Depression;	chr6:28329536	chr6:28943877~28944537:+
BRCA	cis	rs7226408	0.901	rs10502671	ENSG00000267707.2	RP11-95O2.5	4.82	1.63e-06	0.000159	0.22	0.15	Obesity-related traits;	chr18:37161148	chr18:37243776~37247506:+
BRCA	cis	rs1499614	1	rs2141924	ENSG00000275400.1	RP4-756H11.5	4.82	1.63e-06	0.000159	0.27	0.15	Gout;	chr7:66721259	chr7:66553805~66554199:-
BRCA	cis	rs2638953	0.671	rs10843101	ENSG00000278733.1	RP11-425D17.1	-4.82	1.63e-06	0.000159	-0.21	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28117129	chr12:28185625~28186190:-
BRCA	cis	rs718433	0.584	rs4982495	ENSG00000256379.1	TRAV8-5	4.82	1.63e-06	0.000159	0.17	0.15	Intraocular pressure;	chr14:21752285	chr14:21903077~21903598:+
BRCA	cis	rs3812049	0.667	rs6888037	ENSG00000245937.6	LINC01184	4.82	1.63e-06	0.000159	0.2	0.15	Lymphocyte counts;Red cell distribution width;	chr5:128070567	chr5:127940426~128083172:-
BRCA	cis	rs962856	1	rs6546294	ENSG00000236780.4	AC078941.1	4.82	1.63e-06	0.000159	0.19	0.15	Pancreatic cancer;	chr2:67335098	chr2:67123357~67215319:-
BRCA	cis	rs9868809	0.656	rs13324119	ENSG00000270441.1	RP11-694I15.7	4.82	1.63e-06	0.000159	0.26	0.15	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48673173	chr3:49140086~49160851:-
BRCA	cis	rs1913185	0.787	rs2864794	ENSG00000240032.1	RP11-274H2.3	-4.82	1.63e-06	0.000159	-0.24	-0.15	Obesity-related traits;	chr3:146148583	chr3:146066344~146069185:-
BRCA	cis	rs2446066	0.872	rs11170516	ENSG00000257379.1	RP11-793H13.8	4.82	1.63e-06	0.000159	0.23	0.15	Red blood cell count;	chr12:53358908	chr12:53441741~53467528:+
BRCA	cis	rs6728642	0.908	rs17842456	ENSG00000230606.9	AC159540.1	-4.82	1.63e-06	0.000159	-0.25	-0.15	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:97359380	chr2:97416165~97433527:-
BRCA	cis	rs7267979	0.816	rs405822	ENSG00000274973.1	RP13-401N8.7	-4.82	1.63e-06	0.000159	-0.17	-0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25520678	chr20:25845497~25845862:+
BRCA	cis	rs7267979	0.816	rs409853	ENSG00000274973.1	RP13-401N8.7	-4.82	1.63e-06	0.000159	-0.17	-0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25525431	chr20:25845497~25845862:+
BRCA	cis	rs2303319	0.504	rs55840249	ENSG00000227403.1	AC009299.3	4.82	1.64e-06	0.000159	0.35	0.15	Cognitive function;	chr2:161570339	chr2:161244739~161249050:+
BRCA	cis	rs10829156	0.625	rs10828906	ENSG00000225527.1	RP11-383B4.4	-4.82	1.64e-06	0.000159	-0.2	-0.15	Sudden cardiac arrest;	chr10:18552866	chr10:18531849~18533336:-
BRCA	cis	rs4819052	0.851	rs2838866	ENSG00000184274.3	LINC00315	-4.82	1.64e-06	0.000159	-0.2	-0.15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45293099	chr21:45300245~45305257:-
BRCA	cis	rs642803	0.591	rs620088	ENSG00000255557.1	RP11-770G2.2	-4.82	1.64e-06	0.000159	-0.19	-0.15	Urate levels;	chr11:65741515	chr11:65745729~65771585:+
BRCA	cis	rs9473147	0.543	rs9369716	ENSG00000270761.1	RP11-385F7.1	-4.82	1.64e-06	0.000159	-0.16	-0.15	Platelet distribution width;Mean platelet volume;	chr6:47584444	chr6:47477243~47477572:-
BRCA	cis	rs35146811	0.807	rs6465761	ENSG00000214313.7	AZGP1P1	4.82	1.64e-06	0.000159	0.16	0.15	Coronary artery disease;	chr7:100022654	chr7:99980762~99987535:+
BRCA	cis	rs6723226	0.593	rs176401	ENSG00000276334.1	AL133243.1	-4.82	1.64e-06	0.000159	-0.19	-0.15	Intelligence (multi-trait analysis);	chr2:32411443	chr2:32521927~32523547:+
BRCA	cis	rs1865760	0.686	rs12210098	ENSG00000272462.2	U91328.19	-4.82	1.64e-06	0.000159	-0.19	-0.15	Height;	chr6:25963738	chr6:25992662~26001775:+
BRCA	cis	rs4853525	0.561	rs13414648	ENSG00000235852.1	AC005540.3	4.82	1.64e-06	0.000159	0.19	0.15	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190929310	chr2:190880797~190882059:-
BRCA	cis	rs651907	0.557	rs11712748	ENSG00000256628.3	ZBTB11-AS1	4.82	1.64e-06	0.000159	0.18	0.15	Colorectal cancer;	chr3:101664718	chr3:101676475~101679217:+
BRCA	cis	rs4356203	0.87	rs10766381	ENSG00000272034.1	SNORD14A	-4.82	1.64e-06	0.000159	-0.15	-0.15	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17235498	chr11:17074654~17074744:-
BRCA	cis	rs17767294	0.708	rs79956881	ENSG00000204709.4	LINC01556	4.82	1.64e-06	0.000159	0.4	0.15	Parkinson's disease;	chr6:28062372	chr6:28943877~28944537:+
BRCA	cis	rs1552244	0.572	rs6785976	ENSG00000232901.1	CYCSP10	4.82	1.64e-06	0.000159	0.22	0.15	Alzheimer's disease;	chr3:10126963	chr3:10000647~10000940:-
BRCA	cis	rs11098499	0.738	rs28408407	ENSG00000260091.1	RP11-33B1.4	-4.82	1.64e-06	0.000159	-0.13	-0.15	Corneal astigmatism;	chr4:119454875	chr4:119409333~119410233:+
BRCA	cis	rs10504130	1	rs77712895	ENSG00000253844.1	RP11-546K22.1	-4.82	1.64e-06	0.000159	-0.25	-0.15	Venous thromboembolism (SNP x SNP interaction);	chr8:51821121	chr8:51961458~52022974:+
BRCA	cis	rs1387259	0.64	rs10783243	ENSG00000240399.1	RP1-228P16.1	-4.82	1.64e-06	0.000159	-0.16	-0.15	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48259220	chr12:48054813~48055591:-
BRCA	cis	rs11098499	0.865	rs28634456	ENSG00000260091.1	RP11-33B1.4	-4.82	1.64e-06	0.00016	-0.13	-0.15	Corneal astigmatism;	chr4:119454623	chr4:119409333~119410233:+
BRCA	cis	rs7637701	0.818	rs10936038	ENSG00000240875.4	LINC00886	-4.82	1.64e-06	0.00016	-0.17	-0.15	Breast cancer;	chr3:156814877	chr3:156747346~156817062:-
BRCA	cis	rs7637701	0.818	rs11711674	ENSG00000240875.4	LINC00886	-4.82	1.64e-06	0.00016	-0.17	-0.15	Breast cancer;	chr3:156815164	chr3:156747346~156817062:-
BRCA	cis	rs7811142	0.83	rs11761253	ENSG00000078319.8	PMS2P1	-4.82	1.64e-06	0.00016	-0.24	-0.15	Platelet count;	chr7:100341698	chr7:100320992~100341908:-
BRCA	cis	rs7267979	0.844	rs6076343	ENSG00000125804.12	FAM182A	4.82	1.64e-06	0.00016	0.19	0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25396027	chr20:26054655~26086917:+
BRCA	cis	rs10129255	0.957	rs7493713	ENSG00000274576.2	IGHV2-70	4.82	1.64e-06	0.00016	0.13	0.15	Kawasaki disease;	chr14:106783685	chr14:106770577~106771020:-
BRCA	cis	rs10129255	0.912	rs35468694	ENSG00000274576.2	IGHV2-70	4.82	1.64e-06	0.00016	0.13	0.15	Kawasaki disease;	chr14:106784199	chr14:106770577~106771020:-
BRCA	cis	rs7615952	0.688	rs17334074	ENSG00000241288.6	RP11-379B18.5	4.82	1.64e-06	0.00016	0.19	0.15	Blood pressure (smoking interaction);	chr3:125821617	chr3:125827238~125916384:-
BRCA	cis	rs2286503	1	rs2286501	ENSG00000226329.2	AC005682.6	4.82	1.64e-06	0.00016	0.13	0.15	Fibrinogen;	chr7:22817166	chr7:22863874~22881350:-
BRCA	cis	rs13108904	0.846	rs12643212	ENSG00000254094.1	AC078852.1	-4.82	1.65e-06	0.00016	-0.17	-0.15	Obesity-related traits;	chr4:1231160	chr4:1356581~1358075:+
BRCA	cis	rs7267979	0.816	rs390123	ENSG00000274414.1	RP5-965G21.4	-4.82	1.65e-06	0.00016	-0.17	-0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25499469	chr20:25239007~25245229:-
BRCA	cis	rs4819052	0.851	rs7275468	ENSG00000184274.3	LINC00315	-4.82	1.65e-06	0.00016	-0.2	-0.15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45236584	chr21:45300245~45305257:-
BRCA	cis	rs8056446	0.563	rs12716848	ENSG00000260816.2	RP11-319G9.3	4.82	1.65e-06	0.00016	0.17	0.15	Pulmonary function (smoking interaction);	chr16:78133761	chr16:78895361~78899644:+
BRCA	cis	rs62244186	0.593	rs9814298	ENSG00000214820.3	MPRIPP1	4.82	1.65e-06	0.00016	0.17	0.15	Depressive symptoms;	chr3:44830407	chr3:44579938~44581026:-
BRCA	cis	rs10266483	0.515	rs17689514	ENSG00000228653.2	HNRNPCP7	4.82	1.65e-06	0.00016	0.21	0.15	Response to statin therapy;	chr7:64279269	chr7:64500825~64501729:+
BRCA	cis	rs10266483	0.545	rs12540100	ENSG00000228653.2	HNRNPCP7	-4.82	1.65e-06	0.00016	-0.21	-0.15	Response to statin therapy;	chr7:64289924	chr7:64500825~64501729:+
BRCA	cis	rs67766926	0.812	rs10208309	ENSG00000271889.1	RP11-493E12.1	4.82	1.65e-06	0.00016	0.21	0.15	Inflammatory skin disease;	chr2:60951374	chr2:61151433~61162105:-
BRCA	cis	rs9863	0.828	rs11057412	ENSG00000270028.1	RP11-380L11.4	4.82	1.65e-06	0.00016	0.18	0.15	White blood cell count;	chr12:124004595	chr12:123925461~123926083:-
BRCA	cis	rs7569084	1	rs7583469	ENSG00000204929.10	AC074391.1	4.82	1.65e-06	0.00016	0.19	0.15	Sum eosinophil basophil counts;	chr2:65424222	chr2:65436711~66084639:+
BRCA	cis	rs1329650	1	rs10881926	ENSG00000228701.1	TNKS2-AS1	-4.82	1.65e-06	0.00016	-0.19	-0.15	Smoking behavior;	chr10:91584497	chr10:91782839~91798291:-
BRCA	cis	rs78487399	0.908	rs79388962	ENSG00000234936.1	AC010883.5	4.82	1.65e-06	0.00016	0.23	0.15	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43580422	chr2:43229573~43233394:+
BRCA	cis	rs17685	0.712	rs60721456	ENSG00000280388.1	RP11-229D13.3	-4.82	1.65e-06	0.00016	-0.15	-0.15	Coffee consumption (cups per day);Coffee consumption;	chr7:76114502	chr7:76043977~76045963:-
BRCA	cis	rs4713118	0.955	rs9468201	ENSG00000216901.1	AL022393.7	4.82	1.65e-06	0.00016	0.2	0.15	Parkinson's disease;	chr6:27719256	chr6:28176188~28176674:+
BRCA	cis	rs754466	0.914	rs12218917	ENSG00000204049.1	RP11-126H7.4	4.82	1.65e-06	0.00016	0.2	0.15	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77941721	chr10:77866875~77869610:+
BRCA	cis	rs754466	0.914	rs12219971	ENSG00000204049.1	RP11-126H7.4	4.82	1.65e-06	0.00016	0.2	0.15	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77941768	chr10:77866875~77869610:+
BRCA	cis	rs10829156	0.538	rs61840846	ENSG00000240291.1	RP11-499P20.2	4.82	1.65e-06	0.00016	0.18	0.15	Sudden cardiac arrest;	chr10:18606393	chr10:18513115~18545651:-
BRCA	cis	rs3799378	0.582	rs1796518	ENSG00000124549.13	BTN2A3P	-4.82	1.65e-06	0.00016	-0.16	-0.15	Intelligence (multi-trait analysis);	chr6:26388444	chr6:26421391~26432383:+
BRCA	cis	rs11089937	0.616	rs7286793	ENSG00000211638.2	IGLV8-61	-4.82	1.65e-06	0.000161	-0.14	-0.15	Periodontitis (PAL4Q3);	chr22:22182951	chr22:22098700~22099212:+
BRCA	cis	rs6439153	0.967	rs12695513	ENSG00000231305.3	RP11-723O4.2	4.82	1.65e-06	0.000161	0.17	0.15	Pneumococcal bacteremia;	chr3:129003469	chr3:128861313~128871540:-
BRCA	cis	rs7811142	0.83	rs41280971	ENSG00000078319.8	PMS2P1	-4.82	1.65e-06	0.000161	-0.24	-0.15	Platelet count;	chr7:100356834	chr7:100320992~100341908:-
BRCA	cis	rs7811142	0.83	rs11761426	ENSG00000078319.8	PMS2P1	-4.82	1.65e-06	0.000161	-0.24	-0.15	Platelet count;	chr7:100359270	chr7:100320992~100341908:-
BRCA	cis	rs7811142	0.83	rs77861211	ENSG00000078319.8	PMS2P1	-4.82	1.65e-06	0.000161	-0.24	-0.15	Platelet count;	chr7:100364473	chr7:100320992~100341908:-
BRCA	cis	rs2839186	0.605	rs2839174	ENSG00000228137.1	AP001469.7	4.82	1.65e-06	0.000161	0.16	0.15	Testicular germ cell tumor;	chr21:46257020	chr21:46246890~46247682:+
BRCA	cis	rs7267979	0.844	rs35735333	ENSG00000274414.1	RP5-965G21.4	4.82	1.65e-06	0.000161	0.17	0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25356569	chr20:25239007~25245229:-
BRCA	cis	rs4853525	0.561	rs17746911	ENSG00000235852.1	AC005540.3	4.82	1.66e-06	0.000161	0.18	0.15	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190854640	chr2:190880797~190882059:-
BRCA	cis	rs4356203	0.87	rs7936310	ENSG00000272034.1	SNORD14A	4.82	1.66e-06	0.000161	0.15	0.15	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17248741	chr11:17074654~17074744:-
BRCA	cis	rs2749097	0.668	rs2269240	ENSG00000244256.3	RN7SL130P	-4.82	1.66e-06	0.000161	-0.2	-0.15	Alcohol consumption (transferrin glycosylation);	chr1:63643593	chr1:63655743~63656047:+
BRCA	cis	rs2638953	0.962	rs61920565	ENSG00000247934.4	RP11-967K21.1	-4.82	1.66e-06	0.000161	-0.2	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28377192	chr12:28163298~28190738:-
BRCA	cis	rs2243480	1	rs778729	ENSG00000275400.1	RP4-756H11.5	4.82	1.66e-06	0.000161	0.27	0.15	Diabetic kidney disease;	chr7:66359432	chr7:66553805~66554199:-
BRCA	cis	rs7267979	0.816	rs443009	ENSG00000277938.1	RP5-965G21.3	-4.82	1.66e-06	0.000161	-0.17	-0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25519181	chr20:25229150~25231933:+
BRCA	cis	rs6832769	1	rs12643926	ENSG00000223305.1	RN7SKP30	4.82	1.66e-06	0.000161	0.18	0.15	Personality dimensions;	chr4:55444454	chr4:55540502~55540835:-
BRCA	cis	rs6832769	0.961	rs12647034	ENSG00000223305.1	RN7SKP30	4.82	1.66e-06	0.000161	0.18	0.15	Personality dimensions;	chr4:55444455	chr4:55540502~55540835:-
BRCA	cis	rs1707322	0.827	rs6694302	ENSG00000234329.1	RP11-767N6.2	4.82	1.66e-06	0.000161	0.16	0.15	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45779973	chr1:45651039~45651826:-
BRCA	cis	rs1707322	0.827	rs12125508	ENSG00000234329.1	RP11-767N6.2	4.82	1.66e-06	0.000161	0.16	0.15	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45780338	chr1:45651039~45651826:-
BRCA	cis	rs897984	0.52	rs4889614	ENSG00000260911.2	RP11-196G11.2	-4.82	1.66e-06	0.000161	-0.15	-0.15	Dementia with Lewy bodies;	chr16:30850814	chr16:31043150~31049868:+
BRCA	cis	rs10752881	0.652	rs10911262	ENSG00000224468.3	RP11-181K3.4	-4.82	1.66e-06	0.000161	-0.16	-0.15	Colorectal cancer;	chr1:183145821	chr1:183138402~183141282:-
BRCA	cis	rs4835473	0.932	rs1877235	ENSG00000249741.2	RP11-673E1.3	4.82	1.66e-06	0.000161	0.16	0.15	Immature fraction of reticulocytes;	chr4:143986961	chr4:143911514~143912053:-
BRCA	cis	rs2153535	0.563	rs1796687	ENSG00000251164.1	HULC	-4.82	1.66e-06	0.000161	-0.18	-0.15	Motion sickness;	chr6:8535885	chr6:8652137~8653846:+
BRCA	cis	rs7267979	0.844	rs35735333	ENSG00000125804.12	FAM182A	4.82	1.66e-06	0.000161	0.19	0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25356569	chr20:26054655~26086917:+
BRCA	cis	rs2273156	0.706	rs8015622	ENSG00000226677.3	IGBP1P1	-4.82	1.66e-06	0.000161	-0.24	-0.15	Immunoglobulin light chain (AL) amyloidosis;	chr14:35017894	chr14:34939324~34940332:+
BRCA	cis	rs4218	0.597	rs12442301	ENSG00000277144.1	RP11-59H7.4	-4.82	1.66e-06	0.000161	-0.2	-0.15	Social communication problems;	chr15:59065968	chr15:59115547~59116089:-
BRCA	cis	rs4666002	0.956	rs3749147	ENSG00000234072.1	AC074117.10	4.82	1.66e-06	0.000161	0.16	0.15	Phospholipid levels (plasma);	chr2:27629051	chr2:27356246~27367622:+
BRCA	cis	rs9467773	0.62	rs2451732	ENSG00000124549.13	BTN2A3P	-4.82	1.66e-06	0.000161	-0.15	-0.15	Intelligence (multi-trait analysis);	chr6:26622676	chr6:26421391~26432383:+
BRCA	cis	rs8180040	0.62	rs749511	ENSG00000276925.1	RP11-708J19.3	4.82	1.66e-06	0.000161	0.17	0.15	Colorectal cancer;	chr3:46994245	chr3:47469777~47469987:+
BRCA	cis	rs1043099	0.912	rs4820008	ENSG00000279699.1	RP1-102K2.9	-4.82	1.66e-06	0.000161	-0.24	-0.15	Rheumatoid arthritis;	chr22:30353352	chr22:30275215~30276951:-
BRCA	cis	rs539096	0.872	rs2478978	ENSG00000236200.4	KDM4A-AS1	4.82	1.66e-06	0.000161	0.19	0.15	Intelligence (multi-trait analysis);	chr1:43565986	chr1:43699765~43708138:-
BRCA	cis	rs7119	0.717	rs12902912	ENSG00000259362.2	RP11-307C19.1	-4.82	1.66e-06	0.000162	-0.2	-0.15	Type 2 diabetes;	chr15:77516828	chr15:77525540~77534110:+
BRCA	cis	rs8098244	0.964	rs8085137	ENSG00000264745.1	TTC39C-AS1	4.82	1.66e-06	0.000162	0.2	0.15	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23766840	chr18:23994213~24015339:-
BRCA	cis	rs8098244	0.964	rs8086148	ENSG00000264745.1	TTC39C-AS1	4.82	1.66e-06	0.000162	0.2	0.15	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23766912	chr18:23994213~24015339:-
BRCA	cis	rs7267979	0.844	rs6107027	ENSG00000204556.4	CTD-2514C3.1	-4.82	1.66e-06	0.000162	-0.2	-0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25307996	chr20:26018832~26020684:+
BRCA	cis	rs7204230	1	rs8063660	ENSG00000261291.1	RP11-295M3.2	4.82	1.67e-06	0.000162	0.19	0.15	Fibrinogen;	chr16:53319247	chr16:53168522~53169450:+
BRCA	cis	rs4948275	0.773	rs2185051	ENSG00000237233.2	TMEM26-AS1	-4.82	1.67e-06	0.000162	-0.17	-0.15	Night sleep phenotypes;	chr10:61480114	chr10:61452639~61481956:+
BRCA	cis	rs1499614	1	rs1267818	ENSG00000275400.1	RP4-756H11.5	4.82	1.67e-06	0.000162	0.27	0.15	Gout;	chr7:66642037	chr7:66553805~66554199:-
BRCA	cis	rs2278170	1	rs11032351	ENSG00000225101.4	OR52K3P	-4.82	1.67e-06	0.000162	-0.2	-0.15	Amyotrophic lateral sclerosis;	chr11:4465471	chr11:4474813~4475755:+
BRCA	cis	rs250585	0.92	rs391662	ENSG00000260136.4	CTD-2270L9.4	4.82	1.67e-06	0.000162	0.17	0.15	Egg allergy;	chr16:23442800	chr16:23452758~23457606:+
BRCA	cis	rs11239930	0.517	rs492243	ENSG00000230832.3	RP11-325P15.2	-4.82	1.67e-06	0.000162	-0.21	-0.15	AIDS progression;	chr1:147077930	chr1:147082338~147083578:-
BRCA	cis	rs35740288	0.857	rs3803506	ENSG00000202081.1	RNU6-1280P	4.82	1.67e-06	0.000162	0.2	0.15	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85747709	chr15:85651522~85651628:-
BRCA	cis	rs7487075	0.619	rs11183479	ENSG00000274723.1	RP11-618L22.1	4.82	1.67e-06	0.000162	0.2	0.15	Itch intensity from mosquito bite;	chr12:46430381	chr12:46970504~46972155:+
BRCA	cis	rs7487075	0.656	rs3936214	ENSG00000274723.1	RP11-618L22.1	4.82	1.67e-06	0.000162	0.2	0.15	Itch intensity from mosquito bite;	chr12:46432029	chr12:46970504~46972155:+
BRCA	cis	rs10411936	1	rs873636	ENSG00000280332.1	CTD-2013N17.6	4.82	1.67e-06	0.000162	0.12	0.15	Multiple sclerosis;White blood cell count;	chr19:16403960	chr19:16356329~16358327:-
BRCA	cis	rs2278702	1	rs2278702	ENSG00000259495.2	RP11-210M15.2	-4.82	1.67e-06	0.000162	-0.2	-0.15	Bipolar disorder;	chr15:80402580	chr15:80344853~80403575:-
BRCA	cis	rs12501370	0.721	rs6831604	ENSG00000201736.1	RNA5SP160	4.82	1.67e-06	0.000162	0.18	0.15	Iris color (L* coordinate);	chr4:41059032	chr4:40990154~40990273:+
BRCA	cis	rs2153535	0.585	rs7762631	ENSG00000230939.1	RP11-314C16.1	4.82	1.67e-06	0.000162	0.17	0.15	Motion sickness;	chr6:8635339	chr6:8784178~8785445:+
BRCA	cis	rs17428076	0.793	rs12622772	ENSG00000228389.1	AC068039.4	-4.82	1.67e-06	0.000162	-0.21	-0.15	Myopia;	chr2:171769227	chr2:171773482~171775844:+
BRCA	cis	rs10266483	0.545	rs73132069	ENSG00000228653.2	HNRNPCP7	4.82	1.67e-06	0.000162	0.21	0.15	Response to statin therapy;	chr7:64258440	chr7:64500825~64501729:+
BRCA	cis	rs10266483	0.576	rs2863327	ENSG00000228653.2	HNRNPCP7	4.82	1.67e-06	0.000162	0.21	0.15	Response to statin therapy;	chr7:64268698	chr7:64500825~64501729:+
BRCA	cis	rs7809615	0.901	rs10226310	ENSG00000244219.5	GS1-259H13.2	-4.82	1.67e-06	0.000162	-0.26	-0.15	Blood metabolite ratios;	chr7:99520697	chr7:99598066~99610813:+
BRCA	cis	rs4664293	0.867	rs2357531	ENSG00000224152.1	AC009506.1	-4.82	1.67e-06	0.000162	-0.17	-0.15	Monocyte percentage of white cells;	chr2:159740907	chr2:159615296~159617082:+
BRCA	cis	rs4664293	0.867	rs16844269	ENSG00000224152.1	AC009506.1	-4.82	1.67e-06	0.000162	-0.17	-0.15	Monocyte percentage of white cells;	chr2:159742569	chr2:159615296~159617082:+
BRCA	cis	rs4664293	0.836	rs4664300	ENSG00000224152.1	AC009506.1	-4.82	1.67e-06	0.000162	-0.17	-0.15	Monocyte percentage of white cells;	chr2:159743927	chr2:159615296~159617082:+
BRCA	cis	rs4664293	0.867	rs16822556	ENSG00000224152.1	AC009506.1	-4.82	1.67e-06	0.000162	-0.17	-0.15	Monocyte percentage of white cells;	chr2:159744392	chr2:159615296~159617082:+
BRCA	cis	rs4664293	0.867	rs16822558	ENSG00000224152.1	AC009506.1	-4.82	1.67e-06	0.000162	-0.17	-0.15	Monocyte percentage of white cells;	chr2:159744496	chr2:159615296~159617082:+
BRCA	cis	rs4664293	0.867	rs1834761	ENSG00000224152.1	AC009506.1	-4.82	1.67e-06	0.000162	-0.17	-0.15	Monocyte percentage of white cells;	chr2:159745278	chr2:159615296~159617082:+
BRCA	cis	rs2243480	1	rs313824	ENSG00000222364.1	RNU6-96P	-4.82	1.67e-06	0.000162	-0.27	-0.15	Diabetic kidney disease;	chr7:66116220	chr7:66395191~66395286:+
BRCA	cis	rs2243480	1	rs186378	ENSG00000222364.1	RNU6-96P	-4.82	1.67e-06	0.000162	-0.27	-0.15	Diabetic kidney disease;	chr7:66117071	chr7:66395191~66395286:+
BRCA	cis	rs2243480	1	rs160637	ENSG00000222364.1	RNU6-96P	-4.82	1.67e-06	0.000162	-0.27	-0.15	Diabetic kidney disease;	chr7:66119331	chr7:66395191~66395286:+
BRCA	cis	rs6600671	1	rs10903159	ENSG00000275538.1	RNVU1-19	4.82	1.67e-06	0.000162	0.17	0.15	Hip geometry;	chr1:121440138	chr1:120850819~120850985:-
BRCA	cis	rs11673344	0.562	rs7250507	ENSG00000226686.6	LINC01535	4.82	1.67e-06	0.000163	0.19	0.15	Obesity-related traits;	chr19:37095772	chr19:37251912~37265535:+
BRCA	cis	rs6928977	0.675	rs58761508	ENSG00000234084.1	RP3-388E23.2	4.82	1.68e-06	0.000163	0.15	0.15	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135514763	chr6:135301568~135307158:+
BRCA	cis	rs6928977	0.631	rs9385726	ENSG00000234084.1	RP3-388E23.2	4.82	1.68e-06	0.000163	0.15	0.15	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135515824	chr6:135301568~135307158:+
BRCA	cis	rs6442522	0.56	rs2305612	ENSG00000249786.6	EAF1-AS1	4.82	1.68e-06	0.000163	0.15	0.15	Uric acid levels;	chr3:15477224	chr3:15436171~15455940:-
BRCA	cis	rs62025270	0.632	rs7181796	ENSG00000259762.1	RP11-158M2.4	-4.82	1.68e-06	0.000163	-0.23	-0.15	Idiopathic pulmonary fibrosis;	chr15:85689778	chr15:85750336~85752901:-
BRCA	cis	rs6163	0.588	rs12763284	ENSG00000213061.2	PFN1P11	-4.82	1.68e-06	0.000163	-0.18	-0.15	Waist circumference;Hip circumference;	chr10:102748445	chr10:102838011~102845473:-
BRCA	cis	rs7818688	1	rs28496357	ENSG00000253528.2	RP11-347C18.4	-4.82	1.68e-06	0.000163	-0.22	-0.15	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95018283	chr8:94974573~94974853:-
BRCA	cis	rs4662750	0.58	rs4662742	ENSG00000236682.1	AC068282.3	4.82	1.68e-06	0.000163	0.19	0.15	Renal cell carcinoma;	chr2:127593169	chr2:127389130~127400580:+
BRCA	cis	rs1979679	0.879	rs1002863	ENSG00000278733.1	RP11-425D17.1	-4.82	1.68e-06	0.000163	-0.19	-0.15	Ossification of the posterior longitudinal ligament of the spine;	chr12:28500768	chr12:28185625~28186190:-
BRCA	cis	rs287982	0.611	rs80268780	ENSG00000269973.1	RP11-95D17.1	-4.82	1.68e-06	0.000163	-0.24	-0.15	Nonsyndromic cleft lip with cleft palate;	chr2:9840948	chr2:9936360~9939590:+
BRCA	cis	rs7201929	1	rs12920514	ENSG00000278665.1	RP11-666O2.4	-4.82	1.68e-06	0.000163	-0.17	-0.15	QT interval;	chr16:28824579	chr16:28599241~28601881:-
BRCA	cis	rs2153535	0.58	rs1577470	ENSG00000251164.1	HULC	-4.82	1.68e-06	0.000163	-0.18	-0.15	Motion sickness;	chr6:8462193	chr6:8652137~8653846:+
BRCA	cis	rs4415084	0.804	rs4866922	ENSG00000251141.4	RP11-53O19.1	-4.82	1.68e-06	0.000163	-0.14	-0.15	Breast cancer;	chr5:44932403	chr5:44744900~44808777:-
BRCA	cis	rs10129255	0.957	rs12589190	ENSG00000274576.2	IGHV2-70	4.82	1.68e-06	0.000163	0.13	0.15	Kawasaki disease;	chr14:106783079	chr14:106770577~106771020:-
BRCA	cis	rs7615952	0.599	rs12485717	ENSG00000171084.14	FAM86JP	-4.82	1.68e-06	0.000163	-0.23	-0.15	Blood pressure (smoking interaction);	chr3:125988232	chr3:125916620~125930024:+
BRCA	cis	rs6088590	0.561	rs6087600	ENSG00000276073.1	RP5-1125A11.7	-4.82	1.68e-06	0.000163	-0.16	-0.15	Coronary artery disease;	chr20:34569413	chr20:33985617~33988989:-
BRCA	cis	rs972578	1	rs2038062	ENSG00000230319.1	AL022476.2	4.82	1.68e-06	0.000163	0.17	0.15	Mean platelet volume;	chr22:43001960	chr22:43038585~43052366:+
BRCA	cis	rs1729951	0.575	rs361244	ENSG00000239213.4	NCK1-AS1	4.82	1.68e-06	0.000163	0.15	0.15	Neuroticism;	chr3:136978664	chr3:136841726~136862054:-
BRCA	cis	rs1729951	0.575	rs361243	ENSG00000239213.4	NCK1-AS1	4.82	1.68e-06	0.000163	0.15	0.15	Neuroticism;	chr3:136978944	chr3:136841726~136862054:-
BRCA	cis	rs12446632	0.509	rs72769533	ENSG00000261195.1	CTD-2380F24.1	-4.82	1.68e-06	0.000163	-0.28	-0.15	Hip circumference;Body mass index (joint analysis main effects and smoking interaction);BMI in smokers;Menarche (age at onset);Obesity;Childhood body mass index;Waist circumference;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Body mass index;	chr16:19739888	chr16:19761172~19766099:-
BRCA	cis	rs1707322	1	rs12097761	ENSG00000234329.1	RP11-767N6.2	4.82	1.68e-06	0.000163	0.15	0.15	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45825490	chr1:45651039~45651826:-
BRCA	cis	rs13043901	0.861	rs2766666	ENSG00000197670.6	RP4-724E16.2	-4.82	1.68e-06	0.000163	-0.15	-0.15	Type 2 diabetes (age of onset);	chr20:53555602	chr20:53552770~53575863:+
BRCA	cis	rs6847067	0.683	rs11097028	ENSG00000180769.7	WDFY3-AS2	-4.82	1.68e-06	0.000163	-0.14	-0.15	Oropharynx cancer;	chr4:84948630	chr4:84965682~85011277:+
BRCA	cis	rs6832769	0.925	rs60992571	ENSG00000272969.1	RP11-528I4.2	-4.82	1.69e-06	0.000164	-0.17	-0.15	Personality dimensions;	chr4:55574645	chr4:55547112~55547889:+
BRCA	cis	rs4664293	0.867	rs11681245	ENSG00000224152.1	AC009506.1	-4.82	1.69e-06	0.000164	-0.17	-0.15	Monocyte percentage of white cells;	chr2:159772882	chr2:159615296~159617082:+
BRCA	cis	rs10506328	0.689	rs4759348	ENSG00000249388.1	RP11-834C11.6	-4.82	1.69e-06	0.000164	-0.21	-0.15	Mean platelet volume;	chr12:54236733	chr12:54082118~54102693:+
BRCA	cis	rs6496044	0.568	rs12899946	ENSG00000259295.5	CSPG4P12	4.82	1.69e-06	0.000164	0.18	0.15	Interstitial lung disease;	chr15:85522851	chr15:85191438~85213905:+
BRCA	cis	rs6496044	0.568	rs12898783	ENSG00000259295.5	CSPG4P12	4.82	1.69e-06	0.000164	0.18	0.15	Interstitial lung disease;	chr15:85522869	chr15:85191438~85213905:+
BRCA	cis	rs6496044	0.568	rs11855789	ENSG00000259295.5	CSPG4P12	4.82	1.69e-06	0.000164	0.18	0.15	Interstitial lung disease;	chr15:85523172	chr15:85191438~85213905:+
BRCA	cis	rs7577696	0.889	rs212759	ENSG00000272716.1	RP11-563N4.1	4.82	1.69e-06	0.000164	0.17	0.15	Inflammatory biomarkers;	chr2:32201753	chr2:32165046~32165757:-
BRCA	cis	rs859767	0.501	rs1123184	ENSG00000224043.6	CCNT2-AS1	4.82	1.69e-06	0.000164	0.2	0.15	Neuroticism;	chr2:134673487	chr2:134735464~134918710:-
BRCA	cis	rs8127691	0.967	rs4635612	ENSG00000237604.1	AP001056.1	4.82	1.69e-06	0.000164	0.16	0.15	Inflammatory bowel disease;	chr21:44196080	chr21:44175489~44176453:+
BRCA	cis	rs2153535	0.58	rs6914276	ENSG00000251164.1	HULC	4.82	1.69e-06	0.000164	0.18	0.15	Motion sickness;	chr6:8450202	chr6:8652137~8653846:+
BRCA	cis	rs2288884	0.505	rs2278414	ENSG00000275055.1	CTC-471J1.11	-4.82	1.69e-06	0.000164	-0.25	-0.15	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:51964569	chr19:52049007~52049754:+
BRCA	cis	rs1075265	0.704	rs9631059	ENSG00000235937.1	AC008280.1	4.82	1.69e-06	0.000164	0.16	0.15	Chronotype;Morning vs. evening chronotype;	chr2:54015160	chr2:54029552~54030682:-
BRCA	cis	rs11638815	0.603	rs7171180	ENSG00000259429.4	UBE2Q2P2	4.82	1.69e-06	0.000164	0.14	0.15	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82640357	chr15:82355142~82420075:+
BRCA	cis	rs4781563	0.621	rs11649492	ENSG00000242307.1	RPS26P52	-4.81	1.69e-06	0.000164	-0.17	-0.15	Bilirubin levels;	chr16:13915561	chr16:13922332~13922679:-
BRCA	cis	rs6095360	0.933	rs2426122	ENSG00000222365.1	SNORD12B	-4.81	1.69e-06	0.000164	-0.16	-0.15	Intelligence (multi-trait analysis);	chr20:49081402	chr20:49280319~49280409:+
BRCA	cis	rs1223397	0.938	rs9381884	ENSG00000215022.6	RP1-257A7.4	-4.81	1.69e-06	0.000164	-0.2	-0.15	Blood pressure;	chr6:13278556	chr6:13264861~13295586:-
BRCA	cis	rs9308731	1	rs6750599	ENSG00000227992.1	AC108463.2	4.81	1.69e-06	0.000164	0.17	0.15	Chronic lymphocytic leukemia;	chr2:111136292	chr2:111203964~111206215:-
BRCA	cis	rs6840360	0.606	rs2709814	ENSG00000251603.1	RP11-164P12.4	-4.81	1.69e-06	0.000164	-0.14	-0.15	Intelligence (multi-trait analysis);	chr4:151439718	chr4:151667224~151670502:+
BRCA	cis	rs9868809	0.881	rs2286652	ENSG00000270441.1	RP11-694I15.7	4.81	1.69e-06	0.000164	0.27	0.15	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48651759	chr3:49140086~49160851:-
BRCA	cis	rs35146811	0.555	rs2525539	ENSG00000235713.1	RP4-604G5.3	-4.81	1.69e-06	0.000164	-0.18	-0.15	Coronary artery disease;	chr7:99947686	chr7:99992397~99993050:+
BRCA	cis	rs9543976	0.623	rs4611344	ENSG00000261105.4	LMO7-AS1	4.81	1.69e-06	0.000164	0.22	0.15	Diabetic retinopathy;	chr13:75601192	chr13:75604700~75635994:-
BRCA	cis	rs703842	1	rs1875124	ENSG00000270039.1	RP11-571M6.17	-4.81	1.69e-06	0.000164	-0.21	-0.15	Multiple sclerosis;	chr12:57803019	chr12:57803838~57804415:+
BRCA	cis	rs6847067	0.827	rs36036245	ENSG00000180769.7	WDFY3-AS2	4.81	1.7e-06	0.000164	0.15	0.15	Oropharynx cancer;	chr4:84721790	chr4:84965682~85011277:+
BRCA	cis	rs6570726	0.846	rs446031	ENSG00000270638.1	RP3-466P17.1	4.81	1.7e-06	0.000164	0.17	0.15	Lobe attachment (rater-scored or self-reported);	chr6:145564456	chr6:145735570~145737218:+
BRCA	cis	rs1383484	1	rs1383484	ENSG00000230373.7	GOLGA6L5P	-4.81	1.7e-06	0.000164	-0.17	-0.15	Height;	chr15:83854003	chr15:84507885~84516814:-
BRCA	cis	rs11098499	0.754	rs12510269	ENSG00000249244.1	RP11-548H18.2	4.81	1.7e-06	0.000165	0.17	0.15	Corneal astigmatism;	chr4:119320491	chr4:119391831~119395335:-
BRCA	cis	rs10760158	0.51	rs7020643	ENSG00000226752.6	PSMD5-AS1	-4.81	1.7e-06	0.000165	-0.18	-0.15	Pulse pressure;	chr9:121099578	chr9:120824828~120854385:+
BRCA	cis	rs256438	0.831	rs2438632	ENSG00000251050.1	RP11-168A11.4	-4.81	1.7e-06	0.000165	-0.17	-0.15	Serum thyroid-stimulating hormone levels;	chr5:80096370	chr5:80019609~80019920:+
BRCA	cis	rs13113518	0.902	rs11133386	ENSG00000249700.7	SRD5A3-AS1	4.81	1.7e-06	0.000165	0.18	0.15	Height;	chr4:55461320	chr4:55363971~55395847:-
BRCA	cis	rs13113518	0.967	rs4340844	ENSG00000249700.7	SRD5A3-AS1	4.81	1.7e-06	0.000165	0.18	0.15	Height;	chr4:55462689	chr4:55363971~55395847:-
BRCA	cis	rs11239930	0.538	rs59064267	ENSG00000278811.3	LINC00624	4.81	1.7e-06	0.000165	0.18	0.15	AIDS progression;	chr1:147089146	chr1:147258885~147517875:-
BRCA	cis	rs6431644	0.929	rs213545	ENSG00000224287.2	MSL3P1	4.81	1.7e-06	0.000165	0.17	0.15	Left atrial antero-posterior diameter;	chr2:233867295	chr2:233865437~233868444:-
BRCA	cis	rs7267979	0.844	rs869358	ENSG00000274973.1	RP13-401N8.7	4.81	1.7e-06	0.000165	0.17	0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25394038	chr20:25845497~25845862:+
BRCA	cis	rs9300255	0.62	rs1727311	ENSG00000235423.7	RP11-282O18.3	4.81	1.7e-06	0.000165	0.21	0.15	Neutrophil percentage of white cells;	chr12:123176169	chr12:123252030~123261483:-
BRCA	cis	rs9300255	0.544	rs1716174	ENSG00000235423.7	RP11-282O18.3	4.81	1.7e-06	0.000165	0.21	0.15	Neutrophil percentage of white cells;	chr12:123176170	chr12:123252030~123261483:-
BRCA	cis	rs10266483	0.515	rs6949304	ENSG00000228653.2	HNRNPCP7	4.81	1.7e-06	0.000165	0.21	0.15	Response to statin therapy;	chr7:64257903	chr7:64500825~64501729:+
BRCA	cis	rs6847067	0.8	rs12503215	ENSG00000180769.7	WDFY3-AS2	4.81	1.7e-06	0.000165	0.13	0.15	Oropharynx cancer;	chr4:84937335	chr4:84965682~85011277:+
BRCA	cis	rs6496044	0.507	rs7175731	ENSG00000259295.5	CSPG4P12	-4.81	1.7e-06	0.000165	-0.18	-0.15	Interstitial lung disease;	chr15:85611115	chr15:85191438~85213905:+
BRCA	cis	rs4819052	0.724	rs1304487	ENSG00000184274.3	LINC00315	4.81	1.7e-06	0.000165	0.19	0.15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45237368	chr21:45300245~45305257:-
BRCA	cis	rs6847067	0.965	rs11097024	ENSG00000180769.7	WDFY3-AS2	4.81	1.7e-06	0.000165	0.13	0.15	Oropharynx cancer;	chr4:84728404	chr4:84965682~85011277:+
BRCA	cis	rs9525927	0.625	rs9533801	ENSG00000227258.4	SMIM2-AS1	4.81	1.7e-06	0.000165	0.24	0.15	Dupuytren's disease;	chr13:44242433	chr13:44110451~44240517:+
BRCA	cis	rs4664293	0.967	rs12611922	ENSG00000226266.5	AC009961.3	-4.81	1.7e-06	0.000165	-0.18	-0.15	Monocyte percentage of white cells;	chr2:159606238	chr2:159670708~159712435:-
BRCA	cis	rs595244	1	rs11638586	ENSG00000259705.1	RP11-227D13.1	4.81	1.7e-06	0.000165	0.27	0.15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48480646	chr15:48645951~48652016:+
BRCA	cis	rs4706831	0.625	rs638056	ENSG00000233967.5	RP11-250B2.3	-4.81	1.7e-06	0.000165	-0.14	-0.15	Joint mobility (Beighton score);	chr6:80271091	chr6:80443344~80465927:+
BRCA	cis	rs4356203	0.792	rs677540	ENSG00000272034.1	SNORD14A	-4.81	1.7e-06	0.000165	-0.15	-0.15	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17192212	chr11:17074654~17074744:-
BRCA	cis	rs4865762	1	rs4865762	ENSG00000247796.2	CTD-2366F13.1	-4.81	1.7e-06	0.000165	-0.15	-0.15	Intraocular pressure;	chr5:53287101	chr5:53109842~53115126:+
BRCA	cis	rs4666002	0.789	rs12998770	ENSG00000234072.1	AC074117.10	4.81	1.71e-06	0.000165	0.17	0.15	Phospholipid levels (plasma);	chr2:27690321	chr2:27356246~27367622:+
BRCA	cis	rs12612619	0.732	rs12616092	ENSG00000229122.1	AGBL5-IT1	4.81	1.71e-06	0.000165	0.15	0.15	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:26994360	chr2:27061038~27061815:+
BRCA	cis	rs6832769	1	rs7673908	ENSG00000272969.1	RP11-528I4.2	-4.81	1.71e-06	0.000165	-0.17	-0.15	Personality dimensions;	chr4:55528652	chr4:55547112~55547889:+
BRCA	cis	rs6750047	0.719	rs336035	ENSG00000235848.3	RMDN2-AS1	4.81	1.71e-06	0.000165	0.19	0.15	Cutaneous malignant melanoma;Melanoma;	chr2:38034324	chr2:37949911~38067041:-
BRCA	cis	rs2243480	1	rs383402	ENSG00000164669.11	INTS4P1	-4.81	1.71e-06	0.000165	-0.28	-0.15	Diabetic kidney disease;	chr7:66121666	chr7:65141225~65234216:+
BRCA	cis	rs2303759	0.67	rs45549132	ENSG00000268686.1	AC010524.2	-4.81	1.71e-06	0.000165	-0.24	-0.15	Multiple sclerosis;	chr19:49290771	chr19:49368705~49388081:-
BRCA	cis	rs6840360	0.642	rs11099815	ENSG00000278978.1	RP11-164P12.5	-4.81	1.71e-06	0.000166	-0.16	-0.15	Intelligence (multi-trait analysis);	chr4:151422736	chr4:151669786~151670503:+
BRCA	cis	rs1910358	0.621	rs6871540	ENSG00000248874.4	C5orf17	-4.81	1.71e-06	0.000166	-0.22	-0.15	Venous thromboembolism (SNP x SNP interaction);	chr5:23860955	chr5:23951348~24178263:+
BRCA	cis	rs516805	0.667	rs225080	ENSG00000279453.1	RP3-425C14.4	-4.81	1.71e-06	0.000166	-0.21	-0.15	Lymphocyte counts;	chr6:122295949	chr6:122436789~122439223:-
BRCA	cis	rs11098499	0.954	rs6822679	ENSG00000250412.1	KLHL2P1	4.81	1.71e-06	0.000166	0.18	0.15	Corneal astigmatism;	chr4:119481547	chr4:119334329~119378233:+
BRCA	cis	rs13113518	1	rs4865004	ENSG00000249700.7	SRD5A3-AS1	4.81	1.71e-06	0.000166	0.18	0.15	Height;	chr4:55515118	chr4:55363971~55395847:-
BRCA	cis	rs9907295	0.901	rs78905197	ENSG00000271013.1	AC015849.15	-4.81	1.71e-06	0.000166	-0.24	-0.15	Fibroblast growth factor basic levels;	chr17:35850189	chr17:35912635~35918010:-
BRCA	cis	rs794185	0.652	rs2819585	ENSG00000231249.1	ITPR1-AS1	-4.81	1.71e-06	0.000166	-0.17	-0.15	Multiple sclerosis--Brain Glutamate Levels;	chr3:4470463	chr3:4490891~4493163:-
BRCA	cis	rs10129255	0.957	rs8019272	ENSG00000280411.1	IGHV1-69-2	-4.81	1.71e-06	0.000166	-0.1	-0.15	Kawasaki disease;	chr14:106784709	chr14:106762092~106762588:-
BRCA	cis	rs6452524	0.532	rs27363	ENSG00000281327.1	LINC01338	4.81	1.71e-06	0.000166	0.18	0.15	Hypertension (SNP x SNP interaction);	chr5:83040943	chr5:82850864~82859836:-
BRCA	cis	rs1223397	0.651	rs2458309	ENSG00000215022.6	RP1-257A7.4	-4.81	1.71e-06	0.000166	-0.17	-0.15	Blood pressure;	chr6:13311854	chr6:13264861~13295586:-
BRCA	cis	rs2638953	0.707	rs11049711	ENSG00000247934.4	RP11-967K21.1	-4.81	1.71e-06	0.000166	-0.19	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28553171	chr12:28163298~28190738:-
BRCA	cis	rs4819052	0.851	rs4819046	ENSG00000184274.3	LINC00315	-4.81	1.71e-06	0.000166	-0.2	-0.15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245040	chr21:45300245~45305257:-
BRCA	cis	rs2839186	0.814	rs2839167	ENSG00000239415.1	AP001469.9	4.81	1.71e-06	0.000166	0.15	0.15	Testicular germ cell tumor;	chr21:46241673	chr21:46251549~46254133:-
BRCA	cis	rs12497850	0.865	rs7649458	ENSG00000225399.4	RP11-3B7.1	4.81	1.71e-06	0.000166	0.14	0.15	Parkinson's disease;	chr3:48882694	chr3:49260085~49261316:+
BRCA	cis	rs516805	0.748	rs155458	ENSG00000279114.1	RP3-425C14.5	4.81	1.71e-06	0.000166	0.18	0.15	Lymphocyte counts;	chr6:122493636	chr6:122471923~122484161:+
BRCA	cis	rs9650657	0.537	rs11250092	ENSG00000154316.13	TDH	-4.81	1.71e-06	0.000166	-0.19	-0.15	Neuroticism;	chr8:10929033	chr8:11339637~11368452:+
BRCA	cis	rs34929064	0.536	rs2905307	ENSG00000179428.2	AC073072.5	-4.81	1.72e-06	0.000166	-0.16	-0.15	Major depression and alcohol dependence;	chr7:22599344	chr7:22725395~22727620:-
BRCA	cis	rs11758351	0.866	rs56186759	ENSG00000241549.7	GUSBP2	-4.81	1.72e-06	0.000166	-0.21	-0.15	Renal underexcretion gout;Gout;	chr6:26206953	chr6:26871484~26956554:-
BRCA	cis	rs11758351	0.866	rs55815656	ENSG00000241549.7	GUSBP2	-4.81	1.72e-06	0.000166	-0.21	-0.15	Renal underexcretion gout;Gout;	chr6:26207075	chr6:26871484~26956554:-
BRCA	cis	rs11758351	0.866	rs77889957	ENSG00000241549.7	GUSBP2	-4.81	1.72e-06	0.000166	-0.21	-0.15	Renal underexcretion gout;Gout;	chr6:26207207	chr6:26871484~26956554:-
BRCA	cis	rs4664293	0.867	rs7562060	ENSG00000224152.1	AC009506.1	-4.81	1.72e-06	0.000166	-0.17	-0.15	Monocyte percentage of white cells;	chr2:159730618	chr2:159615296~159617082:+
BRCA	cis	rs6867032	0.57	rs13166888	ENSG00000248994.1	RP11-259O2.1	-4.81	1.72e-06	0.000166	-0.21	-0.15	Gut microbiome composition (winter);	chr5:1982852	chr5:1933863~1959176:+
BRCA	cis	rs8054556	0.787	rs35105141	ENSG00000261367.1	RP11-455F5.4	-4.81	1.72e-06	0.000166	-0.17	-0.15	Autism spectrum disorder or schizophrenia;	chr16:30045827	chr16:30107675~30110541:+
BRCA	cis	rs17428076	0.836	rs12053046	ENSG00000228389.1	AC068039.4	-4.81	1.72e-06	0.000166	-0.21	-0.15	Myopia;	chr2:171816889	chr2:171773482~171775844:+
BRCA	cis	rs1832886	1	rs1832886	ENSG00000236493.2	EIF2S2P3	4.81	1.72e-06	0.000166	0.2	0.15	Body mass index;	chr10:92717782	chr10:92668745~92669743:-
BRCA	cis	rs4494364	0.502	rs2222839	ENSG00000258100.1	RP11-121E16.1	4.81	1.72e-06	0.000166	0.21	0.15	Systolic blood pressure (alcohol consumption interaction);	chr12:91013250	chr12:91362196~91368606:+
BRCA	cis	rs4494364	0.502	rs7964466	ENSG00000258100.1	RP11-121E16.1	4.81	1.72e-06	0.000166	0.21	0.15	Systolic blood pressure (alcohol consumption interaction);	chr12:91016962	chr12:91362196~91368606:+
BRCA	cis	rs17801127	0.748	rs35762145	ENSG00000231969.1	AC144449.1	4.81	1.72e-06	0.000167	0.3	0.15	Liver enzyme levels (alanine transaminase);	chr2:149822604	chr2:149587196~149848233:+
BRCA	cis	rs875971	0.798	rs6460304	ENSG00000236529.1	RP13-254B10.1	4.81	1.72e-06	0.000167	0.16	0.15	Aortic root size;	chr7:66499741	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.862	rs6945775	ENSG00000236529.1	RP13-254B10.1	4.81	1.72e-06	0.000167	0.16	0.15	Aortic root size;	chr7:66503987	chr7:65840212~65840596:+
BRCA	cis	rs792448	0.743	rs10019	ENSG00000226251.4	RP11-15I11.3	-4.81	1.72e-06	0.000167	-0.19	-0.15	White blood cell count (basophil);	chr1:212361035	chr1:212225278~212238977:-
BRCA	cis	rs11098499	0.697	rs35280960	ENSG00000249244.1	RP11-548H18.2	4.81	1.72e-06	0.000167	0.17	0.15	Corneal astigmatism;	chr4:119335904	chr4:119391831~119395335:-
BRCA	cis	rs2625529	0.689	rs12898728	ENSG00000260037.4	CTD-2524L6.3	-4.81	1.72e-06	0.000167	-0.19	-0.15	Red blood cell count;	chr15:71820512	chr15:71818396~71823384:+
BRCA	cis	rs7487075	0.619	rs11183478	ENSG00000274723.1	RP11-618L22.1	4.81	1.72e-06	0.000167	0.19	0.15	Itch intensity from mosquito bite;	chr12:46430283	chr12:46970504~46972155:+
BRCA	cis	rs454217	0.846	rs2119575	ENSG00000277851.1	RP11-756G20.1	4.81	1.72e-06	0.000167	0.17	0.15	Smoking quantity;	chr12:92309812	chr12:92247756~92363832:-
BRCA	cis	rs6968419	1	rs10953813	ENSG00000279086.1	RP11-667F14.1	-4.81	1.72e-06	0.000167	-0.15	-0.15	Intraocular pressure;	chr7:116183926	chr7:116209234~116211511:-
BRCA	cis	rs12744310	0.887	rs36015391	ENSG00000235358.1	RP11-399E6.1	4.81	1.73e-06	0.000167	0.22	0.15	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41319133	chr1:41242373~41284861:+
BRCA	cis	rs12744310	0.887	rs28399806	ENSG00000235358.1	RP11-399E6.1	4.81	1.73e-06	0.000167	0.22	0.15	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41319299	chr1:41242373~41284861:+
BRCA	cis	rs12744310	0.887	rs12047875	ENSG00000235358.1	RP11-399E6.1	4.81	1.73e-06	0.000167	0.22	0.15	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41319504	chr1:41242373~41284861:+
BRCA	cis	rs12744310	0.887	rs35932978	ENSG00000235358.1	RP11-399E6.1	4.81	1.73e-06	0.000167	0.22	0.15	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41319773	chr1:41242373~41284861:+
BRCA	cis	rs7131987	0.565	rs7974254	ENSG00000275476.1	RP11-996F15.4	4.81	1.73e-06	0.000167	0.16	0.15	QT interval;	chr12:29246592	chr12:29277397~29277882:-
BRCA	cis	rs6545883	0.929	rs2593635	ENSG00000212978.6	AC016747.3	-4.81	1.73e-06	0.000167	-0.21	-0.15	Tuberculosis;	chr2:61407571	chr2:61141592~61144969:-
BRCA	cis	rs559555	0.612	rs564310	ENSG00000272716.1	RP11-563N4.1	-4.81	1.73e-06	0.000167	-0.16	-0.15	Blood metabolite ratios;Blood metabolite levels;	chr2:31667273	chr2:32165046~32165757:-
BRCA	cis	rs7474896	0.537	rs1208591	ENSG00000120555.12	SEPT7P9	4.81	1.73e-06	0.000167	0.2	0.15	Obesity (extreme);	chr10:37923574	chr10:38383069~38402916:-
BRCA	cis	rs4415084	0.87	rs10447145	ENSG00000251141.4	RP11-53O19.1	4.81	1.73e-06	0.000167	0.14	0.15	Breast cancer;	chr5:44689694	chr5:44744900~44808777:-
BRCA	cis	rs7312933	0.558	rs1796384	ENSG00000257225.1	RP11-328C8.4	4.81	1.73e-06	0.000167	0.18	0.15	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42386766	chr12:42459366~42466128:+
BRCA	cis	rs718433	0.677	rs4982494	ENSG00000256379.1	TRAV8-5	4.81	1.73e-06	0.000167	0.18	0.15	Intraocular pressure;	chr14:21751141	chr14:21903077~21903598:+
BRCA	cis	rs7671261	0.571	rs12645173	ENSG00000270720.1	RP11-84C13.2	4.81	1.73e-06	0.000168	0.17	0.15	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr4:89114948	chr4:89119284~89119871:+
BRCA	cis	rs2243480	0.708	rs35825036	ENSG00000275400.1	RP4-756H11.5	4.81	1.73e-06	0.000168	0.27	0.15	Diabetic kidney disease;	chr7:66521515	chr7:66553805~66554199:-
BRCA	cis	rs2243480	1	rs13237037	ENSG00000275400.1	RP4-756H11.5	4.81	1.73e-06	0.000168	0.27	0.15	Diabetic kidney disease;	chr7:66532895	chr7:66553805~66554199:-
BRCA	cis	rs2243480	1	rs1796228	ENSG00000275400.1	RP4-756H11.5	4.81	1.73e-06	0.000168	0.27	0.15	Diabetic kidney disease;	chr7:66568097	chr7:66553805~66554199:-
BRCA	cis	rs253959	0.545	rs4920905	ENSG00000271918.1	CTD-2287O16.5	4.81	1.73e-06	0.000168	0.13	0.15	Bipolar disorder and schizophrenia;	chr5:116090771	chr5:116083807~116085416:-
BRCA	cis	rs9300255	0.544	rs1727309	ENSG00000235423.7	RP11-282O18.3	4.81	1.73e-06	0.000168	0.21	0.15	Neutrophil percentage of white cells;	chr12:123173711	chr12:123252030~123261483:-
BRCA	cis	rs1707322	1	rs4606257	ENSG00000234329.1	RP11-767N6.2	4.81	1.73e-06	0.000168	0.15	0.15	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45841596	chr1:45651039~45651826:-
BRCA	cis	rs2832191	0.791	rs2832196	ENSG00000176054.6	RPL23P2	-4.81	1.73e-06	0.000168	-0.15	-0.15	Dental caries;	chr21:29125091	chr21:28997613~28998033:-
BRCA	cis	rs6756513	0.5	rs2290452	ENSG00000231024.1	AC092431.3	-4.81	1.74e-06	0.000168	-0.21	-0.15	Breast cancer;Platelet count;	chr2:69820512	chr2:69700192~69713847:-
BRCA	cis	rs6832769	0.961	rs3736545	ENSG00000223305.1	RN7SKP30	4.81	1.74e-06	0.000168	0.18	0.15	Personality dimensions;	chr4:55444176	chr4:55540502~55540835:-
BRCA	cis	rs2638953	0.606	rs10843213	ENSG00000247934.4	RP11-967K21.1	-4.81	1.74e-06	0.000168	-0.2	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28582853	chr12:28163298~28190738:-
BRCA	cis	rs10129255	0.5	rs7157975	ENSG00000211959.2	IGHV4-39	4.81	1.74e-06	0.000168	0.1	0.15	Kawasaki disease;	chr14:106804049	chr14:106421711~106422218:-
BRCA	cis	rs12612619	0.732	rs11681562	ENSG00000229122.1	AGBL5-IT1	4.81	1.74e-06	0.000168	0.16	0.15	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27027735	chr2:27061038~27061815:+
BRCA	cis	rs9545047	0.716	rs9318638	ENSG00000227354.5	RBM26-AS1	-4.81	1.74e-06	0.000168	-0.16	-0.15	Schizophrenia;	chr13:79412018	chr13:79406309~79424328:+
BRCA	cis	rs10504130	0.932	rs75990306	ENSG00000253844.1	RP11-546K22.1	-4.81	1.74e-06	0.000168	-0.25	-0.15	Venous thromboembolism (SNP x SNP interaction);	chr8:51837641	chr8:51961458~52022974:+
BRCA	cis	rs6847067	0.8	rs4131745	ENSG00000180769.7	WDFY3-AS2	4.81	1.74e-06	0.000168	0.13	0.15	Oropharynx cancer;	chr4:84915301	chr4:84965682~85011277:+
BRCA	cis	rs2898681	0.739	rs1047959	ENSG00000248375.1	RP11-177B4.1	-4.81	1.74e-06	0.000168	-0.21	-0.15	Optic nerve measurement (cup area);	chr4:52873689	chr4:52720081~52720831:-
BRCA	cis	rs6545883	0.859	rs7561672	ENSG00000212978.6	AC016747.3	-4.81	1.74e-06	0.000168	-0.2	-0.15	Tuberculosis;	chr2:61291959	chr2:61141592~61144969:-
BRCA	cis	rs10129255	0.957	rs10141009	ENSG00000274576.2	IGHV2-70	4.81	1.74e-06	0.000168	0.13	0.15	Kawasaki disease;	chr14:106776695	chr14:106770577~106771020:-
BRCA	cis	rs2243480	1	rs465359	ENSG00000275400.1	RP4-756H11.5	4.81	1.74e-06	0.000168	0.27	0.15	Diabetic kidney disease;	chr7:66093177	chr7:66553805~66554199:-
BRCA	cis	rs2243480	1	rs462853	ENSG00000275400.1	RP4-756H11.5	4.81	1.74e-06	0.000168	0.27	0.15	Diabetic kidney disease;	chr7:66093180	chr7:66553805~66554199:-
BRCA	cis	rs2243480	1	rs160644	ENSG00000275400.1	RP4-756H11.5	4.81	1.74e-06	0.000168	0.27	0.15	Diabetic kidney disease;	chr7:66093199	chr7:66553805~66554199:-
BRCA	cis	rs2243480	1	rs160642	ENSG00000275400.1	RP4-756H11.5	4.81	1.74e-06	0.000168	0.27	0.15	Diabetic kidney disease;	chr7:66093386	chr7:66553805~66554199:-
BRCA	cis	rs2243480	0.614	rs34032527	ENSG00000275400.1	RP4-756H11.5	4.81	1.74e-06	0.000168	0.27	0.15	Diabetic kidney disease;	chr7:66100154	chr7:66553805~66554199:-
BRCA	cis	rs2235642	0.893	rs2076440	ENSG00000260989.1	LA16c-395F10.2	-4.81	1.74e-06	0.000168	-0.15	-0.15	Coronary artery disease;	chr16:1537321	chr16:1580527~1610328:+
BRCA	cis	rs11168618	1	rs12815544	ENSG00000240399.1	RP1-228P16.1	4.81	1.74e-06	0.000168	0.17	0.15	Adiponectin levels;	chr12:48555825	chr12:48054813~48055591:-
BRCA	cis	rs12435908	1	rs73268521	ENSG00000276116.2	FUT8-AS1	-4.81	1.74e-06	0.000169	-0.23	-0.15	Ischemic stroke;	chr14:65626525	chr14:65411170~65412690:-
BRCA	cis	rs6569038	0.528	rs794262	ENSG00000253194.1	RP11-351A11.1	4.81	1.74e-06	0.000169	0.19	0.15	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr6:119005947	chr6:118934785~119031541:+
BRCA	cis	rs67311347	1	rs962847	ENSG00000280739.1	EIF1B-AS1	-4.81	1.74e-06	0.000169	-0.16	-0.15	Renal cell carcinoma;	chr3:40453665	chr3:40173145~40309698:-
BRCA	cis	rs2790457	0.833	rs1265846	ENSG00000254635.4	WAC-AS1	-4.81	1.74e-06	0.000169	-0.18	-0.15	Multiple myeloma;	chr10:28640168	chr10:28522652~28532743:-
BRCA	cis	rs600231	0.708	rs1784100	ENSG00000173727.10	CMB9-22P13.1	4.81	1.74e-06	0.000169	0.19	0.15	Bone mineral density;	chr11:65481756	chr11:65455258~65466720:+
BRCA	cis	rs875971	0.651	rs2420596	ENSG00000236529.1	RP13-254B10.1	4.81	1.74e-06	0.000169	0.16	0.15	Aortic root size;	chr7:66450996	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.52	rs2420597	ENSG00000236529.1	RP13-254B10.1	4.81	1.74e-06	0.000169	0.16	0.15	Aortic root size;	chr7:66450999	chr7:65840212~65840596:+
BRCA	cis	rs11098499	0.779	rs28495013	ENSG00000260091.1	RP11-33B1.4	-4.81	1.75e-06	0.000169	-0.13	-0.15	Corneal astigmatism;	chr4:119454676	chr4:119409333~119410233:+
BRCA	cis	rs7572733	0.773	rs970552	ENSG00000231621.1	AC013264.2	4.81	1.75e-06	0.000169	0.14	0.15	Dermatomyositis;	chr2:197632788	chr2:197197991~197199273:+
BRCA	cis	rs1223397	0.589	rs2439540	ENSG00000215022.6	RP1-257A7.4	-4.81	1.75e-06	0.000169	-0.18	-0.15	Blood pressure;	chr6:13309110	chr6:13264861~13295586:-
BRCA	cis	rs11098499	0.821	rs10032151	ENSG00000260091.1	RP11-33B1.4	-4.81	1.75e-06	0.000169	-0.13	-0.15	Corneal astigmatism;	chr4:119470473	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.865	rs10032158	ENSG00000260091.1	RP11-33B1.4	-4.81	1.75e-06	0.000169	-0.13	-0.15	Corneal astigmatism;	chr4:119470477	chr4:119409333~119410233:+
BRCA	cis	rs442309	0.812	rs224092	ENSG00000238280.1	RP11-436D10.3	-4.81	1.75e-06	0.000169	-0.19	-0.15	Vogt-Koyanagi-Harada syndrome;	chr10:62781644	chr10:62793562~62805887:-
BRCA	cis	rs4781563	1	rs3136213	ENSG00000242307.1	RPS26P52	-4.81	1.75e-06	0.000169	-0.18	-0.15	Bilirubin levels;	chr16:13946296	chr16:13922332~13922679:-
BRCA	cis	rs2243480	0.522	rs12698511	ENSG00000232559.3	GS1-124K5.12	4.81	1.75e-06	0.000169	0.33	0.15	Diabetic kidney disease;	chr7:66009932	chr7:66554588~66576923:-
BRCA	cis	rs12646107	0.943	rs10025117	ENSG00000261672.1	RP11-475B2.1	-4.81	1.75e-06	0.000169	-0.2	-0.15	Response to amphetamines;	chr4:173594754	chr4:173593672~173594556:+
BRCA	cis	rs2403083	0.578	rs6605627	ENSG00000258256.1	RP11-219B4.5	-4.81	1.75e-06	0.000169	-0.18	-0.15	Plasma amyloid beta peptide concentrations (ABx-40);	chr8:85157680	chr8:85222446~85245717:-
BRCA	cis	rs4865762	0.967	rs977575	ENSG00000247796.2	CTD-2366F13.1	-4.81	1.75e-06	0.000169	-0.15	-0.15	Intraocular pressure;	chr5:53261716	chr5:53109842~53115126:+
BRCA	cis	rs13113518	1	rs13113518	ENSG00000249700.7	SRD5A3-AS1	4.81	1.75e-06	0.000169	0.18	0.15	Height;	chr4:55533481	chr4:55363971~55395847:-
BRCA	cis	rs1707322	0.964	rs785516	ENSG00000234329.1	RP11-767N6.2	-4.81	1.75e-06	0.000169	-0.16	-0.15	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46099086	chr1:45651039~45651826:-
BRCA	cis	rs1707322	1	rs785517	ENSG00000234329.1	RP11-767N6.2	-4.81	1.75e-06	0.000169	-0.16	-0.15	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46101863	chr1:45651039~45651826:-
BRCA	cis	rs1707322	1	rs785484	ENSG00000234329.1	RP11-767N6.2	-4.81	1.75e-06	0.000169	-0.16	-0.15	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46108343	chr1:45651039~45651826:-
BRCA	cis	rs2235642	0.787	rs2235646	ENSG00000260989.1	LA16c-395F10.2	-4.81	1.75e-06	0.000169	-0.15	-0.15	Coronary artery disease;	chr16:1551286	chr16:1580527~1610328:+
BRCA	cis	rs591584	0.659	rs638397	ENSG00000255893.1	RP11-685N10.1	-4.81	1.75e-06	0.000169	-0.16	-0.15	Macrophage Migration Inhibitory Factor levels;	chr11:94600942	chr11:94472908~94473570:-
BRCA	cis	rs4664293	0.669	rs1863219	ENSG00000224152.1	AC009506.1	4.81	1.75e-06	0.000169	0.16	0.15	Monocyte percentage of white cells;	chr2:159561660	chr2:159615296~159617082:+
BRCA	cis	rs73193808	0.851	rs2223036	ENSG00000236056.1	GAPDHP14	4.81	1.75e-06	0.000169	0.21	0.15	Coronary artery disease;	chr21:29232461	chr21:29222321~29223257:+
BRCA	cis	rs4948275	0.742	rs2650707	ENSG00000237233.2	TMEM26-AS1	-4.81	1.75e-06	0.000169	-0.17	-0.15	Night sleep phenotypes;	chr10:61480725	chr10:61452639~61481956:+
BRCA	cis	rs7267979	1	rs2856	ENSG00000274973.1	RP13-401N8.7	-4.81	1.75e-06	0.000169	-0.17	-0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25452900	chr20:25845497~25845862:+
BRCA	cis	rs6714710	0.603	rs11678591	ENSG00000230606.9	AC159540.1	-4.81	1.75e-06	0.000169	-0.17	-0.15	Posterior cortical atrophy and Alzheimer's disease;	chr2:97924538	chr2:97416165~97433527:-
BRCA	cis	rs4950322	0.547	rs6660507	ENSG00000244371.2	PFN1P8	-4.81	1.75e-06	0.000169	-0.18	-0.15	Protein quantitative trait loci;	chr1:147148574	chr1:146957117~146957659:-
BRCA	cis	rs7833986	0.501	rs2719226	ENSG00000253603.1	CTA-397H3.3	-4.81	1.75e-06	0.000169	-0.22	-0.15	Height;	chr8:56131507	chr8:56074592~56075274:+
BRCA	cis	rs2832191	0.935	rs67287920	ENSG00000236056.1	GAPDHP14	4.81	1.75e-06	0.000169	0.16	0.15	Dental caries;	chr21:29151198	chr21:29222321~29223257:+
BRCA	cis	rs3764563	0.735	rs62106282	ENSG00000267594.5	CYP4F24P	-4.81	1.75e-06	0.00017	-0.28	-0.15	Inflammatory biomarkers;	chr19:15616313	chr19:15760241~15779909:-
BRCA	cis	rs10833905	0.938	rs10833918	ENSG00000246225.5	RP11-17A1.3	-4.81	1.75e-06	0.00017	-0.21	-0.15	Sudden cardiac arrest;	chr11:23040402	chr11:22829380~22945393:+
BRCA	cis	rs3764021	0.87	rs7970116	ENSG00000256673.1	RP11-599J14.2	4.81	1.75e-06	0.00017	0.16	0.15	Type 1 diabetes;	chr12:9727518	chr12:9398355~9414851:-
BRCA	cis	rs6571943	0.517	rs10483536	ENSG00000258526.4	RP11-111A21.1	-4.81	1.75e-06	0.00017	-0.19	-0.15	Verbal memory performance (residualized delayed recall level);	chr14:39557694	chr14:39474840~39513780:+
BRCA	cis	rs256438	0.642	rs9293797	ENSG00000251050.1	RP11-168A11.4	-4.81	1.75e-06	0.00017	-0.17	-0.15	Serum thyroid-stimulating hormone levels;	chr5:80029041	chr5:80019609~80019920:+
BRCA	cis	rs2243480	0.901	rs778687	ENSG00000222364.1	RNU6-96P	-4.81	1.75e-06	0.00017	-0.27	-0.15	Diabetic kidney disease;	chr7:66370832	chr7:66395191~66395286:+
BRCA	cis	rs2243480	1	rs778704	ENSG00000222364.1	RNU6-96P	-4.81	1.75e-06	0.00017	-0.27	-0.15	Diabetic kidney disease;	chr7:66398480	chr7:66395191~66395286:+
BRCA	cis	rs2243480	0.901	rs778693	ENSG00000222364.1	RNU6-96P	-4.81	1.75e-06	0.00017	-0.27	-0.15	Diabetic kidney disease;	chr7:66407358	chr7:66395191~66395286:+
BRCA	cis	rs2243480	1	rs778691	ENSG00000222364.1	RNU6-96P	-4.81	1.75e-06	0.00017	-0.27	-0.15	Diabetic kidney disease;	chr7:66408105	chr7:66395191~66395286:+
BRCA	cis	rs2243480	1	rs13235972	ENSG00000222364.1	RNU6-96P	-4.81	1.75e-06	0.00017	-0.27	-0.15	Diabetic kidney disease;	chr7:66418618	chr7:66395191~66395286:+
BRCA	cis	rs2243480	1	rs34192067	ENSG00000222364.1	RNU6-96P	-4.81	1.75e-06	0.00017	-0.27	-0.15	Diabetic kidney disease;	chr7:66422670	chr7:66395191~66395286:+
BRCA	cis	rs2251381	0.75	rs2255055	ENSG00000176054.6	RPL23P2	4.81	1.75e-06	0.00017	0.17	0.15	Selective IgA deficiency;	chr21:29164724	chr21:28997613~28998033:-
BRCA	cis	rs10510102	0.872	rs12264952	ENSG00000226864.1	ATE1-AS1	4.81	1.76e-06	0.00017	0.26	0.15	Breast cancer;	chr10:121885673	chr10:121928312~121951965:+
BRCA	cis	rs300890	0.662	rs300898	ENSG00000250326.1	RP11-284M14.1	-4.81	1.76e-06	0.00017	-0.17	-0.15	Nasopharyngeal carcinoma;	chr4:143311391	chr4:142933195~143184861:-
BRCA	cis	rs2243480	1	rs6964245	ENSG00000275400.1	RP4-756H11.5	-4.81	1.76e-06	0.00017	-0.26	-0.15	Diabetic kidney disease;	chr7:66253730	chr7:66553805~66554199:-
BRCA	cis	rs2708977	0.933	rs2464914	ENSG00000237510.6	AC008268.2	-4.81	1.76e-06	0.00017	-0.19	-0.15	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96514091	chr2:95789654~95800166:+
BRCA	cis	rs11239930	0.538	rs630630	ENSG00000278811.3	LINC00624	4.81	1.76e-06	0.00017	0.18	0.15	AIDS progression;	chr1:147080377	chr1:147258885~147517875:-
BRCA	cis	rs11239930	0.538	rs618575	ENSG00000278811.3	LINC00624	4.81	1.76e-06	0.00017	0.18	0.15	AIDS progression;	chr1:147080759	chr1:147258885~147517875:-
BRCA	cis	rs3764563	0.799	rs7249233	ENSG00000267594.5	CYP4F24P	-4.81	1.76e-06	0.00017	-0.28	-0.15	Inflammatory biomarkers;	chr19:15612780	chr19:15760241~15779909:-
BRCA	cis	rs9402743	0.634	rs9494289	ENSG00000231028.7	LINC00271	-4.81	1.76e-06	0.00017	-0.15	-0.15	Systemic lupus erythematosus;	chr6:135594751	chr6:135497801~135716055:+
BRCA	cis	rs7312933	0.558	rs1796388	ENSG00000257225.1	RP11-328C8.4	4.81	1.76e-06	0.00017	0.17	0.15	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42392185	chr12:42459366~42466128:+
BRCA	cis	rs3764021	0.87	rs7956831	ENSG00000256673.1	RP11-599J14.2	4.81	1.76e-06	0.00017	0.16	0.15	Type 1 diabetes;	chr12:9736561	chr12:9398355~9414851:-
BRCA	cis	rs10938353	0.68	rs17654223	ENSG00000273369.1	RP11-700J17.1	4.81	1.76e-06	0.00017	0.18	0.15	Body mass index;	chr4:44741551	chr4:44693946~44694386:-
BRCA	cis	rs6832769	1	rs2177129	ENSG00000223305.1	RN7SKP30	4.81	1.76e-06	0.00017	0.18	0.15	Personality dimensions;	chr4:55499247	chr4:55540502~55540835:-
BRCA	cis	rs7136702	1	rs7136702	ENSG00000272368.2	RP4-605O3.4	4.81	1.76e-06	0.00017	0.15	0.15	Colorectal cancer (SNP x SNP interaction);	chr12:50486433	chr12:50112197~50165618:+
BRCA	cis	rs7176527	0.784	rs62021162	ENSG00000230373.7	GOLGA6L5P	4.81	1.76e-06	0.00017	0.2	0.15	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84565602	chr15:84507885~84516814:-
BRCA	cis	rs897984	0.52	rs4889536	ENSG00000260911.2	RP11-196G11.2	-4.81	1.76e-06	0.00017	-0.15	-0.15	Dementia with Lewy bodies;	chr16:30860434	chr16:31043150~31049868:+
BRCA	cis	rs6832769	1	rs6853192	ENSG00000223305.1	RN7SKP30	-4.81	1.76e-06	0.00017	-0.18	-0.15	Personality dimensions;	chr4:55543087	chr4:55540502~55540835:-
BRCA	cis	rs875971	1	rs2077593	ENSG00000223473.2	GS1-124K5.3	4.81	1.76e-06	0.00017	0.11	0.15	Aortic root size;	chr7:66427543	chr7:66491049~66493566:-
BRCA	cis	rs4356203	0.905	rs1989405	ENSG00000272034.1	SNORD14A	4.81	1.76e-06	0.00017	0.15	0.15	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17163272	chr11:17074654~17074744:-
BRCA	cis	rs10129255	0.957	rs7493713	ENSG00000280411.1	IGHV1-69-2	-4.81	1.76e-06	0.00017	-0.1	-0.15	Kawasaki disease;	chr14:106783685	chr14:106762092~106762588:-
BRCA	cis	rs10129255	0.912	rs35468694	ENSG00000280411.1	IGHV1-69-2	-4.81	1.76e-06	0.00017	-0.1	-0.15	Kawasaki disease;	chr14:106784199	chr14:106762092~106762588:-
BRCA	cis	rs875971	0.862	rs11773628	ENSG00000236529.1	RP13-254B10.1	-4.81	1.76e-06	0.00017	-0.16	-0.15	Aortic root size;	chr7:66517644	chr7:65840212~65840596:+
BRCA	cis	rs2638953	0.815	rs10843188	ENSG00000247934.4	RP11-967K21.1	-4.81	1.76e-06	0.00017	-0.18	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28504200	chr12:28163298~28190738:-
BRCA	cis	rs4664293	0.867	rs7566802	ENSG00000224152.1	AC009506.1	-4.81	1.76e-06	0.000171	-0.17	-0.15	Monocyte percentage of white cells;	chr2:159728480	chr2:159615296~159617082:+
BRCA	cis	rs7267979	1	rs2500448	ENSG00000276952.1	RP5-965G21.6	-4.81	1.76e-06	0.000171	-0.18	-0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25423391	chr20:25284915~25285588:-
BRCA	cis	rs11239930	0.538	rs4950359	ENSG00000278811.3	LINC00624	4.81	1.77e-06	0.000171	0.18	0.15	AIDS progression;	chr1:147087196	chr1:147258885~147517875:-
BRCA	cis	rs10504130	1	rs10504130	ENSG00000253844.1	RP11-546K22.1	-4.81	1.77e-06	0.000171	-0.25	-0.15	Venous thromboembolism (SNP x SNP interaction);	chr8:51844533	chr8:51961458~52022974:+
BRCA	cis	rs853679	0.546	rs36092177	ENSG00000204709.4	LINC01556	4.81	1.77e-06	0.000171	0.39	0.15	Depression;	chr6:28390030	chr6:28943877~28944537:+
BRCA	cis	rs853679	0.546	rs2232429	ENSG00000204709.4	LINC01556	4.81	1.77e-06	0.000171	0.39	0.15	Depression;	chr6:28391855	chr6:28943877~28944537:+
BRCA	cis	rs853679	0.546	rs2232426	ENSG00000204709.4	LINC01556	4.81	1.77e-06	0.000171	0.39	0.15	Depression;	chr6:28392882	chr6:28943877~28944537:+
BRCA	cis	rs853679	0.546	rs2232423	ENSG00000204709.4	LINC01556	4.81	1.77e-06	0.000171	0.39	0.15	Depression;	chr6:28398374	chr6:28943877~28944537:+
BRCA	cis	rs529866	0.555	rs367569	ENSG00000262703.1	RP11-485G7.6	4.81	1.77e-06	0.000171	0.16	0.15	Inflammatory bowel disease;Crohn's disease;	chr16:11271643	chr16:11348143~11349321:-
BRCA	cis	rs7772486	0.79	rs4075694	ENSG00000270638.1	RP3-466P17.1	-4.81	1.77e-06	0.000171	-0.17	-0.15	Lobe attachment (rater-scored or self-reported);	chr6:145929972	chr6:145735570~145737218:+
BRCA	cis	rs2403083	0.535	rs2896454	ENSG00000258256.1	RP11-219B4.5	-4.81	1.77e-06	0.000171	-0.18	-0.15	Plasma amyloid beta peptide concentrations (ABx-40);	chr8:85147837	chr8:85222446~85245717:-
BRCA	cis	rs2403083	0.578	rs7004765	ENSG00000258256.1	RP11-219B4.5	-4.81	1.77e-06	0.000171	-0.18	-0.15	Plasma amyloid beta peptide concentrations (ABx-40);	chr8:85150260	chr8:85222446~85245717:-
BRCA	cis	rs11239930	0.517	rs556976	ENSG00000230832.3	RP11-325P15.2	-4.81	1.77e-06	0.000171	-0.21	-0.15	AIDS progression;	chr1:147073643	chr1:147082338~147083578:-
BRCA	cis	rs227275	0.526	rs223497	ENSG00000251288.2	RP11-10L12.2	-4.81	1.77e-06	0.000171	-0.18	-0.15	Allergic disease (asthma, hay fever or eczema);	chr4:102732819	chr4:102751401~102752641:+
BRCA	cis	rs6723226	0.766	rs398290	ENSG00000276334.1	AL133243.1	4.81	1.77e-06	0.000171	0.19	0.15	Intelligence (multi-trait analysis);	chr2:32278457	chr2:32521927~32523547:+
BRCA	cis	rs962856	1	rs4671794	ENSG00000236780.4	AC078941.1	4.81	1.77e-06	0.000171	0.18	0.15	Pancreatic cancer;	chr2:67339526	chr2:67123357~67215319:-
BRCA	cis	rs7674212	0.57	rs1031804	ENSG00000246560.2	RP11-10L12.4	4.81	1.77e-06	0.000171	0.15	0.15	Type 2 diabetes;	chr4:103144892	chr4:102828055~102844075:+
BRCA	cis	rs7818688	0.578	rs13279040	ENSG00000245080.5	RP11-320N21.1	-4.81	1.77e-06	0.000171	-0.25	-0.15	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95068161	chr8:95066808~95073182:-
BRCA	cis	rs11976180	1	rs2951353	ENSG00000244479.5	OR2A1-AS1	4.81	1.77e-06	0.000171	0.2	0.15	Obesity-related traits;	chr7:144064023	chr7:144251264~144356181:-
BRCA	cis	rs73198271	0.613	rs11249892	ENSG00000253893.2	FAM85B	4.8	1.78e-06	0.000172	0.2	0.15	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8799730	chr8:8167819~8226614:-
BRCA	cis	rs7243790	0.805	rs12458280	ENSG00000277324.1	RP11-850A17.1	-4.8	1.78e-06	0.000172	-0.16	-0.15	Diastolic blood pressure;	chr18:54386772	chr18:54268346~54270028:-
BRCA	cis	rs7246967	0.736	rs436595	ENSG00000198153.8	ZNF849P	-4.8	1.78e-06	0.000172	-0.23	-0.15	Bronchopulmonary dysplasia;	chr19:22810243	chr19:22685167~22686732:+
BRCA	cis	rs2243480	0.803	rs13224048	ENSG00000275400.1	RP4-756H11.5	4.8	1.78e-06	0.000172	0.27	0.15	Diabetic kidney disease;	chr7:66528779	chr7:66553805~66554199:-
BRCA	cis	rs1832007	0.529	rs4612705	ENSG00000224034.1	RP11-445P17.8	-4.8	1.78e-06	0.000172	-0.24	-0.15	Triglyceride levels;Triglycerides;	chr10:5201635	chr10:5266033~5271236:-
BRCA	cis	rs10504130	0.932	rs11777016	ENSG00000272024.1	RP11-546K22.3	-4.8	1.78e-06	0.000172	-0.26	-0.15	Venous thromboembolism (SNP x SNP interaction);	chr8:51874258	chr8:51950284~51950690:+
BRCA	cis	rs6496044	0.547	rs7173125	ENSG00000202081.1	RNU6-1280P	-4.8	1.78e-06	0.000172	-0.17	-0.15	Interstitial lung disease;	chr15:85512214	chr15:85651522~85651628:-
BRCA	cis	rs6545883	0.894	rs4672431	ENSG00000212978.6	AC016747.3	-4.8	1.78e-06	0.000172	-0.2	-0.15	Tuberculosis;	chr2:61292787	chr2:61141592~61144969:-
BRCA	cis	rs9907295	0.818	rs4796109	ENSG00000271013.1	AC015849.15	-4.8	1.78e-06	0.000172	-0.23	-0.15	Fibroblast growth factor basic levels;	chr17:35811904	chr17:35912635~35918010:-
BRCA	cis	rs875971	0.545	rs7783889	ENSG00000232546.1	RP11-458F8.1	4.8	1.78e-06	0.000172	0.14	0.15	Aortic root size;	chr7:66283366	chr7:66848496~66858136:+
BRCA	cis	rs597539	0.69	rs497149	ENSG00000261625.1	RP11-554A11.4	-4.8	1.78e-06	0.000172	-0.15	-0.15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68859171	chr11:69000765~69002048:-
BRCA	cis	rs875971	1	rs7781698	ENSG00000223473.2	GS1-124K5.3	4.8	1.78e-06	0.000172	0.11	0.15	Aortic root size;	chr7:66431325	chr7:66491049~66493566:-
BRCA	cis	rs7833986	0.501	rs2719255	ENSG00000253603.1	CTA-397H3.3	-4.8	1.78e-06	0.000172	-0.22	-0.15	Height;	chr8:56124099	chr8:56074592~56075274:+
BRCA	cis	rs7833986	0.501	rs72653990	ENSG00000253603.1	CTA-397H3.3	-4.8	1.78e-06	0.000172	-0.22	-0.15	Height;	chr8:56124556	chr8:56074592~56075274:+
BRCA	cis	rs7833986	0.501	rs17815934	ENSG00000253603.1	CTA-397H3.3	-4.8	1.78e-06	0.000172	-0.22	-0.15	Height;	chr8:56125836	chr8:56074592~56075274:+
BRCA	cis	rs7591472	1	rs7591472	ENSG00000183308.6	AC005037.3	4.8	1.78e-06	0.000172	0.25	0.15	Triptolide cytotoxicity;	chr2:201025028	chr2:200963263~201009102:+
BRCA	cis	rs8103033	0.786	rs997104	ENSG00000226025.8	LGALS17A	-4.8	1.78e-06	0.000172	-0.16	-0.15	Obesity-related traits;	chr19:39658690	chr19:39679374~39686373:+
BRCA	cis	rs67981189	0.613	rs4366661	ENSG00000269927.1	RP6-91H8.3	-4.8	1.78e-06	0.000172	-0.18	-0.15	Schizophrenia;	chr14:70985599	chr14:71141125~71143253:-
BRCA	cis	rs7772486	0.754	rs9497434	ENSG00000270638.1	RP3-466P17.1	-4.8	1.78e-06	0.000172	-0.17	-0.15	Lobe attachment (rater-scored or self-reported);	chr6:145939617	chr6:145735570~145737218:+
BRCA	cis	rs2617170	0.883	rs2733851	ENSG00000245648.1	RP11-277P12.20	4.8	1.78e-06	0.000172	0.2	0.15	Behcet's disease;	chr12:10376498	chr12:10363769~10398506:+
BRCA	cis	rs2803122	0.936	rs10117865	ENSG00000273226.1	RP11-513M16.8	-4.8	1.78e-06	0.000172	-0.16	-0.15	Pulse pressure;	chr9:19314433	chr9:19375451~19375996:+
BRCA	cis	rs9907295	0.71	rs9894083	ENSG00000271013.1	AC015849.15	-4.8	1.79e-06	0.000172	-0.24	-0.15	Fibroblast growth factor basic levels;	chr17:35842151	chr17:35912635~35918010:-
BRCA	cis	rs7134599	0.561	rs10784670	ENSG00000255733.4	IFNG-AS1	-4.8	1.79e-06	0.000172	-0.12	-0.15	Inflammatory bowel disease;Ulcerative colitis;	chr12:68080315	chr12:67989445~68234686:+
BRCA	cis	rs4713118	0.955	rs9468200	ENSG00000216901.1	AL022393.7	4.8	1.79e-06	0.000173	0.2	0.15	Parkinson's disease;	chr6:27715284	chr6:28176188~28176674:+
BRCA	cis	rs6596100	0.821	rs7730930	ENSG00000248648.1	RP11-485M7.1	-4.8	1.79e-06	0.000173	-0.19	-0.15	Breast cancer;	chr5:133050992	chr5:133003119~133003365:+
BRCA	cis	rs4237845	0.537	rs10747787	ENSG00000257159.1	RP11-58A17.3	4.8	1.79e-06	0.000173	0.17	0.15	Intelligence (multi-trait analysis);	chr12:57866874	chr12:57967058~57968399:+
BRCA	cis	rs13325613	0.834	rs13092160	ENSG00000223552.1	RP11-24F11.2	-4.8	1.79e-06	0.000173	-0.23	-0.15	Monocyte count;	chr3:46213300	chr3:46364955~46407059:-
BRCA	cis	rs11098499	0.789	rs1980024	ENSG00000260404.2	RP11-384K6.6	4.8	1.79e-06	0.000173	0.13	0.15	Corneal astigmatism;	chr4:119331892	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.754	rs34425882	ENSG00000260404.2	RP11-384K6.6	4.8	1.79e-06	0.000173	0.13	0.15	Corneal astigmatism;	chr4:119332022	chr4:118591773~118633729:+
BRCA	cis	rs2403083	0.578	rs3779899	ENSG00000258256.1	RP11-219B4.5	4.8	1.79e-06	0.000173	0.18	0.15	Plasma amyloid beta peptide concentrations (ABx-40);	chr8:85145768	chr8:85222446~85245717:-
BRCA	cis	rs7772486	0.754	rs9399567	ENSG00000270638.1	RP3-466P17.1	4.8	1.79e-06	0.000173	0.17	0.15	Lobe attachment (rater-scored or self-reported);	chr6:145826159	chr6:145735570~145737218:+
BRCA	cis	rs9377188	0.744	rs2500537	ENSG00000236591.1	RP11-162J8.3	-4.8	1.79e-06	0.000173	-0.19	-0.15	Cancer;	chr6:149008736	chr6:149027700~149032573:-
BRCA	cis	rs6442522	0.606	rs3274	ENSG00000249786.6	EAF1-AS1	4.8	1.79e-06	0.000173	0.15	0.15	Uric acid levels;	chr3:15450249	chr3:15436171~15455940:-
BRCA	cis	rs6570726	0.791	rs435671	ENSG00000270638.1	RP3-466P17.1	4.8	1.79e-06	0.000173	0.17	0.15	Lobe attachment (rater-scored or self-reported);	chr6:145560079	chr6:145735570~145737218:+
BRCA	cis	rs853679	0.546	rs35017208	ENSG00000204709.4	LINC01556	4.8	1.79e-06	0.000173	0.39	0.15	Depression;	chr6:28377505	chr6:28943877~28944537:+
BRCA	cis	rs2243480	1	rs778679	ENSG00000275400.1	RP4-756H11.5	4.8	1.79e-06	0.000173	0.27	0.15	Diabetic kidney disease;	chr7:66375924	chr7:66553805~66554199:-
BRCA	cis	rs4662750	0.536	rs4662744	ENSG00000236682.1	AC068282.3	4.8	1.79e-06	0.000173	0.19	0.15	Renal cell carcinoma;	chr2:127593390	chr2:127389130~127400580:+
BRCA	cis	rs6430585	0.583	rs78364332	ENSG00000231890.6	DARS-AS1	-4.8	1.79e-06	0.000173	-0.23	-0.15	Corneal structure;	chr2:135882531	chr2:135985176~136022593:+
BRCA	cis	rs4356203	0.905	rs7946165	ENSG00000272034.1	SNORD14A	-4.8	1.79e-06	0.000173	-0.15	-0.15	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17057080	chr11:17074654~17074744:-
BRCA	cis	rs1005277	0.602	rs1831315	ENSG00000099251.13	HSD17B7P2	4.8	1.79e-06	0.000173	0.16	0.15	Extrinsic epigenetic age acceleration;	chr10:38184425	chr10:38356380~38378505:+
BRCA	cis	rs860295	0.702	rs5005770	ENSG00000160766.13	GBAP1	4.8	1.79e-06	0.000173	0.16	0.15	Body mass index;	chr1:155375252	chr1:155213821~155227422:-
BRCA	cis	rs7572733	0.534	rs1607374	ENSG00000231621.1	AC013264.2	-4.8	1.79e-06	0.000173	-0.15	-0.15	Dermatomyositis;	chr2:197935716	chr2:197197991~197199273:+
BRCA	cis	rs11976180	1	rs2371247	ENSG00000244479.5	OR2A1-AS1	4.8	1.79e-06	0.000173	0.2	0.15	Obesity-related traits;	chr7:144067086	chr7:144251264~144356181:-
BRCA	cis	rs12712135	0.709	rs10201184	ENSG00000234389.1	AC007278.3	4.8	1.79e-06	0.000173	0.13	0.15	Blood protein levels;	chr2:102472618	chr2:102438713~102440475:+
BRCA	cis	rs7927592	0.913	rs10896330	ENSG00000212093.1	AP000807.1	4.8	1.79e-06	0.000173	0.16	0.15	Total body bone mineral density;	chr11:68487530	chr11:68506083~68506166:-
BRCA	cis	rs7226408	0.857	rs72892516	ENSG00000267707.2	RP11-95O2.5	4.8	1.79e-06	0.000173	0.22	0.15	Obesity-related traits;	chr18:37085085	chr18:37243776~37247506:+
BRCA	cis	rs7226408	0.857	rs72892518	ENSG00000267707.2	RP11-95O2.5	4.8	1.79e-06	0.000173	0.22	0.15	Obesity-related traits;	chr18:37085457	chr18:37243776~37247506:+
BRCA	cis	rs2243480	0.901	rs34807232	ENSG00000275400.1	RP4-756H11.5	4.8	1.79e-06	0.000173	0.27	0.15	Diabetic kidney disease;	chr7:66500146	chr7:66553805~66554199:-
BRCA	cis	rs2243480	0.901	rs35823062	ENSG00000275400.1	RP4-756H11.5	4.8	1.79e-06	0.000173	0.27	0.15	Diabetic kidney disease;	chr7:66500834	chr7:66553805~66554199:-
BRCA	cis	rs11673344	0.504	rs1667378	ENSG00000226686.6	LINC01535	4.8	1.8e-06	0.000173	0.19	0.15	Obesity-related traits;	chr19:37001171	chr19:37251912~37265535:+
BRCA	cis	rs1990950	1	rs1990950	ENSG00000248544.2	CTB-47B11.3	-4.8	1.8e-06	0.000173	-0.17	-0.15	Lung function (FEV1/FVC);	chr5:157493748	chr5:157375741~157384950:-
BRCA	cis	rs10191773	0.589	rs11676628	ENSG00000243389.1	AC012442.5	-4.8	1.8e-06	0.000173	-0.28	-0.15	Yeast infection;	chr2:112195778	chr2:112589040~112614431:+
BRCA	cis	rs11722228	0.508	rs2241473	ENSG00000261490.1	RP11-448G15.3	4.8	1.8e-06	0.000173	0.17	0.15	Urate levels;Serum uric acid levels;Gout;	chr4:10084325	chr4:10068089~10073019:-
BRCA	cis	rs875971	0.522	rs4502988	ENSG00000182722.5	SEPHS1P1	-4.8	1.8e-06	0.000174	-0.18	-0.15	Aortic root size;	chr7:65832759	chr7:64852397~64853354:-
BRCA	cis	rs4356203	0.905	rs7927240	ENSG00000272034.1	SNORD14A	-4.8	1.8e-06	0.000174	-0.15	-0.15	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17056681	chr11:17074654~17074744:-
BRCA	cis	rs6570726	0.791	rs446362	ENSG00000270638.1	RP3-466P17.1	4.8	1.8e-06	0.000174	0.17	0.15	Lobe attachment (rater-scored or self-reported);	chr6:145557580	chr6:145735570~145737218:+
BRCA	cis	rs6570726	0.791	rs414600	ENSG00000270638.1	RP3-466P17.1	4.8	1.8e-06	0.000174	0.17	0.15	Lobe attachment (rater-scored or self-reported);	chr6:145558470	chr6:145735570~145737218:+
BRCA	cis	rs4948275	0.773	rs2650718	ENSG00000237233.2	TMEM26-AS1	-4.8	1.8e-06	0.000174	-0.17	-0.15	Night sleep phenotypes;	chr10:61486116	chr10:61452639~61481956:+
BRCA	cis	rs4948275	0.773	rs2787729	ENSG00000237233.2	TMEM26-AS1	-4.8	1.8e-06	0.000174	-0.17	-0.15	Night sleep phenotypes;	chr10:61486282	chr10:61452639~61481956:+
BRCA	cis	rs4948275	0.773	rs2250017	ENSG00000237233.2	TMEM26-AS1	-4.8	1.8e-06	0.000174	-0.17	-0.15	Night sleep phenotypes;	chr10:61486696	chr10:61452639~61481956:+
BRCA	cis	rs4948275	0.773	rs2250016	ENSG00000237233.2	TMEM26-AS1	-4.8	1.8e-06	0.000174	-0.17	-0.15	Night sleep phenotypes;	chr10:61486705	chr10:61452639~61481956:+
BRCA	cis	rs4948275	0.773	rs2249939	ENSG00000237233.2	TMEM26-AS1	-4.8	1.8e-06	0.000174	-0.17	-0.15	Night sleep phenotypes;	chr10:61486987	chr10:61452639~61481956:+
BRCA	cis	rs11051970	0.918	rs11051969	ENSG00000274964.1	RP11-817I4.1	-4.8	1.8e-06	0.000174	-0.19	-0.15	Response to tocilizumab in rheumatoid arthritis;	chr12:32384189	chr12:32339368~32340724:+
BRCA	cis	rs763121	0.524	rs760645	ENSG00000228274.3	RP3-508I15.9	-4.8	1.8e-06	0.000174	-0.16	-0.15	Menopause (age at onset);	chr22:38636265	chr22:38667585~38681820:-
BRCA	cis	rs4699052	0.662	rs6848091	ENSG00000248740.4	RP11-328K4.1	4.8	1.8e-06	0.000174	0.16	0.15	Testicular germ cell tumor;	chr4:103328944	chr4:103256159~103453658:+
BRCA	cis	rs728616	0.867	rs55666905	ENSG00000225484.5	NUTM2B-AS1	-4.8	1.8e-06	0.000174	-0.41	-0.15	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80193883	chr10:79663088~79826594:-
BRCA	cis	rs78487399	0.808	rs75097983	ENSG00000234936.1	AC010883.5	4.8	1.8e-06	0.000174	0.24	0.15	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43498485	chr2:43229573~43233394:+
BRCA	cis	rs792448	0.743	rs351380	ENSG00000226251.4	RP11-15I11.3	-4.8	1.8e-06	0.000174	-0.19	-0.15	White blood cell count (basophil);	chr1:212309510	chr1:212225278~212238977:-
BRCA	cis	rs12893668	0.644	rs12890820	ENSG00000244691.1	RPL10AP1	-4.8	1.8e-06	0.000174	-0.2	-0.15	Reticulocyte count;	chr14:103568512	chr14:103412119~103412761:-
BRCA	cis	rs6571943	0.517	rs10134241	ENSG00000258526.4	RP11-111A21.1	-4.8	1.8e-06	0.000174	-0.19	-0.15	Verbal memory performance (residualized delayed recall level);	chr14:39553759	chr14:39474840~39513780:+
BRCA	cis	rs6430585	0.941	rs7589832	ENSG00000224043.6	CCNT2-AS1	-4.8	1.8e-06	0.000174	-0.23	-0.15	Corneal structure;	chr2:135746531	chr2:134735464~134918710:-
BRCA	cis	rs9925964	0.967	rs1978487	ENSG00000232748.3	RP11-196G11.6	-4.8	1.8e-06	0.000174	-0.18	-0.15	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31118621	chr16:31056460~31062803:+
BRCA	cis	rs703842	1	rs3825079	ENSG00000270039.1	RP11-571M6.17	-4.8	1.8e-06	0.000174	-0.21	-0.15	Multiple sclerosis;	chr12:57809571	chr12:57803838~57804415:+
BRCA	cis	rs7811142	0.83	rs6948685	ENSG00000078319.8	PMS2P1	-4.8	1.8e-06	0.000174	-0.24	-0.15	Platelet count;	chr7:100372565	chr7:100320992~100341908:-
BRCA	cis	rs454217	0.714	rs395142	ENSG00000277851.1	RP11-756G20.1	-4.8	1.8e-06	0.000174	-0.16	-0.15	Smoking quantity;	chr12:92341860	chr12:92247756~92363832:-
BRCA	cis	rs6439153	0.967	rs12695512	ENSG00000231305.3	RP11-723O4.2	4.8	1.8e-06	0.000174	0.17	0.15	Pneumococcal bacteremia;	chr3:129003239	chr3:128861313~128871540:-
BRCA	cis	rs690037	0.78	rs690437	ENSG00000272498.1	RP11-415F23.3	4.8	1.8e-06	0.000174	0.14	0.15	Optic nerve measurement (cup-to-disc ratio);Optic nerve measurement (cup area);	chr3:16339383	chr3:16339308~16339871:+
BRCA	cis	rs4356203	0.905	rs214939	ENSG00000272034.1	SNORD14A	4.8	1.8e-06	0.000174	0.15	0.15	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17165992	chr11:17074654~17074744:-
BRCA	cis	rs2280018	0.963	rs11075255	ENSG00000270580.4	PKD1P6	4.8	1.81e-06	0.000174	0.15	0.15	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15072375	chr16:15104723~15131601:-
BRCA	cis	rs9868809	0.772	rs28452701	ENSG00000270441.1	RP11-694I15.7	4.8	1.81e-06	0.000174	0.27	0.15	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48671142	chr3:49140086~49160851:-
BRCA	cis	rs2278170	1	rs11032345	ENSG00000225101.4	OR52K3P	-4.8	1.81e-06	0.000174	-0.2	-0.15	Amyotrophic lateral sclerosis;	chr11:4462448	chr11:4474813~4475755:+
BRCA	cis	rs6570726	0.935	rs419854	ENSG00000270638.1	RP3-466P17.1	4.8	1.81e-06	0.000174	0.16	0.15	Lobe attachment (rater-scored or self-reported);	chr6:145522949	chr6:145735570~145737218:+
BRCA	cis	rs6570726	0.935	rs365658	ENSG00000270638.1	RP3-466P17.1	4.8	1.81e-06	0.000174	0.16	0.15	Lobe attachment (rater-scored or self-reported);	chr6:145523452	chr6:145735570~145737218:+
BRCA	cis	rs7682317	0.674	rs1795739	ENSG00000270720.1	RP11-84C13.2	-4.8	1.81e-06	0.000174	-0.16	-0.15	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr4:89009162	chr4:89119284~89119871:+
BRCA	cis	rs600231	0.708	rs3132767	ENSG00000173727.10	CMB9-22P13.1	4.8	1.81e-06	0.000174	0.19	0.15	Bone mineral density;	chr11:65467389	chr11:65455258~65466720:+
BRCA	cis	rs9921338	0.887	rs7189044	ENSG00000262636.1	CTD-3088G3.4	-4.8	1.81e-06	0.000174	-0.23	-0.15	Vein graft stenosis in coronary artery bypass grafting;	chr16:11348339	chr16:11380859~11381118:-
BRCA	cis	rs6747488	0.551	rs1090828	ENSG00000272716.1	RP11-563N4.1	4.8	1.81e-06	0.000174	0.16	0.15	Interleukin-18 levels;	chr2:31730320	chr2:32165046~32165757:-
BRCA	cis	rs2242116	0.592	rs6442039	ENSG00000276925.1	RP11-708J19.3	-4.8	1.81e-06	0.000174	-0.2	-0.15	Birth weight;	chr3:46919307	chr3:47469777~47469987:+
BRCA	cis	rs739496	0.542	rs12423926	ENSG00000257595.2	RP3-473L9.4	-4.8	1.81e-06	0.000175	-0.19	-0.15	Platelet count;	chr12:111343251	chr12:111369282~111403310:+
BRCA	cis	rs853679	1	rs853676	ENSG00000216901.1	AL022393.7	4.8	1.81e-06	0.000175	0.25	0.15	Depression;	chr6:28331910	chr6:28176188~28176674:+
BRCA	cis	rs7267979	0.789	rs4815400	ENSG00000277938.1	RP5-965G21.3	-4.8	1.81e-06	0.000175	-0.18	-0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25311924	chr20:25229150~25231933:+
BRCA	cis	rs1555322	1	rs2425041	ENSG00000126005.14	MMP24-AS1	-4.8	1.81e-06	0.000175	-0.25	-0.15	Attention deficit hyperactivity disorder;	chr20:35271210	chr20:35216462~35278131:-
BRCA	cis	rs7819412	0.745	rs4841498	ENSG00000255046.1	RP11-297N6.4	4.8	1.81e-06	0.000175	0.17	0.15	Triglycerides;	chr8:11127922	chr8:11797928~11802568:-
BRCA	cis	rs910316	0.763	rs735452	ENSG00000279594.1	RP11-950C14.10	-4.8	1.81e-06	0.000175	-0.16	-0.15	Height;	chr14:75031281	chr14:75011269~75012851:-
BRCA	cis	rs11051970	0.559	rs4931621	ENSG00000274964.1	RP11-817I4.1	-4.8	1.81e-06	0.000175	-0.19	-0.15	Response to tocilizumab in rheumatoid arthritis;	chr12:32333569	chr12:32339368~32340724:+
BRCA	cis	rs7646881	1	rs59918529	ENSG00000240207.5	RP11-379F4.4	-4.8	1.81e-06	0.000175	-0.21	-0.15	Tetralogy of Fallot;	chr3:158734916	chr3:158732263~158784070:+
BRCA	cis	rs4664293	0.867	rs13415025	ENSG00000224152.1	AC009506.1	-4.8	1.81e-06	0.000175	-0.17	-0.15	Monocyte percentage of white cells;	chr2:159729799	chr2:159615296~159617082:+
BRCA	cis	rs6496044	0.507	rs1471455	ENSG00000259295.5	CSPG4P12	-4.8	1.81e-06	0.000175	-0.18	-0.15	Interstitial lung disease;	chr15:85611496	chr15:85191438~85213905:+
BRCA	cis	rs111226991	0.505	rs77207476	ENSG00000273080.1	RP11-301O19.1	4.8	1.81e-06	0.000175	0.23	0.15	Glomerular filtration rate in chronic kidney disease;	chr2:86371847	chr2:86195590~86196049:+
BRCA	cis	rs13326165	0.76	rs390802	ENSG00000243224.1	RP5-1157M23.2	-4.8	1.81e-06	0.000175	-0.21	-0.15	HDL cholesterol levels;HDL cholesterol;	chr3:52397655	chr3:52239258~52241097:+
BRCA	cis	rs6442522	0.606	rs3846128	ENSG00000249786.6	EAF1-AS1	4.8	1.81e-06	0.000175	0.15	0.15	Uric acid levels;	chr3:15450643	chr3:15436171~15455940:-
BRCA	cis	rs7246657	0.653	rs10402050	ENSG00000267422.1	CTD-2554C21.1	-4.8	1.82e-06	0.000175	-0.25	-0.15	Coronary artery calcification;	chr19:37198056	chr19:37779686~37792865:+
BRCA	cis	rs2239547	0.657	rs4687554	ENSG00000242142.1	SERBP1P3	4.8	1.82e-06	0.000175	0.18	0.15	Schizophrenia;	chr3:52830119	chr3:53064283~53065091:-
BRCA	cis	rs7267979	0.903	rs6115109	ENSG00000276952.1	RP5-965G21.6	4.8	1.82e-06	0.000175	0.18	0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25259031	chr20:25284915~25285588:-
BRCA	cis	rs7267979	0.833	rs4619688	ENSG00000276952.1	RP5-965G21.6	4.8	1.82e-06	0.000175	0.18	0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25263465	chr20:25284915~25285588:-
BRCA	cis	rs2286503	0.966	rs6949233	ENSG00000226329.2	AC005682.6	4.8	1.82e-06	0.000175	0.13	0.15	Fibrinogen;	chr7:22818572	chr7:22863874~22881350:-
BRCA	cis	rs7191700	0.511	rs243330	ENSG00000262636.1	CTD-3088G3.4	4.8	1.82e-06	0.000175	0.19	0.15	Multiple sclerosis;	chr16:11257134	chr16:11380859~11381118:-
BRCA	cis	rs9291683	0.588	rs4697705	ENSG00000250413.1	RP11-448G15.1	4.8	1.82e-06	0.000175	0.19	0.15	Bone mineral density;	chr4:10106503	chr4:10006482~10009725:+
BRCA	cis	rs721917	0.506	rs2493725	ENSG00000242600.5	MBL1P	4.8	1.82e-06	0.000175	0.18	0.15	Chronic obstructive pulmonary disease;	chr10:79898126	chr10:79904898~79950336:+
BRCA	cis	rs2011013	1	rs56373916	ENSG00000225151.9	GOLGA2P7	4.8	1.82e-06	0.000175	0.18	0.15	Sitting height ratio;	chr15:83957989	chr15:84199311~84230136:-
BRCA	cis	rs9863	0.861	rs34878139	ENSG00000270028.1	RP11-380L11.4	4.8	1.82e-06	0.000176	0.18	0.15	White blood cell count;	chr12:123961706	chr12:123925461~123926083:-
BRCA	cis	rs9863	0.861	rs11833002	ENSG00000270028.1	RP11-380L11.4	4.8	1.82e-06	0.000176	0.18	0.15	White blood cell count;	chr12:123962069	chr12:123925461~123926083:-
BRCA	cis	rs10129255	0.957	rs2007467	ENSG00000211974.3	IGHV2-70	-4.8	1.82e-06	0.000176	-0.15	-0.15	Kawasaki disease;	chr14:106771605	chr14:106723574~106724093:-
BRCA	cis	rs10129255	0.956	rs10137268	ENSG00000274576.2	IGHV2-70	4.8	1.82e-06	0.000176	0.14	0.15	Kawasaki disease;	chr14:106697402	chr14:106770577~106771020:-
BRCA	cis	rs10129255	0.701	rs2005643	ENSG00000211972.2	IGHV3-66	4.8	1.82e-06	0.000176	0.11	0.15	Kawasaki disease;	chr14:106676288	chr14:106675017~106675544:-
BRCA	cis	rs2638953	0.924	rs12369144	ENSG00000247934.4	RP11-967K21.1	-4.8	1.82e-06	0.000176	-0.21	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28341109	chr12:28163298~28190738:-
BRCA	cis	rs3781264	0.583	rs12778016	ENSG00000273450.1	RP11-76P2.4	4.8	1.82e-06	0.000176	0.24	0.15	Esophageal cancer and gastric cancer;	chr10:94290660	chr10:94314907~94315327:-
BRCA	cis	rs13325613	0.915	rs34079287	ENSG00000223552.1	RP11-24F11.2	-4.8	1.82e-06	0.000176	-0.31	-0.15	Monocyte count;	chr3:46259379	chr3:46364955~46407059:-
BRCA	cis	rs66887589	0.934	rs41464847	ENSG00000245958.5	RP11-33B1.1	4.8	1.82e-06	0.000176	0.13	0.15	Diastolic blood pressure;	chr4:119611246	chr4:119454791~119552025:+
BRCA	cis	rs9921338	0.961	rs72773833	ENSG00000262703.1	RP11-485G7.6	-4.8	1.82e-06	0.000176	-0.18	-0.15	Vein graft stenosis in coronary artery bypass grafting;	chr16:11319417	chr16:11348143~11349321:-
BRCA	cis	rs7267979	0.816	rs6138593	ENSG00000274973.1	RP13-401N8.7	-4.8	1.83e-06	0.000176	-0.17	-0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25523856	chr20:25845497~25845862:+
BRCA	cis	rs9543976	0.557	rs6562916	ENSG00000261105.4	LMO7-AS1	4.8	1.83e-06	0.000176	0.22	0.15	Diabetic retinopathy;	chr13:75597086	chr13:75604700~75635994:-
BRCA	cis	rs9543976	0.623	rs4885322	ENSG00000261105.4	LMO7-AS1	4.8	1.83e-06	0.000176	0.22	0.15	Diabetic retinopathy;	chr13:75597195	chr13:75604700~75635994:-
BRCA	cis	rs454217	0.502	rs11106515	ENSG00000277851.1	RP11-756G20.1	4.8	1.83e-06	0.000176	0.18	0.15	Smoking quantity;	chr12:92336894	chr12:92247756~92363832:-
BRCA	cis	rs6543140	0.601	rs78178597	ENSG00000234389.1	AC007278.3	4.8	1.83e-06	0.000176	0.16	0.15	Blood protein levels;	chr2:102407136	chr2:102438713~102440475:+
BRCA	cis	rs10911251	0.528	rs10911265	ENSG00000224468.3	RP11-181K3.4	-4.8	1.83e-06	0.000176	-0.16	-0.15	Colorectal cancer;	chr1:183145936	chr1:183138402~183141282:-
BRCA	cis	rs11098499	0.754	rs10213554	ENSG00000260404.2	RP11-384K6.6	-4.8	1.83e-06	0.000176	-0.14	-0.15	Corneal astigmatism;	chr4:119339630	chr4:118591773~118633729:+
BRCA	cis	rs13113518	0.729	rs13120134	ENSG00000272969.1	RP11-528I4.2	4.8	1.83e-06	0.000176	0.19	0.15	Height;	chr4:55415153	chr4:55547112~55547889:+
BRCA	cis	rs7267979	1	rs4815417	ENSG00000277938.1	RP5-965G21.3	-4.8	1.83e-06	0.000176	-0.17	-0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25398890	chr20:25229150~25231933:+
BRCA	cis	rs10911251	0.528	rs4652779	ENSG00000224468.3	RP11-181K3.4	-4.8	1.83e-06	0.000176	-0.16	-0.15	Colorectal cancer;	chr1:183135417	chr1:183138402~183141282:-
BRCA	cis	rs828999	0.688	rs7555964	ENSG00000280186.1	RP11-483I13.6	-4.8	1.83e-06	0.000176	-0.17	-0.15	Monocyte percentage of white cells;	chr1:108155223	chr1:108200413~108202743:+
BRCA	cis	rs875971	0.545	rs2420456	ENSG00000230295.1	RP11-458F8.2	4.8	1.83e-06	0.000176	0.14	0.15	Aortic root size;	chr7:66280619	chr7:66880708~66882981:+
BRCA	cis	rs9378688	0.654	rs2479011	ENSG00000250903.7	GMDS-AS1	4.8	1.83e-06	0.000177	0.18	0.15	Caudate nucleus volume;	chr6:2355515	chr6:2245748~2482022:+
BRCA	cis	rs1124769	0.619	rs4598846	ENSG00000273674.3	CTD-2378E12.1	4.8	1.83e-06	0.000177	0.18	0.15	Cognitive performance;	chr15:51095918	chr15:50839875~50908599:-
BRCA	cis	rs6951245	1	rs1997243	ENSG00000229043.2	AC091729.9	-4.8	1.83e-06	0.000177	-0.26	-0.15	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1044141	chr7:1160374~1165267:+
BRCA	cis	rs6951245	1	rs77760339	ENSG00000229043.2	AC091729.9	-4.8	1.83e-06	0.000177	-0.26	-0.15	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1044291	chr7:1160374~1165267:+
BRCA	cis	rs7481584	0.626	rs2071103	ENSG00000247473.2	CARS-AS1	-4.8	1.83e-06	0.000177	-0.18	-0.15	Calcium levels;	chr11:3018857	chr11:3029009~3041260:+
BRCA	cis	rs6596100	0.915	rs4705880	ENSG00000248648.1	RP11-485M7.1	-4.8	1.83e-06	0.000177	-0.19	-0.15	Breast cancer;	chr5:133097926	chr5:133003119~133003365:+
BRCA	cis	rs2638953	0.962	rs12366617	ENSG00000247934.4	RP11-967K21.1	-4.8	1.83e-06	0.000177	-0.2	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28395726	chr12:28163298~28190738:-
BRCA	cis	rs12893668	0.572	rs11540512	ENSG00000269958.1	RP11-73M18.8	4.8	1.83e-06	0.000177	0.17	0.15	Reticulocyte count;	chr14:103681040	chr14:103696353~103697163:+
BRCA	cis	rs12612619	0.732	rs2053385	ENSG00000229122.1	AGBL5-IT1	4.8	1.83e-06	0.000177	0.15	0.15	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27008277	chr2:27061038~27061815:+
BRCA	cis	rs881375	0.501	rs10156413	ENSG00000226752.6	PSMD5-AS1	-4.8	1.83e-06	0.000177	-0.18	-0.15	Rheumatoid arthritis;	chr9:121105504	chr9:120824828~120854385:+
BRCA	cis	rs6921919	0.525	rs11760133	ENSG00000220721.1	OR1F12	4.8	1.84e-06	0.000177	0.18	0.15	Autism spectrum disorder or schizophrenia;	chr6:28418962	chr6:28073316~28074233:+
BRCA	cis	rs875971	0.83	rs6976714	ENSG00000273448.1	RP11-166O4.6	4.8	1.84e-06	0.000177	0.14	0.15	Aortic root size;	chr7:66426474	chr7:67333047~67334383:+
BRCA	cis	rs67981189	0.537	rs917067	ENSG00000269927.1	RP6-91H8.3	-4.8	1.84e-06	0.000177	-0.18	-0.15	Schizophrenia;	chr14:70905187	chr14:71141125~71143253:-
BRCA	cis	rs2243480	0.711	rs2420172	ENSG00000222364.1	RNU6-96P	4.8	1.84e-06	0.000177	0.27	0.15	Diabetic kidney disease;	chr7:66170354	chr7:66395191~66395286:+
BRCA	cis	rs17685	0.712	rs1859794	ENSG00000280388.1	RP11-229D13.3	-4.8	1.84e-06	0.000177	-0.15	-0.15	Coffee consumption (cups per day);Coffee consumption;	chr7:76192226	chr7:76043977~76045963:-
BRCA	cis	rs4356203	0.905	rs7938820	ENSG00000272034.1	SNORD14A	4.8	1.84e-06	0.000177	0.15	0.15	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17055905	chr11:17074654~17074744:-
BRCA	cis	rs9816784	0.525	rs41301371	ENSG00000242086.7	LINC00969	4.8	1.84e-06	0.000177	0.17	0.15	Mean corpuscular hemoglobin;	chr3:196072696	chr3:195658062~195739964:+
BRCA	cis	rs2243480	1	rs160646	ENSG00000275400.1	RP4-756H11.5	4.8	1.84e-06	0.000177	0.27	0.15	Diabetic kidney disease;	chr7:66091293	chr7:66553805~66554199:-
BRCA	cis	rs919433	0.617	rs700638	ENSG00000231621.1	AC013264.2	-4.8	1.84e-06	0.000177	-0.14	-0.15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197724226	chr2:197197991~197199273:+
BRCA	cis	rs4787491	0.704	rs35605010	ENSG00000261367.1	RP11-455F5.4	-4.8	1.84e-06	0.000177	-0.16	-0.15	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30022107	chr16:30107675~30110541:+
BRCA	cis	rs7811142	0.83	rs11769057	ENSG00000078319.8	PMS2P1	-4.8	1.84e-06	0.000177	-0.24	-0.15	Platelet count;	chr7:100367038	chr7:100320992~100341908:-
BRCA	cis	rs9840812	0.725	rs696517	ENSG00000273486.1	RP11-731C17.2	4.8	1.84e-06	0.000177	0.2	0.15	Fibrinogen levels;	chr3:136348813	chr3:136837338~136839021:-
BRCA	cis	rs7481584	0.624	rs80871	ENSG00000247473.2	CARS-AS1	-4.8	1.84e-06	0.000177	-0.18	-0.15	Calcium levels;	chr11:3028613	chr11:3029009~3041260:+
BRCA	cis	rs1552244	1	rs55822690	ENSG00000232901.1	CYCSP10	4.8	1.84e-06	0.000177	0.21	0.15	Alzheimer's disease;	chr3:10086319	chr3:10000647~10000940:-
BRCA	cis	rs11853189	1	rs78994386	ENSG00000259562.2	RP11-762H8.2	4.8	1.84e-06	0.000177	0.19	0.15	Red cell distribution width;	chr15:78278383	chr15:78290527~78291221:-
BRCA	cis	rs6430585	0.528	rs309167	ENSG00000231890.6	DARS-AS1	-4.8	1.84e-06	0.000177	-0.23	-0.15	Corneal structure;	chr2:135911694	chr2:135985176~136022593:+
BRCA	cis	rs4718428	0.705	rs4717331	ENSG00000229180.5	GS1-124K5.11	4.8	1.84e-06	0.000177	0.14	0.15	Corneal structure;	chr7:66913899	chr7:66526088~66542624:-
BRCA	cis	rs11098499	0.874	rs12502503	ENSG00000249244.1	RP11-548H18.2	4.8	1.84e-06	0.000177	0.18	0.15	Corneal astigmatism;	chr4:119195100	chr4:119391831~119395335:-
BRCA	cis	rs838147	0.844	rs12975033	ENSG00000232871.7	SEC1P	-4.8	1.84e-06	0.000177	-0.16	-0.15	Dietary macronutrient intake;	chr19:48746186	chr19:48638071~48682245:+
BRCA	cis	rs919433	0.617	rs2037590	ENSG00000231621.1	AC013264.2	4.8	1.84e-06	0.000178	0.14	0.15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197720051	chr2:197197991~197199273:+
BRCA	cis	rs2562456	0.917	rs2562468	ENSG00000268535.1	RP11-420K14.3	-4.8	1.84e-06	0.000178	-0.2	-0.15	Pain;	chr19:21532048	chr19:21709522~21710191:+
BRCA	cis	rs2562456	0.917	rs2562471	ENSG00000268535.1	RP11-420K14.3	-4.8	1.84e-06	0.000178	-0.2	-0.15	Pain;	chr19:21533017	chr19:21709522~21710191:+
BRCA	cis	rs5758659	0.714	rs2284087	ENSG00000270083.1	RP1-257I20.14	-4.8	1.84e-06	0.000178	-0.16	-0.15	Cognitive function;	chr22:42089667	chr22:42089630~42090028:-
BRCA	cis	rs6430585	0.528	rs3099429	ENSG00000231890.6	DARS-AS1	-4.8	1.84e-06	0.000178	-0.23	-0.15	Corneal structure;	chr2:135898012	chr2:135985176~136022593:+
BRCA	cis	rs7772486	0.79	rs4314514	ENSG00000270638.1	RP3-466P17.1	-4.8	1.85e-06	0.000178	-0.17	-0.15	Lobe attachment (rater-scored or self-reported);	chr6:145938874	chr6:145735570~145737218:+
BRCA	cis	rs1161098	0.767	rs1152883	ENSG00000256037.1	MRPL40P1	-4.8	1.85e-06	0.000178	-0.24	-0.15	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr12:67436034	chr12:67351436~67352039:+
BRCA	cis	rs78487399	0.71	rs13408002	ENSG00000234936.1	AC010883.5	4.8	1.85e-06	0.000178	0.23	0.15	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43382888	chr2:43229573~43233394:+
BRCA	cis	rs73193808	0.901	rs1997569	ENSG00000236056.1	GAPDHP14	-4.8	1.85e-06	0.000178	-0.21	-0.15	Coronary artery disease;	chr21:29213027	chr21:29222321~29223257:+
BRCA	cis	rs4356203	0.87	rs2171615	ENSG00000272034.1	SNORD14A	-4.8	1.85e-06	0.000178	-0.15	-0.15	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17231094	chr11:17074654~17074744:-
BRCA	cis	rs62025270	0.632	rs78572940	ENSG00000259762.1	RP11-158M2.4	-4.8	1.85e-06	0.000178	-0.22	-0.15	Idiopathic pulmonary fibrosis;	chr15:85696539	chr15:85750336~85752901:-
BRCA	cis	rs2253762	0.54	rs79586669	ENSG00000276742.1	RP11-500G22.4	4.8	1.85e-06	0.000178	0.25	0.15	Breast cancer;	chr10:122015153	chr10:121956782~121957098:+
BRCA	cis	rs9659323	0.601	rs12033970	ENSG00000231365.4	RP11-418J17.1	-4.8	1.85e-06	0.000178	-0.17	-0.15	Body mass index;	chr1:119097778	chr1:119140396~119275973:+
BRCA	cis	rs853679	0.628	rs9368560	ENSG00000216901.1	AL022393.7	4.8	1.85e-06	0.000178	0.21	0.15	Depression;	chr6:28192182	chr6:28176188~28176674:+
BRCA	cis	rs4653663	1	rs4653663	ENSG00000226349.1	RP11-145A3.2	4.8	1.85e-06	0.000178	0.19	0.15	Neuroticism;	chr1:225739516	chr1:225710968~225736274:-
BRCA	cis	rs6442522	0.56	rs924811	ENSG00000249786.6	EAF1-AS1	4.8	1.85e-06	0.000178	0.15	0.15	Uric acid levels;	chr3:15475313	chr3:15436171~15455940:-
BRCA	cis	rs300890	0.513	rs4277733	ENSG00000250326.1	RP11-284M14.1	4.8	1.85e-06	0.000178	0.17	0.15	Nasopharyngeal carcinoma;	chr4:143126893	chr4:142933195~143184861:-
BRCA	cis	rs10946940	0.965	rs6456799	ENSG00000220721.1	OR1F12	-4.8	1.85e-06	0.000178	-0.17	-0.15	Systemic lupus erythematosus;	chr6:27605757	chr6:28073316~28074233:+
BRCA	cis	rs1371614	0.635	rs9309559	ENSG00000229122.1	AGBL5-IT1	4.8	1.85e-06	0.000178	0.16	0.15	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26918647	chr2:27061038~27061815:+
BRCA	cis	rs2243480	1	rs1267820	ENSG00000222364.1	RNU6-96P	-4.8	1.85e-06	0.000178	-0.27	-0.15	Diabetic kidney disease;	chr7:66585308	chr7:66395191~66395286:+
BRCA	cis	rs7577696	0.853	rs212699	ENSG00000272716.1	RP11-563N4.1	4.8	1.85e-06	0.000178	0.16	0.15	Inflammatory biomarkers;	chr2:32218450	chr2:32165046~32165757:-
BRCA	cis	rs7577696	0.853	rs212701	ENSG00000272716.1	RP11-563N4.1	4.8	1.85e-06	0.000178	0.16	0.15	Inflammatory biomarkers;	chr2:32218985	chr2:32165046~32165757:-
BRCA	cis	rs2562456	0.917	rs10420016	ENSG00000268535.1	RP11-420K14.3	-4.8	1.85e-06	0.000178	-0.2	-0.15	Pain;	chr19:21505800	chr19:21709522~21710191:+
BRCA	cis	rs1889642	1	rs1360812	ENSG00000227354.5	RBM26-AS1	-4.8	1.85e-06	0.000178	-0.17	-0.15	Colonoscopy-negative controls vs population controls;	chr13:79829486	chr13:79406309~79424328:+
BRCA	cis	rs11667325	1	rs11667325	ENSG00000268316.1	AC006272.2	4.8	1.85e-06	0.000178	0.18	0.15	Neutrophil percentage of granulocytes;	chr19:51797810	chr19:51839771~51840945:-
BRCA	cis	rs17695224	0.545	rs4802884	ENSG00000269483.1	AC006272.1	4.8	1.85e-06	0.000178	0.18	0.15	HDL cholesterol;HDL cholesterol levels;	chr19:51845202	chr19:51839924~51843324:-
BRCA	cis	rs7487075	0.619	rs4768709	ENSG00000274723.1	RP11-618L22.1	4.8	1.85e-06	0.000178	0.2	0.15	Itch intensity from mosquito bite;	chr12:46411982	chr12:46970504~46972155:+
BRCA	cis	rs4713118	0.955	rs9368528	ENSG00000216901.1	AL022393.7	4.8	1.85e-06	0.000179	0.2	0.15	Parkinson's disease;	chr6:27716019	chr6:28176188~28176674:+
BRCA	cis	rs4713118	0.955	rs9380011	ENSG00000216901.1	AL022393.7	4.8	1.85e-06	0.000179	0.2	0.15	Parkinson's disease;	chr6:27716145	chr6:28176188~28176674:+
BRCA	cis	rs4713118	0.955	rs9380012	ENSG00000216901.1	AL022393.7	4.8	1.85e-06	0.000179	0.2	0.15	Parkinson's disease;	chr6:27716875	chr6:28176188~28176674:+
BRCA	cis	rs1218582	0.772	rs12069356	ENSG00000270361.1	RP11-307C12.13	-4.8	1.86e-06	0.000179	-0.16	-0.15	Prostate cancer;	chr1:154877295	chr1:154937370~154938059:+
BRCA	cis	rs17818399	0.533	rs4384837	ENSG00000279254.1	RP11-536C12.1	-4.8	1.86e-06	0.000179	-0.18	-0.15	Height;	chr2:46562375	chr2:46668870~46670778:+
BRCA	cis	rs4664293	0.836	rs13016015	ENSG00000226266.5	AC009961.3	-4.8	1.86e-06	0.000179	-0.18	-0.15	Monocyte percentage of white cells;	chr2:159790018	chr2:159670708~159712435:-
BRCA	cis	rs7226408	0.901	rs17652935	ENSG00000267707.2	RP11-95O2.5	4.8	1.86e-06	0.000179	0.22	0.15	Obesity-related traits;	chr18:37176567	chr18:37243776~37247506:+
BRCA	cis	rs4664293	0.867	rs2357532	ENSG00000224152.1	AC009506.1	-4.8	1.86e-06	0.000179	-0.17	-0.15	Monocyte percentage of white cells;	chr2:159740916	chr2:159615296~159617082:+
BRCA	cis	rs7474896	0.609	rs1830612	ENSG00000120555.12	SEPT7P9	4.8	1.86e-06	0.000179	0.21	0.15	Obesity (extreme);	chr10:37710955	chr10:38383069~38402916:-
BRCA	cis	rs6095360	0.87	rs1569749	ENSG00000222365.1	SNORD12B	-4.8	1.86e-06	0.000179	-0.16	-0.15	Intelligence (multi-trait analysis);	chr20:48984972	chr20:49280319~49280409:+
BRCA	cis	rs7267979	0.816	rs6138593	ENSG00000274414.1	RP5-965G21.4	-4.8	1.86e-06	0.000179	-0.17	-0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25523856	chr20:25239007~25245229:-
BRCA	cis	rs4713118	0.513	rs156739	ENSG00000219392.1	RP1-265C24.5	-4.8	1.86e-06	0.000179	-0.2	-0.15	Parkinson's disease;	chr6:28045632	chr6:28115628~28116551:+
BRCA	cis	rs878939	0.625	rs2193352	ENSG00000233690.1	EBAG9P1	4.8	1.86e-06	0.000179	0.21	0.15	Warfarin maintenance dose;	chr10:99586852	chr10:99697407~99697949:-
BRCA	cis	rs8114671	0.836	rs6060165	ENSG00000126005.14	MMP24-AS1	4.8	1.86e-06	0.000179	0.17	0.15	Height;	chr20:35031677	chr20:35216462~35278131:-
BRCA	cis	rs78487399	0.908	rs12466060	ENSG00000234936.1	AC010883.5	4.8	1.86e-06	0.000179	0.23	0.15	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43578238	chr2:43229573~43233394:+
BRCA	cis	rs703842	1	rs10783847	ENSG00000270039.1	RP11-571M6.17	-4.8	1.86e-06	0.000179	-0.2	-0.15	Multiple sclerosis;	chr12:57802664	chr12:57803838~57804415:+
BRCA	cis	rs78487399	0.808	rs78098795	ENSG00000234936.1	AC010883.5	4.8	1.86e-06	0.000179	0.24	0.15	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43613222	chr2:43229573~43233394:+
BRCA	cis	rs1218582	0.741	rs10908444	ENSG00000270361.1	RP11-307C12.13	-4.8	1.86e-06	0.000179	-0.17	-0.15	Prostate cancer;	chr1:154867811	chr1:154937370~154938059:+
BRCA	cis	rs1858037	0.836	rs17475335	ENSG00000237979.1	AC007389.1	4.8	1.86e-06	0.000179	0.19	0.15	Rheumatoid arthritis;	chr2:65378646	chr2:65500993~65502138:-
BRCA	cis	rs2708977	0.699	rs631746	ENSG00000237510.6	AC008268.2	-4.8	1.86e-06	0.000179	-0.19	-0.15	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96399761	chr2:95789654~95800166:+
BRCA	cis	rs8180040	0.966	rs2101247	ENSG00000271161.1	BOLA2P2	-4.8	1.86e-06	0.000179	-0.16	-0.15	Colorectal cancer;	chr3:47452813	chr3:47499841~47500407:+
BRCA	cis	rs230529	0.51	rs1120986	ENSG00000246560.2	RP11-10L12.4	4.8	1.86e-06	0.000179	0.16	0.15	Schizophrenia (treatment resistant);	chr4:102515484	chr4:102828055~102844075:+
BRCA	cis	rs6095360	1	rs6512567	ENSG00000222365.1	SNORD12B	-4.8	1.86e-06	0.000179	-0.16	-0.15	Intelligence (multi-trait analysis);	chr20:49072083	chr20:49280319~49280409:+
BRCA	cis	rs6095360	1	rs2075676	ENSG00000222365.1	SNORD12B	-4.8	1.86e-06	0.000179	-0.16	-0.15	Intelligence (multi-trait analysis);	chr20:49074674	chr20:49280319~49280409:+
BRCA	cis	rs6832769	1	rs11726609	ENSG00000223305.1	RN7SKP30	4.79	1.86e-06	0.000179	0.19	0.15	Personality dimensions;	chr4:55534702	chr4:55540502~55540835:-
BRCA	cis	rs4218	0.597	rs10431762	ENSG00000277144.1	RP11-59H7.4	-4.79	1.86e-06	0.000179	-0.2	-0.15	Social communication problems;	chr15:59066330	chr15:59115547~59116089:-
BRCA	cis	rs26949	0.511	rs2898287	ENSG00000215032.2	GNL3LP1	-4.79	1.87e-06	0.000179	-0.18	-0.15	Intelligence (multi-trait analysis);	chr5:60588406	chr5:60891935~60893577:-
BRCA	cis	rs11096990	0.551	rs11724855	ENSG00000249685.1	RP11-360F5.3	4.79	1.87e-06	0.000179	0.19	0.15	Cognitive function;	chr4:39163379	chr4:39133913~39135608:+
BRCA	cis	rs10504130	1	rs11780891	ENSG00000272024.1	RP11-546K22.3	-4.79	1.87e-06	0.00018	-0.26	-0.15	Venous thromboembolism (SNP x SNP interaction);	chr8:51762067	chr8:51950284~51950690:+
BRCA	cis	rs10504130	0.569	rs60153173	ENSG00000272024.1	RP11-546K22.3	-4.79	1.87e-06	0.00018	-0.21	-0.15	Venous thromboembolism (SNP x SNP interaction);	chr8:51778064	chr8:51950284~51950690:+
BRCA	cis	rs6570726	0.967	rs373704	ENSG00000270638.1	RP3-466P17.1	4.79	1.87e-06	0.00018	0.16	0.15	Lobe attachment (rater-scored or self-reported);	chr6:145539482	chr6:145735570~145737218:+
BRCA	cis	rs7618915	0.547	rs2268026	ENSG00000243224.1	RP5-1157M23.2	-4.79	1.87e-06	0.00018	-0.16	-0.15	Bipolar disorder;	chr3:52744331	chr3:52239258~52241097:+
BRCA	cis	rs7829975	0.688	rs13270194	ENSG00000253981.4	ALG1L13P	4.79	1.87e-06	0.00018	0.17	0.15	Mood instability;	chr8:8520592	chr8:8236003~8244667:-
BRCA	cis	rs62184315	0.536	rs2289405	ENSG00000253559.1	OSGEPL1-AS1	-4.79	1.87e-06	0.00018	-0.26	-0.15	Alcohol dependence (age at onset);	chr2:189771313	chr2:189762704~189765556:+
BRCA	cis	rs6847067	0.683	rs6820517	ENSG00000180769.7	WDFY3-AS2	4.79	1.87e-06	0.00018	0.15	0.15	Oropharynx cancer;	chr4:84949472	chr4:84965682~85011277:+
BRCA	cis	rs2243480	1	rs464895	ENSG00000222364.1	RNU6-96P	-4.79	1.87e-06	0.00018	-0.29	-0.15	Diabetic kidney disease;	chr7:66062119	chr7:66395191~66395286:+
BRCA	cis	rs6095360	1	rs1885163	ENSG00000222365.1	SNORD12B	-4.79	1.87e-06	0.00018	-0.16	-0.15	Intelligence (multi-trait analysis);	chr20:49085228	chr20:49280319~49280409:+
BRCA	cis	rs736408	0.509	rs2590838	ENSG00000243224.1	RP5-1157M23.2	-4.79	1.87e-06	0.00018	-0.15	-0.15	Bipolar disorder;	chr3:52588070	chr3:52239258~52241097:+
BRCA	cis	rs4835473	0.932	rs4835126	ENSG00000249741.2	RP11-673E1.3	-4.79	1.87e-06	0.00018	-0.16	-0.15	Immature fraction of reticulocytes;	chr4:143997740	chr4:143911514~143912053:-
BRCA	cis	rs4835473	0.699	rs4835127	ENSG00000249741.2	RP11-673E1.3	-4.79	1.87e-06	0.00018	-0.16	-0.15	Immature fraction of reticulocytes;	chr4:143997972	chr4:143911514~143912053:-
BRCA	cis	rs7772486	0.754	rs4895682	ENSG00000270638.1	RP3-466P17.1	-4.79	1.87e-06	0.00018	-0.17	-0.15	Lobe attachment (rater-scored or self-reported);	chr6:145741725	chr6:145735570~145737218:+
BRCA	cis	rs4948275	0.773	rs3104842	ENSG00000237233.2	TMEM26-AS1	-4.79	1.87e-06	0.00018	-0.17	-0.15	Night sleep phenotypes;	chr10:61485229	chr10:61452639~61481956:+
BRCA	cis	rs728616	0.867	rs61860417	ENSG00000225484.5	NUTM2B-AS1	-4.79	1.87e-06	0.00018	-0.37	-0.15	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79974971	chr10:79663088~79826594:-
BRCA	cis	rs35740288	0.862	rs11637444	ENSG00000259407.1	RP11-158M2.3	-4.79	1.87e-06	0.00018	-0.2	-0.15	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85767957	chr15:85744109~85750281:-
BRCA	cis	rs7267979	0.844	rs6083845	ENSG00000274414.1	RP5-965G21.4	4.79	1.88e-06	0.00018	0.17	0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25407454	chr20:25239007~25245229:-
BRCA	cis	rs2115630	1	rs10220733	ENSG00000259295.5	CSPG4P12	-4.79	1.88e-06	0.00018	-0.17	-0.15	P wave terminal force;	chr15:84737633	chr15:85191438~85213905:+
BRCA	cis	rs7312933	0.531	rs2708059	ENSG00000257225.1	RP11-328C8.4	4.79	1.88e-06	0.00018	0.17	0.15	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42457206	chr12:42459366~42466128:+
BRCA	cis	rs8180040	0.966	rs1872164	ENSG00000271161.1	BOLA2P2	-4.79	1.88e-06	0.000181	-0.16	-0.15	Colorectal cancer;	chr3:47373610	chr3:47499841~47500407:+
BRCA	cis	rs7618915	0.547	rs34017441	ENSG00000243224.1	RP5-1157M23.2	-4.79	1.88e-06	0.000181	-0.16	-0.15	Bipolar disorder;	chr3:52708397	chr3:52239258~52241097:+
BRCA	cis	rs739496	0.579	rs57046217	ENSG00000226469.1	ADAM1B	4.79	1.88e-06	0.000181	0.19	0.15	Platelet count;	chr12:111847312	chr12:111927018~111929017:+
BRCA	cis	rs13113518	0.934	rs11133397	ENSG00000249700.7	SRD5A3-AS1	4.79	1.88e-06	0.000181	0.18	0.15	Height;	chr4:55534166	chr4:55363971~55395847:-
BRCA	cis	rs13113518	0.934	rs11133398	ENSG00000249700.7	SRD5A3-AS1	4.79	1.88e-06	0.000181	0.18	0.15	Height;	chr4:55534180	chr4:55363971~55395847:-
BRCA	cis	rs6490294	0.904	rs1016078	ENSG00000226469.1	ADAM1B	4.79	1.88e-06	0.000181	0.19	0.15	Mean platelet volume;	chr12:111972273	chr12:111927018~111929017:+
BRCA	cis	rs10129255	0.957	rs8019272	ENSG00000274576.2	IGHV2-70	4.79	1.88e-06	0.000181	0.13	0.15	Kawasaki disease;	chr14:106784709	chr14:106770577~106771020:-
BRCA	cis	rs4664293	0.867	rs1427329	ENSG00000226266.5	AC009961.3	-4.79	1.88e-06	0.000181	-0.18	-0.15	Monocyte percentage of white cells;	chr2:159748301	chr2:159670708~159712435:-
BRCA	cis	rs919433	0.519	rs700656	ENSG00000231621.1	AC013264.2	-4.79	1.88e-06	0.000181	-0.14	-0.15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197788943	chr2:197197991~197199273:+
BRCA	cis	rs10861342	0.786	rs11112386	ENSG00000257999.1	RP11-61E11.2	-4.79	1.88e-06	0.000181	-0.3	-0.15	IgG glycosylation;	chr12:105144980	chr12:105102472~105107179:-
BRCA	cis	rs12893668	0.603	rs12896171	ENSG00000269958.1	RP11-73M18.8	4.79	1.88e-06	0.000181	0.17	0.15	Reticulocyte count;	chr14:103669629	chr14:103696353~103697163:+
BRCA	cis	rs7976269	0.609	rs10771478	ENSG00000275476.1	RP11-996F15.4	4.79	1.88e-06	0.000181	0.17	0.15	Male-pattern baldness;	chr12:29075351	chr12:29277397~29277882:-
BRCA	cis	rs7577696	0.626	rs13431540	ENSG00000272716.1	RP11-563N4.1	4.79	1.88e-06	0.000181	0.16	0.15	Inflammatory biomarkers;	chr2:32109784	chr2:32165046~32165757:-
BRCA	cis	rs11976180	0.953	rs2951355	ENSG00000244479.5	OR2A1-AS1	4.79	1.89e-06	0.000181	0.2	0.15	Obesity-related traits;	chr7:144063469	chr7:144251264~144356181:-
BRCA	cis	rs11976180	1	rs2951354	ENSG00000244479.5	OR2A1-AS1	4.79	1.89e-06	0.000181	0.2	0.15	Obesity-related traits;	chr7:144063908	chr7:144251264~144356181:-
BRCA	cis	rs11976180	1	rs2961125	ENSG00000244479.5	OR2A1-AS1	4.79	1.89e-06	0.000181	0.2	0.15	Obesity-related traits;	chr7:144064677	chr7:144251264~144356181:-
BRCA	cis	rs11976180	1	rs2961126	ENSG00000244479.5	OR2A1-AS1	4.79	1.89e-06	0.000181	0.2	0.15	Obesity-related traits;	chr7:144065643	chr7:144251264~144356181:-
BRCA	cis	rs11976180	0.953	rs2961127	ENSG00000244479.5	OR2A1-AS1	4.79	1.89e-06	0.000181	0.2	0.15	Obesity-related traits;	chr7:144065644	chr7:144251264~144356181:-
BRCA	cis	rs11976180	1	rs1919948	ENSG00000244479.5	OR2A1-AS1	4.79	1.89e-06	0.000181	0.2	0.15	Obesity-related traits;	chr7:144065750	chr7:144251264~144356181:-
BRCA	cis	rs11976180	1	rs2961128	ENSG00000244479.5	OR2A1-AS1	4.79	1.89e-06	0.000181	0.2	0.15	Obesity-related traits;	chr7:144066390	chr7:144251264~144356181:-
BRCA	cis	rs11976180	1	rs2371248	ENSG00000244479.5	OR2A1-AS1	4.79	1.89e-06	0.000181	0.2	0.15	Obesity-related traits;	chr7:144067096	chr7:144251264~144356181:-
BRCA	cis	rs8180040	0.934	rs4858811	ENSG00000271161.1	BOLA2P2	-4.79	1.89e-06	0.000181	-0.16	-0.15	Colorectal cancer;	chr3:47439034	chr3:47499841~47500407:+
BRCA	cis	rs4415084	1	rs6871484	ENSG00000251141.4	RP11-53O19.1	4.79	1.89e-06	0.000181	0.14	0.15	Breast cancer;	chr5:44676203	chr5:44744900~44808777:-
BRCA	cis	rs62560775	0.688	rs3217986	ENSG00000265194.1	RP11-70L8.4	4.79	1.89e-06	0.000181	0.23	0.15	Lung cancer;Lung adenocarcinoma;	chr9:22005331	chr9:21858910~21861926:-
BRCA	cis	rs2243480	1	rs10807701	ENSG00000275400.1	RP4-756H11.5	-4.79	1.89e-06	0.000181	-0.26	-0.15	Diabetic kidney disease;	chr7:66259699	chr7:66553805~66554199:-
BRCA	cis	rs9341808	0.556	rs10455370	ENSG00000233967.5	RP11-250B2.3	-4.79	1.89e-06	0.000181	-0.15	-0.15	Sitting height ratio;	chr6:80331150	chr6:80443344~80465927:+
BRCA	cis	rs2243480	1	rs313824	ENSG00000275400.1	RP4-756H11.5	4.79	1.89e-06	0.000181	0.27	0.15	Diabetic kidney disease;	chr7:66116220	chr7:66553805~66554199:-
BRCA	cis	rs2243480	1	rs186378	ENSG00000275400.1	RP4-756H11.5	4.79	1.89e-06	0.000181	0.27	0.15	Diabetic kidney disease;	chr7:66117071	chr7:66553805~66554199:-
BRCA	cis	rs2243480	1	rs160637	ENSG00000275400.1	RP4-756H11.5	4.79	1.89e-06	0.000181	0.27	0.15	Diabetic kidney disease;	chr7:66119331	chr7:66553805~66554199:-
BRCA	cis	rs78487399	0.908	rs60868396	ENSG00000234936.1	AC010883.5	4.79	1.89e-06	0.000182	0.2	0.15	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43609738	chr2:43229573~43233394:+
BRCA	cis	rs1707322	0.721	rs11211181	ENSG00000234329.1	RP11-767N6.2	4.79	1.89e-06	0.000182	0.15	0.15	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45771128	chr1:45651039~45651826:-
BRCA	cis	rs2562456	0.833	rs516519	ENSG00000268658.4	LINC00664	-4.79	1.89e-06	0.000182	-0.23	-0.15	Pain;	chr19:21298730	chr19:21483374~21503238:+
BRCA	cis	rs1656368	0.726	rs16829104	ENSG00000279311.1	RP11-170K4.2	4.79	1.89e-06	0.000182	0.19	0.15	Lobe attachment (rater-scored or self-reported);	chr3:158540631	chr3:158869898~158871821:+
BRCA	cis	rs7200543	1	rs16966947	ENSG00000275910.1	RP11-680G24.6	-4.79	1.89e-06	0.000182	-0.17	-0.15	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15047188	chr16:15015828~15016390:-
BRCA	cis	rs11098499	0.954	rs4577559	ENSG00000250412.1	KLHL2P1	4.79	1.89e-06	0.000182	0.18	0.15	Corneal astigmatism;	chr4:119482888	chr4:119334329~119378233:+
BRCA	cis	rs11098499	0.954	rs7656252	ENSG00000250412.1	KLHL2P1	4.79	1.89e-06	0.000182	0.18	0.15	Corneal astigmatism;	chr4:119483113	chr4:119334329~119378233:+
BRCA	cis	rs11098499	0.865	rs28845498	ENSG00000250412.1	KLHL2P1	4.79	1.89e-06	0.000182	0.18	0.15	Corneal astigmatism;	chr4:119484031	chr4:119334329~119378233:+
BRCA	cis	rs11098499	0.954	rs56270433	ENSG00000250412.1	KLHL2P1	4.79	1.89e-06	0.000182	0.18	0.15	Corneal astigmatism;	chr4:119484875	chr4:119334329~119378233:+
BRCA	cis	rs4919687	0.55	rs17784294	ENSG00000213061.2	PFN1P11	4.79	1.89e-06	0.000182	0.2	0.15	Colorectal cancer;	chr10:102719628	chr10:102838011~102845473:-
BRCA	cis	rs2562456	0.917	rs6511256	ENSG00000268535.1	RP11-420K14.3	-4.79	1.89e-06	0.000182	-0.2	-0.15	Pain;	chr19:21510513	chr19:21709522~21710191:+
BRCA	cis	rs2286503	1	rs2286503	ENSG00000226329.2	AC005682.6	4.79	1.89e-06	0.000182	0.13	0.15	Fibrinogen;	chr7:22816987	chr7:22863874~22881350:-
BRCA	cis	rs12893668	0.572	rs4906356	ENSG00000269958.1	RP11-73M18.8	4.79	1.89e-06	0.000182	0.17	0.15	Reticulocyte count;	chr14:103672364	chr14:103696353~103697163:+
BRCA	cis	rs853679	0.55	rs1233707	ENSG00000216901.1	AL022393.7	4.79	1.89e-06	0.000182	0.2	0.15	Depression;	chr6:28205175	chr6:28176188~28176674:+
BRCA	cis	rs73193808	0.802	rs7281059	ENSG00000236056.1	GAPDHP14	-4.79	1.89e-06	0.000182	-0.21	-0.15	Coronary artery disease;	chr21:29216947	chr21:29222321~29223257:+
BRCA	cis	rs11638815	0.626	rs1367841	ENSG00000259429.4	UBE2Q2P2	4.79	1.89e-06	0.000182	0.14	0.15	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82641874	chr15:82355142~82420075:+
BRCA	cis	rs8180040	0.902	rs73081205	ENSG00000271161.1	BOLA2P2	-4.79	1.89e-06	0.000182	-0.16	-0.15	Colorectal cancer;	chr3:47476180	chr3:47499841~47500407:+
BRCA	cis	rs5751614	0.537	rs5759679	ENSG00000240160.3	RN7SL263P	4.79	1.89e-06	0.000182	0.19	0.15	Height;	chr22:23286826	chr22:23261782~23262071:-
BRCA	cis	rs2839186	0.934	rs17182538	ENSG00000228137.1	AP001469.7	4.79	1.89e-06	0.000182	0.15	0.15	Testicular germ cell tumor;	chr21:46285759	chr21:46246890~46247682:+
BRCA	cis	rs1729951	0.575	rs361242	ENSG00000239213.4	NCK1-AS1	4.79	1.89e-06	0.000182	0.15	0.15	Neuroticism;	chr3:136979488	chr3:136841726~136862054:-
BRCA	cis	rs2403083	0.697	rs2403084	ENSG00000258256.1	RP11-219B4.5	-4.79	1.89e-06	0.000182	-0.18	-0.15	Plasma amyloid beta peptide concentrations (ABx-40);	chr8:85199247	chr8:85222446~85245717:-
BRCA	cis	rs7818688	0.697	rs11778553	ENSG00000253528.2	RP11-347C18.4	-4.79	1.89e-06	0.000182	-0.22	-0.15	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94966032	chr8:94974573~94974853:-
BRCA	cis	rs1371614	0.635	rs12618836	ENSG00000272148.1	RP11-195B17.1	4.79	1.9e-06	0.000182	0.16	0.15	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26914748	chr2:27062428~27062907:-
BRCA	cis	rs7246657	0.722	rs8103647	ENSG00000226686.6	LINC01535	-4.79	1.9e-06	0.000182	-0.22	-0.15	Coronary artery calcification;	chr19:37609551	chr19:37251912~37265535:+
BRCA	cis	rs2489715	0.817	rs2801944	ENSG00000185904.10	LINC00839	-4.79	1.9e-06	0.000182	-0.2	-0.15	Helix rolling;	chr10:42452982	chr10:42475543~42495336:+
BRCA	cis	rs4950322	0.57	rs4593887	ENSG00000278811.3	LINC00624	4.79	1.9e-06	0.000182	0.19	0.15	Protein quantitative trait loci;	chr1:147234246	chr1:147258885~147517875:-
BRCA	cis	rs7119	0.717	rs62007348	ENSG00000259362.2	RP11-307C19.1	-4.79	1.9e-06	0.000182	-0.21	-0.15	Type 2 diabetes;	chr15:77512159	chr15:77525540~77534110:+
BRCA	cis	rs2638953	0.672	rs11049715	ENSG00000247934.4	RP11-967K21.1	-4.79	1.9e-06	0.000182	-0.2	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28561520	chr12:28163298~28190738:-
BRCA	cis	rs1161098	0.716	rs1732627	ENSG00000256037.1	MRPL40P1	-4.79	1.9e-06	0.000182	-0.24	-0.15	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr12:67449083	chr12:67351436~67352039:+
BRCA	cis	rs10833905	1	rs5005787	ENSG00000246225.5	RP11-17A1.3	-4.79	1.9e-06	0.000182	-0.21	-0.15	Sudden cardiac arrest;	chr11:23022940	chr11:22829380~22945393:+
BRCA	cis	rs4218	0.597	rs12438962	ENSG00000277144.1	RP11-59H7.4	-4.79	1.9e-06	0.000182	-0.2	-0.15	Social communication problems;	chr15:59065694	chr15:59115547~59116089:-
BRCA	cis	rs442309	0.871	rs224043	ENSG00000238280.1	RP11-436D10.3	-4.79	1.9e-06	0.000182	-0.19	-0.15	Vogt-Koyanagi-Harada syndrome;	chr10:62765232	chr10:62793562~62805887:-
BRCA	cis	rs875971	0.862	rs778720	ENSG00000236529.1	RP13-254B10.1	-4.79	1.9e-06	0.000183	-0.16	-0.15	Aortic root size;	chr7:66381288	chr7:65840212~65840596:+
BRCA	cis	rs256438	0.602	rs10042207	ENSG00000251050.1	RP11-168A11.4	-4.79	1.9e-06	0.000183	-0.2	-0.15	Serum thyroid-stimulating hormone levels;	chr5:80064712	chr5:80019609~80019920:+
BRCA	cis	rs10129255	0.957	rs10141052	ENSG00000274576.2	IGHV2-70	4.79	1.9e-06	0.000183	0.13	0.15	Kawasaki disease;	chr14:106776528	chr14:106770577~106771020:-
BRCA	cis	rs6125597	0.967	rs6067025	ENSG00000222365.1	SNORD12B	4.79	1.9e-06	0.000183	0.15	0.15	Intelligence (multi-trait analysis);	chr20:49237483	chr20:49280319~49280409:+
BRCA	cis	rs853679	0.527	rs9461443	ENSG00000219392.1	RP1-265C24.5	-4.79	1.91e-06	0.000183	-0.22	-0.15	Depression;	chr6:28226851	chr6:28115628~28116551:+
BRCA	cis	rs4218	0.597	rs62002543	ENSG00000277144.1	RP11-59H7.4	-4.79	1.91e-06	0.000183	-0.2	-0.15	Social communication problems;	chr15:59066646	chr15:59115547~59116089:-
BRCA	cis	rs6012564	0.788	rs6095404	ENSG00000222365.1	SNORD12B	4.79	1.91e-06	0.000183	0.15	0.15	Anger;	chr20:49040144	chr20:49280319~49280409:+
BRCA	cis	rs10504130	1	rs118116154	ENSG00000253844.1	RP11-546K22.1	-4.79	1.91e-06	0.000183	-0.25	-0.15	Venous thromboembolism (SNP x SNP interaction);	chr8:51833124	chr8:51961458~52022974:+
BRCA	cis	rs890448	0.726	rs2850368	ENSG00000254531.1	FLJ20021	-4.79	1.91e-06	0.000183	-0.17	-0.15	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101311472	chr4:101347780~101348883:+
BRCA	cis	rs6714710	0.603	rs2044458	ENSG00000230606.9	AC159540.1	-4.79	1.91e-06	0.000183	-0.17	-0.15	Posterior cortical atrophy and Alzheimer's disease;	chr2:97761049	chr2:97416165~97433527:-
BRCA	cis	rs2243480	0.708	rs35825036	ENSG00000222364.1	RNU6-96P	-4.79	1.91e-06	0.000183	-0.27	-0.15	Diabetic kidney disease;	chr7:66521515	chr7:66395191~66395286:+
BRCA	cis	rs2243480	1	rs13237037	ENSG00000222364.1	RNU6-96P	-4.79	1.91e-06	0.000183	-0.27	-0.15	Diabetic kidney disease;	chr7:66532895	chr7:66395191~66395286:+
BRCA	cis	rs2243480	1	rs1796228	ENSG00000222364.1	RNU6-96P	-4.79	1.91e-06	0.000183	-0.27	-0.15	Diabetic kidney disease;	chr7:66568097	chr7:66395191~66395286:+
BRCA	cis	rs4266144	0.569	rs729257	ENSG00000241770.1	RP11-555M1.3	-4.79	1.91e-06	0.000183	-0.19	-0.15	Coronary artery disease;	chr3:157111034	chr3:157163452~157169133:+
BRCA	cis	rs10833905	1	rs12279454	ENSG00000246225.5	RP11-17A1.3	-4.79	1.91e-06	0.000183	-0.21	-0.15	Sudden cardiac arrest;	chr11:23020769	chr11:22829380~22945393:+
BRCA	cis	rs7674212	0.539	rs6533056	ENSG00000251288.2	RP11-10L12.2	-4.79	1.91e-06	0.000183	-0.17	-0.15	Type 2 diabetes;	chr4:103199840	chr4:102751401~102752641:+
BRCA	cis	rs7618915	0.547	rs11719685	ENSG00000243224.1	RP5-1157M23.2	-4.79	1.91e-06	0.000183	-0.17	-0.15	Bipolar disorder;	chr3:52642049	chr3:52239258~52241097:+
BRCA	cis	rs2562456	0.876	rs7252585	ENSG00000268535.1	RP11-420K14.3	-4.79	1.91e-06	0.000183	-0.19	-0.15	Pain;	chr19:21475141	chr19:21709522~21710191:+
BRCA	cis	rs13113518	0.934	rs11935823	ENSG00000223305.1	RN7SKP30	4.79	1.91e-06	0.000184	0.18	0.15	Height;	chr4:55589624	chr4:55540502~55540835:-
BRCA	cis	rs7572733	0.576	rs1865586	ENSG00000231621.1	AC013264.2	4.79	1.91e-06	0.000184	0.14	0.15	Dermatomyositis;	chr2:197894144	chr2:197197991~197199273:+
BRCA	cis	rs7918232	0.83	rs7915902	ENSG00000262412.1	RP11-85G18.6	4.79	1.91e-06	0.000184	0.24	0.15	Breast cancer;	chr10:27121805	chr10:27243130~27250804:+
BRCA	cis	rs7918232	0.941	rs10741128	ENSG00000262412.1	RP11-85G18.6	4.79	1.91e-06	0.000184	0.24	0.15	Breast cancer;	chr10:27122580	chr10:27243130~27250804:+
BRCA	cis	rs7918232	0.941	rs6482598	ENSG00000262412.1	RP11-85G18.6	4.79	1.91e-06	0.000184	0.24	0.15	Breast cancer;	chr10:27137446	chr10:27243130~27250804:+
BRCA	cis	rs7918232	0.941	rs10829195	ENSG00000262412.1	RP11-85G18.6	4.79	1.91e-06	0.000184	0.24	0.15	Breast cancer;	chr10:27142635	chr10:27243130~27250804:+
BRCA	cis	rs7918232	0.83	rs7911024	ENSG00000262412.1	RP11-85G18.6	4.79	1.91e-06	0.000184	0.24	0.15	Breast cancer;	chr10:27144707	chr10:27243130~27250804:+
BRCA	cis	rs7618915	0.621	rs6788993	ENSG00000243224.1	RP5-1157M23.2	-4.79	1.91e-06	0.000184	-0.16	-0.15	Bipolar disorder;	chr3:52571120	chr3:52239258~52241097:+
BRCA	cis	rs2833693	0.615	rs9974274	ENSG00000261610.1	AP000265.1	4.79	1.92e-06	0.000184	0.18	0.15	Temperament;	chr21:32196563	chr21:32259804~32261585:-
BRCA	cis	rs950169	0.58	rs2271431	ENSG00000176700.18	SCAND2P	-4.79	1.92e-06	0.000184	-0.15	-0.15	Schizophrenia;	chr15:84646233	chr15:84631451~84647478:+
BRCA	cis	rs718433	0.616	rs10438000	ENSG00000256379.1	TRAV8-5	4.79	1.92e-06	0.000184	0.18	0.15	Intraocular pressure;	chr14:21741707	chr14:21903077~21903598:+
BRCA	cis	rs11239930	0.538	rs17160592	ENSG00000278811.3	LINC00624	4.79	1.92e-06	0.000184	0.18	0.15	AIDS progression;	chr1:147083644	chr1:147258885~147517875:-
BRCA	cis	rs11239930	0.538	rs56060937	ENSG00000278811.3	LINC00624	4.79	1.92e-06	0.000184	0.18	0.15	AIDS progression;	chr1:147083854	chr1:147258885~147517875:-
BRCA	cis	rs2562456	0.917	rs2681377	ENSG00000268535.1	RP11-420K14.3	-4.79	1.92e-06	0.000184	-0.2	-0.15	Pain;	chr19:21533718	chr19:21709522~21710191:+
BRCA	cis	rs11098499	0.738	rs34566984	ENSG00000260091.1	RP11-33B1.4	-4.79	1.92e-06	0.000184	-0.13	-0.15	Corneal astigmatism;	chr4:119440115	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.954	rs9685777	ENSG00000260091.1	RP11-33B1.4	-4.79	1.92e-06	0.000184	-0.13	-0.15	Corneal astigmatism;	chr4:119444810	chr4:119409333~119410233:+
BRCA	cis	rs7829975	0.688	rs6601703	ENSG00000253981.4	ALG1L13P	4.79	1.92e-06	0.000184	0.17	0.15	Mood instability;	chr8:8522714	chr8:8236003~8244667:-
BRCA	cis	rs4356203	0.905	rs214937	ENSG00000272034.1	SNORD14A	4.79	1.92e-06	0.000184	0.15	0.15	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17168005	chr11:17074654~17074744:-
BRCA	cis	rs13326165	0.585	rs17052053	ENSG00000243224.1	RP5-1157M23.2	-4.79	1.92e-06	0.000184	-0.23	-0.15	HDL cholesterol levels;HDL cholesterol;	chr3:52300577	chr3:52239258~52241097:+
BRCA	cis	rs1707322	0.964	rs7512395	ENSG00000234329.1	RP11-767N6.2	4.79	1.92e-06	0.000184	0.15	0.15	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45895505	chr1:45651039~45651826:-
BRCA	cis	rs11673344	0.504	rs4239587	ENSG00000226686.6	LINC01535	4.79	1.92e-06	0.000184	0.18	0.15	Obesity-related traits;	chr19:37136211	chr19:37251912~37265535:+
BRCA	cis	rs7481584	0.517	rs80872	ENSG00000247473.2	CARS-AS1	-4.79	1.92e-06	0.000184	-0.18	-0.15	Calcium levels;	chr11:3028754	chr11:3029009~3041260:+
BRCA	cis	rs9341808	0.519	rs607130	ENSG00000233967.5	RP11-250B2.3	-4.79	1.92e-06	0.000185	-0.15	-0.15	Sitting height ratio;	chr6:80289516	chr6:80443344~80465927:+
BRCA	cis	rs853679	0.55	rs1225598	ENSG00000216901.1	AL022393.7	4.79	1.92e-06	0.000185	0.2	0.15	Depression;	chr6:28193021	chr6:28176188~28176674:+
BRCA	cis	rs4218	0.681	rs58335303	ENSG00000259732.1	RP11-59H7.3	-4.79	1.92e-06	0.000185	-0.18	-0.15	Social communication problems;	chr15:59073206	chr15:59121034~59133250:+
BRCA	cis	rs2732480	0.5	rs11168468	ENSG00000257735.1	RP11-370I10.6	4.79	1.92e-06	0.000185	0.18	0.15	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48218682	chr12:48350945~48442411:+
BRCA	cis	rs5758659	0.714	rs133373	ENSG00000273366.1	CTA-989H11.1	-4.79	1.92e-06	0.000185	-0.17	-0.15	Cognitive function;	chr22:42069784	chr22:42278188~42278846:+
BRCA	cis	rs7226408	0.948	rs72883565	ENSG00000267707.2	RP11-95O2.5	4.79	1.93e-06	0.000185	0.24	0.15	Obesity-related traits;	chr18:36800185	chr18:37243776~37247506:+
BRCA	cis	rs7772486	0.754	rs9497401	ENSG00000270638.1	RP3-466P17.1	-4.79	1.93e-06	0.000185	-0.17	-0.15	Lobe attachment (rater-scored or self-reported);	chr6:145730135	chr6:145735570~145737218:+
BRCA	cis	rs7772486	0.754	rs1055212	ENSG00000270638.1	RP3-466P17.1	-4.79	1.93e-06	0.000185	-0.17	-0.15	Lobe attachment (rater-scored or self-reported);	chr6:145737179	chr6:145735570~145737218:+
BRCA	cis	rs4948275	0.743	rs2787735	ENSG00000237233.2	TMEM26-AS1	-4.79	1.93e-06	0.000185	-0.17	-0.15	Night sleep phenotypes;	chr10:61490277	chr10:61452639~61481956:+
BRCA	cis	rs4948275	0.743	rs2650736	ENSG00000237233.2	TMEM26-AS1	-4.79	1.93e-06	0.000185	-0.17	-0.15	Night sleep phenotypes;	chr10:61490280	chr10:61452639~61481956:+
BRCA	cis	rs6081541	0.689	rs723768	ENSG00000179447.2	RP5-1027G4.3	-4.79	1.93e-06	0.000185	-0.18	-0.15	Psychosis (atypical);	chr20:19234998	chr20:19242302~19284596:-
BRCA	cis	rs703842	0.928	rs724834	ENSG00000270039.1	RP11-571M6.17	-4.79	1.93e-06	0.000185	-0.21	-0.15	Multiple sclerosis;	chr12:57786633	chr12:57803838~57804415:+
BRCA	cis	rs807029	0.533	rs3824783	ENSG00000236662.1	RP11-108L7.4	4.79	1.93e-06	0.000185	0.18	0.15	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100991094	chr10:100980507~100985614:-
BRCA	cis	rs17684571	0.637	rs35566812	ENSG00000231441.1	RP11-472M19.2	4.79	1.93e-06	0.000185	0.23	0.15	Schizophrenia;	chr6:56792077	chr6:56844002~56864078:+
BRCA	cis	rs17684571	0.7	rs62411375	ENSG00000231441.1	RP11-472M19.2	4.79	1.93e-06	0.000185	0.23	0.15	Schizophrenia;	chr6:56794361	chr6:56844002~56864078:+
BRCA	cis	rs17684571	0.7	rs13220851	ENSG00000231441.1	RP11-472M19.2	4.79	1.93e-06	0.000185	0.23	0.15	Schizophrenia;	chr6:56796753	chr6:56844002~56864078:+
BRCA	cis	rs17684571	0.7	rs59432342	ENSG00000231441.1	RP11-472M19.2	4.79	1.93e-06	0.000185	0.23	0.15	Schizophrenia;	chr6:56797506	chr6:56844002~56864078:+
BRCA	cis	rs7267979	1	rs2500404	ENSG00000276952.1	RP5-965G21.6	-4.79	1.93e-06	0.000185	-0.18	-0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25379122	chr20:25284915~25285588:-
BRCA	cis	rs7267979	1	rs2500405	ENSG00000276952.1	RP5-965G21.6	-4.79	1.93e-06	0.000185	-0.18	-0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25380190	chr20:25284915~25285588:-
BRCA	cis	rs7267979	1	rs2482941	ENSG00000276952.1	RP5-965G21.6	-4.79	1.93e-06	0.000185	-0.18	-0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25380580	chr20:25284915~25285588:-
BRCA	cis	rs7267979	0.903	rs2500423	ENSG00000276952.1	RP5-965G21.6	-4.79	1.93e-06	0.000185	-0.18	-0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25394246	chr20:25284915~25285588:-
BRCA	cis	rs1867631	1	rs10889636	ENSG00000248458.2	RP4-598P13.1	-4.79	1.93e-06	0.000185	-0.15	-0.15	Menopause (age at onset);	chr1:66624241	chr1:66665864~66677027:-
BRCA	cis	rs9543976	0.545	rs2328963	ENSG00000261105.4	LMO7-AS1	4.79	1.93e-06	0.000185	0.22	0.15	Diabetic retinopathy;	chr13:75601390	chr13:75604700~75635994:-
BRCA	cis	rs11758351	1	rs76722536	ENSG00000241549.7	GUSBP2	-4.79	1.93e-06	0.000185	-0.22	-0.15	Renal underexcretion gout;Gout;	chr6:26192718	chr6:26871484~26956554:-
BRCA	cis	rs1371614	0.513	rs13010712	ENSG00000272148.1	RP11-195B17.1	-4.79	1.93e-06	0.000185	-0.17	-0.15	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26864841	chr2:27062428~27062907:-
BRCA	cis	rs2562456	0.52	rs25760	ENSG00000268535.1	RP11-420K14.3	4.79	1.93e-06	0.000185	0.22	0.15	Pain;	chr19:21211375	chr19:21709522~21710191:+
BRCA	cis	rs13326165	0.585	rs11706541	ENSG00000243224.1	RP5-1157M23.2	-4.79	1.93e-06	0.000185	-0.24	-0.15	HDL cholesterol levels;HDL cholesterol;	chr3:52252333	chr3:52239258~52241097:+
BRCA	cis	rs13326165	0.585	rs1767	ENSG00000243224.1	RP5-1157M23.2	-4.79	1.93e-06	0.000185	-0.24	-0.15	HDL cholesterol levels;HDL cholesterol;	chr3:52256458	chr3:52239258~52241097:+
BRCA	cis	rs12744310	0.887	rs12757611	ENSG00000235358.1	RP11-399E6.1	4.79	1.93e-06	0.000185	0.22	0.15	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41343300	chr1:41242373~41284861:+
BRCA	cis	rs10833905	1	rs1426849	ENSG00000246225.5	RP11-17A1.3	-4.79	1.93e-06	0.000185	-0.2	-0.15	Sudden cardiac arrest;	chr11:23026393	chr11:22829380~22945393:+
BRCA	cis	rs11098499	0.954	rs11098525	ENSG00000260091.1	RP11-33B1.4	-4.79	1.93e-06	0.000185	-0.13	-0.15	Corneal astigmatism;	chr4:119468997	chr4:119409333~119410233:+
BRCA	cis	rs1669338	0.588	rs7629889	ENSG00000271870.1	RP11-97C16.1	4.79	1.93e-06	0.000185	0.18	0.15	White matter integrity;	chr3:3145959	chr3:3152942~3153435:+
BRCA	cis	rs7674212	0.57	rs6841136	ENSG00000251288.2	RP11-10L12.2	-4.79	1.93e-06	0.000185	-0.17	-0.15	Type 2 diabetes;	chr4:103182352	chr4:102751401~102752641:+
BRCA	cis	rs12439619	0.693	rs4778989	ENSG00000255769.6	GOLGA2P10	-4.79	1.93e-06	0.000185	-0.2	-0.15	Intelligence (multi-trait analysis);	chr15:82276963	chr15:82472993~82513950:-
BRCA	cis	rs4356203	0.87	rs214921	ENSG00000272034.1	SNORD14A	-4.79	1.93e-06	0.000185	-0.15	-0.15	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17215914	chr11:17074654~17074744:-
BRCA	cis	rs4578769	0.76	rs7227956	ENSG00000265939.1	UBE2CP2	4.79	1.93e-06	0.000185	0.17	0.15	Eosinophil percentage of white cells;	chr18:22933855	chr18:22900486~22900995:-
BRCA	cis	rs4908760	0.965	rs10864356	ENSG00000232912.4	RP5-1115A15.1	4.79	1.93e-06	0.000185	0.14	0.15	Vitiligo;	chr1:8509812	chr1:8424645~8434838:+
BRCA	cis	rs4908768	0.501	rs11121194	ENSG00000232912.4	RP5-1115A15.1	4.79	1.93e-06	0.000185	0.14	0.15	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8509847	chr1:8424645~8434838:+
BRCA	cis	rs1656368	0.726	rs73154326	ENSG00000279311.1	RP11-170K4.2	4.79	1.93e-06	0.000185	0.19	0.15	Lobe attachment (rater-scored or self-reported);	chr3:158537017	chr3:158869898~158871821:+
BRCA	cis	rs11096990	0.593	rs1026235	ENSG00000249685.1	RP11-360F5.3	4.79	1.94e-06	0.000186	0.19	0.15	Cognitive function;	chr4:39226629	chr4:39133913~39135608:+
BRCA	cis	rs11758351	1	rs11758351	ENSG00000241549.7	GUSBP2	-4.79	1.94e-06	0.000186	-0.21	-0.15	Renal underexcretion gout;Gout;	chr6:26203682	chr6:26871484~26956554:-
BRCA	cis	rs4699052	0.626	rs10017383	ENSG00000248740.4	RP11-328K4.1	4.79	1.94e-06	0.000186	0.16	0.15	Testicular germ cell tumor;	chr4:103328800	chr4:103256159~103453658:+
BRCA	cis	rs11239930	0.538	rs59064267	ENSG00000230832.3	RP11-325P15.2	-4.79	1.94e-06	0.000186	-0.21	-0.15	AIDS progression;	chr1:147089146	chr1:147082338~147083578:-
BRCA	cis	rs792448	0.743	rs1774249	ENSG00000226251.4	RP11-15I11.3	-4.79	1.94e-06	0.000186	-0.19	-0.15	White blood cell count (basophil);	chr1:212342271	chr1:212225278~212238977:-
BRCA	cis	rs1876905	0.597	rs354538	ENSG00000230177.1	RP5-1112D6.4	-4.79	1.94e-06	0.000186	-0.21	-0.15	Mean corpuscular hemoglobin;	chr6:111196863	chr6:111277932~111278742:+
BRCA	cis	rs7481584	0.646	rs434114	ENSG00000247473.2	CARS-AS1	-4.79	1.94e-06	0.000186	-0.18	-0.15	Calcium levels;	chr11:3028980	chr11:3029009~3041260:+
BRCA	cis	rs7481584	0.624	rs511990	ENSG00000247473.2	CARS-AS1	-4.79	1.94e-06	0.000186	-0.18	-0.15	Calcium levels;	chr11:3031706	chr11:3029009~3041260:+
BRCA	cis	rs7481584	0.581	rs366422	ENSG00000247473.2	CARS-AS1	-4.79	1.94e-06	0.000186	-0.18	-0.15	Calcium levels;	chr11:3032643	chr11:3029009~3041260:+
BRCA	cis	rs6430538	0.671	rs6740829	ENSG00000224043.6	CCNT2-AS1	-4.79	1.94e-06	0.000186	-0.2	-0.15	Parkinson's disease;	chr2:134815694	chr2:134735464~134918710:-
BRCA	cis	rs1124769	0.619	rs8182062	ENSG00000259378.1	DCAF13P3	4.79	1.94e-06	0.000186	0.19	0.15	Cognitive performance;	chr15:50962305	chr15:50944663~50945996:+
BRCA	cis	rs3845817	1	rs3911863	ENSG00000237979.1	AC007389.1	-4.79	1.94e-06	0.000186	-0.17	-0.15	Bipolar disorder;	chr2:65532630	chr2:65500993~65502138:-
BRCA	cis	rs3845817	0.966	rs3845818	ENSG00000237979.1	AC007389.1	-4.79	1.94e-06	0.000186	-0.17	-0.15	Bipolar disorder;	chr2:65533349	chr2:65500993~65502138:-
BRCA	cis	rs9818758	0.607	rs9311439	ENSG00000270441.1	RP11-694I15.7	4.79	1.94e-06	0.000186	0.28	0.15	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49272975	chr3:49140086~49160851:-
BRCA	cis	rs1440410	0.83	rs6816223	ENSG00000250326.1	RP11-284M14.1	-4.79	1.94e-06	0.000186	-0.16	-0.15	Ischemic stroke;	chr4:143260558	chr4:142933195~143184861:-
BRCA	cis	rs1440410	0.83	rs6832943	ENSG00000250326.1	RP11-284M14.1	-4.79	1.94e-06	0.000186	-0.16	-0.15	Ischemic stroke;	chr4:143260564	chr4:142933195~143184861:-
BRCA	cis	rs9291683	0.575	rs3756223	ENSG00000250413.1	RP11-448G15.1	-4.79	1.94e-06	0.000186	-0.19	-0.15	Bone mineral density;	chr4:10104173	chr4:10006482~10009725:+
BRCA	cis	rs13326165	0.585	rs114645176	ENSG00000243224.1	RP5-1157M23.2	-4.79	1.94e-06	0.000186	-0.24	-0.15	HDL cholesterol levels;HDL cholesterol;	chr3:52245935	chr3:52239258~52241097:+
BRCA	cis	rs13108904	0.875	rs1564509	ENSG00000253399.1	AC078852.2	-4.79	1.94e-06	0.000186	-0.16	-0.15	Obesity-related traits;	chr4:1242774	chr4:1358479~1359461:+
BRCA	cis	rs6570726	0.837	rs636894	ENSG00000270638.1	RP3-466P17.1	4.79	1.94e-06	0.000186	0.16	0.15	Lobe attachment (rater-scored or self-reported);	chr6:145542986	chr6:145735570~145737218:+
BRCA	cis	rs6570726	0.526	rs9376934	ENSG00000235652.6	RP11-545I5.3	4.79	1.94e-06	0.000186	0.14	0.15	Lobe attachment (rater-scored or self-reported);	chr6:145417566	chr6:145799409~145886585:+
BRCA	cis	rs2243480	1	rs2420171	ENSG00000222364.1	RNU6-96P	4.79	1.94e-06	0.000186	0.27	0.15	Diabetic kidney disease;	chr7:66172773	chr7:66395191~66395286:+
BRCA	cis	rs9818758	0.607	rs67831908	ENSG00000270441.1	RP11-694I15.7	4.79	1.94e-06	0.000186	0.29	0.15	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49276080	chr3:49140086~49160851:-
BRCA	cis	rs2041840	0.686	rs2110965	ENSG00000272054.1	RP11-423P10.2	-4.79	1.94e-06	0.000186	-0.13	-0.15	Chronic lymphocytic leukemia;	chr2:37245661	chr2:37208875~37212677:+
BRCA	cis	rs4660214	0.666	rs4660550	ENSG00000237624.1	OXCT2P1	-4.79	1.94e-06	0.000186	-0.18	-0.15	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39222787	chr1:39514956~39516490:+
BRCA	cis	rs2115630	0.905	rs1975277	ENSG00000259728.4	LINC00933	-4.79	1.94e-06	0.000186	-0.17	-0.15	P wave terminal force;	chr15:84786327	chr15:84570649~84580175:+
BRCA	cis	rs4948275	0.773	rs2650710	ENSG00000237233.2	TMEM26-AS1	-4.79	1.94e-06	0.000186	-0.17	-0.15	Night sleep phenotypes;	chr10:61483455	chr10:61452639~61481956:+
BRCA	cis	rs559555	0.568	rs546935	ENSG00000272716.1	RP11-563N4.1	4.79	1.94e-06	0.000186	0.17	0.15	Blood metabolite ratios;Blood metabolite levels;	chr2:31628605	chr2:32165046~32165757:-
BRCA	cis	rs1979679	0.918	rs10771427	ENSG00000278733.1	RP11-425D17.1	4.79	1.94e-06	0.000186	0.19	0.15	Ossification of the posterior longitudinal ligament of the spine;	chr12:28452493	chr12:28185625~28186190:-
BRCA	cis	rs9287719	0.935	rs61424402	ENSG00000243819.4	RN7SL832P	4.79	1.94e-06	0.000186	0.14	0.15	Prostate cancer;	chr2:10618245	chr2:10690344~10692099:+
BRCA	cis	rs6921919	0.583	rs740622	ENSG00000220721.1	OR1F12	4.79	1.94e-06	0.000186	0.18	0.15	Autism spectrum disorder or schizophrenia;	chr6:28430514	chr6:28073316~28074233:+
BRCA	cis	rs7487075	0.578	rs4768119	ENSG00000274723.1	RP11-618L22.1	4.79	1.94e-06	0.000186	0.2	0.15	Itch intensity from mosquito bite;	chr12:46414119	chr12:46970504~46972155:+
BRCA	cis	rs7487075	0.578	rs4258438	ENSG00000274723.1	RP11-618L22.1	4.79	1.94e-06	0.000186	0.2	0.15	Itch intensity from mosquito bite;	chr12:46415343	chr12:46970504~46972155:+
BRCA	cis	rs875971	0.545	rs10950025	ENSG00000230295.1	RP11-458F8.2	4.79	1.94e-06	0.000186	0.14	0.15	Aortic root size;	chr7:66158946	chr7:66880708~66882981:+
BRCA	cis	rs875971	0.52	rs12666485	ENSG00000230295.1	RP11-458F8.2	4.79	1.94e-06	0.000186	0.14	0.15	Aortic root size;	chr7:66160135	chr7:66880708~66882981:+
BRCA	cis	rs875971	0.545	rs67688847	ENSG00000230295.1	RP11-458F8.2	4.79	1.94e-06	0.000186	0.14	0.15	Aortic root size;	chr7:66161064	chr7:66880708~66882981:+
BRCA	cis	rs755249	0.51	rs582883	ENSG00000237624.1	OXCT2P1	4.79	1.95e-06	0.000186	0.18	0.15	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39369868	chr1:39514956~39516490:+
BRCA	cis	rs9595908	0.931	rs9595630	ENSG00000281026.1	N4BP2L2-IT2	4.79	1.95e-06	0.000187	0.13	0.15	Body mass index;	chr13:32491306	chr13:32504506~32509395:-
BRCA	cis	rs28472312	0.894	rs7498491	ENSG00000278665.1	RP11-666O2.4	4.79	1.95e-06	0.000187	0.17	0.15	Intelligence (multi-trait analysis);	chr16:28832747	chr16:28599241~28601881:-
BRCA	cis	rs11239930	0.538	rs9663073	ENSG00000230832.3	RP11-325P15.2	-4.79	1.95e-06	0.000187	-0.21	-0.15	AIDS progression;	chr1:147083022	chr1:147082338~147083578:-
BRCA	cis	rs7267979	0.668	rs4815398	ENSG00000277938.1	RP5-965G21.3	-4.79	1.95e-06	0.000187	-0.18	-0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25256702	chr20:25229150~25231933:+
BRCA	cis	rs853679	0.824	rs34712084	ENSG00000280107.1	AL022393.9	-4.79	1.95e-06	0.000187	-0.31	-0.15	Depression;	chr6:28076050	chr6:28170845~28172521:+
BRCA	cis	rs853679	0.824	rs1321505	ENSG00000280107.1	AL022393.9	-4.79	1.95e-06	0.000187	-0.31	-0.15	Depression;	chr6:28085045	chr6:28170845~28172521:+
BRCA	cis	rs9840812	0.861	rs645040	ENSG00000239213.4	NCK1-AS1	-4.79	1.95e-06	0.000187	-0.18	-0.15	Fibrinogen levels;	chr3:136207780	chr3:136841726~136862054:-
BRCA	cis	rs9990333	0.687	rs62285383	ENSG00000242086.7	LINC00969	4.79	1.95e-06	0.000187	0.16	0.15	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196087052	chr3:195658062~195739964:+
BRCA	cis	rs11051970	0.918	rs73084101	ENSG00000274964.1	RP11-817I4.1	-4.79	1.95e-06	0.000187	-0.19	-0.15	Response to tocilizumab in rheumatoid arthritis;	chr12:32391405	chr12:32339368~32340724:+
BRCA	cis	rs987724	0.57	rs4680318	ENSG00000240875.4	LINC00886	-4.79	1.95e-06	0.000187	-0.23	-0.15	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156953850	chr3:156747346~156817062:-
BRCA	cis	rs987724	0.515	rs4234315	ENSG00000240875.4	LINC00886	-4.79	1.95e-06	0.000187	-0.23	-0.15	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156955749	chr3:156747346~156817062:-
BRCA	cis	rs739496	0.579	rs75080921	ENSG00000226469.1	ADAM1B	4.79	1.95e-06	0.000187	0.19	0.15	Platelet count;	chr12:111861168	chr12:111927018~111929017:+
BRCA	cis	rs4713118	0.513	rs9368547	ENSG00000219392.1	RP1-265C24.5	-4.79	1.95e-06	0.000187	-0.2	-0.15	Parkinson's disease;	chr6:28060289	chr6:28115628~28116551:+
BRCA	cis	rs4713118	0.513	rs183244	ENSG00000219392.1	RP1-265C24.5	-4.79	1.95e-06	0.000187	-0.2	-0.15	Parkinson's disease;	chr6:28064060	chr6:28115628~28116551:+
BRCA	cis	rs78487399	0.908	rs12471904	ENSG00000234936.1	AC010883.5	4.79	1.95e-06	0.000187	0.22	0.15	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43613534	chr2:43229573~43233394:+
BRCA	cis	rs6545883	0.794	rs12053388	ENSG00000270820.4	RP11-355B11.2	-4.79	1.95e-06	0.000187	-0.17	-0.15	Tuberculosis;	chr2:61305185	chr2:61471188~61484130:+
BRCA	cis	rs57221529	0.713	rs56328416	ENSG00000271781.1	CTD-2589H19.6	-4.79	1.95e-06	0.000187	-0.22	-0.15	Lung disease severity in cystic fibrosis;	chr5:591023	chr5:675826~676616:+
BRCA	cis	rs6545883	0.868	rs28749199	ENSG00000270820.4	RP11-355B11.2	4.79	1.95e-06	0.000187	0.17	0.15	Tuberculosis;	chr2:61599917	chr2:61471188~61484130:+
BRCA	cis	rs7674212	0.539	rs6815783	ENSG00000251288.2	RP11-10L12.2	-4.79	1.95e-06	0.000187	-0.17	-0.15	Type 2 diabetes;	chr4:103200989	chr4:102751401~102752641:+
BRCA	cis	rs991427	1	rs11105974	ENSG00000258100.1	RP11-121E16.1	-4.79	1.95e-06	0.000187	-0.2	-0.15	Systolic blood pressure (alcohol consumption interaction);	chr12:91082704	chr12:91362196~91368606:+
BRCA	cis	rs991427	1	rs10859106	ENSG00000258100.1	RP11-121E16.1	-4.79	1.95e-06	0.000187	-0.2	-0.15	Systolic blood pressure (alcohol consumption interaction);	chr12:91082791	chr12:91362196~91368606:+
BRCA	cis	rs991427	1	rs4423247	ENSG00000258100.1	RP11-121E16.1	-4.79	1.95e-06	0.000187	-0.2	-0.15	Systolic blood pressure (alcohol consumption interaction);	chr12:91083098	chr12:91362196~91368606:+
BRCA	cis	rs991427	0.73	rs4494364	ENSG00000258100.1	RP11-121E16.1	-4.79	1.95e-06	0.000187	-0.2	-0.15	Systolic blood pressure (alcohol consumption interaction);	chr12:91083337	chr12:91362196~91368606:+
BRCA	cis	rs17213965	0.561	rs9929598	ENSG00000260872.1	RP11-680G24.5	-4.79	1.95e-06	0.000187	-0.17	-0.15	Waist-hip ratio;	chr16:15786153	chr16:15018106~15020488:-
BRCA	cis	rs7267979	0.899	rs6115213	ENSG00000125804.12	FAM182A	-4.79	1.95e-06	0.000187	-0.19	-0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25569736	chr20:26054655~26086917:+
BRCA	cis	rs10419113	0.668	rs2360535	ENSG00000268545.1	VN1R107P	4.79	1.95e-06	0.000187	0.17	0.15	Pediatric bone mineral density (spine);	chr19:57668813	chr19:57459912~57460120:+
BRCA	cis	rs4722166	0.695	rs7808122	ENSG00000225541.1	AC002480.5	-4.79	1.95e-06	0.000187	-0.15	-0.15	Lung cancer;	chr7:22758461	chr7:22571607~22661792:-
BRCA	cis	rs7674212	0.539	rs6850461	ENSG00000251288.2	RP11-10L12.2	-4.79	1.95e-06	0.000187	-0.17	-0.15	Type 2 diabetes;	chr4:103198884	chr4:102751401~102752641:+
BRCA	cis	rs71636778	0.509	rs34889971	ENSG00000260063.1	RP5-968P14.2	-4.79	1.96e-06	0.000187	-0.35	-0.15	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26861566	chr1:26692132~26694131:-
BRCA	cis	rs9840812	0.522	rs711976	ENSG00000239213.4	NCK1-AS1	4.78	1.96e-06	0.000187	0.19	0.15	Fibrinogen levels;	chr3:136510180	chr3:136841726~136862054:-
BRCA	cis	rs11096990	0.613	rs9997015	ENSG00000249685.1	RP11-360F5.3	-4.78	1.96e-06	0.000187	-0.18	-0.15	Cognitive function;	chr4:39222677	chr4:39133913~39135608:+
BRCA	cis	rs13113518	1	rs13152173	ENSG00000249700.7	SRD5A3-AS1	4.78	1.96e-06	0.000187	0.18	0.15	Height;	chr4:55534788	chr4:55363971~55395847:-
BRCA	cis	rs13113518	1	rs13141049	ENSG00000249700.7	SRD5A3-AS1	4.78	1.96e-06	0.000187	0.18	0.15	Height;	chr4:55535489	chr4:55363971~55395847:-
BRCA	cis	rs13113518	0.967	rs12507722	ENSG00000249700.7	SRD5A3-AS1	4.78	1.96e-06	0.000187	0.18	0.15	Height;	chr4:55536421	chr4:55363971~55395847:-
BRCA	cis	rs7674212	0.54	rs2720469	ENSG00000246560.2	RP11-10L12.4	4.78	1.96e-06	0.000187	0.15	0.15	Type 2 diabetes;	chr4:103165327	chr4:102828055~102844075:+
BRCA	cis	rs11048434	0.535	rs2377680	ENSG00000256937.1	KRT17P8	-4.78	1.96e-06	0.000187	-0.18	-0.15	Sjögren's syndrome;	chr12:9038809	chr12:9127783~9128645:+
BRCA	cis	rs11098499	0.866	rs72676074	ENSG00000260091.1	RP11-33B1.4	-4.78	1.96e-06	0.000188	-0.13	-0.15	Corneal astigmatism;	chr4:119438686	chr4:119409333~119410233:+
BRCA	cis	rs13108904	0.901	rs6826029	ENSG00000196810.4	CTBP1-AS2	4.78	1.96e-06	0.000188	0.15	0.15	Obesity-related traits;	chr4:1313901	chr4:1249300~1288291:+
BRCA	cis	rs2243480	1	rs709607	ENSG00000232559.3	GS1-124K5.12	-4.78	1.96e-06	0.000188	-0.27	-0.15	Diabetic kidney disease;	chr7:65984554	chr7:66554588~66576923:-
BRCA	cis	rs2562456	0.874	rs9304986	ENSG00000268535.1	RP11-420K14.3	-4.78	1.96e-06	0.000188	-0.2	-0.15	Pain;	chr19:21499260	chr19:21709522~21710191:+
BRCA	cis	rs6496932	0.774	rs12901648	ENSG00000259774.1	RP11-182J1.13	-4.78	1.96e-06	0.000188	-0.25	-0.15	Central corneal thickness;Corneal structure;	chr15:85408487	chr15:84422618~84425882:+
BRCA	cis	rs4143844	1	rs12917339	ENSG00000259251.2	RP11-643M14.1	4.78	1.96e-06	0.000188	0.35	0.15	Bipolar disorder and schizophrenia;	chr15:62054591	chr15:62060503~62062434:+
BRCA	cis	rs3176789	0.914	rs724668	ENSG00000256673.1	RP11-599J14.2	4.78	1.96e-06	0.000188	0.18	0.15	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9770233	chr12:9398355~9414851:-
BRCA	cis	rs1729951	0.575	rs1682333	ENSG00000239213.4	NCK1-AS1	4.78	1.96e-06	0.000188	0.15	0.15	Neuroticism;	chr3:136969776	chr3:136841726~136862054:-
BRCA	cis	rs8127691	1	rs2838517	ENSG00000237604.1	AP001056.1	4.78	1.96e-06	0.000188	0.16	0.15	Inflammatory bowel disease;	chr21:44193942	chr21:44175489~44176453:+
BRCA	cis	rs2880765	0.527	rs35184622	ENSG00000259295.5	CSPG4P12	4.78	1.96e-06	0.000188	0.2	0.15	Coronary artery disease;	chr15:85529804	chr15:85191438~85213905:+
BRCA	cis	rs2880765	0.527	rs1483578	ENSG00000259295.5	CSPG4P12	4.78	1.96e-06	0.000188	0.2	0.15	Coronary artery disease;	chr15:85532186	chr15:85191438~85213905:+
BRCA	cis	rs62246343	0.605	rs34665459	ENSG00000254485.4	RP11-380O24.1	4.78	1.96e-06	0.000188	0.19	0.15	Fibrinogen levels;	chr3:9423041	chr3:9292588~9363303:-
BRCA	cis	rs6596100	0.868	rs14355	ENSG00000248648.1	RP11-485M7.1	-4.78	1.96e-06	0.000188	-0.19	-0.15	Breast cancer;	chr5:133104593	chr5:133003119~133003365:+
BRCA	cis	rs2904967	0.759	rs625427	ENSG00000255200.1	AP003068.18	-4.78	1.96e-06	0.000188	-0.25	-0.15	Mean corpuscular volume;	chr11:65236341	chr11:65174117~65176470:-
BRCA	cis	rs4908760	0.827	rs2401138	ENSG00000232912.4	RP5-1115A15.1	-4.78	1.96e-06	0.000188	-0.15	-0.15	Vitiligo;	chr1:8644000	chr1:8424645~8434838:+
BRCA	cis	rs4356203	0.905	rs512852	ENSG00000272034.1	SNORD14A	-4.78	1.96e-06	0.000188	-0.15	-0.15	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17193382	chr11:17074654~17074744:-
BRCA	cis	rs10129255	1	rs11621409	ENSG00000211974.3	IGHV2-70	4.78	1.96e-06	0.000188	0.16	0.15	Kawasaki disease;	chr14:106695603	chr14:106723574~106724093:-
BRCA	cis	rs7487075	0.619	rs12298616	ENSG00000274723.1	RP11-618L22.1	4.78	1.96e-06	0.000188	0.19	0.15	Itch intensity from mosquito bite;	chr12:46448389	chr12:46970504~46972155:+
BRCA	cis	rs7818688	0.614	rs11782617	ENSG00000253528.2	RP11-347C18.4	4.78	1.96e-06	0.000188	0.2	0.15	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94862994	chr8:94974573~94974853:-
BRCA	cis	rs2638953	0.962	rs11494780	ENSG00000247934.4	RP11-967K21.1	-4.78	1.97e-06	0.000188	-0.2	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28402269	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.962	rs11049574	ENSG00000247934.4	RP11-967K21.1	-4.78	1.97e-06	0.000188	-0.2	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28406130	chr12:28163298~28190738:-
BRCA	cis	rs2638953	0.962	rs10506033	ENSG00000247934.4	RP11-967K21.1	-4.78	1.97e-06	0.000188	-0.2	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28415032	chr12:28163298~28190738:-
BRCA	cis	rs7572733	0.773	rs13427590	ENSG00000231621.1	AC013264.2	-4.78	1.97e-06	0.000188	-0.14	-0.15	Dermatomyositis;	chr2:197652097	chr2:197197991~197199273:+
BRCA	cis	rs4072705	0.616	rs915033	ENSG00000224020.1	MIR181A2HG	-4.78	1.97e-06	0.000188	-0.17	-0.15	Menarche (age at onset);	chr9:124483279	chr9:124658467~124698631:+
BRCA	cis	rs7918232	0.941	rs4749230	ENSG00000262412.1	RP11-85G18.6	4.78	1.97e-06	0.000188	0.23	0.15	Breast cancer;	chr10:27152289	chr10:27243130~27250804:+
BRCA	cis	rs13236243	0.673	rs4721596	ENSG00000237773.4	AC003075.4	-4.78	1.97e-06	0.000188	-0.21	-0.15	Sensory disturbances after bilateral sagittal split ramus osteotomy;	chr7:17380483	chr7:17279834~17299357:-
BRCA	cis	rs1124769	0.57	rs2614765	ENSG00000259378.1	DCAF13P3	-4.78	1.97e-06	0.000188	-0.19	-0.15	Cognitive performance;	chr15:50851805	chr15:50944663~50945996:+
BRCA	cis	rs10829156	0.741	rs9731044	ENSG00000240291.1	RP11-499P20.2	4.78	1.97e-06	0.000188	0.17	0.15	Sudden cardiac arrest;	chr10:18605356	chr10:18513115~18545651:-
BRCA	cis	rs7226408	0.948	rs11665642	ENSG00000267707.2	RP11-95O2.5	-4.78	1.97e-06	0.000188	-0.23	-0.15	Obesity-related traits;	chr18:36807475	chr18:37243776~37247506:+
BRCA	cis	rs62025270	0.806	rs62025262	ENSG00000202081.1	RNU6-1280P	-4.78	1.97e-06	0.000188	-0.22	-0.15	Idiopathic pulmonary fibrosis;	chr15:85750002	chr15:85651522~85651628:-
BRCA	cis	rs2562456	0.833	rs552800	ENSG00000268658.4	LINC00664	-4.78	1.97e-06	0.000188	-0.23	-0.15	Pain;	chr19:21301840	chr19:21483374~21503238:+
BRCA	cis	rs11098499	0.722	rs28713555	ENSG00000260404.2	RP11-384K6.6	4.78	1.97e-06	0.000188	0.13	0.15	Corneal astigmatism;	chr4:119330840	chr4:118591773~118633729:+
BRCA	cis	rs67311347	1	rs1047855	ENSG00000280739.1	EIF1B-AS1	-4.78	1.97e-06	0.000188	-0.18	-0.15	Renal cell carcinoma;	chr3:40427405	chr3:40173145~40309698:-
BRCA	cis	rs8017423	0.586	rs2896134	ENSG00000275198.1	RP11-471B22.3	4.78	1.97e-06	0.000189	0.17	0.15	Mortality in heart failure;	chr14:90364949	chr14:90383365~90387973:+
BRCA	cis	rs7267979	1	rs2027003	ENSG00000276952.1	RP5-965G21.6	-4.78	1.97e-06	0.000189	-0.18	-0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25369862	chr20:25284915~25285588:-
BRCA	cis	rs7267979	1	rs2027004	ENSG00000276952.1	RP5-965G21.6	-4.78	1.97e-06	0.000189	-0.18	-0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25369982	chr20:25284915~25285588:-
BRCA	cis	rs7267979	0.934	rs2500399	ENSG00000276952.1	RP5-965G21.6	-4.78	1.97e-06	0.000189	-0.18	-0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25374058	chr20:25284915~25285588:-
BRCA	cis	rs10649609	1	rs10649609	ENSG00000223318.1	RNA5SP111	4.78	1.97e-06	0.000189	0.17	0.15	Reticulocyte count;	chr2:164696196	chr2:164895677~164895777:-
BRCA	cis	rs875971	0.545	rs316324	ENSG00000232546.1	RP11-458F8.1	-4.78	1.97e-06	0.000189	-0.14	-0.15	Aortic root size;	chr7:66145627	chr7:66848496~66858136:+
BRCA	cis	rs875971	0.545	rs316323	ENSG00000232546.1	RP11-458F8.1	-4.78	1.97e-06	0.000189	-0.14	-0.15	Aortic root size;	chr7:66146002	chr7:66848496~66858136:+
BRCA	cis	rs1862618	0.641	rs252893	ENSG00000271828.1	CTD-2310F14.1	4.78	1.97e-06	0.000189	0.18	0.15	Initial pursuit acceleration;	chr5:56928887	chr5:56927874~56929573:+
BRCA	cis	rs7246657	0.722	rs2909102	ENSG00000226686.6	LINC01535	4.78	1.97e-06	0.000189	0.22	0.15	Coronary artery calcification;	chr19:37676463	chr19:37251912~37265535:+
BRCA	cis	rs1722141	0.669	rs788740	ENSG00000237471.1	AC073115.6	4.78	1.97e-06	0.000189	0.19	0.15	Sitting height ratio;	chr7:46001501	chr7:45969657~45980191:+
BRCA	cis	rs12501370	0.569	rs10938471	ENSG00000201736.1	RNA5SP160	4.78	1.97e-06	0.000189	0.17	0.15	Iris color (L* coordinate);	chr4:40980453	chr4:40990154~40990273:+
BRCA	cis	rs7618501	0.54	rs11130241	ENSG00000228008.1	CTD-2330K9.3	-4.78	1.97e-06	0.000189	-0.14	-0.15	Intelligence (multi-trait analysis);	chr3:50094026	chr3:49903845~49916937:+
BRCA	cis	rs5742933	0.512	rs80277863	ENSG00000253559.1	OSGEPL1-AS1	-4.78	1.97e-06	0.000189	-0.19	-0.15	Ferritin levels;	chr2:189766733	chr2:189762704~189765556:+
BRCA	cis	rs13358904	0.518	rs10478076	ENSG00000278921.2	EPB41L4A-AS2	4.78	1.97e-06	0.000189	0.2	0.15	Suicide ideation score in major depressive disorder;	chr5:112274226	chr5:112419583~112420978:+
BRCA	cis	rs10129255	0.957	rs11846893	ENSG00000280411.1	IGHV1-69-2	-4.78	1.98e-06	0.000189	-0.1	-0.15	Kawasaki disease;	chr14:106779068	chr14:106762092~106762588:-
BRCA	cis	rs7618501	0.602	rs2240326	ENSG00000228008.1	CTD-2330K9.3	-4.78	1.98e-06	0.000189	-0.14	-0.15	Intelligence (multi-trait analysis);	chr3:50090953	chr3:49903845~49916937:+
BRCA	cis	rs721917	0.506	rs2819097	ENSG00000278616.1	BEND3P3	-4.78	1.98e-06	0.000189	-0.14	-0.15	Chronic obstructive pulmonary disease;	chr10:79940225	chr10:79682997~79685436:+
BRCA	cis	rs6596100	0.915	rs55800184	ENSG00000248648.1	RP11-485M7.1	-4.78	1.98e-06	0.000189	-0.19	-0.15	Breast cancer;	chr5:133095000	chr5:133003119~133003365:+
BRCA	cis	rs12701220	0.901	rs12701713	ENSG00000229043.2	AC091729.9	-4.78	1.98e-06	0.000189	-0.22	-0.15	Bronchopulmonary dysplasia;	chr7:1050869	chr7:1160374~1165267:+
BRCA	cis	rs1362153	0.73	rs2486008	ENSG00000237950.1	RP11-7O11.3	4.78	1.98e-06	0.000189	0.25	0.15	Alcohol dependence (age at onset);	chr1:43974113	chr1:43944370~43946551:-
BRCA	cis	rs7119	0.717	rs12898656	ENSG00000259362.2	RP11-307C19.1	4.78	1.98e-06	0.000189	0.21	0.15	Type 2 diabetes;	chr15:77515653	chr15:77525540~77534110:+
BRCA	cis	rs6840360	0.642	rs2724574	ENSG00000251603.1	RP11-164P12.4	4.78	1.98e-06	0.000189	0.13	0.15	Intelligence (multi-trait analysis);	chr4:151460648	chr4:151667224~151670502:+
BRCA	cis	rs6430585	0.528	rs309151	ENSG00000231890.6	DARS-AS1	-4.78	1.98e-06	0.000189	-0.23	-0.15	Corneal structure;	chr2:135903580	chr2:135985176~136022593:+
BRCA	cis	rs2562456	0.754	rs11673234	ENSG00000268658.4	LINC00664	4.78	1.98e-06	0.000189	0.25	0.15	Pain;	chr19:21324800	chr19:21483374~21503238:+
BRCA	cis	rs2562456	0.754	rs11673320	ENSG00000268658.4	LINC00664	4.78	1.98e-06	0.000189	0.25	0.15	Pain;	chr19:21324801	chr19:21483374~21503238:+
BRCA	cis	rs11673344	0.542	rs826327	ENSG00000226686.6	LINC01535	4.78	1.98e-06	0.000189	0.19	0.15	Obesity-related traits;	chr19:37004397	chr19:37251912~37265535:+
BRCA	cis	rs7267979	0.868	rs6138553	ENSG00000276952.1	RP5-965G21.6	4.78	1.98e-06	0.000189	0.18	0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25258597	chr20:25284915~25285588:-
BRCA	cis	rs739401	0.611	rs494427	ENSG00000183562.3	CTC-343N3.1	-4.78	1.98e-06	0.000189	-0.16	-0.15	Longevity;	chr11:3026910	chr11:2989863~2991344:+
BRCA	cis	rs6840360	0.642	rs7682837	ENSG00000251611.1	RP11-610P16.1	-4.78	1.98e-06	0.000189	-0.13	-0.15	Intelligence (multi-trait analysis);	chr4:151506534	chr4:151407551~151408835:-
BRCA	cis	rs459482	0.504	rs469288	ENSG00000228318.3	AP001610.5	4.78	1.98e-06	0.000189	0.17	0.15	IgG glycosylation;	chr21:41445655	chr21:41441056~41445708:-
BRCA	cis	rs6832769	0.961	rs10026692	ENSG00000272969.1	RP11-528I4.2	-4.78	1.98e-06	0.000189	-0.17	-0.15	Personality dimensions;	chr4:55586539	chr4:55547112~55547889:+
BRCA	cis	rs4718428	0.662	rs34577323	ENSG00000229180.5	GS1-124K5.11	4.78	1.98e-06	0.000189	0.14	0.15	Corneal structure;	chr7:66845054	chr7:66526088~66542624:-
BRCA	cis	rs12681366	0.511	rs2919670	ENSG00000253704.1	RP11-267M23.4	4.78	1.98e-06	0.00019	0.16	0.15	Nonsyndromic cleft lip with cleft palate;	chr8:94444390	chr8:94553722~94569745:+
BRCA	cis	rs11758351	0.66	rs55848726	ENSG00000241549.7	GUSBP2	-4.78	1.98e-06	0.00019	-0.21	-0.15	Renal underexcretion gout;Gout;	chr6:26224206	chr6:26871484~26956554:-
BRCA	cis	rs11758351	0.66	rs16891446	ENSG00000241549.7	GUSBP2	-4.78	1.98e-06	0.00019	-0.21	-0.15	Renal underexcretion gout;Gout;	chr6:26226768	chr6:26871484~26956554:-
BRCA	cis	rs6860540	0.796	rs55635824	ENSG00000248544.2	CTB-47B11.3	-4.78	1.98e-06	0.00019	-0.19	-0.15	Inflammatory skin disease;	chr5:157466414	chr5:157375741~157384950:-
BRCA	cis	rs2803122	0.905	rs10757053	ENSG00000273226.1	RP11-513M16.8	-4.78	1.98e-06	0.00019	-0.16	-0.15	Pulse pressure;	chr9:19314156	chr9:19375451~19375996:+
BRCA	cis	rs3768617	0.51	rs10911239	ENSG00000224468.3	RP11-181K3.4	-4.78	1.98e-06	0.00019	-0.16	-0.15	Fuchs's corneal dystrophy;	chr1:183093315	chr1:183138402~183141282:-
BRCA	cis	rs3768617	0.528	rs10911240	ENSG00000224468.3	RP11-181K3.4	-4.78	1.98e-06	0.00019	-0.16	-0.15	Fuchs's corneal dystrophy;	chr1:183093813	chr1:183138402~183141282:-
BRCA	cis	rs6430585	0.528	rs56064699	ENSG00000224043.6	CCNT2-AS1	-4.78	1.98e-06	0.00019	-0.26	-0.15	Corneal structure;	chr2:135838136	chr2:134735464~134918710:-
BRCA	cis	rs57221529	0.766	rs12522140	ENSG00000271781.1	CTD-2589H19.6	-4.78	1.98e-06	0.00019	-0.22	-0.15	Lung disease severity in cystic fibrosis;	chr5:587146	chr5:675826~676616:+
BRCA	cis	rs57221529	0.766	rs72703064	ENSG00000271781.1	CTD-2589H19.6	-4.78	1.98e-06	0.00019	-0.22	-0.15	Lung disease severity in cystic fibrosis;	chr5:587710	chr5:675826~676616:+
BRCA	cis	rs57221529	0.766	rs72703065	ENSG00000271781.1	CTD-2589H19.6	-4.78	1.98e-06	0.00019	-0.22	-0.15	Lung disease severity in cystic fibrosis;	chr5:588008	chr5:675826~676616:+
BRCA	cis	rs57221529	0.766	rs1399381	ENSG00000271781.1	CTD-2589H19.6	-4.78	1.98e-06	0.00019	-0.22	-0.15	Lung disease severity in cystic fibrosis;	chr5:589738	chr5:675826~676616:+
BRCA	cis	rs7818688	0.697	rs11782818	ENSG00000253528.2	RP11-347C18.4	-4.78	1.98e-06	0.00019	-0.21	-0.15	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94965993	chr8:94974573~94974853:-
BRCA	cis	rs66887589	0.934	rs7672519	ENSG00000245958.5	RP11-33B1.1	4.78	1.98e-06	0.00019	0.13	0.15	Diastolic blood pressure;	chr4:119622957	chr4:119454791~119552025:+
BRCA	cis	rs13108904	0.87	rs1564508	ENSG00000253399.1	AC078852.2	-4.78	1.98e-06	0.00019	-0.16	-0.15	Obesity-related traits;	chr4:1251091	chr4:1358479~1359461:+
BRCA	cis	rs12893668	0.645	rs12889403	ENSG00000244691.1	RPL10AP1	-4.78	1.99e-06	0.00019	-0.2	-0.15	Reticulocyte count;	chr14:103568409	chr14:103412119~103412761:-
BRCA	cis	rs12893668	0.703	rs12894729	ENSG00000244691.1	RPL10AP1	-4.78	1.99e-06	0.00019	-0.2	-0.15	Reticulocyte count;	chr14:103568955	chr14:103412119~103412761:-
BRCA	cis	rs2243480	1	rs383402	ENSG00000222364.1	RNU6-96P	4.78	1.99e-06	0.00019	0.26	0.15	Diabetic kidney disease;	chr7:66121666	chr7:66395191~66395286:+
BRCA	cis	rs2835345	0.561	rs5026478	ENSG00000279365.1	KB-176G8.1	4.78	1.99e-06	0.00019	0.19	0.15	Pulmonary function;	chr21:36453531	chr21:36485867~36487760:+
BRCA	cis	rs2153535	0.58	rs6597335	ENSG00000251164.1	HULC	-4.78	1.99e-06	0.00019	-0.18	-0.15	Motion sickness;	chr6:8527481	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.58	rs9328486	ENSG00000251164.1	HULC	-4.78	1.99e-06	0.00019	-0.18	-0.15	Motion sickness;	chr6:8527775	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.58	rs2183112	ENSG00000251164.1	HULC	-4.78	1.99e-06	0.00019	-0.18	-0.15	Motion sickness;	chr6:8527979	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.601	rs2143353	ENSG00000251164.1	HULC	-4.78	1.99e-06	0.00019	-0.18	-0.15	Motion sickness;	chr6:8529878	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.601	rs2143352	ENSG00000251164.1	HULC	-4.78	1.99e-06	0.00019	-0.18	-0.15	Motion sickness;	chr6:8530015	chr6:8652137~8653846:+
BRCA	cis	rs890448	0.726	rs2850366	ENSG00000254531.1	FLJ20021	-4.78	1.99e-06	0.00019	-0.17	-0.15	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101309867	chr4:101347780~101348883:+
BRCA	cis	rs3892630	0.824	rs2287882	ENSG00000267567.1	CTD-2538C1.3	4.78	1.99e-06	0.00019	0.24	0.15	Red blood cell traits;	chr19:32842046	chr19:32718298~32719595:-
BRCA	cis	rs66887589	0.934	rs6817317	ENSG00000245958.5	RP11-33B1.1	4.78	1.99e-06	0.00019	0.13	0.15	Diastolic blood pressure;	chr4:119621672	chr4:119454791~119552025:+
BRCA	cis	rs6430585	0.528	rs16832440	ENSG00000231890.6	DARS-AS1	-4.78	1.99e-06	0.00019	-0.24	-0.15	Corneal structure;	chr2:135996613	chr2:135985176~136022593:+
BRCA	cis	rs6430538	0.597	rs4300887	ENSG00000224043.6	CCNT2-AS1	-4.78	1.99e-06	0.00019	-0.2	-0.15	Parkinson's disease;	chr2:134815240	chr2:134735464~134918710:-
BRCA	cis	rs2303790	1	rs2303790	ENSG00000261270.1	RP11-325K4.3	-4.78	1.99e-06	0.00019	-0.33	-0.15	Exudative age-related macular degeneration;	chr16:56983380	chr16:56940278~56941342:+
BRCA	cis	rs7647973	0.961	rs62259943	ENSG00000244380.1	RP11-24C3.2	-4.78	1.99e-06	0.000191	-0.2	-0.15	Menarche (age at onset);	chr3:49387734	chr3:48440352~48446656:-
BRCA	cis	rs66887589	0.87	rs59590064	ENSG00000245958.5	RP11-33B1.1	4.78	1.99e-06	0.000191	0.13	0.15	Diastolic blood pressure;	chr4:119618598	chr4:119454791~119552025:+
BRCA	cis	rs17711722	0.522	rs4642526	ENSG00000275400.1	RP4-756H11.5	-4.78	1.99e-06	0.000191	-0.17	-0.15	Calcium levels;	chr7:65751755	chr7:66553805~66554199:-
BRCA	cis	rs924712	0.545	rs12203709	ENSG00000261116.1	RP3-523K23.2	4.78	1.99e-06	0.000191	0.17	0.15	Breast cancer;	chr6:54842819	chr6:54943167~54945099:+
BRCA	cis	rs1075265	0.836	rs11687324	ENSG00000235937.1	AC008280.1	4.78	2e-06	0.000191	0.16	0.15	Chronotype;Morning vs. evening chronotype;	chr2:54046589	chr2:54029552~54030682:-
BRCA	cis	rs2832191	0.791	rs2832199	ENSG00000176054.6	RPL23P2	-4.78	2e-06	0.000191	-0.15	-0.15	Dental caries;	chr21:29126180	chr21:28997613~28998033:-
BRCA	cis	rs8180040	0.966	rs56351005	ENSG00000271161.1	BOLA2P2	-4.78	2e-06	0.000191	-0.16	-0.15	Colorectal cancer;	chr3:47388696	chr3:47499841~47500407:+
BRCA	cis	rs3768617	0.51	rs7542640	ENSG00000224468.3	RP11-181K3.4	-4.78	2e-06	0.000191	-0.16	-0.15	Fuchs's corneal dystrophy;	chr1:183094603	chr1:183138402~183141282:-
BRCA	cis	rs3768617	0.51	rs10458355	ENSG00000224468.3	RP11-181K3.4	-4.78	2e-06	0.000191	-0.16	-0.15	Fuchs's corneal dystrophy;	chr1:183094858	chr1:183138402~183141282:-
BRCA	cis	rs3768617	0.51	rs4491025	ENSG00000224468.3	RP11-181K3.4	-4.78	2e-06	0.000191	-0.16	-0.15	Fuchs's corneal dystrophy;	chr1:183096048	chr1:183138402~183141282:-
BRCA	cis	rs3768617	0.51	rs6424884	ENSG00000224468.3	RP11-181K3.4	-4.78	2e-06	0.000191	-0.16	-0.15	Fuchs's corneal dystrophy;	chr1:183096769	chr1:183138402~183141282:-
BRCA	cis	rs3768617	0.51	rs6424885	ENSG00000224468.3	RP11-181K3.4	-4.78	2e-06	0.000191	-0.16	-0.15	Fuchs's corneal dystrophy;	chr1:183097119	chr1:183138402~183141282:-
BRCA	cis	rs651907	0.557	rs35850993	ENSG00000256628.3	ZBTB11-AS1	4.78	2e-06	0.000191	0.18	0.15	Colorectal cancer;	chr3:101718589	chr3:101676475~101679217:+
BRCA	cis	rs4356203	0.905	rs598946	ENSG00000272034.1	SNORD14A	-4.78	2e-06	0.000191	-0.15	-0.15	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17187540	chr11:17074654~17074744:-
BRCA	cis	rs4356203	0.905	rs545773	ENSG00000272034.1	SNORD14A	-4.78	2e-06	0.000191	-0.15	-0.15	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17192089	chr11:17074654~17074744:-
BRCA	cis	rs4356203	0.905	rs511119	ENSG00000272034.1	SNORD14A	-4.78	2e-06	0.000191	-0.15	-0.15	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17193570	chr11:17074654~17074744:-
BRCA	cis	rs3764021	0.87	rs2401395	ENSG00000278635.1	CTD-2318O12.1	-4.78	2e-06	0.000191	-0.14	-0.15	Type 1 diabetes;	chr12:9726944	chr12:9415641~9416718:+
BRCA	cis	rs6088590	0.561	rs6059932	ENSG00000276073.1	RP5-1125A11.7	-4.78	2e-06	0.000191	-0.16	-0.15	Coronary artery disease;	chr20:34587662	chr20:33985617~33988989:-
BRCA	cis	rs11098499	0.779	rs80242894	ENSG00000260091.1	RP11-33B1.4	-4.78	2e-06	0.000191	-0.13	-0.15	Corneal astigmatism;	chr4:119454597	chr4:119409333~119410233:+
BRCA	cis	rs13108904	0.539	rs11247997	ENSG00000253399.1	AC078852.2	-4.78	2e-06	0.000191	-0.19	-0.15	Obesity-related traits;	chr4:1367269	chr4:1358479~1359461:+
BRCA	cis	rs11158026	0.757	rs56206440	ENSG00000258413.1	RP11-665C16.6	-4.78	2e-06	0.000191	-0.19	-0.15	Parkinson's disease;	chr14:54984168	chr14:55262767~55272075:-
BRCA	cis	rs11239930	0.517	rs3011809	ENSG00000230832.3	RP11-325P15.2	-4.78	2e-06	0.000191	-0.21	-0.15	AIDS progression;	chr1:147077593	chr1:147082338~147083578:-
BRCA	cis	rs1656368	0.655	rs10936144	ENSG00000279311.1	RP11-170K4.2	4.78	2e-06	0.000191	0.19	0.15	Lobe attachment (rater-scored or self-reported);	chr3:158472173	chr3:158869898~158871821:+
BRCA	cis	rs1656368	0.655	rs10936145	ENSG00000279311.1	RP11-170K4.2	4.78	2e-06	0.000191	0.19	0.15	Lobe attachment (rater-scored or self-reported);	chr3:158475347	chr3:158869898~158871821:+
BRCA	cis	rs4865762	0.557	rs12515400	ENSG00000247796.2	CTD-2366F13.1	-4.78	2e-06	0.000191	-0.17	-0.15	Intraocular pressure;	chr5:53285349	chr5:53109842~53115126:+
BRCA	cis	rs7772486	0.701	rs11155438	ENSG00000270638.1	RP3-466P17.1	4.78	2e-06	0.000191	0.17	0.15	Lobe attachment (rater-scored or self-reported);	chr6:145628976	chr6:145735570~145737218:+
BRCA	cis	rs12435908	1	rs73286169	ENSG00000276116.2	FUT8-AS1	-4.78	2e-06	0.000191	-0.23	-0.15	Ischemic stroke;	chr14:65611730	chr14:65411170~65412690:-
BRCA	cis	rs922692	1	rs11638372	ENSG00000261143.1	ADAMTS7P3	-4.78	2e-06	0.000191	-0.19	-0.15	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78691217	chr15:77976042~77993057:+
BRCA	cis	rs13113518	1	rs4864993	ENSG00000249700.7	SRD5A3-AS1	4.78	2e-06	0.000192	0.18	0.15	Height;	chr4:55450662	chr4:55363971~55395847:-
BRCA	cis	rs2562456	0.833	rs516519	ENSG00000213976.4	CTD-2561J22.2	4.78	2e-06	0.000192	0.17	0.15	Pain;	chr19:21298730	chr19:21382865~21387177:+
BRCA	cis	rs26949	0.526	rs3899221	ENSG00000215032.2	GNL3LP1	-4.78	2e-06	0.000192	-0.18	-0.15	Intelligence (multi-trait analysis);	chr5:60740550	chr5:60891935~60893577:-
BRCA	cis	rs26949	0.526	rs10058456	ENSG00000215032.2	GNL3LP1	-4.78	2e-06	0.000192	-0.18	-0.15	Intelligence (multi-trait analysis);	chr5:60742114	chr5:60891935~60893577:-
BRCA	cis	rs11758351	0.587	rs2050950	ENSG00000241549.7	GUSBP2	-4.78	2e-06	0.000192	-0.21	-0.15	Renal underexcretion gout;Gout;	chr6:26234655	chr6:26871484~26956554:-
BRCA	cis	rs11758351	0.588	rs2050948	ENSG00000241549.7	GUSBP2	-4.78	2e-06	0.000192	-0.21	-0.15	Renal underexcretion gout;Gout;	chr6:26234724	chr6:26871484~26956554:-
BRCA	cis	rs1707322	1	rs4074225	ENSG00000234329.1	RP11-767N6.2	4.78	2.01e-06	0.000192	0.15	0.15	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45926692	chr1:45651039~45651826:-
BRCA	cis	rs11159086	0.941	rs11846588	ENSG00000270000.1	RP3-449M8.9	4.78	2.01e-06	0.000192	0.23	0.15	Advanced glycation end-product levels;	chr14:74505398	chr14:74471930~74472360:-
BRCA	cis	rs2562456	0.833	rs2968076	ENSG00000268535.1	RP11-420K14.3	-4.78	2.01e-06	0.000192	-0.2	-0.15	Pain;	chr19:21454299	chr19:21709522~21710191:+
BRCA	cis	rs4819052	0.851	rs2838826	ENSG00000184274.3	LINC00315	-4.78	2.01e-06	0.000192	-0.19	-0.15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45235870	chr21:45300245~45305257:-
BRCA	cis	rs11098499	0.954	rs2306455	ENSG00000250412.1	KLHL2P1	4.78	2.01e-06	0.000192	0.18	0.15	Corneal astigmatism;	chr4:119500814	chr4:119334329~119378233:+
BRCA	cis	rs853679	0.882	rs4713140	ENSG00000280107.1	AL022393.9	-4.78	2.01e-06	0.000192	-0.3	-0.15	Depression;	chr6:28129415	chr6:28170845~28172521:+
BRCA	cis	rs6088590	0.523	rs6059913	ENSG00000276073.1	RP5-1125A11.7	-4.78	2.01e-06	0.000192	-0.16	-0.15	Coronary artery disease;	chr20:34555484	chr20:33985617~33988989:-
BRCA	cis	rs6756513	0.5	rs72839869	ENSG00000231024.1	AC092431.3	-4.78	2.01e-06	0.000192	-0.21	-0.15	Breast cancer;Platelet count;	chr2:69814049	chr2:69700192~69713847:-
BRCA	cis	rs6756513	0.5	rs72839870	ENSG00000231024.1	AC092431.3	-4.78	2.01e-06	0.000192	-0.21	-0.15	Breast cancer;Platelet count;	chr2:69815783	chr2:69700192~69713847:-
BRCA	cis	rs7674212	0.51	rs55715738	ENSG00000248740.4	RP11-328K4.1	4.78	2.01e-06	0.000192	0.17	0.15	Type 2 diabetes;	chr4:103209032	chr4:103256159~103453658:+
BRCA	cis	rs2011013	1	rs2011013	ENSG00000225151.9	GOLGA2P7	4.78	2.01e-06	0.000192	0.18	0.15	Sitting height ratio;	chr15:83957014	chr15:84199311~84230136:-
BRCA	cis	rs11758351	0.66	rs75156165	ENSG00000241549.7	GUSBP2	-4.78	2.01e-06	0.000192	-0.21	-0.15	Renal underexcretion gout;Gout;	chr6:26235471	chr6:26871484~26956554:-
BRCA	cis	rs11758351	0.587	rs16891466	ENSG00000241549.7	GUSBP2	-4.78	2.01e-06	0.000192	-0.21	-0.15	Renal underexcretion gout;Gout;	chr6:26235509	chr6:26871484~26956554:-
BRCA	cis	rs9840812	0.691	rs833752	ENSG00000273486.1	RP11-731C17.2	4.78	2.01e-06	0.000192	0.18	0.15	Fibrinogen levels;	chr3:136536327	chr3:136837338~136839021:-
BRCA	cis	rs4664293	0.836	rs10190704	ENSG00000224152.1	AC009506.1	-4.78	2.01e-06	0.000192	-0.16	-0.15	Monocyte percentage of white cells;	chr2:159738451	chr2:159615296~159617082:+
BRCA	cis	rs3764021	0.87	rs10466829	ENSG00000278635.1	CTD-2318O12.1	-4.78	2.01e-06	0.000192	-0.15	-0.15	Type 1 diabetes;	chr12:9723495	chr12:9415641~9416718:+
BRCA	cis	rs9652601	0.691	rs9933507	ENSG00000274038.1	RP11-66H6.4	-4.78	2.01e-06	0.000192	-0.16	-0.15	Systemic lupus erythematosus;	chr16:11107571	chr16:11056556~11057034:+
BRCA	cis	rs6751744	0.855	rs6432534	ENSG00000226266.5	AC009961.3	-4.78	2.01e-06	0.000192	-0.2	-0.15	Dysphagia;	chr2:159521561	chr2:159670708~159712435:-
BRCA	cis	rs6547741	0.935	rs12615690	ENSG00000234072.1	AC074117.10	4.78	2.01e-06	0.000192	0.13	0.15	Oral cavity cancer;	chr2:27628253	chr2:27356246~27367622:+
BRCA	cis	rs919433	0.617	rs4850809	ENSG00000231621.1	AC013264.2	4.78	2.01e-06	0.000192	0.14	0.15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197718679	chr2:197197991~197199273:+
BRCA	cis	rs11098499	0.913	rs10006304	ENSG00000249244.1	RP11-548H18.2	4.78	2.01e-06	0.000193	0.18	0.15	Corneal astigmatism;	chr4:119203150	chr4:119391831~119395335:-
BRCA	cis	rs9393692	0.905	rs6916289	ENSG00000241549.7	GUSBP2	-4.78	2.02e-06	0.000193	-0.16	-0.15	Educational attainment;	chr6:26288894	chr6:26871484~26956554:-
BRCA	cis	rs4713118	0.513	rs156738	ENSG00000219392.1	RP1-265C24.5	-4.78	2.02e-06	0.000193	-0.2	-0.15	Parkinson's disease;	chr6:28046247	chr6:28115628~28116551:+
BRCA	cis	rs62025270	0.848	rs2554	ENSG00000259295.5	CSPG4P12	-4.78	2.02e-06	0.000193	-0.23	-0.15	Idiopathic pulmonary fibrosis;	chr15:85759412	chr15:85191438~85213905:+
BRCA	cis	rs2153535	0.58	rs1855769	ENSG00000251164.1	HULC	-4.78	2.02e-06	0.000193	-0.18	-0.15	Motion sickness;	chr6:8472862	chr6:8652137~8653846:+
BRCA	cis	rs4713118	0.513	rs149958	ENSG00000219392.1	RP1-265C24.5	-4.78	2.02e-06	0.000193	-0.2	-0.15	Parkinson's disease;	chr6:28045839	chr6:28115628~28116551:+
BRCA	cis	rs7811142	0.83	rs1063945	ENSG00000078319.8	PMS2P1	-4.78	2.02e-06	0.000193	-0.24	-0.15	Platelet count;	chr7:100332824	chr7:100320992~100341908:-
BRCA	cis	rs10792665	0.649	rs948182	ENSG00000246067.6	RAB30-AS1	-4.78	2.02e-06	0.000193	-0.15	-0.15	Obesity-related traits;	chr11:83035189	chr11:83072066~83106719:+
BRCA	cis	rs4819052	0.851	rs7279182	ENSG00000184274.3	LINC00315	-4.78	2.02e-06	0.000193	-0.2	-0.15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45236197	chr21:45300245~45305257:-
BRCA	cis	rs2839186	0.632	rs2839184	ENSG00000228137.1	AP001469.7	4.78	2.02e-06	0.000193	0.17	0.15	Testicular germ cell tumor;	chr21:46269099	chr21:46246890~46247682:+
BRCA	cis	rs2243480	0.803	rs13224048	ENSG00000222364.1	RNU6-96P	-4.78	2.02e-06	0.000193	-0.27	-0.15	Diabetic kidney disease;	chr7:66528779	chr7:66395191~66395286:+
BRCA	cis	rs897984	0.568	rs8063565	ENSG00000260911.2	RP11-196G11.2	-4.78	2.02e-06	0.000193	-0.15	-0.15	Dementia with Lewy bodies;	chr16:30872644	chr16:31043150~31049868:+
BRCA	cis	rs897984	0.52	rs12928081	ENSG00000260911.2	RP11-196G11.2	-4.78	2.02e-06	0.000193	-0.15	-0.15	Dementia with Lewy bodies;	chr16:30873838	chr16:31043150~31049868:+
BRCA	cis	rs11098499	0.697	rs28655325	ENSG00000260091.1	RP11-33B1.4	-4.78	2.02e-06	0.000193	-0.13	-0.15	Corneal astigmatism;	chr4:119451844	chr4:119409333~119410233:+
BRCA	cis	rs910316	0.967	rs2268619	ENSG00000279594.1	RP11-950C14.10	-4.78	2.02e-06	0.000193	-0.16	-0.15	Height;	chr14:75173651	chr14:75011269~75012851:-
BRCA	cis	rs7621331	1	rs13325914	ENSG00000273486.1	RP11-731C17.2	4.78	2.02e-06	0.000193	0.17	0.15	Waist circumference adjusted for body mass index;	chr3:135998375	chr3:136837338~136839021:-
BRCA	cis	rs7682317	0.767	rs10015415	ENSG00000270720.1	RP11-84C13.2	-4.78	2.02e-06	0.000193	-0.16	-0.15	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr4:89007052	chr4:89119284~89119871:+
BRCA	cis	rs17428076	0.831	rs3736499	ENSG00000228389.1	AC068039.4	-4.78	2.02e-06	0.000193	-0.21	-0.15	Myopia;	chr2:171833908	chr2:171773482~171775844:+
BRCA	cis	rs4950322	0.57	rs72691004	ENSG00000278811.3	LINC00624	4.78	2.02e-06	0.000193	0.19	0.15	Protein quantitative trait loci;	chr1:147234309	chr1:147258885~147517875:-
BRCA	cis	rs308403	0.509	rs1849430	ENSG00000224786.1	CETN4P	4.78	2.03e-06	0.000193	0.19	0.15	Blood protein levels;	chr4:122753546	chr4:122730548~122732193:-
BRCA	cis	rs26949	0.526	rs1960479	ENSG00000215032.2	GNL3LP1	-4.78	2.03e-06	0.000193	-0.18	-0.15	Intelligence (multi-trait analysis);	chr5:60740388	chr5:60891935~60893577:-
BRCA	cis	rs11955398	0.546	rs10050803	ENSG00000215032.2	GNL3LP1	-4.78	2.03e-06	0.000193	-0.18	-0.15	Intelligence (multi-trait analysis);	chr5:60742398	chr5:60891935~60893577:-
BRCA	cis	rs17685	0.753	rs13240967	ENSG00000280388.1	RP11-229D13.3	4.78	2.03e-06	0.000193	0.15	0.15	Coffee consumption (cups per day);Coffee consumption;	chr7:76028879	chr7:76043977~76045963:-
BRCA	cis	rs4908760	0.899	rs61783642	ENSG00000232912.4	RP5-1115A15.1	4.78	2.03e-06	0.000193	0.14	0.15	Vitiligo;	chr1:8531338	chr1:8424645~8434838:+
BRCA	cis	rs11673344	0.504	rs6510588	ENSG00000226686.6	LINC01535	-4.78	2.03e-06	0.000193	-0.19	-0.15	Obesity-related traits;	chr19:37106493	chr19:37251912~37265535:+
BRCA	cis	rs7481584	0.624	rs693687	ENSG00000247473.2	CARS-AS1	-4.78	2.03e-06	0.000194	-0.17	-0.15	Calcium levels;	chr11:3031264	chr11:3029009~3041260:+
BRCA	cis	rs9863	0.828	rs4765562	ENSG00000270028.1	RP11-380L11.4	4.78	2.03e-06	0.000194	0.18	0.15	White blood cell count;	chr12:123988024	chr12:123925461~123926083:-
BRCA	cis	rs7208859	0.673	rs3816780	ENSG00000280069.1	CTD-2349P21.3	-4.78	2.03e-06	0.000194	-0.21	-0.15	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30834340	chr17:30738182~30740275:+
BRCA	cis	rs8064024	0.65	rs8056889	ENSG00000267077.1	RP11-127I20.5	4.78	2.03e-06	0.000194	0.15	0.15	Cancer;	chr16:4853242	chr16:4795265~4796532:-
BRCA	cis	rs11239930	0.517	rs493000	ENSG00000230832.3	RP11-325P15.2	-4.78	2.03e-06	0.000194	-0.21	-0.15	AIDS progression;	chr1:147077979	chr1:147082338~147083578:-
BRCA	cis	rs875971	0.502	rs11769702	ENSG00000230295.1	RP11-458F8.2	4.78	2.03e-06	0.000194	0.14	0.15	Aortic root size;	chr7:66255529	chr7:66880708~66882981:+
BRCA	cis	rs6442522	0.611	rs1983085	ENSG00000249786.6	EAF1-AS1	-4.78	2.03e-06	0.000194	-0.15	-0.15	Uric acid levels;	chr3:15488036	chr3:15436171~15455940:-
BRCA	cis	rs6847067	0.683	rs55871210	ENSG00000180769.7	WDFY3-AS2	4.78	2.03e-06	0.000194	0.14	0.15	Oropharynx cancer;	chr4:84942499	chr4:84965682~85011277:+
BRCA	cis	rs13113518	1	rs13133579	ENSG00000249700.7	SRD5A3-AS1	4.78	2.03e-06	0.000194	0.18	0.15	Height;	chr4:55459921	chr4:55363971~55395847:-
BRCA	cis	rs7726839	1	rs7726839	ENSG00000225138.6	CTD-2228K2.7	4.78	2.03e-06	0.000194	0.18	0.15	Obesity-related traits;	chr5:618471	chr5:473236~480884:+
BRCA	cis	rs10129255	0.5	rs2105989	ENSG00000211967.3	IGHV3-53	-4.78	2.03e-06	0.000194	-0.1	-0.15	Kawasaki disease;	chr14:106682199	chr14:106592676~106593347:-
BRCA	cis	rs5758659	0.679	rs134870	ENSG00000182057.4	OGFRP1	4.78	2.03e-06	0.000194	0.16	0.15	Cognitive function;	chr22:42256311	chr22:42269753~42275196:+
BRCA	cis	rs11051970	0.559	rs12578899	ENSG00000274964.1	RP11-817I4.1	-4.78	2.03e-06	0.000194	-0.19	-0.15	Response to tocilizumab in rheumatoid arthritis;	chr12:32332017	chr12:32339368~32340724:+
BRCA	cis	rs6487679	1	rs7298108	ENSG00000111788.10	RP11-22B23.1	-4.78	2.03e-06	0.000194	-0.16	-0.15	Non-alcoholic fatty liver disease histology (AST);	chr12:9223572	chr12:9277235~9313241:+
BRCA	cis	rs792448	0.743	rs3767861	ENSG00000226251.4	RP11-15I11.3	-4.78	2.03e-06	0.000194	-0.19	-0.15	White blood cell count (basophil);	chr1:212364211	chr1:212225278~212238977:-
BRCA	cis	rs792448	0.743	rs3767862	ENSG00000226251.4	RP11-15I11.3	-4.78	2.03e-06	0.000194	-0.19	-0.15	White blood cell count (basophil);	chr1:212364360	chr1:212225278~212238977:-
BRCA	cis	rs12681366	0.762	rs67639046	ENSG00000253704.1	RP11-267M23.4	4.78	2.03e-06	0.000194	0.15	0.15	Nonsyndromic cleft lip with cleft palate;	chr8:94373552	chr8:94553722~94569745:+
BRCA	cis	rs793571	0.784	rs28800895	ENSG00000259250.1	RP11-50C13.1	-4.78	2.03e-06	0.000194	-0.22	-0.15	Schizophrenia;	chr15:58792837	chr15:58587507~58591676:+
BRCA	cis	rs1876905	0.68	rs373526	ENSG00000272356.1	RP5-1112D6.8	4.78	2.04e-06	0.000194	0.19	0.15	Mean corpuscular hemoglobin;	chr6:111190261	chr6:111309203~111313517:+
BRCA	cis	rs6738627	0.931	rs7592412	ENSG00000223318.1	RNA5SP111	4.78	2.04e-06	0.000194	0.17	0.15	circulating leptin levels adjusted for BMI;Body fat percentage;circulating leptin levels;	chr2:164669828	chr2:164895677~164895777:-
BRCA	cis	rs442309	0.846	rs224072	ENSG00000238280.1	RP11-436D10.3	-4.78	2.04e-06	0.000194	-0.2	-0.15	Vogt-Koyanagi-Harada syndrome;	chr10:62748961	chr10:62793562~62805887:-
BRCA	cis	rs253959	0.545	rs4921057	ENSG00000271918.1	CTD-2287O16.5	4.78	2.04e-06	0.000194	0.13	0.15	Bipolar disorder and schizophrenia;	chr5:116090723	chr5:116083807~116085416:-
BRCA	cis	rs4853525	0.59	rs2355576	ENSG00000235852.1	AC005540.3	4.78	2.04e-06	0.000194	0.18	0.15	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190850374	chr2:190880797~190882059:-
BRCA	cis	rs4853525	0.59	rs4513327	ENSG00000235852.1	AC005540.3	4.78	2.04e-06	0.000194	0.18	0.15	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190850695	chr2:190880797~190882059:-
BRCA	cis	rs11098499	0.657	rs71614442	ENSG00000260091.1	RP11-33B1.4	-4.78	2.04e-06	0.000194	-0.13	-0.15	Corneal astigmatism;	chr4:119458191	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.954	rs2892848	ENSG00000260091.1	RP11-33B1.4	-4.78	2.04e-06	0.000194	-0.13	-0.15	Corneal astigmatism;	chr4:119460186	chr4:119409333~119410233:+
BRCA	cis	rs2790457	0.833	rs1265847	ENSG00000254635.4	WAC-AS1	-4.78	2.04e-06	0.000194	-0.18	-0.15	Multiple myeloma;	chr10:28640757	chr10:28522652~28532743:-
BRCA	cis	rs17428076	0.793	rs7584258	ENSG00000228389.1	AC068039.4	-4.78	2.04e-06	0.000194	-0.21	-0.15	Myopia;	chr2:171803326	chr2:171773482~171775844:+
BRCA	cis	rs7487075	0.619	rs2408498	ENSG00000274723.1	RP11-618L22.1	4.78	2.04e-06	0.000195	0.18	0.15	Itch intensity from mosquito bite;	chr12:46403117	chr12:46970504~46972155:+
BRCA	cis	rs3764021	0.87	rs2401394	ENSG00000278635.1	CTD-2318O12.1	-4.78	2.04e-06	0.000195	-0.14	-0.15	Type 1 diabetes;	chr12:9726830	chr12:9415641~9416718:+
BRCA	cis	rs4763879	0.634	rs7974396	ENSG00000278635.1	CTD-2318O12.1	4.78	2.04e-06	0.000195	0.14	0.15	Type 1 diabetes;	chr12:9708101	chr12:9415641~9416718:+
BRCA	cis	rs4950322	0.542	rs2883434	ENSG00000244371.2	PFN1P8	-4.78	2.04e-06	0.000195	-0.18	-0.15	Protein quantitative trait loci;	chr1:147177505	chr1:146957117~146957659:-
BRCA	cis	rs11098499	0.954	rs10518328	ENSG00000250412.1	KLHL2P1	4.78	2.04e-06	0.000195	0.18	0.15	Corneal astigmatism;	chr4:119480624	chr4:119334329~119378233:+
BRCA	cis	rs454217	0.791	rs337650	ENSG00000277851.1	RP11-756G20.1	4.78	2.04e-06	0.000195	0.17	0.15	Smoking quantity;	chr12:92309130	chr12:92247756~92363832:-
BRCA	cis	rs427691	0.625	rs845733	ENSG00000271849.1	CTC-332L22.1	-4.78	2.04e-06	0.000195	-0.24	-0.15	Autism spectrum disorder or schizophrenia;	chr5:109687700	chr5:109687802~109688329:-
BRCA	cis	rs4578769	0.879	rs7243408	ENSG00000265939.1	UBE2CP2	4.78	2.04e-06	0.000195	0.17	0.15	Eosinophil percentage of white cells;	chr18:22861647	chr18:22900486~22900995:-
BRCA	cis	rs9659323	0.632	rs10923743	ENSG00000231365.4	RP11-418J17.1	-4.78	2.04e-06	0.000195	-0.17	-0.15	Body mass index;	chr1:119070009	chr1:119140396~119275973:+
BRCA	cis	rs9659323	0.632	rs10923744	ENSG00000231365.4	RP11-418J17.1	-4.78	2.04e-06	0.000195	-0.17	-0.15	Body mass index;	chr1:119071318	chr1:119140396~119275973:+
BRCA	cis	rs8016982	0.657	rs8021125	ENSG00000258999.1	RP11-114N19.3	-4.78	2.04e-06	0.000195	-0.17	-0.15	Schizophrenia;	chr14:81238443	chr14:81107033~81170414:-
BRCA	cis	rs7487075	0.619	rs9669404	ENSG00000274723.1	RP11-618L22.1	-4.78	2.04e-06	0.000195	-0.18	-0.15	Itch intensity from mosquito bite;	chr12:46405180	chr12:46970504~46972155:+
BRCA	cis	rs2638953	0.927	rs11049630	ENSG00000247934.4	RP11-967K21.1	-4.78	2.04e-06	0.000195	-0.19	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28460240	chr12:28163298~28190738:-
BRCA	cis	rs4356203	0.905	rs35933265	ENSG00000272034.1	SNORD14A	-4.78	2.05e-06	0.000195	-0.15	-0.15	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17093707	chr11:17074654~17074744:-
BRCA	cis	rs1075265	0.597	rs11694711	ENSG00000235937.1	AC008280.1	4.78	2.05e-06	0.000195	0.16	0.15	Chronotype;Morning vs. evening chronotype;	chr2:53971924	chr2:54029552~54030682:-
BRCA	cis	rs4908760	0.73	rs10779704	ENSG00000232912.4	RP5-1115A15.1	4.78	2.05e-06	0.000195	0.14	0.15	Vitiligo;	chr1:8633478	chr1:8424645~8434838:+
BRCA	cis	rs2412819	0.571	rs11070411	ENSG00000166763.7	STRCP1	-4.78	2.05e-06	0.000195	-0.21	-0.15	Lung cancer;	chr15:43766436	chr15:43699488~43718184:-
BRCA	cis	rs3845817	0.966	rs13028180	ENSG00000237979.1	AC007389.1	-4.78	2.05e-06	0.000195	-0.17	-0.15	Bipolar disorder;	chr2:65536906	chr2:65500993~65502138:-
BRCA	cis	rs6951245	1	rs113575110	ENSG00000229043.2	AC091729.9	-4.78	2.05e-06	0.000195	-0.26	-0.15	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1044758	chr7:1160374~1165267:+
BRCA	cis	rs6951245	1	rs1881123	ENSG00000229043.2	AC091729.9	-4.78	2.05e-06	0.000195	-0.26	-0.15	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1045070	chr7:1160374~1165267:+
BRCA	cis	rs6951245	0.872	rs77569514	ENSG00000229043.2	AC091729.9	-4.78	2.05e-06	0.000195	-0.26	-0.15	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1045872	chr7:1160374~1165267:+
BRCA	cis	rs9659323	0.632	rs12045138	ENSG00000231365.4	RP11-418J17.1	-4.78	2.05e-06	0.000195	-0.17	-0.15	Body mass index;	chr1:119076825	chr1:119140396~119275973:+
BRCA	cis	rs73193808	1	rs2832227	ENSG00000236056.1	GAPDHP14	-4.78	2.05e-06	0.000195	-0.21	-0.15	Coronary artery disease;	chr21:29160755	chr21:29222321~29223257:+
BRCA	cis	rs9635324	0.555	rs2034650	ENSG00000223313.1	RNU6-516P	-4.78	2.05e-06	0.000195	-0.17	-0.15	Blood metabolite ratios;Blood metabolite levels;	chr15:40425103	chr15:40529570~40529673:+
BRCA	cis	rs57221529	0.545	rs55955015	ENSG00000225138.6	CTD-2228K2.7	4.78	2.05e-06	0.000195	0.23	0.15	Lung disease severity in cystic fibrosis;	chr5:575067	chr5:473236~480884:+
BRCA	cis	rs11098499	0.789	rs10212719	ENSG00000260404.2	RP11-384K6.6	4.78	2.05e-06	0.000195	0.13	0.15	Corneal astigmatism;	chr4:119333282	chr4:118591773~118633729:+
BRCA	cis	rs10129255	0.957	rs8009464	ENSG00000280411.1	IGHV1-69-2	-4.78	2.05e-06	0.000195	-0.1	-0.15	Kawasaki disease;	chr14:106777611	chr14:106762092~106762588:-
BRCA	cis	rs6840360	0.642	rs6855845	ENSG00000251603.1	RP11-164P12.4	-4.78	2.05e-06	0.000195	-0.13	-0.15	Intelligence (multi-trait analysis);	chr4:151496228	chr4:151667224~151670502:+
BRCA	cis	rs1371614	0.545	rs3769137	ENSG00000229122.1	AGBL5-IT1	-4.78	2.05e-06	0.000195	-0.15	-0.15	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26946622	chr2:27061038~27061815:+
BRCA	cis	rs9840812	0.623	rs9854084	ENSG00000273486.1	RP11-731C17.2	4.78	2.05e-06	0.000196	0.18	0.15	Fibrinogen levels;	chr3:136475901	chr3:136837338~136839021:-
BRCA	cis	rs6088590	0.561	rs11167239	ENSG00000276073.1	RP5-1125A11.7	-4.78	2.05e-06	0.000196	-0.16	-0.15	Coronary artery disease;	chr20:34552668	chr20:33985617~33988989:-
BRCA	cis	rs1979679	0.879	rs2061759	ENSG00000278733.1	RP11-425D17.1	4.78	2.05e-06	0.000196	0.19	0.15	Ossification of the posterior longitudinal ligament of the spine;	chr12:28310394	chr12:28185625~28186190:-
BRCA	cis	rs67311347	0.605	rs1880762	ENSG00000280739.1	EIF1B-AS1	4.78	2.05e-06	0.000196	0.16	0.15	Renal cell carcinoma;	chr3:40241724	chr3:40173145~40309698:-
BRCA	cis	rs13326165	0.585	rs10461027	ENSG00000243224.1	RP5-1157M23.2	-4.78	2.05e-06	0.000196	-0.25	-0.15	HDL cholesterol levels;HDL cholesterol;	chr3:52307110	chr3:52239258~52241097:+
BRCA	cis	rs7226408	0.901	rs11081991	ENSG00000267707.2	RP11-95O2.5	4.78	2.05e-06	0.000196	0.22	0.15	Obesity-related traits;	chr18:37163985	chr18:37243776~37247506:+
BRCA	cis	rs2638953	0.815	rs11049634	ENSG00000247934.4	RP11-967K21.1	4.78	2.05e-06	0.000196	0.2	0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28461296	chr12:28163298~28190738:-
BRCA	cis	rs7226408	0.901	rs17652953	ENSG00000267707.2	RP11-95O2.5	4.78	2.05e-06	0.000196	0.22	0.15	Obesity-related traits;	chr18:37181742	chr18:37243776~37247506:+
BRCA	cis	rs4948275	0.773	rs2650737	ENSG00000237233.2	TMEM26-AS1	-4.78	2.05e-06	0.000196	-0.17	-0.15	Night sleep phenotypes;	chr10:61490549	chr10:61452639~61481956:+
BRCA	cis	rs4948275	0.773	rs2787737	ENSG00000237233.2	TMEM26-AS1	-4.78	2.05e-06	0.000196	-0.17	-0.15	Night sleep phenotypes;	chr10:61491027	chr10:61452639~61481956:+
BRCA	cis	rs60843830	1	rs9213	ENSG00000272342.1	RP13-539J13.1	4.77	2.05e-06	0.000196	0.19	0.15	Spherical equivalent (joint analysis main effects and education interaction);	chr2:218386	chr2:739588~740164:-
BRCA	cis	rs7772486	0.754	rs4896841	ENSG00000270638.1	RP3-466P17.1	-4.77	2.05e-06	0.000196	-0.17	-0.15	Lobe attachment (rater-scored or self-reported);	chr6:145720386	chr6:145735570~145737218:+
BRCA	cis	rs7682317	0.738	rs2178586	ENSG00000270720.1	RP11-84C13.2	-4.77	2.06e-06	0.000196	-0.16	-0.15	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr4:89004169	chr4:89119284~89119871:+
BRCA	cis	rs7682317	0.797	rs6852288	ENSG00000270720.1	RP11-84C13.2	-4.77	2.06e-06	0.000196	-0.16	-0.15	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr4:89004659	chr4:89119284~89119871:+
BRCA	cis	rs7246657	0.722	rs2287229	ENSG00000276846.1	CTD-3220F14.3	-4.77	2.06e-06	0.000196	-0.2	-0.15	Coronary artery calcification;	chr19:37697751	chr19:37314868~37315620:-
BRCA	cis	rs1862618	0.671	rs2591970	ENSG00000271828.1	CTD-2310F14.1	-4.77	2.06e-06	0.000196	-0.18	-0.15	Initial pursuit acceleration;	chr5:56936768	chr5:56927874~56929573:+
BRCA	cis	rs4853525	0.59	rs12614693	ENSG00000235852.1	AC005540.3	4.77	2.06e-06	0.000196	0.18	0.15	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190854882	chr2:190880797~190882059:-
BRCA	cis	rs9816784	0.525	rs422772	ENSG00000242086.7	LINC00969	4.77	2.06e-06	0.000196	0.17	0.15	Mean corpuscular hemoglobin;	chr3:196079601	chr3:195658062~195739964:+
BRCA	cis	rs3892630	0.824	rs2287882	ENSG00000267475.1	CTD-2538C1.2	-4.77	2.06e-06	0.000196	-0.23	-0.15	Red blood cell traits;	chr19:32842046	chr19:32687089~32691750:-
BRCA	cis	rs2243480	1	rs67536397	ENSG00000275400.1	RP4-756H11.5	4.77	2.06e-06	0.000196	0.27	0.15	Diabetic kidney disease;	chr7:66482930	chr7:66553805~66554199:-
BRCA	cis	rs2243480	1	rs58669269	ENSG00000275400.1	RP4-756H11.5	4.77	2.06e-06	0.000196	0.27	0.15	Diabetic kidney disease;	chr7:66486966	chr7:66553805~66554199:-
BRCA	cis	rs7617773	0.963	rs6766754	ENSG00000228638.1	FCF1P2	4.77	2.06e-06	0.000196	0.14	0.15	Coronary artery disease;	chr3:48141099	chr3:48290793~48291375:-
BRCA	cis	rs7617773	0.832	rs6775114	ENSG00000228638.1	FCF1P2	4.77	2.06e-06	0.000196	0.14	0.15	Coronary artery disease;	chr3:48141130	chr3:48290793~48291375:-
BRCA	cis	rs4578769	0.797	rs9304261	ENSG00000265939.1	UBE2CP2	-4.77	2.06e-06	0.000196	-0.18	-0.15	Eosinophil percentage of white cells;	chr18:23026633	chr18:22900486~22900995:-
BRCA	cis	rs4356203	0.905	rs621246	ENSG00000272034.1	SNORD14A	-4.77	2.06e-06	0.000197	-0.15	-0.15	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17182218	chr11:17074654~17074744:-
BRCA	cis	rs6847067	0.794	rs7675324	ENSG00000180769.7	WDFY3-AS2	4.77	2.06e-06	0.000197	0.13	0.15	Oropharynx cancer;	chr4:85021460	chr4:84965682~85011277:+
BRCA	cis	rs34421088	0.532	rs2736258	ENSG00000255046.1	RP11-297N6.4	-4.77	2.06e-06	0.000197	-0.19	-0.15	Neuroticism;	chr8:11312940	chr8:11797928~11802568:-
BRCA	cis	rs62025270	0.688	rs62022941	ENSG00000259762.1	RP11-158M2.4	-4.77	2.06e-06	0.000197	-0.22	-0.15	Idiopathic pulmonary fibrosis;	chr15:85712824	chr15:85750336~85752901:-
BRCA	cis	rs6095360	1	rs1569750	ENSG00000222365.1	SNORD12B	-4.77	2.07e-06	0.000197	-0.16	-0.15	Intelligence (multi-trait analysis);	chr20:48986704	chr20:49280319~49280409:+
BRCA	cis	rs7226408	0.901	rs1503359	ENSG00000267707.2	RP11-95O2.5	4.77	2.07e-06	0.000197	0.22	0.15	Obesity-related traits;	chr18:37162452	chr18:37243776~37247506:+
BRCA	cis	rs10419113	0.668	rs2360533	ENSG00000268545.1	VN1R107P	4.77	2.07e-06	0.000197	0.17	0.15	Pediatric bone mineral density (spine);	chr19:57668907	chr19:57459912~57460120:+
BRCA	cis	rs739496	0.579	rs3741998	ENSG00000226469.1	ADAM1B	4.77	2.07e-06	0.000197	0.19	0.15	Platelet count;	chr12:111902039	chr12:111927018~111929017:+
BRCA	cis	rs739496	0.527	rs12319165	ENSG00000226469.1	ADAM1B	4.77	2.07e-06	0.000197	0.19	0.15	Platelet count;	chr12:111902930	chr12:111927018~111929017:+
BRCA	cis	rs739496	0.579	rs73426310	ENSG00000226469.1	ADAM1B	4.77	2.07e-06	0.000197	0.19	0.15	Platelet count;	chr12:111904606	chr12:111927018~111929017:+
BRCA	cis	rs739496	0.527	rs12427012	ENSG00000226469.1	ADAM1B	4.77	2.07e-06	0.000197	0.19	0.15	Platelet count;	chr12:111905570	chr12:111927018~111929017:+
BRCA	cis	rs739496	0.579	rs12316525	ENSG00000226469.1	ADAM1B	4.77	2.07e-06	0.000197	0.19	0.15	Platelet count;	chr12:111906315	chr12:111927018~111929017:+
BRCA	cis	rs739496	0.579	rs73426314	ENSG00000226469.1	ADAM1B	4.77	2.07e-06	0.000197	0.19	0.15	Platelet count;	chr12:111907252	chr12:111927018~111929017:+
BRCA	cis	rs739496	0.579	rs12582302	ENSG00000226469.1	ADAM1B	4.77	2.07e-06	0.000197	0.19	0.15	Platelet count;	chr12:111907830	chr12:111927018~111929017:+
BRCA	cis	rs739496	0.579	rs11066077	ENSG00000226469.1	ADAM1B	4.77	2.07e-06	0.000197	0.19	0.15	Platelet count;	chr12:111908857	chr12:111927018~111929017:+
BRCA	cis	rs2243480	1	rs313820	ENSG00000275400.1	RP4-756H11.5	4.77	2.07e-06	0.000197	0.27	0.15	Diabetic kidney disease;	chr7:66109479	chr7:66553805~66554199:-
BRCA	cis	rs17092148	0.636	rs6058107	ENSG00000126005.14	MMP24-AS1	4.77	2.07e-06	0.000197	0.19	0.15	Neuroticism;	chr20:34700742	chr20:35216462~35278131:-
BRCA	cis	rs2273156	0.706	rs7153550	ENSG00000226677.3	IGBP1P1	-4.77	2.07e-06	0.000197	-0.23	-0.15	Immunoglobulin light chain (AL) amyloidosis;	chr14:35032594	chr14:34939324~34940332:+
BRCA	cis	rs6756513	0.5	rs60168146	ENSG00000231024.1	AC092431.3	-4.77	2.07e-06	0.000197	-0.21	-0.15	Breast cancer;Platelet count;	chr2:69815200	chr2:69700192~69713847:-
BRCA	cis	rs9840812	0.728	rs6439646	ENSG00000273486.1	RP11-731C17.2	4.77	2.07e-06	0.000197	0.18	0.15	Fibrinogen levels;	chr3:136554721	chr3:136837338~136839021:-
BRCA	cis	rs256438	0.642	rs11738491	ENSG00000251050.1	RP11-168A11.4	-4.77	2.07e-06	0.000197	-0.17	-0.15	Serum thyroid-stimulating hormone levels;	chr5:80039149	chr5:80019609~80019920:+
BRCA	cis	rs4948275	0.742	rs3104841	ENSG00000237233.2	TMEM26-AS1	-4.77	2.07e-06	0.000197	-0.17	-0.15	Night sleep phenotypes;	chr10:61485227	chr10:61452639~61481956:+
BRCA	cis	rs2842346	0.568	rs2525527	ENSG00000258623.1	CTD-2325P2.3	-4.77	2.07e-06	0.000197	-0.19	-0.15	Breast cancer;	chr14:68543022	chr14:68683411~68685565:-
BRCA	cis	rs7577696	0.962	rs11691879	ENSG00000272716.1	RP11-563N4.1	-4.77	2.07e-06	0.000197	-0.16	-0.15	Inflammatory biomarkers;	chr2:32049148	chr2:32165046~32165757:-
BRCA	cis	rs35146811	0.961	rs11771139	ENSG00000235713.1	RP4-604G5.3	4.77	2.07e-06	0.000197	0.18	0.15	Coronary artery disease;	chr7:100138436	chr7:99992397~99993050:+
BRCA	cis	rs875971	0.798	rs57739047	ENSG00000236529.1	RP13-254B10.1	4.77	2.07e-06	0.000197	0.16	0.15	Aortic root size;	chr7:66507579	chr7:65840212~65840596:+
BRCA	cis	rs2243480	1	rs422164	ENSG00000275400.1	RP4-756H11.5	4.77	2.07e-06	0.000198	0.27	0.15	Diabetic kidney disease;	chr7:66121618	chr7:66553805~66554199:-
BRCA	cis	rs13108904	0.517	rs4974551	ENSG00000253399.1	AC078852.2	-4.77	2.07e-06	0.000198	-0.18	-0.15	Obesity-related traits;	chr4:1342622	chr4:1358479~1359461:+
BRCA	cis	rs3764021	1	rs3764021	ENSG00000256582.1	RP11-75L1.1	4.77	2.07e-06	0.000198	0.15	0.15	Type 1 diabetes;	chr12:9681032	chr12:9704077~9709350:+
BRCA	cis	rs6951245	1	rs74785791	ENSG00000229043.2	AC091729.9	-4.77	2.07e-06	0.000198	-0.26	-0.15	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1048858	chr7:1160374~1165267:+
BRCA	cis	rs6951245	1	rs74366004	ENSG00000229043.2	AC091729.9	-4.77	2.07e-06	0.000198	-0.26	-0.15	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1048994	chr7:1160374~1165267:+
BRCA	cis	rs6951245	1	rs77702926	ENSG00000229043.2	AC091729.9	-4.77	2.07e-06	0.000198	-0.26	-0.15	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1049202	chr7:1160374~1165267:+
BRCA	cis	rs6951245	0.935	rs78573577	ENSG00000229043.2	AC091729.9	-4.77	2.07e-06	0.000198	-0.26	-0.15	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1049451	chr7:1160374~1165267:+
BRCA	cis	rs934734	0.532	rs10153675	ENSG00000204929.10	AC074391.1	-4.77	2.08e-06	0.000198	-0.18	-0.15	Rheumatoid arthritis;	chr2:65422446	chr2:65436711~66084639:+
BRCA	cis	rs7626444	0.51	rs7649045	ENSG00000272359.1	U4	-4.77	2.08e-06	0.000198	-0.18	-0.15	Monocyte count;	chr3:196793007	chr3:196747192~196747324:-
BRCA	cis	rs35612822	0.723	rs12990340	ENSG00000232485.2	AC098820.3	-4.77	2.08e-06	0.000198	-0.18	-0.15	Kidney disease (early stage) in type 1 diabetes;	chr2:216401394	chr2:216479030~216498761:-
BRCA	cis	rs1707322	1	rs785510	ENSG00000234329.1	RP11-767N6.2	-4.77	2.08e-06	0.000198	-0.15	-0.15	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46062946	chr1:45651039~45651826:-
BRCA	cis	rs700651	0.856	rs9288280	ENSG00000231621.1	AC013264.2	-4.77	2.08e-06	0.000198	-0.14	-0.15	Intracranial aneurysm;	chr2:197879600	chr2:197197991~197199273:+
BRCA	cis	rs2153535	0.58	rs9328484	ENSG00000251164.1	HULC	-4.77	2.08e-06	0.000198	-0.18	-0.15	Motion sickness;	chr6:8524610	chr6:8652137~8653846:+
BRCA	cis	rs875971	0.502	rs11769702	ENSG00000232546.1	RP11-458F8.1	4.77	2.08e-06	0.000198	0.14	0.15	Aortic root size;	chr7:66255529	chr7:66848496~66858136:+
BRCA	cis	rs875971	0.8	rs427557	ENSG00000223473.2	GS1-124K5.3	4.77	2.08e-06	0.000198	0.11	0.15	Aortic root size;	chr7:66054263	chr7:66491049~66493566:-
BRCA	cis	rs1075265	0.756	rs805423	ENSG00000235937.1	AC008280.1	4.77	2.08e-06	0.000198	0.16	0.15	Chronotype;Morning vs. evening chronotype;	chr2:53899904	chr2:54029552~54030682:-
BRCA	cis	rs3739034	0.582	rs62171431	ENSG00000224043.6	CCNT2-AS1	-4.77	2.08e-06	0.000198	-0.29	-0.15	Gut microbiome composition (winter);	chr2:134806102	chr2:134735464~134918710:-
BRCA	cis	rs2179367	0.6	rs9498352	ENSG00000223701.3	RAET1E-AS1	4.77	2.08e-06	0.000198	0.22	0.15	Dupuytren's disease;	chr6:149439108	chr6:149884431~149919508:+
BRCA	cis	rs7208859	0.673	rs11657270	ENSG00000280069.1	CTD-2349P21.3	-4.77	2.08e-06	0.000198	-0.22	-0.15	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887369	chr17:30738182~30740275:+
BRCA	cis	rs13108904	0.557	rs1250086	ENSG00000254094.1	AC078852.1	4.77	2.08e-06	0.000198	0.17	0.15	Obesity-related traits;	chr4:1254263	chr4:1356581~1358075:+
BRCA	cis	rs2115630	0.905	rs6496401	ENSG00000259295.5	CSPG4P12	-4.77	2.08e-06	0.000198	-0.17	-0.15	P wave terminal force;	chr15:84754562	chr15:85191438~85213905:+
BRCA	cis	rs7226408	0.894	rs11659465	ENSG00000267707.2	RP11-95O2.5	4.77	2.08e-06	0.000198	0.24	0.15	Obesity-related traits;	chr18:36795524	chr18:37243776~37247506:+
BRCA	cis	rs12681366	0.537	rs2197004	ENSG00000253704.1	RP11-267M23.4	4.77	2.08e-06	0.000198	0.16	0.15	Nonsyndromic cleft lip with cleft palate;	chr8:94444748	chr8:94553722~94569745:+
BRCA	cis	rs867371	0.929	rs1501371	ENSG00000255769.6	GOLGA2P10	-4.77	2.08e-06	0.000198	-0.17	-0.15	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82168099	chr15:82472993~82513950:-
BRCA	cis	rs4323050	0.546	rs13124157	ENSG00000249741.2	RP11-673E1.3	-4.77	2.08e-06	0.000198	-0.16	-0.15	High light scatter reticulocyte percentage of red cells;	chr4:143975741	chr4:143911514~143912053:-
BRCA	cis	rs7267979	1	rs2482911	ENSG00000125804.12	FAM182A	4.77	2.08e-06	0.000198	0.19	0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25414892	chr20:26054655~26086917:+
BRCA	cis	rs7772486	0.875	rs865913	ENSG00000270638.1	RP3-466P17.1	4.77	2.08e-06	0.000198	0.17	0.15	Lobe attachment (rater-scored or self-reported);	chr6:145987738	chr6:145735570~145737218:+
BRCA	cis	rs7772486	0.875	rs2814873	ENSG00000270638.1	RP3-466P17.1	4.77	2.08e-06	0.000198	0.17	0.15	Lobe attachment (rater-scored or self-reported);	chr6:145987796	chr6:145735570~145737218:+
BRCA	cis	rs7772486	0.84	rs2777478	ENSG00000270638.1	RP3-466P17.1	4.77	2.08e-06	0.000198	0.17	0.15	Lobe attachment (rater-scored or self-reported);	chr6:145987981	chr6:145735570~145737218:+
BRCA	cis	rs7772486	0.875	rs2814872	ENSG00000270638.1	RP3-466P17.1	4.77	2.08e-06	0.000198	0.17	0.15	Lobe attachment (rater-scored or self-reported);	chr6:145989098	chr6:145735570~145737218:+
BRCA	cis	rs7267979	0.903	rs6115118	ENSG00000276952.1	RP5-965G21.6	4.77	2.08e-06	0.000198	0.18	0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25266098	chr20:25284915~25285588:-
BRCA	cis	rs7267979	0.903	rs1118963	ENSG00000276952.1	RP5-965G21.6	4.77	2.08e-06	0.000198	0.18	0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25266813	chr20:25284915~25285588:-
BRCA	cis	rs4664293	1	rs6745766	ENSG00000224152.1	AC009506.1	-4.77	2.08e-06	0.000198	-0.16	-0.15	Monocyte percentage of white cells;	chr2:159598284	chr2:159615296~159617082:+
BRCA	cis	rs11239930	0.517	rs535827	ENSG00000230832.3	RP11-325P15.2	-4.77	2.08e-06	0.000199	-0.21	-0.15	AIDS progression;	chr1:147076642	chr1:147082338~147083578:-
BRCA	cis	rs7226408	0.948	rs11665195	ENSG00000267707.2	RP11-95O2.5	4.77	2.08e-06	0.000199	0.23	0.15	Obesity-related traits;	chr18:36809977	chr18:37243776~37247506:+
BRCA	cis	rs7226408	0.948	rs72883588	ENSG00000267707.2	RP11-95O2.5	4.77	2.08e-06	0.000199	0.23	0.15	Obesity-related traits;	chr18:36810510	chr18:37243776~37247506:+
BRCA	cis	rs7226408	0.948	rs72883590	ENSG00000267707.2	RP11-95O2.5	4.77	2.08e-06	0.000199	0.23	0.15	Obesity-related traits;	chr18:36810830	chr18:37243776~37247506:+
BRCA	cis	rs7226408	0.842	rs72883593	ENSG00000267707.2	RP11-95O2.5	4.77	2.08e-06	0.000199	0.23	0.15	Obesity-related traits;	chr18:36810877	chr18:37243776~37247506:+
BRCA	cis	rs7226408	0.842	rs17652345	ENSG00000267707.2	RP11-95O2.5	4.77	2.08e-06	0.000199	0.23	0.15	Obesity-related traits;	chr18:36811530	chr18:37243776~37247506:+
BRCA	cis	rs7226408	0.948	rs72883595	ENSG00000267707.2	RP11-95O2.5	4.77	2.08e-06	0.000199	0.23	0.15	Obesity-related traits;	chr18:36812827	chr18:37243776~37247506:+
BRCA	cis	rs7226408	0.894	rs72883597	ENSG00000267707.2	RP11-95O2.5	4.77	2.08e-06	0.000199	0.23	0.15	Obesity-related traits;	chr18:36813234	chr18:37243776~37247506:+
BRCA	cis	rs1005277	0.579	rs1780130	ENSG00000099251.13	HSD17B7P2	4.77	2.09e-06	0.000199	0.16	0.15	Extrinsic epigenetic age acceleration;	chr10:38196450	chr10:38356380~38378505:+
BRCA	cis	rs6496044	0.568	rs12708554	ENSG00000202081.1	RNU6-1280P	4.77	2.09e-06	0.000199	0.17	0.15	Interstitial lung disease;	chr15:85531066	chr15:85651522~85651628:-
BRCA	cis	rs7829975	0.688	rs6601703	ENSG00000233609.3	RP11-62H7.2	4.77	2.09e-06	0.000199	0.14	0.15	Mood instability;	chr8:8522714	chr8:8961200~8979025:+
BRCA	cis	rs881375	0.501	rs10739591	ENSG00000226752.6	PSMD5-AS1	-4.77	2.09e-06	0.000199	-0.18	-0.15	Rheumatoid arthritis;	chr9:121123450	chr9:120824828~120854385:+
BRCA	cis	rs1722141	0.669	rs34479156	ENSG00000237471.1	AC073115.6	4.77	2.09e-06	0.000199	0.21	0.15	Sitting height ratio;	chr7:46010517	chr7:45969657~45980191:+
BRCA	cis	rs17695224	0.545	rs11666614	ENSG00000269483.1	AC006272.1	4.77	2.09e-06	0.000199	0.18	0.15	HDL cholesterol;HDL cholesterol levels;	chr19:51842833	chr19:51839924~51843324:-
BRCA	cis	rs1656368	0.726	rs12491598	ENSG00000279311.1	RP11-170K4.2	4.77	2.09e-06	0.000199	0.19	0.15	Lobe attachment (rater-scored or self-reported);	chr3:158545365	chr3:158869898~158871821:+
BRCA	cis	rs6756513	0.5	rs56222989	ENSG00000231024.1	AC092431.3	-4.77	2.09e-06	0.000199	-0.21	-0.15	Breast cancer;Platelet count;	chr2:69861998	chr2:69700192~69713847:-
BRCA	cis	rs60843830	0.928	rs2306060	ENSG00000272342.1	RP13-539J13.1	4.77	2.09e-06	0.000199	0.18	0.15	Spherical equivalent (joint analysis main effects and education interaction);	chr2:230912	chr2:739588~740164:-
BRCA	cis	rs7577696	0.924	rs72862234	ENSG00000272716.1	RP11-563N4.1	-4.77	2.09e-06	0.000199	-0.16	-0.15	Inflammatory biomarkers;	chr2:32045077	chr2:32165046~32165757:-
BRCA	cis	rs7569084	0.566	rs7584295	ENSG00000204929.10	AC074391.1	4.77	2.09e-06	0.000199	0.18	0.15	Sum eosinophil basophil counts;	chr2:65353940	chr2:65436711~66084639:+
BRCA	cis	rs934734	0.563	rs11695373	ENSG00000204929.10	AC074391.1	4.77	2.09e-06	0.000199	0.18	0.15	Rheumatoid arthritis;	chr2:65354066	chr2:65436711~66084639:+
BRCA	cis	rs17270561	0.779	rs17271767	ENSG00000272462.2	U91328.19	-4.77	2.09e-06	0.000199	-0.19	-0.15	Iron status biomarkers;	chr6:25886693	chr6:25992662~26001775:+
BRCA	cis	rs7226408	0.948	rs11665141	ENSG00000267707.2	RP11-95O2.5	4.77	2.09e-06	0.000199	0.24	0.15	Obesity-related traits;	chr18:36794902	chr18:37243776~37247506:+
BRCA	cis	rs853679	0.55	rs1237875	ENSG00000216901.1	AL022393.7	-4.77	2.09e-06	0.000199	-0.2	-0.15	Depression;	chr6:28205232	chr6:28176188~28176674:+
BRCA	cis	rs9467773	0.62	rs2504600	ENSG00000124549.13	BTN2A3P	4.77	2.09e-06	0.000199	0.15	0.15	Intelligence (multi-trait analysis);	chr6:26648106	chr6:26421391~26432383:+
BRCA	cis	rs9467773	0.62	rs2130657	ENSG00000124549.13	BTN2A3P	4.77	2.09e-06	0.000199	0.15	0.15	Intelligence (multi-trait analysis);	chr6:26650598	chr6:26421391~26432383:+
BRCA	cis	rs9467773	0.62	rs2498351	ENSG00000124549.13	BTN2A3P	4.77	2.09e-06	0.000199	0.15	0.15	Intelligence (multi-trait analysis);	chr6:26659414	chr6:26421391~26432383:+
BRCA	cis	rs9467773	0.62	rs2504566	ENSG00000124549.13	BTN2A3P	4.77	2.09e-06	0.000199	0.15	0.15	Intelligence (multi-trait analysis);	chr6:26660260	chr6:26421391~26432383:+
BRCA	cis	rs9990333	0.544	rs11915082	ENSG00000242086.7	LINC00969	4.77	2.09e-06	0.000199	0.17	0.15	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196082268	chr3:195658062~195739964:+
BRCA	cis	rs926392	0.965	rs6129167	ENSG00000274825.1	RP4-616B8.5	4.77	2.09e-06	0.000199	0.14	0.15	Dialysis-related mortality;	chr20:39060585	chr20:38955910~38956547:+
BRCA	cis	rs11098499	0.874	rs10022508	ENSG00000249244.1	RP11-548H18.2	4.77	2.09e-06	0.000199	0.18	0.15	Corneal astigmatism;	chr4:119194073	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.865	rs28753180	ENSG00000250412.1	KLHL2P1	4.77	2.1e-06	0.000199	0.18	0.15	Corneal astigmatism;	chr4:119484212	chr4:119334329~119378233:+
BRCA	cis	rs6921919	0.583	rs2041230	ENSG00000220721.1	OR1F12	4.77	2.1e-06	2e-04	0.18	0.15	Autism spectrum disorder or schizophrenia;	chr6:28397738	chr6:28073316~28074233:+
BRCA	cis	rs9652601	0.691	rs7198004	ENSG00000274038.1	RP11-66H6.4	-4.77	2.1e-06	2e-04	-0.16	-0.15	Systemic lupus erythematosus;	chr16:11113760	chr16:11056556~11057034:+
BRCA	cis	rs871012	0.502	rs56259240	ENSG00000248544.2	CTB-47B11.3	-4.77	2.1e-06	2e-04	-0.19	-0.15	IgG glycosylation;	chr5:157464523	chr5:157375741~157384950:-
BRCA	cis	rs66887589	0.934	rs2389873	ENSG00000245958.5	RP11-33B1.1	4.77	2.1e-06	2e-04	0.13	0.15	Diastolic blood pressure;	chr4:119633559	chr4:119454791~119552025:+
BRCA	cis	rs66887589	0.934	rs4834792	ENSG00000245958.5	RP11-33B1.1	4.77	2.1e-06	2e-04	0.13	0.15	Diastolic blood pressure;	chr4:119634541	chr4:119454791~119552025:+
BRCA	cis	rs57221529	0.766	rs12518859	ENSG00000271781.1	CTD-2589H19.6	-4.77	2.1e-06	2e-04	-0.22	-0.15	Lung disease severity in cystic fibrosis;	chr5:587317	chr5:675826~676616:+
BRCA	cis	rs4908760	0.613	rs12028160	ENSG00000232912.4	RP5-1115A15.1	-4.77	2.1e-06	2e-04	-0.14	-0.15	Vitiligo;	chr1:8752155	chr1:8424645~8434838:+
BRCA	cis	rs4415084	0.834	rs11957920	ENSG00000251141.4	RP11-53O19.1	-4.77	2.1e-06	2e-04	-0.13	-0.15	Breast cancer;	chr5:44904984	chr5:44744900~44808777:-
BRCA	cis	rs4415084	0.804	rs10070339	ENSG00000251141.4	RP11-53O19.1	-4.77	2.1e-06	2e-04	-0.13	-0.15	Breast cancer;	chr5:44907780	chr5:44744900~44808777:-
BRCA	cis	rs6561151	0.957	rs3764147	ENSG00000274001.1	RP11-5G9.5	-4.77	2.1e-06	2e-04	-0.18	-0.15	Crohn's disease;	chr13:43883789	chr13:43877715~43878163:-
BRCA	cis	rs308403	0.509	rs7690133	ENSG00000224786.1	CETN4P	4.77	2.1e-06	2e-04	0.19	0.15	Blood protein levels;	chr4:122752654	chr4:122730548~122732193:-
BRCA	cis	rs2665103	0.632	rs3902959	ENSG00000276710.3	CSPG4P8	-4.77	2.1e-06	2e-04	-0.15	-0.15	Intelligence (multi-trait analysis);	chr15:82252586	chr15:82459472~82477258:+
BRCA	cis	rs7577696	0.575	rs212704	ENSG00000272716.1	RP11-563N4.1	4.77	2.1e-06	2e-04	0.16	0.15	Inflammatory biomarkers;	chr2:32225279	chr2:32165046~32165757:-
BRCA	cis	rs7141336	0.8	rs8016414	ENSG00000258884.1	CTD-3035D6.2	4.77	2.1e-06	2e-04	0.19	0.15	Anxiety disorder;	chr14:90822036	chr14:90822365~90828128:-
BRCA	cis	rs67981189	0.542	rs1012725	ENSG00000258571.1	PTTG4P	4.77	2.1e-06	2e-04	0.18	0.15	Schizophrenia;	chr14:71138994	chr14:71085482~71085833:-
BRCA	cis	rs7615952	0.515	rs4441610	ENSG00000250012.1	RP11-124N2.1	-4.77	2.11e-06	2e-04	-0.19	-0.15	Blood pressure (smoking interaction);	chr3:125962464	chr3:126084220~126095349:+
BRCA	cis	rs7621331	1	rs9843725	ENSG00000273486.1	RP11-731C17.2	4.77	2.11e-06	2e-04	0.18	0.15	Waist circumference adjusted for body mass index;	chr3:135984023	chr3:136837338~136839021:-
BRCA	cis	rs6570726	0.846	rs973856	ENSG00000270638.1	RP3-466P17.1	-4.77	2.11e-06	0.000201	-0.16	-0.15	Lobe attachment (rater-scored or self-reported);	chr6:145460780	chr6:145735570~145737218:+
BRCA	cis	rs6832769	1	rs11733864	ENSG00000223305.1	RN7SKP30	4.77	2.11e-06	0.000201	0.18	0.15	Personality dimensions;	chr4:55455363	chr4:55540502~55540835:-
BRCA	cis	rs62025270	0.688	rs12148571	ENSG00000259762.1	RP11-158M2.4	-4.77	2.11e-06	0.000201	-0.23	-0.15	Idiopathic pulmonary fibrosis;	chr15:85724162	chr15:85750336~85752901:-
BRCA	cis	rs2835345	0.63	rs55681268	ENSG00000279365.1	KB-176G8.1	4.77	2.11e-06	0.000201	0.19	0.15	Pulmonary function;	chr21:36449419	chr21:36485867~36487760:+
BRCA	cis	rs9863	0.861	rs7973683	ENSG00000270028.1	RP11-380L11.4	4.77	2.11e-06	0.000201	0.18	0.15	White blood cell count;	chr12:123964676	chr12:123925461~123926083:-
BRCA	cis	rs7572733	0.773	rs7601762	ENSG00000231621.1	AC013264.2	-4.77	2.11e-06	0.000201	-0.13	-0.15	Dermatomyositis;	chr2:197664513	chr2:197197991~197199273:+
BRCA	cis	rs6756513	0.5	rs3771535	ENSG00000231024.1	AC092431.3	-4.77	2.11e-06	0.000201	-0.21	-0.15	Breast cancer;Platelet count;	chr2:69816643	chr2:69700192~69713847:-
BRCA	cis	rs4718428	1	rs12534637	ENSG00000229180.5	GS1-124K5.11	4.77	2.11e-06	0.000201	0.13	0.15	Corneal structure;	chr7:66862667	chr7:66526088~66542624:-
BRCA	cis	rs6570726	0.791	rs6915094	ENSG00000270638.1	RP3-466P17.1	4.77	2.11e-06	0.000201	0.17	0.15	Lobe attachment (rater-scored or self-reported);	chr6:145562404	chr6:145735570~145737218:+
BRCA	cis	rs1520333	0.54	rs13282611	ENSG00000254352.1	RP11-578O24.2	-4.77	2.11e-06	0.000201	-0.22	-0.15	Multiple sclerosis;	chr8:78452661	chr8:78723796~78724136:-
BRCA	cis	rs4561483	0.645	rs2192645	ENSG00000261216.1	RP11-166B2.5	-4.77	2.11e-06	0.000201	-0.17	-0.15	Testicular germ cell tumor;	chr16:11834162	chr16:11908208~11908916:+
BRCA	cis	rs17221829	0.703	rs10830336	ENSG00000280385.1	AP000648.5	-4.77	2.11e-06	0.000201	-0.17	-0.15	Anxiety in major depressive disorder;	chr11:89673293	chr11:90193614~90198120:+
BRCA	cis	rs6714710	0.603	rs11679828	ENSG00000230606.9	AC159540.1	-4.77	2.11e-06	0.000201	-0.17	-0.15	Posterior cortical atrophy and Alzheimer's disease;	chr2:97901163	chr2:97416165~97433527:-
BRCA	cis	rs6714710	0.58	rs11692470	ENSG00000230606.9	AC159540.1	-4.77	2.11e-06	0.000201	-0.17	-0.15	Posterior cortical atrophy and Alzheimer's disease;	chr2:97904101	chr2:97416165~97433527:-
BRCA	cis	rs7267979	1	rs2500432	ENSG00000125804.12	FAM182A	-4.77	2.11e-06	0.000201	-0.19	-0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25309876	chr20:26054655~26086917:+
BRCA	cis	rs2833693	0.572	rs11088213	ENSG00000261610.1	AP000265.1	4.77	2.11e-06	0.000201	0.18	0.15	Temperament;	chr21:32241398	chr21:32259804~32261585:-
BRCA	cis	rs2011013	0.6	rs34047645	ENSG00000230373.7	GOLGA6L5P	4.77	2.12e-06	0.000201	0.24	0.15	Sitting height ratio;	chr15:83942615	chr15:84507885~84516814:-
BRCA	cis	rs875971	0.862	rs778702	ENSG00000273448.1	RP11-166O4.6	4.77	2.12e-06	0.000201	0.14	0.15	Aortic root size;	chr7:66399848	chr7:67333047~67334383:+
BRCA	cis	rs4664293	0.867	rs7566584	ENSG00000224152.1	AC009506.1	-4.77	2.12e-06	0.000201	-0.16	-0.15	Monocyte percentage of white cells;	chr2:159728284	chr2:159615296~159617082:+
BRCA	cis	rs4664293	0.867	rs3732289	ENSG00000224152.1	AC009506.1	-4.77	2.12e-06	0.000201	-0.16	-0.15	Monocyte percentage of white cells;	chr2:159728887	chr2:159615296~159617082:+
BRCA	cis	rs4664293	0.867	rs3821299	ENSG00000224152.1	AC009506.1	-4.77	2.12e-06	0.000201	-0.16	-0.15	Monocyte percentage of white cells;	chr2:159729229	chr2:159615296~159617082:+
BRCA	cis	rs4664293	0.867	rs13415100	ENSG00000224152.1	AC009506.1	-4.77	2.12e-06	0.000201	-0.16	-0.15	Monocyte percentage of white cells;	chr2:159729716	chr2:159615296~159617082:+
BRCA	cis	rs4664293	0.867	rs13389662	ENSG00000224152.1	AC009506.1	-4.77	2.12e-06	0.000201	-0.16	-0.15	Monocyte percentage of white cells;	chr2:159729926	chr2:159615296~159617082:+
BRCA	cis	rs4664293	0.867	rs4665110	ENSG00000224152.1	AC009506.1	-4.77	2.12e-06	0.000201	-0.16	-0.15	Monocyte percentage of white cells;	chr2:159731014	chr2:159615296~159617082:+
BRCA	cis	rs4664293	0.867	rs34893664	ENSG00000224152.1	AC009506.1	-4.77	2.12e-06	0.000201	-0.16	-0.15	Monocyte percentage of white cells;	chr2:159732266	chr2:159615296~159617082:+
BRCA	cis	rs4664293	0.867	rs34795915	ENSG00000224152.1	AC009506.1	-4.77	2.12e-06	0.000201	-0.16	-0.15	Monocyte percentage of white cells;	chr2:159732420	chr2:159615296~159617082:+
BRCA	cis	rs4664293	0.867	rs10204867	ENSG00000224152.1	AC009506.1	-4.77	2.12e-06	0.000201	-0.16	-0.15	Monocyte percentage of white cells;	chr2:159732674	chr2:159615296~159617082:+
BRCA	cis	rs4664293	0.867	rs35196716	ENSG00000224152.1	AC009506.1	-4.77	2.12e-06	0.000201	-0.16	-0.15	Monocyte percentage of white cells;	chr2:159733266	chr2:159615296~159617082:+
BRCA	cis	rs4664293	0.867	rs6432557	ENSG00000224152.1	AC009506.1	-4.77	2.12e-06	0.000201	-0.16	-0.15	Monocyte percentage of white cells;	chr2:159735699	chr2:159615296~159617082:+
BRCA	cis	rs4664293	0.867	rs7603274	ENSG00000224152.1	AC009506.1	-4.77	2.12e-06	0.000201	-0.16	-0.15	Monocyte percentage of white cells;	chr2:159736179	chr2:159615296~159617082:+
BRCA	cis	rs4664293	0.836	rs13403371	ENSG00000224152.1	AC009506.1	-4.77	2.12e-06	0.000201	-0.16	-0.15	Monocyte percentage of white cells;	chr2:159736603	chr2:159615296~159617082:+
BRCA	cis	rs4664293	0.867	rs13428679	ENSG00000224152.1	AC009506.1	-4.77	2.12e-06	0.000201	-0.16	-0.15	Monocyte percentage of white cells;	chr2:159736687	chr2:159615296~159617082:+
BRCA	cis	rs4664293	0.867	rs12623283	ENSG00000224152.1	AC009506.1	-4.77	2.12e-06	0.000201	-0.16	-0.15	Monocyte percentage of white cells;	chr2:159736959	chr2:159615296~159617082:+
BRCA	cis	rs4664293	0.867	rs2098976	ENSG00000224152.1	AC009506.1	-4.77	2.12e-06	0.000201	-0.16	-0.15	Monocyte percentage of white cells;	chr2:159737264	chr2:159615296~159617082:+
BRCA	cis	rs4664293	0.867	rs2081723	ENSG00000224152.1	AC009506.1	-4.77	2.12e-06	0.000201	-0.16	-0.15	Monocyte percentage of white cells;	chr2:159737649	chr2:159615296~159617082:+
BRCA	cis	rs4664293	0.867	rs2081722	ENSG00000224152.1	AC009506.1	-4.77	2.12e-06	0.000201	-0.16	-0.15	Monocyte percentage of white cells;	chr2:159737697	chr2:159615296~159617082:+
BRCA	cis	rs4664293	0.867	rs10166694	ENSG00000224152.1	AC009506.1	-4.77	2.12e-06	0.000201	-0.16	-0.15	Monocyte percentage of white cells;	chr2:159738380	chr2:159615296~159617082:+
BRCA	cis	rs4664293	0.867	rs2357529	ENSG00000224152.1	AC009506.1	-4.77	2.12e-06	0.000201	-0.16	-0.15	Monocyte percentage of white cells;	chr2:159738922	chr2:159615296~159617082:+
BRCA	cis	rs4664293	0.867	rs12692562	ENSG00000224152.1	AC009506.1	-4.77	2.12e-06	0.000201	-0.16	-0.15	Monocyte percentage of white cells;	chr2:159739199	chr2:159615296~159617082:+
BRCA	cis	rs4664293	0.867	rs12998291	ENSG00000224152.1	AC009506.1	-4.77	2.12e-06	0.000201	-0.16	-0.15	Monocyte percentage of white cells;	chr2:159739392	chr2:159615296~159617082:+
BRCA	cis	rs7267979	0.816	rs405822	ENSG00000274414.1	RP5-965G21.4	-4.77	2.12e-06	0.000201	-0.17	-0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25520678	chr20:25239007~25245229:-
BRCA	cis	rs7267979	0.816	rs409853	ENSG00000274414.1	RP5-965G21.4	-4.77	2.12e-06	0.000201	-0.17	-0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25525431	chr20:25239007~25245229:-
BRCA	cis	rs9921338	0.961	rs7206749	ENSG00000262703.1	RP11-485G7.6	-4.77	2.12e-06	0.000202	-0.18	-0.15	Vein graft stenosis in coronary artery bypass grafting;	chr16:11283065	chr16:11348143~11349321:-
BRCA	cis	rs875971	0.862	rs6962717	ENSG00000273448.1	RP11-166O4.6	4.77	2.12e-06	0.000202	0.14	0.15	Aortic root size;	chr7:66418748	chr7:67333047~67334383:+
BRCA	cis	rs66887589	0.72	rs2036858	ENSG00000249244.1	RP11-548H18.2	4.77	2.12e-06	0.000202	0.16	0.15	Diastolic blood pressure;	chr4:119328082	chr4:119391831~119395335:-
BRCA	cis	rs2186369	1	rs9620326	ENSG00000272733.1	KB-208E9.1	4.77	2.12e-06	0.000202	0.21	0.15	IgG N-glycosylation phenotypes (multivariate analysis);IgG digalactosylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG glycosylation;IgG fucosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);	chr22:23804442	chr22:23580880~23583859:-
BRCA	cis	rs853679	0.699	rs9468318	ENSG00000280107.1	AL022393.9	-4.77	2.12e-06	0.000202	-0.23	-0.15	Depression;	chr6:28241753	chr6:28170845~28172521:+
BRCA	cis	rs7481584	0.581	rs105686	ENSG00000247473.2	CARS-AS1	-4.77	2.12e-06	0.000202	-0.17	-0.15	Calcium levels;	chr11:3041237	chr11:3029009~3041260:+
BRCA	cis	rs654950	0.783	rs668359	ENSG00000230638.4	RP11-486B10.4	4.77	2.12e-06	0.000202	0.18	0.15	Airway imaging phenotypes;	chr1:41537754	chr1:41542069~41544310:+
BRCA	cis	rs4906332	1	rs7155822	ENSG00000244691.1	RPL10AP1	-4.77	2.12e-06	0.000202	-0.19	-0.15	Coronary artery disease;	chr14:103456053	chr14:103412119~103412761:-
BRCA	cis	rs7618915	0.547	rs6762813	ENSG00000243224.1	RP5-1157M23.2	-4.77	2.12e-06	0.000202	-0.16	-0.15	Bipolar disorder;	chr3:52692679	chr3:52239258~52241097:+
BRCA	cis	rs6840360	0.667	rs2709832	ENSG00000251611.1	RP11-610P16.1	-4.77	2.12e-06	0.000202	-0.13	-0.15	Intelligence (multi-trait analysis);	chr4:151458242	chr4:151407551~151408835:-
BRCA	cis	rs13108904	0.905	rs34490749	ENSG00000253399.1	AC078852.2	-4.77	2.12e-06	0.000202	-0.16	-0.15	Obesity-related traits;	chr4:1224193	chr4:1358479~1359461:+
BRCA	cis	rs6951245	1	rs76804143	ENSG00000229043.2	AC091729.9	-4.77	2.12e-06	0.000202	-0.26	-0.15	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1042385	chr7:1160374~1165267:+
BRCA	cis	rs172166	0.694	rs2791332	ENSG00000219392.1	RP1-265C24.5	-4.77	2.13e-06	0.000202	-0.2	-0.15	Cardiac Troponin-T levels;	chr6:28141010	chr6:28115628~28116551:+
BRCA	cis	rs8180040	0.966	rs60369822	ENSG00000271161.1	BOLA2P2	-4.77	2.13e-06	0.000202	-0.16	-0.15	Colorectal cancer;	chr3:47438245	chr3:47499841~47500407:+
BRCA	cis	rs1075265	0.87	rs1363062	ENSG00000235937.1	AC008280.1	4.77	2.13e-06	0.000202	0.16	0.15	Chronotype;Morning vs. evening chronotype;	chr2:54054625	chr2:54029552~54030682:-
BRCA	cis	rs2625529	0.689	rs12898868	ENSG00000260037.4	CTD-2524L6.3	4.77	2.13e-06	0.000202	0.18	0.15	Red blood cell count;	chr15:71820577	chr15:71818396~71823384:+
BRCA	cis	rs10129255	0.536	rs3944157	ENSG00000211959.2	IGHV4-39	4.77	2.13e-06	0.000202	0.1	0.15	Kawasaki disease;	chr14:106682286	chr14:106421711~106422218:-
BRCA	cis	rs3764021	0.509	rs10772071	ENSG00000256673.1	RP11-599J14.2	-4.77	2.13e-06	0.000202	-0.18	-0.15	Type 1 diabetes;	chr12:9717324	chr12:9398355~9414851:-
BRCA	cis	rs651907	0.967	rs641432	ENSG00000244119.1	PDCL3P4	4.77	2.13e-06	0.000202	0.12	0.15	Colorectal cancer;	chr3:101868722	chr3:101712472~101713191:+
BRCA	cis	rs651907	0.935	rs2926538	ENSG00000244119.1	PDCL3P4	4.77	2.13e-06	0.000202	0.12	0.15	Colorectal cancer;	chr3:101868741	chr3:101712472~101713191:+
BRCA	cis	rs651907	0.935	rs2929922	ENSG00000244119.1	PDCL3P4	4.77	2.13e-06	0.000202	0.12	0.15	Colorectal cancer;	chr3:101869090	chr3:101712472~101713191:+
BRCA	cis	rs7083	0.716	rs687740	ENSG00000278768.1	BACE1-AS	-4.77	2.13e-06	0.000202	-0.16	-0.15	Blood protein levels;	chr11:117306887	chr11:117290874~117293571:+
BRCA	cis	rs57221529	0.825	rs7443550	ENSG00000271781.1	CTD-2589H19.6	-4.77	2.13e-06	0.000202	-0.22	-0.15	Lung disease severity in cystic fibrosis;	chr5:578289	chr5:675826~676616:+
BRCA	cis	rs57221529	0.766	rs4245972	ENSG00000271781.1	CTD-2589H19.6	-4.77	2.13e-06	0.000202	-0.22	-0.15	Lung disease severity in cystic fibrosis;	chr5:578457	chr5:675826~676616:+
BRCA	cis	rs57221529	0.766	rs72703042	ENSG00000271781.1	CTD-2589H19.6	-4.77	2.13e-06	0.000202	-0.22	-0.15	Lung disease severity in cystic fibrosis;	chr5:579154	chr5:675826~676616:+
BRCA	cis	rs875971	0.83	rs6950137	ENSG00000236529.1	RP13-254B10.1	4.77	2.13e-06	0.000202	0.16	0.15	Aortic root size;	chr7:66511623	chr7:65840212~65840596:+
BRCA	cis	rs6570726	0.935	rs380883	ENSG00000270638.1	RP3-466P17.1	4.77	2.13e-06	0.000202	0.16	0.15	Lobe attachment (rater-scored or self-reported);	chr6:145501856	chr6:145735570~145737218:+
BRCA	cis	rs925228	0.504	rs7568272	ENSG00000232642.1	AC008073.7	-4.77	2.13e-06	0.000203	-0.25	-0.15	Reticulocyte count;Reticulocyte fraction of red cells;	chr2:24090915	chr2:24165884~24175005:-
BRCA	cis	rs6095360	0.934	rs6095395	ENSG00000222365.1	SNORD12B	-4.77	2.13e-06	0.000203	-0.16	-0.15	Intelligence (multi-trait analysis);	chr20:49010558	chr20:49280319~49280409:+
BRCA	cis	rs11239930	0.538	rs17160592	ENSG00000230832.3	RP11-325P15.2	-4.77	2.13e-06	0.000203	-0.21	-0.15	AIDS progression;	chr1:147083644	chr1:147082338~147083578:-
BRCA	cis	rs11239930	0.538	rs56060937	ENSG00000230832.3	RP11-325P15.2	-4.77	2.13e-06	0.000203	-0.21	-0.15	AIDS progression;	chr1:147083854	chr1:147082338~147083578:-
BRCA	cis	rs2243480	0.706	rs6460257	ENSG00000228409.4	CCT6P1	4.77	2.13e-06	0.000203	0.17	0.15	Diabetic kidney disease;	chr7:65731813	chr7:65751142~65763354:+
BRCA	cis	rs11742741	0.714	rs6878191	ENSG00000248874.4	C5orf17	-4.77	2.13e-06	0.000203	-0.19	-0.15	Educational attainment;	chr5:24134711	chr5:23951348~24178263:+
BRCA	cis	rs11976180	1	rs1320893	ENSG00000244479.5	OR2A1-AS1	4.77	2.14e-06	0.000203	0.19	0.15	Obesity-related traits;	chr7:144055019	chr7:144251264~144356181:-
BRCA	cis	rs2915864	0.8	rs6886204	ENSG00000280047.1	CTC-463A16.1	4.77	2.14e-06	0.000203	0.25	0.15	Facial morphology (factor 20);	chr5:142117198	chr5:142165767~142168387:+
BRCA	cis	rs78487399	0.808	rs17030890	ENSG00000234936.1	AC010883.5	4.77	2.14e-06	0.000203	0.24	0.15	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43476953	chr2:43229573~43233394:+
BRCA	cis	rs7818688	0.697	rs75349998	ENSG00000253528.2	RP11-347C18.4	-4.77	2.14e-06	0.000203	-0.22	-0.15	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94978690	chr8:94974573~94974853:-
BRCA	cis	rs6088590	0.561	rs6087605	ENSG00000276073.1	RP5-1125A11.7	-4.77	2.14e-06	0.000203	-0.16	-0.15	Coronary artery disease;	chr20:34592820	chr20:33985617~33988989:-
BRCA	cis	rs3858526	0.606	rs10838883	ENSG00000224295.2	AC087380.14	-4.77	2.14e-06	0.000203	-0.19	-0.15	DNA methylation (variation);	chr11:5930917	chr11:5518441~5524955:-
BRCA	cis	rs539096	0.915	rs2842194	ENSG00000236200.4	KDM4A-AS1	4.77	2.14e-06	0.000203	0.19	0.15	Intelligence (multi-trait analysis);	chr1:43563291	chr1:43699765~43708138:-
BRCA	cis	rs60843830	1	rs3791221	ENSG00000272342.1	RP13-539J13.1	4.77	2.14e-06	0.000203	0.18	0.15	Spherical equivalent (joint analysis main effects and education interaction);	chr2:226933	chr2:739588~740164:-
BRCA	cis	rs7772486	0.72	rs6901888	ENSG00000270638.1	RP3-466P17.1	-4.77	2.14e-06	0.000203	-0.17	-0.15	Lobe attachment (rater-scored or self-reported);	chr6:145702008	chr6:145735570~145737218:+
BRCA	cis	rs442309	0.841	rs224044	ENSG00000238280.1	RP11-436D10.3	-4.77	2.14e-06	0.000203	-0.19	-0.15	Vogt-Koyanagi-Harada syndrome;	chr10:62765310	chr10:62793562~62805887:-
BRCA	cis	rs926392	1	rs926391	ENSG00000274825.1	RP4-616B8.5	-4.77	2.14e-06	0.000204	-0.14	-0.15	Dialysis-related mortality;	chr20:39061842	chr20:38955910~38956547:+
BRCA	cis	rs7937890	0.904	rs67623158	ENSG00000254418.1	RP11-21L19.1	-4.77	2.14e-06	0.000204	-0.17	-0.15	Mitochondrial DNA levels;	chr11:14273650	chr11:14262846~14273691:-
BRCA	cis	rs4143844	0.867	rs17271312	ENSG00000259251.2	RP11-643M14.1	4.77	2.14e-06	0.000204	0.35	0.15	Bipolar disorder and schizophrenia;	chr15:62044080	chr15:62060503~62062434:+
BRCA	cis	rs12681366	0.801	rs2043988	ENSG00000253175.1	RP11-267M23.6	4.77	2.14e-06	0.000204	0.18	0.15	Nonsyndromic cleft lip with cleft palate;	chr8:94457327	chr8:94565036~94565715:+
BRCA	cis	rs7267979	0.816	rs404775	ENSG00000274973.1	RP13-401N8.7	-4.77	2.14e-06	0.000204	-0.16	-0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25500481	chr20:25845497~25845862:+
BRCA	cis	rs7267979	0.816	rs374701	ENSG00000274973.1	RP13-401N8.7	-4.77	2.14e-06	0.000204	-0.16	-0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25502980	chr20:25845497~25845862:+
BRCA	cis	rs2070615	0.525	rs2860360	ENSG00000239617.1	RP11-302B13.1	-4.77	2.15e-06	0.000204	-0.19	-0.15	Bipolar disorder;	chr12:48812399	chr12:48903418~48903813:-
BRCA	cis	rs6714710	0.603	rs55776387	ENSG00000230606.9	AC159540.1	-4.77	2.15e-06	0.000204	-0.17	-0.15	Posterior cortical atrophy and Alzheimer's disease;	chr2:97788571	chr2:97416165~97433527:-
BRCA	cis	rs416603	0.967	rs11644184	ENSG00000262703.1	RP11-485G7.6	-4.77	2.15e-06	0.000204	-0.15	-0.15	Type 1 diabetes;	chr16:11271247	chr16:11348143~11349321:-
BRCA	cis	rs1223397	0.651	rs2439535	ENSG00000215022.6	RP1-257A7.4	-4.77	2.15e-06	0.000204	-0.18	-0.15	Blood pressure;	chr6:13305590	chr6:13264861~13295586:-
BRCA	cis	rs7267979	1	rs11087520	ENSG00000125804.12	FAM182A	-4.77	2.15e-06	0.000204	-0.19	-0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25456191	chr20:26054655~26086917:+
BRCA	cis	rs7246657	0.654	rs10407568	ENSG00000226686.6	LINC01535	-4.77	2.15e-06	0.000204	-0.22	-0.15	Coronary artery calcification;	chr19:37632108	chr19:37251912~37265535:+
BRCA	cis	rs919433	0.617	rs10931793	ENSG00000231621.1	AC013264.2	4.77	2.15e-06	0.000204	0.14	0.15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197712861	chr2:197197991~197199273:+
BRCA	cis	rs6951245	1	rs78896566	ENSG00000229043.2	AC091729.9	-4.77	2.15e-06	0.000204	-0.26	-0.15	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1040546	chr7:1160374~1165267:+
BRCA	cis	rs6951245	1	rs79422648	ENSG00000229043.2	AC091729.9	-4.77	2.15e-06	0.000204	-0.26	-0.15	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1040605	chr7:1160374~1165267:+
BRCA	cis	rs6951245	0.872	rs113119264	ENSG00000229043.2	AC091729.9	-4.77	2.15e-06	0.000204	-0.26	-0.15	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1040928	chr7:1160374~1165267:+
BRCA	cis	rs6921919	0.583	rs16894108	ENSG00000220721.1	OR1F12	4.77	2.15e-06	0.000204	0.18	0.15	Autism spectrum disorder or schizophrenia;	chr6:28434013	chr6:28073316~28074233:+
BRCA	cis	rs16846053	0.786	rs72873607	ENSG00000227403.1	AC009299.3	4.77	2.15e-06	0.000204	0.35	0.15	Blood osmolality (transformed sodium);	chr2:161614664	chr2:161244739~161249050:+
BRCA	cis	rs7226408	0.779	rs72896202	ENSG00000267707.2	RP11-95O2.5	4.77	2.15e-06	0.000204	0.22	0.15	Obesity-related traits;	chr18:37186309	chr18:37243776~37247506:+
BRCA	cis	rs6430585	0.528	rs75524146	ENSG00000231890.6	DARS-AS1	-4.77	2.15e-06	0.000204	-0.24	-0.15	Corneal structure;	chr2:135967889	chr2:135985176~136022593:+
BRCA	cis	rs721917	0.7	rs2493719	ENSG00000244733.5	RP11-506M13.3	4.77	2.15e-06	0.000204	0.17	0.15	Chronic obstructive pulmonary disease;	chr10:79896305	chr10:79660891~79677996:+
BRCA	cis	rs7819412	0.668	rs920047	ENSG00000154316.13	TDH	4.77	2.15e-06	0.000204	0.19	0.15	Triglycerides;	chr8:11229966	chr8:11339637~11368452:+
BRCA	cis	rs202072	0.585	rs2119485	ENSG00000272379.1	RP1-257A7.5	-4.77	2.15e-06	0.000204	-0.18	-0.15	HIV-1 viral setpoint;	chr6:13278030	chr6:13290018~13290490:-
BRCA	cis	rs2835345	0.563	rs12483690	ENSG00000279365.1	KB-176G8.1	4.77	2.15e-06	0.000204	0.19	0.15	Pulmonary function;	chr21:36451265	chr21:36485867~36487760:+
BRCA	cis	rs2835345	0.596	rs12482097	ENSG00000279365.1	KB-176G8.1	4.77	2.15e-06	0.000204	0.19	0.15	Pulmonary function;	chr21:36451592	chr21:36485867~36487760:+
BRCA	cis	rs2835345	0.596	rs12482138	ENSG00000279365.1	KB-176G8.1	4.77	2.15e-06	0.000204	0.19	0.15	Pulmonary function;	chr21:36451608	chr21:36485867~36487760:+
BRCA	cis	rs2835345	0.563	rs12482257	ENSG00000279365.1	KB-176G8.1	4.77	2.15e-06	0.000204	0.19	0.15	Pulmonary function;	chr21:36451660	chr21:36485867~36487760:+
BRCA	cis	rs651907	0.557	rs62284198	ENSG00000256628.3	ZBTB11-AS1	4.77	2.15e-06	0.000205	0.18	0.15	Colorectal cancer;	chr3:101755855	chr3:101676475~101679217:+
BRCA	cis	rs651907	0.557	rs2318090	ENSG00000256628.3	ZBTB11-AS1	4.77	2.15e-06	0.000205	0.18	0.15	Colorectal cancer;	chr3:101756089	chr3:101676475~101679217:+
BRCA	cis	rs1722133	0.555	rs788729	ENSG00000237471.1	AC073115.6	-4.77	2.15e-06	0.000205	-0.2	-0.15	Sitting height ratio;	chr7:46054338	chr7:45969657~45980191:+
BRCA	cis	rs1198872	0.503	rs1627163	ENSG00000272275.1	RP11-791G15.2	-4.77	2.15e-06	0.000205	-0.18	-0.15	Cardiac Troponin-T levels;	chr2:10814718	chr2:10767875~10770058:-
BRCA	cis	rs6430585	0.583	rs3769001	ENSG00000231890.6	DARS-AS1	-4.77	2.15e-06	0.000205	-0.23	-0.15	Corneal structure;	chr2:135868508	chr2:135985176~136022593:+
BRCA	cis	rs10504130	0.932	rs79196243	ENSG00000253844.1	RP11-546K22.1	-4.77	2.15e-06	0.000205	-0.25	-0.15	Venous thromboembolism (SNP x SNP interaction);	chr8:51834855	chr8:51961458~52022974:+
BRCA	cis	rs7178375	0.607	rs71474639	ENSG00000270015.1	RP11-540B6.6	4.77	2.15e-06	0.000205	0.22	0.15	Hypertriglyceridemia;	chr15:30921054	chr15:30926514~30928407:+
BRCA	cis	rs7923837	1	rs7087591	ENSG00000236493.2	EIF2S2P3	4.77	2.15e-06	0.000205	0.19	0.15	Multiple sclerosis;Body mass index;	chr10:92713872	chr10:92668745~92669743:-
BRCA	cis	rs6832769	1	rs17085889	ENSG00000223305.1	RN7SKP30	-4.77	2.16e-06	0.000205	-0.18	-0.15	Personality dimensions;	chr4:55535948	chr4:55540502~55540835:-
BRCA	cis	rs12612619	0.732	rs1465881	ENSG00000229122.1	AGBL5-IT1	4.77	2.16e-06	0.000205	0.15	0.15	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27014746	chr2:27061038~27061815:+
BRCA	cis	rs3768617	0.51	rs10911242	ENSG00000224468.3	RP11-181K3.4	-4.76	2.16e-06	0.000205	-0.16	-0.15	Fuchs's corneal dystrophy;	chr1:183103012	chr1:183138402~183141282:-
BRCA	cis	rs755249	0.762	rs1775654	ENSG00000182109.6	RP11-69E11.4	4.76	2.16e-06	0.000205	0.18	0.15	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39484408	chr1:39522280~39546187:-
BRCA	cis	rs6840258	0.64	rs28734493	ENSG00000251411.1	RP11-397E7.4	-4.76	2.16e-06	0.000205	-0.19	-0.15	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87151541	chr4:86913266~86914817:-
BRCA	cis	rs721917	0.525	rs2250652	ENSG00000242600.5	MBL1P	4.76	2.16e-06	0.000205	0.17	0.15	Chronic obstructive pulmonary disease;	chr10:79902893	chr10:79904898~79950336:+
BRCA	cis	rs739401	1	rs739401	ENSG00000183562.3	CTC-343N3.1	4.76	2.16e-06	0.000205	0.15	0.15	Longevity;	chr11:3015094	chr11:2989863~2991344:+
BRCA	cis	rs8180040	0.966	rs2062278	ENSG00000276925.1	RP11-708J19.3	-4.76	2.16e-06	0.000205	-0.17	-0.15	Colorectal cancer;	chr3:47375271	chr3:47469777~47469987:+
BRCA	cis	rs4713118	0.699	rs200978	ENSG00000219392.1	RP1-265C24.5	-4.76	2.16e-06	0.000205	-0.22	-0.15	Parkinson's disease;	chr6:27885390	chr6:28115628~28116551:+
BRCA	cis	rs1223397	0.651	rs402705	ENSG00000215022.6	RP1-257A7.4	-4.76	2.16e-06	0.000205	-0.17	-0.15	Blood pressure;	chr6:13296207	chr6:13264861~13295586:-
BRCA	cis	rs9921338	0.961	rs55707838	ENSG00000262703.1	RP11-485G7.6	-4.76	2.16e-06	0.000205	-0.18	-0.15	Vein graft stenosis in coronary artery bypass grafting;	chr16:11284218	chr16:11348143~11349321:-
BRCA	cis	rs1722141	0.669	rs17578201	ENSG00000229628.1	AC073115.7	-4.76	2.16e-06	0.000205	-0.21	-0.15	Sitting height ratio;	chr7:46007681	chr7:45990905~46000898:+
BRCA	cis	rs10761482	0.532	rs1938533	ENSG00000254271.1	RP11-131N11.4	4.76	2.16e-06	0.000205	0.2	0.15	Schizophrenia;	chr10:60474351	chr10:60734342~60741828:+
BRCA	cis	rs8114671	0.562	rs6120739	ENSG00000269202.1	RP4-614O4.12	-4.76	2.16e-06	0.000205	-0.15	-0.15	Height;	chr20:34817424	chr20:35201747~35203288:-
BRCA	cis	rs12893668	0.572	rs12590968	ENSG00000269958.1	RP11-73M18.8	4.76	2.16e-06	0.000205	0.17	0.15	Reticulocyte count;	chr14:103670296	chr14:103696353~103697163:+
BRCA	cis	rs10833905	1	rs7107632	ENSG00000246225.5	RP11-17A1.3	-4.76	2.16e-06	0.000205	-0.21	-0.15	Sudden cardiac arrest;	chr11:23044835	chr11:22829380~22945393:+
BRCA	cis	rs4218	0.648	rs12915899	ENSG00000277144.1	RP11-59H7.4	-4.76	2.16e-06	0.000205	-0.19	-0.15	Social communication problems;	chr15:59084332	chr15:59115547~59116089:-
BRCA	cis	rs6832769	0.961	rs2412646	ENSG00000223305.1	RN7SKP30	4.76	2.16e-06	0.000205	0.18	0.15	Personality dimensions;	chr4:55452605	chr4:55540502~55540835:-
BRCA	cis	rs8098244	0.964	rs4239438	ENSG00000264745.1	TTC39C-AS1	4.76	2.16e-06	0.000205	0.2	0.15	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23761286	chr18:23994213~24015339:-
BRCA	cis	rs919433	0.679	rs13000656	ENSG00000231621.1	AC013264.2	4.76	2.16e-06	0.000205	0.15	0.15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197657402	chr2:197197991~197199273:+
BRCA	cis	rs2403083	0.626	rs4150868	ENSG00000258256.1	RP11-219B4.5	-4.76	2.16e-06	0.000205	-0.18	-0.15	Plasma amyloid beta peptide concentrations (ABx-40);	chr8:85187399	chr8:85222446~85245717:-
BRCA	cis	rs13325613	0.915	rs7631853	ENSG00000223552.1	RP11-24F11.2	-4.76	2.16e-06	0.000205	-0.26	-0.15	Monocyte count;	chr3:46264983	chr3:46364955~46407059:-
BRCA	cis	rs13160562	0.509	rs26501	ENSG00000272109.1	CTD-2260A17.3	-4.76	2.16e-06	0.000205	-0.18	-0.15	Alcohol dependence;	chr5:96765060	chr5:96804353~96806105:+
BRCA	cis	rs867186	1	rs114948279	ENSG00000126005.14	MMP24-AS1	-4.76	2.16e-06	0.000205	-0.29	-0.15	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35145838	chr20:35216462~35278131:-
BRCA	cis	rs7226408	0.948	rs11660414	ENSG00000267707.2	RP11-95O2.5	4.76	2.17e-06	0.000205	0.24	0.15	Obesity-related traits;	chr18:36796602	chr18:37243776~37247506:+
BRCA	cis	rs1005277	0.579	rs2008449	ENSG00000263064.2	RP11-291L22.7	-4.76	2.17e-06	0.000205	-0.18	-0.15	Extrinsic epigenetic age acceleration;	chr10:38125276	chr10:38448689~38448949:+
BRCA	cis	rs10829156	0.66	rs4338439	ENSG00000240291.1	RP11-499P20.2	4.76	2.17e-06	0.000206	0.17	0.15	Sudden cardiac arrest;	chr10:18594220	chr10:18513115~18545651:-
BRCA	cis	rs13108904	0.967	rs12502916	ENSG00000254094.1	AC078852.1	4.76	2.17e-06	0.000206	0.16	0.15	Obesity-related traits;	chr4:1282561	chr4:1356581~1358075:+
BRCA	cis	rs4415084	0.774	rs4571481	ENSG00000251141.4	RP11-53O19.1	4.76	2.17e-06	0.000206	0.14	0.15	Breast cancer;	chr5:44687331	chr5:44744900~44808777:-
BRCA	cis	rs4763879	0.778	rs1044771	ENSG00000278635.1	CTD-2318O12.1	4.76	2.17e-06	0.000206	0.15	0.15	Type 1 diabetes;	chr12:9699333	chr12:9415641~9416718:+
BRCA	cis	rs14027	0.512	rs28711081	ENSG00000279347.1	RP11-85I17.2	-4.76	2.17e-06	0.000206	-0.14	-0.15	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119713469	chr8:119838736~119840385:-
BRCA	cis	rs11098499	0.954	rs3733520	ENSG00000260091.1	RP11-33B1.4	-4.76	2.17e-06	0.000206	-0.13	-0.15	Corneal astigmatism;	chr4:119502325	chr4:119409333~119410233:+
BRCA	cis	rs721917	0.525	rs4281433	ENSG00000244733.5	RP11-506M13.3	-4.76	2.17e-06	0.000206	-0.17	-0.15	Chronic obstructive pulmonary disease;	chr10:79982904	chr10:79660891~79677996:+
BRCA	cis	rs2832191	0.791	rs2832178	ENSG00000215533.7	LINC00189	4.76	2.17e-06	0.000206	0.16	0.15	Dental caries;	chr21:29107537	chr21:29193480~29288205:+
BRCA	cis	rs6832769	1	rs7677526	ENSG00000272969.1	RP11-528I4.2	4.76	2.17e-06	0.000206	0.17	0.15	Personality dimensions;	chr4:55483741	chr4:55547112~55547889:+
BRCA	cis	rs6545883	0.929	rs10190332	ENSG00000270820.4	RP11-355B11.2	-4.76	2.17e-06	0.000206	-0.17	-0.15	Tuberculosis;	chr2:61392132	chr2:61471188~61484130:+
BRCA	cis	rs7772486	0.79	rs7753696	ENSG00000270638.1	RP3-466P17.1	-4.76	2.17e-06	0.000206	-0.17	-0.15	Lobe attachment (rater-scored or self-reported);	chr6:145957962	chr6:145735570~145737218:+
BRCA	cis	rs9307551	0.584	rs12510243	ENSG00000250334.4	LINC00989	-4.76	2.17e-06	0.000206	-0.2	-0.15	Refractive error;	chr4:79551905	chr4:79492416~79576460:+
BRCA	cis	rs12681366	0.537	rs10095298	ENSG00000253704.1	RP11-267M23.4	4.76	2.17e-06	0.000206	0.16	0.15	Nonsyndromic cleft lip with cleft palate;	chr8:94472353	chr8:94553722~94569745:+
BRCA	cis	rs8127691	0.967	rs4380337	ENSG00000237604.1	AP001056.1	4.76	2.17e-06	0.000206	0.16	0.15	Inflammatory bowel disease;	chr21:44196166	chr21:44175489~44176453:+
BRCA	cis	rs7487075	0.619	rs12314541	ENSG00000274723.1	RP11-618L22.1	4.76	2.17e-06	0.000206	0.18	0.15	Itch intensity from mosquito bite;	chr12:46400983	chr12:46970504~46972155:+
BRCA	cis	rs300890	0.56	rs300921	ENSG00000250326.1	RP11-284M14.1	-4.76	2.17e-06	0.000206	-0.17	-0.15	Nasopharyngeal carcinoma;	chr4:143259922	chr4:142933195~143184861:-
BRCA	cis	rs1910358	0.554	rs10060895	ENSG00000248874.4	C5orf17	-4.76	2.17e-06	0.000206	-0.21	-0.15	Venous thromboembolism (SNP x SNP interaction);	chr5:23825307	chr5:23951348~24178263:+
BRCA	cis	rs6928977	0.675	rs7750586	ENSG00000234084.1	RP3-388E23.2	4.76	2.18e-06	0.000206	0.15	0.15	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135506535	chr6:135301568~135307158:+
BRCA	cis	rs8031584	0.958	rs1043742	ENSG00000259845.1	HERC2P10	4.76	2.18e-06	0.000206	0.17	0.15	Huntington's disease progression;	chr15:30940378	chr15:30815271~30844153:+
BRCA	cis	rs7811142	0.72	rs7795656	ENSG00000078319.8	PMS2P1	-4.76	2.18e-06	0.000206	-0.24	-0.15	Platelet count;	chr7:100352674	chr7:100320992~100341908:-
BRCA	cis	rs867186	1	rs11907010	ENSG00000126005.14	MMP24-AS1	-4.76	2.18e-06	0.000206	-0.29	-0.15	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35149858	chr20:35216462~35278131:-
BRCA	cis	rs11887277	0.684	rs2082610	ENSG00000272148.1	RP11-195B17.1	-4.76	2.18e-06	0.000206	-0.17	-0.15	Obesity-related traits;	chr2:26810572	chr2:27062428~27062907:-
BRCA	cis	rs7833986	0.501	rs72653986	ENSG00000253603.1	CTA-397H3.3	-4.76	2.18e-06	0.000206	-0.21	-0.15	Height;	chr8:56122489	chr8:56074592~56075274:+
BRCA	cis	rs9816784	0.525	rs555412	ENSG00000242086.7	LINC00969	4.76	2.18e-06	0.000206	0.17	0.15	Mean corpuscular hemoglobin;	chr3:196078047	chr3:195658062~195739964:+
BRCA	cis	rs4780355	0.877	rs243317	ENSG00000262636.1	CTD-3088G3.4	-4.76	2.18e-06	0.000206	-0.2	-0.15	Crohn's disease and psoriasis;	chr16:11263474	chr16:11380859~11381118:-
BRCA	cis	rs2186369	1	rs17630758	ENSG00000272733.1	KB-208E9.1	4.76	2.18e-06	0.000207	0.21	0.15	IgG N-glycosylation phenotypes (multivariate analysis);IgG digalactosylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG glycosylation;IgG fucosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);	chr22:23794355	chr22:23580880~23583859:-
BRCA	cis	rs699371	0.525	rs7140692	ENSG00000270000.1	RP3-449M8.9	4.76	2.18e-06	0.000207	0.18	0.15	Height;	chr14:74434484	chr14:74471930~74472360:-
BRCA	cis	rs8098244	0.964	rs7244162	ENSG00000264745.1	TTC39C-AS1	4.76	2.18e-06	0.000207	0.2	0.15	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23760077	chr18:23994213~24015339:-
BRCA	cis	rs7045881	0.935	rs7851582	ENSG00000254396.1	RP11-56F10.3	4.76	2.18e-06	0.000207	0.25	0.15	Schizophrenia;	chr9:26902782	chr9:27102630~27104728:+
BRCA	cis	rs62184315	0.536	rs5743047	ENSG00000253559.1	OSGEPL1-AS1	4.76	2.18e-06	0.000207	0.25	0.15	Alcohol dependence (age at onset);	chr2:189819942	chr2:189762704~189765556:+
BRCA	cis	rs4650994	0.544	rs2476561	ENSG00000273384.1	RP5-1098D14.1	4.76	2.18e-06	0.000207	0.19	0.15	HDL cholesterol;HDL cholesterol levels;	chr1:178650765	chr1:178651706~178652282:+
BRCA	cis	rs2380205	0.651	rs1886057	ENSG00000232807.2	RP11-536K7.3	4.76	2.18e-06	0.000207	0.14	0.15	Breast cancer;	chr10:5883532	chr10:5934270~5945900:-
BRCA	cis	rs991427	1	rs17018731	ENSG00000258100.1	RP11-121E16.1	-4.76	2.18e-06	0.000207	-0.19	-0.15	Systolic blood pressure (alcohol consumption interaction);	chr12:91105590	chr12:91362196~91368606:+
BRCA	cis	rs9818758	0.607	rs11552724	ENSG00000270441.1	RP11-694I15.7	4.76	2.18e-06	0.000207	0.31	0.15	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49119040	chr3:49140086~49160851:-
BRCA	cis	rs8180040	0.966	rs7651762	ENSG00000271161.1	BOLA2P2	-4.76	2.18e-06	0.000207	-0.16	-0.15	Colorectal cancer;	chr3:47428994	chr3:47499841~47500407:+
BRCA	cis	rs559555	0.511	rs614173	ENSG00000272716.1	RP11-563N4.1	4.76	2.18e-06	0.000207	0.17	0.15	Blood metabolite ratios;Blood metabolite levels;	chr2:31628133	chr2:32165046~32165757:-
BRCA	cis	rs7267979	0.844	rs2424703	ENSG00000274414.1	RP5-965G21.4	-4.76	2.18e-06	0.000207	-0.17	-0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25289488	chr20:25239007~25245229:-
BRCA	cis	rs1598856	1	rs3774932	ENSG00000246560.2	RP11-10L12.4	4.76	2.18e-06	0.000207	0.16	0.15	Primary biliary cholangitis;	chr4:102503036	chr4:102828055~102844075:+
BRCA	cis	rs10845170	1	rs10845170	ENSG00000256667.5	KLRAP1	-4.76	2.18e-06	0.000207	-0.13	-0.15	Itch intensity from mosquito bite adjusted by bite size;	chr12:10571818	chr12:10588063~10599669:-
BRCA	cis	rs6545883	0.894	rs778157	ENSG00000270820.4	RP11-355B11.2	4.76	2.18e-06	0.000207	0.17	0.15	Tuberculosis;	chr2:61327154	chr2:61471188~61484130:+
BRCA	cis	rs7772486	0.875	rs854148	ENSG00000270638.1	RP3-466P17.1	4.76	2.18e-06	0.000207	0.17	0.15	Lobe attachment (rater-scored or self-reported);	chr6:145989843	chr6:145735570~145737218:+
BRCA	cis	rs1862618	0.62	rs2591967	ENSG00000271828.1	CTD-2310F14.1	-4.76	2.18e-06	0.000207	-0.18	-0.15	Initial pursuit acceleration;	chr5:56937724	chr5:56927874~56929573:+
BRCA	cis	rs2531992	0.686	rs2041247	ENSG00000262185.1	RP11-462G12.1	-4.76	2.18e-06	0.000207	-0.21	-0.15	Waist circumference;	chr16:3982580	chr16:3947609~3950444:-
BRCA	cis	rs300890	0.513	rs7684017	ENSG00000250326.1	RP11-284M14.1	-4.76	2.18e-06	0.000207	-0.17	-0.15	Nasopharyngeal carcinoma;	chr4:143124212	chr4:142933195~143184861:-
BRCA	cis	rs17684571	0.7	rs35440822	ENSG00000231441.1	RP11-472M19.2	4.76	2.19e-06	0.000207	0.23	0.15	Schizophrenia;	chr6:56801006	chr6:56844002~56864078:+
BRCA	cis	rs1030877	0.515	rs2679895	ENSG00000235319.1	AC012360.4	-4.76	2.19e-06	0.000207	-0.2	-0.15	Obesity-related traits;	chr2:105290023	chr2:105324210~105330529:+
BRCA	cis	rs2303319	0.504	rs72873624	ENSG00000227403.1	AC009299.3	4.76	2.19e-06	0.000207	0.35	0.15	Cognitive function;	chr2:161624943	chr2:161244739~161249050:+
BRCA	cis	rs7267979	0.816	rs390123	ENSG00000274973.1	RP13-401N8.7	-4.76	2.19e-06	0.000207	-0.16	-0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25499469	chr20:25845497~25845862:+
BRCA	cis	rs6095360	1	rs2295033	ENSG00000222365.1	SNORD12B	-4.76	2.19e-06	0.000207	-0.16	-0.15	Intelligence (multi-trait analysis);	chr20:48994359	chr20:49280319~49280409:+
BRCA	cis	rs7927592	0.956	rs7106259	ENSG00000212093.1	AP000807.1	4.76	2.19e-06	0.000207	0.16	0.15	Total body bone mineral density;	chr11:68531044	chr11:68506083~68506166:-
BRCA	cis	rs13113518	1	rs6838882	ENSG00000249700.7	SRD5A3-AS1	4.76	2.19e-06	0.000207	0.18	0.15	Height;	chr4:55489310	chr4:55363971~55395847:-
BRCA	cis	rs6968419	1	rs6979486	ENSG00000279086.1	RP11-667F14.1	-4.76	2.19e-06	0.000207	-0.14	-0.15	Intraocular pressure;	chr7:116192384	chr7:116209234~116211511:-
BRCA	cis	rs1707322	1	rs1612419	ENSG00000234329.1	RP11-767N6.2	-4.76	2.19e-06	0.000207	-0.15	-0.15	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46081273	chr1:45651039~45651826:-
BRCA	cis	rs4853525	0.544	rs61187415	ENSG00000235852.1	AC005540.3	4.76	2.19e-06	0.000208	0.18	0.15	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190846184	chr2:190880797~190882059:-
BRCA	cis	rs7246657	0.722	rs10402671	ENSG00000226686.6	LINC01535	-4.76	2.19e-06	0.000208	-0.22	-0.15	Coronary artery calcification;	chr19:37626185	chr19:37251912~37265535:+
BRCA	cis	rs7246657	0.722	rs10417576	ENSG00000226686.6	LINC01535	-4.76	2.19e-06	0.000208	-0.22	-0.15	Coronary artery calcification;	chr19:37628311	chr19:37251912~37265535:+
BRCA	cis	rs4143844	1	rs62007448	ENSG00000259251.2	RP11-643M14.1	4.76	2.19e-06	0.000208	0.35	0.15	Bipolar disorder and schizophrenia;	chr15:62036971	chr15:62060503~62062434:+
BRCA	cis	rs4143844	1	rs11634312	ENSG00000259251.2	RP11-643M14.1	4.76	2.19e-06	0.000208	0.35	0.15	Bipolar disorder and schizophrenia;	chr15:62038868	chr15:62060503~62062434:+
BRCA	cis	rs6452524	0.967	rs2731861	ENSG00000281327.1	LINC01338	4.76	2.19e-06	0.000208	0.17	0.15	Hypertension (SNP x SNP interaction);	chr5:83189445	chr5:82850864~82859836:-
BRCA	cis	rs14027	0.512	rs6992632	ENSG00000279347.1	RP11-85I17.2	-4.76	2.19e-06	0.000208	-0.14	-0.15	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119711969	chr8:119838736~119840385:-
BRCA	cis	rs6840360	0.642	rs1596290	ENSG00000251603.1	RP11-164P12.4	-4.76	2.19e-06	0.000208	-0.13	-0.15	Intelligence (multi-trait analysis);	chr4:151489388	chr4:151667224~151670502:+
BRCA	cis	rs2904967	1	rs2904967	ENSG00000255200.1	AP003068.18	4.76	2.19e-06	0.000208	0.25	0.15	Mean corpuscular volume;	chr11:65324138	chr11:65174117~65176470:-
BRCA	cis	rs595244	1	rs686861	ENSG00000259705.1	RP11-227D13.1	4.76	2.19e-06	0.000208	0.26	0.15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48592808	chr15:48645951~48652016:+
BRCA	cis	rs7572733	0.773	rs10196961	ENSG00000231621.1	AC013264.2	-4.76	2.2e-06	0.000208	-0.13	-0.15	Dermatomyositis;	chr2:197649206	chr2:197197991~197199273:+
BRCA	cis	rs26949	0.503	rs1867702	ENSG00000215032.2	GNL3LP1	4.76	2.2e-06	0.000208	0.18	0.15	Intelligence (multi-trait analysis);	chr5:60602156	chr5:60891935~60893577:-
BRCA	cis	rs10129255	0.957	rs8022165	ENSG00000274576.2	IGHV2-70	4.76	2.2e-06	0.000208	0.12	0.15	Kawasaki disease;	chr14:106781682	chr14:106770577~106771020:-
BRCA	cis	rs2274273	0.624	rs67412516	ENSG00000259318.1	RP11-454L9.2	4.76	2.2e-06	0.000208	0.13	0.15	Protein biomarker;	chr14:55386519	chr14:55394940~55395233:-
BRCA	cis	rs875971	0.862	rs1643375	ENSG00000273448.1	RP11-166O4.6	4.76	2.2e-06	0.000209	0.14	0.15	Aortic root size;	chr7:66407690	chr7:67333047~67334383:+
BRCA	cis	rs739496	0.579	rs3752630	ENSG00000226469.1	ADAM1B	4.76	2.2e-06	0.000209	0.19	0.15	Platelet count;	chr12:111938186	chr12:111927018~111929017:+
BRCA	cis	rs60695258	1	rs60695258	ENSG00000251411.1	RP11-397E7.4	-4.76	2.2e-06	0.000209	-0.16	-0.15	Hematocrit;	chr4:87101557	chr4:86913266~86914817:-
BRCA	cis	rs4415084	0.804	rs10077814	ENSG00000251141.4	RP11-53O19.1	-4.76	2.2e-06	0.000209	-0.13	-0.15	Breast cancer;	chr5:44916687	chr5:44744900~44808777:-
BRCA	cis	rs8054556	0.647	rs4787488	ENSG00000261367.1	RP11-455F5.4	4.76	2.2e-06	0.000209	0.16	0.15	Autism spectrum disorder or schizophrenia;	chr16:29984482	chr16:30107675~30110541:+
BRCA	cis	rs6006893	0.515	rs7286363	ENSG00000280383.1	CTA-941F9.10	-4.76	2.2e-06	0.000209	-0.3	-0.15	Binge eating behaviour in bipolar disorder;	chr22:44842515	chr22:45657019~45680130:+
BRCA	cis	rs7618915	0.547	rs62255371	ENSG00000243224.1	RP5-1157M23.2	-4.76	2.2e-06	0.000209	-0.16	-0.15	Bipolar disorder;	chr3:52713305	chr3:52239258~52241097:+
BRCA	cis	rs4819052	0.851	rs8134392	ENSG00000184274.3	LINC00315	4.76	2.2e-06	0.000209	0.2	0.15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45243875	chr21:45300245~45305257:-
BRCA	cis	rs11976180	1	rs1919949	ENSG00000244479.5	OR2A1-AS1	4.76	2.21e-06	0.000209	0.19	0.15	Obesity-related traits;	chr7:144070630	chr7:144251264~144356181:-
BRCA	cis	rs7772486	0.754	rs864148	ENSG00000270638.1	RP3-466P17.1	-4.76	2.21e-06	0.000209	-0.17	-0.15	Lobe attachment (rater-scored or self-reported);	chr6:145655539	chr6:145735570~145737218:+
BRCA	cis	rs16958440	1	rs61316646	ENSG00000280212.1	RP11-49K24.3	4.76	2.21e-06	0.000209	0.3	0.15	Sitting height ratio;	chr18:47084299	chr18:47076117~47076594:+
BRCA	cis	rs794185	0.592	rs304079	ENSG00000231249.1	ITPR1-AS1	4.76	2.21e-06	0.000209	0.16	0.15	Multiple sclerosis--Brain Glutamate Levels;	chr3:4490785	chr3:4490891~4493163:-
BRCA	cis	rs754466	0.874	rs55910200	ENSG00000204049.1	RP11-126H7.4	4.76	2.21e-06	0.000209	0.2	0.15	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77905415	chr10:77866875~77869610:+
BRCA	cis	rs875971	0.862	rs778680	ENSG00000273448.1	RP11-166O4.6	4.76	2.21e-06	0.000209	0.14	0.15	Aortic root size;	chr7:66375427	chr7:67333047~67334383:+
BRCA	cis	rs875971	0.862	rs11769079	ENSG00000273448.1	RP11-166O4.6	4.76	2.21e-06	0.000209	0.14	0.15	Aortic root size;	chr7:66377141	chr7:67333047~67334383:+
BRCA	cis	rs875971	0.862	rs1695820	ENSG00000273448.1	RP11-166O4.6	4.76	2.21e-06	0.000209	0.14	0.15	Aortic root size;	chr7:66379576	chr7:67333047~67334383:+
BRCA	cis	rs733175	0.855	rs9291641	ENSG00000250413.1	RP11-448G15.1	-4.76	2.21e-06	0.000209	-0.21	-0.15	Psychosis and Alzheimer's disease;	chr4:10005635	chr4:10006482~10009725:+
BRCA	cis	rs6442522	0.56	rs2305614	ENSG00000249786.6	EAF1-AS1	4.76	2.21e-06	0.000209	0.15	0.15	Uric acid levels;	chr3:15475811	chr3:15436171~15455940:-
BRCA	cis	rs1729951	0.575	rs168635	ENSG00000239213.4	NCK1-AS1	4.76	2.21e-06	0.000209	0.15	0.15	Neuroticism;	chr3:136980236	chr3:136841726~136862054:-
BRCA	cis	rs4415084	1	rs6861560	ENSG00000251141.4	RP11-53O19.1	4.76	2.21e-06	0.000209	0.13	0.15	Breast cancer;	chr5:44708276	chr5:44744900~44808777:-
BRCA	cis	rs9907295	0.688	rs9890583	ENSG00000271013.1	AC015849.15	-4.76	2.21e-06	0.000209	-0.19	-0.15	Fibroblast growth factor basic levels;	chr17:35919389	chr17:35912635~35918010:-
BRCA	cis	rs60695258	0.895	rs2280954	ENSG00000251411.1	RP11-397E7.4	-4.76	2.21e-06	0.000209	-0.16	-0.15	Hematocrit;	chr4:87067710	chr4:86913266~86914817:-
BRCA	cis	rs6860806	0.603	rs112300250	ENSG00000233006.5	AC034220.3	4.76	2.21e-06	0.000209	0.1	0.15	Breast cancer;	chr5:132247599	chr5:132311285~132369916:-
BRCA	cis	rs11673344	0.504	rs11666786	ENSG00000226686.6	LINC01535	4.76	2.21e-06	0.000209	0.18	0.15	Obesity-related traits;	chr19:37133947	chr19:37251912~37265535:+
BRCA	cis	rs2976388	0.556	rs4736323	ENSG00000253196.1	RP11-706C16.7	-4.76	2.21e-06	0.000209	-0.15	-0.15	Urinary tract infection frequency;	chr8:142748941	chr8:142763116~142766427:+
BRCA	cis	rs7923609	0.875	rs10761741	ENSG00000232075.1	MRPL35P2	-4.76	2.21e-06	0.000209	-0.18	-0.15	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63306426	chr10:63634317~63634827:-
BRCA	cis	rs950169	0.544	rs62021193	ENSG00000275120.1	RP11-182J1.17	4.76	2.21e-06	0.000209	0.2	0.15	Schizophrenia;	chr15:84627352	chr15:84599434~84606463:-
BRCA	cis	rs2303319	0.504	rs56100249	ENSG00000227403.1	AC009299.3	4.76	2.21e-06	0.000209	0.35	0.15	Cognitive function;	chr2:161558647	chr2:161244739~161249050:+
BRCA	cis	rs13108904	0.936	rs4974540	ENSG00000253399.1	AC078852.2	-4.76	2.21e-06	0.000209	-0.16	-0.15	Obesity-related traits;	chr4:1219675	chr4:1358479~1359461:+
BRCA	cis	rs595244	1	rs75225368	ENSG00000259705.1	RP11-227D13.1	4.76	2.21e-06	0.00021	0.27	0.15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48493009	chr15:48645951~48652016:+
BRCA	cis	rs11239930	0.538	rs3011810	ENSG00000278811.3	LINC00624	4.76	2.21e-06	0.00021	0.17	0.15	AIDS progression;	chr1:147082079	chr1:147258885~147517875:-
BRCA	cis	rs281408	0.559	rs281381	ENSG00000232871.7	SEC1P	4.76	2.21e-06	0.00021	0.17	0.15	Urinary metabolites (H-NMR features);	chr19:48711491	chr19:48638071~48682245:+
BRCA	cis	rs7267979	0.844	rs2257649	ENSG00000125804.12	FAM182A	-4.76	2.21e-06	0.00021	-0.19	-0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25282821	chr20:26054655~26086917:+
BRCA	cis	rs6832769	0.925	rs1965467	ENSG00000223305.1	RN7SKP30	4.76	2.21e-06	0.00021	0.18	0.15	Personality dimensions;	chr4:55456573	chr4:55540502~55540835:-
BRCA	cis	rs9990333	0.562	rs56038600	ENSG00000242086.7	LINC00969	4.76	2.21e-06	0.00021	0.16	0.15	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196090109	chr3:195658062~195739964:+
BRCA	cis	rs14027	0.512	rs10095282	ENSG00000279347.1	RP11-85I17.2	-4.76	2.22e-06	0.00021	-0.14	-0.15	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119712629	chr8:119838736~119840385:-
BRCA	cis	rs14027	0.512	rs10103886	ENSG00000279347.1	RP11-85I17.2	-4.76	2.22e-06	0.00021	-0.14	-0.15	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119715158	chr8:119838736~119840385:-
BRCA	cis	rs14027	0.512	rs7825803	ENSG00000279347.1	RP11-85I17.2	-4.76	2.22e-06	0.00021	-0.14	-0.15	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119716558	chr8:119838736~119840385:-
BRCA	cis	rs62025270	0.632	rs8029034	ENSG00000259295.5	CSPG4P12	-4.76	2.22e-06	0.00021	-0.22	-0.15	Idiopathic pulmonary fibrosis;	chr15:85582497	chr15:85191438~85213905:+
BRCA	cis	rs4356203	0.87	rs11024208	ENSG00000272034.1	SNORD14A	-4.76	2.22e-06	0.00021	-0.15	-0.15	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17238432	chr11:17074654~17074744:-
BRCA	cis	rs922692	0.71	rs1994016	ENSG00000261143.1	ADAMTS7P3	4.76	2.22e-06	0.00021	0.18	0.15	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78787892	chr15:77976042~77993057:+
BRCA	cis	rs17684571	0.7	rs13200166	ENSG00000231441.1	RP11-472M19.2	4.76	2.22e-06	0.00021	0.23	0.15	Schizophrenia;	chr6:56816414	chr6:56844002~56864078:+
BRCA	cis	rs17684571	0.7	rs17752046	ENSG00000231441.1	RP11-472M19.2	4.76	2.22e-06	0.00021	0.23	0.15	Schizophrenia;	chr6:56816550	chr6:56844002~56864078:+
BRCA	cis	rs2153535	0.505	rs1737583	ENSG00000251164.1	HULC	-4.76	2.22e-06	0.00021	-0.18	-0.15	Motion sickness;	chr6:8536579	chr6:8652137~8653846:+
BRCA	cis	rs7646881	0.812	rs79303235	ENSG00000240207.5	RP11-379F4.4	-4.76	2.22e-06	0.00021	-0.23	-0.15	Tetralogy of Fallot;	chr3:158727004	chr3:158732263~158784070:+
BRCA	cis	rs6738627	0.84	rs6717858	ENSG00000223318.1	RNA5SP111	-4.76	2.22e-06	0.00021	-0.16	-0.15	circulating leptin levels adjusted for BMI;Body fat percentage;circulating leptin levels;	chr2:164683151	chr2:164895677~164895777:-
BRCA	cis	rs9646944	0.519	rs1041973	ENSG00000234389.1	AC007278.3	-4.76	2.22e-06	0.00021	-0.15	-0.15	Blood protein levels;	chr2:102339008	chr2:102438713~102440475:+
BRCA	cis	rs11098499	0.909	rs1809406	ENSG00000260091.1	RP11-33B1.4	-4.76	2.22e-06	0.00021	-0.13	-0.15	Corneal astigmatism;	chr4:119455967	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.865	rs2389809	ENSG00000260091.1	RP11-33B1.4	-4.76	2.22e-06	0.00021	-0.13	-0.15	Corneal astigmatism;	chr4:119456244	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.909	rs9994810	ENSG00000260091.1	RP11-33B1.4	-4.76	2.22e-06	0.00021	-0.13	-0.15	Corneal astigmatism;	chr4:119460435	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.697	rs10020027	ENSG00000260091.1	RP11-33B1.4	-4.76	2.22e-06	0.00021	-0.13	-0.15	Corneal astigmatism;	chr4:119460724	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.779	rs7356491	ENSG00000260091.1	RP11-33B1.4	-4.76	2.22e-06	0.00021	-0.13	-0.15	Corneal astigmatism;	chr4:119460819	chr4:119409333~119410233:+
BRCA	cis	rs2904967	0.759	rs625427	ENSG00000254614.2	AP003068.23	-4.76	2.22e-06	0.00021	-0.27	-0.15	Mean corpuscular volume;	chr11:65236341	chr11:65177606~65181834:-
BRCA	cis	rs2070615	0.545	rs2926804	ENSG00000239617.1	RP11-302B13.1	4.76	2.22e-06	0.00021	0.18	0.15	Bipolar disorder;	chr12:48803595	chr12:48903418~48903813:-
BRCA	cis	rs11955398	0.604	rs11951950	ENSG00000215032.2	GNL3LP1	4.76	2.22e-06	0.00021	0.18	0.15	Intelligence (multi-trait analysis);	chr5:60581113	chr5:60891935~60893577:-
BRCA	cis	rs6723226	0.593	rs176401	ENSG00000276517.1	AL133243.2	4.76	2.22e-06	0.00021	0.18	0.15	Intelligence (multi-trait analysis);	chr2:32411443	chr2:32526504~32529507:+
BRCA	cis	rs6832769	0.925	rs6817267	ENSG00000223305.1	RN7SKP30	4.76	2.22e-06	0.00021	0.18	0.15	Personality dimensions;	chr4:55472374	chr4:55540502~55540835:-
BRCA	cis	rs6832769	1	rs11931061	ENSG00000223305.1	RN7SKP30	4.76	2.22e-06	0.00021	0.18	0.15	Personality dimensions;	chr4:55472626	chr4:55540502~55540835:-
BRCA	cis	rs6832769	0.961	rs11947476	ENSG00000223305.1	RN7SKP30	4.76	2.22e-06	0.00021	0.18	0.15	Personality dimensions;	chr4:55473584	chr4:55540502~55540835:-
BRCA	cis	rs6928977	0.675	rs6908428	ENSG00000234084.1	RP3-388E23.2	-4.76	2.22e-06	0.000211	-0.15	-0.15	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135472568	chr6:135301568~135307158:+
BRCA	cis	rs60695258	0.55	rs340648	ENSG00000251411.1	RP11-397E7.4	4.76	2.22e-06	0.000211	0.16	0.15	Hematocrit;	chr4:87019788	chr4:86913266~86914817:-
BRCA	cis	rs2832191	0.74	rs6516890	ENSG00000176054.6	RPL23P2	4.76	2.22e-06	0.000211	0.15	0.15	Dental caries;	chr21:29104491	chr21:28997613~28998033:-
BRCA	cis	rs13113518	1	rs11726198	ENSG00000249700.7	SRD5A3-AS1	4.76	2.23e-06	0.000211	0.18	0.15	Height;	chr4:55523835	chr4:55363971~55395847:-
BRCA	cis	rs13113518	0.966	rs11133396	ENSG00000249700.7	SRD5A3-AS1	4.76	2.23e-06	0.000211	0.18	0.15	Height;	chr4:55524246	chr4:55363971~55395847:-
BRCA	cis	rs13113518	1	rs7675109	ENSG00000249700.7	SRD5A3-AS1	4.76	2.23e-06	0.000211	0.18	0.15	Height;	chr4:55525589	chr4:55363971~55395847:-
BRCA	cis	rs13113518	1	rs4865005	ENSG00000249700.7	SRD5A3-AS1	4.76	2.23e-06	0.000211	0.18	0.15	Height;	chr4:55525781	chr4:55363971~55395847:-
BRCA	cis	rs2115630	0.755	rs7169629	ENSG00000259295.5	CSPG4P12	4.76	2.23e-06	0.000211	0.17	0.15	P wave terminal force;	chr15:84648043	chr15:85191438~85213905:+
BRCA	cis	rs2115630	0.967	rs12595786	ENSG00000259728.4	LINC00933	-4.76	2.23e-06	0.000211	-0.16	-0.15	P wave terminal force;	chr15:84793439	chr15:84570649~84580175:+
BRCA	cis	rs6832769	0.961	rs11939815	ENSG00000272969.1	RP11-528I4.2	4.76	2.23e-06	0.000211	0.17	0.15	Personality dimensions;	chr4:55492116	chr4:55547112~55547889:+
BRCA	cis	rs6832769	0.826	rs58894703	ENSG00000272969.1	RP11-528I4.2	4.76	2.23e-06	0.000211	0.17	0.15	Personality dimensions;	chr4:55492371	chr4:55547112~55547889:+
BRCA	cis	rs6832769	1	rs3805157	ENSG00000272969.1	RP11-528I4.2	4.76	2.23e-06	0.000211	0.17	0.15	Personality dimensions;	chr4:55497936	chr4:55547112~55547889:+
BRCA	cis	rs12681366	0.564	rs2165405	ENSG00000253704.1	RP11-267M23.4	4.76	2.23e-06	0.000211	0.16	0.15	Nonsyndromic cleft lip with cleft palate;	chr8:94442079	chr8:94553722~94569745:+
BRCA	cis	rs9308731	1	rs1980045	ENSG00000230499.1	AC108463.1	-4.76	2.23e-06	0.000211	-0.17	-0.15	Chronic lymphocytic leukemia;	chr2:111146964	chr2:111195963~111206494:+
BRCA	cis	rs875971	0.522	rs4718285	ENSG00000182722.5	SEPHS1P1	-4.76	2.23e-06	0.000211	-0.18	-0.15	Aortic root size;	chr7:65827018	chr7:64852397~64853354:-
BRCA	cis	rs7927592	0.913	rs7106010	ENSG00000212093.1	AP000807.1	4.76	2.23e-06	0.000211	0.16	0.15	Total body bone mineral density;	chr11:68597744	chr11:68506083~68506166:-
BRCA	cis	rs6570726	0.791	rs9497357	ENSG00000270638.1	RP3-466P17.1	4.76	2.23e-06	0.000211	0.17	0.15	Lobe attachment (rater-scored or self-reported);	chr6:145591752	chr6:145735570~145737218:+
BRCA	cis	rs718433	0.648	rs10133882	ENSG00000256379.1	TRAV8-5	4.76	2.23e-06	0.000211	0.18	0.15	Intraocular pressure;	chr14:21746222	chr14:21903077~21903598:+
BRCA	cis	rs67311347	1	rs1454497	ENSG00000280739.1	EIF1B-AS1	-4.76	2.23e-06	0.000211	-0.16	-0.15	Renal cell carcinoma;	chr3:40454835	chr3:40173145~40309698:-
BRCA	cis	rs10833905	1	rs61889442	ENSG00000246225.5	RP11-17A1.3	-4.76	2.23e-06	0.000211	-0.21	-0.15	Sudden cardiac arrest;	chr11:23034201	chr11:22829380~22945393:+
BRCA	cis	rs10833905	1	rs61889452	ENSG00000246225.5	RP11-17A1.3	-4.76	2.23e-06	0.000211	-0.21	-0.15	Sudden cardiac arrest;	chr11:23037966	chr11:22829380~22945393:+
BRCA	cis	rs2839186	0.934	rs17176520	ENSG00000228137.1	AP001469.7	4.76	2.23e-06	0.000211	0.15	0.15	Testicular germ cell tumor;	chr21:46262167	chr21:46246890~46247682:+
BRCA	cis	rs10129255	1	rs10129407	ENSG00000224373.3	IGHV4-59	4.76	2.23e-06	0.000211	0.09	0.15	Kawasaki disease;	chr14:106767956	chr14:106627249~106627825:-
BRCA	cis	rs1722141	0.669	rs788736	ENSG00000229628.1	AC073115.7	-4.76	2.23e-06	0.000211	-0.19	-0.15	Sitting height ratio;	chr7:45990601	chr7:45990905~46000898:+
BRCA	cis	rs6832769	0.925	rs6554292	ENSG00000272969.1	RP11-528I4.2	-4.76	2.23e-06	0.000211	-0.17	-0.15	Personality dimensions;	chr4:55584943	chr4:55547112~55547889:+
BRCA	cis	rs6751744	1	rs6751744	ENSG00000226266.5	AC009961.3	-4.76	2.23e-06	0.000211	-0.2	-0.15	Dysphagia;	chr2:159550974	chr2:159670708~159712435:-
BRCA	cis	rs11098499	0.874	rs13123591	ENSG00000249244.1	RP11-548H18.2	4.76	2.23e-06	0.000211	0.18	0.15	Corneal astigmatism;	chr4:119184835	chr4:119391831~119395335:-
BRCA	cis	rs1161098	0.767	rs1161084	ENSG00000256037.1	MRPL40P1	-4.76	2.23e-06	0.000211	-0.24	-0.15	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr12:67435106	chr12:67351436~67352039:+
BRCA	cis	rs57221529	0.766	rs72703070	ENSG00000271781.1	CTD-2589H19.6	-4.76	2.23e-06	0.000211	-0.22	-0.15	Lung disease severity in cystic fibrosis;	chr5:590343	chr5:675826~676616:+
BRCA	cis	rs57221529	0.713	rs72703072	ENSG00000271781.1	CTD-2589H19.6	-4.76	2.23e-06	0.000211	-0.22	-0.15	Lung disease severity in cystic fibrosis;	chr5:590511	chr5:675826~676616:+
BRCA	cis	rs57221529	0.713	rs12522724	ENSG00000271781.1	CTD-2589H19.6	-4.76	2.23e-06	0.000211	-0.22	-0.15	Lung disease severity in cystic fibrosis;	chr5:590627	chr5:675826~676616:+
BRCA	cis	rs6490294	0.528	rs12579336	ENSG00000226469.1	ADAM1B	4.76	2.23e-06	0.000211	0.25	0.15	Mean platelet volume;	chr12:112177734	chr12:111927018~111929017:+
BRCA	cis	rs13113518	1	rs12501636	ENSG00000249700.7	SRD5A3-AS1	4.76	2.23e-06	0.000211	0.18	0.15	Height;	chr4:55482317	chr4:55363971~55395847:-
BRCA	cis	rs2277027	0.956	rs13361953	ENSG00000248544.2	CTB-47B11.3	4.76	2.23e-06	0.000211	0.18	0.15	Pulmonary function;Pulmonary function (smoking interaction);	chr5:157499434	chr5:157375741~157384950:-
BRCA	cis	rs60695258	1	rs17605615	ENSG00000251411.1	RP11-397E7.4	-4.76	2.24e-06	0.000211	-0.16	-0.15	Hematocrit;	chr4:87075593	chr4:86913266~86914817:-
BRCA	cis	rs2018683	0.523	rs886834	ENSG00000228421.2	AC005013.5	4.76	2.24e-06	0.000211	0.19	0.15	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28981720	chr7:28957667~28959345:+
BRCA	cis	rs1499614	0.901	rs2178742	ENSG00000222364.1	RNU6-96P	-4.76	2.24e-06	0.000211	-0.27	-0.15	Gout;	chr7:66732812	chr7:66395191~66395286:+
BRCA	cis	rs4666002	0.789	rs13023094	ENSG00000234072.1	AC074117.10	-4.76	2.24e-06	0.000211	-0.17	-0.15	Phospholipid levels (plasma);	chr2:27687839	chr2:27356246~27367622:+
BRCA	cis	rs1440410	0.795	rs6822299	ENSG00000250326.1	RP11-284M14.1	-4.76	2.24e-06	0.000212	-0.16	-0.15	Ischemic stroke;	chr4:143261210	chr4:142933195~143184861:-
BRCA	cis	rs7772486	0.84	rs2814867	ENSG00000270638.1	RP3-466P17.1	4.76	2.24e-06	0.000212	0.17	0.15	Lobe attachment (rater-scored or self-reported);	chr6:146012894	chr6:145735570~145737218:+
BRCA	cis	rs2835345	0.563	rs12627167	ENSG00000279365.1	KB-176G8.1	4.76	2.24e-06	0.000212	0.19	0.15	Pulmonary function;	chr21:36449855	chr21:36485867~36487760:+
BRCA	cis	rs2832077	0.506	rs2832093	ENSG00000215533.7	LINC00189	4.76	2.24e-06	0.000212	0.18	0.15	Cognitive test performance;	chr21:28792533	chr21:29193480~29288205:+
BRCA	cis	rs11154801	0.589	rs6924066	ENSG00000231028.7	LINC00271	-4.76	2.24e-06	0.000212	-0.15	-0.15	Multiple sclerosis;	chr6:135598006	chr6:135497801~135716055:+
BRCA	cis	rs2835345	0.563	rs78113480	ENSG00000279365.1	KB-176G8.1	4.76	2.24e-06	0.000212	0.19	0.15	Pulmonary function;	chr21:36452022	chr21:36485867~36487760:+
BRCA	cis	rs2835345	0.563	rs4378885	ENSG00000279365.1	KB-176G8.1	4.76	2.24e-06	0.000212	0.19	0.15	Pulmonary function;	chr21:36452613	chr21:36485867~36487760:+
BRCA	cis	rs2835345	0.563	rs4481073	ENSG00000279365.1	KB-176G8.1	4.76	2.24e-06	0.000212	0.19	0.15	Pulmonary function;	chr21:36452657	chr21:36485867~36487760:+
BRCA	cis	rs2835345	0.563	rs2835361	ENSG00000279365.1	KB-176G8.1	4.76	2.24e-06	0.000212	0.19	0.15	Pulmonary function;	chr21:36452699	chr21:36485867~36487760:+
BRCA	cis	rs4906332	1	rs3783397	ENSG00000244691.1	RPL10AP1	-4.76	2.24e-06	0.000212	-0.18	-0.15	Coronary artery disease;	chr14:103480952	chr14:103412119~103412761:-
BRCA	cis	rs875971	0.545	rs73376394	ENSG00000273142.1	RP11-458F8.4	4.76	2.24e-06	0.000212	0.14	0.15	Aortic root size;	chr7:66172694	chr7:66902857~66906297:+
BRCA	cis	rs5758511	0.68	rs5758681	ENSG00000227370.1	RP4-669P10.19	4.76	2.24e-06	0.000212	0.19	0.15	Birth weight;	chr22:42249085	chr22:42132543~42132998:+
BRCA	cis	rs6847067	0.683	rs1508670	ENSG00000180769.7	WDFY3-AS2	4.76	2.24e-06	0.000212	0.14	0.15	Oropharynx cancer;	chr4:84923506	chr4:84965682~85011277:+
BRCA	cis	rs7819412	0.505	rs17782536	ENSG00000154316.13	TDH	4.76	2.24e-06	0.000212	0.2	0.15	Triglycerides;	chr8:11164172	chr8:11339637~11368452:+
BRCA	cis	rs875971	0.545	rs2420456	ENSG00000232546.1	RP11-458F8.1	4.76	2.24e-06	0.000212	0.14	0.15	Aortic root size;	chr7:66280619	chr7:66848496~66858136:+
BRCA	cis	rs78487399	0.908	rs76621120	ENSG00000234936.1	AC010883.5	4.76	2.24e-06	0.000212	0.22	0.15	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43583512	chr2:43229573~43233394:+
BRCA	cis	rs13113518	0.902	rs12642716	ENSG00000249700.7	SRD5A3-AS1	4.76	2.24e-06	0.000212	0.18	0.15	Height;	chr4:55479996	chr4:55363971~55395847:-
BRCA	cis	rs7011507	0.505	rs55962116	ENSG00000279881.1	RP11-513O13.1	-4.76	2.24e-06	0.000212	-0.23	-0.15	Inflammatory bowel disease;Ulcerative colitis;	chr8:48342114	chr8:48428143~48431041:-
BRCA	cis	rs2904967	0.852	rs1633466	ENSG00000255200.1	AP003068.18	-4.76	2.24e-06	0.000212	-0.25	-0.15	Mean corpuscular volume;	chr11:65248702	chr11:65174117~65176470:-
BRCA	cis	rs11758351	0.66	rs11753131	ENSG00000241549.7	GUSBP2	-4.76	2.24e-06	0.000212	-0.21	-0.15	Renal underexcretion gout;Gout;	chr6:26219156	chr6:26871484~26956554:-
BRCA	cis	rs11758351	0.66	rs11757754	ENSG00000241549.7	GUSBP2	-4.76	2.24e-06	0.000212	-0.21	-0.15	Renal underexcretion gout;Gout;	chr6:26219516	chr6:26871484~26956554:-
BRCA	cis	rs11758351	0.66	rs16891443	ENSG00000241549.7	GUSBP2	-4.76	2.24e-06	0.000212	-0.21	-0.15	Renal underexcretion gout;Gout;	chr6:26221709	chr6:26871484~26956554:-
BRCA	cis	rs3768617	0.51	rs12078729	ENSG00000224468.3	RP11-181K3.4	-4.76	2.24e-06	0.000212	-0.16	-0.15	Fuchs's corneal dystrophy;	chr1:183090937	chr1:183138402~183141282:-
BRCA	cis	rs4653663	0.785	rs11589433	ENSG00000226349.1	RP11-145A3.2	4.76	2.24e-06	0.000212	0.18	0.15	Neuroticism;	chr1:225734457	chr1:225710968~225736274:-
BRCA	cis	rs7833986	0.534	rs17759244	ENSG00000253603.1	CTA-397H3.3	-4.76	2.24e-06	0.000212	-0.21	-0.15	Height;	chr8:56121209	chr8:56074592~56075274:+
BRCA	cis	rs1707322	1	rs4134387	ENSG00000234329.1	RP11-767N6.2	4.76	2.25e-06	0.000212	0.15	0.15	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45929486	chr1:45651039~45651826:-
BRCA	cis	rs78487399	0.808	rs77377889	ENSG00000234936.1	AC010883.5	4.76	2.25e-06	0.000212	0.24	0.15	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43461185	chr2:43229573~43233394:+
BRCA	cis	rs6081541	0.689	rs1547100	ENSG00000179447.2	RP5-1027G4.3	4.76	2.25e-06	0.000212	0.18	0.15	Psychosis (atypical);	chr20:19220625	chr20:19242302~19284596:-
BRCA	cis	rs2179367	0.959	rs480034	ENSG00000268592.3	RAET1E-AS1	-4.76	2.25e-06	0.000213	-0.19	-0.15	Dupuytren's disease;	chr6:149414294	chr6:149863494~149919507:+
BRCA	cis	rs3892630	0.878	rs2903759	ENSG00000267567.1	CTD-2538C1.3	4.76	2.25e-06	0.000213	0.23	0.15	Red blood cell traits;	chr19:32705041	chr19:32718298~32719595:-
BRCA	cis	rs651907	0.557	rs13099674	ENSG00000256628.3	ZBTB11-AS1	4.76	2.25e-06	0.000213	0.18	0.15	Colorectal cancer;	chr3:101770785	chr3:101676475~101679217:+
BRCA	cis	rs11098499	0.874	rs9995277	ENSG00000249244.1	RP11-548H18.2	4.76	2.25e-06	0.000213	0.18	0.15	Corneal astigmatism;	chr4:119187448	chr4:119391831~119395335:-
BRCA	cis	rs4415084	0.804	rs10044096	ENSG00000251141.4	RP11-53O19.1	-4.76	2.25e-06	0.000213	-0.13	-0.15	Breast cancer;	chr5:44927263	chr5:44744900~44808777:-
BRCA	cis	rs4489787	1	rs2705126	ENSG00000240399.1	RP1-228P16.1	4.76	2.25e-06	0.000213	0.23	0.15	Prostate cancer (SNP x SNP interaction);	chr12:48488779	chr12:48054813~48055591:-
BRCA	cis	rs875971	1	rs2220626	ENSG00000236529.1	RP13-254B10.1	-4.76	2.25e-06	0.000213	-0.16	-0.15	Aortic root size;	chr7:66081075	chr7:65840212~65840596:+
BRCA	cis	rs2243480	1	rs778679	ENSG00000222364.1	RNU6-96P	-4.76	2.25e-06	0.000213	-0.27	-0.15	Diabetic kidney disease;	chr7:66375924	chr7:66395191~66395286:+
BRCA	cis	rs6095360	0.932	rs7264180	ENSG00000222365.1	SNORD12B	-4.76	2.25e-06	0.000213	-0.16	-0.15	Intelligence (multi-trait analysis);	chr20:48963243	chr20:49280319~49280409:+
BRCA	cis	rs6095360	0.934	rs2295031	ENSG00000222365.1	SNORD12B	-4.76	2.25e-06	0.000213	-0.16	-0.15	Intelligence (multi-trait analysis);	chr20:48963810	chr20:49280319~49280409:+
BRCA	cis	rs10266483	0.545	rs1812912	ENSG00000228653.2	HNRNPCP7	4.76	2.25e-06	0.000213	0.21	0.15	Response to statin therapy;	chr7:64282891	chr7:64500825~64501729:+
BRCA	cis	rs7246657	0.722	rs968073	ENSG00000276846.1	CTD-3220F14.3	-4.76	2.25e-06	0.000213	-0.2	-0.15	Coronary artery calcification;	chr19:37701120	chr19:37314868~37315620:-
BRCA	cis	rs2277027	1	rs11134779	ENSG00000248544.2	CTB-47B11.3	-4.76	2.26e-06	0.000213	-0.17	-0.15	Pulmonary function;Pulmonary function (smoking interaction);	chr5:157509758	chr5:157375741~157384950:-
BRCA	cis	rs17801127	0.688	rs34250677	ENSG00000231969.1	AC144449.1	4.76	2.26e-06	0.000213	0.29	0.15	Liver enzyme levels (alanine transaminase);	chr2:149790443	chr2:149587196~149848233:+
BRCA	cis	rs7682317	0.797	rs1708667	ENSG00000270720.1	RP11-84C13.2	-4.76	2.26e-06	0.000213	-0.16	-0.15	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr4:89008459	chr4:89119284~89119871:+
BRCA	cis	rs2835345	0.563	rs12482435	ENSG00000279365.1	KB-176G8.1	4.76	2.26e-06	0.000213	0.19	0.15	Pulmonary function;	chr21:36448658	chr21:36485867~36487760:+
BRCA	cis	rs1552244	0.572	rs58862481	ENSG00000232901.1	CYCSP10	4.76	2.26e-06	0.000213	0.23	0.15	Alzheimer's disease;	chr3:10122624	chr3:10000647~10000940:-
BRCA	cis	rs875971	0.83	rs809025	ENSG00000273448.1	RP11-166O4.6	4.76	2.26e-06	0.000213	0.14	0.15	Aortic root size;	chr7:66384832	chr7:67333047~67334383:+
BRCA	cis	rs2115630	1	rs55646601	ENSG00000259728.4	LINC00933	-4.76	2.26e-06	0.000213	-0.16	-0.15	P wave terminal force;	chr15:84780337	chr15:84570649~84580175:+
BRCA	cis	rs4763879	0.739	rs2895988	ENSG00000278635.1	CTD-2318O12.1	4.76	2.26e-06	0.000213	0.15	0.15	Type 1 diabetes;	chr12:9675831	chr12:9415641~9416718:+
BRCA	cis	rs17685	0.712	rs2158867	ENSG00000280388.1	RP11-229D13.3	-4.76	2.26e-06	0.000214	-0.15	-0.15	Coffee consumption (cups per day);Coffee consumption;	chr7:76185823	chr7:76043977~76045963:-
BRCA	cis	rs6928977	0.675	rs11154803	ENSG00000234084.1	RP3-388E23.2	-4.76	2.26e-06	0.000214	-0.15	-0.15	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135477707	chr6:135301568~135307158:+
BRCA	cis	rs7474896	0.583	rs11011347	ENSG00000120555.12	SEPT7P9	4.76	2.26e-06	0.000214	0.21	0.15	Obesity (extreme);	chr10:37730336	chr10:38383069~38402916:-
BRCA	cis	rs11239930	0.517	rs4950354	ENSG00000278811.3	LINC00624	4.76	2.26e-06	0.000214	0.17	0.15	AIDS progression;	chr1:147082674	chr1:147258885~147517875:-
BRCA	cis	rs11239930	0.538	rs4950355	ENSG00000278811.3	LINC00624	4.76	2.26e-06	0.000214	0.17	0.15	AIDS progression;	chr1:147082700	chr1:147258885~147517875:-
BRCA	cis	rs875971	1	rs875971	ENSG00000223473.2	GS1-124K5.3	-4.76	2.26e-06	0.000214	-0.11	-0.15	Aortic root size;	chr7:66152608	chr7:66491049~66493566:-
BRCA	cis	rs4713118	0.513	rs149959	ENSG00000219392.1	RP1-265C24.5	-4.76	2.26e-06	0.000214	-0.2	-0.15	Parkinson's disease;	chr6:28046076	chr6:28115628~28116551:+
BRCA	cis	rs1043099	0.912	rs2041199	ENSG00000279699.1	RP1-102K2.9	-4.76	2.26e-06	0.000214	-0.23	-0.15	Rheumatoid arthritis;	chr22:30336247	chr22:30275215~30276951:-
BRCA	cis	rs9863	0.827	rs12823740	ENSG00000270028.1	RP11-380L11.4	4.76	2.26e-06	0.000214	0.18	0.15	White blood cell count;	chr12:123973455	chr12:123925461~123926083:-
BRCA	cis	rs853679	1	rs853694	ENSG00000204709.4	LINC01556	4.76	2.26e-06	0.000214	0.26	0.15	Depression;	chr6:28311323	chr6:28943877~28944537:+
BRCA	cis	rs2832191	0.791	rs2832202	ENSG00000176054.6	RPL23P2	-4.76	2.26e-06	0.000214	-0.15	-0.15	Dental caries;	chr21:29129021	chr21:28997613~28998033:-
BRCA	cis	rs57221529	0.766	rs4957053	ENSG00000225138.6	CTD-2228K2.7	4.75	2.26e-06	0.000214	0.22	0.15	Lung disease severity in cystic fibrosis;	chr5:575812	chr5:473236~480884:+
BRCA	cis	rs375066	0.551	rs349032	ENSG00000267058.1	RP11-15A1.3	-4.75	2.26e-06	0.000214	-0.17	-0.15	Breast cancer;	chr19:43813208	chr19:43891804~43901805:-
BRCA	cis	rs1667284	0.846	rs1667280	ENSG00000266521.1	RP11-650P15.1	4.75	2.26e-06	0.000214	0.17	0.15	Problematic alcohol use in trauma-exposed individuals;	chr18:31639209	chr18:31496645~31497195:-
BRCA	cis	rs867186	1	rs75635914	ENSG00000126005.14	MMP24-AS1	-4.75	2.26e-06	0.000214	-0.27	-0.15	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:34968012	chr20:35216462~35278131:-
BRCA	cis	rs11098499	0.754	rs1849457	ENSG00000249244.1	RP11-548H18.2	4.75	2.26e-06	0.000214	0.17	0.15	Corneal astigmatism;	chr4:119333200	chr4:119391831~119395335:-
BRCA	cis	rs6832769	1	rs10005989	ENSG00000223305.1	RN7SKP30	-4.75	2.27e-06	0.000214	-0.18	-0.15	Personality dimensions;	chr4:55539039	chr4:55540502~55540835:-
BRCA	cis	rs2115630	1	rs1030863	ENSG00000259295.5	CSPG4P12	-4.75	2.27e-06	0.000214	-0.17	-0.15	P wave terminal force;	chr15:84739404	chr15:85191438~85213905:+
BRCA	cis	rs1020064	0.945	rs1030878	ENSG00000235319.1	AC012360.4	-4.75	2.27e-06	0.000214	-0.21	-0.15	AIDS;	chr2:105294141	chr2:105324210~105330529:+
BRCA	cis	rs7481584	0.624	rs440130	ENSG00000247473.2	CARS-AS1	-4.75	2.27e-06	0.000214	-0.17	-0.15	Calcium levels;	chr11:3030246	chr11:3029009~3041260:+
BRCA	cis	rs11673344	0.504	rs35162188	ENSG00000226686.6	LINC01535	4.75	2.27e-06	0.000214	0.19	0.15	Obesity-related traits;	chr19:37088908	chr19:37251912~37265535:+
BRCA	cis	rs6545883	0.929	rs778155	ENSG00000270820.4	RP11-355B11.2	-4.75	2.27e-06	0.000214	-0.17	-0.15	Tuberculosis;	chr2:61420766	chr2:61471188~61484130:+
BRCA	cis	rs2286503	0.646	rs17147344	ENSG00000228649.7	AC005682.5	4.75	2.27e-06	0.000214	0.14	0.15	Fibrinogen;	chr7:22841237	chr7:22854178~22861579:+
BRCA	cis	rs7141336	0.77	rs12890577	ENSG00000258884.1	CTD-3035D6.2	4.75	2.27e-06	0.000214	0.19	0.15	Anxiety disorder;	chr14:90827103	chr14:90822365~90828128:-
BRCA	cis	rs11098499	0.662	rs13108589	ENSG00000249244.1	RP11-548H18.2	4.75	2.27e-06	0.000214	0.17	0.15	Corneal astigmatism;	chr4:119346947	chr4:119391831~119395335:-
BRCA	cis	rs950169	0.58	rs17598114	ENSG00000275120.1	RP11-182J1.17	4.75	2.27e-06	0.000214	0.2	0.15	Schizophrenia;	chr15:84628086	chr15:84599434~84606463:-
BRCA	cis	rs7772486	0.754	rs6570708	ENSG00000270638.1	RP3-466P17.1	-4.75	2.27e-06	0.000214	-0.17	-0.15	Lobe attachment (rater-scored or self-reported);	chr6:145668292	chr6:145735570~145737218:+
BRCA	cis	rs16958440	0.867	rs79078752	ENSG00000280212.1	RP11-49K24.3	4.75	2.27e-06	0.000214	0.34	0.15	Sitting height ratio;	chr18:47141091	chr18:47076117~47076594:+
BRCA	cis	rs16958440	0.867	rs61689863	ENSG00000280212.1	RP11-49K24.3	4.75	2.27e-06	0.000214	0.34	0.15	Sitting height ratio;	chr18:47142786	chr18:47076117~47076594:+
BRCA	cis	rs16958440	0.867	rs80064497	ENSG00000280212.1	RP11-49K24.3	4.75	2.27e-06	0.000214	0.34	0.15	Sitting height ratio;	chr18:47143282	chr18:47076117~47076594:+
BRCA	cis	rs16958440	0.867	rs78547658	ENSG00000280212.1	RP11-49K24.3	4.75	2.27e-06	0.000214	0.34	0.15	Sitting height ratio;	chr18:47143481	chr18:47076117~47076594:+
BRCA	cis	rs16958440	0.867	rs12386092	ENSG00000280212.1	RP11-49K24.3	4.75	2.27e-06	0.000214	0.34	0.15	Sitting height ratio;	chr18:47145687	chr18:47076117~47076594:+
BRCA	cis	rs3764021	0.87	rs11052710	ENSG00000278635.1	CTD-2318O12.1	-4.75	2.27e-06	0.000215	-0.14	-0.15	Type 1 diabetes;	chr12:9723754	chr12:9415641~9416718:+
BRCA	cis	rs11098499	0.874	rs7661020	ENSG00000249244.1	RP11-548H18.2	4.75	2.27e-06	0.000215	0.18	0.15	Corneal astigmatism;	chr4:119185827	chr4:119391831~119395335:-
BRCA	cis	rs875971	0.862	rs778686	ENSG00000273448.1	RP11-166O4.6	4.75	2.27e-06	0.000215	0.13	0.15	Aortic root size;	chr7:66370923	chr7:67333047~67334383:+
BRCA	cis	rs10129255	0.957	rs6576233	ENSG00000280411.1	IGHV1-69-2	-4.75	2.27e-06	0.000215	-0.1	-0.15	Kawasaki disease;	chr14:106787239	chr14:106762092~106762588:-
BRCA	cis	rs9467773	0.583	rs2498380	ENSG00000224843.5	LINC00240	4.75	2.27e-06	0.000215	0.16	0.15	Intelligence (multi-trait analysis);	chr6:26643768	chr6:26956992~27023924:+
BRCA	cis	rs6832769	1	rs13102385	ENSG00000223305.1	RN7SKP30	4.75	2.28e-06	0.000215	0.18	0.15	Personality dimensions;	chr4:55479088	chr4:55540502~55540835:-
BRCA	cis	rs6832769	0.961	rs11947623	ENSG00000223305.1	RN7SKP30	4.75	2.28e-06	0.000215	0.18	0.15	Personality dimensions;	chr4:55483023	chr4:55540502~55540835:-
BRCA	cis	rs17684571	0.7	rs17684748	ENSG00000231441.1	RP11-472M19.2	4.75	2.28e-06	0.000215	0.23	0.15	Schizophrenia;	chr6:56809419	chr6:56844002~56864078:+
BRCA	cis	rs11767557	1	rs11767557	ENSG00000229153.4	EPHA1-AS1	4.75	2.28e-06	0.000215	0.2	0.15	Alzheimer's disease (late onset);	chr7:143412046	chr7:143407813~143523449:+
BRCA	cis	rs4072705	0.646	rs2416933	ENSG00000224020.1	MIR181A2HG	4.75	2.28e-06	0.000215	0.16	0.15	Menarche (age at onset);	chr9:124483250	chr9:124658467~124698631:+
BRCA	cis	rs10129255	1	rs4612959	ENSG00000274576.2	IGHV2-70	4.75	2.28e-06	0.000215	0.13	0.15	Kawasaki disease;	chr14:106767055	chr14:106770577~106771020:-
BRCA	cis	rs4489787	0.892	rs4448729	ENSG00000240399.1	RP1-228P16.1	-4.75	2.28e-06	0.000215	-0.24	-0.15	Prostate cancer (SNP x SNP interaction);	chr12:48428545	chr12:48054813~48055591:-
BRCA	cis	rs7428	1	rs72840063	ENSG00000273196.1	RP11-717A5.2	4.75	2.28e-06	0.000215	0.18	0.15	Ear protrusion;	chr2:85323273	chr2:85387074~85387146:-
BRCA	cis	rs1552244	1	rs17032283	ENSG00000232901.1	CYCSP10	4.75	2.28e-06	0.000215	0.2	0.15	Alzheimer's disease;	chr3:10039861	chr3:10000647~10000940:-
BRCA	cis	rs9981595	1	rs9981595	ENSG00000238141.2	BRWD1-AS1	4.75	2.28e-06	0.000215	0.26	0.15	Venous thromboembolism (SNP x SNP interaction);	chr21:39188752	chr21:39315707~39323218:+
BRCA	cis	rs12744310	0.887	rs35592291	ENSG00000235358.1	RP11-399E6.1	4.75	2.28e-06	0.000215	0.22	0.15	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41325599	chr1:41242373~41284861:+
BRCA	cis	rs12744310	0.887	rs2363811	ENSG00000235358.1	RP11-399E6.1	4.75	2.28e-06	0.000215	0.22	0.15	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41326193	chr1:41242373~41284861:+
BRCA	cis	rs12744310	0.887	rs12026778	ENSG00000235358.1	RP11-399E6.1	4.75	2.28e-06	0.000215	0.22	0.15	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41326602	chr1:41242373~41284861:+
BRCA	cis	rs4950322	0.576	rs4950427	ENSG00000244371.2	PFN1P8	4.75	2.28e-06	0.000215	0.17	0.15	Protein quantitative trait loci;	chr1:147391175	chr1:146957117~146957659:-
BRCA	cis	rs11098499	0.697	rs11941899	ENSG00000260091.1	RP11-33B1.4	-4.75	2.28e-06	0.000215	-0.13	-0.15	Corneal astigmatism;	chr4:119461603	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.909	rs7681978	ENSG00000260091.1	RP11-33B1.4	-4.75	2.28e-06	0.000215	-0.13	-0.15	Corneal astigmatism;	chr4:119462620	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.821	rs28665282	ENSG00000260091.1	RP11-33B1.4	-4.75	2.28e-06	0.000215	-0.13	-0.15	Corneal astigmatism;	chr4:119463031	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.738	rs10026493	ENSG00000260091.1	RP11-33B1.4	-4.75	2.28e-06	0.000215	-0.13	-0.15	Corneal astigmatism;	chr4:119463039	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.909	rs7681214	ENSG00000260091.1	RP11-33B1.4	-4.75	2.28e-06	0.000215	-0.13	-0.15	Corneal astigmatism;	chr4:119464165	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.909	rs28632018	ENSG00000260091.1	RP11-33B1.4	-4.75	2.28e-06	0.000215	-0.13	-0.15	Corneal astigmatism;	chr4:119465575	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.908	rs71614449	ENSG00000260091.1	RP11-33B1.4	-4.75	2.28e-06	0.000215	-0.13	-0.15	Corneal astigmatism;	chr4:119465900	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.954	rs35063680	ENSG00000260091.1	RP11-33B1.4	-4.75	2.28e-06	0.000215	-0.13	-0.15	Corneal astigmatism;	chr4:119465947	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.954	rs34858317	ENSG00000260091.1	RP11-33B1.4	-4.75	2.28e-06	0.000215	-0.13	-0.15	Corneal astigmatism;	chr4:119465955	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.954	rs17046116	ENSG00000260091.1	RP11-33B1.4	-4.75	2.28e-06	0.000215	-0.13	-0.15	Corneal astigmatism;	chr4:119466104	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.909	rs17046118	ENSG00000260091.1	RP11-33B1.4	-4.75	2.28e-06	0.000215	-0.13	-0.15	Corneal astigmatism;	chr4:119466341	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.954	rs7654587	ENSG00000260091.1	RP11-33B1.4	-4.75	2.28e-06	0.000215	-0.13	-0.15	Corneal astigmatism;	chr4:119467251	chr4:119409333~119410233:+
BRCA	cis	rs2735413	0.514	rs7192129	ENSG00000276007.1	RP11-358L22.3	4.75	2.28e-06	0.000215	0.18	0.15	Systolic blood pressure (alcohol consumption interaction);	chr16:78102517	chr16:78123243~78124332:+
BRCA	cis	rs1971762	0.527	rs2365343	ENSG00000270175.1	RP11-793H13.11	4.75	2.28e-06	0.000215	0.13	0.15	Height;	chr12:53644365	chr12:53500162~53500936:-
BRCA	cis	rs7131987	0.565	rs2882294	ENSG00000275476.1	RP11-996F15.4	4.75	2.28e-06	0.000215	0.16	0.15	QT interval;	chr12:29245019	chr12:29277397~29277882:-
BRCA	cis	rs11098499	0.874	rs17839089	ENSG00000249244.1	RP11-548H18.2	4.75	2.28e-06	0.000215	0.18	0.15	Corneal astigmatism;	chr4:119189914	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.874	rs6826823	ENSG00000249244.1	RP11-548H18.2	4.75	2.28e-06	0.000215	0.18	0.15	Corneal astigmatism;	chr4:119190943	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.874	rs12509054	ENSG00000249244.1	RP11-548H18.2	4.75	2.28e-06	0.000215	0.18	0.15	Corneal astigmatism;	chr4:119193920	chr4:119391831~119395335:-
BRCA	cis	rs6951245	1	rs78523927	ENSG00000229043.2	AC091729.9	-4.75	2.28e-06	0.000215	-0.26	-0.15	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1049822	chr7:1160374~1165267:+
BRCA	cis	rs6840360	0.582	rs6535796	ENSG00000251603.1	RP11-164P12.4	-4.75	2.28e-06	0.000215	-0.14	-0.15	Intelligence (multi-trait analysis);	chr4:151383576	chr4:151667224~151670502:+
BRCA	cis	rs2617170	0.922	rs1351113	ENSG00000245648.1	RP11-277P12.20	-4.75	2.28e-06	0.000215	-0.2	-0.15	Behcet's disease;	chr12:10373045	chr12:10363769~10398506:+
BRCA	cis	rs7727544	0.716	rs4705928	ENSG00000233006.5	AC034220.3	-4.75	2.28e-06	0.000215	-0.11	-0.15	Blood metabolite levels;	chr5:132242944	chr5:132311285~132369916:-
BRCA	cis	rs9308731	0.692	rs604126	ENSG00000230499.1	AC108463.1	-4.75	2.28e-06	0.000216	-0.18	-0.15	Chronic lymphocytic leukemia;	chr2:111185623	chr2:111195963~111206494:+
BRCA	cis	rs9635324	0.516	rs8040128	ENSG00000223313.1	RNU6-516P	4.75	2.28e-06	0.000216	0.17	0.15	Blood metabolite ratios;Blood metabolite levels;	chr15:40425194	chr15:40529570~40529673:+
BRCA	cis	rs2692947	0.77	rs4527246	ENSG00000168992.4	OR7E102P	4.75	2.28e-06	0.000216	0.2	0.15	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95894555	chr2:95546531~95547545:+
BRCA	cis	rs4538475	0.606	rs2302465	ENSG00000273133.1	RP11-799M12.2	-4.75	2.28e-06	0.000216	-0.28	-0.15	Parkinson's disease;	chr4:15707569	chr4:15563698~15564253:-
BRCA	cis	rs7267979	0.844	rs4815413	ENSG00000125804.12	FAM182A	4.75	2.28e-06	0.000216	0.19	0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25378593	chr20:26054655~26086917:+
BRCA	cis	rs7267979	0.844	rs6083824	ENSG00000125804.12	FAM182A	4.75	2.28e-06	0.000216	0.19	0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25382421	chr20:26054655~26086917:+
BRCA	cis	rs3764021	0.527	rs12227655	ENSG00000256673.1	RP11-599J14.2	-4.75	2.29e-06	0.000216	-0.18	-0.15	Type 1 diabetes;	chr12:9715652	chr12:9398355~9414851:-
BRCA	cis	rs3764021	0.506	rs12228641	ENSG00000256673.1	RP11-599J14.2	-4.75	2.29e-06	0.000216	-0.18	-0.15	Type 1 diabetes;	chr12:9715680	chr12:9398355~9414851:-
BRCA	cis	rs8078723	0.668	rs3859192	ENSG00000264968.1	RP11-387H17.4	-4.75	2.29e-06	0.000216	-0.17	-0.15	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count (neutrophil);White blood cell count;	chr17:39972395	chr17:39927742~39939601:+
BRCA	cis	rs56322409	0.631	rs11188399	ENSG00000226688.5	ENTPD1-AS1	4.75	2.29e-06	0.000216	0.15	0.15	Blood metabolite levels;	chr10:95611560	chr10:95753206~96090238:-
BRCA	cis	rs11098499	0.909	rs1546502	ENSG00000250412.1	KLHL2P1	4.75	2.29e-06	0.000216	0.17	0.15	Corneal astigmatism;	chr4:119314743	chr4:119334329~119378233:+
BRCA	cis	rs7119	0.679	rs12914932	ENSG00000259362.2	RP11-307C19.1	-4.75	2.29e-06	0.000216	-0.21	-0.15	Type 2 diabetes;	chr15:77546709	chr15:77525540~77534110:+
BRCA	cis	rs6714710	0.58	rs11680018	ENSG00000230606.9	AC159540.1	-4.75	2.29e-06	0.000216	-0.17	-0.15	Posterior cortical atrophy and Alzheimer's disease;	chr2:97863118	chr2:97416165~97433527:-
BRCA	cis	rs12900463	0.752	rs12904777	ENSG00000259728.4	LINC00933	4.75	2.29e-06	0.000216	0.18	0.15	Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine);	chr15:84872514	chr15:84570649~84580175:+
BRCA	cis	rs828999	0.638	rs6703282	ENSG00000280186.1	RP11-483I13.6	-4.75	2.29e-06	0.000216	-0.16	-0.15	Monocyte percentage of white cells;	chr1:108154726	chr1:108200413~108202743:+
BRCA	cis	rs934734	0.532	rs13383320	ENSG00000204929.10	AC074391.1	-4.75	2.29e-06	0.000216	-0.18	-0.15	Rheumatoid arthritis;	chr2:65418003	chr2:65436711~66084639:+
BRCA	cis	rs5758659	0.819	rs134871	ENSG00000273366.1	CTA-989H11.1	-4.75	2.29e-06	0.000216	-0.17	-0.15	Cognitive function;	chr22:42256710	chr22:42278188~42278846:+
BRCA	cis	rs9467773	0.525	rs1535274	ENSG00000124549.13	BTN2A3P	4.75	2.29e-06	0.000216	0.15	0.15	Intelligence (multi-trait analysis);	chr6:26520519	chr6:26421391~26432383:+
BRCA	cis	rs10208649	0.831	rs6545368	ENSG00000233266.1	HMGB1P31	4.75	2.29e-06	0.000216	0.27	0.15	Body mass index;	chr2:53813267	chr2:54051334~54051760:+
BRCA	cis	rs859767	0.741	rs4954156	ENSG00000224043.6	CCNT2-AS1	4.75	2.29e-06	0.000216	0.2	0.15	Neuroticism;	chr2:134638293	chr2:134735464~134918710:-
BRCA	cis	rs739496	0.579	rs3752631	ENSG00000226469.1	ADAM1B	4.75	2.29e-06	0.000216	0.19	0.15	Platelet count;	chr12:111938353	chr12:111927018~111929017:+
BRCA	cis	rs739496	0.579	rs7959619	ENSG00000226469.1	ADAM1B	4.75	2.29e-06	0.000216	0.19	0.15	Platelet count;	chr12:111938793	chr12:111927018~111929017:+
BRCA	cis	rs2227564	0.574	rs3849969	ENSG00000271816.1	BMS1P4	-4.75	2.29e-06	0.000216	-0.15	-0.15	Crohn's disease;Inflammatory bowel disease;	chr10:73766241	chr10:73699151~73730487:-
BRCA	cis	rs454217	0.818	rs381750	ENSG00000277851.1	RP11-756G20.1	4.75	2.29e-06	0.000217	0.16	0.15	Smoking quantity;	chr12:92323106	chr12:92247756~92363832:-
BRCA	cis	rs4713118	0.868	rs9468220	ENSG00000216901.1	AL022393.7	-4.75	2.29e-06	0.000217	-0.21	-0.15	Parkinson's disease;	chr6:27765197	chr6:28176188~28176674:+
BRCA	cis	rs10504130	0.867	rs11786167	ENSG00000272024.1	RP11-546K22.3	-4.75	2.29e-06	0.000217	-0.26	-0.15	Venous thromboembolism (SNP x SNP interaction);	chr8:51763097	chr8:51950284~51950690:+
BRCA	cis	rs9467773	0.933	rs35355150	ENSG00000124549.13	BTN2A3P	4.75	2.3e-06	0.000217	0.15	0.15	Intelligence (multi-trait analysis);	chr6:26525811	chr6:26421391~26432383:+
BRCA	cis	rs1979679	0.573	rs7134807	ENSG00000278733.1	RP11-425D17.1	4.75	2.3e-06	0.000217	0.19	0.15	Ossification of the posterior longitudinal ligament of the spine;	chr12:28576317	chr12:28185625~28186190:-
BRCA	cis	rs2278170	0.961	rs331533	ENSG00000225101.4	OR52K3P	-4.75	2.3e-06	0.000217	-0.2	-0.15	Amyotrophic lateral sclerosis;	chr11:4456789	chr11:4474813~4475755:+
BRCA	cis	rs739496	0.579	rs12423041	ENSG00000226469.1	ADAM1B	4.75	2.3e-06	0.000217	0.19	0.15	Platelet count;	chr12:111887042	chr12:111927018~111929017:+
BRCA	cis	rs42490	0.664	rs368812	ENSG00000251136.7	RP11-37B2.1	-4.75	2.3e-06	0.000217	-0.14	-0.15	Leprosy;	chr8:89822269	chr8:89609409~89757727:-
BRCA	cis	rs4356203	0.905	rs214936	ENSG00000272034.1	SNORD14A	4.75	2.3e-06	0.000217	0.15	0.15	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17169472	chr11:17074654~17074744:-
BRCA	cis	rs11098499	0.954	rs6838814	ENSG00000260091.1	RP11-33B1.4	-4.75	2.3e-06	0.000217	-0.13	-0.15	Corneal astigmatism;	chr4:119471288	chr4:119409333~119410233:+
BRCA	cis	rs6430585	0.583	rs3769013	ENSG00000231890.6	DARS-AS1	-4.75	2.3e-06	0.000217	-0.22	-0.15	Corneal structure;	chr2:135798612	chr2:135985176~136022593:+
BRCA	cis	rs10129255	0.917	rs8022493	ENSG00000274576.2	IGHV2-70	4.75	2.3e-06	0.000217	0.12	0.15	Kawasaki disease;	chr14:106781820	chr14:106770577~106771020:-
BRCA	cis	rs6832769	1	rs28582059	ENSG00000223305.1	RN7SKP30	-4.75	2.3e-06	0.000217	-0.18	-0.15	Personality dimensions;	chr4:55542237	chr4:55540502~55540835:-
BRCA	cis	rs10129255	0.5	rs2027902	ENSG00000211959.2	IGHV4-39	4.75	2.3e-06	0.000217	0.1	0.15	Kawasaki disease;	chr14:106807157	chr14:106421711~106422218:-
BRCA	cis	rs1552244	1	rs61077902	ENSG00000232901.1	CYCSP10	4.75	2.3e-06	0.000217	0.2	0.15	Alzheimer's disease;	chr3:10084469	chr3:10000647~10000940:-
BRCA	cis	rs6847067	0.794	rs11732309	ENSG00000180769.7	WDFY3-AS2	-4.75	2.3e-06	0.000217	-0.14	-0.15	Oropharynx cancer;	chr4:85012150	chr4:84965682~85011277:+
BRCA	cis	rs11098499	0.738	rs72918577	ENSG00000260091.1	RP11-33B1.4	-4.75	2.3e-06	0.000217	-0.13	-0.15	Corneal astigmatism;	chr4:119405546	chr4:119409333~119410233:+
BRCA	cis	rs2011013	0.956	rs2277849	ENSG00000225151.9	GOLGA2P7	4.75	2.3e-06	0.000217	0.18	0.15	Sitting height ratio;	chr15:83970598	chr15:84199311~84230136:-
BRCA	cis	rs6490294	0.904	rs2339908	ENSG00000234608.6	MAPKAPK5-AS1	4.75	2.3e-06	0.000217	0.18	0.15	Mean platelet volume;	chr12:111980692	chr12:111839764~111842902:-
BRCA	cis	rs7727544	0.606	rs11950562	ENSG00000233006.5	AC034220.3	4.75	2.3e-06	0.000217	0.11	0.15	Blood metabolite levels;	chr5:132316836	chr5:132311285~132369916:-
BRCA	cis	rs12135996	0.592	rs2774279	ENSG00000232879.2	RP11-544M22.3	-4.75	2.31e-06	0.000217	-0.16	-0.15	Night sleep phenotypes;	chr1:161047766	chr1:161034834~161035006:+
BRCA	cis	rs8017423	0.647	rs12895269	ENSG00000275198.1	RP11-471B22.3	4.75	2.31e-06	0.000217	0.17	0.15	Mortality in heart failure;	chr14:90356086	chr14:90383365~90387973:+
BRCA	cis	rs8017423	0.647	rs12590712	ENSG00000275198.1	RP11-471B22.3	4.75	2.31e-06	0.000217	0.17	0.15	Mortality in heart failure;	chr14:90356137	chr14:90383365~90387973:+
BRCA	cis	rs8017423	0.569	rs10141476	ENSG00000275198.1	RP11-471B22.3	4.75	2.31e-06	0.000217	0.17	0.15	Mortality in heart failure;	chr14:90357007	chr14:90383365~90387973:+
BRCA	cis	rs8017423	0.647	rs1958345	ENSG00000275198.1	RP11-471B22.3	4.75	2.31e-06	0.000217	0.17	0.15	Mortality in heart failure;	chr14:90357426	chr14:90383365~90387973:+
BRCA	cis	rs8017423	0.647	rs1958346	ENSG00000275198.1	RP11-471B22.3	4.75	2.31e-06	0.000217	0.17	0.15	Mortality in heart failure;	chr14:90357667	chr14:90383365~90387973:+
BRCA	cis	rs17428076	0.874	rs72885529	ENSG00000228389.1	AC068039.4	-4.75	2.31e-06	0.000218	-0.21	-0.15	Myopia;	chr2:171827522	chr2:171773482~171775844:+
BRCA	cis	rs17428076	0.874	rs72885532	ENSG00000228389.1	AC068039.4	-4.75	2.31e-06	0.000218	-0.21	-0.15	Myopia;	chr2:171827523	chr2:171773482~171775844:+
BRCA	cis	rs875971	0.862	rs11763189	ENSG00000236529.1	RP13-254B10.1	4.75	2.31e-06	0.000218	0.16	0.15	Aortic root size;	chr7:66518542	chr7:65840212~65840596:+
BRCA	cis	rs2835345	0.563	rs12627161	ENSG00000279365.1	KB-176G8.1	4.75	2.31e-06	0.000218	0.19	0.15	Pulmonary function;	chr21:36449649	chr21:36485867~36487760:+
BRCA	cis	rs2835345	0.563	rs12627241	ENSG00000279365.1	KB-176G8.1	4.75	2.31e-06	0.000218	0.19	0.15	Pulmonary function;	chr21:36449689	chr21:36485867~36487760:+
BRCA	cis	rs2835345	0.563	rs12627173	ENSG00000279365.1	KB-176G8.1	4.75	2.31e-06	0.000218	0.19	0.15	Pulmonary function;	chr21:36449715	chr21:36485867~36487760:+
BRCA	cis	rs7833790	1	rs7833384	ENSG00000254689.1	RP11-354A14.1	4.75	2.31e-06	0.000218	0.2	0.15	Diastolic blood pressure;	chr8:81818680	chr8:81885377~81923193:+
BRCA	cis	rs2278170	1	rs2915038	ENSG00000225101.4	OR52K3P	-4.75	2.31e-06	0.000218	-0.2	-0.15	Amyotrophic lateral sclerosis;	chr11:4456509	chr11:4474813~4475755:+
BRCA	cis	rs8180040	0.966	rs11130128	ENSG00000271161.1	BOLA2P2	-4.75	2.31e-06	0.000218	-0.16	-0.15	Colorectal cancer;	chr3:47445142	chr3:47499841~47500407:+
BRCA	cis	rs739496	0.579	rs12321677	ENSG00000226469.1	ADAM1B	-4.75	2.31e-06	0.000218	-0.18	-0.15	Platelet count;	chr12:111901211	chr12:111927018~111929017:+
BRCA	cis	rs757081	0.658	rs214101	ENSG00000184669.7	OR7E14P	-4.75	2.31e-06	0.000218	-0.19	-0.15	Systolic blood pressure;	chr11:17267807	chr11:17013998~17053024:+
BRCA	cis	rs9308731	0.765	rs6738028	ENSG00000230499.1	AC108463.1	-4.75	2.31e-06	0.000218	-0.18	-0.15	Chronic lymphocytic leukemia;	chr2:111191750	chr2:111195963~111206494:+
BRCA	cis	rs9868809	0.505	rs11719291	ENSG00000270441.1	RP11-694I15.7	4.75	2.31e-06	0.000218	0.24	0.15	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48698273	chr3:49140086~49160851:-
BRCA	cis	rs7829975	0.56	rs17154599	ENSG00000253893.2	FAM85B	4.75	2.31e-06	0.000218	0.18	0.15	Mood instability;	chr8:8693908	chr8:8167819~8226614:-
BRCA	cis	rs739496	0.579	rs7980569	ENSG00000226469.1	ADAM1B	4.75	2.31e-06	0.000218	0.19	0.15	Platelet count;	chr12:111843580	chr12:111927018~111929017:+
BRCA	cis	rs739496	0.579	rs7970847	ENSG00000226469.1	ADAM1B	4.75	2.31e-06	0.000218	0.19	0.15	Platelet count;	chr12:111843689	chr12:111927018~111929017:+
BRCA	cis	rs5751614	0.557	rs928781	ENSG00000240160.3	RN7SL263P	-4.75	2.31e-06	0.000218	-0.19	-0.15	Height;	chr22:23257826	chr22:23261782~23262071:-
BRCA	cis	rs7267979	0.816	rs422148	ENSG00000274414.1	RP5-965G21.4	-4.75	2.32e-06	0.000218	-0.17	-0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25531968	chr20:25239007~25245229:-
BRCA	cis	rs2692947	0.832	rs62153679	ENSG00000168992.4	OR7E102P	4.75	2.32e-06	0.000218	0.2	0.15	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95892652	chr2:95546531~95547545:+
BRCA	cis	rs2073316	0.626	rs11687212	ENSG00000272716.1	RP11-563N4.1	4.75	2.32e-06	0.000218	0.16	0.15	Interleukin-18 levels;	chr2:31453454	chr2:32165046~32165757:-
BRCA	cis	rs57221529	0.766	rs58015612	ENSG00000225138.6	CTD-2228K2.7	4.75	2.32e-06	0.000218	0.22	0.15	Lung disease severity in cystic fibrosis;	chr5:580550	chr5:473236~480884:+
BRCA	cis	rs57221529	0.766	rs56216231	ENSG00000225138.6	CTD-2228K2.7	4.75	2.32e-06	0.000218	0.22	0.15	Lung disease severity in cystic fibrosis;	chr5:581078	chr5:473236~480884:+
BRCA	cis	rs7209700	0.889	rs11079769	ENSG00000228782.6	CTD-2026D20.3	-4.75	2.32e-06	0.000218	-0.17	-0.15	IgG glycosylation;	chr17:47272365	chr17:47450568~47492492:-
BRCA	cis	rs7267979	0.844	rs6115188	ENSG00000277938.1	RP5-965G21.3	4.75	2.32e-06	0.000218	0.17	0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25451534	chr20:25229150~25231933:+
BRCA	cis	rs7178909	0.872	rs17241560	ENSG00000259677.1	RP11-493E3.1	4.75	2.32e-06	0.000218	0.17	0.15	Common traits (Other);	chr15:89885970	chr15:89876540~89877285:+
BRCA	cis	rs8017423	0.647	rs4904680	ENSG00000275198.1	RP11-471B22.3	4.75	2.32e-06	0.000218	0.17	0.15	Mortality in heart failure;	chr14:90355731	chr14:90383365~90387973:+
BRCA	cis	rs4143844	1	rs12911422	ENSG00000259251.2	RP11-643M14.1	4.75	2.32e-06	0.000219	0.35	0.15	Bipolar disorder and schizophrenia;	chr15:62035935	chr15:62060503~62062434:+
BRCA	cis	rs6832769	0.961	rs11133379	ENSG00000272969.1	RP11-528I4.2	4.75	2.32e-06	0.000219	0.17	0.15	Personality dimensions;	chr4:55439944	chr4:55547112~55547889:+
BRCA	cis	rs8054556	1	rs4788197	ENSG00000214725.6	CDIPT-AS1	-4.75	2.32e-06	0.000219	-0.17	-0.15	Autism spectrum disorder or schizophrenia;	chr16:29959513	chr16:29863593~29868053:+
BRCA	cis	rs8054556	1	rs4788198	ENSG00000214725.6	CDIPT-AS1	-4.75	2.32e-06	0.000219	-0.17	-0.15	Autism spectrum disorder or schizophrenia;	chr16:29959514	chr16:29863593~29868053:+
BRCA	cis	rs3892630	0.878	rs66788054	ENSG00000267567.1	CTD-2538C1.3	4.75	2.32e-06	0.000219	0.23	0.15	Red blood cell traits;	chr19:32699240	chr19:32718298~32719595:-
BRCA	cis	rs60695258	0.895	rs236681	ENSG00000251411.1	RP11-397E7.4	-4.75	2.32e-06	0.000219	-0.16	-0.15	Hematocrit;	chr4:87067356	chr4:86913266~86914817:-
BRCA	cis	rs60695258	0.864	rs2280952	ENSG00000251411.1	RP11-397E7.4	-4.75	2.32e-06	0.000219	-0.16	-0.15	Hematocrit;	chr4:87067388	chr4:86913266~86914817:-
BRCA	cis	rs60695258	0.895	rs2280953	ENSG00000251411.1	RP11-397E7.4	-4.75	2.32e-06	0.000219	-0.16	-0.15	Hematocrit;	chr4:87067438	chr4:86913266~86914817:-
BRCA	cis	rs867186	1	rs80109502	ENSG00000126005.14	MMP24-AS1	-4.75	2.32e-06	0.000219	-0.28	-0.15	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:34999793	chr20:35216462~35278131:-
BRCA	cis	rs60695258	0.55	rs340636	ENSG00000251411.1	RP11-397E7.4	4.75	2.32e-06	0.000219	0.16	0.15	Hematocrit;	chr4:87009608	chr4:86913266~86914817:-
BRCA	cis	rs7116495	0.529	rs575871	ENSG00000248671.6	ALG1L9P	-4.75	2.32e-06	0.000219	-0.31	-0.15	Severe influenza A (H1N1) infection;	chr11:72067776	chr11:71794363~71818238:-
BRCA	cis	rs11098499	0.532	rs4833624	ENSG00000249244.1	RP11-548H18.2	4.75	2.32e-06	0.000219	0.17	0.15	Corneal astigmatism;	chr4:119664342	chr4:119391831~119395335:-
BRCA	cis	rs6747488	0.551	rs806584	ENSG00000272716.1	RP11-563N4.1	4.75	2.32e-06	0.000219	0.16	0.15	Interleukin-18 levels;	chr2:31687095	chr2:32165046~32165757:-
BRCA	cis	rs11239930	0.538	rs719969	ENSG00000278811.3	LINC00624	4.75	2.32e-06	0.000219	0.17	0.15	AIDS progression;	chr1:147084111	chr1:147258885~147517875:-
BRCA	cis	rs12681366	0.762	rs6997115	ENSG00000253704.1	RP11-267M23.4	4.75	2.33e-06	0.000219	0.15	0.15	Nonsyndromic cleft lip with cleft palate;	chr8:94353657	chr8:94553722~94569745:+
BRCA	cis	rs4699052	0.662	rs6848593	ENSG00000248740.4	RP11-328K4.1	4.75	2.33e-06	0.000219	0.16	0.15	Testicular germ cell tumor;	chr4:103328956	chr4:103256159~103453658:+
BRCA	cis	rs6847067	0.683	rs72664957	ENSG00000180769.7	WDFY3-AS2	4.75	2.33e-06	0.000219	0.14	0.15	Oropharynx cancer;	chr4:84927520	chr4:84965682~85011277:+
BRCA	cis	rs3892630	0.818	rs80137870	ENSG00000267567.1	CTD-2538C1.3	4.75	2.33e-06	0.000219	0.23	0.15	Red blood cell traits;	chr19:32691844	chr19:32718298~32719595:-
BRCA	cis	rs854765	0.547	rs4584886	ENSG00000281749.1	Y_RNA	4.75	2.33e-06	0.000219	0.17	0.15	Total body bone mineral density;	chr17:17992891	chr17:18001101~18001195:-
BRCA	cis	rs115344852	0.575	rs1015811	ENSG00000216901.1	AL022393.7	4.75	2.33e-06	0.000219	0.19	0.15	Epithelial ovarian cancer;	chr6:28480309	chr6:28176188~28176674:+
BRCA	cis	rs559928	0.606	rs1011219	ENSG00000236935.1	AP003774.1	-4.75	2.33e-06	0.000219	-0.18	-0.15	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64205924	chr11:64325050~64329504:-
BRCA	cis	rs2278170	1	rs1292642	ENSG00000225101.4	OR52K3P	-4.75	2.33e-06	0.000219	-0.2	-0.15	Amyotrophic lateral sclerosis;	chr11:4455037	chr11:4474813~4475755:+
BRCA	cis	rs1122401	0.515	rs2564985	ENSG00000280159.1	CTD-2591A1.1	4.75	2.33e-06	0.000219	0.23	0.15	Smoking initiation;	chr5:54568467	chr5:54643557~54645987:+
BRCA	cis	rs2268667	0.511	rs1874807	ENSG00000223653.4	RP11-131L23.1	-4.75	2.33e-06	0.000219	-0.16	-0.15	Asymmetrical dimethylarginine levels;	chr1:85313710	chr1:85276715~85448124:+
BRCA	cis	rs7819412	0.561	rs2001328	ENSG00000255046.1	RP11-297N6.4	4.75	2.33e-06	0.00022	0.17	0.15	Triglycerides;	chr8:11129689	chr8:11797928~11802568:-
BRCA	cis	rs8042543	0.707	rs4779526	ENSG00000270055.1	CTD-3092A11.2	-4.75	2.33e-06	0.00022	-0.18	-0.15	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);	chr15:31413480	chr15:30487963~30490313:+
BRCA	cis	rs13325613	0.748	rs7649905	ENSG00000223552.1	RP11-24F11.2	-4.75	2.33e-06	0.00022	-0.27	-0.15	Monocyte count;	chr3:46274514	chr3:46364955~46407059:-
BRCA	cis	rs4489787	1	rs12231229	ENSG00000240399.1	RP1-228P16.1	-4.75	2.33e-06	0.00022	-0.24	-0.15	Prostate cancer (SNP x SNP interaction);	chr12:48416125	chr12:48054813~48055591:-
BRCA	cis	rs10129255	0.957	rs10141052	ENSG00000280411.1	IGHV1-69-2	-4.75	2.33e-06	0.00022	-0.1	-0.15	Kawasaki disease;	chr14:106776528	chr14:106762092~106762588:-
BRCA	cis	rs4072705	0.646	rs915034	ENSG00000224020.1	MIR181A2HG	-4.75	2.33e-06	0.00022	-0.17	-0.15	Menarche (age at onset);	chr9:124482676	chr9:124658467~124698631:+
BRCA	cis	rs7267979	0.873	rs6037062	ENSG00000274973.1	RP13-401N8.7	-4.75	2.33e-06	0.00022	-0.17	-0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25222256	chr20:25845497~25845862:+
BRCA	cis	rs12893668	0.572	rs4900590	ENSG00000269958.1	RP11-73M18.8	4.75	2.33e-06	0.00022	0.17	0.15	Reticulocyte count;	chr14:103680084	chr14:103696353~103697163:+
BRCA	cis	rs7302981	0.9	rs836180	ENSG00000272368.2	RP4-605O3.4	4.75	2.33e-06	0.00022	0.16	0.15	Systolic blood pressure;	chr12:50109486	chr12:50112197~50165618:+
BRCA	cis	rs6696239	0.513	rs2492634	ENSG00000227711.2	RP11-275O4.5	4.75	2.33e-06	0.00022	0.16	0.15	Height;	chr1:227517157	chr1:227509028~227520477:-
BRCA	cis	rs9921338	0.561	rs11859280	ENSG00000262703.1	RP11-485G7.6	-4.75	2.33e-06	0.00022	-0.23	-0.15	Vein graft stenosis in coronary artery bypass grafting;	chr16:11376515	chr16:11348143~11349321:-
BRCA	cis	rs9925964	0.933	rs9929899	ENSG00000260911.2	RP11-196G11.2	-4.75	2.33e-06	0.00022	-0.14	-0.15	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31051380	chr16:31043150~31049868:+
BRCA	cis	rs2803122	0.934	rs10119618	ENSG00000273226.1	RP11-513M16.8	-4.75	2.34e-06	0.00022	-0.16	-0.15	Pulse pressure;	chr9:19251643	chr9:19375451~19375996:+
BRCA	cis	rs5742933	1	rs4666783	ENSG00000253559.1	OSGEPL1-AS1	-4.75	2.34e-06	0.00022	-0.2	-0.15	Ferritin levels;	chr2:189748254	chr2:189762704~189765556:+
BRCA	cis	rs3764021	0.743	rs7973535	ENSG00000256673.1	RP11-599J14.2	-4.75	2.34e-06	0.00022	-0.16	-0.15	Type 1 diabetes;	chr12:9727801	chr12:9398355~9414851:-
BRCA	cis	rs3764021	0.87	rs7973638	ENSG00000256673.1	RP11-599J14.2	-4.75	2.34e-06	0.00022	-0.16	-0.15	Type 1 diabetes;	chr12:9727845	chr12:9398355~9414851:-
BRCA	cis	rs9425766	0.64	rs2295366	ENSG00000200674.1	RN7SKP160	4.75	2.34e-06	0.00022	0.21	0.15	Life satisfaction;	chr1:173856554	chr1:173791548~173791887:+
BRCA	cis	rs6714710	0.603	rs11680321	ENSG00000230606.9	AC159540.1	-4.75	2.34e-06	0.00022	-0.17	-0.15	Posterior cortical atrophy and Alzheimer's disease;	chr2:97762804	chr2:97416165~97433527:-
BRCA	cis	rs6714710	0.58	rs6711101	ENSG00000230606.9	AC159540.1	-4.75	2.34e-06	0.00022	-0.17	-0.15	Posterior cortical atrophy and Alzheimer's disease;	chr2:97763350	chr2:97416165~97433527:-
BRCA	cis	rs3764021	0.87	rs7956831	ENSG00000278635.1	CTD-2318O12.1	4.75	2.34e-06	0.00022	0.14	0.15	Type 1 diabetes;	chr12:9736561	chr12:9415641~9416718:+
BRCA	cis	rs4578769	0.842	rs7243256	ENSG00000265939.1	UBE2CP2	4.75	2.34e-06	0.00022	0.17	0.15	Eosinophil percentage of white cells;	chr18:22936411	chr18:22900486~22900995:-
BRCA	cis	rs4578769	0.842	rs9966323	ENSG00000265939.1	UBE2CP2	4.75	2.34e-06	0.00022	0.17	0.15	Eosinophil percentage of white cells;	chr18:22936418	chr18:22900486~22900995:-
BRCA	cis	rs875971	0.571	rs160641	ENSG00000232546.1	RP11-458F8.1	-4.75	2.34e-06	0.000221	-0.14	-0.15	Aortic root size;	chr7:66112359	chr7:66848496~66858136:+
BRCA	cis	rs6832769	1	rs6819660	ENSG00000272969.1	RP11-528I4.2	4.75	2.34e-06	0.000221	0.17	0.15	Personality dimensions;	chr4:55508410	chr4:55547112~55547889:+
BRCA	cis	rs9921338	0.961	rs56010295	ENSG00000262703.1	RP11-485G7.6	-4.75	2.34e-06	0.000221	-0.18	-0.15	Vein graft stenosis in coronary artery bypass grafting;	chr16:11285050	chr16:11348143~11349321:-
BRCA	cis	rs1218582	0.741	rs7544528	ENSG00000270361.1	RP11-307C12.13	-4.75	2.34e-06	0.000221	-0.17	-0.15	Prostate cancer;	chr1:154872109	chr1:154937370~154938059:+
BRCA	cis	rs12030196	0.871	rs12042725	ENSG00000230812.4	LINC01358	4.75	2.34e-06	0.000221	0.16	0.15	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr1:59004057	chr1:59020387~59044614:+
BRCA	cis	rs7208859	0.623	rs122898	ENSG00000266490.1	CTD-2349P21.9	-4.75	2.34e-06	0.000221	-0.22	-0.15	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30578236	chr17:30792372~30792833:+
BRCA	cis	rs736408	0.546	rs3733046	ENSG00000243224.1	RP5-1157M23.2	-4.75	2.34e-06	0.000221	-0.15	-0.15	Bipolar disorder;	chr3:52587611	chr3:52239258~52241097:+
BRCA	cis	rs7474896	0.583	rs11011341	ENSG00000120555.12	SEPT7P9	4.75	2.35e-06	0.000221	0.21	0.15	Obesity (extreme);	chr10:37709572	chr10:38383069~38402916:-
BRCA	cis	rs867186	1	rs76191812	ENSG00000126005.14	MMP24-AS1	-4.75	2.35e-06	0.000221	-0.27	-0.15	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:34976108	chr20:35216462~35278131:-
BRCA	cis	rs2638953	0.671	rs11049357	ENSG00000278733.1	RP11-425D17.1	-4.75	2.35e-06	0.000221	-0.21	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28119856	chr12:28185625~28186190:-
BRCA	cis	rs11051970	0.527	rs7977938	ENSG00000274964.1	RP11-817I4.1	-4.75	2.35e-06	0.000221	-0.19	-0.15	Response to tocilizumab in rheumatoid arthritis;	chr12:32322406	chr12:32339368~32340724:+
BRCA	cis	rs17428076	0.874	rs17581347	ENSG00000228389.1	AC068039.4	-4.75	2.35e-06	0.000221	-0.21	-0.15	Myopia;	chr2:171826091	chr2:171773482~171775844:+
BRCA	cis	rs17428076	0.874	rs17581361	ENSG00000228389.1	AC068039.4	-4.75	2.35e-06	0.000221	-0.21	-0.15	Myopia;	chr2:171826102	chr2:171773482~171775844:+
BRCA	cis	rs17428076	0.874	rs62182372	ENSG00000228389.1	AC068039.4	-4.75	2.35e-06	0.000221	-0.21	-0.15	Myopia;	chr2:171827977	chr2:171773482~171775844:+
BRCA	cis	rs17428076	0.874	rs62182373	ENSG00000228389.1	AC068039.4	-4.75	2.35e-06	0.000221	-0.21	-0.15	Myopia;	chr2:171829045	chr2:171773482~171775844:+
BRCA	cis	rs793571	0.784	rs8029301	ENSG00000259250.1	RP11-50C13.1	-4.75	2.35e-06	0.000221	-0.23	-0.15	Schizophrenia;	chr15:58829637	chr15:58587507~58591676:+
BRCA	cis	rs11239930	0.517	rs4950354	ENSG00000230832.3	RP11-325P15.2	-4.75	2.35e-06	0.000221	-0.21	-0.15	AIDS progression;	chr1:147082674	chr1:147082338~147083578:-
BRCA	cis	rs11239930	0.538	rs4950355	ENSG00000230832.3	RP11-325P15.2	-4.75	2.35e-06	0.000221	-0.21	-0.15	AIDS progression;	chr1:147082700	chr1:147082338~147083578:-
BRCA	cis	rs6714710	0.603	rs34974566	ENSG00000230606.9	AC159540.1	-4.75	2.35e-06	0.000221	-0.17	-0.15	Posterior cortical atrophy and Alzheimer's disease;	chr2:97935836	chr2:97416165~97433527:-
BRCA	cis	rs57221529	0.766	rs56350081	ENSG00000271781.1	CTD-2589H19.6	-4.75	2.35e-06	0.000221	-0.22	-0.15	Lung disease severity in cystic fibrosis;	chr5:583083	chr5:675826~676616:+
BRCA	cis	rs2277027	0.956	rs12522418	ENSG00000248544.2	CTB-47B11.3	4.75	2.35e-06	0.000221	0.18	0.15	Pulmonary function;Pulmonary function (smoking interaction);	chr5:157499769	chr5:157375741~157384950:-
BRCA	cis	rs703842	1	rs11172349	ENSG00000270039.1	RP11-571M6.17	-4.75	2.35e-06	0.000221	-0.21	-0.15	Multiple sclerosis;	chr12:57818745	chr12:57803838~57804415:+
BRCA	cis	rs2692947	0.683	rs2315416	ENSG00000168992.4	OR7E102P	4.75	2.35e-06	0.000222	0.2	0.15	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95892729	chr2:95546531~95547545:+
BRCA	cis	rs7618915	0.57	rs11130319	ENSG00000243224.1	RP5-1157M23.2	-4.75	2.35e-06	0.000222	-0.16	-0.15	Bipolar disorder;	chr3:52721576	chr3:52239258~52241097:+
BRCA	cis	rs3892630	0.878	rs8108621	ENSG00000267475.1	CTD-2538C1.2	-4.75	2.35e-06	0.000222	-0.22	-0.15	Red blood cell traits;	chr19:32692385	chr19:32687089~32691750:-
BRCA	cis	rs7487075	0.619	rs4768723	ENSG00000274723.1	RP11-618L22.1	4.75	2.35e-06	0.000222	0.19	0.15	Itch intensity from mosquito bite;	chr12:46451941	chr12:46970504~46972155:+
BRCA	cis	rs11096990	0.613	rs7690414	ENSG00000249685.1	RP11-360F5.3	4.75	2.36e-06	0.000222	0.18	0.15	Cognitive function;	chr4:39210669	chr4:39133913~39135608:+
BRCA	cis	rs35740288	0.822	rs17574774	ENSG00000202081.1	RNU6-1280P	-4.75	2.36e-06	0.000222	-0.2	-0.15	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85690139	chr15:85651522~85651628:-
BRCA	cis	rs7618915	0.501	rs3733045	ENSG00000243224.1	RP5-1157M23.2	-4.75	2.36e-06	0.000222	-0.16	-0.15	Bipolar disorder;	chr3:52609291	chr3:52239258~52241097:+
BRCA	cis	rs2562456	0.833	rs552800	ENSG00000213976.4	CTD-2561J22.2	4.75	2.36e-06	0.000222	0.17	0.15	Pain;	chr19:21301840	chr19:21382865~21387177:+
BRCA	cis	rs2115630	1	rs11854313	ENSG00000259295.5	CSPG4P12	-4.75	2.36e-06	0.000222	-0.17	-0.15	P wave terminal force;	chr15:84760817	chr15:85191438~85213905:+
BRCA	cis	rs6847067	0.683	rs35190829	ENSG00000180769.7	WDFY3-AS2	4.75	2.36e-06	0.000222	0.15	0.15	Oropharynx cancer;	chr4:84881176	chr4:84965682~85011277:+
BRCA	cis	rs1043099	0.912	rs929454	ENSG00000279699.1	RP1-102K2.9	4.75	2.36e-06	0.000222	0.22	0.15	Rheumatoid arthritis;	chr22:30296364	chr22:30275215~30276951:-
BRCA	cis	rs4831837	0.616	rs4831834	ENSG00000270074.1	RP11-351I21.11	4.75	2.36e-06	0.000222	0.18	0.15	Morbidity-free survival;	chr8:12829989	chr8:12412827~12414373:+
BRCA	cis	rs3892630	0.757	rs8109823	ENSG00000267567.1	CTD-2538C1.3	4.75	2.36e-06	0.000222	0.23	0.15	Red blood cell traits;	chr19:32692410	chr19:32718298~32719595:-
BRCA	cis	rs4865762	1	rs4865763	ENSG00000247796.2	CTD-2366F13.1	4.75	2.36e-06	0.000222	0.15	0.15	Intraocular pressure;	chr5:53300560	chr5:53109842~53115126:+
BRCA	cis	rs56322409	0.596	rs112093476	ENSG00000226688.5	ENTPD1-AS1	4.75	2.36e-06	0.000222	0.16	0.15	Blood metabolite levels;	chr10:95665285	chr10:95753206~96090238:-
BRCA	cis	rs11098499	0.738	rs34965784	ENSG00000260091.1	RP11-33B1.4	-4.75	2.36e-06	0.000222	-0.13	-0.15	Corneal astigmatism;	chr4:119440431	chr4:119409333~119410233:+
BRCA	cis	rs651907	0.557	rs7651406	ENSG00000256628.3	ZBTB11-AS1	4.75	2.36e-06	0.000222	0.18	0.15	Colorectal cancer;	chr3:101674452	chr3:101676475~101679217:+
BRCA	cis	rs7267979	1	rs2482940	ENSG00000125804.12	FAM182A	4.75	2.36e-06	0.000222	0.19	0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25369194	chr20:26054655~26086917:+
BRCA	cis	rs11673344	0.504	rs7252940	ENSG00000226686.6	LINC01535	4.75	2.36e-06	0.000222	0.18	0.15	Obesity-related traits;	chr19:37138589	chr19:37251912~37265535:+
BRCA	cis	rs559555	0.812	rs2300701	ENSG00000272716.1	RP11-563N4.1	-4.75	2.36e-06	0.000222	-0.16	-0.15	Blood metabolite ratios;Blood metabolite levels;	chr2:31561938	chr2:32165046~32165757:-
BRCA	cis	rs7811142	1	rs11771241	ENSG00000078319.8	PMS2P1	-4.75	2.36e-06	0.000222	-0.23	-0.15	Platelet count;	chr7:100397162	chr7:100320992~100341908:-
BRCA	cis	rs11673344	0.504	rs4805202	ENSG00000226686.6	LINC01535	4.75	2.37e-06	0.000223	0.18	0.15	Obesity-related traits;	chr19:37136499	chr19:37251912~37265535:+
BRCA	cis	rs8042543	0.593	rs7165900	ENSG00000270055.1	CTD-3092A11.2	-4.75	2.37e-06	0.000223	-0.19	-0.15	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);	chr15:31419999	chr15:30487963~30490313:+
BRCA	cis	rs8042543	0.707	rs9744263	ENSG00000270055.1	CTD-3092A11.2	-4.75	2.37e-06	0.000223	-0.19	-0.15	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);	chr15:31423200	chr15:30487963~30490313:+
BRCA	cis	rs6088580	0.57	rs6058057	ENSG00000276073.1	RP5-1125A11.7	-4.75	2.37e-06	0.000223	-0.16	-0.15	Glomerular filtration rate (creatinine);	chr20:34477478	chr20:33985617~33988989:-
BRCA	cis	rs11673344	0.504	rs4805203	ENSG00000226686.6	LINC01535	4.75	2.37e-06	0.000223	0.18	0.15	Obesity-related traits;	chr19:37136586	chr19:37251912~37265535:+
BRCA	cis	rs1345301	0.518	rs17689452	ENSG00000234389.1	AC007278.3	-4.75	2.37e-06	0.000223	-0.13	-0.15	Waist circumference;	chr2:102248221	chr2:102438713~102440475:+
BRCA	cis	rs56322409	0.833	rs2861153	ENSG00000226688.5	ENTPD1-AS1	4.75	2.37e-06	0.000223	0.17	0.15	Blood metabolite levels;	chr10:95863499	chr10:95753206~96090238:-
BRCA	cis	rs2303319	0.504	rs62187653	ENSG00000227403.1	AC009299.3	4.75	2.37e-06	0.000223	0.35	0.15	Cognitive function;	chr2:161612618	chr2:161244739~161249050:+
BRCA	cis	rs2303319	0.504	rs72873603	ENSG00000227403.1	AC009299.3	4.75	2.37e-06	0.000223	0.35	0.15	Cognitive function;	chr2:161613155	chr2:161244739~161249050:+
BRCA	cis	rs10129255	0.5	rs9324092	ENSG00000232216.1	IGHV3-43	-4.75	2.37e-06	0.000223	-0.11	-0.15	Kawasaki disease;	chr14:106683806	chr14:106470264~106470800:-
BRCA	cis	rs11098499	0.73	rs78971550	ENSG00000249244.1	RP11-548H18.2	4.75	2.37e-06	0.000223	0.17	0.15	Corneal astigmatism;	chr4:119359886	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.645	rs78422072	ENSG00000249244.1	RP11-548H18.2	4.75	2.37e-06	0.000223	0.17	0.15	Corneal astigmatism;	chr4:119359887	chr4:119391831~119395335:-
BRCA	cis	rs7916697	0.593	rs3740587	ENSG00000233590.1	RP11-153K11.3	4.75	2.37e-06	0.000223	0.18	0.15	Optic disc area;	chr10:68261045	chr10:68233251~68242379:-
BRCA	cis	rs17684571	0.7	rs34171958	ENSG00000231441.1	RP11-472M19.2	4.75	2.37e-06	0.000223	0.23	0.15	Schizophrenia;	chr6:56800000	chr6:56844002~56864078:+
BRCA	cis	rs6439153	0.933	rs1871951	ENSG00000231305.3	RP11-723O4.2	4.75	2.37e-06	0.000223	0.17	0.15	Pneumococcal bacteremia;	chr3:129001644	chr3:128861313~128871540:-
BRCA	cis	rs7618915	0.57	rs11714088	ENSG00000243224.1	RP5-1157M23.2	-4.75	2.37e-06	0.000223	-0.16	-0.15	Bipolar disorder;	chr3:52724926	chr3:52239258~52241097:+
BRCA	cis	rs1707322	0.821	rs10749857	ENSG00000234329.1	RP11-767N6.2	4.74	2.38e-06	0.000224	0.15	0.15	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45782471	chr1:45651039~45651826:-
BRCA	cis	rs6545883	0.929	rs1186707	ENSG00000270820.4	RP11-355B11.2	4.74	2.38e-06	0.000224	0.17	0.15	Tuberculosis;	chr2:61446385	chr2:61471188~61484130:+
BRCA	cis	rs7811142	0.83	rs7792525	ENSG00000078319.8	PMS2P1	-4.74	2.38e-06	0.000224	-0.24	-0.15	Platelet count;	chr7:100374499	chr7:100320992~100341908:-
BRCA	cis	rs13113518	1	rs13146987	ENSG00000249700.7	SRD5A3-AS1	4.74	2.38e-06	0.000224	0.18	0.15	Height;	chr4:55491628	chr4:55363971~55395847:-
BRCA	cis	rs13113518	1	rs7677085	ENSG00000249700.7	SRD5A3-AS1	4.74	2.38e-06	0.000224	0.18	0.15	Height;	chr4:55495801	chr4:55363971~55395847:-
BRCA	cis	rs13113518	0.966	rs12510681	ENSG00000249700.7	SRD5A3-AS1	4.74	2.38e-06	0.000224	0.18	0.15	Height;	chr4:55496737	chr4:55363971~55395847:-
BRCA	cis	rs13113518	1	rs12500162	ENSG00000249700.7	SRD5A3-AS1	4.74	2.38e-06	0.000224	0.18	0.15	Height;	chr4:55496933	chr4:55363971~55395847:-
BRCA	cis	rs13113518	1	rs7686261	ENSG00000249700.7	SRD5A3-AS1	4.74	2.38e-06	0.000224	0.18	0.15	Height;	chr4:55500224	chr4:55363971~55395847:-
BRCA	cis	rs13113518	1	rs11729220	ENSG00000249700.7	SRD5A3-AS1	4.74	2.38e-06	0.000224	0.18	0.15	Height;	chr4:55501629	chr4:55363971~55395847:-
BRCA	cis	rs13113518	1	rs11133390	ENSG00000249700.7	SRD5A3-AS1	4.74	2.38e-06	0.000224	0.18	0.15	Height;	chr4:55501726	chr4:55363971~55395847:-
BRCA	cis	rs13113518	1	rs11133391	ENSG00000249700.7	SRD5A3-AS1	4.74	2.38e-06	0.000224	0.18	0.15	Height;	chr4:55501788	chr4:55363971~55395847:-
BRCA	cis	rs13113518	0.966	rs13133484	ENSG00000249700.7	SRD5A3-AS1	4.74	2.38e-06	0.000224	0.18	0.15	Height;	chr4:55504176	chr4:55363971~55395847:-
BRCA	cis	rs13113518	0.934	rs13127906	ENSG00000249700.7	SRD5A3-AS1	4.74	2.38e-06	0.000224	0.18	0.15	Height;	chr4:55504201	chr4:55363971~55395847:-
BRCA	cis	rs10829156	0.786	rs7077786	ENSG00000240291.1	RP11-499P20.2	4.74	2.38e-06	0.000224	0.17	0.15	Sudden cardiac arrest;	chr10:18603453	chr10:18513115~18545651:-
BRCA	cis	rs7647973	0.516	rs4955418	ENSG00000225399.4	RP11-3B7.1	4.74	2.38e-06	0.000224	0.14	0.15	Menarche (age at onset);	chr3:49163194	chr3:49260085~49261316:+
BRCA	cis	rs6088813	1	rs4911496	ENSG00000126005.14	MMP24-AS1	-4.74	2.38e-06	0.000224	-0.17	-0.15	Height;	chr20:35384250	chr20:35216462~35278131:-
BRCA	cis	rs6088580	0.561	rs3761147	ENSG00000276073.1	RP5-1125A11.7	4.74	2.38e-06	0.000224	0.16	0.15	Glomerular filtration rate (creatinine);	chr20:34408883	chr20:33985617~33988989:-
BRCA	cis	rs6088580	0.634	rs6087587	ENSG00000276073.1	RP5-1125A11.7	-4.74	2.38e-06	0.000224	-0.16	-0.15	Glomerular filtration rate (creatinine);	chr20:34470823	chr20:33985617~33988989:-
BRCA	cis	rs983392	0.599	rs7232	ENSG00000275344.1	MIR6503	-4.74	2.38e-06	0.000224	-0.15	-0.15	Alzheimer's disease (late onset);	chr11:60173126	chr11:60209071~60209156:-
BRCA	cis	rs7772486	0.764	rs2265468	ENSG00000270638.1	RP3-466P17.1	4.74	2.38e-06	0.000224	0.17	0.15	Lobe attachment (rater-scored or self-reported);	chr6:145897210	chr6:145735570~145737218:+
BRCA	cis	rs2638953	0.853	rs17433981	ENSG00000247934.4	RP11-967K21.1	-4.74	2.39e-06	0.000224	-0.2	-0.15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28393634	chr12:28163298~28190738:-
BRCA	cis	rs7577696	0.962	rs2365555	ENSG00000272716.1	RP11-563N4.1	4.74	2.39e-06	0.000224	0.16	0.15	Inflammatory biomarkers;	chr2:32055630	chr2:32165046~32165757:-
BRCA	cis	rs6750795	0.746	rs2916579	ENSG00000223198.1	RNU2-22P	-4.74	2.39e-06	0.000224	-0.18	-0.15	Height;	chr2:231556448	chr2:231501990~231502201:-
BRCA	cis	rs6095360	1	rs1048590	ENSG00000222365.1	SNORD12B	-4.74	2.39e-06	0.000224	-0.16	-0.15	Intelligence (multi-trait analysis);	chr20:48993760	chr20:49280319~49280409:+
BRCA	cis	rs11239930	0.538	rs630630	ENSG00000230832.3	RP11-325P15.2	-4.74	2.39e-06	0.000225	-0.21	-0.15	AIDS progression;	chr1:147080377	chr1:147082338~147083578:-
BRCA	cis	rs11239930	0.538	rs618575	ENSG00000230832.3	RP11-325P15.2	-4.74	2.39e-06	0.000225	-0.21	-0.15	AIDS progression;	chr1:147080759	chr1:147082338~147083578:-
BRCA	cis	rs7141336	0.77	rs10135763	ENSG00000258884.1	CTD-3035D6.2	4.74	2.39e-06	0.000225	0.19	0.15	Anxiety disorder;	chr14:90827295	chr14:90822365~90828128:-
BRCA	cis	rs11098499	0.954	rs10006525	ENSG00000250412.1	KLHL2P1	4.74	2.39e-06	0.000225	0.17	0.15	Corneal astigmatism;	chr4:119487776	chr4:119334329~119378233:+
BRCA	cis	rs7487075	0.619	rs7968897	ENSG00000274723.1	RP11-618L22.1	4.74	2.39e-06	0.000225	0.19	0.15	Itch intensity from mosquito bite;	chr12:46420041	chr12:46970504~46972155:+
BRCA	cis	rs7487075	0.619	rs6582646	ENSG00000274723.1	RP11-618L22.1	4.74	2.39e-06	0.000225	0.19	0.15	Itch intensity from mosquito bite;	chr12:46420074	chr12:46970504~46972155:+
BRCA	cis	rs4415084	1	rs13156930	ENSG00000251141.4	RP11-53O19.1	4.74	2.39e-06	0.000225	0.13	0.15	Breast cancer;	chr5:44697933	chr5:44744900~44808777:-
BRCA	cis	rs9659323	0.632	rs6658479	ENSG00000231365.4	RP11-418J17.1	-4.74	2.39e-06	0.000225	-0.17	-0.15	Body mass index;	chr1:119085233	chr1:119140396~119275973:+
BRCA	cis	rs66823261	0.778	rs2906332	ENSG00000223508.5	RPL23AP53	4.74	2.4e-06	0.000225	0.21	0.15	Breast cancer (estrogen-receptor negative);Breast cancer;	chr8:244943	chr8:213186~232231:-
BRCA	cis	rs6570726	0.818	rs412350	ENSG00000270638.1	RP3-466P17.1	4.74	2.4e-06	0.000225	0.17	0.15	Lobe attachment (rater-scored or self-reported);	chr6:145531273	chr6:145735570~145737218:+
BRCA	cis	rs13113518	0.934	rs3805155	ENSG00000249700.7	SRD5A3-AS1	4.74	2.4e-06	0.000225	0.18	0.15	Height;	chr4:55497842	chr4:55363971~55395847:-
BRCA	cis	rs2179367	0.632	rs997682	ENSG00000268592.3	RAET1E-AS1	-4.74	2.4e-06	0.000225	-0.21	-0.15	Dupuytren's disease;	chr6:149345484	chr6:149863494~149919507:+
BRCA	cis	rs801193	0.613	rs2016325	ENSG00000232546.1	RP11-458F8.1	4.74	2.4e-06	0.000225	0.12	0.15	Aortic root size;	chr7:66858513	chr7:66848496~66858136:+
BRCA	cis	rs6686842	0.965	rs2802551	ENSG00000235358.1	RP11-399E6.1	4.74	2.4e-06	0.000226	0.18	0.15	Height;	chr1:41031771	chr1:41242373~41284861:+
BRCA	cis	rs16958440	0.867	rs12386076	ENSG00000280212.1	RP11-49K24.3	4.74	2.4e-06	0.000226	0.33	0.15	Sitting height ratio;	chr18:47146969	chr18:47076117~47076594:+
BRCA	cis	rs2562456	0.876	rs62110202	ENSG00000268535.1	RP11-420K14.3	4.74	2.4e-06	0.000226	0.19	0.15	Pain;	chr19:21571799	chr19:21709522~21710191:+
BRCA	cis	rs7592578	0.771	rs4258824	ENSG00000272979.1	RP11-647K16.1	-4.74	2.4e-06	0.000226	-0.24	-0.15	Diastolic blood pressure;	chr2:190530301	chr2:190454092~190454521:-
BRCA	cis	rs1499614	1	rs2659913	ENSG00000222364.1	RNU6-96P	-4.74	2.4e-06	0.000226	-0.27	-0.15	Gout;	chr7:66692349	chr7:66395191~66395286:+
BRCA	cis	rs1499614	1	rs2659911	ENSG00000222364.1	RNU6-96P	-4.74	2.4e-06	0.000226	-0.27	-0.15	Gout;	chr7:66693433	chr7:66395191~66395286:+
BRCA	cis	rs1499614	1	rs2707838	ENSG00000222364.1	RNU6-96P	-4.74	2.4e-06	0.000226	-0.27	-0.15	Gout;	chr7:66694214	chr7:66395191~66395286:+
BRCA	cis	rs1499614	1	rs60326618	ENSG00000222364.1	RNU6-96P	-4.74	2.4e-06	0.000226	-0.27	-0.15	Gout;	chr7:66701371	chr7:66395191~66395286:+
BRCA	cis	rs1499614	1	rs2707830	ENSG00000222364.1	RNU6-96P	-4.74	2.4e-06	0.000226	-0.27	-0.15	Gout;	chr7:66702658	chr7:66395191~66395286:+
BRCA	cis	rs1499614	1	rs2707828	ENSG00000222364.1	RNU6-96P	-4.74	2.4e-06	0.000226	-0.27	-0.15	Gout;	chr7:66706390	chr7:66395191~66395286:+
BRCA	cis	rs1499614	0.803	rs1922723	ENSG00000222364.1	RNU6-96P	-4.74	2.4e-06	0.000226	-0.27	-0.15	Gout;	chr7:66710076	chr7:66395191~66395286:+
BRCA	cis	rs6088813	0.885	rs224331	ENSG00000126005.14	MMP24-AS1	-4.74	2.4e-06	0.000226	-0.18	-0.15	Height;	chr20:35434589	chr20:35216462~35278131:-
BRCA	cis	rs16958440	1	rs60422392	ENSG00000280212.1	RP11-49K24.3	4.74	2.4e-06	0.000226	0.3	0.15	Sitting height ratio;	chr18:47095102	chr18:47076117~47076594:+
BRCA	cis	rs16958440	1	rs2289130	ENSG00000280212.1	RP11-49K24.3	4.74	2.4e-06	0.000226	0.3	0.15	Sitting height ratio;	chr18:47100259	chr18:47076117~47076594:+
BRCA	cis	rs16958440	1	rs62096463	ENSG00000280212.1	RP11-49K24.3	4.74	2.4e-06	0.000226	0.3	0.15	Sitting height ratio;	chr18:47102557	chr18:47076117~47076594:+
BRCA	cis	rs16958440	1	rs62096464	ENSG00000280212.1	RP11-49K24.3	4.74	2.4e-06	0.000226	0.3	0.15	Sitting height ratio;	chr18:47102836	chr18:47076117~47076594:+
BRCA	cis	rs16958440	1	rs16958432	ENSG00000280212.1	RP11-49K24.3	4.74	2.4e-06	0.000226	0.3	0.15	Sitting height ratio;	chr18:47105402	chr18:47076117~47076594:+
BRCA	cis	rs16958440	1	rs16958440	ENSG00000280212.1	RP11-49K24.3	4.74	2.4e-06	0.000226	0.3	0.15	Sitting height ratio;	chr18:47106513	chr18:47076117~47076594:+
BRCA	cis	rs16958440	1	rs75800624	ENSG00000280212.1	RP11-49K24.3	4.74	2.4e-06	0.000226	0.3	0.15	Sitting height ratio;	chr18:47107234	chr18:47076117~47076594:+
BRCA	cis	rs875971	0.83	rs778715	ENSG00000273448.1	RP11-166O4.6	4.74	2.4e-06	0.000226	0.13	0.15	Aortic root size;	chr7:66384222	chr7:67333047~67334383:+
BRCA	cis	rs4356203	0.783	rs7113964	ENSG00000272034.1	SNORD14A	-4.74	2.4e-06	0.000226	-0.15	-0.15	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17234374	chr11:17074654~17074744:-
BRCA	cis	rs4650994	0.544	rs2761469	ENSG00000273384.1	RP5-1098D14.1	-4.74	2.4e-06	0.000226	-0.19	-0.15	HDL cholesterol;HDL cholesterol levels;	chr1:178621503	chr1:178651706~178652282:+
BRCA	cis	rs6545883	0.894	rs778148	ENSG00000212978.6	AC016747.3	-4.74	2.4e-06	0.000226	-0.2	-0.15	Tuberculosis;	chr2:61379731	chr2:61141592~61144969:-
BRCA	cis	rs738722	1	rs1807609	ENSG00000279978.1	chr22-38_28785274-29006793.1	-4.74	2.4e-06	0.000226	-0.2	-0.15	Optic cup area;Esophageal cancer and gastric cancer;	chr22:28735141	chr22:28930201~29197572:+
BRCA	cis	rs9467773	0.62	rs2451711	ENSG00000241549.7	GUSBP2	4.74	2.4e-06	0.000226	0.15	0.15	Intelligence (multi-trait analysis);	chr6:26662882	chr6:26871484~26956554:-
BRCA	cis	rs7267979	0.816	rs376742	ENSG00000125804.12	FAM182A	-4.74	2.4e-06	0.000226	-0.19	-0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25506781	chr20:26054655~26086917:+
BRCA	cis	rs300890	0.662	rs13102116	ENSG00000250326.1	RP11-284M14.1	-4.74	2.4e-06	0.000226	-0.17	-0.15	Nasopharyngeal carcinoma;	chr4:143312502	chr4:142933195~143184861:-
BRCA	cis	rs6832769	1	rs7673908	ENSG00000223305.1	RN7SKP30	-4.74	2.4e-06	0.000226	-0.18	-0.15	Personality dimensions;	chr4:55528652	chr4:55540502~55540835:-
BRCA	cis	rs6545883	0.929	rs1186710	ENSG00000270820.4	RP11-355B11.2	4.74	2.41e-06	0.000226	0.17	0.15	Tuberculosis;	chr2:61461592	chr2:61471188~61484130:+
BRCA	cis	rs7811142	0.83	rs6945952	ENSG00000078319.8	PMS2P1	-4.74	2.41e-06	0.000226	-0.23	-0.15	Platelet count;	chr7:100384152	chr7:100320992~100341908:-
BRCA	cis	rs7811142	0.83	rs73401451	ENSG00000078319.8	PMS2P1	-4.74	2.41e-06	0.000226	-0.23	-0.15	Platelet count;	chr7:100384272	chr7:100320992~100341908:-
BRCA	cis	rs10777288	0.568	rs1882146	ENSG00000258100.1	RP11-121E16.1	4.74	2.41e-06	0.000226	0.21	0.15	Pulmonary function (smoking interaction);	chr12:90969646	chr12:91362196~91368606:+
BRCA	cis	rs2136613	0.728	rs10761676	ENSG00000238280.1	RP11-436D10.3	4.74	2.41e-06	0.000226	0.18	0.15	Selective IgA deficiency;	chr10:62863689	chr10:62793562~62805887:-
BRCA	cis	rs6570726	0.967	rs439017	ENSG00000270638.1	RP3-466P17.1	4.74	2.41e-06	0.000226	0.16	0.15	Lobe attachment (rater-scored or self-reported);	chr6:145484987	chr6:145735570~145737218:+
BRCA	cis	rs2906856	0.526	rs2906852	ENSG00000236946.2	HNRNPA1P70	-4.74	2.41e-06	0.000226	-0.13	-0.15	Mosquito bite size;	chr12:67985701	chr12:68035767~68036853:+
BRCA	cis	rs11976180	1	rs2961118	ENSG00000244479.5	OR2A1-AS1	4.74	2.41e-06	0.000226	0.19	0.15	Obesity-related traits;	chr7:144058350	chr7:144251264~144356181:-
BRCA	cis	rs10788972	0.634	rs12033409	ENSG00000225183.1	RP4-758J24.4	-4.74	2.41e-06	0.000226	-0.19	-0.15	Parkinson disease and lewy body pathology;	chr1:54087238	chr1:54089856~54090093:+
BRCA	cis	rs11976180	1	rs2961120	ENSG00000244479.5	OR2A1-AS1	4.74	2.41e-06	0.000226	0.2	0.15	Obesity-related traits;	chr7:144059492	chr7:144251264~144356181:-
BRCA	cis	rs2253762	0.54	rs12249581	ENSG00000276742.1	RP11-500G22.4	4.74	2.41e-06	0.000226	0.25	0.15	Breast cancer;	chr10:122013486	chr10:121956782~121957098:+
BRCA	cis	rs6570726	0.935	rs453609	ENSG00000270638.1	RP3-466P17.1	4.74	2.41e-06	0.000226	0.16	0.15	Lobe attachment (rater-scored or self-reported);	chr6:145491196	chr6:145735570~145737218:+
BRCA	cis	rs7191700	0.511	rs243330	ENSG00000262703.1	RP11-485G7.6	4.74	2.41e-06	0.000227	0.15	0.15	Multiple sclerosis;	chr16:11257134	chr16:11348143~11349321:-
BRCA	cis	rs7226408	1	rs72883560	ENSG00000267707.2	RP11-95O2.5	4.74	2.41e-06	0.000227	0.24	0.15	Obesity-related traits;	chr18:36792317	chr18:37243776~37247506:+
BRCA	cis	rs9467773	0.565	rs4343916	ENSG00000124549.13	BTN2A3P	4.74	2.41e-06	0.000227	0.15	0.15	Intelligence (multi-trait analysis);	chr6:26522447	chr6:26421391~26432383:+
BRCA	cis	rs6840360	0.642	rs2709825	ENSG00000251603.1	RP11-164P12.4	-4.74	2.41e-06	0.000227	-0.13	-0.15	Intelligence (multi-trait analysis);	chr4:151444411	chr4:151667224~151670502:+
BRCA	cis	rs6840360	0.607	rs2724547	ENSG00000251603.1	RP11-164P12.4	-4.74	2.41e-06	0.000227	-0.13	-0.15	Intelligence (multi-trait analysis);	chr4:151444424	chr4:151667224~151670502:+
BRCA	cis	rs198426	0.813	rs2017861	ENSG00000243742.4	RPLP0P2	4.74	2.41e-06	0.000227	0.21	0.15	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr11:61714456	chr11:61615036~61639449:+
BRCA	cis	rs2243480	1	rs1979823	ENSG00000222364.1	RNU6-96P	4.74	2.41e-06	0.000227	0.27	0.15	Diabetic kidney disease;	chr7:66239626	chr7:66395191~66395286:+
BRCA	cis	rs4143844	1	rs34311301	ENSG00000259251.2	RP11-643M14.1	4.74	2.41e-06	0.000227	0.35	0.15	Bipolar disorder and schizophrenia;	chr15:62050356	chr15:62060503~62062434:+
BRCA	cis	rs4143844	1	rs12148573	ENSG00000259251.2	RP11-643M14.1	4.74	2.41e-06	0.000227	0.35	0.15	Bipolar disorder and schizophrenia;	chr15:62051994	chr15:62060503~62062434:+
BRCA	cis	rs4143844	1	rs75520981	ENSG00000259251.2	RP11-643M14.1	4.74	2.41e-06	0.000227	0.35	0.15	Bipolar disorder and schizophrenia;	chr15:62052478	chr15:62060503~62062434:+
BRCA	cis	rs115575488	0.683	rs12727967	ENSG00000231365.4	RP11-418J17.1	4.74	2.42e-06	0.000227	0.21	0.15	Lobe attachment (rater-scored or self-reported);	chr1:119053313	chr1:119140396~119275973:+
BRCA	cis	rs10129255	0.957	rs12590799	ENSG00000274576.2	IGHV2-70	4.74	2.42e-06	0.000227	0.12	0.15	Kawasaki disease;	chr14:106779713	chr14:106770577~106771020:-
BRCA	cis	rs10266483	0.545	rs7777148	ENSG00000228653.2	HNRNPCP7	4.74	2.42e-06	0.000227	0.21	0.15	Response to statin therapy;	chr7:64285795	chr7:64500825~64501729:+
BRCA	cis	rs11098499	0.874	rs6832670	ENSG00000249244.1	RP11-548H18.2	4.74	2.42e-06	0.000227	0.18	0.15	Corneal astigmatism;	chr4:119197637	chr4:119391831~119395335:-
BRCA	cis	rs7178909	0.835	rs17241302	ENSG00000259677.1	RP11-493E3.1	4.74	2.42e-06	0.000227	0.17	0.15	Common traits (Other);	chr15:89863305	chr15:89876540~89877285:+
BRCA	cis	rs7200543	1	rs72774845	ENSG00000260735.1	RP11-72I8.1	-4.74	2.42e-06	0.000227	-0.17	-0.15	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15054097	chr16:15094411~15109197:+
BRCA	cis	rs3892630	0.817	rs35408716	ENSG00000267567.1	CTD-2538C1.3	4.74	2.42e-06	0.000227	0.23	0.15	Red blood cell traits;	chr19:32697055	chr19:32718298~32719595:-
BRCA	cis	rs3892630	0.878	rs8112955	ENSG00000267567.1	CTD-2538C1.3	4.74	2.42e-06	0.000227	0.23	0.15	Red blood cell traits;	chr19:32700286	chr19:32718298~32719595:-
BRCA	cis	rs2179367	0.959	rs652807	ENSG00000268592.3	RAET1E-AS1	-4.74	2.42e-06	0.000227	-0.18	-0.15	Dupuytren's disease;	chr6:149416359	chr6:149863494~149919507:+
BRCA	cis	rs3768617	0.51	rs10797835	ENSG00000224468.3	RP11-181K3.4	-4.74	2.42e-06	0.000227	-0.16	-0.15	Fuchs's corneal dystrophy;	chr1:183103773	chr1:183138402~183141282:-
BRCA	cis	rs6430585	0.583	rs3769001	ENSG00000224043.6	CCNT2-AS1	-4.74	2.42e-06	0.000227	-0.25	-0.15	Corneal structure;	chr2:135868508	chr2:134735464~134918710:-
BRCA	cis	rs7811142	0.83	rs78256546	ENSG00000078319.8	PMS2P1	-4.74	2.42e-06	0.000227	-0.23	-0.15	Platelet count;	chr7:100355347	chr7:100320992~100341908:-
BRCA	cis	rs12744310	0.887	rs28566545	ENSG00000235358.1	RP11-399E6.1	4.74	2.42e-06	0.000227	0.22	0.15	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41317561	chr1:41242373~41284861:+
BRCA	cis	rs13326165	0.585	rs55847657	ENSG00000243224.1	RP5-1157M23.2	-4.74	2.42e-06	0.000227	-0.24	-0.15	HDL cholesterol levels;HDL cholesterol;	chr3:52259296	chr3:52239258~52241097:+
BRCA	cis	rs7246657	0.524	rs10411251	ENSG00000267422.1	CTD-2554C21.1	-4.74	2.42e-06	0.000227	-0.23	-0.15	Coronary artery calcification;	chr19:36937853	chr19:37779686~37792865:+
BRCA	cis	rs321358	0.895	rs73015175	ENSG00000271390.1	RP11-89C3.3	4.74	2.42e-06	0.000227	0.23	0.15	Body mass index;	chr11:111088593	chr11:111089870~111090368:-
BRCA	cis	rs321358	0.895	rs17536143	ENSG00000271390.1	RP11-89C3.3	4.74	2.42e-06	0.000227	0.23	0.15	Body mass index;	chr11:111088619	chr11:111089870~111090368:-
BRCA	cis	rs321358	0.895	rs12419745	ENSG00000271390.1	RP11-89C3.3	4.74	2.42e-06	0.000227	0.23	0.15	Body mass index;	chr11:111090741	chr11:111089870~111090368:-
BRCA	cis	rs2278702	0.622	rs77924420	ENSG00000259495.2	RP11-210M15.2	-4.74	2.42e-06	0.000228	-0.24	-0.15	Bipolar disorder;	chr15:80380626	chr15:80344853~80403575:-
BRCA	cis	rs4218	0.681	rs4531679	ENSG00000259732.1	RP11-59H7.3	-4.74	2.42e-06	0.000228	-0.18	-0.15	Social communication problems;	chr15:59083246	chr15:59121034~59133250:+
BRCA	cis	rs11051970	0.559	rs7956708	ENSG00000274964.1	RP11-817I4.1	-4.74	2.42e-06	0.000228	-0.2	-0.15	Response to tocilizumab in rheumatoid arthritis;	chr12:32315908	chr12:32339368~32340724:+
BRCA	cis	rs7267979	0.932	rs2387891	ENSG00000125804.12	FAM182A	-4.74	2.43e-06	0.000228	-0.19	-0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25489692	chr20:26054655~26086917:+
BRCA	cis	rs12893668	0.572	rs34000399	ENSG00000269958.1	RP11-73M18.8	4.74	2.43e-06	0.000228	0.16	0.15	Reticulocyte count;	chr14:103635080	chr14:103696353~103697163:+
BRCA	cis	rs2243480	1	rs160652	ENSG00000275400.1	RP4-756H11.5	4.74	2.43e-06	0.000228	0.28	0.15	Diabetic kidney disease;	chr7:66073444	chr7:66553805~66554199:-
BRCA	cis	rs6951245	1	rs76129108	ENSG00000229043.2	AC091729.9	-4.74	2.43e-06	0.000228	-0.26	-0.15	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1049523	chr7:1160374~1165267:+
BRCA	cis	rs10129255	0.957	rs8009464	ENSG00000274576.2	IGHV2-70	4.74	2.43e-06	0.000228	0.13	0.15	Kawasaki disease;	chr14:106777611	chr14:106770577~106771020:-
BRCA	cis	rs6430585	0.528	rs12464050	ENSG00000231890.6	DARS-AS1	-4.74	2.43e-06	0.000228	-0.24	-0.15	Corneal structure;	chr2:135905540	chr2:135985176~136022593:+
BRCA	cis	rs10833905	0.938	rs10833919	ENSG00000246225.5	RP11-17A1.3	-4.74	2.43e-06	0.000228	-0.21	-0.15	Sudden cardiac arrest;	chr11:23042483	chr11:22829380~22945393:+
BRCA	cis	rs7119	0.651	rs8025968	ENSG00000259362.2	RP11-307C19.1	-4.74	2.43e-06	0.000228	-0.21	-0.15	Type 2 diabetes;	chr15:77547274	chr15:77525540~77534110:+
BRCA	cis	rs12030196	0.917	rs11207367	ENSG00000230812.4	LINC01358	4.74	2.43e-06	0.000228	0.16	0.15	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr1:59004767	chr1:59020387~59044614:+
BRCA	cis	rs2243480	1	rs437889	ENSG00000222364.1	RNU6-96P	-4.74	2.43e-06	0.000228	-0.27	-0.15	Diabetic kidney disease;	chr7:66044247	chr7:66395191~66395286:+
BRCA	cis	rs4664293	0.934	rs1365800	ENSG00000226266.5	AC009961.3	-4.74	2.43e-06	0.000228	-0.19	-0.15	Monocyte percentage of white cells;	chr2:159699112	chr2:159670708~159712435:-
BRCA	cis	rs739496	0.579	rs7973309	ENSG00000226469.1	ADAM1B	4.74	2.44e-06	0.000229	0.18	0.15	Platelet count;	chr12:111944447	chr12:111927018~111929017:+
BRCA	cis	rs11758351	1	rs74363821	ENSG00000241549.7	GUSBP2	-4.74	2.44e-06	0.000229	-0.21	-0.15	Renal underexcretion gout;Gout;	chr6:26189296	chr6:26871484~26956554:-
BRCA	cis	rs1722133	0.555	rs788730	ENSG00000237471.1	AC073115.6	4.74	2.44e-06	0.000229	0.2	0.15	Sitting height ratio;	chr7:46051077	chr7:45969657~45980191:+
BRCA	cis	rs300890	0.536	rs10033104	ENSG00000250326.1	RP11-284M14.1	-4.74	2.44e-06	0.000229	-0.17	-0.15	Nasopharyngeal carcinoma;	chr4:143252330	chr4:142933195~143184861:-
BRCA	cis	rs2562456	0.833	rs2154302	ENSG00000268658.4	LINC00664	4.74	2.44e-06	0.000229	0.24	0.15	Pain;	chr19:21307609	chr19:21483374~21503238:+
BRCA	cis	rs17767294	0.541	rs733743	ENSG00000204709.4	LINC01556	-4.74	2.44e-06	0.000229	-0.3	-0.15	Parkinson's disease;	chr6:28359594	chr6:28943877~28944537:+
BRCA	cis	rs638893	0.842	rs480791	ENSG00000255239.1	AP002954.6	4.74	2.44e-06	0.000229	0.25	0.15	Vitiligo;	chr11:118833546	chr11:118688039~118690600:-
BRCA	cis	rs6545883	0.929	rs2593627	ENSG00000270820.4	RP11-355B11.2	-4.74	2.44e-06	0.000229	-0.17	-0.15	Tuberculosis;	chr2:61391439	chr2:61471188~61484130:+
BRCA	cis	rs35740288	0.77	rs12906580	ENSG00000202081.1	RNU6-1280P	-4.74	2.44e-06	0.000229	-0.19	-0.15	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85612056	chr15:85651522~85651628:-
BRCA	cis	rs4781563	1	rs11644666	ENSG00000242307.1	RPS26P52	-4.74	2.44e-06	0.000229	-0.18	-0.15	Bilirubin levels;	chr16:13952615	chr16:13922332~13922679:-
BRCA	cis	rs4781563	1	rs3784872	ENSG00000242307.1	RPS26P52	-4.74	2.44e-06	0.000229	-0.18	-0.15	Bilirubin levels;	chr16:13952407	chr16:13922332~13922679:-
BRCA	cis	rs4950322	1	rs72694715	ENSG00000244371.2	PFN1P8	-4.74	2.44e-06	0.000229	-0.21	-0.15	Protein quantitative trait loci;	chr1:147368468	chr1:146957117~146957659:-
BRCA	cis	rs8180040	0.62	rs7373821	ENSG00000276925.1	RP11-708J19.3	-4.74	2.44e-06	0.000229	-0.17	-0.15	Colorectal cancer;	chr3:47038637	chr3:47469777~47469987:+
BRCA	cis	rs7267979	0.649	rs2500406	ENSG00000125804.12	FAM182A	4.74	2.44e-06	0.000229	0.2	0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25421226	chr20:26054655~26086917:+
BRCA	cis	rs2243480	1	rs410128	ENSG00000222364.1	RNU6-96P	-4.74	2.44e-06	0.000229	-0.28	-0.15	Diabetic kidney disease;	chr7:66138186	chr7:66395191~66395286:+
BRCA	cis	rs6802315	0.604	rs2115941	ENSG00000272247.1	RP11-379F4.9	-4.74	2.44e-06	0.000229	-0.16	-0.15	Periodontitis (CDC/AAP);	chr3:158781906	chr3:158801257~158801935:-
BRCA	cis	rs867186	1	rs2295700	ENSG00000126005.14	MMP24-AS1	-4.74	2.44e-06	0.000229	-0.28	-0.15	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35003824	chr20:35216462~35278131:-
BRCA	cis	rs2273788	1	rs12554057	ENSG00000204173.9	LRRC37A5P	4.74	2.45e-06	0.00023	0.18	0.15	Monocyte count;	chr9:111582948	chr9:111602831~111631289:-
BRCA	cis	rs4132699	0.62	rs4405007	ENSG00000225460.1	RP13-93L13.1	4.74	2.45e-06	0.00023	0.16	0.15	Nonsyndromic cleft lip with or without cleft palate;Orofacial clefts;	chr9:89485889	chr9:89472237~89472692:+
BRCA	cis	rs8114671	0.562	rs2425005	ENSG00000126005.14	MMP24-AS1	4.74	2.45e-06	0.00023	0.19	0.15	Height;	chr20:34819912	chr20:35216462~35278131:-
BRCA	cis	rs754466	0.83	rs61854186	ENSG00000204049.1	RP11-126H7.4	4.74	2.45e-06	0.00023	0.2	0.15	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77943497	chr10:77866875~77869610:+
BRCA	cis	rs867186	1	rs8123978	ENSG00000126005.14	MMP24-AS1	-4.74	2.45e-06	0.00023	-0.28	-0.15	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35010986	chr20:35216462~35278131:-
BRCA	cis	rs13113518	1	rs4865007	ENSG00000249700.7	SRD5A3-AS1	-4.74	2.45e-06	0.00023	-0.18	-0.15	Height;	chr4:55537550	chr4:55363971~55395847:-
BRCA	cis	rs11051970	0.559	rs11051928	ENSG00000274964.1	RP11-817I4.1	-4.74	2.45e-06	0.00023	-0.19	-0.15	Response to tocilizumab in rheumatoid arthritis;	chr12:32319580	chr12:32339368~32340724:+
BRCA	cis	rs11051970	0.559	rs11051929	ENSG00000274964.1	RP11-817I4.1	-4.74	2.45e-06	0.00023	-0.19	-0.15	Response to tocilizumab in rheumatoid arthritis;	chr12:32319617	chr12:32339368~32340724:+
BRCA	cis	rs11051970	0.592	rs58926489	ENSG00000274964.1	RP11-817I4.1	-4.74	2.45e-06	0.00023	-0.19	-0.15	Response to tocilizumab in rheumatoid arthritis;	chr12:32319949	chr12:32339368~32340724:+
BRCA	cis	rs6840360	0.642	rs4235219	ENSG00000251603.1	RP11-164P12.4	-4.74	2.45e-06	0.00023	-0.13	-0.15	Intelligence (multi-trait analysis);	chr4:151424951	chr4:151667224~151670502:+
BRCA	cis	rs6840360	0.642	rs6851814	ENSG00000251603.1	RP11-164P12.4	-4.74	2.45e-06	0.00023	-0.13	-0.15	Intelligence (multi-trait analysis);	chr4:151425285	chr4:151667224~151670502:+
BRCA	cis	rs6840360	0.606	rs10028035	ENSG00000251603.1	RP11-164P12.4	-4.74	2.45e-06	0.00023	-0.13	-0.15	Intelligence (multi-trait analysis);	chr4:151426673	chr4:151667224~151670502:+
BRCA	cis	rs6840360	0.667	rs4266275	ENSG00000251603.1	RP11-164P12.4	-4.74	2.45e-06	0.00023	-0.13	-0.15	Intelligence (multi-trait analysis);	chr4:151426912	chr4:151667224~151670502:+
BRCA	cis	rs7665090	0.51	rs223498	ENSG00000251288.2	RP11-10L12.2	4.74	2.45e-06	0.00023	0.17	0.15	Primary biliary cholangitis;	chr4:102730805	chr4:102751401~102752641:+
BRCA	cis	rs6125597	0.967	rs6122781	ENSG00000222365.1	SNORD12B	4.74	2.45e-06	0.00023	0.15	0.15	Intelligence (multi-trait analysis);	chr20:49287289	chr20:49280319~49280409:+
BRCA	cis	rs6125597	0.967	rs6125610	ENSG00000222365.1	SNORD12B	4.74	2.45e-06	0.00023	0.15	0.15	Intelligence (multi-trait analysis);	chr20:49287761	chr20:49280319~49280409:+
BRCA	cis	rs6125597	0.967	rs6125611	ENSG00000222365.1	SNORD12B	4.74	2.45e-06	0.00023	0.15	0.15	Intelligence (multi-trait analysis);	chr20:49288197	chr20:49280319~49280409:+
BRCA	cis	rs6125597	0.901	rs6125612	ENSG00000222365.1	SNORD12B	4.74	2.45e-06	0.00023	0.15	0.15	Intelligence (multi-trait analysis);	chr20:49290021	chr20:49280319~49280409:+
BRCA	cis	rs6125597	0.935	rs6067034	ENSG00000222365.1	SNORD12B	4.74	2.45e-06	0.00023	0.15	0.15	Intelligence (multi-trait analysis);	chr20:49283627	chr20:49280319~49280409:+
BRCA	cis	rs62184315	0.938	rs17806132	ENSG00000253559.1	OSGEPL1-AS1	4.74	2.45e-06	0.00023	0.24	0.15	Alcohol dependence (age at onset);	chr2:189843561	chr2:189762704~189765556:+
BRCA	cis	rs7086627	0.515	rs6585994	ENSG00000226659.1	RP11-137H2.4	-4.74	2.45e-06	0.00023	-0.19	-0.15	Post bronchodilator FEV1;	chr10:80431887	chr10:80529597~80535942:-
BRCA	cis	rs867186	1	rs75866240	ENSG00000126005.14	MMP24-AS1	-4.74	2.45e-06	0.00023	-0.27	-0.15	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:34971036	chr20:35216462~35278131:-
BRCA	cis	rs7243790	1	rs7243790	ENSG00000277324.1	RP11-850A17.1	-4.74	2.45e-06	0.00023	-0.17	-0.15	Diastolic blood pressure;	chr18:54435393	chr18:54268346~54270028:-
BRCA	cis	rs7267979	0.789	rs4815400	ENSG00000274414.1	RP5-965G21.4	4.74	2.45e-06	0.00023	0.17	0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25311924	chr20:25239007~25245229:-
BRCA	cis	rs6831352	0.819	rs1154401	ENSG00000272777.1	RP11-571L19.8	-4.74	2.45e-06	0.00023	-0.15	-0.15	Alcohol dependence;	chr4:99088587	chr4:99067256~99068125:-
BRCA	cis	rs6570726	0.935	rs397418	ENSG00000270638.1	RP3-466P17.1	4.74	2.45e-06	0.00023	0.16	0.15	Lobe attachment (rater-scored or self-reported);	chr6:145521226	chr6:145735570~145737218:+
BRCA	cis	rs7572733	0.773	rs7603839	ENSG00000231621.1	AC013264.2	-4.74	2.45e-06	0.00023	-0.13	-0.15	Dermatomyositis;	chr2:197669984	chr2:197197991~197199273:+
BRCA	cis	rs7119	0.651	rs8041520	ENSG00000259362.2	RP11-307C19.1	-4.74	2.45e-06	0.00023	-0.2	-0.15	Type 2 diabetes;	chr15:77546827	chr15:77525540~77534110:+
BRCA	cis	rs6840360	0.642	rs6855845	ENSG00000251611.1	RP11-610P16.1	-4.74	2.45e-06	0.00023	-0.13	-0.15	Intelligence (multi-trait analysis);	chr4:151496228	chr4:151407551~151408835:-
BRCA	cis	rs4664293	0.867	rs3771721	ENSG00000226266.5	AC009961.3	-4.74	2.45e-06	0.00023	-0.18	-0.15	Monocyte percentage of white cells;	chr2:159771644	chr2:159670708~159712435:-
BRCA	cis	rs739496	0.579	rs3782885	ENSG00000226469.1	ADAM1B	4.74	2.45e-06	0.00023	0.19	0.15	Platelet count;	chr12:111844779	chr12:111927018~111929017:+
BRCA	cis	rs739496	0.579	rs11066046	ENSG00000226469.1	ADAM1B	4.74	2.45e-06	0.00023	0.19	0.15	Platelet count;	chr12:111846077	chr12:111927018~111929017:+
BRCA	cis	rs739496	0.579	rs2158030	ENSG00000226469.1	ADAM1B	4.74	2.45e-06	0.00023	0.19	0.15	Platelet count;	chr12:111847787	chr12:111927018~111929017:+
BRCA	cis	rs6490294	0.799	rs7315642	ENSG00000226469.1	ADAM1B	4.74	2.45e-06	0.00023	0.19	0.15	Mean platelet volume;	chr12:111848992	chr12:111927018~111929017:+
BRCA	cis	rs739496	0.579	rs12302040	ENSG00000226469.1	ADAM1B	4.74	2.45e-06	0.00023	0.19	0.15	Platelet count;	chr12:111850375	chr12:111927018~111929017:+
BRCA	cis	rs739496	0.579	rs12322899	ENSG00000226469.1	ADAM1B	4.74	2.45e-06	0.00023	0.19	0.15	Platelet count;	chr12:111850398	chr12:111927018~111929017:+
BRCA	cis	rs739496	0.579	rs12307192	ENSG00000226469.1	ADAM1B	4.74	2.45e-06	0.00023	0.19	0.15	Platelet count;	chr12:111852542	chr12:111927018~111929017:+
BRCA	cis	rs739496	0.579	rs12307365	ENSG00000226469.1	ADAM1B	4.74	2.45e-06	0.00023	0.19	0.15	Platelet count;	chr12:111852847	chr12:111927018~111929017:+
BRCA	cis	rs739496	0.579	rs6489817	ENSG00000226469.1	ADAM1B	4.74	2.45e-06	0.00023	0.19	0.15	Platelet count;	chr12:111853438	chr12:111927018~111929017:+
BRCA	cis	rs739496	0.579	rs7296199	ENSG00000226469.1	ADAM1B	4.74	2.45e-06	0.00023	0.19	0.15	Platelet count;	chr12:111854040	chr12:111927018~111929017:+
BRCA	cis	rs739496	0.579	rs12313385	ENSG00000226469.1	ADAM1B	4.74	2.45e-06	0.00023	0.19	0.15	Platelet count;	chr12:111854343	chr12:111927018~111929017:+
BRCA	cis	rs739496	0.579	rs7310605	ENSG00000226469.1	ADAM1B	4.74	2.45e-06	0.00023	0.19	0.15	Platelet count;	chr12:111854666	chr12:111927018~111929017:+
BRCA	cis	rs739496	0.579	rs57427612	ENSG00000226469.1	ADAM1B	4.74	2.45e-06	0.00023	0.19	0.15	Platelet count;	chr12:111856192	chr12:111927018~111929017:+
BRCA	cis	rs739496	0.579	rs7976557	ENSG00000226469.1	ADAM1B	4.74	2.45e-06	0.00023	0.19	0.15	Platelet count;	chr12:111862976	chr12:111927018~111929017:+
BRCA	cis	rs739496	0.579	rs11066054	ENSG00000226469.1	ADAM1B	4.74	2.45e-06	0.00023	0.19	0.15	Platelet count;	chr12:111868361	chr12:111927018~111929017:+
BRCA	cis	rs739496	0.579	rs7297760	ENSG00000226469.1	ADAM1B	4.74	2.45e-06	0.00023	0.19	0.15	Platelet count;	chr12:111875884	chr12:111927018~111929017:+
BRCA	cis	rs6490294	0.799	rs12426566	ENSG00000226469.1	ADAM1B	4.74	2.45e-06	0.00023	0.19	0.15	Mean platelet volume;	chr12:111877368	chr12:111927018~111929017:+
BRCA	cis	rs739496	0.527	rs2097701	ENSG00000226469.1	ADAM1B	4.74	2.45e-06	0.00023	0.19	0.15	Platelet count;	chr12:111878970	chr12:111927018~111929017:+
BRCA	cis	rs739496	0.579	rs7294623	ENSG00000226469.1	ADAM1B	4.74	2.45e-06	0.00023	0.19	0.15	Platelet count;	chr12:111879292	chr12:111927018~111929017:+
BRCA	cis	rs6840360	0.642	rs6843639	ENSG00000251611.1	RP11-610P16.1	-4.74	2.45e-06	0.00023	-0.13	-0.15	Intelligence (multi-trait analysis);	chr4:151494863	chr4:151407551~151408835:-
BRCA	cis	rs270601	0.683	rs81598	ENSG00000233006.5	AC034220.3	4.74	2.45e-06	0.00023	0.11	0.15	Acylcarnitine levels;	chr5:132252267	chr5:132311285~132369916:-
BRCA	cis	rs7246657	0.714	rs12972195	ENSG00000267422.1	CTD-2554C21.1	-4.74	2.45e-06	0.00023	-0.22	-0.15	Coronary artery calcification;	chr19:37261603	chr19:37779686~37792865:+
BRCA	cis	rs739496	0.527	rs7136469	ENSG00000226469.1	ADAM1B	4.74	2.46e-06	0.00023	0.18	0.15	Platelet count;	chr12:111910387	chr12:111927018~111929017:+
BRCA	cis	rs6490294	0.799	rs11066082	ENSG00000226469.1	ADAM1B	4.74	2.46e-06	0.00023	0.18	0.15	Mean platelet volume;	chr12:111913544	chr12:111927018~111929017:+
BRCA	cis	rs4578769	0.918	rs8085287	ENSG00000265939.1	UBE2CP2	4.74	2.46e-06	0.00023	0.17	0.15	Eosinophil percentage of white cells;	chr18:22884208	chr18:22900486~22900995:-
BRCA	cis	rs57221529	0.545	rs55955015	ENSG00000271781.1	CTD-2589H19.6	-4.74	2.46e-06	0.00023	-0.22	-0.15	Lung disease severity in cystic fibrosis;	chr5:575067	chr5:675826~676616:+
BRCA	cis	rs11098499	0.754	rs12711071	ENSG00000260404.2	RP11-384K6.6	4.74	2.46e-06	0.00023	0.13	0.15	Corneal astigmatism;	chr4:119319779	chr4:118591773~118633729:+
BRCA	cis	rs2562456	0.793	rs62110424	ENSG00000268081.1	RP11-678G14.2	4.74	2.46e-06	0.00023	0.24	0.15	Pain;	chr19:21416835	chr19:21554640~21569237:-
BRCA	cis	rs13113518	1	rs11133392	ENSG00000249700.7	SRD5A3-AS1	4.74	2.46e-06	0.000231	0.18	0.15	Height;	chr4:55507729	chr4:55363971~55395847:-
BRCA	cis	rs13113518	1	rs6838305	ENSG00000249700.7	SRD5A3-AS1	4.74	2.46e-06	0.000231	0.18	0.15	Height;	chr4:55508587	chr4:55363971~55395847:-
BRCA	cis	rs13113518	0.902	rs12503578	ENSG00000249700.7	SRD5A3-AS1	4.74	2.46e-06	0.000231	0.18	0.15	Height;	chr4:55509367	chr4:55363971~55395847:-
BRCA	cis	rs13113518	0.966	rs3828480	ENSG00000249700.7	SRD5A3-AS1	4.74	2.46e-06	0.000231	0.18	0.15	Height;	chr4:55510352	chr4:55363971~55395847:-
BRCA	cis	rs13113518	1	rs3762837	ENSG00000249700.7	SRD5A3-AS1	4.74	2.46e-06	0.000231	0.18	0.15	Height;	chr4:55511198	chr4:55363971~55395847:-
BRCA	cis	rs6430538	0.597	rs4954181	ENSG00000224043.6	CCNT2-AS1	-4.74	2.46e-06	0.000231	-0.2	-0.15	Parkinson's disease;	chr2:134812802	chr2:134735464~134918710:-
BRCA	cis	rs4948275	0.678	rs2650711	ENSG00000237233.2	TMEM26-AS1	-4.74	2.46e-06	0.000231	-0.17	-0.15	Night sleep phenotypes;	chr10:61483678	chr10:61452639~61481956:+
BRCA	cis	rs7727544	0.647	rs72793280	ENSG00000233006.5	AC034220.3	4.74	2.46e-06	0.000231	0.11	0.15	Blood metabolite levels;	chr5:132227207	chr5:132311285~132369916:-
BRCA	cis	rs991427	1	rs1920790	ENSG00000258100.1	RP11-121E16.1	-4.74	2.46e-06	0.000231	-0.2	-0.15	Systolic blood pressure (alcohol consumption interaction);	chr12:91099011	chr12:91362196~91368606:+
BRCA	cis	rs308403	0.509	rs10016979	ENSG00000224786.1	CETN4P	4.74	2.46e-06	0.000231	0.19	0.15	Blood protein levels;	chr4:122752037	chr4:122730548~122732193:-
BRCA	cis	rs9393692	0.572	rs4145878	ENSG00000241549.7	GUSBP2	-4.74	2.46e-06	0.000231	-0.15	-0.15	Educational attainment;	chr6:26197818	chr6:26871484~26956554:-
BRCA	cis	rs7674212	0.541	rs2251322	ENSG00000246560.2	RP11-10L12.4	4.74	2.46e-06	0.000231	0.15	0.15	Type 2 diabetes;	chr4:103158267	chr4:102828055~102844075:+
BRCA	cis	rs7674212	0.57	rs2251634	ENSG00000246560.2	RP11-10L12.4	4.74	2.46e-06	0.000231	0.15	0.15	Type 2 diabetes;	chr4:103161192	chr4:102828055~102844075:+
BRCA	cis	rs1020064	0.895	rs2250659	ENSG00000235319.1	AC012360.4	-4.74	2.46e-06	0.000231	-0.21	-0.15	AIDS;	chr2:105273227	chr2:105324210~105330529:+
BRCA	cis	rs13113518	1	rs13114841	ENSG00000249700.7	SRD5A3-AS1	4.74	2.46e-06	0.000231	0.18	0.15	Height;	chr4:55485974	chr4:55363971~55395847:-
BRCA	cis	rs7246657	0.722	rs10409605	ENSG00000226686.6	LINC01535	-4.74	2.46e-06	0.000231	-0.22	-0.15	Coronary artery calcification;	chr19:37632236	chr19:37251912~37265535:+
BRCA	cis	rs17597773	0.638	rs12145674	ENSG00000238078.1	LINC01352	4.74	2.46e-06	0.000231	0.17	0.15	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220826931	chr1:220829255~220832429:+
BRCA	cis	rs1707322	1	rs785490	ENSG00000234329.1	RP11-767N6.2	-4.74	2.46e-06	0.000231	-0.16	-0.15	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46111452	chr1:45651039~45651826:-
BRCA	cis	rs6545883	0.826	rs2694651	ENSG00000212978.6	AC016747.3	-4.74	2.46e-06	0.000231	-0.2	-0.15	Tuberculosis;	chr2:61361507	chr2:61141592~61144969:-
BRCA	cis	rs9467773	0.596	rs3001369	ENSG00000124549.13	BTN2A3P	4.74	2.46e-06	0.000231	0.15	0.15	Intelligence (multi-trait analysis);	chr6:26670741	chr6:26421391~26432383:+
BRCA	cis	rs6430585	0.528	rs721765	ENSG00000231890.6	DARS-AS1	-4.74	2.46e-06	0.000231	-0.24	-0.15	Corneal structure;	chr2:135991209	chr2:135985176~136022593:+
BRCA	cis	rs13113518	0.966	rs11133387	ENSG00000273257.1	RP11-177J6.1	4.74	2.47e-06	0.000231	0.19	0.15	Height;	chr4:55475130	chr4:55387949~55388271:+
BRCA	cis	rs13113518	1	rs4864999	ENSG00000273257.1	RP11-177J6.1	4.74	2.47e-06	0.000231	0.19	0.15	Height;	chr4:55476736	chr4:55387949~55388271:+
BRCA	cis	rs13113518	0.966	rs10517344	ENSG00000273257.1	RP11-177J6.1	4.74	2.47e-06	0.000231	0.19	0.15	Height;	chr4:55477545	chr4:55387949~55388271:+
BRCA	cis	rs9921338	0.961	rs9302459	ENSG00000262703.1	RP11-485G7.6	4.74	2.47e-06	0.000231	0.18	0.15	Vein graft stenosis in coronary artery bypass grafting;	chr16:11326482	chr16:11348143~11349321:-
BRCA	cis	rs4356203	0.905	rs2052188	ENSG00000272034.1	SNORD14A	4.74	2.47e-06	0.000231	0.15	0.15	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17105123	chr11:17074654~17074744:-
BRCA	cis	rs3845817	0.838	rs697150	ENSG00000237979.1	AC007389.1	4.74	2.47e-06	0.000231	0.17	0.15	Bipolar disorder;	chr2:65522950	chr2:65500993~65502138:-
BRCA	cis	rs3764021	0.87	rs10772085	ENSG00000278635.1	CTD-2318O12.1	-4.74	2.47e-06	0.000231	-0.14	-0.15	Type 1 diabetes;	chr12:9724281	chr12:9415641~9416718:+
BRCA	cis	rs2832191	0.935	rs11910316	ENSG00000236056.1	GAPDHP14	4.74	2.47e-06	0.000231	0.16	0.15	Dental caries;	chr21:29147408	chr21:29222321~29223257:+
BRCA	cis	rs3002142	0.554	rs17531063	ENSG00000272750.1	RP11-378J18.8	4.74	2.47e-06	0.000231	0.31	0.15	LDL peak particle diameter (total fat intake interaction);	chr1:222648367	chr1:222658867~222661512:-
BRCA	cis	rs1823913	0.614	rs1947457	ENSG00000227542.1	AC092614.2	4.74	2.47e-06	0.000232	0.28	0.15	Obesity-related traits;	chr2:191298970	chr2:191229165~191246172:-
BRCA	cis	rs7613051	0.58	rs11720449	ENSG00000223899.1	SEC13P1	4.74	2.47e-06	0.000232	0.23	0.15	Atopic dermatitis;	chr3:33024975	chr3:33033863~33034810:+
BRCA	cis	rs4415084	1	rs920329	ENSG00000251141.4	RP11-53O19.1	4.74	2.47e-06	0.000232	0.13	0.15	Breast cancer;	chr5:44702405	chr5:44744900~44808777:-
BRCA	cis	rs2562456	0.917	rs2562466	ENSG00000268535.1	RP11-420K14.3	-4.74	2.47e-06	0.000232	-0.2	-0.15	Pain;	chr19:21531402	chr19:21709522~21710191:+
BRCA	cis	rs12744310	0.887	rs12048805	ENSG00000235358.1	RP11-399E6.1	4.74	2.47e-06	0.000232	0.22	0.15	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41348604	chr1:41242373~41284861:+
BRCA	cis	rs867186	1	rs75537616	ENSG00000126005.14	MMP24-AS1	-4.74	2.47e-06	0.000232	-0.28	-0.15	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35004785	chr20:35216462~35278131:-
BRCA	cis	rs6723226	0.721	rs10172510	ENSG00000276517.1	AL133243.2	-4.74	2.47e-06	0.000232	-0.17	-0.15	Intelligence (multi-trait analysis);	chr2:32395820	chr2:32526504~32529507:+
BRCA	cis	rs10129255	0.53	rs11624912	ENSG00000254174.1	IGHV1-12	4.74	2.48e-06	0.000232	0.11	0.15	Kawasaki disease;	chr14:106673891	chr14:106122420~106122709:-
BRCA	cis	rs812925	0.537	rs778139	ENSG00000270820.4	RP11-355B11.2	-4.74	2.48e-06	0.000232	-0.15	-0.15	Immature fraction of reticulocytes;	chr2:61457429	chr2:61471188~61484130:+
BRCA	cis	rs470119	1	rs470119	ENSG00000273272.1	CTA-384D8.34	4.74	2.48e-06	0.000232	0.14	0.15	Mean corpuscular hemoglobin;	chr22:50528485	chr22:50542650~50543011:+
BRCA	cis	rs7646881	1	rs73015654	ENSG00000240207.5	RP11-379F4.4	-4.74	2.48e-06	0.000232	-0.21	-0.15	Tetralogy of Fallot;	chr3:158733865	chr3:158732263~158784070:+
BRCA	cis	rs7646881	0.953	rs73015657	ENSG00000240207.5	RP11-379F4.4	-4.74	2.48e-06	0.000232	-0.21	-0.15	Tetralogy of Fallot;	chr3:158734143	chr3:158732263~158784070:+
BRCA	cis	rs62025270	0.632	rs7163838	ENSG00000259762.1	RP11-158M2.4	-4.74	2.48e-06	0.000232	-0.21	-0.15	Idiopathic pulmonary fibrosis;	chr15:85664390	chr15:85750336~85752901:-
BRCA	cis	rs11239930	0.517	rs678111	ENSG00000278811.3	LINC00624	4.74	2.48e-06	0.000232	0.17	0.15	AIDS progression;	chr1:147076613	chr1:147258885~147517875:-
BRCA	cis	rs13113518	1	rs34648901	ENSG00000249700.7	SRD5A3-AS1	4.74	2.48e-06	0.000232	0.18	0.15	Height;	chr4:55541259	chr4:55363971~55395847:-
BRCA	cis	rs11098499	0.874	rs6851169	ENSG00000249244.1	RP11-548H18.2	4.74	2.48e-06	0.000233	0.18	0.15	Corneal astigmatism;	chr4:119196355	chr4:119391831~119395335:-
BRCA	cis	rs2278170	1	rs331529	ENSG00000225101.4	OR52K3P	-4.74	2.48e-06	0.000233	-0.19	-0.15	Amyotrophic lateral sclerosis;	chr11:4457161	chr11:4474813~4475755:+
BRCA	cis	rs6496044	0.611	rs8026938	ENSG00000259295.5	CSPG4P12	-4.74	2.48e-06	0.000233	-0.18	-0.15	Interstitial lung disease;	chr15:85525887	chr15:85191438~85213905:+
BRCA	cis	rs453301	0.606	rs7462373	ENSG00000254153.1	CTA-398F10.2	-4.74	2.48e-06	0.000233	-0.18	-0.15	Joint mobility (Beighton score);	chr8:9041808	chr8:8456909~8461337:-
BRCA	cis	rs11250097	0.549	rs11784897	ENSG00000254866.2	DEFB109P3	4.74	2.48e-06	0.000233	0.2	0.15	Neuroticism;	chr8:11452933	chr8:12150895~12151134:-
BRCA	cis	rs7772486	0.754	rs697055	ENSG00000270638.1	RP3-466P17.1	4.74	2.48e-06	0.000233	0.17	0.15	Lobe attachment (rater-scored or self-reported);	chr6:145682654	chr6:145735570~145737218:+
BRCA	cis	rs11239930	0.517	rs584107	ENSG00000278811.3	LINC00624	-4.74	2.49e-06	0.000233	-0.17	-0.15	AIDS progression;	chr1:147075862	chr1:147258885~147517875:-
BRCA	cis	rs4356203	0.905	rs7123301	ENSG00000272034.1	SNORD14A	-4.74	2.49e-06	0.000233	-0.15	-0.15	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17141880	chr11:17074654~17074744:-
BRCA	cis	rs6738627	0.931	rs13432797	ENSG00000223318.1	RNA5SP111	-4.74	2.49e-06	0.000233	-0.17	-0.15	circulating leptin levels adjusted for BMI;Body fat percentage;circulating leptin levels;	chr2:164670077	chr2:164895677~164895777:-
BRCA	cis	rs10129255	0.957	rs12590667	ENSG00000280411.1	IGHV1-69-2	4.74	2.49e-06	0.000233	0.1	0.15	Kawasaki disease;	chr14:106779223	chr14:106762092~106762588:-
BRCA	cis	rs7829975	0.535	rs4841005	ENSG00000233609.3	RP11-62H7.2	-4.74	2.49e-06	0.000233	-0.14	-0.15	Mood instability;	chr8:8643720	chr8:8961200~8979025:+
BRCA	cis	rs11098499	0.874	rs6822498	ENSG00000249244.1	RP11-548H18.2	4.74	2.49e-06	0.000233	0.18	0.15	Corneal astigmatism;	chr4:119199028	chr4:119391831~119395335:-
BRCA	cis	rs7829975	0.688	rs7837587	ENSG00000233609.3	RP11-62H7.2	4.74	2.49e-06	0.000233	0.14	0.15	Mood instability;	chr8:8521482	chr8:8961200~8979025:+
BRCA	cis	rs4722166	0.695	rs4722177	ENSG00000225541.1	AC002480.5	-4.74	2.49e-06	0.000233	-0.15	-0.15	Lung cancer;	chr7:22758912	chr7:22571607~22661792:-
BRCA	cis	rs3764021	0.933	rs2268146	ENSG00000256582.1	RP11-75L1.1	4.74	2.49e-06	0.000233	0.15	0.15	Type 1 diabetes;	chr12:9716675	chr12:9704077~9709350:+
BRCA	cis	rs7572733	0.773	rs11690844	ENSG00000231621.1	AC013264.2	-4.74	2.49e-06	0.000233	-0.13	-0.15	Dermatomyositis;	chr2:197650812	chr2:197197991~197199273:+
BRCA	cis	rs13108904	0.901	rs12641735	ENSG00000253399.1	AC078852.2	-4.74	2.49e-06	0.000233	-0.16	-0.15	Obesity-related traits;	chr4:1310646	chr4:1358479~1359461:+
BRCA	cis	rs792448	0.743	rs4951589	ENSG00000226251.4	RP11-15I11.3	-4.74	2.49e-06	0.000233	-0.19	-0.15	White blood cell count (basophil);	chr1:212327351	chr1:212225278~212238977:-
BRCA	cis	rs10129255	0.957	rs10136781	ENSG00000274576.2	IGHV2-70	4.74	2.49e-06	0.000233	0.12	0.15	Kawasaki disease;	chr14:106780451	chr14:106770577~106771020:-
BRCA	cis	rs6452524	0.967	rs2974448	ENSG00000281327.1	LINC01338	4.74	2.49e-06	0.000233	0.17	0.15	Hypertension (SNP x SNP interaction);	chr5:83190937	chr5:82850864~82859836:-
BRCA	cis	rs10129255	0.518	rs12590732	ENSG00000211967.3	IGHV3-53	4.74	2.49e-06	0.000233	0.1	0.15	Kawasaki disease;	chr14:106779612	chr14:106592676~106593347:-
BRCA	cis	rs62103177	0.525	rs62101233	ENSG00000278000.1	AC139100.4	4.74	2.49e-06	0.000233	0.22	0.15	Opioid sensitivity;	chr18:79964288	chr18:80161752~80162413:+
BRCA	cis	rs61869271	0.805	rs769119	ENSG00000236799.1	RP11-383C6.2	-4.73	2.49e-06	0.000234	-0.17	-0.15	Tonsillectomy;	chr10:115018916	chr10:114994657~114996593:+
BRCA	cis	rs3845817	0.703	rs1673458	ENSG00000237979.1	AC007389.1	4.73	2.49e-06	0.000234	0.17	0.15	Bipolar disorder;	chr2:65544512	chr2:65500993~65502138:-
BRCA	cis	rs4662750	0.58	rs7558838	ENSG00000236682.1	AC068282.3	4.73	2.49e-06	0.000234	0.19	0.15	Renal cell carcinoma;	chr2:127593771	chr2:127389130~127400580:+
BRCA	cis	rs11577354	0.548	rs11301	ENSG00000207181.1	SNORA14B	4.73	2.49e-06	0.000234	0.17	0.15	Obesity-related traits;	chr1:235109864	chr1:235127803~235127937:-
BRCA	cis	rs6840360	0.607	rs2724565	ENSG00000251603.1	RP11-164P12.4	-4.73	2.49e-06	0.000234	-0.13	-0.15	Intelligence (multi-trait analysis);	chr4:151429153	chr4:151667224~151670502:+
BRCA	cis	rs2692947	0.77	rs2315421	ENSG00000168992.4	OR7E102P	4.73	2.5e-06	0.000234	0.2	0.15	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95831768	chr2:95546531~95547545:+
BRCA	cis	rs7226408	1	rs72883558	ENSG00000267707.2	RP11-95O2.5	4.73	2.5e-06	0.000234	0.24	0.15	Obesity-related traits;	chr18:36792073	chr18:37243776~37247506:+
BRCA	cis	rs3768617	0.51	rs2296288	ENSG00000224468.3	RP11-181K3.4	-4.73	2.5e-06	0.000234	-0.16	-0.15	Fuchs's corneal dystrophy;	chr1:183103455	chr1:183138402~183141282:-
BRCA	cis	rs2562456	0.917	rs2650793	ENSG00000268658.4	LINC00664	-4.73	2.5e-06	0.000234	-0.22	-0.15	Pain;	chr19:21493313	chr19:21483374~21503238:+
BRCA	cis	rs718433	0.584	rs7158042	ENSG00000256379.1	TRAV8-5	-4.73	2.5e-06	0.000234	-0.16	-0.15	Intraocular pressure;	chr14:21752794	chr14:21903077~21903598:+
BRCA	cis	rs9510787	0.649	rs7991222	ENSG00000205861.10	C1QTNF9B-AS1	-4.73	2.5e-06	0.000234	-0.2	-0.15	Nasopharyngeal carcinoma;	chr13:23640518	chr13:23888889~23897263:+
BRCA	cis	rs2243480	1	rs1553174	ENSG00000275400.1	RP4-756H11.5	-4.73	2.5e-06	0.000234	-0.26	-0.15	Diabetic kidney disease;	chr7:66266207	chr7:66553805~66554199:-
BRCA	cis	rs2243480	1	rs10950032	ENSG00000275400.1	RP4-756H11.5	-4.73	2.5e-06	0.000234	-0.26	-0.15	Diabetic kidney disease;	chr7:66273604	chr7:66553805~66554199:-
BRCA	cis	rs2625529	0.775	rs4777466	ENSG00000260037.4	CTD-2524L6.3	-4.73	2.5e-06	0.000234	-0.18	-0.15	Red blood cell count;	chr15:71844531	chr15:71818396~71823384:+
BRCA	cis	rs6951245	0.872	rs75493422	ENSG00000229043.2	AC091729.9	-4.73	2.5e-06	0.000234	-0.26	-0.15	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1033254	chr7:1160374~1165267:+
BRCA	cis	rs6951245	1	rs79765398	ENSG00000229043.2	AC091729.9	-4.73	2.5e-06	0.000234	-0.26	-0.15	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1034128	chr7:1160374~1165267:+
BRCA	cis	rs9880211	0.606	rs9852406	ENSG00000239213.4	NCK1-AS1	4.73	2.5e-06	0.000234	0.19	0.15	Height;Body mass index;	chr3:135906656	chr3:136841726~136862054:-
BRCA	cis	rs2243480	1	rs466983	ENSG00000222364.1	RNU6-96P	-4.73	2.5e-06	0.000234	-0.27	-0.15	Diabetic kidney disease;	chr7:66055509	chr7:66395191~66395286:+
BRCA	cis	rs13113518	1	rs6849433	ENSG00000249700.7	SRD5A3-AS1	4.73	2.5e-06	0.000234	0.18	0.15	Height;	chr4:55506498	chr4:55363971~55395847:-
BRCA	cis	rs13113518	0.966	rs12501327	ENSG00000249700.7	SRD5A3-AS1	4.73	2.5e-06	0.000234	0.18	0.15	Height;	chr4:55507248	chr4:55363971~55395847:-
BRCA	cis	rs7772486	0.79	rs6923545	ENSG00000270638.1	RP3-466P17.1	-4.73	2.5e-06	0.000234	-0.17	-0.15	Lobe attachment (rater-scored or self-reported);	chr6:145923607	chr6:145735570~145737218:+
BRCA	cis	rs7772486	0.754	rs6922507	ENSG00000270638.1	RP3-466P17.1	-4.73	2.5e-06	0.000234	-0.17	-0.15	Lobe attachment (rater-scored or self-reported);	chr6:145929019	chr6:145735570~145737218:+
BRCA	cis	rs853679	0.76	rs967005	ENSG00000280107.1	AL022393.9	-4.73	2.5e-06	0.000234	-0.23	-0.15	Depression;	chr6:28242910	chr6:28170845~28172521:+
BRCA	cis	rs2832191	0.791	rs7282843	ENSG00000236056.1	GAPDHP14	-4.73	2.5e-06	0.000234	-0.16	-0.15	Dental caries;	chr21:29102905	chr21:29222321~29223257:+
BRCA	cis	rs321358	1	rs73019214	ENSG00000271390.1	RP11-89C3.3	4.73	2.5e-06	0.000235	0.24	0.15	Body mass index;	chr11:111131680	chr11:111089870~111090368:-
BRCA	cis	rs807029	0.577	rs701835	ENSG00000236662.1	RP11-108L7.4	4.73	2.51e-06	0.000235	0.18	0.15	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:101002370	chr10:100980507~100985614:-
BRCA	cis	rs10129255	0.5	rs9324092	ENSG00000211967.3	IGHV3-53	4.73	2.51e-06	0.000235	0.1	0.15	Kawasaki disease;	chr14:106683806	chr14:106592676~106593347:-
BRCA	cis	rs6847067	0.794	rs7663580	ENSG00000180769.7	WDFY3-AS2	4.73	2.51e-06	0.000235	0.13	0.15	Oropharynx cancer;	chr4:85007163	chr4:84965682~85011277:+
BRCA	cis	rs6490294	0.851	rs56814171	ENSG00000226469.1	ADAM1B	4.73	2.51e-06	0.000235	0.18	0.15	Mean platelet volume;	chr12:111965146	chr12:111927018~111929017:+
BRCA	cis	rs5751614	0.537	rs5996508	ENSG00000240160.3	RN7SL263P	4.73	2.51e-06	0.000235	0.19	0.15	Height;	chr22:23270441	chr22:23261782~23262071:-
BRCA	cis	rs7621331	1	rs13097946	ENSG00000273486.1	RP11-731C17.2	-4.73	2.51e-06	0.000235	-0.17	-0.15	Waist circumference adjusted for body mass index;	chr3:135994780	chr3:136837338~136839021:-
BRCA	cis	rs11124272	0.763	rs558803	ENSG00000272716.1	RP11-563N4.1	4.73	2.51e-06	0.000235	0.17	0.15	Interleukin-18 levels;	chr2:31619731	chr2:32165046~32165757:-
BRCA	cis	rs11250097	0.507	rs2409779	ENSG00000254866.2	DEFB109P3	4.73	2.51e-06	0.000235	0.2	0.15	Neuroticism;	chr8:11453831	chr8:12150895~12151134:-
BRCA	cis	rs8180040	0.966	rs922957	ENSG00000271161.1	BOLA2P2	-4.73	2.51e-06	0.000235	-0.16	-0.15	Colorectal cancer;	chr3:47380662	chr3:47499841~47500407:+
BRCA	cis	rs4664293	0.747	rs7600347	ENSG00000224152.1	AC009506.1	-4.73	2.51e-06	0.000235	-0.17	-0.15	Monocyte percentage of white cells;	chr2:159800981	chr2:159615296~159617082:+
BRCA	cis	rs7308116	0.546	rs7294794	ENSG00000274395.1	RP11-554D14.8	-4.73	2.51e-06	0.000235	-0.18	-0.15	Pelvic organ prolapse (moderate/severe);	chr12:107838611	chr12:107835541~107836555:-
BRCA	cis	rs1161098	0.723	rs1178001	ENSG00000256037.1	MRPL40P1	-4.73	2.51e-06	0.000235	-0.24	-0.15	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr12:67432018	chr12:67351436~67352039:+
BRCA	cis	rs7818688	0.932	rs10111154	ENSG00000253528.2	RP11-347C18.4	-4.73	2.51e-06	0.000235	-0.21	-0.15	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95028659	chr8:94974573~94974853:-
BRCA	cis	rs12744310	0.887	rs12732820	ENSG00000235358.1	RP11-399E6.1	4.73	2.51e-06	0.000235	0.22	0.15	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41333101	chr1:41242373~41284861:+
BRCA	cis	rs9467773	0.565	rs6925047	ENSG00000124549.13	BTN2A3P	4.73	2.51e-06	0.000235	0.15	0.15	Intelligence (multi-trait analysis);	chr6:26521207	chr6:26421391~26432383:+
BRCA	cis	rs73193808	0.901	rs8135008	ENSG00000236056.1	GAPDHP14	4.73	2.51e-06	0.000235	0.21	0.15	Coronary artery disease;	chr21:29222780	chr21:29222321~29223257:+
BRCA	cis	rs1707322	1	rs4660332	ENSG00000234329.1	RP11-767N6.2	4.73	2.51e-06	0.000235	0.15	0.15	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45995746	chr1:45651039~45651826:-
BRCA	cis	rs7481584	0.581	rs399565	ENSG00000247473.2	CARS-AS1	-4.73	2.51e-06	0.000235	-0.17	-0.15	Calcium levels;	chr11:3040550	chr11:3029009~3041260:+
BRCA	cis	rs10504130	1	rs763550	ENSG00000272024.1	RP11-546K22.3	4.73	2.51e-06	0.000235	0.26	0.15	Venous thromboembolism (SNP x SNP interaction);	chr8:51802905	chr8:51950284~51950690:+
BRCA	cis	rs11096990	0.656	rs6531710	ENSG00000249685.1	RP11-360F5.3	-4.73	2.51e-06	0.000235	-0.18	-0.15	Cognitive function;	chr4:39300658	chr4:39133913~39135608:+
BRCA	cis	rs1635	0.655	rs9380024	ENSG00000216901.1	AL022393.7	4.73	2.51e-06	0.000235	0.33	0.15	Schizophrenia;	chr6:27862576	chr6:28176188~28176674:+
BRCA	cis	rs9840812	0.728	rs12635723	ENSG00000273486.1	RP11-731C17.2	4.73	2.51e-06	0.000235	0.17	0.15	Fibrinogen levels;	chr3:136581890	chr3:136837338~136839021:-
BRCA	cis	rs2070615	0.525	rs10875876	ENSG00000239617.1	RP11-302B13.1	-4.73	2.51e-06	0.000235	-0.18	-0.15	Bipolar disorder;	chr12:48801606	chr12:48903418~48903813:-
BRCA	cis	rs9818758	0.607	rs35673421	ENSG00000270441.1	RP11-694I15.7	4.73	2.52e-06	0.000235	0.31	0.15	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49101973	chr3:49140086~49160851:-
BRCA	cis	rs2732480	0.577	rs2732457	ENSG00000257735.1	RP11-370I10.6	-4.73	2.52e-06	0.000236	-0.18	-0.15	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48364596	chr12:48350945~48442411:+
BRCA	cis	rs4237845	0.537	rs9645819	ENSG00000257159.1	RP11-58A17.3	4.73	2.52e-06	0.000236	0.17	0.15	Intelligence (multi-trait analysis);	chr12:57876280	chr12:57967058~57968399:+
BRCA	cis	rs13108904	0.875	rs73069950	ENSG00000253399.1	AC078852.2	4.73	2.52e-06	0.000236	0.16	0.15	Obesity-related traits;	chr4:1282257	chr4:1358479~1359461:+
BRCA	cis	rs2833693	0.572	rs4817477	ENSG00000261610.1	AP000265.1	4.73	2.52e-06	0.000236	0.17	0.15	Temperament;	chr21:32213799	chr21:32259804~32261585:-
BRCA	cis	rs62025270	0.632	rs7177107	ENSG00000259762.1	RP11-158M2.4	-4.73	2.52e-06	0.000236	-0.22	-0.15	Idiopathic pulmonary fibrosis;	chr15:85580133	chr15:85750336~85752901:-
BRCA	cis	rs2070615	0.525	rs931570	ENSG00000239617.1	RP11-302B13.1	-4.73	2.52e-06	0.000236	-0.19	-0.15	Bipolar disorder;	chr12:48801341	chr12:48903418~48903813:-
BRCA	cis	rs17685	0.712	rs11764119	ENSG00000280388.1	RP11-229D13.3	-4.73	2.52e-06	0.000236	-0.15	-0.15	Coffee consumption (cups per day);Coffee consumption;	chr7:76183040	chr7:76043977~76045963:-
BRCA	cis	rs7726839	1	rs7726839	ENSG00000271781.1	CTD-2589H19.6	-4.73	2.52e-06	0.000236	-0.17	-0.15	Obesity-related traits;	chr5:618471	chr5:675826~676616:+
BRCA	cis	rs7160336	1	rs4243645	ENSG00000259065.1	RP5-1021I20.1	4.73	2.52e-06	0.000236	0.16	0.15	Blood protein levels;	chr14:74071605	chr14:73787360~73803270:+
BRCA	cis	rs2835345	0.528	rs12483650	ENSG00000279365.1	KB-176G8.1	4.73	2.52e-06	0.000236	0.19	0.15	Pulmonary function;	chr21:36450778	chr21:36485867~36487760:+
BRCA	cis	rs2835345	0.563	rs12483621	ENSG00000279365.1	KB-176G8.1	4.73	2.52e-06	0.000236	0.19	0.15	Pulmonary function;	chr21:36450798	chr21:36485867~36487760:+
BRCA	cis	rs2243480	1	rs1873494	ENSG00000275400.1	RP4-756H11.5	-4.73	2.52e-06	0.000236	-0.26	-0.15	Diabetic kidney disease;	chr7:66184912	chr7:66553805~66554199:-
BRCA	cis	rs2243480	1	rs6959002	ENSG00000275400.1	RP4-756H11.5	-4.73	2.52e-06	0.000236	-0.26	-0.15	Diabetic kidney disease;	chr7:66185509	chr7:66553805~66554199:-
BRCA	cis	rs2274273	0.712	rs9806049	ENSG00000258413.1	RP11-665C16.6	-4.73	2.52e-06	0.000236	-0.19	-0.15	Protein biomarker;	chr14:55058871	chr14:55262767~55272075:-
BRCA	cis	rs1395	0.778	rs34618115	ENSG00000234072.1	AC074117.10	-4.73	2.52e-06	0.000236	-0.16	-0.15	Blood metabolite levels;	chr2:27195421	chr2:27356246~27367622:+
BRCA	cis	rs316341	0.651	rs15286	ENSG00000230438.6	SERPINB9P1	4.73	2.52e-06	0.000236	0.2	0.15	Cerebrospinal fluid AB1-42 levels;	chr6:2833505	chr6:2854657~2881407:-
BRCA	cis	rs1499614	1	rs2659903	ENSG00000222364.1	RNU6-96P	-4.73	2.52e-06	0.000236	-0.27	-0.15	Gout;	chr7:66715944	chr7:66395191~66395286:+
BRCA	cis	rs11673344	0.504	rs2385375	ENSG00000226686.6	LINC01535	4.73	2.52e-06	0.000236	0.19	0.15	Obesity-related traits;	chr19:37087620	chr19:37251912~37265535:+
BRCA	cis	rs4698412	0.561	rs17405811	ENSG00000214846.4	RP11-115L11.1	4.73	2.52e-06	0.000236	0.17	0.15	Parkinson's disease;	chr4:15684182	chr4:15730962~15731627:-
BRCA	cis	rs4698412	0.561	rs10005305	ENSG00000214846.4	RP11-115L11.1	4.73	2.52e-06	0.000236	0.17	0.15	Parkinson's disease;	chr4:15693267	chr4:15730962~15731627:-
BRCA	cis	rs2835345	0.563	rs73204246	ENSG00000279365.1	KB-176G8.1	4.73	2.52e-06	0.000236	0.19	0.15	Pulmonary function;	chr21:36452402	chr21:36485867~36487760:+
BRCA	cis	rs2835345	0.563	rs73204248	ENSG00000279365.1	KB-176G8.1	4.73	2.52e-06	0.000236	0.19	0.15	Pulmonary function;	chr21:36452411	chr21:36485867~36487760:+
BRCA	cis	rs7647973	1	rs73088137	ENSG00000244380.1	RP11-24C3.2	-4.73	2.53e-06	0.000236	-0.19	-0.15	Menarche (age at onset);	chr3:49410990	chr3:48440352~48446656:-
BRCA	cis	rs35343117	1	rs35343117	ENSG00000259295.5	CSPG4P12	4.73	2.53e-06	0.000236	0.2	0.15	Psoriasis;	chr15:85535884	chr15:85191438~85213905:+
BRCA	cis	rs11096990	0.593	rs7685619	ENSG00000249685.1	RP11-360F5.3	4.73	2.53e-06	0.000236	0.18	0.15	Cognitive function;	chr4:39211779	chr4:39133913~39135608:+
BRCA	cis	rs4819052	0.885	rs9980676	ENSG00000184274.3	LINC00315	-4.73	2.53e-06	0.000236	-0.2	-0.15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245515	chr21:45300245~45305257:-
BRCA	cis	rs35146811	0.807	rs10228764	ENSG00000214313.7	AZGP1P1	4.73	2.53e-06	0.000236	0.16	0.15	Coronary artery disease;	chr7:100010406	chr7:99980762~99987535:+
BRCA	cis	rs4781563	0.956	rs6498486	ENSG00000242307.1	RPS26P52	-4.73	2.53e-06	0.000236	-0.17	-0.15	Bilirubin levels;	chr16:13919809	chr16:13922332~13922679:-
BRCA	cis	rs2905347	0.755	rs2961288	ENSG00000179428.2	AC073072.5	4.73	2.53e-06	0.000237	0.16	0.15	Major depression and alcohol dependence;	chr7:22625510	chr7:22725395~22727620:-
BRCA	cis	rs11098499	0.908	rs11098527	ENSG00000250412.1	KLHL2P1	4.73	2.53e-06	0.000237	0.17	0.15	Corneal astigmatism;	chr4:119478751	chr4:119334329~119378233:+
BRCA	cis	rs11673344	0.504	rs10403728	ENSG00000226686.6	LINC01535	4.73	2.53e-06	0.000237	0.19	0.15	Obesity-related traits;	chr19:37091569	chr19:37251912~37265535:+
BRCA	cis	rs4494364	0.502	rs1920786	ENSG00000258100.1	RP11-121E16.1	4.73	2.53e-06	0.000237	0.21	0.15	Systolic blood pressure (alcohol consumption interaction);	chr12:90987647	chr12:91362196~91368606:+
BRCA	cis	rs4494364	0.502	rs1920769	ENSG00000258100.1	RP11-121E16.1	4.73	2.53e-06	0.000237	0.21	0.15	Systolic blood pressure (alcohol consumption interaction);	chr12:90987939	chr12:91362196~91368606:+
BRCA	cis	rs853679	0.546	rs13214023	ENSG00000220721.1	OR1F12	-4.73	2.53e-06	0.000237	-0.31	-0.15	Depression;	chr6:28364364	chr6:28073316~28074233:+
BRCA	cis	rs10938353	0.68	rs1491313	ENSG00000273369.1	RP11-700J17.1	4.73	2.53e-06	0.000237	0.18	0.15	Body mass index;	chr4:44783372	chr4:44693946~44694386:-
BRCA	cis	rs1015362	0.503	rs4911371	ENSG00000276073.1	RP5-1125A11.7	-4.73	2.53e-06	0.000237	-0.21	-0.15	Freckles;Red vs. non-red hair color;Skin sensitivity to sun;Burning and freckling;	chr20:33904096	chr20:33985617~33988989:-
BRCA	cis	rs7246657	0.722	rs12979640	ENSG00000226686.6	LINC01535	4.73	2.53e-06	0.000237	0.22	0.15	Coronary artery calcification;	chr19:37688255	chr19:37251912~37265535:+
BRCA	cis	rs17685	0.672	rs6465011	ENSG00000280388.1	RP11-229D13.3	-4.73	2.53e-06	0.000237	-0.15	-0.15	Coffee consumption (cups per day);Coffee consumption;	chr7:76181979	chr7:76043977~76045963:-
BRCA	cis	rs1858037	0.836	rs2576923	ENSG00000237979.1	AC007389.1	-4.73	2.53e-06	0.000237	-0.19	-0.15	Rheumatoid arthritis;	chr2:65406750	chr2:65500993~65502138:-
BRCA	cis	rs13113518	0.966	rs12506788	ENSG00000273257.1	RP11-177J6.1	4.73	2.53e-06	0.000237	0.19	0.15	Height;	chr4:55477426	chr4:55387949~55388271:+
BRCA	cis	rs828999	0.654	rs10785836	ENSG00000280186.1	RP11-483I13.6	-4.73	2.53e-06	0.000237	-0.16	-0.15	Monocyte percentage of white cells;	chr1:108154558	chr1:108200413~108202743:+
BRCA	cis	rs828999	0.654	rs6678223	ENSG00000280186.1	RP11-483I13.6	-4.73	2.53e-06	0.000237	-0.16	-0.15	Monocyte percentage of white cells;	chr1:108154568	chr1:108200413~108202743:+
BRCA	cis	rs828999	0.62	rs6703140	ENSG00000280186.1	RP11-483I13.6	-4.73	2.53e-06	0.000237	-0.16	-0.15	Monocyte percentage of white cells;	chr1:108154602	chr1:108200413~108202743:+
BRCA	cis	rs7267979	0.789	rs1983974	ENSG00000204556.4	CTD-2514C3.1	4.73	2.53e-06	0.000237	0.19	0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25549983	chr20:26018832~26020684:+
BRCA	cis	rs1910358	0.718	rs17500497	ENSG00000248874.4	C5orf17	-4.73	2.54e-06	0.000237	-0.19	-0.15	Venous thromboembolism (SNP x SNP interaction);	chr5:23868046	chr5:23951348~24178263:+
BRCA	cis	rs7618915	0.501	rs3852066	ENSG00000243224.1	RP5-1157M23.2	-4.73	2.54e-06	0.000237	-0.15	-0.15	Bipolar disorder;	chr3:52587823	chr3:52239258~52241097:+
BRCA	cis	rs7618915	0.501	rs2336146	ENSG00000243224.1	RP5-1157M23.2	-4.73	2.54e-06	0.000237	-0.15	-0.15	Bipolar disorder;	chr3:52592630	chr3:52239258~52241097:+
BRCA	cis	rs12744310	0.887	rs12026404	ENSG00000235358.1	RP11-399E6.1	4.73	2.54e-06	0.000237	0.22	0.15	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41336240	chr1:41242373~41284861:+
BRCA	cis	rs12744310	0.887	rs12047272	ENSG00000235358.1	RP11-399E6.1	4.73	2.54e-06	0.000237	0.22	0.15	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41336271	chr1:41242373~41284861:+
BRCA	cis	rs739496	0.579	rs11066095	ENSG00000226469.1	ADAM1B	4.73	2.54e-06	0.000237	0.18	0.15	Platelet count;	chr12:111939733	chr12:111927018~111929017:+
BRCA	cis	rs739496	0.579	rs7133881	ENSG00000226469.1	ADAM1B	4.73	2.54e-06	0.000237	0.18	0.15	Platelet count;	chr12:111940964	chr12:111927018~111929017:+
BRCA	cis	rs6490294	0.748	rs7295665	ENSG00000226469.1	ADAM1B	4.73	2.54e-06	0.000237	0.18	0.15	Mean platelet volume;	chr12:111941467	chr12:111927018~111929017:+
BRCA	cis	rs739496	0.614	rs7137889	ENSG00000226469.1	ADAM1B	4.73	2.54e-06	0.000237	0.18	0.15	Platelet count;	chr12:111941783	chr12:111927018~111929017:+
BRCA	cis	rs6490294	0.904	rs12579298	ENSG00000226469.1	ADAM1B	4.73	2.54e-06	0.000237	0.18	0.15	Mean platelet volume;	chr12:111956218	chr12:111927018~111929017:+
BRCA	cis	rs6490294	0.904	rs12306814	ENSG00000226469.1	ADAM1B	4.73	2.54e-06	0.000237	0.18	0.15	Mean platelet volume;	chr12:111966009	chr12:111927018~111929017:+
BRCA	cis	rs7226408	0.948	rs11660669	ENSG00000267707.2	RP11-95O2.5	4.73	2.54e-06	0.000237	0.23	0.15	Obesity-related traits;	chr18:36814518	chr18:37243776~37247506:+
BRCA	cis	rs7226408	0.894	rs72885207	ENSG00000267707.2	RP11-95O2.5	4.73	2.54e-06	0.000237	0.23	0.15	Obesity-related traits;	chr18:36817381	chr18:37243776~37247506:+
BRCA	cis	rs7226408	0.948	rs17567550	ENSG00000267707.2	RP11-95O2.5	4.73	2.54e-06	0.000237	0.23	0.15	Obesity-related traits;	chr18:36818715	chr18:37243776~37247506:+
BRCA	cis	rs7226408	0.894	rs72885212	ENSG00000267707.2	RP11-95O2.5	4.73	2.54e-06	0.000237	0.23	0.15	Obesity-related traits;	chr18:36819168	chr18:37243776~37247506:+
BRCA	cis	rs7226408	0.948	rs11662292	ENSG00000267707.2	RP11-95O2.5	4.73	2.54e-06	0.000237	0.23	0.15	Obesity-related traits;	chr18:36819731	chr18:37243776~37247506:+
BRCA	cis	rs7226408	0.948	rs2217110	ENSG00000267707.2	RP11-95O2.5	4.73	2.54e-06	0.000237	0.23	0.15	Obesity-related traits;	chr18:36820819	chr18:37243776~37247506:+
BRCA	cis	rs7226408	0.948	rs72885219	ENSG00000267707.2	RP11-95O2.5	4.73	2.54e-06	0.000237	0.23	0.15	Obesity-related traits;	chr18:36821032	chr18:37243776~37247506:+
BRCA	cis	rs7226408	0.948	rs72885222	ENSG00000267707.2	RP11-95O2.5	4.73	2.54e-06	0.000237	0.23	0.15	Obesity-related traits;	chr18:36821221	chr18:37243776~37247506:+
BRCA	cis	rs7226408	0.948	rs72885224	ENSG00000267707.2	RP11-95O2.5	4.73	2.54e-06	0.000237	0.23	0.15	Obesity-related traits;	chr18:36821415	chr18:37243776~37247506:+
BRCA	cis	rs7226408	0.948	rs72885226	ENSG00000267707.2	RP11-95O2.5	4.73	2.54e-06	0.000237	0.23	0.15	Obesity-related traits;	chr18:36821843	chr18:37243776~37247506:+
BRCA	cis	rs6802315	0.604	rs4680467	ENSG00000272247.1	RP11-379F4.9	-4.73	2.54e-06	0.000237	-0.16	-0.15	Periodontitis (CDC/AAP);	chr3:158782988	chr3:158801257~158801935:-
BRCA	cis	rs13113518	1	rs11724094	ENSG00000249700.7	SRD5A3-AS1	4.73	2.54e-06	0.000238	0.18	0.15	Height;	chr4:55501479	chr4:55363971~55395847:-
BRCA	cis	rs1499614	1	rs1267817	ENSG00000275400.1	RP4-756H11.5	4.73	2.54e-06	0.000238	0.27	0.15	Gout;	chr7:66645053	chr7:66553805~66554199:-
BRCA	cis	rs7267979	0.789	rs4815429	ENSG00000277938.1	RP5-965G21.3	-4.73	2.54e-06	0.000238	-0.17	-0.15	Liver enzyme levels (alkaline phosphatase);	chr20:25540975	chr20:25229150~25231933:+
BRCA	cis	rs13108904	0.875	rs3822017	ENSG00000253399.1	AC078852.2	-4.73	2.54e-06	0.000238	-0.16	-0.15	Obesity-related traits;	chr4:1242524	chr4:1358479~1359461:+
BRCA	cis	rs2832191	0.791	rs2832202	ENSG00000236056.1	GAPDHP14	4.73	2.54e-06	0.000238	0.16	0.15	Dental caries;	chr21:29129021	chr21:29222321~29223257:+
BRCA	cis	rs12681366	0.762	rs1598713	ENSG00000253704.1	RP11-267M23.4	4.73	2.54e-06	0.000238	0.15	0.15	Nonsyndromic cleft lip with cleft palate;	chr8:94369061	chr8:94553722~94569745:+
BRCA	cis	rs6430585	0.583	rs111837148	ENSG00000224043.6	CCNT2-AS1	-4.73	2.55e-06	0.000238	-0.24	-0.15	Corneal structure;	chr2:135854466	chr2:134735464~134918710:-
BRCA	cis	rs4218	0.543	rs11852461	ENSG00000259732.1	RP11-59H7.3	-4.73	2.55e-06	0.000238	-0.17	-0.15	Social communication problems;	chr15:59021728	chr15:59121034~59133250:+
BRCA	cis	rs11098499	0.954	rs10031483	ENSG00000250412.1	KLHL2P1	4.73	2.55e-06	0.000238	0.17	0.15	Corneal astigmatism;	chr4:119501481	chr4:119334329~119378233:+
BRCA	cis	rs11098499	0.954	rs10031665	ENSG00000250412.1	KLHL2P1	4.73	2.55e-06	0.000238	0.17	0.15	Corneal astigmatism;	chr4:119501697	chr4:119334329~119378233:+
BRCA	cis	rs11098499	0.954	rs3733523	ENSG00000250412.1	KLHL2P1	4.73	2.55e-06	0.000238	0.17	0.15	Corneal astigmatism;	chr4:119502564	chr4:119334329~119378233:+
BRCA	cis	rs843532	1	rs1718417	ENSG00000272359.1	U4	-4.73	2.55e-06	0.000238	-0.28	-0.15	Glucose homeostasis traits;	chr3:196792674	chr3:196747192~196747324:-
BRCA	cis	rs7674212	0.57	rs12501621	ENSG00000251288.2	RP11-10L12.2	-4.73	2.55e-06	0.000238	-0.17	-0.14	Type 2 diabetes;	chr4:103174348	chr4:102751401~102752641:+
BRCA	cis	rs16958440	0.867	rs77348110	ENSG00000280212.1	RP11-49K24.3	4.73	2.55e-06	0.000238	0.33	0.14	Sitting height ratio;	chr18:47147796	chr18:47076117~47076594:+
BRCA	cis	rs4218	0.588	rs9788719	ENSG00000259732.1	RP11-59H7.3	-4.73	2.55e-06	0.000238	-0.17	-0.14	Social communication problems;	chr15:59028920	chr15:59121034~59133250:+
BRCA	cis	rs3213958	0.574	rs73138030	ENSG00000249274.1	PDLIM1P4	-4.73	2.55e-06	0.000238	-0.24	-0.14	Blood protein levels;	chr3:98855209	chr3:98782188~98783193:+
BRCA	cis	rs1707322	1	rs10890376	ENSG00000234329.1	RP11-767N6.2	4.73	2.55e-06	0.000238	0.15	0.14	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45940910	chr1:45651039~45651826:-
BRCA	cis	rs1395	0.778	rs2580759	ENSG00000234072.1	AC074117.10	4.73	2.55e-06	0.000238	0.16	0.14	Blood metabolite levels;	chr2:27209632	chr2:27356246~27367622:+
BRCA	cis	rs754466	1	rs12220902	ENSG00000204049.1	RP11-126H7.4	4.73	2.55e-06	0.000238	0.19	0.14	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77923160	chr10:77866875~77869610:+
BRCA	cis	rs12612619	0.704	rs10185736	ENSG00000229122.1	AGBL5-IT1	-4.73	2.55e-06	0.000238	-0.16	-0.14	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27098356	chr2:27061038~27061815:+
BRCA	cis	rs4664293	0.867	rs12620924	ENSG00000226266.5	AC009961.3	-4.73	2.55e-06	0.000238	-0.18	-0.14	Monocyte percentage of white cells;	chr2:159746452	chr2:159670708~159712435:-
BRCA	cis	rs7246657	0.55	rs10411176	ENSG00000267422.1	CTD-2554C21.1	-4.73	2.55e-06	0.000239	-0.25	-0.14	Coronary artery calcification;	chr19:37196051	chr19:37779686~37792865:+
BRCA	cis	rs13113518	1	rs13118237	ENSG00000273257.1	RP11-177J6.1	4.73	2.55e-06	0.000239	0.18	0.14	Height;	chr4:55474259	chr4:55387949~55388271:+
BRCA	cis	rs6545883	0.929	rs2121660	ENSG00000270820.4	RP11-355B11.2	-4.73	2.55e-06	0.000239	-0.17	-0.14	Tuberculosis;	chr2:61425923	chr2:61471188~61484130:+
BRCA	cis	rs6570726	0.935	rs366308	ENSG00000270638.1	RP3-466P17.1	4.73	2.55e-06	0.000239	0.16	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145493396	chr6:145735570~145737218:+
BRCA	cis	rs6570726	0.935	rs384806	ENSG00000270638.1	RP3-466P17.1	4.73	2.55e-06	0.000239	0.16	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145493753	chr6:145735570~145737218:+
BRCA	cis	rs6570726	0.935	rs385185	ENSG00000270638.1	RP3-466P17.1	4.73	2.55e-06	0.000239	0.16	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145493856	chr6:145735570~145737218:+
BRCA	cis	rs6570726	0.935	rs384453	ENSG00000270638.1	RP3-466P17.1	4.73	2.55e-06	0.000239	0.16	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145494009	chr6:145735570~145737218:+
BRCA	cis	rs6570726	0.935	rs372378	ENSG00000270638.1	RP3-466P17.1	4.73	2.55e-06	0.000239	0.16	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145495091	chr6:145735570~145737218:+
BRCA	cis	rs6570726	0.905	rs388728	ENSG00000270638.1	RP3-466P17.1	4.73	2.55e-06	0.000239	0.16	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145495283	chr6:145735570~145737218:+
BRCA	cis	rs12149862	1	rs9930728	ENSG00000196696.11	PDXDC2P	4.73	2.55e-06	0.000239	0.16	0.14	Blood pressure (smoking interaction);	chr16:69432372	chr16:69976297~70065948:-
BRCA	cis	rs4908768	0.501	rs6668508	ENSG00000232912.4	RP5-1115A15.1	4.73	2.55e-06	0.000239	0.14	0.14	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8514059	chr1:8424645~8434838:+
BRCA	cis	rs7829975	0.711	rs4841051	ENSG00000233609.3	RP11-62H7.2	-4.73	2.55e-06	0.000239	-0.13	-0.14	Mood instability;	chr8:8828136	chr8:8961200~8979025:+
BRCA	cis	rs4831837	0.69	rs12678520	ENSG00000270074.1	RP11-351I21.11	4.73	2.55e-06	0.000239	0.18	0.14	Morbidity-free survival;	chr8:12835400	chr8:12412827~12414373:+
BRCA	cis	rs56322409	0.897	rs11188506	ENSG00000226688.5	ENTPD1-AS1	4.73	2.55e-06	0.000239	0.17	0.14	Blood metabolite levels;	chr10:95852244	chr10:95753206~96090238:-
BRCA	cis	rs56322409	0.865	rs11188509	ENSG00000226688.5	ENTPD1-AS1	4.73	2.55e-06	0.000239	0.17	0.14	Blood metabolite levels;	chr10:95855780	chr10:95753206~96090238:-
BRCA	cis	rs56322409	0.833	rs12360382	ENSG00000226688.5	ENTPD1-AS1	4.73	2.55e-06	0.000239	0.17	0.14	Blood metabolite levels;	chr10:95856285	chr10:95753206~96090238:-
BRCA	cis	rs739496	0.527	rs61612992	ENSG00000226469.1	ADAM1B	4.73	2.56e-06	0.000239	0.18	0.14	Platelet count;	chr12:111920260	chr12:111927018~111929017:+
BRCA	cis	rs739496	0.527	rs7300320	ENSG00000226469.1	ADAM1B	4.73	2.56e-06	0.000239	0.18	0.14	Platelet count;	chr12:111922364	chr12:111927018~111929017:+
BRCA	cis	rs739496	0.527	rs11066089	ENSG00000226469.1	ADAM1B	4.73	2.56e-06	0.000239	0.18	0.14	Platelet count;	chr12:111925463	chr12:111927018~111929017:+
BRCA	cis	rs2153535	0.541	rs6923558	ENSG00000251164.1	HULC	-4.73	2.56e-06	0.000239	-0.18	-0.14	Motion sickness;	chr6:8461234	chr6:8652137~8653846:+
BRCA	cis	rs910316	0.687	rs11627442	ENSG00000279594.1	RP11-950C14.10	-4.73	2.56e-06	0.000239	-0.16	-0.14	Height;	chr14:75202946	chr14:75011269~75012851:-
BRCA	cis	rs11239930	0.538	rs4950359	ENSG00000230832.3	RP11-325P15.2	-4.73	2.56e-06	0.000239	-0.21	-0.14	AIDS progression;	chr1:147087196	chr1:147082338~147083578:-
BRCA	cis	rs17214007	0.597	rs4781677	ENSG00000279866.1	CTB-193M12.4	4.73	2.56e-06	0.000239	0.23	0.14	Cognitive function;	chr16:15636388	chr16:15704410~15705984:+
BRCA	cis	rs984222	0.501	rs1361906	ENSG00000231365.4	RP11-418J17.1	-4.73	2.56e-06	0.000239	-0.16	-0.14	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:118942021	chr1:119140396~119275973:+
BRCA	cis	rs728616	0.867	rs12781912	ENSG00000225484.5	NUTM2B-AS1	-4.73	2.56e-06	0.000239	-0.33	-0.14	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80158372	chr10:79663088~79826594:-
BRCA	cis	rs6840360	0.539	rs1443087	ENSG00000251603.1	RP11-164P12.4	-4.73	2.56e-06	0.000239	-0.13	-0.14	Intelligence (multi-trait analysis);	chr4:151528943	chr4:151667224~151670502:+
BRCA	cis	rs6840360	0.642	rs1443088	ENSG00000251603.1	RP11-164P12.4	-4.73	2.56e-06	0.000239	-0.13	-0.14	Intelligence (multi-trait analysis);	chr4:151528974	chr4:151667224~151670502:+
BRCA	cis	rs57221529	0.709	rs111352378	ENSG00000271781.1	CTD-2589H19.6	-4.73	2.56e-06	0.000239	-0.22	-0.14	Lung disease severity in cystic fibrosis;	chr5:576964	chr5:675826~676616:+
BRCA	cis	rs57221529	0.709	rs72703034	ENSG00000271781.1	CTD-2589H19.6	-4.73	2.56e-06	0.000239	-0.22	-0.14	Lung disease severity in cystic fibrosis;	chr5:576986	chr5:675826~676616:+
BRCA	cis	rs26949	0.526	rs10069929	ENSG00000215032.2	GNL3LP1	-4.73	2.56e-06	0.000239	-0.18	-0.14	Intelligence (multi-trait analysis);	chr5:60744233	chr5:60891935~60893577:-
BRCA	cis	rs3845817	0.67	rs840787	ENSG00000237979.1	AC007389.1	4.73	2.56e-06	0.000239	0.17	0.14	Bipolar disorder;	chr2:65548756	chr2:65500993~65502138:-
BRCA	cis	rs35146811	0.807	rs6953441	ENSG00000214313.7	AZGP1P1	4.73	2.56e-06	0.000239	0.16	0.14	Coronary artery disease;	chr7:100019444	chr7:99980762~99987535:+
BRCA	cis	rs35146811	0.771	rs6465762	ENSG00000214313.7	AZGP1P1	4.73	2.56e-06	0.000239	0.16	0.14	Coronary artery disease;	chr7:100022931	chr7:99980762~99987535:+
BRCA	cis	rs7267979	0.816	rs422148	ENSG00000277938.1	RP5-965G21.3	4.73	2.56e-06	0.000239	0.17	0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25531968	chr20:25229150~25231933:+
BRCA	cis	rs875971	0.83	rs587360	ENSG00000223473.2	GS1-124K5.3	4.73	2.56e-06	0.000239	0.11	0.14	Aortic root size;	chr7:66057711	chr7:66491049~66493566:-
BRCA	cis	rs4218	0.648	rs35769647	ENSG00000277144.1	RP11-59H7.4	-4.73	2.56e-06	0.000239	-0.2	-0.14	Social communication problems;	chr15:59081670	chr15:59115547~59116089:-
BRCA	cis	rs7927592	0.956	rs948315	ENSG00000212093.1	AP000807.1	4.73	2.56e-06	0.00024	0.16	0.14	Total body bone mineral density;	chr11:68541672	chr11:68506083~68506166:-
BRCA	cis	rs7246657	0.722	rs11083432	ENSG00000276846.1	CTD-3220F14.3	-4.73	2.56e-06	0.00024	-0.19	-0.14	Coronary artery calcification;	chr19:37691732	chr19:37314868~37315620:-
BRCA	cis	rs11758351	0.778	rs41266801	ENSG00000241549.7	GUSBP2	-4.73	2.56e-06	0.00024	-0.21	-0.14	Renal underexcretion gout;Gout;	chr6:26197265	chr6:26871484~26956554:-
BRCA	cis	rs1823874	0.584	rs9806196	ENSG00000182397.13	DNM1P46	-4.73	2.57e-06	0.00024	-0.15	-0.14	IgG glycosylation;	chr15:99842201	chr15:99790156~99806927:-
BRCA	cis	rs13113518	1	rs4864547	ENSG00000249700.7	SRD5A3-AS1	4.73	2.57e-06	0.00024	0.18	0.14	Height;	chr4:55538228	chr4:55363971~55395847:-
BRCA	cis	rs7772486	0.701	rs697056	ENSG00000270638.1	RP3-466P17.1	-4.73	2.57e-06	0.00024	-0.17	-0.14	Lobe attachment (rater-scored or self-reported);	chr6:145682761	chr6:145735570~145737218:+
BRCA	cis	rs13108904	0.517	rs13128825	ENSG00000253399.1	AC078852.2	-4.73	2.57e-06	0.00024	-0.18	-0.14	Obesity-related traits;	chr4:1340219	chr4:1358479~1359461:+
BRCA	cis	rs72482608	0.826	rs10919475	ENSG00000271811.1	RP1-79C4.4	4.73	2.57e-06	0.00024	0.16	0.14	Emphysema imaging phenotypes;	chr1:170802165	chr1:170667381~170669425:+
BRCA	cis	rs4356203	0.905	rs7946010	ENSG00000272034.1	SNORD14A	4.73	2.57e-06	0.00024	0.15	0.14	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17154510	chr11:17074654~17074744:-
BRCA	cis	rs7226408	1	rs72883555	ENSG00000267707.2	RP11-95O2.5	4.73	2.57e-06	0.00024	0.24	0.14	Obesity-related traits;	chr18:36784130	chr18:37243776~37247506:+
BRCA	cis	rs6832769	0.89	rs1980273	ENSG00000223305.1	RN7SKP30	4.73	2.57e-06	0.00024	0.18	0.14	Personality dimensions;	chr4:55501234	chr4:55540502~55540835:-
BRCA	cis	rs11098499	0.754	rs12711071	ENSG00000249244.1	RP11-548H18.2	4.73	2.57e-06	0.00024	0.17	0.14	Corneal astigmatism;	chr4:119319779	chr4:119391831~119395335:-
BRCA	cis	rs1223397	0.651	rs2439537	ENSG00000215022.6	RP1-257A7.4	-4.73	2.57e-06	0.00024	-0.18	-0.14	Blood pressure;	chr6:13307592	chr6:13264861~13295586:-
BRCA	cis	rs2243480	1	rs1499613	ENSG00000275400.1	RP4-756H11.5	-4.73	2.57e-06	0.00024	-0.26	-0.14	Diabetic kidney disease;	chr7:66265873	chr7:66553805~66554199:-
BRCA	cis	rs754466	1	rs754466	ENSG00000204049.1	RP11-126H7.4	4.73	2.57e-06	0.00024	0.19	0.14	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77920676	chr10:77866875~77869610:+
BRCA	cis	rs867186	1	rs11908683	ENSG00000126005.14	MMP24-AS1	-4.73	2.57e-06	0.00024	-0.28	-0.14	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35133117	chr20:35216462~35278131:-
BRCA	cis	rs62103177	0.81	rs62096746	ENSG00000261126.6	RP11-795F19.1	4.73	2.57e-06	0.00024	0.22	0.14	Opioid sensitivity;	chr18:79859556	chr18:80046900~80095482:+
BRCA	cis	rs62103177	0.733	rs62096747	ENSG00000261126.6	RP11-795F19.1	4.73	2.57e-06	0.00024	0.22	0.14	Opioid sensitivity;	chr18:79859568	chr18:80046900~80095482:+
BRCA	cis	rs6890684	0.551	rs589794	ENSG00000215032.2	GNL3LP1	4.73	2.57e-06	0.00024	0.17	0.14	Intelligence (multi-trait analysis);	chr5:61220292	chr5:60891935~60893577:-
BRCA	cis	rs6890684	0.576	rs702565	ENSG00000215032.2	GNL3LP1	4.73	2.57e-06	0.00024	0.17	0.14	Intelligence (multi-trait analysis);	chr5:61221243	chr5:60891935~60893577:-
BRCA	cis	rs11096990	0.572	rs35040563	ENSG00000249685.1	RP11-360F5.3	4.73	2.58e-06	0.00024	0.18	0.14	Cognitive function;	chr4:39154262	chr4:39133913~39135608:+
BRCA	cis	rs8098244	0.964	rs11872306	ENSG00000264745.1	TTC39C-AS1	4.73	2.58e-06	0.00024	0.2	0.14	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23787668	chr18:23994213~24015339:-
BRCA	cis	rs10819861	1	rs10819861	ENSG00000175611.10	LINC00476	-4.73	2.58e-06	0.00024	-0.15	-0.14	Electrocardiographic traits;	chr9:96105531	chr9:95759231~95875977:-
BRCA	cis	rs4388249	0.687	rs2300995	ENSG00000271849.1	CTC-332L22.1	-4.73	2.58e-06	0.00024	-0.19	-0.14	Schizophrenia;	chr5:109746724	chr5:109687802~109688329:-
BRCA	cis	rs2810114	0.834	rs36559	ENSG00000258571.1	PTTG4P	-4.73	2.58e-06	0.00024	-0.17	-0.14	Alcohol dependence;	chr14:70888232	chr14:71085482~71085833:-
BRCA	cis	rs7267979	0.966	rs2500417	ENSG00000125804.12	FAM182A	4.73	2.58e-06	0.000241	0.19	0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25402651	chr20:26054655~26086917:+
BRCA	cis	rs4664293	0.867	rs7594329	ENSG00000224152.1	AC009506.1	-4.73	2.58e-06	0.000241	-0.16	-0.14	Monocyte percentage of white cells;	chr2:159716207	chr2:159615296~159617082:+
BRCA	cis	rs4664293	0.867	rs7582124	ENSG00000224152.1	AC009506.1	-4.73	2.58e-06	0.000241	-0.16	-0.14	Monocyte percentage of white cells;	chr2:159716326	chr2:159615296~159617082:+
BRCA	cis	rs7226408	1	rs485935	ENSG00000267707.2	RP11-95O2.5	4.73	2.58e-06	0.000241	0.24	0.14	Obesity-related traits;	chr18:36790540	chr18:37243776~37247506:+
BRCA	cis	rs6840360	0.582	rs2724555	ENSG00000278978.1	RP11-164P12.5	-4.73	2.58e-06	0.000241	-0.16	-0.14	Intelligence (multi-trait analysis);	chr4:151420726	chr4:151669786~151670503:+
BRCA	cis	rs7927592	0.956	rs11228269	ENSG00000212093.1	AP000807.1	4.73	2.58e-06	0.000241	0.16	0.14	Total body bone mineral density;	chr11:68522328	chr11:68506083~68506166:-
BRCA	cis	rs860295	0.702	rs12239100	ENSG00000160766.13	GBAP1	-4.73	2.58e-06	0.000241	-0.16	-0.14	Body mass index;	chr1:155458685	chr1:155213821~155227422:-
BRCA	cis	rs2303319	0.504	rs62187652	ENSG00000227403.1	AC009299.3	4.73	2.58e-06	0.000241	0.35	0.14	Cognitive function;	chr2:161611523	chr2:161244739~161249050:+
BRCA	cis	rs1722141	0.576	rs788755	ENSG00000229628.1	AC073115.7	4.73	2.58e-06	0.000241	0.21	0.14	Sitting height ratio;	chr7:46011227	chr7:45990905~46000898:+
BRCA	cis	rs9467773	0.62	rs2451711	ENSG00000124549.13	BTN2A3P	4.73	2.58e-06	0.000241	0.14	0.14	Intelligence (multi-trait analysis);	chr6:26662882	chr6:26421391~26432383:+
BRCA	cis	rs7481584	0.624	rs451060	ENSG00000247473.2	CARS-AS1	-4.73	2.58e-06	0.000241	-0.17	-0.14	Calcium levels;	chr11:3035159	chr11:3029009~3041260:+
BRCA	cis	rs6840360	0.642	rs28666858	ENSG00000251611.1	RP11-610P16.1	-4.73	2.58e-06	0.000241	-0.13	-0.14	Intelligence (multi-trait analysis);	chr4:151495230	chr4:151407551~151408835:-
BRCA	cis	rs2832191	0.791	rs2065270	ENSG00000236056.1	GAPDHP14	4.73	2.58e-06	0.000241	0.16	0.14	Dental caries;	chr21:29113099	chr21:29222321~29223257:+
BRCA	cis	rs2032366	0.606	rs9783923	ENSG00000267279.1	RP11-879F14.2	-4.73	2.59e-06	0.000241	-0.2	-0.14	Obesity-related traits;	chr18:61635518	chr18:61585746~61606916:-
BRCA	cis	rs4143844	0.867	rs11639286	ENSG00000259251.2	RP11-643M14.1	4.73	2.59e-06	0.000241	0.35	0.14	Bipolar disorder and schizophrenia;	chr15:62024397	chr15:62060503~62062434:+
BRCA	cis	rs4143844	0.867	rs34958705	ENSG00000259251.2	RP11-643M14.1	4.73	2.59e-06	0.000241	0.35	0.14	Bipolar disorder and schizophrenia;	chr15:62024558	chr15:62060503~62062434:+
BRCA	cis	rs12744310	0.887	rs12724690	ENSG00000235358.1	RP11-399E6.1	4.73	2.59e-06	0.000241	0.22	0.14	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41334585	chr1:41242373~41284861:+
BRCA	cis	rs12744310	0.887	rs34152153	ENSG00000235358.1	RP11-399E6.1	4.73	2.59e-06	0.000241	0.22	0.14	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41335736	chr1:41242373~41284861:+
BRCA	cis	rs12744310	0.887	rs36040148	ENSG00000235358.1	RP11-399E6.1	4.73	2.59e-06	0.000241	0.22	0.14	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41335776	chr1:41242373~41284861:+
BRCA	cis	rs12744310	0.887	rs35807669	ENSG00000235358.1	RP11-399E6.1	4.73	2.59e-06	0.000241	0.22	0.14	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41335980	chr1:41242373~41284861:+
BRCA	cis	rs925228	0.504	rs7568176	ENSG00000232642.1	AC008073.7	-4.73	2.59e-06	0.000241	-0.24	-0.14	Reticulocyte count;Reticulocyte fraction of red cells;	chr2:24090888	chr2:24165884~24175005:-
BRCA	cis	rs2243480	1	rs402418	ENSG00000222364.1	RNU6-96P	-4.73	2.59e-06	0.000241	-0.27	-0.14	Diabetic kidney disease;	chr7:66044482	chr7:66395191~66395286:+
BRCA	cis	rs950169	0.58	rs11634322	ENSG00000275120.1	RP11-182J1.17	4.73	2.59e-06	0.000242	0.2	0.14	Schizophrenia;	chr15:84628978	chr15:84599434~84606463:-
BRCA	cis	rs6847067	0.8	rs12648852	ENSG00000180769.7	WDFY3-AS2	4.73	2.59e-06	0.000242	0.13	0.14	Oropharynx cancer;	chr4:84919080	chr4:84965682~85011277:+
BRCA	cis	rs2179367	0.6	rs9498355	ENSG00000268592.3	RAET1E-AS1	-4.73	2.59e-06	0.000242	-0.22	-0.14	Dupuytren's disease;	chr6:149442274	chr6:149863494~149919507:+
BRCA	cis	rs4578769	0.959	rs1031651	ENSG00000265939.1	UBE2CP2	4.73	2.59e-06	0.000242	0.17	0.14	Eosinophil percentage of white cells;	chr18:22915716	chr18:22900486~22900995:-
BRCA	cis	rs4578769	0.959	rs4800439	ENSG00000265939.1	UBE2CP2	4.73	2.59e-06	0.000242	0.17	0.14	Eosinophil percentage of white cells;	chr18:22920492	chr18:22900486~22900995:-
BRCA	cis	rs4578769	0.959	rs8096389	ENSG00000265939.1	UBE2CP2	4.73	2.59e-06	0.000242	0.17	0.14	Eosinophil percentage of white cells;	chr18:22921952	chr18:22900486~22900995:-
BRCA	cis	rs4578769	0.959	rs9949696	ENSG00000265939.1	UBE2CP2	4.73	2.59e-06	0.000242	0.17	0.14	Eosinophil percentage of white cells;	chr18:22923688	chr18:22900486~22900995:-
BRCA	cis	rs4578769	0.959	rs930910	ENSG00000265939.1	UBE2CP2	4.73	2.59e-06	0.000242	0.17	0.14	Eosinophil percentage of white cells;	chr18:22930178	chr18:22900486~22900995:-
BRCA	cis	rs79040073	0.911	rs34895054	ENSG00000259531.2	RP11-295H24.3	4.73	2.59e-06	0.000242	0.23	0.14	Lung cancer in ever smokers;	chr15:48992804	chr15:49365124~49366685:-
BRCA	cis	rs11051970	0.559	rs11051925	ENSG00000274964.1	RP11-817I4.1	-4.73	2.59e-06	0.000242	-0.19	-0.14	Response to tocilizumab in rheumatoid arthritis;	chr12:32314860	chr12:32339368~32340724:+
BRCA	cis	rs11051970	0.559	rs10431283	ENSG00000274964.1	RP11-817I4.1	-4.73	2.59e-06	0.000242	-0.19	-0.14	Response to tocilizumab in rheumatoid arthritis;	chr12:32315070	chr12:32339368~32340724:+
BRCA	cis	rs11051970	0.559	rs10431225	ENSG00000274964.1	RP11-817I4.1	-4.73	2.59e-06	0.000242	-0.19	-0.14	Response to tocilizumab in rheumatoid arthritis;	chr12:32315177	chr12:32339368~32340724:+
BRCA	cis	rs7267979	0.789	rs9927	ENSG00000125804.12	FAM182A	-4.73	2.59e-06	0.000242	-0.19	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25296608	chr20:26054655~26086917:+
BRCA	cis	rs2051773	0.567	rs7924495	ENSG00000184669.7	OR7E14P	4.73	2.59e-06	0.000242	0.21	0.14	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);	chr11:17017181	chr11:17013998~17053024:+
BRCA	cis	rs4950322	0.518	rs4950306	ENSG00000244371.2	PFN1P8	-4.73	2.59e-06	0.000242	-0.2	-0.14	Protein quantitative trait loci;	chr1:147117838	chr1:146957117~146957659:-
BRCA	cis	rs17597773	0.635	rs1494368	ENSG00000238078.1	LINC01352	-4.73	2.59e-06	0.000242	-0.17	-0.14	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220830826	chr1:220829255~220832429:+
BRCA	cis	rs12497850	0.864	rs4955410	ENSG00000225399.4	RP11-3B7.1	4.73	2.59e-06	0.000242	0.14	0.14	Parkinson's disease;	chr3:49143785	chr3:49260085~49261316:+
BRCA	cis	rs7011507	0.582	rs72637678	ENSG00000279881.1	RP11-513O13.1	-4.73	2.59e-06	0.000242	-0.23	-0.14	Inflammatory bowel disease;Ulcerative colitis;	chr8:48348830	chr8:48428143~48431041:-
BRCA	cis	rs7267979	0.873	rs6083853	ENSG00000276952.1	RP5-965G21.6	-4.73	2.59e-06	0.000242	-0.18	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25423905	chr20:25284915~25285588:-
BRCA	cis	rs7267979	0.934	rs2482913	ENSG00000276952.1	RP5-965G21.6	-4.73	2.59e-06	0.000242	-0.18	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25424450	chr20:25284915~25285588:-
BRCA	cis	rs57221529	0.709	rs111352378	ENSG00000225138.6	CTD-2228K2.7	4.73	2.59e-06	0.000242	0.22	0.14	Lung disease severity in cystic fibrosis;	chr5:576964	chr5:473236~480884:+
BRCA	cis	rs57221529	0.709	rs72703034	ENSG00000225138.6	CTD-2228K2.7	4.73	2.59e-06	0.000242	0.22	0.14	Lung disease severity in cystic fibrosis;	chr5:576986	chr5:473236~480884:+
BRCA	cis	rs703842	1	rs10431505	ENSG00000270039.1	RP11-571M6.17	-4.73	2.6e-06	0.000242	-0.2	-0.14	Multiple sclerosis;	chr12:57784806	chr12:57803838~57804415:+
BRCA	cis	rs6490294	0.904	rs9971871	ENSG00000226469.1	ADAM1B	4.73	2.6e-06	0.000242	0.18	0.14	Mean platelet volume;	chr12:111970572	chr12:111927018~111929017:+
BRCA	cis	rs10129255	0.5	rs2105989	ENSG00000232216.1	IGHV3-43	4.73	2.6e-06	0.000242	0.11	0.14	Kawasaki disease;	chr14:106682199	chr14:106470264~106470800:-
BRCA	cis	rs6545883	0.718	rs6715259	ENSG00000271889.1	RP11-493E12.1	4.73	2.6e-06	0.000242	0.18	0.14	Tuberculosis;	chr2:61624710	chr2:61151433~61162105:-
BRCA	cis	rs12612619	0.732	rs13032059	ENSG00000229122.1	AGBL5-IT1	4.73	2.6e-06	0.000242	0.15	0.14	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27010921	chr2:27061038~27061815:+
BRCA	cis	rs12612619	0.732	rs13032100	ENSG00000229122.1	AGBL5-IT1	4.73	2.6e-06	0.000242	0.15	0.14	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27010991	chr2:27061038~27061815:+
BRCA	cis	rs1876905	0.68	rs373526	ENSG00000230177.1	RP5-1112D6.4	4.73	2.6e-06	0.000242	0.2	0.14	Mean corpuscular hemoglobin;	chr6:111190261	chr6:111277932~111278742:+
BRCA	cis	rs6686842	0.56	rs213751	ENSG00000235358.1	RP11-399E6.1	-4.73	2.6e-06	0.000242	-0.19	-0.14	Height;	chr1:41144214	chr1:41242373~41284861:+
BRCA	cis	rs10266483	0.774	rs1404679	ENSG00000227986.1	TRIM60P18	4.73	2.6e-06	0.000242	0.16	0.14	Response to statin therapy;	chr7:64358254	chr7:64355078~64356199:+
BRCA	cis	rs2708977	0.901	rs2579505	ENSG00000237510.6	AC008268.2	-4.73	2.6e-06	0.000242	-0.19	-0.14	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96502225	chr2:95789654~95800166:+
BRCA	cis	rs2834288	0.575	rs2239564	ENSG00000273102.1	AP000569.9	-4.73	2.6e-06	0.000243	-0.17	-0.14	Gut microbiota (bacterial taxa);	chr21:33908245	chr21:33967101~33968573:-
BRCA	cis	rs9467773	0.62	rs9461275	ENSG00000124549.13	BTN2A3P	4.73	2.6e-06	0.000243	0.14	0.14	Intelligence (multi-trait analysis);	chr6:26590573	chr6:26421391~26432383:+
BRCA	cis	rs6832769	0.89	rs1980273	ENSG00000272969.1	RP11-528I4.2	4.73	2.6e-06	0.000243	0.17	0.14	Personality dimensions;	chr4:55501234	chr4:55547112~55547889:+
BRCA	cis	rs300890	0.536	rs300924	ENSG00000250326.1	RP11-284M14.1	-4.73	2.6e-06	0.000243	-0.17	-0.14	Nasopharyngeal carcinoma;	chr4:143261032	chr4:142933195~143184861:-
BRCA	cis	rs10895987	0.531	rs7943007	ENSG00000255200.1	AP003068.18	-4.73	2.6e-06	0.000243	-0.18	-0.14	Blood protein levels;	chr11:65089626	chr11:65174117~65176470:-
BRCA	cis	rs465969	0.744	rs6939657	ENSG00000230177.1	RP5-1112D6.4	4.73	2.6e-06	0.000243	0.3	0.14	Psoriasis;	chr6:111521822	chr6:111277932~111278742:+
BRCA	cis	rs7267979	0.966	rs910996	ENSG00000125804.12	FAM182A	-4.73	2.6e-06	0.000243	-0.19	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25283560	chr20:26054655~26086917:+
BRCA	cis	rs6570726	0.935	rs906774	ENSG00000270638.1	RP3-466P17.1	4.73	2.6e-06	0.000243	0.16	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145492634	chr6:145735570~145737218:+
BRCA	cis	rs17767294	0.708	rs72848773	ENSG00000204709.4	LINC01556	4.73	2.6e-06	0.000243	0.39	0.14	Parkinson's disease;	chr6:27958742	chr6:28943877~28944537:+
BRCA	cis	rs17767294	0.708	rs76223516	ENSG00000204709.4	LINC01556	4.73	2.6e-06	0.000243	0.39	0.14	Parkinson's disease;	chr6:27971697	chr6:28943877~28944537:+
BRCA	cis	rs17767294	0.708	rs72848776	ENSG00000204709.4	LINC01556	4.73	2.6e-06	0.000243	0.39	0.14	Parkinson's disease;	chr6:27987048	chr6:28943877~28944537:+
BRCA	cis	rs2506028	0.507	rs2506032	ENSG00000273008.1	RP11-351D16.3	4.73	2.6e-06	0.000243	0.16	0.14	Blood protein levels;	chr10:42956352	chr10:43136824~43138334:-
BRCA	cis	rs2072883	0.669	rs5759111	ENSG00000230319.1	AL022476.2	-4.73	2.61e-06	0.000243	-0.16	-0.14	Schizophrenia;	chr22:43046593	chr22:43038585~43052366:+
BRCA	cis	rs13108904	0.901	rs7695691	ENSG00000253399.1	AC078852.2	-4.73	2.61e-06	0.000243	-0.16	-0.14	Obesity-related traits;	chr4:1310844	chr4:1358479~1359461:+
BRCA	cis	rs9300255	0.566	rs1716169	ENSG00000235423.7	RP11-282O18.3	4.73	2.61e-06	0.000243	0.21	0.14	Neutrophil percentage of white cells;	chr12:123232383	chr12:123252030~123261483:-
BRCA	cis	rs875971	0.862	rs10256544	ENSG00000236529.1	RP13-254B10.1	4.73	2.61e-06	0.000243	0.16	0.14	Aortic root size;	chr7:66210141	chr7:65840212~65840596:+
BRCA	cis	rs2839186	1	rs2839186	ENSG00000228137.1	AP001469.7	4.73	2.61e-06	0.000243	0.15	0.14	Testicular germ cell tumor;	chr21:46270154	chr21:46246890~46247682:+
BRCA	cis	rs9638182	1	rs62465144	ENSG00000274080.1	CTA-315H11.2	4.73	2.61e-06	0.000243	0.25	0.14	Triglycerides;	chr7:73468776	chr7:73609262~73611502:-
BRCA	cis	rs7772486	0.79	rs9376971	ENSG00000270638.1	RP3-466P17.1	-4.73	2.61e-06	0.000243	-0.17	-0.14	Lobe attachment (rater-scored or self-reported);	chr6:145938369	chr6:145735570~145737218:+
BRCA	cis	rs7772486	0.72	rs9403757	ENSG00000270638.1	RP3-466P17.1	-4.73	2.61e-06	0.000243	-0.17	-0.14	Lobe attachment (rater-scored or self-reported);	chr6:145940135	chr6:145735570~145737218:+
BRCA	cis	rs62184315	0.536	rs56324258	ENSG00000253559.1	OSGEPL1-AS1	-4.73	2.61e-06	0.000243	-0.25	-0.14	Alcohol dependence (age at onset);	chr2:189811589	chr2:189762704~189765556:+
BRCA	cis	rs2179367	0.6	rs11155654	ENSG00000223701.3	RAET1E-AS1	4.73	2.61e-06	0.000244	0.21	0.14	Dupuytren's disease;	chr6:149442001	chr6:149884431~149919508:+
BRCA	cis	rs117785887	0.536	rs12205195	ENSG00000270638.1	RP3-466P17.1	4.73	2.61e-06	0.000244	0.26	0.14	Interleukin-17 levels;	chr6:146043164	chr6:145735570~145737218:+
BRCA	cis	rs3764021	0.87	rs10844597	ENSG00000278635.1	CTD-2318O12.1	-4.73	2.61e-06	0.000244	-0.14	-0.14	Type 1 diabetes;	chr12:9722303	chr12:9415641~9416718:+
BRCA	cis	rs6496044	0.963	rs6496050	ENSG00000259295.5	CSPG4P12	4.73	2.61e-06	0.000244	0.18	0.14	Interstitial lung disease;	chr15:85526019	chr15:85191438~85213905:+
BRCA	cis	rs7267979	1	rs2500418	ENSG00000125804.12	FAM182A	4.73	2.61e-06	0.000244	0.19	0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25401632	chr20:26054655~26086917:+
BRCA	cis	rs739496	0.579	rs3213628	ENSG00000226469.1	ADAM1B	4.73	2.61e-06	0.000244	0.19	0.14	Platelet count;	chr12:111842969	chr12:111927018~111929017:+
BRCA	cis	rs6596100	0.91	rs62375250	ENSG00000248648.1	RP11-485M7.1	-4.73	2.61e-06	0.000244	-0.19	-0.14	Breast cancer;	chr5:133108018	chr5:133003119~133003365:+
BRCA	cis	rs6430585	0.583	rs3769012	ENSG00000224043.6	CCNT2-AS1	-4.73	2.61e-06	0.000244	-0.24	-0.14	Corneal structure;	chr2:135798910	chr2:134735464~134918710:-
BRCA	cis	rs1722141	0.669	rs788743	ENSG00000237471.1	AC073115.6	4.73	2.61e-06	0.000244	0.19	0.14	Sitting height ratio;	chr7:45997886	chr7:45969657~45980191:+
BRCA	cis	rs4356203	0.905	rs550667	ENSG00000272034.1	SNORD14A	-4.73	2.61e-06	0.000244	-0.15	-0.14	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17197428	chr11:17074654~17074744:-
BRCA	cis	rs4356203	0.905	rs656623	ENSG00000272034.1	SNORD14A	-4.73	2.61e-06	0.000244	-0.15	-0.14	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17197632	chr11:17074654~17074744:-
BRCA	cis	rs1950832	0.689	rs10138326	ENSG00000258636.1	CTD-2298J14.2	-4.73	2.62e-06	0.000244	-0.17	-0.14	Urate levels in obese individuals;	chr14:41662180	chr14:41587861~41604856:-
BRCA	cis	rs12435908	1	rs59204447	ENSG00000276116.2	FUT8-AS1	-4.73	2.62e-06	0.000244	-0.23	-0.14	Ischemic stroke;	chr14:65640009	chr14:65411170~65412690:-
BRCA	cis	rs4948275	0.743	rs2249641	ENSG00000237233.2	TMEM26-AS1	-4.72	2.62e-06	0.000244	-0.17	-0.14	Night sleep phenotypes;	chr10:61489607	chr10:61452639~61481956:+
BRCA	cis	rs10028773	0.546	rs13117947	ENSG00000245958.5	RP11-33B1.1	-4.72	2.62e-06	0.000244	-0.13	-0.14	Educational attainment;	chr4:119335905	chr4:119454791~119552025:+
BRCA	cis	rs5751614	0.517	rs928780	ENSG00000240160.3	RN7SL263P	4.72	2.62e-06	0.000244	0.19	0.14	Height;	chr22:23257682	chr22:23261782~23262071:-
BRCA	cis	rs1124769	0.57	rs1276856	ENSG00000259378.1	DCAF13P3	-4.72	2.62e-06	0.000244	-0.19	-0.14	Cognitive performance;	chr15:50863689	chr15:50944663~50945996:+
BRCA	cis	rs2692947	0.8	rs61409777	ENSG00000168992.4	OR7E102P	4.72	2.62e-06	0.000244	0.2	0.14	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95915625	chr2:95546531~95547545:+
BRCA	cis	rs2908197	0.788	rs6465111	ENSG00000186704.9	DTX2P1	4.72	2.62e-06	0.000244	0.17	0.14	3-hydroxypropylmercapturic acid levels in smokers;	chr7:76362061	chr7:76978617~77004308:+
BRCA	cis	rs6686842	1	rs2749418	ENSG00000235358.1	RP11-399E6.1	-4.72	2.62e-06	0.000244	-0.18	-0.14	Height;	chr1:41044002	chr1:41242373~41284861:+
BRCA	cis	rs1529102	1	rs1529102	ENSG00000225889.6	AC074289.1	-4.72	2.62e-06	0.000244	-0.13	-0.14	Breast size;	chr2:64268493	chr2:64143239~64252859:+
BRCA	cis	rs2235642	0.821	rs2281236	ENSG00000260989.1	LA16c-395F10.2	-4.72	2.62e-06	0.000244	-0.15	-0.14	Coronary artery disease;	chr16:1553575	chr16:1580527~1610328:+
BRCA	cis	rs8054556	1	rs10871451	ENSG00000214725.6	CDIPT-AS1	-4.72	2.62e-06	0.000244	-0.17	-0.14	Autism spectrum disorder or schizophrenia;	chr16:29974884	chr16:29863593~29868053:+
BRCA	cis	rs253959	0.545	rs7734133	ENSG00000271918.1	CTD-2287O16.5	4.72	2.62e-06	0.000244	0.13	0.14	Bipolar disorder and schizophrenia;	chr5:116096418	chr5:116083807~116085416:-
BRCA	cis	rs10129255	0.957	rs4387509	ENSG00000274576.2	IGHV2-70	4.72	2.62e-06	0.000244	0.14	0.14	Kawasaki disease;	chr14:106704386	chr14:106770577~106771020:-
BRCA	cis	rs6840258	0.64	rs1481947	ENSG00000251411.1	RP11-397E7.4	-4.72	2.62e-06	0.000244	-0.19	-0.14	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87159990	chr4:86913266~86914817:-
BRCA	cis	rs13113518	0.738	rs6849883	ENSG00000272969.1	RP11-528I4.2	4.72	2.62e-06	0.000245	0.17	0.14	Height;	chr4:55387515	chr4:55547112~55547889:+
BRCA	cis	rs2898681	1	rs2003198	ENSG00000248375.1	RP11-177B4.1	-4.72	2.62e-06	0.000245	-0.23	-0.14	Optic nerve measurement (cup area);	chr4:52882416	chr4:52720081~52720831:-
BRCA	cis	rs2665103	0.589	rs3858953	ENSG00000276710.3	CSPG4P8	-4.72	2.62e-06	0.000245	-0.15	-0.14	Intelligence (multi-trait analysis);	chr15:82238049	chr15:82459472~82477258:+
BRCA	cis	rs7577696	0.545	rs481126	ENSG00000272716.1	RP11-563N4.1	4.72	2.63e-06	0.000245	0.16	0.14	Inflammatory biomarkers;	chr2:31653174	chr2:32165046~32165757:-
BRCA	cis	rs7508	0.512	rs12544390	ENSG00000253671.1	RP11-806O11.1	-4.72	2.63e-06	0.000245	-0.17	-0.14	Atrial fibrillation;	chr8:18018039	chr8:17808941~17820868:+
BRCA	cis	rs11976180	1	rs1533268	ENSG00000244479.5	OR2A1-AS1	4.72	2.63e-06	0.000245	0.19	0.14	Obesity-related traits;	chr7:144069265	chr7:144251264~144356181:-
BRCA	cis	rs13113518	0.967	rs7696832	ENSG00000249700.7	SRD5A3-AS1	4.72	2.63e-06	0.000245	0.18	0.14	Height;	chr4:55537080	chr4:55363971~55395847:-
BRCA	cis	rs4763879	0.729	rs10844472	ENSG00000278635.1	CTD-2318O12.1	4.72	2.63e-06	0.000245	0.15	0.14	Type 1 diabetes;	chr12:9691137	chr12:9415641~9416718:+
BRCA	cis	rs11098499	0.908	rs28499576	ENSG00000260091.1	RP11-33B1.4	-4.72	2.63e-06	0.000245	-0.13	-0.14	Corneal astigmatism;	chr4:119465522	chr4:119409333~119410233:+
BRCA	cis	rs8017423	0.647	rs11626821	ENSG00000275198.1	RP11-471B22.3	4.72	2.63e-06	0.000245	0.17	0.14	Mortality in heart failure;	chr14:90358601	chr14:90383365~90387973:+
BRCA	cis	rs6847067	0.794	rs12640378	ENSG00000180769.7	WDFY3-AS2	-4.72	2.63e-06	0.000245	-0.13	-0.14	Oropharynx cancer;	chr4:85028969	chr4:84965682~85011277:+
BRCA	cis	rs6430585	0.528	rs16832417	ENSG00000231890.6	DARS-AS1	-4.72	2.63e-06	0.000245	-0.24	-0.14	Corneal structure;	chr2:135987108	chr2:135985176~136022593:+
BRCA	cis	rs7246657	0.551	rs11084873	ENSG00000267422.1	CTD-2554C21.1	-4.72	2.63e-06	0.000245	-0.25	-0.14	Coronary artery calcification;	chr19:37093008	chr19:37779686~37792865:+
BRCA	cis	rs4356203	0.905	rs635802	ENSG00000272034.1	SNORD14A	-4.72	2.63e-06	0.000245	-0.15	-0.14	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17183246	chr11:17074654~17074744:-
BRCA	cis	rs991427	1	rs73197065	ENSG00000258100.1	RP11-121E16.1	-4.72	2.64e-06	0.000246	-0.2	-0.14	Systolic blood pressure (alcohol consumption interaction);	chr12:91083660	chr12:91362196~91368606:+
BRCA	cis	rs1395	0.744	rs11679220	ENSG00000234072.1	AC074117.10	-4.72	2.64e-06	0.000246	-0.16	-0.14	Blood metabolite levels;	chr2:27253510	chr2:27356246~27367622:+
BRCA	cis	rs4356203	0.905	rs662711	ENSG00000272034.1	SNORD14A	-4.72	2.64e-06	0.000246	-0.15	-0.14	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17184641	chr11:17074654~17074744:-
BRCA	cis	rs4819052	0.851	rs2838837	ENSG00000184274.3	LINC00315	-4.72	2.64e-06	0.000246	-0.2	-0.14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45246073	chr21:45300245~45305257:-
BRCA	cis	rs926392	0.799	rs742274	ENSG00000274825.1	RP4-616B8.5	-4.72	2.64e-06	0.000246	-0.14	-0.14	Dialysis-related mortality;	chr20:39052301	chr20:38955910~38956547:+
BRCA	cis	rs6957923	0.655	rs7781714	ENSG00000234286.1	AC006026.13	-4.72	2.64e-06	0.000246	-0.16	-0.14	Height;	chr7:23553860	chr7:23680195~23680786:-
BRCA	cis	rs651907	0.505	rs2926540	ENSG00000244119.1	PDCL3P4	4.72	2.64e-06	0.000246	0.11	0.14	Colorectal cancer;	chr3:101867885	chr3:101712472~101713191:+
BRCA	cis	rs4787491	0.729	rs4238960	ENSG00000261367.1	RP11-455F5.4	-4.72	2.64e-06	0.000246	-0.16	-0.14	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30027327	chr16:30107675~30110541:+
BRCA	cis	rs1862618	0.613	rs252889	ENSG00000271828.1	CTD-2310F14.1	4.72	2.64e-06	0.000246	0.18	0.14	Initial pursuit acceleration;	chr5:56931242	chr5:56927874~56929573:+
BRCA	cis	rs6832769	0.961	rs11939815	ENSG00000223305.1	RN7SKP30	4.72	2.64e-06	0.000246	0.18	0.14	Personality dimensions;	chr4:55492116	chr4:55540502~55540835:-
BRCA	cis	rs6832769	0.826	rs58894703	ENSG00000223305.1	RN7SKP30	4.72	2.64e-06	0.000246	0.18	0.14	Personality dimensions;	chr4:55492371	chr4:55540502~55540835:-
BRCA	cis	rs6832769	1	rs3805157	ENSG00000223305.1	RN7SKP30	4.72	2.64e-06	0.000246	0.18	0.14	Personality dimensions;	chr4:55497936	chr4:55540502~55540835:-
BRCA	cis	rs6840360	0.642	rs7684462	ENSG00000251603.1	RP11-164P12.4	-4.72	2.64e-06	0.000246	-0.13	-0.14	Intelligence (multi-trait analysis);	chr4:151427270	chr4:151667224~151670502:+
BRCA	cis	rs2562456	0.917	rs2681392	ENSG00000268535.1	RP11-420K14.3	-4.72	2.64e-06	0.000246	-0.2	-0.14	Pain;	chr19:21513185	chr19:21709522~21710191:+
BRCA	cis	rs9291683	0.655	rs55941493	ENSG00000250413.1	RP11-448G15.1	4.72	2.64e-06	0.000246	0.19	0.14	Bone mineral density;	chr4:10098717	chr4:10006482~10009725:+
BRCA	cis	rs6442522	0.526	rs2124491	ENSG00000249786.6	EAF1-AS1	4.72	2.64e-06	0.000246	0.15	0.14	Uric acid levels;	chr3:15487898	chr3:15436171~15455940:-
BRCA	cis	rs7200786	0.692	rs9935445	ENSG00000274038.1	RP11-66H6.4	-4.72	2.65e-06	0.000246	-0.16	-0.14	Systemic lupus erythematosus;Multiple sclerosis;	chr16:10995532	chr16:11056556~11057034:+
BRCA	cis	rs9291683	0.62	rs717615	ENSG00000250413.1	RP11-448G15.1	-4.72	2.65e-06	0.000247	-0.19	-0.14	Bone mineral density;	chr4:10103046	chr4:10006482~10009725:+
BRCA	cis	rs2526882	0.541	rs2526859	ENSG00000269927.1	RP6-91H8.3	-4.72	2.65e-06	0.000247	-0.18	-0.14	Schizophrenia;	chr14:70945490	chr14:71141125~71143253:-
BRCA	cis	rs16958440	1	rs2289132	ENSG00000267724.1	RP11-49K24.8	4.72	2.65e-06	0.000247	0.26	0.14	Sitting height ratio;	chr18:47075921	chr18:47105946~47108062:+
BRCA	cis	rs16958440	1	rs2289131	ENSG00000267724.1	RP11-49K24.8	4.72	2.65e-06	0.000247	0.26	0.14	Sitting height ratio;	chr18:47076493	chr18:47105946~47108062:+
BRCA	cis	rs2243480	1	rs7794661	ENSG00000226002.1	RP11-460N20.5	-4.72	2.65e-06	0.000247	-0.24	-0.14	Diabetic kidney disease;	chr7:65924743	chr7:65084103~65100232:+
BRCA	cis	rs2638953	0.924	rs11049606	ENSG00000278733.1	RP11-425D17.1	-4.72	2.65e-06	0.000247	-0.18	-0.14	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28444213	chr12:28185625~28186190:-
BRCA	cis	rs7772486	0.875	rs1929523	ENSG00000270638.1	RP3-466P17.1	4.72	2.65e-06	0.000247	0.17	0.14	Lobe attachment (rater-scored or self-reported);	chr6:146018853	chr6:145735570~145737218:+
BRCA	cis	rs4218	0.543	rs8027536	ENSG00000259732.1	RP11-59H7.3	-4.72	2.65e-06	0.000247	-0.17	-0.14	Social communication problems;	chr15:59022364	chr15:59121034~59133250:+
BRCA	cis	rs4494364	0.502	rs9308291	ENSG00000258100.1	RP11-121E16.1	4.72	2.65e-06	0.000247	0.21	0.14	Systolic blood pressure (alcohol consumption interaction);	chr12:90986893	chr12:91362196~91368606:+
BRCA	cis	rs4494364	0.502	rs1882143	ENSG00000258100.1	RP11-121E16.1	4.72	2.65e-06	0.000247	0.21	0.14	Systolic blood pressure (alcohol consumption interaction);	chr12:90987104	chr12:91362196~91368606:+
BRCA	cis	rs9921338	0.961	rs72773829	ENSG00000262703.1	RP11-485G7.6	-4.72	2.65e-06	0.000247	-0.18	-0.14	Vein graft stenosis in coronary artery bypass grafting;	chr16:11318766	chr16:11348143~11349321:-
BRCA	cis	rs17767294	0.708	rs61744109	ENSG00000204709.4	LINC01556	4.72	2.65e-06	0.000247	0.38	0.14	Parkinson's disease;	chr6:28107741	chr6:28943877~28944537:+
BRCA	cis	rs17767294	0.708	rs72851168	ENSG00000204709.4	LINC01556	4.72	2.65e-06	0.000247	0.38	0.14	Parkinson's disease;	chr6:28112230	chr6:28943877~28944537:+
BRCA	cis	rs17767294	0.708	rs77450054	ENSG00000204709.4	LINC01556	4.72	2.65e-06	0.000247	0.38	0.14	Parkinson's disease;	chr6:28116171	chr6:28943877~28944537:+
BRCA	cis	rs4478858	0.775	rs6701861	ENSG00000223907.1	LINC01226	-4.72	2.66e-06	0.000247	-0.17	-0.14	Alcohol dependence;	chr1:31235278	chr1:31518435~31524245:+
BRCA	cis	rs4948275	0.773	rs2249689	ENSG00000237233.2	TMEM26-AS1	-4.72	2.66e-06	0.000247	-0.17	-0.14	Night sleep phenotypes;	chr10:61488782	chr10:61452639~61481956:+
BRCA	cis	rs4948275	0.773	rs2249680	ENSG00000237233.2	TMEM26-AS1	-4.72	2.66e-06	0.000247	-0.17	-0.14	Night sleep phenotypes;	chr10:61488847	chr10:61452639~61481956:+
BRCA	cis	rs4948275	0.743	rs2249671	ENSG00000237233.2	TMEM26-AS1	-4.72	2.66e-06	0.000247	-0.17	-0.14	Night sleep phenotypes;	chr10:61488975	chr10:61452639~61481956:+
BRCA	cis	rs10492201	0.529	rs12422954	ENSG00000236946.2	HNRNPA1P70	-4.72	2.66e-06	0.000247	-0.14	-0.14	Itch intensity from mosquito bite adjusted by bite size;	chr12:68007611	chr12:68035767~68036853:+
BRCA	cis	rs12368653	0.641	rs12826708	ENSG00000257159.1	RP11-58A17.3	-4.72	2.66e-06	0.000247	-0.17	-0.14	Multiple sclerosis;	chr12:57664590	chr12:57967058~57968399:+
BRCA	cis	rs9818758	0.607	rs34326553	ENSG00000270441.1	RP11-694I15.7	4.72	2.66e-06	0.000247	0.31	0.14	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49096996	chr3:49140086~49160851:-
BRCA	cis	rs10911232	0.507	rs3935384	ENSG00000224468.3	RP11-181K3.4	-4.72	2.66e-06	0.000248	-0.15	-0.14	Hypertriglyceridemia;	chr1:183059835	chr1:183138402~183141282:-
BRCA	cis	rs17684571	0.7	rs13201733	ENSG00000231441.1	RP11-472M19.2	4.72	2.66e-06	0.000248	0.23	0.14	Schizophrenia;	chr6:56804226	chr6:56844002~56864078:+
BRCA	cis	rs17684571	0.7	rs17684730	ENSG00000231441.1	RP11-472M19.2	4.72	2.66e-06	0.000248	0.23	0.14	Schizophrenia;	chr6:56804425	chr6:56844002~56864078:+
BRCA	cis	rs17684571	0.7	rs4371846	ENSG00000231441.1	RP11-472M19.2	4.72	2.66e-06	0.000248	0.23	0.14	Schizophrenia;	chr6:56805767	chr6:56844002~56864078:+
BRCA	cis	rs9840812	0.769	rs606725	ENSG00000239213.4	NCK1-AS1	-4.72	2.66e-06	0.000248	-0.16	-0.14	Fibrinogen levels;	chr3:136267245	chr3:136841726~136862054:-
BRCA	cis	rs1707322	1	rs12403666	ENSG00000234329.1	RP11-767N6.2	4.72	2.66e-06	0.000248	0.15	0.14	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45965949	chr1:45651039~45651826:-
BRCA	cis	rs597539	0.654	rs655816	ENSG00000261625.1	RP11-554A11.4	-4.72	2.66e-06	0.000248	-0.14	-0.14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68858937	chr11:69000765~69002048:-
BRCA	cis	rs4819052	0.851	rs2838836	ENSG00000184274.3	LINC00315	-4.72	2.66e-06	0.000248	-0.2	-0.14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245960	chr21:45300245~45305257:-
BRCA	cis	rs7818688	1	rs16917233	ENSG00000253528.2	RP11-347C18.4	4.72	2.66e-06	0.000248	0.22	0.14	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95032739	chr8:94974573~94974853:-
BRCA	cis	rs10129255	1	rs10134517	ENSG00000280411.1	IGHV1-69-2	-4.72	2.66e-06	0.000248	-0.11	-0.14	Kawasaki disease;	chr14:106718498	chr14:106762092~106762588:-
BRCA	cis	rs10129255	0.5	rs10131875	ENSG00000211959.2	IGHV4-39	4.72	2.66e-06	0.000248	0.1	0.14	Kawasaki disease;	chr14:106792798	chr14:106421711~106422218:-
BRCA	cis	rs77372450	0.688	rs6875485	ENSG00000251405.2	CTB-109A12.1	4.72	2.67e-06	0.000248	0.24	0.14	Bipolar disorder (body mass index interaction);	chr5:157539587	chr5:157362615~157460078:-
BRCA	cis	rs8180040	0.62	rs9845728	ENSG00000276925.1	RP11-708J19.3	-4.72	2.67e-06	0.000248	-0.17	-0.14	Colorectal cancer;	chr3:47061886	chr3:47469777~47469987:+
BRCA	cis	rs8180040	0.62	rs9844122	ENSG00000276925.1	RP11-708J19.3	-4.72	2.67e-06	0.000248	-0.17	-0.14	Colorectal cancer;	chr3:47066840	chr3:47469777~47469987:+
BRCA	cis	rs4664293	1	rs10432413	ENSG00000226266.5	AC009961.3	-4.72	2.67e-06	0.000248	-0.19	-0.14	Monocyte percentage of white cells;	chr2:159639243	chr2:159670708~159712435:-
BRCA	cis	rs10129255	0.5	rs11628999	ENSG00000211959.2	IGHV4-39	4.72	2.67e-06	0.000248	0.1	0.14	Kawasaki disease;	chr14:106800208	chr14:106421711~106422218:-
BRCA	cis	rs1371614	0.566	rs11902826	ENSG00000229122.1	AGBL5-IT1	-4.72	2.67e-06	0.000248	-0.15	-0.14	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26954677	chr2:27061038~27061815:+
BRCA	cis	rs2153535	0.563	rs7739249	ENSG00000251164.1	HULC	-4.72	2.67e-06	0.000248	-0.18	-0.14	Motion sickness;	chr6:8534357	chr6:8652137~8653846:+
BRCA	cis	rs2337406	0.538	rs10141701	ENSG00000223648.3	IGHV3-64	4.72	2.67e-06	0.000248	0.14	0.14	Alzheimer's disease (late onset);	chr14:106633467	chr14:106643132~106658258:-
BRCA	cis	rs6756513	0.5	rs1377996	ENSG00000231024.1	AC092431.3	-4.72	2.67e-06	0.000248	-0.2	-0.14	Breast cancer;Platelet count;	chr2:69837795	chr2:69700192~69713847:-
BRCA	cis	rs11158026	0.603	rs59323730	ENSG00000258413.1	RP11-665C16.6	-4.72	2.67e-06	0.000248	-0.19	-0.14	Parkinson's disease;	chr14:54972357	chr14:55262767~55272075:-
BRCA	cis	rs11158026	0.603	rs943914	ENSG00000258413.1	RP11-665C16.6	-4.72	2.67e-06	0.000248	-0.19	-0.14	Parkinson's disease;	chr14:54973350	chr14:55262767~55272075:-
BRCA	cis	rs11158026	0.603	rs11846514	ENSG00000258413.1	RP11-665C16.6	-4.72	2.67e-06	0.000248	-0.19	-0.14	Parkinson's disease;	chr14:54973622	chr14:55262767~55272075:-
BRCA	cis	rs4938330	0.629	rs12269901	ENSG00000254851.1	RP11-109L13.1	4.72	2.67e-06	0.000248	0.18	0.14	Blood protein levels;	chr11:117103213	chr11:117135528~117138582:+
BRCA	cis	rs7772486	0.875	rs2748482	ENSG00000270638.1	RP3-466P17.1	4.72	2.67e-06	0.000249	0.17	0.14	Lobe attachment (rater-scored or self-reported);	chr6:146015396	chr6:145735570~145737218:+
BRCA	cis	rs7772486	0.875	rs1331637	ENSG00000270638.1	RP3-466P17.1	4.72	2.67e-06	0.000249	0.17	0.14	Lobe attachment (rater-scored or self-reported);	chr6:146015951	chr6:145735570~145737218:+
BRCA	cis	rs7772486	0.846	rs1331636	ENSG00000270638.1	RP3-466P17.1	4.72	2.67e-06	0.000249	0.17	0.14	Lobe attachment (rater-scored or self-reported);	chr6:146017690	chr6:145735570~145737218:+
BRCA	cis	rs11051970	0.559	rs11051932	ENSG00000274964.1	RP11-817I4.1	-4.72	2.67e-06	0.000249	-0.19	-0.14	Response to tocilizumab in rheumatoid arthritis;	chr12:32320701	chr12:32339368~32340724:+
BRCA	cis	rs4948275	0.742	rs2250815	ENSG00000237233.2	TMEM26-AS1	-4.72	2.67e-06	0.000249	-0.17	-0.14	Night sleep phenotypes;	chr10:61479806	chr10:61452639~61481956:+
BRCA	cis	rs7226408	1	rs72883547	ENSG00000267707.2	RP11-95O2.5	4.72	2.67e-06	0.000249	0.24	0.14	Obesity-related traits;	chr18:36781264	chr18:37243776~37247506:+
BRCA	cis	rs12744310	0.887	rs12043581	ENSG00000235358.1	RP11-399E6.1	4.72	2.67e-06	0.000249	0.21	0.14	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41322593	chr1:41242373~41284861:+
BRCA	cis	rs13113518	1	rs939823	ENSG00000249700.7	SRD5A3-AS1	4.72	2.67e-06	0.000249	0.18	0.14	Height;	chr4:55487368	chr4:55363971~55395847:-
BRCA	cis	rs7646881	0.812	rs75267618	ENSG00000240207.5	RP11-379F4.4	-4.72	2.67e-06	0.000249	-0.23	-0.14	Tetralogy of Fallot;	chr3:158726027	chr3:158732263~158784070:+
BRCA	cis	rs6840360	0.582	rs2709827	ENSG00000278978.1	RP11-164P12.5	-4.72	2.68e-06	0.000249	-0.16	-0.14	Intelligence (multi-trait analysis);	chr4:151410100	chr4:151669786~151670503:+
BRCA	cis	rs6430585	0.528	rs309159	ENSG00000231890.6	DARS-AS1	-4.72	2.68e-06	0.000249	-0.22	-0.14	Corneal structure;	chr2:135927370	chr2:135985176~136022593:+
BRCA	cis	rs1322639	0.614	rs6900964	ENSG00000223485.1	RP11-417E7.1	-4.72	2.68e-06	0.000249	-0.21	-0.14	Pulse pressure;	chr6:169166668	chr6:169158092~169162924:-
BRCA	cis	rs11638815	0.626	rs11635624	ENSG00000259429.4	UBE2Q2P2	-4.72	2.68e-06	0.000249	-0.14	-0.14	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82646980	chr15:82355142~82420075:+
BRCA	cis	rs308403	0.509	rs9990804	ENSG00000224786.1	CETN4P	4.72	2.68e-06	0.000249	0.19	0.14	Blood protein levels;	chr4:122750829	chr4:122730548~122732193:-
BRCA	cis	rs2153535	0.58	rs6421948	ENSG00000251164.1	HULC	-4.72	2.68e-06	0.000249	-0.18	-0.14	Motion sickness;	chr6:8530787	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.58	rs6421949	ENSG00000251164.1	HULC	-4.72	2.68e-06	0.000249	-0.18	-0.14	Motion sickness;	chr6:8531536	chr6:8652137~8653846:+
BRCA	cis	rs4664293	0.565	rs10165197	ENSG00000230783.1	AC009961.2	4.72	2.68e-06	0.000249	0.17	0.14	Monocyte percentage of white cells;	chr2:159537137	chr2:159689217~159690291:-
BRCA	cis	rs7824557	0.628	rs11250129	ENSG00000154316.13	TDH	-4.72	2.68e-06	0.000249	-0.18	-0.14	Retinal vascular caliber;	chr8:11344645	chr8:11339637~11368452:+
BRCA	cis	rs1322639	0.614	rs6900200	ENSG00000223485.1	RP11-417E7.1	-4.72	2.68e-06	0.000249	-0.21	-0.14	Pulse pressure;	chr6:169166078	chr6:169158092~169162924:-
BRCA	cis	rs2832191	0.72	rs4643617	ENSG00000215533.7	LINC00189	4.72	2.68e-06	0.00025	0.16	0.14	Dental caries;	chr21:29112957	chr21:29193480~29288205:+
BRCA	cis	rs2832191	0.791	rs2832187	ENSG00000215533.7	LINC00189	4.72	2.68e-06	0.00025	0.16	0.14	Dental caries;	chr21:29113222	chr21:29193480~29288205:+
BRCA	cis	rs1395	0.71	rs72817533	ENSG00000234072.1	AC074117.10	-4.72	2.68e-06	0.00025	-0.16	-0.14	Blood metabolite levels;	chr2:27259744	chr2:27356246~27367622:+
BRCA	cis	rs9467773	0.62	rs9295701	ENSG00000241549.7	GUSBP2	4.72	2.68e-06	0.00025	0.15	0.14	Intelligence (multi-trait analysis);	chr6:26627280	chr6:26871484~26956554:-
BRCA	cis	rs2278170	1	rs331525	ENSG00000225101.4	OR52K3P	-4.72	2.68e-06	0.00025	-0.2	-0.14	Amyotrophic lateral sclerosis;	chr11:4458605	chr11:4474813~4475755:+
BRCA	cis	rs875971	0.83	rs427575	ENSG00000223473.2	GS1-124K5.3	4.72	2.69e-06	0.00025	0.11	0.14	Aortic root size;	chr7:66054232	chr7:66491049~66493566:-
BRCA	cis	rs2839186	0.609	rs2839189	ENSG00000228137.1	AP001469.7	-4.72	2.69e-06	0.00025	-0.17	-0.14	Testicular germ cell tumor;	chr21:46274443	chr21:46246890~46247682:+
BRCA	cis	rs6756513	0.5	rs1013083	ENSG00000231024.1	AC092431.3	-4.72	2.69e-06	0.00025	-0.21	-0.14	Breast cancer;Platelet count;	chr2:69872292	chr2:69700192~69713847:-
BRCA	cis	rs11250097	0.549	rs11778177	ENSG00000254866.2	DEFB109P3	4.72	2.69e-06	0.00025	0.2	0.14	Neuroticism;	chr8:11452853	chr8:12150895~12151134:-
BRCA	cis	rs9467773	0.62	rs2504592	ENSG00000241549.7	GUSBP2	4.72	2.69e-06	0.00025	0.15	0.14	Intelligence (multi-trait analysis);	chr6:26640723	chr6:26871484~26956554:-
BRCA	cis	rs3796352	1	rs13058817	ENSG00000242142.1	SERBP1P3	-4.72	2.69e-06	0.00025	-0.29	-0.14	Immune reponse to smallpox (secreted IL-2);	chr3:52990123	chr3:53064283~53065091:-
BRCA	cis	rs4948275	0.773	rs2606077	ENSG00000237233.2	TMEM26-AS1	-4.72	2.69e-06	0.00025	-0.19	-0.14	Night sleep phenotypes;	chr10:61528621	chr10:61452639~61481956:+
BRCA	cis	rs6686842	0.93	rs11209342	ENSG00000235358.1	RP11-399E6.1	4.72	2.69e-06	0.00025	0.19	0.14	Height;	chr1:41003994	chr1:41242373~41284861:+
BRCA	cis	rs57221529	0.766	rs4957053	ENSG00000271781.1	CTD-2589H19.6	-4.72	2.69e-06	0.00025	-0.22	-0.14	Lung disease severity in cystic fibrosis;	chr5:575812	chr5:675826~676616:+
BRCA	cis	rs7200543	1	rs72774845	ENSG00000260872.1	RP11-680G24.5	-4.72	2.69e-06	0.00025	-0.16	-0.14	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15054097	chr16:15018106~15020488:-
BRCA	cis	rs442309	0.807	rs224069	ENSG00000238280.1	RP11-436D10.3	-4.72	2.69e-06	0.00025	-0.2	-0.14	Vogt-Koyanagi-Harada syndrome;	chr10:62748366	chr10:62793562~62805887:-
BRCA	cis	rs871012	0.502	rs951959	ENSG00000248544.2	CTB-47B11.3	-4.72	2.69e-06	0.00025	-0.19	-0.14	IgG glycosylation;	chr5:157462211	chr5:157375741~157384950:-
BRCA	cis	rs8180040	0.62	rs9875235	ENSG00000276925.1	RP11-708J19.3	-4.72	2.69e-06	0.00025	-0.17	-0.14	Colorectal cancer;	chr3:47042131	chr3:47469777~47469987:+
BRCA	cis	rs1867631	1	rs10889640	ENSG00000248458.2	RP4-598P13.1	4.72	2.69e-06	0.000251	0.15	0.14	Menopause (age at onset);	chr1:66662168	chr1:66665864~66677027:-
BRCA	cis	rs7811142	0.83	rs73401450	ENSG00000078319.8	PMS2P1	-4.72	2.69e-06	0.000251	-0.23	-0.14	Platelet count;	chr7:100384236	chr7:100320992~100341908:-
BRCA	cis	rs7226408	1	rs72883550	ENSG00000267707.2	RP11-95O2.5	4.72	2.69e-06	0.000251	0.24	0.14	Obesity-related traits;	chr18:36781584	chr18:37243776~37247506:+
BRCA	cis	rs4713118	0.513	rs149942	ENSG00000219392.1	RP1-265C24.5	-4.72	2.7e-06	0.000251	-0.2	-0.14	Parkinson's disease;	chr6:28033832	chr6:28115628~28116551:+
BRCA	cis	rs4713118	0.513	rs149944	ENSG00000219392.1	RP1-265C24.5	-4.72	2.7e-06	0.000251	-0.2	-0.14	Parkinson's disease;	chr6:28035040	chr6:28115628~28116551:+
BRCA	cis	rs4713118	0.513	rs149945	ENSG00000219392.1	RP1-265C24.5	-4.72	2.7e-06	0.000251	-0.2	-0.14	Parkinson's disease;	chr6:28035075	chr6:28115628~28116551:+
BRCA	cis	rs886774	0.717	rs6964905	ENSG00000273055.1	CTB-13F3.1	4.72	2.7e-06	0.000251	0.15	0.14	Ulcerative colitis;	chr7:107859316	chr7:107942116~107942740:+
BRCA	cis	rs829883	0.714	rs249847	ENSG00000227825.4	SLC9A7P1	4.72	2.7e-06	0.000251	0.17	0.14	Colorectal adenoma (advanced);	chr12:98473938	chr12:98453835~98457145:-
BRCA	cis	rs6088580	0.634	rs6120644	ENSG00000276073.1	RP5-1125A11.7	-4.72	2.7e-06	0.000251	-0.16	-0.14	Glomerular filtration rate (creatinine);	chr20:34436005	chr20:33985617~33988989:-
BRCA	cis	rs853679	0.55	rs1150689	ENSG00000216901.1	AL022393.7	4.72	2.7e-06	0.000251	0.2	0.14	Depression;	chr6:28197321	chr6:28176188~28176674:+
BRCA	cis	rs853679	0.55	rs1225599	ENSG00000216901.1	AL022393.7	4.72	2.7e-06	0.000251	0.2	0.14	Depression;	chr6:28197412	chr6:28176188~28176674:+
BRCA	cis	rs853679	0.574	rs1233705	ENSG00000216901.1	AL022393.7	4.72	2.7e-06	0.000251	0.2	0.14	Depression;	chr6:28198669	chr6:28176188~28176674:+
BRCA	cis	rs2403083	0.626	rs10091710	ENSG00000258256.1	RP11-219B4.5	-4.72	2.7e-06	0.000251	-0.18	-0.14	Plasma amyloid beta peptide concentrations (ABx-40);	chr8:85180382	chr8:85222446~85245717:-
BRCA	cis	rs4664293	0.967	rs13020365	ENSG00000224152.1	AC009506.1	-4.72	2.7e-06	0.000251	-0.16	-0.14	Monocyte percentage of white cells;	chr2:159619893	chr2:159615296~159617082:+
BRCA	cis	rs4664293	1	rs13014418	ENSG00000224152.1	AC009506.1	-4.72	2.7e-06	0.000251	-0.16	-0.14	Monocyte percentage of white cells;	chr2:159627174	chr2:159615296~159617082:+
BRCA	cis	rs6832769	0.961	rs11133382	ENSG00000272969.1	RP11-528I4.2	4.72	2.7e-06	0.000251	0.17	0.14	Personality dimensions;	chr4:55450813	chr4:55547112~55547889:+
BRCA	cis	rs6890684	0.503	rs256377	ENSG00000215032.2	GNL3LP1	4.72	2.7e-06	0.000251	0.18	0.14	Intelligence (multi-trait analysis);	chr5:61210447	chr5:60891935~60893577:-
BRCA	cis	rs2880765	0.835	rs4536419	ENSG00000202081.1	RNU6-1280P	4.72	2.7e-06	0.000251	0.17	0.14	Coronary artery disease;	chr15:85496240	chr15:85651522~85651628:-
BRCA	cis	rs7818688	0.578	rs35518242	ENSG00000253528.2	RP11-347C18.4	-4.72	2.7e-06	0.000251	-0.23	-0.14	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95066867	chr8:94974573~94974853:-
BRCA	cis	rs11758351	0.518	rs79922979	ENSG00000241549.7	GUSBP2	-4.72	2.7e-06	0.000251	-0.21	-0.14	Renal underexcretion gout;Gout;	chr6:26224747	chr6:26871484~26956554:-
BRCA	cis	rs115575488	0.61	rs12741635	ENSG00000231365.4	RP11-418J17.1	4.72	2.7e-06	0.000251	0.21	0.14	Lobe attachment (rater-scored or self-reported);	chr1:119051198	chr1:119140396~119275973:+
BRCA	cis	rs2562456	0.641	rs62107468	ENSG00000268658.4	LINC00664	4.72	2.7e-06	0.000251	0.24	0.14	Pain;	chr19:21307177	chr19:21483374~21503238:+
BRCA	cis	rs721917	0.586	rs2758550	ENSG00000278616.1	BEND3P3	-4.72	2.7e-06	0.000251	-0.14	-0.14	Chronic obstructive pulmonary disease;	chr10:79932606	chr10:79682997~79685436:+
BRCA	cis	rs2278170	1	rs331530	ENSG00000225101.4	OR52K3P	-4.72	2.7e-06	0.000251	-0.19	-0.14	Amyotrophic lateral sclerosis;	chr11:4457054	chr11:4474813~4475755:+
BRCA	cis	rs4664293	0.833	rs3764969	ENSG00000224152.1	AC009506.1	-4.72	2.7e-06	0.000251	-0.16	-0.14	Monocyte percentage of white cells;	chr2:159764337	chr2:159615296~159617082:+
BRCA	cis	rs3808502	0.516	rs6983727	ENSG00000154316.13	TDH	-4.72	2.7e-06	0.000251	-0.19	-0.14	Neuroticism;	chr8:11558303	chr8:11339637~11368452:+
BRCA	cis	rs904251	0.605	rs4257849	ENSG00000204110.6	RP1-153P14.8	-4.72	2.71e-06	0.000252	-0.18	-0.14	Cognitive performance;	chr6:37443193	chr6:37507348~37535616:+
BRCA	cis	rs8054556	0.787	rs12444108	ENSG00000261367.1	RP11-455F5.4	-4.72	2.71e-06	0.000252	-0.16	-0.14	Autism spectrum disorder or schizophrenia;	chr16:30016373	chr16:30107675~30110541:+
BRCA	cis	rs3213958	0.621	rs17278047	ENSG00000249274.1	PDLIM1P4	-4.72	2.71e-06	0.000252	-0.24	-0.14	Blood protein levels;	chr3:98880100	chr3:98782188~98783193:+
BRCA	cis	rs3213958	0.574	rs6805605	ENSG00000249274.1	PDLIM1P4	-4.72	2.71e-06	0.000252	-0.24	-0.14	Blood protein levels;	chr3:98884146	chr3:98782188~98783193:+
BRCA	cis	rs6452524	0.967	rs4616871	ENSG00000281327.1	LINC01338	4.72	2.71e-06	0.000252	0.17	0.14	Hypertension (SNP x SNP interaction);	chr5:83175271	chr5:82850864~82859836:-
BRCA	cis	rs7646881	1	rs73015649	ENSG00000240207.5	RP11-379F4.4	-4.72	2.71e-06	0.000252	-0.21	-0.14	Tetralogy of Fallot;	chr3:158732509	chr3:158732263~158784070:+
BRCA	cis	rs6095360	1	rs1997854	ENSG00000222365.1	SNORD12B	4.72	2.71e-06	0.000252	0.16	0.14	Intelligence (multi-trait analysis);	chr20:48985802	chr20:49280319~49280409:+
BRCA	cis	rs2235642	0.891	rs2281231	ENSG00000260989.1	LA16c-395F10.2	-4.72	2.71e-06	0.000252	-0.15	-0.14	Coronary artery disease;	chr16:1551878	chr16:1580527~1610328:+
BRCA	cis	rs7833986	0.501	rs72653981	ENSG00000253603.1	CTA-397H3.3	-4.72	2.71e-06	0.000252	-0.21	-0.14	Height;	chr8:56115255	chr8:56074592~56075274:+
BRCA	cis	rs7833986	0.501	rs2976036	ENSG00000253603.1	CTA-397H3.3	-4.72	2.71e-06	0.000252	-0.21	-0.14	Height;	chr8:56119162	chr8:56074592~56075274:+
BRCA	cis	rs853679	0.76	rs9393910	ENSG00000280107.1	AL022393.9	-4.72	2.71e-06	0.000252	-0.23	-0.14	Depression;	chr6:28240414	chr6:28170845~28172521:+
BRCA	cis	rs2898681	1	rs4864690	ENSG00000248375.1	RP11-177B4.1	-4.72	2.71e-06	0.000252	-0.23	-0.14	Optic nerve measurement (cup area);	chr4:52884604	chr4:52720081~52720831:-
BRCA	cis	rs8141529	1	rs8141529	ENSG00000226471.5	CTA-292E10.6	-4.72	2.71e-06	0.000252	-0.17	-0.14	Lymphocyte counts;	chr22:28873704	chr22:28800683~28848559:+
BRCA	cis	rs4218	0.648	rs877269	ENSG00000277144.1	RP11-59H7.4	-4.72	2.71e-06	0.000252	-0.19	-0.14	Social communication problems;	chr15:59081595	chr15:59115547~59116089:-
BRCA	cis	rs12681366	0.761	rs2197003	ENSG00000253175.1	RP11-267M23.6	4.72	2.71e-06	0.000252	0.18	0.14	Nonsyndromic cleft lip with cleft palate;	chr8:94444758	chr8:94565036~94565715:+
BRCA	cis	rs12681366	0.801	rs2921386	ENSG00000253175.1	RP11-267M23.6	4.72	2.71e-06	0.000252	0.18	0.14	Nonsyndromic cleft lip with cleft palate;	chr8:94446672	chr8:94565036~94565715:+
BRCA	cis	rs6847067	0.965	rs17009247	ENSG00000180769.7	WDFY3-AS2	4.72	2.71e-06	0.000252	0.13	0.14	Oropharynx cancer;	chr4:84746519	chr4:84965682~85011277:+
BRCA	cis	rs11098499	0.954	rs1022145	ENSG00000250412.1	KLHL2P1	4.72	2.71e-06	0.000252	0.17	0.14	Corneal astigmatism;	chr4:119309824	chr4:119334329~119378233:+
BRCA	cis	rs853679	0.76	rs9368563	ENSG00000280107.1	AL022393.9	-4.72	2.71e-06	0.000252	-0.23	-0.14	Depression;	chr6:28240780	chr6:28170845~28172521:+
BRCA	cis	rs853679	0.76	rs9295768	ENSG00000280107.1	AL022393.9	-4.72	2.71e-06	0.000252	-0.23	-0.14	Depression;	chr6:28241324	chr6:28170845~28172521:+
BRCA	cis	rs4664293	0.836	rs73967923	ENSG00000224152.1	AC009506.1	-4.72	2.71e-06	0.000252	-0.17	-0.14	Monocyte percentage of white cells;	chr2:159801754	chr2:159615296~159617082:+
BRCA	cis	rs6452524	0.967	rs2940542	ENSG00000281327.1	LINC01338	4.72	2.71e-06	0.000252	0.17	0.14	Hypertension (SNP x SNP interaction);	chr5:83185734	chr5:82850864~82859836:-
BRCA	cis	rs72615157	0.561	rs113401658	ENSG00000242294.5	STAG3L5P	4.72	2.72e-06	0.000252	0.14	0.14	Lung function (FEV1/FVC);	chr7:100260882	chr7:100336079~100351900:+
BRCA	cis	rs2153535	0.58	rs1119688	ENSG00000251164.1	HULC	-4.72	2.72e-06	0.000252	-0.18	-0.14	Motion sickness;	chr6:8460617	chr6:8652137~8653846:+
BRCA	cis	rs5758511	0.68	rs739146	ENSG00000227370.1	RP4-669P10.19	4.72	2.72e-06	0.000252	0.19	0.14	Birth weight;	chr22:42264408	chr22:42132543~42132998:+
BRCA	cis	rs35740288	0.77	rs4843082	ENSG00000202081.1	RNU6-1280P	4.72	2.72e-06	0.000253	0.19	0.14	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85610159	chr15:85651522~85651628:-
BRCA	cis	rs9990333	1	rs9990333	ENSG00000231464.1	AC024937.4	-4.72	2.72e-06	0.000253	-0.18	-0.14	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196100334	chr3:195996738~195998233:+
BRCA	cis	rs6088580	0.634	rs4911420	ENSG00000276073.1	RP5-1125A11.7	4.72	2.72e-06	0.000253	0.16	0.14	Glomerular filtration rate (creatinine);	chr20:34410848	chr20:33985617~33988989:-
BRCA	cis	rs6847067	0.929	rs1484660	ENSG00000180769.7	WDFY3-AS2	4.72	2.72e-06	0.000253	0.13	0.14	Oropharynx cancer;	chr4:84861028	chr4:84965682~85011277:+
BRCA	cis	rs739496	0.527	rs16941703	ENSG00000226469.1	ADAM1B	4.72	2.72e-06	0.000253	0.18	0.14	Platelet count;	chr12:111880930	chr12:111927018~111929017:+
BRCA	cis	rs739496	0.527	rs61440627	ENSG00000226469.1	ADAM1B	4.72	2.72e-06	0.000253	0.18	0.14	Platelet count;	chr12:111881193	chr12:111927018~111929017:+
BRCA	cis	rs2243480	0.615	rs34363376	ENSG00000275400.1	RP4-756H11.5	4.72	2.72e-06	0.000253	0.27	0.14	Diabetic kidney disease;	chr7:66474549	chr7:66553805~66554199:-
BRCA	cis	rs4218	0.689	rs73418863	ENSG00000277144.1	RP11-59H7.4	-4.72	2.72e-06	0.000253	-0.19	-0.14	Social communication problems;	chr15:59098923	chr15:59115547~59116089:-
BRCA	cis	rs17685	0.725	rs6947068	ENSG00000280388.1	RP11-229D13.3	4.72	2.72e-06	0.000253	0.15	0.14	Coffee consumption (cups per day);Coffee consumption;	chr7:76032738	chr7:76043977~76045963:-
BRCA	cis	rs9467773	0.62	rs2504540	ENSG00000241549.7	GUSBP2	4.72	2.72e-06	0.000253	0.15	0.14	Intelligence (multi-trait analysis);	chr6:26641398	chr6:26871484~26956554:-
BRCA	cis	rs7178909	0.902	rs3853638	ENSG00000259677.1	RP11-493E3.1	-4.72	2.72e-06	0.000253	-0.17	-0.14	Common traits (Other);	chr15:89899908	chr15:89876540~89877285:+
BRCA	cis	rs9291683	0.62	rs4383618	ENSG00000250413.1	RP11-448G15.1	4.72	2.72e-06	0.000253	0.19	0.14	Bone mineral density;	chr4:10123527	chr4:10006482~10009725:+
BRCA	cis	rs736408	0.511	rs12637632	ENSG00000243224.1	RP5-1157M23.2	-4.72	2.72e-06	0.000253	-0.16	-0.14	Bipolar disorder;	chr3:52674057	chr3:52239258~52241097:+
BRCA	cis	rs1635	0.574	rs7757215	ENSG00000220721.1	OR1F12	-4.72	2.72e-06	0.000253	-0.31	-0.14	Schizophrenia;	chr6:28244711	chr6:28073316~28074233:+
BRCA	cis	rs13160562	0.527	rs27581	ENSG00000272109.1	CTD-2260A17.3	-4.72	2.72e-06	0.000253	-0.18	-0.14	Alcohol dependence;	chr5:96772070	chr5:96804353~96806105:+
BRCA	cis	rs17428076	0.874	rs12614709	ENSG00000228389.1	AC068039.4	-4.72	2.73e-06	0.000253	-0.21	-0.14	Myopia;	chr2:171824362	chr2:171773482~171775844:+
BRCA	cis	rs10938353	0.871	rs6820273	ENSG00000273369.1	RP11-700J17.1	-4.72	2.73e-06	0.000253	-0.16	-0.14	Body mass index;	chr4:44581490	chr4:44693946~44694386:-
BRCA	cis	rs6547741	0.935	rs4665384	ENSG00000234072.1	AC074117.10	4.72	2.73e-06	0.000253	0.13	0.14	Oral cavity cancer;	chr2:27625530	chr2:27356246~27367622:+
BRCA	cis	rs875971	0.545	rs4441996	ENSG00000232546.1	RP11-458F8.1	-4.72	2.73e-06	0.000253	-0.13	-0.14	Aortic root size;	chr7:66123233	chr7:66848496~66858136:+
BRCA	cis	rs7772486	0.875	rs2777476	ENSG00000270638.1	RP3-466P17.1	4.72	2.73e-06	0.000253	0.17	0.14	Lobe attachment (rater-scored or self-reported);	chr6:146023888	chr6:145735570~145737218:+
BRCA	cis	rs1075265	0.73	rs7597188	ENSG00000235937.1	AC008280.1	4.72	2.73e-06	0.000253	0.16	0.14	Chronotype;Morning vs. evening chronotype;	chr2:54014732	chr2:54029552~54030682:-
BRCA	cis	rs2242663	0.531	rs2511225	ENSG00000255517.5	CTD-3074O7.5	4.72	2.73e-06	0.000253	0.16	0.14	Bipolar disorder;	chr11:66480960	chr11:66473490~66480233:-
BRCA	cis	rs6991838	0.806	rs17302392	ENSG00000200714.1	Y_RNA	4.72	2.73e-06	0.000253	0.17	0.14	Intelligence (multi-trait analysis);	chr8:65551073	chr8:65592731~65592820:+
BRCA	cis	rs8177876	0.642	rs10514513	ENSG00000261061.1	RP11-303E16.2	-4.72	2.73e-06	0.000254	-0.19	-0.14	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81080578	chr16:81030770~81031485:+
BRCA	cis	rs853679	0.76	rs11962305	ENSG00000216901.1	AL022393.7	4.72	2.73e-06	0.000254	0.22	0.14	Depression;	chr6:28232159	chr6:28176188~28176674:+
BRCA	cis	rs7200543	1	rs35574015	ENSG00000275910.1	RP11-680G24.6	-4.72	2.73e-06	0.000254	-0.17	-0.14	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15052204	chr16:15015828~15016390:-
BRCA	cis	rs56322409	0.865	rs11598475	ENSG00000226688.5	ENTPD1-AS1	4.72	2.73e-06	0.000254	0.17	0.14	Blood metabolite levels;	chr10:95861509	chr10:95753206~96090238:-
BRCA	cis	rs6088580	0.634	rs3736762	ENSG00000276073.1	RP5-1125A11.7	-4.72	2.73e-06	0.000254	-0.16	-0.14	Glomerular filtration rate (creatinine);	chr20:34449531	chr20:33985617~33988989:-
BRCA	cis	rs6088580	0.634	rs6058051	ENSG00000276073.1	RP5-1125A11.7	-4.72	2.73e-06	0.000254	-0.16	-0.14	Glomerular filtration rate (creatinine);	chr20:34457057	chr20:33985617~33988989:-
BRCA	cis	rs172166	0.652	rs476167	ENSG00000219392.1	RP1-265C24.5	-4.72	2.73e-06	0.000254	-0.2	-0.14	Cardiac Troponin-T levels;	chr6:28098110	chr6:28115628~28116551:+
BRCA	cis	rs4218	0.541	rs8030246	ENSG00000277144.1	RP11-59H7.4	-4.72	2.73e-06	0.000254	-0.18	-0.14	Social communication problems;	chr15:59049447	chr15:59115547~59116089:-
BRCA	cis	rs17685	0.753	rs4398845	ENSG00000280388.1	RP11-229D13.3	-4.72	2.74e-06	0.000254	-0.15	-0.14	Coffee consumption (cups per day);Coffee consumption;	chr7:76087463	chr7:76043977~76045963:-
BRCA	cis	rs10946940	1	rs10946940	ENSG00000220721.1	OR1F12	-4.72	2.74e-06	0.000254	-0.17	-0.14	Systemic lupus erythematosus;	chr6:27592808	chr6:28073316~28074233:+
BRCA	cis	rs1387259	0.619	rs2130095	ENSG00000240399.1	RP1-228P16.1	-4.72	2.74e-06	0.000254	-0.15	-0.14	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48244972	chr12:48054813~48055591:-
BRCA	cis	rs1707322	1	rs785493	ENSG00000234329.1	RP11-767N6.2	-4.72	2.74e-06	0.000254	-0.16	-0.14	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46119187	chr1:45651039~45651826:-
BRCA	cis	rs1707322	0.964	rs785496	ENSG00000234329.1	RP11-767N6.2	-4.72	2.74e-06	0.000254	-0.16	-0.14	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46122334	chr1:45651039~45651826:-
BRCA	cis	rs1707322	1	rs785497	ENSG00000234329.1	RP11-767N6.2	-4.72	2.74e-06	0.000254	-0.16	-0.14	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46126231	chr1:45651039~45651826:-
BRCA	cis	rs4713118	0.955	rs9380010	ENSG00000216901.1	AL022393.7	4.72	2.74e-06	0.000255	0.2	0.14	Parkinson's disease;	chr6:27715793	chr6:28176188~28176674:+
BRCA	cis	rs9527	0.615	rs7899622	ENSG00000213061.2	PFN1P11	4.72	2.74e-06	0.000255	0.19	0.14	Arsenic metabolism;	chr10:102967576	chr10:102838011~102845473:-
BRCA	cis	rs2430307	0.556	rs3930019	ENSG00000242435.1	UPK3BP1	4.72	2.74e-06	0.000255	0.21	0.14	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index;	chr7:76912293	chr7:77004662~77005774:+
BRCA	cis	rs11239930	0.517	rs678111	ENSG00000230832.3	RP11-325P15.2	-4.72	2.74e-06	0.000255	-0.21	-0.14	AIDS progression;	chr1:147076613	chr1:147082338~147083578:-
BRCA	cis	rs4784227	1	rs4784227	ENSG00000260963.1	RP11-297L17.2	-4.72	2.74e-06	0.000255	-0.18	-0.14	Breast cancer (estrogen-receptor negative);Breast cancer;Parkinson's disease;	chr16:52565276	chr16:52607349~52613908:+
BRCA	cis	rs13113518	0.702	rs78829811	ENSG00000249700.7	SRD5A3-AS1	4.72	2.74e-06	0.000255	0.18	0.14	Height;	chr4:55558258	chr4:55363971~55395847:-
BRCA	cis	rs13113518	0.702	rs75801206	ENSG00000249700.7	SRD5A3-AS1	4.72	2.74e-06	0.000255	0.18	0.14	Height;	chr4:55558259	chr4:55363971~55395847:-
BRCA	cis	rs13113518	0.702	rs34658078	ENSG00000249700.7	SRD5A3-AS1	4.72	2.74e-06	0.000255	0.18	0.14	Height;	chr4:55558261	chr4:55363971~55395847:-
BRCA	cis	rs7200786	0.667	rs12448611	ENSG00000274038.1	RP11-66H6.4	4.71	2.75e-06	0.000255	0.16	0.14	Systemic lupus erythematosus;Multiple sclerosis;	chr16:10986594	chr16:11056556~11057034:+
BRCA	cis	rs7011507	0.541	rs56399102	ENSG00000279881.1	RP11-513O13.1	-4.71	2.75e-06	0.000255	-0.23	-0.14	Inflammatory bowel disease;Ulcerative colitis;	chr8:48349828	chr8:48428143~48431041:-
BRCA	cis	rs12681366	0.801	rs1372048	ENSG00000253175.1	RP11-267M23.6	4.71	2.75e-06	0.000255	0.18	0.14	Nonsyndromic cleft lip with cleft palate;	chr8:94455013	chr8:94565036~94565715:+
BRCA	cis	rs6490294	0.904	rs12423126	ENSG00000234608.6	MAPKAPK5-AS1	4.71	2.75e-06	0.000255	0.18	0.14	Mean platelet volume;	chr12:111991665	chr12:111839764~111842902:-
BRCA	cis	rs2446066	0.872	rs2002555	ENSG00000257379.1	RP11-793H13.8	4.71	2.75e-06	0.000255	0.23	0.14	Red blood cell count;	chr12:53423453	chr12:53441741~53467528:+
BRCA	cis	rs6714710	0.603	rs17489984	ENSG00000230606.9	AC159540.1	-4.71	2.75e-06	0.000255	-0.17	-0.14	Posterior cortical atrophy and Alzheimer's disease;	chr2:97804901	chr2:97416165~97433527:-
BRCA	cis	rs385076	0.527	rs10779914	ENSG00000272716.1	RP11-563N4.1	-4.71	2.75e-06	0.000255	-0.17	-0.14	Interleukin-18 levels;	chr2:31880971	chr2:32165046~32165757:-
BRCA	cis	rs10129255	1	rs10129407	ENSG00000274576.2	IGHV2-70	4.71	2.75e-06	0.000255	0.13	0.14	Kawasaki disease;	chr14:106767956	chr14:106770577~106771020:-
BRCA	cis	rs6095360	0.934	rs6012581	ENSG00000222365.1	SNORD12B	-4.71	2.75e-06	0.000255	-0.16	-0.14	Intelligence (multi-trait analysis);	chr20:49011308	chr20:49280319~49280409:+
BRCA	cis	rs6088580	0.602	rs6059840	ENSG00000276073.1	RP5-1125A11.7	-4.71	2.75e-06	0.000255	-0.16	-0.14	Glomerular filtration rate (creatinine);	chr20:34442600	chr20:33985617~33988989:-
BRCA	cis	rs6832769	0.925	rs60992571	ENSG00000223305.1	RN7SKP30	-4.71	2.75e-06	0.000255	-0.18	-0.14	Personality dimensions;	chr4:55574645	chr4:55540502~55540835:-
BRCA	cis	rs6832769	0.961	rs11133382	ENSG00000223305.1	RN7SKP30	4.71	2.75e-06	0.000255	0.18	0.14	Personality dimensions;	chr4:55450813	chr4:55540502~55540835:-
BRCA	cis	rs7577696	0.671	rs13427170	ENSG00000272716.1	RP11-563N4.1	-4.71	2.75e-06	0.000255	-0.16	-0.14	Inflammatory biomarkers;	chr2:32173041	chr2:32165046~32165757:-
BRCA	cis	rs6095360	0.934	rs3818224	ENSG00000222365.1	SNORD12B	-4.71	2.75e-06	0.000255	-0.16	-0.14	Intelligence (multi-trait analysis);	chr20:49011633	chr20:49280319~49280409:+
BRCA	cis	rs3764021	1	rs3764021	ENSG00000278635.1	CTD-2318O12.1	-4.71	2.75e-06	0.000256	-0.14	-0.14	Type 1 diabetes;	chr12:9681032	chr12:9415641~9416718:+
BRCA	cis	rs9467773	0.62	rs2504599	ENSG00000241549.7	GUSBP2	4.71	2.75e-06	0.000256	0.15	0.14	Intelligence (multi-trait analysis);	chr6:26640832	chr6:26871484~26956554:-
BRCA	cis	rs6756513	0.5	rs2124007	ENSG00000231024.1	AC092431.3	-4.71	2.75e-06	0.000256	-0.21	-0.14	Breast cancer;Platelet count;	chr2:69880277	chr2:69700192~69713847:-
BRCA	cis	rs12030196	0.827	rs932772	ENSG00000230812.4	LINC01358	4.71	2.75e-06	0.000256	0.15	0.14	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr1:58968221	chr1:59020387~59044614:+
BRCA	cis	rs12681366	0.537	rs10956913	ENSG00000253704.1	RP11-267M23.4	4.71	2.75e-06	0.000256	0.16	0.14	Nonsyndromic cleft lip with cleft palate;	chr8:94471459	chr8:94553722~94569745:+
BRCA	cis	rs9990333	0.562	rs12632706	ENSG00000242086.7	LINC00969	4.71	2.75e-06	0.000256	0.16	0.14	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196088723	chr3:195658062~195739964:+
BRCA	cis	rs7116495	0.609	rs577435	ENSG00000248671.6	ALG1L9P	-4.71	2.76e-06	0.000256	-0.36	-0.14	Severe influenza A (H1N1) infection;	chr11:72083635	chr11:71794363~71818238:-
BRCA	cis	rs2243480	0.908	rs313822	ENSG00000222364.1	RNU6-96P	-4.71	2.76e-06	0.000256	-0.27	-0.14	Diabetic kidney disease;	chr7:66108952	chr7:66395191~66395286:+
BRCA	cis	rs2229238	0.911	rs7556449	ENSG00000272030.1	RP1-178F15.4	4.71	2.76e-06	0.000256	0.2	0.14	Coronary heart disease;	chr1:154533410	chr1:153631438~153634397:-
BRCA	cis	rs6840360	0.642	rs2724578	ENSG00000251603.1	RP11-164P12.4	-4.71	2.76e-06	0.000256	-0.13	-0.14	Intelligence (multi-trait analysis);	chr4:151446152	chr4:151667224~151670502:+
BRCA	cis	rs6840360	0.574	rs2709844	ENSG00000251603.1	RP11-164P12.4	-4.71	2.76e-06	0.000256	-0.13	-0.14	Intelligence (multi-trait analysis);	chr4:151447060	chr4:151667224~151670502:+
BRCA	cis	rs2562456	0.833	rs4321312	ENSG00000268658.4	LINC00664	4.71	2.76e-06	0.000256	0.24	0.14	Pain;	chr19:21336614	chr19:21483374~21503238:+
BRCA	cis	rs783540	0.656	rs783524	ENSG00000276710.3	CSPG4P8	4.71	2.76e-06	0.000256	0.16	0.14	Schizophrenia;	chr15:82615393	chr15:82459472~82477258:+
BRCA	cis	rs783540	0.592	rs2567632	ENSG00000276710.3	CSPG4P8	4.71	2.76e-06	0.000256	0.16	0.14	Schizophrenia;	chr15:82616053	chr15:82459472~82477258:+
BRCA	cis	rs2235544	0.565	rs928441	ENSG00000225183.1	RP4-758J24.4	-4.71	2.76e-06	0.000256	-0.17	-0.14	Thyroid hormone levels;Multiple myeloma (hyperdiploidy);	chr1:54007695	chr1:54089856~54090093:+
BRCA	cis	rs10946940	0.93	rs10807029	ENSG00000220721.1	OR1F12	-4.71	2.76e-06	0.000256	-0.17	-0.14	Systemic lupus erythematosus;	chr6:27605684	chr6:28073316~28074233:+
BRCA	cis	rs7772486	0.875	rs2224120	ENSG00000270638.1	RP3-466P17.1	4.71	2.76e-06	0.000256	0.17	0.14	Lobe attachment (rater-scored or self-reported);	chr6:146022144	chr6:145735570~145737218:+
BRCA	cis	rs6840360	0.642	rs2709838	ENSG00000251603.1	RP11-164P12.4	-4.71	2.76e-06	0.000256	-0.13	-0.14	Intelligence (multi-trait analysis);	chr4:151450212	chr4:151667224~151670502:+
BRCA	cis	rs17767294	0.708	rs72851138	ENSG00000204709.4	LINC01556	4.71	2.76e-06	0.000256	0.38	0.14	Parkinson's disease;	chr6:28074876	chr6:28943877~28944537:+
BRCA	cis	rs17767294	0.708	rs72851139	ENSG00000204709.4	LINC01556	4.71	2.76e-06	0.000256	0.38	0.14	Parkinson's disease;	chr6:28074920	chr6:28943877~28944537:+
BRCA	cis	rs17767294	0.708	rs72851156	ENSG00000204709.4	LINC01556	4.71	2.76e-06	0.000256	0.38	0.14	Parkinson's disease;	chr6:28092308	chr6:28943877~28944537:+
BRCA	cis	rs17767294	0.708	rs72851158	ENSG00000204709.4	LINC01556	4.71	2.76e-06	0.000256	0.38	0.14	Parkinson's disease;	chr6:28092707	chr6:28943877~28944537:+
BRCA	cis	rs17767294	0.708	rs72851160	ENSG00000204709.4	LINC01556	4.71	2.76e-06	0.000256	0.38	0.14	Parkinson's disease;	chr6:28100063	chr6:28943877~28944537:+
BRCA	cis	rs9468199	0.51	rs72851161	ENSG00000204709.4	LINC01556	4.71	2.76e-06	0.000256	0.38	0.14	Parkinson's disease;	chr6:28103345	chr6:28943877~28944537:+
BRCA	cis	rs17767294	0.708	rs77689085	ENSG00000204709.4	LINC01556	4.71	2.76e-06	0.000256	0.38	0.14	Parkinson's disease;	chr6:28104758	chr6:28943877~28944537:+
BRCA	cis	rs2115630	1	rs11854291	ENSG00000259728.4	LINC00933	-4.71	2.76e-06	0.000256	-0.16	-0.14	P wave terminal force;	chr15:84820477	chr15:84570649~84580175:+
BRCA	cis	rs60695258	0.55	rs4693800	ENSG00000251411.1	RP11-397E7.4	4.71	2.76e-06	0.000256	0.16	0.14	Hematocrit;	chr4:86994468	chr4:86913266~86914817:-
BRCA	cis	rs7267979	0.932	rs6115214	ENSG00000125804.12	FAM182A	4.71	2.76e-06	0.000256	0.19	0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25576790	chr20:26054655~26086917:+
BRCA	cis	rs6088580	0.634	rs6059860	ENSG00000276073.1	RP5-1125A11.7	-4.71	2.76e-06	0.000256	-0.16	-0.14	Glomerular filtration rate (creatinine);	chr20:34476025	chr20:33985617~33988989:-
BRCA	cis	rs6088580	0.624	rs6120645	ENSG00000276073.1	RP5-1125A11.7	-4.71	2.76e-06	0.000256	-0.16	-0.14	Glomerular filtration rate (creatinine);	chr20:34437366	chr20:33985617~33988989:-
BRCA	cis	rs9307551	0.948	rs10022663	ENSG00000250334.4	LINC00989	-4.71	2.76e-06	0.000256	-0.21	-0.14	Refractive error;	chr4:79568460	chr4:79492416~79576460:+
BRCA	cis	rs7267979	0.789	rs4815429	ENSG00000274973.1	RP13-401N8.7	4.71	2.76e-06	0.000256	0.16	0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25540975	chr20:25845497~25845862:+
BRCA	cis	rs1005277	0.505	rs200931	ENSG00000226578.1	RP11-258F22.1	-4.71	2.76e-06	0.000256	-0.16	-0.14	Extrinsic epigenetic age acceleration;	chr10:37839506	chr10:37775371~37784131:-
BRCA	cis	rs6832769	0.767	rs6850524	ENSG00000223305.1	RN7SKP30	4.71	2.76e-06	0.000256	0.18	0.14	Personality dimensions;	chr4:55515830	chr4:55540502~55540835:-
BRCA	cis	rs6832769	0.767	rs11133394	ENSG00000223305.1	RN7SKP30	4.71	2.76e-06	0.000256	0.18	0.14	Personality dimensions;	chr4:55517071	chr4:55540502~55540835:-
BRCA	cis	rs12612619	0.704	rs11680633	ENSG00000229122.1	AGBL5-IT1	4.71	2.76e-06	0.000256	0.15	0.14	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27001341	chr2:27061038~27061815:+
BRCA	cis	rs6128907	0.898	rs62202466	ENSG00000224635.1	RP4-564F22.5	4.71	2.76e-06	0.000256	0.22	0.14	Liver fibrosis in pediatric non-alcoholic fatty acid liver disease;	chr20:38753004	chr20:38406011~38416797:-
BRCA	cis	rs6128907	1	rs62202467	ENSG00000224635.1	RP4-564F22.5	4.71	2.76e-06	0.000256	0.22	0.14	Liver fibrosis in pediatric non-alcoholic fatty acid liver disease;	chr20:38753138	chr20:38406011~38416797:-
BRCA	cis	rs2286503	1	rs1029740	ENSG00000226329.2	AC005682.6	4.71	2.76e-06	0.000256	0.13	0.14	Fibrinogen;	chr7:22833967	chr7:22863874~22881350:-
BRCA	cis	rs9467773	1	rs1321479	ENSG00000124549.13	BTN2A3P	-4.71	2.76e-06	0.000256	-0.14	-0.14	Intelligence (multi-trait analysis);	chr6:26501669	chr6:26421391~26432383:+
BRCA	cis	rs12681366	0.801	rs2919657	ENSG00000253175.1	RP11-267M23.6	4.71	2.76e-06	0.000256	0.18	0.14	Nonsyndromic cleft lip with cleft palate;	chr8:94460724	chr8:94565036~94565715:+
BRCA	cis	rs3768617	0.51	rs10752895	ENSG00000224468.3	RP11-181K3.4	-4.71	2.77e-06	0.000257	-0.16	-0.14	Fuchs's corneal dystrophy;	chr1:183099370	chr1:183138402~183141282:-
BRCA	cis	rs7686660	0.911	rs955722	ENSG00000250326.1	RP11-284M14.1	-4.71	2.77e-06	0.000257	-0.18	-0.14	Asthma;	chr4:143011987	chr4:142933195~143184861:-
BRCA	cis	rs12497850	0.829	rs8926	ENSG00000225399.4	RP11-3B7.1	4.71	2.77e-06	0.000257	0.14	0.14	Parkinson's disease;	chr3:49015352	chr3:49260085~49261316:+
BRCA	cis	rs60695258	0.55	rs4693798	ENSG00000251411.1	RP11-397E7.4	4.71	2.77e-06	0.000257	0.16	0.14	Hematocrit;	chr4:86993136	chr4:86913266~86914817:-
BRCA	cis	rs867186	1	rs55734215	ENSG00000126005.14	MMP24-AS1	-4.71	2.77e-06	0.000257	-0.27	-0.14	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:34997634	chr20:35216462~35278131:-
BRCA	cis	rs7674212	0.539	rs6821617	ENSG00000251288.2	RP11-10L12.2	-4.71	2.77e-06	0.000257	-0.17	-0.14	Type 2 diabetes;	chr4:103207253	chr4:102751401~102752641:+
BRCA	cis	rs11673344	0.504	rs7245882	ENSG00000276846.1	CTD-3220F14.3	-4.71	2.77e-06	0.000257	-0.17	-0.14	Obesity-related traits;	chr19:37089513	chr19:37314868~37315620:-
BRCA	cis	rs5751614	0.557	rs5759665	ENSG00000240160.3	RN7SL263P	4.71	2.77e-06	0.000257	0.18	0.14	Height;	chr22:23260033	chr22:23261782~23262071:-
BRCA	cis	rs1387259	0.839	rs7487682	ENSG00000226413.2	OR8T1P	-4.71	2.77e-06	0.000257	-0.19	-0.14	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48185882	chr12:48442030~48442947:-
BRCA	cis	rs2073316	0.6	rs12469125	ENSG00000272716.1	RP11-563N4.1	4.71	2.77e-06	0.000257	0.15	0.14	Interleukin-18 levels;	chr2:31479740	chr2:32165046~32165757:-
BRCA	cis	rs6847067	0.696	rs13114115	ENSG00000180769.7	WDFY3-AS2	4.71	2.77e-06	0.000257	0.13	0.14	Oropharynx cancer;	chr4:84911274	chr4:84965682~85011277:+
BRCA	cis	rs1713985	0.698	rs1277281	ENSG00000269949.1	RP11-738E22.3	-4.71	2.77e-06	0.000257	-0.29	-0.14	Age-related macular degeneration;	chr4:56989926	chr4:56960927~56961373:-
BRCA	cis	rs7918232	0.941	rs7907988	ENSG00000262412.1	RP11-85G18.6	4.71	2.77e-06	0.000257	0.24	0.14	Breast cancer;	chr10:27155415	chr10:27243130~27250804:+
BRCA	cis	rs7674212	0.539	rs6854709	ENSG00000248740.4	RP11-328K4.1	4.71	2.77e-06	0.000257	0.16	0.14	Type 2 diabetes;	chr4:103208629	chr4:103256159~103453658:+
BRCA	cis	rs7267979	1	rs2027003	ENSG00000125804.12	FAM182A	4.71	2.77e-06	0.000257	0.19	0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25369862	chr20:26054655~26086917:+
BRCA	cis	rs7267979	1	rs2027004	ENSG00000125804.12	FAM182A	4.71	2.77e-06	0.000257	0.19	0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25369982	chr20:26054655~26086917:+
BRCA	cis	rs7267979	0.934	rs2500399	ENSG00000125804.12	FAM182A	4.71	2.77e-06	0.000257	0.19	0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25374058	chr20:26054655~26086917:+
BRCA	cis	rs7267979	0.844	rs2257649	ENSG00000274414.1	RP5-965G21.4	-4.71	2.77e-06	0.000257	-0.17	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25282821	chr20:25239007~25245229:-
BRCA	cis	rs2073316	0.592	rs68051008	ENSG00000272716.1	RP11-563N4.1	4.71	2.77e-06	0.000257	0.16	0.14	Interleukin-18 levels;	chr2:31455152	chr2:32165046~32165757:-
BRCA	cis	rs843532	0.925	rs1718416	ENSG00000272359.1	U4	4.71	2.77e-06	0.000257	0.27	0.14	Glucose homeostasis traits;	chr3:196792362	chr3:196747192~196747324:-
BRCA	cis	rs5758511	0.68	rs5758684	ENSG00000227370.1	RP4-669P10.19	4.71	2.78e-06	0.000257	0.19	0.14	Birth weight;	chr22:42253503	chr22:42132543~42132998:+
BRCA	cis	rs875971	0.898	rs6977501	ENSG00000236529.1	RP13-254B10.1	-4.71	2.78e-06	0.000257	-0.16	-0.14	Aortic root size;	chr7:66228355	chr7:65840212~65840596:+
BRCA	cis	rs12030196	0.827	rs932773	ENSG00000230812.4	LINC01358	-4.71	2.78e-06	0.000257	-0.15	-0.14	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr1:58967949	chr1:59020387~59044614:+
BRCA	cis	rs4650994	0.544	rs2811311	ENSG00000273384.1	RP5-1098D14.1	-4.71	2.78e-06	0.000258	-0.19	-0.14	HDL cholesterol;HDL cholesterol levels;	chr1:178648202	chr1:178651706~178652282:+
BRCA	cis	rs6570726	0.791	rs443628	ENSG00000270638.1	RP3-466P17.1	4.71	2.78e-06	0.000258	0.17	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145562348	chr6:145735570~145737218:+
BRCA	cis	rs72843506	0.528	rs73981803	ENSG00000261033.1	RP11-209D14.2	4.71	2.78e-06	0.000258	0.27	0.14	Schizophrenia;	chr17:20088952	chr17:20008051~20009234:-
BRCA	cis	rs35146811	0.771	rs1060544	ENSG00000214313.7	AZGP1P1	4.71	2.78e-06	0.000258	0.16	0.14	Coronary artery disease;	chr7:100015853	chr7:99980762~99987535:+
BRCA	cis	rs11051970	0.592	rs58236386	ENSG00000274964.1	RP11-817I4.1	-4.71	2.78e-06	0.000258	-0.19	-0.14	Response to tocilizumab in rheumatoid arthritis;	chr12:32320143	chr12:32339368~32340724:+
BRCA	cis	rs1161098	0.716	rs1161179	ENSG00000256037.1	MRPL40P1	-4.71	2.78e-06	0.000258	-0.24	-0.14	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr12:67432144	chr12:67351436~67352039:+
BRCA	cis	rs896854	0.517	rs1011796	ENSG00000253528.2	RP11-347C18.4	-4.71	2.78e-06	0.000258	-0.16	-0.14	Type 2 diabetes;	chr8:94939045	chr8:94974573~94974853:-
BRCA	cis	rs1722141	0.669	rs788734	ENSG00000237471.1	AC073115.6	4.71	2.78e-06	0.000258	0.19	0.14	Sitting height ratio;	chr7:45993654	chr7:45969657~45980191:+
BRCA	cis	rs2562456	0.917	rs2681389	ENSG00000268535.1	RP11-420K14.3	-4.71	2.78e-06	0.000258	-0.2	-0.14	Pain;	chr19:21509773	chr19:21709522~21710191:+
BRCA	cis	rs6490294	0.95	rs7313892	ENSG00000234608.6	MAPKAPK5-AS1	4.71	2.78e-06	0.000258	0.18	0.14	Mean platelet volume;	chr12:111983548	chr12:111839764~111842902:-
BRCA	cis	rs6490294	0.904	rs73426401	ENSG00000234608.6	MAPKAPK5-AS1	4.71	2.78e-06	0.000258	0.18	0.14	Mean platelet volume;	chr12:111985482	chr12:111839764~111842902:-
BRCA	cis	rs6490294	0.904	rs7956483	ENSG00000234608.6	MAPKAPK5-AS1	4.71	2.78e-06	0.000258	0.18	0.14	Mean platelet volume;	chr12:111986766	chr12:111839764~111842902:-
BRCA	cis	rs2554380	0.628	rs890311	ENSG00000230373.7	GOLGA6L5P	-4.71	2.78e-06	0.000258	-0.17	-0.14	Height;	chr15:83772200	chr15:84507885~84516814:-
BRCA	cis	rs13113518	1	rs13116194	ENSG00000273257.1	RP11-177J6.1	4.71	2.78e-06	0.000258	0.18	0.14	Height;	chr4:55531150	chr4:55387949~55388271:+
BRCA	cis	rs13113518	1	rs13117836	ENSG00000273257.1	RP11-177J6.1	4.71	2.78e-06	0.000258	0.18	0.14	Height;	chr4:55531218	chr4:55387949~55388271:+
BRCA	cis	rs13113518	0.966	rs7668429	ENSG00000273257.1	RP11-177J6.1	4.71	2.78e-06	0.000258	0.18	0.14	Height;	chr4:55531811	chr4:55387949~55388271:+
BRCA	cis	rs4950322	0.58	rs7515160	ENSG00000244371.2	PFN1P8	-4.71	2.78e-06	0.000258	-0.19	-0.14	Protein quantitative trait loci;	chr1:147120714	chr1:146957117~146957659:-
BRCA	cis	rs7191439	0.657	rs3826076	ENSG00000260121.1	RP5-1142A6.9	-4.71	2.78e-06	0.000258	-0.19	-0.14	Plateletcrit;	chr16:88714110	chr16:88718615~88720459:+
BRCA	cis	rs2253762	0.54	rs11200313	ENSG00000226864.1	ATE1-AS1	4.71	2.78e-06	0.000258	0.27	0.14	Breast cancer;	chr10:121996523	chr10:121928312~121951965:+
BRCA	cis	rs2253762	0.54	rs10887036	ENSG00000226864.1	ATE1-AS1	4.71	2.78e-06	0.000258	0.27	0.14	Breast cancer;	chr10:121997570	chr10:121928312~121951965:+
BRCA	cis	rs2253762	0.54	rs10887037	ENSG00000226864.1	ATE1-AS1	4.71	2.78e-06	0.000258	0.27	0.14	Breast cancer;	chr10:121997572	chr10:121928312~121951965:+
BRCA	cis	rs7204230	1	rs8057688	ENSG00000261291.1	RP11-295M3.2	-4.71	2.79e-06	0.000258	-0.18	-0.14	Fibrinogen;	chr16:53294067	chr16:53168522~53169450:+
BRCA	cis	rs7246657	0.524	rs28542490	ENSG00000276846.1	CTD-3220F14.3	4.71	2.79e-06	0.000258	0.22	0.14	Coronary artery calcification;	chr19:36965682	chr19:37314868~37315620:-
BRCA	cis	rs17221829	0.733	rs11600011	ENSG00000280385.1	AP000648.5	-4.71	2.79e-06	0.000258	-0.16	-0.14	Anxiety in major depressive disorder;	chr11:89674812	chr11:90193614~90198120:+
BRCA	cis	rs7226408	0.948	rs11664088	ENSG00000267707.2	RP11-95O2.5	4.71	2.79e-06	0.000258	0.23	0.14	Obesity-related traits;	chr18:36800454	chr18:37243776~37247506:+
BRCA	cis	rs7226408	0.842	rs11660045	ENSG00000267707.2	RP11-95O2.5	4.71	2.79e-06	0.000258	0.23	0.14	Obesity-related traits;	chr18:36801196	chr18:37243776~37247506:+
BRCA	cis	rs7226408	0.948	rs11660227	ENSG00000267707.2	RP11-95O2.5	4.71	2.79e-06	0.000258	0.23	0.14	Obesity-related traits;	chr18:36801860	chr18:37243776~37247506:+
BRCA	cis	rs7226408	0.948	rs72883570	ENSG00000267707.2	RP11-95O2.5	4.71	2.79e-06	0.000258	0.23	0.14	Obesity-related traits;	chr18:36802078	chr18:37243776~37247506:+
BRCA	cis	rs7226408	0.948	rs72883571	ENSG00000267707.2	RP11-95O2.5	4.71	2.79e-06	0.000258	0.23	0.14	Obesity-related traits;	chr18:36802282	chr18:37243776~37247506:+
BRCA	cis	rs7226408	0.948	rs72883572	ENSG00000267707.2	RP11-95O2.5	4.71	2.79e-06	0.000258	0.23	0.14	Obesity-related traits;	chr18:36802371	chr18:37243776~37247506:+
BRCA	cis	rs7226408	0.948	rs72883576	ENSG00000267707.2	RP11-95O2.5	4.71	2.79e-06	0.000258	0.23	0.14	Obesity-related traits;	chr18:36803751	chr18:37243776~37247506:+
BRCA	cis	rs7226408	0.894	rs55797519	ENSG00000267707.2	RP11-95O2.5	4.71	2.79e-06	0.000258	0.23	0.14	Obesity-related traits;	chr18:36806057	chr18:37243776~37247506:+
BRCA	cis	rs7226408	0.901	rs56209075	ENSG00000267707.2	RP11-95O2.5	4.71	2.79e-06	0.000258	0.23	0.14	Obesity-related traits;	chr18:36806070	chr18:37243776~37247506:+
BRCA	cis	rs7226408	0.948	rs11665609	ENSG00000267707.2	RP11-95O2.5	4.71	2.79e-06	0.000258	0.23	0.14	Obesity-related traits;	chr18:36807385	chr18:37243776~37247506:+
BRCA	cis	rs7577696	0.962	rs12989936	ENSG00000272716.1	RP11-563N4.1	-4.71	2.79e-06	0.000258	-0.16	-0.14	Inflammatory biomarkers;	chr2:32043517	chr2:32165046~32165757:-
BRCA	cis	rs6840360	0.642	rs2034061	ENSG00000251611.1	RP11-610P16.1	-4.71	2.79e-06	0.000258	-0.13	-0.14	Intelligence (multi-trait analysis);	chr4:151499604	chr4:151407551~151408835:-
BRCA	cis	rs11098499	0.954	rs9998585	ENSG00000250412.1	KLHL2P1	4.71	2.79e-06	0.000258	0.17	0.14	Corneal astigmatism;	chr4:119475647	chr4:119334329~119378233:+
BRCA	cis	rs11098499	0.909	rs6842762	ENSG00000250412.1	KLHL2P1	4.71	2.79e-06	0.000258	0.17	0.14	Corneal astigmatism;	chr4:119477081	chr4:119334329~119378233:+
BRCA	cis	rs6832769	0.922	rs6825994	ENSG00000223305.1	RN7SKP30	-4.71	2.79e-06	0.000259	-0.18	-0.14	Personality dimensions;	chr4:55524244	chr4:55540502~55540835:-
BRCA	cis	rs2253762	0.54	rs4752631	ENSG00000226864.1	ATE1-AS1	4.71	2.79e-06	0.000259	0.27	0.14	Breast cancer;	chr10:121996442	chr10:121928312~121951965:+
BRCA	cis	rs2073316	0.626	rs59770035	ENSG00000272716.1	RP11-563N4.1	4.71	2.79e-06	0.000259	0.16	0.14	Interleukin-18 levels;	chr2:31445247	chr2:32165046~32165757:-
BRCA	cis	rs7772486	0.875	rs854146	ENSG00000270638.1	RP3-466P17.1	4.71	2.79e-06	0.000259	0.17	0.14	Lobe attachment (rater-scored or self-reported);	chr6:146019897	chr6:145735570~145737218:+
BRCA	cis	rs4578769	0.879	rs11659315	ENSG00000265939.1	UBE2CP2	-4.71	2.79e-06	0.000259	-0.17	-0.14	Eosinophil percentage of white cells;	chr18:22836405	chr18:22900486~22900995:-
BRCA	cis	rs4578769	0.879	rs11659384	ENSG00000265939.1	UBE2CP2	-4.71	2.79e-06	0.000259	-0.17	-0.14	Eosinophil percentage of white cells;	chr18:22836662	chr18:22900486~22900995:-
BRCA	cis	rs8031584	0.958	rs8034856	ENSG00000259845.1	HERC2P10	4.71	2.79e-06	0.000259	0.17	0.14	Huntington's disease progression;	chr15:30948754	chr15:30815271~30844153:+
BRCA	cis	rs10129255	0.556	rs9324093	ENSG00000211959.2	IGHV4-39	4.71	2.79e-06	0.000259	0.1	0.14	Kawasaki disease;	chr14:106683893	chr14:106421711~106422218:-
BRCA	cis	rs7246657	0.722	rs2909098	ENSG00000226686.6	LINC01535	4.71	2.79e-06	0.000259	0.22	0.14	Coronary artery calcification;	chr19:37713347	chr19:37251912~37265535:+
BRCA	cis	rs4948275	0.773	rs2650703	ENSG00000237233.2	TMEM26-AS1	-4.71	2.79e-06	0.000259	-0.17	-0.14	Night sleep phenotypes;	chr10:61476953	chr10:61452639~61481956:+
BRCA	cis	rs4948275	0.714	rs2787725	ENSG00000237233.2	TMEM26-AS1	-4.71	2.79e-06	0.000259	-0.17	-0.14	Night sleep phenotypes;	chr10:61477622	chr10:61452639~61481956:+
BRCA	cis	rs4948275	0.773	rs2650704	ENSG00000237233.2	TMEM26-AS1	-4.71	2.79e-06	0.000259	-0.17	-0.14	Night sleep phenotypes;	chr10:61477722	chr10:61452639~61481956:+
BRCA	cis	rs7824557	0.614	rs2736286	ENSG00000255020.1	AF131216.5	4.71	2.79e-06	0.000259	0.17	0.14	Retinal vascular caliber;	chr8:11369595	chr8:11345748~11347502:-
BRCA	cis	rs9921338	0.924	rs7204628	ENSG00000262636.1	CTD-3088G3.4	-4.71	2.79e-06	0.000259	-0.23	-0.14	Vein graft stenosis in coronary artery bypass grafting;	chr16:11350715	chr16:11380859~11381118:-
BRCA	cis	rs7686660	1	rs12648157	ENSG00000250326.1	RP11-284M14.1	-4.71	2.79e-06	0.000259	-0.18	-0.14	Asthma;	chr4:143005897	chr4:142933195~143184861:-
BRCA	cis	rs7267979	0.868	rs6107019	ENSG00000276952.1	RP5-965G21.6	4.71	2.79e-06	0.000259	0.18	0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25253349	chr20:25284915~25285588:-
BRCA	cis	rs7048146	1	rs7046565	ENSG00000213539.4	YBX1P6	4.71	2.79e-06	0.000259	0.16	0.14	Vascular brain injury;	chr9:109539940	chr9:109532830~109534332:-
BRCA	cis	rs7247513	0.701	rs8107642	ENSG00000230310.1	CTD-2192J16.11	-4.71	2.79e-06	0.000259	-0.18	-0.14	Bipolar disorder;	chr19:12655556	chr19:12552597~12553644:+
BRCA	cis	rs4763879	0.778	rs1056151	ENSG00000278635.1	CTD-2318O12.1	4.71	2.79e-06	0.000259	0.14	0.14	Type 1 diabetes;	chr12:9698427	chr12:9415641~9416718:+
BRCA	cis	rs1167827	0.68	rs1167796	ENSG00000205583.12	STAG3L1	-4.71	2.8e-06	0.000259	-0.16	-0.14	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75543861	chr7:75359194~75395383:+
BRCA	cis	rs12497850	0.966	rs6792510	ENSG00000225399.4	RP11-3B7.1	4.71	2.8e-06	0.000259	0.14	0.14	Parkinson's disease;	chr3:48685869	chr3:49260085~49261316:+
BRCA	cis	rs2277027	1	rs4331881	ENSG00000248544.2	CTB-47B11.3	4.71	2.8e-06	0.000259	0.18	0.14	Pulmonary function;Pulmonary function (smoking interaction);	chr5:157517467	chr5:157375741~157384950:-
BRCA	cis	rs7592578	0.664	rs10931461	ENSG00000272979.1	RP11-647K16.1	4.71	2.8e-06	0.000259	0.24	0.14	Diastolic blood pressure;	chr2:190540554	chr2:190454092~190454521:-
BRCA	cis	rs8031584	0.958	rs11293	ENSG00000259845.1	HERC2P10	4.71	2.8e-06	0.000259	0.17	0.14	Huntington's disease progression;	chr15:30942778	chr15:30815271~30844153:+
BRCA	cis	rs859767	0.704	rs9287437	ENSG00000224043.6	CCNT2-AS1	4.71	2.8e-06	0.000259	0.2	0.14	Neuroticism;	chr2:134599932	chr2:134735464~134918710:-
BRCA	cis	rs7811142	0.83	rs6979910	ENSG00000078319.8	PMS2P1	-4.71	2.8e-06	0.000259	-0.22	-0.14	Platelet count;	chr7:100343007	chr7:100320992~100341908:-
BRCA	cis	rs7481584	0.624	rs1077335	ENSG00000247473.2	CARS-AS1	-4.71	2.8e-06	0.000259	-0.17	-0.14	Calcium levels;	chr11:3009294	chr11:3029009~3041260:+
BRCA	cis	rs875971	1	rs697970	ENSG00000236529.1	RP13-254B10.1	-4.71	2.8e-06	0.00026	-0.16	-0.14	Aortic root size;	chr7:66095065	chr7:65840212~65840596:+
BRCA	cis	rs10510102	0.872	rs12244199	ENSG00000226864.1	ATE1-AS1	4.71	2.8e-06	0.00026	0.27	0.14	Breast cancer;	chr10:121965117	chr10:121928312~121951965:+
BRCA	cis	rs6840360	0.617	rs2724563	ENSG00000251603.1	RP11-164P12.4	-4.71	2.8e-06	0.00026	-0.13	-0.14	Intelligence (multi-trait analysis);	chr4:151428807	chr4:151667224~151670502:+
BRCA	cis	rs6840360	0.617	rs2724564	ENSG00000251603.1	RP11-164P12.4	-4.71	2.8e-06	0.00026	-0.13	-0.14	Intelligence (multi-trait analysis);	chr4:151428810	chr4:151667224~151670502:+
BRCA	cis	rs871012	0.502	rs57064749	ENSG00000248544.2	CTB-47B11.3	-4.71	2.8e-06	0.00026	-0.19	-0.14	IgG glycosylation;	chr5:157462690	chr5:157375741~157384950:-
BRCA	cis	rs2153535	0.584	rs9502721	ENSG00000251164.1	HULC	-4.71	2.8e-06	0.00026	-0.18	-0.14	Motion sickness;	chr6:8541146	chr6:8652137~8653846:+
BRCA	cis	rs6696239	0.513	rs903684	ENSG00000227711.2	RP11-275O4.5	-4.71	2.8e-06	0.00026	-0.17	-0.14	Height;	chr1:227509398	chr1:227509028~227520477:-
BRCA	cis	rs950169	0.58	rs11634320	ENSG00000275120.1	RP11-182J1.17	-4.71	2.8e-06	0.00026	-0.19	-0.14	Schizophrenia;	chr15:84628952	chr15:84599434~84606463:-
BRCA	cis	rs1005277	0.54	rs2474598	ENSG00000263064.2	RP11-291L22.7	-4.71	2.8e-06	0.00026	-0.18	-0.14	Extrinsic epigenetic age acceleration;	chr10:38141368	chr10:38448689~38448949:+
BRCA	cis	rs6545883	0.894	rs2694643	ENSG00000212978.6	AC016747.3	4.71	2.8e-06	0.00026	0.2	0.14	Tuberculosis;	chr2:61377248	chr2:61141592~61144969:-
BRCA	cis	rs7572733	0.84	rs700655	ENSG00000231621.1	AC013264.2	-4.71	2.8e-06	0.00026	-0.13	-0.14	Dermatomyositis;	chr2:197778907	chr2:197197991~197199273:+
BRCA	cis	rs9652601	0.691	rs9939397	ENSG00000274038.1	RP11-66H6.4	-4.71	2.8e-06	0.00026	-0.16	-0.14	Systemic lupus erythematosus;	chr16:11115907	chr16:11056556~11057034:+
BRCA	cis	rs6714710	0.603	rs12988571	ENSG00000230606.9	AC159540.1	-4.71	2.81e-06	0.00026	-0.17	-0.14	Posterior cortical atrophy and Alzheimer's disease;	chr2:97789232	chr2:97416165~97433527:-
BRCA	cis	rs2915864	0.8	rs13185299	ENSG00000280047.1	CTC-463A16.1	4.71	2.81e-06	0.00026	0.21	0.14	Facial morphology (factor 20);	chr5:142146055	chr5:142165767~142168387:+
BRCA	cis	rs807029	0.533	rs3740485	ENSG00000236662.1	RP11-108L7.4	4.71	2.81e-06	0.00026	0.18	0.14	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100990864	chr10:100980507~100985614:-
BRCA	cis	rs807029	0.533	rs3740486	ENSG00000236662.1	RP11-108L7.4	4.71	2.81e-06	0.00026	0.18	0.14	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100990866	chr10:100980507~100985614:-
BRCA	cis	rs1858037	0.867	rs871974	ENSG00000237979.1	AC007389.1	-4.71	2.81e-06	0.00026	-0.18	-0.14	Rheumatoid arthritis;	chr2:65330153	chr2:65500993~65502138:-
BRCA	cis	rs2243480	1	rs1499614	ENSG00000222364.1	RNU6-96P	-4.71	2.81e-06	0.00026	-0.26	-0.14	Diabetic kidney disease;	chr7:66265811	chr7:66395191~66395286:+
BRCA	cis	rs9818758	0.607	rs9855123	ENSG00000270441.1	RP11-694I15.7	4.71	2.81e-06	0.00026	0.28	0.14	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49192024	chr3:49140086~49160851:-
BRCA	cis	rs750460	0.966	rs4243042	ENSG00000261801.4	LOXL1-AS1	4.71	2.81e-06	0.00026	0.16	0.14	Height;	chr15:73949283	chr15:73908071~73928248:-
BRCA	cis	rs763121	0.889	rs4820335	ENSG00000273076.1	RP3-508I15.22	-4.71	2.81e-06	0.00026	-0.15	-0.14	Menopause (age at onset);	chr22:38539922	chr22:38743495~38743910:+
BRCA	cis	rs11977670	0.785	rs13225058	ENSG00000251728.1	Y_RNA	4.71	2.81e-06	0.00026	0.15	0.14	Breast cancer;	chr7:140246253	chr7:140094697~140094792:-
BRCA	cis	rs11098499	0.754	rs10212714	ENSG00000260404.2	RP11-384K6.6	4.71	2.81e-06	0.00026	0.13	0.14	Corneal astigmatism;	chr4:119333147	chr4:118591773~118633729:+
BRCA	cis	rs6832769	1	rs6819660	ENSG00000223305.1	RN7SKP30	4.71	2.81e-06	0.00026	0.18	0.14	Personality dimensions;	chr4:55508410	chr4:55540502~55540835:-
BRCA	cis	rs8180040	0.966	rs12486969	ENSG00000271161.1	BOLA2P2	-4.71	2.81e-06	0.00026	-0.16	-0.14	Colorectal cancer;	chr3:47387513	chr3:47499841~47500407:+
BRCA	cis	rs12744310	0.887	rs12047439	ENSG00000235358.1	RP11-399E6.1	4.71	2.81e-06	0.00026	0.21	0.14	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41343968	chr1:41242373~41284861:+
BRCA	cis	rs7811142	0.775	rs1059129	ENSG00000078319.8	PMS2P1	-4.71	2.82e-06	0.000261	-0.22	-0.14	Platelet count;	chr7:100328899	chr7:100320992~100341908:-
BRCA	cis	rs6603134	0.502	rs10411185	ENSG00000269139.2	CTD-3193O13.8	4.71	2.82e-06	0.000261	0.16	0.14	Blood protein levels;	chr19:8038997	chr19:7926001~7926810:+
BRCA	cis	rs6840360	0.642	rs2724580	ENSG00000251603.1	RP11-164P12.4	-4.71	2.82e-06	0.000261	-0.13	-0.14	Intelligence (multi-trait analysis);	chr4:151451353	chr4:151667224~151670502:+
BRCA	cis	rs7267979	1	rs2482931	ENSG00000125804.12	FAM182A	4.71	2.82e-06	0.000261	0.19	0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25353809	chr20:26054655~26086917:+
BRCA	cis	rs7267979	0.816	rs6037158	ENSG00000274973.1	RP13-401N8.7	-4.71	2.82e-06	0.000261	-0.16	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25614830	chr20:25845497~25845862:+
BRCA	cis	rs7308116	0.546	rs61938605	ENSG00000274395.1	RP11-554D14.8	-4.71	2.82e-06	0.000261	-0.18	-0.14	Pelvic organ prolapse (moderate/severe);	chr12:107815210	chr12:107835541~107836555:-
BRCA	cis	rs2980439	0.846	rs2980437	ENSG00000173295.6	FAM86B3P	-4.71	2.82e-06	0.000261	-0.15	-0.14	Neuroticism;	chr8:8237241	chr8:8228595~8244865:+
BRCA	cis	rs172166	0.694	rs203892	ENSG00000219392.1	RP1-265C24.5	-4.71	2.82e-06	0.000261	-0.2	-0.14	Cardiac Troponin-T levels;	chr6:28099418	chr6:28115628~28116551:+
BRCA	cis	rs172166	0.694	rs188105	ENSG00000219392.1	RP1-265C24.5	-4.71	2.82e-06	0.000261	-0.2	-0.14	Cardiac Troponin-T levels;	chr6:28103615	chr6:28115628~28116551:+
BRCA	cis	rs7674212	0.57	rs2126470	ENSG00000246560.2	RP11-10L12.4	4.71	2.82e-06	0.000261	0.15	0.14	Type 2 diabetes;	chr4:103140605	chr4:102828055~102844075:+
BRCA	cis	rs924712	0.545	rs72954815	ENSG00000224984.1	RP11-524H19.2	4.71	2.82e-06	0.000261	0.17	0.14	Breast cancer;	chr6:54843291	chr6:54840118~54840855:-
BRCA	cis	rs924712	0.545	rs12205222	ENSG00000224984.1	RP11-524H19.2	4.71	2.82e-06	0.000261	0.17	0.14	Breast cancer;	chr6:54843292	chr6:54840118~54840855:-
BRCA	cis	rs6545883	0.826	rs777593	ENSG00000212978.6	AC016747.3	4.71	2.82e-06	0.000261	0.2	0.14	Tuberculosis;	chr2:61191968	chr2:61141592~61144969:-
BRCA	cis	rs8016982	1	rs12147118	ENSG00000258999.1	RP11-114N19.3	-4.71	2.82e-06	0.000261	-0.18	-0.14	Schizophrenia;	chr14:81186631	chr14:81107033~81170414:-
BRCA	cis	rs11098499	0.908	rs1002152	ENSG00000250412.1	KLHL2P1	4.71	2.82e-06	0.000261	0.17	0.14	Corneal astigmatism;	chr4:119352232	chr4:119334329~119378233:+
BRCA	cis	rs595244	1	rs1678981	ENSG00000259705.1	RP11-227D13.1	4.71	2.82e-06	0.000262	0.26	0.14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48607900	chr15:48645951~48652016:+
BRCA	cis	rs9868809	0.772	rs2302295	ENSG00000270441.1	RP11-694I15.7	4.71	2.83e-06	0.000262	0.25	0.14	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48652677	chr3:49140086~49160851:-
BRCA	cis	rs867186	1	rs75535620	ENSG00000126005.14	MMP24-AS1	-4.71	2.83e-06	0.000262	-0.28	-0.14	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35013695	chr20:35216462~35278131:-
BRCA	cis	rs6847067	0.794	rs4470615	ENSG00000180769.7	WDFY3-AS2	4.71	2.83e-06	0.000262	0.13	0.14	Oropharynx cancer;	chr4:85034218	chr4:84965682~85011277:+
BRCA	cis	rs2278170	1	rs331534	ENSG00000225101.4	OR52K3P	-4.71	2.83e-06	0.000262	-0.2	-0.14	Amyotrophic lateral sclerosis;	chr11:4455850	chr11:4474813~4475755:+
BRCA	cis	rs4835473	0.932	rs36018946	ENSG00000249741.2	RP11-673E1.3	4.71	2.83e-06	0.000262	0.16	0.14	Immature fraction of reticulocytes;	chr4:143980942	chr4:143911514~143912053:-
BRCA	cis	rs6570726	0.791	rs383841	ENSG00000270638.1	RP3-466P17.1	-4.71	2.83e-06	0.000262	-0.17	-0.14	Lobe attachment (rater-scored or self-reported);	chr6:145567193	chr6:145735570~145737218:+
BRCA	cis	rs6570726	0.935	rs382910	ENSG00000270638.1	RP3-466P17.1	4.71	2.83e-06	0.000262	0.16	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145544805	chr6:145735570~145737218:+
BRCA	cis	rs5167	0.505	rs7257468	ENSG00000280087.1	CTB-129P6.7	4.71	2.83e-06	0.000262	0.17	0.14	Blood protein levels;	chr19:44949887	chr19:44909375~44914968:+
BRCA	cis	rs5167	0.504	rs7258345	ENSG00000280087.1	CTB-129P6.7	4.71	2.83e-06	0.000262	0.17	0.14	Blood protein levels;	chr19:44949894	chr19:44909375~44914968:+
BRCA	cis	rs6088590	0.561	rs6088528	ENSG00000276073.1	RP5-1125A11.7	-4.71	2.83e-06	0.000262	-0.16	-0.14	Coronary artery disease;	chr20:34568938	chr20:33985617~33988989:-
BRCA	cis	rs848490	0.894	rs6465773	ENSG00000214293.7	APTR	4.71	2.83e-06	0.000262	0.17	0.14	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77677384	chr7:77657660~77696265:-
BRCA	cis	rs4664293	0.967	rs12611922	ENSG00000224152.1	AC009506.1	-4.71	2.83e-06	0.000262	-0.16	-0.14	Monocyte percentage of white cells;	chr2:159606238	chr2:159615296~159617082:+
BRCA	cis	rs17270561	0.666	rs4712976	ENSG00000272462.2	U91328.19	-4.71	2.83e-06	0.000262	-0.18	-0.14	Iron status biomarkers;	chr6:25841975	chr6:25992662~26001775:+
BRCA	cis	rs2562456	0.52	rs582992	ENSG00000268535.1	RP11-420K14.3	-4.71	2.83e-06	0.000262	-0.23	-0.14	Pain;	chr19:21266744	chr19:21709522~21710191:+
BRCA	cis	rs1075265	0.756	rs809280	ENSG00000235937.1	AC008280.1	4.71	2.83e-06	0.000262	0.16	0.14	Chronotype;Morning vs. evening chronotype;	chr2:53921270	chr2:54029552~54030682:-
BRCA	cis	rs9467773	0.596	rs2451750	ENSG00000124549.13	BTN2A3P	4.71	2.83e-06	0.000262	0.14	0.14	Intelligence (multi-trait analysis);	chr6:26646351	chr6:26421391~26432383:+
BRCA	cis	rs9467773	0.596	rs2451751	ENSG00000124549.13	BTN2A3P	4.71	2.83e-06	0.000262	0.14	0.14	Intelligence (multi-trait analysis);	chr6:26646486	chr6:26421391~26432383:+
BRCA	cis	rs2255336	0.938	rs2617151	ENSG00000245648.1	RP11-277P12.20	4.71	2.83e-06	0.000262	0.22	0.14	Blood protein levels;	chr12:10379835	chr12:10363769~10398506:+
BRCA	cis	rs8180040	0.62	rs11715121	ENSG00000276925.1	RP11-708J19.3	4.71	2.83e-06	0.000262	0.17	0.14	Colorectal cancer;	chr3:47031131	chr3:47469777~47469987:+
BRCA	cis	rs8180040	0.62	rs11709660	ENSG00000276925.1	RP11-708J19.3	4.71	2.83e-06	0.000262	0.17	0.14	Colorectal cancer;	chr3:47033437	chr3:47469777~47469987:+
BRCA	cis	rs8180040	0.62	rs6768722	ENSG00000276925.1	RP11-708J19.3	-4.71	2.83e-06	0.000262	-0.17	-0.14	Colorectal cancer;	chr3:47037622	chr3:47469777~47469987:+
BRCA	cis	rs736408	0.648	rs3774354	ENSG00000243224.1	RP5-1157M23.2	-4.71	2.83e-06	0.000262	-0.16	-0.14	Bipolar disorder;	chr3:52783659	chr3:52239258~52241097:+
BRCA	cis	rs9311474	0.713	rs352167	ENSG00000243224.1	RP5-1157M23.2	4.71	2.84e-06	0.000263	0.15	0.14	Electroencephalogram traits;	chr3:52204640	chr3:52239258~52241097:+
BRCA	cis	rs11976180	1	rs2961119	ENSG00000244479.5	OR2A1-AS1	4.71	2.84e-06	0.000263	0.19	0.14	Obesity-related traits;	chr7:144058759	chr7:144251264~144356181:-
BRCA	cis	rs9638182	1	rs6976930	ENSG00000274080.1	CTA-315H11.2	4.71	2.84e-06	0.000263	0.25	0.14	Triglycerides;	chr7:73471480	chr7:73609262~73611502:-
BRCA	cis	rs17767294	0.708	rs72848792	ENSG00000204709.4	LINC01556	4.71	2.84e-06	0.000263	0.39	0.14	Parkinson's disease;	chr6:28029878	chr6:28943877~28944537:+
BRCA	cis	rs9468199	0.505	rs72848793	ENSG00000204709.4	LINC01556	4.71	2.84e-06	0.000263	0.39	0.14	Parkinson's disease;	chr6:28031800	chr6:28943877~28944537:+
BRCA	cis	rs2839186	0.967	rs9637172	ENSG00000228137.1	AP001469.7	4.71	2.84e-06	0.000263	0.15	0.14	Testicular germ cell tumor;	chr21:46265873	chr21:46246890~46247682:+
BRCA	cis	rs859767	0.501	rs6705916	ENSG00000224043.6	CCNT2-AS1	4.71	2.84e-06	0.000263	0.19	0.14	Neuroticism;	chr2:134639999	chr2:134735464~134918710:-
BRCA	cis	rs12497850	0.931	rs7430198	ENSG00000225399.4	RP11-3B7.1	4.71	2.84e-06	0.000263	0.14	0.14	Parkinson's disease;	chr3:48951327	chr3:49260085~49261316:+
BRCA	cis	rs12497850	0.866	rs6791234	ENSG00000225399.4	RP11-3B7.1	4.71	2.84e-06	0.000263	0.14	0.14	Parkinson's disease;	chr3:48958704	chr3:49260085~49261316:+
BRCA	cis	rs12497850	0.931	rs6446196	ENSG00000225399.4	RP11-3B7.1	4.71	2.84e-06	0.000263	0.14	0.14	Parkinson's disease;	chr3:48967290	chr3:49260085~49261316:+
BRCA	cis	rs9311474	0.713	rs352165	ENSG00000243224.1	RP5-1157M23.2	-4.71	2.84e-06	0.000263	-0.15	-0.14	Electroencephalogram traits;	chr3:52208886	chr3:52239258~52241097:+
BRCA	cis	rs859767	0.501	rs10193171	ENSG00000224043.6	CCNT2-AS1	-4.71	2.84e-06	0.000263	-0.19	-0.14	Neuroticism;	chr2:134645629	chr2:134735464~134918710:-
BRCA	cis	rs6445975	0.726	rs6762098	ENSG00000272360.1	RP11-359I18.5	-4.71	2.84e-06	0.000263	-0.16	-0.14	Systemic lupus erythematosus;	chr3:58482701	chr3:58490830~58491291:-
BRCA	cis	rs875971	0.502	rs2465121	ENSG00000230295.1	RP11-458F8.2	-4.71	2.84e-06	0.000263	-0.14	-0.14	Aortic root size;	chr7:66156017	chr7:66880708~66882981:+
BRCA	cis	rs8031584	0.958	rs34294266	ENSG00000259845.1	HERC2P10	4.71	2.84e-06	0.000263	0.17	0.14	Huntington's disease progression;	chr15:30954637	chr15:30815271~30844153:+
BRCA	cis	rs7811142	0.779	rs28680963	ENSG00000078319.8	PMS2P1	-4.71	2.84e-06	0.000263	-0.24	-0.14	Platelet count;	chr7:100307852	chr7:100320992~100341908:-
BRCA	cis	rs6840360	0.642	rs2709819	ENSG00000251603.1	RP11-164P12.4	-4.71	2.84e-06	0.000263	-0.13	-0.14	Intelligence (multi-trait analysis);	chr4:151462680	chr4:151667224~151670502:+
BRCA	cis	rs867186	0.841	rs76223987	ENSG00000126005.14	MMP24-AS1	-4.71	2.85e-06	0.000263	-0.28	-0.14	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35030669	chr20:35216462~35278131:-
BRCA	cis	rs867186	1	rs78055011	ENSG00000126005.14	MMP24-AS1	-4.71	2.85e-06	0.000263	-0.28	-0.14	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35030803	chr20:35216462~35278131:-
BRCA	cis	rs867186	1	rs76507298	ENSG00000126005.14	MMP24-AS1	-4.71	2.85e-06	0.000263	-0.28	-0.14	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35035719	chr20:35216462~35278131:-
BRCA	cis	rs8031584	0.541	rs2955797	ENSG00000259845.1	HERC2P10	-4.71	2.85e-06	0.000263	-0.16	-0.14	Huntington's disease progression;	chr15:30918778	chr15:30815271~30844153:+
BRCA	cis	rs721917	0.506	rs1923540	ENSG00000278616.1	BEND3P3	-4.71	2.85e-06	0.000264	-0.14	-0.14	Chronic obstructive pulmonary disease;	chr10:79930616	chr10:79682997~79685436:+
BRCA	cis	rs7267979	1	rs2500404	ENSG00000125804.12	FAM182A	4.71	2.85e-06	0.000264	0.19	0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25379122	chr20:26054655~26086917:+
BRCA	cis	rs7267979	1	rs2500405	ENSG00000125804.12	FAM182A	4.71	2.85e-06	0.000264	0.19	0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25380190	chr20:26054655~26086917:+
BRCA	cis	rs7267979	1	rs2482941	ENSG00000125804.12	FAM182A	4.71	2.85e-06	0.000264	0.19	0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25380580	chr20:26054655~26086917:+
BRCA	cis	rs7267979	0.903	rs2500423	ENSG00000125804.12	FAM182A	4.71	2.85e-06	0.000264	0.19	0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25394246	chr20:26054655~26086917:+
BRCA	cis	rs6088580	0.634	rs6120650	ENSG00000276073.1	RP5-1125A11.7	-4.71	2.85e-06	0.000264	-0.16	-0.14	Glomerular filtration rate (creatinine);	chr20:34452168	chr20:33985617~33988989:-
BRCA	cis	rs17597773	0.674	rs2378425	ENSG00000238078.1	LINC01352	-4.71	2.85e-06	0.000264	-0.17	-0.14	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220842716	chr1:220829255~220832429:+
BRCA	cis	rs919433	0.653	rs700651	ENSG00000231621.1	AC013264.2	-4.71	2.85e-06	0.000264	-0.14	-0.14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197766990	chr2:197197991~197199273:+
BRCA	cis	rs2115630	0.967	rs12595786	ENSG00000259295.5	CSPG4P12	-4.71	2.85e-06	0.000264	-0.17	-0.14	P wave terminal force;	chr15:84793439	chr15:85191438~85213905:+
BRCA	cis	rs875971	0.545	rs4718325	ENSG00000273142.1	RP11-458F8.4	4.71	2.85e-06	0.000264	0.14	0.14	Aortic root size;	chr7:66215323	chr7:66902857~66906297:+
BRCA	cis	rs7674212	0.512	rs2720462	ENSG00000251288.2	RP11-10L12.2	-4.71	2.85e-06	0.000264	-0.17	-0.14	Type 2 diabetes;	chr4:103135053	chr4:102751401~102752641:+
BRCA	cis	rs4950322	0.542	rs4950382	ENSG00000244371.2	PFN1P8	-4.71	2.86e-06	0.000264	-0.17	-0.14	Protein quantitative trait loci;	chr1:147176645	chr1:146957117~146957659:-
BRCA	cis	rs6570726	0.935	rs447818	ENSG00000270638.1	RP3-466P17.1	4.71	2.86e-06	0.000264	0.16	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145547860	chr6:145735570~145737218:+
BRCA	cis	rs9914544	0.966	rs1737943	ENSG00000264885.1	RP11-815I9.4	4.71	2.86e-06	0.000264	0.15	0.14	Educational attainment (years of education);	chr17:18938277	chr17:18667629~18669461:-
BRCA	cis	rs5758659	0.714	rs133373	ENSG00000270083.1	RP1-257I20.14	4.71	2.86e-06	0.000264	0.16	0.14	Cognitive function;	chr22:42069784	chr22:42089630~42090028:-
BRCA	cis	rs1862618	0.671	rs173763	ENSG00000271828.1	CTD-2310F14.1	4.71	2.86e-06	0.000264	0.18	0.14	Initial pursuit acceleration;	chr5:56929591	chr5:56927874~56929573:+
BRCA	cis	rs1862618	0.62	rs189695	ENSG00000271828.1	CTD-2310F14.1	4.71	2.86e-06	0.000264	0.18	0.14	Initial pursuit acceleration;	chr5:56929942	chr5:56927874~56929573:+
BRCA	cis	rs35740288	0.822	rs17636864	ENSG00000202081.1	RNU6-1280P	4.71	2.86e-06	0.000265	0.2	0.14	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85691358	chr15:85651522~85651628:-
BRCA	cis	rs7674212	0.57	rs6813563	ENSG00000248740.4	RP11-328K4.1	4.71	2.86e-06	0.000265	0.17	0.14	Type 2 diabetes;	chr4:103177953	chr4:103256159~103453658:+
BRCA	cis	rs16958440	1	rs62096466	ENSG00000280212.1	RP11-49K24.3	4.71	2.86e-06	0.000265	0.3	0.14	Sitting height ratio;	chr18:47109800	chr18:47076117~47076594:+
BRCA	cis	rs16958440	1	rs76594057	ENSG00000280212.1	RP11-49K24.3	4.71	2.86e-06	0.000265	0.3	0.14	Sitting height ratio;	chr18:47110901	chr18:47076117~47076594:+
BRCA	cis	rs16958440	1	rs62096469	ENSG00000280212.1	RP11-49K24.3	4.71	2.86e-06	0.000265	0.3	0.14	Sitting height ratio;	chr18:47111927	chr18:47076117~47076594:+
BRCA	cis	rs16958440	1	rs60228288	ENSG00000280212.1	RP11-49K24.3	4.71	2.86e-06	0.000265	0.3	0.14	Sitting height ratio;	chr18:47114041	chr18:47076117~47076594:+
BRCA	cis	rs16958440	1	rs62096470	ENSG00000280212.1	RP11-49K24.3	4.71	2.86e-06	0.000265	0.3	0.14	Sitting height ratio;	chr18:47115095	chr18:47076117~47076594:+
BRCA	cis	rs16958440	1	rs62096471	ENSG00000280212.1	RP11-49K24.3	4.71	2.86e-06	0.000265	0.3	0.14	Sitting height ratio;	chr18:47117443	chr18:47076117~47076594:+
BRCA	cis	rs16958440	1	rs4609941	ENSG00000280212.1	RP11-49K24.3	4.71	2.86e-06	0.000265	0.3	0.14	Sitting height ratio;	chr18:47119120	chr18:47076117~47076594:+
BRCA	cis	rs16958440	1	rs57928699	ENSG00000280212.1	RP11-49K24.3	4.71	2.86e-06	0.000265	0.3	0.14	Sitting height ratio;	chr18:47119222	chr18:47076117~47076594:+
BRCA	cis	rs10504130	0.932	rs80143499	ENSG00000253844.1	RP11-546K22.1	-4.71	2.86e-06	0.000265	-0.25	-0.14	Venous thromboembolism (SNP x SNP interaction);	chr8:51808915	chr8:51961458~52022974:+
BRCA	cis	rs10504130	0.932	rs79612913	ENSG00000253844.1	RP11-546K22.1	-4.71	2.86e-06	0.000265	-0.25	-0.14	Venous thromboembolism (SNP x SNP interaction);	chr8:51808916	chr8:51961458~52022974:+
BRCA	cis	rs10504130	1	rs75257860	ENSG00000253844.1	RP11-546K22.1	-4.71	2.86e-06	0.000265	-0.25	-0.14	Venous thromboembolism (SNP x SNP interaction);	chr8:51811887	chr8:51961458~52022974:+
BRCA	cis	rs10504130	1	rs79299366	ENSG00000253844.1	RP11-546K22.1	-4.71	2.86e-06	0.000265	-0.25	-0.14	Venous thromboembolism (SNP x SNP interaction);	chr8:51812800	chr8:51961458~52022974:+
BRCA	cis	rs6442522	0.56	rs7631005	ENSG00000249786.6	EAF1-AS1	4.71	2.86e-06	0.000265	0.15	0.14	Uric acid levels;	chr3:15473554	chr3:15436171~15455940:-
BRCA	cis	rs2790457	0.833	rs1265843	ENSG00000254635.4	WAC-AS1	-4.71	2.87e-06	0.000265	-0.18	-0.14	Multiple myeloma;	chr10:28636088	chr10:28522652~28532743:-
BRCA	cis	rs7615952	0.558	rs17334039	ENSG00000241288.6	RP11-379B18.5	-4.71	2.87e-06	0.000265	-0.19	-0.14	Blood pressure (smoking interaction);	chr3:125821465	chr3:125827238~125916384:-
BRCA	cis	rs6860540	0.796	rs3734029	ENSG00000248544.2	CTB-47B11.3	-4.71	2.87e-06	0.000265	-0.18	-0.14	Inflammatory skin disease;	chr5:157473742	chr5:157375741~157384950:-
BRCA	cis	rs875971	0.564	rs313804	ENSG00000223473.2	GS1-124K5.3	4.71	2.87e-06	0.000265	0.11	0.14	Aortic root size;	chr7:66049635	chr7:66491049~66493566:-
BRCA	cis	rs875971	0.662	rs448725	ENSG00000223473.2	GS1-124K5.3	4.71	2.87e-06	0.000265	0.11	0.14	Aortic root size;	chr7:66049641	chr7:66491049~66493566:-
BRCA	cis	rs853679	0.76	rs11962305	ENSG00000280107.1	AL022393.9	-4.71	2.87e-06	0.000265	-0.23	-0.14	Depression;	chr6:28232159	chr6:28170845~28172521:+
BRCA	cis	rs2638953	0.925	rs11049520	ENSG00000247934.4	RP11-967K21.1	-4.71	2.87e-06	0.000265	-0.2	-0.14	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28310656	chr12:28163298~28190738:-
BRCA	cis	rs10266483	0.739	rs10949900	ENSG00000227986.1	TRIM60P18	4.71	2.87e-06	0.000265	0.16	0.14	Response to statin therapy;	chr7:64351751	chr7:64355078~64356199:+
BRCA	cis	rs600231	0.708	rs661403	ENSG00000173727.10	CMB9-22P13.1	4.71	2.87e-06	0.000265	0.19	0.14	Bone mineral density;	chr11:65475007	chr11:65455258~65466720:+
BRCA	cis	rs4908760	0.864	rs12136766	ENSG00000232912.4	RP5-1115A15.1	4.71	2.87e-06	0.000265	0.14	0.14	Vitiligo;	chr1:8603762	chr1:8424645~8434838:+
BRCA	cis	rs7246657	0.722	rs2972430	ENSG00000276846.1	CTD-3220F14.3	-4.71	2.87e-06	0.000266	-0.2	-0.14	Coronary artery calcification;	chr19:37691210	chr19:37314868~37315620:-
BRCA	cis	rs14027	0.512	rs7010808	ENSG00000279347.1	RP11-85I17.2	-4.71	2.87e-06	0.000266	-0.14	-0.14	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119712216	chr8:119838736~119840385:-
BRCA	cis	rs997295	0.713	rs3784695	ENSG00000270964.1	RP11-502I4.3	-4.71	2.88e-06	0.000266	-0.16	-0.14	Motion sickness;	chr15:67710264	chr15:67541072~67542604:-
BRCA	cis	rs1858037	0.867	rs4671660	ENSG00000281920.1	RP11-418H16.1	4.71	2.88e-06	0.000266	0.19	0.14	Rheumatoid arthritis;	chr2:65349302	chr2:65623272~65628424:+
BRCA	cis	rs9925964	0.933	rs4889530	ENSG00000260911.2	RP11-196G11.2	-4.71	2.88e-06	0.000266	-0.14	-0.14	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31054597	chr16:31043150~31049868:+
BRCA	cis	rs2835345	0.563	rs60511692	ENSG00000279365.1	KB-176G8.1	4.71	2.88e-06	0.000266	0.19	0.14	Pulmonary function;	chr21:36454091	chr21:36485867~36487760:+
BRCA	cis	rs7308116	0.546	rs1863527	ENSG00000274395.1	RP11-554D14.8	-4.71	2.88e-06	0.000266	-0.17	-0.14	Pelvic organ prolapse (moderate/severe);	chr12:107814774	chr12:107835541~107836555:-
BRCA	cis	rs7308116	0.546	rs12227690	ENSG00000274395.1	RP11-554D14.8	-4.71	2.88e-06	0.000266	-0.17	-0.14	Pelvic organ prolapse (moderate/severe);	chr12:107816295	chr12:107835541~107836555:-
BRCA	cis	rs12744310	0.887	rs1892419	ENSG00000235358.1	RP11-399E6.1	4.71	2.88e-06	0.000266	0.22	0.14	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41315479	chr1:41242373~41284861:+
BRCA	cis	rs12744310	0.887	rs28541673	ENSG00000235358.1	RP11-399E6.1	4.71	2.88e-06	0.000266	0.22	0.14	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41316322	chr1:41242373~41284861:+
BRCA	cis	rs12744310	0.887	rs12041352	ENSG00000235358.1	RP11-399E6.1	4.71	2.88e-06	0.000266	0.22	0.14	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41317109	chr1:41242373~41284861:+
BRCA	cis	rs807029	0.533	rs3740487	ENSG00000236662.1	RP11-108L7.4	4.71	2.88e-06	0.000266	0.18	0.14	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100991026	chr10:100980507~100985614:-
BRCA	cis	rs7923609	0.875	rs10740118	ENSG00000232075.1	MRPL35P2	4.71	2.88e-06	0.000266	0.18	0.14	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63341447	chr10:63634317~63634827:-
BRCA	cis	rs7568498	1	rs10164593	ENSG00000235724.7	AC009299.2	4.71	2.88e-06	0.000266	0.22	0.14	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);	chr2:161125461	chr2:161222785~161308303:-
BRCA	cis	rs7923609	0.846	rs7073753	ENSG00000232075.1	MRPL35P2	-4.7	2.88e-06	0.000266	-0.18	-0.14	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63303060	chr10:63634317~63634827:-
BRCA	cis	rs1858037	0.867	rs953312	ENSG00000237979.1	AC007389.1	4.7	2.88e-06	0.000266	0.18	0.14	Rheumatoid arthritis;	chr2:65340556	chr2:65500993~65502138:-
BRCA	cis	rs1858037	0.867	rs9789444	ENSG00000237979.1	AC007389.1	4.7	2.88e-06	0.000266	0.18	0.14	Rheumatoid arthritis;	chr2:65342093	chr2:65500993~65502138:-
BRCA	cis	rs2625529	0.652	rs2415128	ENSG00000260037.4	CTD-2524L6.3	4.7	2.88e-06	0.000267	0.18	0.14	Red blood cell count;	chr15:71898732	chr15:71818396~71823384:+
BRCA	cis	rs950169	0.614	rs765524	ENSG00000275120.1	RP11-182J1.17	4.7	2.88e-06	0.000267	0.21	0.14	Schizophrenia;	chr15:84013030	chr15:84599434~84606463:-
BRCA	cis	rs17684571	0.7	rs17751977	ENSG00000231441.1	RP11-472M19.2	4.7	2.88e-06	0.000267	0.23	0.14	Schizophrenia;	chr6:56809820	chr6:56844002~56864078:+
BRCA	cis	rs17684571	0.7	rs17684772	ENSG00000231441.1	RP11-472M19.2	4.7	2.88e-06	0.000267	0.23	0.14	Schizophrenia;	chr6:56810415	chr6:56844002~56864078:+
BRCA	cis	rs7772486	0.902	rs1125462	ENSG00000270638.1	RP3-466P17.1	4.7	2.89e-06	0.000267	0.16	0.14	Lobe attachment (rater-scored or self-reported);	chr6:146096696	chr6:145735570~145737218:+
BRCA	cis	rs7428	0.527	rs7607284	ENSG00000273196.1	RP11-717A5.2	4.7	2.89e-06	0.000267	0.17	0.14	Ear protrusion;	chr2:85320253	chr2:85387074~85387146:-
BRCA	cis	rs7428	0.527	rs4459734	ENSG00000273196.1	RP11-717A5.2	4.7	2.89e-06	0.000267	0.17	0.14	Ear protrusion;	chr2:85320306	chr2:85387074~85387146:-
BRCA	cis	rs6570726	0.791	rs1280276	ENSG00000270638.1	RP3-466P17.1	4.7	2.89e-06	0.000267	0.17	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145571214	chr6:145735570~145737218:+
BRCA	cis	rs6714710	0.603	rs34373359	ENSG00000230606.9	AC159540.1	-4.7	2.89e-06	0.000267	-0.17	-0.14	Posterior cortical atrophy and Alzheimer's disease;	chr2:97825739	chr2:97416165~97433527:-
BRCA	cis	rs6714710	0.603	rs2044459	ENSG00000230606.9	AC159540.1	-4.7	2.89e-06	0.000267	-0.17	-0.14	Posterior cortical atrophy and Alzheimer's disease;	chr2:97830541	chr2:97416165~97433527:-
BRCA	cis	rs6714710	0.557	rs17490429	ENSG00000230606.9	AC159540.1	-4.7	2.89e-06	0.000267	-0.17	-0.14	Posterior cortical atrophy and Alzheimer's disease;	chr2:97832561	chr2:97416165~97433527:-
BRCA	cis	rs4713118	0.513	rs149897	ENSG00000219392.1	RP1-265C24.5	-4.7	2.89e-06	0.000267	-0.2	-0.14	Parkinson's disease;	chr6:28038872	chr6:28115628~28116551:+
BRCA	cis	rs4713118	0.513	rs156734	ENSG00000219392.1	RP1-265C24.5	-4.7	2.89e-06	0.000267	-0.2	-0.14	Parkinson's disease;	chr6:28039579	chr6:28115628~28116551:+
BRCA	cis	rs6951245	1	rs2363286	ENSG00000229043.2	AC091729.9	-4.7	2.89e-06	0.000267	-0.25	-0.14	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1051989	chr7:1160374~1165267:+
BRCA	cis	rs7312933	0.558	rs1796382	ENSG00000257225.1	RP11-328C8.4	4.7	2.89e-06	0.000267	0.17	0.14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42447153	chr12:42459366~42466128:+
BRCA	cis	rs7914558	0.966	rs10786719	ENSG00000236937.2	PTGES3P4	-4.7	2.89e-06	0.000267	-0.19	-0.14	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102878235	chr10:102845595~102845950:+
BRCA	cis	rs17684571	0.575	rs71564855	ENSG00000231441.1	RP11-472M19.2	4.7	2.89e-06	0.000267	0.23	0.14	Schizophrenia;	chr6:56801117	chr6:56844002~56864078:+
BRCA	cis	rs17684571	0.7	rs13218913	ENSG00000231441.1	RP11-472M19.2	4.7	2.89e-06	0.000267	0.23	0.14	Schizophrenia;	chr6:56801247	chr6:56844002~56864078:+
BRCA	cis	rs721917	0.565	rs7476563	ENSG00000244733.5	RP11-506M13.3	-4.7	2.89e-06	0.000267	-0.17	-0.14	Chronic obstructive pulmonary disease;	chr10:79975318	chr10:79660891~79677996:+
BRCA	cis	rs763121	1	rs1946990	ENSG00000273076.1	RP3-508I15.22	-4.7	2.89e-06	0.000267	-0.15	-0.14	Menopause (age at onset);	chr22:38516766	chr22:38743495~38743910:+
BRCA	cis	rs12893668	0.703	rs8017993	ENSG00000244691.1	RPL10AP1	-4.7	2.9e-06	0.000268	-0.19	-0.14	Reticulocyte count;	chr14:103581397	chr14:103412119~103412761:-
BRCA	cis	rs1371614	0.523	rs2891534	ENSG00000229122.1	AGBL5-IT1	4.7	2.9e-06	0.000268	0.15	0.14	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26961578	chr2:27061038~27061815:+
BRCA	cis	rs7665090	1	rs3733202	ENSG00000251288.2	RP11-10L12.2	-4.7	2.9e-06	0.000268	-0.17	-0.14	Primary biliary cholangitis;	chr4:102635704	chr4:102751401~102752641:+
BRCA	cis	rs10129255	0.957	rs10136781	ENSG00000280411.1	IGHV1-69-2	-4.7	2.9e-06	0.000268	-0.1	-0.14	Kawasaki disease;	chr14:106780451	chr14:106762092~106762588:-
BRCA	cis	rs7089973	0.523	rs7090904	ENSG00000236799.1	RP11-383C6.2	-4.7	2.9e-06	0.000268	-0.17	-0.14	Bipolar disorder or attention deficit hyperactivity disorder;	chr10:115016126	chr10:114994657~114996593:+
BRCA	cis	rs7267979	0.903	rs6115118	ENSG00000125804.12	FAM182A	-4.7	2.9e-06	0.000268	-0.19	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25266098	chr20:26054655~26086917:+
BRCA	cis	rs7267979	0.903	rs1118963	ENSG00000125804.12	FAM182A	-4.7	2.9e-06	0.000268	-0.19	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25266813	chr20:26054655~26086917:+
BRCA	cis	rs1707322	0.963	rs6429581	ENSG00000234329.1	RP11-767N6.2	4.7	2.9e-06	0.000268	0.15	0.14	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45853424	chr1:45651039~45651826:-
BRCA	cis	rs7178909	0.872	rs3867167	ENSG00000259677.1	RP11-493E3.1	4.7	2.9e-06	0.000268	0.17	0.14	Common traits (Other);	chr15:89890558	chr15:89876540~89877285:+
BRCA	cis	rs7428	0.527	rs1554110	ENSG00000273196.1	RP11-717A5.2	4.7	2.9e-06	0.000268	0.17	0.14	Ear protrusion;	chr2:85320840	chr2:85387074~85387146:-
BRCA	cis	rs1950326	0.515	rs12881979	ENSG00000258526.4	RP11-111A21.1	4.7	2.91e-06	0.000268	0.19	0.14	Verbal memory performance (residualized delayed recall level);	chr14:39568834	chr14:39474840~39513780:+
BRCA	cis	rs9300255	0.544	rs1790123	ENSG00000235423.7	RP11-282O18.3	4.7	2.91e-06	0.000268	0.2	0.14	Neutrophil percentage of white cells;	chr12:123174995	chr12:123252030~123261483:-
BRCA	cis	rs12744310	0.887	rs12042464	ENSG00000235358.1	RP11-399E6.1	-4.7	2.91e-06	0.000268	-0.22	-0.14	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41321182	chr1:41242373~41284861:+
BRCA	cis	rs1122401	0.515	rs2548638	ENSG00000280159.1	CTD-2591A1.1	4.7	2.91e-06	0.000268	0.24	0.14	Smoking initiation;	chr5:54573746	chr5:54643557~54645987:+
BRCA	cis	rs4950322	0.518	rs56151278	ENSG00000244371.2	PFN1P8	-4.7	2.91e-06	0.000268	-0.19	-0.14	Protein quantitative trait loci;	chr1:147117421	chr1:146957117~146957659:-
BRCA	cis	rs6840360	0.642	rs10454251	ENSG00000278978.1	RP11-164P12.5	-4.7	2.91e-06	0.000269	-0.16	-0.14	Intelligence (multi-trait analysis);	chr4:151462810	chr4:151669786~151670503:+
BRCA	cis	rs2153535	0.58	rs2327060	ENSG00000251164.1	HULC	-4.7	2.91e-06	0.000269	-0.18	-0.14	Motion sickness;	chr6:8446878	chr6:8652137~8653846:+
BRCA	cis	rs11098499	0.644	rs10009566	ENSG00000249244.1	RP11-548H18.2	4.7	2.91e-06	0.000269	0.16	0.14	Corneal astigmatism;	chr4:119637453	chr4:119391831~119395335:-
BRCA	cis	rs7200543	1	rs35574015	ENSG00000258354.1	MIR3180-1	-4.7	2.91e-06	0.000269	-0.19	-0.14	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15052204	chr16:14909887~14911345:-
BRCA	cis	rs5758511	0.68	rs5758698	ENSG00000227370.1	RP4-669P10.19	4.7	2.91e-06	0.000269	0.19	0.14	Birth weight;	chr22:42288812	chr22:42132543~42132998:+
BRCA	cis	rs17818399	0.612	rs4952834	ENSG00000279254.1	RP11-536C12.1	-4.7	2.91e-06	0.000269	-0.18	-0.14	Height;	chr2:46550323	chr2:46668870~46670778:+
BRCA	cis	rs2839186	0.786	rs7409792	ENSG00000228137.1	AP001469.7	4.7	2.91e-06	0.000269	0.15	0.14	Testicular germ cell tumor;	chr21:46271815	chr21:46246890~46247682:+
BRCA	cis	rs71520386	0.846	rs35247857	ENSG00000228649.7	AC005682.5	-4.7	2.91e-06	0.000269	-0.16	-0.14	Fibrinogen levels;	chr7:22780901	chr7:22854178~22861579:+
BRCA	cis	rs6570726	0.935	rs413916	ENSG00000270638.1	RP3-466P17.1	4.7	2.91e-06	0.000269	0.16	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145510264	chr6:145735570~145737218:+
BRCA	cis	rs2243480	0.901	rs13237344	ENSG00000222364.1	RNU6-96P	-4.7	2.92e-06	0.000269	-0.27	-0.14	Diabetic kidney disease;	chr7:66557269	chr7:66395191~66395286:+
BRCA	cis	rs17507216	0.609	rs1431716	ENSG00000255769.6	GOLGA2P10	-4.7	2.92e-06	0.000269	-0.22	-0.14	Excessive daytime sleepiness;	chr15:82676180	chr15:82472993~82513950:-
BRCA	cis	rs924712	0.545	rs9475034	ENSG00000261116.1	RP3-523K23.2	4.7	2.92e-06	0.000269	0.17	0.14	Breast cancer;	chr6:54837491	chr6:54943167~54945099:+
BRCA	cis	rs875971	0.862	rs778734	ENSG00000273448.1	RP11-166O4.6	4.7	2.92e-06	0.000269	0.13	0.14	Aortic root size;	chr7:66349862	chr7:67333047~67334383:+
BRCA	cis	rs1729951	0.546	rs361246	ENSG00000239213.4	NCK1-AS1	4.7	2.92e-06	0.000269	0.15	0.14	Neuroticism;	chr3:136976825	chr3:136841726~136862054:-
BRCA	cis	rs12893668	0.603	rs61637848	ENSG00000269958.1	RP11-73M18.8	4.7	2.92e-06	0.000269	0.16	0.14	Reticulocyte count;	chr14:103629694	chr14:103696353~103697163:+
BRCA	cis	rs7119	0.604	rs1055691	ENSG00000259362.2	RP11-307C19.1	4.7	2.92e-06	0.000269	0.19	0.14	Type 2 diabetes;	chr15:77572283	chr15:77525540~77534110:+
BRCA	cis	rs13113518	0.702	rs78829811	ENSG00000273257.1	RP11-177J6.1	4.7	2.92e-06	0.00027	0.19	0.14	Height;	chr4:55558258	chr4:55387949~55388271:+
BRCA	cis	rs13113518	0.702	rs75801206	ENSG00000273257.1	RP11-177J6.1	4.7	2.92e-06	0.00027	0.19	0.14	Height;	chr4:55558259	chr4:55387949~55388271:+
BRCA	cis	rs13113518	0.702	rs34658078	ENSG00000273257.1	RP11-177J6.1	4.7	2.92e-06	0.00027	0.19	0.14	Height;	chr4:55558261	chr4:55387949~55388271:+
BRCA	cis	rs9307551	0.636	rs1440861	ENSG00000250334.4	LINC00989	4.7	2.92e-06	0.00027	0.19	0.14	Refractive error;	chr4:79505470	chr4:79492416~79576460:+
BRCA	cis	rs67981189	0.634	rs2526875	ENSG00000269927.1	RP6-91H8.3	-4.7	2.92e-06	0.00027	-0.18	-0.14	Schizophrenia;	chr14:70911643	chr14:71141125~71143253:-
BRCA	cis	rs875971	0.545	rs73142245	ENSG00000273142.1	RP11-458F8.4	4.7	2.92e-06	0.00027	0.14	0.14	Aortic root size;	chr7:66226662	chr7:66902857~66906297:+
BRCA	cis	rs9921338	0.961	rs7202814	ENSG00000262703.1	RP11-485G7.6	-4.7	2.92e-06	0.00027	-0.18	-0.14	Vein graft stenosis in coronary artery bypass grafting;	chr16:11295917	chr16:11348143~11349321:-
BRCA	cis	rs875971	0.545	rs17138156	ENSG00000273142.1	RP11-458F8.4	4.7	2.92e-06	0.00027	0.14	0.14	Aortic root size;	chr7:66249708	chr7:66902857~66906297:+
BRCA	cis	rs2562456	0.755	rs1879234	ENSG00000268535.1	RP11-420K14.3	-4.7	2.92e-06	0.00027	-0.2	-0.14	Pain;	chr19:21521677	chr19:21709522~21710191:+
BRCA	cis	rs4494364	0.502	rs11105901	ENSG00000258100.1	RP11-121E16.1	4.7	2.92e-06	0.00027	0.21	0.14	Systolic blood pressure (alcohol consumption interaction);	chr12:90980976	chr12:91362196~91368606:+
BRCA	cis	rs9840812	0.592	rs35418151	ENSG00000273486.1	RP11-731C17.2	4.7	2.92e-06	0.00027	0.17	0.14	Fibrinogen levels;	chr3:136443779	chr3:136837338~136839021:-
BRCA	cis	rs739496	0.579	rs73422318	ENSG00000226469.1	ADAM1B	4.7	2.92e-06	0.00027	0.18	0.14	Platelet count;	chr12:111838169	chr12:111927018~111929017:+
BRCA	cis	rs739496	0.579	rs7314870	ENSG00000226469.1	ADAM1B	4.7	2.92e-06	0.00027	0.18	0.14	Platelet count;	chr12:111838660	chr12:111927018~111929017:+
BRCA	cis	rs7246657	0.722	rs35863684	ENSG00000226686.6	LINC01535	-4.7	2.92e-06	0.00027	-0.21	-0.14	Coronary artery calcification;	chr19:37618876	chr19:37251912~37265535:+
BRCA	cis	rs4925386	0.681	rs2427295	ENSG00000273619.1	RP5-908M14.9	-4.7	2.92e-06	0.00027	-0.13	-0.14	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62352375	chr20:62386303~62386970:-
BRCA	cis	rs862034	0.509	rs7149930	ENSG00000270000.1	RP3-449M8.9	4.7	2.93e-06	0.00027	0.18	0.14	Height;	chr14:74487356	chr14:74471930~74472360:-
BRCA	cis	rs8114671	0.836	rs6058154	ENSG00000126005.14	MMP24-AS1	4.7	2.93e-06	0.00027	0.17	0.14	Height;	chr20:34998031	chr20:35216462~35278131:-
BRCA	cis	rs4578769	0.531	rs9951973	ENSG00000265939.1	UBE2CP2	-4.7	2.93e-06	0.00027	-0.16	-0.14	Eosinophil percentage of white cells;	chr18:22974353	chr18:22900486~22900995:-
BRCA	cis	rs7312933	0.526	rs1669892	ENSG00000257225.1	RP11-328C8.4	4.7	2.93e-06	0.00027	0.17	0.14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42417503	chr12:42459366~42466128:+
BRCA	cis	rs253959	0.502	rs10478275	ENSG00000271918.1	CTD-2287O16.5	4.7	2.93e-06	0.00027	0.13	0.14	Bipolar disorder and schizophrenia;	chr5:116092399	chr5:116083807~116085416:-
BRCA	cis	rs3176789	0.671	rs11052969	ENSG00000256673.1	RP11-599J14.2	4.7	2.93e-06	0.000271	0.16	0.14	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9766655	chr12:9398355~9414851:-
BRCA	cis	rs3176789	0.671	rs11052971	ENSG00000256673.1	RP11-599J14.2	4.7	2.93e-06	0.000271	0.16	0.14	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9766683	chr12:9398355~9414851:-
BRCA	cis	rs890448	0.726	rs2850370	ENSG00000254531.1	FLJ20021	-4.7	2.93e-06	0.000271	-0.16	-0.14	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101315584	chr4:101347780~101348883:+
BRCA	cis	rs10938353	0.911	rs1866511	ENSG00000273369.1	RP11-700J17.1	4.7	2.93e-06	0.000271	0.16	0.14	Body mass index;	chr4:44590153	chr4:44693946~44694386:-
BRCA	cis	rs2880765	0.835	rs4281668	ENSG00000230373.7	GOLGA6L5P	4.7	2.93e-06	0.000271	0.16	0.14	Coronary artery disease;	chr15:85504055	chr15:84507885~84516814:-
BRCA	cis	rs5758511	0.68	rs5758684	ENSG00000226450.2	CYP2D8P	4.7	2.93e-06	0.000271	0.17	0.14	Birth weight;	chr22:42253503	chr22:42149886~42155001:-
BRCA	cis	rs7818688	0.578	rs71532343	ENSG00000253528.2	RP11-347C18.4	-4.7	2.93e-06	0.000271	-0.23	-0.14	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95064585	chr8:94974573~94974853:-
BRCA	cis	rs2235544	0.541	rs928442	ENSG00000225183.1	RP4-758J24.4	-4.7	2.93e-06	0.000271	-0.17	-0.14	Thyroid hormone levels;Multiple myeloma (hyperdiploidy);	chr1:54007815	chr1:54089856~54090093:+
BRCA	cis	rs17428076	0.793	rs72881938	ENSG00000228389.1	AC068039.4	-4.7	2.93e-06	0.000271	-0.21	-0.14	Myopia;	chr2:171772242	chr2:171773482~171775844:+
BRCA	cis	rs11673344	0.523	rs10420330	ENSG00000226686.6	LINC01535	4.7	2.93e-06	0.000271	0.18	0.14	Obesity-related traits;	chr19:37111269	chr19:37251912~37265535:+
BRCA	cis	rs8054556	0.647	rs11649149	ENSG00000261367.1	RP11-455F5.4	-4.7	2.93e-06	0.000271	-0.16	-0.14	Autism spectrum disorder or schizophrenia;	chr16:29997323	chr16:30107675~30110541:+
BRCA	cis	rs4237845	0.537	rs10747786	ENSG00000257159.1	RP11-58A17.3	4.7	2.94e-06	0.000271	0.17	0.14	Intelligence (multi-trait analysis);	chr12:57866818	chr12:57967058~57968399:+
BRCA	cis	rs7312933	0.558	rs1669936	ENSG00000257225.1	RP11-328C8.4	4.7	2.94e-06	0.000271	0.17	0.14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42419707	chr12:42459366~42466128:+
BRCA	cis	rs2380205	0.651	rs1512694	ENSG00000232807.2	RP11-536K7.3	4.7	2.94e-06	0.000271	0.14	0.14	Breast cancer;	chr10:5874808	chr10:5934270~5945900:-
BRCA	cis	rs6125597	0.967	rs6063380	ENSG00000222365.1	SNORD12B	4.7	2.94e-06	0.000271	0.15	0.14	Intelligence (multi-trait analysis);	chr20:49265044	chr20:49280319~49280409:+
BRCA	cis	rs6125597	0.805	rs6063382	ENSG00000222365.1	SNORD12B	4.7	2.94e-06	0.000271	0.15	0.14	Intelligence (multi-trait analysis);	chr20:49273421	chr20:49280319~49280409:+
BRCA	cis	rs6125597	0.967	rs6122779	ENSG00000222365.1	SNORD12B	4.7	2.94e-06	0.000271	0.15	0.14	Intelligence (multi-trait analysis);	chr20:49276477	chr20:49280319~49280409:+
BRCA	cis	rs2832191	0.791	rs8134407	ENSG00000236056.1	GAPDHP14	-4.7	2.94e-06	0.000271	-0.15	-0.14	Dental caries;	chr21:29104265	chr21:29222321~29223257:+
BRCA	cis	rs4950322	0.518	rs61838951	ENSG00000244371.2	PFN1P8	-4.7	2.94e-06	0.000271	-0.19	-0.14	Protein quantitative trait loci;	chr1:147116081	chr1:146957117~146957659:-
BRCA	cis	rs10129255	0.912	rs6576227	ENSG00000280411.1	IGHV1-69-2	-4.7	2.94e-06	0.000271	-0.1	-0.14	Kawasaki disease;	chr14:106778202	chr14:106762092~106762588:-
BRCA	cis	rs10129255	0.957	rs6576228	ENSG00000280411.1	IGHV1-69-2	-4.7	2.94e-06	0.000271	-0.1	-0.14	Kawasaki disease;	chr14:106778401	chr14:106762092~106762588:-
BRCA	cis	rs6490294	0.615	rs78729142	ENSG00000226469.1	ADAM1B	4.7	2.94e-06	0.000271	0.25	0.14	Mean platelet volume;	chr12:111919456	chr12:111927018~111929017:+
BRCA	cis	rs6490294	0.528	rs79976090	ENSG00000226469.1	ADAM1B	4.7	2.94e-06	0.000271	0.25	0.14	Mean platelet volume;	chr12:111928314	chr12:111927018~111929017:+
BRCA	cis	rs6921919	0.583	rs2071965	ENSG00000273712.1	RP5-874C20.7	4.7	2.94e-06	0.000271	0.19	0.14	Autism spectrum disorder or schizophrenia;	chr6:28435448	chr6:28315613~28315883:-
BRCA	cis	rs6840360	0.642	rs7676493	ENSG00000251611.1	RP11-610P16.1	-4.7	2.94e-06	0.000271	-0.13	-0.14	Intelligence (multi-trait analysis);	chr4:151505613	chr4:151407551~151408835:-
BRCA	cis	rs6840360	0.642	rs11735957	ENSG00000251611.1	RP11-610P16.1	-4.7	2.94e-06	0.000271	-0.13	-0.14	Intelligence (multi-trait analysis);	chr4:151506354	chr4:151407551~151408835:-
BRCA	cis	rs6840360	0.642	rs2053566	ENSG00000251611.1	RP11-610P16.1	-4.7	2.94e-06	0.000271	-0.13	-0.14	Intelligence (multi-trait analysis);	chr4:151524679	chr4:151407551~151408835:-
BRCA	cis	rs6840360	0.607	rs1561918	ENSG00000251611.1	RP11-610P16.1	-4.7	2.94e-06	0.000271	-0.13	-0.14	Intelligence (multi-trait analysis);	chr4:151525680	chr4:151407551~151408835:-
BRCA	cis	rs300890	0.76	rs7655782	ENSG00000250326.1	RP11-284M14.1	-4.7	2.94e-06	0.000271	-0.16	-0.14	Nasopharyngeal carcinoma;	chr4:143285095	chr4:142933195~143184861:-
BRCA	cis	rs9921338	0.961	rs4390613	ENSG00000262703.1	RP11-485G7.6	4.7	2.94e-06	0.000271	0.18	0.14	Vein graft stenosis in coronary artery bypass grafting;	chr16:11328979	chr16:11348143~11349321:-
BRCA	cis	rs934734	0.509	rs12185577	ENSG00000204929.10	AC074391.1	-4.7	2.94e-06	0.000271	-0.18	-0.14	Rheumatoid arthritis;	chr2:65432354	chr2:65436711~66084639:+
BRCA	cis	rs10129255	0.957	rs10141009	ENSG00000280411.1	IGHV1-69-2	-4.7	2.94e-06	0.000271	-0.1	-0.14	Kawasaki disease;	chr14:106776695	chr14:106762092~106762588:-
BRCA	cis	rs2919009	0.598	rs2420896	ENSG00000271670.1	RP11-95I16.4	4.7	2.94e-06	0.000272	0.19	0.14	Obesity-related traits;	chr10:120936893	chr10:120879256~120880667:-
BRCA	cis	rs2919009	0.581	rs2420897	ENSG00000271670.1	RP11-95I16.4	4.7	2.94e-06	0.000272	0.19	0.14	Obesity-related traits;	chr10:120936918	chr10:120879256~120880667:-
BRCA	cis	rs2919009	0.62	rs4437952	ENSG00000271670.1	RP11-95I16.4	4.7	2.94e-06	0.000272	0.19	0.14	Obesity-related traits;	chr10:120937138	chr10:120879256~120880667:-
BRCA	cis	rs14027	0.559	rs9297603	ENSG00000279347.1	RP11-85I17.2	-4.7	2.94e-06	0.000272	-0.14	-0.14	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119707078	chr8:119838736~119840385:-
BRCA	cis	rs7818688	0.697	rs11781757	ENSG00000253528.2	RP11-347C18.4	-4.7	2.94e-06	0.000272	-0.22	-0.14	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94975663	chr8:94974573~94974853:-
BRCA	cis	rs4780355	0.918	rs243323	ENSG00000262703.1	RP11-485G7.6	4.7	2.95e-06	0.000272	0.16	0.14	Crohn's disease and psoriasis;	chr16:11267345	chr16:11348143~11349321:-
BRCA	cis	rs11822910	0.737	rs2581924	ENSG00000265566.2	RN7SL605P	4.7	2.95e-06	0.000272	0.19	0.14	Platelet distribution width;	chr11:57440995	chr11:57528085~57528365:-
BRCA	cis	rs7615952	0.932	rs13325495	ENSG00000241288.6	RP11-379B18.5	-4.7	2.95e-06	0.000272	-0.21	-0.14	Blood pressure (smoking interaction);	chr3:125918573	chr3:125827238~125916384:-
BRCA	cis	rs4934494	0.539	rs11185777	ENSG00000240996.1	RP11-80H5.7	-4.7	2.95e-06	0.000272	-0.18	-0.14	Red blood cell count;	chr10:89594453	chr10:89694295~89697928:-
BRCA	cis	rs11098499	0.708	rs1546506	ENSG00000249244.1	RP11-548H18.2	4.7	2.95e-06	0.000272	0.16	0.14	Corneal astigmatism;	chr4:119320085	chr4:119391831~119395335:-
BRCA	cis	rs13113518	1	rs1522112	ENSG00000273257.1	RP11-177J6.1	4.7	2.95e-06	0.000272	0.18	0.14	Height;	chr4:55463606	chr4:55387949~55388271:+
BRCA	cis	rs13113518	1	rs4864997	ENSG00000273257.1	RP11-177J6.1	4.7	2.95e-06	0.000272	0.18	0.14	Height;	chr4:55466010	chr4:55387949~55388271:+
BRCA	cis	rs13113518	1	rs960152	ENSG00000273257.1	RP11-177J6.1	4.7	2.95e-06	0.000272	0.18	0.14	Height;	chr4:55467308	chr4:55387949~55388271:+
BRCA	cis	rs13113518	0.967	rs12644948	ENSG00000273257.1	RP11-177J6.1	4.7	2.95e-06	0.000272	0.18	0.14	Height;	chr4:55470266	chr4:55387949~55388271:+
BRCA	cis	rs13113518	1	rs3805151	ENSG00000273257.1	RP11-177J6.1	4.7	2.95e-06	0.000272	0.18	0.14	Height;	chr4:55470874	chr4:55387949~55388271:+
BRCA	cis	rs13236243	0.603	rs10452776	ENSG00000237773.4	AC003075.4	-4.7	2.95e-06	0.000272	-0.21	-0.14	Sensory disturbances after bilateral sagittal split ramus osteotomy;	chr7:17287119	chr7:17279834~17299357:-
BRCA	cis	rs7119	0.717	rs12916682	ENSG00000259362.2	RP11-307C19.1	-4.7	2.95e-06	0.000272	-0.2	-0.14	Type 2 diabetes;	chr15:77515595	chr15:77525540~77534110:+
BRCA	cis	rs875971	0.545	rs6979636	ENSG00000232546.1	RP11-458F8.1	4.7	2.95e-06	0.000272	0.14	0.14	Aortic root size;	chr7:66276638	chr7:66848496~66858136:+
BRCA	cis	rs7647973	1	rs62259947	ENSG00000244380.1	RP11-24C3.2	-4.7	2.95e-06	0.000272	-0.19	-0.14	Menarche (age at onset);	chr3:49402491	chr3:48440352~48446656:-
BRCA	cis	rs7647973	1	rs6446262	ENSG00000244380.1	RP11-24C3.2	4.7	2.95e-06	0.000272	0.19	0.14	Menarche (age at onset);	chr3:49363720	chr3:48440352~48446656:-
BRCA	cis	rs316341	0.723	rs316339	ENSG00000230438.6	SERPINB9P1	4.7	2.95e-06	0.000272	0.2	0.14	Cerebrospinal fluid AB1-42 levels;	chr6:2837812	chr6:2854657~2881407:-
BRCA	cis	rs2880765	0.566	rs12911430	ENSG00000202081.1	RNU6-1280P	4.7	2.95e-06	0.000272	0.18	0.14	Coronary artery disease;	chr15:85468033	chr15:85651522~85651628:-
BRCA	cis	rs2337406	0.587	rs10139664	ENSG00000211974.3	IGHV2-70	-4.7	2.95e-06	0.000272	-0.18	-0.14	Alzheimer's disease (late onset);	chr14:106647254	chr14:106723574~106724093:-
BRCA	cis	rs1008375	1	rs7673500	ENSG00000249502.1	AC006160.5	-4.7	2.95e-06	0.000272	-0.17	-0.14	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17619760	chr4:17587467~17614571:-
BRCA	cis	rs739496	0.546	rs11066055	ENSG00000226469.1	ADAM1B	4.7	2.95e-06	0.000272	0.18	0.14	Platelet count;	chr12:111875412	chr12:111927018~111929017:+
BRCA	cis	rs6738627	0.861	rs6713419	ENSG00000223318.1	RNA5SP111	4.7	2.95e-06	0.000272	0.16	0.14	circulating leptin levels adjusted for BMI;Body fat percentage;circulating leptin levels;	chr2:164651790	chr2:164895677~164895777:-
BRCA	cis	rs5758659	0.819	rs134871	ENSG00000182057.4	OGFRP1	4.7	2.96e-06	0.000273	0.16	0.14	Cognitive function;	chr22:42256710	chr22:42269753~42275196:+
BRCA	cis	rs10504130	0.696	rs11785805	ENSG00000253844.1	RP11-546K22.1	-4.7	2.96e-06	0.000273	-0.22	-0.14	Venous thromboembolism (SNP x SNP interaction);	chr8:51929310	chr8:51961458~52022974:+
BRCA	cis	rs67766926	1	rs17538840	ENSG00000271889.1	RP11-493E12.1	-4.7	2.96e-06	0.000273	-0.21	-0.14	Inflammatory skin disease;	chr2:60850682	chr2:61151433~61162105:-
BRCA	cis	rs2738459	0.522	rs2738457	ENSG00000212497.1	RNA5SP465	4.7	2.96e-06	0.000273	0.18	0.14	LDL cholesterol;	chr19:11126593	chr19:12027913~12028021:-
BRCA	cis	rs1122401	0.515	rs2564981	ENSG00000280159.1	CTD-2591A1.1	4.7	2.96e-06	0.000273	0.23	0.14	Smoking initiation;	chr5:54575075	chr5:54643557~54645987:+
BRCA	cis	rs11048434	0.518	rs4883206	ENSG00000256937.1	KRT17P8	-4.7	2.96e-06	0.000273	-0.15	-0.14	Sjögren's syndrome;	chr12:9021169	chr12:9127783~9128645:+
BRCA	cis	rs2243480	1	rs313814	ENSG00000222364.1	RNU6-96P	-4.7	2.96e-06	0.000273	-0.27	-0.14	Diabetic kidney disease;	chr7:66038306	chr7:66395191~66395286:+
BRCA	cis	rs1910358	0.621	rs2055140	ENSG00000248874.4	C5orf17	-4.7	2.96e-06	0.000273	-0.21	-0.14	Venous thromboembolism (SNP x SNP interaction);	chr5:23859035	chr5:23951348~24178263:+
BRCA	cis	rs2279168	0.867	rs11074223	ENSG00000259407.1	RP11-158M2.3	4.7	2.96e-06	0.000273	0.27	0.14	Response to platinum-based chemotherapy (carboplatin);	chr15:85413359	chr15:85744109~85750281:-
BRCA	cis	rs12497850	0.931	rs9876848	ENSG00000225399.4	RP11-3B7.1	4.7	2.96e-06	0.000273	0.14	0.14	Parkinson's disease;	chr3:48806626	chr3:49260085~49261316:+
BRCA	cis	rs853679	0.882	rs4713139	ENSG00000280107.1	AL022393.9	-4.7	2.96e-06	0.000273	-0.3	-0.14	Depression;	chr6:28124907	chr6:28170845~28172521:+
BRCA	cis	rs4781563	0.789	rs1799797	ENSG00000242307.1	RPS26P52	-4.7	2.96e-06	0.000273	-0.18	-0.14	Bilirubin levels;	chr16:13920136	chr16:13922332~13922679:-
BRCA	cis	rs1161098	0.723	rs1178001	ENSG00000203585.3	RP11-542B15.1	-4.7	2.96e-06	0.000273	-0.22	-0.14	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr12:67432018	chr12:67519829~67567126:+
BRCA	cis	rs16958440	1	rs61316646	ENSG00000267724.1	RP11-49K24.8	4.7	2.96e-06	0.000273	0.25	0.14	Sitting height ratio;	chr18:47084299	chr18:47105946~47108062:+
BRCA	cis	rs2179367	0.959	rs521845	ENSG00000268592.3	RAET1E-AS1	-4.7	2.96e-06	0.000273	-0.18	-0.14	Dupuytren's disease;	chr6:149350562	chr6:149863494~149919507:+
BRCA	cis	rs10129255	0.912	rs61997792	ENSG00000211974.3	IGHV2-70	4.7	2.96e-06	0.000273	0.15	0.14	Kawasaki disease;	chr14:106799304	chr14:106723574~106724093:-
BRCA	cis	rs13326165	0.585	rs76103861	ENSG00000243224.1	RP5-1157M23.2	-4.7	2.96e-06	0.000273	-0.27	-0.14	HDL cholesterol levels;HDL cholesterol;	chr3:52252870	chr3:52239258~52241097:+
BRCA	cis	rs10540	1	rs12418639	ENSG00000279672.1	CMB9-55F22.1	-4.7	2.96e-06	0.000273	-0.26	-0.14	Body mass index;	chr11:473300	chr11:779617~780755:+
BRCA	cis	rs2243480	1	rs431318	ENSG00000222364.1	RNU6-96P	-4.7	2.96e-06	0.000273	-0.27	-0.14	Diabetic kidney disease;	chr7:66046610	chr7:66395191~66395286:+
BRCA	cis	rs13108904	0.539	rs13145722	ENSG00000253399.1	AC078852.2	-4.7	2.97e-06	0.000273	-0.18	-0.14	Obesity-related traits;	chr4:1344634	chr4:1358479~1359461:+
BRCA	cis	rs1153858	1	rs56806728	ENSG00000275672.1	GATM-AS1	-4.7	2.97e-06	0.000274	-0.18	-0.14	Homoarginine levels;	chr15:45345616	chr15:45378700~45380123:+
BRCA	cis	rs6951245	1	rs113146460	ENSG00000229043.2	AC091729.9	-4.7	2.97e-06	0.000274	-0.26	-0.14	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1065528	chr7:1160374~1165267:+
BRCA	cis	rs6951245	0.935	rs61753396	ENSG00000229043.2	AC091729.9	-4.7	2.97e-06	0.000274	-0.26	-0.14	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1065736	chr7:1160374~1165267:+
BRCA	cis	rs6951245	1	rs79327308	ENSG00000229043.2	AC091729.9	-4.7	2.97e-06	0.000274	-0.26	-0.14	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1068505	chr7:1160374~1165267:+
BRCA	cis	rs6951245	0.938	rs117729148	ENSG00000229043.2	AC091729.9	-4.7	2.97e-06	0.000274	-0.26	-0.14	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1068895	chr7:1160374~1165267:+
BRCA	cis	rs4218	0.597	rs62002544	ENSG00000277144.1	RP11-59H7.4	-4.7	2.97e-06	0.000274	-0.2	-0.14	Social communication problems;	chr15:59066663	chr15:59115547~59116089:-
BRCA	cis	rs16958440	1	rs62096474	ENSG00000280212.1	RP11-49K24.3	4.7	2.97e-06	0.000274	0.3	0.14	Sitting height ratio;	chr18:47121133	chr18:47076117~47076594:+
BRCA	cis	rs919433	0.679	rs6737060	ENSG00000231621.1	AC013264.2	-4.7	2.97e-06	0.000274	-0.14	-0.14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197660161	chr2:197197991~197199273:+
BRCA	cis	rs919433	0.679	rs6708239	ENSG00000231621.1	AC013264.2	-4.7	2.97e-06	0.000274	-0.14	-0.14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197660360	chr2:197197991~197199273:+
BRCA	cis	rs919433	0.647	rs6741205	ENSG00000231621.1	AC013264.2	-4.7	2.97e-06	0.000274	-0.14	-0.14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197661273	chr2:197197991~197199273:+
BRCA	cis	rs919433	0.679	rs6741314	ENSG00000231621.1	AC013264.2	-4.7	2.97e-06	0.000274	-0.14	-0.14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197661364	chr2:197197991~197199273:+
BRCA	cis	rs919433	0.588	rs11690163	ENSG00000231621.1	AC013264.2	-4.7	2.97e-06	0.000274	-0.14	-0.14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197662783	chr2:197197991~197199273:+
BRCA	cis	rs919433	0.679	rs61155920	ENSG00000231621.1	AC013264.2	-4.7	2.97e-06	0.000274	-0.14	-0.14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197664157	chr2:197197991~197199273:+
BRCA	cis	rs9652601	0.691	rs3893660	ENSG00000274038.1	RP11-66H6.4	-4.7	2.97e-06	0.000274	-0.16	-0.14	Systemic lupus erythematosus;	chr16:11100073	chr16:11056556~11057034:+
BRCA	cis	rs2904967	0.852	rs1858783	ENSG00000255200.1	AP003068.18	4.7	2.97e-06	0.000274	0.23	0.14	Mean corpuscular volume;	chr11:65275470	chr11:65174117~65176470:-
BRCA	cis	rs4780355	0.776	rs9936459	ENSG00000262703.1	RP11-485G7.6	-4.7	2.97e-06	0.000274	-0.15	-0.14	Crohn's disease and psoriasis;	chr16:11343922	chr16:11348143~11349321:-
BRCA	cis	rs1161098	0.716	rs1732627	ENSG00000203585.3	RP11-542B15.1	-4.7	2.97e-06	0.000274	-0.22	-0.14	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr12:67449083	chr12:67519829~67567126:+
BRCA	cis	rs256438	0.894	rs2434286	ENSG00000251050.1	RP11-168A11.4	-4.7	2.97e-06	0.000274	-0.16	-0.14	Serum thyroid-stimulating hormone levels;	chr5:80096154	chr5:80019609~80019920:+
BRCA	cis	rs2803122	0.777	rs6475326	ENSG00000273226.1	RP11-513M16.8	4.7	2.97e-06	0.000274	0.15	0.14	Pulse pressure;	chr9:19386567	chr9:19375451~19375996:+
BRCA	cis	rs4908760	0.864	rs6674832	ENSG00000232912.4	RP5-1115A15.1	4.7	2.97e-06	0.000274	0.14	0.14	Vitiligo;	chr1:8631820	chr1:8424645~8434838:+
BRCA	cis	rs7674212	0.57	rs12501621	ENSG00000246560.2	RP11-10L12.4	4.7	2.97e-06	0.000274	0.15	0.14	Type 2 diabetes;	chr4:103174348	chr4:102828055~102844075:+
BRCA	cis	rs11098499	0.754	rs9991959	ENSG00000260404.2	RP11-384K6.6	-4.7	2.97e-06	0.000274	-0.13	-0.14	Corneal astigmatism;	chr4:119332618	chr4:118591773~118633729:+
BRCA	cis	rs9467773	0.587	rs3208733	ENSG00000124549.13	BTN2A3P	-4.7	2.97e-06	0.000274	-0.15	-0.14	Intelligence (multi-trait analysis);	chr6:26414197	chr6:26421391~26432383:+
BRCA	cis	rs6921919	0.583	rs7740351	ENSG00000273712.1	RP5-874C20.7	4.7	2.97e-06	0.000274	0.19	0.14	Autism spectrum disorder or schizophrenia;	chr6:28431635	chr6:28315613~28315883:-
BRCA	cis	rs4781563	1	rs3136173	ENSG00000242307.1	RPS26P52	-4.7	2.97e-06	0.000274	-0.18	-0.14	Bilirubin levels;	chr16:13939210	chr16:13922332~13922679:-
BRCA	cis	rs7267979	0.868	rs6138553	ENSG00000125804.12	FAM182A	-4.7	2.98e-06	0.000274	-0.19	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25258597	chr20:26054655~26086917:+
BRCA	cis	rs4713118	0.955	rs9393848	ENSG00000216901.1	AL022393.7	4.7	2.98e-06	0.000274	0.2	0.14	Parkinson's disease;	chr6:27720590	chr6:28176188~28176674:+
BRCA	cis	rs6430585	0.591	rs77096272	ENSG00000231890.6	DARS-AS1	-4.7	2.98e-06	0.000274	-0.23	-0.14	Corneal structure;	chr2:135906035	chr2:135985176~136022593:+
BRCA	cis	rs11603691	1	rs11603691	ENSG00000254662.1	RP11-872D17.4	-4.7	2.98e-06	0.000274	-0.33	-0.14	Low high density lipoprotein cholesterol levels;	chr11:57340143	chr11:57325603~57327958:+
BRCA	cis	rs6840258	0.64	rs28882732	ENSG00000251411.1	RP11-397E7.4	-4.7	2.98e-06	0.000275	-0.19	-0.14	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87154824	chr4:86913266~86914817:-
BRCA	cis	rs6840258	0.582	rs7437661	ENSG00000251411.1	RP11-397E7.4	-4.7	2.98e-06	0.000275	-0.19	-0.14	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87156860	chr4:86913266~86914817:-
BRCA	cis	rs6840258	0.582	rs1021104	ENSG00000251411.1	RP11-397E7.4	-4.7	2.98e-06	0.000275	-0.19	-0.14	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87157017	chr4:86913266~86914817:-
BRCA	cis	rs1800795	0.53	rs62449494	ENSG00000179428.2	AC073072.5	-4.7	2.98e-06	0.000275	-0.15	-0.14	Cerebrospinal fluid clusterin levels in APOEe4- carriers;	chr7:22718416	chr7:22725395~22727620:-
BRCA	cis	rs16958440	1	rs60422392	ENSG00000267724.1	RP11-49K24.8	4.7	2.98e-06	0.000275	0.25	0.14	Sitting height ratio;	chr18:47095102	chr18:47105946~47108062:+
BRCA	cis	rs16958440	1	rs2289130	ENSG00000267724.1	RP11-49K24.8	4.7	2.98e-06	0.000275	0.25	0.14	Sitting height ratio;	chr18:47100259	chr18:47105946~47108062:+
BRCA	cis	rs16958440	1	rs62096463	ENSG00000267724.1	RP11-49K24.8	4.7	2.98e-06	0.000275	0.25	0.14	Sitting height ratio;	chr18:47102557	chr18:47105946~47108062:+
BRCA	cis	rs16958440	1	rs62096464	ENSG00000267724.1	RP11-49K24.8	4.7	2.98e-06	0.000275	0.25	0.14	Sitting height ratio;	chr18:47102836	chr18:47105946~47108062:+
BRCA	cis	rs16958440	1	rs16958432	ENSG00000267724.1	RP11-49K24.8	4.7	2.98e-06	0.000275	0.25	0.14	Sitting height ratio;	chr18:47105402	chr18:47105946~47108062:+
BRCA	cis	rs16958440	1	rs16958440	ENSG00000267724.1	RP11-49K24.8	4.7	2.98e-06	0.000275	0.25	0.14	Sitting height ratio;	chr18:47106513	chr18:47105946~47108062:+
BRCA	cis	rs16958440	1	rs75800624	ENSG00000267724.1	RP11-49K24.8	4.7	2.98e-06	0.000275	0.25	0.14	Sitting height ratio;	chr18:47107234	chr18:47105946~47108062:+
BRCA	cis	rs13108904	0.901	rs1316393	ENSG00000254094.1	AC078852.1	4.7	2.98e-06	0.000275	0.16	0.14	Obesity-related traits;	chr4:1321831	chr4:1356581~1358075:+
BRCA	cis	rs11239930	0.538	rs719969	ENSG00000230832.3	RP11-325P15.2	-4.7	2.98e-06	0.000275	-0.21	-0.14	AIDS progression;	chr1:147084111	chr1:147082338~147083578:-
BRCA	cis	rs7474896	0.583	rs12776092	ENSG00000120555.12	SEPT7P9	4.7	2.98e-06	0.000275	0.2	0.14	Obesity (extreme);	chr10:37726867	chr10:38383069~38402916:-
BRCA	cis	rs12497850	0.805	rs6446198	ENSG00000225399.4	RP11-3B7.1	4.7	2.98e-06	0.000275	0.14	0.14	Parkinson's disease;	chr3:48970205	chr3:49260085~49261316:+
BRCA	cis	rs6840360	0.653	rs13136369	ENSG00000270265.1	RP11-731D1.4	4.7	2.98e-06	0.000275	0.16	0.14	Intelligence (multi-trait analysis);	chr4:151810131	chr4:151333775~151353224:-
BRCA	cis	rs2839186	0.749	rs62226488	ENSG00000228137.1	AP001469.7	4.7	2.98e-06	0.000275	0.15	0.14	Testicular germ cell tumor;	chr21:46290603	chr21:46246890~46247682:+
BRCA	cis	rs2839186	0.749	rs62226489	ENSG00000228137.1	AP001469.7	4.7	2.98e-06	0.000275	0.15	0.14	Testicular germ cell tumor;	chr21:46290605	chr21:46246890~46247682:+
BRCA	cis	rs919433	0.679	rs9967823	ENSG00000231621.1	AC013264.2	-4.7	2.98e-06	0.000275	-0.14	-0.14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197666805	chr2:197197991~197199273:+
BRCA	cis	rs11742741	0.714	rs1428200	ENSG00000248874.4	C5orf17	-4.7	2.99e-06	0.000275	-0.19	-0.14	Educational attainment;	chr5:24138128	chr5:23951348~24178263:+
BRCA	cis	rs2839186	0.869	rs17176513	ENSG00000228137.1	AP001469.7	4.7	2.99e-06	0.000275	0.15	0.14	Testicular germ cell tumor;	chr21:46262514	chr21:46246890~46247682:+
BRCA	cis	rs6832769	1	rs6851838	ENSG00000272969.1	RP11-528I4.2	-4.7	2.99e-06	0.000275	-0.17	-0.14	Personality dimensions;	chr4:55554580	chr4:55547112~55547889:+
BRCA	cis	rs2277027	1	rs11134789	ENSG00000248544.2	CTB-47B11.3	4.7	2.99e-06	0.000275	0.17	0.14	Pulmonary function;Pulmonary function (smoking interaction);	chr5:157517191	chr5:157375741~157384950:-
BRCA	cis	rs6840360	0.573	rs11099806	ENSG00000270265.1	RP11-731D1.4	-4.7	2.99e-06	0.000275	-0.16	-0.14	Intelligence (multi-trait analysis);	chr4:151347964	chr4:151333775~151353224:-
BRCA	cis	rs8048589	0.948	rs35318501	ENSG00000175604.2	RP11-276H1.3	-4.7	2.99e-06	0.000275	-0.23	-0.14	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);	chr16:12088674	chr16:12086746~12090302:-
BRCA	cis	rs1510272	0.728	rs4680287	ENSG00000243926.1	TIPARP-AS1	-4.7	2.99e-06	0.000275	-0.16	-0.14	Testicular germ cell tumor;	chr3:156611391	chr3:156671862~156674378:-
BRCA	cis	rs12497850	0.931	rs13064784	ENSG00000225399.4	RP11-3B7.1	4.7	2.99e-06	0.000276	0.14	0.14	Parkinson's disease;	chr3:49098528	chr3:49260085~49261316:+
BRCA	cis	rs7243790	0.774	rs7240534	ENSG00000277324.1	RP11-850A17.1	-4.7	2.99e-06	0.000276	-0.16	-0.14	Diastolic blood pressure;	chr18:54359527	chr18:54268346~54270028:-
BRCA	cis	rs2562456	0.876	rs62110163	ENSG00000268658.4	LINC00664	4.7	2.99e-06	0.000276	0.23	0.14	Pain;	chr19:21546020	chr19:21483374~21503238:+
BRCA	cis	rs2562456	0.761	rs35008138	ENSG00000268658.4	LINC00664	4.7	2.99e-06	0.000276	0.23	0.14	Pain;	chr19:21548822	chr19:21483374~21503238:+
BRCA	cis	rs2562456	0.833	rs2681388	ENSG00000268658.4	LINC00664	4.7	2.99e-06	0.000276	0.23	0.14	Pain;	chr19:21549451	chr19:21483374~21503238:+
BRCA	cis	rs2562456	0.876	rs2681370	ENSG00000268658.4	LINC00664	4.7	2.99e-06	0.000276	0.23	0.14	Pain;	chr19:21554036	chr19:21483374~21503238:+
BRCA	cis	rs2562456	0.876	rs11668606	ENSG00000268658.4	LINC00664	4.7	2.99e-06	0.000276	0.23	0.14	Pain;	chr19:21554618	chr19:21483374~21503238:+
BRCA	cis	rs2562456	0.876	rs2681395	ENSG00000268658.4	LINC00664	4.7	2.99e-06	0.000276	0.23	0.14	Pain;	chr19:21555338	chr19:21483374~21503238:+
BRCA	cis	rs2243480	0.803	rs160649	ENSG00000222364.1	RNU6-96P	-4.7	3e-06	0.000276	-0.27	-0.14	Diabetic kidney disease;	chr7:66078212	chr7:66395191~66395286:+
BRCA	cis	rs2243480	1	rs160648	ENSG00000222364.1	RNU6-96P	-4.7	3e-06	0.000276	-0.27	-0.14	Diabetic kidney disease;	chr7:66078397	chr7:66395191~66395286:+
BRCA	cis	rs7572733	0.773	rs13396312	ENSG00000231621.1	AC013264.2	4.7	3e-06	0.000276	0.13	0.14	Dermatomyositis;	chr2:197628979	chr2:197197991~197199273:+
BRCA	cis	rs10504130	0.569	rs34073804	ENSG00000272024.1	RP11-546K22.3	-4.7	3e-06	0.000276	-0.21	-0.14	Venous thromboembolism (SNP x SNP interaction);	chr8:51776808	chr8:51950284~51950690:+
BRCA	cis	rs8040855	0.597	rs994989	ENSG00000230373.7	GOLGA6L5P	4.7	3e-06	0.000276	0.19	0.14	Bulimia nervosa;	chr15:85117485	chr15:84507885~84516814:-
BRCA	cis	rs9659323	0.73	rs10802070	ENSG00000231365.4	RP11-418J17.1	-4.7	3e-06	0.000276	-0.17	-0.14	Body mass index;	chr1:118998863	chr1:119140396~119275973:+
BRCA	cis	rs9467773	0.62	rs2504567	ENSG00000241549.7	GUSBP2	4.7	3e-06	0.000276	0.15	0.14	Intelligence (multi-trait analysis);	chr6:26662692	chr6:26871484~26956554:-
BRCA	cis	rs867186	1	rs77437249	ENSG00000126005.14	MMP24-AS1	-4.7	3e-06	0.000276	-0.27	-0.14	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:34976935	chr20:35216462~35278131:-
BRCA	cis	rs60695258	0.55	rs340641	ENSG00000251411.1	RP11-397E7.4	4.7	3e-06	0.000276	0.16	0.14	Hematocrit;	chr4:87030241	chr4:86913266~86914817:-
BRCA	cis	rs9467773	0.62	rs2494700	ENSG00000241549.7	GUSBP2	4.7	3e-06	0.000276	0.15	0.14	Intelligence (multi-trait analysis);	chr6:26631078	chr6:26871484~26956554:-
BRCA	cis	rs9467773	0.584	rs1021372	ENSG00000241549.7	GUSBP2	4.7	3e-06	0.000276	0.15	0.14	Intelligence (multi-trait analysis);	chr6:26632216	chr6:26871484~26956554:-
BRCA	cis	rs9467773	0.583	rs1021373	ENSG00000241549.7	GUSBP2	4.7	3e-06	0.000276	0.15	0.14	Intelligence (multi-trait analysis);	chr6:26632229	chr6:26871484~26956554:-
BRCA	cis	rs9467773	0.62	rs2451744	ENSG00000241549.7	GUSBP2	4.7	3e-06	0.000276	0.15	0.14	Intelligence (multi-trait analysis);	chr6:26633235	chr6:26871484~26956554:-
BRCA	cis	rs9467773	0.62	rs2494701	ENSG00000241549.7	GUSBP2	4.7	3e-06	0.000276	0.15	0.14	Intelligence (multi-trait analysis);	chr6:26634204	chr6:26871484~26956554:-
BRCA	cis	rs9467773	0.62	rs1027204	ENSG00000241549.7	GUSBP2	4.7	3e-06	0.000276	0.15	0.14	Intelligence (multi-trait analysis);	chr6:26639385	chr6:26871484~26956554:-
BRCA	cis	rs62103177	0.733	rs62096748	ENSG00000261126.6	RP11-795F19.1	4.7	3e-06	0.000276	0.22	0.14	Opioid sensitivity;	chr18:79859699	chr18:80046900~80095482:+
BRCA	cis	rs6847067	0.8	rs13141322	ENSG00000180769.7	WDFY3-AS2	4.7	3e-06	0.000276	0.13	0.14	Oropharynx cancer;	chr4:84911425	chr4:84965682~85011277:+
BRCA	cis	rs8054556	0.669	rs9972866	ENSG00000261367.1	RP11-455F5.4	-4.7	3e-06	0.000277	-0.16	-0.14	Autism spectrum disorder or schizophrenia;	chr16:30007661	chr16:30107675~30110541:+
BRCA	cis	rs7267979	0.844	rs6107027	ENSG00000274414.1	RP5-965G21.4	-4.7	3e-06	0.000277	-0.17	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25307996	chr20:25239007~25245229:-
BRCA	cis	rs7243790	0.846	rs56053948	ENSG00000277324.1	RP11-850A17.1	-4.7	3e-06	0.000277	-0.17	-0.14	Diastolic blood pressure;	chr18:54434295	chr18:54268346~54270028:-
BRCA	cis	rs853679	0.723	rs9366718	ENSG00000216901.1	AL022393.7	4.7	3e-06	0.000277	0.22	0.14	Depression;	chr6:28237724	chr6:28176188~28176674:+
BRCA	cis	rs2243480	0.901	rs73148097	ENSG00000226002.1	RP11-460N20.5	-4.7	3.01e-06	0.000277	-0.24	-0.14	Diabetic kidney disease;	chr7:65966800	chr7:65084103~65100232:+
BRCA	cis	rs2243480	1	rs906134	ENSG00000226002.1	RP11-460N20.5	-4.7	3.01e-06	0.000277	-0.24	-0.14	Diabetic kidney disease;	chr7:65979301	chr7:65084103~65100232:+
BRCA	cis	rs9311474	0.508	rs7652191	ENSG00000243224.1	RP5-1157M23.2	-4.7	3.01e-06	0.000277	-0.15	-0.14	Electroencephalogram traits;	chr3:52576399	chr3:52239258~52241097:+
BRCA	cis	rs708547	0.581	rs10020462	ENSG00000269949.1	RP11-738E22.3	-4.7	3.01e-06	0.000277	-0.18	-0.14	Response to bleomycin (chromatid breaks);	chr4:56959427	chr4:56960927~56961373:-
BRCA	cis	rs2243480	1	rs2961102	ENSG00000226002.1	RP11-460N20.5	-4.7	3.01e-06	0.000277	-0.24	-0.14	Diabetic kidney disease;	chr7:65959671	chr7:65084103~65100232:+
BRCA	cis	rs11098499	0.754	rs12510269	ENSG00000260404.2	RP11-384K6.6	4.7	3.01e-06	0.000277	0.13	0.14	Corneal astigmatism;	chr4:119320491	chr4:118591773~118633729:+
BRCA	cis	rs34217772	0.883	rs72668818	ENSG00000258636.1	CTD-2298J14.2	4.7	3.01e-06	0.000277	0.2	0.14	Myopia;	chr14:41761485	chr14:41587861~41604856:-
BRCA	cis	rs34217772	0.883	rs61992434	ENSG00000258636.1	CTD-2298J14.2	4.7	3.01e-06	0.000277	0.2	0.14	Myopia;	chr14:41762055	chr14:41587861~41604856:-
BRCA	cis	rs10129255	0.957	rs8014696	ENSG00000211974.3	IGHV2-70	-4.7	3.01e-06	0.000277	-0.14	-0.14	Kawasaki disease;	chr14:106769752	chr14:106723574~106724093:-
BRCA	cis	rs11096990	0.656	rs2123028	ENSG00000249685.1	RP11-360F5.3	-4.7	3.01e-06	0.000277	-0.18	-0.14	Cognitive function;	chr4:39301859	chr4:39133913~39135608:+
BRCA	cis	rs2919009	0.766	rs56102659	ENSG00000271670.1	RP11-95I16.4	4.7	3.01e-06	0.000277	0.19	0.14	Obesity-related traits;	chr10:120786205	chr10:120879256~120880667:-
BRCA	cis	rs6441961	0.628	rs4683211	ENSG00000223552.1	RP11-24F11.2	-4.7	3.01e-06	0.000277	-0.18	-0.14	Celiac disease;	chr3:46303922	chr3:46364955~46407059:-
BRCA	cis	rs2281636	1	rs2231675	ENSG00000233690.1	EBAG9P1	-4.7	3.01e-06	0.000277	-0.15	-0.14	Obesity-related traits;	chr10:99732484	chr10:99697407~99697949:-
BRCA	cis	rs6596100	0.956	rs4574536	ENSG00000248648.1	RP11-485M7.1	-4.7	3.01e-06	0.000277	-0.19	-0.14	Breast cancer;	chr5:133048997	chr5:133003119~133003365:+
BRCA	cis	rs6832769	0.885	rs6815516	ENSG00000223305.1	RN7SKP30	-4.7	3.01e-06	0.000277	-0.18	-0.14	Personality dimensions;	chr4:55533017	chr4:55540502~55540835:-
BRCA	cis	rs11051970	0.559	rs10844179	ENSG00000274964.1	RP11-817I4.1	4.7	3.01e-06	0.000277	0.19	0.14	Response to tocilizumab in rheumatoid arthritis;	chr12:32316667	chr12:32339368~32340724:+
BRCA	cis	rs4664293	0.802	rs13025347	ENSG00000224152.1	AC009506.1	-4.7	3.01e-06	0.000277	-0.16	-0.14	Monocyte percentage of white cells;	chr2:159721056	chr2:159615296~159617082:+
BRCA	cis	rs4664293	0.867	rs6432554	ENSG00000224152.1	AC009506.1	-4.7	3.01e-06	0.000277	-0.16	-0.14	Monocyte percentage of white cells;	chr2:159722573	chr2:159615296~159617082:+
BRCA	cis	rs4664293	0.867	rs6760485	ENSG00000224152.1	AC009506.1	-4.7	3.01e-06	0.000277	-0.16	-0.14	Monocyte percentage of white cells;	chr2:159723179	chr2:159615296~159617082:+
BRCA	cis	rs721917	0.506	rs2758543	ENSG00000242600.5	MBL1P	4.7	3.01e-06	0.000278	0.17	0.14	Chronic obstructive pulmonary disease;	chr10:79902710	chr10:79904898~79950336:+
BRCA	cis	rs721917	0.525	rs2250473	ENSG00000242600.5	MBL1P	4.7	3.01e-06	0.000278	0.17	0.14	Chronic obstructive pulmonary disease;	chr10:79904639	chr10:79904898~79950336:+
BRCA	cis	rs950169	0.58	rs11634322	ENSG00000176700.18	SCAND2P	-4.7	3.02e-06	0.000278	-0.15	-0.14	Schizophrenia;	chr15:84628978	chr15:84631451~84647478:+
BRCA	cis	rs4356203	0.905	rs7930058	ENSG00000272034.1	SNORD14A	-4.7	3.02e-06	0.000278	-0.15	-0.14	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17045071	chr11:17074654~17074744:-
BRCA	cis	rs2832191	0.729	rs2832201	ENSG00000215533.7	LINC00189	4.7	3.02e-06	0.000278	0.17	0.14	Dental caries;	chr21:29127520	chr21:29193480~29288205:+
BRCA	cis	rs4489787	0.764	rs2705162	ENSG00000240399.1	RP1-228P16.1	4.7	3.02e-06	0.000278	0.24	0.14	Prostate cancer (SNP x SNP interaction);	chr12:48504734	chr12:48054813~48055591:-
BRCA	cis	rs34217772	0.766	rs61992404	ENSG00000258636.1	CTD-2298J14.2	4.7	3.02e-06	0.000278	0.21	0.14	Myopia;	chr14:41747596	chr14:41587861~41604856:-
BRCA	cis	rs7226408	0.948	rs72883563	ENSG00000267707.2	RP11-95O2.5	4.7	3.02e-06	0.000278	0.24	0.14	Obesity-related traits;	chr18:36799390	chr18:37243776~37247506:+
BRCA	cis	rs9543976	0.623	rs6562915	ENSG00000261105.4	LMO7-AS1	4.7	3.02e-06	0.000278	0.21	0.14	Diabetic retinopathy;	chr13:75596750	chr13:75604700~75635994:-
BRCA	cis	rs6596100	0.915	rs10463900	ENSG00000248648.1	RP11-485M7.1	-4.7	3.02e-06	0.000278	-0.18	-0.14	Breast cancer;	chr5:133098957	chr5:133003119~133003365:+
BRCA	cis	rs6570726	0.791	rs365869	ENSG00000270638.1	RP3-466P17.1	4.7	3.02e-06	0.000278	0.17	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145563615	chr6:145735570~145737218:+
BRCA	cis	rs7246657	0.551	rs12978093	ENSG00000267422.1	CTD-2554C21.1	-4.7	3.02e-06	0.000278	-0.25	-0.14	Coronary artery calcification;	chr19:37093514	chr19:37779686~37792865:+
BRCA	cis	rs454217	1	rs454217	ENSG00000277851.1	RP11-756G20.1	4.69	3.02e-06	0.000278	0.17	0.14	Smoking quantity;	chr12:92324782	chr12:92247756~92363832:-
BRCA	cis	rs1858037	0.867	rs953312	ENSG00000281920.1	RP11-418H16.1	4.69	3.02e-06	0.000278	0.19	0.14	Rheumatoid arthritis;	chr2:65340556	chr2:65623272~65628424:+
BRCA	cis	rs1858037	0.867	rs9789444	ENSG00000281920.1	RP11-418H16.1	4.69	3.02e-06	0.000278	0.19	0.14	Rheumatoid arthritis;	chr2:65342093	chr2:65623272~65628424:+
BRCA	cis	rs73222236	0.782	rs1484250	ENSG00000273486.1	RP11-731C17.2	4.69	3.02e-06	0.000278	0.16	0.14	Coronary artery disease;	chr3:136650695	chr3:136837338~136839021:-
BRCA	cis	rs4831837	0.64	rs10087837	ENSG00000270074.1	RP11-351I21.11	4.69	3.02e-06	0.000278	0.18	0.14	Morbidity-free survival;	chr8:12831170	chr8:12412827~12414373:+
BRCA	cis	rs12681366	0.96	rs2930961	ENSG00000253175.1	RP11-267M23.6	4.69	3.02e-06	0.000278	0.16	0.14	Nonsyndromic cleft lip with cleft palate;	chr8:94431578	chr8:94565036~94565715:+
BRCA	cis	rs7580658	0.614	rs7585198	ENSG00000236682.1	AC068282.3	4.69	3.02e-06	0.000278	0.21	0.14	Protein C levels;	chr2:127205059	chr2:127389130~127400580:+
BRCA	cis	rs1529102	0.844	rs2698533	ENSG00000225889.6	AC074289.1	-4.69	3.03e-06	0.000279	-0.13	-0.14	Breast size;	chr2:64271271	chr2:64143239~64252859:+
BRCA	cis	rs904251	0.686	rs2776911	ENSG00000204110.6	RP1-153P14.8	-4.69	3.03e-06	0.000279	-0.18	-0.14	Cognitive performance;	chr6:37472174	chr6:37507348~37535616:+
BRCA	cis	rs2562456	0.917	rs2650804	ENSG00000268658.4	LINC00664	4.69	3.03e-06	0.000279	0.22	0.14	Pain;	chr19:21497382	chr19:21483374~21503238:+
BRCA	cis	rs875971	0.545	rs2707851	ENSG00000273142.1	RP11-458F8.4	-4.69	3.03e-06	0.000279	-0.14	-0.14	Aortic root size;	chr7:66624178	chr7:66902857~66906297:+
BRCA	cis	rs8017423	0.626	rs8003363	ENSG00000275198.1	RP11-471B22.3	4.69	3.03e-06	0.000279	0.17	0.14	Mortality in heart failure;	chr14:90360496	chr14:90383365~90387973:+
BRCA	cis	rs57221529	0.825	rs7443550	ENSG00000225138.6	CTD-2228K2.7	4.69	3.03e-06	0.000279	0.22	0.14	Lung disease severity in cystic fibrosis;	chr5:578289	chr5:473236~480884:+
BRCA	cis	rs57221529	0.766	rs4245972	ENSG00000225138.6	CTD-2228K2.7	4.69	3.03e-06	0.000279	0.22	0.14	Lung disease severity in cystic fibrosis;	chr5:578457	chr5:473236~480884:+
BRCA	cis	rs57221529	0.766	rs72703042	ENSG00000225138.6	CTD-2228K2.7	4.69	3.03e-06	0.000279	0.22	0.14	Lung disease severity in cystic fibrosis;	chr5:579154	chr5:473236~480884:+
BRCA	cis	rs710913	0.531	rs1180331	ENSG00000182109.6	RP11-69E11.4	-4.69	3.03e-06	0.000279	-0.16	-0.14	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39546512	chr1:39522280~39546187:-
BRCA	cis	rs12497850	0.931	rs13064911	ENSG00000225399.4	RP11-3B7.1	4.69	3.03e-06	0.000279	0.14	0.14	Parkinson's disease;	chr3:48914952	chr3:49260085~49261316:+
BRCA	cis	rs2281636	0.965	rs2006077	ENSG00000233690.1	EBAG9P1	-4.69	3.03e-06	0.000279	-0.15	-0.14	Obesity-related traits;	chr10:99733076	chr10:99697407~99697949:-
BRCA	cis	rs6832769	1	rs10034433	ENSG00000223305.1	RN7SKP30	-4.69	3.04e-06	0.000279	-0.18	-0.14	Personality dimensions;	chr4:55555009	chr4:55540502~55540835:-
BRCA	cis	rs7267979	1	rs4815420	ENSG00000274973.1	RP13-401N8.7	4.69	3.04e-06	0.000279	0.16	0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25403343	chr20:25845497~25845862:+
BRCA	cis	rs8031584	0.958	rs34909055	ENSG00000259845.1	HERC2P10	4.69	3.04e-06	0.000279	0.17	0.14	Huntington's disease progression;	chr15:30991967	chr15:30815271~30844153:+
BRCA	cis	rs970548	0.643	rs7068039	ENSG00000230869.1	CTGLF10P	4.69	3.04e-06	0.00028	0.2	0.14	Total cholesterol levels;HDL cholesterol;HDL cholesterol levels;Cholesterol, total;	chr10:45436816	chr10:45678692~45700532:+
BRCA	cis	rs7727544	0.507	rs11741341	ENSG00000233006.5	AC034220.3	4.69	3.04e-06	0.00028	0.11	0.14	Blood metabolite levels;	chr5:132234525	chr5:132311285~132369916:-
BRCA	cis	rs2179367	0.6	rs9498352	ENSG00000268592.3	RAET1E-AS1	4.69	3.04e-06	0.00028	0.21	0.14	Dupuytren's disease;	chr6:149439108	chr6:149863494~149919507:+
BRCA	cis	rs783540	0.5	rs1313494	ENSG00000255769.6	GOLGA2P10	4.69	3.04e-06	0.00028	0.18	0.14	Schizophrenia;	chr15:82605530	chr15:82472993~82513950:-
BRCA	cis	rs10504130	1	rs75527521	ENSG00000272024.1	RP11-546K22.3	-4.69	3.04e-06	0.00028	-0.26	-0.14	Venous thromboembolism (SNP x SNP interaction);	chr8:51769788	chr8:51950284~51950690:+
BRCA	cis	rs4356203	0.905	rs6486352	ENSG00000272034.1	SNORD14A	4.69	3.04e-06	0.00028	0.15	0.14	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17150823	chr11:17074654~17074744:-
BRCA	cis	rs1395	0.778	rs11126918	ENSG00000234072.1	AC074117.10	-4.69	3.04e-06	0.00028	-0.16	-0.14	Blood metabolite levels;	chr2:27215842	chr2:27356246~27367622:+
BRCA	cis	rs6088590	0.523	rs6088536	ENSG00000276073.1	RP5-1125A11.7	-4.69	3.04e-06	0.00028	-0.16	-0.14	Coronary artery disease;	chr20:34601302	chr20:33985617~33988989:-
BRCA	cis	rs853679	1	rs6905391	ENSG00000204709.4	LINC01556	4.69	3.04e-06	0.00028	0.25	0.14	Depression;	chr6:28294909	chr6:28943877~28944537:+
BRCA	cis	rs16958440	1	rs60854219	ENSG00000280212.1	RP11-49K24.3	4.69	3.05e-06	0.00028	0.3	0.14	Sitting height ratio;	chr18:47120293	chr18:47076117~47076594:+
BRCA	cis	rs4664293	0.967	rs13397722	ENSG00000226266.5	AC009961.3	-4.69	3.05e-06	0.00028	-0.19	-0.14	Monocyte percentage of white cells;	chr2:159659140	chr2:159670708~159712435:-
BRCA	cis	rs11098499	0.754	rs9991959	ENSG00000249244.1	RP11-548H18.2	-4.69	3.05e-06	0.00028	-0.16	-0.14	Corneal astigmatism;	chr4:119332618	chr4:119391831~119395335:-
BRCA	cis	rs13113518	1	rs12651640	ENSG00000249700.7	SRD5A3-AS1	4.69	3.05e-06	0.00028	0.18	0.14	Height;	chr4:55454154	chr4:55363971~55395847:-
BRCA	cis	rs13113518	1	rs1554483	ENSG00000249700.7	SRD5A3-AS1	4.69	3.05e-06	0.00028	0.18	0.14	Height;	chr4:55455650	chr4:55363971~55395847:-
BRCA	cis	rs13113518	1	rs1464490	ENSG00000249700.7	SRD5A3-AS1	4.69	3.05e-06	0.00028	0.18	0.14	Height;	chr4:55456620	chr4:55363971~55395847:-
BRCA	cis	rs13113518	1	rs10517346	ENSG00000249700.7	SRD5A3-AS1	4.69	3.05e-06	0.00028	0.18	0.14	Height;	chr4:55457027	chr4:55363971~55395847:-
BRCA	cis	rs13113518	1	rs11133384	ENSG00000249700.7	SRD5A3-AS1	4.69	3.05e-06	0.00028	0.18	0.14	Height;	chr4:55457086	chr4:55363971~55395847:-
BRCA	cis	rs7576126	0.563	rs1807337	ENSG00000204929.10	AC074391.1	-4.69	3.05e-06	0.00028	-0.18	-0.14	Severe influenza A (H1N1) infection;	chr2:65436033	chr2:65436711~66084639:+
BRCA	cis	rs4664293	0.867	rs6432558	ENSG00000226266.5	AC009961.3	-4.69	3.05e-06	0.00028	-0.18	-0.14	Monocyte percentage of white cells;	chr2:159745397	chr2:159670708~159712435:-
BRCA	cis	rs4664293	0.836	rs7567818	ENSG00000226266.5	AC009961.3	-4.69	3.05e-06	0.00028	-0.18	-0.14	Monocyte percentage of white cells;	chr2:159746186	chr2:159670708~159712435:-
BRCA	cis	rs4664293	0.867	rs12692563	ENSG00000226266.5	AC009961.3	-4.69	3.05e-06	0.00028	-0.18	-0.14	Monocyte percentage of white cells;	chr2:159746300	chr2:159670708~159712435:-
BRCA	cis	rs4664293	0.836	rs13397597	ENSG00000226266.5	AC009961.3	-4.69	3.05e-06	0.00028	-0.18	-0.14	Monocyte percentage of white cells;	chr2:159747084	chr2:159670708~159712435:-
BRCA	cis	rs4948275	0.773	rs2787733	ENSG00000237233.2	TMEM26-AS1	-4.69	3.05e-06	0.00028	-0.17	-0.14	Night sleep phenotypes;	chr10:61488649	chr10:61452639~61481956:+
BRCA	cis	rs10129255	0.518	rs10150460	ENSG00000211967.3	IGHV3-53	4.69	3.05e-06	0.000281	0.1	0.14	Kawasaki disease;	chr14:106677179	chr14:106592676~106593347:-
BRCA	cis	rs1858037	0.867	rs1039765	ENSG00000237979.1	AC007389.1	-4.69	3.05e-06	0.000281	-0.18	-0.14	Rheumatoid arthritis;	chr2:65387228	chr2:65500993~65502138:-
BRCA	cis	rs7621331	1	rs17197552	ENSG00000273486.1	RP11-731C17.2	4.69	3.05e-06	0.000281	0.17	0.14	Waist circumference adjusted for body mass index;	chr3:136003422	chr3:136837338~136839021:-
BRCA	cis	rs6570726	0.935	rs379164	ENSG00000270638.1	RP3-466P17.1	4.69	3.05e-06	0.000281	0.16	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145507957	chr6:145735570~145737218:+
BRCA	cis	rs10129255	0.536	rs3944157	ENSG00000224373.3	IGHV4-59	4.69	3.05e-06	0.000281	0.08	0.14	Kawasaki disease;	chr14:106682286	chr14:106627249~106627825:-
BRCA	cis	rs6832769	1	rs10034433	ENSG00000272969.1	RP11-528I4.2	-4.69	3.05e-06	0.000281	-0.17	-0.14	Personality dimensions;	chr4:55555009	chr4:55547112~55547889:+
BRCA	cis	rs6596100	0.778	rs73272725	ENSG00000248648.1	RP11-485M7.1	-4.69	3.05e-06	0.000281	-0.18	-0.14	Breast cancer;	chr5:133094462	chr5:133003119~133003365:+
BRCA	cis	rs56322409	1	rs11188417	ENSG00000226688.5	ENTPD1-AS1	-4.69	3.05e-06	0.000281	-0.17	-0.14	Blood metabolite levels;	chr10:95651923	chr10:95753206~96090238:-
BRCA	cis	rs853679	0.55	rs1233704	ENSG00000216901.1	AL022393.7	-4.69	3.06e-06	0.000281	-0.2	-0.14	Depression;	chr6:28199145	chr6:28176188~28176674:+
BRCA	cis	rs6840258	0.582	rs10000784	ENSG00000251411.1	RP11-397E7.4	-4.69	3.06e-06	0.000281	-0.19	-0.14	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87166331	chr4:86913266~86914817:-
BRCA	cis	rs10504130	1	rs61326367	ENSG00000272024.1	RP11-546K22.3	-4.69	3.06e-06	0.000281	-0.26	-0.14	Venous thromboembolism (SNP x SNP interaction);	chr8:51775466	chr8:51950284~51950690:+
BRCA	cis	rs875971	0.545	rs73142233	ENSG00000273142.1	RP11-458F8.4	4.69	3.06e-06	0.000281	0.14	0.14	Aortic root size;	chr7:66221293	chr7:66902857~66906297:+
BRCA	cis	rs62025270	1	rs62025270	ENSG00000259295.5	CSPG4P12	-4.69	3.06e-06	0.000281	-0.23	-0.14	Idiopathic pulmonary fibrosis;	chr15:85756967	chr15:85191438~85213905:+
BRCA	cis	rs6500395	1	rs9924078	ENSG00000261267.1	RP11-44I10.3	4.69	3.06e-06	0.000281	0.18	0.14	Response to tocilizumab in rheumatoid arthritis;	chr16:48524007	chr16:48559661~48587403:+
BRCA	cis	rs4699052	0.963	rs2085978	ENSG00000248740.4	RP11-328K4.1	4.69	3.06e-06	0.000281	0.17	0.14	Testicular germ cell tumor;	chr4:103272457	chr4:103256159~103453658:+
BRCA	cis	rs6088580	0.634	rs6120642	ENSG00000276073.1	RP5-1125A11.7	-4.69	3.06e-06	0.000281	-0.16	-0.14	Glomerular filtration rate (creatinine);	chr20:34424725	chr20:33985617~33988989:-
BRCA	cis	rs7267979	0.903	rs6115109	ENSG00000125804.12	FAM182A	-4.69	3.06e-06	0.000281	-0.19	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25259031	chr20:26054655~26086917:+
BRCA	cis	rs7267979	0.833	rs4619688	ENSG00000125804.12	FAM182A	-4.69	3.06e-06	0.000281	-0.19	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25263465	chr20:26054655~26086917:+
BRCA	cis	rs11096990	0.634	rs12651217	ENSG00000249685.1	RP11-360F5.3	4.69	3.06e-06	0.000281	0.18	0.14	Cognitive function;	chr4:39271964	chr4:39133913~39135608:+
BRCA	cis	rs62025270	0.747	rs17639314	ENSG00000202081.1	RNU6-1280P	-4.69	3.06e-06	0.000282	-0.22	-0.14	Idiopathic pulmonary fibrosis;	chr15:85766678	chr15:85651522~85651628:-
BRCA	cis	rs8017423	0.608	rs12588149	ENSG00000275198.1	RP11-471B22.3	4.69	3.06e-06	0.000282	0.17	0.14	Mortality in heart failure;	chr14:90356332	chr14:90383365~90387973:+
BRCA	cis	rs2898681	0.511	rs881743	ENSG00000248375.1	RP11-177B4.1	-4.69	3.06e-06	0.000282	-0.19	-0.14	Optic nerve measurement (cup area);	chr4:52861283	chr4:52720081~52720831:-
BRCA	cis	rs2153535	0.58	rs6929206	ENSG00000251164.1	HULC	-4.69	3.06e-06	0.000282	-0.18	-0.14	Motion sickness;	chr6:8447728	chr6:8652137~8653846:+
BRCA	cis	rs7246967	0.673	rs73022717	ENSG00000198153.8	ZNF849P	-4.69	3.07e-06	0.000282	-0.24	-0.14	Bronchopulmonary dysplasia;	chr19:22694257	chr19:22685167~22686732:+
BRCA	cis	rs5758511	0.773	rs62241023	ENSG00000205702.9	CYP2D7	4.69	3.07e-06	0.000282	0.15	0.14	Birth weight;	chr22:41989425	chr22:42140203~42144577:-
BRCA	cis	rs2739330	0.76	rs1002286	ENSG00000228039.3	KB-1125A3.10	-4.69	3.07e-06	0.000282	-0.17	-0.14	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23963780~23964374:+
BRCA	cis	rs6088580	0.634	rs6059878	ENSG00000276073.1	RP5-1125A11.7	-4.69	3.07e-06	0.000282	-0.16	-0.14	Glomerular filtration rate (creatinine);	chr20:34499361	chr20:33985617~33988989:-
BRCA	cis	rs6088580	0.601	rs6120668	ENSG00000276073.1	RP5-1125A11.7	-4.69	3.07e-06	0.000282	-0.16	-0.14	Glomerular filtration rate (creatinine);	chr20:34511988	chr20:33985617~33988989:-
BRCA	cis	rs6088580	0.634	rs6059887	ENSG00000276073.1	RP5-1125A11.7	-4.69	3.07e-06	0.000282	-0.16	-0.14	Glomerular filtration rate (creatinine);	chr20:34513297	chr20:33985617~33988989:-
BRCA	cis	rs6088580	0.634	rs6059892	ENSG00000276073.1	RP5-1125A11.7	-4.69	3.07e-06	0.000282	-0.16	-0.14	Glomerular filtration rate (creatinine);	chr20:34517961	chr20:33985617~33988989:-
BRCA	cis	rs6088580	0.609	rs2378205	ENSG00000276073.1	RP5-1125A11.7	-4.69	3.07e-06	0.000282	-0.16	-0.14	Glomerular filtration rate (creatinine);	chr20:34522998	chr20:33985617~33988989:-
BRCA	cis	rs2153535	0.58	rs9505467	ENSG00000251164.1	HULC	-4.69	3.07e-06	0.000282	-0.18	-0.14	Motion sickness;	chr6:8519986	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.58	rs1360054	ENSG00000251164.1	HULC	-4.69	3.07e-06	0.000282	-0.18	-0.14	Motion sickness;	chr6:8520144	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.58	rs9328483	ENSG00000251164.1	HULC	-4.69	3.07e-06	0.000282	-0.18	-0.14	Motion sickness;	chr6:8521062	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.58	rs9393033	ENSG00000251164.1	HULC	-4.69	3.07e-06	0.000282	-0.18	-0.14	Motion sickness;	chr6:8521213	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.541	rs6938688	ENSG00000251164.1	HULC	-4.69	3.07e-06	0.000282	-0.18	-0.14	Motion sickness;	chr6:8521396	chr6:8652137~8653846:+
BRCA	cis	rs2278170	1	rs9633900	ENSG00000225101.4	OR52K3P	-4.69	3.07e-06	0.000282	-0.2	-0.14	Amyotrophic lateral sclerosis;	chr11:4477088	chr11:4474813~4475755:+
BRCA	cis	rs1499614	1	rs2707832	ENSG00000222364.1	RNU6-96P	-4.69	3.07e-06	0.000282	-0.26	-0.14	Gout;	chr7:66671562	chr7:66395191~66395286:+
BRCA	cis	rs4218	0.701	rs7174277	ENSG00000259732.1	RP11-59H7.3	-4.69	3.07e-06	0.000282	-0.16	-0.14	Social communication problems;	chr15:59150390	chr15:59121034~59133250:+
BRCA	cis	rs1499614	1	rs2707840	ENSG00000222364.1	RNU6-96P	-4.69	3.07e-06	0.000282	-0.27	-0.14	Gout;	chr7:66693028	chr7:66395191~66395286:+
BRCA	cis	rs6570726	0.818	rs398812	ENSG00000270638.1	RP3-466P17.1	4.69	3.07e-06	0.000282	0.16	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145496135	chr6:145735570~145737218:+
BRCA	cis	rs17508449	0.69	rs4839333	ENSG00000232450.1	RP4-730K3.3	-4.69	3.07e-06	0.000282	-0.28	-0.14	Leprosy;	chr1:113676539	chr1:113698884~113699631:-
BRCA	cis	rs6840360	0.642	rs1470281	ENSG00000251603.1	RP11-164P12.4	-4.69	3.07e-06	0.000282	-0.13	-0.14	Intelligence (multi-trait analysis);	chr4:151510400	chr4:151667224~151670502:+
BRCA	cis	rs6671200	1	rs12755552	ENSG00000235501.4	RP4-639F20.1	-4.69	3.07e-06	0.000282	-0.34	-0.14	Stearic acid (18:0) levels;	chr1:95219470	chr1:94927566~94963270:+
BRCA	cis	rs9659323	0.73	rs7512189	ENSG00000231365.4	RP11-418J17.1	-4.69	3.07e-06	0.000282	-0.17	-0.14	Body mass index;	chr1:118999909	chr1:119140396~119275973:+
BRCA	cis	rs794185	0.681	rs901870	ENSG00000231249.1	ITPR1-AS1	4.69	3.07e-06	0.000282	0.16	0.14	Multiple sclerosis--Brain Glutamate Levels;	chr3:4469418	chr3:4490891~4493163:-
BRCA	cis	rs16958440	1	rs2289132	ENSG00000280212.1	RP11-49K24.3	4.69	3.07e-06	0.000283	0.3	0.14	Sitting height ratio;	chr18:47075921	chr18:47076117~47076594:+
BRCA	cis	rs16958440	1	rs2289131	ENSG00000280212.1	RP11-49K24.3	4.69	3.07e-06	0.000283	0.3	0.14	Sitting height ratio;	chr18:47076493	chr18:47076117~47076594:+
BRCA	cis	rs3764021	0.527	rs11052604	ENSG00000256673.1	RP11-599J14.2	-4.69	3.07e-06	0.000283	-0.18	-0.14	Type 1 diabetes;	chr12:9709952	chr12:9398355~9414851:-
BRCA	cis	rs7200543	0.961	rs3803573	ENSG00000275910.1	RP11-680G24.6	-4.69	3.08e-06	0.000283	-0.17	-0.14	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15044556	chr16:15015828~15016390:-
BRCA	cis	rs4780355	0.918	rs1646019	ENSG00000262703.1	RP11-485G7.6	4.69	3.08e-06	0.000283	0.16	0.14	Crohn's disease and psoriasis;	chr16:11265823	chr16:11348143~11349321:-
BRCA	cis	rs853679	0.55	rs34477097	ENSG00000219392.1	RP1-265C24.5	-4.69	3.08e-06	0.000283	-0.21	-0.14	Depression;	chr6:28229408	chr6:28115628~28116551:+
BRCA	cis	rs6840360	0.642	rs2709828	ENSG00000251603.1	RP11-164P12.4	-4.69	3.08e-06	0.000283	-0.13	-0.14	Intelligence (multi-trait analysis);	chr4:151434116	chr4:151667224~151670502:+
BRCA	cis	rs6840360	0.642	rs2724551	ENSG00000251603.1	RP11-164P12.4	-4.69	3.08e-06	0.000283	-0.13	-0.14	Intelligence (multi-trait analysis);	chr4:151434231	chr4:151667224~151670502:+
BRCA	cis	rs6840360	0.667	rs2709829	ENSG00000251603.1	RP11-164P12.4	-4.69	3.08e-06	0.000283	-0.13	-0.14	Intelligence (multi-trait analysis);	chr4:151434238	chr4:151667224~151670502:+
BRCA	cis	rs6840360	0.606	rs2709813	ENSG00000251603.1	RP11-164P12.4	-4.69	3.08e-06	0.000283	-0.13	-0.14	Intelligence (multi-trait analysis);	chr4:151436292	chr4:151667224~151670502:+
BRCA	cis	rs6840360	0.606	rs2724550	ENSG00000251603.1	RP11-164P12.4	-4.69	3.08e-06	0.000283	-0.13	-0.14	Intelligence (multi-trait analysis);	chr4:151437834	chr4:151667224~151670502:+
BRCA	cis	rs6840360	0.642	rs2709815	ENSG00000251603.1	RP11-164P12.4	-4.69	3.08e-06	0.000283	-0.13	-0.14	Intelligence (multi-trait analysis);	chr4:151442620	chr4:151667224~151670502:+
BRCA	cis	rs6095360	0.7	rs4599176	ENSG00000222365.1	SNORD12B	-4.69	3.08e-06	0.000283	-0.19	-0.14	Intelligence (multi-trait analysis);	chr20:48903557	chr20:49280319~49280409:+
BRCA	cis	rs8054556	0.669	rs12931955	ENSG00000261367.1	RP11-455F5.4	-4.69	3.08e-06	0.000283	-0.16	-0.14	Autism spectrum disorder or schizophrenia;	chr16:30001745	chr16:30107675~30110541:+
BRCA	cis	rs2836974	0.583	rs9981884	ENSG00000255568.3	BRWD1-AS2	4.69	3.08e-06	0.000283	0.14	0.14	Cognitive function;	chr21:39213707	chr21:39313935~39314962:+
BRCA	cis	rs4218	0.689	rs35066133	ENSG00000277144.1	RP11-59H7.4	-4.69	3.08e-06	0.000283	-0.18	-0.14	Social communication problems;	chr15:59081917	chr15:59115547~59116089:-
BRCA	cis	rs793571	0.628	rs11071397	ENSG00000259250.1	RP11-50C13.1	-4.69	3.08e-06	0.000283	-0.24	-0.14	Schizophrenia;	chr15:58815298	chr15:58587507~58591676:+
BRCA	cis	rs6840360	0.642	rs7678823	ENSG00000251603.1	RP11-164P12.4	-4.69	3.09e-06	0.000283	-0.13	-0.14	Intelligence (multi-trait analysis);	chr4:151435967	chr4:151667224~151670502:+
BRCA	cis	rs8098244	0.8	rs2878906	ENSG00000264745.1	TTC39C-AS1	4.69	3.09e-06	0.000284	0.2	0.14	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23784678	chr18:23994213~24015339:-
BRCA	cis	rs792448	0.743	rs7519959	ENSG00000226251.4	RP11-15I11.3	-4.69	3.09e-06	0.000284	-0.19	-0.14	White blood cell count (basophil);	chr1:212325310	chr1:212225278~212238977:-
BRCA	cis	rs12435908	1	rs8005309	ENSG00000276116.2	FUT8-AS1	-4.69	3.09e-06	0.000284	-0.23	-0.14	Ischemic stroke;	chr14:65589790	chr14:65411170~65412690:-
BRCA	cis	rs771767	0.808	rs4359791	ENSG00000244119.1	PDCL3P4	4.69	3.09e-06	0.000284	0.12	0.14	Multiple sclerosis;	chr3:102030137	chr3:101712472~101713191:+
BRCA	cis	rs4415084	0.804	rs57300972	ENSG00000251141.4	RP11-53O19.1	-4.69	3.09e-06	0.000284	-0.13	-0.14	Breast cancer;	chr5:44897734	chr5:44744900~44808777:-
BRCA	cis	rs807029	0.577	rs3740488	ENSG00000236662.1	RP11-108L7.4	4.69	3.09e-06	0.000284	0.18	0.14	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100994276	chr10:100980507~100985614:-
BRCA	cis	rs1030877	0.515	rs2576736	ENSG00000235319.1	AC012360.4	-4.69	3.09e-06	0.000284	-0.2	-0.14	Obesity-related traits;	chr2:105274514	chr2:105324210~105330529:+
BRCA	cis	rs4664293	0.867	rs12617546	ENSG00000226266.5	AC009961.3	-4.69	3.09e-06	0.000284	-0.18	-0.14	Monocyte percentage of white cells;	chr2:159767079	chr2:159670708~159712435:-
BRCA	cis	rs6570726	0.935	rs12663211	ENSG00000270638.1	RP3-466P17.1	4.69	3.09e-06	0.000284	0.16	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145497291	chr6:145735570~145737218:+
BRCA	cis	rs6570726	0.934	rs430003	ENSG00000270638.1	RP3-466P17.1	4.69	3.09e-06	0.000284	0.16	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145498370	chr6:145735570~145737218:+
BRCA	cis	rs6570726	0.935	rs395948	ENSG00000270638.1	RP3-466P17.1	4.69	3.09e-06	0.000284	0.16	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145499049	chr6:145735570~145737218:+
BRCA	cis	rs6570726	0.935	rs452552	ENSG00000270638.1	RP3-466P17.1	4.69	3.09e-06	0.000284	0.16	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145499645	chr6:145735570~145737218:+
BRCA	cis	rs6570726	0.935	rs451349	ENSG00000270638.1	RP3-466P17.1	4.69	3.09e-06	0.000284	0.16	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145499758	chr6:145735570~145737218:+
BRCA	cis	rs6570726	0.905	rs406799	ENSG00000270638.1	RP3-466P17.1	4.69	3.09e-06	0.000284	0.16	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145500701	chr6:145735570~145737218:+
BRCA	cis	rs6570726	0.935	rs1883406	ENSG00000270638.1	RP3-466P17.1	4.69	3.09e-06	0.000284	0.16	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145502069	chr6:145735570~145737218:+
BRCA	cis	rs6570726	0.87	rs370653	ENSG00000270638.1	RP3-466P17.1	4.69	3.09e-06	0.000284	0.16	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145502506	chr6:145735570~145737218:+
BRCA	cis	rs6570726	0.935	rs391524	ENSG00000270638.1	RP3-466P17.1	4.69	3.09e-06	0.000284	0.16	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145502708	chr6:145735570~145737218:+
BRCA	cis	rs2253762	0.507	rs75383663	ENSG00000226864.1	ATE1-AS1	4.69	3.09e-06	0.000284	0.26	0.14	Breast cancer;	chr10:121993340	chr10:121928312~121951965:+
BRCA	cis	rs6569038	0.502	rs11967889	ENSG00000253194.1	RP11-351A11.1	-4.69	3.09e-06	0.000284	-0.18	-0.14	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr6:118992468	chr6:118934785~119031541:+
BRCA	cis	rs77372450	0.591	rs6879838	ENSG00000251405.2	CTB-109A12.1	4.69	3.09e-06	0.000284	0.24	0.14	Bipolar disorder (body mass index interaction);	chr5:157539559	chr5:157362615~157460078:-
BRCA	cis	rs875971	0.965	rs6971509	ENSG00000236529.1	RP13-254B10.1	-4.69	3.09e-06	0.000284	-0.16	-0.14	Aortic root size;	chr7:66249983	chr7:65840212~65840596:+
BRCA	cis	rs1153858	1	rs7179743	ENSG00000275672.1	GATM-AS1	-4.69	3.09e-06	0.000284	-0.18	-0.14	Homoarginine levels;	chr15:45346133	chr15:45378700~45380123:+
BRCA	cis	rs4356203	0.905	rs9919600	ENSG00000272034.1	SNORD14A	-4.69	3.09e-06	0.000284	-0.15	-0.14	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17058198	chr11:17074654~17074744:-
BRCA	cis	rs4356203	0.905	rs7939750	ENSG00000272034.1	SNORD14A	-4.69	3.09e-06	0.000284	-0.15	-0.14	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17058208	chr11:17074654~17074744:-
BRCA	cis	rs7918232	0.941	rs1085782	ENSG00000262412.1	RP11-85G18.6	-4.69	3.1e-06	0.000284	-0.25	-0.14	Breast cancer;	chr10:27151588	chr10:27243130~27250804:+
BRCA	cis	rs7918232	0.941	rs1775350	ENSG00000262412.1	RP11-85G18.6	-4.69	3.1e-06	0.000284	-0.25	-0.14	Breast cancer;	chr10:27153044	chr10:27243130~27250804:+
BRCA	cis	rs4948275	0.742	rs2249808	ENSG00000237233.2	TMEM26-AS1	-4.69	3.1e-06	0.000284	-0.17	-0.14	Night sleep phenotypes;	chr10:61488298	chr10:61452639~61481956:+
BRCA	cis	rs2136613	0.728	rs4141618	ENSG00000238280.1	RP11-436D10.3	-4.69	3.1e-06	0.000284	-0.18	-0.14	Selective IgA deficiency;	chr10:62854449	chr10:62793562~62805887:-
BRCA	cis	rs4494364	0.502	rs1920763	ENSG00000258100.1	RP11-121E16.1	4.69	3.1e-06	0.000284	0.21	0.14	Systolic blood pressure (alcohol consumption interaction);	chr12:90991957	chr12:91362196~91368606:+
BRCA	cis	rs6570726	0.935	rs408723	ENSG00000270638.1	RP3-466P17.1	4.69	3.1e-06	0.000285	0.16	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145517399	chr6:145735570~145737218:+
BRCA	cis	rs3176789	0.914	rs4519175	ENSG00000256673.1	RP11-599J14.2	4.69	3.1e-06	0.000285	0.18	0.14	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9772568	chr12:9398355~9414851:-
BRCA	cis	rs6832769	1	rs7668147	ENSG00000223305.1	RN7SKP30	4.69	3.1e-06	0.000285	0.18	0.14	Personality dimensions;	chr4:55473217	chr4:55540502~55540835:-
BRCA	cis	rs11673344	0.526	rs57654288	ENSG00000267422.1	CTD-2554C21.1	4.69	3.1e-06	0.000285	0.18	0.14	Obesity-related traits;	chr19:37587870	chr19:37779686~37792865:+
BRCA	cis	rs881375	0.502	rs4837811	ENSG00000226752.6	PSMD5-AS1	-4.69	3.1e-06	0.000285	-0.18	-0.14	Rheumatoid arthritis;	chr9:121139316	chr9:120824828~120854385:+
BRCA	cis	rs11051970	0.559	rs2036304	ENSG00000274964.1	RP11-817I4.1	-4.69	3.1e-06	0.000285	-0.19	-0.14	Response to tocilizumab in rheumatoid arthritis;	chr12:32325441	chr12:32339368~32340724:+
BRCA	cis	rs6840360	0.541	rs4696251	ENSG00000270265.1	RP11-731D1.4	-4.69	3.1e-06	0.000285	-0.16	-0.14	Intelligence (multi-trait analysis);	chr4:151345174	chr4:151333775~151353224:-
BRCA	cis	rs6452524	0.869	rs10051155	ENSG00000281327.1	LINC01338	4.69	3.1e-06	0.000285	0.17	0.14	Hypertension (SNP x SNP interaction);	chr5:83160851	chr5:82850864~82859836:-
BRCA	cis	rs1434579	0.966	rs7246892	ENSG00000176761.7	ZNF285B	-4.69	3.1e-06	0.000285	-0.17	-0.14	Tuberculosis;	chr19:44424496	chr19:44467641~44473227:+
BRCA	cis	rs1075265	0.568	rs10865278	ENSG00000235937.1	AC008280.1	4.69	3.1e-06	0.000285	0.16	0.14	Chronotype;Morning vs. evening chronotype;	chr2:54074902	chr2:54029552~54030682:-
BRCA	cis	rs11096990	0.593	rs4580660	ENSG00000249685.1	RP11-360F5.3	4.69	3.1e-06	0.000285	0.18	0.14	Cognitive function;	chr4:39152216	chr4:39133913~39135608:+
BRCA	cis	rs2073316	0.592	rs4952263	ENSG00000272716.1	RP11-563N4.1	-4.69	3.1e-06	0.000285	-0.16	-0.14	Interleukin-18 levels;	chr2:31482745	chr2:32165046~32165757:-
BRCA	cis	rs2243480	1	rs160633	ENSG00000222364.1	RNU6-96P	-4.69	3.1e-06	0.000285	-0.28	-0.14	Diabetic kidney disease;	chr7:66063241	chr7:66395191~66395286:+
BRCA	cis	rs13108904	0.901	rs13119532	ENSG00000253399.1	AC078852.2	-4.69	3.11e-06	0.000285	-0.17	-0.14	Obesity-related traits;	chr4:1310717	chr4:1358479~1359461:+
BRCA	cis	rs8177876	0.822	rs16954582	ENSG00000261061.1	RP11-303E16.2	-4.69	3.11e-06	0.000285	-0.18	-0.14	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81080552	chr16:81030770~81031485:+
BRCA	cis	rs3796352	0.892	rs35076015	ENSG00000242142.1	SERBP1P3	-4.69	3.11e-06	0.000285	-0.29	-0.14	Immune reponse to smallpox (secreted IL-2);	chr3:52992350	chr3:53064283~53065091:-
BRCA	cis	rs3796352	0.881	rs34238610	ENSG00000242142.1	SERBP1P3	-4.69	3.11e-06	0.000285	-0.29	-0.14	Immune reponse to smallpox (secreted IL-2);	chr3:52992464	chr3:53064283~53065091:-
BRCA	cis	rs7267979	0.903	rs6132819	ENSG00000125804.12	FAM182A	-4.69	3.11e-06	0.000285	-0.19	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25237982	chr20:26054655~26086917:+
BRCA	cis	rs9291683	0.62	rs11722946	ENSG00000250413.1	RP11-448G15.1	4.69	3.11e-06	0.000285	0.19	0.14	Bone mineral density;	chr4:10124366	chr4:10006482~10009725:+
BRCA	cis	rs2153535	0.585	rs1814213	ENSG00000230939.1	RP11-314C16.1	-4.69	3.11e-06	0.000285	-0.17	-0.14	Motion sickness;	chr6:8619632	chr6:8784178~8785445:+
BRCA	cis	rs8180040	0.62	rs6414435	ENSG00000276925.1	RP11-708J19.3	-4.69	3.11e-06	0.000285	-0.16	-0.14	Colorectal cancer;	chr3:47079650	chr3:47469777~47469987:+
BRCA	cis	rs919433	0.679	rs6757632	ENSG00000231621.1	AC013264.2	-4.69	3.11e-06	0.000285	-0.14	-0.14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197665542	chr2:197197991~197199273:+
BRCA	cis	rs919433	0.679	rs6757669	ENSG00000231621.1	AC013264.2	-4.69	3.11e-06	0.000285	-0.14	-0.14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197665631	chr2:197197991~197199273:+
BRCA	cis	rs728616	0.867	rs7893241	ENSG00000225484.5	NUTM2B-AS1	-4.69	3.11e-06	0.000285	-0.37	-0.14	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80194582	chr10:79663088~79826594:-
BRCA	cis	rs4356203	0.87	rs12286505	ENSG00000272034.1	SNORD14A	4.69	3.11e-06	0.000286	0.15	0.14	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17142178	chr11:17074654~17074744:-
BRCA	cis	rs2243480	1	rs316332	ENSG00000222364.1	RNU6-96P	-4.69	3.11e-06	0.000286	-0.26	-0.14	Diabetic kidney disease;	chr7:66139312	chr7:66395191~66395286:+
BRCA	cis	rs1395	0.778	rs4665960	ENSG00000234072.1	AC074117.10	-4.69	3.11e-06	0.000286	-0.16	-0.14	Blood metabolite levels;	chr2:27244730	chr2:27356246~27367622:+
BRCA	cis	rs6672530	0.518	rs2018654	ENSG00000227711.2	RP11-275O4.5	4.69	3.11e-06	0.000286	0.17	0.14	Hip circumference adjusted for BMI;	chr1:227508332	chr1:227509028~227520477:-
BRCA	cis	rs16958440	1	rs62096474	ENSG00000267724.1	RP11-49K24.8	4.69	3.11e-06	0.000286	0.25	0.14	Sitting height ratio;	chr18:47121133	chr18:47105946~47108062:+
BRCA	cis	rs4662750	0.58	rs4662745	ENSG00000236682.1	AC068282.3	4.69	3.11e-06	0.000286	0.19	0.14	Renal cell carcinoma;	chr2:127595288	chr2:127389130~127400580:+
BRCA	cis	rs919433	0.679	rs10931787	ENSG00000231621.1	AC013264.2	-4.69	3.11e-06	0.000286	-0.14	-0.14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197655891	chr2:197197991~197199273:+
BRCA	cis	rs919433	0.679	rs1902249	ENSG00000231621.1	AC013264.2	-4.69	3.11e-06	0.000286	-0.14	-0.14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197656632	chr2:197197991~197199273:+
BRCA	cis	rs919433	0.679	rs67492914	ENSG00000231621.1	AC013264.2	-4.69	3.11e-06	0.000286	-0.14	-0.14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197658678	chr2:197197991~197199273:+
BRCA	cis	rs6696239	0.513	rs2018828	ENSG00000227711.2	RP11-275O4.5	4.69	3.12e-06	0.000286	0.17	0.14	Height;	chr1:227508301	chr1:227509028~227520477:-
BRCA	cis	rs859767	0.741	rs35599954	ENSG00000224043.6	CCNT2-AS1	4.69	3.12e-06	0.000286	0.2	0.14	Neuroticism;	chr2:134634911	chr2:134735464~134918710:-
BRCA	cis	rs6445975	0.726	rs7616659	ENSG00000272360.1	RP11-359I18.5	-4.69	3.12e-06	0.000286	-0.15	-0.14	Systemic lupus erythematosus;	chr3:58481860	chr3:58490830~58491291:-
BRCA	cis	rs78487399	0.908	rs12469959	ENSG00000234936.1	AC010883.5	4.69	3.12e-06	0.000286	0.22	0.14	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43576587	chr2:43229573~43233394:+
BRCA	cis	rs739496	0.579	rs2879603	ENSG00000226469.1	ADAM1B	4.69	3.12e-06	0.000286	0.18	0.14	Platelet count;	chr12:111840221	chr12:111927018~111929017:+
BRCA	cis	rs4919694	0.536	rs12414777	ENSG00000213277.3	MARCKSL1P1	4.69	3.12e-06	0.000286	0.19	0.14	Arsenic metabolism;	chr10:102938024	chr10:103175554~103176094:+
BRCA	cis	rs6570726	0.935	rs421268	ENSG00000270638.1	RP3-466P17.1	4.69	3.12e-06	0.000286	0.16	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145524422	chr6:145735570~145737218:+
BRCA	cis	rs853679	0.76	rs11967137	ENSG00000280107.1	AL022393.9	-4.69	3.12e-06	0.000286	-0.23	-0.14	Depression;	chr6:28231986	chr6:28170845~28172521:+
BRCA	cis	rs12744310	0.83	rs4406620	ENSG00000235358.1	RP11-399E6.1	4.69	3.12e-06	0.000286	0.21	0.14	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41327093	chr1:41242373~41284861:+
BRCA	cis	rs180730	0.95	rs2198032	ENSG00000251609.2	SETP12	4.69	3.12e-06	0.000286	0.21	0.14	Fasting plasma glucose;	chr4:120918993	chr4:120895494~120897083:-
BRCA	cis	rs6832769	1	rs7677526	ENSG00000223305.1	RN7SKP30	4.69	3.12e-06	0.000286	0.18	0.14	Personality dimensions;	chr4:55483741	chr4:55540502~55540835:-
BRCA	cis	rs539096	0.872	rs10890255	ENSG00000236200.4	KDM4A-AS1	-4.69	3.12e-06	0.000286	-0.17	-0.14	Intelligence (multi-trait analysis);	chr1:43565822	chr1:43699765~43708138:-
BRCA	cis	rs4934494	0.677	rs7905163	ENSG00000240996.1	RP11-80H5.7	-4.69	3.12e-06	0.000286	-0.19	-0.14	Red blood cell count;	chr10:89624173	chr10:89694295~89697928:-
BRCA	cis	rs6088580	0.634	rs6059850	ENSG00000276073.1	RP5-1125A11.7	-4.69	3.12e-06	0.000287	-0.16	-0.14	Glomerular filtration rate (creatinine);	chr20:34456979	chr20:33985617~33988989:-
BRCA	cis	rs453301	0.686	rs6601280	ENSG00000253981.4	ALG1L13P	4.69	3.12e-06	0.000287	0.17	0.14	Joint mobility (Beighton score);	chr8:9051726	chr8:8236003~8244667:-
BRCA	cis	rs2243480	1	rs34193460	ENSG00000226002.1	RP11-460N20.5	-4.69	3.12e-06	0.000287	-0.24	-0.14	Diabetic kidney disease;	chr7:65928123	chr7:65084103~65100232:+
BRCA	cis	rs12534093	0.562	rs6461715	ENSG00000234286.1	AC006026.13	-4.69	3.12e-06	0.000287	-0.18	-0.14	Infant length;Height;	chr7:23539496	chr7:23680195~23680786:-
BRCA	cis	rs73193808	0.901	rs73354869	ENSG00000236056.1	GAPDHP14	-4.69	3.12e-06	0.000287	-0.2	-0.14	Coronary artery disease;	chr21:29194964	chr21:29222321~29223257:+
BRCA	cis	rs1979679	0.608	rs1355472	ENSG00000278733.1	RP11-425D17.1	4.69	3.13e-06	0.000287	0.19	0.14	Ossification of the posterior longitudinal ligament of the spine;	chr12:28568481	chr12:28185625~28186190:-
BRCA	cis	rs35146811	0.555	rs2525539	ENSG00000214313.7	AZGP1P1	-4.69	3.13e-06	0.000287	-0.16	-0.14	Coronary artery disease;	chr7:99947686	chr7:99980762~99987535:+
BRCA	cis	rs409045	0.965	rs406210	ENSG00000271874.1	CTD-2024P10.2	-4.69	3.13e-06	0.000287	-0.19	-0.14	Left ventricular mass;	chr5:34634285	chr5:34651457~34651888:-
BRCA	cis	rs13160562	0.527	rs152479	ENSG00000272109.1	CTD-2260A17.3	-4.69	3.13e-06	0.000287	-0.18	-0.14	Alcohol dependence;	chr5:96769339	chr5:96804353~96806105:+
BRCA	cis	rs2243480	1	rs67728539	ENSG00000275400.1	RP4-756H11.5	4.69	3.13e-06	0.000287	0.26	0.14	Diabetic kidney disease;	chr7:65913137	chr7:66553805~66554199:-
BRCA	cis	rs13326165	0.585	rs4082828	ENSG00000243224.1	RP5-1157M23.2	-4.69	3.13e-06	0.000287	-0.24	-0.14	HDL cholesterol levels;HDL cholesterol;	chr3:52240726	chr3:52239258~52241097:+
BRCA	cis	rs8180040	0.966	rs11705957	ENSG00000271161.1	BOLA2P2	-4.69	3.13e-06	0.000287	-0.16	-0.14	Colorectal cancer;	chr3:47401772	chr3:47499841~47500407:+
BRCA	cis	rs6832769	1	rs6851838	ENSG00000223305.1	RN7SKP30	-4.69	3.13e-06	0.000287	-0.18	-0.14	Personality dimensions;	chr4:55554580	chr4:55540502~55540835:-
BRCA	cis	rs1198430	1	rs1198430	ENSG00000271420.1	RP5-1057J7.7	-4.69	3.13e-06	0.000287	-0.19	-0.14	Total cholesterol levels;	chr1:23429020	chr1:23378380~23379029:-
BRCA	cis	rs2179367	0.6	rs9498353	ENSG00000268592.3	RAET1E-AS1	4.69	3.13e-06	0.000287	0.21	0.14	Dupuytren's disease;	chr6:149439860	chr6:149863494~149919507:+
BRCA	cis	rs6890684	0.544	rs34634	ENSG00000215032.2	GNL3LP1	4.69	3.13e-06	0.000287	0.17	0.14	Intelligence (multi-trait analysis);	chr5:61217739	chr5:60891935~60893577:-
BRCA	cis	rs3002142	0.554	rs17531300	ENSG00000272750.1	RP11-378J18.8	4.69	3.13e-06	0.000287	0.31	0.14	LDL peak particle diameter (total fat intake interaction);	chr1:222657890	chr1:222658867~222661512:-
BRCA	cis	rs62103177	0.81	rs62103178	ENSG00000261126.6	RP11-795F19.1	4.69	3.13e-06	0.000287	0.22	0.14	Opioid sensitivity;	chr18:79864555	chr18:80046900~80095482:+
BRCA	cis	rs10829156	0.786	rs7093907	ENSG00000240291.1	RP11-499P20.2	4.69	3.13e-06	0.000287	0.17	0.14	Sudden cardiac arrest;	chr10:18587225	chr10:18513115~18545651:-
BRCA	cis	rs2055375	0.818	rs190947	ENSG00000215032.2	GNL3LP1	4.69	3.13e-06	0.000287	0.18	0.14	Intelligence (multi-trait analysis);	chr5:61209988	chr5:60891935~60893577:-
BRCA	cis	rs12744310	0.943	rs7521544	ENSG00000235358.1	RP11-399E6.1	4.69	3.13e-06	0.000287	0.22	0.14	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41306454	chr1:41242373~41284861:+
BRCA	cis	rs12744310	1	rs7513682	ENSG00000235358.1	RP11-399E6.1	4.69	3.13e-06	0.000287	0.22	0.14	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41306495	chr1:41242373~41284861:+
BRCA	cis	rs12744310	1	rs34008156	ENSG00000235358.1	RP11-399E6.1	4.69	3.13e-06	0.000287	0.22	0.14	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41307510	chr1:41242373~41284861:+
BRCA	cis	rs12744310	1	rs12744310	ENSG00000235358.1	RP11-399E6.1	4.69	3.13e-06	0.000287	0.22	0.14	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41307830	chr1:41242373~41284861:+
BRCA	cis	rs12744310	1	rs56077539	ENSG00000235358.1	RP11-399E6.1	4.69	3.13e-06	0.000287	0.22	0.14	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41308270	chr1:41242373~41284861:+
BRCA	cis	rs12744310	1	rs55892603	ENSG00000235358.1	RP11-399E6.1	4.69	3.13e-06	0.000287	0.22	0.14	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41308322	chr1:41242373~41284861:+
BRCA	cis	rs12744310	1	rs55929643	ENSG00000235358.1	RP11-399E6.1	4.69	3.13e-06	0.000287	0.22	0.14	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41308540	chr1:41242373~41284861:+
BRCA	cis	rs12744310	1	rs34759578	ENSG00000235358.1	RP11-399E6.1	4.69	3.13e-06	0.000287	0.22	0.14	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41308678	chr1:41242373~41284861:+
BRCA	cis	rs12744310	0.945	rs72665690	ENSG00000235358.1	RP11-399E6.1	4.69	3.13e-06	0.000287	0.22	0.14	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41309564	chr1:41242373~41284861:+
BRCA	cis	rs12744310	0.945	rs72665691	ENSG00000235358.1	RP11-399E6.1	4.69	3.13e-06	0.000287	0.22	0.14	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41309573	chr1:41242373~41284861:+
BRCA	cis	rs12744310	0.945	rs72665692	ENSG00000235358.1	RP11-399E6.1	4.69	3.13e-06	0.000287	0.22	0.14	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41309707	chr1:41242373~41284861:+
BRCA	cis	rs12744310	0.887	rs72665694	ENSG00000235358.1	RP11-399E6.1	4.69	3.13e-06	0.000287	0.22	0.14	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41309712	chr1:41242373~41284861:+
BRCA	cis	rs12744310	1	rs72665698	ENSG00000235358.1	RP11-399E6.1	4.69	3.13e-06	0.000287	0.22	0.14	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41309917	chr1:41242373~41284861:+
BRCA	cis	rs12744310	1	rs12756822	ENSG00000235358.1	RP11-399E6.1	4.69	3.13e-06	0.000287	0.22	0.14	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41311655	chr1:41242373~41284861:+
BRCA	cis	rs9921338	0.636	rs56069754	ENSG00000262703.1	RP11-485G7.6	-4.69	3.13e-06	0.000287	-0.18	-0.14	Vein graft stenosis in coronary artery bypass grafting;	chr16:11268783	chr16:11348143~11349321:-
BRCA	cis	rs4950322	0.634	rs4950415	ENSG00000244371.2	PFN1P8	-4.69	3.13e-06	0.000288	-0.21	-0.14	Protein quantitative trait loci;	chr1:147350951	chr1:146957117~146957659:-
BRCA	cis	rs7621331	1	rs13098245	ENSG00000273486.1	RP11-731C17.2	4.69	3.13e-06	0.000288	0.17	0.14	Waist circumference adjusted for body mass index;	chr3:135994792	chr3:136837338~136839021:-
BRCA	cis	rs904251	0.686	rs1224128	ENSG00000204110.6	RP1-153P14.8	-4.69	3.13e-06	0.000288	-0.18	-0.14	Cognitive performance;	chr6:37447900	chr6:37507348~37535616:+
BRCA	cis	rs7620503	0.721	rs6769488	ENSG00000228221.4	LINC00578	4.69	3.14e-06	0.000288	0.18	0.14	Corneal structure;	chr3:177590370	chr3:177441921~177752305:+
BRCA	cis	rs7267979	0.816	rs6037158	ENSG00000204556.4	CTD-2514C3.1	-4.69	3.14e-06	0.000288	-0.19	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25614830	chr20:26018832~26020684:+
BRCA	cis	rs4218	0.734	rs12912071	ENSG00000277144.1	RP11-59H7.4	-4.69	3.14e-06	0.000288	-0.17	-0.14	Social communication problems;	chr15:59150951	chr15:59115547~59116089:-
BRCA	cis	rs5167	0.504	rs7257476	ENSG00000280087.1	CTB-129P6.7	4.69	3.14e-06	0.000288	0.17	0.14	Blood protein levels;	chr19:44949908	chr19:44909375~44914968:+
BRCA	cis	rs12744310	0.945	rs72665696	ENSG00000235358.1	RP11-399E6.1	4.69	3.14e-06	0.000288	0.22	0.14	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41309757	chr1:41242373~41284861:+
BRCA	cis	rs12744310	0.943	rs12751511	ENSG00000235358.1	RP11-399E6.1	4.69	3.14e-06	0.000288	0.22	0.14	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41310731	chr1:41242373~41284861:+
BRCA	cis	rs12744310	1	rs34073585	ENSG00000235358.1	RP11-399E6.1	4.69	3.14e-06	0.000288	0.22	0.14	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41311527	chr1:41242373~41284861:+
BRCA	cis	rs2153535	0.58	rs7743418	ENSG00000251164.1	HULC	-4.69	3.14e-06	0.000288	-0.18	-0.14	Motion sickness;	chr6:8437895	chr6:8652137~8653846:+
BRCA	cis	rs6598266	1	rs6598266	ENSG00000182397.13	DNM1P46	4.69	3.14e-06	0.000288	0.19	0.14	Major depressive disorder;	chr15:99759034	chr15:99790156~99806927:-
BRCA	cis	rs10761482	0.638	rs10761507	ENSG00000254271.1	RP11-131N11.4	-4.69	3.14e-06	0.000288	-0.2	-0.14	Schizophrenia;	chr10:60483474	chr10:60734342~60741828:+
BRCA	cis	rs1713985	0.698	rs1277307	ENSG00000269949.1	RP11-738E22.3	-4.69	3.14e-06	0.000288	-0.28	-0.14	Age-related macular degeneration;	chr4:57030533	chr4:56960927~56961373:-
BRCA	cis	rs1371614	0.545	rs12105356	ENSG00000229122.1	AGBL5-IT1	4.69	3.14e-06	0.000288	0.15	0.14	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26952702	chr2:27061038~27061815:+
BRCA	cis	rs2243480	0.808	rs12698508	ENSG00000226002.1	RP11-460N20.5	-4.69	3.14e-06	0.000288	-0.24	-0.14	Diabetic kidney disease;	chr7:65946971	chr7:65084103~65100232:+
BRCA	cis	rs516805	0.528	rs2606628	ENSG00000279453.1	RP3-425C14.4	-4.69	3.14e-06	0.000288	-0.2	-0.14	Lymphocyte counts;	chr6:122097460	chr6:122436789~122439223:-
BRCA	cis	rs7074356	0.523	rs7087728	ENSG00000225484.5	NUTM2B-AS1	-4.69	3.15e-06	0.000288	-0.24	-0.14	Borderline personality disorder;	chr10:80273714	chr10:79663088~79826594:-
BRCA	cis	rs372883	0.6	rs1236460	ENSG00000176054.6	RPL23P2	-4.69	3.15e-06	0.000289	-0.17	-0.14	Pancreatic cancer;	chr21:29243192	chr21:28997613~28998033:-
BRCA	cis	rs919433	0.679	rs10931788	ENSG00000231621.1	AC013264.2	-4.69	3.15e-06	0.000289	-0.14	-0.14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197666360	chr2:197197991~197199273:+
BRCA	cis	rs300890	0.689	rs11947952	ENSG00000250326.1	RP11-284M14.1	-4.69	3.15e-06	0.000289	-0.17	-0.14	Nasopharyngeal carcinoma;	chr4:143331811	chr4:142933195~143184861:-
BRCA	cis	rs13113518	0.812	rs12648271	ENSG00000272969.1	RP11-528I4.2	4.69	3.15e-06	0.000289	0.19	0.14	Height;	chr4:55501955	chr4:55547112~55547889:+
BRCA	cis	rs11098499	0.909	rs2127821	ENSG00000250412.1	KLHL2P1	4.69	3.15e-06	0.000289	0.17	0.14	Corneal astigmatism;	chr4:119473380	chr4:119334329~119378233:+
BRCA	cis	rs10457838	0.887	rs10872632	ENSG00000236591.1	RP11-162J8.3	-4.69	3.15e-06	0.000289	-0.2	-0.14	Post-traumatic stress disorder;	chr6:149070055	chr6:149027700~149032573:-
BRCA	cis	rs2179367	0.613	rs62426122	ENSG00000268592.3	RAET1E-AS1	4.69	3.15e-06	0.000289	0.2	0.14	Dupuytren's disease;	chr6:149427449	chr6:149863494~149919507:+
BRCA	cis	rs7617773	0.539	rs13087050	ENSG00000228638.1	FCF1P2	-4.69	3.15e-06	0.000289	-0.15	-0.14	Coronary artery disease;	chr3:48351310	chr3:48290793~48291375:-
BRCA	cis	rs2153535	0.58	rs5001130	ENSG00000251164.1	HULC	-4.69	3.15e-06	0.000289	-0.18	-0.14	Motion sickness;	chr6:8442065	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.58	rs1577466	ENSG00000251164.1	HULC	-4.69	3.15e-06	0.000289	-0.18	-0.14	Motion sickness;	chr6:8443959	chr6:8652137~8653846:+
BRCA	cis	rs6547741	0.935	rs6547738	ENSG00000234072.1	AC074117.10	4.69	3.15e-06	0.000289	0.13	0.14	Oral cavity cancer;	chr2:27629770	chr2:27356246~27367622:+
BRCA	cis	rs10844706	1	rs10844706	ENSG00000256673.1	RP11-599J14.2	-4.69	3.15e-06	0.000289	-0.17	-0.14	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9757536	chr12:9398355~9414851:-
BRCA	cis	rs7267979	0.903	rs6115101	ENSG00000125804.12	FAM182A	-4.69	3.15e-06	0.000289	-0.19	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25248928	chr20:26054655~26086917:+
BRCA	cis	rs79040073	1	rs79040073	ENSG00000259531.2	RP11-295H24.3	4.69	3.16e-06	0.000289	0.24	0.14	Lung cancer in ever smokers;	chr15:49038657	chr15:49365124~49366685:-
BRCA	cis	rs2688608	0.592	rs7923045	ENSG00000213731.2	RAB5CP1	-4.69	3.16e-06	0.000289	-0.16	-0.14	Inflammatory bowel disease;	chr10:73727740	chr10:74423435~74424014:-
BRCA	cis	rs3733585	0.605	rs4697710	ENSG00000250413.1	RP11-448G15.1	4.69	3.16e-06	0.00029	0.19	0.14	Cleft plate (environmental tobacco smoke interaction);	chr4:10121025	chr4:10006482~10009725:+
BRCA	cis	rs6570726	0.935	rs429306	ENSG00000270638.1	RP3-466P17.1	4.69	3.16e-06	0.00029	0.16	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145505880	chr6:145735570~145737218:+
BRCA	cis	rs6570726	0.935	rs428659	ENSG00000270638.1	RP3-466P17.1	4.69	3.16e-06	0.00029	0.16	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145505903	chr6:145735570~145737218:+
BRCA	cis	rs6570726	0.935	rs376991	ENSG00000270638.1	RP3-466P17.1	4.69	3.16e-06	0.00029	0.16	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145506937	chr6:145735570~145737218:+
BRCA	cis	rs6570726	0.935	rs401888	ENSG00000270638.1	RP3-466P17.1	4.69	3.16e-06	0.00029	0.16	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145510399	chr6:145735570~145737218:+
BRCA	cis	rs6570726	0.935	rs414646	ENSG00000270638.1	RP3-466P17.1	4.69	3.16e-06	0.00029	0.16	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145510549	chr6:145735570~145737218:+
BRCA	cis	rs6570726	0.935	rs454614	ENSG00000270638.1	RP3-466P17.1	4.69	3.16e-06	0.00029	0.16	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145511497	chr6:145735570~145737218:+
BRCA	cis	rs6570726	0.846	rs411468	ENSG00000270638.1	RP3-466P17.1	4.69	3.16e-06	0.00029	0.16	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145511656	chr6:145735570~145737218:+
BRCA	cis	rs6570726	0.935	rs425731	ENSG00000270638.1	RP3-466P17.1	4.69	3.16e-06	0.00029	0.16	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145513015	chr6:145735570~145737218:+
BRCA	cis	rs6570726	0.935	rs421690	ENSG00000270638.1	RP3-466P17.1	4.69	3.16e-06	0.00029	0.16	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145513458	chr6:145735570~145737218:+
BRCA	cis	rs6570726	0.935	rs399169	ENSG00000270638.1	RP3-466P17.1	4.69	3.16e-06	0.00029	0.16	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145515217	chr6:145735570~145737218:+
BRCA	cis	rs6570726	0.935	rs377130	ENSG00000270638.1	RP3-466P17.1	4.69	3.16e-06	0.00029	0.16	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145515496	chr6:145735570~145737218:+
BRCA	cis	rs6570726	0.935	rs422540	ENSG00000270638.1	RP3-466P17.1	4.69	3.16e-06	0.00029	0.16	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145516679	chr6:145735570~145737218:+
BRCA	cis	rs6570726	0.935	rs425717	ENSG00000270638.1	RP3-466P17.1	4.69	3.16e-06	0.00029	0.16	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145517484	chr6:145735570~145737218:+
BRCA	cis	rs6570726	0.935	rs409121	ENSG00000270638.1	RP3-466P17.1	4.69	3.16e-06	0.00029	0.16	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145518657	chr6:145735570~145737218:+
BRCA	cis	rs6570726	0.935	rs424263	ENSG00000270638.1	RP3-466P17.1	4.69	3.16e-06	0.00029	0.16	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145518937	chr6:145735570~145737218:+
BRCA	cis	rs6570726	0.905	rs419575	ENSG00000270638.1	RP3-466P17.1	4.69	3.16e-06	0.00029	0.16	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145519038	chr6:145735570~145737218:+
BRCA	cis	rs6570726	0.935	rs409725	ENSG00000270638.1	RP3-466P17.1	4.69	3.16e-06	0.00029	0.16	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145519204	chr6:145735570~145737218:+
BRCA	cis	rs6570726	0.935	rs386823	ENSG00000270638.1	RP3-466P17.1	4.69	3.16e-06	0.00029	0.16	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145520229	chr6:145735570~145737218:+
BRCA	cis	rs56322409	0.759	rs3192654	ENSG00000226688.5	ENTPD1-AS1	4.69	3.16e-06	0.00029	0.17	0.14	Blood metabolite levels;	chr10:95873051	chr10:95753206~96090238:-
BRCA	cis	rs11098499	1	rs1011054	ENSG00000260091.1	RP11-33B1.4	4.69	3.16e-06	0.00029	0.13	0.14	Corneal astigmatism;	chr4:119281232	chr4:119409333~119410233:+
BRCA	cis	rs6738627	1	rs7609045	ENSG00000223318.1	RNA5SP111	4.69	3.16e-06	0.00029	0.16	0.14	circulating leptin levels adjusted for BMI;Body fat percentage;circulating leptin levels;	chr2:164698697	chr2:164895677~164895777:-
BRCA	cis	rs73222236	0.817	rs9845950	ENSG00000273486.1	RP11-731C17.2	4.69	3.16e-06	0.00029	0.16	0.14	Coronary artery disease;	chr3:136637756	chr3:136837338~136839021:-
BRCA	cis	rs73222236	0.817	rs7644346	ENSG00000273486.1	RP11-731C17.2	4.69	3.16e-06	0.00029	0.16	0.14	Coronary artery disease;	chr3:136639645	chr3:136837338~136839021:-
BRCA	cis	rs73222236	0.817	rs28682370	ENSG00000273486.1	RP11-731C17.2	4.69	3.16e-06	0.00029	0.16	0.14	Coronary artery disease;	chr3:136644222	chr3:136837338~136839021:-
BRCA	cis	rs853679	0.545	rs35949109	ENSG00000204709.4	LINC01556	4.69	3.16e-06	0.00029	0.29	0.14	Depression;	chr6:28058148	chr6:28943877~28944537:+
BRCA	cis	rs11098499	0.954	rs7436506	ENSG00000260091.1	RP11-33B1.4	-4.69	3.16e-06	0.00029	-0.13	-0.14	Corneal astigmatism;	chr4:119472614	chr4:119409333~119410233:+
BRCA	cis	rs7577696	0.962	rs7600173	ENSG00000272716.1	RP11-563N4.1	-4.69	3.17e-06	0.00029	-0.16	-0.14	Inflammatory biomarkers;	chr2:32043341	chr2:32165046~32165757:-
BRCA	cis	rs4494364	0.502	rs1882145	ENSG00000258100.1	RP11-121E16.1	4.69	3.17e-06	0.00029	0.2	0.14	Systolic blood pressure (alcohol consumption interaction);	chr12:90969742	chr12:91362196~91368606:+
BRCA	cis	rs10129255	0.5	rs6576232	ENSG00000211959.2	IGHV4-39	4.69	3.17e-06	0.00029	0.1	0.14	Kawasaki disease;	chr14:106787090	chr14:106421711~106422218:-
BRCA	cis	rs13113518	1	rs6858803	ENSG00000249700.7	SRD5A3-AS1	4.69	3.17e-06	0.00029	0.18	0.14	Height;	chr4:55484534	chr4:55363971~55395847:-
BRCA	cis	rs11089937	0.616	rs5995616	ENSG00000211638.2	IGLV8-61	4.69	3.17e-06	0.00029	0.14	0.14	Periodontitis (PAL4Q3);	chr22:22186667	chr22:22098700~22099212:+
BRCA	cis	rs1950832	0.566	rs1900599	ENSG00000258636.1	CTD-2298J14.2	-4.69	3.17e-06	0.00029	-0.16	-0.14	Urate levels in obese individuals;	chr14:41671998	chr14:41587861~41604856:-
BRCA	cis	rs7246967	0.673	rs74664155	ENSG00000198153.8	ZNF849P	-4.69	3.17e-06	0.00029	-0.24	-0.14	Bronchopulmonary dysplasia;	chr19:22697530	chr19:22685167~22686732:+
BRCA	cis	rs7646881	0.767	rs73015629	ENSG00000240207.5	RP11-379F4.4	-4.69	3.17e-06	0.00029	-0.23	-0.14	Tetralogy of Fallot;	chr3:158716051	chr3:158732263~158784070:+
BRCA	cis	rs4664293	0.669	rs35299907	ENSG00000226266.5	AC009961.3	4.68	3.17e-06	0.000291	0.17	0.14	Monocyte percentage of white cells;	chr2:159562142	chr2:159670708~159712435:-
BRCA	cis	rs6546324	0.559	rs4381768	ENSG00000236780.4	AC078941.1	4.68	3.17e-06	0.000291	0.25	0.14	Endometriosis;	chr2:67552256	chr2:67123357~67215319:-
BRCA	cis	rs172166	0.611	rs203882	ENSG00000219392.1	RP1-265C24.5	-4.68	3.17e-06	0.000291	-0.2	-0.14	Cardiac Troponin-T levels;	chr6:28110724	chr6:28115628~28116551:+
BRCA	cis	rs1161098	0.716	rs1161179	ENSG00000203585.3	RP11-542B15.1	-4.68	3.17e-06	0.000291	-0.22	-0.14	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr12:67432144	chr12:67519829~67567126:+
BRCA	cis	rs4787491	0.729	rs8043883	ENSG00000261367.1	RP11-455F5.4	-4.68	3.18e-06	0.000291	-0.16	-0.14	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30033260	chr16:30107675~30110541:+
BRCA	cis	rs9473147	0.602	rs9296567	ENSG00000270761.1	RP11-385F7.1	-4.68	3.18e-06	0.000291	-0.16	-0.14	Platelet distribution width;Mean platelet volume;	chr6:47585666	chr6:47477243~47477572:-
BRCA	cis	rs9473147	0.571	rs9395285	ENSG00000270761.1	RP11-385F7.1	-4.68	3.18e-06	0.000291	-0.16	-0.14	Platelet distribution width;Mean platelet volume;	chr6:47586441	chr6:47477243~47477572:-
BRCA	cis	rs7267979	1	rs2500446	ENSG00000125804.12	FAM182A	4.68	3.18e-06	0.000291	0.19	0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25359028	chr20:26054655~26086917:+
BRCA	cis	rs34792	0.853	rs153807	ENSG00000207425.1	Y_RNA	4.68	3.18e-06	0.000291	0.16	0.14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15462646	chr16:14915457~14915556:-
BRCA	cis	rs2303319	0.504	rs62188961	ENSG00000227403.1	AC009299.3	4.68	3.18e-06	0.000291	0.35	0.14	Cognitive function;	chr2:161638889	chr2:161244739~161249050:+
BRCA	cis	rs2303319	0.504	rs16845960	ENSG00000227403.1	AC009299.3	4.68	3.18e-06	0.000291	0.35	0.14	Cognitive function;	chr2:161645103	chr2:161244739~161249050:+
BRCA	cis	rs2303319	0.504	rs62188984	ENSG00000227403.1	AC009299.3	4.68	3.18e-06	0.000291	0.35	0.14	Cognitive function;	chr2:161658008	chr2:161244739~161249050:+
BRCA	cis	rs2303319	0.504	rs56039028	ENSG00000227403.1	AC009299.3	4.68	3.18e-06	0.000291	0.35	0.14	Cognitive function;	chr2:161659853	chr2:161244739~161249050:+
BRCA	cis	rs2303319	0.504	rs16845997	ENSG00000227403.1	AC009299.3	4.68	3.18e-06	0.000291	0.35	0.14	Cognitive function;	chr2:161664536	chr2:161244739~161249050:+
BRCA	cis	rs256438	0.731	rs7723567	ENSG00000251050.1	RP11-168A11.4	-4.68	3.18e-06	0.000291	-0.17	-0.14	Serum thyroid-stimulating hormone levels;	chr5:80048466	chr5:80019609~80019920:+
BRCA	cis	rs7267979	1	rs2482937	ENSG00000125804.12	FAM182A	4.68	3.18e-06	0.000291	0.19	0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25360150	chr20:26054655~26086917:+
BRCA	cis	rs10504130	1	rs58583070	ENSG00000272024.1	RP11-546K22.3	-4.68	3.18e-06	0.000291	-0.26	-0.14	Venous thromboembolism (SNP x SNP interaction);	chr8:51775492	chr8:51950284~51950690:+
BRCA	cis	rs300890	0.513	rs4605600	ENSG00000250326.1	RP11-284M14.1	-4.68	3.18e-06	0.000291	-0.17	-0.14	Nasopharyngeal carcinoma;	chr4:143124552	chr4:142933195~143184861:-
BRCA	cis	rs300890	0.536	rs4279157	ENSG00000250326.1	RP11-284M14.1	-4.68	3.18e-06	0.000291	-0.17	-0.14	Nasopharyngeal carcinoma;	chr4:143124849	chr4:142933195~143184861:-
BRCA	cis	rs7308116	0.546	rs61938609	ENSG00000274395.1	RP11-554D14.8	-4.68	3.18e-06	0.000291	-0.18	-0.14	Pelvic organ prolapse (moderate/severe);	chr12:107816842	chr12:107835541~107836555:-
BRCA	cis	rs690037	0.809	rs690023	ENSG00000272498.1	RP11-415F23.3	4.68	3.18e-06	0.000292	0.14	0.14	Optic nerve measurement (cup-to-disc ratio);Optic nerve measurement (cup area);	chr3:16344847	chr3:16339308~16339871:+
BRCA	cis	rs8180040	0.62	rs2305635	ENSG00000276925.1	RP11-708J19.3	4.68	3.18e-06	0.000292	0.17	0.14	Colorectal cancer;	chr3:47002132	chr3:47469777~47469987:+
BRCA	cis	rs7312933	0.558	rs1669886	ENSG00000257225.1	RP11-328C8.4	4.68	3.18e-06	0.000292	0.17	0.14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42444438	chr12:42459366~42466128:+
BRCA	cis	rs1665050	1	rs1665050	ENSG00000277144.1	RP11-59H7.4	4.68	3.19e-06	0.000292	0.18	0.14	Atopic dermatitis;	chr15:59001406	chr15:59115547~59116089:-
BRCA	cis	rs6570726	0.935	rs419847	ENSG00000270638.1	RP3-466P17.1	4.68	3.19e-06	0.000292	0.16	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145506142	chr6:145735570~145737218:+
BRCA	cis	rs6570726	0.935	rs419850	ENSG00000270638.1	RP3-466P17.1	4.68	3.19e-06	0.000292	0.16	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145506145	chr6:145735570~145737218:+
BRCA	cis	rs227932	1	rs227932	ENSG00000234286.1	AC006026.13	-4.68	3.19e-06	0.000292	-0.26	-0.14	Schizophrenia;	chr7:23584856	chr7:23680195~23680786:-
BRCA	cis	rs924712	0.535	rs1393778	ENSG00000224984.1	RP11-524H19.2	4.68	3.19e-06	0.000292	0.17	0.14	Breast cancer;	chr6:54835751	chr6:54840118~54840855:-
BRCA	cis	rs9467773	1	rs9295695	ENSG00000241549.7	GUSBP2	-4.68	3.19e-06	0.000292	-0.16	-0.14	Intelligence (multi-trait analysis);	chr6:26528022	chr6:26871484~26956554:-
BRCA	cis	rs7048146	0.966	rs1411691	ENSG00000213539.4	YBX1P6	4.68	3.19e-06	0.000292	0.16	0.14	Vascular brain injury;	chr9:109542444	chr9:109532830~109534332:-
BRCA	cis	rs7119	0.679	rs12902698	ENSG00000259362.2	RP11-307C19.1	-4.68	3.19e-06	0.000292	-0.2	-0.14	Type 2 diabetes;	chr15:77516668	chr15:77525540~77534110:+
BRCA	cis	rs7119	0.717	rs12902852	ENSG00000259362.2	RP11-307C19.1	-4.68	3.19e-06	0.000292	-0.2	-0.14	Type 2 diabetes;	chr15:77516674	chr15:77525540~77534110:+
BRCA	cis	rs7809615	0.901	rs13243267	ENSG00000244219.5	GS1-259H13.2	4.68	3.19e-06	0.000292	0.24	0.14	Blood metabolite ratios;	chr7:99455691	chr7:99598066~99610813:+
BRCA	cis	rs2011013	1	rs12148239	ENSG00000225151.9	GOLGA2P7	-4.68	3.19e-06	0.000292	-0.19	-0.14	Sitting height ratio;	chr15:83972266	chr15:84199311~84230136:-
BRCA	cis	rs7428	0.545	rs7572750	ENSG00000273196.1	RP11-717A5.2	4.68	3.19e-06	0.000292	0.17	0.14	Ear protrusion;	chr2:85325063	chr2:85387074~85387146:-
BRCA	cis	rs4950322	0.542	rs12046706	ENSG00000244371.2	PFN1P8	-4.68	3.19e-06	0.000292	-0.17	-0.14	Protein quantitative trait loci;	chr1:147189758	chr1:146957117~146957659:-
BRCA	cis	rs2243480	0.615	rs34363376	ENSG00000222364.1	RNU6-96P	-4.68	3.19e-06	0.000292	-0.27	-0.14	Diabetic kidney disease;	chr7:66474549	chr7:66395191~66395286:+
BRCA	cis	rs78487399	0.908	rs75030714	ENSG00000234936.1	AC010883.5	4.68	3.19e-06	0.000292	0.22	0.14	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43617733	chr2:43229573~43233394:+
BRCA	cis	rs4787491	0.729	rs4788213	ENSG00000261367.1	RP11-455F5.4	-4.68	3.19e-06	0.000292	-0.16	-0.14	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30023203	chr16:30107675~30110541:+
BRCA	cis	rs4787491	0.679	rs7204852	ENSG00000261367.1	RP11-455F5.4	-4.68	3.19e-06	0.000292	-0.16	-0.14	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30028857	chr16:30107675~30110541:+
BRCA	cis	rs4787491	0.729	rs12446378	ENSG00000261367.1	RP11-455F5.4	-4.68	3.19e-06	0.000292	-0.16	-0.14	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30031789	chr16:30107675~30110541:+
BRCA	cis	rs2243480	0.708	rs13242216	ENSG00000275400.1	RP4-756H11.5	4.68	3.19e-06	0.000292	0.26	0.14	Diabetic kidney disease;	chr7:66433290	chr7:66553805~66554199:-
BRCA	cis	rs4218	0.871	rs2414621	ENSG00000259732.1	RP11-59H7.3	-4.68	3.19e-06	0.000292	-0.17	-0.14	Social communication problems;	chr15:59142129	chr15:59121034~59133250:+
BRCA	cis	rs10208649	0.611	rs12620667	ENSG00000272156.1	RP11-477N3.1	4.68	3.19e-06	0.000293	0.26	0.14	Body mass index;	chr2:54063860	chr2:54082554~54085066:+
BRCA	cis	rs4478858	0.775	rs6701667	ENSG00000223907.1	LINC01226	-4.68	3.2e-06	0.000293	-0.17	-0.14	Alcohol dependence;	chr1:31235124	chr1:31518435~31524245:+
BRCA	cis	rs6545883	0.894	rs4672436	ENSG00000212978.6	AC016747.3	-4.68	3.2e-06	0.000293	-0.2	-0.14	Tuberculosis;	chr2:61376222	chr2:61141592~61144969:-
BRCA	cis	rs6545883	0.859	rs35760550	ENSG00000212978.6	AC016747.3	-4.68	3.2e-06	0.000293	-0.2	-0.14	Tuberculosis;	chr2:61376730	chr2:61141592~61144969:-
BRCA	cis	rs6545883	0.859	rs62149714	ENSG00000212978.6	AC016747.3	-4.68	3.2e-06	0.000293	-0.2	-0.14	Tuberculosis;	chr2:61376734	chr2:61141592~61144969:-
BRCA	cis	rs3892630	0.878	rs2903759	ENSG00000267475.1	CTD-2538C1.2	-4.68	3.2e-06	0.000293	-0.22	-0.14	Red blood cell traits;	chr19:32705041	chr19:32687089~32691750:-
BRCA	cis	rs6545883	0.525	rs1177274	ENSG00000273302.1	RP11-493E12.2	4.68	3.2e-06	0.000293	0.13	0.14	Tuberculosis;	chr2:61141397	chr2:61199979~61200769:+
BRCA	cis	rs17507216	0.958	rs72751643	ENSG00000259429.4	UBE2Q2P2	-4.68	3.2e-06	0.000293	-0.17	-0.14	Excessive daytime sleepiness;	chr15:82559444	chr15:82355142~82420075:+
BRCA	cis	rs9467773	0.62	rs2494716	ENSG00000241549.7	GUSBP2	4.68	3.2e-06	0.000293	0.15	0.14	Intelligence (multi-trait analysis);	chr6:26662508	chr6:26871484~26956554:-
BRCA	cis	rs875971	1	rs1540651	ENSG00000236529.1	RP13-254B10.1	-4.68	3.2e-06	0.000293	-0.16	-0.14	Aortic root size;	chr7:66185134	chr7:65840212~65840596:+
BRCA	cis	rs11098499	0.697	rs28655325	ENSG00000250412.1	KLHL2P1	4.68	3.2e-06	0.000293	0.17	0.14	Corneal astigmatism;	chr4:119451844	chr4:119334329~119378233:+
BRCA	cis	rs60843830	0.964	rs17713879	ENSG00000272342.1	RP13-539J13.1	4.68	3.2e-06	0.000293	0.17	0.14	Spherical equivalent (joint analysis main effects and education interaction);	chr2:254215	chr2:739588~740164:-
BRCA	cis	rs6686842	0.56	rs6672914	ENSG00000235358.1	RP11-399E6.1	-4.68	3.2e-06	0.000293	-0.19	-0.14	Height;	chr1:41201257	chr1:41242373~41284861:+
BRCA	cis	rs115769866	0.609	rs974334	ENSG00000204709.4	LINC01556	4.68	3.2e-06	0.000293	0.2	0.14	Bipolar disorder;	chr6:28506441	chr6:28943877~28944537:+
BRCA	cis	rs4781563	0.956	rs762521	ENSG00000242307.1	RPS26P52	-4.68	3.2e-06	0.000293	-0.18	-0.14	Bilirubin levels;	chr16:13920383	chr16:13922332~13922679:-
BRCA	cis	rs875971	1	rs11971949	ENSG00000236529.1	RP13-254B10.1	-4.68	3.2e-06	0.000293	-0.16	-0.14	Aortic root size;	chr7:66161027	chr7:65840212~65840596:+
BRCA	cis	rs11098499	0.863	rs1552095	ENSG00000250412.1	KLHL2P1	4.68	3.21e-06	0.000293	0.18	0.14	Corneal astigmatism;	chr4:119539151	chr4:119334329~119378233:+
BRCA	cis	rs7267979	0.932	rs6115215	ENSG00000125804.12	FAM182A	-4.68	3.21e-06	0.000293	-0.19	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25581864	chr20:26054655~26086917:+
BRCA	cis	rs2505998	0.833	rs2505536	ENSG00000273008.1	RP11-351D16.3	4.68	3.21e-06	0.000294	0.17	0.14	Hirschsprung disease;	chr10:43096756	chr10:43136824~43138334:-
BRCA	cis	rs253959	0.564	rs4921064	ENSG00000271918.1	CTD-2287O16.5	4.68	3.21e-06	0.000294	0.13	0.14	Bipolar disorder and schizophrenia;	chr5:116111637	chr5:116083807~116085416:-
BRCA	cis	rs17711722	0.675	rs6947132	ENSG00000182722.5	SEPHS1P1	4.68	3.21e-06	0.000294	0.18	0.14	Calcium levels;	chr7:65808508	chr7:64852397~64853354:-
BRCA	cis	rs11098499	0.954	rs10006706	ENSG00000250412.1	KLHL2P1	4.68	3.21e-06	0.000294	0.17	0.14	Corneal astigmatism;	chr4:119487997	chr4:119334329~119378233:+
BRCA	cis	rs7772486	0.79	rs3924499	ENSG00000270638.1	RP3-466P17.1	-4.68	3.21e-06	0.000294	-0.17	-0.14	Lobe attachment (rater-scored or self-reported);	chr6:145911842	chr6:145735570~145737218:+
BRCA	cis	rs12612619	0.732	rs6716275	ENSG00000229122.1	AGBL5-IT1	-4.68	3.21e-06	0.000294	-0.15	-0.14	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27004839	chr2:27061038~27061815:+
BRCA	cis	rs17292804	0.506	rs71417868	ENSG00000244691.1	RPL10AP1	-4.68	3.21e-06	0.000294	-0.19	-0.14	Autism spectrum disorder or schizophrenia;	chr14:103580255	chr14:103412119~103412761:-
BRCA	cis	rs35740288	0.822	rs2241268	ENSG00000202081.1	RNU6-1280P	4.68	3.21e-06	0.000294	0.2	0.14	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85735078	chr15:85651522~85651628:-
BRCA	cis	rs6603134	0.502	rs10405582	ENSG00000269139.2	CTD-3193O13.8	4.68	3.21e-06	0.000294	0.16	0.14	Blood protein levels;	chr19:8038654	chr19:7926001~7926810:+
BRCA	cis	rs12468226	0.808	rs77251002	ENSG00000226261.1	AC064836.3	4.68	3.21e-06	0.000294	0.26	0.14	Urate levels;	chr2:202150236	chr2:202336024~202336727:-
BRCA	cis	rs8064024	0.619	rs9935080	ENSG00000267077.1	RP11-127I20.5	4.68	3.22e-06	0.000294	0.15	0.14	Cancer;	chr16:4852206	chr16:4795265~4796532:-
BRCA	cis	rs10833905	0.938	rs11026931	ENSG00000246225.5	RP11-17A1.3	-4.68	3.22e-06	0.000295	-0.2	-0.14	Sudden cardiac arrest;	chr11:23043651	chr11:22829380~22945393:+
BRCA	cis	rs7923609	0.818	rs10822159	ENSG00000232075.1	MRPL35P2	-4.68	3.22e-06	0.000295	-0.18	-0.14	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63336490	chr10:63634317~63634827:-
BRCA	cis	rs7674212	0.57	rs6841136	ENSG00000246560.2	RP11-10L12.4	4.68	3.22e-06	0.000295	0.15	0.14	Type 2 diabetes;	chr4:103182352	chr4:102828055~102844075:+
BRCA	cis	rs651907	0.64	rs771574	ENSG00000244119.1	PDCL3P4	4.68	3.22e-06	0.000295	0.12	0.14	Colorectal cancer;	chr3:101901838	chr3:101712472~101713191:+
BRCA	cis	rs2645424	0.53	rs1293303	ENSG00000255046.1	RP11-297N6.4	-4.68	3.22e-06	0.000295	-0.17	-0.14	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);	chr8:11862718	chr8:11797928~11802568:-
BRCA	cis	rs11009175	0.746	rs17230579	ENSG00000273038.2	RP11-479G22.8	4.68	3.22e-06	0.000295	0.23	0.14	Depression (quantitative trait);	chr10:33059117	chr10:32887255~32889311:-
BRCA	cis	rs2562456	0.617	rs34203148	ENSG00000268658.4	LINC00664	4.68	3.22e-06	0.000295	0.23	0.14	Pain;	chr19:21590743	chr19:21483374~21503238:+
BRCA	cis	rs17507216	0.718	rs28587782	ENSG00000255769.6	GOLGA2P10	-4.68	3.23e-06	0.000295	-0.21	-0.14	Excessive daytime sleepiness;	chr15:82576881	chr15:82472993~82513950:-
BRCA	cis	rs7200786	0.692	rs8054758	ENSG00000274038.1	RP11-66H6.4	-4.68	3.23e-06	0.000295	-0.16	-0.14	Systemic lupus erythematosus;Multiple sclerosis;	chr16:10997269	chr16:11056556~11057034:+
BRCA	cis	rs6603134	0.502	rs10405588	ENSG00000269139.2	CTD-3193O13.8	4.68	3.23e-06	0.000295	0.16	0.14	Blood protein levels;	chr19:8038663	chr19:7926001~7926810:+
BRCA	cis	rs875971	0.545	rs13311962	ENSG00000230295.1	RP11-458F8.2	-4.68	3.23e-06	0.000295	-0.14	-0.14	Aortic root size;	chr7:66603142	chr7:66880708~66882981:+
BRCA	cis	rs1153858	1	rs4775906	ENSG00000275672.1	GATM-AS1	-4.68	3.23e-06	0.000295	-0.18	-0.14	Homoarginine levels;	chr15:45346096	chr15:45378700~45380123:+
BRCA	cis	rs2842992	0.692	rs9347342	ENSG00000237927.1	RP3-393E18.2	-4.68	3.23e-06	0.000296	-0.19	-0.14	Age-related macular degeneration (geographic atrophy);	chr6:159772097	chr6:159586955~159589169:-
BRCA	cis	rs5742933	1	rs1550388	ENSG00000253559.1	OSGEPL1-AS1	4.68	3.23e-06	0.000296	0.2	0.14	Ferritin levels;	chr2:189739054	chr2:189762704~189765556:+
BRCA	cis	rs6832769	0.961	rs10026692	ENSG00000223305.1	RN7SKP30	-4.68	3.23e-06	0.000296	-0.18	-0.14	Personality dimensions;	chr4:55586539	chr4:55540502~55540835:-
BRCA	cis	rs8031584	0.872	rs11634761	ENSG00000259845.1	HERC2P10	4.68	3.24e-06	0.000296	0.17	0.14	Huntington's disease progression;	chr15:30950970	chr15:30815271~30844153:+
BRCA	cis	rs10208649	0.611	rs7583626	ENSG00000272156.1	RP11-477N3.1	4.68	3.24e-06	0.000296	0.26	0.14	Body mass index;	chr2:54063635	chr2:54082554~54085066:+
BRCA	cis	rs13113518	1	rs9312661	ENSG00000273257.1	RP11-177J6.1	4.68	3.24e-06	0.000296	0.18	0.14	Height;	chr4:55476159	chr4:55387949~55388271:+
BRCA	cis	rs17684571	0.7	rs71564856	ENSG00000231441.1	RP11-472M19.2	4.68	3.24e-06	0.000296	0.23	0.14	Schizophrenia;	chr6:56803447	chr6:56844002~56864078:+
BRCA	cis	rs6600671	0.902	rs2222371	ENSG00000275538.1	RNVU1-19	-4.68	3.24e-06	0.000296	-0.18	-0.14	Hip geometry;	chr1:121547320	chr1:120850819~120850985:-
BRCA	cis	rs4908768	0.501	rs6577491	ENSG00000232912.4	RP5-1115A15.1	4.68	3.24e-06	0.000296	0.14	0.14	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8514913	chr1:8424645~8434838:+
BRCA	cis	rs9921338	0.961	rs72773832	ENSG00000262703.1	RP11-485G7.6	-4.68	3.24e-06	0.000296	-0.18	-0.14	Vein graft stenosis in coronary artery bypass grafting;	chr16:11319266	chr16:11348143~11349321:-
BRCA	cis	rs9921338	0.961	rs72773834	ENSG00000262703.1	RP11-485G7.6	-4.68	3.24e-06	0.000296	-0.18	-0.14	Vein graft stenosis in coronary artery bypass grafting;	chr16:11319436	chr16:11348143~11349321:-
BRCA	cis	rs10946940	0.965	rs62401383	ENSG00000220721.1	OR1F12	-4.68	3.24e-06	0.000296	-0.16	-0.14	Systemic lupus erythematosus;	chr6:27596768	chr6:28073316~28074233:+
BRCA	cis	rs13108904	0.517	rs13134568	ENSG00000253399.1	AC078852.2	-4.68	3.24e-06	0.000297	-0.17	-0.14	Obesity-related traits;	chr4:1340501	chr4:1358479~1359461:+
BRCA	cis	rs7665090	0.87	rs228616	ENSG00000251288.2	RP11-10L12.2	4.68	3.24e-06	0.000297	0.17	0.14	Primary biliary cholangitis;	chr4:102658534	chr4:102751401~102752641:+
BRCA	cis	rs6840258	0.64	rs3193672	ENSG00000251411.1	RP11-397E7.4	-4.68	3.24e-06	0.000297	-0.19	-0.14	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87161955	chr4:86913266~86914817:-
BRCA	cis	rs2303319	0.504	rs12473088	ENSG00000227403.1	AC009299.3	4.68	3.24e-06	0.000297	0.35	0.14	Cognitive function;	chr2:161628563	chr2:161244739~161249050:+
BRCA	cis	rs6125597	0.967	rs1079661	ENSG00000222365.1	SNORD12B	4.68	3.25e-06	0.000297	0.15	0.14	Intelligence (multi-trait analysis);	chr20:49234077	chr20:49280319~49280409:+
BRCA	cis	rs9925964	0.869	rs2288004	ENSG00000260911.2	RP11-196G11.2	-4.68	3.25e-06	0.000297	-0.14	-0.14	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31042719	chr16:31043150~31049868:+
BRCA	cis	rs6430585	0.583	rs12475516	ENSG00000226806.1	AC011893.3	4.68	3.25e-06	0.000297	0.18	0.14	Corneal structure;	chr2:135803191	chr2:135820191~135823087:+
BRCA	cis	rs6430585	0.583	rs2304370	ENSG00000226806.1	AC011893.3	4.68	3.25e-06	0.000297	0.18	0.14	Corneal structure;	chr2:135804165	chr2:135820191~135823087:+
BRCA	cis	rs6728642	0.908	rs11901495	ENSG00000230606.9	AC159540.1	-4.68	3.25e-06	0.000297	-0.22	-0.14	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:97355895	chr2:97416165~97433527:-
BRCA	cis	rs7267979	0.866	rs6138609	ENSG00000125804.12	FAM182A	-4.68	3.25e-06	0.000297	-0.19	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25590349	chr20:26054655~26086917:+
BRCA	cis	rs8054556	0.73	rs4788190	ENSG00000183604.13	SMG1P5	-4.68	3.25e-06	0.000297	-0.14	-0.14	Autism spectrum disorder or schizophrenia;	chr16:29937080	chr16:30267553~30335374:-
BRCA	cis	rs35740288	0.545	rs12916187	ENSG00000202081.1	RNU6-1280P	4.68	3.25e-06	0.000297	0.21	0.14	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85782893	chr15:85651522~85651628:-
BRCA	cis	rs16958440	1	rs60854219	ENSG00000267724.1	RP11-49K24.8	4.68	3.25e-06	0.000297	0.25	0.14	Sitting height ratio;	chr18:47120293	chr18:47105946~47108062:+
BRCA	cis	rs11976020	1	rs11976020	ENSG00000205578.5	POM121B	-4.68	3.25e-06	0.000297	-0.2	-0.14	Educational attainment (years of education);	chr7:72782785	chr7:73293497~73301161:+
BRCA	cis	rs934734	0.532	rs1437466	ENSG00000281920.1	RP11-418H16.1	-4.68	3.25e-06	0.000297	-0.17	-0.14	Rheumatoid arthritis;	chr2:65437216	chr2:65623272~65628424:+
BRCA	cis	rs2880765	0.566	rs11630381	ENSG00000202081.1	RNU6-1280P	4.68	3.25e-06	0.000297	0.18	0.14	Coronary artery disease;	chr15:85469272	chr15:85651522~85651628:-
BRCA	cis	rs13113518	1	rs11133381	ENSG00000249700.7	SRD5A3-AS1	4.68	3.26e-06	0.000298	0.18	0.14	Height;	chr4:55450812	chr4:55363971~55395847:-
BRCA	cis	rs13113518	1	rs4864995	ENSG00000249700.7	SRD5A3-AS1	4.68	3.26e-06	0.000298	0.18	0.14	Height;	chr4:55452853	chr4:55363971~55395847:-
BRCA	cis	rs4835473	0.932	rs13147170	ENSG00000249741.2	RP11-673E1.3	-4.68	3.26e-06	0.000298	-0.16	-0.14	Immature fraction of reticulocytes;	chr4:143975848	chr4:143911514~143912053:-
BRCA	cis	rs4835473	0.932	rs13147184	ENSG00000249741.2	RP11-673E1.3	-4.68	3.26e-06	0.000298	-0.16	-0.14	Immature fraction of reticulocytes;	chr4:143975873	chr4:143911514~143912053:-
BRCA	cis	rs12744310	1	rs56409354	ENSG00000235358.1	RP11-399E6.1	4.68	3.26e-06	0.000298	0.22	0.14	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41307299	chr1:41242373~41284861:+
BRCA	cis	rs6738627	0.766	rs1128249	ENSG00000223318.1	RNA5SP111	4.68	3.26e-06	0.000298	0.16	0.14	circulating leptin levels adjusted for BMI;Body fat percentage;circulating leptin levels;	chr2:164672114	chr2:164895677~164895777:-
BRCA	cis	rs4763879	0.778	rs2895989	ENSG00000278635.1	CTD-2318O12.1	4.68	3.26e-06	0.000298	0.14	0.14	Type 1 diabetes;	chr12:9688735	chr12:9415641~9416718:+
BRCA	cis	rs8180040	0.966	rs11707895	ENSG00000276925.1	RP11-708J19.3	4.68	3.26e-06	0.000298	0.17	0.14	Colorectal cancer;	chr3:47533447	chr3:47469777~47469987:+
BRCA	cis	rs6088580	0.634	rs4911418	ENSG00000276073.1	RP5-1125A11.7	4.68	3.26e-06	0.000298	0.16	0.14	Glomerular filtration rate (creatinine);	chr20:34406451	chr20:33985617~33988989:-
BRCA	cis	rs6088580	0.634	rs6579165	ENSG00000276073.1	RP5-1125A11.7	4.68	3.26e-06	0.000298	0.16	0.14	Glomerular filtration rate (creatinine);	chr20:34406909	chr20:33985617~33988989:-
BRCA	cis	rs6088580	0.634	rs4911419	ENSG00000276073.1	RP5-1125A11.7	4.68	3.26e-06	0.000298	0.16	0.14	Glomerular filtration rate (creatinine);	chr20:34408067	chr20:33985617~33988989:-
BRCA	cis	rs6088580	0.634	rs4911421	ENSG00000276073.1	RP5-1125A11.7	4.68	3.26e-06	0.000298	0.16	0.14	Glomerular filtration rate (creatinine);	chr20:34411142	chr20:33985617~33988989:-
BRCA	cis	rs6088580	0.634	rs4911422	ENSG00000276073.1	RP5-1125A11.7	4.68	3.26e-06	0.000298	0.16	0.14	Glomerular filtration rate (creatinine);	chr20:34411539	chr20:33985617~33988989:-
BRCA	cis	rs6088580	0.634	rs2225837	ENSG00000276073.1	RP5-1125A11.7	4.68	3.26e-06	0.000298	0.16	0.14	Glomerular filtration rate (creatinine);	chr20:34417828	chr20:33985617~33988989:-
BRCA	cis	rs6840360	0.642	rs2709834	ENSG00000251603.1	RP11-164P12.4	-4.68	3.26e-06	0.000298	-0.13	-0.14	Intelligence (multi-trait analysis);	chr4:151454272	chr4:151667224~151670502:+
BRCA	cis	rs9467773	0.62	rs2504565	ENSG00000241549.7	GUSBP2	4.68	3.26e-06	0.000298	0.15	0.14	Intelligence (multi-trait analysis);	chr6:26656662	chr6:26871484~26956554:-
BRCA	cis	rs6840360	0.642	rs11099819	ENSG00000251611.1	RP11-610P16.1	-4.68	3.26e-06	0.000298	-0.13	-0.14	Intelligence (multi-trait analysis);	chr4:151509026	chr4:151407551~151408835:-
BRCA	cis	rs6840360	0.607	rs6815320	ENSG00000251611.1	RP11-610P16.1	-4.68	3.26e-06	0.000298	-0.13	-0.14	Intelligence (multi-trait analysis);	chr4:151511348	chr4:151407551~151408835:-
BRCA	cis	rs6840360	0.642	rs11726254	ENSG00000251611.1	RP11-610P16.1	-4.68	3.26e-06	0.000298	-0.13	-0.14	Intelligence (multi-trait analysis);	chr4:151517698	chr4:151407551~151408835:-
BRCA	cis	rs11976180	1	rs1533267	ENSG00000244479.5	OR2A1-AS1	4.68	3.26e-06	0.000298	0.19	0.14	Obesity-related traits;	chr7:144069347	chr7:144251264~144356181:-
BRCA	cis	rs6921919	0.583	rs16894108	ENSG00000273712.1	RP5-874C20.7	4.68	3.26e-06	0.000298	0.19	0.14	Autism spectrum disorder or schizophrenia;	chr6:28434013	chr6:28315613~28315883:-
BRCA	cis	rs2574985	0.927	rs920136	ENSG00000231345.3	BEND3P1	-4.68	3.26e-06	0.000298	-0.22	-0.14	Subjective well-being;	chr10:50373834	chr10:50655967~50660472:+
BRCA	cis	rs11098499	0.954	rs878373	ENSG00000260404.2	RP11-384K6.6	4.68	3.27e-06	0.000298	0.14	0.14	Corneal astigmatism;	chr4:119316329	chr4:118591773~118633729:+
BRCA	cis	rs6847067	0.965	rs4529041	ENSG00000180769.7	WDFY3-AS2	4.68	3.27e-06	0.000298	0.13	0.14	Oropharynx cancer;	chr4:84700259	chr4:84965682~85011277:+
BRCA	cis	rs7226408	1	rs72883551	ENSG00000267707.2	RP11-95O2.5	4.68	3.27e-06	0.000298	0.23	0.14	Obesity-related traits;	chr18:36782873	chr18:37243776~37247506:+
BRCA	cis	rs2018683	0.835	rs7782264	ENSG00000228421.2	AC005013.5	-4.68	3.27e-06	0.000299	-0.17	-0.14	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28939369	chr7:28957667~28959345:+
BRCA	cis	rs17228178	0.961	rs10152953	ENSG00000270055.1	CTD-3092A11.2	-4.68	3.27e-06	0.000299	-0.18	-0.14	Facial depth;Facial morphology (factor 1, breadth of lateral portion of upper face);	chr15:31175740	chr15:30487963~30490313:+
BRCA	cis	rs739496	0.579	rs7488629	ENSG00000226469.1	ADAM1B	4.68	3.27e-06	0.000299	0.18	0.14	Platelet count;	chr12:111835696	chr12:111927018~111929017:+
BRCA	cis	rs6490294	0.748	rs73422316	ENSG00000226469.1	ADAM1B	4.68	3.27e-06	0.000299	0.18	0.14	Mean platelet volume;	chr12:111835870	chr12:111927018~111929017:+
BRCA	cis	rs875971	0.545	rs2460427	ENSG00000230295.1	RP11-458F8.2	-4.68	3.27e-06	0.000299	-0.13	-0.14	Aortic root size;	chr7:66154218	chr7:66880708~66882981:+
BRCA	cis	rs7615952	0.688	rs12638240	ENSG00000241288.6	RP11-379B18.5	-4.68	3.27e-06	0.000299	-0.19	-0.14	Blood pressure (smoking interaction);	chr3:125822395	chr3:125827238~125916384:-
BRCA	cis	rs11239930	0.517	rs685741	ENSG00000278811.3	LINC00624	4.68	3.27e-06	0.000299	0.17	0.14	AIDS progression;	chr1:147074503	chr1:147258885~147517875:-
BRCA	cis	rs13236243	0.519	rs4719495	ENSG00000237773.4	AC003075.4	4.68	3.27e-06	0.000299	0.21	0.14	Sensory disturbances after bilateral sagittal split ramus osteotomy;	chr7:17283059	chr7:17279834~17299357:-
BRCA	cis	rs394563	0.591	rs237018	ENSG00000231760.4	RP11-350J20.5	4.68	3.27e-06	0.000299	0.18	0.14	Dupuytren's disease;	chr6:149422794	chr6:149796151~149826294:-
BRCA	cis	rs1161098	0.68	rs1152880	ENSG00000203585.3	RP11-542B15.1	4.68	3.27e-06	0.000299	0.22	0.14	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr12:67441881	chr12:67519829~67567126:+
BRCA	cis	rs17292804	0.527	rs12887734	ENSG00000244691.1	RPL10AP1	-4.68	3.27e-06	0.000299	-0.19	-0.14	Autism spectrum disorder or schizophrenia;	chr14:103580497	chr14:103412119~103412761:-
BRCA	cis	rs9467773	0.62	rs2494716	ENSG00000124549.13	BTN2A3P	4.68	3.27e-06	0.000299	0.14	0.14	Intelligence (multi-trait analysis);	chr6:26662508	chr6:26421391~26432383:+
BRCA	cis	rs6479891	0.63	rs4545434	ENSG00000232075.1	MRPL35P2	4.68	3.27e-06	0.000299	0.24	0.14	Arthritis (juvenile idiopathic);	chr10:63115985	chr10:63634317~63634827:-
BRCA	cis	rs13113518	0.966	rs12647677	ENSG00000249700.7	SRD5A3-AS1	4.68	3.27e-06	0.000299	0.18	0.14	Height;	chr4:55444253	chr4:55363971~55395847:-
BRCA	cis	rs13113518	0.902	rs3805150	ENSG00000249700.7	SRD5A3-AS1	4.68	3.27e-06	0.000299	0.18	0.14	Height;	chr4:55446869	chr4:55363971~55395847:-
BRCA	cis	rs13113518	1	rs4864990	ENSG00000249700.7	SRD5A3-AS1	4.68	3.27e-06	0.000299	0.18	0.14	Height;	chr4:55447523	chr4:55363971~55395847:-
BRCA	cis	rs11098499	0.826	rs4472123	ENSG00000260404.2	RP11-384K6.6	4.68	3.28e-06	0.000299	0.13	0.14	Corneal astigmatism;	chr4:119315475	chr4:118591773~118633729:+
BRCA	cis	rs7618915	0.501	rs2336149	ENSG00000243224.1	RP5-1157M23.2	-4.68	3.28e-06	0.000299	-0.15	-0.14	Bipolar disorder;	chr3:52658108	chr3:52239258~52241097:+
BRCA	cis	rs7618915	0.501	rs7611731	ENSG00000243224.1	RP5-1157M23.2	-4.68	3.28e-06	0.000299	-0.15	-0.14	Bipolar disorder;	chr3:52658705	chr3:52239258~52241097:+
BRCA	cis	rs7618915	0.501	rs6804145	ENSG00000243224.1	RP5-1157M23.2	-4.68	3.28e-06	0.000299	-0.15	-0.14	Bipolar disorder;	chr3:52660182	chr3:52239258~52241097:+
BRCA	cis	rs62560775	0.541	rs12352425	ENSG00000265194.1	RP11-70L8.4	4.68	3.28e-06	3e-04	0.19	0.14	Lung cancer;Lung adenocarcinoma;	chr9:22042087	chr9:21858910~21861926:-
BRCA	cis	rs1707322	0.964	rs785499	ENSG00000234329.1	RP11-767N6.2	-4.68	3.28e-06	3e-04	-0.15	-0.14	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46126748	chr1:45651039~45651826:-
BRCA	cis	rs13113518	1	rs3805149	ENSG00000249700.7	SRD5A3-AS1	4.68	3.28e-06	3e-04	0.18	0.14	Height;	chr4:55442184	chr4:55363971~55395847:-
BRCA	cis	rs13113518	1	rs11945370	ENSG00000249700.7	SRD5A3-AS1	4.68	3.28e-06	3e-04	0.18	0.14	Height;	chr4:55442875	chr4:55363971~55395847:-
BRCA	cis	rs12612619	0.732	rs12613822	ENSG00000229122.1	AGBL5-IT1	4.68	3.28e-06	3e-04	0.15	0.14	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:26994234	chr2:27061038~27061815:+
BRCA	cis	rs6603134	0.502	rs6603133	ENSG00000269139.2	CTD-3193O13.8	4.68	3.28e-06	3e-04	0.16	0.14	Blood protein levels;	chr19:8038352	chr19:7926001~7926810:+
BRCA	cis	rs3892630	0.588	rs2287881	ENSG00000267475.1	CTD-2538C1.2	4.68	3.28e-06	3e-04	0.2	0.14	Red blood cell traits;	chr19:32842249	chr19:32687089~32691750:-
BRCA	cis	rs7923609	0.812	rs10822155	ENSG00000232075.1	MRPL35P2	-4.68	3.29e-06	3e-04	-0.18	-0.14	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63311455	chr10:63634317~63634827:-
BRCA	cis	rs4218	0.689	rs11853828	ENSG00000259732.1	RP11-59H7.3	-4.68	3.29e-06	3e-04	-0.18	-0.14	Social communication problems;	chr15:59136031	chr15:59121034~59133250:+
BRCA	cis	rs875971	0.545	rs10950029	ENSG00000273142.1	RP11-458F8.4	4.68	3.29e-06	3e-04	0.14	0.14	Aortic root size;	chr7:66169334	chr7:66902857~66906297:+
BRCA	cis	rs875971	0.545	rs1796217	ENSG00000232546.1	RP11-458F8.1	-4.68	3.29e-06	3e-04	-0.14	-0.14	Aortic root size;	chr7:66620931	chr7:66848496~66858136:+
BRCA	cis	rs2278702	0.943	rs57384130	ENSG00000259495.2	RP11-210M15.2	-4.68	3.29e-06	3e-04	-0.22	-0.14	Bipolar disorder;	chr15:80392604	chr15:80344853~80403575:-
BRCA	cis	rs703842	1	rs11172344	ENSG00000270039.1	RP11-571M6.17	-4.68	3.29e-06	3e-04	-0.2	-0.14	Multiple sclerosis;	chr12:57799665	chr12:57803838~57804415:+
BRCA	cis	rs703842	1	rs10783848	ENSG00000270039.1	RP11-571M6.17	-4.68	3.29e-06	3e-04	-0.2	-0.14	Multiple sclerosis;	chr12:57802745	chr12:57803838~57804415:+
BRCA	cis	rs11096990	0.613	rs4974995	ENSG00000249685.1	RP11-360F5.3	-4.68	3.29e-06	0.000301	-0.18	-0.14	Cognitive function;	chr4:39216503	chr4:39133913~39135608:+
BRCA	cis	rs6088580	0.634	rs6059829	ENSG00000276073.1	RP5-1125A11.7	-4.68	3.29e-06	0.000301	-0.16	-0.14	Glomerular filtration rate (creatinine);	chr20:34429268	chr20:33985617~33988989:-
BRCA	cis	rs7818688	0.697	rs17665737	ENSG00000253528.2	RP11-347C18.4	-4.68	3.29e-06	0.000301	-0.22	-0.14	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94974078	chr8:94974573~94974853:-
BRCA	cis	rs13160562	0.527	rs25863	ENSG00000272109.1	CTD-2260A17.3	-4.68	3.29e-06	0.000301	-0.18	-0.14	Alcohol dependence;	chr5:96770222	chr5:96804353~96806105:+
BRCA	cis	rs2880765	0.546	rs11639291	ENSG00000259295.5	CSPG4P12	4.68	3.3e-06	0.000301	0.19	0.14	Coronary artery disease;	chr15:85520899	chr15:85191438~85213905:+
BRCA	cis	rs420259	0.727	rs35635	ENSG00000260136.4	CTD-2270L9.4	-4.68	3.3e-06	0.000301	-0.13	-0.14	Bipolar disorder;	chr16:23682449	chr16:23452758~23457606:+
BRCA	cis	rs2115536	1	rs2115536	ENSG00000278600.1	RP11-81A1.6	-4.68	3.3e-06	0.000301	-0.13	-0.14	Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Eosinophil counts;Neutrophil percentage of granulocytes;	chr15:79901905	chr15:79920195~79922455:-
BRCA	cis	rs6840360	0.693	rs28622593	ENSG00000251603.1	RP11-164P12.4	-4.68	3.3e-06	0.000301	-0.13	-0.14	Intelligence (multi-trait analysis);	chr4:151452928	chr4:151667224~151670502:+
BRCA	cis	rs7267979	1	rs2482930	ENSG00000125804.12	FAM182A	4.68	3.3e-06	0.000301	0.19	0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25353479	chr20:26054655~26086917:+
BRCA	cis	rs17374749	0.528	rs1440698	ENSG00000273486.1	RP11-731C17.2	-4.68	3.3e-06	0.000301	-0.18	-0.14	Anxiety in major depressive disorder;	chr3:137145996	chr3:136837338~136839021:-
BRCA	cis	rs6832769	1	rs28514423	ENSG00000223305.1	RN7SKP30	-4.68	3.3e-06	0.000301	-0.18	-0.14	Personality dimensions;	chr4:55563072	chr4:55540502~55540835:-
BRCA	cis	rs2692947	0.77	rs2315417	ENSG00000168992.4	OR7E102P	4.68	3.3e-06	0.000301	0.19	0.14	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95834541	chr2:95546531~95547545:+
BRCA	cis	rs1075265	0.749	rs805379	ENSG00000235937.1	AC008280.1	4.68	3.3e-06	0.000301	0.16	0.14	Chronotype;Morning vs. evening chronotype;	chr2:53865847	chr2:54029552~54030682:-
BRCA	cis	rs10266483	0.545	rs114664455	ENSG00000228653.2	HNRNPCP7	4.68	3.3e-06	0.000301	0.2	0.14	Response to statin therapy;	chr7:64263634	chr7:64500825~64501729:+
BRCA	cis	rs6088590	0.523	rs6058084	ENSG00000276073.1	RP5-1125A11.7	-4.68	3.3e-06	0.000301	-0.16	-0.14	Coronary artery disease;	chr20:34596000	chr20:33985617~33988989:-
BRCA	cis	rs4664293	0.867	rs34392518	ENSG00000226266.5	AC009961.3	-4.68	3.3e-06	0.000301	-0.18	-0.14	Monocyte percentage of white cells;	chr2:159749367	chr2:159670708~159712435:-
BRCA	cis	rs4664293	0.805	rs6432559	ENSG00000226266.5	AC009961.3	-4.68	3.3e-06	0.000301	-0.18	-0.14	Monocyte percentage of white cells;	chr2:159750649	chr2:159670708~159712435:-
BRCA	cis	rs4664293	0.867	rs6432560	ENSG00000226266.5	AC009961.3	-4.68	3.3e-06	0.000301	-0.18	-0.14	Monocyte percentage of white cells;	chr2:159750758	chr2:159670708~159712435:-
BRCA	cis	rs4664293	0.867	rs3863924	ENSG00000226266.5	AC009961.3	-4.68	3.3e-06	0.000301	-0.18	-0.14	Monocyte percentage of white cells;	chr2:159758247	chr2:159670708~159712435:-
BRCA	cis	rs4664293	0.867	rs11681565	ENSG00000226266.5	AC009961.3	-4.68	3.3e-06	0.000301	-0.18	-0.14	Monocyte percentage of white cells;	chr2:159760362	chr2:159670708~159712435:-
BRCA	cis	rs4664293	0.836	rs11687502	ENSG00000226266.5	AC009961.3	-4.68	3.3e-06	0.000301	-0.18	-0.14	Monocyte percentage of white cells;	chr2:159760464	chr2:159670708~159712435:-
BRCA	cis	rs4664293	0.836	rs13401087	ENSG00000226266.5	AC009961.3	-4.68	3.3e-06	0.000301	-0.18	-0.14	Monocyte percentage of white cells;	chr2:159760957	chr2:159670708~159712435:-
BRCA	cis	rs4664293	0.867	rs12692564	ENSG00000226266.5	AC009961.3	-4.68	3.3e-06	0.000301	-0.18	-0.14	Monocyte percentage of white cells;	chr2:159761326	chr2:159670708~159712435:-
BRCA	cis	rs4664293	0.867	rs1427328	ENSG00000226266.5	AC009961.3	-4.68	3.3e-06	0.000301	-0.18	-0.14	Monocyte percentage of white cells;	chr2:159762064	chr2:159670708~159712435:-
BRCA	cis	rs4664293	0.613	rs9784044	ENSG00000226266.5	AC009961.3	-4.68	3.3e-06	0.000301	-0.18	-0.14	Monocyte percentage of white cells;	chr2:159765854	chr2:159670708~159712435:-
BRCA	cis	rs4664293	0.867	rs4664301	ENSG00000226266.5	AC009961.3	-4.68	3.3e-06	0.000301	-0.18	-0.14	Monocyte percentage of white cells;	chr2:159766855	chr2:159670708~159712435:-
BRCA	cis	rs6832769	0.922	rs501679	ENSG00000223305.1	RN7SKP30	4.68	3.3e-06	0.000302	0.18	0.14	Personality dimensions;	chr4:55371160	chr4:55540502~55540835:-
BRCA	cis	rs10208649	1	rs6731217	ENSG00000233266.1	HMGB1P31	-4.68	3.3e-06	0.000302	-0.3	-0.14	Body mass index;	chr2:53903956	chr2:54051334~54051760:+
BRCA	cis	rs2243480	1	rs2465120	ENSG00000222364.1	RNU6-96P	-4.68	3.3e-06	0.000302	-0.26	-0.14	Diabetic kidney disease;	chr7:66155987	chr7:66395191~66395286:+
BRCA	cis	rs2243480	0.908	rs2460431	ENSG00000222364.1	RNU6-96P	4.68	3.3e-06	0.000302	0.26	0.14	Diabetic kidney disease;	chr7:66157859	chr7:66395191~66395286:+
BRCA	cis	rs2243480	1	rs4718309	ENSG00000222364.1	RNU6-96P	4.68	3.3e-06	0.000302	0.26	0.14	Diabetic kidney disease;	chr7:66162777	chr7:66395191~66395286:+
BRCA	cis	rs2243480	1	rs6460274	ENSG00000222364.1	RNU6-96P	4.68	3.3e-06	0.000302	0.26	0.14	Diabetic kidney disease;	chr7:66163497	chr7:66395191~66395286:+
BRCA	cis	rs2243480	1	rs7787230	ENSG00000222364.1	RNU6-96P	4.68	3.3e-06	0.000302	0.26	0.14	Diabetic kidney disease;	chr7:66164112	chr7:66395191~66395286:+
BRCA	cis	rs878939	0.625	rs7476059	ENSG00000233690.1	EBAG9P1	4.68	3.3e-06	0.000302	0.21	0.14	Warfarin maintenance dose;	chr10:99587281	chr10:99697407~99697949:-
BRCA	cis	rs12435908	1	rs17826790	ENSG00000276116.2	FUT8-AS1	-4.68	3.3e-06	0.000302	-0.22	-0.14	Ischemic stroke;	chr14:65636709	chr14:65411170~65412690:-
BRCA	cis	rs7772486	0.79	rs2265472	ENSG00000270638.1	RP3-466P17.1	4.68	3.31e-06	0.000302	0.17	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145899622	chr6:145735570~145737218:+
BRCA	cis	rs7772486	0.79	rs2265919	ENSG00000270638.1	RP3-466P17.1	4.68	3.31e-06	0.000302	0.17	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145900617	chr6:145735570~145737218:+
BRCA	cis	rs7772486	0.738	rs2246334	ENSG00000270638.1	RP3-466P17.1	4.68	3.31e-06	0.000302	0.17	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145862499	chr6:145735570~145737218:+
BRCA	cis	rs11148252	0.514	rs9526843	ENSG00000278238.1	RP11-245D16.4	-4.68	3.31e-06	0.000302	-0.16	-0.14	Lewy body disease;	chr13:52155921	chr13:52454775~52455331:-
BRCA	cis	rs7267979	0.903	rs6107015	ENSG00000125804.12	FAM182A	-4.68	3.31e-06	0.000302	-0.19	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25236128	chr20:26054655~26086917:+
BRCA	cis	rs3733585	0.605	rs56178126	ENSG00000250413.1	RP11-448G15.1	4.68	3.31e-06	0.000302	0.2	0.14	Cleft plate (environmental tobacco smoke interaction);	chr4:10121957	chr4:10006482~10009725:+
BRCA	cis	rs7772486	0.738	rs75288066	ENSG00000270638.1	RP3-466P17.1	4.68	3.31e-06	0.000302	0.17	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145998250	chr6:145735570~145737218:+
BRCA	cis	rs7772486	0.713	rs79248977	ENSG00000270638.1	RP3-466P17.1	4.68	3.31e-06	0.000302	0.17	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145998252	chr6:145735570~145737218:+
BRCA	cis	rs2186369	1	rs9624326	ENSG00000272733.1	KB-208E9.1	-4.68	3.31e-06	0.000302	-0.21	-0.14	IgG N-glycosylation phenotypes (multivariate analysis);IgG digalactosylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG glycosylation;IgG fucosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);	chr22:23792856	chr22:23580880~23583859:-
BRCA	cis	rs2692947	0.55	rs12623771	ENSG00000168992.4	OR7E102P	4.68	3.31e-06	0.000302	0.19	0.14	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95967756	chr2:95546531~95547545:+
BRCA	cis	rs2303319	0.504	rs2389549	ENSG00000227403.1	AC009299.3	-4.68	3.31e-06	0.000302	-0.33	-0.14	Cognitive function;	chr2:161605699	chr2:161244739~161249050:+
BRCA	cis	rs6452524	0.904	rs10076056	ENSG00000281327.1	LINC01338	-4.68	3.31e-06	0.000302	-0.17	-0.14	Hypertension (SNP x SNP interaction);	chr5:83161702	chr5:82850864~82859836:-
BRCA	cis	rs651907	0.557	rs3806654	ENSG00000256628.3	ZBTB11-AS1	4.68	3.31e-06	0.000302	0.18	0.14	Colorectal cancer;	chr3:101677685	chr3:101676475~101679217:+
BRCA	cis	rs6723226	0.503	rs4952262	ENSG00000276517.1	AL133243.2	4.68	3.31e-06	0.000302	0.17	0.14	Intelligence (multi-trait analysis);	chr2:32372166	chr2:32526504~32529507:+
BRCA	cis	rs9543976	0.623	rs9543990	ENSG00000261105.4	LMO7-AS1	4.68	3.31e-06	0.000302	0.22	0.14	Diabetic retinopathy;	chr13:75598298	chr13:75604700~75635994:-
BRCA	cis	rs2735413	0.564	rs4324138	ENSG00000276007.1	RP11-358L22.3	4.68	3.32e-06	0.000303	0.23	0.14	Systolic blood pressure (alcohol consumption interaction);	chr16:78067475	chr16:78123243~78124332:+
BRCA	cis	rs1005277	0.579	rs2505198	ENSG00000263064.2	RP11-291L22.7	4.68	3.32e-06	0.000303	0.17	0.14	Extrinsic epigenetic age acceleration;	chr10:38104255	chr10:38448689~38448949:+
BRCA	cis	rs9818758	0.607	rs13077498	ENSG00000225399.4	RP11-3B7.1	-4.68	3.32e-06	0.000303	-0.24	-0.14	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49276545	chr3:49260085~49261316:+
BRCA	cis	rs733175	0.855	rs10023068	ENSG00000250413.1	RP11-448G15.1	4.68	3.32e-06	0.000303	0.21	0.14	Psychosis and Alzheimer's disease;	chr4:10003208	chr4:10006482~10009725:+
BRCA	cis	rs4925386	0.84	rs8124907	ENSG00000273619.1	RP5-908M14.9	-4.68	3.32e-06	0.000303	-0.13	-0.14	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62338071	chr20:62386303~62386970:-
BRCA	cis	rs2692947	0.726	rs13009727	ENSG00000168992.4	OR7E102P	-4.68	3.32e-06	0.000303	-0.19	-0.14	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96104135	chr2:95546531~95547545:+
BRCA	cis	rs4865762	0.902	rs3910971	ENSG00000247796.2	CTD-2366F13.1	-4.68	3.32e-06	0.000303	-0.15	-0.14	Intraocular pressure;	chr5:53295506	chr5:53109842~53115126:+
BRCA	cis	rs6088580	0.602	rs6059834	ENSG00000276073.1	RP5-1125A11.7	-4.68	3.32e-06	0.000303	-0.16	-0.14	Glomerular filtration rate (creatinine);	chr20:34431493	chr20:33985617~33988989:-
BRCA	cis	rs6088580	0.634	rs6059835	ENSG00000276073.1	RP5-1125A11.7	-4.68	3.32e-06	0.000303	-0.16	-0.14	Glomerular filtration rate (creatinine);	chr20:34432335	chr20:33985617~33988989:-
BRCA	cis	rs6840360	0.642	rs2709842	ENSG00000251603.1	RP11-164P12.4	4.68	3.32e-06	0.000303	0.13	0.14	Intelligence (multi-trait analysis);	chr4:151449485	chr4:151667224~151670502:+
BRCA	cis	rs8054556	1	rs11150577	ENSG00000273724.1	RP11-347C12.12	-4.68	3.32e-06	0.000303	-0.16	-0.14	Autism spectrum disorder or schizophrenia;	chr16:29975204	chr16:30336400~30343336:+
BRCA	cis	rs3808502	0.527	rs4410870	ENSG00000154316.13	TDH	4.68	3.32e-06	0.000303	0.19	0.14	Neuroticism;	chr8:11298611	chr8:11339637~11368452:+
BRCA	cis	rs4356203	0.905	rs7396382	ENSG00000272034.1	SNORD14A	4.68	3.32e-06	0.000303	0.15	0.14	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17129925	chr11:17074654~17074744:-
BRCA	cis	rs7267979	1	rs2500424	ENSG00000125804.12	FAM182A	4.68	3.32e-06	0.000303	0.19	0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25411333	chr20:26054655~26086917:+
BRCA	cis	rs1499614	0.901	rs3936	ENSG00000222364.1	RNU6-96P	-4.68	3.32e-06	0.000303	-0.27	-0.14	Gout;	chr7:66661502	chr7:66395191~66395286:+
BRCA	cis	rs7048146	0.966	rs4978825	ENSG00000213539.4	YBX1P6	-4.67	3.33e-06	0.000303	-0.16	-0.14	Vascular brain injury;	chr9:109540184	chr9:109532830~109534332:-
BRCA	cis	rs6840360	0.642	rs2709842	ENSG00000251611.1	RP11-610P16.1	4.67	3.33e-06	0.000303	0.12	0.14	Intelligence (multi-trait analysis);	chr4:151449485	chr4:151407551~151408835:-
BRCA	cis	rs853679	0.882	rs9461432	ENSG00000280107.1	AL022393.9	-4.67	3.33e-06	0.000303	-0.3	-0.14	Depression;	chr6:28119105	chr6:28170845~28172521:+
BRCA	cis	rs210138	0.706	rs444697	ENSG00000197251.3	LINC00336	4.67	3.33e-06	0.000304	0.19	0.14	Testicular germ cell tumor;	chr6:33607232	chr6:33586106~33593338:-
BRCA	cis	rs6088580	0.609	rs945674	ENSG00000276073.1	RP5-1125A11.7	4.67	3.33e-06	0.000304	0.16	0.14	Glomerular filtration rate (creatinine);	chr20:34376441	chr20:33985617~33988989:-
BRCA	cis	rs66887589	0.72	rs11724758	ENSG00000249244.1	RP11-548H18.2	4.67	3.33e-06	0.000304	0.15	0.14	Diastolic blood pressure;	chr4:119318723	chr4:119391831~119395335:-
BRCA	cis	rs12612619	0.732	rs11680032	ENSG00000229122.1	AGBL5-IT1	4.67	3.33e-06	0.000304	0.15	0.14	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:26975280	chr2:27061038~27061815:+
BRCA	cis	rs11955398	0.584	rs62372964	ENSG00000215032.2	GNL3LP1	4.67	3.33e-06	0.000304	0.17	0.14	Intelligence (multi-trait analysis);	chr5:60589971	chr5:60891935~60893577:-
BRCA	cis	rs2243480	1	rs160655	ENSG00000222364.1	RNU6-96P	-4.67	3.33e-06	0.000304	-0.27	-0.14	Diabetic kidney disease;	chr7:66068227	chr7:66395191~66395286:+
BRCA	cis	rs5762752	0.539	rs1807477	ENSG00000279978.1	chr22-38_28785274-29006793.1	-4.67	3.33e-06	0.000304	-0.19	-0.14	Optic disc area;	chr22:28693107	chr22:28930201~29197572:+
BRCA	cis	rs987724	0.515	rs6787457	ENSG00000240875.4	LINC00886	-4.67	3.33e-06	0.000304	-0.23	-0.14	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156891157	chr3:156747346~156817062:-
BRCA	cis	rs2380205	0.651	rs7072283	ENSG00000232807.2	RP11-536K7.3	4.67	3.34e-06	0.000304	0.14	0.14	Breast cancer;	chr10:5876684	chr10:5934270~5945900:-
BRCA	cis	rs1941184	0.526	rs10084010	ENSG00000266521.1	RP11-650P15.1	-4.67	3.34e-06	0.000304	-0.22	-0.14	Parkinson's disease (age of onset);	chr18:31447782	chr18:31496645~31497195:-
BRCA	cis	rs2243480	0.711	rs2460426	ENSG00000222364.1	RNU6-96P	4.67	3.34e-06	0.000304	0.26	0.14	Diabetic kidney disease;	chr7:66158142	chr7:66395191~66395286:+
BRCA	cis	rs17711722	0.503	rs453835	ENSG00000275400.1	RP4-756H11.5	4.67	3.34e-06	0.000304	0.17	0.14	Calcium levels;	chr7:66046172	chr7:66553805~66554199:-
BRCA	cis	rs771767	0.808	rs2398688	ENSG00000244119.1	PDCL3P4	4.67	3.34e-06	0.000304	0.12	0.14	Multiple sclerosis;	chr3:102025410	chr3:101712472~101713191:+
BRCA	cis	rs771767	0.808	rs1828668	ENSG00000244119.1	PDCL3P4	4.67	3.34e-06	0.000304	0.12	0.14	Multiple sclerosis;	chr3:102027886	chr3:101712472~101713191:+
BRCA	cis	rs771767	0.808	rs4683959	ENSG00000244119.1	PDCL3P4	4.67	3.34e-06	0.000304	0.12	0.14	Multiple sclerosis;	chr3:102030058	chr3:101712472~101713191:+
BRCA	cis	rs771767	0.808	rs4325907	ENSG00000244119.1	PDCL3P4	4.67	3.34e-06	0.000304	0.12	0.14	Multiple sclerosis;	chr3:102030178	chr3:101712472~101713191:+
BRCA	cis	rs11239930	0.538	rs3011810	ENSG00000230832.3	RP11-325P15.2	-4.67	3.34e-06	0.000304	-0.21	-0.14	AIDS progression;	chr1:147082079	chr1:147082338~147083578:-
BRCA	cis	rs1387259	0.619	rs7134565	ENSG00000240399.1	RP1-228P16.1	-4.67	3.34e-06	0.000305	-0.15	-0.14	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48236241	chr12:48054813~48055591:-
BRCA	cis	rs2255336	0.938	rs2126888	ENSG00000245648.1	RP11-277P12.20	4.67	3.34e-06	0.000305	0.22	0.14	Blood protein levels;	chr12:10393789	chr12:10363769~10398506:+
BRCA	cis	rs6452524	0.967	rs2974444	ENSG00000281327.1	LINC01338	4.67	3.34e-06	0.000305	0.17	0.14	Hypertension (SNP x SNP interaction);	chr5:83185174	chr5:82850864~82859836:-
BRCA	cis	rs3892630	0.62	rs10413279	ENSG00000267475.1	CTD-2538C1.2	-4.67	3.34e-06	0.000305	-0.2	-0.14	Red blood cell traits;	chr19:32691840	chr19:32687089~32691750:-
BRCA	cis	rs9818758	0.607	rs10049462	ENSG00000225399.4	RP11-3B7.1	-4.67	3.34e-06	0.000305	-0.24	-0.14	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49272251	chr3:49260085~49261316:+
BRCA	cis	rs2303319	0.504	rs62189012	ENSG00000227403.1	AC009299.3	4.67	3.34e-06	0.000305	0.35	0.14	Cognitive function;	chr2:161726631	chr2:161244739~161249050:+
BRCA	cis	rs4713118	0.955	rs34752872	ENSG00000216901.1	AL022393.7	4.67	3.34e-06	0.000305	0.2	0.14	Parkinson's disease;	chr6:27715465	chr6:28176188~28176674:+
BRCA	cis	rs6832769	1	rs28514423	ENSG00000272969.1	RP11-528I4.2	-4.67	3.35e-06	0.000305	-0.17	-0.14	Personality dimensions;	chr4:55563072	chr4:55547112~55547889:+
BRCA	cis	rs2574985	0.702	rs2983350	ENSG00000231345.3	BEND3P1	-4.67	3.35e-06	0.000305	-0.22	-0.14	Subjective well-being;	chr10:50528088	chr10:50655967~50660472:+
BRCA	cis	rs10129255	0.957	rs6576233	ENSG00000211974.3	IGHV2-70	4.67	3.35e-06	0.000305	0.14	0.14	Kawasaki disease;	chr14:106787239	chr14:106723574~106724093:-
BRCA	cis	rs13325613	0.915	rs6793370	ENSG00000223552.1	RP11-24F11.2	-4.67	3.35e-06	0.000305	-0.26	-0.14	Monocyte count;	chr3:46271356	chr3:46364955~46407059:-
BRCA	cis	rs13325613	0.915	rs9810242	ENSG00000223552.1	RP11-24F11.2	-4.67	3.35e-06	0.000305	-0.26	-0.14	Monocyte count;	chr3:46271843	chr3:46364955~46407059:-
BRCA	cis	rs875971	0.862	rs6460302	ENSG00000273448.1	RP11-166O4.6	4.67	3.35e-06	0.000305	0.13	0.14	Aortic root size;	chr7:66495270	chr7:67333047~67334383:+
BRCA	cis	rs72482608	0.835	rs12044001	ENSG00000271811.1	RP1-79C4.4	4.67	3.35e-06	0.000305	0.16	0.14	Emphysema imaging phenotypes;	chr1:170778324	chr1:170667381~170669425:+
BRCA	cis	rs6598266	1	rs6598272	ENSG00000182397.13	DNM1P46	-4.67	3.35e-06	0.000305	-0.2	-0.14	Major depressive disorder;	chr15:99759468	chr15:99790156~99806927:-
BRCA	cis	rs10504130	1	rs12675907	ENSG00000272024.1	RP11-546K22.3	-4.67	3.35e-06	0.000305	-0.25	-0.14	Venous thromboembolism (SNP x SNP interaction);	chr8:51773102	chr8:51950284~51950690:+
BRCA	cis	rs9467773	0.549	rs9461273	ENSG00000124549.13	BTN2A3P	-4.67	3.35e-06	0.000305	-0.14	-0.14	Intelligence (multi-trait analysis);	chr6:26584298	chr6:26421391~26432383:+
BRCA	cis	rs4664293	0.667	rs6432562	ENSG00000226266.5	AC009961.3	-4.67	3.35e-06	0.000305	-0.17	-0.14	Monocyte percentage of white cells;	chr2:159791495	chr2:159670708~159712435:-
BRCA	cis	rs35740288	0.822	rs10520599	ENSG00000202081.1	RNU6-1280P	4.67	3.35e-06	0.000305	0.19	0.14	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85679866	chr15:85651522~85651628:-
BRCA	cis	rs11124272	0.857	rs7587666	ENSG00000272716.1	RP11-563N4.1	-4.67	3.35e-06	0.000305	-0.17	-0.14	Interleukin-18 levels;	chr2:31830821	chr2:32165046~32165757:-
BRCA	cis	rs10992797	0.527	rs10821172	ENSG00000227603.1	RP11-165J3.6	-4.67	3.35e-06	0.000305	-0.16	-0.14	Intelligence (multi-trait analysis);	chr9:93599969	chr9:93435332~93437121:-
BRCA	cis	rs721917	0.506	rs1923538	ENSG00000278616.1	BEND3P3	-4.67	3.35e-06	0.000305	-0.13	-0.14	Chronic obstructive pulmonary disease;	chr10:79935276	chr10:79682997~79685436:+
BRCA	cis	rs853679	0.546	rs13214023	ENSG00000204709.4	LINC01556	-4.67	3.35e-06	0.000305	-0.34	-0.14	Depression;	chr6:28364364	chr6:28943877~28944537:+
BRCA	cis	rs5758511	0.68	rs5758688	ENSG00000227370.1	RP4-669P10.19	4.67	3.35e-06	0.000306	0.19	0.14	Birth weight;	chr22:42266495	chr22:42132543~42132998:+
BRCA	cis	rs2073316	0.554	rs1884723	ENSG00000272716.1	RP11-563N4.1	4.67	3.35e-06	0.000306	0.15	0.14	Interleukin-18 levels;	chr2:31477017	chr2:32165046~32165757:-
BRCA	cis	rs739401	0.611	rs572373	ENSG00000183562.3	CTC-343N3.1	-4.67	3.35e-06	0.000306	-0.15	-0.14	Longevity;	chr11:3034131	chr11:2989863~2991344:+
BRCA	cis	rs6840360	0.642	rs7677131	ENSG00000251603.1	RP11-164P12.4	-4.67	3.35e-06	0.000306	-0.13	-0.14	Intelligence (multi-trait analysis);	chr4:151431863	chr4:151667224~151670502:+
BRCA	cis	rs6452524	0.967	rs2974443	ENSG00000281327.1	LINC01338	4.67	3.35e-06	0.000306	0.17	0.14	Hypertension (SNP x SNP interaction);	chr5:83184595	chr5:82850864~82859836:-
BRCA	cis	rs10946940	0.965	rs9393830	ENSG00000219392.1	RP1-265C24.5	-4.67	3.35e-06	0.000306	-0.18	-0.14	Systemic lupus erythematosus;	chr6:27619248	chr6:28115628~28116551:+
BRCA	cis	rs6088580	0.634	rs2424992	ENSG00000276073.1	RP5-1125A11.7	-4.67	3.35e-06	0.000306	-0.16	-0.14	Glomerular filtration rate (creatinine);	chr20:34424254	chr20:33985617~33988989:-
BRCA	cis	rs6088580	0.634	rs6119497	ENSG00000276073.1	RP5-1125A11.7	-4.67	3.35e-06	0.000306	-0.16	-0.14	Glomerular filtration rate (creatinine);	chr20:34424723	chr20:33985617~33988989:-
BRCA	cis	rs4578769	0.918	rs4800138	ENSG00000265939.1	UBE2CP2	-4.67	3.35e-06	0.000306	-0.17	-0.14	Eosinophil percentage of white cells;	chr18:22934334	chr18:22900486~22900995:-
BRCA	cis	rs11662586	0.517	rs11663082	ENSG00000261126.6	RP11-795F19.1	4.67	3.35e-06	0.000306	0.14	0.14	Exploratory eye movement dysfunction in schizophrenia (responsive search score);	chr18:79953494	chr18:80046900~80095482:+
BRCA	cis	rs11662586	0.517	rs11662894	ENSG00000261126.6	RP11-795F19.1	4.67	3.35e-06	0.000306	0.14	0.14	Exploratory eye movement dysfunction in schizophrenia (responsive search score);	chr18:79953591	chr18:80046900~80095482:+
BRCA	cis	rs9952991	0.941	rs34920518	ENSG00000260302.1	RP11-973H7.1	4.67	3.35e-06	0.000306	0.24	0.14	Inflammatory skin disease;	chr18:12783087	chr18:12774651~12775923:-
BRCA	cis	rs721917	0.506	rs2758547	ENSG00000278616.1	BEND3P3	-4.67	3.36e-06	0.000306	-0.13	-0.14	Chronic obstructive pulmonary disease;	chr10:79937368	chr10:79682997~79685436:+
BRCA	cis	rs7267979	0.816	rs6076358	ENSG00000125804.12	FAM182A	4.67	3.36e-06	0.000306	0.18	0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25538767	chr20:26054655~26086917:+
BRCA	cis	rs78487399	0.614	rs77061610	ENSG00000234936.1	AC010883.5	4.67	3.36e-06	0.000306	0.24	0.14	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43432831	chr2:43229573~43233394:+
BRCA	cis	rs6449502	0.541	rs10054247	ENSG00000251279.1	CTC-436P18.1	4.67	3.36e-06	0.000306	0.29	0.14	Mean platelet volume;	chr5:61131357	chr5:61162070~61232040:+
BRCA	cis	rs11098499	0.954	rs10008459	ENSG00000250412.1	KLHL2P1	4.67	3.36e-06	0.000306	0.17	0.14	Corneal astigmatism;	chr4:119473076	chr4:119334329~119378233:+
BRCA	cis	rs2243480	1	rs57057549	ENSG00000226002.1	RP11-460N20.5	-4.67	3.36e-06	0.000306	-0.24	-0.14	Diabetic kidney disease;	chr7:65940751	chr7:65084103~65100232:+
BRCA	cis	rs78487399	0.908	rs17031095	ENSG00000234936.1	AC010883.5	4.67	3.36e-06	0.000306	0.2	0.14	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43592000	chr2:43229573~43233394:+
BRCA	cis	rs16958440	1	rs62096466	ENSG00000267724.1	RP11-49K24.8	4.67	3.36e-06	0.000306	0.25	0.14	Sitting height ratio;	chr18:47109800	chr18:47105946~47108062:+
BRCA	cis	rs16958440	1	rs76594057	ENSG00000267724.1	RP11-49K24.8	4.67	3.36e-06	0.000306	0.25	0.14	Sitting height ratio;	chr18:47110901	chr18:47105946~47108062:+
BRCA	cis	rs16958440	1	rs62096469	ENSG00000267724.1	RP11-49K24.8	4.67	3.36e-06	0.000306	0.25	0.14	Sitting height ratio;	chr18:47111927	chr18:47105946~47108062:+
BRCA	cis	rs16958440	1	rs60228288	ENSG00000267724.1	RP11-49K24.8	4.67	3.36e-06	0.000306	0.25	0.14	Sitting height ratio;	chr18:47114041	chr18:47105946~47108062:+
BRCA	cis	rs16958440	1	rs62096470	ENSG00000267724.1	RP11-49K24.8	4.67	3.36e-06	0.000306	0.25	0.14	Sitting height ratio;	chr18:47115095	chr18:47105946~47108062:+
BRCA	cis	rs16958440	1	rs62096471	ENSG00000267724.1	RP11-49K24.8	4.67	3.36e-06	0.000306	0.25	0.14	Sitting height ratio;	chr18:47117443	chr18:47105946~47108062:+
BRCA	cis	rs16958440	1	rs4609941	ENSG00000267724.1	RP11-49K24.8	4.67	3.36e-06	0.000306	0.25	0.14	Sitting height ratio;	chr18:47119120	chr18:47105946~47108062:+
BRCA	cis	rs16958440	1	rs57928699	ENSG00000267724.1	RP11-49K24.8	4.67	3.36e-06	0.000306	0.25	0.14	Sitting height ratio;	chr18:47119222	chr18:47105946~47108062:+
BRCA	cis	rs11758351	0.66	rs11759904	ENSG00000241549.7	GUSBP2	-4.67	3.36e-06	0.000306	-0.21	-0.14	Renal underexcretion gout;Gout;	chr6:26231215	chr6:26871484~26956554:-
BRCA	cis	rs11758351	0.66	rs77337633	ENSG00000241549.7	GUSBP2	-4.67	3.36e-06	0.000306	-0.21	-0.14	Renal underexcretion gout;Gout;	chr6:26233382	chr6:26871484~26956554:-
BRCA	cis	rs11758351	0.587	rs16891456	ENSG00000241549.7	GUSBP2	-4.67	3.36e-06	0.000306	-0.21	-0.14	Renal underexcretion gout;Gout;	chr6:26233899	chr6:26871484~26956554:-
BRCA	cis	rs7572733	0.534	rs700685	ENSG00000231621.1	AC013264.2	-4.67	3.36e-06	0.000306	-0.14	-0.14	Dermatomyositis;	chr2:197851248	chr2:197197991~197199273:+
BRCA	cis	rs771767	0.808	rs12638112	ENSG00000244119.1	PDCL3P4	4.67	3.36e-06	0.000306	0.12	0.14	Multiple sclerosis;	chr3:102027242	chr3:101712472~101713191:+
BRCA	cis	rs6570726	0.738	rs7746330	ENSG00000270638.1	RP3-466P17.1	4.67	3.36e-06	0.000306	0.17	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145578121	chr6:145735570~145737218:+
BRCA	cis	rs6570726	0.791	rs12208812	ENSG00000270638.1	RP3-466P17.1	4.67	3.36e-06	0.000306	0.17	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145579788	chr6:145735570~145737218:+
BRCA	cis	rs6490294	0.904	rs11066098	ENSG00000226469.1	ADAM1B	4.67	3.36e-06	0.000306	0.18	0.14	Mean platelet volume;	chr12:111950324	chr12:111927018~111929017:+
BRCA	cis	rs801193	0.613	rs2016325	ENSG00000237310.1	GS1-124K5.4	-4.67	3.36e-06	0.000306	-0.15	-0.14	Aortic root size;	chr7:66858513	chr7:66493706~66495474:+
BRCA	cis	rs7615952	0.546	rs2979306	ENSG00000171084.14	FAM86JP	4.67	3.36e-06	0.000306	0.23	0.14	Blood pressure (smoking interaction);	chr3:125593286	chr3:125916620~125930024:+
BRCA	cis	rs13326165	0.543	rs60382084	ENSG00000243224.1	RP5-1157M23.2	-4.67	3.36e-06	0.000306	-0.23	-0.14	HDL cholesterol levels;HDL cholesterol;	chr3:52264145	chr3:52239258~52241097:+
BRCA	cis	rs4831837	0.717	rs10094149	ENSG00000270074.1	RP11-351I21.11	4.67	3.36e-06	0.000306	0.18	0.14	Morbidity-free survival;	chr8:12832601	chr8:12412827~12414373:+
BRCA	cis	rs755249	0.565	rs722357	ENSG00000182109.6	RP11-69E11.4	-4.67	3.36e-06	0.000307	-0.17	-0.14	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39479096	chr1:39522280~39546187:-
BRCA	cis	rs6570726	0.935	rs12663204	ENSG00000270638.1	RP3-466P17.1	4.67	3.36e-06	0.000307	0.16	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145497237	chr6:145735570~145737218:+
BRCA	cis	rs6570726	0.935	rs12663205	ENSG00000270638.1	RP3-466P17.1	4.67	3.36e-06	0.000307	0.16	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145497242	chr6:145735570~145737218:+
BRCA	cis	rs1193	0.616	rs4832306	ENSG00000231259.4	AC125232.1	-4.67	3.37e-06	0.000307	-0.17	-0.14	High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;High light scatter reticulocyte count;	chr2:86662837	chr2:87031815~87053069:-
BRCA	cis	rs2880765	0.835	rs7174323	ENSG00000202081.1	RNU6-1280P	4.67	3.37e-06	0.000307	0.16	0.14	Coronary artery disease;	chr15:85506488	chr15:85651522~85651628:-
BRCA	cis	rs35740288	0.822	rs17637142	ENSG00000202081.1	RNU6-1280P	4.67	3.37e-06	0.000307	0.2	0.14	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85697272	chr15:85651522~85651628:-
BRCA	cis	rs300890	0.56	rs6857078	ENSG00000250326.1	RP11-284M14.1	-4.67	3.37e-06	0.000307	-0.16	-0.14	Nasopharyngeal carcinoma;	chr4:143266435	chr4:142933195~143184861:-
BRCA	cis	rs300890	0.56	rs4461474	ENSG00000250326.1	RP11-284M14.1	-4.67	3.37e-06	0.000307	-0.16	-0.14	Nasopharyngeal carcinoma;	chr4:143266726	chr4:142933195~143184861:-
BRCA	cis	rs5751614	0.537	rs9608093	ENSG00000240160.3	RN7SL263P	4.67	3.37e-06	0.000307	0.19	0.14	Height;	chr22:23271352	chr22:23261782~23262071:-
BRCA	cis	rs6832769	0.961	rs13128582	ENSG00000272969.1	RP11-528I4.2	4.67	3.37e-06	0.000307	0.17	0.14	Personality dimensions;	chr4:55462777	chr4:55547112~55547889:+
BRCA	cis	rs6547741	0.935	rs6749426	ENSG00000234072.1	AC074117.10	4.67	3.37e-06	0.000307	0.13	0.14	Oral cavity cancer;	chr2:27624739	chr2:27356246~27367622:+
BRCA	cis	rs2898681	0.837	rs2017237	ENSG00000248375.1	RP11-177B4.1	-4.67	3.38e-06	0.000308	-0.2	-0.14	Optic nerve measurement (cup area);	chr4:52882348	chr4:52720081~52720831:-
BRCA	cis	rs2880765	0.631	rs55767890	ENSG00000230373.7	GOLGA6L5P	4.67	3.38e-06	0.000308	0.16	0.14	Coronary artery disease;	chr15:85460911	chr15:84507885~84516814:-
BRCA	cis	rs984222	0.559	rs61807010	ENSG00000231365.4	RP11-418J17.1	4.67	3.38e-06	0.000308	0.18	0.14	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119200568	chr1:119140396~119275973:+
BRCA	cis	rs7646881	1	rs59313096	ENSG00000240207.5	RP11-379F4.4	-4.67	3.38e-06	0.000308	-0.21	-0.14	Tetralogy of Fallot;	chr3:158734453	chr3:158732263~158784070:+
BRCA	cis	rs7267979	0.932	rs6132848	ENSG00000125804.12	FAM182A	-4.67	3.38e-06	0.000308	-0.19	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25581009	chr20:26054655~26086917:+
BRCA	cis	rs35146811	0.624	rs1727134	ENSG00000235713.1	RP4-604G5.3	-4.67	3.38e-06	0.000308	-0.17	-0.14	Coronary artery disease;	chr7:100216049	chr7:99992397~99993050:+
BRCA	cis	rs35146811	0.735	rs1636978	ENSG00000235713.1	RP4-604G5.3	-4.67	3.38e-06	0.000308	-0.17	-0.14	Coronary artery disease;	chr7:100216289	chr7:99992397~99993050:+
BRCA	cis	rs6840360	0.642	rs10857260	ENSG00000251611.1	RP11-610P16.1	-4.67	3.38e-06	0.000308	-0.13	-0.14	Intelligence (multi-trait analysis);	chr4:151502904	chr4:151407551~151408835:-
BRCA	cis	rs2253762	0.54	rs77032313	ENSG00000226864.1	ATE1-AS1	4.67	3.38e-06	0.000308	0.26	0.14	Breast cancer;	chr10:121995687	chr10:121928312~121951965:+
BRCA	cis	rs149866169	1	rs149866169	ENSG00000220721.1	OR1F12	4.67	3.38e-06	0.000308	0.29	0.14	Subjective well-being (multi-trait analysis);Lung cancer;Neuroticism (multi-trait analysis);Lung cancer in ever smokers;Squamous cell lung carcinoma;	chr6:27473944	chr6:28073316~28074233:+
BRCA	cis	rs2692947	0.695	rs12464148	ENSG00000168992.4	OR7E102P	4.67	3.38e-06	0.000308	0.19	0.14	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95930962	chr2:95546531~95547545:+
BRCA	cis	rs7665090	1	rs11727546	ENSG00000251288.2	RP11-10L12.2	-4.67	3.38e-06	0.000308	-0.17	-0.14	Primary biliary cholangitis;	chr4:102636507	chr4:102751401~102752641:+
BRCA	cis	rs2908197	0.806	rs12534035	ENSG00000186704.9	DTX2P1	4.67	3.39e-06	0.000308	0.16	0.14	3-hydroxypropylmercapturic acid levels in smokers;	chr7:76351629	chr7:76978617~77004308:+
BRCA	cis	rs6840360	0.642	rs2034061	ENSG00000251603.1	RP11-164P12.4	-4.67	3.39e-06	0.000308	-0.13	-0.14	Intelligence (multi-trait analysis);	chr4:151499604	chr4:151667224~151670502:+
BRCA	cis	rs4664293	1	rs4665083	ENSG00000226266.5	AC009961.3	4.67	3.39e-06	0.000308	0.17	0.14	Monocyte percentage of white cells;	chr2:159573616	chr2:159670708~159712435:-
BRCA	cis	rs1722141	0.669	rs788733	ENSG00000237471.1	AC073115.6	4.67	3.39e-06	0.000308	0.19	0.14	Sitting height ratio;	chr7:45994491	chr7:45969657~45980191:+
BRCA	cis	rs78487399	0.808	rs17030967	ENSG00000234936.1	AC010883.5	4.67	3.39e-06	0.000308	0.23	0.14	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43521844	chr2:43229573~43233394:+
BRCA	cis	rs34929064	0.536	rs2961279	ENSG00000179428.2	AC073072.5	4.67	3.39e-06	0.000308	0.16	0.14	Major depression and alcohol dependence;	chr7:22598535	chr7:22725395~22727620:-
BRCA	cis	rs1077773	0.7	rs10259316	ENSG00000237773.4	AC003075.4	-4.67	3.39e-06	0.000309	-0.18	-0.14	Ulcerative colitis;Inflammatory bowel disease;	chr7:17406082	chr7:17279834~17299357:-
BRCA	cis	rs11051970	0.559	rs7963887	ENSG00000274964.1	RP11-817I4.1	-4.67	3.39e-06	0.000309	-0.19	-0.14	Response to tocilizumab in rheumatoid arthritis;	chr12:32323073	chr12:32339368~32340724:+
BRCA	cis	rs11051970	0.559	rs10844184	ENSG00000274964.1	RP11-817I4.1	-4.67	3.39e-06	0.000309	-0.19	-0.14	Response to tocilizumab in rheumatoid arthritis;	chr12:32323918	chr12:32339368~32340724:+
BRCA	cis	rs62025270	1	rs62025270	ENSG00000259762.1	RP11-158M2.4	-4.67	3.39e-06	0.000309	-0.22	-0.14	Idiopathic pulmonary fibrosis;	chr15:85756967	chr15:85750336~85752901:-
BRCA	cis	rs2904967	0.81	rs507005	ENSG00000255200.1	AP003068.18	4.67	3.39e-06	0.000309	0.23	0.14	Mean corpuscular volume;	chr11:65278144	chr11:65174117~65176470:-
BRCA	cis	rs2904967	0.852	rs668735	ENSG00000255200.1	AP003068.18	4.67	3.39e-06	0.000309	0.23	0.14	Mean corpuscular volume;	chr11:65278254	chr11:65174117~65176470:-
BRCA	cis	rs763014	0.932	rs35067229	ENSG00000260394.2	LA16c-313D11.9	-4.67	3.39e-06	0.000309	-0.14	-0.14	Height;	chr16:599638	chr16:678504~679777:-
BRCA	cis	rs11696845	0.761	rs11698203	ENSG00000276223.1	RP4-781B1.5	4.67	3.39e-06	0.000309	0.14	0.14	Obesity-related traits;	chr20:44729258	chr20:44746642~44747201:+
BRCA	cis	rs860295	0.702	rs11264381	ENSG00000160766.13	GBAP1	4.67	3.39e-06	0.000309	0.16	0.14	Body mass index;	chr1:155552781	chr1:155213821~155227422:-
BRCA	cis	rs6452524	0.967	rs2974441	ENSG00000281327.1	LINC01338	4.67	3.39e-06	0.000309	0.17	0.14	Hypertension (SNP x SNP interaction);	chr5:83193330	chr5:82850864~82859836:-
BRCA	cis	rs8180040	0.966	rs11130129	ENSG00000271161.1	BOLA2P2	-4.67	3.39e-06	0.000309	-0.15	-0.14	Colorectal cancer;	chr3:47448395	chr3:47499841~47500407:+
BRCA	cis	rs6832769	0.922	rs501679	ENSG00000272969.1	RP11-528I4.2	4.67	3.39e-06	0.000309	0.17	0.14	Personality dimensions;	chr4:55371160	chr4:55547112~55547889:+
BRCA	cis	rs6990255	0.681	rs1495236	ENSG00000272338.2	RP11-722E23.2	4.67	3.39e-06	0.000309	0.22	0.14	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Bipolar disorder;	chr8:34262232	chr8:33360839~33361415:-
BRCA	cis	rs721917	0.507	rs2819101	ENSG00000278616.1	BEND3P3	-4.67	3.39e-06	0.000309	-0.13	-0.14	Chronic obstructive pulmonary disease;	chr10:79936986	chr10:79682997~79685436:+
BRCA	cis	rs6756513	0.5	rs17037194	ENSG00000231024.1	AC092431.3	4.67	3.39e-06	0.000309	0.21	0.14	Breast cancer;Platelet count;	chr2:69876670	chr2:69700192~69713847:-
BRCA	cis	rs6545883	0.929	rs2463100	ENSG00000212978.6	AC016747.3	4.67	3.4e-06	0.000309	0.21	0.14	Tuberculosis;	chr2:61432064	chr2:61141592~61144969:-
BRCA	cis	rs7267979	0.764	rs2474767	ENSG00000125804.12	FAM182A	-4.67	3.4e-06	0.000309	-0.19	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25266097	chr20:26054655~26086917:+
BRCA	cis	rs10129255	0.872	rs8015406	ENSG00000232216.1	IGHV3-43	4.67	3.4e-06	0.00031	0.12	0.14	Kawasaki disease;	chr14:106670611	chr14:106470264~106470800:-
BRCA	cis	rs10504130	0.778	rs74866791	ENSG00000253844.1	RP11-546K22.1	-4.67	3.4e-06	0.00031	-0.24	-0.14	Venous thromboembolism (SNP x SNP interaction);	chr8:51909787	chr8:51961458~52022974:+
BRCA	cis	rs62025270	0.688	rs17575870	ENSG00000259762.1	RP11-158M2.4	-4.67	3.4e-06	0.00031	-0.21	-0.14	Idiopathic pulmonary fibrosis;	chr15:85713926	chr15:85750336~85752901:-
BRCA	cis	rs13113518	0.966	rs13144598	ENSG00000249700.7	SRD5A3-AS1	4.67	3.4e-06	0.00031	0.18	0.14	Height;	chr4:55570311	chr4:55363971~55395847:-
BRCA	cis	rs7267979	0.527	rs6076369	ENSG00000204556.4	CTD-2514C3.1	4.67	3.4e-06	0.00031	0.19	0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25596147	chr20:26018832~26020684:+
BRCA	cis	rs6125597	0.967	rs6067030	ENSG00000222365.1	SNORD12B	4.67	3.4e-06	0.00031	0.15	0.14	Intelligence (multi-trait analysis);	chr20:49267866	chr20:49280319~49280409:+
BRCA	cis	rs6738627	0.766	rs13389219	ENSG00000223318.1	RNA5SP111	4.67	3.4e-06	0.00031	0.16	0.14	circulating leptin levels adjusted for BMI;Body fat percentage;circulating leptin levels;	chr2:164672366	chr2:164895677~164895777:-
BRCA	cis	rs17270561	0.779	rs78589800	ENSG00000272462.2	U91328.19	-4.67	3.4e-06	0.00031	-0.19	-0.14	Iron status biomarkers;	chr6:25883272	chr6:25992662~26001775:+
BRCA	cis	rs67981189	0.574	rs2526848	ENSG00000269927.1	RP6-91H8.3	-4.67	3.4e-06	0.00031	-0.17	-0.14	Schizophrenia;	chr14:70953025	chr14:71141125~71143253:-
BRCA	cis	rs6095360	0.933	rs3817652	ENSG00000222365.1	SNORD12B	-4.67	3.4e-06	0.00031	-0.16	-0.14	Intelligence (multi-trait analysis);	chr20:49046831	chr20:49280319~49280409:+
BRCA	cis	rs7267979	0.868	rs6107019	ENSG00000125804.12	FAM182A	-4.67	3.41e-06	0.00031	-0.19	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25253349	chr20:26054655~26086917:+
BRCA	cis	rs6847067	0.8	rs6531777	ENSG00000180769.7	WDFY3-AS2	4.67	3.41e-06	0.00031	0.13	0.14	Oropharynx cancer;	chr4:84943942	chr4:84965682~85011277:+
BRCA	cis	rs3764021	0.87	rs10743819	ENSG00000278635.1	CTD-2318O12.1	-4.67	3.41e-06	0.00031	-0.14	-0.14	Type 1 diabetes;	chr12:9724172	chr12:9415641~9416718:+
BRCA	cis	rs6570726	0.935	rs366621	ENSG00000270638.1	RP3-466P17.1	4.67	3.41e-06	0.00031	0.16	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145540139	chr6:145735570~145737218:+
BRCA	cis	rs12497850	0.931	rs7627404	ENSG00000225399.4	RP11-3B7.1	4.67	3.41e-06	0.00031	0.14	0.14	Parkinson's disease;	chr3:48782235	chr3:49260085~49261316:+
BRCA	cis	rs2411233	0.967	rs11856829	ENSG00000259278.1	RP11-62C7.2	4.67	3.41e-06	0.00031	0.23	0.14	Platelet count;	chr15:38985580	chr15:39019233~39024918:+
BRCA	cis	rs2243480	0.901	rs34807232	ENSG00000222364.1	RNU6-96P	-4.67	3.41e-06	0.00031	-0.27	-0.14	Diabetic kidney disease;	chr7:66500146	chr7:66395191~66395286:+
BRCA	cis	rs2243480	0.901	rs35823062	ENSG00000222364.1	RNU6-96P	-4.67	3.41e-06	0.00031	-0.27	-0.14	Diabetic kidney disease;	chr7:66500834	chr7:66395191~66395286:+
BRCA	cis	rs7267979	0.844	rs869358	ENSG00000125804.12	FAM182A	4.67	3.41e-06	0.000311	0.19	0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25394038	chr20:26054655~26086917:+
BRCA	cis	rs10740039	0.516	rs10740035	ENSG00000254271.1	RP11-131N11.4	-4.67	3.42e-06	0.000311	-0.19	-0.14	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60592848	chr10:60734342~60741828:+
BRCA	cis	rs5167	0.506	rs35193317	ENSG00000214855.8	APOC1P1	-4.67	3.42e-06	0.000311	-0.17	-0.14	Blood protein levels;	chr19:44967087	chr19:44926804~44931386:+
BRCA	cis	rs7819412	0.525	rs10086521	ENSG00000255020.1	AF131216.5	4.67	3.42e-06	0.000311	0.18	0.14	Triglycerides;	chr8:10926259	chr8:11345748~11347502:-
BRCA	cis	rs1867631	1	rs10789213	ENSG00000248458.2	RP4-598P13.1	4.67	3.42e-06	0.000311	0.15	0.14	Menopause (age at onset);	chr1:66662518	chr1:66665864~66677027:-
BRCA	cis	rs9467773	0.595	rs6907924	ENSG00000124549.13	BTN2A3P	-4.67	3.42e-06	0.000311	-0.15	-0.14	Intelligence (multi-trait analysis);	chr6:26438589	chr6:26421391~26432383:+
BRCA	cis	rs9467773	0.55	rs9379874	ENSG00000124549.13	BTN2A3P	-4.67	3.42e-06	0.000311	-0.15	-0.14	Intelligence (multi-trait analysis);	chr6:26440201	chr6:26421391~26432383:+
BRCA	cis	rs2243480	1	rs7794661	ENSG00000275400.1	RP4-756H11.5	4.67	3.42e-06	0.000311	0.25	0.14	Diabetic kidney disease;	chr7:65924743	chr7:66553805~66554199:-
BRCA	cis	rs7267979	1	rs398036	ENSG00000125804.12	FAM182A	-4.67	3.42e-06	0.000311	-0.19	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25459214	chr20:26054655~26086917:+
BRCA	cis	rs7267979	1	rs397119	ENSG00000125804.12	FAM182A	-4.67	3.42e-06	0.000311	-0.19	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25459551	chr20:26054655~26086917:+
BRCA	cis	rs10829156	0.699	rs4747353	ENSG00000225527.1	RP11-383B4.4	-4.67	3.42e-06	0.000311	-0.19	-0.14	Sudden cardiac arrest;	chr10:18548028	chr10:18531849~18533336:-
BRCA	cis	rs9409565	0.513	rs16912862	ENSG00000232063.1	RP11-307E17.8	-4.67	3.42e-06	0.000311	-0.15	-0.14	Colorectal cancer (alcohol consumption interaction);	chr9:94287723	chr9:94332476~94360948:+
BRCA	cis	rs2243480	1	rs35432774	ENSG00000222364.1	RNU6-96P	-4.67	3.42e-06	0.000311	-0.25	-0.14	Diabetic kidney disease;	chr7:65928032	chr7:66395191~66395286:+
BRCA	cis	rs2278702	0.943	rs78285258	ENSG00000259495.2	RP11-210M15.2	-4.67	3.42e-06	0.000311	-0.22	-0.14	Bipolar disorder;	chr15:80392771	chr15:80344853~80403575:-
BRCA	cis	rs11239930	0.517	rs3011809	ENSG00000278811.3	LINC00624	4.67	3.42e-06	0.000312	0.17	0.14	AIDS progression;	chr1:147077593	chr1:147258885~147517875:-
BRCA	cis	rs8180040	0.966	rs6792461	ENSG00000271161.1	BOLA2P2	-4.67	3.43e-06	0.000312	-0.15	-0.14	Colorectal cancer;	chr3:47431678	chr3:47499841~47500407:+
BRCA	cis	rs7267979	0.903	rs6132819	ENSG00000276952.1	RP5-965G21.6	4.67	3.43e-06	0.000312	0.18	0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25237982	chr20:25284915~25285588:-
BRCA	cis	rs853679	0.76	rs9357067	ENSG00000280107.1	AL022393.9	-4.67	3.43e-06	0.000312	-0.23	-0.14	Depression;	chr6:28242515	chr6:28170845~28172521:+
BRCA	cis	rs763014	1	rs2269558	ENSG00000260394.2	LA16c-313D11.9	-4.67	3.43e-06	0.000312	-0.14	-0.14	Height;	chr16:632250	chr16:678504~679777:-
BRCA	cis	rs7267979	0.718	rs2983489	ENSG00000125804.12	FAM182A	-4.67	3.43e-06	0.000312	-0.19	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25263484	chr20:26054655~26086917:+
BRCA	cis	rs7976269	0.609	rs4141946	ENSG00000275476.1	RP11-996F15.4	-4.67	3.43e-06	0.000312	-0.17	-0.14	Male-pattern baldness;	chr12:29066432	chr12:29277397~29277882:-
BRCA	cis	rs2835345	0.563	rs73204244	ENSG00000279365.1	KB-176G8.1	4.67	3.43e-06	0.000312	0.19	0.14	Pulmonary function;	chr21:36452373	chr21:36485867~36487760:+
BRCA	cis	rs8103278	0.826	rs11669442	ENSG00000267395.4	AC074212.6	4.67	3.43e-06	0.000312	0.15	0.14	Coronary artery disease;	chr19:45871299	chr19:45767796~45772504:+
BRCA	cis	rs6832769	0.925	rs6817267	ENSG00000272969.1	RP11-528I4.2	4.67	3.43e-06	0.000312	0.17	0.14	Personality dimensions;	chr4:55472374	chr4:55547112~55547889:+
BRCA	cis	rs6832769	1	rs11931061	ENSG00000272969.1	RP11-528I4.2	4.67	3.43e-06	0.000312	0.17	0.14	Personality dimensions;	chr4:55472626	chr4:55547112~55547889:+
BRCA	cis	rs6832769	0.961	rs11947476	ENSG00000272969.1	RP11-528I4.2	4.67	3.43e-06	0.000312	0.17	0.14	Personality dimensions;	chr4:55473584	chr4:55547112~55547889:+
BRCA	cis	rs11686241	0.748	rs13411746	ENSG00000241520.1	AC098820.4	4.67	3.43e-06	0.000312	0.26	0.14	Cancer;	chr2:216441893	chr2:216483032~216487196:-
BRCA	cis	rs10208649	0.611	rs3929001	ENSG00000233266.1	HMGB1P31	-4.67	3.43e-06	0.000312	-0.29	-0.14	Body mass index;	chr2:54055750	chr2:54051334~54051760:+
BRCA	cis	rs6832769	1	rs7668147	ENSG00000272969.1	RP11-528I4.2	4.67	3.44e-06	0.000313	0.17	0.14	Personality dimensions;	chr4:55473217	chr4:55547112~55547889:+
BRCA	cis	rs6088580	0.601	rs6059872	ENSG00000276073.1	RP5-1125A11.7	-4.67	3.44e-06	0.000313	-0.16	-0.14	Glomerular filtration rate (creatinine);	chr20:34494970	chr20:33985617~33988989:-
BRCA	cis	rs6832769	0.961	rs13128582	ENSG00000223305.1	RN7SKP30	4.67	3.44e-06	0.000313	0.18	0.14	Personality dimensions;	chr4:55462777	chr4:55540502~55540835:-
BRCA	cis	rs11758351	0.66	rs113205297	ENSG00000241549.7	GUSBP2	-4.67	3.44e-06	0.000313	-0.2	-0.14	Renal underexcretion gout;Gout;	chr6:26210580	chr6:26871484~26956554:-
BRCA	cis	rs5758659	0.729	rs134866	ENSG00000273366.1	CTA-989H11.1	-4.67	3.44e-06	0.000313	-0.17	-0.14	Cognitive function;	chr22:42254657	chr22:42278188~42278846:+
BRCA	cis	rs6847067	0.794	rs10856852	ENSG00000180769.7	WDFY3-AS2	4.67	3.44e-06	0.000313	0.13	0.14	Oropharynx cancer;	chr4:84976382	chr4:84965682~85011277:+
BRCA	cis	rs2625529	0.824	rs2415121	ENSG00000260037.4	CTD-2524L6.3	-4.67	3.44e-06	0.000313	-0.18	-0.14	Red blood cell count;	chr15:71841677	chr15:71818396~71823384:+
BRCA	cis	rs11098499	0.954	rs12510138	ENSG00000260091.1	RP11-33B1.4	-4.67	3.44e-06	0.000313	-0.13	-0.14	Corneal astigmatism;	chr4:119502780	chr4:119409333~119410233:+
BRCA	cis	rs11892454	0.565	rs10190878	ENSG00000217643.1	PTGES3P2	-4.67	3.44e-06	0.000313	-0.15	-0.14	Heschl's gyrus morphology;	chr2:25720505	chr2:25822469~25822950:+
BRCA	cis	rs7702057	0.53	rs17138834	ENSG00000272265.1	CTD-2287O16.4	-4.67	3.44e-06	0.000313	-0.27	-0.14	Amyotrophic lateral sclerosis;	chr5:116076625	chr5:116078110~116078570:-
BRCA	cis	rs73222236	0.787	rs35681043	ENSG00000273486.1	RP11-731C17.2	4.67	3.44e-06	0.000313	0.16	0.14	Coronary artery disease;	chr3:136261583	chr3:136837338~136839021:-
BRCA	cis	rs9834975	0.967	rs6768280	ENSG00000272758.4	RP11-299J3.8	4.67	3.44e-06	0.000313	0.14	0.14	Diastolic blood pressure;	chr3:122406205	chr3:122416207~122443180:+
BRCA	cis	rs7976269	0.515	rs10743637	ENSG00000275476.1	RP11-996F15.4	4.67	3.44e-06	0.000313	0.16	0.14	Male-pattern baldness;	chr12:29025962	chr12:29277397~29277882:-
BRCA	cis	rs2243480	1	rs6964530	ENSG00000222364.1	RNU6-96P	4.67	3.44e-06	0.000313	0.26	0.14	Diabetic kidney disease;	chr7:66253864	chr7:66395191~66395286:+
BRCA	cis	rs4650994	1	rs4650994	ENSG00000273384.1	RP5-1098D14.1	-4.67	3.44e-06	0.000313	-0.17	-0.14	HDL cholesterol;HDL cholesterol levels;	chr1:178546177	chr1:178651706~178652282:+
BRCA	cis	rs9467773	0.935	rs1884947	ENSG00000241549.7	GUSBP2	4.67	3.44e-06	0.000313	0.16	0.14	Intelligence (multi-trait analysis);	chr6:26553045	chr6:26871484~26956554:-
BRCA	cis	rs11239930	0.517	rs584107	ENSG00000230832.3	RP11-325P15.2	4.67	3.45e-06	0.000313	0.2	0.14	AIDS progression;	chr1:147075862	chr1:147082338~147083578:-
BRCA	cis	rs2153535	0.58	rs2327057	ENSG00000251164.1	HULC	-4.67	3.45e-06	0.000313	-0.18	-0.14	Motion sickness;	chr6:8443086	chr6:8652137~8653846:+
BRCA	cis	rs10504130	0.74	rs17277222	ENSG00000253844.1	RP11-546K22.1	4.67	3.45e-06	0.000314	0.27	0.14	Venous thromboembolism (SNP x SNP interaction);	chr8:51654801	chr8:51961458~52022974:+
BRCA	cis	rs516805	0.63	rs2606642	ENSG00000279114.1	RP3-425C14.5	4.67	3.45e-06	0.000314	0.18	0.14	Lymphocyte counts;	chr6:122103758	chr6:122471923~122484161:+
BRCA	cis	rs4578769	0.918	rs4239434	ENSG00000265939.1	UBE2CP2	-4.67	3.45e-06	0.000314	-0.17	-0.14	Eosinophil percentage of white cells;	chr18:22995160	chr18:22900486~22900995:-
BRCA	cis	rs73222236	0.75	rs3932048	ENSG00000273486.1	RP11-731C17.2	4.67	3.45e-06	0.000314	0.16	0.14	Coronary artery disease;	chr3:136540082	chr3:136837338~136839021:-
BRCA	cis	rs7829975	0.688	rs7826654	ENSG00000253981.4	ALG1L13P	4.67	3.45e-06	0.000314	0.16	0.14	Mood instability;	chr8:8521596	chr8:8236003~8244667:-
BRCA	cis	rs7829975	0.688	rs7826660	ENSG00000253981.4	ALG1L13P	4.67	3.45e-06	0.000314	0.16	0.14	Mood instability;	chr8:8521597	chr8:8236003~8244667:-
BRCA	cis	rs2243480	1	rs316321	ENSG00000222364.1	RNU6-96P	-4.67	3.45e-06	0.000314	-0.26	-0.14	Diabetic kidney disease;	chr7:66146626	chr7:66395191~66395286:+
BRCA	cis	rs2243480	1	rs316318	ENSG00000222364.1	RNU6-96P	-4.67	3.45e-06	0.000314	-0.26	-0.14	Diabetic kidney disease;	chr7:66147917	chr7:66395191~66395286:+
BRCA	cis	rs2243480	1	rs316317	ENSG00000222364.1	RNU6-96P	-4.67	3.45e-06	0.000314	-0.26	-0.14	Diabetic kidney disease;	chr7:66148650	chr7:66395191~66395286:+
BRCA	cis	rs2243480	1	rs316304	ENSG00000222364.1	RNU6-96P	-4.67	3.45e-06	0.000314	-0.26	-0.14	Diabetic kidney disease;	chr7:66151907	chr7:66395191~66395286:+
BRCA	cis	rs2227564	0.672	rs10824042	ENSG00000271816.1	BMS1P4	4.67	3.45e-06	0.000314	0.16	0.14	Crohn's disease;Inflammatory bowel disease;	chr10:73885870	chr10:73699151~73730487:-
BRCA	cis	rs7818688	1	rs10112230	ENSG00000253528.2	RP11-347C18.4	-4.67	3.45e-06	0.000314	-0.21	-0.14	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95025844	chr8:94974573~94974853:-
BRCA	cis	rs7818688	1	rs10106491	ENSG00000253528.2	RP11-347C18.4	-4.67	3.45e-06	0.000314	-0.21	-0.14	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95026731	chr8:94974573~94974853:-
BRCA	cis	rs7818688	1	rs73276444	ENSG00000253528.2	RP11-347C18.4	-4.67	3.45e-06	0.000314	-0.21	-0.14	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95027019	chr8:94974573~94974853:-
BRCA	cis	rs6723226	0.75	rs1033751	ENSG00000276517.1	AL133243.2	-4.67	3.45e-06	0.000314	-0.17	-0.14	Intelligence (multi-trait analysis);	chr2:32470691	chr2:32526504~32529507:+
BRCA	cis	rs1075265	0.704	rs10181999	ENSG00000235937.1	AC008280.1	4.67	3.45e-06	0.000314	0.15	0.14	Chronotype;Morning vs. evening chronotype;	chr2:54025360	chr2:54029552~54030682:-
BRCA	cis	rs9467773	0.62	rs2451732	ENSG00000241549.7	GUSBP2	-4.67	3.46e-06	0.000314	-0.15	-0.14	Intelligence (multi-trait analysis);	chr6:26622676	chr6:26871484~26956554:-
BRCA	cis	rs7577696	0.962	rs13017189	ENSG00000272716.1	RP11-563N4.1	-4.67	3.46e-06	0.000314	-0.16	-0.14	Inflammatory biomarkers;	chr2:32056211	chr2:32165046~32165757:-
BRCA	cis	rs4781563	0.634	rs11648736	ENSG00000242307.1	RPS26P52	-4.67	3.46e-06	0.000314	-0.17	-0.14	Bilirubin levels;	chr16:13957035	chr16:13922332~13922679:-
BRCA	cis	rs2243480	1	rs6964530	ENSG00000275400.1	RP4-756H11.5	-4.67	3.46e-06	0.000314	-0.26	-0.14	Diabetic kidney disease;	chr7:66253864	chr7:66553805~66554199:-
BRCA	cis	rs2243480	1	rs313831	ENSG00000222364.1	RNU6-96P	-4.67	3.46e-06	0.000315	-0.27	-0.14	Diabetic kidney disease;	chr7:66086239	chr7:66395191~66395286:+
BRCA	cis	rs11758351	0.66	rs16891455	ENSG00000241549.7	GUSBP2	-4.67	3.46e-06	0.000315	-0.21	-0.14	Renal underexcretion gout;Gout;	chr6:26230257	chr6:26871484~26956554:-
BRCA	cis	rs559555	0.553	rs633233	ENSG00000272716.1	RP11-563N4.1	4.67	3.46e-06	0.000315	0.17	0.14	Blood metabolite ratios;Blood metabolite levels;	chr2:31616881	chr2:32165046~32165757:-
BRCA	cis	rs10833905	0.938	rs11026939	ENSG00000246225.5	RP11-17A1.3	-4.67	3.46e-06	0.000315	-0.21	-0.14	Sudden cardiac arrest;	chr11:23051420	chr11:22829380~22945393:+
BRCA	cis	rs7302981	0.9	rs836179	ENSG00000272368.2	RP4-605O3.4	4.67	3.46e-06	0.000315	0.15	0.14	Systolic blood pressure;	chr12:50109299	chr12:50112197~50165618:+
BRCA	cis	rs2446066	0.818	rs10876434	ENSG00000257379.1	RP11-793H13.8	4.67	3.46e-06	0.000315	0.22	0.14	Red blood cell count;	chr12:53340891	chr12:53441741~53467528:+
BRCA	cis	rs610932	0.517	rs1285231	ENSG00000275344.1	MIR6503	4.67	3.46e-06	0.000315	0.14	0.14	Alzheimer's disease;	chr11:60211935	chr11:60209071~60209156:-
BRCA	cis	rs8054556	0.787	rs1140239	ENSG00000261367.1	RP11-455F5.4	-4.67	3.47e-06	0.000315	-0.17	-0.14	Autism spectrum disorder or schizophrenia;	chr16:30010081	chr16:30107675~30110541:+
BRCA	cis	rs4763879	0.634	rs12424826	ENSG00000278635.1	CTD-2318O12.1	4.67	3.47e-06	0.000315	0.14	0.14	Type 1 diabetes;	chr12:9701981	chr12:9415641~9416718:+
BRCA	cis	rs4781563	1	rs9646272	ENSG00000242307.1	RPS26P52	-4.67	3.47e-06	0.000315	-0.18	-0.14	Bilirubin levels;	chr16:13954987	chr16:13922332~13922679:-
BRCA	cis	rs9863	0.861	rs4765305	ENSG00000270028.1	RP11-380L11.4	4.67	3.47e-06	0.000315	0.18	0.14	White blood cell count;	chr12:123946065	chr12:123925461~123926083:-
BRCA	cis	rs7312933	0.558	rs4768411	ENSG00000257225.1	RP11-328C8.4	4.67	3.47e-06	0.000315	0.17	0.14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42461588	chr12:42459366~42466128:+
BRCA	cis	rs2073316	0.559	rs67603251	ENSG00000272716.1	RP11-563N4.1	4.67	3.47e-06	0.000315	0.16	0.14	Interleukin-18 levels;	chr2:31457757	chr2:32165046~32165757:-
BRCA	cis	rs78487399	0.908	rs76163151	ENSG00000234936.1	AC010883.5	4.67	3.47e-06	0.000315	0.22	0.14	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43617077	chr2:43229573~43233394:+
BRCA	cis	rs1953600	0.818	rs2152546	ENSG00000226659.1	RP11-137H2.4	-4.67	3.47e-06	0.000315	-0.18	-0.14	Sarcoidosis;	chr10:80146628	chr10:80529597~80535942:-
BRCA	cis	rs1005277	0.579	rs2474587	ENSG00000099251.13	HSD17B7P2	4.67	3.47e-06	0.000315	0.16	0.14	Extrinsic epigenetic age acceleration;	chr10:38131738	chr10:38356380~38378505:+
BRCA	cis	rs1005277	0.579	rs2474588	ENSG00000099251.13	HSD17B7P2	4.67	3.47e-06	0.000315	0.16	0.14	Extrinsic epigenetic age acceleration;	chr10:38131942	chr10:38356380~38378505:+
BRCA	cis	rs2348418	0.515	rs17434556	ENSG00000247934.4	RP11-967K21.1	4.67	3.47e-06	0.000315	0.19	0.14	Lung function (FEV1);Lung function (FVC);	chr12:28442760	chr12:28163298~28190738:-
BRCA	cis	rs33995560	0.708	rs4796144	ENSG00000270871.1	AC015849.19	-4.67	3.47e-06	0.000315	-0.19	-0.14	Blood protein levels;	chr17:35965995	chr17:35816717~35830293:-
BRCA	cis	rs7674212	0.57	rs6810571	ENSG00000246560.2	RP11-10L12.4	4.67	3.47e-06	0.000315	0.15	0.14	Type 2 diabetes;	chr4:103165630	chr4:102828055~102844075:+
BRCA	cis	rs11976180	1	rs2951360	ENSG00000244479.5	OR2A1-AS1	4.67	3.47e-06	0.000316	0.19	0.14	Obesity-related traits;	chr7:144060256	chr7:144251264~144356181:-
BRCA	cis	rs300890	0.76	rs12643013	ENSG00000250326.1	RP11-284M14.1	-4.67	3.47e-06	0.000316	-0.16	-0.14	Nasopharyngeal carcinoma;	chr4:143285795	chr4:142933195~143184861:-
BRCA	cis	rs9307551	0.697	rs7356151	ENSG00000250334.4	LINC00989	-4.67	3.47e-06	0.000316	-0.2	-0.14	Refractive error;	chr4:79539532	chr4:79492416~79576460:+
BRCA	cis	rs4267450	0.649	rs12151045	ENSG00000261770.1	CTC-459F4.1	-4.67	3.47e-06	0.000316	-0.26	-0.14	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);	chr19:28316162	chr19:27757184~27760849:-
BRCA	cis	rs11098499	0.874	rs28452522	ENSG00000249244.1	RP11-548H18.2	4.67	3.48e-06	0.000316	0.18	0.14	Corneal astigmatism;	chr4:119189629	chr4:119391831~119395335:-
BRCA	cis	rs1707322	0.963	rs12145287	ENSG00000234329.1	RP11-767N6.2	4.67	3.48e-06	0.000316	0.15	0.14	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45859330	chr1:45651039~45651826:-
BRCA	cis	rs919433	0.617	rs700642	ENSG00000231621.1	AC013264.2	4.67	3.48e-06	0.000316	0.14	0.14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197736006	chr2:197197991~197199273:+
BRCA	cis	rs6445967	0.53	rs12490706	ENSG00000273493.1	RP11-80H18.4	4.67	3.48e-06	0.000316	0.2	0.14	Platelet count;	chr3:58422520	chr3:58329965~58330118:+
BRCA	cis	rs1858037	0.867	rs876933	ENSG00000281920.1	RP11-418H16.1	4.67	3.48e-06	0.000316	0.19	0.14	Rheumatoid arthritis;	chr2:65382303	chr2:65623272~65628424:+
BRCA	cis	rs7119	0.717	rs8040702	ENSG00000259362.2	RP11-307C19.1	-4.67	3.48e-06	0.000316	-0.2	-0.14	Type 2 diabetes;	chr15:77511273	chr15:77525540~77534110:+
BRCA	cis	rs600550	0.927	rs603568	ENSG00000275344.1	MIR6503	4.67	3.48e-06	0.000316	0.14	0.14	Lipoprotein-associated phospholipase A2 activity and mass;	chr11:60214146	chr11:60209071~60209156:-
BRCA	cis	rs610932	0.517	rs670854	ENSG00000275344.1	MIR6503	4.67	3.48e-06	0.000316	0.14	0.14	Alzheimer's disease;	chr11:60214296	chr11:60209071~60209156:-
BRCA	cis	rs2880765	0.835	rs7180923	ENSG00000202081.1	RNU6-1280P	4.67	3.48e-06	0.000316	0.16	0.14	Coronary artery disease;	chr15:85507659	chr15:85651522~85651628:-
BRCA	cis	rs11123406	0.501	rs10864954	ENSG00000230499.1	AC108463.1	-4.67	3.48e-06	0.000317	-0.2	-0.14	Type 2 diabetes;	chr2:111209370	chr2:111195963~111206494:+
BRCA	cis	rs8040855	0.657	rs6496733	ENSG00000230373.7	GOLGA6L5P	-4.67	3.49e-06	0.000317	-0.18	-0.14	Bulimia nervosa;	chr15:85129945	chr15:84507885~84516814:-
BRCA	cis	rs13113518	0.902	rs11133386	ENSG00000273257.1	RP11-177J6.1	4.67	3.49e-06	0.000317	0.18	0.14	Height;	chr4:55461320	chr4:55387949~55388271:+
BRCA	cis	rs13113518	0.967	rs4340844	ENSG00000273257.1	RP11-177J6.1	4.67	3.49e-06	0.000317	0.18	0.14	Height;	chr4:55462689	chr4:55387949~55388271:+
BRCA	cis	rs7267979	0.727	rs2474765	ENSG00000125804.12	FAM182A	-4.67	3.49e-06	0.000317	-0.19	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25265314	chr20:26054655~26086917:+
BRCA	cis	rs4664293	0.867	rs11681245	ENSG00000226266.5	AC009961.3	-4.67	3.49e-06	0.000317	-0.18	-0.14	Monocyte percentage of white cells;	chr2:159772882	chr2:159670708~159712435:-
BRCA	cis	rs172166	0.611	rs203883	ENSG00000219392.1	RP1-265C24.5	-4.66	3.49e-06	0.000317	-0.2	-0.14	Cardiac Troponin-T levels;	chr6:28110578	chr6:28115628~28116551:+
BRCA	cis	rs253959	0.545	rs10072417	ENSG00000271918.1	CTD-2287O16.5	4.66	3.49e-06	0.000317	0.13	0.14	Bipolar disorder and schizophrenia;	chr5:116097906	chr5:116083807~116085416:-
BRCA	cis	rs11638815	0.626	rs4779039	ENSG00000259429.4	UBE2Q2P2	4.66	3.49e-06	0.000317	0.14	0.14	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82649016	chr15:82355142~82420075:+
BRCA	cis	rs13113518	1	rs4864993	ENSG00000273257.1	RP11-177J6.1	4.66	3.49e-06	0.000317	0.18	0.14	Height;	chr4:55450662	chr4:55387949~55388271:+
BRCA	cis	rs8180040	0.967	rs4858890	ENSG00000276925.1	RP11-708J19.3	4.66	3.49e-06	0.000317	0.16	0.14	Colorectal cancer;	chr3:47363966	chr3:47469777~47469987:+
BRCA	cis	rs950169	0.519	rs7237	ENSG00000275120.1	RP11-182J1.17	4.66	3.49e-06	0.000317	0.2	0.14	Schizophrenia;	chr15:84643346	chr15:84599434~84606463:-
BRCA	cis	rs703842	0.963	rs923829	ENSG00000270039.1	RP11-571M6.17	-4.66	3.49e-06	0.000317	-0.2	-0.14	Multiple sclerosis;	chr12:57780523	chr12:57803838~57804415:+
BRCA	cis	rs13113518	1	rs4865007	ENSG00000273257.1	RP11-177J6.1	-4.66	3.49e-06	0.000317	-0.18	-0.14	Height;	chr4:55537550	chr4:55387949~55388271:+
BRCA	cis	rs7308116	0.546	rs57425194	ENSG00000274395.1	RP11-554D14.8	-4.66	3.49e-06	0.000317	-0.17	-0.14	Pelvic organ prolapse (moderate/severe);	chr12:107821090	chr12:107835541~107836555:-
BRCA	cis	rs13113518	1	rs56362210	ENSG00000273257.1	RP11-177J6.1	4.66	3.49e-06	0.000317	0.18	0.14	Height;	chr4:55540972	chr4:55387949~55388271:+
BRCA	cis	rs853679	1	rs853685	ENSG00000216901.1	AL022393.7	4.66	3.5e-06	0.000318	0.24	0.14	Depression;	chr6:28321008	chr6:28176188~28176674:+
BRCA	cis	rs2692947	0.76	rs2438924	ENSG00000168992.4	OR7E102P	4.66	3.5e-06	0.000318	0.19	0.14	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95979321	chr2:95546531~95547545:+
BRCA	cis	rs2692947	0.826	rs7423942	ENSG00000168992.4	OR7E102P	4.66	3.5e-06	0.000318	0.19	0.14	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95979509	chr2:95546531~95547545:+
BRCA	cis	rs6545883	0.791	rs2600665	ENSG00000212978.6	AC016747.3	4.66	3.5e-06	0.000318	0.19	0.14	Tuberculosis;	chr2:61178660	chr2:61141592~61144969:-
BRCA	cis	rs7107174	1	rs2373115	ENSG00000251323.2	RP11-452H21.4	4.66	3.5e-06	0.000318	0.18	0.14	Testicular germ cell tumor;	chr11:78380104	chr11:78423982~78429836:-
BRCA	cis	rs2278170	1	rs331531	ENSG00000225101.4	OR52K3P	-4.66	3.5e-06	0.000318	-0.19	-0.14	Amyotrophic lateral sclerosis;	chr11:4457006	chr11:4474813~4475755:+
BRCA	cis	rs6496044	0.568	rs1982743	ENSG00000259295.5	CSPG4P12	4.66	3.5e-06	0.000318	0.17	0.14	Interstitial lung disease;	chr15:85525528	chr15:85191438~85213905:+
BRCA	cis	rs2839186	0.77	rs2280956	ENSG00000239415.1	AP001469.9	-4.66	3.5e-06	0.000318	-0.15	-0.14	Testicular germ cell tumor;	chr21:46222409	chr21:46251549~46254133:-
BRCA	cis	rs2288884	0.505	rs8110213	ENSG00000275055.1	CTC-471J1.11	-4.66	3.5e-06	0.000318	-0.23	-0.14	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:51958730	chr19:52049007~52049754:+
BRCA	cis	rs853679	0.882	rs9468287	ENSG00000280107.1	AL022393.9	-4.66	3.5e-06	0.000318	-0.3	-0.14	Depression;	chr6:28111963	chr6:28170845~28172521:+
BRCA	cis	rs2562456	0.876	rs10424079	ENSG00000268658.4	LINC00664	4.66	3.5e-06	0.000318	0.23	0.14	Pain;	chr19:21406377	chr19:21483374~21503238:+
BRCA	cis	rs6496044	0.568	rs1982742	ENSG00000259295.5	CSPG4P12	4.66	3.5e-06	0.000318	0.17	0.14	Interstitial lung disease;	chr15:85525519	chr15:85191438~85213905:+
BRCA	cis	rs6496044	0.568	rs6496049	ENSG00000259295.5	CSPG4P12	4.66	3.5e-06	0.000318	0.17	0.14	Interstitial lung disease;	chr15:85525974	chr15:85191438~85213905:+
BRCA	cis	rs6750047	0.756	rs336038	ENSG00000235848.3	RMDN2-AS1	-4.66	3.5e-06	0.000318	-0.18	-0.14	Cutaneous malignant melanoma;Melanoma;	chr2:38033607	chr2:37949911~38067041:-
BRCA	cis	rs6921919	0.583	rs740622	ENSG00000273712.1	RP5-874C20.7	4.66	3.5e-06	0.000318	0.19	0.14	Autism spectrum disorder or schizophrenia;	chr6:28430514	chr6:28315613~28315883:-
BRCA	cis	rs4713118	0.513	rs149989	ENSG00000219392.1	RP1-265C24.5	-4.66	3.51e-06	0.000318	-0.2	-0.14	Parkinson's disease;	chr6:28030406	chr6:28115628~28116551:+
BRCA	cis	rs2832191	0.791	rs2832199	ENSG00000236056.1	GAPDHP14	4.66	3.51e-06	0.000318	0.16	0.14	Dental caries;	chr21:29126180	chr21:29222321~29223257:+
BRCA	cis	rs7189233	0.955	rs8054299	ENSG00000279722.1	RP11-44F14.6	4.66	3.51e-06	0.000319	0.18	0.14	Intelligence (multi-trait analysis);	chr16:53464743	chr16:53487607~53489943:-
BRCA	cis	rs8031584	0.918	rs61997139	ENSG00000270015.1	RP11-540B6.6	-4.66	3.51e-06	0.000319	-0.15	-0.14	Huntington's disease progression;	chr15:30981399	chr15:30926514~30928407:+
BRCA	cis	rs11096990	0.613	rs6840578	ENSG00000249685.1	RP11-360F5.3	4.66	3.51e-06	0.000319	0.18	0.14	Cognitive function;	chr4:39206996	chr4:39133913~39135608:+
BRCA	cis	rs11168249	0.819	rs2525051	ENSG00000276691.1	RP5-1057I20.5	4.66	3.51e-06	0.000319	0.14	0.14	Lymphocyte counts;Inflammatory bowel disease;Ulcerative colitis;	chr12:47802156	chr12:47788426~47788971:+
BRCA	cis	rs7267979	1	rs2482928	ENSG00000125804.12	FAM182A	4.66	3.51e-06	0.000319	0.19	0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25350894	chr20:26054655~26086917:+
BRCA	cis	rs2227564	0.729	rs2688617	ENSG00000271816.1	BMS1P4	4.66	3.51e-06	0.000319	0.16	0.14	Crohn's disease;Inflammatory bowel disease;	chr10:73886389	chr10:73699151~73730487:-
BRCA	cis	rs1387259	0.931	rs11168474	ENSG00000226413.2	OR8T1P	4.66	3.51e-06	0.000319	0.19	0.14	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48227601	chr12:48442030~48442947:-
BRCA	cis	rs13108904	0.875	rs73069950	ENSG00000254094.1	AC078852.1	4.66	3.51e-06	0.000319	0.15	0.14	Obesity-related traits;	chr4:1282257	chr4:1356581~1358075:+
BRCA	cis	rs11096990	0.634	rs3733287	ENSG00000249685.1	RP11-360F5.3	4.66	3.51e-06	0.000319	0.18	0.14	Cognitive function;	chr4:39215732	chr4:39133913~39135608:+
BRCA	cis	rs4664293	0.867	rs10194483	ENSG00000226266.5	AC009961.3	-4.66	3.51e-06	0.000319	-0.18	-0.14	Monocyte percentage of white cells;	chr2:159739883	chr2:159670708~159712435:-
BRCA	cis	rs2380205	0.651	rs6602312	ENSG00000232807.2	RP11-536K7.3	4.66	3.51e-06	0.000319	0.14	0.14	Breast cancer;	chr10:5884968	chr10:5934270~5945900:-
BRCA	cis	rs875971	0.545	rs316306	ENSG00000230295.1	RP11-458F8.2	-4.66	3.51e-06	0.000319	-0.13	-0.14	Aortic root size;	chr7:66153687	chr7:66880708~66882981:+
BRCA	cis	rs6901004	0.605	rs2297939	ENSG00000231889.6	TRAF3IP2-AS1	4.66	3.52e-06	0.000319	0.15	0.14	Blood metabolite levels;	chr6:111227959	chr6:111483511~111598302:+
BRCA	cis	rs17695224	0.545	rs8099997	ENSG00000269483.1	AC006272.1	4.66	3.52e-06	0.000319	0.17	0.14	HDL cholesterol;HDL cholesterol levels;	chr19:51842216	chr19:51839924~51843324:-
BRCA	cis	rs3213958	0.574	rs73138004	ENSG00000249274.1	PDLIM1P4	-4.66	3.52e-06	0.000319	-0.24	-0.14	Blood protein levels;	chr3:98825460	chr3:98782188~98783193:+
BRCA	cis	rs10938353	0.68	rs66691259	ENSG00000273369.1	RP11-700J17.1	4.66	3.52e-06	0.000319	0.17	0.14	Body mass index;	chr4:44705036	chr4:44693946~44694386:-
BRCA	cis	rs77372450	0.591	rs17054697	ENSG00000251405.2	CTB-109A12.1	4.66	3.52e-06	0.000319	0.24	0.14	Bipolar disorder (body mass index interaction);	chr5:157539217	chr5:157362615~157460078:-
BRCA	cis	rs9638182	0.697	rs7793710	ENSG00000274080.1	CTA-315H11.2	4.66	3.52e-06	0.000319	0.2	0.14	Triglycerides;	chr7:73557201	chr7:73609262~73611502:-
BRCA	cis	rs8098244	0.603	rs1788813	ENSG00000264745.1	TTC39C-AS1	4.66	3.52e-06	0.000319	0.17	0.14	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23701204	chr18:23994213~24015339:-
BRCA	cis	rs812925	0.511	rs11886950	ENSG00000273302.1	RP11-493E12.2	4.66	3.52e-06	0.000319	0.12	0.14	Immature fraction of reticulocytes;	chr2:61172182	chr2:61199979~61200769:+
BRCA	cis	rs1005277	0.54	rs2474598	ENSG00000099251.13	HSD17B7P2	-4.66	3.52e-06	0.00032	-0.16	-0.14	Extrinsic epigenetic age acceleration;	chr10:38141368	chr10:38356380~38378505:+
BRCA	cis	rs7824557	0.547	rs2409745	ENSG00000154316.13	TDH	-4.66	3.52e-06	0.00032	-0.19	-0.14	Retinal vascular caliber;	chr8:11219126	chr8:11339637~11368452:+
BRCA	cis	rs11098499	0.505	rs75122014	ENSG00000260091.1	RP11-33B1.4	-4.66	3.52e-06	0.00032	-0.13	-0.14	Corneal astigmatism;	chr4:119441271	chr4:119409333~119410233:+
BRCA	cis	rs6430585	1	rs73958618	ENSG00000224043.6	CCNT2-AS1	-4.66	3.52e-06	0.00032	-0.23	-0.14	Corneal structure;	chr2:135742905	chr2:134735464~134918710:-
BRCA	cis	rs9333029	0.524	rs12047326	ENSG00000238145.2	RP11-346M5.1	4.66	3.52e-06	0.00032	0.15	0.14	Blood metabolite levels;	chr1:46939981	chr1:46891639~46892830:+
BRCA	cis	rs9921338	0.924	rs7204628	ENSG00000262703.1	RP11-485G7.6	-4.66	3.52e-06	0.00032	-0.17	-0.14	Vein graft stenosis in coronary artery bypass grafting;	chr16:11350715	chr16:11348143~11349321:-
BRCA	cis	rs11098499	0.954	rs12499324	ENSG00000250412.1	KLHL2P1	4.66	3.52e-06	0.00032	0.17	0.14	Corneal astigmatism;	chr4:119472631	chr4:119334329~119378233:+
BRCA	cis	rs13325613	0.915	rs13100243	ENSG00000223552.1	RP11-24F11.2	-4.66	3.53e-06	0.00032	-0.27	-0.14	Monocyte count;	chr3:46276407	chr3:46364955~46407059:-
BRCA	cis	rs6095360	1	rs1983639	ENSG00000222365.1	SNORD12B	-4.66	3.53e-06	0.00032	-0.16	-0.14	Intelligence (multi-trait analysis);	chr20:48955745	chr20:49280319~49280409:+
BRCA	cis	rs2179367	0.613	rs62426122	ENSG00000223701.3	RAET1E-AS1	4.66	3.53e-06	0.00032	0.2	0.14	Dupuytren's disease;	chr6:149427449	chr6:149884431~149919508:+
BRCA	cis	rs860295	0.702	rs5005770	ENSG00000225855.5	RUSC1-AS1	-4.66	3.53e-06	0.00032	-0.12	-0.14	Body mass index;	chr1:155375252	chr1:155316863~155324176:-
BRCA	cis	rs56322409	0.802	rs11597849	ENSG00000226688.5	ENTPD1-AS1	4.66	3.53e-06	0.00032	0.16	0.14	Blood metabolite levels;	chr10:95705494	chr10:95753206~96090238:-
BRCA	cis	rs67981189	0.593	rs2810101	ENSG00000269927.1	RP6-91H8.3	-4.66	3.53e-06	0.000321	-0.17	-0.14	Schizophrenia;	chr14:70963110	chr14:71141125~71143253:-
BRCA	cis	rs2303319	0.504	rs12479001	ENSG00000227403.1	AC009299.3	4.66	3.53e-06	0.000321	0.35	0.14	Cognitive function;	chr2:161721815	chr2:161244739~161249050:+
BRCA	cis	rs5758511	0.596	rs55644935	ENSG00000227370.1	RP4-669P10.19	4.66	3.53e-06	0.000321	0.18	0.14	Birth weight;	chr22:42270063	chr22:42132543~42132998:+
BRCA	cis	rs8031584	0.723	rs11632229	ENSG00000259845.1	HERC2P10	-4.66	3.53e-06	0.000321	-0.16	-0.14	Huntington's disease progression;	chr15:30887331	chr15:30815271~30844153:+
BRCA	cis	rs875971	0.545	rs1909508	ENSG00000273142.1	RP11-458F8.4	4.66	3.53e-06	0.000321	0.14	0.14	Aortic root size;	chr7:66301366	chr7:66902857~66906297:+
BRCA	cis	rs600550	0.963	rs4939329	ENSG00000275344.1	MIR6503	4.66	3.53e-06	0.000321	0.15	0.14	Lipoprotein-associated phospholipase A2 activity and mass;	chr11:60254034	chr11:60209071~60209156:-
BRCA	cis	rs62184315	0.536	rs62185897	ENSG00000253559.1	OSGEPL1-AS1	-4.66	3.53e-06	0.000321	-0.25	-0.14	Alcohol dependence (age at onset);	chr2:189721279	chr2:189762704~189765556:+
BRCA	cis	rs11051970	0.918	rs12229856	ENSG00000274964.1	RP11-817I4.1	-4.66	3.53e-06	0.000321	-0.18	-0.14	Response to tocilizumab in rheumatoid arthritis;	chr12:32378286	chr12:32339368~32340724:+
BRCA	cis	rs12497850	0.931	rs6446205	ENSG00000225399.4	RP11-3B7.1	4.66	3.53e-06	0.000321	0.14	0.14	Parkinson's disease;	chr3:48997778	chr3:49260085~49261316:+
BRCA	cis	rs256438	0.671	rs3813667	ENSG00000251050.1	RP11-168A11.4	-4.66	3.53e-06	0.000321	-0.17	-0.14	Serum thyroid-stimulating hormone levels;	chr5:80034736	chr5:80019609~80019920:+
BRCA	cis	rs349045	0.56	rs11083725	ENSG00000267058.1	RP11-15A1.3	4.66	3.54e-06	0.000321	0.16	0.14	Reading or mathematical ability;	chr19:43796424	chr19:43891804~43901805:-
BRCA	cis	rs6570726	0.935	rs411641	ENSG00000270638.1	RP3-466P17.1	4.66	3.54e-06	0.000321	0.16	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145506396	chr6:145735570~145737218:+
BRCA	cis	rs6095360	0.966	rs927160	ENSG00000222365.1	SNORD12B	-4.66	3.54e-06	0.000321	-0.16	-0.14	Intelligence (multi-trait analysis);	chr20:49038027	chr20:49280319~49280409:+
BRCA	cis	rs8031584	1	rs1474380	ENSG00000259845.1	HERC2P10	4.66	3.54e-06	0.000321	0.17	0.14	Huntington's disease progression;	chr15:30977032	chr15:30815271~30844153:+
BRCA	cis	rs2839186	0.869	rs17176513	ENSG00000239415.1	AP001469.9	4.66	3.54e-06	0.000321	0.15	0.14	Testicular germ cell tumor;	chr21:46262514	chr21:46251549~46254133:-
BRCA	cis	rs4415084	0.966	rs4571480	ENSG00000251141.4	RP11-53O19.1	-4.66	3.54e-06	0.000321	-0.13	-0.14	Breast cancer;	chr5:44687086	chr5:44744900~44808777:-
BRCA	cis	rs651907	0.557	rs3864012	ENSG00000256628.3	ZBTB11-AS1	4.66	3.54e-06	0.000322	0.18	0.14	Colorectal cancer;	chr3:101678779	chr3:101676475~101679217:+
BRCA	cis	rs10129255	0.5	rs8004923	ENSG00000211959.2	IGHV4-39	4.66	3.55e-06	0.000322	0.1	0.14	Kawasaki disease;	chr14:106785926	chr14:106421711~106422218:-
BRCA	cis	rs875971	0.545	rs6979636	ENSG00000230295.1	RP11-458F8.2	4.66	3.55e-06	0.000322	0.14	0.14	Aortic root size;	chr7:66276638	chr7:66880708~66882981:+
BRCA	cis	rs10844706	0.604	rs7964018	ENSG00000256673.1	RP11-599J14.2	4.66	3.55e-06	0.000322	0.17	0.14	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9713803	chr12:9398355~9414851:-
BRCA	cis	rs12534093	0.562	rs6461716	ENSG00000234286.1	AC006026.13	-4.66	3.55e-06	0.000322	-0.18	-0.14	Infant length;Height;	chr7:23540935	chr7:23680195~23680786:-
BRCA	cis	rs11758351	1	rs2143347	ENSG00000241549.7	GUSBP2	-4.66	3.55e-06	0.000322	-0.21	-0.14	Renal underexcretion gout;Gout;	chr6:26198266	chr6:26871484~26956554:-
BRCA	cis	rs9393777	0.92	rs13195040	ENSG00000216901.1	AL022393.7	-4.66	3.55e-06	0.000322	-0.32	-0.14	Intelligence (multi-trait analysis);	chr6:27446145	chr6:28176188~28176674:+
BRCA	cis	rs4908760	0.864	rs1953827	ENSG00000232912.4	RP5-1115A15.1	4.66	3.55e-06	0.000322	0.14	0.14	Vitiligo;	chr1:8619789	chr1:8424645~8434838:+
BRCA	cis	rs2367970	0.57	rs7123583	ENSG00000280143.1	AP000892.6	-4.66	3.55e-06	0.000322	-0.15	-0.14	HDL cholesterol;	chr11:116729305	chr11:117204967~117210292:+
BRCA	cis	rs2905347	0.757	rs2905318	ENSG00000179428.2	AC073072.5	-4.66	3.55e-06	0.000322	-0.15	-0.14	Major depression and alcohol dependence;	chr7:22657034	chr7:22725395~22727620:-
BRCA	cis	rs651907	0.557	rs11924013	ENSG00000256628.3	ZBTB11-AS1	4.66	3.55e-06	0.000322	0.18	0.14	Colorectal cancer;	chr3:101647854	chr3:101676475~101679217:+
BRCA	cis	rs755249	0.567	rs4660214	ENSG00000182109.6	RP11-69E11.4	4.66	3.55e-06	0.000322	0.2	0.14	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39265878	chr1:39522280~39546187:-
BRCA	cis	rs300890	0.513	rs10007896	ENSG00000250326.1	RP11-284M14.1	-4.66	3.55e-06	0.000322	-0.17	-0.14	Nasopharyngeal carcinoma;	chr4:143122808	chr4:142933195~143184861:-
BRCA	cis	rs375066	0.935	rs396874	ENSG00000267191.1	RP11-15A1.2	-4.66	3.55e-06	0.000322	-0.18	-0.14	Breast cancer;	chr19:43893073	chr19:43902001~43926545:+
BRCA	cis	rs6121246	0.697	rs6060446	ENSG00000230613.1	HM13-AS1	4.66	3.56e-06	0.000322	0.21	0.14	Mean corpuscular hemoglobin;	chr20:31643834	chr20:31567707~31573263:-
BRCA	cis	rs11048434	0.518	rs2377679	ENSG00000256937.1	KRT17P8	-4.66	3.56e-06	0.000322	-0.15	-0.14	Sjögren's syndrome;	chr12:9023874	chr12:9127783~9128645:+
BRCA	cis	rs6738627	1	rs6752978	ENSG00000223318.1	RNA5SP111	4.66	3.56e-06	0.000323	0.16	0.14	circulating leptin levels adjusted for BMI;Body fat percentage;circulating leptin levels;	chr2:164696432	chr2:164895677~164895777:-
BRCA	cis	rs1193	0.616	rs4832047	ENSG00000231259.4	AC125232.1	-4.66	3.56e-06	0.000323	-0.17	-0.14	High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;High light scatter reticulocyte count;	chr2:86662792	chr2:87031815~87053069:-
BRCA	cis	rs17597773	0.638	rs12139139	ENSG00000238078.1	LINC01352	-4.66	3.56e-06	0.000323	-0.17	-0.14	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220827284	chr1:220829255~220832429:+
BRCA	cis	rs1858037	0.867	rs2118305	ENSG00000237979.1	AC007389.1	4.66	3.56e-06	0.000323	0.18	0.14	Rheumatoid arthritis;	chr2:65378086	chr2:65500993~65502138:-
BRCA	cis	rs77204473	1	rs12294657	ENSG00000280143.1	AP000892.6	-4.66	3.56e-06	0.000323	-0.26	-0.14	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116936652	chr11:117204967~117210292:+
BRCA	cis	rs77204473	1	rs77136879	ENSG00000280143.1	AP000892.6	-4.66	3.56e-06	0.000323	-0.26	-0.14	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116937737	chr11:117204967~117210292:+
BRCA	cis	rs77204473	1	rs7480278	ENSG00000280143.1	AP000892.6	-4.66	3.56e-06	0.000323	-0.26	-0.14	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116939073	chr11:117204967~117210292:+
BRCA	cis	rs77204473	1	rs80015203	ENSG00000280143.1	AP000892.6	-4.66	3.56e-06	0.000323	-0.26	-0.14	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116940190	chr11:117204967~117210292:+
BRCA	cis	rs77204473	1	rs117877581	ENSG00000280143.1	AP000892.6	-4.66	3.56e-06	0.000323	-0.26	-0.14	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116940238	chr11:117204967~117210292:+
BRCA	cis	rs77204473	1	rs116597701	ENSG00000280143.1	AP000892.6	-4.66	3.56e-06	0.000323	-0.26	-0.14	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116940771	chr11:117204967~117210292:+
BRCA	cis	rs77204473	1	rs78066444	ENSG00000280143.1	AP000892.6	-4.66	3.56e-06	0.000323	-0.26	-0.14	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116941342	chr11:117204967~117210292:+
BRCA	cis	rs7772486	0.79	rs9390365	ENSG00000270638.1	RP3-466P17.1	-4.66	3.56e-06	0.000323	-0.17	-0.14	Lobe attachment (rater-scored or self-reported);	chr6:145914490	chr6:145735570~145737218:+
BRCA	cis	rs390966	0.585	rs13420242	ENSG00000205847.5	OR7E91P	-4.66	3.56e-06	0.000323	-0.22	-0.14	Erythema nodosum in inflammatory bowel disease;	chr2:71036638	chr2:71029028~71029893:+
BRCA	cis	rs7674212	0.541	rs2251322	ENSG00000251288.2	RP11-10L12.2	-4.66	3.56e-06	0.000323	-0.17	-0.14	Type 2 diabetes;	chr4:103158267	chr4:102751401~102752641:+
BRCA	cis	rs7674212	0.57	rs2251634	ENSG00000251288.2	RP11-10L12.2	-4.66	3.56e-06	0.000323	-0.17	-0.14	Type 2 diabetes;	chr4:103161192	chr4:102751401~102752641:+
BRCA	cis	rs4489787	0.892	rs2731101	ENSG00000240399.1	RP1-228P16.1	4.66	3.57e-06	0.000323	0.24	0.14	Prostate cancer (SNP x SNP interaction);	chr12:48510456	chr12:48054813~48055591:-
BRCA	cis	rs7200786	0.692	rs1700820	ENSG00000274038.1	RP11-66H6.4	4.66	3.57e-06	0.000323	0.16	0.14	Systemic lupus erythematosus;Multiple sclerosis;	chr16:10962761	chr16:11056556~11057034:+
BRCA	cis	rs9467773	0.935	rs11752946	ENSG00000241549.7	GUSBP2	4.66	3.57e-06	0.000323	0.16	0.14	Intelligence (multi-trait analysis);	chr6:26560136	chr6:26871484~26956554:-
BRCA	cis	rs2905347	0.895	rs2961280	ENSG00000179428.2	AC073072.5	4.66	3.57e-06	0.000323	0.15	0.14	Major depression and alcohol dependence;	chr7:22600098	chr7:22725395~22727620:-
BRCA	cis	rs6714710	0.663	rs71429376	ENSG00000230606.9	AC159540.1	-4.66	3.57e-06	0.000323	-0.16	-0.14	Posterior cortical atrophy and Alzheimer's disease;	chr2:97917949	chr2:97416165~97433527:-
BRCA	cis	rs4936099	0.766	rs10894192	ENSG00000175773.11	RP11-121M22.1	4.66	3.57e-06	0.000324	0.16	0.14	Optic cup area;Vertical cup-disc ratio;	chr11:130396222	chr11:130314993~130403657:+
BRCA	cis	rs875971	0.545	rs73142265	ENSG00000273142.1	RP11-458F8.4	4.66	3.57e-06	0.000324	0.14	0.14	Aortic root size;	chr7:66234510	chr7:66902857~66906297:+
BRCA	cis	rs10829156	0.57	rs7904365	ENSG00000240291.1	RP11-499P20.2	4.66	3.58e-06	0.000324	0.16	0.14	Sudden cardiac arrest;	chr10:18542375	chr10:18513115~18545651:-
BRCA	cis	rs17428076	0.874	rs17615262	ENSG00000228389.1	AC068039.4	-4.66	3.58e-06	0.000324	-0.2	-0.14	Myopia;	chr2:171826971	chr2:171773482~171775844:+
BRCA	cis	rs2243480	1	rs464895	ENSG00000275400.1	RP4-756H11.5	4.66	3.58e-06	0.000324	0.27	0.14	Diabetic kidney disease;	chr7:66062119	chr7:66553805~66554199:-
BRCA	cis	rs13113518	1	rs13122619	ENSG00000249700.7	SRD5A3-AS1	4.66	3.58e-06	0.000324	0.18	0.14	Height;	chr4:55479339	chr4:55363971~55395847:-
BRCA	cis	rs300890	0.76	rs1532981	ENSG00000250326.1	RP11-284M14.1	-4.66	3.58e-06	0.000324	-0.16	-0.14	Nasopharyngeal carcinoma;	chr4:143294193	chr4:142933195~143184861:-
BRCA	cis	rs4282054	0.631	rs13081155	ENSG00000243224.1	RP5-1157M23.2	-4.66	3.58e-06	0.000324	-0.15	-0.14	Cognitive function;	chr3:52698413	chr3:52239258~52241097:+
BRCA	cis	rs7923837	1	rs7923866	ENSG00000236493.2	EIF2S2P3	4.66	3.58e-06	0.000324	0.2	0.14	Multiple sclerosis;Body mass index;	chr10:92722319	chr10:92668745~92669743:-
BRCA	cis	rs11758351	0.66	rs11755943	ENSG00000241549.7	GUSBP2	-4.66	3.58e-06	0.000325	-0.2	-0.14	Renal underexcretion gout;Gout;	chr6:26211140	chr6:26871484~26956554:-
BRCA	cis	rs2073316	0.56	rs60441502	ENSG00000272716.1	RP11-563N4.1	4.66	3.58e-06	0.000325	0.16	0.14	Interleukin-18 levels;	chr2:31476146	chr2:32165046~32165757:-
BRCA	cis	rs9818758	0.556	rs9835439	ENSG00000270441.1	RP11-694I15.7	4.66	3.58e-06	0.000325	0.28	0.14	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49182897	chr3:49140086~49160851:-
BRCA	cis	rs2243480	1	rs313809	ENSG00000226002.1	RP11-460N20.5	-4.66	3.58e-06	0.000325	-0.24	-0.14	Diabetic kidney disease;	chr7:66034996	chr7:65084103~65100232:+
BRCA	cis	rs7487075	0.647	rs4077708	ENSG00000274723.1	RP11-618L22.1	4.66	3.58e-06	0.000325	0.19	0.14	Itch intensity from mosquito bite;	chr12:46463590	chr12:46970504~46972155:+
BRCA	cis	rs1395	0.71	rs58965570	ENSG00000234072.1	AC074117.10	-4.66	3.58e-06	0.000325	-0.16	-0.14	Blood metabolite levels;	chr2:27258592	chr2:27356246~27367622:+
BRCA	cis	rs67981189	0.513	rs7154395	ENSG00000269927.1	RP6-91H8.3	4.66	3.59e-06	0.000325	0.17	0.14	Schizophrenia;	chr14:71099583	chr14:71141125~71143253:-
BRCA	cis	rs78487399	0.908	rs6717791	ENSG00000234936.1	AC010883.5	4.66	3.59e-06	0.000325	0.2	0.14	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43594867	chr2:43229573~43233394:+
BRCA	cis	rs17684571	0.7	rs13205667	ENSG00000231441.1	RP11-472M19.2	4.66	3.59e-06	0.000325	0.25	0.14	Schizophrenia;	chr6:56775176	chr6:56844002~56864078:+
BRCA	cis	rs17684571	0.7	rs13200559	ENSG00000231441.1	RP11-472M19.2	4.66	3.59e-06	0.000325	0.25	0.14	Schizophrenia;	chr6:56777522	chr6:56844002~56864078:+
BRCA	cis	rs2303319	0.504	rs62189007	ENSG00000227403.1	AC009299.3	4.66	3.59e-06	0.000325	0.35	0.14	Cognitive function;	chr2:161717813	chr2:161244739~161249050:+
BRCA	cis	rs2303319	0.504	rs62189008	ENSG00000227403.1	AC009299.3	4.66	3.59e-06	0.000325	0.35	0.14	Cognitive function;	chr2:161717926	chr2:161244739~161249050:+
BRCA	cis	rs2303319	0.504	rs72875596	ENSG00000227403.1	AC009299.3	4.66	3.59e-06	0.000325	0.35	0.14	Cognitive function;	chr2:161718547	chr2:161244739~161249050:+
BRCA	cis	rs2303319	0.504	rs72875598	ENSG00000227403.1	AC009299.3	4.66	3.59e-06	0.000325	0.35	0.14	Cognitive function;	chr2:161718586	chr2:161244739~161249050:+
BRCA	cis	rs2303319	0.504	rs62189009	ENSG00000227403.1	AC009299.3	4.66	3.59e-06	0.000325	0.35	0.14	Cognitive function;	chr2:161718668	chr2:161244739~161249050:+
BRCA	cis	rs7246967	0.611	rs8102927	ENSG00000198153.8	ZNF849P	-4.66	3.59e-06	0.000325	-0.24	-0.14	Bronchopulmonary dysplasia;	chr19:22696554	chr19:22685167~22686732:+
BRCA	cis	rs3858526	0.727	rs10769353	ENSG00000224295.2	AC087380.14	-4.66	3.59e-06	0.000325	-0.18	-0.14	DNA methylation (variation);	chr11:5933579	chr11:5518441~5524955:-
BRCA	cis	rs7160336	1	rs34836016	ENSG00000259065.1	RP5-1021I20.1	-4.66	3.59e-06	0.000325	-0.16	-0.14	Blood protein levels;	chr14:74160055	chr14:73787360~73803270:+
BRCA	cis	rs4578769	0.877	rs7232963	ENSG00000265939.1	UBE2CP2	4.66	3.59e-06	0.000325	0.17	0.14	Eosinophil percentage of white cells;	chr18:23011231	chr18:22900486~22900995:-
BRCA	cis	rs17597773	0.638	rs6668666	ENSG00000238078.1	LINC01352	-4.66	3.59e-06	0.000325	-0.17	-0.14	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220826069	chr1:220829255~220832429:+
BRCA	cis	rs1713985	0.925	rs1713992	ENSG00000269949.1	RP11-738E22.3	-4.66	3.59e-06	0.000326	-0.3	-0.14	Age-related macular degeneration;	chr4:56961498	chr4:56960927~56961373:-
BRCA	cis	rs2115630	0.755	rs7169629	ENSG00000259728.4	LINC00933	4.66	3.59e-06	0.000326	0.16	0.14	P wave terminal force;	chr15:84648043	chr15:84570649~84580175:+
BRCA	cis	rs2243480	1	rs781150	ENSG00000226002.1	RP11-460N20.5	-4.66	3.59e-06	0.000326	-0.24	-0.14	Diabetic kidney disease;	chr7:66015986	chr7:65084103~65100232:+
BRCA	cis	rs2243480	1	rs313798	ENSG00000226002.1	RP11-460N20.5	-4.66	3.59e-06	0.000326	-0.24	-0.14	Diabetic kidney disease;	chr7:66028044	chr7:65084103~65100232:+
BRCA	cis	rs17221829	0.733	rs11018725	ENSG00000280385.1	AP000648.5	-4.66	3.59e-06	0.000326	-0.16	-0.14	Anxiety in major depressive disorder;	chr11:89680083	chr11:90193614~90198120:+
BRCA	cis	rs6570726	0.791	rs378937	ENSG00000270638.1	RP3-466P17.1	4.66	3.6e-06	0.000326	0.17	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145513609	chr6:145735570~145737218:+
BRCA	cis	rs8098244	0.565	rs2850205	ENSG00000264745.1	TTC39C-AS1	4.66	3.6e-06	0.000326	0.17	0.14	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23677531	chr18:23994213~24015339:-
BRCA	cis	rs6696239	0.531	rs2644140	ENSG00000227711.2	RP11-275O4.5	-4.66	3.6e-06	0.000326	-0.17	-0.14	Height;	chr1:227509680	chr1:227509028~227520477:-
BRCA	cis	rs6696239	0.531	rs2018401	ENSG00000227711.2	RP11-275O4.5	-4.66	3.6e-06	0.000326	-0.17	-0.14	Height;	chr1:227509952	chr1:227509028~227520477:-
BRCA	cis	rs1858037	0.867	rs72621551	ENSG00000281920.1	RP11-418H16.1	4.66	3.6e-06	0.000326	0.18	0.14	Rheumatoid arthritis;	chr2:65388087	chr2:65623272~65628424:+
BRCA	cis	rs7074356	0.569	rs17102596	ENSG00000225484.5	NUTM2B-AS1	-4.66	3.6e-06	0.000326	-0.24	-0.14	Borderline personality disorder;	chr10:80275417	chr10:79663088~79826594:-
BRCA	cis	rs1429411	1	rs1429411	ENSG00000231621.1	AC013264.2	4.66	3.6e-06	0.000326	0.14	0.14	Interferon alpha levels in systemic lupus erythematosus;	chr2:197279278	chr2:197197991~197199273:+
BRCA	cis	rs300890	0.56	rs763918	ENSG00000250326.1	RP11-284M14.1	-4.66	3.61e-06	0.000327	-0.16	-0.14	Nasopharyngeal carcinoma;	chr4:143271964	chr4:142933195~143184861:-
BRCA	cis	rs300890	0.56	rs13114280	ENSG00000250326.1	RP11-284M14.1	-4.66	3.61e-06	0.000327	-0.16	-0.14	Nasopharyngeal carcinoma;	chr4:143272542	chr4:142933195~143184861:-
BRCA	cis	rs494453	0.807	rs2786966	ENSG00000227811.2	FAM212B-AS1	4.66	3.61e-06	0.000327	0.18	0.14	Osteoporosis-related phenotypes;	chr1:111638035	chr1:111739841~111747798:+
BRCA	cis	rs9921338	0.887	rs6498183	ENSG00000262703.1	RP11-485G7.6	-4.66	3.61e-06	0.000327	-0.18	-0.14	Vein graft stenosis in coronary artery bypass grafting;	chr16:11337051	chr16:11348143~11349321:-
BRCA	cis	rs10504130	0.932	rs79067987	ENSG00000253844.1	RP11-546K22.1	-4.66	3.61e-06	0.000327	-0.26	-0.14	Venous thromboembolism (SNP x SNP interaction);	chr8:51935697	chr8:51961458~52022974:+
BRCA	cis	rs6847067	0.794	rs34239067	ENSG00000180769.7	WDFY3-AS2	4.66	3.61e-06	0.000327	0.13	0.14	Oropharynx cancer;	chr4:85030551	chr4:84965682~85011277:+
BRCA	cis	rs2446066	0.872	rs11170549	ENSG00000257379.1	RP11-793H13.8	4.66	3.61e-06	0.000327	0.22	0.14	Red blood cell count;	chr12:53420596	chr12:53441741~53467528:+
BRCA	cis	rs2446066	0.872	rs11170550	ENSG00000257379.1	RP11-793H13.8	4.66	3.61e-06	0.000327	0.22	0.14	Red blood cell count;	chr12:53420930	chr12:53441741~53467528:+
BRCA	cis	rs1713985	0.8	rs10032625	ENSG00000269949.1	RP11-738E22.3	-4.66	3.61e-06	0.000327	-0.3	-0.14	Age-related macular degeneration;	chr4:56963048	chr4:56960927~56961373:-
BRCA	cis	rs1005277	0.54	rs2224248	ENSG00000263064.2	RP11-291L22.7	4.66	3.61e-06	0.000327	0.17	0.14	Extrinsic epigenetic age acceleration;	chr10:38162958	chr10:38448689~38448949:+
BRCA	cis	rs2524005	1	rs2524005	ENSG00000243753.4	HLA-L	-4.66	3.61e-06	0.000327	-0.23	-0.14	Bipolar disorder and schizophrenia;	chr6:29931900	chr6:30259584~30293014:+
BRCA	cis	rs867186	1	rs10485508	ENSG00000126005.14	MMP24-AS1	-4.66	3.61e-06	0.000327	-0.27	-0.14	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35017295	chr20:35216462~35278131:-
BRCA	cis	rs42490	0.689	rs43228	ENSG00000251136.7	RP11-37B2.1	-4.66	3.61e-06	0.000327	-0.13	-0.14	Leprosy;	chr8:89816790	chr8:89609409~89757727:-
BRCA	cis	rs300890	0.516	rs476417	ENSG00000250326.1	RP11-284M14.1	-4.66	3.61e-06	0.000327	-0.17	-0.14	Nasopharyngeal carcinoma;	chr4:143298339	chr4:142933195~143184861:-
BRCA	cis	rs17507216	0.718	rs72751657	ENSG00000259429.4	UBE2Q2P2	-4.66	3.61e-06	0.000327	-0.19	-0.14	Excessive daytime sleepiness;	chr15:82581259	chr15:82355142~82420075:+
BRCA	cis	rs11976180	1	rs2961132	ENSG00000244479.5	OR2A1-AS1	4.66	3.62e-06	0.000328	0.19	0.14	Obesity-related traits;	chr7:144071035	chr7:144251264~144356181:-
BRCA	cis	rs875971	0.862	rs778684	ENSG00000273448.1	RP11-166O4.6	4.66	3.62e-06	0.000328	0.13	0.14	Aortic root size;	chr7:66371416	chr7:67333047~67334383:+
BRCA	cis	rs13113518	0.841	rs11133400	ENSG00000249700.7	SRD5A3-AS1	4.66	3.62e-06	0.000328	0.18	0.14	Height;	chr4:55578787	chr4:55363971~55395847:-
BRCA	cis	rs370915	0.501	rs7692658	ENSG00000250971.1	RP11-696F12.1	4.66	3.62e-06	0.000328	0.15	0.14	Gout;	chr4:186827871	chr4:187060099~187060930:+
BRCA	cis	rs2243480	1	rs1638734	ENSG00000222364.1	RNU6-96P	-4.66	3.62e-06	0.000328	-0.26	-0.14	Diabetic kidney disease;	chr7:66632552	chr7:66395191~66395286:+
BRCA	cis	rs172166	0.694	rs203884	ENSG00000219392.1	RP1-265C24.5	-4.66	3.62e-06	0.000328	-0.19	-0.14	Cardiac Troponin-T levels;	chr6:28109596	chr6:28115628~28116551:+
BRCA	cis	rs6686842	0.866	rs2802550	ENSG00000235358.1	RP11-399E6.1	4.66	3.62e-06	0.000328	0.18	0.14	Height;	chr1:41031956	chr1:41242373~41284861:+
BRCA	cis	rs11239930	0.517	rs632861	ENSG00000278811.3	LINC00624	4.66	3.62e-06	0.000328	0.17	0.14	AIDS progression;	chr1:147079826	chr1:147258885~147517875:-
BRCA	cis	rs7772486	0.875	rs9322045	ENSG00000270638.1	RP3-466P17.1	4.66	3.63e-06	0.000328	0.16	0.14	Lobe attachment (rater-scored or self-reported);	chr6:146063814	chr6:145735570~145737218:+
BRCA	cis	rs7618915	0.547	rs11130323	ENSG00000243224.1	RP5-1157M23.2	-4.66	3.63e-06	0.000328	-0.16	-0.14	Bipolar disorder;	chr3:52736261	chr3:52239258~52241097:+
BRCA	cis	rs3213958	0.574	rs17210963	ENSG00000249274.1	PDLIM1P4	-4.66	3.63e-06	0.000328	-0.24	-0.14	Blood protein levels;	chr3:98778815	chr3:98782188~98783193:+
BRCA	cis	rs516805	0.528	rs2606632	ENSG00000279453.1	RP3-425C14.4	-4.66	3.63e-06	0.000328	-0.2	-0.14	Lymphocyte counts;	chr6:122099728	chr6:122436789~122439223:-
BRCA	cis	rs516805	0.528	rs2606634	ENSG00000279453.1	RP3-425C14.4	-4.66	3.63e-06	0.000328	-0.2	-0.14	Lymphocyte counts;	chr6:122100337	chr6:122436789~122439223:-
BRCA	cis	rs2179367	0.6	rs9498354	ENSG00000223701.3	RAET1E-AS1	-4.66	3.63e-06	0.000328	-0.21	-0.14	Dupuytren's disease;	chr6:149441715	chr6:149884431~149919508:+
BRCA	cis	rs2243480	1	rs4718315	ENSG00000275400.1	RP4-756H11.5	-4.66	3.63e-06	0.000328	-0.26	-0.14	Diabetic kidney disease;	chr7:66183554	chr7:66553805~66554199:-
BRCA	cis	rs2243480	1	rs4718316	ENSG00000275400.1	RP4-756H11.5	-4.66	3.63e-06	0.000328	-0.26	-0.14	Diabetic kidney disease;	chr7:66183744	chr7:66553805~66554199:-
BRCA	cis	rs12497850	0.931	rs6414613	ENSG00000225399.4	RP11-3B7.1	4.66	3.63e-06	0.000328	0.14	0.14	Parkinson's disease;	chr3:48998452	chr3:49260085~49261316:+
BRCA	cis	rs7918232	0.941	rs788220	ENSG00000262412.1	RP11-85G18.6	-4.66	3.63e-06	0.000328	-0.24	-0.14	Breast cancer;	chr10:27158276	chr10:27243130~27250804:+
BRCA	cis	rs10129255	0.957	rs12590799	ENSG00000280411.1	IGHV1-69-2	-4.66	3.63e-06	0.000329	-0.1	-0.14	Kawasaki disease;	chr14:106779713	chr14:106762092~106762588:-
BRCA	cis	rs13236243	0.632	rs713150	ENSG00000237773.4	AC003075.4	-4.66	3.63e-06	0.000329	-0.21	-0.14	Sensory disturbances after bilateral sagittal split ramus osteotomy;	chr7:17300533	chr7:17279834~17299357:-
BRCA	cis	rs7772486	0.79	rs6917482	ENSG00000270638.1	RP3-466P17.1	-4.66	3.63e-06	0.000329	-0.17	-0.14	Lobe attachment (rater-scored or self-reported);	chr6:145922445	chr6:145735570~145737218:+
BRCA	cis	rs7772486	0.754	rs4566902	ENSG00000270638.1	RP3-466P17.1	-4.66	3.63e-06	0.000329	-0.17	-0.14	Lobe attachment (rater-scored or self-reported);	chr6:145922992	chr6:145735570~145737218:+
BRCA	cis	rs6657613	0.68	rs11203287	ENSG00000186301.8	MST1P2	4.66	3.63e-06	0.000329	0.12	0.14	Hip circumference adjusted for BMI;	chr1:17045902	chr1:16645622~16650289:+
BRCA	cis	rs2904967	0.929	rs592050	ENSG00000255200.1	AP003068.18	4.66	3.63e-06	0.000329	0.23	0.14	Mean corpuscular volume;	chr11:65262718	chr11:65174117~65176470:-
BRCA	cis	rs2904967	0.929	rs554122	ENSG00000255200.1	AP003068.18	4.66	3.63e-06	0.000329	0.23	0.14	Mean corpuscular volume;	chr11:65266403	chr11:65174117~65176470:-
BRCA	cis	rs2904967	0.852	rs488289	ENSG00000255200.1	AP003068.18	4.66	3.63e-06	0.000329	0.23	0.14	Mean corpuscular volume;	chr11:65271793	chr11:65174117~65176470:-
BRCA	cis	rs6847067	0.794	rs9790649	ENSG00000180769.7	WDFY3-AS2	4.66	3.63e-06	0.000329	0.13	0.14	Oropharynx cancer;	chr4:85032830	chr4:84965682~85011277:+
BRCA	cis	rs35146811	0.555	rs1981549	ENSG00000235713.1	RP4-604G5.3	4.66	3.63e-06	0.000329	0.17	0.14	Coronary artery disease;	chr7:99944013	chr7:99992397~99993050:+
BRCA	cis	rs35146811	0.555	rs1981550	ENSG00000235713.1	RP4-604G5.3	4.66	3.63e-06	0.000329	0.17	0.14	Coronary artery disease;	chr7:99944329	chr7:99992397~99993050:+
BRCA	cis	rs6570726	0.935	rs385134	ENSG00000270638.1	RP3-466P17.1	4.66	3.63e-06	0.000329	0.16	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145529869	chr6:145735570~145737218:+
BRCA	cis	rs6570726	0.935	rs415590	ENSG00000270638.1	RP3-466P17.1	4.66	3.63e-06	0.000329	0.16	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145530108	chr6:145735570~145737218:+
BRCA	cis	rs875971	0.928	rs2036263	ENSG00000273448.1	RP11-166O4.6	-4.66	3.64e-06	0.000329	-0.13	-0.14	Aortic root size;	chr7:66335210	chr7:67333047~67334383:+
BRCA	cis	rs875971	0.862	rs10240949	ENSG00000273448.1	RP11-166O4.6	-4.66	3.64e-06	0.000329	-0.13	-0.14	Aortic root size;	chr7:66339430	chr7:67333047~67334383:+
BRCA	cis	rs875971	0.862	rs7782704	ENSG00000273448.1	RP11-166O4.6	-4.66	3.64e-06	0.000329	-0.13	-0.14	Aortic root size;	chr7:66340379	chr7:67333047~67334383:+
BRCA	cis	rs11239930	0.517	rs493000	ENSG00000278811.3	LINC00624	4.66	3.64e-06	0.000329	0.17	0.14	AIDS progression;	chr1:147077979	chr1:147258885~147517875:-
BRCA	cis	rs8054556	0.647	rs4788211	ENSG00000261367.1	RP11-455F5.4	-4.66	3.64e-06	0.000329	-0.16	-0.14	Autism spectrum disorder or schizophrenia;	chr16:30004244	chr16:30107675~30110541:+
BRCA	cis	rs6723226	0.772	rs2366894	ENSG00000276334.1	AL133243.1	4.66	3.64e-06	0.000329	0.18	0.14	Intelligence (multi-trait analysis);	chr2:32488639	chr2:32521927~32523547:+
BRCA	cis	rs8054556	0.787	rs12325400	ENSG00000183604.13	SMG1P5	-4.66	3.64e-06	0.000329	-0.14	-0.14	Autism spectrum disorder or schizophrenia;	chr16:30012465	chr16:30267553~30335374:-
BRCA	cis	rs10504130	0.53	rs4292674	ENSG00000272024.1	RP11-546K22.3	-4.66	3.64e-06	0.000329	-0.21	-0.14	Venous thromboembolism (SNP x SNP interaction);	chr8:51767212	chr8:51950284~51950690:+
BRCA	cis	rs10504130	0.569	rs4292675	ENSG00000272024.1	RP11-546K22.3	-4.66	3.64e-06	0.000329	-0.21	-0.14	Venous thromboembolism (SNP x SNP interaction);	chr8:51767414	chr8:51950284~51950690:+
BRCA	cis	rs10504130	0.569	rs76746661	ENSG00000272024.1	RP11-546K22.3	-4.66	3.64e-06	0.000329	-0.21	-0.14	Venous thromboembolism (SNP x SNP interaction);	chr8:51769206	chr8:51950284~51950690:+
BRCA	cis	rs10504130	0.66	rs79691523	ENSG00000272024.1	RP11-546K22.3	-4.66	3.64e-06	0.000329	-0.21	-0.14	Venous thromboembolism (SNP x SNP interaction);	chr8:51772173	chr8:51950284~51950690:+
BRCA	cis	rs3102460	0.507	rs3123706	ENSG00000225401.2	TGIF2P1	-4.66	3.64e-06	0.000329	-0.16	-0.14	Obesity-related traits;	chr1:244390492	chr1:244394976~244395660:-
BRCA	cis	rs1075265	0.692	rs805361	ENSG00000235937.1	AC008280.1	4.66	3.64e-06	0.000329	0.16	0.14	Chronotype;Morning vs. evening chronotype;	chr2:53938709	chr2:54029552~54030682:-
BRCA	cis	rs5758659	0.714	rs5758589	ENSG00000270083.1	RP1-257I20.14	-4.66	3.64e-06	0.000329	-0.16	-0.14	Cognitive function;	chr22:42122378	chr22:42089630~42090028:-
BRCA	cis	rs2153535	0.58	rs6921036	ENSG00000251164.1	HULC	-4.66	3.64e-06	0.00033	-0.18	-0.14	Motion sickness;	chr6:8455167	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.58	rs6926759	ENSG00000251164.1	HULC	-4.66	3.64e-06	0.00033	-0.18	-0.14	Motion sickness;	chr6:8455943	chr6:8652137~8653846:+
BRCA	cis	rs3768617	0.51	rs3768616	ENSG00000224468.3	RP11-181K3.4	-4.66	3.64e-06	0.00033	-0.15	-0.14	Fuchs's corneal dystrophy;	chr1:183134416	chr1:183138402~183141282:-
BRCA	cis	rs853679	0.76	rs9468317	ENSG00000280107.1	AL022393.9	-4.66	3.64e-06	0.00033	-0.23	-0.14	Depression;	chr6:28230678	chr6:28170845~28172521:+
BRCA	cis	rs2273156	0.929	rs12894820	ENSG00000226677.3	IGBP1P1	4.66	3.64e-06	0.00033	0.21	0.14	Immunoglobulin light chain (AL) amyloidosis;	chr14:34966319	chr14:34939324~34940332:+
BRCA	cis	rs28374715	0.733	rs9568	ENSG00000247556.5	OIP5-AS1	4.66	3.65e-06	0.00033	0.16	0.14	Ulcerative colitis;	chr15:41281414	chr15:41283990~41309737:+
BRCA	cis	rs1005277	0.579	rs2505257	ENSG00000099251.13	HSD17B7P2	4.66	3.65e-06	0.00033	0.16	0.14	Extrinsic epigenetic age acceleration;	chr10:38083736	chr10:38356380~38378505:+
BRCA	cis	rs13326165	0.585	rs17052052	ENSG00000243224.1	RP5-1157M23.2	-4.66	3.65e-06	0.00033	-0.23	-0.14	HDL cholesterol levels;HDL cholesterol;	chr3:52297777	chr3:52239258~52241097:+
BRCA	cis	rs6431644	0.731	rs2361515	ENSG00000224287.2	MSL3P1	4.66	3.65e-06	0.00033	0.18	0.14	Left atrial antero-posterior diameter;	chr2:233882452	chr2:233865437~233868444:-
BRCA	cis	rs12435908	1	rs59685862	ENSG00000276116.2	FUT8-AS1	-4.66	3.65e-06	0.00033	-0.22	-0.14	Ischemic stroke;	chr14:65613412	chr14:65411170~65412690:-
BRCA	cis	rs11977715	0.538	rs10248407	ENSG00000233942.1	AC004012.1	-4.66	3.65e-06	0.00033	-0.18	-0.14	Middle childhood and early adolescence aggressive behavior;	chr7:95499441	chr7:95471835~95473998:+
BRCA	cis	rs875971	0.767	rs1643394	ENSG00000273448.1	RP11-166O4.6	4.66	3.65e-06	0.00033	0.13	0.14	Aortic root size;	chr7:66371107	chr7:67333047~67334383:+
BRCA	cis	rs1656368	0.726	rs17628988	ENSG00000279311.1	RP11-170K4.2	4.66	3.65e-06	0.000331	0.18	0.14	Lobe attachment (rater-scored or self-reported);	chr3:158539605	chr3:158869898~158871821:+
BRCA	cis	rs1656368	0.726	rs73154329	ENSG00000279311.1	RP11-170K4.2	4.66	3.65e-06	0.000331	0.18	0.14	Lobe attachment (rater-scored or self-reported);	chr3:158539973	chr3:158869898~158871821:+
BRCA	cis	rs1559040	0.79	rs55666400	ENSG00000272156.1	RP11-477N3.1	-4.66	3.65e-06	0.000331	-0.28	-0.14	Sudden cardiac arrest;	chr2:54029350	chr2:54082554~54085066:+
BRCA	cis	rs1559040	0.79	rs115324582	ENSG00000272156.1	RP11-477N3.1	-4.66	3.65e-06	0.000331	-0.28	-0.14	Sudden cardiac arrest;	chr2:54037461	chr2:54082554~54085066:+
BRCA	cis	rs1559040	0.79	rs28416116	ENSG00000272156.1	RP11-477N3.1	-4.66	3.65e-06	0.000331	-0.28	-0.14	Sudden cardiac arrest;	chr2:54039080	chr2:54082554~54085066:+
BRCA	cis	rs8067545	0.641	rs119672	ENSG00000270091.1	RP11-78O7.2	-4.66	3.65e-06	0.000331	-0.14	-0.14	Schizophrenia;	chr17:19915288	chr17:19896590~19897287:-
BRCA	cis	rs7428	0.545	rs2366404	ENSG00000273196.1	RP11-717A5.2	4.65	3.66e-06	0.000331	0.16	0.14	Ear protrusion;	chr2:85324656	chr2:85387074~85387146:-
BRCA	cis	rs7119	0.651	rs12917044	ENSG00000259362.2	RP11-307C19.1	4.65	3.66e-06	0.000331	0.19	0.14	Type 2 diabetes;	chr15:77557804	chr15:77525540~77534110:+
BRCA	cis	rs4143844	0.867	rs35324423	ENSG00000259251.2	RP11-643M14.1	4.65	3.66e-06	0.000331	0.35	0.14	Bipolar disorder and schizophrenia;	chr15:62019946	chr15:62060503~62062434:+
BRCA	cis	rs4143844	0.867	rs4143845	ENSG00000259251.2	RP11-643M14.1	4.65	3.66e-06	0.000331	0.35	0.14	Bipolar disorder and schizophrenia;	chr15:62020894	chr15:62060503~62062434:+
BRCA	cis	rs4143844	0.867	rs36126734	ENSG00000259251.2	RP11-643M14.1	4.65	3.66e-06	0.000331	0.35	0.14	Bipolar disorder and schizophrenia;	chr15:62022710	chr15:62060503~62062434:+
BRCA	cis	rs4143844	0.867	rs34088392	ENSG00000259251.2	RP11-643M14.1	4.65	3.66e-06	0.000331	0.35	0.14	Bipolar disorder and schizophrenia;	chr15:62022843	chr15:62060503~62062434:+
BRCA	cis	rs4650994	1	rs4077194	ENSG00000273384.1	RP5-1098D14.1	-4.65	3.66e-06	0.000331	-0.17	-0.14	HDL cholesterol;HDL cholesterol levels;	chr1:178564697	chr1:178651706~178652282:+
BRCA	cis	rs7107174	1	rs1017908	ENSG00000251323.2	RP11-452H21.4	4.65	3.66e-06	0.000331	0.21	0.14	Testicular germ cell tumor;	chr11:78237049	chr11:78423982~78429836:-
BRCA	cis	rs55704346	0.74	rs3733548	ENSG00000281501.1	SEPSECS-AS1	4.65	3.66e-06	0.000331	0.17	0.14	Tonsillectomy;	chr4:25154861	chr4:25160641~25201440:+
BRCA	cis	rs6573604	0.681	rs28595734	ENSG00000276116.2	FUT8-AS1	-4.65	3.66e-06	0.000331	-0.22	-0.14	N-glycan levels;	chr14:65325551	chr14:65411170~65412690:-
BRCA	cis	rs10916772	0.609	rs12024068	ENSG00000236963.4	LINC01141	-4.65	3.66e-06	0.000331	-0.26	-0.14	Psychosis proneness (perceptual aberration scale);	chr1:20383026	chr1:20360579~20431234:-
BRCA	cis	rs10129255	0.957	rs10138532	ENSG00000211974.3	IGHV2-70	4.65	3.66e-06	0.000331	0.16	0.14	Kawasaki disease;	chr14:106803901	chr14:106723574~106724093:-
BRCA	cis	rs1223397	0.651	rs2439549	ENSG00000215022.6	RP1-257A7.4	-4.65	3.66e-06	0.000331	-0.17	-0.14	Blood pressure;	chr6:13315229	chr6:13264861~13295586:-
BRCA	cis	rs4831760	0.963	rs2098507	ENSG00000250483.1	PPM1AP1	-4.65	3.66e-06	0.000331	-0.2	-0.14	Pulmonary function decline;	chr8:15682854	chr8:15806149~15807283:-
BRCA	cis	rs35612822	0.723	rs4674084	ENSG00000232485.2	AC098820.3	-4.65	3.66e-06	0.000331	-0.17	-0.14	Kidney disease (early stage) in type 1 diabetes;	chr2:216405231	chr2:216479030~216498761:-
BRCA	cis	rs12591650	0.556	rs12914092	ENSG00000259591.1	RP11-554D20.1	4.65	3.67e-06	0.000331	0.24	0.14	Subcutaneous adipose tissue;	chr15:60792131	chr15:60763906~60765625:+
BRCA	cis	rs7011507	0.582	rs1912568	ENSG00000279881.1	RP11-513O13.1	-4.65	3.67e-06	0.000331	-0.23	-0.14	Inflammatory bowel disease;Ulcerative colitis;	chr8:48340249	chr8:48428143~48431041:-
BRCA	cis	rs9543976	0.623	rs6562918	ENSG00000261105.4	LMO7-AS1	4.65	3.67e-06	0.000331	0.22	0.14	Diabetic retinopathy;	chr13:75600441	chr13:75604700~75635994:-
BRCA	cis	rs2562456	0.833	rs2562487	ENSG00000268658.4	LINC00664	4.65	3.67e-06	0.000331	0.23	0.14	Pain;	chr19:21468580	chr19:21483374~21503238:+
BRCA	cis	rs7474896	0.583	rs7071147	ENSG00000120555.12	SEPT7P9	4.65	3.67e-06	0.000331	0.2	0.14	Obesity (extreme);	chr10:37714448	chr10:38383069~38402916:-
BRCA	cis	rs13113518	1	rs55699500	ENSG00000273257.1	RP11-177J6.1	4.65	3.67e-06	0.000332	0.18	0.14	Height;	chr4:55540912	chr4:55387949~55388271:+
BRCA	cis	rs3845817	0.703	rs702919	ENSG00000237979.1	AC007389.1	4.65	3.67e-06	0.000332	0.17	0.14	Bipolar disorder;	chr2:65545157	chr2:65500993~65502138:-
BRCA	cis	rs10833905	0.938	rs11026959	ENSG00000246225.5	RP11-17A1.3	4.65	3.67e-06	0.000332	0.21	0.14	Sudden cardiac arrest;	chr11:23067229	chr11:22829380~22945393:+
BRCA	cis	rs1499614	1	rs1638731	ENSG00000222364.1	RNU6-96P	-4.65	3.67e-06	0.000332	-0.27	-0.14	Gout;	chr7:66679692	chr7:66395191~66395286:+
BRCA	cis	rs1499614	1	rs1882655	ENSG00000222364.1	RNU6-96P	4.65	3.67e-06	0.000332	0.27	0.14	Gout;	chr7:66682070	chr7:66395191~66395286:+
BRCA	cis	rs1499614	0.831	rs3800822	ENSG00000222364.1	RNU6-96P	4.65	3.67e-06	0.000332	0.27	0.14	Gout;	chr7:66682162	chr7:66395191~66395286:+
BRCA	cis	rs4787491	0.729	rs11642399	ENSG00000261367.1	RP11-455F5.4	-4.65	3.67e-06	0.000332	-0.16	-0.14	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30048272	chr16:30107675~30110541:+
BRCA	cis	rs7246657	0.507	rs8107654	ENSG00000276846.1	CTD-3220F14.3	4.65	3.67e-06	0.000332	0.24	0.14	Coronary artery calcification;	chr19:36962632	chr19:37314868~37315620:-
BRCA	cis	rs7246657	0.722	rs2972458	ENSG00000226686.6	LINC01535	4.65	3.68e-06	0.000332	0.21	0.14	Coronary artery calcification;	chr19:37644502	chr19:37251912~37265535:+
BRCA	cis	rs559555	0.74	rs413836	ENSG00000272716.1	RP11-563N4.1	4.65	3.68e-06	0.000332	0.16	0.14	Blood metabolite ratios;Blood metabolite levels;	chr2:31532977	chr2:32165046~32165757:-
BRCA	cis	rs7811142	0.83	rs10085549	ENSG00000078319.8	PMS2P1	-4.65	3.68e-06	0.000333	-0.22	-0.14	Platelet count;	chr7:100385512	chr7:100320992~100341908:-
BRCA	cis	rs669446	0.562	rs304303	ENSG00000237950.1	RP11-7O11.3	4.65	3.68e-06	0.000333	0.18	0.14	Amyotrophic lateral sclerosis (age of onset);	chr1:43712399	chr1:43944370~43946551:-
BRCA	cis	rs7772486	0.782	rs7747576	ENSG00000270638.1	RP3-466P17.1	-4.65	3.68e-06	0.000333	-0.17	-0.14	Lobe attachment (rater-scored or self-reported);	chr6:145956691	chr6:145735570~145737218:+
BRCA	cis	rs1043099	0.912	rs740219	ENSG00000279699.1	RP1-102K2.9	-4.65	3.68e-06	0.000333	-0.23	-0.14	Rheumatoid arthritis;	chr22:30318695	chr22:30275215~30276951:-
BRCA	cis	rs6832769	0.925	rs6554292	ENSG00000223305.1	RN7SKP30	-4.65	3.68e-06	0.000333	-0.18	-0.14	Personality dimensions;	chr4:55584943	chr4:55540502~55540835:-
BRCA	cis	rs13217239	0.646	rs10456351	ENSG00000224843.5	LINC00240	-4.65	3.68e-06	0.000333	-0.16	-0.14	Schizophrenia;	chr6:27019013	chr6:26956992~27023924:+
BRCA	cis	rs7428	0.527	rs7608892	ENSG00000273196.1	RP11-717A5.2	4.65	3.68e-06	0.000333	0.17	0.14	Ear protrusion;	chr2:85315595	chr2:85387074~85387146:-
BRCA	cis	rs5167	0.525	rs10402642	ENSG00000280087.1	CTB-129P6.7	4.65	3.69e-06	0.000333	0.17	0.14	Blood protein levels;	chr19:44950621	chr19:44909375~44914968:+
BRCA	cis	rs875971	0.658	rs432667	ENSG00000223473.2	GS1-124K5.3	4.65	3.69e-06	0.000333	0.11	0.14	Aortic root size;	chr7:66049646	chr7:66491049~66493566:-
BRCA	cis	rs4948275	0.693	rs2787708	ENSG00000237233.2	TMEM26-AS1	-4.65	3.69e-06	0.000333	-0.17	-0.14	Night sleep phenotypes;	chr10:61556326	chr10:61452639~61481956:+
BRCA	cis	rs4648045	0.565	rs62327181	ENSG00000251288.2	RP11-10L12.2	-4.65	3.69e-06	0.000333	-0.19	-0.14	Lymphocyte percentage of white cells;	chr4:102624981	chr4:102751401~102752641:+
BRCA	cis	rs1950832	0.723	rs1447580	ENSG00000258636.1	CTD-2298J14.2	-4.65	3.69e-06	0.000333	-0.16	-0.14	Urate levels in obese individuals;	chr14:41656388	chr14:41587861~41604856:-
BRCA	cis	rs7772486	0.79	rs3923579	ENSG00000270638.1	RP3-466P17.1	-4.65	3.69e-06	0.000333	-0.17	-0.14	Lobe attachment (rater-scored or self-reported);	chr6:145909096	chr6:145735570~145737218:+
BRCA	cis	rs7772486	0.79	rs2247666	ENSG00000270638.1	RP3-466P17.1	4.65	3.69e-06	0.000333	0.17	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145899273	chr6:145735570~145737218:+
BRCA	cis	rs7617773	0.746	rs4130995	ENSG00000199476.1	Y_RNA	-4.65	3.69e-06	0.000334	-0.19	-0.14	Coronary artery disease;	chr3:48316765	chr3:48288587~48288694:+
BRCA	cis	rs3768617	0.811	rs12144261	ENSG00000224468.3	RP11-181K3.4	-4.65	3.69e-06	0.000334	-0.16	-0.14	Fuchs's corneal dystrophy;	chr1:183045013	chr1:183138402~183141282:-
BRCA	cis	rs2562456	0.876	rs2359144	ENSG00000268658.4	LINC00664	4.65	3.69e-06	0.000334	0.23	0.14	Pain;	chr19:21407834	chr19:21483374~21503238:+
BRCA	cis	rs2562456	0.876	rs4638726	ENSG00000268658.4	LINC00664	4.65	3.69e-06	0.000334	0.23	0.14	Pain;	chr19:21409710	chr19:21483374~21503238:+
BRCA	cis	rs2243480	1	rs427044	ENSG00000222364.1	RNU6-96P	-4.65	3.69e-06	0.000334	-0.27	-0.14	Diabetic kidney disease;	chr7:66043558	chr7:66395191~66395286:+
BRCA	cis	rs5758511	0.68	rs5758682	ENSG00000227370.1	RP4-669P10.19	4.65	3.69e-06	0.000334	0.19	0.14	Birth weight;	chr22:42249196	chr22:42132543~42132998:+
BRCA	cis	rs6452524	1	rs7732092	ENSG00000281327.1	LINC01338	4.65	3.69e-06	0.000334	0.16	0.14	Hypertension (SNP x SNP interaction);	chr5:83141110	chr5:82850864~82859836:-
BRCA	cis	rs2562784	0.638	rs2585064	ENSG00000225151.9	GOLGA2P7	-4.65	3.69e-06	0.000334	-0.25	-0.14	Height;	chr15:83594757	chr15:84199311~84230136:-
BRCA	cis	rs7577696	0.524	rs61399065	ENSG00000272716.1	RP11-563N4.1	-4.65	3.69e-06	0.000334	-0.17	-0.14	Inflammatory biomarkers;	chr2:31983485	chr2:32165046~32165757:-
BRCA	cis	rs721917	0.569	rs2247820	ENSG00000244733.5	RP11-506M13.3	-4.65	3.7e-06	0.000334	-0.17	-0.14	Chronic obstructive pulmonary disease;	chr10:79963123	chr10:79660891~79677996:+
BRCA	cis	rs300890	0.61	rs4690783	ENSG00000250326.1	RP11-284M14.1	-4.65	3.7e-06	0.000334	-0.16	-0.14	Nasopharyngeal carcinoma;	chr4:143270801	chr4:142933195~143184861:-
BRCA	cis	rs4664293	0.737	rs1549579	ENSG00000230783.1	AC009961.2	-4.65	3.7e-06	0.000334	-0.17	-0.14	Monocyte percentage of white cells;	chr2:159812150	chr2:159689217~159690291:-
BRCA	cis	rs1440410	0.83	rs6833582	ENSG00000250326.1	RP11-284M14.1	4.65	3.7e-06	0.000334	0.15	0.14	Ischemic stroke;	chr4:143260839	chr4:142933195~143184861:-
BRCA	cis	rs853679	0.55	rs1233699	ENSG00000216901.1	AL022393.7	4.65	3.7e-06	0.000334	0.2	0.14	Depression;	chr6:28201380	chr6:28176188~28176674:+
BRCA	cis	rs17428076	0.836	rs57718990	ENSG00000228389.1	AC068039.4	-4.65	3.7e-06	0.000334	-0.2	-0.14	Myopia;	chr2:171806104	chr2:171773482~171775844:+
BRCA	cis	rs3764021	0.87	rs2401393	ENSG00000256673.1	RP11-599J14.2	-4.65	3.7e-06	0.000334	-0.16	-0.14	Type 1 diabetes;	chr12:9726488	chr12:9398355~9414851:-
BRCA	cis	rs4650994	0.524	rs2811299	ENSG00000273384.1	RP5-1098D14.1	-4.65	3.7e-06	0.000334	-0.18	-0.14	HDL cholesterol;HDL cholesterol levels;	chr1:178617242	chr1:178651706~178652282:+
BRCA	cis	rs9467773	0.549	rs9467805	ENSG00000124549.13	BTN2A3P	4.65	3.7e-06	0.000335	0.14	0.14	Intelligence (multi-trait analysis);	chr6:26583138	chr6:26421391~26432383:+
BRCA	cis	rs4787491	0.729	rs4788215	ENSG00000261367.1	RP11-455F5.4	-4.65	3.71e-06	0.000335	-0.16	-0.14	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30036609	chr16:30107675~30110541:+
BRCA	cis	rs13108904	0.967	rs12502916	ENSG00000253399.1	AC078852.2	4.65	3.71e-06	0.000335	0.16	0.14	Obesity-related traits;	chr4:1282561	chr4:1358479~1359461:+
BRCA	cis	rs10895275	0.847	rs4447144	ENSG00000277459.1	RP11-732A21.3	4.65	3.71e-06	0.000335	0.14	0.14	Migraine;	chr11:102179590	chr11:102109827~102110457:-
BRCA	cis	rs1722141	0.669	rs788732	ENSG00000237471.1	AC073115.6	4.65	3.71e-06	0.000335	0.2	0.14	Sitting height ratio;	chr7:45995450	chr7:45969657~45980191:+
BRCA	cis	rs1979679	0.801	rs6487686	ENSG00000278733.1	RP11-425D17.1	-4.65	3.71e-06	0.000335	-0.19	-0.14	Ossification of the posterior longitudinal ligament of the spine;	chr12:28548362	chr12:28185625~28186190:-
BRCA	cis	rs12744310	1	rs12036554	ENSG00000235358.1	RP11-399E6.1	4.65	3.71e-06	0.000335	0.21	0.14	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41312317	chr1:41242373~41284861:+
BRCA	cis	rs12744310	1	rs12036555	ENSG00000235358.1	RP11-399E6.1	4.65	3.71e-06	0.000335	0.21	0.14	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41312318	chr1:41242373~41284861:+
BRCA	cis	rs7119	0.717	rs12901338	ENSG00000259362.2	RP11-307C19.1	-4.65	3.71e-06	0.000335	-0.2	-0.14	Type 2 diabetes;	chr15:77512558	chr15:77525540~77534110:+
BRCA	cis	rs2803122	0.745	rs6475325	ENSG00000273226.1	RP11-513M16.8	4.65	3.71e-06	0.000335	0.15	0.14	Pulse pressure;	chr9:19386375	chr9:19375451~19375996:+
BRCA	cis	rs3768617	0.51	rs1413387	ENSG00000224468.3	RP11-181K3.4	-4.65	3.71e-06	0.000335	-0.15	-0.14	Fuchs's corneal dystrophy;	chr1:183127639	chr1:183138402~183141282:-
BRCA	cis	rs2278702	0.943	rs78815690	ENSG00000259495.2	RP11-210M15.2	-4.65	3.72e-06	0.000336	-0.22	-0.14	Bipolar disorder;	chr15:80391946	chr15:80344853~80403575:-
BRCA	cis	rs2278702	0.943	rs57525871	ENSG00000259495.2	RP11-210M15.2	-4.65	3.72e-06	0.000336	-0.22	-0.14	Bipolar disorder;	chr15:80392605	chr15:80344853~80403575:-
BRCA	cis	rs300890	0.76	rs6537152	ENSG00000250326.1	RP11-284M14.1	-4.65	3.72e-06	0.000336	-0.16	-0.14	Nasopharyngeal carcinoma;	chr4:143280891	chr4:142933195~143184861:-
BRCA	cis	rs754466	0.58	rs1866437	ENSG00000213514.2	RP11-428P16.2	4.65	3.72e-06	0.000336	0.2	0.14	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77767008	chr10:77730766~77734769:+
BRCA	cis	rs7829975	0.711	rs12682352	ENSG00000233609.3	RP11-62H7.2	4.65	3.72e-06	0.000336	0.13	0.14	Mood instability;	chr8:8788736	chr8:8961200~8979025:+
BRCA	cis	rs11098499	0.954	rs28685688	ENSG00000250412.1	KLHL2P1	4.65	3.72e-06	0.000336	0.17	0.14	Corneal astigmatism;	chr4:119499179	chr4:119334329~119378233:+
BRCA	cis	rs11098499	0.954	rs7687843	ENSG00000250412.1	KLHL2P1	4.65	3.72e-06	0.000336	0.17	0.14	Corneal astigmatism;	chr4:119500056	chr4:119334329~119378233:+
BRCA	cis	rs6088580	0.608	rs8114616	ENSG00000276073.1	RP5-1125A11.7	4.65	3.72e-06	0.000336	0.16	0.14	Glomerular filtration rate (creatinine);	chr20:34381286	chr20:33985617~33988989:-
BRCA	cis	rs11051970	0.918	rs73084099	ENSG00000274964.1	RP11-817I4.1	-4.65	3.72e-06	0.000336	-0.19	-0.14	Response to tocilizumab in rheumatoid arthritis;	chr12:32386817	chr12:32339368~32340724:+
BRCA	cis	rs11051970	0.918	rs7309115	ENSG00000274964.1	RP11-817I4.1	-4.65	3.72e-06	0.000336	-0.19	-0.14	Response to tocilizumab in rheumatoid arthritis;	chr12:32388307	chr12:32339368~32340724:+
BRCA	cis	rs7818688	0.697	rs77402106	ENSG00000253528.2	RP11-347C18.4	-4.65	3.73e-06	0.000336	-0.22	-0.14	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94958256	chr8:94974573~94974853:-
BRCA	cis	rs654950	0.783	rs640688	ENSG00000230638.4	RP11-486B10.4	4.65	3.73e-06	0.000337	0.17	0.14	Airway imaging phenotypes;	chr1:41536160	chr1:41542069~41544310:+
BRCA	cis	rs17711722	0.64	rs13237956	ENSG00000182722.5	SEPHS1P1	-4.65	3.73e-06	0.000337	-0.18	-0.14	Calcium levels;	chr7:65853042	chr7:64852397~64853354:-
BRCA	cis	rs5167	0.504	rs3760628	ENSG00000280087.1	CTB-129P6.7	4.65	3.73e-06	0.000337	0.17	0.14	Blood protein levels;	chr19:44953968	chr19:44909375~44914968:+
BRCA	cis	rs6431644	0.931	rs2215172	ENSG00000224287.2	MSL3P1	4.65	3.73e-06	0.000337	0.17	0.14	Left atrial antero-posterior diameter;	chr2:233892360	chr2:233865437~233868444:-
BRCA	cis	rs6431644	0.931	rs7596657	ENSG00000224287.2	MSL3P1	4.65	3.73e-06	0.000337	0.17	0.14	Left atrial antero-posterior diameter;	chr2:233893093	chr2:233865437~233868444:-
BRCA	cis	rs13113518	1	rs3749474	ENSG00000249700.7	SRD5A3-AS1	4.65	3.73e-06	0.000337	0.18	0.14	Height;	chr4:55434518	chr4:55363971~55395847:-
BRCA	cis	rs12744310	1	rs1343775	ENSG00000235358.1	RP11-399E6.1	4.65	3.73e-06	0.000337	0.21	0.14	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41292321	chr1:41242373~41284861:+
BRCA	cis	rs8180040	0.62	rs17784127	ENSG00000276925.1	RP11-708J19.3	4.65	3.73e-06	0.000337	0.16	0.14	Colorectal cancer;	chr3:47020210	chr3:47469777~47469987:+
BRCA	cis	rs67766926	0.953	rs10193964	ENSG00000271889.1	RP11-493E12.1	4.65	3.73e-06	0.000337	0.21	0.14	Inflammatory skin disease;	chr2:60899529	chr2:61151433~61162105:-
BRCA	cis	rs6430585	0.583	rs61253125	ENSG00000224043.6	CCNT2-AS1	-4.65	3.73e-06	0.000337	-0.24	-0.14	Corneal structure;	chr2:135860608	chr2:134735464~134918710:-
BRCA	cis	rs6430585	0.583	rs4988201	ENSG00000224043.6	CCNT2-AS1	-4.65	3.73e-06	0.000337	-0.24	-0.14	Corneal structure;	chr2:135860937	chr2:134735464~134918710:-
BRCA	cis	rs6430585	0.583	rs3087343	ENSG00000224043.6	CCNT2-AS1	-4.65	3.73e-06	0.000337	-0.24	-0.14	Corneal structure;	chr2:135864973	chr2:134735464~134918710:-
BRCA	cis	rs454217	0.875	rs7958204	ENSG00000277851.1	RP11-756G20.1	4.65	3.73e-06	0.000337	0.17	0.14	Smoking quantity;	chr12:92323167	chr12:92247756~92363832:-
BRCA	cis	rs1858037	0.867	rs55945621	ENSG00000281920.1	RP11-418H16.1	4.65	3.74e-06	0.000337	0.18	0.14	Rheumatoid arthritis;	chr2:65388220	chr2:65623272~65628424:+
BRCA	cis	rs1499614	0.803	rs1796229	ENSG00000222364.1	RNU6-96P	-4.65	3.74e-06	0.000337	-0.26	-0.14	Gout;	chr7:66654674	chr7:66395191~66395286:+
BRCA	cis	rs62025270	0.688	rs7164373	ENSG00000259762.1	RP11-158M2.4	-4.65	3.74e-06	0.000337	-0.21	-0.14	Idiopathic pulmonary fibrosis;	chr15:85722432	chr15:85750336~85752901:-
BRCA	cis	rs6545883	0.63	rs12998475	ENSG00000212978.6	AC016747.3	-4.65	3.74e-06	0.000337	-0.19	-0.14	Tuberculosis;	chr2:61210352	chr2:61141592~61144969:-
BRCA	cis	rs11051970	0.918	rs1055876	ENSG00000274964.1	RP11-817I4.1	-4.65	3.74e-06	0.000338	-0.18	-0.14	Response to tocilizumab in rheumatoid arthritis;	chr12:32383266	chr12:32339368~32340724:+
BRCA	cis	rs2692947	0.726	rs13019188	ENSG00000168992.4	OR7E102P	-4.65	3.74e-06	0.000338	-0.19	-0.14	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96108451	chr2:95546531~95547545:+
BRCA	cis	rs6686842	0.56	rs17357905	ENSG00000235358.1	RP11-399E6.1	4.65	3.74e-06	0.000338	0.19	0.14	Height;	chr1:41018645	chr1:41242373~41284861:+
BRCA	cis	rs13113518	1	rs13108499	ENSG00000273257.1	RP11-177J6.1	4.65	3.74e-06	0.000338	0.18	0.14	Height;	chr4:55526514	chr4:55387949~55388271:+
BRCA	cis	rs7267979	0.899	rs2104734	ENSG00000125804.12	FAM182A	-4.65	3.74e-06	0.000338	-0.18	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25546032	chr20:26054655~26086917:+
BRCA	cis	rs10504130	0.569	rs12680128	ENSG00000272024.1	RP11-546K22.3	-4.65	3.74e-06	0.000338	-0.21	-0.14	Venous thromboembolism (SNP x SNP interaction);	chr8:51766683	chr8:51950284~51950690:+
BRCA	cis	rs6840360	0.642	rs7698816	ENSG00000251603.1	RP11-164P12.4	-4.65	3.74e-06	0.000338	-0.13	-0.14	Intelligence (multi-trait analysis);	chr4:151431820	chr4:151667224~151670502:+
BRCA	cis	rs4787491	0.729	rs11544328	ENSG00000261367.1	RP11-455F5.4	-4.65	3.74e-06	0.000338	-0.16	-0.14	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30025807	chr16:30107675~30110541:+
BRCA	cis	rs8031584	0.958	rs3512	ENSG00000259845.1	HERC2P10	4.65	3.74e-06	0.000338	0.17	0.14	Huntington's disease progression;	chr15:30942802	chr15:30815271~30844153:+
BRCA	cis	rs801193	0.569	rs10950050	ENSG00000273448.1	RP11-166O4.6	4.65	3.75e-06	0.000338	0.13	0.14	Aortic root size;	chr7:66774601	chr7:67333047~67334383:+
BRCA	cis	rs4356203	0.875	rs7939614	ENSG00000272034.1	SNORD14A	-4.65	3.75e-06	0.000338	-0.15	-0.14	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17058073	chr11:17074654~17074744:-
BRCA	cis	rs4356203	0.905	rs9919540	ENSG00000272034.1	SNORD14A	-4.65	3.75e-06	0.000338	-0.15	-0.14	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17058786	chr11:17074654~17074744:-
BRCA	cis	rs55704346	0.74	rs11943612	ENSG00000281501.1	SEPSECS-AS1	-4.65	3.75e-06	0.000338	-0.17	-0.14	Tonsillectomy;	chr4:25119696	chr4:25160641~25201440:+
BRCA	cis	rs12497850	0.897	rs6781790	ENSG00000225399.4	RP11-3B7.1	4.65	3.75e-06	0.000338	0.14	0.14	Parkinson's disease;	chr3:49007334	chr3:49260085~49261316:+
BRCA	cis	rs2562456	0.917	rs11085463	ENSG00000268535.1	RP11-420K14.3	4.65	3.75e-06	0.000338	0.19	0.14	Pain;	chr19:21568500	chr19:21709522~21710191:+
BRCA	cis	rs2243480	1	rs6974723	ENSG00000275400.1	RP4-756H11.5	-4.65	3.75e-06	0.000338	-0.26	-0.14	Diabetic kidney disease;	chr7:66172952	chr7:66553805~66554199:-
BRCA	cis	rs2243480	1	rs9769882	ENSG00000275400.1	RP4-756H11.5	-4.65	3.75e-06	0.000338	-0.26	-0.14	Diabetic kidney disease;	chr7:66177938	chr7:66553805~66554199:-
BRCA	cis	rs2243480	1	rs6966322	ENSG00000275400.1	RP4-756H11.5	-4.65	3.75e-06	0.000338	-0.26	-0.14	Diabetic kidney disease;	chr7:66181767	chr7:66553805~66554199:-
BRCA	cis	rs2243480	1	rs4145008	ENSG00000275400.1	RP4-756H11.5	-4.65	3.75e-06	0.000338	-0.26	-0.14	Diabetic kidney disease;	chr7:66182524	chr7:66553805~66554199:-
BRCA	cis	rs2412819	0.571	rs28410121	ENSG00000166763.7	STRCP1	-4.65	3.75e-06	0.000338	-0.2	-0.14	Lung cancer;	chr15:43777831	chr15:43699488~43718184:-
BRCA	cis	rs9907295	0.818	rs4251702	ENSG00000270977.1	AC015849.16	4.65	3.75e-06	0.000338	0.25	0.14	Fibroblast growth factor basic levels;	chr17:35807933	chr17:35893707~35911023:-
BRCA	cis	rs6747488	0.513	rs223647	ENSG00000272716.1	RP11-563N4.1	4.65	3.75e-06	0.000339	0.15	0.14	Interleukin-18 levels;	chr2:31776066	chr2:32165046~32165757:-
BRCA	cis	rs2277027	1	rs1422795	ENSG00000248544.2	CTB-47B11.3	-4.65	3.75e-06	0.000339	-0.17	-0.14	Pulmonary function;Pulmonary function (smoking interaction);	chr5:157509356	chr5:157375741~157384950:-
BRCA	cis	rs10833905	1	rs11026933	ENSG00000246225.5	RP11-17A1.3	-4.65	3.75e-06	0.000339	-0.2	-0.14	Sudden cardiac arrest;	chr11:23045112	chr11:22829380~22945393:+
BRCA	cis	rs8031584	0.56	rs1056118	ENSG00000259845.1	HERC2P10	-4.65	3.75e-06	0.000339	-0.16	-0.14	Huntington's disease progression;	chr15:30911583	chr15:30815271~30844153:+
BRCA	cis	rs3771395	1	rs3771395	ENSG00000237751.2	LINC01143	4.65	3.75e-06	0.000339	0.21	0.14	Corneal astigmatism;	chr2:70905884	chr2:70887871~70889959:+
BRCA	cis	rs867186	1	rs6579211	ENSG00000126005.14	MMP24-AS1	-4.65	3.76e-06	0.000339	-0.27	-0.14	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35018054	chr20:35216462~35278131:-
BRCA	cis	rs9549328	0.756	rs2993291	ENSG00000269376.1	RP11-120K24.5	-4.65	3.76e-06	0.000339	-0.2	-0.14	Systolic blood pressure;	chr13:112999532	chr13:113009671~113010319:+
BRCA	cis	rs4853525	0.561	rs12693589	ENSG00000235852.1	AC005540.3	4.65	3.76e-06	0.000339	0.18	0.14	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190967936	chr2:190880797~190882059:-
BRCA	cis	rs316341	1	rs316341	ENSG00000230438.6	SERPINB9P1	4.65	3.76e-06	0.000339	0.19	0.14	Cerebrospinal fluid AB1-42 levels;	chr6:2838014	chr6:2854657~2881407:-
BRCA	cis	rs4664293	0.867	rs1126842	ENSG00000224152.1	AC009506.1	-4.65	3.76e-06	0.000339	-0.16	-0.14	Monocyte percentage of white cells;	chr2:159770806	chr2:159615296~159617082:+
BRCA	cis	rs256438	0.93	rs2434283	ENSG00000251050.1	RP11-168A11.4	-4.65	3.76e-06	0.000339	-0.16	-0.14	Serum thyroid-stimulating hormone levels;	chr5:80094902	chr5:80019609~80019920:+
BRCA	cis	rs256438	0.93	rs2438636	ENSG00000251050.1	RP11-168A11.4	-4.65	3.76e-06	0.000339	-0.16	-0.14	Serum thyroid-stimulating hormone levels;	chr5:80094981	chr5:80019609~80019920:+
BRCA	cis	rs256438	0.93	rs2438634	ENSG00000251050.1	RP11-168A11.4	-4.65	3.76e-06	0.000339	-0.16	-0.14	Serum thyroid-stimulating hormone levels;	chr5:80095807	chr5:80019609~80019920:+
BRCA	cis	rs10266483	0.774	rs10949901	ENSG00000227986.1	TRIM60P18	4.65	3.76e-06	0.000339	0.15	0.14	Response to statin therapy;	chr7:64352396	chr7:64355078~64356199:+
BRCA	cis	rs9921338	0.923	rs4563054	ENSG00000262703.1	RP11-485G7.6	-4.65	3.76e-06	0.000339	-0.18	-0.14	Vein graft stenosis in coronary artery bypass grafting;	chr16:11353689	chr16:11348143~11349321:-
BRCA	cis	rs6545883	0.929	rs1186700	ENSG00000212978.6	AC016747.3	4.65	3.76e-06	0.000339	0.2	0.14	Tuberculosis;	chr2:61436237	chr2:61141592~61144969:-
BRCA	cis	rs2253762	0.507	rs10159998	ENSG00000226864.1	ATE1-AS1	4.65	3.76e-06	0.000339	0.26	0.14	Breast cancer;	chr10:121994550	chr10:121928312~121951965:+
BRCA	cis	rs2253762	0.54	rs11200311	ENSG00000226864.1	ATE1-AS1	4.65	3.76e-06	0.000339	0.26	0.14	Breast cancer;	chr10:121995094	chr10:121928312~121951965:+
BRCA	cis	rs2253762	0.54	rs79069897	ENSG00000226864.1	ATE1-AS1	4.65	3.76e-06	0.000339	0.26	0.14	Breast cancer;	chr10:121995680	chr10:121928312~121951965:+
BRCA	cis	rs875971	0.862	rs6959268	ENSG00000273448.1	RP11-166O4.6	-4.65	3.76e-06	0.000339	-0.13	-0.14	Aortic root size;	chr7:66347979	chr7:67333047~67334383:+
BRCA	cis	rs12893668	0.572	rs4906350	ENSG00000269958.1	RP11-73M18.8	4.65	3.76e-06	0.00034	0.16	0.14	Reticulocyte count;	chr14:103645457	chr14:103696353~103697163:+
BRCA	cis	rs983392	0.836	rs17602572	ENSG00000275344.1	MIR6503	-4.65	3.76e-06	0.00034	-0.15	-0.14	Alzheimer's disease (late onset);	chr11:60180901	chr11:60209071~60209156:-
BRCA	cis	rs13108904	0.518	rs4974603	ENSG00000253399.1	AC078852.2	-4.65	3.76e-06	0.00034	-0.17	-0.14	Obesity-related traits;	chr4:1349380	chr4:1358479~1359461:+
BRCA	cis	rs6500602	0.964	rs62039173	ENSG00000280063.1	RP11-295D4.3	4.65	3.76e-06	0.00034	0.11	0.14	Schizophrenia;	chr16:4413845	chr16:4346694~4348648:-
BRCA	cis	rs801193	1	rs13239306	ENSG00000272831.1	RP11-792A8.4	-4.65	3.77e-06	0.00034	-0.13	-0.14	Aortic root size;	chr7:66671030	chr7:66739829~66740385:-
BRCA	cis	rs6840258	0.569	rs17012516	ENSG00000251411.1	RP11-397E7.4	4.65	3.77e-06	0.00034	0.17	0.14	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87147991	chr4:86913266~86914817:-
BRCA	cis	rs4664293	0.836	rs13032500	ENSG00000226266.5	AC009961.3	-4.65	3.77e-06	0.00034	-0.18	-0.14	Monocyte percentage of white cells;	chr2:159749740	chr2:159670708~159712435:-
BRCA	cis	rs1707322	1	rs1707317	ENSG00000234329.1	RP11-767N6.2	-4.65	3.77e-06	0.00034	-0.15	-0.14	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46044970	chr1:45651039~45651826:-
BRCA	cis	rs2731006	0.543	rs11181696	ENSG00000257114.2	RP11-25I15.3	4.65	3.77e-06	0.00034	0.21	0.14	Panic disorder;	chr12:42815339	chr12:42692216~42717119:+
BRCA	cis	rs1030877	0.515	rs2679893	ENSG00000235319.1	AC012360.4	-4.65	3.77e-06	0.00034	-0.2	-0.14	Obesity-related traits;	chr2:105293097	chr2:105324210~105330529:+
BRCA	cis	rs8180040	0.587	rs62246398	ENSG00000276925.1	RP11-708J19.3	4.65	3.77e-06	0.00034	0.16	0.14	Colorectal cancer;	chr3:47024713	chr3:47469777~47469987:+
BRCA	cis	rs651907	0.557	rs13081846	ENSG00000256628.3	ZBTB11-AS1	4.65	3.78e-06	0.000341	0.18	0.14	Colorectal cancer;	chr3:101664477	chr3:101676475~101679217:+
BRCA	cis	rs11976180	1	rs1919950	ENSG00000244479.5	OR2A1-AS1	4.65	3.78e-06	0.000341	0.19	0.14	Obesity-related traits;	chr7:144070805	chr7:144251264~144356181:-
BRCA	cis	rs6496044	0.507	rs8034676	ENSG00000259295.5	CSPG4P12	4.65	3.78e-06	0.000341	0.17	0.14	Interstitial lung disease;	chr15:85616031	chr15:85191438~85213905:+
BRCA	cis	rs9959145	0.543	rs11664013	ENSG00000267199.1	RP11-861E21.2	-4.65	3.78e-06	0.000341	-0.17	-0.14	Immune response to smallpox vaccine (IL-6);	chr18:12582789	chr18:12438890~12448205:+
BRCA	cis	rs6095360	1	rs6090939	ENSG00000222365.1	SNORD12B	-4.65	3.78e-06	0.000341	-0.16	-0.14	Intelligence (multi-trait analysis);	chr20:49049288	chr20:49280319~49280409:+
BRCA	cis	rs6095360	1	rs6012590	ENSG00000222365.1	SNORD12B	-4.65	3.78e-06	0.000341	-0.16	-0.14	Intelligence (multi-trait analysis);	chr20:49050700	chr20:49280319~49280409:+
BRCA	cis	rs6095360	0.901	rs6012591	ENSG00000222365.1	SNORD12B	-4.65	3.78e-06	0.000341	-0.16	-0.14	Intelligence (multi-trait analysis);	chr20:49050805	chr20:49280319~49280409:+
BRCA	cis	rs6095360	1	rs7509369	ENSG00000222365.1	SNORD12B	-4.65	3.78e-06	0.000341	-0.16	-0.14	Intelligence (multi-trait analysis);	chr20:49051500	chr20:49280319~49280409:+
BRCA	cis	rs6095360	1	rs2869694	ENSG00000222365.1	SNORD12B	-4.65	3.78e-06	0.000341	-0.16	-0.14	Intelligence (multi-trait analysis);	chr20:49051846	chr20:49280319~49280409:+
BRCA	cis	rs9880211	0.613	rs13081671	ENSG00000239213.4	NCK1-AS1	4.65	3.78e-06	0.000341	0.17	0.14	Height;Body mass index;	chr3:136157707	chr3:136841726~136862054:-
BRCA	cis	rs6847067	0.8	rs10856851	ENSG00000180769.7	WDFY3-AS2	4.65	3.78e-06	0.000341	0.13	0.14	Oropharynx cancer;	chr4:84908450	chr4:84965682~85011277:+
BRCA	cis	rs2839186	0.5	rs13049893	ENSG00000228137.1	AP001469.7	4.65	3.79e-06	0.000341	0.16	0.14	Testicular germ cell tumor;	chr21:46287140	chr21:46246890~46247682:+
BRCA	cis	rs35306767	0.953	rs11253521	ENSG00000229869.1	RP11-363N22.2	-4.65	3.79e-06	0.000341	-0.2	-0.14	Eosinophil percentage of granulocytes;	chr10:930476	chr10:933026~942743:+
BRCA	cis	rs6921919	0.583	rs3800328	ENSG00000273712.1	RP5-874C20.7	4.65	3.79e-06	0.000341	0.19	0.14	Autism spectrum disorder or schizophrenia;	chr6:28423066	chr6:28315613~28315883:-
BRCA	cis	rs9467773	0.804	rs2073526	ENSG00000241549.7	GUSBP2	-4.65	3.79e-06	0.000341	-0.16	-0.14	Intelligence (multi-trait analysis);	chr6:26374430	chr6:26871484~26956554:-
BRCA	cis	rs7833986	0.501	rs2976038	ENSG00000253603.1	CTA-397H3.3	-4.65	3.79e-06	0.000341	-0.21	-0.14	Height;	chr8:56116305	chr8:56074592~56075274:+
BRCA	cis	rs4356203	0.792	rs620241	ENSG00000272034.1	SNORD14A	-4.65	3.79e-06	0.000342	-0.15	-0.14	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17175343	chr11:17074654~17074744:-
BRCA	cis	rs8040855	0.627	rs12904238	ENSG00000230373.7	GOLGA6L5P	4.65	3.79e-06	0.000342	0.18	0.14	Bulimia nervosa;	chr15:85096610	chr15:84507885~84516814:-
BRCA	cis	rs6832769	1	rs13102385	ENSG00000272969.1	RP11-528I4.2	4.65	3.79e-06	0.000342	0.17	0.14	Personality dimensions;	chr4:55479088	chr4:55547112~55547889:+
BRCA	cis	rs6832769	0.961	rs11947623	ENSG00000272969.1	RP11-528I4.2	4.65	3.79e-06	0.000342	0.17	0.14	Personality dimensions;	chr4:55483023	chr4:55547112~55547889:+
BRCA	cis	rs11742741	0.69	rs60235942	ENSG00000248874.4	C5orf17	-4.65	3.79e-06	0.000342	-0.19	-0.14	Educational attainment;	chr5:24138735	chr5:23951348~24178263:+
BRCA	cis	rs9467773	0.62	rs2451731	ENSG00000241549.7	GUSBP2	4.65	3.79e-06	0.000342	0.15	0.14	Intelligence (multi-trait analysis);	chr6:26624594	chr6:26871484~26956554:-
BRCA	cis	rs256438	0.731	rs13181102	ENSG00000251050.1	RP11-168A11.4	-4.65	3.79e-06	0.000342	-0.16	-0.14	Serum thyroid-stimulating hormone levels;	chr5:80041334	chr5:80019609~80019920:+
BRCA	cis	rs595244	1	rs591519	ENSG00000259705.1	RP11-227D13.1	4.65	3.79e-06	0.000342	0.25	0.14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48602003	chr15:48645951~48652016:+
BRCA	cis	rs5751614	0.557	rs16802	ENSG00000240160.3	RN7SL263P	-4.65	3.79e-06	0.000342	-0.18	-0.14	Height;	chr22:23290326	chr22:23261782~23262071:-
BRCA	cis	rs2562456	0.833	rs55790393	ENSG00000268658.4	LINC00664	4.65	3.79e-06	0.000342	0.24	0.14	Pain;	chr19:21323382	chr19:21483374~21503238:+
BRCA	cis	rs2562456	0.793	rs11672341	ENSG00000268658.4	LINC00664	4.65	3.79e-06	0.000342	0.24	0.14	Pain;	chr19:21324502	chr19:21483374~21503238:+
BRCA	cis	rs7208859	0.673	rs3816780	ENSG00000264538.5	SUZ12P1	-4.65	3.79e-06	0.000342	-0.2	-0.14	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30834340	chr17:30709299~30790908:+
BRCA	cis	rs2832191	0.791	rs7282843	ENSG00000176054.6	RPL23P2	4.65	3.8e-06	0.000342	0.15	0.14	Dental caries;	chr21:29102905	chr21:28997613~28998033:-
BRCA	cis	rs6547741	0.935	rs6761095	ENSG00000234072.1	AC074117.10	4.65	3.8e-06	0.000342	0.13	0.14	Oral cavity cancer;	chr2:27555143	chr2:27356246~27367622:+
BRCA	cis	rs6840360	0.642	rs6845648	ENSG00000251603.1	RP11-164P12.4	-4.65	3.8e-06	0.000342	-0.13	-0.14	Intelligence (multi-trait analysis);	chr4:151454898	chr4:151667224~151670502:+
BRCA	cis	rs6840360	0.642	rs2724571	ENSG00000251603.1	RP11-164P12.4	-4.65	3.8e-06	0.000342	-0.13	-0.14	Intelligence (multi-trait analysis);	chr4:151455643	chr4:151667224~151670502:+
BRCA	cis	rs6840360	0.642	rs2709833	ENSG00000251603.1	RP11-164P12.4	-4.65	3.8e-06	0.000342	-0.13	-0.14	Intelligence (multi-trait analysis);	chr4:151456470	chr4:151667224~151670502:+
BRCA	cis	rs2562456	0.833	rs2968078	ENSG00000268658.4	LINC00664	-4.65	3.8e-06	0.000342	-0.22	-0.14	Pain;	chr19:21458942	chr19:21483374~21503238:+
BRCA	cis	rs1707322	1	rs785467	ENSG00000234329.1	RP11-767N6.2	-4.65	3.8e-06	0.000342	-0.15	-0.14	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46055887	chr1:45651039~45651826:-
BRCA	cis	rs7267979	1	rs2258719	ENSG00000125804.12	FAM182A	-4.65	3.8e-06	0.000343	-0.19	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25295207	chr20:26054655~26086917:+
BRCA	cis	rs12539814	1	rs12666210	ENSG00000244198.4	RP4-545C24.1	-4.65	3.8e-06	0.000343	-0.25	-0.14	Diastolic blood pressure;	chr7:144435635	chr7:144194858~144280547:+
BRCA	cis	rs7267979	1	rs2482927	ENSG00000125804.12	FAM182A	4.65	3.8e-06	0.000343	0.19	0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25346515	chr20:26054655~26086917:+
BRCA	cis	rs5751614	0.537	rs7292656	ENSG00000240160.3	RN7SL263P	4.65	3.8e-06	0.000343	0.18	0.14	Height;	chr22:23287415	chr22:23261782~23262071:-
BRCA	cis	rs2286503	1	rs2286498	ENSG00000226329.2	AC005682.6	-4.65	3.8e-06	0.000343	-0.13	-0.14	Fibrinogen;	chr7:22817885	chr7:22863874~22881350:-
BRCA	cis	rs365302	1	rs294920	ENSG00000235086.1	FNDC1-IT1	4.65	3.8e-06	0.000343	0.16	0.14	Coronary heart disease;	chr6:159201770	chr6:159240786~159243329:+
BRCA	cis	rs10504130	0.569	rs34364864	ENSG00000272024.1	RP11-546K22.3	-4.65	3.81e-06	0.000343	-0.21	-0.14	Venous thromboembolism (SNP x SNP interaction);	chr8:51817086	chr8:51950284~51950690:+
BRCA	cis	rs867371	0.614	rs7183805	ENSG00000259429.4	UBE2Q2P2	-4.65	3.81e-06	0.000343	-0.16	-0.14	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82247090	chr15:82355142~82420075:+
BRCA	cis	rs10504130	0.569	rs34319820	ENSG00000272024.1	RP11-546K22.3	-4.65	3.81e-06	0.000343	-0.21	-0.14	Venous thromboembolism (SNP x SNP interaction);	chr8:51777314	chr8:51950284~51950690:+
BRCA	cis	rs983392	0.868	rs7926954	ENSG00000275344.1	MIR6503	-4.65	3.81e-06	0.000343	-0.15	-0.14	Alzheimer's disease (late onset);	chr11:60165106	chr11:60209071~60209156:-
BRCA	cis	rs6545883	0.602	rs11125871	ENSG00000273302.1	RP11-493E12.2	-4.65	3.81e-06	0.000343	-0.13	-0.14	Tuberculosis;	chr2:61242991	chr2:61199979~61200769:+
BRCA	cis	rs7829975	0.711	rs4841051	ENSG00000254153.1	CTA-398F10.2	-4.65	3.81e-06	0.000343	-0.17	-0.14	Mood instability;	chr8:8828136	chr8:8456909~8461337:-
BRCA	cis	rs11758351	1	rs111596617	ENSG00000241549.7	GUSBP2	-4.65	3.81e-06	0.000343	-0.21	-0.14	Renal underexcretion gout;Gout;	chr6:26191450	chr6:26871484~26956554:-
BRCA	cis	rs11758351	1	rs112751982	ENSG00000241549.7	GUSBP2	-4.65	3.81e-06	0.000343	-0.21	-0.14	Renal underexcretion gout;Gout;	chr6:26191730	chr6:26871484~26956554:-
BRCA	cis	rs11758351	0.925	rs10452600	ENSG00000241549.7	GUSBP2	-4.65	3.81e-06	0.000343	-0.21	-0.14	Renal underexcretion gout;Gout;	chr6:26192274	chr6:26871484~26956554:-
BRCA	cis	rs875971	0.545	rs1796217	ENSG00000230295.1	RP11-458F8.2	-4.65	3.81e-06	0.000343	-0.14	-0.14	Aortic root size;	chr7:66620931	chr7:66880708~66882981:+
BRCA	cis	rs2073316	0.62	rs766273	ENSG00000272716.1	RP11-563N4.1	4.65	3.81e-06	0.000343	0.15	0.14	Interleukin-18 levels;	chr2:31447657	chr2:32165046~32165757:-
BRCA	cis	rs11742741	1	rs57263486	ENSG00000248874.4	C5orf17	-4.65	3.81e-06	0.000343	-0.19	-0.14	Educational attainment;	chr5:24136583	chr5:23951348~24178263:+
BRCA	cis	rs516805	0.528	rs2816085	ENSG00000279453.1	RP3-425C14.4	-4.65	3.81e-06	0.000344	-0.2	-0.14	Lymphocyte counts;	chr6:122097324	chr6:122436789~122439223:-
BRCA	cis	rs11673344	0.504	rs6510593	ENSG00000226686.6	LINC01535	4.65	3.81e-06	0.000344	0.18	0.14	Obesity-related traits;	chr19:37143153	chr19:37251912~37265535:+
BRCA	cis	rs13113518	1	rs7691799	ENSG00000273257.1	RP11-177J6.1	4.65	3.81e-06	0.000344	0.18	0.14	Height;	chr4:55545574	chr4:55387949~55388271:+
BRCA	cis	rs4072705	0.646	rs915032	ENSG00000224020.1	MIR181A2HG	-4.65	3.81e-06	0.000344	-0.16	-0.14	Menarche (age at onset);	chr9:124483403	chr9:124658467~124698631:+
BRCA	cis	rs2243480	1	rs67536397	ENSG00000222364.1	RNU6-96P	-4.65	3.81e-06	0.000344	-0.27	-0.14	Diabetic kidney disease;	chr7:66482930	chr7:66395191~66395286:+
BRCA	cis	rs2243480	1	rs58669269	ENSG00000222364.1	RNU6-96P	-4.65	3.81e-06	0.000344	-0.27	-0.14	Diabetic kidney disease;	chr7:66486966	chr7:66395191~66395286:+
BRCA	cis	rs2915864	0.8	rs13172358	ENSG00000280047.1	CTC-463A16.1	4.65	3.81e-06	0.000344	0.2	0.14	Facial morphology (factor 20);	chr5:142104560	chr5:142165767~142168387:+
BRCA	cis	rs3764021	0.527	rs10844456	ENSG00000256673.1	RP11-599J14.2	-4.65	3.82e-06	0.000344	-0.18	-0.14	Type 1 diabetes;	chr12:9689319	chr12:9398355~9414851:-
BRCA	cis	rs2832191	0.791	rs2832179	ENSG00000236056.1	GAPDHP14	4.65	3.82e-06	0.000344	0.15	0.14	Dental caries;	chr21:29108045	chr21:29222321~29223257:+
BRCA	cis	rs2832191	0.791	rs4817270	ENSG00000236056.1	GAPDHP14	4.65	3.82e-06	0.000344	0.15	0.14	Dental caries;	chr21:29108047	chr21:29222321~29223257:+
BRCA	cis	rs4072705	0.646	rs7037254	ENSG00000224020.1	MIR181A2HG	4.65	3.82e-06	0.000344	0.16	0.14	Menarche (age at onset);	chr9:124483133	chr9:124658467~124698631:+
BRCA	cis	rs853679	1	rs1936365	ENSG00000204709.4	LINC01556	-4.65	3.82e-06	0.000344	-0.24	-0.14	Depression;	chr6:28300675	chr6:28943877~28944537:+
BRCA	cis	rs7200543	1	rs6498541	ENSG00000260735.1	RP11-72I8.1	-4.65	3.82e-06	0.000344	-0.17	-0.14	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15046800	chr16:15094411~15109197:+
BRCA	cis	rs972578	0.791	rs738383	ENSG00000230319.1	AL022476.2	4.65	3.82e-06	0.000345	0.16	0.14	Mean platelet volume;	chr22:42919387	chr22:43038585~43052366:+
BRCA	cis	rs2755237	0.656	rs2755238	ENSG00000176268.5	CYCSP34	-4.65	3.82e-06	0.000345	-0.25	-0.14	Central corneal thickness;	chr13:40536133	chr13:40863599~40863902:-
BRCA	cis	rs8098244	0.603	rs1711455	ENSG00000264745.1	TTC39C-AS1	4.65	3.83e-06	0.000345	0.17	0.14	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23695207	chr18:23994213~24015339:-
BRCA	cis	rs7923609	0.846	rs7090111	ENSG00000232075.1	MRPL35P2	-4.65	3.83e-06	0.000345	-0.18	-0.14	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63318234	chr10:63634317~63634827:-
BRCA	cis	rs338389	0.516	rs11855801	ENSG00000260657.2	RP11-315D16.4	4.65	3.83e-06	0.000345	0.17	0.14	Survival in rectal cancer;	chr15:68020994	chr15:68267792~68277994:-
BRCA	cis	rs56322409	0.833	rs7074866	ENSG00000226688.5	ENTPD1-AS1	4.65	3.83e-06	0.000345	0.17	0.14	Blood metabolite levels;	chr10:95890752	chr10:95753206~96090238:-
BRCA	cis	rs12497850	0.931	rs9682444	ENSG00000225399.4	RP11-3B7.1	4.65	3.83e-06	0.000345	0.14	0.14	Parkinson's disease;	chr3:48815206	chr3:49260085~49261316:+
BRCA	cis	rs12497850	0.931	rs9835307	ENSG00000225399.4	RP11-3B7.1	4.65	3.83e-06	0.000345	0.14	0.14	Parkinson's disease;	chr3:48820372	chr3:49260085~49261316:+
BRCA	cis	rs12497850	0.931	rs9755490	ENSG00000225399.4	RP11-3B7.1	4.65	3.83e-06	0.000345	0.14	0.14	Parkinson's disease;	chr3:48834231	chr3:49260085~49261316:+
BRCA	cis	rs9467773	0.595	rs3846845	ENSG00000124549.13	BTN2A3P	-4.65	3.83e-06	0.000345	-0.15	-0.14	Intelligence (multi-trait analysis);	chr6:26444687	chr6:26421391~26432383:+
BRCA	cis	rs9467773	0.572	rs3846846	ENSG00000124549.13	BTN2A3P	-4.65	3.83e-06	0.000345	-0.15	-0.14	Intelligence (multi-trait analysis);	chr6:26444811	chr6:26421391~26432383:+
BRCA	cis	rs1665050	0.901	rs1665051	ENSG00000277144.1	RP11-59H7.4	-4.65	3.83e-06	0.000345	-0.18	-0.14	Atopic dermatitis;	chr15:59003025	chr15:59115547~59116089:-
BRCA	cis	rs6545883	0.56	rs11677775	ENSG00000273302.1	RP11-493E12.2	-4.65	3.83e-06	0.000345	-0.12	-0.14	Tuberculosis;	chr2:61275975	chr2:61199979~61200769:+
BRCA	cis	rs7577696	0.853	rs212698	ENSG00000272716.1	RP11-563N4.1	4.65	3.83e-06	0.000345	0.16	0.14	Inflammatory biomarkers;	chr2:32217928	chr2:32165046~32165757:-
BRCA	cis	rs12264252	0.767	rs7902355	ENSG00000226659.1	RP11-137H2.4	4.65	3.83e-06	0.000345	0.23	0.14	Coronary artery disease;	chr10:80489352	chr10:80529597~80535942:-
BRCA	cis	rs2692947	0.76	rs2438924	ENSG00000232931.4	LINC00342	4.65	3.83e-06	0.000345	0.14	0.14	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95979321	chr2:95807118~95816215:-
BRCA	cis	rs2692947	0.826	rs7423942	ENSG00000232931.4	LINC00342	4.65	3.83e-06	0.000345	0.14	0.14	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95979509	chr2:95807118~95816215:-
BRCA	cis	rs859767	0.741	rs13432068	ENSG00000224043.6	CCNT2-AS1	4.65	3.83e-06	0.000345	0.2	0.14	Neuroticism;	chr2:134625344	chr2:134735464~134918710:-
BRCA	cis	rs4908760	0.832	rs11121209	ENSG00000232912.4	RP5-1115A15.1	4.65	3.83e-06	0.000345	0.14	0.14	Vitiligo;	chr1:8626803	chr1:8424645~8434838:+
BRCA	cis	rs4218	0.608	rs16941014	ENSG00000277144.1	RP11-59H7.4	-4.65	3.83e-06	0.000345	-0.19	-0.14	Social communication problems;	chr15:59091503	chr15:59115547~59116089:-
BRCA	cis	rs60843830	1	rs2290911	ENSG00000272342.1	RP13-539J13.1	4.65	3.84e-06	0.000345	0.18	0.14	Spherical equivalent (joint analysis main effects and education interaction);	chr2:224919	chr2:739588~740164:-
BRCA	cis	rs7615952	0.688	rs12638224	ENSG00000241288.6	RP11-379B18.5	-4.64	3.84e-06	0.000346	-0.19	-0.14	Blood pressure (smoking interaction);	chr3:125822477	chr3:125827238~125916384:-
BRCA	cis	rs2312236	0.759	rs12742287	ENSG00000225171.2	DUTP6	-4.64	3.84e-06	0.000346	-0.21	-0.14	Post-traumatic stress disorder;	chr1:166755601	chr1:166868748~166869209:+
BRCA	cis	rs4698412	0.561	rs6815296	ENSG00000214846.4	RP11-115L11.1	4.64	3.84e-06	0.000346	0.17	0.14	Parkinson's disease;	chr4:15690513	chr4:15730962~15731627:-
BRCA	cis	rs983392	0.776	rs2278867	ENSG00000275344.1	MIR6503	-4.64	3.84e-06	0.000346	-0.15	-0.14	Alzheimer's disease (late onset);	chr11:60175636	chr11:60209071~60209156:-
BRCA	cis	rs11051970	0.527	rs7962680	ENSG00000274964.1	RP11-817I4.1	-4.64	3.84e-06	0.000346	-0.21	-0.14	Response to tocilizumab in rheumatoid arthritis;	chr12:32322377	chr12:32339368~32340724:+
BRCA	cis	rs3824867	0.92	rs3740684	ENSG00000280615.1	Y_RNA	-4.64	3.84e-06	0.000346	-0.17	-0.14	Mean corpuscular hemoglobin;	chr11:47447268	chr11:47614898~47614994:-
BRCA	cis	rs2835345	0.531	rs2409816	ENSG00000279365.1	KB-176G8.1	4.64	3.84e-06	0.000346	0.19	0.14	Pulmonary function;	chr21:36453663	chr21:36485867~36487760:+
BRCA	cis	rs7267979	0.816	rs6037158	ENSG00000274414.1	RP5-965G21.4	-4.64	3.84e-06	0.000346	-0.17	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25614830	chr20:25239007~25245229:-
BRCA	cis	rs2303319	0.504	rs62187646	ENSG00000227403.1	AC009299.3	4.64	3.84e-06	0.000346	0.34	0.14	Cognitive function;	chr2:161588978	chr2:161244739~161249050:+
BRCA	cis	rs642803	0.613	rs565427	ENSG00000255557.1	RP11-770G2.2	-4.64	3.84e-06	0.000346	-0.18	-0.14	Urate levels;	chr11:65765354	chr11:65745729~65771585:+
BRCA	cis	rs875971	0.545	rs316305	ENSG00000230295.1	RP11-458F8.2	-4.64	3.84e-06	0.000346	-0.13	-0.14	Aortic root size;	chr7:66152984	chr7:66880708~66882981:+
BRCA	cis	rs6921919	0.583	rs35560946	ENSG00000273712.1	RP5-874C20.7	4.64	3.85e-06	0.000346	0.19	0.14	Autism spectrum disorder or schizophrenia;	chr6:28427660	chr6:28315613~28315883:-
BRCA	cis	rs17428076	0.874	rs62182374	ENSG00000228389.1	AC068039.4	-4.64	3.85e-06	0.000347	-0.2	-0.14	Myopia;	chr2:171829172	chr2:171773482~171775844:+
BRCA	cis	rs838147	0.76	rs412712	ENSG00000232871.7	SEC1P	-4.64	3.85e-06	0.000347	-0.16	-0.14	Dietary macronutrient intake;	chr19:48731042	chr19:48638071~48682245:+
BRCA	cis	rs1950832	0.689	rs11623805	ENSG00000258636.1	CTD-2298J14.2	4.64	3.85e-06	0.000347	0.17	0.14	Urate levels in obese individuals;	chr14:41695287	chr14:41587861~41604856:-
BRCA	cis	rs13113518	0.902	rs12642716	ENSG00000273257.1	RP11-177J6.1	4.64	3.85e-06	0.000347	0.18	0.14	Height;	chr4:55479996	chr4:55387949~55388271:+
BRCA	cis	rs10457838	0.851	rs1934220	ENSG00000236591.1	RP11-162J8.3	-4.64	3.85e-06	0.000347	-0.2	-0.14	Post-traumatic stress disorder;	chr6:149046975	chr6:149027700~149032573:-
BRCA	cis	rs2692947	0.711	rs56791141	ENSG00000168992.4	OR7E102P	4.64	3.85e-06	0.000347	0.19	0.14	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95921748	chr2:95546531~95547545:+
BRCA	cis	rs7811142	0.83	rs3087502	ENSG00000078319.8	PMS2P1	-4.64	3.85e-06	0.000347	-0.23	-0.14	Platelet count;	chr7:100357741	chr7:100320992~100341908:-
BRCA	cis	rs7811142	0.83	rs61735533	ENSG00000078319.8	PMS2P1	-4.64	3.85e-06	0.000347	-0.23	-0.14	Platelet count;	chr7:100358243	chr7:100320992~100341908:-
BRCA	cis	rs11123406	0.501	rs62160380	ENSG00000230499.1	AC108463.1	4.64	3.85e-06	0.000347	0.2	0.14	Type 2 diabetes;	chr2:111213187	chr2:111195963~111206494:+
BRCA	cis	rs6738627	1	rs12692737	ENSG00000223318.1	RNA5SP111	4.64	3.85e-06	0.000347	0.16	0.14	circulating leptin levels adjusted for BMI;Body fat percentage;circulating leptin levels;	chr2:164697799	chr2:164895677~164895777:-
BRCA	cis	rs10761482	0.544	rs1934760	ENSG00000254271.1	RP11-131N11.4	4.64	3.85e-06	0.000347	0.19	0.14	Schizophrenia;	chr10:60496987	chr10:60734342~60741828:+
BRCA	cis	rs2288884	0.505	rs2278415	ENSG00000275055.1	CTC-471J1.11	-4.64	3.86e-06	0.000347	-0.23	-0.14	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:51964950	chr19:52049007~52049754:+
BRCA	cis	rs2288884	0.505	rs3764538	ENSG00000275055.1	CTC-471J1.11	-4.64	3.86e-06	0.000347	-0.23	-0.14	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:51965334	chr19:52049007~52049754:+
BRCA	cis	rs9300255	0.543	rs1617156	ENSG00000235423.7	RP11-282O18.3	4.64	3.86e-06	0.000347	0.18	0.14	Neutrophil percentage of white cells;	chr12:123105618	chr12:123252030~123261483:-
BRCA	cis	rs2153535	0.563	rs3117071	ENSG00000251164.1	HULC	-4.64	3.86e-06	0.000347	-0.18	-0.14	Motion sickness;	chr6:8537675	chr6:8652137~8653846:+
BRCA	cis	rs7927592	0.731	rs10896350	ENSG00000212093.1	AP000807.1	4.64	3.86e-06	0.000347	0.15	0.14	Total body bone mineral density;	chr11:68618905	chr11:68506083~68506166:-
BRCA	cis	rs11098499	0.954	rs13107475	ENSG00000260091.1	RP11-33B1.4	-4.64	3.86e-06	0.000347	-0.12	-0.14	Corneal astigmatism;	chr4:119471856	chr4:119409333~119410233:+
BRCA	cis	rs8098244	0.603	rs1711457	ENSG00000264745.1	TTC39C-AS1	4.64	3.86e-06	0.000347	0.17	0.14	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23699494	chr18:23994213~24015339:-
BRCA	cis	rs7246657	0.722	rs2927747	ENSG00000226686.6	LINC01535	4.64	3.86e-06	0.000347	0.21	0.14	Coronary artery calcification;	chr19:37668629	chr19:37251912~37265535:+
BRCA	cis	rs2692947	0.702	rs4907291	ENSG00000168992.4	OR7E102P	4.64	3.86e-06	0.000347	0.18	0.14	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95988857	chr2:95546531~95547545:+
BRCA	cis	rs1198430	1	rs1198439	ENSG00000271420.1	RP5-1057J7.7	4.64	3.86e-06	0.000348	0.18	0.14	Total cholesterol levels;	chr1:23423100	chr1:23378380~23379029:-
BRCA	cis	rs875971	0.54	rs35510581	ENSG00000273024.4	INTS4P2	4.64	3.86e-06	0.000348	0.16	0.14	Aortic root size;	chr7:66113790	chr7:65647864~65715661:+
BRCA	cis	rs7674212	0.541	rs2615539	ENSG00000251288.2	RP11-10L12.2	-4.64	3.86e-06	0.000348	-0.17	-0.14	Type 2 diabetes;	chr4:103159949	chr4:102751401~102752641:+
BRCA	cis	rs7665090	1	rs10027437	ENSG00000251288.2	RP11-10L12.2	-4.64	3.86e-06	0.000348	-0.17	-0.14	Primary biliary cholangitis;	chr4:102636094	chr4:102751401~102752641:+
BRCA	cis	rs6125597	0.904	rs2273146	ENSG00000222365.1	SNORD12B	4.64	3.86e-06	0.000348	0.15	0.14	Intelligence (multi-trait analysis);	chr20:49223116	chr20:49280319~49280409:+
BRCA	cis	rs6125597	1	rs6125597	ENSG00000222365.1	SNORD12B	4.64	3.86e-06	0.000348	0.15	0.14	Intelligence (multi-trait analysis);	chr20:49224235	chr20:49280319~49280409:+
BRCA	cis	rs7572733	0.576	rs4850441	ENSG00000231621.1	AC013264.2	4.64	3.86e-06	0.000348	0.14	0.14	Dermatomyositis;	chr2:198048689	chr2:197197991~197199273:+
BRCA	cis	rs9921338	0.961	rs4780358	ENSG00000262703.1	RP11-485G7.6	-4.64	3.86e-06	0.000348	-0.18	-0.14	Vein graft stenosis in coronary artery bypass grafting;	chr16:11280355	chr16:11348143~11349321:-
BRCA	cis	rs4578769	0.959	rs3911557	ENSG00000265939.1	UBE2CP2	-4.64	3.86e-06	0.000348	-0.17	-0.14	Eosinophil percentage of white cells;	chr18:22892600	chr18:22900486~22900995:-
BRCA	cis	rs6442522	0.56	rs2255897	ENSG00000249786.6	EAF1-AS1	-4.64	3.86e-06	0.000348	-0.15	-0.14	Uric acid levels;	chr3:15479170	chr3:15436171~15455940:-
BRCA	cis	rs256438	0.731	rs9293799	ENSG00000251050.1	RP11-168A11.4	-4.64	3.87e-06	0.000348	-0.17	-0.14	Serum thyroid-stimulating hormone levels;	chr5:80049726	chr5:80019609~80019920:+
BRCA	cis	rs2692947	0.55	rs12623771	ENSG00000232931.4	LINC00342	4.64	3.87e-06	0.000348	0.14	0.14	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95967756	chr2:95807118~95816215:-
BRCA	cis	rs62025270	0.747	rs12324721	ENSG00000259295.5	CSPG4P12	-4.64	3.87e-06	0.000348	-0.22	-0.14	Idiopathic pulmonary fibrosis;	chr15:85767741	chr15:85191438~85213905:+
BRCA	cis	rs4780355	0.918	rs243318	ENSG00000262703.1	RP11-485G7.6	4.64	3.87e-06	0.000348	0.15	0.14	Crohn's disease and psoriasis;	chr16:11264161	chr16:11348143~11349321:-
BRCA	cis	rs10129255	0.5	rs2027902	ENSG00000254174.1	IGHV1-12	4.64	3.87e-06	0.000348	0.11	0.14	Kawasaki disease;	chr14:106807157	chr14:106122420~106122709:-
BRCA	cis	rs11098499	0.954	rs7681544	ENSG00000250412.1	KLHL2P1	4.64	3.87e-06	0.000348	0.17	0.14	Corneal astigmatism;	chr4:119490100	chr4:119334329~119378233:+
BRCA	cis	rs11673344	0.504	rs10403975	ENSG00000226686.6	LINC01535	4.64	3.87e-06	0.000348	0.18	0.14	Obesity-related traits;	chr19:37082172	chr19:37251912~37265535:+
BRCA	cis	rs9467773	0.967	rs6924865	ENSG00000241549.7	GUSBP2	4.64	3.87e-06	0.000348	0.15	0.14	Intelligence (multi-trait analysis);	chr6:26521125	chr6:26871484~26956554:-
BRCA	cis	rs4356203	0.905	rs214906	ENSG00000272034.1	SNORD14A	4.64	3.87e-06	0.000349	0.15	0.14	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17159793	chr11:17074654~17074744:-
BRCA	cis	rs6686842	0.965	rs2802548	ENSG00000235358.1	RP11-399E6.1	-4.64	3.87e-06	0.000349	-0.18	-0.14	Height;	chr1:41035441	chr1:41242373~41284861:+
BRCA	cis	rs2880765	0.545	rs11631739	ENSG00000202081.1	RNU6-1280P	4.64	3.87e-06	0.000349	0.18	0.14	Coronary artery disease;	chr15:85469347	chr15:85651522~85651628:-
BRCA	cis	rs7428	0.527	rs4832164	ENSG00000273196.1	RP11-717A5.2	4.64	3.88e-06	0.000349	0.17	0.14	Ear protrusion;	chr2:85319809	chr2:85387074~85387146:-
BRCA	cis	rs3768617	0.51	rs10752896	ENSG00000224468.3	RP11-181K3.4	-4.64	3.88e-06	0.000349	-0.16	-0.14	Fuchs's corneal dystrophy;	chr1:183099381	chr1:183138402~183141282:-
BRCA	cis	rs7267979	0.744	rs6050463	ENSG00000274973.1	RP13-401N8.7	-4.64	3.88e-06	0.000349	-0.16	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25228354	chr20:25845497~25845862:+
BRCA	cis	rs4699052	0.625	rs2138592	ENSG00000248740.4	RP11-328K4.1	4.64	3.88e-06	0.000349	0.16	0.14	Testicular germ cell tumor;	chr4:103334561	chr4:103256159~103453658:+
BRCA	cis	rs1005277	0.579	rs1985707	ENSG00000263064.2	RP11-291L22.7	4.64	3.88e-06	0.000349	0.17	0.14	Extrinsic epigenetic age acceleration;	chr10:38145170	chr10:38448689~38448949:+
BRCA	cis	rs1345301	0.552	rs67880537	ENSG00000234389.1	AC007278.3	-4.64	3.88e-06	0.000349	-0.13	-0.14	Waist circumference;	chr2:102247646	chr2:102438713~102440475:+
BRCA	cis	rs6860806	0.631	rs6863548	ENSG00000233006.5	AC034220.3	4.64	3.88e-06	0.000349	0.1	0.14	Breast cancer;	chr5:132240227	chr5:132311285~132369916:-
BRCA	cis	rs2562456	0.724	rs58001930	ENSG00000268658.4	LINC00664	4.64	3.88e-06	0.00035	0.22	0.14	Pain;	chr19:21560061	chr19:21483374~21503238:+
BRCA	cis	rs7818688	1	rs10098197	ENSG00000253528.2	RP11-347C18.4	-4.64	3.89e-06	0.00035	-0.21	-0.14	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95030662	chr8:94974573~94974853:-
BRCA	cis	rs7818688	1	rs56901035	ENSG00000253528.2	RP11-347C18.4	-4.64	3.89e-06	0.00035	-0.21	-0.14	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95030960	chr8:94974573~94974853:-
BRCA	cis	rs2554380	0.891	rs1896816	ENSG00000230373.7	GOLGA6L5P	-4.64	3.89e-06	0.00035	-0.2	-0.14	Height;	chr15:83630619	chr15:84507885~84516814:-
BRCA	cis	rs10861342	1	rs10861357	ENSG00000257999.1	RP11-61E11.2	-4.64	3.89e-06	0.00035	-0.3	-0.14	IgG glycosylation;	chr12:105150476	chr12:105102472~105107179:-
BRCA	cis	rs9467773	0.595	rs4320356	ENSG00000124549.13	BTN2A3P	-4.64	3.89e-06	0.00035	-0.15	-0.14	Intelligence (multi-trait analysis);	chr6:26423332	chr6:26421391~26432383:+
BRCA	cis	rs1371614	0.523	rs893789	ENSG00000229122.1	AGBL5-IT1	4.64	3.89e-06	0.00035	0.15	0.14	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26961102	chr2:27061038~27061815:+
BRCA	cis	rs11096990	0.634	rs2381372	ENSG00000249685.1	RP11-360F5.3	4.64	3.89e-06	0.00035	0.18	0.14	Cognitive function;	chr4:39271471	chr4:39133913~39135608:+
BRCA	cis	rs7829975	0.688	rs7837587	ENSG00000253981.4	ALG1L13P	4.64	3.89e-06	0.00035	0.16	0.14	Mood instability;	chr8:8521482	chr8:8236003~8244667:-
BRCA	cis	rs300890	0.662	rs4544668	ENSG00000250326.1	RP11-284M14.1	-4.64	3.89e-06	0.00035	-0.17	-0.14	Nasopharyngeal carcinoma;	chr4:143314650	chr4:142933195~143184861:-
BRCA	cis	rs10266483	0.656	rs670966	ENSG00000227986.1	TRIM60P18	-4.64	3.89e-06	0.00035	-0.15	-0.14	Response to statin therapy;	chr7:64302521	chr7:64355078~64356199:+
BRCA	cis	rs1005277	0.557	rs1854563	ENSG00000263064.2	RP11-291L22.7	4.64	3.89e-06	0.00035	0.17	0.14	Extrinsic epigenetic age acceleration;	chr10:38146033	chr10:38448689~38448949:+
BRCA	cis	rs1005277	0.579	rs2505240	ENSG00000263064.2	RP11-291L22.7	4.64	3.89e-06	0.00035	0.17	0.14	Extrinsic epigenetic age acceleration;	chr10:38153491	chr10:38448689~38448949:+
BRCA	cis	rs6095360	1	rs3092427	ENSG00000222365.1	SNORD12B	-4.64	3.89e-06	0.00035	-0.16	-0.14	Intelligence (multi-trait analysis);	chr20:49158244	chr20:49280319~49280409:+
BRCA	cis	rs6095360	0.933	rs348267	ENSG00000222365.1	SNORD12B	-4.64	3.89e-06	0.00035	-0.16	-0.14	Intelligence (multi-trait analysis);	chr20:49159384	chr20:49280319~49280409:+
BRCA	cis	rs7618915	0.501	rs34754793	ENSG00000243224.1	RP5-1157M23.2	-4.64	3.89e-06	0.00035	-0.15	-0.14	Bipolar disorder;	chr3:52595161	chr3:52239258~52241097:+
BRCA	cis	rs7618915	0.501	rs9917834	ENSG00000243224.1	RP5-1157M23.2	-4.64	3.89e-06	0.00035	-0.15	-0.14	Bipolar disorder;	chr3:52600603	chr3:52239258~52241097:+
BRCA	cis	rs7618915	0.501	rs11130308	ENSG00000243224.1	RP5-1157M23.2	-4.64	3.89e-06	0.00035	-0.15	-0.14	Bipolar disorder;	chr3:52605241	chr3:52239258~52241097:+
BRCA	cis	rs12744310	0.887	rs35690915	ENSG00000235358.1	RP11-399E6.1	4.64	3.89e-06	0.00035	0.21	0.14	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41332327	chr1:41242373~41284861:+
BRCA	cis	rs6452524	0.935	rs10043698	ENSG00000281327.1	LINC01338	4.64	3.9e-06	0.00035	0.17	0.14	Hypertension (SNP x SNP interaction);	chr5:83169100	chr5:82850864~82859836:-
BRCA	cis	rs9311474	0.508	rs7625743	ENSG00000243224.1	RP5-1157M23.2	-4.64	3.9e-06	0.000351	-0.15	-0.14	Electroencephalogram traits;	chr3:52572350	chr3:52239258~52241097:+
BRCA	cis	rs9311474	0.508	rs6805156	ENSG00000243224.1	RP5-1157M23.2	-4.64	3.9e-06	0.000351	-0.15	-0.14	Electroencephalogram traits;	chr3:52575346	chr3:52239258~52241097:+
BRCA	cis	rs7200543	1	rs72774845	ENSG00000275910.1	RP11-680G24.6	-4.64	3.9e-06	0.000351	-0.17	-0.14	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15054097	chr16:15015828~15016390:-
BRCA	cis	rs1075265	0.73	rs7597189	ENSG00000235937.1	AC008280.1	4.64	3.9e-06	0.000351	0.15	0.14	Chronotype;Morning vs. evening chronotype;	chr2:54014733	chr2:54029552~54030682:-
BRCA	cis	rs4713118	0.868	rs35069907	ENSG00000216901.1	AL022393.7	4.64	3.9e-06	0.000351	0.2	0.14	Parkinson's disease;	chr6:27778913	chr6:28176188~28176674:+
BRCA	cis	rs2839186	0.934	rs2839194	ENSG00000228137.1	AP001469.7	4.64	3.9e-06	0.000351	0.15	0.14	Testicular germ cell tumor;	chr21:46279523	chr21:46246890~46247682:+
BRCA	cis	rs6840360	0.642	rs2709816	ENSG00000251603.1	RP11-164P12.4	-4.64	3.9e-06	0.000351	-0.13	-0.14	Intelligence (multi-trait analysis);	chr4:151459117	chr4:151667224~151670502:+
BRCA	cis	rs10129255	0.957	rs8022165	ENSG00000280411.1	IGHV1-69-2	-4.64	3.9e-06	0.000351	-0.1	-0.14	Kawasaki disease;	chr14:106781682	chr14:106762092~106762588:-
BRCA	cis	rs7914558	0.646	rs10883799	ENSG00000213061.2	PFN1P11	4.64	3.9e-06	0.000351	0.2	0.14	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102903553	chr10:102838011~102845473:-
BRCA	cis	rs34421088	0.585	rs1390950	ENSG00000255046.1	RP11-297N6.4	4.64	3.9e-06	0.000351	0.18	0.14	Neuroticism;	chr8:11738320	chr8:11797928~11802568:-
BRCA	cis	rs6840360	0.642	rs1443089	ENSG00000251603.1	RP11-164P12.4	-4.64	3.9e-06	0.000351	-0.13	-0.14	Intelligence (multi-trait analysis);	chr4:151529148	chr4:151667224~151670502:+
BRCA	cis	rs4865762	0.967	rs57244200	ENSG00000247796.2	CTD-2366F13.1	-4.64	3.9e-06	0.000351	-0.15	-0.14	Intraocular pressure;	chr5:53268141	chr5:53109842~53115126:+
BRCA	cis	rs4948275	0.804	rs2650754	ENSG00000237233.2	TMEM26-AS1	-4.64	3.9e-06	0.000351	-0.16	-0.14	Night sleep phenotypes;	chr10:61502195	chr10:61452639~61481956:+
BRCA	cis	rs736408	0.648	rs3774355	ENSG00000243224.1	RP5-1157M23.2	-4.64	3.9e-06	0.000351	-0.16	-0.14	Bipolar disorder;	chr3:52783762	chr3:52239258~52241097:+
BRCA	cis	rs559555	0.521	rs223631	ENSG00000272716.1	RP11-563N4.1	4.64	3.9e-06	0.000351	0.15	0.14	Blood metabolite ratios;Blood metabolite levels;	chr2:31760994	chr2:32165046~32165757:-
BRCA	cis	rs9818758	0.556	rs9880309	ENSG00000225399.4	RP11-3B7.1	-4.64	3.9e-06	0.000351	-0.23	-0.14	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49266896	chr3:49260085~49261316:+
BRCA	cis	rs4434138	0.683	rs13063160	ENSG00000243224.1	RP5-1157M23.2	-4.64	3.9e-06	0.000351	-0.15	-0.14	Intelligence (multi-trait analysis);	chr3:52568258	chr3:52239258~52241097:+
BRCA	cis	rs9311474	0.508	rs6786043	ENSG00000243224.1	RP5-1157M23.2	-4.64	3.9e-06	0.000351	-0.15	-0.14	Electroencephalogram traits;	chr3:52570845	chr3:52239258~52241097:+
BRCA	cis	rs738722	1	rs1033667	ENSG00000279978.1	chr22-38_28785274-29006793.1	4.64	3.9e-06	0.000351	0.19	0.14	Optic cup area;Esophageal cancer and gastric cancer;	chr22:28734312	chr22:28930201~29197572:+
BRCA	cis	rs4831760	0.963	rs7844322	ENSG00000250483.1	PPM1AP1	4.64	3.9e-06	0.000351	0.2	0.14	Pulmonary function decline;	chr8:15678569	chr8:15806149~15807283:-
BRCA	cis	rs3812762	0.833	rs10500705	ENSG00000254860.4	TMEM9B-AS1	4.64	3.9e-06	0.000351	0.14	0.14	Hypospadias;	chr11:8783714	chr11:8964675~8977527:+
BRCA	cis	rs1395	0.778	rs11693660	ENSG00000234072.1	AC074117.10	-4.64	3.91e-06	0.000351	-0.16	-0.14	Blood metabolite levels;	chr2:27245988	chr2:27356246~27367622:+
BRCA	cis	rs4722166	0.695	rs7793125	ENSG00000225541.1	AC002480.5	-4.64	3.91e-06	0.000351	-0.15	-0.14	Lung cancer;	chr7:22769541	chr7:22571607~22661792:-
BRCA	cis	rs11124272	0.857	rs11683744	ENSG00000272716.1	RP11-563N4.1	-4.64	3.91e-06	0.000352	-0.17	-0.14	Interleukin-18 levels;	chr2:31760239	chr2:32165046~32165757:-
BRCA	cis	rs6088580	0.634	rs6088488	ENSG00000276073.1	RP5-1125A11.7	4.64	3.91e-06	0.000352	0.16	0.14	Glomerular filtration rate (creatinine);	chr20:34404825	chr20:33985617~33988989:-
BRCA	cis	rs7267979	0.816	rs376742	ENSG00000204556.4	CTD-2514C3.1	-4.64	3.91e-06	0.000352	-0.19	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25506781	chr20:26018832~26020684:+
BRCA	cis	rs4948275	0.773	rs2256597	ENSG00000237233.2	TMEM26-AS1	-4.64	3.91e-06	0.000352	-0.17	-0.14	Night sleep phenotypes;	chr10:61503536	chr10:61452639~61481956:+
BRCA	cis	rs13113518	0.934	rs11935823	ENSG00000249700.7	SRD5A3-AS1	4.64	3.91e-06	0.000352	0.18	0.14	Height;	chr4:55589624	chr4:55363971~55395847:-
BRCA	cis	rs7615952	0.515	rs4441610	ENSG00000171084.14	FAM86JP	4.64	3.91e-06	0.000352	0.21	0.14	Blood pressure (smoking interaction);	chr3:125962464	chr3:125916620~125930024:+
BRCA	cis	rs2115630	0.691	rs2292462	ENSG00000275120.1	RP11-182J1.17	-4.64	3.91e-06	0.000352	-0.17	-0.14	P wave terminal force;	chr15:84657523	chr15:84599434~84606463:-
BRCA	cis	rs6570726	0.935	rs434298	ENSG00000270638.1	RP3-466P17.1	4.64	3.92e-06	0.000352	0.16	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145525737	chr6:145735570~145737218:+
BRCA	cis	rs1371614	0.566	rs11695406	ENSG00000229122.1	AGBL5-IT1	-4.64	3.92e-06	0.000352	-0.15	-0.14	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26955261	chr2:27061038~27061815:+
BRCA	cis	rs9628987	0.5	rs55823627	ENSG00000232912.4	RP5-1115A15.1	-4.64	3.92e-06	0.000352	-0.19	-0.14	Breast cancer;	chr1:8402019	chr1:8424645~8434838:+
BRCA	cis	rs7937890	1	rs2970335	ENSG00000254418.1	RP11-21L19.1	4.64	3.92e-06	0.000352	0.16	0.14	Mitochondrial DNA levels;	chr11:14303855	chr11:14262846~14273691:-
BRCA	cis	rs1322639	0.614	rs6925188	ENSG00000223485.1	RP11-417E7.1	-4.64	3.92e-06	0.000352	-0.2	-0.14	Pulse pressure;	chr6:169163242	chr6:169158092~169162924:-
BRCA	cis	rs9473147	0.571	rs9369717	ENSG00000270761.1	RP11-385F7.1	-4.64	3.92e-06	0.000352	-0.15	-0.14	Platelet distribution width;Mean platelet volume;	chr6:47586732	chr6:47477243~47477572:-
BRCA	cis	rs17711722	1	rs17711722	ENSG00000182722.5	SEPHS1P1	4.64	3.92e-06	0.000352	0.18	0.14	Calcium levels;	chr7:65806210	chr7:64852397~64853354:-
BRCA	cis	rs13108904	0.846	rs4974574	ENSG00000254094.1	AC078852.1	-4.64	3.92e-06	0.000352	-0.16	-0.14	Obesity-related traits;	chr4:1231023	chr4:1356581~1358075:+
BRCA	cis	rs7592578	0.723	rs4371384	ENSG00000272979.1	RP11-647K16.1	4.64	3.92e-06	0.000353	0.24	0.14	Diastolic blood pressure;	chr2:190566015	chr2:190454092~190454521:-
BRCA	cis	rs2070615	0.545	rs2453478	ENSG00000239617.1	RP11-302B13.1	-4.64	3.92e-06	0.000353	-0.18	-0.14	Bipolar disorder;	chr12:48808960	chr12:48903418~48903813:-
BRCA	cis	rs72615157	0.645	rs76281814	ENSG00000242294.5	STAG3L5P	4.64	3.92e-06	0.000353	0.14	0.14	Lung function (FEV1/FVC);	chr7:100248791	chr7:100336079~100351900:+
BRCA	cis	rs72615157	0.595	rs112241539	ENSG00000242294.5	STAG3L5P	4.64	3.92e-06	0.000353	0.14	0.14	Lung function (FEV1/FVC);	chr7:100249614	chr7:100336079~100351900:+
BRCA	cis	rs10844706	0.699	rs10844630	ENSG00000214776.8	RP11-726G1.1	4.64	3.93e-06	0.000353	0.17	0.14	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9734268	chr12:9467552~9576275:+
BRCA	cis	rs10946940	0.965	rs9393830	ENSG00000216901.1	AL022393.7	4.64	3.93e-06	0.000353	0.17	0.14	Systemic lupus erythematosus;	chr6:27619248	chr6:28176188~28176674:+
BRCA	cis	rs13113518	1	rs7660980	ENSG00000273257.1	RP11-177J6.1	-4.64	3.93e-06	0.000353	-0.18	-0.14	Height;	chr4:55542948	chr4:55387949~55388271:+
BRCA	cis	rs2243480	0.708	rs13242216	ENSG00000222364.1	RNU6-96P	-4.64	3.93e-06	0.000353	-0.26	-0.14	Diabetic kidney disease;	chr7:66433290	chr7:66395191~66395286:+
BRCA	cis	rs375066	0.935	rs11673020	ENSG00000267191.1	RP11-15A1.2	-4.64	3.93e-06	0.000353	-0.18	-0.14	Breast cancer;	chr19:43870479	chr19:43902001~43926545:+
BRCA	cis	rs10266483	0.774	rs10253630	ENSG00000227986.1	TRIM60P18	4.64	3.93e-06	0.000353	0.15	0.14	Response to statin therapy;	chr7:64366962	chr7:64355078~64356199:+
BRCA	cis	rs13326165	0.585	rs7628461	ENSG00000243224.1	RP5-1157M23.2	-4.64	3.93e-06	0.000353	-0.24	-0.14	HDL cholesterol levels;HDL cholesterol;	chr3:52238012	chr3:52239258~52241097:+
BRCA	cis	rs11239930	0.517	rs492243	ENSG00000278811.3	LINC00624	4.64	3.93e-06	0.000353	0.17	0.14	AIDS progression;	chr1:147077930	chr1:147258885~147517875:-
BRCA	cis	rs12497850	0.897	rs6446252	ENSG00000225399.4	RP11-3B7.1	4.64	3.93e-06	0.000354	0.14	0.14	Parkinson's disease;	chr3:48873692	chr3:49260085~49261316:+
BRCA	cis	rs6847067	0.55	rs12502559	ENSG00000180769.7	WDFY3-AS2	4.64	3.94e-06	0.000354	0.14	0.14	Oropharynx cancer;	chr4:84954487	chr4:84965682~85011277:+
BRCA	cis	rs1223397	0.651	rs641758	ENSG00000215022.6	RP1-257A7.4	-4.64	3.94e-06	0.000354	-0.17	-0.14	Blood pressure;	chr6:13300270	chr6:13264861~13295586:-
BRCA	cis	rs3812049	0.826	rs34576922	ENSG00000245937.6	LINC01184	-4.64	3.94e-06	0.000354	-0.19	-0.14	Lymphocyte counts;Red cell distribution width;	chr5:128028411	chr5:127940426~128083172:-
BRCA	cis	rs7772486	0.875	rs2777484	ENSG00000270638.1	RP3-466P17.1	4.64	3.94e-06	0.000354	0.16	0.14	Lobe attachment (rater-scored or self-reported);	chr6:146013026	chr6:145735570~145737218:+
BRCA	cis	rs6696239	0.513	rs12042653	ENSG00000227711.2	RP11-275O4.5	4.64	3.94e-06	0.000354	0.16	0.14	Height;	chr1:227524509	chr1:227509028~227520477:-
BRCA	cis	rs78487399	0.908	rs78471316	ENSG00000234936.1	AC010883.5	4.64	3.94e-06	0.000354	0.22	0.14	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43617309	chr2:43229573~43233394:+
BRCA	cis	rs17270561	0.887	rs9358870	ENSG00000272462.2	U91328.19	-4.64	3.94e-06	0.000354	-0.2	-0.14	Iron status biomarkers;	chr6:25718982	chr6:25992662~26001775:+
BRCA	cis	rs7011507	0.532	rs55902055	ENSG00000279881.1	RP11-513O13.1	-4.64	3.94e-06	0.000354	-0.23	-0.14	Inflammatory bowel disease;Ulcerative colitis;	chr8:48316315	chr8:48428143~48431041:-
BRCA	cis	rs11048434	0.535	rs2377680	ENSG00000256720.1	RP11-436I9.6	-4.64	3.94e-06	0.000354	-0.16	-0.14	Sjögren's syndrome;	chr12:9038809	chr12:9135084~9135591:+
BRCA	cis	rs2288912	0.807	rs7251501	ENSG00000280087.1	CTB-129P6.7	4.64	3.94e-06	0.000354	0.17	0.14	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr19:44952449	chr19:44909375~44914968:+
BRCA	cis	rs2288912	0.838	rs7251503	ENSG00000280087.1	CTB-129P6.7	4.64	3.94e-06	0.000354	0.17	0.14	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr19:44952458	chr19:44909375~44914968:+
BRCA	cis	rs5167	0.504	rs4803779	ENSG00000280087.1	CTB-129P6.7	4.64	3.94e-06	0.000354	0.17	0.14	Blood protein levels;	chr19:44953240	chr19:44909375~44914968:+
BRCA	cis	rs6832769	1	rs10005989	ENSG00000272969.1	RP11-528I4.2	-4.64	3.94e-06	0.000354	-0.17	-0.14	Personality dimensions;	chr4:55539039	chr4:55547112~55547889:+
BRCA	cis	rs3176789	0.914	rs10844737	ENSG00000256673.1	RP11-599J14.2	4.64	3.95e-06	0.000354	0.17	0.14	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9770056	chr12:9398355~9414851:-
BRCA	cis	rs6088580	0.634	rs6120669	ENSG00000276073.1	RP5-1125A11.7	-4.64	3.95e-06	0.000355	-0.16	-0.14	Glomerular filtration rate (creatinine);	chr20:34517223	chr20:33985617~33988989:-
BRCA	cis	rs3768617	0.51	rs2333620	ENSG00000224468.3	RP11-181K3.4	-4.64	3.95e-06	0.000355	-0.15	-0.14	Fuchs's corneal dystrophy;	chr1:183131420	chr1:183138402~183141282:-
BRCA	cis	rs6921919	0.609	rs67211468	ENSG00000273712.1	RP5-874C20.7	4.64	3.95e-06	0.000355	0.19	0.14	Autism spectrum disorder or schizophrenia;	chr6:28424210	chr6:28315613~28315883:-
BRCA	cis	rs736408	0.562	rs12497998	ENSG00000243224.1	RP5-1157M23.2	-4.64	3.95e-06	0.000355	-0.15	-0.14	Bipolar disorder;	chr3:52759586	chr3:52239258~52241097:+
BRCA	cis	rs7246657	0.639	rs3112434	ENSG00000276846.1	CTD-3220F14.3	-4.64	3.95e-06	0.000355	-0.2	-0.14	Coronary artery calcification;	chr19:37707247	chr19:37314868~37315620:-
BRCA	cis	rs6430585	0.528	rs79826902	ENSG00000231890.6	DARS-AS1	-4.64	3.95e-06	0.000355	-0.23	-0.14	Corneal structure;	chr2:135912849	chr2:135985176~136022593:+
BRCA	cis	rs34792	0.528	rs153804	ENSG00000207425.1	Y_RNA	4.64	3.95e-06	0.000355	0.16	0.14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15459197	chr16:14915457~14915556:-
BRCA	cis	rs516805	0.528	rs2606627	ENSG00000279453.1	RP3-425C14.4	-4.64	3.95e-06	0.000355	-0.2	-0.14	Lymphocyte counts;	chr6:122097129	chr6:122436789~122439223:-
BRCA	cis	rs6921919	0.583	rs740621	ENSG00000273712.1	RP5-874C20.7	4.64	3.95e-06	0.000355	0.19	0.14	Autism spectrum disorder or schizophrenia;	chr6:28430010	chr6:28315613~28315883:-
BRCA	cis	rs4662750	0.58	rs6715608	ENSG00000236682.1	AC068282.3	-4.64	3.95e-06	0.000355	-0.18	-0.14	Renal cell carcinoma;	chr2:127596130	chr2:127389130~127400580:+
BRCA	cis	rs2227564	0.729	rs2633303	ENSG00000271816.1	BMS1P4	4.64	3.96e-06	0.000355	0.16	0.14	Crohn's disease;Inflammatory bowel disease;	chr10:73886124	chr10:73699151~73730487:-
BRCA	cis	rs2562456	0.917	rs2650793	ENSG00000268535.1	RP11-420K14.3	-4.64	3.96e-06	0.000355	-0.19	-0.14	Pain;	chr19:21493313	chr19:21709522~21710191:+
BRCA	cis	rs3768617	0.811	rs61808068	ENSG00000224468.3	RP11-181K3.4	-4.64	3.96e-06	0.000355	-0.16	-0.14	Fuchs's corneal dystrophy;	chr1:183010242	chr1:183138402~183141282:-
BRCA	cis	rs3768617	0.811	rs12138049	ENSG00000224468.3	RP11-181K3.4	-4.64	3.96e-06	0.000355	-0.16	-0.14	Fuchs's corneal dystrophy;	chr1:183010411	chr1:183138402~183141282:-
BRCA	cis	rs755249	0.501	rs2455648	ENSG00000237624.1	OXCT2P1	4.64	3.96e-06	0.000355	0.18	0.14	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39178040	chr1:39514956~39516490:+
BRCA	cis	rs10129255	0.917	rs8022493	ENSG00000280411.1	IGHV1-69-2	-4.64	3.96e-06	0.000356	-0.1	-0.14	Kawasaki disease;	chr14:106781820	chr14:106762092~106762588:-
BRCA	cis	rs1371614	0.545	rs3769136	ENSG00000229122.1	AGBL5-IT1	4.64	3.96e-06	0.000356	0.15	0.14	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26945875	chr2:27061038~27061815:+
BRCA	cis	rs4713118	0.513	rs149941	ENSG00000219392.1	RP1-265C24.5	-4.64	3.96e-06	0.000356	-0.2	-0.14	Parkinson's disease;	chr6:28033255	chr6:28115628~28116551:+
BRCA	cis	rs7674212	0.57	rs2711898	ENSG00000246560.2	RP11-10L12.4	4.64	3.96e-06	0.000356	0.15	0.14	Type 2 diabetes;	chr4:103141914	chr4:102828055~102844075:+
BRCA	cis	rs5167	0.525	rs11083752	ENSG00000280087.1	CTB-129P6.7	4.64	3.96e-06	0.000356	0.17	0.14	Blood protein levels;	chr19:44951106	chr19:44909375~44914968:+
BRCA	cis	rs5167	0.504	rs7248162	ENSG00000280087.1	CTB-129P6.7	4.64	3.96e-06	0.000356	0.17	0.14	Blood protein levels;	chr19:44951429	chr19:44909375~44914968:+
BRCA	cis	rs6840360	0.582	rs2709823	ENSG00000251611.1	RP11-610P16.1	-4.64	3.96e-06	0.000356	-0.12	-0.14	Intelligence (multi-trait analysis);	chr4:151419294	chr4:151407551~151408835:-
BRCA	cis	rs62025270	0.632	rs7181796	ENSG00000259295.5	CSPG4P12	-4.64	3.96e-06	0.000356	-0.23	-0.14	Idiopathic pulmonary fibrosis;	chr15:85689778	chr15:85191438~85213905:+
BRCA	cis	rs7267979	1	rs6115182	ENSG00000274973.1	RP13-401N8.7	4.64	3.96e-06	0.000356	0.16	0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25429623	chr20:25845497~25845862:+
BRCA	cis	rs11098499	0.954	rs11098526	ENSG00000250412.1	KLHL2P1	4.64	3.96e-06	0.000356	0.17	0.14	Corneal astigmatism;	chr4:119469204	chr4:119334329~119378233:+
BRCA	cis	rs1124769	0.523	rs1276855	ENSG00000259378.1	DCAF13P3	-4.64	3.96e-06	0.000356	-0.19	-0.14	Cognitive performance;	chr15:50862083	chr15:50944663~50945996:+
BRCA	cis	rs12497850	0.931	rs9840684	ENSG00000225399.4	RP11-3B7.1	4.64	3.96e-06	0.000356	0.14	0.14	Parkinson's disease;	chr3:48856347	chr3:49260085~49261316:+
BRCA	cis	rs2243480	1	rs2257790	ENSG00000222364.1	RNU6-96P	-4.64	3.96e-06	0.000356	-0.26	-0.14	Diabetic kidney disease;	chr7:66135463	chr7:66395191~66395286:+
BRCA	cis	rs13113518	0.595	rs13120635	ENSG00000223305.1	RN7SKP30	4.64	3.97e-06	0.000356	0.2	0.14	Height;	chr4:55361200	chr4:55540502~55540835:-
BRCA	cis	rs6832769	0.961	rs3736545	ENSG00000272969.1	RP11-528I4.2	4.64	3.97e-06	0.000356	0.17	0.14	Personality dimensions;	chr4:55444176	chr4:55547112~55547889:+
BRCA	cis	rs7200543	1	rs72774845	ENSG00000258354.1	MIR3180-1	-4.64	3.97e-06	0.000356	-0.19	-0.14	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15054097	chr16:14909887~14911345:-
BRCA	cis	rs4819052	0.807	rs4819047	ENSG00000184274.3	LINC00315	-4.64	3.97e-06	0.000356	-0.2	-0.14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245224	chr21:45300245~45305257:-
BRCA	cis	rs13113518	0.934	rs10866425	ENSG00000249700.7	SRD5A3-AS1	4.64	3.97e-06	0.000356	0.18	0.14	Height;	chr4:55582068	chr4:55363971~55395847:-
BRCA	cis	rs2599510	0.693	rs2754514	ENSG00000276334.1	AL133243.1	4.64	3.97e-06	0.000356	0.18	0.14	Interleukin-18 levels;	chr2:32563769	chr2:32521927~32523547:+
BRCA	cis	rs4356203	0.875	rs667984	ENSG00000272034.1	SNORD14A	-4.64	3.97e-06	0.000356	-0.15	-0.14	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17179219	chr11:17074654~17074744:-
BRCA	cis	rs2574985	0.777	rs2983347	ENSG00000231345.3	BEND3P1	-4.64	3.97e-06	0.000356	-0.24	-0.14	Subjective well-being;	chr10:50519590	chr10:50655967~50660472:+
BRCA	cis	rs8040855	0.659	rs8037886	ENSG00000230373.7	GOLGA6L5P	-4.64	3.97e-06	0.000356	-0.18	-0.14	Bulimia nervosa;	chr15:85143533	chr15:84507885~84516814:-
BRCA	cis	rs13113518	1	rs4864547	ENSG00000273257.1	RP11-177J6.1	4.64	3.97e-06	0.000356	0.18	0.14	Height;	chr4:55538228	chr4:55387949~55388271:+
BRCA	cis	rs6832769	1	rs17085889	ENSG00000272969.1	RP11-528I4.2	-4.64	3.97e-06	0.000356	-0.17	-0.14	Personality dimensions;	chr4:55535948	chr4:55547112~55547889:+
BRCA	cis	rs913672	0.609	rs8116154	ENSG00000224397.4	LINC01272	4.64	3.97e-06	0.000356	0.16	0.14	Monocyte count;	chr20:50276198	chr20:50267486~50279795:+
BRCA	cis	rs1371614	0.632	rs6708148	ENSG00000229122.1	AGBL5-IT1	4.64	3.97e-06	0.000357	0.15	0.14	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26944452	chr2:27061038~27061815:+
BRCA	cis	rs2904967	0.929	rs626802	ENSG00000255200.1	AP003068.18	-4.64	3.97e-06	0.000357	-0.23	-0.14	Mean corpuscular volume;	chr11:65254141	chr11:65174117~65176470:-
BRCA	cis	rs6672530	0.518	rs2018651	ENSG00000227711.2	RP11-275O4.5	4.64	3.97e-06	0.000357	0.17	0.14	Hip circumference adjusted for BMI;	chr1:227508409	chr1:227509028~227520477:-
BRCA	cis	rs11098499	0.954	rs6857105	ENSG00000250412.1	KLHL2P1	4.64	3.97e-06	0.000357	0.17	0.14	Corneal astigmatism;	chr4:119301143	chr4:119334329~119378233:+
BRCA	cis	rs6095360	0.727	rs13044144	ENSG00000222365.1	SNORD12B	-4.64	3.97e-06	0.000357	-0.18	-0.14	Intelligence (multi-trait analysis);	chr20:48912271	chr20:49280319~49280409:+
BRCA	cis	rs11758351	1	rs79264785	ENSG00000241549.7	GUSBP2	-4.64	3.97e-06	0.000357	-0.21	-0.14	Renal underexcretion gout;Gout;	chr6:26193893	chr6:26871484~26956554:-
BRCA	cis	rs11758351	0.925	rs78932312	ENSG00000241549.7	GUSBP2	-4.64	3.97e-06	0.000357	-0.21	-0.14	Renal underexcretion gout;Gout;	chr6:26194641	chr6:26871484~26956554:-
BRCA	cis	rs11758351	1	rs3734530	ENSG00000241549.7	GUSBP2	-4.64	3.97e-06	0.000357	-0.21	-0.14	Renal underexcretion gout;Gout;	chr6:26195180	chr6:26871484~26956554:-
BRCA	cis	rs11758351	1	rs1341759	ENSG00000241549.7	GUSBP2	-4.64	3.97e-06	0.000357	-0.21	-0.14	Renal underexcretion gout;Gout;	chr6:26195274	chr6:26871484~26956554:-
BRCA	cis	rs11758351	1	rs76329209	ENSG00000241549.7	GUSBP2	-4.64	3.97e-06	0.000357	-0.21	-0.14	Renal underexcretion gout;Gout;	chr6:26196202	chr6:26871484~26956554:-
BRCA	cis	rs12612619	0.704	rs2119026	ENSG00000272148.1	RP11-195B17.1	-4.64	3.97e-06	0.000357	-0.16	-0.14	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27087525	chr2:27062428~27062907:-
BRCA	cis	rs12612619	0.704	rs7602823	ENSG00000229122.1	AGBL5-IT1	-4.64	3.98e-06	0.000357	-0.15	-0.14	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27086538	chr2:27061038~27061815:+
BRCA	cis	rs300890	0.513	rs4270544	ENSG00000250326.1	RP11-284M14.1	4.64	3.98e-06	0.000357	0.16	0.14	Nasopharyngeal carcinoma;	chr4:143123185	chr4:142933195~143184861:-
BRCA	cis	rs7818688	0.697	rs78802294	ENSG00000253528.2	RP11-347C18.4	-4.64	3.98e-06	0.000357	-0.22	-0.14	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94965746	chr8:94974573~94974853:-
BRCA	cis	rs10911902	0.643	rs76991105	ENSG00000229739.2	RP11-295K2.3	-4.64	3.98e-06	0.000357	-0.23	-0.14	Schizophrenia;	chr1:186376920	chr1:186435161~186470291:+
BRCA	cis	rs4489787	1	rs17122979	ENSG00000240399.1	RP1-228P16.1	-4.64	3.98e-06	0.000357	-0.23	-0.14	Prostate cancer (SNP x SNP interaction);	chr12:48419914	chr12:48054813~48055591:-
BRCA	cis	rs6723226	0.679	rs116617324	ENSG00000276517.1	AL133243.2	4.64	3.98e-06	0.000357	0.17	0.14	Intelligence (multi-trait analysis);	chr2:32397641	chr2:32526504~32529507:+
BRCA	cis	rs718433	0.584	rs2204934	ENSG00000256379.1	TRAV8-5	4.64	3.98e-06	0.000357	0.16	0.14	Intraocular pressure;	chr14:21744121	chr14:21903077~21903598:+
BRCA	cis	rs7520050	0.645	rs1768809	ENSG00000281133.1	AL355480.3	4.64	3.98e-06	0.000357	0.17	0.14	Reticulocyte count;Red blood cell count;	chr1:46037164	chr1:45580892~45580996:-
BRCA	cis	rs8022179	0.58	rs8013228	ENSG00000244691.1	RPL10AP1	-4.64	3.98e-06	0.000357	-0.2	-0.14	Monocyte count;	chr14:103376313	chr14:103412119~103412761:-
BRCA	cis	rs9457247	0.668	rs2236313	ENSG00000227598.1	RP1-167A14.2	-4.64	3.98e-06	0.000357	-0.14	-0.14	Crohn's disease;	chr6:166946901	chr6:166969626~166999065:-
BRCA	cis	rs6570726	0.935	rs454370	ENSG00000270638.1	RP3-466P17.1	4.64	3.98e-06	0.000358	0.16	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145525593	chr6:145735570~145737218:+
BRCA	cis	rs6570726	0.935	rs416987	ENSG00000270638.1	RP3-466P17.1	4.64	3.98e-06	0.000358	0.16	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145525869	chr6:145735570~145737218:+
BRCA	cis	rs6570726	0.905	rs452770	ENSG00000270638.1	RP3-466P17.1	4.64	3.98e-06	0.000358	0.16	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145526026	chr6:145735570~145737218:+
BRCA	cis	rs6570726	0.935	rs442254	ENSG00000270638.1	RP3-466P17.1	4.64	3.98e-06	0.000358	0.16	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145527982	chr6:145735570~145737218:+
BRCA	cis	rs6570726	0.846	rs441575	ENSG00000270638.1	RP3-466P17.1	4.64	3.98e-06	0.000358	0.16	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145528069	chr6:145735570~145737218:+
BRCA	cis	rs6570726	0.935	rs436212	ENSG00000270638.1	RP3-466P17.1	4.64	3.98e-06	0.000358	0.16	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145528264	chr6:145735570~145737218:+
BRCA	cis	rs6570726	0.935	rs414222	ENSG00000270638.1	RP3-466P17.1	4.64	3.98e-06	0.000358	0.16	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145529346	chr6:145735570~145737218:+
BRCA	cis	rs77204473	1	rs12278117	ENSG00000280143.1	AP000892.6	-4.64	3.98e-06	0.000358	-0.26	-0.14	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116877453	chr11:117204967~117210292:+
BRCA	cis	rs11098499	0.954	rs12502423	ENSG00000250412.1	KLHL2P1	4.64	3.99e-06	0.000358	0.17	0.14	Corneal astigmatism;	chr4:119503017	chr4:119334329~119378233:+
BRCA	cis	rs610932	0.517	rs599862	ENSG00000275344.1	MIR6503	4.64	3.99e-06	0.000358	0.14	0.14	Alzheimer's disease;	chr11:60205415	chr11:60209071~60209156:-
BRCA	cis	rs610932	0.517	rs588084	ENSG00000275344.1	MIR6503	4.64	3.99e-06	0.000358	0.14	0.14	Alzheimer's disease;	chr11:60205586	chr11:60209071~60209156:-
BRCA	cis	rs2625529	0.652	rs12148078	ENSG00000260037.4	CTD-2524L6.3	4.64	3.99e-06	0.000358	0.18	0.14	Red blood cell count;	chr15:72008130	chr15:71818396~71823384:+
BRCA	cis	rs763014	0.932	rs2269560	ENSG00000260394.2	LA16c-313D11.9	-4.64	3.99e-06	0.000358	-0.14	-0.14	Height;	chr16:632442	chr16:678504~679777:-
BRCA	cis	rs926392	0.965	rs714108	ENSG00000274825.1	RP4-616B8.5	-4.64	3.99e-06	0.000358	-0.14	-0.14	Dialysis-related mortality;	chr20:39059195	chr20:38955910~38956547:+
BRCA	cis	rs11051970	0.918	rs7309706	ENSG00000274964.1	RP11-817I4.1	-4.64	3.99e-06	0.000358	-0.19	-0.14	Response to tocilizumab in rheumatoid arthritis;	chr12:32385274	chr12:32339368~32340724:+
BRCA	cis	rs875971	1	rs1167612	ENSG00000236529.1	RP13-254B10.1	-4.64	3.99e-06	0.000358	-0.16	-0.14	Aortic root size;	chr7:66102989	chr7:65840212~65840596:+
BRCA	cis	rs6430585	1	rs6732236	ENSG00000224043.6	CCNT2-AS1	-4.64	3.99e-06	0.000358	-0.23	-0.14	Corneal structure;	chr2:135743939	chr2:134735464~134918710:-
BRCA	cis	rs2562456	0.754	rs55771551	ENSG00000268658.4	LINC00664	4.64	3.99e-06	0.000358	0.22	0.14	Pain;	chr19:21563578	chr19:21483374~21503238:+
BRCA	cis	rs6088580	0.634	rs2184836	ENSG00000276073.1	RP5-1125A11.7	4.64	3.99e-06	0.000358	0.16	0.14	Glomerular filtration rate (creatinine);	chr20:34375563	chr20:33985617~33988989:-
BRCA	cis	rs6088580	0.609	rs6058029	ENSG00000276073.1	RP5-1125A11.7	4.64	3.99e-06	0.000358	0.16	0.14	Glomerular filtration rate (creatinine);	chr20:34381837	chr20:33985617~33988989:-
BRCA	cis	rs6088580	0.608	rs2105109	ENSG00000276073.1	RP5-1125A11.7	4.64	3.99e-06	0.000358	0.16	0.14	Glomerular filtration rate (creatinine);	chr20:34384126	chr20:33985617~33988989:-
BRCA	cis	rs4781563	1	rs3136187	ENSG00000242307.1	RPS26P52	-4.64	3.99e-06	0.000358	-0.17	-0.14	Bilirubin levels;	chr16:13940642	chr16:13922332~13922679:-
BRCA	cis	rs7968440	0.933	rs4768885	ENSG00000272368.2	RP4-605O3.4	-4.64	4e-06	0.000358	-0.14	-0.14	Fibrinogen;	chr12:50527989	chr12:50112197~50165618:+
BRCA	cis	rs1552244	0.572	rs7645667	ENSG00000232901.1	CYCSP10	4.64	4e-06	0.000359	0.22	0.14	Alzheimer's disease;	chr3:10115653	chr3:10000647~10000940:-
BRCA	cis	rs7008867	0.589	rs7824718	ENSG00000253390.1	CTC-756D1.2	4.64	4e-06	0.000359	0.23	0.14	Hip circumference adjusted for BMI;	chr8:23510370	chr8:23458601~23484971:+
BRCA	cis	rs7481584	0.624	rs449164	ENSG00000247473.2	CARS-AS1	-4.64	4e-06	0.000359	-0.17	-0.14	Calcium levels;	chr11:3032224	chr11:3029009~3041260:+
BRCA	cis	rs17507216	0.718	rs72751657	ENSG00000255769.6	GOLGA2P10	-4.64	4e-06	0.000359	-0.22	-0.14	Excessive daytime sleepiness;	chr15:82581259	chr15:82472993~82513950:-
BRCA	cis	rs62244186	0.566	rs3762636	ENSG00000214820.3	MPRIPP1	4.64	4e-06	0.000359	0.16	0.14	Depressive symptoms;	chr3:44813071	chr3:44579938~44581026:-
BRCA	cis	rs10266483	0.774	rs10239221	ENSG00000227986.1	TRIM60P18	4.64	4e-06	0.000359	0.15	0.14	Response to statin therapy;	chr7:64352852	chr7:64355078~64356199:+
BRCA	cis	rs3768617	0.51	rs3768615	ENSG00000224468.3	RP11-181K3.4	-4.64	4e-06	0.000359	-0.15	-0.14	Fuchs's corneal dystrophy;	chr1:183134469	chr1:183138402~183141282:-
BRCA	cis	rs7824557	0.591	rs2736283	ENSG00000255046.1	RP11-297N6.4	4.64	4e-06	0.000359	0.17	0.14	Retinal vascular caliber;	chr8:11368401	chr8:11797928~11802568:-
BRCA	cis	rs9921338	0.961	rs8048768	ENSG00000262703.1	RP11-485G7.6	-4.64	4e-06	0.000359	-0.18	-0.14	Vein graft stenosis in coronary artery bypass grafting;	chr16:11302983	chr16:11348143~11349321:-
BRCA	cis	rs17818399	0.926	rs13032670	ENSG00000279254.1	RP11-536C12.1	-4.64	4e-06	0.000359	-0.19	-0.14	Height;	chr2:46603655	chr2:46668870~46670778:+
BRCA	cis	rs748404	0.666	rs12899865	ENSG00000205771.5	CATSPER2P1	-4.64	4e-06	0.000359	-0.21	-0.14	Lung cancer;	chr15:43448819	chr15:43726918~43747094:-
BRCA	cis	rs6545883	0.894	rs12620105	ENSG00000212978.6	AC016747.3	-4.64	4e-06	0.000359	-0.19	-0.14	Tuberculosis;	chr2:61285186	chr2:61141592~61144969:-
BRCA	cis	rs904251	0.647	rs2776908	ENSG00000204110.6	RP1-153P14.8	-4.64	4e-06	0.000359	-0.18	-0.14	Cognitive performance;	chr6:37467081	chr6:37507348~37535616:+
BRCA	cis	rs12612619	0.732	rs2304681	ENSG00000229122.1	AGBL5-IT1	-4.64	4e-06	0.000359	-0.15	-0.14	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27092384	chr2:27061038~27061815:+
BRCA	cis	rs6125597	0.967	rs6067048	ENSG00000222365.1	SNORD12B	4.64	4e-06	0.000359	0.15	0.14	Intelligence (multi-trait analysis);	chr20:49310024	chr20:49280319~49280409:+
BRCA	cis	rs7746199	0.668	rs34864796	ENSG00000220721.1	OR1F12	4.64	4.01e-06	0.000359	0.29	0.14	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27492144	chr6:28073316~28074233:+
BRCA	cis	rs13108904	0.846	rs4974574	ENSG00000253399.1	AC078852.2	-4.64	4.01e-06	0.00036	-0.16	-0.14	Obesity-related traits;	chr4:1231023	chr4:1358479~1359461:+
BRCA	cis	rs11051970	0.879	rs73081911	ENSG00000274964.1	RP11-817I4.1	-4.64	4.01e-06	0.00036	-0.19	-0.14	Response to tocilizumab in rheumatoid arthritis;	chr12:32386190	chr12:32339368~32340724:+
BRCA	cis	rs4834770	0.765	rs1511016	ENSG00000178636.7	RP11-455G16.1	-4.64	4.01e-06	0.00036	-0.18	-0.14	Blood protein levels;	chr4:119249200	chr4:119192773~119212644:-
BRCA	cis	rs10504130	0.569	rs12679983	ENSG00000272024.1	RP11-546K22.3	-4.64	4.01e-06	0.00036	-0.21	-0.14	Venous thromboembolism (SNP x SNP interaction);	chr8:51765596	chr8:51950284~51950690:+
BRCA	cis	rs651907	0.557	rs11711079	ENSG00000256628.3	ZBTB11-AS1	4.64	4.01e-06	0.00036	0.18	0.14	Colorectal cancer;	chr3:101668074	chr3:101676475~101679217:+
BRCA	cis	rs926392	0.965	rs6129168	ENSG00000274825.1	RP4-616B8.5	-4.64	4.01e-06	0.00036	-0.14	-0.14	Dialysis-related mortality;	chr20:39060717	chr20:38955910~38956547:+
BRCA	cis	rs7818688	0.697	rs77055525	ENSG00000253528.2	RP11-347C18.4	-4.64	4.01e-06	0.00036	-0.22	-0.14	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94968355	chr8:94974573~94974853:-
BRCA	cis	rs7818688	0.697	rs112411609	ENSG00000253528.2	RP11-347C18.4	-4.64	4.01e-06	0.00036	-0.22	-0.14	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94968626	chr8:94974573~94974853:-
BRCA	cis	rs7818688	0.697	rs74633621	ENSG00000253528.2	RP11-347C18.4	-4.64	4.01e-06	0.00036	-0.22	-0.14	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94968809	chr8:94974573~94974853:-
BRCA	cis	rs7818688	0.697	rs76815619	ENSG00000253528.2	RP11-347C18.4	-4.64	4.01e-06	0.00036	-0.22	-0.14	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94969102	chr8:94974573~94974853:-
BRCA	cis	rs7818688	0.697	rs74633235	ENSG00000253528.2	RP11-347C18.4	-4.64	4.01e-06	0.00036	-0.22	-0.14	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94969248	chr8:94974573~94974853:-
BRCA	cis	rs7818688	0.697	rs10504939	ENSG00000253528.2	RP11-347C18.4	-4.64	4.01e-06	0.00036	-0.22	-0.14	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94971126	chr8:94974573~94974853:-
BRCA	cis	rs7818688	0.697	rs60003497	ENSG00000253528.2	RP11-347C18.4	-4.64	4.01e-06	0.00036	-0.22	-0.14	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94971195	chr8:94974573~94974853:-
BRCA	cis	rs7818688	0.697	rs77805255	ENSG00000253528.2	RP11-347C18.4	-4.64	4.01e-06	0.00036	-0.22	-0.14	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94971338	chr8:94974573~94974853:-
BRCA	cis	rs7674212	0.541	rs4699051	ENSG00000246560.2	RP11-10L12.4	4.64	4.01e-06	0.00036	0.15	0.14	Type 2 diabetes;	chr4:103193237	chr4:102828055~102844075:+
BRCA	cis	rs11096990	0.593	rs35552004	ENSG00000249685.1	RP11-360F5.3	4.64	4.01e-06	0.00036	0.18	0.14	Cognitive function;	chr4:39170914	chr4:39133913~39135608:+
BRCA	cis	rs2115630	0.967	rs7171167	ENSG00000259728.4	LINC00933	-4.64	4.01e-06	0.00036	-0.16	-0.14	P wave terminal force;	chr15:84695892	chr15:84570649~84580175:+
BRCA	cis	rs733175	0.855	rs9291640	ENSG00000250413.1	RP11-448G15.1	-4.64	4.01e-06	0.00036	-0.2	-0.14	Psychosis and Alzheimer's disease;	chr4:10005462	chr4:10006482~10009725:+
BRCA	cis	rs11071559	0.935	rs8025689	ENSG00000259591.1	RP11-554D20.1	-4.64	4.01e-06	0.00036	-0.2	-0.14	Asthma;	chr15:60767062	chr15:60763906~60765625:+
BRCA	cis	rs4698412	0.561	rs11722300	ENSG00000214846.4	RP11-115L11.1	4.64	4.02e-06	0.00036	0.17	0.14	Parkinson's disease;	chr4:15683428	chr4:15730962~15731627:-
BRCA	cis	rs11098499	0.954	rs6834796	ENSG00000250412.1	KLHL2P1	4.64	4.02e-06	0.000361	0.17	0.14	Corneal astigmatism;	chr4:119493538	chr4:119334329~119378233:+
BRCA	cis	rs11098499	0.954	rs11734241	ENSG00000250412.1	KLHL2P1	4.64	4.02e-06	0.000361	0.17	0.14	Corneal astigmatism;	chr4:119495717	chr4:119334329~119378233:+
BRCA	cis	rs2235642	0.859	rs12599207	ENSG00000260989.1	LA16c-395F10.2	-4.64	4.02e-06	0.000361	-0.15	-0.14	Coronary artery disease;	chr16:1556444	chr16:1580527~1610328:+
BRCA	cis	rs7395581	0.775	rs2269434	ENSG00000280615.1	Y_RNA	4.63	4.02e-06	0.000361	0.17	0.14	HDL cholesterol;	chr11:47338861	chr11:47614898~47614994:-
BRCA	cis	rs7267979	0.903	rs6115101	ENSG00000276952.1	RP5-965G21.6	4.63	4.02e-06	0.000361	0.18	0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25248928	chr20:25284915~25285588:-
BRCA	cis	rs7592578	0.771	rs4439990	ENSG00000272979.1	RP11-647K16.1	-4.63	4.02e-06	0.000361	-0.24	-0.14	Diastolic blood pressure;	chr2:190533627	chr2:190454092~190454521:-
BRCA	cis	rs1864585	0.806	rs17778223	ENSG00000255310.2	AF131215.2	4.63	4.03e-06	0.000361	0.17	0.14	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr8:10872182	chr8:11107788~11109726:-
BRCA	cis	rs595244	1	rs655015	ENSG00000259705.1	RP11-227D13.1	4.63	4.03e-06	0.000361	0.25	0.14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48598910	chr15:48645951~48652016:+
BRCA	cis	rs516805	0.667	rs17729938	ENSG00000279453.1	RP3-425C14.4	4.63	4.03e-06	0.000361	0.19	0.14	Lymphocyte counts;	chr6:122340364	chr6:122436789~122439223:-
BRCA	cis	rs11098499	0.954	rs10008459	ENSG00000260091.1	RP11-33B1.4	-4.63	4.03e-06	0.000361	-0.13	-0.14	Corneal astigmatism;	chr4:119473076	chr4:119409333~119410233:+
BRCA	cis	rs6095360	1	rs1538482	ENSG00000222365.1	SNORD12B	-4.63	4.03e-06	0.000361	-0.16	-0.14	Intelligence (multi-trait analysis);	chr20:49088959	chr20:49280319~49280409:+
BRCA	cis	rs7176527	0.784	rs62021162	ENSG00000225151.9	GOLGA2P7	4.63	4.03e-06	0.000361	0.21	0.14	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84565602	chr15:84199311~84230136:-
BRCA	cis	rs256438	0.93	rs2438638	ENSG00000251050.1	RP11-168A11.4	4.63	4.03e-06	0.000361	0.16	0.14	Serum thyroid-stimulating hormone levels;	chr5:80094377	chr5:80019609~80019920:+
BRCA	cis	rs7246657	0.722	rs2927739	ENSG00000226686.6	LINC01535	4.63	4.03e-06	0.000362	0.21	0.14	Coronary artery calcification;	chr19:37658429	chr19:37251912~37265535:+
BRCA	cis	rs7800418	0.609	rs11983370	ENSG00000214870.7	AC004540.5	-4.63	4.03e-06	0.000362	-0.17	-0.14	Cognitive function;	chr7:26579861	chr7:26398593~26494256:+
BRCA	cis	rs1077773	0.509	rs6965584	ENSG00000237773.4	AC003075.4	-4.63	4.03e-06	0.000362	-0.19	-0.14	Ulcerative colitis;Inflammatory bowel disease;	chr7:17394681	chr7:17279834~17299357:-
BRCA	cis	rs13113518	1	rs7662966	ENSG00000249700.7	SRD5A3-AS1	4.63	4.03e-06	0.000362	0.18	0.14	Height;	chr4:55548261	chr4:55363971~55395847:-
BRCA	cis	rs6832769	0.857	rs28377791	ENSG00000223305.1	RN7SKP30	-4.63	4.04e-06	0.000362	-0.18	-0.14	Personality dimensions;	chr4:55607014	chr4:55540502~55540835:-
BRCA	cis	rs6968419	0.963	rs4436065	ENSG00000279086.1	RP11-667F14.1	-4.63	4.04e-06	0.000362	-0.14	-0.14	Intraocular pressure;	chr7:116181326	chr7:116209234~116211511:-
BRCA	cis	rs6968419	0.747	rs1004109	ENSG00000279086.1	RP11-667F14.1	4.63	4.04e-06	0.000362	0.15	0.14	Intraocular pressure;	chr7:116222242	chr7:116209234~116211511:-
BRCA	cis	rs10129255	1	rs10129255	ENSG00000274576.2	IGHV2-70	-4.63	4.04e-06	0.000362	-0.13	-0.14	Kawasaki disease;	chr14:106767970	chr14:106770577~106771020:-
BRCA	cis	rs6968419	0.649	rs58624059	ENSG00000279086.1	RP11-667F14.1	-4.63	4.04e-06	0.000362	-0.16	-0.14	Intraocular pressure;	chr7:116228744	chr7:116209234~116211511:-
BRCA	cis	rs13108904	0.935	rs6853002	ENSG00000196810.4	CTBP1-AS2	4.63	4.04e-06	0.000362	0.15	0.14	Obesity-related traits;	chr4:1302203	chr4:1249300~1288291:+
BRCA	cis	rs7916697	0.626	rs3858146	ENSG00000233590.1	RP11-153K11.3	-4.63	4.04e-06	0.000362	-0.18	-0.14	Optic disc area;	chr10:68253493	chr10:68233251~68242379:-
BRCA	cis	rs7772486	0.79	rs9403755	ENSG00000270638.1	RP3-466P17.1	-4.63	4.04e-06	0.000362	-0.17	-0.14	Lobe attachment (rater-scored or self-reported);	chr6:145910334	chr6:145735570~145737218:+
BRCA	cis	rs6570726	0.935	rs447247	ENSG00000270638.1	RP3-466P17.1	4.63	4.04e-06	0.000362	0.16	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145491542	chr6:145735570~145737218:+
BRCA	cis	rs9467773	0.62	rs2101582	ENSG00000224843.5	LINC00240	-4.63	4.04e-06	0.000362	-0.15	-0.14	Intelligence (multi-trait analysis);	chr6:26622506	chr6:26956992~27023924:+
BRCA	cis	rs4781563	0.81	rs3136065	ENSG00000242307.1	RPS26P52	-4.63	4.05e-06	0.000363	-0.16	-0.14	Bilirubin levels;	chr16:13923591	chr16:13922332~13922679:-
BRCA	cis	rs559555	0.553	rs2754530	ENSG00000276334.1	AL133243.1	4.63	4.05e-06	0.000363	0.18	0.14	Blood metabolite ratios;Blood metabolite levels;	chr2:31578333	chr2:32521927~32523547:+
BRCA	cis	rs559555	0.553	rs2268799	ENSG00000276334.1	AL133243.1	4.63	4.05e-06	0.000363	0.18	0.14	Blood metabolite ratios;Blood metabolite levels;	chr2:31578425	chr2:32521927~32523547:+
BRCA	cis	rs253959	0.576	rs1588268	ENSG00000271918.1	CTD-2287O16.5	4.63	4.05e-06	0.000363	0.13	0.14	Bipolar disorder and schizophrenia;	chr5:116101091	chr5:116083807~116085416:-
BRCA	cis	rs792448	0.66	rs12035647	ENSG00000226251.4	RP11-15I11.3	-4.63	4.05e-06	0.000363	-0.19	-0.14	White blood cell count (basophil);	chr1:212313969	chr1:212225278~212238977:-
BRCA	cis	rs8040855	0.627	rs4843019	ENSG00000230373.7	GOLGA6L5P	-4.63	4.05e-06	0.000363	-0.18	-0.14	Bulimia nervosa;	chr15:85101228	chr15:84507885~84516814:-
BRCA	cis	rs5758511	0.633	rs5758689	ENSG00000227370.1	RP4-669P10.19	4.63	4.05e-06	0.000363	0.19	0.14	Birth weight;	chr22:42268966	chr22:42132543~42132998:+
BRCA	cis	rs7772486	0.79	rs4435956	ENSG00000270638.1	RP3-466P17.1	-4.63	4.05e-06	0.000363	-0.17	-0.14	Lobe attachment (rater-scored or self-reported);	chr6:145911267	chr6:145735570~145737218:+
BRCA	cis	rs7772486	0.79	rs6926076	ENSG00000270638.1	RP3-466P17.1	-4.63	4.05e-06	0.000363	-0.17	-0.14	Lobe attachment (rater-scored or self-reported);	chr6:145911668	chr6:145735570~145737218:+
BRCA	cis	rs6095360	0.966	rs3795082	ENSG00000222365.1	SNORD12B	-4.63	4.05e-06	0.000363	-0.15	-0.14	Intelligence (multi-trait analysis);	chr20:49056465	chr20:49280319~49280409:+
BRCA	cis	rs35740288	0.545	rs11637283	ENSG00000202081.1	RNU6-1280P	4.63	4.05e-06	0.000363	0.21	0.14	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85772872	chr15:85651522~85651628:-
BRCA	cis	rs11168351	0.833	rs6580652	ENSG00000257763.1	OR5BK1P	-4.63	4.05e-06	0.000363	-0.15	-0.14	Bipolar disorder and schizophrenia;	chr12:48053322	chr12:48355792~48356614:-
BRCA	cis	rs1371614	0.523	rs7585127	ENSG00000229122.1	AGBL5-IT1	4.63	4.05e-06	0.000363	0.15	0.14	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26956503	chr2:27061038~27061815:+
BRCA	cis	rs1707322	0.789	rs10789473	ENSG00000234329.1	RP11-767N6.2	4.63	4.06e-06	0.000363	0.15	0.14	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45782459	chr1:45651039~45651826:-
BRCA	cis	rs9307551	1	rs6855486	ENSG00000250334.4	LINC00989	4.63	4.06e-06	0.000364	0.21	0.14	Refractive error;	chr4:79612886	chr4:79492416~79576460:+
BRCA	cis	rs1387259	0.57	rs12368659	ENSG00000257763.1	OR5BK1P	4.63	4.06e-06	0.000364	0.15	0.14	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48168516	chr12:48355792~48356614:-
BRCA	cis	rs7818688	0.697	rs74861094	ENSG00000253528.2	RP11-347C18.4	-4.63	4.06e-06	0.000364	-0.22	-0.14	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94969157	chr8:94974573~94974853:-
BRCA	cis	rs10861342	1	rs11112373	ENSG00000257999.1	RP11-61E11.2	-4.63	4.06e-06	0.000364	-0.29	-0.14	IgG glycosylation;	chr12:105109930	chr12:105102472~105107179:-
BRCA	cis	rs1153858	1	rs56669689	ENSG00000275672.1	GATM-AS1	-4.63	4.06e-06	0.000364	-0.18	-0.14	Homoarginine levels;	chr15:45345531	chr15:45378700~45380123:+
BRCA	cis	rs2073316	0.626	rs66492775	ENSG00000272716.1	RP11-563N4.1	4.63	4.06e-06	0.000364	0.16	0.14	Interleukin-18 levels;	chr2:31424303	chr2:32165046~32165757:-
BRCA	cis	rs9834975	1	rs9818363	ENSG00000272758.4	RP11-299J3.8	-4.63	4.06e-06	0.000364	-0.14	-0.14	Diastolic blood pressure;	chr3:122393444	chr3:122416207~122443180:+
BRCA	cis	rs3768617	0.51	rs6666259	ENSG00000224468.3	RP11-181K3.4	-4.63	4.06e-06	0.000364	-0.15	-0.14	Fuchs's corneal dystrophy;	chr1:183133720	chr1:183138402~183141282:-
BRCA	cis	rs13108904	0.87	rs4974541	ENSG00000253399.1	AC078852.2	-4.63	4.06e-06	0.000364	-0.16	-0.14	Obesity-related traits;	chr4:1250249	chr4:1358479~1359461:+
BRCA	cis	rs1395	0.677	rs113353646	ENSG00000234072.1	AC074117.10	-4.63	4.07e-06	0.000364	-0.16	-0.14	Blood metabolite levels;	chr2:27269806	chr2:27356246~27367622:+
BRCA	cis	rs9393692	0.676	rs806977	ENSG00000241549.7	GUSBP2	-4.63	4.07e-06	0.000364	-0.16	-0.14	Educational attainment;	chr6:26189387	chr6:26871484~26956554:-
BRCA	cis	rs7818688	1	rs10096455	ENSG00000253528.2	RP11-347C18.4	-4.63	4.07e-06	0.000364	-0.21	-0.14	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95029022	chr8:94974573~94974853:-
BRCA	cis	rs7818688	1	rs9297951	ENSG00000253528.2	RP11-347C18.4	-4.63	4.07e-06	0.000364	-0.21	-0.14	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95029209	chr8:94974573~94974853:-
BRCA	cis	rs7818688	1	rs11781040	ENSG00000253528.2	RP11-347C18.4	-4.63	4.07e-06	0.000364	-0.21	-0.14	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95029518	chr8:94974573~94974853:-
BRCA	cis	rs7246967	0.611	rs8108452	ENSG00000198153.8	ZNF849P	-4.63	4.07e-06	0.000365	-0.24	-0.14	Bronchopulmonary dysplasia;	chr19:22670816	chr19:22685167~22686732:+
BRCA	cis	rs7246967	0.611	rs12973627	ENSG00000198153.8	ZNF849P	-4.63	4.07e-06	0.000365	-0.24	-0.14	Bronchopulmonary dysplasia;	chr19:22684903	chr19:22685167~22686732:+
BRCA	cis	rs7246967	0.611	rs62120304	ENSG00000198153.8	ZNF849P	-4.63	4.07e-06	0.000365	-0.24	-0.14	Bronchopulmonary dysplasia;	chr19:22689466	chr19:22685167~22686732:+
BRCA	cis	rs10504130	0.569	rs35509250	ENSG00000272024.1	RP11-546K22.3	-4.63	4.07e-06	0.000365	-0.21	-0.14	Venous thromboembolism (SNP x SNP interaction);	chr8:51774993	chr8:51950284~51950690:+
BRCA	cis	rs10129255	0.5	rs8011115	ENSG00000254174.1	IGHV1-12	4.63	4.07e-06	0.000365	0.11	0.14	Kawasaki disease;	chr14:106786292	chr14:106122420~106122709:-
BRCA	cis	rs11098499	0.954	rs11729521	ENSG00000250412.1	KLHL2P1	4.63	4.07e-06	0.000365	0.17	0.14	Corneal astigmatism;	chr4:119495633	chr4:119334329~119378233:+
BRCA	cis	rs12612619	0.579	rs827884	ENSG00000272148.1	RP11-195B17.1	-4.63	4.07e-06	0.000365	-0.16	-0.14	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:26871974	chr2:27062428~27062907:-
BRCA	cis	rs11098499	0.954	rs10006877	ENSG00000260404.2	RP11-384K6.6	4.63	4.07e-06	0.000365	0.13	0.14	Corneal astigmatism;	chr4:119321638	chr4:118591773~118633729:+
BRCA	cis	rs3764021	0.84	rs10743823	ENSG00000256673.1	RP11-599J14.2	-4.63	4.08e-06	0.000365	-0.16	-0.14	Type 1 diabetes;	chr12:9728529	chr12:9398355~9414851:-
BRCA	cis	rs7481584	0.624	rs369461	ENSG00000247473.2	CARS-AS1	-4.63	4.08e-06	0.000365	-0.17	-0.14	Calcium levels;	chr11:3040762	chr11:3029009~3041260:+
BRCA	cis	rs4648739	0.613	rs13303201	ENSG00000268575.1	RP1-283E3.8	4.63	4.08e-06	0.000365	0.15	0.14	Severe influenza A (H1N1) infection;	chr1:1972273	chr1:1702736~1737688:-
BRCA	cis	rs9311474	0.508	rs4687629	ENSG00000243224.1	RP5-1157M23.2	-4.63	4.08e-06	0.000365	-0.15	-0.14	Electroencephalogram traits;	chr3:52581211	chr3:52239258~52241097:+
BRCA	cis	rs11742741	1	rs1428544	ENSG00000248874.4	C5orf17	-4.63	4.08e-06	0.000365	-0.18	-0.14	Educational attainment;	chr5:24154446	chr5:23951348~24178263:+
BRCA	cis	rs6570726	0.935	rs432086	ENSG00000270638.1	RP3-466P17.1	-4.63	4.08e-06	0.000365	-0.16	-0.14	Lobe attachment (rater-scored or self-reported);	chr6:145520457	chr6:145735570~145737218:+
BRCA	cis	rs6840360	0.642	rs11099815	ENSG00000251611.1	RP11-610P16.1	-4.63	4.08e-06	0.000365	-0.12	-0.14	Intelligence (multi-trait analysis);	chr4:151422736	chr4:151407551~151408835:-
BRCA	cis	rs6772849	0.93	rs4857912	ENSG00000242551.2	POU5F1P6	-4.63	4.08e-06	0.000365	-0.18	-0.14	Monocyte percentage of white cells;Monocyte count;	chr3:128610381	chr3:128674735~128677005:-
BRCA	cis	rs12744310	0.887	rs35021924	ENSG00000235358.1	RP11-399E6.1	4.63	4.08e-06	0.000366	0.21	0.14	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41321235	chr1:41242373~41284861:+
BRCA	cis	rs6832769	1	rs6853192	ENSG00000272969.1	RP11-528I4.2	-4.63	4.08e-06	0.000366	-0.17	-0.14	Personality dimensions;	chr4:55543087	chr4:55547112~55547889:+
BRCA	cis	rs10504130	1	rs41453644	ENSG00000253844.1	RP11-546K22.1	4.63	4.08e-06	0.000366	0.24	0.14	Venous thromboembolism (SNP x SNP interaction);	chr8:51820984	chr8:51961458~52022974:+
BRCA	cis	rs62025270	0.632	rs74025655	ENSG00000259762.1	RP11-158M2.4	-4.63	4.08e-06	0.000366	-0.2	-0.14	Idiopathic pulmonary fibrosis;	chr15:85674319	chr15:85750336~85752901:-
BRCA	cis	rs3845817	0.703	rs702915	ENSG00000237979.1	AC007389.1	4.63	4.08e-06	0.000366	0.17	0.14	Bipolar disorder;	chr2:65543462	chr2:65500993~65502138:-
BRCA	cis	rs61869271	0.871	rs6585309	ENSG00000236799.1	RP11-383C6.2	4.63	4.08e-06	0.000366	0.17	0.14	Tonsillectomy;	chr10:114970578	chr10:114994657~114996593:+
BRCA	cis	rs1075265	0.509	rs10178643	ENSG00000235937.1	AC008280.1	4.63	4.08e-06	0.000366	0.16	0.14	Chronotype;Morning vs. evening chronotype;	chr2:53728341	chr2:54029552~54030682:-
BRCA	cis	rs11648785	0.661	rs870856	ENSG00000222019.6	URAHP	4.63	4.08e-06	0.000366	0.14	0.14	Tanning;	chr16:90023055	chr16:90039761~90047773:-
BRCA	cis	rs3808502	0.549	rs7831039	ENSG00000154316.13	TDH	4.63	4.08e-06	0.000366	0.18	0.14	Neuroticism;	chr8:11570128	chr8:11339637~11368452:+
BRCA	cis	rs6840360	0.642	rs7676493	ENSG00000251603.1	RP11-164P12.4	-4.63	4.09e-06	0.000366	-0.13	-0.14	Intelligence (multi-trait analysis);	chr4:151505613	chr4:151667224~151670502:+
BRCA	cis	rs6840360	0.642	rs11735957	ENSG00000251603.1	RP11-164P12.4	-4.63	4.09e-06	0.000366	-0.13	-0.14	Intelligence (multi-trait analysis);	chr4:151506354	chr4:151667224~151670502:+
BRCA	cis	rs6840360	0.642	rs2053566	ENSG00000251603.1	RP11-164P12.4	-4.63	4.09e-06	0.000366	-0.13	-0.14	Intelligence (multi-trait analysis);	chr4:151524679	chr4:151667224~151670502:+
BRCA	cis	rs6840360	0.607	rs1561918	ENSG00000251603.1	RP11-164P12.4	-4.63	4.09e-06	0.000366	-0.13	-0.14	Intelligence (multi-trait analysis);	chr4:151525680	chr4:151667224~151670502:+
BRCA	cis	rs1395	0.813	rs11685326	ENSG00000234072.1	AC074117.10	-4.63	4.09e-06	0.000366	-0.15	-0.14	Blood metabolite levels;	chr2:27230811	chr2:27356246~27367622:+
BRCA	cis	rs73186030	1	rs73186044	ENSG00000272758.4	RP11-299J3.8	4.63	4.09e-06	0.000366	0.22	0.14	Serum parathyroid hormone levels;	chr3:122309629	chr3:122416207~122443180:+
BRCA	cis	rs919433	0.647	rs13404366	ENSG00000231621.1	AC013264.2	-4.63	4.09e-06	0.000366	-0.13	-0.14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197657908	chr2:197197991~197199273:+
BRCA	cis	rs2073316	0.592	rs4952251	ENSG00000272716.1	RP11-563N4.1	4.63	4.09e-06	0.000366	0.15	0.14	Interleukin-18 levels;	chr2:31459683	chr2:32165046~32165757:-
BRCA	cis	rs3774749	0.565	rs2518795	ENSG00000228008.1	CTD-2330K9.3	4.63	4.09e-06	0.000366	0.14	0.14	Intelligence (multi-trait analysis);	chr3:50171386	chr3:49903845~49916937:+
BRCA	cis	rs957448	1	rs1023767	ENSG00000254315.1	RP11-267M23.3	4.63	4.09e-06	0.000367	0.18	0.14	Nonsyndromic cleft lip with cleft palate;	chr8:94518741	chr8:94533628~94534391:+
BRCA	cis	rs7129556	1	rs7129556	ENSG00000254459.1	RP11-91P24.7	-4.63	4.09e-06	0.000367	-0.19	-0.14	Weight loss (gastric bypass surgery);	chr11:77589003	chr11:77829654~77872262:-
BRCA	cis	rs13113518	1	rs56154935	ENSG00000249700.7	SRD5A3-AS1	4.63	4.1e-06	0.000367	0.18	0.14	Height;	chr4:55546378	chr4:55363971~55395847:-
BRCA	cis	rs7620503	0.721	rs11709335	ENSG00000228221.4	LINC00578	4.63	4.1e-06	0.000367	0.18	0.14	Corneal structure;	chr3:177591101	chr3:177441921~177752305:+
BRCA	cis	rs5167	0.504	rs3760625	ENSG00000280087.1	CTB-129P6.7	4.63	4.1e-06	0.000367	0.17	0.14	Blood protein levels;	chr19:44953684	chr19:44909375~44914968:+
BRCA	cis	rs7608910	1	rs7608697	ENSG00000271889.1	RP11-493E12.1	4.63	4.1e-06	0.000367	0.18	0.14	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;	chr2:60977506	chr2:61151433~61162105:-
BRCA	cis	rs4781563	1	rs56012340	ENSG00000242307.1	RPS26P52	-4.63	4.1e-06	0.000367	-0.17	-0.14	Bilirubin levels;	chr16:13950924	chr16:13922332~13922679:-
BRCA	cis	rs1198430	1	rs946268	ENSG00000271420.1	RP5-1057J7.7	4.63	4.1e-06	0.000367	0.18	0.14	Total cholesterol levels;	chr1:23421273	chr1:23378380~23379029:-
BRCA	cis	rs56804039	0.524	rs4840989	ENSG00000253893.2	FAM85B	-4.63	4.1e-06	0.000367	-0.24	-0.14	Cervical cancer;	chr8:8548236	chr8:8167819~8226614:-
BRCA	cis	rs6088580	0.634	rs6120666	ENSG00000276073.1	RP5-1125A11.7	-4.63	4.1e-06	0.000367	-0.15	-0.14	Glomerular filtration rate (creatinine);	chr20:34502913	chr20:33985617~33988989:-
BRCA	cis	rs9467773	0.596	rs2451750	ENSG00000241549.7	GUSBP2	4.63	4.1e-06	0.000367	0.15	0.14	Intelligence (multi-trait analysis);	chr6:26646351	chr6:26871484~26956554:-
BRCA	cis	rs9467773	0.596	rs2451751	ENSG00000241549.7	GUSBP2	4.63	4.1e-06	0.000367	0.15	0.14	Intelligence (multi-trait analysis);	chr6:26646486	chr6:26871484~26956554:-
BRCA	cis	rs116095464	0.558	rs10065239	ENSG00000248925.1	CTD-2083E4.6	4.63	4.1e-06	0.000367	0.28	0.14	Breast cancer;	chr5:275173	chr5:269858~271516:-
BRCA	cis	rs2273156	1	rs71421920	ENSG00000226677.3	IGBP1P1	-4.63	4.1e-06	0.000367	-0.21	-0.14	Immunoglobulin light chain (AL) amyloidosis;	chr14:34977539	chr14:34939324~34940332:+
BRCA	cis	rs8114671	0.836	rs3746432	ENSG00000279253.1	RP4-614O4.13	4.63	4.11e-06	0.000367	0.16	0.14	Height;	chr20:35004960	chr20:35262727~35264187:-
BRCA	cis	rs11673344	0.523	rs2562605	ENSG00000226686.6	LINC01535	4.63	4.11e-06	0.000368	0.18	0.14	Obesity-related traits;	chr19:37029302	chr19:37251912~37265535:+
BRCA	cis	rs875971	0.545	rs1796219	ENSG00000230295.1	RP11-458F8.2	-4.63	4.11e-06	0.000368	-0.14	-0.14	Aortic root size;	chr7:66645977	chr7:66880708~66882981:+
BRCA	cis	rs17489649	1	rs2068964	ENSG00000271849.1	CTC-332L22.1	4.63	4.11e-06	0.000368	0.18	0.14	Intelligence (multi-trait analysis);	chr5:109779300	chr5:109687802~109688329:-
BRCA	cis	rs6828577	0.729	rs35604604	ENSG00000269893.5	SNHG8	-4.63	4.11e-06	0.000368	-0.16	-0.14	Perioperative myocardial infarction in coronary artery bypass surgery;	chr4:118499997	chr4:118278709~118279823:+
BRCA	cis	rs2880765	0.566	rs55899824	ENSG00000230373.7	GOLGA6L5P	4.63	4.11e-06	0.000368	0.16	0.14	Coronary artery disease;	chr15:85460860	chr15:84507885~84516814:-
BRCA	cis	rs10129255	0.912	rs8009135	ENSG00000280411.1	IGHV1-69-2	-4.63	4.11e-06	0.000368	-0.1	-0.14	Kawasaki disease;	chr14:106777528	chr14:106762092~106762588:-
BRCA	cis	rs1395	0.778	rs6749393	ENSG00000234072.1	AC074117.10	-4.63	4.11e-06	0.000368	-0.15	-0.14	Blood metabolite levels;	chr2:27228132	chr2:27356246~27367622:+
BRCA	cis	rs5758659	0.652	rs133305	ENSG00000273366.1	CTA-989H11.1	-4.63	4.11e-06	0.000368	-0.17	-0.14	Cognitive function;	chr22:41999956	chr22:42278188~42278846:+
BRCA	cis	rs5758659	0.682	rs133306	ENSG00000273366.1	CTA-989H11.1	-4.63	4.11e-06	0.000368	-0.17	-0.14	Cognitive function;	chr22:42000146	chr22:42278188~42278846:+
BRCA	cis	rs1510272	0.889	rs2063352	ENSG00000243926.1	TIPARP-AS1	-4.63	4.11e-06	0.000368	-0.16	-0.14	Testicular germ cell tumor;	chr3:156610691	chr3:156671862~156674378:-
BRCA	cis	rs4950322	0.547	rs17355509	ENSG00000237188.3	RP11-337C18.8	4.63	4.11e-06	0.000368	0.18	0.14	Protein quantitative trait loci;	chr1:147123139	chr1:147172771~147211568:+
BRCA	cis	rs6095360	1	rs6019618	ENSG00000222365.1	SNORD12B	-4.63	4.11e-06	0.000368	-0.15	-0.14	Intelligence (multi-trait analysis);	chr20:49055001	chr20:49280319~49280409:+
BRCA	cis	rs4834770	1	rs4834770	ENSG00000245958.5	RP11-33B1.1	-4.63	4.11e-06	0.000368	-0.13	-0.14	Blood protein levels;	chr4:119320694	chr4:119454791~119552025:+
BRCA	cis	rs4664293	0.718	rs4477859	ENSG00000226266.5	AC009961.3	4.63	4.11e-06	0.000368	0.17	0.14	Monocyte percentage of white cells;	chr2:159738616	chr2:159670708~159712435:-
BRCA	cis	rs2243480	1	rs422164	ENSG00000222364.1	RNU6-96P	-4.63	4.11e-06	0.000368	-0.26	-0.14	Diabetic kidney disease;	chr7:66121618	chr7:66395191~66395286:+
BRCA	cis	rs2278170	1	rs2278170	ENSG00000225101.4	OR52K3P	-4.63	4.12e-06	0.000368	-0.2	-0.14	Amyotrophic lateral sclerosis;	chr11:4475616	chr11:4474813~4475755:+
BRCA	cis	rs7267979	1	rs2500443	ENSG00000125804.12	FAM182A	4.63	4.12e-06	0.000368	0.19	0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25350806	chr20:26054655~26086917:+
BRCA	cis	rs16846053	1	rs16846053	ENSG00000227403.1	AC009299.3	4.63	4.12e-06	0.000368	0.34	0.14	Blood osmolality (transformed sodium);	chr2:161709535	chr2:161244739~161249050:+
BRCA	cis	rs13113518	0.934	rs11133397	ENSG00000273257.1	RP11-177J6.1	4.63	4.12e-06	0.000368	0.18	0.14	Height;	chr4:55534166	chr4:55387949~55388271:+
BRCA	cis	rs13113518	0.934	rs11133398	ENSG00000273257.1	RP11-177J6.1	4.63	4.12e-06	0.000368	0.18	0.14	Height;	chr4:55534180	chr4:55387949~55388271:+
BRCA	cis	rs6603134	0.502	rs10406540	ENSG00000269139.2	CTD-3193O13.8	4.63	4.12e-06	0.000369	0.16	0.14	Blood protein levels;	chr19:8039113	chr19:7926001~7926810:+
BRCA	cis	rs4908760	0.965	rs7542312	ENSG00000232912.4	RP5-1115A15.1	4.63	4.12e-06	0.000369	0.14	0.14	Vitiligo;	chr1:8513412	chr1:8424645~8434838:+
BRCA	cis	rs10911902	0.643	rs75235608	ENSG00000229739.2	RP11-295K2.3	-4.63	4.13e-06	0.000369	-0.23	-0.14	Schizophrenia;	chr1:186303471	chr1:186435161~186470291:+
BRCA	cis	rs2832191	0.791	rs2832182	ENSG00000236056.1	GAPDHP14	4.63	4.13e-06	0.000369	0.15	0.14	Dental caries;	chr21:29109291	chr21:29222321~29223257:+
BRCA	cis	rs7968440	0.933	rs7308872	ENSG00000272368.2	RP4-605O3.4	-4.63	4.13e-06	0.000369	-0.14	-0.14	Fibrinogen;	chr12:50726391	chr12:50112197~50165618:+
BRCA	cis	rs3764021	0.743	rs7973535	ENSG00000278635.1	CTD-2318O12.1	-4.63	4.13e-06	0.000369	-0.14	-0.14	Type 1 diabetes;	chr12:9727801	chr12:9415641~9416718:+
BRCA	cis	rs3764021	0.87	rs7973638	ENSG00000278635.1	CTD-2318O12.1	-4.63	4.13e-06	0.000369	-0.14	-0.14	Type 1 diabetes;	chr12:9727845	chr12:9415641~9416718:+
BRCA	cis	rs17270561	0.723	rs12213243	ENSG00000272462.2	U91328.19	-4.63	4.13e-06	0.000369	-0.19	-0.14	Iron status biomarkers;	chr6:25889880	chr6:25992662~26001775:+
BRCA	cis	rs828999	0.653	rs6666316	ENSG00000280186.1	RP11-483I13.6	-4.63	4.13e-06	0.000369	-0.16	-0.14	Monocyte percentage of white cells;	chr1:108153538	chr1:108200413~108202743:+
BRCA	cis	rs828999	0.688	rs10785835	ENSG00000280186.1	RP11-483I13.6	-4.63	4.13e-06	0.000369	-0.16	-0.14	Monocyte percentage of white cells;	chr1:108153642	chr1:108200413~108202743:+
BRCA	cis	rs1559040	0.656	rs11688581	ENSG00000272156.1	RP11-477N3.1	-4.63	4.13e-06	0.000369	-0.27	-0.14	Sudden cardiac arrest;	chr2:54022591	chr2:54082554~54085066:+
BRCA	cis	rs10833905	1	rs10833904	ENSG00000246225.5	RP11-17A1.3	4.63	4.13e-06	0.000369	0.2	0.14	Sudden cardiac arrest;	chr11:23018465	chr11:22829380~22945393:+
BRCA	cis	rs7829975	0.714	rs11784052	ENSG00000233609.3	RP11-62H7.2	4.63	4.13e-06	0.00037	0.13	0.14	Mood instability;	chr8:8814452	chr8:8961200~8979025:+
BRCA	cis	rs35146811	0.735	rs858505	ENSG00000235713.1	RP4-604G5.3	-4.63	4.13e-06	0.00037	-0.17	-0.14	Coronary artery disease;	chr7:100221954	chr7:99992397~99993050:+
BRCA	cis	rs10989172	0.714	rs10739798	ENSG00000175611.10	LINC00476	4.63	4.13e-06	0.00037	0.15	0.14	Common carotid intima-media thickness in HIV negative individuals;	chr9:96079335	chr9:95759231~95875977:-
BRCA	cis	rs62103177	0.81	rs62103175	ENSG00000261126.6	RP11-795F19.1	4.63	4.13e-06	0.00037	0.22	0.14	Opioid sensitivity;	chr18:79862467	chr18:80046900~80095482:+
BRCA	cis	rs6598266	1	rs6598267	ENSG00000182397.13	DNM1P46	-4.63	4.14e-06	0.00037	-0.19	-0.14	Major depressive disorder;	chr15:99759090	chr15:99790156~99806927:-
BRCA	cis	rs10938353	0.911	rs4330385	ENSG00000273369.1	RP11-700J17.1	-4.63	4.14e-06	0.00037	-0.16	-0.14	Body mass index;	chr4:44585482	chr4:44693946~44694386:-
BRCA	cis	rs10938353	0.911	rs4504296	ENSG00000273369.1	RP11-700J17.1	-4.63	4.14e-06	0.00037	-0.16	-0.14	Body mass index;	chr4:44585515	chr4:44693946~44694386:-
BRCA	cis	rs2288912	0.807	rs3760626	ENSG00000280087.1	CTB-129P6.7	4.63	4.14e-06	0.00037	0.17	0.14	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr19:44953848	chr19:44909375~44914968:+
BRCA	cis	rs7246657	0.722	rs2927746	ENSG00000226686.6	LINC01535	4.63	4.14e-06	0.00037	0.21	0.14	Coronary artery calcification;	chr19:37665669	chr19:37251912~37265535:+
BRCA	cis	rs7572733	0.84	rs4850437	ENSG00000231621.1	AC013264.2	4.63	4.14e-06	0.00037	0.13	0.14	Dermatomyositis;	chr2:197704327	chr2:197197991~197199273:+
BRCA	cis	rs7246657	0.722	rs1975937	ENSG00000226686.6	LINC01535	-4.63	4.14e-06	0.00037	-0.21	-0.14	Coronary artery calcification;	chr19:37601031	chr19:37251912~37265535:+
BRCA	cis	rs6490294	0.904	rs12423061	ENSG00000226469.1	ADAM1B	4.63	4.14e-06	0.00037	0.18	0.14	Mean platelet volume;	chr12:111967091	chr12:111927018~111929017:+
BRCA	cis	rs6490294	0.904	rs112426410	ENSG00000226469.1	ADAM1B	4.63	4.14e-06	0.00037	0.18	0.14	Mean platelet volume;	chr12:111969634	chr12:111927018~111929017:+
BRCA	cis	rs7809615	0.901	rs10808111	ENSG00000244219.5	GS1-259H13.2	-4.63	4.14e-06	0.00037	-0.25	-0.14	Blood metabolite ratios;	chr7:99473261	chr7:99598066~99610813:+
BRCA	cis	rs6570726	0.935	rs369458	ENSG00000270638.1	RP3-466P17.1	4.63	4.14e-06	0.00037	0.16	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145491673	chr6:145735570~145737218:+
BRCA	cis	rs4713118	0.629	rs203887	ENSG00000219392.1	RP1-265C24.5	-4.63	4.14e-06	0.000371	-0.22	-0.14	Parkinson's disease;	chr6:28053491	chr6:28115628~28116551:+
BRCA	cis	rs9834975	0.873	rs9882772	ENSG00000272758.4	RP11-299J3.8	-4.63	4.15e-06	0.000371	-0.14	-0.14	Diastolic blood pressure;	chr3:122391302	chr3:122416207~122443180:+
BRCA	cis	rs910316	0.763	rs175057	ENSG00000259138.1	RP11-950C14.7	-4.63	4.15e-06	0.000371	-0.15	-0.14	Height;	chr14:75022929	chr14:75127153~75136930:+
BRCA	cis	rs7615952	0.515	rs7630575	ENSG00000250012.1	RP11-124N2.1	-4.63	4.15e-06	0.000371	-0.19	-0.14	Blood pressure (smoking interaction);	chr3:125963487	chr3:126084220~126095349:+
BRCA	cis	rs7772486	0.764	rs7762562	ENSG00000270638.1	RP3-466P17.1	4.63	4.15e-06	0.000371	0.16	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145837858	chr6:145735570~145737218:+
BRCA	cis	rs950169	0.614	rs12903883	ENSG00000275120.1	RP11-182J1.17	4.63	4.15e-06	0.000371	0.21	0.14	Schizophrenia;	chr15:84011801	chr15:84599434~84606463:-
BRCA	cis	rs758747	0.574	rs12933120	ENSG00000262312.2	LA16c-390H2.4	4.63	4.15e-06	0.000371	0.18	0.14	Body mass index;	chr16:3584745	chr16:3542739~3545785:+
BRCA	cis	rs10129255	0.957	rs8005468	ENSG00000211974.3	IGHV2-70	4.63	4.15e-06	0.000371	0.15	0.14	Kawasaki disease;	chr14:106686431	chr14:106723574~106724093:-
BRCA	cis	rs13160562	0.527	rs152479	ENSG00000248734.2	CTD-2260A17.1	4.63	4.16e-06	0.000372	0.15	0.14	Alcohol dependence;	chr5:96769339	chr5:96784777~96785999:+
BRCA	cis	rs11098499	0.662	rs13108589	ENSG00000260091.1	RP11-33B1.4	-4.63	4.16e-06	0.000372	-0.12	-0.14	Corneal astigmatism;	chr4:119346947	chr4:119409333~119410233:+
BRCA	cis	rs6430585	0.583	rs2322813	ENSG00000224043.6	CCNT2-AS1	-4.63	4.16e-06	0.000372	-0.24	-0.14	Corneal structure;	chr2:135825239	chr2:134735464~134918710:-
BRCA	cis	rs4835473	0.932	rs28668841	ENSG00000249741.2	RP11-673E1.3	4.63	4.16e-06	0.000372	0.16	0.14	Immature fraction of reticulocytes;	chr4:143982530	chr4:143911514~143912053:-
BRCA	cis	rs9788721	0.836	rs17483929	ENSG00000261762.1	RP11-650L12.2	-4.63	4.16e-06	0.000372	-0.17	-0.14	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78450034	chr15:78589123~78591276:-
BRCA	cis	rs10938353	0.68	rs73191059	ENSG00000273369.1	RP11-700J17.1	4.63	4.16e-06	0.000372	0.19	0.14	Body mass index;	chr4:44629998	chr4:44693946~44694386:-
BRCA	cis	rs6452524	1	rs6882179	ENSG00000281327.1	LINC01338	4.63	4.16e-06	0.000372	0.16	0.14	Hypertension (SNP x SNP interaction);	chr5:83139582	chr5:82850864~82859836:-
BRCA	cis	rs6088580	0.634	rs6088498	ENSG00000276073.1	RP5-1125A11.7	-4.63	4.16e-06	0.000372	-0.16	-0.14	Glomerular filtration rate (creatinine);	chr20:34432640	chr20:33985617~33988989:-
BRCA	cis	rs13113518	0.902	rs12505266	ENSG00000249700.7	SRD5A3-AS1	4.63	4.16e-06	0.000372	0.18	0.14	Height;	chr4:55546002	chr4:55363971~55395847:-
BRCA	cis	rs3845817	0.703	rs702904	ENSG00000237979.1	AC007389.1	4.63	4.17e-06	0.000372	0.17	0.14	Bipolar disorder;	chr2:65538960	chr2:65500993~65502138:-
BRCA	cis	rs3845817	0.733	rs702906	ENSG00000237979.1	AC007389.1	4.63	4.17e-06	0.000372	0.17	0.14	Bipolar disorder;	chr2:65539745	chr2:65500993~65502138:-
BRCA	cis	rs6430538	0.597	rs6731271	ENSG00000224043.6	CCNT2-AS1	-4.63	4.17e-06	0.000373	-0.2	-0.14	Parkinson's disease;	chr2:134802502	chr2:134735464~134918710:-
BRCA	cis	rs7968440	0.902	rs4768886	ENSG00000272368.2	RP4-605O3.4	-4.63	4.17e-06	0.000373	-0.14	-0.14	Fibrinogen;	chr12:50528196	chr12:50112197~50165618:+
BRCA	cis	rs6832769	1	rs13121235	ENSG00000272969.1	RP11-528I4.2	4.63	4.17e-06	0.000373	0.17	0.14	Personality dimensions;	chr4:55445780	chr4:55547112~55547889:+
BRCA	cis	rs4906332	0.966	rs12894275	ENSG00000244691.1	RPL10AP1	4.63	4.17e-06	0.000373	0.18	0.14	Coronary artery disease;	chr14:103435087	chr14:103412119~103412761:-
BRCA	cis	rs11742741	1	rs2331579	ENSG00000248874.4	C5orf17	-4.63	4.17e-06	0.000373	-0.18	-0.14	Educational attainment;	chr5:24157646	chr5:23951348~24178263:+
BRCA	cis	rs7772486	0.875	rs9322044	ENSG00000270638.1	RP3-466P17.1	4.63	4.17e-06	0.000373	0.16	0.14	Lobe attachment (rater-scored or self-reported);	chr6:146048472	chr6:145735570~145737218:+
BRCA	cis	rs4767841	0.552	rs11064861	ENSG00000248636.5	RP11-768F21.1	-4.63	4.17e-06	0.000373	-0.19	-0.14	Urgency urinary incontinence;	chr12:119633855	chr12:119387987~119668079:-
BRCA	cis	rs10504130	0.569	rs2069119	ENSG00000272024.1	RP11-546K22.3	-4.63	4.18e-06	0.000373	-0.21	-0.14	Venous thromboembolism (SNP x SNP interaction);	chr8:51773876	chr8:51950284~51950690:+
BRCA	cis	rs10504130	0.569	rs35603537	ENSG00000272024.1	RP11-546K22.3	-4.63	4.18e-06	0.000373	-0.21	-0.14	Venous thromboembolism (SNP x SNP interaction);	chr8:51773899	chr8:51950284~51950690:+
BRCA	cis	rs10504130	0.502	rs71513552	ENSG00000272024.1	RP11-546K22.3	-4.63	4.18e-06	0.000373	-0.21	-0.14	Venous thromboembolism (SNP x SNP interaction);	chr8:51776662	chr8:51950284~51950690:+
BRCA	cis	rs6095360	0.966	rs6090940	ENSG00000222365.1	SNORD12B	-4.63	4.18e-06	0.000373	-0.15	-0.14	Intelligence (multi-trait analysis);	chr20:49049490	chr20:49280319~49280409:+
BRCA	cis	rs7474896	0.537	rs2749589	ENSG00000120555.12	SEPT7P9	-4.63	4.18e-06	0.000374	-0.2	-0.14	Obesity (extreme);	chr10:37977942	chr10:38383069~38402916:-
BRCA	cis	rs858239	0.614	rs10229956	ENSG00000230042.1	AK3P3	4.63	4.18e-06	0.000374	0.16	0.14	Cerebrospinal fluid biomarker levels;	chr7:23363317	chr7:23129178~23129841:+
BRCA	cis	rs9291683	0.585	rs12648479	ENSG00000250413.1	RP11-448G15.1	4.63	4.18e-06	0.000374	0.18	0.14	Bone mineral density;	chr4:10102947	chr4:10006482~10009725:+
BRCA	cis	rs13113518	1	rs12501636	ENSG00000273257.1	RP11-177J6.1	4.63	4.18e-06	0.000374	0.18	0.14	Height;	chr4:55482317	chr4:55387949~55388271:+
BRCA	cis	rs7267979	1	rs6037086	ENSG00000125804.12	FAM182A	4.63	4.18e-06	0.000374	0.19	0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25325702	chr20:26054655~26086917:+
BRCA	cis	rs7267979	0.966	rs2482923	ENSG00000125804.12	FAM182A	4.63	4.18e-06	0.000374	0.19	0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25328345	chr20:26054655~26086917:+
BRCA	cis	rs10129255	0.5	rs2105989	ENSG00000211959.2	IGHV4-39	4.63	4.18e-06	0.000374	0.1	0.14	Kawasaki disease;	chr14:106682199	chr14:106421711~106422218:-
BRCA	cis	rs6547741	0.935	rs2384626	ENSG00000234072.1	AC074117.10	4.63	4.19e-06	0.000374	0.13	0.14	Oral cavity cancer;	chr2:27550781	chr2:27356246~27367622:+
BRCA	cis	rs1858037	0.867	rs964505	ENSG00000281920.1	RP11-418H16.1	4.63	4.19e-06	0.000374	0.18	0.14	Rheumatoid arthritis;	chr2:65396055	chr2:65623272~65628424:+
BRCA	cis	rs4781563	1	rs3136211	ENSG00000242307.1	RPS26P52	-4.63	4.19e-06	0.000374	-0.17	-0.14	Bilirubin levels;	chr16:13945791	chr16:13922332~13922679:-
BRCA	cis	rs11098499	0.954	rs17009122	ENSG00000260091.1	RP11-33B1.4	-4.63	4.19e-06	0.000374	-0.13	-0.14	Corneal astigmatism;	chr4:119441248	chr4:119409333~119410233:+
BRCA	cis	rs4908768	0.501	rs2045820	ENSG00000232912.4	RP5-1115A15.1	4.63	4.19e-06	0.000374	0.14	0.14	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8678076	chr1:8424645~8434838:+
BRCA	cis	rs2625529	0.73	rs6494990	ENSG00000260037.4	CTD-2524L6.3	4.63	4.19e-06	0.000374	0.18	0.14	Red blood cell count;	chr15:72108733	chr15:71818396~71823384:+
BRCA	cis	rs6095360	0.615	rs6019506	ENSG00000222365.1	SNORD12B	-4.63	4.19e-06	0.000374	-0.18	-0.14	Intelligence (multi-trait analysis);	chr20:48899655	chr20:49280319~49280409:+
BRCA	cis	rs11673344	0.562	rs7257320	ENSG00000226686.6	LINC01535	4.63	4.19e-06	0.000375	0.18	0.14	Obesity-related traits;	chr19:37080933	chr19:37251912~37265535:+
BRCA	cis	rs755249	0.756	rs72637908	ENSG00000182109.6	RP11-69E11.4	4.63	4.19e-06	0.000375	0.17	0.14	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39557375	chr1:39522280~39546187:-
BRCA	cis	rs1005277	0.579	rs2505241	ENSG00000263064.2	RP11-291L22.7	4.63	4.2e-06	0.000375	0.17	0.14	Extrinsic epigenetic age acceleration;	chr10:38153493	chr10:38448689~38448949:+
BRCA	cis	rs9467773	0.62	rs9467810	ENSG00000241549.7	GUSBP2	4.63	4.2e-06	0.000375	0.15	0.14	Intelligence (multi-trait analysis);	chr6:26608033	chr6:26871484~26956554:-
BRCA	cis	rs28735056	0.596	rs3744879	ENSG00000261126.6	RP11-795F19.1	-4.63	4.2e-06	0.000375	-0.14	-0.14	Schizophrenia;	chr18:79919006	chr18:80046900~80095482:+
BRCA	cis	rs1395	0.744	rs3739092	ENSG00000234072.1	AC074117.10	-4.63	4.2e-06	0.000375	-0.15	-0.14	Blood metabolite levels;	chr2:27239208	chr2:27356246~27367622:+
BRCA	cis	rs1401492	1	rs1401492	ENSG00000271976.1	RP11-884K10.7	-4.63	4.2e-06	0.000375	-0.31	-0.14	Insulin resistance/response;	chr3:53646097	chr3:53858994~53861576:-
BRCA	cis	rs983392	0.836	rs7946992	ENSG00000275344.1	MIR6503	-4.63	4.2e-06	0.000375	-0.15	-0.14	Alzheimer's disease (late onset);	chr11:60177337	chr11:60209071~60209156:-
BRCA	cis	rs6600671	1	rs6600671	ENSG00000275538.1	RNVU1-19	-4.63	4.2e-06	0.000375	-0.17	-0.14	Hip geometry;	chr1:121458637	chr1:120850819~120850985:-
BRCA	cis	rs11098499	0.954	rs7436506	ENSG00000250412.1	KLHL2P1	4.63	4.2e-06	0.000375	0.17	0.14	Corneal astigmatism;	chr4:119472614	chr4:119334329~119378233:+
BRCA	cis	rs2243480	1	rs316307	ENSG00000222364.1	RNU6-96P	-4.63	4.2e-06	0.000375	-0.26	-0.14	Diabetic kidney disease;	chr7:66105184	chr7:66395191~66395286:+
BRCA	cis	rs853679	1	rs853679	ENSG00000216901.1	AL022393.7	4.63	4.2e-06	0.000375	0.24	0.14	Depression;	chr6:28329086	chr6:28176188~28176674:+
BRCA	cis	rs853679	1	rs853678	ENSG00000216901.1	AL022393.7	4.63	4.2e-06	0.000375	0.24	0.14	Depression;	chr6:28329536	chr6:28176188~28176674:+
BRCA	cis	rs11892454	0.515	rs11888036	ENSG00000217643.1	PTGES3P2	4.63	4.21e-06	0.000376	0.15	0.14	Heschl's gyrus morphology;	chr2:25840906	chr2:25822469~25822950:+
BRCA	cis	rs11098499	0.954	rs6849171	ENSG00000260091.1	RP11-33B1.4	-4.63	4.21e-06	0.000376	-0.12	-0.14	Corneal astigmatism;	chr4:119488394	chr4:119409333~119410233:+
BRCA	cis	rs4356203	0.875	rs527810	ENSG00000272034.1	SNORD14A	-4.63	4.21e-06	0.000376	-0.14	-0.14	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17179519	chr11:17074654~17074744:-
BRCA	cis	rs1320333	0.685	rs6710875	ENSG00000272342.1	RP13-539J13.1	4.63	4.21e-06	0.000376	0.24	0.14	Obesity-related traits;	chr2:699976	chr2:739588~740164:-
BRCA	cis	rs7615952	0.932	rs13065725	ENSG00000250012.1	RP11-124N2.1	-4.63	4.21e-06	0.000376	-0.22	-0.14	Blood pressure (smoking interaction);	chr3:125913446	chr3:126084220~126095349:+
BRCA	cis	rs7246657	0.722	rs2075284	ENSG00000276846.1	CTD-3220F14.3	-4.63	4.21e-06	0.000376	-0.2	-0.14	Coronary artery calcification;	chr19:37698715	chr19:37314868~37315620:-
BRCA	cis	rs7119	0.745	rs12911649	ENSG00000259362.2	RP11-307C19.1	-4.63	4.21e-06	0.000376	-0.19	-0.14	Type 2 diabetes;	chr15:77514785	chr15:77525540~77534110:+
BRCA	cis	rs7665090	1	rs9996834	ENSG00000251288.2	RP11-10L12.2	-4.63	4.21e-06	0.000376	-0.17	-0.14	Primary biliary cholangitis;	chr4:102636372	chr4:102751401~102752641:+
BRCA	cis	rs6840360	0.642	rs11099819	ENSG00000251603.1	RP11-164P12.4	-4.63	4.21e-06	0.000376	-0.13	-0.14	Intelligence (multi-trait analysis);	chr4:151509026	chr4:151667224~151670502:+
BRCA	cis	rs6840360	0.607	rs6815320	ENSG00000251603.1	RP11-164P12.4	-4.63	4.21e-06	0.000376	-0.13	-0.14	Intelligence (multi-trait analysis);	chr4:151511348	chr4:151667224~151670502:+
BRCA	cis	rs6840360	0.642	rs11726254	ENSG00000251603.1	RP11-164P12.4	-4.63	4.21e-06	0.000376	-0.13	-0.14	Intelligence (multi-trait analysis);	chr4:151517698	chr4:151667224~151670502:+
BRCA	cis	rs6832769	1	rs11733864	ENSG00000272969.1	RP11-528I4.2	4.63	4.21e-06	0.000376	0.17	0.14	Personality dimensions;	chr4:55455363	chr4:55547112~55547889:+
BRCA	cis	rs6573604	0.681	rs10144503	ENSG00000276116.2	FUT8-AS1	-4.63	4.21e-06	0.000376	-0.22	-0.14	N-glycan levels;	chr14:65317391	chr14:65411170~65412690:-
BRCA	cis	rs875971	0.577	rs35072105	ENSG00000273024.4	INTS4P2	4.63	4.21e-06	0.000376	0.16	0.14	Aortic root size;	chr7:66144830	chr7:65647864~65715661:+
BRCA	cis	rs7818688	0.697	rs11783878	ENSG00000253528.2	RP11-347C18.4	4.63	4.21e-06	0.000376	0.22	0.14	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94967033	chr8:94974573~94974853:-
BRCA	cis	rs7811142	0.779	rs111312383	ENSG00000078319.8	PMS2P1	-4.63	4.21e-06	0.000376	-0.23	-0.14	Platelet count;	chr7:100307702	chr7:100320992~100341908:-
BRCA	cis	rs2554380	0.891	rs2562782	ENSG00000230373.7	GOLGA6L5P	-4.62	4.22e-06	0.000377	-0.2	-0.14	Height;	chr15:83631329	chr15:84507885~84516814:-
BRCA	cis	rs2839186	0.585	rs2839154	ENSG00000223901.2	AP001469.5	-4.62	4.22e-06	0.000377	-0.14	-0.14	Testicular germ cell tumor;	chr21:46217846	chr21:46220269~46225364:+
BRCA	cis	rs7474896	0.583	rs10827818	ENSG00000120555.12	SEPT7P9	4.62	4.22e-06	0.000377	0.2	0.14	Obesity (extreme);	chr10:37711928	chr10:38383069~38402916:-
BRCA	cis	rs9981595	1	rs9981595	ENSG00000255568.3	BRWD1-AS2	4.62	4.22e-06	0.000377	0.21	0.14	Venous thromboembolism (SNP x SNP interaction);	chr21:39188752	chr21:39313935~39314962:+
BRCA	cis	rs9652601	0.691	rs6498160	ENSG00000274038.1	RP11-66H6.4	-4.62	4.23e-06	0.000377	-0.16	-0.14	Systemic lupus erythematosus;	chr16:11105590	chr16:11056556~11057034:+
BRCA	cis	rs897984	0.553	rs2335013	ENSG00000260911.2	RP11-196G11.2	-4.62	4.23e-06	0.000377	-0.14	-0.14	Dementia with Lewy bodies;	chr16:30866025	chr16:31043150~31049868:+
BRCA	cis	rs6598266	1	rs8026166	ENSG00000182397.13	DNM1P46	-4.62	4.23e-06	0.000377	-0.19	-0.14	Major depressive disorder;	chr15:99759209	chr15:99790156~99806927:-
BRCA	cis	rs6598266	0.908	rs8040391	ENSG00000182397.13	DNM1P46	-4.62	4.23e-06	0.000377	-0.19	-0.14	Major depressive disorder;	chr15:99759243	chr15:99790156~99806927:-
BRCA	cis	rs6598266	1	rs6598271	ENSG00000182397.13	DNM1P46	-4.62	4.23e-06	0.000377	-0.19	-0.14	Major depressive disorder;	chr15:99759428	chr15:99790156~99806927:-
BRCA	cis	rs7226408	0.857	rs17567681	ENSG00000267707.2	RP11-95O2.5	-4.62	4.23e-06	0.000377	-0.2	-0.14	Obesity-related traits;	chr18:36901904	chr18:37243776~37247506:+
BRCA	cis	rs9467773	0.967	rs6456732	ENSG00000241549.7	GUSBP2	4.62	4.23e-06	0.000378	0.15	0.14	Intelligence (multi-trait analysis);	chr6:26514217	chr6:26871484~26956554:-
BRCA	cis	rs2574985	0.813	rs3011773	ENSG00000231345.3	BEND3P1	4.62	4.23e-06	0.000378	0.24	0.14	Subjective well-being;	chr10:50516325	chr10:50655967~50660472:+
BRCA	cis	rs8040855	0.627	rs3816105	ENSG00000230373.7	GOLGA6L5P	4.62	4.23e-06	0.000378	0.18	0.14	Bulimia nervosa;	chr15:85097680	chr15:84507885~84516814:-
BRCA	cis	rs8040855	0.627	rs2304418	ENSG00000230373.7	GOLGA6L5P	4.62	4.23e-06	0.000378	0.18	0.14	Bulimia nervosa;	chr15:85097752	chr15:84507885~84516814:-
BRCA	cis	rs2227564	0.729	rs2633304	ENSG00000271816.1	BMS1P4	4.62	4.23e-06	0.000378	0.16	0.14	Crohn's disease;Inflammatory bowel disease;	chr10:73890892	chr10:73699151~73730487:-
BRCA	cis	rs2227564	0.729	rs2688616	ENSG00000271816.1	BMS1P4	4.62	4.23e-06	0.000378	0.16	0.14	Crohn's disease;Inflammatory bowel disease;	chr10:73890894	chr10:73699151~73730487:-
BRCA	cis	rs4356203	0.905	rs589319	ENSG00000272034.1	SNORD14A	-4.62	4.23e-06	0.000378	-0.15	-0.14	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17181050	chr11:17074654~17074744:-
BRCA	cis	rs11098499	0.954	rs9993199	ENSG00000250412.1	KLHL2P1	-4.62	4.24e-06	0.000378	-0.17	-0.14	Corneal astigmatism;	chr4:119471718	chr4:119334329~119378233:+
BRCA	cis	rs7665090	1	rs6810869	ENSG00000251288.2	RP11-10L12.2	-4.62	4.24e-06	0.000378	-0.17	-0.14	Primary biliary cholangitis;	chr4:102637357	chr4:102751401~102752641:+
BRCA	cis	rs2915864	0.8	rs3911911	ENSG00000280047.1	CTC-463A16.1	4.62	4.24e-06	0.000378	0.21	0.14	Facial morphology (factor 20);	chr5:142147632	chr5:142165767~142168387:+
BRCA	cis	rs5758659	0.716	rs86669	ENSG00000273366.1	CTA-989H11.1	-4.62	4.24e-06	0.000378	-0.17	-0.14	Cognitive function;	chr22:42284794	chr22:42278188~42278846:+
BRCA	cis	rs7193541	0.691	rs3851728	ENSG00000262904.1	TMPOP2	-4.62	4.24e-06	0.000378	-0.14	-0.14	Multiple myeloma;	chr16:74446762	chr16:74667506~74668706:+
BRCA	cis	rs7178909	0.835	rs12437459	ENSG00000259677.1	RP11-493E3.1	4.62	4.24e-06	0.000378	0.17	0.14	Common traits (Other);	chr15:89877541	chr15:89876540~89877285:+
BRCA	cis	rs12681366	0.762	rs7831073	ENSG00000253704.1	RP11-267M23.4	4.62	4.24e-06	0.000378	0.15	0.14	Nonsyndromic cleft lip with cleft palate;	chr8:94342138	chr8:94553722~94569745:+
BRCA	cis	rs934734	0.571	rs7572922	ENSG00000204929.10	AC074391.1	-4.62	4.24e-06	0.000378	-0.18	-0.14	Rheumatoid arthritis;	chr2:65425022	chr2:65436711~66084639:+
BRCA	cis	rs13326165	0.531	rs35976326	ENSG00000243224.1	RP5-1157M23.2	-4.62	4.24e-06	0.000378	-0.23	-0.14	HDL cholesterol levels;HDL cholesterol;	chr3:52291023	chr3:52239258~52241097:+
BRCA	cis	rs13326165	0.585	rs55676974	ENSG00000243224.1	RP5-1157M23.2	-4.62	4.24e-06	0.000378	-0.23	-0.14	HDL cholesterol levels;HDL cholesterol;	chr3:52294008	chr3:52239258~52241097:+
BRCA	cis	rs17270561	0.779	rs12210620	ENSG00000272462.2	U91328.19	-4.62	4.24e-06	0.000378	-0.19	-0.14	Iron status biomarkers;	chr6:25884557	chr6:25992662~26001775:+
BRCA	cis	rs1043099	0.871	rs10427610	ENSG00000279699.1	RP1-102K2.9	-4.62	4.24e-06	0.000378	-0.23	-0.14	Rheumatoid arthritis;	chr22:30352229	chr22:30275215~30276951:-
BRCA	cis	rs7772486	0.754	rs702304	ENSG00000270638.1	RP3-466P17.1	-4.62	4.24e-06	0.000379	-0.16	-0.14	Lobe attachment (rater-scored or self-reported);	chr6:145669661	chr6:145735570~145737218:+
BRCA	cis	rs13108904	0.901	rs6851528	ENSG00000253399.1	AC078852.2	-4.62	4.24e-06	0.000379	-0.16	-0.14	Obesity-related traits;	chr4:1302221	chr4:1358479~1359461:+
BRCA	cis	rs12477438	0.765	rs56167745	ENSG00000231822.1	AC019097.7	-4.62	4.24e-06	0.000379	-0.15	-0.14	Chronic sinus infection;	chr2:98984015	chr2:99102018~99102752:+
BRCA	cis	rs7665090	1	rs2866413	ENSG00000251288.2	RP11-10L12.2	-4.62	4.25e-06	0.000379	-0.17	-0.14	Primary biliary cholangitis;	chr4:102635920	chr4:102751401~102752641:+
BRCA	cis	rs7665090	1	rs4547797	ENSG00000251288.2	RP11-10L12.2	-4.62	4.25e-06	0.000379	-0.17	-0.14	Primary biliary cholangitis;	chr4:102636035	chr4:102751401~102752641:+
BRCA	cis	rs7665090	1	rs2866414	ENSG00000251288.2	RP11-10L12.2	-4.62	4.25e-06	0.000379	-0.17	-0.14	Primary biliary cholangitis;	chr4:102636062	chr4:102751401~102752641:+
BRCA	cis	rs7665090	1	rs2903283	ENSG00000251288.2	RP11-10L12.2	-4.62	4.25e-06	0.000379	-0.17	-0.14	Primary biliary cholangitis;	chr4:102636596	chr4:102751401~102752641:+
BRCA	cis	rs7665090	1	rs4579121	ENSG00000251288.2	RP11-10L12.2	-4.62	4.25e-06	0.000379	-0.17	-0.14	Primary biliary cholangitis;	chr4:102637012	chr4:102751401~102752641:+
BRCA	cis	rs7665090	0.934	rs6533020	ENSG00000251288.2	RP11-10L12.2	-4.62	4.25e-06	0.000379	-0.17	-0.14	Primary biliary cholangitis;	chr4:102637648	chr4:102751401~102752641:+
BRCA	cis	rs7665090	0.934	rs6533021	ENSG00000251288.2	RP11-10L12.2	-4.62	4.25e-06	0.000379	-0.17	-0.14	Primary biliary cholangitis;	chr4:102637696	chr4:102751401~102752641:+
BRCA	cis	rs7246967	0.611	rs62118770	ENSG00000198153.8	ZNF849P	-4.62	4.25e-06	0.000379	-0.24	-0.14	Bronchopulmonary dysplasia;	chr19:22641227	chr19:22685167~22686732:+
BRCA	cis	rs7246967	0.611	rs62118771	ENSG00000198153.8	ZNF849P	-4.62	4.25e-06	0.000379	-0.24	-0.14	Bronchopulmonary dysplasia;	chr19:22641496	chr19:22685167~22686732:+
BRCA	cis	rs1005277	0.557	rs2983338	ENSG00000099251.13	HSD17B7P2	4.62	4.25e-06	0.000379	0.16	0.14	Extrinsic epigenetic age acceleration;	chr10:38261806	chr10:38356380~38378505:+
BRCA	cis	rs875971	0.545	rs6970498	ENSG00000230295.1	RP11-458F8.2	4.62	4.25e-06	0.000379	0.14	0.14	Aortic root size;	chr7:66275908	chr7:66880708~66882981:+
BRCA	cis	rs7818688	0.697	rs76631135	ENSG00000253528.2	RP11-347C18.4	-4.62	4.25e-06	0.000379	-0.22	-0.14	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94968760	chr8:94974573~94974853:-
BRCA	cis	rs7818688	0.697	rs57890591	ENSG00000253528.2	RP11-347C18.4	-4.62	4.25e-06	0.000379	-0.22	-0.14	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94970902	chr8:94974573~94974853:-
BRCA	cis	rs9834975	0.967	rs6438737	ENSG00000272758.4	RP11-299J3.8	4.62	4.25e-06	0.000379	0.14	0.14	Diastolic blood pressure;	chr3:122510127	chr3:122416207~122443180:+
BRCA	cis	rs4819052	0.808	rs2838825	ENSG00000184274.3	LINC00315	-4.62	4.26e-06	0.00038	-0.19	-0.14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45235736	chr21:45300245~45305257:-
BRCA	cis	rs875971	1	rs11974264	ENSG00000236529.1	RP13-254B10.1	-4.62	4.26e-06	0.00038	-0.15	-0.14	Aortic root size;	chr7:66182595	chr7:65840212~65840596:+
BRCA	cis	rs35146811	0.555	rs2527898	ENSG00000235713.1	RP4-604G5.3	4.62	4.26e-06	0.00038	0.17	0.14	Coronary artery disease;	chr7:99936407	chr7:99992397~99993050:+
BRCA	cis	rs6430585	0.528	rs10496738	ENSG00000231890.6	DARS-AS1	-4.62	4.26e-06	0.00038	-0.23	-0.14	Corneal structure;	chr2:135993918	chr2:135985176~136022593:+
BRCA	cis	rs9784649	1	rs1493479	ENSG00000245662.2	RP11-184E9.1	4.62	4.26e-06	0.00038	0.21	0.14	Peripheral arterial disease (traffic-related air pollution interaction);	chr5:24987659	chr5:25190682~25306172:+
BRCA	cis	rs1223397	0.651	rs2496156	ENSG00000215022.6	RP1-257A7.4	-4.62	4.26e-06	0.00038	-0.17	-0.14	Blood pressure;	chr6:13315146	chr6:13264861~13295586:-
BRCA	cis	rs9921338	0.961	rs4781069	ENSG00000262703.1	RP11-485G7.6	-4.62	4.26e-06	0.00038	-0.18	-0.14	Vein graft stenosis in coronary artery bypass grafting;	chr16:11334905	chr16:11348143~11349321:-
BRCA	cis	rs13160562	0.527	rs25863	ENSG00000248734.2	CTD-2260A17.1	4.62	4.26e-06	0.00038	0.15	0.14	Alcohol dependence;	chr5:96770222	chr5:96784777~96785999:+
BRCA	cis	rs10946940	0.965	rs6915266	ENSG00000220721.1	OR1F12	-4.62	4.27e-06	0.000381	-0.16	-0.14	Systemic lupus erythematosus;	chr6:27560864	chr6:28073316~28074233:+
BRCA	cis	rs7772486	0.79	rs9399571	ENSG00000270638.1	RP3-466P17.1	-4.62	4.27e-06	0.000381	-0.17	-0.14	Lobe attachment (rater-scored or self-reported);	chr6:145960925	chr6:145735570~145737218:+
BRCA	cis	rs9921338	0.961	rs11074958	ENSG00000262703.1	RP11-485G7.6	-4.62	4.27e-06	0.000381	-0.18	-0.14	Vein graft stenosis in coronary artery bypass grafting;	chr16:11303222	chr16:11348143~11349321:-
BRCA	cis	rs875971	0.545	rs221986	ENSG00000232546.1	RP11-458F8.1	-4.62	4.27e-06	0.000381	-0.14	-0.14	Aortic root size;	chr7:66105323	chr7:66848496~66858136:+
BRCA	cis	rs6840258	0.64	rs1552144	ENSG00000251411.1	RP11-397E7.4	4.62	4.27e-06	0.000381	0.18	0.14	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87173498	chr4:86913266~86914817:-
BRCA	cis	rs3764021	0.527	rs11052426	ENSG00000256673.1	RP11-599J14.2	-4.62	4.27e-06	0.000381	-0.18	-0.14	Type 1 diabetes;	chr12:9688330	chr12:9398355~9414851:-
BRCA	cis	rs1713985	0.8	rs4280804	ENSG00000269949.1	RP11-738E22.3	-4.62	4.27e-06	0.000381	-0.31	-0.14	Age-related macular degeneration;	chr4:56928204	chr4:56960927~56961373:-
BRCA	cis	rs6430585	0.528	rs309151	ENSG00000224043.6	CCNT2-AS1	-4.62	4.27e-06	0.000381	-0.24	-0.14	Corneal structure;	chr2:135903580	chr2:134735464~134918710:-
BRCA	cis	rs8054556	1	rs9932196	ENSG00000214725.6	CDIPT-AS1	-4.62	4.27e-06	0.000381	-0.17	-0.14	Autism spectrum disorder or schizophrenia;	chr16:29971798	chr16:29863593~29868053:+
BRCA	cis	rs78487399	0.731	rs75050485	ENSG00000234936.1	AC010883.5	4.62	4.27e-06	0.000381	0.23	0.14	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43551331	chr2:43229573~43233394:+
BRCA	cis	rs2446066	0.872	rs10876452	ENSG00000257379.1	RP11-793H13.8	4.62	4.27e-06	0.000381	0.22	0.14	Red blood cell count;	chr12:53420474	chr12:53441741~53467528:+
BRCA	cis	rs2253762	0.507	rs11200310	ENSG00000226864.1	ATE1-AS1	4.62	4.27e-06	0.000381	0.26	0.14	Breast cancer;	chr10:121989944	chr10:121928312~121951965:+
BRCA	cis	rs991427	0.643	rs11836408	ENSG00000258100.1	RP11-121E16.1	-4.62	4.27e-06	0.000381	-0.22	-0.14	Systolic blood pressure (alcohol consumption interaction);	chr12:91070557	chr12:91362196~91368606:+
BRCA	cis	rs6430585	0.528	rs114760827	ENSG00000231890.6	DARS-AS1	-4.62	4.28e-06	0.000381	-0.23	-0.14	Corneal structure;	chr2:135903540	chr2:135985176~136022593:+
BRCA	cis	rs12681366	0.762	rs7824722	ENSG00000253704.1	RP11-267M23.4	4.62	4.28e-06	0.000381	0.15	0.14	Nonsyndromic cleft lip with cleft palate;	chr8:94338623	chr8:94553722~94569745:+
BRCA	cis	rs2832191	0.967	rs3787660	ENSG00000236056.1	GAPDHP14	-4.62	4.28e-06	0.000382	-0.15	-0.14	Dental caries;	chr21:29148586	chr21:29222321~29223257:+
BRCA	cis	rs7011507	0.594	rs1123189	ENSG00000279881.1	RP11-513O13.1	-4.62	4.28e-06	0.000382	-0.2	-0.14	Inflammatory bowel disease;Ulcerative colitis;	chr8:48445879	chr8:48428143~48431041:-
BRCA	cis	rs67311347	1	rs9835219	ENSG00000280739.1	EIF1B-AS1	4.62	4.28e-06	0.000382	0.16	0.14	Renal cell carcinoma;	chr3:40382602	chr3:40173145~40309698:-
BRCA	cis	rs7246967	0.611	rs12983761	ENSG00000198153.8	ZNF849P	-4.62	4.28e-06	0.000382	-0.24	-0.14	Bronchopulmonary dysplasia;	chr19:22657795	chr19:22685167~22686732:+
BRCA	cis	rs2908197	0.806	rs6465098	ENSG00000186704.9	DTX2P1	4.62	4.28e-06	0.000382	0.16	0.14	3-hydroxypropylmercapturic acid levels in smokers;	chr7:76343630	chr7:76978617~77004308:+
BRCA	cis	rs7267979	1	rs2424716	ENSG00000125804.12	FAM182A	-4.62	4.28e-06	0.000382	-0.18	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25442902	chr20:26054655~26086917:+
BRCA	cis	rs7267979	1	rs761025	ENSG00000125804.12	FAM182A	-4.62	4.28e-06	0.000382	-0.18	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25446332	chr20:26054655~26086917:+
BRCA	cis	rs1395	0.626	rs72817537	ENSG00000234072.1	AC074117.10	-4.62	4.28e-06	0.000382	-0.16	-0.14	Blood metabolite levels;	chr2:27274681	chr2:27356246~27367622:+
BRCA	cis	rs1713985	1	rs802920	ENSG00000269949.1	RP11-738E22.3	-4.62	4.28e-06	0.000382	-0.31	-0.14	Age-related macular degeneration;	chr4:56907332	chr4:56960927~56961373:-
BRCA	cis	rs11051970	1	rs6488051	ENSG00000274964.1	RP11-817I4.1	-4.62	4.28e-06	0.000382	-0.17	-0.14	Response to tocilizumab in rheumatoid arthritis;	chr12:32379799	chr12:32339368~32340724:+
BRCA	cis	rs10129255	0.872	rs1858683	ENSG00000232216.1	IGHV3-43	4.62	4.28e-06	0.000382	0.12	0.14	Kawasaki disease;	chr14:106670217	chr14:106470264~106470800:-
BRCA	cis	rs1153858	1	rs4775907	ENSG00000275672.1	GATM-AS1	-4.62	4.28e-06	0.000382	-0.18	-0.14	Homoarginine levels;	chr15:45346449	chr15:45378700~45380123:+
BRCA	cis	rs6430585	0.527	rs1900306	ENSG00000224043.6	CCNT2-AS1	-4.62	4.28e-06	0.000382	-0.24	-0.14	Corneal structure;	chr2:135658963	chr2:134735464~134918710:-
BRCA	cis	rs6081541	1	rs6081548	ENSG00000179447.2	RP5-1027G4.3	-4.62	4.28e-06	0.000382	-0.19	-0.14	Psychosis (atypical);	chr20:19249683	chr20:19242302~19284596:-
BRCA	cis	rs860295	0.665	rs12028416	ENSG00000225855.5	RUSC1-AS1	4.62	4.28e-06	0.000382	0.12	0.14	Body mass index;	chr1:155431370	chr1:155316863~155324176:-
BRCA	cis	rs860295	0.629	rs12026638	ENSG00000225855.5	RUSC1-AS1	4.62	4.28e-06	0.000382	0.12	0.14	Body mass index;	chr1:155431469	chr1:155316863~155324176:-
BRCA	cis	rs1122401	0.532	rs10067633	ENSG00000280159.1	CTD-2591A1.1	4.62	4.28e-06	0.000382	0.2	0.14	Smoking initiation;	chr5:54578346	chr5:54643557~54645987:+
BRCA	cis	rs6545883	0.859	rs2694644	ENSG00000212978.6	AC016747.3	-4.62	4.28e-06	0.000382	-0.19	-0.14	Tuberculosis;	chr2:61377721	chr2:61141592~61144969:-
BRCA	cis	rs4715166	0.798	rs4715169	ENSG00000272379.1	RP1-257A7.5	4.62	4.29e-06	0.000382	0.16	0.14	Hip geometry;	chr6:13223996	chr6:13290018~13290490:-
BRCA	cis	rs2243480	0.901	rs57126451	ENSG00000275400.1	RP4-756H11.5	4.62	4.29e-06	0.000382	0.25	0.14	Diabetic kidney disease;	chr7:65951319	chr7:66553805~66554199:-
BRCA	cis	rs11673344	0.523	rs2562609	ENSG00000226686.6	LINC01535	4.62	4.29e-06	0.000382	0.18	0.14	Obesity-related traits;	chr19:37036255	chr19:37251912~37265535:+
BRCA	cis	rs6832769	0.885	rs6815516	ENSG00000272969.1	RP11-528I4.2	-4.62	4.29e-06	0.000382	-0.17	-0.14	Personality dimensions;	chr4:55533017	chr4:55547112~55547889:+
BRCA	cis	rs11098499	0.908	rs28559989	ENSG00000260091.1	RP11-33B1.4	-4.62	4.29e-06	0.000383	-0.13	-0.14	Corneal astigmatism;	chr4:119465472	chr4:119409333~119410233:+
BRCA	cis	rs13113518	1	rs4864549	ENSG00000249700.7	SRD5A3-AS1	4.62	4.29e-06	0.000383	0.18	0.14	Height;	chr4:55554380	chr4:55363971~55395847:-
BRCA	cis	rs1075265	0.933	rs2287642	ENSG00000235937.1	AC008280.1	4.62	4.29e-06	0.000383	0.15	0.14	Chronotype;Morning vs. evening chronotype;	chr2:54108447	chr2:54029552~54030682:-
BRCA	cis	rs7637701	0.818	rs1560415	ENSG00000240875.4	LINC00886	-4.62	4.29e-06	0.000383	-0.16	-0.14	Breast cancer;	chr3:156819569	chr3:156747346~156817062:-
BRCA	cis	rs7637701	0.818	rs1560416	ENSG00000240875.4	LINC00886	-4.62	4.29e-06	0.000383	-0.16	-0.14	Breast cancer;	chr3:156819630	chr3:156747346~156817062:-
BRCA	cis	rs7637701	0.818	rs9837271	ENSG00000240875.4	LINC00886	-4.62	4.29e-06	0.000383	-0.16	-0.14	Breast cancer;	chr3:156820949	chr3:156747346~156817062:-
BRCA	cis	rs700651	0.789	rs6715070	ENSG00000231621.1	AC013264.2	4.62	4.29e-06	0.000383	0.13	0.14	Intracranial aneurysm;	chr2:198033541	chr2:197197991~197199273:+
BRCA	cis	rs4715166	0.926	rs2840336	ENSG00000272379.1	RP1-257A7.5	4.62	4.3e-06	0.000383	0.16	0.14	Hip geometry;	chr6:13225563	chr6:13290018~13290490:-
BRCA	cis	rs17270561	0.723	rs12192635	ENSG00000272462.2	U91328.19	-4.62	4.3e-06	0.000383	-0.19	-0.14	Iron status biomarkers;	chr6:25880679	chr6:25992662~26001775:+
BRCA	cis	rs5758659	0.519	rs133307	ENSG00000273366.1	CTA-989H11.1	-4.62	4.3e-06	0.000383	-0.17	-0.14	Cognitive function;	chr22:42000564	chr22:42278188~42278846:+
BRCA	cis	rs7119	0.651	rs12904823	ENSG00000259362.2	RP11-307C19.1	-4.62	4.3e-06	0.000383	-0.2	-0.14	Type 2 diabetes;	chr15:77545320	chr15:77525540~77534110:+
BRCA	cis	rs11239930	0.538	rs9663073	ENSG00000278811.3	LINC00624	4.62	4.3e-06	0.000383	0.17	0.14	AIDS progression;	chr1:147083022	chr1:147258885~147517875:-
BRCA	cis	rs7674212	0.54	rs2720469	ENSG00000251288.2	RP11-10L12.2	-4.62	4.3e-06	0.000383	-0.16	-0.14	Type 2 diabetes;	chr4:103165327	chr4:102751401~102752641:+
BRCA	cis	rs7927592	0.871	rs871212	ENSG00000212093.1	AP000807.1	4.62	4.3e-06	0.000383	0.16	0.14	Total body bone mineral density;	chr11:68581227	chr11:68506083~68506166:-
BRCA	cis	rs651907	0.557	rs7629753	ENSG00000256628.3	ZBTB11-AS1	-4.62	4.3e-06	0.000384	-0.18	-0.14	Colorectal cancer;	chr3:101653078	chr3:101676475~101679217:+
BRCA	cis	rs721917	0.506	rs2819100	ENSG00000278616.1	BEND3P3	-4.62	4.3e-06	0.000384	-0.13	-0.14	Chronic obstructive pulmonary disease;	chr10:79937163	chr10:79682997~79685436:+
BRCA	cis	rs7267979	0.808	rs84816	ENSG00000125804.12	FAM182A	-4.62	4.3e-06	0.000384	-0.18	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25479283	chr20:26054655~26086917:+
BRCA	cis	rs7141336	0.8	rs8016042	ENSG00000258884.1	CTD-3035D6.2	4.62	4.31e-06	0.000384	0.19	0.14	Anxiety disorder;	chr14:90821842	chr14:90822365~90828128:-
BRCA	cis	rs2243480	0.901	rs35087093	ENSG00000275400.1	RP4-756H11.5	4.62	4.31e-06	0.000384	0.25	0.14	Diabetic kidney disease;	chr7:65940221	chr7:66553805~66554199:-
BRCA	cis	rs13108904	0.557	rs1250098	ENSG00000254094.1	AC078852.1	4.62	4.31e-06	0.000384	0.17	0.14	Obesity-related traits;	chr4:1244468	chr4:1356581~1358075:+
BRCA	cis	rs17428076	0.831	rs3821093	ENSG00000228389.1	AC068039.4	-4.62	4.31e-06	0.000384	-0.21	-0.14	Myopia;	chr2:171838077	chr2:171773482~171775844:+
BRCA	cis	rs2835345	0.596	rs62229441	ENSG00000279365.1	KB-176G8.1	4.62	4.31e-06	0.000384	0.2	0.14	Pulmonary function;	chr21:36447559	chr21:36485867~36487760:+
BRCA	cis	rs7119	0.717	rs12911963	ENSG00000259362.2	RP11-307C19.1	-4.62	4.31e-06	0.000384	-0.19	-0.14	Type 2 diabetes;	chr15:77514833	chr15:77525540~77534110:+
BRCA	cis	rs6728642	0.908	rs10203833	ENSG00000230606.9	AC159540.1	4.62	4.31e-06	0.000384	0.23	0.14	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:97356336	chr2:97416165~97433527:-
BRCA	cis	rs17711722	0.522	rs4642526	ENSG00000226767.1	RP11-328P23.3	4.62	4.31e-06	0.000385	0.16	0.14	Calcium levels;	chr7:65751755	chr7:65508773~65508944:-
BRCA	cis	rs6832769	0.925	rs1965467	ENSG00000272969.1	RP11-528I4.2	4.62	4.32e-06	0.000385	0.17	0.14	Personality dimensions;	chr4:55456573	chr4:55547112~55547889:+
BRCA	cis	rs6840360	0.642	rs2709831	ENSG00000251603.1	RP11-164P12.4	-4.62	4.32e-06	0.000385	-0.13	-0.14	Intelligence (multi-trait analysis);	chr4:151458499	chr4:151667224~151670502:+
BRCA	cis	rs11146838	1	rs11146838	ENSG00000276805.1	RP11-291L22.6	4.62	4.32e-06	0.000385	0.15	0.14	Breast cancer;	chr10:38856846	chr10:38451030~38451785:+
BRCA	cis	rs10129255	0.536	rs6576201	ENSG00000211959.2	IGHV4-39	-4.62	4.32e-06	0.000385	-0.1	-0.14	Kawasaki disease;	chr14:106683696	chr14:106421711~106422218:-
BRCA	cis	rs6095360	1	rs2426139	ENSG00000222365.1	SNORD12B	-4.62	4.32e-06	0.000385	-0.16	-0.14	Intelligence (multi-trait analysis);	chr20:49163568	chr20:49280319~49280409:+
BRCA	cis	rs60843830	0.964	rs17713568	ENSG00000272342.1	RP13-539J13.1	4.62	4.32e-06	0.000385	0.18	0.14	Spherical equivalent (joint analysis main effects and education interaction);	chr2:242132	chr2:739588~740164:-
BRCA	cis	rs1325195	0.507	rs10798652	ENSG00000261060.1	RP11-545A16.4	-4.62	4.32e-06	0.000385	-0.18	-0.14	IgE grass sensitization;	chr1:179092292	chr1:179590372~179591305:+
BRCA	cis	rs875971	0.545	rs7783889	ENSG00000273142.1	RP11-458F8.4	4.62	4.32e-06	0.000385	0.14	0.14	Aortic root size;	chr7:66283366	chr7:66902857~66906297:+
BRCA	cis	rs17767294	0.708	rs72848790	ENSG00000204709.4	LINC01556	4.62	4.32e-06	0.000385	0.39	0.14	Parkinson's disease;	chr6:28018074	chr6:28943877~28944537:+
BRCA	cis	rs78545713	0.536	rs116337444	ENSG00000241549.7	GUSBP2	-4.62	4.32e-06	0.000385	-0.27	-0.14	Iron status biomarkers (total iron binding capacity);	chr6:26208041	chr6:26871484~26956554:-
BRCA	cis	rs763014	0.966	rs4984904	ENSG00000260394.2	LA16c-313D11.9	-4.62	4.32e-06	0.000385	-0.14	-0.14	Height;	chr16:630809	chr16:678504~679777:-
BRCA	cis	rs755249	0.501	rs2484133	ENSG00000237624.1	OXCT2P1	4.62	4.32e-06	0.000385	0.18	0.14	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39188322	chr1:39514956~39516490:+
BRCA	cis	rs7811142	1	rs11771419	ENSG00000078319.8	PMS2P1	-4.62	4.32e-06	0.000385	-0.22	-0.14	Platelet count;	chr7:100390780	chr7:100320992~100341908:-
BRCA	cis	rs2486012	1	rs61770289	ENSG00000237950.1	RP11-7O11.3	-4.62	4.33e-06	0.000385	-0.25	-0.14	Intelligence (multi-trait analysis);	chr1:43898038	chr1:43944370~43946551:-
BRCA	cis	rs7246967	0.551	rs59127381	ENSG00000198153.8	ZNF849P	-4.62	4.33e-06	0.000385	-0.24	-0.14	Bronchopulmonary dysplasia;	chr19:22702233	chr19:22685167~22686732:+
BRCA	cis	rs2243480	1	rs316307	ENSG00000275400.1	RP4-756H11.5	4.62	4.33e-06	0.000385	0.26	0.14	Diabetic kidney disease;	chr7:66105184	chr7:66553805~66554199:-
BRCA	cis	rs7824557	1	rs2736371	ENSG00000154316.13	TDH	4.62	4.33e-06	0.000385	0.19	0.14	Retinal vascular caliber;	chr8:11248020	chr8:11339637~11368452:+
BRCA	cis	rs4218	0.734	rs12912071	ENSG00000259732.1	RP11-59H7.3	-4.62	4.33e-06	0.000385	-0.16	-0.14	Social communication problems;	chr15:59150951	chr15:59121034~59133250:+
BRCA	cis	rs7674212	0.57	rs1031804	ENSG00000251288.2	RP11-10L12.2	-4.62	4.33e-06	0.000386	-0.16	-0.14	Type 2 diabetes;	chr4:103144892	chr4:102751401~102752641:+
BRCA	cis	rs12681366	0.659	rs2470735	ENSG00000253704.1	RP11-267M23.4	-4.62	4.33e-06	0.000386	-0.14	-0.14	Nonsyndromic cleft lip with cleft palate;	chr8:94403670	chr8:94553722~94569745:+
BRCA	cis	rs12681366	0.636	rs2246066	ENSG00000253704.1	RP11-267M23.4	-4.62	4.33e-06	0.000386	-0.14	-0.14	Nonsyndromic cleft lip with cleft palate;	chr8:94406927	chr8:94553722~94569745:+
BRCA	cis	rs6599077	1	rs9822454	ENSG00000223797.4	ENTPD3-AS1	4.62	4.33e-06	0.000386	0.17	0.14	Sleep-related phenotypes;	chr3:40054280	chr3:40313802~40453329:-
BRCA	cis	rs7923609	0.846	rs7896518	ENSG00000232075.1	MRPL35P2	-4.62	4.33e-06	0.000386	-0.18	-0.14	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63344740	chr10:63634317~63634827:-
BRCA	cis	rs11638815	0.626	rs4779041	ENSG00000259429.4	UBE2Q2P2	4.62	4.33e-06	0.000386	0.14	0.14	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82668307	chr15:82355142~82420075:+
BRCA	cis	rs1014246	0.807	rs12784789	ENSG00000232767.1	RP11-498B4.5	-4.62	4.33e-06	0.000386	-0.16	-0.14	Age at smoking initiation in chronic obstructive pulmonary disease;	chr10:116714082	chr10:116670103~116672739:+
BRCA	cis	rs62244186	0.593	rs9814298	ENSG00000233509.2	ZNF197-AS1	4.62	4.33e-06	0.000386	0.17	0.14	Depressive symptoms;	chr3:44830407	chr3:44617128~44624797:-
BRCA	cis	rs2288912	0.807	rs10423208	ENSG00000280087.1	CTB-129P6.7	4.62	4.33e-06	0.000386	0.17	0.14	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr19:44950399	chr19:44909375~44914968:+
BRCA	cis	rs7674212	0.541	rs2615539	ENSG00000246560.2	RP11-10L12.4	4.62	4.33e-06	0.000386	0.15	0.14	Type 2 diabetes;	chr4:103159949	chr4:102828055~102844075:+
BRCA	cis	rs13113518	1	rs3805146	ENSG00000249700.7	SRD5A3-AS1	4.62	4.33e-06	0.000386	0.18	0.14	Height;	chr4:55436985	chr4:55363971~55395847:-
BRCA	cis	rs13113518	1	rs11133378	ENSG00000249700.7	SRD5A3-AS1	4.62	4.33e-06	0.000386	0.18	0.14	Height;	chr4:55439472	chr4:55363971~55395847:-
BRCA	cis	rs13113518	1	rs11942279	ENSG00000249700.7	SRD5A3-AS1	4.62	4.33e-06	0.000386	0.18	0.14	Height;	chr4:55439652	chr4:55363971~55395847:-
BRCA	cis	rs10833905	1	rs11026934	ENSG00000246225.5	RP11-17A1.3	-4.62	4.33e-06	0.000386	-0.2	-0.14	Sudden cardiac arrest;	chr11:23045574	chr11:22829380~22945393:+
BRCA	cis	rs12477438	0.605	rs4585080	ENSG00000231822.1	AC019097.7	-4.62	4.34e-06	0.000386	-0.16	-0.14	Chronic sinus infection;	chr2:98940864	chr2:99102018~99102752:+
BRCA	cis	rs11098499	0.954	rs6838814	ENSG00000250412.1	KLHL2P1	4.62	4.34e-06	0.000386	0.17	0.14	Corneal astigmatism;	chr4:119471288	chr4:119334329~119378233:+
BRCA	cis	rs1510272	0.961	rs9861440	ENSG00000243926.1	TIPARP-AS1	-4.62	4.34e-06	0.000386	-0.16	-0.14	Testicular germ cell tumor;	chr3:156599590	chr3:156671862~156674378:-
BRCA	cis	rs7267979	1	rs6515651	ENSG00000125804.12	FAM182A	4.62	4.34e-06	0.000386	0.18	0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25433903	chr20:26054655~26086917:+
BRCA	cis	rs1044826	0.553	rs295469	ENSG00000178631.7	ACTG1P1	4.62	4.34e-06	0.000387	0.16	0.14	Obesity-related traits;	chr3:139494058	chr3:139493809~139494937:+
BRCA	cis	rs3120667	0.72	rs2146117	ENSG00000237975.5	FLG-AS1	-4.62	4.34e-06	0.000387	-0.21	-0.14	Eating disorders;	chr1:152444433	chr1:152168125~152445456:+
BRCA	cis	rs17597773	0.638	rs11118615	ENSG00000238078.1	LINC01352	-4.62	4.34e-06	0.000387	-0.17	-0.14	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220823271	chr1:220829255~220832429:+
BRCA	cis	rs4715166	0.926	rs7749528	ENSG00000272379.1	RP1-257A7.5	4.62	4.34e-06	0.000387	0.16	0.14	Hip geometry;	chr6:13224591	chr6:13290018~13290490:-
BRCA	cis	rs6968419	0.887	rs10235059	ENSG00000279086.1	RP11-667F14.1	-4.62	4.34e-06	0.000387	-0.14	-0.14	Intraocular pressure;	chr7:116198216	chr7:116209234~116211511:-
BRCA	cis	rs9788721	1	rs8031948	ENSG00000261762.1	RP11-650L12.2	-4.62	4.35e-06	0.000387	-0.17	-0.14	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78523715	chr15:78589123~78591276:-
BRCA	cis	rs2115630	1	rs6496441	ENSG00000259728.4	LINC00933	-4.62	4.35e-06	0.000387	-0.16	-0.14	P wave terminal force;	chr15:84820117	chr15:84570649~84580175:+
BRCA	cis	rs10208649	0.611	rs1363060	ENSG00000272156.1	RP11-477N3.1	4.62	4.35e-06	0.000387	0.25	0.14	Body mass index;	chr2:54057447	chr2:54082554~54085066:+
BRCA	cis	rs7772486	0.79	rs6926657	ENSG00000270638.1	RP3-466P17.1	-4.62	4.35e-06	0.000388	-0.17	-0.14	Lobe attachment (rater-scored or self-reported);	chr6:145934658	chr6:145735570~145737218:+
BRCA	cis	rs12497850	0.931	rs4072859	ENSG00000225399.4	RP11-3B7.1	4.62	4.35e-06	0.000388	0.14	0.14	Parkinson's disease;	chr3:48994772	chr3:49260085~49261316:+
BRCA	cis	rs7312933	0.558	rs11181501	ENSG00000257225.1	RP11-328C8.4	-4.62	4.35e-06	0.000388	-0.17	-0.14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42428869	chr12:42459366~42466128:+
BRCA	cis	rs7267979	0.932	rs1541061	ENSG00000125804.12	FAM182A	-4.62	4.35e-06	0.000388	-0.18	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25540421	chr20:26054655~26086917:+
BRCA	cis	rs6832769	1	rs12643926	ENSG00000272969.1	RP11-528I4.2	4.62	4.36e-06	0.000388	0.17	0.14	Personality dimensions;	chr4:55444454	chr4:55547112~55547889:+
BRCA	cis	rs6832769	0.961	rs12647034	ENSG00000272969.1	RP11-528I4.2	4.62	4.36e-06	0.000388	0.17	0.14	Personality dimensions;	chr4:55444455	chr4:55547112~55547889:+
BRCA	cis	rs6430538	0.621	rs6757855	ENSG00000224043.6	CCNT2-AS1	4.62	4.36e-06	0.000388	0.19	0.14	Parkinson's disease;	chr2:134816593	chr2:134735464~134918710:-
BRCA	cis	rs8040855	0.794	rs4843024	ENSG00000230373.7	GOLGA6L5P	-4.62	4.36e-06	0.000388	-0.17	-0.14	Bulimia nervosa;	chr15:85162669	chr15:84507885~84516814:-
BRCA	cis	rs3764021	0.527	rs17806710	ENSG00000256673.1	RP11-599J14.2	-4.62	4.36e-06	0.000388	-0.18	-0.14	Type 1 diabetes;	chr12:9688368	chr12:9398355~9414851:-
BRCA	cis	rs4781563	1	rs3136172	ENSG00000242307.1	RPS26P52	-4.62	4.36e-06	0.000388	-0.17	-0.14	Bilirubin levels;	chr16:13939019	chr16:13922332~13922679:-
BRCA	cis	rs1850744	1	rs1533615	ENSG00000163612.10	FAM86KP	4.62	4.36e-06	0.000388	0.33	0.14	Economic and political preferences;	chr4:9802900	chr4:9153296~9165451:+
BRCA	cis	rs7475343	0.501	rs17134533	ENSG00000224034.1	RP11-445P17.8	-4.62	4.36e-06	0.000388	-0.27	-0.14	Intelligence;	chr10:5205135	chr10:5266033~5271236:-
BRCA	cis	rs2303319	0.504	rs62187657	ENSG00000227403.1	AC009299.3	4.62	4.36e-06	0.000388	0.34	0.14	Cognitive function;	chr2:161631581	chr2:161244739~161249050:+
BRCA	cis	rs2303319	0.504	rs62187658	ENSG00000227403.1	AC009299.3	4.62	4.36e-06	0.000388	0.34	0.14	Cognitive function;	chr2:161631585	chr2:161244739~161249050:+
BRCA	cis	rs11098499	0.954	rs10034623	ENSG00000260091.1	RP11-33B1.4	-4.62	4.36e-06	0.000388	-0.12	-0.14	Corneal astigmatism;	chr4:119476674	chr4:119409333~119410233:+
BRCA	cis	rs1858037	0.836	rs17475335	ENSG00000281920.1	RP11-418H16.1	4.62	4.36e-06	0.000388	0.18	0.14	Rheumatoid arthritis;	chr2:65378646	chr2:65623272~65628424:+
BRCA	cis	rs17711722	0.51	rs11767457	ENSG00000226767.1	RP11-328P23.3	4.62	4.36e-06	0.000388	0.16	0.14	Calcium levels;	chr7:65825628	chr7:65508773~65508944:-
BRCA	cis	rs6430585	0.527	rs6753232	ENSG00000231890.6	DARS-AS1	4.62	4.36e-06	0.000388	0.22	0.14	Corneal structure;	chr2:135678747	chr2:135985176~136022593:+
BRCA	cis	rs6452524	0.967	rs2662243	ENSG00000281327.1	LINC01338	4.62	4.36e-06	0.000389	0.16	0.14	Hypertension (SNP x SNP interaction);	chr5:83192630	chr5:82850864~82859836:-
BRCA	cis	rs4143844	1	rs34017665	ENSG00000259251.2	RP11-643M14.1	4.62	4.37e-06	0.000389	0.34	0.14	Bipolar disorder and schizophrenia;	chr15:62027008	chr15:62060503~62062434:+
BRCA	cis	rs7923609	0.846	rs10761739	ENSG00000232075.1	MRPL35P2	4.62	4.37e-06	0.000389	0.18	0.14	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63302248	chr10:63634317~63634827:-
BRCA	cis	rs16944613	0.51	rs8035793	ENSG00000245479.2	LINC01585	4.62	4.37e-06	0.000389	0.17	0.14	Colorectal cancer;	chr15:90606852	chr15:90660234~90664967:+
BRCA	cis	rs35146811	1	rs35146811	ENSG00000214313.7	AZGP1P1	4.62	4.37e-06	0.000389	0.15	0.14	Coronary artery disease;	chr7:100123371	chr7:99980762~99987535:+
BRCA	cis	rs12681366	0.801	rs2930956	ENSG00000253175.1	RP11-267M23.6	4.62	4.37e-06	0.000389	0.18	0.14	Nonsyndromic cleft lip with cleft palate;	chr8:94460840	chr8:94565036~94565715:+
BRCA	cis	rs9818758	0.607	rs34343820	ENSG00000225399.4	RP11-3B7.1	-4.62	4.37e-06	0.000389	-0.23	-0.14	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49272101	chr3:49260085~49261316:+
BRCA	cis	rs375066	0.935	rs10414702	ENSG00000267191.1	RP11-15A1.2	-4.62	4.37e-06	0.000389	-0.18	-0.14	Breast cancer;	chr19:43876384	chr19:43902001~43926545:+
BRCA	cis	rs375066	0.935	rs10421518	ENSG00000267191.1	RP11-15A1.2	-4.62	4.37e-06	0.000389	-0.18	-0.14	Breast cancer;	chr19:43877134	chr19:43902001~43926545:+
BRCA	cis	rs375066	0.87	rs7258418	ENSG00000267191.1	RP11-15A1.2	-4.62	4.37e-06	0.000389	-0.18	-0.14	Breast cancer;	chr19:43878931	chr19:43902001~43926545:+
BRCA	cis	rs4478858	0.839	rs10798834	ENSG00000223907.1	LINC01226	-4.62	4.37e-06	0.000389	-0.17	-0.14	Alcohol dependence;	chr1:31236130	chr1:31518435~31524245:+
BRCA	cis	rs860295	0.702	rs10796943	ENSG00000225855.5	RUSC1-AS1	4.62	4.37e-06	0.000389	0.12	0.14	Body mass index;	chr1:155444938	chr1:155316863~155324176:-
BRCA	cis	rs35306767	0.953	rs10904583	ENSG00000229869.1	RP11-363N22.2	-4.62	4.38e-06	0.000389	-0.21	-0.14	Eosinophil percentage of granulocytes;	chr10:937558	chr10:933026~942743:+
BRCA	cis	rs6832769	0.961	rs11133379	ENSG00000223305.1	RN7SKP30	4.62	4.38e-06	0.000389	0.18	0.14	Personality dimensions;	chr4:55439944	chr4:55540502~55540835:-
BRCA	cis	rs2839186	0.872	rs2250213	ENSG00000239415.1	AP001469.9	4.62	4.38e-06	0.00039	0.15	0.14	Testicular germ cell tumor;	chr21:46254361	chr21:46251549~46254133:-
BRCA	cis	rs7200543	1	rs16966947	ENSG00000260735.1	RP11-72I8.1	-4.62	4.38e-06	0.00039	-0.17	-0.14	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15047188	chr16:15094411~15109197:+
BRCA	cis	rs3768617	0.51	rs2093984	ENSG00000224468.3	RP11-181K3.4	-4.62	4.38e-06	0.00039	-0.15	-0.14	Fuchs's corneal dystrophy;	chr1:183125179	chr1:183138402~183141282:-
BRCA	cis	rs13113518	1	rs34648901	ENSG00000273257.1	RP11-177J6.1	4.62	4.38e-06	0.00039	0.18	0.14	Height;	chr4:55541259	chr4:55387949~55388271:+
BRCA	cis	rs1722133	0.555	rs788723	ENSG00000237471.1	AC073115.6	4.62	4.38e-06	0.00039	0.19	0.14	Sitting height ratio;	chr7:46047186	chr7:45969657~45980191:+
BRCA	cis	rs7772486	0.754	rs9390358	ENSG00000270638.1	RP3-466P17.1	4.62	4.38e-06	0.00039	0.16	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145824542	chr6:145735570~145737218:+
BRCA	cis	rs7191700	0.511	rs8043625	ENSG00000262703.1	RP11-485G7.6	-4.62	4.38e-06	0.00039	-0.15	-0.14	Multiple sclerosis;	chr16:11268038	chr16:11348143~11349321:-
BRCA	cis	rs2243480	1	rs313832	ENSG00000222364.1	RNU6-96P	-4.62	4.38e-06	0.00039	-0.27	-0.14	Diabetic kidney disease;	chr7:66085904	chr7:66395191~66395286:+
BRCA	cis	rs9467773	0.62	rs3800303	ENSG00000241549.7	GUSBP2	4.62	4.38e-06	0.00039	0.15	0.14	Intelligence (multi-trait analysis);	chr6:26597960	chr6:26871484~26956554:-
BRCA	cis	rs11638815	0.581	rs783535	ENSG00000259429.4	UBE2Q2P2	-4.62	4.38e-06	0.00039	-0.14	-0.14	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82581676	chr15:82355142~82420075:+
BRCA	cis	rs1858037	0.867	rs4671660	ENSG00000237979.1	AC007389.1	4.62	4.38e-06	0.00039	0.18	0.14	Rheumatoid arthritis;	chr2:65349302	chr2:65500993~65502138:-
BRCA	cis	rs494453	0.736	rs548129	ENSG00000227811.2	FAM212B-AS1	-4.62	4.39e-06	0.000391	-0.18	-0.14	Osteoporosis-related phenotypes;	chr1:111658548	chr1:111739841~111747798:+
BRCA	cis	rs853679	1	rs853694	ENSG00000216901.1	AL022393.7	4.62	4.39e-06	0.000391	0.24	0.14	Depression;	chr6:28311323	chr6:28176188~28176674:+
BRCA	cis	rs11577354	0.548	rs7554276	ENSG00000207181.1	SNORA14B	-4.62	4.39e-06	0.000391	-0.16	-0.14	Obesity-related traits;	chr1:235104702	chr1:235127803~235127937:-
BRCA	cis	rs13108904	0.901	rs2293634	ENSG00000253399.1	AC078852.2	-4.62	4.39e-06	0.000391	-0.16	-0.14	Obesity-related traits;	chr4:1297923	chr4:1358479~1359461:+
BRCA	cis	rs4664293	0.867	rs3771718	ENSG00000226266.5	AC009961.3	-4.62	4.39e-06	0.000391	-0.18	-0.14	Monocyte percentage of white cells;	chr2:159780397	chr2:159670708~159712435:-
BRCA	cis	rs7914558	0.621	rs10786722	ENSG00000213061.2	PFN1P11	4.62	4.4e-06	0.000391	0.2	0.14	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102900311	chr10:102838011~102845473:-
BRCA	cis	rs904251	0.714	rs2776910	ENSG00000204110.6	RP1-153P14.8	-4.62	4.4e-06	0.000391	-0.18	-0.14	Cognitive performance;	chr6:37468508	chr6:37507348~37535616:+
BRCA	cis	rs34217772	0.824	rs61992433	ENSG00000258636.1	CTD-2298J14.2	4.62	4.4e-06	0.000391	0.2	0.14	Myopia;	chr14:41757997	chr14:41587861~41604856:-
BRCA	cis	rs6439153	0.933	rs2630262	ENSG00000261159.1	RP11-723O4.9	-4.62	4.4e-06	0.000391	-0.15	-0.14	Pneumococcal bacteremia;	chr3:128958255	chr3:128859716~128860526:-
BRCA	cis	rs7937890	0.9	rs7118682	ENSG00000254418.1	RP11-21L19.1	-4.62	4.4e-06	0.000391	-0.16	-0.14	Mitochondrial DNA levels;	chr11:14253004	chr11:14262846~14273691:-
BRCA	cis	rs1371614	0.635	rs9309559	ENSG00000272148.1	RP11-195B17.1	4.62	4.4e-06	0.000391	0.16	0.14	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26918647	chr2:27062428~27062907:-
BRCA	cis	rs4650994	1	rs17361251	ENSG00000273384.1	RP5-1098D14.1	4.62	4.4e-06	0.000392	0.17	0.14	HDL cholesterol;HDL cholesterol levels;	chr1:178551442	chr1:178651706~178652282:+
BRCA	cis	rs5758659	0.652	rs5758537	ENSG00000273366.1	CTA-989H11.1	-4.62	4.4e-06	0.000392	-0.17	-0.14	Cognitive function;	chr22:42001038	chr22:42278188~42278846:+
BRCA	cis	rs11098499	0.913	rs56122576	ENSG00000249244.1	RP11-548H18.2	4.62	4.4e-06	0.000392	0.18	0.14	Corneal astigmatism;	chr4:119208181	chr4:119391831~119395335:-
BRCA	cis	rs1008375	0.932	rs6835077	ENSG00000249502.1	AC006160.5	-4.62	4.4e-06	0.000392	-0.17	-0.14	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17651662	chr4:17587467~17614571:-
BRCA	cis	rs2832191	0.967	rs2832216	ENSG00000232855.5	AF131217.1	-4.62	4.4e-06	0.000392	-0.17	-0.14	Dental caries;	chr21:29149600	chr21:28439346~28674848:-
BRCA	cis	rs10833905	1	rs7924512	ENSG00000246225.5	RP11-17A1.3	-4.62	4.41e-06	0.000392	-0.2	-0.14	Sudden cardiac arrest;	chr11:23025503	chr11:22829380~22945393:+
BRCA	cis	rs10540	1	rs79808876	ENSG00000279672.1	CMB9-55F22.1	4.62	4.41e-06	0.000392	0.25	0.14	Body mass index;	chr11:465763	chr11:779617~780755:+
BRCA	cis	rs10540	1	rs35068485	ENSG00000279672.1	CMB9-55F22.1	4.62	4.41e-06	0.000392	0.25	0.14	Body mass index;	chr11:466032	chr11:779617~780755:+
BRCA	cis	rs10540	1	rs61876326	ENSG00000279672.1	CMB9-55F22.1	4.62	4.41e-06	0.000392	0.25	0.14	Body mass index;	chr11:467368	chr11:779617~780755:+
BRCA	cis	rs1656368	0.726	rs11708784	ENSG00000279311.1	RP11-170K4.2	4.62	4.41e-06	0.000392	0.18	0.14	Lobe attachment (rater-scored or self-reported);	chr3:158537898	chr3:158869898~158871821:+
BRCA	cis	rs459482	0.504	rs469073	ENSG00000228318.3	AP001610.5	4.62	4.41e-06	0.000392	0.16	0.14	IgG glycosylation;	chr21:41444274	chr21:41441056~41445708:-
BRCA	cis	rs875971	0.545	rs10950027	ENSG00000273142.1	RP11-458F8.4	4.62	4.41e-06	0.000392	0.14	0.14	Aortic root size;	chr7:66169164	chr7:66902857~66906297:+
BRCA	cis	rs4919694	0.536	rs12414777	ENSG00000213061.2	PFN1P11	4.62	4.41e-06	0.000392	0.22	0.14	Arsenic metabolism;	chr10:102938024	chr10:102838011~102845473:-
BRCA	cis	rs2574985	0.813	rs3011787	ENSG00000231345.3	BEND3P1	-4.62	4.41e-06	0.000392	-0.24	-0.14	Subjective well-being;	chr10:50479563	chr10:50655967~50660472:+
BRCA	cis	rs690037	0.551	rs690522	ENSG00000272498.1	RP11-415F23.3	4.62	4.41e-06	0.000392	0.15	0.14	Optic nerve measurement (cup-to-disc ratio);Optic nerve measurement (cup area);	chr3:16335560	chr3:16339308~16339871:+
BRCA	cis	rs6430585	0.528	rs309167	ENSG00000224043.6	CCNT2-AS1	-4.62	4.41e-06	0.000392	-0.24	-0.14	Corneal structure;	chr2:135911694	chr2:134735464~134918710:-
BRCA	cis	rs9595908	0.669	rs9591303	ENSG00000212293.1	SNORA16	4.62	4.41e-06	0.000392	0.16	0.14	Body mass index;	chr13:32748278	chr13:32420390~32420516:-
BRCA	cis	rs13236243	0.632	rs765623	ENSG00000237773.4	AC003075.4	-4.62	4.41e-06	0.000393	-0.21	-0.14	Sensory disturbances after bilateral sagittal split ramus osteotomy;	chr7:17289778	chr7:17279834~17299357:-
BRCA	cis	rs7267979	0.789	rs4815429	ENSG00000125804.12	FAM182A	4.62	4.41e-06	0.000393	0.18	0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25540975	chr20:26054655~26086917:+
BRCA	cis	rs11098499	0.954	rs11098525	ENSG00000250412.1	KLHL2P1	4.62	4.42e-06	0.000393	0.17	0.14	Corneal astigmatism;	chr4:119468997	chr4:119334329~119378233:+
BRCA	cis	rs2243480	1	rs35046236	ENSG00000275400.1	RP4-756H11.5	4.62	4.42e-06	0.000393	0.25	0.14	Diabetic kidney disease;	chr7:65943626	chr7:66553805~66554199:-
BRCA	cis	rs2243480	1	rs36068983	ENSG00000275400.1	RP4-756H11.5	4.62	4.42e-06	0.000393	0.25	0.14	Diabetic kidney disease;	chr7:65944004	chr7:66553805~66554199:-
BRCA	cis	rs2243480	1	rs68189316	ENSG00000275400.1	RP4-756H11.5	4.62	4.42e-06	0.000393	0.25	0.14	Diabetic kidney disease;	chr7:65944182	chr7:66553805~66554199:-
BRCA	cis	rs394563	0.601	rs439495	ENSG00000231760.4	RP11-350J20.5	-4.62	4.42e-06	0.000393	-0.18	-0.14	Dupuytren's disease;	chr6:149472088	chr6:149796151~149826294:-
BRCA	cis	rs1499614	1	rs2659903	ENSG00000275400.1	RP4-756H11.5	4.62	4.42e-06	0.000393	0.26	0.14	Gout;	chr7:66715944	chr7:66553805~66554199:-
BRCA	cis	rs6565180	1	rs8049108	ENSG00000183604.13	SMG1P5	-4.62	4.42e-06	0.000393	-0.14	-0.14	Tonsillectomy;	chr16:30365165	chr16:30267553~30335374:-
BRCA	cis	rs6430585	0.583	rs4988145	ENSG00000231890.6	DARS-AS1	-4.62	4.42e-06	0.000393	-0.22	-0.14	Corneal structure;	chr2:135874730	chr2:135985176~136022593:+
BRCA	cis	rs78487399	0.71	rs76675804	ENSG00000234936.1	AC010883.5	4.61	4.42e-06	0.000393	0.25	0.14	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43384744	chr2:43229573~43233394:+
BRCA	cis	rs1008375	0.897	rs6820164	ENSG00000249502.1	AC006160.5	-4.61	4.42e-06	0.000393	-0.17	-0.14	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17628492	chr4:17587467~17614571:-
BRCA	cis	rs71537559	1	rs71537559	ENSG00000216901.1	AL022393.7	4.61	4.42e-06	0.000393	0.33	0.14	Squamous cell lung carcinoma;	chr6:27342000	chr6:28176188~28176674:+
BRCA	cis	rs13113518	0.967	rs7696832	ENSG00000273257.1	RP11-177J6.1	4.61	4.43e-06	0.000394	0.18	0.14	Height;	chr4:55537080	chr4:55387949~55388271:+
BRCA	cis	rs10844706	0.699	rs10844626	ENSG00000214776.8	RP11-726G1.1	4.61	4.43e-06	0.000394	0.17	0.14	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9733757	chr12:9467552~9576275:+
BRCA	cis	rs2243480	0.803	rs423187	ENSG00000222364.1	RNU6-96P	-4.61	4.43e-06	0.000394	-0.27	-0.14	Diabetic kidney disease;	chr7:66044512	chr7:66395191~66395286:+
BRCA	cis	rs7267979	1	rs2482927	ENSG00000276952.1	RP5-965G21.6	-4.61	4.43e-06	0.000394	-0.18	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25346515	chr20:25284915~25285588:-
BRCA	cis	rs78487399	0.808	rs13431070	ENSG00000234936.1	AC010883.5	-4.61	4.43e-06	0.000394	-0.19	-0.14	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43494815	chr2:43229573~43233394:+
BRCA	cis	rs7246657	0.722	rs10410588	ENSG00000226686.6	LINC01535	-4.61	4.43e-06	0.000394	-0.21	-0.14	Coronary artery calcification;	chr19:37551508	chr19:37251912~37265535:+
BRCA	cis	rs1499614	1	rs2707840	ENSG00000275400.1	RP4-756H11.5	4.61	4.43e-06	0.000394	0.26	0.14	Gout;	chr7:66693028	chr7:66553805~66554199:-
BRCA	cis	rs4218	0.681	rs2121236	ENSG00000277144.1	RP11-59H7.4	-4.61	4.43e-06	0.000394	-0.18	-0.14	Social communication problems;	chr15:59091923	chr15:59115547~59116089:-
BRCA	cis	rs4415084	0.834	rs13362132	ENSG00000251141.4	RP11-53O19.1	4.61	4.43e-06	0.000394	0.13	0.14	Breast cancer;	chr5:44858158	chr5:44744900~44808777:-
BRCA	cis	rs4781563	1	rs9646273	ENSG00000242307.1	RPS26P52	-4.61	4.44e-06	0.000394	-0.18	-0.14	Bilirubin levels;	chr16:13955322	chr16:13922332~13922679:-
BRCA	cis	rs2915864	0.747	rs3850577	ENSG00000280047.1	CTC-463A16.1	4.61	4.44e-06	0.000394	0.21	0.14	Facial morphology (factor 20);	chr5:142147398	chr5:142165767~142168387:+
BRCA	cis	rs11742741	1	rs72745787	ENSG00000248874.4	C5orf17	-4.61	4.44e-06	0.000394	-0.18	-0.14	Educational attainment;	chr5:24147359	chr5:23951348~24178263:+
BRCA	cis	rs11742741	1	rs11749981	ENSG00000248874.4	C5orf17	-4.61	4.44e-06	0.000394	-0.18	-0.14	Educational attainment;	chr5:24148460	chr5:23951348~24178263:+
BRCA	cis	rs4906332	0.834	rs12882130	ENSG00000244691.1	RPL10AP1	-4.61	4.44e-06	0.000395	-0.18	-0.14	Coronary artery disease;	chr14:103412437	chr14:103412119~103412761:-
BRCA	cis	rs6840258	0.64	rs28505236	ENSG00000251411.1	RP11-397E7.4	-4.61	4.44e-06	0.000395	-0.18	-0.14	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87172309	chr4:86913266~86914817:-
BRCA	cis	rs13113518	1	rs13152173	ENSG00000273257.1	RP11-177J6.1	4.61	4.44e-06	0.000395	0.18	0.14	Height;	chr4:55534788	chr4:55387949~55388271:+
BRCA	cis	rs13113518	1	rs13141049	ENSG00000273257.1	RP11-177J6.1	4.61	4.44e-06	0.000395	0.18	0.14	Height;	chr4:55535489	chr4:55387949~55388271:+
BRCA	cis	rs13113518	0.967	rs12507722	ENSG00000273257.1	RP11-177J6.1	4.61	4.44e-06	0.000395	0.18	0.14	Height;	chr4:55536421	chr4:55387949~55388271:+
BRCA	cis	rs1429524	0.922	rs2163086	ENSG00000243144.5	RP11-115N4.1	4.61	4.44e-06	0.000395	0.19	0.14	Ejection fraction in Tripanosoma cruzi seropositivity;	chr7:91305031	chr7:91311368~91515409:+
BRCA	cis	rs6686842	1	rs213734	ENSG00000235358.1	RP11-399E6.1	-4.61	4.44e-06	0.000395	-0.18	-0.14	Height;	chr1:41110027	chr1:41242373~41284861:+
BRCA	cis	rs11051970	0.918	rs76930558	ENSG00000274964.1	RP11-817I4.1	-4.61	4.44e-06	0.000395	-0.18	-0.14	Response to tocilizumab in rheumatoid arthritis;	chr12:32385905	chr12:32339368~32340724:+
BRCA	cis	rs2033711	0.654	rs734380	ENSG00000269473.1	CTD-2619J13.19	4.61	4.44e-06	0.000395	0.17	0.14	Uric acid clearance;	chr19:58387596	chr19:58440448~58445849:+
BRCA	cis	rs7267979	0.844	rs2474780	ENSG00000274414.1	RP5-965G21.4	-4.61	4.45e-06	0.000395	-0.17	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25305199	chr20:25239007~25245229:-
BRCA	cis	rs7267979	0.844	rs2474780	ENSG00000125804.12	FAM182A	-4.61	4.45e-06	0.000395	-0.18	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25305199	chr20:26054655~26086917:+
BRCA	cis	rs9907295	0.591	rs3760327	ENSG00000271013.1	AC015849.15	-4.61	4.45e-06	0.000395	-0.16	-0.14	Fibroblast growth factor basic levels;	chr17:35836383	chr17:35912635~35918010:-
BRCA	cis	rs10129255	0.53	rs11624912	ENSG00000232216.1	IGHV3-43	4.61	4.45e-06	0.000395	0.11	0.14	Kawasaki disease;	chr14:106673891	chr14:106470264~106470800:-
BRCA	cis	rs6600671	1	rs2319969	ENSG00000275538.1	RNVU1-19	4.61	4.45e-06	0.000395	0.17	0.14	Hip geometry;	chr1:121465481	chr1:120850819~120850985:-
BRCA	cis	rs5758659	0.652	rs133301	ENSG00000273366.1	CTA-989H11.1	-4.61	4.45e-06	0.000395	-0.17	-0.14	Cognitive function;	chr22:41994089	chr22:42278188~42278846:+
BRCA	cis	rs6686842	1	rs479493	ENSG00000235358.1	RP11-399E6.1	-4.61	4.45e-06	0.000396	-0.18	-0.14	Height;	chr1:41101530	chr1:41242373~41284861:+
BRCA	cis	rs13113518	1	rs12651640	ENSG00000273257.1	RP11-177J6.1	4.61	4.45e-06	0.000396	0.18	0.14	Height;	chr4:55454154	chr4:55387949~55388271:+
BRCA	cis	rs13113518	1	rs1554483	ENSG00000273257.1	RP11-177J6.1	4.61	4.45e-06	0.000396	0.18	0.14	Height;	chr4:55455650	chr4:55387949~55388271:+
BRCA	cis	rs13113518	1	rs1464490	ENSG00000273257.1	RP11-177J6.1	4.61	4.45e-06	0.000396	0.18	0.14	Height;	chr4:55456620	chr4:55387949~55388271:+
BRCA	cis	rs13113518	1	rs10517346	ENSG00000273257.1	RP11-177J6.1	4.61	4.45e-06	0.000396	0.18	0.14	Height;	chr4:55457027	chr4:55387949~55388271:+
BRCA	cis	rs13113518	1	rs11133384	ENSG00000273257.1	RP11-177J6.1	4.61	4.45e-06	0.000396	0.18	0.14	Height;	chr4:55457086	chr4:55387949~55388271:+
BRCA	cis	rs4660214	0.614	rs6688708	ENSG00000237624.1	OXCT2P1	-4.61	4.45e-06	0.000396	-0.17	-0.14	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39293321	chr1:39514956~39516490:+
BRCA	cis	rs13108904	0.967	rs1732107	ENSG00000254094.1	AC078852.1	4.61	4.46e-06	0.000396	0.15	0.14	Obesity-related traits;	chr4:1282970	chr4:1356581~1358075:+
BRCA	cis	rs62025270	0.632	rs16943251	ENSG00000259762.1	RP11-158M2.4	-4.61	4.46e-06	0.000396	-0.21	-0.14	Idiopathic pulmonary fibrosis;	chr15:85692004	chr15:85750336~85752901:-
BRCA	cis	rs875971	1	rs6961717	ENSG00000236529.1	RP13-254B10.1	-4.61	4.46e-06	0.000396	-0.15	-0.14	Aortic root size;	chr7:66122550	chr7:65840212~65840596:+
BRCA	cis	rs11742741	1	rs11742741	ENSG00000248874.4	C5orf17	-4.61	4.46e-06	0.000396	-0.18	-0.14	Educational attainment;	chr5:24162832	chr5:23951348~24178263:+
BRCA	cis	rs1722141	0.669	rs17578201	ENSG00000237471.1	AC073115.6	-4.61	4.46e-06	0.000396	-0.2	-0.14	Sitting height ratio;	chr7:46007681	chr7:45969657~45980191:+
BRCA	cis	rs4578769	0.765	rs61311054	ENSG00000265939.1	UBE2CP2	-4.61	4.46e-06	0.000396	-0.18	-0.14	Eosinophil percentage of white cells;	chr18:22906406	chr18:22900486~22900995:-
BRCA	cis	rs924712	0.545	rs10948862	ENSG00000224984.1	RP11-524H19.2	4.61	4.46e-06	0.000396	0.17	0.14	Breast cancer;	chr6:54846673	chr6:54840118~54840855:-
BRCA	cis	rs924712	0.506	rs62412647	ENSG00000224984.1	RP11-524H19.2	4.61	4.46e-06	0.000396	0.17	0.14	Breast cancer;	chr6:54846906	chr6:54840118~54840855:-
BRCA	cis	rs924712	0.526	rs12664732	ENSG00000224984.1	RP11-524H19.2	4.61	4.46e-06	0.000396	0.17	0.14	Breast cancer;	chr6:54846916	chr6:54840118~54840855:-
BRCA	cis	rs459482	0.504	rs363882	ENSG00000228318.3	AP001610.5	4.61	4.46e-06	0.000396	0.16	0.14	IgG glycosylation;	chr21:41446346	chr21:41441056~41445708:-
BRCA	cis	rs2842992	0.513	rs7759086	ENSG00000237927.1	RP3-393E18.2	-4.61	4.46e-06	0.000396	-0.19	-0.14	Age-related macular degeneration (geographic atrophy);	chr6:159772821	chr6:159586955~159589169:-
BRCA	cis	rs9921338	0.886	rs4780363	ENSG00000262703.1	RP11-485G7.6	4.61	4.46e-06	0.000396	0.17	0.14	Vein graft stenosis in coronary artery bypass grafting;	chr16:11322034	chr16:11348143~11349321:-
BRCA	cis	rs13217239	0.646	rs10946897	ENSG00000224843.5	LINC00240	-4.61	4.46e-06	0.000396	-0.16	-0.14	Schizophrenia;	chr6:27027472	chr6:26956992~27023924:+
BRCA	cis	rs34217772	0.883	rs12435558	ENSG00000258636.1	CTD-2298J14.2	4.61	4.46e-06	0.000396	0.2	0.14	Myopia;	chr14:41759255	chr14:41587861~41604856:-
BRCA	cis	rs2380205	0.935	rs907689	ENSG00000232807.2	RP11-536K7.3	4.61	4.46e-06	0.000396	0.15	0.14	Breast cancer;	chr10:5859010	chr10:5934270~5945900:-
BRCA	cis	rs34217772	0.883	rs59348864	ENSG00000258636.1	CTD-2298J14.2	4.61	4.46e-06	0.000397	0.2	0.14	Myopia;	chr14:41768184	chr14:41587861~41604856:-
BRCA	cis	rs375066	0.934	rs2191564	ENSG00000267191.1	RP11-15A1.2	-4.61	4.47e-06	0.000397	-0.18	-0.14	Breast cancer;	chr19:43863459	chr19:43902001~43926545:+
BRCA	cis	rs10266483	0.739	rs2692104	ENSG00000227986.1	TRIM60P18	-4.61	4.47e-06	0.000397	-0.15	-0.14	Response to statin therapy;	chr7:64300577	chr7:64355078~64356199:+
BRCA	cis	rs13326165	0.585	rs73088773	ENSG00000243224.1	RP5-1157M23.2	-4.61	4.47e-06	0.000397	-0.23	-0.14	HDL cholesterol levels;HDL cholesterol;	chr3:52252569	chr3:52239258~52241097:+
BRCA	cis	rs12744310	0.887	rs12040046	ENSG00000235358.1	RP11-399E6.1	-4.61	4.47e-06	0.000397	-0.21	-0.14	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41331911	chr1:41242373~41284861:+
BRCA	cis	rs2839186	0.967	rs17176131	ENSG00000228137.1	AP001469.7	4.61	4.47e-06	0.000397	0.15	0.14	Testicular germ cell tumor;	chr21:46285323	chr21:46246890~46247682:+
BRCA	cis	rs6430585	0.583	rs79633114	ENSG00000224043.6	CCNT2-AS1	-4.61	4.47e-06	0.000397	-0.24	-0.14	Corneal structure;	chr2:135829255	chr2:134735464~134918710:-
BRCA	cis	rs9467773	0.595	rs3799379	ENSG00000124549.13	BTN2A3P	-4.61	4.47e-06	0.000397	-0.15	-0.14	Intelligence (multi-trait analysis);	chr6:26404466	chr6:26421391~26432383:+
BRCA	cis	rs13113518	1	rs7691799	ENSG00000249700.7	SRD5A3-AS1	4.61	4.47e-06	0.000397	0.18	0.14	Height;	chr4:55545574	chr4:55363971~55395847:-
BRCA	cis	rs7246657	0.653	rs10406612	ENSG00000267422.1	CTD-2554C21.1	-4.61	4.47e-06	0.000397	-0.24	-0.14	Coronary artery calcification;	chr19:37225709	chr19:37779686~37792865:+
BRCA	cis	rs2073316	0.565	rs2365778	ENSG00000272716.1	RP11-563N4.1	-4.61	4.47e-06	0.000397	-0.15	-0.14	Interleukin-18 levels;	chr2:31513149	chr2:32165046~32165757:-
BRCA	cis	rs832187	0.704	rs832195	ENSG00000280620.1	SCAANT1	-4.61	4.47e-06	0.000397	-0.18	-0.14	Schizophrenia;	chr3:63878936	chr3:63911518~63911772:-
BRCA	cis	rs4934494	0.834	rs1359624	ENSG00000232229.4	LINC00865	-4.61	4.47e-06	0.000397	-0.19	-0.14	Red blood cell count;	chr10:89635671	chr10:89829510~89840861:+
BRCA	cis	rs9650657	0.562	rs10090444	ENSG00000255046.1	RP11-297N6.4	-4.61	4.47e-06	0.000397	-0.17	-0.14	Neuroticism;	chr8:10887959	chr8:11797928~11802568:-
BRCA	cis	rs2243480	1	rs316329	ENSG00000222364.1	RNU6-96P	-4.61	4.47e-06	0.000397	-0.25	-0.14	Diabetic kidney disease;	chr7:66143429	chr7:66395191~66395286:+
BRCA	cis	rs1867631	1	rs10789212	ENSG00000248458.2	RP4-598P13.1	4.61	4.47e-06	0.000397	0.15	0.14	Menopause (age at onset);	chr1:66662472	chr1:66665864~66677027:-
BRCA	cis	rs7819412	0.521	rs11777887	ENSG00000255046.1	RP11-297N6.4	-4.61	4.48e-06	0.000398	-0.17	-0.14	Triglycerides;	chr8:11179290	chr8:11797928~11802568:-
BRCA	cis	rs2836974	0.563	rs6517522	ENSG00000238141.2	BRWD1-AS1	4.61	4.48e-06	0.000398	0.16	0.14	Cognitive function;	chr21:39181919	chr21:39315707~39323218:+
BRCA	cis	rs11096990	0.656	rs2066786	ENSG00000249685.1	RP11-360F5.3	4.61	4.48e-06	0.000398	0.18	0.14	Cognitive function;	chr4:39300409	chr4:39133913~39135608:+
BRCA	cis	rs12744310	0.887	rs35410722	ENSG00000235358.1	RP11-399E6.1	4.61	4.48e-06	0.000398	0.21	0.14	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41330592	chr1:41242373~41284861:+
BRCA	cis	rs12744310	0.887	rs34539673	ENSG00000235358.1	RP11-399E6.1	4.61	4.48e-06	0.000398	0.21	0.14	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41331145	chr1:41242373~41284861:+
BRCA	cis	rs4787491	0.765	rs8054507	ENSG00000261367.1	RP11-455F5.4	-4.61	4.48e-06	0.000398	-0.15	-0.14	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30034721	chr16:30107675~30110541:+
BRCA	cis	rs7811142	1	rs7783159	ENSG00000078319.8	PMS2P1	-4.61	4.48e-06	0.000398	-0.24	-0.14	Platelet count;	chr7:100419831	chr7:100320992~100341908:-
BRCA	cis	rs5758511	0.68	rs5758687	ENSG00000227370.1	RP4-669P10.19	4.61	4.48e-06	0.000398	0.18	0.14	Birth weight;	chr22:42260582	chr22:42132543~42132998:+
BRCA	cis	rs2280018	1	rs2280018	ENSG00000270580.4	PKD1P6	4.61	4.48e-06	0.000398	0.15	0.14	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15056976	chr16:15104723~15131601:-
BRCA	cis	rs2839186	0.9	rs56840278	ENSG00000228137.1	AP001469.7	4.61	4.48e-06	0.000398	0.15	0.14	Testicular germ cell tumor;	chr21:46289019	chr21:46246890~46247682:+
BRCA	cis	rs2839186	0.933	rs56955294	ENSG00000228137.1	AP001469.7	4.61	4.48e-06	0.000398	0.15	0.14	Testicular germ cell tumor;	chr21:46289039	chr21:46246890~46247682:+
BRCA	cis	rs12501370	0.721	rs35131021	ENSG00000201736.1	RNA5SP160	4.61	4.48e-06	0.000398	0.17	0.14	Iris color (L* coordinate);	chr4:41046929	chr4:40990154~40990273:+
BRCA	cis	rs7727544	0.507	rs10051679	ENSG00000233006.5	AC034220.3	4.61	4.48e-06	0.000398	0.11	0.14	Blood metabolite levels;	chr5:132235238	chr5:132311285~132369916:-
BRCA	cis	rs957448	0.507	rs1984711	ENSG00000253175.1	RP11-267M23.6	4.61	4.48e-06	0.000398	0.17	0.14	Nonsyndromic cleft lip with cleft palate;	chr8:94600276	chr8:94565036~94565715:+
BRCA	cis	rs9467773	0.62	rs2451737	ENSG00000241549.7	GUSBP2	4.61	4.49e-06	0.000398	0.15	0.14	Intelligence (multi-trait analysis);	chr6:26618813	chr6:26871484~26956554:-
BRCA	cis	rs9467773	0.596	rs2494693	ENSG00000241549.7	GUSBP2	4.61	4.49e-06	0.000398	0.15	0.14	Intelligence (multi-trait analysis);	chr6:26618998	chr6:26871484~26956554:-
BRCA	cis	rs9467773	0.62	rs2494694	ENSG00000241549.7	GUSBP2	4.61	4.49e-06	0.000398	0.15	0.14	Intelligence (multi-trait analysis);	chr6:26619100	chr6:26871484~26956554:-
BRCA	cis	rs10129255	0.957	rs8014696	ENSG00000274576.2	IGHV2-70	-4.61	4.49e-06	0.000398	-0.12	-0.14	Kawasaki disease;	chr14:106769752	chr14:106770577~106771020:-
BRCA	cis	rs651907	0.64	rs771573	ENSG00000244119.1	PDCL3P4	4.61	4.49e-06	0.000398	0.12	0.14	Colorectal cancer;	chr3:101902052	chr3:101712472~101713191:+
BRCA	cis	rs11239930	0.517	rs942689	ENSG00000230832.3	RP11-325P15.2	-4.61	4.49e-06	0.000399	-0.21	-0.14	AIDS progression;	chr1:147079231	chr1:147082338~147083578:-
BRCA	cis	rs6750047	0.691	rs336032	ENSG00000235848.3	RMDN2-AS1	4.61	4.49e-06	0.000399	0.19	0.14	Cutaneous malignant melanoma;Melanoma;	chr2:38037645	chr2:37949911~38067041:-
BRCA	cis	rs4356203	0.905	rs11024148	ENSG00000272034.1	SNORD14A	-4.61	4.49e-06	0.000399	-0.15	-0.14	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17074512	chr11:17074654~17074744:-
BRCA	cis	rs2574985	0.566	rs2574959	ENSG00000231345.3	BEND3P1	4.61	4.49e-06	0.000399	0.19	0.14	Subjective well-being;	chr10:50364303	chr10:50655967~50660472:+
BRCA	cis	rs2136613	0.728	rs10822065	ENSG00000238280.1	RP11-436D10.3	-4.61	4.49e-06	0.000399	-0.18	-0.14	Selective IgA deficiency;	chr10:62851172	chr10:62793562~62805887:-
BRCA	cis	rs11124272	0.716	rs527112	ENSG00000272716.1	RP11-563N4.1	4.61	4.49e-06	0.000399	0.17	0.14	Interleukin-18 levels;	chr2:31640549	chr2:32165046~32165757:-
BRCA	cis	rs934734	0.532	rs12185610	ENSG00000204929.10	AC074391.1	-4.61	4.49e-06	0.000399	-0.18	-0.14	Rheumatoid arthritis;	chr2:65434334	chr2:65436711~66084639:+
BRCA	cis	rs372883	0.6	rs1153276	ENSG00000176054.6	RPL23P2	-4.61	4.5e-06	0.000399	-0.16	-0.14	Pancreatic cancer;	chr21:29289373	chr21:28997613~28998033:-
BRCA	cis	rs1665050	0.895	rs8028752	ENSG00000277144.1	RP11-59H7.4	-4.61	4.5e-06	0.000399	-0.19	-0.14	Atopic dermatitis;	chr15:59003803	chr15:59115547~59116089:-
BRCA	cis	rs13325613	0.915	rs13067058	ENSG00000223552.1	RP11-24F11.2	-4.61	4.5e-06	0.000399	-0.3	-0.14	Monocyte count;	chr3:46232275	chr3:46364955~46407059:-
BRCA	cis	rs7772486	0.79	rs3924498	ENSG00000270638.1	RP3-466P17.1	-4.61	4.5e-06	0.000399	-0.17	-0.14	Lobe attachment (rater-scored or self-reported);	chr6:145912202	chr6:145735570~145737218:+
BRCA	cis	rs4664293	0.867	rs2303550	ENSG00000226266.5	AC009961.3	-4.61	4.5e-06	0.000399	-0.18	-0.14	Monocyte percentage of white cells;	chr2:159781110	chr2:159670708~159712435:-
BRCA	cis	rs10833905	0.938	rs11026935	ENSG00000246225.5	RP11-17A1.3	-4.61	4.5e-06	0.000399	-0.2	-0.14	Sudden cardiac arrest;	chr11:23046740	chr11:22829380~22945393:+
BRCA	cis	rs453301	0.658	rs12114954	ENSG00000254153.1	CTA-398F10.2	-4.61	4.5e-06	0.000399	-0.17	-0.14	Joint mobility (Beighton score);	chr8:9047352	chr8:8456909~8461337:-
BRCA	cis	rs6802315	0.573	rs7635993	ENSG00000272247.1	RP11-379F4.9	-4.61	4.5e-06	4e-04	-0.16	-0.14	Periodontitis (CDC/AAP);	chr3:158742187	chr3:158801257~158801935:-
BRCA	cis	rs35740288	0.77	rs1871285	ENSG00000202081.1	RNU6-1280P	4.61	4.5e-06	4e-04	0.18	0.14	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85609256	chr15:85651522~85651628:-
BRCA	cis	rs35740288	0.77	rs4843081	ENSG00000202081.1	RNU6-1280P	4.61	4.5e-06	4e-04	0.18	0.14	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85609813	chr15:85651522~85651628:-
BRCA	cis	rs321358	0.943	rs17537987	ENSG00000271390.1	RP11-89C3.3	4.61	4.5e-06	4e-04	0.24	0.14	Body mass index;	chr11:111134144	chr11:111089870~111090368:-
BRCA	cis	rs321358	1	rs73019218	ENSG00000271390.1	RP11-89C3.3	4.61	4.5e-06	4e-04	0.24	0.14	Body mass index;	chr11:111134521	chr11:111089870~111090368:-
BRCA	cis	rs12612619	0.732	rs7560595	ENSG00000229122.1	AGBL5-IT1	4.61	4.5e-06	4e-04	0.15	0.14	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27006504	chr2:27061038~27061815:+
BRCA	cis	rs10266483	0.739	rs682662	ENSG00000227986.1	TRIM60P18	-4.61	4.51e-06	4e-04	-0.15	-0.14	Response to statin therapy;	chr7:64306107	chr7:64355078~64356199:+
BRCA	cis	rs10266483	0.739	rs679966	ENSG00000227986.1	TRIM60P18	-4.61	4.51e-06	4e-04	-0.15	-0.14	Response to statin therapy;	chr7:64306688	chr7:64355078~64356199:+
BRCA	cis	rs4706831	0.647	rs9350847	ENSG00000272129.1	RP11-250B2.6	4.61	4.51e-06	4e-04	0.18	0.14	Joint mobility (Beighton score);	chr6:80179300	chr6:80355424~80356859:+
BRCA	cis	rs17428076	0.831	rs55957712	ENSG00000228389.1	AC068039.4	-4.61	4.51e-06	4e-04	-0.2	-0.14	Myopia;	chr2:171731446	chr2:171773482~171775844:+
BRCA	cis	rs13113518	1	rs11133388	ENSG00000273257.1	RP11-177J6.1	-4.61	4.51e-06	0.000401	-0.18	-0.14	Height;	chr4:55477866	chr4:55387949~55388271:+
BRCA	cis	rs1979679	0.573	rs7316056	ENSG00000278733.1	RP11-425D17.1	-4.61	4.51e-06	0.000401	-0.19	-0.14	Ossification of the posterior longitudinal ligament of the spine;	chr12:28575743	chr12:28185625~28186190:-
BRCA	cis	rs1867631	0.958	rs7520226	ENSG00000248458.2	RP4-598P13.1	4.61	4.51e-06	0.000401	0.15	0.14	Menopause (age at onset);	chr1:66615312	chr1:66665864~66677027:-
BRCA	cis	rs6452524	0.967	rs2974445	ENSG00000281327.1	LINC01338	-4.61	4.51e-06	0.000401	-0.16	-0.14	Hypertension (SNP x SNP interaction);	chr5:83185561	chr5:82850864~82859836:-
BRCA	cis	rs8114671	0.742	rs6058161	ENSG00000279253.1	RP4-614O4.13	4.61	4.51e-06	0.000401	0.16	0.14	Height;	chr20:35032223	chr20:35262727~35264187:-
BRCA	cis	rs6714710	0.58	rs11690737	ENSG00000230606.9	AC159540.1	-4.61	4.52e-06	0.000401	-0.16	-0.14	Posterior cortical atrophy and Alzheimer's disease;	chr2:97845490	chr2:97416165~97433527:-
BRCA	cis	rs4699052	0.893	rs4699058	ENSG00000248740.4	RP11-328K4.1	4.61	4.52e-06	0.000401	0.16	0.14	Testicular germ cell tumor;	chr4:103250164	chr4:103256159~103453658:+
BRCA	cis	rs6832769	0.922	rs6825994	ENSG00000272969.1	RP11-528I4.2	-4.61	4.52e-06	0.000401	-0.17	-0.14	Personality dimensions;	chr4:55524244	chr4:55547112~55547889:+
BRCA	cis	rs7577696	0.509	rs681482	ENSG00000272716.1	RP11-563N4.1	4.61	4.52e-06	0.000401	0.16	0.14	Inflammatory biomarkers;	chr2:31646187	chr2:32165046~32165757:-
BRCA	cis	rs2273156	1	rs17102970	ENSG00000226677.3	IGBP1P1	-4.61	4.53e-06	0.000402	-0.21	-0.14	Immunoglobulin light chain (AL) amyloidosis;	chr14:35011363	chr14:34939324~34940332:+
BRCA	cis	rs1910358	0.621	rs12109110	ENSG00000248874.4	C5orf17	-4.61	4.53e-06	0.000402	-0.21	-0.14	Venous thromboembolism (SNP x SNP interaction);	chr5:23845772	chr5:23951348~24178263:+
BRCA	cis	rs1858037	0.867	rs67817304	ENSG00000281920.1	RP11-418H16.1	4.61	4.53e-06	0.000402	0.18	0.14	Rheumatoid arthritis;	chr2:65346982	chr2:65623272~65628424:+
BRCA	cis	rs12744310	0.887	rs67483852	ENSG00000235358.1	RP11-399E6.1	4.61	4.53e-06	0.000402	0.21	0.14	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41318793	chr1:41242373~41284861:+
BRCA	cis	rs4781563	0.956	rs744154	ENSG00000242307.1	RPS26P52	-4.61	4.53e-06	0.000402	-0.17	-0.14	Bilirubin levels;	chr16:13921224	chr16:13922332~13922679:-
BRCA	cis	rs7772486	0.764	rs2265471	ENSG00000270638.1	RP3-466P17.1	4.61	4.53e-06	0.000402	0.16	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145899114	chr6:145735570~145737218:+
BRCA	cis	rs56322409	0.897	rs11188444	ENSG00000226688.5	ENTPD1-AS1	4.61	4.53e-06	0.000402	0.16	0.14	Blood metabolite levels;	chr10:95718089	chr10:95753206~96090238:-
BRCA	cis	rs1434579	0.966	rs1062098	ENSG00000176761.7	ZNF285B	-4.61	4.53e-06	0.000402	-0.17	-0.14	Tuberculosis;	chr19:44426566	chr19:44467641~44473227:+
BRCA	cis	rs7267979	1	rs2482931	ENSG00000276952.1	RP5-965G21.6	-4.61	4.53e-06	0.000402	-0.18	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25353809	chr20:25284915~25285588:-
BRCA	cis	rs7727544	0.716	rs7720230	ENSG00000233006.5	AC034220.3	4.61	4.53e-06	0.000402	0.11	0.14	Blood metabolite levels;	chr5:132256712	chr5:132311285~132369916:-
BRCA	cis	rs6430538	0.621	rs11900331	ENSG00000224043.6	CCNT2-AS1	-4.61	4.53e-06	0.000402	-0.2	-0.14	Parkinson's disease;	chr2:134814333	chr2:134735464~134918710:-
BRCA	cis	rs7119	0.717	rs12910951	ENSG00000259362.2	RP11-307C19.1	-4.61	4.53e-06	0.000402	-0.19	-0.14	Type 2 diabetes;	chr15:77514455	chr15:77525540~77534110:+
BRCA	cis	rs9527	0.518	rs12776863	ENSG00000213061.2	PFN1P11	4.61	4.54e-06	0.000402	0.27	0.14	Arsenic metabolism;	chr10:102881922	chr10:102838011~102845473:-
BRCA	cis	rs6586111	1	rs6586111	ENSG00000226659.1	RP11-137H2.4	-4.61	4.54e-06	0.000403	-0.18	-0.14	Capecitabine sensitivity;	chr10:80617834	chr10:80529597~80535942:-
BRCA	cis	rs2574985	0.813	rs1203407	ENSG00000231345.3	BEND3P1	-4.61	4.54e-06	0.000403	-0.22	-0.14	Subjective well-being;	chr10:50438213	chr10:50655967~50660472:+
BRCA	cis	rs13113518	1	rs13133579	ENSG00000273257.1	RP11-177J6.1	4.61	4.54e-06	0.000403	0.18	0.14	Height;	chr4:55459921	chr4:55387949~55388271:+
BRCA	cis	rs6545883	0.894	rs6709441	ENSG00000212978.6	AC016747.3	-4.61	4.54e-06	0.000403	-0.2	-0.14	Tuberculosis;	chr2:61209795	chr2:61141592~61144969:-
BRCA	cis	rs7674212	0.54	rs2711897	ENSG00000251288.2	RP11-10L12.2	-4.61	4.54e-06	0.000403	-0.17	-0.14	Type 2 diabetes;	chr4:103102410	chr4:102751401~102752641:+
BRCA	cis	rs7267979	1	rs884613	ENSG00000125804.12	FAM182A	4.61	4.55e-06	0.000403	0.19	0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25307869	chr20:26054655~26086917:+
BRCA	cis	rs7267979	1	rs1888998	ENSG00000125804.12	FAM182A	4.61	4.55e-06	0.000403	0.19	0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25311190	chr20:26054655~26086917:+
BRCA	cis	rs9921338	0.632	rs149310	ENSG00000262703.1	RP11-485G7.6	4.61	4.55e-06	0.000403	0.18	0.14	Vein graft stenosis in coronary artery bypass grafting;	chr16:11251842	chr16:11348143~11349321:-
BRCA	cis	rs9652601	0.696	rs12917656	ENSG00000274038.1	RP11-66H6.4	-4.61	4.55e-06	0.000403	-0.15	-0.14	Systemic lupus erythematosus;	chr16:11094005	chr16:11056556~11057034:+
BRCA	cis	rs11239930	0.517	rs2477569	ENSG00000230832.3	RP11-325P15.2	4.61	4.55e-06	0.000403	0.2	0.14	AIDS progression;	chr1:147076261	chr1:147082338~147083578:-
BRCA	cis	rs2692947	0.702	rs4907291	ENSG00000232931.4	LINC00342	4.61	4.55e-06	0.000404	0.14	0.14	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95988857	chr2:95807118~95816215:-
BRCA	cis	rs7267979	1	rs6050609	ENSG00000274973.1	RP13-401N8.7	4.61	4.55e-06	0.000404	0.16	0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25431115	chr20:25845497~25845862:+
BRCA	cis	rs1043099	0.912	rs5753080	ENSG00000279699.1	RP1-102K2.9	-4.61	4.55e-06	0.000404	-0.23	-0.14	Rheumatoid arthritis;	chr22:30342748	chr22:30275215~30276951:-
BRCA	cis	rs595244	1	rs11634611	ENSG00000259705.1	RP11-227D13.1	4.61	4.55e-06	0.000404	0.22	0.14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48522100	chr15:48645951~48652016:+
BRCA	cis	rs6832769	1	rs28582059	ENSG00000272969.1	RP11-528I4.2	-4.61	4.55e-06	0.000404	-0.17	-0.14	Personality dimensions;	chr4:55542237	chr4:55547112~55547889:+
BRCA	cis	rs7048146	1	rs7030085	ENSG00000213539.4	YBX1P6	4.61	4.55e-06	0.000404	0.16	0.14	Vascular brain injury;	chr9:109539735	chr9:109532830~109534332:-
BRCA	cis	rs256438	0.896	rs2438637	ENSG00000251050.1	RP11-168A11.4	-4.61	4.55e-06	0.000404	-0.16	-0.14	Serum thyroid-stimulating hormone levels;	chr5:80094553	chr5:80019609~80019920:+
BRCA	cis	rs6598266	1	rs6598268	ENSG00000182397.13	DNM1P46	-4.61	4.56e-06	0.000404	-0.19	-0.14	Major depressive disorder;	chr15:99759095	chr15:99790156~99806927:-
BRCA	cis	rs9784649	1	rs56004901	ENSG00000245662.2	RP11-184E9.1	4.61	4.56e-06	0.000404	0.21	0.14	Peripheral arterial disease (traffic-related air pollution interaction);	chr5:24998859	chr5:25190682~25306172:+
BRCA	cis	rs9784649	1	rs56156666	ENSG00000245662.2	RP11-184E9.1	4.61	4.56e-06	0.000404	0.21	0.14	Peripheral arterial disease (traffic-related air pollution interaction);	chr5:24999331	chr5:25190682~25306172:+
BRCA	cis	rs828999	0.715	rs1020174	ENSG00000280186.1	RP11-483I13.6	-4.61	4.56e-06	0.000404	-0.16	-0.14	Monocyte percentage of white cells;	chr1:108154138	chr1:108200413~108202743:+
BRCA	cis	rs3764021	0.84	rs10743823	ENSG00000278635.1	CTD-2318O12.1	-4.61	4.56e-06	0.000404	-0.14	-0.14	Type 1 diabetes;	chr12:9728529	chr12:9415641~9416718:+
BRCA	cis	rs7487075	0.578	rs4768118	ENSG00000274723.1	RP11-618L22.1	4.61	4.56e-06	0.000404	0.17	0.14	Itch intensity from mosquito bite;	chr12:46390961	chr12:46970504~46972155:+
BRCA	cis	rs8180040	0.966	rs13079098	ENSG00000276925.1	RP11-708J19.3	-4.61	4.56e-06	0.000404	-0.16	-0.14	Colorectal cancer;	chr3:47401373	chr3:47469777~47469987:+
BRCA	cis	rs7312933	0.533	rs11181499	ENSG00000257225.1	RP11-328C8.4	-4.61	4.56e-06	0.000405	-0.17	-0.14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42424959	chr12:42459366~42466128:+
BRCA	cis	rs9513627	0.92	rs7334943	ENSG00000280710.1	RP11-214F16.8	4.61	4.56e-06	0.000405	0.24	0.14	Obesity-related traits;	chr13:99469033	chr13:99498524~99501315:+
BRCA	cis	rs189798	0.592	rs10111263	ENSG00000233609.3	RP11-62H7.2	-4.61	4.56e-06	0.000405	-0.14	-0.14	Myopia (pathological);	chr8:9111923	chr8:8961200~8979025:+
BRCA	cis	rs4948275	0.693	rs2253375	ENSG00000237233.2	TMEM26-AS1	-4.61	4.56e-06	0.000405	-0.17	-0.14	Night sleep phenotypes;	chr10:61565735	chr10:61452639~61481956:+
BRCA	cis	rs4948275	0.693	rs2650739	ENSG00000237233.2	TMEM26-AS1	-4.61	4.56e-06	0.000405	-0.17	-0.14	Night sleep phenotypes;	chr10:61567679	chr10:61452639~61481956:+
BRCA	cis	rs3764021	0.87	rs2401391	ENSG00000278635.1	CTD-2318O12.1	-4.61	4.56e-06	0.000405	-0.14	-0.14	Type 1 diabetes;	chr12:9725987	chr12:9415641~9416718:+
BRCA	cis	rs2692947	0.727	rs749459	ENSG00000168992.4	OR7E102P	4.61	4.56e-06	0.000405	0.19	0.14	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96129975	chr2:95546531~95547545:+
BRCA	cis	rs875971	1	rs2087647	ENSG00000236529.1	RP13-254B10.1	-4.61	4.56e-06	0.000405	-0.15	-0.14	Aortic root size;	chr7:66128201	chr7:65840212~65840596:+
BRCA	cis	rs12497850	0.931	rs4974079	ENSG00000225399.4	RP11-3B7.1	4.61	4.57e-06	0.000405	0.14	0.14	Parkinson's disease;	chr3:48869036	chr3:49260085~49261316:+
BRCA	cis	rs11096990	0.634	rs10010352	ENSG00000249685.1	RP11-360F5.3	4.61	4.57e-06	0.000405	0.18	0.14	Cognitive function;	chr4:39240657	chr4:39133913~39135608:+
BRCA	cis	rs7267979	0.753	rs400357	ENSG00000274973.1	RP13-401N8.7	-4.61	4.57e-06	0.000405	-0.16	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25498422	chr20:25845497~25845862:+
BRCA	cis	rs970548	0.643	rs7080474	ENSG00000230869.1	CTGLF10P	4.61	4.57e-06	0.000405	0.2	0.14	Total cholesterol levels;HDL cholesterol;HDL cholesterol levels;Cholesterol, total;	chr10:45436451	chr10:45678692~45700532:+
BRCA	cis	rs4650994	1	rs4511075	ENSG00000273384.1	RP5-1098D14.1	4.61	4.57e-06	0.000405	0.17	0.14	HDL cholesterol;HDL cholesterol levels;	chr1:178549501	chr1:178651706~178652282:+
BRCA	cis	rs67311347	1	rs7642552	ENSG00000280739.1	EIF1B-AS1	4.61	4.57e-06	0.000405	0.16	0.14	Renal cell carcinoma;	chr3:40383325	chr3:40173145~40309698:-
BRCA	cis	rs7267979	0.78	rs2500413	ENSG00000274973.1	RP13-401N8.7	-4.61	4.57e-06	0.000405	-0.16	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25260519	chr20:25845497~25845862:+
BRCA	cis	rs7267979	0.714	rs2474763	ENSG00000274973.1	RP13-401N8.7	-4.61	4.57e-06	0.000405	-0.16	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25260659	chr20:25845497~25845862:+
BRCA	cis	rs1979679	0.879	rs2638950	ENSG00000278733.1	RP11-425D17.1	4.61	4.57e-06	0.000406	0.18	0.14	Ossification of the posterior longitudinal ligament of the spine;	chr12:28398634	chr12:28185625~28186190:-
BRCA	cis	rs1823874	0.542	rs1962946	ENSG00000182397.13	DNM1P46	-4.61	4.57e-06	0.000406	-0.15	-0.14	IgG glycosylation;	chr15:99834410	chr15:99790156~99806927:-
BRCA	cis	rs11976180	1	rs1533266	ENSG00000244479.5	OR2A1-AS1	4.61	4.58e-06	0.000406	0.19	0.14	Obesity-related traits;	chr7:144069621	chr7:144251264~144356181:-
BRCA	cis	rs459482	0.504	rs467773	ENSG00000228318.3	AP001610.5	4.61	4.58e-06	0.000406	0.16	0.14	IgG glycosylation;	chr21:41446179	chr21:41441056~41445708:-
BRCA	cis	rs7246657	0.663	rs10408619	ENSG00000226686.6	LINC01535	-4.61	4.58e-06	0.000406	-0.21	-0.14	Coronary artery calcification;	chr19:37579573	chr19:37251912~37265535:+
BRCA	cis	rs7209700	0.745	rs8074348	ENSG00000228782.6	CTD-2026D20.3	-4.61	4.58e-06	0.000406	-0.16	-0.14	IgG glycosylation;	chr17:47276047	chr17:47450568~47492492:-
BRCA	cis	rs1979679	0.573	rs4930825	ENSG00000278733.1	RP11-425D17.1	-4.61	4.58e-06	0.000406	-0.19	-0.14	Ossification of the posterior longitudinal ligament of the spine;	chr12:28574174	chr12:28185625~28186190:-
BRCA	cis	rs12439619	0.693	rs8034801	ENSG00000255769.6	GOLGA2P10	-4.61	4.58e-06	0.000406	-0.19	-0.14	Intelligence (multi-trait analysis);	chr15:82183996	chr15:82472993~82513950:-
BRCA	cis	rs7246657	0.722	rs2927742	ENSG00000226686.6	LINC01535	4.61	4.58e-06	0.000406	0.21	0.14	Coronary artery calcification;	chr19:37642717	chr19:37251912~37265535:+
BRCA	cis	rs2048656	0.635	rs7830613	ENSG00000233609.3	RP11-62H7.2	-4.61	4.59e-06	0.000406	-0.14	-0.14	Schizophrenia;	chr8:9792259	chr8:8961200~8979025:+
BRCA	cis	rs6840360	0.582	rs2724555	ENSG00000251611.1	RP11-610P16.1	-4.61	4.59e-06	0.000406	-0.12	-0.14	Intelligence (multi-trait analysis);	chr4:151420726	chr4:151407551~151408835:-
BRCA	cis	rs5167	0.504	rs10426750	ENSG00000280087.1	CTB-129P6.7	4.61	4.59e-06	0.000407	0.17	0.14	Blood protein levels;	chr19:44954427	chr19:44909375~44914968:+
BRCA	cis	rs4143844	0.867	rs11638455	ENSG00000259251.2	RP11-643M14.1	4.61	4.59e-06	0.000407	0.35	0.14	Bipolar disorder and schizophrenia;	chr15:61870969	chr15:62060503~62062434:+
BRCA	cis	rs172166	0.694	rs536704	ENSG00000219392.1	RP1-265C24.5	-4.61	4.59e-06	0.000407	-0.19	-0.14	Cardiac Troponin-T levels;	chr6:28124825	chr6:28115628~28116551:+
BRCA	cis	rs7914558	0.646	rs1046778	ENSG00000213061.2	PFN1P11	4.61	4.59e-06	0.000407	0.2	0.14	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102901727	chr10:102838011~102845473:-
BRCA	cis	rs2303319	0.504	rs62188990	ENSG00000227403.1	AC009299.3	4.61	4.59e-06	0.000407	0.34	0.14	Cognitive function;	chr2:161684125	chr2:161244739~161249050:+
BRCA	cis	rs11098499	0.954	rs11940028	ENSG00000250412.1	KLHL2P1	4.61	4.59e-06	0.000407	0.17	0.14	Corneal astigmatism;	chr4:119490752	chr4:119334329~119378233:+
BRCA	cis	rs11098499	0.954	rs11935596	ENSG00000250412.1	KLHL2P1	4.61	4.59e-06	0.000407	0.17	0.14	Corneal astigmatism;	chr4:119491302	chr4:119334329~119378233:+
BRCA	cis	rs11098499	0.954	rs12507964	ENSG00000250412.1	KLHL2P1	4.61	4.59e-06	0.000407	0.17	0.14	Corneal astigmatism;	chr4:119491906	chr4:119334329~119378233:+
BRCA	cis	rs11098499	0.909	rs11098530	ENSG00000250412.1	KLHL2P1	4.61	4.59e-06	0.000407	0.17	0.14	Corneal astigmatism;	chr4:119491999	chr4:119334329~119378233:+
BRCA	cis	rs7772486	0.79	rs2265917	ENSG00000270638.1	RP3-466P17.1	4.61	4.59e-06	0.000407	0.16	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145891149	chr6:145735570~145737218:+
BRCA	cis	rs7267979	1	rs2482940	ENSG00000276952.1	RP5-965G21.6	-4.61	4.59e-06	0.000407	-0.18	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25369194	chr20:25284915~25285588:-
BRCA	cis	rs7267979	0.966	rs3002698	ENSG00000125804.12	FAM182A	4.61	4.6e-06	0.000407	0.19	0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25322743	chr20:26054655~26086917:+
BRCA	cis	rs7267979	0.844	rs6107027	ENSG00000277938.1	RP5-965G21.3	4.61	4.6e-06	0.000407	0.17	0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25307996	chr20:25229150~25231933:+
BRCA	cis	rs4664293	0.867	rs1126842	ENSG00000226266.5	AC009961.3	-4.61	4.6e-06	0.000408	-0.18	-0.14	Monocyte percentage of white cells;	chr2:159770806	chr2:159670708~159712435:-
BRCA	cis	rs6840360	0.642	rs1443089	ENSG00000251611.1	RP11-610P16.1	-4.61	4.6e-06	0.000408	-0.12	-0.14	Intelligence (multi-trait analysis);	chr4:151529148	chr4:151407551~151408835:-
BRCA	cis	rs2109514	0.902	rs1007751	ENSG00000237813.3	AC002066.1	4.61	4.6e-06	0.000408	0.17	0.14	Prevalent atrial fibrillation;	chr7:116470001	chr7:116238260~116499465:-
BRCA	cis	rs1371614	0.513	rs562311	ENSG00000272148.1	RP11-195B17.1	-4.61	4.6e-06	0.000408	-0.16	-0.14	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26875218	chr2:27062428~27062907:-
BRCA	cis	rs2257011	0.733	rs1896796	ENSG00000230373.7	GOLGA6L5P	-4.61	4.6e-06	0.000408	-0.15	-0.14	Height;	chr15:83606228	chr15:84507885~84516814:-
BRCA	cis	rs10181042	0.514	rs1177283	ENSG00000273302.1	RP11-493E12.2	4.61	4.6e-06	0.000408	0.13	0.14	Crohn's disease;	chr2:61121669	chr2:61199979~61200769:+
BRCA	cis	rs12291225	0.839	rs4757244	ENSG00000251991.1	RNU7-49P	-4.61	4.6e-06	0.000408	-0.16	-0.14	Sense of smell;	chr11:14237109	chr11:14478892~14478953:+
BRCA	cis	rs6545883	0.525	rs1729658	ENSG00000212978.6	AC016747.3	4.61	4.6e-06	0.000408	0.19	0.14	Tuberculosis;	chr2:61146385	chr2:61141592~61144969:-
BRCA	cis	rs7772486	0.875	rs2814875	ENSG00000270638.1	RP3-466P17.1	4.61	4.61e-06	0.000408	0.17	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145984674	chr6:145735570~145737218:+
BRCA	cis	rs7772486	0.875	rs2814874	ENSG00000270638.1	RP3-466P17.1	4.61	4.61e-06	0.000408	0.17	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145984759	chr6:145735570~145737218:+
BRCA	cis	rs7267979	0.966	rs2263204	ENSG00000125804.12	FAM182A	4.61	4.61e-06	0.000409	0.19	0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25397052	chr20:26054655~26086917:+
BRCA	cis	rs6831352	0.734	rs1154400	ENSG00000272777.1	RP11-571L19.8	-4.61	4.61e-06	0.000409	-0.15	-0.14	Alcohol dependence;	chr4:99088859	chr4:99067256~99068125:-
BRCA	cis	rs316341	0.755	rs386915	ENSG00000230438.6	SERPINB9P1	-4.61	4.61e-06	0.000409	-0.19	-0.14	Cerebrospinal fluid AB1-42 levels;	chr6:2834031	chr6:2854657~2881407:-
BRCA	cis	rs1707322	0.826	rs10890349	ENSG00000234329.1	RP11-767N6.2	4.61	4.61e-06	0.000409	0.15	0.14	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45784283	chr1:45651039~45651826:-
BRCA	cis	rs1707322	0.758	rs10789474	ENSG00000234329.1	RP11-767N6.2	4.61	4.61e-06	0.000409	0.15	0.14	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45784368	chr1:45651039~45651826:-
BRCA	cis	rs7246967	0.611	rs62118780	ENSG00000198153.8	ZNF849P	-4.61	4.61e-06	0.000409	-0.24	-0.14	Bronchopulmonary dysplasia;	chr19:22648312	chr19:22685167~22686732:+
BRCA	cis	rs7246967	0.611	rs4933019	ENSG00000198153.8	ZNF849P	-4.61	4.61e-06	0.000409	-0.24	-0.14	Bronchopulmonary dysplasia;	chr19:22649184	chr19:22685167~22686732:+
BRCA	cis	rs4835473	0.868	rs1828503	ENSG00000249741.2	RP11-673E1.3	4.61	4.61e-06	0.000409	0.16	0.14	Immature fraction of reticulocytes;	chr4:143993354	chr4:143911514~143912053:-
BRCA	cis	rs4763879	0.778	rs11052497	ENSG00000278635.1	CTD-2318O12.1	4.61	4.61e-06	0.000409	0.14	0.14	Type 1 diabetes;	chr12:9696679	chr12:9415641~9416718:+
BRCA	cis	rs13108904	0.539	rs13135102	ENSG00000253399.1	AC078852.2	-4.61	4.62e-06	0.000409	-0.17	-0.14	Obesity-related traits;	chr4:1337195	chr4:1358479~1359461:+
BRCA	cis	rs17597773	0.638	rs17596850	ENSG00000238078.1	LINC01352	-4.61	4.62e-06	0.000409	-0.17	-0.14	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220819001	chr1:220829255~220832429:+
BRCA	cis	rs321358	1	rs321353	ENSG00000271390.1	RP11-89C3.3	-4.61	4.62e-06	0.000409	-0.22	-0.14	Body mass index;	chr11:111123841	chr11:111089870~111090368:-
BRCA	cis	rs12497850	0.931	rs62262517	ENSG00000225399.4	RP11-3B7.1	4.61	4.62e-06	0.000409	0.14	0.14	Parkinson's disease;	chr3:49097481	chr3:49260085~49261316:+
BRCA	cis	rs2880765	0.835	rs6496027	ENSG00000202081.1	RNU6-1280P	4.61	4.62e-06	0.000409	0.16	0.14	Coronary artery disease;	chr15:85506757	chr15:85651522~85651628:-
BRCA	cis	rs1043099	0.912	rs5753071	ENSG00000279699.1	RP1-102K2.9	-4.61	4.62e-06	0.000409	-0.22	-0.14	Rheumatoid arthritis;	chr22:30330837	chr22:30275215~30276951:-
BRCA	cis	rs1043099	0.912	rs10376	ENSG00000279699.1	RP1-102K2.9	-4.61	4.62e-06	0.000409	-0.22	-0.14	Rheumatoid arthritis;	chr22:30332367	chr22:30275215~30276951:-
BRCA	cis	rs17685	0.712	rs28456330	ENSG00000280388.1	RP11-229D13.3	-4.61	4.62e-06	0.000409	-0.15	-0.14	Coffee consumption (cups per day);Coffee consumption;	chr7:76181224	chr7:76043977~76045963:-
BRCA	cis	rs7811142	0.562	rs7786844	ENSG00000078319.8	PMS2P1	-4.61	4.63e-06	0.00041	-0.22	-0.14	Platelet count;	chr7:100336385	chr7:100320992~100341908:-
BRCA	cis	rs10752881	0.602	rs9425569	ENSG00000224468.3	RP11-181K3.4	-4.61	4.63e-06	0.00041	-0.16	-0.14	Colorectal cancer;	chr1:182973067	chr1:183138402~183141282:-
BRCA	cis	rs56322409	0.897	rs6946	ENSG00000226688.5	ENTPD1-AS1	4.61	4.63e-06	0.00041	0.16	0.14	Blood metabolite levels;	chr10:95663951	chr10:95753206~96090238:-
BRCA	cis	rs7671261	0.638	rs6846010	ENSG00000270720.1	RP11-84C13.2	4.61	4.63e-06	0.00041	0.17	0.14	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr4:89098936	chr4:89119284~89119871:+
BRCA	cis	rs7015630	0.738	rs11785163	ENSG00000251136.7	RP11-37B2.1	-4.61	4.63e-06	0.00041	-0.17	-0.14	Inflammatory bowel disease;Crohn's disease;	chr8:89857181	chr8:89609409~89757727:-
BRCA	cis	rs7682317	0.797	rs6852928	ENSG00000270720.1	RP11-84C13.2	-4.61	4.63e-06	0.00041	-0.15	-0.14	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr4:89005042	chr4:89119284~89119871:+
BRCA	cis	rs1434579	0.572	rs926052	ENSG00000176761.7	ZNF285B	-4.61	4.63e-06	0.00041	-0.16	-0.14	Tuberculosis;	chr19:44448048	chr19:44467641~44473227:+
BRCA	cis	rs13160562	0.527	rs27581	ENSG00000248734.2	CTD-2260A17.1	4.61	4.63e-06	0.00041	0.15	0.14	Alcohol dependence;	chr5:96772070	chr5:96784777~96785999:+
BRCA	cis	rs7914558	0.621	rs7896290	ENSG00000213061.2	PFN1P11	4.61	4.63e-06	0.00041	0.2	0.14	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102896258	chr10:102838011~102845473:-
BRCA	cis	rs1371614	0.523	rs4233714	ENSG00000229122.1	AGBL5-IT1	-4.61	4.63e-06	0.00041	-0.15	-0.14	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26958586	chr2:27061038~27061815:+
BRCA	cis	rs10266483	0.739	rs2692099	ENSG00000227986.1	TRIM60P18	-4.61	4.63e-06	0.00041	-0.15	-0.14	Response to statin therapy;	chr7:64307384	chr7:64355078~64356199:+
BRCA	cis	rs1707322	0.963	rs10789478	ENSG00000234329.1	RP11-767N6.2	4.6	4.64e-06	0.000411	0.15	0.14	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45884834	chr1:45651039~45651826:-
BRCA	cis	rs859767	0.501	rs10928507	ENSG00000224043.6	CCNT2-AS1	-4.6	4.64e-06	0.000411	-0.19	-0.14	Neuroticism;	chr2:134639061	chr2:134735464~134918710:-
BRCA	cis	rs7726839	0.54	rs4957080	ENSG00000271781.1	CTD-2589H19.6	4.6	4.64e-06	0.000411	0.2	0.14	Obesity-related traits;	chr5:644437	chr5:675826~676616:+
BRCA	cis	rs7267979	0.932	rs6138600	ENSG00000125804.12	FAM182A	-4.6	4.64e-06	0.000411	-0.18	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25540710	chr20:26054655~26086917:+
BRCA	cis	rs3768617	0.51	rs1413390	ENSG00000224468.3	RP11-181K3.4	-4.6	4.64e-06	0.000411	-0.15	-0.14	Fuchs's corneal dystrophy;	chr1:183127499	chr1:183138402~183141282:-
BRCA	cis	rs3768617	0.51	rs1413389	ENSG00000224468.3	RP11-181K3.4	-4.6	4.64e-06	0.000411	-0.15	-0.14	Fuchs's corneal dystrophy;	chr1:183127533	chr1:183138402~183141282:-
BRCA	cis	rs3768617	0.51	rs1413388	ENSG00000224468.3	RP11-181K3.4	-4.6	4.64e-06	0.000411	-0.15	-0.14	Fuchs's corneal dystrophy;	chr1:183127559	chr1:183138402~183141282:-
BRCA	cis	rs3768617	0.51	rs10797851	ENSG00000224468.3	RP11-181K3.4	-4.6	4.64e-06	0.000411	-0.15	-0.14	Fuchs's corneal dystrophy;	chr1:183128866	chr1:183138402~183141282:-
BRCA	cis	rs3768617	0.528	rs10737242	ENSG00000224468.3	RP11-181K3.4	-4.6	4.64e-06	0.000411	-0.15	-0.14	Fuchs's corneal dystrophy;	chr1:183129114	chr1:183138402~183141282:-
BRCA	cis	rs10752881	0.743	rs10737244	ENSG00000224468.3	RP11-181K3.4	-4.6	4.64e-06	0.000411	-0.15	-0.14	Colorectal cancer;	chr1:183129282	chr1:183138402~183141282:-
BRCA	cis	rs3770081	1	rs78032828	ENSG00000273080.1	RP11-301O19.1	-4.6	4.65e-06	0.000411	-0.32	-0.14	Facial emotion recognition (sad faces);	chr2:86081909	chr2:86195590~86196049:+
BRCA	cis	rs11603691	1	rs117981067	ENSG00000254662.1	RP11-872D17.4	-4.6	4.65e-06	0.000411	-0.34	-0.14	Low high density lipoprotein cholesterol levels;	chr11:57296638	chr11:57325603~57327958:+
BRCA	cis	rs875971	0.545	rs6460276	ENSG00000273142.1	RP11-458F8.4	4.6	4.65e-06	0.000411	0.14	0.14	Aortic root size;	chr7:66182290	chr7:66902857~66906297:+
BRCA	cis	rs7267979	1	rs6050632	ENSG00000125804.12	FAM182A	-4.6	4.65e-06	0.000412	-0.18	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25451965	chr20:26054655~26086917:+
BRCA	cis	rs4835473	0.9	rs13101531	ENSG00000249741.2	RP11-673E1.3	4.6	4.65e-06	0.000412	0.16	0.14	Immature fraction of reticulocytes;	chr4:143982197	chr4:143911514~143912053:-
BRCA	cis	rs7267979	0.509	rs6115218	ENSG00000230772.1	VN1R108P	4.6	4.65e-06	0.000412	0.17	0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25585849	chr20:25734264~25735093:+
BRCA	cis	rs79387448	0.638	rs7600961	ENSG00000234389.1	AC007278.3	4.6	4.65e-06	0.000412	0.19	0.14	Gut microbiota (bacterial taxa);	chr2:102418995	chr2:102438713~102440475:+
BRCA	cis	rs13113518	0.966	rs1474271	ENSG00000249700.7	SRD5A3-AS1	4.6	4.65e-06	0.000412	0.18	0.14	Height;	chr4:55435912	chr4:55363971~55395847:-
BRCA	cis	rs7674212	0.57	rs6810571	ENSG00000251288.2	RP11-10L12.2	-4.6	4.65e-06	0.000412	-0.16	-0.14	Type 2 diabetes;	chr4:103165630	chr4:102751401~102752641:+
BRCA	cis	rs2273788	1	rs2273788	ENSG00000204173.9	LRRC37A5P	4.6	4.65e-06	0.000412	0.2	0.14	Monocyte count;	chr9:111586337	chr9:111602831~111631289:-
BRCA	cis	rs6570726	0.526	rs9403699	ENSG00000270638.1	RP3-466P17.1	4.6	4.65e-06	0.000412	0.16	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145409549	chr6:145735570~145737218:+
BRCA	cis	rs8180040	0.522	rs749512	ENSG00000276925.1	RP11-708J19.3	4.6	4.65e-06	0.000412	0.17	0.14	Colorectal cancer;	chr3:46994410	chr3:47469777~47469987:+
BRCA	cis	rs11098499	0.954	rs67265404	ENSG00000260091.1	RP11-33B1.4	-4.6	4.65e-06	0.000412	-0.13	-0.14	Corneal astigmatism;	chr4:119438115	chr4:119409333~119410233:+
BRCA	cis	rs3892630	0.612	rs10413282	ENSG00000267475.1	CTD-2538C1.2	-4.6	4.65e-06	0.000412	-0.19	-0.14	Red blood cell traits;	chr19:32691845	chr19:32687089~32691750:-
BRCA	cis	rs12497850	0.897	rs6795025	ENSG00000225399.4	RP11-3B7.1	4.6	4.65e-06	0.000412	0.14	0.14	Parkinson's disease;	chr3:49043814	chr3:49260085~49261316:+
BRCA	cis	rs6565180	0.926	rs4787643	ENSG00000261332.1	RP11-297C4.1	4.6	4.66e-06	0.000412	0.19	0.14	Tonsillectomy;	chr16:30382339	chr16:30498766~30499554:-
BRCA	cis	rs6565180	0.926	rs4788409	ENSG00000261332.1	RP11-297C4.1	4.6	4.66e-06	0.000412	0.19	0.14	Tonsillectomy;	chr16:30382450	chr16:30498766~30499554:-
BRCA	cis	rs7267979	0.789	rs1983974	ENSG00000277938.1	RP5-965G21.3	-4.6	4.66e-06	0.000412	-0.17	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25549983	chr20:25229150~25231933:+
BRCA	cis	rs11098499	0.954	rs12508504	ENSG00000260091.1	RP11-33B1.4	-4.6	4.66e-06	0.000412	-0.13	-0.14	Corneal astigmatism;	chr4:119489452	chr4:119409333~119410233:+
BRCA	cis	rs2136613	0.728	rs10822062	ENSG00000238280.1	RP11-436D10.3	-4.6	4.66e-06	0.000412	-0.18	-0.14	Selective IgA deficiency;	chr10:62837761	chr10:62793562~62805887:-
BRCA	cis	rs7829975	0.742	rs1533058	ENSG00000173295.6	FAM86B3P	4.6	4.66e-06	0.000413	0.15	0.14	Mood instability;	chr8:8827680	chr8:8228595~8244865:+
BRCA	cis	rs6095360	0.934	rs6019582	ENSG00000222365.1	SNORD12B	-4.6	4.66e-06	0.000413	-0.15	-0.14	Intelligence (multi-trait analysis);	chr20:49011068	chr20:49280319~49280409:+
BRCA	cis	rs6545883	0.929	rs1186711	ENSG00000212978.6	AC016747.3	4.6	4.66e-06	0.000413	0.2	0.14	Tuberculosis;	chr2:61461370	chr2:61141592~61144969:-
BRCA	cis	rs17270561	0.943	rs4478398	ENSG00000272462.2	U91328.19	-4.6	4.66e-06	0.000413	-0.2	-0.14	Iron status biomarkers;	chr6:25694456	chr6:25992662~26001775:+
BRCA	cis	rs6832769	0.961	rs13152650	ENSG00000272969.1	RP11-528I4.2	4.6	4.66e-06	0.000413	0.17	0.14	Personality dimensions;	chr4:55491691	chr4:55547112~55547889:+
BRCA	cis	rs1950832	0.723	rs6572104	ENSG00000258636.1	CTD-2298J14.2	-4.6	4.67e-06	0.000413	-0.16	-0.14	Urate levels in obese individuals;	chr14:41671064	chr14:41587861~41604856:-
BRCA	cis	rs6081541	1	rs3827976	ENSG00000179447.2	RP5-1027G4.3	-4.6	4.67e-06	0.000413	-0.19	-0.14	Psychosis (atypical);	chr20:19244211	chr20:19242302~19284596:-
BRCA	cis	rs2278702	0.943	rs77597614	ENSG00000259495.2	RP11-210M15.2	-4.6	4.67e-06	0.000413	-0.21	-0.14	Bipolar disorder;	chr15:80394618	chr15:80344853~80403575:-
BRCA	cis	rs17406451	1	rs6714067	ENSG00000234936.1	AC010883.5	-4.6	4.67e-06	0.000413	-0.14	-0.14	Mitochondrial DNA levels;	chr2:43405061	chr2:43229573~43233394:+
BRCA	cis	rs13326165	0.543	rs1769	ENSG00000243224.1	RP5-1157M23.2	-4.6	4.67e-06	0.000413	-0.22	-0.14	HDL cholesterol levels;HDL cholesterol;	chr3:52256534	chr3:52239258~52241097:+
BRCA	cis	rs6570726	0.935	rs384519	ENSG00000270638.1	RP3-466P17.1	4.6	4.67e-06	0.000413	0.16	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145524881	chr6:145735570~145737218:+
BRCA	cis	rs6840360	0.642	rs7657670	ENSG00000251603.1	RP11-164P12.4	-4.6	4.67e-06	0.000413	-0.13	-0.14	Intelligence (multi-trait analysis);	chr4:151432223	chr4:151667224~151670502:+
BRCA	cis	rs7200543	1	rs4500751	ENSG00000260735.1	RP11-72I8.1	-4.6	4.67e-06	0.000413	-0.16	-0.14	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15046354	chr16:15094411~15109197:+
BRCA	cis	rs2243480	0.711	rs2420172	ENSG00000275400.1	RP4-756H11.5	-4.6	4.67e-06	0.000413	-0.25	-0.14	Diabetic kidney disease;	chr7:66170354	chr7:66553805~66554199:-
BRCA	cis	rs10986311	0.832	rs10818951	ENSG00000227200.1	RP11-121A14.3	4.6	4.67e-06	0.000413	0.16	0.14	Vitiligo;	chr9:124368783	chr9:124262876~124265809:+
BRCA	cis	rs11098499	0.909	rs1546504	ENSG00000260404.2	RP11-384K6.6	4.6	4.67e-06	0.000413	0.13	0.14	Corneal astigmatism;	chr4:119320024	chr4:118591773~118633729:+
BRCA	cis	rs4699052	0.662	rs1996346	ENSG00000248740.4	RP11-328K4.1	4.6	4.67e-06	0.000413	0.16	0.14	Testicular germ cell tumor;	chr4:103329167	chr4:103256159~103453658:+
BRCA	cis	rs78545713	0.649	rs114015443	ENSG00000241549.7	GUSBP2	-4.6	4.67e-06	0.000414	-0.27	-0.14	Iron status biomarkers (total iron binding capacity);	chr6:26221751	chr6:26871484~26956554:-
BRCA	cis	rs78545713	0.649	rs77727979	ENSG00000241549.7	GUSBP2	-4.6	4.67e-06	0.000414	-0.27	-0.14	Iron status biomarkers (total iron binding capacity);	chr6:26221798	chr6:26871484~26956554:-
BRCA	cis	rs78545713	0.541	rs111465843	ENSG00000241549.7	GUSBP2	-4.6	4.67e-06	0.000414	-0.27	-0.14	Iron status biomarkers (total iron binding capacity);	chr6:26222595	chr6:26871484~26956554:-
BRCA	cis	rs78545713	0.649	rs113407109	ENSG00000241549.7	GUSBP2	-4.6	4.67e-06	0.000414	-0.27	-0.14	Iron status biomarkers (total iron binding capacity);	chr6:26224175	chr6:26871484~26956554:-
BRCA	cis	rs875971	0.545	rs316316	ENSG00000230295.1	RP11-458F8.2	-4.6	4.68e-06	0.000414	-0.13	-0.14	Aortic root size;	chr7:66149270	chr7:66880708~66882981:+
BRCA	cis	rs853679	0.76	rs2299029	ENSG00000280107.1	AL022393.9	-4.6	4.68e-06	0.000414	-0.23	-0.14	Depression;	chr6:28231053	chr6:28170845~28172521:+
BRCA	cis	rs62025270	0.632	rs55981798	ENSG00000259295.5	CSPG4P12	-4.6	4.68e-06	0.000414	-0.22	-0.14	Idiopathic pulmonary fibrosis;	chr15:85600869	chr15:85191438~85213905:+
BRCA	cis	rs62025270	0.576	rs17633959	ENSG00000259295.5	CSPG4P12	-4.6	4.68e-06	0.000414	-0.22	-0.14	Idiopathic pulmonary fibrosis;	chr15:85600950	chr15:85191438~85213905:+
BRCA	cis	rs17428076	0.793	rs3770449	ENSG00000228389.1	AC068039.4	-4.6	4.68e-06	0.000414	-0.21	-0.14	Myopia;	chr2:171835538	chr2:171773482~171775844:+
BRCA	cis	rs79387448	0.638	rs116055209	ENSG00000234389.1	AC007278.3	4.6	4.68e-06	0.000414	0.2	0.14	Gut microbiota (bacterial taxa);	chr2:102415729	chr2:102438713~102440475:+
BRCA	cis	rs4819052	0.851	rs7279011	ENSG00000184274.3	LINC00315	-4.6	4.68e-06	0.000414	-0.19	-0.14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45236080	chr21:45300245~45305257:-
BRCA	cis	rs4650994	0.967	rs4650998	ENSG00000273384.1	RP5-1098D14.1	4.6	4.68e-06	0.000414	0.17	0.14	HDL cholesterol;HDL cholesterol levels;	chr1:178562715	chr1:178651706~178652282:+
BRCA	cis	rs10129255	0.913	rs10140943	ENSG00000274576.2	IGHV2-70	4.6	4.68e-06	0.000415	0.13	0.14	Kawasaki disease;	chr14:106767441	chr14:106770577~106771020:-
BRCA	cis	rs17428076	0.836	rs3770455	ENSG00000228389.1	AC068039.4	-4.6	4.68e-06	0.000415	-0.2	-0.14	Myopia;	chr2:171811385	chr2:171773482~171775844:+
BRCA	cis	rs13113518	0.966	rs7677952	ENSG00000249700.7	SRD5A3-AS1	4.6	4.68e-06	0.000415	0.18	0.14	Height;	chr4:55425312	chr4:55363971~55395847:-
BRCA	cis	rs13113518	1	rs1047354	ENSG00000249700.7	SRD5A3-AS1	4.6	4.68e-06	0.000415	0.18	0.14	Height;	chr4:55429416	chr4:55363971~55395847:-
BRCA	cis	rs13113518	1	rs1056547	ENSG00000249700.7	SRD5A3-AS1	4.6	4.68e-06	0.000415	0.18	0.14	Height;	chr4:55430596	chr4:55363971~55395847:-
BRCA	cis	rs13113518	1	rs1056545	ENSG00000249700.7	SRD5A3-AS1	4.6	4.68e-06	0.000415	0.18	0.14	Height;	chr4:55430730	chr4:55363971~55395847:-
BRCA	cis	rs13113518	1	rs5863	ENSG00000249700.7	SRD5A3-AS1	4.6	4.68e-06	0.000415	0.18	0.14	Height;	chr4:55430740	chr4:55363971~55395847:-
BRCA	cis	rs13113518	0.966	rs6828570	ENSG00000249700.7	SRD5A3-AS1	4.6	4.68e-06	0.000415	0.18	0.14	Height;	chr4:55431595	chr4:55363971~55395847:-
BRCA	cis	rs2303319	0.504	rs16846050	ENSG00000227403.1	AC009299.3	-4.6	4.69e-06	0.000415	-0.34	-0.14	Cognitive function;	chr2:161707043	chr2:161244739~161249050:+
BRCA	cis	rs1816213	1	rs1996992	ENSG00000273466.1	RP11-548H3.1	4.6	4.69e-06	0.000415	0.27	0.14	Diastolic blood pressure;	chr2:218786626	chr2:218633256~218634014:-
BRCA	cis	rs6981523	0.553	rs11783045	ENSG00000154316.13	TDH	4.6	4.69e-06	0.000415	0.19	0.14	Neuroticism;	chr8:11198666	chr8:11339637~11368452:+
BRCA	cis	rs7246657	0.722	rs1564208	ENSG00000226686.6	LINC01535	-4.6	4.69e-06	0.000415	-0.21	-0.14	Coronary artery calcification;	chr19:37550319	chr19:37251912~37265535:+
BRCA	cis	rs6802315	0.74	rs9822005	ENSG00000272087.1	RP11-379F4.7	4.6	4.69e-06	0.000415	0.17	0.14	Periodontitis (CDC/AAP);	chr3:158794592	chr3:158693120~158693768:-
BRCA	cis	rs3213958	0.509	rs55650073	ENSG00000249274.1	PDLIM1P4	-4.6	4.69e-06	0.000415	-0.23	-0.14	Blood protein levels;	chr3:98900476	chr3:98782188~98783193:+
BRCA	cis	rs867371	0.614	rs1814739	ENSG00000259429.4	UBE2Q2P2	-4.6	4.69e-06	0.000415	-0.16	-0.14	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82234283	chr15:82355142~82420075:+
BRCA	cis	rs7772486	0.79	rs2265469	ENSG00000270638.1	RP3-466P17.1	4.6	4.69e-06	0.000415	0.16	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145897913	chr6:145735570~145737218:+
BRCA	cis	rs7772486	0.79	rs2265918	ENSG00000270638.1	RP3-466P17.1	4.6	4.69e-06	0.000415	0.16	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145898028	chr6:145735570~145737218:+
BRCA	cis	rs60843830	1	rs62114548	ENSG00000272342.1	RP13-539J13.1	4.6	4.69e-06	0.000415	0.18	0.14	Spherical equivalent (joint analysis main effects and education interaction);	chr2:274672	chr2:739588~740164:-
BRCA	cis	rs3768617	0.51	rs4651145	ENSG00000224468.3	RP11-181K3.4	-4.6	4.69e-06	0.000415	-0.15	-0.14	Fuchs's corneal dystrophy;	chr1:183129765	chr1:183138402~183141282:-
BRCA	cis	rs3768617	0.51	rs2296300	ENSG00000224468.3	RP11-181K3.4	-4.6	4.69e-06	0.000415	-0.15	-0.14	Fuchs's corneal dystrophy;	chr1:183130566	chr1:183138402~183141282:-
BRCA	cis	rs3768617	0.51	rs6691755	ENSG00000224468.3	RP11-181K3.4	-4.6	4.69e-06	0.000415	-0.15	-0.14	Fuchs's corneal dystrophy;	chr1:183130686	chr1:183138402~183141282:-
BRCA	cis	rs3768617	0.51	rs10752903	ENSG00000224468.3	RP11-181K3.4	-4.6	4.69e-06	0.000415	-0.15	-0.14	Fuchs's corneal dystrophy;	chr1:183131728	chr1:183138402~183141282:-
BRCA	cis	rs3768617	0.51	rs10737245	ENSG00000224468.3	RP11-181K3.4	-4.6	4.69e-06	0.000415	-0.15	-0.14	Fuchs's corneal dystrophy;	chr1:183131749	chr1:183138402~183141282:-
BRCA	cis	rs3768617	0.51	rs10752904	ENSG00000224468.3	RP11-181K3.4	-4.6	4.69e-06	0.000415	-0.15	-0.14	Fuchs's corneal dystrophy;	chr1:183131903	chr1:183138402~183141282:-
BRCA	cis	rs3768617	0.51	rs12061219	ENSG00000224468.3	RP11-181K3.4	-4.6	4.69e-06	0.000415	-0.15	-0.14	Fuchs's corneal dystrophy;	chr1:183132336	chr1:183138402~183141282:-
BRCA	cis	rs3768617	0.51	rs12095664	ENSG00000224468.3	RP11-181K3.4	-4.6	4.69e-06	0.000415	-0.15	-0.14	Fuchs's corneal dystrophy;	chr1:183132551	chr1:183138402~183141282:-
BRCA	cis	rs1722141	0.669	rs1722124	ENSG00000229628.1	AC073115.7	4.6	4.69e-06	0.000415	0.2	0.14	Sitting height ratio;	chr7:45987446	chr7:45990905~46000898:+
BRCA	cis	rs875971	1	rs697970	ENSG00000229180.5	GS1-124K5.11	-4.6	4.7e-06	0.000415	-0.12	-0.14	Aortic root size;	chr7:66095065	chr7:66526088~66542624:-
BRCA	cis	rs12477438	0.501	rs12619780	ENSG00000231822.1	AC019097.7	4.6	4.7e-06	0.000415	0.14	0.14	Chronic sinus infection;	chr2:99090844	chr2:99102018~99102752:+
BRCA	cis	rs4781563	0.913	rs2238462	ENSG00000242307.1	RPS26P52	-4.6	4.7e-06	0.000415	-0.17	-0.14	Bilirubin levels;	chr16:13921453	chr16:13922332~13922679:-
BRCA	cis	rs7811142	0.83	rs6975660	ENSG00000078319.8	PMS2P1	-4.6	4.7e-06	0.000416	-0.22	-0.14	Platelet count;	chr7:100377643	chr7:100320992~100341908:-
BRCA	cis	rs7811142	0.83	rs73401443	ENSG00000078319.8	PMS2P1	-4.6	4.7e-06	0.000416	-0.22	-0.14	Platelet count;	chr7:100379959	chr7:100320992~100341908:-
BRCA	cis	rs2731006	0.591	rs11181695	ENSG00000257114.2	RP11-25I15.3	-4.6	4.7e-06	0.000416	-0.21	-0.14	Panic disorder;	chr12:42815306	chr12:42692216~42717119:+
BRCA	cis	rs7267979	1	rs2387884	ENSG00000277938.1	RP5-965G21.3	-4.6	4.7e-06	0.000416	-0.17	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25398433	chr20:25229150~25231933:+
BRCA	cis	rs7226408	0.948	rs17567496	ENSG00000267707.2	RP11-95O2.5	4.6	4.7e-06	0.000416	0.23	0.14	Obesity-related traits;	chr18:36775616	chr18:37243776~37247506:+
BRCA	cis	rs904251	0.686	rs931649	ENSG00000204110.6	RP1-153P14.8	-4.6	4.7e-06	0.000416	-0.18	-0.14	Cognitive performance;	chr6:37498303	chr6:37507348~37535616:+
BRCA	cis	rs26949	0.681	rs40512	ENSG00000215032.2	GNL3LP1	4.6	4.71e-06	0.000416	0.18	0.14	Intelligence (multi-trait analysis);	chr5:60509640	chr5:60891935~60893577:-
BRCA	cis	rs13108904	0.56	rs11247994	ENSG00000253399.1	AC078852.2	-4.6	4.71e-06	0.000416	-0.17	-0.14	Obesity-related traits;	chr4:1349932	chr4:1358479~1359461:+
BRCA	cis	rs1223397	0.651	rs2496145	ENSG00000215022.6	RP1-257A7.4	4.6	4.71e-06	0.000416	0.17	0.14	Blood pressure;	chr6:13312061	chr6:13264861~13295586:-
BRCA	cis	rs2436845	0.627	rs1897787	ENSG00000253320.4	KB-1507C5.2	4.6	4.71e-06	0.000416	0.18	0.14	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102850195	chr8:102864300~102977876:+
BRCA	cis	rs7308116	0.53	rs11113578	ENSG00000274395.1	RP11-554D14.8	-4.6	4.71e-06	0.000416	-0.16	-0.14	Pelvic organ prolapse (moderate/severe);	chr12:107906609	chr12:107835541~107836555:-
BRCA	cis	rs4906332	0.811	rs2021965	ENSG00000244691.1	RPL10AP1	4.6	4.71e-06	0.000417	0.2	0.14	Coronary artery disease;	chr14:103530911	chr14:103412119~103412761:-
BRCA	cis	rs6723226	0.732	rs390480	ENSG00000276334.1	AL133243.1	-4.6	4.71e-06	0.000417	-0.18	-0.14	Intelligence (multi-trait analysis);	chr2:32285003	chr2:32521927~32523547:+
BRCA	cis	rs7914558	0.646	rs11191459	ENSG00000213061.2	PFN1P11	4.6	4.71e-06	0.000417	0.2	0.14	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102902361	chr10:102838011~102845473:-
BRCA	cis	rs7772486	0.875	rs863820	ENSG00000270638.1	RP3-466P17.1	-4.6	4.71e-06	0.000417	-0.16	-0.14	Lobe attachment (rater-scored or self-reported);	chr6:146026266	chr6:145735570~145737218:+
BRCA	cis	rs2832191	0.791	rs2832181	ENSG00000236056.1	GAPDHP14	4.6	4.71e-06	0.000417	0.15	0.14	Dental caries;	chr21:29109050	chr21:29222321~29223257:+
BRCA	cis	rs375066	0.967	rs8104290	ENSG00000267191.1	RP11-15A1.2	-4.6	4.71e-06	0.000417	-0.18	-0.14	Breast cancer;	chr19:43863186	chr19:43902001~43926545:+
BRCA	cis	rs10777288	0.561	rs1920784	ENSG00000258100.1	RP11-121E16.1	4.6	4.72e-06	0.000417	0.2	0.14	Pulmonary function (smoking interaction);	chr12:91026583	chr12:91362196~91368606:+
BRCA	cis	rs807029	0.577	rs11190786	ENSG00000236662.1	RP11-108L7.4	4.6	4.72e-06	0.000417	0.18	0.14	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100997685	chr10:100980507~100985614:-
BRCA	cis	rs807029	0.577	rs7902510	ENSG00000236662.1	RP11-108L7.4	4.6	4.72e-06	0.000417	0.18	0.14	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100998177	chr10:100980507~100985614:-
BRCA	cis	rs807029	0.577	rs7903239	ENSG00000236662.1	RP11-108L7.4	4.6	4.72e-06	0.000417	0.18	0.14	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100998580	chr10:100980507~100985614:-
BRCA	cis	rs1005277	0.579	rs1740735	ENSG00000099251.13	HSD17B7P2	4.6	4.72e-06	0.000417	0.16	0.14	Extrinsic epigenetic age acceleration;	chr10:38208849	chr10:38356380~38378505:+
BRCA	cis	rs7615952	0.932	rs13065725	ENSG00000241288.6	RP11-379B18.5	-4.6	4.72e-06	0.000417	-0.21	-0.14	Blood pressure (smoking interaction);	chr3:125913446	chr3:125827238~125916384:-
BRCA	cis	rs7819412	0.595	rs10503416	ENSG00000255046.1	RP11-297N6.4	-4.6	4.72e-06	0.000417	-0.17	-0.14	Triglycerides;	chr8:11130043	chr8:11797928~11802568:-
BRCA	cis	rs7267979	1	rs2500432	ENSG00000274414.1	RP5-965G21.4	-4.6	4.72e-06	0.000417	-0.17	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25309876	chr20:25239007~25245229:-
BRCA	cis	rs1048886	0.872	rs12525538	ENSG00000271967.1	RP11-134K13.4	-4.6	4.72e-06	0.000417	-0.2	-0.14	Type 2 diabetes;	chr6:70575198	chr6:70596438~70596980:+
BRCA	cis	rs1048886	0.872	rs34246525	ENSG00000271967.1	RP11-134K13.4	-4.6	4.72e-06	0.000417	-0.2	-0.14	Type 2 diabetes;	chr6:70575239	chr6:70596438~70596980:+
BRCA	cis	rs2073316	0.588	rs9636426	ENSG00000272716.1	RP11-563N4.1	4.6	4.72e-06	0.000417	0.15	0.14	Interleukin-18 levels;	chr2:31488631	chr2:32165046~32165757:-
BRCA	cis	rs7246967	0.551	rs73022749	ENSG00000198153.8	ZNF849P	-4.6	4.72e-06	0.000418	-0.24	-0.14	Bronchopulmonary dysplasia;	chr19:22704458	chr19:22685167~22686732:+
BRCA	cis	rs34217772	1	rs34217772	ENSG00000258636.1	CTD-2298J14.2	4.6	4.72e-06	0.000418	0.19	0.14	Myopia;	chr14:41804367	chr14:41587861~41604856:-
BRCA	cis	rs859767	0.501	rs1568121	ENSG00000224043.6	CCNT2-AS1	4.6	4.73e-06	0.000418	0.19	0.14	Neuroticism;	chr2:134649036	chr2:134735464~134918710:-
BRCA	cis	rs859767	0.501	rs1568120	ENSG00000224043.6	CCNT2-AS1	4.6	4.73e-06	0.000418	0.19	0.14	Neuroticism;	chr2:134649320	chr2:134735464~134918710:-
BRCA	cis	rs859767	0.54	rs6739706	ENSG00000224043.6	CCNT2-AS1	4.6	4.73e-06	0.000418	0.19	0.14	Neuroticism;	chr2:134649839	chr2:134735464~134918710:-
BRCA	cis	rs7267979	0.764	rs2474767	ENSG00000204556.4	CTD-2514C3.1	-4.6	4.73e-06	0.000418	-0.19	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25266097	chr20:26018832~26020684:+
BRCA	cis	rs6545883	0.894	rs2694642	ENSG00000212978.6	AC016747.3	-4.6	4.73e-06	0.000418	-0.19	-0.14	Tuberculosis;	chr2:61369045	chr2:61141592~61144969:-
BRCA	cis	rs11158026	0.603	rs66820631	ENSG00000258413.1	RP11-665C16.6	-4.6	4.73e-06	0.000418	-0.19	-0.14	Parkinson's disease;	chr14:54998835	chr14:55262767~55272075:-
BRCA	cis	rs442309	0.783	rs224111	ENSG00000238280.1	RP11-436D10.3	4.6	4.73e-06	0.000418	0.19	0.14	Vogt-Koyanagi-Harada syndrome;	chr10:62792250	chr10:62793562~62805887:-
BRCA	cis	rs11158026	0.603	rs4335711	ENSG00000258413.1	RP11-665C16.6	-4.6	4.73e-06	0.000418	-0.19	-0.14	Parkinson's disease;	chr14:55004145	chr14:55262767~55272075:-
BRCA	cis	rs3812049	0.737	rs790155	ENSG00000245937.6	LINC01184	4.6	4.73e-06	0.000418	0.19	0.14	Lymphocyte counts;Red cell distribution width;	chr5:128162688	chr5:127940426~128083172:-
BRCA	cis	rs8127691	0.967	rs2838520	ENSG00000237604.1	AP001056.1	4.6	4.73e-06	0.000418	0.16	0.14	Inflammatory bowel disease;	chr21:44196013	chr21:44175489~44176453:+
BRCA	cis	rs4664293	0.967	rs13020365	ENSG00000226266.5	AC009961.3	-4.6	4.73e-06	0.000418	-0.17	-0.14	Monocyte percentage of white cells;	chr2:159619893	chr2:159670708~159712435:-
BRCA	cis	rs4664293	1	rs13014418	ENSG00000226266.5	AC009961.3	-4.6	4.73e-06	0.000418	-0.17	-0.14	Monocyte percentage of white cells;	chr2:159627174	chr2:159670708~159712435:-
BRCA	cis	rs7312933	0.533	rs17551006	ENSG00000257225.1	RP11-328C8.4	-4.6	4.73e-06	0.000418	-0.17	-0.14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42454936	chr12:42459366~42466128:+
BRCA	cis	rs6832769	0.922	rs60797008	ENSG00000223305.1	RN7SKP30	-4.6	4.73e-06	0.000418	-0.18	-0.14	Personality dimensions;	chr4:55522505	chr4:55540502~55540835:-
BRCA	cis	rs2280018	0.963	rs4985147	ENSG00000270580.4	PKD1P6	4.6	4.73e-06	0.000418	0.15	0.14	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15074903	chr16:15104723~15131601:-
BRCA	cis	rs2731006	0.543	rs908666	ENSG00000257114.2	RP11-25I15.3	4.6	4.73e-06	0.000418	0.21	0.14	Panic disorder;	chr12:42815567	chr12:42692216~42717119:+
BRCA	cis	rs2731006	0.591	rs11181697	ENSG00000257114.2	RP11-25I15.3	4.6	4.73e-06	0.000418	0.21	0.14	Panic disorder;	chr12:42816666	chr12:42692216~42717119:+
BRCA	cis	rs35146811	0.555	rs2527896	ENSG00000235713.1	RP4-604G5.3	4.6	4.74e-06	0.000419	0.17	0.14	Coronary artery disease;	chr7:99940030	chr7:99992397~99993050:+
BRCA	cis	rs287982	0.611	rs112561492	ENSG00000269973.1	RP11-95D17.1	-4.6	4.74e-06	0.000419	-0.23	-0.14	Nonsyndromic cleft lip with cleft palate;	chr2:9838991	chr2:9936360~9939590:+
BRCA	cis	rs56322409	0.897	rs11188504	ENSG00000226688.5	ENTPD1-AS1	4.6	4.74e-06	0.000419	0.16	0.14	Blood metabolite levels;	chr10:95846467	chr10:95753206~96090238:-
BRCA	cis	rs12477438	0.798	rs12468419	ENSG00000231822.1	AC019097.7	-4.6	4.74e-06	0.000419	-0.15	-0.14	Chronic sinus infection;	chr2:98963217	chr2:99102018~99102752:+
BRCA	cis	rs875971	1	rs6958484	ENSG00000236529.1	RP13-254B10.1	-4.6	4.74e-06	0.000419	-0.15	-0.14	Aortic root size;	chr7:66134459	chr7:65840212~65840596:+
BRCA	cis	rs9840812	0.691	rs1070232	ENSG00000273486.1	RP11-731C17.2	4.6	4.74e-06	0.000419	0.17	0.14	Fibrinogen levels;	chr3:136529245	chr3:136837338~136839021:-
BRCA	cis	rs2446066	0.872	rs10876455	ENSG00000257379.1	RP11-793H13.8	4.6	4.74e-06	0.000419	0.24	0.14	Red blood cell count;	chr12:53431541	chr12:53441741~53467528:+
BRCA	cis	rs6493858	0.868	rs2682059	ENSG00000277245.1	RP11-48G14.3	-4.6	4.74e-06	0.000419	-0.16	-0.14	Relative hand skill in reading disability;	chr15:56264752	chr15:56447120~56447697:+
BRCA	cis	rs7246967	0.551	rs12974117	ENSG00000198153.8	ZNF849P	-4.6	4.74e-06	0.000419	-0.24	-0.14	Bronchopulmonary dysplasia;	chr19:22685074	chr19:22685167~22686732:+
BRCA	cis	rs7267979	1	rs6050617	ENSG00000125804.12	FAM182A	-4.6	4.75e-06	0.000419	-0.18	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25441012	chr20:26054655~26086917:+
BRCA	cis	rs7267979	0.933	rs2387887	ENSG00000125804.12	FAM182A	-4.6	4.75e-06	0.000419	-0.18	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25446445	chr20:26054655~26086917:+
BRCA	cis	rs7267979	1	rs6037121	ENSG00000125804.12	FAM182A	-4.6	4.75e-06	0.000419	-0.18	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25447675	chr20:26054655~26086917:+
BRCA	cis	rs7267979	1	rs1047171	ENSG00000125804.12	FAM182A	-4.6	4.75e-06	0.000419	-0.18	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25448150	chr20:26054655~26086917:+
BRCA	cis	rs7267979	1	rs6050629	ENSG00000125804.12	FAM182A	-4.6	4.75e-06	0.000419	-0.18	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25450044	chr20:26054655~26086917:+
BRCA	cis	rs7267979	1	rs6050630	ENSG00000125804.12	FAM182A	-4.6	4.75e-06	0.000419	-0.18	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25450109	chr20:26054655~26086917:+
BRCA	cis	rs6088580	0.601	rs6059827	ENSG00000276073.1	RP5-1125A11.7	-4.6	4.75e-06	0.000419	-0.15	-0.14	Glomerular filtration rate (creatinine);	chr20:34428552	chr20:33985617~33988989:-
BRCA	cis	rs1395	0.778	rs724311	ENSG00000234072.1	AC074117.10	-4.6	4.75e-06	0.000419	-0.15	-0.14	Blood metabolite levels;	chr2:27218777	chr2:27356246~27367622:+
BRCA	cis	rs71520386	0.607	rs4308627	ENSG00000226329.2	AC005682.6	-4.6	4.75e-06	0.000419	-0.15	-0.14	Fibrinogen levels;	chr7:22840285	chr7:22863874~22881350:-
BRCA	cis	rs17684571	0.7	rs62411366	ENSG00000231441.1	RP11-472M19.2	4.6	4.75e-06	0.00042	0.24	0.14	Schizophrenia;	chr6:56773015	chr6:56844002~56864078:+
BRCA	cis	rs1371614	0.611	rs4665922	ENSG00000272148.1	RP11-195B17.1	-4.6	4.75e-06	0.00042	-0.16	-0.14	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26911066	chr2:27062428~27062907:-
BRCA	cis	rs12744310	1	rs55707527	ENSG00000235358.1	RP11-399E6.1	4.6	4.75e-06	0.00042	0.21	0.14	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41303441	chr1:41242373~41284861:+
BRCA	cis	rs5758511	0.68	rs5758682	ENSG00000226450.2	CYP2D8P	4.6	4.75e-06	0.00042	0.16	0.14	Birth weight;	chr22:42249196	chr22:42149886~42155001:-
BRCA	cis	rs7267979	0.74	rs2259961	ENSG00000274414.1	RP5-965G21.4	-4.6	4.75e-06	0.00042	-0.17	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25301990	chr20:25239007~25245229:-
BRCA	cis	rs3768617	0.51	rs20557	ENSG00000224468.3	RP11-181K3.4	-4.6	4.75e-06	0.00042	-0.15	-0.14	Fuchs's corneal dystrophy;	chr1:183124740	chr1:183138402~183141282:-
BRCA	cis	rs10911251	0.528	rs2093982	ENSG00000224468.3	RP11-181K3.4	-4.6	4.75e-06	0.00042	-0.15	-0.14	Colorectal cancer;	chr1:183125056	chr1:183138402~183141282:-
BRCA	cis	rs10752881	0.839	rs2093983	ENSG00000224468.3	RP11-181K3.4	-4.6	4.75e-06	0.00042	-0.15	-0.14	Colorectal cancer;	chr1:183125075	chr1:183138402~183141282:-
BRCA	cis	rs3768617	0.51	rs20558	ENSG00000224468.3	RP11-181K3.4	-4.6	4.75e-06	0.00042	-0.15	-0.14	Fuchs's corneal dystrophy;	chr1:183125412	chr1:183138402~183141282:-
BRCA	cis	rs3768617	0.51	rs1886499	ENSG00000224468.3	RP11-181K3.4	-4.6	4.75e-06	0.00042	-0.15	-0.14	Fuchs's corneal dystrophy;	chr1:183125889	chr1:183138402~183141282:-
BRCA	cis	rs3768617	0.51	rs1886500	ENSG00000224468.3	RP11-181K3.4	-4.6	4.75e-06	0.00042	-0.15	-0.14	Fuchs's corneal dystrophy;	chr1:183125913	chr1:183138402~183141282:-
BRCA	cis	rs3768617	0.51	rs1886501	ENSG00000224468.3	RP11-181K3.4	-4.6	4.75e-06	0.00042	-0.15	-0.14	Fuchs's corneal dystrophy;	chr1:183126099	chr1:183138402~183141282:-
BRCA	cis	rs3768617	0.51	rs2296293	ENSG00000224468.3	RP11-181K3.4	-4.6	4.75e-06	0.00042	-0.15	-0.14	Fuchs's corneal dystrophy;	chr1:183126342	chr1:183138402~183141282:-
BRCA	cis	rs3768617	0.51	rs2296294	ENSG00000224468.3	RP11-181K3.4	-4.6	4.75e-06	0.00042	-0.15	-0.14	Fuchs's corneal dystrophy;	chr1:183126461	chr1:183138402~183141282:-
BRCA	cis	rs3768617	0.51	rs2224933	ENSG00000224468.3	RP11-181K3.4	-4.6	4.75e-06	0.00042	-0.15	-0.14	Fuchs's corneal dystrophy;	chr1:183126630	chr1:183138402~183141282:-
BRCA	cis	rs1075265	0.73	rs805391	ENSG00000235937.1	AC008280.1	-4.6	4.75e-06	0.00042	-0.15	-0.14	Chronotype;Morning vs. evening chronotype;	chr2:53877181	chr2:54029552~54030682:-
BRCA	cis	rs854765	0.52	rs9899355	ENSG00000281749.1	Y_RNA	4.6	4.75e-06	0.00042	0.16	0.14	Total body bone mineral density;	chr17:17994929	chr17:18001101~18001195:-
BRCA	cis	rs5167	0.504	rs3760627	ENSG00000280087.1	CTB-129P6.7	4.6	4.75e-06	0.00042	0.17	0.14	Blood protein levels;	chr19:44953923	chr19:44909375~44914968:+
BRCA	cis	rs4722166	0.695	rs6946509	ENSG00000225541.1	AC002480.5	-4.6	4.76e-06	0.00042	-0.14	-0.14	Lung cancer;	chr7:22769871	chr7:22571607~22661792:-
BRCA	cis	rs13108904	0.935	rs1732100	ENSG00000196810.4	CTBP1-AS2	-4.6	4.76e-06	0.00042	-0.15	-0.14	Obesity-related traits;	chr4:1287973	chr4:1249300~1288291:+
BRCA	cis	rs6545883	0.894	rs12622458	ENSG00000212978.6	AC016747.3	-4.6	4.76e-06	0.00042	-0.19	-0.14	Tuberculosis;	chr2:61296419	chr2:61141592~61144969:-
BRCA	cis	rs7267979	0.549	rs6138536	ENSG00000276952.1	RP5-965G21.6	4.6	4.76e-06	0.00042	0.18	0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25202012	chr20:25284915~25285588:-
BRCA	cis	rs2179367	0.553	rs7762222	ENSG00000268592.3	RAET1E-AS1	4.6	4.76e-06	0.00042	0.21	0.14	Dupuytren's disease;	chr6:149444846	chr6:149863494~149919507:+
BRCA	cis	rs9788721	0.63	rs77681598	ENSG00000279373.1	RP11-650L12.4	-4.6	4.76e-06	0.00042	-0.17	-0.14	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78613761	chr15:78537681~78538946:+
BRCA	cis	rs4578769	0.681	rs6507455	ENSG00000265939.1	UBE2CP2	4.6	4.76e-06	0.000421	0.18	0.14	Eosinophil percentage of white cells;	chr18:23032669	chr18:22900486~22900995:-
BRCA	cis	rs287982	0.611	rs111493633	ENSG00000269973.1	RP11-95D17.1	-4.6	4.76e-06	0.000421	-0.24	-0.14	Nonsyndromic cleft lip with cleft palate;	chr2:9840033	chr2:9936360~9939590:+
BRCA	cis	rs6095360	1	rs6019573	ENSG00000222365.1	SNORD12B	-4.6	4.76e-06	0.000421	-0.16	-0.14	Intelligence (multi-trait analysis);	chr20:48986295	chr20:49280319~49280409:+
BRCA	cis	rs12744310	0.887	rs12728217	ENSG00000235358.1	RP11-399E6.1	4.6	4.77e-06	0.000421	0.21	0.14	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41332597	chr1:41242373~41284861:+
BRCA	cis	rs4588572	0.644	rs1428864	ENSG00000245556.2	SCAMP1-AS1	-4.6	4.77e-06	0.000421	-0.16	-0.14	Triglycerides;	chr5:78484440	chr5:78342365~78360507:-
BRCA	cis	rs13113518	1	rs11133381	ENSG00000273257.1	RP11-177J6.1	4.6	4.77e-06	0.000421	0.18	0.14	Height;	chr4:55450812	chr4:55387949~55388271:+
BRCA	cis	rs13113518	1	rs4864995	ENSG00000273257.1	RP11-177J6.1	4.6	4.77e-06	0.000421	0.18	0.14	Height;	chr4:55452853	chr4:55387949~55388271:+
BRCA	cis	rs2243480	1	rs465359	ENSG00000222364.1	RNU6-96P	-4.6	4.77e-06	0.000421	-0.26	-0.14	Diabetic kidney disease;	chr7:66093177	chr7:66395191~66395286:+
BRCA	cis	rs2243480	1	rs462853	ENSG00000222364.1	RNU6-96P	-4.6	4.77e-06	0.000421	-0.26	-0.14	Diabetic kidney disease;	chr7:66093180	chr7:66395191~66395286:+
BRCA	cis	rs2243480	1	rs160644	ENSG00000222364.1	RNU6-96P	-4.6	4.77e-06	0.000421	-0.26	-0.14	Diabetic kidney disease;	chr7:66093199	chr7:66395191~66395286:+
BRCA	cis	rs2243480	1	rs160642	ENSG00000222364.1	RNU6-96P	-4.6	4.77e-06	0.000421	-0.26	-0.14	Diabetic kidney disease;	chr7:66093386	chr7:66395191~66395286:+
BRCA	cis	rs2243480	0.614	rs34032527	ENSG00000222364.1	RNU6-96P	-4.6	4.77e-06	0.000421	-0.26	-0.14	Diabetic kidney disease;	chr7:66100154	chr7:66395191~66395286:+
BRCA	cis	rs7824557	0.592	rs2572371	ENSG00000154316.13	TDH	-4.6	4.77e-06	0.000421	-0.17	-0.14	Retinal vascular caliber;	chr8:11366284	chr8:11339637~11368452:+
BRCA	cis	rs117785887	0.536	rs3811105	ENSG00000270638.1	RP3-466P17.1	4.6	4.77e-06	0.000421	0.26	0.14	Interleukin-17 levels;	chr6:146028615	chr6:145735570~145737218:+
BRCA	cis	rs1008375	0.932	rs6841784	ENSG00000249502.1	AC006160.5	-4.6	4.77e-06	0.000421	-0.17	-0.14	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17624795	chr4:17587467~17614571:-
BRCA	cis	rs10792665	0.724	rs10898071	ENSG00000246067.6	RAB30-AS1	-4.6	4.77e-06	0.000421	-0.15	-0.14	Obesity-related traits;	chr11:83016849	chr11:83072066~83106719:+
BRCA	cis	rs6570726	0.935	rs446242	ENSG00000270638.1	RP3-466P17.1	4.6	4.77e-06	0.000421	0.16	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145522730	chr6:145735570~145737218:+
BRCA	cis	rs1499614	1	rs2659913	ENSG00000275400.1	RP4-756H11.5	4.6	4.77e-06	0.000421	0.26	0.14	Gout;	chr7:66692349	chr7:66553805~66554199:-
BRCA	cis	rs1499614	1	rs2659911	ENSG00000275400.1	RP4-756H11.5	4.6	4.77e-06	0.000421	0.26	0.14	Gout;	chr7:66693433	chr7:66553805~66554199:-
BRCA	cis	rs1499614	1	rs2707838	ENSG00000275400.1	RP4-756H11.5	4.6	4.77e-06	0.000421	0.26	0.14	Gout;	chr7:66694214	chr7:66553805~66554199:-
BRCA	cis	rs1499614	1	rs60326618	ENSG00000275400.1	RP4-756H11.5	4.6	4.77e-06	0.000421	0.26	0.14	Gout;	chr7:66701371	chr7:66553805~66554199:-
BRCA	cis	rs1499614	1	rs2707830	ENSG00000275400.1	RP4-756H11.5	4.6	4.77e-06	0.000421	0.26	0.14	Gout;	chr7:66702658	chr7:66553805~66554199:-
BRCA	cis	rs1499614	1	rs2707828	ENSG00000275400.1	RP4-756H11.5	4.6	4.77e-06	0.000421	0.26	0.14	Gout;	chr7:66706390	chr7:66553805~66554199:-
BRCA	cis	rs1499614	0.803	rs1922723	ENSG00000275400.1	RP4-756H11.5	4.6	4.77e-06	0.000421	0.26	0.14	Gout;	chr7:66710076	chr7:66553805~66554199:-
BRCA	cis	rs9952991	0.941	rs1893217	ENSG00000260302.1	RP11-973H7.1	4.6	4.77e-06	0.000421	0.23	0.14	Inflammatory skin disease;	chr18:12809341	chr18:12774651~12775923:-
BRCA	cis	rs78487399	0.908	rs73925554	ENSG00000234936.1	AC010883.5	4.6	4.77e-06	0.000421	0.19	0.14	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43583600	chr2:43229573~43233394:+
BRCA	cis	rs12612619	0.732	rs11897106	ENSG00000272148.1	RP11-195B17.1	-4.6	4.77e-06	0.000422	-0.15	-0.14	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:26973431	chr2:27062428~27062907:-
BRCA	cis	rs13113518	1	rs3805148	ENSG00000249700.7	SRD5A3-AS1	4.6	4.78e-06	0.000422	0.18	0.14	Height;	chr4:55440643	chr4:55363971~55395847:-
BRCA	cis	rs13113518	1	rs11133380	ENSG00000249700.7	SRD5A3-AS1	4.6	4.78e-06	0.000422	0.18	0.14	Height;	chr4:55441110	chr4:55363971~55395847:-
BRCA	cis	rs13113518	1	rs12510110	ENSG00000249700.7	SRD5A3-AS1	4.6	4.78e-06	0.000422	0.18	0.14	Height;	chr4:55441567	chr4:55363971~55395847:-
BRCA	cis	rs13113518	0.966	rs12510990	ENSG00000249700.7	SRD5A3-AS1	4.6	4.78e-06	0.000422	0.18	0.14	Height;	chr4:55441907	chr4:55363971~55395847:-
BRCA	cis	rs6095360	1	rs6019602	ENSG00000222365.1	SNORD12B	-4.6	4.78e-06	0.000422	-0.15	-0.14	Intelligence (multi-trait analysis);	chr20:49034955	chr20:49280319~49280409:+
BRCA	cis	rs6095360	1	rs707533	ENSG00000222365.1	SNORD12B	-4.6	4.78e-06	0.000422	-0.15	-0.14	Intelligence (multi-trait analysis);	chr20:49035717	chr20:49280319~49280409:+
BRCA	cis	rs6095360	1	rs707534	ENSG00000222365.1	SNORD12B	-4.6	4.78e-06	0.000422	-0.15	-0.14	Intelligence (multi-trait analysis);	chr20:49035801	chr20:49280319~49280409:+
BRCA	cis	rs6095360	0.901	rs16994347	ENSG00000222365.1	SNORD12B	-4.6	4.78e-06	0.000422	-0.15	-0.14	Intelligence (multi-trait analysis);	chr20:49036824	chr20:49280319~49280409:+
BRCA	cis	rs6095360	1	rs6019603	ENSG00000222365.1	SNORD12B	-4.6	4.78e-06	0.000422	-0.15	-0.14	Intelligence (multi-trait analysis);	chr20:49036869	chr20:49280319~49280409:+
BRCA	cis	rs2562456	0.833	rs55920089	ENSG00000268658.4	LINC00664	4.6	4.78e-06	0.000422	0.23	0.14	Pain;	chr19:21337891	chr19:21483374~21503238:+
BRCA	cis	rs1867631	1	rs11208927	ENSG00000248458.2	RP4-598P13.1	4.6	4.78e-06	0.000422	0.15	0.14	Menopause (age at onset);	chr1:66623878	chr1:66665864~66677027:-
BRCA	cis	rs7267979	1	rs2424712	ENSG00000125804.12	FAM182A	-4.6	4.78e-06	0.000422	-0.18	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25436306	chr20:26054655~26086917:+
BRCA	cis	rs7267979	0.966	rs2424714	ENSG00000125804.12	FAM182A	-4.6	4.78e-06	0.000422	-0.18	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25438045	chr20:26054655~26086917:+
BRCA	cis	rs7267979	0.966	rs2424715	ENSG00000125804.12	FAM182A	-4.6	4.78e-06	0.000422	-0.18	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25439441	chr20:26054655~26086917:+
BRCA	cis	rs867186	1	rs7271729	ENSG00000126005.14	MMP24-AS1	-4.6	4.79e-06	0.000423	-0.27	-0.14	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35023189	chr20:35216462~35278131:-
BRCA	cis	rs12497850	0.931	rs4974080	ENSG00000225399.4	RP11-3B7.1	4.6	4.79e-06	0.000423	0.14	0.14	Parkinson's disease;	chr3:48993395	chr3:49260085~49261316:+
BRCA	cis	rs11638815	0.603	rs783520	ENSG00000259429.4	UBE2Q2P2	-4.6	4.79e-06	0.000423	-0.14	-0.14	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82610755	chr15:82355142~82420075:+
BRCA	cis	rs78487399	0.808	rs17031005	ENSG00000234936.1	AC010883.5	4.6	4.79e-06	0.000423	0.21	0.14	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43534160	chr2:43229573~43233394:+
BRCA	cis	rs4950322	0.58	rs2083720	ENSG00000237188.3	RP11-337C18.8	4.6	4.79e-06	0.000423	0.18	0.14	Protein quantitative trait loci;	chr1:147122296	chr1:147172771~147211568:+
BRCA	cis	rs7246967	0.611	rs67531478	ENSG00000198153.8	ZNF849P	-4.6	4.79e-06	0.000423	-0.24	-0.14	Bronchopulmonary dysplasia;	chr19:22706702	chr19:22685167~22686732:+
BRCA	cis	rs7481584	0.624	rs375579	ENSG00000247473.2	CARS-AS1	-4.6	4.79e-06	0.000423	-0.17	-0.14	Calcium levels;	chr11:3044070	chr11:3029009~3041260:+
BRCA	cis	rs7923837	1	rs11187144	ENSG00000236493.2	EIF2S2P3	4.6	4.79e-06	0.000423	0.19	0.14	Multiple sclerosis;Body mass index;	chr10:92710223	chr10:92668745~92669743:-
BRCA	cis	rs77204473	1	rs12418208	ENSG00000280143.1	AP000892.6	-4.6	4.79e-06	0.000423	-0.27	-0.14	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116916917	chr11:117204967~117210292:+
BRCA	cis	rs77204473	1	rs1006176	ENSG00000280143.1	AP000892.6	-4.6	4.79e-06	0.000423	-0.27	-0.14	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116917417	chr11:117204967~117210292:+
BRCA	cis	rs3845817	0.671	rs840785	ENSG00000237979.1	AC007389.1	4.6	4.8e-06	0.000423	0.17	0.14	Bipolar disorder;	chr2:65541842	chr2:65500993~65502138:-
BRCA	cis	rs4781563	0.778	rs3136130	ENSG00000242307.1	RPS26P52	-4.6	4.8e-06	0.000423	-0.16	-0.14	Bilirubin levels;	chr16:13933094	chr16:13922332~13922679:-
BRCA	cis	rs11098499	0.954	rs10006525	ENSG00000260091.1	RP11-33B1.4	-4.6	4.8e-06	0.000423	-0.13	-0.14	Corneal astigmatism;	chr4:119487776	chr4:119409333~119410233:+
BRCA	cis	rs6545883	0.791	rs2600665	ENSG00000270820.4	RP11-355B11.2	4.6	4.8e-06	0.000423	0.16	0.14	Tuberculosis;	chr2:61178660	chr2:61471188~61484130:+
BRCA	cis	rs13113518	1	rs13115828	ENSG00000249700.7	SRD5A3-AS1	4.6	4.8e-06	0.000423	0.18	0.14	Height;	chr4:55551447	chr4:55363971~55395847:-
BRCA	cis	rs13113518	1	rs13136282	ENSG00000249700.7	SRD5A3-AS1	4.6	4.8e-06	0.000423	0.18	0.14	Height;	chr4:55551845	chr4:55363971~55395847:-
BRCA	cis	rs7267979	1	rs6076345	ENSG00000277938.1	RP5-965G21.3	-4.6	4.8e-06	0.000423	-0.17	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25401259	chr20:25229150~25231933:+
BRCA	cis	rs2446066	0.872	rs2071558	ENSG00000257379.1	RP11-793H13.8	4.6	4.8e-06	0.000424	0.22	0.14	Red blood cell count;	chr12:53425683	chr12:53441741~53467528:+
BRCA	cis	rs1707322	1	rs10789479	ENSG00000234329.1	RP11-767N6.2	4.6	4.8e-06	0.000424	0.15	0.14	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45886828	chr1:45651039~45651826:-
BRCA	cis	rs926392	0.896	rs1569538	ENSG00000274825.1	RP4-616B8.5	4.6	4.8e-06	0.000424	0.13	0.14	Dialysis-related mortality;	chr20:39056573	chr20:38955910~38956547:+
BRCA	cis	rs2243480	1	rs160633	ENSG00000275400.1	RP4-756H11.5	4.6	4.81e-06	0.000424	0.27	0.14	Diabetic kidney disease;	chr7:66063241	chr7:66553805~66554199:-
BRCA	cis	rs6430585	0.583	rs4594504	ENSG00000231890.6	DARS-AS1	-4.6	4.81e-06	0.000424	-0.22	-0.14	Corneal structure;	chr2:135867543	chr2:135985176~136022593:+
BRCA	cis	rs7772486	0.754	rs2328709	ENSG00000270638.1	RP3-466P17.1	-4.6	4.81e-06	0.000424	-0.16	-0.14	Lobe attachment (rater-scored or self-reported);	chr6:145785683	chr6:145735570~145737218:+
BRCA	cis	rs1153858	0.943	rs28605551	ENSG00000275672.1	GATM-AS1	-4.6	4.81e-06	0.000424	-0.18	-0.14	Homoarginine levels;	chr15:45349522	chr15:45378700~45380123:+
BRCA	cis	rs4218	0.648	rs57361749	ENSG00000277144.1	RP11-59H7.4	-4.6	4.81e-06	0.000424	-0.19	-0.14	Social communication problems;	chr15:59091352	chr15:59115547~59116089:-
BRCA	cis	rs116095464	0.558	rs56081398	ENSG00000248925.1	CTD-2083E4.6	4.6	4.81e-06	0.000424	0.28	0.14	Breast cancer;	chr5:247203	chr5:269858~271516:-
BRCA	cis	rs12497850	0.543	rs6446218	ENSG00000225399.4	RP11-3B7.1	4.6	4.81e-06	0.000425	0.14	0.14	Parkinson's disease;	chr3:49038080	chr3:49260085~49261316:+
BRCA	cis	rs57221529	0.766	rs4081846	ENSG00000225138.6	CTD-2228K2.7	4.6	4.81e-06	0.000425	0.21	0.14	Lung disease severity in cystic fibrosis;	chr5:573904	chr5:473236~480884:+
BRCA	cis	rs4698412	0.561	rs6848779	ENSG00000214846.4	RP11-115L11.1	4.6	4.81e-06	0.000425	0.17	0.14	Parkinson's disease;	chr4:15693874	chr4:15730962~15731627:-
BRCA	cis	rs6430585	0.591	rs1374330	ENSG00000231890.6	DARS-AS1	-4.6	4.81e-06	0.000425	-0.24	-0.14	Corneal structure;	chr2:135663338	chr2:135985176~136022593:+
BRCA	cis	rs6832769	0.961	rs2412646	ENSG00000272969.1	RP11-528I4.2	4.6	4.81e-06	0.000425	0.17	0.14	Personality dimensions;	chr4:55452605	chr4:55547112~55547889:+
BRCA	cis	rs7243790	0.805	rs12458588	ENSG00000277324.1	RP11-850A17.1	-4.6	4.82e-06	0.000425	-0.16	-0.14	Diastolic blood pressure;	chr18:54377323	chr18:54268346~54270028:-
BRCA	cis	rs2562456	0.52	rs279793	ENSG00000240522.1	RPL7AP10	-4.6	4.82e-06	0.000425	-0.18	-0.14	Pain;	chr19:21272972	chr19:21149648~21150438:-
BRCA	cis	rs4664293	0.805	rs7593273	ENSG00000226266.5	AC009961.3	-4.6	4.82e-06	0.000425	-0.18	-0.14	Monocyte percentage of white cells;	chr2:159749349	chr2:159670708~159712435:-
BRCA	cis	rs7246657	0.678	rs2972446	ENSG00000226686.6	LINC01535	4.6	4.82e-06	0.000425	0.21	0.14	Coronary artery calcification;	chr19:37638992	chr19:37251912~37265535:+
BRCA	cis	rs6095360	1	rs348276	ENSG00000222365.1	SNORD12B	-4.6	4.82e-06	0.000425	-0.16	-0.14	Intelligence (multi-trait analysis);	chr20:49169653	chr20:49280319~49280409:+
BRCA	cis	rs875971	1	rs6946143	ENSG00000223473.2	GS1-124K5.3	4.6	4.82e-06	0.000425	0.11	0.14	Aortic root size;	chr7:66114735	chr7:66491049~66493566:-
BRCA	cis	rs6847067	0.763	rs56194765	ENSG00000180769.7	WDFY3-AS2	4.6	4.82e-06	0.000425	0.13	0.14	Oropharynx cancer;	chr4:85004309	chr4:84965682~85011277:+
BRCA	cis	rs78545713	0.649	rs79662647	ENSG00000241549.7	GUSBP2	-4.6	4.82e-06	0.000425	-0.27	-0.14	Iron status biomarkers (total iron binding capacity);	chr6:26217617	chr6:26871484~26956554:-
BRCA	cis	rs6430538	0.621	rs6725916	ENSG00000224043.6	CCNT2-AS1	-4.6	4.82e-06	0.000426	-0.2	-0.14	Parkinson's disease;	chr2:134806488	chr2:134735464~134918710:-
BRCA	cis	rs8114671	0.836	rs62213676	ENSG00000279253.1	RP4-614O4.13	4.6	4.83e-06	0.000426	0.16	0.14	Height;	chr20:35024873	chr20:35262727~35264187:-
BRCA	cis	rs739401	0.595	rs2237903	ENSG00000183562.3	CTC-343N3.1	-4.6	4.83e-06	0.000426	-0.15	-0.14	Longevity;	chr11:2946671	chr11:2989863~2991344:+
BRCA	cis	rs651907	0.557	rs3094296	ENSG00000256628.3	ZBTB11-AS1	4.6	4.83e-06	0.000426	0.18	0.14	Colorectal cancer;	chr3:101681323	chr3:101676475~101679217:+
BRCA	cis	rs1552244	0.572	rs67227131	ENSG00000180385.7	EMC3-AS1	4.6	4.83e-06	0.000426	0.22	0.14	Alzheimer's disease;	chr3:10131060	chr3:9986893~10006990:+
BRCA	cis	rs17597773	0.638	rs7544735	ENSG00000238078.1	LINC01352	4.6	4.83e-06	0.000426	0.17	0.14	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220825571	chr1:220829255~220832429:+
BRCA	cis	rs7267979	1	rs6083828	ENSG00000277938.1	RP5-965G21.3	-4.6	4.83e-06	0.000426	-0.17	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25389282	chr20:25229150~25231933:+
BRCA	cis	rs2638953	0.672	rs11049713	ENSG00000247934.4	RP11-967K21.1	-4.6	4.83e-06	0.000426	-0.2	-0.14	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28558612	chr12:28163298~28190738:-
BRCA	cis	rs2243480	1	rs35432774	ENSG00000275400.1	RP4-756H11.5	4.6	4.83e-06	0.000426	0.25	0.14	Diabetic kidney disease;	chr7:65928032	chr7:66553805~66554199:-
BRCA	cis	rs6751744	1	rs6751744	ENSG00000224152.1	AC009506.1	-4.6	4.83e-06	0.000426	-0.17	-0.14	Dysphagia;	chr2:159550974	chr2:159615296~159617082:+
BRCA	cis	rs1223397	0.651	rs2439548	ENSG00000215022.6	RP1-257A7.4	-4.6	4.83e-06	0.000426	-0.17	-0.14	Blood pressure;	chr6:13314951	chr6:13264861~13295586:-
BRCA	cis	rs300890	0.717	rs300947	ENSG00000250326.1	RP11-284M14.1	-4.6	4.83e-06	0.000426	-0.16	-0.14	Nasopharyngeal carcinoma;	chr4:143288636	chr4:142933195~143184861:-
BRCA	cis	rs3120667	0.79	rs726863	ENSG00000237975.5	FLG-AS1	-4.6	4.84e-06	0.000426	-0.19	-0.14	Eating disorders;	chr1:152427885	chr1:152168125~152445456:+
BRCA	cis	rs9840812	0.861	rs645040	ENSG00000273486.1	RP11-731C17.2	-4.6	4.84e-06	0.000426	-0.18	-0.14	Fibrinogen levels;	chr3:136207780	chr3:136837338~136839021:-
BRCA	cis	rs67311347	1	rs112619360	ENSG00000280739.1	EIF1B-AS1	4.6	4.84e-06	0.000427	0.16	0.14	Renal cell carcinoma;	chr3:40391154	chr3:40173145~40309698:-
BRCA	cis	rs13034020	0.522	rs72809436	ENSG00000271889.1	RP11-493E12.1	-4.6	4.84e-06	0.000427	-0.24	-0.14	Hodgkin's lymphoma;	chr2:61024010	chr2:61151433~61162105:-
BRCA	cis	rs875971	0.545	rs13311962	ENSG00000232546.1	RP11-458F8.1	-4.6	4.84e-06	0.000427	-0.13	-0.14	Aortic root size;	chr7:66603142	chr7:66848496~66858136:+
BRCA	cis	rs41357746	0.525	rs57030473	ENSG00000260657.2	RP11-315D16.4	4.6	4.84e-06	0.000427	0.17	0.14	Total body bone mineral density;	chr15:67484340	chr15:68267792~68277994:-
BRCA	cis	rs4869313	0.687	rs2549778	ENSG00000248734.2	CTD-2260A17.1	-4.6	4.85e-06	0.000427	-0.15	-0.14	Pediatric autoimmune diseases;	chr5:96868551	chr5:96784777~96785999:+
BRCA	cis	rs925228	0.504	rs6755030	ENSG00000232642.1	AC008073.7	-4.6	4.85e-06	0.000427	-0.23	-0.14	Reticulocyte count;Reticulocyte fraction of red cells;	chr2:24095473	chr2:24165884~24175005:-
BRCA	cis	rs10208649	0.611	rs58851686	ENSG00000272156.1	RP11-477N3.1	4.6	4.85e-06	0.000427	0.25	0.14	Body mass index;	chr2:54057179	chr2:54082554~54085066:+
BRCA	cis	rs2243480	1	rs4149468	ENSG00000275400.1	RP4-756H11.5	4.6	4.85e-06	0.000427	0.26	0.14	Diabetic kidney disease;	chr7:66360703	chr7:66553805~66554199:-
BRCA	cis	rs7312933	0.558	rs11181422	ENSG00000257225.1	RP11-328C8.4	4.6	4.85e-06	0.000428	0.17	0.14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42324750	chr12:42459366~42466128:+
BRCA	cis	rs7312933	0.558	rs3747560	ENSG00000257225.1	RP11-328C8.4	4.6	4.85e-06	0.000428	0.17	0.14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42326088	chr12:42459366~42466128:+
BRCA	cis	rs7312933	0.531	rs2406674	ENSG00000257225.1	RP11-328C8.4	4.6	4.85e-06	0.000428	0.17	0.14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42326348	chr12:42459366~42466128:+
BRCA	cis	rs17597773	0.674	rs1494371	ENSG00000238078.1	LINC01352	-4.6	4.85e-06	0.000428	-0.16	-0.14	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220841256	chr1:220829255~220832429:+
BRCA	cis	rs11096990	0.656	rs6531709	ENSG00000249685.1	RP11-360F5.3	-4.6	4.85e-06	0.000428	-0.17	-0.14	Cognitive function;	chr4:39300629	chr4:39133913~39135608:+
BRCA	cis	rs2911132	0.564	rs731827	ENSG00000272109.1	CTD-2260A17.3	-4.6	4.85e-06	0.000428	-0.2	-0.14	Urate levels (BMI interaction);	chr5:96751311	chr5:96804353~96806105:+
BRCA	cis	rs4713118	0.911	rs2394000	ENSG00000216901.1	AL022393.7	4.6	4.85e-06	0.000428	0.19	0.14	Parkinson's disease;	chr6:27719212	chr6:28176188~28176674:+
BRCA	cis	rs4713118	0.955	rs9393847	ENSG00000216901.1	AL022393.7	4.6	4.85e-06	0.000428	0.19	0.14	Parkinson's disease;	chr6:27720194	chr6:28176188~28176674:+
BRCA	cis	rs6840360	0.642	rs2709817	ENSG00000251603.1	RP11-164P12.4	-4.6	4.86e-06	0.000428	-0.13	-0.14	Intelligence (multi-trait analysis);	chr4:151460898	chr4:151667224~151670502:+
BRCA	cis	rs6840360	0.642	rs2709818	ENSG00000251603.1	RP11-164P12.4	-4.6	4.86e-06	0.000428	-0.13	-0.14	Intelligence (multi-trait analysis);	chr4:151461482	chr4:151667224~151670502:+
BRCA	cis	rs2243480	1	rs937108	ENSG00000275400.1	RP4-756H11.5	4.59	4.86e-06	0.000428	0.25	0.14	Diabetic kidney disease;	chr7:65963465	chr7:66553805~66554199:-
BRCA	cis	rs2243480	1	rs316326	ENSG00000222364.1	RNU6-96P	-4.59	4.86e-06	0.000428	-0.26	-0.14	Diabetic kidney disease;	chr7:66144466	chr7:66395191~66395286:+
BRCA	cis	rs2243480	1	rs316325	ENSG00000222364.1	RNU6-96P	-4.59	4.86e-06	0.000428	-0.26	-0.14	Diabetic kidney disease;	chr7:66144531	chr7:66395191~66395286:+
BRCA	cis	rs6430585	0.583	rs60253740	ENSG00000231890.6	DARS-AS1	-4.59	4.86e-06	0.000428	-0.21	-0.14	Corneal structure;	chr2:135814282	chr2:135985176~136022593:+
BRCA	cis	rs1077773	0.7	rs7804230	ENSG00000237773.4	AC003075.4	-4.59	4.86e-06	0.000428	-0.18	-0.14	Ulcerative colitis;Inflammatory bowel disease;	chr7:17405884	chr7:17279834~17299357:-
BRCA	cis	rs7487075	0.93	rs4076248	ENSG00000272369.1	RP11-446N19.1	4.59	4.86e-06	0.000428	0.16	0.14	Itch intensity from mosquito bite;	chr12:46439822	chr12:46537502~46652550:+
BRCA	cis	rs7665090	0.967	rs6533022	ENSG00000251288.2	RP11-10L12.2	-4.59	4.86e-06	0.000428	-0.17	-0.14	Primary biliary cholangitis;	chr4:102637794	chr4:102751401~102752641:+
BRCA	cis	rs4713118	0.513	rs149962	ENSG00000219392.1	RP1-265C24.5	-4.59	4.86e-06	0.000428	-0.19	-0.14	Parkinson's disease;	chr6:28048140	chr6:28115628~28116551:+
BRCA	cis	rs172166	0.769	rs149965	ENSG00000219392.1	RP1-265C24.5	-4.59	4.86e-06	0.000428	-0.19	-0.14	Cardiac Troponin-T levels;	chr6:28050911	chr6:28115628~28116551:+
BRCA	cis	rs7811142	0.667	rs3873746	ENSG00000078319.8	PMS2P1	-4.59	4.86e-06	0.000429	-0.22	-0.14	Platelet count;	chr7:100337474	chr7:100320992~100341908:-
BRCA	cis	rs12264252	0.767	rs35998463	ENSG00000226659.1	RP11-137H2.4	4.59	4.86e-06	0.000429	0.21	0.14	Coronary artery disease;	chr10:80485754	chr10:80529597~80535942:-
BRCA	cis	rs1223397	0.651	rs2439545	ENSG00000215022.6	RP1-257A7.4	4.59	4.86e-06	0.000429	0.16	0.14	Blood pressure;	chr6:13313612	chr6:13264861~13295586:-
BRCA	cis	rs6832769	0.922	rs60797008	ENSG00000272969.1	RP11-528I4.2	-4.59	4.86e-06	0.000429	-0.17	-0.14	Personality dimensions;	chr4:55522505	chr4:55547112~55547889:+
BRCA	cis	rs6044112	0.56	rs6075083	ENSG00000273998.1	RP4-777L9.2	4.59	4.86e-06	0.000429	0.28	0.14	Response to taxane treatment (docetaxel);	chr20:16605097	chr20:16576068~16579615:+
BRCA	cis	rs7615952	0.551	rs6438945	ENSG00000241288.6	RP11-379B18.5	-4.59	4.86e-06	0.000429	-0.21	-0.14	Blood pressure (smoking interaction);	chr3:125915630	chr3:125827238~125916384:-
BRCA	cis	rs4819052	0.765	rs2838868	ENSG00000184274.3	LINC00315	4.59	4.87e-06	0.000429	0.2	0.14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45294726	chr21:45300245~45305257:-
BRCA	cis	rs6500602	0.964	rs13335685	ENSG00000280063.1	RP11-295D4.3	4.59	4.87e-06	0.000429	0.11	0.14	Schizophrenia;	chr16:4419283	chr16:4346694~4348648:-
BRCA	cis	rs13326165	0.543	rs77020200	ENSG00000243224.1	RP5-1157M23.2	-4.59	4.87e-06	0.000429	-0.23	-0.14	HDL cholesterol levels;HDL cholesterol;	chr3:52278960	chr3:52239258~52241097:+
BRCA	cis	rs1223397	0.651	rs449727	ENSG00000215022.6	RP1-257A7.4	-4.59	4.87e-06	0.000429	-0.17	-0.14	Blood pressure;	chr6:13296078	chr6:13264861~13295586:-
BRCA	cis	rs6832769	1	rs576779	ENSG00000223305.1	RN7SKP30	4.59	4.87e-06	0.000429	0.17	0.14	Personality dimensions;	chr4:55408140	chr4:55540502~55540835:-
BRCA	cis	rs6832769	0.961	rs480479	ENSG00000223305.1	RN7SKP30	4.59	4.87e-06	0.000429	0.17	0.14	Personality dimensions;	chr4:55408163	chr4:55540502~55540835:-
BRCA	cis	rs3768617	0.811	rs10911200	ENSG00000224468.3	RP11-181K3.4	-4.59	4.87e-06	0.000429	-0.16	-0.14	Fuchs's corneal dystrophy;	chr1:183029242	chr1:183138402~183141282:-
BRCA	cis	rs9329221	0.537	rs6986911	ENSG00000272267.2	RP11-375N15.2	-4.59	4.87e-06	0.00043	-0.16	-0.14	Neuroticism;	chr8:10121013	chr8:9555144~9556520:-
BRCA	cis	rs4664293	0.867	rs6761145	ENSG00000224152.1	AC009506.1	-4.59	4.88e-06	0.00043	-0.16	-0.14	Monocyte percentage of white cells;	chr2:159725673	chr2:159615296~159617082:+
BRCA	cis	rs4664293	0.867	rs6732987	ENSG00000224152.1	AC009506.1	-4.59	4.88e-06	0.00043	-0.16	-0.14	Monocyte percentage of white cells;	chr2:159725918	chr2:159615296~159617082:+
BRCA	cis	rs4664293	0.867	rs7589941	ENSG00000224152.1	AC009506.1	-4.59	4.88e-06	0.00043	-0.16	-0.14	Monocyte percentage of white cells;	chr2:159727589	chr2:159615296~159617082:+
BRCA	cis	rs12612619	0.732	rs10432697	ENSG00000272148.1	RP11-195B17.1	4.59	4.88e-06	0.00043	0.16	0.14	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27049184	chr2:27062428~27062907:-
BRCA	cis	rs13034020	0.522	rs12464096	ENSG00000271889.1	RP11-493E12.1	-4.59	4.88e-06	0.00043	-0.23	-0.14	Hodgkin's lymphoma;	chr2:61012197	chr2:61151433~61162105:-
BRCA	cis	rs13034020	0.522	rs13005116	ENSG00000271889.1	RP11-493E12.1	-4.59	4.88e-06	0.00043	-0.23	-0.14	Hodgkin's lymphoma;	chr2:61014432	chr2:61151433~61162105:-
BRCA	cis	rs6496044	0.568	rs2880765	ENSG00000259295.5	CSPG4P12	-4.59	4.88e-06	0.00043	-0.17	-0.14	Interstitial lung disease;	chr15:85513231	chr15:85191438~85213905:+
BRCA	cis	rs11098499	0.865	rs9994730	ENSG00000250412.1	KLHL2P1	4.59	4.89e-06	0.00043	0.17	0.14	Corneal astigmatism;	chr4:119460409	chr4:119334329~119378233:+
BRCA	cis	rs7819412	0.806	rs6980856	ENSG00000255046.1	RP11-297N6.4	-4.59	4.89e-06	0.00043	-0.17	-0.14	Triglycerides;	chr8:11080750	chr8:11797928~11802568:-
BRCA	cis	rs1124769	0.57	rs2414052	ENSG00000259378.1	DCAF13P3	4.59	4.89e-06	0.00043	0.18	0.14	Cognitive performance;	chr15:50848104	chr15:50944663~50945996:+
BRCA	cis	rs6044112	1	rs880800	ENSG00000273998.1	RP4-777L9.2	4.59	4.89e-06	0.00043	0.26	0.14	Response to taxane treatment (docetaxel);	chr20:16547892	chr20:16576068~16579615:+
BRCA	cis	rs9834975	0.903	rs9873684	ENSG00000272758.4	RP11-299J3.8	-4.59	4.89e-06	0.000431	-0.14	-0.14	Diastolic blood pressure;	chr3:122386273	chr3:122416207~122443180:+
BRCA	cis	rs10129255	0.509	rs756583	ENSG00000224373.3	IGHV4-59	4.59	4.89e-06	0.000431	0.08	0.14	Kawasaki disease;	chr14:106680002	chr14:106627249~106627825:-
BRCA	cis	rs1889642	0.743	rs9574484	ENSG00000227354.5	RBM26-AS1	-4.59	4.89e-06	0.000431	-0.15	-0.14	Colonoscopy-negative controls vs population controls;	chr13:79795111	chr13:79406309~79424328:+
BRCA	cis	rs16846053	0.792	rs72875528	ENSG00000227403.1	AC009299.3	4.59	4.89e-06	0.000431	0.34	0.14	Blood osmolality (transformed sodium);	chr2:161677013	chr2:161244739~161249050:+
BRCA	cis	rs2303319	0.504	rs56274002	ENSG00000227403.1	AC009299.3	4.59	4.89e-06	0.000431	0.34	0.14	Cognitive function;	chr2:161680205	chr2:161244739~161249050:+
BRCA	cis	rs2273156	1	rs17102904	ENSG00000226677.3	IGBP1P1	4.59	4.89e-06	0.000431	0.21	0.14	Immunoglobulin light chain (AL) amyloidosis;	chr14:34971843	chr14:34939324~34940332:+
BRCA	cis	rs7267979	0.933	rs2424708	ENSG00000125804.12	FAM182A	-4.59	4.89e-06	0.000431	-0.19	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25300762	chr20:26054655~26086917:+
BRCA	cis	rs11673344	0.523	rs2562607	ENSG00000226686.6	LINC01535	4.59	4.89e-06	0.000431	0.18	0.14	Obesity-related traits;	chr19:37031358	chr19:37251912~37265535:+
BRCA	cis	rs490234	0.627	rs4838276	ENSG00000232630.1	PRPS1P2	4.59	4.89e-06	0.000431	0.14	0.14	Mean arterial pressure;	chr9:125602622	chr9:125150653~125151589:+
BRCA	cis	rs7428	0.527	rs1053560	ENSG00000273196.1	RP11-717A5.2	4.59	4.89e-06	0.000431	0.17	0.14	Ear protrusion;	chr2:85319069	chr2:85387074~85387146:-
BRCA	cis	rs16846053	0.605	rs16846181	ENSG00000227403.1	AC009299.3	4.59	4.89e-06	0.000431	0.32	0.14	Blood osmolality (transformed sodium);	chr2:161899744	chr2:161244739~161249050:+
BRCA	cis	rs2273156	1	rs8014327	ENSG00000226677.3	IGBP1P1	-4.59	4.89e-06	0.000431	-0.21	-0.14	Immunoglobulin light chain (AL) amyloidosis;	chr14:34965530	chr14:34939324~34940332:+
BRCA	cis	rs42490	0.789	rs383592	ENSG00000251136.7	RP11-37B2.1	-4.59	4.89e-06	0.000431	-0.13	-0.14	Leprosy;	chr8:89792100	chr8:89609409~89757727:-
BRCA	cis	rs6723108	0.713	rs6728095	ENSG00000224043.6	CCNT2-AS1	4.59	4.89e-06	0.000431	0.19	0.14	Type 2 diabetes;	chr2:134618502	chr2:134735464~134918710:-
BRCA	cis	rs2255336	0.873	rs10743888	ENSG00000245648.1	RP11-277P12.20	4.59	4.89e-06	0.000431	0.21	0.14	Blood protein levels;	chr12:10368255	chr12:10363769~10398506:+
BRCA	cis	rs6840360	0.642	rs7666571	ENSG00000251611.1	RP11-610P16.1	-4.59	4.89e-06	0.000431	-0.12	-0.14	Intelligence (multi-trait analysis);	chr4:151522121	chr4:151407551~151408835:-
BRCA	cis	rs454217	0.521	rs10859302	ENSG00000277851.1	RP11-756G20.1	4.59	4.89e-06	0.000431	0.17	0.14	Smoking quantity;	chr12:92321991	chr12:92247756~92363832:-
BRCA	cis	rs3764021	0.87	rs2401393	ENSG00000278635.1	CTD-2318O12.1	-4.59	4.89e-06	0.000431	-0.14	-0.14	Type 1 diabetes;	chr12:9726488	chr12:9415641~9416718:+
BRCA	cis	rs1167827	1	rs1167827	ENSG00000223705.8	NSUN5P1	4.59	4.9e-06	0.000431	0.11	0.14	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75533848	chr7:75410322~75416787:+
BRCA	cis	rs7160336	1	rs10151964	ENSG00000259065.1	RP5-1021I20.1	4.59	4.9e-06	0.000431	0.15	0.14	Blood protein levels;	chr14:74097079	chr14:73787360~73803270:+
BRCA	cis	rs308403	0.509	rs13117125	ENSG00000224786.1	CETN4P	4.59	4.9e-06	0.000431	0.18	0.14	Blood protein levels;	chr4:122749669	chr4:122730548~122732193:-
BRCA	cis	rs7621331	0.963	rs13317459	ENSG00000273486.1	RP11-731C17.2	-4.59	4.9e-06	0.000431	-0.17	-0.14	Waist circumference adjusted for body mass index;	chr3:135951214	chr3:136837338~136839021:-
BRCA	cis	rs672203	0.714	rs663649	ENSG00000271992.1	RP11-42O15.3	4.59	4.9e-06	0.000431	0.19	0.14	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);	chr1:70431500	chr1:70445071~70445536:+
BRCA	cis	rs7651446	0.649	rs7609996	ENSG00000240875.4	LINC00886	-4.59	4.9e-06	0.000432	-0.27	-0.14	Ovarian cancer;Epithelial ovarian cancer;	chr3:156646024	chr3:156747346~156817062:-
BRCA	cis	rs6686842	0.965	rs2802566	ENSG00000235358.1	RP11-399E6.1	-4.59	4.9e-06	0.000432	-0.18	-0.14	Height;	chr1:41086309	chr1:41242373~41284861:+
BRCA	cis	rs6686842	0.864	rs6662279	ENSG00000235358.1	RP11-399E6.1	-4.59	4.9e-06	0.000432	-0.18	-0.14	Height;	chr1:41087889	chr1:41242373~41284861:+
BRCA	cis	rs6832769	0.89	rs564762	ENSG00000272969.1	RP11-528I4.2	4.59	4.9e-06	0.000432	0.17	0.14	Personality dimensions;	chr4:55418464	chr4:55547112~55547889:+
BRCA	cis	rs62244186	0.566	rs3762636	ENSG00000233509.2	ZNF197-AS1	4.59	4.91e-06	0.000432	0.17	0.14	Depressive symptoms;	chr3:44813071	chr3:44617128~44624797:-
BRCA	cis	rs67981189	0.593	rs9806042	ENSG00000269927.1	RP6-91H8.3	4.59	4.91e-06	0.000432	0.17	0.14	Schizophrenia;	chr14:71064276	chr14:71141125~71143253:-
BRCA	cis	rs4578769	0.959	rs6507323	ENSG00000265939.1	UBE2CP2	-4.59	4.91e-06	0.000432	-0.17	-0.14	Eosinophil percentage of white cells;	chr18:22846715	chr18:22900486~22900995:-
BRCA	cis	rs6756513	0.505	rs2228203	ENSG00000231024.1	AC092431.3	-4.59	4.91e-06	0.000432	-0.2	-0.14	Breast cancer;Platelet count;	chr2:69806452	chr2:69700192~69713847:-
BRCA	cis	rs1707322	0.927	rs6690386	ENSG00000234329.1	RP11-767N6.2	4.59	4.91e-06	0.000432	0.15	0.14	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45787339	chr1:45651039~45651826:-
BRCA	cis	rs13113518	0.702	rs78829811	ENSG00000272969.1	RP11-528I4.2	4.59	4.91e-06	0.000432	0.16	0.14	Height;	chr4:55558258	chr4:55547112~55547889:+
BRCA	cis	rs13113518	0.702	rs75801206	ENSG00000272969.1	RP11-528I4.2	4.59	4.91e-06	0.000432	0.16	0.14	Height;	chr4:55558259	chr4:55547112~55547889:+
BRCA	cis	rs13113518	0.702	rs34658078	ENSG00000272969.1	RP11-528I4.2	4.59	4.91e-06	0.000432	0.16	0.14	Height;	chr4:55558261	chr4:55547112~55547889:+
BRCA	cis	rs6832769	1	rs1522110	ENSG00000272969.1	RP11-528I4.2	4.59	4.91e-06	0.000432	0.17	0.14	Personality dimensions;	chr4:55514116	chr4:55547112~55547889:+
BRCA	cis	rs9467773	1	rs9393729	ENSG00000241549.7	GUSBP2	4.59	4.91e-06	0.000432	0.15	0.14	Intelligence (multi-trait analysis);	chr6:26513938	chr6:26871484~26956554:-
BRCA	cis	rs654950	0.783	rs639298	ENSG00000230638.4	RP11-486B10.4	4.59	4.91e-06	0.000433	0.17	0.14	Airway imaging phenotypes;	chr1:41535859	chr1:41542069~41544310:+
BRCA	cis	rs7686660	0.956	rs58945764	ENSG00000250326.1	RP11-284M14.1	-4.59	4.91e-06	0.000433	-0.18	-0.14	Asthma;	chr4:143028554	chr4:142933195~143184861:-
BRCA	cis	rs6430585	0.528	rs16832205	ENSG00000231890.6	DARS-AS1	-4.59	4.91e-06	0.000433	-0.23	-0.14	Corneal structure;	chr2:135927062	chr2:135985176~136022593:+
BRCA	cis	rs1395	0.778	rs4665959	ENSG00000234072.1	AC074117.10	-4.59	4.91e-06	0.000433	-0.15	-0.14	Blood metabolite levels;	chr2:27220388	chr2:27356246~27367622:+
BRCA	cis	rs11083475	1	rs56365761	ENSG00000267892.1	CTD-2540F13.2	4.59	4.92e-06	0.000433	0.16	0.14	Heart rate;	chr19:38657463	chr19:38738284~38739863:+
BRCA	cis	rs6600671	0.934	rs11249431	ENSG00000275538.1	RNVU1-19	-4.59	4.92e-06	0.000433	-0.17	-0.14	Hip geometry;	chr1:121544405	chr1:120850819~120850985:-
BRCA	cis	rs6545883	0.868	rs2518932	ENSG00000270820.4	RP11-355B11.2	4.59	4.92e-06	0.000433	0.16	0.14	Tuberculosis;	chr2:61574142	chr2:61471188~61484130:+
BRCA	cis	rs828999	0.688	rs1020173	ENSG00000280186.1	RP11-483I13.6	-4.59	4.92e-06	0.000433	-0.16	-0.14	Monocyte percentage of white cells;	chr1:108153279	chr1:108200413~108202743:+
BRCA	cis	rs7523050	0.643	rs71655970	ENSG00000203897.3	SPATA42	-4.59	4.92e-06	0.000433	-0.27	-0.14	Fat distribution (HIV);	chr1:108861273	chr1:108857217~108858524:+
BRCA	cis	rs6490294	0.528	rs7980579	ENSG00000234608.6	MAPKAPK5-AS1	4.59	4.92e-06	0.000433	0.21	0.14	Mean platelet volume;	chr12:112009556	chr12:111839764~111842902:-
BRCA	cis	rs6490294	0.571	rs7952986	ENSG00000234608.6	MAPKAPK5-AS1	4.59	4.92e-06	0.000433	0.21	0.14	Mean platelet volume;	chr12:112010358	chr12:111839764~111842902:-
BRCA	cis	rs6490294	0.571	rs7132863	ENSG00000234608.6	MAPKAPK5-AS1	4.59	4.92e-06	0.000433	0.21	0.14	Mean platelet volume;	chr12:112011079	chr12:111839764~111842902:-
BRCA	cis	rs6490294	0.571	rs11066128	ENSG00000234608.6	MAPKAPK5-AS1	4.59	4.92e-06	0.000433	0.21	0.14	Mean platelet volume;	chr12:112012950	chr12:111839764~111842902:-
BRCA	cis	rs62388641	0.547	rs4513844	ENSG00000218027.2	RP11-157J24.1	4.59	4.92e-06	0.000433	0.17	0.14	Daytime sleep phenotypes;	chr6:1551747	chr6:1513698~1515289:-
BRCA	cis	rs7481584	0.624	rs397919	ENSG00000247473.2	CARS-AS1	-4.59	4.93e-06	0.000434	-0.17	-0.14	Calcium levels;	chr11:3041864	chr11:3029009~3041260:+
BRCA	cis	rs6686842	1	rs656917	ENSG00000235358.1	RP11-399E6.1	-4.59	4.93e-06	0.000434	-0.18	-0.14	Height;	chr1:41104036	chr1:41242373~41284861:+
BRCA	cis	rs17406451	0.788	rs6751139	ENSG00000234936.1	AC010883.5	4.59	4.93e-06	0.000434	0.14	0.14	Mitochondrial DNA levels;	chr2:43400224	chr2:43229573~43233394:+
BRCA	cis	rs4664293	0.967	rs3940435	ENSG00000224152.1	AC009506.1	-4.59	4.93e-06	0.000434	-0.16	-0.14	Monocyte percentage of white cells;	chr2:159638272	chr2:159615296~159617082:+
BRCA	cis	rs11048434	0.518	rs4883206	ENSG00000256720.1	RP11-436I9.6	-4.59	4.93e-06	0.000434	-0.14	-0.14	Sjögren's syndrome;	chr12:9021169	chr12:9135084~9135591:+
BRCA	cis	rs13034020	0.522	rs13017457	ENSG00000271889.1	RP11-493E12.1	-4.59	4.93e-06	0.000434	-0.23	-0.14	Hodgkin's lymphoma;	chr2:61021510	chr2:61151433~61162105:-
BRCA	cis	rs7259811	0.74	rs55802602	ENSG00000268266.1	AC003005.2	4.59	4.93e-06	0.000434	0.2	0.14	Western dietary pattern;	chr19:56721214	chr19:57477649~57482996:+
BRCA	cis	rs62184315	0.536	rs62185874	ENSG00000253559.1	OSGEPL1-AS1	-4.59	4.93e-06	0.000434	-0.24	-0.14	Alcohol dependence (age at onset);	chr2:189704288	chr2:189762704~189765556:+
BRCA	cis	rs10504130	1	rs75219463	ENSG00000272024.1	RP11-546K22.3	-4.59	4.93e-06	0.000434	-0.24	-0.14	Venous thromboembolism (SNP x SNP interaction);	chr8:51852803	chr8:51950284~51950690:+
BRCA	cis	rs2243480	1	rs958550	ENSG00000228409.4	CCT6P1	-4.59	4.94e-06	0.000435	-0.19	-0.14	Diabetic kidney disease;	chr7:66170692	chr7:65751142~65763354:+
BRCA	cis	rs17270561	0.943	rs76703022	ENSG00000272462.2	U91328.19	-4.59	4.94e-06	0.000435	-0.2	-0.14	Iron status biomarkers;	chr6:25703301	chr6:25992662~26001775:+
BRCA	cis	rs863750	0.777	rs825456	ENSG00000275389.1	RP11-214K3.24	4.59	4.94e-06	0.000435	0.18	0.14	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-hip ratio;	chr12:124053028	chr12:124085761~124088598:+
BRCA	cis	rs56322409	0.897	rs17461546	ENSG00000226688.5	ENTPD1-AS1	4.59	4.94e-06	0.000435	0.16	0.14	Blood metabolite levels;	chr10:95683238	chr10:95753206~96090238:-
BRCA	cis	rs9467773	0.587	rs12214031	ENSG00000124549.13	BTN2A3P	-4.59	4.94e-06	0.000435	-0.15	-0.14	Intelligence (multi-trait analysis);	chr6:26376400	chr6:26421391~26432383:+
BRCA	cis	rs2255336	0.938	rs2617172	ENSG00000245648.1	RP11-277P12.20	4.59	4.94e-06	0.000435	0.22	0.14	Blood protein levels;	chr12:10409887	chr12:10363769~10398506:+
BRCA	cis	rs7011507	0.594	rs907176	ENSG00000279881.1	RP11-513O13.1	-4.59	4.94e-06	0.000435	-0.21	-0.14	Inflammatory bowel disease;Ulcerative colitis;	chr8:48445169	chr8:48428143~48431041:-
BRCA	cis	rs9982086	0.793	rs2226328	ENSG00000260583.1	AP000223.42	4.59	4.94e-06	0.000435	0.3	0.14	Carboplatin disposition in epthelial ovarian cancer;	chr21:25614096	chr21:25582770~25583326:-
BRCA	cis	rs2466254	0.657	rs2460915	ENSG00000251468.2	RP11-369K16.1	4.59	4.95e-06	0.000435	0.23	0.14	Pneumonia;	chr8:12968527	chr8:12958387~12962200:+
BRCA	cis	rs4713675	0.649	rs568901	ENSG00000224557.6	HLA-DPB2	4.59	4.95e-06	0.000435	0.17	0.14	Plateletcrit;	chr6:33742261	chr6:33112451~33129084:+
BRCA	cis	rs8054556	0.967	rs12918652	ENSG00000214725.6	CDIPT-AS1	-4.59	4.95e-06	0.000435	-0.17	-0.14	Autism spectrum disorder or schizophrenia;	chr16:29953036	chr16:29863593~29868053:+
BRCA	cis	rs1707322	0.721	rs4660883	ENSG00000234329.1	RP11-767N6.2	4.59	4.95e-06	0.000435	0.15	0.14	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45770426	chr1:45651039~45651826:-
BRCA	cis	rs6840360	0.667	rs2709832	ENSG00000251603.1	RP11-164P12.4	-4.59	4.95e-06	0.000436	-0.13	-0.14	Intelligence (multi-trait analysis);	chr4:151458242	chr4:151667224~151670502:+
BRCA	cis	rs8054556	0.647	rs8048433	ENSG00000183604.13	SMG1P5	-4.59	4.95e-06	0.000436	-0.14	-0.14	Autism spectrum disorder or schizophrenia;	chr16:29920272	chr16:30267553~30335374:-
BRCA	cis	rs4588572	0.644	rs11742212	ENSG00000245556.2	SCAMP1-AS1	-4.59	4.95e-06	0.000436	-0.17	-0.14	Triglycerides;	chr5:78483210	chr5:78342365~78360507:-
BRCA	cis	rs2278170	1	rs2278173	ENSG00000225101.4	OR52K3P	-4.59	4.95e-06	0.000436	-0.19	-0.14	Amyotrophic lateral sclerosis;	chr11:4475867	chr11:4474813~4475755:+
BRCA	cis	rs62025270	0.632	rs80036674	ENSG00000259295.5	CSPG4P12	-4.59	4.95e-06	0.000436	-0.21	-0.14	Idiopathic pulmonary fibrosis;	chr15:85571217	chr15:85191438~85213905:+
BRCA	cis	rs6545883	0.929	rs10193666	ENSG00000270820.4	RP11-355B11.2	-4.59	4.95e-06	0.000436	-0.16	-0.14	Tuberculosis;	chr2:61402273	chr2:61471188~61484130:+
BRCA	cis	rs7267979	0.966	rs6083855	ENSG00000274973.1	RP13-401N8.7	4.59	4.96e-06	0.000436	0.16	0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25424482	chr20:25845497~25845862:+
BRCA	cis	rs7267979	1	rs4815426	ENSG00000274973.1	RP13-401N8.7	4.59	4.96e-06	0.000436	0.16	0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25424550	chr20:25845497~25845862:+
BRCA	cis	rs503425	1	rs503425	ENSG00000255239.1	AP002954.6	4.59	4.96e-06	0.000436	0.2	0.14	Systemic lupus erythematosus;	chr11:118822018	chr11:118688039~118690600:-
BRCA	cis	rs6686842	1	rs213733	ENSG00000235358.1	RP11-399E6.1	-4.59	4.96e-06	0.000436	-0.18	-0.14	Height;	chr1:41111317	chr1:41242373~41284861:+
BRCA	cis	rs17818399	0.926	rs35682608	ENSG00000279254.1	RP11-536C12.1	-4.59	4.96e-06	0.000436	-0.19	-0.14	Height;	chr2:46609403	chr2:46668870~46670778:+
BRCA	cis	rs2255336	0.938	rs2617169	ENSG00000245648.1	RP11-277P12.20	4.59	4.96e-06	0.000436	0.22	0.14	Blood protein levels;	chr12:10408225	chr12:10363769~10398506:+
BRCA	cis	rs12468226	0.702	rs114634431	ENSG00000226261.1	AC064836.3	4.59	4.96e-06	0.000436	0.25	0.14	Urate levels;	chr2:202142530	chr2:202336024~202336727:-
BRCA	cis	rs739496	0.542	rs7306529	ENSG00000257595.2	RP3-473L9.4	4.59	4.96e-06	0.000437	0.18	0.14	Platelet count;	chr12:111342840	chr12:111369282~111403310:+
BRCA	cis	rs6095360	1	rs34984028	ENSG00000222365.1	SNORD12B	-4.59	4.96e-06	0.000437	-0.15	-0.14	Intelligence (multi-trait analysis);	chr20:48932510	chr20:49280319~49280409:+
BRCA	cis	rs11638815	0.581	rs28808991	ENSG00000259429.4	UBE2Q2P2	-4.59	4.97e-06	0.000437	-0.14	-0.14	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82592229	chr15:82355142~82420075:+
BRCA	cis	rs4356203	0.905	rs11024159	ENSG00000272034.1	SNORD14A	-4.59	4.97e-06	0.000437	-0.14	-0.14	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17105795	chr11:17074654~17074744:-
BRCA	cis	rs4819052	0.851	rs2838833	ENSG00000184274.3	LINC00315	-4.59	4.97e-06	0.000437	-0.19	-0.14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245245	chr21:45300245~45305257:-
BRCA	cis	rs867186	1	rs2889873	ENSG00000126005.14	MMP24-AS1	-4.59	4.97e-06	0.000437	-0.27	-0.14	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35059038	chr20:35216462~35278131:-
BRCA	cis	rs867186	1	rs7263253	ENSG00000126005.14	MMP24-AS1	-4.59	4.97e-06	0.000437	-0.27	-0.14	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35061573	chr20:35216462~35278131:-
BRCA	cis	rs867186	0.92	rs2145558	ENSG00000126005.14	MMP24-AS1	-4.59	4.97e-06	0.000437	-0.27	-0.14	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35062266	chr20:35216462~35278131:-
BRCA	cis	rs12612619	0.732	rs6547355	ENSG00000229122.1	AGBL5-IT1	4.59	4.97e-06	0.000437	0.15	0.14	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:26987337	chr2:27061038~27061815:+
BRCA	cis	rs8180040	0.966	rs7649234	ENSG00000276925.1	RP11-708J19.3	-4.59	4.97e-06	0.000437	-0.16	-0.14	Colorectal cancer;	chr3:47452890	chr3:47469777~47469987:+
BRCA	cis	rs453301	0.658	rs3855900	ENSG00000254153.1	CTA-398F10.2	-4.59	4.97e-06	0.000437	-0.17	-0.14	Joint mobility (Beighton score);	chr8:9044411	chr8:8456909~8461337:-
BRCA	cis	rs9834975	0.935	rs9863881	ENSG00000272758.4	RP11-299J3.8	-4.59	4.97e-06	0.000437	-0.14	-0.14	Diastolic blood pressure;	chr3:122381176	chr3:122416207~122443180:+
BRCA	cis	rs1941184	0.5	rs7234091	ENSG00000266521.1	RP11-650P15.1	-4.59	4.97e-06	0.000437	-0.2	-0.14	Parkinson's disease (age of onset);	chr18:31439866	chr18:31496645~31497195:-
BRCA	cis	rs287982	0.611	rs76011221	ENSG00000269973.1	RP11-95D17.1	-4.59	4.97e-06	0.000437	-0.23	-0.14	Nonsyndromic cleft lip with cleft palate;	chr2:9837504	chr2:9936360~9939590:+
BRCA	cis	rs287982	0.611	rs77359699	ENSG00000269973.1	RP11-95D17.1	-4.59	4.97e-06	0.000437	-0.23	-0.14	Nonsyndromic cleft lip with cleft palate;	chr2:9839170	chr2:9936360~9939590:+
BRCA	cis	rs8048589	0.75	rs12926900	ENSG00000175604.2	RP11-276H1.3	-4.59	4.97e-06	0.000437	-0.19	-0.14	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);	chr16:12090227	chr16:12086746~12090302:-
BRCA	cis	rs6802315	0.712	rs7615751	ENSG00000272087.1	RP11-379F4.7	4.59	4.97e-06	0.000437	0.17	0.14	Periodontitis (CDC/AAP);	chr3:158792041	chr3:158693120~158693768:-
BRCA	cis	rs442309	0.749	rs224109	ENSG00000238280.1	RP11-436D10.3	-4.59	4.97e-06	0.000437	-0.18	-0.14	Vogt-Koyanagi-Harada syndrome;	chr10:62790311	chr10:62793562~62805887:-
BRCA	cis	rs11051970	0.918	rs6488050	ENSG00000274964.1	RP11-817I4.1	-4.59	4.97e-06	0.000438	-0.18	-0.14	Response to tocilizumab in rheumatoid arthritis;	chr12:32379565	chr12:32339368~32340724:+
BRCA	cis	rs11673344	0.504	rs6510588	ENSG00000276846.1	CTD-3220F14.3	-4.59	4.98e-06	0.000438	-0.16	-0.14	Obesity-related traits;	chr19:37106493	chr19:37314868~37315620:-
BRCA	cis	rs409045	1	rs409045	ENSG00000271874.1	CTD-2024P10.2	4.59	4.98e-06	0.000438	0.19	0.14	Left ventricular mass;	chr5:34628522	chr5:34651457~34651888:-
BRCA	cis	rs6840258	0.831	rs236676	ENSG00000251411.1	RP11-397E7.4	4.59	4.98e-06	0.000438	0.18	0.14	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87088468	chr4:86913266~86914817:-
BRCA	cis	rs11096990	0.634	rs4975001	ENSG00000249685.1	RP11-360F5.3	-4.59	4.98e-06	0.000438	-0.17	-0.14	Cognitive function;	chr4:39264844	chr4:39133913~39135608:+
BRCA	cis	rs7572733	0.84	rs12622674	ENSG00000231621.1	AC013264.2	4.59	4.98e-06	0.000438	0.13	0.14	Dermatomyositis;	chr2:197687088	chr2:197197991~197199273:+
BRCA	cis	rs7572733	0.84	rs2341510	ENSG00000231621.1	AC013264.2	4.59	4.98e-06	0.000438	0.13	0.14	Dermatomyositis;	chr2:197693955	chr2:197197991~197199273:+
BRCA	cis	rs13108904	0.87	rs3755924	ENSG00000253399.1	AC078852.2	-4.59	4.98e-06	0.000438	-0.16	-0.14	Obesity-related traits;	chr4:1244575	chr4:1358479~1359461:+
BRCA	cis	rs13108904	0.87	rs3775094	ENSG00000253399.1	AC078852.2	-4.59	4.98e-06	0.000438	-0.16	-0.14	Obesity-related traits;	chr4:1245071	chr4:1358479~1359461:+
BRCA	cis	rs828999	0.688	rs1020172	ENSG00000280186.1	RP11-483I13.6	-4.59	4.98e-06	0.000438	-0.16	-0.14	Monocyte percentage of white cells;	chr1:108153180	chr1:108200413~108202743:+
BRCA	cis	rs7674212	0.51	rs6856593	ENSG00000248740.4	RP11-328K4.1	4.59	4.99e-06	0.000439	0.16	0.14	Type 2 diabetes;	chr4:103256542	chr4:103256159~103453658:+
BRCA	cis	rs4218	0.648	rs12910987	ENSG00000277144.1	RP11-59H7.4	-4.59	4.99e-06	0.000439	-0.19	-0.14	Social communication problems;	chr15:59092782	chr15:59115547~59116089:-
BRCA	cis	rs7615952	0.546	rs11718647	ENSG00000171084.14	FAM86JP	4.59	4.99e-06	0.000439	0.23	0.14	Blood pressure (smoking interaction);	chr3:125633178	chr3:125916620~125930024:+
BRCA	cis	rs12497850	0.897	rs7432989	ENSG00000225399.4	RP11-3B7.1	4.59	4.99e-06	0.000439	0.14	0.14	Parkinson's disease;	chr3:49067703	chr3:49260085~49261316:+
BRCA	cis	rs7674212	0.57	rs6813563	ENSG00000251288.2	RP11-10L12.2	-4.59	4.99e-06	0.000439	-0.17	-0.14	Type 2 diabetes;	chr4:103177953	chr4:102751401~102752641:+
BRCA	cis	rs754466	1	rs12220328	ENSG00000204049.1	RP11-126H7.4	4.59	4.99e-06	0.000439	0.18	0.14	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77921724	chr10:77866875~77869610:+
BRCA	cis	rs4781563	0.956	rs3136079	ENSG00000242307.1	RPS26P52	-4.59	4.99e-06	0.000439	-0.17	-0.14	Bilirubin levels;	chr16:13925380	chr16:13922332~13922679:-
BRCA	cis	rs4664293	0.967	rs3940435	ENSG00000226266.5	AC009961.3	-4.59	4.99e-06	0.000439	-0.17	-0.14	Monocyte percentage of white cells;	chr2:159638272	chr2:159670708~159712435:-
BRCA	cis	rs7572733	0.84	rs7340470	ENSG00000231621.1	AC013264.2	4.59	5e-06	0.000439	0.13	0.14	Dermatomyositis;	chr2:197680738	chr2:197197991~197199273:+
BRCA	cis	rs4218	0.701	rs7174277	ENSG00000277144.1	RP11-59H7.4	-4.59	5e-06	0.000439	-0.17	-0.14	Social communication problems;	chr15:59150390	chr15:59115547~59116089:-
BRCA	cis	rs3768617	0.528	rs4652778	ENSG00000224468.3	RP11-181K3.4	-4.59	5.01e-06	0.00044	-0.15	-0.14	Fuchs's corneal dystrophy;	chr1:183128285	chr1:183138402~183141282:-
BRCA	cis	rs3768617	0.528	rs4651144	ENSG00000224468.3	RP11-181K3.4	-4.59	5.01e-06	0.00044	-0.15	-0.14	Fuchs's corneal dystrophy;	chr1:183128286	chr1:183138402~183141282:-
BRCA	cis	rs6747488	0.515	rs600015	ENSG00000272716.1	RP11-563N4.1	4.59	5.01e-06	0.00044	0.16	0.14	Interleukin-18 levels;	chr2:31595231	chr2:32165046~32165757:-
BRCA	cis	rs6445967	0.832	rs1055973	ENSG00000273493.1	RP11-80H18.4	-4.59	5.01e-06	0.00044	-0.18	-0.14	Platelet count;	chr3:58323233	chr3:58329965~58330118:+
BRCA	cis	rs7048146	0.966	rs10816831	ENSG00000213539.4	YBX1P6	4.59	5.01e-06	0.000441	0.16	0.14	Vascular brain injury;	chr9:109538337	chr9:109532830~109534332:-
BRCA	cis	rs7048146	0.966	rs10816833	ENSG00000213539.4	YBX1P6	4.59	5.01e-06	0.000441	0.16	0.14	Vascular brain injury;	chr9:109538551	chr9:109532830~109534332:-
BRCA	cis	rs1707322	1	rs1707322	ENSG00000234329.1	RP11-767N6.2	4.59	5.01e-06	0.000441	0.14	0.14	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46039475	chr1:45651039~45651826:-
BRCA	cis	rs6545883	0.894	rs2694649	ENSG00000270820.4	RP11-355B11.2	-4.59	5.01e-06	0.000441	-0.16	-0.14	Tuberculosis;	chr2:61346691	chr2:61471188~61484130:+
BRCA	cis	rs7200543	0.583	rs4985149	ENSG00000260735.1	RP11-72I8.1	-4.59	5.01e-06	0.000441	-0.17	-0.14	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15053481	chr16:15094411~15109197:+
BRCA	cis	rs17801127	0.901	rs34550472	ENSG00000231969.1	AC144449.1	4.59	5.02e-06	0.000441	0.28	0.14	Liver enzyme levels (alanine transaminase);	chr2:149685555	chr2:149587196~149848233:+
BRCA	cis	rs7819412	0.525	rs10086521	ENSG00000154316.13	TDH	4.59	5.02e-06	0.000441	0.19	0.14	Triglycerides;	chr8:10926259	chr8:11339637~11368452:+
BRCA	cis	rs3770752	0.93	rs10184179	ENSG00000272054.1	RP11-423P10.2	4.59	5.02e-06	0.000441	0.13	0.14	Schizophrenia;	chr2:37252613	chr2:37208875~37212677:+
BRCA	cis	rs9925964	0.967	rs2855475	ENSG00000232748.3	RP11-196G11.6	-4.59	5.02e-06	0.000441	-0.17	-0.14	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31136227	chr16:31056460~31062803:+
BRCA	cis	rs7119	0.651	rs35577135	ENSG00000259362.2	RP11-307C19.1	-4.59	5.02e-06	0.000441	-0.2	-0.14	Type 2 diabetes;	chr15:77547732	chr15:77525540~77534110:+
BRCA	cis	rs2070615	0.525	rs2860360	ENSG00000257964.1	RP11-133N21.10	-4.59	5.02e-06	0.000441	-0.16	-0.14	Bipolar disorder;	chr12:48812399	chr12:49576840~49577505:-
BRCA	cis	rs1862618	0.671	rs2591966	ENSG00000271828.1	CTD-2310F14.1	-4.59	5.02e-06	0.000441	-0.17	-0.14	Initial pursuit acceleration;	chr5:56937861	chr5:56927874~56929573:+
BRCA	cis	rs6452524	1	rs7716962	ENSG00000281327.1	LINC01338	4.59	5.02e-06	0.000441	0.16	0.14	Hypertension (SNP x SNP interaction);	chr5:83138913	chr5:82850864~82859836:-
BRCA	cis	rs893818	0.851	rs59755145	ENSG00000261801.4	LOXL1-AS1	4.59	5.02e-06	0.000442	0.19	0.14	Exfoliation glaucoma or exfoliation syndrome;	chr15:73938319	chr15:73908071~73928248:-
BRCA	cis	rs610932	0.517	rs668287	ENSG00000275344.1	MIR6503	4.59	5.02e-06	0.000442	0.14	0.14	Alzheimer's disease;	chr11:60207156	chr11:60209071~60209156:-
BRCA	cis	rs610932	0.517	rs673141	ENSG00000275344.1	MIR6503	4.59	5.02e-06	0.000442	0.14	0.14	Alzheimer's disease;	chr11:60208237	chr11:60209071~60209156:-
BRCA	cis	rs6847067	0.672	rs13108722	ENSG00000180769.7	WDFY3-AS2	4.59	5.02e-06	0.000442	0.14	0.14	Oropharynx cancer;	chr4:84713335	chr4:84965682~85011277:+
BRCA	cis	rs6430585	0.583	rs61253125	ENSG00000231890.6	DARS-AS1	-4.59	5.02e-06	0.000442	-0.22	-0.14	Corneal structure;	chr2:135860608	chr2:135985176~136022593:+
BRCA	cis	rs6430585	0.583	rs4988201	ENSG00000231890.6	DARS-AS1	-4.59	5.02e-06	0.000442	-0.22	-0.14	Corneal structure;	chr2:135860937	chr2:135985176~136022593:+
BRCA	cis	rs6430585	0.583	rs3087343	ENSG00000231890.6	DARS-AS1	-4.59	5.02e-06	0.000442	-0.22	-0.14	Corneal structure;	chr2:135864973	chr2:135985176~136022593:+
BRCA	cis	rs10129255	0.5	rs7161740	ENSG00000232216.1	IGHV3-43	4.59	5.03e-06	0.000442	0.1	0.14	Kawasaki disease;	chr14:106776119	chr14:106470264~106470800:-
BRCA	cis	rs3782123	0.539	rs10902111	ENSG00000277290.1	RP11-326C3.16	4.59	5.03e-06	0.000442	0.18	0.14	Red cell distribution width;Glycated hemoglobin levels;	chr11:241489	chr11:243099~243483:-
BRCA	cis	rs5751614	0.537	rs5759681	ENSG00000240160.3	RN7SL263P	-4.59	5.03e-06	0.000442	-0.18	-0.14	Height;	chr22:23287365	chr22:23261782~23262071:-
BRCA	cis	rs17767294	0.708	rs72848752	ENSG00000219392.1	RP1-265C24.5	-4.59	5.03e-06	0.000442	-0.34	-0.14	Parkinson's disease;	chr6:27910490	chr6:28115628~28116551:+
BRCA	cis	rs792448	0.798	rs612414	ENSG00000226251.4	RP11-15I11.3	-4.59	5.03e-06	0.000442	-0.18	-0.14	White blood cell count (basophil);	chr1:212428834	chr1:212225278~212238977:-
BRCA	cis	rs755249	0.517	rs66880209	ENSG00000228060.1	RP11-69E11.8	-4.59	5.03e-06	0.000442	-0.19	-0.14	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39254140	chr1:39565160~39573203:+
BRCA	cis	rs854765	0.624	rs9899634	ENSG00000281749.1	Y_RNA	-4.59	5.03e-06	0.000442	-0.16	-0.14	Total body bone mineral density;	chr17:17824629	chr17:18001101~18001195:-
BRCA	cis	rs7572733	0.555	rs11903129	ENSG00000231621.1	AC013264.2	-4.59	5.04e-06	0.000443	-0.14	-0.14	Dermatomyositis;	chr2:198053867	chr2:197197991~197199273:+
BRCA	cis	rs4664293	0.867	rs7562060	ENSG00000226266.5	AC009961.3	-4.59	5.04e-06	0.000443	-0.18	-0.14	Monocyte percentage of white cells;	chr2:159730618	chr2:159670708~159712435:-
BRCA	cis	rs7833986	0.501	rs2953898	ENSG00000253603.1	CTA-397H3.3	-4.59	5.04e-06	0.000443	-0.2	-0.14	Height;	chr8:56068244	chr8:56074592~56075274:+
BRCA	cis	rs2073316	0.626	rs56247470	ENSG00000272716.1	RP11-563N4.1	4.59	5.04e-06	0.000443	0.15	0.14	Interleukin-18 levels;	chr2:31475825	chr2:32165046~32165757:-
BRCA	cis	rs4443100	0.726	rs5996449	ENSG00000230701.2	FBXW4P1	4.59	5.04e-06	0.000443	0.18	0.14	Serum parathyroid hormone levels;	chr22:23023133	chr22:23262767~23265005:+
BRCA	cis	rs7674212	0.57	rs2711898	ENSG00000251288.2	RP11-10L12.2	-4.59	5.04e-06	0.000443	-0.16	-0.14	Type 2 diabetes;	chr4:103141914	chr4:102751401~102752641:+
BRCA	cis	rs7243790	0.805	rs12604412	ENSG00000277324.1	RP11-850A17.1	-4.59	5.04e-06	0.000443	-0.16	-0.14	Diastolic blood pressure;	chr18:54372922	chr18:54268346~54270028:-
BRCA	cis	rs2243480	0.831	rs7806717	ENSG00000275400.1	RP4-756H11.5	-4.59	5.04e-06	0.000443	-0.25	-0.14	Diabetic kidney disease;	chr7:65928187	chr7:66553805~66554199:-
BRCA	cis	rs2243480	1	rs34933526	ENSG00000275400.1	RP4-756H11.5	4.59	5.04e-06	0.000443	0.25	0.14	Diabetic kidney disease;	chr7:65918212	chr7:66553805~66554199:-
BRCA	cis	rs2243480	1	rs6949812	ENSG00000275400.1	RP4-756H11.5	4.59	5.04e-06	0.000443	0.25	0.14	Diabetic kidney disease;	chr7:65922114	chr7:66553805~66554199:-
BRCA	cis	rs2243480	1	rs6970243	ENSG00000275400.1	RP4-756H11.5	4.59	5.04e-06	0.000443	0.25	0.14	Diabetic kidney disease;	chr7:65923503	chr7:66553805~66554199:-
BRCA	cis	rs2243480	0.708	rs35310401	ENSG00000275400.1	RP4-756H11.5	4.59	5.04e-06	0.000443	0.25	0.14	Diabetic kidney disease;	chr7:65925372	chr7:66553805~66554199:-
BRCA	cis	rs4950322	0.947	rs72694723	ENSG00000244371.2	PFN1P8	-4.59	5.04e-06	0.000443	-0.2	-0.14	Protein quantitative trait loci;	chr1:147373174	chr1:146957117~146957659:-
BRCA	cis	rs7111546	0.565	rs733296	ENSG00000246225.5	RP11-17A1.3	4.59	5.04e-06	0.000443	0.24	0.14	Dialysis-related mortality;	chr11:22915033	chr11:22829380~22945393:+
BRCA	cis	rs11742741	1	rs1469417	ENSG00000248874.4	C5orf17	-4.59	5.04e-06	0.000443	-0.18	-0.14	Educational attainment;	chr5:24136065	chr5:23951348~24178263:+
BRCA	cis	rs6545883	0.602	rs11125871	ENSG00000270820.4	RP11-355B11.2	-4.59	5.05e-06	0.000443	-0.16	-0.14	Tuberculosis;	chr2:61242991	chr2:61471188~61484130:+
BRCA	cis	rs6981523	0.553	rs11783045	ENSG00000255046.1	RP11-297N6.4	4.59	5.05e-06	0.000443	0.17	0.14	Neuroticism;	chr8:11198666	chr8:11797928~11802568:-
BRCA	cis	rs78545713	0.649	rs77362785	ENSG00000241549.7	GUSBP2	-4.59	5.05e-06	0.000443	-0.27	-0.14	Iron status biomarkers (total iron binding capacity);	chr6:26232123	chr6:26871484~26956554:-
BRCA	cis	rs11673344	0.504	rs8099987	ENSG00000226686.6	LINC01535	4.59	5.05e-06	0.000443	0.18	0.14	Obesity-related traits;	chr19:37132570	chr19:37251912~37265535:+
BRCA	cis	rs11673344	0.504	rs8110796	ENSG00000226686.6	LINC01535	4.59	5.05e-06	0.000443	0.18	0.14	Obesity-related traits;	chr19:37132682	chr19:37251912~37265535:+
BRCA	cis	rs11673344	0.504	rs8111285	ENSG00000226686.6	LINC01535	4.59	5.05e-06	0.000443	0.18	0.14	Obesity-related traits;	chr19:37132747	chr19:37251912~37265535:+
BRCA	cis	rs11673344	0.504	rs6510591	ENSG00000226686.6	LINC01535	4.59	5.05e-06	0.000443	0.18	0.14	Obesity-related traits;	chr19:37133186	chr19:37251912~37265535:+
BRCA	cis	rs11673344	0.504	rs6510592	ENSG00000226686.6	LINC01535	4.59	5.05e-06	0.000443	0.18	0.14	Obesity-related traits;	chr19:37133430	chr19:37251912~37265535:+
BRCA	cis	rs11673344	0.542	rs2562598	ENSG00000226686.6	LINC01535	4.59	5.05e-06	0.000444	0.18	0.14	Obesity-related traits;	chr19:37025318	chr19:37251912~37265535:+
BRCA	cis	rs12681366	0.801	rs2919658	ENSG00000253175.1	RP11-267M23.6	4.59	5.05e-06	0.000444	0.18	0.14	Nonsyndromic cleft lip with cleft palate;	chr8:94459550	chr8:94565036~94565715:+
BRCA	cis	rs2562456	0.833	rs1781872	ENSG00000268658.4	LINC00664	4.59	5.05e-06	0.000444	0.24	0.14	Pain;	chr19:21294601	chr19:21483374~21503238:+
BRCA	cis	rs4415084	0.8	rs1821934	ENSG00000251141.4	RP11-53O19.1	4.59	5.05e-06	0.000444	0.13	0.14	Breast cancer;	chr5:44789070	chr5:44744900~44808777:-
BRCA	cis	rs11673344	0.504	rs35579954	ENSG00000226686.6	LINC01535	4.59	5.06e-06	0.000444	0.18	0.14	Obesity-related traits;	chr19:37139308	chr19:37251912~37265535:+
BRCA	cis	rs2638953	0.64	rs10843211	ENSG00000247934.4	RP11-967K21.1	-4.59	5.06e-06	0.000444	-0.19	-0.14	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28577717	chr12:28163298~28190738:-
BRCA	cis	rs7916697	0.626	rs3858145	ENSG00000233590.1	RP11-153K11.3	-4.59	5.06e-06	0.000444	-0.17	-0.14	Optic disc area;	chr10:68252081	chr10:68233251~68242379:-
BRCA	cis	rs793571	0.628	rs12595057	ENSG00000259250.1	RP11-50C13.1	-4.59	5.06e-06	0.000444	-0.24	-0.14	Schizophrenia;	chr15:58830627	chr15:58587507~58591676:+
BRCA	cis	rs35146811	0.844	rs10281368	ENSG00000214313.7	AZGP1P1	4.59	5.06e-06	0.000444	0.15	0.14	Coronary artery disease;	chr7:100058274	chr7:99980762~99987535:+
BRCA	cis	rs9949617	0.663	rs1276322	ENSG00000266495.1	RP11-17J14.2	-4.59	5.06e-06	0.000444	-0.25	-0.14	Hypertriglyceridemia;	chr18:23341165	chr18:23257164~23260354:-
BRCA	cis	rs4831837	0.717	rs35491563	ENSG00000270074.1	RP11-351I21.11	4.59	5.06e-06	0.000445	0.17	0.14	Morbidity-free survival;	chr8:12832392	chr8:12412827~12414373:+
BRCA	cis	rs2243480	1	rs1499614	ENSG00000275400.1	RP4-756H11.5	4.59	5.06e-06	0.000445	0.25	0.14	Diabetic kidney disease;	chr7:66265811	chr7:66553805~66554199:-
BRCA	cis	rs10461617	0.617	rs1423623	ENSG00000271828.1	CTD-2310F14.1	-4.59	5.06e-06	0.000445	-0.17	-0.14	Type 2 diabetes;	chr5:56769748	chr5:56927874~56929573:+
BRCA	cis	rs9527	0.518	rs4633383	ENSG00000213061.2	PFN1P11	4.59	5.07e-06	0.000445	0.27	0.14	Arsenic metabolism;	chr10:103035966	chr10:102838011~102845473:-
BRCA	cis	rs10504130	0.569	rs71513549	ENSG00000272024.1	RP11-546K22.3	-4.59	5.07e-06	0.000445	-0.21	-0.14	Venous thromboembolism (SNP x SNP interaction);	chr8:51770326	chr8:51950284~51950690:+
BRCA	cis	rs10504130	0.502	rs4321994	ENSG00000272024.1	RP11-546K22.3	-4.59	5.07e-06	0.000445	-0.21	-0.14	Venous thromboembolism (SNP x SNP interaction);	chr8:51771680	chr8:51950284~51950690:+
BRCA	cis	rs890448	0.726	rs28664200	ENSG00000254531.1	FLJ20021	-4.59	5.07e-06	0.000445	-0.16	-0.14	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101330344	chr4:101347780~101348883:+
BRCA	cis	rs7674212	0.541	rs4699051	ENSG00000251288.2	RP11-10L12.2	-4.59	5.07e-06	0.000445	-0.16	-0.14	Type 2 diabetes;	chr4:103193237	chr4:102751401~102752641:+
BRCA	cis	rs8103278	1	rs8109951	ENSG00000267395.4	AC074212.6	4.59	5.07e-06	0.000445	0.15	0.14	Coronary artery disease;	chr19:45786245	chr19:45767796~45772504:+
BRCA	cis	rs6840360	0.642	rs4696089	ENSG00000251603.1	RP11-164P12.4	-4.59	5.07e-06	0.000445	-0.13	-0.14	Intelligence (multi-trait analysis);	chr4:151474581	chr4:151667224~151670502:+
BRCA	cis	rs6840360	0.642	rs11932398	ENSG00000251603.1	RP11-164P12.4	-4.59	5.07e-06	0.000445	-0.13	-0.14	Intelligence (multi-trait analysis);	chr4:151476402	chr4:151667224~151670502:+
BRCA	cis	rs6840360	0.642	rs4263379	ENSG00000251603.1	RP11-164P12.4	-4.59	5.07e-06	0.000445	-0.13	-0.14	Intelligence (multi-trait analysis);	chr4:151477979	chr4:151667224~151670502:+
BRCA	cis	rs1005277	0.579	rs2505248	ENSG00000263064.2	RP11-291L22.7	4.59	5.07e-06	0.000445	0.17	0.14	Extrinsic epigenetic age acceleration;	chr10:38170169	chr10:38448689~38448949:+
BRCA	cis	rs853679	0.882	rs9468300	ENSG00000280107.1	AL022393.9	-4.59	5.07e-06	0.000445	-0.29	-0.14	Depression;	chr6:28159062	chr6:28170845~28172521:+
BRCA	cis	rs9532669	0.511	rs3783164	ENSG00000168852.11	TPTE2P5	-4.59	5.07e-06	0.000445	-0.14	-0.14	Cervical cancer;	chr13:40806227	chr13:40822296~40921749:-
BRCA	cis	rs7176527	0.579	rs366717	ENSG00000225151.9	GOLGA2P7	4.59	5.07e-06	0.000445	0.19	0.14	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84544848	chr15:84199311~84230136:-
BRCA	cis	rs9467773	0.595	rs9366657	ENSG00000124549.13	BTN2A3P	4.59	5.07e-06	0.000445	0.15	0.14	Intelligence (multi-trait analysis);	chr6:26434686	chr6:26421391~26432383:+
BRCA	cis	rs2562456	0.793	rs7259396	ENSG00000268658.4	LINC00664	4.59	5.08e-06	0.000446	0.23	0.14	Pain;	chr19:21340661	chr19:21483374~21503238:+
BRCA	cis	rs2562456	0.678	rs7260140	ENSG00000268658.4	LINC00664	4.59	5.08e-06	0.000446	0.23	0.14	Pain;	chr19:21340723	chr19:21483374~21503238:+
BRCA	cis	rs2562456	0.833	rs11880624	ENSG00000268658.4	LINC00664	4.59	5.08e-06	0.000446	0.23	0.14	Pain;	chr19:21341028	chr19:21483374~21503238:+
BRCA	cis	rs600550	0.857	rs12221613	ENSG00000275344.1	MIR6503	4.59	5.08e-06	0.000446	0.14	0.14	Lipoprotein-associated phospholipase A2 activity and mass;	chr11:60234789	chr11:60209071~60209156:-
BRCA	cis	rs11051970	0.513	rs7972023	ENSG00000274964.1	RP11-817I4.1	-4.59	5.08e-06	0.000446	-0.19	-0.14	Response to tocilizumab in rheumatoid arthritis;	chr12:32312174	chr12:32339368~32340724:+
BRCA	cis	rs3845817	1	rs3845817	ENSG00000237979.1	AC007389.1	-4.59	5.08e-06	0.000446	-0.17	-0.14	Bipolar disorder;	chr2:65531391	chr2:65500993~65502138:-
BRCA	cis	rs7811142	1	rs73161759	ENSG00000078319.8	PMS2P1	-4.59	5.08e-06	0.000446	-0.22	-0.14	Platelet count;	chr7:100412371	chr7:100320992~100341908:-
BRCA	cis	rs17507216	0.628	rs4627310	ENSG00000255769.6	GOLGA2P10	-4.59	5.09e-06	0.000446	-0.21	-0.14	Excessive daytime sleepiness;	chr15:82708330	chr15:82472993~82513950:-
BRCA	cis	rs2408955	0.522	rs4760679	ENSG00000257763.1	OR5BK1P	-4.59	5.09e-06	0.000446	-0.15	-0.14	Glycated hemoglobin levels;	chr12:48067852	chr12:48355792~48356614:-
BRCA	cis	rs13108904	0.775	rs2279282	ENSG00000253399.1	AC078852.2	-4.59	5.09e-06	0.000447	-0.16	-0.14	Obesity-related traits;	chr4:1222245	chr4:1358479~1359461:+
BRCA	cis	rs372883	0.935	rs1153294	ENSG00000215533.7	LINC00189	-4.59	5.09e-06	0.000447	-0.15	-0.14	Pancreatic cancer;	chr21:29328775	chr21:29193480~29288205:+
BRCA	cis	rs875971	0.545	rs1547529	ENSG00000273142.1	RP11-458F8.4	4.59	5.09e-06	0.000447	0.14	0.14	Aortic root size;	chr7:66258859	chr7:66902857~66906297:+
BRCA	cis	rs738722	1	rs738722	ENSG00000279978.1	chr22-38_28785274-29006793.1	4.59	5.09e-06	0.000447	0.19	0.14	Optic cup area;Esophageal cancer and gastric cancer;	chr22:28734024	chr22:28930201~29197572:+
BRCA	cis	rs8098244	0.603	rs1788787	ENSG00000264745.1	TTC39C-AS1	4.59	5.09e-06	0.000447	0.16	0.14	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23694775	chr18:23994213~24015339:-
BRCA	cis	rs6545883	0.894	rs7566035	ENSG00000212978.6	AC016747.3	-4.58	5.09e-06	0.000447	-0.19	-0.14	Tuberculosis;	chr2:61293680	chr2:61141592~61144969:-
BRCA	cis	rs67981189	0.574	rs2526884	ENSG00000269927.1	RP6-91H8.3	-4.58	5.09e-06	0.000447	-0.17	-0.14	Schizophrenia;	chr14:70901250	chr14:71141125~71143253:-
BRCA	cis	rs1077773	0.509	rs2123745	ENSG00000237773.4	AC003075.4	-4.58	5.09e-06	0.000447	-0.19	-0.14	Ulcerative colitis;Inflammatory bowel disease;	chr7:17401458	chr7:17279834~17299357:-
BRCA	cis	rs7727544	0.716	rs6863213	ENSG00000233006.5	AC034220.3	4.58	5.09e-06	0.000447	0.11	0.14	Blood metabolite levels;	chr5:132240239	chr5:132311285~132369916:-
BRCA	cis	rs2303319	0.504	rs12474713	ENSG00000227403.1	AC009299.3	4.58	5.1e-06	0.000447	0.34	0.14	Cognitive function;	chr2:161712831	chr2:161244739~161249050:+
BRCA	cis	rs7914558	0.646	rs7909286	ENSG00000213061.2	PFN1P11	4.58	5.1e-06	0.000447	0.2	0.14	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102899235	chr10:102838011~102845473:-
BRCA	cis	rs7914558	0.646	rs7909591	ENSG00000213061.2	PFN1P11	4.58	5.1e-06	0.000447	0.2	0.14	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102899261	chr10:102838011~102845473:-
BRCA	cis	rs8114671	0.836	rs6142284	ENSG00000279253.1	RP4-614O4.13	4.58	5.1e-06	0.000447	0.16	0.14	Height;	chr20:35053564	chr20:35262727~35264187:-
BRCA	cis	rs7772486	0.875	rs2748483	ENSG00000270638.1	RP3-466P17.1	-4.58	5.1e-06	0.000447	-0.16	-0.14	Lobe attachment (rater-scored or self-reported);	chr6:146014424	chr6:145735570~145737218:+
BRCA	cis	rs11673344	0.523	rs2385415	ENSG00000226686.6	LINC01535	4.58	5.1e-06	0.000448	0.18	0.14	Obesity-related traits;	chr19:37035291	chr19:37251912~37265535:+
BRCA	cis	rs13113518	1	rs11934897	ENSG00000249700.7	SRD5A3-AS1	4.58	5.1e-06	0.000448	0.17	0.14	Height;	chr4:55553396	chr4:55363971~55395847:-
BRCA	cis	rs13113518	0.934	rs11932293	ENSG00000249700.7	SRD5A3-AS1	4.58	5.1e-06	0.000448	0.17	0.14	Height;	chr4:55554025	chr4:55363971~55395847:-
BRCA	cis	rs7818688	0.697	rs80217195	ENSG00000253528.2	RP11-347C18.4	-4.58	5.1e-06	0.000448	-0.21	-0.14	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94974625	chr8:94974573~94974853:-
BRCA	cis	rs11051970	1	rs11051970	ENSG00000274964.1	RP11-817I4.1	-4.58	5.1e-06	0.000448	-0.17	-0.14	Response to tocilizumab in rheumatoid arthritis;	chr12:32384554	chr12:32339368~32340724:+
BRCA	cis	rs6088580	0.634	rs6087579	ENSG00000276073.1	RP5-1125A11.7	4.58	5.1e-06	0.000448	0.15	0.14	Glomerular filtration rate (creatinine);	chr20:34397349	chr20:33985617~33988989:-
BRCA	cis	rs644148	0.693	rs2686772	ENSG00000176761.7	ZNF285B	4.58	5.1e-06	0.000448	0.17	0.14	Personality dimensions;	chr19:44495668	chr19:44467641~44473227:+
BRCA	cis	rs559555	0.597	rs676033	ENSG00000272716.1	RP11-563N4.1	4.58	5.1e-06	0.000448	0.16	0.14	Blood metabolite ratios;Blood metabolite levels;	chr2:31583901	chr2:32165046~32165757:-
BRCA	cis	rs1858037	0.867	rs1553675	ENSG00000237979.1	AC007389.1	-4.58	5.11e-06	0.000448	-0.18	-0.14	Rheumatoid arthritis;	chr2:65343173	chr2:65500993~65502138:-
BRCA	cis	rs8048589	0.604	rs12929519	ENSG00000175604.2	RP11-276H1.3	4.58	5.11e-06	0.000448	0.24	0.14	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);	chr16:12113582	chr16:12086746~12090302:-
BRCA	cis	rs2839186	0.732	rs8131458	ENSG00000228137.1	AP001469.7	4.58	5.11e-06	0.000448	0.15	0.14	Testicular germ cell tumor;	chr21:46274798	chr21:46246890~46247682:+
BRCA	cis	rs2904967	0.866	rs526502	ENSG00000255200.1	AP003068.18	-4.58	5.11e-06	0.000448	-0.22	-0.14	Mean corpuscular volume;	chr11:65259119	chr11:65174117~65176470:-
BRCA	cis	rs13113518	1	rs4865011	ENSG00000249700.7	SRD5A3-AS1	4.58	5.11e-06	0.000448	0.17	0.14	Height;	chr4:55554456	chr4:55363971~55395847:-
BRCA	cis	rs7191700	0.511	rs8058983	ENSG00000262703.1	RP11-485G7.6	-4.58	5.11e-06	0.000448	-0.15	-0.14	Multiple sclerosis;	chr16:11266992	chr16:11348143~11349321:-
BRCA	cis	rs308403	0.509	rs6811183	ENSG00000224786.1	CETN4P	4.58	5.11e-06	0.000448	0.18	0.14	Blood protein levels;	chr4:122750396	chr4:122730548~122732193:-
BRCA	cis	rs4908769	0.55	rs7546225	ENSG00000270282.1	RP5-1115A15.2	-4.58	5.11e-06	0.000448	-0.16	-0.14	Allergy;	chr1:8811906	chr1:8512653~8513021:+
BRCA	cis	rs12030196	1	rs12031587	ENSG00000230812.4	LINC01358	4.58	5.11e-06	0.000448	0.15	0.14	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr1:59006381	chr1:59020387~59044614:+
BRCA	cis	rs7811142	0.83	rs7792959	ENSG00000078319.8	PMS2P1	-4.58	5.11e-06	0.000449	-0.22	-0.14	Platelet count;	chr7:100374780	chr7:100320992~100341908:-
BRCA	cis	rs10208649	0.656	rs60191560	ENSG00000272156.1	RP11-477N3.1	4.58	5.11e-06	0.000449	0.25	0.14	Body mass index;	chr2:54058661	chr2:54082554~54085066:+
BRCA	cis	rs1707322	1	rs11211232	ENSG00000234329.1	RP11-767N6.2	4.58	5.11e-06	0.000449	0.15	0.14	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45945474	chr1:45651039~45651826:-
BRCA	cis	rs117785887	0.536	rs10457790	ENSG00000270638.1	RP3-466P17.1	4.58	5.12e-06	0.000449	0.25	0.14	Interleukin-17 levels;	chr6:146038729	chr6:145735570~145737218:+
BRCA	cis	rs4831760	1	rs7819021	ENSG00000250483.1	PPM1AP1	4.58	5.12e-06	0.000449	0.2	0.14	Pulmonary function decline;	chr8:15678084	chr8:15806149~15807283:-
BRCA	cis	rs4831760	1	rs62502114	ENSG00000250483.1	PPM1AP1	4.58	5.12e-06	0.000449	0.2	0.14	Pulmonary function decline;	chr8:15678089	chr8:15806149~15807283:-
BRCA	cis	rs651907	0.588	rs1672380	ENSG00000244119.1	PDCL3P4	4.58	5.12e-06	0.000449	0.11	0.14	Colorectal cancer;	chr3:101914327	chr3:101712472~101713191:+
BRCA	cis	rs11742741	0.967	rs56043326	ENSG00000248874.4	C5orf17	-4.58	5.12e-06	0.000449	-0.18	-0.14	Educational attainment;	chr5:24158848	chr5:23951348~24178263:+
BRCA	cis	rs7818688	0.697	rs78088250	ENSG00000253528.2	RP11-347C18.4	-4.58	5.12e-06	0.000449	-0.22	-0.14	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94960490	chr8:94974573~94974853:-
BRCA	cis	rs7818688	0.697	rs11787303	ENSG00000253528.2	RP11-347C18.4	-4.58	5.12e-06	0.000449	-0.22	-0.14	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94960636	chr8:94974573~94974853:-
BRCA	cis	rs4415084	0.804	rs7705343	ENSG00000251141.4	RP11-53O19.1	4.58	5.12e-06	0.000449	0.13	0.14	Breast cancer;	chr5:44879475	chr5:44744900~44808777:-
BRCA	cis	rs4948275	0.773	rs2085347	ENSG00000237233.2	TMEM26-AS1	-4.58	5.12e-06	0.000449	-0.17	-0.14	Night sleep phenotypes;	chr10:61524888	chr10:61452639~61481956:+
BRCA	cis	rs11696845	0.966	rs1467474	ENSG00000276223.1	RP4-781B1.5	-4.58	5.13e-06	0.00045	-0.14	-0.14	Obesity-related traits;	chr20:44743364	chr20:44746642~44747201:+
BRCA	cis	rs875971	0.545	rs2420456	ENSG00000273142.1	RP11-458F8.4	4.58	5.13e-06	0.00045	0.14	0.14	Aortic root size;	chr7:66280619	chr7:66902857~66906297:+
BRCA	cis	rs7267979	0.844	rs6107027	ENSG00000125804.12	FAM182A	-4.58	5.13e-06	0.00045	-0.18	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25307996	chr20:26054655~26086917:+
BRCA	cis	rs2919009	0.62	rs11199664	ENSG00000271670.1	RP11-95I16.4	4.58	5.13e-06	0.00045	0.19	0.14	Obesity-related traits;	chr10:120936790	chr10:120879256~120880667:-
BRCA	cis	rs7312933	0.533	rs3747557	ENSG00000257225.1	RP11-328C8.4	4.58	5.13e-06	0.00045	0.16	0.14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42324159	chr12:42459366~42466128:+
BRCA	cis	rs17345786	0.511	rs13061565	ENSG00000256628.3	ZBTB11-AS1	4.58	5.13e-06	0.00045	0.18	0.14	Colonoscopy-negative controls vs population controls;	chr3:101673426	chr3:101676475~101679217:+
BRCA	cis	rs651907	0.557	rs7651404	ENSG00000256628.3	ZBTB11-AS1	4.58	5.13e-06	0.00045	0.18	0.14	Colorectal cancer;	chr3:101674450	chr3:101676475~101679217:+
BRCA	cis	rs2243480	1	rs35820085	ENSG00000226002.1	RP11-460N20.5	-4.58	5.13e-06	0.00045	-0.23	-0.14	Diabetic kidney disease;	chr7:65977771	chr7:65084103~65100232:+
BRCA	cis	rs172166	0.694	rs1225716	ENSG00000219392.1	RP1-265C24.5	-4.58	5.13e-06	0.00045	-0.2	-0.14	Cardiac Troponin-T levels;	chr6:28145968	chr6:28115628~28116551:+
BRCA	cis	rs2273156	1	rs17102967	ENSG00000226677.3	IGBP1P1	-4.58	5.14e-06	0.00045	-0.22	-0.14	Immunoglobulin light chain (AL) amyloidosis;	chr14:35011182	chr14:34939324~34940332:+
BRCA	cis	rs2880765	0.835	rs900573	ENSG00000202081.1	RNU6-1280P	-4.58	5.14e-06	0.00045	-0.16	-0.14	Coronary artery disease;	chr15:85494762	chr15:85651522~85651628:-
BRCA	cis	rs6088590	0.502	rs6059861	ENSG00000276073.1	RP5-1125A11.7	-4.58	5.14e-06	0.000451	-0.15	-0.14	Coronary artery disease;	chr20:34480758	chr20:33985617~33988989:-
BRCA	cis	rs6545883	0.894	rs9677047	ENSG00000212978.6	AC016747.3	-4.58	5.14e-06	0.000451	-0.19	-0.14	Tuberculosis;	chr2:61358160	chr2:61141592~61144969:-
BRCA	cis	rs875971	0.502	rs6460311	ENSG00000230295.1	RP11-458F8.2	-4.58	5.14e-06	0.000451	-0.14	-0.14	Aortic root size;	chr7:66646886	chr7:66880708~66882981:+
BRCA	cis	rs7671261	0.638	rs6843986	ENSG00000270720.1	RP11-84C13.2	4.58	5.14e-06	0.000451	0.16	0.14	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr4:89098214	chr4:89119284~89119871:+
BRCA	cis	rs11096990	0.552	rs7655170	ENSG00000249685.1	RP11-360F5.3	4.58	5.14e-06	0.000451	0.18	0.14	Cognitive function;	chr4:39171984	chr4:39133913~39135608:+
BRCA	cis	rs4218	0.517	rs2899640	ENSG00000259732.1	RP11-59H7.3	-4.58	5.15e-06	0.000451	-0.17	-0.14	Social communication problems;	chr15:59060281	chr15:59121034~59133250:+
BRCA	cis	rs1713985	1	rs1718828	ENSG00000269949.1	RP11-738E22.3	-4.58	5.15e-06	0.000451	-0.3	-0.14	Age-related macular degeneration;	chr4:56941319	chr4:56960927~56961373:-
BRCA	cis	rs78487399	0.808	rs13414619	ENSG00000234936.1	AC010883.5	4.58	5.15e-06	0.000451	0.19	0.14	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43472267	chr2:43229573~43233394:+
BRCA	cis	rs16958440	0.737	rs16958699	ENSG00000267724.1	RP11-49K24.8	4.58	5.15e-06	0.000451	0.25	0.14	Sitting height ratio;	chr18:47128475	chr18:47105946~47108062:+
BRCA	cis	rs16958440	1	rs16958701	ENSG00000267724.1	RP11-49K24.8	4.58	5.15e-06	0.000451	0.25	0.14	Sitting height ratio;	chr18:47128870	chr18:47105946~47108062:+
BRCA	cis	rs9309473	0.583	rs6713196	ENSG00000163016.8	ALMS1P	4.58	5.15e-06	0.000451	0.17	0.14	Metabolite levels;	chr2:73349277	chr2:73644919~73685576:+
BRCA	cis	rs6452524	0.935	rs2731846	ENSG00000281327.1	LINC01338	4.58	5.15e-06	0.000452	0.16	0.14	Hypertension (SNP x SNP interaction);	chr5:83193781	chr5:82850864~82859836:-
BRCA	cis	rs911555	0.655	rs10141157	ENSG00000244691.1	RPL10AP1	-4.58	5.15e-06	0.000452	-0.16	-0.14	Intelligence (multi-trait analysis);	chr14:103551768	chr14:103412119~103412761:-
BRCA	cis	rs2554380	0.843	rs7182216	ENSG00000230373.7	GOLGA6L5P	4.58	5.15e-06	0.000452	0.19	0.14	Height;	chr15:83753754	chr15:84507885~84516814:-
BRCA	cis	rs1008375	0.966	rs6832962	ENSG00000249502.1	AC006160.5	-4.58	5.15e-06	0.000452	-0.17	-0.14	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17650510	chr4:17587467~17614571:-
BRCA	cis	rs13358904	0.868	rs4958028	ENSG00000278921.2	EPB41L4A-AS2	4.58	5.15e-06	0.000452	0.18	0.14	Suicide ideation score in major depressive disorder;	chr5:112259522	chr5:112419583~112420978:+
BRCA	cis	rs9311474	0.713	rs352166	ENSG00000243224.1	RP5-1157M23.2	-4.58	5.16e-06	0.000452	-0.15	-0.14	Electroencephalogram traits;	chr3:52204661	chr3:52239258~52241097:+
BRCA	cis	rs651907	0.588	rs1378838	ENSG00000244119.1	PDCL3P4	4.58	5.16e-06	0.000452	0.11	0.14	Colorectal cancer;	chr3:101915699	chr3:101712472~101713191:+
BRCA	cis	rs56322409	0.897	rs10882649	ENSG00000226688.5	ENTPD1-AS1	-4.58	5.16e-06	0.000452	-0.16	-0.14	Blood metabolite levels;	chr10:95666329	chr10:95753206~96090238:-
BRCA	cis	rs926392	0.896	rs7268772	ENSG00000274825.1	RP4-616B8.5	-4.58	5.16e-06	0.000452	-0.13	-0.14	Dialysis-related mortality;	chr20:39055858	chr20:38955910~38956547:+
BRCA	cis	rs7246657	0.525	rs1667351	ENSG00000276846.1	CTD-3220F14.3	4.58	5.16e-06	0.000453	0.19	0.14	Coronary artery calcification;	chr19:36987125	chr19:37314868~37315620:-
BRCA	cis	rs859767	0.741	rs1467194	ENSG00000224043.6	CCNT2-AS1	4.58	5.16e-06	0.000453	0.19	0.14	Neuroticism;	chr2:134673051	chr2:134735464~134918710:-
BRCA	cis	rs2255336	0.817	rs10743889	ENSG00000245648.1	RP11-277P12.20	4.58	5.17e-06	0.000453	0.21	0.14	Blood protein levels;	chr12:10368790	chr12:10363769~10398506:+
BRCA	cis	rs7267979	0.816	rs376742	ENSG00000274973.1	RP13-401N8.7	-4.58	5.17e-06	0.000453	-0.16	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25506781	chr20:25845497~25845862:+
BRCA	cis	rs4650994	1	rs4650993	ENSG00000273384.1	RP5-1098D14.1	4.58	5.17e-06	0.000453	0.17	0.14	HDL cholesterol;HDL cholesterol levels;	chr1:178546052	chr1:178651706~178652282:+
BRCA	cis	rs4650994	1	rs10798616	ENSG00000273384.1	RP5-1098D14.1	4.58	5.17e-06	0.000453	0.17	0.14	HDL cholesterol;HDL cholesterol levels;	chr1:178546507	chr1:178651706~178652282:+
BRCA	cis	rs807029	0.533	rs67813203	ENSG00000236662.1	RP11-108L7.4	4.58	5.17e-06	0.000453	0.18	0.14	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100978794	chr10:100980507~100985614:-
BRCA	cis	rs1850744	0.702	rs10939428	ENSG00000163612.10	FAM86KP	-4.58	5.17e-06	0.000453	-0.31	-0.14	Economic and political preferences;	chr4:9628417	chr4:9153296~9165451:+
BRCA	cis	rs6095360	0.934	rs2273531	ENSG00000222365.1	SNORD12B	-4.58	5.17e-06	0.000453	-0.15	-0.14	Intelligence (multi-trait analysis);	chr20:49011897	chr20:49280319~49280409:+
BRCA	cis	rs9921338	0.887	rs13330151	ENSG00000262703.1	RP11-485G7.6	-4.58	5.17e-06	0.000453	-0.18	-0.14	Vein graft stenosis in coronary artery bypass grafting;	chr16:11308542	chr16:11348143~11349321:-
BRCA	cis	rs875971	0.545	rs73136346	ENSG00000232546.1	RP11-458F8.1	-4.58	5.17e-06	0.000453	-0.14	-0.14	Aortic root size;	chr7:66101095	chr7:66848496~66858136:+
BRCA	cis	rs1005277	0.541	rs2472177	ENSG00000263064.2	RP11-291L22.7	4.58	5.17e-06	0.000453	0.17	0.14	Extrinsic epigenetic age acceleration;	chr10:38095087	chr10:38448689~38448949:+
BRCA	cis	rs1910358	0.621	rs1586723	ENSG00000248874.4	C5orf17	-4.58	5.17e-06	0.000453	-0.21	-0.14	Venous thromboembolism (SNP x SNP interaction);	chr5:23829129	chr5:23951348~24178263:+
BRCA	cis	rs7048146	0.966	rs10816834	ENSG00000213539.4	YBX1P6	4.58	5.17e-06	0.000453	0.16	0.14	Vascular brain injury;	chr9:109538626	chr9:109532830~109534332:-
BRCA	cis	rs6676180	0.555	rs12060730	ENSG00000231365.4	RP11-418J17.1	-4.58	5.17e-06	0.000453	-0.16	-0.14	Monobrow;	chr1:119228079	chr1:119140396~119275973:+
BRCA	cis	rs2625529	0.652	rs2957728	ENSG00000260037.4	CTD-2524L6.3	4.58	5.17e-06	0.000453	0.18	0.14	Red blood cell count;	chr15:71944091	chr15:71818396~71823384:+
BRCA	cis	rs8030379	0.967	rs10520573	ENSG00000230373.7	GOLGA6L5P	-4.58	5.18e-06	0.000454	-0.14	-0.14	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83922823	chr15:84507885~84516814:-
BRCA	cis	rs2273156	1	rs8019179	ENSG00000226677.3	IGBP1P1	-4.58	5.18e-06	0.000454	-0.21	-0.14	Immunoglobulin light chain (AL) amyloidosis;	chr14:34978589	chr14:34939324~34940332:+
BRCA	cis	rs6095360	0.644	rs35269800	ENSG00000222365.1	SNORD12B	-4.58	5.18e-06	0.000454	-0.18	-0.14	Intelligence (multi-trait analysis);	chr20:48896484	chr20:49280319~49280409:+
BRCA	cis	rs2408955	0.5	rs12816820	ENSG00000257763.1	OR5BK1P	4.58	5.18e-06	0.000454	0.15	0.14	Glycated hemoglobin levels;	chr12:48164542	chr12:48355792~48356614:-
BRCA	cis	rs7246657	0.722	rs2972447	ENSG00000226686.6	LINC01535	4.58	5.18e-06	0.000454	0.21	0.14	Coronary artery calcification;	chr19:37638835	chr19:37251912~37265535:+
BRCA	cis	rs2235642	0.505	rs56359342	ENSG00000260989.1	LA16c-395F10.2	-4.58	5.18e-06	0.000454	-0.15	-0.14	Coronary artery disease;	chr16:1604947	chr16:1580527~1610328:+
BRCA	cis	rs7809615	0.901	rs6947941	ENSG00000244219.5	GS1-259H13.2	-4.58	5.18e-06	0.000454	-0.25	-0.14	Blood metabolite ratios;	chr7:99558823	chr7:99598066~99610813:+
BRCA	cis	rs7809615	0.901	rs17161761	ENSG00000244219.5	GS1-259H13.2	-4.58	5.18e-06	0.000454	-0.25	-0.14	Blood metabolite ratios;	chr7:99559311	chr7:99598066~99610813:+
BRCA	cis	rs2253762	0.54	rs7358186	ENSG00000226864.1	ATE1-AS1	4.58	5.18e-06	0.000454	0.26	0.14	Breast cancer;	chr10:122000816	chr10:121928312~121951965:+
BRCA	cis	rs11154801	0.696	rs4432992	ENSG00000234084.1	RP3-388E23.2	-4.58	5.19e-06	0.000454	-0.15	-0.14	Multiple sclerosis;	chr6:135612356	chr6:135301568~135307158:+
BRCA	cis	rs6430585	0.583	rs79633114	ENSG00000231890.6	DARS-AS1	-4.58	5.19e-06	0.000454	-0.22	-0.14	Corneal structure;	chr2:135829255	chr2:135985176~136022593:+
BRCA	cis	rs2073316	0.592	rs11124261	ENSG00000272716.1	RP11-563N4.1	4.58	5.19e-06	0.000455	0.15	0.14	Interleukin-18 levels;	chr2:31475653	chr2:32165046~32165757:-
BRCA	cis	rs1858037	0.836	rs1396209	ENSG00000237979.1	AC007389.1	4.58	5.19e-06	0.000455	0.18	0.14	Rheumatoid arthritis;	chr2:65374100	chr2:65500993~65502138:-
BRCA	cis	rs13098911	0.54	rs34452002	ENSG00000223552.1	RP11-24F11.2	-4.58	5.19e-06	0.000455	-0.23	-0.14	Celiac disease;	chr3:46101695	chr3:46364955~46407059:-
BRCA	cis	rs11098499	0.754	rs1980025	ENSG00000260091.1	RP11-33B1.4	4.58	5.19e-06	0.000455	0.12	0.14	Corneal astigmatism;	chr4:119331651	chr4:119409333~119410233:+
BRCA	cis	rs11239930	0.517	rs942689	ENSG00000278811.3	LINC00624	4.58	5.19e-06	0.000455	0.17	0.14	AIDS progression;	chr1:147079231	chr1:147258885~147517875:-
BRCA	cis	rs9527	0.59	rs3781281	ENSG00000269609.4	RPARP-AS1	4.58	5.19e-06	0.000455	0.13	0.14	Arsenic metabolism;	chr10:103092891	chr10:102449817~102461106:+
BRCA	cis	rs10857712	0.754	rs2297031	ENSG00000214279.11	SCART1	-4.58	5.19e-06	0.000455	-0.15	-0.14	Systemic lupus erythematosus;	chr10:133419150	chr10:133453928~133523558:+
BRCA	cis	rs7226408	0.857	rs11081985	ENSG00000267707.2	RP11-95O2.5	-4.58	5.19e-06	0.000455	-0.21	-0.14	Obesity-related traits;	chr18:37103007	chr18:37243776~37247506:+
BRCA	cis	rs2227564	0.729	rs2675675	ENSG00000271816.1	BMS1P4	4.58	5.2e-06	0.000455	0.15	0.14	Crohn's disease;Inflammatory bowel disease;	chr10:73889290	chr10:73699151~73730487:-
BRCA	cis	rs13113518	1	rs4864994	ENSG00000249700.7	SRD5A3-AS1	4.58	5.2e-06	0.000455	0.17	0.14	Height;	chr4:55451955	chr4:55363971~55395847:-
BRCA	cis	rs950169	0.614	rs12911536	ENSG00000275120.1	RP11-182J1.17	4.58	5.2e-06	0.000455	0.21	0.14	Schizophrenia;	chr15:84004278	chr15:84599434~84606463:-
BRCA	cis	rs10129255	0.536	rs6576201	ENSG00000211967.3	IGHV3-53	4.58	5.2e-06	0.000456	0.09	0.14	Kawasaki disease;	chr14:106683696	chr14:106592676~106593347:-
BRCA	cis	rs6723226	0.806	rs2249109	ENSG00000276334.1	AL133243.1	4.58	5.2e-06	0.000456	0.18	0.14	Intelligence (multi-trait analysis);	chr2:32525812	chr2:32521927~32523547:+
BRCA	cis	rs7246657	0.722	rs1531549	ENSG00000226686.6	LINC01535	-4.58	5.2e-06	0.000456	-0.21	-0.14	Coronary artery calcification;	chr19:37597108	chr19:37251912~37265535:+
BRCA	cis	rs11096990	0.634	rs7666632	ENSG00000249685.1	RP11-360F5.3	4.58	5.2e-06	0.000456	0.18	0.14	Cognitive function;	chr4:39238568	chr4:39133913~39135608:+
BRCA	cis	rs8058578	0.945	rs8058961	ENSG00000260911.2	RP11-196G11.2	4.58	5.21e-06	0.000456	0.14	0.14	Multiple myeloma;	chr16:30797742	chr16:31043150~31049868:+
BRCA	cis	rs6430585	0.583	rs4594504	ENSG00000224043.6	CCNT2-AS1	-4.58	5.21e-06	0.000456	-0.24	-0.14	Corneal structure;	chr2:135867543	chr2:134735464~134918710:-
BRCA	cis	rs4834770	1	rs10034579	ENSG00000245958.5	RP11-33B1.1	-4.58	5.21e-06	0.000456	-0.13	-0.14	Blood protein levels;	chr4:119322874	chr4:119454791~119552025:+
BRCA	cis	rs4578769	0.722	rs1010801	ENSG00000265939.1	UBE2CP2	4.58	5.21e-06	0.000456	0.18	0.14	Eosinophil percentage of white cells;	chr18:23027435	chr18:22900486~22900995:-
BRCA	cis	rs11098499	0.821	rs10032151	ENSG00000250412.1	KLHL2P1	4.58	5.21e-06	0.000456	0.17	0.14	Corneal astigmatism;	chr4:119470473	chr4:119334329~119378233:+
BRCA	cis	rs11098499	0.865	rs10032158	ENSG00000250412.1	KLHL2P1	4.58	5.21e-06	0.000456	0.17	0.14	Corneal astigmatism;	chr4:119470477	chr4:119334329~119378233:+
BRCA	cis	rs4143844	0.737	rs11634818	ENSG00000259251.2	RP11-643M14.1	4.58	5.21e-06	0.000457	0.34	0.14	Bipolar disorder and schizophrenia;	chr15:62064187	chr15:62060503~62062434:+
BRCA	cis	rs4713118	0.868	rs10484401	ENSG00000216901.1	AL022393.7	-4.58	5.21e-06	0.000457	-0.2	-0.14	Parkinson's disease;	chr6:27778811	chr6:28176188~28176674:+
BRCA	cis	rs1048886	0.872	rs77054685	ENSG00000271967.1	RP11-134K13.4	-4.58	5.21e-06	0.000457	-0.19	-0.14	Type 2 diabetes;	chr6:70572469	chr6:70596438~70596980:+
BRCA	cis	rs7267979	1	rs7019	ENSG00000125804.12	FAM182A	-4.58	5.22e-06	0.000457	-0.18	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25297642	chr20:26054655~26086917:+
BRCA	cis	rs11673344	0.504	rs7259332	ENSG00000226686.6	LINC01535	4.58	5.22e-06	0.000457	0.18	0.14	Obesity-related traits;	chr19:37143389	chr19:37251912~37265535:+
BRCA	cis	rs6832769	0.925	rs11133383	ENSG00000223305.1	RN7SKP30	-4.58	5.22e-06	0.000457	-0.18	-0.14	Personality dimensions;	chr4:55450878	chr4:55540502~55540835:-
BRCA	cis	rs7178909	0.835	rs2174292	ENSG00000259677.1	RP11-493E3.1	4.58	5.22e-06	0.000457	0.17	0.14	Common traits (Other);	chr15:89872349	chr15:89876540~89877285:+
BRCA	cis	rs4415084	0.84	rs60707950	ENSG00000251141.4	RP11-53O19.1	4.58	5.22e-06	0.000457	0.14	0.14	Breast cancer;	chr5:44684141	chr5:44744900~44808777:-
BRCA	cis	rs16958440	0.867	rs58061761	ENSG00000267724.1	RP11-49K24.8	4.58	5.22e-06	0.000457	0.28	0.14	Sitting height ratio;	chr18:47159794	chr18:47105946~47108062:+
BRCA	cis	rs5167	0.504	rs892101	ENSG00000280087.1	CTB-129P6.7	4.58	5.22e-06	0.000457	0.17	0.14	Blood protein levels;	chr19:44952201	chr19:44909375~44914968:+
BRCA	cis	rs4763879	0.739	rs7310460	ENSG00000278635.1	CTD-2318O12.1	4.58	5.22e-06	0.000457	0.14	0.14	Type 1 diabetes;	chr12:9688177	chr12:9415641~9416718:+
BRCA	cis	rs7200543	1	rs16966947	ENSG00000260872.1	RP11-680G24.5	-4.58	5.23e-06	0.000458	-0.15	-0.14	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15047188	chr16:15018106~15020488:-
BRCA	cis	rs2303319	0.504	rs62187611	ENSG00000227403.1	AC009299.3	4.58	5.23e-06	0.000458	0.34	0.14	Cognitive function;	chr2:161575436	chr2:161244739~161249050:+
BRCA	cis	rs2303319	0.504	rs12473497	ENSG00000227403.1	AC009299.3	4.58	5.23e-06	0.000458	0.34	0.14	Cognitive function;	chr2:161577256	chr2:161244739~161249050:+
BRCA	cis	rs2303319	0.504	rs12469302	ENSG00000227403.1	AC009299.3	4.58	5.23e-06	0.000458	0.34	0.14	Cognitive function;	chr2:161577321	chr2:161244739~161249050:+
BRCA	cis	rs2303319	0.504	rs62187613	ENSG00000227403.1	AC009299.3	4.58	5.23e-06	0.000458	0.34	0.14	Cognitive function;	chr2:161577964	chr2:161244739~161249050:+
BRCA	cis	rs2278702	0.943	rs17315116	ENSG00000259495.2	RP11-210M15.2	-4.58	5.23e-06	0.000458	-0.22	-0.14	Bipolar disorder;	chr15:80396263	chr15:80344853~80403575:-
BRCA	cis	rs1858037	0.867	rs871974	ENSG00000281920.1	RP11-418H16.1	-4.58	5.23e-06	0.000458	-0.18	-0.14	Rheumatoid arthritis;	chr2:65330153	chr2:65623272~65628424:+
BRCA	cis	rs7267979	1	rs6050632	ENSG00000274973.1	RP13-401N8.7	-4.58	5.23e-06	0.000458	-0.16	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25451965	chr20:25845497~25845862:+
BRCA	cis	rs459482	0.504	rs469483	ENSG00000228318.3	AP001610.5	4.58	5.23e-06	0.000458	0.16	0.14	IgG glycosylation;	chr21:41446588	chr21:41441056~41445708:-
BRCA	cis	rs10833905	0.938	rs12285669	ENSG00000246225.5	RP11-17A1.3	-4.58	5.23e-06	0.000458	-0.2	-0.14	Sudden cardiac arrest;	chr11:23041871	chr11:22829380~22945393:+
BRCA	cis	rs12477438	0.765	rs7591794	ENSG00000231822.1	AC019097.7	-4.58	5.23e-06	0.000458	-0.15	-0.14	Chronic sinus infection;	chr2:98951051	chr2:99102018~99102752:+
BRCA	cis	rs72482608	0.865	rs10800542	ENSG00000271811.1	RP1-79C4.4	4.58	5.23e-06	0.000458	0.15	0.14	Emphysema imaging phenotypes;	chr1:170795774	chr1:170667381~170669425:+
BRCA	cis	rs7665090	1	rs2125211	ENSG00000251288.2	RP11-10L12.2	4.58	5.23e-06	0.000458	0.17	0.14	Primary biliary cholangitis;	chr4:102638719	chr4:102751401~102752641:+
BRCA	cis	rs11779988	0.545	rs436506	ENSG00000253671.1	RP11-806O11.1	4.58	5.23e-06	0.000458	0.22	0.14	Breast cancer;	chr8:17940734	chr8:17808941~17820868:+
BRCA	cis	rs7772486	0.79	rs2247429	ENSG00000270638.1	RP3-466P17.1	4.58	5.23e-06	0.000458	0.16	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145896633	chr6:145735570~145737218:+
BRCA	cis	rs11168618	0.875	rs11168606	ENSG00000240399.1	RP1-228P16.1	4.58	5.23e-06	0.000458	0.16	0.14	Adiponectin levels;	chr12:48498906	chr12:48054813~48055591:-
BRCA	cis	rs7267979	0.714	rs3787082	ENSG00000274973.1	RP13-401N8.7	-4.58	5.23e-06	0.000458	-0.16	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25255100	chr20:25845497~25845862:+
BRCA	cis	rs4664293	0.967	rs9646765	ENSG00000224152.1	AC009506.1	-4.58	5.24e-06	0.000458	-0.16	-0.14	Monocyte percentage of white cells;	chr2:159709137	chr2:159615296~159617082:+
BRCA	cis	rs2562456	0.754	rs58338799	ENSG00000268658.4	LINC00664	4.58	5.24e-06	0.000459	0.23	0.14	Pain;	chr19:21339009	chr19:21483374~21503238:+
BRCA	cis	rs12681366	0.762	rs10109060	ENSG00000253704.1	RP11-267M23.4	4.58	5.24e-06	0.000459	0.15	0.14	Nonsyndromic cleft lip with cleft palate;	chr8:94365140	chr8:94553722~94569745:+
BRCA	cis	rs2253762	0.54	rs79547192	ENSG00000226864.1	ATE1-AS1	4.58	5.24e-06	0.000459	0.26	0.14	Breast cancer;	chr10:121998664	chr10:121928312~121951965:+
BRCA	cis	rs2579519	0.547	rs2463560	ENSG00000168992.4	OR7E102P	4.58	5.24e-06	0.000459	0.18	0.14	Diastolic blood pressure;	chr2:95929841	chr2:95546531~95547545:+
BRCA	cis	rs10844706	0.699	rs11052750	ENSG00000214776.8	RP11-726G1.1	4.58	5.24e-06	0.000459	0.17	0.14	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9735090	chr12:9467552~9576275:+
BRCA	cis	rs16958440	0.867	rs76922914	ENSG00000267724.1	RP11-49K24.8	4.58	5.24e-06	0.000459	0.28	0.14	Sitting height ratio;	chr18:47162083	chr18:47105946~47108062:+
BRCA	cis	rs10540	0.908	rs1044707	ENSG00000279672.1	CMB9-55F22.1	-4.58	5.24e-06	0.000459	-0.24	-0.14	Body mass index;	chr11:491334	chr11:779617~780755:+
BRCA	cis	rs16958440	0.867	rs12326412	ENSG00000267724.1	RP11-49K24.8	4.58	5.24e-06	0.000459	0.28	0.14	Sitting height ratio;	chr18:47157223	chr18:47105946~47108062:+
BRCA	cis	rs16958440	0.867	rs77615793	ENSG00000267724.1	RP11-49K24.8	4.58	5.24e-06	0.000459	0.28	0.14	Sitting height ratio;	chr18:47158093	chr18:47105946~47108062:+
BRCA	cis	rs16958440	0.867	rs75287977	ENSG00000267724.1	RP11-49K24.8	4.58	5.24e-06	0.000459	0.28	0.14	Sitting height ratio;	chr18:47160452	chr18:47105946~47108062:+
BRCA	cis	rs16958440	0.867	rs28578518	ENSG00000267724.1	RP11-49K24.8	4.58	5.24e-06	0.000459	0.28	0.14	Sitting height ratio;	chr18:47161177	chr18:47105946~47108062:+
BRCA	cis	rs16958440	0.867	rs28587821	ENSG00000267724.1	RP11-49K24.8	4.58	5.24e-06	0.000459	0.28	0.14	Sitting height ratio;	chr18:47161535	chr18:47105946~47108062:+
BRCA	cis	rs16958440	0.867	rs77599321	ENSG00000267724.1	RP11-49K24.8	4.58	5.24e-06	0.000459	0.28	0.14	Sitting height ratio;	chr18:47163271	chr18:47105946~47108062:+
BRCA	cis	rs16958440	0.867	rs75901436	ENSG00000267724.1	RP11-49K24.8	4.58	5.24e-06	0.000459	0.28	0.14	Sitting height ratio;	chr18:47163273	chr18:47105946~47108062:+
BRCA	cis	rs16958440	0.867	rs74845165	ENSG00000267724.1	RP11-49K24.8	4.58	5.24e-06	0.000459	0.28	0.14	Sitting height ratio;	chr18:47164481	chr18:47105946~47108062:+
BRCA	cis	rs16958440	0.867	rs114475395	ENSG00000267724.1	RP11-49K24.8	4.58	5.24e-06	0.000459	0.28	0.14	Sitting height ratio;	chr18:47164639	chr18:47105946~47108062:+
BRCA	cis	rs16958440	0.867	rs16949157	ENSG00000267724.1	RP11-49K24.8	4.58	5.24e-06	0.000459	0.28	0.14	Sitting height ratio;	chr18:47164953	chr18:47105946~47108062:+
BRCA	cis	rs16958440	0.867	rs75808931	ENSG00000267724.1	RP11-49K24.8	4.58	5.24e-06	0.000459	0.28	0.14	Sitting height ratio;	chr18:47166671	chr18:47105946~47108062:+
BRCA	cis	rs16958440	0.867	rs59217333	ENSG00000267724.1	RP11-49K24.8	4.58	5.24e-06	0.000459	0.28	0.14	Sitting height ratio;	chr18:47168473	chr18:47105946~47108062:+
BRCA	cis	rs16958440	0.867	rs10083937	ENSG00000267724.1	RP11-49K24.8	4.58	5.24e-06	0.000459	0.28	0.14	Sitting height ratio;	chr18:47169231	chr18:47105946~47108062:+
BRCA	cis	rs16958440	0.867	rs80006910	ENSG00000267724.1	RP11-49K24.8	4.58	5.24e-06	0.000459	0.28	0.14	Sitting height ratio;	chr18:47170011	chr18:47105946~47108062:+
BRCA	cis	rs4218	0.689	rs12900369	ENSG00000277144.1	RP11-59H7.4	-4.58	5.24e-06	0.000459	-0.18	-0.14	Social communication problems;	chr15:59099254	chr15:59115547~59116089:-
BRCA	cis	rs4218	0.689	rs28514475	ENSG00000277144.1	RP11-59H7.4	-4.58	5.24e-06	0.000459	-0.18	-0.14	Social communication problems;	chr15:59099896	chr15:59115547~59116089:-
BRCA	cis	rs4218	0.689	rs28610479	ENSG00000277144.1	RP11-59H7.4	-4.58	5.24e-06	0.000459	-0.18	-0.14	Social communication problems;	chr15:59099906	chr15:59115547~59116089:-
BRCA	cis	rs4865762	0.967	rs67239762	ENSG00000247796.2	CTD-2366F13.1	-4.58	5.24e-06	0.000459	-0.15	-0.14	Intraocular pressure;	chr5:53308163	chr5:53109842~53115126:+
BRCA	cis	rs7267979	1	rs6050617	ENSG00000274973.1	RP13-401N8.7	-4.58	5.25e-06	0.000459	-0.16	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25441012	chr20:25845497~25845862:+
BRCA	cis	rs7267979	0.933	rs2387887	ENSG00000274973.1	RP13-401N8.7	-4.58	5.25e-06	0.000459	-0.16	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25446445	chr20:25845497~25845862:+
BRCA	cis	rs7267979	1	rs6037121	ENSG00000274973.1	RP13-401N8.7	-4.58	5.25e-06	0.000459	-0.16	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25447675	chr20:25845497~25845862:+
BRCA	cis	rs7267979	1	rs1047171	ENSG00000274973.1	RP13-401N8.7	-4.58	5.25e-06	0.000459	-0.16	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25448150	chr20:25845497~25845862:+
BRCA	cis	rs7267979	1	rs6050629	ENSG00000274973.1	RP13-401N8.7	-4.58	5.25e-06	0.000459	-0.16	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25450044	chr20:25845497~25845862:+
BRCA	cis	rs7267979	1	rs6050630	ENSG00000274973.1	RP13-401N8.7	-4.58	5.25e-06	0.000459	-0.16	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25450109	chr20:25845497~25845862:+
BRCA	cis	rs11098499	0.739	rs9996382	ENSG00000260404.2	RP11-384K6.6	4.58	5.25e-06	0.000459	0.13	0.14	Corneal astigmatism;	chr4:119229857	chr4:118591773~118633729:+
BRCA	cis	rs17695224	0.545	rs7252805	ENSG00000269483.1	AC006272.1	4.58	5.25e-06	0.000459	0.17	0.14	HDL cholesterol;HDL cholesterol levels;	chr19:51840169	chr19:51839924~51843324:-
BRCA	cis	rs6728642	0.908	rs10207116	ENSG00000230606.9	AC159540.1	4.58	5.25e-06	0.000459	0.24	0.14	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:97355418	chr2:97416165~97433527:-
BRCA	cis	rs12744310	0.887	rs16828067	ENSG00000235358.1	RP11-399E6.1	4.58	5.25e-06	0.000459	0.21	0.14	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41317880	chr1:41242373~41284861:+
BRCA	cis	rs12744310	0.887	rs16828071	ENSG00000235358.1	RP11-399E6.1	4.58	5.25e-06	0.000459	0.21	0.14	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41317931	chr1:41242373~41284861:+
BRCA	cis	rs1008375	0.932	rs7697329	ENSG00000249502.1	AC006160.5	-4.58	5.25e-06	0.000459	-0.17	-0.14	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17656230	chr4:17587467~17614571:-
BRCA	cis	rs180730	1	rs343197	ENSG00000251609.2	SETP12	4.58	5.25e-06	0.000459	0.2	0.14	Fasting plasma glucose;	chr4:120877330	chr4:120895494~120897083:-
BRCA	cis	rs7246657	0.722	rs2972437	ENSG00000226686.6	LINC01535	-4.58	5.25e-06	0.000459	-0.21	-0.14	Coronary artery calcification;	chr19:37719610	chr19:37251912~37265535:+
BRCA	cis	rs57221529	0.713	rs12521091	ENSG00000225138.6	CTD-2228K2.7	4.58	5.25e-06	0.000459	0.21	0.14	Lung disease severity in cystic fibrosis;	chr5:590595	chr5:473236~480884:+
BRCA	cis	rs755249	0.567	rs16826000	ENSG00000182109.6	RP11-69E11.4	4.58	5.25e-06	0.000459	0.2	0.14	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39248188	chr1:39522280~39546187:-
BRCA	cis	rs7818688	0.654	rs75680386	ENSG00000253528.2	RP11-347C18.4	-4.58	5.25e-06	0.000459	-0.22	-0.14	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94973920	chr8:94974573~94974853:-
BRCA	cis	rs7615952	0.932	rs9841157	ENSG00000241288.6	RP11-379B18.5	-4.58	5.25e-06	0.000459	-0.21	-0.14	Blood pressure (smoking interaction);	chr3:125916812	chr3:125827238~125916384:-
BRCA	cis	rs7615952	0.551	rs12695470	ENSG00000241288.6	RP11-379B18.5	-4.58	5.25e-06	0.000459	-0.21	-0.14	Blood pressure (smoking interaction);	chr3:125916875	chr3:125827238~125916384:-
BRCA	cis	rs7267979	0.816	rs6076358	ENSG00000274973.1	RP13-401N8.7	4.58	5.25e-06	0.000459	0.16	0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25538767	chr20:25845497~25845862:+
BRCA	cis	rs6840360	0.642	rs6843639	ENSG00000251603.1	RP11-164P12.4	-4.58	5.25e-06	0.000459	-0.13	-0.14	Intelligence (multi-trait analysis);	chr4:151494863	chr4:151667224~151670502:+
BRCA	cis	rs4218	0.531	rs8026611	ENSG00000259732.1	RP11-59H7.3	-4.58	5.25e-06	0.000459	-0.16	-0.14	Social communication problems;	chr15:59048927	chr15:59121034~59133250:+
BRCA	cis	rs1707322	1	rs4073847	ENSG00000234329.1	RP11-767N6.2	-4.58	5.25e-06	0.000459	-0.14	-0.14	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45997340	chr1:45651039~45651826:-
BRCA	cis	rs875971	0.571	rs160641	ENSG00000230295.1	RP11-458F8.2	-4.58	5.25e-06	0.00046	-0.13	-0.14	Aortic root size;	chr7:66112359	chr7:66880708~66882981:+
BRCA	cis	rs16846053	0.786	rs62187647	ENSG00000227403.1	AC009299.3	4.58	5.25e-06	0.00046	0.33	0.14	Blood osmolality (transformed sodium);	chr2:161589508	chr2:161244739~161249050:+
BRCA	cis	rs5167	0.504	rs7247227	ENSG00000280087.1	CTB-129P6.7	4.58	5.26e-06	0.00046	0.17	0.14	Blood protein levels;	chr19:44951502	chr19:44909375~44914968:+
BRCA	cis	rs10510102	0.516	rs12244921	ENSG00000226864.1	ATE1-AS1	4.58	5.26e-06	0.00046	0.26	0.14	Breast cancer;	chr10:121990342	chr10:121928312~121951965:+
BRCA	cis	rs10911902	0.643	rs75158977	ENSG00000229739.2	RP11-295K2.3	-4.58	5.26e-06	0.00046	-0.22	-0.14	Schizophrenia;	chr1:186324597	chr1:186435161~186470291:+
BRCA	cis	rs10129255	0.556	rs9324093	ENSG00000254174.1	IGHV1-12	4.58	5.26e-06	0.00046	0.11	0.14	Kawasaki disease;	chr14:106683893	chr14:106122420~106122709:-
BRCA	cis	rs1979679	0.541	rs4931085	ENSG00000278733.1	RP11-425D17.1	-4.58	5.26e-06	0.00046	-0.19	-0.14	Ossification of the posterior longitudinal ligament of the spine;	chr12:28574577	chr12:28185625~28186190:-
BRCA	cis	rs1656368	0.77	rs73154340	ENSG00000279311.1	RP11-170K4.2	4.58	5.26e-06	0.00046	0.18	0.14	Lobe attachment (rater-scored or self-reported);	chr3:158559125	chr3:158869898~158871821:+
BRCA	cis	rs56174355	1	rs17759471	ENSG00000264513.1	RP11-556O9.2	4.58	5.26e-06	0.00046	0.25	0.14	Diastolic blood pressure;	chr17:62915027	chr17:63117019~63130947:-
BRCA	cis	rs763014	0.966	rs15564	ENSG00000260394.2	LA16c-313D11.9	-4.58	5.26e-06	0.00046	-0.14	-0.14	Height;	chr16:627854	chr16:678504~679777:-
BRCA	cis	rs8114671	0.836	rs6058154	ENSG00000279253.1	RP4-614O4.13	4.58	5.26e-06	0.00046	0.16	0.14	Height;	chr20:34998031	chr20:35262727~35264187:-
BRCA	cis	rs2243480	1	rs709607	ENSG00000222364.1	RNU6-96P	4.58	5.26e-06	0.00046	0.25	0.14	Diabetic kidney disease;	chr7:65984554	chr7:66395191~66395286:+
BRCA	cis	rs6430585	0.591	rs1374330	ENSG00000224043.6	CCNT2-AS1	-4.58	5.26e-06	0.00046	-0.25	-0.14	Corneal structure;	chr2:135663338	chr2:134735464~134918710:-
BRCA	cis	rs13325613	0.915	rs35203745	ENSG00000223552.1	RP11-24F11.2	-4.58	5.27e-06	0.000461	-0.26	-0.14	Monocyte count;	chr3:46280798	chr3:46364955~46407059:-
BRCA	cis	rs7824557	0.843	rs2736375	ENSG00000154316.13	TDH	4.58	5.27e-06	0.000461	0.19	0.14	Retinal vascular caliber;	chr8:11258240	chr8:11339637~11368452:+
BRCA	cis	rs7829975	0.711	rs12682352	ENSG00000254153.1	CTA-398F10.2	4.58	5.27e-06	0.000461	0.16	0.14	Mood instability;	chr8:8788736	chr8:8456909~8461337:-
BRCA	cis	rs8180040	0.62	rs11720139	ENSG00000276925.1	RP11-708J19.3	4.58	5.27e-06	0.000461	0.16	0.14	Colorectal cancer;	chr3:46995266	chr3:47469777~47469987:+
BRCA	cis	rs672203	0.714	rs577476	ENSG00000271992.1	RP11-42O15.3	4.58	5.27e-06	0.000461	0.19	0.14	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);	chr1:70425436	chr1:70445071~70445536:+
BRCA	cis	rs4781563	1	rs9646271	ENSG00000242307.1	RPS26P52	4.58	5.27e-06	0.000461	0.17	0.14	Bilirubin levels;	chr16:13953561	chr16:13922332~13922679:-
BRCA	cis	rs17406451	0.759	rs6544651	ENSG00000234936.1	AC010883.5	4.58	5.27e-06	0.000461	0.14	0.14	Mitochondrial DNA levels;	chr2:43396656	chr2:43229573~43233394:+
BRCA	cis	rs7615952	0.673	rs7632557	ENSG00000241288.6	RP11-379B18.5	-4.58	5.27e-06	0.000461	-0.21	-0.14	Blood pressure (smoking interaction);	chr3:125916038	chr3:125827238~125916384:-
BRCA	cis	rs7811142	1	rs67471932	ENSG00000078319.8	PMS2P1	-4.58	5.27e-06	0.000461	-0.22	-0.14	Platelet count;	chr7:100412362	chr7:100320992~100341908:-
BRCA	cis	rs2439831	0.702	rs28699233	ENSG00000275601.1	AC011330.13	-4.58	5.28e-06	0.000462	-0.26	-0.14	Lung cancer in ever smokers;	chr15:43830668	chr15:43642389~43643023:-
BRCA	cis	rs7267979	1	rs2424712	ENSG00000274973.1	RP13-401N8.7	-4.58	5.28e-06	0.000462	-0.16	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25436306	chr20:25845497~25845862:+
BRCA	cis	rs7267979	0.966	rs2424714	ENSG00000274973.1	RP13-401N8.7	-4.58	5.28e-06	0.000462	-0.16	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25438045	chr20:25845497~25845862:+
BRCA	cis	rs7267979	0.966	rs2424715	ENSG00000274973.1	RP13-401N8.7	-4.58	5.28e-06	0.000462	-0.16	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25439441	chr20:25845497~25845862:+
BRCA	cis	rs755249	0.501	rs661316	ENSG00000237624.1	OXCT2P1	4.58	5.28e-06	0.000462	0.18	0.14	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39165625	chr1:39514956~39516490:+
BRCA	cis	rs2638953	1	rs2638953	ENSG00000247934.4	RP11-967K21.1	4.58	5.28e-06	0.000462	0.18	0.14	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28381482	chr12:28163298~28190738:-
BRCA	cis	rs7923609	0.905	rs7088799	ENSG00000232075.1	MRPL35P2	-4.58	5.28e-06	0.000462	-0.18	-0.14	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63256414	chr10:63634317~63634827:-
BRCA	cis	rs3768617	0.811	rs12022720	ENSG00000224468.3	RP11-181K3.4	-4.58	5.28e-06	0.000462	-0.16	-0.14	Fuchs's corneal dystrophy;	chr1:183048088	chr1:183138402~183141282:-
BRCA	cis	rs17597773	0.638	rs12145674	ENSG00000257551.1	HLX-AS1	4.58	5.28e-06	0.000462	0.17	0.14	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220826931	chr1:220832763~220880140:-
BRCA	cis	rs1077773	0.782	rs2389762	ENSG00000237773.4	AC003075.4	-4.58	5.28e-06	0.000462	-0.17	-0.14	Ulcerative colitis;Inflammatory bowel disease;	chr7:17390934	chr7:17279834~17299357:-
BRCA	cis	rs1124769	0.523	rs1276855	ENSG00000273674.3	CTD-2378E12.1	-4.58	5.29e-06	0.000462	-0.17	-0.14	Cognitive performance;	chr15:50862083	chr15:50839875~50908599:-
BRCA	cis	rs6570726	1	rs405622	ENSG00000270638.1	RP3-466P17.1	4.58	5.29e-06	0.000462	0.16	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145550761	chr6:145735570~145737218:+
BRCA	cis	rs6570726	1	rs455109	ENSG00000270638.1	RP3-466P17.1	4.58	5.29e-06	0.000462	0.16	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145551529	chr6:145735570~145737218:+
BRCA	cis	rs6723226	0.767	rs10172308	ENSG00000276334.1	AL133243.1	-4.58	5.29e-06	0.000462	-0.18	-0.14	Intelligence (multi-trait analysis);	chr2:32330691	chr2:32521927~32523547:+
BRCA	cis	rs1005277	0.579	rs932538	ENSG00000263064.2	RP11-291L22.7	4.58	5.29e-06	0.000462	0.17	0.14	Extrinsic epigenetic age acceleration;	chr10:38092386	chr10:38448689~38448949:+
BRCA	cis	rs10458561	0.605	rs1145919	ENSG00000271992.1	RP11-42O15.3	4.58	5.29e-06	0.000462	0.19	0.14	Antipsychotic drug-induced QTc interval prolongation;	chr1:70418312	chr1:70445071~70445536:+
BRCA	cis	rs1322639	0.618	rs9505942	ENSG00000223485.1	RP11-417E7.1	-4.58	5.29e-06	0.000462	-0.2	-0.14	Pulse pressure;	chr6:169191698	chr6:169158092~169162924:-
BRCA	cis	rs6847067	0.655	rs58074983	ENSG00000180769.7	WDFY3-AS2	4.58	5.29e-06	0.000462	0.14	0.14	Oropharynx cancer;	chr4:84964394	chr4:84965682~85011277:+
BRCA	cis	rs6847067	0.683	rs67624868	ENSG00000180769.7	WDFY3-AS2	4.58	5.29e-06	0.000462	0.14	0.14	Oropharynx cancer;	chr4:84965615	chr4:84965682~85011277:+
BRCA	cis	rs72482608	0.896	rs2206310	ENSG00000271811.1	RP1-79C4.4	4.58	5.29e-06	0.000462	0.15	0.14	Emphysema imaging phenotypes;	chr1:170803635	chr1:170667381~170669425:+
BRCA	cis	rs2731006	0.591	rs10880366	ENSG00000257114.2	RP11-25I15.3	4.58	5.29e-06	0.000462	0.21	0.14	Panic disorder;	chr12:42816935	chr12:42692216~42717119:+
BRCA	cis	rs1008375	0.932	rs6814465	ENSG00000249502.1	AC006160.5	-4.58	5.29e-06	0.000463	-0.17	-0.14	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17657411	chr4:17587467~17614571:-
BRCA	cis	rs1008375	0.932	rs6844593	ENSG00000249502.1	AC006160.5	-4.58	5.29e-06	0.000463	-0.17	-0.14	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17657416	chr4:17587467~17614571:-
BRCA	cis	rs11098499	0.754	rs1849457	ENSG00000260404.2	RP11-384K6.6	4.58	5.29e-06	0.000463	0.13	0.14	Corneal astigmatism;	chr4:119333200	chr4:118591773~118633729:+
BRCA	cis	rs6981523	0.5	rs4412337	ENSG00000154316.13	TDH	-4.58	5.29e-06	0.000463	-0.19	-0.14	Neuroticism;	chr8:11214511	chr8:11339637~11368452:+
BRCA	cis	rs4218	0.681	rs12913177	ENSG00000277144.1	RP11-59H7.4	4.58	5.29e-06	0.000463	0.19	0.14	Social communication problems;	chr15:59066273	chr15:59115547~59116089:-
BRCA	cis	rs7800418	0.521	rs10951141	ENSG00000214870.7	AC004540.5	4.58	5.3e-06	0.000463	0.17	0.14	Cognitive function;	chr7:26573939	chr7:26398593~26494256:+
BRCA	cis	rs8017423	0.63	rs4904678	ENSG00000275198.1	RP11-471B22.3	4.58	5.3e-06	0.000463	0.16	0.14	Mortality in heart failure;	chr14:90355326	chr14:90383365~90387973:+
BRCA	cis	rs8017423	0.63	rs4900038	ENSG00000275198.1	RP11-471B22.3	4.58	5.3e-06	0.000463	0.16	0.14	Mortality in heart failure;	chr14:90355333	chr14:90383365~90387973:+
BRCA	cis	rs8017423	0.647	rs4904679	ENSG00000275198.1	RP11-471B22.3	4.58	5.3e-06	0.000463	0.16	0.14	Mortality in heart failure;	chr14:90355457	chr14:90383365~90387973:+
BRCA	cis	rs651907	0.557	rs13069443	ENSG00000256628.3	ZBTB11-AS1	4.58	5.3e-06	0.000463	0.18	0.14	Colorectal cancer;	chr3:101654461	chr3:101676475~101679217:+
BRCA	cis	rs7772486	0.727	rs4896843	ENSG00000270638.1	RP3-466P17.1	-4.58	5.3e-06	0.000463	-0.16	-0.14	Lobe attachment (rater-scored or self-reported);	chr6:145742315	chr6:145735570~145737218:+
BRCA	cis	rs672203	0.714	rs473334	ENSG00000271992.1	RP11-42O15.3	4.58	5.3e-06	0.000463	0.19	0.14	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);	chr1:70431284	chr1:70445071~70445536:+
BRCA	cis	rs6840360	0.582	rs2709812	ENSG00000251603.1	RP11-164P12.4	4.58	5.3e-06	0.000463	0.13	0.14	Intelligence (multi-trait analysis);	chr4:151414597	chr4:151667224~151670502:+
BRCA	cis	rs6570726	1	rs373778	ENSG00000270638.1	RP3-466P17.1	4.58	5.3e-06	0.000463	0.16	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145552116	chr6:145735570~145737218:+
BRCA	cis	rs35306767	0.953	rs1106064	ENSG00000229869.1	RP11-363N22.2	-4.58	5.31e-06	0.000464	-0.21	-0.14	Eosinophil percentage of granulocytes;	chr10:911271	chr10:933026~942743:+
BRCA	cis	rs651907	0.588	rs2860329	ENSG00000244119.1	PDCL3P4	4.58	5.31e-06	0.000464	0.11	0.14	Colorectal cancer;	chr3:101913582	chr3:101712472~101713191:+
BRCA	cis	rs6860540	0.796	rs10475585	ENSG00000248544.2	CTB-47B11.3	-4.58	5.31e-06	0.000464	-0.18	-0.14	Inflammatory skin disease;	chr5:157488080	chr5:157375741~157384950:-
BRCA	cis	rs721917	0.525	rs2819106	ENSG00000278616.1	BEND3P3	-4.58	5.31e-06	0.000464	-0.13	-0.14	Chronic obstructive pulmonary disease;	chr10:79926324	chr10:79682997~79685436:+
BRCA	cis	rs12497850	0.897	rs9681717	ENSG00000225399.4	RP11-3B7.1	4.58	5.31e-06	0.000464	0.14	0.14	Parkinson's disease;	chr3:48835565	chr3:49260085~49261316:+
BRCA	cis	rs11098499	0.954	rs878373	ENSG00000225892.3	RP11-384K6.2	4.58	5.31e-06	0.000464	0.14	0.14	Corneal astigmatism;	chr4:119316329	chr4:118632274~118634759:+
BRCA	cis	rs939563	0.894	rs2302460	ENSG00000236618.2	PITPNA-AS1	4.58	5.31e-06	0.000464	0.14	0.14	Mean platelet volume;	chr17:1541408	chr17:1516931~1518096:+
BRCA	cis	rs11096990	0.613	rs4974996	ENSG00000249685.1	RP11-360F5.3	4.58	5.32e-06	0.000465	0.18	0.14	Cognitive function;	chr4:39225928	chr4:39133913~39135608:+
BRCA	cis	rs67981189	0.593	rs8007425	ENSG00000269927.1	RP6-91H8.3	4.58	5.32e-06	0.000465	0.17	0.14	Schizophrenia;	chr14:71041483	chr14:71141125~71143253:-
BRCA	cis	rs739401	0.572	rs389285	ENSG00000247473.2	CARS-AS1	4.58	5.32e-06	0.000465	0.16	0.14	Longevity;	chr11:3041443	chr11:3029009~3041260:+
BRCA	cis	rs7226408	0.802	rs11081969	ENSG00000267707.2	RP11-95O2.5	4.58	5.32e-06	0.000465	0.21	0.14	Obesity-related traits;	chr18:36903228	chr18:37243776~37247506:+
BRCA	cis	rs11742741	1	rs6859733	ENSG00000248874.4	C5orf17	-4.58	5.32e-06	0.000465	-0.18	-0.14	Educational attainment;	chr5:24165535	chr5:23951348~24178263:+
BRCA	cis	rs8114671	0.836	rs4911461	ENSG00000279253.1	RP4-614O4.13	4.58	5.32e-06	0.000465	0.16	0.14	Height;	chr20:35042190	chr20:35262727~35264187:-
BRCA	cis	rs11742741	1	rs17445131	ENSG00000248874.4	C5orf17	-4.58	5.32e-06	0.000465	-0.18	-0.14	Educational attainment;	chr5:24143245	chr5:23951348~24178263:+
BRCA	cis	rs2243480	1	rs6460260	ENSG00000226002.1	RP11-460N20.5	4.58	5.33e-06	0.000465	0.23	0.14	Diabetic kidney disease;	chr7:65750468	chr7:65084103~65100232:+
BRCA	cis	rs2243480	1	rs6460261	ENSG00000226002.1	RP11-460N20.5	4.58	5.33e-06	0.000465	0.23	0.14	Diabetic kidney disease;	chr7:65750593	chr7:65084103~65100232:+
BRCA	cis	rs6968419	0.755	rs4730719	ENSG00000279086.1	RP11-667F14.1	4.58	5.33e-06	0.000465	0.15	0.14	Intraocular pressure;	chr7:116254956	chr7:116209234~116211511:-
BRCA	cis	rs950169	0.544	rs62021193	ENSG00000176700.18	SCAND2P	-4.58	5.33e-06	0.000466	-0.14	-0.14	Schizophrenia;	chr15:84627352	chr15:84631451~84647478:+
BRCA	cis	rs875971	0.545	rs6979636	ENSG00000273142.1	RP11-458F8.4	4.58	5.33e-06	0.000466	0.14	0.14	Aortic root size;	chr7:66276638	chr7:66902857~66906297:+
BRCA	cis	rs16958440	0.867	rs80106524	ENSG00000267724.1	RP11-49K24.8	4.58	5.33e-06	0.000466	0.28	0.14	Sitting height ratio;	chr18:47150268	chr18:47105946~47108062:+
BRCA	cis	rs16958440	0.867	rs79712753	ENSG00000267724.1	RP11-49K24.8	4.58	5.33e-06	0.000466	0.28	0.14	Sitting height ratio;	chr18:47150356	chr18:47105946~47108062:+
BRCA	cis	rs16958440	0.867	rs3809965	ENSG00000267724.1	RP11-49K24.8	4.58	5.33e-06	0.000466	0.28	0.14	Sitting height ratio;	chr18:47150501	chr18:47105946~47108062:+
BRCA	cis	rs16958440	0.867	rs74411203	ENSG00000267724.1	RP11-49K24.8	4.58	5.33e-06	0.000466	0.28	0.14	Sitting height ratio;	chr18:47151095	chr18:47105946~47108062:+
BRCA	cis	rs16958440	0.867	rs74346439	ENSG00000267724.1	RP11-49K24.8	4.58	5.33e-06	0.000466	0.28	0.14	Sitting height ratio;	chr18:47151096	chr18:47105946~47108062:+
BRCA	cis	rs16958440	0.867	rs3809966	ENSG00000267724.1	RP11-49K24.8	4.58	5.33e-06	0.000466	0.28	0.14	Sitting height ratio;	chr18:47151256	chr18:47105946~47108062:+
BRCA	cis	rs16958440	0.867	rs12326457	ENSG00000267724.1	RP11-49K24.8	4.58	5.33e-06	0.000466	0.28	0.14	Sitting height ratio;	chr18:47152054	chr18:47105946~47108062:+
BRCA	cis	rs16958440	0.867	rs12326465	ENSG00000267724.1	RP11-49K24.8	4.58	5.33e-06	0.000466	0.28	0.14	Sitting height ratio;	chr18:47152274	chr18:47105946~47108062:+
BRCA	cis	rs16958440	0.867	rs75934126	ENSG00000267724.1	RP11-49K24.8	4.58	5.33e-06	0.000466	0.28	0.14	Sitting height ratio;	chr18:47153410	chr18:47105946~47108062:+
BRCA	cis	rs7200543	1	rs6498541	ENSG00000258354.1	MIR3180-1	-4.58	5.33e-06	0.000466	-0.18	-0.14	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15046800	chr16:14909887~14911345:-
BRCA	cis	rs7267979	1	rs6115140	ENSG00000125804.12	FAM182A	-4.58	5.33e-06	0.000466	-0.18	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25304871	chr20:26054655~26086917:+
BRCA	cis	rs875971	0.862	rs778720	ENSG00000273448.1	RP11-166O4.6	-4.58	5.33e-06	0.000466	-0.13	-0.14	Aortic root size;	chr7:66381288	chr7:67333047~67334383:+
BRCA	cis	rs1858037	0.867	rs67817304	ENSG00000237979.1	AC007389.1	4.58	5.33e-06	0.000466	0.18	0.14	Rheumatoid arthritis;	chr2:65346982	chr2:65500993~65502138:-
BRCA	cis	rs308403	0.509	rs1849431	ENSG00000224786.1	CETN4P	4.58	5.33e-06	0.000466	0.18	0.14	Blood protein levels;	chr4:122753607	chr4:122730548~122732193:-
BRCA	cis	rs12501370	0.765	rs56010156	ENSG00000201736.1	RNA5SP160	4.58	5.33e-06	0.000466	0.17	0.14	Iris color (L* coordinate);	chr4:41047202	chr4:40990154~40990273:+
BRCA	cis	rs6968419	0.755	rs4730720	ENSG00000279086.1	RP11-667F14.1	4.58	5.33e-06	0.000466	0.15	0.14	Intraocular pressure;	chr7:116255181	chr7:116209234~116211511:-
BRCA	cis	rs7200543	0.883	rs4985148	ENSG00000275910.1	RP11-680G24.6	-4.58	5.33e-06	0.000466	-0.16	-0.14	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15053931	chr16:15015828~15016390:-
BRCA	cis	rs2880765	0.835	rs4843063	ENSG00000202081.1	RNU6-1280P	4.58	5.33e-06	0.000466	0.16	0.14	Coronary artery disease;	chr15:85505517	chr15:85651522~85651628:-
BRCA	cis	rs2179367	0.959	rs480034	ENSG00000223701.3	RAET1E-AS1	-4.57	5.34e-06	0.000466	-0.18	-0.14	Dupuytren's disease;	chr6:149414294	chr6:149884431~149919508:+
BRCA	cis	rs9527	0.615	rs17725614	ENSG00000213061.2	PFN1P11	4.57	5.34e-06	0.000466	0.19	0.14	Arsenic metabolism;	chr10:102925736	chr10:102838011~102845473:-
BRCA	cis	rs7260598	0.642	rs4313914	ENSG00000268442.1	CTD-2027I19.2	4.57	5.34e-06	0.000466	0.22	0.14	Response to taxane treatment (placlitaxel);	chr19:23994194	chr19:24162370~24163425:-
BRCA	cis	rs6840360	0.642	rs2709820	ENSG00000251603.1	RP11-164P12.4	-4.57	5.34e-06	0.000466	-0.13	-0.14	Intelligence (multi-trait analysis);	chr4:151462887	chr4:151667224~151670502:+
BRCA	cis	rs4356203	0.875	rs7125607	ENSG00000272034.1	SNORD14A	-4.57	5.34e-06	0.000466	-0.14	-0.14	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17074603	chr11:17074654~17074744:-
BRCA	cis	rs10861342	0.892	rs11112418	ENSG00000257999.1	RP11-61E11.2	-4.57	5.34e-06	0.000466	-0.29	-0.14	IgG glycosylation;	chr12:105236685	chr12:105102472~105107179:-
BRCA	cis	rs516805	0.667	rs2606598	ENSG00000279114.1	RP3-425C14.5	4.57	5.34e-06	0.000467	0.19	0.14	Lymphocyte counts;	chr6:122206501	chr6:122471923~122484161:+
BRCA	cis	rs6723226	0.521	rs1991626	ENSG00000276517.1	AL133243.2	4.57	5.34e-06	0.000467	0.17	0.14	Intelligence (multi-trait analysis);	chr2:32377382	chr2:32526504~32529507:+
BRCA	cis	rs287982	0.611	rs79083459	ENSG00000269973.1	RP11-95D17.1	-4.57	5.34e-06	0.000467	-0.23	-0.14	Nonsyndromic cleft lip with cleft palate;	chr2:9838286	chr2:9936360~9939590:+
BRCA	cis	rs7811142	0.666	rs28401739	ENSG00000078319.8	PMS2P1	-4.57	5.34e-06	0.000467	-0.22	-0.14	Platelet count;	chr7:100308061	chr7:100320992~100341908:-
BRCA	cis	rs7243790	1	rs55756660	ENSG00000277324.1	RP11-850A17.1	-4.57	5.34e-06	0.000467	-0.16	-0.14	Diastolic blood pressure;	chr18:54436614	chr18:54268346~54270028:-
BRCA	cis	rs10829156	0.679	rs4747352	ENSG00000240291.1	RP11-499P20.2	4.57	5.34e-06	0.000467	0.16	0.14	Sudden cardiac arrest;	chr10:18539734	chr10:18513115~18545651:-
BRCA	cis	rs987360	0.536	rs6832097	ENSG00000248869.4	RP11-138I17.1	4.57	5.34e-06	0.000467	0.15	0.14	Temperament;	chr4:137297827	chr4:136796722~137212799:-
BRCA	cis	rs801193	1	rs10252765	ENSG00000229180.5	GS1-124K5.11	4.57	5.34e-06	0.000467	0.12	0.14	Aortic root size;	chr7:66763745	chr7:66526088~66542624:-
BRCA	cis	rs1371614	0.635	rs12714002	ENSG00000272148.1	RP11-195B17.1	-4.57	5.34e-06	0.000467	-0.16	-0.14	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26912057	chr2:27062428~27062907:-
BRCA	cis	rs17756712	0.666	rs1099773	ENSG00000271911.1	RP11-532F6.5	-4.57	5.35e-06	0.000467	-0.17	-0.14	Vertical cup-disc ratio;	chr6:646076	chr6:761675~780648:+
BRCA	cis	rs6840360	0.642	rs7682770	ENSG00000251603.1	RP11-164P12.4	-4.57	5.35e-06	0.000467	-0.13	-0.14	Intelligence (multi-trait analysis);	chr4:151469261	chr4:151667224~151670502:+
BRCA	cis	rs6840360	0.667	rs9994482	ENSG00000251603.1	RP11-164P12.4	-4.57	5.35e-06	0.000467	-0.13	-0.14	Intelligence (multi-trait analysis);	chr4:151470078	chr4:151667224~151670502:+
BRCA	cis	rs6840360	0.642	rs11729923	ENSG00000251603.1	RP11-164P12.4	-4.57	5.35e-06	0.000467	-0.13	-0.14	Intelligence (multi-trait analysis);	chr4:151470884	chr4:151667224~151670502:+
BRCA	cis	rs6840360	0.642	rs7676059	ENSG00000251603.1	RP11-164P12.4	-4.57	5.35e-06	0.000467	-0.13	-0.14	Intelligence (multi-trait analysis);	chr4:151472115	chr4:151667224~151670502:+
BRCA	cis	rs6840360	0.642	rs7657747	ENSG00000251603.1	RP11-164P12.4	-4.57	5.35e-06	0.000467	-0.13	-0.14	Intelligence (multi-trait analysis);	chr4:151473102	chr4:151667224~151670502:+
BRCA	cis	rs12446632	0.882	rs11639988	ENSG00000261195.1	CTD-2380F24.1	-4.57	5.35e-06	0.000467	-0.22	-0.14	Hip circumference;Body mass index (joint analysis main effects and smoking interaction);BMI in smokers;Menarche (age at onset);Obesity;Childhood body mass index;Waist circumference;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Body mass index;	chr16:19933041	chr16:19761172~19766099:-
BRCA	cis	rs757081	0.613	rs11024151	ENSG00000184669.7	OR7E14P	-4.57	5.35e-06	0.000467	-0.2	-0.14	Systolic blood pressure;	chr11:17084183	chr11:17013998~17053024:+
BRCA	cis	rs8103278	1	rs11671524	ENSG00000267395.4	AC074212.6	4.57	5.35e-06	0.000467	0.15	0.14	Coronary artery disease;	chr19:45823908	chr19:45767796~45772504:+
BRCA	cis	rs8017423	0.647	rs4900037	ENSG00000275198.1	RP11-471B22.3	-4.57	5.35e-06	0.000467	-0.16	-0.14	Mortality in heart failure;	chr14:90355134	chr14:90383365~90387973:+
BRCA	cis	rs13113518	0.966	rs11942472	ENSG00000249700.7	SRD5A3-AS1	4.57	5.35e-06	0.000467	0.17	0.14	Height;	chr4:55574959	chr4:55363971~55395847:-
BRCA	cis	rs7048146	1	rs7022179	ENSG00000213539.4	YBX1P6	4.57	5.35e-06	0.000467	0.16	0.14	Vascular brain injury;	chr9:109538280	chr9:109532830~109534332:-
BRCA	cis	rs2253762	0.507	rs12264894	ENSG00000226864.1	ATE1-AS1	4.57	5.35e-06	0.000468	0.26	0.14	Breast cancer;	chr10:121992087	chr10:121928312~121951965:+
BRCA	cis	rs7824557	0.724	rs2572398	ENSG00000154316.13	TDH	-4.57	5.36e-06	0.000468	-0.18	-0.14	Retinal vascular caliber;	chr8:11320584	chr8:11339637~11368452:+
BRCA	cis	rs1979679	0.573	rs7315906	ENSG00000278733.1	RP11-425D17.1	-4.57	5.36e-06	0.000468	-0.18	-0.14	Ossification of the posterior longitudinal ligament of the spine;	chr12:28575612	chr12:28185625~28186190:-
BRCA	cis	rs6860806	0.661	rs2171247	ENSG00000233006.5	AC034220.3	4.57	5.36e-06	0.000468	0.1	0.14	Breast cancer;	chr5:132244541	chr5:132311285~132369916:-
BRCA	cis	rs2562456	0.752	rs7258562	ENSG00000268658.4	LINC00664	4.57	5.36e-06	0.000468	0.23	0.14	Pain;	chr19:21331762	chr19:21483374~21503238:+
BRCA	cis	rs7267979	1	rs6050609	ENSG00000125804.12	FAM182A	4.57	5.36e-06	0.000468	0.18	0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25431115	chr20:26054655~26086917:+
BRCA	cis	rs11098499	0.866	rs12501602	ENSG00000249244.1	RP11-548H18.2	4.57	5.36e-06	0.000468	0.16	0.14	Corneal astigmatism;	chr4:119366780	chr4:119391831~119395335:-
BRCA	cis	rs2625529	0.652	rs2929525	ENSG00000260037.4	CTD-2524L6.3	4.57	5.36e-06	0.000468	0.18	0.14	Red blood cell count;	chr15:71995515	chr15:71818396~71823384:+
BRCA	cis	rs7267979	0.727	rs2474765	ENSG00000204556.4	CTD-2514C3.1	-4.57	5.36e-06	0.000468	-0.19	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25265314	chr20:26018832~26020684:+
BRCA	cis	rs3764021	0.527	rs3764022	ENSG00000256673.1	RP11-599J14.2	-4.57	5.37e-06	0.000468	-0.18	-0.14	Type 1 diabetes;	chr12:9680928	chr12:9398355~9414851:-
BRCA	cis	rs4666002	0.564	rs13030345	ENSG00000234072.1	AC074117.10	-4.57	5.37e-06	0.000468	-0.17	-0.14	Phospholipid levels (plasma);	chr2:27780307	chr2:27356246~27367622:+
BRCA	cis	rs1008375	0.932	rs6449317	ENSG00000249502.1	AC006160.5	-4.57	5.37e-06	0.000469	-0.17	-0.14	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17629630	chr4:17587467~17614571:-
BRCA	cis	rs2273156	1	rs12893021	ENSG00000226677.3	IGBP1P1	-4.57	5.37e-06	0.000469	-0.21	-0.14	Immunoglobulin light chain (AL) amyloidosis;	chr14:34971474	chr14:34939324~34940332:+
BRCA	cis	rs10129255	0.536	rs10139058	ENSG00000211959.2	IGHV4-39	4.57	5.37e-06	0.000469	0.1	0.14	Kawasaki disease;	chr14:106685899	chr14:106421711~106422218:-
BRCA	cis	rs610932	0.517	rs670139	ENSG00000275344.1	MIR6503	4.57	5.37e-06	0.000469	0.14	0.14	Alzheimer's disease;	chr11:60204322	chr11:60209071~60209156:-
BRCA	cis	rs875971	1	rs3981131	ENSG00000229180.5	GS1-124K5.11	4.57	5.37e-06	0.000469	0.12	0.14	Aortic root size;	chr7:66486690	chr7:66526088~66542624:-
BRCA	cis	rs2337406	0.587	rs10129888	ENSG00000211974.3	IGHV2-70	-4.57	5.37e-06	0.000469	-0.17	-0.14	Alzheimer's disease (late onset);	chr14:106647421	chr14:106723574~106724093:-
BRCA	cis	rs1043099	0.912	rs5749066	ENSG00000279699.1	RP1-102K2.9	-4.57	5.37e-06	0.000469	-0.22	-0.14	Rheumatoid arthritis;	chr22:30340922	chr22:30275215~30276951:-
BRCA	cis	rs4787491	0.704	rs67218159	ENSG00000261367.1	RP11-455F5.4	-4.57	5.37e-06	0.000469	-0.15	-0.14	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30039184	chr16:30107675~30110541:+
BRCA	cis	rs6828577	0.862	rs167246	ENSG00000281731.1	RP11-384K6.8	-4.57	5.37e-06	0.000469	-0.16	-0.14	Perioperative myocardial infarction in coronary artery bypass surgery;	chr4:118684965	chr4:118664087~118685341:-
BRCA	cis	rs2638953	0.671	rs10843102	ENSG00000278733.1	RP11-425D17.1	4.57	5.37e-06	0.000469	0.2	0.14	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28119368	chr12:28185625~28186190:-
BRCA	cis	rs6921919	0.583	rs4642462	ENSG00000220721.1	OR1F12	4.57	5.37e-06	0.000469	0.17	0.14	Autism spectrum disorder or schizophrenia;	chr6:28421474	chr6:28073316~28074233:+
BRCA	cis	rs875971	0.545	rs1638724	ENSG00000230295.1	RP11-458F8.2	-4.57	5.38e-06	0.000469	-0.13	-0.14	Aortic root size;	chr7:66575494	chr7:66880708~66882981:+
BRCA	cis	rs8031584	0.958	rs34909055	ENSG00000270015.1	RP11-540B6.6	-4.57	5.38e-06	0.000469	-0.15	-0.14	Huntington's disease progression;	chr15:30991967	chr15:30926514~30928407:+
BRCA	cis	rs9527	0.615	rs10883800	ENSG00000213061.2	PFN1P11	4.57	5.38e-06	0.000469	0.19	0.14	Arsenic metabolism;	chr10:102911455	chr10:102838011~102845473:-
BRCA	cis	rs9527	0.615	rs7073295	ENSG00000213061.2	PFN1P11	4.57	5.38e-06	0.000469	0.19	0.14	Arsenic metabolism;	chr10:102912476	chr10:102838011~102845473:-
BRCA	cis	rs2115630	0.967	rs11073731	ENSG00000259728.4	LINC00933	-4.57	5.38e-06	0.000469	-0.16	-0.14	P wave terminal force;	chr15:84811882	chr15:84570649~84580175:+
BRCA	cis	rs11577354	0.613	rs10925533	ENSG00000207181.1	SNORA14B	-4.57	5.38e-06	0.000469	-0.16	-0.14	Obesity-related traits;	chr1:235106706	chr1:235127803~235127937:-
BRCA	cis	rs2562456	0.793	rs73537884	ENSG00000268658.4	LINC00664	4.57	5.38e-06	0.000469	0.23	0.14	Pain;	chr19:21321908	chr19:21483374~21503238:+
BRCA	cis	rs2562456	0.793	rs78467454	ENSG00000268658.4	LINC00664	4.57	5.38e-06	0.000469	0.23	0.14	Pain;	chr19:21321930	chr19:21483374~21503238:+
BRCA	cis	rs1434579	0.865	rs1434573	ENSG00000176761.7	ZNF285B	-4.57	5.38e-06	0.000469	-0.17	-0.14	Tuberculosis;	chr19:44419111	chr19:44467641~44473227:+
BRCA	cis	rs7918232	0.882	rs2149413	ENSG00000262412.1	RP11-85G18.6	-4.57	5.38e-06	0.00047	-0.24	-0.14	Breast cancer;	chr10:27141382	chr10:27243130~27250804:+
BRCA	cis	rs7918232	0.941	rs4749228	ENSG00000262412.1	RP11-85G18.6	-4.57	5.38e-06	0.00047	-0.24	-0.14	Breast cancer;	chr10:27144689	chr10:27243130~27250804:+
BRCA	cis	rs7772486	0.754	rs6570718	ENSG00000270638.1	RP3-466P17.1	-4.57	5.38e-06	0.00047	-0.16	-0.14	Lobe attachment (rater-scored or self-reported);	chr6:145767307	chr6:145735570~145737218:+
BRCA	cis	rs16944613	0.541	rs4288973	ENSG00000271396.1	RP11-697E2.9	-4.57	5.38e-06	0.00047	-0.22	-0.14	Colorectal cancer;	chr15:90550444	chr15:90284376~90285580:-
BRCA	cis	rs2489715	1	rs2505859	ENSG00000185904.10	LINC00839	-4.57	5.38e-06	0.00047	-0.19	-0.14	Helix rolling;	chr10:42410463	chr10:42475543~42495336:+
BRCA	cis	rs6686842	0.56	rs213738	ENSG00000235358.1	RP11-399E6.1	4.57	5.38e-06	0.00047	0.19	0.14	Height;	chr1:41156676	chr1:41242373~41284861:+
BRCA	cis	rs2243480	0.803	rs34804747	ENSG00000275400.1	RP4-756H11.5	4.57	5.38e-06	0.00047	0.25	0.14	Diabetic kidney disease;	chr7:65947955	chr7:66553805~66554199:-
BRCA	cis	rs2243480	1	rs59794892	ENSG00000275400.1	RP4-756H11.5	4.57	5.38e-06	0.00047	0.25	0.14	Diabetic kidney disease;	chr7:65950886	chr7:66553805~66554199:-
BRCA	cis	rs2243480	0.803	rs36004293	ENSG00000275400.1	RP4-756H11.5	4.57	5.38e-06	0.00047	0.25	0.14	Diabetic kidney disease;	chr7:65951525	chr7:66553805~66554199:-
BRCA	cis	rs2243480	0.803	rs35268390	ENSG00000275400.1	RP4-756H11.5	4.57	5.38e-06	0.00047	0.25	0.14	Diabetic kidney disease;	chr7:65951549	chr7:66553805~66554199:-
BRCA	cis	rs2243480	1	rs35058610	ENSG00000275400.1	RP4-756H11.5	4.57	5.38e-06	0.00047	0.25	0.14	Diabetic kidney disease;	chr7:65925938	chr7:66553805~66554199:-
BRCA	cis	rs7701440	0.512	rs40506	ENSG00000215032.2	GNL3LP1	4.57	5.39e-06	0.00047	0.17	0.14	Educational attainment;	chr5:61229383	chr5:60891935~60893577:-
BRCA	cis	rs7927592	0.956	rs10896337	ENSG00000212093.1	AP000807.1	4.57	5.39e-06	0.00047	0.16	0.14	Total body bone mineral density;	chr11:68516768	chr11:68506083~68506166:-
BRCA	cis	rs6570726	0.935	rs585292	ENSG00000270638.1	RP3-466P17.1	4.57	5.39e-06	0.00047	0.16	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145541092	chr6:145735570~145737218:+
BRCA	cis	rs6570726	0.837	rs419991	ENSG00000270638.1	RP3-466P17.1	4.57	5.39e-06	0.00047	0.16	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145543076	chr6:145735570~145737218:+
BRCA	cis	rs987360	0.61	rs7681206	ENSG00000248869.4	RP11-138I17.1	4.57	5.39e-06	0.000471	0.14	0.14	Temperament;	chr4:137263852	chr4:136796722~137212799:-
BRCA	cis	rs4819052	0.788	rs35323494	ENSG00000184274.3	LINC00315	-4.57	5.39e-06	0.000471	-0.19	-0.14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45283824	chr21:45300245~45305257:-
BRCA	cis	rs754466	0.957	rs61854183	ENSG00000204049.1	RP11-126H7.4	4.57	5.4e-06	0.000471	0.19	0.14	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77938319	chr10:77866875~77869610:+
BRCA	cis	rs6430585	0.583	rs111837148	ENSG00000231890.6	DARS-AS1	-4.57	5.4e-06	0.000471	-0.22	-0.14	Corneal structure;	chr2:135854466	chr2:135985176~136022593:+
BRCA	cis	rs2243480	0.901	rs2900904	ENSG00000226002.1	RP11-460N20.5	-4.57	5.4e-06	0.000471	-0.23	-0.14	Diabetic kidney disease;	chr7:65739282	chr7:65084103~65100232:+
BRCA	cis	rs35612822	0.723	rs10181065	ENSG00000232485.2	AC098820.3	-4.57	5.4e-06	0.000471	-0.17	-0.14	Kidney disease (early stage) in type 1 diabetes;	chr2:216402501	chr2:216479030~216498761:-
BRCA	cis	rs600231	0.706	rs3782091	ENSG00000173727.10	CMB9-22P13.1	-4.57	5.4e-06	0.000471	-0.19	-0.14	Bone mineral density;	chr11:65569012	chr11:65455258~65466720:+
BRCA	cis	rs4699052	0.963	rs7657390	ENSG00000248740.4	RP11-328K4.1	4.57	5.4e-06	0.000471	0.16	0.14	Testicular germ cell tumor;	chr4:103291957	chr4:103256159~103453658:+
BRCA	cis	rs11096990	0.634	rs3733281	ENSG00000249685.1	RP11-360F5.3	-4.57	5.4e-06	0.000471	-0.17	-0.14	Cognitive function;	chr4:39270293	chr4:39133913~39135608:+
BRCA	cis	rs7940866	0.903	rs1433980	ENSG00000255455.2	RP11-890B15.3	-4.57	5.4e-06	0.000471	-0.13	-0.14	Schizophrenia;	chr11:131001061	chr11:130866254~130870247:-
BRCA	cis	rs4950322	0.58	rs72706441	ENSG00000237188.3	RP11-337C18.8	4.57	5.4e-06	0.000471	0.18	0.14	Protein quantitative trait loci;	chr1:147122601	chr1:147172771~147211568:+
BRCA	cis	rs10844706	0.699	rs11052751	ENSG00000214776.8	RP11-726G1.1	4.57	5.4e-06	0.000471	0.17	0.14	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9735136	chr12:9467552~9576275:+
BRCA	cis	rs3796352	1	rs71617204	ENSG00000242142.1	SERBP1P3	-4.57	5.4e-06	0.000472	-0.28	-0.14	Immune reponse to smallpox (secreted IL-2);	chr3:53008935	chr3:53064283~53065091:-
BRCA	cis	rs7923609	0.778	rs7075195	ENSG00000232075.1	MRPL35P2	-4.57	5.41e-06	0.000472	-0.18	-0.14	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63290899	chr10:63634317~63634827:-
BRCA	cis	rs11098499	0.909	rs78332141	ENSG00000250412.1	KLHL2P1	4.57	5.41e-06	0.000472	0.17	0.14	Corneal astigmatism;	chr4:119454627	chr4:119334329~119378233:+
BRCA	cis	rs7811142	0.83	rs28495773	ENSG00000078319.8	PMS2P1	-4.57	5.41e-06	0.000472	-0.24	-0.14	Platelet count;	chr7:100345960	chr7:100320992~100341908:-
BRCA	cis	rs2638953	0.85	rs10843111	ENSG00000247934.4	RP11-967K21.1	-4.57	5.41e-06	0.000472	-0.19	-0.14	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28141022	chr12:28163298~28190738:-
BRCA	cis	rs1499614	1	rs1267817	ENSG00000222364.1	RNU6-96P	-4.57	5.41e-06	0.000472	-0.26	-0.14	Gout;	chr7:66645053	chr7:66395191~66395286:+
BRCA	cis	rs2303319	0.504	rs16845945	ENSG00000227403.1	AC009299.3	4.57	5.41e-06	0.000472	0.34	0.14	Cognitive function;	chr2:161624174	chr2:161244739~161249050:+
BRCA	cis	rs34929064	0.75	rs2961299	ENSG00000179428.2	AC073072.5	-4.57	5.41e-06	0.000472	-0.16	-0.14	Major depression and alcohol dependence;	chr7:22668551	chr7:22725395~22727620:-
BRCA	cis	rs2243480	1	rs431076	ENSG00000222364.1	RNU6-96P	-4.57	5.41e-06	0.000472	-0.26	-0.14	Diabetic kidney disease;	chr7:66135333	chr7:66395191~66395286:+
BRCA	cis	rs2243480	1	rs2460422	ENSG00000222364.1	RNU6-96P	-4.57	5.41e-06	0.000472	-0.26	-0.14	Diabetic kidney disease;	chr7:66136518	chr7:66395191~66395286:+
BRCA	cis	rs2243480	1	rs316334	ENSG00000222364.1	RNU6-96P	-4.57	5.41e-06	0.000472	-0.26	-0.14	Diabetic kidney disease;	chr7:66137139	chr7:66395191~66395286:+
BRCA	cis	rs7267979	0.966	rs6083855	ENSG00000125804.12	FAM182A	4.57	5.41e-06	0.000472	0.18	0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25424482	chr20:26054655~26086917:+
BRCA	cis	rs7267979	1	rs4815426	ENSG00000125804.12	FAM182A	4.57	5.41e-06	0.000472	0.18	0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25424550	chr20:26054655~26086917:+
BRCA	cis	rs2708977	0.698	rs772161	ENSG00000237510.6	AC008268.2	-4.57	5.41e-06	0.000472	-0.19	-0.14	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96378065	chr2:95789654~95800166:+
BRCA	cis	rs7267979	0.932	rs6107052	ENSG00000125804.12	FAM182A	-4.57	5.41e-06	0.000472	-0.18	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25550202	chr20:26054655~26086917:+
BRCA	cis	rs10504130	1	rs12675786	ENSG00000272024.1	RP11-546K22.3	-4.57	5.41e-06	0.000472	-0.24	-0.14	Venous thromboembolism (SNP x SNP interaction);	chr8:51852132	chr8:51950284~51950690:+
BRCA	cis	rs10504130	1	rs11781330	ENSG00000272024.1	RP11-546K22.3	-4.57	5.41e-06	0.000472	-0.24	-0.14	Venous thromboembolism (SNP x SNP interaction);	chr8:51853231	chr8:51950284~51950690:+
BRCA	cis	rs10129255	0.957	rs10136817	ENSG00000211974.3	IGHV2-70	4.57	5.41e-06	0.000472	0.15	0.14	Kawasaki disease;	chr14:106787730	chr14:106723574~106724093:-
BRCA	cis	rs2179367	0.6	rs9498354	ENSG00000216906.2	RP11-350J20.9	-4.57	5.42e-06	0.000472	-0.2	-0.14	Dupuytren's disease;	chr6:149441715	chr6:149904243~149906418:+
BRCA	cis	rs7160336	1	rs36030304	ENSG00000259065.1	RP5-1021I20.1	4.57	5.42e-06	0.000472	0.16	0.14	Blood protein levels;	chr14:74062797	chr14:73787360~73803270:+
BRCA	cis	rs7923837	0.663	rs5015480	ENSG00000236493.2	EIF2S2P3	4.57	5.42e-06	0.000472	0.18	0.14	Multiple sclerosis;Body mass index;	chr10:92705802	chr10:92668745~92669743:-
BRCA	cis	rs9532580	0.614	rs61963261	ENSG00000168852.11	TPTE2P5	4.57	5.42e-06	0.000473	0.19	0.14	Mean corpuscular hemoglobin;	chr13:40568158	chr13:40822296~40921749:-
BRCA	cis	rs17597773	0.674	rs12073837	ENSG00000238078.1	LINC01352	-4.57	5.42e-06	0.000473	-0.16	-0.14	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220836863	chr1:220829255~220832429:+
BRCA	cis	rs57221529	0.766	rs4081847	ENSG00000225138.6	CTD-2228K2.7	4.57	5.42e-06	0.000473	0.21	0.14	Lung disease severity in cystic fibrosis;	chr5:573957	chr5:473236~480884:+
BRCA	cis	rs287982	0.611	rs7580521	ENSG00000269973.1	RP11-95D17.1	-4.57	5.42e-06	0.000473	-0.22	-0.14	Nonsyndromic cleft lip with cleft palate;	chr2:9835555	chr2:9936360~9939590:+
BRCA	cis	rs287982	0.611	rs80336909	ENSG00000269973.1	RP11-95D17.1	-4.57	5.42e-06	0.000473	-0.22	-0.14	Nonsyndromic cleft lip with cleft palate;	chr2:9835645	chr2:9936360~9939590:+
BRCA	cis	rs287982	0.611	rs76624418	ENSG00000269973.1	RP11-95D17.1	-4.57	5.42e-06	0.000473	-0.22	-0.14	Nonsyndromic cleft lip with cleft palate;	chr2:9836389	chr2:9936360~9939590:+
BRCA	cis	rs6088580	0.584	rs2378203	ENSG00000276073.1	RP5-1125A11.7	4.57	5.42e-06	0.000473	0.15	0.14	Glomerular filtration rate (creatinine);	chr20:34406040	chr20:33985617~33988989:-
BRCA	cis	rs875971	0.545	rs1796226	ENSG00000230295.1	RP11-458F8.2	4.57	5.42e-06	0.000473	0.13	0.14	Aortic root size;	chr7:66622723	chr7:66880708~66882981:+
BRCA	cis	rs4831837	0.789	rs4831838	ENSG00000270074.1	RP11-351I21.11	4.57	5.42e-06	0.000473	0.17	0.14	Morbidity-free survival;	chr8:12854438	chr8:12412827~12414373:+
BRCA	cis	rs10129255	0.536	rs17113249	ENSG00000254174.1	IGHV1-12	4.57	5.43e-06	0.000473	0.11	0.14	Kawasaki disease;	chr14:106678273	chr14:106122420~106122709:-
BRCA	cis	rs11673344	0.504	rs12984458	ENSG00000226686.6	LINC01535	-4.57	5.43e-06	0.000473	-0.17	-0.14	Obesity-related traits;	chr19:37138189	chr19:37251912~37265535:+
BRCA	cis	rs9300255	0.516	rs6488868	ENSG00000256028.2	RP11-197N18.2	4.57	5.43e-06	0.000473	0.13	0.14	Neutrophil percentage of white cells;	chr12:123315427	chr12:122975320~122982907:+
BRCA	cis	rs13326165	0.76	rs11714402	ENSG00000243224.1	RP5-1157M23.2	4.57	5.43e-06	0.000473	0.19	0.14	HDL cholesterol levels;HDL cholesterol;	chr3:52357719	chr3:52239258~52241097:+
BRCA	cis	rs7818688	0.697	rs11776186	ENSG00000253528.2	RP11-347C18.4	-4.57	5.43e-06	0.000474	-0.22	-0.14	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94959740	chr8:94974573~94974853:-
BRCA	cis	rs2692947	0.795	rs2252697	ENSG00000168992.4	OR7E102P	-4.57	5.44e-06	0.000474	-0.19	-0.14	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96112442	chr2:95546531~95547545:+
BRCA	cis	rs2273156	1	rs12894365	ENSG00000226677.3	IGBP1P1	-4.57	5.44e-06	0.000474	-0.21	-0.14	Immunoglobulin light chain (AL) amyloidosis;	chr14:34966185	chr14:34939324~34940332:+
BRCA	cis	rs7618915	0.501	rs13085775	ENSG00000243224.1	RP5-1157M23.2	-4.57	5.44e-06	0.000474	-0.15	-0.14	Bipolar disorder;	chr3:52644354	chr3:52239258~52241097:+
BRCA	cis	rs610932	0.517	rs604085	ENSG00000275344.1	MIR6503	4.57	5.45e-06	0.000475	0.14	0.14	Alzheimer's disease;	chr11:60209928	chr11:60209071~60209156:-
BRCA	cis	rs7160336	0.967	rs7140415	ENSG00000259065.1	RP5-1021I20.1	4.57	5.45e-06	0.000475	0.16	0.14	Blood protein levels;	chr14:74062150	chr14:73787360~73803270:+
BRCA	cis	rs17597773	0.674	rs11118619	ENSG00000238078.1	LINC01352	-4.57	5.45e-06	0.000475	-0.17	-0.14	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220838921	chr1:220829255~220832429:+
BRCA	cis	rs2273788	1	rs12555931	ENSG00000204173.9	LRRC37A5P	4.57	5.45e-06	0.000475	0.17	0.14	Monocyte count;	chr9:111581096	chr9:111602831~111631289:-
BRCA	cis	rs4218	0.648	rs17236453	ENSG00000277144.1	RP11-59H7.4	-4.57	5.45e-06	0.000475	-0.19	-0.14	Social communication problems;	chr15:59092156	chr15:59115547~59116089:-
BRCA	cis	rs13217239	0.646	rs4403259	ENSG00000224843.5	LINC00240	-4.57	5.45e-06	0.000475	-0.16	-0.14	Schizophrenia;	chr6:27029838	chr6:26956992~27023924:+
BRCA	cis	rs7267979	0.718	rs2983489	ENSG00000204556.4	CTD-2514C3.1	-4.57	5.45e-06	0.000475	-0.19	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25263484	chr20:26018832~26020684:+
BRCA	cis	rs8031584	0.918	rs34331396	ENSG00000259845.1	HERC2P10	4.57	5.45e-06	0.000475	0.17	0.14	Huntington's disease progression;	chr15:30956533	chr15:30815271~30844153:+
BRCA	cis	rs1950832	0.509	rs12883547	ENSG00000258636.1	CTD-2298J14.2	-4.57	5.45e-06	0.000475	-0.17	-0.14	Urate levels in obese individuals;	chr14:41697311	chr14:41587861~41604856:-
BRCA	cis	rs6968419	1	rs2402053	ENSG00000279086.1	RP11-667F14.1	-4.57	5.45e-06	0.000475	-0.14	-0.14	Intraocular pressure;	chr7:116196743	chr7:116209234~116211511:-
BRCA	cis	rs1005277	0.579	rs2472178	ENSG00000263064.2	RP11-291L22.7	4.57	5.45e-06	0.000475	0.17	0.14	Extrinsic epigenetic age acceleration;	chr10:38095822	chr10:38448689~38448949:+
BRCA	cis	rs1005277	0.579	rs2474572	ENSG00000263064.2	RP11-291L22.7	4.57	5.45e-06	0.000475	0.17	0.14	Extrinsic epigenetic age acceleration;	chr10:38096388	chr10:38448689~38448949:+
BRCA	cis	rs7267979	1	rs6083828	ENSG00000125804.12	FAM182A	4.57	5.46e-06	0.000475	0.18	0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25389282	chr20:26054655~26086917:+
BRCA	cis	rs11742741	1	rs62350797	ENSG00000248874.4	C5orf17	-4.57	5.46e-06	0.000475	-0.18	-0.14	Educational attainment;	chr5:24147593	chr5:23951348~24178263:+
BRCA	cis	rs12497850	0.931	rs28642807	ENSG00000225399.4	RP11-3B7.1	4.57	5.46e-06	0.000476	0.14	0.14	Parkinson's disease;	chr3:48889383	chr3:49260085~49261316:+
BRCA	cis	rs6088580	0.634	rs6088471	ENSG00000276073.1	RP5-1125A11.7	4.57	5.46e-06	0.000476	0.15	0.14	Glomerular filtration rate (creatinine);	chr20:34344837	chr20:33985617~33988989:-
BRCA	cis	rs9650657	0.529	rs10108618	ENSG00000255046.1	RP11-297N6.4	4.57	5.46e-06	0.000476	0.17	0.14	Neuroticism;	chr8:11095582	chr8:11797928~11802568:-
BRCA	cis	rs4664293	0.967	rs9646765	ENSG00000226266.5	AC009961.3	-4.57	5.46e-06	0.000476	-0.17	-0.14	Monocyte percentage of white cells;	chr2:159709137	chr2:159670708~159712435:-
BRCA	cis	rs651907	0.557	rs34624546	ENSG00000256628.3	ZBTB11-AS1	4.57	5.46e-06	0.000476	0.18	0.14	Colorectal cancer;	chr3:101655382	chr3:101676475~101679217:+
BRCA	cis	rs1656368	0.726	rs12492884	ENSG00000279311.1	RP11-170K4.2	4.57	5.46e-06	0.000476	0.18	0.14	Lobe attachment (rater-scored or self-reported);	chr3:158534777	chr3:158869898~158871821:+
BRCA	cis	rs7665090	1	rs4586937	ENSG00000251288.2	RP11-10L12.2	4.57	5.47e-06	0.000476	0.17	0.14	Primary biliary cholangitis;	chr4:102635305	chr4:102751401~102752641:+
BRCA	cis	rs7048146	0.966	rs10816832	ENSG00000213539.4	YBX1P6	4.57	5.47e-06	0.000476	0.16	0.14	Vascular brain injury;	chr9:109538494	chr9:109532830~109534332:-
BRCA	cis	rs7918232	0.882	rs788237	ENSG00000262412.1	RP11-85G18.6	-4.57	5.47e-06	0.000476	-0.24	-0.14	Breast cancer;	chr10:27169003	chr10:27243130~27250804:+
BRCA	cis	rs3770081	1	rs17584578	ENSG00000273080.1	RP11-301O19.1	4.57	5.47e-06	0.000476	0.31	0.14	Facial emotion recognition (sad faces);	chr2:86080501	chr2:86195590~86196049:+
BRCA	cis	rs924712	0.545	rs12203709	ENSG00000224984.1	RP11-524H19.2	4.57	5.47e-06	0.000477	0.17	0.14	Breast cancer;	chr6:54842819	chr6:54840118~54840855:-
BRCA	cis	rs6088580	0.634	rs6088483	ENSG00000276073.1	RP5-1125A11.7	4.57	5.47e-06	0.000477	0.15	0.14	Glomerular filtration rate (creatinine);	chr20:34396908	chr20:33985617~33988989:-
BRCA	cis	rs6095360	0.934	rs2295578	ENSG00000222365.1	SNORD12B	-4.57	5.47e-06	0.000477	-0.15	-0.14	Intelligence (multi-trait analysis);	chr20:49010064	chr20:49280319~49280409:+
BRCA	cis	rs4787491	0.765	rs4788216	ENSG00000261367.1	RP11-455F5.4	-4.57	5.47e-06	0.000477	-0.15	-0.14	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30036756	chr16:30107675~30110541:+
BRCA	cis	rs2243480	0.711	rs1626926	ENSG00000275400.1	RP4-756H11.5	4.57	5.47e-06	0.000477	0.25	0.14	Diabetic kidney disease;	chr7:65970805	chr7:66553805~66554199:-
BRCA	cis	rs6951245	1	rs74652290	ENSG00000229043.2	AC091729.9	-4.57	5.47e-06	0.000477	-0.24	-0.14	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1050473	chr7:1160374~1165267:+
BRCA	cis	rs6441961	0.501	rs41502550	ENSG00000223552.1	RP11-24F11.2	4.57	5.47e-06	0.000477	0.18	0.14	Celiac disease;	chr3:46238732	chr3:46364955~46407059:-
BRCA	cis	rs7771547	0.603	rs10947614	ENSG00000224666.3	RP1-50J22.4	4.57	5.47e-06	0.000477	0.18	0.14	Platelet distribution width;	chr6:36606045	chr6:36386831~36393462:+
BRCA	cis	rs9921338	0.961	rs11074958	ENSG00000262636.1	CTD-3088G3.4	-4.57	5.47e-06	0.000477	-0.23	-0.14	Vein graft stenosis in coronary artery bypass grafting;	chr16:11303222	chr16:11380859~11381118:-
BRCA	cis	rs10266483	0.774	rs28580000	ENSG00000227986.1	TRIM60P18	4.57	5.48e-06	0.000477	0.15	0.14	Response to statin therapy;	chr7:64341531	chr7:64355078~64356199:+
BRCA	cis	rs793571	0.628	rs28412567	ENSG00000259250.1	RP11-50C13.1	-4.57	5.48e-06	0.000477	-0.24	-0.14	Schizophrenia;	chr15:58810014	chr15:58587507~58591676:+
BRCA	cis	rs793571	0.628	rs12439632	ENSG00000259250.1	RP11-50C13.1	-4.57	5.48e-06	0.000477	-0.24	-0.14	Schizophrenia;	chr15:58811764	chr15:58587507~58591676:+
BRCA	cis	rs1910358	0.596	rs1121277	ENSG00000248874.4	C5orf17	-4.57	5.48e-06	0.000478	-0.21	-0.14	Venous thromboembolism (SNP x SNP interaction);	chr5:23835358	chr5:23951348~24178263:+
BRCA	cis	rs1910358	0.621	rs7714949	ENSG00000248874.4	C5orf17	-4.57	5.48e-06	0.000478	-0.21	-0.14	Venous thromboembolism (SNP x SNP interaction);	chr5:23836146	chr5:23951348~24178263:+
BRCA	cis	rs860818	1	rs858234	ENSG00000230658.1	KLHL7-AS1	4.57	5.48e-06	0.000478	0.33	0.14	Initial pursuit acceleration;	chr7:23201196	chr7:23101228~23105703:-
BRCA	cis	rs10946940	0.965	rs6456799	ENSG00000219392.1	RP1-265C24.5	4.57	5.48e-06	0.000478	0.18	0.14	Systemic lupus erythematosus;	chr6:27605757	chr6:28115628~28116551:+
BRCA	cis	rs7772486	0.719	rs2206141	ENSG00000270638.1	RP3-466P17.1	-4.57	5.49e-06	0.000478	-0.16	-0.14	Lobe attachment (rater-scored or self-reported);	chr6:145765056	chr6:145735570~145737218:+
BRCA	cis	rs7772486	0.654	rs6906402	ENSG00000270638.1	RP3-466P17.1	-4.57	5.49e-06	0.000478	-0.16	-0.14	Lobe attachment (rater-scored or self-reported);	chr6:145768171	chr6:145735570~145737218:+
BRCA	cis	rs2179367	0.6	rs9498356	ENSG00000268592.3	RAET1E-AS1	4.57	5.49e-06	0.000478	0.21	0.14	Dupuytren's disease;	chr6:149443337	chr6:149863494~149919507:+
BRCA	cis	rs4356203	0.875	rs214935	ENSG00000272034.1	SNORD14A	-4.57	5.49e-06	0.000478	-0.14	-0.14	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17171575	chr11:17074654~17074744:-
BRCA	cis	rs6964587	0.967	rs7801058	ENSG00000188693.7	CYP51A1-AS1	-4.57	5.49e-06	0.000478	-0.15	-0.14	Breast cancer;	chr7:92155067	chr7:92134604~92180725:+
BRCA	cis	rs13113518	1	rs4864542	ENSG00000273257.1	RP11-177J6.1	-4.57	5.49e-06	0.000478	-0.18	-0.14	Height;	chr4:55487920	chr4:55387949~55388271:+
BRCA	cis	rs4688759	0.719	rs73079018	ENSG00000225399.4	RP11-3B7.1	-4.57	5.49e-06	0.000478	-0.26	-0.14	Blood protein levels;	chr3:49837894	chr3:49260085~49261316:+
BRCA	cis	rs13113518	0.966	rs4864544	ENSG00000273257.1	RP11-177J6.1	4.57	5.49e-06	0.000478	0.18	0.14	Height;	chr4:55515292	chr4:55387949~55388271:+
BRCA	cis	rs6723226	0.806	rs6543658	ENSG00000276517.1	AL133243.2	-4.57	5.49e-06	0.000478	-0.17	-0.14	Intelligence (multi-trait analysis);	chr2:32493782	chr2:32526504~32529507:+
BRCA	cis	rs6840360	0.642	rs7658169	ENSG00000251603.1	RP11-164P12.4	-4.57	5.5e-06	0.000479	-0.13	-0.14	Intelligence (multi-trait analysis);	chr4:151432262	chr4:151667224~151670502:+
BRCA	cis	rs11239930	0.517	rs632861	ENSG00000230832.3	RP11-325P15.2	-4.57	5.5e-06	0.000479	-0.2	-0.14	AIDS progression;	chr1:147079826	chr1:147082338~147083578:-
BRCA	cis	rs2236295	0.533	rs10995356	ENSG00000238280.1	RP11-436D10.3	-4.57	5.5e-06	0.000479	-0.19	-0.14	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks);	chr10:62896153	chr10:62793562~62805887:-
BRCA	cis	rs9467773	0.523	rs2498399	ENSG00000124549.13	BTN2A3P	4.57	5.5e-06	0.000479	0.14	0.14	Intelligence (multi-trait analysis);	chr6:26795343	chr6:26421391~26432383:+
BRCA	cis	rs1371614	0.635	rs6706127	ENSG00000272148.1	RP11-195B17.1	-4.57	5.5e-06	0.000479	-0.16	-0.14	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26917873	chr2:27062428~27062907:-
BRCA	cis	rs9925964	0.933	rs56314408	ENSG00000232748.3	RP11-196G11.6	-4.57	5.5e-06	0.000479	-0.17	-0.14	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31106068	chr16:31056460~31062803:+
BRCA	cis	rs867371	0.502	rs28610286	ENSG00000276710.3	CSPG4P8	-4.57	5.5e-06	0.000479	-0.14	-0.14	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82233314	chr15:82459472~82477258:+
BRCA	cis	rs6570726	0.935	rs407721	ENSG00000270638.1	RP3-466P17.1	4.57	5.5e-06	0.000479	0.16	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145550218	chr6:145735570~145737218:+
BRCA	cis	rs7665090	0.934	rs35112949	ENSG00000251288.2	RP11-10L12.2	-4.57	5.51e-06	0.00048	-0.17	-0.14	Primary biliary cholangitis;	chr4:102638473	chr4:102751401~102752641:+
BRCA	cis	rs7665090	0.87	rs34349956	ENSG00000251288.2	RP11-10L12.2	-4.57	5.51e-06	0.00048	-0.17	-0.14	Primary biliary cholangitis;	chr4:102638476	chr4:102751401~102752641:+
BRCA	cis	rs1005277	0.579	rs2505194	ENSG00000263064.2	RP11-291L22.7	4.57	5.51e-06	0.00048	0.17	0.14	Extrinsic epigenetic age acceleration;	chr10:38104953	chr10:38448689~38448949:+
BRCA	cis	rs516805	0.528	rs2606611	ENSG00000279453.1	RP3-425C14.4	-4.57	5.51e-06	0.00048	-0.19	-0.14	Lymphocyte counts;	chr6:122094502	chr6:122436789~122439223:-
BRCA	cis	rs516805	0.528	rs1402537	ENSG00000279453.1	RP3-425C14.4	-4.57	5.51e-06	0.00048	-0.19	-0.14	Lymphocyte counts;	chr6:122094962	chr6:122436789~122439223:-
BRCA	cis	rs516805	0.528	rs2606622	ENSG00000279453.1	RP3-425C14.4	-4.57	5.51e-06	0.00048	-0.19	-0.14	Lymphocyte counts;	chr6:122096367	chr6:122436789~122439223:-
BRCA	cis	rs1019173	0.966	rs10232678	ENSG00000261455.1	LINC01003	-4.57	5.51e-06	0.00048	-0.17	-0.14	Kidney function decline traits;	chr7:152015986	chr7:152463786~152465549:+
BRCA	cis	rs7267979	0.933	rs2424708	ENSG00000276952.1	RP5-965G21.6	4.57	5.51e-06	0.00048	0.17	0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25300762	chr20:25284915~25285588:-
BRCA	cis	rs600550	0.963	rs592894	ENSG00000275344.1	MIR6503	4.57	5.51e-06	0.00048	0.14	0.14	Lipoprotein-associated phospholipase A2 activity and mass;	chr11:60247423	chr11:60209071~60209156:-
BRCA	cis	rs1387259	0.698	rs4579969	ENSG00000273765.1	RP11-370I10.11	-4.57	5.51e-06	0.00048	-0.16	-0.14	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48385779	chr12:48360920~48361377:+
BRCA	cis	rs2239547	0.618	rs1573815	ENSG00000242142.1	SERBP1P3	-4.57	5.52e-06	0.00048	-0.17	-0.14	Schizophrenia;	chr3:52836116	chr3:53064283~53065091:-
BRCA	cis	rs7829975	0.711	rs12682352	ENSG00000253981.4	ALG1L13P	4.57	5.52e-06	0.00048	0.16	0.14	Mood instability;	chr8:8788736	chr8:8236003~8244667:-
BRCA	cis	rs995000	0.662	rs11208009	ENSG00000235545.1	RP11-230B22.1	4.57	5.52e-06	0.00048	0.16	0.14	Triglyceride levels;	chr1:62730021	chr1:62688482~62710694:+
BRCA	cis	rs875971	0.545	rs11767262	ENSG00000230295.1	RP11-458F8.2	4.57	5.52e-06	0.000481	0.13	0.14	Aortic root size;	chr7:66302237	chr7:66880708~66882981:+
BRCA	cis	rs9840812	0.953	rs34330586	ENSG00000239213.4	NCK1-AS1	-4.57	5.52e-06	0.000481	-0.17	-0.14	Fibrinogen levels;	chr3:136081567	chr3:136841726~136862054:-
BRCA	cis	rs6847067	0.794	rs4626191	ENSG00000180769.7	WDFY3-AS2	4.57	5.52e-06	0.000481	0.13	0.14	Oropharynx cancer;	chr4:85015526	chr4:84965682~85011277:+
BRCA	cis	rs9311474	0.508	rs11720159	ENSG00000243224.1	RP5-1157M23.2	-4.57	5.53e-06	0.000481	-0.15	-0.14	Electroencephalogram traits;	chr3:52583786	chr3:52239258~52241097:+
BRCA	cis	rs6088590	1	rs12626122	ENSG00000276073.1	RP5-1125A11.7	-4.57	5.53e-06	0.000481	-0.17	-0.14	Coronary artery disease;	chr20:34837997	chr20:33985617~33988989:-
BRCA	cis	rs725613	0.512	rs4781033	ENSG00000274038.1	RP11-66H6.4	-4.57	5.53e-06	0.000481	-0.15	-0.14	Primary sclerosing cholangitis;	chr16:10993045	chr16:11056556~11057034:+
BRCA	cis	rs17597773	0.674	rs1494372	ENSG00000238078.1	LINC01352	-4.57	5.53e-06	0.000481	-0.16	-0.14	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220841279	chr1:220829255~220832429:+
BRCA	cis	rs4474465	1	rs7395344	ENSG00000251323.2	RP11-452H21.4	4.57	5.53e-06	0.000482	0.18	0.14	Alzheimer's disease (survival time);	chr11:78491342	chr11:78423982~78429836:-
BRCA	cis	rs736408	0.509	rs1108842	ENSG00000243224.1	RP5-1157M23.2	-4.57	5.53e-06	0.000482	-0.15	-0.14	Bipolar disorder;	chr3:52686064	chr3:52239258~52241097:+
BRCA	cis	rs7267979	1	rs4815417	ENSG00000274973.1	RP13-401N8.7	4.57	5.53e-06	0.000482	0.16	0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25398890	chr20:25845497~25845862:+
BRCA	cis	rs116095464	0.558	rs9687621	ENSG00000248925.1	CTD-2083E4.6	4.57	5.54e-06	0.000482	0.27	0.14	Breast cancer;	chr5:229079	chr5:269858~271516:-
BRCA	cis	rs11048434	0.518	rs11048496	ENSG00000256720.1	RP11-436I9.6	-4.57	5.54e-06	0.000482	-0.14	-0.14	Sjögren's syndrome;	chr12:9019825	chr12:9135084~9135591:+
BRCA	cis	rs2599510	0.744	rs2254106	ENSG00000276334.1	AL133243.1	4.57	5.54e-06	0.000482	0.17	0.14	Interleukin-18 levels;	chr2:32543730	chr2:32521927~32523547:+
BRCA	cis	rs10761482	0.5	rs2211220	ENSG00000254271.1	RP11-131N11.4	4.57	5.54e-06	0.000482	0.19	0.14	Schizophrenia;	chr10:60511733	chr10:60734342~60741828:+
BRCA	cis	rs7960884	0.712	rs61917102	ENSG00000226472.6	RP11-551L14.4	4.57	5.54e-06	0.000482	0.19	0.14	Systolic blood pressure response to hydrochlorothiazide in hypertension;	chr12:31221908	chr12:30978308~31006010:-
BRCA	cis	rs4780355	0.877	rs243317	ENSG00000262703.1	RP11-485G7.6	-4.57	5.54e-06	0.000483	-0.15	-0.14	Crohn's disease and psoriasis;	chr16:11263474	chr16:11348143~11349321:-
BRCA	cis	rs875971	0.545	rs1267814	ENSG00000232546.1	RP11-458F8.1	-4.57	5.55e-06	0.000483	-0.13	-0.14	Aortic root size;	chr7:66579422	chr7:66848496~66858136:+
BRCA	cis	rs3764021	0.527	rs10844503	ENSG00000256673.1	RP11-599J14.2	-4.57	5.55e-06	0.000483	-0.18	-0.14	Type 1 diabetes;	chr12:9701660	chr12:9398355~9414851:-
BRCA	cis	rs7200543	1	rs7200543	ENSG00000260735.1	RP11-72I8.1	4.57	5.55e-06	0.000483	0.16	0.14	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15036113	chr16:15094411~15109197:+
BRCA	cis	rs11098499	0.644	rs34835603	ENSG00000249244.1	RP11-548H18.2	4.57	5.55e-06	0.000483	0.16	0.14	Corneal astigmatism;	chr4:119632273	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.615	rs28850368	ENSG00000249244.1	RP11-548H18.2	4.57	5.55e-06	0.000483	0.16	0.14	Corneal astigmatism;	chr4:119633158	chr4:119391831~119395335:-
BRCA	cis	rs2834288	0.734	rs9984662	ENSG00000273102.1	AP000569.9	4.57	5.55e-06	0.000483	0.16	0.14	Gut microbiota (bacterial taxa);	chr21:33892504	chr21:33967101~33968573:-
BRCA	cis	rs7141336	0.864	rs7148903	ENSG00000258884.1	CTD-3035D6.2	4.57	5.55e-06	0.000483	0.19	0.14	Anxiety disorder;	chr14:90821483	chr14:90822365~90828128:-
BRCA	cis	rs17489649	0.955	rs6894260	ENSG00000271849.1	CTC-332L22.1	4.57	5.55e-06	0.000483	0.18	0.14	Intelligence (multi-trait analysis);	chr5:109774836	chr5:109687802~109688329:-
BRCA	cis	rs4831760	1	rs7818067	ENSG00000250483.1	PPM1AP1	4.57	5.55e-06	0.000483	0.2	0.14	Pulmonary function decline;	chr8:15678207	chr8:15806149~15807283:-
BRCA	cis	rs6545883	0.868	rs2441381	ENSG00000270820.4	RP11-355B11.2	4.57	5.55e-06	0.000483	0.16	0.14	Tuberculosis;	chr2:61571694	chr2:61471188~61484130:+
BRCA	cis	rs3768617	0.811	rs4285667	ENSG00000224468.3	RP11-181K3.4	-4.57	5.56e-06	0.000484	-0.16	-0.14	Fuchs's corneal dystrophy;	chr1:183001090	chr1:183138402~183141282:-
BRCA	cis	rs253959	0.595	rs11241361	ENSG00000271918.1	CTD-2287O16.5	4.57	5.56e-06	0.000484	0.13	0.14	Bipolar disorder and schizophrenia;	chr5:116112611	chr5:116083807~116085416:-
BRCA	cis	rs7267979	1	rs448396	ENSG00000125804.12	FAM182A	-4.57	5.56e-06	0.000484	-0.18	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25459633	chr20:26054655~26086917:+
BRCA	cis	rs9921338	0.961	rs77552156	ENSG00000262703.1	RP11-485G7.6	-4.57	5.56e-06	0.000484	-0.18	-0.14	Vein graft stenosis in coronary artery bypass grafting;	chr16:11332542	chr16:11348143~11349321:-
BRCA	cis	rs7811142	0.83	rs11768967	ENSG00000078319.8	PMS2P1	-4.57	5.56e-06	0.000484	-0.22	-0.14	Platelet count;	chr7:100370021	chr7:100320992~100341908:-
BRCA	cis	rs721917	0.7	rs2493719	ENSG00000242600.5	MBL1P	-4.57	5.56e-06	0.000484	-0.17	-0.14	Chronic obstructive pulmonary disease;	chr10:79896305	chr10:79904898~79950336:+
BRCA	cis	rs875971	0.502	rs11769702	ENSG00000273142.1	RP11-458F8.4	4.57	5.56e-06	0.000484	0.14	0.14	Aortic root size;	chr7:66255529	chr7:66902857~66906297:+
BRCA	cis	rs6828577	0.819	rs298984	ENSG00000281731.1	RP11-384K6.8	-4.57	5.56e-06	0.000484	-0.16	-0.14	Perioperative myocardial infarction in coronary artery bypass surgery;	chr4:118682650	chr4:118664087~118685341:-
BRCA	cis	rs7727544	0.582	rs2278398	ENSG00000233006.5	AC034220.3	-4.57	5.57e-06	0.000484	-0.1	-0.14	Blood metabolite levels;	chr5:132194748	chr5:132311285~132369916:-
BRCA	cis	rs6570726	0.935	rs408768	ENSG00000270638.1	RP3-466P17.1	4.57	5.57e-06	0.000484	0.16	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145550599	chr6:145735570~145737218:+
BRCA	cis	rs736408	0.509	rs3774349	ENSG00000243224.1	RP5-1157M23.2	-4.57	5.57e-06	0.000484	-0.15	-0.14	Bipolar disorder;	chr3:52688319	chr3:52239258~52241097:+
BRCA	cis	rs17428076	0.681	rs788163	ENSG00000228389.1	AC068039.4	-4.57	5.57e-06	0.000485	-0.19	-0.14	Myopia;	chr2:172066831	chr2:171773482~171775844:+
BRCA	cis	rs7829975	0.659	rs4382480	ENSG00000233609.3	RP11-62H7.2	4.57	5.57e-06	0.000485	0.13	0.14	Mood instability;	chr8:8863963	chr8:8961200~8979025:+
BRCA	cis	rs672203	0.607	rs1967189	ENSG00000271992.1	RP11-42O15.3	4.57	5.57e-06	0.000485	0.19	0.14	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);	chr1:70456677	chr1:70445071~70445536:+
BRCA	cis	rs2243480	1	rs781142	ENSG00000275400.1	RP4-756H11.5	4.57	5.57e-06	0.000485	0.25	0.14	Diabetic kidney disease;	chr7:65973791	chr7:66553805~66554199:-
BRCA	cis	rs17345786	0.511	rs1138818	ENSG00000256628.3	ZBTB11-AS1	4.57	5.57e-06	0.000485	0.18	0.14	Colonoscopy-negative controls vs population controls;	chr3:101680739	chr3:101676475~101679217:+
BRCA	cis	rs6545883	0.826	rs1186697	ENSG00000212978.6	AC016747.3	4.57	5.58e-06	0.000485	0.2	0.14	Tuberculosis;	chr2:61434282	chr2:61141592~61144969:-
BRCA	cis	rs983392	0.792	rs1303621	ENSG00000275344.1	MIR6503	-4.57	5.58e-06	0.000485	-0.14	-0.14	Alzheimer's disease (late onset);	chr11:60123201	chr11:60209071~60209156:-
BRCA	cis	rs375066	0.935	rs397346	ENSG00000267191.1	RP11-15A1.2	-4.57	5.58e-06	0.000485	-0.18	-0.14	Breast cancer;	chr19:43894963	chr19:43902001~43926545:+
BRCA	cis	rs10129255	0.912	rs8009135	ENSG00000274576.2	IGHV2-70	4.57	5.58e-06	0.000485	0.12	0.14	Kawasaki disease;	chr14:106777528	chr14:106770577~106771020:-
BRCA	cis	rs13113518	0.966	rs13108409	ENSG00000273257.1	RP11-177J6.1	4.57	5.58e-06	0.000485	0.18	0.14	Height;	chr4:55520278	chr4:55387949~55388271:+
BRCA	cis	rs2312236	0.714	rs12566009	ENSG00000225171.2	DUTP6	-4.57	5.58e-06	0.000485	-0.2	-0.14	Post-traumatic stress disorder;	chr1:166752048	chr1:166868748~166869209:+
BRCA	cis	rs11096990	0.613	rs4974990	ENSG00000249685.1	RP11-360F5.3	4.57	5.58e-06	0.000485	0.18	0.14	Cognitive function;	chr4:39191645	chr4:39133913~39135608:+
BRCA	cis	rs34787248	1	rs34787248	ENSG00000280107.1	AL022393.9	-4.57	5.58e-06	0.000485	-0.23	-0.14	Autism spectrum disorder or schizophrenia;	chr6:28230108	chr6:28170845~28172521:+
BRCA	cis	rs7914558	0.646	rs12768205	ENSG00000213061.2	PFN1P11	4.57	5.58e-06	0.000486	0.2	0.14	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102888092	chr10:102838011~102845473:-
BRCA	cis	rs7914558	0.646	rs10883795	ENSG00000213061.2	PFN1P11	4.57	5.58e-06	0.000486	0.2	0.14	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102894820	chr10:102838011~102845473:-
BRCA	cis	rs7914558	0.646	rs10883796	ENSG00000213061.2	PFN1P11	4.57	5.58e-06	0.000486	0.2	0.14	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102895558	chr10:102838011~102845473:-
BRCA	cis	rs7914558	0.646	rs4363528	ENSG00000213061.2	PFN1P11	4.57	5.58e-06	0.000486	0.2	0.14	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102895758	chr10:102838011~102845473:-
BRCA	cis	rs6480314	0.542	rs61854804	ENSG00000233590.1	RP11-153K11.3	-4.57	5.58e-06	0.000486	-0.23	-0.14	Optic nerve measurement (disc area);	chr10:68255819	chr10:68233251~68242379:-
BRCA	cis	rs62247992	0.59	rs11708331	ENSG00000227245.1	RP11-136C24.2	4.57	5.58e-06	0.000486	0.21	0.14	Facial morphology (factor 15, philtrum width);	chr3:43117465	chr3:43087479~43088068:+
BRCA	cis	rs11955398	0.502	rs169700	ENSG00000272308.1	RP11-231G3.1	-4.57	5.58e-06	0.000486	-0.16	-0.14	Intelligence (multi-trait analysis);	chr5:60969281	chr5:60866457~60866935:-
BRCA	cis	rs11976180	1	rs2371244	ENSG00000244479.5	OR2A1-AS1	4.57	5.59e-06	0.000486	0.19	0.14	Obesity-related traits;	chr7:144060518	chr7:144251264~144356181:-
BRCA	cis	rs77106637	0.556	rs7123876	ENSG00000256633.1	RP11-169D4.2	4.57	5.59e-06	0.000486	0.16	0.14	Type 2 diabetes;	chr11:72733538	chr11:72584572~72587979:+
BRCA	cis	rs7811142	1	rs68116612	ENSG00000078319.8	PMS2P1	-4.57	5.59e-06	0.000486	-0.21	-0.14	Platelet count;	chr7:100408870	chr7:100320992~100341908:-
BRCA	cis	rs875971	0.545	rs6970498	ENSG00000232546.1	RP11-458F8.1	4.57	5.59e-06	0.000486	0.14	0.14	Aortic root size;	chr7:66275908	chr7:66848496~66858136:+
BRCA	cis	rs9425766	0.64	rs2208850	ENSG00000227373.4	RP11-160H22.5	4.57	5.59e-06	0.000486	0.21	0.14	Life satisfaction;	chr1:173862569	chr1:174115300~174160004:-
BRCA	cis	rs3176789	0.647	rs11052970	ENSG00000256673.1	RP11-599J14.2	4.56	5.59e-06	0.000486	0.16	0.14	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9766671	chr12:9398355~9414851:-
BRCA	cis	rs13098911	0.54	rs35883205	ENSG00000223552.1	RP11-24F11.2	-4.56	5.59e-06	0.000486	-0.23	-0.14	Celiac disease;	chr3:46012476	chr3:46364955~46407059:-
BRCA	cis	rs2243480	0.522	rs73150635	ENSG00000229886.1	RP5-1132H15.3	4.56	5.59e-06	0.000486	0.31	0.14	Diabetic kidney disease;	chr7:66507503	chr7:66025126~66031544:-
BRCA	cis	rs35612822	0.723	rs62178624	ENSG00000232485.2	AC098820.3	-4.56	5.59e-06	0.000486	-0.17	-0.14	Kidney disease (early stage) in type 1 diabetes;	chr2:216405037	chr2:216479030~216498761:-
BRCA	cis	rs8054556	0.787	rs12935701	ENSG00000183604.13	SMG1P5	-4.56	5.59e-06	0.000486	-0.14	-0.14	Autism spectrum disorder or schizophrenia;	chr16:30015427	chr16:30267553~30335374:-
BRCA	cis	rs4781563	1	rs3136176	ENSG00000242307.1	RPS26P52	-4.56	5.59e-06	0.000487	-0.17	-0.14	Bilirubin levels;	chr16:13939439	chr16:13922332~13922679:-
BRCA	cis	rs1707322	0.963	rs4508055	ENSG00000234329.1	RP11-767N6.2	4.56	5.6e-06	0.000487	0.15	0.14	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45792059	chr1:45651039~45651826:-
BRCA	cis	rs7267979	1	rs6050626	ENSG00000274973.1	RP13-401N8.7	-4.56	5.6e-06	0.000487	-0.16	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25447625	chr20:25845497~25845862:+
BRCA	cis	rs12922040	1	rs2075516	ENSG00000279866.1	CTB-193M12.4	-4.56	5.6e-06	0.000487	-0.17	-0.14	Serum uric acid levels in response to allopurinol in gout;	chr16:15775668	chr16:15704410~15705984:+
BRCA	cis	rs4415084	0.804	rs9790879	ENSG00000251141.4	RP11-53O19.1	-4.56	5.6e-06	0.000487	-0.13	-0.14	Breast cancer;	chr5:44899783	chr5:44744900~44808777:-
BRCA	cis	rs792448	1	rs518793	ENSG00000226251.4	RP11-15I11.3	-4.56	5.6e-06	0.000487	-0.19	-0.14	White blood cell count (basophil);	chr1:212414864	chr1:212225278~212238977:-
BRCA	cis	rs7727544	0.716	rs11949055	ENSG00000233006.5	AC034220.3	4.56	5.6e-06	0.000487	0.11	0.14	Blood metabolite levels;	chr5:132241044	chr5:132311285~132369916:-
BRCA	cis	rs7727544	0.716	rs3844312	ENSG00000233006.5	AC034220.3	4.56	5.6e-06	0.000487	0.1	0.14	Blood metabolite levels;	chr5:132246663	chr5:132311285~132369916:-
BRCA	cis	rs11673344	0.523	rs7260488	ENSG00000226686.6	LINC01535	4.56	5.6e-06	0.000487	0.18	0.14	Obesity-related traits;	chr19:37058883	chr19:37251912~37265535:+
BRCA	cis	rs12744310	0.887	rs35464028	ENSG00000235358.1	RP11-399E6.1	4.56	5.6e-06	0.000487	0.21	0.14	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41334802	chr1:41242373~41284861:+
BRCA	cis	rs4664293	0.867	rs2357531	ENSG00000226266.5	AC009961.3	-4.56	5.6e-06	0.000487	-0.18	-0.14	Monocyte percentage of white cells;	chr2:159740907	chr2:159670708~159712435:-
BRCA	cis	rs4664293	0.867	rs16844269	ENSG00000226266.5	AC009961.3	-4.56	5.6e-06	0.000487	-0.18	-0.14	Monocyte percentage of white cells;	chr2:159742569	chr2:159670708~159712435:-
BRCA	cis	rs4664293	0.836	rs4664300	ENSG00000226266.5	AC009961.3	-4.56	5.6e-06	0.000487	-0.18	-0.14	Monocyte percentage of white cells;	chr2:159743927	chr2:159670708~159712435:-
BRCA	cis	rs4664293	0.867	rs16822556	ENSG00000226266.5	AC009961.3	-4.56	5.6e-06	0.000487	-0.18	-0.14	Monocyte percentage of white cells;	chr2:159744392	chr2:159670708~159712435:-
BRCA	cis	rs4664293	0.867	rs16822558	ENSG00000226266.5	AC009961.3	-4.56	5.6e-06	0.000487	-0.18	-0.14	Monocyte percentage of white cells;	chr2:159744496	chr2:159670708~159712435:-
BRCA	cis	rs4664293	0.867	rs1834761	ENSG00000226266.5	AC009961.3	-4.56	5.6e-06	0.000487	-0.18	-0.14	Monocyte percentage of white cells;	chr2:159745278	chr2:159670708~159712435:-
BRCA	cis	rs2841277	0.738	rs1036713	ENSG00000258701.1	LINC00638	-4.56	5.61e-06	0.000488	-0.15	-0.14	Rheumatoid arthritis;	chr14:104930356	chr14:104821201~104823718:+
BRCA	cis	rs6081541	1	rs6081547	ENSG00000179447.2	RP5-1027G4.3	-4.56	5.61e-06	0.000488	-0.2	-0.14	Psychosis (atypical);	chr20:19243943	chr20:19242302~19284596:-
BRCA	cis	rs7200543	0.883	rs4985148	ENSG00000260872.1	RP11-680G24.5	-4.56	5.61e-06	0.000488	-0.15	-0.14	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15053931	chr16:15018106~15020488:-
BRCA	cis	rs10504130	0.569	rs34372756	ENSG00000253844.1	RP11-546K22.1	-4.56	5.61e-06	0.000488	-0.21	-0.14	Venous thromboembolism (SNP x SNP interaction);	chr8:51908796	chr8:51961458~52022974:+
BRCA	cis	rs11673344	0.523	rs8110158	ENSG00000226686.6	LINC01535	4.56	5.61e-06	0.000488	0.18	0.14	Obesity-related traits;	chr19:37063491	chr19:37251912~37265535:+
BRCA	cis	rs35740288	0.77	rs1382534	ENSG00000202081.1	RNU6-1280P	4.56	5.61e-06	0.000488	0.18	0.14	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85598939	chr15:85651522~85651628:-
BRCA	cis	rs7772486	0.79	rs2814880	ENSG00000270638.1	RP3-466P17.1	4.56	5.62e-06	0.000488	0.16	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145887801	chr6:145735570~145737218:+
BRCA	cis	rs4512344	0.509	rs2409784	ENSG00000255020.1	AF131216.5	4.56	5.62e-06	0.000488	0.16	0.14	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:11539347	chr8:11345748~11347502:-
BRCA	cis	rs7686660	1	rs11100764	ENSG00000250326.1	RP11-284M14.1	-4.56	5.62e-06	0.000488	-0.17	-0.14	Asthma;	chr4:143008706	chr4:142933195~143184861:-
BRCA	cis	rs6686842	0.965	rs10889792	ENSG00000235358.1	RP11-399E6.1	-4.56	5.62e-06	0.000489	-0.18	-0.14	Height;	chr1:41025213	chr1:41242373~41284861:+
BRCA	cis	rs67981189	0.593	rs2526883	ENSG00000269927.1	RP6-91H8.3	-4.56	5.62e-06	0.000489	-0.17	-0.14	Schizophrenia;	chr14:70902858	chr14:71141125~71143253:-
BRCA	cis	rs2834288	0.734	rs1557269	ENSG00000273102.1	AP000569.9	-4.56	5.63e-06	0.000489	-0.16	-0.14	Gut microbiota (bacterial taxa);	chr21:33894091	chr21:33967101~33968573:-
BRCA	cis	rs875971	0.54	rs4717275	ENSG00000182722.5	SEPHS1P1	4.56	5.63e-06	0.000489	0.17	0.14	Aortic root size;	chr7:65800193	chr7:64852397~64853354:-
BRCA	cis	rs4834770	1	rs6823963	ENSG00000245958.5	RP11-33B1.1	-4.56	5.63e-06	0.000489	-0.13	-0.14	Blood protein levels;	chr4:119321009	chr4:119454791~119552025:+
BRCA	cis	rs4834770	1	rs4834771	ENSG00000245958.5	RP11-33B1.1	-4.56	5.63e-06	0.000489	-0.13	-0.14	Blood protein levels;	chr4:119321617	chr4:119454791~119552025:+
BRCA	cis	rs4834770	1	rs1397613	ENSG00000245958.5	RP11-33B1.1	-4.56	5.63e-06	0.000489	-0.13	-0.14	Blood protein levels;	chr4:119321774	chr4:119454791~119552025:+
BRCA	cis	rs4834770	1	rs6857641	ENSG00000245958.5	RP11-33B1.1	-4.56	5.63e-06	0.000489	-0.13	-0.14	Blood protein levels;	chr4:119322356	chr4:119454791~119552025:+
BRCA	cis	rs4834770	1	rs2282688	ENSG00000245958.5	RP11-33B1.1	-4.56	5.63e-06	0.000489	-0.13	-0.14	Blood protein levels;	chr4:119322567	chr4:119454791~119552025:+
BRCA	cis	rs9311676	0.609	rs11719450	ENSG00000244161.1	FLNB-AS1	4.56	5.63e-06	0.000489	0.12	0.14	Systemic lupus erythematosus;	chr3:58471084	chr3:58162547~58170636:-
BRCA	cis	rs17270561	0.779	rs12209218	ENSG00000272462.2	U91328.19	-4.56	5.63e-06	0.000489	-0.19	-0.14	Iron status biomarkers;	chr6:25887548	chr6:25992662~26001775:+
BRCA	cis	rs10911232	0.507	rs4652772	ENSG00000224468.3	RP11-181K3.4	4.56	5.63e-06	0.000489	0.15	0.14	Hypertriglyceridemia;	chr1:183054561	chr1:183138402~183141282:-
BRCA	cis	rs4287000	0.508	rs62574558	ENSG00000227603.1	RP11-165J3.6	-4.56	5.63e-06	0.000489	-0.16	-0.14	Itch intensity from mosquito bite adjusted by bite size;	chr9:93600380	chr9:93435332~93437121:-
BRCA	cis	rs7267979	1	rs2482919	ENSG00000125804.12	FAM182A	4.56	5.63e-06	0.00049	0.19	0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25319120	chr20:26054655~26086917:+
BRCA	cis	rs6496044	0.568	rs2880765	ENSG00000202081.1	RNU6-1280P	-4.56	5.64e-06	0.00049	-0.16	-0.14	Interstitial lung disease;	chr15:85513231	chr15:85651522~85651628:-
BRCA	cis	rs1395	0.71	rs11682913	ENSG00000234072.1	AC074117.10	-4.56	5.64e-06	0.00049	-0.15	-0.14	Blood metabolite levels;	chr2:27250781	chr2:27356246~27367622:+
BRCA	cis	rs950169	0.579	rs881983	ENSG00000275120.1	RP11-182J1.17	4.56	5.64e-06	0.00049	0.21	0.14	Schizophrenia;	chr15:83978556	chr15:84599434~84606463:-
BRCA	cis	rs4664293	0.867	rs6740910	ENSG00000224152.1	AC009506.1	-4.56	5.64e-06	0.00049	-0.16	-0.14	Monocyte percentage of white cells;	chr2:159792709	chr2:159615296~159617082:+
BRCA	cis	rs6449502	0.541	rs11744226	ENSG00000251279.1	CTC-436P18.1	4.56	5.64e-06	0.00049	0.29	0.14	Mean platelet volume;	chr5:61115072	chr5:61162070~61232040:+
BRCA	cis	rs13113518	1	rs2279458	ENSG00000249700.7	SRD5A3-AS1	4.56	5.64e-06	0.00049	0.18	0.14	Height;	chr4:55562653	chr4:55363971~55395847:-
BRCA	cis	rs4356203	0.905	rs6486354	ENSG00000272034.1	SNORD14A	-4.56	5.64e-06	0.00049	-0.14	-0.14	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17178561	chr11:17074654~17074744:-
BRCA	cis	rs950169	0.58	rs17598114	ENSG00000176700.18	SCAND2P	-4.56	5.65e-06	0.000491	-0.14	-0.14	Schizophrenia;	chr15:84628086	chr15:84631451~84647478:+
BRCA	cis	rs910316	0.737	rs175045	ENSG00000279594.1	RP11-950C14.10	-4.56	5.65e-06	0.000491	-0.16	-0.14	Height;	chr14:75008572	chr14:75011269~75012851:-
BRCA	cis	rs11096990	0.613	rs35391082	ENSG00000249685.1	RP11-360F5.3	4.56	5.65e-06	0.000491	0.18	0.14	Cognitive function;	chr4:39191033	chr4:39133913~39135608:+
BRCA	cis	rs9467773	0.596	rs62396201	ENSG00000124549.13	BTN2A3P	4.56	5.65e-06	0.000491	0.14	0.14	Intelligence (multi-trait analysis);	chr6:26667988	chr6:26421391~26432383:+
BRCA	cis	rs7665090	0.87	rs228614	ENSG00000251288.2	RP11-10L12.2	4.56	5.65e-06	0.000491	0.17	0.14	Primary biliary cholangitis;	chr4:102657480	chr4:102751401~102752641:+
BRCA	cis	rs4831837	0.717	rs2068280	ENSG00000270074.1	RP11-351I21.11	4.56	5.65e-06	0.000491	0.17	0.14	Morbidity-free survival;	chr8:12834613	chr8:12412827~12414373:+
BRCA	cis	rs9926296	0.618	rs8058179	ENSG00000275734.1	RP11-368I7.6	-4.56	5.65e-06	0.000491	-0.15	-0.14	Vitiligo;	chr16:89780579	chr16:89684642~89685304:+
BRCA	cis	rs2055375	0.521	rs34633	ENSG00000272308.1	RP11-231G3.1	4.56	5.65e-06	0.000491	0.16	0.14	Intelligence (multi-trait analysis);	chr5:61228703	chr5:60866457~60866935:-
BRCA	cis	rs7726354	0.546	rs77982563	ENSG00000271828.1	CTD-2310F14.1	4.56	5.65e-06	0.000491	0.29	0.14	Breast cancer (early onset);	chr5:56897840	chr5:56927874~56929573:+
BRCA	cis	rs7818688	0.674	rs74632106	ENSG00000253528.2	RP11-347C18.4	-4.56	5.65e-06	0.000491	-0.21	-0.14	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94965804	chr8:94974573~94974853:-
BRCA	cis	rs7818688	0.697	rs112076731	ENSG00000253528.2	RP11-347C18.4	-4.56	5.65e-06	0.000491	-0.21	-0.14	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94965893	chr8:94974573~94974853:-
BRCA	cis	rs2880765	0.546	rs36098649	ENSG00000259295.5	CSPG4P12	4.56	5.66e-06	0.000491	0.19	0.14	Coronary artery disease;	chr15:85513576	chr15:85191438~85213905:+
BRCA	cis	rs4908768	0.501	rs11121186	ENSG00000232912.4	RP5-1115A15.1	4.56	5.66e-06	0.000491	0.13	0.14	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8480281	chr1:8424645~8434838:+
BRCA	cis	rs58521262	0.556	rs290582	ENSG00000268105.1	RP11-369G6.2	4.56	5.66e-06	0.000492	0.19	0.14	Testicular germ cell tumor;	chr19:23015301	chr19:23125665~23128543:+
BRCA	cis	rs6430585	0.583	rs2322813	ENSG00000231890.6	DARS-AS1	-4.56	5.66e-06	0.000492	-0.22	-0.14	Corneal structure;	chr2:135825239	chr2:135985176~136022593:+
BRCA	cis	rs67981189	0.593	rs2526871	ENSG00000269927.1	RP6-91H8.3	-4.56	5.66e-06	0.000492	-0.17	-0.14	Schizophrenia;	chr14:70918396	chr14:71141125~71143253:-
BRCA	cis	rs67981189	0.574	rs2810118	ENSG00000269927.1	RP6-91H8.3	-4.56	5.66e-06	0.000492	-0.17	-0.14	Schizophrenia;	chr14:70921858	chr14:71141125~71143253:-
BRCA	cis	rs651907	0.737	rs9844218	ENSG00000244119.1	PDCL3P4	-4.56	5.66e-06	0.000492	-0.12	-0.14	Colorectal cancer;	chr3:101866139	chr3:101712472~101713191:+
BRCA	cis	rs3113494	0.931	rs2705616	ENSG00000251411.1	RP11-397E7.4	4.56	5.66e-06	0.000492	0.16	0.14	Amyotrophic lateral sclerosis;	chr4:86941244	chr4:86913266~86914817:-
BRCA	cis	rs5758659	0.714	rs5758574	ENSG00000270083.1	RP1-257I20.14	-4.56	5.67e-06	0.000492	-0.16	-0.14	Cognitive function;	chr22:42085396	chr22:42089630~42090028:-
BRCA	cis	rs4287000	0.508	rs4744259	ENSG00000227603.1	RP11-165J3.6	-4.56	5.67e-06	0.000492	-0.16	-0.14	Itch intensity from mosquito bite adjusted by bite size;	chr9:93600636	chr9:93435332~93437121:-
BRCA	cis	rs7267979	1	rs6115182	ENSG00000125804.12	FAM182A	4.56	5.67e-06	0.000492	0.18	0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25429623	chr20:26054655~26086917:+
BRCA	cis	rs7577696	0.507	rs41280625	ENSG00000272716.1	RP11-563N4.1	4.56	5.67e-06	0.000492	0.15	0.14	Inflammatory biomarkers;	chr2:31943054	chr2:32165046~32165757:-
BRCA	cis	rs7647973	1	rs892974	ENSG00000244380.1	RP11-24C3.2	4.56	5.67e-06	0.000492	0.19	0.14	Menarche (age at onset);	chr3:49361081	chr3:48440352~48446656:-
BRCA	cis	rs721917	0.506	rs2265961	ENSG00000242600.5	MBL1P	4.56	5.67e-06	0.000492	0.17	0.14	Chronic obstructive pulmonary disease;	chr10:79886101	chr10:79904898~79950336:+
BRCA	cis	rs721917	0.506	rs7088752	ENSG00000242600.5	MBL1P	4.56	5.67e-06	0.000492	0.17	0.14	Chronic obstructive pulmonary disease;	chr10:79886704	chr10:79904898~79950336:+
BRCA	cis	rs721917	0.506	rs7078242	ENSG00000242600.5	MBL1P	4.56	5.67e-06	0.000492	0.17	0.14	Chronic obstructive pulmonary disease;	chr10:79886885	chr10:79904898~79950336:+
BRCA	cis	rs721917	0.525	rs2244001	ENSG00000242600.5	MBL1P	4.56	5.67e-06	0.000492	0.17	0.14	Chronic obstructive pulmonary disease;	chr10:79888813	chr10:79904898~79950336:+
BRCA	cis	rs721917	0.506	rs1811886	ENSG00000242600.5	MBL1P	4.56	5.67e-06	0.000492	0.17	0.14	Chronic obstructive pulmonary disease;	chr10:79889812	chr10:79904898~79950336:+
BRCA	cis	rs2692947	0.77	rs6719831	ENSG00000168992.4	OR7E102P	4.56	5.67e-06	0.000492	0.19	0.14	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95836842	chr2:95546531~95547545:+
BRCA	cis	rs853679	1	rs9986596	ENSG00000280107.1	AL022393.9	-4.56	5.67e-06	0.000492	-0.25	-0.14	Depression;	chr6:28251883	chr6:28170845~28172521:+
BRCA	cis	rs7949566	0.557	rs4937126	ENSG00000254905.1	RP11-712L6.7	4.56	5.67e-06	0.000492	0.17	0.14	Platelet distribution width;Mean platelet volume;	chr11:126412002	chr11:126292922~126294254:-
BRCA	cis	rs1008375	1	rs10012335	ENSG00000249502.1	AC006160.5	-4.56	5.67e-06	0.000492	-0.16	-0.14	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17627007	chr4:17587467~17614571:-
BRCA	cis	rs62458065	1	rs79538247	ENSG00000229358.3	DPY19L1P1	-4.56	5.67e-06	0.000493	-0.18	-0.14	Metabolite levels (HVA/MHPG ratio);	chr7:32428180	chr7:32580949~32761787:-
BRCA	cis	rs6832769	0.961	rs1011095	ENSG00000223305.1	RN7SKP30	4.56	5.67e-06	0.000493	0.17	0.14	Personality dimensions;	chr4:55398774	chr4:55540502~55540835:-
BRCA	cis	rs13113518	1	rs13113518	ENSG00000273257.1	RP11-177J6.1	4.56	5.67e-06	0.000493	0.18	0.14	Height;	chr4:55533481	chr4:55387949~55388271:+
BRCA	cis	rs2235642	0.893	rs2076445	ENSG00000260989.1	LA16c-395F10.2	-4.56	5.67e-06	0.000493	-0.14	-0.14	Coronary artery disease;	chr16:1542265	chr16:1580527~1610328:+
BRCA	cis	rs4650994	1	rs12138561	ENSG00000273384.1	RP5-1098D14.1	4.56	5.67e-06	0.000493	0.17	0.14	HDL cholesterol;HDL cholesterol levels;	chr1:178549649	chr1:178651706~178652282:+
BRCA	cis	rs11742741	0.967	rs62347899	ENSG00000248874.4	C5orf17	-4.56	5.67e-06	0.000493	-0.18	-0.14	Educational attainment;	chr5:24223592	chr5:23951348~24178263:+
BRCA	cis	rs1823874	0.71	rs8042933	ENSG00000182397.13	DNM1P46	4.56	5.68e-06	0.000493	0.15	0.14	IgG glycosylation;	chr15:99824641	chr15:99790156~99806927:-
BRCA	cis	rs9921338	0.961	rs8048768	ENSG00000262636.1	CTD-3088G3.4	-4.56	5.68e-06	0.000493	-0.23	-0.14	Vein graft stenosis in coronary artery bypass grafting;	chr16:11302983	chr16:11380859~11381118:-
BRCA	cis	rs7267979	0.966	rs4815425	ENSG00000274973.1	RP13-401N8.7	4.56	5.68e-06	0.000493	0.16	0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25418240	chr20:25845497~25845862:+
BRCA	cis	rs17711722	0.523	rs365896	ENSG00000226767.1	RP11-328P23.3	-4.56	5.68e-06	0.000493	-0.16	-0.14	Calcium levels;	chr7:66045710	chr7:65508773~65508944:-
BRCA	cis	rs9467773	0.62	rs2504600	ENSG00000241549.7	GUSBP2	4.56	5.69e-06	0.000494	0.15	0.14	Intelligence (multi-trait analysis);	chr6:26648106	chr6:26871484~26956554:-
BRCA	cis	rs9467773	0.62	rs2130657	ENSG00000241549.7	GUSBP2	4.56	5.69e-06	0.000494	0.15	0.14	Intelligence (multi-trait analysis);	chr6:26650598	chr6:26871484~26956554:-
BRCA	cis	rs9467773	0.62	rs2498351	ENSG00000241549.7	GUSBP2	4.56	5.69e-06	0.000494	0.15	0.14	Intelligence (multi-trait analysis);	chr6:26659414	chr6:26871484~26956554:-
BRCA	cis	rs9467773	0.62	rs2504566	ENSG00000241549.7	GUSBP2	4.56	5.69e-06	0.000494	0.15	0.14	Intelligence (multi-trait analysis);	chr6:26660260	chr6:26871484~26956554:-
BRCA	cis	rs35306767	0.953	rs35693858	ENSG00000229869.1	RP11-363N22.2	-4.56	5.69e-06	0.000494	-0.21	-0.14	Eosinophil percentage of granulocytes;	chr10:933873	chr10:933026~942743:+
BRCA	cis	rs7809615	0.901	rs11761528	ENSG00000244219.5	GS1-259H13.2	-4.56	5.69e-06	0.000494	-0.25	-0.14	Blood metabolite ratios;	chr7:99521178	chr7:99598066~99610813:+
BRCA	cis	rs300890	0.689	rs300943	ENSG00000250326.1	RP11-284M14.1	-4.56	5.69e-06	0.000494	-0.16	-0.14	Nasopharyngeal carcinoma;	chr4:143285000	chr4:142933195~143184861:-
BRCA	cis	rs9921338	0.961	rs7626	ENSG00000262703.1	RP11-485G7.6	-4.56	5.69e-06	0.000494	-0.18	-0.14	Vein graft stenosis in coronary artery bypass grafting;	chr16:11351739	chr16:11348143~11349321:-
BRCA	cis	rs9921338	0.961	rs7193278	ENSG00000262703.1	RP11-485G7.6	-4.56	5.69e-06	0.000494	-0.18	-0.14	Vein graft stenosis in coronary artery bypass grafting;	chr16:11351974	chr16:11348143~11349321:-
BRCA	cis	rs718433	0.584	rs8015812	ENSG00000256379.1	TRAV8-5	4.56	5.69e-06	0.000494	0.16	0.14	Intraocular pressure;	chr14:21746791	chr14:21903077~21903598:+
BRCA	cis	rs442309	0.841	rs377859	ENSG00000238280.1	RP11-436D10.3	-4.56	5.69e-06	0.000494	-0.19	-0.14	Vogt-Koyanagi-Harada syndrome;	chr10:62756305	chr10:62793562~62805887:-
BRCA	cis	rs7226408	0.894	rs17652340	ENSG00000267707.2	RP11-95O2.5	-4.56	5.7e-06	0.000495	-0.22	-0.14	Obesity-related traits;	chr18:36811140	chr18:37243776~37247506:+
BRCA	cis	rs7011507	0.582	rs72637609	ENSG00000279881.1	RP11-513O13.1	-4.56	5.7e-06	0.000495	-0.23	-0.14	Inflammatory bowel disease;Ulcerative colitis;	chr8:48331838	chr8:48428143~48431041:-
BRCA	cis	rs7772486	0.875	rs7767660	ENSG00000270638.1	RP3-466P17.1	4.56	5.7e-06	0.000495	0.16	0.14	Lobe attachment (rater-scored or self-reported);	chr6:146115414	chr6:145735570~145737218:+
BRCA	cis	rs7789940	0.951	rs73140055	ENSG00000280388.1	RP11-229D13.3	-4.56	5.7e-06	0.000495	-0.15	-0.14	Multiple sclerosis;	chr7:76346460	chr7:76043977~76045963:-
BRCA	cis	rs2243480	1	rs34529418	ENSG00000275400.1	RP4-756H11.5	4.56	5.7e-06	0.000495	0.25	0.14	Diabetic kidney disease;	chr7:65938222	chr7:66553805~66554199:-
BRCA	cis	rs6430585	0.583	rs1435577	ENSG00000231890.6	DARS-AS1	-4.56	5.7e-06	0.000495	-0.22	-0.14	Corneal structure;	chr2:135867377	chr2:135985176~136022593:+
BRCA	cis	rs67981189	0.593	rs2526871	ENSG00000258571.1	PTTG4P	4.56	5.7e-06	0.000495	0.15	0.14	Schizophrenia;	chr14:70918396	chr14:71085482~71085833:-
BRCA	cis	rs67981189	0.574	rs2810118	ENSG00000258571.1	PTTG4P	4.56	5.7e-06	0.000495	0.15	0.14	Schizophrenia;	chr14:70921858	chr14:71085482~71085833:-
BRCA	cis	rs730566	1	rs730566	ENSG00000229759.1	MRPS18AP1	-4.56	5.7e-06	0.000495	-0.18	-0.14	Prion diseases;	chr3:48445644	chr3:48256350~48256938:-
BRCA	cis	rs75804782	0.63	rs74404946	ENSG00000186235.9	AC016757.3	4.56	5.71e-06	0.000496	0.36	0.14	Chronotype;Morning vs. evening chronotype;	chr2:238392131	chr2:238224552~238231677:-
BRCA	cis	rs75804782	0.63	rs3739070	ENSG00000186235.9	AC016757.3	4.56	5.71e-06	0.000496	0.36	0.14	Chronotype;Morning vs. evening chronotype;	chr2:238397627	chr2:238224552~238231677:-
BRCA	cis	rs442309	0.875	rs224061	ENSG00000238280.1	RP11-436D10.3	-4.56	5.71e-06	0.000496	-0.19	-0.14	Vogt-Koyanagi-Harada syndrome;	chr10:62742409	chr10:62793562~62805887:-
BRCA	cis	rs7686660	1	rs12505602	ENSG00000250326.1	RP11-284M14.1	-4.56	5.71e-06	0.000496	-0.17	-0.14	Asthma;	chr4:143018103	chr4:142933195~143184861:-
BRCA	cis	rs7686660	1	rs28817081	ENSG00000250326.1	RP11-284M14.1	-4.56	5.71e-06	0.000496	-0.17	-0.14	Asthma;	chr4:143018155	chr4:142933195~143184861:-
BRCA	cis	rs1510272	0.806	rs4234313	ENSG00000243926.1	TIPARP-AS1	-4.56	5.71e-06	0.000496	-0.15	-0.14	Testicular germ cell tumor;	chr3:156611893	chr3:156671862~156674378:-
BRCA	cis	rs72482608	0.865	rs10753819	ENSG00000271811.1	RP1-79C4.4	4.56	5.71e-06	0.000496	0.15	0.14	Emphysema imaging phenotypes;	chr1:170793495	chr1:170667381~170669425:+
BRCA	cis	rs2303319	0.504	rs55782047	ENSG00000227403.1	AC009299.3	4.56	5.71e-06	0.000496	0.33	0.14	Cognitive function;	chr2:161583745	chr2:161244739~161249050:+
BRCA	cis	rs2243480	1	rs387676	ENSG00000222364.1	RNU6-96P	-4.56	5.72e-06	0.000496	-0.26	-0.14	Diabetic kidney disease;	chr7:66133233	chr7:66395191~66395286:+
BRCA	cis	rs516805	0.528	rs1379094	ENSG00000279453.1	RP3-425C14.4	4.56	5.72e-06	0.000496	0.19	0.14	Lymphocyte counts;	chr6:122098054	chr6:122436789~122439223:-
BRCA	cis	rs763014	0.966	rs4984903	ENSG00000260394.2	LA16c-313D11.9	-4.56	5.72e-06	0.000496	-0.14	-0.14	Height;	chr16:630695	chr16:678504~679777:-
BRCA	cis	rs34929064	0.527	rs2961285	ENSG00000179428.2	AC073072.5	4.56	5.72e-06	0.000496	0.15	0.14	Major depression and alcohol dependence;	chr7:22615349	chr7:22725395~22727620:-
BRCA	cis	rs721917	0.506	rs2758561	ENSG00000242600.5	MBL1P	4.56	5.73e-06	0.000497	0.17	0.14	Chronic obstructive pulmonary disease;	chr10:79909718	chr10:79904898~79950336:+
BRCA	cis	rs1722133	0.555	rs788730	ENSG00000229628.1	AC073115.7	4.56	5.73e-06	0.000497	0.19	0.14	Sitting height ratio;	chr7:46051077	chr7:45990905~46000898:+
BRCA	cis	rs4908768	0.501	rs4908761	ENSG00000232912.4	RP5-1115A15.1	4.56	5.73e-06	0.000497	0.13	0.14	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8492159	chr1:8424645~8434838:+
BRCA	cis	rs60843830	1	rs55946380	ENSG00000272342.1	RP13-539J13.1	4.56	5.73e-06	0.000497	0.18	0.14	Spherical equivalent (joint analysis main effects and education interaction);	chr2:268293	chr2:739588~740164:-
BRCA	cis	rs60843830	1	rs62114544	ENSG00000272342.1	RP13-539J13.1	4.56	5.73e-06	0.000497	0.18	0.14	Spherical equivalent (joint analysis main effects and education interaction);	chr2:269679	chr2:739588~740164:-
BRCA	cis	rs7686660	0.955	rs11728404	ENSG00000250326.1	RP11-284M14.1	-4.56	5.73e-06	0.000497	-0.17	-0.14	Asthma;	chr4:143017556	chr4:142933195~143184861:-
BRCA	cis	rs2243480	1	rs34136756	ENSG00000275400.1	RP4-756H11.5	4.56	5.73e-06	0.000498	0.25	0.14	Diabetic kidney disease;	chr7:65916269	chr7:66553805~66554199:-
BRCA	cis	rs11686241	0.935	rs284524	ENSG00000241520.1	AC098820.4	4.56	5.74e-06	0.000498	0.2	0.14	Cancer;	chr2:216478050	chr2:216483032~216487196:-
BRCA	cis	rs12612619	0.659	rs12997235	ENSG00000229122.1	AGBL5-IT1	-4.56	5.74e-06	0.000498	-0.15	-0.14	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27006211	chr2:27061038~27061815:+
BRCA	cis	rs11048434	0.518	rs7311267	ENSG00000256720.1	RP11-436I9.6	4.56	5.74e-06	0.000498	0.13	0.14	Sjögren's syndrome;	chr12:9026082	chr12:9135084~9135591:+
BRCA	cis	rs1005277	0.579	rs2474587	ENSG00000263064.2	RP11-291L22.7	4.56	5.74e-06	0.000498	0.17	0.14	Extrinsic epigenetic age acceleration;	chr10:38131738	chr10:38448689~38448949:+
BRCA	cis	rs1005277	0.579	rs2474588	ENSG00000263064.2	RP11-291L22.7	4.56	5.74e-06	0.000498	0.17	0.14	Extrinsic epigenetic age acceleration;	chr10:38131942	chr10:38448689~38448949:+
BRCA	cis	rs2303319	0.582	rs56094729	ENSG00000227403.1	AC009299.3	4.56	5.74e-06	0.000498	0.33	0.14	Cognitive function;	chr2:161608325	chr2:161244739~161249050:+
BRCA	cis	rs2839186	0.843	rs17182671	ENSG00000228137.1	AP001469.7	4.56	5.74e-06	0.000498	0.14	0.14	Testicular germ cell tumor;	chr21:46276324	chr21:46246890~46247682:+
BRCA	cis	rs2839186	0.739	rs7282763	ENSG00000228137.1	AP001469.7	4.56	5.74e-06	0.000498	0.14	0.14	Testicular germ cell tumor;	chr21:46276886	chr21:46246890~46247682:+
BRCA	cis	rs6997458	0.776	rs1496531	ENSG00000258256.1	RP11-219B4.5	4.56	5.75e-06	0.000498	0.16	0.14	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85341833	chr8:85222446~85245717:-
BRCA	cis	rs7617773	0.539	rs12486935	ENSG00000228638.1	FCF1P2	-4.56	5.75e-06	0.000499	-0.15	-0.14	Coronary artery disease;	chr3:48348674	chr3:48290793~48291375:-
BRCA	cis	rs427691	0.625	rs845735	ENSG00000271849.1	CTC-332L22.1	4.56	5.75e-06	0.000499	0.23	0.14	Autism spectrum disorder or schizophrenia;	chr5:109688170	chr5:109687802~109688329:-
BRCA	cis	rs7160336	1	rs2024109	ENSG00000259065.1	RP5-1021I20.1	4.56	5.75e-06	0.000499	0.15	0.14	Blood protein levels;	chr14:74107019	chr14:73787360~73803270:+
BRCA	cis	rs4650994	1	rs12138541	ENSG00000273384.1	RP5-1098D14.1	4.56	5.75e-06	0.000499	0.17	0.14	HDL cholesterol;HDL cholesterol levels;	chr1:178549572	chr1:178651706~178652282:+
BRCA	cis	rs73186030	0.92	rs55784797	ENSG00000272758.4	RP11-299J3.8	4.56	5.75e-06	0.000499	0.21	0.14	Serum parathyroid hormone levels;	chr3:122335788	chr3:122416207~122443180:+
BRCA	cis	rs1823874	0.584	rs1823872	ENSG00000182397.13	DNM1P46	-4.56	5.76e-06	0.000499	-0.14	-0.14	IgG glycosylation;	chr15:99839246	chr15:99790156~99806927:-
BRCA	cis	rs9467773	0.62	rs1490488	ENSG00000241549.7	GUSBP2	4.56	5.76e-06	0.000499	0.15	0.14	Intelligence (multi-trait analysis);	chr6:26614580	chr6:26871484~26956554:-
BRCA	cis	rs9467773	0.62	rs2494692	ENSG00000241549.7	GUSBP2	4.56	5.76e-06	0.000499	0.15	0.14	Intelligence (multi-trait analysis);	chr6:26614995	chr6:26871484~26956554:-
BRCA	cis	rs2839186	1	rs2839181	ENSG00000228137.1	AP001469.7	4.56	5.76e-06	0.000499	0.14	0.14	Testicular germ cell tumor;	chr21:46266025	chr21:46246890~46247682:+
BRCA	cis	rs7048146	1	rs10979904	ENSG00000213539.4	YBX1P6	4.56	5.76e-06	0.000499	0.16	0.14	Vascular brain injury;	chr9:109538136	chr9:109532830~109534332:-
BRCA	cis	rs12922040	0.651	rs35288467	ENSG00000279866.1	CTB-193M12.4	4.56	5.76e-06	5e-04	0.17	0.14	Serum uric acid levels in response to allopurinol in gout;	chr16:15773097	chr16:15704410~15705984:+
BRCA	cis	rs7818688	0.697	rs11779698	ENSG00000253528.2	RP11-347C18.4	-4.56	5.76e-06	5e-04	-0.22	-0.14	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94967536	chr8:94974573~94974853:-
BRCA	cis	rs7818688	0.654	rs11783262	ENSG00000253528.2	RP11-347C18.4	-4.56	5.76e-06	5e-04	-0.22	-0.14	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94967588	chr8:94974573~94974853:-
BRCA	cis	rs7818688	0.697	rs11783985	ENSG00000253528.2	RP11-347C18.4	-4.56	5.76e-06	5e-04	-0.22	-0.14	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94967658	chr8:94974573~94974853:-
BRCA	cis	rs7818688	0.697	rs17665714	ENSG00000253528.2	RP11-347C18.4	-4.56	5.76e-06	5e-04	-0.22	-0.14	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94970314	chr8:94974573~94974853:-
BRCA	cis	rs875971	1	rs55962648	ENSG00000236529.1	RP13-254B10.1	-4.56	5.76e-06	5e-04	-0.15	-0.14	Aortic root size;	chr7:66160764	chr7:65840212~65840596:+
BRCA	cis	rs6832769	0.696	rs7660054	ENSG00000223305.1	RN7SKP30	4.56	5.76e-06	5e-04	0.18	0.14	Personality dimensions;	chr4:55402340	chr4:55540502~55540835:-
BRCA	cis	rs4489787	1	rs2705154	ENSG00000240399.1	RP1-228P16.1	4.56	5.76e-06	5e-04	0.24	0.14	Prostate cancer (SNP x SNP interaction);	chr12:48514010	chr12:48054813~48055591:-
BRCA	cis	rs7005380	1	rs7005380	ENSG00000245330.4	KB-1471A8.1	-4.56	5.77e-06	5e-04	-0.19	-0.14	Interstitial lung disease;	chr8:119941633	chr8:119867419~119874488:-
BRCA	cis	rs7818688	0.697	rs11784212	ENSG00000253528.2	RP11-347C18.4	-4.56	5.77e-06	5e-04	-0.22	-0.14	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94964767	chr8:94974573~94974853:-
BRCA	cis	rs9308731	0.777	rs590097	ENSG00000230499.1	AC108463.1	-4.56	5.77e-06	5e-04	-0.17	-0.14	Chronic lymphocytic leukemia;	chr2:111176530	chr2:111195963~111206494:+
BRCA	cis	rs2018683	0.834	rs2012754	ENSG00000233517.1	AC005162.5	-4.56	5.77e-06	5e-04	-0.17	-0.14	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28986641	chr7:28987028~28988899:+
BRCA	cis	rs7789940	0.904	rs73140040	ENSG00000280388.1	RP11-229D13.3	-4.56	5.77e-06	5e-04	-0.15	-0.14	Multiple sclerosis;	chr7:76306923	chr7:76043977~76045963:-
BRCA	cis	rs2880765	0.546	rs35316253	ENSG00000259295.5	CSPG4P12	4.56	5.77e-06	5e-04	0.19	0.14	Coronary artery disease;	chr15:85522329	chr15:85191438~85213905:+
BRCA	cis	rs7119	0.651	rs12909292	ENSG00000259362.2	RP11-307C19.1	-4.56	5.77e-06	5e-04	-0.2	-0.14	Type 2 diabetes;	chr15:77545640	chr15:77525540~77534110:+
BRCA	cis	rs17406451	0.788	rs12712886	ENSG00000234936.1	AC010883.5	4.56	5.77e-06	0.000501	0.14	0.14	Mitochondrial DNA levels;	chr2:43472277	chr2:43229573~43233394:+
BRCA	cis	rs7800418	0.521	rs12540234	ENSG00000214870.7	AC004540.5	4.56	5.77e-06	0.000501	0.17	0.14	Cognitive function;	chr7:26580432	chr7:26398593~26494256:+
BRCA	cis	rs7487075	0.754	rs10880962	ENSG00000272369.1	RP11-446N19.1	4.56	5.77e-06	0.000501	0.15	0.14	Itch intensity from mosquito bite;	chr12:46379661	chr12:46537502~46652550:+
BRCA	cis	rs4699052	0.59	rs4698892	ENSG00000248740.4	RP11-328K4.1	4.56	5.77e-06	0.000501	0.16	0.14	Testicular germ cell tumor;	chr4:103340114	chr4:103256159~103453658:+
BRCA	cis	rs73193808	0.901	rs8131103	ENSG00000236056.1	GAPDHP14	-4.56	5.78e-06	0.000501	-0.2	-0.14	Coronary artery disease;	chr21:29193427	chr21:29222321~29223257:+
BRCA	cis	rs11098499	0.657	rs71614442	ENSG00000250412.1	KLHL2P1	4.56	5.78e-06	0.000501	0.17	0.14	Corneal astigmatism;	chr4:119458191	chr4:119334329~119378233:+
BRCA	cis	rs11098499	0.954	rs2892848	ENSG00000250412.1	KLHL2P1	4.56	5.78e-06	0.000501	0.17	0.14	Corneal astigmatism;	chr4:119460186	chr4:119334329~119378233:+
BRCA	cis	rs6498068	0.633	rs1504884	ENSG00000260468.1	LINC01290	-4.56	5.78e-06	0.000501	-0.2	-0.14	Metabolite levels (MHPG);	chr16:10538128	chr16:10514842~10528202:-
BRCA	cis	rs7243790	0.837	rs1992129	ENSG00000277324.1	RP11-850A17.1	-4.56	5.78e-06	0.000501	-0.16	-0.14	Diastolic blood pressure;	chr18:54419723	chr18:54268346~54270028:-
BRCA	cis	rs4948275	0.631	rs2606117	ENSG00000237233.2	TMEM26-AS1	-4.56	5.78e-06	0.000501	-0.16	-0.14	Night sleep phenotypes;	chr10:61592045	chr10:61452639~61481956:+
BRCA	cis	rs690037	0.673	rs690573	ENSG00000272498.1	RP11-415F23.3	4.56	5.78e-06	0.000501	0.14	0.14	Optic nerve measurement (cup-to-disc ratio);Optic nerve measurement (cup area);	chr3:16334933	chr3:16339308~16339871:+
BRCA	cis	rs863750	0.721	rs851132	ENSG00000275389.1	RP11-214K3.24	4.56	5.78e-06	0.000501	0.18	0.14	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-hip ratio;	chr12:124050277	chr12:124085761~124088598:+
BRCA	cis	rs2288884	0.634	rs17835649	ENSG00000275055.1	CTC-471J1.11	-4.56	5.78e-06	0.000501	-0.2	-0.14	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:51997362	chr19:52049007~52049754:+
BRCA	cis	rs6832769	0.925	rs6829182	ENSG00000272969.1	RP11-528I4.2	4.56	5.79e-06	0.000502	0.16	0.14	Personality dimensions;	chr4:55587989	chr4:55547112~55547889:+
BRCA	cis	rs3812049	0.826	rs6860245	ENSG00000245937.6	LINC01184	-4.56	5.79e-06	0.000502	-0.19	-0.14	Lymphocyte counts;Red cell distribution width;	chr5:128032306	chr5:127940426~128083172:-
BRCA	cis	rs4948275	0.773	rs2100559	ENSG00000237233.2	TMEM26-AS1	-4.56	5.79e-06	0.000502	-0.17	-0.14	Night sleep phenotypes;	chr10:61528566	chr10:61452639~61481956:+
BRCA	cis	rs6802315	0.604	rs9863103	ENSG00000272247.1	RP11-379F4.9	4.56	5.79e-06	0.000502	0.16	0.14	Periodontitis (CDC/AAP);	chr3:158746014	chr3:158801257~158801935:-
BRCA	cis	rs2303319	0.504	rs62189003	ENSG00000227403.1	AC009299.3	4.56	5.79e-06	0.000502	0.34	0.14	Cognitive function;	chr2:161691594	chr2:161244739~161249050:+
BRCA	cis	rs6671200	0.92	rs7555236	ENSG00000235501.4	RP4-639F20.1	-4.56	5.79e-06	0.000502	-0.32	-0.14	Stearic acid (18:0) levels;	chr1:95165758	chr1:94927566~94963270:+
BRCA	cis	rs2403083	0.578	rs10100442	ENSG00000258256.1	RP11-219B4.5	-4.56	5.79e-06	0.000502	-0.17	-0.14	Plasma amyloid beta peptide concentrations (ABx-40);	chr8:85175871	chr8:85222446~85245717:-
BRCA	cis	rs13113518	0.966	rs12647677	ENSG00000273257.1	RP11-177J6.1	4.56	5.79e-06	0.000502	0.18	0.14	Height;	chr4:55444253	chr4:55387949~55388271:+
BRCA	cis	rs13113518	0.902	rs3805150	ENSG00000273257.1	RP11-177J6.1	4.56	5.79e-06	0.000502	0.18	0.14	Height;	chr4:55446869	chr4:55387949~55388271:+
BRCA	cis	rs13113518	1	rs4864990	ENSG00000273257.1	RP11-177J6.1	4.56	5.79e-06	0.000502	0.18	0.14	Height;	chr4:55447523	chr4:55387949~55388271:+
BRCA	cis	rs2832191	0.74	rs2832175	ENSG00000232855.5	AF131217.1	4.56	5.79e-06	0.000502	0.17	0.14	Dental caries;	chr21:29103285	chr21:28439346~28674848:-
BRCA	cis	rs5758659	0.714	rs5758589	ENSG00000227370.1	RP4-669P10.19	4.56	5.79e-06	0.000502	0.15	0.14	Cognitive function;	chr22:42122378	chr22:42132543~42132998:+
BRCA	cis	rs17684571	0.7	rs13208409	ENSG00000231441.1	RP11-472M19.2	4.56	5.79e-06	0.000502	0.24	0.14	Schizophrenia;	chr6:56763747	chr6:56844002~56864078:+
BRCA	cis	rs4699052	0.963	rs7679365	ENSG00000248740.4	RP11-328K4.1	4.56	5.8e-06	0.000502	0.16	0.14	Testicular germ cell tumor;	chr4:103291823	chr4:103256159~103453658:+
BRCA	cis	rs801193	0.66	rs2659897	ENSG00000223473.2	GS1-124K5.3	-4.56	5.8e-06	0.000502	-0.11	-0.14	Aortic root size;	chr7:66722728	chr7:66491049~66493566:-
BRCA	cis	rs35740288	0.721	rs4843093	ENSG00000202081.1	RNU6-1280P	4.56	5.8e-06	0.000502	0.19	0.14	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85694202	chr15:85651522~85651628:-
BRCA	cis	rs10276381	0.685	rs56398224	ENSG00000234336.5	JAZF1-AS1	-4.56	5.8e-06	0.000503	-0.3	-0.14	Crohn's disease;	chr7:28166129	chr7:28180322~28243917:+
BRCA	cis	rs13034020	0.522	rs12998880	ENSG00000271889.1	RP11-493E12.1	-4.56	5.8e-06	0.000503	-0.23	-0.14	Hodgkin's lymphoma;	chr2:61013747	chr2:61151433~61162105:-
BRCA	cis	rs13034020	0.522	rs35976602	ENSG00000271889.1	RP11-493E12.1	-4.56	5.8e-06	0.000503	-0.23	-0.14	Hodgkin's lymphoma;	chr2:61014447	chr2:61151433~61162105:-
BRCA	cis	rs2880765	0.545	rs17553734	ENSG00000202081.1	RNU6-1280P	-4.56	5.8e-06	0.000503	-0.17	-0.14	Coronary artery disease;	chr15:85469828	chr15:85651522~85651628:-
BRCA	cis	rs4948275	0.693	rs2814027	ENSG00000237233.2	TMEM26-AS1	4.56	5.8e-06	0.000503	0.16	0.14	Night sleep phenotypes;	chr10:61582354	chr10:61452639~61481956:+
BRCA	cis	rs7839435	0.592	rs111659883	ENSG00000234770.1	GULOP	-4.56	5.81e-06	0.000503	-0.18	-0.14	Lung adenocarcinoma;	chr8:27580056	chr8:27560274~27589073:+
BRCA	cis	rs7923609	0.846	rs7098181	ENSG00000232075.1	MRPL35P2	-4.56	5.81e-06	0.000503	-0.18	-0.14	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63267383	chr10:63634317~63634827:-
BRCA	cis	rs2227564	0.729	rs2688611	ENSG00000271816.1	BMS1P4	4.56	5.81e-06	0.000503	0.15	0.14	Crohn's disease;Inflammatory bowel disease;	chr10:73893614	chr10:73699151~73730487:-
BRCA	cis	rs2236295	0.533	rs73279609	ENSG00000238280.1	RP11-436D10.3	-4.56	5.81e-06	0.000503	-0.19	-0.14	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks);	chr10:62889873	chr10:62793562~62805887:-
BRCA	cis	rs9392653	0.847	rs9405254	ENSG00000220685.3	RP11-530A18.1	-4.56	5.81e-06	0.000504	-0.19	-0.14	Venous thromboembolism (SNP x SNP interaction);	chr6:5064686	chr6:5065795~5066982:-
BRCA	cis	rs4356203	0.84	rs7942094	ENSG00000272034.1	SNORD14A	-4.56	5.81e-06	0.000504	-0.14	-0.14	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17237862	chr11:17074654~17074744:-
BRCA	cis	rs2235544	0.565	rs928444	ENSG00000225183.1	RP4-758J24.4	4.56	5.81e-06	0.000504	0.17	0.14	Thyroid hormone levels;Multiple myeloma (hyperdiploidy);	chr1:54007875	chr1:54089856~54090093:+
BRCA	cis	rs2273156	1	rs12897044	ENSG00000226677.3	IGBP1P1	-4.56	5.81e-06	0.000504	-0.21	-0.14	Immunoglobulin light chain (AL) amyloidosis;	chr14:34953938	chr14:34939324~34940332:+
BRCA	cis	rs11976180	1	rs4726669	ENSG00000244479.5	OR2A1-AS1	4.56	5.82e-06	0.000504	0.19	0.14	Obesity-related traits;	chr7:144061098	chr7:144251264~144356181:-
BRCA	cis	rs2738459	0.5	rs4804143	ENSG00000212497.1	RNA5SP465	4.56	5.82e-06	0.000504	0.17	0.14	LDL cholesterol;	chr19:11124828	chr19:12027913~12028021:-
BRCA	cis	rs7818688	0.697	rs61591488	ENSG00000253528.2	RP11-347C18.4	-4.56	5.82e-06	0.000504	-0.22	-0.14	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94972727	chr8:94974573~94974853:-
BRCA	cis	rs7818688	0.697	rs58314911	ENSG00000253528.2	RP11-347C18.4	-4.56	5.82e-06	0.000504	-0.22	-0.14	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94972883	chr8:94974573~94974853:-
BRCA	cis	rs17507216	0.718	rs4779034	ENSG00000255769.6	GOLGA2P10	-4.56	5.82e-06	0.000504	-0.19	-0.14	Excessive daytime sleepiness;	chr15:82576799	chr15:82472993~82513950:-
BRCA	cis	rs6951245	1	rs78158942	ENSG00000229043.2	AC091729.9	-4.56	5.82e-06	0.000504	-0.25	-0.14	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1050804	chr7:1160374~1165267:+
BRCA	cis	rs2904967	0.568	rs2904966	ENSG00000254614.2	AP003068.23	4.56	5.82e-06	0.000504	0.28	0.14	Mean corpuscular volume;	chr11:65323256	chr11:65177606~65181834:-
BRCA	cis	rs1153858	1	rs7169587	ENSG00000275672.1	GATM-AS1	-4.56	5.82e-06	0.000504	-0.18	-0.14	Homoarginine levels;	chr15:45348181	chr15:45378700~45380123:+
BRCA	cis	rs2229238	0.911	rs7551873	ENSG00000272030.1	RP1-178F15.4	4.56	5.82e-06	0.000504	0.19	0.14	Coronary heart disease;	chr1:154533381	chr1:153631438~153634397:-
BRCA	cis	rs4699052	0.963	rs6533078	ENSG00000248740.4	RP11-328K4.1	4.56	5.83e-06	0.000505	0.16	0.14	Testicular germ cell tumor;	chr4:103290999	chr4:103256159~103453658:+
BRCA	cis	rs4699052	0.963	rs7672802	ENSG00000248740.4	RP11-328K4.1	4.56	5.83e-06	0.000505	0.16	0.14	Testicular germ cell tumor;	chr4:103291076	chr4:103256159~103453658:+
BRCA	cis	rs13113518	1	rs3805146	ENSG00000272969.1	RP11-528I4.2	4.56	5.83e-06	0.000505	0.16	0.14	Height;	chr4:55436985	chr4:55547112~55547889:+
BRCA	cis	rs13113518	1	rs11133378	ENSG00000272969.1	RP11-528I4.2	4.56	5.83e-06	0.000505	0.16	0.14	Height;	chr4:55439472	chr4:55547112~55547889:+
BRCA	cis	rs13113518	1	rs11942279	ENSG00000272969.1	RP11-528I4.2	4.56	5.83e-06	0.000505	0.16	0.14	Height;	chr4:55439652	chr4:55547112~55547889:+
BRCA	cis	rs7918232	0.941	rs788210	ENSG00000262412.1	RP11-85G18.6	-4.56	5.83e-06	0.000505	-0.24	-0.14	Breast cancer;	chr10:27188019	chr10:27243130~27250804:+
BRCA	cis	rs1005277	0.579	rs2504143	ENSG00000099251.13	HSD17B7P2	4.56	5.83e-06	0.000505	0.15	0.14	Extrinsic epigenetic age acceleration;	chr10:38094778	chr10:38356380~38378505:+
BRCA	cis	rs2243480	1	rs11538349	ENSG00000275400.1	RP4-756H11.5	4.56	5.83e-06	0.000505	0.25	0.14	Diabetic kidney disease;	chr7:65956884	chr7:66553805~66554199:-
BRCA	cis	rs3770081	1	rs17027011	ENSG00000273080.1	RP11-301O19.1	-4.56	5.83e-06	0.000505	-0.31	-0.14	Facial emotion recognition (sad faces);	chr2:86179433	chr2:86195590~86196049:+
BRCA	cis	rs2904967	0.568	rs2904966	ENSG00000255200.1	AP003068.18	4.56	5.83e-06	0.000505	0.26	0.14	Mean corpuscular volume;	chr11:65323256	chr11:65174117~65176470:-
BRCA	cis	rs6480314	0.636	rs7914274	ENSG00000233590.1	RP11-153K11.3	-4.56	5.83e-06	0.000505	-0.23	-0.14	Optic nerve measurement (disc area);	chr10:68240300	chr10:68233251~68242379:-
BRCA	cis	rs7824557	0.724	rs2572398	ENSG00000255046.1	RP11-297N6.4	-4.56	5.84e-06	0.000505	-0.17	-0.14	Retinal vascular caliber;	chr8:11320584	chr8:11797928~11802568:-
BRCA	cis	rs4664293	0.764	rs1425044	ENSG00000224152.1	AC009506.1	-4.56	5.84e-06	0.000506	-0.15	-0.14	Monocyte percentage of white cells;	chr2:159618426	chr2:159615296~159617082:+
BRCA	cis	rs5167	0.504	rs7246900	ENSG00000280087.1	CTB-129P6.7	4.56	5.84e-06	0.000506	0.16	0.14	Blood protein levels;	chr19:44950979	chr19:44909375~44914968:+
BRCA	cis	rs7048146	1	rs7021839	ENSG00000213539.4	YBX1P6	4.56	5.84e-06	0.000506	0.16	0.14	Vascular brain injury;	chr9:109538257	chr9:109532830~109534332:-
BRCA	cis	rs755249	0.567	rs4660543	ENSG00000182109.6	RP11-69E11.4	4.56	5.84e-06	0.000506	0.19	0.14	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39213318	chr1:39522280~39546187:-
BRCA	cis	rs13113518	1	rs13122619	ENSG00000273257.1	RP11-177J6.1	4.56	5.84e-06	0.000506	0.18	0.14	Height;	chr4:55479339	chr4:55387949~55388271:+
BRCA	cis	rs3768617	0.51	rs7529465	ENSG00000224468.3	RP11-181K3.4	-4.56	5.84e-06	0.000506	-0.15	-0.14	Fuchs's corneal dystrophy;	chr1:183127745	chr1:183138402~183141282:-
BRCA	cis	rs3768617	0.51	rs4651140	ENSG00000224468.3	RP11-181K3.4	-4.56	5.84e-06	0.000506	-0.15	-0.14	Fuchs's corneal dystrophy;	chr1:183127817	chr1:183138402~183141282:-
BRCA	cis	rs9467773	0.62	rs2494696	ENSG00000241549.7	GUSBP2	4.56	5.85e-06	0.000506	0.15	0.14	Intelligence (multi-trait analysis);	chr6:26620666	chr6:26871484~26956554:-
BRCA	cis	rs12612619	0.732	rs11687536	ENSG00000229122.1	AGBL5-IT1	-4.56	5.85e-06	0.000506	-0.15	-0.14	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:26976886	chr2:27061038~27061815:+
BRCA	cis	rs7243790	0.805	rs3809947	ENSG00000277324.1	RP11-850A17.1	-4.56	5.85e-06	0.000506	-0.16	-0.14	Diastolic blood pressure;	chr18:54380396	chr18:54268346~54270028:-
BRCA	cis	rs7647973	1	rs11710434	ENSG00000244380.1	RP11-24C3.2	4.56	5.85e-06	0.000507	0.18	0.14	Menarche (age at onset);	chr3:49308697	chr3:48440352~48446656:-
BRCA	cis	rs7665090	0.87	rs227361	ENSG00000251288.2	RP11-10L12.2	-4.56	5.85e-06	0.000507	-0.16	-0.14	Primary biliary cholangitis;	chr4:102665820	chr4:102751401~102752641:+
BRCA	cis	rs950169	0.58	rs11634320	ENSG00000176700.18	SCAND2P	4.56	5.85e-06	0.000507	0.14	0.14	Schizophrenia;	chr15:84628952	chr15:84631451~84647478:+
BRCA	cis	rs859767	0.501	rs12691869	ENSG00000224043.6	CCNT2-AS1	4.56	5.86e-06	0.000507	0.19	0.14	Neuroticism;	chr2:134650071	chr2:134735464~134918710:-
BRCA	cis	rs13098911	0.54	rs1491950	ENSG00000223552.1	RP11-24F11.2	-4.55	5.86e-06	0.000507	-0.23	-0.14	Celiac disease;	chr3:46096615	chr3:46364955~46407059:-
BRCA	cis	rs6921919	0.583	rs2027361	ENSG00000220721.1	OR1F12	4.55	5.86e-06	0.000507	0.17	0.14	Autism spectrum disorder or schizophrenia;	chr6:28420531	chr6:28073316~28074233:+
BRCA	cis	rs12368653	1	rs12368653	ENSG00000257159.1	RP11-58A17.3	4.55	5.86e-06	0.000507	0.16	0.14	Multiple sclerosis;	chr12:57739473	chr12:57967058~57968399:+
BRCA	cis	rs17597773	0.674	rs12089958	ENSG00000238078.1	LINC01352	-4.55	5.86e-06	0.000507	-0.17	-0.14	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220828021	chr1:220829255~220832429:+
BRCA	cis	rs13217239	0.646	rs12209886	ENSG00000224843.5	LINC00240	-4.55	5.86e-06	0.000507	-0.16	-0.14	Schizophrenia;	chr6:27016978	chr6:26956992~27023924:+
BRCA	cis	rs6940638	0.531	rs12211984	ENSG00000224843.5	LINC00240	-4.55	5.86e-06	0.000507	-0.16	-0.14	Intelligence (multi-trait analysis);	chr6:27018275	chr6:26956992~27023924:+
BRCA	cis	rs13326165	0.585	rs3210487	ENSG00000243224.1	RP5-1157M23.2	-4.55	5.86e-06	0.000508	-0.23	-0.14	HDL cholesterol levels;HDL cholesterol;	chr3:52259843	chr3:52239258~52241097:+
BRCA	cis	rs7577696	0.924	rs6748621	ENSG00000272716.1	RP11-563N4.1	-4.55	5.86e-06	0.000508	-0.16	-0.14	Inflammatory biomarkers;	chr2:32037132	chr2:32165046~32165757:-
BRCA	cis	rs11673344	0.583	rs7254411	ENSG00000226686.6	LINC01535	4.55	5.87e-06	0.000508	0.18	0.14	Obesity-related traits;	chr19:37034969	chr19:37251912~37265535:+
BRCA	cis	rs6545883	0.826	rs2694617	ENSG00000270820.4	RP11-355B11.2	-4.55	5.87e-06	0.000508	-0.16	-0.14	Tuberculosis;	chr2:61310079	chr2:61471188~61484130:+
BRCA	cis	rs35146811	0.555	rs2527898	ENSG00000214313.7	AZGP1P1	4.55	5.87e-06	0.000508	0.15	0.14	Coronary artery disease;	chr7:99936407	chr7:99980762~99987535:+
BRCA	cis	rs745109	0.882	rs113652961	ENSG00000273080.1	RP11-301O19.1	4.55	5.87e-06	0.000508	0.23	0.14	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86555379	chr2:86195590~86196049:+
BRCA	cis	rs10504130	0.569	rs9650179	ENSG00000253844.1	RP11-546K22.1	-4.55	5.88e-06	0.000509	-0.2	-0.14	Venous thromboembolism (SNP x SNP interaction);	chr8:51912127	chr8:51961458~52022974:+
BRCA	cis	rs8040855	0.627	rs11632658	ENSG00000230373.7	GOLGA6L5P	-4.55	5.88e-06	0.000509	-0.18	-0.14	Bulimia nervosa;	chr15:85062982	chr15:84507885~84516814:-
BRCA	cis	rs934734	0.532	rs6752053	ENSG00000281920.1	RP11-418H16.1	-4.55	5.88e-06	0.000509	-0.16	-0.14	Rheumatoid arthritis;	chr2:65439540	chr2:65623272~65628424:+
BRCA	cis	rs6696239	0.531	rs2644151	ENSG00000227711.2	RP11-275O4.5	-4.55	5.88e-06	0.000509	-0.16	-0.14	Height;	chr1:227514993	chr1:227509028~227520477:-
BRCA	cis	rs2243480	1	rs2462569	ENSG00000222364.1	RNU6-96P	4.55	5.88e-06	0.000509	0.24	0.14	Diabetic kidney disease;	chr7:66009859	chr7:66395191~66395286:+
BRCA	cis	rs9834975	0.967	rs6787230	ENSG00000272758.4	RP11-299J3.8	-4.55	5.88e-06	0.000509	-0.14	-0.14	Diastolic blood pressure;	chr3:122392403	chr3:122416207~122443180:+
BRCA	cis	rs11096990	0.634	rs1451818	ENSG00000249685.1	RP11-360F5.3	4.55	5.88e-06	0.000509	0.18	0.14	Cognitive function;	chr4:39257151	chr4:39133913~39135608:+
BRCA	cis	rs2688608	0.967	rs2688609	ENSG00000271816.1	BMS1P4	-4.55	5.88e-06	0.000509	-0.14	-0.14	Inflammatory bowel disease;	chr10:73898423	chr10:73699151~73730487:-
BRCA	cis	rs2562456	0.833	rs62107547	ENSG00000268658.4	LINC00664	4.55	5.88e-06	0.000509	0.23	0.14	Pain;	chr19:21341245	chr19:21483374~21503238:+
BRCA	cis	rs2562456	0.52	rs660063	ENSG00000240522.1	RPL7AP10	4.55	5.89e-06	0.000509	0.18	0.14	Pain;	chr19:21271103	chr19:21149648~21150438:-
BRCA	cis	rs11098499	0.954	rs10518331	ENSG00000250412.1	KLHL2P1	4.55	5.89e-06	0.000509	0.17	0.14	Corneal astigmatism;	chr4:119402440	chr4:119334329~119378233:+
BRCA	cis	rs7772486	0.754	rs2064185	ENSG00000270638.1	RP3-466P17.1	-4.55	5.89e-06	0.00051	-0.16	-0.14	Lobe attachment (rater-scored or self-reported);	chr6:145745678	chr6:145735570~145737218:+
BRCA	cis	rs6545883	0.894	rs2593633	ENSG00000212978.6	AC016747.3	-4.55	5.89e-06	0.00051	-0.19	-0.14	Tuberculosis;	chr2:61344378	chr2:61141592~61144969:-
BRCA	cis	rs4664293	0.967	rs1006192	ENSG00000226266.5	AC009961.3	-4.55	5.89e-06	0.00051	-0.17	-0.14	Monocyte percentage of white cells;	chr2:159711078	chr2:159670708~159712435:-
BRCA	cis	rs5167	0.504	rs73047641	ENSG00000280087.1	CTB-129P6.7	4.55	5.89e-06	0.00051	0.17	0.14	Blood protein levels;	chr19:44954120	chr19:44909375~44914968:+
BRCA	cis	rs73186030	0.92	rs73186059	ENSG00000272758.4	RP11-299J3.8	4.55	5.89e-06	0.00051	0.22	0.14	Serum parathyroid hormone levels;	chr3:122332336	chr3:122416207~122443180:+
BRCA	cis	rs2243480	1	rs160652	ENSG00000222364.1	RNU6-96P	-4.55	5.89e-06	0.00051	-0.27	-0.14	Diabetic kidney disease;	chr7:66073444	chr7:66395191~66395286:+
BRCA	cis	rs67981189	0.634	rs2526875	ENSG00000258571.1	PTTG4P	4.55	5.89e-06	0.00051	0.15	0.14	Schizophrenia;	chr14:70911643	chr14:71085482~71085833:-
BRCA	cis	rs11098499	0.954	rs6847248	ENSG00000260404.2	RP11-384K6.6	4.55	5.89e-06	0.00051	0.14	0.14	Corneal astigmatism;	chr4:119304800	chr4:118591773~118633729:+
BRCA	cis	rs934734	0.532	rs12185610	ENSG00000281920.1	RP11-418H16.1	-4.55	5.89e-06	0.00051	-0.17	-0.14	Rheumatoid arthritis;	chr2:65434334	chr2:65623272~65628424:+
BRCA	cis	rs838147	0.76	rs12979144	ENSG00000232871.7	SEC1P	-4.55	5.9e-06	0.00051	-0.16	-0.14	Dietary macronutrient intake;	chr19:48734290	chr19:48638071~48682245:+
BRCA	cis	rs838147	0.733	rs12978499	ENSG00000232871.7	SEC1P	-4.55	5.9e-06	0.00051	-0.16	-0.14	Dietary macronutrient intake;	chr19:48734295	chr19:48638071~48682245:+
BRCA	cis	rs2288884	0.634	rs80309583	ENSG00000275055.1	CTC-471J1.11	-4.55	5.9e-06	0.00051	-0.2	-0.14	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:51996949	chr19:52049007~52049754:+
BRCA	cis	rs11742741	0.806	rs12153719	ENSG00000248874.4	C5orf17	-4.55	5.9e-06	0.000511	-0.18	-0.14	Educational attainment;	chr5:24014779	chr5:23951348~24178263:+
BRCA	cis	rs7267979	0.966	rs2500433	ENSG00000276952.1	RP5-965G21.6	-4.55	5.9e-06	0.000511	-0.17	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25315699	chr20:25284915~25285588:-
BRCA	cis	rs7267979	0.966	rs2482948	ENSG00000276952.1	RP5-965G21.6	-4.55	5.9e-06	0.000511	-0.17	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25315863	chr20:25284915~25285588:-
BRCA	cis	rs651907	0.505	rs688058	ENSG00000244119.1	PDCL3P4	4.55	5.9e-06	0.000511	0.11	0.14	Colorectal cancer;	chr3:101866623	chr3:101712472~101713191:+
BRCA	cis	rs6802315	0.575	rs1864508	ENSG00000272247.1	RP11-379F4.9	-4.55	5.91e-06	0.000511	-0.16	-0.14	Periodontitis (CDC/AAP);	chr3:158765024	chr3:158801257~158801935:-
BRCA	cis	rs8054556	0.787	rs11649274	ENSG00000183604.13	SMG1P5	-4.55	5.91e-06	0.000511	-0.14	-0.14	Autism spectrum disorder or schizophrenia;	chr16:30015148	chr16:30267553~30335374:-
BRCA	cis	rs6840360	0.642	rs2724568	ENSG00000251603.1	RP11-164P12.4	-4.55	5.91e-06	0.000511	-0.13	-0.14	Intelligence (multi-trait analysis);	chr4:151431071	chr4:151667224~151670502:+
BRCA	cis	rs9818758	0.607	rs56306491	ENSG00000225399.4	RP11-3B7.1	-4.55	5.91e-06	0.000511	-0.26	-0.14	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49277527	chr3:49260085~49261316:+
BRCA	cis	rs12612619	0.704	rs6742004	ENSG00000272148.1	RP11-195B17.1	4.55	5.91e-06	0.000511	0.16	0.14	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27086791	chr2:27062428~27062907:-
BRCA	cis	rs13108904	0.87	rs3755927	ENSG00000253399.1	AC078852.2	-4.55	5.91e-06	0.000511	-0.15	-0.14	Obesity-related traits;	chr4:1244458	chr4:1358479~1359461:+
BRCA	cis	rs6840360	0.557	rs1143036	ENSG00000251603.1	RP11-164P12.4	-4.55	5.91e-06	0.000511	-0.13	-0.14	Intelligence (multi-trait analysis);	chr4:151408252	chr4:151667224~151670502:+
BRCA	cis	rs10504130	1	rs16916865	ENSG00000272024.1	RP11-546K22.3	-4.55	5.91e-06	0.000511	-0.23	-0.14	Venous thromboembolism (SNP x SNP interaction);	chr8:51833290	chr8:51950284~51950690:+
BRCA	cis	rs4272382	1	rs4272382	ENSG00000253893.2	FAM85B	-4.55	5.91e-06	0.000512	-0.28	-0.14	Response to cytidine analogues (gemcitabine);	chr8:8575978	chr8:8167819~8226614:-
BRCA	cis	rs7487075	0.897	rs7979418	ENSG00000257261.4	RP11-96H19.1	4.55	5.92e-06	0.000512	0.16	0.14	Itch intensity from mosquito bite;	chr12:46380988	chr12:46383679~46876159:+
BRCA	cis	rs10129255	0.957	rs10150241	ENSG00000280411.1	IGHV1-69-2	4.55	5.92e-06	0.000512	0.1	0.14	Kawasaki disease;	chr14:106775945	chr14:106762092~106762588:-
BRCA	cis	rs2073316	0.592	rs55708293	ENSG00000272716.1	RP11-563N4.1	4.55	5.92e-06	0.000512	0.15	0.14	Interleukin-18 levels;	chr2:31453386	chr2:32165046~32165757:-
BRCA	cis	rs5770917	1	rs5770917	ENSG00000273272.1	CTA-384D8.34	4.55	5.92e-06	0.000512	0.27	0.14	Narcolepsy;	chr22:50578924	chr22:50542650~50543011:+
BRCA	cis	rs2227564	0.649	rs2948689	ENSG00000271816.1	BMS1P4	4.55	5.92e-06	0.000512	0.15	0.14	Crohn's disease;Inflammatory bowel disease;	chr10:73898102	chr10:73699151~73730487:-
BRCA	cis	rs924712	0.545	rs9475040	ENSG00000224984.1	RP11-524H19.2	4.55	5.92e-06	0.000512	0.17	0.14	Breast cancer;	chr6:54847760	chr6:54840118~54840855:-
BRCA	cis	rs6828666	0.909	rs2053345	ENSG00000271817.2	U3	4.55	5.92e-06	0.000512	0.19	0.14	Depression;	chr4:158918843	chr4:158700691~158700909:+
BRCA	cis	rs60843830	1	rs7605824	ENSG00000272342.1	RP13-539J13.1	-4.55	5.92e-06	0.000512	-0.17	-0.14	Spherical equivalent (joint analysis main effects and education interaction);	chr2:280819	chr2:739588~740164:-
BRCA	cis	rs7267979	1	rs4815418	ENSG00000277938.1	RP5-965G21.3	-4.55	5.93e-06	0.000513	-0.17	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25401575	chr20:25229150~25231933:+
BRCA	cis	rs4831760	0.964	rs1961471	ENSG00000250483.1	PPM1AP1	4.55	5.93e-06	0.000513	0.2	0.14	Pulmonary function decline;	chr8:15682604	chr8:15806149~15807283:-
BRCA	cis	rs875971	0.545	rs73376394	ENSG00000232546.1	RP11-458F8.1	4.55	5.93e-06	0.000513	0.13	0.14	Aortic root size;	chr7:66172694	chr7:66848496~66858136:+
BRCA	cis	rs6600671	1	rs11249351	ENSG00000270392.2	PFN1P2	4.55	5.93e-06	0.000513	0.15	0.14	Hip geometry;	chr1:121430082	chr1:120432204~120434052:-
BRCA	cis	rs216345	0.642	rs307675	ENSG00000260947.1	RP11-384P7.7	4.55	5.93e-06	0.000513	0.15	0.14	Bipolar disorder;	chr9:33969354	chr9:33697459~33700986:+
BRCA	cis	rs11098499	0.954	rs3890049	ENSG00000250412.1	KLHL2P1	4.55	5.93e-06	0.000513	0.17	0.14	Corneal astigmatism;	chr4:119405128	chr4:119334329~119378233:+
BRCA	cis	rs300890	0.513	rs587254	ENSG00000250326.1	RP11-284M14.1	-4.55	5.93e-06	0.000513	-0.17	-0.14	Nasopharyngeal carcinoma;	chr4:143245068	chr4:142933195~143184861:-
BRCA	cis	rs300890	0.513	rs534750	ENSG00000250326.1	RP11-284M14.1	-4.55	5.93e-06	0.000513	-0.17	-0.14	Nasopharyngeal carcinoma;	chr4:143245103	chr4:142933195~143184861:-
BRCA	cis	rs934734	0.511	rs62141115	ENSG00000281920.1	RP11-418H16.1	-4.55	5.93e-06	0.000513	-0.17	-0.14	Rheumatoid arthritis;	chr2:65445058	chr2:65623272~65628424:+
BRCA	cis	rs12435908	0.609	rs73268524	ENSG00000276116.2	FUT8-AS1	-4.55	5.93e-06	0.000513	-0.21	-0.14	Ischemic stroke;	chr14:65629815	chr14:65411170~65412690:-
BRCA	cis	rs11096990	0.593	rs35937374	ENSG00000249685.1	RP11-360F5.3	4.55	5.93e-06	0.000513	0.18	0.14	Cognitive function;	chr4:39184735	chr4:39133913~39135608:+
BRCA	cis	rs7308116	0.967	rs2005101	ENSG00000274395.1	RP11-554D14.8	-4.55	5.94e-06	0.000513	-0.15	-0.14	Pelvic organ prolapse (moderate/severe);	chr12:107808907	chr12:107835541~107836555:-
BRCA	cis	rs721917	0.506	rs2819098	ENSG00000278616.1	BEND3P3	-4.55	5.94e-06	0.000513	-0.13	-0.14	Chronic obstructive pulmonary disease;	chr10:79938341	chr10:79682997~79685436:+
BRCA	cis	rs2439831	1	rs9920763	ENSG00000275601.1	AC011330.13	-4.55	5.94e-06	0.000513	-0.24	-0.14	Lung cancer in ever smokers;	chr15:43468310	chr15:43642389~43643023:-
BRCA	cis	rs3796352	1	rs35174175	ENSG00000242142.1	SERBP1P3	-4.55	5.94e-06	0.000513	-0.28	-0.14	Immune reponse to smallpox (secreted IL-2);	chr3:53007493	chr3:53064283~53065091:-
BRCA	cis	rs3796352	1	rs11713859	ENSG00000242142.1	SERBP1P3	-4.55	5.94e-06	0.000513	-0.28	-0.14	Immune reponse to smallpox (secreted IL-2);	chr3:53008064	chr3:53064283~53065091:-
BRCA	cis	rs321358	1	rs321357	ENSG00000271390.1	RP11-89C3.3	4.55	5.94e-06	0.000514	0.22	0.14	Body mass index;	chr11:111125002	chr11:111089870~111090368:-
BRCA	cis	rs35146811	0.844	rs13232115	ENSG00000235713.1	RP4-604G5.3	4.55	5.94e-06	0.000514	0.17	0.14	Coronary artery disease;	chr7:100073309	chr7:99992397~99993050:+
BRCA	cis	rs6545883	0.894	rs10496092	ENSG00000212978.6	AC016747.3	-4.55	5.94e-06	0.000514	-0.19	-0.14	Tuberculosis;	chr2:61297544	chr2:61141592~61144969:-
BRCA	cis	rs1005277	0.579	rs176880	ENSG00000263064.2	RP11-291L22.7	-4.55	5.94e-06	0.000514	-0.17	-0.14	Extrinsic epigenetic age acceleration;	chr10:38112489	chr10:38448689~38448949:+
BRCA	cis	rs10028773	0.7	rs7671797	ENSG00000225892.3	RP11-384K6.2	4.55	5.94e-06	0.000514	0.14	0.14	Educational attainment;	chr4:119327002	chr4:118632274~118634759:+
BRCA	cis	rs7818688	0.697	rs74553842	ENSG00000253528.2	RP11-347C18.4	-4.55	5.94e-06	0.000514	-0.22	-0.14	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94972164	chr8:94974573~94974853:-
BRCA	cis	rs7818688	0.697	rs78777150	ENSG00000253528.2	RP11-347C18.4	-4.55	5.94e-06	0.000514	-0.22	-0.14	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94972183	chr8:94974573~94974853:-
BRCA	cis	rs2839186	0.934	rs13049797	ENSG00000228137.1	AP001469.7	4.55	5.95e-06	0.000514	0.14	0.14	Testicular germ cell tumor;	chr21:46287668	chr21:46246890~46247682:+
BRCA	cis	rs2839186	0.732	rs55904887	ENSG00000228137.1	AP001469.7	4.55	5.95e-06	0.000514	0.14	0.14	Testicular germ cell tumor;	chr21:46287897	chr21:46246890~46247682:+
BRCA	cis	rs2839186	0.934	rs2839197	ENSG00000228137.1	AP001469.7	4.55	5.95e-06	0.000514	0.14	0.14	Testicular germ cell tumor;	chr21:46288219	chr21:46246890~46247682:+
BRCA	cis	rs2839186	0.868	rs2839199	ENSG00000228137.1	AP001469.7	4.55	5.95e-06	0.000514	0.14	0.14	Testicular germ cell tumor;	chr21:46288355	chr21:46246890~46247682:+
BRCA	cis	rs2839186	0.933	rs4818832	ENSG00000228137.1	AP001469.7	4.55	5.95e-06	0.000514	0.14	0.14	Testicular germ cell tumor;	chr21:46288720	chr21:46246890~46247682:+
BRCA	cis	rs2839186	0.9	rs59828751	ENSG00000228137.1	AP001469.7	4.55	5.95e-06	0.000514	0.14	0.14	Testicular germ cell tumor;	chr21:46289004	chr21:46246890~46247682:+
BRCA	cis	rs7176527	1	rs7176527	ENSG00000225151.9	GOLGA2P7	4.55	5.95e-06	0.000514	0.21	0.14	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84597563	chr15:84199311~84230136:-
BRCA	cis	rs754466	0.958	rs58916802	ENSG00000204049.1	RP11-126H7.4	4.55	5.95e-06	0.000514	0.19	0.14	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77936112	chr10:77866875~77869610:+
BRCA	cis	rs7665090	1	rs2866406	ENSG00000251288.2	RP11-10L12.2	-4.55	5.95e-06	0.000515	-0.17	-0.14	Primary biliary cholangitis;	chr4:102632862	chr4:102751401~102752641:+
BRCA	cis	rs6452524	1	rs6863300	ENSG00000281327.1	LINC01338	4.55	5.95e-06	0.000515	0.16	0.14	Hypertension (SNP x SNP interaction);	chr5:83139629	chr5:82850864~82859836:-
BRCA	cis	rs1075265	0.836	rs1421622	ENSG00000235937.1	AC008280.1	-4.55	5.96e-06	0.000515	-0.15	-0.14	Chronotype;Morning vs. evening chronotype;	chr2:54062644	chr2:54029552~54030682:-
BRCA	cis	rs11098499	0.908	rs7696649	ENSG00000250412.1	KLHL2P1	4.55	5.96e-06	0.000515	0.17	0.14	Corneal astigmatism;	chr4:119401022	chr4:119334329~119378233:+
BRCA	cis	rs2842346	0.509	rs2525525	ENSG00000258623.1	CTD-2325P2.3	4.55	5.96e-06	0.000515	0.18	0.14	Breast cancer;	chr14:68541858	chr14:68683411~68685565:-
BRCA	cis	rs10266483	0.843	rs10272639	ENSG00000228653.2	HNRNPCP7	-4.55	5.96e-06	0.000515	-0.16	-0.14	Response to statin therapy;	chr7:64278944	chr7:64500825~64501729:+
BRCA	cis	rs2839186	0.867	rs13050387	ENSG00000228137.1	AP001469.7	4.55	5.96e-06	0.000515	0.14	0.14	Testicular germ cell tumor;	chr21:46281509	chr21:46246890~46247682:+
BRCA	cis	rs2839186	0.872	rs13046834	ENSG00000228137.1	AP001469.7	4.55	5.96e-06	0.000515	0.14	0.14	Testicular germ cell tumor;	chr21:46281571	chr21:46246890~46247682:+
BRCA	cis	rs2839186	0.721	rs13051200	ENSG00000228137.1	AP001469.7	4.55	5.96e-06	0.000515	0.14	0.14	Testicular germ cell tumor;	chr21:46281779	chr21:46246890~46247682:+
BRCA	cis	rs1322639	0.614	rs6908401	ENSG00000223485.1	RP11-417E7.1	4.55	5.96e-06	0.000515	0.19	0.14	Pulse pressure;	chr6:169164621	chr6:169158092~169162924:-
BRCA	cis	rs7267979	1	rs6050631	ENSG00000125804.12	FAM182A	-4.55	5.96e-06	0.000515	-0.18	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25451113	chr20:26054655~26086917:+
BRCA	cis	rs6088580	0.634	rs6059851	ENSG00000276073.1	RP5-1125A11.7	-4.55	5.96e-06	0.000515	-0.15	-0.14	Glomerular filtration rate (creatinine);	chr20:34460140	chr20:33985617~33988989:-
BRCA	cis	rs11098499	0.698	rs4422403	ENSG00000260404.2	RP11-384K6.6	4.55	5.96e-06	0.000515	0.12	0.14	Corneal astigmatism;	chr4:119337039	chr4:118591773~118633729:+
BRCA	cis	rs5758511	0.68	rs5758686	ENSG00000227370.1	RP4-669P10.19	4.55	5.96e-06	0.000516	0.19	0.14	Birth weight;	chr22:42259371	chr22:42132543~42132998:+
BRCA	cis	rs9527	0.518	rs12771834	ENSG00000213061.2	PFN1P11	4.55	5.97e-06	0.000516	0.27	0.14	Arsenic metabolism;	chr10:102895662	chr10:102838011~102845473:-
BRCA	cis	rs1858037	0.867	rs67453645	ENSG00000237979.1	AC007389.1	4.55	5.97e-06	0.000516	0.18	0.14	Rheumatoid arthritis;	chr2:65358908	chr2:65500993~65502138:-
BRCA	cis	rs853679	0.76	rs9393909	ENSG00000216901.1	AL022393.7	-4.55	5.97e-06	0.000516	-0.22	-0.14	Depression;	chr6:28239422	chr6:28176188~28176674:+
BRCA	cis	rs10129255	0.509	rs756583	ENSG00000211959.2	IGHV4-39	4.55	5.97e-06	0.000516	0.1	0.14	Kawasaki disease;	chr14:106680002	chr14:106421711~106422218:-
BRCA	cis	rs1161098	1	rs1161098	ENSG00000256037.1	MRPL40P1	4.55	5.97e-06	0.000516	0.2	0.14	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr12:67453680	chr12:67351436~67352039:+
BRCA	cis	rs7829975	0.667	rs1877119	ENSG00000254153.1	CTA-398F10.2	4.55	5.97e-06	0.000516	0.17	0.14	Mood instability;	chr8:8849687	chr8:8456909~8461337:-
BRCA	cis	rs17818399	0.926	rs13033177	ENSG00000279254.1	RP11-536C12.1	-4.55	5.97e-06	0.000516	-0.19	-0.14	Height;	chr2:46603923	chr2:46668870~46670778:+
BRCA	cis	rs5003154	0.81	rs12676670	ENSG00000253214.1	RP11-1149M10.2	4.55	5.97e-06	0.000516	0.16	0.14	Bladder cancer;	chr8:81069026	chr8:81154279~81164599:+
BRCA	cis	rs2136613	0.728	rs7078554	ENSG00000238280.1	RP11-436D10.3	-4.55	5.97e-06	0.000516	-0.18	-0.14	Selective IgA deficiency;	chr10:62835274	chr10:62793562~62805887:-
BRCA	cis	rs514024	0.729	rs4836575	ENSG00000225032.4	RP11-228B15.4	-4.55	5.98e-06	0.000516	-0.13	-0.14	Eating disorders (purging via substances);	chr9:127684214	chr9:127816066~127822520:+
BRCA	cis	rs4948275	0.773	rs2606078	ENSG00000237233.2	TMEM26-AS1	-4.55	5.98e-06	0.000517	-0.17	-0.14	Night sleep phenotypes;	chr10:61529457	chr10:61452639~61481956:+
BRCA	cis	rs4948275	0.773	rs2606079	ENSG00000237233.2	TMEM26-AS1	-4.55	5.98e-06	0.000517	-0.17	-0.14	Night sleep phenotypes;	chr10:61529877	chr10:61452639~61481956:+
BRCA	cis	rs4948275	0.773	rs2787694	ENSG00000237233.2	TMEM26-AS1	-4.55	5.98e-06	0.000517	-0.17	-0.14	Night sleep phenotypes;	chr10:61530078	chr10:61452639~61481956:+
BRCA	cis	rs7829975	0.509	rs7838674	ENSG00000254153.1	CTA-398F10.2	-4.55	5.98e-06	0.000517	-0.17	-0.14	Mood instability;	chr8:8939563	chr8:8456909~8461337:-
BRCA	cis	rs9921338	0.961	rs7199821	ENSG00000262703.1	RP11-485G7.6	-4.55	5.98e-06	0.000517	-0.18	-0.14	Vein graft stenosis in coronary artery bypass grafting;	chr16:11331154	chr16:11348143~11349321:-
BRCA	cis	rs12368653	1	rs12371356	ENSG00000257159.1	RP11-58A17.3	-4.55	5.98e-06	0.000517	-0.16	-0.14	Multiple sclerosis;	chr12:57741637	chr12:57967058~57968399:+
BRCA	cis	rs4948275	0.631	rs2814024	ENSG00000237233.2	TMEM26-AS1	-4.55	5.98e-06	0.000517	-0.17	-0.14	Night sleep phenotypes;	chr10:61590868	chr10:61452639~61481956:+
BRCA	cis	rs4948275	0.598	rs2650742	ENSG00000237233.2	TMEM26-AS1	-4.55	5.98e-06	0.000517	-0.17	-0.14	Night sleep phenotypes;	chr10:61591188	chr10:61452639~61481956:+
BRCA	cis	rs12428035	0.772	rs12430152	ENSG00000247400.3	DNAJC3-AS1	4.55	5.98e-06	0.000517	0.21	0.14	Glomerular filtration rate (cystatin C);Response to statins (LDL cholesterol change);	chr13:95819783	chr13:95648733~95676925:-
BRCA	cis	rs13113518	1	rs11937487	ENSG00000249700.7	SRD5A3-AS1	4.55	5.99e-06	0.000517	0.17	0.14	Height;	chr4:55436576	chr4:55363971~55395847:-
BRCA	cis	rs6840360	0.681	rs4519779	ENSG00000251603.1	RP11-164P12.4	-4.55	5.99e-06	0.000517	-0.13	-0.14	Intelligence (multi-trait analysis);	chr4:151380033	chr4:151667224~151670502:+
BRCA	cis	rs9467773	1	rs6910899	ENSG00000241549.7	GUSBP2	4.55	5.99e-06	0.000517	0.15	0.14	Intelligence (multi-trait analysis);	chr6:26524111	chr6:26871484~26956554:-
BRCA	cis	rs2839186	0.814	rs13052376	ENSG00000228137.1	AP001469.7	4.55	5.99e-06	0.000517	0.14	0.14	Testicular germ cell tumor;	chr21:46287489	chr21:46246890~46247682:+
BRCA	cis	rs2839186	0.934	rs13046494	ENSG00000228137.1	AP001469.7	4.55	5.99e-06	0.000517	0.14	0.14	Testicular germ cell tumor;	chr21:46287516	chr21:46246890~46247682:+
BRCA	cis	rs2839186	0.872	rs13052495	ENSG00000228137.1	AP001469.7	4.55	5.99e-06	0.000517	0.14	0.14	Testicular germ cell tumor;	chr21:46287560	chr21:46246890~46247682:+
BRCA	cis	rs2562456	0.833	rs62109229	ENSG00000268658.4	LINC00664	4.55	5.99e-06	0.000517	0.23	0.14	Pain;	chr19:21354380	chr19:21483374~21503238:+
BRCA	cis	rs2562456	0.833	rs11670815	ENSG00000268658.4	LINC00664	4.55	5.99e-06	0.000517	0.23	0.14	Pain;	chr19:21356515	chr19:21483374~21503238:+
BRCA	cis	rs2562456	0.833	rs11666540	ENSG00000268658.4	LINC00664	4.55	5.99e-06	0.000517	0.23	0.14	Pain;	chr19:21356550	chr19:21483374~21503238:+
BRCA	cis	rs2562456	0.833	rs11667361	ENSG00000268658.4	LINC00664	4.55	5.99e-06	0.000517	0.23	0.14	Pain;	chr19:21356580	chr19:21483374~21503238:+
BRCA	cis	rs2179367	0.509	rs9485390	ENSG00000268592.3	RAET1E-AS1	4.55	5.99e-06	0.000517	0.2	0.14	Dupuytren's disease;	chr6:149421004	chr6:149863494~149919507:+
BRCA	cis	rs62025270	0.576	rs55639123	ENSG00000259295.5	CSPG4P12	-4.55	5.99e-06	0.000517	-0.22	-0.14	Idiopathic pulmonary fibrosis;	chr15:85617037	chr15:85191438~85213905:+
BRCA	cis	rs710913	0.531	rs1180331	ENSG00000228060.1	RP11-69E11.8	4.55	5.99e-06	0.000518	0.14	0.14	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39546512	chr1:39565160~39573203:+
BRCA	cis	rs7618915	0.501	rs3774366	ENSG00000243224.1	RP5-1157M23.2	-4.55	5.99e-06	0.000518	-0.15	-0.14	Bipolar disorder;	chr3:52607239	chr3:52239258~52241097:+
BRCA	cis	rs1153858	1	rs11852800	ENSG00000275672.1	GATM-AS1	4.55	5.99e-06	0.000518	0.18	0.14	Homoarginine levels;	chr15:45346933	chr15:45378700~45380123:+
BRCA	cis	rs9467773	1	rs4713006	ENSG00000241549.7	GUSBP2	4.55	5.99e-06	0.000518	0.15	0.14	Intelligence (multi-trait analysis);	chr6:26519644	chr6:26871484~26956554:-
BRCA	cis	rs10504130	1	rs77712895	ENSG00000272024.1	RP11-546K22.3	-4.55	5.99e-06	0.000518	-0.24	-0.14	Venous thromboembolism (SNP x SNP interaction);	chr8:51821121	chr8:51950284~51950690:+
BRCA	cis	rs7727544	0.507	rs9791170	ENSG00000233006.5	AC034220.3	4.55	5.99e-06	0.000518	0.1	0.14	Blood metabolite levels;	chr5:132233934	chr5:132311285~132369916:-
BRCA	cis	rs7819412	0.595	rs2409712	ENSG00000154316.13	TDH	4.55	5.99e-06	0.000518	0.18	0.14	Triglycerides;	chr8:11129327	chr8:11339637~11368452:+
BRCA	cis	rs6860806	0.661	rs334902	ENSG00000233006.5	AC034220.3	4.55	5.99e-06	0.000518	0.1	0.14	Breast cancer;	chr5:132250866	chr5:132311285~132369916:-
BRCA	cis	rs6708331	1	rs10195155	ENSG00000231024.1	AC092431.3	-4.55	6e-06	0.000518	-0.19	-0.14	Obesity-related traits;	chr2:70127343	chr2:69700192~69713847:-
BRCA	cis	rs6686842	0.56	rs61781830	ENSG00000235358.1	RP11-399E6.1	-4.55	6e-06	0.000518	-0.19	-0.14	Height;	chr1:41167695	chr1:41242373~41284861:+
BRCA	cis	rs6686842	0.56	rs12127030	ENSG00000235358.1	RP11-399E6.1	-4.55	6e-06	0.000518	-0.19	-0.14	Height;	chr1:41172726	chr1:41242373~41284861:+
BRCA	cis	rs2154319	0.559	rs213746	ENSG00000235358.1	RP11-399E6.1	4.55	6e-06	0.000518	0.19	0.14	Height;	chr1:41163143	chr1:41242373~41284861:+
BRCA	cis	rs9527	0.569	rs10883801	ENSG00000213061.2	PFN1P11	4.55	6e-06	0.000518	0.19	0.14	Arsenic metabolism;	chr10:102918130	chr10:102838011~102845473:-
BRCA	cis	rs12497850	0.931	rs4974087	ENSG00000225399.4	RP11-3B7.1	4.55	6e-06	0.000518	0.14	0.14	Parkinson's disease;	chr3:48881799	chr3:49260085~49261316:+
BRCA	cis	rs651907	0.557	rs34181125	ENSG00000256628.3	ZBTB11-AS1	4.55	6e-06	0.000519	0.18	0.14	Colorectal cancer;	chr3:101771434	chr3:101676475~101679217:+
BRCA	cis	rs2617170	0.922	rs1049172	ENSG00000245648.1	RP11-277P12.20	4.55	6e-06	0.000519	0.19	0.14	Behcet's disease;	chr12:10373141	chr12:10363769~10398506:+
BRCA	cis	rs7847628	0.55	rs12343516	ENSG00000238181.2	AHCYP2	-4.55	6e-06	0.000519	-0.18	-0.14	Birth weight;	chr9:120841191	chr9:120720673~120721972:+
BRCA	cis	rs924712	0.604	rs10807484	ENSG00000261116.1	RP3-523K23.2	4.55	6e-06	0.000519	0.17	0.14	Breast cancer;	chr6:54854687	chr6:54943167~54945099:+
BRCA	cis	rs6565180	1	rs68051857	ENSG00000183604.13	SMG1P5	-4.55	6.01e-06	0.000519	-0.14	-0.14	Tonsillectomy;	chr16:30348690	chr16:30267553~30335374:-
BRCA	cis	rs35740288	0.77	rs36044792	ENSG00000202081.1	RNU6-1280P	4.55	6.01e-06	0.000519	0.18	0.14	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85603320	chr15:85651522~85651628:-
BRCA	cis	rs17507216	1	rs17356118	ENSG00000259429.4	UBE2Q2P2	-4.55	6.01e-06	0.000519	-0.16	-0.14	Excessive daytime sleepiness;	chr15:82569149	chr15:82355142~82420075:+
BRCA	cis	rs1322639	0.657	rs12203887	ENSG00000223485.1	RP11-417E7.1	-4.55	6.02e-06	0.000519	-0.2	-0.14	Pulse pressure;	chr6:169172157	chr6:169158092~169162924:-
BRCA	cis	rs6696239	0.531	rs2644150	ENSG00000227711.2	RP11-275O4.5	-4.55	6.02e-06	0.00052	-0.16	-0.14	Height;	chr1:227514120	chr1:227509028~227520477:-
BRCA	cis	rs17507216	0.718	rs72751662	ENSG00000255769.6	GOLGA2P10	-4.55	6.02e-06	0.00052	-0.21	-0.14	Excessive daytime sleepiness;	chr15:82594705	chr15:82472993~82513950:-
BRCA	cis	rs1858037	0.836	rs2576923	ENSG00000281920.1	RP11-418H16.1	-4.55	6.02e-06	0.00052	-0.18	-0.14	Rheumatoid arthritis;	chr2:65406750	chr2:65623272~65628424:+
BRCA	cis	rs2408955	0.522	rs973398	ENSG00000257763.1	OR5BK1P	-4.55	6.02e-06	0.00052	-0.15	-0.14	Glycated hemoglobin levels;	chr12:48097265	chr12:48355792~48356614:-
BRCA	cis	rs6430585	0.528	rs12474975	ENSG00000231890.6	DARS-AS1	-4.55	6.02e-06	0.00052	-0.23	-0.14	Corneal structure;	chr2:135944548	chr2:135985176~136022593:+
BRCA	cis	rs867186	0.764	rs78517073	ENSG00000126005.14	MMP24-AS1	-4.55	6.02e-06	0.00052	-0.27	-0.14	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35095627	chr20:35216462~35278131:-
BRCA	cis	rs7923609	0.846	rs9787438	ENSG00000232075.1	MRPL35P2	-4.55	6.02e-06	0.00052	-0.18	-0.14	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63278270	chr10:63634317~63634827:-
BRCA	cis	rs8031584	0.918	rs34095794	ENSG00000270015.1	RP11-540B6.6	-4.55	6.02e-06	0.00052	-0.14	-0.14	Huntington's disease progression;	chr15:30977488	chr15:30926514~30928407:+
BRCA	cis	rs7918232	0.941	rs1753413	ENSG00000262412.1	RP11-85G18.6	4.55	6.02e-06	0.00052	0.24	0.14	Breast cancer;	chr10:27108183	chr10:27243130~27250804:+
BRCA	cis	rs12744310	1	rs68132196	ENSG00000235358.1	RP11-399E6.1	4.55	6.02e-06	0.00052	0.21	0.14	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41304948	chr1:41242373~41284861:+
BRCA	cis	rs10129255	0.556	rs6576222	ENSG00000232216.1	IGHV3-43	4.55	6.02e-06	0.00052	0.1	0.14	Kawasaki disease;	chr14:106776442	chr14:106470264~106470800:-
BRCA	cis	rs1005277	0.579	rs2474568	ENSG00000099251.13	HSD17B7P2	4.55	6.02e-06	0.00052	0.15	0.14	Extrinsic epigenetic age acceleration;	chr10:38094219	chr10:38356380~38378505:+
BRCA	cis	rs4948275	0.693	rs2814028	ENSG00000237233.2	TMEM26-AS1	-4.55	6.03e-06	0.00052	-0.16	-0.14	Night sleep phenotypes;	chr10:61578535	chr10:61452639~61481956:+
BRCA	cis	rs4948275	0.693	rs2606103	ENSG00000237233.2	TMEM26-AS1	-4.55	6.03e-06	0.00052	-0.16	-0.14	Night sleep phenotypes;	chr10:61578805	chr10:61452639~61481956:+
BRCA	cis	rs4948275	0.658	rs1933444	ENSG00000237233.2	TMEM26-AS1	-4.55	6.03e-06	0.00052	-0.16	-0.14	Night sleep phenotypes;	chr10:61579286	chr10:61452639~61481956:+
BRCA	cis	rs2692947	0.832	rs2438972	ENSG00000168992.4	OR7E102P	4.55	6.03e-06	0.00052	0.19	0.14	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96025125	chr2:95546531~95547545:+
BRCA	cis	rs11096990	0.551	rs2060005	ENSG00000249685.1	RP11-360F5.3	4.55	6.03e-06	0.000521	0.18	0.14	Cognitive function;	chr4:39160901	chr4:39133913~39135608:+
BRCA	cis	rs1061377	0.501	rs62308278	ENSG00000249685.1	RP11-360F5.3	4.55	6.03e-06	0.000521	0.18	0.14	Uric acid levels;	chr4:39161038	chr4:39133913~39135608:+
BRCA	cis	rs13113518	1	rs3805149	ENSG00000273257.1	RP11-177J6.1	4.55	6.03e-06	0.000521	0.18	0.14	Height;	chr4:55442184	chr4:55387949~55388271:+
BRCA	cis	rs13113518	1	rs11945370	ENSG00000273257.1	RP11-177J6.1	4.55	6.03e-06	0.000521	0.18	0.14	Height;	chr4:55442875	chr4:55387949~55388271:+
BRCA	cis	rs11742741	0.742	rs12152957	ENSG00000248874.4	C5orf17	-4.55	6.03e-06	0.000521	-0.18	-0.14	Educational attainment;	chr5:24015053	chr5:23951348~24178263:+
BRCA	cis	rs9921338	0.597	rs181582	ENSG00000262703.1	RP11-485G7.6	-4.55	6.03e-06	0.000521	-0.18	-0.14	Vein graft stenosis in coronary artery bypass grafting;	chr16:11249690	chr16:11348143~11349321:-
BRCA	cis	rs17406451	0.731	rs7605661	ENSG00000234936.1	AC010883.5	4.55	6.04e-06	0.000521	0.14	0.14	Mitochondrial DNA levels;	chr2:43397939	chr2:43229573~43233394:+
BRCA	cis	rs4664293	0.867	rs2114626	ENSG00000224152.1	AC009506.1	4.55	6.04e-06	0.000521	0.16	0.14	Monocyte percentage of white cells;	chr2:159783459	chr2:159615296~159617082:+
BRCA	cis	rs6921919	0.583	rs6928771	ENSG00000273712.1	RP5-874C20.7	4.55	6.04e-06	0.000521	0.18	0.14	Autism spectrum disorder or schizophrenia;	chr6:28407432	chr6:28315613~28315883:-
BRCA	cis	rs6921919	0.583	rs6928773	ENSG00000273712.1	RP5-874C20.7	4.55	6.04e-06	0.000521	0.18	0.14	Autism spectrum disorder or schizophrenia;	chr6:28407433	chr6:28315613~28315883:-
BRCA	cis	rs10504130	0.569	rs4626585	ENSG00000272024.1	RP11-546K22.3	4.55	6.04e-06	0.000521	0.2	0.14	Venous thromboembolism (SNP x SNP interaction);	chr8:51767380	chr8:51950284~51950690:+
BRCA	cis	rs6738627	1	rs9653282	ENSG00000223318.1	RNA5SP111	4.55	6.04e-06	0.000521	0.16	0.14	circulating leptin levels adjusted for BMI;Body fat percentage;circulating leptin levels;	chr2:164698148	chr2:164895677~164895777:-
BRCA	cis	rs7914558	0.621	rs12219346	ENSG00000213061.2	PFN1P11	4.55	6.04e-06	0.000521	0.2	0.14	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102897543	chr10:102838011~102845473:-
BRCA	cis	rs4650994	1	rs17276527	ENSG00000273384.1	RP5-1098D14.1	4.55	6.04e-06	0.000522	0.17	0.14	HDL cholesterol;HDL cholesterol levels;	chr1:178551545	chr1:178651706~178652282:+
BRCA	cis	rs1005277	0.579	rs2472173	ENSG00000099251.13	HSD17B7P2	4.55	6.04e-06	0.000522	0.15	0.14	Extrinsic epigenetic age acceleration;	chr10:38085710	chr10:38356380~38378505:+
BRCA	cis	rs1005277	0.579	rs2472174	ENSG00000099251.13	HSD17B7P2	4.55	6.04e-06	0.000522	0.15	0.14	Extrinsic epigenetic age acceleration;	chr10:38086454	chr10:38356380~38378505:+
BRCA	cis	rs11098499	0.865	rs28634456	ENSG00000250412.1	KLHL2P1	4.55	6.05e-06	0.000522	0.17	0.14	Corneal astigmatism;	chr4:119454623	chr4:119334329~119378233:+
BRCA	cis	rs4664293	0.867	rs3764968	ENSG00000224152.1	AC009506.1	-4.55	6.05e-06	0.000522	-0.16	-0.14	Monocyte percentage of white cells;	chr2:159790579	chr2:159615296~159617082:+
BRCA	cis	rs763014	0.932	rs34498660	ENSG00000260394.2	LA16c-313D11.9	-4.55	6.05e-06	0.000522	-0.14	-0.14	Height;	chr16:616149	chr16:678504~679777:-
BRCA	cis	rs77204473	1	rs2186844	ENSG00000280143.1	AP000892.6	4.55	6.05e-06	0.000522	0.25	0.14	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117026197	chr11:117204967~117210292:+
BRCA	cis	rs35612822	0.723	rs7577388	ENSG00000232485.2	AC098820.3	-4.55	6.05e-06	0.000522	-0.16	-0.14	Kidney disease (early stage) in type 1 diabetes;	chr2:216397781	chr2:216479030~216498761:-
BRCA	cis	rs35612822	0.723	rs7563407	ENSG00000232485.2	AC098820.3	-4.55	6.05e-06	0.000522	-0.16	-0.14	Kidney disease (early stage) in type 1 diabetes;	chr2:216397878	chr2:216479030~216498761:-
BRCA	cis	rs35612822	0.723	rs13385640	ENSG00000232485.2	AC098820.3	-4.55	6.05e-06	0.000522	-0.16	-0.14	Kidney disease (early stage) in type 1 diabetes;	chr2:216398519	chr2:216479030~216498761:-
BRCA	cis	rs35612822	0.688	rs13410937	ENSG00000232485.2	AC098820.3	-4.55	6.05e-06	0.000522	-0.16	-0.14	Kidney disease (early stage) in type 1 diabetes;	chr2:216398563	chr2:216479030~216498761:-
BRCA	cis	rs35612822	0.688	rs13399149	ENSG00000232485.2	AC098820.3	-4.55	6.05e-06	0.000522	-0.16	-0.14	Kidney disease (early stage) in type 1 diabetes;	chr2:216398662	chr2:216479030~216498761:-
BRCA	cis	rs56322409	0.897	rs11188484	ENSG00000226688.5	ENTPD1-AS1	4.55	6.05e-06	0.000522	0.16	0.14	Blood metabolite levels;	chr10:95779980	chr10:95753206~96090238:-
BRCA	cis	rs17680741	0.542	rs35521186	ENSG00000226659.1	RP11-137H2.4	4.55	6.05e-06	0.000522	0.24	0.14	Coronary artery disease;	chr10:80484325	chr10:80529597~80535942:-
BRCA	cis	rs7267979	1	rs12428	ENSG00000274973.1	RP13-401N8.7	4.55	6.05e-06	0.000522	0.16	0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25453185	chr20:25845497~25845862:+
BRCA	cis	rs9467773	0.595	rs7767847	ENSG00000241549.7	GUSBP2	4.55	6.05e-06	0.000522	0.15	0.14	Intelligence (multi-trait analysis);	chr6:26597665	chr6:26871484~26956554:-
BRCA	cis	rs2255336	0.817	rs12318583	ENSG00000245648.1	RP11-277P12.20	-4.55	6.05e-06	0.000523	-0.21	-0.14	Blood protein levels;	chr12:10426485	chr12:10363769~10398506:+
BRCA	cis	rs9818758	0.607	rs13068038	ENSG00000270441.1	RP11-694I15.7	4.55	6.05e-06	0.000523	0.27	0.14	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49256817	chr3:49140086~49160851:-
BRCA	cis	rs10504130	0.569	rs12678646	ENSG00000272024.1	RP11-546K22.3	-4.55	6.06e-06	0.000523	-0.21	-0.14	Venous thromboembolism (SNP x SNP interaction);	chr8:51755611	chr8:51950284~51950690:+
BRCA	cis	rs610932	0.517	rs676309	ENSG00000275344.1	MIR6503	4.55	6.06e-06	0.000523	0.14	0.14	Alzheimer's disease;	chr11:60234100	chr11:60209071~60209156:-
BRCA	cis	rs875971	0.66	rs12698534	ENSG00000273142.1	RP11-458F8.4	-4.55	6.06e-06	0.000523	-0.12	-0.14	Aortic root size;	chr7:66521858	chr7:66902857~66906297:+
BRCA	cis	rs73607972	0.501	rs73614583	ENSG00000275191.1	RP11-36I17.2	-4.55	6.06e-06	0.000523	-0.21	-0.14	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53554597	chr16:53628256~53628816:-
BRCA	cis	rs4948275	0.71	rs2787698	ENSG00000237233.2	TMEM26-AS1	-4.55	6.06e-06	0.000523	-0.17	-0.14	Night sleep phenotypes;	chr10:61537692	chr10:61452639~61481956:+
BRCA	cis	rs12681366	0.563	rs6999103	ENSG00000253704.1	RP11-267M23.4	4.55	6.06e-06	0.000523	0.15	0.14	Nonsyndromic cleft lip with cleft palate;	chr8:94470309	chr8:94553722~94569745:+
BRCA	cis	rs2562456	0.833	rs4644962	ENSG00000268658.4	LINC00664	4.55	6.06e-06	0.000523	0.23	0.14	Pain;	chr19:21338125	chr19:21483374~21503238:+
BRCA	cis	rs8031584	0.918	rs34095794	ENSG00000259845.1	HERC2P10	4.55	6.06e-06	0.000523	0.16	0.14	Huntington's disease progression;	chr15:30977488	chr15:30815271~30844153:+
BRCA	cis	rs2839186	1	rs2839181	ENSG00000239415.1	AP001469.9	4.55	6.06e-06	0.000523	0.15	0.14	Testicular germ cell tumor;	chr21:46266025	chr21:46251549~46254133:-
BRCA	cis	rs11098499	1	rs3749591	ENSG00000260404.2	RP11-384K6.6	4.55	6.06e-06	0.000523	0.14	0.14	Corneal astigmatism;	chr4:119292875	chr4:118591773~118633729:+
BRCA	cis	rs7833986	0.501	rs2719257	ENSG00000253603.1	CTA-397H3.3	-4.55	6.06e-06	0.000523	-0.2	-0.14	Height;	chr8:56027614	chr8:56074592~56075274:+
BRCA	cis	rs6088580	0.634	rs3746455	ENSG00000276073.1	RP5-1125A11.7	4.55	6.06e-06	0.000523	0.15	0.14	Glomerular filtration rate (creatinine);	chr20:34369410	chr20:33985617~33988989:-
BRCA	cis	rs2243480	0.764	rs2460423	ENSG00000222364.1	RNU6-96P	-4.55	6.06e-06	0.000523	-0.26	-0.14	Diabetic kidney disease;	chr7:66136229	chr7:66395191~66395286:+
BRCA	cis	rs287982	0.611	rs80238678	ENSG00000269973.1	RP11-95D17.1	-4.55	6.07e-06	0.000524	-0.22	-0.14	Nonsyndromic cleft lip with cleft palate;	chr2:9836053	chr2:9936360~9939590:+
BRCA	cis	rs172166	0.694	rs1631552	ENSG00000219392.1	RP1-265C24.5	-4.55	6.07e-06	0.000524	-0.19	-0.14	Cardiac Troponin-T levels;	chr6:28121921	chr6:28115628~28116551:+
BRCA	cis	rs77372450	0.591	rs17054697	ENSG00000248544.2	CTB-47B11.3	4.55	6.07e-06	0.000524	0.22	0.14	Bipolar disorder (body mass index interaction);	chr5:157539217	chr5:157375741~157384950:-
BRCA	cis	rs11696845	0.787	rs6017408	ENSG00000276223.1	RP4-781B1.5	-4.55	6.07e-06	0.000524	-0.14	-0.14	Obesity-related traits;	chr20:44734888	chr20:44746642~44747201:+
BRCA	cis	rs11098499	0.909	rs9759478	ENSG00000260091.1	RP11-33B1.4	-4.55	6.08e-06	0.000524	-0.13	-0.14	Corneal astigmatism;	chr4:119446843	chr4:119409333~119410233:+
BRCA	cis	rs13113518	1	rs4864994	ENSG00000273257.1	RP11-177J6.1	4.55	6.08e-06	0.000524	0.18	0.14	Height;	chr4:55451955	chr4:55387949~55388271:+
BRCA	cis	rs4713118	0.512	rs2622319	ENSG00000219392.1	RP1-265C24.5	-4.55	6.08e-06	0.000524	-0.19	-0.14	Parkinson's disease;	chr6:28152623	chr6:28115628~28116551:+
BRCA	cis	rs172166	0.694	rs1150666	ENSG00000219392.1	RP1-265C24.5	-4.55	6.08e-06	0.000524	-0.19	-0.14	Cardiac Troponin-T levels;	chr6:28156150	chr6:28115628~28116551:+
BRCA	cis	rs7200543	1	rs55727637	ENSG00000260735.1	RP11-72I8.1	-4.55	6.08e-06	0.000525	-0.16	-0.14	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15051395	chr16:15094411~15109197:+
BRCA	cis	rs7267979	1	rs404394	ENSG00000125804.12	FAM182A	-4.55	6.08e-06	0.000525	-0.18	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25467260	chr20:26054655~26086917:+
BRCA	cis	rs2286503	1	rs2286499	ENSG00000226329.2	AC005682.6	4.55	6.08e-06	0.000525	0.13	0.14	Fibrinogen;	chr7:22817858	chr7:22863874~22881350:-
BRCA	cis	rs2115630	1	rs2115630	ENSG00000259295.5	CSPG4P12	-4.55	6.09e-06	0.000525	-0.16	-0.14	P wave terminal force;	chr15:84821285	chr15:85191438~85213905:+
BRCA	cis	rs6860540	0.796	rs6879450	ENSG00000248544.2	CTB-47B11.3	-4.55	6.09e-06	0.000525	-0.18	-0.14	Inflammatory skin disease;	chr5:157471959	chr5:157375741~157384950:-
BRCA	cis	rs12435908	1	rs2073294	ENSG00000276116.2	FUT8-AS1	-4.55	6.09e-06	0.000525	-0.22	-0.14	Ischemic stroke;	chr14:65615775	chr14:65411170~65412690:-
BRCA	cis	rs6723108	0.651	rs6724774	ENSG00000224043.6	CCNT2-AS1	4.55	6.09e-06	0.000525	0.19	0.14	Type 2 diabetes;	chr2:134649715	chr2:134735464~134918710:-
BRCA	cis	rs859767	0.501	rs6724777	ENSG00000224043.6	CCNT2-AS1	4.55	6.09e-06	0.000525	0.19	0.14	Neuroticism;	chr2:134649722	chr2:134735464~134918710:-
BRCA	cis	rs6723108	0.651	rs6724866	ENSG00000224043.6	CCNT2-AS1	4.55	6.09e-06	0.000525	0.19	0.14	Type 2 diabetes;	chr2:134649740	chr2:134735464~134918710:-
BRCA	cis	rs6723108	0.616	rs6752634	ENSG00000224043.6	CCNT2-AS1	4.55	6.09e-06	0.000525	0.19	0.14	Type 2 diabetes;	chr2:134649785	chr2:134735464~134918710:-
BRCA	cis	rs859767	0.501	rs6742638	ENSG00000224043.6	CCNT2-AS1	4.55	6.09e-06	0.000525	0.19	0.14	Neuroticism;	chr2:134649790	chr2:134735464~134918710:-
BRCA	cis	rs559555	0.553	rs2754530	ENSG00000272716.1	RP11-563N4.1	4.55	6.09e-06	0.000525	0.16	0.14	Blood metabolite ratios;Blood metabolite levels;	chr2:31578333	chr2:32165046~32165757:-
BRCA	cis	rs559555	0.553	rs2268799	ENSG00000272716.1	RP11-563N4.1	4.55	6.09e-06	0.000525	0.16	0.14	Blood metabolite ratios;Blood metabolite levels;	chr2:31578425	chr2:32165046~32165757:-
BRCA	cis	rs11673344	0.523	rs2562594	ENSG00000226686.6	LINC01535	4.55	6.09e-06	0.000526	0.18	0.14	Obesity-related traits;	chr19:37023783	chr19:37251912~37265535:+
BRCA	cis	rs11673344	0.523	rs8101392	ENSG00000226686.6	LINC01535	4.55	6.09e-06	0.000526	0.18	0.14	Obesity-related traits;	chr19:37024416	chr19:37251912~37265535:+
BRCA	cis	rs11673344	0.523	rs10406110	ENSG00000226686.6	LINC01535	4.55	6.09e-06	0.000526	0.18	0.14	Obesity-related traits;	chr19:37160027	chr19:37251912~37265535:+
BRCA	cis	rs2708977	0.698	rs772159	ENSG00000237510.6	AC008268.2	-4.55	6.09e-06	0.000526	-0.18	-0.14	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96370701	chr2:95789654~95800166:+
BRCA	cis	rs1153858	1	rs12591058	ENSG00000275672.1	GATM-AS1	-4.55	6.09e-06	0.000526	-0.18	-0.14	Homoarginine levels;	chr15:45347974	chr15:45378700~45380123:+
BRCA	cis	rs6714710	0.603	rs11690687	ENSG00000230606.9	AC159540.1	-4.55	6.1e-06	0.000526	-0.16	-0.14	Posterior cortical atrophy and Alzheimer's disease;	chr2:97845358	chr2:97416165~97433527:-
BRCA	cis	rs6840360	0.642	rs2709819	ENSG00000251611.1	RP11-610P16.1	-4.55	6.1e-06	0.000526	-0.12	-0.14	Intelligence (multi-trait analysis);	chr4:151462680	chr4:151407551~151408835:-
BRCA	cis	rs10129255	0.536	rs6576223	ENSG00000232216.1	IGHV3-43	4.55	6.1e-06	0.000526	0.1	0.14	Kawasaki disease;	chr14:106776448	chr14:106470264~106470800:-
BRCA	cis	rs7267979	0.932	rs433352	ENSG00000274414.1	RP5-965G21.4	4.55	6.1e-06	0.000526	0.16	0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25487356	chr20:25239007~25245229:-
BRCA	cis	rs2251381	0.75	rs8129616	ENSG00000176054.6	RPL23P2	-4.55	6.1e-06	0.000526	-0.16	-0.14	Selective IgA deficiency;	chr21:29147764	chr21:28997613~28998033:-
BRCA	cis	rs9818758	0.556	rs116432667	ENSG00000270441.1	RP11-694I15.7	4.55	6.11e-06	0.000527	0.29	0.14	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:48910156	chr3:49140086~49160851:-
BRCA	cis	rs9818758	0.607	rs13087930	ENSG00000270441.1	RP11-694I15.7	4.55	6.11e-06	0.000527	0.29	0.14	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:48924293	chr3:49140086~49160851:-
BRCA	cis	rs6840360	0.642	rs1470281	ENSG00000251611.1	RP11-610P16.1	-4.55	6.11e-06	0.000527	-0.12	-0.14	Intelligence (multi-trait analysis);	chr4:151510400	chr4:151407551~151408835:-
BRCA	cis	rs7918232	0.941	rs1755399	ENSG00000262412.1	RP11-85G18.6	4.55	6.11e-06	0.000527	0.24	0.14	Breast cancer;	chr10:27106029	chr10:27243130~27250804:+
BRCA	cis	rs7918232	0.941	rs1753415	ENSG00000262412.1	RP11-85G18.6	4.55	6.11e-06	0.000527	0.24	0.14	Breast cancer;	chr10:27106173	chr10:27243130~27250804:+
BRCA	cis	rs2574985	0.813	rs1203405	ENSG00000231345.3	BEND3P1	-4.55	6.11e-06	0.000527	-0.22	-0.14	Subjective well-being;	chr10:50438969	chr10:50655967~50660472:+
BRCA	cis	rs6603134	0.502	rs10406511	ENSG00000269139.2	CTD-3193O13.8	4.55	6.11e-06	0.000527	0.16	0.14	Blood protein levels;	chr19:8039061	chr19:7926001~7926810:+
BRCA	cis	rs1048886	0.872	rs9455160	ENSG00000271967.1	RP11-134K13.4	4.55	6.11e-06	0.000527	0.18	0.14	Type 2 diabetes;	chr6:70564116	chr6:70596438~70596980:+
BRCA	cis	rs11673344	0.542	rs2562585	ENSG00000226686.6	LINC01535	4.55	6.11e-06	0.000527	0.18	0.14	Obesity-related traits;	chr19:37018321	chr19:37251912~37265535:+
BRCA	cis	rs308403	0.533	rs12644866	ENSG00000224786.1	CETN4P	4.55	6.11e-06	0.000527	0.18	0.14	Blood protein levels;	chr4:122746449	chr4:122730548~122732193:-
BRCA	cis	rs4218	0.681	rs4531679	ENSG00000277144.1	RP11-59H7.4	-4.55	6.11e-06	0.000527	-0.18	-0.14	Social communication problems;	chr15:59083246	chr15:59115547~59116089:-
BRCA	cis	rs2579519	0.547	rs2463560	ENSG00000232931.4	LINC00342	4.55	6.12e-06	0.000527	0.14	0.14	Diastolic blood pressure;	chr2:95929841	chr2:95807118~95816215:-
BRCA	cis	rs6847067	0.8	rs12510410	ENSG00000180769.7	WDFY3-AS2	-4.55	6.12e-06	0.000528	-0.12	-0.14	Oropharynx cancer;	chr4:84945649	chr4:84965682~85011277:+
BRCA	cis	rs77204473	1	rs12292614	ENSG00000280143.1	AP000892.6	-4.55	6.12e-06	0.000528	-0.26	-0.14	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116877799	chr11:117204967~117210292:+
BRCA	cis	rs2039553	0.603	rs7327527	ENSG00000227354.5	RBM26-AS1	-4.55	6.12e-06	0.000528	-0.16	-0.14	Pancreatic cancer;	chr13:79786265	chr13:79406309~79424328:+
BRCA	cis	rs11098499	0.954	rs12502423	ENSG00000260091.1	RP11-33B1.4	-4.55	6.12e-06	0.000528	-0.13	-0.14	Corneal astigmatism;	chr4:119503017	chr4:119409333~119410233:+
BRCA	cis	rs7267979	0.816	rs422148	ENSG00000274973.1	RP13-401N8.7	-4.55	6.12e-06	0.000528	-0.16	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25531968	chr20:25845497~25845862:+
BRCA	cis	rs6968419	0.65	rs1881287	ENSG00000279086.1	RP11-667F14.1	-4.55	6.12e-06	0.000528	-0.15	-0.14	Intraocular pressure;	chr7:116226300	chr7:116209234~116211511:-
BRCA	cis	rs7923609	0.846	rs10761731	ENSG00000232075.1	MRPL35P2	-4.55	6.12e-06	0.000528	-0.18	-0.14	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63267850	chr10:63634317~63634827:-
BRCA	cis	rs7246967	0.604	rs8111899	ENSG00000198153.8	ZNF849P	-4.55	6.12e-06	0.000528	-0.24	-0.14	Bronchopulmonary dysplasia;	chr19:22716069	chr19:22685167~22686732:+
BRCA	cis	rs739496	0.579	rs80017658	ENSG00000226469.1	ADAM1B	4.55	6.12e-06	0.000528	0.18	0.14	Platelet count;	chr12:111942568	chr12:111927018~111929017:+
BRCA	cis	rs739496	0.579	rs73426362	ENSG00000226469.1	ADAM1B	4.55	6.12e-06	0.000528	0.18	0.14	Platelet count;	chr12:111942666	chr12:111927018~111929017:+
BRCA	cis	rs2235642	1	rs2235642	ENSG00000260989.1	LA16c-395F10.2	-4.55	6.13e-06	0.000528	-0.14	-0.14	Coronary artery disease;	chr16:1534865	chr16:1580527~1610328:+
BRCA	cis	rs7267979	0.714	rs6115107	ENSG00000274973.1	RP13-401N8.7	-4.55	6.13e-06	0.000528	-0.16	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25256754	chr20:25845497~25845862:+
BRCA	cis	rs2243480	1	rs2420171	ENSG00000275400.1	RP4-756H11.5	-4.55	6.13e-06	0.000528	-0.25	-0.14	Diabetic kidney disease;	chr7:66172773	chr7:66553805~66554199:-
BRCA	cis	rs2243480	1	rs316313	ENSG00000222364.1	RNU6-96P	-4.55	6.13e-06	0.000528	-0.26	-0.14	Diabetic kidney disease;	chr7:66128561	chr7:66395191~66395286:+
BRCA	cis	rs2243480	1	rs316312	ENSG00000222364.1	RNU6-96P	-4.55	6.13e-06	0.000528	-0.26	-0.14	Diabetic kidney disease;	chr7:66131504	chr7:66395191~66395286:+
BRCA	cis	rs2243480	1	rs419603	ENSG00000222364.1	RNU6-96P	-4.55	6.13e-06	0.000528	-0.26	-0.14	Diabetic kidney disease;	chr7:66132354	chr7:66395191~66395286:+
BRCA	cis	rs10829156	0.66	rs10764587	ENSG00000225527.1	RP11-383B4.4	-4.55	6.13e-06	0.000528	-0.19	-0.14	Sudden cardiac arrest;	chr10:18548901	chr10:18531849~18533336:-
BRCA	cis	rs7267979	1	rs2424710	ENSG00000125804.12	FAM182A	-4.55	6.13e-06	0.000528	-0.18	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25303250	chr20:26054655~26086917:+
BRCA	cis	rs10129255	0.5	rs8011115	ENSG00000211959.2	IGHV4-39	4.55	6.13e-06	0.000529	0.09	0.14	Kawasaki disease;	chr14:106786292	chr14:106421711~106422218:-
BRCA	cis	rs10861342	0.892	rs74971338	ENSG00000257999.1	RP11-61E11.2	-4.55	6.13e-06	0.000529	-0.29	-0.14	IgG glycosylation;	chr12:105105979	chr12:105102472~105107179:-
BRCA	cis	rs7923609	0.756	rs7080386	ENSG00000232075.1	MRPL35P2	-4.55	6.14e-06	0.000529	-0.18	-0.14	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63288546	chr10:63634317~63634827:-
BRCA	cis	rs7302981	0.746	rs646782	ENSG00000272368.2	RP4-605O3.4	4.55	6.14e-06	0.000529	0.14	0.14	Systolic blood pressure;	chr12:50088428	chr12:50112197~50165618:+
BRCA	cis	rs10844706	0.699	rs10844635	ENSG00000214776.8	RP11-726G1.1	4.54	6.14e-06	0.000529	0.17	0.14	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9735313	chr12:9467552~9576275:+
BRCA	cis	rs10844706	0.699	rs10844637	ENSG00000214776.8	RP11-726G1.1	4.54	6.14e-06	0.000529	0.17	0.14	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9735495	chr12:9467552~9576275:+
BRCA	cis	rs10844706	0.699	rs10844638	ENSG00000214776.8	RP11-726G1.1	4.54	6.14e-06	0.000529	0.17	0.14	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9735800	chr12:9467552~9576275:+
BRCA	cis	rs2303319	0.504	rs1515184	ENSG00000227403.1	AC009299.3	4.54	6.14e-06	0.000529	0.33	0.14	Cognitive function;	chr2:161704837	chr2:161244739~161249050:+
BRCA	cis	rs2303319	0.504	rs16846047	ENSG00000227403.1	AC009299.3	4.54	6.14e-06	0.000529	0.33	0.14	Cognitive function;	chr2:161705436	chr2:161244739~161249050:+
BRCA	cis	rs2303319	0.504	rs62189005	ENSG00000227403.1	AC009299.3	4.54	6.14e-06	0.000529	0.33	0.14	Cognitive function;	chr2:161705876	chr2:161244739~161249050:+
BRCA	cis	rs35612822	0.754	rs13405529	ENSG00000232485.2	AC098820.3	-4.54	6.14e-06	0.000529	-0.16	-0.14	Kidney disease (early stage) in type 1 diabetes;	chr2:216399947	chr2:216479030~216498761:-
BRCA	cis	rs60843830	1	rs7595075	ENSG00000272342.1	RP13-539J13.1	4.54	6.14e-06	0.000529	0.17	0.14	Spherical equivalent (joint analysis main effects and education interaction);	chr2:264019	chr2:739588~740164:-
BRCA	cis	rs6570726	0.689	rs411785	ENSG00000270638.1	RP3-466P17.1	4.54	6.14e-06	0.000529	0.16	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145567262	chr6:145735570~145737218:+
BRCA	cis	rs2692947	0.695	rs12464148	ENSG00000232931.4	LINC00342	4.54	6.14e-06	0.000529	0.14	0.14	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95930962	chr2:95807118~95816215:-
BRCA	cis	rs2288912	0.808	rs35670684	ENSG00000280087.1	CTB-129P6.7	4.54	6.14e-06	0.00053	0.16	0.14	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr19:44952728	chr19:44909375~44914968:+
BRCA	cis	rs11098499	0.754	rs10518300	ENSG00000260404.2	RP11-384K6.6	-4.54	6.15e-06	0.00053	-0.13	-0.14	Corneal astigmatism;	chr4:119328344	chr4:118591773~118633729:+
BRCA	cis	rs442309	0.846	rs224130	ENSG00000238280.1	RP11-436D10.3	-4.54	6.15e-06	0.00053	-0.19	-0.14	Vogt-Koyanagi-Harada syndrome;	chr10:62705211	chr10:62793562~62805887:-
BRCA	cis	rs442309	0.846	rs224131	ENSG00000238280.1	RP11-436D10.3	-4.54	6.15e-06	0.00053	-0.19	-0.14	Vogt-Koyanagi-Harada syndrome;	chr10:62705334	chr10:62793562~62805887:-
BRCA	cis	rs2243480	1	rs78803505	ENSG00000275400.1	RP4-756H11.5	4.54	6.15e-06	0.00053	0.25	0.14	Diabetic kidney disease;	chr7:65917585	chr7:66553805~66554199:-
BRCA	cis	rs2243480	1	rs34577383	ENSG00000275400.1	RP4-756H11.5	4.54	6.15e-06	0.00053	0.25	0.14	Diabetic kidney disease;	chr7:65920739	chr7:66553805~66554199:-
BRCA	cis	rs2243480	1	rs55895244	ENSG00000275400.1	RP4-756H11.5	4.54	6.15e-06	0.00053	0.25	0.14	Diabetic kidney disease;	chr7:65922691	chr7:66553805~66554199:-
BRCA	cis	rs2243480	1	rs7795242	ENSG00000275400.1	RP4-756H11.5	4.54	6.15e-06	0.00053	0.25	0.14	Diabetic kidney disease;	chr7:65925107	chr7:66553805~66554199:-
BRCA	cis	rs2243480	1	rs2177703	ENSG00000275400.1	RP4-756H11.5	4.54	6.15e-06	0.00053	0.25	0.14	Diabetic kidney disease;	chr7:65926730	chr7:66553805~66554199:-
BRCA	cis	rs2243480	1	rs56985706	ENSG00000275400.1	RP4-756H11.5	4.54	6.15e-06	0.00053	0.25	0.14	Diabetic kidney disease;	chr7:65929575	chr7:66553805~66554199:-
BRCA	cis	rs2243480	1	rs60683927	ENSG00000275400.1	RP4-756H11.5	4.54	6.15e-06	0.00053	0.25	0.14	Diabetic kidney disease;	chr7:65929781	chr7:66553805~66554199:-
BRCA	cis	rs2243480	1	rs58062456	ENSG00000275400.1	RP4-756H11.5	4.54	6.15e-06	0.00053	0.25	0.14	Diabetic kidney disease;	chr7:65929865	chr7:66553805~66554199:-
BRCA	cis	rs651907	0.557	rs56291106	ENSG00000256628.3	ZBTB11-AS1	4.54	6.15e-06	0.00053	0.18	0.14	Colorectal cancer;	chr3:101658630	chr3:101676475~101679217:+
BRCA	cis	rs6968419	0.755	rs3823977	ENSG00000279086.1	RP11-667F14.1	-4.54	6.15e-06	0.00053	-0.15	-0.14	Intraocular pressure;	chr7:116253353	chr7:116209234~116211511:-
BRCA	cis	rs1950832	0.627	rs118064958	ENSG00000258636.1	CTD-2298J14.2	-4.54	6.15e-06	0.00053	-0.16	-0.14	Urate levels in obese individuals;	chr14:41659634	chr14:41587861~41604856:-
BRCA	cis	rs2243480	1	rs13310597	ENSG00000222364.1	RNU6-96P	-4.54	6.15e-06	0.00053	-0.26	-0.14	Diabetic kidney disease;	chr7:66133553	chr7:66395191~66395286:+
BRCA	cis	rs9467773	0.534	rs34453863	ENSG00000241549.7	GUSBP2	4.54	6.16e-06	0.00053	0.16	0.14	Intelligence (multi-trait analysis);	chr6:26627777	chr6:26871484~26956554:-
BRCA	cis	rs11157436	0.918	rs7159024	ENSG00000211813.2	TRAV34	4.54	6.16e-06	0.00053	0.15	0.14	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22228760	chr14:22207522~22208129:+
BRCA	cis	rs1665050	0.545	rs59540276	ENSG00000277144.1	RP11-59H7.4	-4.54	6.16e-06	0.00053	-0.17	-0.14	Atopic dermatitis;	chr15:59037559	chr15:59115547~59116089:-
BRCA	cis	rs1077773	0.782	rs7777586	ENSG00000237773.4	AC003075.4	4.54	6.16e-06	0.000531	0.17	0.14	Ulcerative colitis;Inflammatory bowel disease;	chr7:17390380	chr7:17279834~17299357:-
BRCA	cis	rs2274273	0.87	rs8013713	ENSG00000259318.1	RP11-454L9.2	-4.54	6.16e-06	0.000531	-0.12	-0.14	Protein biomarker;	chr14:55374534	chr14:55394940~55395233:-
BRCA	cis	rs10861342	1	rs10861337	ENSG00000257999.1	RP11-61E11.2	-4.54	6.16e-06	0.000531	-0.31	-0.14	IgG glycosylation;	chr12:105058664	chr12:105102472~105107179:-
BRCA	cis	rs11758351	0.66	rs1997768	ENSG00000241549.7	GUSBP2	4.54	6.16e-06	0.000531	0.2	0.14	Renal underexcretion gout;Gout;	chr6:26217500	chr6:26871484~26956554:-
BRCA	cis	rs10129255	0.5	rs6576225	ENSG00000232216.1	IGHV3-43	4.54	6.16e-06	0.000531	0.1	0.14	Kawasaki disease;	chr14:106778120	chr14:106470264~106470800:-
BRCA	cis	rs10129255	0.5	rs6576226	ENSG00000232216.1	IGHV3-43	4.54	6.16e-06	0.000531	0.1	0.14	Kawasaki disease;	chr14:106778135	chr14:106470264~106470800:-
BRCA	cis	rs1005277	0.579	rs9418322	ENSG00000099251.13	HSD17B7P2	4.54	6.16e-06	0.000531	0.15	0.14	Extrinsic epigenetic age acceleration;	chr10:38088368	chr10:38356380~38378505:+
BRCA	cis	rs490234	0.683	rs9409281	ENSG00000232630.1	PRPS1P2	-4.54	6.16e-06	0.000531	-0.14	-0.14	Mean arterial pressure;	chr9:125396892	chr9:125150653~125151589:+
BRCA	cis	rs7818688	0.697	rs11781397	ENSG00000253528.2	RP11-347C18.4	-4.54	6.16e-06	0.000531	-0.22	-0.14	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94962278	chr8:94974573~94974853:-
BRCA	cis	rs10504130	1	rs10504130	ENSG00000272024.1	RP11-546K22.3	-4.54	6.16e-06	0.000531	-0.23	-0.14	Venous thromboembolism (SNP x SNP interaction);	chr8:51844533	chr8:51950284~51950690:+
BRCA	cis	rs2073316	0.626	rs72794610	ENSG00000272716.1	RP11-563N4.1	4.54	6.16e-06	0.000531	0.15	0.14	Interleukin-18 levels;	chr2:31471692	chr2:32165046~32165757:-
BRCA	cis	rs2273156	1	rs35106382	ENSG00000226677.3	IGBP1P1	-4.54	6.17e-06	0.000531	-0.21	-0.14	Immunoglobulin light chain (AL) amyloidosis;	chr14:34965085	chr14:34939324~34940332:+
BRCA	cis	rs721917	0.506	rs2819102	ENSG00000278616.1	BEND3P3	-4.54	6.17e-06	0.000531	-0.13	-0.14	Chronic obstructive pulmonary disease;	chr10:79928914	chr10:79682997~79685436:+
BRCA	cis	rs2255336	0.938	rs1382264	ENSG00000245648.1	RP11-277P12.20	-4.54	6.17e-06	0.000532	-0.21	-0.14	Blood protein levels;	chr12:10390740	chr12:10363769~10398506:+
BRCA	cis	rs6545883	0.894	rs2600672	ENSG00000270820.4	RP11-355B11.2	4.54	6.17e-06	0.000532	0.16	0.14	Tuberculosis;	chr2:61309605	chr2:61471188~61484130:+
BRCA	cis	rs13326165	0.616	rs82825	ENSG00000243224.1	RP5-1157M23.2	4.54	6.17e-06	0.000532	0.19	0.14	HDL cholesterol levels;HDL cholesterol;	chr3:52437926	chr3:52239258~52241097:+
BRCA	cis	rs9925964	0.967	rs1978487	ENSG00000262766.1	RP11-196G11.4	4.54	6.17e-06	0.000532	0.12	0.14	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31118621	chr16:31118078~31118747:+
BRCA	cis	rs9818758	0.556	rs9880309	ENSG00000270441.1	RP11-694I15.7	4.54	6.17e-06	0.000532	0.27	0.14	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49266896	chr3:49140086~49160851:-
BRCA	cis	rs6802315	0.573	rs7635993	ENSG00000272087.1	RP11-379F4.7	4.54	6.17e-06	0.000532	0.17	0.14	Periodontitis (CDC/AAP);	chr3:158742187	chr3:158693120~158693768:-
BRCA	cis	rs465969	1	rs4509157	ENSG00000230177.1	RP5-1112D6.4	4.54	6.17e-06	0.000532	0.28	0.14	Psoriasis;	chr6:111513875	chr6:111277932~111278742:+
BRCA	cis	rs10829156	0.773	rs7909552	ENSG00000240291.1	RP11-499P20.2	4.54	6.17e-06	0.000532	0.16	0.14	Sudden cardiac arrest;	chr10:18620407	chr10:18513115~18545651:-
BRCA	cis	rs6832769	0.857	rs61072181	ENSG00000223305.1	RN7SKP30	-4.54	6.18e-06	0.000532	-0.18	-0.14	Personality dimensions;	chr4:55617210	chr4:55540502~55540835:-
BRCA	cis	rs67340775	0.541	rs200968	ENSG00000216901.1	AL022393.7	4.54	6.18e-06	0.000532	0.23	0.14	Lung cancer in ever smokers;	chr6:27891790	chr6:28176188~28176674:+
BRCA	cis	rs4388249	0.687	rs2301016	ENSG00000271849.1	CTC-332L22.1	-4.54	6.18e-06	0.000532	-0.19	-0.14	Schizophrenia;	chr5:109807901	chr5:109687802~109688329:-
BRCA	cis	rs4388249	0.687	rs11745926	ENSG00000271849.1	CTC-332L22.1	-4.54	6.18e-06	0.000532	-0.19	-0.14	Schizophrenia;	chr5:109809489	chr5:109687802~109688329:-
BRCA	cis	rs9545047	0.604	rs2057573	ENSG00000227354.5	RBM26-AS1	-4.54	6.18e-06	0.000532	-0.15	-0.14	Schizophrenia;	chr13:79357736	chr13:79406309~79424328:+
BRCA	cis	rs7833986	0.501	rs72653978	ENSG00000253603.1	CTA-397H3.3	-4.54	6.18e-06	0.000532	-0.2	-0.14	Height;	chr8:56105834	chr8:56074592~56075274:+
BRCA	cis	rs4494364	0.536	rs12306136	ENSG00000258100.1	RP11-121E16.1	-4.54	6.18e-06	0.000532	-0.21	-0.14	Systolic blood pressure (alcohol consumption interaction);	chr12:91068123	chr12:91362196~91368606:+
BRCA	cis	rs875971	0.545	rs313828	ENSG00000232546.1	RP11-458F8.1	-4.54	6.18e-06	0.000532	-0.13	-0.14	Aortic root size;	chr7:66087627	chr7:66848496~66858136:+
BRCA	cis	rs6088590	0.561	rs764597	ENSG00000276073.1	RP5-1125A11.7	-4.54	6.18e-06	0.000532	-0.15	-0.14	Coronary artery disease;	chr20:34573421	chr20:33985617~33988989:-
BRCA	cis	rs2303319	0.504	rs12470743	ENSG00000227403.1	AC009299.3	4.54	6.18e-06	0.000532	0.33	0.14	Cognitive function;	chr2:161754692	chr2:161244739~161249050:+
BRCA	cis	rs867371	0.502	rs8025964	ENSG00000276710.3	CSPG4P8	-4.54	6.18e-06	0.000532	-0.14	-0.14	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82229429	chr15:82459472~82477258:+
BRCA	cis	rs13113518	0.783	rs11943206	ENSG00000272969.1	RP11-528I4.2	4.54	6.18e-06	0.000533	0.16	0.14	Height;	chr4:55570843	chr4:55547112~55547889:+
BRCA	cis	rs7665090	0.875	rs6813687	ENSG00000251288.2	RP11-10L12.2	-4.54	6.18e-06	0.000533	-0.16	-0.14	Primary biliary cholangitis;	chr4:102634455	chr4:102751401~102752641:+
BRCA	cis	rs2408955	0.522	rs2051851	ENSG00000257763.1	OR5BK1P	-4.54	6.19e-06	0.000533	-0.15	-0.14	Glycated hemoglobin levels;	chr12:48092157	chr12:48355792~48356614:-
BRCA	cis	rs924712	0.586	rs6908745	ENSG00000261116.1	RP3-523K23.2	4.54	6.19e-06	0.000533	0.17	0.14	Breast cancer;	chr6:54852409	chr6:54943167~54945099:+
BRCA	cis	rs924712	0.604	rs12194667	ENSG00000261116.1	RP3-523K23.2	4.54	6.19e-06	0.000533	0.17	0.14	Breast cancer;	chr6:54853795	chr6:54943167~54945099:+
BRCA	cis	rs180730	0.847	rs1450459	ENSG00000251609.2	SETP12	4.54	6.19e-06	0.000533	0.21	0.14	Fasting plasma glucose;	chr4:120925312	chr4:120895494~120897083:-
BRCA	cis	rs7818688	0.697	rs35032356	ENSG00000253528.2	RP11-347C18.4	-4.54	6.19e-06	0.000533	-0.21	-0.14	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94965256	chr8:94974573~94974853:-
BRCA	cis	rs736408	0.522	rs11130310	ENSG00000243224.1	RP5-1157M23.2	-4.54	6.19e-06	0.000533	-0.15	-0.14	Bipolar disorder;	chr3:52640651	chr3:52239258~52241097:+
BRCA	cis	rs721917	0.506	rs2819113	ENSG00000242600.5	MBL1P	4.54	6.19e-06	0.000533	0.17	0.14	Chronic obstructive pulmonary disease;	chr10:79890987	chr10:79904898~79950336:+
BRCA	cis	rs6840360	0.539	rs1443087	ENSG00000251611.1	RP11-610P16.1	-4.54	6.19e-06	0.000533	-0.12	-0.14	Intelligence (multi-trait analysis);	chr4:151528943	chr4:151407551~151408835:-
BRCA	cis	rs6840360	0.642	rs1443088	ENSG00000251611.1	RP11-610P16.1	-4.54	6.19e-06	0.000533	-0.12	-0.14	Intelligence (multi-trait analysis);	chr4:151528974	chr4:151407551~151408835:-
BRCA	cis	rs7267979	0.932	rs2260997	ENSG00000276952.1	RP5-965G21.6	-4.54	6.19e-06	0.000533	-0.17	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25275630	chr20:25284915~25285588:-
BRCA	cis	rs7829975	0.626	rs907183	ENSG00000254153.1	CTA-398F10.2	-4.54	6.2e-06	0.000533	-0.17	-0.14	Mood instability;	chr8:8872251	chr8:8456909~8461337:-
BRCA	cis	rs853679	1	rs1936365	ENSG00000216901.1	AL022393.7	-4.54	6.2e-06	0.000533	-0.23	-0.14	Depression;	chr6:28300675	chr6:28176188~28176674:+
BRCA	cis	rs6430585	0.528	rs309172	ENSG00000224043.6	CCNT2-AS1	-4.54	6.2e-06	0.000534	-0.23	-0.14	Corneal structure;	chr2:135916458	chr2:134735464~134918710:-
BRCA	cis	rs2115630	1	rs11854313	ENSG00000259728.4	LINC00933	-4.54	6.2e-06	0.000534	-0.15	-0.14	P wave terminal force;	chr15:84760817	chr15:84570649~84580175:+
BRCA	cis	rs6128907	1	rs6128906	ENSG00000224635.1	RP4-564F22.5	4.54	6.2e-06	0.000534	0.22	0.14	Liver fibrosis in pediatric non-alcoholic fatty acid liver disease;	chr20:38758939	chr20:38406011~38416797:-
BRCA	cis	rs9834975	0.967	rs9823467	ENSG00000272758.4	RP11-299J3.8	-4.54	6.2e-06	0.000534	-0.14	-0.14	Diastolic blood pressure;	chr3:122403245	chr3:122416207~122443180:+
BRCA	cis	rs7267979	1	rs1888997	ENSG00000125804.12	FAM182A	4.54	6.2e-06	0.000534	0.18	0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25318352	chr20:26054655~26086917:+
BRCA	cis	rs539096	0.715	rs6665014	ENSG00000237950.1	RP11-7O11.3	-4.54	6.21e-06	0.000534	-0.19	-0.14	Intelligence (multi-trait analysis);	chr1:43760333	chr1:43944370~43946551:-
BRCA	cis	rs1722141	0.6	rs788738	ENSG00000229628.1	AC073115.7	4.54	6.21e-06	0.000534	0.19	0.14	Sitting height ratio;	chr7:46001766	chr7:45990905~46000898:+
BRCA	cis	rs11098499	0.535	rs7671759	ENSG00000225892.3	RP11-384K6.2	4.54	6.21e-06	0.000534	0.14	0.14	Corneal astigmatism;	chr4:119326939	chr4:118632274~118634759:+
BRCA	cis	rs1043099	0.912	rs737950	ENSG00000279699.1	RP1-102K2.9	-4.54	6.21e-06	0.000535	-0.22	-0.14	Rheumatoid arthritis;	chr22:30361306	chr22:30275215~30276951:-
BRCA	cis	rs4415084	0.716	rs7703497	ENSG00000251141.4	RP11-53O19.1	4.54	6.21e-06	0.000535	0.13	0.14	Breast cancer;	chr5:44856926	chr5:44744900~44808777:-
BRCA	cis	rs12744310	0.887	rs1892420	ENSG00000235358.1	RP11-399E6.1	4.54	6.21e-06	0.000535	0.21	0.14	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41315738	chr1:41242373~41284861:+
BRCA	cis	rs12744310	0.887	rs12724625	ENSG00000235358.1	RP11-399E6.1	4.54	6.21e-06	0.000535	0.21	0.14	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41316598	chr1:41242373~41284861:+
BRCA	cis	rs35306767	0.904	rs10904584	ENSG00000229869.1	RP11-363N22.2	-4.54	6.21e-06	0.000535	-0.2	-0.14	Eosinophil percentage of granulocytes;	chr10:937807	chr10:933026~942743:+
BRCA	cis	rs4664293	0.836	rs2556102	ENSG00000224152.1	AC009506.1	-4.54	6.21e-06	0.000535	-0.16	-0.14	Monocyte percentage of white cells;	chr2:159798611	chr2:159615296~159617082:+
BRCA	cis	rs919433	0.617	rs700645	ENSG00000231621.1	AC013264.2	-4.54	6.21e-06	0.000535	-0.14	-0.14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197740790	chr2:197197991~197199273:+
BRCA	cis	rs9652601	0.691	rs3893661	ENSG00000274038.1	RP11-66H6.4	-4.54	6.21e-06	0.000535	-0.15	-0.14	Systemic lupus erythematosus;	chr16:11100023	chr16:11056556~11057034:+
BRCA	cis	rs1707322	1	rs4660335	ENSG00000234329.1	RP11-767N6.2	4.54	6.22e-06	0.000535	0.15	0.14	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46009046	chr1:45651039~45651826:-
BRCA	cis	rs9467773	0.595	rs2451736	ENSG00000241549.7	GUSBP2	4.54	6.22e-06	0.000535	0.15	0.14	Intelligence (multi-trait analysis);	chr6:26620316	chr6:26871484~26956554:-
BRCA	cis	rs5751614	0.537	rs9608100	ENSG00000240160.3	RN7SL263P	4.54	6.22e-06	0.000535	0.18	0.14	Height;	chr22:23290070	chr22:23261782~23262071:-
BRCA	cis	rs2408955	0.561	rs9971924	ENSG00000257763.1	OR5BK1P	-4.54	6.22e-06	0.000535	-0.15	-0.14	Glycated hemoglobin levels;	chr12:48086049	chr12:48355792~48356614:-
BRCA	cis	rs172166	0.694	rs9295760	ENSG00000219392.1	RP1-265C24.5	-4.54	6.22e-06	0.000535	-0.19	-0.14	Cardiac Troponin-T levels;	chr6:28179607	chr6:28115628~28116551:+
BRCA	cis	rs6599077	1	rs9842262	ENSG00000223797.4	ENTPD3-AS1	4.54	6.22e-06	0.000535	0.17	0.14	Sleep-related phenotypes;	chr3:40054184	chr3:40313802~40453329:-
BRCA	cis	rs6599077	1	rs7637811	ENSG00000223797.4	ENTPD3-AS1	4.54	6.22e-06	0.000535	0.17	0.14	Sleep-related phenotypes;	chr3:40054921	chr3:40313802~40453329:-
BRCA	cis	rs6599077	1	rs6599077	ENSG00000223797.4	ENTPD3-AS1	4.54	6.22e-06	0.000535	0.17	0.14	Sleep-related phenotypes;	chr3:40055127	chr3:40313802~40453329:-
BRCA	cis	rs6599077	1	rs6599078	ENSG00000223797.4	ENTPD3-AS1	4.54	6.22e-06	0.000535	0.17	0.14	Sleep-related phenotypes;	chr3:40055180	chr3:40313802~40453329:-
BRCA	cis	rs6599077	1	rs6808392	ENSG00000223797.4	ENTPD3-AS1	4.54	6.22e-06	0.000535	0.17	0.14	Sleep-related phenotypes;	chr3:40055259	chr3:40313802~40453329:-
BRCA	cis	rs7267979	0.966	rs2500433	ENSG00000125804.12	FAM182A	4.54	6.22e-06	0.000535	0.19	0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25315699	chr20:26054655~26086917:+
BRCA	cis	rs7267979	0.966	rs2482948	ENSG00000125804.12	FAM182A	4.54	6.22e-06	0.000535	0.19	0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25315863	chr20:26054655~26086917:+
BRCA	cis	rs13108904	0.935	rs1680072	ENSG00000196810.4	CTBP1-AS2	-4.54	6.22e-06	0.000535	-0.15	-0.14	Obesity-related traits;	chr4:1287907	chr4:1249300~1288291:+
BRCA	cis	rs11673344	0.523	rs7246739	ENSG00000226686.6	LINC01535	4.54	6.22e-06	0.000536	0.18	0.14	Obesity-related traits;	chr19:37040829	chr19:37251912~37265535:+
BRCA	cis	rs2136613	0.728	rs10761664	ENSG00000238280.1	RP11-436D10.3	4.54	6.22e-06	0.000536	0.18	0.14	Selective IgA deficiency;	chr10:62847301	chr10:62793562~62805887:-
BRCA	cis	rs73193808	0.901	rs8128235	ENSG00000236056.1	GAPDHP14	-4.54	6.22e-06	0.000536	-0.19	-0.14	Coronary artery disease;	chr21:29193197	chr21:29222321~29223257:+
BRCA	cis	rs75804782	0.625	rs11889723	ENSG00000186235.9	AC016757.3	4.54	6.22e-06	0.000536	0.24	0.14	Chronotype;Morning vs. evening chronotype;	chr2:238562828	chr2:238224552~238231677:-
BRCA	cis	rs16958440	0.867	rs77149690	ENSG00000267724.1	RP11-49K24.8	4.54	6.22e-06	0.000536	0.28	0.14	Sitting height ratio;	chr18:47170772	chr18:47105946~47108062:+
BRCA	cis	rs16958440	0.867	rs79285649	ENSG00000267724.1	RP11-49K24.8	4.54	6.22e-06	0.000536	0.28	0.14	Sitting height ratio;	chr18:47172648	chr18:47105946~47108062:+
BRCA	cis	rs16958440	0.867	rs57744138	ENSG00000267724.1	RP11-49K24.8	4.54	6.22e-06	0.000536	0.28	0.14	Sitting height ratio;	chr18:47174111	chr18:47105946~47108062:+
BRCA	cis	rs16958440	0.867	rs16949275	ENSG00000267724.1	RP11-49K24.8	4.54	6.22e-06	0.000536	0.28	0.14	Sitting height ratio;	chr18:47174332	chr18:47105946~47108062:+
BRCA	cis	rs1722141	0.669	rs788735	ENSG00000229628.1	AC073115.7	4.54	6.23e-06	0.000536	0.19	0.14	Sitting height ratio;	chr7:45990801	chr7:45990905~46000898:+
BRCA	cis	rs875971	0.66	rs801211	ENSG00000273142.1	RP11-458F8.4	4.54	6.23e-06	0.000536	0.12	0.14	Aortic root size;	chr7:66550702	chr7:66902857~66906297:+
BRCA	cis	rs875971	0.638	rs801205	ENSG00000273142.1	RP11-458F8.4	4.54	6.23e-06	0.000536	0.12	0.14	Aortic root size;	chr7:66557157	chr7:66902857~66906297:+
BRCA	cis	rs875971	0.617	rs810400	ENSG00000273142.1	RP11-458F8.4	4.54	6.23e-06	0.000536	0.12	0.14	Aortic root size;	chr7:66557902	chr7:66902857~66906297:+
BRCA	cis	rs1371614	0.635	rs9309558	ENSG00000272148.1	RP11-195B17.1	-4.54	6.23e-06	0.000536	-0.15	-0.14	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26918636	chr2:27062428~27062907:-
BRCA	cis	rs1707322	0.638	rs1416706	ENSG00000281133.1	AL355480.3	4.54	6.23e-06	0.000536	0.18	0.14	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46137172	chr1:45580892~45580996:-
BRCA	cis	rs10129255	0.785	rs10150044	ENSG00000280411.1	IGHV1-69-2	-4.54	6.23e-06	0.000536	-0.1	-0.14	Kawasaki disease;	chr14:106775695	chr14:106762092~106762588:-
BRCA	cis	rs875971	1	rs2420168	ENSG00000236529.1	RP13-254B10.1	-4.54	6.23e-06	0.000536	-0.15	-0.14	Aortic root size;	chr7:66165644	chr7:65840212~65840596:+
BRCA	cis	rs807029	0.533	rs722435	ENSG00000236662.1	RP11-108L7.4	4.54	6.23e-06	0.000536	0.18	0.14	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100985305	chr10:100980507~100985614:-
BRCA	cis	rs7615952	0.932	rs11922218	ENSG00000248787.1	RP11-666A20.4	-4.54	6.23e-06	0.000536	-0.23	-0.14	Blood pressure (smoking interaction);	chr3:125912446	chr3:125908005~125910272:-
BRCA	cis	rs7615952	0.866	rs11922276	ENSG00000248787.1	RP11-666A20.4	-4.54	6.23e-06	0.000536	-0.23	-0.14	Blood pressure (smoking interaction);	chr3:125912483	chr3:125908005~125910272:-
BRCA	cis	rs4143844	1	rs34173668	ENSG00000259251.2	RP11-643M14.1	4.54	6.24e-06	0.000537	0.34	0.14	Bipolar disorder and schizophrenia;	chr15:62013385	chr15:62060503~62062434:+
BRCA	cis	rs2562456	0.833	rs4334427	ENSG00000268658.4	LINC00664	4.54	6.24e-06	0.000537	0.23	0.14	Pain;	chr19:21338090	chr19:21483374~21503238:+
BRCA	cis	rs5742933	0.857	rs2289226	ENSG00000253559.1	OSGEPL1-AS1	-4.54	6.24e-06	0.000537	-0.17	-0.14	Ferritin levels;	chr2:189661479	chr2:189762704~189765556:+
BRCA	cis	rs4664293	0.867	rs2357532	ENSG00000226266.5	AC009961.3	-4.54	6.24e-06	0.000537	-0.17	-0.14	Monocyte percentage of white cells;	chr2:159740916	chr2:159670708~159712435:-
BRCA	cis	rs2018683	1	rs4719963	ENSG00000228421.2	AC005013.5	-4.54	6.24e-06	0.000537	-0.17	-0.14	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28971448	chr7:28957667~28959345:+
BRCA	cis	rs10131894	0.611	rs175001	ENSG00000279594.1	RP11-950C14.10	4.54	6.24e-06	0.000537	0.15	0.14	Coronary artery disease;	chr14:74969749	chr14:75011269~75012851:-
BRCA	cis	rs17818399	0.926	rs1824050	ENSG00000279254.1	RP11-536C12.1	-4.54	6.24e-06	0.000537	-0.19	-0.14	Height;	chr2:46612338	chr2:46668870~46670778:+
BRCA	cis	rs17818399	0.926	rs1378764	ENSG00000279254.1	RP11-536C12.1	-4.54	6.24e-06	0.000537	-0.19	-0.14	Height;	chr2:46612542	chr2:46668870~46670778:+
BRCA	cis	rs3812049	0.826	rs17764730	ENSG00000245937.6	LINC01184	4.54	6.24e-06	0.000537	0.19	0.14	Lymphocyte counts;Red cell distribution width;	chr5:128021834	chr5:127940426~128083172:-
BRCA	cis	rs8017423	0.607	rs10142482	ENSG00000275198.1	RP11-471B22.3	4.54	6.24e-06	0.000537	0.16	0.14	Mortality in heart failure;	chr14:90381936	chr14:90383365~90387973:+
BRCA	cis	rs3764021	1	rs7977720	ENSG00000278635.1	CTD-2318O12.1	-4.54	6.24e-06	0.000537	-0.14	-0.14	Type 1 diabetes;	chr12:9713753	chr12:9415641~9416718:+
BRCA	cis	rs6801605	0.743	rs4687751	ENSG00000271916.1	RP11-884K10.6	-4.54	6.24e-06	0.000537	-0.12	-0.14	Blood protein levels;	chr3:53849883	chr3:53797764~53798019:-
BRCA	cis	rs10419113	0.668	rs10403851	ENSG00000268545.1	VN1R107P	-4.54	6.25e-06	0.000537	-0.16	-0.14	Pediatric bone mineral density (spine);	chr19:57667866	chr19:57459912~57460120:+
BRCA	cis	rs9903692	0.954	rs9899461	ENSG00000263412.1	RP5-890E16.2	4.54	6.25e-06	0.000537	0.15	0.14	Pulse pressure;	chr17:48051991	chr17:48045141~48048073:-
BRCA	cis	rs1832007	0.554	rs7101071	ENSG00000224034.1	RP11-445P17.8	-4.54	6.25e-06	0.000537	-0.22	-0.14	Triglyceride levels;Triglycerides;	chr10:5200674	chr10:5266033~5271236:-
BRCA	cis	rs13108904	0.901	rs12642410	ENSG00000253399.1	AC078852.2	-4.54	6.25e-06	0.000537	-0.16	-0.14	Obesity-related traits;	chr4:1314621	chr4:1358479~1359461:+
BRCA	cis	rs9921338	0.961	rs7187870	ENSG00000262703.1	RP11-485G7.6	-4.54	6.25e-06	0.000538	-0.18	-0.14	Vein graft stenosis in coronary artery bypass grafting;	chr16:11338062	chr16:11348143~11349321:-
BRCA	cis	rs875971	0.66	rs13224319	ENSG00000273142.1	RP11-458F8.4	-4.54	6.25e-06	0.000538	-0.12	-0.14	Aortic root size;	chr7:66542376	chr7:66902857~66906297:+
BRCA	cis	rs875971	0.66	rs801217	ENSG00000273142.1	RP11-458F8.4	4.54	6.25e-06	0.000538	0.12	0.14	Aortic root size;	chr7:66545590	chr7:66902857~66906297:+
BRCA	cis	rs875971	0.638	rs801216	ENSG00000273142.1	RP11-458F8.4	4.54	6.25e-06	0.000538	0.12	0.14	Aortic root size;	chr7:66546680	chr7:66902857~66906297:+
BRCA	cis	rs643177	0.722	rs674451	ENSG00000226004.1	RP11-10J5.1	-4.54	6.25e-06	0.000538	-0.12	-0.14	Psoriasis;Inflammatory skin disease;	chr6:137895651	chr6:137943079~137945802:-
BRCA	cis	rs6121246	0.697	rs6088864	ENSG00000230613.1	HM13-AS1	4.54	6.26e-06	0.000538	0.21	0.14	Mean corpuscular hemoglobin;	chr20:31640354	chr20:31567707~31573263:-
BRCA	cis	rs7267979	0.74	rs2259961	ENSG00000125804.12	FAM182A	-4.54	6.26e-06	0.000538	-0.18	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25301990	chr20:26054655~26086917:+
BRCA	cis	rs7665090	0.875	rs6813322	ENSG00000251288.2	RP11-10L12.2	-4.54	6.26e-06	0.000538	-0.16	-0.14	Primary biliary cholangitis;	chr4:102634462	chr4:102751401~102752641:+
BRCA	cis	rs644148	0.902	rs12982159	ENSG00000176761.7	ZNF285B	4.54	6.26e-06	0.000538	0.16	0.14	Personality dimensions;	chr19:44460081	chr19:44467641~44473227:+
BRCA	cis	rs1707322	1	rs10890382	ENSG00000234329.1	RP11-767N6.2	4.54	6.26e-06	0.000538	0.15	0.14	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46004002	chr1:45651039~45651826:-
BRCA	cis	rs859767	0.709	rs4954154	ENSG00000224043.6	CCNT2-AS1	4.54	6.26e-06	0.000538	0.2	0.14	Neuroticism;	chr2:134613086	chr2:134735464~134918710:-
BRCA	cis	rs859767	0.741	rs2176341	ENSG00000224043.6	CCNT2-AS1	4.54	6.26e-06	0.000538	0.2	0.14	Neuroticism;	chr2:134613851	chr2:134735464~134918710:-
BRCA	cis	rs859767	0.741	rs4954155	ENSG00000224043.6	CCNT2-AS1	4.54	6.26e-06	0.000538	0.2	0.14	Neuroticism;	chr2:134625934	chr2:134735464~134918710:-
BRCA	cis	rs62025270	0.688	rs17638180	ENSG00000259762.1	RP11-158M2.4	-4.54	6.26e-06	0.000538	-0.22	-0.14	Idiopathic pulmonary fibrosis;	chr15:85735164	chr15:85750336~85752901:-
BRCA	cis	rs736408	0.545	rs6445529	ENSG00000243224.1	RP5-1157M23.2	-4.54	6.26e-06	0.000539	-0.15	-0.14	Bipolar disorder;	chr3:52628706	chr3:52239258~52241097:+
BRCA	cis	rs875971	0.545	rs10261710	ENSG00000232546.1	RP11-458F8.1	4.54	6.27e-06	0.000539	0.14	0.14	Aortic root size;	chr7:66249202	chr7:66848496~66858136:+
BRCA	cis	rs11168618	0.904	rs7136845	ENSG00000240399.1	RP1-228P16.1	4.54	6.27e-06	0.000539	0.16	0.14	Adiponectin levels;	chr12:48513246	chr12:48054813~48055591:-
BRCA	cis	rs867186	1	rs114007205	ENSG00000126005.14	MMP24-AS1	-4.54	6.27e-06	0.000539	-0.27	-0.14	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35059700	chr20:35216462~35278131:-
BRCA	cis	rs11098499	0.58	rs12509234	ENSG00000250412.1	KLHL2P1	4.54	6.27e-06	0.000539	0.17	0.14	Corneal astigmatism;	chr4:119398279	chr4:119334329~119378233:+
BRCA	cis	rs11098499	0.909	rs10014719	ENSG00000250412.1	KLHL2P1	4.54	6.27e-06	0.000539	0.17	0.14	Corneal astigmatism;	chr4:119399560	chr4:119334329~119378233:+
BRCA	cis	rs17507216	0.628	rs28737193	ENSG00000255769.6	GOLGA2P10	-4.54	6.27e-06	0.000539	-0.21	-0.14	Excessive daytime sleepiness;	chr15:82701318	chr15:82472993~82513950:-
BRCA	cis	rs2832191	0.72	rs4643617	ENSG00000176054.6	RPL23P2	-4.54	6.27e-06	0.000539	-0.14	-0.14	Dental caries;	chr21:29112957	chr21:28997613~28998033:-
BRCA	cis	rs2832191	0.791	rs2832187	ENSG00000176054.6	RPL23P2	-4.54	6.27e-06	0.000539	-0.14	-0.14	Dental caries;	chr21:29113222	chr21:28997613~28998033:-
BRCA	cis	rs11992162	0.636	rs11250182	ENSG00000254866.2	DEFB109P3	4.54	6.27e-06	0.000539	0.17	0.14	Monocyte count;	chr8:11950067	chr8:12150895~12151134:-
BRCA	cis	rs4218	0.689	rs28391430	ENSG00000277144.1	RP11-59H7.4	-4.54	6.27e-06	0.000539	-0.18	-0.14	Social communication problems;	chr15:59100318	chr15:59115547~59116089:-
BRCA	cis	rs10833905	0.818	rs4430508	ENSG00000246225.5	RP11-17A1.3	-4.54	6.27e-06	0.000539	-0.2	-0.14	Sudden cardiac arrest;	chr11:23045957	chr11:22829380~22945393:+
BRCA	cis	rs4650994	0.967	rs4650992	ENSG00000273384.1	RP5-1098D14.1	4.54	6.27e-06	0.00054	0.17	0.14	HDL cholesterol;HDL cholesterol levels;	chr1:178546000	chr1:178651706~178652282:+
BRCA	cis	rs12554020	0.786	rs12551314	ENSG00000227603.1	RP11-165J3.6	4.54	6.28e-06	0.00054	0.21	0.14	Schizophrenia;	chr9:93617515	chr9:93435332~93437121:-
BRCA	cis	rs2832191	0.791	rs2832186	ENSG00000236056.1	GAPDHP14	4.54	6.28e-06	0.00054	0.15	0.14	Dental caries;	chr21:29111830	chr21:29222321~29223257:+
BRCA	cis	rs1075265	0.568	rs805416	ENSG00000235937.1	AC008280.1	-4.54	6.28e-06	0.00054	-0.15	-0.14	Chronotype;Morning vs. evening chronotype;	chr2:53898121	chr2:54029552~54030682:-
BRCA	cis	rs6128907	1	rs62202471	ENSG00000224635.1	RP4-564F22.5	4.54	6.28e-06	0.00054	0.22	0.14	Liver fibrosis in pediatric non-alcoholic fatty acid liver disease;	chr20:38757278	chr20:38406011~38416797:-
BRCA	cis	rs10129255	0.518	rs8009612	ENSG00000211967.3	IGHV3-53	-4.54	6.29e-06	0.00054	-0.09	-0.14	Kawasaki disease;	chr14:106777510	chr14:106592676~106593347:-
BRCA	cis	rs2337406	1	rs17095456	ENSG00000223648.3	IGHV3-64	4.54	6.29e-06	0.000541	0.15	0.14	Alzheimer's disease (late onset);	chr14:106676559	chr14:106643132~106658258:-
BRCA	cis	rs6088580	0.634	rs1205334	ENSG00000276073.1	RP5-1125A11.7	4.54	6.29e-06	0.000541	0.15	0.14	Glomerular filtration rate (creatinine);	chr20:34342563	chr20:33985617~33988989:-
BRCA	cis	rs7487075	0.619	rs4427617	ENSG00000274723.1	RP11-618L22.1	4.54	6.29e-06	0.000541	0.19	0.14	Itch intensity from mosquito bite;	chr12:46400719	chr12:46970504~46972155:+
BRCA	cis	rs1371614	0.635	rs10175737	ENSG00000272148.1	RP11-195B17.1	-4.54	6.29e-06	0.000541	-0.15	-0.14	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26916879	chr2:27062428~27062907:-
BRCA	cis	rs1371614	0.577	rs877274	ENSG00000272148.1	RP11-195B17.1	-4.54	6.29e-06	0.000541	-0.15	-0.14	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26917231	chr2:27062428~27062907:-
BRCA	cis	rs442309	0.846	rs224125	ENSG00000238280.1	RP11-436D10.3	-4.54	6.3e-06	0.000541	-0.19	-0.14	Vogt-Koyanagi-Harada syndrome;	chr10:62694329	chr10:62793562~62805887:-
BRCA	cis	rs7267979	0.873	rs6037062	ENSG00000274414.1	RP5-965G21.4	-4.54	6.3e-06	0.000541	-0.17	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25222256	chr20:25239007~25245229:-
BRCA	cis	rs8098244	0.597	rs12958312	ENSG00000265752.2	RP11-403A21.1	-4.54	6.3e-06	0.000541	-0.15	-0.14	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23784372	chr18:23957754~23982556:-
BRCA	cis	rs17406451	0.836	rs7557989	ENSG00000234936.1	AC010883.5	4.54	6.3e-06	0.000541	0.15	0.14	Mitochondrial DNA levels;	chr2:43403518	chr2:43229573~43233394:+
BRCA	cis	rs72482608	0.865	rs10753820	ENSG00000271811.1	RP1-79C4.4	4.54	6.3e-06	0.000541	0.15	0.14	Emphysema imaging phenotypes;	chr1:170794495	chr1:170667381~170669425:+
BRCA	cis	rs651907	0.505	rs599849	ENSG00000244119.1	PDCL3P4	4.54	6.3e-06	0.000541	0.11	0.14	Colorectal cancer;	chr3:101857918	chr3:101712472~101713191:+
BRCA	cis	rs755249	0.567	rs72637906	ENSG00000182109.6	RP11-69E11.4	4.54	6.3e-06	0.000541	0.2	0.14	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39242630	chr1:39522280~39546187:-
BRCA	cis	rs755249	0.567	rs67886352	ENSG00000182109.6	RP11-69E11.4	4.54	6.3e-06	0.000541	0.2	0.14	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39243031	chr1:39522280~39546187:-
BRCA	cis	rs755249	0.567	rs60323161	ENSG00000182109.6	RP11-69E11.4	4.54	6.3e-06	0.000541	0.2	0.14	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39244787	chr1:39522280~39546187:-
BRCA	cis	rs755249	0.567	rs66727439	ENSG00000182109.6	RP11-69E11.4	4.54	6.3e-06	0.000541	0.2	0.14	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39246258	chr1:39522280~39546187:-
BRCA	cis	rs1008375	1	rs10032326	ENSG00000249502.1	AC006160.5	-4.54	6.3e-06	0.000541	-0.16	-0.14	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17629094	chr4:17587467~17614571:-
BRCA	cis	rs6968419	1	rs6947586	ENSG00000279086.1	RP11-667F14.1	-4.54	6.3e-06	0.000542	-0.14	-0.14	Intraocular pressure;	chr7:116186706	chr7:116209234~116211511:-
BRCA	cis	rs9921338	0.961	rs57579443	ENSG00000262636.1	CTD-3088G3.4	-4.54	6.3e-06	0.000542	-0.22	-0.14	Vein graft stenosis in coronary artery bypass grafting;	chr16:11349140	chr16:11380859~11381118:-
BRCA	cis	rs10946940	0.93	rs10807029	ENSG00000219392.1	RP1-265C24.5	4.54	6.3e-06	0.000542	0.18	0.14	Systemic lupus erythematosus;	chr6:27605684	chr6:28115628~28116551:+
BRCA	cis	rs2562456	0.833	rs56187954	ENSG00000268658.4	LINC00664	4.54	6.3e-06	0.000542	0.23	0.14	Pain;	chr19:21345258	chr19:21483374~21503238:+
BRCA	cis	rs12922040	0.701	rs12149912	ENSG00000279866.1	CTB-193M12.4	4.54	6.3e-06	0.000542	0.17	0.14	Serum uric acid levels in response to allopurinol in gout;	chr16:15774798	chr16:15704410~15705984:+
BRCA	cis	rs2839186	0.814	rs2276257	ENSG00000228137.1	AP001469.7	4.54	6.31e-06	0.000542	0.14	0.14	Testicular germ cell tumor;	chr21:46291315	chr21:46246890~46247682:+
BRCA	cis	rs6968419	1	rs6967663	ENSG00000279086.1	RP11-667F14.1	-4.54	6.31e-06	0.000542	-0.14	-0.14	Intraocular pressure;	chr7:116195756	chr7:116209234~116211511:-
BRCA	cis	rs926392	0.932	rs4812360	ENSG00000274825.1	RP4-616B8.5	-4.54	6.31e-06	0.000542	-0.13	-0.14	Dialysis-related mortality;	chr20:39060616	chr20:38955910~38956547:+
BRCA	cis	rs6545883	0.894	rs6734628	ENSG00000212978.6	AC016747.3	-4.54	6.31e-06	0.000542	-0.19	-0.14	Tuberculosis;	chr2:61224125	chr2:61141592~61144969:-
BRCA	cis	rs7617773	1	rs12496784	ENSG00000199476.1	Y_RNA	4.54	6.31e-06	0.000543	0.18	0.14	Coronary artery disease;	chr3:48144777	chr3:48288587~48288694:+
BRCA	cis	rs34217772	1	rs10483522	ENSG00000258636.1	CTD-2298J14.2	4.54	6.31e-06	0.000543	0.18	0.14	Myopia;	chr14:41806761	chr14:41587861~41604856:-
BRCA	cis	rs9543976	0.623	rs6562913	ENSG00000261105.4	LMO7-AS1	4.54	6.31e-06	0.000543	0.21	0.14	Diabetic retinopathy;	chr13:75593297	chr13:75604700~75635994:-
BRCA	cis	rs875971	0.66	rs62465434	ENSG00000273142.1	RP11-458F8.4	-4.54	6.32e-06	0.000543	-0.12	-0.14	Aortic root size;	chr7:66540165	chr7:66902857~66906297:+
BRCA	cis	rs7572733	0.515	rs6726506	ENSG00000231621.1	AC013264.2	-4.54	6.32e-06	0.000543	-0.14	-0.14	Dermatomyositis;	chr2:197981762	chr2:197197991~197199273:+
BRCA	cis	rs35612822	0.687	rs12989690	ENSG00000232485.2	AC098820.3	-4.54	6.32e-06	0.000543	-0.16	-0.14	Kidney disease (early stage) in type 1 diabetes;	chr2:216401110	chr2:216479030~216498761:-
BRCA	cis	rs35612822	0.723	rs12990098	ENSG00000232485.2	AC098820.3	-4.54	6.32e-06	0.000543	-0.16	-0.14	Kidney disease (early stage) in type 1 diabetes;	chr2:216401290	chr2:216479030~216498761:-
BRCA	cis	rs35612822	0.586	rs28670085	ENSG00000232485.2	AC098820.3	-4.54	6.32e-06	0.000543	-0.16	-0.14	Kidney disease (early stage) in type 1 diabetes;	chr2:216401695	chr2:216479030~216498761:-
BRCA	cis	rs35612822	0.723	rs13399493	ENSG00000232485.2	AC098820.3	-4.54	6.32e-06	0.000543	-0.16	-0.14	Kidney disease (early stage) in type 1 diabetes;	chr2:216401982	chr2:216479030~216498761:-
BRCA	cis	rs35612822	0.687	rs10204303	ENSG00000232485.2	AC098820.3	-4.54	6.32e-06	0.000543	-0.16	-0.14	Kidney disease (early stage) in type 1 diabetes;	chr2:216402433	chr2:216479030~216498761:-
BRCA	cis	rs7267979	1	rs6050573	ENSG00000125804.12	FAM182A	-4.54	6.32e-06	0.000543	-0.18	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25385429	chr20:26054655~26086917:+
BRCA	cis	rs8114671	0.527	rs3736802	ENSG00000269202.1	RP4-614O4.12	4.54	6.32e-06	0.000543	0.14	0.14	Height;	chr20:35016239	chr20:35201747~35203288:-
BRCA	cis	rs56322409	0.897	rs11188455	ENSG00000226688.5	ENTPD1-AS1	4.54	6.33e-06	0.000544	0.16	0.14	Blood metabolite levels;	chr10:95731166	chr10:95753206~96090238:-
BRCA	cis	rs56322409	0.897	rs61869573	ENSG00000226688.5	ENTPD1-AS1	4.54	6.33e-06	0.000544	0.16	0.14	Blood metabolite levels;	chr10:95731913	chr10:95753206~96090238:-
BRCA	cis	rs56322409	0.897	rs11188464	ENSG00000226688.5	ENTPD1-AS1	4.54	6.33e-06	0.000544	0.16	0.14	Blood metabolite levels;	chr10:95739096	chr10:95753206~96090238:-
BRCA	cis	rs1005277	0.563	rs2505216	ENSG00000099251.13	HSD17B7P2	4.54	6.33e-06	0.000544	0.15	0.14	Extrinsic epigenetic age acceleration;	chr10:38193902	chr10:38356380~38378505:+
BRCA	cis	rs6095360	1	rs7270848	ENSG00000222365.1	SNORD12B	-4.54	6.33e-06	0.000544	-0.15	-0.14	Intelligence (multi-trait analysis);	chr20:49023200	chr20:49280319~49280409:+
BRCA	cis	rs6095360	1	rs6019591	ENSG00000222365.1	SNORD12B	-4.54	6.33e-06	0.000544	-0.15	-0.14	Intelligence (multi-trait analysis);	chr20:49023492	chr20:49280319~49280409:+
BRCA	cis	rs6095360	1	rs66970580	ENSG00000222365.1	SNORD12B	-4.54	6.33e-06	0.000544	-0.15	-0.14	Intelligence (multi-trait analysis);	chr20:49024802	chr20:49280319~49280409:+
BRCA	cis	rs6095360	1	rs7262379	ENSG00000222365.1	SNORD12B	-4.54	6.33e-06	0.000544	-0.15	-0.14	Intelligence (multi-trait analysis);	chr20:49026042	chr20:49280319~49280409:+
BRCA	cis	rs6095360	0.933	rs6019594	ENSG00000222365.1	SNORD12B	-4.54	6.33e-06	0.000544	-0.15	-0.14	Intelligence (multi-trait analysis);	chr20:49027017	chr20:49280319~49280409:+
BRCA	cis	rs6095360	1	rs6019595	ENSG00000222365.1	SNORD12B	-4.54	6.33e-06	0.000544	-0.15	-0.14	Intelligence (multi-trait analysis);	chr20:49027495	chr20:49280319~49280409:+
BRCA	cis	rs6095360	1	rs6095400	ENSG00000222365.1	SNORD12B	-4.54	6.33e-06	0.000544	-0.15	-0.14	Intelligence (multi-trait analysis);	chr20:49029452	chr20:49280319~49280409:+
BRCA	cis	rs6095360	0.87	rs6095401	ENSG00000222365.1	SNORD12B	-4.54	6.33e-06	0.000544	-0.15	-0.14	Intelligence (multi-trait analysis);	chr20:49030084	chr20:49280319~49280409:+
BRCA	cis	rs6095360	1	rs13042947	ENSG00000222365.1	SNORD12B	-4.54	6.33e-06	0.000544	-0.15	-0.14	Intelligence (multi-trait analysis);	chr20:49031339	chr20:49280319~49280409:+
BRCA	cis	rs763121	0.853	rs2076028	ENSG00000273076.1	RP3-508I15.22	4.54	6.33e-06	0.000544	0.16	0.14	Menopause (age at onset);	chr22:38754445	chr22:38743495~38743910:+
BRCA	cis	rs4664293	0.867	rs7579206	ENSG00000226266.5	AC009961.3	-4.54	6.33e-06	0.000544	-0.18	-0.14	Monocyte percentage of white cells;	chr2:159715992	chr2:159670708~159712435:-
BRCA	cis	rs867186	1	rs7268447	ENSG00000126005.14	MMP24-AS1	-4.54	6.33e-06	0.000544	-0.27	-0.14	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35061790	chr20:35216462~35278131:-
BRCA	cis	rs2235642	0.928	rs1057610	ENSG00000260989.1	LA16c-395F10.2	-4.54	6.33e-06	0.000544	-0.14	-0.14	Coronary artery disease;	chr16:1555536	chr16:1580527~1610328:+
BRCA	cis	rs6586111	0.765	rs11186273	ENSG00000226659.1	RP11-137H2.4	-4.54	6.34e-06	0.000544	-0.18	-0.14	Capecitabine sensitivity;	chr10:80611556	chr10:80529597~80535942:-
BRCA	cis	rs256438	0.671	rs17878919	ENSG00000251050.1	RP11-168A11.4	-4.54	6.34e-06	0.000544	-0.17	-0.14	Serum thyroid-stimulating hormone levels;	chr5:80033715	chr5:80019609~80019920:+
BRCA	cis	rs4869313	0.837	rs27998	ENSG00000248734.2	CTD-2260A17.1	-4.54	6.34e-06	0.000544	-0.14	-0.14	Pediatric autoimmune diseases;	chr5:97031704	chr5:96784777~96785999:+
BRCA	cis	rs6095360	0.934	rs730544	ENSG00000222365.1	SNORD12B	-4.54	6.34e-06	0.000544	-0.15	-0.14	Intelligence (multi-trait analysis);	chr20:49019281	chr20:49280319~49280409:+
BRCA	cis	rs9921338	0.961	rs8043692	ENSG00000262703.1	RP11-485G7.6	-4.54	6.34e-06	0.000544	-0.17	-0.14	Vein graft stenosis in coronary artery bypass grafting;	chr16:11333100	chr16:11348143~11349321:-
BRCA	cis	rs9921338	0.923	rs6498181	ENSG00000262703.1	RP11-485G7.6	-4.54	6.34e-06	0.000544	-0.17	-0.14	Vein graft stenosis in coronary artery bypass grafting;	chr16:11333336	chr16:11348143~11349321:-
BRCA	cis	rs1707322	1	rs10890381	ENSG00000234329.1	RP11-767N6.2	4.54	6.34e-06	0.000545	0.15	0.14	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45986099	chr1:45651039~45651826:-
BRCA	cis	rs2446066	0.728	rs10876444	ENSG00000257379.1	RP11-793H13.8	4.54	6.34e-06	0.000545	0.22	0.14	Red blood cell count;	chr12:53358697	chr12:53441741~53467528:+
BRCA	cis	rs2153535	0.542	rs915354	ENSG00000251164.1	HULC	-4.54	6.34e-06	0.000545	-0.17	-0.14	Motion sickness;	chr6:8440124	chr6:8652137~8653846:+
BRCA	cis	rs503425	1	rs503425	ENSG00000255422.1	AP002954.4	-4.54	6.35e-06	0.000545	-0.2	-0.14	Systemic lupus erythematosus;	chr11:118822018	chr11:118704607~118750263:+
BRCA	cis	rs733175	0.855	rs6853437	ENSG00000250413.1	RP11-448G15.1	4.54	6.35e-06	0.000545	0.2	0.14	Psychosis and Alzheimer's disease;	chr4:10003811	chr4:10006482~10009725:+
BRCA	cis	rs2243480	1	rs316322	ENSG00000222364.1	RNU6-96P	-4.54	6.35e-06	0.000545	-0.25	-0.14	Diabetic kidney disease;	chr7:66146246	chr7:66395191~66395286:+
BRCA	cis	rs3845817	0.868	rs702942	ENSG00000237979.1	AC007389.1	4.54	6.35e-06	0.000545	0.17	0.14	Bipolar disorder;	chr2:65529831	chr2:65500993~65502138:-
BRCA	cis	rs6012564	1	rs6066975	ENSG00000227431.4	CSE1L-AS1	-4.54	6.35e-06	0.000546	-0.18	-0.14	Anger;	chr20:49133840	chr20:49040463~49046044:-
BRCA	cis	rs172166	0.694	rs1770131	ENSG00000219392.1	RP1-265C24.5	-4.54	6.35e-06	0.000546	-0.19	-0.14	Cardiac Troponin-T levels;	chr6:28118635	chr6:28115628~28116551:+
BRCA	cis	rs17818399	0.815	rs35837037	ENSG00000279254.1	RP11-536C12.1	-4.54	6.35e-06	0.000546	-0.18	-0.14	Height;	chr2:46634161	chr2:46668870~46670778:+
BRCA	cis	rs6545883	0.894	rs12615783	ENSG00000212978.6	AC016747.3	-4.54	6.36e-06	0.000546	-0.19	-0.14	Tuberculosis;	chr2:61213812	chr2:61141592~61144969:-
BRCA	cis	rs17684571	0.751	rs7771085	ENSG00000231441.1	RP11-472M19.2	4.54	6.36e-06	0.000546	0.22	0.14	Schizophrenia;	chr6:56818631	chr6:56844002~56864078:+
BRCA	cis	rs7772486	0.79	rs9376970	ENSG00000270638.1	RP3-466P17.1	-4.54	6.36e-06	0.000546	-0.16	-0.14	Lobe attachment (rater-scored or self-reported);	chr6:145920336	chr6:145735570~145737218:+
BRCA	cis	rs7726839	0.555	rs4541696	ENSG00000225138.6	CTD-2228K2.7	4.54	6.36e-06	0.000546	0.16	0.14	Obesity-related traits;	chr5:580938	chr5:473236~480884:+
BRCA	cis	rs2115630	1	rs10220733	ENSG00000259728.4	LINC00933	-4.54	6.36e-06	0.000546	-0.15	-0.14	P wave terminal force;	chr15:84737633	chr15:84570649~84580175:+
BRCA	cis	rs2731006	0.591	rs10880365	ENSG00000257114.2	RP11-25I15.3	4.54	6.36e-06	0.000546	0.2	0.14	Panic disorder;	chr12:42816805	chr12:42692216~42717119:+
BRCA	cis	rs7923837	0.616	rs12778642	ENSG00000236493.2	EIF2S2P3	4.54	6.36e-06	0.000546	0.18	0.14	Multiple sclerosis;Body mass index;	chr10:92704550	chr10:92668745~92669743:-
BRCA	cis	rs2839186	0.585	rs2839154	ENSG00000239415.1	AP001469.9	-4.54	6.36e-06	0.000546	-0.15	-0.14	Testicular germ cell tumor;	chr21:46217846	chr21:46251549~46254133:-
BRCA	cis	rs308403	0.509	rs7690409	ENSG00000224786.1	CETN4P	4.54	6.36e-06	0.000546	0.18	0.14	Blood protein levels;	chr4:122745602	chr4:122730548~122732193:-
BRCA	cis	rs2408955	0.542	rs7975632	ENSG00000257763.1	OR5BK1P	4.54	6.36e-06	0.000546	0.15	0.14	Glycated hemoglobin levels;	chr12:48049265	chr12:48355792~48356614:-
BRCA	cis	rs6847067	0.631	rs2120091	ENSG00000180769.7	WDFY3-AS2	4.54	6.36e-06	0.000546	0.13	0.14	Oropharynx cancer;	chr4:84616672	chr4:84965682~85011277:+
BRCA	cis	rs9650657	0.589	rs6985109	ENSG00000154316.13	TDH	-4.54	6.36e-06	0.000546	-0.18	-0.14	Neuroticism;	chr8:10904075	chr8:11339637~11368452:+
BRCA	cis	rs2018683	0.6	rs6948880	ENSG00000233517.1	AC005162.5	-4.54	6.36e-06	0.000546	-0.17	-0.14	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28963862	chr7:28987028~28988899:+
BRCA	cis	rs10266483	0.774	rs10949894	ENSG00000227986.1	TRIM60P18	4.54	6.36e-06	0.000546	0.15	0.14	Response to statin therapy;	chr7:64340143	chr7:64355078~64356199:+
BRCA	cis	rs116095464	0.558	rs10065584	ENSG00000248925.1	CTD-2083E4.6	4.54	6.36e-06	0.000546	0.28	0.14	Breast cancer;	chr5:253882	chr5:269858~271516:-
BRCA	cis	rs6012564	0.559	rs61418814	ENSG00000227431.4	CSE1L-AS1	4.54	6.37e-06	0.000547	0.18	0.14	Anger;	chr20:49153301	chr20:49040463~49046044:-
BRCA	cis	rs9467773	1	rs9467783	ENSG00000241549.7	GUSBP2	4.54	6.37e-06	0.000547	0.15	0.14	Intelligence (multi-trait analysis);	chr6:26542666	chr6:26871484~26956554:-
BRCA	cis	rs9990333	0.544	rs73208092	ENSG00000242086.7	LINC00969	4.54	6.37e-06	0.000547	0.16	0.14	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196091703	chr3:195658062~195739964:+
BRCA	cis	rs6747488	0.55	rs1272585	ENSG00000272716.1	RP11-563N4.1	4.54	6.37e-06	0.000547	0.15	0.14	Interleukin-18 levels;	chr2:31875990	chr2:32165046~32165757:-
BRCA	cis	rs9952991	0.941	rs8096138	ENSG00000260302.1	RP11-973H7.1	4.54	6.37e-06	0.000547	0.23	0.14	Inflammatory skin disease;	chr18:12808141	chr18:12774651~12775923:-
BRCA	cis	rs6490294	0.571	rs12300496	ENSG00000234608.6	MAPKAPK5-AS1	4.54	6.37e-06	0.000547	0.21	0.14	Mean platelet volume;	chr12:112012629	chr12:111839764~111842902:-
BRCA	cis	rs1707322	1	rs6677777	ENSG00000234329.1	RP11-767N6.2	4.54	6.37e-06	0.000547	0.15	0.14	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46010164	chr1:45651039~45651826:-
BRCA	cis	rs651907	0.588	rs1707608	ENSG00000244119.1	PDCL3P4	4.54	6.38e-06	0.000547	0.11	0.14	Colorectal cancer;	chr3:101925925	chr3:101712472~101713191:+
BRCA	cis	rs4948275	0.693	rs2650729	ENSG00000237233.2	TMEM26-AS1	-4.54	6.38e-06	0.000547	-0.16	-0.14	Night sleep phenotypes;	chr10:61577411	chr10:61452639~61481956:+
BRCA	cis	rs73193808	0.627	rs2832233	ENSG00000215533.7	LINC00189	4.54	6.38e-06	0.000547	0.24	0.14	Coronary artery disease;	chr21:29173679	chr21:29193480~29288205:+
BRCA	cis	rs2109514	0.765	rs11769417	ENSG00000237813.3	AC002066.1	4.54	6.38e-06	0.000548	0.17	0.14	Prevalent atrial fibrillation;	chr7:116463724	chr7:116238260~116499465:-
BRCA	cis	rs9818758	0.607	rs13068038	ENSG00000225399.4	RP11-3B7.1	-4.54	6.38e-06	0.000548	-0.23	-0.14	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49256817	chr3:49260085~49261316:+
BRCA	cis	rs12534093	0.595	rs11767313	ENSG00000234286.1	AC006026.13	-4.54	6.38e-06	0.000548	-0.24	-0.14	Infant length;Height;	chr7:23544903	chr7:23680195~23680786:-
BRCA	cis	rs11098499	0.954	rs71629403	ENSG00000250412.1	KLHL2P1	4.54	6.38e-06	0.000548	0.17	0.14	Corneal astigmatism;	chr4:119451412	chr4:119334329~119378233:+
BRCA	cis	rs11098499	0.909	rs28571712	ENSG00000250412.1	KLHL2P1	4.54	6.38e-06	0.000548	0.17	0.14	Corneal astigmatism;	chr4:119454825	chr4:119334329~119378233:+
BRCA	cis	rs4578769	0.55	rs4473296	ENSG00000273232.1	RP11-370A5.2	-4.54	6.39e-06	0.000548	-0.17	-0.14	Eosinophil percentage of white cells;	chr18:22986421	chr18:22882825~22883357:-
BRCA	cis	rs13113518	1	rs11937487	ENSG00000272969.1	RP11-528I4.2	4.54	6.39e-06	0.000548	0.16	0.14	Height;	chr4:55436576	chr4:55547112~55547889:+
BRCA	cis	rs6088580	0.609	rs6059845	ENSG00000276073.1	RP5-1125A11.7	-4.54	6.39e-06	0.000548	-0.15	-0.14	Glomerular filtration rate (creatinine);	chr20:34448695	chr20:33985617~33988989:-
BRCA	cis	rs1823874	0.677	rs1993295	ENSG00000182397.13	DNM1P46	-4.54	6.39e-06	0.000549	-0.15	-0.14	IgG glycosylation;	chr15:99823332	chr15:99790156~99806927:-
BRCA	cis	rs7246657	0.722	rs2075284	ENSG00000226686.6	LINC01535	4.54	6.39e-06	0.000549	0.21	0.14	Coronary artery calcification;	chr19:37698715	chr19:37251912~37265535:+
BRCA	cis	rs2834288	0.734	rs8126592	ENSG00000273102.1	AP000569.9	-4.54	6.4e-06	0.000549	-0.16	-0.14	Gut microbiota (bacterial taxa);	chr21:33895961	chr21:33967101~33968573:-
BRCA	cis	rs4237845	0.537	rs7969844	ENSG00000257159.1	RP11-58A17.3	4.54	6.4e-06	0.000549	0.16	0.14	Intelligence (multi-trait analysis);	chr12:57884488	chr12:57967058~57968399:+
BRCA	cis	rs11673344	0.504	rs4806408	ENSG00000226686.6	LINC01535	4.54	6.4e-06	0.000549	0.18	0.14	Obesity-related traits;	chr19:37097875	chr19:37251912~37265535:+
BRCA	cis	rs10129255	0.518	rs10136903	ENSG00000232216.1	IGHV3-43	4.54	6.4e-06	0.000549	0.1	0.14	Kawasaki disease;	chr14:106778866	chr14:106470264~106470800:-
BRCA	cis	rs7267979	0.727	rs4815431	ENSG00000277938.1	RP5-965G21.3	-4.54	6.41e-06	0.00055	-0.16	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25551769	chr20:25229150~25231933:+
BRCA	cis	rs9818758	0.545	rs55921200	ENSG00000270441.1	RP11-694I15.7	4.54	6.41e-06	0.00055	0.34	0.14	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49151883	chr3:49140086~49160851:-
BRCA	cis	rs875971	0.965	rs28682868	ENSG00000236529.1	RP13-254B10.1	-4.54	6.41e-06	0.00055	-0.15	-0.14	Aortic root size;	chr7:66224822	chr7:65840212~65840596:+
BRCA	cis	rs2115630	0.905	rs6496401	ENSG00000259728.4	LINC00933	-4.54	6.41e-06	0.00055	-0.15	-0.14	P wave terminal force;	chr15:84754562	chr15:84570649~84580175:+
BRCA	cis	rs875971	0.638	rs3898855	ENSG00000273142.1	RP11-458F8.4	4.54	6.41e-06	0.00055	0.12	0.14	Aortic root size;	chr7:66571411	chr7:66902857~66906297:+
BRCA	cis	rs875971	0.638	rs10278816	ENSG00000273142.1	RP11-458F8.4	4.54	6.41e-06	0.00055	0.12	0.14	Aortic root size;	chr7:66572000	chr7:66902857~66906297:+
BRCA	cis	rs875971	0.66	rs10281080	ENSG00000273142.1	RP11-458F8.4	4.54	6.41e-06	0.00055	0.12	0.14	Aortic root size;	chr7:66577454	chr7:66902857~66906297:+
BRCA	cis	rs875971	0.66	rs10950044	ENSG00000273142.1	RP11-458F8.4	4.54	6.41e-06	0.00055	0.12	0.14	Aortic root size;	chr7:66577989	chr7:66902857~66906297:+
BRCA	cis	rs4388249	0.687	rs2416218	ENSG00000271849.1	CTC-332L22.1	-4.54	6.41e-06	0.00055	-0.18	-0.14	Schizophrenia;	chr5:109736511	chr5:109687802~109688329:-
BRCA	cis	rs7200786	0.584	rs4781030	ENSG00000274038.1	RP11-66H6.4	4.54	6.41e-06	0.00055	0.15	0.14	Systemic lupus erythematosus;Multiple sclerosis;	chr16:10988606	chr16:11056556~11057034:+
BRCA	cis	rs6570726	0.875	rs12524077	ENSG00000270638.1	RP3-466P17.1	4.54	6.41e-06	0.00055	0.15	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145545197	chr6:145735570~145737218:+
BRCA	cis	rs6570726	0.875	rs416243	ENSG00000270638.1	RP3-466P17.1	4.54	6.41e-06	0.00055	0.15	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145546945	chr6:145735570~145737218:+
BRCA	cis	rs11096990	0.613	rs12505690	ENSG00000249685.1	RP11-360F5.3	4.54	6.41e-06	0.00055	0.18	0.14	Cognitive function;	chr4:39167425	chr4:39133913~39135608:+
BRCA	cis	rs4722166	0.568	rs1880241	ENSG00000225541.1	AC002480.5	-4.54	6.41e-06	0.00055	-0.14	-0.14	Lung cancer;	chr7:22719850	chr7:22571607~22661792:-
BRCA	cis	rs7267979	0.706	rs6037069	ENSG00000274414.1	RP5-965G21.4	-4.54	6.41e-06	0.00055	-0.17	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25253530	chr20:25239007~25245229:-
BRCA	cis	rs2235642	0.928	rs9932984	ENSG00000260989.1	LA16c-395F10.2	-4.54	6.42e-06	0.00055	-0.14	-0.14	Coronary artery disease;	chr16:1555050	chr16:1580527~1610328:+
BRCA	cis	rs1707322	0.964	rs12067716	ENSG00000234329.1	RP11-767N6.2	4.54	6.42e-06	0.000551	0.15	0.14	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45968756	chr1:45651039~45651826:-
BRCA	cis	rs853679	1	rs853676	ENSG00000204709.4	LINC01556	4.54	6.42e-06	0.000551	0.25	0.14	Depression;	chr6:28331910	chr6:28943877~28944537:+
BRCA	cis	rs875971	0.898	rs6977501	ENSG00000229180.5	GS1-124K5.11	-4.54	6.43e-06	0.000551	-0.12	-0.14	Aortic root size;	chr7:66228355	chr7:66526088~66542624:-
BRCA	cis	rs4865169	0.811	rs6841086	ENSG00000269949.1	RP11-738E22.3	4.54	6.43e-06	0.000551	0.16	0.14	Breast cancer;	chr4:57037102	chr4:56960927~56961373:-
BRCA	cis	rs721917	0.506	rs4320898	ENSG00000242600.5	MBL1P	4.54	6.43e-06	0.000551	0.17	0.14	Chronic obstructive pulmonary disease;	chr10:79891322	chr10:79904898~79950336:+
BRCA	cis	rs721917	0.506	rs4322333	ENSG00000242600.5	MBL1P	4.54	6.43e-06	0.000551	0.17	0.14	Chronic obstructive pulmonary disease;	chr10:79891340	chr10:79904898~79950336:+
BRCA	cis	rs4356203	0.905	rs651513	ENSG00000272034.1	SNORD14A	-4.54	6.43e-06	0.000551	-0.14	-0.14	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17177781	chr11:17074654~17074744:-
BRCA	cis	rs7267979	1	rs6132835	ENSG00000125804.12	FAM182A	-4.54	6.43e-06	0.000551	-0.18	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25454031	chr20:26054655~26086917:+
BRCA	cis	rs7267979	0.933	rs11699203	ENSG00000125804.12	FAM182A	-4.54	6.43e-06	0.000551	-0.18	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25454533	chr20:26054655~26086917:+
BRCA	cis	rs7267979	0.933	rs6138571	ENSG00000125804.12	FAM182A	-4.54	6.43e-06	0.000551	-0.18	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25454752	chr20:26054655~26086917:+
BRCA	cis	rs7267979	0.966	rs416745	ENSG00000125804.12	FAM182A	-4.54	6.43e-06	0.000551	-0.18	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25458232	chr20:26054655~26086917:+
BRCA	cis	rs7267979	1	rs447722	ENSG00000125804.12	FAM182A	-4.54	6.43e-06	0.000551	-0.18	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25462874	chr20:26054655~26086917:+
BRCA	cis	rs7267979	1	rs422424	ENSG00000125804.12	FAM182A	-4.54	6.43e-06	0.000551	-0.18	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25464810	chr20:26054655~26086917:+
BRCA	cis	rs7267979	1	rs422844	ENSG00000125804.12	FAM182A	-4.54	6.43e-06	0.000551	-0.18	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25464955	chr20:26054655~26086917:+
BRCA	cis	rs7267979	1	rs401166	ENSG00000125804.12	FAM182A	-4.54	6.43e-06	0.000551	-0.18	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25465672	chr20:26054655~26086917:+
BRCA	cis	rs115769866	0.609	rs974334	ENSG00000216901.1	AL022393.7	4.53	6.43e-06	0.000551	0.19	0.14	Bipolar disorder;	chr6:28506441	chr6:28176188~28176674:+
BRCA	cis	rs6890684	0.544	rs581318	ENSG00000215032.2	GNL3LP1	-4.53	6.43e-06	0.000551	-0.17	-0.14	Intelligence (multi-trait analysis);	chr5:61219967	chr5:60891935~60893577:-
BRCA	cis	rs12439619	0.693	rs28689861	ENSG00000255769.6	GOLGA2P10	-4.53	6.43e-06	0.000552	-0.18	-0.14	Intelligence (multi-trait analysis);	chr15:82206369	chr15:82472993~82513950:-
BRCA	cis	rs253959	0.545	rs11241362	ENSG00000271918.1	CTD-2287O16.5	4.53	6.43e-06	0.000552	0.13	0.14	Bipolar disorder and schizophrenia;	chr5:116112630	chr5:116083807~116085416:-
BRCA	cis	rs10504130	0.778	rs71513564	ENSG00000253844.1	RP11-546K22.1	-4.53	6.43e-06	0.000552	-0.23	-0.14	Venous thromboembolism (SNP x SNP interaction);	chr8:51910177	chr8:51961458~52022974:+
BRCA	cis	rs2186369	1	rs9620326	ENSG00000211683.3	KB-1572G7.3	4.53	6.43e-06	0.000552	0.21	0.14	IgG N-glycosylation phenotypes (multivariate analysis);IgG digalactosylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG glycosylation;IgG fucosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);	chr22:23804442	chr22:23630618~23638941:-
BRCA	cis	rs2273156	0.929	rs34678475	ENSG00000226677.3	IGBP1P1	-4.53	6.44e-06	0.000552	-0.21	-0.14	Immunoglobulin light chain (AL) amyloidosis;	chr14:34981897	chr14:34939324~34940332:+
BRCA	cis	rs11673344	0.504	rs11666786	ENSG00000276846.1	CTD-3220F14.3	4.53	6.44e-06	0.000553	0.16	0.14	Obesity-related traits;	chr19:37133947	chr19:37314868~37315620:-
BRCA	cis	rs7824557	0.564	rs2736295	ENSG00000255046.1	RP11-297N6.4	-4.53	6.45e-06	0.000553	-0.16	-0.14	Retinal vascular caliber;	chr8:11377271	chr8:11797928~11802568:-
BRCA	cis	rs9393777	0.92	rs41269265	ENSG00000216901.1	AL022393.7	4.53	6.45e-06	0.000553	0.32	0.14	Intelligence (multi-trait analysis);	chr6:27457570	chr6:28176188~28176674:+
BRCA	cis	rs7789940	0.904	rs12531348	ENSG00000280388.1	RP11-229D13.3	-4.53	6.45e-06	0.000553	-0.15	-0.14	Multiple sclerosis;	chr7:76307874	chr7:76043977~76045963:-
BRCA	cis	rs7789940	0.904	rs61294900	ENSG00000280388.1	RP11-229D13.3	-4.53	6.45e-06	0.000553	-0.15	-0.14	Multiple sclerosis;	chr7:76307895	chr7:76043977~76045963:-
BRCA	cis	rs73198271	0.813	rs17697237	ENSG00000254153.1	CTA-398F10.2	4.53	6.45e-06	0.000553	0.18	0.14	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8758364	chr8:8456909~8461337:-
BRCA	cis	rs11892454	0.604	rs7574653	ENSG00000217643.1	PTGES3P2	-4.53	6.45e-06	0.000553	-0.15	-0.14	Heschl's gyrus morphology;	chr2:25720908	chr2:25822469~25822950:+
BRCA	cis	rs9990343	0.783	rs4267678	ENSG00000223552.1	RP11-24F11.2	-4.53	6.45e-06	0.000553	-0.14	-0.14	Brain structure;	chr3:46294694	chr3:46364955~46407059:-
BRCA	cis	rs9990343	0.783	rs6441955	ENSG00000223552.1	RP11-24F11.2	-4.53	6.45e-06	0.000553	-0.14	-0.14	Brain structure;	chr3:46294844	chr3:46364955~46407059:-
BRCA	cis	rs9990343	0.783	rs6441956	ENSG00000223552.1	RP11-24F11.2	-4.53	6.45e-06	0.000553	-0.14	-0.14	Brain structure;	chr3:46294910	chr3:46364955~46407059:-
BRCA	cis	rs1005277	0.579	rs2504148	ENSG00000263064.2	RP11-291L22.7	4.53	6.46e-06	0.000554	0.17	0.14	Extrinsic epigenetic age acceleration;	chr10:38111860	chr10:38448689~38448949:+
BRCA	cis	rs9990333	0.87	rs58758084	ENSG00000207650.1	MIR570	-4.53	6.46e-06	0.000554	-0.16	-0.14	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196086110	chr3:195699401~195699497:+
BRCA	cis	rs934734	0.532	rs10184881	ENSG00000281920.1	RP11-418H16.1	-4.53	6.46e-06	0.000554	-0.16	-0.14	Rheumatoid arthritis;	chr2:65457018	chr2:65623272~65628424:+
BRCA	cis	rs7267979	1	rs2482919	ENSG00000276952.1	RP5-965G21.6	-4.53	6.46e-06	0.000554	-0.17	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25319120	chr20:25284915~25285588:-
BRCA	cis	rs2235642	0.893	rs2143285	ENSG00000260989.1	LA16c-395F10.2	-4.53	6.46e-06	0.000554	-0.14	-0.14	Coronary artery disease;	chr16:1543170	chr16:1580527~1610328:+
BRCA	cis	rs763121	0.853	rs6001214	ENSG00000273076.1	RP3-508I15.22	4.53	6.47e-06	0.000554	0.16	0.14	Menopause (age at onset);	chr22:38753150	chr22:38743495~38743910:+
BRCA	cis	rs2880765	0.566	rs55899824	ENSG00000259630.2	CTD-2262B20.1	-4.53	6.47e-06	0.000554	-0.17	-0.14	Coronary artery disease;	chr15:85460860	chr15:85415228~85415633:+
BRCA	cis	rs4908760	0.613	rs4908511	ENSG00000232912.4	RP5-1115A15.1	-4.53	6.47e-06	0.000555	-0.13	-0.14	Vitiligo;	chr1:8752331	chr1:8424645~8434838:+
BRCA	cis	rs7226408	0.79	rs55935783	ENSG00000267707.2	RP11-95O2.5	4.53	6.47e-06	0.000555	0.23	0.14	Obesity-related traits;	chr18:36766157	chr18:37243776~37247506:+
BRCA	cis	rs6088580	0.634	rs6059897	ENSG00000276073.1	RP5-1125A11.7	-4.53	6.48e-06	0.000555	-0.15	-0.14	Glomerular filtration rate (creatinine);	chr20:34525419	chr20:33985617~33988989:-
BRCA	cis	rs7665090	0.905	rs2866410	ENSG00000251288.2	RP11-10L12.2	-4.53	6.48e-06	0.000555	-0.17	-0.14	Primary biliary cholangitis;	chr4:102633178	chr4:102751401~102752641:+
BRCA	cis	rs7267979	0.816	rs6115094	ENSG00000274973.1	RP13-401N8.7	-4.53	6.48e-06	0.000555	-0.16	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25230191	chr20:25845497~25845862:+
BRCA	cis	rs7665090	0.936	rs2866411	ENSG00000251288.2	RP11-10L12.2	-4.53	6.48e-06	0.000556	-0.17	-0.14	Primary biliary cholangitis;	chr4:102633183	chr4:102751401~102752641:+
BRCA	cis	rs2227564	0.672	rs2461864	ENSG00000271816.1	BMS1P4	4.53	6.48e-06	0.000556	0.15	0.14	Crohn's disease;Inflammatory bowel disease;	chr10:73900114	chr10:73699151~73730487:-
BRCA	cis	rs6573604	0.681	rs9635250	ENSG00000276116.2	FUT8-AS1	-4.53	6.48e-06	0.000556	-0.21	-0.14	N-glycan levels;	chr14:65332630	chr14:65411170~65412690:-
BRCA	cis	rs6600671	0.967	rs12069545	ENSG00000270392.2	PFN1P2	4.53	6.48e-06	0.000556	0.15	0.14	Hip geometry;	chr1:121430343	chr1:120432204~120434052:-
BRCA	cis	rs1979679	0.766	rs10843202	ENSG00000278733.1	RP11-425D17.1	-4.53	6.49e-06	0.000556	-0.18	-0.14	Ossification of the posterior longitudinal ligament of the spine;	chr12:28563111	chr12:28185625~28186190:-
BRCA	cis	rs7818688	0.591	rs10098025	ENSG00000253528.2	RP11-347C18.4	-4.53	6.49e-06	0.000556	-0.21	-0.14	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94977355	chr8:94974573~94974853:-
BRCA	cis	rs7577696	0.525	rs11124272	ENSG00000272716.1	RP11-563N4.1	4.53	6.49e-06	0.000556	0.17	0.14	Inflammatory biomarkers;	chr2:31917451	chr2:32165046~32165757:-
BRCA	cis	rs9308731	1	rs6750599	ENSG00000230499.1	AC108463.1	4.53	6.5e-06	0.000557	0.16	0.14	Chronic lymphocytic leukemia;	chr2:111136292	chr2:111195963~111206494:+
BRCA	cis	rs919433	0.617	rs700643	ENSG00000231621.1	AC013264.2	-4.53	6.5e-06	0.000557	-0.14	-0.14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197736646	chr2:197197991~197199273:+
BRCA	cis	rs935334	1	rs2121070	ENSG00000258454.1	RP11-361H10.3	4.53	6.5e-06	0.000557	0.22	0.14	Blood pressure;	chr14:76184421	chr14:76235817~76263474:+
BRCA	cis	rs6430585	0.528	rs115553816	ENSG00000231890.6	DARS-AS1	-4.53	6.5e-06	0.000557	-0.23	-0.14	Corneal structure;	chr2:135935323	chr2:135985176~136022593:+
BRCA	cis	rs3768617	0.811	rs4396114	ENSG00000224468.3	RP11-181K3.4	-4.53	6.5e-06	0.000557	-0.16	-0.14	Fuchs's corneal dystrophy;	chr1:183038306	chr1:183138402~183141282:-
BRCA	cis	rs12435908	1	rs11844747	ENSG00000276116.2	FUT8-AS1	4.53	6.5e-06	0.000557	0.22	0.14	Ischemic stroke;	chr14:65403410	chr14:65411170~65412690:-
BRCA	cis	rs832187	0.776	rs854622	ENSG00000280620.1	SCAANT1	4.53	6.5e-06	0.000557	0.17	0.14	Schizophrenia;	chr3:63877166	chr3:63911518~63911772:-
BRCA	cis	rs7178909	0.902	rs3853640	ENSG00000259677.1	RP11-493E3.1	4.53	6.5e-06	0.000557	0.16	0.14	Common traits (Other);	chr15:89900488	chr15:89876540~89877285:+
BRCA	cis	rs860295	0.557	rs11264372	ENSG00000160766.13	GBAP1	-4.53	6.5e-06	0.000557	-0.16	-0.14	Body mass index;	chr1:155443139	chr1:155213821~155227422:-
BRCA	cis	rs4494364	0.502	rs2408418	ENSG00000258100.1	RP11-121E16.1	4.53	6.5e-06	0.000557	0.21	0.14	Systolic blood pressure (alcohol consumption interaction);	chr12:90955665	chr12:91362196~91368606:+
BRCA	cis	rs2243480	0.522	rs12698511	ENSG00000237026.1	RP11-328P23.2	4.53	6.51e-06	0.000557	0.31	0.14	Diabetic kidney disease;	chr7:66009932	chr7:65235790~65236723:-
BRCA	cis	rs875971	0.867	rs1002053	ENSG00000229180.5	GS1-124K5.11	-4.53	6.51e-06	0.000557	-0.12	-0.14	Aortic root size;	chr7:66333558	chr7:66526088~66542624:-
BRCA	cis	rs983392	0.836	rs12453	ENSG00000275344.1	MIR6503	-4.53	6.51e-06	0.000558	-0.14	-0.14	Alzheimer's disease (late onset);	chr11:60178272	chr11:60209071~60209156:-
BRCA	cis	rs34217772	0.771	rs61992388	ENSG00000258636.1	CTD-2298J14.2	4.53	6.51e-06	0.000558	0.2	0.14	Myopia;	chr14:41740677	chr14:41587861~41604856:-
BRCA	cis	rs4650994	1	rs10798617	ENSG00000273384.1	RP5-1098D14.1	4.53	6.51e-06	0.000558	0.17	0.14	HDL cholesterol;HDL cholesterol levels;	chr1:178546671	chr1:178651706~178652282:+
BRCA	cis	rs4650994	1	rs4650995	ENSG00000273384.1	RP5-1098D14.1	4.53	6.51e-06	0.000558	0.17	0.14	HDL cholesterol;HDL cholesterol levels;	chr1:178548181	chr1:178651706~178652282:+
BRCA	cis	rs10266483	0.741	rs10254313	ENSG00000228653.2	HNRNPCP7	-4.53	6.51e-06	0.000558	-0.16	-0.14	Response to statin therapy;	chr7:64278935	chr7:64500825~64501729:+
BRCA	cis	rs10266483	0.741	rs35244017	ENSG00000228653.2	HNRNPCP7	-4.53	6.51e-06	0.000558	-0.16	-0.14	Response to statin therapy;	chr7:64278939	chr7:64500825~64501729:+
BRCA	cis	rs8012947	0.607	rs1051858	ENSG00000257621.6	PSMA3-AS1	4.53	6.51e-06	0.000558	0.12	0.14	Alcohol consumption in current drinkers;	chr14:58364424	chr14:58265365~58298134:-
BRCA	cis	rs11892454	0.515	rs10185886	ENSG00000217643.1	PTGES3P2	4.53	6.52e-06	0.000558	0.15	0.14	Heschl's gyrus morphology;	chr2:25855078	chr2:25822469~25822950:+
BRCA	cis	rs6847067	0.702	rs13110728	ENSG00000180769.7	WDFY3-AS2	4.53	6.52e-06	0.000558	0.13	0.14	Oropharynx cancer;	chr4:84622305	chr4:84965682~85011277:+
BRCA	cis	rs4415084	0.8	rs2330572	ENSG00000251141.4	RP11-53O19.1	-4.53	6.52e-06	0.000558	-0.13	-0.14	Breast cancer;	chr5:44740887	chr5:44744900~44808777:-
BRCA	cis	rs7818688	0.697	rs58282276	ENSG00000253528.2	RP11-347C18.4	-4.53	6.52e-06	0.000559	-0.21	-0.14	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94973163	chr8:94974573~94974853:-
BRCA	cis	rs1510272	0.889	rs2063349	ENSG00000243926.1	TIPARP-AS1	-4.53	6.53e-06	0.000559	-0.15	-0.14	Testicular germ cell tumor;	chr3:156612356	chr3:156671862~156674378:-
BRCA	cis	rs7246657	0.722	rs3101746	ENSG00000226686.6	LINC01535	4.53	6.53e-06	0.000559	0.21	0.14	Coronary artery calcification;	chr19:37655499	chr19:37251912~37265535:+
BRCA	cis	rs7789940	0.904	rs6948661	ENSG00000280388.1	RP11-229D13.3	-4.53	6.53e-06	0.000559	-0.15	-0.14	Multiple sclerosis;	chr7:76332330	chr7:76043977~76045963:-
BRCA	cis	rs721917	0.525	rs2758545	ENSG00000278616.1	BEND3P3	-4.53	6.53e-06	0.000559	-0.13	-0.14	Chronic obstructive pulmonary disease;	chr10:79940334	chr10:79682997~79685436:+
BRCA	cis	rs62244186	0.566	rs55852922	ENSG00000214820.3	MPRIPP1	4.53	6.53e-06	0.000559	0.16	0.14	Depressive symptoms;	chr3:44784696	chr3:44579938~44581026:-
BRCA	cis	rs62244186	0.566	rs55901755	ENSG00000214820.3	MPRIPP1	4.53	6.53e-06	0.000559	0.16	0.14	Depressive symptoms;	chr3:44793215	chr3:44579938~44581026:-
BRCA	cis	rs7701440	0.508	rs476099	ENSG00000215032.2	GNL3LP1	4.53	6.53e-06	0.000559	0.17	0.14	Educational attainment;	chr5:61237147	chr5:60891935~60893577:-
BRCA	cis	rs6012564	0.963	rs6063359	ENSG00000227431.4	CSE1L-AS1	4.53	6.53e-06	0.000559	0.17	0.14	Anger;	chr20:49128547	chr20:49040463~49046044:-
BRCA	cis	rs3764021	0.933	rs2268146	ENSG00000278635.1	CTD-2318O12.1	-4.53	6.53e-06	0.00056	-0.14	-0.14	Type 1 diabetes;	chr12:9716675	chr12:9415641~9416718:+
BRCA	cis	rs11168618	1	rs11168618	ENSG00000240399.1	RP1-228P16.1	4.53	6.53e-06	0.00056	0.16	0.14	Adiponectin levels;	chr12:48539450	chr12:48054813~48055591:-
BRCA	cis	rs1665050	1	rs1665050	ENSG00000259732.1	RP11-59H7.3	4.53	6.54e-06	0.00056	0.17	0.14	Atopic dermatitis;	chr15:59001406	chr15:59121034~59133250:+
BRCA	cis	rs11603691	1	rs11228973	ENSG00000254662.1	RP11-872D17.4	-4.53	6.54e-06	0.00056	-0.33	-0.14	Low high density lipoprotein cholesterol levels;	chr11:57262770	chr11:57325603~57327958:+
BRCA	cis	rs1075265	0.935	rs6545384	ENSG00000235937.1	AC008280.1	4.53	6.54e-06	0.00056	0.15	0.14	Chronotype;Morning vs. evening chronotype;	chr2:54073927	chr2:54029552~54030682:-
BRCA	cis	rs1383484	0.64	rs12101685	ENSG00000225151.9	GOLGA2P7	4.53	6.54e-06	0.00056	0.17	0.14	Height;	chr15:83974905	chr15:84199311~84230136:-
BRCA	cis	rs651907	0.512	rs771324	ENSG00000244119.1	PDCL3P4	4.53	6.54e-06	0.00056	0.12	0.14	Colorectal cancer;	chr3:101891521	chr3:101712472~101713191:+
BRCA	cis	rs7701440	0.512	rs10939886	ENSG00000215032.2	GNL3LP1	4.53	6.54e-06	0.00056	0.17	0.14	Educational attainment;	chr5:61235738	chr5:60891935~60893577:-
BRCA	cis	rs78487399	0.908	rs77994584	ENSG00000234936.1	AC010883.5	4.53	6.54e-06	0.000561	0.2	0.14	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43589937	chr2:43229573~43233394:+
BRCA	cis	rs11098499	0.908	rs28559989	ENSG00000250412.1	KLHL2P1	4.53	6.55e-06	0.000561	0.17	0.14	Corneal astigmatism;	chr4:119465472	chr4:119334329~119378233:+
BRCA	cis	rs2337406	1	rs10459466	ENSG00000223648.3	IGHV3-64	4.53	6.55e-06	0.000561	0.16	0.14	Alzheimer's disease (late onset);	chr14:106689255	chr14:106643132~106658258:-
BRCA	cis	rs372883	0.613	rs1153274	ENSG00000176054.6	RPL23P2	-4.53	6.55e-06	0.000561	-0.16	-0.14	Pancreatic cancer;	chr21:29287705	chr21:28997613~28998033:-
BRCA	cis	rs62025270	0.688	rs62022941	ENSG00000259295.5	CSPG4P12	-4.53	6.56e-06	0.000561	-0.22	-0.14	Idiopathic pulmonary fibrosis;	chr15:85712824	chr15:85191438~85213905:+
BRCA	cis	rs7674212	0.57	rs6813563	ENSG00000246560.2	RP11-10L12.4	4.53	6.56e-06	0.000562	0.15	0.14	Type 2 diabetes;	chr4:103177953	chr4:102828055~102844075:+
BRCA	cis	rs62064224	0.589	rs9904964	ENSG00000279781.1	RP11-466A19.7	-4.53	6.56e-06	0.000562	-0.17	-0.14	Schizophrenia;	chr17:32335813	chr17:32518322~32518934:-
BRCA	cis	rs13108904	0.935	rs922698	ENSG00000196810.4	CTBP1-AS2	-4.53	6.56e-06	0.000562	-0.15	-0.14	Obesity-related traits;	chr4:1288934	chr4:1249300~1288291:+
BRCA	cis	rs10170310	0.515	rs35628318	ENSG00000241772.2	AC092620.2	4.53	6.56e-06	0.000562	0.26	0.14	Response to antipsychotic treatment;	chr2:138561405	chr2:138569090~138574458:+
BRCA	cis	rs8103278	1	rs17571725	ENSG00000267395.4	AC074212.6	4.53	6.57e-06	0.000562	0.14	0.14	Coronary artery disease;	chr19:45787564	chr19:45767796~45772504:+
BRCA	cis	rs6570726	0.935	rs110289	ENSG00000270638.1	RP3-466P17.1	4.53	6.57e-06	0.000562	0.15	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145544040	chr6:145735570~145737218:+
BRCA	cis	rs12435908	1	rs1953417	ENSG00000276116.2	FUT8-AS1	-4.53	6.57e-06	0.000562	-0.22	-0.14	Ischemic stroke;	chr14:65412191	chr14:65411170~65412690:-
BRCA	cis	rs6430585	0.528	rs56064699	ENSG00000231890.6	DARS-AS1	-4.53	6.57e-06	0.000562	-0.23	-0.14	Corneal structure;	chr2:135838136	chr2:135985176~136022593:+
BRCA	cis	rs11098499	0.909	rs1546504	ENSG00000225892.3	RP11-384K6.2	4.53	6.57e-06	0.000563	0.14	0.14	Corneal astigmatism;	chr4:119320024	chr4:118632274~118634759:+
BRCA	cis	rs13113518	0.966	rs7677952	ENSG00000272969.1	RP11-528I4.2	4.53	6.57e-06	0.000563	0.16	0.14	Height;	chr4:55425312	chr4:55547112~55547889:+
BRCA	cis	rs13113518	1	rs1047354	ENSG00000272969.1	RP11-528I4.2	4.53	6.57e-06	0.000563	0.16	0.14	Height;	chr4:55429416	chr4:55547112~55547889:+
BRCA	cis	rs13113518	1	rs1056547	ENSG00000272969.1	RP11-528I4.2	4.53	6.57e-06	0.000563	0.16	0.14	Height;	chr4:55430596	chr4:55547112~55547889:+
BRCA	cis	rs13113518	1	rs1056545	ENSG00000272969.1	RP11-528I4.2	4.53	6.57e-06	0.000563	0.16	0.14	Height;	chr4:55430730	chr4:55547112~55547889:+
BRCA	cis	rs13113518	1	rs5863	ENSG00000272969.1	RP11-528I4.2	4.53	6.57e-06	0.000563	0.16	0.14	Height;	chr4:55430740	chr4:55547112~55547889:+
BRCA	cis	rs13113518	0.966	rs6828570	ENSG00000272969.1	RP11-528I4.2	4.53	6.57e-06	0.000563	0.16	0.14	Height;	chr4:55431595	chr4:55547112~55547889:+
BRCA	cis	rs13113518	1	rs3749474	ENSG00000272969.1	RP11-528I4.2	4.53	6.57e-06	0.000563	0.16	0.14	Height;	chr4:55434518	chr4:55547112~55547889:+
BRCA	cis	rs13108904	0.539	rs13141169	ENSG00000253399.1	AC078852.2	-4.53	6.58e-06	0.000563	-0.17	-0.14	Obesity-related traits;	chr4:1346565	chr4:1358479~1359461:+
BRCA	cis	rs4072980	0.524	rs16824514	ENSG00000212541.1	RNU6-510P	-4.53	6.58e-06	0.000563	-0.18	-0.14	Coronary artery disease;	chr1:37930275	chr1:37991462~37991569:+
BRCA	cis	rs67981189	0.593	rs221924	ENSG00000269927.1	RP6-91H8.3	-4.53	6.58e-06	0.000563	-0.17	-0.14	Schizophrenia;	chr14:71114061	chr14:71141125~71143253:-
BRCA	cis	rs6831352	0.734	rs1311620	ENSG00000272777.1	RP11-571L19.8	-4.53	6.58e-06	0.000563	-0.15	-0.14	Alcohol dependence;	chr4:99091940	chr4:99067256~99068125:-
BRCA	cis	rs957448	0.561	rs12679785	ENSG00000253175.1	RP11-267M23.6	4.53	6.58e-06	0.000564	0.16	0.14	Nonsyndromic cleft lip with cleft palate;	chr8:94593349	chr8:94565036~94565715:+
BRCA	cis	rs7572733	0.84	rs6743671	ENSG00000231621.1	AC013264.2	4.53	6.58e-06	0.000564	0.13	0.14	Dermatomyositis;	chr2:197698918	chr2:197197991~197199273:+
BRCA	cis	rs8114671	0.805	rs6060168	ENSG00000126005.14	MMP24-AS1	-4.53	6.59e-06	0.000564	-0.16	-0.14	Height;	chr20:35033214	chr20:35216462~35278131:-
BRCA	cis	rs73186030	0.92	rs73186053	ENSG00000272758.4	RP11-299J3.8	4.53	6.59e-06	0.000564	0.21	0.14	Serum parathyroid hormone levels;	chr3:122322009	chr3:122416207~122443180:+
BRCA	cis	rs853679	0.766	rs9368561	ENSG00000280107.1	AL022393.9	-4.53	6.59e-06	0.000564	-0.29	-0.14	Depression;	chr6:28200565	chr6:28170845~28172521:+
BRCA	cis	rs62025270	0.632	rs62022918	ENSG00000259762.1	RP11-158M2.4	-4.53	6.59e-06	0.000564	-0.2	-0.14	Idiopathic pulmonary fibrosis;	chr15:85675053	chr15:85750336~85752901:-
BRCA	cis	rs4415084	1	rs4415084	ENSG00000251141.4	RP11-53O19.1	4.53	6.59e-06	0.000564	0.13	0.14	Breast cancer;	chr5:44662413	chr5:44744900~44808777:-
BRCA	cis	rs490234	0.702	rs10986788	ENSG00000232630.1	PRPS1P2	-4.53	6.6e-06	0.000565	-0.15	-0.14	Mean arterial pressure;	chr9:125541663	chr9:125150653~125151589:+
BRCA	cis	rs718433	0.584	rs2075478	ENSG00000256379.1	TRAV8-5	4.53	6.6e-06	0.000565	0.16	0.14	Intraocular pressure;	chr14:21749767	chr14:21903077~21903598:+
BRCA	cis	rs718433	0.584	rs2874142	ENSG00000256379.1	TRAV8-5	4.53	6.6e-06	0.000565	0.16	0.14	Intraocular pressure;	chr14:21750036	chr14:21903077~21903598:+
BRCA	cis	rs2253762	0.507	rs10159582	ENSG00000226864.1	ATE1-AS1	4.53	6.6e-06	0.000565	0.25	0.14	Breast cancer;	chr10:121993110	chr10:121928312~121951965:+
BRCA	cis	rs2253762	0.507	rs10159583	ENSG00000226864.1	ATE1-AS1	4.53	6.6e-06	0.000565	0.25	0.14	Breast cancer;	chr10:121993154	chr10:121928312~121951965:+
BRCA	cis	rs2489715	1	rs2505841	ENSG00000185904.10	LINC00839	-4.53	6.6e-06	0.000565	-0.19	-0.14	Helix rolling;	chr10:42391338	chr10:42475543~42495336:+
BRCA	cis	rs2243480	0.522	rs1638736	ENSG00000229886.1	RP5-1132H15.3	4.53	6.6e-06	0.000565	0.29	0.14	Diabetic kidney disease;	chr7:66627321	chr7:66025126~66031544:-
BRCA	cis	rs1153858	1	rs11858495	ENSG00000275672.1	GATM-AS1	4.53	6.6e-06	0.000565	0.18	0.14	Homoarginine levels;	chr15:45345464	chr15:45378700~45380123:+
BRCA	cis	rs6686842	0.897	rs2802565	ENSG00000235358.1	RP11-399E6.1	-4.53	6.6e-06	0.000565	-0.17	-0.14	Height;	chr1:41086147	chr1:41242373~41284861:+
BRCA	cis	rs2408955	0.522	rs7139330	ENSG00000257763.1	OR5BK1P	-4.53	6.61e-06	0.000565	-0.15	-0.14	Glycated hemoglobin levels;	chr12:48089701	chr12:48355792~48356614:-
BRCA	cis	rs7621331	0.963	rs9289503	ENSG00000273486.1	RP11-731C17.2	4.53	6.61e-06	0.000566	0.16	0.14	Waist circumference adjusted for body mass index;	chr3:136020499	chr3:136837338~136839021:-
BRCA	cis	rs516805	0.667	rs2816139	ENSG00000279114.1	RP3-425C14.5	-4.53	6.61e-06	0.000566	-0.19	-0.14	Lymphocyte counts;	chr6:122182267	chr6:122471923~122484161:+
BRCA	cis	rs6441961	0.501	rs41418050	ENSG00000223552.1	RP11-24F11.2	4.53	6.61e-06	0.000566	0.17	0.14	Celiac disease;	chr3:46238755	chr3:46364955~46407059:-
BRCA	cis	rs1153858	1	rs7167900	ENSG00000275672.1	GATM-AS1	-4.53	6.61e-06	0.000566	-0.18	-0.14	Homoarginine levels;	chr15:45347273	chr15:45378700~45380123:+
BRCA	cis	rs4713118	0.588	rs200994	ENSG00000219392.1	RP1-265C24.5	4.53	6.61e-06	0.000566	0.21	0.14	Parkinson's disease;	chr6:27846035	chr6:28115628~28116551:+
BRCA	cis	rs62458065	1	rs979355	ENSG00000229358.3	DPY19L1P1	4.53	6.61e-06	0.000566	0.18	0.14	Metabolite levels (HVA/MHPG ratio);	chr7:32424321	chr7:32580949~32761787:-
BRCA	cis	rs4664293	0.867	rs7566584	ENSG00000226266.5	AC009961.3	-4.53	6.61e-06	0.000566	-0.17	-0.14	Monocyte percentage of white cells;	chr2:159728284	chr2:159670708~159712435:-
BRCA	cis	rs4664293	0.867	rs3732289	ENSG00000226266.5	AC009961.3	-4.53	6.61e-06	0.000566	-0.17	-0.14	Monocyte percentage of white cells;	chr2:159728887	chr2:159670708~159712435:-
BRCA	cis	rs4664293	0.867	rs3821299	ENSG00000226266.5	AC009961.3	-4.53	6.61e-06	0.000566	-0.17	-0.14	Monocyte percentage of white cells;	chr2:159729229	chr2:159670708~159712435:-
BRCA	cis	rs4664293	0.867	rs13415100	ENSG00000226266.5	AC009961.3	-4.53	6.61e-06	0.000566	-0.17	-0.14	Monocyte percentage of white cells;	chr2:159729716	chr2:159670708~159712435:-
BRCA	cis	rs4664293	0.867	rs13389662	ENSG00000226266.5	AC009961.3	-4.53	6.61e-06	0.000566	-0.17	-0.14	Monocyte percentage of white cells;	chr2:159729926	chr2:159670708~159712435:-
BRCA	cis	rs4664293	0.867	rs4665110	ENSG00000226266.5	AC009961.3	-4.53	6.61e-06	0.000566	-0.17	-0.14	Monocyte percentage of white cells;	chr2:159731014	chr2:159670708~159712435:-
BRCA	cis	rs4664293	0.867	rs34893664	ENSG00000226266.5	AC009961.3	-4.53	6.61e-06	0.000566	-0.17	-0.14	Monocyte percentage of white cells;	chr2:159732266	chr2:159670708~159712435:-
BRCA	cis	rs4664293	0.867	rs34795915	ENSG00000226266.5	AC009961.3	-4.53	6.61e-06	0.000566	-0.17	-0.14	Monocyte percentage of white cells;	chr2:159732420	chr2:159670708~159712435:-
BRCA	cis	rs4664293	0.867	rs10204867	ENSG00000226266.5	AC009961.3	-4.53	6.61e-06	0.000566	-0.17	-0.14	Monocyte percentage of white cells;	chr2:159732674	chr2:159670708~159712435:-
BRCA	cis	rs4664293	0.867	rs35196716	ENSG00000226266.5	AC009961.3	-4.53	6.61e-06	0.000566	-0.17	-0.14	Monocyte percentage of white cells;	chr2:159733266	chr2:159670708~159712435:-
BRCA	cis	rs4664293	0.867	rs6432557	ENSG00000226266.5	AC009961.3	-4.53	6.61e-06	0.000566	-0.17	-0.14	Monocyte percentage of white cells;	chr2:159735699	chr2:159670708~159712435:-
BRCA	cis	rs4664293	0.867	rs7603274	ENSG00000226266.5	AC009961.3	-4.53	6.61e-06	0.000566	-0.17	-0.14	Monocyte percentage of white cells;	chr2:159736179	chr2:159670708~159712435:-
BRCA	cis	rs4664293	0.836	rs13403371	ENSG00000226266.5	AC009961.3	-4.53	6.61e-06	0.000566	-0.17	-0.14	Monocyte percentage of white cells;	chr2:159736603	chr2:159670708~159712435:-
BRCA	cis	rs4664293	0.867	rs13428679	ENSG00000226266.5	AC009961.3	-4.53	6.61e-06	0.000566	-0.17	-0.14	Monocyte percentage of white cells;	chr2:159736687	chr2:159670708~159712435:-
BRCA	cis	rs4664293	0.867	rs12623283	ENSG00000226266.5	AC009961.3	-4.53	6.61e-06	0.000566	-0.17	-0.14	Monocyte percentage of white cells;	chr2:159736959	chr2:159670708~159712435:-
BRCA	cis	rs4664293	0.867	rs2098976	ENSG00000226266.5	AC009961.3	-4.53	6.61e-06	0.000566	-0.17	-0.14	Monocyte percentage of white cells;	chr2:159737264	chr2:159670708~159712435:-
BRCA	cis	rs4664293	0.867	rs2081723	ENSG00000226266.5	AC009961.3	-4.53	6.61e-06	0.000566	-0.17	-0.14	Monocyte percentage of white cells;	chr2:159737649	chr2:159670708~159712435:-
BRCA	cis	rs4664293	0.867	rs2081722	ENSG00000226266.5	AC009961.3	-4.53	6.61e-06	0.000566	-0.17	-0.14	Monocyte percentage of white cells;	chr2:159737697	chr2:159670708~159712435:-
BRCA	cis	rs4664293	0.867	rs10166694	ENSG00000226266.5	AC009961.3	-4.53	6.61e-06	0.000566	-0.17	-0.14	Monocyte percentage of white cells;	chr2:159738380	chr2:159670708~159712435:-
BRCA	cis	rs4664293	0.867	rs2357529	ENSG00000226266.5	AC009961.3	-4.53	6.61e-06	0.000566	-0.17	-0.14	Monocyte percentage of white cells;	chr2:159738922	chr2:159670708~159712435:-
BRCA	cis	rs4664293	0.867	rs12692562	ENSG00000226266.5	AC009961.3	-4.53	6.61e-06	0.000566	-0.17	-0.14	Monocyte percentage of white cells;	chr2:159739199	chr2:159670708~159712435:-
BRCA	cis	rs4664293	0.867	rs12998291	ENSG00000226266.5	AC009961.3	-4.53	6.61e-06	0.000566	-0.17	-0.14	Monocyte percentage of white cells;	chr2:159739392	chr2:159670708~159712435:-
BRCA	cis	rs1075265	0.744	rs10203576	ENSG00000235937.1	AC008280.1	4.53	6.62e-06	0.000566	0.15	0.14	Chronotype;Morning vs. evening chronotype;	chr2:54060939	chr2:54029552~54030682:-
BRCA	cis	rs300890	0.513	rs1440419	ENSG00000250326.1	RP11-284M14.1	-4.53	6.62e-06	0.000566	-0.17	-0.14	Nasopharyngeal carcinoma;	chr4:143242187	chr4:142933195~143184861:-
BRCA	cis	rs300890	0.513	rs11732484	ENSG00000250326.1	RP11-284M14.1	-4.53	6.62e-06	0.000566	-0.17	-0.14	Nasopharyngeal carcinoma;	chr4:143242330	chr4:142933195~143184861:-
BRCA	cis	rs13113518	1	rs6847529	ENSG00000273257.1	RP11-177J6.1	4.53	6.62e-06	0.000566	0.18	0.14	Height;	chr4:55518776	chr4:55387949~55388271:+
BRCA	cis	rs13113518	1	rs6822740	ENSG00000273257.1	RP11-177J6.1	4.53	6.62e-06	0.000566	0.18	0.14	Height;	chr4:55518922	chr4:55387949~55388271:+
BRCA	cis	rs6088580	0.634	rs6059779	ENSG00000276073.1	RP5-1125A11.7	4.53	6.62e-06	0.000566	0.15	0.14	Glomerular filtration rate (creatinine);	chr20:34362519	chr20:33985617~33988989:-
BRCA	cis	rs4218	0.689	rs35555888	ENSG00000277144.1	RP11-59H7.4	-4.53	6.62e-06	0.000566	-0.18	-0.14	Social communication problems;	chr15:59093935	chr15:59115547~59116089:-
BRCA	cis	rs7160336	1	rs1468507	ENSG00000259065.1	RP5-1021I20.1	4.53	6.62e-06	0.000566	0.15	0.14	Blood protein levels;	chr14:74105395	chr14:73787360~73803270:+
BRCA	cis	rs2832191	0.72	rs4643617	ENSG00000236056.1	GAPDHP14	4.53	6.62e-06	0.000567	0.15	0.14	Dental caries;	chr21:29112957	chr21:29222321~29223257:+
BRCA	cis	rs2832191	0.791	rs2832187	ENSG00000236056.1	GAPDHP14	4.53	6.62e-06	0.000567	0.15	0.14	Dental caries;	chr21:29113222	chr21:29222321~29223257:+
BRCA	cis	rs12477438	0.834	rs1563108	ENSG00000231822.1	AC019097.7	-4.53	6.62e-06	0.000567	-0.15	-0.14	Chronic sinus infection;	chr2:99084690	chr2:99102018~99102752:+
BRCA	cis	rs7267979	0.789	rs4815400	ENSG00000125804.12	FAM182A	4.53	6.62e-06	0.000567	0.18	0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25311924	chr20:26054655~26086917:+
BRCA	cis	rs6968419	0.755	rs2896180	ENSG00000279086.1	RP11-667F14.1	-4.53	6.63e-06	0.000567	-0.15	-0.14	Intraocular pressure;	chr7:116257817	chr7:116209234~116211511:-
BRCA	cis	rs35612822	0.723	rs13428500	ENSG00000232485.2	AC098820.3	-4.53	6.63e-06	0.000567	-0.17	-0.14	Kidney disease (early stage) in type 1 diabetes;	chr2:216403187	chr2:216479030~216498761:-
BRCA	cis	rs7686660	1	rs12650233	ENSG00000250326.1	RP11-284M14.1	-4.53	6.63e-06	0.000567	-0.16	-0.14	Asthma;	chr4:143004215	chr4:142933195~143184861:-
BRCA	cis	rs7686660	0.784	rs4690746	ENSG00000250326.1	RP11-284M14.1	-4.53	6.63e-06	0.000567	-0.16	-0.14	Asthma;	chr4:143007595	chr4:142933195~143184861:-
BRCA	cis	rs7772486	0.875	rs2474356	ENSG00000270638.1	RP3-466P17.1	4.53	6.63e-06	0.000567	0.16	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145975662	chr6:145735570~145737218:+
BRCA	cis	rs35740288	0.52	rs56183577	ENSG00000259407.1	RP11-158M2.3	-4.53	6.63e-06	0.000567	-0.2	-0.14	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85776475	chr15:85744109~85750281:-
BRCA	cis	rs7200543	1	rs4500751	ENSG00000258354.1	MIR3180-1	-4.53	6.63e-06	0.000567	-0.18	-0.14	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15046354	chr16:14909887~14911345:-
BRCA	cis	rs7267979	0.565	rs6107060	ENSG00000231081.1	RP4-760C5.3	-4.53	6.63e-06	0.000567	-0.18	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25611840	chr20:26008791~26010531:-
BRCA	cis	rs6496932	0.774	rs12901648	ENSG00000259630.2	CTD-2262B20.1	-4.53	6.63e-06	0.000567	-0.24	-0.14	Central corneal thickness;Corneal structure;	chr15:85408487	chr15:85415228~85415633:+
BRCA	cis	rs755249	0.565	rs7539261	ENSG00000237624.1	OXCT2P1	-4.53	6.64e-06	0.000568	-0.16	-0.14	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39584831	chr1:39514956~39516490:+
BRCA	cis	rs6088580	0.542	rs6059882	ENSG00000276073.1	RP5-1125A11.7	-4.53	6.64e-06	0.000568	-0.15	-0.14	Glomerular filtration rate (creatinine);	chr20:34502362	chr20:33985617~33988989:-
BRCA	cis	rs6657613	0.68	rs10887994	ENSG00000186715.9	MST1L	4.53	6.64e-06	0.000568	0.13	0.14	Hip circumference adjusted for BMI;	chr1:17045260	chr1:16754910~16770237:-
BRCA	cis	rs6968419	0.963	rs10261818	ENSG00000279086.1	RP11-667F14.1	-4.53	6.64e-06	0.000568	-0.14	-0.14	Intraocular pressure;	chr7:116185232	chr7:116209234~116211511:-
BRCA	cis	rs6968419	0.781	rs10261823	ENSG00000279086.1	RP11-667F14.1	-4.53	6.64e-06	0.000568	-0.14	-0.14	Intraocular pressure;	chr7:116185237	chr7:116209234~116211511:-
BRCA	cis	rs9990333	0.521	rs3862281	ENSG00000242086.7	LINC00969	4.53	6.64e-06	0.000568	0.16	0.14	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196092985	chr3:195658062~195739964:+
BRCA	cis	rs1555322	1	rs2425041	ENSG00000279253.1	RP4-614O4.13	-4.53	6.64e-06	0.000568	-0.23	-0.14	Attention deficit hyperactivity disorder;	chr20:35271210	chr20:35262727~35264187:-
BRCA	cis	rs7819412	0.502	rs4841499	ENSG00000154316.13	TDH	4.53	6.64e-06	0.000568	0.2	0.14	Triglycerides;	chr8:11130628	chr8:11339637~11368452:+
BRCA	cis	rs9840812	0.769	rs534944	ENSG00000273486.1	RP11-731C17.2	4.53	6.64e-06	0.000568	0.17	0.14	Fibrinogen levels;	chr3:136242189	chr3:136837338~136839021:-
BRCA	cis	rs763121	0.853	rs5750630	ENSG00000225450.1	RP3-508I15.14	-4.53	6.65e-06	0.000568	-0.15	-0.14	Menopause (age at onset);	chr22:38589813	chr22:38739003~38749041:+
BRCA	cis	rs1707322	0.964	rs6675259	ENSG00000234329.1	RP11-767N6.2	-4.53	6.65e-06	0.000569	-0.15	-0.14	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46036623	chr1:45651039~45651826:-
BRCA	cis	rs755249	0.501	rs1889830	ENSG00000237624.1	OXCT2P1	-4.53	6.65e-06	0.000569	-0.18	-0.14	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39264500	chr1:39514956~39516490:+
BRCA	cis	rs1979679	0.608	rs3803087	ENSG00000278733.1	RP11-425D17.1	-4.53	6.66e-06	0.000569	-0.19	-0.14	Ossification of the posterior longitudinal ligament of the spine;	chr12:28573701	chr12:28185625~28186190:-
BRCA	cis	rs875971	0.545	rs313830	ENSG00000232546.1	RP11-458F8.1	-4.53	6.66e-06	0.00057	-0.13	-0.14	Aortic root size;	chr7:66086944	chr7:66848496~66858136:+
BRCA	cis	rs11098499	0.697	rs11941899	ENSG00000250412.1	KLHL2P1	4.53	6.66e-06	0.00057	0.16	0.14	Corneal astigmatism;	chr4:119461603	chr4:119334329~119378233:+
BRCA	cis	rs11098499	0.909	rs7681978	ENSG00000250412.1	KLHL2P1	4.53	6.66e-06	0.00057	0.16	0.14	Corneal astigmatism;	chr4:119462620	chr4:119334329~119378233:+
BRCA	cis	rs11098499	0.821	rs28665282	ENSG00000250412.1	KLHL2P1	4.53	6.66e-06	0.00057	0.16	0.14	Corneal astigmatism;	chr4:119463031	chr4:119334329~119378233:+
BRCA	cis	rs11098499	0.738	rs10026493	ENSG00000250412.1	KLHL2P1	4.53	6.66e-06	0.00057	0.16	0.14	Corneal astigmatism;	chr4:119463039	chr4:119334329~119378233:+
BRCA	cis	rs11098499	0.909	rs7681214	ENSG00000250412.1	KLHL2P1	4.53	6.66e-06	0.00057	0.16	0.14	Corneal astigmatism;	chr4:119464165	chr4:119334329~119378233:+
BRCA	cis	rs11098499	0.909	rs28632018	ENSG00000250412.1	KLHL2P1	4.53	6.66e-06	0.00057	0.16	0.14	Corneal astigmatism;	chr4:119465575	chr4:119334329~119378233:+
BRCA	cis	rs11098499	0.908	rs71614449	ENSG00000250412.1	KLHL2P1	4.53	6.66e-06	0.00057	0.16	0.14	Corneal astigmatism;	chr4:119465900	chr4:119334329~119378233:+
BRCA	cis	rs11098499	0.954	rs35063680	ENSG00000250412.1	KLHL2P1	4.53	6.66e-06	0.00057	0.16	0.14	Corneal astigmatism;	chr4:119465947	chr4:119334329~119378233:+
BRCA	cis	rs11098499	0.954	rs34858317	ENSG00000250412.1	KLHL2P1	4.53	6.66e-06	0.00057	0.16	0.14	Corneal astigmatism;	chr4:119465955	chr4:119334329~119378233:+
BRCA	cis	rs11098499	0.954	rs17046116	ENSG00000250412.1	KLHL2P1	4.53	6.66e-06	0.00057	0.16	0.14	Corneal astigmatism;	chr4:119466104	chr4:119334329~119378233:+
BRCA	cis	rs11098499	0.909	rs17046118	ENSG00000250412.1	KLHL2P1	4.53	6.66e-06	0.00057	0.16	0.14	Corneal astigmatism;	chr4:119466341	chr4:119334329~119378233:+
BRCA	cis	rs11098499	0.954	rs7654587	ENSG00000250412.1	KLHL2P1	4.53	6.66e-06	0.00057	0.16	0.14	Corneal astigmatism;	chr4:119467251	chr4:119334329~119378233:+
BRCA	cis	rs442309	0.812	rs224090	ENSG00000238280.1	RP11-436D10.3	4.53	6.66e-06	0.00057	0.18	0.14	Vogt-Koyanagi-Harada syndrome;	chr10:62781559	chr10:62793562~62805887:-
BRCA	cis	rs1005277	0.541	rs2505193	ENSG00000263064.2	RP11-291L22.7	4.53	6.67e-06	0.00057	0.17	0.14	Extrinsic epigenetic age acceleration;	chr10:38105710	chr10:38448689~38448949:+
BRCA	cis	rs10761482	0.5	rs2153525	ENSG00000254271.1	RP11-131N11.4	-4.53	6.67e-06	0.00057	-0.19	-0.14	Schizophrenia;	chr10:60509816	chr10:60734342~60741828:+
BRCA	cis	rs6671200	0.831	rs35917978	ENSG00000235501.4	RP4-639F20.1	-4.53	6.67e-06	0.00057	-0.32	-0.14	Stearic acid (18:0) levels;	chr1:95138432	chr1:94927566~94963270:+
BRCA	cis	rs3812049	0.737	rs790154	ENSG00000245937.6	LINC01184	4.53	6.67e-06	0.00057	0.19	0.14	Lymphocyte counts;Red cell distribution width;	chr5:128165543	chr5:127940426~128083172:-
BRCA	cis	rs2834288	0.734	rs743336	ENSG00000273102.1	AP000569.9	-4.53	6.67e-06	0.00057	-0.16	-0.14	Gut microbiota (bacterial taxa);	chr21:33893080	chr21:33967101~33968573:-
BRCA	cis	rs2834288	0.734	rs743337	ENSG00000273102.1	AP000569.9	-4.53	6.67e-06	0.00057	-0.16	-0.14	Gut microbiota (bacterial taxa);	chr21:33893220	chr21:33967101~33968573:-
BRCA	cis	rs2243480	1	rs35542501	ENSG00000275400.1	RP4-756H11.5	4.53	6.67e-06	0.00057	0.24	0.14	Diabetic kidney disease;	chr7:65966228	chr7:66553805~66554199:-
BRCA	cis	rs2243480	0.708	rs781141	ENSG00000275400.1	RP4-756H11.5	4.53	6.67e-06	0.00057	0.24	0.14	Diabetic kidney disease;	chr7:65973566	chr7:66553805~66554199:-
BRCA	cis	rs875971	0.502	rs6460311	ENSG00000273142.1	RP11-458F8.4	-4.53	6.67e-06	0.00057	-0.14	-0.14	Aortic root size;	chr7:66646886	chr7:66902857~66906297:+
BRCA	cis	rs9840812	0.861	rs687339	ENSG00000239213.4	NCK1-AS1	4.53	6.68e-06	0.000571	0.18	0.14	Fibrinogen levels;	chr3:136213517	chr3:136841726~136862054:-
BRCA	cis	rs7617773	0.963	rs6800730	ENSG00000228638.1	FCF1P2	-4.53	6.68e-06	0.000571	-0.14	-0.14	Coronary artery disease;	chr3:48132720	chr3:48290793~48291375:-
BRCA	cis	rs2833693	0.656	rs2833697	ENSG00000261610.1	AP000265.1	4.53	6.68e-06	0.000571	0.17	0.14	Temperament;	chr21:32183825	chr21:32259804~32261585:-
BRCA	cis	rs6430585	0.583	rs59243420	ENSG00000224043.6	CCNT2-AS1	-4.53	6.68e-06	0.000571	-0.23	-0.14	Corneal structure;	chr2:135826968	chr2:134735464~134918710:-
BRCA	cis	rs7818688	0.697	rs76215523	ENSG00000253528.2	RP11-347C18.4	-4.53	6.68e-06	0.000571	-0.21	-0.14	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94974787	chr8:94974573~94974853:-
BRCA	cis	rs7818688	0.697	rs3802192	ENSG00000253528.2	RP11-347C18.4	-4.53	6.68e-06	0.000571	-0.21	-0.14	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94975243	chr8:94974573~94974853:-
BRCA	cis	rs7818688	0.697	rs11784140	ENSG00000253528.2	RP11-347C18.4	-4.53	6.68e-06	0.000571	-0.21	-0.14	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94975252	chr8:94974573~94974853:-
BRCA	cis	rs7818688	1	rs10093594	ENSG00000253528.2	RP11-347C18.4	4.53	6.68e-06	0.000571	0.21	0.14	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95021008	chr8:94974573~94974853:-
BRCA	cis	rs12681366	0.537	rs9297939	ENSG00000253704.1	RP11-267M23.4	4.53	6.68e-06	0.000571	0.15	0.14	Nonsyndromic cleft lip with cleft palate;	chr8:94467961	chr8:94553722~94569745:+
BRCA	cis	rs6840360	0.642	rs10857260	ENSG00000251603.1	RP11-164P12.4	-4.53	6.68e-06	0.000571	-0.13	-0.14	Intelligence (multi-trait analysis);	chr4:151502904	chr4:151667224~151670502:+
BRCA	cis	rs2243480	1	rs316330	ENSG00000222364.1	RNU6-96P	-4.53	6.68e-06	0.000571	-0.26	-0.14	Diabetic kidney disease;	chr7:66140385	chr7:66395191~66395286:+
BRCA	cis	rs9510787	0.649	rs9510793	ENSG00000205861.10	C1QTNF9B-AS1	-4.53	6.68e-06	0.000571	-0.19	-0.14	Nasopharyngeal carcinoma;	chr13:23638981	chr13:23888889~23897263:+
BRCA	cis	rs6088580	0.66	rs6059893	ENSG00000276073.1	RP5-1125A11.7	-4.53	6.68e-06	0.000571	-0.15	-0.14	Glomerular filtration rate (creatinine);	chr20:34518092	chr20:33985617~33988989:-
BRCA	cis	rs2073316	0.626	rs12473298	ENSG00000272716.1	RP11-563N4.1	4.53	6.68e-06	0.000571	0.15	0.14	Interleukin-18 levels;	chr2:31479636	chr2:32165046~32165757:-
BRCA	cis	rs1867631	1	rs7546090	ENSG00000248458.2	RP4-598P13.1	4.53	6.68e-06	0.000571	0.15	0.14	Menopause (age at onset);	chr1:66618298	chr1:66665864~66677027:-
BRCA	cis	rs7615952	0.932	rs11922218	ENSG00000250012.1	RP11-124N2.1	-4.53	6.68e-06	0.000571	-0.2	-0.14	Blood pressure (smoking interaction);	chr3:125912446	chr3:126084220~126095349:+
BRCA	cis	rs7615952	0.866	rs11922276	ENSG00000250012.1	RP11-124N2.1	-4.53	6.68e-06	0.000571	-0.2	-0.14	Blood pressure (smoking interaction);	chr3:125912483	chr3:126084220~126095349:+
BRCA	cis	rs9788721	0.934	rs1317286	ENSG00000261762.1	RP11-650L12.2	-4.53	6.69e-06	0.000571	-0.17	-0.14	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78603787	chr15:78589123~78591276:-
BRCA	cis	rs2412819	0.571	rs528764	ENSG00000166763.7	STRCP1	-4.53	6.69e-06	0.000571	-0.19	-0.14	Lung cancer;	chr15:43838650	chr15:43699488~43718184:-
BRCA	cis	rs72827839	0.739	rs16953235	ENSG00000263412.1	RP5-890E16.2	4.53	6.69e-06	0.000571	0.18	0.14	Ease of getting up in the morning;	chr17:48167586	chr17:48045141~48048073:-
BRCA	cis	rs6095360	1	rs6019535	ENSG00000222365.1	SNORD12B	-4.53	6.69e-06	0.000571	-0.15	-0.14	Intelligence (multi-trait analysis);	chr20:48924980	chr20:49280319~49280409:+
BRCA	cis	rs1910358	0.621	rs7734054	ENSG00000248874.4	C5orf17	-4.53	6.69e-06	0.000571	-0.2	-0.14	Venous thromboembolism (SNP x SNP interaction);	chr5:23858070	chr5:23951348~24178263:+
BRCA	cis	rs9907295	0.901	rs4796119	ENSG00000270977.1	AC015849.16	4.53	6.69e-06	0.000572	0.24	0.14	Fibroblast growth factor basic levels;	chr17:35866084	chr17:35893707~35911023:-
BRCA	cis	rs1005277	0.579	rs9299760	ENSG00000099251.13	HSD17B7P2	4.53	6.69e-06	0.000572	0.15	0.14	Extrinsic epigenetic age acceleration;	chr10:38088992	chr10:38356380~38378505:+
BRCA	cis	rs1005277	0.579	rs2023351	ENSG00000099251.13	HSD17B7P2	4.53	6.69e-06	0.000572	0.15	0.14	Extrinsic epigenetic age acceleration;	chr10:38089886	chr10:38356380~38378505:+
BRCA	cis	rs60695258	0.512	rs2053770	ENSG00000251411.1	RP11-397E7.4	4.53	6.69e-06	0.000572	0.16	0.14	Hematocrit;	chr4:86986933	chr4:86913266~86914817:-
BRCA	cis	rs1005277	0.579	rs2008449	ENSG00000099251.13	HSD17B7P2	-4.53	6.69e-06	0.000572	-0.15	-0.14	Extrinsic epigenetic age acceleration;	chr10:38125276	chr10:38356380~38378505:+
BRCA	cis	rs6847067	0.794	rs12498787	ENSG00000180769.7	WDFY3-AS2	4.53	6.7e-06	0.000572	0.13	0.14	Oropharynx cancer;	chr4:85024761	chr4:84965682~85011277:+
BRCA	cis	rs10504130	0.569	rs35032384	ENSG00000253844.1	RP11-546K22.1	-4.53	6.7e-06	0.000572	-0.2	-0.14	Venous thromboembolism (SNP x SNP interaction);	chr8:51910524	chr8:51961458~52022974:+
BRCA	cis	rs11638815	0.603	rs10162807	ENSG00000259429.4	UBE2Q2P2	-4.53	6.7e-06	0.000573	-0.14	-0.14	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82620430	chr15:82355142~82420075:+
BRCA	cis	rs6599077	1	rs11920120	ENSG00000223797.4	ENTPD3-AS1	4.53	6.7e-06	0.000573	0.16	0.14	Sleep-related phenotypes;	chr3:40053304	chr3:40313802~40453329:-
BRCA	cis	rs6599077	1	rs2068977	ENSG00000223797.4	ENTPD3-AS1	4.53	6.7e-06	0.000573	0.16	0.14	Sleep-related phenotypes;	chr3:40053661	chr3:40313802~40453329:-
BRCA	cis	rs6599077	1	rs9842085	ENSG00000223797.4	ENTPD3-AS1	4.53	6.7e-06	0.000573	0.16	0.14	Sleep-related phenotypes;	chr3:40054053	chr3:40313802~40453329:-
BRCA	cis	rs6599077	1	rs9822101	ENSG00000223797.4	ENTPD3-AS1	4.53	6.7e-06	0.000573	0.16	0.14	Sleep-related phenotypes;	chr3:40054063	chr3:40313802~40453329:-
BRCA	cis	rs3796352	1	rs11717619	ENSG00000242142.1	SERBP1P3	-4.53	6.7e-06	0.000573	-0.25	-0.14	Immune reponse to smallpox (secreted IL-2);	chr3:52969163	chr3:53064283~53065091:-
BRCA	cis	rs11168618	1	rs10875830	ENSG00000240399.1	RP1-228P16.1	4.53	6.7e-06	0.000573	0.15	0.14	Adiponectin levels;	chr12:48543727	chr12:48054813~48055591:-
BRCA	cis	rs11098499	0.909	rs73842633	ENSG00000250412.1	KLHL2P1	4.53	6.7e-06	0.000573	0.17	0.14	Corneal astigmatism;	chr4:119454309	chr4:119334329~119378233:+
BRCA	cis	rs17507216	0.518	rs1877240	ENSG00000255769.6	GOLGA2P10	-4.53	6.71e-06	0.000573	-0.21	-0.14	Excessive daytime sleepiness;	chr15:82770126	chr15:82472993~82513950:-
BRCA	cis	rs2268667	0.565	rs6657732	ENSG00000223653.4	RP11-131L23.1	-4.53	6.71e-06	0.000573	-0.15	-0.14	Asymmetrical dimethylarginine levels;	chr1:85408812	chr1:85276715~85448124:+
BRCA	cis	rs61160187	0.582	rs67555188	ENSG00000272308.1	RP11-231G3.1	-4.53	6.71e-06	0.000573	-0.16	-0.14	Educational attainment (years of education);Educational attainment (college completion);	chr5:60847401	chr5:60866457~60866935:-
BRCA	cis	rs61160187	0.582	rs67858932	ENSG00000272308.1	RP11-231G3.1	-4.53	6.71e-06	0.000573	-0.16	-0.14	Educational attainment (years of education);Educational attainment (college completion);	chr5:60847424	chr5:60866457~60866935:-
BRCA	cis	rs17684571	0.7	rs62411376	ENSG00000231441.1	RP11-472M19.2	4.53	6.71e-06	0.000573	0.22	0.14	Schizophrenia;	chr6:56794436	chr6:56844002~56864078:+
BRCA	cis	rs17684571	0.7	rs34228698	ENSG00000231441.1	RP11-472M19.2	4.53	6.71e-06	0.000573	0.22	0.14	Schizophrenia;	chr6:56795962	chr6:56844002~56864078:+
BRCA	cis	rs6546324	0.559	rs4671806	ENSG00000236780.4	AC078941.1	4.53	6.71e-06	0.000573	0.24	0.14	Endometriosis;	chr2:67550026	chr2:67123357~67215319:-
BRCA	cis	rs2273156	1	rs12895051	ENSG00000226677.3	IGBP1P1	-4.53	6.71e-06	0.000573	-0.2	-0.14	Immunoglobulin light chain (AL) amyloidosis;	chr14:34974864	chr14:34939324~34940332:+
BRCA	cis	rs2273156	1	rs35090385	ENSG00000226677.3	IGBP1P1	-4.53	6.71e-06	0.000573	-0.2	-0.14	Immunoglobulin light chain (AL) amyloidosis;	chr14:34975229	chr14:34939324~34940332:+
BRCA	cis	rs12681366	0.537	rs6999976	ENSG00000253704.1	RP11-267M23.4	4.53	6.71e-06	0.000573	0.15	0.14	Nonsyndromic cleft lip with cleft palate;	chr8:94470194	chr8:94553722~94569745:+
BRCA	cis	rs7577696	0.695	rs10172468	ENSG00000272716.1	RP11-563N4.1	4.53	6.71e-06	0.000574	0.15	0.14	Inflammatory biomarkers;	chr2:32207128	chr2:32165046~32165757:-
BRCA	cis	rs7487075	0.619	rs2131371	ENSG00000274723.1	RP11-618L22.1	4.53	6.71e-06	0.000574	0.19	0.14	Itch intensity from mosquito bite;	chr12:46402739	chr12:46970504~46972155:+
BRCA	cis	rs10129255	0.719	rs7156660	ENSG00000232216.1	IGHV3-43	4.53	6.71e-06	0.000574	0.11	0.14	Kawasaki disease;	chr14:106673171	chr14:106470264~106470800:-
BRCA	cis	rs6686842	1	rs12134073	ENSG00000235358.1	RP11-399E6.1	4.53	6.72e-06	0.000574	0.17	0.14	Height;	chr1:41223611	chr1:41242373~41284861:+
BRCA	cis	rs950776	0.593	rs621849	ENSG00000279373.1	RP11-650L12.4	-4.53	6.72e-06	0.000574	-0.16	-0.14	Sudden cardiac arrest;	chr15:78580519	chr15:78537681~78538946:+
BRCA	cis	rs9863	0.861	rs3789967	ENSG00000270028.1	RP11-380L11.4	4.53	6.72e-06	0.000574	0.17	0.14	White blood cell count;	chr12:123962792	chr12:123925461~123926083:-
BRCA	cis	rs2273156	1	rs12880809	ENSG00000226677.3	IGBP1P1	-4.53	6.72e-06	0.000574	-0.21	-0.14	Immunoglobulin light chain (AL) amyloidosis;	chr14:35006450	chr14:34939324~34940332:+
BRCA	cis	rs2273156	1	rs12880928	ENSG00000226677.3	IGBP1P1	-4.53	6.72e-06	0.000574	-0.21	-0.14	Immunoglobulin light chain (AL) amyloidosis;	chr14:35006472	chr14:34939324~34940332:+
BRCA	cis	rs7772486	0.875	rs2814876	ENSG00000270638.1	RP3-466P17.1	4.53	6.72e-06	0.000574	0.16	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145982894	chr6:145735570~145737218:+
BRCA	cis	rs6125597	0.967	rs6063378	ENSG00000222365.1	SNORD12B	4.53	6.72e-06	0.000574	0.14	0.14	Intelligence (multi-trait analysis);	chr20:49249874	chr20:49280319~49280409:+
BRCA	cis	rs1005277	0.579	rs2474580	ENSG00000263064.2	RP11-291L22.7	4.53	6.72e-06	0.000574	0.17	0.14	Extrinsic epigenetic age acceleration;	chr10:38109785	chr10:38448689~38448949:+
BRCA	cis	rs2554380	0.628	rs11853983	ENSG00000230373.7	GOLGA6L5P	4.53	6.73e-06	0.000575	0.16	0.14	Height;	chr15:83794058	chr15:84507885~84516814:-
BRCA	cis	rs6095360	0.966	rs6019545	ENSG00000222365.1	SNORD12B	-4.53	6.73e-06	0.000575	-0.15	-0.14	Intelligence (multi-trait analysis);	chr20:48940477	chr20:49280319~49280409:+
BRCA	cis	rs4650994	1	rs4076205	ENSG00000273384.1	RP5-1098D14.1	4.53	6.73e-06	0.000575	0.17	0.14	HDL cholesterol;HDL cholesterol levels;	chr1:178565022	chr1:178651706~178652282:+
BRCA	cis	rs875971	0.545	rs316324	ENSG00000230295.1	RP11-458F8.2	-4.53	6.73e-06	0.000575	-0.13	-0.14	Aortic root size;	chr7:66145627	chr7:66880708~66882981:+
BRCA	cis	rs875971	0.545	rs316323	ENSG00000230295.1	RP11-458F8.2	-4.53	6.73e-06	0.000575	-0.13	-0.14	Aortic root size;	chr7:66146002	chr7:66880708~66882981:+
BRCA	cis	rs442309	0.846	rs224050	ENSG00000238280.1	RP11-436D10.3	4.53	6.73e-06	0.000575	0.18	0.14	Vogt-Koyanagi-Harada syndrome;	chr10:62733462	chr10:62793562~62805887:-
BRCA	cis	rs7142002	0.881	rs1904298	ENSG00000259088.1	CTD-2017C7.2	4.52	6.74e-06	0.000575	0.24	0.14	Autism;	chr14:101890138	chr14:101796555~101810321:-
BRCA	cis	rs2108622	0.958	rs79400241	ENSG00000267218.2	AC005336.5	4.52	6.74e-06	0.000575	0.18	0.14	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15873592	chr19:15902300~15903238:-
BRCA	cis	rs7520050	0.778	rs2991985	ENSG00000234329.1	RP11-767N6.2	-4.52	6.74e-06	0.000575	-0.13	-0.14	Reticulocyte count;Red blood cell count;	chr1:45614858	chr1:45651039~45651826:-
BRCA	cis	rs56322409	0.897	rs12354848	ENSG00000226688.5	ENTPD1-AS1	4.52	6.74e-06	0.000575	0.16	0.14	Blood metabolite levels;	chr10:95835939	chr10:95753206~96090238:-
BRCA	cis	rs67981189	0.634	rs221900	ENSG00000269927.1	RP6-91H8.3	4.52	6.74e-06	0.000576	0.18	0.14	Schizophrenia;	chr14:71137637	chr14:71141125~71143253:-
BRCA	cis	rs13217239	0.646	rs10456352	ENSG00000224843.5	LINC00240	-4.52	6.74e-06	0.000576	-0.16	-0.14	Schizophrenia;	chr6:27022579	chr6:26956992~27023924:+
BRCA	cis	rs13217239	0.646	rs4583981	ENSG00000224843.5	LINC00240	-4.52	6.74e-06	0.000576	-0.16	-0.14	Schizophrenia;	chr6:27024244	chr6:26956992~27023924:+
BRCA	cis	rs11098499	1	rs1011054	ENSG00000249244.1	RP11-548H18.2	-4.52	6.74e-06	0.000576	-0.17	-0.14	Corneal astigmatism;	chr4:119281232	chr4:119391831~119395335:-
BRCA	cis	rs2625529	0.938	rs8747	ENSG00000260037.4	CTD-2524L6.3	-4.52	6.74e-06	0.000576	-0.2	-0.14	Red blood cell count;	chr15:71823200	chr15:71818396~71823384:+
BRCA	cis	rs4948275	0.693	rs753245	ENSG00000237233.2	TMEM26-AS1	-4.52	6.74e-06	0.000576	-0.17	-0.14	Night sleep phenotypes;	chr10:61582778	chr10:61452639~61481956:+
BRCA	cis	rs859767	0.704	rs6750788	ENSG00000224043.6	CCNT2-AS1	4.52	6.75e-06	0.000576	0.2	0.14	Neuroticism;	chr2:134605411	chr2:134735464~134918710:-
BRCA	cis	rs2574985	0.813	rs1740761	ENSG00000231345.3	BEND3P1	-4.52	6.75e-06	0.000576	-0.23	-0.14	Subjective well-being;	chr10:50459793	chr10:50655967~50660472:+
BRCA	cis	rs7267979	0.527	rs6076369	ENSG00000231081.1	RP4-760C5.3	4.52	6.75e-06	0.000576	0.18	0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25596147	chr20:26008791~26010531:-
BRCA	cis	rs77204473	1	rs2044426	ENSG00000280143.1	AP000892.6	-4.52	6.75e-06	0.000576	-0.22	-0.14	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116885467	chr11:117204967~117210292:+
BRCA	cis	rs4660214	0.666	rs598415	ENSG00000237624.1	OXCT2P1	4.52	6.75e-06	0.000576	0.17	0.14	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39366735	chr1:39514956~39516490:+
BRCA	cis	rs2625529	0.878	rs2929511	ENSG00000260037.4	CTD-2524L6.3	4.52	6.75e-06	0.000576	0.18	0.14	Red blood cell count;	chr15:71939341	chr15:71818396~71823384:+
BRCA	cis	rs2692947	0.86	rs2579520	ENSG00000168992.4	OR7E102P	-4.52	6.75e-06	0.000577	-0.18	-0.14	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95994552	chr2:95546531~95547545:+
BRCA	cis	rs7243790	0.805	rs7243441	ENSG00000277324.1	RP11-850A17.1	-4.52	6.75e-06	0.000577	-0.16	-0.14	Diastolic blood pressure;	chr18:54391363	chr18:54268346~54270028:-
BRCA	cis	rs10266483	0.774	rs1404678	ENSG00000227986.1	TRIM60P18	4.52	6.76e-06	0.000577	0.15	0.14	Response to statin therapy;	chr7:64342138	chr7:64355078~64356199:+
BRCA	cis	rs3764021	0.527	rs10844427	ENSG00000256673.1	RP11-599J14.2	-4.52	6.76e-06	0.000577	-0.17	-0.14	Type 1 diabetes;	chr12:9681798	chr12:9398355~9414851:-
BRCA	cis	rs6088580	0.634	rs6059890	ENSG00000276073.1	RP5-1125A11.7	-4.52	6.76e-06	0.000577	-0.15	-0.14	Glomerular filtration rate (creatinine);	chr20:34513848	chr20:33985617~33988989:-
BRCA	cis	rs763014	0.932	rs2269559	ENSG00000260394.2	LA16c-313D11.9	-4.52	6.76e-06	0.000577	-0.14	-0.14	Height;	chr16:632297	chr16:678504~679777:-
BRCA	cis	rs2273156	1	rs2273158	ENSG00000226677.3	IGBP1P1	4.52	6.77e-06	0.000578	0.21	0.14	Immunoglobulin light chain (AL) amyloidosis;	chr14:34996578	chr14:34939324~34940332:+
BRCA	cis	rs4831837	0.717	rs4831836	ENSG00000270074.1	RP11-351I21.11	4.52	6.77e-06	0.000578	0.17	0.14	Morbidity-free survival;	chr8:12831923	chr8:12412827~12414373:+
BRCA	cis	rs4143844	0.609	rs11632560	ENSG00000259251.2	RP11-643M14.1	4.52	6.77e-06	0.000578	0.34	0.14	Bipolar disorder and schizophrenia;	chr15:62009299	chr15:62060503~62062434:+
BRCA	cis	rs80285556	0.579	rs11883067	ENSG00000161643.11	SIGLEC16	4.52	6.77e-06	0.000578	0.22	0.14	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50037214	chr19:49969673~49975814:+
BRCA	cis	rs1005277	0.579	rs2474563	ENSG00000099251.13	HSD17B7P2	4.52	6.77e-06	0.000578	0.15	0.14	Extrinsic epigenetic age acceleration;	chr10:38087010	chr10:38356380~38378505:+
BRCA	cis	rs984222	0.563	rs7518538	ENSG00000231365.4	RP11-418J17.1	4.52	6.77e-06	0.000578	0.17	0.14	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119207788	chr1:119140396~119275973:+
BRCA	cis	rs763121	0.889	rs2267390	ENSG00000228274.3	RP3-508I15.9	-4.52	6.77e-06	0.000578	-0.16	-0.14	Menopause (age at onset);	chr22:38493652	chr22:38667585~38681820:-
BRCA	cis	rs10504130	0.569	rs9650305	ENSG00000253844.1	RP11-546K22.1	-4.52	6.77e-06	0.000578	-0.21	-0.14	Venous thromboembolism (SNP x SNP interaction);	chr8:51912113	chr8:51961458~52022974:+
BRCA	cis	rs10504130	0.569	rs9650180	ENSG00000253844.1	RP11-546K22.1	-4.52	6.77e-06	0.000578	-0.21	-0.14	Venous thromboembolism (SNP x SNP interaction);	chr8:51912306	chr8:51961458~52022974:+
BRCA	cis	rs1555322	1	rs2425031	ENSG00000126005.14	MMP24-AS1	-4.52	6.77e-06	0.000578	-0.22	-0.14	Attention deficit hyperactivity disorder;	chr20:35267481	chr20:35216462~35278131:-
BRCA	cis	rs2236295	0.513	rs2393934	ENSG00000238280.1	RP11-436D10.3	-4.52	6.77e-06	0.000578	-0.18	-0.14	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks);	chr10:62885433	chr10:62793562~62805887:-
BRCA	cis	rs8058578	1	rs2289442	ENSG00000260911.2	RP11-196G11.2	4.52	6.77e-06	0.000578	0.13	0.14	Multiple myeloma;	chr16:30728598	chr16:31043150~31049868:+
BRCA	cis	rs7246657	0.55	rs9941475	ENSG00000226686.6	LINC01535	-4.52	6.77e-06	0.000578	-0.21	-0.14	Coronary artery calcification;	chr19:37573615	chr19:37251912~37265535:+
BRCA	cis	rs7246657	0.765	rs4803262	ENSG00000226686.6	LINC01535	-4.52	6.77e-06	0.000578	-0.21	-0.14	Coronary artery calcification;	chr19:37575858	chr19:37251912~37265535:+
BRCA	cis	rs7246657	0.712	rs4803263	ENSG00000226686.6	LINC01535	-4.52	6.77e-06	0.000578	-0.21	-0.14	Coronary artery calcification;	chr19:37575880	chr19:37251912~37265535:+
BRCA	cis	rs7246657	0.722	rs10412510	ENSG00000226686.6	LINC01535	-4.52	6.77e-06	0.000578	-0.21	-0.14	Coronary artery calcification;	chr19:37585043	chr19:37251912~37265535:+
BRCA	cis	rs7246657	0.722	rs3829688	ENSG00000226686.6	LINC01535	-4.52	6.77e-06	0.000578	-0.21	-0.14	Coronary artery calcification;	chr19:37586199	chr19:37251912~37265535:+
BRCA	cis	rs7246657	0.722	rs13744	ENSG00000226686.6	LINC01535	-4.52	6.77e-06	0.000578	-0.21	-0.14	Coronary artery calcification;	chr19:37587011	chr19:37251912~37265535:+
BRCA	cis	rs7246657	0.722	rs10403173	ENSG00000226686.6	LINC01535	-4.52	6.77e-06	0.000578	-0.21	-0.14	Coronary artery calcification;	chr19:37587779	chr19:37251912~37265535:+
BRCA	cis	rs7246657	0.679	rs12461113	ENSG00000226686.6	LINC01535	-4.52	6.77e-06	0.000578	-0.21	-0.14	Coronary artery calcification;	chr19:37592287	chr19:37251912~37265535:+
BRCA	cis	rs7246657	0.639	rs12459015	ENSG00000226686.6	LINC01535	-4.52	6.77e-06	0.000578	-0.21	-0.14	Coronary artery calcification;	chr19:37592288	chr19:37251912~37265535:+
BRCA	cis	rs11098499	0.569	rs10023641	ENSG00000260404.2	RP11-384K6.6	4.52	6.78e-06	0.000578	0.12	0.14	Corneal astigmatism;	chr4:119337255	chr4:118591773~118633729:+
BRCA	cis	rs2708377	0.789	rs3911150	ENSG00000270863.1	DDX55P1	-4.52	6.78e-06	0.000578	-0.25	-0.14	Bitter taste perception;	chr12:11049649	chr12:11512723~11514136:+
BRCA	cis	rs4660214	0.666	rs1180376	ENSG00000237624.1	OXCT2P1	4.52	6.78e-06	0.000578	0.17	0.14	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39418761	chr1:39514956~39516490:+
BRCA	cis	rs6686842	0.896	rs11209725	ENSG00000235358.1	RP11-399E6.1	4.52	6.78e-06	0.000578	0.17	0.14	Height;	chr1:41228345	chr1:41242373~41284861:+
BRCA	cis	rs9392653	0.96	rs9378928	ENSG00000220685.3	RP11-530A18.1	4.52	6.78e-06	0.000579	0.19	0.14	Venous thromboembolism (SNP x SNP interaction);	chr6:5068291	chr6:5065795~5066982:-
BRCA	cis	rs10946940	0.965	rs4713112	ENSG00000220721.1	OR1F12	-4.52	6.78e-06	0.000579	-0.16	-0.14	Systemic lupus erythematosus;	chr6:27549054	chr6:28073316~28074233:+
BRCA	cis	rs6012564	1	rs11696396	ENSG00000227431.4	CSE1L-AS1	4.52	6.79e-06	0.000579	0.17	0.14	Anger;	chr20:49136482	chr20:49040463~49046044:-
BRCA	cis	rs6012564	1	rs6066978	ENSG00000227431.4	CSE1L-AS1	4.52	6.79e-06	0.000579	0.17	0.14	Anger;	chr20:49139205	chr20:49040463~49046044:-
BRCA	cis	rs6012564	1	rs6063361	ENSG00000227431.4	CSE1L-AS1	4.52	6.79e-06	0.000579	0.17	0.14	Anger;	chr20:49141426	chr20:49040463~49046044:-
BRCA	cis	rs11098499	0.908	rs7695996	ENSG00000250412.1	KLHL2P1	4.52	6.79e-06	0.00058	0.17	0.14	Corneal astigmatism;	chr4:119400878	chr4:119334329~119378233:+
BRCA	cis	rs4713118	0.513	rs1225591	ENSG00000219392.1	RP1-265C24.5	-4.52	6.79e-06	0.00058	-0.2	-0.14	Parkinson's disease;	chr6:28180974	chr6:28115628~28116551:+
BRCA	cis	rs11673344	0.523	rs8108509	ENSG00000226686.6	LINC01535	4.52	6.8e-06	0.00058	0.18	0.14	Obesity-related traits;	chr19:37060370	chr19:37251912~37265535:+
BRCA	cis	rs6802315	0.575	rs57932243	ENSG00000272247.1	RP11-379F4.9	-4.52	6.8e-06	0.00058	-0.16	-0.14	Periodontitis (CDC/AAP);	chr3:158754187	chr3:158801257~158801935:-
BRCA	cis	rs7119	0.651	rs12902072	ENSG00000259362.2	RP11-307C19.1	-4.52	6.8e-06	0.00058	-0.2	-0.14	Type 2 diabetes;	chr15:77556390	chr15:77525540~77534110:+
BRCA	cis	rs35306767	0.953	rs34405399	ENSG00000229869.1	RP11-363N22.2	-4.52	6.8e-06	0.00058	-0.2	-0.14	Eosinophil percentage of granulocytes;	chr10:935075	chr10:933026~942743:+
BRCA	cis	rs1910358	0.508	rs68152875	ENSG00000248874.4	C5orf17	-4.52	6.8e-06	0.00058	-0.18	-0.14	Venous thromboembolism (SNP x SNP interaction);	chr5:23883275	chr5:23951348~24178263:+
BRCA	cis	rs17597773	0.638	rs7544735	ENSG00000257551.1	HLX-AS1	4.52	6.8e-06	0.00058	0.16	0.14	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220825571	chr1:220832763~220880140:-
BRCA	cis	rs721917	0.506	rs2758538	ENSG00000244733.5	RP11-506M13.3	-4.52	6.8e-06	0.00058	-0.16	-0.14	Chronic obstructive pulmonary disease;	chr10:79893047	chr10:79660891~79677996:+
BRCA	cis	rs1005277	0.691	rs2474558	ENSG00000263064.2	RP11-291L22.7	-4.52	6.8e-06	0.00058	-0.18	-0.14	Extrinsic epigenetic age acceleration;	chr10:38197213	chr10:38448689~38448949:+
BRCA	cis	rs11098499	0.954	rs10006877	ENSG00000225892.3	RP11-384K6.2	4.52	6.8e-06	0.00058	0.14	0.14	Corneal astigmatism;	chr4:119321638	chr4:118632274~118634759:+
BRCA	cis	rs12681366	0.564	rs10808669	ENSG00000253704.1	RP11-267M23.4	4.52	6.8e-06	0.00058	0.15	0.14	Nonsyndromic cleft lip with cleft palate;	chr8:94468833	chr8:94553722~94569745:+
BRCA	cis	rs13325613	0.915	rs28677778	ENSG00000223552.1	RP11-24F11.2	-4.52	6.8e-06	0.000581	-0.26	-0.14	Monocyte count;	chr3:46280680	chr3:46364955~46407059:-
BRCA	cis	rs9952991	0.941	rs2542151	ENSG00000260302.1	RP11-973H7.1	-4.52	6.8e-06	0.000581	-0.22	-0.14	Inflammatory skin disease;	chr18:12779948	chr18:12774651~12775923:-
BRCA	cis	rs116095464	0.558	rs56298907	ENSG00000248925.1	CTD-2083E4.6	4.52	6.81e-06	0.000581	0.28	0.14	Breast cancer;	chr5:283165	chr5:269858~271516:-
BRCA	cis	rs116095464	0.558	rs7356535	ENSG00000248925.1	CTD-2083E4.6	4.52	6.81e-06	0.000581	0.28	0.14	Breast cancer;	chr5:284002	chr5:269858~271516:-
BRCA	cis	rs116095464	0.558	rs55833259	ENSG00000248925.1	CTD-2083E4.6	4.52	6.81e-06	0.000581	0.28	0.14	Breast cancer;	chr5:286613	chr5:269858~271516:-
BRCA	cis	rs9291683	1	rs9291683	ENSG00000250413.1	RP11-448G15.1	-4.52	6.81e-06	0.000581	-0.18	-0.14	Bone mineral density;	chr4:10322536	chr4:10006482~10009725:+
BRCA	cis	rs6088580	0.634	rs6059868	ENSG00000276073.1	RP5-1125A11.7	-4.52	6.81e-06	0.000581	-0.15	-0.14	Glomerular filtration rate (creatinine);	chr20:34491655	chr20:33985617~33988989:-
BRCA	cis	rs11603691	1	rs11602266	ENSG00000254662.1	RP11-872D17.4	-4.52	6.81e-06	0.000581	-0.31	-0.14	Low high density lipoprotein cholesterol levels;	chr11:57327035	chr11:57325603~57327958:+
BRCA	cis	rs1075265	0.756	rs1075264	ENSG00000235937.1	AC008280.1	4.52	6.81e-06	0.000581	0.15	0.14	Chronotype;Morning vs. evening chronotype;	chr2:54127916	chr2:54029552~54030682:-
BRCA	cis	rs11168618	0.875	rs11458	ENSG00000240399.1	RP1-228P16.1	4.52	6.81e-06	0.000581	0.16	0.14	Adiponectin levels;	chr12:48494811	chr12:48054813~48055591:-
BRCA	cis	rs651907	0.617	rs797776	ENSG00000244119.1	PDCL3P4	4.52	6.81e-06	0.000581	0.11	0.14	Colorectal cancer;	chr3:101891399	chr3:101712472~101713191:+
BRCA	cis	rs651907	0.588	rs1707613	ENSG00000244119.1	PDCL3P4	4.52	6.82e-06	0.000581	0.11	0.14	Colorectal cancer;	chr3:101918345	chr3:101712472~101713191:+
BRCA	cis	rs3768617	0.51	rs7549768	ENSG00000224468.3	RP11-181K3.4	-4.52	6.82e-06	0.000581	-0.15	-0.14	Fuchs's corneal dystrophy;	chr1:183128247	chr1:183138402~183141282:-
BRCA	cis	rs3768617	0.51	rs4651142	ENSG00000224468.3	RP11-181K3.4	-4.52	6.82e-06	0.000581	-0.15	-0.14	Fuchs's corneal dystrophy;	chr1:183128251	chr1:183138402~183141282:-
BRCA	cis	rs3768617	0.51	rs4651143	ENSG00000224468.3	RP11-181K3.4	-4.52	6.82e-06	0.000581	-0.15	-0.14	Fuchs's corneal dystrophy;	chr1:183128263	chr1:183138402~183141282:-
BRCA	cis	rs75804782	0.63	rs79693451	ENSG00000186235.9	AC016757.3	4.52	6.82e-06	0.000582	0.37	0.14	Chronotype;Morning vs. evening chronotype;	chr2:238387832	chr2:238224552~238231677:-
BRCA	cis	rs2904967	0.584	rs3015997	ENSG00000255200.1	AP003068.18	4.52	6.82e-06	0.000582	0.27	0.14	Mean corpuscular volume;	chr11:65232773	chr11:65174117~65176470:-
BRCA	cis	rs2154319	0.609	rs2275931	ENSG00000235358.1	RP11-399E6.1	-4.52	6.82e-06	0.000582	-0.19	-0.14	Height;	chr1:41264479	chr1:41242373~41284861:+
BRCA	cis	rs12744310	1	rs56381773	ENSG00000235358.1	RP11-399E6.1	4.52	6.82e-06	0.000582	0.21	0.14	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41305046	chr1:41242373~41284861:+
BRCA	cis	rs12744310	1	rs56096486	ENSG00000235358.1	RP11-399E6.1	4.52	6.82e-06	0.000582	0.21	0.14	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41305558	chr1:41242373~41284861:+
BRCA	cis	rs12744310	1	rs57529969	ENSG00000235358.1	RP11-399E6.1	4.52	6.82e-06	0.000582	0.21	0.14	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41306011	chr1:41242373~41284861:+
BRCA	cis	rs12744310	1	rs60825180	ENSG00000235358.1	RP11-399E6.1	4.52	6.82e-06	0.000582	0.21	0.14	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41306072	chr1:41242373~41284861:+
BRCA	cis	rs12744310	0.778	rs61477144	ENSG00000235358.1	RP11-399E6.1	4.52	6.82e-06	0.000582	0.21	0.14	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41306121	chr1:41242373~41284861:+
BRCA	cis	rs10958369	0.613	rs7812717	ENSG00000260484.1	RP11-1081M5.2	4.52	6.82e-06	0.000582	0.17	0.14	Response to antineoplastic agents;	chr8:53521362	chr8:53388701~53390872:-
BRCA	cis	rs8054556	0.647	rs4077410	ENSG00000261367.1	RP11-455F5.4	-4.52	6.82e-06	0.000582	-0.15	-0.14	Autism spectrum disorder or schizophrenia;	chr16:29986879	chr16:30107675~30110541:+
BRCA	cis	rs2803122	0.502	rs1854552	ENSG00000273226.1	RP11-513M16.8	4.52	6.82e-06	0.000582	0.16	0.14	Pulse pressure;	chr9:19235049	chr9:19375451~19375996:+
BRCA	cis	rs7178909	0.872	rs2165070	ENSG00000259677.1	RP11-493E3.1	4.52	6.83e-06	0.000582	0.17	0.14	Common traits (Other);	chr15:89865744	chr15:89876540~89877285:+
BRCA	cis	rs600550	0.963	rs4939328	ENSG00000275344.1	MIR6503	4.52	6.83e-06	0.000582	0.14	0.14	Lipoprotein-associated phospholipase A2 activity and mass;	chr11:60254033	chr11:60209071~60209156:-
BRCA	cis	rs1656368	0.726	rs55842512	ENSG00000279311.1	RP11-170K4.2	4.52	6.83e-06	0.000582	0.18	0.14	Lobe attachment (rater-scored or self-reported);	chr3:158548746	chr3:158869898~158871821:+
BRCA	cis	rs9467773	0.967	rs9295694	ENSG00000241549.7	GUSBP2	4.52	6.83e-06	0.000582	0.15	0.14	Intelligence (multi-trait analysis);	chr6:26512766	chr6:26871484~26956554:-
BRCA	cis	rs9467773	0.967	rs9467775	ENSG00000241549.7	GUSBP2	4.52	6.83e-06	0.000582	0.15	0.14	Intelligence (multi-trait analysis);	chr6:26513207	chr6:26871484~26956554:-
BRCA	cis	rs6723226	0.572	rs176411	ENSG00000276517.1	AL133243.2	-4.52	6.83e-06	0.000583	-0.16	-0.14	Intelligence (multi-trait analysis);	chr2:32418460	chr2:32526504~32529507:+
BRCA	cis	rs35740288	0.52	rs56183577	ENSG00000202081.1	RNU6-1280P	4.52	6.83e-06	0.000583	0.2	0.14	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85776475	chr15:85651522~85651628:-
BRCA	cis	rs11096990	0.574	rs34070258	ENSG00000249685.1	RP11-360F5.3	4.52	6.83e-06	0.000583	0.18	0.14	Cognitive function;	chr4:39188132	chr4:39133913~39135608:+
BRCA	cis	rs7267979	1	rs6050590	ENSG00000274973.1	RP13-401N8.7	4.52	6.84e-06	0.000583	0.16	0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25404358	chr20:25845497~25845862:+
BRCA	cis	rs7267979	1	rs4813566	ENSG00000274973.1	RP13-401N8.7	4.52	6.84e-06	0.000583	0.16	0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25405829	chr20:25845497~25845862:+
BRCA	cis	rs7267979	1	rs4815421	ENSG00000274973.1	RP13-401N8.7	4.52	6.84e-06	0.000583	0.16	0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25405873	chr20:25845497~25845862:+
BRCA	cis	rs6870983	0.895	rs1430204	ENSG00000247828.6	TMEM161B-AS1	-4.52	6.84e-06	0.000583	-0.18	-0.14	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index;	chr5:88382815	chr5:88268895~88436685:+
BRCA	cis	rs6870983	0.895	rs10043347	ENSG00000247828.6	TMEM161B-AS1	-4.52	6.84e-06	0.000583	-0.18	-0.14	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index;	chr5:88383508	chr5:88268895~88436685:+
BRCA	cis	rs752010	0.571	rs10890135	ENSG00000230638.4	RP11-486B10.4	-4.52	6.84e-06	0.000583	-0.17	-0.14	Lupus nephritis in systemic lupus erythematosus;	chr1:41588413	chr1:41542069~41544310:+
BRCA	cis	rs7572733	0.773	rs13413470	ENSG00000231621.1	AC013264.2	-4.52	6.84e-06	0.000583	-0.13	-0.14	Dermatomyositis;	chr2:197648125	chr2:197197991~197199273:+
BRCA	cis	rs1722141	0.567	rs2960427	ENSG00000229628.1	AC073115.7	4.52	6.84e-06	0.000583	0.19	0.14	Sitting height ratio;	chr7:46003093	chr7:45990905~46000898:+
BRCA	cis	rs73186030	0.92	rs73186057	ENSG00000272758.4	RP11-299J3.8	4.52	6.84e-06	0.000583	0.21	0.14	Serum parathyroid hormone levels;	chr3:122325058	chr3:122416207~122443180:+
BRCA	cis	rs6095360	0.934	rs6019580	ENSG00000222365.1	SNORD12B	-4.52	6.85e-06	0.000584	-0.15	-0.14	Intelligence (multi-trait analysis);	chr20:49009368	chr20:49280319~49280409:+
BRCA	cis	rs6095360	0.899	rs3818223	ENSG00000222365.1	SNORD12B	-4.52	6.85e-06	0.000584	-0.15	-0.14	Intelligence (multi-trait analysis);	chr20:49009948	chr20:49280319~49280409:+
BRCA	cis	rs8180040	0.966	rs7628631	ENSG00000276925.1	RP11-708J19.3	4.52	6.85e-06	0.000584	0.16	0.14	Colorectal cancer;	chr3:47519373	chr3:47469777~47469987:+
BRCA	cis	rs1832007	0.554	rs11594448	ENSG00000224034.1	RP11-445P17.8	-4.52	6.85e-06	0.000584	-0.22	-0.14	Triglyceride levels;Triglycerides;	chr10:5203328	chr10:5266033~5271236:-
BRCA	cis	rs60843830	1	rs79716074	ENSG00000272342.1	RP13-539J13.1	4.52	6.85e-06	0.000584	0.17	0.14	Spherical equivalent (joint analysis main effects and education interaction);	chr2:277003	chr2:739588~740164:-
BRCA	cis	rs11098499	0.954	rs17005535	ENSG00000250412.1	KLHL2P1	4.52	6.85e-06	0.000584	0.16	0.14	Corneal astigmatism;	chr4:119490407	chr4:119334329~119378233:+
BRCA	cis	rs1153858	1	rs9783731	ENSG00000275672.1	GATM-AS1	4.52	6.85e-06	0.000584	0.18	0.14	Homoarginine levels;	chr15:45350686	chr15:45378700~45380123:+
BRCA	cis	rs8040855	0.627	rs35668291	ENSG00000230373.7	GOLGA6L5P	4.52	6.85e-06	0.000584	0.18	0.14	Bulimia nervosa;	chr15:85109582	chr15:84507885~84516814:-
BRCA	cis	rs6496044	0.634	rs4843066	ENSG00000202081.1	RNU6-1280P	4.52	6.85e-06	0.000584	0.16	0.14	Interstitial lung disease;	chr15:85519680	chr15:85651522~85651628:-
BRCA	cis	rs2278170	1	rs9633906	ENSG00000225101.4	OR52K3P	-4.52	6.86e-06	0.000585	-0.19	-0.14	Amyotrophic lateral sclerosis;	chr11:4477120	chr11:4474813~4475755:+
BRCA	cis	rs4948275	0.693	rs2814031	ENSG00000237233.2	TMEM26-AS1	-4.52	6.86e-06	0.000585	-0.16	-0.14	Night sleep phenotypes;	chr10:61577762	chr10:61452639~61481956:+
BRCA	cis	rs2274273	0.554	rs3742564	ENSG00000258413.1	RP11-665C16.6	4.52	6.86e-06	0.000585	0.18	0.14	Protein biomarker;	chr14:55063402	chr14:55262767~55272075:-
BRCA	cis	rs2835345	0.507	rs7280011	ENSG00000279365.1	KB-176G8.1	4.52	6.86e-06	0.000585	0.2	0.14	Pulmonary function;	chr21:36455256	chr21:36485867~36487760:+
BRCA	cis	rs1858037	0.867	rs57913336	ENSG00000237979.1	AC007389.1	4.52	6.86e-06	0.000585	0.18	0.14	Rheumatoid arthritis;	chr2:65360485	chr2:65500993~65502138:-
BRCA	cis	rs151450	1	rs151450	ENSG00000251411.1	RP11-397E7.4	-4.52	6.86e-06	0.000585	-0.16	-0.14	Basophil percentage of white cells;	chr4:87095362	chr4:86913266~86914817:-
BRCA	cis	rs2033711	0.503	rs6510141	ENSG00000268307.1	CTD-2619J13.13	-4.52	6.86e-06	0.000585	-0.16	-0.14	Uric acid clearance;	chr19:58374419	chr19:58400221~58400679:+
BRCA	cis	rs10129255	0.518	rs8009594	ENSG00000232216.1	IGHV3-43	4.52	6.86e-06	0.000585	0.1	0.14	Kawasaki disease;	chr14:106777494	chr14:106470264~106470800:-
BRCA	cis	rs9818758	0.505	rs67286839	ENSG00000270441.1	RP11-694I15.7	4.52	6.86e-06	0.000585	0.27	0.14	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49228311	chr3:49140086~49160851:-
BRCA	cis	rs2625529	0.652	rs2957724	ENSG00000260037.4	CTD-2524L6.3	4.52	6.87e-06	0.000585	0.17	0.14	Red blood cell count;	chr15:71956133	chr15:71818396~71823384:+
BRCA	cis	rs4415084	0.804	rs13177711	ENSG00000251141.4	RP11-53O19.1	4.52	6.87e-06	0.000585	0.13	0.14	Breast cancer;	chr5:44796860	chr5:44744900~44808777:-
BRCA	cis	rs8031584	0.918	rs35784593	ENSG00000259845.1	HERC2P10	4.52	6.87e-06	0.000585	0.16	0.14	Huntington's disease progression;	chr15:30962385	chr15:30815271~30844153:+
BRCA	cis	rs6430585	0.583	rs58116536	ENSG00000224043.6	CCNT2-AS1	-4.52	6.87e-06	0.000586	-0.23	-0.14	Corneal structure;	chr2:135827753	chr2:134735464~134918710:-
BRCA	cis	rs35146811	0.735	rs1138417	ENSG00000235713.1	RP4-604G5.3	-4.52	6.87e-06	0.000586	-0.16	-0.14	Coronary artery disease;	chr7:100209523	chr7:99992397~99993050:+
BRCA	cis	rs370915	0.542	rs1425953	ENSG00000250971.1	RP11-696F12.1	4.52	6.87e-06	0.000586	0.14	0.14	Gout;	chr4:186912498	chr4:187060099~187060930:+
BRCA	cis	rs4664293	0.802	rs13025347	ENSG00000226266.5	AC009961.3	-4.52	6.87e-06	0.000586	-0.17	-0.14	Monocyte percentage of white cells;	chr2:159721056	chr2:159670708~159712435:-
BRCA	cis	rs4664293	0.867	rs6432554	ENSG00000226266.5	AC009961.3	-4.52	6.87e-06	0.000586	-0.17	-0.14	Monocyte percentage of white cells;	chr2:159722573	chr2:159670708~159712435:-
BRCA	cis	rs4664293	0.867	rs6760485	ENSG00000226266.5	AC009961.3	-4.52	6.87e-06	0.000586	-0.17	-0.14	Monocyte percentage of white cells;	chr2:159723179	chr2:159670708~159712435:-
BRCA	cis	rs6095360	0.615	rs2869689	ENSG00000222365.1	SNORD12B	-4.52	6.88e-06	0.000586	-0.17	-0.14	Intelligence (multi-trait analysis);	chr20:48898389	chr20:49280319~49280409:+
BRCA	cis	rs35740288	0.822	rs4843092	ENSG00000202081.1	RNU6-1280P	4.52	6.88e-06	0.000586	0.19	0.14	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85689949	chr15:85651522~85651628:-
BRCA	cis	rs56322409	0.772	rs7896876	ENSG00000226688.5	ENTPD1-AS1	4.52	6.88e-06	0.000586	0.17	0.14	Blood metabolite levels;	chr10:95892581	chr10:95753206~96090238:-
BRCA	cis	rs300890	0.76	rs10028909	ENSG00000250326.1	RP11-284M14.1	-4.52	6.88e-06	0.000586	-0.15	-0.14	Nasopharyngeal carcinoma;	chr4:143279439	chr4:142933195~143184861:-
BRCA	cis	rs2235642	1	rs2076438	ENSG00000260989.1	LA16c-395F10.2	-4.52	6.88e-06	0.000587	-0.14	-0.14	Coronary artery disease;	chr16:1534617	chr16:1580527~1610328:+
BRCA	cis	rs7267979	0.789	rs4815429	ENSG00000204556.4	CTD-2514C3.1	4.52	6.88e-06	0.000587	0.19	0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25540975	chr20:26018832~26020684:+
BRCA	cis	rs10946940	0.965	rs62401383	ENSG00000219392.1	RP1-265C24.5	4.52	6.89e-06	0.000587	0.18	0.14	Systemic lupus erythematosus;	chr6:27596768	chr6:28115628~28116551:+
BRCA	cis	rs454217	0.502	rs4760435	ENSG00000277851.1	RP11-756G20.1	4.52	6.89e-06	0.000587	0.17	0.14	Smoking quantity;	chr12:92328576	chr12:92247756~92363832:-
BRCA	cis	rs11673344	0.523	rs7255724	ENSG00000226686.6	LINC01535	4.52	6.89e-06	0.000587	0.18	0.14	Obesity-related traits;	chr19:37158675	chr19:37251912~37265535:+
BRCA	cis	rs720475	0.732	rs7784282	ENSG00000228960.5	OR2A9P	-4.52	6.89e-06	0.000587	-0.2	-0.14	Breast cancer;	chr7:144431561	chr7:144294480~144300934:+
BRCA	cis	rs4664293	1	rs6753181	ENSG00000224152.1	AC009506.1	-4.52	6.89e-06	0.000587	-0.15	-0.14	Monocyte percentage of white cells;	chr2:159635927	chr2:159615296~159617082:+
BRCA	cis	rs7246657	0.508	rs1628959	ENSG00000267422.1	CTD-2554C21.1	-4.52	6.89e-06	0.000587	-0.24	-0.14	Coronary artery calcification;	chr19:36999474	chr19:37779686~37792865:+
BRCA	cis	rs35306767	0.953	rs7908138	ENSG00000229869.1	RP11-363N22.2	-4.52	6.89e-06	0.000587	-0.2	-0.14	Eosinophil percentage of granulocytes;	chr10:917038	chr10:933026~942743:+
BRCA	cis	rs559555	0.612	rs585890	ENSG00000272716.1	RP11-563N4.1	4.52	6.89e-06	0.000587	0.15	0.14	Blood metabolite ratios;Blood metabolite levels;	chr2:31594361	chr2:32165046~32165757:-
BRCA	cis	rs4664293	0.833	rs3764969	ENSG00000226266.5	AC009961.3	-4.52	6.89e-06	0.000587	-0.17	-0.14	Monocyte percentage of white cells;	chr2:159764337	chr2:159670708~159712435:-
BRCA	cis	rs2562456	0.526	rs950504	ENSG00000268555.1	RP11-678G14.3	4.52	6.89e-06	0.000587	0.17	0.14	Pain;	chr19:21601193	chr19:21570822~21587322:-
BRCA	cis	rs991427	1	rs11105972	ENSG00000258100.1	RP11-121E16.1	-4.52	6.89e-06	0.000587	-0.19	-0.14	Systolic blood pressure (alcohol consumption interaction);	chr12:91078178	chr12:91362196~91368606:+
BRCA	cis	rs991427	1	rs11105973	ENSG00000258100.1	RP11-121E16.1	-4.52	6.89e-06	0.000587	-0.19	-0.14	Systolic blood pressure (alcohol consumption interaction);	chr12:91078570	chr12:91362196~91368606:+
BRCA	cis	rs991427	1	rs73197056	ENSG00000258100.1	RP11-121E16.1	-4.52	6.89e-06	0.000587	-0.19	-0.14	Systolic blood pressure (alcohol consumption interaction);	chr12:91079881	chr12:91362196~91368606:+
BRCA	cis	rs991427	1	rs17018691	ENSG00000258100.1	RP11-121E16.1	-4.52	6.89e-06	0.000587	-0.19	-0.14	Systolic blood pressure (alcohol consumption interaction);	chr12:91080123	chr12:91362196~91368606:+
BRCA	cis	rs991427	1	rs17018694	ENSG00000258100.1	RP11-121E16.1	-4.52	6.89e-06	0.000587	-0.19	-0.14	Systolic blood pressure (alcohol consumption interaction);	chr12:91080275	chr12:91362196~91368606:+
BRCA	cis	rs7646881	0.812	rs9864589	ENSG00000240207.5	RP11-379F4.4	-4.52	6.89e-06	0.000587	-0.22	-0.14	Tetralogy of Fallot;	chr3:158712917	chr3:158732263~158784070:+
BRCA	cis	rs7191700	0.583	rs243314	ENSG00000262703.1	RP11-485G7.6	4.52	6.89e-06	0.000587	0.14	0.14	Multiple sclerosis;	chr16:11291247	chr16:11348143~11349321:-
BRCA	cis	rs2274273	0.87	rs3783652	ENSG00000259318.1	RP11-454L9.2	4.52	6.89e-06	0.000587	0.12	0.14	Protein biomarker;	chr14:55387490	chr14:55394940~55395233:-
BRCA	cis	rs454217	0.521	rs7978464	ENSG00000277851.1	RP11-756G20.1	4.52	6.89e-06	0.000587	0.17	0.14	Smoking quantity;	chr12:92324689	chr12:92247756~92363832:-
BRCA	cis	rs7665090	1	rs2866407	ENSG00000251288.2	RP11-10L12.2	-4.52	6.9e-06	0.000588	-0.16	-0.14	Primary biliary cholangitis;	chr4:102632951	chr4:102751401~102752641:+
BRCA	cis	rs7665090	1	rs2866408	ENSG00000251288.2	RP11-10L12.2	-4.52	6.9e-06	0.000588	-0.16	-0.14	Primary biliary cholangitis;	chr4:102632956	chr4:102751401~102752641:+
BRCA	cis	rs6747488	0.551	rs223665	ENSG00000272716.1	RP11-563N4.1	4.52	6.9e-06	0.000588	0.15	0.14	Interleukin-18 levels;	chr2:31794678	chr2:32165046~32165757:-
BRCA	cis	rs4763879	0.865	rs4763840	ENSG00000278635.1	CTD-2318O12.1	4.52	6.9e-06	0.000588	0.14	0.14	Type 1 diabetes;	chr12:9731814	chr12:9415641~9416718:+
BRCA	cis	rs2179367	0.959	rs9373589	ENSG00000223701.3	RAET1E-AS1	4.52	6.9e-06	0.000588	0.18	0.14	Dupuytren's disease;	chr6:149386152	chr6:149884431~149919508:+
BRCA	cis	rs17507216	0.628	rs28371837	ENSG00000255769.6	GOLGA2P10	-4.52	6.91e-06	0.000588	-0.21	-0.14	Excessive daytime sleepiness;	chr15:82714435	chr15:82472993~82513950:-
BRCA	cis	rs7267979	0.833	rs6138556	ENSG00000276952.1	RP5-965G21.6	4.52	6.91e-06	0.000588	0.17	0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25262674	chr20:25284915~25285588:-
BRCA	cis	rs7772486	0.875	rs13198450	ENSG00000270638.1	RP3-466P17.1	4.52	6.91e-06	0.000589	0.16	0.14	Lobe attachment (rater-scored or self-reported);	chr6:146049388	chr6:145735570~145737218:+
BRCA	cis	rs11098499	0.954	rs10017543	ENSG00000250412.1	KLHL2P1	4.52	6.91e-06	0.000589	0.17	0.14	Corneal astigmatism;	chr4:119400265	chr4:119334329~119378233:+
BRCA	cis	rs4781563	0.956	rs1799800	ENSG00000242307.1	RPS26P52	-4.52	6.91e-06	0.000589	-0.17	-0.14	Bilirubin levels;	chr16:13944695	chr16:13922332~13922679:-
BRCA	cis	rs859767	0.741	rs7602801	ENSG00000224043.6	CCNT2-AS1	4.52	6.91e-06	0.000589	0.2	0.14	Neuroticism;	chr2:134606300	chr2:134735464~134918710:-
BRCA	cis	rs7572733	0.773	rs13429970	ENSG00000231621.1	AC013264.2	-4.52	6.91e-06	0.000589	-0.13	-0.14	Dermatomyositis;	chr2:197657911	chr2:197197991~197199273:+
BRCA	cis	rs13113518	1	rs4865004	ENSG00000273257.1	RP11-177J6.1	4.52	6.91e-06	0.000589	0.18	0.14	Height;	chr4:55515118	chr4:55387949~55388271:+
BRCA	cis	rs610932	0.517	rs678384	ENSG00000275344.1	MIR6503	4.52	6.92e-06	0.000589	0.14	0.14	Alzheimer's disease;	chr11:60234719	chr11:60209071~60209156:-
BRCA	cis	rs7789940	0.809	rs12533836	ENSG00000186704.9	DTX2P1	4.52	6.92e-06	0.00059	0.17	0.14	Multiple sclerosis;	chr7:76306305	chr7:76978617~77004308:+
BRCA	cis	rs924712	0.625	rs12191386	ENSG00000261116.1	RP3-523K23.2	-4.52	6.92e-06	0.00059	-0.17	-0.14	Breast cancer;	chr6:54855645	chr6:54943167~54945099:+
BRCA	cis	rs11892454	0.604	rs13418772	ENSG00000217643.1	PTGES3P2	-4.52	6.92e-06	0.00059	-0.15	-0.14	Heschl's gyrus morphology;	chr2:25719736	chr2:25822469~25822950:+
BRCA	cis	rs647097	0.551	rs16954164	ENSG00000272788.1	RP11-674N23.4	-4.52	6.92e-06	0.00059	-0.22	-0.14	Chronic obstructive pulmonary disease;	chr18:8789383	chr18:8801656~8802305:+
BRCA	cis	rs699371	0.525	rs1156021	ENSG00000270000.1	RP3-449M8.9	4.52	6.93e-06	0.00059	0.16	0.14	Height;	chr14:74432889	chr14:74471930~74472360:-
BRCA	cis	rs2562456	0.839	rs2562411	ENSG00000268658.4	LINC00664	4.52	6.93e-06	0.00059	0.23	0.14	Pain;	chr19:21419181	chr19:21483374~21503238:+
BRCA	cis	rs2562456	0.876	rs2562413	ENSG00000268658.4	LINC00664	4.52	6.93e-06	0.00059	0.23	0.14	Pain;	chr19:21420084	chr19:21483374~21503238:+
BRCA	cis	rs2562456	0.916	rs1967182	ENSG00000268658.4	LINC00664	4.52	6.93e-06	0.00059	0.23	0.14	Pain;	chr19:21420337	chr19:21483374~21503238:+
BRCA	cis	rs4218	0.636	rs4775116	ENSG00000259732.1	RP11-59H7.3	4.52	6.93e-06	0.00059	0.17	0.14	Social communication problems;	chr15:59135608	chr15:59121034~59133250:+
BRCA	cis	rs6570726	0.935	rs369214	ENSG00000270638.1	RP3-466P17.1	4.52	6.93e-06	0.000591	0.15	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145535573	chr6:145735570~145737218:+
BRCA	cis	rs6570726	0.935	rs390252	ENSG00000270638.1	RP3-466P17.1	4.52	6.93e-06	0.000591	0.15	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145535760	chr6:145735570~145737218:+
BRCA	cis	rs17428076	0.793	rs3765167	ENSG00000228389.1	AC068039.4	-4.52	6.93e-06	0.000591	-0.2	-0.14	Myopia;	chr2:171837434	chr2:171773482~171775844:+
BRCA	cis	rs7968440	0.808	rs829112	ENSG00000272368.2	RP4-605O3.4	-4.52	6.93e-06	0.000591	-0.15	-0.14	Fibrinogen;	chr12:50813921	chr12:50112197~50165618:+
BRCA	cis	rs2708977	0.966	rs749027	ENSG00000237510.6	AC008268.2	-4.52	6.94e-06	0.000591	-0.19	-0.14	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96537400	chr2:95789654~95800166:+
BRCA	cis	rs4664293	0.867	rs7566802	ENSG00000226266.5	AC009961.3	-4.52	6.94e-06	0.000591	-0.17	-0.14	Monocyte percentage of white cells;	chr2:159728480	chr2:159670708~159712435:-
BRCA	cis	rs7701440	0.512	rs34631	ENSG00000215032.2	GNL3LP1	4.52	6.94e-06	0.000591	0.17	0.14	Educational attainment;	chr5:61230499	chr5:60891935~60893577:-
BRCA	cis	rs34286592	0.929	rs1057452	ENSG00000214725.6	CDIPT-AS1	4.52	6.94e-06	0.000591	0.24	0.14	Multiple sclerosis;	chr16:29822393	chr16:29863593~29868053:+
BRCA	cis	rs2839186	0.967	rs4819222	ENSG00000228137.1	AP001469.7	4.52	6.94e-06	0.000591	0.14	0.14	Testicular germ cell tumor;	chr21:46287864	chr21:46246890~46247682:+
BRCA	cis	rs718314	0.64	rs7302344	ENSG00000256894.1	RP11-283G6.3	4.52	6.94e-06	0.000591	0.16	0.14	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Renal cell carcinoma;Waist circumference adjusted for body mass index;	chr12:26335249	chr12:26125155~26126617:-
BRCA	cis	rs7246657	0.722	rs1564206	ENSG00000226686.6	LINC01535	-4.52	6.94e-06	0.000591	-0.21	-0.14	Coronary artery calcification;	chr19:37549174	chr19:37251912~37265535:+
BRCA	cis	rs2070615	0.545	rs10875877	ENSG00000239617.1	RP11-302B13.1	-4.52	6.94e-06	0.000591	-0.18	-0.14	Bipolar disorder;	chr12:48804156	chr12:48903418~48903813:-
BRCA	cis	rs930395	0.514	rs9791164	ENSG00000251141.4	RP11-53O19.1	4.52	6.95e-06	0.000592	0.12	0.14	Breast cancer;	chr5:44903928	chr5:44744900~44808777:-
BRCA	cis	rs35146811	0.961	rs1880949	ENSG00000214313.7	AZGP1P1	-4.52	6.95e-06	0.000592	-0.15	-0.14	Coronary artery disease;	chr7:100124643	chr7:99980762~99987535:+
BRCA	cis	rs10266483	0.739	rs12671185	ENSG00000227986.1	TRIM60P18	4.52	6.95e-06	0.000592	0.15	0.14	Response to statin therapy;	chr7:64333329	chr7:64355078~64356199:+
BRCA	cis	rs9392653	0.847	rs9405255	ENSG00000220685.3	RP11-530A18.1	4.52	6.95e-06	0.000592	0.18	0.14	Venous thromboembolism (SNP x SNP interaction);	chr6:5065805	chr6:5065795~5066982:-
BRCA	cis	rs1005277	0.505	rs200939	ENSG00000226578.1	RP11-258F22.1	-4.52	6.95e-06	0.000592	-0.15	-0.14	Extrinsic epigenetic age acceleration;	chr10:37850555	chr10:37775371~37784131:-
BRCA	cis	rs2839186	0.967	rs2839191	ENSG00000228137.1	AP001469.7	4.52	6.95e-06	0.000592	0.14	0.14	Testicular germ cell tumor;	chr21:46275481	chr21:46246890~46247682:+
BRCA	cis	rs13217239	0.646	rs35691005	ENSG00000224843.5	LINC00240	-4.52	6.95e-06	0.000592	-0.16	-0.14	Schizophrenia;	chr6:27004291	chr6:26956992~27023924:+
BRCA	cis	rs13217239	0.646	rs10946891	ENSG00000224843.5	LINC00240	-4.52	6.95e-06	0.000592	-0.16	-0.14	Schizophrenia;	chr6:27005436	chr6:26956992~27023924:+
BRCA	cis	rs13217239	0.646	rs12201393	ENSG00000224843.5	LINC00240	-4.52	6.95e-06	0.000592	-0.16	-0.14	Schizophrenia;	chr6:27007911	chr6:26956992~27023924:+
BRCA	cis	rs6095360	1	rs6019600	ENSG00000222365.1	SNORD12B	-4.52	6.95e-06	0.000592	-0.15	-0.14	Intelligence (multi-trait analysis);	chr20:49030395	chr20:49280319~49280409:+
BRCA	cis	rs62025270	0.632	rs7177107	ENSG00000259295.5	CSPG4P12	-4.52	6.96e-06	0.000592	-0.22	-0.14	Idiopathic pulmonary fibrosis;	chr15:85580133	chr15:85191438~85213905:+
BRCA	cis	rs867186	1	rs76648234	ENSG00000126005.14	MMP24-AS1	-4.52	6.96e-06	0.000592	-0.26	-0.14	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35102138	chr20:35216462~35278131:-
BRCA	cis	rs1005277	0.579	rs2505198	ENSG00000099251.13	HSD17B7P2	4.52	6.96e-06	0.000592	0.15	0.14	Extrinsic epigenetic age acceleration;	chr10:38104255	chr10:38356380~38378505:+
BRCA	cis	rs559928	1	rs641168	ENSG00000236935.1	AP003774.1	-4.52	6.96e-06	0.000592	-0.17	-0.14	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64378817	chr11:64325050~64329504:-
BRCA	cis	rs7819412	0.749	rs11991118	ENSG00000255046.1	RP11-297N6.4	-4.52	6.96e-06	0.000592	-0.17	-0.14	Triglycerides;	chr8:11081763	chr8:11797928~11802568:-
BRCA	cis	rs1910358	0.621	rs1490761	ENSG00000248874.4	C5orf17	-4.52	6.96e-06	0.000593	-0.2	-0.14	Venous thromboembolism (SNP x SNP interaction);	chr5:23838237	chr5:23951348~24178263:+
BRCA	cis	rs2153535	0.601	rs7738877	ENSG00000251164.1	HULC	-4.52	6.97e-06	0.000593	-0.17	-0.14	Motion sickness;	chr6:8541997	chr6:8652137~8653846:+
BRCA	cis	rs6686842	0.965	rs1121866	ENSG00000235358.1	RP11-399E6.1	4.52	6.97e-06	0.000593	0.17	0.14	Height;	chr1:41242427	chr1:41242373~41284861:+
BRCA	cis	rs7914558	0.646	rs7100709	ENSG00000213061.2	PFN1P11	4.52	6.97e-06	0.000593	0.2	0.14	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102889972	chr10:102838011~102845473:-
BRCA	cis	rs4948275	0.693	rs2246190	ENSG00000237233.2	TMEM26-AS1	-4.52	6.97e-06	0.000593	-0.16	-0.14	Night sleep phenotypes;	chr10:61580354	chr10:61452639~61481956:+
BRCA	cis	rs1656368	0.69	rs73154313	ENSG00000279311.1	RP11-170K4.2	4.52	6.97e-06	0.000593	0.18	0.14	Lobe attachment (rater-scored or self-reported);	chr3:158507696	chr3:158869898~158871821:+
BRCA	cis	rs886774	0.559	rs2158836	ENSG00000273055.1	CTB-13F3.1	-4.52	6.97e-06	0.000593	-0.14	-0.14	Ulcerative colitis;	chr7:107940394	chr7:107942116~107942740:+
BRCA	cis	rs1320333	0.772	rs2867136	ENSG00000272342.1	RP13-539J13.1	4.52	6.97e-06	0.000593	0.23	0.14	Obesity-related traits;	chr2:701455	chr2:739588~740164:-
BRCA	cis	rs7267979	0.549	rs11698185	ENSG00000276952.1	RP5-965G21.6	4.52	6.97e-06	0.000594	0.17	0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25201362	chr20:25284915~25285588:-
BRCA	cis	rs10129255	0.5	rs6576230	ENSG00000232216.1	IGHV3-43	4.52	6.98e-06	0.000594	0.1	0.14	Kawasaki disease;	chr14:106778539	chr14:106470264~106470800:-
BRCA	cis	rs1008375	0.932	rs964012	ENSG00000249502.1	AC006160.5	-4.52	6.98e-06	0.000594	-0.16	-0.14	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17617561	chr4:17587467~17614571:-
BRCA	cis	rs11673344	0.542	rs826324	ENSG00000226686.6	LINC01535	4.52	6.98e-06	0.000594	0.18	0.14	Obesity-related traits;	chr19:37014343	chr19:37251912~37265535:+
BRCA	cis	rs875971	0.545	rs313830	ENSG00000230295.1	RP11-458F8.2	-4.52	6.98e-06	0.000594	-0.13	-0.14	Aortic root size;	chr7:66086944	chr7:66880708~66882981:+
BRCA	cis	rs470119	1	rs131801	ENSG00000273272.1	CTA-384D8.34	-4.52	6.98e-06	0.000594	-0.14	-0.14	Mean corpuscular hemoglobin;	chr22:50528205	chr22:50542650~50543011:+
BRCA	cis	rs9816784	0.566	rs11720913	ENSG00000242086.7	LINC00969	4.52	6.98e-06	0.000594	0.16	0.14	Mean corpuscular hemoglobin;	chr3:196105689	chr3:195658062~195739964:+
BRCA	cis	rs1950832	0.689	rs712405	ENSG00000258636.1	CTD-2298J14.2	-4.52	6.98e-06	0.000594	-0.15	-0.14	Urate levels in obese individuals;	chr14:41645024	chr14:41587861~41604856:-
BRCA	cis	rs7569084	0.687	rs963539	ENSG00000281920.1	RP11-418H16.1	-4.52	6.98e-06	0.000594	-0.17	-0.14	Sum eosinophil basophil counts;	chr2:65421413	chr2:65623272~65628424:+
BRCA	cis	rs7011507	0.532	rs72635702	ENSG00000279881.1	RP11-513O13.1	-4.52	6.98e-06	0.000594	-0.23	-0.14	Inflammatory bowel disease;Ulcerative colitis;	chr8:48314190	chr8:48428143~48431041:-
BRCA	cis	rs7772486	0.875	rs2224121	ENSG00000270638.1	RP3-466P17.1	4.52	6.98e-06	0.000594	0.16	0.14	Lobe attachment (rater-scored or self-reported);	chr6:146022078	chr6:145735570~145737218:+
BRCA	cis	rs8031584	0.958	rs7176569	ENSG00000259845.1	HERC2P10	-4.52	6.99e-06	0.000594	-0.16	-0.14	Huntington's disease progression;	chr15:30952292	chr15:30815271~30844153:+
BRCA	cis	rs1005277	0.505	rs10827835	ENSG00000226578.1	RP11-258F22.1	4.52	6.99e-06	0.000594	0.15	0.14	Extrinsic epigenetic age acceleration;	chr10:37861781	chr10:37775371~37784131:-
BRCA	cis	rs5752326	0.867	rs929131	ENSG00000261188.1	CTA-445C9.14	-4.52	6.99e-06	0.000594	-0.24	-0.14	Ischemic stroke;	chr22:26448803	chr22:26512537~26514568:+
BRCA	cis	rs9296095	0.747	rs12206050	ENSG00000224557.6	HLA-DPB2	-4.52	6.99e-06	0.000594	-0.19	-0.14	Platelet count;	chr6:33596519	chr6:33112451~33129084:+
BRCA	cis	rs10411936	0.608	rs7259642	ENSG00000280332.1	CTD-2013N17.6	4.52	6.99e-06	0.000595	0.12	0.14	Multiple sclerosis;White blood cell count;	chr19:16491115	chr19:16356329~16358327:-
BRCA	cis	rs6441961	0.628	rs6441960	ENSG00000223552.1	RP11-24F11.2	4.52	6.99e-06	0.000595	0.17	0.14	Celiac disease;	chr3:46310383	chr3:46364955~46407059:-
BRCA	cis	rs4689592	0.554	rs3951346	ENSG00000245468.3	RP11-367J11.3	4.52	6.99e-06	0.000595	0.15	0.14	Monocyte percentage of white cells;	chr4:7071594	chr4:7094571~7103385:-
BRCA	cis	rs1030877	0.515	rs2576735	ENSG00000235319.1	AC012360.4	-4.52	6.99e-06	0.000595	-0.19	-0.14	Obesity-related traits;	chr2:105272382	chr2:105324210~105330529:+
BRCA	cis	rs3764021	0.527	rs10844380	ENSG00000256673.1	RP11-599J14.2	-4.52	6.99e-06	0.000595	-0.17	-0.14	Type 1 diabetes;	chr12:9670678	chr12:9398355~9414851:-
BRCA	cis	rs10129255	0.5	rs9324092	ENSG00000211959.2	IGHV4-39	-4.52	7e-06	0.000595	-0.1	-0.14	Kawasaki disease;	chr14:106683806	chr14:106421711~106422218:-
BRCA	cis	rs6430585	0.583	rs58509842	ENSG00000231890.6	DARS-AS1	-4.52	7e-06	0.000595	-0.21	-0.14	Corneal structure;	chr2:135828457	chr2:135985176~136022593:+
BRCA	cis	rs6430585	0.583	rs3769008	ENSG00000231890.6	DARS-AS1	-4.52	7e-06	0.000595	-0.21	-0.14	Corneal structure;	chr2:135828613	chr2:135985176~136022593:+
BRCA	cis	rs6430585	0.583	rs12373779	ENSG00000231890.6	DARS-AS1	-4.52	7e-06	0.000595	-0.21	-0.14	Corneal structure;	chr2:135829270	chr2:135985176~136022593:+
BRCA	cis	rs6095360	1	rs6019601	ENSG00000222365.1	SNORD12B	-4.52	7e-06	0.000595	-0.15	-0.14	Intelligence (multi-trait analysis);	chr20:49031125	chr20:49280319~49280409:+
BRCA	cis	rs1005277	0.54	rs2224248	ENSG00000099251.13	HSD17B7P2	4.52	7e-06	0.000596	0.15	0.14	Extrinsic epigenetic age acceleration;	chr10:38162958	chr10:38356380~38378505:+
BRCA	cis	rs754466	0.874	rs61855849	ENSG00000204049.1	RP11-126H7.4	4.52	7e-06	0.000596	0.19	0.14	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77900176	chr10:77866875~77869610:+
BRCA	cis	rs442309	0.846	rs224133	ENSG00000238280.1	RP11-436D10.3	-4.52	7e-06	0.000596	-0.19	-0.14	Vogt-Koyanagi-Harada syndrome;	chr10:62706743	chr10:62793562~62805887:-
BRCA	cis	rs442309	0.819	rs224134	ENSG00000238280.1	RP11-436D10.3	-4.52	7e-06	0.000596	-0.19	-0.14	Vogt-Koyanagi-Harada syndrome;	chr10:62706867	chr10:62793562~62805887:-
BRCA	cis	rs56114371	0.53	rs9348774	ENSG00000216901.1	AL022393.7	4.52	7.01e-06	0.000596	0.21	0.14	Breast cancer;	chr6:27721151	chr6:28176188~28176674:+
BRCA	cis	rs2803122	0.87	rs10738534	ENSG00000273226.1	RP11-513M16.8	-4.52	7.01e-06	0.000596	-0.15	-0.14	Pulse pressure;	chr9:19293780	chr9:19375451~19375996:+
BRCA	cis	rs2255336	0.938	rs2733845	ENSG00000245648.1	RP11-277P12.20	-4.52	7.01e-06	0.000596	-0.2	-0.14	Blood protein levels;	chr12:10387216	chr12:10363769~10398506:+
BRCA	cis	rs11992162	0.591	rs4240678	ENSG00000255495.1	AC145124.2	-4.52	7.01e-06	0.000596	-0.16	-0.14	Monocyte count;	chr8:11944917	chr8:12194467~12196280:+
BRCA	cis	rs35146811	0.555	rs2527896	ENSG00000214313.7	AZGP1P1	4.52	7.01e-06	0.000596	0.15	0.14	Coronary artery disease;	chr7:99940030	chr7:99980762~99987535:+
BRCA	cis	rs2574985	0.813	rs1203394	ENSG00000231345.3	BEND3P1	-4.52	7.01e-06	0.000597	-0.22	-0.14	Subjective well-being;	chr10:50443000	chr10:50655967~50660472:+
BRCA	cis	rs2574985	0.813	rs1203393	ENSG00000231345.3	BEND3P1	-4.52	7.01e-06	0.000597	-0.22	-0.14	Subjective well-being;	chr10:50444327	chr10:50655967~50660472:+
BRCA	cis	rs2243480	0.908	rs55876148	ENSG00000275400.1	RP4-756H11.5	4.52	7.02e-06	0.000597	0.25	0.14	Diabetic kidney disease;	chr7:65914813	chr7:66553805~66554199:-
BRCA	cis	rs9435732	0.594	rs2647166	ENSG00000186715.9	MST1L	-4.52	7.02e-06	0.000597	-0.15	-0.14	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);	chr1:17016240	chr1:16754910~16770237:-
BRCA	cis	rs7572733	0.773	rs6757852	ENSG00000231621.1	AC013264.2	-4.52	7.02e-06	0.000597	-0.13	-0.14	Dermatomyositis;	chr2:197665569	chr2:197197991~197199273:+
BRCA	cis	rs983392	0.719	rs610932	ENSG00000275344.1	MIR6503	4.52	7.02e-06	0.000597	0.14	0.14	Alzheimer's disease (late onset);	chr11:60171834	chr11:60209071~60209156:-
BRCA	cis	rs4664293	0.867	rs7594329	ENSG00000226266.5	AC009961.3	-4.52	7.02e-06	0.000597	-0.17	-0.14	Monocyte percentage of white cells;	chr2:159716207	chr2:159670708~159712435:-
BRCA	cis	rs4664293	0.867	rs7582124	ENSG00000226266.5	AC009961.3	-4.52	7.02e-06	0.000597	-0.17	-0.14	Monocyte percentage of white cells;	chr2:159716326	chr2:159670708~159712435:-
BRCA	cis	rs2790457	0.792	rs1265845	ENSG00000254635.4	WAC-AS1	-4.52	7.02e-06	0.000597	-0.17	-0.14	Multiple myeloma;	chr10:28638294	chr10:28522652~28532743:-
BRCA	cis	rs1223397	1	rs1223399	ENSG00000215022.6	RP1-257A7.4	-4.52	7.02e-06	0.000597	-0.18	-0.14	Blood pressure;	chr6:13270988	chr6:13264861~13295586:-
BRCA	cis	rs2562456	0.837	rs62110205	ENSG00000268658.4	LINC00664	4.52	7.02e-06	0.000597	0.22	0.14	Pain;	chr19:21577269	chr19:21483374~21503238:+
BRCA	cis	rs8098244	0.603	rs3017550	ENSG00000264745.1	TTC39C-AS1	4.52	7.02e-06	0.000597	0.16	0.14	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23696510	chr18:23994213~24015339:-
BRCA	cis	rs12680842	0.842	rs34691145	ENSG00000253175.1	RP11-267M23.6	4.52	7.02e-06	0.000597	0.16	0.14	Body mass index;	chr8:94597715	chr8:94565036~94565715:+
BRCA	cis	rs1722141	0.669	rs788740	ENSG00000229628.1	AC073115.7	4.52	7.02e-06	0.000597	0.18	0.14	Sitting height ratio;	chr7:46001501	chr7:45990905~46000898:+
BRCA	cis	rs13113518	0.966	rs1474271	ENSG00000272969.1	RP11-528I4.2	4.52	7.03e-06	0.000598	0.16	0.14	Height;	chr4:55435912	chr4:55547112~55547889:+
BRCA	cis	rs7818688	0.697	rs11780130	ENSG00000253528.2	RP11-347C18.4	-4.52	7.03e-06	0.000598	-0.21	-0.14	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94963855	chr8:94974573~94974853:-
BRCA	cis	rs8114671	0.836	rs6142280	ENSG00000279253.1	RP4-614O4.13	4.52	7.03e-06	0.000598	0.16	0.14	Height;	chr20:35034439	chr20:35262727~35264187:-
BRCA	cis	rs2832191	0.791	rs2832178	ENSG00000236056.1	GAPDHP14	4.52	7.03e-06	0.000598	0.15	0.14	Dental caries;	chr21:29107537	chr21:29222321~29223257:+
BRCA	cis	rs6997458	0.554	rs2291787	ENSG00000258256.1	RP11-219B4.5	-4.52	7.03e-06	0.000598	-0.16	-0.14	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85329491	chr8:85222446~85245717:-
BRCA	cis	rs875971	0.502	rs1796227	ENSG00000230295.1	RP11-458F8.2	-4.52	7.03e-06	0.000598	-0.13	-0.14	Aortic root size;	chr7:66622032	chr7:66880708~66882981:+
BRCA	cis	rs10411936	0.924	rs8110761	ENSG00000280332.1	CTD-2013N17.6	4.52	7.03e-06	0.000598	0.12	0.14	Multiple sclerosis;White blood cell count;	chr19:16390194	chr19:16356329~16358327:-
BRCA	cis	rs16958440	0.737	rs16958699	ENSG00000280212.1	RP11-49K24.3	4.52	7.03e-06	0.000598	0.29	0.14	Sitting height ratio;	chr18:47128475	chr18:47076117~47076594:+
BRCA	cis	rs16958440	1	rs16958701	ENSG00000280212.1	RP11-49K24.3	4.52	7.03e-06	0.000598	0.29	0.14	Sitting height ratio;	chr18:47128870	chr18:47076117~47076594:+
BRCA	cis	rs6545883	0.507	rs62149712	ENSG00000273302.1	RP11-493E12.2	-4.52	7.03e-06	0.000598	-0.12	-0.14	Tuberculosis;	chr2:61374137	chr2:61199979~61200769:+
BRCA	cis	rs651907	0.557	rs62284199	ENSG00000256628.3	ZBTB11-AS1	4.52	7.04e-06	0.000598	0.18	0.14	Colorectal cancer;	chr3:101759687	chr3:101676475~101679217:+
BRCA	cis	rs11673344	0.526	rs8101610	ENSG00000267422.1	CTD-2554C21.1	-4.52	7.04e-06	0.000598	-0.19	-0.14	Obesity-related traits;	chr19:37566604	chr19:37779686~37792865:+
BRCA	cis	rs67981189	0.574	rs2010713	ENSG00000269927.1	RP6-91H8.3	-4.52	7.04e-06	0.000598	-0.17	-0.14	Schizophrenia;	chr14:70902018	chr14:71141125~71143253:-
BRCA	cis	rs6723226	0.881	rs10181198	ENSG00000276517.1	AL133243.2	-4.52	7.04e-06	0.000598	-0.17	-0.14	Intelligence (multi-trait analysis);	chr2:32461514	chr2:32526504~32529507:+
BRCA	cis	rs924712	0.625	rs12191299	ENSG00000261116.1	RP3-523K23.2	4.52	7.04e-06	0.000598	0.17	0.14	Breast cancer;	chr6:54855687	chr6:54943167~54945099:+
BRCA	cis	rs2446066	0.872	rs10876450	ENSG00000257379.1	RP11-793H13.8	-4.52	7.04e-06	0.000598	-0.2	-0.14	Red blood cell count;	chr12:53417250	chr12:53441741~53467528:+
BRCA	cis	rs875971	0.862	rs709596	ENSG00000273448.1	RP11-166O4.6	4.52	7.04e-06	0.000598	0.13	0.14	Aortic root size;	chr7:66360926	chr7:67333047~67334383:+
BRCA	cis	rs4886920	0.519	rs75789686	ENSG00000260776.4	RP11-114H24.2	4.52	7.04e-06	0.000599	0.22	0.14	Neuroticism;	chr15:77821235	chr15:77914217~77926846:-
BRCA	cis	rs13113518	0.507	rs11943456	ENSG00000223305.1	RN7SKP30	4.52	7.04e-06	0.000599	0.17	0.14	Height;	chr4:55410167	chr4:55540502~55540835:-
BRCA	cis	rs10844706	0.699	rs10844633	ENSG00000214776.8	RP11-726G1.1	4.52	7.04e-06	0.000599	0.17	0.14	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9734790	chr12:9467552~9576275:+
BRCA	cis	rs9392653	0.855	rs11242988	ENSG00000220685.3	RP11-530A18.1	-4.52	7.05e-06	0.000599	-0.19	-0.14	Venous thromboembolism (SNP x SNP interaction);	chr6:5065379	chr6:5065795~5066982:-
BRCA	cis	rs7267979	0.816	rs6076358	ENSG00000204556.4	CTD-2514C3.1	4.52	7.05e-06	0.000599	0.18	0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25538767	chr20:26018832~26020684:+
BRCA	cis	rs8054556	1	rs4787486	ENSG00000214725.6	CDIPT-AS1	-4.52	7.05e-06	0.000599	-0.17	-0.14	Autism spectrum disorder or schizophrenia;	chr16:29966241	chr16:29863593~29868053:+
BRCA	cis	rs10129255	0.957	rs10142859	ENSG00000211974.3	IGHV2-70	4.52	7.05e-06	0.000599	0.14	0.14	Kawasaki disease;	chr14:106782238	chr14:106723574~106724093:-
BRCA	cis	rs4950322	0.57	rs72691090	ENSG00000237188.3	RP11-337C18.8	4.51	7.06e-06	6e-04	0.18	0.14	Protein quantitative trait loci;	chr1:147297884	chr1:147172771~147211568:+
BRCA	cis	rs950776	0.752	rs2869546	ENSG00000279373.1	RP11-650L12.4	-4.51	7.06e-06	6e-04	-0.17	-0.14	Sudden cardiac arrest;	chr15:78615003	chr15:78537681~78538946:+
BRCA	cis	rs9863	0.931	rs4765335	ENSG00000270028.1	RP11-380L11.4	4.51	7.06e-06	6e-04	0.17	0.14	White blood cell count;	chr12:123946265	chr12:123925461~123926083:-
BRCA	cis	rs6840360	0.547	rs9991859	ENSG00000270265.1	RP11-731D1.4	-4.51	7.06e-06	6e-04	-0.15	-0.14	Intelligence (multi-trait analysis);	chr4:151344420	chr4:151333775~151353224:-
BRCA	cis	rs35740288	0.753	rs4843095	ENSG00000202081.1	RNU6-1280P	4.51	7.06e-06	6e-04	0.19	0.14	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85731900	chr15:85651522~85651628:-
BRCA	cis	rs1223397	0.651	rs9349564	ENSG00000215022.6	RP1-257A7.4	-4.51	7.06e-06	6e-04	-0.17	-0.14	Blood pressure;	chr6:13315792	chr6:13264861~13295586:-
BRCA	cis	rs6890684	0.569	rs34627	ENSG00000215032.2	GNL3LP1	4.51	7.07e-06	0.000601	0.17	0.14	Intelligence (multi-trait analysis);	chr5:61232979	chr5:60891935~60893577:-
BRCA	cis	rs6890684	0.569	rs159360	ENSG00000215032.2	GNL3LP1	4.51	7.07e-06	0.000601	0.17	0.14	Intelligence (multi-trait analysis);	chr5:61233623	chr5:60891935~60893577:-
BRCA	cis	rs4699052	0.537	rs1580278	ENSG00000246560.2	RP11-10L12.4	-4.51	7.07e-06	0.000601	-0.15	-0.14	Testicular germ cell tumor;	chr4:103219691	chr4:102828055~102844075:+
BRCA	cis	rs35612822	0.723	rs10176384	ENSG00000232485.2	AC098820.3	-4.51	7.07e-06	0.000601	-0.17	-0.14	Kidney disease (early stage) in type 1 diabetes;	chr2:216406139	chr2:216479030~216498761:-
BRCA	cis	rs35612822	0.723	rs10176393	ENSG00000232485.2	AC098820.3	-4.51	7.07e-06	0.000601	-0.17	-0.14	Kidney disease (early stage) in type 1 diabetes;	chr2:216406153	chr2:216479030~216498761:-
BRCA	cis	rs6570726	0.875	rs373313	ENSG00000270638.1	RP3-466P17.1	4.51	7.07e-06	0.000601	0.15	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145536655	chr6:145735570~145737218:+
BRCA	cis	rs6128907	1	rs6128907	ENSG00000224635.1	RP4-564F22.5	4.51	7.07e-06	0.000601	0.21	0.14	Liver fibrosis in pediatric non-alcoholic fatty acid liver disease;	chr20:38759219	chr20:38406011~38416797:-
BRCA	cis	rs11098499	0.675	rs11098534	ENSG00000249244.1	RP11-548H18.2	4.51	7.08e-06	0.000601	0.16	0.14	Corneal astigmatism;	chr4:119635617	chr4:119391831~119395335:-
BRCA	cis	rs4948275	0.741	rs2787695	ENSG00000237233.2	TMEM26-AS1	-4.51	7.08e-06	0.000601	-0.17	-0.14	Night sleep phenotypes;	chr10:61532087	chr10:61452639~61481956:+
BRCA	cis	rs4948275	0.773	rs2787696	ENSG00000237233.2	TMEM26-AS1	-4.51	7.08e-06	0.000601	-0.17	-0.14	Night sleep phenotypes;	chr10:61533449	chr10:61452639~61481956:+
BRCA	cis	rs9467773	0.62	rs2504565	ENSG00000124549.13	BTN2A3P	4.51	7.08e-06	0.000602	0.14	0.14	Intelligence (multi-trait analysis);	chr6:26656662	chr6:26421391~26432383:+
BRCA	cis	rs5751614	0.537	rs2227939	ENSG00000240160.3	RN7SL263P	4.51	7.08e-06	0.000602	0.18	0.14	Height;	chr22:23289614	chr22:23261782~23262071:-
BRCA	cis	rs6430585	0.583	rs730005	ENSG00000224043.6	CCNT2-AS1	-4.51	7.08e-06	0.000602	-0.23	-0.14	Corneal structure;	chr2:135825124	chr2:134735464~134918710:-
BRCA	cis	rs9467773	0.595	rs2237236	ENSG00000124549.13	BTN2A3P	-4.51	7.08e-06	0.000602	-0.15	-0.14	Intelligence (multi-trait analysis);	chr6:26451325	chr6:26421391~26432383:+
BRCA	cis	rs2574985	0.813	rs1203382	ENSG00000231345.3	BEND3P1	-4.51	7.08e-06	0.000602	-0.22	-0.14	Subjective well-being;	chr10:50452549	chr10:50655967~50660472:+
BRCA	cis	rs7116495	0.609	rs1892920	ENSG00000248671.6	ALG1L9P	-4.51	7.09e-06	0.000602	-0.36	-0.14	Severe influenza A (H1N1) infection;	chr11:71991385	chr11:71794363~71818238:-
BRCA	cis	rs62244186	0.545	rs9284880	ENSG00000214820.3	MPRIPP1	4.51	7.09e-06	0.000602	0.16	0.14	Depressive symptoms;	chr3:44717897	chr3:44579938~44581026:-
BRCA	cis	rs2273156	1	rs12050390	ENSG00000226677.3	IGBP1P1	-4.51	7.09e-06	0.000602	-0.21	-0.14	Immunoglobulin light chain (AL) amyloidosis;	chr14:34991873	chr14:34939324~34940332:+
BRCA	cis	rs2273156	1	rs12050402	ENSG00000226677.3	IGBP1P1	-4.51	7.09e-06	0.000602	-0.21	-0.14	Immunoglobulin light chain (AL) amyloidosis;	chr14:34992610	chr14:34939324~34940332:+
BRCA	cis	rs2273156	1	rs12050404	ENSG00000226677.3	IGBP1P1	-4.51	7.09e-06	0.000602	-0.21	-0.14	Immunoglobulin light chain (AL) amyloidosis;	chr14:34992664	chr14:34939324~34940332:+
BRCA	cis	rs67517081	1	rs67517081	ENSG00000275263.1	RP11-1072A3.4	4.51	7.09e-06	0.000602	0.17	0.14	Mean corpuscular hemoglobin;	chr16:30976060	chr16:30956872~30957199:-
BRCA	cis	rs1371614	0.655	rs509047	ENSG00000272148.1	RP11-195B17.1	-4.51	7.09e-06	0.000602	-0.15	-0.14	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26905661	chr2:27062428~27062907:-
BRCA	cis	rs875971	0.83	rs12673450	ENSG00000229886.1	RP5-1132H15.3	4.51	7.09e-06	0.000603	0.16	0.14	Aortic root size;	chr7:66544233	chr7:66025126~66031544:-
BRCA	cis	rs35740288	0.571	rs11631009	ENSG00000202081.1	RNU6-1280P	4.51	7.09e-06	0.000603	0.2	0.14	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85775422	chr15:85651522~85651628:-
BRCA	cis	rs991427	1	rs7488394	ENSG00000258100.1	RP11-121E16.1	-4.51	7.09e-06	0.000603	-0.19	-0.14	Systolic blood pressure (alcohol consumption interaction);	chr12:91086225	chr12:91362196~91368606:+
BRCA	cis	rs6088580	0.634	rs4911423	ENSG00000276073.1	RP5-1125A11.7	4.51	7.09e-06	0.000603	0.15	0.14	Glomerular filtration rate (creatinine);	chr20:34411580	chr20:33985617~33988989:-
BRCA	cis	rs6088580	0.634	rs6141471	ENSG00000276073.1	RP5-1125A11.7	4.51	7.09e-06	0.000603	0.15	0.14	Glomerular filtration rate (creatinine);	chr20:34418924	chr20:33985617~33988989:-
BRCA	cis	rs7267979	0.745	rs6132845	ENSG00000125804.12	FAM182A	-4.51	7.09e-06	0.000603	-0.18	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25567131	chr20:26054655~26086917:+
BRCA	cis	rs6430585	0.878	rs9677760	ENSG00000224043.6	CCNT2-AS1	4.51	7.1e-06	0.000603	0.21	0.14	Corneal structure;	chr2:135781369	chr2:134735464~134918710:-
BRCA	cis	rs62244186	0.545	rs7640654	ENSG00000214820.3	MPRIPP1	4.51	7.1e-06	0.000603	0.16	0.14	Depressive symptoms;	chr3:44721545	chr3:44579938~44581026:-
BRCA	cis	rs10504130	1	rs75061868	ENSG00000272024.1	RP11-546K22.3	-4.51	7.1e-06	0.000603	-0.24	-0.14	Venous thromboembolism (SNP x SNP interaction);	chr8:51883380	chr8:51950284~51950690:+
BRCA	cis	rs10504130	1	rs2176120	ENSG00000272024.1	RP11-546K22.3	-4.51	7.1e-06	0.000603	-0.24	-0.14	Venous thromboembolism (SNP x SNP interaction);	chr8:51885462	chr8:51950284~51950690:+
BRCA	cis	rs10504130	1	rs80340160	ENSG00000272024.1	RP11-546K22.3	-4.51	7.1e-06	0.000603	-0.24	-0.14	Venous thromboembolism (SNP x SNP interaction);	chr8:51885628	chr8:51950284~51950690:+
BRCA	cis	rs10504130	1	rs9792352	ENSG00000272024.1	RP11-546K22.3	-4.51	7.1e-06	0.000603	-0.24	-0.14	Venous thromboembolism (SNP x SNP interaction);	chr8:51886862	chr8:51950284~51950690:+
BRCA	cis	rs10504130	1	rs2037138	ENSG00000272024.1	RP11-546K22.3	-4.51	7.1e-06	0.000603	-0.24	-0.14	Venous thromboembolism (SNP x SNP interaction);	chr8:51892153	chr8:51950284~51950690:+
BRCA	cis	rs10504130	1	rs2037139	ENSG00000272024.1	RP11-546K22.3	-4.51	7.1e-06	0.000603	-0.24	-0.14	Venous thromboembolism (SNP x SNP interaction);	chr8:51892324	chr8:51950284~51950690:+
BRCA	cis	rs4664293	0.867	rs7565297	ENSG00000224152.1	AC009506.1	-4.51	7.1e-06	0.000603	-0.16	-0.14	Monocyte percentage of white cells;	chr2:159716008	chr2:159615296~159617082:+
BRCA	cis	rs2880765	0.835	rs7178991	ENSG00000202081.1	RNU6-1280P	4.51	7.11e-06	0.000604	0.16	0.14	Coronary artery disease;	chr15:85507713	chr15:85651522~85651628:-
BRCA	cis	rs62103177	0.525	rs62101233	ENSG00000267270.4	PARD6G-AS1	4.51	7.11e-06	0.000604	0.23	0.14	Opioid sensitivity;	chr18:79964288	chr18:80147924~80178432:+
BRCA	cis	rs2832191	0.933	rs2832236	ENSG00000176054.6	RPL23P2	-4.51	7.11e-06	0.000604	-0.15	-0.14	Dental caries;	chr21:29175281	chr21:28997613~28998033:-
BRCA	cis	rs77204473	0.744	rs12420200	ENSG00000278768.1	BACE1-AS	4.51	7.11e-06	0.000604	0.23	0.14	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117127590	chr11:117290874~117293571:+
BRCA	cis	rs651907	0.514	rs12636046	ENSG00000256628.3	ZBTB11-AS1	4.51	7.11e-06	0.000604	0.18	0.14	Colorectal cancer;	chr3:101715604	chr3:101676475~101679217:+
BRCA	cis	rs4869313	0.655	rs1230358	ENSG00000248734.2	CTD-2260A17.1	4.51	7.11e-06	0.000604	0.14	0.14	Pediatric autoimmune diseases;	chr5:96876037	chr5:96784777~96785999:+
BRCA	cis	rs72482608	0.865	rs10800543	ENSG00000271811.1	RP1-79C4.4	4.51	7.11e-06	0.000604	0.15	0.14	Emphysema imaging phenotypes;	chr1:170796627	chr1:170667381~170669425:+
BRCA	cis	rs2446066	0.872	rs11614010	ENSG00000257379.1	RP11-793H13.8	4.51	7.11e-06	0.000604	0.22	0.14	Red blood cell count;	chr12:53426253	chr12:53441741~53467528:+
BRCA	cis	rs7829975	0.508	rs4841006	ENSG00000233609.3	RP11-62H7.2	-4.51	7.11e-06	0.000604	-0.13	-0.14	Mood instability;	chr8:8643964	chr8:8961200~8979025:+
BRCA	cis	rs11779988	0.545	rs422746	ENSG00000253671.1	RP11-806O11.1	-4.51	7.11e-06	0.000604	-0.2	-0.14	Breast cancer;	chr8:17926977	chr8:17808941~17820868:+
BRCA	cis	rs926392	0.932	rs6124105	ENSG00000274825.1	RP4-616B8.5	-4.51	7.11e-06	0.000604	-0.13	-0.14	Dialysis-related mortality;	chr20:39057438	chr20:38955910~38956547:+
BRCA	cis	rs7617773	0.539	rs12486935	ENSG00000199476.1	Y_RNA	-4.51	7.11e-06	0.000604	-0.19	-0.14	Coronary artery disease;	chr3:48348674	chr3:48288587~48288694:+
BRCA	cis	rs56322409	0.897	rs10882650	ENSG00000226688.5	ENTPD1-AS1	4.51	7.12e-06	0.000604	0.16	0.14	Blood metabolite levels;	chr10:95672939	chr10:95753206~96090238:-
BRCA	cis	rs12468226	0.752	rs116078354	ENSG00000226261.1	AC064836.3	4.51	7.12e-06	0.000605	0.25	0.14	Urate levels;	chr2:202136356	chr2:202336024~202336727:-
BRCA	cis	rs11098499	0.954	rs17005535	ENSG00000260091.1	RP11-33B1.4	-4.51	7.12e-06	0.000605	-0.12	-0.14	Corneal astigmatism;	chr4:119490407	chr4:119409333~119410233:+
BRCA	cis	rs11096990	0.613	rs6829660	ENSG00000249685.1	RP11-360F5.3	4.51	7.12e-06	0.000605	0.17	0.14	Cognitive function;	chr4:39280943	chr4:39133913~39135608:+
BRCA	cis	rs9516	0.564	rs10898993	ENSG00000254631.4	RP11-702H23.4	4.51	7.12e-06	0.000605	0.17	0.14	Facial morphology (factor 15, philtrum width);	chr11:74463919	chr11:74397549~74485742:+
BRCA	cis	rs13326165	0.543	rs7643913	ENSG00000243224.1	RP5-1157M23.2	-4.51	7.12e-06	0.000605	-0.23	-0.14	HDL cholesterol levels;HDL cholesterol;	chr3:52269197	chr3:52239258~52241097:+
BRCA	cis	rs3812049	0.784	rs2617617	ENSG00000245937.6	LINC01184	4.51	7.13e-06	0.000605	0.19	0.14	Lymphocyte counts;Red cell distribution width;	chr5:128119316	chr5:127940426~128083172:-
BRCA	cis	rs2562456	0.876	rs7252585	ENSG00000268658.4	LINC00664	-4.51	7.13e-06	0.000606	-0.2	-0.14	Pain;	chr19:21475141	chr19:21483374~21503238:+
BRCA	cis	rs7267979	1	rs4815418	ENSG00000274973.1	RP13-401N8.7	4.51	7.13e-06	0.000606	0.16	0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25401575	chr20:25845497~25845862:+
BRCA	cis	rs2839186	0.632	rs17176110	ENSG00000228137.1	AP001469.7	4.51	7.13e-06	0.000606	0.15	0.14	Testicular germ cell tumor;	chr21:46286621	chr21:46246890~46247682:+
BRCA	cis	rs7200543	1	rs6498541	ENSG00000275910.1	RP11-680G24.6	-4.51	7.13e-06	0.000606	-0.16	-0.14	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15046800	chr16:15015828~15016390:-
BRCA	cis	rs216345	0.67	rs307703	ENSG00000260947.1	RP11-384P7.7	4.51	7.13e-06	0.000606	0.15	0.14	Bipolar disorder;	chr9:33985467	chr9:33697459~33700986:+
BRCA	cis	rs763014	0.932	rs2384975	ENSG00000260394.2	LA16c-313D11.9	-4.51	7.14e-06	0.000606	-0.14	-0.14	Height;	chr16:601115	chr16:678504~679777:-
BRCA	cis	rs7246657	0.722	rs2291002	ENSG00000226686.6	LINC01535	-4.51	7.14e-06	0.000606	-0.21	-0.14	Coronary artery calcification;	chr19:37543024	chr19:37251912~37265535:+
BRCA	cis	rs7246657	0.722	rs10404031	ENSG00000226686.6	LINC01535	-4.51	7.14e-06	0.000606	-0.21	-0.14	Coronary artery calcification;	chr19:37545052	chr19:37251912~37265535:+
BRCA	cis	rs7246657	0.722	rs10406379	ENSG00000226686.6	LINC01535	-4.51	7.14e-06	0.000606	-0.21	-0.14	Coronary artery calcification;	chr19:37545823	chr19:37251912~37265535:+
BRCA	cis	rs4819052	0.959	rs8130866	ENSG00000184274.3	LINC00315	-4.51	7.14e-06	0.000606	-0.2	-0.14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45252197	chr21:45300245~45305257:-
BRCA	cis	rs4650994	0.935	rs12039531	ENSG00000273384.1	RP5-1098D14.1	4.51	7.14e-06	0.000606	0.17	0.14	HDL cholesterol;HDL cholesterol levels;	chr1:178546477	chr1:178651706~178652282:+
BRCA	cis	rs11098499	0.657	rs10434028	ENSG00000249244.1	RP11-548H18.2	4.51	7.14e-06	0.000606	0.16	0.14	Corneal astigmatism;	chr4:119373309	chr4:119391831~119395335:-
BRCA	cis	rs6012564	0.928	rs1043357	ENSG00000227431.4	CSE1L-AS1	4.51	7.14e-06	0.000606	0.18	0.14	Anger;	chr20:49114691	chr20:49040463~49046044:-
BRCA	cis	rs180730	1	rs343166	ENSG00000251609.2	SETP12	-4.51	7.14e-06	0.000607	-0.2	-0.14	Fasting plasma glucose;	chr4:120897567	chr4:120895494~120897083:-
BRCA	cis	rs35740288	0.822	rs11630549	ENSG00000202081.1	RNU6-1280P	4.51	7.15e-06	0.000607	0.19	0.14	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85732565	chr15:85651522~85651628:-
BRCA	cis	rs6095360	1	rs6019604	ENSG00000222365.1	SNORD12B	-4.51	7.15e-06	0.000607	-0.15	-0.14	Intelligence (multi-trait analysis);	chr20:49036961	chr20:49280319~49280409:+
BRCA	cis	rs11673344	0.523	rs2562599	ENSG00000226686.6	LINC01535	-4.51	7.15e-06	0.000607	-0.18	-0.14	Obesity-related traits;	chr19:37025472	chr19:37251912~37265535:+
BRCA	cis	rs10986311	0.681	rs35068124	ENSG00000227200.1	RP11-121A14.3	-4.51	7.15e-06	0.000607	-0.17	-0.14	Vitiligo;	chr9:124265531	chr9:124262876~124265809:+
BRCA	cis	rs7772486	0.79	rs11760	ENSG00000270638.1	RP3-466P17.1	4.51	7.15e-06	0.000607	0.16	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145884837	chr6:145735570~145737218:+
BRCA	cis	rs56322409	0.897	rs7089668	ENSG00000226688.5	ENTPD1-AS1	-4.51	7.15e-06	0.000607	-0.16	-0.14	Blood metabolite levels;	chr10:95848665	chr10:95753206~96090238:-
BRCA	cis	rs11098499	0.779	rs80242894	ENSG00000250412.1	KLHL2P1	4.51	7.15e-06	0.000607	0.16	0.14	Corneal astigmatism;	chr4:119454597	chr4:119334329~119378233:+
BRCA	cis	rs2303319	0.582	rs72870248	ENSG00000227403.1	AC009299.3	4.51	7.16e-06	0.000608	0.33	0.14	Cognitive function;	chr2:161579339	chr2:161244739~161249050:+
BRCA	cis	rs11098499	0.908	rs2017057	ENSG00000260404.2	RP11-384K6.6	4.51	7.16e-06	0.000608	0.13	0.14	Corneal astigmatism;	chr4:119336556	chr4:118591773~118633729:+
BRCA	cis	rs35306767	0.953	rs35174953	ENSG00000229869.1	RP11-363N22.2	-4.51	7.16e-06	0.000608	-0.2	-0.14	Eosinophil percentage of granulocytes;	chr10:915251	chr10:933026~942743:+
BRCA	cis	rs1722141	0.669	rs1722120	ENSG00000229628.1	AC073115.7	4.51	7.16e-06	0.000608	0.19	0.14	Sitting height ratio;	chr7:45993346	chr7:45990905~46000898:+
BRCA	cis	rs9921338	0.924	rs7193645	ENSG00000262703.1	RP11-485G7.6	-4.51	7.16e-06	0.000608	-0.17	-0.14	Vein graft stenosis in coronary artery bypass grafting;	chr16:11287179	chr16:11348143~11349321:-
BRCA	cis	rs77204473	1	rs10892040	ENSG00000280143.1	AP000892.6	-4.51	7.16e-06	0.000608	-0.26	-0.14	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116886270	chr11:117204967~117210292:+
BRCA	cis	rs651907	0.557	rs3806653	ENSG00000256628.3	ZBTB11-AS1	4.51	7.16e-06	0.000608	0.17	0.14	Colorectal cancer;	chr3:101678128	chr3:101676475~101679217:+
BRCA	cis	rs12468226	0.689	rs17651413	ENSG00000226261.1	AC064836.3	4.51	7.16e-06	0.000608	0.25	0.14	Urate levels;	chr2:202104086	chr2:202336024~202336727:-
BRCA	cis	rs2692947	0.864	rs2579518	ENSG00000168992.4	OR7E102P	4.51	7.17e-06	0.000608	0.19	0.14	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96009511	chr2:95546531~95547545:+
BRCA	cis	rs9818758	0.607	rs9837237	ENSG00000270441.1	RP11-694I15.7	4.51	7.17e-06	0.000608	0.26	0.14	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49178150	chr3:49140086~49160851:-
BRCA	cis	rs6545883	0.895	rs2442029	ENSG00000212978.6	AC016747.3	4.51	7.17e-06	0.000608	0.19	0.14	Tuberculosis;	chr2:61452417	chr2:61141592~61144969:-
BRCA	cis	rs6545883	0.929	rs2256615	ENSG00000212978.6	AC016747.3	4.51	7.17e-06	0.000608	0.19	0.14	Tuberculosis;	chr2:61452759	chr2:61141592~61144969:-
BRCA	cis	rs10992471	0.56	rs10992513	ENSG00000187984.11	ANKRD19P	-4.51	7.17e-06	0.000608	-0.13	-0.14	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr9:92890818	chr9:92809388~92888693:+
BRCA	cis	rs10208649	1	rs72906711	ENSG00000272156.1	RP11-477N3.1	4.51	7.17e-06	0.000608	0.29	0.14	Body mass index;	chr2:54036465	chr2:54082554~54085066:+
BRCA	cis	rs10208649	0.908	rs13387890	ENSG00000272156.1	RP11-477N3.1	4.51	7.17e-06	0.000608	0.29	0.14	Body mass index;	chr2:54039249	chr2:54082554~54085066:+
BRCA	cis	rs7141336	0.8	rs10136977	ENSG00000258884.1	CTD-3035D6.2	4.51	7.17e-06	0.000608	0.18	0.14	Anxiety disorder;	chr14:90822467	chr14:90822365~90828128:-
BRCA	cis	rs7665090	0.87	rs228615	ENSG00000251288.2	RP11-10L12.2	4.51	7.17e-06	0.000609	0.16	0.14	Primary biliary cholangitis;	chr4:102658303	chr4:102751401~102752641:+
BRCA	cis	rs442309	0.812	rs224089	ENSG00000238280.1	RP11-436D10.3	-4.51	7.17e-06	0.000609	-0.18	-0.14	Vogt-Koyanagi-Harada syndrome;	chr10:62780161	chr10:62793562~62805887:-
BRCA	cis	rs11577354	0.509	rs7522498	ENSG00000207181.1	SNORA14B	-4.51	7.18e-06	0.000609	-0.16	-0.14	Obesity-related traits;	chr1:235104719	chr1:235127803~235127937:-
BRCA	cis	rs10129255	0.5	rs988134	ENSG00000232216.1	IGHV3-43	4.51	7.18e-06	0.000609	0.1	0.14	Kawasaki disease;	chr14:106776698	chr14:106470264~106470800:-
BRCA	cis	rs10129255	0.5	rs988133	ENSG00000232216.1	IGHV3-43	4.51	7.18e-06	0.000609	0.1	0.14	Kawasaki disease;	chr14:106776724	chr14:106470264~106470800:-
BRCA	cis	rs2446066	0.872	rs10876453	ENSG00000257379.1	RP11-793H13.8	4.51	7.18e-06	0.000609	0.22	0.14	Red blood cell count;	chr12:53426404	chr12:53441741~53467528:+
BRCA	cis	rs745109	0.882	rs72930400	ENSG00000273080.1	RP11-301O19.1	4.51	7.18e-06	0.000609	0.23	0.14	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86477757	chr2:86195590~86196049:+
BRCA	cis	rs875971	0.545	rs1796219	ENSG00000232546.1	RP11-458F8.1	-4.51	7.18e-06	0.00061	-0.13	-0.14	Aortic root size;	chr7:66645977	chr7:66848496~66858136:+
BRCA	cis	rs3176789	0.914	rs724666	ENSG00000256673.1	RP11-599J14.2	4.51	7.18e-06	0.00061	0.17	0.14	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9770517	chr12:9398355~9414851:-
BRCA	cis	rs77204473	1	rs12416987	ENSG00000280143.1	AP000892.6	-4.51	7.18e-06	0.00061	-0.26	-0.14	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116883549	chr11:117204967~117210292:+
BRCA	cis	rs7312933	0.558	rs11181507	ENSG00000257225.1	RP11-328C8.4	-4.51	7.18e-06	0.00061	-0.17	-0.14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42450961	chr12:42459366~42466128:+
BRCA	cis	rs7577696	0.711	rs385076	ENSG00000272716.1	RP11-563N4.1	4.51	7.19e-06	0.00061	0.16	0.14	Inflammatory biomarkers;	chr2:32264782	chr2:32165046~32165757:-
BRCA	cis	rs610932	0.517	rs652303	ENSG00000275344.1	MIR6503	4.51	7.19e-06	0.00061	0.14	0.14	Alzheimer's disease;	chr11:60202574	chr11:60209071~60209156:-
BRCA	cis	rs2834288	0.959	rs2834294	ENSG00000273102.1	AP000569.9	-4.51	7.19e-06	0.00061	-0.15	-0.14	Gut microbiota (bacterial taxa);	chr21:33908326	chr21:33967101~33968573:-
BRCA	cis	rs991427	0.818	rs11105975	ENSG00000258100.1	RP11-121E16.1	-4.51	7.19e-06	0.00061	-0.19	-0.14	Systolic blood pressure (alcohol consumption interaction);	chr12:91085377	chr12:91362196~91368606:+
BRCA	cis	rs991427	0.908	rs1882141	ENSG00000258100.1	RP11-121E16.1	-4.51	7.19e-06	0.00061	-0.19	-0.14	Systolic blood pressure (alcohol consumption interaction);	chr12:91086000	chr12:91362196~91368606:+
BRCA	cis	rs991427	1	rs1882140	ENSG00000258100.1	RP11-121E16.1	-4.51	7.19e-06	0.00061	-0.19	-0.14	Systolic blood pressure (alcohol consumption interaction);	chr12:91086049	chr12:91362196~91368606:+
BRCA	cis	rs991427	1	rs114827034	ENSG00000258100.1	RP11-121E16.1	-4.51	7.19e-06	0.00061	-0.19	-0.14	Systolic blood pressure (alcohol consumption interaction);	chr12:91086265	chr12:91362196~91368606:+
BRCA	cis	rs991427	1	rs11105983	ENSG00000258100.1	RP11-121E16.1	-4.51	7.19e-06	0.00061	-0.19	-0.14	Systolic blood pressure (alcohol consumption interaction);	chr12:91087199	chr12:91362196~91368606:+
BRCA	cis	rs991427	1	rs73197078	ENSG00000258100.1	RP11-121E16.1	-4.51	7.19e-06	0.00061	-0.19	-0.14	Systolic blood pressure (alcohol consumption interaction);	chr12:91087781	chr12:91362196~91368606:+
BRCA	cis	rs991427	1	rs12372754	ENSG00000258100.1	RP11-121E16.1	-4.51	7.19e-06	0.00061	-0.19	-0.14	Systolic blood pressure (alcohol consumption interaction);	chr12:91087801	chr12:91362196~91368606:+
BRCA	cis	rs991427	0.643	rs116519901	ENSG00000258100.1	RP11-121E16.1	-4.51	7.19e-06	0.00061	-0.19	-0.14	Systolic blood pressure (alcohol consumption interaction);	chr12:91087842	chr12:91362196~91368606:+
BRCA	cis	rs991427	1	rs11513822	ENSG00000258100.1	RP11-121E16.1	-4.51	7.19e-06	0.00061	-0.19	-0.14	Systolic blood pressure (alcohol consumption interaction);	chr12:91088228	chr12:91362196~91368606:+
BRCA	cis	rs991427	1	rs11519665	ENSG00000258100.1	RP11-121E16.1	-4.51	7.19e-06	0.00061	-0.19	-0.14	Systolic blood pressure (alcohol consumption interaction);	chr12:91088259	chr12:91362196~91368606:+
BRCA	cis	rs991427	1	rs11513751	ENSG00000258100.1	RP11-121E16.1	-4.51	7.19e-06	0.00061	-0.19	-0.14	Systolic blood pressure (alcohol consumption interaction);	chr12:91088403	chr12:91362196~91368606:+
BRCA	cis	rs991427	1	rs11513752	ENSG00000258100.1	RP11-121E16.1	-4.51	7.19e-06	0.00061	-0.19	-0.14	Systolic blood pressure (alcohol consumption interaction);	chr12:91088421	chr12:91362196~91368606:+
BRCA	cis	rs991427	1	rs11513823	ENSG00000258100.1	RP11-121E16.1	-4.51	7.19e-06	0.00061	-0.19	-0.14	Systolic blood pressure (alcohol consumption interaction);	chr12:91088582	chr12:91362196~91368606:+
BRCA	cis	rs991427	0.908	rs73197083	ENSG00000258100.1	RP11-121E16.1	-4.51	7.19e-06	0.00061	-0.19	-0.14	Systolic blood pressure (alcohol consumption interaction);	chr12:91089167	chr12:91362196~91368606:+
BRCA	cis	rs991427	1	rs1961779	ENSG00000258100.1	RP11-121E16.1	-4.51	7.19e-06	0.00061	-0.19	-0.14	Systolic blood pressure (alcohol consumption interaction);	chr12:91089362	chr12:91362196~91368606:+
BRCA	cis	rs11976180	1	rs7777389	ENSG00000244479.5	OR2A1-AS1	4.51	7.19e-06	0.00061	0.18	0.14	Obesity-related traits;	chr7:144047709	chr7:144251264~144356181:-
BRCA	cis	rs11976180	1	rs67239267	ENSG00000244479.5	OR2A1-AS1	4.51	7.19e-06	0.00061	0.18	0.14	Obesity-related traits;	chr7:144048023	chr7:144251264~144356181:-
BRCA	cis	rs6545883	0.929	rs12612982	ENSG00000270820.4	RP11-355B11.2	4.51	7.19e-06	0.00061	0.16	0.14	Tuberculosis;	chr2:61520220	chr2:61471188~61484130:+
BRCA	cis	rs10129255	0.957	rs8009948	ENSG00000211974.3	IGHV2-70	4.51	7.19e-06	0.00061	0.15	0.14	Kawasaki disease;	chr14:106805607	chr14:106723574~106724093:-
BRCA	cis	rs10129255	0.518	rs2006284	ENSG00000254174.1	IGHV1-12	4.51	7.19e-06	0.00061	0.11	0.14	Kawasaki disease;	chr14:106676185	chr14:106122420~106122709:-
BRCA	cis	rs13098911	0.54	rs13063527	ENSG00000223552.1	RP11-24F11.2	-4.51	7.19e-06	0.00061	-0.23	-0.14	Celiac disease;	chr3:46094198	chr3:46364955~46407059:-
BRCA	cis	rs13098911	0.54	rs13068570	ENSG00000223552.1	RP11-24F11.2	-4.51	7.19e-06	0.00061	-0.23	-0.14	Celiac disease;	chr3:46094946	chr3:46364955~46407059:-
BRCA	cis	rs13098911	0.54	rs4373103	ENSG00000223552.1	RP11-24F11.2	-4.51	7.19e-06	0.00061	-0.23	-0.14	Celiac disease;	chr3:46096963	chr3:46364955~46407059:-
BRCA	cis	rs13098911	0.54	rs34492478	ENSG00000223552.1	RP11-24F11.2	-4.51	7.19e-06	0.00061	-0.23	-0.14	Celiac disease;	chr3:46097350	chr3:46364955~46407059:-
BRCA	cis	rs13098911	0.54	rs71327024	ENSG00000223552.1	RP11-24F11.2	-4.51	7.19e-06	0.00061	-0.23	-0.14	Celiac disease;	chr3:46098581	chr3:46364955~46407059:-
BRCA	cis	rs11976180	1	rs2951364	ENSG00000244479.5	OR2A1-AS1	4.51	7.19e-06	0.00061	0.18	0.14	Obesity-related traits;	chr7:144057390	chr7:144251264~144356181:-
BRCA	cis	rs8048589	0.578	rs11075049	ENSG00000175604.2	RP11-276H1.3	-4.51	7.2e-06	0.000611	-0.2	-0.14	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);	chr16:12079682	chr16:12086746~12090302:-
BRCA	cis	rs77204473	1	rs11216174	ENSG00000280143.1	AP000892.6	-4.51	7.2e-06	0.000611	-0.26	-0.14	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116886532	chr11:117204967~117210292:+
BRCA	cis	rs77204473	1	rs11216175	ENSG00000280143.1	AP000892.6	-4.51	7.2e-06	0.000611	-0.26	-0.14	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116886682	chr11:117204967~117210292:+
BRCA	cis	rs1371614	0.635	rs877273	ENSG00000272148.1	RP11-195B17.1	-4.51	7.2e-06	0.000611	-0.15	-0.14	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26917154	chr2:27062428~27062907:-
BRCA	cis	rs1153858	1	rs7163720	ENSG00000275672.1	GATM-AS1	-4.51	7.2e-06	0.000611	-0.18	-0.14	Homoarginine levels;	chr15:45347176	chr15:45378700~45380123:+
BRCA	cis	rs1371614	0.635	rs9309558	ENSG00000229122.1	AGBL5-IT1	-4.51	7.2e-06	0.000611	-0.15	-0.14	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26918636	chr2:27061038~27061815:+
BRCA	cis	rs56322409	0.897	rs7918339	ENSG00000226688.5	ENTPD1-AS1	4.51	7.2e-06	0.000611	0.16	0.14	Blood metabolite levels;	chr10:95745170	chr10:95753206~96090238:-
BRCA	cis	rs10458771	0.667	rs2803543	ENSG00000227896.2	RP11-77P6.2	4.51	7.21e-06	0.000612	0.22	0.14	Amyotrophic lateral sclerosis (sporadic);	chr10:86541574	chr10:86521945~86525101:+
BRCA	cis	rs2018683	0.624	rs6462119	ENSG00000233517.1	AC005162.5	-4.51	7.21e-06	0.000612	-0.17	-0.14	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28964109	chr7:28987028~28988899:+
BRCA	cis	rs6496044	0.568	rs1351196	ENSG00000259295.5	CSPG4P12	4.51	7.21e-06	0.000612	0.17	0.14	Interstitial lung disease;	chr15:85534173	chr15:85191438~85213905:+
BRCA	cis	rs10761482	0.6	rs72807911	ENSG00000254271.1	RP11-131N11.4	-4.51	7.22e-06	0.000612	-0.21	-0.14	Schizophrenia;	chr10:60468530	chr10:60734342~60741828:+
BRCA	cis	rs1656368	0.77	rs6784511	ENSG00000279311.1	RP11-170K4.2	4.51	7.22e-06	0.000612	0.18	0.14	Lobe attachment (rater-scored or self-reported);	chr3:158560817	chr3:158869898~158871821:+
BRCA	cis	rs2617170	0.885	rs7975996	ENSG00000245648.1	RP11-277P12.20	4.51	7.22e-06	0.000612	0.19	0.14	Behcet's disease;	chr12:10372324	chr12:10363769~10398506:+
BRCA	cis	rs6545883	0.859	rs13004855	ENSG00000212978.6	AC016747.3	-4.51	7.22e-06	0.000612	-0.19	-0.14	Tuberculosis;	chr2:61277937	chr2:61141592~61144969:-
BRCA	cis	rs2243480	1	rs313814	ENSG00000275400.1	RP4-756H11.5	4.51	7.22e-06	0.000613	0.26	0.14	Diabetic kidney disease;	chr7:66038306	chr7:66553805~66554199:-
BRCA	cis	rs651907	0.557	rs1056579	ENSG00000256628.3	ZBTB11-AS1	4.51	7.23e-06	0.000613	0.17	0.14	Colorectal cancer;	chr3:101679033	chr3:101676475~101679217:+
BRCA	cis	rs13034020	0.522	rs12996059	ENSG00000271889.1	RP11-493E12.1	-4.51	7.23e-06	0.000613	-0.23	-0.14	Hodgkin's lymphoma;	chr2:61018416	chr2:61151433~61162105:-
BRCA	cis	rs13034020	0.522	rs35217978	ENSG00000271889.1	RP11-493E12.1	-4.51	7.23e-06	0.000613	-0.23	-0.14	Hodgkin's lymphoma;	chr2:61019413	chr2:61151433~61162105:-
BRCA	cis	rs10129255	1	rs8010605	ENSG00000274576.2	IGHV2-70	4.51	7.24e-06	0.000614	0.13	0.14	Kawasaki disease;	chr14:106678742	chr14:106770577~106771020:-
BRCA	cis	rs7302981	0.746	rs836172	ENSG00000272368.2	RP4-605O3.4	4.51	7.24e-06	0.000614	0.14	0.14	Systolic blood pressure;	chr12:50096316	chr12:50112197~50165618:+
BRCA	cis	rs2109514	0.765	rs9649392	ENSG00000237813.3	AC002066.1	4.51	7.24e-06	0.000614	0.16	0.14	Prevalent atrial fibrillation;	chr7:116467332	chr7:116238260~116499465:-
BRCA	cis	rs7267979	1	rs6050590	ENSG00000277938.1	RP5-965G21.3	-4.51	7.24e-06	0.000614	-0.16	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25404358	chr20:25229150~25231933:+
BRCA	cis	rs7267979	1	rs4813566	ENSG00000277938.1	RP5-965G21.3	-4.51	7.24e-06	0.000614	-0.16	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25405829	chr20:25229150~25231933:+
BRCA	cis	rs7267979	1	rs4815421	ENSG00000277938.1	RP5-965G21.3	-4.51	7.24e-06	0.000614	-0.16	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25405873	chr20:25229150~25231933:+
BRCA	cis	rs7916697	0.593	rs10762198	ENSG00000233590.1	RP11-153K11.3	4.51	7.24e-06	0.000614	0.17	0.14	Optic disc area;	chr10:68263296	chr10:68233251~68242379:-
BRCA	cis	rs10504130	0.932	rs80143499	ENSG00000272024.1	RP11-546K22.3	-4.51	7.24e-06	0.000614	-0.24	-0.14	Venous thromboembolism (SNP x SNP interaction);	chr8:51808915	chr8:51950284~51950690:+
BRCA	cis	rs10504130	0.932	rs79612913	ENSG00000272024.1	RP11-546K22.3	-4.51	7.24e-06	0.000614	-0.24	-0.14	Venous thromboembolism (SNP x SNP interaction);	chr8:51808916	chr8:51950284~51950690:+
BRCA	cis	rs10504130	1	rs75257860	ENSG00000272024.1	RP11-546K22.3	-4.51	7.24e-06	0.000614	-0.24	-0.14	Venous thromboembolism (SNP x SNP interaction);	chr8:51811887	chr8:51950284~51950690:+
BRCA	cis	rs10504130	1	rs79299366	ENSG00000272024.1	RP11-546K22.3	-4.51	7.24e-06	0.000614	-0.24	-0.14	Venous thromboembolism (SNP x SNP interaction);	chr8:51812800	chr8:51950284~51950690:+
BRCA	cis	rs11742741	0.837	rs1428196	ENSG00000248874.4	C5orf17	-4.51	7.24e-06	0.000614	-0.18	-0.14	Educational attainment;	chr5:24128751	chr5:23951348~24178263:+
BRCA	cis	rs1479090	0.851	rs2320333	ENSG00000250027.1	RP11-563E2.2	-4.51	7.25e-06	0.000614	-0.2	-0.14	Lung cancer;	chr4:163108095	chr4:163108785~163119965:+
BRCA	cis	rs1371614	0.635	rs6706127	ENSG00000229122.1	AGBL5-IT1	-4.51	7.25e-06	0.000614	-0.15	-0.14	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26917873	chr2:27061038~27061815:+
BRCA	cis	rs10946940	0.897	rs6456801	ENSG00000219392.1	RP1-265C24.5	-4.51	7.25e-06	0.000614	-0.18	-0.14	Systemic lupus erythematosus;	chr6:27657753	chr6:28115628~28116551:+
BRCA	cis	rs1005277	0.557	rs1854563	ENSG00000099251.13	HSD17B7P2	4.51	7.25e-06	0.000614	0.15	0.14	Extrinsic epigenetic age acceleration;	chr10:38146033	chr10:38356380~38378505:+
BRCA	cis	rs1005277	0.579	rs2505240	ENSG00000099251.13	HSD17B7P2	4.51	7.25e-06	0.000614	0.15	0.14	Extrinsic epigenetic age acceleration;	chr10:38153491	chr10:38356380~38378505:+
BRCA	cis	rs700651	0.789	rs6434949	ENSG00000231621.1	AC013264.2	-4.51	7.25e-06	0.000615	-0.14	-0.14	Intracranial aneurysm;	chr2:197990786	chr2:197197991~197199273:+
BRCA	cis	rs7572733	0.515	rs6724526	ENSG00000231621.1	AC013264.2	-4.51	7.25e-06	0.000615	-0.14	-0.14	Dermatomyositis;	chr2:197993677	chr2:197197991~197199273:+
BRCA	cis	rs7572733	0.515	rs893808	ENSG00000231621.1	AC013264.2	-4.51	7.25e-06	0.000615	-0.14	-0.14	Dermatomyositis;	chr2:197996113	chr2:197197991~197199273:+
BRCA	cis	rs67981189	0.593	rs2877708	ENSG00000269927.1	RP6-91H8.3	4.51	7.25e-06	0.000615	0.17	0.14	Schizophrenia;	chr14:71017409	chr14:71141125~71143253:-
BRCA	cis	rs11098499	0.863	rs12508173	ENSG00000250412.1	KLHL2P1	4.51	7.25e-06	0.000615	0.16	0.14	Corneal astigmatism;	chr4:119397371	chr4:119334329~119378233:+
BRCA	cis	rs11098499	0.908	rs12504149	ENSG00000250412.1	KLHL2P1	4.51	7.25e-06	0.000615	0.16	0.14	Corneal astigmatism;	chr4:119397422	chr4:119334329~119378233:+
BRCA	cis	rs7119	0.717	rs35284122	ENSG00000259362.2	RP11-307C19.1	-4.51	7.25e-06	0.000615	-0.19	-0.14	Type 2 diabetes;	chr15:77512226	chr15:77525540~77534110:+
BRCA	cis	rs7119	0.717	rs62007350	ENSG00000259362.2	RP11-307C19.1	-4.51	7.25e-06	0.000615	-0.19	-0.14	Type 2 diabetes;	chr15:77512248	chr15:77525540~77534110:+
BRCA	cis	rs11758351	1	rs11754744	ENSG00000241549.7	GUSBP2	-4.51	7.26e-06	0.000615	-0.2	-0.14	Renal underexcretion gout;Gout;	chr6:26202377	chr6:26871484~26956554:-
BRCA	cis	rs11758351	1	rs11755210	ENSG00000241549.7	GUSBP2	-4.51	7.26e-06	0.000615	-0.2	-0.14	Renal underexcretion gout;Gout;	chr6:26202540	chr6:26871484~26956554:-
BRCA	cis	rs8114671	0.836	rs2038504	ENSG00000279253.1	RP4-614O4.13	4.51	7.26e-06	0.000615	0.16	0.14	Height;	chr20:35060384	chr20:35262727~35264187:-
BRCA	cis	rs8114671	0.836	rs2104083	ENSG00000279253.1	RP4-614O4.13	4.51	7.26e-06	0.000615	0.16	0.14	Height;	chr20:35061330	chr20:35262727~35264187:-
BRCA	cis	rs8114671	0.839	rs2104084	ENSG00000279253.1	RP4-614O4.13	4.51	7.26e-06	0.000615	0.16	0.14	Height;	chr20:35061414	chr20:35262727~35264187:-
BRCA	cis	rs736408	0.677	rs2286798	ENSG00000243224.1	RP5-1157M23.2	4.51	7.26e-06	0.000615	0.15	0.14	Bipolar disorder;	chr3:52787161	chr3:52239258~52241097:+
BRCA	cis	rs4869313	0.869	rs2910686	ENSG00000248734.2	CTD-2260A17.1	4.51	7.26e-06	0.000615	0.14	0.14	Pediatric autoimmune diseases;	chr5:96916885	chr5:96784777~96785999:+
BRCA	cis	rs4660214	0.666	rs625384	ENSG00000237624.1	OXCT2P1	4.51	7.26e-06	0.000615	0.17	0.14	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39427421	chr1:39514956~39516490:+
BRCA	cis	rs3764021	0.506	rs10844468	ENSG00000256673.1	RP11-599J14.2	-4.51	7.26e-06	0.000615	-0.17	-0.14	Type 1 diabetes;	chr12:9690799	chr12:9398355~9414851:-
BRCA	cis	rs2243480	0.803	rs36127118	ENSG00000222364.1	RNU6-96P	-4.51	7.26e-06	0.000615	-0.25	-0.14	Diabetic kidney disease;	chr7:66100518	chr7:66395191~66395286:+
BRCA	cis	rs5758659	0.652	rs133326	ENSG00000273366.1	CTA-989H11.1	-4.51	7.26e-06	0.000616	-0.16	-0.14	Cognitive function;	chr22:42010881	chr22:42278188~42278846:+
BRCA	cis	rs6430585	0.528	rs309123	ENSG00000231890.6	DARS-AS1	-4.51	7.27e-06	0.000616	-0.21	-0.14	Corneal structure;	chr2:136003605	chr2:135985176~136022593:+
BRCA	cis	rs6997458	0.576	rs6605613	ENSG00000258256.1	RP11-219B4.5	-4.51	7.27e-06	0.000616	-0.16	-0.14	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85315040	chr8:85222446~85245717:-
BRCA	cis	rs6088580	0.634	rs6058073	ENSG00000276073.1	RP5-1125A11.7	-4.51	7.27e-06	0.000616	-0.15	-0.14	Glomerular filtration rate (creatinine);	chr20:34528678	chr20:33985617~33988989:-
BRCA	cis	rs17228178	0.961	rs10152953	ENSG00000215302.7	CTD-3092A11.1	-4.51	7.27e-06	0.000616	-0.18	-0.14	Facial depth;Facial morphology (factor 1, breadth of lateral portion of upper face);	chr15:31175740	chr15:30470779~30507623:+
BRCA	cis	rs1665050	0.652	rs9302206	ENSG00000259732.1	RP11-59H7.3	-4.51	7.27e-06	0.000616	-0.16	-0.14	Atopic dermatitis;	chr15:59017274	chr15:59121034~59133250:+
BRCA	cis	rs4878712	0.632	rs1886909	ENSG00000230188.1	RP11-405L18.4	-4.51	7.27e-06	0.000616	-0.16	-0.14	HIV-1 susceptibility;	chr9:37656215	chr9:37490421~37490893:-
BRCA	cis	rs2554380	0.843	rs1426160	ENSG00000230373.7	GOLGA6L5P	-4.51	7.27e-06	0.000616	-0.19	-0.14	Height;	chr15:83739882	chr15:84507885~84516814:-
BRCA	cis	rs1501911	0.509	rs692759	ENSG00000246763.5	RGMB-AS1	-4.51	7.27e-06	0.000616	-0.16	-0.14	Lung function (FEV1/FVC);	chr5:98856841	chr5:98769618~98773469:-
BRCA	cis	rs807029	0.577	rs750866	ENSG00000236662.1	RP11-108L7.4	4.51	7.28e-06	0.000617	0.18	0.14	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:101001701	chr10:100980507~100985614:-
BRCA	cis	rs1005277	0.579	rs1621040	ENSG00000099251.13	HSD17B7P2	4.51	7.28e-06	0.000617	0.15	0.14	Extrinsic epigenetic age acceleration;	chr10:38208304	chr10:38356380~38378505:+
BRCA	cis	rs6570726	0.935	rs388394	ENSG00000270638.1	RP3-466P17.1	4.51	7.28e-06	0.000617	0.15	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145531553	chr6:145735570~145737218:+
BRCA	cis	rs7111546	1	rs12271805	ENSG00000246225.5	RP11-17A1.3	4.51	7.28e-06	0.000617	0.22	0.14	Dialysis-related mortality;	chr11:22805919	chr11:22829380~22945393:+
BRCA	cis	rs859767	0.741	rs6729090	ENSG00000224043.6	CCNT2-AS1	4.51	7.28e-06	0.000617	0.19	0.14	Neuroticism;	chr2:134644308	chr2:134735464~134918710:-
BRCA	cis	rs372883	0.648	rs4817279	ENSG00000176054.6	RPL23P2	-4.51	7.28e-06	0.000617	-0.16	-0.14	Pancreatic cancer;	chr21:29265964	chr21:28997613~28998033:-
BRCA	cis	rs8054556	0.967	rs9932702	ENSG00000214725.6	CDIPT-AS1	-4.51	7.29e-06	0.000617	-0.17	-0.14	Autism spectrum disorder or schizophrenia;	chr16:29971640	chr16:29863593~29868053:+
BRCA	cis	rs8054556	1	rs9925102	ENSG00000214725.6	CDIPT-AS1	-4.51	7.29e-06	0.000617	-0.17	-0.14	Autism spectrum disorder or schizophrenia;	chr16:29971827	chr16:29863593~29868053:+
BRCA	cis	rs6545883	0.894	rs7602859	ENSG00000212978.6	AC016747.3	-4.51	7.29e-06	0.000617	-0.19	-0.14	Tuberculosis;	chr2:61231071	chr2:61141592~61144969:-
BRCA	cis	rs16944613	0.51	rs7165476	ENSG00000245479.2	LINC01585	4.51	7.29e-06	0.000617	0.16	0.14	Colorectal cancer;	chr15:90608716	chr15:90660234~90664967:+
BRCA	cis	rs926392	0.896	rs4812357	ENSG00000274825.1	RP4-616B8.5	4.51	7.29e-06	0.000618	0.13	0.14	Dialysis-related mortality;	chr20:39054428	chr20:38955910~38956547:+
BRCA	cis	rs1075265	0.692	rs805358	ENSG00000235937.1	AC008280.1	4.51	7.29e-06	0.000618	0.15	0.14	Chronotype;Morning vs. evening chronotype;	chr2:53934885	chr2:54029552~54030682:-
BRCA	cis	rs4819052	0.765	rs2838827	ENSG00000184274.3	LINC00315	-4.51	7.29e-06	0.000618	-0.19	-0.14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45236231	chr21:45300245~45305257:-
BRCA	cis	rs7829975	0.626	rs907183	ENSG00000253981.4	ALG1L13P	-4.51	7.29e-06	0.000618	-0.16	-0.14	Mood instability;	chr8:8872251	chr8:8236003~8244667:-
BRCA	cis	rs7572733	0.515	rs11891555	ENSG00000231621.1	AC013264.2	-4.51	7.29e-06	0.000618	-0.14	-0.14	Dermatomyositis;	chr2:197988816	chr2:197197991~197199273:+
BRCA	cis	rs9952991	0.941	rs45450798	ENSG00000260302.1	RP11-973H7.1	4.51	7.29e-06	0.000618	0.23	0.14	Inflammatory skin disease;	chr18:12792941	chr18:12774651~12775923:-
BRCA	cis	rs2115630	1	rs1030863	ENSG00000259728.4	LINC00933	-4.51	7.29e-06	0.000618	-0.15	-0.14	P wave terminal force;	chr15:84739404	chr15:84570649~84580175:+
BRCA	cis	rs2380205	0.967	rs2380208	ENSG00000232807.2	RP11-536K7.3	-4.51	7.3e-06	0.000618	-0.14	-0.14	Breast cancer;	chr10:5858069	chr10:5934270~5945900:-
BRCA	cis	rs17345786	1	rs58907984	ENSG00000244119.1	PDCL3P4	4.51	7.3e-06	0.000618	0.12	0.14	Colonoscopy-negative controls vs population controls;	chr3:101586326	chr3:101712472~101713191:+
BRCA	cis	rs7665090	1	rs5026473	ENSG00000251288.2	RP11-10L12.2	-4.51	7.3e-06	0.000618	-0.16	-0.14	Primary biliary cholangitis;	chr4:102633636	chr4:102751401~102752641:+
BRCA	cis	rs300890	0.708	rs300894	ENSG00000250326.1	RP11-284M14.1	-4.51	7.3e-06	0.000619	-0.16	-0.14	Nasopharyngeal carcinoma;	chr4:143334845	chr4:142933195~143184861:-
BRCA	cis	rs12435908	0.867	rs11849862	ENSG00000276116.2	FUT8-AS1	-4.51	7.3e-06	0.000619	-0.21	-0.14	Ischemic stroke;	chr14:65631307	chr14:65411170~65412690:-
BRCA	cis	rs1322639	0.614	rs6925201	ENSG00000223485.1	RP11-417E7.1	4.51	7.31e-06	0.000619	0.19	0.14	Pulse pressure;	chr6:169163262	chr6:169158092~169162924:-
BRCA	cis	rs718433	0.584	rs10438076	ENSG00000256379.1	TRAV8-5	4.51	7.31e-06	0.000619	0.16	0.14	Intraocular pressure;	chr14:21741785	chr14:21903077~21903598:+
BRCA	cis	rs700651	0.789	rs10184395	ENSG00000231621.1	AC013264.2	-4.51	7.31e-06	0.000619	-0.13	-0.14	Intracranial aneurysm;	chr2:198029561	chr2:197197991~197199273:+
BRCA	cis	rs465969	0.793	rs34288099	ENSG00000230177.1	RP5-1112D6.4	4.51	7.31e-06	0.000619	0.26	0.14	Psoriasis;	chr6:111424034	chr6:111277932~111278742:+
BRCA	cis	rs2273156	1	rs36008567	ENSG00000226677.3	IGBP1P1	-4.51	7.32e-06	0.00062	-0.2	-0.14	Immunoglobulin light chain (AL) amyloidosis;	chr14:34951870	chr14:34939324~34940332:+
BRCA	cis	rs2273156	0.925	rs12890056	ENSG00000226677.3	IGBP1P1	-4.51	7.32e-06	0.00062	-0.2	-0.14	Immunoglobulin light chain (AL) amyloidosis;	chr14:34952928	chr14:34939324~34940332:+
BRCA	cis	rs2273156	1	rs12161905	ENSG00000226677.3	IGBP1P1	-4.51	7.32e-06	0.00062	-0.2	-0.14	Immunoglobulin light chain (AL) amyloidosis;	chr14:34953087	chr14:34939324~34940332:+
BRCA	cis	rs2273156	1	rs12888272	ENSG00000226677.3	IGBP1P1	-4.51	7.32e-06	0.00062	-0.2	-0.14	Immunoglobulin light chain (AL) amyloidosis;	chr14:34956396	chr14:34939324~34940332:+
BRCA	cis	rs6900992	1	rs6900992	ENSG00000234147.1	RP3-460G2.2	4.51	7.32e-06	0.00062	0.17	0.14	Night sleep phenotypes;	chr6:140700714	chr6:140845958~140852924:-
BRCA	cis	rs7740706	1	rs7740706	ENSG00000234147.1	RP3-460G2.2	4.51	7.32e-06	0.00062	0.17	0.14	Night sleep phenotypes;	chr6:140701399	chr6:140845958~140852924:-
BRCA	cis	rs9467773	1	rs6903973	ENSG00000241549.7	GUSBP2	4.51	7.32e-06	0.00062	0.15	0.14	Intelligence (multi-trait analysis);	chr6:26499714	chr6:26871484~26956554:-
BRCA	cis	rs5758511	0.68	rs1107554	ENSG00000227370.1	RP4-669P10.19	4.51	7.32e-06	0.00062	0.18	0.14	Birth weight;	chr22:42271588	chr22:42132543~42132998:+
BRCA	cis	rs13113518	1	rs6838882	ENSG00000273257.1	RP11-177J6.1	4.51	7.32e-06	0.00062	0.18	0.14	Height;	chr4:55489310	chr4:55387949~55388271:+
BRCA	cis	rs12468226	0.752	rs77319662	ENSG00000226261.1	AC064836.3	4.51	7.32e-06	0.00062	0.24	0.14	Urate levels;	chr2:202126928	chr2:202336024~202336727:-
BRCA	cis	rs2688608	0.933	rs2633307	ENSG00000271816.1	BMS1P4	4.51	7.33e-06	0.00062	0.14	0.14	Inflammatory bowel disease;	chr10:73894123	chr10:73699151~73730487:-
BRCA	cis	rs2235544	0.588	rs664758	ENSG00000225183.1	RP4-758J24.4	4.51	7.33e-06	0.00062	0.16	0.14	Thyroid hormone levels;Multiple myeloma (hyperdiploidy);	chr1:53995590	chr1:54089856~54090093:+
BRCA	cis	rs7918232	0.83	rs9833	ENSG00000262412.1	RP11-85G18.6	4.51	7.33e-06	0.000621	0.24	0.14	Breast cancer;	chr10:27111932	chr10:27243130~27250804:+
BRCA	cis	rs8177876	0.822	rs12443549	ENSG00000245059.2	RP11-303E16.7	-4.51	7.33e-06	0.000621	-0.3	-0.14	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81070596	chr16:81077319~81078861:+
BRCA	cis	rs9840812	0.656	rs4678437	ENSG00000273486.1	RP11-731C17.2	4.51	7.33e-06	0.000621	0.16	0.14	Fibrinogen levels;	chr3:136598823	chr3:136837338~136839021:-
BRCA	cis	rs2692947	0.702	rs6717101	ENSG00000168992.4	OR7E102P	4.51	7.33e-06	0.000621	0.19	0.14	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95839804	chr2:95546531~95547545:+
BRCA	cis	rs6570726	0.935	rs368848	ENSG00000270638.1	RP3-466P17.1	4.51	7.33e-06	0.000621	0.15	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145534145	chr6:145735570~145737218:+
BRCA	cis	rs6570726	0.935	rs374000	ENSG00000270638.1	RP3-466P17.1	4.51	7.33e-06	0.000621	0.15	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145534154	chr6:145735570~145737218:+
BRCA	cis	rs6547741	0.935	rs12714204	ENSG00000234072.1	AC074117.10	4.51	7.33e-06	0.000621	0.13	0.14	Oral cavity cancer;	chr2:27564673	chr2:27356246~27367622:+
BRCA	cis	rs4664293	0.867	rs7606046	ENSG00000224152.1	AC009506.1	-4.51	7.33e-06	0.000621	-0.16	-0.14	Monocyte percentage of white cells;	chr2:159719647	chr2:159615296~159617082:+
BRCA	cis	rs35146811	0.806	rs1534310	ENSG00000214313.7	AZGP1P1	4.51	7.34e-06	0.000621	0.15	0.14	Coronary artery disease;	chr7:100101546	chr7:99980762~99987535:+
BRCA	cis	rs1075265	0.605	rs805418	ENSG00000235937.1	AC008280.1	4.51	7.34e-06	0.000621	0.15	0.14	Chronotype;Morning vs. evening chronotype;	chr2:53898634	chr2:54029552~54030682:-
BRCA	cis	rs991427	0.818	rs11105977	ENSG00000258100.1	RP11-121E16.1	-4.51	7.34e-06	0.000621	-0.19	-0.14	Systolic blood pressure (alcohol consumption interaction);	chr12:91085491	chr12:91362196~91368606:+
BRCA	cis	rs2274273	0.529	rs10131562	ENSG00000259318.1	RP11-454L9.2	4.51	7.34e-06	0.000621	0.12	0.14	Protein biomarker;	chr14:55380297	chr14:55394940~55395233:-
BRCA	cis	rs11742741	0.905	rs1428194	ENSG00000248874.4	C5orf17	-4.51	7.34e-06	0.000621	-0.18	-0.14	Educational attainment;	chr5:24112220	chr5:23951348~24178263:+
BRCA	cis	rs27434	0.607	rs34750	ENSG00000248734.2	CTD-2260A17.1	4.51	7.34e-06	0.000622	0.15	0.14	Ankylosing spondylitis;	chr5:96807103	chr5:96784777~96785999:+
BRCA	cis	rs10829156	0.738	rs4748502	ENSG00000240291.1	RP11-499P20.2	4.51	7.34e-06	0.000622	0.15	0.14	Sudden cardiac arrest;	chr10:18647032	chr10:18513115~18545651:-
BRCA	cis	rs957448	0.561	rs13258635	ENSG00000253175.1	RP11-267M23.6	4.51	7.34e-06	0.000622	0.16	0.14	Nonsyndromic cleft lip with cleft palate;	chr8:94595629	chr8:94565036~94565715:+
BRCA	cis	rs7824557	0.547	rs2409745	ENSG00000255046.1	RP11-297N6.4	-4.51	7.34e-06	0.000622	-0.17	-0.14	Retinal vascular caliber;	chr8:11219126	chr8:11797928~11802568:-
BRCA	cis	rs1005277	0.579	rs2474594	ENSG00000263064.2	RP11-291L22.7	4.51	7.35e-06	0.000622	0.17	0.14	Extrinsic epigenetic age acceleration;	chr10:38137733	chr10:38448689~38448949:+
BRCA	cis	rs1005277	0.579	rs11011461	ENSG00000263064.2	RP11-291L22.7	4.51	7.35e-06	0.000622	0.17	0.14	Extrinsic epigenetic age acceleration;	chr10:38142499	chr10:38448689~38448949:+
BRCA	cis	rs875971	0.52	rs160645	ENSG00000232546.1	RP11-458F8.1	-4.51	7.35e-06	0.000622	-0.13	-0.14	Aortic root size;	chr7:66091320	chr7:66848496~66858136:+
BRCA	cis	rs718433	0.584	rs1002180	ENSG00000256379.1	TRAV8-5	4.51	7.35e-06	0.000622	0.16	0.14	Intraocular pressure;	chr14:21748768	chr14:21903077~21903598:+
BRCA	cis	rs12681366	0.537	rs2381886	ENSG00000253704.1	RP11-267M23.4	4.51	7.36e-06	0.000623	0.15	0.14	Nonsyndromic cleft lip with cleft palate;	chr8:94464825	chr8:94553722~94569745:+
BRCA	cis	rs6490294	0.898	rs57646770	ENSG00000234608.6	MAPKAPK5-AS1	4.51	7.36e-06	0.000623	0.17	0.14	Mean platelet volume;	chr12:111993408	chr12:111839764~111842902:-
BRCA	cis	rs2243480	1	rs1723269	ENSG00000226002.1	RP11-460N20.5	-4.51	7.36e-06	0.000623	-0.23	-0.14	Diabetic kidney disease;	chr7:66007799	chr7:65084103~65100232:+
BRCA	cis	rs926392	0.932	rs6513588	ENSG00000274825.1	RP4-616B8.5	-4.51	7.36e-06	0.000623	-0.13	-0.14	Dialysis-related mortality;	chr20:39057638	chr20:38955910~38956547:+
BRCA	cis	rs2880765	0.743	rs7168345	ENSG00000230373.7	GOLGA6L5P	-4.51	7.36e-06	0.000623	-0.15	-0.14	Coronary artery disease;	chr15:85470370	chr15:84507885~84516814:-
BRCA	cis	rs4356203	0.905	rs17472886	ENSG00000272034.1	SNORD14A	-4.51	7.36e-06	0.000623	-0.14	-0.14	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17064620	chr11:17074654~17074744:-
BRCA	cis	rs2273156	1	rs12890307	ENSG00000226677.3	IGBP1P1	-4.51	7.36e-06	0.000623	-0.21	-0.14	Immunoglobulin light chain (AL) amyloidosis;	chr14:34982926	chr14:34939324~34940332:+
BRCA	cis	rs11976180	1	rs1320894	ENSG00000244479.5	OR2A1-AS1	4.51	7.36e-06	0.000623	0.18	0.14	Obesity-related traits;	chr7:144054709	chr7:144251264~144356181:-
BRCA	cis	rs11976180	1	rs2951369	ENSG00000244479.5	OR2A1-AS1	4.51	7.36e-06	0.000623	0.18	0.14	Obesity-related traits;	chr7:144055545	chr7:144251264~144356181:-
BRCA	cis	rs61160187	0.517	rs7709522	ENSG00000272308.1	RP11-231G3.1	-4.51	7.36e-06	0.000623	-0.15	-0.14	Educational attainment (years of education);Educational attainment (college completion);	chr5:61022188	chr5:60866457~60866935:-
BRCA	cis	rs7746199	0.736	rs35848276	ENSG00000216901.1	AL022393.7	4.51	7.37e-06	0.000623	0.36	0.14	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27553317	chr6:28176188~28176674:+
BRCA	cis	rs6600671	0.934	rs67718113	ENSG00000275538.1	RNVU1-19	-4.51	7.37e-06	0.000623	-0.17	-0.14	Hip geometry;	chr1:121497112	chr1:120850819~120850985:-
BRCA	cis	rs651907	0.541	rs2925325	ENSG00000244119.1	PDCL3P4	4.51	7.37e-06	0.000624	0.11	0.14	Colorectal cancer;	chr3:101911824	chr3:101712472~101713191:+
BRCA	cis	rs4715166	0.926	rs12205644	ENSG00000272379.1	RP1-257A7.5	-4.51	7.37e-06	0.000624	-0.16	-0.14	Hip geometry;	chr6:13223764	chr6:13290018~13290490:-
BRCA	cis	rs67311347	1	rs72861689	ENSG00000280739.1	EIF1B-AS1	4.51	7.37e-06	0.000624	0.15	0.14	Renal cell carcinoma;	chr3:40394399	chr3:40173145~40309698:-
BRCA	cis	rs9467773	1	rs9467782	ENSG00000241549.7	GUSBP2	4.51	7.37e-06	0.000624	0.15	0.14	Intelligence (multi-trait analysis);	chr6:26542545	chr6:26871484~26956554:-
BRCA	cis	rs2243480	1	rs1546059	ENSG00000275400.1	RP4-756H11.5	-4.51	7.38e-06	0.000624	-0.25	-0.14	Diabetic kidney disease;	chr7:66189722	chr7:66553805~66554199:-
BRCA	cis	rs2243480	1	rs2420170	ENSG00000275400.1	RP4-756H11.5	-4.51	7.38e-06	0.000624	-0.25	-0.14	Diabetic kidney disease;	chr7:66191066	chr7:66553805~66554199:-
BRCA	cis	rs2574985	0.813	rs2983368	ENSG00000231345.3	BEND3P1	-4.51	7.38e-06	0.000624	-0.23	-0.14	Subjective well-being;	chr10:50478621	chr10:50655967~50660472:+
BRCA	cis	rs7141336	0.8	rs28688311	ENSG00000258884.1	CTD-3035D6.2	4.51	7.38e-06	0.000624	0.18	0.14	Anxiety disorder;	chr14:90824070	chr14:90822365~90828128:-
BRCA	cis	rs7665090	1	rs12498722	ENSG00000251288.2	RP11-10L12.2	-4.51	7.38e-06	0.000624	-0.16	-0.14	Primary biliary cholangitis;	chr4:102633365	chr4:102751401~102752641:+
BRCA	cis	rs11098499	0.754	rs1814813	ENSG00000249244.1	RP11-548H18.2	-4.51	7.38e-06	0.000624	-0.15	-0.14	Corneal astigmatism;	chr4:119337052	chr4:119391831~119395335:-
BRCA	cis	rs6500602	0.789	rs2404546	ENSG00000280063.1	RP11-295D4.3	4.51	7.38e-06	0.000624	0.1	0.14	Schizophrenia;	chr16:4429733	chr16:4346694~4348648:-
BRCA	cis	rs202072	0.818	rs405078	ENSG00000215022.6	RP1-257A7.4	-4.51	7.38e-06	0.000625	-0.18	-0.14	HIV-1 viral setpoint;	chr6:13279635	chr6:13264861~13295586:-
BRCA	cis	rs7727544	0.584	rs7714191	ENSG00000233006.5	AC034220.3	4.51	7.38e-06	0.000625	0.1	0.14	Blood metabolite levels;	chr5:132005848	chr5:132311285~132369916:-
BRCA	cis	rs10946940	1	rs10946940	ENSG00000219392.1	RP1-265C24.5	4.51	7.38e-06	0.000625	0.18	0.14	Systemic lupus erythematosus;	chr6:27592808	chr6:28115628~28116551:+
BRCA	cis	rs7833986	0.534	rs10504198	ENSG00000253603.1	CTA-397H3.3	-4.51	7.38e-06	0.000625	-0.2	-0.14	Height;	chr8:56093695	chr8:56074592~56075274:+
BRCA	cis	rs7833986	0.534	rs2976022	ENSG00000253603.1	CTA-397H3.3	-4.51	7.38e-06	0.000625	-0.2	-0.14	Height;	chr8:56095284	chr8:56074592~56075274:+
BRCA	cis	rs7833986	0.501	rs2976018	ENSG00000253603.1	CTA-397H3.3	-4.51	7.38e-06	0.000625	-0.2	-0.14	Height;	chr8:56102193	chr8:56074592~56075274:+
BRCA	cis	rs7308116	1	rs61938593	ENSG00000274395.1	RP11-554D14.8	-4.51	7.39e-06	0.000625	-0.15	-0.14	Pelvic organ prolapse (moderate/severe);	chr12:107808636	chr12:107835541~107836555:-
BRCA	cis	rs10540	1	rs61876335	ENSG00000279672.1	CMB9-55F22.1	4.5	7.39e-06	0.000625	0.24	0.14	Body mass index;	chr11:488878	chr11:779617~780755:+
BRCA	cis	rs2562456	0.833	rs1626404	ENSG00000268658.4	LINC00664	4.5	7.39e-06	0.000625	0.23	0.14	Pain;	chr19:21300986	chr19:21483374~21503238:+
BRCA	cis	rs9341808	0.519	rs3805878	ENSG00000233967.5	RP11-250B2.3	4.5	7.39e-06	0.000625	0.14	0.14	Sitting height ratio;	chr6:80304138	chr6:80443344~80465927:+
BRCA	cis	rs10129255	0.5	rs10143242	ENSG00000232216.1	IGHV3-43	4.5	7.39e-06	0.000625	0.1	0.14	Kawasaki disease;	chr14:106681814	chr14:106470264~106470800:-
BRCA	cis	rs1371614	0.679	rs4441421	ENSG00000272148.1	RP11-195B17.1	4.5	7.4e-06	0.000626	0.15	0.14	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26919223	chr2:27062428~27062907:-
BRCA	cis	rs2638953	0.821	rs7964793	ENSG00000247934.4	RP11-967K21.1	4.5	7.4e-06	0.000626	0.18	0.14	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28298776	chr12:28163298~28190738:-
BRCA	cis	rs372883	0.509	rs1999322	ENSG00000215533.7	LINC00189	4.5	7.4e-06	0.000626	0.16	0.14	Pancreatic cancer;	chr21:29161638	chr21:29193480~29288205:+
BRCA	cis	rs2708977	0.966	rs2708978	ENSG00000237510.6	AC008268.2	-4.5	7.4e-06	0.000626	-0.18	-0.14	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96536506	chr2:95789654~95800166:+
BRCA	cis	rs4415084	1	rs1438825	ENSG00000251141.4	RP11-53O19.1	4.5	7.4e-06	0.000626	0.13	0.14	Breast cancer;	chr5:44706829	chr5:44744900~44808777:-
BRCA	cis	rs6840360	0.582	rs2709823	ENSG00000251603.1	RP11-164P12.4	-4.5	7.4e-06	0.000626	-0.13	-0.14	Intelligence (multi-trait analysis);	chr4:151419294	chr4:151667224~151670502:+
BRCA	cis	rs644148	0.836	rs2571111	ENSG00000176761.7	ZNF285B	4.5	7.4e-06	0.000626	0.16	0.14	Personality dimensions;	chr19:44496520	chr19:44467641~44473227:+
BRCA	cis	rs6957923	0.668	rs6956784	ENSG00000234286.1	AC006026.13	-4.5	7.4e-06	0.000626	-0.16	-0.14	Height;	chr7:23534379	chr7:23680195~23680786:-
BRCA	cis	rs7615952	0.611	rs35321002	ENSG00000241288.6	RP11-379B18.5	-4.5	7.41e-06	0.000626	-0.22	-0.14	Blood pressure (smoking interaction);	chr3:125893222	chr3:125827238~125916384:-
BRCA	cis	rs1005277	0.579	rs2474584	ENSG00000263064.2	RP11-291L22.7	4.5	7.41e-06	0.000627	0.17	0.14	Extrinsic epigenetic age acceleration;	chr10:38127461	chr10:38448689~38448949:+
BRCA	cis	rs1005277	0.579	rs2474586	ENSG00000263064.2	RP11-291L22.7	4.5	7.41e-06	0.000627	0.17	0.14	Extrinsic epigenetic age acceleration;	chr10:38129954	chr10:38448689~38448949:+
BRCA	cis	rs2337406	0.925	rs2011167	ENSG00000223648.3	IGHV3-64	4.5	7.41e-06	0.000627	0.15	0.14	Alzheimer's disease (late onset);	chr14:106680831	chr14:106643132~106658258:-
BRCA	cis	rs4948275	0.693	rs2650732	ENSG00000237233.2	TMEM26-AS1	-4.5	7.41e-06	0.000627	-0.16	-0.14	Night sleep phenotypes;	chr10:61562549	chr10:61452639~61481956:+
BRCA	cis	rs4948275	0.693	rs1456284	ENSG00000237233.2	TMEM26-AS1	-4.5	7.41e-06	0.000627	-0.16	-0.14	Night sleep phenotypes;	chr10:61563057	chr10:61452639~61481956:+
BRCA	cis	rs6568686	0.786	rs4458728	ENSG00000231889.6	TRAF3IP2-AS1	-4.5	7.41e-06	0.000627	-0.21	-0.14	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr6:111519359	chr6:111483511~111598302:+
BRCA	cis	rs595244	1	rs11635605	ENSG00000259705.1	RP11-227D13.1	4.5	7.41e-06	0.000627	0.26	0.14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48494720	chr15:48645951~48652016:+
BRCA	cis	rs11742741	0.967	rs4352569	ENSG00000248874.4	C5orf17	-4.5	7.42e-06	0.000627	-0.18	-0.14	Educational attainment;	chr5:24225107	chr5:23951348~24178263:+
BRCA	cis	rs6088580	0.609	rs6059844	ENSG00000276073.1	RP5-1125A11.7	-4.5	7.42e-06	0.000627	-0.15	-0.14	Glomerular filtration rate (creatinine);	chr20:34448677	chr20:33985617~33988989:-
BRCA	cis	rs1371614	0.635	rs12612520	ENSG00000272148.1	RP11-195B17.1	-4.5	7.42e-06	0.000627	-0.15	-0.14	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26914439	chr2:27062428~27062907:-
BRCA	cis	rs1005277	0.579	rs1985707	ENSG00000099251.13	HSD17B7P2	4.5	7.42e-06	0.000627	0.15	0.14	Extrinsic epigenetic age acceleration;	chr10:38145170	chr10:38356380~38378505:+
BRCA	cis	rs1722141	0.669	rs34479156	ENSG00000229628.1	AC073115.7	4.5	7.42e-06	0.000628	0.2	0.14	Sitting height ratio;	chr7:46010517	chr7:45990905~46000898:+
BRCA	cis	rs300890	0.689	rs668011	ENSG00000250326.1	RP11-284M14.1	-4.5	7.43e-06	0.000628	-0.16	-0.14	Nasopharyngeal carcinoma;	chr4:143293747	chr4:142933195~143184861:-
BRCA	cis	rs875971	0.545	rs1796226	ENSG00000232546.1	RP11-458F8.1	4.5	7.43e-06	0.000628	0.13	0.14	Aortic root size;	chr7:66622723	chr7:66848496~66858136:+
BRCA	cis	rs7267979	0.816	rs376742	ENSG00000274414.1	RP5-965G21.4	-4.5	7.43e-06	0.000628	-0.16	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25506781	chr20:25239007~25245229:-
BRCA	cis	rs6570726	0.902	rs373321	ENSG00000270638.1	RP3-466P17.1	4.5	7.43e-06	0.000628	0.15	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145533014	chr6:145735570~145737218:+
BRCA	cis	rs6570726	0.967	rs374728	ENSG00000270638.1	RP3-466P17.1	4.5	7.43e-06	0.000628	0.15	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145533462	chr6:145735570~145737218:+
BRCA	cis	rs597539	0.69	rs647661	ENSG00000261625.1	RP11-554A11.4	-4.5	7.43e-06	0.000628	-0.14	-0.14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68858407	chr11:69000765~69002048:-
BRCA	cis	rs12744310	1	rs12035012	ENSG00000235358.1	RP11-399E6.1	4.5	7.43e-06	0.000628	0.2	0.14	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41284976	chr1:41242373~41284861:+
BRCA	cis	rs11098499	0.954	rs3890049	ENSG00000260091.1	RP11-33B1.4	-4.5	7.43e-06	0.000628	-0.12	-0.14	Corneal astigmatism;	chr4:119405128	chr4:119409333~119410233:+
BRCA	cis	rs8054556	0.647	rs11863174	ENSG00000261367.1	RP11-455F5.4	-4.5	7.44e-06	0.000629	-0.15	-0.14	Autism spectrum disorder or schizophrenia;	chr16:30008054	chr16:30107675~30110541:+
BRCA	cis	rs35612822	0.723	rs13432107	ENSG00000232485.2	AC098820.3	-4.5	7.44e-06	0.000629	-0.16	-0.14	Kidney disease (early stage) in type 1 diabetes;	chr2:216404247	chr2:216479030~216498761:-
BRCA	cis	rs17428076	0.793	rs56275355	ENSG00000228389.1	AC068039.4	-4.5	7.44e-06	0.000629	-0.2	-0.14	Myopia;	chr2:171853670	chr2:171773482~171775844:+
BRCA	cis	rs10833905	1	rs7934818	ENSG00000246225.5	RP11-17A1.3	-4.5	7.44e-06	0.000629	-0.19	-0.14	Sudden cardiac arrest;	chr11:23039003	chr11:22829380~22945393:+
BRCA	cis	rs7746199	0.668	rs7749305	ENSG00000220721.1	OR1F12	4.5	7.44e-06	0.000629	0.28	0.14	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27478787	chr6:28073316~28074233:+
BRCA	cis	rs875971	1	rs6460292	ENSG00000229180.5	GS1-124K5.11	-4.5	7.44e-06	0.000629	-0.12	-0.14	Aortic root size;	chr7:66345088	chr7:66526088~66542624:-
BRCA	cis	rs7824557	0.806	rs10503418	ENSG00000154316.13	TDH	4.5	7.44e-06	0.000629	0.19	0.14	Retinal vascular caliber;	chr8:11261474	chr8:11339637~11368452:+
BRCA	cis	rs1665050	0.598	rs8041221	ENSG00000259732.1	RP11-59H7.3	-4.5	7.44e-06	0.000629	-0.16	-0.14	Atopic dermatitis;	chr15:59042609	chr15:59121034~59133250:+
BRCA	cis	rs4489787	1	rs4489787	ENSG00000240399.1	RP1-228P16.1	4.5	7.44e-06	0.000629	0.22	0.14	Prostate cancer (SNP x SNP interaction);	chr12:48417317	chr12:48054813~48055591:-
BRCA	cis	rs683250	0.629	rs681259	ENSG00000254551.1	RP11-727A23.7	4.5	7.44e-06	0.000629	0.16	0.14	Subcortical brain region volumes;	chr11:83222984	chr11:83209431~83213379:-
BRCA	cis	rs8180040	0.726	rs4682842	ENSG00000276925.1	RP11-708J19.3	4.5	7.44e-06	0.000629	0.16	0.14	Colorectal cancer;	chr3:46941283	chr3:47469777~47469987:+
BRCA	cis	rs35612822	0.723	rs10181053	ENSG00000232485.2	AC098820.3	-4.5	7.45e-06	0.000629	-0.16	-0.14	Kidney disease (early stage) in type 1 diabetes;	chr2:216402470	chr2:216479030~216498761:-
BRCA	cis	rs35612822	0.723	rs12019162	ENSG00000232485.2	AC098820.3	-4.5	7.45e-06	0.000629	-0.16	-0.14	Kidney disease (early stage) in type 1 diabetes;	chr2:216404331	chr2:216479030~216498761:-
BRCA	cis	rs11671005	0.779	rs3794970	ENSG00000269600.1	AC016629.3	4.5	7.45e-06	0.000629	0.22	0.14	Mean platelet volume;	chr19:58474893	chr19:58593896~58599355:-
BRCA	cis	rs7246657	0.551	rs12972146	ENSG00000267422.1	CTD-2554C21.1	-4.5	7.45e-06	0.000629	-0.24	-0.14	Coronary artery calcification;	chr19:37135193	chr19:37779686~37792865:+
BRCA	cis	rs828999	0.688	rs6659201	ENSG00000280186.1	RP11-483I13.6	-4.5	7.45e-06	0.00063	-0.16	-0.14	Monocyte percentage of white cells;	chr1:108151496	chr1:108200413~108202743:+
BRCA	cis	rs9818758	0.607	rs35283189	ENSG00000270441.1	RP11-694I15.7	4.5	7.45e-06	0.00063	0.29	0.14	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49076235	chr3:49140086~49160851:-
BRCA	cis	rs9818758	0.607	rs34580506	ENSG00000270441.1	RP11-694I15.7	4.5	7.45e-06	0.00063	0.29	0.14	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49076280	chr3:49140086~49160851:-
BRCA	cis	rs7809615	0.901	rs1581492	ENSG00000244219.5	GS1-259H13.2	-4.5	7.45e-06	0.00063	-0.24	-0.14	Blood metabolite ratios;	chr7:99589203	chr7:99598066~99610813:+
BRCA	cis	rs35146811	0.555	rs1981549	ENSG00000214313.7	AZGP1P1	4.5	7.45e-06	0.00063	0.15	0.14	Coronary artery disease;	chr7:99944013	chr7:99980762~99987535:+
BRCA	cis	rs35146811	0.555	rs1981550	ENSG00000214313.7	AZGP1P1	4.5	7.45e-06	0.00063	0.15	0.14	Coronary artery disease;	chr7:99944329	chr7:99980762~99987535:+
BRCA	cis	rs10129255	0.957	rs17113284	ENSG00000274576.2	IGHV2-70	-4.5	7.45e-06	0.00063	-0.12	-0.14	Kawasaki disease;	chr14:106684476	chr14:106770577~106771020:-
BRCA	cis	rs3796352	1	rs35737577	ENSG00000242142.1	SERBP1P3	-4.5	7.45e-06	0.00063	-0.26	-0.14	Immune reponse to smallpox (secreted IL-2);	chr3:52968541	chr3:53064283~53065091:-
BRCA	cis	rs3796352	1	rs35849389	ENSG00000242142.1	SERBP1P3	-4.5	7.45e-06	0.00063	-0.26	-0.14	Immune reponse to smallpox (secreted IL-2);	chr3:52971219	chr3:53064283~53065091:-
BRCA	cis	rs754466	0.874	rs10430531	ENSG00000204049.1	RP11-126H7.4	4.5	7.45e-06	0.00063	0.19	0.14	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77900367	chr10:77866875~77869610:+
BRCA	cis	rs10829156	0.607	rs7908550	ENSG00000240291.1	RP11-499P20.2	4.5	7.46e-06	0.00063	0.17	0.14	Sudden cardiac arrest;	chr10:18573282	chr10:18513115~18545651:-
BRCA	cis	rs12681366	0.734	rs4735288	ENSG00000253704.1	RP11-267M23.4	4.5	7.46e-06	0.00063	0.15	0.14	Nonsyndromic cleft lip with cleft palate;	chr8:94354316	chr8:94553722~94569745:+
BRCA	cis	rs853679	0.55	rs1233701	ENSG00000216901.1	AL022393.7	-4.5	7.46e-06	0.00063	-0.19	-0.14	Depression;	chr6:28200948	chr6:28176188~28176674:+
BRCA	cis	rs5751614	0.537	rs11090228	ENSG00000240160.3	RN7SL263P	4.5	7.46e-06	0.000631	0.18	0.14	Height;	chr22:23289452	chr22:23261782~23262071:-
BRCA	cis	rs1322639	0.614	rs9294967	ENSG00000223485.1	RP11-417E7.1	4.5	7.46e-06	0.000631	0.2	0.14	Pulse pressure;	chr6:169165311	chr6:169158092~169162924:-
BRCA	cis	rs7302981	0.51	rs860698	ENSG00000272368.2	RP4-605O3.4	4.5	7.46e-06	0.000631	0.14	0.14	Systolic blood pressure;	chr12:50092539	chr12:50112197~50165618:+
BRCA	cis	rs6128907	1	rs62202464	ENSG00000224635.1	RP4-564F22.5	4.5	7.47e-06	0.000631	0.22	0.14	Liver fibrosis in pediatric non-alcoholic fatty acid liver disease;	chr20:38750439	chr20:38406011~38416797:-
BRCA	cis	rs7572733	0.84	rs13034353	ENSG00000231621.1	AC013264.2	4.5	7.47e-06	0.000631	0.13	0.14	Dermatomyositis;	chr2:197701039	chr2:197197991~197199273:+
BRCA	cis	rs4237845	0.537	rs59401446	ENSG00000257159.1	RP11-58A17.3	4.5	7.47e-06	0.000631	0.16	0.14	Intelligence (multi-trait analysis);	chr12:57865781	chr12:57967058~57968399:+
BRCA	cis	rs27434	0.605	rs39840	ENSG00000272109.1	CTD-2260A17.3	-4.5	7.47e-06	0.000631	-0.22	-0.14	Ankylosing spondylitis;	chr5:96784350	chr5:96804353~96806105:+
BRCA	cis	rs600550	0.963	rs627081	ENSG00000275344.1	MIR6503	4.5	7.47e-06	0.000631	0.14	0.14	Lipoprotein-associated phospholipase A2 activity and mass;	chr11:60244681	chr11:60209071~60209156:-
BRCA	cis	rs28829049	0.597	rs34215816	ENSG00000270728.1	RP4-657E11.10	-4.5	7.47e-06	0.000631	-0.14	-0.14	QRS duration in Tripanosoma cruzi seropositivity;	chr1:19107459	chr1:19297080~19297903:+
BRCA	cis	rs4834770	1	rs878375	ENSG00000250412.1	KLHL2P1	4.5	7.47e-06	0.000631	0.15	0.14	Blood protein levels;	chr4:119316419	chr4:119334329~119378233:+
BRCA	cis	rs1656368	0.726	rs28431969	ENSG00000279311.1	RP11-170K4.2	4.5	7.47e-06	0.000631	0.18	0.14	Lobe attachment (rater-scored or self-reported);	chr3:158551365	chr3:158869898~158871821:+
BRCA	cis	rs1656368	0.77	rs12495085	ENSG00000279311.1	RP11-170K4.2	4.5	7.47e-06	0.000631	0.18	0.14	Lobe attachment (rater-scored or self-reported);	chr3:158554843	chr3:158869898~158871821:+
BRCA	cis	rs4938303	0.718	rs10892020	ENSG00000280143.1	AP000892.6	4.5	7.48e-06	0.000632	0.15	0.14	Triglycerides;	chr11:116718936	chr11:117204967~117210292:+
BRCA	cis	rs11098499	0.618	rs35265692	ENSG00000260091.1	RP11-33B1.4	-4.5	7.48e-06	0.000632	-0.12	-0.14	Corneal astigmatism;	chr4:119403980	chr4:119409333~119410233:+
BRCA	cis	rs651907	0.64	rs771578	ENSG00000244119.1	PDCL3P4	4.5	7.48e-06	0.000632	0.12	0.14	Colorectal cancer;	chr3:101894590	chr3:101712472~101713191:+
BRCA	cis	rs300890	0.76	rs6823434	ENSG00000250326.1	RP11-284M14.1	-4.5	7.48e-06	0.000632	-0.15	-0.14	Nasopharyngeal carcinoma;	chr4:143278700	chr4:142933195~143184861:-
BRCA	cis	rs6723226	0.766	rs398290	ENSG00000276517.1	AL133243.2	-4.5	7.48e-06	0.000632	-0.17	-0.14	Intelligence (multi-trait analysis);	chr2:32278457	chr2:32526504~32529507:+
BRCA	cis	rs1371614	0.611	rs3843322	ENSG00000272148.1	RP11-195B17.1	4.5	7.48e-06	0.000632	0.15	0.14	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26908981	chr2:27062428~27062907:-
BRCA	cis	rs6981523	0.553	rs11989369	ENSG00000255046.1	RP11-297N6.4	-4.5	7.49e-06	0.000632	-0.18	-0.14	Neuroticism;	chr8:11197876	chr8:11797928~11802568:-
BRCA	cis	rs300890	0.689	rs624170	ENSG00000250326.1	RP11-284M14.1	-4.5	7.49e-06	0.000632	-0.16	-0.14	Nasopharyngeal carcinoma;	chr4:143324205	chr4:142933195~143184861:-
BRCA	cis	rs216345	0.7	rs844305	ENSG00000260947.1	RP11-384P7.7	4.5	7.49e-06	0.000633	0.15	0.14	Bipolar disorder;	chr9:33976579	chr9:33697459~33700986:+
BRCA	cis	rs875971	1	rs6963646	ENSG00000236529.1	RP13-254B10.1	-4.5	7.49e-06	0.000633	-0.15	-0.14	Aortic root size;	chr7:66220780	chr7:65840212~65840596:+
BRCA	cis	rs6708331	1	rs12999430	ENSG00000231024.1	AC092431.3	-4.5	7.49e-06	0.000633	-0.2	-0.14	Obesity-related traits;	chr2:70079653	chr2:69700192~69713847:-
BRCA	cis	rs950169	0.579	rs12913054	ENSG00000275120.1	RP11-182J1.17	4.5	7.49e-06	0.000633	0.21	0.14	Schizophrenia;	chr15:83995704	chr15:84599434~84606463:-
BRCA	cis	rs6840360	0.642	rs1899550	ENSG00000251603.1	RP11-164P12.4	-4.5	7.49e-06	0.000633	-0.13	-0.14	Intelligence (multi-trait analysis);	chr4:151486084	chr4:151667224~151670502:+
BRCA	cis	rs11976180	1	rs13243677	ENSG00000244479.5	OR2A1-AS1	4.5	7.49e-06	0.000633	0.18	0.14	Obesity-related traits;	chr7:144049479	chr7:144251264~144356181:-
BRCA	cis	rs9341808	0.538	rs7756067	ENSG00000233967.5	RP11-250B2.3	-4.5	7.49e-06	0.000633	-0.14	-0.14	Sitting height ratio;	chr6:80310077	chr6:80443344~80465927:+
BRCA	cis	rs6840360	0.642	rs28666858	ENSG00000251603.1	RP11-164P12.4	-4.5	7.5e-06	0.000633	-0.13	-0.14	Intelligence (multi-trait analysis);	chr4:151495230	chr4:151667224~151670502:+
BRCA	cis	rs2273156	1	rs8018114	ENSG00000226677.3	IGBP1P1	-4.5	7.5e-06	0.000634	-0.21	-0.14	Immunoglobulin light chain (AL) amyloidosis;	chr14:35000813	chr14:34939324~34940332:+
BRCA	cis	rs6545883	0.895	rs4430924	ENSG00000212978.6	AC016747.3	4.5	7.5e-06	0.000634	0.19	0.14	Tuberculosis;	chr2:61476721	chr2:61141592~61144969:-
BRCA	cis	rs1005277	0.579	rs2474608	ENSG00000263064.2	RP11-291L22.7	4.5	7.5e-06	0.000634	0.17	0.14	Extrinsic epigenetic age acceleration;	chr10:38168181	chr10:38448689~38448949:+
BRCA	cis	rs11098499	0.754	rs9999724	ENSG00000225892.3	RP11-384K6.2	4.5	7.51e-06	0.000634	0.13	0.14	Corneal astigmatism;	chr4:119318789	chr4:118632274~118634759:+
BRCA	cis	rs721917	0.506	rs2244451	ENSG00000242600.5	MBL1P	4.5	7.51e-06	0.000635	0.17	0.14	Chronic obstructive pulmonary disease;	chr10:79885234	chr10:79904898~79950336:+
BRCA	cis	rs6600671	1	rs4844616	ENSG00000270392.2	PFN1P2	4.5	7.52e-06	0.000635	0.15	0.14	Hip geometry;	chr1:121429348	chr1:120432204~120434052:-
BRCA	cis	rs13113518	1	rs11726198	ENSG00000273257.1	RP11-177J6.1	4.5	7.52e-06	0.000635	0.18	0.14	Height;	chr4:55523835	chr4:55387949~55388271:+
BRCA	cis	rs13113518	0.966	rs11133396	ENSG00000273257.1	RP11-177J6.1	4.5	7.52e-06	0.000635	0.18	0.14	Height;	chr4:55524246	chr4:55387949~55388271:+
BRCA	cis	rs13113518	1	rs7675109	ENSG00000273257.1	RP11-177J6.1	4.5	7.52e-06	0.000635	0.18	0.14	Height;	chr4:55525589	chr4:55387949~55388271:+
BRCA	cis	rs13113518	1	rs4865005	ENSG00000273257.1	RP11-177J6.1	4.5	7.52e-06	0.000635	0.18	0.14	Height;	chr4:55525781	chr4:55387949~55388271:+
BRCA	cis	rs10129255	0.872	rs1858683	ENSG00000211967.3	IGHV3-53	-4.5	7.52e-06	0.000635	-0.1	-0.14	Kawasaki disease;	chr14:106670217	chr14:106592676~106593347:-
BRCA	cis	rs736408	0.505	rs2083180	ENSG00000243224.1	RP5-1157M23.2	-4.5	7.52e-06	0.000635	-0.15	-0.14	Bipolar disorder;	chr3:52634103	chr3:52239258~52241097:+
BRCA	cis	rs6452524	1	rs1382368	ENSG00000281327.1	LINC01338	4.5	7.52e-06	0.000635	0.16	0.14	Hypertension (SNP x SNP interaction);	chr5:83155256	chr5:82850864~82859836:-
BRCA	cis	rs6452524	1	rs1382366	ENSG00000281327.1	LINC01338	4.5	7.52e-06	0.000635	0.16	0.14	Hypertension (SNP x SNP interaction);	chr5:83156352	chr5:82850864~82859836:-
BRCA	cis	rs1005277	0.579	rs2800485	ENSG00000099251.13	HSD17B7P2	4.5	7.52e-06	0.000635	0.15	0.14	Extrinsic epigenetic age acceleration;	chr10:38253660	chr10:38356380~38378505:+
BRCA	cis	rs6802315	0.604	rs9881462	ENSG00000272247.1	RP11-379F4.9	-4.5	7.52e-06	0.000635	-0.15	-0.14	Periodontitis (CDC/AAP);	chr3:158763333	chr3:158801257~158801935:-
BRCA	cis	rs11098499	0.738	rs34965784	ENSG00000250412.1	KLHL2P1	4.5	7.53e-06	0.000636	0.16	0.14	Corneal astigmatism;	chr4:119440431	chr4:119334329~119378233:+
BRCA	cis	rs216345	0.731	rs4879734	ENSG00000260947.1	RP11-384P7.7	4.5	7.53e-06	0.000636	0.15	0.14	Bipolar disorder;	chr9:33915906	chr9:33697459~33700986:+
BRCA	cis	rs4415084	0.87	rs920328	ENSG00000251141.4	RP11-53O19.1	4.5	7.53e-06	0.000636	0.13	0.14	Breast cancer;	chr5:44698949	chr5:44744900~44808777:-
BRCA	cis	rs2243480	0.901	rs12530490	ENSG00000275400.1	RP4-756H11.5	-4.5	7.53e-06	0.000636	-0.25	-0.14	Diabetic kidney disease;	chr7:66226660	chr7:66553805~66554199:-
BRCA	cis	rs2243480	1	rs7778911	ENSG00000275400.1	RP4-756H11.5	-4.5	7.53e-06	0.000636	-0.25	-0.14	Diabetic kidney disease;	chr7:66229519	chr7:66553805~66554199:-
BRCA	cis	rs11098499	0.954	rs13133522	ENSG00000250412.1	KLHL2P1	4.5	7.54e-06	0.000636	0.16	0.14	Corneal astigmatism;	chr4:119403269	chr4:119334329~119378233:+
BRCA	cis	rs11098499	0.954	rs35091806	ENSG00000250412.1	KLHL2P1	4.5	7.54e-06	0.000636	0.16	0.14	Corneal astigmatism;	chr4:119404374	chr4:119334329~119378233:+
BRCA	cis	rs11098499	0.909	rs35165976	ENSG00000250412.1	KLHL2P1	4.5	7.54e-06	0.000636	0.16	0.14	Corneal astigmatism;	chr4:119404475	chr4:119334329~119378233:+
BRCA	cis	rs11098499	0.954	rs6846442	ENSG00000250412.1	KLHL2P1	4.5	7.54e-06	0.000636	0.16	0.14	Corneal astigmatism;	chr4:119405168	chr4:119334329~119378233:+
BRCA	cis	rs11098499	0.954	rs71614438	ENSG00000250412.1	KLHL2P1	4.5	7.54e-06	0.000636	0.16	0.14	Corneal astigmatism;	chr4:119450097	chr4:119334329~119378233:+
BRCA	cis	rs11098499	0.954	rs66506550	ENSG00000250412.1	KLHL2P1	4.5	7.54e-06	0.000636	0.16	0.14	Corneal astigmatism;	chr4:119450290	chr4:119334329~119378233:+
BRCA	cis	rs11098499	0.909	rs7659501	ENSG00000250412.1	KLHL2P1	4.5	7.54e-06	0.000636	0.16	0.14	Corneal astigmatism;	chr4:119450397	chr4:119334329~119378233:+
BRCA	cis	rs755249	0.517	rs66880209	ENSG00000182109.6	RP11-69E11.4	4.5	7.54e-06	0.000636	0.22	0.14	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39254140	chr1:39522280~39546187:-
BRCA	cis	rs2832191	0.74	rs13048618	ENSG00000232855.5	AF131217.1	-4.5	7.54e-06	0.000636	-0.17	-0.14	Dental caries;	chr21:29086363	chr21:28439346~28674848:-
BRCA	cis	rs875971	0.545	rs11767262	ENSG00000232546.1	RP11-458F8.1	4.5	7.54e-06	0.000636	0.13	0.14	Aortic root size;	chr7:66302237	chr7:66848496~66858136:+
BRCA	cis	rs10752881	0.839	rs6692207	ENSG00000224468.3	RP11-181K3.4	-4.5	7.54e-06	0.000636	-0.15	-0.14	Colorectal cancer;	chr1:183116169	chr1:183138402~183141282:-
BRCA	cis	rs1005277	0.505	rs200910	ENSG00000226578.1	RP11-258F22.1	-4.5	7.54e-06	0.000637	-0.15	-0.14	Extrinsic epigenetic age acceleration;	chr10:37819248	chr10:37775371~37784131:-
BRCA	cis	rs7246657	0.722	rs16958861	ENSG00000226686.6	LINC01535	-4.5	7.54e-06	0.000637	-0.21	-0.14	Coronary artery calcification;	chr19:37633278	chr19:37251912~37265535:+
BRCA	cis	rs2692947	0.711	rs34639392	ENSG00000168992.4	OR7E102P	4.5	7.55e-06	0.000637	0.19	0.14	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95843228	chr2:95546531~95547545:+
BRCA	cis	rs603446	0.967	rs180340	ENSG00000280143.1	AP000892.6	4.5	7.55e-06	0.000637	0.13	0.14	Triglycerides;	chr11:116745686	chr11:117204967~117210292:+
BRCA	cis	rs11098499	0.779	rs28495013	ENSG00000250412.1	KLHL2P1	4.5	7.55e-06	0.000637	0.16	0.14	Corneal astigmatism;	chr4:119454676	chr4:119334329~119378233:+
BRCA	cis	rs7811142	0.83	rs6955367	ENSG00000078319.8	PMS2P1	-4.5	7.55e-06	0.000637	-0.21	-0.14	Platelet count;	chr7:100363571	chr7:100320992~100341908:-
BRCA	cis	rs11098499	0.909	rs2127821	ENSG00000260091.1	RP11-33B1.4	-4.5	7.55e-06	0.000637	-0.12	-0.14	Corneal astigmatism;	chr4:119473380	chr4:119409333~119410233:+
BRCA	cis	rs1005277	0.505	rs200936	ENSG00000226578.1	RP11-258F22.1	-4.5	7.55e-06	0.000638	-0.15	-0.14	Extrinsic epigenetic age acceleration;	chr10:37846007	chr10:37775371~37784131:-
BRCA	cis	rs1005277	0.505	rs200937	ENSG00000226578.1	RP11-258F22.1	-4.5	7.55e-06	0.000638	-0.15	-0.14	Extrinsic epigenetic age acceleration;	chr10:37846844	chr10:37775371~37784131:-
BRCA	cis	rs1005277	0.579	rs1548255	ENSG00000263064.2	RP11-291L22.7	4.5	7.55e-06	0.000638	0.17	0.14	Extrinsic epigenetic age acceleration;	chr10:38128265	chr10:38448689~38448949:+
BRCA	cis	rs600550	0.926	rs675655	ENSG00000275344.1	MIR6503	4.5	7.56e-06	0.000638	0.14	0.14	Lipoprotein-associated phospholipase A2 activity and mass;	chr11:60253401	chr11:60209071~60209156:-
BRCA	cis	rs7572733	0.515	rs1836234	ENSG00000231621.1	AC013264.2	-4.5	7.56e-06	0.000638	-0.13	-0.14	Dermatomyositis;	chr2:198018149	chr2:197197991~197199273:+
BRCA	cis	rs700651	0.789	rs116165148	ENSG00000231621.1	AC013264.2	-4.5	7.56e-06	0.000638	-0.13	-0.14	Intracranial aneurysm;	chr2:198023623	chr2:197197991~197199273:+
BRCA	cis	rs700651	0.789	rs1978889	ENSG00000231621.1	AC013264.2	-4.5	7.56e-06	0.000638	-0.13	-0.14	Intracranial aneurysm;	chr2:198024642	chr2:197197991~197199273:+
BRCA	cis	rs7267979	0.966	rs2261795	ENSG00000277938.1	RP5-965G21.3	4.5	7.56e-06	0.000638	0.17	0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25282500	chr20:25229150~25231933:+
BRCA	cis	rs8180040	0.934	rs62260710	ENSG00000276925.1	RP11-708J19.3	4.5	7.56e-06	0.000638	0.16	0.14	Colorectal cancer;	chr3:47522972	chr3:47469777~47469987:+
BRCA	cis	rs8180040	0.966	rs62260711	ENSG00000276925.1	RP11-708J19.3	4.5	7.56e-06	0.000638	0.16	0.14	Colorectal cancer;	chr3:47523001	chr3:47469777~47469987:+
BRCA	cis	rs4948275	0.68	rs2650722	ENSG00000237233.2	TMEM26-AS1	-4.5	7.56e-06	0.000638	-0.17	-0.14	Night sleep phenotypes;	chr10:61545931	chr10:61452639~61481956:+
BRCA	cis	rs12612619	0.732	rs722911	ENSG00000229122.1	AGBL5-IT1	4.5	7.56e-06	0.000638	0.15	0.14	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:26988344	chr2:27061038~27061815:+
BRCA	cis	rs7674212	0.539	rs7676041	ENSG00000251288.2	RP11-10L12.2	-4.5	7.56e-06	0.000638	-0.16	-0.14	Type 2 diabetes;	chr4:103205264	chr4:102751401~102752641:+
BRCA	cis	rs2136613	0.533	rs7089121	ENSG00000238280.1	RP11-436D10.3	-4.5	7.56e-06	0.000638	-0.18	-0.14	Selective IgA deficiency;	chr10:62846850	chr10:62793562~62805887:-
BRCA	cis	rs7665090	1	rs2866409	ENSG00000251288.2	RP11-10L12.2	-4.5	7.56e-06	0.000638	-0.16	-0.14	Primary biliary cholangitis;	chr4:102633104	chr4:102751401~102752641:+
BRCA	cis	rs11159086	1	rs11159087	ENSG00000270000.1	RP3-449M8.9	4.5	7.56e-06	0.000638	0.22	0.14	Advanced glycation end-product levels;	chr14:74504671	chr14:74471930~74472360:-
BRCA	cis	rs372883	0.935	rs379592	ENSG00000215533.7	LINC00189	-4.5	7.56e-06	0.000638	-0.15	-0.14	Pancreatic cancer;	chr21:29334149	chr21:29193480~29288205:+
BRCA	cis	rs1722141	0.634	rs2462326	ENSG00000229628.1	AC073115.7	4.5	7.57e-06	0.000638	0.19	0.14	Sitting height ratio;	chr7:46003037	chr7:45990905~46000898:+
BRCA	cis	rs1005277	0.579	rs176886	ENSG00000263064.2	RP11-291L22.7	4.5	7.57e-06	0.000638	0.17	0.14	Extrinsic epigenetic age acceleration;	chr10:38115046	chr10:38448689~38448949:+
BRCA	cis	rs1005277	0.557	rs176887	ENSG00000263064.2	RP11-291L22.7	4.5	7.57e-06	0.000638	0.17	0.14	Extrinsic epigenetic age acceleration;	chr10:38117166	chr10:38448689~38448949:+
BRCA	cis	rs7267979	0.966	rs2387885	ENSG00000276952.1	RP5-965G21.6	-4.5	7.57e-06	0.000638	-0.17	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25434588	chr20:25284915~25285588:-
BRCA	cis	rs7267979	1	rs2424713	ENSG00000276952.1	RP5-965G21.6	4.5	7.57e-06	0.000638	0.17	0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25437846	chr20:25284915~25285588:-
BRCA	cis	rs7267979	0.932	rs13040655	ENSG00000125804.12	FAM182A	-4.5	7.57e-06	0.000638	-0.18	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25601561	chr20:26054655~26086917:+
BRCA	cis	rs9921338	0.509	rs7199847	ENSG00000262636.1	CTD-3088G3.4	4.5	7.58e-06	0.000639	0.18	0.14	Vein graft stenosis in coronary artery bypass grafting;	chr16:11353415	chr16:11380859~11381118:-
BRCA	cis	rs7651446	0.649	rs12488104	ENSG00000240875.4	LINC00886	-4.5	7.58e-06	0.000639	-0.27	-0.14	Ovarian cancer;Epithelial ovarian cancer;	chr3:156647635	chr3:156747346~156817062:-
BRCA	cis	rs7980687	0.638	rs7299943	ENSG00000235423.7	RP11-282O18.3	4.5	7.58e-06	0.000639	0.18	0.14	Head circumference (infant);Educational attainment;Height;	chr12:123108938	chr12:123252030~123261483:-
BRCA	cis	rs1552244	0.572	rs3843008	ENSG00000180385.7	EMC3-AS1	4.5	7.58e-06	0.000639	0.21	0.14	Alzheimer's disease;	chr3:10132058	chr3:9986893~10006990:+
BRCA	cis	rs6088580	0.634	rs4911151	ENSG00000276073.1	RP5-1125A11.7	4.5	7.58e-06	0.000639	0.15	0.14	Glomerular filtration rate (creatinine);	chr20:34344467	chr20:33985617~33988989:-
BRCA	cis	rs7267979	1	rs10966	ENSG00000277938.1	RP5-965G21.3	4.5	7.58e-06	0.000639	0.17	0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25302308	chr20:25229150~25231933:+
BRCA	cis	rs4835473	0.932	rs34570929	ENSG00000249741.2	RP11-673E1.3	4.5	7.58e-06	0.00064	0.16	0.14	Immature fraction of reticulocytes;	chr4:143730766	chr4:143911514~143912053:-
BRCA	cis	rs4835473	0.9	rs17750172	ENSG00000249741.2	RP11-673E1.3	4.5	7.58e-06	0.00064	0.16	0.14	Immature fraction of reticulocytes;	chr4:143731094	chr4:143911514~143912053:-
BRCA	cis	rs651907	0.557	rs11925001	ENSG00000256628.3	ZBTB11-AS1	4.5	7.58e-06	0.00064	0.17	0.14	Colorectal cancer;	chr3:101655122	chr3:101676475~101679217:+
BRCA	cis	rs9990333	0.562	rs75681503	ENSG00000242086.7	LINC00969	4.5	7.58e-06	0.00064	0.16	0.14	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196095414	chr3:195658062~195739964:+
BRCA	cis	rs1371614	0.589	rs527267	ENSG00000272148.1	RP11-195B17.1	-4.5	7.58e-06	0.00064	-0.15	-0.14	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26896787	chr2:27062428~27062907:-
BRCA	cis	rs9393692	0.676	rs1543681	ENSG00000241549.7	GUSBP2	-4.5	7.59e-06	0.00064	-0.16	-0.14	Educational attainment;	chr6:26187555	chr6:26871484~26956554:-
BRCA	cis	rs4869313	0.777	rs74393176	ENSG00000248734.2	CTD-2260A17.1	4.5	7.59e-06	0.00064	0.14	0.14	Pediatric autoimmune diseases;	chr5:96944544	chr5:96784777~96785999:+
BRCA	cis	rs416603	0.901	rs149597	ENSG00000262703.1	RP11-485G7.6	-4.5	7.59e-06	0.00064	-0.14	-0.14	Type 1 diabetes;	chr16:11250085	chr16:11348143~11349321:-
BRCA	cis	rs828999	0.688	rs11185285	ENSG00000280186.1	RP11-483I13.6	-4.5	7.6e-06	0.000641	-0.16	-0.14	Monocyte percentage of white cells;	chr1:108152399	chr1:108200413~108202743:+
BRCA	cis	rs828999	0.715	rs6663170	ENSG00000280186.1	RP11-483I13.6	-4.5	7.6e-06	0.000641	-0.16	-0.14	Monocyte percentage of white cells;	chr1:108152918	chr1:108200413~108202743:+
BRCA	cis	rs2408955	0.521	rs7301003	ENSG00000257763.1	OR5BK1P	4.5	7.6e-06	0.000641	0.14	0.14	Glycated hemoglobin levels;	chr12:48156444	chr12:48355792~48356614:-
BRCA	cis	rs9467773	0.967	rs1535276	ENSG00000241549.7	GUSBP2	4.5	7.6e-06	0.000641	0.15	0.14	Intelligence (multi-trait analysis);	chr6:26520713	chr6:26871484~26956554:-
BRCA	cis	rs1910358	0.548	rs2172769	ENSG00000248874.4	C5orf17	-4.5	7.61e-06	0.000641	-0.18	-0.14	Venous thromboembolism (SNP x SNP interaction);	chr5:23872601	chr5:23951348~24178263:+
BRCA	cis	rs2253762	0.54	rs10887051	ENSG00000276742.1	RP11-500G22.4	4.5	7.61e-06	0.000641	0.23	0.14	Breast cancer;	chr10:122026030	chr10:121956782~121957098:+
BRCA	cis	rs10995356	0.646	rs10761677	ENSG00000238280.1	RP11-436D10.3	-4.5	7.61e-06	0.000642	-0.17	-0.14	Temperament;	chr10:62892846	chr10:62793562~62805887:-
BRCA	cis	rs718314	0.956	rs10842704	ENSG00000256894.1	RP11-283G6.3	4.5	7.61e-06	0.000642	0.17	0.14	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Renal cell carcinoma;Waist circumference adjusted for body mass index;	chr12:26310049	chr12:26125155~26126617:-
BRCA	cis	rs35740288	0.822	rs56322219	ENSG00000202081.1	RNU6-1280P	4.5	7.61e-06	0.000642	0.19	0.14	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85733109	chr15:85651522~85651628:-
BRCA	cis	rs2154319	0.559	rs183334	ENSG00000235358.1	RP11-399E6.1	4.5	7.61e-06	0.000642	0.18	0.14	Height;	chr1:41146431	chr1:41242373~41284861:+
BRCA	cis	rs6596100	0.915	rs11747001	ENSG00000248648.1	RP11-485M7.1	-4.5	7.61e-06	0.000642	-0.18	-0.14	Breast cancer;	chr5:133076607	chr5:133003119~133003365:+
BRCA	cis	rs9467773	0.595	rs12525810	ENSG00000124549.13	BTN2A3P	4.5	7.61e-06	0.000642	0.14	0.14	Intelligence (multi-trait analysis);	chr6:26623283	chr6:26421391~26432383:+
BRCA	cis	rs4763879	0.752	rs10772083	ENSG00000278635.1	CTD-2318O12.1	-4.5	7.61e-06	0.000642	-0.14	-0.14	Type 1 diabetes;	chr12:9722302	chr12:9415641~9416718:+
BRCA	cis	rs1322639	0.614	rs7751131	ENSG00000223485.1	RP11-417E7.1	-4.5	7.62e-06	0.000642	-0.2	-0.14	Pulse pressure;	chr6:169178615	chr6:169158092~169162924:-
BRCA	cis	rs1322639	0.574	rs9364360	ENSG00000223485.1	RP11-417E7.1	-4.5	7.62e-06	0.000642	-0.2	-0.14	Pulse pressure;	chr6:169180079	chr6:169158092~169162924:-
BRCA	cis	rs300890	0.513	rs300934	ENSG00000250326.1	RP11-284M14.1	4.5	7.62e-06	0.000643	0.16	0.14	Nasopharyngeal carcinoma;	chr4:143250595	chr4:142933195~143184861:-
BRCA	cis	rs11098499	0.954	rs3733519	ENSG00000250412.1	KLHL2P1	4.5	7.62e-06	0.000643	0.17	0.14	Corneal astigmatism;	chr4:119502293	chr4:119334329~119378233:+
BRCA	cis	rs6125597	0.967	rs6067037	ENSG00000222365.1	SNORD12B	4.5	7.62e-06	0.000643	0.15	0.14	Intelligence (multi-trait analysis);	chr20:49297041	chr20:49280319~49280409:+
BRCA	cis	rs7833790	1	rs7460277	ENSG00000254689.1	RP11-354A14.1	4.5	7.62e-06	0.000643	0.19	0.14	Diastolic blood pressure;	chr8:81797542	chr8:81885377~81923193:+
BRCA	cis	rs807029	0.577	rs3740490	ENSG00000236662.1	RP11-108L7.4	4.5	7.62e-06	0.000643	0.18	0.14	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100996986	chr10:100980507~100985614:-
BRCA	cis	rs35612822	0.719	rs6715548	ENSG00000232485.2	AC098820.3	-4.5	7.62e-06	0.000643	-0.16	-0.14	Kidney disease (early stage) in type 1 diabetes;	chr2:216405671	chr2:216479030~216498761:-
BRCA	cis	rs35612822	0.723	rs6715563	ENSG00000232485.2	AC098820.3	-4.5	7.62e-06	0.000643	-0.16	-0.14	Kidney disease (early stage) in type 1 diabetes;	chr2:216405727	chr2:216479030~216498761:-
BRCA	cis	rs7011507	0.7	rs72639005	ENSG00000279881.1	RP11-513O13.1	-4.5	7.63e-06	0.000643	-0.22	-0.14	Inflammatory bowel disease;Ulcerative colitis;	chr8:48409401	chr8:48428143~48431041:-
BRCA	cis	rs7771547	0.603	rs7743396	ENSG00000224666.3	RP1-50J22.4	4.5	7.63e-06	0.000643	0.18	0.14	Platelet distribution width;	chr6:36611475	chr6:36386831~36393462:+
BRCA	cis	rs4865762	0.904	rs12522488	ENSG00000247796.2	CTD-2366F13.1	-4.5	7.63e-06	0.000643	-0.14	-0.14	Intraocular pressure;	chr5:53288031	chr5:53109842~53115126:+
BRCA	cis	rs17684571	0.7	rs17752002	ENSG00000231441.1	RP11-472M19.2	4.5	7.63e-06	0.000643	0.22	0.14	Schizophrenia;	chr6:56812209	chr6:56844002~56864078:+
BRCA	cis	rs1005277	0.579	rs2472175	ENSG00000099251.13	HSD17B7P2	4.5	7.64e-06	0.000644	0.15	0.14	Extrinsic epigenetic age acceleration;	chr10:38093973	chr10:38356380~38378505:+
BRCA	cis	rs1005277	0.579	rs2472176	ENSG00000099251.13	HSD17B7P2	4.5	7.64e-06	0.000644	0.15	0.14	Extrinsic epigenetic age acceleration;	chr10:38093993	chr10:38356380~38378505:+
BRCA	cis	rs1005277	0.579	rs2983343	ENSG00000099251.13	HSD17B7P2	4.5	7.64e-06	0.000644	0.15	0.14	Extrinsic epigenetic age acceleration;	chr10:38094404	chr10:38356380~38378505:+
BRCA	cis	rs1005277	0.579	rs2474569	ENSG00000099251.13	HSD17B7P2	4.5	7.64e-06	0.000644	0.15	0.14	Extrinsic epigenetic age acceleration;	chr10:38094563	chr10:38356380~38378505:+
BRCA	cis	rs1005277	0.602	rs2504142	ENSG00000099251.13	HSD17B7P2	4.5	7.64e-06	0.000644	0.15	0.14	Extrinsic epigenetic age acceleration;	chr10:38094865	chr10:38356380~38378505:+
BRCA	cis	rs6545883	0.929	rs10200055	ENSG00000270820.4	RP11-355B11.2	-4.5	7.64e-06	0.000644	-0.16	-0.14	Tuberculosis;	chr2:61400882	chr2:61471188~61484130:+
BRCA	cis	rs4664293	0.867	rs13415025	ENSG00000226266.5	AC009961.3	-4.5	7.64e-06	0.000644	-0.17	-0.14	Monocyte percentage of white cells;	chr2:159729799	chr2:159670708~159712435:-
BRCA	cis	rs9311474	0.508	rs11720243	ENSG00000243224.1	RP5-1157M23.2	-4.5	7.64e-06	0.000644	-0.15	-0.14	Electroencephalogram traits;	chr3:52584002	chr3:52239258~52241097:+
BRCA	cis	rs9467773	0.62	rs2101581	ENSG00000241549.7	GUSBP2	4.5	7.65e-06	0.000644	0.15	0.14	Intelligence (multi-trait analysis);	chr6:26622541	chr6:26871484~26956554:-
BRCA	cis	rs2731006	0.64	rs1554251	ENSG00000257114.2	RP11-25I15.3	4.5	7.65e-06	0.000644	0.22	0.14	Panic disorder;	chr12:42775903	chr12:42692216~42717119:+
BRCA	cis	rs2731006	0.64	rs1554250	ENSG00000257114.2	RP11-25I15.3	4.5	7.65e-06	0.000644	0.22	0.14	Panic disorder;	chr12:42775924	chr12:42692216~42717119:+
BRCA	cis	rs2731006	0.64	rs1554249	ENSG00000257114.2	RP11-25I15.3	4.5	7.65e-06	0.000644	0.22	0.14	Panic disorder;	chr12:42775949	chr12:42692216~42717119:+
BRCA	cis	rs755249	0.567	rs41270799	ENSG00000182109.6	RP11-69E11.4	4.5	7.65e-06	0.000645	0.19	0.14	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39282990	chr1:39522280~39546187:-
BRCA	cis	rs4835473	0.932	rs17750042	ENSG00000249741.2	RP11-673E1.3	4.5	7.65e-06	0.000645	0.16	0.14	Immature fraction of reticulocytes;	chr4:143726691	chr4:143911514~143912053:-
BRCA	cis	rs4835473	0.932	rs1375989	ENSG00000249741.2	RP11-673E1.3	4.5	7.65e-06	0.000645	0.16	0.14	Immature fraction of reticulocytes;	chr4:143726893	chr4:143911514~143912053:-
BRCA	cis	rs897984	0.762	rs8062719	ENSG00000275263.1	RP11-1072A3.4	4.5	7.65e-06	0.000645	0.17	0.14	Dementia with Lewy bodies;	chr16:30991343	chr16:30956872~30957199:-
BRCA	cis	rs8180040	0.726	rs4682844	ENSG00000276925.1	RP11-708J19.3	4.5	7.65e-06	0.000645	0.16	0.14	Colorectal cancer;	chr3:46941247	chr3:47469777~47469987:+
BRCA	cis	rs35740288	0.539	rs4843101	ENSG00000202081.1	RNU6-1280P	4.5	7.66e-06	0.000645	0.21	0.14	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85796430	chr15:85651522~85651628:-
BRCA	cis	rs10208649	0.611	rs1363060	ENSG00000233266.1	HMGB1P31	4.5	7.66e-06	0.000645	0.29	0.14	Body mass index;	chr2:54057447	chr2:54051334~54051760:+
BRCA	cis	rs11051970	0.879	rs2651363	ENSG00000274964.1	RP11-817I4.1	4.5	7.66e-06	0.000645	0.16	0.14	Response to tocilizumab in rheumatoid arthritis;	chr12:32434616	chr12:32339368~32340724:+
BRCA	cis	rs11098499	0.644	rs7676296	ENSG00000249244.1	RP11-548H18.2	4.5	7.66e-06	0.000645	0.16	0.14	Corneal astigmatism;	chr4:119634532	chr4:119391831~119395335:-
BRCA	cis	rs2624839	0.63	rs2624841	ENSG00000228008.1	CTD-2330K9.3	4.5	7.66e-06	0.000646	0.15	0.14	Intelligence (multi-trait analysis);	chr3:50160982	chr3:49903845~49916937:+
BRCA	cis	rs10411262	0.935	rs2871987	ENSG00000245598.5	DACT3-AS1	-4.5	7.67e-06	0.000646	-0.17	-0.14	Tonsillectomy;	chr19:46672271	chr19:46660364~46677447:+
BRCA	cis	rs991427	0.643	rs7296835	ENSG00000258100.1	RP11-121E16.1	-4.5	7.67e-06	0.000646	-0.21	-0.14	Systolic blood pressure (alcohol consumption interaction);	chr12:91065283	chr12:91362196~91368606:+
BRCA	cis	rs2179367	0.613	rs12207047	ENSG00000268592.3	RAET1E-AS1	4.5	7.67e-06	0.000646	0.2	0.14	Dupuytren's disease;	chr6:149423496	chr6:149863494~149919507:+
BRCA	cis	rs12612619	0.689	rs11681145	ENSG00000229122.1	AGBL5-IT1	4.5	7.67e-06	0.000647	0.15	0.14	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27067657	chr2:27061038~27061815:+
BRCA	cis	rs7618915	0.501	rs34157897	ENSG00000243224.1	RP5-1157M23.2	-4.5	7.68e-06	0.000647	-0.15	-0.14	Bipolar disorder;	chr3:52682921	chr3:52239258~52241097:+
BRCA	cis	rs736408	0.507	rs6445531	ENSG00000243224.1	RP5-1157M23.2	-4.5	7.68e-06	0.000647	-0.15	-0.14	Bipolar disorder;	chr3:52683266	chr3:52239258~52241097:+
BRCA	cis	rs7772486	0.79	rs1062067	ENSG00000270638.1	RP3-466P17.1	4.5	7.68e-06	0.000647	0.16	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145886427	chr6:145735570~145737218:+
BRCA	cis	rs7772486	0.79	rs2256998	ENSG00000270638.1	RP3-466P17.1	4.5	7.68e-06	0.000647	0.16	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145886521	chr6:145735570~145737218:+
BRCA	cis	rs17684571	0.654	rs4348308	ENSG00000231441.1	RP11-472M19.2	4.5	7.68e-06	0.000647	0.22	0.14	Schizophrenia;	chr6:56815545	chr6:56844002~56864078:+
BRCA	cis	rs17684571	0.7	rs34640766	ENSG00000231441.1	RP11-472M19.2	4.5	7.68e-06	0.000647	0.22	0.14	Schizophrenia;	chr6:56815876	chr6:56844002~56864078:+
BRCA	cis	rs793571	0.628	rs28876251	ENSG00000259250.1	RP11-50C13.1	-4.5	7.68e-06	0.000647	-0.23	-0.14	Schizophrenia;	chr15:58819121	chr15:58587507~58591676:+
BRCA	cis	rs8002861	0.781	rs3816311	ENSG00000274001.1	RP11-5G9.5	4.5	7.68e-06	0.000647	0.16	0.14	Leprosy;	chr13:43879647	chr13:43877715~43878163:-
BRCA	cis	rs27434	0.66	rs27043	ENSG00000272109.1	CTD-2260A17.3	4.5	7.69e-06	0.000647	0.22	0.14	Ankylosing spondylitis;	chr5:96781596	chr5:96804353~96806105:+
BRCA	cis	rs1713985	0.92	rs62310289	ENSG00000269949.1	RP11-738E22.3	4.5	7.69e-06	0.000647	0.29	0.14	Age-related macular degeneration;	chr4:56962760	chr4:56960927~56961373:-
BRCA	cis	rs10129255	0.828	rs10140989	ENSG00000232216.1	IGHV3-43	4.5	7.69e-06	0.000648	0.12	0.14	Kawasaki disease;	chr14:106668657	chr14:106470264~106470800:-
BRCA	cis	rs10129255	0.719	rs7156660	ENSG00000211972.2	IGHV3-66	4.5	7.69e-06	0.000648	0.1	0.14	Kawasaki disease;	chr14:106673171	chr14:106675017~106675544:-
BRCA	cis	rs9303029	0.611	rs8008	ENSG00000265458.1	RP13-20L14.6	-4.5	7.69e-06	0.000648	-0.27	-0.14	Protein quantitative trait loci;	chr17:82442879	chr17:82454273~82458521:-
BRCA	cis	rs7927592	0.763	rs10896351	ENSG00000212093.1	AP000807.1	4.5	7.69e-06	0.000648	0.15	0.14	Total body bone mineral density;	chr11:68619428	chr11:68506083~68506166:-
BRCA	cis	rs1005277	0.522	rs200943	ENSG00000226578.1	RP11-258F22.1	-4.5	7.69e-06	0.000648	-0.15	-0.14	Extrinsic epigenetic age acceleration;	chr10:37859802	chr10:37775371~37784131:-
BRCA	cis	rs7119	0.651	rs34829483	ENSG00000259362.2	RP11-307C19.1	-4.5	7.69e-06	0.000648	-0.19	-0.14	Type 2 diabetes;	chr15:77543644	chr15:77525540~77534110:+
BRCA	cis	rs875971	0.545	rs316328	ENSG00000230295.1	RP11-458F8.2	-4.5	7.69e-06	0.000648	-0.12	-0.14	Aortic root size;	chr7:66143851	chr7:66880708~66882981:+
BRCA	cis	rs60695258	1	rs2035403	ENSG00000251411.1	RP11-397E7.4	-4.5	7.69e-06	0.000648	-0.16	-0.14	Hematocrit;	chr4:87097839	chr4:86913266~86914817:-
BRCA	cis	rs2749097	0.545	rs2301054	ENSG00000244256.3	RN7SL130P	-4.5	7.69e-06	0.000648	-0.19	-0.14	Alcohol consumption (transferrin glycosylation);	chr1:63641357	chr1:63655743~63656047:+
BRCA	cis	rs11742741	0.902	rs2059825	ENSG00000248874.4	C5orf17	-4.5	7.7e-06	0.000648	-0.18	-0.14	Educational attainment;	chr5:24131708	chr5:23951348~24178263:+
BRCA	cis	rs62025270	0.632	rs13379832	ENSG00000259762.1	RP11-158M2.4	-4.5	7.7e-06	0.000648	-0.2	-0.14	Idiopathic pulmonary fibrosis;	chr15:85572669	chr15:85750336~85752901:-
BRCA	cis	rs2839186	0.9	rs2839200	ENSG00000228137.1	AP001469.7	4.5	7.7e-06	0.000648	0.14	0.14	Testicular germ cell tumor;	chr21:46289181	chr21:46246890~46247682:+
BRCA	cis	rs7267979	0.903	rs6050482	ENSG00000274414.1	RP5-965G21.4	-4.5	7.7e-06	0.000648	-0.16	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25245691	chr20:25239007~25245229:-
BRCA	cis	rs6997458	0.576	rs1496533	ENSG00000258256.1	RP11-219B4.5	-4.5	7.7e-06	0.000648	-0.16	-0.14	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85321245	chr8:85222446~85245717:-
BRCA	cis	rs2506028	0.507	rs2506033	ENSG00000273008.1	RP11-351D16.3	-4.5	7.7e-06	0.000648	-0.16	-0.14	Blood protein levels;	chr10:42956533	chr10:43136824~43138334:-
BRCA	cis	rs6599077	1	rs6808614	ENSG00000223797.4	ENTPD3-AS1	4.5	7.7e-06	0.000649	0.16	0.14	Sleep-related phenotypes;	chr3:40055509	chr3:40313802~40453329:-
BRCA	cis	rs6599077	1	rs6808524	ENSG00000223797.4	ENTPD3-AS1	4.5	7.7e-06	0.000649	0.16	0.14	Sleep-related phenotypes;	chr3:40055638	chr3:40313802~40453329:-
BRCA	cis	rs792448	0.743	rs351393	ENSG00000226251.4	RP11-15I11.3	4.5	7.7e-06	0.000649	0.18	0.14	White blood cell count (basophil);	chr1:212303177	chr1:212225278~212238977:-
BRCA	cis	rs75804782	0.572	rs74979875	ENSG00000186235.9	AC016757.3	4.5	7.71e-06	0.000649	0.36	0.14	Chronotype;Morning vs. evening chronotype;	chr2:238393927	chr2:238224552~238231677:-
BRCA	cis	rs62025270	0.848	rs2554	ENSG00000202081.1	RNU6-1280P	-4.5	7.71e-06	0.000649	-0.2	-0.14	Idiopathic pulmonary fibrosis;	chr15:85759412	chr15:85651522~85651628:-
BRCA	cis	rs3096299	0.685	rs4785571	ENSG00000261118.1	RP11-104N10.1	4.5	7.71e-06	0.000649	0.15	0.14	Multiple myeloma (IgH translocation);	chr16:89498761	chr16:89492017~89504460:-
BRCA	cis	rs8180040	0.966	rs3736177	ENSG00000271161.1	BOLA2P2	-4.5	7.71e-06	0.000649	-0.15	-0.14	Colorectal cancer;	chr3:47409921	chr3:47499841~47500407:+
BRCA	cis	rs9311474	0.508	rs12637627	ENSG00000243224.1	RP5-1157M23.2	-4.5	7.71e-06	0.00065	-0.15	-0.14	Electroencephalogram traits;	chr3:52585946	chr3:52239258~52241097:+
BRCA	cis	rs6686842	0.536	rs61774688	ENSG00000235358.1	RP11-399E6.1	-4.5	7.71e-06	0.00065	-0.19	-0.14	Height;	chr1:41212213	chr1:41242373~41284861:+
BRCA	cis	rs9818758	0.607	rs80170003	ENSG00000270441.1	RP11-694I15.7	4.5	7.72e-06	0.00065	0.3	0.14	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:48914207	chr3:49140086~49160851:-
BRCA	cis	rs6840360	0.642	rs2724567	ENSG00000251603.1	RP11-164P12.4	4.5	7.72e-06	0.00065	0.12	0.14	Intelligence (multi-trait analysis);	chr4:151430008	chr4:151667224~151670502:+
BRCA	cis	rs8180040	0.62	rs56217494	ENSG00000276925.1	RP11-708J19.3	4.5	7.72e-06	0.00065	0.16	0.14	Colorectal cancer;	chr3:47006962	chr3:47469777~47469987:+
BRCA	cis	rs1910358	0.548	rs2055522	ENSG00000248874.4	C5orf17	-4.5	7.72e-06	0.00065	-0.18	-0.14	Venous thromboembolism (SNP x SNP interaction);	chr5:23931067	chr5:23951348~24178263:+
BRCA	cis	rs35740288	0.77	rs11635190	ENSG00000202081.1	RNU6-1280P	4.5	7.72e-06	0.00065	0.18	0.14	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85605300	chr15:85651522~85651628:-
BRCA	cis	rs35740288	0.77	rs11631449	ENSG00000202081.1	RNU6-1280P	4.5	7.72e-06	0.00065	0.18	0.14	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85605422	chr15:85651522~85651628:-
BRCA	cis	rs10946940	0.965	rs6921256	ENSG00000219392.1	RP1-265C24.5	-4.5	7.72e-06	0.00065	-0.18	-0.14	Systemic lupus erythematosus;	chr6:27619739	chr6:28115628~28116551:+
BRCA	cis	rs860295	0.676	rs11264374	ENSG00000225855.5	RUSC1-AS1	4.5	7.73e-06	0.000651	0.11	0.14	Body mass index;	chr1:155451721	chr1:155316863~155324176:-
BRCA	cis	rs2136613	0.533	rs10761673	ENSG00000238280.1	RP11-436D10.3	-4.5	7.73e-06	0.000651	-0.17	-0.14	Selective IgA deficiency;	chr10:62855691	chr10:62793562~62805887:-
BRCA	cis	rs801193	0.66	rs1962050	ENSG00000223473.2	GS1-124K5.3	-4.5	7.74e-06	0.000651	-0.1	-0.14	Aortic root size;	chr7:66775021	chr7:66491049~66493566:-
BRCA	cis	rs1707322	0.963	rs4630155	ENSG00000234329.1	RP11-767N6.2	4.5	7.74e-06	0.000651	0.15	0.14	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45791438	chr1:45651039~45651826:-
BRCA	cis	rs1707322	0.963	rs12076580	ENSG00000234329.1	RP11-767N6.2	4.5	7.74e-06	0.000651	0.15	0.14	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45792487	chr1:45651039~45651826:-
BRCA	cis	rs2255336	0.938	rs59906810	ENSG00000245648.1	RP11-277P12.20	-4.49	7.74e-06	0.000651	-0.2	-0.14	Blood protein levels;	chr12:10446021	chr12:10363769~10398506:+
BRCA	cis	rs6596100	0.915	rs56121115	ENSG00000248648.1	RP11-485M7.1	-4.49	7.74e-06	0.000651	-0.18	-0.14	Breast cancer;	chr5:133073382	chr5:133003119~133003365:+
BRCA	cis	rs2408955	0.501	rs8716	ENSG00000257763.1	OR5BK1P	4.49	7.74e-06	0.000652	0.14	0.14	Glycated hemoglobin levels;	chr12:48145699	chr12:48355792~48356614:-
BRCA	cis	rs12612619	0.732	rs11680032	ENSG00000272148.1	RP11-195B17.1	4.49	7.74e-06	0.000652	0.15	0.14	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:26975280	chr2:27062428~27062907:-
BRCA	cis	rs7301826	1	rs4759787	ENSG00000256299.1	RP11-989F5.3	-4.49	7.74e-06	0.000652	-0.28	-0.14	Plasma plasminogen activator levels;	chr12:130805635	chr12:130810821~130812622:-
BRCA	cis	rs6430585	0.528	rs895285	ENSG00000231890.6	DARS-AS1	-4.49	7.75e-06	0.000652	-0.22	-0.14	Corneal structure;	chr2:135952984	chr2:135985176~136022593:+
BRCA	cis	rs1484642	0.881	rs7005350	ENSG00000253641.4	RP11-981G7.2	-4.49	7.75e-06	0.000652	-0.25	-0.14	Bipolar disorder and schizophrenia;	chr8:10132588	chr8:10474565~10481974:+
BRCA	cis	rs7520050	0.807	rs72688483	ENSG00000234329.1	RP11-767N6.2	4.49	7.75e-06	0.000652	0.13	0.14	Reticulocyte count;Red blood cell count;	chr1:45683537	chr1:45651039~45651826:-
BRCA	cis	rs2179367	0.568	rs6932778	ENSG00000223701.3	RAET1E-AS1	4.49	7.75e-06	0.000652	0.21	0.14	Dupuytren's disease;	chr6:149328293	chr6:149884431~149919508:+
BRCA	cis	rs13098911	0.54	rs71327023	ENSG00000223552.1	RP11-24F11.2	-4.49	7.76e-06	0.000653	-0.23	-0.14	Celiac disease;	chr3:46089733	chr3:46364955~46407059:-
BRCA	cis	rs8103278	0.793	rs59093775	ENSG00000267395.4	AC074212.6	4.49	7.76e-06	0.000653	0.15	0.14	Coronary artery disease;	chr19:45870779	chr19:45767796~45772504:+
BRCA	cis	rs4578769	0.959	rs9955664	ENSG00000265939.1	UBE2CP2	4.49	7.76e-06	0.000653	0.16	0.14	Eosinophil percentage of white cells;	chr18:22901330	chr18:22900486~22900995:-
BRCA	cis	rs62244186	0.545	rs725866	ENSG00000214820.3	MPRIPP1	4.49	7.76e-06	0.000653	0.15	0.14	Depressive symptoms;	chr3:44724041	chr3:44579938~44581026:-
BRCA	cis	rs4664293	0.967	rs12999124	ENSG00000224152.1	AC009506.1	-4.49	7.76e-06	0.000653	-0.15	-0.14	Monocyte percentage of white cells;	chr2:159674817	chr2:159615296~159617082:+
BRCA	cis	rs807029	0.533	rs2295716	ENSG00000236662.1	RP11-108L7.4	4.49	7.76e-06	0.000653	0.18	0.14	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100984457	chr10:100980507~100985614:-
BRCA	cis	rs5758659	0.652	rs133313	ENSG00000273366.1	CTA-989H11.1	-4.49	7.77e-06	0.000654	-0.16	-0.14	Cognitive function;	chr22:42005745	chr22:42278188~42278846:+
BRCA	cis	rs5758659	0.652	rs133314	ENSG00000273366.1	CTA-989H11.1	-4.49	7.77e-06	0.000654	-0.16	-0.14	Cognitive function;	chr22:42005837	chr22:42278188~42278846:+
BRCA	cis	rs1552244	1	rs12374115	ENSG00000232901.1	CYCSP10	-4.49	7.77e-06	0.000654	-0.19	-0.14	Alzheimer's disease;	chr3:10093082	chr3:10000647~10000940:-
BRCA	cis	rs9818758	0.607	rs3923475	ENSG00000270441.1	RP11-694I15.7	4.49	7.77e-06	0.000654	0.29	0.14	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49018355	chr3:49140086~49160851:-
BRCA	cis	rs9818758	0.607	rs11706052	ENSG00000270441.1	RP11-694I15.7	4.49	7.77e-06	0.000654	0.29	0.14	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49026677	chr3:49140086~49160851:-
BRCA	cis	rs11719291	0.584	rs13080725	ENSG00000270441.1	RP11-694I15.7	4.49	7.77e-06	0.000654	0.29	0.14	Cognitive function;	chr3:49038659	chr3:49140086~49160851:-
BRCA	cis	rs9818758	0.607	rs35108630	ENSG00000270441.1	RP11-694I15.7	4.49	7.77e-06	0.000654	0.29	0.14	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49050923	chr3:49140086~49160851:-
BRCA	cis	rs13256369	1	rs4841017	ENSG00000254153.1	CTA-398F10.2	4.49	7.77e-06	0.000654	0.18	0.14	Obesity-related traits;	chr8:8719583	chr8:8456909~8461337:-
BRCA	cis	rs10411936	0.692	rs3810196	ENSG00000280332.1	CTD-2013N17.6	4.49	7.78e-06	0.000654	0.12	0.14	Multiple sclerosis;White blood cell count;	chr19:16490343	chr19:16356329~16358327:-
BRCA	cis	rs7646881	1	rs73015651	ENSG00000240207.5	RP11-379F4.4	-4.49	7.78e-06	0.000655	-0.2	-0.14	Tetralogy of Fallot;	chr3:158733133	chr3:158732263~158784070:+
BRCA	cis	rs73193808	0.901	rs12626758	ENSG00000236056.1	GAPDHP14	-4.49	7.79e-06	0.000655	-0.19	-0.14	Coronary artery disease;	chr21:29194430	chr21:29222321~29223257:+
BRCA	cis	rs73193808	0.901	rs67211015	ENSG00000236056.1	GAPDHP14	-4.49	7.79e-06	0.000655	-0.19	-0.14	Coronary artery disease;	chr21:29194901	chr21:29222321~29223257:+
BRCA	cis	rs73193808	0.802	rs66691348	ENSG00000236056.1	GAPDHP14	-4.49	7.79e-06	0.000655	-0.19	-0.14	Coronary artery disease;	chr21:29195220	chr21:29222321~29223257:+
BRCA	cis	rs2303319	0.504	rs56405014	ENSG00000227403.1	AC009299.3	4.49	7.79e-06	0.000655	0.34	0.14	Cognitive function;	chr2:161641093	chr2:161244739~161249050:+
BRCA	cis	rs2303319	0.504	rs55638078	ENSG00000227403.1	AC009299.3	4.49	7.79e-06	0.000655	0.34	0.14	Cognitive function;	chr2:161668487	chr2:161244739~161249050:+
BRCA	cis	rs10129255	0.957	rs10142859	ENSG00000274576.2	IGHV2-70	4.49	7.79e-06	0.000655	0.12	0.14	Kawasaki disease;	chr14:106782238	chr14:106770577~106771020:-
BRCA	cis	rs801193	0.66	rs1016265	ENSG00000236529.1	RP13-254B10.1	4.49	7.79e-06	0.000655	0.15	0.14	Aortic root size;	chr7:66749580	chr7:65840212~65840596:+
BRCA	cis	rs801193	0.66	rs4610622	ENSG00000236529.1	RP13-254B10.1	4.49	7.79e-06	0.000655	0.15	0.14	Aortic root size;	chr7:66759510	chr7:65840212~65840596:+
BRCA	cis	rs2136613	0.728	rs10995325	ENSG00000238280.1	RP11-436D10.3	-4.49	7.8e-06	0.000656	-0.17	-0.14	Selective IgA deficiency;	chr10:62842577	chr10:62793562~62805887:-
BRCA	cis	rs3774749	0.565	rs2188151	ENSG00000228008.1	CTD-2330K9.3	-4.49	7.8e-06	0.000656	-0.14	-0.14	Intelligence (multi-trait analysis);	chr3:50164491	chr3:49903845~49916937:+
BRCA	cis	rs7523050	0.643	rs34801874	ENSG00000203897.3	SPATA42	-4.49	7.8e-06	0.000656	-0.26	-0.14	Fat distribution (HIV);	chr1:108861760	chr1:108857217~108858524:+
BRCA	cis	rs7523050	0.643	rs35860016	ENSG00000203897.3	SPATA42	-4.49	7.8e-06	0.000656	-0.26	-0.14	Fat distribution (HIV);	chr1:108862017	chr1:108857217~108858524:+
BRCA	cis	rs7523050	0.643	rs35050241	ENSG00000203897.3	SPATA42	-4.49	7.8e-06	0.000656	-0.26	-0.14	Fat distribution (HIV);	chr1:108862254	chr1:108857217~108858524:+
BRCA	cis	rs7523050	0.643	rs35526993	ENSG00000203897.3	SPATA42	-4.49	7.8e-06	0.000656	-0.26	-0.14	Fat distribution (HIV);	chr1:108862485	chr1:108857217~108858524:+
BRCA	cis	rs6565180	0.791	rs4247355	ENSG00000261332.1	RP11-297C4.1	4.49	7.8e-06	0.000656	0.19	0.14	Tonsillectomy;	chr16:30380778	chr16:30498766~30499554:-
BRCA	cis	rs13217239	0.646	rs7768407	ENSG00000224843.5	LINC00240	-4.49	7.8e-06	0.000656	-0.16	-0.14	Schizophrenia;	chr6:27049016	chr6:26956992~27023924:+
BRCA	cis	rs4073582	0.595	rs555360	ENSG00000255320.1	RP11-755F10.1	4.49	7.8e-06	0.000656	0.17	0.14	Gout;	chr11:66192590	chr11:66244840~66246239:-
BRCA	cis	rs3764563	1	rs4239612	ENSG00000267594.5	CYP4F24P	-4.49	7.8e-06	0.000656	-0.27	-0.14	Inflammatory biomarkers;	chr19:15616631	chr19:15760241~15779909:-
BRCA	cis	rs4388249	0.687	rs6877418	ENSG00000271849.1	CTC-332L22.1	-4.49	7.8e-06	0.000656	-0.18	-0.14	Schizophrenia;	chr5:109738408	chr5:109687802~109688329:-
BRCA	cis	rs13113518	1	rs3805148	ENSG00000273257.1	RP11-177J6.1	4.49	7.8e-06	0.000656	0.18	0.14	Height;	chr4:55440643	chr4:55387949~55388271:+
BRCA	cis	rs13113518	1	rs11133380	ENSG00000273257.1	RP11-177J6.1	4.49	7.8e-06	0.000656	0.18	0.14	Height;	chr4:55441110	chr4:55387949~55388271:+
BRCA	cis	rs13113518	1	rs12510110	ENSG00000273257.1	RP11-177J6.1	4.49	7.8e-06	0.000656	0.18	0.14	Height;	chr4:55441567	chr4:55387949~55388271:+
BRCA	cis	rs13113518	0.966	rs12510990	ENSG00000273257.1	RP11-177J6.1	4.49	7.8e-06	0.000656	0.18	0.14	Height;	chr4:55441907	chr4:55387949~55388271:+
BRCA	cis	rs957448	0.561	rs4734282	ENSG00000253175.1	RP11-267M23.6	4.49	7.8e-06	0.000656	0.16	0.14	Nonsyndromic cleft lip with cleft palate;	chr8:94603827	chr8:94565036~94565715:+
BRCA	cis	rs17684571	0.7	rs17684784	ENSG00000231441.1	RP11-472M19.2	-4.49	7.8e-06	0.000656	-0.21	-0.14	Schizophrenia;	chr6:56813644	chr6:56844002~56864078:+
BRCA	cis	rs911555	0.755	rs2756122	ENSG00000269958.1	RP11-73M18.8	4.49	7.81e-06	0.000657	0.15	0.14	Intelligence (multi-trait analysis);	chr14:103516696	chr14:103696353~103697163:+
BRCA	cis	rs11096990	0.634	rs6531702	ENSG00000249685.1	RP11-360F5.3	4.49	7.81e-06	0.000657	0.17	0.14	Cognitive function;	chr4:39273774	chr4:39133913~39135608:+
BRCA	cis	rs8031584	0.918	rs11639169	ENSG00000270015.1	RP11-540B6.6	-4.49	7.81e-06	0.000657	-0.15	-0.14	Huntington's disease progression;	chr15:30963235	chr15:30926514~30928407:+
BRCA	cis	rs6840360	0.642	rs12647555	ENSG00000251603.1	RP11-164P12.4	-4.49	7.81e-06	0.000657	-0.13	-0.14	Intelligence (multi-trait analysis);	chr4:151479946	chr4:151667224~151670502:+
BRCA	cis	rs6686842	1	rs11209718	ENSG00000235358.1	RP11-399E6.1	4.49	7.81e-06	0.000657	0.17	0.14	Height;	chr1:41223266	chr1:41242373~41284861:+
BRCA	cis	rs17711722	0.565	rs4717276	ENSG00000226767.1	RP11-328P23.3	4.49	7.82e-06	0.000658	0.16	0.14	Calcium levels;	chr7:65829754	chr7:65508773~65508944:-
BRCA	cis	rs1005277	0.579	rs2505237	ENSG00000263064.2	RP11-291L22.7	4.49	7.82e-06	0.000658	0.17	0.14	Extrinsic epigenetic age acceleration;	chr10:38149970	chr10:38448689~38448949:+
BRCA	cis	rs1005277	0.579	rs2474599	ENSG00000263064.2	RP11-291L22.7	4.49	7.82e-06	0.000658	0.17	0.14	Extrinsic epigenetic age acceleration;	chr10:38150011	chr10:38448689~38448949:+
BRCA	cis	rs17818399	0.926	rs35350086	ENSG00000279254.1	RP11-536C12.1	-4.49	7.82e-06	0.000658	-0.18	-0.14	Height;	chr2:46606897	chr2:46668870~46670778:+
BRCA	cis	rs7833986	0.501	rs72653959	ENSG00000253603.1	CTA-397H3.3	-4.49	7.82e-06	0.000658	-0.2	-0.14	Height;	chr8:56083957	chr8:56074592~56075274:+
BRCA	cis	rs7833986	0.501	rs72653962	ENSG00000253603.1	CTA-397H3.3	-4.49	7.82e-06	0.000658	-0.2	-0.14	Height;	chr8:56084946	chr8:56074592~56075274:+
BRCA	cis	rs7833986	0.501	rs72653967	ENSG00000253603.1	CTA-397H3.3	-4.49	7.82e-06	0.000658	-0.2	-0.14	Height;	chr8:56086873	chr8:56074592~56075274:+
BRCA	cis	rs13326165	0.585	rs11710014	ENSG00000243224.1	RP5-1157M23.2	-4.49	7.82e-06	0.000658	-0.22	-0.14	HDL cholesterol levels;HDL cholesterol;	chr3:52325956	chr3:52239258~52241097:+
BRCA	cis	rs6088580	0.634	rs6088484	ENSG00000276073.1	RP5-1125A11.7	4.49	7.83e-06	0.000658	0.15	0.14	Glomerular filtration rate (creatinine);	chr20:34398155	chr20:33985617~33988989:-
BRCA	cis	rs12144309	0.58	rs12129076	ENSG00000232450.1	RP4-730K3.3	4.49	7.83e-06	0.000658	0.19	0.14	Coronary artery disease;	chr1:113666792	chr1:113698884~113699631:-
BRCA	cis	rs2229238	0.911	rs4633282	ENSG00000272030.1	RP1-178F15.4	-4.49	7.83e-06	0.000658	-0.19	-0.14	Coronary heart disease;	chr1:154535423	chr1:153631438~153634397:-
BRCA	cis	rs12681366	0.537	rs10956914	ENSG00000253175.1	RP11-267M23.6	-4.49	7.83e-06	0.000658	-0.16	-0.14	Nonsyndromic cleft lip with cleft palate;	chr8:94471495	chr8:94565036~94565715:+
BRCA	cis	rs2412819	0.571	rs2930531	ENSG00000166763.7	STRCP1	-4.49	7.83e-06	0.000659	-0.19	-0.14	Lung cancer;	chr15:43829372	chr15:43699488~43718184:-
BRCA	cis	rs35740288	0.77	rs11631018	ENSG00000202081.1	RNU6-1280P	4.49	7.83e-06	0.000659	0.18	0.14	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85597303	chr15:85651522~85651628:-
BRCA	cis	rs10938353	0.871	rs1439358	ENSG00000273369.1	RP11-700J17.1	-4.49	7.84e-06	0.000659	-0.16	-0.14	Body mass index;	chr4:44607167	chr4:44693946~44694386:-
BRCA	cis	rs17428076	0.836	rs12622895	ENSG00000228389.1	AC068039.4	4.49	7.84e-06	0.000659	0.2	0.14	Myopia;	chr2:171829794	chr2:171773482~171775844:+
BRCA	cis	rs35612822	0.723	rs10199760	ENSG00000232485.2	AC098820.3	-4.49	7.84e-06	0.000659	-0.16	-0.14	Kidney disease (early stage) in type 1 diabetes;	chr2:216406195	chr2:216479030~216498761:-
BRCA	cis	rs256438	0.731	rs10474606	ENSG00000251050.1	RP11-168A11.4	4.49	7.84e-06	0.000659	0.16	0.14	Serum thyroid-stimulating hormone levels;	chr5:80057163	chr5:80019609~80019920:+
BRCA	cis	rs2227564	0.672	rs2459449	ENSG00000271816.1	BMS1P4	4.49	7.84e-06	0.000659	0.15	0.14	Crohn's disease;Inflammatory bowel disease;	chr10:73909255	chr10:73699151~73730487:-
BRCA	cis	rs6452524	0.935	rs72767160	ENSG00000281327.1	LINC01338	4.49	7.84e-06	0.000659	0.17	0.14	Hypertension (SNP x SNP interaction);	chr5:83161102	chr5:82850864~82859836:-
BRCA	cis	rs13113518	1	rs13146987	ENSG00000273257.1	RP11-177J6.1	4.49	7.84e-06	0.000659	0.18	0.14	Height;	chr4:55491628	chr4:55387949~55388271:+
BRCA	cis	rs13113518	1	rs7677085	ENSG00000273257.1	RP11-177J6.1	4.49	7.84e-06	0.000659	0.18	0.14	Height;	chr4:55495801	chr4:55387949~55388271:+
BRCA	cis	rs13113518	0.966	rs12510681	ENSG00000273257.1	RP11-177J6.1	4.49	7.84e-06	0.000659	0.18	0.14	Height;	chr4:55496737	chr4:55387949~55388271:+
BRCA	cis	rs13113518	1	rs12500162	ENSG00000273257.1	RP11-177J6.1	4.49	7.84e-06	0.000659	0.18	0.14	Height;	chr4:55496933	chr4:55387949~55388271:+
BRCA	cis	rs13113518	1	rs7686261	ENSG00000273257.1	RP11-177J6.1	4.49	7.84e-06	0.000659	0.18	0.14	Height;	chr4:55500224	chr4:55387949~55388271:+
BRCA	cis	rs13113518	1	rs11729220	ENSG00000273257.1	RP11-177J6.1	4.49	7.84e-06	0.000659	0.18	0.14	Height;	chr4:55501629	chr4:55387949~55388271:+
BRCA	cis	rs13113518	1	rs11133390	ENSG00000273257.1	RP11-177J6.1	4.49	7.84e-06	0.000659	0.18	0.14	Height;	chr4:55501726	chr4:55387949~55388271:+
BRCA	cis	rs13113518	1	rs11133391	ENSG00000273257.1	RP11-177J6.1	4.49	7.84e-06	0.000659	0.18	0.14	Height;	chr4:55501788	chr4:55387949~55388271:+
BRCA	cis	rs13113518	0.966	rs13133484	ENSG00000273257.1	RP11-177J6.1	4.49	7.84e-06	0.000659	0.18	0.14	Height;	chr4:55504176	chr4:55387949~55388271:+
BRCA	cis	rs13113518	0.934	rs13127906	ENSG00000273257.1	RP11-177J6.1	4.49	7.84e-06	0.000659	0.18	0.14	Height;	chr4:55504201	chr4:55387949~55388271:+
BRCA	cis	rs77204473	1	rs17120132	ENSG00000280143.1	AP000892.6	-4.49	7.84e-06	0.000659	-0.26	-0.14	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116902602	chr11:117204967~117210292:+
BRCA	cis	rs77204473	1	rs17120136	ENSG00000280143.1	AP000892.6	-4.49	7.84e-06	0.000659	-0.26	-0.14	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116903045	chr11:117204967~117210292:+
BRCA	cis	rs77204473	1	rs78694306	ENSG00000280143.1	AP000892.6	-4.49	7.84e-06	0.000659	-0.26	-0.14	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116903528	chr11:117204967~117210292:+
BRCA	cis	rs77204473	1	rs115971514	ENSG00000280143.1	AP000892.6	-4.49	7.84e-06	0.000659	-0.26	-0.14	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116903783	chr11:117204967~117210292:+
BRCA	cis	rs77204473	1	rs12280030	ENSG00000280143.1	AP000892.6	-4.49	7.84e-06	0.000659	-0.26	-0.14	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116904480	chr11:117204967~117210292:+
BRCA	cis	rs12144309	0.554	rs12119076	ENSG00000232450.1	RP4-730K3.3	4.49	7.85e-06	0.00066	0.19	0.14	Coronary artery disease;	chr1:113667853	chr1:113698884~113699631:-
BRCA	cis	rs6430585	0.528	rs309162	ENSG00000231890.6	DARS-AS1	-4.49	7.85e-06	0.00066	-0.21	-0.14	Corneal structure;	chr2:135933213	chr2:135985176~136022593:+
BRCA	cis	rs2688608	0.967	rs72814394	ENSG00000271816.1	BMS1P4	4.49	7.85e-06	0.00066	0.14	0.14	Inflammatory bowel disease;	chr10:73896567	chr10:73699151~73730487:-
BRCA	cis	rs2688608	0.905	rs2633300	ENSG00000271816.1	BMS1P4	4.49	7.85e-06	0.00066	0.14	0.14	Inflammatory bowel disease;	chr10:73896889	chr10:73699151~73730487:-
BRCA	cis	rs6565180	1	rs6565180	ENSG00000183604.13	SMG1P5	-4.49	7.85e-06	0.00066	-0.14	-0.14	Tonsillectomy;	chr16:30350020	chr16:30267553~30335374:-
BRCA	cis	rs2253762	0.54	rs10159634	ENSG00000226864.1	ATE1-AS1	-4.49	7.85e-06	0.00066	-0.25	-0.14	Breast cancer;	chr10:121994520	chr10:121928312~121951965:+
BRCA	cis	rs7674212	0.539	rs6821617	ENSG00000246560.2	RP11-10L12.4	4.49	7.85e-06	0.00066	0.14	0.14	Type 2 diabetes;	chr4:103207253	chr4:102828055~102844075:+
BRCA	cis	rs763014	1	rs763014	ENSG00000260394.2	LA16c-313D11.9	-4.49	7.86e-06	0.00066	-0.14	-0.14	Height;	chr16:625680	chr16:678504~679777:-
BRCA	cis	rs7637701	0.818	rs4680305	ENSG00000240875.4	LINC00886	-4.49	7.86e-06	0.00066	-0.16	-0.14	Breast cancer;	chr3:156815614	chr3:156747346~156817062:-
BRCA	cis	rs6686842	0.56	rs6672508	ENSG00000235358.1	RP11-399E6.1	4.49	7.86e-06	0.00066	0.18	0.14	Height;	chr1:41200899	chr1:41242373~41284861:+
BRCA	cis	rs6088580	0.634	rs1890000	ENSG00000276073.1	RP5-1125A11.7	4.49	7.86e-06	0.00066	0.15	0.14	Glomerular filtration rate (creatinine);	chr20:34380506	chr20:33985617~33988989:-
BRCA	cis	rs453301	0.686	rs3989373	ENSG00000254153.1	CTA-398F10.2	-4.49	7.86e-06	0.00066	-0.16	-0.14	Joint mobility (Beighton score);	chr8:9053798	chr8:8456909~8461337:-
BRCA	cis	rs11638815	0.626	rs11633829	ENSG00000259429.4	UBE2Q2P2	4.49	7.86e-06	0.000661	0.14	0.14	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82658186	chr15:82355142~82420075:+
BRCA	cis	rs1722141	0.669	rs2462684	ENSG00000229628.1	AC073115.7	-4.49	7.86e-06	0.000661	-0.19	-0.14	Sitting height ratio;	chr7:45999922	chr7:45990905~46000898:+
BRCA	cis	rs1722141	0.669	rs700744	ENSG00000229628.1	AC073115.7	4.49	7.86e-06	0.000661	0.19	0.14	Sitting height ratio;	chr7:45998408	chr7:45990905~46000898:+
BRCA	cis	rs1722141	0.705	rs1085925	ENSG00000229628.1	AC073115.7	4.49	7.86e-06	0.000661	0.19	0.14	Sitting height ratio;	chr7:46002166	chr7:45990905~46000898:+
BRCA	cis	rs4948275	0.693	rs1378889	ENSG00000237233.2	TMEM26-AS1	-4.49	7.86e-06	0.000661	-0.16	-0.14	Night sleep phenotypes;	chr10:61575134	chr10:61452639~61481956:+
BRCA	cis	rs12681366	0.537	rs2919667	ENSG00000253704.1	RP11-267M23.4	4.49	7.86e-06	0.000661	0.15	0.14	Nonsyndromic cleft lip with cleft palate;	chr8:94452974	chr8:94553722~94569745:+
BRCA	cis	rs859767	0.741	rs6430529	ENSG00000224043.6	CCNT2-AS1	4.49	7.87e-06	0.000661	0.19	0.14	Neuroticism;	chr2:134675453	chr2:134735464~134918710:-
BRCA	cis	rs651907	0.712	rs796410	ENSG00000244119.1	PDCL3P4	4.49	7.87e-06	0.000661	0.11	0.14	Colorectal cancer;	chr3:101891345	chr3:101712472~101713191:+
BRCA	cis	rs6723226	0.75	rs10182170	ENSG00000276334.1	AL133243.1	4.49	7.87e-06	0.000661	0.17	0.14	Intelligence (multi-trait analysis);	chr2:32479118	chr2:32521927~32523547:+
BRCA	cis	rs2235642	0.928	rs56289115	ENSG00000260989.1	LA16c-395F10.2	-4.49	7.87e-06	0.000661	-0.14	-0.14	Coronary artery disease;	chr16:1558933	chr16:1580527~1610328:+
BRCA	cis	rs7829975	0.564	rs2921060	ENSG00000254153.1	CTA-398F10.2	-4.49	7.87e-06	0.000661	-0.17	-0.14	Mood instability;	chr8:8460307	chr8:8456909~8461337:-
BRCA	cis	rs27434	0.607	rs695965	ENSG00000248734.2	CTD-2260A17.1	4.49	7.87e-06	0.000662	0.16	0.14	Ankylosing spondylitis;	chr5:96812663	chr5:96784777~96785999:+
BRCA	cis	rs4073582	0.595	rs9326370	ENSG00000255320.1	RP11-755F10.1	-4.49	7.87e-06	0.000662	-0.17	-0.14	Gout;	chr11:66224537	chr11:66244840~66246239:-
BRCA	cis	rs11892454	0.604	rs7564034	ENSG00000217643.1	PTGES3P2	-4.49	7.88e-06	0.000662	-0.15	-0.14	Heschl's gyrus morphology;	chr2:25718764	chr2:25822469~25822950:+
BRCA	cis	rs2337406	1	rs11845269	ENSG00000223648.3	IGHV3-64	4.49	7.88e-06	0.000662	0.14	0.14	Alzheimer's disease (late onset);	chr14:106683851	chr14:106643132~106658258:-
BRCA	cis	rs7487075	0.619	rs11183483	ENSG00000274723.1	RP11-618L22.1	4.49	7.88e-06	0.000662	0.18	0.14	Itch intensity from mosquito bite;	chr12:46432698	chr12:46970504~46972155:+
BRCA	cis	rs62184315	0.536	rs16831873	ENSG00000253559.1	OSGEPL1-AS1	-4.49	7.88e-06	0.000662	-0.23	-0.14	Alcohol dependence (age at onset);	chr2:189692172	chr2:189762704~189765556:+
BRCA	cis	rs2574985	0.813	rs1203409	ENSG00000231345.3	BEND3P1	-4.49	7.89e-06	0.000663	-0.22	-0.14	Subjective well-being;	chr10:50437435	chr10:50655967~50660472:+
BRCA	cis	rs4388249	0.687	rs2301002	ENSG00000271849.1	CTC-332L22.1	-4.49	7.89e-06	0.000663	-0.19	-0.14	Schizophrenia;	chr5:109766130	chr5:109687802~109688329:-
BRCA	cis	rs17122021	0.625	rs3759001	ENSG00000280032.1	RP11-832A4.7	4.49	7.89e-06	0.000663	0.13	0.14	Pain;	chr11:118265030	chr11:118264593~118266817:+
BRCA	cis	rs13113518	1	rs4865013	ENSG00000249700.7	SRD5A3-AS1	4.49	7.89e-06	0.000663	0.17	0.14	Height;	chr4:55559957	chr4:55363971~55395847:-
BRCA	cis	rs2692947	0.8	rs4332959	ENSG00000168992.4	OR7E102P	4.49	7.89e-06	0.000663	0.19	0.14	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95883373	chr2:95546531~95547545:+
BRCA	cis	rs7686660	1	rs11100765	ENSG00000250326.1	RP11-284M14.1	-4.49	7.89e-06	0.000663	-0.17	-0.14	Asthma;	chr4:143034007	chr4:142933195~143184861:-
BRCA	cis	rs2136613	0.533	rs10822071	ENSG00000238280.1	RP11-436D10.3	-4.49	7.89e-06	0.000663	-0.17	-0.14	Selective IgA deficiency;	chr10:62855716	chr10:62793562~62805887:-
BRCA	cis	rs752010	0.545	rs6600379	ENSG00000230638.4	RP11-486B10.4	-4.49	7.89e-06	0.000663	-0.17	-0.14	Lupus nephritis in systemic lupus erythematosus;	chr1:41587826	chr1:41542069~41544310:+
BRCA	cis	rs8040855	0.627	rs12904238	ENSG00000259774.1	RP11-182J1.13	4.49	7.89e-06	0.000663	0.19	0.14	Bulimia nervosa;	chr15:85096610	chr15:84422618~84425882:+
BRCA	cis	rs2164068	0.547	rs61435657	ENSG00000231621.1	AC013264.2	-4.49	7.89e-06	0.000663	-0.14	-0.14	Allergy;	chr2:197960782	chr2:197197991~197199273:+
BRCA	cis	rs8103278	1	rs7256192	ENSG00000267395.4	AC074212.6	4.49	7.9e-06	0.000663	0.14	0.14	Coronary artery disease;	chr19:45835234	chr19:45767796~45772504:+
BRCA	cis	rs807029	0.544	rs55646950	ENSG00000236662.1	RP11-108L7.4	4.49	7.9e-06	0.000663	0.18	0.14	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:101001239	chr10:100980507~100985614:-
BRCA	cis	rs651907	0.557	rs34376498	ENSG00000256628.3	ZBTB11-AS1	4.49	7.9e-06	0.000663	0.18	0.14	Colorectal cancer;	chr3:101761312	chr3:101676475~101679217:+
BRCA	cis	rs7674212	0.539	rs6854709	ENSG00000246560.2	RP11-10L12.4	4.49	7.9e-06	0.000664	0.14	0.14	Type 2 diabetes;	chr4:103208629	chr4:102828055~102844075:+
BRCA	cis	rs6596100	0.915	rs62375204	ENSG00000248648.1	RP11-485M7.1	-4.49	7.9e-06	0.000664	-0.18	-0.14	Breast cancer;	chr5:133055770	chr5:133003119~133003365:+
BRCA	cis	rs72799341	0.706	rs1060506	ENSG00000279196.1	RP11-1072A3.3	4.49	7.91e-06	0.000664	0.15	0.14	Diastolic blood pressure;	chr16:31122128	chr16:30984630~30988270:-
BRCA	cis	rs1005277	0.563	rs2505215	ENSG00000099251.13	HSD17B7P2	4.49	7.91e-06	0.000664	0.15	0.14	Extrinsic epigenetic age acceleration;	chr10:38192345	chr10:38356380~38378505:+
BRCA	cis	rs4218	0.543	rs8025246	ENSG00000259732.1	RP11-59H7.3	-4.49	7.91e-06	0.000664	-0.16	-0.14	Social communication problems;	chr15:59025814	chr15:59121034~59133250:+
BRCA	cis	rs2136613	0.533	rs10822072	ENSG00000238280.1	RP11-436D10.3	-4.49	7.91e-06	0.000664	-0.17	-0.14	Selective IgA deficiency;	chr10:62856010	chr10:62793562~62805887:-
BRCA	cis	rs35306767	0.953	rs11253509	ENSG00000229869.1	RP11-363N22.2	-4.49	7.91e-06	0.000665	-0.2	-0.14	Eosinophil percentage of granulocytes;	chr10:918366	chr10:933026~942743:+
BRCA	cis	rs6088580	0.634	rs6088478	ENSG00000276073.1	RP5-1125A11.7	4.49	7.91e-06	0.000665	0.15	0.14	Glomerular filtration rate (creatinine);	chr20:34383913	chr20:33985617~33988989:-
BRCA	cis	rs6893300	0.745	rs6639	ENSG00000225051.5	HMGB3P22	4.49	7.91e-06	0.000665	0.17	0.14	Resting heart rate;	chr5:179729781	chr5:179679032~179694768:+
BRCA	cis	rs6599077	1	rs2068978	ENSG00000223797.4	ENTPD3-AS1	4.49	7.91e-06	0.000665	0.16	0.14	Sleep-related phenotypes;	chr3:40053747	chr3:40313802~40453329:-
BRCA	cis	rs2403083	0.556	rs6605608	ENSG00000258256.1	RP11-219B4.5	-4.49	7.92e-06	0.000665	-0.17	-0.14	Plasma amyloid beta peptide concentrations (ABx-40);	chr8:85163242	chr8:85222446~85245717:-
BRCA	cis	rs924712	0.625	rs10807485	ENSG00000261116.1	RP3-523K23.2	4.49	7.92e-06	0.000665	0.17	0.14	Breast cancer;	chr6:54854893	chr6:54943167~54945099:+
BRCA	cis	rs6547741	0.874	rs58737572	ENSG00000234072.1	AC074117.10	4.49	7.92e-06	0.000665	0.13	0.14	Oral cavity cancer;	chr2:27629251	chr2:27356246~27367622:+
BRCA	cis	rs950776	0.593	rs601079	ENSG00000279373.1	RP11-650L12.4	-4.49	7.92e-06	0.000665	-0.16	-0.14	Sudden cardiac arrest;	chr15:78577237	chr15:78537681~78538946:+
BRCA	cis	rs950776	0.593	rs680244	ENSG00000279373.1	RP11-650L12.4	-4.49	7.92e-06	0.000665	-0.16	-0.14	Sudden cardiac arrest;	chr15:78578946	chr15:78537681~78538946:+
BRCA	cis	rs1048886	0.745	rs6455370	ENSG00000271967.1	RP11-134K13.4	-4.49	7.92e-06	0.000665	-0.18	-0.14	Type 2 diabetes;	chr6:70563532	chr6:70596438~70596980:+
BRCA	cis	rs7191700	0.511	rs12923756	ENSG00000262703.1	RP11-485G7.6	-4.49	7.92e-06	0.000665	-0.14	-0.14	Multiple sclerosis;	chr16:11265818	chr16:11348143~11349321:-
BRCA	cis	rs7475343	0.501	rs75406471	ENSG00000224034.1	RP11-445P17.8	-4.49	7.93e-06	0.000666	-0.26	-0.14	Intelligence;	chr10:5215684	chr10:5266033~5271236:-
BRCA	cis	rs708547	0.581	rs781661	ENSG00000269949.1	RP11-738E22.3	-4.49	7.93e-06	0.000666	-0.17	-0.14	Response to bleomycin (chromatid breaks);	chr4:56914141	chr4:56960927~56961373:-
BRCA	cis	rs6738627	1	rs10187501	ENSG00000223318.1	RNA5SP111	4.49	7.93e-06	0.000666	0.16	0.14	circulating leptin levels adjusted for BMI;Body fat percentage;circulating leptin levels;	chr2:164675944	chr2:164895677~164895777:-
BRCA	cis	rs7646881	1	rs59217052	ENSG00000240207.5	RP11-379F4.4	-4.49	7.93e-06	0.000666	-0.2	-0.14	Tetralogy of Fallot;	chr3:158734667	chr3:158732263~158784070:+
BRCA	cis	rs7646881	1	rs7646881	ENSG00000240207.5	RP11-379F4.4	-4.49	7.93e-06	0.000666	-0.2	-0.14	Tetralogy of Fallot;	chr3:158735490	chr3:158732263~158784070:+
BRCA	cis	rs736408	0.66	rs2019065	ENSG00000243224.1	RP5-1157M23.2	4.49	7.93e-06	0.000666	0.15	0.14	Bipolar disorder;	chr3:52775509	chr3:52239258~52241097:+
BRCA	cis	rs7789940	1	rs7789940	ENSG00000280388.1	RP11-229D13.3	-4.49	7.93e-06	0.000666	-0.15	-0.14	Multiple sclerosis;	chr7:76321913	chr7:76043977~76045963:-
BRCA	cis	rs4415084	0.834	rs1438821	ENSG00000251141.4	RP11-53O19.1	-4.49	7.93e-06	0.000666	-0.12	-0.14	Breast cancer;	chr5:44858349	chr5:44744900~44808777:-
BRCA	cis	rs6671200	0.831	rs113525652	ENSG00000235501.4	RP4-639F20.1	-4.49	7.94e-06	0.000666	-0.3	-0.14	Stearic acid (18:0) levels;	chr1:95139118	chr1:94927566~94963270:+
BRCA	cis	rs721917	0.525	rs2246111	ENSG00000278616.1	BEND3P3	-4.49	7.94e-06	0.000666	-0.13	-0.14	Chronic obstructive pulmonary disease;	chr10:79929985	chr10:79682997~79685436:+
BRCA	cis	rs718433	0.556	rs1569287	ENSG00000256379.1	TRAV8-5	4.49	7.94e-06	0.000666	0.16	0.14	Intraocular pressure;	chr14:21747309	chr14:21903077~21903598:+
BRCA	cis	rs8130944	1	rs4920141	ENSG00000225731.1	AP001627.1	-4.49	7.94e-06	0.000666	-0.15	-0.14	Perceived unattractiveness to mosquitoes;	chr21:42721519	chr21:42733594~42741758:-
BRCA	cis	rs62184315	0.938	rs7563391	ENSG00000253559.1	OSGEPL1-AS1	-4.49	7.94e-06	0.000666	-0.21	-0.14	Alcohol dependence (age at onset);	chr2:189915077	chr2:189762704~189765556:+
BRCA	cis	rs61542988	0.797	rs4329182	ENSG00000228649.7	AC005682.5	4.49	7.94e-06	0.000667	0.13	0.14	Fibrinogen levels;	chr7:22843002	chr7:22854178~22861579:+
BRCA	cis	rs61542988	0.756	rs5013587	ENSG00000228649.7	AC005682.5	4.49	7.94e-06	0.000667	0.13	0.14	Fibrinogen levels;	chr7:22843041	chr7:22854178~22861579:+
BRCA	cis	rs9435732	1	rs9435732	ENSG00000186301.8	MST1P2	-4.49	7.94e-06	0.000667	-0.13	-0.14	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);	chr1:16981663	chr1:16645622~16650289:+
BRCA	cis	rs17680741	0.697	rs11185829	ENSG00000226659.1	RP11-137H2.4	4.49	7.95e-06	0.000667	0.24	0.14	Coronary artery disease;	chr10:80508094	chr10:80529597~80535942:-
BRCA	cis	rs2243480	1	rs34529418	ENSG00000222364.1	RNU6-96P	-4.49	7.95e-06	0.000667	-0.25	-0.14	Diabetic kidney disease;	chr7:65938222	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.638	rs10249404	ENSG00000273142.1	RP11-458F8.4	4.49	7.95e-06	0.000667	0.12	0.14	Aortic root size;	chr7:66581737	chr7:66902857~66906297:+
BRCA	cis	rs35612822	0.723	rs35058455	ENSG00000232485.2	AC098820.3	-4.49	7.96e-06	0.000668	-0.16	-0.14	Kidney disease (early stage) in type 1 diabetes;	chr2:216404116	chr2:216479030~216498761:-
BRCA	cis	rs859767	0.704	rs1818614	ENSG00000224043.6	CCNT2-AS1	4.49	7.96e-06	0.000668	0.19	0.14	Neuroticism;	chr2:134598781	chr2:134735464~134918710:-
BRCA	cis	rs7119	0.717	rs12898370	ENSG00000259362.2	RP11-307C19.1	-4.49	7.96e-06	0.000668	-0.19	-0.14	Type 2 diabetes;	chr15:77516256	chr15:77525540~77534110:+
BRCA	cis	rs7045881	0.935	rs62544450	ENSG00000254396.1	RP11-56F10.3	4.49	7.96e-06	0.000668	0.22	0.14	Schizophrenia;	chr9:26934761	chr9:27102630~27104728:+
BRCA	cis	rs7045881	0.935	rs62544451	ENSG00000254396.1	RP11-56F10.3	4.49	7.96e-06	0.000668	0.22	0.14	Schizophrenia;	chr9:26934898	chr9:27102630~27104728:+
BRCA	cis	rs6547741	0.904	rs2384659	ENSG00000234072.1	AC074117.10	4.49	7.96e-06	0.000668	0.13	0.14	Oral cavity cancer;	chr2:27633926	chr2:27356246~27367622:+
BRCA	cis	rs7246657	0.551	rs4806413	ENSG00000267422.1	CTD-2554C21.1	-4.49	7.96e-06	0.000668	-0.24	-0.14	Coronary artery calcification;	chr19:37126814	chr19:37779686~37792865:+
BRCA	cis	rs11779988	0.545	rs427168	ENSG00000253671.1	RP11-806O11.1	-4.49	7.97e-06	0.000669	-0.2	-0.14	Breast cancer;	chr8:17927320	chr8:17808941~17820868:+
BRCA	cis	rs11779988	0.545	rs4124900	ENSG00000253671.1	RP11-806O11.1	-4.49	7.97e-06	0.000669	-0.2	-0.14	Breast cancer;	chr8:17927757	chr8:17808941~17820868:+
BRCA	cis	rs2243480	1	rs12698509	ENSG00000275400.1	RP4-756H11.5	4.49	7.97e-06	0.000669	0.24	0.14	Diabetic kidney disease;	chr7:65953889	chr7:66553805~66554199:-
BRCA	cis	rs9402743	0.671	rs2143681	ENSG00000234084.1	RP3-388E23.2	-4.49	7.97e-06	0.000669	-0.14	-0.14	Systemic lupus erythematosus;	chr6:135611867	chr6:135301568~135307158:+
BRCA	cis	rs7674212	0.57	rs2069274	ENSG00000251288.2	RP11-10L12.2	-4.49	7.97e-06	0.000669	-0.16	-0.14	Type 2 diabetes;	chr4:103099624	chr4:102751401~102752641:+
BRCA	cis	rs11039131	0.754	rs2291119	ENSG00000280615.1	Y_RNA	-4.49	7.97e-06	0.000669	-0.18	-0.14	Schizophrenia;	chr11:47276650	chr11:47614898~47614994:-
BRCA	cis	rs7200543	1	rs55727637	ENSG00000275910.1	RP11-680G24.6	-4.49	7.97e-06	0.000669	-0.16	-0.14	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15051395	chr16:15015828~15016390:-
BRCA	cis	rs7308116	1	rs4075447	ENSG00000274395.1	RP11-554D14.8	-4.49	7.98e-06	0.000669	-0.15	-0.14	Pelvic organ prolapse (moderate/severe);	chr12:107808728	chr12:107835541~107836555:-
BRCA	cis	rs1371614	0.566	rs11887401	ENSG00000229122.1	AGBL5-IT1	4.49	7.98e-06	0.00067	0.14	0.14	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26958244	chr2:27061038~27061815:+
BRCA	cis	rs4713675	0.584	rs509539	ENSG00000224557.6	HLA-DPB2	4.49	7.98e-06	0.00067	0.16	0.14	Plateletcrit;	chr6:33740413	chr6:33112451~33129084:+
BRCA	cis	rs2739330	0.789	rs5760109	ENSG00000228039.3	KB-1125A3.10	4.49	7.98e-06	0.00067	0.16	0.14	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23963780~23964374:+
BRCA	cis	rs10457838	0.851	rs17669693	ENSG00000236591.1	RP11-162J8.3	-4.49	7.98e-06	0.00067	-0.19	-0.14	Post-traumatic stress disorder;	chr6:149046282	chr6:149027700~149032573:-
BRCA	cis	rs17428076	0.756	rs62181743	ENSG00000228389.1	AC068039.4	-4.49	7.99e-06	0.00067	-0.24	-0.14	Myopia;	chr2:171695491	chr2:171773482~171775844:+
BRCA	cis	rs1005277	0.579	rs2474567	ENSG00000099251.13	HSD17B7P2	4.49	7.99e-06	0.00067	0.15	0.14	Extrinsic epigenetic age acceleration;	chr10:38093564	chr10:38356380~38378505:+
BRCA	cis	rs2880765	0.631	rs55767890	ENSG00000259630.2	CTD-2262B20.1	-4.49	7.99e-06	0.00067	-0.17	-0.14	Coronary artery disease;	chr15:85460911	chr15:85415228~85415633:+
BRCA	cis	rs763014	0.593	rs28455838	ENSG00000260394.2	LA16c-313D11.9	-4.49	7.99e-06	0.00067	-0.14	-0.14	Height;	chr16:631966	chr16:678504~679777:-
BRCA	cis	rs6430585	0.591	rs12466487	ENSG00000224043.6	CCNT2-AS1	4.49	7.99e-06	0.000671	0.25	0.14	Corneal structure;	chr2:135649508	chr2:134735464~134918710:-
BRCA	cis	rs1823874	0.71	rs58572174	ENSG00000182397.13	DNM1P46	-4.49	8e-06	0.000671	-0.15	-0.14	IgG glycosylation;	chr15:99822635	chr15:99790156~99806927:-
BRCA	cis	rs1823874	0.71	rs1993297	ENSG00000182397.13	DNM1P46	-4.49	8e-06	0.000671	-0.15	-0.14	IgG glycosylation;	chr15:99823423	chr15:99790156~99806927:-
BRCA	cis	rs1823874	0.613	rs4608318	ENSG00000182397.13	DNM1P46	-4.49	8e-06	0.000671	-0.15	-0.14	IgG glycosylation;	chr15:99823621	chr15:99790156~99806927:-
BRCA	cis	rs950169	0.579	rs12912716	ENSG00000275120.1	RP11-182J1.17	4.49	8e-06	0.000671	0.21	0.14	Schizophrenia;	chr15:83995511	chr15:84599434~84606463:-
BRCA	cis	rs757081	0.658	rs105290	ENSG00000184669.7	OR7E14P	-4.49	8e-06	0.000671	-0.18	-0.14	Systolic blood pressure;	chr11:17270521	chr11:17013998~17053024:+
BRCA	cis	rs7811142	1	rs67315960	ENSG00000078319.8	PMS2P1	-4.49	8e-06	0.000671	-0.22	-0.14	Platelet count;	chr7:100417501	chr7:100320992~100341908:-
BRCA	cis	rs74665712	0.591	rs71540775	ENSG00000232400.1	RAD17P1	4.49	8e-06	0.000671	0.16	0.14	Residual cognition;	chr7:16911200	chr7:16864267~16866308:-
BRCA	cis	rs6452524	0.711	rs1478486	ENSG00000281327.1	LINC01338	4.49	8e-06	0.000671	0.16	0.14	Hypertension (SNP x SNP interaction);	chr5:83081185	chr5:82850864~82859836:-
BRCA	cis	rs2243480	1	rs57057549	ENSG00000275400.1	RP4-756H11.5	4.49	8e-06	0.000671	0.25	0.14	Diabetic kidney disease;	chr7:65940751	chr7:66553805~66554199:-
BRCA	cis	rs984222	0.677	rs6428792	ENSG00000231365.4	RP11-418J17.1	-4.49	8e-06	0.000671	-0.17	-0.14	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119114244	chr1:119140396~119275973:+
BRCA	cis	rs1729951	0.575	rs361245	ENSG00000239213.4	NCK1-AS1	4.49	8e-06	0.000671	0.14	0.14	Neuroticism;	chr3:136976864	chr3:136841726~136862054:-
BRCA	cis	rs11779988	0.545	rs397096	ENSG00000253671.1	RP11-806O11.1	4.49	8e-06	0.000671	0.2	0.14	Breast cancer;	chr8:17941339	chr8:17808941~17820868:+
BRCA	cis	rs7789940	1	rs2072435	ENSG00000280388.1	RP11-229D13.3	-4.49	8e-06	0.000671	-0.15	-0.14	Multiple sclerosis;	chr7:76329871	chr7:76043977~76045963:-
BRCA	cis	rs77204473	1	rs12273762	ENSG00000280143.1	AP000892.6	-4.49	8.01e-06	0.000671	-0.26	-0.14	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116906347	chr11:117204967~117210292:+
BRCA	cis	rs77204473	1	rs9651681	ENSG00000280143.1	AP000892.6	-4.49	8.01e-06	0.000671	-0.26	-0.14	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116907349	chr11:117204967~117210292:+
BRCA	cis	rs6545883	0.894	rs2463102	ENSG00000270820.4	RP11-355B11.2	-4.49	8.01e-06	0.000672	-0.16	-0.14	Tuberculosis;	chr2:61344160	chr2:61471188~61484130:+
BRCA	cis	rs2625529	0.938	rs2742323	ENSG00000260037.4	CTD-2524L6.3	4.49	8.01e-06	0.000672	0.2	0.14	Red blood cell count;	chr15:71824437	chr15:71818396~71823384:+
BRCA	cis	rs2625529	0.652	rs11634608	ENSG00000260037.4	CTD-2524L6.3	4.49	8.01e-06	0.000672	0.17	0.14	Red blood cell count;	chr15:71963377	chr15:71818396~71823384:+
BRCA	cis	rs875971	0.502	rs2946580	ENSG00000230295.1	RP11-458F8.2	-4.49	8.02e-06	0.000672	-0.13	-0.14	Aortic root size;	chr7:66066855	chr7:66880708~66882981:+
BRCA	cis	rs253959	0.545	rs2416425	ENSG00000271918.1	CTD-2287O16.5	4.49	8.02e-06	0.000673	0.12	0.14	Bipolar disorder and schizophrenia;	chr5:116101727	chr5:116083807~116085416:-
BRCA	cis	rs3176789	0.651	rs12819552	ENSG00000256673.1	RP11-599J14.2	4.49	8.02e-06	0.000673	0.16	0.14	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9767236	chr12:9398355~9414851:-
BRCA	cis	rs6686842	1	rs17571940	ENSG00000235358.1	RP11-399E6.1	-4.49	8.03e-06	0.000673	-0.17	-0.14	Height;	chr1:41100519	chr1:41242373~41284861:+
BRCA	cis	rs763121	0.853	rs2072798	ENSG00000273076.1	RP3-508I15.22	4.49	8.03e-06	0.000673	0.16	0.14	Menopause (age at onset);	chr22:38752478	chr22:38743495~38743910:+
BRCA	cis	rs987360	0.775	rs10012193	ENSG00000248869.4	RP11-138I17.1	4.49	8.03e-06	0.000673	0.14	0.14	Temperament;	chr4:137276360	chr4:136796722~137212799:-
BRCA	cis	rs4781563	0.81	rs3136064	ENSG00000242307.1	RPS26P52	-4.49	8.03e-06	0.000673	-0.16	-0.14	Bilirubin levels;	chr16:13923524	chr16:13922332~13922679:-
BRCA	cis	rs6545883	0.894	rs2600660	ENSG00000212978.6	AC016747.3	-4.49	8.03e-06	0.000673	-0.19	-0.14	Tuberculosis;	chr2:61322465	chr2:61141592~61144969:-
BRCA	cis	rs1005277	0.579	rs1780136	ENSG00000099251.13	HSD17B7P2	4.49	8.03e-06	0.000674	0.15	0.14	Extrinsic epigenetic age acceleration;	chr10:38212525	chr10:38356380~38378505:+
BRCA	cis	rs1005277	0.579	rs1780138	ENSG00000099251.13	HSD17B7P2	4.49	8.03e-06	0.000674	0.15	0.14	Extrinsic epigenetic age acceleration;	chr10:38212726	chr10:38356380~38378505:+
BRCA	cis	rs1005277	0.579	rs1780139	ENSG00000099251.13	HSD17B7P2	4.49	8.03e-06	0.000674	0.15	0.14	Extrinsic epigenetic age acceleration;	chr10:38214090	chr10:38356380~38378505:+
BRCA	cis	rs1005277	0.602	rs1780141	ENSG00000099251.13	HSD17B7P2	4.49	8.03e-06	0.000674	0.15	0.14	Extrinsic epigenetic age acceleration;	chr10:38215371	chr10:38356380~38378505:+
BRCA	cis	rs7592578	0.679	rs4287794	ENSG00000272979.1	RP11-647K16.1	-4.49	8.03e-06	0.000674	-0.22	-0.14	Diastolic blood pressure;	chr2:190462421	chr2:190454092~190454521:-
BRCA	cis	rs1005277	0.579	rs2474568	ENSG00000263064.2	RP11-291L22.7	4.49	8.04e-06	0.000674	0.17	0.14	Extrinsic epigenetic age acceleration;	chr10:38094219	chr10:38448689~38448949:+
BRCA	cis	rs1005277	0.603	rs1998062	ENSG00000263064.2	RP11-291L22.7	4.49	8.04e-06	0.000674	0.17	0.14	Extrinsic epigenetic age acceleration;	chr10:38168724	chr10:38448689~38448949:+
BRCA	cis	rs35740288	0.77	rs11635711	ENSG00000202081.1	RNU6-1280P	4.49	8.04e-06	0.000674	0.18	0.14	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85583255	chr15:85651522~85651628:-
BRCA	cis	rs6840360	0.573	rs6810430	ENSG00000270265.1	RP11-731D1.4	-4.49	8.04e-06	0.000674	-0.15	-0.14	Intelligence (multi-trait analysis);	chr4:151338607	chr4:151333775~151353224:-
BRCA	cis	rs2243480	1	rs34933526	ENSG00000222364.1	RNU6-96P	-4.49	8.04e-06	0.000674	-0.25	-0.14	Diabetic kidney disease;	chr7:65918212	chr7:66395191~66395286:+
BRCA	cis	rs2243480	1	rs6949812	ENSG00000222364.1	RNU6-96P	-4.49	8.04e-06	0.000674	-0.25	-0.14	Diabetic kidney disease;	chr7:65922114	chr7:66395191~66395286:+
BRCA	cis	rs2243480	1	rs6970243	ENSG00000222364.1	RNU6-96P	-4.49	8.04e-06	0.000674	-0.25	-0.14	Diabetic kidney disease;	chr7:65923503	chr7:66395191~66395286:+
BRCA	cis	rs2243480	0.708	rs35310401	ENSG00000222364.1	RNU6-96P	-4.49	8.04e-06	0.000674	-0.25	-0.14	Diabetic kidney disease;	chr7:65925372	chr7:66395191~66395286:+
BRCA	cis	rs2243480	0.831	rs7806717	ENSG00000222364.1	RNU6-96P	4.49	8.04e-06	0.000674	0.25	0.14	Diabetic kidney disease;	chr7:65928187	chr7:66395191~66395286:+
BRCA	cis	rs11250098	0.547	rs2409764	ENSG00000255046.1	RP11-297N6.4	-4.49	8.04e-06	0.000674	-0.16	-0.14	Morning vs. evening chronotype;	chr8:11423764	chr8:11797928~11802568:-
BRCA	cis	rs6430585	0.528	rs309172	ENSG00000231890.6	DARS-AS1	-4.49	8.04e-06	0.000674	-0.21	-0.14	Corneal structure;	chr2:135916458	chr2:135985176~136022593:+
BRCA	cis	rs875971	0.545	rs6970498	ENSG00000273142.1	RP11-458F8.4	4.49	8.04e-06	0.000674	0.14	0.14	Aortic root size;	chr7:66275908	chr7:66902857~66906297:+
BRCA	cis	rs6430585	0.583	rs58116536	ENSG00000231890.6	DARS-AS1	-4.49	8.04e-06	0.000674	-0.21	-0.14	Corneal structure;	chr2:135827753	chr2:135985176~136022593:+
BRCA	cis	rs12612435	0.83	rs12995207	ENSG00000226806.1	AC011893.3	4.49	8.04e-06	0.000674	0.16	0.14	Takotsubo syndrome;	chr2:136368828	chr2:135820191~135823087:+
BRCA	cis	rs12612435	0.784	rs34594438	ENSG00000226806.1	AC011893.3	4.49	8.04e-06	0.000674	0.16	0.14	Takotsubo syndrome;	chr2:136368943	chr2:135820191~135823087:+
BRCA	cis	rs4664293	0.967	rs12999124	ENSG00000226266.5	AC009961.3	-4.49	8.05e-06	0.000675	-0.17	-0.14	Monocyte percentage of white cells;	chr2:159674817	chr2:159670708~159712435:-
BRCA	cis	rs2033711	0.503	rs6510141	ENSG00000269473.1	CTD-2619J13.19	-4.49	8.05e-06	0.000675	-0.16	-0.14	Uric acid clearance;	chr19:58374419	chr19:58440448~58445849:+
BRCA	cis	rs2708977	0.933	rs2579502	ENSG00000237510.6	AC008268.2	-4.49	8.05e-06	0.000675	-0.18	-0.14	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96533063	chr2:95789654~95800166:+
BRCA	cis	rs4650994	1	rs10798619	ENSG00000273384.1	RP5-1098D14.1	4.49	8.06e-06	0.000675	0.17	0.14	HDL cholesterol;HDL cholesterol levels;	chr1:178563382	chr1:178651706~178652282:+
BRCA	cis	rs853679	1	rs6905391	ENSG00000216901.1	AL022393.7	4.49	8.06e-06	0.000675	0.23	0.14	Depression;	chr6:28294909	chr6:28176188~28176674:+
BRCA	cis	rs2243480	0.901	rs35087093	ENSG00000222364.1	RNU6-96P	-4.49	8.06e-06	0.000676	-0.25	-0.14	Diabetic kidney disease;	chr7:65940221	chr7:66395191~66395286:+
BRCA	cis	rs7811142	0.943	rs111757992	ENSG00000078319.8	PMS2P1	-4.49	8.06e-06	0.000676	-0.21	-0.14	Platelet count;	chr7:100418731	chr7:100320992~100341908:-
BRCA	cis	rs7267979	1	rs2258719	ENSG00000276952.1	RP5-965G21.6	4.49	8.07e-06	0.000676	0.17	0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25295207	chr20:25284915~25285588:-
BRCA	cis	rs10129255	0.556	rs8010005	ENSG00000232216.1	IGHV3-43	4.49	8.07e-06	0.000676	0.1	0.14	Kawasaki disease;	chr14:106777987	chr14:106470264~106470800:-
BRCA	cis	rs10129255	0.556	rs6576224	ENSG00000232216.1	IGHV3-43	4.49	8.07e-06	0.000676	0.1	0.14	Kawasaki disease;	chr14:106777997	chr14:106470264~106470800:-
BRCA	cis	rs10129255	0.518	rs8010020	ENSG00000232216.1	IGHV3-43	4.49	8.07e-06	0.000676	0.1	0.14	Kawasaki disease;	chr14:106778016	chr14:106470264~106470800:-
BRCA	cis	rs9402743	0.635	rs9373135	ENSG00000234084.1	RP3-388E23.2	-4.49	8.07e-06	0.000676	-0.14	-0.14	Systemic lupus erythematosus;	chr6:135611101	chr6:135301568~135307158:+
BRCA	cis	rs9402743	0.564	rs9376113	ENSG00000234084.1	RP3-388E23.2	-4.49	8.07e-06	0.000676	-0.14	-0.14	Systemic lupus erythematosus;	chr6:135612254	chr6:135301568~135307158:+
BRCA	cis	rs9402743	0.671	rs6934482	ENSG00000234084.1	RP3-388E23.2	-4.49	8.07e-06	0.000676	-0.14	-0.14	Systemic lupus erythematosus;	chr6:135612363	chr6:135301568~135307158:+
BRCA	cis	rs9402743	0.671	rs9402724	ENSG00000234084.1	RP3-388E23.2	-4.49	8.07e-06	0.000676	-0.14	-0.14	Systemic lupus erythematosus;	chr6:135614046	chr6:135301568~135307158:+
BRCA	cis	rs9402743	0.564	rs2327649	ENSG00000234084.1	RP3-388E23.2	-4.49	8.07e-06	0.000676	-0.14	-0.14	Systemic lupus erythematosus;	chr6:135615097	chr6:135301568~135307158:+
BRCA	cis	rs728478	0.566	rs1451508	ENSG00000266992.1	DHX40P1	4.49	8.07e-06	0.000676	0.16	0.14	QT interval;	chr17:59399874	chr17:59976009~60002384:-
BRCA	cis	rs875971	0.545	rs1796219	ENSG00000273142.1	RP11-458F8.4	-4.49	8.07e-06	0.000676	-0.14	-0.14	Aortic root size;	chr7:66645977	chr7:66902857~66906297:+
BRCA	cis	rs2243480	1	rs35058610	ENSG00000222364.1	RNU6-96P	-4.49	8.07e-06	0.000677	-0.25	-0.14	Diabetic kidney disease;	chr7:65925938	chr7:66395191~66395286:+
BRCA	cis	rs6545883	0.965	rs10186325	ENSG00000270820.4	RP11-355B11.2	4.49	8.07e-06	0.000677	0.16	0.14	Tuberculosis;	chr2:61530586	chr2:61471188~61484130:+
BRCA	cis	rs6439153	0.743	rs71331685	ENSG00000261159.1	RP11-723O4.9	4.49	8.08e-06	0.000677	0.15	0.14	Pneumococcal bacteremia;	chr3:128992582	chr3:128859716~128860526:-
BRCA	cis	rs13113518	0.934	rs3805155	ENSG00000273257.1	RP11-177J6.1	4.49	8.08e-06	0.000677	0.18	0.14	Height;	chr4:55497842	chr4:55387949~55388271:+
BRCA	cis	rs516805	0.748	rs6930548	ENSG00000279453.1	RP3-425C14.4	-4.49	8.09e-06	0.000678	-0.19	-0.14	Lymphocyte counts;	chr6:122375807	chr6:122436789~122439223:-
BRCA	cis	rs12681366	0.537	rs2919664	ENSG00000253704.1	RP11-267M23.4	4.49	8.09e-06	0.000678	0.15	0.14	Nonsyndromic cleft lip with cleft palate;	chr8:94456485	chr8:94553722~94569745:+
BRCA	cis	rs35146811	0.883	rs4134903	ENSG00000214313.7	AZGP1P1	4.49	8.09e-06	0.000678	0.15	0.14	Coronary artery disease;	chr7:100113417	chr7:99980762~99987535:+
BRCA	cis	rs3764021	0.87	rs10844622	ENSG00000256673.1	RP11-599J14.2	-4.49	8.09e-06	0.000678	-0.15	-0.14	Type 1 diabetes;	chr12:9732486	chr12:9398355~9414851:-
BRCA	cis	rs1979679	0.918	rs3858544	ENSG00000278733.1	RP11-425D17.1	-4.49	8.09e-06	0.000678	-0.17	-0.14	Ossification of the posterior longitudinal ligament of the spine;	chr12:28442911	chr12:28185625~28186190:-
BRCA	cis	rs10129255	0.957	rs10142918	ENSG00000211974.3	IGHV2-70	4.49	8.1e-06	0.000679	0.14	0.14	Kawasaki disease;	chr14:106782206	chr14:106723574~106724093:-
BRCA	cis	rs934734	0.532	rs62141075	ENSG00000281920.1	RP11-418H16.1	-4.48	8.1e-06	0.000679	-0.16	-0.14	Rheumatoid arthritis;	chr2:65417482	chr2:65623272~65628424:+
BRCA	cis	rs10129255	0.556	rs9324093	ENSG00000224373.3	IGHV4-59	4.48	8.1e-06	0.000679	0.08	0.14	Kawasaki disease;	chr14:106683893	chr14:106627249~106627825:-
BRCA	cis	rs1005277	0.579	rs1780133	ENSG00000099251.13	HSD17B7P2	4.48	8.1e-06	0.000679	0.15	0.14	Extrinsic epigenetic age acceleration;	chr10:38210581	chr10:38356380~38378505:+
BRCA	cis	rs6445975	0.726	rs6764512	ENSG00000272360.1	RP11-359I18.5	4.48	8.11e-06	0.000679	0.15	0.14	Systemic lupus erythematosus;	chr3:58482509	chr3:58490830~58491291:-
BRCA	cis	rs56322409	0.897	rs4568937	ENSG00000226688.5	ENTPD1-AS1	4.48	8.11e-06	0.000679	0.16	0.14	Blood metabolite levels;	chr10:95742840	chr10:95753206~96090238:-
BRCA	cis	rs1008375	1	rs6846238	ENSG00000249502.1	AC006160.5	-4.48	8.11e-06	0.000679	-0.16	-0.14	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17628316	chr4:17587467~17614571:-
BRCA	cis	rs1018697	0.518	rs2250301	ENSG00000236937.2	PTGES3P4	-4.48	8.11e-06	0.00068	-0.21	-0.14	Colorectal adenoma (advanced);	chr10:102788636	chr10:102845595~102845950:+
BRCA	cis	rs926392	1	rs2867898	ENSG00000274825.1	RP4-616B8.5	-4.48	8.11e-06	0.00068	-0.13	-0.14	Dialysis-related mortality;	chr20:39062309	chr20:38955910~38956547:+
BRCA	cis	rs2243480	1	rs78803505	ENSG00000222364.1	RNU6-96P	-4.48	8.11e-06	0.00068	-0.25	-0.14	Diabetic kidney disease;	chr7:65917585	chr7:66395191~66395286:+
BRCA	cis	rs2243480	1	rs34577383	ENSG00000222364.1	RNU6-96P	-4.48	8.11e-06	0.00068	-0.25	-0.14	Diabetic kidney disease;	chr7:65920739	chr7:66395191~66395286:+
BRCA	cis	rs2243480	1	rs55895244	ENSG00000222364.1	RNU6-96P	-4.48	8.11e-06	0.00068	-0.25	-0.14	Diabetic kidney disease;	chr7:65922691	chr7:66395191~66395286:+
BRCA	cis	rs2243480	1	rs7795242	ENSG00000222364.1	RNU6-96P	-4.48	8.11e-06	0.00068	-0.25	-0.14	Diabetic kidney disease;	chr7:65925107	chr7:66395191~66395286:+
BRCA	cis	rs2243480	1	rs2177703	ENSG00000222364.1	RNU6-96P	-4.48	8.11e-06	0.00068	-0.25	-0.14	Diabetic kidney disease;	chr7:65926730	chr7:66395191~66395286:+
BRCA	cis	rs2243480	1	rs56985706	ENSG00000222364.1	RNU6-96P	-4.48	8.11e-06	0.00068	-0.25	-0.14	Diabetic kidney disease;	chr7:65929575	chr7:66395191~66395286:+
BRCA	cis	rs2243480	1	rs60683927	ENSG00000222364.1	RNU6-96P	-4.48	8.11e-06	0.00068	-0.25	-0.14	Diabetic kidney disease;	chr7:65929781	chr7:66395191~66395286:+
BRCA	cis	rs2243480	1	rs58062456	ENSG00000222364.1	RNU6-96P	-4.48	8.11e-06	0.00068	-0.25	-0.14	Diabetic kidney disease;	chr7:65929865	chr7:66395191~66395286:+
BRCA	cis	rs853679	0.769	rs17720293	ENSG00000219392.1	RP1-265C24.5	-4.48	8.12e-06	0.00068	-0.32	-0.14	Depression;	chr6:28246920	chr6:28115628~28116551:+
BRCA	cis	rs11048434	0.518	rs34651717	ENSG00000256937.1	KRT17P8	-4.48	8.12e-06	0.00068	-0.15	-0.14	Sjögren's syndrome;	chr12:9025154	chr12:9127783~9128645:+
BRCA	cis	rs11048434	0.518	rs35176717	ENSG00000256937.1	KRT17P8	-4.48	8.12e-06	0.00068	-0.15	-0.14	Sjögren's syndrome;	chr12:9025170	chr12:9127783~9128645:+
BRCA	cis	rs11048434	0.518	rs34533518	ENSG00000256937.1	KRT17P8	-4.48	8.12e-06	0.00068	-0.15	-0.14	Sjögren's syndrome;	chr12:9025302	chr12:9127783~9128645:+
BRCA	cis	rs2273156	1	rs56686328	ENSG00000226677.3	IGBP1P1	-4.48	8.12e-06	0.00068	-0.2	-0.14	Immunoglobulin light chain (AL) amyloidosis;	chr14:34988864	chr14:34939324~34940332:+
BRCA	cis	rs35146811	0.695	rs1623264	ENSG00000235713.1	RP4-604G5.3	-4.48	8.12e-06	0.00068	-0.16	-0.14	Coronary artery disease;	chr7:100213581	chr7:99992397~99993050:+
BRCA	cis	rs3768617	0.528	rs3736888	ENSG00000224468.3	RP11-181K3.4	-4.48	8.12e-06	0.00068	-0.15	-0.14	Fuchs's corneal dystrophy;	chr1:183115472	chr1:183138402~183141282:-
BRCA	cis	rs3768617	0.528	rs2027082	ENSG00000224468.3	RP11-181K3.4	-4.48	8.12e-06	0.00068	-0.15	-0.14	Fuchs's corneal dystrophy;	chr1:183115473	chr1:183138402~183141282:-
BRCA	cis	rs72843506	0.656	rs80250684	ENSG00000261033.1	RP11-209D14.2	4.48	8.12e-06	0.00068	0.25	0.14	Schizophrenia;	chr17:20054983	chr17:20008051~20009234:-
BRCA	cis	rs72843506	0.586	rs75048432	ENSG00000261033.1	RP11-209D14.2	4.48	8.12e-06	0.00068	0.25	0.14	Schizophrenia;	chr17:20057571	chr17:20008051~20009234:-
BRCA	cis	rs73186030	0.92	rs73186060	ENSG00000272758.4	RP11-299J3.8	4.48	8.12e-06	0.00068	0.21	0.14	Serum parathyroid hormone levels;	chr3:122333507	chr3:122416207~122443180:+
BRCA	cis	rs73186030	0.841	rs112779893	ENSG00000272758.4	RP11-299J3.8	4.48	8.12e-06	0.00068	0.21	0.14	Serum parathyroid hormone levels;	chr3:122334433	chr3:122416207~122443180:+
BRCA	cis	rs2273156	1	rs12897612	ENSG00000226677.3	IGBP1P1	-4.48	8.12e-06	0.00068	-0.2	-0.14	Immunoglobulin light chain (AL) amyloidosis;	chr14:35001941	chr14:34939324~34940332:+
BRCA	cis	rs10504130	0.569	rs12676345	ENSG00000272024.1	RP11-546K22.3	-4.48	8.12e-06	0.00068	-0.2	-0.14	Venous thromboembolism (SNP x SNP interaction);	chr8:51773249	chr8:51950284~51950690:+
BRCA	cis	rs721917	0.525	rs2258874	ENSG00000242600.5	MBL1P	4.48	8.13e-06	0.00068	0.17	0.14	Chronic obstructive pulmonary disease;	chr10:79919400	chr10:79904898~79950336:+
BRCA	cis	rs875971	0.964	rs697969	ENSG00000236529.1	RP13-254B10.1	-4.48	8.13e-06	0.000681	-0.15	-0.14	Aortic root size;	chr7:66093491	chr7:65840212~65840596:+
BRCA	cis	rs875971	1	rs1182882	ENSG00000236529.1	RP13-254B10.1	-4.48	8.13e-06	0.000681	-0.15	-0.14	Aortic root size;	chr7:66097076	chr7:65840212~65840596:+
BRCA	cis	rs957448	0.561	rs7459558	ENSG00000253175.1	RP11-267M23.6	4.48	8.13e-06	0.000681	0.16	0.14	Nonsyndromic cleft lip with cleft palate;	chr8:94598618	chr8:94565036~94565715:+
BRCA	cis	rs12477438	0.52	rs13031919	ENSG00000231822.1	AC019097.7	4.48	8.13e-06	0.000681	0.14	0.14	Chronic sinus infection;	chr2:99232469	chr2:99102018~99102752:+
BRCA	cis	rs1005277	0.579	rs2749612	ENSG00000099251.13	HSD17B7P2	4.48	8.13e-06	0.000681	0.15	0.14	Extrinsic epigenetic age acceleration;	chr10:38199682	chr10:38356380~38378505:+
BRCA	cis	rs8040855	0.627	rs17541051	ENSG00000230373.7	GOLGA6L5P	4.48	8.13e-06	0.000681	0.18	0.14	Bulimia nervosa;	chr15:85106122	chr15:84507885~84516814:-
BRCA	cis	rs7914558	0.646	rs7897654	ENSG00000213061.2	PFN1P11	4.48	8.13e-06	0.000681	0.19	0.14	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102902701	chr10:102838011~102845473:-
BRCA	cis	rs2832191	0.716	rs9983051	ENSG00000215533.7	LINC00189	-4.48	8.13e-06	0.000681	-0.16	-0.14	Dental caries;	chr21:28999569	chr21:29193480~29288205:+
BRCA	cis	rs7267979	0.932	rs928121	ENSG00000125804.12	FAM182A	-4.48	8.14e-06	0.000681	-0.18	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25554182	chr20:26054655~26086917:+
BRCA	cis	rs700651	0.789	rs1976772	ENSG00000231621.1	AC013264.2	-4.48	8.14e-06	0.000682	-0.13	-0.14	Intracranial aneurysm;	chr2:198003477	chr2:197197991~197199273:+
BRCA	cis	rs2115630	1	rs11073730	ENSG00000259728.4	LINC00933	-4.48	8.14e-06	0.000682	-0.15	-0.14	P wave terminal force;	chr15:84811365	chr15:84570649~84580175:+
BRCA	cis	rs6928977	0.5	rs12211833	ENSG00000234084.1	RP3-388E23.2	-4.48	8.14e-06	0.000682	-0.14	-0.14	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135629066	chr6:135301568~135307158:+
BRCA	cis	rs9467773	0.62	rs2504571	ENSG00000241549.7	GUSBP2	4.48	8.15e-06	0.000682	0.15	0.14	Intelligence (multi-trait analysis);	chr6:26643207	chr6:26871484~26956554:-
BRCA	cis	rs2562456	0.833	rs2928211	ENSG00000213976.4	CTD-2561J22.2	4.48	8.15e-06	0.000682	0.17	0.14	Pain;	chr19:21358495	chr19:21382865~21387177:+
BRCA	cis	rs9402743	0.671	rs9376115	ENSG00000234084.1	RP3-388E23.2	4.48	8.15e-06	0.000682	0.14	0.14	Systemic lupus erythematosus;	chr6:135616579	chr6:135301568~135307158:+
BRCA	cis	rs875971	0.545	rs67397473	ENSG00000273142.1	RP11-458F8.4	4.48	8.15e-06	0.000682	0.13	0.14	Aortic root size;	chr7:66168318	chr7:66902857~66906297:+
BRCA	cis	rs3764021	0.933	rs10492165	ENSG00000256673.1	RP11-599J14.2	-4.48	8.15e-06	0.000683	-0.15	-0.14	Type 1 diabetes;	chr12:9733365	chr12:9398355~9414851:-
BRCA	cis	rs2832191	0.703	rs2853827	ENSG00000232855.5	AF131217.1	-4.48	8.15e-06	0.000683	-0.17	-0.14	Dental caries;	chr21:29071275	chr21:28439346~28674848:-
BRCA	cis	rs13108904	0.901	rs1316394	ENSG00000253399.1	AC078852.2	-4.48	8.16e-06	0.000683	-0.16	-0.14	Obesity-related traits;	chr4:1322032	chr4:1358479~1359461:+
BRCA	cis	rs13108904	0.934	rs13115173	ENSG00000253399.1	AC078852.2	-4.48	8.16e-06	0.000683	-0.16	-0.14	Obesity-related traits;	chr4:1323036	chr4:1358479~1359461:+
BRCA	cis	rs1953600	0.805	rs2819947	ENSG00000226659.1	RP11-137H2.4	4.48	8.16e-06	0.000683	0.18	0.14	Sarcoidosis;	chr10:80188001	chr10:80529597~80535942:-
BRCA	cis	rs6671200	0.831	rs71654413	ENSG00000235501.4	RP4-639F20.1	-4.48	8.16e-06	0.000683	-0.32	-0.14	Stearic acid (18:0) levels;	chr1:95141532	chr1:94927566~94963270:+
BRCA	cis	rs17507216	0.718	rs7161977	ENSG00000259429.4	UBE2Q2P2	-4.48	8.16e-06	0.000683	-0.18	-0.14	Excessive daytime sleepiness;	chr15:82646782	chr15:82355142~82420075:+
BRCA	cis	rs2153535	0.607	rs9502722	ENSG00000251164.1	HULC	-4.48	8.17e-06	0.000683	-0.17	-0.14	Motion sickness;	chr6:8541250	chr6:8652137~8653846:+
BRCA	cis	rs9425766	0.64	rs2281486	ENSG00000200674.1	RN7SKP160	4.48	8.17e-06	0.000684	0.22	0.14	Life satisfaction;	chr1:173853083	chr1:173791548~173791887:+
BRCA	cis	rs9425766	0.64	rs16846439	ENSG00000200674.1	RN7SKP160	4.48	8.17e-06	0.000684	0.22	0.14	Life satisfaction;	chr1:173854900	chr1:173791548~173791887:+
BRCA	cis	rs4835473	0.932	rs10016223	ENSG00000249741.2	RP11-673E1.3	-4.48	8.17e-06	0.000684	-0.14	-0.14	Immature fraction of reticulocytes;	chr4:143777429	chr4:143911514~143912053:-
BRCA	cis	rs6708331	1	rs35734267	ENSG00000231024.1	AC092431.3	-4.48	8.17e-06	0.000684	-0.2	-0.14	Obesity-related traits;	chr2:70054058	chr2:69700192~69713847:-
BRCA	cis	rs6452524	1	rs6864479	ENSG00000281327.1	LINC01338	4.48	8.17e-06	0.000684	0.16	0.14	Hypertension (SNP x SNP interaction);	chr5:83166421	chr5:82850864~82859836:-
BRCA	cis	rs7811142	1	rs28490152	ENSG00000078319.8	PMS2P1	-4.48	8.17e-06	0.000684	-0.21	-0.14	Platelet count;	chr7:100423359	chr7:100320992~100341908:-
BRCA	cis	rs10504130	0.932	rs75990306	ENSG00000272024.1	RP11-546K22.3	-4.48	8.18e-06	0.000685	-0.24	-0.14	Venous thromboembolism (SNP x SNP interaction);	chr8:51837641	chr8:51950284~51950690:+
BRCA	cis	rs7246657	0.722	rs954504	ENSG00000226686.6	LINC01535	-4.48	8.18e-06	0.000685	-0.2	-0.14	Coronary artery calcification;	chr19:37554492	chr19:37251912~37265535:+
BRCA	cis	rs7246657	0.722	rs8110865	ENSG00000226686.6	LINC01535	-4.48	8.18e-06	0.000685	-0.2	-0.14	Coronary artery calcification;	chr19:37556485	chr19:37251912~37265535:+
BRCA	cis	rs7246657	0.678	rs4802024	ENSG00000226686.6	LINC01535	-4.48	8.18e-06	0.000685	-0.2	-0.14	Coronary artery calcification;	chr19:37561291	chr19:37251912~37265535:+
BRCA	cis	rs7246657	0.722	rs4802029	ENSG00000226686.6	LINC01535	-4.48	8.18e-06	0.000685	-0.2	-0.14	Coronary artery calcification;	chr19:37564710	chr19:37251912~37265535:+
BRCA	cis	rs7246657	0.722	rs28512414	ENSG00000226686.6	LINC01535	-4.48	8.18e-06	0.000685	-0.2	-0.14	Coronary artery calcification;	chr19:37565672	chr19:37251912~37265535:+
BRCA	cis	rs7246657	0.722	rs6508736	ENSG00000226686.6	LINC01535	-4.48	8.18e-06	0.000685	-0.2	-0.14	Coronary artery calcification;	chr19:37570855	chr19:37251912~37265535:+
BRCA	cis	rs7811142	0.943	rs28660238	ENSG00000078319.8	PMS2P1	-4.48	8.18e-06	0.000685	-0.21	-0.14	Platelet count;	chr7:100425685	chr7:100320992~100341908:-
BRCA	cis	rs10829156	0.898	rs7095666	ENSG00000240291.1	RP11-499P20.2	-4.48	8.19e-06	0.000685	-0.15	-0.14	Sudden cardiac arrest;	chr10:18650538	chr10:18513115~18545651:-
BRCA	cis	rs6545883	0.894	rs778144	ENSG00000212978.6	AC016747.3	-4.48	8.19e-06	0.000685	-0.18	-0.14	Tuberculosis;	chr2:61355993	chr2:61141592~61144969:-
BRCA	cis	rs4143844	1	rs12909386	ENSG00000259251.2	RP11-643M14.1	4.48	8.19e-06	0.000685	0.33	0.14	Bipolar disorder and schizophrenia;	chr15:62040700	chr15:62060503~62062434:+
BRCA	cis	rs7620503	0.729	rs13082698	ENSG00000228221.4	LINC00578	4.48	8.19e-06	0.000685	0.18	0.14	Corneal structure;	chr3:177588160	chr3:177441921~177752305:+
BRCA	cis	rs7481584	0.624	rs436580	ENSG00000247473.2	CARS-AS1	-4.48	8.19e-06	0.000685	-0.16	-0.14	Calcium levels;	chr11:3042731	chr11:3029009~3041260:+
BRCA	cis	rs17684571	0.637	rs34359353	ENSG00000231441.1	RP11-472M19.2	4.48	8.19e-06	0.000685	0.22	0.14	Schizophrenia;	chr6:56800963	chr6:56844002~56864078:+
BRCA	cis	rs300890	0.56	rs6844866	ENSG00000250326.1	RP11-284M14.1	4.48	8.19e-06	0.000686	0.16	0.14	Nasopharyngeal carcinoma;	chr4:143265304	chr4:142933195~143184861:-
BRCA	cis	rs983392	0.667	rs632185	ENSG00000275344.1	MIR6503	4.48	8.19e-06	0.000686	0.14	0.14	Alzheimer's disease (late onset);	chr11:60183960	chr11:60209071~60209156:-
BRCA	cis	rs4948275	0.693	rs2787713	ENSG00000237233.2	TMEM26-AS1	4.48	8.2e-06	0.000686	0.16	0.14	Night sleep phenotypes;	chr10:61558446	chr10:61452639~61481956:+
BRCA	cis	rs9990343	0.748	rs11130087	ENSG00000223552.1	RP11-24F11.2	-4.48	8.2e-06	0.000686	-0.13	-0.14	Brain structure;	chr3:46293138	chr3:46364955~46407059:-
BRCA	cis	rs11955398	0.502	rs290514	ENSG00000272308.1	RP11-231G3.1	-4.48	8.2e-06	0.000686	-0.16	-0.14	Intelligence (multi-trait analysis);	chr5:60934494	chr5:60866457~60866935:-
BRCA	cis	rs1484642	0.881	rs7005350	ENSG00000272505.1	RP11-981G7.6	-4.48	8.2e-06	0.000686	-0.21	-0.14	Bipolar disorder and schizophrenia;	chr8:10132588	chr8:10486807~10489666:+
BRCA	cis	rs3617	0.625	rs56019197	ENSG00000279144.1	RP11-894J14.2	-4.48	8.2e-06	0.000686	-0.17	-0.14	Red blood cell count;Autism spectrum disorder or schizophrenia;	chr3:52840737	chr3:52848085~52848553:-
BRCA	cis	rs754466	0.561	rs67332822	ENSG00000204049.1	RP11-126H7.4	4.48	8.21e-06	0.000687	0.23	0.14	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77946360	chr10:77866875~77869610:+
BRCA	cis	rs6686842	0.56	rs10889885	ENSG00000235358.1	RP11-399E6.1	-4.48	8.21e-06	0.000687	-0.19	-0.14	Height;	chr1:41199081	chr1:41242373~41284861:+
BRCA	cis	rs1722141	0.669	rs788743	ENSG00000229628.1	AC073115.7	4.48	8.21e-06	0.000687	0.18	0.14	Sitting height ratio;	chr7:45997886	chr7:45990905~46000898:+
BRCA	cis	rs2243480	0.808	rs12698508	ENSG00000275400.1	RP4-756H11.5	4.48	8.21e-06	0.000687	0.25	0.14	Diabetic kidney disease;	chr7:65946971	chr7:66553805~66554199:-
BRCA	cis	rs11048434	0.518	rs7311267	ENSG00000256937.1	KRT17P8	4.48	8.21e-06	0.000687	0.14	0.14	Sjögren's syndrome;	chr12:9026082	chr12:9127783~9128645:+
BRCA	cis	rs1510272	0.81	rs907059	ENSG00000243926.1	TIPARP-AS1	-4.48	8.21e-06	0.000687	-0.16	-0.14	Testicular germ cell tumor;	chr3:156574572	chr3:156671862~156674378:-
BRCA	cis	rs9990343	0.715	rs11922338	ENSG00000223552.1	RP11-24F11.2	-4.48	8.22e-06	0.000687	-0.13	-0.14	Brain structure;	chr3:46292869	chr3:46364955~46407059:-
BRCA	cis	rs7572733	0.935	rs771016	ENSG00000231621.1	AC013264.2	-4.48	8.22e-06	0.000688	-0.13	-0.14	Dermatomyositis;	chr2:197800796	chr2:197197991~197199273:+
BRCA	cis	rs459482	0.504	rs469390	ENSG00000228318.3	AP001610.5	-4.48	8.22e-06	0.000688	-0.15	-0.14	IgG glycosylation;	chr21:41446003	chr21:41441056~41445708:-
BRCA	cis	rs651907	0.535	rs58658478	ENSG00000256628.3	ZBTB11-AS1	4.48	8.22e-06	0.000688	0.18	0.14	Colorectal cancer;	chr3:101792823	chr3:101676475~101679217:+
BRCA	cis	rs72799341	0.706	rs11865499	ENSG00000279196.1	RP11-1072A3.3	4.48	8.22e-06	0.000688	0.15	0.14	Diastolic blood pressure;	chr16:31120929	chr16:30984630~30988270:-
BRCA	cis	rs1005277	0.505	rs719569	ENSG00000226578.1	RP11-258F22.1	4.48	8.23e-06	0.000688	0.15	0.14	Extrinsic epigenetic age acceleration;	chr10:37865487	chr10:37775371~37784131:-
BRCA	cis	rs3733585	0.579	rs4235353	ENSG00000250413.1	RP11-448G15.1	4.48	8.23e-06	0.000688	0.19	0.14	Cleft plate (environmental tobacco smoke interaction);	chr4:10121310	chr4:10006482~10009725:+
BRCA	cis	rs3733585	0.605	rs4235354	ENSG00000250413.1	RP11-448G15.1	4.48	8.23e-06	0.000688	0.19	0.14	Cleft plate (environmental tobacco smoke interaction);	chr4:10121318	chr4:10006482~10009725:+
BRCA	cis	rs6012564	0.964	rs6125547	ENSG00000227431.4	CSE1L-AS1	4.48	8.23e-06	0.000688	0.18	0.14	Anger;	chr20:49100868	chr20:49040463~49046044:-
BRCA	cis	rs11098499	0.908	rs2017057	ENSG00000225892.3	RP11-384K6.2	4.48	8.23e-06	0.000688	0.14	0.14	Corneal astigmatism;	chr4:119336556	chr4:118632274~118634759:+
BRCA	cis	rs1005277	0.579	rs2103938	ENSG00000099251.13	HSD17B7P2	4.48	8.23e-06	0.000688	0.15	0.14	Extrinsic epigenetic age acceleration;	chr10:38205070	chr10:38356380~38378505:+
BRCA	cis	rs644148	0.704	rs2686761	ENSG00000176761.7	ZNF285B	4.48	8.23e-06	0.000688	0.16	0.14	Personality dimensions;	chr19:44485541	chr19:44467641~44473227:+
BRCA	cis	rs2839186	0.807	rs2032226	ENSG00000239415.1	AP001469.9	4.48	8.23e-06	0.000689	0.15	0.14	Testicular germ cell tumor;	chr21:46260438	chr21:46251549~46254133:-
BRCA	cis	rs1538970	0.781	rs12049503	ENSG00000281133.1	AL355480.3	-4.48	8.23e-06	0.000689	-0.2	-0.14	Platelet count;	chr1:45555884	chr1:45580892~45580996:-
BRCA	cis	rs7618915	0.501	rs7622694	ENSG00000243224.1	RP5-1157M23.2	-4.48	8.24e-06	0.000689	-0.15	-0.14	Bipolar disorder;	chr3:52629866	chr3:52239258~52241097:+
BRCA	cis	rs295490	0.748	rs74340696	ENSG00000272656.1	RP11-219D15.3	4.48	8.24e-06	0.000689	0.35	0.14	PR interval in Tripanosoma cruzi seropositivity;	chr3:139341859	chr3:139349024~139349371:-
BRCA	cis	rs2617170	0.922	rs11838084	ENSG00000245648.1	RP11-277P12.20	-4.48	8.24e-06	0.000689	-0.18	-0.14	Behcet's disease;	chr12:10427704	chr12:10363769~10398506:+
BRCA	cis	rs2109514	0.902	rs7810505	ENSG00000237813.3	AC002066.1	4.48	8.24e-06	0.000689	0.16	0.14	Prevalent atrial fibrillation;	chr7:116471024	chr7:116238260~116499465:-
BRCA	cis	rs35740288	0.77	rs4843085	ENSG00000202081.1	RNU6-1280P	4.48	8.24e-06	0.000689	0.18	0.14	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85615268	chr15:85651522~85651628:-
BRCA	cis	rs7267979	0.873	rs7453	ENSG00000204556.4	CTD-2514C3.1	-4.48	8.24e-06	0.000689	-0.19	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25226438	chr20:26018832~26020684:+
BRCA	cis	rs1008375	1	rs4698635	ENSG00000249502.1	AC006160.5	-4.48	8.24e-06	0.000689	-0.16	-0.14	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17628619	chr4:17587467~17614571:-
BRCA	cis	rs6012564	0.826	rs2869715	ENSG00000227431.4	CSE1L-AS1	4.48	8.24e-06	0.000689	0.17	0.14	Anger;	chr20:49143463	chr20:49040463~49046044:-
BRCA	cis	rs6012564	0.793	rs6066979	ENSG00000227431.4	CSE1L-AS1	4.48	8.24e-06	0.000689	0.17	0.14	Anger;	chr20:49144319	chr20:49040463~49046044:-
BRCA	cis	rs6012564	0.762	rs6066980	ENSG00000227431.4	CSE1L-AS1	4.48	8.24e-06	0.000689	0.17	0.14	Anger;	chr20:49144320	chr20:49040463~49046044:-
BRCA	cis	rs711830	1	rs711830	ENSG00000226363.3	HAGLROS	4.48	8.25e-06	0.00069	0.2	0.14	Serous invasive ovarian cancer;Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;High-grade serous ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;	chr2:176172583	chr2:176177717~176179008:+
BRCA	cis	rs7226408	0.842	rs62083201	ENSG00000267707.2	RP11-95O2.5	4.48	8.25e-06	0.00069	0.23	0.14	Obesity-related traits;	chr18:36767873	chr18:37243776~37247506:+
BRCA	cis	rs6802315	0.604	rs2364927	ENSG00000272247.1	RP11-379F4.9	-4.48	8.25e-06	0.00069	-0.16	-0.14	Periodontitis (CDC/AAP);	chr3:158760066	chr3:158801257~158801935:-
BRCA	cis	rs7833986	0.501	rs2976012	ENSG00000253603.1	CTA-397H3.3	-4.48	8.25e-06	0.00069	-0.2	-0.14	Height;	chr8:56061784	chr8:56074592~56075274:+
BRCA	cis	rs7833986	0.501	rs2953922	ENSG00000253603.1	CTA-397H3.3	-4.48	8.25e-06	0.00069	-0.2	-0.14	Height;	chr8:56064926	chr8:56074592~56075274:+
BRCA	cis	rs7833986	0.501	rs2953897	ENSG00000253603.1	CTA-397H3.3	-4.48	8.25e-06	0.00069	-0.2	-0.14	Height;	chr8:56068010	chr8:56074592~56075274:+
BRCA	cis	rs7833986	0.501	rs2953901	ENSG00000253603.1	CTA-397H3.3	-4.48	8.25e-06	0.00069	-0.2	-0.14	Height;	chr8:56069265	chr8:56074592~56075274:+
BRCA	cis	rs370915	0.963	rs59452206	ENSG00000250971.1	RP11-696F12.1	4.48	8.25e-06	0.00069	0.15	0.14	Gout;	chr4:186895330	chr4:187060099~187060930:+
BRCA	cis	rs7927592	0.763	rs3740628	ENSG00000212093.1	AP000807.1	4.48	8.25e-06	0.00069	0.14	0.14	Total body bone mineral density;	chr11:68613947	chr11:68506083~68506166:-
BRCA	cis	rs1858037	0.867	rs1553675	ENSG00000281920.1	RP11-418H16.1	-4.48	8.25e-06	0.00069	-0.17	-0.14	Rheumatoid arthritis;	chr2:65343173	chr2:65623272~65628424:+
BRCA	cis	rs11098499	0.954	rs71629403	ENSG00000260091.1	RP11-33B1.4	-4.48	8.25e-06	0.00069	-0.12	-0.14	Corneal astigmatism;	chr4:119451412	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.909	rs28571712	ENSG00000260091.1	RP11-33B1.4	-4.48	8.25e-06	0.00069	-0.12	-0.14	Corneal astigmatism;	chr4:119454825	chr4:119409333~119410233:+
BRCA	cis	rs867186	1	rs79048371	ENSG00000126005.14	MMP24-AS1	-4.48	8.26e-06	0.000691	-0.27	-0.14	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35143681	chr20:35216462~35278131:-
BRCA	cis	rs6596100	0.915	rs57060554	ENSG00000248648.1	RP11-485M7.1	-4.48	8.26e-06	0.000691	-0.18	-0.14	Breast cancer;	chr5:133068195	chr5:133003119~133003365:+
BRCA	cis	rs853679	0.513	rs13437444	ENSG00000216901.1	AL022393.7	4.48	8.27e-06	0.000691	0.23	0.14	Depression;	chr6:28103220	chr6:28176188~28176674:+
BRCA	cis	rs2411233	0.713	rs11070169	ENSG00000259278.1	RP11-62C7.2	-4.48	8.27e-06	0.000691	-0.16	-0.14	Platelet count;	chr15:39027810	chr15:39019233~39024918:+
BRCA	cis	rs442309	0.812	rs224123	ENSG00000238280.1	RP11-436D10.3	-4.48	8.27e-06	0.000691	-0.19	-0.14	Vogt-Koyanagi-Harada syndrome;	chr10:62691473	chr10:62793562~62805887:-
BRCA	cis	rs828999	0.583	rs10494090	ENSG00000280186.1	RP11-483I13.6	-4.48	8.27e-06	0.000692	-0.16	-0.14	Monocyte percentage of white cells;	chr1:108150714	chr1:108200413~108202743:+
BRCA	cis	rs6686842	1	rs6600365	ENSG00000235358.1	RP11-399E6.1	-4.48	8.28e-06	0.000692	-0.17	-0.14	Height;	chr1:41090581	chr1:41242373~41284861:+
BRCA	cis	rs867186	1	rs117316403	ENSG00000126005.14	MMP24-AS1	-4.48	8.28e-06	0.000692	-0.26	-0.14	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35105372	chr20:35216462~35278131:-
BRCA	cis	rs7487075	0.93	rs11183468	ENSG00000272369.1	RP11-446N19.1	4.48	8.28e-06	0.000692	0.15	0.14	Itch intensity from mosquito bite;	chr12:46412478	chr12:46537502~46652550:+
BRCA	cis	rs854765	0.583	rs2350977	ENSG00000281749.1	Y_RNA	4.48	8.28e-06	0.000692	0.15	0.14	Total body bone mineral density;	chr17:17899465	chr17:18001101~18001195:-
BRCA	cis	rs8040855	0.627	rs4980357	ENSG00000230373.7	GOLGA6L5P	4.48	8.28e-06	0.000692	0.18	0.14	Bulimia nervosa;	chr15:85064878	chr15:84507885~84516814:-
BRCA	cis	rs8040855	0.627	rs4980356	ENSG00000230373.7	GOLGA6L5P	4.48	8.28e-06	0.000692	0.18	0.14	Bulimia nervosa;	chr15:85064901	chr15:84507885~84516814:-
BRCA	cis	rs11098499	0.954	rs10017371	ENSG00000250412.1	KLHL2P1	4.48	8.28e-06	0.000693	0.17	0.14	Corneal astigmatism;	chr4:119372621	chr4:119334329~119378233:+
BRCA	cis	rs8177876	0.749	rs11537	ENSG00000245059.2	RP11-303E16.7	4.48	8.29e-06	0.000693	0.3	0.14	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81046894	chr16:81077319~81078861:+
BRCA	cis	rs9990333	0.562	rs55970879	ENSG00000242086.7	LINC00969	4.48	8.29e-06	0.000693	0.16	0.14	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196095095	chr3:195658062~195739964:+
BRCA	cis	rs10911902	0.643	rs111828305	ENSG00000229739.2	RP11-295K2.3	-4.48	8.29e-06	0.000693	-0.22	-0.14	Schizophrenia;	chr1:186393069	chr1:186435161~186470291:+
BRCA	cis	rs2070615	0.525	rs1532365	ENSG00000257964.1	RP11-133N21.10	4.48	8.29e-06	0.000693	0.15	0.14	Bipolar disorder;	chr12:48810638	chr12:49576840~49577505:-
BRCA	cis	rs7833790	0.927	rs61020899	ENSG00000254689.1	RP11-354A14.1	-4.48	8.3e-06	0.000694	-0.19	-0.14	Diastolic blood pressure;	chr8:81844855	chr8:81885377~81923193:+
BRCA	cis	rs13113518	1	rs6847529	ENSG00000272969.1	RP11-528I4.2	4.48	8.3e-06	0.000694	0.16	0.14	Height;	chr4:55518776	chr4:55547112~55547889:+
BRCA	cis	rs13113518	1	rs6822740	ENSG00000272969.1	RP11-528I4.2	4.48	8.3e-06	0.000694	0.16	0.14	Height;	chr4:55518922	chr4:55547112~55547889:+
BRCA	cis	rs11158026	0.603	rs66769866	ENSG00000258413.1	RP11-665C16.6	-4.48	8.3e-06	0.000694	-0.18	-0.14	Parkinson's disease;	chr14:54979435	chr14:55262767~55272075:-
BRCA	cis	rs11158026	0.603	rs7151670	ENSG00000258413.1	RP11-665C16.6	-4.48	8.3e-06	0.000694	-0.18	-0.14	Parkinson's disease;	chr14:54986041	chr14:55262767~55272075:-
BRCA	cis	rs10411936	0.692	rs62118141	ENSG00000280332.1	CTD-2013N17.6	4.48	8.3e-06	0.000694	0.12	0.14	Multiple sclerosis;White blood cell count;	chr19:16491997	chr19:16356329~16358327:-
BRCA	cis	rs4356203	0.87	rs214925	ENSG00000272034.1	SNORD14A	-4.48	8.3e-06	0.000694	-0.14	-0.14	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17213037	chr11:17074654~17074744:-
BRCA	cis	rs4713675	0.546	rs791903	ENSG00000224557.6	HLA-DPB2	4.48	8.3e-06	0.000694	0.16	0.14	Plateletcrit;	chr6:33734868	chr6:33112451~33129084:+
BRCA	cis	rs2562456	0.876	rs7252585	ENSG00000213976.4	CTD-2561J22.2	4.48	8.3e-06	0.000694	0.15	0.14	Pain;	chr19:21475141	chr19:21382865~21387177:+
BRCA	cis	rs9393777	0.92	rs34071253	ENSG00000216901.1	AL022393.7	4.48	8.31e-06	0.000694	0.31	0.14	Intelligence (multi-trait analysis);	chr6:27424023	chr6:28176188~28176674:+
BRCA	cis	rs67981189	0.593	rs2240341	ENSG00000258571.1	PTTG4P	4.48	8.31e-06	0.000694	0.15	0.14	Schizophrenia;	chr14:70906863	chr14:71085482~71085833:-
BRCA	cis	rs1005277	0.579	rs2472181	ENSG00000263064.2	RP11-291L22.7	4.48	8.31e-06	0.000694	0.17	0.14	Extrinsic epigenetic age acceleration;	chr10:38097836	chr10:38448689~38448949:+
BRCA	cis	rs1005277	0.579	rs2474574	ENSG00000263064.2	RP11-291L22.7	4.48	8.31e-06	0.000694	0.17	0.14	Extrinsic epigenetic age acceleration;	chr10:38098367	chr10:38448689~38448949:+
BRCA	cis	rs1005277	0.579	rs2504140	ENSG00000263064.2	RP11-291L22.7	4.48	8.31e-06	0.000694	0.17	0.14	Extrinsic epigenetic age acceleration;	chr10:38098651	chr10:38448689~38448949:+
BRCA	cis	rs1005277	0.579	rs2472182	ENSG00000263064.2	RP11-291L22.7	4.48	8.31e-06	0.000694	0.17	0.14	Extrinsic epigenetic age acceleration;	chr10:38099937	chr10:38448689~38448949:+
BRCA	cis	rs1005277	0.579	rs2021649	ENSG00000263064.2	RP11-291L22.7	4.48	8.31e-06	0.000694	0.17	0.14	Extrinsic epigenetic age acceleration;	chr10:38103194	chr10:38448689~38448949:+
BRCA	cis	rs1005277	0.579	rs2505197	ENSG00000263064.2	RP11-291L22.7	4.48	8.31e-06	0.000694	0.17	0.14	Extrinsic epigenetic age acceleration;	chr10:38104382	chr10:38448689~38448949:+
BRCA	cis	rs1005277	0.579	rs2505196	ENSG00000263064.2	RP11-291L22.7	4.48	8.31e-06	0.000694	0.17	0.14	Extrinsic epigenetic age acceleration;	chr10:38104635	chr10:38448689~38448949:+
BRCA	cis	rs11673344	0.504	rs12984458	ENSG00000276846.1	CTD-3220F14.3	-4.48	8.31e-06	0.000694	-0.16	-0.14	Obesity-related traits;	chr19:37138189	chr19:37314868~37315620:-
BRCA	cis	rs4664293	0.867	rs6761145	ENSG00000226266.5	AC009961.3	-4.48	8.31e-06	0.000694	-0.17	-0.14	Monocyte percentage of white cells;	chr2:159725673	chr2:159670708~159712435:-
BRCA	cis	rs4664293	0.867	rs6732987	ENSG00000226266.5	AC009961.3	-4.48	8.31e-06	0.000694	-0.17	-0.14	Monocyte percentage of white cells;	chr2:159725918	chr2:159670708~159712435:-
BRCA	cis	rs4664293	0.867	rs7589941	ENSG00000226266.5	AC009961.3	-4.48	8.31e-06	0.000694	-0.17	-0.14	Monocyte percentage of white cells;	chr2:159727589	chr2:159670708~159712435:-
BRCA	cis	rs35306767	0.953	rs10904581	ENSG00000229869.1	RP11-363N22.2	-4.48	8.31e-06	0.000694	-0.2	-0.14	Eosinophil percentage of granulocytes;	chr10:918745	chr10:933026~942743:+
BRCA	cis	rs75804782	0.572	rs77008212	ENSG00000186235.9	AC016757.3	4.48	8.31e-06	0.000695	0.36	0.14	Chronotype;Morning vs. evening chronotype;	chr2:238398472	chr2:238224552~238231677:-
BRCA	cis	rs6128907	1	rs62202470	ENSG00000224635.1	RP4-564F22.5	4.48	8.31e-06	0.000695	0.21	0.14	Liver fibrosis in pediatric non-alcoholic fatty acid liver disease;	chr20:38755510	chr20:38406011~38416797:-
BRCA	cis	rs9467773	1	rs6925703	ENSG00000241549.7	GUSBP2	4.48	8.31e-06	0.000695	0.15	0.14	Intelligence (multi-trait analysis);	chr6:26521361	chr6:26871484~26956554:-
BRCA	cis	rs11098499	0.863	rs10019674	ENSG00000260404.2	RP11-384K6.6	-4.48	8.31e-06	0.000695	-0.13	-0.14	Corneal astigmatism;	chr4:119522334	chr4:118591773~118633729:+
BRCA	cis	rs17711722	0.523	rs313812	ENSG00000226767.1	RP11-328P23.3	-4.48	8.32e-06	0.000695	-0.15	-0.14	Calcium levels;	chr7:66040056	chr7:65508773~65508944:-
BRCA	cis	rs6431644	0.931	rs719155	ENSG00000224287.2	MSL3P1	4.48	8.32e-06	0.000695	0.16	0.14	Left atrial antero-posterior diameter;	chr2:233890562	chr2:233865437~233868444:-
BRCA	cis	rs7665090	0.936	rs5026474	ENSG00000251288.2	RP11-10L12.2	-4.48	8.32e-06	0.000695	-0.16	-0.14	Primary biliary cholangitis;	chr4:102633653	chr4:102751401~102752641:+
BRCA	cis	rs6968419	0.747	rs12670683	ENSG00000279086.1	RP11-667F14.1	-4.48	8.32e-06	0.000695	-0.15	-0.14	Intraocular pressure;	chr7:116234412	chr7:116209234~116211511:-
BRCA	cis	rs6968419	0.747	rs2030978	ENSG00000279086.1	RP11-667F14.1	-4.48	8.32e-06	0.000695	-0.15	-0.14	Intraocular pressure;	chr7:116234506	chr7:116209234~116211511:-
BRCA	cis	rs6968419	0.747	rs2030977	ENSG00000279086.1	RP11-667F14.1	-4.48	8.32e-06	0.000695	-0.15	-0.14	Intraocular pressure;	chr7:116235305	chr7:116209234~116211511:-
BRCA	cis	rs6968419	0.747	rs6959237	ENSG00000279086.1	RP11-667F14.1	-4.48	8.32e-06	0.000695	-0.15	-0.14	Intraocular pressure;	chr7:116236311	chr7:116209234~116211511:-
BRCA	cis	rs11764932	0.662	rs10046550	ENSG00000229108.1	MEOX2-AS1	-4.48	8.32e-06	0.000695	-0.17	-0.14	Kidney function decline traits;	chr7:15673439	chr7:15688378~15695491:+
BRCA	cis	rs56322409	0.931	rs4258314	ENSG00000226688.5	ENTPD1-AS1	4.48	8.32e-06	0.000695	0.16	0.14	Blood metabolite levels;	chr10:95648846	chr10:95753206~96090238:-
BRCA	cis	rs651907	0.505	rs592332	ENSG00000244119.1	PDCL3P4	4.48	8.32e-06	0.000695	0.11	0.14	Colorectal cancer;	chr3:101866191	chr3:101712472~101713191:+
BRCA	cis	rs9467773	0.595	rs13207371	ENSG00000124549.13	BTN2A3P	4.48	8.32e-06	0.000695	0.14	0.14	Intelligence (multi-trait analysis);	chr6:26590846	chr6:26421391~26432383:+
BRCA	cis	rs2738459	0.522	rs2569537	ENSG00000212497.1	RNA5SP465	4.48	8.32e-06	0.000695	0.17	0.14	LDL cholesterol;	chr19:11129377	chr19:12027913~12028021:-
BRCA	cis	rs12210905	1	rs6917419	ENSG00000216901.1	AL022393.7	4.48	8.33e-06	0.000696	0.24	0.14	Hip circumference adjusted for BMI;	chr6:27275701	chr6:28176188~28176674:+
BRCA	cis	rs2179367	0.613	rs12207261	ENSG00000268592.3	RAET1E-AS1	4.48	8.33e-06	0.000696	0.2	0.14	Dupuytren's disease;	chr6:149423722	chr6:149863494~149919507:+
BRCA	cis	rs2073316	0.592	rs59964343	ENSG00000272716.1	RP11-563N4.1	4.48	8.33e-06	0.000696	0.15	0.14	Interleukin-18 levels;	chr2:31427295	chr2:32165046~32165757:-
BRCA	cis	rs8127691	0.904	rs7282490	ENSG00000237604.1	AP001056.1	4.48	8.33e-06	0.000696	0.15	0.14	Inflammatory bowel disease;	chr21:44195858	chr21:44175489~44176453:+
BRCA	cis	rs10504130	0.569	rs4626585	ENSG00000253844.1	RP11-546K22.1	4.48	8.33e-06	0.000696	0.2	0.14	Venous thromboembolism (SNP x SNP interaction);	chr8:51767380	chr8:51961458~52022974:+
BRCA	cis	rs1707322	1	rs1622208	ENSG00000234329.1	RP11-767N6.2	-4.48	8.34e-06	0.000696	-0.14	-0.14	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46032703	chr1:45651039~45651826:-
BRCA	cis	rs7111546	0.945	rs7127004	ENSG00000246225.5	RP11-17A1.3	4.48	8.34e-06	0.000696	0.21	0.14	Dialysis-related mortality;	chr11:22814967	chr11:22829380~22945393:+
BRCA	cis	rs875971	0.545	rs10261710	ENSG00000273142.1	RP11-458F8.4	4.48	8.34e-06	0.000696	0.14	0.14	Aortic root size;	chr7:66249202	chr7:66902857~66906297:+
BRCA	cis	rs180730	1	rs1530799	ENSG00000251609.2	SETP12	4.48	8.34e-06	0.000697	0.2	0.14	Fasting plasma glucose;	chr4:120923267	chr4:120895494~120897083:-
BRCA	cis	rs36051895	0.559	rs10815172	ENSG00000236254.1	MTND4P14	-4.48	8.34e-06	0.000697	-0.16	-0.14	Pediatric autoimmune diseases;	chr9:5212254	chr9:5107937~5109290:+
BRCA	cis	rs281408	0.559	rs204248	ENSG00000232871.7	SEC1P	-4.48	8.34e-06	0.000697	-0.16	-0.14	Urinary metabolites (H-NMR features);	chr19:48712967	chr19:48638071~48682245:+
BRCA	cis	rs12612619	0.732	rs7585410	ENSG00000229122.1	AGBL5-IT1	4.48	8.34e-06	0.000697	0.14	0.14	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:26979252	chr2:27061038~27061815:+
BRCA	cis	rs17674580	0.582	rs11662680	ENSG00000267193.4	RP11-116O18.3	-4.48	8.34e-06	0.000697	-0.15	-0.14	Bladder cancer;	chr18:45753220	chr18:45669367~45747215:-
BRCA	cis	rs60843830	1	rs55936726	ENSG00000272342.1	RP13-539J13.1	4.48	8.34e-06	0.000697	0.17	0.14	Spherical equivalent (joint analysis main effects and education interaction);	chr2:258210	chr2:739588~740164:-
BRCA	cis	rs7665090	0.967	rs5026469	ENSG00000251288.2	RP11-10L12.2	-4.48	8.35e-06	0.000697	-0.16	-0.14	Primary biliary cholangitis;	chr4:102633556	chr4:102751401~102752641:+
BRCA	cis	rs7665090	0.967	rs5026470	ENSG00000251288.2	RP11-10L12.2	-4.48	8.35e-06	0.000697	-0.16	-0.14	Primary biliary cholangitis;	chr4:102633565	chr4:102751401~102752641:+
BRCA	cis	rs7665090	0.967	rs5026471	ENSG00000251288.2	RP11-10L12.2	-4.48	8.35e-06	0.000697	-0.16	-0.14	Primary biliary cholangitis;	chr4:102633576	chr4:102751401~102752641:+
BRCA	cis	rs13113518	0.966	rs13144598	ENSG00000273257.1	RP11-177J6.1	4.48	8.35e-06	0.000697	0.18	0.14	Height;	chr4:55570311	chr4:55387949~55388271:+
BRCA	cis	rs9543976	0.623	rs7139740	ENSG00000261105.4	LMO7-AS1	4.48	8.35e-06	0.000698	0.21	0.14	Diabetic retinopathy;	chr13:75592806	chr13:75604700~75635994:-
BRCA	cis	rs11951515	0.508	rs67261887	ENSG00000248240.1	RP11-159F24.5	-4.48	8.35e-06	0.000698	-0.17	-0.14	Metabolite levels  (X-11787);	chr5:43612339	chr5:43515274~43525310:+
BRCA	cis	rs6439153	0.967	rs61480393	ENSG00000261159.1	RP11-723O4.9	4.48	8.36e-06	0.000698	0.15	0.14	Pneumococcal bacteremia;	chr3:128980916	chr3:128859716~128860526:-
BRCA	cis	rs13326165	0.76	rs13076890	ENSG00000243224.1	RP5-1157M23.2	-4.48	8.36e-06	0.000698	-0.19	-0.14	HDL cholesterol levels;HDL cholesterol;	chr3:52373917	chr3:52239258~52241097:+
BRCA	cis	rs10181042	0.514	rs1177289	ENSG00000273302.1	RP11-493E12.2	4.48	8.36e-06	0.000698	0.13	0.14	Crohn's disease;	chr2:61126121	chr2:61199979~61200769:+
BRCA	cis	rs3768617	0.51	rs10797852	ENSG00000224468.3	RP11-181K3.4	-4.48	8.36e-06	0.000698	-0.15	-0.14	Fuchs's corneal dystrophy;	chr1:183132167	chr1:183138402~183141282:-
BRCA	cis	rs1910358	0.614	rs7721412	ENSG00000248874.4	C5orf17	-4.48	8.37e-06	0.000699	-0.18	-0.14	Venous thromboembolism (SNP x SNP interaction);	chr5:23933135	chr5:23951348~24178263:+
BRCA	cis	rs1910358	0.614	rs7714895	ENSG00000248874.4	C5orf17	-4.48	8.37e-06	0.000699	-0.18	-0.14	Venous thromboembolism (SNP x SNP interaction);	chr5:23937383	chr5:23951348~24178263:+
BRCA	cis	rs35306767	0.953	rs12762973	ENSG00000229869.1	RP11-363N22.2	-4.48	8.37e-06	0.000699	-0.21	-0.14	Eosinophil percentage of granulocytes;	chr10:914821	chr10:933026~942743:+
BRCA	cis	rs875971	1	rs10244498	ENSG00000236529.1	RP13-254B10.1	4.48	8.37e-06	0.000699	0.15	0.14	Aortic root size;	chr7:66651069	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.619	rs12533585	ENSG00000273142.1	RP11-458F8.4	-4.48	8.37e-06	0.000699	-0.12	-0.14	Aortic root size;	chr7:66519618	chr7:66902857~66906297:+
BRCA	cis	rs10861342	1	rs11112394	ENSG00000257999.1	RP11-61E11.2	4.48	8.37e-06	0.000699	0.29	0.14	IgG glycosylation;	chr12:105157792	chr12:105102472~105107179:-
BRCA	cis	rs71537559	1	rs71537559	ENSG00000220721.1	OR1F12	4.48	8.38e-06	0.000699	0.3	0.14	Squamous cell lung carcinoma;	chr6:27342000	chr6:28073316~28074233:+
BRCA	cis	rs28829049	0.731	rs7537573	ENSG00000270728.1	RP4-657E11.10	-4.48	8.38e-06	0.000699	-0.13	-0.14	QRS duration in Tripanosoma cruzi seropositivity;	chr1:19047111	chr1:19297080~19297903:+
BRCA	cis	rs6840360	0.582	rs11732918	ENSG00000251603.1	RP11-164P12.4	-4.48	8.38e-06	7e-04	-0.13	-0.14	Intelligence (multi-trait analysis);	chr4:151397893	chr4:151667224~151670502:+
BRCA	cis	rs720064	0.537	rs2676106	ENSG00000264745.1	TTC39C-AS1	4.48	8.38e-06	7e-04	0.16	0.14	Strep throat;	chr18:23685075	chr18:23994213~24015339:-
BRCA	cis	rs6600671	1	rs1591882	ENSG00000231429.2	RP11-343N15.2	-4.48	8.38e-06	7e-04	-0.16	-0.14	Hip geometry;	chr1:121441455	chr1:121412719~121429274:+
BRCA	cis	rs2235642	0.928	rs2076435	ENSG00000260989.1	LA16c-395F10.2	-4.48	8.38e-06	7e-04	-0.14	-0.14	Coronary artery disease;	chr16:1557573	chr16:1580527~1610328:+
BRCA	cis	rs7772486	0.846	rs9373482	ENSG00000270638.1	RP3-466P17.1	4.48	8.38e-06	7e-04	0.16	0.14	Lobe attachment (rater-scored or self-reported);	chr6:146041987	chr6:145735570~145737218:+
BRCA	cis	rs7615952	0.673	rs7632557	ENSG00000250012.1	RP11-124N2.1	-4.48	8.38e-06	7e-04	-0.21	-0.14	Blood pressure (smoking interaction);	chr3:125916038	chr3:126084220~126095349:+
BRCA	cis	rs875971	0.545	rs17138149	ENSG00000273142.1	RP11-458F8.4	4.48	8.39e-06	7e-04	0.13	0.14	Aortic root size;	chr7:66228193	chr7:66902857~66906297:+
BRCA	cis	rs721917	0.506	rs2758556	ENSG00000278616.1	BEND3P3	4.48	8.39e-06	7e-04	0.13	0.14	Chronic obstructive pulmonary disease;	chr10:79931229	chr10:79682997~79685436:+
BRCA	cis	rs11673344	0.562	rs6510580	ENSG00000226686.6	LINC01535	4.48	8.39e-06	7e-04	0.18	0.14	Obesity-related traits;	chr19:37038452	chr19:37251912~37265535:+
BRCA	cis	rs11673344	0.523	rs2082009	ENSG00000226686.6	LINC01535	4.48	8.39e-06	7e-04	0.18	0.14	Obesity-related traits;	chr19:37039834	chr19:37251912~37265535:+
BRCA	cis	rs10829156	0.755	rs10732437	ENSG00000240291.1	RP11-499P20.2	4.48	8.39e-06	0.000701	0.16	0.14	Sudden cardiac arrest;	chr10:18626973	chr10:18513115~18545651:-
BRCA	cis	rs2288884	0.505	rs12459170	ENSG00000275055.1	CTC-471J1.11	-4.48	8.39e-06	0.000701	-0.22	-0.14	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:51955005	chr19:52049007~52049754:+
BRCA	cis	rs7811142	1	rs66632384	ENSG00000078319.8	PMS2P1	-4.48	8.39e-06	0.000701	-0.22	-0.14	Platelet count;	chr7:100421281	chr7:100320992~100341908:-
BRCA	cis	rs7811142	0.943	rs73403312	ENSG00000078319.8	PMS2P1	-4.48	8.39e-06	0.000701	-0.22	-0.14	Platelet count;	chr7:100426530	chr7:100320992~100341908:-
BRCA	cis	rs2574985	0.813	rs76883711	ENSG00000231345.3	BEND3P1	-4.48	8.4e-06	0.000701	-0.23	-0.14	Subjective well-being;	chr10:50476017	chr10:50655967~50660472:+
BRCA	cis	rs7246967	0.611	rs56276210	ENSG00000198153.8	ZNF849P	-4.48	8.4e-06	0.000701	-0.24	-0.14	Bronchopulmonary dysplasia;	chr19:22716841	chr19:22685167~22686732:+
BRCA	cis	rs875971	1	rs1565531	ENSG00000236529.1	RP13-254B10.1	-4.48	8.4e-06	0.000701	-0.15	-0.14	Aortic root size;	chr7:66198126	chr7:65840212~65840596:+
BRCA	cis	rs3764021	0.527	rs10844537	ENSG00000256673.1	RP11-599J14.2	-4.48	8.4e-06	0.000701	-0.17	-0.14	Type 1 diabetes;	chr12:9709528	chr12:9398355~9414851:-
BRCA	cis	rs1005277	0.579	rs176838	ENSG00000099251.13	HSD17B7P2	-4.48	8.4e-06	0.000701	-0.15	-0.14	Extrinsic epigenetic age acceleration;	chr10:38082971	chr10:38356380~38378505:+
BRCA	cis	rs1005277	0.541	rs2263163	ENSG00000263064.2	RP11-291L22.7	4.48	8.4e-06	0.000701	0.17	0.14	Extrinsic epigenetic age acceleration;	chr10:38100959	chr10:38448689~38448949:+
BRCA	cis	rs7246657	0.722	rs4802051	ENSG00000226686.6	LINC01535	-4.48	8.4e-06	0.000701	-0.2	-0.14	Coronary artery calcification;	chr19:37581427	chr19:37251912~37265535:+
BRCA	cis	rs7246657	0.663	rs4803276	ENSG00000226686.6	LINC01535	-4.48	8.4e-06	0.000701	-0.2	-0.14	Coronary artery calcification;	chr19:37581429	chr19:37251912~37265535:+
BRCA	cis	rs7927592	0.763	rs624003	ENSG00000212093.1	AP000807.1	4.48	8.4e-06	0.000701	0.15	0.14	Total body bone mineral density;	chr11:68463772	chr11:68506083~68506166:-
BRCA	cis	rs11124272	0.682	rs623419	ENSG00000272716.1	RP11-563N4.1	4.48	8.4e-06	0.000701	0.16	0.14	Interleukin-18 levels;	chr2:31609009	chr2:32165046~32165757:-
BRCA	cis	rs11098499	0.954	rs12505469	ENSG00000260404.2	RP11-384K6.6	4.48	8.4e-06	0.000701	0.13	0.14	Corneal astigmatism;	chr4:119328430	chr4:118591773~118633729:+
BRCA	cis	rs5758659	0.714	rs133373	ENSG00000227370.1	RP4-669P10.19	-4.48	8.41e-06	0.000702	-0.14	-0.14	Cognitive function;	chr22:42069784	chr22:42132543~42132998:+
BRCA	cis	rs62246343	0.605	rs17050395	ENSG00000254485.4	RP11-380O24.1	4.48	8.41e-06	0.000702	0.18	0.14	Fibrinogen levels;	chr3:9492290	chr3:9292588~9363303:-
BRCA	cis	rs11158026	1	rs2183081	ENSG00000258413.1	RP11-665C16.6	-4.48	8.41e-06	0.000702	-0.18	-0.14	Parkinson's disease;	chr14:54870033	chr14:55262767~55272075:-
BRCA	cis	rs7308116	1	rs10861792	ENSG00000274395.1	RP11-554D14.8	-4.48	8.42e-06	0.000703	-0.15	-0.14	Pelvic organ prolapse (moderate/severe);	chr12:107809589	chr12:107835541~107836555:-
BRCA	cis	rs875971	0.545	rs10261710	ENSG00000230295.1	RP11-458F8.2	4.48	8.42e-06	0.000703	0.13	0.14	Aortic root size;	chr7:66249202	chr7:66880708~66882981:+
BRCA	cis	rs7267979	0.966	rs6037097	ENSG00000274973.1	RP13-401N8.7	-4.48	8.42e-06	0.000703	-0.16	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25366585	chr20:25845497~25845862:+
BRCA	cis	rs1005277	0.541	rs2505193	ENSG00000099251.13	HSD17B7P2	4.48	8.42e-06	0.000703	0.15	0.14	Extrinsic epigenetic age acceleration;	chr10:38105710	chr10:38356380~38378505:+
BRCA	cis	rs1040	1	rs1040	ENSG00000226445.1	XXyac-YX65C7_A.2	-4.48	8.43e-06	0.000703	-0.15	-0.14	Joint mobility (Beighton score);	chr6:169216252	chr6:169213254~169239565:+
BRCA	cis	rs875971	1	rs2220626	ENSG00000229180.5	GS1-124K5.11	-4.48	8.43e-06	0.000703	-0.12	-0.14	Aortic root size;	chr7:66081075	chr7:66526088~66542624:-
BRCA	cis	rs17711722	0.565	rs4275112	ENSG00000226767.1	RP11-328P23.3	-4.48	8.43e-06	0.000703	-0.15	-0.14	Calcium levels;	chr7:65733651	chr7:65508773~65508944:-
BRCA	cis	rs7246657	0.551	rs10419174	ENSG00000267422.1	CTD-2554C21.1	-4.48	8.43e-06	0.000703	-0.24	-0.14	Coronary artery calcification;	chr19:37114439	chr19:37779686~37792865:+
BRCA	cis	rs12908161	0.959	rs17598603	ENSG00000259295.5	CSPG4P12	-4.48	8.43e-06	0.000703	-0.19	-0.14	Schizophrenia;	chr15:84656980	chr15:85191438~85213905:+
BRCA	cis	rs4869313	0.869	rs27300	ENSG00000248734.2	CTD-2260A17.1	4.48	8.43e-06	0.000703	0.14	0.14	Pediatric autoimmune diseases;	chr5:97027703	chr5:96784777~96785999:+
BRCA	cis	rs256438	0.694	rs4703797	ENSG00000251050.1	RP11-168A11.4	4.48	8.43e-06	0.000703	0.16	0.14	Serum thyroid-stimulating hormone levels;	chr5:80069186	chr5:80019609~80019920:+
BRCA	cis	rs2486012	1	rs2248305	ENSG00000237950.1	RP11-7O11.3	-4.48	8.43e-06	0.000703	-0.25	-0.14	Intelligence (multi-trait analysis);	chr1:43913821	chr1:43944370~43946551:-
BRCA	cis	rs2486012	1	rs1859725	ENSG00000237950.1	RP11-7O11.3	-4.48	8.43e-06	0.000703	-0.25	-0.14	Intelligence (multi-trait analysis);	chr1:43913905	chr1:43944370~43946551:-
BRCA	cis	rs11098499	0.754	rs1980025	ENSG00000249244.1	RP11-548H18.2	-4.48	8.43e-06	0.000703	-0.16	-0.14	Corneal astigmatism;	chr4:119331651	chr4:119391831~119395335:-
BRCA	cis	rs1005277	0.579	rs2505248	ENSG00000099251.13	HSD17B7P2	4.48	8.43e-06	0.000703	0.15	0.14	Extrinsic epigenetic age acceleration;	chr10:38170169	chr10:38356380~38378505:+
BRCA	cis	rs7267979	1	rs6050602	ENSG00000274973.1	RP13-401N8.7	4.48	8.44e-06	0.000704	0.16	0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25420567	chr20:25845497~25845862:+
BRCA	cis	rs7665090	0.967	rs6812747	ENSG00000251288.2	RP11-10L12.2	-4.48	8.44e-06	0.000704	-0.16	-0.14	Primary biliary cholangitis;	chr4:102634260	chr4:102751401~102752641:+
BRCA	cis	rs7665090	1	rs6839064	ENSG00000251288.2	RP11-10L12.2	-4.48	8.44e-06	0.000704	-0.16	-0.14	Primary biliary cholangitis;	chr4:102634519	chr4:102751401~102752641:+
BRCA	cis	rs7665090	1	rs2272695	ENSG00000251288.2	RP11-10L12.2	-4.48	8.44e-06	0.000704	-0.16	-0.14	Primary biliary cholangitis;	chr4:102634646	chr4:102751401~102752641:+
BRCA	cis	rs7665090	1	rs2272696	ENSG00000251288.2	RP11-10L12.2	-4.48	8.44e-06	0.000704	-0.16	-0.14	Primary biliary cholangitis;	chr4:102634664	chr4:102751401~102752641:+
BRCA	cis	rs7701440	0.512	rs7443733	ENSG00000215032.2	GNL3LP1	4.48	8.44e-06	0.000704	0.16	0.14	Educational attainment;	chr5:61238155	chr5:60891935~60893577:-
BRCA	cis	rs2574985	0.813	rs1203386	ENSG00000231345.3	BEND3P1	-4.48	8.44e-06	0.000704	-0.22	-0.14	Subjective well-being;	chr10:50446871	chr10:50655967~50660472:+
BRCA	cis	rs60695258	0.512	rs2053769	ENSG00000251411.1	RP11-397E7.4	4.48	8.44e-06	0.000704	0.16	0.14	Hematocrit;	chr4:86986855	chr4:86913266~86914817:-
BRCA	cis	rs11758351	1	rs2143346	ENSG00000241549.7	GUSBP2	4.48	8.44e-06	0.000704	0.2	0.14	Renal underexcretion gout;Gout;	chr6:26198221	chr6:26871484~26956554:-
BRCA	cis	rs516805	0.63	rs2816072	ENSG00000279114.1	RP3-425C14.5	-4.48	8.44e-06	0.000704	-0.17	-0.14	Lymphocyte counts;	chr6:122106871	chr6:122471923~122484161:+
BRCA	cis	rs1371614	0.635	rs877273	ENSG00000229122.1	AGBL5-IT1	-4.48	8.44e-06	0.000704	-0.14	-0.14	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26917154	chr2:27061038~27061815:+
BRCA	cis	rs6490294	0.571	rs12423960	ENSG00000234608.6	MAPKAPK5-AS1	4.48	8.44e-06	0.000704	0.21	0.14	Mean platelet volume;	chr12:112004612	chr12:111839764~111842902:-
BRCA	cis	rs6490294	0.571	rs10849992	ENSG00000234608.6	MAPKAPK5-AS1	4.48	8.44e-06	0.000704	0.21	0.14	Mean platelet volume;	chr12:112005213	chr12:111839764~111842902:-
BRCA	cis	rs6490294	0.571	rs7310545	ENSG00000234608.6	MAPKAPK5-AS1	4.48	8.44e-06	0.000704	0.21	0.14	Mean platelet volume;	chr12:112006156	chr12:111839764~111842902:-
BRCA	cis	rs6490294	0.571	rs7296841	ENSG00000234608.6	MAPKAPK5-AS1	4.48	8.44e-06	0.000704	0.21	0.14	Mean platelet volume;	chr12:112006305	chr12:111839764~111842902:-
BRCA	cis	rs9393692	0.627	rs2179517	ENSG00000241549.7	GUSBP2	-4.48	8.45e-06	0.000705	-0.15	-0.14	Educational attainment;	chr6:26198617	chr6:26871484~26956554:-
BRCA	cis	rs9921338	0.961	rs4356497	ENSG00000262703.1	RP11-485G7.6	4.48	8.45e-06	0.000705	0.16	0.14	Vein graft stenosis in coronary artery bypass grafting;	chr16:11320339	chr16:11348143~11349321:-
BRCA	cis	rs35146811	0.735	rs1637001	ENSG00000235713.1	RP4-604G5.3	-4.48	8.45e-06	0.000705	-0.16	-0.14	Coronary artery disease;	chr7:100210528	chr7:99992397~99993050:+
BRCA	cis	rs35740288	0.929	rs1978391	ENSG00000202081.1	RNU6-1280P	-4.48	8.45e-06	0.000705	-0.18	-0.14	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85768464	chr15:85651522~85651628:-
BRCA	cis	rs10829156	0.732	rs10828834	ENSG00000240291.1	RP11-499P20.2	4.48	8.45e-06	0.000705	0.16	0.14	Sudden cardiac arrest;	chr10:18523505	chr10:18513115~18545651:-
BRCA	cis	rs8099594	0.601	rs7235696	ENSG00000266696.1	RP11-30L3.2	4.48	8.45e-06	0.000705	0.16	0.14	Height;	chr18:49388901	chr18:49205912~49208781:+
BRCA	cis	rs8054556	0.513	rs12596042	ENSG00000183604.13	SMG1P5	-4.48	8.45e-06	0.000705	-0.13	-0.14	Autism spectrum disorder or schizophrenia;	chr16:29923433	chr16:30267553~30335374:-
BRCA	cis	rs1982963	0.951	rs2516592	ENSG00000277050.1	RP11-102G14.1	-4.48	8.45e-06	0.000705	-0.17	-0.14	Waist-to-hip ratio adjusted for body mass index;	chr14:52036827	chr14:51637348~51637947:-
BRCA	cis	rs2136613	0.563	rs1509957	ENSG00000238280.1	RP11-436D10.3	-4.48	8.45e-06	0.000705	-0.17	-0.14	Selective IgA deficiency;	chr10:62850958	chr10:62793562~62805887:-
BRCA	cis	rs1538970	0.748	rs11211137	ENSG00000281133.1	AL355480.3	-4.48	8.45e-06	0.000705	-0.2	-0.14	Platelet count;	chr1:45548220	chr1:45580892~45580996:-
BRCA	cis	rs4143844	1	rs4143844	ENSG00000259251.2	RP11-643M14.1	-4.48	8.46e-06	0.000706	-0.31	-0.14	Bipolar disorder and schizophrenia;	chr15:62020641	chr15:62060503~62062434:+
BRCA	cis	rs7592578	0.713	rs60915953	ENSG00000272979.1	RP11-647K16.1	-4.48	8.46e-06	0.000706	-0.24	-0.14	Diastolic blood pressure;	chr2:190466578	chr2:190454092~190454521:-
BRCA	cis	rs7772486	0.754	rs697054	ENSG00000270638.1	RP3-466P17.1	4.48	8.47e-06	0.000706	0.16	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145682634	chr6:145735570~145737218:+
BRCA	cis	rs8054556	0.74	rs9936474	ENSG00000183604.13	SMG1P5	-4.48	8.47e-06	0.000706	-0.13	-0.14	Autism spectrum disorder or schizophrenia;	chr16:29921370	chr16:30267553~30335374:-
BRCA	cis	rs10844706	0.604	rs7964018	ENSG00000214776.8	RP11-726G1.1	-4.48	8.47e-06	0.000706	-0.16	-0.14	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9713803	chr12:9467552~9576275:+
BRCA	cis	rs3764021	0.527	rs11052423	ENSG00000256673.1	RP11-599J14.2	4.48	8.47e-06	0.000707	0.17	0.14	Type 1 diabetes;	chr12:9687442	chr12:9398355~9414851:-
BRCA	cis	rs4781563	1	rs3136067	ENSG00000242307.1	RPS26P52	-4.48	8.48e-06	0.000707	-0.17	-0.14	Bilirubin levels;	chr16:13923702	chr16:13922332~13922679:-
BRCA	cis	rs11096990	0.634	rs11736790	ENSG00000249685.1	RP11-360F5.3	4.47	8.48e-06	0.000707	0.17	0.14	Cognitive function;	chr4:39254704	chr4:39133913~39135608:+
BRCA	cis	rs4819052	0.807	rs1075788	ENSG00000184274.3	LINC00315	-4.47	8.49e-06	0.000708	-0.19	-0.14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45246649	chr21:45300245~45305257:-
BRCA	cis	rs7665090	1	rs5026476	ENSG00000251288.2	RP11-10L12.2	-4.47	8.49e-06	0.000708	-0.16	-0.14	Primary biliary cholangitis;	chr4:102633753	chr4:102751401~102752641:+
BRCA	cis	rs7665090	1	rs2272697	ENSG00000251288.2	RP11-10L12.2	-4.47	8.49e-06	0.000708	-0.16	-0.14	Primary biliary cholangitis;	chr4:102634835	chr4:102751401~102752641:+
BRCA	cis	rs991427	0.818	rs11105976	ENSG00000258100.1	RP11-121E16.1	-4.47	8.49e-06	0.000708	-0.19	-0.14	Systolic blood pressure (alcohol consumption interaction);	chr12:91085445	chr12:91362196~91368606:+
BRCA	cis	rs5167	0.504	rs7259679	ENSG00000280087.1	CTB-129P6.7	4.47	8.49e-06	0.000708	0.16	0.14	Blood protein levels;	chr19:44954049	chr19:44909375~44914968:+
BRCA	cis	rs11098499	0.954	rs1480931	ENSG00000260091.1	RP11-33B1.4	-4.47	8.49e-06	0.000708	-0.12	-0.14	Corneal astigmatism;	chr4:119474654	chr4:119409333~119410233:+
BRCA	cis	rs75804782	0.572	rs112551758	ENSG00000186235.9	AC016757.3	4.47	8.49e-06	0.000708	0.36	0.14	Chronotype;Morning vs. evening chronotype;	chr2:238391129	chr2:238224552~238231677:-
BRCA	cis	rs10129255	0.701	rs2005643	ENSG00000211974.3	IGHV2-70	4.47	8.49e-06	0.000708	0.14	0.14	Kawasaki disease;	chr14:106676288	chr14:106723574~106724093:-
BRCA	cis	rs754466	0.561	rs72806025	ENSG00000204049.1	RP11-126H7.4	4.47	8.49e-06	0.000708	0.23	0.14	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77947268	chr10:77866875~77869610:+
BRCA	cis	rs7772486	0.875	rs9403764	ENSG00000270638.1	RP3-466P17.1	4.47	8.5e-06	0.000708	0.16	0.14	Lobe attachment (rater-scored or self-reported);	chr6:146039446	chr6:145735570~145737218:+
BRCA	cis	rs2273156	1	rs36112862	ENSG00000226677.3	IGBP1P1	-4.47	8.5e-06	0.000709	-0.2	-0.14	Immunoglobulin light chain (AL) amyloidosis;	chr14:35009227	chr14:34939324~34940332:+
BRCA	cis	rs7267979	1	rs884613	ENSG00000276952.1	RP5-965G21.6	-4.47	8.5e-06	0.000709	-0.17	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25307869	chr20:25284915~25285588:-
BRCA	cis	rs7267979	1	rs1888998	ENSG00000276952.1	RP5-965G21.6	-4.47	8.5e-06	0.000709	-0.17	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25311190	chr20:25284915~25285588:-
BRCA	cis	rs755249	0.532	rs17343193	ENSG00000182109.6	RP11-69E11.4	4.47	8.5e-06	0.000709	0.19	0.14	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39415796	chr1:39522280~39546187:-
BRCA	cis	rs853679	0.76	rs967005	ENSG00000216901.1	AL022393.7	4.47	8.51e-06	0.000709	0.21	0.14	Depression;	chr6:28242910	chr6:28176188~28176674:+
BRCA	cis	rs1383484	0.545	rs7171383	ENSG00000225151.9	GOLGA2P7	4.47	8.51e-06	0.000709	0.17	0.14	Height;	chr15:83976087	chr15:84199311~84230136:-
BRCA	cis	rs7267979	1	rs4815411	ENSG00000274973.1	RP13-401N8.7	4.47	8.51e-06	0.000709	0.16	0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25369587	chr20:25845497~25845862:+
BRCA	cis	rs10266483	0.739	rs12665990	ENSG00000227986.1	TRIM60P18	4.47	8.51e-06	0.000709	0.16	0.14	Response to statin therapy;	chr7:64404622	chr7:64355078~64356199:+
BRCA	cis	rs3764021	0.506	rs11052372	ENSG00000256594.6	RP11-705C15.2	4.47	8.51e-06	0.000709	0.19	0.14	Type 1 diabetes;	chr12:9679363	chr12:9633419~9658412:+
BRCA	cis	rs2227564	0.649	rs2242258	ENSG00000271816.1	BMS1P4	-4.47	8.51e-06	0.000709	-0.15	-0.14	Crohn's disease;Inflammatory bowel disease;	chr10:73847410	chr10:73699151~73730487:-
BRCA	cis	rs6600671	0.934	rs7528274	ENSG00000275538.1	RNVU1-19	4.47	8.51e-06	0.00071	0.16	0.14	Hip geometry;	chr1:121545103	chr1:120850819~120850985:-
BRCA	cis	rs6968419	0.747	rs3807975	ENSG00000279086.1	RP11-667F14.1	-4.47	8.51e-06	0.00071	-0.15	-0.14	Intraocular pressure;	chr7:116240223	chr7:116209234~116211511:-
BRCA	cis	rs4662750	0.619	rs2244042	ENSG00000236682.1	AC068282.3	-4.47	8.51e-06	0.00071	-0.19	-0.14	Renal cell carcinoma;	chr2:127647423	chr2:127389130~127400580:+
BRCA	cis	rs13113518	1	rs13114841	ENSG00000273257.1	RP11-177J6.1	4.47	8.52e-06	0.00071	0.18	0.14	Height;	chr4:55485974	chr4:55387949~55388271:+
BRCA	cis	rs7665090	0.936	rs2866412	ENSG00000251288.2	RP11-10L12.2	-4.47	8.52e-06	0.00071	-0.16	-0.14	Primary biliary cholangitis;	chr4:102633193	chr4:102751401~102752641:+
BRCA	cis	rs12612619	0.695	rs4665935	ENSG00000229122.1	AGBL5-IT1	-4.47	8.52e-06	0.00071	-0.14	-0.14	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27007024	chr2:27061038~27061815:+
BRCA	cis	rs886427	0.838	rs4149782	ENSG00000272079.2	LA16c-380H5.5	-4.47	8.52e-06	0.00071	-0.18	-0.14	Metabolic syndrome;	chr16:2977295	chr16:3006120~3007388:+
BRCA	cis	rs12893668	0.667	rs8017628	ENSG00000244691.1	RPL10AP1	-4.47	8.52e-06	0.00071	-0.18	-0.14	Reticulocyte count;	chr14:103581091	chr14:103412119~103412761:-
BRCA	cis	rs6671200	0.831	rs13375406	ENSG00000235501.4	RP4-639F20.1	-4.47	8.52e-06	0.00071	-0.3	-0.14	Stearic acid (18:0) levels;	chr1:95140749	chr1:94927566~94963270:+
BRCA	cis	rs1910358	0.506	rs2331688	ENSG00000248874.4	C5orf17	-4.47	8.52e-06	0.00071	-0.18	-0.14	Venous thromboembolism (SNP x SNP interaction);	chr5:23940321	chr5:23951348~24178263:+
BRCA	cis	rs1910358	0.592	rs4315895	ENSG00000248874.4	C5orf17	-4.47	8.52e-06	0.00071	-0.18	-0.14	Venous thromboembolism (SNP x SNP interaction);	chr5:23940473	chr5:23951348~24178263:+
BRCA	cis	rs1910358	0.614	rs35378139	ENSG00000248874.4	C5orf17	-4.47	8.52e-06	0.00071	-0.18	-0.14	Venous thromboembolism (SNP x SNP interaction);	chr5:23942261	chr5:23951348~24178263:+
BRCA	cis	rs1910358	0.614	rs1119833	ENSG00000248874.4	C5orf17	-4.47	8.52e-06	0.00071	-0.18	-0.14	Venous thromboembolism (SNP x SNP interaction);	chr5:23945905	chr5:23951348~24178263:+
BRCA	cis	rs7772486	0.79	rs1062068	ENSG00000270638.1	RP3-466P17.1	4.47	8.53e-06	0.00071	0.16	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145886329	chr6:145735570~145737218:+
BRCA	cis	rs7937890	1	rs2970334	ENSG00000254418.1	RP11-21L19.1	-4.47	8.53e-06	0.000711	-0.16	-0.14	Mitochondrial DNA levels;	chr11:14307809	chr11:14262846~14273691:-
BRCA	cis	rs4143844	1	rs12913358	ENSG00000259251.2	RP11-643M14.1	4.47	8.53e-06	0.000711	0.33	0.14	Bipolar disorder and schizophrenia;	chr15:62032293	chr15:62060503~62062434:+
BRCA	cis	rs7267979	1	rs6037086	ENSG00000276952.1	RP5-965G21.6	-4.47	8.53e-06	0.000711	-0.17	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25325702	chr20:25284915~25285588:-
BRCA	cis	rs7267979	0.966	rs2482923	ENSG00000276952.1	RP5-965G21.6	-4.47	8.53e-06	0.000711	-0.17	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25328345	chr20:25284915~25285588:-
BRCA	cis	rs10129255	0.957	rs10140904	ENSG00000211974.3	IGHV2-70	4.47	8.53e-06	0.000711	0.14	0.14	Kawasaki disease;	chr14:106776558	chr14:106723574~106724093:-
BRCA	cis	rs1913185	0.891	rs67325724	ENSG00000240032.1	RP11-274H2.3	-4.47	8.53e-06	0.000711	-0.24	-0.14	Obesity-related traits;	chr3:146156940	chr3:146066344~146069185:-
BRCA	cis	rs991427	0.908	rs7977400	ENSG00000258100.1	RP11-121E16.1	-4.47	8.54e-06	0.000711	-0.18	-0.14	Systolic blood pressure (alcohol consumption interaction);	chr12:91095350	chr12:91362196~91368606:+
BRCA	cis	rs987724	0.519	rs9820830	ENSG00000240875.4	LINC00886	-4.47	8.54e-06	0.000711	-0.16	-0.14	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156824915	chr3:156747346~156817062:-
BRCA	cis	rs9925964	0.967	rs749767	ENSG00000262766.1	RP11-196G11.4	4.47	8.54e-06	0.000711	0.12	0.14	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31113086	chr16:31118078~31118747:+
BRCA	cis	rs490234	0.683	rs2841326	ENSG00000232630.1	PRPS1P2	-4.47	8.54e-06	0.000711	-0.14	-0.14	Mean arterial pressure;	chr9:125399489	chr9:125150653~125151589:+
BRCA	cis	rs754466	0.561	rs11002343	ENSG00000204049.1	RP11-126H7.4	4.47	8.54e-06	0.000711	0.23	0.14	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77946113	chr10:77866875~77869610:+
BRCA	cis	rs2033711	0.503	rs7254299	ENSG00000269473.1	CTD-2619J13.19	4.47	8.54e-06	0.000712	0.16	0.14	Uric acid clearance;	chr19:58373598	chr19:58440448~58445849:+
BRCA	cis	rs9652601	0.691	rs12917716	ENSG00000274038.1	RP11-66H6.4	-4.47	8.54e-06	0.000712	-0.15	-0.14	Systemic lupus erythematosus;	chr16:11095291	chr16:11056556~11057034:+
BRCA	cis	rs6751744	0.855	rs7585513	ENSG00000230783.1	AC009961.2	-4.47	8.54e-06	0.000712	-0.18	-0.14	Dysphagia;	chr2:159550379	chr2:159689217~159690291:-
BRCA	cis	rs8113308	0.81	rs8108525	ENSG00000269483.1	AC006272.1	4.47	8.54e-06	0.000712	0.24	0.14	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51940883	chr19:51839924~51843324:-
BRCA	cis	rs8113308	0.81	rs7258701	ENSG00000269483.1	AC006272.1	4.47	8.54e-06	0.000712	0.24	0.14	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51941816	chr19:51839924~51843324:-
BRCA	cis	rs853679	0.76	rs9357067	ENSG00000216901.1	AL022393.7	4.47	8.55e-06	0.000712	0.21	0.14	Depression;	chr6:28242515	chr6:28176188~28176674:+
BRCA	cis	rs10129255	0.518	rs10150460	ENSG00000254174.1	IGHV1-12	-4.47	8.55e-06	0.000712	-0.11	-0.14	Kawasaki disease;	chr14:106677179	chr14:106122420~106122709:-
BRCA	cis	rs11168618	0.87	rs7302209	ENSG00000240399.1	RP1-228P16.1	4.47	8.55e-06	0.000713	0.16	0.14	Adiponectin levels;	chr12:48501601	chr12:48054813~48055591:-
BRCA	cis	rs2154319	0.609	rs11589478	ENSG00000235358.1	RP11-399E6.1	-4.47	8.55e-06	0.000713	-0.19	-0.14	Height;	chr1:41270555	chr1:41242373~41284861:+
BRCA	cis	rs7267979	1	rs6050602	ENSG00000125804.12	FAM182A	4.47	8.56e-06	0.000713	0.18	0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25420567	chr20:26054655~26086917:+
BRCA	cis	rs9527	0.615	rs1556960	ENSG00000213061.2	PFN1P11	4.47	8.56e-06	0.000713	0.18	0.14	Arsenic metabolism;	chr10:102966916	chr10:102838011~102845473:-
BRCA	cis	rs28374715	0.532	rs7164211	ENSG00000247556.5	OIP5-AS1	4.47	8.56e-06	0.000713	0.15	0.14	Ulcerative colitis;	chr15:41412843	chr15:41283990~41309737:+
BRCA	cis	rs13108904	0.71	rs11937232	ENSG00000253399.1	AC078852.2	-4.47	8.56e-06	0.000713	-0.15	-0.14	Obesity-related traits;	chr4:1213809	chr4:1358479~1359461:+
BRCA	cis	rs6600671	1	rs1832558	ENSG00000275538.1	RNVU1-19	4.47	8.56e-06	0.000713	0.16	0.14	Hip geometry;	chr1:121435521	chr1:120850819~120850985:-
BRCA	cis	rs6600671	0.967	rs11249349	ENSG00000275538.1	RNVU1-19	4.47	8.56e-06	0.000713	0.16	0.14	Hip geometry;	chr1:121437310	chr1:120850819~120850985:-
BRCA	cis	rs11051970	0.797	rs4540912	ENSG00000274964.1	RP11-817I4.1	-4.47	8.57e-06	0.000714	-0.17	-0.14	Response to tocilizumab in rheumatoid arthritis;	chr12:32314259	chr12:32339368~32340724:+
BRCA	cis	rs6847067	0.794	rs11732347	ENSG00000180769.7	WDFY3-AS2	4.47	8.57e-06	0.000714	0.12	0.14	Oropharynx cancer;	chr4:85012297	chr4:84965682~85011277:+
BRCA	cis	rs1371614	0.545	rs13035643	ENSG00000229122.1	AGBL5-IT1	-4.47	8.57e-06	0.000714	-0.15	-0.14	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26950473	chr2:27061038~27061815:+
BRCA	cis	rs1371614	0.545	rs4665930	ENSG00000229122.1	AGBL5-IT1	-4.47	8.57e-06	0.000714	-0.15	-0.14	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26950652	chr2:27061038~27061815:+
BRCA	cis	rs911119	1	rs6048956	ENSG00000270001.1	RP11-218C14.8	-4.47	8.57e-06	0.000714	-0.18	-0.14	Chronic kidney disease;	chr20:23628664	chr20:23631826~23632316:-
BRCA	cis	rs911119	1	rs34374560	ENSG00000270001.1	RP11-218C14.8	-4.47	8.57e-06	0.000714	-0.18	-0.14	Chronic kidney disease;	chr20:23628825	chr20:23631826~23632316:-
BRCA	cis	rs11696845	0.896	rs61356009	ENSG00000276223.1	RP4-781B1.5	-4.47	8.57e-06	0.000714	-0.14	-0.14	Obesity-related traits;	chr20:44743750	chr20:44746642~44747201:+
BRCA	cis	rs10129255	0.5	rs11627315	ENSG00000254174.1	IGHV1-12	4.47	8.57e-06	0.000714	0.11	0.14	Kawasaki disease;	chr14:106802182	chr14:106122420~106122709:-
BRCA	cis	rs35612822	0.723	rs17557636	ENSG00000232485.2	AC098820.3	-4.47	8.57e-06	0.000714	-0.17	-0.14	Kidney disease (early stage) in type 1 diabetes;	chr2:216395833	chr2:216479030~216498761:-
BRCA	cis	rs13113518	1	rs939823	ENSG00000273257.1	RP11-177J6.1	4.47	8.58e-06	0.000715	0.18	0.14	Height;	chr4:55487368	chr4:55387949~55388271:+
BRCA	cis	rs1910358	0.614	rs1604453	ENSG00000248874.4	C5orf17	-4.47	8.58e-06	0.000715	-0.18	-0.14	Venous thromboembolism (SNP x SNP interaction);	chr5:23945779	chr5:23951348~24178263:+
BRCA	cis	rs34217772	0.883	rs61992374	ENSG00000258636.1	CTD-2298J14.2	4.47	8.58e-06	0.000715	0.2	0.14	Myopia;	chr14:41738042	chr14:41587861~41604856:-
BRCA	cis	rs4578769	0.765	rs8091950	ENSG00000265939.1	UBE2CP2	4.47	8.59e-06	0.000715	0.17	0.14	Eosinophil percentage of white cells;	chr18:22859136	chr18:22900486~22900995:-
BRCA	cis	rs4662750	0.58	rs4662743	ENSG00000236682.1	AC068282.3	-4.47	8.59e-06	0.000715	-0.18	-0.14	Renal cell carcinoma;	chr2:127593233	chr2:127389130~127400580:+
BRCA	cis	rs7267979	0.739	rs6138555	ENSG00000125804.12	FAM182A	-4.47	8.59e-06	0.000715	-0.18	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25262274	chr20:26054655~26086917:+
BRCA	cis	rs55780018	0.675	rs35860033	ENSG00000224137.1	AC079767.4	4.47	8.59e-06	0.000715	0.12	0.14	Systolic blood pressure;	chr2:207640954	chr2:207662375~207667024:+
BRCA	cis	rs10129255	0.536	rs10139058	ENSG00000224373.3	IGHV4-59	4.47	8.59e-06	0.000716	0.08	0.14	Kawasaki disease;	chr14:106685899	chr14:106627249~106627825:-
BRCA	cis	rs718314	0.507	rs9442	ENSG00000256894.1	RP11-283G6.3	-4.47	8.6e-06	0.000716	-0.14	-0.14	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Renal cell carcinoma;Waist circumference adjusted for body mass index;	chr12:26335572	chr12:26125155~26126617:-
BRCA	cis	rs8031584	0.918	rs61997139	ENSG00000259845.1	HERC2P10	4.47	8.6e-06	0.000716	0.16	0.14	Huntington's disease progression;	chr15:30981399	chr15:30815271~30844153:+
BRCA	cis	rs6921919	0.609	rs1005127	ENSG00000220721.1	OR1F12	4.47	8.61e-06	0.000717	0.17	0.14	Autism spectrum disorder or schizophrenia;	chr6:28399881	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.515	rs4580862	ENSG00000220721.1	OR1F12	4.47	8.61e-06	0.000717	0.17	0.14	Depression;	chr6:28399886	chr6:28073316~28074233:+
BRCA	cis	rs6921919	0.583	rs4357130	ENSG00000220721.1	OR1F12	4.47	8.61e-06	0.000717	0.17	0.14	Autism spectrum disorder or schizophrenia;	chr6:28399906	chr6:28073316~28074233:+
BRCA	cis	rs17684571	0.751	rs13194625	ENSG00000231441.1	RP11-472M19.2	4.47	8.61e-06	0.000717	0.23	0.14	Schizophrenia;	chr6:56820446	chr6:56844002~56864078:+
BRCA	cis	rs2574985	0.777	rs74998492	ENSG00000231345.3	BEND3P1	-4.47	8.61e-06	0.000717	-0.22	-0.14	Subjective well-being;	chr10:50476347	chr10:50655967~50660472:+
BRCA	cis	rs2832191	0.935	rs67287920	ENSG00000232855.5	AF131217.1	4.47	8.61e-06	0.000717	0.16	0.14	Dental caries;	chr21:29151198	chr21:28439346~28674848:-
BRCA	cis	rs66887589	0.934	rs2715016	ENSG00000245958.5	RP11-33B1.1	4.47	8.61e-06	0.000717	0.12	0.14	Diastolic blood pressure;	chr4:119531201	chr4:119454791~119552025:+
BRCA	cis	rs6921919	0.806	rs213230	ENSG00000273712.1	RP5-874C20.7	4.47	8.61e-06	0.000717	0.19	0.14	Autism spectrum disorder or schizophrenia;	chr6:28362487	chr6:28315613~28315883:-
BRCA	cis	rs1005277	0.579	rs2474575	ENSG00000263064.2	RP11-291L22.7	4.47	8.61e-06	0.000717	0.17	0.14	Extrinsic epigenetic age acceleration;	chr10:38098973	chr10:38448689~38448949:+
BRCA	cis	rs11955398	0.502	rs158938	ENSG00000272308.1	RP11-231G3.1	-4.47	8.61e-06	0.000717	-0.16	-0.14	Intelligence (multi-trait analysis);	chr5:60939413	chr5:60866457~60866935:-
BRCA	cis	rs13113518	0.966	rs1474271	ENSG00000273257.1	RP11-177J6.1	4.47	8.62e-06	0.000718	0.18	0.14	Height;	chr4:55435912	chr4:55387949~55388271:+
BRCA	cis	rs13113518	1	rs2279458	ENSG00000272969.1	RP11-528I4.2	4.47	8.62e-06	0.000718	0.16	0.14	Height;	chr4:55562653	chr4:55547112~55547889:+
BRCA	cis	rs1153858	1	rs4775909	ENSG00000275672.1	GATM-AS1	-4.47	8.63e-06	0.000718	-0.18	-0.14	Homoarginine levels;	chr15:45350844	chr15:45378700~45380123:+
BRCA	cis	rs6490294	0.851	rs1016079	ENSG00000234608.6	MAPKAPK5-AS1	-4.47	8.63e-06	0.000718	-0.17	-0.14	Mean platelet volume;	chr12:111972382	chr12:111839764~111842902:-
BRCA	cis	rs13108904	0.518	rs4974602	ENSG00000253399.1	AC078852.2	-4.47	8.63e-06	0.000718	-0.17	-0.14	Obesity-related traits;	chr4:1348603	chr4:1358479~1359461:+
BRCA	cis	rs1005277	0.579	rs2472183	ENSG00000099251.13	HSD17B7P2	4.47	8.63e-06	0.000719	0.15	0.14	Extrinsic epigenetic age acceleration;	chr10:38103567	chr10:38356380~38378505:+
BRCA	cis	rs7267979	0.527	rs6083891	ENSG00000204556.4	CTD-2514C3.1	4.47	8.63e-06	0.000719	0.19	0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25593636	chr20:26018832~26020684:+
BRCA	cis	rs10129255	0.518	rs8009612	ENSG00000232216.1	IGHV3-43	4.47	8.63e-06	0.000719	0.1	0.14	Kawasaki disease;	chr14:106777510	chr14:106470264~106470800:-
BRCA	cis	rs13126694	0.71	rs4574459	ENSG00000251073.1	NUDT19P5	4.47	8.64e-06	0.000719	0.13	0.14	Blood osmolality (transformed sodium);	chr4:157991482	chr4:158182825~158183393:+
BRCA	cis	rs17428076	0.793	rs3765166	ENSG00000228389.1	AC068039.4	-4.47	8.64e-06	0.000719	-0.2	-0.14	Myopia;	chr2:171837270	chr2:171773482~171775844:+
BRCA	cis	rs7475343	0.543	rs17134601	ENSG00000224034.1	RP11-445P17.8	4.47	8.64e-06	0.000719	0.26	0.14	Intelligence;	chr10:5219212	chr10:5266033~5271236:-
BRCA	cis	rs4449834	0.851	rs6996775	ENSG00000254432.1	RP11-33I11.2	-4.47	8.64e-06	0.000719	-0.18	-0.14	Sum eosinophil basophil counts;	chr8:60829231	chr8:60808735~60809606:-
BRCA	cis	rs1722133	0.555	rs788724	ENSG00000229628.1	AC073115.7	-4.47	8.64e-06	0.000719	-0.19	-0.14	Sitting height ratio;	chr7:46049548	chr7:45990905~46000898:+
BRCA	cis	rs11673344	0.563	rs4805199	ENSG00000226686.6	LINC01535	4.47	8.64e-06	0.000719	0.17	0.14	Obesity-related traits;	chr19:37115527	chr19:37251912~37265535:+
BRCA	cis	rs7267979	1	rs6050626	ENSG00000125804.12	FAM182A	-4.47	8.64e-06	0.000719	-0.18	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25447625	chr20:26054655~26086917:+
BRCA	cis	rs10911902	0.643	rs3753565	ENSG00000229739.2	RP11-295K2.3	4.47	8.64e-06	0.000719	0.21	0.14	Schizophrenia;	chr1:186347356	chr1:186435161~186470291:+
BRCA	cis	rs10129255	0.957	rs10142918	ENSG00000274576.2	IGHV2-70	4.47	8.65e-06	0.00072	0.12	0.14	Kawasaki disease;	chr14:106782206	chr14:106770577~106771020:-
BRCA	cis	rs651907	0.535	rs17347156	ENSG00000256628.3	ZBTB11-AS1	4.47	8.65e-06	0.00072	0.18	0.14	Colorectal cancer;	chr3:101785830	chr3:101676475~101679217:+
BRCA	cis	rs17711722	0.522	rs6957759	ENSG00000226767.1	RP11-328P23.3	4.47	8.65e-06	0.00072	0.15	0.14	Calcium levels;	chr7:65806798	chr7:65508773~65508944:-
BRCA	cis	rs11976180	1	rs2951308	ENSG00000244479.5	OR2A1-AS1	-4.47	8.65e-06	0.00072	-0.18	-0.14	Obesity-related traits;	chr7:144070056	chr7:144251264~144356181:-
BRCA	cis	rs12477438	0.798	rs13414153	ENSG00000231822.1	AC019097.7	-4.47	8.65e-06	0.00072	-0.15	-0.14	Chronic sinus infection;	chr2:99008285	chr2:99102018~99102752:+
BRCA	cis	rs11098499	0.913	rs67073020	ENSG00000250412.1	KLHL2P1	4.47	8.65e-06	0.00072	0.17	0.14	Corneal astigmatism;	chr4:119231402	chr4:119334329~119378233:+
BRCA	cis	rs9311474	0.713	rs181274	ENSG00000243224.1	RP5-1157M23.2	-4.47	8.65e-06	0.00072	-0.15	-0.14	Electroencephalogram traits;	chr3:52199845	chr3:52239258~52241097:+
BRCA	cis	rs6001482	0.702	rs5757586	ENSG00000279278.1	CH17-264L24.1	4.47	8.65e-06	0.00072	0.11	0.14	Diastolic blood pressure;	chr22:22234458	chr22:22264601~22273020:+
BRCA	cis	rs7572733	0.773	rs6748788	ENSG00000231621.1	AC013264.2	4.47	8.65e-06	0.00072	0.12	0.14	Dermatomyositis;	chr2:197668882	chr2:197197991~197199273:+
BRCA	cis	rs7523050	0.643	rs36047249	ENSG00000203897.3	SPATA42	-4.47	8.65e-06	0.00072	-0.26	-0.14	Fat distribution (HIV);	chr1:108858877	chr1:108857217~108858524:+
BRCA	cis	rs7523050	0.643	rs17563938	ENSG00000203897.3	SPATA42	-4.47	8.65e-06	0.00072	-0.26	-0.14	Fat distribution (HIV);	chr1:108859032	chr1:108857217~108858524:+
BRCA	cis	rs7523050	0.643	rs34572569	ENSG00000203897.3	SPATA42	-4.47	8.65e-06	0.00072	-0.26	-0.14	Fat distribution (HIV);	chr1:108859234	chr1:108857217~108858524:+
BRCA	cis	rs7523050	0.643	rs35885176	ENSG00000203897.3	SPATA42	-4.47	8.65e-06	0.00072	-0.26	-0.14	Fat distribution (HIV);	chr1:108859246	chr1:108857217~108858524:+
BRCA	cis	rs7523050	0.643	rs67091034	ENSG00000203897.3	SPATA42	-4.47	8.65e-06	0.00072	-0.26	-0.14	Fat distribution (HIV);	chr1:108859945	chr1:108857217~108858524:+
BRCA	cis	rs7523050	0.643	rs67567504	ENSG00000203897.3	SPATA42	-4.47	8.65e-06	0.00072	-0.26	-0.14	Fat distribution (HIV);	chr1:108859958	chr1:108857217~108858524:+
BRCA	cis	rs7523050	0.643	rs35438081	ENSG00000203897.3	SPATA42	-4.47	8.65e-06	0.00072	-0.26	-0.14	Fat distribution (HIV);	chr1:108860209	chr1:108857217~108858524:+
BRCA	cis	rs7523050	0.643	rs34114412	ENSG00000203897.3	SPATA42	-4.47	8.65e-06	0.00072	-0.26	-0.14	Fat distribution (HIV);	chr1:108860244	chr1:108857217~108858524:+
BRCA	cis	rs7523050	0.643	rs36052234	ENSG00000203897.3	SPATA42	-4.47	8.65e-06	0.00072	-0.26	-0.14	Fat distribution (HIV);	chr1:108860321	chr1:108857217~108858524:+
BRCA	cis	rs3768617	0.51	rs10752900	ENSG00000224468.3	RP11-181K3.4	-4.47	8.65e-06	0.00072	-0.15	-0.14	Fuchs's corneal dystrophy;	chr1:183117103	chr1:183138402~183141282:-
BRCA	cis	rs4831760	1	rs13276710	ENSG00000250483.1	PPM1AP1	4.47	8.66e-06	0.00072	0.2	0.14	Pulmonary function decline;	chr8:15680166	chr8:15806149~15807283:-
BRCA	cis	rs35740288	0.787	rs2291048	ENSG00000202081.1	RNU6-1280P	-4.47	8.66e-06	0.00072	-0.18	-0.14	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85682427	chr15:85651522~85651628:-
BRCA	cis	rs6001482	0.686	rs9623125	ENSG00000279278.1	CH17-264L24.1	4.47	8.66e-06	0.000721	0.11	0.14	Diastolic blood pressure;	chr22:22234600	chr22:22264601~22273020:+
BRCA	cis	rs6001482	0.702	rs9623126	ENSG00000279278.1	CH17-264L24.1	4.47	8.66e-06	0.000721	0.11	0.14	Diastolic blood pressure;	chr22:22234624	chr22:22264601~22273020:+
BRCA	cis	rs9818758	0.545	rs11717978	ENSG00000270441.1	RP11-694I15.7	4.47	8.66e-06	0.000721	0.29	0.14	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:48931603	chr3:49140086~49160851:-
BRCA	cis	rs9818758	0.556	rs13086240	ENSG00000270441.1	RP11-694I15.7	4.47	8.66e-06	0.000721	0.29	0.14	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:48963976	chr3:49140086~49160851:-
BRCA	cis	rs4948275	0.773	rs2249816	ENSG00000237233.2	TMEM26-AS1	4.47	8.67e-06	0.000721	0.16	0.14	Night sleep phenotypes;	chr10:61488037	chr10:61452639~61481956:+
BRCA	cis	rs253959	0.545	rs10072350	ENSG00000271918.1	CTD-2287O16.5	4.47	8.67e-06	0.000721	0.12	0.14	Bipolar disorder and schizophrenia;	chr5:116097829	chr5:116083807~116085416:-
BRCA	cis	rs6968419	0.708	rs57321537	ENSG00000279086.1	RP11-667F14.1	-4.47	8.67e-06	0.000722	-0.15	-0.14	Intraocular pressure;	chr7:116243399	chr7:116209234~116211511:-
BRCA	cis	rs6968419	0.747	rs6953050	ENSG00000279086.1	RP11-667F14.1	-4.47	8.67e-06	0.000722	-0.15	-0.14	Intraocular pressure;	chr7:116248108	chr7:116209234~116211511:-
BRCA	cis	rs6968419	0.747	rs6957561	ENSG00000279086.1	RP11-667F14.1	-4.47	8.67e-06	0.000722	-0.15	-0.14	Intraocular pressure;	chr7:116248285	chr7:116209234~116211511:-
BRCA	cis	rs11892454	0.515	rs11898327	ENSG00000217643.1	PTGES3P2	-4.47	8.67e-06	0.000722	-0.14	-0.14	Heschl's gyrus morphology;	chr2:25867380	chr2:25822469~25822950:+
BRCA	cis	rs7048146	1	rs7048146	ENSG00000213539.4	YBX1P6	4.47	8.67e-06	0.000722	0.15	0.14	Vascular brain injury;	chr9:109537042	chr9:109532830~109534332:-
BRCA	cis	rs7686660	1	rs10015475	ENSG00000250326.1	RP11-284M14.1	-4.47	8.68e-06	0.000722	-0.16	-0.14	Asthma;	chr4:143035737	chr4:142933195~143184861:-
BRCA	cis	rs7267979	0.966	rs2261795	ENSG00000274973.1	RP13-401N8.7	-4.47	8.68e-06	0.000722	-0.16	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25282500	chr20:25845497~25845862:+
BRCA	cis	rs6439153	0.967	rs9821769	ENSG00000261159.1	RP11-723O4.9	4.47	8.68e-06	0.000722	0.15	0.14	Pneumococcal bacteremia;	chr3:129007423	chr3:128859716~128860526:-
BRCA	cis	rs10129255	0.957	rs6576233	ENSG00000211972.2	IGHV3-66	4.47	8.68e-06	0.000722	0.1	0.14	Kawasaki disease;	chr14:106787239	chr14:106675017~106675544:-
BRCA	cis	rs6441961	0.501	rs71327045	ENSG00000223552.1	RP11-24F11.2	4.47	8.69e-06	0.000723	0.17	0.14	Celiac disease;	chr3:46240087	chr3:46364955~46407059:-
BRCA	cis	rs4143844	1	rs62006969	ENSG00000259251.2	RP11-643M14.1	4.47	8.69e-06	0.000723	0.34	0.14	Bipolar disorder and schizophrenia;	chr15:62001213	chr15:62060503~62062434:+
BRCA	cis	rs448720	1	rs7172137	ENSG00000260657.2	RP11-315D16.4	-4.47	8.7e-06	0.000723	-0.16	-0.14	Cognitive performance;	chr15:67912019	chr15:68267792~68277994:-
BRCA	cis	rs4664293	0.632	rs2059697	ENSG00000224152.1	AC009506.1	4.47	8.7e-06	0.000723	0.15	0.14	Monocyte percentage of white cells;	chr2:159799079	chr2:159615296~159617082:+
BRCA	cis	rs2832191	0.755	rs2832193	ENSG00000236056.1	GAPDHP14	4.47	8.7e-06	0.000724	0.15	0.14	Dental caries;	chr21:29121268	chr21:29222321~29223257:+
BRCA	cis	rs2412819	0.571	rs2729494	ENSG00000166763.7	STRCP1	-4.47	8.7e-06	0.000724	-0.19	-0.14	Lung cancer;	chr15:43837395	chr15:43699488~43718184:-
BRCA	cis	rs180730	0.519	rs1470696	ENSG00000251609.2	SETP12	4.47	8.7e-06	0.000724	0.18	0.14	Fasting plasma glucose;	chr4:120921412	chr4:120895494~120897083:-
BRCA	cis	rs4218	0.531	rs1374156	ENSG00000259732.1	RP11-59H7.3	-4.47	8.71e-06	0.000725	-0.16	-0.14	Social communication problems;	chr15:59046746	chr15:59121034~59133250:+
BRCA	cis	rs875971	0.66	rs28698552	ENSG00000273142.1	RP11-458F8.4	-4.47	8.71e-06	0.000725	-0.12	-0.14	Aortic root size;	chr7:66540031	chr7:66902857~66906297:+
BRCA	cis	rs1075265	0.692	rs805318	ENSG00000235937.1	AC008280.1	4.47	8.71e-06	0.000725	0.15	0.14	Chronotype;Morning vs. evening chronotype;	chr2:53907915	chr2:54029552~54030682:-
BRCA	cis	rs340630	0.967	rs13126334	ENSG00000251411.1	RP11-397E7.4	4.47	8.72e-06	0.000725	0.16	0.14	Systemic lupus erythematosus;	chr4:86988738	chr4:86913266~86914817:-
BRCA	cis	rs4718428	0.705	rs13227468	ENSG00000229180.5	GS1-124K5.11	4.47	8.72e-06	0.000725	0.13	0.14	Corneal structure;	chr7:66968576	chr7:66526088~66542624:-
BRCA	cis	rs9341808	0.718	rs9352806	ENSG00000272129.1	RP11-250B2.6	4.47	8.72e-06	0.000726	0.17	0.14	Sitting height ratio;	chr6:80270340	chr6:80355424~80356859:+
BRCA	cis	rs7727544	0.678	rs7735891	ENSG00000233006.5	AC034220.3	4.47	8.73e-06	0.000726	0.1	0.14	Blood metabolite levels;	chr5:132261312	chr5:132311285~132369916:-
BRCA	cis	rs7267979	0.966	rs454723	ENSG00000125804.12	FAM182A	-4.47	8.73e-06	0.000726	-0.18	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25458292	chr20:26054655~26086917:+
BRCA	cis	rs4478858	0.647	rs10798835	ENSG00000223907.1	LINC01226	-4.47	8.73e-06	0.000726	-0.17	-0.14	Alcohol dependence;	chr1:31236208	chr1:31518435~31524245:+
BRCA	cis	rs2842992	0.724	rs15982	ENSG00000237927.1	RP3-393E18.2	-4.47	8.73e-06	0.000726	-0.18	-0.14	Age-related macular degeneration (geographic atrophy);	chr6:159778655	chr6:159586955~159589169:-
BRCA	cis	rs11098499	0.722	rs7673476	ENSG00000260404.2	RP11-384K6.6	4.47	8.73e-06	0.000726	0.12	0.14	Corneal astigmatism;	chr4:119327528	chr4:118591773~118633729:+
BRCA	cis	rs62025270	0.649	rs12148610	ENSG00000259295.5	CSPG4P12	-4.47	8.73e-06	0.000726	-0.22	-0.14	Idiopathic pulmonary fibrosis;	chr15:85702697	chr15:85191438~85213905:+
BRCA	cis	rs4835473	0.932	rs7356157	ENSG00000249741.2	RP11-673E1.3	-4.47	8.73e-06	0.000726	-0.14	-0.14	Immature fraction of reticulocytes;	chr4:143739233	chr4:143911514~143912053:-
BRCA	cis	rs910316	0.967	rs11159121	ENSG00000259138.1	RP11-950C14.7	-4.47	8.74e-06	0.000727	-0.14	-0.14	Height;	chr14:75199326	chr14:75127153~75136930:+
BRCA	cis	rs11146838	1	rs11146838	ENSG00000099251.13	HSD17B7P2	4.47	8.74e-06	0.000727	0.15	0.14	Breast cancer;	chr10:38856846	chr10:38356380~38378505:+
BRCA	cis	rs6736093	0.966	rs13003919	ENSG00000236307.2	EEF1E1P1	4.47	8.74e-06	0.000727	0.17	0.14	Coronary artery disease;	chr2:111996373	chr2:111887914~111888741:+
BRCA	cis	rs2555155	0.633	rs2723663	ENSG00000254595.1	CTD-2010I16.1	4.47	8.74e-06	0.000727	0.16	0.14	DNA methylation (variation);	chr11:6462280	chr11:6488186~6489377:-
BRCA	cis	rs1005277	0.565	rs2474565	ENSG00000099251.13	HSD17B7P2	4.47	8.75e-06	0.000727	0.15	0.14	Extrinsic epigenetic age acceleration;	chr10:38091900	chr10:38356380~38378505:+
BRCA	cis	rs7267979	0.714	rs1555329	ENSG00000274973.1	RP13-401N8.7	-4.47	8.75e-06	0.000727	-0.16	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25251222	chr20:25845497~25845862:+
BRCA	cis	rs4835473	0.9	rs10025455	ENSG00000249741.2	RP11-673E1.3	4.47	8.75e-06	0.000727	0.15	0.14	Immature fraction of reticulocytes;	chr4:143998417	chr4:143911514~143912053:-
BRCA	cis	rs6840360	0.642	rs4696092	ENSG00000251603.1	RP11-164P12.4	-4.47	8.75e-06	0.000727	-0.12	-0.14	Intelligence (multi-trait analysis);	chr4:151491451	chr4:151667224~151670502:+
BRCA	cis	rs12887734	0.566	rs8548	ENSG00000269940.1	RP11-73M18.7	4.47	8.75e-06	0.000727	0.16	0.14	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103733243	chr14:103694560~103695170:+
BRCA	cis	rs875971	0.545	rs1796217	ENSG00000273142.1	RP11-458F8.4	-4.47	8.75e-06	0.000728	-0.14	-0.14	Aortic root size;	chr7:66620931	chr7:66902857~66906297:+
BRCA	cis	rs6908034	0.66	rs12525506	ENSG00000228412.5	RP4-625H18.2	4.47	8.75e-06	0.000728	0.3	0.14	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19794003	chr6:19802164~19804752:-
BRCA	cis	rs4664293	0.801	rs7589771	ENSG00000230783.1	AC009961.2	-4.47	8.76e-06	0.000728	-0.17	-0.14	Monocyte percentage of white cells;	chr2:159727621	chr2:159689217~159690291:-
BRCA	cis	rs7674212	0.51	rs55715738	ENSG00000251288.2	RP11-10L12.2	-4.47	8.76e-06	0.000728	-0.16	-0.14	Type 2 diabetes;	chr4:103209032	chr4:102751401~102752641:+
BRCA	cis	rs10266483	0.774	rs11765812	ENSG00000228653.2	HNRNPCP7	4.47	8.76e-06	0.000728	0.17	0.14	Response to statin therapy;	chr7:64385366	chr7:64500825~64501729:+
BRCA	cis	rs4143844	1	rs11629645	ENSG00000259251.2	RP11-643M14.1	4.47	8.76e-06	0.000728	0.34	0.14	Bipolar disorder and schizophrenia;	chr15:62014275	chr15:62060503~62062434:+
BRCA	cis	rs7824557	0.603	rs6995404	ENSG00000154316.13	TDH	-4.47	8.77e-06	0.000729	-0.17	-0.14	Retinal vascular caliber;	chr8:11324639	chr8:11339637~11368452:+
BRCA	cis	rs738144	0.502	rs9611034	ENSG00000225450.1	RP3-508I15.14	-4.47	8.77e-06	0.000729	-0.16	-0.14	IgG glycosylation;	chr22:38834879	chr22:38739003~38749041:+
BRCA	cis	rs7312933	0.524	rs11181465	ENSG00000257225.1	RP11-328C8.4	-4.47	8.77e-06	0.000729	-0.17	-0.14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42371296	chr12:42459366~42466128:+
BRCA	cis	rs10129255	0.536	rs8004835	ENSG00000224373.3	IGHV4-59	4.47	8.77e-06	0.000729	0.08	0.14	Kawasaki disease;	chr14:106686361	chr14:106627249~106627825:-
BRCA	cis	rs651907	1	rs665211	ENSG00000244119.1	PDCL3P4	4.47	8.77e-06	0.000729	0.1	0.14	Colorectal cancer;	chr3:101881184	chr3:101712472~101713191:+
BRCA	cis	rs9402743	0.671	rs6925684	ENSG00000234084.1	RP3-388E23.2	-4.47	8.78e-06	0.00073	-0.14	-0.14	Systemic lupus erythematosus;	chr6:135615740	chr6:135301568~135307158:+
BRCA	cis	rs9402743	0.671	rs6905536	ENSG00000234084.1	RP3-388E23.2	-4.47	8.78e-06	0.00073	-0.14	-0.14	Systemic lupus erythematosus;	chr6:135615865	chr6:135301568~135307158:+
BRCA	cis	rs9402743	0.671	rs6905555	ENSG00000234084.1	RP3-388E23.2	-4.47	8.78e-06	0.00073	-0.14	-0.14	Systemic lupus erythematosus;	chr6:135615894	chr6:135301568~135307158:+
BRCA	cis	rs9402743	0.671	rs9402725	ENSG00000234084.1	RP3-388E23.2	-4.47	8.78e-06	0.00073	-0.14	-0.14	Systemic lupus erythematosus;	chr6:135616509	chr6:135301568~135307158:+
BRCA	cis	rs6981523	0.553	rs2409730	ENSG00000154316.13	TDH	4.47	8.78e-06	0.00073	0.19	0.14	Neuroticism;	chr8:11203129	chr8:11339637~11368452:+
BRCA	cis	rs10266483	0.515	rs6948710	ENSG00000227986.1	TRIM60P18	4.47	8.78e-06	0.00073	0.16	0.14	Response to statin therapy;	chr7:64405625	chr7:64355078~64356199:+
BRCA	cis	rs300890	0.56	rs13118943	ENSG00000250326.1	RP11-284M14.1	-4.47	8.79e-06	0.00073	-0.16	-0.14	Nasopharyngeal carcinoma;	chr4:143264276	chr4:142933195~143184861:-
BRCA	cis	rs2280018	0.963	rs12928424	ENSG00000270580.4	PKD1P6	4.47	8.79e-06	0.00073	0.14	0.14	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15056916	chr16:15104723~15131601:-
BRCA	cis	rs2506028	0.507	rs2506034	ENSG00000273008.1	RP11-351D16.3	-4.47	8.79e-06	0.00073	-0.16	-0.14	Blood protein levels;	chr10:42956988	chr10:43136824~43138334:-
BRCA	cis	rs1075265	0.669	rs805317	ENSG00000235937.1	AC008280.1	4.47	8.79e-06	0.00073	0.15	0.14	Chronotype;Morning vs. evening chronotype;	chr2:53907867	chr2:54029552~54030682:-
BRCA	cis	rs2243480	1	rs4718269	ENSG00000222364.1	RNU6-96P	4.47	8.79e-06	0.000731	0.24	0.14	Diabetic kidney disease;	chr7:65735810	chr7:66395191~66395286:+
BRCA	cis	rs7771547	0.821	rs10947613	ENSG00000224666.3	RP1-50J22.4	4.47	8.79e-06	0.000731	0.16	0.14	Platelet distribution width;	chr6:36604563	chr6:36386831~36393462:+
BRCA	cis	rs516805	0.63	rs720205	ENSG00000279114.1	RP3-425C14.5	-4.47	8.8e-06	0.000731	-0.17	-0.14	Lymphocyte counts;	chr6:122107329	chr6:122471923~122484161:+
BRCA	cis	rs9952991	0.883	rs11663253	ENSG00000260302.1	RP11-973H7.1	4.47	8.8e-06	0.000731	0.23	0.14	Inflammatory skin disease;	chr18:12789557	chr18:12774651~12775923:-
BRCA	cis	rs6044112	1	rs6080296	ENSG00000273998.1	RP4-777L9.2	4.47	8.8e-06	0.000731	0.25	0.14	Response to taxane treatment (docetaxel);	chr20:16540883	chr20:16576068~16579615:+
BRCA	cis	rs490234	0.702	rs13302549	ENSG00000232630.1	PRPS1P2	-4.47	8.8e-06	0.000731	-0.14	-0.14	Mean arterial pressure;	chr9:125522496	chr9:125150653~125151589:+
BRCA	cis	rs703842	1	rs6581155	ENSG00000270039.1	RP11-571M6.17	-4.47	8.8e-06	0.000731	-0.18	-0.14	Multiple sclerosis;	chr12:57784379	chr12:57803838~57804415:+
BRCA	cis	rs7308116	1	rs7134892	ENSG00000274395.1	RP11-554D14.8	-4.47	8.8e-06	0.000732	-0.15	-0.14	Pelvic organ prolapse (moderate/severe);	chr12:107809392	chr12:107835541~107836555:-
BRCA	cis	rs12612619	0.732	rs4665366	ENSG00000229122.1	AGBL5-IT1	-4.47	8.81e-06	0.000732	-0.14	-0.14	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:26989728	chr2:27061038~27061815:+
BRCA	cis	rs875971	0.545	rs313828	ENSG00000230295.1	RP11-458F8.2	-4.47	8.81e-06	0.000732	-0.13	-0.14	Aortic root size;	chr7:66087627	chr7:66880708~66882981:+
BRCA	cis	rs2408955	0.521	rs10875753	ENSG00000257763.1	OR5BK1P	4.47	8.81e-06	0.000732	0.14	0.14	Glycated hemoglobin levels;	chr12:48163358	chr12:48355792~48356614:-
BRCA	cis	rs6603134	0.502	rs6603132	ENSG00000269139.2	CTD-3193O13.8	4.47	8.81e-06	0.000732	0.16	0.14	Blood protein levels;	chr19:8037908	chr19:7926001~7926810:+
BRCA	cis	rs7592578	0.679	rs59929070	ENSG00000272979.1	RP11-647K16.1	-4.47	8.81e-06	0.000732	-0.22	-0.14	Diastolic blood pressure;	chr2:190463126	chr2:190454092~190454521:-
BRCA	cis	rs2839186	0.749	rs62226488	ENSG00000239415.1	AP001469.9	4.47	8.81e-06	0.000732	0.15	0.14	Testicular germ cell tumor;	chr21:46290603	chr21:46251549~46254133:-
BRCA	cis	rs2839186	0.749	rs62226489	ENSG00000239415.1	AP001469.9	4.47	8.81e-06	0.000732	0.15	0.14	Testicular germ cell tumor;	chr21:46290605	chr21:46251549~46254133:-
BRCA	cis	rs9377188	0.744	rs2486419	ENSG00000236591.1	RP11-162J8.3	4.47	8.81e-06	0.000732	0.18	0.14	Cancer;	chr6:149008635	chr6:149027700~149032573:-
BRCA	cis	rs1823874	0.677	rs2168069	ENSG00000182397.13	DNM1P46	-4.47	8.81e-06	0.000732	-0.15	-0.14	IgG glycosylation;	chr15:99823798	chr15:99790156~99806927:-
BRCA	cis	rs17507216	0.718	rs7165690	ENSG00000259429.4	UBE2Q2P2	-4.47	8.81e-06	0.000732	-0.17	-0.14	Excessive daytime sleepiness;	chr15:82654804	chr15:82355142~82420075:+
BRCA	cis	rs757081	0.648	rs10832752	ENSG00000184669.7	OR7E14P	-4.47	8.82e-06	0.000732	-0.18	-0.14	Systolic blood pressure;	chr11:17263940	chr11:17013998~17053024:+
BRCA	cis	rs7726839	0.526	rs11960159	ENSG00000271781.1	CTD-2589H19.6	-4.47	8.82e-06	0.000732	-0.18	-0.14	Obesity-related traits;	chr5:568570	chr5:675826~676616:+
BRCA	cis	rs4143844	1	rs35119291	ENSG00000259251.2	RP11-643M14.1	4.47	8.82e-06	0.000733	0.33	0.14	Bipolar disorder and schizophrenia;	chr15:62042007	chr15:62060503~62062434:+
BRCA	cis	rs6997458	0.576	rs28374336	ENSG00000258256.1	RP11-219B4.5	-4.47	8.82e-06	0.000733	-0.16	-0.14	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85303314	chr8:85222446~85245717:-
BRCA	cis	rs4449834	0.816	rs6471898	ENSG00000254432.1	RP11-33I11.2	4.47	8.82e-06	0.000733	0.17	0.14	Sum eosinophil basophil counts;	chr8:60745803	chr8:60808735~60809606:-
BRCA	cis	rs13108904	0.539	rs13140926	ENSG00000253399.1	AC078852.2	-4.47	8.82e-06	0.000733	-0.17	-0.14	Obesity-related traits;	chr4:1347151	chr4:1358479~1359461:+
BRCA	cis	rs7665090	1	rs7664828	ENSG00000251288.2	RP11-10L12.2	-4.47	8.83e-06	0.000733	-0.16	-0.14	Primary biliary cholangitis;	chr4:102630219	chr4:102751401~102752641:+
BRCA	cis	rs7665090	0.967	rs7690123	ENSG00000251288.2	RP11-10L12.2	-4.47	8.83e-06	0.000733	-0.16	-0.14	Primary biliary cholangitis;	chr4:102630602	chr4:102751401~102752641:+
BRCA	cis	rs7665090	1	rs7665659	ENSG00000251288.2	RP11-10L12.2	-4.47	8.83e-06	0.000733	-0.16	-0.14	Primary biliary cholangitis;	chr4:102630661	chr4:102751401~102752641:+
BRCA	cis	rs7665090	1	rs7665854	ENSG00000251288.2	RP11-10L12.2	-4.47	8.83e-06	0.000733	-0.16	-0.14	Primary biliary cholangitis;	chr4:102630752	chr4:102751401~102752641:+
BRCA	cis	rs7665090	0.846	rs7690700	ENSG00000251288.2	RP11-10L12.2	-4.47	8.83e-06	0.000733	-0.16	-0.14	Primary biliary cholangitis;	chr4:102630911	chr4:102751401~102752641:+
BRCA	cis	rs7665090	1	rs12644381	ENSG00000251288.2	RP11-10L12.2	-4.47	8.83e-06	0.000733	-0.16	-0.14	Primary biliary cholangitis;	chr4:102631273	chr4:102751401~102752641:+
BRCA	cis	rs7665090	1	rs1054037	ENSG00000251288.2	RP11-10L12.2	-4.47	8.83e-06	0.000733	-0.16	-0.14	Primary biliary cholangitis;	chr4:102631552	chr4:102751401~102752641:+
BRCA	cis	rs9311474	0.507	rs6787154	ENSG00000243224.1	RP5-1157M23.2	-4.47	8.83e-06	0.000733	-0.15	-0.14	Electroencephalogram traits;	chr3:52750400	chr3:52239258~52241097:+
BRCA	cis	rs6452524	0.935	rs6887915	ENSG00000281327.1	LINC01338	4.47	8.83e-06	0.000733	0.16	0.14	Hypertension (SNP x SNP interaction);	chr5:83170837	chr5:82850864~82859836:-
BRCA	cis	rs17270561	0.697	rs9366633	ENSG00000272462.2	U91328.19	-4.47	8.83e-06	0.000733	-0.17	-0.14	Iron status biomarkers;	chr6:25837826	chr6:25992662~26001775:+
BRCA	cis	rs13113518	1	rs6849433	ENSG00000273257.1	RP11-177J6.1	4.47	8.83e-06	0.000734	0.18	0.14	Height;	chr4:55506498	chr4:55387949~55388271:+
BRCA	cis	rs13113518	0.966	rs12501327	ENSG00000273257.1	RP11-177J6.1	4.47	8.83e-06	0.000734	0.18	0.14	Height;	chr4:55507248	chr4:55387949~55388271:+
BRCA	cis	rs6723226	0.806	rs2710606	ENSG00000276517.1	AL133243.2	-4.47	8.84e-06	0.000734	-0.18	-0.14	Intelligence (multi-trait analysis);	chr2:32586842	chr2:32526504~32529507:+
BRCA	cis	rs1656368	0.726	rs55720154	ENSG00000279311.1	RP11-170K4.2	4.47	8.84e-06	0.000734	0.18	0.14	Lobe attachment (rater-scored or self-reported);	chr3:158558021	chr3:158869898~158871821:+
BRCA	cis	rs11098499	0.954	rs1546505	ENSG00000260404.2	RP11-384K6.6	4.47	8.84e-06	0.000734	0.13	0.14	Corneal astigmatism;	chr4:119320069	chr4:118591773~118633729:+
BRCA	cis	rs8098244	0.964	rs2337182	ENSG00000264745.1	TTC39C-AS1	4.47	8.84e-06	0.000735	0.19	0.14	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23768548	chr18:23994213~24015339:-
BRCA	cis	rs728616	0.681	rs35014047	ENSG00000225484.5	NUTM2B-AS1	-4.47	8.85e-06	0.000735	-0.32	-0.14	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80152641	chr10:79663088~79826594:-
BRCA	cis	rs7243790	1	rs17473264	ENSG00000277324.1	RP11-850A17.1	-4.47	8.85e-06	0.000735	-0.16	-0.14	Diastolic blood pressure;	chr18:54436534	chr18:54268346~54270028:-
BRCA	cis	rs651907	0.613	rs1707618	ENSG00000244119.1	PDCL3P4	4.47	8.85e-06	0.000735	0.11	0.14	Colorectal cancer;	chr3:101912363	chr3:101712472~101713191:+
BRCA	cis	rs7974517	1	rs7974517	ENSG00000272368.2	RP4-605O3.4	-4.47	8.85e-06	0.000735	-0.14	-0.14	Male-pattern baldness;	chr12:50751299	chr12:50112197~50165618:+
BRCA	cis	rs2243480	1	rs2961102	ENSG00000275400.1	RP4-756H11.5	4.47	8.85e-06	0.000735	0.25	0.14	Diabetic kidney disease;	chr7:65959671	chr7:66553805~66554199:-
BRCA	cis	rs321358	1	rs321361	ENSG00000271390.1	RP11-89C3.3	4.47	8.86e-06	0.000735	0.22	0.14	Body mass index;	chr11:111125495	chr11:111089870~111090368:-
BRCA	cis	rs321358	1	rs321362	ENSG00000271390.1	RP11-89C3.3	4.47	8.86e-06	0.000735	0.22	0.14	Body mass index;	chr11:111125754	chr11:111089870~111090368:-
BRCA	cis	rs321358	1	rs321363	ENSG00000271390.1	RP11-89C3.3	4.47	8.86e-06	0.000735	0.22	0.14	Body mass index;	chr11:111125929	chr11:111089870~111090368:-
BRCA	cis	rs7771547	0.821	rs7755461	ENSG00000224666.3	RP1-50J22.4	4.47	8.86e-06	0.000735	0.16	0.14	Platelet distribution width;	chr6:36607055	chr6:36386831~36393462:+
BRCA	cis	rs1371614	0.632	rs3820823	ENSG00000272148.1	RP11-195B17.1	4.47	8.86e-06	0.000736	0.15	0.14	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26941938	chr2:27062428~27062907:-
BRCA	cis	rs7267979	0.565	rs4815432	ENSG00000231081.1	RP4-760C5.3	4.47	8.86e-06	0.000736	0.17	0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25575767	chr20:26008791~26010531:-
BRCA	cis	rs610932	0.517	rs474123	ENSG00000275344.1	MIR6503	-4.47	8.86e-06	0.000736	-0.14	-0.14	Alzheimer's disease;	chr11:60133949	chr11:60209071~60209156:-
BRCA	cis	rs4942486	1	rs4942486	ENSG00000215515.2	IFIT1P1	4.47	8.86e-06	0.000736	0.15	0.14	LDL cholesterol levels;LDL cholesterol;	chr13:32379251	chr13:32384660~32386108:+
BRCA	cis	rs56322409	0.897	rs12357173	ENSG00000226688.5	ENTPD1-AS1	4.47	8.86e-06	0.000736	0.16	0.14	Blood metabolite levels;	chr10:95684846	chr10:95753206~96090238:-
BRCA	cis	rs7809950	0.559	rs2248465	ENSG00000238832.1	snoU109	4.47	8.86e-06	0.000736	0.18	0.14	Coronary artery disease;	chr7:107663183	chr7:107603363~107603507:+
BRCA	cis	rs875971	0.66	rs801192	ENSG00000273142.1	RP11-458F8.4	4.47	8.87e-06	0.000736	0.12	0.14	Aortic root size;	chr7:66566965	chr7:66902857~66906297:+
BRCA	cis	rs875971	0.66	rs801190	ENSG00000273142.1	RP11-458F8.4	4.47	8.87e-06	0.000736	0.12	0.14	Aortic root size;	chr7:66568046	chr7:66902857~66906297:+
BRCA	cis	rs875971	0.66	rs3857686	ENSG00000273142.1	RP11-458F8.4	4.47	8.87e-06	0.000736	0.12	0.14	Aortic root size;	chr7:66571204	chr7:66902857~66906297:+
BRCA	cis	rs7267979	1	rs12428	ENSG00000125804.12	FAM182A	4.47	8.87e-06	0.000736	0.18	0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25453185	chr20:26054655~26086917:+
BRCA	cis	rs6480314	0.522	rs4746754	ENSG00000233590.1	RP11-153K11.3	4.47	8.87e-06	0.000737	0.21	0.14	Optic nerve measurement (disc area);	chr10:68289862	chr10:68233251~68242379:-
BRCA	cis	rs6480314	0.522	rs10762204	ENSG00000233590.1	RP11-153K11.3	4.47	8.87e-06	0.000737	0.21	0.14	Optic nerve measurement (disc area);	chr10:68290006	chr10:68233251~68242379:-
BRCA	cis	rs12571093	0.571	rs10762205	ENSG00000233590.1	RP11-153K11.3	4.47	8.87e-06	0.000737	0.21	0.14	Optic nerve measurement (disc area);	chr10:68290145	chr10:68233251~68242379:-
BRCA	cis	rs1075265	0.756	rs6751105	ENSG00000235937.1	AC008280.1	4.47	8.87e-06	0.000737	0.15	0.14	Chronotype;Morning vs. evening chronotype;	chr2:54129214	chr2:54029552~54030682:-
BRCA	cis	rs7789940	1	rs758944	ENSG00000280388.1	RP11-229D13.3	-4.47	8.88e-06	0.000737	-0.15	-0.14	Multiple sclerosis;	chr7:76323980	chr7:76043977~76045963:-
BRCA	cis	rs2880765	0.835	rs7169632	ENSG00000202081.1	RNU6-1280P	4.46	8.88e-06	0.000738	0.16	0.14	Coronary artery disease;	chr15:85501436	chr15:85651522~85651628:-
BRCA	cis	rs10986311	0.588	rs1139641	ENSG00000227200.1	RP11-121A14.3	-4.46	8.89e-06	0.000738	-0.16	-0.14	Vitiligo;	chr9:124357367	chr9:124262876~124265809:+
BRCA	cis	rs755249	0.529	rs3768299	ENSG00000182109.6	RP11-69E11.4	4.46	8.89e-06	0.000738	0.19	0.14	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39391520	chr1:39522280~39546187:-
BRCA	cis	rs71520386	0.807	rs10263435	ENSG00000228649.7	AC005682.5	-4.46	8.89e-06	0.000738	-0.15	-0.14	Fibrinogen levels;	chr7:22790243	chr7:22854178~22861579:+
BRCA	cis	rs13108904	0.539	rs13141992	ENSG00000253399.1	AC078852.2	-4.46	8.89e-06	0.000738	-0.17	-0.14	Obesity-related traits;	chr4:1346977	chr4:1358479~1359461:+
BRCA	cis	rs793571	0.628	rs2013098	ENSG00000259250.1	RP11-50C13.1	-4.46	8.89e-06	0.000738	-0.23	-0.14	Schizophrenia;	chr15:58804600	chr15:58587507~58591676:+
BRCA	cis	rs10833905	1	rs1863627	ENSG00000246225.5	RP11-17A1.3	-4.46	8.89e-06	0.000738	-0.19	-0.14	Sudden cardiac arrest;	chr11:23044317	chr11:22829380~22945393:+
BRCA	cis	rs3845817	1	rs3845816	ENSG00000237979.1	AC007389.1	-4.46	8.89e-06	0.000738	-0.16	-0.14	Bipolar disorder;	chr2:65531221	chr2:65500993~65502138:-
BRCA	cis	rs11098499	0.954	rs10008392	ENSG00000250412.1	KLHL2P1	4.46	8.89e-06	0.000738	0.16	0.14	Corneal astigmatism;	chr4:119397684	chr4:119334329~119378233:+
BRCA	cis	rs17597773	0.674	rs2279638	ENSG00000238078.1	LINC01352	-4.46	8.9e-06	0.000739	-0.16	-0.14	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220828445	chr1:220829255~220832429:+
BRCA	cis	rs372883	0.6	rs1153277	ENSG00000176054.6	RPL23P2	-4.46	8.9e-06	0.000739	-0.15	-0.14	Pancreatic cancer;	chr21:29294546	chr21:28997613~28998033:-
BRCA	cis	rs11673344	0.523	rs6510584	ENSG00000226686.6	LINC01535	4.46	8.9e-06	0.000739	0.18	0.14	Obesity-related traits;	chr19:37058699	chr19:37251912~37265535:+
BRCA	cis	rs2832191	0.935	rs11910316	ENSG00000232855.5	AF131217.1	4.46	8.9e-06	0.000739	0.16	0.14	Dental caries;	chr21:29147408	chr21:28439346~28674848:-
BRCA	cis	rs8177876	0.915	rs8059692	ENSG00000261838.4	RP11-303E16.6	4.46	8.9e-06	0.000739	0.27	0.14	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81096889	chr16:81069854~81076598:+
BRCA	cis	rs12612619	0.704	rs6754356	ENSG00000272148.1	RP11-195B17.1	4.46	8.9e-06	0.000739	0.16	0.14	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27092153	chr2:27062428~27062907:-
BRCA	cis	rs10435719	0.902	rs4840599	ENSG00000154316.13	TDH	4.46	8.9e-06	0.000739	0.17	0.14	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11947871	chr8:11339637~11368452:+
BRCA	cis	rs2073316	0.592	rs7595578	ENSG00000272716.1	RP11-563N4.1	4.46	8.9e-06	0.000739	0.15	0.14	Interleukin-18 levels;	chr2:31433514	chr2:32165046~32165757:-
BRCA	cis	rs1371614	0.589	rs4665919	ENSG00000272148.1	RP11-195B17.1	-4.46	8.9e-06	0.000739	-0.15	-0.14	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26892436	chr2:27062428~27062907:-
BRCA	cis	rs1865760	0.929	rs12195653	ENSG00000272462.2	U91328.19	-4.46	8.91e-06	0.000739	-0.16	-0.14	Height;	chr6:25958393	chr6:25992662~26001775:+
BRCA	cis	rs911555	0.511	rs2296483	ENSG00000269958.1	RP11-73M18.8	4.46	8.91e-06	0.00074	0.14	0.14	Intelligence (multi-trait analysis);	chr14:103563455	chr14:103696353~103697163:+
BRCA	cis	rs8054556	1	rs9924686	ENSG00000261367.1	RP11-455F5.4	-4.46	8.91e-06	0.00074	-0.16	-0.14	Autism spectrum disorder or schizophrenia;	chr16:29991755	chr16:30107675~30110541:+
BRCA	cis	rs6828577	0.862	rs299005	ENSG00000281731.1	RP11-384K6.8	-4.46	8.91e-06	0.00074	-0.16	-0.14	Perioperative myocardial infarction in coronary artery bypass surgery;	chr4:118674209	chr4:118664087~118685341:-
BRCA	cis	rs4835473	0.932	rs2323200	ENSG00000249741.2	RP11-673E1.3	-4.46	8.91e-06	0.00074	-0.14	-0.14	Immature fraction of reticulocytes;	chr4:143765448	chr4:143911514~143912053:-
BRCA	cis	rs6430585	0.583	rs7581814	ENSG00000224043.6	CCNT2-AS1	4.46	8.92e-06	0.00074	0.23	0.14	Corneal structure;	chr2:135884023	chr2:134735464~134918710:-
BRCA	cis	rs11098499	0.57	rs6832740	ENSG00000249244.1	RP11-548H18.2	4.46	8.92e-06	0.00074	0.16	0.14	Corneal astigmatism;	chr4:119624981	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.644	rs6855918	ENSG00000249244.1	RP11-548H18.2	4.46	8.92e-06	0.00074	0.16	0.14	Corneal astigmatism;	chr4:119625144	chr4:119391831~119395335:-
BRCA	cis	rs9788721	1	rs8034191	ENSG00000261762.1	RP11-650L12.2	-4.46	8.92e-06	0.00074	-0.17	-0.14	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78513681	chr15:78589123~78591276:-
BRCA	cis	rs4819052	1	rs2297286	ENSG00000184274.3	LINC00315	-4.46	8.92e-06	0.00074	-0.2	-0.14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45287982	chr21:45300245~45305257:-
BRCA	cis	rs6921919	0.583	rs6907950	ENSG00000220721.1	OR1F12	4.46	8.92e-06	0.00074	0.17	0.14	Autism spectrum disorder or schizophrenia;	chr6:28402469	chr6:28073316~28074233:+
BRCA	cis	rs7141336	0.8	rs11624683	ENSG00000258884.1	CTD-3035D6.2	4.46	8.92e-06	0.00074	0.18	0.14	Anxiety disorder;	chr14:90822766	chr14:90822365~90828128:-
BRCA	cis	rs7141336	0.77	rs12898117	ENSG00000258884.1	CTD-3035D6.2	4.46	8.92e-06	0.00074	0.18	0.14	Anxiety disorder;	chr14:90823136	chr14:90822365~90828128:-
BRCA	cis	rs957448	0.554	rs12682601	ENSG00000261437.1	RP11-22C11.2	4.46	8.92e-06	0.00074	0.13	0.14	Nonsyndromic cleft lip with cleft palate;	chr8:94582492	chr8:94637285~94639467:-
BRCA	cis	rs12612619	0.667	rs11126871	ENSG00000272148.1	RP11-195B17.1	-4.46	8.92e-06	0.00074	-0.16	-0.14	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27121589	chr2:27062428~27062907:-
BRCA	cis	rs77204473	1	rs79711490	ENSG00000280143.1	AP000892.6	-4.46	8.93e-06	0.000741	-0.26	-0.14	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116914625	chr11:117204967~117210292:+
BRCA	cis	rs6831352	0.819	rs2851274	ENSG00000272777.1	RP11-571L19.8	-4.46	8.93e-06	0.000741	-0.14	-0.14	Alcohol dependence;	chr4:99104715	chr4:99067256~99068125:-
BRCA	cis	rs7701440	0.512	rs7444594	ENSG00000215032.2	GNL3LP1	4.46	8.93e-06	0.000741	0.16	0.14	Educational attainment;	chr5:61238832	chr5:60891935~60893577:-
BRCA	cis	rs2273156	1	rs7153068	ENSG00000226677.3	IGBP1P1	-4.46	8.93e-06	0.000741	-0.2	-0.14	Immunoglobulin light chain (AL) amyloidosis;	chr14:34990275	chr14:34939324~34940332:+
BRCA	cis	rs2273156	1	rs12050447	ENSG00000226677.3	IGBP1P1	-4.46	8.93e-06	0.000741	-0.2	-0.14	Immunoglobulin light chain (AL) amyloidosis;	chr14:34992759	chr14:34939324~34940332:+
BRCA	cis	rs6005807	0.719	rs73430168	ENSG00000272858.1	CTA-292E10.8	-4.46	8.94e-06	0.000741	-0.25	-0.14	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28589440	chr22:28814914~28815662:+
BRCA	cis	rs67981189	0.513	rs2526856	ENSG00000269927.1	RP6-91H8.3	4.46	8.94e-06	0.000741	0.17	0.14	Schizophrenia;	chr14:70946000	chr14:71141125~71143253:-
BRCA	cis	rs11148252	0.669	rs61958050	ENSG00000278238.1	RP11-245D16.4	-4.46	8.94e-06	0.000742	-0.15	-0.14	Lewy body disease;	chr13:52420292	chr13:52454775~52455331:-
BRCA	cis	rs8054556	1	rs4787489	ENSG00000261367.1	RP11-455F5.4	-4.46	8.94e-06	0.000742	-0.16	-0.14	Autism spectrum disorder or schizophrenia;	chr16:29984559	chr16:30107675~30110541:+
BRCA	cis	rs997295	0.713	rs12905509	ENSG00000270964.1	RP11-502I4.3	-4.46	8.94e-06	0.000742	-0.15	-0.14	Motion sickness;	chr15:67701770	chr15:67541072~67542604:-
BRCA	cis	rs11758351	0.715	rs75390741	ENSG00000241549.7	GUSBP2	-4.46	8.94e-06	0.000742	-0.2	-0.14	Renal underexcretion gout;Gout;	chr6:26209556	chr6:26871484~26956554:-
BRCA	cis	rs7267979	0.934	rs4815423	ENSG00000125804.12	FAM182A	4.46	8.95e-06	0.000743	0.18	0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25406885	chr20:26054655~26086917:+
BRCA	cis	rs4908768	0.501	rs6669503	ENSG00000232912.4	RP5-1115A15.1	4.46	8.96e-06	0.000743	0.13	0.14	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8504241	chr1:8424645~8434838:+
BRCA	cis	rs7312933	0.501	rs3810793	ENSG00000257225.1	RP11-328C8.4	-4.46	8.96e-06	0.000743	-0.16	-0.14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42335605	chr12:42459366~42466128:+
BRCA	cis	rs7727544	0.716	rs2089855	ENSG00000233006.5	AC034220.3	4.46	8.96e-06	0.000743	0.1	0.14	Blood metabolite levels;	chr5:132237836	chr5:132311285~132369916:-
BRCA	cis	rs2832191	0.716	rs2249028	ENSG00000215533.7	LINC00189	-4.46	8.96e-06	0.000743	-0.16	-0.14	Dental caries;	chr21:28993001	chr21:29193480~29288205:+
BRCA	cis	rs7727544	0.582	rs7703009	ENSG00000233006.5	AC034220.3	4.46	8.96e-06	0.000743	0.1	0.14	Blood metabolite levels;	chr5:132216692	chr5:132311285~132369916:-
BRCA	cis	rs2154319	0.609	rs12131741	ENSG00000235358.1	RP11-399E6.1	-4.46	8.96e-06	0.000744	-0.19	-0.14	Height;	chr1:41249191	chr1:41242373~41284861:+
BRCA	cis	rs2574985	0.813	rs3011771	ENSG00000231345.3	BEND3P1	-4.46	8.97e-06	0.000744	-0.23	-0.14	Subjective well-being;	chr10:50477528	chr10:50655967~50660472:+
BRCA	cis	rs516805	0.634	rs2816159	ENSG00000279114.1	RP3-425C14.5	-4.46	8.97e-06	0.000744	-0.18	-0.14	Lymphocyte counts;	chr6:122121982	chr6:122471923~122484161:+
BRCA	cis	rs7119	0.651	rs17394732	ENSG00000259362.2	RP11-307C19.1	4.46	8.97e-06	0.000744	0.19	0.14	Type 2 diabetes;	chr15:77543315	chr15:77525540~77534110:+
BRCA	cis	rs6714710	0.603	rs6738389	ENSG00000230606.9	AC159540.1	-4.46	8.97e-06	0.000744	-0.16	-0.14	Posterior cortical atrophy and Alzheimer's disease;	chr2:97770268	chr2:97416165~97433527:-
BRCA	cis	rs13160562	0.509	rs26501	ENSG00000248734.2	CTD-2260A17.1	4.46	8.97e-06	0.000744	0.15	0.14	Alcohol dependence;	chr5:96765060	chr5:96784777~96785999:+
BRCA	cis	rs10411936	0.712	rs8103521	ENSG00000280332.1	CTD-2013N17.6	4.46	8.97e-06	0.000744	0.12	0.14	Multiple sclerosis;White blood cell count;	chr19:16478939	chr19:16356329~16358327:-
BRCA	cis	rs13108904	0.875	rs10024013	ENSG00000196810.4	CTBP1-AS2	-4.46	8.98e-06	0.000745	-0.14	-0.14	Obesity-related traits;	chr4:1287004	chr4:1249300~1288291:+
BRCA	cis	rs6570726	0.791	rs392612	ENSG00000270638.1	RP3-466P17.1	-4.46	8.98e-06	0.000745	-0.16	-0.14	Lobe attachment (rater-scored or self-reported);	chr6:145560450	chr6:145735570~145737218:+
BRCA	cis	rs8098244	0.58	rs1711452	ENSG00000264745.1	TTC39C-AS1	4.46	8.98e-06	0.000745	0.16	0.14	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23692607	chr18:23994213~24015339:-
BRCA	cis	rs78487399	0.908	rs77888770	ENSG00000234936.1	AC010883.5	4.46	8.98e-06	0.000745	0.22	0.14	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43559968	chr2:43229573~43233394:+
BRCA	cis	rs2505998	0.957	rs2506005	ENSG00000273008.1	RP11-351D16.3	-4.46	8.98e-06	0.000745	-0.16	-0.14	Hirschsprung disease;	chr10:43086532	chr10:43136824~43138334:-
BRCA	cis	rs11673344	0.503	rs703531	ENSG00000226686.6	LINC01535	4.46	8.99e-06	0.000745	0.18	0.14	Obesity-related traits;	chr19:37010050	chr19:37251912~37265535:+
BRCA	cis	rs13108904	0.905	rs1732108	ENSG00000254094.1	AC078852.1	4.46	8.99e-06	0.000745	0.15	0.14	Obesity-related traits;	chr4:1282762	chr4:1356581~1358075:+
BRCA	cis	rs10861342	1	rs1444608	ENSG00000257999.1	RP11-61E11.2	-4.46	8.99e-06	0.000745	-0.29	-0.14	IgG glycosylation;	chr12:105165379	chr12:105102472~105107179:-
BRCA	cis	rs7267979	1	rs2482911	ENSG00000276952.1	RP5-965G21.6	-4.46	8.99e-06	0.000745	-0.17	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25414892	chr20:25284915~25285588:-
BRCA	cis	rs11098499	0.954	rs2389803	ENSG00000250412.1	KLHL2P1	-4.46	8.99e-06	0.000745	-0.16	-0.14	Corneal astigmatism;	chr4:119472356	chr4:119334329~119378233:+
BRCA	cis	rs416603	0.967	rs7191538	ENSG00000262703.1	RP11-485G7.6	-4.46	8.99e-06	0.000745	-0.14	-0.14	Type 1 diabetes;	chr16:11269532	chr16:11348143~11349321:-
BRCA	cis	rs11071559	0.935	rs11639084	ENSG00000259591.1	RP11-554D20.1	-4.46	8.99e-06	0.000746	-0.18	-0.14	Asthma;	chr15:60774317	chr15:60763906~60765625:+
BRCA	cis	rs10844706	0.699	rs2401390	ENSG00000256673.1	RP11-599J14.2	-4.46	8.99e-06	0.000746	-0.17	-0.14	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9719218	chr12:9398355~9414851:-
BRCA	cis	rs2115630	1	rs8037423	ENSG00000259728.4	LINC00933	-4.46	8.99e-06	0.000746	-0.15	-0.14	P wave terminal force;	chr15:84812263	chr15:84570649~84580175:+
BRCA	cis	rs10129255	0.957	rs12590735	ENSG00000274576.2	IGHV2-70	4.46	9e-06	0.000746	0.12	0.14	Kawasaki disease;	chr14:106779660	chr14:106770577~106771020:-
BRCA	cis	rs2115630	1	rs7183401	ENSG00000275120.1	RP11-182J1.17	-4.46	9e-06	0.000746	-0.16	-0.14	P wave terminal force;	chr15:84828713	chr15:84599434~84606463:-
BRCA	cis	rs783540	0.632	rs17356528	ENSG00000276710.3	CSPG4P8	4.46	9e-06	0.000746	0.16	0.14	Schizophrenia;	chr15:82636799	chr15:82459472~82477258:+
BRCA	cis	rs6430585	0.583	rs59243420	ENSG00000231890.6	DARS-AS1	-4.46	9e-06	0.000746	-0.21	-0.14	Corneal structure;	chr2:135826968	chr2:135985176~136022593:+
BRCA	cis	rs4834770	0.718	rs4833618	ENSG00000245958.5	RP11-33B1.1	4.46	9e-06	0.000747	0.12	0.14	Blood protein levels;	chr4:119388345	chr4:119454791~119552025:+
BRCA	cis	rs2839186	0.967	rs4819222	ENSG00000239415.1	AP001469.9	4.46	9e-06	0.000747	0.15	0.14	Testicular germ cell tumor;	chr21:46287864	chr21:46251549~46254133:-
BRCA	cis	rs1910358	0.515	rs1521002	ENSG00000248874.4	C5orf17	-4.46	9.01e-06	0.000747	-0.2	-0.14	Venous thromboembolism (SNP x SNP interaction);	chr5:23726490	chr5:23951348~24178263:+
BRCA	cis	rs17228178	1	rs17228178	ENSG00000215302.7	CTD-3092A11.1	-4.46	9.01e-06	0.000747	-0.18	-0.14	Facial depth;Facial morphology (factor 1, breadth of lateral portion of upper face);	chr15:31177725	chr15:30470779~30507623:+
BRCA	cis	rs13325613	0.749	rs13070099	ENSG00000223552.1	RP11-24F11.2	-4.46	9.01e-06	0.000747	-0.27	-0.14	Monocyte count;	chr3:46211723	chr3:46364955~46407059:-
BRCA	cis	rs13325613	0.834	rs34047458	ENSG00000223552.1	RP11-24F11.2	-4.46	9.01e-06	0.000747	-0.27	-0.14	Monocyte count;	chr3:46212108	chr3:46364955~46407059:-
BRCA	cis	rs13325613	0.834	rs35429781	ENSG00000223552.1	RP11-24F11.2	-4.46	9.01e-06	0.000747	-0.27	-0.14	Monocyte count;	chr3:46212116	chr3:46364955~46407059:-
BRCA	cis	rs13325613	0.834	rs13095946	ENSG00000223552.1	RP11-24F11.2	-4.46	9.01e-06	0.000747	-0.27	-0.14	Monocyte count;	chr3:46212321	chr3:46364955~46407059:-
BRCA	cis	rs853679	0.699	rs9468318	ENSG00000216901.1	AL022393.7	4.46	9.01e-06	0.000747	0.21	0.14	Depression;	chr6:28241753	chr6:28176188~28176674:+
BRCA	cis	rs10129255	0.5	rs10143242	ENSG00000254174.1	IGHV1-12	4.46	9.01e-06	0.000747	0.11	0.14	Kawasaki disease;	chr14:106681814	chr14:106122420~106122709:-
BRCA	cis	rs9868809	0.772	rs9812200	ENSG00000225399.4	RP11-3B7.1	4.46	9.01e-06	0.000747	0.18	0.14	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48658234	chr3:49260085~49261316:+
BRCA	cis	rs6490294	0.571	rs11066118	ENSG00000234608.6	MAPKAPK5-AS1	4.46	9.01e-06	0.000747	0.2	0.14	Mean platelet volume;	chr12:111996348	chr12:111839764~111842902:-
BRCA	cis	rs5751614	0.62	rs1811017	ENSG00000240160.3	RN7SL263P	4.46	9.01e-06	0.000747	0.17	0.14	Height;	chr22:23264771	chr22:23261782~23262071:-
BRCA	cis	rs17597773	0.638	rs10495152	ENSG00000238078.1	LINC01352	-4.46	9.01e-06	0.000747	-0.15	-0.14	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220817013	chr1:220829255~220832429:+
BRCA	cis	rs12073837	0.784	rs6673877	ENSG00000238078.1	LINC01352	-4.46	9.01e-06	0.000747	-0.15	-0.14	F-cell distribution;	chr1:220817642	chr1:220829255~220832429:+
BRCA	cis	rs62025270	0.522	rs338519	ENSG00000259295.5	CSPG4P12	-4.46	9.01e-06	0.000747	-0.18	-0.14	Idiopathic pulmonary fibrosis;	chr15:85671648	chr15:85191438~85213905:+
BRCA	cis	rs11098499	0.754	rs714899	ENSG00000225892.3	RP11-384K6.2	4.46	9.01e-06	0.000747	0.13	0.14	Corneal astigmatism;	chr4:119321880	chr4:118632274~118634759:+
BRCA	cis	rs1371614	0.588	rs11126784	ENSG00000229122.1	AGBL5-IT1	4.46	9.02e-06	0.000748	0.14	0.14	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26946974	chr2:27061038~27061815:+
BRCA	cis	rs2229238	0.911	rs73023331	ENSG00000272030.1	RP1-178F15.4	-4.46	9.02e-06	0.000748	-0.19	-0.14	Coronary heart disease;	chr1:154535734	chr1:153631438~153634397:-
BRCA	cis	rs2229238	0.826	rs111742980	ENSG00000272030.1	RP1-178F15.4	-4.46	9.02e-06	0.000748	-0.19	-0.14	Coronary heart disease;	chr1:154536288	chr1:153631438~153634397:-
BRCA	cis	rs2229238	0.911	rs4639752	ENSG00000272030.1	RP1-178F15.4	-4.46	9.02e-06	0.000748	-0.19	-0.14	Coronary heart disease;	chr1:154536498	chr1:153631438~153634397:-
BRCA	cis	rs1910358	0.515	rs10073904	ENSG00000248874.4	C5orf17	-4.46	9.02e-06	0.000748	-0.2	-0.14	Venous thromboembolism (SNP x SNP interaction);	chr5:23724265	chr5:23951348~24178263:+
BRCA	cis	rs860295	0.702	rs11264375	ENSG00000225855.5	RUSC1-AS1	-4.46	9.02e-06	0.000748	-0.11	-0.14	Body mass index;	chr1:155454274	chr1:155316863~155324176:-
BRCA	cis	rs6921919	0.583	rs16894060	ENSG00000273712.1	RP5-874C20.7	4.46	9.03e-06	0.000748	0.18	0.14	Autism spectrum disorder or schizophrenia;	chr6:28394694	chr6:28315613~28315883:-
BRCA	cis	rs11673344	0.504	rs4239587	ENSG00000276846.1	CTD-3220F14.3	4.46	9.03e-06	0.000748	0.16	0.14	Obesity-related traits;	chr19:37136211	chr19:37314868~37315620:-
BRCA	cis	rs7312933	0.558	rs4768402	ENSG00000257225.1	RP11-328C8.4	4.46	9.03e-06	0.000749	0.16	0.14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42361774	chr12:42459366~42466128:+
BRCA	cis	rs10916772	0.609	rs1925667	ENSG00000236963.4	LINC01141	4.46	9.03e-06	0.000749	0.25	0.14	Psychosis proneness (perceptual aberration scale);	chr1:20393584	chr1:20360579~20431234:-
BRCA	cis	rs7267979	0.565	rs6076364	ENSG00000231081.1	RP4-760C5.3	4.46	9.04e-06	0.000749	0.17	0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25576165	chr20:26008791~26010531:-
BRCA	cis	rs2273156	0.929	rs7144646	ENSG00000226677.3	IGBP1P1	-4.46	9.04e-06	0.000749	-0.2	-0.14	Immunoglobulin light chain (AL) amyloidosis;	chr14:34985495	chr14:34939324~34940332:+
BRCA	cis	rs889312	0.924	rs1910020	ENSG00000271828.1	CTD-2310F14.1	-4.46	9.04e-06	0.000749	-0.17	-0.14	Breast cancer (early onset);Breast cancer;	chr5:56730673	chr5:56927874~56929573:+
BRCA	cis	rs8054556	0.74	rs4407079	ENSG00000183604.13	SMG1P5	-4.46	9.04e-06	0.00075	-0.13	-0.14	Autism spectrum disorder or schizophrenia;	chr16:29920578	chr16:30267553~30335374:-
BRCA	cis	rs56322409	0.897	rs3763707	ENSG00000226688.5	ENTPD1-AS1	4.46	9.04e-06	0.00075	0.16	0.14	Blood metabolite levels;	chr10:95657417	chr10:95753206~96090238:-
BRCA	cis	rs7618915	0.501	rs12635140	ENSG00000243224.1	RP5-1157M23.2	4.46	9.05e-06	0.00075	0.15	0.14	Bipolar disorder;	chr3:52704149	chr3:52239258~52241097:+
BRCA	cis	rs867186	1	rs79438986	ENSG00000126005.14	MMP24-AS1	-4.46	9.05e-06	0.00075	-0.27	-0.14	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35114477	chr20:35216462~35278131:-
BRCA	cis	rs4715166	0.736	rs6928740	ENSG00000272379.1	RP1-257A7.5	4.46	9.05e-06	0.00075	0.16	0.14	Hip geometry;	chr6:13232744	chr6:13290018~13290490:-
BRCA	cis	rs4388249	0.651	rs31601	ENSG00000249476.1	CTD-2587M2.1	4.46	9.05e-06	0.00075	0.21	0.14	Schizophrenia;	chr5:109669781	chr5:109237120~109326369:-
BRCA	cis	rs9863	0.827	rs4930724	ENSG00000270028.1	RP11-380L11.4	4.46	9.06e-06	0.000751	0.18	0.14	White blood cell count;	chr12:123939270	chr12:123925461~123926083:-
BRCA	cis	rs10829156	0.699	rs10764584	ENSG00000225527.1	RP11-383B4.4	4.46	9.06e-06	0.000751	0.18	0.14	Sudden cardiac arrest;	chr10:18546396	chr10:18531849~18533336:-
BRCA	cis	rs1005277	0.505	rs10827836	ENSG00000226578.1	RP11-258F22.1	4.46	9.06e-06	0.000751	0.15	0.14	Extrinsic epigenetic age acceleration;	chr10:37926513	chr10:37775371~37784131:-
BRCA	cis	rs9903692	0.954	rs2109984	ENSG00000263412.1	RP5-890E16.2	-4.46	9.06e-06	0.000751	-0.15	-0.14	Pulse pressure;	chr17:48093737	chr17:48045141~48048073:-
BRCA	cis	rs13113518	1	rs11133392	ENSG00000273257.1	RP11-177J6.1	4.46	9.06e-06	0.000751	0.18	0.14	Height;	chr4:55507729	chr4:55387949~55388271:+
BRCA	cis	rs13113518	1	rs6838305	ENSG00000273257.1	RP11-177J6.1	4.46	9.06e-06	0.000751	0.18	0.14	Height;	chr4:55508587	chr4:55387949~55388271:+
BRCA	cis	rs13113518	0.902	rs12503578	ENSG00000273257.1	RP11-177J6.1	4.46	9.06e-06	0.000751	0.18	0.14	Height;	chr4:55509367	chr4:55387949~55388271:+
BRCA	cis	rs13113518	0.966	rs3828480	ENSG00000273257.1	RP11-177J6.1	4.46	9.06e-06	0.000751	0.18	0.14	Height;	chr4:55510352	chr4:55387949~55388271:+
BRCA	cis	rs13113518	1	rs3762837	ENSG00000273257.1	RP11-177J6.1	4.46	9.06e-06	0.000751	0.18	0.14	Height;	chr4:55511198	chr4:55387949~55388271:+
BRCA	cis	rs13113518	1	rs3749474	ENSG00000273257.1	RP11-177J6.1	4.46	9.06e-06	0.000751	0.18	0.14	Height;	chr4:55434518	chr4:55387949~55388271:+
BRCA	cis	rs886774	0.644	rs10953555	ENSG00000273055.1	CTB-13F3.1	-4.46	9.06e-06	0.000751	-0.14	-0.14	Ulcerative colitis;	chr7:107940901	chr7:107942116~107942740:+
BRCA	cis	rs7665090	1	rs4013	ENSG00000251288.2	RP11-10L12.2	-4.46	9.07e-06	0.000751	-0.16	-0.14	Primary biliary cholangitis;	chr4:102631656	chr4:102751401~102752641:+
BRCA	cis	rs7665090	0.967	rs4019	ENSG00000251288.2	RP11-10L12.2	-4.46	9.07e-06	0.000751	-0.16	-0.14	Primary biliary cholangitis;	chr4:102631673	chr4:102751401~102752641:+
BRCA	cis	rs8054556	1	rs3814884	ENSG00000261367.1	RP11-455F5.4	-4.46	9.07e-06	0.000752	-0.16	-0.14	Autism spectrum disorder or schizophrenia;	chr16:29983415	chr16:30107675~30110541:+
BRCA	cis	rs853679	1	rs2799077	ENSG00000280107.1	AL022393.9	-4.46	9.07e-06	0.000752	-0.24	-0.14	Depression;	chr6:28266819	chr6:28170845~28172521:+
BRCA	cis	rs8130944	0.964	rs7280645	ENSG00000225731.1	AP001627.1	4.46	9.07e-06	0.000752	0.16	0.14	Perceived unattractiveness to mosquitoes;	chr21:42716515	chr21:42733594~42741758:-
BRCA	cis	rs216345	0.67	rs307664	ENSG00000260947.1	RP11-384P7.7	4.46	9.07e-06	0.000752	0.14	0.14	Bipolar disorder;	chr9:33961354	chr9:33697459~33700986:+
BRCA	cis	rs2276314	0.512	rs7227264	ENSG00000278986.1	RP11-723J4.3	-4.46	9.08e-06	0.000752	-0.16	-0.14	Endometriosis;Drug-induced torsades de pointes;	chr18:35874668	chr18:35972151~35973916:+
BRCA	cis	rs6847067	0.672	rs56094216	ENSG00000180769.7	WDFY3-AS2	4.46	9.08e-06	0.000752	0.14	0.14	Oropharynx cancer;	chr4:85021158	chr4:84965682~85011277:+
BRCA	cis	rs6439153	0.933	rs9822511	ENSG00000261159.1	RP11-723O4.9	4.46	9.08e-06	0.000752	0.15	0.14	Pneumococcal bacteremia;	chr3:128986724	chr3:128859716~128860526:-
BRCA	cis	rs6570726	0.935	rs380433	ENSG00000270638.1	RP3-466P17.1	4.46	9.08e-06	0.000752	0.15	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145538465	chr6:145735570~145737218:+
BRCA	cis	rs6570726	0.935	rs367643	ENSG00000270638.1	RP3-466P17.1	4.46	9.08e-06	0.000752	0.15	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145538466	chr6:145735570~145737218:+
BRCA	cis	rs738722	0.658	rs5762752	ENSG00000279978.1	chr22-38_28785274-29006793.1	-4.46	9.08e-06	0.000752	-0.18	-0.14	Optic cup area;Esophageal cancer and gastric cancer;	chr22:28704989	chr22:28930201~29197572:+
BRCA	cis	rs7800418	0.545	rs10270966	ENSG00000214870.7	AC004540.5	4.46	9.08e-06	0.000752	0.19	0.14	Cognitive function;	chr7:26537943	chr7:26398593~26494256:+
BRCA	cis	rs4831760	1	rs13277232	ENSG00000250483.1	PPM1AP1	4.46	9.08e-06	0.000753	0.2	0.14	Pulmonary function decline;	chr8:15680316	chr8:15806149~15807283:-
BRCA	cis	rs4831760	1	rs34672838	ENSG00000250483.1	PPM1AP1	4.46	9.08e-06	0.000753	0.2	0.14	Pulmonary function decline;	chr8:15680487	chr8:15806149~15807283:-
BRCA	cis	rs17428076	0.749	rs788161	ENSG00000228389.1	AC068039.4	-4.46	9.08e-06	0.000753	-0.2	-0.14	Myopia;	chr2:172061943	chr2:171773482~171775844:+
BRCA	cis	rs409045	1	rs372645	ENSG00000271874.1	CTD-2024P10.2	4.46	9.08e-06	0.000753	0.18	0.14	Left ventricular mass;	chr5:34627473	chr5:34651457~34651888:-
BRCA	cis	rs7829975	0.54	rs2976909	ENSG00000233609.3	RP11-62H7.2	-4.46	9.09e-06	0.000753	-0.13	-0.14	Mood instability;	chr8:8489180	chr8:8961200~8979025:+
BRCA	cis	rs10129255	0.5	rs988134	ENSG00000211967.3	IGHV3-53	-4.46	9.09e-06	0.000753	-0.09	-0.14	Kawasaki disease;	chr14:106776698	chr14:106592676~106593347:-
BRCA	cis	rs10129255	0.5	rs988133	ENSG00000211967.3	IGHV3-53	-4.46	9.09e-06	0.000753	-0.09	-0.14	Kawasaki disease;	chr14:106776724	chr14:106592676~106593347:-
BRCA	cis	rs6128907	1	rs6128913	ENSG00000224635.1	RP4-564F22.5	4.46	9.09e-06	0.000753	0.21	0.14	Liver fibrosis in pediatric non-alcoholic fatty acid liver disease;	chr20:38761531	chr20:38406011~38416797:-
BRCA	cis	rs17597773	0.638	rs12139139	ENSG00000257551.1	HLX-AS1	-4.46	9.09e-06	0.000753	-0.16	-0.14	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220827284	chr1:220832763~220880140:-
BRCA	cis	rs6088580	0.66	rs6087592	ENSG00000276073.1	RP5-1125A11.7	-4.46	9.09e-06	0.000753	-0.15	-0.14	Glomerular filtration rate (creatinine);	chr20:34526698	chr20:33985617~33988989:-
BRCA	cis	rs35740288	0.694	rs17618909	ENSG00000202081.1	RNU6-1280P	4.46	9.1e-06	0.000753	0.18	0.14	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85552231	chr15:85651522~85651628:-
BRCA	cis	rs6686842	1	rs34454389	ENSG00000235358.1	RP11-399E6.1	4.46	9.1e-06	0.000754	0.17	0.14	Height;	chr1:41197564	chr1:41242373~41284861:+
BRCA	cis	rs2073316	0.592	rs11674100	ENSG00000272716.1	RP11-563N4.1	4.46	9.1e-06	0.000754	0.15	0.14	Interleukin-18 levels;	chr2:31434426	chr2:32165046~32165757:-
BRCA	cis	rs6686842	0.932	rs1008505	ENSG00000235358.1	RP11-399E6.1	-4.46	9.1e-06	0.000754	-0.17	-0.14	Height;	chr1:41094563	chr1:41242373~41284861:+
BRCA	cis	rs287982	0.611	rs77095920	ENSG00000269973.1	RP11-95D17.1	-4.46	9.1e-06	0.000754	-0.23	-0.14	Nonsyndromic cleft lip with cleft palate;	chr2:9833092	chr2:9936360~9939590:+
BRCA	cis	rs4723738	0.729	rs10226230	ENSG00000227191.5	TRGC2	4.46	9.1e-06	0.000754	0.12	0.14	Treatment response for severe sepsis;	chr7:38229691	chr7:38239580~38368091:-
BRCA	cis	rs6545883	0.507	rs12617371	ENSG00000273302.1	RP11-493E12.2	-4.46	9.11e-06	0.000754	-0.12	-0.14	Tuberculosis;	chr2:61341999	chr2:61199979~61200769:+
BRCA	cis	rs8040855	0.579	rs6496797	ENSG00000259762.1	RP11-158M2.4	-4.46	9.11e-06	0.000754	-0.16	-0.14	Bulimia nervosa;	chr15:85183624	chr15:85750336~85752901:-
BRCA	cis	rs2011013	1	rs56278218	ENSG00000225151.9	GOLGA2P7	4.46	9.11e-06	0.000755	0.18	0.14	Sitting height ratio;	chr15:83957942	chr15:84199311~84230136:-
BRCA	cis	rs10833905	1	rs10833906	ENSG00000246225.5	RP11-17A1.3	4.46	9.11e-06	0.000755	0.19	0.14	Sudden cardiac arrest;	chr11:23023828	chr11:22829380~22945393:+
BRCA	cis	rs2919009	0.766	rs56259440	ENSG00000271670.1	RP11-95I16.4	4.46	9.11e-06	0.000755	0.19	0.14	Obesity-related traits;	chr10:120809566	chr10:120879256~120880667:-
BRCA	cis	rs17345786	1	rs17345786	ENSG00000244119.1	PDCL3P4	-4.46	9.12e-06	0.000755	-0.12	-0.14	Colonoscopy-negative controls vs population controls;	chr3:101599474	chr3:101712472~101713191:+
BRCA	cis	rs321358	1	rs321352	ENSG00000271390.1	RP11-89C3.3	4.46	9.12e-06	0.000755	0.22	0.14	Body mass index;	chr11:111123001	chr11:111089870~111090368:-
BRCA	cis	rs8180040	1	rs2159400	ENSG00000276925.1	RP11-708J19.3	4.46	9.12e-06	0.000755	0.16	0.14	Colorectal cancer;	chr3:47334400	chr3:47469777~47469987:+
BRCA	cis	rs1876905	0.68	rs395564	ENSG00000272356.1	RP5-1112D6.8	-4.46	9.12e-06	0.000756	-0.18	-0.14	Mean corpuscular hemoglobin;	chr6:111176176	chr6:111309203~111313517:+
BRCA	cis	rs17684571	0.7	rs13198204	ENSG00000231441.1	RP11-472M19.2	4.46	9.12e-06	0.000756	0.21	0.14	Schizophrenia;	chr6:56804057	chr6:56844002~56864078:+
BRCA	cis	rs17684571	0.7	rs13201639	ENSG00000231441.1	RP11-472M19.2	4.46	9.12e-06	0.000756	0.21	0.14	Schizophrenia;	chr6:56804329	chr6:56844002~56864078:+
BRCA	cis	rs17684571	0.7	rs71564861	ENSG00000231441.1	RP11-472M19.2	4.46	9.12e-06	0.000756	0.21	0.14	Schizophrenia;	chr6:56806793	chr6:56844002~56864078:+
BRCA	cis	rs17684571	0.7	rs35251663	ENSG00000231441.1	RP11-472M19.2	4.46	9.12e-06	0.000756	0.21	0.14	Schizophrenia;	chr6:56806940	chr6:56844002~56864078:+
BRCA	cis	rs4950322	1	rs72694720	ENSG00000244371.2	PFN1P8	-4.46	9.13e-06	0.000756	-0.2	-0.14	Protein quantitative trait loci;	chr1:147371939	chr1:146957117~146957659:-
BRCA	cis	rs7267979	0.844	rs6050477	ENSG00000231081.1	RP4-760C5.3	4.46	9.13e-06	0.000756	0.18	0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25240911	chr20:26008791~26010531:-
BRCA	cis	rs718433	0.681	rs2097262	ENSG00000256379.1	TRAV8-5	4.46	9.13e-06	0.000756	0.17	0.14	Intraocular pressure;	chr14:21781015	chr14:21903077~21903598:+
BRCA	cis	rs216345	0.667	rs7357700	ENSG00000260947.1	RP11-384P7.7	4.46	9.13e-06	0.000756	0.15	0.14	Bipolar disorder;	chr9:33892533	chr9:33697459~33700986:+
BRCA	cis	rs516805	0.64	rs55768410	ENSG00000279114.1	RP3-425C14.5	4.46	9.13e-06	0.000756	0.17	0.14	Lymphocyte counts;	chr6:122358588	chr6:122471923~122484161:+
BRCA	cis	rs11096990	0.613	rs2060805	ENSG00000249685.1	RP11-360F5.3	4.46	9.14e-06	0.000756	0.17	0.14	Cognitive function;	chr4:39232788	chr4:39133913~39135608:+
BRCA	cis	rs2625529	0.617	rs2929509	ENSG00000260037.4	CTD-2524L6.3	4.46	9.14e-06	0.000756	0.17	0.14	Red blood cell count;	chr15:71946931	chr15:71818396~71823384:+
BRCA	cis	rs6500602	0.893	rs4786490	ENSG00000280063.1	RP11-295D4.3	-4.46	9.14e-06	0.000757	-0.1	-0.14	Schizophrenia;	chr16:4441189	chr16:4346694~4348648:-
BRCA	cis	rs2070615	0.525	rs1532365	ENSG00000239617.1	RP11-302B13.1	4.46	9.14e-06	0.000757	0.17	0.14	Bipolar disorder;	chr12:48810638	chr12:48903418~48903813:-
BRCA	cis	rs4664293	0.967	rs35975814	ENSG00000226266.5	AC009961.3	-4.46	9.14e-06	0.000757	-0.17	-0.14	Monocyte percentage of white cells;	chr2:159691280	chr2:159670708~159712435:-
BRCA	cis	rs4908769	0.553	rs301792	ENSG00000270282.1	RP5-1115A15.2	4.46	9.14e-06	0.000757	0.16	0.14	Allergy;	chr1:8408218	chr1:8512653~8513021:+
BRCA	cis	rs10129255	0.556	rs8010005	ENSG00000211967.3	IGHV3-53	-4.46	9.15e-06	0.000757	-0.09	-0.14	Kawasaki disease;	chr14:106777987	chr14:106592676~106593347:-
BRCA	cis	rs10129255	0.556	rs6576224	ENSG00000211967.3	IGHV3-53	-4.46	9.15e-06	0.000757	-0.09	-0.14	Kawasaki disease;	chr14:106777997	chr14:106592676~106593347:-
BRCA	cis	rs10129255	0.518	rs8010020	ENSG00000211967.3	IGHV3-53	-4.46	9.15e-06	0.000757	-0.09	-0.14	Kawasaki disease;	chr14:106778016	chr14:106592676~106593347:-
BRCA	cis	rs2832191	0.791	rs2832178	ENSG00000176054.6	RPL23P2	-4.46	9.15e-06	0.000757	-0.14	-0.14	Dental caries;	chr21:29107537	chr21:28997613~28998033:-
BRCA	cis	rs8103278	1	rs8102876	ENSG00000267395.4	AC074212.6	4.46	9.15e-06	0.000757	0.14	0.14	Coronary artery disease;	chr19:45829584	chr19:45767796~45772504:+
BRCA	cis	rs7045881	0.935	rs62544452	ENSG00000254396.1	RP11-56F10.3	4.46	9.15e-06	0.000758	0.22	0.14	Schizophrenia;	chr9:26935320	chr9:27102630~27104728:+
BRCA	cis	rs2286503	0.78	rs981792	ENSG00000226329.2	AC005682.6	4.46	9.15e-06	0.000758	0.13	0.14	Fibrinogen;	chr7:22822020	chr7:22863874~22881350:-
BRCA	cis	rs35306767	0.903	rs12761424	ENSG00000229869.1	RP11-363N22.2	-4.46	9.15e-06	0.000758	-0.2	-0.14	Eosinophil percentage of granulocytes;	chr10:921355	chr10:933026~942743:+
BRCA	cis	rs516805	0.667	rs2606600	ENSG00000279114.1	RP3-425C14.5	4.46	9.15e-06	0.000758	0.18	0.14	Lymphocyte counts;	chr6:122204398	chr6:122471923~122484161:+
BRCA	cis	rs10129255	0.536	rs10139058	ENSG00000254174.1	IGHV1-12	4.46	9.15e-06	0.000758	0.11	0.14	Kawasaki disease;	chr14:106685899	chr14:106122420~106122709:-
BRCA	cis	rs9543976	0.623	rs8192756	ENSG00000261105.4	LMO7-AS1	4.46	9.16e-06	0.000758	0.2	0.14	Diabetic retinopathy;	chr13:75590802	chr13:75604700~75635994:-
BRCA	cis	rs9543976	0.623	rs3783028	ENSG00000261105.4	LMO7-AS1	4.46	9.16e-06	0.000758	0.2	0.14	Diabetic retinopathy;	chr13:75591146	chr13:75604700~75635994:-
BRCA	cis	rs7267979	0.528	rs2387976	ENSG00000204556.4	CTD-2514C3.1	4.46	9.16e-06	0.000758	0.19	0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25618924	chr20:26018832~26020684:+
BRCA	cis	rs7577599	0.812	rs7571570	ENSG00000224220.1	AC104699.1	4.46	9.16e-06	0.000759	0.12	0.14	Multiple myeloma (IgH translocation);Multiple myeloma;	chr2:25398661	chr2:25421117~25427643:+
BRCA	cis	rs1005277	0.579	rs2472183	ENSG00000263064.2	RP11-291L22.7	4.46	9.17e-06	0.000759	0.17	0.14	Extrinsic epigenetic age acceleration;	chr10:38103567	chr10:38448689~38448949:+
BRCA	cis	rs7615952	0.932	rs9841157	ENSG00000250012.1	RP11-124N2.1	-4.46	9.17e-06	0.000759	-0.21	-0.14	Blood pressure (smoking interaction);	chr3:125916812	chr3:126084220~126095349:+
BRCA	cis	rs7615952	0.551	rs12695470	ENSG00000250012.1	RP11-124N2.1	-4.46	9.17e-06	0.000759	-0.21	-0.14	Blood pressure (smoking interaction);	chr3:125916875	chr3:126084220~126095349:+
BRCA	cis	rs7665090	1	rs13112557	ENSG00000251288.2	RP11-10L12.2	-4.46	9.17e-06	0.000759	-0.16	-0.14	Primary biliary cholangitis;	chr4:102631096	chr4:102751401~102752641:+
BRCA	cis	rs875971	0.545	rs316328	ENSG00000232546.1	RP11-458F8.1	-4.46	9.17e-06	0.000759	-0.12	-0.14	Aortic root size;	chr7:66143851	chr7:66848496~66858136:+
BRCA	cis	rs2842346	0.568	rs916962	ENSG00000258623.1	CTD-2325P2.3	-4.46	9.17e-06	0.000759	-0.18	-0.14	Breast cancer;	chr14:68526861	chr14:68683411~68685565:-
BRCA	cis	rs7818688	1	rs112529587	ENSG00000253528.2	RP11-347C18.4	-4.46	9.17e-06	0.000759	-0.22	-0.14	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95047807	chr8:94974573~94974853:-
BRCA	cis	rs6840360	0.573	rs11099807	ENSG00000270265.1	RP11-731D1.4	-4.46	9.17e-06	0.000759	-0.15	-0.14	Intelligence (multi-trait analysis);	chr4:151348076	chr4:151333775~151353224:-
BRCA	cis	rs2073316	0.626	rs58071748	ENSG00000272716.1	RP11-563N4.1	4.46	9.18e-06	0.000759	0.15	0.14	Interleukin-18 levels;	chr2:31429485	chr2:32165046~32165757:-
BRCA	cis	rs2243480	0.901	rs73148097	ENSG00000275400.1	RP4-756H11.5	4.46	9.18e-06	0.000759	0.25	0.14	Diabetic kidney disease;	chr7:65966800	chr7:66553805~66554199:-
BRCA	cis	rs2243480	1	rs906134	ENSG00000275400.1	RP4-756H11.5	4.46	9.18e-06	0.000759	0.25	0.14	Diabetic kidney disease;	chr7:65979301	chr7:66553805~66554199:-
BRCA	cis	rs300890	0.586	rs300901	ENSG00000250326.1	RP11-284M14.1	-4.46	9.18e-06	0.00076	-0.16	-0.14	Nasopharyngeal carcinoma;	chr4:143316394	chr4:142933195~143184861:-
BRCA	cis	rs4474465	1	rs6592780	ENSG00000251323.2	RP11-452H21.4	4.46	9.18e-06	0.00076	0.17	0.14	Alzheimer's disease (survival time);	chr11:78488842	chr11:78423982~78429836:-
BRCA	cis	rs4474465	1	rs952605	ENSG00000251323.2	RP11-452H21.4	4.46	9.18e-06	0.00076	0.17	0.14	Alzheimer's disease (survival time);	chr11:78489381	chr11:78423982~78429836:-
BRCA	cis	rs733175	0.855	rs10018666	ENSG00000250413.1	RP11-448G15.1	-4.46	9.18e-06	0.00076	-0.2	-0.14	Psychosis and Alzheimer's disease;	chr4:10003181	chr4:10006482~10009725:+
BRCA	cis	rs3213958	0.574	rs73136038	ENSG00000249274.1	PDLIM1P4	-4.46	9.18e-06	0.00076	-0.23	-0.14	Blood protein levels;	chr3:98782993	chr3:98782188~98783193:+
BRCA	cis	rs867186	0.92	rs8119351	ENSG00000126005.14	MMP24-AS1	-4.46	9.19e-06	0.00076	-0.27	-0.14	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35166602	chr20:35216462~35278131:-
BRCA	cis	rs7308116	0.546	rs17307888	ENSG00000274395.1	RP11-554D14.8	-4.46	9.2e-06	0.000761	-0.17	-0.14	Pelvic organ prolapse (moderate/severe);	chr12:107818862	chr12:107835541~107836555:-
BRCA	cis	rs853679	0.825	rs8180562	ENSG00000280107.1	AL022393.9	-4.46	9.2e-06	0.000761	-0.28	-0.14	Depression;	chr6:28173682	chr6:28170845~28172521:+
BRCA	cis	rs853679	0.882	rs9380064	ENSG00000280107.1	AL022393.9	-4.46	9.2e-06	0.000761	-0.28	-0.14	Depression;	chr6:28175340	chr6:28170845~28172521:+
BRCA	cis	rs4781563	0.778	rs3136070	ENSG00000242307.1	RPS26P52	-4.46	9.2e-06	0.000762	-0.16	-0.14	Bilirubin levels;	chr16:13923862	chr16:13922332~13922679:-
BRCA	cis	rs9467773	1	rs28558133	ENSG00000241549.7	GUSBP2	4.46	9.21e-06	0.000762	0.15	0.14	Intelligence (multi-trait analysis);	chr6:26531205	chr6:26871484~26956554:-
BRCA	cis	rs10833905	1	rs11026927	ENSG00000246225.5	RP11-17A1.3	-4.46	9.21e-06	0.000762	-0.19	-0.14	Sudden cardiac arrest;	chr11:23035103	chr11:22829380~22945393:+
BRCA	cis	rs10833905	1	rs10833916	ENSG00000246225.5	RP11-17A1.3	-4.46	9.21e-06	0.000762	-0.19	-0.14	Sudden cardiac arrest;	chr11:23036779	chr11:22829380~22945393:+
BRCA	cis	rs9818758	0.607	rs61729488	ENSG00000270441.1	RP11-694I15.7	4.46	9.21e-06	0.000762	0.31	0.14	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49030471	chr3:49140086~49160851:-
BRCA	cis	rs8114671	0.562	rs1013677	ENSG00000269202.1	RP4-614O4.12	-4.46	9.21e-06	0.000762	-0.14	-0.14	Height;	chr20:34880990	chr20:35201747~35203288:-
BRCA	cis	rs7927592	0.913	rs7116994	ENSG00000212093.1	AP000807.1	4.46	9.21e-06	0.000762	0.15	0.14	Total body bone mineral density;	chr11:68487159	chr11:68506083~68506166:-
BRCA	cis	rs7772486	0.875	rs9376975	ENSG00000270638.1	RP3-466P17.1	4.46	9.21e-06	0.000762	0.16	0.14	Lobe attachment (rater-scored or self-reported);	chr6:146034445	chr6:145735570~145737218:+
BRCA	cis	rs7772486	0.846	rs9376976	ENSG00000270638.1	RP3-466P17.1	4.46	9.21e-06	0.000762	0.16	0.14	Lobe attachment (rater-scored or self-reported);	chr6:146034469	chr6:145735570~145737218:+
BRCA	cis	rs7772486	0.875	rs7761033	ENSG00000270638.1	RP3-466P17.1	4.46	9.21e-06	0.000762	0.16	0.14	Lobe attachment (rater-scored or self-reported);	chr6:146034970	chr6:145735570~145737218:+
BRCA	cis	rs7772486	0.875	rs9403763	ENSG00000270638.1	RP3-466P17.1	4.46	9.21e-06	0.000762	0.16	0.14	Lobe attachment (rater-scored or self-reported);	chr6:146036519	chr6:145735570~145737218:+
BRCA	cis	rs4835473	0.637	rs1825040	ENSG00000246448.2	RP13-578N3.3	-4.46	9.21e-06	0.000762	-0.15	-0.14	Immature fraction of reticulocytes;	chr4:143794417	chr4:143700257~143865072:+
BRCA	cis	rs7475343	0.543	rs79717793	ENSG00000224034.1	RP11-445P17.8	-4.46	9.21e-06	0.000762	-0.27	-0.14	Intelligence;	chr10:5220304	chr10:5266033~5271236:-
BRCA	cis	rs7475343	0.501	rs78231592	ENSG00000224034.1	RP11-445P17.8	-4.46	9.21e-06	0.000762	-0.27	-0.14	Intelligence;	chr10:5220527	chr10:5266033~5271236:-
BRCA	cis	rs7475343	0.543	rs75529951	ENSG00000224034.1	RP11-445P17.8	-4.46	9.21e-06	0.000762	-0.27	-0.14	Intelligence;	chr10:5220549	chr10:5266033~5271236:-
BRCA	cis	rs7475343	0.543	rs112455458	ENSG00000224034.1	RP11-445P17.8	-4.46	9.21e-06	0.000762	-0.27	-0.14	Intelligence;	chr10:5220920	chr10:5266033~5271236:-
BRCA	cis	rs7475343	0.543	rs111932715	ENSG00000224034.1	RP11-445P17.8	-4.46	9.21e-06	0.000762	-0.27	-0.14	Intelligence;	chr10:5220978	chr10:5266033~5271236:-
BRCA	cis	rs7475343	0.543	rs17134610	ENSG00000224034.1	RP11-445P17.8	-4.46	9.21e-06	0.000762	-0.27	-0.14	Intelligence;	chr10:5221060	chr10:5266033~5271236:-
BRCA	cis	rs7475343	0.543	rs75413156	ENSG00000224034.1	RP11-445P17.8	-4.46	9.21e-06	0.000762	-0.27	-0.14	Intelligence;	chr10:5221531	chr10:5266033~5271236:-
BRCA	cis	rs7475343	0.543	rs80011059	ENSG00000224034.1	RP11-445P17.8	-4.46	9.21e-06	0.000762	-0.27	-0.14	Intelligence;	chr10:5221553	chr10:5266033~5271236:-
BRCA	cis	rs7475343	0.543	rs17134617	ENSG00000224034.1	RP11-445P17.8	-4.46	9.21e-06	0.000762	-0.27	-0.14	Intelligence;	chr10:5221739	chr10:5266033~5271236:-
BRCA	cis	rs488400	0.558	rs361163	ENSG00000270265.1	RP11-731D1.4	4.46	9.21e-06	0.000762	0.18	0.14	Trans fatty acid levels;	chr4:151878731	chr4:151333775~151353224:-
BRCA	cis	rs17597773	0.638	rs7530074	ENSG00000238078.1	LINC01352	-4.46	9.21e-06	0.000762	-0.15	-0.14	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220815924	chr1:220829255~220832429:+
BRCA	cis	rs516805	0.528	rs2606628	ENSG00000279114.1	RP3-425C14.5	-4.46	9.22e-06	0.000763	-0.17	-0.14	Lymphocyte counts;	chr6:122097460	chr6:122471923~122484161:+
BRCA	cis	rs7267979	0.816	rs6037158	ENSG00000125804.12	FAM182A	-4.46	9.22e-06	0.000763	-0.18	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25614830	chr20:26054655~26086917:+
BRCA	cis	rs10510102	0.516	rs12256693	ENSG00000226864.1	ATE1-AS1	4.46	9.22e-06	0.000763	0.28	0.14	Breast cancer;	chr10:121976839	chr10:121928312~121951965:+
BRCA	cis	rs750460	1	rs750460	ENSG00000261801.4	LOXL1-AS1	-4.46	9.23e-06	0.000763	-0.16	-0.14	Height;	chr15:73949165	chr15:73908071~73928248:-
BRCA	cis	rs6728642	0.901	rs7584641	ENSG00000230606.9	AC159540.1	4.46	9.23e-06	0.000763	0.2	0.14	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:96941918	chr2:97416165~97433527:-
BRCA	cis	rs4478858	0.647	rs6425720	ENSG00000223907.1	LINC01226	-4.46	9.23e-06	0.000763	-0.17	-0.14	Alcohol dependence;	chr1:31236708	chr1:31518435~31524245:+
BRCA	cis	rs7267979	0.966	rs7270835	ENSG00000274414.1	RP5-965G21.4	-4.46	9.23e-06	0.000763	-0.16	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25454431	chr20:25239007~25245229:-
BRCA	cis	rs7267979	1	rs6115191	ENSG00000274414.1	RP5-965G21.4	-4.46	9.23e-06	0.000763	-0.16	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25459842	chr20:25239007~25245229:-
BRCA	cis	rs7267979	1	rs6107045	ENSG00000274414.1	RP5-965G21.4	-4.46	9.23e-06	0.000763	-0.16	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25461300	chr20:25239007~25245229:-
BRCA	cis	rs7267979	1	rs6107046	ENSG00000274414.1	RP5-965G21.4	-4.46	9.23e-06	0.000763	-0.16	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25461413	chr20:25239007~25245229:-
BRCA	cis	rs7267979	1	rs6107047	ENSG00000274414.1	RP5-965G21.4	-4.46	9.23e-06	0.000763	-0.16	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25461461	chr20:25239007~25245229:-
BRCA	cis	rs7520050	0.807	rs28647556	ENSG00000234329.1	RP11-767N6.2	4.46	9.23e-06	0.000764	0.13	0.14	Reticulocyte count;Red blood cell count;	chr1:45740727	chr1:45651039~45651826:-
BRCA	cis	rs7520050	0.807	rs4274104	ENSG00000234329.1	RP11-767N6.2	4.46	9.23e-06	0.000764	0.13	0.14	Reticulocyte count;Red blood cell count;	chr1:45752269	chr1:45651039~45651826:-
BRCA	cis	rs321358	1	rs167683	ENSG00000271390.1	RP11-89C3.3	4.46	9.23e-06	0.000764	0.22	0.14	Body mass index;	chr11:111123131	chr11:111089870~111090368:-
BRCA	cis	rs930395	0.514	rs9791056	ENSG00000251141.4	RP11-53O19.1	-4.46	9.23e-06	0.000764	-0.13	-0.14	Breast cancer;	chr5:44903789	chr5:44744900~44808777:-
BRCA	cis	rs10129255	0.518	rs11847766	ENSG00000211967.3	IGHV3-53	-4.46	9.24e-06	0.000764	-0.09	-0.14	Kawasaki disease;	chr14:106779186	chr14:106592676~106593347:-
BRCA	cis	rs1008375	0.932	rs2302394	ENSG00000249502.1	AC006160.5	-4.46	9.24e-06	0.000764	-0.16	-0.14	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17639565	chr4:17587467~17614571:-
BRCA	cis	rs763121	0.853	rs5750677	ENSG00000273076.1	RP3-508I15.22	4.46	9.24e-06	0.000764	0.16	0.14	Menopause (age at onset);	chr22:38751710	chr22:38743495~38743910:+
BRCA	cis	rs10504130	0.932	rs79196243	ENSG00000272024.1	RP11-546K22.3	-4.46	9.24e-06	0.000764	-0.24	-0.14	Venous thromboembolism (SNP x SNP interaction);	chr8:51834855	chr8:51950284~51950690:+
BRCA	cis	rs904251	0.734	rs2797790	ENSG00000204110.6	RP1-153P14.8	4.46	9.24e-06	0.000764	0.16	0.14	Cognitive performance;	chr6:37479299	chr6:37507348~37535616:+
BRCA	cis	rs4143844	0.867	rs34257602	ENSG00000259251.2	RP11-643M14.1	4.46	9.25e-06	0.000765	0.34	0.14	Bipolar disorder and schizophrenia;	chr15:61993548	chr15:62060503~62062434:+
BRCA	cis	rs4143844	0.867	rs62006964	ENSG00000259251.2	RP11-643M14.1	4.46	9.25e-06	0.000765	0.34	0.14	Bipolar disorder and schizophrenia;	chr15:61995424	chr15:62060503~62062434:+
BRCA	cis	rs7674212	0.57	rs2126470	ENSG00000251288.2	RP11-10L12.2	-4.46	9.25e-06	0.000765	-0.16	-0.14	Type 2 diabetes;	chr4:103140605	chr4:102751401~102752641:+
BRCA	cis	rs7011507	0.594	rs72639032	ENSG00000279881.1	RP11-513O13.1	-4.46	9.25e-06	0.000765	-0.2	-0.14	Inflammatory bowel disease;Ulcerative colitis;	chr8:48443838	chr8:48428143~48431041:-
BRCA	cis	rs62025270	0.688	rs17638180	ENSG00000259295.5	CSPG4P12	-4.46	9.25e-06	0.000765	-0.22	-0.14	Idiopathic pulmonary fibrosis;	chr15:85735164	chr15:85191438~85213905:+
BRCA	cis	rs2136613	0.703	rs10761675	ENSG00000238280.1	RP11-436D10.3	-4.46	9.25e-06	0.000765	-0.17	-0.14	Selective IgA deficiency;	chr10:62863436	chr10:62793562~62805887:-
BRCA	cis	rs13113518	1	rs3805146	ENSG00000273257.1	RP11-177J6.1	4.46	9.25e-06	0.000765	0.17	0.14	Height;	chr4:55436985	chr4:55387949~55388271:+
BRCA	cis	rs13113518	1	rs11133378	ENSG00000273257.1	RP11-177J6.1	4.46	9.25e-06	0.000765	0.17	0.14	Height;	chr4:55439472	chr4:55387949~55388271:+
BRCA	cis	rs13113518	1	rs11942279	ENSG00000273257.1	RP11-177J6.1	4.46	9.25e-06	0.000765	0.17	0.14	Height;	chr4:55439652	chr4:55387949~55388271:+
BRCA	cis	rs12744310	0.895	rs1892417	ENSG00000235358.1	RP11-399E6.1	4.46	9.26e-06	0.000765	0.21	0.14	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41314001	chr1:41242373~41284861:+
BRCA	cis	rs11098499	0.955	rs1511018	ENSG00000250412.1	KLHL2P1	4.46	9.26e-06	0.000765	0.17	0.14	Corneal astigmatism;	chr4:119240425	chr4:119334329~119378233:+
BRCA	cis	rs739496	0.947	rs2301621	ENSG00000234608.6	MAPKAPK5-AS1	4.46	9.26e-06	0.000765	0.17	0.14	Platelet count;	chr12:111457468	chr12:111839764~111842902:-
BRCA	cis	rs6600671	1	rs7532615	ENSG00000270392.2	PFN1P2	-4.46	9.26e-06	0.000765	-0.15	-0.14	Hip geometry;	chr1:121430980	chr1:120432204~120434052:-
BRCA	cis	rs7200543	0.583	rs4985149	ENSG00000258354.1	MIR3180-1	-4.46	9.26e-06	0.000766	-0.18	-0.14	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15053481	chr16:14909887~14911345:-
BRCA	cis	rs8098244	0.603	rs1711456	ENSG00000264745.1	TTC39C-AS1	4.46	9.26e-06	0.000766	0.16	0.14	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23697390	chr18:23994213~24015339:-
BRCA	cis	rs1559040	0.527	rs114498542	ENSG00000272156.1	RP11-477N3.1	-4.46	9.26e-06	0.000766	-0.27	-0.14	Sudden cardiac arrest;	chr2:54006169	chr2:54082554~54085066:+
BRCA	cis	rs1559040	0.722	rs72799301	ENSG00000272156.1	RP11-477N3.1	-4.46	9.26e-06	0.000766	-0.27	-0.14	Sudden cardiac arrest;	chr2:54009336	chr2:54082554~54085066:+
BRCA	cis	rs1559040	0.79	rs11676433	ENSG00000272156.1	RP11-477N3.1	-4.46	9.26e-06	0.000766	-0.27	-0.14	Sudden cardiac arrest;	chr2:54009788	chr2:54082554~54085066:+
BRCA	cis	rs1559040	0.79	rs998381	ENSG00000272156.1	RP11-477N3.1	-4.46	9.26e-06	0.000766	-0.27	-0.14	Sudden cardiac arrest;	chr2:54011519	chr2:54082554~54085066:+
BRCA	cis	rs6430585	0.583	rs76097170	ENSG00000224043.6	CCNT2-AS1	-4.46	9.26e-06	0.000766	-0.22	-0.14	Corneal structure;	chr2:135835928	chr2:134735464~134918710:-
BRCA	cis	rs6545883	0.655	rs11893880	ENSG00000273302.1	RP11-493E12.2	4.46	9.26e-06	0.000766	0.12	0.14	Tuberculosis;	chr2:61194884	chr2:61199979~61200769:+
BRCA	cis	rs10504130	0.932	rs11787229	ENSG00000253844.1	RP11-546K22.1	-4.46	9.27e-06	0.000766	-0.25	-0.14	Venous thromboembolism (SNP x SNP interaction);	chr8:51935311	chr8:51961458~52022974:+
BRCA	cis	rs13326165	0.585	rs6783652	ENSG00000243224.1	RP5-1157M23.2	-4.46	9.27e-06	0.000766	-0.23	-0.14	HDL cholesterol levels;HDL cholesterol;	chr3:52289328	chr3:52239258~52241097:+
BRCA	cis	rs875971	0.502	rs2465121	ENSG00000273142.1	RP11-458F8.4	-4.46	9.27e-06	0.000766	-0.14	-0.14	Aortic root size;	chr7:66156017	chr7:66902857~66906297:+
BRCA	cis	rs6968419	0.781	rs66652906	ENSG00000279086.1	RP11-667F14.1	-4.46	9.27e-06	0.000766	-0.15	-0.14	Intraocular pressure;	chr7:116241105	chr7:116209234~116211511:-
BRCA	cis	rs6968419	0.747	rs58595078	ENSG00000279086.1	RP11-667F14.1	-4.46	9.27e-06	0.000766	-0.15	-0.14	Intraocular pressure;	chr7:116241404	chr7:116209234~116211511:-
BRCA	cis	rs6968419	0.747	rs3757730	ENSG00000279086.1	RP11-667F14.1	-4.46	9.27e-06	0.000766	-0.15	-0.14	Intraocular pressure;	chr7:116242269	chr7:116209234~116211511:-
BRCA	cis	rs2010672	0.5	rs7171218	ENSG00000245479.2	LINC01585	4.46	9.27e-06	0.000766	0.16	0.14	Eosinophil counts;Sum eosinophil basophil counts;Eosinophil percentage of white cells;	chr15:90608853	chr15:90660234~90664967:+
BRCA	cis	rs11098499	0.82	rs13128602	ENSG00000250412.1	KLHL2P1	-4.46	9.27e-06	0.000766	-0.17	-0.14	Corneal astigmatism;	chr4:119538211	chr4:119334329~119378233:+
BRCA	cis	rs17685	0.725	rs7807647	ENSG00000280388.1	RP11-229D13.3	4.46	9.27e-06	0.000766	0.14	0.14	Coffee consumption (cups per day);Coffee consumption;	chr7:75999351	chr7:76043977~76045963:-
BRCA	cis	rs10897473	0.554	rs7115071	ENSG00000236935.1	AP003774.1	-4.46	9.27e-06	0.000766	-0.13	-0.14	Immature fraction of reticulocytes;	chr11:64084161	chr11:64325050~64329504:-
BRCA	cis	rs7833790	0.963	rs6473312	ENSG00000254689.1	RP11-354A14.1	4.46	9.27e-06	0.000766	0.19	0.14	Diastolic blood pressure;	chr8:81820280	chr8:81885377~81923193:+
BRCA	cis	rs780094	0.5	rs7577311	ENSG00000234072.1	AC074117.10	4.46	9.27e-06	0.000767	0.14	0.14	Urate levels in overweight individuals;C-reactive protein;Metabolic syndrome;Red blood cell count;Renal underexcretion gout;Nonalcoholic fatty liver disease;Age-related diseases, mortality and associated endophenotypes;Crohn's disease;Calcium levels;Fasting plasma glucose;Metabolic traits;Fasting blood glucose;Fasting blood insulin;Urate levels in obese individuals;Alcohol consumption (drinks per week);Height;Urate levels;Gondoic acid (20:1n-9) levels;Uric acid levels;Age-related disease endophenotypes;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Homeostasis model assessment of insulin resistance;Alcohol consumption;Fasting blood insulin (BMI interaction);Triglycerides;Fasting blood glucose (BMI interaction);Hypertriglyceridemia;LDL cholesterol;Type 2 diabetes;Triglyceride levels;	chr2:27571054	chr2:27356246~27367622:+
BRCA	cis	rs6708331	1	rs13000817	ENSG00000231024.1	AC092431.3	-4.46	9.27e-06	0.000767	-0.19	-0.14	Obesity-related traits;	chr2:70046575	chr2:69700192~69713847:-
BRCA	cis	rs934734	0.532	rs2028151	ENSG00000281920.1	RP11-418H16.1	-4.46	9.27e-06	0.000767	-0.16	-0.14	Rheumatoid arthritis;	chr2:65428479	chr2:65623272~65628424:+
BRCA	cis	rs7789940	0.904	rs56919252	ENSG00000280388.1	RP11-229D13.3	-4.46	9.28e-06	0.000767	-0.15	-0.14	Multiple sclerosis;	chr7:76308203	chr7:76043977~76045963:-
BRCA	cis	rs9952991	0.941	rs60735058	ENSG00000260302.1	RP11-973H7.1	4.46	9.28e-06	0.000767	0.23	0.14	Inflammatory skin disease;	chr18:12795471	chr18:12774651~12775923:-
BRCA	cis	rs17428076	0.793	rs3770448	ENSG00000228389.1	AC068039.4	-4.46	9.28e-06	0.000767	-0.2	-0.14	Myopia;	chr2:171835755	chr2:171773482~171775844:+
BRCA	cis	rs7772486	0.754	rs6915718	ENSG00000270638.1	RP3-466P17.1	-4.46	9.28e-06	0.000767	-0.16	-0.14	Lobe attachment (rater-scored or self-reported);	chr6:145779540	chr6:145735570~145737218:+
BRCA	cis	rs1075265	0.584	rs10164409	ENSG00000235937.1	AC008280.1	4.46	9.29e-06	0.000768	0.15	0.14	Chronotype;Morning vs. evening chronotype;	chr2:53940867	chr2:54029552~54030682:-
BRCA	cis	rs2243480	1	rs34193460	ENSG00000275400.1	RP4-756H11.5	4.46	9.29e-06	0.000768	0.25	0.14	Diabetic kidney disease;	chr7:65928123	chr7:66553805~66554199:-
BRCA	cis	rs7267979	0.873	rs6115093	ENSG00000276952.1	RP5-965G21.6	4.46	9.29e-06	0.000768	0.17	0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25230094	chr20:25284915~25285588:-
BRCA	cis	rs13217239	0.646	rs10946898	ENSG00000224843.5	LINC00240	-4.46	9.29e-06	0.000768	-0.15	-0.14	Schizophrenia;	chr6:27036105	chr6:26956992~27023924:+
BRCA	cis	rs7160336	1	rs4903187	ENSG00000259065.1	RP5-1021I20.1	4.45	9.3e-06	0.000768	0.15	0.14	Blood protein levels;	chr14:74118055	chr14:73787360~73803270:+
BRCA	cis	rs7160336	1	rs7152050	ENSG00000259065.1	RP5-1021I20.1	4.45	9.3e-06	0.000768	0.15	0.14	Blood protein levels;	chr14:74121470	chr14:73787360~73803270:+
BRCA	cis	rs7160336	0.935	rs7153610	ENSG00000259065.1	RP5-1021I20.1	4.45	9.3e-06	0.000768	0.15	0.14	Blood protein levels;	chr14:74121653	chr14:73787360~73803270:+
BRCA	cis	rs4950322	0.518	rs61838936	ENSG00000244371.2	PFN1P8	-4.45	9.3e-06	0.000769	-0.19	-0.14	Protein quantitative trait loci;	chr1:147098422	chr1:146957117~146957659:-
BRCA	cis	rs321358	1	rs321356	ENSG00000271390.1	RP11-89C3.3	-4.45	9.3e-06	0.000769	-0.21	-0.14	Body mass index;	chr11:111124957	chr11:111089870~111090368:-
BRCA	cis	rs11673344	0.504	rs4805204	ENSG00000226686.6	LINC01535	4.45	9.3e-06	0.000769	0.17	0.14	Obesity-related traits;	chr19:37136666	chr19:37251912~37265535:+
BRCA	cis	rs11673344	0.504	rs4805205	ENSG00000226686.6	LINC01535	4.45	9.3e-06	0.000769	0.17	0.14	Obesity-related traits;	chr19:37136693	chr19:37251912~37265535:+
BRCA	cis	rs7829975	0.593	rs2979241	ENSG00000233609.3	RP11-62H7.2	4.45	9.31e-06	0.000769	0.13	0.14	Mood instability;	chr8:8445843	chr8:8961200~8979025:+
BRCA	cis	rs7577696	0.962	rs13022197	ENSG00000272716.1	RP11-563N4.1	-4.45	9.31e-06	0.000769	-0.15	-0.14	Inflammatory biomarkers;	chr2:32118098	chr2:32165046~32165757:-
BRCA	cis	rs57221529	0.655	rs11948381	ENSG00000271781.1	CTD-2589H19.6	-4.45	9.31e-06	0.000769	-0.19	-0.14	Lung disease severity in cystic fibrosis;	chr5:568298	chr5:675826~676616:+
BRCA	cis	rs7003550	1	rs7003550	ENSG00000253433.1	NCRNA00250	4.45	9.31e-06	0.000769	0.2	0.14	Bone mineral accretion in asthma (oral corticosteroid dose interaction);	chr8:134838655	chr8:134838069~134842637:+
BRCA	cis	rs721917	0.506	rs2475756	ENSG00000242600.5	MBL1P	4.45	9.31e-06	0.000769	0.16	0.14	Chronic obstructive pulmonary disease;	chr10:79897010	chr10:79904898~79950336:+
BRCA	cis	rs516805	0.63	rs2816075	ENSG00000279114.1	RP3-425C14.5	-4.45	9.31e-06	0.000769	-0.17	-0.14	Lymphocyte counts;	chr6:122106110	chr6:122471923~122484161:+
BRCA	cis	rs11694172	0.874	rs12466268	ENSG00000273456.1	RP11-686O6.2	4.45	9.31e-06	0.00077	0.15	0.14	Cholesterol, total;	chr2:202646848	chr2:202374932~202375604:-
BRCA	cis	rs875971	0.528	rs801213	ENSG00000230295.1	RP11-458F8.2	-4.45	9.31e-06	0.00077	-0.13	-0.14	Aortic root size;	chr7:66549931	chr7:66880708~66882981:+
BRCA	cis	rs875971	0.545	rs801212	ENSG00000230295.1	RP11-458F8.2	-4.45	9.31e-06	0.00077	-0.13	-0.14	Aortic root size;	chr7:66550643	chr7:66880708~66882981:+
BRCA	cis	rs1910358	0.614	rs6898311	ENSG00000248874.4	C5orf17	-4.45	9.32e-06	0.00077	-0.18	-0.14	Venous thromboembolism (SNP x SNP interaction);	chr5:23978266	chr5:23951348~24178263:+
BRCA	cis	rs8064024	1	rs8064024	ENSG00000267077.1	RP11-127I20.5	-4.45	9.32e-06	0.00077	-0.14	-0.14	Cancer;	chr16:4805278	chr16:4795265~4796532:-
BRCA	cis	rs12612619	0.732	rs714513	ENSG00000229122.1	AGBL5-IT1	4.45	9.32e-06	0.00077	0.15	0.14	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:26983606	chr2:27061038~27061815:+
BRCA	cis	rs5758659	0.652	rs133321	ENSG00000273366.1	CTA-989H11.1	-4.45	9.32e-06	0.00077	-0.16	-0.14	Cognitive function;	chr22:42009318	chr22:42278188~42278846:+
BRCA	cis	rs5758659	0.652	rs133330	ENSG00000273366.1	CTA-989H11.1	-4.45	9.32e-06	0.00077	-0.16	-0.14	Cognitive function;	chr22:42013452	chr22:42278188~42278846:+
BRCA	cis	rs9650657	0.803	rs13276026	ENSG00000154316.13	TDH	4.45	9.32e-06	0.00077	0.17	0.14	Neuroticism;	chr8:10752445	chr8:11339637~11368452:+
BRCA	cis	rs17597773	0.638	rs7553447	ENSG00000238078.1	LINC01352	-4.45	9.32e-06	0.00077	-0.15	-0.14	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220816192	chr1:220829255~220832429:+
BRCA	cis	rs7927592	0.763	rs2513277	ENSG00000212093.1	AP000807.1	4.45	9.32e-06	0.00077	0.14	0.14	Total body bone mineral density;	chr11:68593419	chr11:68506083~68506166:-
BRCA	cis	rs721917	0.506	rs2758555	ENSG00000278616.1	BEND3P3	-4.45	9.32e-06	0.00077	-0.13	-0.14	Chronic obstructive pulmonary disease;	chr10:79931278	chr10:79682997~79685436:+
BRCA	cis	rs984222	0.586	rs12742258	ENSG00000231365.4	RP11-418J17.1	4.45	9.32e-06	0.00077	0.17	0.14	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119199678	chr1:119140396~119275973:+
BRCA	cis	rs3812049	0.784	rs2568928	ENSG00000245937.6	LINC01184	-4.45	9.32e-06	0.00077	-0.18	-0.14	Lymphocyte counts;Red cell distribution width;	chr5:128151911	chr5:127940426~128083172:-
BRCA	cis	rs2380205	0.967	rs7072174	ENSG00000232807.2	RP11-536K7.3	4.45	9.32e-06	0.00077	0.14	0.14	Breast cancer;	chr10:5856839	chr10:5934270~5945900:-
BRCA	cis	rs7647973	1	rs11720542	ENSG00000244380.1	RP11-24C3.2	4.45	9.32e-06	0.00077	0.17	0.14	Menarche (age at onset);	chr3:49319994	chr3:48440352~48446656:-
BRCA	cis	rs9467773	0.62	rs6925087	ENSG00000241549.7	GUSBP2	4.45	9.32e-06	0.00077	0.15	0.14	Intelligence (multi-trait analysis);	chr6:26592625	chr6:26871484~26956554:-
BRCA	cis	rs9467773	0.62	rs4368798	ENSG00000241549.7	GUSBP2	4.45	9.32e-06	0.00077	0.15	0.14	Intelligence (multi-trait analysis);	chr6:26593243	chr6:26871484~26956554:-
BRCA	cis	rs17507216	0.671	rs4779035	ENSG00000259429.4	UBE2Q2P2	-4.45	9.33e-06	0.000771	-0.18	-0.14	Excessive daytime sleepiness;	chr15:82591686	chr15:82355142~82420075:+
BRCA	cis	rs7131987	0.834	rs1989478	ENSG00000257176.2	RP11-996F15.2	-4.45	9.33e-06	0.000771	-0.16	-0.14	QT interval;	chr12:29289296	chr12:29280418~29317848:-
BRCA	cis	rs7267979	0.966	rs2261795	ENSG00000125804.12	FAM182A	-4.45	9.33e-06	0.000771	-0.18	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25282500	chr20:26054655~26086917:+
BRCA	cis	rs11779988	0.545	rs404186	ENSG00000253671.1	RP11-806O11.1	-4.45	9.33e-06	0.000771	-0.2	-0.14	Breast cancer;	chr8:17937987	chr8:17808941~17820868:+
BRCA	cis	rs4835473	0.897	rs11723113	ENSG00000249741.2	RP11-673E1.3	-4.45	9.33e-06	0.000771	-0.15	-0.14	Immature fraction of reticulocytes;	chr4:143707283	chr4:143911514~143912053:-
BRCA	cis	rs7615952	0.551	rs6438945	ENSG00000250012.1	RP11-124N2.1	-4.45	9.34e-06	0.000771	-0.21	-0.14	Blood pressure (smoking interaction);	chr3:125915630	chr3:126084220~126095349:+
BRCA	cis	rs11098499	0.863	rs58452170	ENSG00000250412.1	KLHL2P1	4.45	9.34e-06	0.000771	0.17	0.14	Corneal astigmatism;	chr4:119538519	chr4:119334329~119378233:+
BRCA	cis	rs10129255	0.518	rs10136903	ENSG00000211967.3	IGHV3-53	-4.45	9.34e-06	0.000771	-0.09	-0.14	Kawasaki disease;	chr14:106778866	chr14:106592676~106593347:-
BRCA	cis	rs17597773	0.638	rs6541161	ENSG00000238078.1	LINC01352	-4.45	9.34e-06	0.000772	-0.15	-0.14	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220820922	chr1:220829255~220832429:+
BRCA	cis	rs7726839	0.526	rs11960158	ENSG00000271781.1	CTD-2589H19.6	-4.45	9.34e-06	0.000772	-0.18	-0.14	Obesity-related traits;	chr5:568550	chr5:675826~676616:+
BRCA	cis	rs13113518	1	rs13115828	ENSG00000272969.1	RP11-528I4.2	4.45	9.35e-06	0.000772	0.16	0.14	Height;	chr4:55551447	chr4:55547112~55547889:+
BRCA	cis	rs13113518	1	rs13136282	ENSG00000272969.1	RP11-528I4.2	4.45	9.35e-06	0.000772	0.16	0.14	Height;	chr4:55551845	chr4:55547112~55547889:+
BRCA	cis	rs7267979	1	rs6083844	ENSG00000274973.1	RP13-401N8.7	4.45	9.35e-06	0.000772	0.15	0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25406196	chr20:25845497~25845862:+
BRCA	cis	rs1529102	1	rs2433388	ENSG00000225889.6	AC074289.1	-4.45	9.35e-06	0.000773	-0.12	-0.14	Breast size;	chr2:64266485	chr2:64143239~64252859:+
BRCA	cis	rs875971	0.545	rs66594357	ENSG00000232546.1	RP11-458F8.1	4.45	9.35e-06	0.000773	0.13	0.14	Aortic root size;	chr7:66327797	chr7:66848496~66858136:+
BRCA	cis	rs372883	0.935	rs1153295	ENSG00000215533.7	LINC00189	-4.45	9.36e-06	0.000773	-0.15	-0.14	Pancreatic cancer;	chr21:29331759	chr21:29193480~29288205:+
BRCA	cis	rs7267979	0.565	rs6107059	ENSG00000204556.4	CTD-2514C3.1	4.45	9.36e-06	0.000773	0.18	0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25611795	chr20:26018832~26020684:+
BRCA	cis	rs7592578	0.679	rs62181019	ENSG00000272979.1	RP11-647K16.1	-4.45	9.36e-06	0.000773	-0.21	-0.14	Diastolic blood pressure;	chr2:190460688	chr2:190454092~190454521:-
BRCA	cis	rs13113518	1	rs9312661	ENSG00000272969.1	RP11-528I4.2	4.45	9.36e-06	0.000773	0.16	0.14	Height;	chr4:55476159	chr4:55547112~55547889:+
BRCA	cis	rs6545883	0.542	rs10177225	ENSG00000273302.1	RP11-493E12.2	-4.45	9.36e-06	0.000773	-0.12	-0.14	Tuberculosis;	chr2:61367363	chr2:61199979~61200769:+
BRCA	cis	rs2255336	0.882	rs2246809	ENSG00000245648.1	RP11-277P12.20	4.45	9.36e-06	0.000773	0.21	0.14	Blood protein levels;	chr12:10404445	chr12:10363769~10398506:+
BRCA	cis	rs10129255	0.536	rs6576223	ENSG00000211967.3	IGHV3-53	-4.45	9.36e-06	0.000773	-0.09	-0.14	Kawasaki disease;	chr14:106776448	chr14:106592676~106593347:-
BRCA	cis	rs9816784	0.576	rs12631246	ENSG00000242086.7	LINC00969	4.45	9.37e-06	0.000774	0.16	0.14	Mean corpuscular hemoglobin;	chr3:196094713	chr3:195658062~195739964:+
BRCA	cis	rs10266483	0.96	rs13221291	ENSG00000228653.2	HNRNPCP7	-4.45	9.37e-06	0.000774	-0.16	-0.14	Response to statin therapy;	chr7:64279114	chr7:64500825~64501729:+
BRCA	cis	rs35612822	0.694	rs6744432	ENSG00000232485.2	AC098820.3	-4.45	9.37e-06	0.000774	-0.17	-0.14	Kidney disease (early stage) in type 1 diabetes;	chr2:216405776	chr2:216479030~216498761:-
BRCA	cis	rs7577696	0.627	rs10208246	ENSG00000272716.1	RP11-563N4.1	4.45	9.37e-06	0.000774	0.15	0.14	Inflammatory biomarkers;	chr2:32161590	chr2:32165046~32165757:-
BRCA	cis	rs7487075	1	rs7301001	ENSG00000257261.4	RP11-96H19.1	4.45	9.37e-06	0.000774	0.15	0.14	Itch intensity from mosquito bite;	chr12:46437058	chr12:46383679~46876159:+
BRCA	cis	rs8114671	0.967	rs12481169	ENSG00000279253.1	RP4-614O4.13	4.45	9.37e-06	0.000774	0.16	0.14	Height;	chr20:35206707	chr20:35262727~35264187:-
BRCA	cis	rs17270561	0.609	rs1892246	ENSG00000272462.2	U91328.19	-4.45	9.38e-06	0.000774	-0.17	-0.14	Iron status biomarkers;	chr6:25764180	chr6:25992662~26001775:+
BRCA	cis	rs1555321	0.571	rs1331317	ENSG00000273038.2	RP11-479G22.8	-4.45	9.38e-06	0.000774	-0.17	-0.14	Coronary artery disease;	chr10:33228719	chr10:32887255~32889311:-
BRCA	cis	rs1858037	0.867	rs2118305	ENSG00000281920.1	RP11-418H16.1	4.45	9.38e-06	0.000775	0.18	0.14	Rheumatoid arthritis;	chr2:65378086	chr2:65623272~65628424:+
BRCA	cis	rs13113518	0.966	rs4864544	ENSG00000272969.1	RP11-528I4.2	4.45	9.38e-06	0.000775	0.16	0.14	Height;	chr4:55515292	chr4:55547112~55547889:+
BRCA	cis	rs755249	0.567	rs16826009	ENSG00000182109.6	RP11-69E11.4	4.45	9.38e-06	0.000775	0.19	0.14	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39251230	chr1:39522280~39546187:-
BRCA	cis	rs1015362	0.504	rs6059552	ENSG00000276073.1	RP5-1125A11.7	-4.45	9.39e-06	0.000775	-0.19	-0.14	Freckles;Red vs. non-red hair color;Skin sensitivity to sun;Burning and freckling;	chr20:33923820	chr20:33985617~33988989:-
BRCA	cis	rs6026584	1	rs6026584	ENSG00000270951.1	RP1-309F20.4	4.45	9.39e-06	0.000775	0.17	0.14	Renal function-related traits (BUN);	chr20:58894018	chr20:58876592~58876981:-
BRCA	cis	rs5758659	0.652	rs133324	ENSG00000273366.1	CTA-989H11.1	-4.45	9.39e-06	0.000775	-0.16	-0.14	Cognitive function;	chr22:42010367	chr22:42278188~42278846:+
BRCA	cis	rs1048886	0.872	rs9446267	ENSG00000271967.1	RP11-134K13.4	-4.45	9.39e-06	0.000775	-0.18	-0.14	Type 2 diabetes;	chr6:70565337	chr6:70596438~70596980:+
BRCA	cis	rs11673344	0.504	rs10402907	ENSG00000226686.6	LINC01535	4.45	9.39e-06	0.000775	0.17	0.14	Obesity-related traits;	chr19:37112874	chr19:37251912~37265535:+
BRCA	cis	rs728616	0.681	rs17100316	ENSG00000225484.5	NUTM2B-AS1	-4.45	9.39e-06	0.000775	-0.32	-0.14	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80153581	chr10:79663088~79826594:-
BRCA	cis	rs7267979	0.966	rs2387882	ENSG00000277938.1	RP5-965G21.3	-4.45	9.39e-06	0.000775	-0.16	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25398166	chr20:25229150~25231933:+
BRCA	cis	rs4388249	0.651	rs253245	ENSG00000249476.1	CTD-2587M2.1	4.45	9.39e-06	0.000775	0.21	0.14	Schizophrenia;	chr5:109668499	chr5:109237120~109326369:-
BRCA	cis	rs8022179	0.58	rs58153827	ENSG00000244691.1	RPL10AP1	4.45	9.39e-06	0.000776	0.2	0.14	Monocyte count;	chr14:103378293	chr14:103412119~103412761:-
BRCA	cis	rs73242632	0.881	rs1277296	ENSG00000269949.1	RP11-738E22.3	-4.45	9.4e-06	0.000776	-0.29	-0.14	Congenital heart disease (maternal effect);	chr4:57062164	chr4:56960927~56961373:-
BRCA	cis	rs6439153	1	rs6439153	ENSG00000261159.1	RP11-723O4.9	4.45	9.4e-06	0.000776	0.15	0.14	Pneumococcal bacteremia;	chr3:128982287	chr3:128859716~128860526:-
BRCA	cis	rs10129255	0.556	rs6576222	ENSG00000211967.3	IGHV3-53	-4.45	9.4e-06	0.000776	-0.09	-0.14	Kawasaki disease;	chr14:106776442	chr14:106592676~106593347:-
BRCA	cis	rs13113518	1	rs11133392	ENSG00000272969.1	RP11-528I4.2	4.45	9.4e-06	0.000776	0.16	0.14	Height;	chr4:55507729	chr4:55547112~55547889:+
BRCA	cis	rs13113518	1	rs6838305	ENSG00000272969.1	RP11-528I4.2	4.45	9.4e-06	0.000776	0.16	0.14	Height;	chr4:55508587	chr4:55547112~55547889:+
BRCA	cis	rs13113518	0.902	rs12503578	ENSG00000272969.1	RP11-528I4.2	4.45	9.4e-06	0.000776	0.16	0.14	Height;	chr4:55509367	chr4:55547112~55547889:+
BRCA	cis	rs13113518	0.966	rs3828480	ENSG00000272969.1	RP11-528I4.2	4.45	9.4e-06	0.000776	0.16	0.14	Height;	chr4:55510352	chr4:55547112~55547889:+
BRCA	cis	rs13113518	1	rs3762837	ENSG00000272969.1	RP11-528I4.2	4.45	9.4e-06	0.000776	0.16	0.14	Height;	chr4:55511198	chr4:55547112~55547889:+
BRCA	cis	rs7674212	0.539	rs7676041	ENSG00000246560.2	RP11-10L12.4	4.45	9.4e-06	0.000776	0.14	0.14	Type 2 diabetes;	chr4:103205264	chr4:102828055~102844075:+
BRCA	cis	rs4494364	0.502	rs2192551	ENSG00000258100.1	RP11-121E16.1	4.45	9.41e-06	0.000776	0.19	0.14	Systolic blood pressure (alcohol consumption interaction);	chr12:91017490	chr12:91362196~91368606:+
BRCA	cis	rs7267979	1	rs6050599	ENSG00000274973.1	RP13-401N8.7	4.45	9.41e-06	0.000777	0.16	0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25419604	chr20:25845497~25845862:+
BRCA	cis	rs3768617	0.528	rs10737241	ENSG00000224468.3	RP11-181K3.4	-4.45	9.41e-06	0.000777	-0.15	-0.14	Fuchs's corneal dystrophy;	chr1:183129073	chr1:183138402~183141282:-
BRCA	cis	rs7048146	0.966	rs10979907	ENSG00000213539.4	YBX1P6	4.45	9.42e-06	0.000777	0.15	0.14	Vascular brain injury;	chr9:109541739	chr9:109532830~109534332:-
BRCA	cis	rs2380205	0.967	rs7099029	ENSG00000232807.2	RP11-536K7.3	4.45	9.42e-06	0.000777	0.14	0.14	Breast cancer;	chr10:5857225	chr10:5934270~5945900:-
BRCA	cis	rs860818	1	rs858249	ENSG00000230658.1	KLHL7-AS1	4.45	9.42e-06	0.000777	0.33	0.14	Initial pursuit acceleration;	chr7:23181020	chr7:23101228~23105703:-
BRCA	cis	rs4879656	0.5	rs12553806	ENSG00000236184.1	TCEA1P4	-4.45	9.42e-06	0.000777	-0.19	-0.14	Menopause (age at onset);	chr9:33083374	chr9:32979560~32980403:-
BRCA	cis	rs700651	0.757	rs6748683	ENSG00000231621.1	AC013264.2	-4.45	9.42e-06	0.000778	-0.13	-0.14	Intracranial aneurysm;	chr2:198013284	chr2:197197991~197199273:+
BRCA	cis	rs7243790	0.774	rs62091573	ENSG00000277324.1	RP11-850A17.1	-4.45	9.43e-06	0.000778	-0.15	-0.14	Diastolic blood pressure;	chr18:54412685	chr18:54268346~54270028:-
BRCA	cis	rs7243790	0.805	rs62091574	ENSG00000277324.1	RP11-850A17.1	-4.45	9.43e-06	0.000778	-0.15	-0.14	Diastolic blood pressure;	chr18:54412693	chr18:54268346~54270028:-
BRCA	cis	rs35612822	0.687	rs13417789	ENSG00000232485.2	AC098820.3	-4.45	9.43e-06	0.000778	-0.16	-0.14	Kidney disease (early stage) in type 1 diabetes;	chr2:216400322	chr2:216479030~216498761:-
BRCA	cis	rs750460	0.816	rs4886778	ENSG00000261801.4	LOXL1-AS1	4.45	9.43e-06	0.000778	0.15	0.14	Height;	chr15:73933047	chr15:73908071~73928248:-
BRCA	cis	rs750460	0.844	rs8027022	ENSG00000261801.4	LOXL1-AS1	4.45	9.43e-06	0.000778	0.15	0.14	Height;	chr15:73933797	chr15:73908071~73928248:-
BRCA	cis	rs750460	0.816	rs4337252	ENSG00000261801.4	LOXL1-AS1	4.45	9.43e-06	0.000778	0.15	0.14	Height;	chr15:73934424	chr15:73908071~73928248:-
BRCA	cis	rs919433	0.617	rs700646	ENSG00000231621.1	AC013264.2	-4.45	9.43e-06	0.000778	-0.13	-0.14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr2:197743787	chr2:197197991~197199273:+
BRCA	cis	rs375066	0.935	rs368089	ENSG00000267191.1	RP11-15A1.2	-4.45	9.43e-06	0.000779	-0.18	-0.14	Breast cancer;	chr19:43894932	chr19:43902001~43926545:+
BRCA	cis	rs2108622	0.727	rs8102532	ENSG00000267218.2	AC005336.5	4.45	9.44e-06	0.000779	0.16	0.14	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15869250	chr19:15902300~15903238:-
BRCA	cis	rs2380205	0.967	rs4567357	ENSG00000232807.2	RP11-536K7.3	4.45	9.44e-06	0.000779	0.14	0.14	Breast cancer;	chr10:5857320	chr10:5934270~5945900:-
BRCA	cis	rs7686660	1	rs4234883	ENSG00000250326.1	RP11-284M14.1	-4.45	9.44e-06	0.000779	-0.16	-0.14	Asthma;	chr4:143050378	chr4:142933195~143184861:-
BRCA	cis	rs7665090	0.967	rs13106304	ENSG00000251288.2	RP11-10L12.2	-4.45	9.44e-06	0.000779	-0.16	-0.14	Primary biliary cholangitis;	chr4:102633818	chr4:102751401~102752641:+
BRCA	cis	rs7665090	0.967	rs13106325	ENSG00000251288.2	RP11-10L12.2	-4.45	9.44e-06	0.000779	-0.16	-0.14	Primary biliary cholangitis;	chr4:102633835	chr4:102751401~102752641:+
BRCA	cis	rs79387448	0.638	rs11465670	ENSG00000234389.1	AC007278.3	4.45	9.44e-06	0.000779	0.19	0.14	Gut microbiota (bacterial taxa);	chr2:102417980	chr2:102438713~102440475:+
BRCA	cis	rs6828577	0.862	rs298995	ENSG00000281731.1	RP11-384K6.8	-4.45	9.44e-06	0.000779	-0.16	-0.14	Perioperative myocardial infarction in coronary artery bypass surgery;	chr4:118704118	chr4:118664087~118685341:-
BRCA	cis	rs2880765	0.835	rs7168860	ENSG00000202081.1	RNU6-1280P	4.45	9.44e-06	0.000779	0.16	0.14	Coronary artery disease;	chr15:85493799	chr15:85651522~85651628:-
BRCA	cis	rs17685	0.753	rs12531559	ENSG00000280388.1	RP11-229D13.3	4.45	9.44e-06	0.000779	0.14	0.14	Coffee consumption (cups per day);Coffee consumption;	chr7:76002379	chr7:76043977~76045963:-
BRCA	cis	rs1005277	0.505	rs200935	ENSG00000226578.1	RP11-258F22.1	-4.45	9.44e-06	0.000779	-0.15	-0.14	Extrinsic epigenetic age acceleration;	chr10:37843882	chr10:37775371~37784131:-
BRCA	cis	rs2115630	1	rs6496452	ENSG00000259728.4	LINC00933	-4.45	9.45e-06	0.00078	-0.15	-0.14	P wave terminal force;	chr15:84829414	chr15:84570649~84580175:+
BRCA	cis	rs2286503	0.839	rs4722189	ENSG00000226329.2	AC005682.6	4.45	9.45e-06	0.00078	0.13	0.14	Fibrinogen;	chr7:22820855	chr7:22863874~22881350:-
BRCA	cis	rs56322409	0.865	rs4918970	ENSG00000226688.5	ENTPD1-AS1	4.45	9.46e-06	0.00078	0.16	0.14	Blood metabolite levels;	chr10:95803250	chr10:95753206~96090238:-
BRCA	cis	rs56322409	0.637	rs117372659	ENSG00000226688.5	ENTPD1-AS1	4.45	9.46e-06	0.00078	0.16	0.14	Blood metabolite levels;	chr10:95809811	chr10:95753206~96090238:-
BRCA	cis	rs7572733	0.711	rs6728904	ENSG00000231621.1	AC013264.2	-4.45	9.46e-06	0.00078	-0.13	-0.14	Dermatomyositis;	chr2:197628113	chr2:197197991~197199273:+
BRCA	cis	rs4950322	1	rs1806618	ENSG00000244371.2	PFN1P8	-4.45	9.46e-06	0.00078	-0.19	-0.14	Protein quantitative trait loci;	chr1:147377075	chr1:146957117~146957659:-
BRCA	cis	rs4950322	1	rs4448568	ENSG00000244371.2	PFN1P8	-4.45	9.46e-06	0.00078	-0.19	-0.14	Protein quantitative trait loci;	chr1:147377296	chr1:146957117~146957659:-
BRCA	cis	rs2880765	0.566	rs17553249	ENSG00000202081.1	RNU6-1280P	4.45	9.46e-06	0.00078	0.17	0.14	Coronary artery disease;	chr15:85463463	chr15:85651522~85651628:-
BRCA	cis	rs6968419	0.755	rs73452247	ENSG00000279086.1	RP11-667F14.1	-4.45	9.46e-06	0.00078	-0.15	-0.14	Intraocular pressure;	chr7:116253843	chr7:116209234~116211511:-
BRCA	cis	rs6968419	0.755	rs17138486	ENSG00000279086.1	RP11-667F14.1	-4.45	9.46e-06	0.00078	-0.15	-0.14	Intraocular pressure;	chr7:116254349	chr7:116209234~116211511:-
BRCA	cis	rs875971	1	rs11974219	ENSG00000236529.1	RP13-254B10.1	-4.45	9.46e-06	0.000781	-0.15	-0.14	Aortic root size;	chr7:66182423	chr7:65840212~65840596:+
BRCA	cis	rs9467773	0.62	rs9461276	ENSG00000241549.7	GUSBP2	4.45	9.46e-06	0.000781	0.14	0.14	Intelligence (multi-trait analysis);	chr6:26594940	chr6:26871484~26956554:-
BRCA	cis	rs11758351	0.715	rs76130408	ENSG00000241549.7	GUSBP2	-4.45	9.47e-06	0.000781	-0.2	-0.14	Renal underexcretion gout;Gout;	chr6:26208734	chr6:26871484~26956554:-
BRCA	cis	rs57221529	0.766	rs72706610	ENSG00000225138.6	CTD-2228K2.7	4.45	9.47e-06	0.000781	0.2	0.14	Lung disease severity in cystic fibrosis;	chr5:560996	chr5:473236~480884:+
BRCA	cis	rs4415084	0.834	rs11746980	ENSG00000251141.4	RP11-53O19.1	4.45	9.47e-06	0.000781	0.12	0.14	Breast cancer;	chr5:44777776	chr5:44744900~44808777:-
BRCA	cis	rs2018683	0.87	rs13232487	ENSG00000228421.2	AC005013.5	4.45	9.47e-06	0.000781	0.17	0.14	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28945502	chr7:28957667~28959345:+
BRCA	cis	rs1510272	0.69	rs62275573	ENSG00000243926.1	TIPARP-AS1	-4.45	9.47e-06	0.000782	-0.15	-0.14	Testicular germ cell tumor;	chr3:156607915	chr3:156671862~156674378:-
BRCA	cis	rs7572733	0.534	rs700688	ENSG00000231621.1	AC013264.2	4.45	9.47e-06	0.000782	0.13	0.14	Dermatomyositis;	chr2:197859109	chr2:197197991~197199273:+
BRCA	cis	rs7119038	0.629	rs10892272	ENSG00000255422.1	AP002954.4	4.45	9.48e-06	0.000782	0.18	0.14	Sjögren's syndrome;	chr11:118731998	chr11:118704607~118750263:+
BRCA	cis	rs11742741	1	rs6864120	ENSG00000248874.4	C5orf17	4.45	9.48e-06	0.000782	0.18	0.14	Educational attainment;	chr5:24176407	chr5:23951348~24178263:+
BRCA	cis	rs6012564	0.929	rs4810898	ENSG00000227431.4	CSE1L-AS1	-4.45	9.48e-06	0.000782	-0.17	-0.14	Anger;	chr20:48937855	chr20:49040463~49046044:-
BRCA	cis	rs514024	0.656	rs537881	ENSG00000225032.4	RP11-228B15.4	4.45	9.48e-06	0.000782	0.12	0.14	Eating disorders (purging via substances);	chr9:127723339	chr9:127816066~127822520:+
BRCA	cis	rs4835473	0.932	rs35598827	ENSG00000249741.2	RP11-673E1.3	4.45	9.48e-06	0.000782	0.16	0.14	Immature fraction of reticulocytes;	chr4:143729605	chr4:143911514~143912053:-
BRCA	cis	rs1223397	0.651	rs202023	ENSG00000215022.6	RP1-257A7.4	-4.45	9.48e-06	0.000782	-0.16	-0.14	Blood pressure;	chr6:13304426	chr6:13264861~13295586:-
BRCA	cis	rs2273156	1	rs8017191	ENSG00000226677.3	IGBP1P1	-4.45	9.48e-06	0.000782	-0.2	-0.14	Immunoglobulin light chain (AL) amyloidosis;	chr14:35000785	chr14:34939324~34940332:+
BRCA	cis	rs1223397	0.651	rs202016	ENSG00000215022.6	RP1-257A7.4	-4.45	9.49e-06	0.000783	-0.16	-0.14	Blood pressure;	chr6:13300811	chr6:13264861~13295586:-
BRCA	cis	rs1223397	0.651	rs202017	ENSG00000215022.6	RP1-257A7.4	-4.45	9.49e-06	0.000783	-0.16	-0.14	Blood pressure;	chr6:13300819	chr6:13264861~13295586:-
BRCA	cis	rs10844706	0.669	rs10772108	ENSG00000256673.1	RP11-599J14.2	-4.45	9.49e-06	0.000783	-0.17	-0.14	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9746454	chr12:9398355~9414851:-
BRCA	cis	rs11758351	0.866	rs75091077	ENSG00000241549.7	GUSBP2	-4.45	9.49e-06	0.000783	-0.19	-0.14	Renal underexcretion gout;Gout;	chr6:26207318	chr6:26871484~26956554:-
BRCA	cis	rs7160336	1	rs3784038	ENSG00000259065.1	RP5-1021I20.1	4.45	9.49e-06	0.000783	0.15	0.14	Blood protein levels;	chr14:74047971	chr14:73787360~73803270:+
BRCA	cis	rs2731006	0.64	rs908663	ENSG00000257114.2	RP11-25I15.3	4.45	9.5e-06	0.000783	0.22	0.14	Panic disorder;	chr12:42775650	chr12:42692216~42717119:+
BRCA	cis	rs2731006	0.544	rs1554252	ENSG00000257114.2	RP11-25I15.3	4.45	9.5e-06	0.000783	0.22	0.14	Panic disorder;	chr12:42775853	chr12:42692216~42717119:+
BRCA	cis	rs2731006	0.64	rs952056	ENSG00000257114.2	RP11-25I15.3	4.45	9.5e-06	0.000783	0.22	0.14	Panic disorder;	chr12:42776100	chr12:42692216~42717119:+
BRCA	cis	rs2731006	0.64	rs952054	ENSG00000257114.2	RP11-25I15.3	4.45	9.5e-06	0.000783	0.22	0.14	Panic disorder;	chr12:42776209	chr12:42692216~42717119:+
BRCA	cis	rs2731006	0.597	rs1400811	ENSG00000257114.2	RP11-25I15.3	4.45	9.5e-06	0.000783	0.22	0.14	Panic disorder;	chr12:42776473	chr12:42692216~42717119:+
BRCA	cis	rs2731006	0.64	rs2459736	ENSG00000257114.2	RP11-25I15.3	4.45	9.5e-06	0.000783	0.22	0.14	Panic disorder;	chr12:42776971	chr12:42692216~42717119:+
BRCA	cis	rs1979679	0.608	rs6487691	ENSG00000278733.1	RP11-425D17.1	-4.45	9.5e-06	0.000783	-0.18	-0.14	Ossification of the posterior longitudinal ligament of the spine;	chr12:28571283	chr12:28185625~28186190:-
BRCA	cis	rs67981189	0.593	rs2526883	ENSG00000258571.1	PTTG4P	4.45	9.5e-06	0.000783	0.15	0.14	Schizophrenia;	chr14:70902858	chr14:71085482~71085833:-
BRCA	cis	rs6696239	0.868	rs74579475	ENSG00000227711.2	RP11-275O4.5	-4.45	9.5e-06	0.000784	-0.19	-0.14	Height;	chr1:227551606	chr1:227509028~227520477:-
BRCA	cis	rs11673344	0.523	rs2562599	ENSG00000276846.1	CTD-3220F14.3	-4.45	9.5e-06	0.000784	-0.16	-0.14	Obesity-related traits;	chr19:37025472	chr19:37314868~37315620:-
BRCA	cis	rs11671005	0.737	rs11673101	ENSG00000269600.1	AC016629.3	-4.45	9.5e-06	0.000784	-0.23	-0.14	Mean platelet volume;	chr19:58483686	chr19:58593896~58599355:-
BRCA	cis	rs9467773	0.62	rs9461275	ENSG00000241549.7	GUSBP2	4.45	9.51e-06	0.000784	0.14	0.14	Intelligence (multi-trait analysis);	chr6:26590573	chr6:26871484~26956554:-
BRCA	cis	rs6012564	1	rs6066982	ENSG00000227431.4	CSE1L-AS1	4.45	9.51e-06	0.000784	0.17	0.14	Anger;	chr20:49147021	chr20:49040463~49046044:-
BRCA	cis	rs6012564	1	rs7272164	ENSG00000227431.4	CSE1L-AS1	4.45	9.51e-06	0.000784	0.17	0.14	Anger;	chr20:49149660	chr20:49040463~49046044:-
BRCA	cis	rs1707322	0.638	rs9429095	ENSG00000281133.1	AL355480.3	4.45	9.51e-06	0.000784	0.17	0.14	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46137676	chr1:45580892~45580996:-
BRCA	cis	rs2562456	0.833	rs2928211	ENSG00000268658.4	LINC00664	-4.45	9.51e-06	0.000784	-0.21	-0.14	Pain;	chr19:21358495	chr19:21483374~21503238:+
BRCA	cis	rs6750047	0.638	rs336031	ENSG00000235848.3	RMDN2-AS1	4.45	9.52e-06	0.000785	0.18	0.14	Cutaneous malignant melanoma;Melanoma;	chr2:38037987	chr2:37949911~38067041:-
BRCA	cis	rs6847067	0.672	rs12503330	ENSG00000180769.7	WDFY3-AS2	4.45	9.52e-06	0.000785	0.14	0.14	Oropharynx cancer;	chr4:85032526	chr4:84965682~85011277:+
BRCA	cis	rs8054556	1	rs11150579	ENSG00000261367.1	RP11-455F5.4	-4.45	9.52e-06	0.000785	-0.16	-0.14	Autism spectrum disorder or schizophrenia;	chr16:29989009	chr16:30107675~30110541:+
BRCA	cis	rs10129255	0.518	rs11847766	ENSG00000232216.1	IGHV3-43	4.45	9.52e-06	0.000785	0.1	0.14	Kawasaki disease;	chr14:106779186	chr14:106470264~106470800:-
BRCA	cis	rs1005277	0.579	rs1548255	ENSG00000099251.13	HSD17B7P2	4.45	9.52e-06	0.000785	0.15	0.14	Extrinsic epigenetic age acceleration;	chr10:38128265	chr10:38356380~38378505:+
BRCA	cis	rs4767841	0.562	rs10849683	ENSG00000248636.5	RP11-768F21.1	-4.45	9.52e-06	0.000785	-0.18	-0.14	Urgency urinary incontinence;	chr12:119624203	chr12:119387987~119668079:-
BRCA	cis	rs651907	1	rs662792	ENSG00000244119.1	PDCL3P4	4.45	9.52e-06	0.000785	0.1	0.14	Colorectal cancer;	chr3:101880764	chr3:101712472~101713191:+
BRCA	cis	rs6496044	0.591	rs979825	ENSG00000202081.1	RNU6-1280P	4.45	9.53e-06	0.000786	0.16	0.14	Interstitial lung disease;	chr15:85537394	chr15:85651522~85651628:-
BRCA	cis	rs6964587	0.967	rs34574955	ENSG00000188693.7	CYP51A1-AS1	-4.45	9.53e-06	0.000786	-0.15	-0.14	Breast cancer;	chr7:92218236	chr7:92134604~92180725:+
BRCA	cis	rs17684571	0.7	rs34805046	ENSG00000231441.1	RP11-472M19.2	4.45	9.53e-06	0.000786	0.23	0.14	Schizophrenia;	chr6:56815813	chr6:56844002~56864078:+
BRCA	cis	rs17684571	0.765	rs34425815	ENSG00000231441.1	RP11-472M19.2	4.45	9.53e-06	0.000786	0.23	0.14	Schizophrenia;	chr6:56816040	chr6:56844002~56864078:+
BRCA	cis	rs12744310	0.887	rs72667608	ENSG00000235358.1	RP11-399E6.1	4.45	9.53e-06	0.000786	0.2	0.14	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41329101	chr1:41242373~41284861:+
BRCA	cis	rs1345301	0.518	rs56238602	ENSG00000234389.1	AC007278.3	-4.45	9.54e-06	0.000786	-0.13	-0.14	Waist circumference;	chr2:102246635	chr2:102438713~102440475:+
BRCA	cis	rs1008375	1	rs4698634	ENSG00000249502.1	AC006160.5	4.45	9.54e-06	0.000786	0.16	0.14	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17628569	chr4:17587467~17614571:-
BRCA	cis	rs962856	0.891	rs638190	ENSG00000236605.1	AC023115.4	4.45	9.54e-06	0.000787	0.16	0.14	Pancreatic cancer;	chr2:67434958	chr2:67324627~67325304:+
BRCA	cis	rs17818399	0.817	rs17767994	ENSG00000279254.1	RP11-536C12.1	4.45	9.54e-06	0.000787	0.18	0.14	Height;	chr2:46632940	chr2:46668870~46670778:+
BRCA	cis	rs6430585	0.583	rs7561565	ENSG00000231890.6	DARS-AS1	-4.45	9.55e-06	0.000787	-0.21	-0.14	Corneal structure;	chr2:135883217	chr2:135985176~136022593:+
BRCA	cis	rs7267979	1	rs1888999	ENSG00000276952.1	RP5-965G21.6	4.45	9.55e-06	0.000787	0.17	0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25311212	chr20:25284915~25285588:-
BRCA	cis	rs10457838	0.783	rs17732007	ENSG00000236591.1	RP11-162J8.3	-4.45	9.55e-06	0.000787	-0.19	-0.14	Post-traumatic stress disorder;	chr6:149071336	chr6:149027700~149032573:-
BRCA	cis	rs10504130	1	rs75371481	ENSG00000272024.1	RP11-546K22.3	-4.45	9.55e-06	0.000787	-0.24	-0.14	Venous thromboembolism (SNP x SNP interaction);	chr8:51863252	chr8:51950284~51950690:+
BRCA	cis	rs10504130	1	rs77082359	ENSG00000272024.1	RP11-546K22.3	-4.45	9.55e-06	0.000787	-0.24	-0.14	Venous thromboembolism (SNP x SNP interaction);	chr8:51866587	chr8:51950284~51950690:+
BRCA	cis	rs10504130	1	rs74769823	ENSG00000272024.1	RP11-546K22.3	-4.45	9.55e-06	0.000787	-0.24	-0.14	Venous thromboembolism (SNP x SNP interaction);	chr8:51867608	chr8:51950284~51950690:+
BRCA	cis	rs10504130	1	rs79727212	ENSG00000272024.1	RP11-546K22.3	-4.45	9.55e-06	0.000787	-0.24	-0.14	Venous thromboembolism (SNP x SNP interaction);	chr8:51868528	chr8:51950284~51950690:+
BRCA	cis	rs10504130	1	rs77534642	ENSG00000272024.1	RP11-546K22.3	-4.45	9.55e-06	0.000787	-0.24	-0.14	Venous thromboembolism (SNP x SNP interaction);	chr8:51868956	chr8:51950284~51950690:+
BRCA	cis	rs10504130	1	rs16916906	ENSG00000272024.1	RP11-546K22.3	-4.45	9.55e-06	0.000787	-0.24	-0.14	Venous thromboembolism (SNP x SNP interaction);	chr8:51869133	chr8:51950284~51950690:+
BRCA	cis	rs10504130	0.935	rs112132091	ENSG00000272024.1	RP11-546K22.3	-4.45	9.55e-06	0.000787	-0.24	-0.14	Venous thromboembolism (SNP x SNP interaction);	chr8:51869344	chr8:51950284~51950690:+
BRCA	cis	rs10504130	1	rs77532876	ENSG00000272024.1	RP11-546K22.3	-4.45	9.55e-06	0.000787	-0.24	-0.14	Venous thromboembolism (SNP x SNP interaction);	chr8:51873542	chr8:51950284~51950690:+
BRCA	cis	rs10504130	1	rs11777714	ENSG00000272024.1	RP11-546K22.3	-4.45	9.55e-06	0.000787	-0.24	-0.14	Venous thromboembolism (SNP x SNP interaction);	chr8:51874273	chr8:51950284~51950690:+
BRCA	cis	rs10504130	1	rs10958300	ENSG00000272024.1	RP11-546K22.3	-4.45	9.55e-06	0.000787	-0.24	-0.14	Venous thromboembolism (SNP x SNP interaction);	chr8:51875389	chr8:51950284~51950690:+
BRCA	cis	rs10504130	1	rs10958301	ENSG00000272024.1	RP11-546K22.3	-4.45	9.55e-06	0.000787	-0.24	-0.14	Venous thromboembolism (SNP x SNP interaction);	chr8:51875676	chr8:51950284~51950690:+
BRCA	cis	rs10504130	0.932	rs77153951	ENSG00000272024.1	RP11-546K22.3	-4.45	9.55e-06	0.000787	-0.24	-0.14	Venous thromboembolism (SNP x SNP interaction);	chr8:51878837	chr8:51950284~51950690:+
BRCA	cis	rs10504130	0.932	rs77140083	ENSG00000272024.1	RP11-546K22.3	-4.45	9.55e-06	0.000787	-0.24	-0.14	Venous thromboembolism (SNP x SNP interaction);	chr8:51880352	chr8:51950284~51950690:+
BRCA	cis	rs2908197	0.653	rs2961034	ENSG00000186704.9	DTX2P1	4.45	9.55e-06	0.000787	0.16	0.14	3-hydroxypropylmercapturic acid levels in smokers;	chr7:76332233	chr7:76978617~77004308:+
BRCA	cis	rs2803122	0.502	rs1329731	ENSG00000273226.1	RP11-513M16.8	-4.45	9.56e-06	0.000788	-0.16	-0.14	Pulse pressure;	chr9:19234910	chr9:19375451~19375996:+
BRCA	cis	rs983392	0.836	rs7935829	ENSG00000275344.1	MIR6503	-4.45	9.56e-06	0.000788	-0.14	-0.14	Alzheimer's disease (late onset);	chr11:60175342	chr11:60209071~60209156:-
BRCA	cis	rs17597773	0.638	rs11118615	ENSG00000257551.1	HLX-AS1	-4.45	9.56e-06	0.000788	-0.16	-0.14	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220823271	chr1:220832763~220880140:-
BRCA	cis	rs8040855	0.627	rs11637512	ENSG00000230373.7	GOLGA6L5P	4.45	9.56e-06	0.000788	0.18	0.14	Bulimia nervosa;	chr15:85105528	chr15:84507885~84516814:-
BRCA	cis	rs886774	0.774	rs4730281	ENSG00000273055.1	CTB-13F3.1	4.45	9.57e-06	0.000789	0.14	0.14	Ulcerative colitis;	chr7:107941491	chr7:107942116~107942740:+
BRCA	cis	rs9868809	0.772	rs9836462	ENSG00000225399.4	RP11-3B7.1	4.45	9.57e-06	0.000789	0.18	0.14	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48675358	chr3:49260085~49261316:+
BRCA	cis	rs7011507	0.582	rs55898556	ENSG00000279881.1	RP11-513O13.1	-4.45	9.57e-06	0.000789	-0.22	-0.14	Inflammatory bowel disease;Ulcerative colitis;	chr8:48343033	chr8:48428143~48431041:-
BRCA	cis	rs6840360	0.642	rs7680013	ENSG00000251603.1	RP11-164P12.4	-4.45	9.58e-06	0.000789	-0.12	-0.14	Intelligence (multi-trait analysis);	chr4:151488325	chr4:151667224~151670502:+
BRCA	cis	rs6840360	0.642	rs7680236	ENSG00000251603.1	RP11-164P12.4	-4.45	9.58e-06	0.000789	-0.12	-0.14	Intelligence (multi-trait analysis);	chr4:151488449	chr4:151667224~151670502:+
BRCA	cis	rs2073316	0.592	rs1033689	ENSG00000272716.1	RP11-563N4.1	4.45	9.58e-06	0.000789	0.15	0.14	Interleukin-18 levels;	chr2:31472863	chr2:32165046~32165757:-
BRCA	cis	rs2380205	0.935	rs4468244	ENSG00000232807.2	RP11-536K7.3	4.45	9.58e-06	0.000789	0.14	0.14	Breast cancer;	chr10:5856580	chr10:5934270~5945900:-
BRCA	cis	rs7826238	0.623	rs2976893	ENSG00000233609.3	RP11-62H7.2	-4.45	9.58e-06	0.000789	-0.13	-0.14	Systolic blood pressure;	chr8:8480709	chr8:8961200~8979025:+
BRCA	cis	rs4908760	0.792	rs4908505	ENSG00000232912.4	RP5-1115A15.1	4.45	9.59e-06	0.00079	0.13	0.14	Vitiligo;	chr1:8668805	chr1:8424645~8434838:+
BRCA	cis	rs2243480	1	rs316321	ENSG00000275400.1	RP4-756H11.5	4.45	9.59e-06	0.00079	0.25	0.14	Diabetic kidney disease;	chr7:66146626	chr7:66553805~66554199:-
BRCA	cis	rs2243480	1	rs316318	ENSG00000275400.1	RP4-756H11.5	4.45	9.59e-06	0.00079	0.25	0.14	Diabetic kidney disease;	chr7:66147917	chr7:66553805~66554199:-
BRCA	cis	rs2243480	1	rs316317	ENSG00000275400.1	RP4-756H11.5	4.45	9.59e-06	0.00079	0.25	0.14	Diabetic kidney disease;	chr7:66148650	chr7:66553805~66554199:-
BRCA	cis	rs2243480	1	rs316304	ENSG00000275400.1	RP4-756H11.5	4.45	9.59e-06	0.00079	0.25	0.14	Diabetic kidney disease;	chr7:66151907	chr7:66553805~66554199:-
BRCA	cis	rs7727544	0.716	rs72793283	ENSG00000233006.5	AC034220.3	4.45	9.59e-06	0.00079	0.1	0.14	Blood metabolite levels;	chr5:132231248	chr5:132311285~132369916:-
BRCA	cis	rs950776	0.752	rs7182583	ENSG00000279373.1	RP11-650L12.4	4.45	9.59e-06	0.00079	0.17	0.14	Sudden cardiac arrest;	chr15:78606868	chr15:78537681~78538946:+
BRCA	cis	rs2506028	0.55	rs1539291	ENSG00000273008.1	RP11-351D16.3	-4.45	9.6e-06	0.00079	-0.16	-0.14	Blood protein levels;	chr10:42941902	chr10:43136824~43138334:-
BRCA	cis	rs10129255	0.5	rs10143242	ENSG00000211959.2	IGHV4-39	4.45	9.6e-06	0.00079	0.09	0.14	Kawasaki disease;	chr14:106681814	chr14:106421711~106422218:-
BRCA	cis	rs6545883	0.507	rs2123111	ENSG00000273302.1	RP11-493E12.2	-4.45	9.6e-06	0.000791	-0.12	-0.14	Tuberculosis;	chr2:61223319	chr2:61199979~61200769:+
BRCA	cis	rs875971	0.502	rs6460311	ENSG00000232546.1	RP11-458F8.1	-4.45	9.6e-06	0.000791	-0.13	-0.14	Aortic root size;	chr7:66646886	chr7:66848496~66858136:+
BRCA	cis	rs6738627	0.895	rs12692735	ENSG00000223318.1	RNA5SP111	4.45	9.6e-06	0.000791	0.16	0.14	circulating leptin levels adjusted for BMI;Body fat percentage;circulating leptin levels;	chr2:164648055	chr2:164895677~164895777:-
BRCA	cis	rs736408	0.562	rs2072390	ENSG00000243224.1	RP5-1157M23.2	-4.45	9.61e-06	0.000792	-0.14	-0.14	Bipolar disorder;	chr3:52746493	chr3:52239258~52241097:+
BRCA	cis	rs6445967	0.689	rs11714574	ENSG00000273493.1	RP11-80H18.4	-4.45	9.61e-06	0.000792	-0.16	-0.14	Platelet count;	chr3:58394738	chr3:58329965~58330118:+
BRCA	cis	rs957448	0.529	rs9642928	ENSG00000253175.1	RP11-267M23.6	4.45	9.61e-06	0.000792	0.16	0.14	Nonsyndromic cleft lip with cleft palate;	chr8:94601698	chr8:94565036~94565715:+
BRCA	cis	rs2109514	0.902	rs717957	ENSG00000237813.3	AC002066.1	4.45	9.61e-06	0.000792	0.16	0.14	Prevalent atrial fibrillation;	chr7:116473053	chr7:116238260~116499465:-
BRCA	cis	rs718314	0.956	rs4963975	ENSG00000256894.1	RP11-283G6.3	4.45	9.61e-06	0.000792	0.16	0.14	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Renal cell carcinoma;Waist circumference adjusted for body mass index;	chr12:26290097	chr12:26125155~26126617:-
BRCA	cis	rs2446066	0.872	rs10876451	ENSG00000257379.1	RP11-793H13.8	4.45	9.61e-06	0.000792	0.21	0.14	Red blood cell count;	chr12:53419640	chr12:53441741~53467528:+
BRCA	cis	rs4835473	0.618	rs7666297	ENSG00000249741.2	RP11-673E1.3	4.45	9.62e-06	0.000792	0.15	0.14	Immature fraction of reticulocytes;	chr4:143999005	chr4:143911514~143912053:-
BRCA	cis	rs11098499	0.644	rs7693919	ENSG00000249244.1	RP11-548H18.2	4.45	9.62e-06	0.000792	0.16	0.14	Corneal astigmatism;	chr4:119619416	chr4:119391831~119395335:-
BRCA	cis	rs17489649	1	rs2301012	ENSG00000271849.1	CTC-332L22.1	4.45	9.62e-06	0.000792	0.18	0.14	Intelligence (multi-trait analysis);	chr5:109800567	chr5:109687802~109688329:-
BRCA	cis	rs11098499	0.863	rs7678400	ENSG00000250412.1	KLHL2P1	4.45	9.62e-06	0.000792	0.17	0.14	Corneal astigmatism;	chr4:119540802	chr4:119334329~119378233:+
BRCA	cis	rs11098499	0.863	rs1480936	ENSG00000250412.1	KLHL2P1	4.45	9.62e-06	0.000792	0.17	0.14	Corneal astigmatism;	chr4:119541706	chr4:119334329~119378233:+
BRCA	cis	rs17489649	1	rs7710031	ENSG00000271849.1	CTC-332L22.1	4.45	9.62e-06	0.000792	0.18	0.14	Intelligence (multi-trait analysis);	chr5:109799144	chr5:109687802~109688329:-
BRCA	cis	rs6921919	0.583	rs9461459	ENSG00000220721.1	OR1F12	4.45	9.62e-06	0.000792	0.17	0.14	Autism spectrum disorder or schizophrenia;	chr6:28394139	chr6:28073316~28074233:+
BRCA	cis	rs6921919	0.583	rs28360638	ENSG00000220721.1	OR1F12	4.45	9.62e-06	0.000792	0.17	0.14	Autism spectrum disorder or schizophrenia;	chr6:28394552	chr6:28073316~28074233:+
BRCA	cis	rs6921919	0.583	rs9468368	ENSG00000220721.1	OR1F12	4.45	9.62e-06	0.000792	0.17	0.14	Autism spectrum disorder or schizophrenia;	chr6:28397172	chr6:28073316~28074233:+
BRCA	cis	rs6657613	0.68	rs7545518	ENSG00000186715.9	MST1L	4.45	9.63e-06	0.000793	0.13	0.14	Hip circumference adjusted for BMI;	chr1:17048247	chr1:16754910~16770237:-
BRCA	cis	rs7267979	0.565	rs4815437	ENSG00000231081.1	RP4-760C5.3	4.45	9.63e-06	0.000793	0.17	0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25604152	chr20:26008791~26010531:-
BRCA	cis	rs780094	0.5	rs4665987	ENSG00000234072.1	AC074117.10	4.45	9.63e-06	0.000793	0.14	0.14	Urate levels in overweight individuals;C-reactive protein;Metabolic syndrome;Red blood cell count;Renal underexcretion gout;Nonalcoholic fatty liver disease;Age-related diseases, mortality and associated endophenotypes;Crohn's disease;Calcium levels;Fasting plasma glucose;Metabolic traits;Fasting blood glucose;Fasting blood insulin;Urate levels in obese individuals;Alcohol consumption (drinks per week);Height;Urate levels;Gondoic acid (20:1n-9) levels;Uric acid levels;Age-related disease endophenotypes;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Homeostasis model assessment of insulin resistance;Alcohol consumption;Fasting blood insulin (BMI interaction);Triglycerides;Fasting blood glucose (BMI interaction);Hypertriglyceridemia;LDL cholesterol;Type 2 diabetes;Triglyceride levels;	chr2:27532958	chr2:27356246~27367622:+
BRCA	cis	rs6452524	1	rs6452531	ENSG00000281327.1	LINC01338	4.45	9.63e-06	0.000793	0.16	0.14	Hypertension (SNP x SNP interaction);	chr5:83170355	chr5:82850864~82859836:-
BRCA	cis	rs516805	0.63	rs2816073	ENSG00000279114.1	RP3-425C14.5	-4.45	9.63e-06	0.000793	-0.17	-0.14	Lymphocyte counts;	chr6:122106794	chr6:122471923~122484161:+
BRCA	cis	rs516805	0.666	rs2816071	ENSG00000279114.1	RP3-425C14.5	-4.45	9.63e-06	0.000793	-0.17	-0.14	Lymphocyte counts;	chr6:122106995	chr6:122471923~122484161:+
BRCA	cis	rs4908768	0.501	rs7520617	ENSG00000232912.4	RP5-1115A15.1	4.45	9.64e-06	0.000793	0.13	0.14	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8513658	chr1:8424645~8434838:+
BRCA	cis	rs16958440	1	rs62096476	ENSG00000280212.1	RP11-49K24.3	4.45	9.64e-06	0.000794	0.28	0.14	Sitting height ratio;	chr18:47132250	chr18:47076117~47076594:+
BRCA	cis	rs16958440	1	rs62096478	ENSG00000280212.1	RP11-49K24.3	4.45	9.64e-06	0.000794	0.28	0.14	Sitting height ratio;	chr18:47136038	chr18:47076117~47076594:+
BRCA	cis	rs11742741	0.967	rs1582945	ENSG00000248874.4	C5orf17	-4.45	9.64e-06	0.000794	-0.18	-0.14	Educational attainment;	chr5:24119452	chr5:23951348~24178263:+
BRCA	cis	rs11742741	0.807	rs4484388	ENSG00000248874.4	C5orf17	-4.45	9.64e-06	0.000794	-0.18	-0.14	Educational attainment;	chr5:24123095	chr5:23951348~24178263:+
BRCA	cis	rs11742741	0.967	rs6883969	ENSG00000248874.4	C5orf17	-4.45	9.64e-06	0.000794	-0.18	-0.14	Educational attainment;	chr5:24127022	chr5:23951348~24178263:+
BRCA	cis	rs934734	0.532	rs2028150	ENSG00000281920.1	RP11-418H16.1	-4.45	9.64e-06	0.000794	-0.16	-0.14	Rheumatoid arthritis;	chr2:65427878	chr2:65623272~65628424:+
BRCA	cis	rs794185	0.592	rs304078	ENSG00000231249.1	ITPR1-AS1	-4.45	9.64e-06	0.000794	-0.15	-0.14	Multiple sclerosis--Brain Glutamate Levels;	chr3:4491474	chr3:4490891~4493163:-
BRCA	cis	rs4950322	0.895	rs17356735	ENSG00000244371.2	PFN1P8	-4.45	9.64e-06	0.000794	-0.19	-0.14	Protein quantitative trait loci;	chr1:147378328	chr1:146957117~146957659:-
BRCA	cis	rs886774	0.587	rs11496130	ENSG00000273055.1	CTB-13F3.1	-4.45	9.65e-06	0.000794	-0.14	-0.14	Ulcerative colitis;	chr7:107940590	chr7:107942116~107942740:+
BRCA	cis	rs2562152	0.706	rs216598	ENSG00000233614.6	DDX11L10	-4.45	9.65e-06	0.000795	-0.22	-0.14	Glioblastoma;	chr16:58586	chr16:11555~14090:+
BRCA	cis	rs4908760	0.613	rs12403640	ENSG00000232912.4	RP5-1115A15.1	4.45	9.65e-06	0.000795	0.13	0.14	Vitiligo;	chr1:8757804	chr1:8424645~8434838:+
BRCA	cis	rs1322639	0.614	rs7768154	ENSG00000223485.1	RP11-417E7.1	-4.45	9.65e-06	0.000795	-0.19	-0.14	Pulse pressure;	chr6:169165375	chr6:169158092~169162924:-
BRCA	cis	rs7267979	0.527	rs6083891	ENSG00000231081.1	RP4-760C5.3	4.45	9.65e-06	0.000795	0.17	0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25593636	chr20:26008791~26010531:-
BRCA	cis	rs11098499	0.954	rs17009122	ENSG00000250412.1	KLHL2P1	4.45	9.65e-06	0.000795	0.16	0.14	Corneal astigmatism;	chr4:119441248	chr4:119334329~119378233:+
BRCA	cis	rs2243480	1	rs6958289	ENSG00000275400.1	RP4-756H11.5	-4.45	9.65e-06	0.000795	-0.25	-0.14	Diabetic kidney disease;	chr7:66192124	chr7:66553805~66554199:-
BRCA	cis	rs7200786	0.715	rs8050144	ENSG00000274038.1	RP11-66H6.4	-4.45	9.65e-06	0.000795	-0.16	-0.14	Systemic lupus erythematosus;Multiple sclerosis;	chr16:10996230	chr16:11056556~11057034:+
BRCA	cis	rs7246967	0.673	rs4446014	ENSG00000198153.8	ZNF849P	-4.45	9.66e-06	0.000795	-0.23	-0.14	Bronchopulmonary dysplasia;	chr19:22714956	chr19:22685167~22686732:+
BRCA	cis	rs36051895	0.559	rs12342390	ENSG00000236254.1	MTND4P14	-4.45	9.66e-06	0.000795	-0.16	-0.14	Pediatric autoimmune diseases;	chr9:5211297	chr9:5107937~5109290:+
BRCA	cis	rs7260598	0.642	rs7256265	ENSG00000268442.1	CTD-2027I19.2	4.45	9.66e-06	0.000795	0.21	0.14	Response to taxane treatment (placlitaxel);	chr19:23950901	chr19:24162370~24163425:-
BRCA	cis	rs9863	0.828	rs7311969	ENSG00000270028.1	RP11-380L11.4	-4.45	9.66e-06	0.000795	-0.17	-0.14	White blood cell count;	chr12:123985786	chr12:123925461~123926083:-
BRCA	cis	rs11168618	0.967	rs1895996	ENSG00000240399.1	RP1-228P16.1	4.45	9.66e-06	0.000795	0.15	0.14	Adiponectin levels;	chr12:48561788	chr12:48054813~48055591:-
BRCA	cis	rs6452524	1	rs4590162	ENSG00000281327.1	LINC01338	4.45	9.66e-06	0.000796	0.16	0.14	Hypertension (SNP x SNP interaction);	chr5:83145621	chr5:82850864~82859836:-
BRCA	cis	rs2289700	1	rs16970287	ENSG00000252061.1	RNU6-415P	-4.45	9.67e-06	0.000796	-0.26	-0.14	Bipolar disorder;	chr15:78935915	chr15:78898840~78898936:-
BRCA	cis	rs9311474	0.508	rs7614498	ENSG00000243224.1	RP5-1157M23.2	-4.45	9.67e-06	0.000796	-0.15	-0.14	Electroencephalogram traits;	chr3:52584925	chr3:52239258~52241097:+
BRCA	cis	rs73186030	1	rs5008830	ENSG00000272758.4	RP11-299J3.8	4.45	9.67e-06	0.000796	0.2	0.14	Serum parathyroid hormone levels;	chr3:122311615	chr3:122416207~122443180:+
BRCA	cis	rs11098499	0.644	rs28787668	ENSG00000249244.1	RP11-548H18.2	4.45	9.67e-06	0.000796	0.16	0.14	Corneal astigmatism;	chr4:119633532	chr4:119391831~119395335:-
BRCA	cis	rs6044112	1	rs6075069	ENSG00000273998.1	RP4-777L9.2	-4.45	9.67e-06	0.000796	-0.25	-0.14	Response to taxane treatment (docetaxel);	chr20:16548269	chr20:16576068~16579615:+
BRCA	cis	rs2673908	1	rs2673908	ENSG00000268581.1	SIGLEC18P	4.45	9.67e-06	0.000796	0.16	0.14	Cerebrospinal fluid biomarker levels;Granulocyte percentage of myeloid white cells;Monocyte percentage of white cells;	chr19:51124509	chr19:51119987~51122965:+
BRCA	cis	rs7818688	0.578	rs13279040	ENSG00000253528.2	RP11-347C18.4	-4.45	9.68e-06	0.000796	-0.21	-0.14	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95068161	chr8:94974573~94974853:-
BRCA	cis	rs728616	0.681	rs36073865	ENSG00000225484.5	NUTM2B-AS1	-4.45	9.68e-06	0.000796	-0.32	-0.14	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80156299	chr10:79663088~79826594:-
BRCA	cis	rs11098499	0.644	rs3986377	ENSG00000260404.2	RP11-384K6.6	4.45	9.68e-06	0.000796	0.12	0.14	Corneal astigmatism;	chr4:119339115	chr4:118591773~118633729:+
BRCA	cis	rs10028773	0.556	rs4473640	ENSG00000260404.2	RP11-384K6.6	4.45	9.68e-06	0.000796	0.12	0.14	Educational attainment;	chr4:119339282	chr4:118591773~118633729:+
BRCA	cis	rs875971	0.545	rs73376401	ENSG00000273142.1	RP11-458F8.4	4.45	9.68e-06	0.000796	0.13	0.14	Aortic root size;	chr7:66174841	chr7:66902857~66906297:+
BRCA	cis	rs5758659	0.716	rs86669	ENSG00000231261.1	HMGN2P10	4.45	9.68e-06	0.000796	0.15	0.14	Cognitive function;	chr22:42284794	chr22:41709225~41709489:-
BRCA	cis	rs1371614	0.635	rs34803465	ENSG00000272148.1	RP11-195B17.1	-4.45	9.68e-06	0.000797	-0.15	-0.14	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26915417	chr2:27062428~27062907:-
BRCA	cis	rs11696739	0.513	rs2209313	ENSG00000242324.1	RP4-576H24.2	-4.45	9.68e-06	0.000797	-0.2	-0.14	Mean platelet volume;	chr20:1618496	chr20:1516759~1557653:-
BRCA	cis	rs6893300	0.776	rs55868831	ENSG00000225051.5	HMGB3P22	4.45	9.69e-06	0.000797	0.17	0.14	Resting heart rate;	chr5:179730295	chr5:179679032~179694768:+
BRCA	cis	rs6893300	0.776	rs56396231	ENSG00000225051.5	HMGB3P22	4.45	9.69e-06	0.000797	0.17	0.14	Resting heart rate;	chr5:179730297	chr5:179679032~179694768:+
BRCA	cis	rs8031584	0.918	rs34693097	ENSG00000259845.1	HERC2P10	4.45	9.69e-06	0.000797	0.16	0.14	Huntington's disease progression;	chr15:30961781	chr15:30815271~30844153:+
BRCA	cis	rs9527	0.615	rs10883810	ENSG00000213061.2	PFN1P11	4.45	9.69e-06	0.000797	0.18	0.14	Arsenic metabolism;	chr10:102967467	chr10:102838011~102845473:-
BRCA	cis	rs9527	0.615	rs10883811	ENSG00000213061.2	PFN1P11	4.45	9.69e-06	0.000797	0.18	0.14	Arsenic metabolism;	chr10:102967522	chr10:102838011~102845473:-
BRCA	cis	rs853679	1	rs1419183	ENSG00000280107.1	AL022393.9	-4.45	9.69e-06	0.000797	-0.24	-0.14	Depression;	chr6:28275017	chr6:28170845~28172521:+
BRCA	cis	rs11123406	0.501	rs3747653	ENSG00000230499.1	AC108463.1	4.45	9.69e-06	0.000797	0.19	0.14	Type 2 diabetes;	chr2:111208963	chr2:111195963~111206494:+
BRCA	cis	rs6696239	0.513	rs2492635	ENSG00000227711.2	RP11-275O4.5	-4.45	9.69e-06	0.000798	-0.16	-0.14	Height;	chr1:227517134	chr1:227509028~227520477:-
BRCA	cis	rs875971	0.862	rs6460290	ENSG00000273448.1	RP11-166O4.6	-4.45	9.7e-06	0.000798	-0.12	-0.14	Aortic root size;	chr7:66344119	chr7:67333047~67334383:+
BRCA	cis	rs1867631	1	rs6665859	ENSG00000248458.2	RP4-598P13.1	4.45	9.7e-06	0.000798	0.14	0.14	Menopause (age at onset);	chr1:66611872	chr1:66665864~66677027:-
BRCA	cis	rs10129255	0.701	rs2005643	ENSG00000211967.3	IGHV3-53	-4.45	9.7e-06	0.000798	-0.1	-0.14	Kawasaki disease;	chr14:106676288	chr14:106592676~106593347:-
BRCA	cis	rs7620503	1	rs6805429	ENSG00000277241.1	RP11-114M1.3	4.45	9.7e-06	0.000798	0.15	0.14	Corneal structure;	chr3:177581481	chr3:177700346~177701072:-
BRCA	cis	rs1510272	0.889	rs4680286	ENSG00000243926.1	TIPARP-AS1	-4.45	9.71e-06	0.000799	-0.15	-0.14	Testicular germ cell tumor;	chr3:156601298	chr3:156671862~156674378:-
BRCA	cis	rs4908769	0.624	rs301790	ENSG00000270282.1	RP5-1115A15.2	4.45	9.71e-06	0.000799	0.16	0.14	Allergy;	chr1:8409224	chr1:8512653~8513021:+
BRCA	cis	rs6921919	0.583	rs6928771	ENSG00000220721.1	OR1F12	4.45	9.71e-06	0.000799	0.17	0.14	Autism spectrum disorder or schizophrenia;	chr6:28407432	chr6:28073316~28074233:+
BRCA	cis	rs6921919	0.583	rs6928773	ENSG00000220721.1	OR1F12	4.45	9.71e-06	0.000799	0.17	0.14	Autism spectrum disorder or schizophrenia;	chr6:28407433	chr6:28073316~28074233:+
BRCA	cis	rs13126694	0.598	rs10005547	ENSG00000251429.1	RP11-597D13.7	4.45	9.71e-06	0.000799	0.14	0.14	Blood osmolality (transformed sodium);	chr4:158092407	chr4:158270378~158278676:+
BRCA	cis	rs13126694	0.633	rs9993747	ENSG00000251429.1	RP11-597D13.7	4.45	9.71e-06	0.000799	0.14	0.14	Blood osmolality (transformed sodium);	chr4:158092421	chr4:158270378~158278676:+
BRCA	cis	rs2243480	0.908	rs4718273	ENSG00000222364.1	RNU6-96P	4.45	9.71e-06	0.000799	0.25	0.14	Diabetic kidney disease;	chr7:65751112	chr7:66395191~66395286:+
BRCA	cis	rs454217	0.521	rs7978613	ENSG00000277851.1	RP11-756G20.1	-4.45	9.71e-06	0.000799	-0.16	-0.14	Smoking quantity;	chr12:92324996	chr12:92247756~92363832:-
BRCA	cis	rs2832191	0.935	rs11910475	ENSG00000176054.6	RPL23P2	-4.45	9.71e-06	0.000799	-0.14	-0.14	Dental caries;	chr21:29147381	chr21:28997613~28998033:-
BRCA	cis	rs1910358	0.515	rs10068750	ENSG00000248874.4	C5orf17	4.45	9.73e-06	8e-04	0.19	0.14	Venous thromboembolism (SNP x SNP interaction);	chr5:23724183	chr5:23951348~24178263:+
BRCA	cis	rs13113518	1	rs4865011	ENSG00000272969.1	RP11-528I4.2	4.45	9.73e-06	8e-04	0.16	0.14	Height;	chr4:55554456	chr4:55547112~55547889:+
BRCA	cis	rs2803122	0.745	rs9802945	ENSG00000273226.1	RP11-513M16.8	4.45	9.73e-06	8e-04	0.15	0.14	Pulse pressure;	chr9:19385224	chr9:19375451~19375996:+
BRCA	cis	rs2018683	0.834	rs2012754	ENSG00000228421.2	AC005013.5	4.45	9.73e-06	8e-04	0.17	0.14	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28986641	chr7:28957667~28959345:+
BRCA	cis	rs8103278	1	rs8108590	ENSG00000267395.4	AC074212.6	4.45	9.73e-06	8e-04	0.14	0.14	Coronary artery disease;	chr19:45798362	chr19:45767796~45772504:+
BRCA	cis	rs983392	0.836	rs72918674	ENSG00000275344.1	MIR6503	-4.44	9.73e-06	8e-04	-0.14	-0.14	Alzheimer's disease (late onset);	chr11:60177107	chr11:60209071~60209156:-
BRCA	cis	rs8054556	0.765	rs11150574	ENSG00000183604.13	SMG1P5	-4.44	9.73e-06	8e-04	-0.13	-0.14	Autism spectrum disorder or schizophrenia;	chr16:29923498	chr16:30267553~30335374:-
BRCA	cis	rs8054556	1	rs11642046	ENSG00000261367.1	RP11-455F5.4	-4.44	9.73e-06	8e-04	-0.15	-0.14	Autism spectrum disorder or schizophrenia;	chr16:29981787	chr16:30107675~30110541:+
BRCA	cis	rs1510272	0.883	rs9819534	ENSG00000243926.1	TIPARP-AS1	-4.44	9.73e-06	8e-04	-0.15	-0.14	Testicular germ cell tumor;	chr3:156593254	chr3:156671862~156674378:-
BRCA	cis	rs10829156	0.625	rs7082235	ENSG00000225527.1	RP11-383B4.4	-4.44	9.73e-06	8e-04	-0.19	-0.14	Sudden cardiac arrest;	chr10:18536765	chr10:18531849~18533336:-
BRCA	cis	rs4869313	0.655	rs2927610	ENSG00000248734.2	CTD-2260A17.1	-4.44	9.74e-06	0.000801	-0.14	-0.14	Pediatric autoimmune diseases;	chr5:96865067	chr5:96784777~96785999:+
BRCA	cis	rs6496044	0.547	rs1564719	ENSG00000230373.7	GOLGA6L5P	4.44	9.74e-06	0.000801	0.15	0.14	Interstitial lung disease;	chr15:85511035	chr15:84507885~84516814:-
BRCA	cis	rs465969	0.546	rs77990243	ENSG00000230177.1	RP5-1112D6.4	4.44	9.74e-06	0.000801	0.28	0.14	Psoriasis;	chr6:111513183	chr6:111277932~111278742:+
BRCA	cis	rs2243480	1	rs34136756	ENSG00000222364.1	RNU6-96P	-4.44	9.74e-06	0.000801	-0.24	-0.14	Diabetic kidney disease;	chr7:65916269	chr7:66395191~66395286:+
BRCA	cis	rs7665090	1	rs7677509	ENSG00000251288.2	RP11-10L12.2	-4.44	9.75e-06	0.000801	-0.16	-0.14	Primary biliary cholangitis;	chr4:102628849	chr4:102751401~102752641:+
BRCA	cis	rs7665090	0.967	rs7699231	ENSG00000251288.2	RP11-10L12.2	-4.44	9.75e-06	0.000801	-0.16	-0.14	Primary biliary cholangitis;	chr4:102628918	chr4:102751401~102752641:+
BRCA	cis	rs7665090	1	rs7699678	ENSG00000251288.2	RP11-10L12.2	-4.44	9.75e-06	0.000801	-0.16	-0.14	Primary biliary cholangitis;	chr4:102628939	chr4:102751401~102752641:+
BRCA	cis	rs7665090	1	rs11724614	ENSG00000251288.2	RP11-10L12.2	-4.44	9.75e-06	0.000801	-0.16	-0.14	Primary biliary cholangitis;	chr4:102629091	chr4:102751401~102752641:+
BRCA	cis	rs5758659	0.652	rs133323	ENSG00000273366.1	CTA-989H11.1	-4.44	9.75e-06	0.000801	-0.16	-0.14	Cognitive function;	chr22:42009918	chr22:42278188~42278846:+
BRCA	cis	rs5758659	0.652	rs133327	ENSG00000273366.1	CTA-989H11.1	-4.44	9.75e-06	0.000801	-0.16	-0.14	Cognitive function;	chr22:42011685	chr22:42278188~42278846:+
BRCA	cis	rs718314	0.913	rs10842705	ENSG00000256894.1	RP11-283G6.3	4.44	9.75e-06	0.000802	0.17	0.14	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Renal cell carcinoma;Waist circumference adjusted for body mass index;	chr12:26316083	chr12:26125155~26126617:-
BRCA	cis	rs718314	0.913	rs10842707	ENSG00000256894.1	RP11-283G6.3	4.44	9.75e-06	0.000802	0.17	0.14	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Renal cell carcinoma;Waist circumference adjusted for body mass index;	chr12:26318431	chr12:26125155~26126617:-
BRCA	cis	rs72843506	0.656	rs80250684	ENSG00000270091.1	RP11-78O7.2	-4.44	9.75e-06	0.000802	-0.2	-0.14	Schizophrenia;	chr17:20054983	chr17:19896590~19897287:-
BRCA	cis	rs72843506	0.586	rs75048432	ENSG00000270091.1	RP11-78O7.2	-4.44	9.75e-06	0.000802	-0.2	-0.14	Schizophrenia;	chr17:20057571	chr17:19896590~19897287:-
BRCA	cis	rs27434	0.66	rs42398	ENSG00000272109.1	CTD-2260A17.3	-4.44	9.75e-06	0.000802	-0.22	-0.14	Ankylosing spondylitis;	chr5:96784751	chr5:96804353~96806105:+
BRCA	cis	rs11992162	0.967	rs10088415	ENSG00000270154.1	RP11-419I17.1	-4.44	9.75e-06	0.000802	-0.16	-0.14	Monocyte count;	chr8:11973316	chr8:12476462~12477122:+
BRCA	cis	rs17756712	0.697	rs2294669	ENSG00000271911.1	RP11-532F6.5	-4.44	9.75e-06	0.000802	-0.17	-0.14	Vertical cup-disc ratio;	chr6:625673	chr6:761675~780648:+
BRCA	cis	rs6452524	1	rs13358361	ENSG00000281327.1	LINC01338	4.44	9.76e-06	0.000802	0.16	0.14	Hypertension (SNP x SNP interaction);	chr5:83160237	chr5:82850864~82859836:-
BRCA	cis	rs10771431	0.597	rs10843144	ENSG00000111788.10	RP11-22B23.1	4.44	9.76e-06	0.000802	0.12	0.14	Breast size;	chr12:9204981	chr12:9277235~9313241:+
BRCA	cis	rs2229238	0.911	rs73020234	ENSG00000272030.1	RP1-178F15.4	-4.44	9.76e-06	0.000803	-0.19	-0.14	Coronary heart disease;	chr1:154510291	chr1:153631438~153634397:-
BRCA	cis	rs10504130	0.866	rs74738864	ENSG00000272024.1	RP11-546K22.3	-4.44	9.76e-06	0.000803	-0.24	-0.14	Venous thromboembolism (SNP x SNP interaction);	chr8:51878654	chr8:51950284~51950690:+
BRCA	cis	rs2834288	0.734	rs8126669	ENSG00000273102.1	AP000569.9	-4.44	9.77e-06	0.000803	-0.16	-0.14	Gut microbiota (bacterial taxa);	chr21:33895836	chr21:33967101~33968573:-
BRCA	cis	rs6430585	0.702	rs3213890	ENSG00000224043.6	CCNT2-AS1	-4.44	9.77e-06	0.000803	-0.23	-0.14	Corneal structure;	chr2:135794618	chr2:134735464~134918710:-
BRCA	cis	rs6430585	0.536	rs3213892	ENSG00000224043.6	CCNT2-AS1	-4.44	9.77e-06	0.000803	-0.23	-0.14	Corneal structure;	chr2:135794947	chr2:134735464~134918710:-
BRCA	cis	rs1499614	1	rs1882655	ENSG00000275400.1	RP4-756H11.5	-4.44	9.77e-06	0.000803	-0.25	-0.14	Gout;	chr7:66682070	chr7:66553805~66554199:-
BRCA	cis	rs1499614	0.831	rs3800822	ENSG00000275400.1	RP4-756H11.5	-4.44	9.77e-06	0.000803	-0.25	-0.14	Gout;	chr7:66682162	chr7:66553805~66554199:-
BRCA	cis	rs1499614	1	rs1638731	ENSG00000275400.1	RP4-756H11.5	4.44	9.77e-06	0.000803	0.25	0.14	Gout;	chr7:66679692	chr7:66553805~66554199:-
BRCA	cis	rs4415084	0.834	rs2118764	ENSG00000251141.4	RP11-53O19.1	4.44	9.77e-06	0.000803	0.12	0.14	Breast cancer;	chr5:44787621	chr5:44744900~44808777:-
BRCA	cis	rs8180040	1	rs2302278	ENSG00000276925.1	RP11-708J19.3	4.44	9.77e-06	0.000803	0.16	0.14	Colorectal cancer;	chr3:47319592	chr3:47469777~47469987:+
BRCA	cis	rs6480314	0.636	rs61854792	ENSG00000233590.1	RP11-153K11.3	-4.44	9.78e-06	0.000804	-0.23	-0.14	Optic nerve measurement (disc area);	chr10:68243902	chr10:68233251~68242379:-
BRCA	cis	rs2688608	0.967	rs2633299	ENSG00000271816.1	BMS1P4	4.44	9.79e-06	0.000804	0.13	0.14	Inflammatory bowel disease;	chr10:73896996	chr10:73699151~73730487:-
BRCA	cis	rs7727544	0.557	rs715285	ENSG00000233006.5	AC034220.3	4.44	9.79e-06	0.000804	0.1	0.14	Blood metabolite levels;	chr5:132149690	chr5:132311285~132369916:-
BRCA	cis	rs11168618	0.967	rs11168619	ENSG00000240399.1	RP1-228P16.1	4.44	9.79e-06	0.000805	0.15	0.14	Adiponectin levels;	chr12:48539822	chr12:48054813~48055591:-
BRCA	cis	rs11048434	0.518	rs2377678	ENSG00000256720.1	RP11-436I9.6	-4.44	9.79e-06	0.000805	-0.13	-0.14	Sjögren's syndrome;	chr12:9021562	chr12:9135084~9135591:+
BRCA	cis	rs755249	0.567	rs113214136	ENSG00000182109.6	RP11-69E11.4	4.44	9.79e-06	0.000805	0.19	0.14	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39408867	chr1:39522280~39546187:-
BRCA	cis	rs755249	0.567	rs61779300	ENSG00000182109.6	RP11-69E11.4	4.44	9.79e-06	0.000805	0.19	0.14	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39420091	chr1:39522280~39546187:-
BRCA	cis	rs10191773	0.589	rs6761440	ENSG00000243389.1	AC012442.5	4.44	9.79e-06	0.000805	0.28	0.14	Yeast infection;	chr2:112201616	chr2:112589040~112614431:+
BRCA	cis	rs12477438	0.765	rs1054042	ENSG00000231822.1	AC019097.7	-4.44	9.79e-06	0.000805	-0.15	-0.14	Chronic sinus infection;	chr2:98997933	chr2:99102018~99102752:+
BRCA	cis	rs10129255	0.957	rs1024349	ENSG00000274576.2	IGHV2-70	4.44	9.79e-06	0.000805	0.12	0.14	Kawasaki disease;	chr14:106689997	chr14:106770577~106771020:-
BRCA	cis	rs10938353	0.68	rs55637944	ENSG00000273369.1	RP11-700J17.1	4.44	9.8e-06	0.000805	0.19	0.14	Body mass index;	chr4:44622791	chr4:44693946~44694386:-
BRCA	cis	rs17507216	0.718	rs72751662	ENSG00000259429.4	UBE2Q2P2	-4.44	9.8e-06	0.000805	-0.18	-0.14	Excessive daytime sleepiness;	chr15:82594705	chr15:82355142~82420075:+
BRCA	cis	rs6968419	0.755	rs2896181	ENSG00000279086.1	RP11-667F14.1	4.44	9.8e-06	0.000805	0.15	0.14	Intraocular pressure;	chr7:116257830	chr7:116209234~116211511:-
BRCA	cis	rs6452524	1	rs6452528	ENSG00000281327.1	LINC01338	4.44	9.8e-06	0.000805	0.16	0.14	Hypertension (SNP x SNP interaction);	chr5:83162560	chr5:82850864~82859836:-
BRCA	cis	rs6756513	0.5	rs7568485	ENSG00000231024.1	AC092431.3	-4.44	9.8e-06	0.000805	-0.19	-0.14	Breast cancer;Platelet count;	chr2:69870603	chr2:69700192~69713847:-
BRCA	cis	rs240993	0.516	rs465646	ENSG00000230177.1	RP5-1112D6.4	-4.44	9.8e-06	0.000805	-0.19	-0.14	Inflammatory skin disease;Psoriasis;	chr6:111299555	chr6:111277932~111278742:+
BRCA	cis	rs6452524	0.935	rs5000997	ENSG00000281327.1	LINC01338	4.44	9.8e-06	0.000806	0.16	0.14	Hypertension (SNP x SNP interaction);	chr5:83164248	chr5:82850864~82859836:-
BRCA	cis	rs4869313	0.905	rs2549794	ENSG00000248734.2	CTD-2260A17.1	-4.44	9.8e-06	0.000806	-0.14	-0.14	Pediatric autoimmune diseases;	chr5:96908845	chr5:96784777~96785999:+
BRCA	cis	rs6545883	0.929	rs2694625	ENSG00000212978.6	AC016747.3	-4.44	9.81e-06	0.000806	-0.19	-0.14	Tuberculosis;	chr2:61388920	chr2:61141592~61144969:-
BRCA	cis	rs12530845	0.943	rs58577912	ENSG00000223718.3	AC093107.7	4.44	9.81e-06	0.000806	0.22	0.14	Red blood cell traits;	chr7:135644521	chr7:135660039~135660647:+
BRCA	cis	rs12530845	0.943	rs55889179	ENSG00000223718.3	AC093107.7	4.44	9.81e-06	0.000806	0.22	0.14	Red blood cell traits;	chr7:135646883	chr7:135660039~135660647:+
BRCA	cis	rs983392	1	rs7124974	ENSG00000275344.1	MIR6503	-4.44	9.81e-06	0.000806	-0.15	-0.14	Alzheimer's disease (late onset);	chr11:60139499	chr11:60209071~60209156:-
BRCA	cis	rs4237845	0.537	rs2002275	ENSG00000270039.1	RP11-571M6.17	-4.44	9.81e-06	0.000806	-0.19	-0.14	Intelligence (multi-trait analysis);	chr12:57889602	chr12:57803838~57804415:+
BRCA	cis	rs10129255	0.536	rs6576201	ENSG00000224373.3	IGHV4-59	-4.44	9.81e-06	0.000806	-0.08	-0.14	Kawasaki disease;	chr14:106683696	chr14:106627249~106627825:-
BRCA	cis	rs8040855	0.627	rs3816105	ENSG00000259774.1	RP11-182J1.13	4.44	9.81e-06	0.000806	0.19	0.14	Bulimia nervosa;	chr15:85097680	chr15:84422618~84425882:+
BRCA	cis	rs8040855	0.627	rs2304418	ENSG00000259774.1	RP11-182J1.13	4.44	9.81e-06	0.000806	0.19	0.14	Bulimia nervosa;	chr15:85097752	chr15:84422618~84425882:+
BRCA	cis	rs6840360	0.642	rs56301462	ENSG00000278978.1	RP11-164P12.5	-4.44	9.81e-06	0.000806	-0.15	-0.14	Intelligence (multi-trait analysis);	chr4:151530976	chr4:151669786~151670503:+
BRCA	cis	rs7915131	1	rs7915131	ENSG00000238280.1	RP11-436D10.3	-4.44	9.81e-06	0.000806	-0.17	-0.14	Schizophrenia;	chr10:62658896	chr10:62793562~62805887:-
BRCA	cis	rs11673344	0.504	rs8105065	ENSG00000226686.6	LINC01535	4.44	9.82e-06	0.000806	0.17	0.14	Obesity-related traits;	chr19:37141003	chr19:37251912~37265535:+
BRCA	cis	rs13113518	1	rs3805148	ENSG00000272969.1	RP11-528I4.2	4.44	9.82e-06	0.000807	0.16	0.14	Height;	chr4:55440643	chr4:55547112~55547889:+
BRCA	cis	rs13113518	1	rs11133380	ENSG00000272969.1	RP11-528I4.2	4.44	9.82e-06	0.000807	0.16	0.14	Height;	chr4:55441110	chr4:55547112~55547889:+
BRCA	cis	rs13113518	1	rs12510110	ENSG00000272969.1	RP11-528I4.2	4.44	9.82e-06	0.000807	0.16	0.14	Height;	chr4:55441567	chr4:55547112~55547889:+
BRCA	cis	rs13113518	0.966	rs12510990	ENSG00000272969.1	RP11-528I4.2	4.44	9.82e-06	0.000807	0.16	0.14	Height;	chr4:55441907	chr4:55547112~55547889:+
BRCA	cis	rs1124769	0.57	rs4142324	ENSG00000273674.3	CTD-2378E12.1	4.44	9.83e-06	0.000807	0.16	0.14	Cognitive performance;	chr15:50871860	chr15:50839875~50908599:-
BRCA	cis	rs516805	0.63	rs2816077	ENSG00000279114.1	RP3-425C14.5	-4.44	9.83e-06	0.000807	-0.17	-0.14	Lymphocyte counts;	chr6:122105669	chr6:122471923~122484161:+
BRCA	cis	rs9840812	0.522	rs699165	ENSG00000273486.1	RP11-731C17.2	4.44	9.83e-06	0.000807	0.17	0.14	Fibrinogen levels;	chr3:136505855	chr3:136837338~136839021:-
BRCA	cis	rs8054556	0.787	rs35105141	ENSG00000183604.13	SMG1P5	-4.44	9.84e-06	0.000808	-0.14	-0.14	Autism spectrum disorder or schizophrenia;	chr16:30045827	chr16:30267553~30335374:-
BRCA	cis	rs4578769	0.729	rs12456891	ENSG00000265939.1	UBE2CP2	-4.44	9.84e-06	0.000809	-0.17	-0.14	Eosinophil percentage of white cells;	chr18:22830243	chr18:22900486~22900995:-
BRCA	cis	rs983392	0.667	rs662196	ENSG00000275344.1	MIR6503	4.44	9.85e-06	0.000809	0.14	0.14	Alzheimer's disease (late onset);	chr11:60175284	chr11:60209071~60209156:-
BRCA	cis	rs12908161	0.96	rs17599989	ENSG00000275120.1	RP11-182J1.17	4.44	9.85e-06	0.000809	0.18	0.14	Schizophrenia;	chr15:84742305	chr15:84599434~84606463:-
BRCA	cis	rs867371	0.502	rs1846908	ENSG00000276710.3	CSPG4P8	-4.44	9.85e-06	0.000809	-0.14	-0.14	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82230185	chr15:82459472~82477258:+
BRCA	cis	rs2665103	0.655	rs1501367	ENSG00000276710.3	CSPG4P8	-4.44	9.85e-06	0.000809	-0.14	-0.14	Intelligence (multi-trait analysis);	chr15:82230475	chr15:82459472~82477258:+
BRCA	cis	rs11098499	0.69	rs34818745	ENSG00000260404.2	RP11-384K6.6	4.44	9.85e-06	0.000809	0.13	0.14	Corneal astigmatism;	chr4:119335900	chr4:118591773~118633729:+
BRCA	cis	rs4494364	0.502	rs887921	ENSG00000258100.1	RP11-121E16.1	4.44	9.85e-06	0.000809	0.2	0.14	Systolic blood pressure (alcohol consumption interaction);	chr12:91034915	chr12:91362196~91368606:+
BRCA	cis	rs911119	1	rs6515375	ENSG00000270001.1	RP11-218C14.8	-4.44	9.85e-06	0.000809	-0.18	-0.14	Chronic kidney disease;	chr20:23630204	chr20:23631826~23632316:-
BRCA	cis	rs9921338	0.961	rs4781055	ENSG00000262636.1	CTD-3088G3.4	-4.44	9.85e-06	0.000809	-0.22	-0.14	Vein graft stenosis in coronary artery bypass grafting;	chr16:11275571	chr16:11380859~11381118:-
BRCA	cis	rs9921338	0.923	rs7186455	ENSG00000262703.1	RP11-485G7.6	-4.44	9.85e-06	0.000809	-0.17	-0.14	Vein graft stenosis in coronary artery bypass grafting;	chr16:11333891	chr16:11348143~11349321:-
BRCA	cis	rs2688608	0.869	rs2633308	ENSG00000271816.1	BMS1P4	4.44	9.86e-06	0.000809	0.13	0.14	Inflammatory bowel disease;	chr10:73894146	chr10:73699151~73730487:-
BRCA	cis	rs321358	1	rs321355	ENSG00000271390.1	RP11-89C3.3	4.44	9.86e-06	0.000809	0.22	0.14	Body mass index;	chr11:111124273	chr11:111089870~111090368:-
BRCA	cis	rs875971	0.862	rs778724	ENSG00000273448.1	RP11-166O4.6	4.44	9.86e-06	0.000809	0.13	0.14	Aortic root size;	chr7:66364304	chr7:67333047~67334383:+
BRCA	cis	rs17660992	0.584	rs11672561	ENSG00000273837.1	LLNLR-470E3.1	-4.44	9.86e-06	0.00081	-0.16	-0.14	Blood protein levels;	chr19:51656353	chr19:51639478~51639931:-
BRCA	cis	rs4950322	0.744	rs2353987	ENSG00000244371.2	PFN1P8	-4.44	9.86e-06	0.00081	-0.19	-0.14	Protein quantitative trait loci;	chr1:147355845	chr1:146957117~146957659:-
BRCA	cis	rs2286503	0.809	rs4719716	ENSG00000226329.2	AC005682.6	4.44	9.87e-06	0.000811	0.13	0.14	Fibrinogen;	chr7:22821750	chr7:22863874~22881350:-
BRCA	cis	rs2286503	0.839	rs2270108	ENSG00000226329.2	AC005682.6	4.44	9.87e-06	0.000811	0.13	0.14	Fibrinogen;	chr7:22822512	chr7:22863874~22881350:-
BRCA	cis	rs2286503	0.839	rs2270107	ENSG00000226329.2	AC005682.6	4.44	9.87e-06	0.000811	0.13	0.14	Fibrinogen;	chr7:22822564	chr7:22863874~22881350:-
BRCA	cis	rs2286503	0.839	rs2270105	ENSG00000226329.2	AC005682.6	4.44	9.87e-06	0.000811	0.13	0.14	Fibrinogen;	chr7:22822848	chr7:22863874~22881350:-
BRCA	cis	rs2286503	0.839	rs2270103	ENSG00000226329.2	AC005682.6	4.44	9.87e-06	0.000811	0.13	0.14	Fibrinogen;	chr7:22823103	chr7:22863874~22881350:-
BRCA	cis	rs2286503	0.839	rs10276099	ENSG00000226329.2	AC005682.6	4.44	9.87e-06	0.000811	0.13	0.14	Fibrinogen;	chr7:22823331	chr7:22863874~22881350:-
BRCA	cis	rs6688613	0.685	rs742048	ENSG00000225171.2	DUTP6	4.44	9.88e-06	0.000811	0.18	0.14	Refractive astigmatism;	chr1:166940908	chr1:166868748~166869209:+
BRCA	cis	rs6545883	0.929	rs10173974	ENSG00000270820.4	RP11-355B11.2	4.44	9.88e-06	0.000811	0.15	0.14	Tuberculosis;	chr2:61521765	chr2:61471188~61484130:+
BRCA	cis	rs1005277	0.563	rs2800550	ENSG00000099251.13	HSD17B7P2	4.44	9.89e-06	0.000812	0.15	0.14	Extrinsic epigenetic age acceleration;	chr10:38194001	chr10:38356380~38378505:+
BRCA	cis	rs13113518	1	rs6858803	ENSG00000273257.1	RP11-177J6.1	4.44	9.89e-06	0.000812	0.18	0.14	Height;	chr4:55484534	chr4:55387949~55388271:+
BRCA	cis	rs7665090	1	rs6821119	ENSG00000251288.2	RP11-10L12.2	-4.44	9.89e-06	0.000812	-0.16	-0.14	Primary biliary cholangitis;	chr4:102634076	chr4:102751401~102752641:+
BRCA	cis	rs7665090	0.934	rs6844332	ENSG00000251288.2	RP11-10L12.2	-4.44	9.89e-06	0.000812	-0.16	-0.14	Primary biliary cholangitis;	chr4:102634095	chr4:102751401~102752641:+
BRCA	cis	rs7665090	0.967	rs6821133	ENSG00000251288.2	RP11-10L12.2	-4.44	9.89e-06	0.000812	-0.16	-0.14	Primary biliary cholangitis;	chr4:102634096	chr4:102751401~102752641:+
BRCA	cis	rs9423406	0.501	rs7075810	ENSG00000215267.7	AKR1C7P	-4.44	9.89e-06	0.000812	-0.22	-0.14	Intelligence;	chr10:5283321	chr10:5275173~5288470:-
BRCA	cis	rs12439619	0.883	rs62012045	ENSG00000255769.6	GOLGA2P10	-4.44	9.89e-06	0.000812	-0.17	-0.14	Intelligence (multi-trait analysis);	chr15:82229366	chr15:82472993~82513950:-
BRCA	cis	rs2832191	0.967	rs1999321	ENSG00000176054.6	RPL23P2	4.44	9.9e-06	0.000812	0.15	0.14	Dental caries;	chr21:29157912	chr21:28997613~28998033:-
BRCA	cis	rs1005277	0.541	rs2263163	ENSG00000099251.13	HSD17B7P2	4.44	9.9e-06	0.000812	0.15	0.14	Extrinsic epigenetic age acceleration;	chr10:38100959	chr10:38356380~38378505:+
BRCA	cis	rs10761482	0.601	rs10733764	ENSG00000254271.1	RP11-131N11.4	4.44	9.9e-06	0.000812	0.19	0.14	Schizophrenia;	chr10:60450587	chr10:60734342~60741828:+
BRCA	cis	rs1510272	0.889	rs6441086	ENSG00000243926.1	TIPARP-AS1	-4.44	9.9e-06	0.000812	-0.15	-0.14	Testicular germ cell tumor;	chr3:156607834	chr3:156671862~156674378:-
BRCA	cis	rs1510272	0.847	rs6802056	ENSG00000243926.1	TIPARP-AS1	-4.44	9.9e-06	0.000812	-0.15	-0.14	Testicular germ cell tumor;	chr3:156608112	chr3:156671862~156674378:-
BRCA	cis	rs6452524	0.904	rs10473867	ENSG00000281327.1	LINC01338	4.44	9.9e-06	0.000813	0.17	0.14	Hypertension (SNP x SNP interaction);	chr5:83141613	chr5:82850864~82859836:-
BRCA	cis	rs889122	0.55	rs8108431	ENSG00000267289.1	CTD-2623N2.11	4.44	9.9e-06	0.000813	0.16	0.14	Menarche (age at onset);	chr19:9886011	chr19:9834079~9835013:-
BRCA	cis	rs35612822	0.723	rs13392290	ENSG00000232485.2	AC098820.3	-4.44	9.9e-06	0.000813	-0.17	-0.14	Kidney disease (early stage) in type 1 diabetes;	chr2:216400165	chr2:216479030~216498761:-
BRCA	cis	rs4356203	0.87	rs7935219	ENSG00000272034.1	SNORD14A	4.44	9.9e-06	0.000813	0.14	0.14	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17146640	chr11:17074654~17074744:-
BRCA	cis	rs6686842	1	rs213748	ENSG00000235358.1	RP11-399E6.1	-4.44	9.9e-06	0.000813	-0.17	-0.14	Height;	chr1:41163058	chr1:41242373~41284861:+
BRCA	cis	rs6686842	1	rs213747	ENSG00000235358.1	RP11-399E6.1	-4.44	9.9e-06	0.000813	-0.17	-0.14	Height;	chr1:41163066	chr1:41242373~41284861:+
BRCA	cis	rs6686842	1	rs2363803	ENSG00000235358.1	RP11-399E6.1	4.44	9.9e-06	0.000813	0.17	0.14	Height;	chr1:41171857	chr1:41242373~41284861:+
BRCA	cis	rs12468226	0.752	rs79058237	ENSG00000226261.1	AC064836.3	4.44	9.91e-06	0.000813	0.24	0.14	Urate levels;	chr2:202140247	chr2:202336024~202336727:-
BRCA	cis	rs2662776	0.967	rs4291481	ENSG00000232995.6	RGS5	4.44	9.91e-06	0.000813	0.14	0.14	Lead levels in blood;	chr1:163182051	chr1:163244505~163321894:-
BRCA	cis	rs12744310	0.887	rs72667610	ENSG00000235358.1	RP11-399E6.1	4.44	9.91e-06	0.000813	0.2	0.14	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41329138	chr1:41242373~41284861:+
BRCA	cis	rs8031584	0.918	rs1425292	ENSG00000259845.1	HERC2P10	4.44	9.91e-06	0.000813	0.16	0.14	Huntington's disease progression;	chr15:30993219	chr15:30815271~30844153:+
BRCA	cis	rs2018683	0.584	rs4722880	ENSG00000233517.1	AC005162.5	-4.44	9.91e-06	0.000814	-0.17	-0.14	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28959581	chr7:28987028~28988899:+
BRCA	cis	rs9818758	0.607	rs5030795	ENSG00000270441.1	RP11-694I15.7	4.44	9.91e-06	0.000814	0.26	0.14	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49103683	chr3:49140086~49160851:-
BRCA	cis	rs6964587	0.967	rs34344935	ENSG00000188693.7	CYP51A1-AS1	-4.44	9.91e-06	0.000814	-0.15	-0.14	Breast cancer;	chr7:92206122	chr7:92134604~92180725:+
BRCA	cis	rs4787491	0.729	rs4788212	ENSG00000261367.1	RP11-455F5.4	4.44	9.92e-06	0.000814	0.15	0.14	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30023148	chr16:30107675~30110541:+
BRCA	cis	rs7829975	0.502	rs7820738	ENSG00000254153.1	CTA-398F10.2	-4.44	9.92e-06	0.000814	-0.16	-0.14	Mood instability;	chr8:8845097	chr8:8456909~8461337:-
BRCA	cis	rs9840812	0.598	rs1145101	ENSG00000239213.4	NCK1-AS1	4.44	9.92e-06	0.000814	0.2	0.14	Fibrinogen levels;	chr3:136350444	chr3:136841726~136862054:-
BRCA	cis	rs878939	0.625	rs17493485	ENSG00000233690.1	EBAG9P1	4.44	9.92e-06	0.000814	0.2	0.14	Warfarin maintenance dose;	chr10:99584123	chr10:99697407~99697949:-
BRCA	cis	rs7590268	0.895	rs2046916	ENSG00000279873.2	LINC01126	-4.44	9.92e-06	0.000814	-0.16	-0.14	Orofacial clefts;	chr2:43459068	chr2:43227210~43228855:+
BRCA	cis	rs10435719	0.902	rs4840599	ENSG00000270154.1	RP11-419I17.1	-4.44	9.92e-06	0.000814	-0.16	-0.14	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11947871	chr8:12476462~12477122:+
BRCA	cis	rs42490	0.528	rs1032516	ENSG00000251136.7	RP11-37B2.1	4.44	9.92e-06	0.000814	0.13	0.14	Leprosy;	chr8:89670055	chr8:89609409~89757727:-
BRCA	cis	rs11637445	0.677	rs1564278	ENSG00000260657.2	RP11-315D16.4	-4.44	9.92e-06	0.000814	-0.17	-0.14	Posterior cortical atrophy and Alzheimer's disease;	chr15:67815050	chr15:68267792~68277994:-
BRCA	cis	rs1979679	0.766	rs7299798	ENSG00000278733.1	RP11-425D17.1	-4.44	9.93e-06	0.000815	-0.17	-0.14	Ossification of the posterior longitudinal ligament of the spine;	chr12:28559224	chr12:28185625~28186190:-
BRCA	cis	rs875971	0.964	rs60193905	ENSG00000229180.5	GS1-124K5.11	4.44	9.93e-06	0.000815	0.12	0.14	Aortic root size;	chr7:66506273	chr7:66526088~66542624:-
BRCA	cis	rs73222236	0.782	rs13433980	ENSG00000273486.1	RP11-731C17.2	-4.44	9.93e-06	0.000815	-0.15	-0.14	Coronary artery disease;	chr3:136631959	chr3:136837338~136839021:-
BRCA	cis	rs13113518	0.966	rs7677952	ENSG00000273257.1	RP11-177J6.1	4.44	9.93e-06	0.000815	0.17	0.14	Height;	chr4:55425312	chr4:55387949~55388271:+
BRCA	cis	rs13113518	1	rs1047354	ENSG00000273257.1	RP11-177J6.1	4.44	9.93e-06	0.000815	0.17	0.14	Height;	chr4:55429416	chr4:55387949~55388271:+
BRCA	cis	rs13113518	1	rs1056547	ENSG00000273257.1	RP11-177J6.1	4.44	9.93e-06	0.000815	0.17	0.14	Height;	chr4:55430596	chr4:55387949~55388271:+
BRCA	cis	rs13113518	1	rs1056545	ENSG00000273257.1	RP11-177J6.1	4.44	9.93e-06	0.000815	0.17	0.14	Height;	chr4:55430730	chr4:55387949~55388271:+
BRCA	cis	rs13113518	1	rs5863	ENSG00000273257.1	RP11-177J6.1	4.44	9.93e-06	0.000815	0.17	0.14	Height;	chr4:55430740	chr4:55387949~55388271:+
BRCA	cis	rs13113518	0.966	rs6828570	ENSG00000273257.1	RP11-177J6.1	4.44	9.93e-06	0.000815	0.17	0.14	Height;	chr4:55431595	chr4:55387949~55388271:+
BRCA	cis	rs17495987	0.75	rs17562330	ENSG00000219545.8	UMAD1	4.44	9.93e-06	0.000815	0.17	0.14	Tonsillectomy;	chr7:7867511	chr7:7640711~8004059:+
BRCA	cis	rs4788196	1	rs4788196	ENSG00000214725.6	CDIPT-AS1	-4.44	9.93e-06	0.000815	-0.16	-0.14	Pubertal anthropometrics;	chr16:29956113	chr16:29863593~29868053:+
BRCA	cis	rs875971	0.789	rs28815324	ENSG00000232546.1	RP11-458F8.1	-4.44	9.94e-06	0.000816	-0.13	-0.14	Aortic root size;	chr7:66100789	chr7:66848496~66858136:+
BRCA	cis	rs11239930	0.517	rs556976	ENSG00000278811.3	LINC00624	4.44	9.94e-06	0.000816	0.16	0.14	AIDS progression;	chr1:147073643	chr1:147258885~147517875:-
BRCA	cis	rs983392	0.805	rs11230180	ENSG00000275344.1	MIR6503	4.44	9.94e-06	0.000816	0.14	0.14	Alzheimer's disease (late onset);	chr11:60194013	chr11:60209071~60209156:-
BRCA	cis	rs11779988	0.545	rs398806	ENSG00000253671.1	RP11-806O11.1	-4.44	9.94e-06	0.000816	-0.2	-0.14	Breast cancer;	chr8:17928717	chr8:17808941~17820868:+
BRCA	cis	rs2235642	0.826	rs8053605	ENSG00000260989.1	LA16c-395F10.2	-4.44	9.94e-06	0.000816	-0.14	-0.14	Coronary artery disease;	chr16:1544157	chr16:1580527~1610328:+
BRCA	cis	rs7312933	0.501	rs7296357	ENSG00000257225.1	RP11-328C8.4	4.44	9.95e-06	0.000816	0.16	0.14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42336089	chr12:42459366~42466128:+
BRCA	cis	rs6860806	0.631	rs4705931	ENSG00000233006.5	AC034220.3	4.44	9.95e-06	0.000816	0.1	0.14	Breast cancer;	chr5:132252652	chr5:132311285~132369916:-
BRCA	cis	rs13326165	0.76	rs59612757	ENSG00000243224.1	RP5-1157M23.2	-4.44	9.95e-06	0.000817	-0.19	-0.14	HDL cholesterol levels;HDL cholesterol;	chr3:52265505	chr3:52239258~52241097:+
BRCA	cis	rs9818758	0.607	rs67060340	ENSG00000270441.1	RP11-694I15.7	4.44	9.95e-06	0.000817	0.28	0.14	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:48877888	chr3:49140086~49160851:-
BRCA	cis	rs983392	0.667	rs583791	ENSG00000275344.1	MIR6503	4.44	9.96e-06	0.000817	0.14	0.14	Alzheimer's disease (late onset);	chr11:60179779	chr11:60209071~60209156:-
BRCA	cis	rs11170468	0.836	rs11170435	ENSG00000257718.1	RP11-396F22.1	-4.44	9.96e-06	0.000817	-0.17	-0.14	Body mass index;	chr12:39030560	chr12:38906451~38909592:+
BRCA	cis	rs7200543	1	rs55727637	ENSG00000258354.1	MIR3180-1	-4.44	9.96e-06	0.000817	-0.18	-0.14	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15051395	chr16:14909887~14911345:-
BRCA	cis	rs1005277	0.502	rs2800484	ENSG00000099251.13	HSD17B7P2	4.44	9.96e-06	0.000817	0.15	0.14	Extrinsic epigenetic age acceleration;	chr10:38253487	chr10:38356380~38378505:+
BRCA	cis	rs4834770	1	rs4336213	ENSG00000250412.1	KLHL2P1	4.44	9.97e-06	0.000817	0.15	0.14	Blood protein levels;	chr4:119315314	chr4:119334329~119378233:+
BRCA	cis	rs718314	0.956	rs4963979	ENSG00000256894.1	RP11-283G6.3	4.44	9.97e-06	0.000817	0.16	0.14	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Renal cell carcinoma;Waist circumference adjusted for body mass index;	chr12:26316031	chr12:26125155~26126617:-
BRCA	cis	rs718314	0.956	rs2175723	ENSG00000256894.1	RP11-283G6.3	4.44	9.97e-06	0.000817	0.16	0.14	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Renal cell carcinoma;Waist circumference adjusted for body mass index;	chr12:26320742	chr12:26125155~26126617:-
BRCA	cis	rs2273156	1	rs7145608	ENSG00000226677.3	IGBP1P1	-4.44	9.97e-06	0.000818	-0.2	-0.14	Immunoglobulin light chain (AL) amyloidosis;	chr14:34994291	chr14:34939324~34940332:+
BRCA	cis	rs748404	0.736	rs542036	ENSG00000205771.5	CATSPER2P1	4.44	9.97e-06	0.000818	0.18	0.14	Lung cancer;	chr15:43248941	chr15:43726918~43747094:-
BRCA	cis	rs2880765	0.835	rs12324277	ENSG00000202081.1	RNU6-1280P	4.44	9.97e-06	0.000818	0.16	0.14	Coronary artery disease;	chr15:85498504	chr15:85651522~85651628:-
BRCA	cis	rs10129255	0.536	rs8004835	ENSG00000211959.2	IGHV4-39	4.44	9.97e-06	0.000818	0.09	0.14	Kawasaki disease;	chr14:106686361	chr14:106421711~106422218:-
BRCA	cis	rs11098499	0.754	rs10213554	ENSG00000260091.1	RP11-33B1.4	4.44	9.97e-06	0.000818	0.12	0.14	Corneal astigmatism;	chr4:119339630	chr4:119409333~119410233:+
BRCA	cis	rs875971	0.571	rs160647	ENSG00000232546.1	RP11-458F8.1	-4.44	9.98e-06	0.000818	-0.13	-0.14	Aortic root size;	chr7:66089365	chr7:66848496~66858136:+
BRCA	cis	rs11976180	1	rs2951368	ENSG00000244479.5	OR2A1-AS1	4.44	9.98e-06	0.000819	0.18	0.14	Obesity-related traits;	chr7:144055728	chr7:144251264~144356181:-
BRCA	cis	rs9467773	1	rs1321480	ENSG00000241549.7	GUSBP2	4.44	9.98e-06	0.000819	0.15	0.14	Intelligence (multi-trait analysis);	chr6:26532514	chr6:26871484~26956554:-
BRCA	cis	rs6964587	0.967	rs58673519	ENSG00000188693.7	CYP51A1-AS1	-4.44	9.98e-06	0.000819	-0.15	-0.14	Breast cancer;	chr7:92194573	chr7:92134604~92180725:+
BRCA	cis	rs5758511	0.689	rs56906457	ENSG00000226450.2	CYP2D8P	4.44	9.99e-06	0.000819	0.18	0.14	Birth weight;	chr22:42232329	chr22:42149886~42155001:-
BRCA	cis	rs5997397	0.934	rs6005864	ENSG00000226471.5	CTA-292E10.6	4.44	9.99e-06	0.000819	0.15	0.14	Red cell distribution width;	chr22:28761499	chr22:28800683~28848559:+
BRCA	cis	rs8103278	1	rs7258283	ENSG00000267395.4	AC074212.6	4.44	9.99e-06	0.000819	0.14	0.14	Coronary artery disease;	chr19:45832253	chr19:45767796~45772504:+
BRCA	cis	rs9652601	0.691	rs3862468	ENSG00000274038.1	RP11-66H6.4	4.44	9.99e-06	0.000819	0.15	0.14	Systemic lupus erythematosus;	chr16:11100161	chr16:11056556~11057034:+
BRCA	cis	rs6430585	0.591	rs12477421	ENSG00000224043.6	CCNT2-AS1	-4.44	9.99e-06	0.00082	-0.24	-0.14	Corneal structure;	chr2:135676170	chr2:134735464~134918710:-
BRCA	cis	rs1722133	0.555	rs788729	ENSG00000229628.1	AC073115.7	-4.44	1e-05	0.00082	-0.19	-0.14	Sitting height ratio;	chr7:46054338	chr7:45990905~46000898:+
BRCA	cis	rs983392	0.667	rs634475	ENSG00000275344.1	MIR6503	4.44	1e-05	0.00082	0.14	0.14	Alzheimer's disease (late onset);	chr11:60174608	chr11:60209071~60209156:-
BRCA	cis	rs6480314	0.542	rs11814858	ENSG00000233590.1	RP11-153K11.3	-4.44	1e-05	0.00082	-0.23	-0.14	Optic nerve measurement (disc area);	chr10:68241950	chr10:68233251~68242379:-
BRCA	cis	rs6121246	0.697	rs6088856	ENSG00000230613.1	HM13-AS1	4.44	1e-05	0.00082	0.2	0.14	Mean corpuscular hemoglobin;	chr20:31638740	chr20:31567707~31573263:-
BRCA	cis	rs9296095	0.796	rs3846855	ENSG00000224557.6	HLA-DPB2	-4.44	1e-05	0.00082	-0.19	-0.14	Platelet count;	chr6:33588100	chr6:33112451~33129084:+
BRCA	cis	rs2179367	0.959	rs9322178	ENSG00000223701.3	RAET1E-AS1	4.44	1e-05	0.00082	0.17	0.14	Dupuytren's disease;	chr6:149372131	chr6:149884431~149919508:+
BRCA	cis	rs7923609	0.54	rs10733789	ENSG00000232075.1	MRPL35P2	4.44	1e-05	0.000821	0.19	0.14	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63188924	chr10:63634317~63634827:-
BRCA	cis	rs911119	1	rs13041070	ENSG00000270001.1	RP11-218C14.8	-4.44	1e-05	0.000821	-0.19	-0.14	Chronic kidney disease;	chr20:23633624	chr20:23631826~23632316:-
BRCA	cis	rs6747488	0.55	rs223621	ENSG00000272716.1	RP11-563N4.1	4.44	1e-05	0.000821	0.15	0.14	Interleukin-18 levels;	chr2:31805423	chr2:32165046~32165757:-
BRCA	cis	rs859767	0.704	rs7558554	ENSG00000224043.6	CCNT2-AS1	-4.44	1e-05	0.000821	-0.19	-0.14	Neuroticism;	chr2:134599633	chr2:134735464~134918710:-
BRCA	cis	rs6686842	1	rs12125555	ENSG00000235358.1	RP11-399E6.1	4.44	1e-05	0.000821	0.17	0.14	Height;	chr1:41241439	chr1:41242373~41284861:+
BRCA	cis	rs1371614	0.635	rs12612619	ENSG00000272148.1	RP11-195B17.1	-4.44	1e-05	0.000821	-0.15	-0.14	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26914803	chr2:27062428~27062907:-
BRCA	cis	rs10958369	0.541	rs1477956	ENSG00000260484.1	RP11-1081M5.2	4.44	1e-05	0.000822	0.17	0.14	Response to antineoplastic agents;	chr8:53522667	chr8:53388701~53390872:-
BRCA	cis	rs2279168	1	rs2279167	ENSG00000259407.1	RP11-158M2.3	4.44	1e-05	0.000822	0.22	0.14	Response to platinum-based chemotherapy (carboplatin);	chr15:85533353	chr15:85744109~85750281:-
BRCA	cis	rs17228156	1	rs17228156	ENSG00000247572.6	CKMT2-AS1	4.44	1e-05	0.000822	0.28	0.14	Response to methylphenidate treatment in attention-deficit/hyperactivity disorder (blood pressure);	chr5:81207084	chr5:81204084~81301560:-
BRCA	cis	rs1005277	0.579	rs2505237	ENSG00000099251.13	HSD17B7P2	4.44	1e-05	0.000822	0.15	0.14	Extrinsic epigenetic age acceleration;	chr10:38149970	chr10:38356380~38378505:+
BRCA	cis	rs1005277	0.579	rs2474599	ENSG00000099251.13	HSD17B7P2	4.44	1e-05	0.000822	0.15	0.14	Extrinsic epigenetic age acceleration;	chr10:38150011	chr10:38356380~38378505:+
BRCA	cis	rs10129255	0.5	rs8022547	ENSG00000232216.1	IGHV3-43	4.44	1e-05	0.000822	0.1	0.14	Kawasaki disease;	chr14:106781985	chr14:106470264~106470800:-
BRCA	cis	rs1910358	0.549	rs10473669	ENSG00000248874.4	C5orf17	-4.44	1e-05	0.000822	-0.18	-0.14	Venous thromboembolism (SNP x SNP interaction);	chr5:23969968	chr5:23951348~24178263:+
BRCA	cis	rs1910358	0.614	rs1501939	ENSG00000248874.4	C5orf17	-4.44	1e-05	0.000822	-0.18	-0.14	Venous thromboembolism (SNP x SNP interaction);	chr5:23971061	chr5:23951348~24178263:+
BRCA	cis	rs1910358	0.591	rs4522961	ENSG00000248874.4	C5orf17	-4.44	1e-05	0.000822	-0.18	-0.14	Venous thromboembolism (SNP x SNP interaction);	chr5:23973660	chr5:23951348~24178263:+
BRCA	cis	rs11673344	0.563	rs55825113	ENSG00000226686.6	LINC01535	4.44	1e-05	0.000822	0.18	0.14	Obesity-related traits;	chr19:37191523	chr19:37251912~37265535:+
BRCA	cis	rs758747	0.514	rs735830	ENSG00000276754.1	RP11-461A8.5	4.44	1e-05	0.000822	0.16	0.14	Body mass index;	chr16:3645353	chr16:3686998~3687380:+
BRCA	cis	rs7927592	0.956	rs7126340	ENSG00000212093.1	AP000807.1	4.44	1e-05	0.000822	0.15	0.14	Total body bone mineral density;	chr11:68489825	chr11:68506083~68506166:-
BRCA	cis	rs11083475	1	rs56113315	ENSG00000267892.1	CTD-2540F13.2	4.44	1e-05	0.000822	0.15	0.14	Heart rate;	chr19:38693526	chr19:38738284~38739863:+
BRCA	cis	rs7772486	0.875	rs9322043	ENSG00000270638.1	RP3-466P17.1	4.44	1e-05	0.000823	0.16	0.14	Lobe attachment (rater-scored or self-reported);	chr6:146031554	chr6:145735570~145737218:+
BRCA	cis	rs2115630	0.755	rs7169629	ENSG00000275120.1	RP11-182J1.17	4.44	1e-05	0.000823	0.15	0.14	P wave terminal force;	chr15:84648043	chr15:84599434~84606463:-
BRCA	cis	rs11633886	0.585	rs17636535	ENSG00000273972.1	CTD-2306A12.1	4.44	1e-05	0.000823	0.16	0.14	Diisocyanate-induced asthma;	chr15:45786680	chr15:45702640~45703183:+
BRCA	cis	rs6600671	1	rs2185281	ENSG00000231429.2	RP11-343N15.2	-4.44	1e-05	0.000823	-0.16	-0.14	Hip geometry;	chr1:121438132	chr1:121412719~121429274:+
BRCA	cis	rs6657613	0.503	rs9435739	ENSG00000186715.9	MST1L	4.44	1e-05	0.000823	0.13	0.14	Hip circumference adjusted for BMI;	chr1:17016429	chr1:16754910~16770237:-
BRCA	cis	rs1005277	0.579	rs2472181	ENSG00000099251.13	HSD17B7P2	4.44	1e-05	0.000823	0.15	0.14	Extrinsic epigenetic age acceleration;	chr10:38097836	chr10:38356380~38378505:+
BRCA	cis	rs1005277	0.579	rs2474574	ENSG00000099251.13	HSD17B7P2	4.44	1e-05	0.000823	0.15	0.14	Extrinsic epigenetic age acceleration;	chr10:38098367	chr10:38356380~38378505:+
BRCA	cis	rs1005277	0.579	rs2504140	ENSG00000099251.13	HSD17B7P2	4.44	1e-05	0.000823	0.15	0.14	Extrinsic epigenetic age acceleration;	chr10:38098651	chr10:38356380~38378505:+
BRCA	cis	rs1005277	0.579	rs2472182	ENSG00000099251.13	HSD17B7P2	4.44	1e-05	0.000823	0.15	0.14	Extrinsic epigenetic age acceleration;	chr10:38099937	chr10:38356380~38378505:+
BRCA	cis	rs1005277	0.579	rs2021649	ENSG00000099251.13	HSD17B7P2	4.44	1e-05	0.000823	0.15	0.14	Extrinsic epigenetic age acceleration;	chr10:38103194	chr10:38356380~38378505:+
BRCA	cis	rs1005277	0.579	rs2505197	ENSG00000099251.13	HSD17B7P2	4.44	1e-05	0.000823	0.15	0.14	Extrinsic epigenetic age acceleration;	chr10:38104382	chr10:38356380~38378505:+
BRCA	cis	rs1005277	0.579	rs2505196	ENSG00000099251.13	HSD17B7P2	4.44	1e-05	0.000823	0.15	0.14	Extrinsic epigenetic age acceleration;	chr10:38104635	chr10:38356380~38378505:+
BRCA	cis	rs6738627	0.895	rs10930133	ENSG00000223318.1	RNA5SP111	4.44	1e-05	0.000823	0.16	0.14	circulating leptin levels adjusted for BMI;Body fat percentage;circulating leptin levels;	chr2:164650214	chr2:164895677~164895777:-
BRCA	cis	rs6738627	0.895	rs6754919	ENSG00000223318.1	RNA5SP111	4.44	1e-05	0.000823	0.16	0.14	circulating leptin levels adjusted for BMI;Body fat percentage;circulating leptin levels;	chr2:164651333	chr2:164895677~164895777:-
BRCA	cis	rs10043228	1	rs13362043	ENSG00000271918.1	CTD-2287O16.5	-4.44	1e-05	0.000823	-0.18	-0.14	Asthma or chronic obstructive pulmonary disease;	chr5:116260565	chr5:116083807~116085416:-
BRCA	cis	rs495337	0.76	rs4810994	ENSG00000229222.1	KRT18P4	-4.44	1e-05	0.000823	-0.17	-0.14	Psoriasis;	chr20:49955136	chr20:49956745~49958032:+
BRCA	cis	rs8040855	0.627	rs11630697	ENSG00000230373.7	GOLGA6L5P	4.44	1e-05	0.000823	0.17	0.14	Bulimia nervosa;	chr15:85063214	chr15:84507885~84516814:-
BRCA	cis	rs11158026	0.603	rs8022049	ENSG00000258413.1	RP11-665C16.6	4.44	1e-05	0.000823	0.18	0.14	Parkinson's disease;	chr14:54996151	chr14:55262767~55272075:-
BRCA	cis	rs1005277	0.579	rs2474608	ENSG00000099251.13	HSD17B7P2	4.44	1e-05	0.000823	0.15	0.14	Extrinsic epigenetic age acceleration;	chr10:38168181	chr10:38356380~38378505:+
BRCA	cis	rs4948275	0.667	rs2650727	ENSG00000237233.2	TMEM26-AS1	-4.44	1.01e-05	0.000824	-0.16	-0.14	Night sleep phenotypes;	chr10:61563814	chr10:61452639~61481956:+
BRCA	cis	rs4218	0.648	rs12441973	ENSG00000259732.1	RP11-59H7.3	-4.44	1.01e-05	0.000824	-0.17	-0.14	Social communication problems;	chr15:59057016	chr15:59121034~59133250:+
BRCA	cis	rs771767	0.808	rs1398609	ENSG00000244119.1	PDCL3P4	-4.44	1.01e-05	0.000824	-0.11	-0.14	Multiple sclerosis;	chr3:102031518	chr3:101712472~101713191:+
BRCA	cis	rs7592578	0.766	rs62181052	ENSG00000272979.1	RP11-647K16.1	-4.44	1.01e-05	0.000824	-0.24	-0.14	Diastolic blood pressure;	chr2:190523132	chr2:190454092~190454521:-
BRCA	cis	rs2731006	0.64	rs2056192	ENSG00000257114.2	RP11-25I15.3	4.44	1.01e-05	0.000824	0.2	0.14	Panic disorder;	chr12:42808192	chr12:42692216~42717119:+
BRCA	cis	rs7686660	0.955	rs10030917	ENSG00000250326.1	RP11-284M14.1	-4.44	1.01e-05	0.000824	-0.16	-0.14	Asthma;	chr4:143005658	chr4:142933195~143184861:-
BRCA	cis	rs17660992	0.519	rs34200125	ENSG00000273837.1	LLNLR-470E3.1	4.44	1.01e-05	0.000824	0.17	0.14	Blood protein levels;	chr19:51659849	chr19:51639478~51639931:-
BRCA	cis	rs3768617	0.51	rs10797849	ENSG00000224468.3	RP11-181K3.4	-4.44	1.01e-05	0.000825	-0.15	-0.14	Fuchs's corneal dystrophy;	chr1:183119853	chr1:183138402~183141282:-
BRCA	cis	rs7267979	1	rs6050598	ENSG00000277938.1	RP5-965G21.3	4.44	1.01e-05	0.000825	0.16	0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25416621	chr20:25229150~25231933:+
BRCA	cis	rs4578769	0.765	rs9949825	ENSG00000265939.1	UBE2CP2	-4.44	1.01e-05	0.000825	-0.17	-0.14	Eosinophil percentage of white cells;	chr18:22806055	chr18:22900486~22900995:-
BRCA	cis	rs490234	0.676	rs4838264	ENSG00000232630.1	PRPS1P2	-4.44	1.01e-05	0.000825	-0.14	-0.14	Mean arterial pressure;	chr9:125463282	chr9:125150653~125151589:+
BRCA	cis	rs891378	1	rs2017760	ENSG00000274245.1	RP11-357P18.2	-4.44	1.01e-05	0.000825	-0.19	-0.14	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207282076	chr1:207372559~207373252:+
BRCA	cis	rs3768617	0.51	rs3768618	ENSG00000224468.3	RP11-181K3.4	-4.44	1.01e-05	0.000825	-0.15	-0.14	Fuchs's corneal dystrophy;	chr1:183123356	chr1:183138402~183141282:-
BRCA	cis	rs12612619	0.732	rs893790	ENSG00000272148.1	RP11-195B17.1	-4.44	1.01e-05	0.000825	-0.15	-0.14	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:26978989	chr2:27062428~27062907:-
BRCA	cis	rs7011507	0.582	rs72637684	ENSG00000279881.1	RP11-513O13.1	-4.44	1.01e-05	0.000826	-0.22	-0.14	Inflammatory bowel disease;Ulcerative colitis;	chr8:48360958	chr8:48428143~48431041:-
BRCA	cis	rs1421334	0.781	rs11778607	ENSG00000254109.4	RBPMS-AS1	4.44	1.01e-05	0.000826	0.18	0.14	Intelligence (multi-trait analysis);	chr8:30982052	chr8:30382119~30385401:-
BRCA	cis	rs13113518	1	rs6849433	ENSG00000272969.1	RP11-528I4.2	4.44	1.01e-05	0.000827	0.16	0.14	Height;	chr4:55506498	chr4:55547112~55547889:+
BRCA	cis	rs13113518	0.966	rs12501327	ENSG00000272969.1	RP11-528I4.2	4.44	1.01e-05	0.000827	0.16	0.14	Height;	chr4:55507248	chr4:55547112~55547889:+
BRCA	cis	rs35740288	0.862	rs11637444	ENSG00000202081.1	RNU6-1280P	4.44	1.01e-05	0.000827	0.18	0.14	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85767957	chr15:85651522~85651628:-
BRCA	cis	rs67981189	0.537	rs917067	ENSG00000258571.1	PTTG4P	4.44	1.01e-05	0.000827	0.15	0.14	Schizophrenia;	chr14:70905187	chr14:71085482~71085833:-
BRCA	cis	rs321358	0.895	rs7110930	ENSG00000271390.1	RP11-89C3.3	-4.44	1.01e-05	0.000827	-0.2	-0.14	Body mass index;	chr11:111088556	chr11:111089870~111090368:-
BRCA	cis	rs7674212	0.51	rs55715738	ENSG00000246560.2	RP11-10L12.4	4.44	1.01e-05	0.000827	0.14	0.14	Type 2 diabetes;	chr4:103209032	chr4:102828055~102844075:+
BRCA	cis	rs2562456	0.833	rs552800	ENSG00000268535.1	RP11-420K14.3	-4.44	1.01e-05	0.000827	-0.18	-0.14	Pain;	chr19:21301840	chr19:21709522~21710191:+
BRCA	cis	rs708547	0.581	rs13121027	ENSG00000269949.1	RP11-738E22.3	-4.44	1.01e-05	0.000828	-0.17	-0.14	Response to bleomycin (chromatid breaks);	chr4:56947203	chr4:56960927~56961373:-
BRCA	cis	rs6430585	0.702	rs1042712	ENSG00000231890.6	DARS-AS1	4.44	1.01e-05	0.000828	0.2	0.14	Corneal structure;	chr2:135788274	chr2:135985176~136022593:+
BRCA	cis	rs875971	1	rs9986696	ENSG00000236529.1	RP13-254B10.1	-4.44	1.01e-05	0.000828	-0.15	-0.14	Aortic root size;	chr7:66239589	chr7:65840212~65840596:+
BRCA	cis	rs763014	0.966	rs4984677	ENSG00000260394.2	LA16c-313D11.9	-4.44	1.01e-05	0.000828	-0.14	-0.14	Height;	chr16:621682	chr16:678504~679777:-
BRCA	cis	rs10861342	0.892	rs2044307	ENSG00000257999.1	RP11-61E11.2	-4.44	1.01e-05	0.000828	-0.29	-0.14	IgG glycosylation;	chr12:105137393	chr12:105102472~105107179:-
BRCA	cis	rs6893300	0.784	rs62404347	ENSG00000225051.5	HMGB3P22	4.44	1.01e-05	0.000828	0.17	0.14	Resting heart rate;	chr5:179718130	chr5:179679032~179694768:+
BRCA	cis	rs10829156	0.699	rs1917209	ENSG00000225527.1	RP11-383B4.4	-4.44	1.01e-05	0.000829	-0.19	-0.14	Sudden cardiac arrest;	chr10:18543631	chr10:18531849~18533336:-
BRCA	cis	rs10129255	0.5	rs6576230	ENSG00000211967.3	IGHV3-53	-4.44	1.01e-05	0.000829	-0.09	-0.14	Kawasaki disease;	chr14:106778539	chr14:106592676~106593347:-
BRCA	cis	rs10129255	0.701	rs2005643	ENSG00000232216.1	IGHV3-43	4.44	1.01e-05	0.000829	0.11	0.14	Kawasaki disease;	chr14:106676288	chr14:106470264~106470800:-
BRCA	cis	rs7200543	0.961	rs1741	ENSG00000207425.1	Y_RNA	-4.44	1.01e-05	0.000829	-0.17	-0.14	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15036494	chr16:14915457~14915556:-
BRCA	cis	rs875971	1	rs6956179	ENSG00000236529.1	RP13-254B10.1	-4.44	1.01e-05	0.000829	-0.15	-0.14	Aortic root size;	chr7:66341672	chr7:65840212~65840596:+
BRCA	cis	rs4886920	0.887	rs7161954	ENSG00000260776.4	RP11-114H24.2	-4.44	1.01e-05	0.000829	-0.17	-0.14	Neuroticism;	chr15:77826613	chr15:77914217~77926846:-
BRCA	cis	rs10266483	0.739	rs12538943	ENSG00000227986.1	TRIM60P18	4.44	1.01e-05	0.000829	0.16	0.14	Response to statin therapy;	chr7:64395990	chr7:64355078~64356199:+
BRCA	cis	rs6545883	0.507	rs10169662	ENSG00000273302.1	RP11-493E12.2	-4.44	1.01e-05	0.000829	-0.12	-0.14	Tuberculosis;	chr2:61280801	chr2:61199979~61200769:+
BRCA	cis	rs67766926	0.953	rs13406503	ENSG00000271889.1	RP11-493E12.1	4.44	1.01e-05	0.000829	0.2	0.14	Inflammatory skin disease;	chr2:60897331	chr2:61151433~61162105:-
BRCA	cis	rs12681366	1	rs2930971	ENSG00000253175.1	RP11-267M23.6	4.44	1.01e-05	0.00083	0.16	0.14	Nonsyndromic cleft lip with cleft palate;	chr8:94420319	chr8:94565036~94565715:+
BRCA	cis	rs7267979	0.833	rs6138556	ENSG00000125804.12	FAM182A	-4.44	1.01e-05	0.00083	-0.18	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25262674	chr20:26054655~26086917:+
BRCA	cis	rs3176789	0.671	rs3136563	ENSG00000256673.1	RP11-599J14.2	4.44	1.01e-05	0.00083	0.15	0.14	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9762849	chr12:9398355~9414851:-
BRCA	cis	rs801193	0.66	rs10950049	ENSG00000236529.1	RP13-254B10.1	4.44	1.01e-05	0.00083	0.15	0.14	Aortic root size;	chr7:66765873	chr7:65840212~65840596:+
BRCA	cis	rs6430585	0.759	rs12467770	ENSG00000224043.6	CCNT2-AS1	-4.44	1.01e-05	0.00083	-0.23	-0.14	Corneal structure;	chr2:135778525	chr2:134735464~134918710:-
BRCA	cis	rs1434579	0.798	rs12460231	ENSG00000176761.7	ZNF285B	-4.44	1.01e-05	0.00083	-0.17	-0.14	Tuberculosis;	chr19:44450500	chr19:44467641~44473227:+
BRCA	cis	rs7800418	0.695	rs1557986	ENSG00000214870.7	AC004540.5	-4.44	1.01e-05	0.00083	-0.16	-0.14	Cognitive function;	chr7:26552253	chr7:26398593~26494256:+
BRCA	cis	rs10181042	0.581	rs1177285	ENSG00000273302.1	RP11-493E12.2	4.44	1.01e-05	0.00083	0.12	0.14	Crohn's disease;	chr2:61123002	chr2:61199979~61200769:+
BRCA	cis	rs755249	0.756	rs72637908	ENSG00000237624.1	OXCT2P1	4.44	1.01e-05	0.00083	0.17	0.14	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39557375	chr1:39514956~39516490:+
BRCA	cis	rs1371614	0.635	rs10175737	ENSG00000229122.1	AGBL5-IT1	-4.44	1.01e-05	0.000831	-0.14	-0.14	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26916879	chr2:27061038~27061815:+
BRCA	cis	rs1371614	0.577	rs877274	ENSG00000229122.1	AGBL5-IT1	-4.44	1.01e-05	0.000831	-0.14	-0.14	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26917231	chr2:27061038~27061815:+
BRCA	cis	rs984222	0.529	rs1325946	ENSG00000231365.4	RP11-418J17.1	-4.44	1.01e-05	0.000831	-0.16	-0.14	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:118943299	chr1:119140396~119275973:+
BRCA	cis	rs1910358	0.614	rs11955052	ENSG00000248874.4	C5orf17	-4.44	1.01e-05	0.000831	-0.18	-0.14	Venous thromboembolism (SNP x SNP interaction);	chr5:23979128	chr5:23951348~24178263:+
BRCA	cis	rs10208649	0.611	rs1974771	ENSG00000233266.1	HMGB1P31	4.44	1.01e-05	0.000831	0.29	0.14	Body mass index;	chr2:54051406	chr2:54051334~54051760:+
BRCA	cis	rs2832191	0.716	rs1984012	ENSG00000232855.5	AF131217.1	-4.44	1.01e-05	0.000831	-0.16	-0.14	Dental caries;	chr21:29020151	chr21:28439346~28674848:-
BRCA	cis	rs4578769	0.648	rs1902921	ENSG00000265939.1	UBE2CP2	-4.44	1.01e-05	0.000831	-0.17	-0.14	Eosinophil percentage of white cells;	chr18:22964380	chr18:22900486~22900995:-
BRCA	cis	rs62458065	0.85	rs7804998	ENSG00000273014.1	RP11-225B17.2	-4.44	1.01e-05	0.000831	-0.21	-0.14	Metabolite levels (HVA/MHPG ratio);	chr7:32421585	chr7:32758882~32759353:+
BRCA	cis	rs73242632	1	rs28474684	ENSG00000269949.1	RP11-738E22.3	4.44	1.02e-05	0.000831	0.32	0.14	Congenital heart disease (maternal effect);	chr4:57009303	chr4:56960927~56961373:-
BRCA	cis	rs7182948	1	rs8040436	ENSG00000259531.2	RP11-295H24.3	-4.44	1.02e-05	0.000831	-0.19	-0.14	Lung adenocarcinoma;	chr15:49522831	chr15:49365124~49366685:-
BRCA	cis	rs875971	0.545	rs801199	ENSG00000230295.1	RP11-458F8.2	-4.44	1.02e-05	0.000831	-0.13	-0.14	Aortic root size;	chr7:66560286	chr7:66880708~66882981:+
BRCA	cis	rs875971	0.545	rs73152714	ENSG00000230295.1	RP11-458F8.2	4.44	1.02e-05	0.000831	0.13	0.14	Aortic root size;	chr7:66534641	chr7:66880708~66882981:+
BRCA	cis	rs875971	0.545	rs4718364	ENSG00000230295.1	RP11-458F8.2	4.44	1.02e-05	0.000831	0.13	0.14	Aortic root size;	chr7:66536353	chr7:66880708~66882981:+
BRCA	cis	rs35740288	0.77	rs55740125	ENSG00000202081.1	RNU6-1280P	4.44	1.02e-05	0.000831	0.18	0.14	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85612505	chr15:85651522~85651628:-
BRCA	cis	rs4835473	0.932	rs1849113	ENSG00000249741.2	RP11-673E1.3	4.44	1.02e-05	0.000831	0.15	0.14	Immature fraction of reticulocytes;	chr4:143962512	chr4:143911514~143912053:-
BRCA	cis	rs367615	0.523	rs4330503	ENSG00000249476.1	CTD-2587M2.1	4.44	1.02e-05	0.000832	0.14	0.14	Colorectal cancer (SNP x SNP interaction);	chr5:109519112	chr5:109237120~109326369:-
BRCA	cis	rs793571	0.628	rs28394222	ENSG00000259250.1	RP11-50C13.1	-4.44	1.02e-05	0.000832	-0.23	-0.14	Schizophrenia;	chr15:58804958	chr15:58587507~58591676:+
BRCA	cis	rs7267979	0.753	rs400357	ENSG00000231081.1	RP4-760C5.3	-4.44	1.02e-05	0.000832	-0.17	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25498422	chr20:26008791~26010531:-
BRCA	cis	rs56322409	0.833	rs1935814	ENSG00000226688.5	ENTPD1-AS1	4.44	1.02e-05	0.000833	0.16	0.14	Blood metabolite levels;	chr10:95884194	chr10:95753206~96090238:-
BRCA	cis	rs875971	0.502	rs1796227	ENSG00000273142.1	RP11-458F8.4	-4.44	1.02e-05	0.000833	-0.14	-0.14	Aortic root size;	chr7:66622032	chr7:66902857~66906297:+
BRCA	cis	rs35740288	0.571	rs11631009	ENSG00000259407.1	RP11-158M2.3	-4.44	1.02e-05	0.000833	-0.2	-0.14	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85775422	chr15:85744109~85750281:-
BRCA	cis	rs7915131	0.965	rs7068164	ENSG00000238280.1	RP11-436D10.3	4.43	1.02e-05	0.000834	0.17	0.14	Schizophrenia;	chr10:62641296	chr10:62793562~62805887:-
BRCA	cis	rs1153858	1	rs16942000	ENSG00000275672.1	GATM-AS1	-4.43	1.02e-05	0.000834	-0.17	-0.14	Homoarginine levels;	chr15:45340805	chr15:45378700~45380123:+
BRCA	cis	rs4835473	0.932	rs1580002	ENSG00000249741.2	RP11-673E1.3	4.43	1.02e-05	0.000834	0.15	0.14	Immature fraction of reticulocytes;	chr4:143766507	chr4:143911514~143912053:-
BRCA	cis	rs4831760	0.555	rs1362865	ENSG00000250483.1	PPM1AP1	4.43	1.02e-05	0.000834	0.16	0.14	Pulmonary function decline;	chr8:15689941	chr8:15806149~15807283:-
BRCA	cis	rs1005277	0.579	rs176880	ENSG00000099251.13	HSD17B7P2	-4.43	1.02e-05	0.000835	-0.15	-0.14	Extrinsic epigenetic age acceleration;	chr10:38112489	chr10:38356380~38378505:+
BRCA	cis	rs2731006	0.64	rs2678141	ENSG00000257114.2	RP11-25I15.3	4.43	1.02e-05	0.000835	0.2	0.14	Panic disorder;	chr12:42807005	chr12:42692216~42717119:+
BRCA	cis	rs62458065	0.713	rs28421905	ENSG00000229358.3	DPY19L1P1	-4.43	1.02e-05	0.000835	-0.19	-0.14	Metabolite levels (HVA/MHPG ratio);	chr7:32449889	chr7:32580949~32761787:-
BRCA	cis	rs10833905	0.759	rs28526534	ENSG00000246225.5	RP11-17A1.3	-4.43	1.02e-05	0.000835	-0.19	-0.14	Sudden cardiac arrest;	chr11:23033690	chr11:22829380~22945393:+
BRCA	cis	rs10833905	0.938	rs61889441	ENSG00000246225.5	RP11-17A1.3	-4.43	1.02e-05	0.000835	-0.19	-0.14	Sudden cardiac arrest;	chr11:23034168	chr11:22829380~22945393:+
BRCA	cis	rs8062405	0.789	rs1968752	ENSG00000261766.1	RP11-22P6.2	-4.43	1.02e-05	0.000835	-0.13	-0.14	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620264	chr16:28862166~28863340:-
BRCA	cis	rs1910358	0.614	rs7725443	ENSG00000248874.4	C5orf17	-4.43	1.02e-05	0.000835	-0.18	-0.14	Venous thromboembolism (SNP x SNP interaction);	chr5:23983631	chr5:23951348~24178263:+
BRCA	cis	rs1722141	0.601	rs809299	ENSG00000229628.1	AC073115.7	4.43	1.02e-05	0.000835	0.18	0.14	Sitting height ratio;	chr7:46015660	chr7:45990905~46000898:+
BRCA	cis	rs13113518	0.934	rs11935823	ENSG00000272969.1	RP11-528I4.2	4.43	1.02e-05	0.000835	0.16	0.14	Height;	chr4:55589624	chr4:55547112~55547889:+
BRCA	cis	rs62025270	0.848	rs62025269	ENSG00000202081.1	RNU6-1280P	-4.43	1.02e-05	0.000835	-0.2	-0.14	Idiopathic pulmonary fibrosis;	chr15:85756859	chr15:85651522~85651628:-
BRCA	cis	rs1005277	0.603	rs1998062	ENSG00000099251.13	HSD17B7P2	4.43	1.02e-05	0.000835	0.15	0.14	Extrinsic epigenetic age acceleration;	chr10:38168724	chr10:38356380~38378505:+
BRCA	cis	rs77204473	1	rs17120131	ENSG00000280143.1	AP000892.6	-4.43	1.02e-05	0.000835	-0.26	-0.14	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116901770	chr11:117204967~117210292:+
BRCA	cis	rs8031584	0.918	rs61997140	ENSG00000259845.1	HERC2P10	4.43	1.02e-05	0.000835	0.16	0.14	Huntington's disease progression;	chr15:30985109	chr15:30815271~30844153:+
BRCA	cis	rs13326165	0.585	rs61644644	ENSG00000243224.1	RP5-1157M23.2	-4.43	1.02e-05	0.000835	-0.22	-0.14	HDL cholesterol levels;HDL cholesterol;	chr3:52273480	chr3:52239258~52241097:+
BRCA	cis	rs9990333	0.562	rs73210005	ENSG00000242086.7	LINC00969	4.43	1.02e-05	0.000836	0.15	0.14	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196100441	chr3:195658062~195739964:+
BRCA	cis	rs1005277	0.579	rs1740742	ENSG00000099251.13	HSD17B7P2	4.43	1.02e-05	0.000836	0.15	0.14	Extrinsic epigenetic age acceleration;	chr10:38229932	chr10:38356380~38378505:+
BRCA	cis	rs1005277	0.602	rs1740743	ENSG00000099251.13	HSD17B7P2	4.43	1.02e-05	0.000836	0.15	0.14	Extrinsic epigenetic age acceleration;	chr10:38230294	chr10:38356380~38378505:+
BRCA	cis	rs1005277	0.579	rs1740745	ENSG00000099251.13	HSD17B7P2	4.43	1.02e-05	0.000836	0.15	0.14	Extrinsic epigenetic age acceleration;	chr10:38231128	chr10:38356380~38378505:+
BRCA	cis	rs1005277	0.579	rs1740747	ENSG00000099251.13	HSD17B7P2	4.43	1.02e-05	0.000836	0.15	0.14	Extrinsic epigenetic age acceleration;	chr10:38231537	chr10:38356380~38378505:+
BRCA	cis	rs1005277	0.579	rs1740749	ENSG00000099251.13	HSD17B7P2	4.43	1.02e-05	0.000836	0.15	0.14	Extrinsic epigenetic age acceleration;	chr10:38232718	chr10:38356380~38378505:+
BRCA	cis	rs1005277	0.579	rs1780115	ENSG00000099251.13	HSD17B7P2	4.43	1.02e-05	0.000836	0.15	0.14	Extrinsic epigenetic age acceleration;	chr10:38235845	chr10:38356380~38378505:+
BRCA	cis	rs1005277	0.541	rs1740741	ENSG00000099251.13	HSD17B7P2	4.43	1.02e-05	0.000836	0.15	0.14	Extrinsic epigenetic age acceleration;	chr10:38226406	chr10:38356380~38378505:+
BRCA	cis	rs1005277	0.528	rs2057228	ENSG00000099251.13	HSD17B7P2	4.43	1.02e-05	0.000836	0.15	0.14	Extrinsic epigenetic age acceleration;	chr10:38226838	chr10:38356380~38378505:+
BRCA	cis	rs8054556	1	rs4583255	ENSG00000261367.1	RP11-455F5.4	-4.43	1.02e-05	0.000836	-0.15	-0.14	Autism spectrum disorder or schizophrenia;	chr16:29977620	chr16:30107675~30110541:+
BRCA	cis	rs1488902	0.785	rs1948188	ENSG00000280367.1	RP11-121L10.2	4.43	1.02e-05	0.000836	0.15	0.14	Amyotrophic lateral sclerosis;	chr11:89600217	chr11:90223153~90226538:+
BRCA	cis	rs12317459	0.591	rs11115389	ENSG00000213270.5	RPL6P25	-4.43	1.02e-05	0.000836	-0.22	-0.14	Prostate cancer (SNP x SNP interaction);	chr12:82769244	chr12:83151331~83152190:+
BRCA	cis	rs12317459	0.591	rs11115398	ENSG00000213270.5	RPL6P25	-4.43	1.02e-05	0.000836	-0.22	-0.14	Prostate cancer (SNP x SNP interaction);	chr12:82769905	chr12:83151331~83152190:+
BRCA	cis	rs6012564	0.858	rs3091427	ENSG00000227431.4	CSE1L-AS1	-4.43	1.02e-05	0.000836	-0.17	-0.14	Anger;	chr20:49046845	chr20:49040463~49046044:-
BRCA	cis	rs9818758	0.607	rs34343820	ENSG00000270441.1	RP11-694I15.7	4.43	1.02e-05	0.000836	0.27	0.14	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49272101	chr3:49140086~49160851:-
BRCA	cis	rs73242632	1	rs12510703	ENSG00000269949.1	RP11-738E22.3	4.43	1.02e-05	0.000836	0.27	0.14	Congenital heart disease (maternal effect);	chr4:56882132	chr4:56960927~56961373:-
BRCA	cis	rs9818758	0.607	rs10049462	ENSG00000270441.1	RP11-694I15.7	4.43	1.02e-05	0.000836	0.27	0.14	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49272251	chr3:49140086~49160851:-
BRCA	cis	rs62458065	0.568	rs62463963	ENSG00000229358.3	DPY19L1P1	-4.43	1.02e-05	0.000836	-0.19	-0.14	Metabolite levels (HVA/MHPG ratio);	chr7:32447079	chr7:32580949~32761787:-
BRCA	cis	rs10958369	0.613	rs1477957	ENSG00000260484.1	RP11-1081M5.2	4.43	1.02e-05	0.000836	0.17	0.14	Response to antineoplastic agents;	chr8:53522873	chr8:53388701~53390872:-
BRCA	cis	rs875971	0.66	rs10272357	ENSG00000273142.1	RP11-458F8.4	4.43	1.02e-05	0.000836	0.12	0.14	Aortic root size;	chr7:66598087	chr7:66902857~66906297:+
BRCA	cis	rs6487679	0.526	rs7305336	ENSG00000214776.8	RP11-726G1.1	-4.43	1.02e-05	0.000836	-0.16	-0.14	Non-alcoholic fatty liver disease histology (AST);	chr12:9222493	chr12:9467552~9576275:+
BRCA	cis	rs1858037	0.867	rs67453645	ENSG00000281920.1	RP11-418H16.1	4.43	1.02e-05	0.000836	0.18	0.14	Rheumatoid arthritis;	chr2:65358908	chr2:65623272~65628424:+
BRCA	cis	rs7011507	0.582	rs56152712	ENSG00000279881.1	RP11-513O13.1	-4.43	1.02e-05	0.000837	-0.22	-0.14	Inflammatory bowel disease;Ulcerative colitis;	chr8:48343187	chr8:48428143~48431041:-
BRCA	cis	rs6671200	0.85	rs259345	ENSG00000226026.4	RP11-57H12.3	-4.43	1.02e-05	0.000837	-0.26	-0.14	Stearic acid (18:0) levels;	chr1:95264093	chr1:95163219~95233982:-
BRCA	cis	rs2880765	0.835	rs7162502	ENSG00000202081.1	RNU6-1280P	4.43	1.02e-05	0.000837	0.16	0.14	Coronary artery disease;	chr15:85501242	chr15:85651522~85651628:-
BRCA	cis	rs2880765	0.835	rs12910373	ENSG00000202081.1	RNU6-1280P	4.43	1.02e-05	0.000837	0.16	0.14	Coronary artery disease;	chr15:85503571	chr15:85651522~85651628:-
BRCA	cis	rs2337406	0.587	rs10150642	ENSG00000231475.3	IGHV4-31	-4.43	1.02e-05	0.000837	-0.12	-0.14	Alzheimer's disease (late onset);	chr14:106647269	chr14:106349283~106349792:-
BRCA	cis	rs13126694	0.633	rs6536298	ENSG00000251429.1	RP11-597D13.7	4.43	1.02e-05	0.000837	0.14	0.14	Blood osmolality (transformed sodium);	chr4:158091213	chr4:158270378~158278676:+
BRCA	cis	rs13126694	0.633	rs11100149	ENSG00000251429.1	RP11-597D13.7	4.43	1.02e-05	0.000837	0.14	0.14	Blood osmolality (transformed sodium);	chr4:158092138	chr4:158270378~158278676:+
BRCA	cis	rs867186	1	rs75888794	ENSG00000126005.14	MMP24-AS1	-4.43	1.02e-05	0.000837	-0.25	-0.14	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35115195	chr20:35216462~35278131:-
BRCA	cis	rs1329650	1	rs4933206	ENSG00000228701.1	TNKS2-AS1	-4.43	1.02e-05	0.000837	-0.18	-0.14	Smoking behavior;	chr10:91578843	chr10:91782839~91798291:-
BRCA	cis	rs7523050	0.643	rs34096625	ENSG00000203897.3	SPATA42	-4.43	1.02e-05	0.000837	-0.26	-0.14	Fat distribution (HIV);	chr1:108858479	chr1:108857217~108858524:+
BRCA	cis	rs75804782	0.515	rs79557340	ENSG00000186235.9	AC016757.3	4.43	1.02e-05	0.000837	0.35	0.14	Chronotype;Morning vs. evening chronotype;	chr2:238389311	chr2:238224552~238231677:-
BRCA	cis	rs718314	0.507	rs10842715	ENSG00000256894.1	RP11-283G6.3	4.43	1.02e-05	0.000837	0.14	0.14	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Renal cell carcinoma;Waist circumference adjusted for body mass index;	chr12:26334250	chr12:26125155~26126617:-
BRCA	cis	rs10411262	0.935	rs314666	ENSG00000245598.5	DACT3-AS1	-4.43	1.02e-05	0.000838	-0.17	-0.14	Tonsillectomy;	chr19:46673568	chr19:46660364~46677447:+
BRCA	cis	rs6430585	0.583	rs730005	ENSG00000231890.6	DARS-AS1	-4.43	1.02e-05	0.000838	-0.21	-0.14	Corneal structure;	chr2:135825124	chr2:135985176~136022593:+
BRCA	cis	rs10411262	0.935	rs2312289	ENSG00000245598.5	DACT3-AS1	-4.43	1.02e-05	0.000838	-0.17	-0.14	Tonsillectomy;	chr19:46672358	chr19:46660364~46677447:+
BRCA	cis	rs7267979	0.903	rs6050481	ENSG00000125804.12	FAM182A	-4.43	1.02e-05	0.000838	-0.18	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25243944	chr20:26054655~26086917:+
BRCA	cis	rs7267979	0.834	rs6115100	ENSG00000125804.12	FAM182A	-4.43	1.02e-05	0.000838	-0.18	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25245302	chr20:26054655~26086917:+
BRCA	cis	rs12681366	0.537	rs10956913	ENSG00000253175.1	RP11-267M23.6	4.43	1.02e-05	0.000838	0.16	0.14	Nonsyndromic cleft lip with cleft palate;	chr8:94471459	chr8:94565036~94565715:+
BRCA	cis	rs8031584	1	rs1474380	ENSG00000270015.1	RP11-540B6.6	-4.43	1.02e-05	0.000838	-0.14	-0.14	Huntington's disease progression;	chr15:30977032	chr15:30926514~30928407:+
BRCA	cis	rs4578769	0.765	rs10502430	ENSG00000265939.1	UBE2CP2	-4.43	1.02e-05	0.000838	-0.17	-0.14	Eosinophil percentage of white cells;	chr18:22916946	chr18:22900486~22900995:-
BRCA	cis	rs2255336	0.873	rs11053806	ENSG00000245648.1	RP11-277P12.20	-4.43	1.02e-05	0.000838	-0.22	-0.14	Blood protein levels;	chr12:10455822	chr12:10363769~10398506:+
BRCA	cis	rs6480314	0.573	rs12573244	ENSG00000233590.1	RP11-153K11.3	-4.43	1.02e-05	0.000838	-0.23	-0.14	Optic nerve measurement (disc area);	chr10:68241488	chr10:68233251~68242379:-
BRCA	cis	rs13108904	0.901	rs1680073	ENSG00000253399.1	AC078852.2	4.43	1.03e-05	0.000839	0.15	0.14	Obesity-related traits;	chr4:1286549	chr4:1358479~1359461:+
BRCA	cis	rs853679	0.76	rs9368563	ENSG00000216901.1	AL022393.7	4.43	1.03e-05	0.000839	0.21	0.14	Depression;	chr6:28240780	chr6:28176188~28176674:+
BRCA	cis	rs853679	0.76	rs9295768	ENSG00000216901.1	AL022393.7	4.43	1.03e-05	0.000839	0.21	0.14	Depression;	chr6:28241324	chr6:28176188~28176674:+
BRCA	cis	rs6430585	0.759	rs4954623	ENSG00000231890.6	DARS-AS1	4.43	1.03e-05	0.000839	0.21	0.14	Corneal structure;	chr2:135778306	chr2:135985176~136022593:+
BRCA	cis	rs6015450	0.85	rs76828114	ENSG00000228340.4	MIR646HG	4.43	1.03e-05	0.000839	0.27	0.14	Hypertension;Blood pressure;Systolic blood pressure;Diastolic blood pressure;	chr20:59152327	chr20:60087840~60527458:+
BRCA	cis	rs71520386	0.898	rs12536144	ENSG00000230658.1	KLHL7-AS1	4.43	1.03e-05	0.000839	0.24	0.14	Fibrinogen levels;	chr7:22782890	chr7:23101228~23105703:-
BRCA	cis	rs6921919	0.525	rs6929825	ENSG00000273712.1	RP5-874C20.7	4.43	1.03e-05	0.000839	0.18	0.14	Autism spectrum disorder or schizophrenia;	chr6:28411182	chr6:28315613~28315883:-
BRCA	cis	rs6921919	0.583	rs35599905	ENSG00000273712.1	RP5-874C20.7	4.43	1.03e-05	0.000839	0.18	0.14	Autism spectrum disorder or schizophrenia;	chr6:28411886	chr6:28315613~28315883:-
BRCA	cis	rs6921919	0.583	rs1124131	ENSG00000273712.1	RP5-874C20.7	4.43	1.03e-05	0.000839	0.18	0.14	Autism spectrum disorder or schizophrenia;	chr6:28412471	chr6:28315613~28315883:-
BRCA	cis	rs6921919	0.583	rs6899389	ENSG00000273712.1	RP5-874C20.7	4.43	1.03e-05	0.000839	0.18	0.14	Autism spectrum disorder or schizophrenia;	chr6:28413363	chr6:28315613~28315883:-
BRCA	cis	rs6921919	0.583	rs6922374	ENSG00000273712.1	RP5-874C20.7	4.43	1.03e-05	0.000839	0.18	0.14	Autism spectrum disorder or schizophrenia;	chr6:28413495	chr6:28315613~28315883:-
BRCA	cis	rs6921919	0.583	rs6899603	ENSG00000273712.1	RP5-874C20.7	4.43	1.03e-05	0.000839	0.18	0.14	Autism spectrum disorder or schizophrenia;	chr6:28413528	chr6:28315613~28315883:-
BRCA	cis	rs6921919	0.583	rs6922429	ENSG00000273712.1	RP5-874C20.7	4.43	1.03e-05	0.000839	0.18	0.14	Autism spectrum disorder or schizophrenia;	chr6:28413568	chr6:28315613~28315883:-
BRCA	cis	rs4648045	0.565	rs11733293	ENSG00000251288.2	RP11-10L12.2	4.43	1.03e-05	0.00084	0.17	0.14	Lymphocyte percentage of white cells;	chr4:102624096	chr4:102751401~102752641:+
BRCA	cis	rs4908760	0.613	rs12024032	ENSG00000232912.4	RP5-1115A15.1	-4.43	1.03e-05	0.00084	-0.13	-0.14	Vitiligo;	chr1:8748126	chr1:8424645~8434838:+
BRCA	cis	rs875971	0.545	rs7787063	ENSG00000273142.1	RP11-458F8.4	4.43	1.03e-05	0.00084	0.13	0.14	Aortic root size;	chr7:66164012	chr7:66902857~66906297:+
BRCA	cis	rs875971	0.545	rs12673308	ENSG00000273142.1	RP11-458F8.4	4.43	1.03e-05	0.00084	0.13	0.14	Aortic root size;	chr7:66166374	chr7:66902857~66906297:+
BRCA	cis	rs860295	0.702	rs10796946	ENSG00000225855.5	RUSC1-AS1	4.43	1.03e-05	0.00084	0.11	0.14	Body mass index;	chr1:155459699	chr1:155316863~155324176:-
BRCA	cis	rs860295	0.676	rs10908466	ENSG00000225855.5	RUSC1-AS1	4.43	1.03e-05	0.00084	0.11	0.14	Body mass index;	chr1:155459934	chr1:155316863~155324176:-
BRCA	cis	rs7267979	1	rs6050565	ENSG00000274973.1	RP13-401N8.7	4.43	1.03e-05	0.00084	0.15	0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25366927	chr20:25845497~25845862:+
BRCA	cis	rs1395	0.778	rs2078616	ENSG00000234072.1	AC074117.10	-4.43	1.03e-05	0.00084	-0.15	-0.14	Blood metabolite levels;	chr2:27219036	chr2:27356246~27367622:+
BRCA	cis	rs2115630	0.967	rs11073702	ENSG00000259728.4	LINC00933	-4.43	1.03e-05	0.00084	-0.15	-0.14	P wave terminal force;	chr15:84766840	chr15:84570649~84580175:+
BRCA	cis	rs7789940	1	rs17149161	ENSG00000280388.1	RP11-229D13.3	-4.43	1.03e-05	0.00084	-0.15	-0.14	Multiple sclerosis;	chr7:76348912	chr7:76043977~76045963:-
BRCA	cis	rs4143844	1	rs34556569	ENSG00000259251.2	RP11-643M14.1	4.43	1.03e-05	0.00084	0.33	0.14	Bipolar disorder and schizophrenia;	chr15:61989619	chr15:62060503~62062434:+
BRCA	cis	rs4143844	1	rs34042779	ENSG00000259251.2	RP11-643M14.1	4.43	1.03e-05	0.00084	0.33	0.14	Bipolar disorder and schizophrenia;	chr15:61990899	chr15:62060503~62062434:+
BRCA	cis	rs2136613	0.533	rs1571922	ENSG00000238280.1	RP11-436D10.3	-4.43	1.03e-05	0.00084	-0.17	-0.14	Selective IgA deficiency;	chr10:62851189	chr10:62793562~62805887:-
BRCA	cis	rs2136613	0.533	rs10822066	ENSG00000238280.1	RP11-436D10.3	-4.43	1.03e-05	0.00084	-0.17	-0.14	Selective IgA deficiency;	chr10:62851432	chr10:62793562~62805887:-
BRCA	cis	rs2136613	0.533	rs10740091	ENSG00000238280.1	RP11-436D10.3	-4.43	1.03e-05	0.00084	-0.17	-0.14	Selective IgA deficiency;	chr10:62851628	chr10:62793562~62805887:-
BRCA	cis	rs2136613	0.533	rs10822067	ENSG00000238280.1	RP11-436D10.3	-4.43	1.03e-05	0.00084	-0.17	-0.14	Selective IgA deficiency;	chr10:62851949	chr10:62793562~62805887:-
BRCA	cis	rs2136613	0.533	rs10761669	ENSG00000238280.1	RP11-436D10.3	-4.43	1.03e-05	0.00084	-0.17	-0.14	Selective IgA deficiency;	chr10:62852050	chr10:62793562~62805887:-
BRCA	cis	rs2136613	0.533	rs10509173	ENSG00000238280.1	RP11-436D10.3	-4.43	1.03e-05	0.00084	-0.17	-0.14	Selective IgA deficiency;	chr10:62852129	chr10:62793562~62805887:-
BRCA	cis	rs2136613	0.533	rs10822068	ENSG00000238280.1	RP11-436D10.3	-4.43	1.03e-05	0.00084	-0.17	-0.14	Selective IgA deficiency;	chr10:62852505	chr10:62793562~62805887:-
BRCA	cis	rs2136613	0.533	rs10822069	ENSG00000238280.1	RP11-436D10.3	-4.43	1.03e-05	0.00084	-0.17	-0.14	Selective IgA deficiency;	chr10:62853482	chr10:62793562~62805887:-
BRCA	cis	rs2136613	0.533	rs10995331	ENSG00000238280.1	RP11-436D10.3	-4.43	1.03e-05	0.00084	-0.17	-0.14	Selective IgA deficiency;	chr10:62853948	chr10:62793562~62805887:-
BRCA	cis	rs2136613	0.533	rs10822070	ENSG00000238280.1	RP11-436D10.3	-4.43	1.03e-05	0.00084	-0.17	-0.14	Selective IgA deficiency;	chr10:62854149	chr10:62793562~62805887:-
BRCA	cis	rs2136613	0.533	rs4141617	ENSG00000238280.1	RP11-436D10.3	-4.43	1.03e-05	0.00084	-0.17	-0.14	Selective IgA deficiency;	chr10:62854308	chr10:62793562~62805887:-
BRCA	cis	rs867371	1	rs1392976	ENSG00000278603.1	RP13-608F4.5	-4.43	1.03e-05	0.00084	-0.18	-0.14	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82153834	chr15:82472203~82472426:+
BRCA	cis	rs12681366	0.537	rs10095298	ENSG00000253175.1	RP11-267M23.6	4.43	1.03e-05	0.00084	0.16	0.14	Nonsyndromic cleft lip with cleft palate;	chr8:94472353	chr8:94565036~94565715:+
BRCA	cis	rs11673344	0.503	rs7246720	ENSG00000226686.6	LINC01535	4.43	1.03e-05	0.000841	0.18	0.14	Obesity-related traits;	chr19:37073726	chr19:37251912~37265535:+
BRCA	cis	rs11603691	0.901	rs61888888	ENSG00000254662.1	RP11-872D17.4	-4.43	1.03e-05	0.000841	-0.28	-0.14	Low high density lipoprotein cholesterol levels;	chr11:57336210	chr11:57325603~57327958:+
BRCA	cis	rs4948275	0.693	rs2787705	ENSG00000237233.2	TMEM26-AS1	-4.43	1.03e-05	0.000841	-0.16	-0.14	Night sleep phenotypes;	chr10:61554198	chr10:61452639~61481956:+
BRCA	cis	rs754466	0.58	rs17516020	ENSG00000204049.1	RP11-126H7.4	4.43	1.03e-05	0.000841	0.19	0.14	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77778976	chr10:77866875~77869610:+
BRCA	cis	rs4925386	0.759	rs2427293	ENSG00000273619.1	RP5-908M14.9	4.43	1.03e-05	0.000841	0.12	0.14	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62350803	chr20:62386303~62386970:-
BRCA	cis	rs2731006	0.64	rs908661	ENSG00000257114.2	RP11-25I15.3	4.43	1.03e-05	0.000841	0.22	0.14	Panic disorder;	chr12:42775255	chr12:42692216~42717119:+
BRCA	cis	rs2731006	0.64	rs908662	ENSG00000257114.2	RP11-25I15.3	4.43	1.03e-05	0.000841	0.22	0.14	Panic disorder;	chr12:42775273	chr12:42692216~42717119:+
BRCA	cis	rs11603691	1	rs7129491	ENSG00000254662.1	RP11-872D17.4	-4.43	1.03e-05	0.000841	-0.29	-0.14	Low high density lipoprotein cholesterol levels;	chr11:57327608	chr11:57325603~57327958:+
BRCA	cis	rs1865760	0.929	rs2876693	ENSG00000272462.2	U91328.19	-4.43	1.03e-05	0.000841	-0.16	-0.14	Height;	chr6:25954206	chr6:25992662~26001775:+
BRCA	cis	rs11955398	0.502	rs34591	ENSG00000272308.1	RP11-231G3.1	-4.43	1.03e-05	0.000842	-0.16	-0.14	Intelligence (multi-trait analysis);	chr5:61034039	chr5:60866457~60866935:-
BRCA	cis	rs11098499	0.954	rs10031483	ENSG00000260091.1	RP11-33B1.4	-4.43	1.03e-05	0.000842	-0.12	-0.14	Corneal astigmatism;	chr4:119501481	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.954	rs10031665	ENSG00000260091.1	RP11-33B1.4	-4.43	1.03e-05	0.000842	-0.12	-0.14	Corneal astigmatism;	chr4:119501697	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.954	rs3733523	ENSG00000260091.1	RP11-33B1.4	-4.43	1.03e-05	0.000842	-0.12	-0.14	Corneal astigmatism;	chr4:119502564	chr4:119409333~119410233:+
BRCA	cis	rs718433	0.584	rs7160973	ENSG00000256379.1	TRAV8-5	4.43	1.03e-05	0.000842	0.16	0.14	Intraocular pressure;	chr14:21748391	chr14:21903077~21903598:+
BRCA	cis	rs73607972	0.935	rs7193194	ENSG00000275191.1	RP11-36I17.2	-4.43	1.03e-05	0.000842	-0.22	-0.14	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53563802	chr16:53628256~53628816:-
BRCA	cis	rs11098499	1	rs13435802	ENSG00000260091.1	RP11-33B1.4	4.43	1.03e-05	0.000842	0.12	0.14	Corneal astigmatism;	chr4:119256805	chr4:119409333~119410233:+
BRCA	cis	rs516805	0.667	rs2606624	ENSG00000279114.1	RP3-425C14.5	-4.43	1.03e-05	0.000842	-0.17	-0.14	Lymphocyte counts;	chr6:122168693	chr6:122471923~122484161:+
BRCA	cis	rs10208649	0.611	rs58851686	ENSG00000233266.1	HMGB1P31	4.43	1.03e-05	0.000843	0.28	0.14	Body mass index;	chr2:54057179	chr2:54051334~54051760:+
BRCA	cis	rs1910358	0.554	rs2343381	ENSG00000248874.4	C5orf17	-4.43	1.03e-05	0.000843	-0.2	-0.14	Venous thromboembolism (SNP x SNP interaction);	chr5:23736629	chr5:23951348~24178263:+
BRCA	cis	rs1910358	0.554	rs2880616	ENSG00000248874.4	C5orf17	-4.43	1.03e-05	0.000843	-0.2	-0.14	Venous thromboembolism (SNP x SNP interaction);	chr5:23736656	chr5:23951348~24178263:+
BRCA	cis	rs6832769	0.925	rs6829182	ENSG00000223305.1	RN7SKP30	4.43	1.03e-05	0.000843	0.17	0.14	Personality dimensions;	chr4:55587989	chr4:55540502~55540835:-
BRCA	cis	rs801193	0.636	rs10233806	ENSG00000236529.1	RP13-254B10.1	-4.43	1.03e-05	0.000843	-0.15	-0.14	Aortic root size;	chr7:66653261	chr7:65840212~65840596:+
BRCA	cis	rs610932	0.517	rs621965	ENSG00000275344.1	MIR6503	4.43	1.03e-05	0.000843	0.14	0.14	Alzheimer's disease;	chr11:60237355	chr11:60209071~60209156:-
BRCA	cis	rs875971	0.66	rs1860468	ENSG00000272831.1	RP11-792A8.4	-4.43	1.03e-05	0.000843	-0.12	-0.14	Aortic root size;	chr7:66642265	chr7:66739829~66740385:-
BRCA	cis	rs11098499	0.738	rs34566984	ENSG00000250412.1	KLHL2P1	4.43	1.03e-05	0.000843	0.16	0.14	Corneal astigmatism;	chr4:119440115	chr4:119334329~119378233:+
BRCA	cis	rs11098499	0.954	rs9685777	ENSG00000250412.1	KLHL2P1	4.43	1.03e-05	0.000843	0.16	0.14	Corneal astigmatism;	chr4:119444810	chr4:119334329~119378233:+
BRCA	cis	rs8054556	0.787	rs12325539	ENSG00000183604.13	SMG1P5	-4.43	1.03e-05	0.000844	-0.14	-0.14	Autism spectrum disorder or schizophrenia;	chr16:30022312	chr16:30267553~30335374:-
BRCA	cis	rs8054556	0.751	rs11642430	ENSG00000183604.13	SMG1P5	-4.43	1.03e-05	0.000844	-0.14	-0.14	Autism spectrum disorder or schizophrenia;	chr16:30034468	chr16:30267553~30335374:-
BRCA	cis	rs77204473	1	rs11216185	ENSG00000280143.1	AP000892.6	-4.43	1.03e-05	0.000844	-0.26	-0.14	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116912258	chr11:117204967~117210292:+
BRCA	cis	rs6921919	0.583	rs6922169	ENSG00000273712.1	RP5-874C20.7	4.43	1.03e-05	0.000844	0.18	0.14	Autism spectrum disorder or schizophrenia;	chr6:28415155	chr6:28315613~28315883:-
BRCA	cis	rs6921919	0.559	rs13210866	ENSG00000273712.1	RP5-874C20.7	4.43	1.03e-05	0.000844	0.18	0.14	Autism spectrum disorder or schizophrenia;	chr6:28416065	chr6:28315613~28315883:-
BRCA	cis	rs950169	0.58	rs2271431	ENSG00000275120.1	RP11-182J1.17	4.43	1.03e-05	0.000844	0.18	0.14	Schizophrenia;	chr15:84646233	chr15:84599434~84606463:-
BRCA	cis	rs17597773	0.638	rs7530176	ENSG00000238078.1	LINC01352	-4.43	1.03e-05	0.000844	-0.15	-0.14	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220816040	chr1:220829255~220832429:+
BRCA	cis	rs926392	0.965	rs6129166	ENSG00000274825.1	RP4-616B8.5	-4.43	1.03e-05	0.000844	-0.13	-0.14	Dialysis-related mortality;	chr20:39060182	chr20:38955910~38956547:+
BRCA	cis	rs1371614	0.502	rs4572551	ENSG00000229122.1	AGBL5-IT1	4.43	1.03e-05	0.000845	0.14	0.14	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26971145	chr2:27061038~27061815:+
BRCA	cis	rs13113518	1	rs11934897	ENSG00000272969.1	RP11-528I4.2	4.43	1.03e-05	0.000845	0.16	0.14	Height;	chr4:55553396	chr4:55547112~55547889:+
BRCA	cis	rs13113518	0.934	rs11932293	ENSG00000272969.1	RP11-528I4.2	4.43	1.03e-05	0.000845	0.16	0.14	Height;	chr4:55554025	chr4:55547112~55547889:+
BRCA	cis	rs1005277	0.579	rs2504148	ENSG00000099251.13	HSD17B7P2	4.43	1.03e-05	0.000845	0.15	0.14	Extrinsic epigenetic age acceleration;	chr10:38111860	chr10:38356380~38378505:+
BRCA	cis	rs2273156	1	rs17102923	ENSG00000226677.3	IGBP1P1	-4.43	1.03e-05	0.000845	-0.2	-0.14	Immunoglobulin light chain (AL) amyloidosis;	chr14:34980633	chr14:34939324~34940332:+
BRCA	cis	rs718433	0.584	rs10133988	ENSG00000256379.1	TRAV8-5	4.43	1.03e-05	0.000845	0.15	0.14	Intraocular pressure;	chr14:21746376	chr14:21903077~21903598:+
BRCA	cis	rs11250098	0.574	rs4240672	ENSG00000154316.13	TDH	4.43	1.03e-05	0.000845	0.17	0.14	Morning vs. evening chronotype;	chr8:10910407	chr8:11339637~11368452:+
BRCA	cis	rs11758351	0.66	rs113208674	ENSG00000241549.7	GUSBP2	-4.43	1.03e-05	0.000846	-0.2	-0.14	Renal underexcretion gout;Gout;	chr6:26210237	chr6:26871484~26956554:-
BRCA	cis	rs11758351	0.66	rs77130538	ENSG00000241549.7	GUSBP2	-4.43	1.03e-05	0.000846	-0.2	-0.14	Renal underexcretion gout;Gout;	chr6:26210495	chr6:26871484~26956554:-
BRCA	cis	rs6831352	0.734	rs12502237	ENSG00000272777.1	RP11-571L19.8	-4.43	1.03e-05	0.000846	-0.15	-0.14	Alcohol dependence;	chr4:99094524	chr4:99067256~99068125:-
BRCA	cis	rs11083475	1	rs62121818	ENSG00000267892.1	CTD-2540F13.2	4.43	1.03e-05	0.000846	0.15	0.14	Heart rate;	chr19:38677120	chr19:38738284~38739863:+
BRCA	cis	rs2625529	0.617	rs3784313	ENSG00000260037.4	CTD-2524L6.3	4.43	1.04e-05	0.000846	0.17	0.14	Red blood cell count;	chr15:71895178	chr15:71818396~71823384:+
BRCA	cis	rs600550	0.926	rs633463	ENSG00000275344.1	MIR6503	4.43	1.04e-05	0.000846	0.14	0.14	Lipoprotein-associated phospholipase A2 activity and mass;	chr11:60237700	chr11:60209071~60209156:-
BRCA	cis	rs7726839	0.794	rs11739663	ENSG00000225138.6	CTD-2228K2.7	4.43	1.04e-05	0.000846	0.17	0.14	Obesity-related traits;	chr5:593968	chr5:473236~480884:+
BRCA	cis	rs7267979	0.966	rs6083818	ENSG00000274973.1	RP13-401N8.7	4.43	1.04e-05	0.000846	0.16	0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25365446	chr20:25845497~25845862:+
BRCA	cis	rs7267979	1	rs4815409	ENSG00000274973.1	RP13-401N8.7	4.43	1.04e-05	0.000846	0.16	0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25366061	chr20:25845497~25845862:+
BRCA	cis	rs10958369	0.613	rs7829521	ENSG00000260484.1	RP11-1081M5.2	4.43	1.04e-05	0.000847	0.17	0.14	Response to antineoplastic agents;	chr8:53521328	chr8:53388701~53390872:-
BRCA	cis	rs1867631	0.585	rs4655642	ENSG00000248458.2	RP4-598P13.1	4.43	1.04e-05	0.000847	0.14	0.14	Menopause (age at onset);	chr1:66624400	chr1:66665864~66677027:-
BRCA	cis	rs11098499	0.71	rs4145952	ENSG00000260404.2	RP11-384K6.6	4.43	1.04e-05	0.000847	0.12	0.14	Corneal astigmatism;	chr4:119234651	chr4:118591773~118633729:+
BRCA	cis	rs4761470	0.577	rs7302972	ENSG00000258365.1	RP11-1105G2.3	-4.43	1.04e-05	0.000847	-0.18	-0.14	Estradiol plasma levels (breast cancer);	chr12:94288831	chr12:94277758~94282844:-
BRCA	cis	rs4143844	0.867	rs11629559	ENSG00000259251.2	RP11-643M14.1	4.43	1.04e-05	0.000847	0.34	0.14	Bipolar disorder and schizophrenia;	chr15:61871348	chr15:62060503~62062434:+
BRCA	cis	rs4143844	0.867	rs17303887	ENSG00000259251.2	RP11-643M14.1	4.43	1.04e-05	0.000847	0.34	0.14	Bipolar disorder and schizophrenia;	chr15:61873354	chr15:62060503~62062434:+
BRCA	cis	rs568617	0.626	rs10896050	ENSG00000254510.1	RP11-867G23.10	4.43	1.04e-05	0.000847	0.18	0.14	Crohn's disease;	chr11:65810045	chr11:66409158~66417137:+
BRCA	cis	rs7789940	1	rs11765693	ENSG00000280388.1	RP11-229D13.3	-4.43	1.04e-05	0.000847	-0.15	-0.14	Multiple sclerosis;	chr7:76356056	chr7:76043977~76045963:-
BRCA	cis	rs7789940	1	rs73140069	ENSG00000280388.1	RP11-229D13.3	-4.43	1.04e-05	0.000847	-0.15	-0.14	Multiple sclerosis;	chr7:76357473	chr7:76043977~76045963:-
BRCA	cis	rs8048589	0.66	rs11075054	ENSG00000175604.2	RP11-276H1.3	-4.43	1.04e-05	0.000848	-0.24	-0.14	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);	chr16:12122438	chr16:12086746~12090302:-
BRCA	cis	rs4934494	0.677	rs1409360	ENSG00000240996.1	RP11-80H5.7	-4.43	1.04e-05	0.000848	-0.18	-0.14	Red blood cell count;	chr10:89625547	chr10:89694295~89697928:-
BRCA	cis	rs2688608	0.934	rs2675679	ENSG00000271816.1	BMS1P4	4.43	1.04e-05	0.000848	0.13	0.14	Inflammatory bowel disease;	chr10:73898823	chr10:73699151~73730487:-
BRCA	cis	rs4831837	0.69	rs4831835	ENSG00000270074.1	RP11-351I21.11	4.43	1.04e-05	0.000848	0.17	0.14	Morbidity-free survival;	chr8:12830100	chr8:12412827~12414373:+
BRCA	cis	rs2243480	1	rs56016656	ENSG00000222364.1	RNU6-96P	-4.43	1.04e-05	0.000848	-0.25	-0.14	Diabetic kidney disease;	chr7:65918494	chr7:66395191~66395286:+
BRCA	cis	rs2243480	1	rs56291018	ENSG00000222364.1	RNU6-96P	-4.43	1.04e-05	0.000848	-0.25	-0.14	Diabetic kidney disease;	chr7:65925352	chr7:66395191~66395286:+
BRCA	cis	rs2243480	1	rs36033484	ENSG00000222364.1	RNU6-96P	-4.43	1.04e-05	0.000848	-0.25	-0.14	Diabetic kidney disease;	chr7:65925571	chr7:66395191~66395286:+
BRCA	cis	rs6545883	0.895	rs4430924	ENSG00000270820.4	RP11-355B11.2	4.43	1.04e-05	0.000848	0.16	0.14	Tuberculosis;	chr2:61476721	chr2:61471188~61484130:+
BRCA	cis	rs17684571	0.751	rs17684941	ENSG00000231441.1	RP11-472M19.2	-4.43	1.04e-05	0.000848	-0.23	-0.14	Schizophrenia;	chr6:56862636	chr6:56844002~56864078:+
BRCA	cis	rs11671005	0.779	rs55875034	ENSG00000269600.1	AC016629.3	-4.43	1.04e-05	0.000849	-0.22	-0.14	Mean platelet volume;	chr19:58472191	chr19:58593896~58599355:-
BRCA	cis	rs11098499	0.754	rs7672372	ENSG00000225892.3	RP11-384K6.2	4.43	1.04e-05	0.000849	0.13	0.14	Corneal astigmatism;	chr4:119327251	chr4:118632274~118634759:+
BRCA	cis	rs7727544	0.582	rs3749756	ENSG00000233006.5	AC034220.3	4.43	1.04e-05	0.000849	0.1	0.14	Blood metabolite levels;	chr5:132198806	chr5:132311285~132369916:-
BRCA	cis	rs3796352	1	rs13072395	ENSG00000242142.1	SERBP1P3	-4.43	1.04e-05	0.000849	-0.28	-0.14	Immune reponse to smallpox (secreted IL-2);	chr3:52946557	chr3:53064283~53065091:-
BRCA	cis	rs62025270	0.747	rs12324721	ENSG00000202081.1	RNU6-1280P	-4.43	1.04e-05	0.000849	-0.2	-0.14	Idiopathic pulmonary fibrosis;	chr15:85767741	chr15:85651522~85651628:-
BRCA	cis	rs7572733	0.522	rs11679484	ENSG00000231621.1	AC013264.2	4.43	1.04e-05	0.000849	0.13	0.14	Dermatomyositis;	chr2:198056880	chr2:197197991~197199273:+
BRCA	cis	rs13113518	0.966	rs12647677	ENSG00000272969.1	RP11-528I4.2	4.43	1.04e-05	0.000849	0.16	0.14	Height;	chr4:55444253	chr4:55547112~55547889:+
BRCA	cis	rs13113518	0.902	rs3805150	ENSG00000272969.1	RP11-528I4.2	4.43	1.04e-05	0.000849	0.16	0.14	Height;	chr4:55446869	chr4:55547112~55547889:+
BRCA	cis	rs13113518	1	rs4864990	ENSG00000272969.1	RP11-528I4.2	4.43	1.04e-05	0.000849	0.16	0.14	Height;	chr4:55447523	chr4:55547112~55547889:+
BRCA	cis	rs7182948	1	rs1605480	ENSG00000259531.2	RP11-295H24.3	-4.43	1.04e-05	0.000849	-0.19	-0.14	Lung adenocarcinoma;	chr15:49526646	chr15:49365124~49366685:-
BRCA	cis	rs7182948	1	rs1546425	ENSG00000259531.2	RP11-295H24.3	-4.43	1.04e-05	0.000849	-0.19	-0.14	Lung adenocarcinoma;	chr15:49531152	chr15:49365124~49366685:-
BRCA	cis	rs73201462	1	rs11715394	ENSG00000242551.2	POU5F1P6	4.43	1.04e-05	0.00085	0.25	0.14	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128174721	chr3:128674735~128677005:-
BRCA	cis	rs17597773	0.638	rs6668666	ENSG00000257551.1	HLX-AS1	-4.43	1.04e-05	0.00085	-0.16	-0.14	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220826069	chr1:220832763~220880140:-
BRCA	cis	rs8180040	0.764	rs4682852	ENSG00000276925.1	RP11-708J19.3	-4.43	1.04e-05	0.00085	-0.15	-0.14	Colorectal cancer;	chr3:47136282	chr3:47469777~47469987:+
BRCA	cis	rs5758659	0.714	rs2284087	ENSG00000227370.1	RP4-669P10.19	4.43	1.04e-05	0.00085	0.14	0.14	Cognitive function;	chr22:42089667	chr22:42132543~42132998:+
BRCA	cis	rs934734	0.532	rs62141075	ENSG00000204929.10	AC074391.1	-4.43	1.04e-05	0.00085	-0.17	-0.14	Rheumatoid arthritis;	chr2:65417482	chr2:65436711~66084639:+
BRCA	cis	rs6964587	1	rs6960867	ENSG00000188693.7	CYP51A1-AS1	-4.43	1.04e-05	0.00085	-0.15	-0.14	Breast cancer;	chr7:92083384	chr7:92134604~92180725:+
BRCA	cis	rs2243480	1	rs34560516	ENSG00000222364.1	RNU6-96P	-4.43	1.04e-05	0.00085	-0.25	-0.14	Diabetic kidney disease;	chr7:65939105	chr7:66395191~66395286:+
BRCA	cis	rs4650994	1	rs4650999	ENSG00000273384.1	RP5-1098D14.1	-4.43	1.04e-05	0.00085	-0.16	-0.14	HDL cholesterol;HDL cholesterol levels;	chr1:178563053	chr1:178651706~178652282:+
BRCA	cis	rs12705849	0.797	rs13230450	ENSG00000214194.7	LINC00998	-4.43	1.04e-05	0.00085	-0.17	-0.14	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Eosinophil counts;	chr7:113114849	chr7:113116718~113118613:-
BRCA	cis	rs5758511	0.689	rs17478227	ENSG00000227370.1	RP4-669P10.19	-4.43	1.04e-05	0.00085	-0.21	-0.14	Birth weight;	chr22:42258321	chr22:42132543~42132998:+
BRCA	cis	rs2832191	0.633	rs2832166	ENSG00000232855.5	AF131217.1	-4.43	1.04e-05	0.00085	-0.17	-0.14	Dental caries;	chr21:29090074	chr21:28439346~28674848:-
BRCA	cis	rs7577599	0.756	rs7583617	ENSG00000224220.1	AC104699.1	4.43	1.04e-05	0.00085	0.11	0.14	Multiple myeloma (IgH translocation);Multiple myeloma;	chr2:25402990	chr2:25421117~25427643:+
BRCA	cis	rs1910358	0.621	rs6891863	ENSG00000248874.4	C5orf17	-4.43	1.04e-05	0.000851	-0.2	-0.14	Venous thromboembolism (SNP x SNP interaction);	chr5:23852557	chr5:23951348~24178263:+
BRCA	cis	rs7927592	0.956	rs12274114	ENSG00000212093.1	AP000807.1	4.43	1.04e-05	0.000851	0.15	0.14	Total body bone mineral density;	chr11:68488109	chr11:68506083~68506166:-
BRCA	cis	rs7927592	0.913	rs12294029	ENSG00000212093.1	AP000807.1	4.43	1.04e-05	0.000851	0.15	0.14	Total body bone mineral density;	chr11:68489591	chr11:68506083~68506166:-
BRCA	cis	rs35306767	0.953	rs12259801	ENSG00000229869.1	RP11-363N22.2	-4.43	1.04e-05	0.000851	-0.2	-0.14	Eosinophil percentage of granulocytes;	chr10:913366	chr10:933026~942743:+
BRCA	cis	rs6500395	1	rs9924078	ENSG00000260052.1	CTC-527H23.3	-4.43	1.04e-05	0.000851	-0.17	-0.14	Response to tocilizumab in rheumatoid arthritis;	chr16:48524007	chr16:48637143~48638719:+
BRCA	cis	rs3824867	0.92	rs3740685	ENSG00000280615.1	Y_RNA	-4.43	1.04e-05	0.000851	-0.17	-0.14	Mean corpuscular hemoglobin;	chr11:47447239	chr11:47614898~47614994:-
BRCA	cis	rs926392	0.932	rs6513589	ENSG00000274825.1	RP4-616B8.5	-4.43	1.04e-05	0.000851	-0.13	-0.14	Dialysis-related mortality;	chr20:39057942	chr20:38955910~38956547:+
BRCA	cis	rs6012564	1	rs3091497	ENSG00000227431.4	CSE1L-AS1	-4.43	1.04e-05	0.000851	-0.17	-0.14	Anger;	chr20:49028890	chr20:49040463~49046044:-
BRCA	cis	rs10833905	0.775	rs10833889	ENSG00000246225.5	RP11-17A1.3	-4.43	1.04e-05	0.000852	-0.19	-0.14	Sudden cardiac arrest;	chr11:23001805	chr11:22829380~22945393:+
BRCA	cis	rs2731006	0.591	rs981248	ENSG00000257114.2	RP11-25I15.3	4.43	1.04e-05	0.000852	0.22	0.14	Panic disorder;	chr12:42779811	chr12:42692216~42717119:+
BRCA	cis	rs2731006	0.64	rs1517671	ENSG00000257114.2	RP11-25I15.3	4.43	1.04e-05	0.000852	0.22	0.14	Panic disorder;	chr12:42780186	chr12:42692216~42717119:+
BRCA	cis	rs860295	0.702	rs11264380	ENSG00000225855.5	RUSC1-AS1	4.43	1.04e-05	0.000852	0.11	0.14	Body mass index;	chr1:155550353	chr1:155316863~155324176:-
BRCA	cis	rs11614913	0.509	rs12300425	ENSG00000250451.4	HOXC-AS1	-4.43	1.04e-05	0.000852	-0.15	-0.14	Waist circumference adjusted for body mass index;	chr12:54001298	chr12:53999022~54000010:-
BRCA	cis	rs875971	0.522	rs1968127	ENSG00000273142.1	RP11-458F8.4	4.43	1.04e-05	0.000852	0.12	0.14	Aortic root size;	chr7:66591816	chr7:66902857~66906297:+
BRCA	cis	rs2276314	0.512	rs9951125	ENSG00000278986.1	RP11-723J4.3	-4.43	1.04e-05	0.000852	-0.16	-0.14	Endometriosis;Drug-induced torsades de pointes;	chr18:35872841	chr18:35972151~35973916:+
BRCA	cis	rs10992797	0.509	rs10992796	ENSG00000227603.1	RP11-165J3.6	-4.43	1.04e-05	0.000852	-0.15	-0.14	Intelligence (multi-trait analysis);	chr9:93598623	chr9:93435332~93437121:-
BRCA	cis	rs13113518	1	rs7662966	ENSG00000272969.1	RP11-528I4.2	4.43	1.04e-05	0.000852	0.16	0.14	Height;	chr4:55548261	chr4:55547112~55547889:+
BRCA	cis	rs12612619	0.732	rs11681562	ENSG00000272148.1	RP11-195B17.1	4.43	1.04e-05	0.000852	0.15	0.14	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27027735	chr2:27062428~27062907:-
BRCA	cis	rs72799341	0.706	rs59735493	ENSG00000279196.1	RP11-1072A3.3	4.43	1.04e-05	0.000852	0.15	0.14	Diastolic blood pressure;	chr16:31121779	chr16:30984630~30988270:-
BRCA	cis	rs6088580	0.634	rs6059880	ENSG00000276073.1	RP5-1125A11.7	-4.43	1.04e-05	0.000852	-0.15	-0.14	Glomerular filtration rate (creatinine);	chr20:34500864	chr20:33985617~33988989:-
BRCA	cis	rs9425766	0.64	rs1322774	ENSG00000227373.4	RP11-160H22.5	4.43	1.04e-05	0.000853	0.2	0.14	Life satisfaction;	chr1:173870102	chr1:174115300~174160004:-
BRCA	cis	rs6893300	0.785	rs11738720	ENSG00000225051.5	HMGB3P22	4.43	1.04e-05	0.000853	0.17	0.14	Resting heart rate;	chr5:179727997	chr5:179679032~179694768:+
BRCA	cis	rs61931739	0.534	rs10844767	ENSG00000258794.3	DUX4L27	4.43	1.05e-05	0.000853	0.2	0.14	Morning vs. evening chronotype;	chr12:33999433	chr12:34208415~34209675:-
BRCA	cis	rs8103278	1	rs36091860	ENSG00000267395.4	AC074212.6	4.43	1.05e-05	0.000853	0.14	0.14	Coronary artery disease;	chr19:45809622	chr19:45767796~45772504:+
BRCA	cis	rs17428076	0.709	rs55791993	ENSG00000228389.1	AC068039.4	-4.43	1.05e-05	0.000853	-0.2	-0.14	Myopia;	chr2:172046984	chr2:171773482~171775844:+
BRCA	cis	rs10510102	0.872	rs7906462	ENSG00000226864.1	ATE1-AS1	4.43	1.05e-05	0.000853	0.24	0.14	Breast cancer;	chr10:121948098	chr10:121928312~121951965:+
BRCA	cis	rs10129255	0.957	rs10137980	ENSG00000280411.1	IGHV1-69-2	-4.43	1.05e-05	0.000853	-0.1	-0.14	Kawasaki disease;	chr14:106775735	chr14:106762092~106762588:-
BRCA	cis	rs1008375	1	rs56974987	ENSG00000249502.1	AC006160.5	-4.43	1.05e-05	0.000853	-0.16	-0.14	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17626233	chr4:17587467~17614571:-
BRCA	cis	rs13326165	0.531	rs73088791	ENSG00000243224.1	RP5-1157M23.2	-4.43	1.05e-05	0.000854	-0.23	-0.14	HDL cholesterol levels;HDL cholesterol;	chr3:52284265	chr3:52239258~52241097:+
BRCA	cis	rs78487399	0.71	rs72881068	ENSG00000234936.1	AC010883.5	4.43	1.05e-05	0.000854	0.19	0.14	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43463721	chr2:43229573~43233394:+
BRCA	cis	rs295490	0.831	rs57707457	ENSG00000272656.1	RP11-219D15.3	4.43	1.05e-05	0.000854	0.3	0.14	PR interval in Tripanosoma cruzi seropositivity;	chr3:139520256	chr3:139349024~139349371:-
BRCA	cis	rs4908760	0.613	rs2401189	ENSG00000232912.4	RP5-1115A15.1	4.43	1.05e-05	0.000854	0.13	0.14	Vitiligo;	chr1:8758541	chr1:8424645~8434838:+
BRCA	cis	rs7577696	0.649	rs56208031	ENSG00000272716.1	RP11-563N4.1	4.43	1.05e-05	0.000854	0.15	0.14	Inflammatory biomarkers;	chr2:32120494	chr2:32165046~32165757:-
BRCA	cis	rs4415084	0.8	rs994793	ENSG00000251141.4	RP11-53O19.1	4.43	1.05e-05	0.000854	0.12	0.14	Breast cancer;	chr5:44743145	chr5:44744900~44808777:-
BRCA	cis	rs56322409	0.897	rs3176884	ENSG00000226688.5	ENTPD1-AS1	4.43	1.05e-05	0.000854	0.16	0.14	Blood metabolite levels;	chr10:95844894	chr10:95753206~96090238:-
BRCA	cis	rs160451	0.782	rs160410	ENSG00000251136.7	RP11-37B2.1	-4.43	1.05e-05	0.000854	-0.14	-0.14	Leprosy;	chr8:89636500	chr8:89609409~89757727:-
BRCA	cis	rs11098499	0.505	rs75122014	ENSG00000250412.1	KLHL2P1	4.43	1.05e-05	0.000854	0.16	0.14	Corneal astigmatism;	chr4:119441271	chr4:119334329~119378233:+
BRCA	cis	rs1910358	0.614	rs7702668	ENSG00000248874.4	C5orf17	-4.43	1.05e-05	0.000855	-0.18	-0.14	Venous thromboembolism (SNP x SNP interaction);	chr5:23975226	chr5:23951348~24178263:+
BRCA	cis	rs7160336	0.875	rs12880122	ENSG00000259065.1	RP5-1021I20.1	4.43	1.05e-05	0.000855	0.15	0.14	Blood protein levels;	chr14:74080051	chr14:73787360~73803270:+
BRCA	cis	rs7160336	0.967	rs4646858	ENSG00000259065.1	RP5-1021I20.1	4.43	1.05e-05	0.000855	0.15	0.14	Blood protein levels;	chr14:74081644	chr14:73787360~73803270:+
BRCA	cis	rs6723226	0.708	rs2754513	ENSG00000276334.1	AL133243.1	4.43	1.05e-05	0.000855	0.17	0.14	Intelligence (multi-trait analysis);	chr2:32557696	chr2:32521927~32523547:+
BRCA	cis	rs600550	0.963	rs657928	ENSG00000275344.1	MIR6503	4.43	1.05e-05	0.000855	0.14	0.14	Lipoprotein-associated phospholipase A2 activity and mass;	chr11:60221433	chr11:60209071~60209156:-
BRCA	cis	rs71520386	0.607	rs11767419	ENSG00000226329.2	AC005682.6	-4.43	1.05e-05	0.000855	-0.14	-0.14	Fibrinogen levels;	chr7:22839364	chr7:22863874~22881350:-
BRCA	cis	rs7811142	0.943	rs67196635	ENSG00000078319.8	PMS2P1	-4.43	1.05e-05	0.000855	-0.21	-0.14	Platelet count;	chr7:100427941	chr7:100320992~100341908:-
BRCA	cis	rs7811142	1	rs6962151	ENSG00000078319.8	PMS2P1	-4.43	1.05e-05	0.000855	-0.21	-0.14	Platelet count;	chr7:100430861	chr7:100320992~100341908:-
BRCA	cis	rs57221529	0.709	rs72706611	ENSG00000225138.6	CTD-2228K2.7	4.43	1.05e-05	0.000856	0.2	0.14	Lung disease severity in cystic fibrosis;	chr5:561031	chr5:473236~480884:+
BRCA	cis	rs57221529	0.709	rs72706612	ENSG00000225138.6	CTD-2228K2.7	4.43	1.05e-05	0.000856	0.2	0.14	Lung disease severity in cystic fibrosis;	chr5:561083	chr5:473236~480884:+
BRCA	cis	rs6600671	1	rs1832558	ENSG00000231429.2	RP11-343N15.2	-4.43	1.05e-05	0.000856	-0.16	-0.14	Hip geometry;	chr1:121435521	chr1:121412719~121429274:+
BRCA	cis	rs6600671	0.967	rs11249349	ENSG00000231429.2	RP11-343N15.2	-4.43	1.05e-05	0.000856	-0.16	-0.14	Hip geometry;	chr1:121437310	chr1:121412719~121429274:+
BRCA	cis	rs7260598	0.685	rs67534545	ENSG00000268442.1	CTD-2027I19.2	4.43	1.05e-05	0.000856	0.21	0.14	Response to taxane treatment (placlitaxel);	chr19:23927339	chr19:24162370~24163425:-
BRCA	cis	rs7260598	0.642	rs28537609	ENSG00000268442.1	CTD-2027I19.2	4.43	1.05e-05	0.000856	0.21	0.14	Response to taxane treatment (placlitaxel);	chr19:23928662	chr19:24162370~24163425:-
BRCA	cis	rs7772486	0.79	rs2254257	ENSG00000270638.1	RP3-466P17.1	4.43	1.05e-05	0.000857	0.16	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145882588	chr6:145735570~145737218:+
BRCA	cis	rs61160187	0.698	rs12517174	ENSG00000272308.1	RP11-231G3.1	4.43	1.05e-05	0.000857	0.15	0.14	Educational attainment (years of education);Educational attainment (college completion);	chr5:60673188	chr5:60866457~60866935:-
BRCA	cis	rs1005277	0.529	rs1780125	ENSG00000099251.13	HSD17B7P2	4.43	1.05e-05	0.000857	0.15	0.14	Extrinsic epigenetic age acceleration;	chr10:38242448	chr10:38356380~38378505:+
BRCA	cis	rs10129255	0.912	rs67410411	ENSG00000274576.2	IGHV2-70	4.43	1.05e-05	0.000857	0.12	0.14	Kawasaki disease;	chr14:106680324	chr14:106770577~106771020:-
BRCA	cis	rs6545883	0.794	rs778152	ENSG00000270820.4	RP11-355B11.2	-4.43	1.05e-05	0.000857	-0.16	-0.14	Tuberculosis;	chr2:61381405	chr2:61471188~61484130:+
BRCA	cis	rs6847067	0.8	rs2046404	ENSG00000180769.7	WDFY3-AS2	4.43	1.05e-05	0.000857	0.12	0.14	Oropharynx cancer;	chr4:84886601	chr4:84965682~85011277:+
BRCA	cis	rs13326165	0.585	rs73088783	ENSG00000243224.1	RP5-1157M23.2	-4.43	1.05e-05	0.000858	-0.22	-0.14	HDL cholesterol levels;HDL cholesterol;	chr3:52271270	chr3:52239258~52241097:+
BRCA	cis	rs7182948	1	rs1546424	ENSG00000259531.2	RP11-295H24.3	-4.43	1.05e-05	0.000858	-0.19	-0.14	Lung adenocarcinoma;	chr15:49531030	chr15:49365124~49366685:-
BRCA	cis	rs2708977	0.665	rs1081717	ENSG00000237510.6	AC008268.2	-4.43	1.05e-05	0.000858	-0.21	-0.14	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96312579	chr2:95789654~95800166:+
BRCA	cis	rs67766926	0.953	rs6545836	ENSG00000271889.1	RP11-493E12.1	-4.43	1.05e-05	0.000858	-0.2	-0.14	Inflammatory skin disease;	chr2:60895838	chr2:61151433~61162105:-
BRCA	cis	rs7811142	0.943	rs67483801	ENSG00000078319.8	PMS2P1	-4.43	1.05e-05	0.000858	-0.21	-0.14	Platelet count;	chr7:100434135	chr7:100320992~100341908:-
BRCA	cis	rs7811142	1	rs11761784	ENSG00000078319.8	PMS2P1	-4.43	1.05e-05	0.000858	-0.21	-0.14	Platelet count;	chr7:100442347	chr7:100320992~100341908:-
BRCA	cis	rs9393777	0.92	rs34953377	ENSG00000216901.1	AL022393.7	4.43	1.05e-05	0.000858	0.32	0.14	Intelligence (multi-trait analysis);	chr6:27413881	chr6:28176188~28176674:+
BRCA	cis	rs9393777	0.778	rs66841633	ENSG00000216901.1	AL022393.7	4.43	1.05e-05	0.000858	0.32	0.14	Intelligence (multi-trait analysis);	chr6:27414607	chr6:28176188~28176674:+
BRCA	cis	rs853679	1	rs1679709	ENSG00000204709.4	LINC01556	-4.43	1.05e-05	0.000858	-0.24	-0.14	Depression;	chr6:28260564	chr6:28943877~28944537:+
BRCA	cis	rs11603691	1	rs61888887	ENSG00000254662.1	RP11-872D17.4	-4.43	1.05e-05	0.000858	-0.3	-0.14	Low high density lipoprotein cholesterol levels;	chr11:57331577	chr11:57325603~57327958:+
BRCA	cis	rs7178909	0.835	rs8035374	ENSG00000259677.1	RP11-493E3.1	4.43	1.05e-05	0.000859	0.16	0.14	Common traits (Other);	chr15:89851966	chr15:89876540~89877285:+
BRCA	cis	rs7789940	0.951	rs7779014	ENSG00000280388.1	RP11-229D13.3	-4.43	1.05e-05	0.000859	-0.15	-0.14	Multiple sclerosis;	chr7:76346269	chr7:76043977~76045963:-
BRCA	cis	rs67766926	0.953	rs12713428	ENSG00000271889.1	RP11-493E12.1	4.43	1.05e-05	0.000859	0.2	0.14	Inflammatory skin disease;	chr2:60890978	chr2:61151433~61162105:-
BRCA	cis	rs4964805	0.507	rs4964786	ENSG00000257681.1	RP11-341G23.4	4.43	1.05e-05	0.000859	0.15	0.14	Attention deficit hyperactivity disorder;	chr12:103810805	chr12:103746315~103768858:-
BRCA	cis	rs1005277	0.579	rs2474594	ENSG00000099251.13	HSD17B7P2	4.43	1.05e-05	0.000859	0.15	0.14	Extrinsic epigenetic age acceleration;	chr10:38137733	chr10:38356380~38378505:+
BRCA	cis	rs1005277	0.579	rs11011461	ENSG00000099251.13	HSD17B7P2	4.43	1.05e-05	0.000859	0.15	0.14	Extrinsic epigenetic age acceleration;	chr10:38142499	chr10:38356380~38378505:+
BRCA	cis	rs35306767	0.953	rs12354639	ENSG00000229869.1	RP11-363N22.2	-4.43	1.05e-05	0.000859	-0.2	-0.14	Eosinophil percentage of granulocytes;	chr10:917741	chr10:933026~942743:+
BRCA	cis	rs6968419	0.714	rs17138472	ENSG00000279086.1	RP11-667F14.1	-4.43	1.05e-05	0.00086	-0.15	-0.14	Intraocular pressure;	chr7:116252684	chr7:116209234~116211511:-
BRCA	cis	rs6968419	0.747	rs3779509	ENSG00000279086.1	RP11-667F14.1	-4.43	1.05e-05	0.00086	-0.15	-0.14	Intraocular pressure;	chr7:116224835	chr7:116209234~116211511:-
BRCA	cis	rs893971	0.535	rs4693947	ENSG00000246375.2	RP11-10L7.1	4.43	1.05e-05	0.00086	0.17	0.14	Conduct disorder (maternal expressed emotions interaction);	chr4:88310252	chr4:88284942~88331421:+
BRCA	cis	rs7312933	0.558	rs1796381	ENSG00000257225.1	RP11-328C8.4	-4.43	1.05e-05	0.00086	-0.16	-0.14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42448673	chr12:42459366~42466128:+
BRCA	cis	rs9840812	0.655	rs4452981	ENSG00000273486.1	RP11-731C17.2	4.43	1.05e-05	0.00086	0.17	0.14	Fibrinogen levels;	chr3:136588925	chr3:136837338~136839021:-
BRCA	cis	rs6128907	1	rs6124014	ENSG00000224635.1	RP4-564F22.5	4.43	1.05e-05	0.00086	0.21	0.14	Liver fibrosis in pediatric non-alcoholic fatty acid liver disease;	chr20:38763855	chr20:38406011~38416797:-
BRCA	cis	rs2073316	0.527	rs12468955	ENSG00000272716.1	RP11-563N4.1	4.43	1.05e-05	0.00086	0.15	0.14	Interleukin-18 levels;	chr2:31444387	chr2:32165046~32165757:-
BRCA	cis	rs6600671	1	rs1856572	ENSG00000231429.2	RP11-343N15.2	-4.43	1.06e-05	0.00086	-0.16	-0.14	Hip geometry;	chr1:121427719	chr1:121412719~121429274:+
BRCA	cis	rs6708331	0.646	rs12989348	ENSG00000231024.1	AC092431.3	4.43	1.06e-05	0.00086	0.26	0.14	Obesity-related traits;	chr2:70150521	chr2:69700192~69713847:-
BRCA	cis	rs2832077	0.689	rs2832055	ENSG00000232855.5	AF131217.1	-4.43	1.06e-05	0.000861	-0.18	-0.14	Cognitive test performance;	chr21:28760060	chr21:28439346~28674848:-
BRCA	cis	rs7475343	0.501	rs117292237	ENSG00000224034.1	RP11-445P17.8	-4.43	1.06e-05	0.000861	-0.25	-0.14	Intelligence;	chr10:5265566	chr10:5266033~5271236:-
BRCA	cis	rs2243480	1	rs316327	ENSG00000222364.1	RNU6-96P	4.43	1.06e-05	0.000861	0.24	0.14	Diabetic kidney disease;	chr7:66144214	chr7:66395191~66395286:+
BRCA	cis	rs10208649	0.908	rs11887593	ENSG00000272156.1	RP11-477N3.1	4.43	1.06e-05	0.000861	0.28	0.14	Body mass index;	chr2:54040638	chr2:54082554~54085066:+
BRCA	cis	rs7267979	1	rs2387880	ENSG00000277938.1	RP5-965G21.3	-4.43	1.06e-05	0.000861	-0.16	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25397151	chr20:25229150~25231933:+
BRCA	cis	rs6570726	1	rs404229	ENSG00000270638.1	RP3-466P17.1	4.43	1.06e-05	0.000861	0.15	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145547064	chr6:145735570~145737218:+
BRCA	cis	rs5758511	0.68	rs5758686	ENSG00000226450.2	CYP2D8P	4.43	1.06e-05	0.000862	0.16	0.14	Birth weight;	chr22:42259371	chr22:42149886~42155001:-
BRCA	cis	rs9952991	1	rs9952991	ENSG00000260302.1	RP11-973H7.1	-4.43	1.06e-05	0.000862	-0.22	-0.14	Inflammatory skin disease;	chr18:12780465	chr18:12774651~12775923:-
BRCA	cis	rs2905347	1	rs2905347	ENSG00000179428.2	AC073072.5	-4.43	1.06e-05	0.000862	-0.14	-0.14	Major depression and alcohol dependence;	chr7:22580700	chr7:22725395~22727620:-
BRCA	cis	rs4218	0.597	rs4775114	ENSG00000259732.1	RP11-59H7.3	-4.43	1.06e-05	0.000862	-0.17	-0.14	Social communication problems;	chr15:59059635	chr15:59121034~59133250:+
BRCA	cis	rs7811142	1	rs1073	ENSG00000078319.8	PMS2P1	-4.43	1.06e-05	0.000863	-0.22	-0.14	Platelet count;	chr7:100433989	chr7:100320992~100341908:-
BRCA	cis	rs10504130	1	rs75221577	ENSG00000272024.1	RP11-546K22.3	-4.43	1.06e-05	0.000863	-0.23	-0.14	Venous thromboembolism (SNP x SNP interaction);	chr8:51856812	chr8:51950284~51950690:+
BRCA	cis	rs10504130	1	rs74681723	ENSG00000272024.1	RP11-546K22.3	-4.43	1.06e-05	0.000863	-0.23	-0.14	Venous thromboembolism (SNP x SNP interaction);	chr8:51857932	chr8:51950284~51950690:+
BRCA	cis	rs2834288	0.5	rs881230	ENSG00000237945.6	LINC00649	4.43	1.06e-05	0.000863	0.16	0.14	Gut microbiota (bacterial taxa);	chr21:33950521	chr21:33915534~33977691:+
BRCA	cis	rs1910358	0.614	rs7714758	ENSG00000248874.4	C5orf17	-4.43	1.06e-05	0.000863	-0.18	-0.14	Venous thromboembolism (SNP x SNP interaction);	chr5:23980922	chr5:23951348~24178263:+
BRCA	cis	rs1910358	0.569	rs6861265	ENSG00000248874.4	C5orf17	-4.43	1.06e-05	0.000863	-0.18	-0.14	Venous thromboembolism (SNP x SNP interaction);	chr5:23984586	chr5:23951348~24178263:+
BRCA	cis	rs1910358	0.614	rs6861270	ENSG00000248874.4	C5orf17	-4.43	1.06e-05	0.000863	-0.18	-0.14	Venous thromboembolism (SNP x SNP interaction);	chr5:23984593	chr5:23951348~24178263:+
BRCA	cis	rs6430538	0.646	rs11887093	ENSG00000224043.6	CCNT2-AS1	-4.43	1.06e-05	0.000863	-0.19	-0.14	Parkinson's disease;	chr2:134780848	chr2:134735464~134918710:-
BRCA	cis	rs17685	0.712	rs7785025	ENSG00000280388.1	RP11-229D13.3	4.43	1.06e-05	0.000863	0.14	0.14	Coffee consumption (cups per day);Coffee consumption;	chr7:75998783	chr7:76043977~76045963:-
BRCA	cis	rs7829975	0.623	rs10087493	ENSG00000173295.6	FAM86B3P	-4.43	1.06e-05	0.000863	-0.14	-0.14	Mood instability;	chr8:8516047	chr8:8228595~8244865:+
BRCA	cis	rs11098499	0.865	rs9994730	ENSG00000260091.1	RP11-33B1.4	-4.43	1.06e-05	0.000863	-0.12	-0.14	Corneal astigmatism;	chr4:119460409	chr4:119409333~119410233:+
BRCA	cis	rs13108904	0.901	rs1316393	ENSG00000253399.1	AC078852.2	4.43	1.06e-05	0.000863	0.16	0.14	Obesity-related traits;	chr4:1321831	chr4:1358479~1359461:+
BRCA	cis	rs4415084	0.652	rs11747159	ENSG00000251141.4	RP11-53O19.1	4.43	1.06e-05	0.000864	0.13	0.14	Breast cancer;	chr5:44737608	chr5:44744900~44808777:-
BRCA	cis	rs11673344	0.504	rs4805202	ENSG00000276846.1	CTD-3220F14.3	4.43	1.06e-05	0.000864	0.16	0.14	Obesity-related traits;	chr19:37136499	chr19:37314868~37315620:-
BRCA	cis	rs11673344	0.504	rs4805203	ENSG00000276846.1	CTD-3220F14.3	4.43	1.06e-05	0.000864	0.16	0.14	Obesity-related traits;	chr19:37136586	chr19:37314868~37315620:-
BRCA	cis	rs1707322	0.752	rs6662164	ENSG00000234329.1	RP11-767N6.2	4.43	1.06e-05	0.000864	0.14	0.14	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45680558	chr1:45651039~45651826:-
BRCA	cis	rs1018697	0.518	rs2482506	ENSG00000236937.2	PTGES3P4	-4.43	1.06e-05	0.000864	-0.2	-0.14	Colorectal adenoma (advanced);	chr10:102803986	chr10:102845595~102845950:+
BRCA	cis	rs6095360	0.903	rs1022688	ENSG00000222365.1	SNORD12B	-4.43	1.06e-05	0.000864	-0.15	-0.14	Intelligence (multi-trait analysis);	chr20:49032319	chr20:49280319~49280409:+
BRCA	cis	rs10208649	0.611	rs7583626	ENSG00000233266.1	HMGB1P31	4.43	1.06e-05	0.000864	0.28	0.14	Body mass index;	chr2:54063635	chr2:54051334~54051760:+
BRCA	cis	rs11673344	0.504	rs7252940	ENSG00000276846.1	CTD-3220F14.3	4.43	1.06e-05	0.000864	0.16	0.14	Obesity-related traits;	chr19:37138589	chr19:37314868~37315620:-
BRCA	cis	rs6005807	0.588	rs6519751	ENSG00000272858.1	CTA-292E10.8	-4.43	1.06e-05	0.000865	-0.22	-0.14	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28449510	chr22:28814914~28815662:+
BRCA	cis	rs7011507	0.541	rs56197321	ENSG00000279881.1	RP11-513O13.1	-4.43	1.06e-05	0.000865	-0.22	-0.14	Inflammatory bowel disease;Ulcerative colitis;	chr8:48360403	chr8:48428143~48431041:-
BRCA	cis	rs11239930	0.517	rs2477569	ENSG00000278811.3	LINC00624	-4.43	1.06e-05	0.000865	-0.16	-0.14	AIDS progression;	chr1:147076261	chr1:147258885~147517875:-
BRCA	cis	rs72772090	0.522	rs75553638	ENSG00000248734.2	CTD-2260A17.1	-4.43	1.06e-05	0.000865	-0.32	-0.14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96656756	chr5:96784777~96785999:+
BRCA	cis	rs9527	0.668	rs7092815	ENSG00000213061.2	PFN1P11	4.43	1.06e-05	0.000865	0.19	0.14	Arsenic metabolism;	chr10:102976588	chr10:102838011~102845473:-
BRCA	cis	rs957448	0.561	rs1808488	ENSG00000253175.1	RP11-267M23.6	4.43	1.06e-05	0.000866	0.16	0.14	Nonsyndromic cleft lip with cleft palate;	chr8:94602636	chr8:94565036~94565715:+
BRCA	cis	rs957448	0.583	rs754275	ENSG00000253175.1	RP11-267M23.6	4.43	1.06e-05	0.000866	0.16	0.14	Nonsyndromic cleft lip with cleft palate;	chr8:94602741	chr8:94565036~94565715:+
BRCA	cis	rs957448	0.561	rs1426172	ENSG00000253175.1	RP11-267M23.6	4.43	1.06e-05	0.000866	0.16	0.14	Nonsyndromic cleft lip with cleft palate;	chr8:94602988	chr8:94565036~94565715:+
BRCA	cis	rs56322409	0.897	rs4918955	ENSG00000226688.5	ENTPD1-AS1	4.43	1.06e-05	0.000866	0.16	0.14	Blood metabolite levels;	chr10:95661517	chr10:95753206~96090238:-
BRCA	cis	rs11779988	0.545	rs438873	ENSG00000253671.1	RP11-806O11.1	-4.43	1.06e-05	0.000866	-0.2	-0.14	Breast cancer;	chr8:17929007	chr8:17808941~17820868:+
BRCA	cis	rs13098911	0.54	rs13095602	ENSG00000223552.1	RP11-24F11.2	-4.43	1.06e-05	0.000866	-0.23	-0.14	Celiac disease;	chr3:46087221	chr3:46364955~46407059:-
BRCA	cis	rs4664293	0.967	rs1346325	ENSG00000226266.5	AC009961.3	-4.43	1.06e-05	0.000866	-0.17	-0.14	Monocyte percentage of white cells;	chr2:159685995	chr2:159670708~159712435:-
BRCA	cis	rs3176789	0.671	rs3176776	ENSG00000256673.1	RP11-599J14.2	4.43	1.06e-05	0.000866	0.15	0.14	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9764225	chr12:9398355~9414851:-
BRCA	cis	rs4578769	0.681	rs72887615	ENSG00000265939.1	UBE2CP2	-4.43	1.06e-05	0.000867	-0.17	-0.14	Eosinophil percentage of white cells;	chr18:22928638	chr18:22900486~22900995:-
BRCA	cis	rs10829156	0.898	rs7923072	ENSG00000240291.1	RP11-499P20.2	4.43	1.06e-05	0.000867	0.16	0.14	Sudden cardiac arrest;	chr10:18649305	chr10:18513115~18545651:-
BRCA	cis	rs559555	0.553	rs806645	ENSG00000272716.1	RP11-563N4.1	-4.43	1.06e-05	0.000867	-0.15	-0.14	Blood metabolite ratios;Blood metabolite levels;	chr2:31582871	chr2:32165046~32165757:-
BRCA	cis	rs61160187	0.582	rs11740632	ENSG00000272308.1	RP11-231G3.1	-4.43	1.06e-05	0.000867	-0.16	-0.14	Educational attainment (years of education);Educational attainment (college completion);	chr5:60845418	chr5:60866457~60866935:-
BRCA	cis	rs4835473	0.932	rs13129702	ENSG00000249741.2	RP11-673E1.3	-4.43	1.06e-05	0.000867	-0.14	-0.14	Immature fraction of reticulocytes;	chr4:143785132	chr4:143911514~143912053:-
BRCA	cis	rs11603691	1	rs11607950	ENSG00000254662.1	RP11-872D17.4	-4.43	1.06e-05	0.000867	-0.29	-0.14	Low high density lipoprotein cholesterol levels;	chr11:57339887	chr11:57325603~57327958:+
BRCA	cis	rs7772486	0.875	rs13204280	ENSG00000270638.1	RP3-466P17.1	4.43	1.06e-05	0.000868	0.16	0.14	Lobe attachment (rater-scored or self-reported);	chr6:146094232	chr6:145735570~145737218:+
BRCA	cis	rs1153858	1	rs10519021	ENSG00000275672.1	GATM-AS1	-4.43	1.07e-05	0.000868	-0.18	-0.14	Homoarginine levels;	chr15:45339597	chr15:45378700~45380123:+
BRCA	cis	rs8030379	1	rs2401173	ENSG00000176700.18	SCAND2P	-4.43	1.07e-05	0.000868	-0.12	-0.14	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83908218	chr15:84631451~84647478:+
BRCA	cis	rs295490	0.748	rs114423015	ENSG00000272656.1	RP11-219D15.3	4.43	1.07e-05	0.000868	0.3	0.14	PR interval in Tripanosoma cruzi seropositivity;	chr3:139488980	chr3:139349024~139349371:-
BRCA	cis	rs1005277	0.579	rs176886	ENSG00000099251.13	HSD17B7P2	4.43	1.07e-05	0.000868	0.15	0.14	Extrinsic epigenetic age acceleration;	chr10:38115046	chr10:38356380~38378505:+
BRCA	cis	rs1005277	0.557	rs176887	ENSG00000099251.13	HSD17B7P2	4.43	1.07e-05	0.000868	0.15	0.14	Extrinsic epigenetic age acceleration;	chr10:38117166	chr10:38356380~38378505:+
BRCA	cis	rs2625529	0.652	rs7497104	ENSG00000260037.4	CTD-2524L6.3	-4.43	1.07e-05	0.000868	-0.17	-0.14	Red blood cell count;	chr15:71861659	chr15:71818396~71823384:+
BRCA	cis	rs853679	0.76	rs9393910	ENSG00000216901.1	AL022393.7	4.43	1.07e-05	0.000868	0.21	0.14	Depression;	chr6:28240414	chr6:28176188~28176674:+
BRCA	cis	rs2839186	0.814	rs13052376	ENSG00000239415.1	AP001469.9	4.43	1.07e-05	0.000868	0.14	0.14	Testicular germ cell tumor;	chr21:46287489	chr21:46251549~46254133:-
BRCA	cis	rs2839186	0.934	rs13046494	ENSG00000239415.1	AP001469.9	4.43	1.07e-05	0.000868	0.14	0.14	Testicular germ cell tumor;	chr21:46287516	chr21:46251549~46254133:-
BRCA	cis	rs2839186	0.872	rs13052495	ENSG00000239415.1	AP001469.9	4.43	1.07e-05	0.000868	0.14	0.14	Testicular germ cell tumor;	chr21:46287560	chr21:46251549~46254133:-
BRCA	cis	rs2880765	0.835	rs4280192	ENSG00000202081.1	RNU6-1280P	4.42	1.07e-05	0.000868	0.16	0.14	Coronary artery disease;	chr15:85499789	chr15:85651522~85651628:-
BRCA	cis	rs2115630	1	rs58581703	ENSG00000275120.1	RP11-182J1.17	-4.42	1.07e-05	0.000869	-0.16	-0.14	P wave terminal force;	chr15:84733704	chr15:84599434~84606463:-
BRCA	cis	rs792448	0.743	rs351377	ENSG00000229983.1	RP11-15I11.2	4.42	1.07e-05	0.000869	0.16	0.14	White blood cell count (basophil);	chr1:212252429	chr1:212168207~212190259:+
BRCA	cis	rs9467773	1	rs11756120	ENSG00000241549.7	GUSBP2	4.42	1.07e-05	0.000869	0.15	0.14	Intelligence (multi-trait analysis);	chr6:26529580	chr6:26871484~26956554:-
BRCA	cis	rs9467773	1	rs9393732	ENSG00000241549.7	GUSBP2	4.42	1.07e-05	0.000869	0.15	0.14	Intelligence (multi-trait analysis);	chr6:26530670	chr6:26871484~26956554:-
BRCA	cis	rs9467773	0.967	rs9358954	ENSG00000241549.7	GUSBP2	4.42	1.07e-05	0.000869	0.15	0.14	Intelligence (multi-trait analysis);	chr6:26530950	chr6:26871484~26956554:-
BRCA	cis	rs9467773	1	rs10946834	ENSG00000241549.7	GUSBP2	4.42	1.07e-05	0.000869	0.15	0.14	Intelligence (multi-trait analysis);	chr6:26533436	chr6:26871484~26956554:-
BRCA	cis	rs9467773	1	rs10946835	ENSG00000241549.7	GUSBP2	4.42	1.07e-05	0.000869	0.15	0.14	Intelligence (multi-trait analysis);	chr6:26533529	chr6:26871484~26956554:-
BRCA	cis	rs9467773	1	rs9467778	ENSG00000241549.7	GUSBP2	4.42	1.07e-05	0.000869	0.15	0.14	Intelligence (multi-trait analysis);	chr6:26534515	chr6:26871484~26956554:-
BRCA	cis	rs2839186	0.934	rs13049797	ENSG00000239415.1	AP001469.9	4.42	1.07e-05	0.000869	0.14	0.14	Testicular germ cell tumor;	chr21:46287668	chr21:46251549~46254133:-
BRCA	cis	rs2839186	0.732	rs55904887	ENSG00000239415.1	AP001469.9	4.42	1.07e-05	0.000869	0.14	0.14	Testicular germ cell tumor;	chr21:46287897	chr21:46251549~46254133:-
BRCA	cis	rs2839186	0.934	rs2839197	ENSG00000239415.1	AP001469.9	4.42	1.07e-05	0.000869	0.14	0.14	Testicular germ cell tumor;	chr21:46288219	chr21:46251549~46254133:-
BRCA	cis	rs2839186	0.868	rs2839199	ENSG00000239415.1	AP001469.9	4.42	1.07e-05	0.000869	0.14	0.14	Testicular germ cell tumor;	chr21:46288355	chr21:46251549~46254133:-
BRCA	cis	rs2839186	0.933	rs4818832	ENSG00000239415.1	AP001469.9	4.42	1.07e-05	0.000869	0.14	0.14	Testicular germ cell tumor;	chr21:46288720	chr21:46251549~46254133:-
BRCA	cis	rs2839186	0.9	rs59828751	ENSG00000239415.1	AP001469.9	4.42	1.07e-05	0.000869	0.14	0.14	Testicular germ cell tumor;	chr21:46289004	chr21:46251549~46254133:-
BRCA	cis	rs1005277	0.579	rs2474580	ENSG00000099251.13	HSD17B7P2	4.42	1.07e-05	0.000869	0.15	0.14	Extrinsic epigenetic age acceleration;	chr10:38109785	chr10:38356380~38378505:+
BRCA	cis	rs9467773	1	rs9393731	ENSG00000241549.7	GUSBP2	4.42	1.07e-05	0.000869	0.15	0.14	Intelligence (multi-trait analysis);	chr6:26529146	chr6:26871484~26956554:-
BRCA	cis	rs6921919	0.583	rs2027361	ENSG00000273712.1	RP5-874C20.7	4.42	1.07e-05	0.000869	0.18	0.14	Autism spectrum disorder or schizophrenia;	chr6:28420531	chr6:28315613~28315883:-
BRCA	cis	rs11603691	0.901	rs61888886	ENSG00000254662.1	RP11-872D17.4	-4.42	1.07e-05	0.000869	-0.3	-0.14	Low high density lipoprotein cholesterol levels;	chr11:57325698	chr11:57325603~57327958:+
BRCA	cis	rs3812049	0.784	rs7734927	ENSG00000245937.6	LINC01184	4.42	1.07e-05	0.000869	0.18	0.14	Lymphocyte counts;Red cell distribution width;	chr5:128118043	chr5:127940426~128083172:-
BRCA	cis	rs516805	0.528	rs2606632	ENSG00000279114.1	RP3-425C14.5	-4.42	1.07e-05	0.000869	-0.17	-0.14	Lymphocyte counts;	chr6:122099728	chr6:122471923~122484161:+
BRCA	cis	rs516805	0.528	rs2606634	ENSG00000279114.1	RP3-425C14.5	-4.42	1.07e-05	0.000869	-0.17	-0.14	Lymphocyte counts;	chr6:122100337	chr6:122471923~122484161:+
BRCA	cis	rs4664293	0.867	rs7565297	ENSG00000226266.5	AC009961.3	-4.42	1.07e-05	0.000869	-0.17	-0.14	Monocyte percentage of white cells;	chr2:159716008	chr2:159670708~159712435:-
BRCA	cis	rs2243480	1	rs10807702	ENSG00000228409.4	CCT6P1	4.42	1.07e-05	0.000869	0.19	0.14	Diabetic kidney disease;	chr7:66302856	chr7:65751142~65763354:+
BRCA	cis	rs11892454	0.645	rs10184492	ENSG00000217643.1	PTGES3P2	-4.42	1.07e-05	0.00087	-0.15	-0.14	Heschl's gyrus morphology;	chr2:25727642	chr2:25822469~25822950:+
BRCA	cis	rs13113518	1	rs56154935	ENSG00000272969.1	RP11-528I4.2	4.42	1.07e-05	0.00087	0.16	0.14	Height;	chr4:55546378	chr4:55547112~55547889:+
BRCA	cis	rs6840360	0.642	rs7666571	ENSG00000251603.1	RP11-164P12.4	-4.42	1.07e-05	0.00087	-0.12	-0.14	Intelligence (multi-trait analysis);	chr4:151522121	chr4:151667224~151670502:+
BRCA	cis	rs2731006	0.592	rs2255231	ENSG00000257114.2	RP11-25I15.3	-4.42	1.07e-05	0.00087	-0.22	-0.14	Panic disorder;	chr12:42775101	chr12:42692216~42717119:+
BRCA	cis	rs4578769	0.959	rs3863525	ENSG00000265939.1	UBE2CP2	4.42	1.07e-05	0.00087	0.16	0.14	Eosinophil percentage of white cells;	chr18:22898714	chr18:22900486~22900995:-
BRCA	cis	rs4578769	0.959	rs4800137	ENSG00000265939.1	UBE2CP2	4.42	1.07e-05	0.00087	0.16	0.14	Eosinophil percentage of white cells;	chr18:22899721	chr18:22900486~22900995:-
BRCA	cis	rs6997458	0.513	rs10111971	ENSG00000258256.1	RP11-219B4.5	-4.42	1.07e-05	0.00087	-0.15	-0.14	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85301078	chr8:85222446~85245717:-
BRCA	cis	rs2337406	0.539	rs2583292	ENSG00000231475.3	IGHV4-31	4.42	1.07e-05	0.00087	0.13	0.14	Alzheimer's disease (late onset);	chr14:106649040	chr14:106349283~106349792:-
BRCA	cis	rs9467773	1	rs2393670	ENSG00000241549.7	GUSBP2	4.42	1.07e-05	0.00087	0.15	0.14	Intelligence (multi-trait analysis);	chr6:26535313	chr6:26871484~26956554:-
BRCA	cis	rs7267979	0.932	rs2387891	ENSG00000274414.1	RP5-965G21.4	-4.42	1.07e-05	0.00087	-0.16	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25489692	chr20:25239007~25245229:-
BRCA	cis	rs6997458	0.598	rs10107686	ENSG00000258256.1	RP11-219B4.5	-4.42	1.07e-05	0.00087	-0.16	-0.14	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85327481	chr8:85222446~85245717:-
BRCA	cis	rs7160336	0.967	rs7150923	ENSG00000259065.1	RP5-1021I20.1	4.42	1.07e-05	0.000871	0.15	0.14	Blood protein levels;	chr14:74039045	chr14:73787360~73803270:+
BRCA	cis	rs7474896	0.832	rs12570943	ENSG00000272983.1	RP11-508N22.12	4.42	1.07e-05	0.000871	0.21	0.14	Obesity (extreme);	chr10:37733541	chr10:38137337~38144399:+
BRCA	cis	rs10457838	0.568	rs11155621	ENSG00000231760.4	RP11-350J20.5	4.42	1.07e-05	0.000871	0.2	0.14	Post-traumatic stress disorder;	chr6:149105771	chr6:149796151~149826294:-
BRCA	cis	rs728616	0.681	rs34816332	ENSG00000225484.5	NUTM2B-AS1	-4.42	1.07e-05	0.000871	-0.31	-0.14	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80148211	chr10:79663088~79826594:-
BRCA	cis	rs7577696	0.637	rs693918	ENSG00000272716.1	RP11-563N4.1	4.42	1.07e-05	0.000871	0.15	0.14	Inflammatory biomarkers;	chr2:31643808	chr2:32165046~32165757:-
BRCA	cis	rs34792	0.599	rs153791	ENSG00000207425.1	Y_RNA	-4.42	1.07e-05	0.000871	-0.15	-0.14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15453224	chr16:14915457~14915556:-
BRCA	cis	rs3764021	0.84	rs12304510	ENSG00000256673.1	RP11-599J14.2	-4.42	1.07e-05	0.000871	-0.15	-0.14	Type 1 diabetes;	chr12:9732930	chr12:9398355~9414851:-
BRCA	cis	rs2179367	0.959	rs628488	ENSG00000223701.3	RAET1E-AS1	4.42	1.07e-05	0.000871	0.17	0.14	Dupuytren's disease;	chr6:149398264	chr6:149884431~149919508:+
BRCA	cis	rs957448	0.561	rs34471170	ENSG00000253175.1	RP11-267M23.6	4.42	1.07e-05	0.000871	0.16	0.14	Nonsyndromic cleft lip with cleft palate;	chr8:94601135	chr8:94565036~94565715:+
BRCA	cis	rs957448	0.561	rs9642927	ENSG00000253175.1	RP11-267M23.6	4.42	1.07e-05	0.000871	0.16	0.14	Nonsyndromic cleft lip with cleft palate;	chr8:94601414	chr8:94565036~94565715:+
BRCA	cis	rs7487075	0.93	rs4076248	ENSG00000274723.1	RP11-618L22.1	4.42	1.07e-05	0.000871	0.17	0.14	Itch intensity from mosquito bite;	chr12:46439822	chr12:46970504~46972155:+
BRCA	cis	rs2109514	0.84	rs13223362	ENSG00000237813.3	AC002066.1	4.42	1.07e-05	0.000871	0.16	0.14	Prevalent atrial fibrillation;	chr7:116496952	chr7:116238260~116499465:-
BRCA	cis	rs10208649	0.908	rs10181332	ENSG00000272156.1	RP11-477N3.1	4.42	1.07e-05	0.000872	0.29	0.14	Body mass index;	chr2:54118288	chr2:54082554~54085066:+
BRCA	cis	rs6870983	0.895	rs2115885	ENSG00000247828.6	TMEM161B-AS1	-4.42	1.07e-05	0.000872	-0.18	-0.14	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index;	chr5:88303001	chr5:88268895~88436685:+
BRCA	cis	rs2731006	0.544	rs2252129	ENSG00000257114.2	RP11-25I15.3	4.42	1.07e-05	0.000872	0.22	0.14	Panic disorder;	chr12:42772899	chr12:42692216~42717119:+
BRCA	cis	rs6095360	0.934	rs2295579	ENSG00000222365.1	SNORD12B	4.42	1.07e-05	0.000872	0.15	0.14	Intelligence (multi-trait analysis);	chr20:49010199	chr20:49280319~49280409:+
BRCA	cis	rs4143844	1	rs62007791	ENSG00000259251.2	RP11-643M14.1	4.42	1.07e-05	0.000872	0.33	0.14	Bipolar disorder and schizophrenia;	chr15:61992487	chr15:62060503~62062434:+
BRCA	cis	rs4143844	0.867	rs35259011	ENSG00000259251.2	RP11-643M14.1	4.42	1.07e-05	0.000872	0.33	0.14	Bipolar disorder and schizophrenia;	chr15:61993260	chr15:62060503~62062434:+
BRCA	cis	rs4143844	1	rs12905264	ENSG00000259251.2	RP11-643M14.1	4.42	1.07e-05	0.000872	0.33	0.14	Bipolar disorder and schizophrenia;	chr15:61994464	chr15:62060503~62062434:+
BRCA	cis	rs4143844	1	rs34424197	ENSG00000259251.2	RP11-643M14.1	4.42	1.07e-05	0.000872	0.33	0.14	Bipolar disorder and schizophrenia;	chr15:61996620	chr15:62060503~62062434:+
BRCA	cis	rs757081	0.648	rs7108316	ENSG00000184669.7	OR7E14P	-4.42	1.07e-05	0.000872	-0.18	-0.14	Systolic blood pressure;	chr11:17253488	chr11:17013998~17053024:+
BRCA	cis	rs748404	0.589	rs3862138	ENSG00000205771.5	CATSPER2P1	-4.42	1.07e-05	0.000872	-0.2	-0.14	Lung cancer;	chr15:43523801	chr15:43726918~43747094:-
BRCA	cis	rs8040855	0.52	rs11629962	ENSG00000259774.1	RP11-182J1.13	4.42	1.07e-05	0.000872	0.2	0.14	Bulimia nervosa;	chr15:84986797	chr15:84422618~84425882:+
BRCA	cis	rs13113518	0.507	rs4549456	ENSG00000223305.1	RN7SKP30	4.42	1.07e-05	0.000872	0.17	0.14	Height;	chr4:55398586	chr4:55540502~55540835:-
BRCA	cis	rs5758511	0.634	rs1001587	ENSG00000227370.1	RP4-669P10.19	4.42	1.07e-05	0.000872	0.18	0.14	Birth weight;	chr22:42274105	chr22:42132543~42132998:+
BRCA	cis	rs6490294	0.904	rs11066111	ENSG00000234608.6	MAPKAPK5-AS1	4.42	1.07e-05	0.000872	0.17	0.14	Mean platelet volume;	chr12:111977375	chr12:111839764~111842902:-
BRCA	cis	rs78487399	0.808	rs79845707	ENSG00000234936.1	AC010883.5	4.42	1.07e-05	0.000872	0.22	0.14	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43561662	chr2:43229573~43233394:+
BRCA	cis	rs6840360	0.582	rs2709826	ENSG00000251611.1	RP11-610P16.1	-4.42	1.07e-05	0.000872	-0.12	-0.14	Intelligence (multi-trait analysis);	chr4:151410968	chr4:151407551~151408835:-
BRCA	cis	rs7686660	1	rs1510141	ENSG00000250326.1	RP11-284M14.1	-4.42	1.07e-05	0.000873	-0.16	-0.14	Asthma;	chr4:143027171	chr4:142933195~143184861:-
BRCA	cis	rs73186030	0.92	rs73186048	ENSG00000272758.4	RP11-299J3.8	4.42	1.07e-05	0.000873	0.21	0.14	Serum parathyroid hormone levels;	chr3:122316515	chr3:122416207~122443180:+
BRCA	cis	rs11637445	0.677	rs3784716	ENSG00000260657.2	RP11-315D16.4	-4.42	1.07e-05	0.000873	-0.17	-0.14	Posterior cortical atrophy and Alzheimer's disease;	chr15:67792112	chr15:68267792~68277994:-
BRCA	cis	rs9307551	0.744	rs4975095	ENSG00000250334.4	LINC00989	-4.42	1.07e-05	0.000873	-0.2	-0.14	Refractive error;	chr4:79563197	chr4:79492416~79576460:+
BRCA	cis	rs2403083	0.578	rs12549289	ENSG00000258256.1	RP11-219B4.5	-4.42	1.07e-05	0.000873	-0.17	-0.14	Plasma amyloid beta peptide concentrations (ABx-40);	chr8:85164202	chr8:85222446~85245717:-
BRCA	cis	rs801193	0.66	rs974239	ENSG00000236529.1	RP13-254B10.1	4.42	1.07e-05	0.000873	0.15	0.14	Aortic root size;	chr7:66748504	chr7:65840212~65840596:+
BRCA	cis	rs67072384	0.818	rs12287481	ENSG00000256633.1	RP11-169D4.2	-4.42	1.07e-05	0.000873	-0.2	-0.14	Alloimmunization response to red blood cell transfusion in sickle cell anemia;	chr11:72761291	chr11:72584572~72587979:+
BRCA	cis	rs7665090	1	rs5026472	ENSG00000251288.2	RP11-10L12.2	-4.42	1.07e-05	0.000873	-0.16	-0.14	Primary biliary cholangitis;	chr4:102633616	chr4:102751401~102752641:+
BRCA	cis	rs6600671	1	rs4844381	ENSG00000275131.1	CH17-472G23.4	-4.42	1.07e-05	0.000874	-0.12	-0.14	Hip geometry;	chr1:121443040	chr1:120489625~120579190:-
BRCA	cis	rs7772486	0.875	rs9399573	ENSG00000270638.1	RP3-466P17.1	4.42	1.07e-05	0.000874	0.16	0.14	Lobe attachment (rater-scored or self-reported);	chr6:146082119	chr6:145735570~145737218:+
BRCA	cis	rs8040855	0.599	rs6496791	ENSG00000259762.1	RP11-158M2.4	-4.42	1.07e-05	0.000874	-0.16	-0.14	Bulimia nervosa;	chr15:85182428	chr15:85750336~85752901:-
BRCA	cis	rs938554	0.513	rs3775947	ENSG00000250413.1	RP11-448G15.1	-4.42	1.07e-05	0.000874	-0.19	-0.14	Blood metabolite levels;	chr4:9993616	chr4:10006482~10009725:+
BRCA	cis	rs6968419	0.755	rs4710	ENSG00000279086.1	RP11-667F14.1	-4.42	1.07e-05	0.000874	-0.15	-0.14	Intraocular pressure;	chr7:116257338	chr7:116209234~116211511:-
BRCA	cis	rs4427176	0.507	rs13273033	ENSG00000272267.2	RP11-375N15.2	-4.42	1.07e-05	0.000875	-0.17	-0.14	Mosquito bite size;	chr8:9683183	chr8:9555144~9556520:-
BRCA	cis	rs1950832	0.689	rs10141927	ENSG00000258636.1	CTD-2298J14.2	-4.42	1.08e-05	0.000875	-0.16	-0.14	Urate levels in obese individuals;	chr14:41700574	chr14:41587861~41604856:-
BRCA	cis	rs6545883	0.895	rs796597	ENSG00000212978.6	AC016747.3	4.42	1.08e-05	0.000875	0.19	0.14	Tuberculosis;	chr2:61453925	chr2:61141592~61144969:-
BRCA	cis	rs7119038	0.818	rs10892287	ENSG00000255422.1	AP002954.4	-4.42	1.08e-05	0.000875	-0.19	-0.14	Sjögren's syndrome;	chr11:118772290	chr11:118704607~118750263:+
BRCA	cis	rs10129255	0.5	rs6576225	ENSG00000211967.3	IGHV3-53	-4.42	1.08e-05	0.000876	-0.09	-0.14	Kawasaki disease;	chr14:106778120	chr14:106592676~106593347:-
BRCA	cis	rs10129255	0.5	rs6576226	ENSG00000211967.3	IGHV3-53	-4.42	1.08e-05	0.000876	-0.09	-0.14	Kawasaki disease;	chr14:106778135	chr14:106592676~106593347:-
BRCA	cis	rs60843830	1	rs36216559	ENSG00000272342.1	RP13-539J13.1	4.42	1.08e-05	0.000876	0.17	0.14	Spherical equivalent (joint analysis main effects and education interaction);	chr2:262335	chr2:739588~740164:-
BRCA	cis	rs669446	0.561	rs571862	ENSG00000236200.4	KDM4A-AS1	-4.42	1.08e-05	0.000876	-0.17	-0.14	Amyotrophic lateral sclerosis (age of onset);	chr1:43617439	chr1:43699765~43708138:-
BRCA	cis	rs4578769	0.531	rs9951973	ENSG00000273232.1	RP11-370A5.2	-4.42	1.08e-05	0.000876	-0.17	-0.14	Eosinophil percentage of white cells;	chr18:22974353	chr18:22882825~22883357:-
BRCA	cis	rs56322409	0.833	rs7091088	ENSG00000226688.5	ENTPD1-AS1	4.42	1.08e-05	0.000876	0.16	0.14	Blood metabolite levels;	chr10:95890983	chr10:95753206~96090238:-
BRCA	cis	rs13113518	1	rs11937487	ENSG00000273257.1	RP11-177J6.1	4.42	1.08e-05	0.000876	0.17	0.14	Height;	chr4:55436576	chr4:55387949~55388271:+
BRCA	cis	rs11742741	0.837	rs12153104	ENSG00000248874.4	C5orf17	-4.42	1.08e-05	0.000876	-0.18	-0.14	Educational attainment;	chr5:24016402	chr5:23951348~24178263:+
BRCA	cis	rs875971	0.545	rs4441996	ENSG00000230295.1	RP11-458F8.2	-4.42	1.08e-05	0.000876	-0.13	-0.14	Aortic root size;	chr7:66123233	chr7:66880708~66882981:+
BRCA	cis	rs7726839	0.561	rs56410216	ENSG00000225138.6	CTD-2228K2.7	4.42	1.08e-05	0.000876	0.19	0.14	Obesity-related traits;	chr5:583101	chr5:473236~480884:+
BRCA	cis	rs7726839	0.561	rs4957048	ENSG00000225138.6	CTD-2228K2.7	4.42	1.08e-05	0.000876	0.19	0.14	Obesity-related traits;	chr5:583327	chr5:473236~480884:+
BRCA	cis	rs7726839	0.561	rs72703058	ENSG00000225138.6	CTD-2228K2.7	4.42	1.08e-05	0.000876	0.19	0.14	Obesity-related traits;	chr5:584404	chr5:473236~480884:+
BRCA	cis	rs10461617	0.592	rs6450403	ENSG00000271828.1	CTD-2310F14.1	4.42	1.08e-05	0.000876	0.17	0.14	Type 2 diabetes;	chr5:56766910	chr5:56927874~56929573:+
BRCA	cis	rs7615952	0.932	rs13325495	ENSG00000250012.1	RP11-124N2.1	-4.42	1.08e-05	0.000876	-0.21	-0.14	Blood pressure (smoking interaction);	chr3:125918573	chr3:126084220~126095349:+
BRCA	cis	rs2278170	1	rs9633905	ENSG00000225101.4	OR52K3P	4.42	1.08e-05	0.000876	0.19	0.14	Amyotrophic lateral sclerosis;	chr11:4475383	chr11:4474813~4475755:+
BRCA	cis	rs13113518	1	rs11133388	ENSG00000272969.1	RP11-528I4.2	-4.42	1.08e-05	0.000876	-0.16	-0.14	Height;	chr4:55477866	chr4:55547112~55547889:+
BRCA	cis	rs1858037	0.836	rs1396209	ENSG00000281920.1	RP11-418H16.1	4.42	1.08e-05	0.000877	0.18	0.14	Rheumatoid arthritis;	chr2:65374100	chr2:65623272~65628424:+
BRCA	cis	rs8054556	0.716	rs11642933	ENSG00000183604.13	SMG1P5	-4.42	1.08e-05	0.000877	-0.13	-0.14	Autism spectrum disorder or schizophrenia;	chr16:29935387	chr16:30267553~30335374:-
BRCA	cis	rs34929064	0.512	rs2157958	ENSG00000179428.2	AC073072.5	4.42	1.08e-05	0.000877	0.15	0.14	Major depression and alcohol dependence;	chr7:22667088	chr7:22725395~22727620:-
BRCA	cis	rs2273156	1	rs74046408	ENSG00000226677.3	IGBP1P1	-4.42	1.08e-05	0.000878	-0.2	-0.14	Immunoglobulin light chain (AL) amyloidosis;	chr14:34997929	chr14:34939324~34940332:+
BRCA	cis	rs755249	0.567	rs61779309	ENSG00000182109.6	RP11-69E11.4	4.42	1.08e-05	0.000878	0.19	0.14	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39474827	chr1:39522280~39546187:-
BRCA	cis	rs875971	0.545	rs1267814	ENSG00000273142.1	RP11-458F8.4	-4.42	1.08e-05	0.000878	-0.13	-0.14	Aortic root size;	chr7:66579422	chr7:66902857~66906297:+
BRCA	cis	rs17818399	0.501	rs13413254	ENSG00000279254.1	RP11-536C12.1	-4.42	1.08e-05	0.000878	-0.16	-0.14	Height;	chr2:46575795	chr2:46668870~46670778:+
BRCA	cis	rs875971	0.545	rs221986	ENSG00000230295.1	RP11-458F8.2	-4.42	1.08e-05	0.000878	-0.13	-0.14	Aortic root size;	chr7:66105323	chr7:66880708~66882981:+
BRCA	cis	rs10946940	0.965	rs6910838	ENSG00000220721.1	OR1F12	-4.42	1.08e-05	0.000878	-0.16	-0.14	Systemic lupus erythematosus;	chr6:27547740	chr6:28073316~28074233:+
BRCA	cis	rs7818688	0.578	rs71532343	ENSG00000245080.5	RP11-320N21.1	-4.42	1.08e-05	0.000878	-0.23	-0.14	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95064585	chr8:95066808~95073182:-
BRCA	cis	rs690037	0.641	rs538525	ENSG00000272498.1	RP11-415F23.3	-4.42	1.08e-05	0.000879	-0.14	-0.14	Optic nerve measurement (cup-to-disc ratio);Optic nerve measurement (cup area);	chr3:16334772	chr3:16339308~16339871:+
BRCA	cis	rs875971	0.545	rs66594357	ENSG00000230295.1	RP11-458F8.2	4.42	1.08e-05	0.000879	0.13	0.14	Aortic root size;	chr7:66327797	chr7:66880708~66882981:+
BRCA	cis	rs35740288	0.77	rs62023931	ENSG00000202081.1	RNU6-1280P	4.42	1.08e-05	0.000879	0.18	0.14	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85589521	chr15:85651522~85651628:-
BRCA	cis	rs4578769	0.765	rs898000	ENSG00000265939.1	UBE2CP2	-4.42	1.08e-05	0.000879	-0.17	-0.14	Eosinophil percentage of white cells;	chr18:22929109	chr18:22900486~22900995:-
BRCA	cis	rs4919687	0.55	rs12775883	ENSG00000213061.2	PFN1P11	4.42	1.08e-05	0.000879	0.19	0.14	Colorectal cancer;	chr10:102725544	chr10:102838011~102845473:-
BRCA	cis	rs6545883	0.895	rs2177961	ENSG00000270820.4	RP11-355B11.2	-4.42	1.08e-05	0.000879	-0.16	-0.14	Tuberculosis;	chr2:61333129	chr2:61471188~61484130:+
BRCA	cis	rs3768617	0.782	rs12143211	ENSG00000224468.3	RP11-181K3.4	-4.42	1.08e-05	0.000879	-0.15	-0.14	Fuchs's corneal dystrophy;	chr1:183021037	chr1:183138402~183141282:-
BRCA	cis	rs6545883	0.894	rs6545867	ENSG00000270820.4	RP11-355B11.2	-4.42	1.08e-05	0.000879	-0.16	-0.14	Tuberculosis;	chr2:61423892	chr2:61471188~61484130:+
BRCA	cis	rs7572733	0.515	rs13382697	ENSG00000231621.1	AC013264.2	-4.42	1.08e-05	0.000879	-0.13	-0.14	Dermatomyositis;	chr2:198055836	chr2:197197991~197199273:+
BRCA	cis	rs950169	0.579	rs62027818	ENSG00000275120.1	RP11-182J1.17	4.42	1.08e-05	0.000879	0.21	0.14	Schizophrenia;	chr15:83992393	chr15:84599434~84606463:-
BRCA	cis	rs875971	1	rs2420820	ENSG00000236529.1	RP13-254B10.1	-4.42	1.08e-05	0.000879	-0.15	-0.14	Aortic root size;	chr7:66626920	chr7:65840212~65840596:+
BRCA	cis	rs5751614	0.577	rs2330369	ENSG00000240160.3	RN7SL263P	4.42	1.08e-05	0.00088	0.17	0.14	Height;	chr22:23265255	chr22:23261782~23262071:-
BRCA	cis	rs938554	0.578	rs7663032	ENSG00000250413.1	RP11-448G15.1	-4.42	1.08e-05	0.00088	-0.19	-0.14	Blood metabolite levels;	chr4:9992214	chr4:10006482~10009725:+
BRCA	cis	rs1223397	0.651	rs2496144	ENSG00000215022.6	RP1-257A7.4	-4.42	1.08e-05	0.00088	-0.16	-0.14	Blood pressure;	chr6:13311709	chr6:13264861~13295586:-
BRCA	cis	rs7428	0.527	rs1061782	ENSG00000273196.1	RP11-717A5.2	-4.42	1.08e-05	0.00088	-0.16	-0.14	Ear protrusion;	chr2:85319492	chr2:85387074~85387146:-
BRCA	cis	rs7829975	0.606	rs10112585	ENSG00000254153.1	CTA-398F10.2	-4.42	1.08e-05	0.00088	-0.16	-0.14	Mood instability;	chr8:8937520	chr8:8456909~8461337:-
BRCA	cis	rs13217239	0.621	rs12527231	ENSG00000224843.5	LINC00240	-4.42	1.08e-05	0.00088	-0.15	-0.14	Schizophrenia;	chr6:27033509	chr6:26956992~27023924:+
BRCA	cis	rs13217239	0.646	rs12523820	ENSG00000224843.5	LINC00240	-4.42	1.08e-05	0.00088	-0.15	-0.14	Schizophrenia;	chr6:27033723	chr6:26956992~27023924:+
BRCA	cis	rs13217239	0.646	rs6937880	ENSG00000224843.5	LINC00240	-4.42	1.08e-05	0.00088	-0.15	-0.14	Schizophrenia;	chr6:27032457	chr6:26956992~27023924:+
BRCA	cis	rs56114371	0.53	rs2056923	ENSG00000216901.1	AL022393.7	4.42	1.08e-05	0.000881	0.22	0.14	Breast cancer;	chr6:27722160	chr6:28176188~28176674:+
BRCA	cis	rs2153535	0.58	rs4960433	ENSG00000251164.1	HULC	-4.42	1.08e-05	0.000881	-0.17	-0.14	Motion sickness;	chr6:8523464	chr6:8652137~8653846:+
BRCA	cis	rs7811142	1	rs74460138	ENSG00000078319.8	PMS2P1	-4.42	1.08e-05	0.000881	-0.22	-0.14	Platelet count;	chr7:100429716	chr7:100320992~100341908:-
BRCA	cis	rs7811142	1	rs4989959	ENSG00000078319.8	PMS2P1	-4.42	1.08e-05	0.000881	-0.22	-0.14	Platelet count;	chr7:100434665	chr7:100320992~100341908:-
BRCA	cis	rs2832191	0.74	rs2012645	ENSG00000232855.5	AF131217.1	-4.42	1.08e-05	0.000881	-0.16	-0.14	Dental caries;	chr21:29073640	chr21:28439346~28674848:-
BRCA	cis	rs2832191	0.716	rs2692625	ENSG00000232855.5	AF131217.1	-4.42	1.08e-05	0.000881	-0.16	-0.14	Dental caries;	chr21:29074039	chr21:28439346~28674848:-
BRCA	cis	rs6490294	0.571	rs11066127	ENSG00000234608.6	MAPKAPK5-AS1	4.42	1.08e-05	0.000881	0.2	0.14	Mean platelet volume;	chr12:112008551	chr12:111839764~111842902:-
BRCA	cis	rs1722141	0.669	rs788733	ENSG00000229628.1	AC073115.7	4.42	1.08e-05	0.000882	0.18	0.14	Sitting height ratio;	chr7:45994491	chr7:45990905~46000898:+
BRCA	cis	rs9307551	0.948	rs11941782	ENSG00000250334.4	LINC00989	-4.42	1.08e-05	0.000882	-0.2	-0.14	Refractive error;	chr4:79562385	chr4:79492416~79576460:+
BRCA	cis	rs757081	0.648	rs11024231	ENSG00000184669.7	OR7E14P	-4.42	1.09e-05	0.000882	-0.18	-0.14	Systolic blood pressure;	chr11:17265703	chr11:17013998~17053024:+
BRCA	cis	rs6672530	0.518	rs7551459	ENSG00000227711.2	RP11-275O4.5	4.42	1.09e-05	0.000882	0.16	0.14	Hip circumference adjusted for BMI;	chr1:227536317	chr1:227509028~227520477:-
BRCA	cis	rs3768617	0.51	rs6424888	ENSG00000224468.3	RP11-181K3.4	4.42	1.09e-05	0.000882	0.14	0.14	Fuchs's corneal dystrophy;	chr1:183116561	chr1:183138402~183141282:-
BRCA	cis	rs2073316	0.592	rs60151591	ENSG00000272716.1	RP11-563N4.1	4.42	1.09e-05	0.000883	0.15	0.14	Interleukin-18 levels;	chr2:31469593	chr2:32165046~32165757:-
BRCA	cis	rs6847067	0.672	rs17009386	ENSG00000180769.7	WDFY3-AS2	4.42	1.09e-05	0.000883	0.14	0.14	Oropharynx cancer;	chr4:85037301	chr4:84965682~85011277:+
BRCA	cis	rs6847067	0.672	rs13141072	ENSG00000180769.7	WDFY3-AS2	4.42	1.09e-05	0.000883	0.14	0.14	Oropharynx cancer;	chr4:85038199	chr4:84965682~85011277:+
BRCA	cis	rs7487075	0.93	rs4768121	ENSG00000257261.4	RP11-96H19.1	4.42	1.09e-05	0.000883	0.15	0.14	Itch intensity from mosquito bite;	chr12:46436069	chr12:46383679~46876159:+
BRCA	cis	rs8114671	0.869	rs66535333	ENSG00000279253.1	RP4-614O4.13	4.42	1.09e-05	0.000883	0.16	0.14	Height;	chr20:35068863	chr20:35262727~35264187:-
BRCA	cis	rs8114671	0.869	rs1544047	ENSG00000279253.1	RP4-614O4.13	4.42	1.09e-05	0.000883	0.16	0.14	Height;	chr20:35082950	chr20:35262727~35264187:-
BRCA	cis	rs8114671	0.836	rs17404569	ENSG00000279253.1	RP4-614O4.13	4.42	1.09e-05	0.000883	0.16	0.14	Height;	chr20:35086274	chr20:35262727~35264187:-
BRCA	cis	rs736408	0.562	rs13071584	ENSG00000243224.1	RP5-1157M23.2	-4.42	1.09e-05	0.000883	-0.15	-0.14	Bipolar disorder;	chr3:52770471	chr3:52239258~52241097:+
BRCA	cis	rs6044112	1	rs6080295	ENSG00000273998.1	RP4-777L9.2	4.42	1.09e-05	0.000883	0.25	0.14	Response to taxane treatment (docetaxel);	chr20:16540689	chr20:16576068~16579615:+
BRCA	cis	rs58521262	0.585	rs2645875	ENSG00000268105.1	RP11-369G6.2	-4.42	1.09e-05	0.000883	-0.18	-0.14	Testicular germ cell tumor;	chr19:23009909	chr19:23125665~23128543:+
BRCA	cis	rs755249	0.567	rs3818806	ENSG00000182109.6	RP11-69E11.4	4.42	1.09e-05	0.000883	0.19	0.14	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39282599	chr1:39522280~39546187:-
BRCA	cis	rs7772486	0.72	rs1890171	ENSG00000270638.1	RP3-466P17.1	-4.42	1.09e-05	0.000883	-0.16	-0.14	Lobe attachment (rater-scored or self-reported);	chr6:145750978	chr6:145735570~145737218:+
BRCA	cis	rs7772486	0.72	rs4896844	ENSG00000270638.1	RP3-466P17.1	-4.42	1.09e-05	0.000883	-0.16	-0.14	Lobe attachment (rater-scored or self-reported);	chr6:145754088	chr6:145735570~145737218:+
BRCA	cis	rs2274273	0.87	rs10139000	ENSG00000259318.1	RP11-454L9.2	4.42	1.09e-05	0.000884	0.12	0.14	Protein biomarker;	chr14:55383158	chr14:55394940~55395233:-
BRCA	cis	rs35146811	0.844	rs12705070	ENSG00000214313.7	AZGP1P1	4.42	1.09e-05	0.000884	0.14	0.14	Coronary artery disease;	chr7:100059304	chr7:99980762~99987535:+
BRCA	cis	rs11758351	0.734	rs56220351	ENSG00000241549.7	GUSBP2	-4.42	1.09e-05	0.000884	-0.19	-0.14	Renal underexcretion gout;Gout;	chr6:26206656	chr6:26871484~26956554:-
BRCA	cis	rs2243480	0.803	rs423187	ENSG00000275400.1	RP4-756H11.5	4.42	1.09e-05	0.000884	0.25	0.14	Diabetic kidney disease;	chr7:66044512	chr7:66553805~66554199:-
BRCA	cis	rs11673344	0.523	rs2891766	ENSG00000226686.6	LINC01535	4.42	1.09e-05	0.000884	0.17	0.14	Obesity-related traits;	chr19:37037057	chr19:37251912~37265535:+
BRCA	cis	rs1722133	0.555	rs788764	ENSG00000237471.1	AC073115.6	4.42	1.09e-05	0.000885	0.19	0.14	Sitting height ratio;	chr7:46103295	chr7:45969657~45980191:+
BRCA	cis	rs1722133	0.555	rs788762	ENSG00000237471.1	AC073115.6	4.42	1.09e-05	0.000885	0.19	0.14	Sitting height ratio;	chr7:46104921	chr7:45969657~45980191:+
BRCA	cis	rs1722133	0.515	rs788760	ENSG00000237471.1	AC073115.6	4.42	1.09e-05	0.000885	0.19	0.14	Sitting height ratio;	chr7:46105307	chr7:45969657~45980191:+
BRCA	cis	rs875971	1	rs1981798	ENSG00000229180.5	GS1-124K5.11	4.42	1.09e-05	0.000885	0.12	0.14	Aortic root size;	chr7:66489916	chr7:66526088~66542624:-
BRCA	cis	rs2243480	1	rs35820085	ENSG00000275400.1	RP4-756H11.5	4.42	1.09e-05	0.000885	0.24	0.14	Diabetic kidney disease;	chr7:65977771	chr7:66553805~66554199:-
BRCA	cis	rs2839186	0.872	rs13052233	ENSG00000228137.1	AP001469.7	4.42	1.09e-05	0.000885	0.14	0.14	Testicular germ cell tumor;	chr21:46287370	chr21:46246890~46247682:+
BRCA	cis	rs651907	0.557	rs13066768	ENSG00000256628.3	ZBTB11-AS1	-4.42	1.09e-05	0.000885	-0.17	-0.14	Colorectal cancer;	chr3:101768076	chr3:101676475~101679217:+
BRCA	cis	rs7809615	0.792	rs45618033	ENSG00000244219.5	GS1-259H13.2	-4.42	1.09e-05	0.000885	-0.24	-0.14	Blood metabolite ratios;	chr7:99448994	chr7:99598066~99610813:+
BRCA	cis	rs7818688	0.578	rs35518242	ENSG00000245080.5	RP11-320N21.1	-4.42	1.09e-05	0.000885	-0.23	-0.14	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95066867	chr8:95066808~95073182:-
BRCA	cis	rs1876905	0.597	rs191631	ENSG00000255389.1	C6orf3	4.42	1.09e-05	0.000885	0.18	0.14	Mean corpuscular hemoglobin;	chr6:111226862	chr6:111599875~111602295:+
BRCA	cis	rs9467773	0.967	rs9461267	ENSG00000241549.7	GUSBP2	4.42	1.09e-05	0.000886	0.15	0.14	Intelligence (multi-trait analysis);	chr6:26525227	chr6:26871484~26956554:-
BRCA	cis	rs2731006	0.591	rs7976494	ENSG00000257114.2	RP11-25I15.3	4.42	1.09e-05	0.000886	0.2	0.14	Panic disorder;	chr12:42814285	chr12:42692216~42717119:+
BRCA	cis	rs7267979	0.932	rs6037125	ENSG00000125804.12	FAM182A	-4.42	1.09e-05	0.000886	-0.17	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25482746	chr20:26054655~26086917:+
BRCA	cis	rs7665090	1	rs735405	ENSG00000251288.2	RP11-10L12.2	-4.42	1.09e-05	0.000886	-0.16	-0.14	Primary biliary cholangitis;	chr4:102632759	chr4:102751401~102752641:+
BRCA	cis	rs7665090	1	rs1077358	ENSG00000251288.2	RP11-10L12.2	-4.42	1.09e-05	0.000886	-0.16	-0.14	Primary biliary cholangitis;	chr4:102632769	chr4:102751401~102752641:+
BRCA	cis	rs1153858	0.887	rs7171163	ENSG00000275672.1	GATM-AS1	-4.42	1.09e-05	0.000886	-0.17	-0.14	Homoarginine levels;	chr15:45344197	chr15:45378700~45380123:+
BRCA	cis	rs2403083	1	rs2403083	ENSG00000258256.1	RP11-219B4.5	-4.42	1.09e-05	0.000887	-0.17	-0.14	Plasma amyloid beta peptide concentrations (ABx-40);	chr8:85195914	chr8:85222446~85245717:-
BRCA	cis	rs5758511	0.68	rs739147	ENSG00000227370.1	RP4-669P10.19	4.42	1.09e-05	0.000887	0.18	0.14	Birth weight;	chr22:42275060	chr22:42132543~42132998:+
BRCA	cis	rs934734	0.532	rs10166100	ENSG00000204929.10	AC074391.1	-4.42	1.09e-05	0.000887	-0.16	-0.14	Rheumatoid arthritis;	chr2:65418616	chr2:65436711~66084639:+
BRCA	cis	rs2108622	0.701	rs3093209	ENSG00000267218.2	AC005336.5	4.42	1.09e-05	0.000887	0.16	0.14	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15877610	chr19:15902300~15903238:-
BRCA	cis	rs10129255	0.5	rs4774008	ENSG00000232216.1	IGHV3-43	4.42	1.09e-05	0.000887	0.1	0.14	Kawasaki disease;	chr14:106681273	chr14:106470264~106470800:-
BRCA	cis	rs1510272	0.924	rs6783873	ENSG00000243926.1	TIPARP-AS1	-4.42	1.09e-05	0.000887	-0.15	-0.14	Testicular germ cell tumor;	chr3:156594525	chr3:156671862~156674378:-
BRCA	cis	rs115575488	0.85	rs17186003	ENSG00000236804.1	RPS3AP12	4.42	1.09e-05	0.000887	0.25	0.14	Lobe attachment (rater-scored or self-reported);	chr1:119074504	chr1:119126539~119127291:-
BRCA	cis	rs8040855	0.52	rs67613323	ENSG00000259774.1	RP11-182J1.13	4.42	1.09e-05	0.000887	0.2	0.14	Bulimia nervosa;	chr15:84986541	chr15:84422618~84425882:+
BRCA	cis	rs610932	0.517	rs600550	ENSG00000275344.1	MIR6503	4.42	1.09e-05	0.000887	0.14	0.14	Alzheimer's disease;	chr11:60230193	chr11:60209071~60209156:-
BRCA	cis	rs6600671	0.967	rs12069545	ENSG00000275538.1	RNVU1-19	4.42	1.09e-05	0.000887	0.16	0.14	Hip geometry;	chr1:121430343	chr1:120850819~120850985:-
BRCA	cis	rs1048886	0.872	rs7741265	ENSG00000271967.1	RP11-134K13.4	-4.42	1.09e-05	0.000888	-0.19	-0.14	Type 2 diabetes;	chr6:70575675	chr6:70596438~70596980:+
BRCA	cis	rs11098499	0.954	rs12505469	ENSG00000225892.3	RP11-384K6.2	4.42	1.09e-05	0.000888	0.14	0.14	Corneal astigmatism;	chr4:119328430	chr4:118632274~118634759:+
BRCA	cis	rs9818758	0.505	rs67286839	ENSG00000225399.4	RP11-3B7.1	-4.42	1.09e-05	0.000888	-0.22	-0.14	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49228311	chr3:49260085~49261316:+
BRCA	cis	rs3176789	0.671	rs3176775	ENSG00000256673.1	RP11-599J14.2	4.42	1.09e-05	0.000888	0.15	0.14	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9764486	chr12:9398355~9414851:-
BRCA	cis	rs4700393	0.589	rs27565	ENSG00000215032.2	GNL3LP1	4.42	1.09e-05	0.000888	0.16	0.14	Intelligence (multi-trait analysis);	chr5:60541764	chr5:60891935~60893577:-
BRCA	cis	rs1005277	0.579	rs2474584	ENSG00000099251.13	HSD17B7P2	4.42	1.09e-05	0.000889	0.15	0.14	Extrinsic epigenetic age acceleration;	chr10:38127461	chr10:38356380~38378505:+
BRCA	cis	rs1005277	0.579	rs2474586	ENSG00000099251.13	HSD17B7P2	4.42	1.09e-05	0.000889	0.15	0.14	Extrinsic epigenetic age acceleration;	chr10:38129954	chr10:38356380~38378505:+
BRCA	cis	rs11098499	0.909	rs73842633	ENSG00000260091.1	RP11-33B1.4	-4.42	1.09e-05	0.000889	-0.12	-0.14	Corneal astigmatism;	chr4:119454309	chr4:119409333~119410233:+
BRCA	cis	rs13113518	1	rs13146987	ENSG00000272969.1	RP11-528I4.2	4.42	1.09e-05	0.000889	0.16	0.14	Height;	chr4:55491628	chr4:55547112~55547889:+
BRCA	cis	rs13113518	1	rs7677085	ENSG00000272969.1	RP11-528I4.2	4.42	1.09e-05	0.000889	0.16	0.14	Height;	chr4:55495801	chr4:55547112~55547889:+
BRCA	cis	rs13113518	0.966	rs12510681	ENSG00000272969.1	RP11-528I4.2	4.42	1.09e-05	0.000889	0.16	0.14	Height;	chr4:55496737	chr4:55547112~55547889:+
BRCA	cis	rs13113518	1	rs12500162	ENSG00000272969.1	RP11-528I4.2	4.42	1.09e-05	0.000889	0.16	0.14	Height;	chr4:55496933	chr4:55547112~55547889:+
BRCA	cis	rs13113518	1	rs7686261	ENSG00000272969.1	RP11-528I4.2	4.42	1.09e-05	0.000889	0.16	0.14	Height;	chr4:55500224	chr4:55547112~55547889:+
BRCA	cis	rs13113518	1	rs11729220	ENSG00000272969.1	RP11-528I4.2	4.42	1.09e-05	0.000889	0.16	0.14	Height;	chr4:55501629	chr4:55547112~55547889:+
BRCA	cis	rs13113518	1	rs11133390	ENSG00000272969.1	RP11-528I4.2	4.42	1.09e-05	0.000889	0.16	0.14	Height;	chr4:55501726	chr4:55547112~55547889:+
BRCA	cis	rs13113518	1	rs11133391	ENSG00000272969.1	RP11-528I4.2	4.42	1.09e-05	0.000889	0.16	0.14	Height;	chr4:55501788	chr4:55547112~55547889:+
BRCA	cis	rs13113518	0.966	rs13133484	ENSG00000272969.1	RP11-528I4.2	4.42	1.09e-05	0.000889	0.16	0.14	Height;	chr4:55504176	chr4:55547112~55547889:+
BRCA	cis	rs13113518	0.934	rs13127906	ENSG00000272969.1	RP11-528I4.2	4.42	1.09e-05	0.000889	0.16	0.14	Height;	chr4:55504201	chr4:55547112~55547889:+
BRCA	cis	rs35612822	0.723	rs12019163	ENSG00000232485.2	AC098820.3	-4.42	1.09e-05	0.000889	-0.16	-0.14	Kidney disease (early stage) in type 1 diabetes;	chr2:216404444	chr2:216479030~216498761:-
BRCA	cis	rs2380205	0.967	rs4294487	ENSG00000232807.2	RP11-536K7.3	4.42	1.09e-05	0.000889	0.14	0.14	Breast cancer;	chr10:5856442	chr10:5934270~5945900:-
BRCA	cis	rs2380205	0.967	rs4421659	ENSG00000232807.2	RP11-536K7.3	4.42	1.09e-05	0.000889	0.14	0.14	Breast cancer;	chr10:5856443	chr10:5934270~5945900:-
BRCA	cis	rs812925	0.519	rs1186706	ENSG00000270820.4	RP11-355B11.2	4.42	1.1e-05	0.000889	0.15	0.14	Immature fraction of reticulocytes;	chr2:61446259	chr2:61471188~61484130:+
BRCA	cis	rs2880765	0.566	rs17553790	ENSG00000202081.1	RNU6-1280P	-4.42	1.1e-05	0.000889	-0.17	-0.14	Coronary artery disease;	chr15:85470434	chr15:85651522~85651628:-
BRCA	cis	rs1910358	0.554	rs2172050	ENSG00000248874.4	C5orf17	-4.42	1.1e-05	0.000889	-0.19	-0.14	Venous thromboembolism (SNP x SNP interaction);	chr5:23804461	chr5:23951348~24178263:+
BRCA	cis	rs1910358	0.554	rs7705749	ENSG00000248874.4	C5orf17	-4.42	1.1e-05	0.000889	-0.19	-0.14	Venous thromboembolism (SNP x SNP interaction);	chr5:23805116	chr5:23951348~24178263:+
BRCA	cis	rs1665650	0.834	rs79692675	ENSG00000232767.1	RP11-498B4.5	4.42	1.1e-05	0.000889	0.16	0.14	Colorectal cancer;	chr10:116718237	chr10:116670103~116672739:+
BRCA	cis	rs9425766	0.679	rs2901785	ENSG00000200674.1	RN7SKP160	4.42	1.1e-05	0.00089	0.18	0.14	Life satisfaction;	chr1:174135605	chr1:173791548~173791887:+
BRCA	cis	rs6963495	0.818	rs6977748	ENSG00000223886.3	RP11-251G23.2	4.42	1.1e-05	0.00089	0.21	0.14	Bipolar disorder (body mass index interaction);	chr7:105527015	chr7:105530209~105530671:+
BRCA	cis	rs2688608	0.62	rs12253408	ENSG00000213731.2	RAB5CP1	-4.42	1.1e-05	0.00089	-0.15	-0.14	Inflammatory bowel disease;	chr10:73736198	chr10:74423435~74424014:-
BRCA	cis	rs58521262	0.556	rs158693	ENSG00000268105.1	RP11-369G6.2	-4.42	1.1e-05	0.00089	-0.18	-0.14	Testicular germ cell tumor;	chr19:23018005	chr19:23125665~23128543:+
BRCA	cis	rs934734	0.532	rs7557569	ENSG00000204929.10	AC074391.1	-4.42	1.1e-05	0.00089	-0.16	-0.14	Rheumatoid arthritis;	chr2:65417427	chr2:65436711~66084639:+
BRCA	cis	rs6095360	0.899	rs6019544	ENSG00000222365.1	SNORD12B	-4.42	1.1e-05	0.00089	-0.15	-0.14	Intelligence (multi-trait analysis);	chr20:48940476	chr20:49280319~49280409:+
BRCA	cis	rs4434138	0.594	rs7653028	ENSG00000243224.1	RP5-1157M23.2	-4.42	1.1e-05	0.000891	-0.15	-0.14	Intelligence (multi-trait analysis);	chr3:52728984	chr3:52239258~52241097:+
BRCA	cis	rs7618915	0.501	rs11714030	ENSG00000243224.1	RP5-1157M23.2	-4.42	1.1e-05	0.000891	-0.15	-0.14	Bipolar disorder;	chr3:52731866	chr3:52239258~52241097:+
BRCA	cis	rs7267979	0.78	rs6050679	ENSG00000277938.1	RP5-965G21.3	4.42	1.1e-05	0.000891	0.16	0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25557191	chr20:25229150~25231933:+
BRCA	cis	rs2439831	0.85	rs12441127	ENSG00000206991.1	RNU6-610P	-4.42	1.1e-05	0.000891	-0.22	-0.14	Lung cancer in ever smokers;	chr15:43728977	chr15:43637632~43637738:-
BRCA	cis	rs7267979	0.932	rs417130	ENSG00000125804.12	FAM182A	-4.42	1.1e-05	0.000892	-0.17	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25477684	chr20:26054655~26086917:+
BRCA	cis	rs7267979	0.932	rs372678	ENSG00000125804.12	FAM182A	-4.42	1.1e-05	0.000892	-0.17	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25484612	chr20:26054655~26086917:+
BRCA	cis	rs1005277	0.579	rs2474575	ENSG00000099251.13	HSD17B7P2	4.42	1.1e-05	0.000892	0.15	0.14	Extrinsic epigenetic age acceleration;	chr10:38098973	chr10:38356380~38378505:+
BRCA	cis	rs7811142	1	rs67163493	ENSG00000078319.8	PMS2P1	-4.42	1.1e-05	0.000892	-0.22	-0.14	Platelet count;	chr7:100426215	chr7:100320992~100341908:-
BRCA	cis	rs300890	0.662	rs300899	ENSG00000250326.1	RP11-284M14.1	-4.42	1.1e-05	0.000892	-0.16	-0.14	Nasopharyngeal carcinoma;	chr4:143323563	chr4:142933195~143184861:-
BRCA	cis	rs2832077	0.506	rs2832085	ENSG00000215533.7	LINC00189	4.42	1.1e-05	0.000892	0.17	0.14	Cognitive test performance;	chr21:28782936	chr21:29193480~29288205:+
BRCA	cis	rs6460942	0.545	rs17448114	ENSG00000226690.5	AC005281.1	4.42	1.1e-05	0.000892	0.28	0.14	Coronary artery disease;	chr7:12484832	chr7:12496429~12541910:+
BRCA	cis	rs6460942	0.597	rs17545416	ENSG00000226690.5	AC005281.1	4.42	1.1e-05	0.000892	0.28	0.14	Coronary artery disease;	chr7:12486318	chr7:12496429~12541910:+
BRCA	cis	rs6460942	0.597	rs13245635	ENSG00000226690.5	AC005281.1	4.42	1.1e-05	0.000892	0.28	0.14	Coronary artery disease;	chr7:12486828	chr7:12496429~12541910:+
BRCA	cis	rs6460942	0.597	rs12699381	ENSG00000226690.5	AC005281.1	4.42	1.1e-05	0.000892	0.28	0.14	Coronary artery disease;	chr7:12487400	chr7:12496429~12541910:+
BRCA	cis	rs708547	0.533	rs3806746	ENSG00000269949.1	RP11-738E22.3	-4.42	1.1e-05	0.000892	-0.17	-0.14	Response to bleomycin (chromatid breaks);	chr4:56907164	chr4:56960927~56961373:-
BRCA	cis	rs859767	0.774	rs6758396	ENSG00000224043.6	CCNT2-AS1	4.42	1.1e-05	0.000893	0.19	0.14	Neuroticism;	chr2:134659287	chr2:134735464~134918710:-
BRCA	cis	rs718433	0.584	rs1569292	ENSG00000256379.1	TRAV8-5	4.42	1.1e-05	0.000893	0.16	0.14	Intraocular pressure;	chr14:21748709	chr14:21903077~21903598:+
BRCA	cis	rs28735056	0.563	rs55642704	ENSG00000261126.6	RP11-795F19.1	-4.42	1.1e-05	0.000893	-0.13	-0.14	Schizophrenia;	chr18:79928124	chr18:80046900~80095482:+
BRCA	cis	rs6088580	0.634	rs6059867	ENSG00000276073.1	RP5-1125A11.7	-4.42	1.1e-05	0.000893	-0.15	-0.14	Glomerular filtration rate (creatinine);	chr20:34490298	chr20:33985617~33988989:-
BRCA	cis	rs4908760	0.539	rs10864367	ENSG00000232912.4	RP5-1115A15.1	4.42	1.1e-05	0.000893	0.13	0.14	Vitiligo;	chr1:8787321	chr1:8424645~8434838:+
BRCA	cis	rs12744310	0.887	rs12037129	ENSG00000235358.1	RP11-399E6.1	4.42	1.1e-05	0.000893	0.2	0.14	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41328629	chr1:41242373~41284861:+
BRCA	cis	rs801193	1	rs10252765	ENSG00000272831.1	RP11-792A8.4	4.42	1.1e-05	0.000893	0.12	0.14	Aortic root size;	chr7:66763745	chr7:66739829~66740385:-
BRCA	cis	rs6957923	0.609	rs2390791	ENSG00000234286.1	AC006026.13	-4.42	1.1e-05	0.000893	-0.16	-0.14	Height;	chr7:23539883	chr7:23680195~23680786:-
BRCA	cis	rs6686842	1	rs213754	ENSG00000235358.1	RP11-399E6.1	-4.42	1.1e-05	0.000893	-0.17	-0.14	Height;	chr1:41133176	chr1:41242373~41284861:+
BRCA	cis	rs8054556	0.74	rs11649612	ENSG00000183604.13	SMG1P5	-4.42	1.1e-05	0.000893	-0.13	-0.14	Autism spectrum disorder or schizophrenia;	chr16:29935349	chr16:30267553~30335374:-
BRCA	cis	rs17818399	0.781	rs4952837	ENSG00000279254.1	RP11-536C12.1	-4.42	1.1e-05	0.000893	-0.18	-0.14	Height;	chr2:46638595	chr2:46668870~46670778:+
BRCA	cis	rs17818399	0.781	rs6746598	ENSG00000279254.1	RP11-536C12.1	-4.42	1.1e-05	0.000893	-0.18	-0.14	Height;	chr2:46638634	chr2:46668870~46670778:+
BRCA	cis	rs6840360	0.642	rs11099815	ENSG00000251603.1	RP11-164P12.4	-4.42	1.1e-05	0.000893	-0.12	-0.14	Intelligence (multi-trait analysis);	chr4:151422736	chr4:151667224~151670502:+
BRCA	cis	rs2625529	0.775	rs16956273	ENSG00000260037.4	CTD-2524L6.3	-4.42	1.1e-05	0.000894	-0.17	-0.14	Red blood cell count;	chr15:71824761	chr15:71818396~71823384:+
BRCA	cis	rs2243480	0.803	rs55700941	ENSG00000222364.1	RNU6-96P	-4.42	1.1e-05	0.000894	-0.25	-0.14	Diabetic kidney disease;	chr7:65924813	chr7:66395191~66395286:+
BRCA	cis	rs911119	1	rs6036476	ENSG00000270001.1	RP11-218C14.8	-4.42	1.1e-05	0.000894	-0.18	-0.14	Chronic kidney disease;	chr20:23629671	chr20:23631826~23632316:-
BRCA	cis	rs11098499	0.954	rs17006190	ENSG00000250412.1	KLHL2P1	4.42	1.1e-05	0.000894	0.16	0.14	Corneal astigmatism;	chr4:119497683	chr4:119334329~119378233:+
BRCA	cis	rs6012564	1	rs3092039	ENSG00000222365.1	SNORD12B	-4.42	1.1e-05	0.000894	-0.14	-0.14	Anger;	chr20:49062233	chr20:49280319~49280409:+
BRCA	cis	rs35740288	0.929	rs11073537	ENSG00000202081.1	RNU6-1280P	4.42	1.1e-05	0.000894	0.18	0.14	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85769450	chr15:85651522~85651628:-
BRCA	cis	rs6964587	0.933	rs10271174	ENSG00000188693.7	CYP51A1-AS1	-4.42	1.1e-05	0.000894	-0.15	-0.14	Breast cancer;	chr7:92156656	chr7:92134604~92180725:+
BRCA	cis	rs2243480	1	rs4718317	ENSG00000237026.1	RP11-328P23.2	-4.42	1.1e-05	0.000895	-0.24	-0.14	Diabetic kidney disease;	chr7:66183914	chr7:65235790~65236723:-
BRCA	cis	rs2179367	0.6	rs9498354	ENSG00000268592.3	RAET1E-AS1	-4.42	1.1e-05	0.000895	-0.2	-0.14	Dupuytren's disease;	chr6:149441715	chr6:149863494~149919507:+
BRCA	cis	rs2731006	0.64	rs2730976	ENSG00000257114.2	RP11-25I15.3	4.42	1.1e-05	0.000895	0.22	0.14	Panic disorder;	chr12:42773413	chr12:42692216~42717119:+
BRCA	cis	rs11098499	0.863	rs34868248	ENSG00000250412.1	KLHL2P1	4.42	1.1e-05	0.000895	0.16	0.14	Corneal astigmatism;	chr4:119521275	chr4:119334329~119378233:+
BRCA	cis	rs859767	0.679	rs4954158	ENSG00000224043.6	CCNT2-AS1	4.42	1.1e-05	0.000895	0.19	0.14	Neuroticism;	chr2:134669048	chr2:134735464~134918710:-
BRCA	cis	rs6964833	0.935	rs34630792	ENSG00000184616.8	AC004166.6	4.42	1.1e-05	0.000895	0.2	0.14	Menarche (age at onset);	chr7:74646869	chr7:74906673~74913256:-
BRCA	cis	rs11048434	0.518	rs1805707	ENSG00000256937.1	KRT17P8	-4.42	1.1e-05	0.000895	-0.15	-0.14	Sjögren's syndrome;	chr12:9029110	chr12:9127783~9128645:+
BRCA	cis	rs1867631	0.585	rs5008753	ENSG00000248458.2	RP4-598P13.1	4.42	1.1e-05	0.000895	0.14	0.14	Menopause (age at onset);	chr1:66626565	chr1:66665864~66677027:-
BRCA	cis	rs728616	0.702	rs78734698	ENSG00000242600.5	MBL1P	4.42	1.1e-05	0.000895	0.34	0.14	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79996693	chr10:79904898~79950336:+
BRCA	cis	rs8133949	0.868	rs62216705	ENSG00000237232.6	ZNF295-AS1	4.42	1.1e-05	0.000895	0.2	0.14	Hand grip strength;	chr21:41994599	chr21:42009194~42024924:+
BRCA	cis	rs375066	0.935	rs396973	ENSG00000267191.1	RP11-15A1.2	4.42	1.1e-05	0.000895	0.17	0.14	Breast cancer;	chr19:43895154	chr19:43902001~43926545:+
BRCA	cis	rs9467773	0.626	rs9379860	ENSG00000124549.13	BTN2A3P	-4.42	1.1e-05	0.000895	-0.14	-0.14	Intelligence (multi-trait analysis);	chr6:26370377	chr6:26421391~26432383:+
BRCA	cis	rs78487399	0.731	rs6747229	ENSG00000234936.1	AC010883.5	4.42	1.1e-05	0.000896	0.21	0.14	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43485471	chr2:43229573~43233394:+
BRCA	cis	rs10861342	0.892	rs3794232	ENSG00000257999.1	RP11-61E11.2	-4.42	1.1e-05	0.000896	-0.28	-0.14	IgG glycosylation;	chr12:105222071	chr12:105102472~105107179:-
BRCA	cis	rs2731006	0.64	rs17091970	ENSG00000257114.2	RP11-25I15.3	4.42	1.1e-05	0.000896	0.22	0.14	Panic disorder;	chr12:42780366	chr12:42692216~42717119:+
BRCA	cis	rs2731006	0.64	rs2678151	ENSG00000257114.2	RP11-25I15.3	4.42	1.1e-05	0.000896	0.22	0.14	Panic disorder;	chr12:42780701	chr12:42692216~42717119:+
BRCA	cis	rs4237845	0.537	rs11172369	ENSG00000270039.1	RP11-571M6.17	-4.42	1.1e-05	0.000896	-0.2	-0.14	Intelligence (multi-trait analysis);	chr12:57886809	chr12:57803838~57804415:+
BRCA	cis	rs9467773	1	rs9467774	ENSG00000241549.7	GUSBP2	4.42	1.1e-05	0.000896	0.14	0.14	Intelligence (multi-trait analysis);	chr6:26504808	chr6:26871484~26956554:-
BRCA	cis	rs9467773	1	rs2208331	ENSG00000241549.7	GUSBP2	4.42	1.1e-05	0.000896	0.14	0.14	Intelligence (multi-trait analysis);	chr6:26507091	chr6:26871484~26956554:-
BRCA	cis	rs13108904	0.935	rs1620928	ENSG00000196810.4	CTBP1-AS2	-4.42	1.1e-05	0.000896	-0.14	-0.14	Obesity-related traits;	chr4:1285336	chr4:1249300~1288291:+
BRCA	cis	rs7726839	0.561	rs3915384	ENSG00000271781.1	CTD-2589H19.6	-4.42	1.1e-05	0.000896	-0.18	-0.14	Obesity-related traits;	chr5:573280	chr5:675826~676616:+
BRCA	cis	rs910316	1	rs8003506	ENSG00000259138.1	RP11-950C14.7	-4.42	1.1e-05	0.000897	-0.15	-0.14	Height;	chr14:75119585	chr14:75127153~75136930:+
BRCA	cis	rs7267979	0.528	rs34485039	ENSG00000204556.4	CTD-2514C3.1	4.42	1.1e-05	0.000897	0.18	0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25603127	chr20:26018832~26020684:+
BRCA	cis	rs1322639	0.657	rs9355135	ENSG00000223485.1	RP11-417E7.1	-4.42	1.11e-05	0.000897	-0.2	-0.14	Pulse pressure;	chr6:169172911	chr6:169158092~169162924:-
BRCA	cis	rs7428	0.545	rs1053561	ENSG00000273196.1	RP11-717A5.2	4.42	1.11e-05	0.000897	0.16	0.14	Ear protrusion;	chr2:85318929	chr2:85387074~85387146:-
BRCA	cis	rs11159086	0.938	rs11623040	ENSG00000270000.1	RP3-449M8.9	4.42	1.11e-05	0.000897	0.25	0.14	Advanced glycation end-product levels;	chr14:74496743	chr14:74471930~74472360:-
BRCA	cis	rs13113518	1	rs7662966	ENSG00000273257.1	RP11-177J6.1	4.42	1.11e-05	0.000897	0.17	0.14	Height;	chr4:55548261	chr4:55387949~55388271:+
BRCA	cis	rs878939	0.625	rs17578367	ENSG00000233690.1	EBAG9P1	4.42	1.11e-05	0.000897	0.19	0.14	Warfarin maintenance dose;	chr10:99584410	chr10:99697407~99697949:-
BRCA	cis	rs2320614	0.679	rs72631678	ENSG00000250027.1	RP11-563E2.2	-4.42	1.11e-05	0.000897	-0.15	-0.14	Lung adenocarcinoma;	chr4:163181563	chr4:163108785~163119965:+
BRCA	cis	rs11951515	0.508	rs10065689	ENSG00000248240.1	RP11-159F24.5	-4.42	1.11e-05	0.000897	-0.17	-0.14	Metabolite levels  (X-11787);	chr5:43604156	chr5:43515274~43525310:+
BRCA	cis	rs13113518	1	rs6838882	ENSG00000272969.1	RP11-528I4.2	4.42	1.11e-05	0.000897	0.16	0.14	Height;	chr4:55489310	chr4:55547112~55547889:+
BRCA	cis	rs3824867	1	rs3824867	ENSG00000280615.1	Y_RNA	-4.42	1.11e-05	0.000898	-0.17	-0.14	Mean corpuscular hemoglobin;	chr11:47447017	chr11:47614898~47614994:-
BRCA	cis	rs875971	1	rs937495	ENSG00000229180.5	GS1-124K5.11	-4.42	1.11e-05	0.000898	-0.12	-0.14	Aortic root size;	chr7:66314811	chr7:66526088~66542624:-
BRCA	cis	rs875971	1	rs2036264	ENSG00000229180.5	GS1-124K5.11	-4.42	1.11e-05	0.000898	-0.12	-0.14	Aortic root size;	chr7:66334917	chr7:66526088~66542624:-
BRCA	cis	rs875971	1	rs7783613	ENSG00000229180.5	GS1-124K5.11	-4.42	1.11e-05	0.000898	-0.12	-0.14	Aortic root size;	chr7:66340274	chr7:66526088~66542624:-
BRCA	cis	rs4356203	0.846	rs1685932	ENSG00000272034.1	SNORD14A	-4.42	1.11e-05	0.000898	-0.14	-0.14	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17202356	chr11:17074654~17074744:-
BRCA	cis	rs1555322	0.932	rs1205411	ENSG00000279253.1	RP4-614O4.13	-4.42	1.11e-05	0.000898	-0.22	-0.14	Attention deficit hyperactivity disorder;	chr20:35269439	chr20:35262727~35264187:-
BRCA	cis	rs559555	0.512	rs655548	ENSG00000272716.1	RP11-563N4.1	4.42	1.11e-05	0.000898	0.16	0.14	Blood metabolite ratios;Blood metabolite levels;	chr2:31611589	chr2:32165046~32165757:-
BRCA	cis	rs256438	0.93	rs34338186	ENSG00000251050.1	RP11-168A11.4	-4.42	1.11e-05	0.000898	-0.15	-0.14	Serum thyroid-stimulating hormone levels;	chr5:80095173	chr5:80019609~80019920:+
BRCA	cis	rs5758511	0.633	rs5758690	ENSG00000227370.1	RP4-669P10.19	4.42	1.11e-05	0.000898	0.17	0.14	Birth weight;	chr22:42272289	chr22:42132543~42132998:+
BRCA	cis	rs11673344	0.543	rs8108429	ENSG00000226686.6	LINC01535	4.42	1.11e-05	0.000898	0.17	0.14	Obesity-related traits;	chr19:37145874	chr19:37251912~37265535:+
BRCA	cis	rs7727544	0.669	rs113823725	ENSG00000233006.5	AC034220.3	4.42	1.11e-05	0.000898	0.1	0.14	Blood metabolite levels;	chr5:132227808	chr5:132311285~132369916:-
BRCA	cis	rs2692947	0.567	rs4907276	ENSG00000168992.4	OR7E102P	-4.42	1.11e-05	0.000898	-0.19	-0.14	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95725361	chr2:95546531~95547545:+
BRCA	cis	rs6921919	0.583	rs1054372	ENSG00000273712.1	RP5-874C20.7	4.42	1.11e-05	0.000898	0.18	0.14	Autism spectrum disorder or schizophrenia;	chr6:28368965	chr6:28315613~28315883:-
BRCA	cis	rs6921919	0.583	rs9468354	ENSG00000273712.1	RP5-874C20.7	4.42	1.11e-05	0.000898	0.18	0.14	Autism spectrum disorder or schizophrenia;	chr6:28370024	chr6:28315613~28315883:-
BRCA	cis	rs6921919	0.583	rs7773051	ENSG00000273712.1	RP5-874C20.7	4.42	1.11e-05	0.000898	0.18	0.14	Autism spectrum disorder or schizophrenia;	chr6:28372539	chr6:28315613~28315883:-
BRCA	cis	rs6921919	0.583	rs12697938	ENSG00000273712.1	RP5-874C20.7	4.42	1.11e-05	0.000898	0.18	0.14	Autism spectrum disorder or schizophrenia;	chr6:28373322	chr6:28315613~28315883:-
BRCA	cis	rs6921919	0.583	rs13437294	ENSG00000273712.1	RP5-874C20.7	4.42	1.11e-05	0.000898	0.18	0.14	Autism spectrum disorder or schizophrenia;	chr6:28373758	chr6:28315613~28315883:-
BRCA	cis	rs6921919	0.609	rs9468357	ENSG00000273712.1	RP5-874C20.7	4.42	1.11e-05	0.000898	0.18	0.14	Autism spectrum disorder or schizophrenia;	chr6:28374276	chr6:28315613~28315883:-
BRCA	cis	rs6921919	0.583	rs34513104	ENSG00000273712.1	RP5-874C20.7	4.42	1.11e-05	0.000898	0.18	0.14	Autism spectrum disorder or schizophrenia;	chr6:28375566	chr6:28315613~28315883:-
BRCA	cis	rs6921919	0.583	rs9461456	ENSG00000273712.1	RP5-874C20.7	4.42	1.11e-05	0.000898	0.18	0.14	Autism spectrum disorder or schizophrenia;	chr6:28376039	chr6:28315613~28315883:-
BRCA	cis	rs6921919	0.525	rs9468360	ENSG00000273712.1	RP5-874C20.7	4.42	1.11e-05	0.000898	0.18	0.14	Autism spectrum disorder or schizophrenia;	chr6:28376661	chr6:28315613~28315883:-
BRCA	cis	rs6921919	0.583	rs16894021	ENSG00000273712.1	RP5-874C20.7	4.42	1.11e-05	0.000898	0.18	0.14	Autism spectrum disorder or schizophrenia;	chr6:28377249	chr6:28315613~28315883:-
BRCA	cis	rs6921919	0.583	rs11751693	ENSG00000273712.1	RP5-874C20.7	4.42	1.11e-05	0.000898	0.18	0.14	Autism spectrum disorder or schizophrenia;	chr6:28377306	chr6:28315613~28315883:-
BRCA	cis	rs6921919	0.583	rs7749736	ENSG00000273712.1	RP5-874C20.7	4.42	1.11e-05	0.000898	0.18	0.14	Autism spectrum disorder or schizophrenia;	chr6:28378254	chr6:28315613~28315883:-
BRCA	cis	rs6921919	0.525	rs9468361	ENSG00000273712.1	RP5-874C20.7	4.42	1.11e-05	0.000898	0.18	0.14	Autism spectrum disorder or schizophrenia;	chr6:28378541	chr6:28315613~28315883:-
BRCA	cis	rs6921919	0.583	rs7775132	ENSG00000273712.1	RP5-874C20.7	4.42	1.11e-05	0.000898	0.18	0.14	Autism spectrum disorder or schizophrenia;	chr6:28379236	chr6:28315613~28315883:-
BRCA	cis	rs6921919	0.583	rs3734563	ENSG00000273712.1	RP5-874C20.7	4.42	1.11e-05	0.000898	0.18	0.14	Autism spectrum disorder or schizophrenia;	chr6:28381948	chr6:28315613~28315883:-
BRCA	cis	rs6921919	0.583	rs1591913	ENSG00000273712.1	RP5-874C20.7	4.42	1.11e-05	0.000898	0.18	0.14	Autism spectrum disorder or schizophrenia;	chr6:28383951	chr6:28315613~28315883:-
BRCA	cis	rs13326165	0.76	rs123602	ENSG00000243224.1	RP5-1157M23.2	-4.42	1.11e-05	0.000898	-0.18	-0.14	HDL cholesterol levels;HDL cholesterol;	chr3:52408338	chr3:52239258~52241097:+
BRCA	cis	rs7617773	0.963	rs6766754	ENSG00000199476.1	Y_RNA	4.42	1.11e-05	0.000898	0.18	0.14	Coronary artery disease;	chr3:48141099	chr3:48288587~48288694:+
BRCA	cis	rs7617773	0.832	rs6775114	ENSG00000199476.1	Y_RNA	4.42	1.11e-05	0.000898	0.18	0.14	Coronary artery disease;	chr3:48141130	chr3:48288587~48288694:+
BRCA	cis	rs11892454	0.515	rs10173557	ENSG00000217643.1	PTGES3P2	-4.42	1.11e-05	0.000898	-0.14	-0.14	Heschl's gyrus morphology;	chr2:25854853	chr2:25822469~25822950:+
BRCA	cis	rs4835473	0.932	rs7697916	ENSG00000249741.2	RP11-673E1.3	4.42	1.11e-05	0.000898	0.16	0.14	Immature fraction of reticulocytes;	chr4:143765628	chr4:143911514~143912053:-
BRCA	cis	rs7308116	1	rs10778579	ENSG00000274395.1	RP11-554D14.8	-4.42	1.11e-05	0.000898	-0.15	-0.14	Pelvic organ prolapse (moderate/severe);	chr12:107808178	chr12:107835541~107836555:-
BRCA	cis	rs875971	0.545	rs73146609	ENSG00000230295.1	RP11-458F8.2	4.42	1.11e-05	0.000899	0.13	0.14	Aortic root size;	chr7:66302477	chr7:66880708~66882981:+
BRCA	cis	rs875971	0.545	rs2173571	ENSG00000230295.1	RP11-458F8.2	4.42	1.11e-05	0.000899	0.13	0.14	Aortic root size;	chr7:66305392	chr7:66880708~66882981:+
BRCA	cis	rs603446	0.901	rs180344	ENSG00000280143.1	AP000892.6	4.42	1.11e-05	0.000899	0.13	0.14	Triglycerides;	chr11:116742468	chr11:117204967~117210292:+
BRCA	cis	rs1865760	0.929	rs9467646	ENSG00000272462.2	U91328.19	-4.42	1.11e-05	0.000899	-0.16	-0.14	Height;	chr6:25957180	chr6:25992662~26001775:+
BRCA	cis	rs7267979	0.565	rs6107059	ENSG00000231081.1	RP4-760C5.3	4.42	1.11e-05	0.000899	0.17	0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25611795	chr20:26008791~26010531:-
BRCA	cis	rs7727544	0.548	rs4705938	ENSG00000233006.5	AC034220.3	4.42	1.11e-05	0.000899	0.1	0.14	Blood metabolite levels;	chr5:132358384	chr5:132311285~132369916:-
BRCA	cis	rs6430585	0.528	rs75753154	ENSG00000231890.6	DARS-AS1	-4.42	1.11e-05	0.000899	-0.22	-0.14	Corneal structure;	chr2:135908141	chr2:135985176~136022593:+
BRCA	cis	rs6430585	0.528	rs7606267	ENSG00000231890.6	DARS-AS1	-4.42	1.11e-05	0.000899	-0.22	-0.14	Corneal structure;	chr2:135910553	chr2:135985176~136022593:+
BRCA	cis	rs6921919	0.583	rs4642462	ENSG00000273712.1	RP5-874C20.7	4.42	1.11e-05	0.000899	0.18	0.14	Autism spectrum disorder or schizophrenia;	chr6:28421474	chr6:28315613~28315883:-
BRCA	cis	rs2227564	1	rs2227564	ENSG00000271816.1	BMS1P4	-4.42	1.11e-05	0.000899	-0.15	-0.14	Crohn's disease;Inflammatory bowel disease;	chr10:73913343	chr10:73699151~73730487:-
BRCA	cis	rs7829975	0.742	rs12547493	ENSG00000173295.6	FAM86B3P	-4.42	1.11e-05	0.000899	-0.14	-0.14	Mood instability;	chr8:8804024	chr8:8228595~8244865:+
BRCA	cis	rs2731006	0.64	rs1517670	ENSG00000257114.2	RP11-25I15.3	4.42	1.11e-05	9e-04	0.22	0.14	Panic disorder;	chr12:42780510	chr12:42692216~42717119:+
BRCA	cis	rs12893668	0.703	rs7148456	ENSG00000244691.1	RPL10AP1	4.42	1.11e-05	9e-04	0.18	0.14	Reticulocyte count;	chr14:103561933	chr14:103412119~103412761:-
BRCA	cis	rs875971	1	rs4718307	ENSG00000236529.1	RP13-254B10.1	-4.42	1.11e-05	9e-04	-0.15	-0.14	Aortic root size;	chr7:66146001	chr7:65840212~65840596:+
BRCA	cis	rs875971	1	rs7801282	ENSG00000236529.1	RP13-254B10.1	-4.42	1.11e-05	9e-04	-0.15	-0.14	Aortic root size;	chr7:66148700	chr7:65840212~65840596:+
BRCA	cis	rs11892454	0.604	rs13430199	ENSG00000217643.1	PTGES3P2	-4.42	1.11e-05	9e-04	-0.15	-0.14	Heschl's gyrus morphology;	chr2:25715308	chr2:25822469~25822950:+
BRCA	cis	rs7937682	0.961	rs11601674	ENSG00000230911.1	PPIHP1	-4.42	1.11e-05	9e-04	-0.19	-0.14	Primary sclerosing cholangitis;	chr11:111763630	chr11:112029858~112030367:-
BRCA	cis	rs11779988	0.545	rs439374	ENSG00000253671.1	RP11-806O11.1	-4.42	1.11e-05	9e-04	-0.19	-0.14	Breast cancer;	chr8:17929309	chr8:17808941~17820868:+
BRCA	cis	rs2731006	0.64	rs1009431	ENSG00000257114.2	RP11-25I15.3	4.42	1.11e-05	9e-04	0.22	0.14	Panic disorder;	chr12:42778619	chr12:42692216~42717119:+
BRCA	cis	rs2731006	0.64	rs1554248	ENSG00000257114.2	RP11-25I15.3	4.42	1.11e-05	9e-04	0.22	0.14	Panic disorder;	chr12:42778750	chr12:42692216~42717119:+
BRCA	cis	rs2731006	0.64	rs2678153	ENSG00000257114.2	RP11-25I15.3	4.42	1.11e-05	9e-04	0.22	0.14	Panic disorder;	chr12:42779053	chr12:42692216~42717119:+
BRCA	cis	rs2731006	0.592	rs2255712	ENSG00000257114.2	RP11-25I15.3	4.42	1.11e-05	9e-04	0.22	0.14	Panic disorder;	chr12:42779424	chr12:42692216~42717119:+
BRCA	cis	rs2731006	0.64	rs2255713	ENSG00000257114.2	RP11-25I15.3	4.42	1.11e-05	9e-04	0.22	0.14	Panic disorder;	chr12:42779430	chr12:42692216~42717119:+
BRCA	cis	rs2243480	1	rs1979823	ENSG00000275400.1	RP4-756H11.5	-4.42	1.11e-05	0.000901	-0.25	-0.14	Diabetic kidney disease;	chr7:66239626	chr7:66553805~66554199:-
BRCA	cis	rs871012	0.502	rs4704865	ENSG00000248544.2	CTB-47B11.3	-4.42	1.11e-05	0.000901	-0.17	-0.14	IgG glycosylation;	chr5:157465802	chr5:157375741~157384950:-
BRCA	cis	rs4664293	1	rs4665083	ENSG00000224152.1	AC009506.1	4.42	1.11e-05	0.000902	0.15	0.14	Monocyte percentage of white cells;	chr2:159573616	chr2:159615296~159617082:+
BRCA	cis	rs6430585	0.64	rs3816155	ENSG00000231890.6	DARS-AS1	4.42	1.11e-05	0.000902	0.2	0.14	Corneal structure;	chr2:135794956	chr2:135985176~136022593:+
BRCA	cis	rs6860806	0.631	rs7736284	ENSG00000233006.5	AC034220.3	4.42	1.11e-05	0.000902	0.1	0.14	Breast cancer;	chr5:132252458	chr5:132311285~132369916:-
BRCA	cis	rs4780355	1	rs1111186	ENSG00000262703.1	RP11-485G7.6	4.42	1.11e-05	0.000903	0.14	0.14	Crohn's disease and psoriasis;	chr16:11253191	chr16:11348143~11349321:-
BRCA	cis	rs801193	0.569	rs35070132	ENSG00000236529.1	RP13-254B10.1	4.42	1.11e-05	0.000903	0.15	0.14	Aortic root size;	chr7:66773096	chr7:65840212~65840596:+
BRCA	cis	rs1555322	1	rs2425027	ENSG00000279253.1	RP4-614O4.13	-4.42	1.11e-05	0.000903	-0.22	-0.14	Attention deficit hyperactivity disorder;	chr20:35261587	chr20:35262727~35264187:-
BRCA	cis	rs7267979	1	rs2474777	ENSG00000277938.1	RP5-965G21.3	4.42	1.12e-05	0.000904	0.16	0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25291997	chr20:25229150~25231933:+
BRCA	cis	rs1005277	0.541	rs2472177	ENSG00000099251.13	HSD17B7P2	4.42	1.12e-05	0.000904	0.15	0.14	Extrinsic epigenetic age acceleration;	chr10:38095087	chr10:38356380~38378505:+
BRCA	cis	rs875971	0.545	rs6950988	ENSG00000230295.1	RP11-458F8.2	4.42	1.12e-05	0.000904	0.13	0.14	Aortic root size;	chr7:66511428	chr7:66880708~66882981:+
BRCA	cis	rs495337	0.76	rs4810995	ENSG00000229222.1	KRT18P4	-4.42	1.12e-05	0.000904	-0.17	-0.14	Psoriasis;	chr20:49955265	chr20:49956745~49958032:+
BRCA	cis	rs7475343	0.543	rs17134616	ENSG00000224034.1	RP11-445P17.8	-4.42	1.12e-05	0.000904	-0.26	-0.14	Intelligence;	chr10:5221498	chr10:5266033~5271236:-
BRCA	cis	rs7267979	0.868	rs6138550	ENSG00000125804.12	FAM182A	-4.41	1.12e-05	0.000904	-0.18	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25242794	chr20:26054655~26086917:+
BRCA	cis	rs10129255	0.719	rs7156660	ENSG00000211974.3	IGHV2-70	4.41	1.12e-05	0.000904	0.14	0.14	Kawasaki disease;	chr14:106673171	chr14:106723574~106724093:-
BRCA	cis	rs10938353	0.911	rs6447362	ENSG00000273369.1	RP11-700J17.1	-4.41	1.12e-05	0.000905	-0.15	-0.14	Body mass index;	chr4:44599880	chr4:44693946~44694386:-
BRCA	cis	rs10938353	0.911	rs1439356	ENSG00000273369.1	RP11-700J17.1	-4.41	1.12e-05	0.000905	-0.15	-0.14	Body mass index;	chr4:44600669	chr4:44693946~44694386:-
BRCA	cis	rs10938353	0.911	rs10805128	ENSG00000273369.1	RP11-700J17.1	-4.41	1.12e-05	0.000905	-0.15	-0.14	Body mass index;	chr4:44601014	chr4:44693946~44694386:-
BRCA	cis	rs6081541	1	rs6106043	ENSG00000179447.2	RP5-1027G4.3	-4.41	1.12e-05	0.000905	-0.18	-0.14	Psychosis (atypical);	chr20:19241607	chr20:19242302~19284596:-
BRCA	cis	rs7833986	0.501	rs2953909	ENSG00000253603.1	CTA-397H3.3	-4.41	1.12e-05	0.000905	-0.2	-0.14	Height;	chr8:56055641	chr8:56074592~56075274:+
BRCA	cis	rs7833986	0.501	rs2953910	ENSG00000253603.1	CTA-397H3.3	-4.41	1.12e-05	0.000905	-0.2	-0.14	Height;	chr8:56056202	chr8:56074592~56075274:+
BRCA	cis	rs2832191	0.716	rs7284006	ENSG00000232855.5	AF131217.1	-4.41	1.12e-05	0.000905	-0.16	-0.14	Dental caries;	chr21:29102865	chr21:28439346~28674848:-
BRCA	cis	rs7829975	0.572	rs7005000	ENSG00000254153.1	CTA-398F10.2	-4.41	1.12e-05	0.000905	-0.16	-0.14	Mood instability;	chr8:8939092	chr8:8456909~8461337:-
BRCA	cis	rs1005277	0.505	rs13503	ENSG00000226578.1	RP11-258F22.1	4.41	1.12e-05	0.000905	0.14	0.14	Extrinsic epigenetic age acceleration;	chr10:37950915	chr10:37775371~37784131:-
BRCA	cis	rs7111546	1	rs12293188	ENSG00000246225.5	RP11-17A1.3	4.41	1.12e-05	0.000906	0.21	0.14	Dialysis-related mortality;	chr11:22797828	chr11:22829380~22945393:+
BRCA	cis	rs875971	0.545	rs67775320	ENSG00000273142.1	RP11-458F8.4	4.41	1.12e-05	0.000906	0.13	0.14	Aortic root size;	chr7:66193792	chr7:66902857~66906297:+
BRCA	cis	rs651907	0.557	rs17411983	ENSG00000256628.3	ZBTB11-AS1	-4.41	1.12e-05	0.000906	-0.17	-0.14	Colorectal cancer;	chr3:101680282	chr3:101676475~101679217:+
BRCA	cis	rs7772486	0.727	rs11155442	ENSG00000270638.1	RP3-466P17.1	4.41	1.12e-05	0.000906	0.16	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145819589	chr6:145735570~145737218:+
BRCA	cis	rs10181042	0.514	rs1177289	ENSG00000212978.6	AC016747.3	4.41	1.12e-05	0.000906	0.18	0.14	Crohn's disease;	chr2:61126121	chr2:61141592~61144969:-
BRCA	cis	rs11779988	0.545	rs448882	ENSG00000253671.1	RP11-806O11.1	-4.41	1.12e-05	0.000906	-0.2	-0.14	Breast cancer;	chr8:17936530	chr8:17808941~17820868:+
BRCA	cis	rs7267979	0.565	rs4815437	ENSG00000204556.4	CTD-2514C3.1	4.41	1.12e-05	0.000906	0.18	0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25604152	chr20:26018832~26020684:+
BRCA	cis	rs3768617	0.811	rs12738377	ENSG00000224468.3	RP11-181K3.4	-4.41	1.12e-05	0.000907	-0.15	-0.14	Fuchs's corneal dystrophy;	chr1:183062121	chr1:183138402~183141282:-
BRCA	cis	rs7927592	0.763	rs4340059	ENSG00000212093.1	AP000807.1	4.41	1.12e-05	0.000907	0.14	0.14	Total body bone mineral density;	chr11:68594965	chr11:68506083~68506166:-
BRCA	cis	rs1005277	0.505	rs7069702	ENSG00000226578.1	RP11-258F22.1	4.41	1.12e-05	0.000907	0.14	0.14	Extrinsic epigenetic age acceleration;	chr10:37958431	chr10:37775371~37784131:-
BRCA	cis	rs6480314	0.636	rs61854788	ENSG00000233590.1	RP11-153K11.3	-4.41	1.12e-05	0.000908	-0.23	-0.14	Optic nerve measurement (disc area);	chr10:68241980	chr10:68233251~68242379:-
BRCA	cis	rs216345	0.642	rs471371	ENSG00000260947.1	RP11-384P7.7	4.41	1.12e-05	0.000908	0.14	0.14	Bipolar disorder;	chr9:33870846	chr9:33697459~33700986:+
BRCA	cis	rs642803	0.613	rs489574	ENSG00000255557.1	RP11-770G2.2	-4.41	1.12e-05	0.000908	-0.17	-0.14	Urate levels;	chr11:65775268	chr11:65745729~65771585:+
BRCA	cis	rs2842346	0.568	rs2525521	ENSG00000258623.1	CTD-2325P2.3	-4.41	1.12e-05	0.000908	-0.18	-0.14	Breast cancer;	chr14:68536600	chr14:68683411~68685565:-
BRCA	cis	rs7646881	0.904	rs112493023	ENSG00000240207.5	RP11-379F4.4	-4.41	1.12e-05	0.000909	-0.19	-0.14	Tetralogy of Fallot;	chr3:158730487	chr3:158732263~158784070:+
BRCA	cis	rs10986311	0.791	rs927610	ENSG00000227200.1	RP11-121A14.3	-4.41	1.12e-05	0.000909	-0.16	-0.14	Vitiligo;	chr9:124338545	chr9:124262876~124265809:+
BRCA	cis	rs11098499	0.863	rs6534139	ENSG00000260404.2	RP11-384K6.6	-4.41	1.12e-05	0.000909	-0.13	-0.14	Corneal astigmatism;	chr4:119528301	chr4:118591773~118633729:+
BRCA	cis	rs10492201	0.529	rs7313068	ENSG00000236946.2	HNRNPA1P70	4.41	1.12e-05	0.00091	0.13	0.14	Itch intensity from mosquito bite adjusted by bite size;	chr12:68011805	chr12:68035767~68036853:+
BRCA	cis	rs7111546	1	rs12281140	ENSG00000246225.5	RP11-17A1.3	4.41	1.12e-05	0.00091	0.21	0.14	Dialysis-related mortality;	chr11:22801788	chr11:22829380~22945393:+
BRCA	cis	rs11742741	0.967	rs10520917	ENSG00000248874.4	C5orf17	-4.41	1.12e-05	0.00091	-0.18	-0.14	Educational attainment;	chr5:24139826	chr5:23951348~24178263:+
BRCA	cis	rs748404	0.666	rs12908460	ENSG00000205771.5	CATSPER2P1	-4.41	1.12e-05	0.000911	-0.2	-0.14	Lung cancer;	chr15:43413472	chr15:43726918~43747094:-
BRCA	cis	rs748404	0.666	rs2230451	ENSG00000205771.5	CATSPER2P1	-4.41	1.12e-05	0.000911	-0.2	-0.14	Lung cancer;	chr15:43415610	chr15:43726918~43747094:-
BRCA	cis	rs748404	0.666	rs62021180	ENSG00000205771.5	CATSPER2P1	-4.41	1.12e-05	0.000911	-0.2	-0.14	Lung cancer;	chr15:43420139	chr15:43726918~43747094:-
BRCA	cis	rs56322409	0.686	rs10882638	ENSG00000226688.5	ENTPD1-AS1	4.41	1.12e-05	0.000911	0.14	0.14	Blood metabolite levels;	chr10:95607967	chr10:95753206~96090238:-
BRCA	cis	rs1823874	0.677	rs4381582	ENSG00000182397.13	DNM1P46	-4.41	1.12e-05	0.000911	-0.15	-0.14	IgG glycosylation;	chr15:99820308	chr15:99790156~99806927:-
BRCA	cis	rs8040855	0.627	rs4843019	ENSG00000259774.1	RP11-182J1.13	-4.41	1.12e-05	0.000911	-0.19	-0.14	Bulimia nervosa;	chr15:85101228	chr15:84422618~84425882:+
BRCA	cis	rs2839186	0.9	rs2839200	ENSG00000239415.1	AP001469.9	4.41	1.12e-05	0.000911	0.14	0.14	Testicular germ cell tumor;	chr21:46289181	chr21:46251549~46254133:-
BRCA	cis	rs7523050	0.643	rs34367763	ENSG00000203897.3	SPATA42	-4.41	1.12e-05	0.000911	-0.26	-0.14	Fat distribution (HIV);	chr1:108858183	chr1:108857217~108858524:+
BRCA	cis	rs7523050	0.643	rs35662800	ENSG00000203897.3	SPATA42	-4.41	1.12e-05	0.000911	-0.26	-0.14	Fat distribution (HIV);	chr1:108858194	chr1:108857217~108858524:+
BRCA	cis	rs7523050	0.643	rs17621851	ENSG00000203897.3	SPATA42	-4.41	1.12e-05	0.000911	-0.26	-0.14	Fat distribution (HIV);	chr1:108858213	chr1:108857217~108858524:+
BRCA	cis	rs7523050	0.643	rs34920128	ENSG00000203897.3	SPATA42	-4.41	1.12e-05	0.000911	-0.26	-0.14	Fat distribution (HIV);	chr1:108858267	chr1:108857217~108858524:+
BRCA	cis	rs2243480	1	rs427044	ENSG00000275400.1	RP4-756H11.5	4.41	1.13e-05	0.000912	0.25	0.14	Diabetic kidney disease;	chr7:66043558	chr7:66553805~66554199:-
BRCA	cis	rs6063349	1	rs6063349	ENSG00000227431.4	CSE1L-AS1	-4.41	1.13e-05	0.000912	-0.18	-0.14	Non-response to citalopram or escitalopram and depression;	chr20:49065345	chr20:49040463~49046044:-
BRCA	cis	rs6968419	0.747	rs56293030	ENSG00000279086.1	RP11-667F14.1	-4.41	1.13e-05	0.000912	-0.15	-0.14	Intraocular pressure;	chr7:116217116	chr7:116209234~116211511:-
BRCA	cis	rs4781563	0.956	rs3136085	ENSG00000242307.1	RPS26P52	-4.41	1.13e-05	0.000912	-0.17	-0.14	Bilirubin levels;	chr16:13925724	chr16:13922332~13922679:-
BRCA	cis	rs71520386	0.846	rs35247857	ENSG00000230658.1	KLHL7-AS1	4.41	1.13e-05	0.000913	0.23	0.14	Fibrinogen levels;	chr7:22780901	chr7:23101228~23105703:-
BRCA	cis	rs7727544	0.582	rs3828675	ENSG00000233006.5	AC034220.3	4.41	1.13e-05	0.000913	0.1	0.14	Blood metabolite levels;	chr5:132211175	chr5:132311285~132369916:-
BRCA	cis	rs6671200	1	rs60929805	ENSG00000235501.4	RP4-639F20.1	-4.41	1.13e-05	0.000913	-0.31	-0.14	Stearic acid (18:0) levels;	chr1:95180830	chr1:94927566~94963270:+
BRCA	cis	rs224278	0.604	rs1040875	ENSG00000238280.1	RP11-436D10.3	-4.41	1.13e-05	0.000913	-0.17	-0.14	Ewing sarcoma;	chr10:62828449	chr10:62793562~62805887:-
BRCA	cis	rs442309	0.875	rs224146	ENSG00000238280.1	RP11-436D10.3	-4.41	1.13e-05	0.000914	-0.17	-0.14	Vogt-Koyanagi-Harada syndrome;	chr10:62723179	chr10:62793562~62805887:-
BRCA	cis	rs7173743	0.518	rs12899452	ENSG00000261143.1	ADAMTS7P3	-4.41	1.13e-05	0.000914	-0.16	-0.14	Coronary artery disease;	chr15:78820208	chr15:77976042~77993057:+
BRCA	cis	rs1371614	0.635	rs4665923	ENSG00000272148.1	RP11-195B17.1	4.41	1.13e-05	0.000914	0.15	0.14	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26916043	chr2:27062428~27062907:-
BRCA	cis	rs10129255	0.872	rs8015406	ENSG00000211967.3	IGHV3-53	-4.41	1.13e-05	0.000914	-0.1	-0.14	Kawasaki disease;	chr14:106670611	chr14:106592676~106593347:-
BRCA	cis	rs4664293	0.625	rs3821300	ENSG00000226266.5	AC009961.3	4.41	1.13e-05	0.000914	0.16	0.14	Monocyte percentage of white cells;	chr2:159710719	chr2:159670708~159712435:-
BRCA	cis	rs2898681	0.874	rs4864688	ENSG00000248375.1	RP11-177B4.1	-4.41	1.13e-05	0.000914	-0.19	-0.14	Optic nerve measurement (cup area);	chr4:52876469	chr4:52720081~52720831:-
BRCA	cis	rs2839186	0.814	rs2276257	ENSG00000239415.1	AP001469.9	4.41	1.13e-05	0.000914	0.14	0.14	Testicular germ cell tumor;	chr21:46291315	chr21:46251549~46254133:-
BRCA	cis	rs6445967	1	rs14927	ENSG00000273493.1	RP11-80H18.4	4.41	1.13e-05	0.000914	0.17	0.14	Platelet count;	chr3:58319306	chr3:58329965~58330118:+
BRCA	cis	rs7487075	0.78	rs12320197	ENSG00000272369.1	RP11-446N19.1	4.41	1.13e-05	0.000914	0.14	0.14	Itch intensity from mosquito bite;	chr12:46345100	chr12:46537502~46652550:+
BRCA	cis	rs6452524	0.868	rs1011981	ENSG00000281327.1	LINC01338	4.41	1.13e-05	0.000914	0.16	0.14	Hypertension (SNP x SNP interaction);	chr5:83097869	chr5:82850864~82859836:-
BRCA	cis	rs6452524	0.868	rs17284218	ENSG00000281327.1	LINC01338	4.41	1.13e-05	0.000914	0.16	0.14	Hypertension (SNP x SNP interaction);	chr5:83099530	chr5:82850864~82859836:-
BRCA	cis	rs6921919	0.609	rs36018474	ENSG00000273712.1	RP5-874C20.7	4.41	1.13e-05	0.000915	0.18	0.14	Autism spectrum disorder or schizophrenia;	chr6:28417752	chr6:28315613~28315883:-
BRCA	cis	rs6921919	0.583	rs13201726	ENSG00000273712.1	RP5-874C20.7	4.41	1.13e-05	0.000915	0.18	0.14	Autism spectrum disorder or schizophrenia;	chr6:28417774	chr6:28315613~28315883:-
BRCA	cis	rs1499614	1	rs1267818	ENSG00000222364.1	RNU6-96P	-4.41	1.13e-05	0.000915	-0.25	-0.14	Gout;	chr7:66642037	chr7:66395191~66395286:+
BRCA	cis	rs6686842	0.56	rs213758	ENSG00000235358.1	RP11-399E6.1	4.41	1.13e-05	0.000915	0.19	0.14	Height;	chr1:41128452	chr1:41242373~41284861:+
BRCA	cis	rs1949733	0.666	rs3103070	ENSG00000205959.3	RP11-689P11.2	4.41	1.13e-05	0.000915	0.13	0.14	Response to antineoplastic agents;	chr4:8507098	chr4:8482270~8512610:+
BRCA	cis	rs7267979	0.528	rs34485039	ENSG00000231081.1	RP4-760C5.3	4.41	1.13e-05	0.000915	0.17	0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25603127	chr20:26008791~26010531:-
BRCA	cis	rs35123781	0.654	rs356486	ENSG00000249526.1	CTB-35F21.1	-4.41	1.13e-05	0.000915	-0.17	-0.14	Schizophrenia;	chr5:139705518	chr5:139684645~139745010:+
BRCA	cis	rs984222	0.648	rs6428801	ENSG00000231365.4	RP11-418J17.1	-4.41	1.13e-05	0.000915	-0.16	-0.14	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119145867	chr1:119140396~119275973:+
BRCA	cis	rs610932	0.517	rs650943	ENSG00000275344.1	MIR6503	-4.41	1.13e-05	0.000915	-0.14	-0.14	Alzheimer's disease;	chr11:60239292	chr11:60209071~60209156:-
BRCA	cis	rs2562456	0.833	rs516519	ENSG00000268535.1	RP11-420K14.3	-4.41	1.13e-05	0.000915	-0.18	-0.14	Pain;	chr19:21298730	chr19:21709522~21710191:+
BRCA	cis	rs4787491	0.704	rs66467443	ENSG00000183604.13	SMG1P5	-4.41	1.13e-05	0.000915	-0.13	-0.14	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30039173	chr16:30267553~30335374:-
BRCA	cis	rs1722141	0.669	rs788734	ENSG00000229628.1	AC073115.7	4.41	1.13e-05	0.000916	0.18	0.14	Sitting height ratio;	chr7:45993654	chr7:45990905~46000898:+
BRCA	cis	rs4908769	0.624	rs3765971	ENSG00000270282.1	RP5-1115A15.2	-4.41	1.13e-05	0.000916	-0.16	-0.14	Allergy;	chr1:8385300	chr1:8512653~8513021:+
BRCA	cis	rs2731006	0.544	rs2252131	ENSG00000257114.2	RP11-25I15.3	4.41	1.13e-05	0.000916	0.22	0.14	Panic disorder;	chr12:42772934	chr12:42692216~42717119:+
BRCA	cis	rs2803122	0.967	rs10123206	ENSG00000273226.1	RP11-513M16.8	4.41	1.13e-05	0.000916	0.15	0.14	Pulse pressure;	chr9:19246846	chr9:19375451~19375996:+
BRCA	cis	rs17270561	1	rs79867288	ENSG00000272462.2	U91328.19	-4.41	1.13e-05	0.000916	-0.2	-0.14	Iron status biomarkers;	chr6:25828188	chr6:25992662~26001775:+
BRCA	cis	rs17270561	1	rs12200962	ENSG00000272462.2	U91328.19	-4.41	1.13e-05	0.000916	-0.2	-0.14	Iron status biomarkers;	chr6:25828758	chr6:25992662~26001775:+
BRCA	cis	rs10129255	0.5	rs6576231	ENSG00000211959.2	IGHV4-39	4.41	1.13e-05	0.000916	0.09	0.14	Kawasaki disease;	chr14:106783693	chr14:106421711~106422218:-
BRCA	cis	rs4869313	0.869	rs7716222	ENSG00000248734.2	CTD-2260A17.1	4.41	1.13e-05	0.000916	0.14	0.14	Pediatric autoimmune diseases;	chr5:96957302	chr5:96784777~96785999:+
BRCA	cis	rs4869313	0.837	rs2351010	ENSG00000248734.2	CTD-2260A17.1	4.41	1.13e-05	0.000916	0.14	0.14	Pediatric autoimmune diseases;	chr5:96958225	chr5:96784777~96785999:+
BRCA	cis	rs7615952	0.932	rs13325495	ENSG00000248787.1	RP11-666A20.4	-4.41	1.13e-05	0.000916	-0.24	-0.14	Blood pressure (smoking interaction);	chr3:125918573	chr3:125908005~125910272:-
BRCA	cis	rs6832769	0.925	rs11133383	ENSG00000272969.1	RP11-528I4.2	-4.41	1.13e-05	0.000916	-0.16	-0.14	Personality dimensions;	chr4:55450878	chr4:55547112~55547889:+
BRCA	cis	rs2179367	0.959	rs579789	ENSG00000223701.3	RAET1E-AS1	4.41	1.13e-05	0.000916	0.17	0.14	Dupuytren's disease;	chr6:149358235	chr6:149884431~149919508:+
BRCA	cis	rs2179367	0.959	rs489551	ENSG00000223701.3	RAET1E-AS1	4.41	1.13e-05	0.000916	0.17	0.14	Dupuytren's disease;	chr6:149368321	chr6:149884431~149919508:+
BRCA	cis	rs6696239	1	rs10916162	ENSG00000227711.2	RP11-275O4.5	-4.41	1.13e-05	0.000916	-0.19	-0.14	Height;	chr1:227550092	chr1:227509028~227520477:-
BRCA	cis	rs2380205	0.967	rs2203197	ENSG00000232807.2	RP11-536K7.3	-4.41	1.13e-05	0.000917	-0.14	-0.14	Breast cancer;	chr10:5862955	chr10:5934270~5945900:-
BRCA	cis	rs17826219	0.789	rs4794873	ENSG00000266490.1	CTD-2349P21.9	4.41	1.13e-05	0.000917	0.2	0.14	Body mass index;	chr17:30421334	chr17:30792372~30792833:+
BRCA	cis	rs8103278	1	rs8108864	ENSG00000267395.4	AC074212.6	4.41	1.13e-05	0.000917	0.14	0.14	Coronary artery disease;	chr19:45798413	chr19:45767796~45772504:+
BRCA	cis	rs6831352	0.734	rs2602856	ENSG00000272777.1	RP11-571L19.8	-4.41	1.13e-05	0.000917	-0.14	-0.14	Alcohol dependence;	chr4:99107994	chr4:99067256~99068125:-
BRCA	cis	rs6430585	0.64	rs58301703	ENSG00000231890.6	DARS-AS1	-4.41	1.13e-05	0.000917	-0.21	-0.14	Corneal structure;	chr2:135774655	chr2:135985176~136022593:+
BRCA	cis	rs1858037	0.806	rs12612780	ENSG00000237979.1	AC007389.1	4.41	1.13e-05	0.000918	0.17	0.14	Rheumatoid arthritis;	chr2:65355967	chr2:65500993~65502138:-
BRCA	cis	rs7577696	0.695	rs62134021	ENSG00000272716.1	RP11-563N4.1	4.41	1.13e-05	0.000918	0.15	0.14	Inflammatory biomarkers;	chr2:32189905	chr2:32165046~32165757:-
BRCA	cis	rs7985	0.523	rs1045362	ENSG00000225783.5	MIAT	-4.41	1.13e-05	0.000918	-0.11	-0.14	Electroencephalogram traits;	chr22:26676177	chr22:26646428~26676475:+
BRCA	cis	rs10863681	1	rs10863681	ENSG00000232679.1	RP11-400N13.3	4.41	1.13e-05	0.000918	0.14	0.14	Metabolite levels (HVA-5-HIAA Factor score);	chr1:222071916	chr1:222041705~222064763:-
BRCA	cis	rs4578769	0.959	rs11082184	ENSG00000265939.1	UBE2CP2	4.41	1.13e-05	0.000918	0.16	0.14	Eosinophil percentage of white cells;	chr18:22872288	chr18:22900486~22900995:-
BRCA	cis	rs2731006	0.64	rs2678102	ENSG00000257114.2	RP11-25I15.3	4.41	1.13e-05	0.000919	0.22	0.14	Panic disorder;	chr12:42775130	chr12:42692216~42717119:+
BRCA	cis	rs875971	0.66	rs1860468	ENSG00000223473.2	GS1-124K5.3	-4.41	1.14e-05	0.000919	-0.1	-0.14	Aortic root size;	chr7:66642265	chr7:66491049~66493566:-
BRCA	cis	rs77204473	1	rs75294699	ENSG00000280143.1	AP000892.6	-4.41	1.14e-05	0.000919	-0.26	-0.14	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116878356	chr11:117204967~117210292:+
BRCA	cis	rs7045881	1	rs7045881	ENSG00000254396.1	RP11-56F10.3	-4.41	1.14e-05	0.000919	-0.22	-0.14	Schizophrenia;	chr9:26935998	chr9:27102630~27104728:+
BRCA	cis	rs7267979	0.739	rs6138555	ENSG00000276952.1	RP5-965G21.6	4.41	1.14e-05	0.000919	0.17	0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25262274	chr20:25284915~25285588:-
BRCA	cis	rs6545883	0.929	rs778140	ENSG00000212978.6	AC016747.3	4.41	1.14e-05	0.000919	0.19	0.14	Tuberculosis;	chr2:61455841	chr2:61141592~61144969:-
BRCA	cis	rs4218	0.689	rs2121237	ENSG00000277144.1	RP11-59H7.4	-4.41	1.14e-05	0.00092	-0.18	-0.14	Social communication problems;	chr15:59091888	chr15:59115547~59116089:-
BRCA	cis	rs4218	0.648	rs35460138	ENSG00000277144.1	RP11-59H7.4	-4.41	1.14e-05	0.00092	-0.18	-0.14	Social communication problems;	chr15:59093200	chr15:59115547~59116089:-
BRCA	cis	rs7260598	0.605	rs67492250	ENSG00000268442.1	CTD-2027I19.2	4.41	1.14e-05	0.00092	0.21	0.14	Response to taxane treatment (placlitaxel);	chr19:23924293	chr19:24162370~24163425:-
BRCA	cis	rs7772486	0.754	rs6906258	ENSG00000270638.1	RP3-466P17.1	-4.41	1.14e-05	0.00092	-0.16	-0.14	Lobe attachment (rater-scored or self-reported);	chr6:145768220	chr6:145735570~145737218:+
BRCA	cis	rs783540	0.681	rs1259178	ENSG00000276710.3	CSPG4P8	4.41	1.14e-05	0.00092	0.15	0.14	Schizophrenia;	chr15:82603127	chr15:82459472~82477258:+
BRCA	cis	rs58521262	0.556	rs158694	ENSG00000268105.1	RP11-369G6.2	-4.41	1.14e-05	0.00092	-0.18	-0.14	Testicular germ cell tumor;	chr19:23019974	chr19:23125665~23128543:+
BRCA	cis	rs412050	0.793	rs17821866	ENSG00000224086.5	LL22NC03-86G7.1	-4.41	1.14e-05	0.00092	-0.21	-0.14	Attention deficit hyperactivity disorder;	chr22:21988067	chr22:21938293~21977632:+
BRCA	cis	rs13113518	0.902	rs12505266	ENSG00000272969.1	RP11-528I4.2	4.41	1.14e-05	0.00092	0.16	0.14	Height;	chr4:55546002	chr4:55547112~55547889:+
BRCA	cis	rs763014	0.932	rs2384972	ENSG00000260394.2	LA16c-313D11.9	-4.41	1.14e-05	0.000921	-0.13	-0.14	Height;	chr16:624424	chr16:678504~679777:-
BRCA	cis	rs67539049	1	rs2001462	ENSG00000154316.13	TDH	-4.41	1.14e-05	0.000921	-0.22	-0.14	Itch intensity from mosquito bite;	chr8:11437301	chr8:11339637~11368452:+
BRCA	cis	rs1707322	0.789	rs7540578	ENSG00000234329.1	RP11-767N6.2	4.41	1.14e-05	0.000921	0.14	0.14	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45786472	chr1:45651039~45651826:-
BRCA	cis	rs7119	0.634	rs2682922	ENSG00000259362.2	RP11-307C19.1	4.41	1.14e-05	0.000921	0.18	0.14	Type 2 diabetes;	chr15:77572664	chr15:77525540~77534110:+
BRCA	cis	rs11098499	0.909	rs28555550	ENSG00000250412.1	KLHL2P1	4.41	1.14e-05	0.000921	0.16	0.14	Corneal astigmatism;	chr4:119289885	chr4:119334329~119378233:+
BRCA	cis	rs11098499	1	rs28419773	ENSG00000250412.1	KLHL2P1	4.41	1.14e-05	0.000921	0.16	0.14	Corneal astigmatism;	chr4:119289906	chr4:119334329~119378233:+
BRCA	cis	rs2446066	0.799	rs76805893	ENSG00000257379.1	RP11-793H13.8	4.41	1.14e-05	0.000921	0.21	0.14	Red blood cell count;	chr12:53436335	chr12:53441741~53467528:+
BRCA	cis	rs1858037	0.867	rs1039765	ENSG00000281920.1	RP11-418H16.1	-4.41	1.14e-05	0.000922	-0.17	-0.14	Rheumatoid arthritis;	chr2:65387228	chr2:65623272~65628424:+
BRCA	cis	rs8054556	1	rs4788209	ENSG00000261367.1	RP11-455F5.4	-4.41	1.14e-05	0.000922	-0.15	-0.14	Autism spectrum disorder or schizophrenia;	chr16:30001945	chr16:30107675~30110541:+
BRCA	cis	rs8054556	1	rs4788210	ENSG00000261367.1	RP11-455F5.4	-4.41	1.14e-05	0.000922	-0.15	-0.14	Autism spectrum disorder or schizophrenia;	chr16:30002353	chr16:30107675~30110541:+
BRCA	cis	rs4664293	0.625	rs7590617	ENSG00000226266.5	AC009961.3	4.41	1.14e-05	0.000922	0.16	0.14	Monocyte percentage of white cells;	chr2:159775437	chr2:159670708~159712435:-
BRCA	cis	rs4664293	0.625	rs7564585	ENSG00000226266.5	AC009961.3	4.41	1.14e-05	0.000922	0.16	0.14	Monocyte percentage of white cells;	chr2:159775582	chr2:159670708~159712435:-
BRCA	cis	rs4664293	0.546	rs7564399	ENSG00000226266.5	AC009961.3	4.41	1.14e-05	0.000922	0.16	0.14	Monocyte percentage of white cells;	chr2:159775608	chr2:159670708~159712435:-
BRCA	cis	rs2832191	0.967	rs2251377	ENSG00000176054.6	RPL23P2	4.41	1.14e-05	0.000922	0.15	0.14	Dental caries;	chr21:29158278	chr21:28997613~28998033:-
BRCA	cis	rs4664293	0.625	rs35481084	ENSG00000226266.5	AC009961.3	4.41	1.14e-05	0.000922	0.16	0.14	Monocyte percentage of white cells;	chr2:159777729	chr2:159670708~159712435:-
BRCA	cis	rs4664293	0.625	rs10460300	ENSG00000226266.5	AC009961.3	4.41	1.14e-05	0.000922	0.16	0.14	Monocyte percentage of white cells;	chr2:159778210	chr2:159670708~159712435:-
BRCA	cis	rs6802315	0.604	rs2364927	ENSG00000272087.1	RP11-379F4.7	4.41	1.14e-05	0.000922	0.16	0.14	Periodontitis (CDC/AAP);	chr3:158760066	chr3:158693120~158693768:-
BRCA	cis	rs2908197	0.699	rs2860469	ENSG00000186704.9	DTX2P1	4.41	1.14e-05	0.000923	0.16	0.14	3-hydroxypropylmercapturic acid levels in smokers;	chr7:76331189	chr7:76978617~77004308:+
BRCA	cis	rs7651446	0.85	rs2665390	ENSG00000240875.4	LINC00886	4.41	1.14e-05	0.000923	0.27	0.14	Ovarian cancer;Epithelial ovarian cancer;	chr3:156679960	chr3:156747346~156817062:-
BRCA	cis	rs2692947	0.727	rs893173	ENSG00000168992.4	OR7E102P	4.41	1.14e-05	0.000923	0.18	0.14	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96124048	chr2:95546531~95547545:+
BRCA	cis	rs7819412	0.522	rs10088853	ENSG00000255046.1	RP11-297N6.4	4.41	1.14e-05	0.000923	0.17	0.14	Triglycerides;	chr8:11130457	chr8:11797928~11802568:-
BRCA	cis	rs7204230	1	rs2287077	ENSG00000261291.1	RP11-295M3.2	4.41	1.14e-05	0.000923	0.17	0.14	Fibrinogen;	chr16:53288208	chr16:53168522~53169450:+
BRCA	cis	rs55780018	0.675	rs59314826	ENSG00000224137.1	AC079767.4	4.41	1.14e-05	0.000923	0.12	0.14	Systolic blood pressure;	chr2:207638834	chr2:207662375~207667024:+
BRCA	cis	rs6596100	0.91	rs56265094	ENSG00000248648.1	RP11-485M7.1	-4.41	1.14e-05	0.000923	-0.18	-0.14	Breast cancer;	chr5:133077156	chr5:133003119~133003365:+
BRCA	cis	rs8054556	1	rs7204797	ENSG00000214725.6	CDIPT-AS1	-4.41	1.14e-05	0.000923	-0.16	-0.14	Autism spectrum disorder or schizophrenia;	chr16:29956694	chr16:29863593~29868053:+
BRCA	cis	rs755249	0.567	rs3768302	ENSG00000182109.6	RP11-69E11.4	4.41	1.14e-05	0.000923	0.19	0.14	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39414647	chr1:39522280~39546187:-
BRCA	cis	rs6600671	1	rs1856572	ENSG00000270392.2	PFN1P2	4.41	1.14e-05	0.000924	0.15	0.14	Hip geometry;	chr1:121427719	chr1:120432204~120434052:-
BRCA	cis	rs6671200	1	rs10747468	ENSG00000226026.4	RP11-57H12.3	4.41	1.14e-05	0.000924	0.24	0.14	Stearic acid (18:0) levels;	chr1:95220735	chr1:95163219~95233982:-
BRCA	cis	rs6802315	0.575	rs57932243	ENSG00000272087.1	RP11-379F4.7	4.41	1.14e-05	0.000924	0.16	0.14	Periodontitis (CDC/AAP);	chr3:158754187	chr3:158693120~158693768:-
BRCA	cis	rs1371614	0.592	rs12613534	ENSG00000272148.1	RP11-195B17.1	-4.41	1.14e-05	0.000924	-0.15	-0.14	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26915726	chr2:27062428~27062907:-
BRCA	cis	rs35306767	0.807	rs11253513	ENSG00000229869.1	RP11-363N22.2	-4.41	1.14e-05	0.000924	-0.19	-0.14	Eosinophil percentage of granulocytes;	chr10:922510	chr10:933026~942743:+
BRCA	cis	rs35306767	0.953	rs12259338	ENSG00000229869.1	RP11-363N22.2	-4.41	1.14e-05	0.000924	-0.19	-0.14	Eosinophil percentage of granulocytes;	chr10:923437	chr10:933026~942743:+
BRCA	cis	rs938554	0.513	rs3775946	ENSG00000250413.1	RP11-448G15.1	-4.41	1.14e-05	0.000924	-0.19	-0.14	Blood metabolite levels;	chr4:9993632	chr4:10006482~10009725:+
BRCA	cis	rs6430585	1	rs6430585	ENSG00000224043.6	CCNT2-AS1	4.41	1.14e-05	0.000924	0.2	0.14	Corneal structure;	chr2:135749357	chr2:134735464~134918710:-
BRCA	cis	rs6480314	0.636	rs61854790	ENSG00000233590.1	RP11-153K11.3	-4.41	1.14e-05	0.000924	-0.23	-0.14	Optic nerve measurement (disc area);	chr10:68242491	chr10:68233251~68242379:-
BRCA	cis	rs6921919	0.525	rs6929825	ENSG00000220721.1	OR1F12	4.41	1.14e-05	0.000924	0.16	0.14	Autism spectrum disorder or schizophrenia;	chr6:28411182	chr6:28073316~28074233:+
BRCA	cis	rs6921919	0.583	rs35599905	ENSG00000220721.1	OR1F12	4.41	1.14e-05	0.000924	0.16	0.14	Autism spectrum disorder or schizophrenia;	chr6:28411886	chr6:28073316~28074233:+
BRCA	cis	rs6921919	0.583	rs1124131	ENSG00000220721.1	OR1F12	4.41	1.14e-05	0.000924	0.16	0.14	Autism spectrum disorder or schizophrenia;	chr6:28412471	chr6:28073316~28074233:+
BRCA	cis	rs6921919	0.583	rs6899389	ENSG00000220721.1	OR1F12	4.41	1.14e-05	0.000924	0.16	0.14	Autism spectrum disorder or schizophrenia;	chr6:28413363	chr6:28073316~28074233:+
BRCA	cis	rs6921919	0.583	rs6922374	ENSG00000220721.1	OR1F12	4.41	1.14e-05	0.000924	0.16	0.14	Autism spectrum disorder or schizophrenia;	chr6:28413495	chr6:28073316~28074233:+
BRCA	cis	rs6921919	0.583	rs6899603	ENSG00000220721.1	OR1F12	4.41	1.14e-05	0.000924	0.16	0.14	Autism spectrum disorder or schizophrenia;	chr6:28413528	chr6:28073316~28074233:+
BRCA	cis	rs6921919	0.583	rs6922429	ENSG00000220721.1	OR1F12	4.41	1.14e-05	0.000924	0.16	0.14	Autism spectrum disorder or schizophrenia;	chr6:28413568	chr6:28073316~28074233:+
BRCA	cis	rs4869313	0.837	rs1363976	ENSG00000248734.2	CTD-2260A17.1	-4.41	1.14e-05	0.000925	-0.14	-0.14	Pediatric autoimmune diseases;	chr5:96913091	chr5:96784777~96785999:+
BRCA	cis	rs11168618	0.904	rs7137866	ENSG00000240399.1	RP1-228P16.1	4.41	1.14e-05	0.000925	0.15	0.14	Adiponectin levels;	chr12:48529019	chr12:48054813~48055591:-
BRCA	cis	rs2041840	0.721	rs10779921	ENSG00000272054.1	RP11-423P10.2	-4.41	1.14e-05	0.000925	-0.12	-0.14	Chronic lymphocytic leukemia;	chr2:37213212	chr2:37208875~37212677:+
BRCA	cis	rs7727544	0.582	rs10075459	ENSG00000233006.5	AC034220.3	4.41	1.14e-05	0.000925	0.1	0.14	Blood metabolite levels;	chr5:132205670	chr5:132311285~132369916:-
BRCA	cis	rs875971	0.545	rs73136346	ENSG00000230295.1	RP11-458F8.2	-4.41	1.14e-05	0.000925	-0.13	-0.14	Aortic root size;	chr7:66101095	chr7:66880708~66882981:+
BRCA	cis	rs957448	0.539	rs9643346	ENSG00000253175.1	RP11-267M23.6	4.41	1.14e-05	0.000925	0.16	0.14	Nonsyndromic cleft lip with cleft palate;	chr8:94601587	chr8:94565036~94565715:+
BRCA	cis	rs7833986	0.501	rs17814658	ENSG00000253603.1	CTA-397H3.3	-4.41	1.14e-05	0.000925	-0.2	-0.14	Height;	chr8:56076571	chr8:56074592~56075274:+
BRCA	cis	rs6750047	0.719	rs100489	ENSG00000235848.3	RMDN2-AS1	4.41	1.14e-05	0.000925	0.18	0.14	Cutaneous malignant melanoma;Melanoma;	chr2:38039335	chr2:37949911~38067041:-
BRCA	cis	rs10266483	0.654	rs6962076	ENSG00000227986.1	TRIM60P18	4.41	1.14e-05	0.000925	0.15	0.14	Response to statin therapy;	chr7:64559214	chr7:64355078~64356199:+
BRCA	cis	rs10129255	0.5	rs2105991	ENSG00000211959.2	IGHV4-39	4.41	1.14e-05	0.000925	0.09	0.14	Kawasaki disease;	chr14:106682022	chr14:106421711~106422218:-
BRCA	cis	rs2834188	0.557	rs1058867	ENSG00000272659.1	AP000295.10	4.41	1.14e-05	0.000925	0.18	0.14	Narcolepsy;	chr21:33297076	chr21:33309491~33310181:+
BRCA	cis	rs7819412	0.691	rs73198970	ENSG00000154316.13	TDH	4.41	1.14e-05	0.000925	0.17	0.14	Triglycerides;	chr8:11182707	chr8:11339637~11368452:+
BRCA	cis	rs1005277	0.579	rs2504143	ENSG00000263064.2	RP11-291L22.7	4.41	1.14e-05	0.000926	0.17	0.14	Extrinsic epigenetic age acceleration;	chr10:38094778	chr10:38448689~38448949:+
BRCA	cis	rs2562456	0.917	rs2650804	ENSG00000213976.4	CTD-2561J22.2	-4.41	1.15e-05	0.000926	-0.16	-0.14	Pain;	chr19:21497382	chr19:21382865~21387177:+
BRCA	cis	rs4660214	0.671	rs16826012	ENSG00000228060.1	RP11-69E11.8	4.41	1.15e-05	0.000926	0.18	0.14	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39253847	chr1:39565160~39573203:+
BRCA	cis	rs6430585	0.528	rs12476127	ENSG00000231890.6	DARS-AS1	-4.41	1.15e-05	0.000926	-0.21	-0.14	Corneal structure;	chr2:136005672	chr2:135985176~136022593:+
BRCA	cis	rs7727544	0.547	rs10076758	ENSG00000233006.5	AC034220.3	4.41	1.15e-05	0.000927	0.1	0.14	Blood metabolite levels;	chr5:132188606	chr5:132311285~132369916:-
BRCA	cis	rs7523050	0.73	rs7519107	ENSG00000203897.3	SPATA42	-4.41	1.15e-05	0.000927	-0.26	-0.14	Fat distribution (HIV);	chr1:108856745	chr1:108857217~108858524:+
BRCA	cis	rs7523050	0.643	rs7519293	ENSG00000203897.3	SPATA42	-4.41	1.15e-05	0.000927	-0.26	-0.14	Fat distribution (HIV);	chr1:108856921	chr1:108857217~108858524:+
BRCA	cis	rs7523050	0.643	rs7522324	ENSG00000203897.3	SPATA42	-4.41	1.15e-05	0.000927	-0.26	-0.14	Fat distribution (HIV);	chr1:108857022	chr1:108857217~108858524:+
BRCA	cis	rs7523050	0.643	rs7551142	ENSG00000203897.3	SPATA42	-4.41	1.15e-05	0.000927	-0.26	-0.14	Fat distribution (HIV);	chr1:108857088	chr1:108857217~108858524:+
BRCA	cis	rs7523050	0.643	rs7551313	ENSG00000203897.3	SPATA42	-4.41	1.15e-05	0.000927	-0.26	-0.14	Fat distribution (HIV);	chr1:108857259	chr1:108857217~108858524:+
BRCA	cis	rs7523050	0.643	rs12736534	ENSG00000203897.3	SPATA42	-4.41	1.15e-05	0.000927	-0.26	-0.14	Fat distribution (HIV);	chr1:108857312	chr1:108857217~108858524:+
BRCA	cis	rs7523050	0.643	rs12741194	ENSG00000203897.3	SPATA42	-4.41	1.15e-05	0.000927	-0.26	-0.14	Fat distribution (HIV);	chr1:108857768	chr1:108857217~108858524:+
BRCA	cis	rs7523050	0.643	rs12741359	ENSG00000203897.3	SPATA42	-4.41	1.15e-05	0.000927	-0.26	-0.14	Fat distribution (HIV);	chr1:108857867	chr1:108857217~108858524:+
BRCA	cis	rs13113518	1	rs3805149	ENSG00000272969.1	RP11-528I4.2	4.41	1.15e-05	0.000927	0.16	0.14	Height;	chr4:55442184	chr4:55547112~55547889:+
BRCA	cis	rs13113518	1	rs11945370	ENSG00000272969.1	RP11-528I4.2	4.41	1.15e-05	0.000927	0.16	0.14	Height;	chr4:55442875	chr4:55547112~55547889:+
BRCA	cis	rs2898681	0.561	rs2200225	ENSG00000248375.1	RP11-177B4.1	-4.41	1.15e-05	0.000927	-0.21	-0.14	Optic nerve measurement (cup area);	chr4:52872244	chr4:52720081~52720831:-
BRCA	cis	rs7800418	0.963	rs10252484	ENSG00000214870.7	AC004540.5	4.41	1.15e-05	0.000927	0.19	0.14	Cognitive function;	chr7:26558727	chr7:26398593~26494256:+
BRCA	cis	rs7772486	0.754	rs9373476	ENSG00000270638.1	RP3-466P17.1	4.41	1.15e-05	0.000927	0.16	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145818605	chr6:145735570~145737218:+
BRCA	cis	rs9868809	0.772	rs9836462	ENSG00000270441.1	RP11-694I15.7	-4.41	1.15e-05	0.000927	-0.21	-0.14	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48675358	chr3:49140086~49160851:-
BRCA	cis	rs875971	0.545	rs6961853	ENSG00000230295.1	RP11-458F8.2	4.41	1.15e-05	0.000927	0.13	0.14	Aortic root size;	chr7:66537035	chr7:66880708~66882981:+
BRCA	cis	rs6951245	1	rs78185558	ENSG00000229043.2	AC091729.9	-4.41	1.15e-05	0.000928	-0.23	-0.14	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1050547	chr7:1160374~1165267:+
BRCA	cis	rs7475343	0.501	rs77364195	ENSG00000224034.1	RP11-445P17.8	-4.41	1.15e-05	0.000928	-0.25	-0.14	Intelligence;	chr10:5266772	chr10:5266033~5271236:-
BRCA	cis	rs8048589	0.615	rs34147612	ENSG00000175604.2	RP11-276H1.3	-4.41	1.15e-05	0.000928	-0.25	-0.14	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);	chr16:12139331	chr16:12086746~12090302:-
BRCA	cis	rs11098499	0.954	rs11098526	ENSG00000260091.1	RP11-33B1.4	-4.41	1.15e-05	0.000928	-0.12	-0.14	Corneal astigmatism;	chr4:119469204	chr4:119409333~119410233:+
BRCA	cis	rs867371	0.964	rs7169961	ENSG00000278603.1	RP13-608F4.5	4.41	1.15e-05	0.000928	0.18	0.14	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82186588	chr15:82472203~82472426:+
BRCA	cis	rs6921919	0.515	rs1558205	ENSG00000220721.1	OR1F12	-4.41	1.15e-05	0.000929	-0.16	-0.14	Autism spectrum disorder or schizophrenia;	chr6:28414485	chr6:28073316~28074233:+
BRCA	cis	rs987360	0.717	rs13129710	ENSG00000248869.4	RP11-138I17.1	-4.41	1.15e-05	0.000929	-0.14	-0.14	Temperament;	chr4:137308393	chr4:136796722~137212799:-
BRCA	cis	rs7267979	1	rs6050561	ENSG00000274973.1	RP13-401N8.7	4.41	1.15e-05	0.000929	0.15	0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25354219	chr20:25845497~25845862:+
BRCA	cis	rs7267979	1	rs6083813	ENSG00000274973.1	RP13-401N8.7	4.41	1.15e-05	0.000929	0.15	0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25357035	chr20:25845497~25845862:+
BRCA	cis	rs62025270	0.806	rs62025266	ENSG00000202081.1	RNU6-1280P	-4.41	1.15e-05	0.000929	-0.2	-0.14	Idiopathic pulmonary fibrosis;	chr15:85755217	chr15:85651522~85651628:-
BRCA	cis	rs7618915	0.501	rs10865974	ENSG00000243224.1	RP5-1157M23.2	4.41	1.15e-05	0.000929	0.14	0.14	Bipolar disorder;	chr3:52684264	chr3:52239258~52241097:+
BRCA	cis	rs7267979	1	rs4815406	ENSG00000274973.1	RP13-401N8.7	4.41	1.15e-05	0.000929	0.15	0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25360680	chr20:25845497~25845862:+
BRCA	cis	rs12317459	0.591	rs10862502	ENSG00000213270.5	RPL6P25	-4.41	1.15e-05	0.000929	-0.22	-0.14	Prostate cancer (SNP x SNP interaction);	chr12:82770468	chr12:83151331~83152190:+
BRCA	cis	rs718314	1	rs1463679	ENSG00000256894.1	RP11-283G6.3	4.41	1.15e-05	0.000929	0.16	0.14	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Renal cell carcinoma;Waist circumference adjusted for body mass index;	chr12:26317236	chr12:26125155~26126617:-
BRCA	cis	rs718314	0.956	rs2137564	ENSG00000256894.1	RP11-283G6.3	4.41	1.15e-05	0.000929	0.16	0.14	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Renal cell carcinoma;Waist circumference adjusted for body mass index;	chr12:26320417	chr12:26125155~26126617:-
BRCA	cis	rs2018683	0.509	rs221192	ENSG00000228421.2	AC005013.5	-4.41	1.15e-05	0.000929	-0.2	-0.14	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28975293	chr7:28957667~28959345:+
BRCA	cis	rs11098499	0.909	rs10017335	ENSG00000250412.1	KLHL2P1	-4.41	1.15e-05	0.000929	-0.16	-0.14	Corneal astigmatism;	chr4:119460368	chr4:119334329~119378233:+
BRCA	cis	rs7833790	0.963	rs72686466	ENSG00000254689.1	RP11-354A14.1	-4.41	1.15e-05	0.00093	-0.19	-0.14	Diastolic blood pressure;	chr8:81846693	chr8:81885377~81923193:+
BRCA	cis	rs7833790	0.926	rs72686467	ENSG00000254689.1	RP11-354A14.1	-4.41	1.15e-05	0.00093	-0.19	-0.14	Diastolic blood pressure;	chr8:81846694	chr8:81885377~81923193:+
BRCA	cis	rs10129255	0.5	rs6576231	ENSG00000232216.1	IGHV3-43	4.41	1.15e-05	0.00093	0.1	0.14	Kawasaki disease;	chr14:106783693	chr14:106470264~106470800:-
BRCA	cis	rs7826238	0.539	rs2945891	ENSG00000253981.4	ALG1L13P	4.41	1.15e-05	0.00093	0.16	0.14	Systolic blood pressure;	chr8:8297953	chr8:8236003~8244667:-
BRCA	cis	rs8056446	0.837	rs4888748	ENSG00000260816.2	RP11-319G9.3	-4.41	1.15e-05	0.00093	-0.15	-0.14	Pulmonary function (smoking interaction);	chr16:78139257	chr16:78895361~78899644:+
BRCA	cis	rs728616	0.681	rs35420115	ENSG00000225484.5	NUTM2B-AS1	-4.41	1.15e-05	0.00093	-0.31	-0.14	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80148432	chr10:79663088~79826594:-
BRCA	cis	rs7800418	0.521	rs13311768	ENSG00000214870.7	AC004540.5	4.41	1.15e-05	0.00093	0.16	0.14	Cognitive function;	chr7:26575674	chr7:26398593~26494256:+
BRCA	cis	rs878939	0.625	rs35564340	ENSG00000233690.1	EBAG9P1	4.41	1.15e-05	0.00093	0.19	0.14	Warfarin maintenance dose;	chr10:99584506	chr10:99697407~99697949:-
BRCA	cis	rs13113518	0.934	rs3805155	ENSG00000272969.1	RP11-528I4.2	4.41	1.15e-05	0.00093	0.16	0.14	Height;	chr4:55497842	chr4:55547112~55547889:+
BRCA	cis	rs13113518	1	rs4865013	ENSG00000272969.1	RP11-528I4.2	4.41	1.15e-05	0.00093	0.16	0.14	Height;	chr4:55559957	chr4:55547112~55547889:+
BRCA	cis	rs10946940	0.965	rs6915266	ENSG00000219392.1	RP1-265C24.5	4.41	1.15e-05	0.000931	0.18	0.14	Systemic lupus erythematosus;	chr6:27560864	chr6:28115628~28116551:+
BRCA	cis	rs2638953	0.815	rs11049669	ENSG00000247934.4	RP11-967K21.1	4.41	1.15e-05	0.000931	0.18	0.14	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28498982	chr12:28163298~28190738:-
BRCA	cis	rs2731006	0.64	rs2678103	ENSG00000257114.2	RP11-25I15.3	4.41	1.15e-05	0.000931	0.22	0.14	Panic disorder;	chr12:42773492	chr12:42692216~42717119:+
BRCA	cis	rs1005277	0.579	rs932538	ENSG00000099251.13	HSD17B7P2	4.41	1.15e-05	0.000931	0.15	0.14	Extrinsic epigenetic age acceleration;	chr10:38092386	chr10:38356380~38378505:+
BRCA	cis	rs6600671	1	rs10794671	ENSG00000231429.2	RP11-343N15.2	-4.41	1.15e-05	0.000931	-0.16	-0.14	Hip geometry;	chr1:121426382	chr1:121412719~121429274:+
BRCA	cis	rs4648045	0.796	rs3817685	ENSG00000246560.2	RP11-10L12.4	4.41	1.15e-05	0.000931	0.15	0.14	Lymphocyte percentage of white cells;	chr4:102613403	chr4:102828055~102844075:+
BRCA	cis	rs62458065	1	rs6462364	ENSG00000229358.3	DPY19L1P1	-4.41	1.15e-05	0.000931	-0.18	-0.14	Metabolite levels (HVA/MHPG ratio);	chr7:32425164	chr7:32580949~32761787:-
BRCA	cis	rs6686842	0.56	rs74069080	ENSG00000235358.1	RP11-399E6.1	-4.41	1.15e-05	0.000931	-0.18	-0.14	Height;	chr1:41185358	chr1:41242373~41284861:+
BRCA	cis	rs4927850	0.501	rs9881504	ENSG00000271662.1	RP11-141C7.3	-4.41	1.15e-05	0.000932	-0.18	-0.14	Pancreatic cancer;	chr3:195929743	chr3:195650146~195651472:-
BRCA	cis	rs2871473	0.951	rs1030025	ENSG00000234389.1	AC007278.3	4.41	1.15e-05	0.000932	0.15	0.14	Blood protein levels;	chr2:102489152	chr2:102438713~102440475:+
BRCA	cis	rs9990343	0.783	rs4683205	ENSG00000223552.1	RP11-24F11.2	4.41	1.15e-05	0.000932	0.13	0.14	Brain structure;	chr3:46293179	chr3:46364955~46407059:-
BRCA	cis	rs13113518	1	rs6858803	ENSG00000272969.1	RP11-528I4.2	4.41	1.15e-05	0.000932	0.16	0.14	Height;	chr4:55484534	chr4:55547112~55547889:+
BRCA	cis	rs699371	0.548	rs2058126	ENSG00000270000.1	RP3-449M8.9	4.41	1.15e-05	0.000932	0.16	0.14	Height;	chr14:74432576	chr14:74471930~74472360:-
BRCA	cis	rs9467773	1	rs2255070	ENSG00000241549.7	GUSBP2	4.41	1.15e-05	0.000932	0.14	0.14	Intelligence (multi-trait analysis);	chr6:26501549	chr6:26871484~26956554:-
BRCA	cis	rs2243480	1	rs4718334	ENSG00000275400.1	RP4-756H11.5	-4.41	1.15e-05	0.000932	-0.25	-0.14	Diabetic kidney disease;	chr7:66324467	chr7:66553805~66554199:-
BRCA	cis	rs5758511	0.68	rs1107554	ENSG00000226450.2	CYP2D8P	4.41	1.15e-05	0.000932	0.15	0.14	Birth weight;	chr22:42271588	chr22:42149886~42155001:-
BRCA	cis	rs9326246	0.643	rs651821	ENSG00000280143.1	AP000892.6	4.41	1.15e-05	0.000932	0.22	0.14	Coronary artery disease;	chr11:116791863	chr11:117204967~117210292:+
BRCA	cis	rs934734	0.532	rs6546151	ENSG00000281920.1	RP11-418H16.1	-4.41	1.15e-05	0.000932	-0.16	-0.14	Rheumatoid arthritis;	chr2:65449449	chr2:65623272~65628424:+
BRCA	cis	rs812925	0.537	rs10208769	ENSG00000273302.1	RP11-493E12.2	-4.41	1.15e-05	0.000933	-0.12	-0.14	Immature fraction of reticulocytes;	chr2:61378479	chr2:61199979~61200769:+
BRCA	cis	rs11098499	0.863	rs3733525	ENSG00000250412.1	KLHL2P1	4.41	1.15e-05	0.000933	0.16	0.14	Corneal astigmatism;	chr4:119525893	chr4:119334329~119378233:+
BRCA	cis	rs11098499	0.863	rs3775847	ENSG00000250412.1	KLHL2P1	4.41	1.15e-05	0.000933	0.16	0.14	Corneal astigmatism;	chr4:119526487	chr4:119334329~119378233:+
BRCA	cis	rs11098499	0.863	rs3775848	ENSG00000250412.1	KLHL2P1	4.41	1.15e-05	0.000933	0.16	0.14	Corneal astigmatism;	chr4:119526569	chr4:119334329~119378233:+
BRCA	cis	rs6088580	0.634	rs6059856	ENSG00000276073.1	RP5-1125A11.7	-4.41	1.15e-05	0.000933	-0.15	-0.14	Glomerular filtration rate (creatinine);	chr20:34470149	chr20:33985617~33988989:-
BRCA	cis	rs7523050	0.643	rs17621922	ENSG00000203897.3	SPATA42	-4.41	1.16e-05	0.000933	-0.24	-0.14	Fat distribution (HIV);	chr1:108861832	chr1:108857217~108858524:+
BRCA	cis	rs1816213	1	rs4646534	ENSG00000273466.1	RP11-548H3.1	-4.41	1.16e-05	0.000933	-0.29	-0.14	Diastolic blood pressure;	chr2:218782732	chr2:218633256~218634014:-
BRCA	cis	rs7107174	0.681	rs10899499	ENSG00000251323.2	RP11-452H21.4	-4.41	1.16e-05	0.000933	-0.19	-0.14	Testicular germ cell tumor;	chr11:78413751	chr11:78423982~78429836:-
BRCA	cis	rs2243480	0.901	rs57126451	ENSG00000222364.1	RNU6-96P	-4.41	1.16e-05	0.000933	-0.24	-0.14	Diabetic kidney disease;	chr7:65951319	chr7:66395191~66395286:+
BRCA	cis	rs559555	0.626	rs499362	ENSG00000272716.1	RP11-563N4.1	4.41	1.16e-05	0.000933	0.15	0.14	Blood metabolite ratios;Blood metabolite levels;	chr2:31586503	chr2:32165046~32165757:-
BRCA	cis	rs2109514	0.765	rs28494601	ENSG00000237813.3	AC002066.1	4.41	1.16e-05	0.000933	0.16	0.14	Prevalent atrial fibrillation;	chr7:116461207	chr7:116238260~116499465:-
BRCA	cis	rs875971	1	rs6946143	ENSG00000236529.1	RP13-254B10.1	4.41	1.16e-05	0.000933	0.15	0.14	Aortic root size;	chr7:66114735	chr7:65840212~65840596:+
BRCA	cis	rs77372450	0.591	rs6879838	ENSG00000248544.2	CTB-47B11.3	4.41	1.16e-05	0.000934	0.21	0.14	Bipolar disorder (body mass index interaction);	chr5:157539559	chr5:157375741~157384950:-
BRCA	cis	rs12612619	0.64	rs7560633	ENSG00000272148.1	RP11-195B17.1	-4.41	1.16e-05	0.000934	-0.16	-0.14	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27119199	chr2:27062428~27062907:-
BRCA	cis	rs4671400	0.543	rs2290324	ENSG00000273302.1	RP11-493E12.2	-4.41	1.16e-05	0.000934	-0.15	-0.14	3-hydroxypropylmercapturic acid levels in smokers;	chr2:61221641	chr2:61199979~61200769:+
BRCA	cis	rs2243480	0.706	rs34466769	ENSG00000230295.1	RP11-458F8.2	-4.41	1.16e-05	0.000934	-0.15	-0.14	Diabetic kidney disease;	chr7:65988305	chr7:66880708~66882981:+
BRCA	cis	rs7772486	0.875	rs932522	ENSG00000270638.1	RP3-466P17.1	-4.41	1.16e-05	0.000934	-0.15	-0.14	Lobe attachment (rater-scored or self-reported);	chr6:146052890	chr6:145735570~145737218:+
BRCA	cis	rs10986311	0.862	rs753788	ENSG00000227200.1	RP11-121A14.3	4.41	1.16e-05	0.000934	0.16	0.14	Vitiligo;	chr9:124332760	chr9:124262876~124265809:+
BRCA	cis	rs8114671	0.804	rs6060139	ENSG00000279253.1	RP4-614O4.13	-4.41	1.16e-05	0.000935	-0.16	-0.14	Height;	chr20:34978696	chr20:35262727~35264187:-
BRCA	cis	rs2073316	0.592	rs761925	ENSG00000272716.1	RP11-563N4.1	4.41	1.16e-05	0.000935	0.15	0.14	Interleukin-18 levels;	chr2:31470585	chr2:32165046~32165757:-
BRCA	cis	rs12570188	1	rs12570188	ENSG00000224934.2	RP11-441O15.3	-4.41	1.16e-05	0.000935	-0.23	-0.14	Asthma (childhood onset);	chr10:99095945	chr10:99431191~99438117:+
BRCA	cis	rs11976180	1	rs2961115	ENSG00000244479.5	OR2A1-AS1	4.41	1.16e-05	0.000935	0.18	0.14	Obesity-related traits;	chr7:144056278	chr7:144251264~144356181:-
BRCA	cis	rs6430585	0.583	rs76097170	ENSG00000231890.6	DARS-AS1	-4.41	1.16e-05	0.000935	-0.21	-0.14	Corneal structure;	chr2:135835928	chr2:135985176~136022593:+
BRCA	cis	rs10043228	1	rs12515466	ENSG00000271918.1	CTD-2287O16.5	-4.41	1.16e-05	0.000935	-0.18	-0.14	Asthma or chronic obstructive pulmonary disease;	chr5:116256180	chr5:116083807~116085416:-
BRCA	cis	rs3824867	0.879	rs4752837	ENSG00000280615.1	Y_RNA	-4.41	1.16e-05	0.000935	-0.17	-0.14	Mean corpuscular hemoglobin;	chr11:47444403	chr11:47614898~47614994:-
BRCA	cis	rs801193	0.66	rs1962050	ENSG00000265600.1	AC006480.1	4.41	1.16e-05	0.000935	0.16	0.14	Aortic root size;	chr7:66775021	chr7:67356680~67356779:+
BRCA	cis	rs11678825	0.639	rs77134676	ENSG00000272663.1	RP11-191L17.1	-4.41	1.16e-05	0.000936	-0.19	-0.14	Reticulocyte fraction of red cells;	chr2:48440510	chr2:48440043~48440597:-
BRCA	cis	rs1008375	0.686	rs34338142	ENSG00000249502.1	AC006160.5	-4.41	1.16e-05	0.000936	-0.16	-0.14	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17624551	chr4:17587467~17614571:-
BRCA	cis	rs3176789	0.624	rs12422989	ENSG00000256673.1	RP11-599J14.2	4.41	1.16e-05	0.000936	0.15	0.14	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9767732	chr12:9398355~9414851:-
BRCA	cis	rs2708977	0.549	rs2678381	ENSG00000230606.9	AC159540.1	4.41	1.16e-05	0.000936	0.17	0.14	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96775529	chr2:97416165~97433527:-
BRCA	cis	rs7267979	0.966	rs6083817	ENSG00000274973.1	RP13-401N8.7	4.41	1.16e-05	0.000936	0.15	0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25363362	chr20:25845497~25845862:+
BRCA	cis	rs7267979	1	rs6050564	ENSG00000274973.1	RP13-401N8.7	4.41	1.16e-05	0.000936	0.15	0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25363595	chr20:25845497~25845862:+
BRCA	cis	rs7160336	1	rs6574162	ENSG00000259065.1	RP5-1021I20.1	4.41	1.16e-05	0.000936	0.15	0.14	Blood protein levels;	chr14:74124538	chr14:73787360~73803270:+
BRCA	cis	rs1371614	0.679	rs4441421	ENSG00000229122.1	AGBL5-IT1	4.41	1.16e-05	0.000936	0.14	0.14	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26919223	chr2:27061038~27061815:+
BRCA	cis	rs6968419	0.747	rs1004107	ENSG00000279086.1	RP11-667F14.1	-4.41	1.16e-05	0.000936	-0.15	-0.14	Intraocular pressure;	chr7:116220729	chr7:116209234~116211511:-
BRCA	cis	rs3617	0.625	rs11715347	ENSG00000279144.1	RP11-894J14.2	-4.41	1.16e-05	0.000936	-0.17	-0.14	Red blood cell count;Autism spectrum disorder or schizophrenia;	chr3:52849054	chr3:52848085~52848553:-
BRCA	cis	rs6071166	0.683	rs6071049	ENSG00000224635.1	RP4-564F22.5	-4.41	1.16e-05	0.000937	-0.16	-0.14	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38677386	chr20:38406011~38416797:-
BRCA	cis	rs12744310	1	rs12037657	ENSG00000235358.1	RP11-399E6.1	4.41	1.16e-05	0.000937	0.2	0.14	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41298503	chr1:41242373~41284861:+
BRCA	cis	rs13113518	1	rs11724094	ENSG00000273257.1	RP11-177J6.1	4.41	1.16e-05	0.000937	0.17	0.14	Height;	chr4:55501479	chr4:55387949~55388271:+
BRCA	cis	rs8054556	0.787	rs1140239	ENSG00000183604.13	SMG1P5	-4.41	1.16e-05	0.000937	-0.14	-0.14	Autism spectrum disorder or schizophrenia;	chr16:30010081	chr16:30267553~30335374:-
BRCA	cis	rs875971	0.545	rs1796226	ENSG00000273142.1	RP11-458F8.4	4.41	1.16e-05	0.000937	0.13	0.14	Aortic root size;	chr7:66622723	chr7:66902857~66906297:+
BRCA	cis	rs11779988	0.545	rs431961	ENSG00000253671.1	RP11-806O11.1	-4.41	1.16e-05	0.000938	-0.2	-0.14	Breast cancer;	chr8:17928695	chr8:17808941~17820868:+
BRCA	cis	rs10861342	0.892	rs77497436	ENSG00000257999.1	RP11-61E11.2	-4.41	1.16e-05	0.000938	-0.28	-0.14	IgG glycosylation;	chr12:105243118	chr12:105102472~105107179:-
BRCA	cis	rs17772222	0.917	rs2004329	ENSG00000258789.1	RP11-507K2.3	-4.41	1.16e-05	0.000938	-0.16	-0.14	Coronary artery calcification;	chr14:88532965	chr14:88551597~88552493:+
BRCA	cis	rs4831837	0.69	rs10102315	ENSG00000270074.1	RP11-351I21.11	4.41	1.16e-05	0.000938	0.17	0.14	Morbidity-free survival;	chr8:12829002	chr8:12412827~12414373:+
BRCA	cis	rs2832191	0.74	rs2832168	ENSG00000232855.5	AF131217.1	-4.41	1.16e-05	0.000938	-0.16	-0.14	Dental caries;	chr21:29091374	chr21:28439346~28674848:-
BRCA	cis	rs6071166	0.873	rs2864948	ENSG00000224635.1	RP4-564F22.5	-4.41	1.16e-05	0.000939	-0.16	-0.14	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38694171	chr20:38406011~38416797:-
BRCA	cis	rs9952991	0.941	rs7237497	ENSG00000260302.1	RP11-973H7.1	-4.41	1.16e-05	0.000939	-0.22	-0.14	Inflammatory skin disease;	chr18:12777326	chr18:12774651~12775923:-
BRCA	cis	rs7209700	0.708	rs2292699	ENSG00000228782.6	CTD-2026D20.3	4.41	1.16e-05	0.000939	0.15	0.14	IgG glycosylation;	chr17:47284929	chr17:47450568~47492492:-
BRCA	cis	rs1910358	0.515	rs10059485	ENSG00000248874.4	C5orf17	-4.41	1.16e-05	0.000939	-0.19	-0.14	Venous thromboembolism (SNP x SNP interaction);	chr5:23724421	chr5:23951348~24178263:+
BRCA	cis	rs867371	0.896	rs6495647	ENSG00000278603.1	RP13-608F4.5	4.41	1.16e-05	0.00094	0.18	0.14	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82244708	chr15:82472203~82472426:+
BRCA	cis	rs6545883	0.862	rs778141	ENSG00000212978.6	AC016747.3	4.41	1.16e-05	0.00094	0.19	0.14	Tuberculosis;	chr2:61455043	chr2:61141592~61144969:-
BRCA	cis	rs2108622	0.727	rs3093216	ENSG00000267218.2	AC005336.5	4.41	1.16e-05	0.00094	0.16	0.14	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15876927	chr19:15902300~15903238:-
BRCA	cis	rs115575488	0.85	rs10494220	ENSG00000236804.1	RPS3AP12	4.41	1.17e-05	0.00094	0.25	0.14	Lobe attachment (rater-scored or self-reported);	chr1:119029775	chr1:119126539~119127291:-
BRCA	cis	rs3743162	0.609	rs12906879	ENSG00000230373.7	GOLGA6L5P	4.41	1.17e-05	0.000941	0.15	0.14	Alzheimer's disease (age of onset);	chr15:84882237	chr15:84507885~84516814:-
BRCA	cis	rs58521262	0.615	rs24833	ENSG00000268105.1	RP11-369G6.2	-4.41	1.17e-05	0.000941	-0.18	-0.14	Testicular germ cell tumor;	chr19:23016898	chr19:23125665~23128543:+
BRCA	cis	rs58521262	0.546	rs158691	ENSG00000268105.1	RP11-369G6.2	-4.41	1.17e-05	0.000941	-0.18	-0.14	Testicular germ cell tumor;	chr19:23017251	chr19:23125665~23128543:+
BRCA	cis	rs58521262	0.556	rs158577	ENSG00000268105.1	RP11-369G6.2	-4.41	1.17e-05	0.000941	-0.18	-0.14	Testicular germ cell tumor;	chr19:23018861	chr19:23125665~23128543:+
BRCA	cis	rs58521262	0.556	rs290586	ENSG00000268105.1	RP11-369G6.2	-4.41	1.17e-05	0.000941	-0.18	-0.14	Testicular germ cell tumor;	chr19:23019577	chr19:23125665~23128543:+
BRCA	cis	rs56322409	0.564	rs12359343	ENSG00000226688.5	ENTPD1-AS1	-4.41	1.17e-05	0.000941	-0.16	-0.14	Blood metabolite levels;	chr10:95900815	chr10:95753206~96090238:-
BRCA	cis	rs60843830	1	rs56167434	ENSG00000272342.1	RP13-539J13.1	4.41	1.17e-05	0.000942	0.17	0.14	Spherical equivalent (joint analysis main effects and education interaction);	chr2:282137	chr2:739588~740164:-
BRCA	cis	rs9652601	0.719	rs12103174	ENSG00000274038.1	RP11-66H6.4	-4.4	1.17e-05	0.000942	-0.15	-0.14	Systemic lupus erythematosus;	chr16:11109873	chr16:11056556~11057034:+
BRCA	cis	rs2303319	0.504	rs12476631	ENSG00000227403.1	AC009299.3	4.4	1.17e-05	0.000942	0.32	0.14	Cognitive function;	chr2:161710426	chr2:161244739~161249050:+
BRCA	cis	rs672203	0.636	rs4650051	ENSG00000271992.1	RP11-42O15.3	-4.4	1.17e-05	0.000942	-0.18	-0.14	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);	chr1:70458337	chr1:70445071~70445536:+
BRCA	cis	rs6452524	0.534	rs10514246	ENSG00000281327.1	LINC01338	4.4	1.17e-05	0.000942	0.16	0.14	Hypertension (SNP x SNP interaction);	chr5:83069979	chr5:82850864~82859836:-
BRCA	cis	rs783540	0.656	rs783538	ENSG00000276710.3	CSPG4P8	4.4	1.17e-05	0.000942	0.15	0.14	Schizophrenia;	chr15:82584394	chr15:82459472~82477258:+
BRCA	cis	rs4781563	1	rs3136189	ENSG00000242307.1	RPS26P52	-4.4	1.17e-05	0.000942	-0.16	-0.14	Bilirubin levels;	chr16:13940844	chr16:13922332~13922679:-
BRCA	cis	rs11977715	0.521	rs6465466	ENSG00000233942.1	AC004012.1	-4.4	1.17e-05	0.000943	-0.17	-0.14	Middle childhood and early adolescence aggressive behavior;	chr7:95502275	chr7:95471835~95473998:+
BRCA	cis	rs7260598	0.642	rs7259787	ENSG00000268442.1	CTD-2027I19.2	4.4	1.17e-05	0.000943	0.21	0.14	Response to taxane treatment (placlitaxel);	chr19:23935633	chr19:24162370~24163425:-
BRCA	cis	rs7260598	0.71	rs10402319	ENSG00000268442.1	CTD-2027I19.2	4.4	1.17e-05	0.000943	0.21	0.14	Response to taxane treatment (placlitaxel);	chr19:23945263	chr19:24162370~24163425:-
BRCA	cis	rs4835473	0.897	rs11100812	ENSG00000249741.2	RP11-673E1.3	-4.4	1.17e-05	0.000943	-0.14	-0.14	Immature fraction of reticulocytes;	chr4:143790400	chr4:143911514~143912053:-
BRCA	cis	rs4835473	0.545	rs10022856	ENSG00000249741.2	RP11-673E1.3	-4.4	1.17e-05	0.000943	-0.14	-0.14	Immature fraction of reticulocytes;	chr4:143793157	chr4:143911514~143912053:-
BRCA	cis	rs7824557	0.591	rs2043510	ENSG00000255020.1	AF131216.5	4.4	1.17e-05	0.000943	0.16	0.14	Retinal vascular caliber;	chr8:11367659	chr8:11345748~11347502:-
BRCA	cis	rs700651	0.752	rs7592556	ENSG00000231621.1	AC013264.2	-4.4	1.17e-05	0.000943	-0.13	-0.14	Intracranial aneurysm;	chr2:198026297	chr2:197197991~197199273:+
BRCA	cis	rs10504130	1	rs118116154	ENSG00000272024.1	RP11-546K22.3	-4.4	1.17e-05	0.000943	-0.23	-0.14	Venous thromboembolism (SNP x SNP interaction);	chr8:51833124	chr8:51950284~51950690:+
BRCA	cis	rs13108904	0.967	rs1732107	ENSG00000253399.1	AC078852.2	4.4	1.17e-05	0.000943	0.15	0.14	Obesity-related traits;	chr4:1282970	chr4:1358479~1359461:+
BRCA	cis	rs2880765	0.835	rs7163958	ENSG00000202081.1	RNU6-1280P	4.4	1.17e-05	0.000943	0.16	0.14	Coronary artery disease;	chr15:85501984	chr15:85651522~85651628:-
BRCA	cis	rs6939532	0.761	rs3799378	ENSG00000124549.13	BTN2A3P	4.4	1.17e-05	0.000943	0.16	0.14	Autism spectrum disorder or schizophrenia;	chr6:26404146	chr6:26421391~26432383:+
BRCA	cis	rs12554020	0.892	rs76488437	ENSG00000227603.1	RP11-165J3.6	4.4	1.17e-05	0.000944	0.2	0.14	Schizophrenia;	chr9:93605514	chr9:93435332~93437121:-
BRCA	cis	rs9652601	0.649	rs767448	ENSG00000274038.1	RP11-66H6.4	-4.4	1.17e-05	0.000944	-0.15	-0.14	Systemic lupus erythematosus;	chr16:11110364	chr16:11056556~11057034:+
BRCA	cis	rs2574985	0.739	rs3011801	ENSG00000231345.3	BEND3P1	-4.4	1.17e-05	0.000944	-0.23	-0.14	Subjective well-being;	chr10:50564502	chr10:50655967~50660472:+
BRCA	cis	rs17684571	0.637	rs17751966	ENSG00000231441.1	RP11-472M19.2	4.4	1.17e-05	0.000944	0.21	0.14	Schizophrenia;	chr6:56804850	chr6:56844002~56864078:+
BRCA	cis	rs950776	0.647	rs495956	ENSG00000279373.1	RP11-650L12.4	-4.4	1.17e-05	0.000944	-0.16	-0.14	Sudden cardiac arrest;	chr15:78577588	chr15:78537681~78538946:+
BRCA	cis	rs1005277	0.579	rs2505257	ENSG00000263064.2	RP11-291L22.7	4.4	1.17e-05	0.000944	0.17	0.14	Extrinsic epigenetic age acceleration;	chr10:38083736	chr10:38448689~38448949:+
BRCA	cis	rs2562456	0.833	rs1781867	ENSG00000268658.4	LINC00664	4.4	1.17e-05	0.000944	0.22	0.14	Pain;	chr19:21304368	chr19:21483374~21503238:+
BRCA	cis	rs8099594	0.565	rs1942998	ENSG00000266696.1	RP11-30L3.2	4.4	1.17e-05	0.000945	0.16	0.14	Height;	chr18:49186420	chr18:49205912~49208781:+
BRCA	cis	rs4415084	0.8	rs11949847	ENSG00000251141.4	RP11-53O19.1	4.4	1.17e-05	0.000945	0.12	0.14	Breast cancer;	chr5:44752067	chr5:44744900~44808777:-
BRCA	cis	rs763014	0.966	rs4247097	ENSG00000260394.2	LA16c-313D11.9	-4.4	1.17e-05	0.000945	-0.13	-0.14	Height;	chr16:604224	chr16:678504~679777:-
BRCA	cis	rs2115630	1	rs11073730	ENSG00000259295.5	CSPG4P12	-4.4	1.17e-05	0.000945	-0.16	-0.14	P wave terminal force;	chr15:84811365	chr15:85191438~85213905:+
BRCA	cis	rs875971	0.965	rs6971509	ENSG00000229180.5	GS1-124K5.11	-4.4	1.17e-05	0.000945	-0.12	-0.14	Aortic root size;	chr7:66249983	chr7:66526088~66542624:-
BRCA	cis	rs7181230	0.961	rs7183977	ENSG00000275636.1	RP11-521C20.5	-4.4	1.17e-05	0.000945	-0.17	-0.14	Dehydroepiandrosterone sulphate levels;	chr15:40084891	chr15:40078892~40079347:+
BRCA	cis	rs321358	0.895	rs73015171	ENSG00000271390.1	RP11-89C3.3	4.4	1.17e-05	0.000945	0.2	0.14	Body mass index;	chr11:111087535	chr11:111089870~111090368:-
BRCA	cis	rs72482608	0.826	rs763770	ENSG00000271811.1	RP1-79C4.4	4.4	1.17e-05	0.000946	0.15	0.14	Emphysema imaging phenotypes;	chr1:170798378	chr1:170667381~170669425:+
BRCA	cis	rs2839186	0.9	rs56840278	ENSG00000239415.1	AP001469.9	4.4	1.17e-05	0.000946	0.14	0.14	Testicular germ cell tumor;	chr21:46289019	chr21:46251549~46254133:-
BRCA	cis	rs2839186	0.933	rs56955294	ENSG00000239415.1	AP001469.9	4.4	1.17e-05	0.000946	0.14	0.14	Testicular germ cell tumor;	chr21:46289039	chr21:46251549~46254133:-
BRCA	cis	rs62025270	0.631	rs55968154	ENSG00000259762.1	RP11-158M2.4	-4.4	1.17e-05	0.000946	-0.2	-0.14	Idiopathic pulmonary fibrosis;	chr15:85725399	chr15:85750336~85752901:-
BRCA	cis	rs62025270	0.688	rs55851385	ENSG00000259762.1	RP11-158M2.4	-4.4	1.17e-05	0.000946	-0.2	-0.14	Idiopathic pulmonary fibrosis;	chr15:85725400	chr15:85750336~85752901:-
BRCA	cis	rs7686660	1	rs10022060	ENSG00000250326.1	RP11-284M14.1	-4.4	1.17e-05	0.000946	-0.16	-0.14	Asthma;	chr4:143034355	chr4:142933195~143184861:-
BRCA	cis	rs2832191	0.692	rs2776240	ENSG00000232855.5	AF131217.1	-4.4	1.17e-05	0.000946	-0.16	-0.14	Dental caries;	chr21:28938317	chr21:28439346~28674848:-
BRCA	cis	rs62025270	0.688	rs17576534	ENSG00000259762.1	RP11-158M2.4	-4.4	1.17e-05	0.000946	-0.21	-0.14	Idiopathic pulmonary fibrosis;	chr15:85742509	chr15:85750336~85752901:-
BRCA	cis	rs4948275	0.693	rs12360246	ENSG00000237233.2	TMEM26-AS1	-4.4	1.17e-05	0.000946	-0.16	-0.14	Night sleep phenotypes;	chr10:61566059	chr10:61452639~61481956:+
BRCA	cis	rs4948275	0.693	rs1824082	ENSG00000237233.2	TMEM26-AS1	-4.4	1.17e-05	0.000946	-0.16	-0.14	Night sleep phenotypes;	chr10:61566762	chr10:61452639~61481956:+
BRCA	cis	rs7267979	0.528	rs6076366	ENSG00000231081.1	RP4-760C5.3	4.4	1.17e-05	0.000947	0.17	0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25583990	chr20:26008791~26010531:-
BRCA	cis	rs6921919	0.583	rs11755942	ENSG00000220721.1	OR1F12	4.4	1.17e-05	0.000947	0.16	0.14	Autism spectrum disorder or schizophrenia;	chr6:28401760	chr6:28073316~28074233:+
BRCA	cis	rs934734	0.935	rs6711791	ENSG00000204929.10	AC074391.1	4.4	1.17e-05	0.000947	0.16	0.14	Rheumatoid arthritis;	chr2:65352094	chr2:65436711~66084639:+
BRCA	cis	rs78472555	1	rs11247124	ENSG00000259363.4	CTD-2054N24.2	-4.4	1.17e-05	0.000947	-0.18	-0.14	Post bronchodilator FEV1/FVC ratio in COPD;	chr15:99725520	chr15:99807023~99877148:+
BRCA	cis	rs7267979	0.565	rs3752273	ENSG00000204556.4	CTD-2514C3.1	4.4	1.17e-05	0.000947	0.18	0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25614147	chr20:26018832~26020684:+
BRCA	cis	rs6860806	0.661	rs4705929	ENSG00000233006.5	AC034220.3	4.4	1.17e-05	0.000948	0.1	0.14	Breast cancer;	chr5:132248485	chr5:132311285~132369916:-
BRCA	cis	rs867371	1	rs8037224	ENSG00000278603.1	RP13-608F4.5	4.4	1.18e-05	0.000948	0.18	0.14	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82172189	chr15:82472203~82472426:+
BRCA	cis	rs17489649	0.956	rs2077221	ENSG00000271849.1	CTC-332L22.1	4.4	1.18e-05	0.000948	0.17	0.14	Intelligence (multi-trait analysis);	chr5:109830827	chr5:109687802~109688329:-
BRCA	cis	rs4700393	0.52	rs206789	ENSG00000215032.2	GNL3LP1	4.4	1.18e-05	0.000948	0.18	0.14	Intelligence (multi-trait analysis);	chr5:60608144	chr5:60891935~60893577:-
BRCA	cis	rs2731006	0.591	rs7962735	ENSG00000257114.2	RP11-25I15.3	4.4	1.18e-05	0.000948	0.2	0.14	Panic disorder;	chr12:42814269	chr12:42692216~42717119:+
BRCA	cis	rs11051970	0.659	rs2728674	ENSG00000274964.1	RP11-817I4.1	-4.4	1.18e-05	0.000948	-0.16	-0.14	Response to tocilizumab in rheumatoid arthritis;	chr12:32434531	chr12:32339368~32340724:+
BRCA	cis	rs1043099	0.912	rs4339043	ENSG00000279699.1	RP1-102K2.9	4.4	1.18e-05	0.000948	0.22	0.14	Rheumatoid arthritis;	chr22:30339919	chr22:30275215~30276951:-
BRCA	cis	rs13326165	0.543	rs73088785	ENSG00000243224.1	RP5-1157M23.2	-4.4	1.18e-05	0.000949	-0.22	-0.14	HDL cholesterol levels;HDL cholesterol;	chr3:52279198	chr3:52239258~52241097:+
BRCA	cis	rs13326165	0.585	rs11718729	ENSG00000243224.1	RP5-1157M23.2	-4.4	1.18e-05	0.000949	-0.22	-0.14	HDL cholesterol levels;HDL cholesterol;	chr3:52279438	chr3:52239258~52241097:+
BRCA	cis	rs4388249	0.687	rs2416217	ENSG00000271849.1	CTC-332L22.1	-4.4	1.18e-05	0.000949	-0.18	-0.14	Schizophrenia;	chr5:109736510	chr5:109687802~109688329:-
BRCA	cis	rs7267979	1	rs6050599	ENSG00000125804.12	FAM182A	4.4	1.18e-05	0.000949	0.18	0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25419604	chr20:26054655~26086917:+
BRCA	cis	rs11603691	1	rs11229003	ENSG00000254662.1	RP11-872D17.4	-4.4	1.18e-05	0.000949	-0.29	-0.14	Low high density lipoprotein cholesterol levels;	chr11:57340817	chr11:57325603~57327958:+
BRCA	cis	rs1014246	1	rs2240705	ENSG00000232767.1	RP11-498B4.5	-4.4	1.18e-05	0.000949	-0.14	-0.14	Age at smoking initiation in chronic obstructive pulmonary disease;	chr10:116707823	chr10:116670103~116672739:+
BRCA	cis	rs7048146	1	rs12336499	ENSG00000213539.4	YBX1P6	4.4	1.18e-05	0.000949	0.15	0.14	Vascular brain injury;	chr9:109537967	chr9:109532830~109534332:-
BRCA	cis	rs7811142	0.943	rs28578163	ENSG00000078319.8	PMS2P1	-4.4	1.18e-05	0.000949	-0.21	-0.14	Platelet count;	chr7:100447131	chr7:100320992~100341908:-
BRCA	cis	rs6431644	0.965	rs4663978	ENSG00000224287.2	MSL3P1	4.4	1.18e-05	0.00095	0.16	0.14	Left atrial antero-posterior diameter;	chr2:233889389	chr2:233865437~233868444:-
BRCA	cis	rs6600671	1	rs11249351	ENSG00000275538.1	RNVU1-19	4.4	1.18e-05	0.00095	0.16	0.14	Hip geometry;	chr1:121430082	chr1:120850819~120850985:-
BRCA	cis	rs11098499	0.754	rs17595608	ENSG00000225892.3	RP11-384K6.2	4.4	1.18e-05	0.00095	0.13	0.14	Corneal astigmatism;	chr4:119329351	chr4:118632274~118634759:+
BRCA	cis	rs12439619	0.921	rs4778672	ENSG00000255769.6	GOLGA2P10	4.4	1.18e-05	0.00095	0.17	0.14	Intelligence (multi-trait analysis);	chr15:82245013	chr15:82472993~82513950:-
BRCA	cis	rs6128907	1	rs16987583	ENSG00000224635.1	RP4-564F22.5	4.4	1.18e-05	0.00095	0.21	0.14	Liver fibrosis in pediatric non-alcoholic fatty acid liver disease;	chr20:38766975	chr20:38406011~38416797:-
BRCA	cis	rs9467773	0.967	rs6932865	ENSG00000241549.7	GUSBP2	4.4	1.18e-05	0.00095	0.14	0.14	Intelligence (multi-trait analysis);	chr6:26539938	chr6:26871484~26956554:-
BRCA	cis	rs9467773	1	rs6933176	ENSG00000241549.7	GUSBP2	4.4	1.18e-05	0.00095	0.14	0.14	Intelligence (multi-trait analysis);	chr6:26539950	chr6:26871484~26956554:-
BRCA	cis	rs2108622	0.683	rs6512067	ENSG00000267218.2	AC005336.5	4.4	1.18e-05	0.00095	0.16	0.14	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15872141	chr19:15902300~15903238:-
BRCA	cis	rs739401	0.611	rs7109088	ENSG00000183562.3	CTC-343N3.1	-4.4	1.18e-05	0.00095	-0.14	-0.14	Longevity;	chr11:3006255	chr11:2989863~2991344:+
BRCA	cis	rs7646881	0.812	rs75107964	ENSG00000240207.5	RP11-379F4.4	-4.4	1.18e-05	0.00095	-0.24	-0.14	Tetralogy of Fallot;	chr3:158740962	chr3:158732263~158784070:+
BRCA	cis	rs2832191	0.716	rs7509628	ENSG00000232855.5	AF131217.1	-4.4	1.18e-05	0.000951	-0.16	-0.14	Dental caries;	chr21:29081931	chr21:28439346~28674848:-
BRCA	cis	rs9467773	1	rs1321481	ENSG00000241549.7	GUSBP2	4.4	1.18e-05	0.000951	0.14	0.14	Intelligence (multi-trait analysis);	chr6:26537982	chr6:26871484~26956554:-
BRCA	cis	rs9467773	1	rs4713008	ENSG00000241549.7	GUSBP2	4.4	1.18e-05	0.000951	0.14	0.14	Intelligence (multi-trait analysis);	chr6:26538040	chr6:26871484~26956554:-
BRCA	cis	rs11696845	1	rs11696845	ENSG00000276223.1	RP4-781B1.5	-4.4	1.18e-05	0.000951	-0.14	-0.14	Obesity-related traits;	chr20:44742679	chr20:44746642~44747201:+
BRCA	cis	rs983392	1	rs61901691	ENSG00000275344.1	MIR6503	-4.4	1.18e-05	0.000951	-0.15	-0.14	Alzheimer's disease (late onset);	chr11:60135326	chr11:60209071~60209156:-
BRCA	cis	rs2505998	1	rs2506006	ENSG00000273008.1	RP11-351D16.3	-4.4	1.18e-05	0.000951	-0.16	-0.14	Hirschsprung disease;	chr10:43086053	chr10:43136824~43138334:-
BRCA	cis	rs10504130	1	rs41453644	ENSG00000272024.1	RP11-546K22.3	4.4	1.18e-05	0.000951	0.23	0.14	Venous thromboembolism (SNP x SNP interaction);	chr8:51820984	chr8:51950284~51950690:+
BRCA	cis	rs2109514	0.87	rs6976316	ENSG00000237813.3	AC002066.1	4.4	1.18e-05	0.000951	0.16	0.14	Prevalent atrial fibrillation;	chr7:116482889	chr7:116238260~116499465:-
BRCA	cis	rs2505998	0.843	rs2506004	ENSG00000273008.1	RP11-351D16.3	-4.4	1.18e-05	0.000951	-0.16	-0.14	Hirschsprung disease;	chr10:43086825	chr10:43136824~43138334:-
BRCA	cis	rs513088	0.681	rs565418	ENSG00000225171.2	DUTP6	4.4	1.18e-05	0.000951	0.19	0.14	Schizophrenia;	chr1:166679839	chr1:166868748~166869209:+
BRCA	cis	rs2505998	1	rs2435356	ENSG00000273008.1	RP11-351D16.3	4.4	1.18e-05	0.000952	0.16	0.14	Hirschsprung disease;	chr10:43087702	chr10:43136824~43138334:-
BRCA	cis	rs7048146	0.966	rs1576591	ENSG00000213539.4	YBX1P6	4.4	1.18e-05	0.000952	0.15	0.14	Vascular brain injury;	chr9:109542724	chr9:109532830~109534332:-
BRCA	cis	rs875971	0.545	rs13311962	ENSG00000273142.1	RP11-458F8.4	-4.4	1.18e-05	0.000952	-0.13	-0.14	Aortic root size;	chr7:66603142	chr7:66902857~66906297:+
BRCA	cis	rs1722133	0.555	rs788723	ENSG00000229628.1	AC073115.7	4.4	1.18e-05	0.000952	0.19	0.14	Sitting height ratio;	chr7:46047186	chr7:45990905~46000898:+
BRCA	cis	rs6430585	0.528	rs6430594	ENSG00000231890.6	DARS-AS1	4.4	1.18e-05	0.000952	0.21	0.14	Corneal structure;	chr2:135961603	chr2:135985176~136022593:+
BRCA	cis	rs17801127	0.591	rs10755045	ENSG00000231969.1	AC144449.1	-4.4	1.18e-05	0.000953	-0.21	-0.14	Liver enzyme levels (alanine transaminase);	chr2:149706334	chr2:149587196~149848233:+
BRCA	cis	rs7267979	0.565	rs13040726	ENSG00000231081.1	RP4-760C5.3	4.4	1.18e-05	0.000953	0.17	0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25579245	chr20:26008791~26010531:-
BRCA	cis	rs7475343	0.501	rs7897822	ENSG00000224034.1	RP11-445P17.8	-4.4	1.18e-05	0.000953	-0.27	-0.14	Intelligence;	chr10:5242594	chr10:5266033~5271236:-
BRCA	cis	rs9921338	0.961	rs4315353	ENSG00000262703.1	RP11-485G7.6	4.4	1.18e-05	0.000953	0.16	0.14	Vein graft stenosis in coronary artery bypass grafting;	chr16:11320303	chr16:11348143~11349321:-
BRCA	cis	rs7800418	0.612	rs17286397	ENSG00000214870.7	AC004540.5	-4.4	1.18e-05	0.000953	-0.18	-0.14	Cognitive function;	chr7:26586594	chr7:26398593~26494256:+
BRCA	cis	rs7246967	0.604	rs8112577	ENSG00000198153.8	ZNF849P	-4.4	1.18e-05	0.000953	-0.23	-0.14	Bronchopulmonary dysplasia;	chr19:22710669	chr19:22685167~22686732:+
BRCA	cis	rs516805	0.561	rs2684239	ENSG00000279453.1	RP3-425C14.4	-4.4	1.18e-05	0.000954	-0.19	-0.14	Lymphocyte counts;	chr6:122086976	chr6:122436789~122439223:-
BRCA	cis	rs516805	0.561	rs2679640	ENSG00000279453.1	RP3-425C14.4	-4.4	1.18e-05	0.000954	-0.19	-0.14	Lymphocyte counts;	chr6:122087013	chr6:122436789~122439223:-
BRCA	cis	rs7267979	0.816	rs404775	ENSG00000231081.1	RP4-760C5.3	-4.4	1.18e-05	0.000954	-0.17	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25500481	chr20:26008791~26010531:-
BRCA	cis	rs7267979	0.816	rs374701	ENSG00000231081.1	RP4-760C5.3	-4.4	1.18e-05	0.000954	-0.17	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25502980	chr20:26008791~26010531:-
BRCA	cis	rs7487075	0.78	rs12320197	ENSG00000274723.1	RP11-618L22.1	4.4	1.18e-05	0.000954	0.16	0.14	Itch intensity from mosquito bite;	chr12:46345100	chr12:46970504~46972155:+
BRCA	cis	rs7267979	1	rs2387884	ENSG00000274973.1	RP13-401N8.7	4.4	1.18e-05	0.000954	0.15	0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25398433	chr20:25845497~25845862:+
BRCA	cis	rs9840812	0.691	rs7621025	ENSG00000273486.1	RP11-731C17.2	4.4	1.18e-05	0.000954	0.17	0.14	Fibrinogen levels;	chr3:136553404	chr3:136837338~136839021:-
BRCA	cis	rs1864585	0.806	rs17778223	ENSG00000269918.1	AF131215.9	4.4	1.18e-05	0.000954	0.17	0.14	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr8:10872182	chr8:11104691~11106704:-
BRCA	cis	rs983392	0.805	rs2081545	ENSG00000275344.1	MIR6503	-4.4	1.18e-05	0.000954	-0.14	-0.14	Alzheimer's disease (late onset);	chr11:60190907	chr11:60209071~60209156:-
BRCA	cis	rs58521262	0.556	rs290583	ENSG00000268105.1	RP11-369G6.2	-4.4	1.18e-05	0.000954	-0.18	-0.14	Testicular germ cell tumor;	chr19:23015635	chr19:23125665~23128543:+
BRCA	cis	rs9527	0.59	rs7894959	ENSG00000213061.2	PFN1P11	4.4	1.18e-05	0.000955	0.18	0.14	Arsenic metabolism;	chr10:102996425	chr10:102838011~102845473:-
BRCA	cis	rs4869313	0.869	rs39602	ENSG00000248734.2	CTD-2260A17.1	-4.4	1.18e-05	0.000955	-0.14	-0.14	Pediatric autoimmune diseases;	chr5:97028750	chr5:96784777~96785999:+
BRCA	cis	rs6487679	1	rs6487679	ENSG00000111788.10	RP11-22B23.1	4.4	1.18e-05	0.000955	0.15	0.14	Non-alcoholic fatty liver disease histology (AST);	chr12:9218736	chr12:9277235~9313241:+
BRCA	cis	rs1910358	0.53	rs1027680	ENSG00000248874.4	C5orf17	-4.4	1.19e-05	0.000955	-0.19	-0.14	Venous thromboembolism (SNP x SNP interaction);	chr5:23792950	chr5:23951348~24178263:+
BRCA	cis	rs8054556	1	rs11150580	ENSG00000261367.1	RP11-455F5.4	-4.4	1.19e-05	0.000955	-0.15	-0.14	Autism spectrum disorder or schizophrenia;	chr16:30003243	chr16:30107675~30110541:+
BRCA	cis	rs2243480	1	rs34560516	ENSG00000275400.1	RP4-756H11.5	4.4	1.19e-05	0.000955	0.24	0.14	Diabetic kidney disease;	chr7:65939105	chr7:66553805~66554199:-
BRCA	cis	rs1005277	0.579	rs2472178	ENSG00000099251.13	HSD17B7P2	4.4	1.19e-05	0.000955	0.15	0.14	Extrinsic epigenetic age acceleration;	chr10:38095822	chr10:38356380~38378505:+
BRCA	cis	rs1005277	0.579	rs2474572	ENSG00000099251.13	HSD17B7P2	4.4	1.19e-05	0.000955	0.15	0.14	Extrinsic epigenetic age acceleration;	chr10:38096388	chr10:38356380~38378505:+
BRCA	cis	rs62244186	0.52	rs9311361	ENSG00000214820.3	MPRIPP1	4.4	1.19e-05	0.000955	0.15	0.14	Depressive symptoms;	chr3:44754640	chr3:44579938~44581026:-
BRCA	cis	rs7204230	0.96	rs6499536	ENSG00000261291.1	RP11-295M3.2	4.4	1.19e-05	0.000956	0.17	0.14	Fibrinogen;	chr16:53289968	chr16:53168522~53169450:+
BRCA	cis	rs10129255	0.518	rs8009594	ENSG00000211967.3	IGHV3-53	-4.4	1.19e-05	0.000956	-0.09	-0.14	Kawasaki disease;	chr14:106777494	chr14:106592676~106593347:-
BRCA	cis	rs11098499	0.954	rs6857105	ENSG00000260404.2	RP11-384K6.6	4.4	1.19e-05	0.000956	0.13	0.14	Corneal astigmatism;	chr4:119301143	chr4:118591773~118633729:+
BRCA	cis	rs2832191	0.967	rs3787660	ENSG00000232855.5	AF131217.1	-4.4	1.19e-05	0.000956	-0.16	-0.14	Dental caries;	chr21:29148586	chr21:28439346~28674848:-
BRCA	cis	rs3768617	0.811	rs4366285	ENSG00000224468.3	RP11-181K3.4	-4.4	1.19e-05	0.000956	-0.15	-0.14	Fuchs's corneal dystrophy;	chr1:183044537	chr1:183138402~183141282:-
BRCA	cis	rs700651	0.789	rs1813106	ENSG00000231621.1	AC013264.2	-4.4	1.19e-05	0.000956	-0.13	-0.14	Intracranial aneurysm;	chr2:198015865	chr2:197197991~197199273:+
BRCA	cis	rs7267979	1	rs3761117	ENSG00000277938.1	RP5-965G21.3	-4.4	1.19e-05	0.000956	-0.16	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25407434	chr20:25229150~25231933:+
BRCA	cis	rs6545883	0.524	rs778159	ENSG00000273302.1	RP11-493E12.2	-4.4	1.19e-05	0.000956	-0.12	-0.14	Tuberculosis;	chr2:61329609	chr2:61199979~61200769:+
BRCA	cis	rs6570726	1	rs444564	ENSG00000270638.1	RP3-466P17.1	4.4	1.19e-05	0.000956	0.15	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145538659	chr6:145735570~145737218:+
BRCA	cis	rs7048146	1	rs1411690	ENSG00000213539.4	YBX1P6	4.4	1.19e-05	0.000956	0.15	0.14	Vascular brain injury;	chr9:109542827	chr9:109532830~109534332:-
BRCA	cis	rs7267979	0.966	rs8123949	ENSG00000277938.1	RP5-965G21.3	-4.4	1.19e-05	0.000956	-0.16	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25407497	chr20:25229150~25231933:+
BRCA	cis	rs7267979	1	rs2184000	ENSG00000277938.1	RP5-965G21.3	-4.4	1.19e-05	0.000956	-0.16	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25415242	chr20:25229150~25231933:+
BRCA	cis	rs8114671	0.562	rs6087641	ENSG00000126005.14	MMP24-AS1	-4.4	1.19e-05	0.000956	-0.15	-0.14	Height;	chr20:34879914	chr20:35216462~35278131:-
BRCA	cis	rs12468226	1	rs13426118	ENSG00000226261.1	AC064836.3	4.4	1.19e-05	0.000957	0.2	0.14	Urate levels;	chr2:202390762	chr2:202336024~202336727:-
BRCA	cis	rs9584850	0.834	rs7334078	ENSG00000231194.1	FARP1-AS1	-4.4	1.19e-05	0.000957	-0.17	-0.14	Neuroticism;	chr13:98468230	chr13:98435405~98435840:-
BRCA	cis	rs871012	0.542	rs58995342	ENSG00000248544.2	CTB-47B11.3	-4.4	1.19e-05	0.000957	-0.18	-0.14	IgG glycosylation;	chr5:157401332	chr5:157375741~157384950:-
BRCA	cis	rs6893300	0.857	rs62406181	ENSG00000225051.5	HMGB3P22	4.4	1.19e-05	0.000958	0.17	0.14	Resting heart rate;	chr5:179744802	chr5:179679032~179694768:+
BRCA	cis	rs7267979	0.816	rs390123	ENSG00000231081.1	RP4-760C5.3	-4.4	1.19e-05	0.000958	-0.17	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25499469	chr20:26008791~26010531:-
BRCA	cis	rs7674212	0.539	rs6533056	ENSG00000246560.2	RP11-10L12.4	4.4	1.19e-05	0.000958	0.14	0.14	Type 2 diabetes;	chr4:103199840	chr4:102828055~102844075:+
BRCA	cis	rs4767841	0.552	rs10849682	ENSG00000248636.5	RP11-768F21.1	-4.4	1.19e-05	0.000958	-0.18	-0.14	Urgency urinary incontinence;	chr12:119622325	chr12:119387987~119668079:-
BRCA	cis	rs8180040	0.701	rs7617689	ENSG00000276925.1	RP11-708J19.3	4.4	1.19e-05	0.000958	0.15	0.14	Colorectal cancer;	chr3:46954952	chr3:47469777~47469987:+
BRCA	cis	rs13113518	1	rs11726198	ENSG00000272969.1	RP11-528I4.2	4.4	1.19e-05	0.000959	0.16	0.14	Height;	chr4:55523835	chr4:55547112~55547889:+
BRCA	cis	rs13113518	0.966	rs11133396	ENSG00000272969.1	RP11-528I4.2	4.4	1.19e-05	0.000959	0.16	0.14	Height;	chr4:55524246	chr4:55547112~55547889:+
BRCA	cis	rs13113518	1	rs7675109	ENSG00000272969.1	RP11-528I4.2	4.4	1.19e-05	0.000959	0.16	0.14	Height;	chr4:55525589	chr4:55547112~55547889:+
BRCA	cis	rs13113518	1	rs4865005	ENSG00000272969.1	RP11-528I4.2	4.4	1.19e-05	0.000959	0.16	0.14	Height;	chr4:55525781	chr4:55547112~55547889:+
BRCA	cis	rs754466	1	rs56256440	ENSG00000204049.1	RP11-126H7.4	4.4	1.19e-05	0.000959	0.18	0.14	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77938449	chr10:77866875~77869610:+
BRCA	cis	rs240993	0.812	rs6937734	ENSG00000230177.1	RP5-1112D6.4	4.4	1.19e-05	0.000959	0.17	0.14	Inflammatory skin disease;Psoriasis;	chr6:111415439	chr6:111277932~111278742:+
BRCA	cis	rs2832191	0.636	rs8131283	ENSG00000176054.6	RPL23P2	-4.4	1.19e-05	0.000959	-0.15	-0.14	Dental caries;	chr21:29144475	chr21:28997613~28998033:-
BRCA	cis	rs10129255	0.5	rs34326748	ENSG00000211959.2	IGHV4-39	4.4	1.19e-05	0.000959	0.09	0.14	Kawasaki disease;	chr14:106782523	chr14:106421711~106422218:-
BRCA	cis	rs10129255	0.5	rs10143385	ENSG00000211959.2	IGHV4-39	4.4	1.19e-05	0.000959	0.09	0.14	Kawasaki disease;	chr14:106782559	chr14:106421711~106422218:-
BRCA	cis	rs6480314	0.636	rs61854797	ENSG00000233590.1	RP11-153K11.3	-4.4	1.19e-05	0.000959	-0.23	-0.14	Optic nerve measurement (disc area);	chr10:68245854	chr10:68233251~68242379:-
BRCA	cis	rs4578769	0.836	rs3844227	ENSG00000273232.1	RP11-370A5.2	4.4	1.19e-05	0.000959	0.18	0.14	Eosinophil percentage of white cells;	chr18:22871067	chr18:22882825~22883357:-
BRCA	cis	rs7246657	0.508	rs1628959	ENSG00000226686.6	LINC01535	-4.4	1.19e-05	0.000959	-0.23	-0.14	Coronary artery calcification;	chr19:36999474	chr19:37251912~37265535:+
BRCA	cis	rs13113518	1	rs4864549	ENSG00000272969.1	RP11-528I4.2	4.4	1.19e-05	0.000959	0.16	0.14	Height;	chr4:55554380	chr4:55547112~55547889:+
BRCA	cis	rs9868809	0.505	rs9811027	ENSG00000225399.4	RP11-3B7.1	-4.4	1.19e-05	0.00096	-0.2	-0.14	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48687581	chr3:49260085~49261316:+
BRCA	cis	rs12497850	0.863	rs4858799	ENSG00000225399.4	RP11-3B7.1	-4.4	1.19e-05	0.00096	-0.2	-0.14	Parkinson's disease;	chr3:48690771	chr3:49260085~49261316:+
BRCA	cis	rs17711722	0.522	rs62469933	ENSG00000226767.1	RP11-328P23.3	4.4	1.19e-05	0.00096	0.15	0.14	Calcium levels;	chr7:65800652	chr7:65508773~65508944:-
BRCA	cis	rs2915864	0.8	rs2043281	ENSG00000280047.1	CTC-463A16.1	4.4	1.19e-05	0.00096	0.2	0.14	Facial morphology (factor 20);	chr5:142143290	chr5:142165767~142168387:+
BRCA	cis	rs10411936	0.75	rs8112401	ENSG00000280332.1	CTD-2013N17.6	4.4	1.19e-05	0.00096	0.12	0.14	Multiple sclerosis;White blood cell count;	chr19:16482201	chr19:16356329~16358327:-
BRCA	cis	rs13113518	1	rs4864542	ENSG00000272969.1	RP11-528I4.2	-4.4	1.19e-05	0.00096	-0.16	-0.14	Height;	chr4:55487920	chr4:55547112~55547889:+
BRCA	cis	rs7572733	0.935	rs4850817	ENSG00000231621.1	AC013264.2	4.4	1.19e-05	0.00096	0.12	0.14	Dermatomyositis;	chr2:197930480	chr2:197197991~197199273:+
BRCA	cis	rs11098499	0.954	rs2389802	ENSG00000250412.1	KLHL2P1	4.4	1.19e-05	0.00096	0.16	0.14	Corneal astigmatism;	chr4:119404577	chr4:119334329~119378233:+
BRCA	cis	rs4415084	0.652	rs10473376	ENSG00000251141.4	RP11-53O19.1	-4.4	1.19e-05	0.00096	-0.13	-0.14	Breast cancer;	chr5:44931126	chr5:44744900~44808777:-
BRCA	cis	rs930395	0.514	rs10473377	ENSG00000251141.4	RP11-53O19.1	-4.4	1.19e-05	0.00096	-0.13	-0.14	Breast cancer;	chr5:44931144	chr5:44744900~44808777:-
BRCA	cis	rs750460	0.844	rs2028386	ENSG00000261801.4	LOXL1-AS1	4.4	1.19e-05	0.000961	0.15	0.14	Height;	chr15:73934367	chr15:73908071~73928248:-
BRCA	cis	rs7789940	0.904	rs6953281	ENSG00000280388.1	RP11-229D13.3	-4.4	1.19e-05	0.000961	-0.15	-0.14	Multiple sclerosis;	chr7:76317626	chr7:76043977~76045963:-
BRCA	cis	rs7789940	0.951	rs7787526	ENSG00000280388.1	RP11-229D13.3	-4.4	1.19e-05	0.000961	-0.15	-0.14	Multiple sclerosis;	chr7:76318236	chr7:76043977~76045963:-
BRCA	cis	rs4356203	0.905	rs7107283	ENSG00000272034.1	SNORD14A	4.4	1.19e-05	0.000961	0.14	0.14	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17067856	chr11:17074654~17074744:-
BRCA	cis	rs13113518	1	rs4864549	ENSG00000273257.1	RP11-177J6.1	4.4	1.19e-05	0.000961	0.17	0.14	Height;	chr4:55554380	chr4:55387949~55388271:+
BRCA	cis	rs12612619	0.732	rs920433	ENSG00000272148.1	RP11-195B17.1	4.4	1.19e-05	0.000962	0.15	0.14	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:26989658	chr2:27062428~27062907:-
BRCA	cis	rs321358	1	rs321365	ENSG00000271390.1	RP11-89C3.3	4.4	1.2e-05	0.000962	0.21	0.14	Body mass index;	chr11:111126676	chr11:111089870~111090368:-
BRCA	cis	rs66887589	0.776	rs10518337	ENSG00000245958.5	RP11-33B1.1	4.4	1.2e-05	0.000962	0.12	0.14	Diastolic blood pressure;	chr4:119653719	chr4:119454791~119552025:+
BRCA	cis	rs375066	0.935	rs108775	ENSG00000267191.1	RP11-15A1.2	-4.4	1.2e-05	0.000962	-0.17	-0.14	Breast cancer;	chr19:43901770	chr19:43902001~43926545:+
BRCA	cis	rs2574985	0.813	rs1203410	ENSG00000231345.3	BEND3P1	4.4	1.2e-05	0.000962	0.21	0.14	Subjective well-being;	chr10:50437185	chr10:50655967~50660472:+
BRCA	cis	rs651907	1	rs651907	ENSG00000244119.1	PDCL3P4	4.4	1.2e-05	0.000962	0.1	0.14	Colorectal cancer;	chr3:101881880	chr3:101712472~101713191:+
BRCA	cis	rs11098499	0.863	rs3736115	ENSG00000260091.1	RP11-33B1.4	4.4	1.2e-05	0.000963	0.12	0.14	Corneal astigmatism;	chr4:119567548	chr4:119409333~119410233:+
BRCA	cis	rs8064024	0.87	rs930854	ENSG00000267077.1	RP11-127I20.5	4.4	1.2e-05	0.000963	0.13	0.14	Cancer;	chr16:4814100	chr16:4795265~4796532:-
BRCA	cis	rs1371614	0.611	rs3845685	ENSG00000272148.1	RP11-195B17.1	-4.4	1.2e-05	0.000963	-0.15	-0.14	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26907464	chr2:27062428~27062907:-
BRCA	cis	rs6545883	0.929	rs2121660	ENSG00000212978.6	AC016747.3	-4.4	1.2e-05	0.000963	-0.19	-0.14	Tuberculosis;	chr2:61425923	chr2:61141592~61144969:-
BRCA	cis	rs6545883	0.929	rs778154	ENSG00000212978.6	AC016747.3	-4.4	1.2e-05	0.000963	-0.19	-0.14	Tuberculosis;	chr2:61419496	chr2:61141592~61144969:-
BRCA	cis	rs6893300	0.857	rs6860716	ENSG00000225051.5	HMGB3P22	4.4	1.2e-05	0.000963	0.17	0.14	Resting heart rate;	chr5:179735839	chr5:179679032~179694768:+
BRCA	cis	rs7937890	0.967	rs963212	ENSG00000254418.1	RP11-21L19.1	-4.4	1.2e-05	0.000963	-0.15	-0.14	Mitochondrial DNA levels;	chr11:14303186	chr11:14262846~14273691:-
BRCA	cis	rs216345	0.7	rs307656	ENSG00000260947.1	RP11-384P7.7	4.4	1.2e-05	0.000963	0.14	0.14	Bipolar disorder;	chr9:33949722	chr9:33697459~33700986:+
BRCA	cis	rs11098499	0.863	rs2306456	ENSG00000250412.1	KLHL2P1	4.4	1.2e-05	0.000964	0.16	0.14	Corneal astigmatism;	chr4:119551267	chr4:119334329~119378233:+
BRCA	cis	rs11098499	0.863	rs11947234	ENSG00000250412.1	KLHL2P1	4.4	1.2e-05	0.000964	0.16	0.14	Corneal astigmatism;	chr4:119553704	chr4:119334329~119378233:+
BRCA	cis	rs11098499	0.863	rs11933966	ENSG00000250412.1	KLHL2P1	4.4	1.2e-05	0.000964	0.16	0.14	Corneal astigmatism;	chr4:119555560	chr4:119334329~119378233:+
BRCA	cis	rs11098499	0.863	rs36040693	ENSG00000250412.1	KLHL2P1	4.4	1.2e-05	0.000964	0.16	0.14	Corneal astigmatism;	chr4:119556461	chr4:119334329~119378233:+
BRCA	cis	rs10043228	1	rs10073364	ENSG00000271918.1	CTD-2287O16.5	-4.4	1.2e-05	0.000964	-0.17	-0.14	Asthma or chronic obstructive pulmonary disease;	chr5:116256885	chr5:116083807~116085416:-
BRCA	cis	rs10043228	1	rs10036292	ENSG00000271918.1	CTD-2287O16.5	-4.4	1.2e-05	0.000964	-0.17	-0.14	Asthma or chronic obstructive pulmonary disease;	chr5:116260174	chr5:116083807~116085416:-
BRCA	cis	rs7267979	1	rs1888999	ENSG00000125804.12	FAM182A	-4.4	1.2e-05	0.000964	-0.18	-0.14	Liver enzyme levels (alkaline phosphatase);	chr20:25311212	chr20:26054655~26086917:+
BRCA	cis	rs7160336	1	rs8022907	ENSG00000259065.1	RP5-1021I20.1	4.4	1.2e-05	0.000964	0.15	0.14	Blood protein levels;	chr14:74076070	chr14:73787360~73803270:+
BRCA	cis	rs13126694	0.598	rs4077777	ENSG00000251429.1	RP11-597D13.7	4.4	1.2e-05	0.000964	0.14	0.14	Blood osmolality (transformed sodium);	chr4:158007502	chr4:158270378~158278676:+
BRCA	cis	rs6973609	0.962	rs10230265	ENSG00000271122.1	RP11-379H18.1	4.4	1.2e-05	0.000964	0.14	0.14	Obesity-related traits;	chr7:35567404	chr7:35695214~35699413:+
BRCA	cis	rs721917	0.526	rs2256574	ENSG00000278616.1	BEND3P3	-4.4	1.2e-05	0.000965	-0.13	-0.14	Chronic obstructive pulmonary disease;	chr10:79925283	chr10:79682997~79685436:+
BRCA	cis	rs11696845	1	rs6073534	ENSG00000276223.1	RP4-781B1.5	-4.4	1.2e-05	0.000965	-0.14	-0.14	Obesity-related traits;	chr20:44736863	chr20:44746642~44747201:+
BRCA	cis	rs7177699	0.557	rs4073322	ENSG00000261143.1	ADAMTS7P3	-4.4	1.2e-05	0.000965	-0.16	-0.14	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78830199	chr15:77976042~77993057:+
BRCA	cis	rs17507216	0.958	rs28648832	ENSG00000259429.4	UBE2Q2P2	-4.4	1.2e-05	0.000965	-0.16	-0.14	Excessive daytime sleepiness;	chr15:82567642	chr15:82355142~82420075:+
BRCA	cis	rs2625529	0.617	rs2128112	ENSG00000260037.4	CTD-2524L6.3	4.4	1.2e-05	0.000965	0.17	0.14	Red blood cell count;	chr15:71893945	chr15:71818396~71823384:+
BRCA	cis	rs7246657	0.663	rs9304568	ENSG00000226686.6	LINC01535	-4.4	1.2e-05	0.000965	-0.2	-0.14	Coronary artery calcification;	chr19:37563606	chr19:37251912~37265535:+
BRCA	cis	rs6128907	1	rs6128947	ENSG00000224635.1	RP4-564F22.5	4.4	1.2e-05	0.000965	0.21	0.14	Liver fibrosis in pediatric non-alcoholic fatty acid liver disease;	chr20:38770845	chr20:38406011~38416797:-
BRCA	cis	rs6128907	0.948	rs6128952	ENSG00000224635.1	RP4-564F22.5	4.4	1.2e-05	0.000965	0.21	0.14	Liver fibrosis in pediatric non-alcoholic fatty acid liver disease;	chr20:38771847	chr20:38406011~38416797:-
BRCA	cis	rs6128907	1	rs6128959	ENSG00000224635.1	RP4-564F22.5	4.4	1.2e-05	0.000965	0.21	0.14	Liver fibrosis in pediatric non-alcoholic fatty acid liver disease;	chr20:38773752	chr20:38406011~38416797:-
BRCA	cis	rs7811142	1	rs6975729	ENSG00000078319.8	PMS2P1	-4.4	1.2e-05	0.000965	-0.22	-0.14	Platelet count;	chr7:100430564	chr7:100320992~100341908:-
BRCA	cis	rs7674212	0.539	rs6815783	ENSG00000246560.2	RP11-10L12.4	4.4	1.2e-05	0.000965	0.14	0.14	Type 2 diabetes;	chr4:103200989	chr4:102828055~102844075:+
BRCA	cis	rs495337	0.76	rs6125830	ENSG00000229222.1	KRT18P4	-4.4	1.2e-05	0.000965	-0.17	-0.14	Psoriasis;	chr20:49955125	chr20:49956745~49958032:+
BRCA	cis	rs7011507	0.577	rs72637676	ENSG00000279881.1	RP11-513O13.1	-4.4	1.2e-05	0.000966	-0.22	-0.14	Inflammatory bowel disease;Ulcerative colitis;	chr8:48347684	chr8:48428143~48431041:-
BRCA	cis	rs7651446	0.649	rs9869194	ENSG00000240875.4	LINC00886	-4.4	1.2e-05	0.000966	-0.27	-0.14	Ovarian cancer;Epithelial ovarian cancer;	chr3:156648945	chr3:156747346~156817062:-
BRCA	cis	rs7918232	0.882	rs788211	ENSG00000262412.1	RP11-85G18.6	-4.4	1.2e-05	0.000966	-0.22	-0.14	Breast cancer;	chr10:27190141	chr10:27243130~27250804:+
BRCA	cis	rs859767	0.709	rs7575742	ENSG00000224043.6	CCNT2-AS1	4.4	1.2e-05	0.000966	0.19	0.14	Neuroticism;	chr2:134671432	chr2:134735464~134918710:-
BRCA	cis	rs703842	1	rs11172333	ENSG00000270039.1	RP11-571M6.17	-4.4	1.2e-05	0.000966	-0.19	-0.14	Multiple sclerosis;	chr12:57776552	chr12:57803838~57804415:+
BRCA	cis	rs867371	1	rs13380319	ENSG00000278603.1	RP13-608F4.5	4.4	1.2e-05	0.000967	0.18	0.14	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82214526	chr15:82472203~82472426:+
BRCA	cis	rs7772486	0.79	rs2254283	ENSG00000270638.1	RP3-466P17.1	4.4	1.2e-05	0.000967	0.16	0.14	Lobe attachment (rater-scored or self-reported);	chr6:145883153	chr6:145735570~145737218:+
BRCA	cis	rs10833905	0.759	rs12224706	ENSG00000246225.5	RP11-17A1.3	-4.4	1.2e-05	0.000967	-0.19	-0.14	Sudden cardiac arrest;	chr11:23035226	chr11:22829380~22945393:+
BRCA	cis	rs6081541	0.921	rs6035258	ENSG00000179447.2	RP5-1027G4.3	4.4	1.2e-05	0.000968	0.18	0.14	Psychosis (atypical);	chr20:19225186	chr20:19242302~19284596:-
BRCA	cis	rs6565180	1	rs11862806	ENSG00000183604.13	SMG1P5	-4.4	1.2e-05	0.000968	-0.13	-0.14	Tonsillectomy;	chr16:30352750	chr16:30267553~30335374:-
BRCA	cis	rs2839186	0.967	rs9637172	ENSG00000239415.1	AP001469.9	4.4	1.2e-05	0.000968	0.14	0.14	Testicular germ cell tumor;	chr21:46265873	chr21:46251549~46254133:-
BRCA	cis	rs2832191	0.716	rs1984012	ENSG00000215533.7	LINC00189	-4.4	1.2e-05	0.000968	-0.15	-0.14	Dental caries;	chr21:29020151	chr21:29193480~29288205:+
BRCA	cis	rs7487075	0.93	rs11183468	ENSG00000274723.1	RP11-618L22.1	4.4	1.2e-05	0.000968	0.16	0.14	Itch intensity from mosquito bite;	chr12:46412478	chr12:46970504~46972155:+
BRCA	cis	rs6968419	0.755	rs3173919	ENSG00000279086.1	RP11-667F14.1	-4.4	1.2e-05	0.000968	-0.15	-0.14	Intraocular pressure;	chr7:116258123	chr7:116209234~116211511:-
BRCA	cis	rs6968419	0.755	rs1141470	ENSG00000279086.1	RP11-667F14.1	-4.4	1.2e-05	0.000968	-0.15	-0.14	Intraocular pressure;	chr7:116258388	chr7:116209234~116211511:-
BRCA	cis	rs6968419	0.755	rs3807983	ENSG00000279086.1	RP11-667F14.1	-4.4	1.2e-05	0.000968	-0.15	-0.14	Intraocular pressure;	chr7:116258937	chr7:116209234~116211511:-
BRCA	cis	rs60843830	1	rs10193373	ENSG00000272342.1	RP13-539J13.1	4.4	1.2e-05	0.000969	0.17	0.14	Spherical equivalent (joint analysis main effects and education interaction);	chr2:281886	chr2:739588~740164:-
BRCA	cis	rs6657613	0.68	rs11203287	ENSG00000186715.9	MST1L	-4.4	1.2e-05	0.000969	-0.13	-0.14	Hip circumference adjusted for BMI;	chr1:17045902	chr1:16754910~16770237:-
BRCA	cis	rs58521262	0.516	rs290587	ENSG00000268105.1	RP11-369G6.2	-4.4	1.2e-05	0.000969	-0.18	-0.14	Testicular germ cell tumor;	chr19:23020559	chr19:23125665~23128543:+
BRCA	cis	rs58521262	0.556	rs158695	ENSG00000268105.1	RP11-369G6.2	-4.4	1.2e-05	0.000969	-0.18	-0.14	Testicular germ cell tumor;	chr19:23020769	chr19:23125665~23128543:+
BRCA	cis	rs2288884	0.505	rs17835435	ENSG00000275055.1	CTC-471J1.11	-4.4	1.2e-05	0.000969	-0.21	-0.14	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:51931453	chr19:52049007~52049754:+
BRCA	cis	rs9921338	0.961	rs7200667	ENSG00000262703.1	RP11-485G7.6	-4.4	1.2e-05	0.000969	-0.17	-0.13	Vein graft stenosis in coronary artery bypass grafting;	chr16:11346547	chr16:11348143~11349321:-
BRCA	cis	rs6088590	0.542	rs6059956	ENSG00000276073.1	RP5-1125A11.7	-4.4	1.2e-05	0.000969	-0.15	-0.13	Coronary artery disease;	chr20:34632266	chr20:33985617~33988989:-
BRCA	cis	rs6490294	0.904	rs11066112	ENSG00000234608.6	MAPKAPK5-AS1	4.4	1.21e-05	0.000969	0.17	0.13	Mean platelet volume;	chr12:111978782	chr12:111839764~111842902:-
BRCA	cis	rs6480314	0.636	rs77760458	ENSG00000233590.1	RP11-153K11.3	-4.4	1.21e-05	0.000969	-0.23	-0.13	Optic nerve measurement (disc area);	chr10:68244248	chr10:68233251~68242379:-
BRCA	cis	rs10844706	0.699	rs741199	ENSG00000256673.1	RP11-599J14.2	-4.4	1.21e-05	0.00097	-0.17	-0.13	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9720769	chr12:9398355~9414851:-
BRCA	cis	rs2235544	0.565	rs676562	ENSG00000225183.1	RP4-758J24.4	4.4	1.21e-05	0.00097	0.16	0.13	Thyroid hormone levels;Multiple myeloma (hyperdiploidy);	chr1:54002965	chr1:54089856~54090093:+
BRCA	cis	rs10863681	1	rs12135862	ENSG00000232679.1	RP11-400N13.3	-4.4	1.21e-05	0.00097	-0.13	-0.13	Metabolite levels (HVA-5-HIAA Factor score);	chr1:222072045	chr1:222041705~222064763:-
BRCA	cis	rs7833986	0.501	rs72653953	ENSG00000253603.1	CTA-397H3.3	-4.4	1.21e-05	0.00097	-0.2	-0.13	Height;	chr8:56058236	chr8:56074592~56075274:+
BRCA	cis	rs77372450	0.688	rs6875485	ENSG00000248544.2	CTB-47B11.3	4.4	1.21e-05	0.00097	0.21	0.13	Bipolar disorder (body mass index interaction);	chr5:157539587	chr5:157375741~157384950:-
BRCA	cis	rs6860806	0.661	rs2136187	ENSG00000233006.5	AC034220.3	4.4	1.21e-05	0.00097	0.1	0.13	Breast cancer;	chr5:132242201	chr5:132311285~132369916:-
BRCA	cis	rs1910358	0.614	rs12656465	ENSG00000248874.4	C5orf17	-4.4	1.21e-05	0.000971	-0.17	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23965369	chr5:23951348~24178263:+
BRCA	cis	rs5758659	0.652	rs6519301	ENSG00000273366.1	CTA-989H11.1	-4.4	1.21e-05	0.000971	-0.16	-0.13	Cognitive function;	chr22:41989963	chr22:42278188~42278846:+
BRCA	cis	rs7428	0.502	rs3184781	ENSG00000273196.1	RP11-717A5.2	4.4	1.21e-05	0.000971	0.16	0.13	Ear protrusion;	chr2:85322404	chr2:85387074~85387146:-
BRCA	cis	rs7428	0.527	rs3184780	ENSG00000273196.1	RP11-717A5.2	4.4	1.21e-05	0.000971	0.16	0.13	Ear protrusion;	chr2:85322424	chr2:85387074~85387146:-
BRCA	cis	rs13113518	0.966	rs13108409	ENSG00000272969.1	RP11-528I4.2	4.4	1.21e-05	0.000971	0.16	0.13	Height;	chr4:55520278	chr4:55547112~55547889:+
BRCA	cis	rs3812762	0.871	rs2173999	ENSG00000254860.4	TMEM9B-AS1	-4.4	1.21e-05	0.000971	-0.12	-0.13	Hypospadias;	chr11:8756530	chr11:8964675~8977527:+
BRCA	cis	rs13113518	0.683	rs9761521	ENSG00000272969.1	RP11-528I4.2	4.4	1.21e-05	0.000971	0.16	0.13	Height;	chr4:55363436	chr4:55547112~55547889:+
BRCA	cis	rs17818399	0.815	rs17819022	ENSG00000279254.1	RP11-536C12.1	-4.4	1.21e-05	0.000971	-0.18	-0.13	Height;	chr2:46623432	chr2:46668870~46670778:+
BRCA	cis	rs1223397	0.651	rs453877	ENSG00000215022.6	RP1-257A7.4	-4.4	1.21e-05	0.000971	-0.16	-0.13	Blood pressure;	chr6:13297231	chr6:13264861~13295586:-
BRCA	cis	rs1910358	0.77	rs7733460	ENSG00000248874.4	C5orf17	-4.4	1.21e-05	0.000972	-0.22	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23915219	chr5:23951348~24178263:+
BRCA	cis	rs8031584	0.706	rs798084	ENSG00000270015.1	RP11-540B6.6	-4.4	1.21e-05	0.000972	-0.15	-0.13	Huntington's disease progression;	chr15:30834732	chr15:30926514~30928407:+
BRCA	cis	rs6570726	0.902	rs396681	ENSG00000270638.1	RP3-466P17.1	4.4	1.21e-05	0.000972	0.15	0.13	Lobe attachment (rater-scored or self-reported);	chr6:145532467	chr6:145735570~145737218:+
BRCA	cis	rs72843506	0.591	rs75334890	ENSG00000270091.1	RP11-78O7.2	-4.4	1.21e-05	0.000972	-0.21	-0.13	Schizophrenia;	chr17:20318087	chr17:19896590~19897287:-
BRCA	cis	rs60843830	1	rs17713729	ENSG00000272342.1	RP13-539J13.1	4.4	1.21e-05	0.000972	0.17	0.13	Spherical equivalent (joint analysis main effects and education interaction);	chr2:249092	chr2:739588~740164:-
BRCA	cis	rs7954584	0.813	rs1523261	ENSG00000212694.7	LINC01089	-4.4	1.21e-05	0.000972	-0.11	-0.13	Mean corpuscular volume;	chr12:122024971	chr12:121795267~121803906:-
BRCA	cis	rs10992797	0.504	rs2994369	ENSG00000227603.1	RP11-165J3.6	-4.4	1.21e-05	0.000972	-0.15	-0.13	Intelligence (multi-trait analysis);	chr9:93604231	chr9:93435332~93437121:-
BRCA	cis	rs3770752	0.808	rs2287093	ENSG00000272054.1	RP11-423P10.2	-4.4	1.21e-05	0.000973	-0.12	-0.13	Schizophrenia;	chr2:37198486	chr2:37208875~37212677:+
BRCA	cis	rs7267979	0.966	rs8123949	ENSG00000274973.1	RP13-401N8.7	4.4	1.21e-05	0.000973	0.15	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25407497	chr20:25845497~25845862:+
BRCA	cis	rs7267979	1	rs2184000	ENSG00000274973.1	RP13-401N8.7	4.4	1.21e-05	0.000973	0.15	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25415242	chr20:25845497~25845862:+
BRCA	cis	rs9788721	0.836	rs11858836	ENSG00000261762.1	RP11-650L12.2	-4.4	1.21e-05	0.000973	-0.17	-0.13	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78490935	chr15:78589123~78591276:-
BRCA	cis	rs11603691	1	rs73470506	ENSG00000254662.1	RP11-872D17.4	-4.4	1.21e-05	0.000973	-0.32	-0.13	Low high density lipoprotein cholesterol levels;	chr11:57240772	chr11:57325603~57327958:+
BRCA	cis	rs11098499	0.644	rs10050092	ENSG00000249244.1	RP11-548H18.2	4.4	1.21e-05	0.000973	0.16	0.13	Corneal astigmatism;	chr4:119610930	chr4:119391831~119395335:-
BRCA	cis	rs3768617	0.811	rs12138053	ENSG00000224468.3	RP11-181K3.4	-4.4	1.21e-05	0.000973	-0.15	-0.13	Fuchs's corneal dystrophy;	chr1:183010425	chr1:183138402~183141282:-
BRCA	cis	rs950776	0.616	rs495090	ENSG00000279373.1	RP11-650L12.4	-4.4	1.21e-05	0.000974	-0.16	-0.13	Sudden cardiac arrest;	chr15:78577661	chr15:78537681~78538946:+
BRCA	cis	rs950776	0.722	rs471889	ENSG00000279373.1	RP11-650L12.4	-4.4	1.21e-05	0.000974	-0.16	-0.13	Sudden cardiac arrest;	chr15:78577893	chr15:78537681~78538946:+
BRCA	cis	rs10129255	0.957	rs11847726	ENSG00000274576.2	IGHV2-70	4.4	1.21e-05	0.000974	0.12	0.13	Kawasaki disease;	chr14:106779116	chr14:106770577~106771020:-
BRCA	cis	rs7267979	1	rs6037099	ENSG00000277938.1	RP5-965G21.3	-4.4	1.21e-05	0.000974	-0.16	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25376240	chr20:25229150~25231933:+
BRCA	cis	rs7267979	0.966	rs4815414	ENSG00000277938.1	RP5-965G21.3	-4.4	1.21e-05	0.000974	-0.16	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25381065	chr20:25229150~25231933:+
BRCA	cis	rs7267979	1	rs6083825	ENSG00000277938.1	RP5-965G21.3	-4.4	1.21e-05	0.000974	-0.16	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25385788	chr20:25229150~25231933:+
BRCA	cis	rs7267979	1	rs34645895	ENSG00000277938.1	RP5-965G21.3	-4.4	1.21e-05	0.000974	-0.16	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25387737	chr20:25229150~25231933:+
BRCA	cis	rs7267979	1	rs6037105	ENSG00000277938.1	RP5-965G21.3	-4.4	1.21e-05	0.000974	-0.16	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25393563	chr20:25229150~25231933:+
BRCA	cis	rs10504130	0.569	rs4418329	ENSG00000272024.1	RP11-546K22.3	-4.4	1.21e-05	0.000974	-0.2	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr8:51758554	chr8:51950284~51950690:+
BRCA	cis	rs10504130	0.569	rs4442134	ENSG00000272024.1	RP11-546K22.3	-4.4	1.21e-05	0.000974	-0.2	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr8:51758584	chr8:51950284~51950690:+
BRCA	cis	rs4957048	0.891	rs11960196	ENSG00000271781.1	CTD-2589H19.6	-4.4	1.21e-05	0.000974	-0.18	-0.13	Ulcerative colitis;	chr5:568742	chr5:675826~676616:+
BRCA	cis	rs9637599	0.513	rs7678928	ENSG00000246375.2	RP11-10L7.1	-4.4	1.21e-05	0.000974	-0.17	-0.13	Metabolite levels (small molecules and protein measures);	chr4:88301675	chr4:88284942~88331421:+
BRCA	cis	rs11018904	0.906	rs17227345	ENSG00000280367.1	RP11-121L10.2	-4.4	1.21e-05	0.000975	-0.22	-0.13	Intelligence (multi-trait analysis);	chr11:90221517	chr11:90223153~90226538:+
BRCA	cis	rs9921338	0.886	rs3931015	ENSG00000262703.1	RP11-485G7.6	4.4	1.21e-05	0.000975	0.16	0.13	Vein graft stenosis in coronary artery bypass grafting;	chr16:11321782	chr16:11348143~11349321:-
BRCA	cis	rs5758659	0.714	rs5758574	ENSG00000227370.1	RP4-669P10.19	4.4	1.21e-05	0.000975	0.14	0.13	Cognitive function;	chr22:42085396	chr22:42132543~42132998:+
BRCA	cis	rs62025270	0.632	rs62022920	ENSG00000259762.1	RP11-158M2.4	-4.4	1.21e-05	0.000975	-0.2	-0.13	Idiopathic pulmonary fibrosis;	chr15:85680159	chr15:85750336~85752901:-
BRCA	cis	rs6968419	0.674	rs4730724	ENSG00000279086.1	RP11-667F14.1	-4.4	1.21e-05	0.000975	-0.15	-0.13	Intraocular pressure;	chr7:116265285	chr7:116209234~116211511:-
BRCA	cis	rs2408955	0.521	rs10875749	ENSG00000257763.1	OR5BK1P	-4.4	1.21e-05	0.000976	-0.14	-0.13	Glycated hemoglobin levels;	chr12:48138134	chr12:48355792~48356614:-
BRCA	cis	rs7674212	0.539	rs6850461	ENSG00000246560.2	RP11-10L12.4	4.4	1.21e-05	0.000976	0.14	0.13	Type 2 diabetes;	chr4:103198884	chr4:102828055~102844075:+
BRCA	cis	rs7267979	1	rs6076345	ENSG00000274973.1	RP13-401N8.7	4.4	1.21e-05	0.000976	0.15	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25401259	chr20:25845497~25845862:+
BRCA	cis	rs7267979	0.789	rs6076347	ENSG00000277938.1	RP5-965G21.3	-4.4	1.21e-05	0.000976	-0.16	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25418154	chr20:25229150~25231933:+
BRCA	cis	rs10916772	0.609	rs12045307	ENSG00000236963.4	LINC01141	4.4	1.21e-05	0.000976	0.25	0.13	Psychosis proneness (perceptual aberration scale);	chr1:20391164	chr1:20360579~20431234:-
BRCA	cis	rs7572733	0.935	rs700669	ENSG00000231621.1	AC013264.2	-4.4	1.21e-05	0.000976	-0.12	-0.13	Dermatomyositis;	chr2:197819743	chr2:197197991~197199273:+
BRCA	cis	rs12744310	1	rs12031169	ENSG00000235358.1	RP11-399E6.1	4.4	1.21e-05	0.000976	0.2	0.13	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41302579	chr1:41242373~41284861:+
BRCA	cis	rs780094	0.5	rs1919127	ENSG00000234072.1	AC074117.10	4.4	1.21e-05	0.000976	0.14	0.13	Urate levels in overweight individuals;C-reactive protein;Metabolic syndrome;Red blood cell count;Renal underexcretion gout;Nonalcoholic fatty liver disease;Age-related diseases, mortality and associated endophenotypes;Crohn's disease;Calcium levels;Fasting plasma glucose;Metabolic traits;Fasting blood glucose;Fasting blood insulin;Urate levels in obese individuals;Alcohol consumption (drinks per week);Height;Urate levels;Gondoic acid (20:1n-9) levels;Uric acid levels;Age-related disease endophenotypes;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Homeostasis model assessment of insulin resistance;Alcohol consumption;Fasting blood insulin (BMI interaction);Triglycerides;Fasting blood glucose (BMI interaction);Hypertriglyceridemia;LDL cholesterol;Type 2 diabetes;Triglyceride levels;	chr2:27578626	chr2:27356246~27367622:+
BRCA	cis	rs7572733	0.84	rs700640	ENSG00000231621.1	AC013264.2	-4.4	1.21e-05	0.000976	-0.12	-0.13	Dermatomyositis;	chr2:197726162	chr2:197197991~197199273:+
BRCA	cis	rs7267979	0.565	rs6076364	ENSG00000204556.4	CTD-2514C3.1	4.4	1.22e-05	0.000977	0.18	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25576165	chr20:26018832~26020684:+
BRCA	cis	rs2871473	1	rs2871473	ENSG00000234389.1	AC007278.3	4.4	1.22e-05	0.000977	0.15	0.13	Blood protein levels;	chr2:102490821	chr2:102438713~102440475:+
BRCA	cis	rs4869313	0.837	rs7703341	ENSG00000248734.2	CTD-2260A17.1	4.4	1.22e-05	0.000977	0.14	0.13	Pediatric autoimmune diseases;	chr5:96954526	chr5:96784777~96785999:+
BRCA	cis	rs10129255	0.5	rs8014529	ENSG00000232216.1	IGHV3-43	4.4	1.22e-05	0.000977	0.1	0.13	Kawasaki disease;	chr14:106784065	chr14:106470264~106470800:-
BRCA	cis	rs875971	0.52	rs160645	ENSG00000230295.1	RP11-458F8.2	-4.4	1.22e-05	0.000977	-0.13	-0.13	Aortic root size;	chr7:66091320	chr7:66880708~66882981:+
BRCA	cis	rs490234	0.702	rs5016056	ENSG00000232630.1	PRPS1P2	-4.4	1.22e-05	0.000977	-0.14	-0.13	Mean arterial pressure;	chr9:125548528	chr9:125150653~125151589:+
BRCA	cis	rs490234	0.702	rs35237975	ENSG00000232630.1	PRPS1P2	-4.4	1.22e-05	0.000977	-0.14	-0.13	Mean arterial pressure;	chr9:125551588	chr9:125150653~125151589:+
BRCA	cis	rs7246657	0.508	rs1644702	ENSG00000267422.1	CTD-2554C21.1	-4.4	1.22e-05	0.000977	-0.23	-0.13	Coronary artery calcification;	chr19:37001005	chr19:37779686~37792865:+
BRCA	cis	rs6545883	0.801	rs778142	ENSG00000212978.6	AC016747.3	4.4	1.22e-05	0.000978	0.19	0.13	Tuberculosis;	chr2:61454293	chr2:61141592~61144969:-
BRCA	cis	rs8114671	0.836	rs6142280	ENSG00000126005.14	MMP24-AS1	4.4	1.22e-05	0.000978	0.16	0.13	Height;	chr20:35034439	chr20:35216462~35278131:-
BRCA	cis	rs425277	0.958	rs626479	ENSG00000269227.1	RP11-345P4.6	-4.4	1.22e-05	0.000978	-0.14	-0.13	Height;	chr1:2178821	chr1:1673275~1674397:+
BRCA	cis	rs1538970	0.816	rs3790583	ENSG00000281133.1	AL355480.3	-4.4	1.22e-05	0.000978	-0.19	-0.13	Platelet count;	chr1:45491156	chr1:45580892~45580996:-
BRCA	cis	rs1538970	0.816	rs11211123	ENSG00000281133.1	AL355480.3	-4.4	1.22e-05	0.000978	-0.19	-0.13	Platelet count;	chr1:45491937	chr1:45580892~45580996:-
BRCA	cis	rs2692947	0.727	rs1657502	ENSG00000168992.4	OR7E102P	4.4	1.22e-05	0.000978	0.18	0.13	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96129869	chr2:95546531~95547545:+
BRCA	cis	rs67766926	1	rs10208155	ENSG00000271889.1	RP11-493E12.1	4.4	1.22e-05	0.000978	0.2	0.13	Inflammatory skin disease;	chr2:60887904	chr2:61151433~61162105:-
BRCA	cis	rs1008375	1	rs2159584	ENSG00000249502.1	AC006160.5	-4.4	1.22e-05	0.000978	-0.15	-0.13	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17618945	chr4:17587467~17614571:-
BRCA	cis	rs2832191	0.716	rs1888440	ENSG00000232855.5	AF131217.1	-4.4	1.22e-05	0.000978	-0.16	-0.13	Dental caries;	chr21:29082163	chr21:28439346~28674848:-
BRCA	cis	rs442309	0.875	rs382424	ENSG00000238280.1	RP11-436D10.3	-4.4	1.22e-05	0.000978	-0.18	-0.13	Vogt-Koyanagi-Harada syndrome;	chr10:62730014	chr10:62793562~62805887:-
BRCA	cis	rs13113518	1	rs13113518	ENSG00000272969.1	RP11-528I4.2	4.4	1.22e-05	0.000979	0.16	0.13	Height;	chr4:55533481	chr4:55547112~55547889:+
BRCA	cis	rs1555322	1	rs2425027	ENSG00000261582.1	RP4-614O4.11	-4.4	1.22e-05	0.000979	-0.19	-0.13	Attention deficit hyperactivity disorder;	chr20:35261587	chr20:35267885~35280043:-
BRCA	cis	rs28472312	0.855	rs12448482	ENSG00000278665.1	RP11-666O2.4	-4.4	1.22e-05	0.000979	-0.15	-0.13	Intelligence (multi-trait analysis);	chr16:28826752	chr16:28599241~28601881:-
BRCA	cis	rs8114671	0.836	rs6141526	ENSG00000279253.1	RP4-614O4.13	4.4	1.22e-05	0.00098	0.16	0.13	Height;	chr20:35027452	chr20:35262727~35264187:-
BRCA	cis	rs7246967	0.551	rs34563787	ENSG00000198153.8	ZNF849P	-4.4	1.22e-05	0.00098	-0.23	-0.13	Bronchopulmonary dysplasia;	chr19:22654934	chr19:22685167~22686732:+
BRCA	cis	rs1008375	1	rs10939740	ENSG00000249502.1	AC006160.5	-4.4	1.22e-05	0.00098	-0.16	-0.13	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17615867	chr4:17587467~17614571:-
BRCA	cis	rs7074356	0.569	rs7090863	ENSG00000225484.5	NUTM2B-AS1	-4.4	1.22e-05	0.00098	-0.23	-0.13	Borderline personality disorder;	chr10:80261637	chr10:79663088~79826594:-
BRCA	cis	rs1371614	0.501	rs4992933	ENSG00000272148.1	RP11-195B17.1	4.4	1.22e-05	0.000981	0.15	0.13	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26956104	chr2:27062428~27062907:-
BRCA	cis	rs1538970	0.739	rs4660863	ENSG00000281133.1	AL355480.3	-4.4	1.22e-05	0.000981	-0.19	-0.13	Platelet count;	chr1:45490196	chr1:45580892~45580996:-
BRCA	cis	rs2380205	0.967	rs4497300	ENSG00000232807.2	RP11-536K7.3	4.4	1.22e-05	0.000981	0.14	0.13	Breast cancer;	chr10:5856278	chr10:5934270~5945900:-
BRCA	cis	rs7811142	1	rs112317829	ENSG00000078319.8	PMS2P1	-4.4	1.22e-05	0.000981	-0.21	-0.13	Platelet count;	chr7:100445550	chr7:100320992~100341908:-
BRCA	cis	rs938554	0.513	rs3775948	ENSG00000250413.1	RP11-448G15.1	-4.4	1.22e-05	0.000981	-0.19	-0.13	Blood metabolite levels;	chr4:9993558	chr4:10006482~10009725:+
BRCA	cis	rs718433	0.584	rs2204935	ENSG00000256379.1	TRAV8-5	4.4	1.22e-05	0.000981	0.15	0.13	Intraocular pressure;	chr14:21744180	chr14:21903077~21903598:+
BRCA	cis	rs718433	0.584	rs4982492	ENSG00000256379.1	TRAV8-5	4.4	1.22e-05	0.000981	0.15	0.13	Intraocular pressure;	chr14:21744535	chr14:21903077~21903598:+
BRCA	cis	rs703842	1	rs2072052	ENSG00000270039.1	RP11-571M6.17	-4.39	1.22e-05	0.000981	-0.19	-0.13	Multiple sclerosis;	chr12:57752936	chr12:57803838~57804415:+
BRCA	cis	rs7772486	0.875	rs854145	ENSG00000270638.1	RP3-466P17.1	4.39	1.22e-05	0.000981	0.15	0.13	Lobe attachment (rater-scored or self-reported);	chr6:146028514	chr6:145735570~145737218:+
BRCA	cis	rs11098499	0.863	rs7699064	ENSG00000250412.1	KLHL2P1	-4.39	1.22e-05	0.000982	-0.16	-0.13	Corneal astigmatism;	chr4:119507154	chr4:119334329~119378233:+
BRCA	cis	rs7520050	0.807	rs3013595	ENSG00000234329.1	RP11-767N6.2	4.39	1.22e-05	0.000982	0.13	0.13	Reticulocyte count;Red blood cell count;	chr1:45687531	chr1:45651039~45651826:-
BRCA	cis	rs6545883	0.825	rs7578139	ENSG00000270820.4	RP11-355B11.2	-4.39	1.22e-05	0.000982	-0.15	-0.13	Tuberculosis;	chr2:61336986	chr2:61471188~61484130:+
BRCA	cis	rs859767	0.501	rs10210052	ENSG00000224043.6	CCNT2-AS1	4.39	1.22e-05	0.000982	0.18	0.13	Neuroticism;	chr2:134659780	chr2:134735464~134918710:-
BRCA	cis	rs9921338	0.961	rs8060767	ENSG00000262636.1	CTD-3088G3.4	-4.39	1.22e-05	0.000982	-0.22	-0.13	Vein graft stenosis in coronary artery bypass grafting;	chr16:11276741	chr16:11380859~11381118:-
BRCA	cis	rs4853525	0.62	rs2066804	ENSG00000235852.1	AC005540.3	4.39	1.22e-05	0.000983	0.17	0.13	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190977033	chr2:190880797~190882059:-
BRCA	cis	rs2880765	0.835	rs2170736	ENSG00000202081.1	RNU6-1280P	4.39	1.22e-05	0.000983	0.16	0.13	Coronary artery disease;	chr15:85500167	chr15:85651522~85651628:-
BRCA	cis	rs9527	0.615	rs9733635	ENSG00000213061.2	PFN1P11	4.39	1.22e-05	0.000983	0.18	0.13	Arsenic metabolism;	chr10:102952183	chr10:102838011~102845473:-
BRCA	cis	rs4478858	0.647	rs10798835	ENSG00000260386.4	LINC01225	-4.39	1.22e-05	0.000983	-0.16	-0.13	Alcohol dependence;	chr1:31236208	chr1:31500085~31540885:+
BRCA	cis	rs2880765	0.835	rs4340287	ENSG00000202081.1	RNU6-1280P	4.39	1.22e-05	0.000983	0.16	0.13	Coronary artery disease;	chr15:85500506	chr15:85651522~85651628:-
BRCA	cis	rs72482608	0.835	rs10919469	ENSG00000271811.1	RP1-79C4.4	4.39	1.22e-05	0.000984	0.15	0.13	Emphysema imaging phenotypes;	chr1:170788330	chr1:170667381~170669425:+
BRCA	cis	rs8103278	0.864	rs2070737	ENSG00000267395.4	AC074212.6	4.39	1.23e-05	0.000984	0.14	0.13	Coronary artery disease;	chr19:45779632	chr19:45767796~45772504:+
BRCA	cis	rs9527	0.615	rs2152915	ENSG00000213061.2	PFN1P11	4.39	1.23e-05	0.000984	0.18	0.13	Arsenic metabolism;	chr10:102931975	chr10:102838011~102845473:-
BRCA	cis	rs9527	0.615	rs3897401	ENSG00000213061.2	PFN1P11	4.39	1.23e-05	0.000984	0.18	0.13	Arsenic metabolism;	chr10:102936622	chr10:102838011~102845473:-
BRCA	cis	rs71520386	0.632	rs28526185	ENSG00000226329.2	AC005682.6	-4.39	1.23e-05	0.000984	-0.14	-0.13	Fibrinogen levels;	chr7:22831699	chr7:22863874~22881350:-
BRCA	cis	rs6968419	0.755	rs17138483	ENSG00000279086.1	RP11-667F14.1	-4.39	1.23e-05	0.000984	-0.15	-0.13	Intraocular pressure;	chr7:116253791	chr7:116209234~116211511:-
BRCA	cis	rs8048589	0.615	rs12924889	ENSG00000175604.2	RP11-276H1.3	-4.39	1.23e-05	0.000985	-0.25	-0.13	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);	chr16:12147911	chr16:12086746~12090302:-
BRCA	cis	rs7191700	0.509	rs415595	ENSG00000262703.1	RP11-485G7.6	4.39	1.23e-05	0.000985	0.14	0.13	Multiple sclerosis;	chr16:11269835	chr16:11348143~11349321:-
BRCA	cis	rs6676180	0.555	rs947430	ENSG00000231365.4	RP11-418J17.1	-4.39	1.23e-05	0.000985	-0.15	-0.13	Monobrow;	chr1:119236111	chr1:119140396~119275973:+
BRCA	cis	rs9467773	0.935	rs9461270	ENSG00000241549.7	GUSBP2	4.39	1.23e-05	0.000985	0.14	0.13	Intelligence (multi-trait analysis);	chr6:26543882	chr6:26871484~26956554:-
BRCA	cis	rs17756712	0.528	rs2073008	ENSG00000271911.1	RP11-532F6.5	4.39	1.23e-05	0.000986	0.19	0.13	Vertical cup-disc ratio;	chr6:638345	chr6:761675~780648:+
BRCA	cis	rs748404	0.589	rs62020612	ENSG00000205771.5	CATSPER2P1	-4.39	1.23e-05	0.000986	-0.2	-0.13	Lung cancer;	chr15:43525881	chr15:43726918~43747094:-
BRCA	cis	rs7267979	0.932	rs928121	ENSG00000277938.1	RP5-965G21.3	4.39	1.23e-05	0.000986	0.16	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25554182	chr20:25229150~25231933:+
BRCA	cis	rs17772222	0.958	rs1816372	ENSG00000258789.1	RP11-507K2.3	-4.39	1.23e-05	0.000986	-0.16	-0.13	Coronary artery calcification;	chr14:88507033	chr14:88551597~88552493:+
BRCA	cis	rs61160187	0.698	rs11955398	ENSG00000272308.1	RP11-231G3.1	-4.39	1.23e-05	0.000986	-0.15	-0.13	Educational attainment (years of education);Educational attainment (college completion);	chr5:60685258	chr5:60866457~60866935:-
BRCA	cis	rs739496	0.579	rs3177647	ENSG00000234608.6	MAPKAPK5-AS1	4.39	1.23e-05	0.000986	0.16	0.13	Platelet count;	chr12:111839772	chr12:111839764~111842902:-
BRCA	cis	rs9467773	1	rs1884946	ENSG00000241549.7	GUSBP2	4.39	1.23e-05	0.000986	0.14	0.13	Intelligence (multi-trait analysis);	chr6:26545080	chr6:26871484~26956554:-
BRCA	cis	rs867186	1	rs75165171	ENSG00000126005.14	MMP24-AS1	-4.39	1.23e-05	0.000987	-0.26	-0.13	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35063650	chr20:35216462~35278131:-
BRCA	cis	rs867186	1	rs117573845	ENSG00000126005.14	MMP24-AS1	-4.39	1.23e-05	0.000987	-0.26	-0.13	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35063818	chr20:35216462~35278131:-
BRCA	cis	rs11671005	0.696	rs73066211	ENSG00000269600.1	AC016629.3	-4.39	1.23e-05	0.000987	-0.22	-0.13	Mean platelet volume;	chr19:58485712	chr19:58593896~58599355:-
BRCA	cis	rs7927592	0.731	rs7108376	ENSG00000212093.1	AP000807.1	-4.39	1.23e-05	0.000987	-0.14	-0.13	Total body bone mineral density;	chr11:68580402	chr11:68506083~68506166:-
BRCA	cis	rs7260598	0.642	rs8102034	ENSG00000268442.1	CTD-2027I19.2	4.39	1.23e-05	0.000987	0.21	0.13	Response to taxane treatment (placlitaxel);	chr19:23914417	chr19:24162370~24163425:-
BRCA	cis	rs17345786	1	rs17345528	ENSG00000244119.1	PDCL3P4	-4.39	1.23e-05	0.000987	-0.12	-0.13	Colonoscopy-negative controls vs population controls;	chr3:101575986	chr3:101712472~101713191:+
BRCA	cis	rs878939	0.625	rs35137159	ENSG00000233690.1	EBAG9P1	4.39	1.23e-05	0.000987	0.19	0.13	Warfarin maintenance dose;	chr10:99584492	chr10:99697407~99697949:-
BRCA	cis	rs1910358	0.554	rs4701399	ENSG00000248874.4	C5orf17	-4.39	1.23e-05	0.000987	-0.19	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23795804	chr5:23951348~24178263:+
BRCA	cis	rs71520386	0.846	rs17778126	ENSG00000230658.1	KLHL7-AS1	4.39	1.23e-05	0.000988	0.24	0.13	Fibrinogen levels;	chr7:22779340	chr7:23101228~23105703:-
BRCA	cis	rs35740288	0.539	rs4843100	ENSG00000259407.1	RP11-158M2.3	-4.39	1.23e-05	0.000988	-0.2	-0.13	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85795979	chr15:85744109~85750281:-
BRCA	cis	rs8016982	0.962	rs8007841	ENSG00000258999.1	RP11-114N19.3	-4.39	1.23e-05	0.000988	-0.17	-0.13	Schizophrenia;	chr14:81181534	chr14:81107033~81170414:-
BRCA	cis	rs7267979	0.528	rs6076366	ENSG00000204556.4	CTD-2514C3.1	4.39	1.23e-05	0.000988	0.18	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25583990	chr20:26018832~26020684:+
BRCA	cis	rs6545883	0.718	rs3771260	ENSG00000270820.4	RP11-355B11.2	4.39	1.23e-05	0.000989	0.15	0.13	Tuberculosis;	chr2:61535249	chr2:61471188~61484130:+
BRCA	cis	rs8098244	0.58	rs1620152	ENSG00000264745.1	TTC39C-AS1	4.39	1.23e-05	0.000989	0.16	0.13	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23678335	chr18:23994213~24015339:-
BRCA	cis	rs11742741	1	rs7722195	ENSG00000248874.4	C5orf17	-4.39	1.23e-05	0.000989	-0.17	-0.13	Educational attainment;	chr5:24173030	chr5:23951348~24178263:+
BRCA	cis	rs9907295	0.901	rs4251729	ENSG00000270977.1	AC015849.16	-4.39	1.23e-05	0.000989	-0.24	-0.13	Fibroblast growth factor basic levels;	chr17:35818348	chr17:35893707~35911023:-
BRCA	cis	rs6968419	0.747	rs9969224	ENSG00000279086.1	RP11-667F14.1	-4.39	1.23e-05	0.00099	-0.15	-0.13	Intraocular pressure;	chr7:116221606	chr7:116209234~116211511:-
BRCA	cis	rs6840360	0.55	rs12651635	ENSG00000278978.1	RP11-164P12.5	-4.39	1.23e-05	0.00099	-0.16	-0.13	Intelligence (multi-trait analysis);	chr4:151636634	chr4:151669786~151670503:+
BRCA	cis	rs13326165	0.76	rs67834575	ENSG00000243224.1	RP5-1157M23.2	-4.39	1.23e-05	0.00099	-0.19	-0.13	HDL cholesterol levels;HDL cholesterol;	chr3:52377913	chr3:52239258~52241097:+
BRCA	cis	rs13326165	0.76	rs67248391	ENSG00000243224.1	RP5-1157M23.2	-4.39	1.23e-05	0.00099	-0.19	-0.13	HDL cholesterol levels;HDL cholesterol;	chr3:52377990	chr3:52239258~52241097:+
BRCA	cis	rs867186	0.698	rs11699306	ENSG00000126005.14	MMP24-AS1	-4.39	1.23e-05	0.00099	-0.24	-0.13	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35213480	chr20:35216462~35278131:-
BRCA	cis	rs2108622	0.727	rs12609468	ENSG00000267218.2	AC005336.5	4.39	1.23e-05	0.000991	0.16	0.13	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15867004	chr19:15902300~15903238:-
BRCA	cis	rs12468226	0.689	rs17656903	ENSG00000226261.1	AC064836.3	-4.39	1.23e-05	0.000991	-0.24	-0.13	Urate levels;	chr2:202106312	chr2:202336024~202336727:-
BRCA	cis	rs950776	0.616	rs12901300	ENSG00000279373.1	RP11-650L12.4	4.39	1.23e-05	0.000991	0.16	0.13	Sudden cardiac arrest;	chr15:78600610	chr15:78537681~78538946:+
BRCA	cis	rs4474465	1	rs10899525	ENSG00000251323.2	RP11-452H21.4	4.39	1.24e-05	0.000991	0.17	0.13	Alzheimer's disease (survival time);	chr11:78490408	chr11:78423982~78429836:-
BRCA	cis	rs4474465	1	rs7124043	ENSG00000251323.2	RP11-452H21.4	-4.39	1.24e-05	0.000991	-0.17	-0.13	Alzheimer's disease (survival time);	chr11:78494598	chr11:78423982~78429836:-
BRCA	cis	rs4474465	1	rs7128417	ENSG00000251323.2	RP11-452H21.4	-4.39	1.24e-05	0.000991	-0.17	-0.13	Alzheimer's disease (survival time);	chr11:78494928	chr11:78423982~78429836:-
BRCA	cis	rs4474465	0.85	rs7117513	ENSG00000251323.2	RP11-452H21.4	-4.39	1.24e-05	0.000991	-0.17	-0.13	Alzheimer's disease (survival time);	chr11:78495372	chr11:78423982~78429836:-
BRCA	cis	rs4474465	0.915	rs7128449	ENSG00000251323.2	RP11-452H21.4	-4.39	1.24e-05	0.000991	-0.17	-0.13	Alzheimer's disease (survival time);	chr11:78495714	chr11:78423982~78429836:-
BRCA	cis	rs4474465	0.92	rs10899527	ENSG00000251323.2	RP11-452H21.4	-4.39	1.24e-05	0.000991	-0.17	-0.13	Alzheimer's disease (survival time);	chr11:78496348	chr11:78423982~78429836:-
BRCA	cis	rs4474465	0.92	rs10899529	ENSG00000251323.2	RP11-452H21.4	-4.39	1.24e-05	0.000991	-0.17	-0.13	Alzheimer's disease (survival time);	chr11:78496802	chr11:78423982~78429836:-
BRCA	cis	rs56322409	0.897	rs3181122	ENSG00000226688.5	ENTPD1-AS1	4.39	1.24e-05	0.000992	0.16	0.13	Blood metabolite levels;	chr10:95847408	chr10:95753206~96090238:-
BRCA	cis	rs6802315	0.604	rs4680467	ENSG00000272087.1	RP11-379F4.7	4.39	1.24e-05	0.000992	0.16	0.13	Periodontitis (CDC/AAP);	chr3:158782988	chr3:158693120~158693768:-
BRCA	cis	rs62458065	0.85	rs7804998	ENSG00000229358.3	DPY19L1P1	-4.39	1.24e-05	0.000992	-0.18	-0.13	Metabolite levels (HVA/MHPG ratio);	chr7:32421585	chr7:32580949~32761787:-
BRCA	cis	rs35740288	0.77	rs62022867	ENSG00000202081.1	RNU6-1280P	4.39	1.24e-05	0.000992	0.17	0.13	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85630050	chr15:85651522~85651628:-
BRCA	cis	rs35740288	0.703	rs10520598	ENSG00000202081.1	RNU6-1280P	4.39	1.24e-05	0.000992	0.17	0.13	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85630150	chr15:85651522~85651628:-
BRCA	cis	rs35740288	0.77	rs11635587	ENSG00000202081.1	RNU6-1280P	4.39	1.24e-05	0.000992	0.17	0.13	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85630402	chr15:85651522~85651628:-
BRCA	cis	rs1153858	0.945	rs7182300	ENSG00000275672.1	GATM-AS1	-4.39	1.24e-05	0.000992	-0.17	-0.13	Homoarginine levels;	chr15:45342730	chr15:45378700~45380123:+
BRCA	cis	rs17772222	0.958	rs10134008	ENSG00000258789.1	RP11-507K2.3	-4.39	1.24e-05	0.000992	-0.17	-0.13	Coronary artery calcification;	chr14:88549183	chr14:88551597~88552493:+
BRCA	cis	rs10043228	1	rs10043228	ENSG00000271918.1	CTD-2287O16.5	-4.39	1.24e-05	0.000992	-0.17	-0.13	Asthma or chronic obstructive pulmonary disease;	chr5:116261351	chr5:116083807~116085416:-
BRCA	cis	rs2486012	1	rs1766964	ENSG00000237950.1	RP11-7O11.3	-4.39	1.24e-05	0.000992	-0.24	-0.13	Intelligence (multi-trait analysis);	chr1:43916175	chr1:43944370~43946551:-
BRCA	cis	rs2486012	1	rs61770291	ENSG00000237950.1	RP11-7O11.3	-4.39	1.24e-05	0.000992	-0.24	-0.13	Intelligence (multi-trait analysis);	chr1:43917451	chr1:43944370~43946551:-
BRCA	cis	rs7116495	0.609	rs2276384	ENSG00000248671.6	ALG1L9P	4.39	1.24e-05	0.000992	0.35	0.13	Severe influenza A (H1N1) infection;	chr11:71990477	chr11:71794363~71818238:-
BRCA	cis	rs10771431	0.597	rs10843142	ENSG00000111788.10	RP11-22B23.1	4.39	1.24e-05	0.000992	0.12	0.13	Breast size;	chr12:9204906	chr12:9277235~9313241:+
BRCA	cis	rs853679	0.882	rs9393908	ENSG00000280107.1	AL022393.9	-4.39	1.24e-05	0.000992	-0.29	-0.13	Depression;	chr6:28223052	chr6:28170845~28172521:+
BRCA	cis	rs853679	0.882	rs9366717	ENSG00000280107.1	AL022393.9	-4.39	1.24e-05	0.000992	-0.29	-0.13	Depression;	chr6:28223279	chr6:28170845~28172521:+
BRCA	cis	rs7481584	0.624	rs412149	ENSG00000247473.2	CARS-AS1	-4.39	1.24e-05	0.000992	-0.16	-0.13	Calcium levels;	chr11:3048713	chr11:3029009~3041260:+
BRCA	cis	rs10129255	0.957	rs28887506	ENSG00000274576.2	IGHV2-70	4.39	1.24e-05	0.000992	0.12	0.13	Kawasaki disease;	chr14:106785589	chr14:106770577~106771020:-
BRCA	cis	rs6968419	1	rs6968419	ENSG00000279086.1	RP11-667F14.1	-4.39	1.24e-05	0.000993	-0.13	-0.13	Intraocular pressure;	chr7:116183330	chr7:116209234~116211511:-
BRCA	cis	rs669446	0.561	rs639929	ENSG00000236200.4	KDM4A-AS1	-4.39	1.24e-05	0.000993	-0.17	-0.13	Amyotrophic lateral sclerosis (age of onset);	chr1:43618203	chr1:43699765~43708138:-
BRCA	cis	rs4834770	0.792	rs7676969	ENSG00000178636.7	RP11-455G16.1	-4.39	1.24e-05	0.000993	-0.17	-0.13	Blood protein levels;	chr4:119252569	chr4:119192773~119212644:-
BRCA	cis	rs4834770	0.685	rs4496567	ENSG00000178636.7	RP11-455G16.1	-4.39	1.24e-05	0.000993	-0.17	-0.13	Blood protein levels;	chr4:119254470	chr4:119192773~119212644:-
BRCA	cis	rs4834770	0.792	rs6823331	ENSG00000178636.7	RP11-455G16.1	-4.39	1.24e-05	0.000993	-0.17	-0.13	Blood protein levels;	chr4:119259635	chr4:119192773~119212644:-
BRCA	cis	rs9921338	0.961	rs7202814	ENSG00000262636.1	CTD-3088G3.4	-4.39	1.24e-05	0.000993	-0.22	-0.13	Vein graft stenosis in coronary artery bypass grafting;	chr16:11295917	chr16:11380859~11381118:-
BRCA	cis	rs867371	0.82	rs7164362	ENSG00000278603.1	RP13-608F4.5	4.39	1.24e-05	0.000993	0.18	0.13	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82194401	chr15:82472203~82472426:+
BRCA	cis	rs17801127	0.688	rs4667407	ENSG00000231969.1	AC144449.1	-4.39	1.24e-05	0.000993	-0.21	-0.13	Liver enzyme levels (alanine transaminase);	chr2:149701332	chr2:149587196~149848233:+
BRCA	cis	rs7011507	0.582	rs72635700	ENSG00000279881.1	RP11-513O13.1	-4.39	1.24e-05	0.000993	-0.22	-0.13	Inflammatory bowel disease;Ulcerative colitis;	chr8:48308740	chr8:48428143~48431041:-
BRCA	cis	rs4699052	0.625	rs11097808	ENSG00000248740.4	RP11-328K4.1	4.39	1.24e-05	0.000994	0.15	0.13	Testicular germ cell tumor;	chr4:103341973	chr4:103256159~103453658:+
BRCA	cis	rs6071166	0.708	rs6071047	ENSG00000224635.1	RP4-564F22.5	-4.39	1.24e-05	0.000994	-0.17	-0.13	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38677363	chr20:38406011~38416797:-
BRCA	cis	rs7474896	0.583	rs11011346	ENSG00000120555.12	SEPT7P9	4.39	1.24e-05	0.000994	0.19	0.13	Obesity (extreme);	chr10:37720555	chr10:38383069~38402916:-
BRCA	cis	rs2708977	1	rs2708977	ENSG00000237510.6	AC008268.2	-4.39	1.24e-05	0.000994	-0.18	-0.13	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96564337	chr2:95789654~95800166:+
BRCA	cis	rs1015362	0.503	rs1883708	ENSG00000276073.1	RP5-1125A11.7	-4.39	1.24e-05	0.000994	-0.19	-0.13	Freckles;Red vs. non-red hair color;Skin sensitivity to sun;Burning and freckling;	chr20:33924107	chr20:33985617~33988989:-
BRCA	cis	rs409045	1	rs377504	ENSG00000271874.1	CTD-2024P10.2	-4.39	1.24e-05	0.000994	-0.18	-0.13	Left ventricular mass;	chr5:34628288	chr5:34651457~34651888:-
BRCA	cis	rs11673344	0.504	rs7259332	ENSG00000276846.1	CTD-3220F14.3	4.39	1.24e-05	0.000994	0.16	0.13	Obesity-related traits;	chr19:37143389	chr19:37314868~37315620:-
BRCA	cis	rs7618915	0.501	rs2164885	ENSG00000243224.1	RP5-1157M23.2	-4.39	1.24e-05	0.000994	-0.14	-0.13	Bipolar disorder;	chr3:52697253	chr3:52239258~52241097:+
BRCA	cis	rs7618915	0.501	rs3733041	ENSG00000243224.1	RP5-1157M23.2	-4.39	1.24e-05	0.000994	-0.14	-0.13	Bipolar disorder;	chr3:52697582	chr3:52239258~52241097:+
BRCA	cis	rs1371614	0.523	rs12991124	ENSG00000229122.1	AGBL5-IT1	-4.39	1.24e-05	0.000994	-0.15	-0.13	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26956624	chr2:27061038~27061815:+
BRCA	cis	rs9990333	0.622	rs57783901	ENSG00000207650.1	MIR570	4.39	1.24e-05	0.000994	0.16	0.13	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196089486	chr3:195699401~195699497:+
BRCA	cis	rs7267979	1	rs6050555	ENSG00000277938.1	RP5-965G21.3	-4.39	1.24e-05	0.000994	-0.16	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25347907	chr20:25229150~25231933:+
BRCA	cis	rs17711722	0.528	rs73138179	ENSG00000275400.1	RP4-756H11.5	-4.39	1.24e-05	0.000994	-0.17	-0.13	Calcium levels;	chr7:65829495	chr7:66553805~66554199:-
BRCA	cis	rs4787491	0.765	rs8054507	ENSG00000183604.13	SMG1P5	-4.39	1.24e-05	0.000994	-0.13	-0.13	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30034721	chr16:30267553~30335374:-
BRCA	cis	rs1371614	0.611	rs877272	ENSG00000272148.1	RP11-195B17.1	4.39	1.24e-05	0.000995	0.15	0.13	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26917020	chr2:27062428~27062907:-
BRCA	cis	rs73201462	1	rs2811539	ENSG00000242551.2	POU5F1P6	4.39	1.24e-05	0.000995	0.22	0.13	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128267630	chr3:128674735~128677005:-
BRCA	cis	rs10411936	0.712	rs9305079	ENSG00000280332.1	CTD-2013N17.6	4.39	1.24e-05	0.000995	0.11	0.13	Multiple sclerosis;White blood cell count;	chr19:16480653	chr19:16356329~16358327:-
BRCA	cis	rs7267979	0.966	rs6107031	ENSG00000277938.1	RP5-965G21.3	-4.39	1.24e-05	0.000995	-0.16	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25370041	chr20:25229150~25231933:+
BRCA	cis	rs7267979	1	rs6115159	ENSG00000277938.1	RP5-965G21.3	-4.39	1.24e-05	0.000995	-0.16	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25370308	chr20:25229150~25231933:+
BRCA	cis	rs7267979	1	rs4813562	ENSG00000277938.1	RP5-965G21.3	-4.39	1.24e-05	0.000995	-0.16	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25371952	chr20:25229150~25231933:+
BRCA	cis	rs5751614	0.537	rs5759682	ENSG00000240160.3	RN7SL263P	4.39	1.24e-05	0.000995	0.18	0.13	Height;	chr22:23288992	chr22:23261782~23262071:-
BRCA	cis	rs7308116	0.53	rs12582286	ENSG00000274395.1	RP11-554D14.8	4.39	1.24e-05	0.000995	0.15	0.13	Pelvic organ prolapse (moderate/severe);	chr12:107907011	chr12:107835541~107836555:-
BRCA	cis	rs1005277	0.579	rs176838	ENSG00000263064.2	RP11-291L22.7	-4.39	1.24e-05	0.000995	-0.16	-0.13	Extrinsic epigenetic age acceleration;	chr10:38082971	chr10:38448689~38448949:+
BRCA	cis	rs763014	0.966	rs12935215	ENSG00000260394.2	LA16c-313D11.9	-4.39	1.24e-05	0.000995	-0.13	-0.13	Height;	chr16:620605	chr16:678504~679777:-
BRCA	cis	rs6603134	0.502	rs6603131	ENSG00000269139.2	CTD-3193O13.8	4.39	1.24e-05	0.000995	0.15	0.13	Blood protein levels;	chr19:8037873	chr19:7926001~7926810:+
BRCA	cis	rs11048434	0.518	rs11048496	ENSG00000256937.1	KRT17P8	-4.39	1.24e-05	0.000995	-0.15	-0.13	Sjögren's syndrome;	chr12:9019825	chr12:9127783~9128645:+
BRCA	cis	rs7474896	0.583	rs12783272	ENSG00000120555.12	SEPT7P9	4.39	1.24e-05	0.000995	0.19	0.13	Obesity (extreme);	chr10:37735957	chr10:38383069~38402916:-
BRCA	cis	rs763014	0.966	rs35642938	ENSG00000260394.2	LA16c-313D11.9	-4.39	1.24e-05	0.000995	-0.13	-0.13	Height;	chr16:592249	chr16:678504~679777:-
BRCA	cis	rs1005277	0.579	rs9418322	ENSG00000263064.2	RP11-291L22.7	4.39	1.24e-05	0.000995	0.16	0.13	Extrinsic epigenetic age acceleration;	chr10:38088368	chr10:38448689~38448949:+
BRCA	cis	rs4415084	0.716	rs4596389	ENSG00000251141.4	RP11-53O19.1	4.39	1.24e-05	0.000995	0.13	0.13	Breast cancer;	chr5:44836454	chr5:44744900~44808777:-
BRCA	cis	rs11098499	0.954	rs12506546	ENSG00000260404.2	RP11-384K6.6	4.39	1.24e-05	0.000995	0.13	0.13	Corneal astigmatism;	chr4:119380463	chr4:118591773~118633729:+
BRCA	cis	rs6449502	0.541	rs13186053	ENSG00000251279.1	CTC-436P18.1	4.39	1.24e-05	0.000995	0.28	0.13	Mean platelet volume;	chr5:61123275	chr5:61162070~61232040:+
BRCA	cis	rs6449502	0.541	rs13190305	ENSG00000251279.1	CTC-436P18.1	4.39	1.24e-05	0.000995	0.28	0.13	Mean platelet volume;	chr5:61123550	chr5:61162070~61232040:+
BRCA	cis	rs6012564	0.819	rs6012565	ENSG00000227431.4	CSE1L-AS1	-4.39	1.24e-05	0.000996	-0.18	-0.13	Anger;	chr20:48938999	chr20:49040463~49046044:-
BRCA	cis	rs6921919	0.583	rs6908137	ENSG00000220721.1	OR1F12	4.39	1.24e-05	0.000996	0.16	0.13	Autism spectrum disorder or schizophrenia;	chr6:28402616	chr6:28073316~28074233:+
BRCA	cis	rs7475343	0.501	rs77714023	ENSG00000224034.1	RP11-445P17.8	-4.39	1.24e-05	0.000996	-0.26	-0.13	Intelligence;	chr10:5263928	chr10:5266033~5271236:-
BRCA	cis	rs7475343	0.501	rs117600605	ENSG00000224034.1	RP11-445P17.8	-4.39	1.24e-05	0.000996	-0.26	-0.13	Intelligence;	chr10:5263996	chr10:5266033~5271236:-
BRCA	cis	rs17784882	0.524	rs7433300	ENSG00000276925.1	RP11-708J19.3	-4.39	1.24e-05	0.000996	-0.16	-0.13	QT interval;	chr3:47079150	chr3:47469777~47469987:+
BRCA	cis	rs11696845	0.966	rs1467473	ENSG00000276223.1	RP4-781B1.5	4.39	1.24e-05	0.000996	0.14	0.13	Obesity-related traits;	chr20:44743337	chr20:44746642~44747201:+
BRCA	cis	rs2839186	0.934	rs4819221	ENSG00000228137.1	AP001469.7	-4.39	1.24e-05	0.000996	-0.14	-0.13	Testicular germ cell tumor;	chr21:46275503	chr21:46246890~46247682:+
BRCA	cis	rs9527	0.615	rs7917295	ENSG00000213061.2	PFN1P11	4.39	1.24e-05	0.000997	0.18	0.13	Arsenic metabolism;	chr10:102941430	chr10:102838011~102845473:-
BRCA	cis	rs6840360	0.573	rs4696249	ENSG00000270265.1	RP11-731D1.4	-4.39	1.24e-05	0.000997	-0.15	-0.13	Intelligence (multi-trait analysis);	chr4:151343495	chr4:151333775~151353224:-
BRCA	cis	rs6840360	0.573	rs10024721	ENSG00000270265.1	RP11-731D1.4	-4.39	1.24e-05	0.000997	-0.15	-0.13	Intelligence (multi-trait analysis);	chr4:151344179	chr4:151333775~151353224:-
BRCA	cis	rs6545883	0.562	rs777588	ENSG00000273302.1	RP11-493E12.2	4.39	1.24e-05	0.000997	0.12	0.13	Tuberculosis;	chr2:61199685	chr2:61199979~61200769:+
BRCA	cis	rs2380205	0.935	rs907686	ENSG00000232807.2	RP11-536K7.3	4.39	1.24e-05	0.000997	0.14	0.13	Breast cancer;	chr10:5858730	chr10:5934270~5945900:-
BRCA	cis	rs4713118	0.699	rs200969	ENSG00000216901.1	AL022393.7	4.39	1.24e-05	0.000997	0.19	0.13	Parkinson's disease;	chr6:27891675	chr6:28176188~28176674:+
BRCA	cis	rs2243480	1	rs35046236	ENSG00000222364.1	RNU6-96P	-4.39	1.24e-05	0.000997	-0.24	-0.13	Diabetic kidney disease;	chr7:65943626	chr7:66395191~66395286:+
BRCA	cis	rs2243480	1	rs36068983	ENSG00000222364.1	RNU6-96P	-4.39	1.24e-05	0.000997	-0.24	-0.13	Diabetic kidney disease;	chr7:65944004	chr7:66395191~66395286:+
BRCA	cis	rs2243480	1	rs68189316	ENSG00000222364.1	RNU6-96P	-4.39	1.24e-05	0.000997	-0.24	-0.13	Diabetic kidney disease;	chr7:65944182	chr7:66395191~66395286:+
BRCA	cis	rs6545883	0.894	rs778158	ENSG00000270820.4	RP11-355B11.2	-4.39	1.24e-05	0.000997	-0.15	-0.13	Tuberculosis;	chr2:61328286	chr2:61471188~61484130:+
BRCA	cis	rs4578769	1	rs4578769	ENSG00000265939.1	UBE2CP2	4.39	1.24e-05	0.000997	0.16	0.13	Eosinophil percentage of white cells;	chr18:22815141	chr18:22900486~22900995:-
BRCA	cis	rs2878628	0.596	rs57039206	ENSG00000243224.1	RP5-1157M23.2	-4.39	1.24e-05	0.000997	-0.14	-0.13	Intelligence (multi-trait analysis);	chr3:52724554	chr3:52239258~52241097:+
BRCA	cis	rs2878628	0.65	rs56098033	ENSG00000243224.1	RP5-1157M23.2	-4.39	1.24e-05	0.000997	-0.14	-0.13	Intelligence (multi-trait analysis);	chr3:52724555	chr3:52239258~52241097:+
BRCA	cis	rs12210905	0.925	rs858986	ENSG00000216901.1	AL022393.7	-4.39	1.24e-05	0.000998	-0.22	-0.13	Hip circumference adjusted for BMI;	chr6:27210744	chr6:28176188~28176674:+
BRCA	cis	rs6928977	0.538	rs17064702	ENSG00000234084.1	RP3-388E23.2	-4.39	1.24e-05	0.000998	-0.14	-0.13	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135607114	chr6:135301568~135307158:+
BRCA	cis	rs6802315	0.604	rs2115941	ENSG00000272087.1	RP11-379F4.7	4.39	1.24e-05	0.000998	0.16	0.13	Periodontitis (CDC/AAP);	chr3:158781906	chr3:158693120~158693768:-
BRCA	cis	rs7267979	0.966	rs6050567	ENSG00000277938.1	RP5-965G21.3	-4.39	1.24e-05	0.000998	-0.16	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25373925	chr20:25229150~25231933:+
BRCA	cis	rs35612822	0.723	rs13405912	ENSG00000232485.2	AC098820.3	-4.39	1.24e-05	0.000998	-0.16	-0.13	Kidney disease (early stage) in type 1 diabetes;	chr2:216400290	chr2:216479030~216498761:-
BRCA	cis	rs8054556	1	rs12921996	ENSG00000261367.1	RP11-455F5.4	-4.39	1.25e-05	0.000998	-0.15	-0.13	Autism spectrum disorder or schizophrenia;	chr16:30000297	chr16:30107675~30110541:+
BRCA	cis	rs3892630	0.878	rs8108621	ENSG00000267567.1	CTD-2538C1.3	4.39	1.25e-05	0.000998	0.21	0.13	Red blood cell traits;	chr19:32692385	chr19:32718298~32719595:-
BRCA	cis	rs7937890	0.904	rs7484197	ENSG00000254418.1	RP11-21L19.1	4.39	1.25e-05	0.000999	0.16	0.13	Mitochondrial DNA levels;	chr11:14262108	chr11:14262846~14273691:-
BRCA	cis	rs13113518	1	rs13115828	ENSG00000273257.1	RP11-177J6.1	4.39	1.25e-05	0.000999	0.17	0.13	Height;	chr4:55551447	chr4:55387949~55388271:+
BRCA	cis	rs13113518	1	rs13136282	ENSG00000273257.1	RP11-177J6.1	4.39	1.25e-05	0.000999	0.17	0.13	Height;	chr4:55551845	chr4:55387949~55388271:+
BRCA	cis	rs13113518	1	rs56154935	ENSG00000273257.1	RP11-177J6.1	4.39	1.25e-05	0.001	0.17	0.13	Height;	chr4:55546378	chr4:55387949~55388271:+
BRCA	cis	rs1371614	0.635	rs4316900	ENSG00000272148.1	RP11-195B17.1	-4.39	1.25e-05	0.001	-0.15	-0.13	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26917474	chr2:27062428~27062907:-
BRCA	cis	rs2904967	0.929	rs3016001	ENSG00000255200.1	AP003068.18	-4.39	1.25e-05	0.001	-0.21	-0.13	Mean corpuscular volume;	chr11:65241300	chr11:65174117~65176470:-
BRCA	cis	rs180730	1	rs3115314	ENSG00000251609.2	SETP12	-4.39	1.25e-05	0.001	-0.2	-0.13	Fasting plasma glucose;	chr4:120888621	chr4:120895494~120897083:-
BRCA	cis	rs180730	1	rs184668	ENSG00000251609.2	SETP12	-4.39	1.25e-05	0.001	-0.2	-0.13	Fasting plasma glucose;	chr4:120888812	chr4:120895494~120897083:-
BRCA	cis	rs962856	0.693	rs2902005	ENSG00000236780.4	AC078941.1	4.39	1.25e-05	0.001	0.19	0.13	Pancreatic cancer;	chr2:67395949	chr2:67123357~67215319:-
BRCA	cis	rs74233809	0.605	rs999867	ENSG00000213277.3	MARCKSL1P1	4.39	1.25e-05	0.001	0.24	0.13	Birth weight;	chr10:102744807	chr10:103175554~103176094:+
BRCA	cis	rs7267979	0.789	rs2260197	ENSG00000277938.1	RP5-965G21.3	4.39	1.25e-05	0.001	0.17	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25303707	chr20:25229150~25231933:+
BRCA	cis	rs2380205	0.967	rs907685	ENSG00000232807.2	RP11-536K7.3	4.39	1.25e-05	0.001	0.14	0.13	Breast cancer;	chr10:5858369	chr10:5934270~5945900:-
BRCA	cis	rs4478858	0.735	rs12129941	ENSG00000223907.1	LINC01226	-4.39	1.25e-05	0.001	-0.17	-0.13	Alcohol dependence;	chr1:31399111	chr1:31518435~31524245:+
BRCA	cis	rs2303319	0.504	rs12470830	ENSG00000227403.1	AC009299.3	4.39	1.25e-05	0.001	0.32	0.13	Cognitive function;	chr2:161573486	chr2:161244739~161249050:+
BRCA	cis	rs2303319	0.504	rs62187609	ENSG00000227403.1	AC009299.3	4.39	1.25e-05	0.001	0.32	0.13	Cognitive function;	chr2:161574990	chr2:161244739~161249050:+
BRCA	cis	rs2303319	0.504	rs62187612	ENSG00000227403.1	AC009299.3	4.39	1.25e-05	0.001	0.32	0.13	Cognitive function;	chr2:161575984	chr2:161244739~161249050:+
BRCA	cis	rs2243480	0.803	rs34804747	ENSG00000222364.1	RNU6-96P	-4.39	1.25e-05	0.001	-0.24	-0.13	Diabetic kidney disease;	chr7:65947955	chr7:66395191~66395286:+
BRCA	cis	rs2243480	1	rs59794892	ENSG00000222364.1	RNU6-96P	-4.39	1.25e-05	0.001	-0.24	-0.13	Diabetic kidney disease;	chr7:65950886	chr7:66395191~66395286:+
BRCA	cis	rs2243480	0.803	rs36004293	ENSG00000222364.1	RNU6-96P	-4.39	1.25e-05	0.001	-0.24	-0.13	Diabetic kidney disease;	chr7:65951525	chr7:66395191~66395286:+
BRCA	cis	rs2243480	0.803	rs35268390	ENSG00000222364.1	RNU6-96P	-4.39	1.25e-05	0.001	-0.24	-0.13	Diabetic kidney disease;	chr7:65951549	chr7:66395191~66395286:+
BRCA	cis	rs13113518	0.934	rs11935823	ENSG00000273257.1	RP11-177J6.1	4.39	1.25e-05	0.001	0.17	0.13	Height;	chr4:55589624	chr4:55387949~55388271:+
BRCA	cis	rs7267979	0.966	rs2500417	ENSG00000276952.1	RP5-965G21.6	-4.39	1.25e-05	0.001	-0.16	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25402651	chr20:25284915~25285588:-
BRCA	cis	rs11976180	1	rs11976037	ENSG00000244479.5	OR2A1-AS1	4.39	1.25e-05	0.001	0.18	0.13	Obesity-related traits;	chr7:144043931	chr7:144251264~144356181:-
BRCA	cis	rs2524005	1	rs2524005	ENSG00000280128.1	XXbac-BPG283O16.9	4.39	1.25e-05	0.001	0.2	0.13	Bipolar disorder and schizophrenia;	chr6:29931900	chr6:30282349~30286054:-
BRCA	cis	rs1858037	0.867	rs57913336	ENSG00000281920.1	RP11-418H16.1	4.39	1.25e-05	0.001	0.17	0.13	Rheumatoid arthritis;	chr2:65360485	chr2:65623272~65628424:+
BRCA	cis	rs721917	0.506	rs2758538	ENSG00000242600.5	MBL1P	4.39	1.25e-05	0.001	0.16	0.13	Chronic obstructive pulmonary disease;	chr10:79893047	chr10:79904898~79950336:+
BRCA	cis	rs983392	0.805	rs11230184	ENSG00000275344.1	MIR6503	-4.39	1.25e-05	0.001	-0.14	-0.13	Alzheimer's disease (late onset);	chr11:60198316	chr11:60209071~60209156:-
BRCA	cis	rs807029	0.577	rs3740489	ENSG00000236662.1	RP11-108L7.4	4.39	1.25e-05	0.001	0.17	0.13	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100994481	chr10:100980507~100985614:-
BRCA	cis	rs71520386	0.632	rs10224419	ENSG00000226329.2	AC005682.6	4.39	1.25e-05	0.001	0.14	0.13	Fibrinogen levels;	chr7:22830397	chr7:22863874~22881350:-
BRCA	cis	rs56322409	1	rs8758	ENSG00000226688.5	ENTPD1-AS1	4.39	1.25e-05	0.00101	0.15	0.13	Blood metabolite levels;	chr10:95606350	chr10:95753206~96090238:-
BRCA	cis	rs11168618	0.904	rs12371700	ENSG00000240399.1	RP1-228P16.1	-4.39	1.26e-05	0.00101	-0.15	-0.13	Adiponectin levels;	chr12:48525430	chr12:48054813~48055591:-
BRCA	cis	rs10911902	0.643	rs16825248	ENSG00000229739.2	RP11-295K2.3	-4.39	1.26e-05	0.00101	-0.2	-0.13	Schizophrenia;	chr1:186358057	chr1:186435161~186470291:+
BRCA	cis	rs9527	0.615	rs11191485	ENSG00000213061.2	PFN1P11	4.39	1.26e-05	0.00101	0.18	0.13	Arsenic metabolism;	chr10:102970059	chr10:102838011~102845473:-
BRCA	cis	rs8054556	0.76	rs12598856	ENSG00000183604.13	SMG1P5	-4.39	1.26e-05	0.00101	-0.14	-0.13	Autism spectrum disorder or schizophrenia;	chr16:30018227	chr16:30267553~30335374:-
BRCA	cis	rs886774	0.644	rs4727693	ENSG00000273055.1	CTB-13F3.1	-4.39	1.26e-05	0.00101	-0.14	-0.13	Ulcerative colitis;	chr7:107941134	chr7:107942116~107942740:+
BRCA	cis	rs1124769	0.57	rs1276856	ENSG00000273674.3	CTD-2378E12.1	-4.39	1.26e-05	0.00101	-0.16	-0.13	Cognitive performance;	chr15:50863689	chr15:50839875~50908599:-
BRCA	cis	rs8040855	0.627	rs12913859	ENSG00000230373.7	GOLGA6L5P	4.39	1.26e-05	0.00101	0.17	0.13	Bulimia nervosa;	chr15:85095187	chr15:84507885~84516814:-
BRCA	cis	rs2832191	0.655	rs2247110	ENSG00000215533.7	LINC00189	4.39	1.26e-05	0.00101	0.15	0.13	Dental caries;	chr21:28951566	chr21:29193480~29288205:+
BRCA	cis	rs73242632	1	rs73242618	ENSG00000269949.1	RP11-738E22.3	4.39	1.26e-05	0.00101	0.31	0.13	Congenital heart disease (maternal effect);	chr4:56943383	chr4:56960927~56961373:-
BRCA	cis	rs4787491	0.729	rs4788213	ENSG00000183604.13	SMG1P5	-4.39	1.26e-05	0.00101	-0.13	-0.13	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30023203	chr16:30267553~30335374:-
BRCA	cis	rs4787491	0.679	rs7204852	ENSG00000183604.13	SMG1P5	-4.39	1.26e-05	0.00101	-0.13	-0.13	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30028857	chr16:30267553~30335374:-
BRCA	cis	rs4787491	0.729	rs12446378	ENSG00000183604.13	SMG1P5	-4.39	1.26e-05	0.00101	-0.13	-0.13	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30031789	chr16:30267553~30335374:-
BRCA	cis	rs3617	0.625	rs11719137	ENSG00000279144.1	RP11-894J14.2	-4.39	1.26e-05	0.00101	-0.17	-0.13	Red blood cell count;Autism spectrum disorder or schizophrenia;	chr3:52842373	chr3:52848085~52848553:-
BRCA	cis	rs1789	0.706	rs7696938	ENSG00000214846.4	RP11-115L11.1	-4.39	1.26e-05	0.00101	-0.18	-0.13	Blood protein levels;	chr4:15701954	chr4:15730962~15731627:-
BRCA	cis	rs13113518	1	rs2279458	ENSG00000273257.1	RP11-177J6.1	4.39	1.26e-05	0.00101	0.17	0.13	Height;	chr4:55562653	chr4:55387949~55388271:+
BRCA	cis	rs2284219	0.565	rs2284217	ENSG00000244480.1	AC005154.7	-4.39	1.26e-05	0.00101	-0.14	-0.13	Type 2 diabetes;	chr7:30673992	chr7:30523143~30524535:-
BRCA	cis	rs67766926	0.951	rs10176601	ENSG00000271889.1	RP11-493E12.1	-4.39	1.26e-05	0.00101	-0.19	-0.13	Inflammatory skin disease;	chr2:60952025	chr2:61151433~61162105:-
BRCA	cis	rs11976180	1	rs2951363	ENSG00000244479.5	OR2A1-AS1	4.39	1.26e-05	0.00101	0.18	0.13	Obesity-related traits;	chr7:144057631	chr7:144251264~144356181:-
BRCA	cis	rs9470794	0.748	rs114621281	ENSG00000204110.6	RP1-153P14.8	-4.39	1.26e-05	0.00101	-0.27	-0.13	Type 2 diabetes;	chr6:37948227	chr6:37507348~37535616:+
BRCA	cis	rs7665090	1	rs7665090	ENSG00000251288.2	RP11-10L12.2	4.39	1.26e-05	0.00101	0.16	0.13	Primary biliary cholangitis;	chr4:102630446	chr4:102751401~102752641:+
BRCA	cis	rs957448	0.561	rs4734282	ENSG00000261437.1	RP11-22C11.2	4.39	1.26e-05	0.00101	0.13	0.13	Nonsyndromic cleft lip with cleft palate;	chr8:94603827	chr8:94637285~94639467:-
BRCA	cis	rs4919687	0.55	rs12259058	ENSG00000213061.2	PFN1P11	4.39	1.26e-05	0.00101	0.19	0.13	Colorectal cancer;	chr10:102725042	chr10:102838011~102845473:-
BRCA	cis	rs17027633	0.867	rs2050607	ENSG00000260948.1	RP11-552M11.8	-4.39	1.26e-05	0.00101	-0.26	-0.13	Cerebrospinal fluid t-tau:AB1-42 ratio;	chr1:111418185	chr1:111431046~111433068:-
BRCA	cis	rs1910358	0.614	rs2036405	ENSG00000248874.4	C5orf17	-4.39	1.26e-05	0.00101	-0.17	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23961128	chr5:23951348~24178263:+
BRCA	cis	rs78487399	0.908	rs12467151	ENSG00000234936.1	AC010883.5	4.39	1.26e-05	0.00101	0.19	0.13	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43586625	chr2:43229573~43233394:+
BRCA	cis	rs13108904	0.905	rs1680074	ENSG00000253399.1	AC078852.2	4.39	1.26e-05	0.00101	0.15	0.13	Obesity-related traits;	chr4:1285833	chr4:1358479~1359461:+
BRCA	cis	rs1005277	0.505	rs7917943	ENSG00000226578.1	RP11-258F22.1	4.39	1.26e-05	0.00101	0.14	0.13	Extrinsic epigenetic age acceleration;	chr10:37906883	chr10:37775371~37784131:-
BRCA	cis	rs11098499	1	rs11098500	ENSG00000250412.1	KLHL2P1	4.39	1.26e-05	0.00101	0.16	0.13	Corneal astigmatism;	chr4:119298084	chr4:119334329~119378233:+
BRCA	cis	rs13358904	0.826	rs4958027	ENSG00000278921.2	EPB41L4A-AS2	4.39	1.26e-05	0.00101	0.17	0.13	Suicide ideation score in major depressive disorder;	chr5:112256196	chr5:112419583~112420978:+
BRCA	cis	rs3764021	0.933	rs10492165	ENSG00000278635.1	CTD-2318O12.1	-4.39	1.26e-05	0.00101	-0.13	-0.13	Type 1 diabetes;	chr12:9733365	chr12:9415641~9416718:+
BRCA	cis	rs7267979	0.966	rs6083818	ENSG00000277938.1	RP5-965G21.3	-4.39	1.26e-05	0.00101	-0.16	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25365446	chr20:25229150~25231933:+
BRCA	cis	rs7267979	1	rs4815409	ENSG00000277938.1	RP5-965G21.3	-4.39	1.26e-05	0.00101	-0.16	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25366061	chr20:25229150~25231933:+
BRCA	cis	rs7071275	0.771	rs12356902	ENSG00000226864.1	ATE1-AS1	-4.39	1.26e-05	0.00101	-0.27	-0.13	Dupuytren's disease;	chr10:121673138	chr10:121928312~121951965:+
BRCA	cis	rs7246657	0.509	rs10426093	ENSG00000267422.1	CTD-2554C21.1	-4.39	1.26e-05	0.00101	-0.23	-0.13	Coronary artery calcification;	chr19:37124727	chr19:37779686~37792865:+
BRCA	cis	rs73607972	0.935	rs7186069	ENSG00000275191.1	RP11-36I17.2	-4.39	1.26e-05	0.00101	-0.22	-0.13	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53563693	chr16:53628256~53628816:-
BRCA	cis	rs2231884	0.697	rs11227332	ENSG00000254510.1	RP11-867G23.10	4.39	1.26e-05	0.00101	0.18	0.13	Inflammatory bowel disease;	chr11:65856268	chr11:66409158~66417137:+
BRCA	cis	rs11696845	0.899	rs2868198	ENSG00000276223.1	RP4-781B1.5	-4.39	1.26e-05	0.00101	-0.14	-0.13	Obesity-related traits;	chr20:44739294	chr20:44746642~44747201:+
BRCA	cis	rs7048146	0.966	rs10979906	ENSG00000213539.4	YBX1P6	4.39	1.26e-05	0.00101	0.15	0.13	Vascular brain injury;	chr9:109541401	chr9:109532830~109534332:-
BRCA	cis	rs7291412	0.662	rs6520015	ENSG00000231711.2	LINC00899	-4.39	1.26e-05	0.00101	-0.15	-0.13	Dupuytren's disease;Subjective well-being;	chr22:46067551	chr22:46039907~46044853:-
BRCA	cis	rs3764021	0.87	rs10844622	ENSG00000278635.1	CTD-2318O12.1	-4.39	1.26e-05	0.00101	-0.13	-0.13	Type 1 diabetes;	chr12:9732486	chr12:9415641~9416718:+
BRCA	cis	rs2904967	0.584	rs3015997	ENSG00000254614.2	AP003068.23	4.39	1.26e-05	0.00101	0.28	0.13	Mean corpuscular volume;	chr11:65232773	chr11:65177606~65181834:-
BRCA	cis	rs256438	0.731	rs2241826	ENSG00000251050.1	RP11-168A11.4	-4.39	1.26e-05	0.00101	-0.16	-0.13	Serum thyroid-stimulating hormone levels;	chr5:80058361	chr5:80019609~80019920:+
BRCA	cis	rs9921338	0.924	rs7202024	ENSG00000262703.1	RP11-485G7.6	-4.39	1.26e-05	0.00101	-0.17	-0.13	Vein graft stenosis in coronary artery bypass grafting;	chr16:11346901	chr16:11348143~11349321:-
BRCA	cis	rs9921338	0.961	rs7206017	ENSG00000262703.1	RP11-485G7.6	-4.39	1.26e-05	0.00101	-0.17	-0.13	Vein graft stenosis in coronary artery bypass grafting;	chr16:11347004	chr16:11348143~11349321:-
BRCA	cis	rs13113518	1	rs939823	ENSG00000272969.1	RP11-528I4.2	4.39	1.26e-05	0.00101	0.16	0.13	Height;	chr4:55487368	chr4:55547112~55547889:+
BRCA	cis	rs2229238	0.866	rs59741504	ENSG00000272030.1	RP1-178F15.4	-4.39	1.26e-05	0.00101	-0.19	-0.13	Coronary heart disease;	chr1:154532125	chr1:153631438~153634397:-
BRCA	cis	rs2229238	0.866	rs61403567	ENSG00000272030.1	RP1-178F15.4	-4.39	1.26e-05	0.00101	-0.19	-0.13	Coronary heart disease;	chr1:154532451	chr1:153631438~153634397:-
BRCA	cis	rs12612435	0.793	rs59951306	ENSG00000226806.1	AC011893.3	4.39	1.26e-05	0.00101	0.17	0.13	Takotsubo syndrome;	chr2:136374497	chr2:135820191~135823087:+
BRCA	cis	rs6545883	0.524	rs2593631	ENSG00000273302.1	RP11-493E12.2	-4.39	1.26e-05	0.00101	-0.12	-0.13	Tuberculosis;	chr2:61345151	chr2:61199979~61200769:+
BRCA	cis	rs983392	0.805	rs7926354	ENSG00000275344.1	MIR6503	-4.39	1.26e-05	0.00101	-0.14	-0.13	Alzheimer's disease (late onset);	chr11:60194716	chr11:60209071~60209156:-
BRCA	cis	rs8113308	0.81	rs8104281	ENSG00000269483.1	AC006272.1	4.39	1.26e-05	0.00101	0.24	0.13	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51939766	chr19:51839924~51843324:-
BRCA	cis	rs8113308	0.81	rs8104121	ENSG00000269483.1	AC006272.1	4.39	1.26e-05	0.00101	0.24	0.13	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51939810	chr19:51839924~51843324:-
BRCA	cis	rs8113308	0.81	rs8104323	ENSG00000269483.1	AC006272.1	4.39	1.26e-05	0.00101	0.24	0.13	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51939992	chr19:51839924~51843324:-
BRCA	cis	rs2278170	1	rs331503	ENSG00000225101.4	OR52K3P	-4.39	1.27e-05	0.00101	-0.19	-0.13	Amyotrophic lateral sclerosis;	chr11:4473798	chr11:4474813~4475755:+
BRCA	cis	rs3768617	0.51	rs3768619	ENSG00000224468.3	RP11-181K3.4	-4.39	1.27e-05	0.00101	-0.14	-0.13	Fuchs's corneal dystrophy;	chr1:183123269	chr1:183138402~183141282:-
BRCA	cis	rs7048146	0.966	rs4978826	ENSG00000213539.4	YBX1P6	4.39	1.27e-05	0.00101	0.15	0.13	Vascular brain injury;	chr9:109540221	chr9:109532830~109534332:-
BRCA	cis	rs2803122	0.846	rs10738535	ENSG00000272842.1	RP11-513M16.7	-4.39	1.27e-05	0.00101	-0.14	-0.13	Pulse pressure;	chr9:19299364	chr9:19371386~19371945:-
BRCA	cis	rs950169	0.58	rs11634320	ENSG00000229212.6	RP11-561C5.4	4.39	1.27e-05	0.00101	0.17	0.13	Schizophrenia;	chr15:84628952	chr15:85205440~85234795:-
BRCA	cis	rs6452524	0.78	rs2386237	ENSG00000281327.1	LINC01338	4.39	1.27e-05	0.00101	0.17	0.13	Hypertension (SNP x SNP interaction);	chr5:83101852	chr5:82850864~82859836:-
BRCA	cis	rs595244	1	rs6493325	ENSG00000259705.1	RP11-227D13.1	4.39	1.27e-05	0.00101	0.23	0.13	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48495048	chr15:48645951~48652016:+
BRCA	cis	rs9307551	0.948	rs13112067	ENSG00000250334.4	LINC00989	-4.39	1.27e-05	0.00101	-0.2	-0.13	Refractive error;	chr4:79561744	chr4:79492416~79576460:+
BRCA	cis	rs867371	0.502	rs7176926	ENSG00000276710.3	CSPG4P8	-4.39	1.27e-05	0.00101	-0.14	-0.13	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82245753	chr15:82459472~82477258:+
BRCA	cis	rs115575488	0.683	rs12727967	ENSG00000236804.1	RPS3AP12	4.39	1.27e-05	0.00101	0.19	0.13	Lobe attachment (rater-scored or self-reported);	chr1:119053313	chr1:119126539~119127291:-
BRCA	cis	rs13108904	0.87	rs2291199	ENSG00000253399.1	AC078852.2	-4.39	1.27e-05	0.00101	-0.16	-0.13	Obesity-related traits;	chr4:1250479	chr4:1358479~1359461:+
BRCA	cis	rs11638815	0.581	rs783537	ENSG00000259429.4	UBE2Q2P2	-4.39	1.27e-05	0.00101	-0.13	-0.13	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82584058	chr15:82355142~82420075:+
BRCA	cis	rs11758351	1	rs3757135	ENSG00000241549.7	GUSBP2	-4.39	1.27e-05	0.00101	-0.19	-0.13	Renal underexcretion gout;Gout;	chr6:26200479	chr6:26871484~26956554:-
BRCA	cis	rs8114671	0.562	rs4911163	ENSG00000126005.14	MMP24-AS1	-4.39	1.27e-05	0.00102	-0.15	-0.13	Height;	chr20:34882891	chr20:35216462~35278131:-
BRCA	cis	rs3796352	1	rs11712653	ENSG00000242142.1	SERBP1P3	4.39	1.27e-05	0.00102	0.24	0.13	Immune reponse to smallpox (secreted IL-2);	chr3:53036859	chr3:53064283~53065091:-
BRCA	cis	rs6968419	0.788	rs72603592	ENSG00000279086.1	RP11-667F14.1	-4.39	1.27e-05	0.00102	-0.15	-0.13	Intraocular pressure;	chr7:116191141	chr7:116209234~116211511:-
BRCA	cis	rs6546324	0.54	rs4671811	ENSG00000236780.4	AC078941.1	4.39	1.27e-05	0.00102	0.23	0.13	Endometriosis;	chr2:67600284	chr2:67123357~67215319:-
BRCA	cis	rs9308731	0.591	rs3898882	ENSG00000230499.1	AC108463.1	-4.39	1.27e-05	0.00102	-0.15	-0.13	Chronic lymphocytic leukemia;	chr2:111189890	chr2:111195963~111206494:+
BRCA	cis	rs17801127	0.901	rs7608496	ENSG00000231969.1	AC144449.1	4.39	1.27e-05	0.00102	0.25	0.13	Liver enzyme levels (alanine transaminase);	chr2:149784299	chr2:149587196~149848233:+
BRCA	cis	rs9377188	0.707	rs2500540	ENSG00000236591.1	RP11-162J8.3	-4.39	1.27e-05	0.00102	-0.17	-0.13	Cancer;	chr6:149009670	chr6:149027700~149032573:-
BRCA	cis	rs9307551	1	rs894054	ENSG00000250334.4	LINC00989	-4.39	1.27e-05	0.00102	-0.2	-0.13	Refractive error;	chr4:79621254	chr4:79492416~79576460:+
BRCA	cis	rs8040855	0.627	rs1532776	ENSG00000230373.7	GOLGA6L5P	4.39	1.27e-05	0.00102	0.17	0.13	Bulimia nervosa;	chr15:85081383	chr15:84507885~84516814:-
BRCA	cis	rs11098499	0.954	rs12508504	ENSG00000260404.2	RP11-384K6.6	4.39	1.27e-05	0.00102	0.13	0.13	Corneal astigmatism;	chr4:119489452	chr4:118591773~118633729:+
BRCA	cis	rs4930561	0.714	rs7950451	ENSG00000184795.9	UNC93B5	-4.39	1.27e-05	0.00102	-0.15	-0.13	Breast cancer in childhood cancer survivors;IgG glycosylation;	chr11:68194939	chr11:67711702~67716005:-
BRCA	cis	rs4930561	0.714	rs7950452	ENSG00000184795.9	UNC93B5	-4.39	1.27e-05	0.00102	-0.15	-0.13	Breast cancer in childhood cancer survivors;IgG glycosylation;	chr11:68194940	chr11:67711702~67716005:-
BRCA	cis	rs4930561	0.765	rs34493482	ENSG00000184795.9	UNC93B5	-4.39	1.27e-05	0.00102	-0.15	-0.13	Breast cancer in childhood cancer survivors;IgG glycosylation;	chr11:68202041	chr11:67711702~67716005:-
BRCA	cis	rs2839186	1	rs2839186	ENSG00000239415.1	AP001469.9	4.39	1.27e-05	0.00102	0.14	0.13	Testicular germ cell tumor;	chr21:46270154	chr21:46251549~46254133:-
BRCA	cis	rs4302906	0.964	rs7869421	ENSG00000187984.11	ANKRD19P	4.39	1.27e-05	0.00102	0.12	0.13	Lobe attachment (rater-scored or self-reported);	chr9:92987623	chr9:92809388~92888693:+
BRCA	cis	rs4869313	0.869	rs4360063	ENSG00000248734.2	CTD-2260A17.1	4.39	1.27e-05	0.00102	0.14	0.13	Pediatric autoimmune diseases;	chr5:96957449	chr5:96784777~96785999:+
BRCA	cis	rs4869313	0.869	rs1363974	ENSG00000248734.2	CTD-2260A17.1	4.39	1.27e-05	0.00102	0.14	0.13	Pediatric autoimmune diseases;	chr5:96958112	chr5:96784777~96785999:+
BRCA	cis	rs4494364	0.502	rs7977147	ENSG00000258100.1	RP11-121E16.1	4.39	1.27e-05	0.00102	0.19	0.13	Systolic blood pressure (alcohol consumption interaction);	chr12:91023820	chr12:91362196~91368606:+
BRCA	cis	rs62103177	0.525	rs4799116	ENSG00000267270.4	PARD6G-AS1	-4.39	1.27e-05	0.00102	-0.21	-0.13	Opioid sensitivity;	chr18:79976735	chr18:80147924~80178432:+
BRCA	cis	rs11976180	1	rs11976180	ENSG00000244479.5	OR2A1-AS1	4.39	1.27e-05	0.00102	0.19	0.13	Obesity-related traits;	chr7:144044487	chr7:144251264~144356181:-
BRCA	cis	rs7772486	0.79	rs2265474	ENSG00000270638.1	RP3-466P17.1	4.39	1.27e-05	0.00102	0.16	0.13	Lobe attachment (rater-scored or self-reported);	chr6:145860956	chr6:145735570~145737218:+
BRCA	cis	rs10911902	0.913	rs3131554	ENSG00000229739.2	RP11-295K2.3	-4.39	1.27e-05	0.00102	-0.19	-0.13	Schizophrenia;	chr1:186482939	chr1:186435161~186470291:+
BRCA	cis	rs7617773	0.539	rs13087050	ENSG00000199476.1	Y_RNA	-4.39	1.27e-05	0.00102	-0.18	-0.13	Coronary artery disease;	chr3:48351310	chr3:48288587~48288694:+
BRCA	cis	rs6723226	0.598	rs2710629	ENSG00000276334.1	AL133243.1	4.39	1.27e-05	0.00102	0.16	0.13	Intelligence (multi-trait analysis);	chr2:32540777	chr2:32521927~32523547:+
BRCA	cis	rs10266483	0.96	rs13221291	ENSG00000227986.1	TRIM60P18	-4.39	1.27e-05	0.00102	-0.14	-0.13	Response to statin therapy;	chr7:64279114	chr7:64355078~64356199:+
BRCA	cis	rs7267979	0.789	rs4815429	ENSG00000274414.1	RP5-965G21.4	4.39	1.27e-05	0.00102	0.16	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25540975	chr20:25239007~25245229:-
BRCA	cis	rs1144713	0.6	rs2683489	ENSG00000276115.1	RP11-817I4.2	-4.39	1.27e-05	0.00102	-0.14	-0.13	Obesity-related traits;	chr12:32098247	chr12:32352349~32354144:+
BRCA	cis	rs7726839	0.561	rs11955068	ENSG00000225138.6	CTD-2228K2.7	4.39	1.27e-05	0.00102	0.19	0.13	Obesity-related traits;	chr5:582209	chr5:473236~480884:+
BRCA	cis	rs4662750	0.674	rs777437	ENSG00000236682.1	AC068282.3	4.39	1.27e-05	0.00102	0.18	0.13	Renal cell carcinoma;	chr2:127600072	chr2:127389130~127400580:+
BRCA	cis	rs8114671	0.562	rs6088655	ENSG00000126005.14	MMP24-AS1	-4.39	1.27e-05	0.00102	-0.16	-0.13	Height;	chr20:34940035	chr20:35216462~35278131:-
BRCA	cis	rs9467773	1	rs6926629	ENSG00000241549.7	GUSBP2	4.39	1.27e-05	0.00102	0.14	0.13	Intelligence (multi-trait analysis);	chr6:26499675	chr6:26871484~26956554:-
BRCA	cis	rs1538970	0.816	rs10789464	ENSG00000281133.1	AL355480.3	-4.39	1.27e-05	0.00102	-0.19	-0.13	Platelet count;	chr1:45493430	chr1:45580892~45580996:-
BRCA	cis	rs73201462	1	rs2955083	ENSG00000242551.2	POU5F1P6	-4.39	1.27e-05	0.00102	-0.24	-0.13	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128242335	chr3:128674735~128677005:-
BRCA	cis	rs950776	0.616	rs56276142	ENSG00000279373.1	RP11-650L12.4	4.39	1.27e-05	0.00102	0.16	0.13	Sudden cardiac arrest;	chr15:78597453	chr15:78537681~78538946:+
BRCA	cis	rs1005277	0.579	rs9299760	ENSG00000263064.2	RP11-291L22.7	4.39	1.27e-05	0.00102	0.16	0.13	Extrinsic epigenetic age acceleration;	chr10:38088992	chr10:38448689~38448949:+
BRCA	cis	rs1005277	0.579	rs2023351	ENSG00000263064.2	RP11-291L22.7	4.39	1.27e-05	0.00102	0.16	0.13	Extrinsic epigenetic age acceleration;	chr10:38089886	chr10:38448689~38448949:+
BRCA	cis	rs7474896	0.583	rs10827817	ENSG00000120555.12	SEPT7P9	4.39	1.27e-05	0.00102	0.19	0.13	Obesity (extreme);	chr10:37709046	chr10:38383069~38402916:-
BRCA	cis	rs67981189	0.593	rs12896829	ENSG00000269927.1	RP6-91H8.3	4.39	1.27e-05	0.00102	0.16	0.13	Schizophrenia;	chr14:70996959	chr14:71141125~71143253:-
BRCA	cis	rs12439619	0.693	rs17269819	ENSG00000255769.6	GOLGA2P10	-4.39	1.27e-05	0.00102	-0.18	-0.13	Intelligence (multi-trait analysis);	chr15:82174660	chr15:82472993~82513950:-
BRCA	cis	rs6452524	0.868	rs62372714	ENSG00000281327.1	LINC01338	4.39	1.28e-05	0.00102	0.17	0.13	Hypertension (SNP x SNP interaction);	chr5:83095449	chr5:82850864~82859836:-
BRCA	cis	rs9573567	0.881	rs1570541	ENSG00000261553.4	RP11-29G8.3	4.39	1.28e-05	0.00102	0.29	0.13	Red blood cell count;Mean corpuscular volume;	chr13:75500729	chr13:75549773~75807120:+
BRCA	cis	rs9341808	0.538	rs9443742	ENSG00000233967.5	RP11-250B2.3	-4.39	1.28e-05	0.00102	-0.14	-0.13	Sitting height ratio;	chr6:80307212	chr6:80443344~80465927:+
BRCA	cis	rs2908197	0.737	rs2109857	ENSG00000186704.9	DTX2P1	4.39	1.28e-05	0.00102	0.16	0.13	3-hydroxypropylmercapturic acid levels in smokers;	chr7:76333852	chr7:76978617~77004308:+
BRCA	cis	rs9467773	1	rs9467773	ENSG00000241549.7	GUSBP2	4.39	1.28e-05	0.00102	0.14	0.13	Intelligence (multi-trait analysis);	chr6:26498198	chr6:26871484~26956554:-
BRCA	cis	rs2243480	1	rs466983	ENSG00000275400.1	RP4-756H11.5	4.39	1.28e-05	0.00102	0.25	0.13	Diabetic kidney disease;	chr7:66055509	chr7:66553805~66554199:-
BRCA	cis	rs67981189	0.593	rs2877708	ENSG00000258571.1	PTTG4P	-4.39	1.28e-05	0.00102	-0.14	-0.13	Schizophrenia;	chr14:71017409	chr14:71085482~71085833:-
BRCA	cis	rs62458065	1	rs10246687	ENSG00000229358.3	DPY19L1P1	-4.39	1.28e-05	0.00102	-0.18	-0.13	Metabolite levels (HVA/MHPG ratio);	chr7:32425571	chr7:32580949~32761787:-
BRCA	cis	rs867371	1	rs1174543	ENSG00000278603.1	RP13-608F4.5	-4.39	1.28e-05	0.00102	-0.18	-0.13	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82155732	chr15:82472203~82472426:+
BRCA	cis	rs10208649	0.808	rs77805752	ENSG00000272156.1	RP11-477N3.1	4.39	1.28e-05	0.00102	0.28	0.13	Body mass index;	chr2:54037506	chr2:54082554~54085066:+
BRCA	cis	rs11098499	0.863	rs3775841	ENSG00000250412.1	KLHL2P1	4.38	1.28e-05	0.00102	0.16	0.13	Corneal astigmatism;	chr4:119504622	chr4:119334329~119378233:+
BRCA	cis	rs13325613	0.915	rs1542755	ENSG00000223552.1	RP11-24F11.2	4.38	1.28e-05	0.00102	0.29	0.13	Monocyte count;	chr3:46230949	chr3:46364955~46407059:-
BRCA	cis	rs4835473	0.932	rs17018238	ENSG00000249741.2	RP11-673E1.3	4.38	1.28e-05	0.00102	0.14	0.13	Immature fraction of reticulocytes;	chr4:143782737	chr4:143911514~143912053:-
BRCA	cis	rs4648045	0.565	rs17033014	ENSG00000246560.2	RP11-10L12.4	4.38	1.28e-05	0.00102	0.15	0.13	Lymphocyte percentage of white cells;	chr4:102625029	chr4:102828055~102844075:+
BRCA	cis	rs9921338	0.961	rs11545336	ENSG00000262636.1	CTD-3088G3.4	-4.38	1.28e-05	0.00102	-0.23	-0.13	Vein graft stenosis in coronary artery bypass grafting;	chr16:11345639	chr16:11380859~11381118:-
BRCA	cis	rs2625529	0.878	rs16956302	ENSG00000260037.4	CTD-2524L6.3	-4.38	1.28e-05	0.00102	-0.19	-0.13	Red blood cell count;	chr15:71843902	chr15:71818396~71823384:+
BRCA	cis	rs7818688	1	rs6651272	ENSG00000253528.2	RP11-347C18.4	4.38	1.28e-05	0.00102	0.21	0.13	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95035705	chr8:94974573~94974853:-
BRCA	cis	rs1858037	0.867	rs61226353	ENSG00000281920.1	RP11-418H16.1	4.38	1.28e-05	0.00102	0.17	0.13	Rheumatoid arthritis;	chr2:65363637	chr2:65623272~65628424:+
BRCA	cis	rs3113494	0.902	rs2594277	ENSG00000251411.1	RP11-397E7.4	4.38	1.28e-05	0.00102	0.15	0.13	Amyotrophic lateral sclerosis;	chr4:86914852	chr4:86913266~86914817:-
BRCA	cis	rs7111546	1	rs7111546	ENSG00000246225.5	RP11-17A1.3	4.38	1.28e-05	0.00102	0.2	0.13	Dialysis-related mortality;	chr11:22808211	chr11:22829380~22945393:+
BRCA	cis	rs465969	0.793	rs7752225	ENSG00000230177.1	RP5-1112D6.4	-4.38	1.28e-05	0.00102	-0.31	-0.13	Psoriasis;	chr6:111459412	chr6:111277932~111278742:+
BRCA	cis	rs7429990	1	rs1665982	ENSG00000199476.1	Y_RNA	4.38	1.28e-05	0.00102	0.2	0.13	Educational attainment (years of education);	chr3:47863589	chr3:48288587~48288694:+
BRCA	cis	rs73242632	1	rs73242621	ENSG00000269949.1	RP11-738E22.3	4.38	1.28e-05	0.00102	0.31	0.13	Congenital heart disease (maternal effect);	chr4:56951915	chr4:56960927~56961373:-
BRCA	cis	rs73242632	1	rs73242622	ENSG00000269949.1	RP11-738E22.3	4.38	1.28e-05	0.00102	0.31	0.13	Congenital heart disease (maternal effect);	chr4:56952398	chr4:56960927~56961373:-
BRCA	cis	rs370915	0.542	rs1895844	ENSG00000250971.1	RP11-696F12.1	4.38	1.28e-05	0.00102	0.14	0.13	Gout;	chr4:186912605	chr4:187060099~187060930:+
BRCA	cis	rs58521262	0.585	rs12978716	ENSG00000268105.1	RP11-369G6.2	-4.38	1.28e-05	0.00102	-0.18	-0.13	Testicular germ cell tumor;	chr19:23033654	chr19:23125665~23128543:+
BRCA	cis	rs34217772	1	rs12884531	ENSG00000258636.1	CTD-2298J14.2	4.38	1.28e-05	0.00102	0.18	0.13	Myopia;	chr14:41803413	chr14:41587861~41604856:-
BRCA	cis	rs56322409	0.897	rs1891536	ENSG00000226688.5	ENTPD1-AS1	4.38	1.28e-05	0.00102	0.15	0.13	Blood metabolite levels;	chr10:95831540	chr10:95753206~96090238:-
BRCA	cis	rs13113518	1	rs4865004	ENSG00000272969.1	RP11-528I4.2	4.38	1.28e-05	0.00102	0.16	0.13	Height;	chr4:55515118	chr4:55547112~55547889:+
BRCA	cis	rs2280018	1	rs2280017	ENSG00000270580.4	PKD1P6	-4.38	1.28e-05	0.00102	-0.14	-0.13	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15057504	chr16:15104723~15131601:-
BRCA	cis	rs11098499	0.754	rs1980027	ENSG00000225892.3	RP11-384K6.2	4.38	1.28e-05	0.00102	0.13	0.13	Corneal astigmatism;	chr4:119330422	chr4:118632274~118634759:+
BRCA	cis	rs867371	1	rs7166570	ENSG00000278603.1	RP13-608F4.5	4.38	1.28e-05	0.00102	0.18	0.13	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82173880	chr15:82472203~82472426:+
BRCA	cis	rs6005807	0.719	rs9625509	ENSG00000272858.1	CTA-292E10.8	-4.38	1.28e-05	0.00102	-0.25	-0.13	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28593258	chr22:28814914~28815662:+
BRCA	cis	rs60843830	1	rs11553746	ENSG00000272342.1	RP13-539J13.1	4.38	1.28e-05	0.00103	0.17	0.13	Spherical equivalent (joint analysis main effects and education interaction);	chr2:272203	chr2:739588~740164:-
BRCA	cis	rs11148252	0.846	rs13431	ENSG00000198384.8	TPTE2P3	4.38	1.28e-05	0.00103	0.15	0.13	Lewy body disease;	chr13:52413342	chr13:52522632~52586906:+
BRCA	cis	rs10829156	0.898	rs4748504	ENSG00000240291.1	RP11-499P20.2	4.38	1.28e-05	0.00103	0.15	0.13	Sudden cardiac arrest;	chr10:18651868	chr10:18513115~18545651:-
BRCA	cis	rs17684571	0.7	rs34966024	ENSG00000231441.1	RP11-472M19.2	4.38	1.28e-05	0.00103	0.2	0.13	Schizophrenia;	chr6:56766213	chr6:56844002~56864078:+
BRCA	cis	rs11673344	0.573	rs73039109	ENSG00000267260.1	CTD-2162K18.4	-4.38	1.28e-05	0.00103	-0.2	-0.13	Obesity-related traits;	chr19:36891073	chr19:36773153~36777078:+
BRCA	cis	rs2273156	1	rs7141293	ENSG00000226677.3	IGBP1P1	-4.38	1.28e-05	0.00103	-0.2	-0.13	Immunoglobulin light chain (AL) amyloidosis;	chr14:34993704	chr14:34939324~34940332:+
BRCA	cis	rs6671200	0.92	rs259350	ENSG00000226026.4	RP11-57H12.3	-4.38	1.28e-05	0.00103	-0.26	-0.13	Stearic acid (18:0) levels;	chr1:95259275	chr1:95163219~95233982:-
BRCA	cis	rs2108622	0.701	rs118144071	ENSG00000267218.2	AC005336.5	4.38	1.28e-05	0.00103	0.16	0.13	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15868384	chr19:15902300~15903238:-
BRCA	cis	rs2617170	0.922	rs2733852	ENSG00000245648.1	RP11-277P12.20	-4.38	1.28e-05	0.00103	-0.18	-0.13	Behcet's disease;	chr12:10375969	chr12:10363769~10398506:+
BRCA	cis	rs10833905	1	rs11026932	ENSG00000246225.5	RP11-17A1.3	-4.38	1.28e-05	0.00103	-0.19	-0.13	Sudden cardiac arrest;	chr11:23043853	chr11:22829380~22945393:+
BRCA	cis	rs2832191	0.716	rs2249028	ENSG00000232855.5	AF131217.1	-4.38	1.28e-05	0.00103	-0.16	-0.13	Dental caries;	chr21:28993001	chr21:28439346~28674848:-
BRCA	cis	rs3768617	0.811	rs12120747	ENSG00000224468.3	RP11-181K3.4	-4.38	1.28e-05	0.00103	-0.15	-0.13	Fuchs's corneal dystrophy;	chr1:183073396	chr1:183138402~183141282:-
BRCA	cis	rs12317459	0.591	rs11115396	ENSG00000213270.5	RPL6P25	-4.38	1.28e-05	0.00103	-0.21	-0.13	Prostate cancer (SNP x SNP interaction);	chr12:82769703	chr12:83151331~83152190:+
BRCA	cis	rs6968419	0.547	rs72603593	ENSG00000279086.1	RP11-667F14.1	-4.38	1.28e-05	0.00103	-0.15	-0.13	Intraocular pressure;	chr7:116254322	chr7:116209234~116211511:-
BRCA	cis	rs6545883	0.894	rs2694632	ENSG00000270820.4	RP11-355B11.2	-4.38	1.28e-05	0.00103	-0.15	-0.13	Tuberculosis;	chr2:61331547	chr2:61471188~61484130:+
BRCA	cis	rs7267979	1	rs6115168	ENSG00000277938.1	RP5-965G21.3	-4.38	1.28e-05	0.00103	-0.16	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25392255	chr20:25229150~25231933:+
BRCA	cis	rs9840812	0.639	rs610860	ENSG00000239213.4	NCK1-AS1	4.38	1.28e-05	0.00103	0.19	0.13	Fibrinogen levels;	chr3:136333974	chr3:136841726~136862054:-
BRCA	cis	rs721917	0.525	rs7903576	ENSG00000244733.5	RP11-506M13.3	-4.38	1.29e-05	0.00103	-0.16	-0.13	Chronic obstructive pulmonary disease;	chr10:79981386	chr10:79660891~79677996:+
BRCA	cis	rs6686842	0.965	rs1472570	ENSG00000235358.1	RP11-399E6.1	-4.38	1.29e-05	0.00103	-0.17	-0.13	Height;	chr1:41248412	chr1:41242373~41284861:+
BRCA	cis	rs7182948	0.918	rs2413947	ENSG00000259531.2	RP11-295H24.3	-4.38	1.29e-05	0.00103	-0.19	-0.13	Lung adenocarcinoma;	chr15:49465188	chr15:49365124~49366685:-
BRCA	cis	rs1510272	0.889	rs2048336	ENSG00000243926.1	TIPARP-AS1	-4.38	1.29e-05	0.00103	-0.15	-0.13	Testicular germ cell tumor;	chr3:156610464	chr3:156671862~156674378:-
BRCA	cis	rs56322409	0.897	rs2861151	ENSG00000226688.5	ENTPD1-AS1	4.38	1.29e-05	0.00103	0.15	0.13	Blood metabolite levels;	chr10:95793213	chr10:95753206~96090238:-
BRCA	cis	rs2018683	0.624	rs2286220	ENSG00000233517.1	AC005162.5	-4.38	1.29e-05	0.00103	-0.16	-0.13	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28959083	chr7:28987028~28988899:+
BRCA	cis	rs2243480	1	rs7794661	ENSG00000222364.1	RNU6-96P	-4.38	1.29e-05	0.00103	-0.24	-0.13	Diabetic kidney disease;	chr7:65924743	chr7:66395191~66395286:+
BRCA	cis	rs4835473	0.932	rs11724752	ENSG00000249741.2	RP11-673E1.3	4.38	1.29e-05	0.00103	0.15	0.13	Immature fraction of reticulocytes;	chr4:143769473	chr4:143911514~143912053:-
BRCA	cis	rs34421088	0.623	rs2572433	ENSG00000255046.1	RP11-297N6.4	-4.38	1.29e-05	0.00103	-0.17	-0.13	Neuroticism;	chr8:11243532	chr8:11797928~11802568:-
BRCA	cis	rs9392653	1	rs9378931	ENSG00000220685.3	RP11-530A18.1	-4.38	1.29e-05	0.00103	-0.18	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr6:5070004	chr6:5065795~5066982:-
BRCA	cis	rs34792	0.528	rs222132	ENSG00000207425.1	Y_RNA	-4.38	1.29e-05	0.00103	-0.15	-0.13	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15451243	chr16:14915457~14915556:-
BRCA	cis	rs7308116	1	rs11113505	ENSG00000274395.1	RP11-554D14.8	-4.38	1.29e-05	0.00103	-0.15	-0.13	Pelvic organ prolapse (moderate/severe);	chr12:107810836	chr12:107835541~107836555:-
BRCA	cis	rs11673344	0.543	rs12980849	ENSG00000226686.6	LINC01535	4.38	1.29e-05	0.00103	0.18	0.13	Obesity-related traits;	chr19:37160812	chr19:37251912~37265535:+
BRCA	cis	rs12073837	0.572	rs61830266	ENSG00000272823.1	RP11-295M18.6	-4.38	1.29e-05	0.00103	-0.14	-0.13	F-cell distribution;	chr1:220800090	chr1:220828676~220829211:-
BRCA	cis	rs56322409	1	rs4037	ENSG00000226688.5	ENTPD1-AS1	4.38	1.29e-05	0.00103	0.15	0.13	Blood metabolite levels;	chr10:95606063	chr10:95753206~96090238:-
BRCA	cis	rs8040855	0.597	rs12902942	ENSG00000230373.7	GOLGA6L5P	4.38	1.29e-05	0.00103	0.17	0.13	Bulimia nervosa;	chr15:85041573	chr15:84507885~84516814:-
BRCA	cis	rs6430585	0.583	rs4988145	ENSG00000224043.6	CCNT2-AS1	-4.38	1.29e-05	0.00103	-0.23	-0.13	Corneal structure;	chr2:135874730	chr2:134735464~134918710:-
BRCA	cis	rs7954584	0.71	rs10840641	ENSG00000272849.1	RP11-347I19.8	-4.38	1.29e-05	0.00103	-0.11	-0.13	Mean corpuscular volume;	chr12:122027925	chr12:121797511~121801972:+
BRCA	cis	rs17507216	0.667	rs72753916	ENSG00000259429.4	UBE2Q2P2	-4.38	1.29e-05	0.00103	-0.16	-0.13	Excessive daytime sleepiness;	chr15:82684001	chr15:82355142~82420075:+
BRCA	cis	rs78487399	0.803	rs75275342	ENSG00000234936.1	AC010883.5	4.38	1.29e-05	0.00103	0.21	0.13	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43535746	chr2:43229573~43233394:+
BRCA	cis	rs78487399	0.808	rs113373412	ENSG00000234936.1	AC010883.5	4.38	1.29e-05	0.00103	0.21	0.13	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43535848	chr2:43229573~43233394:+
BRCA	cis	rs1005277	0.505	rs7099777	ENSG00000226578.1	RP11-258F22.1	4.38	1.29e-05	0.00103	0.14	0.13	Extrinsic epigenetic age acceleration;	chr10:37894641	chr10:37775371~37784131:-
BRCA	cis	rs7011507	0.582	rs72637682	ENSG00000279881.1	RP11-513O13.1	-4.38	1.29e-05	0.00103	-0.22	-0.13	Inflammatory bowel disease;Ulcerative colitis;	chr8:48359766	chr8:48428143~48431041:-
BRCA	cis	rs853679	1	rs68141011	ENSG00000280107.1	AL022393.9	-4.38	1.29e-05	0.00103	-0.24	-0.13	Depression;	chr6:28250019	chr6:28170845~28172521:+
BRCA	cis	rs853679	1	rs13200462	ENSG00000280107.1	AL022393.9	-4.38	1.29e-05	0.00103	-0.24	-0.13	Depression;	chr6:28250421	chr6:28170845~28172521:+
BRCA	cis	rs10129255	0.5	rs8014529	ENSG00000211959.2	IGHV4-39	4.38	1.29e-05	0.00103	0.09	0.13	Kawasaki disease;	chr14:106784065	chr14:106421711~106422218:-
BRCA	cis	rs1005277	0.579	rs1740732	ENSG00000099251.13	HSD17B7P2	4.38	1.29e-05	0.00103	0.15	0.13	Extrinsic epigenetic age acceleration;	chr10:38202457	chr10:38356380~38378505:+
BRCA	cis	rs867371	1	rs9944197	ENSG00000278603.1	RP13-608F4.5	4.38	1.29e-05	0.00103	0.18	0.13	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82158261	chr15:82472203~82472426:+
BRCA	cis	rs644148	0.836	rs2686770	ENSG00000176761.7	ZNF285B	4.38	1.29e-05	0.00103	0.15	0.13	Personality dimensions;	chr19:44494712	chr19:44467641~44473227:+
BRCA	cis	rs516805	0.667	rs2606608	ENSG00000279114.1	RP3-425C14.5	-4.38	1.29e-05	0.00103	-0.17	-0.13	Lymphocyte counts;	chr6:122195051	chr6:122471923~122484161:+
BRCA	cis	rs6921919	0.583	rs6922169	ENSG00000220721.1	OR1F12	4.38	1.29e-05	0.00103	0.16	0.13	Autism spectrum disorder or schizophrenia;	chr6:28415155	chr6:28073316~28074233:+
BRCA	cis	rs6921919	0.559	rs13210866	ENSG00000220721.1	OR1F12	4.38	1.29e-05	0.00103	0.16	0.13	Autism spectrum disorder or schizophrenia;	chr6:28416065	chr6:28073316~28074233:+
BRCA	cis	rs1043099	0.871	rs5749078	ENSG00000279699.1	RP1-102K2.9	-4.38	1.29e-05	0.00103	-0.22	-0.13	Rheumatoid arthritis;	chr22:30365077	chr22:30275215~30276951:-
BRCA	cis	rs1005277	0.579	rs2505241	ENSG00000099251.13	HSD17B7P2	4.38	1.29e-05	0.00103	0.15	0.13	Extrinsic epigenetic age acceleration;	chr10:38153493	chr10:38356380~38378505:+
BRCA	cis	rs6012564	1	rs6066977	ENSG00000227431.4	CSE1L-AS1	4.38	1.29e-05	0.00103	0.16	0.13	Anger;	chr20:49138538	chr20:49040463~49046044:-
BRCA	cis	rs2108622	0.649	rs113055956	ENSG00000214049.6	UCA1	4.38	1.29e-05	0.00103	0.19	0.13	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15866502	chr19:15828961~15836320:+
BRCA	cis	rs6840360	0.567	rs6844259	ENSG00000270265.1	RP11-731D1.4	-4.38	1.29e-05	0.00103	-0.15	-0.13	Intelligence (multi-trait analysis);	chr4:151370032	chr4:151333775~151353224:-
BRCA	cis	rs2412819	0.597	rs514311	ENSG00000166763.7	STRCP1	4.38	1.29e-05	0.00103	0.19	0.13	Lung cancer;	chr15:43869376	chr15:43699488~43718184:-
BRCA	cis	rs6545883	1	rs6742276	ENSG00000270820.4	RP11-355B11.2	4.38	1.29e-05	0.00103	0.15	0.13	Tuberculosis;	chr2:61541610	chr2:61471188~61484130:+
BRCA	cis	rs2048656	0.605	rs13249234	ENSG00000233609.3	RP11-62H7.2	4.38	1.29e-05	0.00103	0.13	0.13	Schizophrenia;	chr8:9792891	chr8:8961200~8979025:+
BRCA	cis	rs11098499	0.754	rs66900435	ENSG00000225892.3	RP11-384K6.2	4.38	1.29e-05	0.00103	0.13	0.13	Corneal astigmatism;	chr4:119328270	chr4:118632274~118634759:+
BRCA	cis	rs7267979	0.966	rs4815425	ENSG00000125804.12	FAM182A	4.38	1.29e-05	0.00103	0.17	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25418240	chr20:26054655~26086917:+
BRCA	cis	rs875971	1	rs11974264	ENSG00000229180.5	GS1-124K5.11	-4.38	1.29e-05	0.00103	-0.12	-0.13	Aortic root size;	chr7:66182595	chr7:66526088~66542624:-
BRCA	cis	rs871012	0.542	rs951958	ENSG00000248544.2	CTB-47B11.3	-4.38	1.29e-05	0.00103	-0.17	-0.13	IgG glycosylation;	chr5:157462089	chr5:157375741~157384950:-
BRCA	cis	rs7829975	0.606	rs7819827	ENSG00000254153.1	CTA-398F10.2	-4.38	1.29e-05	0.00103	-0.16	-0.13	Mood instability;	chr8:8939545	chr8:8456909~8461337:-
BRCA	cis	rs7829975	0.573	rs7842359	ENSG00000254153.1	CTA-398F10.2	-4.38	1.29e-05	0.00103	-0.16	-0.13	Mood instability;	chr8:8939568	chr8:8456909~8461337:-
BRCA	cis	rs2179367	0.959	rs237034	ENSG00000223701.3	RAET1E-AS1	4.38	1.29e-05	0.00103	0.17	0.13	Dupuytren's disease;	chr6:149390726	chr6:149884431~149919508:+
BRCA	cis	rs2625529	0.73	rs7177242	ENSG00000260037.4	CTD-2524L6.3	4.38	1.29e-05	0.00103	0.18	0.13	Red blood cell count;	chr15:71891773	chr15:71818396~71823384:+
BRCA	cis	rs7621025	0.554	rs1471740	ENSG00000273486.1	RP11-731C17.2	4.38	1.29e-05	0.00103	0.17	0.13	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136609428	chr3:136837338~136839021:-
BRCA	cis	rs11955398	0.502	rs34592	ENSG00000272308.1	RP11-231G3.1	-4.38	1.29e-05	0.00103	-0.16	-0.13	Intelligence (multi-trait analysis);	chr5:61033797	chr5:60866457~60866935:-
BRCA	cis	rs6565189	0.865	rs4350585	ENSG00000273724.1	RP11-347C12.12	4.38	1.29e-05	0.00103	0.16	0.13	Tonsillectomy;	chr16:30494192	chr16:30336400~30343336:+
BRCA	cis	rs6686842	0.56	rs213744	ENSG00000235358.1	RP11-399E6.1	4.38	1.29e-05	0.00103	0.18	0.13	Height;	chr1:41154222	chr1:41242373~41284861:+
BRCA	cis	rs651907	0.557	rs11914318	ENSG00000256628.3	ZBTB11-AS1	4.38	1.3e-05	0.00103	0.17	0.13	Colorectal cancer;	chr3:101735014	chr3:101676475~101679217:+
BRCA	cis	rs4853525	0.62	rs6718902	ENSG00000235852.1	AC005540.3	-4.38	1.3e-05	0.00103	-0.16	-0.13	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190973478	chr2:190880797~190882059:-
BRCA	cis	rs1371614	0.611	rs4665920	ENSG00000272148.1	RP11-195B17.1	-4.38	1.3e-05	0.00103	-0.15	-0.13	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26905966	chr2:27062428~27062907:-
BRCA	cis	rs58521262	0.585	rs1066015	ENSG00000268105.1	RP11-369G6.2	-4.38	1.3e-05	0.00103	-0.18	-0.13	Testicular germ cell tumor;	chr19:23006586	chr19:23125665~23128543:+
BRCA	cis	rs6430585	0.528	rs3099429	ENSG00000224043.6	CCNT2-AS1	-4.38	1.3e-05	0.00103	-0.22	-0.13	Corneal structure;	chr2:135898012	chr2:134735464~134918710:-
BRCA	cis	rs4957048	0.577	rs56294732	ENSG00000271781.1	CTD-2589H19.6	-4.38	1.3e-05	0.00104	-0.18	-0.13	Ulcerative colitis;	chr5:568029	chr5:675826~676616:+
BRCA	cis	rs4578769	0.918	rs12458661	ENSG00000265939.1	UBE2CP2	-4.38	1.3e-05	0.00104	-0.16	-0.13	Eosinophil percentage of white cells;	chr18:23004284	chr18:22900486~22900995:-
BRCA	cis	rs2908197	0.663	rs7802264	ENSG00000186704.9	DTX2P1	4.38	1.3e-05	0.00104	0.16	0.13	3-hydroxypropylmercapturic acid levels in smokers;	chr7:76356465	chr7:76978617~77004308:+
BRCA	cis	rs875971	0.571	rs160647	ENSG00000230295.1	RP11-458F8.2	-4.38	1.3e-05	0.00104	-0.13	-0.13	Aortic root size;	chr7:66089365	chr7:66880708~66882981:+
BRCA	cis	rs9300255	0.516	rs6488868	ENSG00000235423.7	RP11-282O18.3	4.38	1.3e-05	0.00104	0.16	0.13	Neutrophil percentage of white cells;	chr12:123315427	chr12:123252030~123261483:-
BRCA	cis	rs13113518	1	rs13114841	ENSG00000272969.1	RP11-528I4.2	4.38	1.3e-05	0.00104	0.16	0.13	Height;	chr4:55485974	chr4:55547112~55547889:+
BRCA	cis	rs6545883	0.894	rs2121661	ENSG00000212978.6	AC016747.3	-4.38	1.3e-05	0.00104	-0.18	-0.13	Tuberculosis;	chr2:61334523	chr2:61141592~61144969:-
BRCA	cis	rs1979679	0.572	rs6487692	ENSG00000278733.1	RP11-425D17.1	-4.38	1.3e-05	0.00104	-0.18	-0.13	Ossification of the posterior longitudinal ligament of the spine;	chr12:28573109	chr12:28185625~28186190:-
BRCA	cis	rs13113518	0.902	rs12505266	ENSG00000273257.1	RP11-177J6.1	4.38	1.3e-05	0.00104	0.17	0.13	Height;	chr4:55546002	chr4:55387949~55388271:+
BRCA	cis	rs7927592	0.912	rs55767696	ENSG00000212093.1	AP000807.1	4.38	1.3e-05	0.00104	0.15	0.13	Total body bone mineral density;	chr11:68607652	chr11:68506083~68506166:-
BRCA	cis	rs6997458	0.576	rs10099251	ENSG00000258256.1	RP11-219B4.5	-4.38	1.3e-05	0.00104	-0.15	-0.13	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85313204	chr8:85222446~85245717:-
BRCA	cis	rs867371	0.826	rs2047678	ENSG00000278603.1	RP13-608F4.5	4.38	1.3e-05	0.00104	0.18	0.13	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82205857	chr15:82472203~82472426:+
BRCA	cis	rs7267979	0.565	rs4815432	ENSG00000204556.4	CTD-2514C3.1	4.38	1.3e-05	0.00104	0.18	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25575767	chr20:26018832~26020684:+
BRCA	cis	rs9527	0.64	rs7089061	ENSG00000213061.2	PFN1P11	4.38	1.3e-05	0.00104	0.18	0.13	Arsenic metabolism;	chr10:102963258	chr10:102838011~102845473:-
BRCA	cis	rs9527	0.615	rs7089065	ENSG00000213061.2	PFN1P11	4.38	1.3e-05	0.00104	0.18	0.13	Arsenic metabolism;	chr10:102963265	chr10:102838011~102845473:-
BRCA	cis	rs934734	0.571	rs7565437	ENSG00000204929.10	AC074391.1	-4.38	1.3e-05	0.00104	-0.17	-0.13	Rheumatoid arthritis;	chr2:65419832	chr2:65436711~66084639:+
BRCA	cis	rs7960884	0.598	rs61917101	ENSG00000226472.6	RP11-551L14.4	4.38	1.3e-05	0.00104	0.18	0.13	Systolic blood pressure response to hydrochlorothiazide in hypertension;	chr12:31220063	chr12:30978308~31006010:-
BRCA	cis	rs67340775	0.541	rs200975	ENSG00000216901.1	AL022393.7	4.38	1.3e-05	0.00104	0.22	0.13	Lung cancer in ever smokers;	chr6:27887847	chr6:28176188~28176674:+
BRCA	cis	rs67340775	0.541	rs200974	ENSG00000216901.1	AL022393.7	4.38	1.3e-05	0.00104	0.22	0.13	Lung cancer in ever smokers;	chr6:27888067	chr6:28176188~28176674:+
BRCA	cis	rs465969	1	rs35856111	ENSG00000230177.1	RP5-1112D6.4	4.38	1.3e-05	0.00104	0.31	0.13	Psoriasis;	chr6:111452265	chr6:111277932~111278742:+
BRCA	cis	rs6968419	1	rs4082046	ENSG00000279086.1	RP11-667F14.1	-4.38	1.3e-05	0.00104	-0.13	-0.13	Intraocular pressure;	chr7:116177133	chr7:116209234~116211511:-
BRCA	cis	rs4948275	0.666	rs2606089	ENSG00000237233.2	TMEM26-AS1	-4.38	1.3e-05	0.00104	-0.16	-0.13	Night sleep phenotypes;	chr10:61554047	chr10:61452639~61481956:+
BRCA	cis	rs7267979	1	rs4815412	ENSG00000274973.1	RP13-401N8.7	-4.38	1.3e-05	0.00104	-0.15	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25369689	chr20:25845497~25845862:+
BRCA	cis	rs1910358	0.554	rs4235528	ENSG00000248874.4	C5orf17	-4.38	1.3e-05	0.00104	-0.19	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23808329	chr5:23951348~24178263:+
BRCA	cis	rs4443100	0.631	rs13054904	ENSG00000230701.2	FBXW4P1	-4.38	1.3e-05	0.00104	-0.18	-0.13	Serum parathyroid hormone levels;	chr22:23068739	chr22:23262767~23265005:+
BRCA	cis	rs7141336	0.896	rs8009816	ENSG00000258884.1	CTD-3035D6.2	4.38	1.3e-05	0.00104	0.17	0.13	Anxiety disorder;	chr14:90820661	chr14:90822365~90828128:-
BRCA	cis	rs2739330	0.828	rs5760107	ENSG00000228039.3	KB-1125A3.10	4.38	1.3e-05	0.00104	0.16	0.13	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23963780~23964374:+
BRCA	cis	rs9840812	0.596	rs571513	ENSG00000273486.1	RP11-731C17.2	4.38	1.3e-05	0.00104	0.17	0.13	Fibrinogen levels;	chr3:136376193	chr3:136837338~136839021:-
BRCA	cis	rs539096	0.872	rs674725	ENSG00000236200.4	KDM4A-AS1	-4.38	1.3e-05	0.00104	-0.18	-0.13	Intelligence (multi-trait analysis);	chr1:43596124	chr1:43699765~43708138:-
BRCA	cis	rs6840360	0.582	rs1372976	ENSG00000278978.1	RP11-164P12.5	-4.38	1.3e-05	0.00104	-0.15	-0.13	Intelligence (multi-trait analysis);	chr4:151530301	chr4:151669786~151670503:+
BRCA	cis	rs2832077	0.505	rs9305386	ENSG00000236056.1	GAPDHP14	-4.38	1.3e-05	0.00104	-0.21	-0.13	Cognitive test performance;	chr21:29014430	chr21:29222321~29223257:+
BRCA	cis	rs4948275	0.667	rs2814030	ENSG00000237233.2	TMEM26-AS1	4.38	1.3e-05	0.00104	0.16	0.13	Night sleep phenotypes;	chr10:61578035	chr10:61452639~61481956:+
BRCA	cis	rs2731006	0.69	rs2730965	ENSG00000257114.2	RP11-25I15.3	4.38	1.3e-05	0.00104	0.22	0.13	Panic disorder;	chr12:42781765	chr12:42692216~42717119:+
BRCA	cis	rs2731006	0.64	rs2678149	ENSG00000257114.2	RP11-25I15.3	4.38	1.3e-05	0.00104	0.22	0.13	Panic disorder;	chr12:42783114	chr12:42692216~42717119:+
BRCA	cis	rs2731006	0.591	rs2678147	ENSG00000257114.2	RP11-25I15.3	4.38	1.3e-05	0.00104	0.22	0.13	Panic disorder;	chr12:42783805	chr12:42692216~42717119:+
BRCA	cis	rs9990333	0.544	rs112577972	ENSG00000242086.7	LINC00969	4.38	1.3e-05	0.00104	0.15	0.13	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196098278	chr3:195658062~195739964:+
BRCA	cis	rs6968419	0.755	rs6967695	ENSG00000279086.1	RP11-667F14.1	-4.38	1.3e-05	0.00104	-0.15	-0.13	Intraocular pressure;	chr7:116255995	chr7:116209234~116211511:-
BRCA	cis	rs6968419	0.755	rs3807981	ENSG00000279086.1	RP11-667F14.1	-4.38	1.3e-05	0.00104	-0.15	-0.13	Intraocular pressure;	chr7:116256662	chr7:116209234~116211511:-
BRCA	cis	rs1510272	0.961	rs1510275	ENSG00000243926.1	TIPARP-AS1	-4.38	1.3e-05	0.00104	-0.15	-0.13	Testicular germ cell tumor;	chr3:156586611	chr3:156671862~156674378:-
BRCA	cis	rs4853525	0.859	rs11897136	ENSG00000235852.1	AC005540.3	4.38	1.3e-05	0.00104	0.15	0.13	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190846354	chr2:190880797~190882059:-
BRCA	cis	rs10129255	0.5	rs7161740	ENSG00000211967.3	IGHV3-53	-4.38	1.3e-05	0.00104	-0.09	-0.13	Kawasaki disease;	chr14:106776119	chr14:106592676~106593347:-
BRCA	cis	rs7267979	0.764	rs2474767	ENSG00000274414.1	RP5-965G21.4	-4.38	1.3e-05	0.00104	-0.16	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25266097	chr20:25239007~25245229:-
BRCA	cis	rs6570726	0.791	rs11155433	ENSG00000270638.1	RP3-466P17.1	-4.38	1.3e-05	0.00104	-0.15	-0.13	Lobe attachment (rater-scored or self-reported);	chr6:145586695	chr6:145735570~145737218:+
BRCA	cis	rs11892454	0.544	rs13004845	ENSG00000217643.1	PTGES3P2	-4.38	1.3e-05	0.00104	-0.14	-0.13	Heschl's gyrus morphology;	chr2:25736608	chr2:25822469~25822950:+
BRCA	cis	rs11892454	0.544	rs10178552	ENSG00000217643.1	PTGES3P2	-4.38	1.3e-05	0.00104	-0.14	-0.13	Heschl's gyrus morphology;	chr2:25750440	chr2:25822469~25822950:+
BRCA	cis	rs6870983	0.895	rs2410763	ENSG00000247828.6	TMEM161B-AS1	4.38	1.3e-05	0.00104	0.17	0.13	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index;	chr5:88370824	chr5:88268895~88436685:+
BRCA	cis	rs7617480	0.61	rs4955420	ENSG00000270441.1	RP11-694I15.7	-4.38	1.3e-05	0.00104	-0.15	-0.13	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:49171432	chr3:49140086~49160851:-
BRCA	cis	rs62458065	1	rs1450868	ENSG00000229358.3	DPY19L1P1	-4.38	1.3e-05	0.00104	-0.18	-0.13	Metabolite levels (HVA/MHPG ratio);	chr7:32424054	chr7:32580949~32761787:-
BRCA	cis	rs7927592	0.731	rs11228288	ENSG00000212093.1	AP000807.1	4.38	1.3e-05	0.00104	0.14	0.13	Total body bone mineral density;	chr11:68586082	chr11:68506083~68506166:-
BRCA	cis	rs9527	0.615	rs10883804	ENSG00000213061.2	PFN1P11	4.38	1.3e-05	0.00104	0.18	0.13	Arsenic metabolism;	chr10:102946763	chr10:102838011~102845473:-
BRCA	cis	rs7048146	0.966	rs7046719	ENSG00000213539.4	YBX1P6	4.38	1.31e-05	0.00104	0.15	0.13	Vascular brain injury;	chr9:109540085	chr9:109532830~109534332:-
BRCA	cis	rs4578769	0.959	rs12964817	ENSG00000265939.1	UBE2CP2	4.38	1.31e-05	0.00104	0.16	0.13	Eosinophil percentage of white cells;	chr18:22876657	chr18:22900486~22900995:-
BRCA	cis	rs62025270	0.632	rs17637411	ENSG00000259295.5	CSPG4P12	-4.38	1.31e-05	0.00104	-0.21	-0.13	Idiopathic pulmonary fibrosis;	chr15:85703216	chr15:85191438~85213905:+
BRCA	cis	rs62025270	0.58	rs62022938	ENSG00000259295.5	CSPG4P12	-4.38	1.31e-05	0.00104	-0.21	-0.13	Idiopathic pulmonary fibrosis;	chr15:85704764	chr15:85191438~85213905:+
BRCA	cis	rs12468226	0.938	rs10931993	ENSG00000272966.1	RP11-686O6.1	4.38	1.31e-05	0.00104	0.22	0.13	Urate levels;	chr2:202243017	chr2:202336739~202337200:+
BRCA	cis	rs62458065	1	rs6462363	ENSG00000229358.3	DPY19L1P1	-4.38	1.31e-05	0.00104	-0.18	-0.13	Metabolite levels (HVA/MHPG ratio);	chr7:32425147	chr7:32580949~32761787:-
BRCA	cis	rs7772486	0.846	rs6908063	ENSG00000270638.1	RP3-466P17.1	4.38	1.31e-05	0.00104	0.15	0.13	Lobe attachment (rater-scored or self-reported);	chr6:146082482	chr6:145735570~145737218:+
BRCA	cis	rs610932	0.517	rs673996	ENSG00000275344.1	MIR6503	4.38	1.31e-05	0.00104	0.13	0.13	Alzheimer's disease;	chr11:60226679	chr11:60209071~60209156:-
BRCA	cis	rs4869313	0.935	rs2617435	ENSG00000248734.2	CTD-2260A17.1	4.38	1.31e-05	0.00104	0.14	0.13	Pediatric autoimmune diseases;	chr5:96937330	chr5:96784777~96785999:+
BRCA	cis	rs4869313	0.869	rs1046396	ENSG00000248734.2	CTD-2260A17.1	4.38	1.31e-05	0.00104	0.14	0.13	Pediatric autoimmune diseases;	chr5:96937483	chr5:96784777~96785999:+
BRCA	cis	rs4869313	0.869	rs2762	ENSG00000248734.2	CTD-2260A17.1	4.38	1.31e-05	0.00104	0.14	0.13	Pediatric autoimmune diseases;	chr5:96937594	chr5:96784777~96785999:+
BRCA	cis	rs4869313	0.869	rs1423566	ENSG00000248734.2	CTD-2260A17.1	4.38	1.31e-05	0.00104	0.14	0.13	Pediatric autoimmune diseases;	chr5:96938063	chr5:96784777~96785999:+
BRCA	cis	rs4869313	0.869	rs2910788	ENSG00000248734.2	CTD-2260A17.1	4.38	1.31e-05	0.00104	0.14	0.13	Pediatric autoimmune diseases;	chr5:96939016	chr5:96784777~96785999:+
BRCA	cis	rs4869313	0.837	rs2548516	ENSG00000248734.2	CTD-2260A17.1	4.38	1.31e-05	0.00104	0.14	0.13	Pediatric autoimmune diseases;	chr5:96939709	chr5:96784777~96785999:+
BRCA	cis	rs78487399	0.808	rs113377695	ENSG00000234936.1	AC010883.5	4.38	1.31e-05	0.00104	0.19	0.13	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43608220	chr2:43229573~43233394:+
BRCA	cis	rs6012564	0.927	rs932451	ENSG00000222365.1	SNORD12B	-4.38	1.31e-05	0.00104	-0.14	-0.13	Anger;	chr20:48957061	chr20:49280319~49280409:+
BRCA	cis	rs10411936	0.712	rs8103486	ENSG00000280332.1	CTD-2013N17.6	4.38	1.31e-05	0.00104	0.12	0.13	Multiple sclerosis;White blood cell count;	chr19:16492296	chr19:16356329~16358327:-
BRCA	cis	rs10895275	0.886	rs2187525	ENSG00000277459.1	RP11-732A21.3	4.38	1.31e-05	0.00104	0.14	0.13	Migraine;	chr11:102178985	chr11:102109827~102110457:-
BRCA	cis	rs886774	0.866	rs2894482	ENSG00000273055.1	CTB-13F3.1	-4.38	1.31e-05	0.00104	-0.14	-0.13	Ulcerative colitis;	chr7:107869336	chr7:107942116~107942740:+
BRCA	cis	rs17597773	0.638	rs17596850	ENSG00000257551.1	HLX-AS1	-4.38	1.31e-05	0.00104	-0.16	-0.13	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220819001	chr1:220832763~220880140:-
BRCA	cis	rs6012564	1	rs3818262	ENSG00000227431.4	CSE1L-AS1	4.38	1.31e-05	0.00104	0.16	0.13	Anger;	chr20:49125019	chr20:49040463~49046044:-
BRCA	cis	rs11098499	0.909	rs1546502	ENSG00000260404.2	RP11-384K6.6	4.38	1.31e-05	0.00104	0.13	0.13	Corneal astigmatism;	chr4:119314743	chr4:118591773~118633729:+
BRCA	cis	rs8114671	0.967	rs2093058	ENSG00000279253.1	RP4-614O4.13	4.38	1.31e-05	0.00104	0.16	0.13	Height;	chr20:35203478	chr20:35262727~35264187:-
BRCA	cis	rs8040855	0.627	rs11631548	ENSG00000230373.7	GOLGA6L5P	4.38	1.31e-05	0.00104	0.17	0.13	Bulimia nervosa;	chr15:85076017	chr15:84507885~84516814:-
BRCA	cis	rs4218	0.597	rs12442301	ENSG00000259732.1	RP11-59H7.3	-4.38	1.31e-05	0.00104	-0.17	-0.13	Social communication problems;	chr15:59065968	chr15:59121034~59133250:+
BRCA	cis	rs2908197	0.662	rs917423	ENSG00000186704.9	DTX2P1	4.38	1.31e-05	0.00104	0.16	0.13	3-hydroxypropylmercapturic acid levels in smokers;	chr7:76355400	chr7:76978617~77004308:+
BRCA	cis	rs7772486	0.754	rs9399561	ENSG00000270638.1	RP3-466P17.1	4.38	1.31e-05	0.00104	0.15	0.13	Lobe attachment (rater-scored or self-reported);	chr6:145634551	chr6:145735570~145737218:+
BRCA	cis	rs56322409	0.865	rs2861154	ENSG00000226688.5	ENTPD1-AS1	4.38	1.31e-05	0.00104	0.16	0.13	Blood metabolite levels;	chr10:95863548	chr10:95753206~96090238:-
BRCA	cis	rs4478858	0.839	rs10798834	ENSG00000260386.4	LINC01225	-4.38	1.31e-05	0.00104	-0.16	-0.13	Alcohol dependence;	chr1:31236130	chr1:31500085~31540885:+
BRCA	cis	rs997295	0.675	rs12902804	ENSG00000270964.1	RP11-502I4.3	-4.38	1.31e-05	0.00104	-0.15	-0.13	Motion sickness;	chr15:67696320	chr15:67541072~67542604:-
BRCA	cis	rs9527	0.569	rs10786730	ENSG00000213061.2	PFN1P11	4.38	1.31e-05	0.00104	0.18	0.13	Arsenic metabolism;	chr10:102964443	chr10:102838011~102845473:-
BRCA	cis	rs35740288	0.77	rs11633893	ENSG00000202081.1	RNU6-1280P	-4.38	1.31e-05	0.00104	-0.18	-0.13	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85605207	chr15:85651522~85651628:-
BRCA	cis	rs757081	0.648	rs7940253	ENSG00000184669.7	OR7E14P	-4.38	1.31e-05	0.00104	-0.18	-0.13	Systolic blood pressure;	chr11:17259049	chr11:17013998~17053024:+
BRCA	cis	rs1867631	1	rs11208928	ENSG00000248458.2	RP4-598P13.1	4.38	1.31e-05	0.00104	0.14	0.13	Menopause (age at onset);	chr1:66623879	chr1:66665864~66677027:-
BRCA	cis	rs2880765	0.805	rs34598679	ENSG00000202081.1	RNU6-1280P	4.38	1.31e-05	0.00105	0.16	0.13	Coronary artery disease;	chr15:85498974	chr15:85651522~85651628:-
BRCA	cis	rs2880765	0.835	rs4344688	ENSG00000202081.1	RNU6-1280P	4.38	1.31e-05	0.00105	0.16	0.13	Coronary artery disease;	chr15:85499776	chr15:85651522~85651628:-
BRCA	cis	rs11892454	0.533	rs13392329	ENSG00000217643.1	PTGES3P2	-4.38	1.31e-05	0.00105	-0.14	-0.13	Heschl's gyrus morphology;	chr2:25842723	chr2:25822469~25822950:+
BRCA	cis	rs60843830	1	rs62114505	ENSG00000272342.1	RP13-539J13.1	4.38	1.31e-05	0.00105	0.17	0.13	Spherical equivalent (joint analysis main effects and education interaction);	chr2:242426	chr2:739588~740164:-
BRCA	cis	rs17270561	0.609	rs1317817	ENSG00000272462.2	U91328.19	-4.38	1.31e-05	0.00105	-0.16	-0.13	Iron status biomarkers;	chr6:25765149	chr6:25992662~26001775:+
BRCA	cis	rs6500637	0.686	rs8048701	ENSG00000267077.1	RP11-127I20.5	4.38	1.31e-05	0.00105	0.15	0.13	Cancer;	chr16:4863536	chr16:4795265~4796532:-
BRCA	cis	rs9788721	0.9	rs4243084	ENSG00000261762.1	RP11-650L12.2	-4.38	1.31e-05	0.00105	-0.16	-0.13	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78619330	chr15:78589123~78591276:-
BRCA	cis	rs13217239	0.646	rs62401067	ENSG00000224843.5	LINC00240	-4.38	1.31e-05	0.00105	-0.15	-0.13	Schizophrenia;	chr6:27050322	chr6:26956992~27023924:+
BRCA	cis	rs4415084	0.834	rs7711697	ENSG00000251141.4	RP11-53O19.1	4.38	1.31e-05	0.00105	0.12	0.13	Breast cancer;	chr5:44780301	chr5:44744900~44808777:-
BRCA	cis	rs490234	0.702	rs10120000	ENSG00000232630.1	PRPS1P2	-4.38	1.31e-05	0.00105	-0.14	-0.13	Mean arterial pressure;	chr9:125526149	chr9:125150653~125151589:+
BRCA	cis	rs9921338	0.961	rs4780357	ENSG00000262636.1	CTD-3088G3.4	-4.38	1.31e-05	0.00105	-0.22	-0.13	Vein graft stenosis in coronary artery bypass grafting;	chr16:11277114	chr16:11380859~11381118:-
BRCA	cis	rs11098499	0.909	rs10020034	ENSG00000225892.3	RP11-384K6.2	4.38	1.31e-05	0.00105	0.14	0.13	Corneal astigmatism;	chr4:119373176	chr4:118632274~118634759:+
BRCA	cis	rs78487399	0.808	rs77852659	ENSG00000234936.1	AC010883.5	4.38	1.31e-05	0.00105	0.21	0.13	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43534513	chr2:43229573~43233394:+
BRCA	cis	rs2073316	0.592	rs1366815	ENSG00000272716.1	RP11-563N4.1	4.38	1.31e-05	0.00105	0.15	0.13	Interleukin-18 levels;	chr2:31467955	chr2:32165046~32165757:-
BRCA	cis	rs12435908	1	rs1998035	ENSG00000276116.2	FUT8-AS1	-4.38	1.31e-05	0.00105	-0.21	-0.13	Ischemic stroke;	chr14:65659512	chr14:65411170~65412690:-
BRCA	cis	rs7246967	0.611	rs35355374	ENSG00000198153.8	ZNF849P	-4.38	1.31e-05	0.00105	-0.23	-0.13	Bronchopulmonary dysplasia;	chr19:22654899	chr19:22685167~22686732:+
BRCA	cis	rs6545883	0.507	rs2442025	ENSG00000273302.1	RP11-493E12.2	-4.38	1.31e-05	0.00105	-0.12	-0.13	Tuberculosis;	chr2:61344310	chr2:61199979~61200769:+
BRCA	cis	rs2115630	0.967	rs8028490	ENSG00000275120.1	RP11-182J1.17	-4.38	1.31e-05	0.00105	-0.16	-0.13	P wave terminal force;	chr15:84734657	chr15:84599434~84606463:-
BRCA	cis	rs755249	0.567	rs4660208	ENSG00000182109.6	RP11-69E11.4	4.38	1.31e-05	0.00105	0.19	0.13	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39256542	chr1:39522280~39546187:-
BRCA	cis	rs1153858	1	rs7171577	ENSG00000275672.1	GATM-AS1	-4.38	1.31e-05	0.00105	-0.17	-0.13	Homoarginine levels;	chr15:45335781	chr15:45378700~45380123:+
BRCA	cis	rs6012564	1	rs2075678	ENSG00000227431.4	CSE1L-AS1	4.38	1.31e-05	0.00105	0.17	0.13	Anger;	chr20:49084802	chr20:49040463~49046044:-
BRCA	cis	rs9308731	0.644	rs1837369	ENSG00000230499.1	AC108463.1	-4.38	1.32e-05	0.00105	-0.15	-0.13	Chronic lymphocytic leukemia;	chr2:111116699	chr2:111195963~111206494:+
BRCA	cis	rs2832191	1	rs9984793	ENSG00000236056.1	GAPDHP14	4.38	1.32e-05	0.00105	0.15	0.13	Dental caries;	chr21:29114150	chr21:29222321~29223257:+
BRCA	cis	rs7665090	1	rs1054029	ENSG00000251288.2	RP11-10L12.2	-4.38	1.32e-05	0.00105	-0.16	-0.13	Primary biliary cholangitis;	chr4:102631896	chr4:102751401~102752641:+
BRCA	cis	rs7665090	1	rs3194585	ENSG00000251288.2	RP11-10L12.2	-4.38	1.32e-05	0.00105	-0.16	-0.13	Primary biliary cholangitis;	chr4:102631933	chr4:102751401~102752641:+
BRCA	cis	rs10986311	0.747	rs2282084	ENSG00000227200.1	RP11-121A14.3	-4.38	1.32e-05	0.00105	-0.16	-0.13	Vitiligo;	chr9:124259253	chr9:124262876~124265809:+
BRCA	cis	rs11758351	0.66	rs56398712	ENSG00000241549.7	GUSBP2	-4.38	1.32e-05	0.00105	-0.19	-0.13	Renal underexcretion gout;Gout;	chr6:26213640	chr6:26871484~26956554:-
BRCA	cis	rs1555322	0.929	rs2247828	ENSG00000126005.14	MMP24-AS1	4.38	1.32e-05	0.00105	0.21	0.13	Attention deficit hyperactivity disorder;	chr20:35252136	chr20:35216462~35278131:-
BRCA	cis	rs829883	0.763	rs249843	ENSG00000227825.4	SLC9A7P1	4.38	1.32e-05	0.00105	0.16	0.13	Colorectal adenoma (advanced);	chr12:98477209	chr12:98453835~98457145:-
BRCA	cis	rs1223397	0.651	rs488297	ENSG00000215022.6	RP1-257A7.4	-4.38	1.32e-05	0.00105	-0.16	-0.13	Blood pressure;	chr6:13300264	chr6:13264861~13295586:-
BRCA	cis	rs4578769	0.918	rs8089471	ENSG00000265939.1	UBE2CP2	4.38	1.32e-05	0.00105	0.16	0.13	Eosinophil percentage of white cells;	chr18:22892994	chr18:22900486~22900995:-
BRCA	cis	rs1950832	0.723	rs853238	ENSG00000258636.1	CTD-2298J14.2	4.38	1.32e-05	0.00105	0.16	0.13	Urate levels in obese individuals;	chr14:41646851	chr14:41587861~41604856:-
BRCA	cis	rs757081	0.648	rs11024223	ENSG00000184669.7	OR7E14P	4.38	1.32e-05	0.00105	0.18	0.13	Systolic blood pressure;	chr11:17256146	chr11:17013998~17053024:+
BRCA	cis	rs6545883	0.929	rs2593635	ENSG00000270820.4	RP11-355B11.2	-4.38	1.32e-05	0.00105	-0.16	-0.13	Tuberculosis;	chr2:61407571	chr2:61471188~61484130:+
BRCA	cis	rs6496044	0.568	rs11636764	ENSG00000202081.1	RNU6-1280P	4.38	1.32e-05	0.00105	0.16	0.13	Interstitial lung disease;	chr15:85536520	chr15:85651522~85651628:-
BRCA	cis	rs6600671	1	rs10794671	ENSG00000270392.2	PFN1P2	4.38	1.32e-05	0.00105	0.15	0.13	Hip geometry;	chr1:121426382	chr1:120432204~120434052:-
BRCA	cis	rs2154319	0.666	rs3845571	ENSG00000235358.1	RP11-399E6.1	-4.38	1.32e-05	0.00105	-0.18	-0.13	Height;	chr1:41250367	chr1:41242373~41284861:+
BRCA	cis	rs763121	0.962	rs2071887	ENSG00000228274.3	RP3-508I15.9	-4.38	1.32e-05	0.00105	-0.14	-0.13	Menopause (age at onset);	chr22:38483005	chr22:38667585~38681820:-
BRCA	cis	rs35306767	0.953	rs11253517	ENSG00000229869.1	RP11-363N22.2	4.38	1.32e-05	0.00105	0.2	0.13	Eosinophil percentage of granulocytes;	chr10:924584	chr10:933026~942743:+
BRCA	cis	rs4218	0.681	rs10518996	ENSG00000259732.1	RP11-59H7.3	-4.38	1.32e-05	0.00105	-0.16	-0.13	Social communication problems;	chr15:59085247	chr15:59121034~59133250:+
BRCA	cis	rs2136613	0.533	rs10761665	ENSG00000238280.1	RP11-436D10.3	-4.38	1.32e-05	0.00105	-0.17	-0.13	Selective IgA deficiency;	chr10:62848538	chr10:62793562~62805887:-
BRCA	cis	rs2731006	0.591	rs2678146	ENSG00000257114.2	RP11-25I15.3	4.38	1.32e-05	0.00105	0.22	0.13	Panic disorder;	chr12:42783878	chr12:42692216~42717119:+
BRCA	cis	rs12819124	0.502	rs10875718	ENSG00000273765.1	RP11-370I10.11	4.38	1.32e-05	0.00105	0.16	0.13	Glycated hemoglobin levels;	chr12:48017319	chr12:48360920~48361377:+
BRCA	cis	rs6500602	0.929	rs9926114	ENSG00000280063.1	RP11-295D4.3	4.38	1.32e-05	0.00105	0.1	0.13	Schizophrenia;	chr16:4428321	chr16:4346694~4348648:-
BRCA	cis	rs11976180	1	rs13226728	ENSG00000244479.5	OR2A1-AS1	4.38	1.32e-05	0.00105	0.18	0.13	Obesity-related traits;	chr7:144049485	chr7:144251264~144356181:-
BRCA	cis	rs3824867	0.879	rs10769267	ENSG00000280615.1	Y_RNA	-4.38	1.32e-05	0.00105	-0.16	-0.13	Mean corpuscular hemoglobin;	chr11:47438547	chr11:47614898~47614994:-
BRCA	cis	rs3824867	0.676	rs7104366	ENSG00000280615.1	Y_RNA	-4.38	1.32e-05	0.00105	-0.16	-0.13	Mean corpuscular hemoglobin;	chr11:47440564	chr11:47614898~47614994:-
BRCA	cis	rs3824867	0.92	rs4752836	ENSG00000280615.1	Y_RNA	-4.38	1.32e-05	0.00105	-0.16	-0.13	Mean corpuscular hemoglobin;	chr11:47443543	chr11:47614898~47614994:-
BRCA	cis	rs11096990	0.576	rs2008679	ENSG00000249685.1	RP11-360F5.3	-4.38	1.32e-05	0.00105	-0.16	-0.13	Cognitive function;	chr4:39266385	chr4:39133913~39135608:+
BRCA	cis	rs4919687	0.55	rs7907503	ENSG00000213061.2	PFN1P11	4.38	1.32e-05	0.00105	0.19	0.13	Colorectal cancer;	chr10:102680293	chr10:102838011~102845473:-
BRCA	cis	rs2179367	0.959	rs9373592	ENSG00000223701.3	RAET1E-AS1	4.38	1.32e-05	0.00105	0.17	0.13	Dupuytren's disease;	chr6:149412119	chr6:149884431~149919508:+
BRCA	cis	rs6452524	1	rs10474093	ENSG00000281327.1	LINC01338	4.38	1.32e-05	0.00105	0.15	0.13	Hypertension (SNP x SNP interaction);	chr5:83141612	chr5:82850864~82859836:-
BRCA	cis	rs6452524	0.935	rs10473868	ENSG00000281327.1	LINC01338	4.38	1.32e-05	0.00105	0.15	0.13	Hypertension (SNP x SNP interaction);	chr5:83141628	chr5:82850864~82859836:-
BRCA	cis	rs8058578	1	rs56656810	ENSG00000260911.2	RP11-196G11.2	4.38	1.32e-05	0.00105	0.13	0.13	Multiple myeloma;	chr16:30777438	chr16:31043150~31049868:+
BRCA	cis	rs7312933	0.558	rs61926593	ENSG00000257225.1	RP11-328C8.4	-4.38	1.32e-05	0.00105	-0.16	-0.13	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42425110	chr12:42459366~42466128:+
BRCA	cis	rs7312933	0.558	rs11181502	ENSG00000257225.1	RP11-328C8.4	-4.38	1.32e-05	0.00105	-0.16	-0.13	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42430031	chr12:42459366~42466128:+
BRCA	cis	rs6968419	0.714	rs12666168	ENSG00000279086.1	RP11-667F14.1	-4.38	1.32e-05	0.00105	-0.15	-0.13	Intraocular pressure;	chr7:116216627	chr7:116209234~116211511:-
BRCA	cis	rs10129255	1	rs10141557	ENSG00000274576.2	IGHV2-70	4.38	1.32e-05	0.00105	0.12	0.13	Kawasaki disease;	chr14:106767990	chr14:106770577~106771020:-
BRCA	cis	rs2832191	0.967	rs2898160	ENSG00000236056.1	GAPDHP14	4.38	1.32e-05	0.00105	0.15	0.13	Dental caries;	chr21:29115175	chr21:29222321~29223257:+
BRCA	cis	rs10411936	1	rs7256818	ENSG00000280332.1	CTD-2013N17.6	-4.38	1.32e-05	0.00105	-0.11	-0.13	Multiple sclerosis;White blood cell count;	chr19:16447955	chr19:16356329~16358327:-
BRCA	cis	rs11098499	0.955	rs1397608	ENSG00000250412.1	KLHL2P1	4.38	1.32e-05	0.00105	0.16	0.13	Corneal astigmatism;	chr4:119240589	chr4:119334329~119378233:+
BRCA	cis	rs11098499	0.955	rs7685268	ENSG00000250412.1	KLHL2P1	4.38	1.32e-05	0.00105	0.16	0.13	Corneal astigmatism;	chr4:119241033	chr4:119334329~119378233:+
BRCA	cis	rs11098499	0.955	rs7684942	ENSG00000250412.1	KLHL2P1	4.38	1.32e-05	0.00105	0.16	0.13	Corneal astigmatism;	chr4:119241046	chr4:119334329~119378233:+
BRCA	cis	rs56322409	0.897	rs11593761	ENSG00000226688.5	ENTPD1-AS1	4.38	1.32e-05	0.00105	0.15	0.13	Blood metabolite levels;	chr10:95777855	chr10:95753206~96090238:-
BRCA	cis	rs2303319	0.504	rs66761688	ENSG00000227403.1	AC009299.3	4.38	1.32e-05	0.00105	0.32	0.13	Cognitive function;	chr2:161722401	chr2:161244739~161249050:+
BRCA	cis	rs1858037	0.867	rs4671658	ENSG00000237979.1	AC007389.1	-4.38	1.32e-05	0.00105	-0.17	-0.13	Rheumatoid arthritis;	chr2:65334258	chr2:65500993~65502138:-
BRCA	cis	rs6840360	0.582	rs2709827	ENSG00000251611.1	RP11-610P16.1	-4.38	1.32e-05	0.00105	-0.12	-0.13	Intelligence (multi-trait analysis);	chr4:151410100	chr4:151407551~151408835:-
BRCA	cis	rs56322409	0.897	rs12358481	ENSG00000226688.5	ENTPD1-AS1	4.38	1.33e-05	0.00105	0.15	0.13	Blood metabolite levels;	chr10:95746346	chr10:95753206~96090238:-
BRCA	cis	rs56322409	0.897	rs17462179	ENSG00000226688.5	ENTPD1-AS1	4.38	1.33e-05	0.00105	0.15	0.13	Blood metabolite levels;	chr10:95746948	chr10:95753206~96090238:-
BRCA	cis	rs56322409	0.897	rs11597321	ENSG00000226688.5	ENTPD1-AS1	4.38	1.33e-05	0.00105	0.15	0.13	Blood metabolite levels;	chr10:95752192	chr10:95753206~96090238:-
BRCA	cis	rs56322409	0.865	rs11593044	ENSG00000226688.5	ENTPD1-AS1	4.38	1.33e-05	0.00105	0.15	0.13	Blood metabolite levels;	chr10:95752208	chr10:95753206~96090238:-
BRCA	cis	rs1510272	0.961	rs13319258	ENSG00000243926.1	TIPARP-AS1	-4.38	1.33e-05	0.00106	-0.15	-0.13	Testicular germ cell tumor;	chr3:156586782	chr3:156671862~156674378:-
BRCA	cis	rs7260598	0.792	rs11669251	ENSG00000268442.1	CTD-2027I19.2	4.38	1.33e-05	0.00106	0.22	0.13	Response to taxane treatment (placlitaxel);	chr19:24154192	chr19:24162370~24163425:-
BRCA	cis	rs6893300	1	rs62406176	ENSG00000250999.1	RP11-1379J22.5	4.38	1.33e-05	0.00106	0.19	0.13	Resting heart rate;	chr5:179737142	chr5:179657762~179664432:+
BRCA	cis	rs17684571	0.7	rs13203327	ENSG00000231441.1	RP11-472M19.2	4.38	1.33e-05	0.00106	0.23	0.13	Schizophrenia;	chr6:56792498	chr6:56844002~56864078:+
BRCA	cis	rs17684571	0.7	rs71564854	ENSG00000231441.1	RP11-472M19.2	4.38	1.33e-05	0.00106	0.23	0.13	Schizophrenia;	chr6:56794662	chr6:56844002~56864078:+
BRCA	cis	rs875971	1	rs1544549	ENSG00000236529.1	RP13-254B10.1	-4.38	1.33e-05	0.00106	-0.15	-0.13	Aortic root size;	chr7:66625676	chr7:65840212~65840596:+
BRCA	cis	rs3892630	1	rs3892630	ENSG00000267567.1	CTD-2538C1.3	-4.38	1.33e-05	0.00106	-0.21	-0.13	Red blood cell traits;	chr19:32690578	chr19:32718298~32719595:-
BRCA	cis	rs5758511	0.68	rs1001586	ENSG00000227370.1	RP4-669P10.19	4.38	1.33e-05	0.00106	0.18	0.13	Birth weight;	chr22:42274287	chr22:42132543~42132998:+
BRCA	cis	rs853679	0.517	rs9380052	ENSG00000216901.1	AL022393.7	4.38	1.33e-05	0.00106	0.19	0.13	Depression;	chr6:28096845	chr6:28176188~28176674:+
BRCA	cis	rs6968419	0.747	rs1000966	ENSG00000279086.1	RP11-667F14.1	-4.38	1.33e-05	0.00106	-0.15	-0.13	Intraocular pressure;	chr7:116222848	chr7:116209234~116211511:-
BRCA	cis	rs867371	1	rs6495643	ENSG00000278603.1	RP13-608F4.5	4.38	1.33e-05	0.00106	0.18	0.13	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82186913	chr15:82472203~82472426:+
BRCA	cis	rs7200543	1	rs6498541	ENSG00000260872.1	RP11-680G24.5	-4.38	1.33e-05	0.00106	-0.14	-0.13	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15046800	chr16:15018106~15020488:-
BRCA	cis	rs721917	0.506	rs2758543	ENSG00000278616.1	BEND3P3	-4.38	1.33e-05	0.00106	-0.12	-0.13	Chronic obstructive pulmonary disease;	chr10:79902710	chr10:79682997~79685436:+
BRCA	cis	rs721917	0.525	rs2250473	ENSG00000278616.1	BEND3P3	-4.38	1.33e-05	0.00106	-0.12	-0.13	Chronic obstructive pulmonary disease;	chr10:79904639	chr10:79682997~79685436:+
BRCA	cis	rs8103278	1	rs9676288	ENSG00000267395.4	AC074212.6	4.38	1.33e-05	0.00106	0.14	0.13	Coronary artery disease;	chr19:45788802	chr19:45767796~45772504:+
BRCA	cis	rs10129255	0.5	rs12101190	ENSG00000211959.2	IGHV4-39	4.38	1.33e-05	0.00106	0.09	0.13	Kawasaki disease;	chr14:106784149	chr14:106421711~106422218:-
BRCA	cis	rs10129255	0.518	rs8004895	ENSG00000211959.2	IGHV4-39	4.38	1.33e-05	0.00106	0.09	0.13	Kawasaki disease;	chr14:106785139	chr14:106421711~106422218:-
BRCA	cis	rs16958440	0.867	rs12386076	ENSG00000267724.1	RP11-49K24.8	4.38	1.33e-05	0.00106	0.26	0.13	Sitting height ratio;	chr18:47146969	chr18:47105946~47108062:+
BRCA	cis	rs12612619	0.732	rs1866655	ENSG00000272148.1	RP11-195B17.1	-4.38	1.33e-05	0.00106	-0.15	-0.13	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:26985999	chr2:27062428~27062907:-
BRCA	cis	rs2617170	0.961	rs1841958	ENSG00000245648.1	RP11-277P12.20	4.38	1.33e-05	0.00106	0.18	0.13	Behcet's disease;	chr12:10409490	chr12:10363769~10398506:+
BRCA	cis	rs9393692	0.627	rs1059486	ENSG00000241549.7	GUSBP2	-4.38	1.33e-05	0.00106	-0.14	-0.13	Educational attainment;	chr6:26199855	chr6:26871484~26956554:-
BRCA	cis	rs73186030	0.92	rs73186050	ENSG00000272758.4	RP11-299J3.8	4.38	1.33e-05	0.00106	0.2	0.13	Serum parathyroid hormone levels;	chr3:122321081	chr3:122416207~122443180:+
BRCA	cis	rs7572733	0.84	rs12472359	ENSG00000231621.1	AC013264.2	4.38	1.33e-05	0.00106	0.12	0.13	Dermatomyositis;	chr2:197723141	chr2:197197991~197199273:+
BRCA	cis	rs9952991	0.941	rs2847280	ENSG00000260302.1	RP11-973H7.1	-4.38	1.33e-05	0.00106	-0.22	-0.13	Inflammatory skin disease;	chr18:12779343	chr18:12774651~12775923:-
BRCA	cis	rs16958440	0.867	rs79078752	ENSG00000267724.1	RP11-49K24.8	4.38	1.33e-05	0.00106	0.26	0.13	Sitting height ratio;	chr18:47141091	chr18:47105946~47108062:+
BRCA	cis	rs16958440	0.867	rs61689863	ENSG00000267724.1	RP11-49K24.8	4.38	1.33e-05	0.00106	0.26	0.13	Sitting height ratio;	chr18:47142786	chr18:47105946~47108062:+
BRCA	cis	rs16958440	0.867	rs80064497	ENSG00000267724.1	RP11-49K24.8	4.38	1.33e-05	0.00106	0.26	0.13	Sitting height ratio;	chr18:47143282	chr18:47105946~47108062:+
BRCA	cis	rs16958440	0.867	rs78547658	ENSG00000267724.1	RP11-49K24.8	4.38	1.33e-05	0.00106	0.26	0.13	Sitting height ratio;	chr18:47143481	chr18:47105946~47108062:+
BRCA	cis	rs16958440	0.867	rs12386092	ENSG00000267724.1	RP11-49K24.8	4.38	1.33e-05	0.00106	0.26	0.13	Sitting height ratio;	chr18:47145687	chr18:47105946~47108062:+
BRCA	cis	rs8114671	0.805	rs4616	ENSG00000279253.1	RP4-614O4.13	4.38	1.33e-05	0.00106	0.16	0.13	Height;	chr20:35002555	chr20:35262727~35264187:-
BRCA	cis	rs2640806	0.505	rs11984998	ENSG00000253105.4	KB-1448A5.1	4.38	1.33e-05	0.00106	0.16	0.13	Obesity-related traits;	chr8:96351786	chr8:96371865~96387438:-
BRCA	cis	rs7267979	0.866	rs2424698	ENSG00000125804.12	FAM182A	-4.38	1.33e-05	0.00106	-0.18	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25275470	chr20:26054655~26086917:+
BRCA	cis	rs7674212	0.539	rs2866635	ENSG00000246560.2	RP11-10L12.4	4.38	1.33e-05	0.00106	0.14	0.13	Type 2 diabetes;	chr4:103200419	chr4:102828055~102844075:+
BRCA	cis	rs7200543	0.883	rs4985148	ENSG00000258354.1	MIR3180-1	-4.38	1.33e-05	0.00106	-0.18	-0.13	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15053931	chr16:14909887~14911345:-
BRCA	cis	rs427691	0.545	rs25914	ENSG00000271849.1	CTC-332L22.1	-4.38	1.33e-05	0.00106	-0.21	-0.13	Autism spectrum disorder or schizophrenia;	chr5:109657320	chr5:109687802~109688329:-
BRCA	cis	rs308403	0.506	rs309365	ENSG00000224786.1	CETN4P	4.38	1.33e-05	0.00106	0.2	0.13	Blood protein levels;	chr4:122738188	chr4:122730548~122732193:-
BRCA	cis	rs375066	0.935	rs371875	ENSG00000267191.1	RP11-15A1.2	-4.38	1.33e-05	0.00106	-0.17	-0.13	Breast cancer;	chr19:43889105	chr19:43902001~43926545:+
BRCA	cis	rs2243480	1	rs11538349	ENSG00000222364.1	RNU6-96P	-4.38	1.33e-05	0.00106	-0.24	-0.13	Diabetic kidney disease;	chr7:65956884	chr7:66395191~66395286:+
BRCA	cis	rs7267979	0.844	rs8184820	ENSG00000125804.12	FAM182A	4.38	1.33e-05	0.00106	0.18	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25269941	chr20:26054655~26086917:+
BRCA	cis	rs409045	1	rs455919	ENSG00000271874.1	CTD-2024P10.2	-4.38	1.33e-05	0.00106	-0.18	-0.13	Left ventricular mass;	chr5:34637098	chr5:34651457~34651888:-
BRCA	cis	rs2303319	0.504	rs12474470	ENSG00000227403.1	AC009299.3	4.38	1.33e-05	0.00106	0.33	0.13	Cognitive function;	chr2:161678826	chr2:161244739~161249050:+
BRCA	cis	rs2303319	0.504	rs16846026	ENSG00000227403.1	AC009299.3	4.38	1.33e-05	0.00106	0.33	0.13	Cognitive function;	chr2:161681181	chr2:161244739~161249050:+
BRCA	cis	rs875971	1	rs709595	ENSG00000229180.5	GS1-124K5.11	4.38	1.33e-05	0.00106	0.12	0.13	Aortic root size;	chr7:66352346	chr7:66526088~66542624:-
BRCA	cis	rs875971	1	rs811880	ENSG00000229180.5	GS1-124K5.11	4.38	1.33e-05	0.00106	0.12	0.13	Aortic root size;	chr7:66353659	chr7:66526088~66542624:-
BRCA	cis	rs875971	1	rs7781698	ENSG00000229180.5	GS1-124K5.11	4.38	1.33e-05	0.00106	0.12	0.13	Aortic root size;	chr7:66431325	chr7:66526088~66542624:-
BRCA	cis	rs5742933	0.69	rs62183657	ENSG00000253559.1	OSGEPL1-AS1	-4.38	1.33e-05	0.00106	-0.2	-0.13	Ferritin levels;	chr2:189669448	chr2:189762704~189765556:+
BRCA	cis	rs1048886	0.938	rs9294871	ENSG00000271967.1	RP11-134K13.4	-4.38	1.33e-05	0.00106	-0.18	-0.13	Type 2 diabetes;	chr6:70463524	chr6:70596438~70596980:+
BRCA	cis	rs1910358	0.614	rs1948767	ENSG00000248874.4	C5orf17	-4.38	1.33e-05	0.00106	-0.17	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23953017	chr5:23951348~24178263:+
BRCA	cis	rs1910358	0.69	rs1604459	ENSG00000248874.4	C5orf17	-4.38	1.33e-05	0.00106	-0.17	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23955425	chr5:23951348~24178263:+
BRCA	cis	rs1910358	0.614	rs1604457	ENSG00000248874.4	C5orf17	-4.38	1.33e-05	0.00106	-0.17	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23955593	chr5:23951348~24178263:+
BRCA	cis	rs1910358	0.614	rs7707657	ENSG00000248874.4	C5orf17	-4.38	1.33e-05	0.00106	-0.17	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23957153	chr5:23951348~24178263:+
BRCA	cis	rs1910358	0.614	rs1501954	ENSG00000248874.4	C5orf17	-4.38	1.33e-05	0.00106	-0.17	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23957889	chr5:23951348~24178263:+
BRCA	cis	rs1910358	0.614	rs34023362	ENSG00000248874.4	C5orf17	-4.38	1.33e-05	0.00106	-0.17	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23958748	chr5:23951348~24178263:+
BRCA	cis	rs524281	0.861	rs9736673	ENSG00000255557.1	RP11-770G2.2	4.38	1.33e-05	0.00106	0.18	0.13	Electroencephalogram traits;	chr11:66156553	chr11:65745729~65771585:+
BRCA	cis	rs2108622	0.683	rs111388185	ENSG00000267218.2	AC005336.5	4.38	1.33e-05	0.00106	0.16	0.13	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15866604	chr19:15902300~15903238:-
BRCA	cis	rs2108622	0.683	rs112571591	ENSG00000267218.2	AC005336.5	4.38	1.33e-05	0.00106	0.16	0.13	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15866635	chr19:15902300~15903238:-
BRCA	cis	rs2108622	0.647	rs111427692	ENSG00000267218.2	AC005336.5	4.38	1.33e-05	0.00106	0.16	0.13	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15866669	chr19:15902300~15903238:-
BRCA	cis	rs1555322	1	rs2425036	ENSG00000279253.1	RP4-614O4.13	-4.38	1.33e-05	0.00106	-0.22	-0.13	Attention deficit hyperactivity disorder;	chr20:35268178	chr20:35262727~35264187:-
BRCA	cis	rs7572733	0.935	rs2880389	ENSG00000231621.1	AC013264.2	-4.38	1.33e-05	0.00106	-0.12	-0.13	Dermatomyositis;	chr2:197936983	chr2:197197991~197199273:+
BRCA	cis	rs801193	0.66	rs2659914	ENSG00000236529.1	RP13-254B10.1	4.38	1.33e-05	0.00106	0.15	0.13	Aortic root size;	chr7:66691927	chr7:65840212~65840596:+
BRCA	cis	rs801193	0.591	rs2707839	ENSG00000236529.1	RP13-254B10.1	4.38	1.33e-05	0.00106	0.15	0.13	Aortic root size;	chr7:66728097	chr7:65840212~65840596:+
BRCA	cis	rs7730262	1	rs7730262	ENSG00000247828.6	TMEM161B-AS1	4.38	1.33e-05	0.00106	0.36	0.13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr5:88892421	chr5:88268895~88436685:+
BRCA	cis	rs6968419	0.788	rs7459377	ENSG00000279086.1	RP11-667F14.1	-4.38	1.33e-05	0.00106	-0.15	-0.13	Intraocular pressure;	chr7:116185554	chr7:116209234~116211511:-
BRCA	cis	rs2574985	0.813	rs1203403	ENSG00000231345.3	BEND3P1	-4.38	1.33e-05	0.00106	-0.23	-0.13	Subjective well-being;	chr10:50439428	chr10:50655967~50660472:+
BRCA	cis	rs7703051	1	rs12654264	ENSG00000271815.1	CTD-2235C13.3	4.38	1.33e-05	0.00106	0.17	0.13	Age-related diseases, mortality and associated endophenotypes;LDL cholesterol;Age-related disease endophenotypes;	chr5:75352778	chr5:75363760~75364242:+
BRCA	cis	rs875971	0.66	rs2013222	ENSG00000229180.5	GS1-124K5.11	-4.38	1.33e-05	0.00106	-0.11	-0.13	Aortic root size;	chr7:66570949	chr7:66526088~66542624:-
BRCA	cis	rs913672	0.609	rs4811019	ENSG00000224397.4	LINC01272	-4.38	1.33e-05	0.00106	-0.15	-0.13	Monocyte count;	chr20:50281932	chr20:50267486~50279795:+
BRCA	cis	rs4908760	0.811	rs301802	ENSG00000270282.1	RP5-1115A15.2	4.38	1.33e-05	0.00106	0.14	0.13	Vitiligo;	chr1:8437247	chr1:8512653~8513021:+
BRCA	cis	rs6700559	0.692	rs12126676	ENSG00000260088.1	RP11-92G12.3	4.38	1.34e-05	0.00106	0.17	0.13	Coronary artery disease;	chr1:200631692	chr1:200669507~200694250:+
BRCA	cis	rs6088580	0.634	rs6058052	ENSG00000276073.1	RP5-1125A11.7	-4.38	1.34e-05	0.00106	-0.14	-0.13	Glomerular filtration rate (creatinine);	chr20:34459279	chr20:33985617~33988989:-
BRCA	cis	rs6088580	0.634	rs6087588	ENSG00000276073.1	RP5-1125A11.7	-4.38	1.34e-05	0.00106	-0.14	-0.13	Glomerular filtration rate (creatinine);	chr20:34478564	chr20:33985617~33988989:-
BRCA	cis	rs6012564	0.89	rs6066976	ENSG00000227431.4	CSE1L-AS1	4.38	1.34e-05	0.00106	0.16	0.13	Anger;	chr20:49134464	chr20:49040463~49046044:-
BRCA	cis	rs7160336	1	rs7148058	ENSG00000259065.1	RP5-1021I20.1	4.38	1.34e-05	0.00106	0.15	0.13	Blood protein levels;	chr14:74035077	chr14:73787360~73803270:+
BRCA	cis	rs7160336	1	rs11846445	ENSG00000259065.1	RP5-1021I20.1	4.38	1.34e-05	0.00106	0.15	0.13	Blood protein levels;	chr14:74035290	chr14:73787360~73803270:+
BRCA	cis	rs7811142	1	rs11763414	ENSG00000078319.8	PMS2P1	-4.38	1.34e-05	0.00106	-0.21	-0.13	Platelet count;	chr7:100419221	chr7:100320992~100341908:-
BRCA	cis	rs997295	0.713	rs17243334	ENSG00000270964.1	RP11-502I4.3	-4.38	1.34e-05	0.00106	-0.15	-0.13	Motion sickness;	chr15:67720741	chr15:67541072~67542604:-
BRCA	cis	rs6012564	0.793	rs6125552	ENSG00000227431.4	CSE1L-AS1	4.38	1.34e-05	0.00106	0.16	0.13	Anger;	chr20:49107788	chr20:49040463~49046044:-
BRCA	cis	rs73186030	1	rs55838400	ENSG00000272758.4	RP11-299J3.8	4.38	1.34e-05	0.00106	0.21	0.13	Serum parathyroid hormone levels;	chr3:122313446	chr3:122416207~122443180:+
BRCA	cis	rs1836229	0.874	rs7864437	ENSG00000225706.1	PTPRD-AS1	-4.38	1.34e-05	0.00106	-0.15	-0.13	Restless legs syndrome;	chr9:8824219	chr9:8858130~8862255:+
BRCA	cis	rs2235642	0.505	rs56359342	ENSG00000280231.1	LA16c-380F5.3	-4.38	1.34e-05	0.00106	-0.18	-0.13	Coronary artery disease;	chr16:1604947	chr16:1553655~1554130:-
BRCA	cis	rs728478	0.566	rs7221185	ENSG00000266992.1	DHX40P1	4.38	1.34e-05	0.00106	0.16	0.13	QT interval;	chr17:59399292	chr17:59976009~60002384:-
BRCA	cis	rs73242632	1	rs73242632	ENSG00000269949.1	RP11-738E22.3	4.38	1.34e-05	0.00106	0.32	0.13	Congenital heart disease (maternal effect);	chr4:57027604	chr4:56960927~56961373:-
BRCA	cis	rs1014246	1	rs2240706	ENSG00000232767.1	RP11-498B4.5	-4.38	1.34e-05	0.00106	-0.14	-0.13	Age at smoking initiation in chronic obstructive pulmonary disease;	chr10:116706786	chr10:116670103~116672739:+
BRCA	cis	rs2919009	0.6	rs55706145	ENSG00000271670.1	RP11-95I16.4	4.37	1.34e-05	0.00106	0.19	0.13	Obesity-related traits;	chr10:120790581	chr10:120879256~120880667:-
BRCA	cis	rs3617	0.652	rs60332615	ENSG00000279144.1	RP11-894J14.2	-4.37	1.34e-05	0.00106	-0.17	-0.13	Red blood cell count;Autism spectrum disorder or schizophrenia;	chr3:52833579	chr3:52848085~52848553:-
BRCA	cis	rs9788721	0.775	rs8040868	ENSG00000261762.1	RP11-650L12.2	4.37	1.34e-05	0.00106	0.15	0.13	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78618839	chr15:78589123~78591276:-
BRCA	cis	rs13113518	1	rs11934897	ENSG00000273257.1	RP11-177J6.1	4.37	1.34e-05	0.00106	0.17	0.13	Height;	chr4:55553396	chr4:55387949~55388271:+
BRCA	cis	rs13113518	0.934	rs11932293	ENSG00000273257.1	RP11-177J6.1	4.37	1.34e-05	0.00106	0.17	0.13	Height;	chr4:55554025	chr4:55387949~55388271:+
BRCA	cis	rs6012564	1	rs6012564	ENSG00000227431.4	CSE1L-AS1	4.37	1.34e-05	0.00106	0.16	0.13	Anger;	chr20:48925063	chr20:49040463~49046044:-
BRCA	cis	rs1371614	0.566	rs10184824	ENSG00000229122.1	AGBL5-IT1	-4.37	1.34e-05	0.00106	-0.14	-0.13	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26955084	chr2:27061038~27061815:+
BRCA	cis	rs9467773	0.523	rs2498399	ENSG00000241549.7	GUSBP2	4.37	1.34e-05	0.00106	0.15	0.13	Intelligence (multi-trait analysis);	chr6:26795343	chr6:26871484~26956554:-
BRCA	cis	rs9834975	0.903	rs56131302	ENSG00000272758.4	RP11-299J3.8	-4.37	1.34e-05	0.00106	-0.13	-0.13	Diastolic blood pressure;	chr3:122499141	chr3:122416207~122443180:+
BRCA	cis	rs9834975	0.935	rs6438735	ENSG00000272758.4	RP11-299J3.8	-4.37	1.34e-05	0.00106	-0.13	-0.13	Diastolic blood pressure;	chr3:122500539	chr3:122416207~122443180:+
BRCA	cis	rs6968419	0.788	rs6946058	ENSG00000279086.1	RP11-667F14.1	-4.37	1.34e-05	0.00106	-0.15	-0.13	Intraocular pressure;	chr7:116199199	chr7:116209234~116211511:-
BRCA	cis	rs6968419	0.963	rs940471	ENSG00000279086.1	RP11-667F14.1	-4.37	1.34e-05	0.00106	-0.13	-0.13	Intraocular pressure;	chr7:116201154	chr7:116209234~116211511:-
BRCA	cis	rs11673344	0.523	rs7245453	ENSG00000226686.6	LINC01535	4.37	1.34e-05	0.00106	0.17	0.13	Obesity-related traits;	chr19:37043447	chr19:37251912~37265535:+
BRCA	cis	rs10266483	0.774	rs4718067	ENSG00000227986.1	TRIM60P18	-4.37	1.34e-05	0.00106	-0.14	-0.13	Response to statin therapy;	chr7:64356018	chr7:64355078~64356199:+
BRCA	cis	rs3812049	0.737	rs1112956	ENSG00000245937.6	LINC01184	-4.37	1.34e-05	0.00107	-0.18	-0.13	Lymphocyte counts;Red cell distribution width;	chr5:128098106	chr5:127940426~128083172:-
BRCA	cis	rs7267979	0.868	rs6138546	ENSG00000125804.12	FAM182A	-4.37	1.34e-05	0.00107	-0.18	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25235898	chr20:26054655~26086917:+
BRCA	cis	rs7267979	0.966	rs6050567	ENSG00000274973.1	RP13-401N8.7	4.37	1.34e-05	0.00107	0.15	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25373925	chr20:25845497~25845862:+
BRCA	cis	rs7160336	1	rs1984511	ENSG00000259065.1	RP5-1021I20.1	4.37	1.34e-05	0.00107	0.15	0.13	Blood protein levels;	chr14:74084546	chr14:73787360~73803270:+
BRCA	cis	rs216345	0.7	rs2248910	ENSG00000260947.1	RP11-384P7.7	4.37	1.34e-05	0.00107	0.14	0.13	Bipolar disorder;	chr9:33838477	chr9:33697459~33700986:+
BRCA	cis	rs216345	0.734	rs2265040	ENSG00000260947.1	RP11-384P7.7	4.37	1.34e-05	0.00107	0.14	0.13	Bipolar disorder;	chr9:33844757	chr9:33697459~33700986:+
BRCA	cis	rs78487399	0.808	rs78481334	ENSG00000234936.1	AC010883.5	4.37	1.34e-05	0.00107	0.22	0.13	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43568996	chr2:43229573~43233394:+
BRCA	cis	rs1156327	0.51	rs8045533	ENSG00000188477.11	AC003003.5	-4.37	1.34e-05	0.00107	-0.32	-0.13	Periodontal disease-related phenotypes;	chr16:19317845	chr16:19285783~19310947:+
BRCA	cis	rs409045	0.965	rs409078	ENSG00000271874.1	CTD-2024P10.2	-4.37	1.34e-05	0.00107	-0.18	-0.13	Left ventricular mass;	chr5:34628764	chr5:34651457~34651888:-
BRCA	cis	rs9952991	0.941	rs9952749	ENSG00000260302.1	RP11-973H7.1	-4.37	1.34e-05	0.00107	-0.22	-0.13	Inflammatory skin disease;	chr18:12780457	chr18:12774651~12775923:-
BRCA	cis	rs867186	1	rs6060245	ENSG00000126005.14	MMP24-AS1	-4.37	1.34e-05	0.00107	-0.25	-0.13	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35111822	chr20:35216462~35278131:-
BRCA	cis	rs867186	1	rs28469723	ENSG00000126005.14	MMP24-AS1	-4.37	1.34e-05	0.00107	-0.25	-0.13	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35112914	chr20:35216462~35278131:-
BRCA	cis	rs913672	0.637	rs2274950	ENSG00000224397.4	LINC01272	-4.37	1.34e-05	0.00107	-0.15	-0.13	Monocyte count;	chr20:50277887	chr20:50267486~50279795:+
BRCA	cis	rs867371	0.502	rs2047679	ENSG00000276710.3	CSPG4P8	-4.37	1.34e-05	0.00107	-0.14	-0.13	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82239540	chr15:82459472~82477258:+
BRCA	cis	rs6012564	1	rs6063360	ENSG00000227431.4	CSE1L-AS1	4.37	1.34e-05	0.00107	0.16	0.13	Anger;	chr20:49131838	chr20:49040463~49046044:-
BRCA	cis	rs6997458	0.576	rs1553016	ENSG00000258256.1	RP11-219B4.5	-4.37	1.34e-05	0.00107	-0.15	-0.13	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85306169	chr8:85222446~85245717:-
BRCA	cis	rs11098499	0.863	rs11098531	ENSG00000250412.1	KLHL2P1	4.37	1.34e-05	0.00107	0.16	0.13	Corneal astigmatism;	chr4:119543846	chr4:119334329~119378233:+
BRCA	cis	rs11098499	0.863	rs28718422	ENSG00000250412.1	KLHL2P1	4.37	1.34e-05	0.00107	0.16	0.13	Corneal astigmatism;	chr4:119545149	chr4:119334329~119378233:+
BRCA	cis	rs11098499	0.818	rs12498599	ENSG00000250412.1	KLHL2P1	4.37	1.34e-05	0.00107	0.16	0.13	Corneal astigmatism;	chr4:119547348	chr4:119334329~119378233:+
BRCA	cis	rs11098499	0.863	rs10009626	ENSG00000250412.1	KLHL2P1	4.37	1.34e-05	0.00107	0.16	0.13	Corneal astigmatism;	chr4:119548850	chr4:119334329~119378233:+
BRCA	cis	rs10129255	0.5	rs12101190	ENSG00000232216.1	IGHV3-43	4.37	1.34e-05	0.00107	0.1	0.13	Kawasaki disease;	chr14:106784149	chr14:106470264~106470800:-
BRCA	cis	rs10129255	0.518	rs8004895	ENSG00000232216.1	IGHV3-43	4.37	1.34e-05	0.00107	0.1	0.13	Kawasaki disease;	chr14:106785139	chr14:106470264~106470800:-
BRCA	cis	rs2731006	0.591	rs7976690	ENSG00000257114.2	RP11-25I15.3	4.37	1.34e-05	0.00107	0.2	0.13	Panic disorder;	chr12:42814392	chr12:42692216~42717119:+
BRCA	cis	rs2731006	0.591	rs7962980	ENSG00000257114.2	RP11-25I15.3	4.37	1.34e-05	0.00107	0.2	0.13	Panic disorder;	chr12:42814441	chr12:42692216~42717119:+
BRCA	cis	rs2731006	0.591	rs11181694	ENSG00000257114.2	RP11-25I15.3	4.37	1.34e-05	0.00107	0.2	0.13	Panic disorder;	chr12:42814797	chr12:42692216~42717119:+
BRCA	cis	rs2662776	1	rs2999859	ENSG00000232995.6	RGS5	-4.37	1.34e-05	0.00107	-0.14	-0.13	Lead levels in blood;	chr1:163196933	chr1:163244505~163321894:-
BRCA	cis	rs11951515	0.508	rs1366410	ENSG00000248240.1	RP11-159F24.5	-4.37	1.34e-05	0.00107	-0.16	-0.13	Metabolite levels  (X-11787);	chr5:43601508	chr5:43515274~43525310:+
BRCA	cis	rs321358	0.895	rs17457658	ENSG00000271390.1	RP11-89C3.3	4.37	1.34e-05	0.00107	0.2	0.13	Body mass index;	chr11:111089448	chr11:111089870~111090368:-
BRCA	cis	rs7267979	0.932	rs433352	ENSG00000125804.12	FAM182A	4.37	1.34e-05	0.00107	0.17	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25487356	chr20:26054655~26086917:+
BRCA	cis	rs2692947	0.86	rs2579520	ENSG00000232931.4	LINC00342	-4.37	1.35e-05	0.00107	-0.13	-0.13	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95994552	chr2:95807118~95816215:-
BRCA	cis	rs10208649	0.611	rs12620667	ENSG00000233266.1	HMGB1P31	4.37	1.35e-05	0.00107	0.28	0.13	Body mass index;	chr2:54063860	chr2:54051334~54051760:+
BRCA	cis	rs2235544	0.565	rs7513522	ENSG00000225183.1	RP4-758J24.4	4.37	1.35e-05	0.00107	0.16	0.13	Thyroid hormone levels;Multiple myeloma (hyperdiploidy);	chr1:54000032	chr1:54089856~54090093:+
BRCA	cis	rs1865760	0.533	rs1408270	ENSG00000272462.2	U91328.19	-4.37	1.35e-05	0.00107	-0.17	-0.13	Height;	chr6:25872956	chr6:25992662~26001775:+
BRCA	cis	rs6545883	0.894	rs2177962	ENSG00000212978.6	AC016747.3	-4.37	1.35e-05	0.00107	-0.18	-0.13	Tuberculosis;	chr2:61360935	chr2:61141592~61144969:-
BRCA	cis	rs2243480	0.901	rs313808	ENSG00000222364.1	RNU6-96P	-4.37	1.35e-05	0.00107	-0.24	-0.13	Diabetic kidney disease;	chr7:66034886	chr7:66395191~66395286:+
BRCA	cis	rs6600671	1	rs10903161	ENSG00000231429.2	RP11-343N15.2	-4.37	1.35e-05	0.00107	-0.16	-0.13	Hip geometry;	chr1:121436882	chr1:121412719~121429274:+
BRCA	cis	rs6968419	0.747	rs3807968	ENSG00000279086.1	RP11-667F14.1	-4.37	1.35e-05	0.00107	-0.15	-0.13	Intraocular pressure;	chr7:116223392	chr7:116209234~116211511:-
BRCA	cis	rs7618915	0.501	rs2079929	ENSG00000243224.1	RP5-1157M23.2	-4.37	1.35e-05	0.00107	-0.14	-0.13	Bipolar disorder;	chr3:52731630	chr3:52239258~52241097:+
BRCA	cis	rs7618915	0.501	rs767418	ENSG00000243224.1	RP5-1157M23.2	-4.37	1.35e-05	0.00107	-0.14	-0.13	Bipolar disorder;	chr3:52733411	chr3:52239258~52241097:+
BRCA	cis	rs7824557	0.836	rs2736378	ENSG00000154316.13	TDH	4.37	1.35e-05	0.00107	0.18	0.13	Retinal vascular caliber;	chr8:11262251	chr8:11339637~11368452:+
BRCA	cis	rs2908197	0.843	rs1076437	ENSG00000186704.9	DTX2P1	4.37	1.35e-05	0.00107	0.16	0.13	3-hydroxypropylmercapturic acid levels in smokers;	chr7:76310404	chr7:76978617~77004308:+
BRCA	cis	rs73193808	0.627	rs73192202	ENSG00000215533.7	LINC00189	-4.37	1.35e-05	0.00107	-0.24	-0.13	Coronary artery disease;	chr21:29148257	chr21:29193480~29288205:+
BRCA	cis	rs853679	1	rs1778508	ENSG00000204709.4	LINC01556	-4.37	1.35e-05	0.00107	-0.24	-0.13	Depression;	chr6:28262103	chr6:28943877~28944537:+
BRCA	cis	rs62025270	0.547	rs1026722	ENSG00000259295.5	CSPG4P12	4.37	1.35e-05	0.00107	0.18	0.13	Idiopathic pulmonary fibrosis;	chr15:85576168	chr15:85191438~85213905:+
BRCA	cis	rs216345	0.7	rs1760822	ENSG00000260947.1	RP11-384P7.7	-4.37	1.35e-05	0.00107	-0.14	-0.13	Bipolar disorder;	chr9:34025952	chr9:33697459~33700986:+
BRCA	cis	rs11098499	0.863	rs10013305	ENSG00000250412.1	KLHL2P1	4.37	1.35e-05	0.00107	0.16	0.13	Corneal astigmatism;	chr4:119529269	chr4:119334329~119378233:+
BRCA	cis	rs11098499	0.863	rs3775849	ENSG00000250412.1	KLHL2P1	4.37	1.35e-05	0.00107	0.16	0.13	Corneal astigmatism;	chr4:119529753	chr4:119334329~119378233:+
BRCA	cis	rs11098499	0.818	rs7688802	ENSG00000250412.1	KLHL2P1	4.37	1.35e-05	0.00107	0.16	0.13	Corneal astigmatism;	chr4:119530513	chr4:119334329~119378233:+
BRCA	cis	rs11098499	0.863	rs7695620	ENSG00000250412.1	KLHL2P1	4.37	1.35e-05	0.00107	0.16	0.13	Corneal astigmatism;	chr4:119531621	chr4:119334329~119378233:+
BRCA	cis	rs11098499	0.863	rs12502389	ENSG00000250412.1	KLHL2P1	4.37	1.35e-05	0.00107	0.16	0.13	Corneal astigmatism;	chr4:119533036	chr4:119334329~119378233:+
BRCA	cis	rs11098499	0.821	rs3775852	ENSG00000250412.1	KLHL2P1	4.37	1.35e-05	0.00107	0.16	0.13	Corneal astigmatism;	chr4:119533401	chr4:119334329~119378233:+
BRCA	cis	rs11098499	0.82	rs6534140	ENSG00000250412.1	KLHL2P1	4.37	1.35e-05	0.00107	0.16	0.13	Corneal astigmatism;	chr4:119534156	chr4:119334329~119378233:+
BRCA	cis	rs11098499	0.863	rs7657849	ENSG00000250412.1	KLHL2P1	4.37	1.35e-05	0.00107	0.16	0.13	Corneal astigmatism;	chr4:119534339	chr4:119334329~119378233:+
BRCA	cis	rs11098499	0.863	rs10034450	ENSG00000250412.1	KLHL2P1	4.37	1.35e-05	0.00107	0.16	0.13	Corneal astigmatism;	chr4:119534494	chr4:119334329~119378233:+
BRCA	cis	rs11098499	0.863	rs1480939	ENSG00000250412.1	KLHL2P1	4.37	1.35e-05	0.00107	0.16	0.13	Corneal astigmatism;	chr4:119535772	chr4:119334329~119378233:+
BRCA	cis	rs12744310	0.943	rs35502198	ENSG00000235358.1	RP11-399E6.1	4.37	1.35e-05	0.00107	0.2	0.13	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41302869	chr1:41242373~41284861:+
BRCA	cis	rs4650943	0.541	rs7515936	ENSG00000227740.1	RP11-318C24.2	4.37	1.35e-05	0.00107	0.15	0.13	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in inactive individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr1:176407296	chr1:175904762~175920513:-
BRCA	cis	rs875971	0.502	rs2946580	ENSG00000232546.1	RP11-458F8.1	-4.37	1.35e-05	0.00107	-0.13	-0.13	Aortic root size;	chr7:66066855	chr7:66848496~66858136:+
BRCA	cis	rs1538970	0.816	rs12029322	ENSG00000281133.1	AL355480.3	-4.37	1.35e-05	0.00107	-0.19	-0.13	Platelet count;	chr1:45504774	chr1:45580892~45580996:-
BRCA	cis	rs35306767	0.953	rs1539174	ENSG00000229869.1	RP11-363N22.2	-4.37	1.35e-05	0.00107	-0.19	-0.13	Eosinophil percentage of granulocytes;	chr10:928930	chr10:933026~942743:+
BRCA	cis	rs56114371	0.53	rs9357045	ENSG00000216901.1	AL022393.7	4.37	1.35e-05	0.00107	0.2	0.13	Breast cancer;	chr6:27721148	chr6:28176188~28176674:+
BRCA	cis	rs6840360	0.557	rs4696261	ENSG00000251603.1	RP11-164P12.4	-4.37	1.35e-05	0.00107	-0.12	-0.13	Intelligence (multi-trait analysis);	chr4:151401507	chr4:151667224~151670502:+
BRCA	cis	rs6968419	0.755	rs6948556	ENSG00000279086.1	RP11-667F14.1	-4.37	1.35e-05	0.00107	-0.15	-0.13	Intraocular pressure;	chr7:116255379	chr7:116209234~116211511:-
BRCA	cis	rs11637445	0.677	rs4386088	ENSG00000260657.2	RP11-315D16.4	-4.37	1.35e-05	0.00107	-0.17	-0.13	Posterior cortical atrophy and Alzheimer's disease;	chr15:67816575	chr15:68267792~68277994:-
BRCA	cis	rs11637445	0.64	rs4508380	ENSG00000260657.2	RP11-315D16.4	-4.37	1.35e-05	0.00107	-0.17	-0.13	Posterior cortical atrophy and Alzheimer's disease;	chr15:67816711	chr15:68267792~68277994:-
BRCA	cis	rs4415084	0.834	rs13160259	ENSG00000251141.4	RP11-53O19.1	4.37	1.35e-05	0.00107	0.12	0.13	Breast cancer;	chr5:44828862	chr5:44744900~44808777:-
BRCA	cis	rs6490294	0.95	rs7313892	ENSG00000257624.1	RP1-128M12.3	4.37	1.35e-05	0.00107	0.18	0.13	Mean platelet volume;	chr12:111983548	chr12:112000739~112000985:-
BRCA	cis	rs6490294	0.904	rs73426401	ENSG00000257624.1	RP1-128M12.3	4.37	1.35e-05	0.00107	0.18	0.13	Mean platelet volume;	chr12:111985482	chr12:112000739~112000985:-
BRCA	cis	rs6490294	0.904	rs7956483	ENSG00000257624.1	RP1-128M12.3	4.37	1.35e-05	0.00107	0.18	0.13	Mean platelet volume;	chr12:111986766	chr12:112000739~112000985:-
BRCA	cis	rs6487679	0.526	rs972111	ENSG00000214776.8	RP11-726G1.1	-4.37	1.35e-05	0.00107	-0.15	-0.13	Non-alcoholic fatty liver disease histology (AST);	chr12:9221777	chr12:9467552~9576275:+
BRCA	cis	rs2115630	0.875	rs8039472	ENSG00000275120.1	RP11-182J1.17	-4.37	1.35e-05	0.00107	-0.16	-0.13	P wave terminal force;	chr15:84818413	chr15:84599434~84606463:-
BRCA	cis	rs11892454	0.544	rs7571093	ENSG00000217643.1	PTGES3P2	-4.37	1.35e-05	0.00107	-0.14	-0.13	Heschl's gyrus morphology;	chr2:25770025	chr2:25822469~25822950:+
BRCA	cis	rs8098244	0.894	rs6507894	ENSG00000264745.1	TTC39C-AS1	4.37	1.35e-05	0.00107	0.17	0.13	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23758312	chr18:23994213~24015339:-
BRCA	cis	rs7308116	1	rs11113503	ENSG00000274395.1	RP11-554D14.8	-4.37	1.35e-05	0.00107	-0.15	-0.13	Pelvic organ prolapse (moderate/severe);	chr12:107810000	chr12:107835541~107836555:-
BRCA	cis	rs6545883	0.929	rs778155	ENSG00000212978.6	AC016747.3	-4.37	1.35e-05	0.00107	-0.19	-0.13	Tuberculosis;	chr2:61420766	chr2:61141592~61144969:-
BRCA	cis	rs7474896	0.609	rs11011336	ENSG00000120555.12	SEPT7P9	4.37	1.35e-05	0.00107	0.19	0.13	Obesity (extreme);	chr10:37696388	chr10:38383069~38402916:-
BRCA	cis	rs2731006	0.64	rs908659	ENSG00000257114.2	RP11-25I15.3	4.37	1.35e-05	0.00108	0.22	0.13	Panic disorder;	chr12:42775216	chr12:42692216~42717119:+
BRCA	cis	rs2731006	0.64	rs908660	ENSG00000257114.2	RP11-25I15.3	4.37	1.35e-05	0.00108	0.22	0.13	Panic disorder;	chr12:42775218	chr12:42692216~42717119:+
BRCA	cis	rs2833693	0.519	rs2833699	ENSG00000261610.1	AP000265.1	4.37	1.35e-05	0.00108	0.16	0.13	Temperament;	chr21:32184240	chr21:32259804~32261585:-
BRCA	cis	rs4664293	0.867	rs6720304	ENSG00000224152.1	AC009506.1	-4.37	1.35e-05	0.00108	-0.16	-0.13	Monocyte percentage of white cells;	chr2:159787321	chr2:159615296~159617082:+
BRCA	cis	rs78545713	0.536	rs80202565	ENSG00000241549.7	GUSBP2	-4.37	1.35e-05	0.00108	-0.25	-0.13	Iron status biomarkers (total iron binding capacity);	chr6:26233654	chr6:26871484~26956554:-
BRCA	cis	rs3764021	0.743	rs7973535	ENSG00000256582.1	RP11-75L1.1	4.37	1.36e-05	0.00108	0.13	0.13	Type 1 diabetes;	chr12:9727801	chr12:9704077~9709350:+
BRCA	cis	rs3764021	0.87	rs7973638	ENSG00000256582.1	RP11-75L1.1	4.37	1.36e-05	0.00108	0.13	0.13	Type 1 diabetes;	chr12:9727845	chr12:9704077~9709350:+
BRCA	cis	rs11976180	1	rs2961117	ENSG00000244479.5	OR2A1-AS1	4.37	1.36e-05	0.00108	0.18	0.13	Obesity-related traits;	chr7:144058160	chr7:144251264~144356181:-
BRCA	cis	rs1005277	0.579	rs2474563	ENSG00000263064.2	RP11-291L22.7	4.37	1.36e-05	0.00108	0.16	0.13	Extrinsic epigenetic age acceleration;	chr10:38087010	chr10:38448689~38448949:+
BRCA	cis	rs6964587	0.967	rs4626516	ENSG00000188693.7	CYP51A1-AS1	-4.37	1.36e-05	0.00108	-0.15	-0.13	Breast cancer;	chr7:92177839	chr7:92134604~92180725:+
BRCA	cis	rs6570726	0.905	rs430248	ENSG00000270638.1	RP3-466P17.1	4.37	1.36e-05	0.00108	0.15	0.13	Lobe attachment (rater-scored or self-reported);	chr6:145552968	chr6:145735570~145737218:+
BRCA	cis	rs8040855	0.627	rs12909130	ENSG00000230373.7	GOLGA6L5P	4.37	1.36e-05	0.00108	0.17	0.13	Bulimia nervosa;	chr15:85047270	chr15:84507885~84516814:-
BRCA	cis	rs12439619	0.921	rs56042848	ENSG00000255769.6	GOLGA2P10	-4.37	1.36e-05	0.00108	-0.17	-0.13	Intelligence (multi-trait analysis);	chr15:82235244	chr15:82472993~82513950:-
BRCA	cis	rs9527	0.518	rs10883802	ENSG00000213061.2	PFN1P11	-4.37	1.36e-05	0.00108	-0.25	-0.13	Arsenic metabolism;	chr10:102920605	chr10:102838011~102845473:-
BRCA	cis	rs2243480	1	rs34970380	ENSG00000275400.1	RP4-756H11.5	4.37	1.36e-05	0.00108	0.24	0.13	Diabetic kidney disease;	chr7:65966506	chr7:66553805~66554199:-
BRCA	cis	rs10938353	0.834	rs13135313	ENSG00000273369.1	RP11-700J17.1	-4.37	1.36e-05	0.00108	-0.15	-0.13	Body mass index;	chr4:44600199	chr4:44693946~44694386:-
BRCA	cis	rs7267979	0.966	rs6107031	ENSG00000274973.1	RP13-401N8.7	4.37	1.36e-05	0.00108	0.15	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25370041	chr20:25845497~25845862:+
BRCA	cis	rs7267979	1	rs6115159	ENSG00000274973.1	RP13-401N8.7	4.37	1.36e-05	0.00108	0.15	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25370308	chr20:25845497~25845862:+
BRCA	cis	rs7267979	1	rs4813562	ENSG00000274973.1	RP13-401N8.7	4.37	1.36e-05	0.00108	0.15	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25371952	chr20:25845497~25845862:+
BRCA	cis	rs6088580	0.634	rs9789792	ENSG00000276073.1	RP5-1125A11.7	4.37	1.36e-05	0.00108	0.15	0.13	Glomerular filtration rate (creatinine);	chr20:34369903	chr20:33985617~33988989:-
BRCA	cis	rs875971	1	rs6979382	ENSG00000229180.5	GS1-124K5.11	4.37	1.36e-05	0.00108	0.12	0.13	Aortic root size;	chr7:66421388	chr7:66526088~66542624:-
BRCA	cis	rs875971	1	rs6961990	ENSG00000229180.5	GS1-124K5.11	4.37	1.36e-05	0.00108	0.12	0.13	Aortic root size;	chr7:66423583	chr7:66526088~66542624:-
BRCA	cis	rs7811142	1	rs67239991	ENSG00000078319.8	PMS2P1	-4.37	1.36e-05	0.00108	-0.21	-0.13	Platelet count;	chr7:100448881	chr7:100320992~100341908:-
BRCA	cis	rs997295	0.52	rs4776971	ENSG00000270964.1	RP11-502I4.3	4.37	1.36e-05	0.00108	0.15	0.13	Motion sickness;	chr15:67788759	chr15:67541072~67542604:-
BRCA	cis	rs7267979	0.714	rs3787082	ENSG00000125804.12	FAM182A	-4.37	1.36e-05	0.00108	-0.18	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25255100	chr20:26054655~26086917:+
BRCA	cis	rs1005277	0.579	rs2472173	ENSG00000263064.2	RP11-291L22.7	4.37	1.36e-05	0.00108	0.16	0.13	Extrinsic epigenetic age acceleration;	chr10:38085710	chr10:38448689~38448949:+
BRCA	cis	rs1005277	0.579	rs2472174	ENSG00000263064.2	RP11-291L22.7	4.37	1.36e-05	0.00108	0.16	0.13	Extrinsic epigenetic age acceleration;	chr10:38086454	chr10:38448689~38448949:+
BRCA	cis	rs6012564	1	rs2295028	ENSG00000222365.1	SNORD12B	-4.37	1.36e-05	0.00108	-0.14	-0.13	Anger;	chr20:48966421	chr20:49280319~49280409:+
BRCA	cis	rs2010672	0.5	rs4261511	ENSG00000245479.2	LINC01585	4.37	1.36e-05	0.00108	0.16	0.13	Eosinophil counts;Sum eosinophil basophil counts;Eosinophil percentage of white cells;	chr15:90608044	chr15:90660234~90664967:+
BRCA	cis	rs6952407	1	rs6952407	ENSG00000273142.1	RP11-458F8.4	4.37	1.36e-05	0.00108	0.12	0.13	Cotinine glucuronidation;	chr7:66580525	chr7:66902857~66906297:+
BRCA	cis	rs11892454	0.504	rs55737015	ENSG00000217643.1	PTGES3P2	-4.37	1.36e-05	0.00108	-0.14	-0.13	Heschl's gyrus morphology;	chr2:25787434	chr2:25822469~25822950:+
BRCA	cis	rs516805	0.63	rs2315816	ENSG00000279114.1	RP3-425C14.5	-4.37	1.36e-05	0.00108	-0.16	-0.13	Lymphocyte counts;	chr6:122102793	chr6:122471923~122484161:+
BRCA	cis	rs2834288	0.5	rs2051189	ENSG00000237945.6	LINC00649	4.37	1.36e-05	0.00108	0.16	0.13	Gut microbiota (bacterial taxa);	chr21:33949712	chr21:33915534~33977691:+
BRCA	cis	rs7487075	0.78	rs12296120	ENSG00000274723.1	RP11-618L22.1	4.37	1.36e-05	0.00108	0.16	0.13	Itch intensity from mosquito bite;	chr12:46343808	chr12:46970504~46972155:+
BRCA	cis	rs7647973	1	rs940045	ENSG00000244380.1	RP11-24C3.2	4.37	1.36e-05	0.00108	0.17	0.13	Menarche (age at onset);	chr3:49412205	chr3:48440352~48446656:-
BRCA	cis	rs6600671	0.934	rs11249348	ENSG00000275538.1	RNVU1-19	4.37	1.36e-05	0.00108	0.16	0.13	Hip geometry;	chr1:121446444	chr1:120850819~120850985:-
BRCA	cis	rs7572733	0.935	rs700665	ENSG00000231621.1	AC013264.2	-4.37	1.36e-05	0.00108	-0.12	-0.13	Dermatomyositis;	chr2:197808655	chr2:197197991~197199273:+
BRCA	cis	rs13034020	0.522	rs62150970	ENSG00000271889.1	RP11-493E12.1	-4.37	1.36e-05	0.00108	-0.21	-0.13	Hodgkin's lymphoma;	chr2:61017275	chr2:61151433~61162105:-
BRCA	cis	rs8098244	0.964	rs12966369	ENSG00000264745.1	TTC39C-AS1	4.37	1.36e-05	0.00108	0.18	0.13	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23767881	chr18:23994213~24015339:-
BRCA	cis	rs13108904	0.875	rs1732099	ENSG00000253399.1	AC078852.2	4.37	1.36e-05	0.00108	0.15	0.13	Obesity-related traits;	chr4:1288908	chr4:1358479~1359461:+
BRCA	cis	rs3733585	0.657	rs62286568	ENSG00000250413.1	RP11-448G15.1	4.37	1.36e-05	0.00108	0.18	0.13	Cleft plate (environmental tobacco smoke interaction);	chr4:10123265	chr4:10006482~10009725:+
BRCA	cis	rs875971	0.964	rs778735	ENSG00000229180.5	GS1-124K5.11	4.37	1.36e-05	0.00108	0.12	0.13	Aortic root size;	chr7:66349822	chr7:66526088~66542624:-
BRCA	cis	rs2243480	1	rs12698509	ENSG00000222364.1	RNU6-96P	-4.37	1.36e-05	0.00108	-0.24	-0.13	Diabetic kidney disease;	chr7:65953889	chr7:66395191~66395286:+
BRCA	cis	rs911119	1	rs6036478	ENSG00000270001.1	RP11-218C14.8	-4.37	1.36e-05	0.00108	-0.18	-0.13	Chronic kidney disease;	chr20:23630722	chr20:23631826~23632316:-
BRCA	cis	rs11892454	0.544	rs13382805	ENSG00000217643.1	PTGES3P2	-4.37	1.36e-05	0.00108	-0.14	-0.13	Heschl's gyrus morphology;	chr2:25774700	chr2:25822469~25822950:+
BRCA	cis	rs2109514	0.902	rs28495552	ENSG00000237813.3	AC002066.1	4.37	1.36e-05	0.00108	0.16	0.13	Prevalent atrial fibrillation;	chr7:116473690	chr7:116238260~116499465:-
BRCA	cis	rs73242632	1	rs2271807	ENSG00000269949.1	RP11-738E22.3	4.37	1.36e-05	0.00108	0.31	0.13	Congenital heart disease (maternal effect);	chr4:57032563	chr4:56960927~56961373:-
BRCA	cis	rs7647973	0.506	rs11920251	ENSG00000225399.4	RP11-3B7.1	4.37	1.36e-05	0.00108	0.13	0.13	Menarche (age at onset);	chr3:49319238	chr3:49260085~49261316:+
BRCA	cis	rs11673344	0.523	rs7248948	ENSG00000226686.6	LINC01535	4.37	1.36e-05	0.00108	0.17	0.13	Obesity-related traits;	chr19:37056317	chr19:37251912~37265535:+
BRCA	cis	rs539096	0.607	rs3001723	ENSG00000236200.4	KDM4A-AS1	4.37	1.36e-05	0.00108	0.15	0.13	Intelligence (multi-trait analysis);	chr1:43572014	chr1:43699765~43708138:-
BRCA	cis	rs7246657	0.507	rs8107654	ENSG00000267422.1	CTD-2554C21.1	-4.37	1.36e-05	0.00108	-0.24	-0.13	Coronary artery calcification;	chr19:36962632	chr19:37779686~37792865:+
BRCA	cis	rs4415084	0.804	rs4412123	ENSG00000251141.4	RP11-53O19.1	-4.37	1.36e-05	0.00108	-0.12	-0.13	Breast cancer;	chr5:44876186	chr5:44744900~44808777:-
BRCA	cis	rs2229238	0.911	rs73023339	ENSG00000272030.1	RP1-178F15.4	-4.37	1.37e-05	0.00108	-0.19	-0.13	Coronary heart disease;	chr1:154538376	chr1:153631438~153634397:-
BRCA	cis	rs11239930	0.517	rs590286	ENSG00000230832.3	RP11-325P15.2	-4.37	1.37e-05	0.00108	-0.19	-0.13	AIDS progression;	chr1:147074056	chr1:147082338~147083578:-
BRCA	cis	rs6600671	1	rs11249350	ENSG00000231429.2	RP11-343N15.2	-4.37	1.37e-05	0.00108	-0.16	-0.13	Hip geometry;	chr1:121436587	chr1:121412719~121429274:+
BRCA	cis	rs11098499	0.908	rs7695996	ENSG00000260091.1	RP11-33B1.4	-4.37	1.37e-05	0.00108	-0.12	-0.13	Corneal astigmatism;	chr4:119400878	chr4:119409333~119410233:+
BRCA	cis	rs35740288	0.688	rs12904047	ENSG00000202081.1	RNU6-1280P	4.37	1.37e-05	0.00108	0.18	0.13	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85669635	chr15:85651522~85651628:-
BRCA	cis	rs7267979	1	rs6037099	ENSG00000274973.1	RP13-401N8.7	4.37	1.37e-05	0.00108	0.15	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25376240	chr20:25845497~25845862:+
BRCA	cis	rs7267979	0.966	rs4815414	ENSG00000274973.1	RP13-401N8.7	4.37	1.37e-05	0.00108	0.15	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25381065	chr20:25845497~25845862:+
BRCA	cis	rs7267979	1	rs6083825	ENSG00000274973.1	RP13-401N8.7	4.37	1.37e-05	0.00108	0.15	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25385788	chr20:25845497~25845862:+
BRCA	cis	rs7267979	1	rs34645895	ENSG00000274973.1	RP13-401N8.7	4.37	1.37e-05	0.00108	0.15	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25387737	chr20:25845497~25845862:+
BRCA	cis	rs7267979	1	rs6037105	ENSG00000274973.1	RP13-401N8.7	4.37	1.37e-05	0.00108	0.15	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25393563	chr20:25845497~25845862:+
BRCA	cis	rs6452524	0.836	rs62372713	ENSG00000281327.1	LINC01338	4.37	1.37e-05	0.00108	0.17	0.13	Hypertension (SNP x SNP interaction);	chr5:83090635	chr5:82850864~82859836:-
BRCA	cis	rs10129255	0.536	rs10142951	ENSG00000232216.1	IGHV3-43	4.37	1.37e-05	0.00108	0.1	0.13	Kawasaki disease;	chr14:106782337	chr14:106470264~106470800:-
BRCA	cis	rs2456568	0.564	rs6483270	ENSG00000250519.5	RP11-680H20.2	4.37	1.37e-05	0.00108	0.16	0.13	Response to serotonin reuptake inhibitors in major depressive disorder;	chr11:93891214	chr11:94238150~94279206:+
BRCA	cis	rs77956314	0.515	rs9804817	ENSG00000277840.1	RP11-103B5.4	4.37	1.37e-05	0.00108	0.21	0.13	Hippocampal volume;Subcortical brain region volumes;	chr12:117002415	chr12:117002463~117003152:+
BRCA	cis	rs950776	0.616	rs6495307	ENSG00000279373.1	RP11-650L12.4	4.37	1.37e-05	0.00108	0.16	0.13	Sudden cardiac arrest;	chr15:78597979	chr15:78537681~78538946:+
BRCA	cis	rs10129255	0.83	rs61997609	ENSG00000274576.2	IGHV2-70	4.37	1.37e-05	0.00108	0.12	0.13	Kawasaki disease;	chr14:106692376	chr14:106770577~106771020:-
BRCA	cis	rs35740288	0.539	rs4843101	ENSG00000259407.1	RP11-158M2.3	-4.37	1.37e-05	0.00109	-0.2	-0.13	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85796430	chr15:85744109~85750281:-
BRCA	cis	rs4742903	0.935	rs1507513	ENSG00000270332.1	SMC2-AS1	4.37	1.37e-05	0.00109	0.15	0.13	Breast cancer;High-grade serous ovarian cancer;	chr9:104211576	chr9:104080024~104093073:-
BRCA	cis	rs10181042	0.514	rs1177288	ENSG00000270820.4	RP11-355B11.2	4.37	1.37e-05	0.00109	0.15	0.13	Crohn's disease;	chr2:61125850	chr2:61471188~61484130:+
BRCA	cis	rs6921919	0.515	rs1339898	ENSG00000273712.1	RP5-874C20.7	4.37	1.37e-05	0.00109	0.17	0.13	Autism spectrum disorder or schizophrenia;	chr6:28427729	chr6:28315613~28315883:-
BRCA	cis	rs875971	0.66	rs3764903	ENSG00000223473.2	GS1-124K5.3	-4.37	1.37e-05	0.00109	-0.1	-0.13	Aortic root size;	chr7:66633495	chr7:66491049~66493566:-
BRCA	cis	rs72482608	0.865	rs10919476	ENSG00000271811.1	RP1-79C4.4	4.37	1.37e-05	0.00109	0.14	0.13	Emphysema imaging phenotypes;	chr1:170802794	chr1:170667381~170669425:+
BRCA	cis	rs11098499	0.754	rs11732087	ENSG00000225892.3	RP11-384K6.2	4.37	1.37e-05	0.00109	0.13	0.13	Corneal astigmatism;	chr4:119318676	chr4:118632274~118634759:+
BRCA	cis	rs651907	0.557	rs1031710	ENSG00000256628.3	ZBTB11-AS1	4.37	1.37e-05	0.00109	0.17	0.13	Colorectal cancer;	chr3:101745051	chr3:101676475~101679217:+
BRCA	cis	rs651907	0.535	rs13065944	ENSG00000256628.3	ZBTB11-AS1	4.37	1.37e-05	0.00109	0.17	0.13	Colorectal cancer;	chr3:101754244	chr3:101676475~101679217:+
BRCA	cis	rs3617	0.625	rs2071042	ENSG00000279144.1	RP11-894J14.2	4.37	1.37e-05	0.00109	0.17	0.13	Red blood cell count;Autism spectrum disorder or schizophrenia;	chr3:52830568	chr3:52848085~52848553:-
BRCA	cis	rs10771431	0.597	rs3759275	ENSG00000111788.10	RP11-22B23.1	4.37	1.37e-05	0.00109	0.12	0.13	Breast size;	chr12:9201232	chr12:9277235~9313241:+
BRCA	cis	rs10771431	0.597	rs3759274	ENSG00000111788.10	RP11-22B23.1	4.37	1.37e-05	0.00109	0.12	0.13	Breast size;	chr12:9201279	chr12:9277235~9313241:+
BRCA	cis	rs10771431	0.597	rs10771412	ENSG00000111788.10	RP11-22B23.1	4.37	1.37e-05	0.00109	0.12	0.13	Breast size;	chr12:9201757	chr12:9277235~9313241:+
BRCA	cis	rs10771431	0.597	rs10771413	ENSG00000111788.10	RP11-22B23.1	4.37	1.37e-05	0.00109	0.12	0.13	Breast size;	chr12:9201817	chr12:9277235~9313241:+
BRCA	cis	rs7646881	1	rs7646987	ENSG00000240207.5	RP11-379F4.4	4.37	1.37e-05	0.00109	0.19	0.13	Tetralogy of Fallot;	chr3:158735653	chr3:158732263~158784070:+
BRCA	cis	rs7572733	0.84	rs13029495	ENSG00000231621.1	AC013264.2	4.37	1.37e-05	0.00109	0.12	0.13	Dermatomyositis;	chr2:197717877	chr2:197197991~197199273:+
BRCA	cis	rs10986311	0.822	rs10818946	ENSG00000227200.1	RP11-121A14.3	-4.37	1.37e-05	0.00109	-0.15	-0.13	Vitiligo;	chr9:124353823	chr9:124262876~124265809:+
BRCA	cis	rs2108622	0.711	rs113059233	ENSG00000267218.2	AC005336.5	4.37	1.37e-05	0.00109	0.16	0.13	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15866558	chr19:15902300~15903238:-
BRCA	cis	rs7690839	0.525	rs1795734	ENSG00000270720.1	RP11-84C13.2	-4.37	1.37e-05	0.00109	-0.15	-0.13	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr4:89012479	chr4:89119284~89119871:+
BRCA	cis	rs6723226	0.75	rs762019	ENSG00000276517.1	AL133243.2	-4.37	1.37e-05	0.00109	-0.16	-0.13	Intelligence (multi-trait analysis);	chr2:32463533	chr2:32526504~32529507:+
BRCA	cis	rs4950322	0.58	rs4950371	ENSG00000244371.2	PFN1P8	-4.37	1.37e-05	0.00109	-0.19	-0.13	Protein quantitative trait loci;	chr1:147114243	chr1:146957117~146957659:-
BRCA	cis	rs9527	0.59	rs10883839	ENSG00000213061.2	PFN1P11	4.37	1.37e-05	0.00109	0.18	0.13	Arsenic metabolism;	chr10:103160584	chr10:102838011~102845473:-
BRCA	cis	rs10751647	0.804	rs3809112	ENSG00000270030.1	RP11-326C3.13	4.37	1.37e-05	0.00109	0.17	0.13	Monocyte count;	chr11:307036	chr11:325703~326294:-
BRCA	cis	rs11892454	0.544	rs6753192	ENSG00000217643.1	PTGES3P2	-4.37	1.37e-05	0.00109	-0.14	-0.13	Heschl's gyrus morphology;	chr2:25763860	chr2:25822469~25822950:+
BRCA	cis	rs736408	0.608	rs6445534	ENSG00000243224.1	RP5-1157M23.2	-4.37	1.37e-05	0.00109	-0.14	-0.13	Bipolar disorder;	chr3:52709368	chr3:52239258~52241097:+
BRCA	cis	rs4648045	0.796	rs9790601	ENSG00000246560.2	RP11-10L12.4	4.37	1.37e-05	0.00109	0.15	0.13	Lymphocyte percentage of white cells;	chr4:102608806	chr4:102828055~102844075:+
BRCA	cis	rs5758659	0.652	rs129857	ENSG00000273366.1	CTA-989H11.1	4.37	1.37e-05	0.00109	0.16	0.13	Cognitive function;	chr22:42003682	chr22:42278188~42278846:+
BRCA	cis	rs6968419	0.755	rs10500059	ENSG00000279086.1	RP11-667F14.1	-4.37	1.37e-05	0.00109	-0.15	-0.13	Intraocular pressure;	chr7:116260340	chr7:116209234~116211511:-
BRCA	cis	rs2243480	1	rs56016656	ENSG00000275400.1	RP4-756H11.5	4.37	1.37e-05	0.00109	0.24	0.13	Diabetic kidney disease;	chr7:65918494	chr7:66553805~66554199:-
BRCA	cis	rs2243480	1	rs56291018	ENSG00000275400.1	RP4-756H11.5	4.37	1.37e-05	0.00109	0.24	0.13	Diabetic kidney disease;	chr7:65925352	chr7:66553805~66554199:-
BRCA	cis	rs2243480	1	rs36033484	ENSG00000275400.1	RP4-756H11.5	4.37	1.37e-05	0.00109	0.24	0.13	Diabetic kidney disease;	chr7:65925571	chr7:66553805~66554199:-
BRCA	cis	rs11098499	0.954	rs11722872	ENSG00000250412.1	KLHL2P1	4.37	1.38e-05	0.00109	0.16	0.13	Corneal astigmatism;	chr4:119311875	chr4:119334329~119378233:+
BRCA	cis	rs860295	0.702	rs12041534	ENSG00000232093.1	RP11-307C12.11	-4.37	1.38e-05	0.00109	-0.14	-0.13	Body mass index;	chr1:155437305	chr1:155045191~155046118:-
BRCA	cis	rs6686842	0.56	rs61781833	ENSG00000235358.1	RP11-399E6.1	-4.37	1.38e-05	0.00109	-0.18	-0.13	Height;	chr1:41175418	chr1:41242373~41284861:+
BRCA	cis	rs17711722	0.503	rs453835	ENSG00000226767.1	RP11-328P23.3	-4.37	1.38e-05	0.00109	-0.16	-0.13	Calcium levels;	chr7:66046172	chr7:65508773~65508944:-
BRCA	cis	rs4143844	0.867	rs34646089	ENSG00000259251.2	RP11-643M14.1	4.37	1.38e-05	0.00109	0.33	0.13	Bipolar disorder and schizophrenia;	chr15:61978298	chr15:62060503~62062434:+
BRCA	cis	rs1479090	0.901	rs936562	ENSG00000250027.1	RP11-563E2.2	-4.37	1.38e-05	0.00109	-0.19	-0.13	Lung cancer;	chr4:163166802	chr4:163108785~163119965:+
BRCA	cis	rs4664293	0.836	rs10190704	ENSG00000226266.5	AC009961.3	-4.37	1.38e-05	0.00109	-0.17	-0.13	Monocyte percentage of white cells;	chr2:159738451	chr2:159670708~159712435:-
BRCA	cis	rs34217772	0.941	rs12893555	ENSG00000258636.1	CTD-2298J14.2	4.37	1.38e-05	0.00109	0.18	0.13	Myopia;	chr14:41801166	chr14:41587861~41604856:-
BRCA	cis	rs17213965	0.561	rs11866891	ENSG00000275910.1	RP11-680G24.6	-4.37	1.38e-05	0.00109	-0.18	-0.13	Waist-hip ratio;	chr16:15781561	chr16:15015828~15016390:-
BRCA	cis	rs6012564	1	rs2426112	ENSG00000227431.4	CSE1L-AS1	-4.37	1.38e-05	0.00109	-0.16	-0.13	Anger;	chr20:49073602	chr20:49040463~49046044:-
BRCA	cis	rs6012564	1	rs2426113	ENSG00000227431.4	CSE1L-AS1	-4.37	1.38e-05	0.00109	-0.16	-0.13	Anger;	chr20:49073652	chr20:49040463~49046044:-
BRCA	cis	rs6012564	0.929	rs2426114	ENSG00000227431.4	CSE1L-AS1	-4.37	1.38e-05	0.00109	-0.16	-0.13	Anger;	chr20:49075855	chr20:49040463~49046044:-
BRCA	cis	rs6012564	1	rs2426116	ENSG00000227431.4	CSE1L-AS1	-4.37	1.38e-05	0.00109	-0.16	-0.13	Anger;	chr20:49076510	chr20:49040463~49046044:-
BRCA	cis	rs875971	0.545	rs10950025	ENSG00000273142.1	RP11-458F8.4	4.37	1.38e-05	0.00109	0.13	0.13	Aortic root size;	chr7:66158946	chr7:66902857~66906297:+
BRCA	cis	rs875971	0.52	rs12666485	ENSG00000273142.1	RP11-458F8.4	4.37	1.38e-05	0.00109	0.13	0.13	Aortic root size;	chr7:66160135	chr7:66902857~66906297:+
BRCA	cis	rs875971	0.545	rs67688847	ENSG00000273142.1	RP11-458F8.4	4.37	1.38e-05	0.00109	0.13	0.13	Aortic root size;	chr7:66161064	chr7:66902857~66906297:+
BRCA	cis	rs10129255	0.536	rs8004835	ENSG00000254174.1	IGHV1-12	4.37	1.38e-05	0.00109	0.1	0.13	Kawasaki disease;	chr14:106686361	chr14:106122420~106122709:-
BRCA	cis	rs16944613	0.51	rs7165429	ENSG00000245479.2	LINC01585	4.37	1.38e-05	0.00109	0.16	0.13	Colorectal cancer;	chr15:90608649	chr15:90660234~90664967:+
BRCA	cis	rs4374383	0.962	rs6541998	ENSG00000243389.1	AC012442.5	-4.37	1.38e-05	0.00109	-0.17	-0.13	Hepatitis C induced liver fibrosis;	chr2:112027660	chr2:112589040~112614431:+
BRCA	cis	rs3733585	0.631	rs4697925	ENSG00000250413.1	RP11-448G15.1	4.37	1.38e-05	0.00109	0.18	0.13	Cleft plate (environmental tobacco smoke interaction);	chr4:10122706	chr4:10006482~10009725:+
BRCA	cis	rs9990333	0.562	rs58079878	ENSG00000242086.7	LINC00969	4.37	1.38e-05	0.00109	0.15	0.13	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196100620	chr3:195658062~195739964:+
BRCA	cis	rs7475343	0.543	rs117849125	ENSG00000224034.1	RP11-445P17.8	-4.37	1.38e-05	0.00109	-0.27	-0.13	Intelligence;	chr10:5219866	chr10:5266033~5271236:-
BRCA	cis	rs7475343	0.543	rs117146235	ENSG00000224034.1	RP11-445P17.8	-4.37	1.38e-05	0.00109	-0.27	-0.13	Intelligence;	chr10:5219867	chr10:5266033~5271236:-
BRCA	cis	rs3617	0.625	rs7652667	ENSG00000279144.1	RP11-894J14.2	-4.37	1.38e-05	0.00109	-0.17	-0.13	Red blood cell count;Autism spectrum disorder or schizophrenia;	chr3:52832519	chr3:52848085~52848553:-
BRCA	cis	rs3617	0.559	rs11915546	ENSG00000279144.1	RP11-894J14.2	-4.37	1.38e-05	0.00109	-0.17	-0.13	Red blood cell count;Autism spectrum disorder or schizophrenia;	chr3:52832829	chr3:52848085~52848553:-
BRCA	cis	rs3617	0.591	rs11918800	ENSG00000279144.1	RP11-894J14.2	-4.37	1.38e-05	0.00109	-0.17	-0.13	Red blood cell count;Autism spectrum disorder or schizophrenia;	chr3:52834129	chr3:52848085~52848553:-
BRCA	cis	rs13113518	1	rs4865011	ENSG00000273257.1	RP11-177J6.1	4.37	1.38e-05	0.00109	0.17	0.13	Height;	chr4:55554456	chr4:55387949~55388271:+
BRCA	cis	rs737008	0.959	rs11865598	ENSG00000262703.1	RP11-485G7.6	4.37	1.38e-05	0.00109	0.14	0.13	Obesity-related traits;	chr16:11309575	chr16:11348143~11349321:-
BRCA	cis	rs6570726	0.967	rs441364	ENSG00000270638.1	RP3-466P17.1	4.37	1.38e-05	0.00109	0.15	0.13	Lobe attachment (rater-scored or self-reported);	chr6:145532526	chr6:145735570~145737218:+
BRCA	cis	rs17597773	0.638	rs4143773	ENSG00000238078.1	LINC01352	-4.37	1.38e-05	0.00109	-0.16	-0.13	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220814900	chr1:220829255~220832429:+
BRCA	cis	rs6596100	0.956	rs4301229	ENSG00000248648.1	RP11-485M7.1	4.37	1.38e-05	0.00109	0.17	0.13	Breast cancer;	chr5:133099796	chr5:133003119~133003365:+
BRCA	cis	rs4781563	0.957	rs957078	ENSG00000242307.1	RPS26P52	-4.37	1.38e-05	0.00109	-0.17	-0.13	Bilirubin levels;	chr16:13925847	chr16:13922332~13922679:-
BRCA	cis	rs6968419	0.714	rs7811984	ENSG00000279086.1	RP11-667F14.1	-4.37	1.38e-05	0.0011	-0.15	-0.13	Intraocular pressure;	chr7:116246025	chr7:116209234~116211511:-
BRCA	cis	rs7960884	0.712	rs7962429	ENSG00000226472.6	RP11-551L14.4	-4.37	1.38e-05	0.0011	-0.17	-0.13	Systolic blood pressure response to hydrochlorothiazide in hypertension;	chr12:31225980	chr12:30978308~31006010:-
BRCA	cis	rs1910358	0.621	rs10454885	ENSG00000248874.4	C5orf17	-4.37	1.38e-05	0.0011	-0.19	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23844704	chr5:23951348~24178263:+
BRCA	cis	rs4718428	0.96	rs6460317	ENSG00000273142.1	RP11-458F8.4	-4.37	1.38e-05	0.0011	-0.12	-0.13	Corneal structure;	chr7:66925268	chr7:66902857~66906297:+
BRCA	cis	rs6921919	0.609	rs36018474	ENSG00000220721.1	OR1F12	4.37	1.38e-05	0.0011	0.16	0.13	Autism spectrum disorder or schizophrenia;	chr6:28417752	chr6:28073316~28074233:+
BRCA	cis	rs6921919	0.583	rs13201726	ENSG00000220721.1	OR1F12	4.37	1.38e-05	0.0011	0.16	0.13	Autism spectrum disorder or schizophrenia;	chr6:28417774	chr6:28073316~28074233:+
BRCA	cis	rs2243480	1	rs160634	ENSG00000237026.1	RP11-328P23.2	-4.37	1.38e-05	0.0011	-0.24	-0.13	Diabetic kidney disease;	chr7:66063677	chr7:65235790~65236723:-
BRCA	cis	rs11637445	0.677	rs12441598	ENSG00000260657.2	RP11-315D16.4	-4.37	1.38e-05	0.0011	-0.16	-0.13	Posterior cortical atrophy and Alzheimer's disease;	chr15:67780867	chr15:68267792~68277994:-
BRCA	cis	rs2832191	0.679	rs2705659	ENSG00000215533.7	LINC00189	-4.37	1.39e-05	0.0011	-0.15	-0.13	Dental caries;	chr21:28991587	chr21:29193480~29288205:+
BRCA	cis	rs4869313	0.869	rs10077945	ENSG00000248734.2	CTD-2260A17.1	4.37	1.39e-05	0.0011	0.14	0.13	Pediatric autoimmune diseases;	chr5:96945698	chr5:96784777~96785999:+
BRCA	cis	rs7615952	0.688	rs9754526	ENSG00000241288.6	RP11-379B18.5	-4.37	1.39e-05	0.0011	-0.18	-0.13	Blood pressure (smoking interaction);	chr3:125824023	chr3:125827238~125916384:-
BRCA	cis	rs8180040	0.701	rs13066214	ENSG00000276925.1	RP11-708J19.3	-4.37	1.39e-05	0.0011	-0.15	-0.13	Colorectal cancer;	chr3:46992447	chr3:47469777~47469987:+
BRCA	cis	rs2880765	0.835	rs4360874	ENSG00000202081.1	RNU6-1280P	4.37	1.39e-05	0.0011	0.16	0.13	Coronary artery disease;	chr15:85497589	chr15:85651522~85651628:-
BRCA	cis	rs10833905	1	rs7932620	ENSG00000246225.5	RP11-17A1.3	-4.37	1.39e-05	0.0011	-0.19	-0.13	Sudden cardiac arrest;	chr11:23003174	chr11:22829380~22945393:+
BRCA	cis	rs6738627	0.965	rs2198550	ENSG00000223318.1	RNA5SP111	4.37	1.39e-05	0.0011	0.15	0.13	circulating leptin levels adjusted for BMI;Body fat percentage;circulating leptin levels;	chr2:164700250	chr2:164895677~164895777:-
BRCA	cis	rs11098499	0.954	rs1480931	ENSG00000250412.1	KLHL2P1	4.37	1.39e-05	0.0011	0.16	0.13	Corneal astigmatism;	chr4:119474654	chr4:119334329~119378233:+
BRCA	cis	rs7618915	0.501	rs2159644	ENSG00000243224.1	RP5-1157M23.2	-4.37	1.39e-05	0.0011	-0.14	-0.13	Bipolar disorder;	chr3:52740514	chr3:52239258~52241097:+
BRCA	cis	rs10897473	0.529	rs10751006	ENSG00000236935.1	AP003774.1	-4.37	1.39e-05	0.0011	-0.12	-0.13	Immature fraction of reticulocytes;	chr11:64084722	chr11:64325050~64329504:-
BRCA	cis	rs2154319	0.666	rs11209765	ENSG00000235358.1	RP11-399E6.1	-4.37	1.39e-05	0.0011	-0.18	-0.13	Height;	chr1:41262424	chr1:41242373~41284861:+
BRCA	cis	rs893818	0.832	rs4077284	ENSG00000261801.4	LOXL1-AS1	-4.37	1.39e-05	0.0011	-0.16	-0.13	Exfoliation glaucoma or exfoliation syndrome;	chr15:73936050	chr15:73908071~73928248:-
BRCA	cis	rs875971	0.545	rs10950036	ENSG00000232546.1	RP11-458F8.1	4.37	1.39e-05	0.0011	0.13	0.13	Aortic root size;	chr7:66353241	chr7:66848496~66858136:+
BRCA	cis	rs11048434	0.518	rs759469	ENSG00000256937.1	KRT17P8	4.37	1.39e-05	0.0011	0.14	0.13	Sjögren's syndrome;	chr12:9023108	chr12:9127783~9128645:+
BRCA	cis	rs7474896	1	rs61858629	ENSG00000272983.1	RP11-508N22.12	4.37	1.39e-05	0.0011	0.21	0.13	Obesity (extreme);	chr10:37725842	chr10:38137337~38144399:+
BRCA	cis	rs7474896	1	rs35258216	ENSG00000272983.1	RP11-508N22.12	4.37	1.39e-05	0.0011	0.21	0.13	Obesity (extreme);	chr10:37729292	chr10:38137337~38144399:+
BRCA	cis	rs875971	0.66	rs1860470	ENSG00000223473.2	GS1-124K5.3	-4.37	1.39e-05	0.0011	-0.1	-0.13	Aortic root size;	chr7:66638707	chr7:66491049~66493566:-
BRCA	cis	rs13108904	0.905	rs1732108	ENSG00000253399.1	AC078852.2	4.37	1.39e-05	0.0011	0.15	0.13	Obesity-related traits;	chr4:1282762	chr4:1358479~1359461:+
BRCA	cis	rs12692119	0.764	rs11899448	ENSG00000272667.1	RP11-395A13.2	-4.37	1.39e-05	0.0011	-0.2	-0.13	Pelvic organ prolapse (moderate/severe);	chr2:126891370	chr2:127886556~127887185:+
BRCA	cis	rs7945705	0.905	rs7947631	ENSG00000254860.4	TMEM9B-AS1	4.37	1.39e-05	0.0011	0.12	0.13	Hemoglobin concentration;	chr11:8823362	chr11:8964675~8977527:+
BRCA	cis	rs7200543	1	rs4500751	ENSG00000275910.1	RP11-680G24.6	-4.37	1.39e-05	0.0011	-0.15	-0.13	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15046354	chr16:15015828~15016390:-
BRCA	cis	rs11083475	0.935	rs28488032	ENSG00000267892.1	CTD-2540F13.2	4.37	1.39e-05	0.0011	0.15	0.13	Heart rate;	chr19:38712248	chr19:38738284~38739863:+
BRCA	cis	rs736408	0.522	rs6445535	ENSG00000243224.1	RP5-1157M23.2	-4.37	1.39e-05	0.0011	-0.14	-0.13	Bipolar disorder;	chr3:52737452	chr3:52239258~52241097:+
BRCA	cis	rs736408	0.521	rs13074853	ENSG00000243224.1	RP5-1157M23.2	-4.37	1.39e-05	0.0011	-0.14	-0.13	Bipolar disorder;	chr3:52745785	chr3:52239258~52241097:+
BRCA	cis	rs17684571	0.7	rs36022925	ENSG00000231441.1	RP11-472M19.2	4.37	1.39e-05	0.0011	0.21	0.13	Schizophrenia;	chr6:56818169	chr6:56844002~56864078:+
BRCA	cis	rs7267979	0.527	rs6076369	ENSG00000125804.12	FAM182A	4.37	1.39e-05	0.0011	0.17	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25596147	chr20:26054655~26086917:+
BRCA	cis	rs7267979	0.727	rs2474765	ENSG00000274414.1	RP5-965G21.4	-4.37	1.39e-05	0.0011	-0.16	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25265314	chr20:25239007~25245229:-
BRCA	cis	rs115575488	0.85	rs17185996	ENSG00000236804.1	RPS3AP12	4.37	1.39e-05	0.0011	0.25	0.13	Lobe attachment (rater-scored or self-reported);	chr1:119066109	chr1:119126539~119127291:-
BRCA	cis	rs7209700	0.777	rs8073827	ENSG00000228782.6	CTD-2026D20.3	-4.37	1.39e-05	0.0011	-0.16	-0.13	IgG glycosylation;	chr17:47267296	chr17:47450568~47492492:-
BRCA	cis	rs9308731	0.644	rs3789065	ENSG00000230499.1	AC108463.1	-4.37	1.39e-05	0.0011	-0.15	-0.13	Chronic lymphocytic leukemia;	chr2:111157445	chr2:111195963~111206494:+
BRCA	cis	rs35740288	0.77	rs11631660	ENSG00000202081.1	RNU6-1280P	-4.37	1.39e-05	0.0011	-0.17	-0.13	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85672181	chr15:85651522~85651628:-
BRCA	cis	rs9907295	0.901	rs4251729	ENSG00000271013.1	AC015849.15	-4.37	1.39e-05	0.0011	-0.22	-0.13	Fibroblast growth factor basic levels;	chr17:35818348	chr17:35912635~35918010:-
BRCA	cis	rs13126694	0.65	rs10028808	ENSG00000248429.4	RP11-597D13.9	4.37	1.39e-05	0.0011	0.12	0.13	Blood osmolality (transformed sodium);	chr4:157939488	chr4:158170752~158202877:+
BRCA	cis	rs12428035	0.764	rs9516621	ENSG00000247400.3	DNAJC3-AS1	4.37	1.39e-05	0.0011	0.2	0.13	Glomerular filtration rate (cystatin C);Response to statins (LDL cholesterol change);	chr13:95894123	chr13:95648733~95676925:-
BRCA	cis	rs930395	0.514	rs6874167	ENSG00000251141.4	RP11-53O19.1	-4.37	1.39e-05	0.0011	-0.13	-0.13	Breast cancer;	chr5:44916572	chr5:44744900~44808777:-
BRCA	cis	rs930395	0.514	rs4866921	ENSG00000251141.4	RP11-53O19.1	-4.37	1.39e-05	0.0011	-0.13	-0.13	Breast cancer;	chr5:44917035	chr5:44744900~44808777:-
BRCA	cis	rs930395	0.514	rs6451783	ENSG00000251141.4	RP11-53O19.1	-4.37	1.39e-05	0.0011	-0.13	-0.13	Breast cancer;	chr5:44918191	chr5:44744900~44808777:-
BRCA	cis	rs930395	0.514	rs7736092	ENSG00000251141.4	RP11-53O19.1	-4.37	1.39e-05	0.0011	-0.13	-0.13	Breast cancer;	chr5:44920893	chr5:44744900~44808777:-
BRCA	cis	rs930395	0.514	rs10941687	ENSG00000251141.4	RP11-53O19.1	-4.37	1.39e-05	0.0011	-0.13	-0.13	Breast cancer;	chr5:44921081	chr5:44744900~44808777:-
BRCA	cis	rs930395	0.514	rs7708506	ENSG00000251141.4	RP11-53O19.1	-4.37	1.39e-05	0.0011	-0.13	-0.13	Breast cancer;	chr5:44922602	chr5:44744900~44808777:-
BRCA	cis	rs930395	0.514	rs7708686	ENSG00000251141.4	RP11-53O19.1	-4.37	1.39e-05	0.0011	-0.13	-0.13	Breast cancer;	chr5:44922736	chr5:44744900~44808777:-
BRCA	cis	rs4415084	0.68	rs10042455	ENSG00000251141.4	RP11-53O19.1	-4.37	1.39e-05	0.0011	-0.13	-0.13	Breast cancer;	chr5:44924916	chr5:44744900~44808777:-
BRCA	cis	rs930395	0.514	rs10039866	ENSG00000251141.4	RP11-53O19.1	-4.37	1.39e-05	0.0011	-0.13	-0.13	Breast cancer;	chr5:44924959	chr5:44744900~44808777:-
BRCA	cis	rs12893668	0.703	rs729438	ENSG00000269910.1	RP11-73M18.10	-4.37	1.39e-05	0.0011	-0.14	-0.13	Reticulocyte count;	chr14:103626452	chr14:103694516~103695050:-
BRCA	cis	rs4835473	0.897	rs34425128	ENSG00000249741.2	RP11-673E1.3	4.37	1.39e-05	0.0011	0.16	0.13	Immature fraction of reticulocytes;	chr4:143725191	chr4:143911514~143912053:-
BRCA	cis	rs4865762	0.967	rs1363920	ENSG00000247796.2	CTD-2366F13.1	-4.37	1.39e-05	0.0011	-0.14	-0.13	Intraocular pressure;	chr5:53325450	chr5:53109842~53115126:+
BRCA	cis	rs7308116	0.935	rs10861793	ENSG00000274395.1	RP11-554D14.8	-4.37	1.39e-05	0.0011	-0.15	-0.13	Pelvic organ prolapse (moderate/severe);	chr12:107809736	chr12:107835541~107836555:-
BRCA	cis	rs7111546	1	rs11026797	ENSG00000246225.5	RP11-17A1.3	4.37	1.39e-05	0.0011	0.21	0.13	Dialysis-related mortality;	chr11:22800724	chr11:22829380~22945393:+
BRCA	cis	rs2562456	0.874	rs2562417	ENSG00000268535.1	RP11-420K14.3	-4.37	1.39e-05	0.0011	-0.19	-0.13	Pain;	chr19:21528400	chr19:21709522~21710191:+
BRCA	cis	rs6430585	0.941	rs12469551	ENSG00000224043.6	CCNT2-AS1	4.37	1.39e-05	0.0011	0.21	0.13	Corneal structure;	chr2:135752442	chr2:134735464~134918710:-
BRCA	cis	rs2421332	1	rs2421332	ENSG00000270820.4	RP11-355B11.2	-4.37	1.39e-05	0.0011	-0.17	-0.13	Homeostasis model assessment of beta-cell function (dietary factor interaction);	chr2:61649830	chr2:61471188~61484130:+
BRCA	cis	rs7954584	1	rs7954584	ENSG00000272849.1	RP11-347I19.8	-4.37	1.39e-05	0.0011	-0.11	-0.13	Mean corpuscular volume;	chr12:122023660	chr12:121797511~121801972:+
BRCA	cis	rs6490294	0.904	rs2339908	ENSG00000257624.1	RP1-128M12.3	4.37	1.39e-05	0.0011	0.18	0.13	Mean platelet volume;	chr12:111980692	chr12:112000739~112000985:-
BRCA	cis	rs2154319	0.609	rs12139276	ENSG00000235358.1	RP11-399E6.1	-4.37	1.39e-05	0.0011	-0.18	-0.13	Height;	chr1:41249201	chr1:41242373~41284861:+
BRCA	cis	rs16846053	0.642	rs16846107	ENSG00000227403.1	AC009299.3	4.37	1.39e-05	0.0011	0.25	0.13	Blood osmolality (transformed sodium);	chr2:161775746	chr2:161244739~161249050:+
BRCA	cis	rs8114671	0.836	rs2425012	ENSG00000126005.14	MMP24-AS1	4.37	1.39e-05	0.0011	0.16	0.13	Height;	chr20:34994152	chr20:35216462~35278131:-
BRCA	cis	rs875971	0.545	rs75840613	ENSG00000230295.1	RP11-458F8.2	4.37	1.39e-05	0.0011	0.13	0.13	Aortic root size;	chr7:66376399	chr7:66880708~66882981:+
BRCA	cis	rs372883	0.901	rs407463	ENSG00000215533.7	LINC00189	-4.37	1.39e-05	0.0011	-0.15	-0.13	Pancreatic cancer;	chr21:29350119	chr21:29193480~29288205:+
BRCA	cis	rs7267979	0.718	rs2983489	ENSG00000274414.1	RP5-965G21.4	-4.37	1.39e-05	0.0011	-0.16	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25263484	chr20:25239007~25245229:-
BRCA	cis	rs6686842	0.56	rs11209659	ENSG00000235358.1	RP11-399E6.1	-4.37	1.39e-05	0.0011	-0.18	-0.13	Height;	chr1:41194607	chr1:41242373~41284861:+
BRCA	cis	rs2136613	0.533	rs7088601	ENSG00000238280.1	RP11-436D10.3	-4.37	1.39e-05	0.0011	-0.17	-0.13	Selective IgA deficiency;	chr10:62846627	chr10:62793562~62805887:-
BRCA	cis	rs1555322	1	rs2425040	ENSG00000279253.1	RP4-614O4.13	-4.37	1.39e-05	0.0011	-0.22	-0.13	Attention deficit hyperactivity disorder;	chr20:35271075	chr20:35262727~35264187:-
BRCA	cis	rs651907	0.557	rs36002990	ENSG00000256628.3	ZBTB11-AS1	4.37	1.39e-05	0.0011	0.17	0.13	Colorectal cancer;	chr3:101719018	chr3:101676475~101679217:+
BRCA	cis	rs651907	0.557	rs11720745	ENSG00000256628.3	ZBTB11-AS1	4.37	1.39e-05	0.0011	0.17	0.13	Colorectal cancer;	chr3:101722846	chr3:101676475~101679217:+
BRCA	cis	rs651907	0.557	rs35117343	ENSG00000256628.3	ZBTB11-AS1	4.37	1.39e-05	0.0011	0.17	0.13	Colorectal cancer;	chr3:101726282	chr3:101676475~101679217:+
BRCA	cis	rs6596100	0.956	rs60306856	ENSG00000248648.1	RP11-485M7.1	-4.37	1.4e-05	0.0011	-0.17	-0.13	Breast cancer;	chr5:133107174	chr5:133003119~133003365:+
BRCA	cis	rs7267979	1	rs11087521	ENSG00000276952.1	RP5-965G21.6	4.37	1.4e-05	0.0011	0.17	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25460012	chr20:25284915~25285588:-
BRCA	cis	rs7267979	0.714	rs6115107	ENSG00000125804.12	FAM182A	-4.37	1.4e-05	0.0011	-0.18	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25256754	chr20:26054655~26086917:+
BRCA	cis	rs4648045	0.536	rs12648696	ENSG00000246560.2	RP11-10L12.4	4.37	1.4e-05	0.00111	0.15	0.13	Lymphocyte percentage of white cells;	chr4:102625739	chr4:102828055~102844075:+
BRCA	cis	rs4842666	0.85	rs11105328	ENSG00000270344.2	RP11-734K2.4	4.37	1.4e-05	0.00111	0.17	0.13	Blood pressure;	chr12:89548613	chr12:89525654~89548005:+
BRCA	cis	rs2834288	0.5	rs881231	ENSG00000237945.6	LINC00649	4.37	1.4e-05	0.00111	0.16	0.13	Gut microbiota (bacterial taxa);	chr21:33950526	chr21:33915534~33977691:+
BRCA	cis	rs7260598	0.792	rs73029291	ENSG00000268442.1	CTD-2027I19.2	4.37	1.4e-05	0.00111	0.22	0.13	Response to taxane treatment (placlitaxel);	chr19:24171866	chr19:24162370~24163425:-
BRCA	cis	rs875971	0.628	rs6974355	ENSG00000273024.4	INTS4P2	-4.37	1.4e-05	0.00111	-0.15	-0.13	Aortic root size;	chr7:66376994	chr7:65647864~65715661:+
BRCA	cis	rs6487679	1	rs10734765	ENSG00000111788.10	RP11-22B23.1	4.37	1.4e-05	0.00111	0.15	0.13	Non-alcoholic fatty liver disease histology (AST);	chr12:9216789	chr12:9277235~9313241:+
BRCA	cis	rs3742264	0.816	rs9534319	ENSG00000235903.6	CPB2-AS1	4.37	1.4e-05	0.00111	0.17	0.13	Blood protein levels;	chr13:46090309	chr13:46052806~46113332:+
BRCA	cis	rs7267979	0.966	rs3827014	ENSG00000277938.1	RP5-965G21.3	-4.36	1.4e-05	0.00111	-0.16	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25390923	chr20:25229150~25231933:+
BRCA	cis	rs60843830	1	rs62114501	ENSG00000272342.1	RP13-539J13.1	4.36	1.4e-05	0.00111	0.17	0.13	Spherical equivalent (joint analysis main effects and education interaction);	chr2:231741	chr2:739588~740164:-
BRCA	cis	rs10043228	1	rs12520568	ENSG00000271918.1	CTD-2287O16.5	-4.36	1.4e-05	0.00111	-0.18	-0.13	Asthma or chronic obstructive pulmonary disease;	chr5:116285808	chr5:116083807~116085416:-
BRCA	cis	rs11992186	0.505	rs7845203	ENSG00000254153.1	CTA-398F10.2	4.36	1.4e-05	0.00111	0.16	0.13	Neuroticism;	chr8:8287918	chr8:8456909~8461337:-
BRCA	cis	rs7618915	0.508	rs7628578	ENSG00000243224.1	RP5-1157M23.2	-4.36	1.4e-05	0.00111	-0.14	-0.13	Bipolar disorder;	chr3:52594305	chr3:52239258~52241097:+
BRCA	cis	rs11098499	0.863	rs11098532	ENSG00000250412.1	KLHL2P1	4.36	1.4e-05	0.00111	0.16	0.13	Corneal astigmatism;	chr4:119569571	chr4:119334329~119378233:+
BRCA	cis	rs13401620	0.81	rs12618050	ENSG00000229326.3	AC069154.4	4.36	1.4e-05	0.00111	0.17	0.13	Breast size;	chr2:119960746	chr2:119698623~119700151:+
BRCA	cis	rs10504130	1	rs74953260	ENSG00000272024.1	RP11-546K22.3	-4.36	1.4e-05	0.00111	-0.23	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr8:51863087	chr8:51950284~51950690:+
BRCA	cis	rs10504130	1	rs75826750	ENSG00000272024.1	RP11-546K22.3	-4.36	1.4e-05	0.00111	-0.23	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr8:51863133	chr8:51950284~51950690:+
BRCA	cis	rs6088580	0.634	rs945673	ENSG00000276073.1	RP5-1125A11.7	4.36	1.4e-05	0.00111	0.15	0.13	Glomerular filtration rate (creatinine);	chr20:34376459	chr20:33985617~33988989:-
BRCA	cis	rs7735319	1	rs7735319	ENSG00000249572.1	CTD-2203K17.1	4.36	1.4e-05	0.00111	0.18	0.13	Systolic blood pressure;	chr5:33156863	chr5:33424025~33440619:-
BRCA	cis	rs8016982	0.963	rs7149672	ENSG00000258999.1	RP11-114N19.3	4.36	1.4e-05	0.00111	0.17	0.13	Schizophrenia;	chr14:81190992	chr14:81107033~81170414:-
BRCA	cis	rs9291059	0.572	rs9831772	ENSG00000236297.1	RP11-175P19.2	4.36	1.4e-05	0.00111	0.29	0.13	Depressive symptoms (multi-trait analysis);	chr3:193648150	chr3:193578812~193593090:-
BRCA	cis	rs10129255	0.5	rs8011115	ENSG00000211967.3	IGHV3-53	-4.36	1.4e-05	0.00111	-0.09	-0.13	Kawasaki disease;	chr14:106786292	chr14:106592676~106593347:-
BRCA	cis	rs4718428	0.924	rs6971897	ENSG00000273142.1	RP11-458F8.4	-4.36	1.4e-05	0.00111	-0.12	-0.13	Corneal structure;	chr7:66947787	chr7:66902857~66906297:+
BRCA	cis	rs2278170	1	rs2278171	ENSG00000225101.4	OR52K3P	-4.36	1.4e-05	0.00111	-0.18	-0.13	Amyotrophic lateral sclerosis;	chr11:4475686	chr11:4474813~4475755:+
BRCA	cis	rs4869313	0.837	rs7731592	ENSG00000248734.2	CTD-2260A17.1	4.36	1.4e-05	0.00111	0.14	0.13	Pediatric autoimmune diseases;	chr5:96953256	chr5:96784777~96785999:+
BRCA	cis	rs4869313	0.693	rs75610088	ENSG00000248734.2	CTD-2260A17.1	4.36	1.4e-05	0.00111	0.14	0.13	Pediatric autoimmune diseases;	chr5:96953339	chr5:96784777~96785999:+
BRCA	cis	rs7111546	1	rs57862275	ENSG00000246225.5	RP11-17A1.3	4.36	1.4e-05	0.00111	0.21	0.13	Dialysis-related mortality;	chr11:22800509	chr11:22829380~22945393:+
BRCA	cis	rs17027633	1	rs1419092	ENSG00000260948.1	RP11-552M11.8	-4.36	1.4e-05	0.00111	-0.26	-0.13	Cerebrospinal fluid t-tau:AB1-42 ratio;	chr1:111419587	chr1:111431046~111433068:-
BRCA	cis	rs35612822	0.653	rs6715549	ENSG00000232485.2	AC098820.3	-4.36	1.4e-05	0.00111	-0.16	-0.13	Kidney disease (early stage) in type 1 diabetes;	chr2:216405677	chr2:216479030~216498761:-
BRCA	cis	rs4787491	0.729	rs4788212	ENSG00000183604.13	SMG1P5	4.36	1.4e-05	0.00111	0.13	0.13	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30023148	chr16:30267553~30335374:-
BRCA	cis	rs10761482	0.566	rs10159663	ENSG00000254271.1	RP11-131N11.4	-4.36	1.4e-05	0.00111	-0.19	-0.13	Schizophrenia;	chr10:60448659	chr10:60734342~60741828:+
BRCA	cis	rs2832191	0.692	rs2245734	ENSG00000215533.7	LINC00189	-4.36	1.4e-05	0.00111	-0.15	-0.13	Dental caries;	chr21:28987644	chr21:29193480~29288205:+
BRCA	cis	rs7833790	0.963	rs10958046	ENSG00000254689.1	RP11-354A14.1	4.36	1.4e-05	0.00111	0.19	0.13	Diastolic blood pressure;	chr8:81816975	chr8:81885377~81923193:+
BRCA	cis	rs4478858	0.735	rs12129941	ENSG00000260386.4	LINC01225	-4.36	1.4e-05	0.00111	-0.16	-0.13	Alcohol dependence;	chr1:31399111	chr1:31500085~31540885:+
BRCA	cis	rs2880765	0.835	rs730372	ENSG00000202081.1	RNU6-1280P	-4.36	1.4e-05	0.00111	-0.15	-0.13	Coronary artery disease;	chr15:85494962	chr15:85651522~85651628:-
BRCA	cis	rs67766926	0.953	rs7604989	ENSG00000271889.1	RP11-493E12.1	4.36	1.4e-05	0.00111	0.2	0.13	Inflammatory skin disease;	chr2:60906658	chr2:61151433~61162105:-
BRCA	cis	rs9425766	0.678	rs1951625	ENSG00000227373.4	RP11-160H22.5	4.36	1.4e-05	0.00111	0.2	0.13	Life satisfaction;	chr1:173867464	chr1:174115300~174160004:-
BRCA	cis	rs6088580	0.634	rs6088502	ENSG00000276073.1	RP5-1125A11.7	-4.36	1.4e-05	0.00111	-0.14	-0.13	Glomerular filtration rate (creatinine);	chr20:34449839	chr20:33985617~33988989:-
BRCA	cis	rs7011507	0.582	rs72635699	ENSG00000279881.1	RP11-513O13.1	-4.36	1.41e-05	0.00111	-0.22	-0.13	Inflammatory bowel disease;Ulcerative colitis;	chr8:48305557	chr8:48428143~48431041:-
BRCA	cis	rs801193	1	rs13239306	ENSG00000223473.2	GS1-124K5.3	-4.36	1.41e-05	0.00111	-0.1	-0.13	Aortic root size;	chr7:66671030	chr7:66491049~66493566:-
BRCA	cis	rs216345	0.674	rs216358	ENSG00000260947.1	RP11-384P7.7	-4.36	1.41e-05	0.00111	-0.14	-0.13	Bipolar disorder;	chr9:33808378	chr9:33697459~33700986:+
BRCA	cis	rs216345	0.666	rs1749268	ENSG00000260947.1	RP11-384P7.7	4.36	1.41e-05	0.00111	0.14	0.13	Bipolar disorder;	chr9:33837332	chr9:33697459~33700986:+
BRCA	cis	rs1876905	0.68	rs395564	ENSG00000271789.1	RP5-1112D6.7	-4.36	1.41e-05	0.00111	-0.2	-0.13	Mean corpuscular hemoglobin;	chr6:111176176	chr6:111297126~111298510:+
BRCA	cis	rs7260598	0.792	rs17620048	ENSG00000268442.1	CTD-2027I19.2	4.36	1.41e-05	0.00111	0.22	0.13	Response to taxane treatment (placlitaxel);	chr19:24174677	chr19:24162370~24163425:-
BRCA	cis	rs2229238	0.78	rs61698846	ENSG00000272030.1	RP1-178F15.4	-4.36	1.41e-05	0.00111	-0.19	-0.13	Coronary heart disease;	chr1:154532378	chr1:153631438~153634397:-
BRCA	cis	rs7487075	1	rs7976280	ENSG00000257261.4	RP11-96H19.1	4.36	1.41e-05	0.00111	0.14	0.13	Itch intensity from mosquito bite;	chr12:46407042	chr12:46383679~46876159:+
BRCA	cis	rs12744310	0.945	rs34961305	ENSG00000235358.1	RP11-399E6.1	4.36	1.41e-05	0.00111	0.19	0.13	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41300272	chr1:41242373~41284861:+
BRCA	cis	rs12744310	1	rs35529558	ENSG00000235358.1	RP11-399E6.1	4.36	1.41e-05	0.00111	0.19	0.13	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41301350	chr1:41242373~41284861:+
BRCA	cis	rs2380205	0.967	rs907688	ENSG00000232807.2	RP11-536K7.3	-4.36	1.41e-05	0.00112	-0.14	-0.13	Breast cancer;	chr10:5858859	chr10:5934270~5945900:-
BRCA	cis	rs10829156	0.732	rs7100884	ENSG00000240291.1	RP11-499P20.2	4.36	1.41e-05	0.00112	0.16	0.13	Sudden cardiac arrest;	chr10:18523768	chr10:18513115~18545651:-
BRCA	cis	rs4443100	0.77	rs9612214	ENSG00000230701.2	FBXW4P1	4.36	1.41e-05	0.00112	0.17	0.13	Serum parathyroid hormone levels;	chr22:23025318	chr22:23262767~23265005:+
BRCA	cis	rs739401	0.527	rs423236	ENSG00000247473.2	CARS-AS1	4.36	1.41e-05	0.00112	0.15	0.13	Longevity;	chr11:3044686	chr11:3029009~3041260:+
BRCA	cis	rs1322639	0.575	rs9294966	ENSG00000223485.1	RP11-417E7.1	-4.36	1.41e-05	0.00112	-0.19	-0.13	Pulse pressure;	chr6:169165223	chr6:169158092~169162924:-
BRCA	cis	rs2108622	0.785	rs3093199	ENSG00000267218.2	AC005336.5	4.36	1.41e-05	0.00112	0.16	0.13	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15879061	chr19:15902300~15903238:-
BRCA	cis	rs7811142	0.887	rs4074838	ENSG00000078319.8	PMS2P1	-4.36	1.41e-05	0.00112	-0.22	-0.13	Platelet count;	chr7:100435042	chr7:100320992~100341908:-
BRCA	cis	rs875971	0.965	rs9969301	ENSG00000229180.5	GS1-124K5.11	-4.36	1.41e-05	0.00112	-0.11	-0.13	Aortic root size;	chr7:66316668	chr7:66526088~66542624:-
BRCA	cis	rs4143844	0.867	rs11637599	ENSG00000259251.2	RP11-643M14.1	4.36	1.41e-05	0.00112	0.33	0.13	Bipolar disorder and schizophrenia;	chr15:62058866	chr15:62060503~62062434:+
BRCA	cis	rs4143844	0.867	rs12902859	ENSG00000259251.2	RP11-643M14.1	4.36	1.41e-05	0.00112	0.33	0.13	Bipolar disorder and schizophrenia;	chr15:61884966	chr15:62060503~62062434:+
BRCA	cis	rs11673344	0.523	rs36096221	ENSG00000226686.6	LINC01535	4.36	1.41e-05	0.00112	0.17	0.13	Obesity-related traits;	chr19:37060838	chr19:37251912~37265535:+
BRCA	cis	rs6585424	1	rs10466228	ENSG00000225484.5	NUTM2B-AS1	-4.36	1.41e-05	0.00112	-0.26	-0.13	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80164617	chr10:79663088~79826594:-
BRCA	cis	rs35740288	0.77	rs17570529	ENSG00000202081.1	RNU6-1280P	4.36	1.41e-05	0.00112	0.17	0.13	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85582376	chr15:85651522~85651628:-
BRCA	cis	rs4763879	0.865	rs4763839	ENSG00000278635.1	CTD-2318O12.1	4.36	1.41e-05	0.00112	0.14	0.13	Type 1 diabetes;	chr12:9730104	chr12:9415641~9416718:+
BRCA	cis	rs9868809	0.656	rs13324119	ENSG00000225399.4	RP11-3B7.1	-4.36	1.41e-05	0.00112	-0.2	-0.13	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48673173	chr3:49260085~49261316:+
BRCA	cis	rs516805	0.528	rs2816085	ENSG00000279114.1	RP3-425C14.5	-4.36	1.41e-05	0.00112	-0.16	-0.13	Lymphocyte counts;	chr6:122097324	chr6:122471923~122484161:+
BRCA	cis	rs6968419	1	rs10245914	ENSG00000279086.1	RP11-667F14.1	4.36	1.41e-05	0.00112	0.13	0.13	Intraocular pressure;	chr7:116177531	chr7:116209234~116211511:-
BRCA	cis	rs610932	0.517	rs612738	ENSG00000275344.1	MIR6503	4.36	1.41e-05	0.00112	0.13	0.13	Alzheimer's disease;	chr11:60223118	chr11:60209071~60209156:-
BRCA	cis	rs17345786	1	rs3804775	ENSG00000244119.1	PDCL3P4	4.36	1.41e-05	0.00112	0.12	0.13	Colonoscopy-negative controls vs population controls;	chr3:101587663	chr3:101712472~101713191:+
BRCA	cis	rs8103278	1	rs1548029	ENSG00000267395.4	AC074212.6	4.36	1.41e-05	0.00112	0.14	0.13	Coronary artery disease;	chr19:45805945	chr19:45767796~45772504:+
BRCA	cis	rs8114671	0.836	rs2425012	ENSG00000279253.1	RP4-614O4.13	4.36	1.41e-05	0.00112	0.15	0.13	Height;	chr20:34994152	chr20:35262727~35264187:-
BRCA	cis	rs13113518	0.595	rs13120635	ENSG00000272969.1	RP11-528I4.2	4.36	1.41e-05	0.00112	0.18	0.13	Height;	chr4:55361200	chr4:55547112~55547889:+
BRCA	cis	rs2243480	1	rs316331	ENSG00000222364.1	RNU6-96P	4.36	1.41e-05	0.00112	0.24	0.13	Diabetic kidney disease;	chr7:66139635	chr7:66395191~66395286:+
BRCA	cis	rs7267979	0.903	rs2500400	ENSG00000125804.12	FAM182A	4.36	1.41e-05	0.00112	0.18	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25374069	chr20:26054655~26086917:+
BRCA	cis	rs7428	0.545	rs17026212	ENSG00000273196.1	RP11-717A5.2	4.36	1.41e-05	0.00112	0.15	0.13	Ear protrusion;	chr2:85324573	chr2:85387074~85387146:-
BRCA	cis	rs739496	1	rs739496	ENSG00000234608.6	MAPKAPK5-AS1	4.36	1.42e-05	0.00112	0.16	0.13	Platelet count;	chr12:111449855	chr12:111839764~111842902:-
BRCA	cis	rs8058578	1	rs8058578	ENSG00000260911.2	RP11-196G11.2	4.36	1.42e-05	0.00112	0.13	0.13	Multiple myeloma;	chr16:30714927	chr16:31043150~31049868:+
BRCA	cis	rs3824867	0.92	rs7111873	ENSG00000280615.1	Y_RNA	-4.36	1.42e-05	0.00112	-0.16	-0.13	Mean corpuscular hemoglobin;	chr11:47447887	chr11:47614898~47614994:-
BRCA	cis	rs984222	0.501	rs1325943	ENSG00000231365.4	RP11-418J17.1	-4.36	1.42e-05	0.00112	-0.15	-0.13	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:118942984	chr1:119140396~119275973:+
BRCA	cis	rs984222	0.501	rs1325945	ENSG00000231365.4	RP11-418J17.1	-4.36	1.42e-05	0.00112	-0.15	-0.13	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:118943148	chr1:119140396~119275973:+
BRCA	cis	rs930395	0.514	rs6871820	ENSG00000251141.4	RP11-53O19.1	-4.36	1.42e-05	0.00112	-0.13	-0.13	Breast cancer;	chr5:44919455	chr5:44744900~44808777:-
BRCA	cis	rs6452524	0.868	rs17205699	ENSG00000281327.1	LINC01338	4.36	1.42e-05	0.00112	0.17	0.13	Hypertension (SNP x SNP interaction);	chr5:83098479	chr5:82850864~82859836:-
BRCA	cis	rs73242632	1	rs28681160	ENSG00000269949.1	RP11-738E22.3	4.36	1.42e-05	0.00112	0.31	0.13	Congenital heart disease (maternal effect);	chr4:57023000	chr4:56960927~56961373:-
BRCA	cis	rs763121	0.889	rs2267390	ENSG00000225450.1	RP3-508I15.14	-4.36	1.42e-05	0.00112	-0.15	-0.13	Menopause (age at onset);	chr22:38493652	chr22:38739003~38749041:+
BRCA	cis	rs755249	0.567	rs61779308	ENSG00000182109.6	RP11-69E11.4	4.36	1.42e-05	0.00112	0.19	0.13	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39472585	chr1:39522280~39546187:-
BRCA	cis	rs360929	0.935	rs360930	ENSG00000245954.5	RP11-18H21.1	4.36	1.42e-05	0.00112	0.14	0.13	Volumetric brain MRI;	chr4:151986758	chr4:152100754~152104720:+
BRCA	cis	rs6012564	1	rs911411	ENSG00000227431.4	CSE1L-AS1	4.36	1.42e-05	0.00112	0.16	0.13	Anger;	chr20:49101894	chr20:49040463~49046044:-
BRCA	cis	rs6012564	1	rs6063352	ENSG00000227431.4	CSE1L-AS1	4.36	1.42e-05	0.00112	0.16	0.13	Anger;	chr20:49102057	chr20:49040463~49046044:-
BRCA	cis	rs6012564	1	rs6063353	ENSG00000227431.4	CSE1L-AS1	4.36	1.42e-05	0.00112	0.16	0.13	Anger;	chr20:49103273	chr20:49040463~49046044:-
BRCA	cis	rs6012564	1	rs6063354	ENSG00000227431.4	CSE1L-AS1	4.36	1.42e-05	0.00112	0.16	0.13	Anger;	chr20:49103412	chr20:49040463~49046044:-
BRCA	cis	rs2898290	0.5	rs11998678	ENSG00000154316.13	TDH	4.36	1.42e-05	0.00112	0.17	0.13	Systolic blood pressure;	chr8:11972641	chr8:11339637~11368452:+
BRCA	cis	rs2115630	1	rs2879828	ENSG00000259728.4	LINC00933	-4.36	1.42e-05	0.00112	-0.15	-0.13	P wave terminal force;	chr15:84818746	chr15:84570649~84580175:+
BRCA	cis	rs748404	0.666	rs35158584	ENSG00000205771.5	CATSPER2P1	-4.36	1.42e-05	0.00112	-0.2	-0.13	Lung cancer;	chr15:43392876	chr15:43726918~43747094:-
BRCA	cis	rs11711311	1	rs7622403	ENSG00000241529.3	RN7SL767P	4.36	1.42e-05	0.00112	0.16	0.13	IgG glycosylation;	chr3:113753587	chr3:113632704~113632998:+
BRCA	cis	rs6452524	0.618	rs4266384	ENSG00000281327.1	LINC01338	4.36	1.42e-05	0.00112	0.15	0.13	Hypertension (SNP x SNP interaction);	chr5:83080872	chr5:82850864~82859836:-
BRCA	cis	rs11098499	0.954	rs11940028	ENSG00000260091.1	RP11-33B1.4	-4.36	1.42e-05	0.00112	-0.12	-0.13	Corneal astigmatism;	chr4:119490752	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.954	rs11935596	ENSG00000260091.1	RP11-33B1.4	-4.36	1.42e-05	0.00112	-0.12	-0.13	Corneal astigmatism;	chr4:119491302	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.954	rs12507964	ENSG00000260091.1	RP11-33B1.4	-4.36	1.42e-05	0.00112	-0.12	-0.13	Corneal astigmatism;	chr4:119491906	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.909	rs11098530	ENSG00000260091.1	RP11-33B1.4	-4.36	1.42e-05	0.00112	-0.12	-0.13	Corneal astigmatism;	chr4:119491999	chr4:119409333~119410233:+
BRCA	cis	rs2625529	0.824	rs12916951	ENSG00000260037.4	CTD-2524L6.3	-4.36	1.42e-05	0.00112	-0.18	-0.13	Red blood cell count;	chr15:71960157	chr15:71818396~71823384:+
BRCA	cis	rs9921338	0.923	rs7186455	ENSG00000262636.1	CTD-3088G3.4	-4.36	1.42e-05	0.00112	-0.21	-0.13	Vein graft stenosis in coronary artery bypass grafting;	chr16:11333891	chr16:11380859~11381118:-
BRCA	cis	rs1005277	0.565	rs2474565	ENSG00000263064.2	RP11-291L22.7	4.36	1.42e-05	0.00112	0.16	0.13	Extrinsic epigenetic age acceleration;	chr10:38091900	chr10:38448689~38448949:+
BRCA	cis	rs12612619	0.695	rs4665935	ENSG00000272148.1	RP11-195B17.1	-4.36	1.42e-05	0.00112	-0.15	-0.13	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27007024	chr2:27062428~27062907:-
BRCA	cis	rs10911902	0.643	rs16825224	ENSG00000229739.2	RP11-295K2.3	-4.36	1.42e-05	0.00112	-0.2	-0.13	Schizophrenia;	chr1:186349723	chr1:186435161~186470291:+
BRCA	cis	rs34792	0.554	rs12933773	ENSG00000260872.1	RP11-680G24.5	-4.36	1.42e-05	0.00112	-0.14	-0.13	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15529325	chr16:15018106~15020488:-
BRCA	cis	rs2880765	0.835	rs4843062	ENSG00000202081.1	RNU6-1280P	4.36	1.42e-05	0.00112	0.15	0.13	Coronary artery disease;	chr15:85496906	chr15:85651522~85651628:-
BRCA	cis	rs9467773	1	rs4871	ENSG00000241549.7	GUSBP2	4.36	1.42e-05	0.00112	0.14	0.13	Intelligence (multi-trait analysis);	chr6:26545404	chr6:26871484~26956554:-
BRCA	cis	rs6968419	0.692	rs10500060	ENSG00000279086.1	RP11-667F14.1	-4.36	1.42e-05	0.00112	-0.15	-0.13	Intraocular pressure;	chr7:116260632	chr7:116209234~116211511:-
BRCA	cis	rs13113518	0.841	rs11133400	ENSG00000273257.1	RP11-177J6.1	4.36	1.42e-05	0.00112	0.17	0.13	Height;	chr4:55578787	chr4:55387949~55388271:+
BRCA	cis	rs2531992	1	rs2531992	ENSG00000262888.1	RP11-462G12.2	-4.36	1.42e-05	0.00112	-0.21	-0.13	Waist circumference;	chr16:3971733	chr16:3931217~3946305:-
BRCA	cis	rs11976180	1	rs2961144	ENSG00000244479.5	OR2A1-AS1	-4.36	1.42e-05	0.00112	-0.17	-0.13	Obesity-related traits;	chr7:144050777	chr7:144251264~144356181:-
BRCA	cis	rs8040855	0.658	rs11634877	ENSG00000230373.7	GOLGA6L5P	4.36	1.42e-05	0.00112	0.17	0.13	Bulimia nervosa;	chr15:85068246	chr15:84507885~84516814:-
BRCA	cis	rs8040855	0.627	rs11632175	ENSG00000230373.7	GOLGA6L5P	4.36	1.42e-05	0.00112	0.17	0.13	Bulimia nervosa;	chr15:85068449	chr15:84507885~84516814:-
BRCA	cis	rs67981189	0.574	rs2010713	ENSG00000258571.1	PTTG4P	4.36	1.42e-05	0.00112	0.14	0.13	Schizophrenia;	chr14:70902018	chr14:71085482~71085833:-
BRCA	cis	rs62103177	0.564	rs11874805	ENSG00000278000.1	AC139100.4	4.36	1.42e-05	0.00112	0.22	0.13	Opioid sensitivity;	chr18:79937110	chr18:80161752~80162413:+
BRCA	cis	rs6921919	0.583	rs1054372	ENSG00000220721.1	OR1F12	4.36	1.42e-05	0.00112	0.16	0.13	Autism spectrum disorder or schizophrenia;	chr6:28368965	chr6:28073316~28074233:+
BRCA	cis	rs6921919	0.583	rs9468354	ENSG00000220721.1	OR1F12	4.36	1.42e-05	0.00112	0.16	0.13	Autism spectrum disorder or schizophrenia;	chr6:28370024	chr6:28073316~28074233:+
BRCA	cis	rs6921919	0.583	rs7773051	ENSG00000220721.1	OR1F12	4.36	1.42e-05	0.00112	0.16	0.13	Autism spectrum disorder or schizophrenia;	chr6:28372539	chr6:28073316~28074233:+
BRCA	cis	rs6921919	0.583	rs12697938	ENSG00000220721.1	OR1F12	4.36	1.42e-05	0.00112	0.16	0.13	Autism spectrum disorder or schizophrenia;	chr6:28373322	chr6:28073316~28074233:+
BRCA	cis	rs6921919	0.583	rs13437294	ENSG00000220721.1	OR1F12	4.36	1.42e-05	0.00112	0.16	0.13	Autism spectrum disorder or schizophrenia;	chr6:28373758	chr6:28073316~28074233:+
BRCA	cis	rs6921919	0.609	rs9468357	ENSG00000220721.1	OR1F12	4.36	1.42e-05	0.00112	0.16	0.13	Autism spectrum disorder or schizophrenia;	chr6:28374276	chr6:28073316~28074233:+
BRCA	cis	rs6921919	0.583	rs34513104	ENSG00000220721.1	OR1F12	4.36	1.42e-05	0.00112	0.16	0.13	Autism spectrum disorder or schizophrenia;	chr6:28375566	chr6:28073316~28074233:+
BRCA	cis	rs6921919	0.583	rs9461456	ENSG00000220721.1	OR1F12	4.36	1.42e-05	0.00112	0.16	0.13	Autism spectrum disorder or schizophrenia;	chr6:28376039	chr6:28073316~28074233:+
BRCA	cis	rs6921919	0.525	rs9468360	ENSG00000220721.1	OR1F12	4.36	1.42e-05	0.00112	0.16	0.13	Autism spectrum disorder or schizophrenia;	chr6:28376661	chr6:28073316~28074233:+
BRCA	cis	rs6921919	0.583	rs16894021	ENSG00000220721.1	OR1F12	4.36	1.42e-05	0.00112	0.16	0.13	Autism spectrum disorder or schizophrenia;	chr6:28377249	chr6:28073316~28074233:+
BRCA	cis	rs6921919	0.583	rs11751693	ENSG00000220721.1	OR1F12	4.36	1.42e-05	0.00112	0.16	0.13	Autism spectrum disorder or schizophrenia;	chr6:28377306	chr6:28073316~28074233:+
BRCA	cis	rs6921919	0.583	rs7749736	ENSG00000220721.1	OR1F12	4.36	1.42e-05	0.00112	0.16	0.13	Autism spectrum disorder or schizophrenia;	chr6:28378254	chr6:28073316~28074233:+
BRCA	cis	rs6921919	0.525	rs9468361	ENSG00000220721.1	OR1F12	4.36	1.42e-05	0.00112	0.16	0.13	Autism spectrum disorder or schizophrenia;	chr6:28378541	chr6:28073316~28074233:+
BRCA	cis	rs6921919	0.583	rs7775132	ENSG00000220721.1	OR1F12	4.36	1.42e-05	0.00112	0.16	0.13	Autism spectrum disorder or schizophrenia;	chr6:28379236	chr6:28073316~28074233:+
BRCA	cis	rs6921919	0.583	rs3734563	ENSG00000220721.1	OR1F12	4.36	1.42e-05	0.00112	0.16	0.13	Autism spectrum disorder or schizophrenia;	chr6:28381948	chr6:28073316~28074233:+
BRCA	cis	rs6921919	0.583	rs1591913	ENSG00000220721.1	OR1F12	4.36	1.42e-05	0.00112	0.16	0.13	Autism spectrum disorder or schizophrenia;	chr6:28383951	chr6:28073316~28074233:+
BRCA	cis	rs7267979	0.844	rs6132824	ENSG00000125804.12	FAM182A	-4.36	1.42e-05	0.00112	-0.18	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25257537	chr20:26054655~26086917:+
BRCA	cis	rs9513627	0.915	rs7327204	ENSG00000203441.2	LINC00449	-4.36	1.42e-05	0.00112	-0.24	-0.13	Obesity-related traits;	chr13:99474698	chr13:99499727~99501052:-
BRCA	cis	rs11955398	0.502	rs42437	ENSG00000272308.1	RP11-231G3.1	-4.36	1.42e-05	0.00113	-0.16	-0.13	Intelligence (multi-trait analysis);	chr5:61052219	chr5:60866457~60866935:-
BRCA	cis	rs10208649	0.656	rs60191560	ENSG00000233266.1	HMGB1P31	4.36	1.42e-05	0.00113	0.28	0.13	Body mass index;	chr2:54058661	chr2:54051334~54051760:+
BRCA	cis	rs2274273	0.588	rs17128145	ENSG00000258413.1	RP11-665C16.6	4.36	1.42e-05	0.00113	0.17	0.13	Protein biomarker;	chr14:55069688	chr14:55262767~55272075:-
BRCA	cis	rs11098499	0.58	rs12509234	ENSG00000260091.1	RP11-33B1.4	-4.36	1.42e-05	0.00113	-0.12	-0.13	Corneal astigmatism;	chr4:119398279	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.909	rs10014719	ENSG00000260091.1	RP11-33B1.4	-4.36	1.42e-05	0.00113	-0.12	-0.13	Corneal astigmatism;	chr4:119399560	chr4:119409333~119410233:+
BRCA	cis	rs2998286	1	rs2998286	ENSG00000237128.1	RP11-351M16.3	4.36	1.43e-05	0.00113	0.16	0.13	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28491444	chr10:28433008~28495813:-
BRCA	cis	rs4578769	0.959	rs9945114	ENSG00000265939.1	UBE2CP2	4.36	1.43e-05	0.00113	0.16	0.13	Eosinophil percentage of white cells;	chr18:22884044	chr18:22900486~22900995:-
BRCA	cis	rs11048434	0.518	rs759469	ENSG00000256720.1	RP11-436I9.6	4.36	1.43e-05	0.00113	0.13	0.13	Sjögren's syndrome;	chr12:9023108	chr12:9135084~9135591:+
BRCA	cis	rs2186369	1	rs17548631	ENSG00000272733.1	KB-208E9.1	-4.36	1.43e-05	0.00113	-0.2	-0.13	IgG N-glycosylation phenotypes (multivariate analysis);IgG digalactosylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG glycosylation;IgG fucosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);	chr22:23801938	chr22:23580880~23583859:-
BRCA	cis	rs792448	0.743	rs351378	ENSG00000229983.1	RP11-15I11.2	4.36	1.43e-05	0.00113	0.16	0.13	White blood cell count (basophil);	chr1:212251854	chr1:212168207~212190259:+
BRCA	cis	rs58521262	0.505	rs460336	ENSG00000268105.1	RP11-369G6.2	4.36	1.43e-05	0.00113	0.18	0.13	Testicular germ cell tumor;	chr19:22940621	chr19:23125665~23128543:+
BRCA	cis	rs5758659	0.714	rs5758589	ENSG00000273366.1	CTA-989H11.1	4.36	1.43e-05	0.00113	0.16	0.13	Cognitive function;	chr22:42122378	chr22:42278188~42278846:+
BRCA	cis	rs4666002	0.956	rs10169065	ENSG00000234072.1	AC074117.10	4.36	1.43e-05	0.00113	0.13	0.13	Phospholipid levels (plasma);	chr2:27555693	chr2:27356246~27367622:+
BRCA	cis	rs4666002	0.956	rs10179872	ENSG00000234072.1	AC074117.10	4.36	1.43e-05	0.00113	0.13	0.13	Phospholipid levels (plasma);	chr2:27555705	chr2:27356246~27367622:+
BRCA	cis	rs2832191	0.636	rs8131295	ENSG00000176054.6	RPL23P2	-4.36	1.43e-05	0.00113	-0.15	-0.13	Dental caries;	chr21:29144498	chr21:28997613~28998033:-
BRCA	cis	rs7572733	0.935	rs700659	ENSG00000231621.1	AC013264.2	-4.36	1.43e-05	0.00113	-0.12	-0.13	Dermatomyositis;	chr2:197795199	chr2:197197991~197199273:+
BRCA	cis	rs73242632	0.867	rs28545156	ENSG00000269949.1	RP11-738E22.3	4.36	1.43e-05	0.00113	0.31	0.13	Congenital heart disease (maternal effect);	chr4:57013174	chr4:56960927~56961373:-
BRCA	cis	rs9784649	1	rs9784649	ENSG00000245662.2	RP11-184E9.1	4.36	1.43e-05	0.00113	0.2	0.13	Peripheral arterial disease (traffic-related air pollution interaction);	chr5:25011415	chr5:25190682~25306172:+
BRCA	cis	rs11168618	0.904	rs4359253	ENSG00000240399.1	RP1-228P16.1	4.36	1.43e-05	0.00113	0.15	0.13	Adiponectin levels;	chr12:48533925	chr12:48054813~48055591:-
BRCA	cis	rs6751744	0.824	rs10205689	ENSG00000224152.1	AC009506.1	-4.36	1.43e-05	0.00113	-0.16	-0.13	Dysphagia;	chr2:159507158	chr2:159615296~159617082:+
BRCA	cis	rs2749592	0.513	rs1208708	ENSG00000099251.13	HSD17B7P2	4.36	1.43e-05	0.00113	0.15	0.13	Age-related hearing impairment (SNP x SNP interaction);	chr10:37796648	chr10:38356380~38378505:+
BRCA	cis	rs12681366	1	rs2960122	ENSG00000253175.1	RP11-267M23.6	4.36	1.43e-05	0.00113	0.15	0.13	Nonsyndromic cleft lip with cleft palate;	chr8:94419858	chr8:94565036~94565715:+
BRCA	cis	rs2731006	0.64	rs1517672	ENSG00000257114.2	RP11-25I15.3	4.36	1.43e-05	0.00113	0.22	0.13	Panic disorder;	chr12:42780156	chr12:42692216~42717119:+
BRCA	cis	rs6460942	0.597	rs35317839	ENSG00000226690.5	AC005281.1	4.36	1.43e-05	0.00113	0.27	0.13	Coronary artery disease;	chr7:12484771	chr7:12496429~12541910:+
BRCA	cis	rs6460942	0.597	rs13227809	ENSG00000226690.5	AC005281.1	4.36	1.43e-05	0.00113	0.27	0.13	Coronary artery disease;	chr7:12485931	chr7:12496429~12541910:+
BRCA	cis	rs6460942	0.597	rs17448193	ENSG00000226690.5	AC005281.1	4.36	1.43e-05	0.00113	0.27	0.13	Coronary artery disease;	chr7:12486015	chr7:12496429~12541910:+
BRCA	cis	rs2243480	1	rs781157	ENSG00000222364.1	RNU6-96P	-4.36	1.43e-05	0.00113	-0.24	-0.13	Diabetic kidney disease;	chr7:66013324	chr7:66395191~66395286:+
BRCA	cis	rs12744310	1	rs2364535	ENSG00000235358.1	RP11-399E6.1	4.36	1.43e-05	0.00113	0.19	0.13	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41300564	chr1:41242373~41284861:+
BRCA	cis	rs875971	0.638	rs6460305	ENSG00000273142.1	RP11-458F8.4	4.36	1.43e-05	0.00113	0.12	0.13	Aortic root size;	chr7:66595421	chr7:66902857~66906297:+
BRCA	cis	rs2073316	0.592	rs7585845	ENSG00000272716.1	RP11-563N4.1	4.36	1.43e-05	0.00113	0.14	0.13	Interleukin-18 levels;	chr2:31446761	chr2:32165046~32165757:-
BRCA	cis	rs6545883	0.894	rs2694649	ENSG00000212978.6	AC016747.3	-4.36	1.43e-05	0.00113	-0.18	-0.13	Tuberculosis;	chr2:61346691	chr2:61141592~61144969:-
BRCA	cis	rs11673344	0.583	rs10425719	ENSG00000267422.1	CTD-2554C21.1	-4.36	1.43e-05	0.00113	-0.16	-0.13	Obesity-related traits;	chr19:37459896	chr19:37779686~37792865:+
BRCA	cis	rs10129255	0.828	rs10140989	ENSG00000211967.3	IGHV3-53	-4.36	1.43e-05	0.00113	-0.1	-0.13	Kawasaki disease;	chr14:106668657	chr14:106592676~106593347:-
BRCA	cis	rs871012	0.502	rs60416963	ENSG00000248544.2	CTB-47B11.3	-4.36	1.43e-05	0.00113	-0.18	-0.13	IgG glycosylation;	chr5:157441157	chr5:157375741~157384950:-
BRCA	cis	rs17772222	0.958	rs1123421	ENSG00000258789.1	RP11-507K2.3	-4.36	1.43e-05	0.00113	-0.16	-0.13	Coronary artery calcification;	chr14:88524651	chr14:88551597~88552493:+
BRCA	cis	rs780094	0.5	rs12478841	ENSG00000234072.1	AC074117.10	4.36	1.43e-05	0.00113	0.13	0.13	Urate levels in overweight individuals;C-reactive protein;Metabolic syndrome;Red blood cell count;Renal underexcretion gout;Nonalcoholic fatty liver disease;Age-related diseases, mortality and associated endophenotypes;Crohn's disease;Calcium levels;Fasting plasma glucose;Metabolic traits;Fasting blood glucose;Fasting blood insulin;Urate levels in obese individuals;Alcohol consumption (drinks per week);Height;Urate levels;Gondoic acid (20:1n-9) levels;Uric acid levels;Age-related disease endophenotypes;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Homeostasis model assessment of insulin resistance;Alcohol consumption;Fasting blood insulin (BMI interaction);Triglycerides;Fasting blood glucose (BMI interaction);Hypertriglyceridemia;LDL cholesterol;Type 2 diabetes;Triglyceride levels;	chr2:27588855	chr2:27356246~27367622:+
BRCA	cis	rs780094	0.5	rs6760250	ENSG00000234072.1	AC074117.10	4.36	1.43e-05	0.00113	0.13	0.13	Urate levels in overweight individuals;C-reactive protein;Metabolic syndrome;Red blood cell count;Renal underexcretion gout;Nonalcoholic fatty liver disease;Age-related diseases, mortality and associated endophenotypes;Crohn's disease;Calcium levels;Fasting plasma glucose;Metabolic traits;Fasting blood glucose;Fasting blood insulin;Urate levels in obese individuals;Alcohol consumption (drinks per week);Height;Urate levels;Gondoic acid (20:1n-9) levels;Uric acid levels;Age-related disease endophenotypes;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Homeostasis model assessment of insulin resistance;Alcohol consumption;Fasting blood insulin (BMI interaction);Triglycerides;Fasting blood glucose (BMI interaction);Hypertriglyceridemia;LDL cholesterol;Type 2 diabetes;Triglyceride levels;	chr2:27589385	chr2:27356246~27367622:+
BRCA	cis	rs875971	0.964	rs697969	ENSG00000229180.5	GS1-124K5.11	-4.36	1.43e-05	0.00113	-0.12	-0.13	Aortic root size;	chr7:66093491	chr7:66526088~66542624:-
BRCA	cis	rs875971	1	rs1182882	ENSG00000229180.5	GS1-124K5.11	-4.36	1.43e-05	0.00113	-0.12	-0.13	Aortic root size;	chr7:66097076	chr7:66526088~66542624:-
BRCA	cis	rs875971	1	rs6460292	ENSG00000236529.1	RP13-254B10.1	-4.36	1.43e-05	0.00113	-0.15	-0.13	Aortic root size;	chr7:66345088	chr7:65840212~65840596:+
BRCA	cis	rs9818758	0.607	rs9850917	ENSG00000225399.4	RP11-3B7.1	-4.36	1.43e-05	0.00113	-0.2	-0.13	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49249550	chr3:49260085~49261316:+
BRCA	cis	rs9818758	0.607	rs9847839	ENSG00000225399.4	RP11-3B7.1	-4.36	1.43e-05	0.00113	-0.2	-0.13	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49251570	chr3:49260085~49261316:+
BRCA	cis	rs924712	0.545	rs9296769	ENSG00000224984.1	RP11-524H19.2	4.36	1.43e-05	0.00113	0.16	0.13	Breast cancer;	chr6:54841180	chr6:54840118~54840855:-
BRCA	cis	rs924712	0.545	rs1910357	ENSG00000224984.1	RP11-524H19.2	4.36	1.43e-05	0.00113	0.16	0.13	Breast cancer;	chr6:54841588	chr6:54840118~54840855:-
BRCA	cis	rs4478858	0.647	rs12752761	ENSG00000223907.1	LINC01226	-4.36	1.43e-05	0.00113	-0.16	-0.13	Alcohol dependence;	chr1:31238041	chr1:31518435~31524245:+
BRCA	cis	rs1552244	0.572	rs67227131	ENSG00000232901.1	CYCSP10	4.36	1.43e-05	0.00113	0.23	0.13	Alzheimer's disease;	chr3:10131060	chr3:10000647~10000940:-
BRCA	cis	rs4664293	0.967	rs35975814	ENSG00000224152.1	AC009506.1	-4.36	1.43e-05	0.00113	-0.15	-0.13	Monocyte percentage of white cells;	chr2:159691280	chr2:159615296~159617082:+
BRCA	cis	rs2625529	0.652	rs28650442	ENSG00000260037.4	CTD-2524L6.3	-4.36	1.43e-05	0.00113	-0.17	-0.13	Red blood cell count;	chr15:71863104	chr15:71818396~71823384:+
BRCA	cis	rs7572733	0.869	rs57862683	ENSG00000231621.1	AC013264.2	-4.36	1.44e-05	0.00113	-0.12	-0.13	Dermatomyositis;	chr2:197882813	chr2:197197991~197199273:+
BRCA	cis	rs17507216	0.718	rs4779033	ENSG00000255769.6	GOLGA2P10	4.36	1.44e-05	0.00113	0.2	0.13	Excessive daytime sleepiness;	chr15:82576634	chr15:82472993~82513950:-
BRCA	cis	rs2765539	0.545	rs1623409	ENSG00000231365.4	RP11-418J17.1	-4.36	1.44e-05	0.00113	-0.19	-0.13	Waist-hip ratio;	chr1:118962218	chr1:119140396~119275973:+
BRCA	cis	rs10995356	0.932	rs10822082	ENSG00000238280.1	RP11-436D10.3	4.36	1.44e-05	0.00113	0.17	0.13	Temperament;	chr10:62917547	chr10:62793562~62805887:-
BRCA	cis	rs875971	0.66	rs79009421	ENSG00000273142.1	RP11-458F8.4	4.36	1.44e-05	0.00113	0.12	0.13	Aortic root size;	chr7:66603522	chr7:66902857~66906297:+
BRCA	cis	rs801193	1	rs7785213	ENSG00000272831.1	RP11-792A8.4	-4.36	1.44e-05	0.00113	-0.12	-0.13	Aortic root size;	chr7:66673991	chr7:66739829~66740385:-
BRCA	cis	rs2075466	0.514	rs76214824	ENSG00000267077.1	RP11-127I20.5	4.36	1.44e-05	0.00113	0.21	0.13	Colonoscopy-negative controls vs population controls;	chr16:4850238	chr16:4795265~4796532:-
BRCA	cis	rs34217772	1	rs17181692	ENSG00000258636.1	CTD-2298J14.2	4.36	1.44e-05	0.00113	0.18	0.13	Myopia;	chr14:41791135	chr14:41587861~41604856:-
BRCA	cis	rs2229238	0.911	rs60760897	ENSG00000272030.1	RP1-178F15.4	-4.36	1.44e-05	0.00114	-0.19	-0.13	Coronary heart disease;	chr1:154532373	chr1:153631438~153634397:-
BRCA	cis	rs860295	0.702	rs11264366	ENSG00000225855.5	RUSC1-AS1	4.36	1.44e-05	0.00114	0.11	0.13	Body mass index;	chr1:155365620	chr1:155316863~155324176:-
BRCA	cis	rs7818688	0.697	rs11782590	ENSG00000253528.2	RP11-347C18.4	-4.36	1.44e-05	0.00114	-0.2	-0.13	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94957930	chr8:94974573~94974853:-
BRCA	cis	rs9834975	0.935	rs6788318	ENSG00000272758.4	RP11-299J3.8	-4.36	1.44e-05	0.00114	-0.14	-0.13	Diastolic blood pressure;	chr3:122387672	chr3:122416207~122443180:+
BRCA	cis	rs17818399	0.781	rs13024534	ENSG00000279254.1	RP11-536C12.1	-4.36	1.44e-05	0.00114	-0.18	-0.13	Height;	chr2:46632247	chr2:46668870~46670778:+
BRCA	cis	rs801193	0.935	rs3800820	ENSG00000272831.1	RP11-792A8.4	-4.36	1.44e-05	0.00114	-0.12	-0.13	Aortic root size;	chr7:66682191	chr7:66739829~66740385:-
BRCA	cis	rs11892454	0.544	rs7560314	ENSG00000217643.1	PTGES3P2	-4.36	1.44e-05	0.00114	-0.14	-0.13	Heschl's gyrus morphology;	chr2:25785090	chr2:25822469~25822950:+
BRCA	cis	rs801193	0.967	rs3800823	ENSG00000229180.5	GS1-124K5.11	-4.36	1.44e-05	0.00114	-0.12	-0.13	Aortic root size;	chr7:66682123	chr7:66526088~66542624:-
BRCA	cis	rs801193	0.613	rs2659900	ENSG00000229180.5	GS1-124K5.11	4.36	1.44e-05	0.00114	0.12	0.13	Aortic root size;	chr7:66719456	chr7:66526088~66542624:-
BRCA	cis	rs7267979	1	rs10966	ENSG00000274973.1	RP13-401N8.7	-4.36	1.44e-05	0.00114	-0.15	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25302308	chr20:25845497~25845862:+
BRCA	cis	rs12612619	0.732	rs11677841	ENSG00000272148.1	RP11-195B17.1	4.36	1.44e-05	0.00114	0.15	0.13	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27017081	chr2:27062428~27062907:-
BRCA	cis	rs16958440	0.867	rs77348110	ENSG00000267724.1	RP11-49K24.8	4.36	1.44e-05	0.00114	0.26	0.13	Sitting height ratio;	chr18:47147796	chr18:47105946~47108062:+
BRCA	cis	rs1549733	0.577	rs35027447	ENSG00000229754.1	CXCR2P1	-4.36	1.44e-05	0.00114	-0.13	-0.13	Optic disc area;	chr2:217555869	chr2:218059155~218065729:-
BRCA	cis	rs6600671	1	rs12145080	ENSG00000275538.1	RNVU1-19	-4.36	1.44e-05	0.00114	-0.16	-0.13	Hip geometry;	chr1:121443673	chr1:120850819~120850985:-
BRCA	cis	rs11892454	0.544	rs6739177	ENSG00000217643.1	PTGES3P2	-4.36	1.44e-05	0.00114	-0.14	-0.13	Heschl's gyrus morphology;	chr2:25729927	chr2:25822469~25822950:+
BRCA	cis	rs13326165	0.585	rs3733063	ENSG00000243224.1	RP5-1157M23.2	-4.36	1.44e-05	0.00114	-0.22	-0.13	HDL cholesterol levels;HDL cholesterol;	chr3:52294517	chr3:52239258~52241097:+
BRCA	cis	rs11742741	1	rs7709087	ENSG00000248874.4	C5orf17	-4.36	1.44e-05	0.00114	-0.17	-0.13	Educational attainment;	chr5:24172941	chr5:23951348~24178263:+
BRCA	cis	rs559555	0.597	rs502139	ENSG00000276334.1	AL133243.1	4.36	1.44e-05	0.00114	0.17	0.13	Blood metabolite ratios;Blood metabolite levels;	chr2:31586199	chr2:32521927~32523547:+
BRCA	cis	rs11673344	0.504	rs4254428	ENSG00000226686.6	LINC01535	4.36	1.44e-05	0.00114	0.17	0.13	Obesity-related traits;	chr19:37093748	chr19:37251912~37265535:+
BRCA	cis	rs7267979	0.565	rs13040726	ENSG00000125804.12	FAM182A	4.36	1.44e-05	0.00114	0.17	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25579245	chr20:26054655~26086917:+
BRCA	cis	rs7789940	0.81	rs12533978	ENSG00000280388.1	RP11-229D13.3	-4.36	1.44e-05	0.00114	-0.15	-0.13	Multiple sclerosis;	chr7:76314035	chr7:76043977~76045963:-
BRCA	cis	rs950169	0.58	rs17532346	ENSG00000176700.18	SCAND2P	-4.36	1.44e-05	0.00114	-0.14	-0.13	Schizophrenia;	chr15:84628264	chr15:84631451~84647478:+
BRCA	cis	rs12435908	1	rs17246035	ENSG00000276116.2	FUT8-AS1	-4.36	1.44e-05	0.00114	-0.21	-0.13	Ischemic stroke;	chr14:65407412	chr14:65411170~65412690:-
BRCA	cis	rs1665650	0.834	rs4752003	ENSG00000232767.1	RP11-498B4.5	4.36	1.44e-05	0.00114	0.15	0.13	Colorectal cancer;	chr10:116713204	chr10:116670103~116672739:+
BRCA	cis	rs2235649	0.833	rs9925460	ENSG00000255198.4	SNHG9	-4.36	1.44e-05	0.00114	-0.15	-0.13	Blood metabolite levels;	chr16:1799942	chr16:1964959~1965509:+
BRCA	cis	rs7577696	0.509	rs589427	ENSG00000272716.1	RP11-563N4.1	4.36	1.44e-05	0.00114	0.16	0.13	Inflammatory biomarkers;	chr2:31647444	chr2:32165046~32165757:-
BRCA	cis	rs17270561	0.636	rs9348696	ENSG00000272462.2	U91328.19	-4.36	1.44e-05	0.00114	-0.16	-0.13	Iron status biomarkers;	chr6:25781710	chr6:25992662~26001775:+
BRCA	cis	rs7520050	0.807	rs4468203	ENSG00000234329.1	RP11-767N6.2	4.36	1.44e-05	0.00114	0.13	0.13	Reticulocyte count;Red blood cell count;	chr1:45647600	chr1:45651039~45651826:-
BRCA	cis	rs6430585	0.64	rs58301703	ENSG00000224043.6	CCNT2-AS1	-4.36	1.44e-05	0.00114	-0.23	-0.13	Corneal structure;	chr2:135774655	chr2:134735464~134918710:-
BRCA	cis	rs2803122	0.502	rs1329731	ENSG00000272842.1	RP11-513M16.7	-4.36	1.44e-05	0.00114	-0.15	-0.13	Pulse pressure;	chr9:19234910	chr9:19371386~19371945:-
BRCA	cis	rs7705093	1	rs7705093	ENSG00000248734.2	CTD-2260A17.1	4.36	1.44e-05	0.00114	0.14	0.13	Birdshot chorioretinopathy;	chr5:96954943	chr5:96784777~96785999:+
BRCA	cis	rs6128907	0.8	rs6129026	ENSG00000224635.1	RP4-564F22.5	4.36	1.45e-05	0.00114	0.24	0.13	Liver fibrosis in pediatric non-alcoholic fatty acid liver disease;	chr20:38787252	chr20:38406011~38416797:-
BRCA	cis	rs12612619	0.704	rs3769139	ENSG00000272148.1	RP11-195B17.1	4.36	1.45e-05	0.00114	0.15	0.13	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27092846	chr2:27062428~27062907:-
BRCA	cis	rs2505998	0.843	rs2506008	ENSG00000273008.1	RP11-351D16.3	-4.36	1.45e-05	0.00114	-0.16	-0.13	Hirschsprung disease;	chr10:43084776	chr10:43136824~43138334:-
BRCA	cis	rs7412746	0.611	rs10888395	ENSG00000231073.1	RP11-316M1.3	4.36	1.45e-05	0.00114	0.14	0.13	Melanoma;	chr1:150789695	chr1:150973123~150975534:+
BRCA	cis	rs3798305	1	rs16899788	ENSG00000198221.8	MLLT4-AS1	4.36	1.45e-05	0.00114	0.32	0.13	Smooth-surface caries;	chr6:167017838	chr6:167823876~167826709:-
BRCA	cis	rs7621331	0.963	rs6809006	ENSG00000273486.1	RP11-731C17.2	4.36	1.45e-05	0.00114	0.16	0.13	Waist circumference adjusted for body mass index;	chr3:136012398	chr3:136837338~136839021:-
BRCA	cis	rs8130944	1	rs2269150	ENSG00000225731.1	AP001627.1	-4.36	1.45e-05	0.00114	-0.15	-0.13	Perceived unattractiveness to mosquitoes;	chr21:42721339	chr21:42733594~42741758:-
BRCA	cis	rs2692947	0.832	rs4907212	ENSG00000168992.4	OR7E102P	4.36	1.45e-05	0.00114	0.18	0.13	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95744300	chr2:95546531~95547545:+
BRCA	cis	rs67766926	1	rs9309331	ENSG00000271889.1	RP11-493E12.1	4.36	1.45e-05	0.00114	0.2	0.13	Inflammatory skin disease;	chr2:60914480	chr2:61151433~61162105:-
BRCA	cis	rs9818758	0.607	rs71324929	ENSG00000270441.1	RP11-694I15.7	4.36	1.45e-05	0.00114	0.31	0.13	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49007280	chr3:49140086~49160851:-
BRCA	cis	rs72772090	0.522	rs111620024	ENSG00000248734.2	CTD-2260A17.1	-4.36	1.45e-05	0.00114	-0.32	-0.13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96662687	chr5:96784777~96785999:+
BRCA	cis	rs6012564	1	rs2295028	ENSG00000227431.4	CSE1L-AS1	-4.36	1.45e-05	0.00114	-0.16	-0.13	Anger;	chr20:48966421	chr20:49040463~49046044:-
BRCA	cis	rs4753788	0.688	rs7926602	ENSG00000255353.1	RP11-382M14.1	-4.36	1.45e-05	0.00114	-0.16	-0.13	Coronary artery disease;	chr11:107183916	chr11:107176286~107177530:+
BRCA	cis	rs867186	1	rs6060246	ENSG00000126005.14	MMP24-AS1	-4.36	1.45e-05	0.00114	-0.24	-0.13	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35113304	chr20:35216462~35278131:-
BRCA	cis	rs2243480	0.711	rs1626926	ENSG00000222364.1	RNU6-96P	-4.36	1.45e-05	0.00114	-0.24	-0.13	Diabetic kidney disease;	chr7:65970805	chr7:66395191~66395286:+
BRCA	cis	rs4666002	0.956	rs2384656	ENSG00000234072.1	AC074117.10	4.36	1.45e-05	0.00114	0.13	0.13	Phospholipid levels (plasma);	chr2:27609188	chr2:27356246~27367622:+
BRCA	cis	rs62025270	0.747	rs17639314	ENSG00000259762.1	RP11-158M2.4	-4.36	1.45e-05	0.00114	-0.2	-0.13	Idiopathic pulmonary fibrosis;	chr15:85766678	chr15:85750336~85752901:-
BRCA	cis	rs7520050	0.751	rs2230657	ENSG00000234329.1	RP11-767N6.2	-4.36	1.45e-05	0.00114	-0.13	-0.13	Reticulocyte count;Red blood cell count;	chr1:45607817	chr1:45651039~45651826:-
BRCA	cis	rs2625529	0.938	rs9120	ENSG00000260037.4	CTD-2524L6.3	-4.36	1.45e-05	0.00114	-0.19	-0.13	Red blood cell count;	chr15:71823422	chr15:71818396~71823384:+
BRCA	cis	rs997295	0.713	rs12904982	ENSG00000270964.1	RP11-502I4.3	-4.36	1.45e-05	0.00114	-0.15	-0.13	Motion sickness;	chr15:67713941	chr15:67541072~67542604:-
BRCA	cis	rs6545883	0.507	rs34668697	ENSG00000273302.1	RP11-493E12.2	-4.36	1.45e-05	0.00114	-0.12	-0.13	Tuberculosis;	chr2:61341214	chr2:61199979~61200769:+
BRCA	cis	rs11951515	0.508	rs6860493	ENSG00000248240.1	RP11-159F24.5	-4.36	1.45e-05	0.00114	-0.17	-0.13	Metabolite levels  (X-11787);	chr5:43602611	chr5:43515274~43525310:+
BRCA	cis	rs72843506	0.591	rs74319100	ENSG00000270091.1	RP11-78O7.2	-4.36	1.45e-05	0.00114	-0.21	-0.13	Schizophrenia;	chr17:20318079	chr17:19896590~19897287:-
BRCA	cis	rs11742741	0.87	rs55884304	ENSG00000248874.4	C5orf17	-4.36	1.45e-05	0.00114	-0.18	-0.13	Educational attainment;	chr5:24242571	chr5:23951348~24178263:+
BRCA	cis	rs11951515	0.508	rs7706431	ENSG00000248240.1	RP11-159F24.5	-4.36	1.45e-05	0.00114	-0.16	-0.13	Metabolite levels  (X-11787);	chr5:43582321	chr5:43515274~43525310:+
BRCA	cis	rs6012564	0.826	rs34778847	ENSG00000227431.4	CSE1L-AS1	4.36	1.45e-05	0.00115	0.16	0.13	Anger;	chr20:49121421	chr20:49040463~49046044:-
BRCA	cis	rs7404843	0.789	rs222907	ENSG00000263065.1	AF001548.6	4.36	1.45e-05	0.00115	0.24	0.13	Testicular germ cell tumor;	chr16:15404950	chr16:15741151~15741791:+
BRCA	cis	rs10129255	0.957	rs2013423	ENSG00000274576.2	IGHV2-70	4.36	1.45e-05	0.00115	0.12	0.13	Kawasaki disease;	chr14:106690675	chr14:106770577~106771020:-
BRCA	cis	rs10129255	0.957	rs56134540	ENSG00000274576.2	IGHV2-70	4.36	1.45e-05	0.00115	0.12	0.13	Kawasaki disease;	chr14:106691290	chr14:106770577~106771020:-
BRCA	cis	rs13098911	0.598	rs13089554	ENSG00000223552.1	RP11-24F11.2	-4.36	1.45e-05	0.00115	-0.22	-0.13	Celiac disease;	chr3:46086065	chr3:46364955~46407059:-
BRCA	cis	rs13098911	0.54	rs13095717	ENSG00000223552.1	RP11-24F11.2	-4.36	1.45e-05	0.00115	-0.22	-0.13	Celiac disease;	chr3:46087050	chr3:46364955~46407059:-
BRCA	cis	rs13098911	0.54	rs13075528	ENSG00000223552.1	RP11-24F11.2	-4.36	1.45e-05	0.00115	-0.22	-0.13	Celiac disease;	chr3:46087217	chr3:46364955~46407059:-
BRCA	cis	rs4689592	0.523	rs3857179	ENSG00000245468.3	RP11-367J11.3	4.36	1.45e-05	0.00115	0.14	0.13	Monocyte percentage of white cells;	chr4:7068769	chr4:7094571~7103385:-
BRCA	cis	rs2243480	1	rs6460260	ENSG00000222364.1	RNU6-96P	4.36	1.45e-05	0.00115	0.24	0.13	Diabetic kidney disease;	chr7:65750468	chr7:66395191~66395286:+
BRCA	cis	rs2243480	1	rs6460261	ENSG00000222364.1	RNU6-96P	4.36	1.45e-05	0.00115	0.24	0.13	Diabetic kidney disease;	chr7:65750593	chr7:66395191~66395286:+
BRCA	cis	rs926392	1	rs926392	ENSG00000274825.1	RP4-616B8.5	-4.36	1.45e-05	0.00115	-0.13	-0.13	Dialysis-related mortality;	chr20:39061821	chr20:38955910~38956547:+
BRCA	cis	rs7267979	0.899	rs442834	ENSG00000125804.12	FAM182A	-4.36	1.46e-05	0.00115	-0.17	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25477460	chr20:26054655~26086917:+
BRCA	cis	rs2839186	0.934	rs17182538	ENSG00000239415.1	AP001469.9	4.36	1.46e-05	0.00115	0.14	0.13	Testicular germ cell tumor;	chr21:46285759	chr21:46251549~46254133:-
BRCA	cis	rs61160187	0.582	rs62372103	ENSG00000272308.1	RP11-231G3.1	-4.36	1.46e-05	0.00115	-0.15	-0.13	Educational attainment (years of education);Educational attainment (college completion);	chr5:60849621	chr5:60866457~60866935:-
BRCA	cis	rs1538970	0.816	rs11211124	ENSG00000281133.1	AL355480.3	-4.36	1.46e-05	0.00115	-0.19	-0.13	Platelet count;	chr1:45496737	chr1:45580892~45580996:-
BRCA	cis	rs930395	0.514	rs6880275	ENSG00000251141.4	RP11-53O19.1	-4.36	1.46e-05	0.00115	-0.13	-0.13	Breast cancer;	chr5:44908833	chr5:44744900~44808777:-
BRCA	cis	rs930395	0.514	rs6870136	ENSG00000251141.4	RP11-53O19.1	-4.36	1.46e-05	0.00115	-0.13	-0.13	Breast cancer;	chr5:44910560	chr5:44744900~44808777:-
BRCA	cis	rs930395	0.514	rs6881563	ENSG00000251141.4	RP11-53O19.1	-4.36	1.46e-05	0.00115	-0.13	-0.13	Breast cancer;	chr5:44912751	chr5:44744900~44808777:-
BRCA	cis	rs10946940	0.864	rs13201411	ENSG00000220721.1	OR1F12	-4.36	1.46e-05	0.00115	-0.15	-0.13	Systemic lupus erythematosus;	chr6:27530438	chr6:28073316~28074233:+
BRCA	cis	rs718314	0.685	rs11048470	ENSG00000256894.1	RP11-283G6.3	4.36	1.46e-05	0.00115	0.16	0.13	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Renal cell carcinoma;Waist circumference adjusted for body mass index;	chr12:26334350	chr12:26125155~26126617:-
BRCA	cis	rs911119	1	rs13038305	ENSG00000270001.1	RP11-218C14.8	-4.36	1.46e-05	0.00115	-0.18	-0.13	Chronic kidney disease;	chr20:23629625	chr20:23631826~23632316:-
BRCA	cis	rs8054556	0.692	rs7201384	ENSG00000183604.13	SMG1P5	-4.36	1.46e-05	0.00115	-0.13	-0.13	Autism spectrum disorder or schizophrenia;	chr16:29913584	chr16:30267553~30335374:-
BRCA	cis	rs17684571	0.7	rs4457154	ENSG00000231441.1	RP11-472M19.2	4.36	1.46e-05	0.00115	0.22	0.13	Schizophrenia;	chr6:56805653	chr6:56844002~56864078:+
BRCA	cis	rs6012564	1	rs11696870	ENSG00000227431.4	CSE1L-AS1	4.36	1.46e-05	0.00115	0.16	0.13	Anger;	chr20:49109070	chr20:49040463~49046044:-
BRCA	cis	rs6012564	0.963	rs6063355	ENSG00000227431.4	CSE1L-AS1	4.36	1.46e-05	0.00115	0.16	0.13	Anger;	chr20:49109592	chr20:49040463~49046044:-
BRCA	cis	rs6012564	1	rs6066968	ENSG00000227431.4	CSE1L-AS1	4.36	1.46e-05	0.00115	0.16	0.13	Anger;	chr20:49110804	chr20:49040463~49046044:-
BRCA	cis	rs6545883	0.894	rs2121661	ENSG00000270820.4	RP11-355B11.2	-4.36	1.46e-05	0.00115	-0.15	-0.13	Tuberculosis;	chr2:61334523	chr2:61471188~61484130:+
BRCA	cis	rs11148252	0.846	rs1056335	ENSG00000198384.8	TPTE2P3	4.36	1.46e-05	0.00115	0.15	0.13	Lewy body disease;	chr13:52415728	chr13:52522632~52586906:+
BRCA	cis	rs10504130	0.569	rs34213209	ENSG00000272024.1	RP11-546K22.3	-4.36	1.46e-05	0.00115	-0.2	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr8:51773341	chr8:51950284~51950690:+
BRCA	cis	rs61160187	0.66	rs12517207	ENSG00000272308.1	RP11-231G3.1	-4.36	1.46e-05	0.00115	-0.15	-0.13	Educational attainment (years of education);Educational attainment (college completion);	chr5:60697441	chr5:60866457~60866935:-
BRCA	cis	rs6928977	0.5	rs9494308	ENSG00000234084.1	RP3-388E23.2	4.36	1.46e-05	0.00115	0.13	0.13	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135627666	chr6:135301568~135307158:+
BRCA	cis	rs7267979	1	rs6050599	ENSG00000277938.1	RP5-965G21.3	-4.36	1.46e-05	0.00115	-0.16	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25419604	chr20:25229150~25231933:+
BRCA	cis	rs7267979	0.706	rs6138542	ENSG00000276952.1	RP5-965G21.6	4.36	1.46e-05	0.00115	0.17	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25227137	chr20:25284915~25285588:-
BRCA	cis	rs2243480	1	rs35542501	ENSG00000222364.1	RNU6-96P	-4.36	1.46e-05	0.00115	-0.24	-0.13	Diabetic kidney disease;	chr7:65966228	chr7:66395191~66395286:+
BRCA	cis	rs2243480	0.708	rs781141	ENSG00000222364.1	RNU6-96P	-4.36	1.46e-05	0.00115	-0.24	-0.13	Diabetic kidney disease;	chr7:65973566	chr7:66395191~66395286:+
BRCA	cis	rs28374715	0.532	rs3204853	ENSG00000247556.5	OIP5-AS1	4.36	1.46e-05	0.00115	0.16	0.13	Ulcerative colitis;	chr15:41396968	chr15:41283990~41309737:+
BRCA	cis	rs6596100	1	rs6596100	ENSG00000248648.1	RP11-485M7.1	-4.36	1.46e-05	0.00115	-0.17	-0.13	Breast cancer;	chr5:133071366	chr5:133003119~133003365:+
BRCA	cis	rs6545883	0.759	rs777585	ENSG00000212978.6	AC016747.3	-4.35	1.46e-05	0.00115	-0.18	-0.13	Tuberculosis;	chr2:61185424	chr2:61141592~61144969:-
BRCA	cis	rs7119	0.651	rs12902449	ENSG00000259362.2	RP11-307C19.1	-4.35	1.46e-05	0.00115	-0.19	-0.13	Type 2 diabetes;	chr15:77558584	chr15:77525540~77534110:+
BRCA	cis	rs11096990	0.656	rs9993224	ENSG00000249685.1	RP11-360F5.3	-4.35	1.46e-05	0.00115	-0.16	-0.13	Cognitive function;	chr4:39298578	chr4:39133913~39135608:+
BRCA	cis	rs5758511	0.68	rs1001586	ENSG00000226450.2	CYP2D8P	4.35	1.46e-05	0.00115	0.15	0.13	Birth weight;	chr22:42274287	chr22:42149886~42155001:-
BRCA	cis	rs2832191	0.632	rs1984011	ENSG00000215533.7	LINC00189	4.35	1.46e-05	0.00115	0.15	0.13	Dental caries;	chr21:28965509	chr21:29193480~29288205:+
BRCA	cis	rs8180040	0.739	rs11719306	ENSG00000276925.1	RP11-708J19.3	-4.35	1.46e-05	0.00115	-0.15	-0.13	Colorectal cancer;	chr3:47142692	chr3:47469777~47469987:+
BRCA	cis	rs35740288	0.77	rs35348278	ENSG00000202081.1	RNU6-1280P	4.35	1.46e-05	0.00115	0.17	0.13	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85657109	chr15:85651522~85651628:-
BRCA	cis	rs2625529	0.73	rs2957368	ENSG00000260037.4	CTD-2524L6.3	-4.35	1.46e-05	0.00115	-0.17	-0.13	Red blood cell count;	chr15:72037565	chr15:71818396~71823384:+
BRCA	cis	rs1823874	0.71	rs67068917	ENSG00000182397.13	DNM1P46	-4.35	1.46e-05	0.00115	-0.15	-0.13	IgG glycosylation;	chr15:99822310	chr15:99790156~99806927:-
BRCA	cis	rs832540	0.669	rs832539	ENSG00000271828.1	CTD-2310F14.1	4.35	1.46e-05	0.00115	0.16	0.13	Coronary artery disease;	chr5:56903559	chr5:56927874~56929573:+
BRCA	cis	rs1400816	0.85	rs12478189	ENSG00000228389.1	AC068039.4	-4.35	1.46e-05	0.00115	-0.23	-0.13	Amyotrophic lateral sclerosis (sporadic);	chr2:171673172	chr2:171773482~171775844:+
BRCA	cis	rs4489787	0.892	rs2731071	ENSG00000240399.1	RP1-228P16.1	4.35	1.47e-05	0.00115	0.2	0.13	Prostate cancer (SNP x SNP interaction);	chr12:48523224	chr12:48054813~48055591:-
BRCA	cis	rs11603691	0.901	rs10896604	ENSG00000254662.1	RP11-872D17.4	4.35	1.47e-05	0.00115	0.28	0.13	Low high density lipoprotein cholesterol levels;	chr11:57317739	chr11:57325603~57327958:+
BRCA	cis	rs7829975	0.502	rs7820738	ENSG00000233609.3	RP11-62H7.2	-4.35	1.47e-05	0.00115	-0.12	-0.13	Mood instability;	chr8:8845097	chr8:8961200~8979025:+
BRCA	cis	rs7824557	0.591	rs2736283	ENSG00000255020.1	AF131216.5	4.35	1.47e-05	0.00115	0.16	0.13	Retinal vascular caliber;	chr8:11368401	chr8:11345748~11347502:-
BRCA	cis	rs853679	0.517	rs4713150	ENSG00000216901.1	AL022393.7	4.35	1.47e-05	0.00115	0.19	0.13	Depression;	chr6:28168434	chr6:28176188~28176674:+
BRCA	cis	rs4713118	0.527	rs4713151	ENSG00000216901.1	AL022393.7	4.35	1.47e-05	0.00115	0.19	0.13	Parkinson's disease;	chr6:28168578	chr6:28176188~28176674:+
BRCA	cis	rs853679	0.517	rs9393901	ENSG00000216901.1	AL022393.7	4.35	1.47e-05	0.00115	0.19	0.13	Depression;	chr6:28169019	chr6:28176188~28176674:+
BRCA	cis	rs853679	0.517	rs3173443	ENSG00000216901.1	AL022393.7	4.35	1.47e-05	0.00115	0.19	0.13	Depression;	chr6:28169249	chr6:28176188~28176674:+
BRCA	cis	rs853679	0.517	rs4713152	ENSG00000216901.1	AL022393.7	4.35	1.47e-05	0.00115	0.19	0.13	Depression;	chr6:28169676	chr6:28176188~28176674:+
BRCA	cis	rs853679	0.517	rs9348797	ENSG00000216901.1	AL022393.7	4.35	1.47e-05	0.00115	0.19	0.13	Depression;	chr6:28169755	chr6:28176188~28176674:+
BRCA	cis	rs853679	0.517	rs9380062	ENSG00000216901.1	AL022393.7	4.35	1.47e-05	0.00115	0.19	0.13	Depression;	chr6:28169791	chr6:28176188~28176674:+
BRCA	cis	rs853679	0.542	rs9380063	ENSG00000216901.1	AL022393.7	4.35	1.47e-05	0.00115	0.19	0.13	Depression;	chr6:28170075	chr6:28176188~28176674:+
BRCA	cis	rs6452524	0.618	rs1478487	ENSG00000281327.1	LINC01338	4.35	1.47e-05	0.00115	0.15	0.13	Hypertension (SNP x SNP interaction);	chr5:83080900	chr5:82850864~82859836:-
BRCA	cis	rs4869313	0.875	rs2548224	ENSG00000248734.2	CTD-2260A17.1	4.35	1.47e-05	0.00115	0.14	0.13	Pediatric autoimmune diseases;	chr5:96936716	chr5:96784777~96785999:+
BRCA	cis	rs890448	0.726	rs1031033	ENSG00000254531.1	FLJ20021	4.35	1.47e-05	0.00116	0.16	0.13	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101327679	chr4:101347780~101348883:+
BRCA	cis	rs11673344	0.504	rs6510593	ENSG00000276846.1	CTD-3220F14.3	4.35	1.47e-05	0.00116	0.16	0.13	Obesity-related traits;	chr19:37143153	chr19:37314868~37315620:-
BRCA	cis	rs7160336	1	rs8004050	ENSG00000259065.1	RP5-1021I20.1	-4.35	1.47e-05	0.00116	-0.15	-0.13	Blood protein levels;	chr14:74158776	chr14:73787360~73803270:+
BRCA	cis	rs7267979	0.866	rs437635	ENSG00000125804.12	FAM182A	-4.35	1.47e-05	0.00116	-0.17	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25476252	chr20:26054655~26086917:+
BRCA	cis	rs7267979	0.932	rs417110	ENSG00000125804.12	FAM182A	-4.35	1.47e-05	0.00116	-0.17	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25477661	chr20:26054655~26086917:+
BRCA	cis	rs7267979	0.932	rs449703	ENSG00000125804.12	FAM182A	-4.35	1.47e-05	0.00116	-0.17	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25477923	chr20:26054655~26086917:+
BRCA	cis	rs6840360	0.582	rs2709826	ENSG00000251603.1	RP11-164P12.4	-4.35	1.47e-05	0.00116	-0.12	-0.13	Intelligence (multi-trait analysis);	chr4:151410968	chr4:151667224~151670502:+
BRCA	cis	rs11148252	0.846	rs4886077	ENSG00000198384.8	TPTE2P3	4.35	1.47e-05	0.00116	0.15	0.13	Lewy body disease;	chr13:52424562	chr13:52522632~52586906:+
BRCA	cis	rs11148252	0.846	rs8001624	ENSG00000198384.8	TPTE2P3	4.35	1.47e-05	0.00116	0.15	0.13	Lewy body disease;	chr13:52428860	chr13:52522632~52586906:+
BRCA	cis	rs2408955	0.541	rs11168428	ENSG00000257763.1	OR5BK1P	-4.35	1.47e-05	0.00116	-0.14	-0.13	Glycated hemoglobin levels;	chr12:48153345	chr12:48355792~48356614:-
BRCA	cis	rs7520050	0.807	rs4660312	ENSG00000234329.1	RP11-767N6.2	4.35	1.47e-05	0.00116	0.12	0.13	Reticulocyte count;Red blood cell count;	chr1:45644900	chr1:45651039~45651826:-
BRCA	cis	rs7709377	0.595	rs40192	ENSG00000271918.1	CTD-2287O16.5	-4.35	1.47e-05	0.00116	-0.11	-0.13	Metabolite levels  (X-11787);	chr5:116293826	chr5:116083807~116085416:-
BRCA	cis	rs338389	0.516	rs6416484	ENSG00000260657.2	RP11-315D16.4	-4.35	1.47e-05	0.00116	-0.16	-0.13	Survival in rectal cancer;	chr15:68020438	chr15:68267792~68277994:-
BRCA	cis	rs2154319	0.609	rs78715416	ENSG00000235358.1	RP11-399E6.1	-4.35	1.47e-05	0.00116	-0.18	-0.13	Height;	chr1:41272417	chr1:41242373~41284861:+
BRCA	cis	rs2154319	0.609	rs13374676	ENSG00000235358.1	RP11-399E6.1	-4.35	1.47e-05	0.00116	-0.18	-0.13	Height;	chr1:41275223	chr1:41242373~41284861:+
BRCA	cis	rs7487075	1	rs12813763	ENSG00000257261.4	RP11-96H19.1	-4.35	1.47e-05	0.00116	-0.14	-0.13	Itch intensity from mosquito bite;	chr12:46429121	chr12:46383679~46876159:+
BRCA	cis	rs6044112	1	rs6080297	ENSG00000273998.1	RP4-777L9.2	4.35	1.47e-05	0.00116	0.25	0.13	Response to taxane treatment (docetaxel);	chr20:16544066	chr20:16576068~16579615:+
BRCA	cis	rs2303319	0.504	rs2020027	ENSG00000227403.1	AC009299.3	4.35	1.47e-05	0.00116	0.31	0.13	Cognitive function;	chr2:161569368	chr2:161244739~161249050:+
BRCA	cis	rs2832191	0.716	rs1543652	ENSG00000232855.5	AF131217.1	-4.35	1.47e-05	0.00116	-0.16	-0.13	Dental caries;	chr21:29075679	chr21:28439346~28674848:-
BRCA	cis	rs58521262	0.585	rs1645766	ENSG00000268105.1	RP11-369G6.2	-4.35	1.47e-05	0.00116	-0.18	-0.13	Testicular germ cell tumor;	chr19:23026439	chr19:23125665~23128543:+
BRCA	cis	rs2108622	0.727	rs12610967	ENSG00000267218.2	AC005336.5	4.35	1.47e-05	0.00116	0.16	0.13	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15867119	chr19:15902300~15903238:-
BRCA	cis	rs2108622	0.711	rs12609820	ENSG00000267218.2	AC005336.5	4.35	1.47e-05	0.00116	0.16	0.13	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15867247	chr19:15902300~15903238:-
BRCA	cis	rs2108622	0.668	rs62106153	ENSG00000267218.2	AC005336.5	4.35	1.47e-05	0.00116	0.16	0.13	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15867697	chr19:15902300~15903238:-
BRCA	cis	rs2108622	0.727	rs12611242	ENSG00000267218.2	AC005336.5	4.35	1.47e-05	0.00116	0.16	0.13	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15867754	chr19:15902300~15903238:-
BRCA	cis	rs2108622	0.727	rs12611308	ENSG00000267218.2	AC005336.5	4.35	1.47e-05	0.00116	0.16	0.13	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15867776	chr19:15902300~15903238:-
BRCA	cis	rs2108622	0.727	rs12610189	ENSG00000267218.2	AC005336.5	4.35	1.47e-05	0.00116	0.16	0.13	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15867831	chr19:15902300~15903238:-
BRCA	cis	rs13401620	0.843	rs7557475	ENSG00000229326.3	AC069154.4	-4.35	1.47e-05	0.00116	-0.17	-0.13	Breast size;	chr2:119875139	chr2:119698623~119700151:+
BRCA	cis	rs9467773	0.967	rs1056347	ENSG00000241549.7	GUSBP2	4.35	1.47e-05	0.00116	0.14	0.13	Intelligence (multi-trait analysis);	chr6:26527296	chr6:26871484~26956554:-
BRCA	cis	rs11098499	0.818	rs55825515	ENSG00000250412.1	KLHL2P1	4.35	1.47e-05	0.00116	0.16	0.13	Corneal astigmatism;	chr4:119565247	chr4:119334329~119378233:+
BRCA	cis	rs6968419	0.714	rs3807980	ENSG00000279086.1	RP11-667F14.1	-4.35	1.47e-05	0.00116	-0.15	-0.13	Intraocular pressure;	chr7:116253593	chr7:116209234~116211511:-
BRCA	cis	rs757081	0.634	rs17472942	ENSG00000184669.7	OR7E14P	-4.35	1.47e-05	0.00116	-0.2	-0.13	Systolic blood pressure;	chr11:17073155	chr11:17013998~17053024:+
BRCA	cis	rs878939	0.625	rs1035209	ENSG00000233690.1	EBAG9P1	4.35	1.47e-05	0.00116	0.19	0.13	Warfarin maintenance dose;	chr10:99585609	chr10:99697407~99697949:-
BRCA	cis	rs35740288	0.77	rs35447727	ENSG00000202081.1	RNU6-1280P	4.35	1.47e-05	0.00116	0.17	0.13	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85631168	chr15:85651522~85651628:-
BRCA	cis	rs35740288	0.77	rs34058174	ENSG00000202081.1	RNU6-1280P	4.35	1.47e-05	0.00116	0.17	0.13	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85631231	chr15:85651522~85651628:-
BRCA	cis	rs35740288	0.587	rs4843089	ENSG00000202081.1	RNU6-1280P	4.35	1.47e-05	0.00116	0.17	0.13	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85632905	chr15:85651522~85651628:-
BRCA	cis	rs420259	1	rs420259	ENSG00000260136.4	CTD-2270L9.4	-4.35	1.47e-05	0.00116	-0.12	-0.13	Bipolar disorder;	chr16:23622705	chr16:23452758~23457606:+
BRCA	cis	rs875971	0.895	rs7788984	ENSG00000229180.5	GS1-124K5.11	4.35	1.47e-05	0.00116	0.12	0.13	Aortic root size;	chr7:66450629	chr7:66526088~66542624:-
BRCA	cis	rs7267979	1	rs2387880	ENSG00000274973.1	RP13-401N8.7	4.35	1.47e-05	0.00116	0.15	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25397151	chr20:25845497~25845862:+
BRCA	cis	rs2832191	1	rs2832189	ENSG00000236056.1	GAPDHP14	4.35	1.47e-05	0.00116	0.15	0.13	Dental caries;	chr21:29115093	chr21:29222321~29223257:+
BRCA	cis	rs7772486	0.875	rs7766463	ENSG00000270638.1	RP3-466P17.1	4.35	1.47e-05	0.00116	0.15	0.13	Lobe attachment (rater-scored or self-reported);	chr6:146043317	chr6:145735570~145737218:+
BRCA	cis	rs35612822	0.723	rs10211039	ENSG00000232485.2	AC098820.3	-4.35	1.47e-05	0.00116	-0.16	-0.13	Kidney disease (early stage) in type 1 diabetes;	chr2:216397237	chr2:216479030~216498761:-
BRCA	cis	rs442309	0.846	rs224143	ENSG00000238280.1	RP11-436D10.3	-4.35	1.47e-05	0.00116	-0.18	-0.13	Vogt-Koyanagi-Harada syndrome;	chr10:62718076	chr10:62793562~62805887:-
BRCA	cis	rs7267979	1	rs1077889	ENSG00000125804.12	FAM182A	-4.35	1.47e-05	0.00116	-0.17	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25287257	chr20:26054655~26086917:+
BRCA	cis	rs669446	0.561	rs568639	ENSG00000236200.4	KDM4A-AS1	-4.35	1.47e-05	0.00116	-0.17	-0.13	Amyotrophic lateral sclerosis (age of onset);	chr1:43620409	chr1:43699765~43708138:-
BRCA	cis	rs801193	0.636	rs2659895	ENSG00000236529.1	RP13-254B10.1	4.35	1.47e-05	0.00116	0.15	0.13	Aortic root size;	chr7:66731484	chr7:65840212~65840596:+
BRCA	cis	rs55966801	0.68	rs6541	ENSG00000255328.1	RP11-326C3.12	4.35	1.47e-05	0.00116	0.2	0.13	Plateletcrit;	chr11:252851	chr11:327171~330122:+
BRCA	cis	rs7267979	1	rs6050561	ENSG00000277938.1	RP5-965G21.3	-4.35	1.47e-05	0.00116	-0.16	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25354219	chr20:25229150~25231933:+
BRCA	cis	rs7267979	1	rs6083813	ENSG00000277938.1	RP5-965G21.3	-4.35	1.47e-05	0.00116	-0.16	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25357035	chr20:25229150~25231933:+
BRCA	cis	rs875971	0.545	rs10950036	ENSG00000230295.1	RP11-458F8.2	4.35	1.47e-05	0.00116	0.13	0.13	Aortic root size;	chr7:66353241	chr7:66880708~66882981:+
BRCA	cis	rs3809912	0.546	rs4797730	ENSG00000266969.1	RP11-773H22.4	-4.35	1.48e-05	0.00116	-0.19	-0.13	Cognitive ability;Cognitive ability (multi-trait analysis);	chr18:13178097	chr18:12984694~12991173:-
BRCA	cis	rs3764021	0.84	rs12304510	ENSG00000278635.1	CTD-2318O12.1	-4.35	1.48e-05	0.00116	-0.13	-0.13	Type 1 diabetes;	chr12:9732930	chr12:9415641~9416718:+
BRCA	cis	rs1223397	0.651	rs202018	ENSG00000215022.6	RP1-257A7.4	-4.35	1.48e-05	0.00116	-0.16	-0.13	Blood pressure;	chr6:13301270	chr6:13264861~13295586:-
BRCA	cis	rs17428076	0.71	rs17499593	ENSG00000228389.1	AC068039.4	-4.35	1.48e-05	0.00116	-0.23	-0.13	Myopia;	chr2:171793245	chr2:171773482~171775844:+
BRCA	cis	rs8180040	0.764	rs11716539	ENSG00000276925.1	RP11-708J19.3	-4.35	1.48e-05	0.00116	-0.15	-0.13	Colorectal cancer;	chr3:47145013	chr3:47469777~47469987:+
BRCA	cis	rs4819052	1	rs2297285	ENSG00000184274.3	LINC00315	4.35	1.48e-05	0.00116	0.21	0.13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45285706	chr21:45300245~45305257:-
BRCA	cis	rs58521262	0.556	rs290584	ENSG00000268105.1	RP11-369G6.2	-4.35	1.48e-05	0.00116	-0.18	-0.13	Testicular germ cell tumor;	chr19:23015674	chr19:23125665~23128543:+
BRCA	cis	rs17507216	0.671	rs4779035	ENSG00000255769.6	GOLGA2P10	-4.35	1.48e-05	0.00116	-0.2	-0.13	Excessive daytime sleepiness;	chr15:82591686	chr15:82472993~82513950:-
BRCA	cis	rs17684571	0.751	rs35081015	ENSG00000231441.1	RP11-472M19.2	4.35	1.48e-05	0.00116	0.22	0.13	Schizophrenia;	chr6:56819757	chr6:56844002~56864078:+
BRCA	cis	rs9470794	0.915	rs79257064	ENSG00000204110.6	RP1-153P14.8	-4.35	1.48e-05	0.00116	-0.27	-0.13	Type 2 diabetes;	chr6:37920283	chr6:37507348~37535616:+
BRCA	cis	rs9470794	0.915	rs11754248	ENSG00000204110.6	RP1-153P14.8	-4.35	1.48e-05	0.00116	-0.27	-0.13	Type 2 diabetes;	chr6:37921386	chr6:37507348~37535616:+
BRCA	cis	rs180730	0.861	rs4833694	ENSG00000251609.2	SETP12	4.35	1.48e-05	0.00116	0.19	0.13	Fasting plasma glucose;	chr4:120928563	chr4:120895494~120897083:-
BRCA	cis	rs11892454	0.544	rs35404220	ENSG00000217643.1	PTGES3P2	-4.35	1.48e-05	0.00116	-0.14	-0.13	Heschl's gyrus morphology;	chr2:25781251	chr2:25822469~25822950:+
BRCA	cis	rs859767	0.501	rs71348712	ENSG00000224043.6	CCNT2-AS1	4.35	1.48e-05	0.00116	0.18	0.13	Neuroticism;	chr2:134634020	chr2:134735464~134918710:-
BRCA	cis	rs58123204	1	rs58123204	ENSG00000257379.1	RP11-793H13.8	4.35	1.48e-05	0.00117	0.21	0.13	Mean corpuscular hemoglobin;	chr12:53366378	chr12:53441741~53467528:+
BRCA	cis	rs11098499	0.863	rs1552092	ENSG00000250412.1	KLHL2P1	4.35	1.48e-05	0.00117	0.16	0.13	Corneal astigmatism;	chr4:119567341	chr4:119334329~119378233:+
BRCA	cis	rs728616	0.614	rs35395602	ENSG00000225484.5	NUTM2B-AS1	-4.35	1.48e-05	0.00117	-0.31	-0.13	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80147014	chr10:79663088~79826594:-
BRCA	cis	rs728616	0.681	rs36023925	ENSG00000225484.5	NUTM2B-AS1	-4.35	1.48e-05	0.00117	-0.31	-0.13	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80147090	chr10:79663088~79826594:-
BRCA	cis	rs216345	0.7	rs307654	ENSG00000260947.1	RP11-384P7.7	4.35	1.48e-05	0.00117	0.14	0.13	Bipolar disorder;	chr9:33948654	chr9:33697459~33700986:+
BRCA	cis	rs4819052	0.851	rs2838834	ENSG00000215447.6	BX322557.10	-4.35	1.48e-05	0.00117	-0.14	-0.13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245293	chr21:45288052~45291738:+
BRCA	cis	rs3812049	0.784	rs1560637	ENSG00000245937.6	LINC01184	4.35	1.48e-05	0.00117	0.18	0.13	Lymphocyte counts;Red cell distribution width;	chr5:128112374	chr5:127940426~128083172:-
BRCA	cis	rs2229238	0.823	rs61275241	ENSG00000272030.1	RP1-178F15.4	-4.35	1.48e-05	0.00117	-0.19	-0.13	Coronary heart disease;	chr1:154532411	chr1:153631438~153634397:-
BRCA	cis	rs1345301	0.518	rs2110661	ENSG00000234389.1	AC007278.3	-4.35	1.48e-05	0.00117	-0.12	-0.13	Waist circumference;	chr2:102246761	chr2:102438713~102440475:+
BRCA	cis	rs11892454	0.573	rs7564262	ENSG00000217643.1	PTGES3P2	-4.35	1.48e-05	0.00117	-0.14	-0.13	Heschl's gyrus morphology;	chr2:25745327	chr2:25822469~25822950:+
BRCA	cis	rs11892454	0.515	rs7609004	ENSG00000217643.1	PTGES3P2	-4.35	1.48e-05	0.00117	-0.14	-0.13	Heschl's gyrus morphology;	chr2:25746181	chr2:25822469~25822950:+
BRCA	cis	rs12073837	0.5	rs11118610	ENSG00000221571.3	RNU6ATAC35P	-4.35	1.48e-05	0.00117	-0.16	-0.13	F-cell distribution;	chr1:220816744	chr1:220825620~220826063:+
BRCA	cis	rs55780018	0.675	rs6740584	ENSG00000224137.1	AC079767.4	4.35	1.48e-05	0.00117	0.11	0.13	Systolic blood pressure;	chr2:207564627	chr2:207662375~207667024:+
BRCA	cis	rs6545883	0.894	rs2694632	ENSG00000212978.6	AC016747.3	-4.35	1.48e-05	0.00117	-0.18	-0.13	Tuberculosis;	chr2:61331547	chr2:61141592~61144969:-
BRCA	cis	rs7772486	0.719	rs7753770	ENSG00000270638.1	RP3-466P17.1	-4.35	1.48e-05	0.00117	-0.15	-0.13	Lobe attachment (rater-scored or self-reported);	chr6:145745025	chr6:145735570~145737218:+
BRCA	cis	rs7772486	0.655	rs2142981	ENSG00000270638.1	RP3-466P17.1	-4.35	1.48e-05	0.00117	-0.15	-0.13	Lobe attachment (rater-scored or self-reported);	chr6:145750559	chr6:145735570~145737218:+
BRCA	cis	rs7772486	0.72	rs6570713	ENSG00000270638.1	RP3-466P17.1	-4.35	1.48e-05	0.00117	-0.15	-0.13	Lobe attachment (rater-scored or self-reported);	chr6:145753949	chr6:145735570~145737218:+
BRCA	cis	rs12612619	0.732	rs11688708	ENSG00000229122.1	AGBL5-IT1	4.35	1.48e-05	0.00117	0.14	0.13	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:26976740	chr2:27061038~27061815:+
BRCA	cis	rs2662776	0.967	rs10753606	ENSG00000232995.6	RGS5	4.35	1.48e-05	0.00117	0.14	0.13	Lead levels in blood;	chr1:163186734	chr1:163244505~163321894:-
BRCA	cis	rs6890684	0.569	rs6864489	ENSG00000215032.2	GNL3LP1	4.35	1.48e-05	0.00117	0.16	0.13	Intelligence (multi-trait analysis);	chr5:61250143	chr5:60891935~60893577:-
BRCA	cis	rs7116495	0.609	rs7113436	ENSG00000248671.6	ALG1L9P	4.35	1.48e-05	0.00117	0.35	0.13	Severe influenza A (H1N1) infection;	chr11:71978553	chr11:71794363~71818238:-
BRCA	cis	rs6686842	0.931	rs4360513	ENSG00000235358.1	RP11-399E6.1	4.35	1.48e-05	0.00117	0.17	0.13	Height;	chr1:41015127	chr1:41242373~41284861:+
BRCA	cis	rs4143844	0.867	rs978141	ENSG00000259251.2	RP11-643M14.1	4.35	1.48e-05	0.00117	0.33	0.13	Bipolar disorder and schizophrenia;	chr15:61974584	chr15:62060503~62062434:+
BRCA	cis	rs3176789	0.671	rs10772128	ENSG00000256673.1	RP11-599J14.2	4.35	1.49e-05	0.00117	0.15	0.13	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9769272	chr12:9398355~9414851:-
BRCA	cis	rs6570726	0.935	rs406343	ENSG00000270638.1	RP3-466P17.1	4.35	1.49e-05	0.00117	0.15	0.13	Lobe attachment (rater-scored or self-reported);	chr6:145553252	chr6:145735570~145737218:+
BRCA	cis	rs6012564	1	rs755587	ENSG00000227431.4	CSE1L-AS1	4.35	1.49e-05	0.00117	0.16	0.13	Anger;	chr20:49104420	chr20:49040463~49046044:-
BRCA	cis	rs4700393	0.589	rs27565	ENSG00000272308.1	RP11-231G3.1	-4.35	1.49e-05	0.00117	-0.15	-0.13	Intelligence (multi-trait analysis);	chr5:60541764	chr5:60866457~60866935:-
BRCA	cis	rs7481584	0.603	rs399467	ENSG00000247473.2	CARS-AS1	-4.35	1.49e-05	0.00117	-0.16	-0.13	Calcium levels;	chr11:3051118	chr11:3029009~3041260:+
BRCA	cis	rs7312933	0.558	rs4768399	ENSG00000257225.1	RP11-328C8.4	4.35	1.49e-05	0.00117	0.16	0.13	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42348894	chr12:42459366~42466128:+
BRCA	cis	rs10266483	0.739	rs12665990	ENSG00000228653.2	HNRNPCP7	4.35	1.49e-05	0.00117	0.17	0.13	Response to statin therapy;	chr7:64404622	chr7:64500825~64501729:+
BRCA	cis	rs7647973	1	rs974495	ENSG00000244380.1	RP11-24C3.2	4.35	1.49e-05	0.00117	0.17	0.13	Menarche (age at onset);	chr3:49363049	chr3:48440352~48446656:-
BRCA	cis	rs7647973	1	rs11719762	ENSG00000244380.1	RP11-24C3.2	4.35	1.49e-05	0.00117	0.17	0.13	Menarche (age at onset);	chr3:49371569	chr3:48440352~48446656:-
BRCA	cis	rs4908769	0.624	rs2120461	ENSG00000270282.1	RP5-1115A15.2	-4.35	1.49e-05	0.00117	-0.15	-0.13	Allergy;	chr1:8387662	chr1:8512653~8513021:+
BRCA	cis	rs7267979	1	rs7268053	ENSG00000274973.1	RP13-401N8.7	4.35	1.49e-05	0.00117	0.15	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25347650	chr20:25845497~25845862:+
BRCA	cis	rs7267979	1	rs6083809	ENSG00000274973.1	RP13-401N8.7	4.35	1.49e-05	0.00117	0.15	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25348673	chr20:25845497~25845862:+
BRCA	cis	rs2337406	0.587	rs10139664	ENSG00000231475.3	IGHV4-31	4.35	1.49e-05	0.00117	0.13	0.13	Alzheimer's disease (late onset);	chr14:106647254	chr14:106349283~106349792:-
BRCA	cis	rs2286503	0.78	rs1304431	ENSG00000226329.2	AC005682.6	4.35	1.49e-05	0.00117	0.13	0.13	Fibrinogen;	chr7:22825793	chr7:22863874~22881350:-
BRCA	cis	rs10504130	0.569	rs35509250	ENSG00000253844.1	RP11-546K22.1	-4.35	1.49e-05	0.00117	-0.2	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr8:51774993	chr8:51961458~52022974:+
BRCA	cis	rs6671200	1	rs62625008	ENSG00000235501.4	RP4-639F20.1	-4.35	1.49e-05	0.00117	-0.32	-0.13	Stearic acid (18:0) levels;	chr1:95237026	chr1:94927566~94963270:+
BRCA	cis	rs6671200	0.92	rs35403759	ENSG00000235501.4	RP4-639F20.1	-4.35	1.49e-05	0.00117	-0.32	-0.13	Stearic acid (18:0) levels;	chr1:95237334	chr1:94927566~94963270:+
BRCA	cis	rs11098499	0.954	rs6820115	ENSG00000249244.1	RP11-548H18.2	4.35	1.49e-05	0.00117	0.15	0.13	Corneal astigmatism;	chr4:119477027	chr4:119391831~119395335:-
BRCA	cis	rs4869313	0.905	rs2910792	ENSG00000248734.2	CTD-2260A17.1	4.35	1.49e-05	0.00117	0.14	0.13	Pediatric autoimmune diseases;	chr5:96940682	chr5:96784777~96785999:+
BRCA	cis	rs4869313	0.905	rs2910789	ENSG00000248734.2	CTD-2260A17.1	4.35	1.49e-05	0.00117	0.14	0.13	Pediatric autoimmune diseases;	chr5:96940691	chr5:96784777~96785999:+
BRCA	cis	rs4869313	0.837	rs6887500	ENSG00000248734.2	CTD-2260A17.1	4.35	1.49e-05	0.00117	0.14	0.13	Pediatric autoimmune diseases;	chr5:96942017	chr5:96784777~96785999:+
BRCA	cis	rs4869313	0.869	rs10051637	ENSG00000248734.2	CTD-2260A17.1	4.35	1.49e-05	0.00117	0.14	0.13	Pediatric autoimmune diseases;	chr5:96943786	chr5:96784777~96785999:+
BRCA	cis	rs7267979	0.966	rs6083818	ENSG00000125804.12	FAM182A	4.35	1.49e-05	0.00117	0.17	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25365446	chr20:26054655~26086917:+
BRCA	cis	rs7267979	1	rs4815409	ENSG00000125804.12	FAM182A	4.35	1.49e-05	0.00117	0.17	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25366061	chr20:26054655~26086917:+
BRCA	cis	rs7267979	0.966	rs6083817	ENSG00000277938.1	RP5-965G21.3	-4.35	1.49e-05	0.00117	-0.16	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25363362	chr20:25229150~25231933:+
BRCA	cis	rs7267979	1	rs6050564	ENSG00000277938.1	RP5-965G21.3	-4.35	1.49e-05	0.00117	-0.16	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25363595	chr20:25229150~25231933:+
BRCA	cis	rs1858037	0.867	rs61226353	ENSG00000237979.1	AC007389.1	4.35	1.49e-05	0.00117	0.17	0.13	Rheumatoid arthritis;	chr2:65363637	chr2:65500993~65502138:-
BRCA	cis	rs35740288	0.822	rs11638720	ENSG00000202081.1	RNU6-1280P	4.35	1.49e-05	0.00117	0.18	0.13	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85686042	chr15:85651522~85651628:-
BRCA	cis	rs35740288	0.822	rs2016517	ENSG00000202081.1	RNU6-1280P	4.35	1.49e-05	0.00117	0.18	0.13	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85686387	chr15:85651522~85651628:-
BRCA	cis	rs7508	0.511	rs2237853	ENSG00000253671.1	RP11-806O11.1	-4.35	1.49e-05	0.00117	-0.19	-0.13	Atrial fibrillation;	chr8:18020371	chr8:17808941~17820868:+
BRCA	cis	rs66887589	0.72	rs2036858	ENSG00000260404.2	RP11-384K6.6	4.35	1.49e-05	0.00117	0.11	0.13	Diastolic blood pressure;	chr4:119328082	chr4:118591773~118633729:+
BRCA	cis	rs7665090	1	rs735404	ENSG00000251288.2	RP11-10L12.2	-4.35	1.49e-05	0.00117	-0.16	-0.13	Primary biliary cholangitis;	chr4:102632508	chr4:102751401~102752641:+
BRCA	cis	rs4664293	0.967	rs1006192	ENSG00000224152.1	AC009506.1	-4.35	1.49e-05	0.00117	-0.15	-0.13	Monocyte percentage of white cells;	chr2:159711078	chr2:159615296~159617082:+
BRCA	cis	rs2731006	0.64	rs908656	ENSG00000257114.2	RP11-25I15.3	4.35	1.49e-05	0.00117	0.22	0.13	Panic disorder;	chr12:42773827	chr12:42692216~42717119:+
BRCA	cis	rs10129255	1	rs10129255	ENSG00000224373.3	IGHV4-59	-4.35	1.49e-05	0.00117	-0.08	-0.13	Kawasaki disease;	chr14:106767970	chr14:106627249~106627825:-
BRCA	cis	rs56322409	0.897	rs4463786	ENSG00000226688.5	ENTPD1-AS1	4.35	1.49e-05	0.00117	0.15	0.13	Blood metabolite levels;	chr10:95775140	chr10:95753206~96090238:-
BRCA	cis	rs28374715	0.532	rs1899	ENSG00000247556.5	OIP5-AS1	4.35	1.49e-05	0.00117	0.15	0.13	Ulcerative colitis;	chr15:41397034	chr15:41283990~41309737:+
BRCA	cis	rs6545883	0.524	rs17482440	ENSG00000270820.4	RP11-355B11.2	-4.35	1.49e-05	0.00117	-0.14	-0.13	Tuberculosis;	chr2:61321722	chr2:61471188~61484130:+
BRCA	cis	rs11098499	0.863	rs1480940	ENSG00000250412.1	KLHL2P1	4.35	1.49e-05	0.00117	0.16	0.13	Corneal astigmatism;	chr4:119536527	chr4:119334329~119378233:+
BRCA	cis	rs61160187	0.698	rs1379116	ENSG00000272308.1	RP11-231G3.1	-4.35	1.49e-05	0.00117	-0.15	-0.13	Educational attainment (years of education);Educational attainment (college completion);	chr5:60646573	chr5:60866457~60866935:-
BRCA	cis	rs61160187	0.673	rs2198865	ENSG00000272308.1	RP11-231G3.1	-4.35	1.49e-05	0.00117	-0.15	-0.13	Educational attainment (years of education);Educational attainment (college completion);	chr5:60658230	chr5:60866457~60866935:-
BRCA	cis	rs61160187	0.698	rs17387940	ENSG00000272308.1	RP11-231G3.1	-4.35	1.49e-05	0.00117	-0.15	-0.13	Educational attainment (years of education);Educational attainment (college completion);	chr5:60671889	chr5:60866457~60866935:-
BRCA	cis	rs61160187	0.698	rs56726435	ENSG00000272308.1	RP11-231G3.1	-4.35	1.49e-05	0.00117	-0.15	-0.13	Educational attainment (years of education);Educational attainment (college completion);	chr5:60679237	chr5:60866457~60866935:-
BRCA	cis	rs61160187	0.698	rs11741754	ENSG00000272308.1	RP11-231G3.1	-4.35	1.49e-05	0.00117	-0.15	-0.13	Educational attainment (years of education);Educational attainment (college completion);	chr5:60681231	chr5:60866457~60866935:-
BRCA	cis	rs9990333	0.562	rs56224853	ENSG00000242086.7	LINC00969	4.35	1.49e-05	0.00117	0.15	0.13	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196102005	chr3:195658062~195739964:+
BRCA	cis	rs9990333	0.544	rs73210008	ENSG00000242086.7	LINC00969	4.35	1.49e-05	0.00117	0.15	0.13	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196102260	chr3:195658062~195739964:+
BRCA	cis	rs7267979	1	rs4815406	ENSG00000277938.1	RP5-965G21.3	-4.35	1.49e-05	0.00117	-0.16	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25360680	chr20:25229150~25231933:+
BRCA	cis	rs12612619	0.732	rs6716275	ENSG00000272148.1	RP11-195B17.1	-4.35	1.49e-05	0.00117	-0.14	-0.13	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27004839	chr2:27062428~27062907:-
BRCA	cis	rs11098499	1	rs11726229	ENSG00000250412.1	KLHL2P1	4.35	1.49e-05	0.00117	0.16	0.13	Corneal astigmatism;	chr4:119290425	chr4:119334329~119378233:+
BRCA	cis	rs420259	0.681	rs26760	ENSG00000260136.4	CTD-2270L9.4	-4.35	1.5e-05	0.00117	-0.12	-0.13	Bipolar disorder;	chr16:23668965	chr16:23452758~23457606:+
BRCA	cis	rs2229238	0.911	rs77184252	ENSG00000272030.1	RP1-178F15.4	-4.35	1.5e-05	0.00117	-0.19	-0.13	Coronary heart disease;	chr1:154520057	chr1:153631438~153634397:-
BRCA	cis	rs10911902	0.866	rs3131556	ENSG00000229739.2	RP11-295K2.3	-4.35	1.5e-05	0.00117	-0.19	-0.13	Schizophrenia;	chr1:186477195	chr1:186435161~186470291:+
BRCA	cis	rs755249	0.567	rs2018212	ENSG00000182109.6	RP11-69E11.4	4.35	1.5e-05	0.00118	0.19	0.13	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39439916	chr1:39522280~39546187:-
BRCA	cis	rs755249	0.567	rs4660751	ENSG00000182109.6	RP11-69E11.4	4.35	1.5e-05	0.00118	0.19	0.13	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39440201	chr1:39522280~39546187:-
BRCA	cis	rs9868809	0.881	rs7631574	ENSG00000225399.4	RP11-3B7.1	4.35	1.5e-05	0.00118	0.18	0.13	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48625613	chr3:49260085~49261316:+
BRCA	cis	rs644148	0.803	rs2686771	ENSG00000176761.7	ZNF285B	4.35	1.5e-05	0.00118	0.15	0.13	Personality dimensions;	chr19:44495433	chr19:44467641~44473227:+
BRCA	cis	rs1832007	0.529	rs72772224	ENSG00000224034.1	RP11-445P17.8	-4.35	1.5e-05	0.00118	-0.21	-0.13	Triglyceride levels;Triglycerides;	chr10:5202739	chr10:5266033~5271236:-
BRCA	cis	rs6893300	0.785	rs12522263	ENSG00000225051.5	HMGB3P22	4.35	1.5e-05	0.00118	0.17	0.13	Resting heart rate;	chr5:179749691	chr5:179679032~179694768:+
BRCA	cis	rs10208649	0.908	rs60776154	ENSG00000272156.1	RP11-477N3.1	4.35	1.5e-05	0.00118	0.28	0.13	Body mass index;	chr2:54026676	chr2:54082554~54085066:+
BRCA	cis	rs10208649	0.831	rs72906704	ENSG00000272156.1	RP11-477N3.1	4.35	1.5e-05	0.00118	0.28	0.13	Body mass index;	chr2:54028088	chr2:54082554~54085066:+
BRCA	cis	rs10208649	0.908	rs11884857	ENSG00000272156.1	RP11-477N3.1	4.35	1.5e-05	0.00118	0.28	0.13	Body mass index;	chr2:54033185	chr2:54082554~54085066:+
BRCA	cis	rs10208649	0.901	rs6748686	ENSG00000272156.1	RP11-477N3.1	4.35	1.5e-05	0.00118	0.28	0.13	Body mass index;	chr2:54037481	chr2:54082554~54085066:+
BRCA	cis	rs10208649	0.908	rs6719990	ENSG00000272156.1	RP11-477N3.1	4.35	1.5e-05	0.00118	0.28	0.13	Body mass index;	chr2:54037515	chr2:54082554~54085066:+
BRCA	cis	rs10208649	0.908	rs72906714	ENSG00000272156.1	RP11-477N3.1	4.35	1.5e-05	0.00118	0.28	0.13	Body mass index;	chr2:54038423	chr2:54082554~54085066:+
BRCA	cis	rs4831837	0.69	rs4831833	ENSG00000270074.1	RP11-351I21.11	4.35	1.5e-05	0.00118	0.16	0.13	Morbidity-free survival;	chr8:12829783	chr8:12412827~12414373:+
BRCA	cis	rs7772486	0.692	rs1577916	ENSG00000270638.1	RP3-466P17.1	-4.35	1.5e-05	0.00118	-0.15	-0.13	Lobe attachment (rater-scored or self-reported);	chr6:145748653	chr6:145735570~145737218:+
BRCA	cis	rs7772486	0.72	rs7752286	ENSG00000270638.1	RP3-466P17.1	-4.35	1.5e-05	0.00118	-0.15	-0.13	Lobe attachment (rater-scored or self-reported);	chr6:145751526	chr6:145735570~145737218:+
BRCA	cis	rs9921338	0.961	rs9936328	ENSG00000262703.1	RP11-485G7.6	-4.35	1.5e-05	0.00118	-0.17	-0.13	Vein graft stenosis in coronary artery bypass grafting;	chr16:11344364	chr16:11348143~11349321:-
BRCA	cis	rs2832191	0.716	rs2297252	ENSG00000215533.7	LINC00189	-4.35	1.5e-05	0.00118	-0.15	-0.13	Dental caries;	chr21:29004783	chr21:29193480~29288205:+
BRCA	cis	rs4948275	0.693	rs1902427	ENSG00000237233.2	TMEM26-AS1	-4.35	1.5e-05	0.00118	-0.16	-0.13	Night sleep phenotypes;	chr10:61550282	chr10:61452639~61481956:+
BRCA	cis	rs4869313	0.655	rs2617438	ENSG00000248734.2	CTD-2260A17.1	-4.35	1.5e-05	0.00118	-0.14	-0.13	Pediatric autoimmune diseases;	chr5:96870670	chr5:96784777~96785999:+
BRCA	cis	rs7726839	0.561	rs72703050	ENSG00000225138.6	CTD-2228K2.7	4.35	1.5e-05	0.00118	0.19	0.13	Obesity-related traits;	chr5:582802	chr5:473236~480884:+
BRCA	cis	rs11098499	1	rs7659194	ENSG00000250412.1	KLHL2P1	4.35	1.5e-05	0.00118	0.16	0.13	Corneal astigmatism;	chr4:119285992	chr4:119334329~119378233:+
BRCA	cis	rs4660214	0.666	rs636083	ENSG00000237624.1	OXCT2P1	4.35	1.5e-05	0.00118	0.16	0.13	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39356009	chr1:39514956~39516490:+
BRCA	cis	rs8040855	0.627	rs17541051	ENSG00000259774.1	RP11-182J1.13	4.35	1.5e-05	0.00118	0.19	0.13	Bulimia nervosa;	chr15:85106122	chr15:84422618~84425882:+
BRCA	cis	rs10411936	0.712	rs10414751	ENSG00000280332.1	CTD-2013N17.6	4.35	1.5e-05	0.00118	0.12	0.13	Multiple sclerosis;White blood cell count;	chr19:16480884	chr19:16356329~16358327:-
BRCA	cis	rs10411936	0.712	rs8100755	ENSG00000280332.1	CTD-2013N17.6	4.35	1.5e-05	0.00118	0.12	0.13	Multiple sclerosis;White blood cell count;	chr19:16482604	chr19:16356329~16358327:-
BRCA	cis	rs1790761	0.587	rs4930431	ENSG00000273819.1	ENPP7P7	-4.35	1.5e-05	0.00118	-0.16	-0.13	Mean corpuscular volume;	chr11:67526837	chr11:67812557~67873367:-
BRCA	cis	rs11048434	0.518	rs2377679	ENSG00000256720.1	RP11-436I9.6	-4.35	1.5e-05	0.00118	-0.13	-0.13	Sjögren's syndrome;	chr12:9023874	chr12:9135084~9135591:+
BRCA	cis	rs11085466	1	rs11085466	ENSG00000268081.1	RP11-678G14.2	-4.35	1.5e-05	0.00118	-0.21	-0.13	Colorectal or endometrial cancer;	chr19:21569009	chr19:21554640~21569237:-
BRCA	cis	rs651907	0.588	rs9881690	ENSG00000244119.1	PDCL3P4	4.35	1.5e-05	0.00118	0.11	0.13	Colorectal cancer;	chr3:101944473	chr3:101712472~101713191:+
BRCA	cis	rs7811142	1	rs11764818	ENSG00000078319.8	PMS2P1	-4.35	1.5e-05	0.00118	-0.22	-0.13	Platelet count;	chr7:100445432	chr7:100320992~100341908:-
BRCA	cis	rs6088580	0.634	rs4911152	ENSG00000276073.1	RP5-1125A11.7	4.35	1.5e-05	0.00118	0.15	0.13	Glomerular filtration rate (creatinine);	chr20:34367218	chr20:33985617~33988989:-
BRCA	cis	rs1656368	0.726	rs17684859	ENSG00000279311.1	RP11-170K4.2	4.35	1.5e-05	0.00118	0.18	0.13	Lobe attachment (rater-scored or self-reported);	chr3:158496052	chr3:158869898~158871821:+
BRCA	cis	rs35740288	0.685	rs12899481	ENSG00000202081.1	RNU6-1280P	4.35	1.5e-05	0.00118	0.18	0.13	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85765739	chr15:85651522~85651628:-
BRCA	cis	rs58521262	0.556	rs2645878	ENSG00000268105.1	RP11-369G6.2	-4.35	1.5e-05	0.00118	-0.18	-0.13	Testicular germ cell tumor;	chr19:23028144	chr19:23125665~23128543:+
BRCA	cis	rs58521262	0.585	rs2935440	ENSG00000268105.1	RP11-369G6.2	-4.35	1.5e-05	0.00118	-0.18	-0.13	Testicular germ cell tumor;	chr19:23028369	chr19:23125665~23128543:+
BRCA	cis	rs61931739	0.534	rs35056575	ENSG00000258794.3	DUX4L27	4.35	1.5e-05	0.00118	0.19	0.13	Morning vs. evening chronotype;	chr12:33989979	chr12:34208415~34209675:-
BRCA	cis	rs2835345	0.596	rs2409817	ENSG00000279365.1	KB-176G8.1	4.35	1.5e-05	0.00118	0.19	0.13	Pulmonary function;	chr21:36455410	chr21:36485867~36487760:+
BRCA	cis	rs638893	0.617	rs7933007	ENSG00000255422.1	AP002954.4	4.35	1.5e-05	0.00118	0.18	0.13	Vitiligo;	chr11:118859960	chr11:118704607~118750263:+
BRCA	cis	rs1371614	0.588	rs10181727	ENSG00000229122.1	AGBL5-IT1	-4.35	1.5e-05	0.00118	-0.14	-0.13	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26948377	chr2:27061038~27061815:+
BRCA	cis	rs1371614	0.545	rs1057115	ENSG00000229122.1	AGBL5-IT1	-4.35	1.5e-05	0.00118	-0.14	-0.13	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26949201	chr2:27061038~27061815:+
BRCA	cis	rs875971	0.965	rs7794930	ENSG00000229180.5	GS1-124K5.11	-4.35	1.5e-05	0.00118	-0.12	-0.13	Aortic root size;	chr7:66313559	chr7:66526088~66542624:-
BRCA	cis	rs13043901	0.539	rs6097480	ENSG00000197670.6	RP4-724E16.2	-4.35	1.5e-05	0.00118	-0.14	-0.13	Type 2 diabetes (age of onset);	chr20:53560021	chr20:53552770~53575863:+
BRCA	cis	rs12744310	1	rs35812095	ENSG00000235358.1	RP11-399E6.1	4.35	1.5e-05	0.00118	0.19	0.13	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41300402	chr1:41242373~41284861:+
BRCA	cis	rs11096990	0.634	rs2381371	ENSG00000249685.1	RP11-360F5.3	4.35	1.5e-05	0.00118	0.17	0.13	Cognitive function;	chr4:39271414	chr4:39133913~39135608:+
BRCA	cis	rs2243480	1	rs937108	ENSG00000222364.1	RNU6-96P	-4.35	1.5e-05	0.00118	-0.24	-0.13	Diabetic kidney disease;	chr7:65963465	chr7:66395191~66395286:+
BRCA	cis	rs4948275	0.693	rs2650730	ENSG00000237233.2	TMEM26-AS1	-4.35	1.51e-05	0.00118	-0.16	-0.13	Night sleep phenotypes;	chr10:61579592	chr10:61452639~61481956:+
BRCA	cis	rs253959	0.545	rs712597	ENSG00000271918.1	CTD-2287O16.5	-4.35	1.51e-05	0.00118	-0.11	-0.13	Bipolar disorder and schizophrenia;	chr5:116322485	chr5:116083807~116085416:-
BRCA	cis	rs11098499	1	rs11098499	ENSG00000250412.1	KLHL2P1	4.35	1.51e-05	0.00118	0.16	0.13	Corneal astigmatism;	chr4:119266456	chr4:119334329~119378233:+
BRCA	cis	rs9840812	0.728	rs665200	ENSG00000273486.1	RP11-731C17.2	4.35	1.51e-05	0.00118	0.16	0.13	Fibrinogen levels;	chr3:136276174	chr3:136837338~136839021:-
BRCA	cis	rs7487075	1	rs7487075	ENSG00000274723.1	RP11-618L22.1	4.35	1.51e-05	0.00118	0.16	0.13	Itch intensity from mosquito bite;	chr12:46435135	chr12:46970504~46972155:+
BRCA	cis	rs8040855	0.627	rs12905036	ENSG00000230373.7	GOLGA6L5P	4.35	1.51e-05	0.00118	0.17	0.13	Bulimia nervosa;	chr15:85094557	chr15:84507885~84516814:-
BRCA	cis	rs610932	0.517	rs620612	ENSG00000275344.1	MIR6503	4.35	1.51e-05	0.00118	0.13	0.13	Alzheimer's disease;	chr11:60224374	chr11:60209071~60209156:-
BRCA	cis	rs7119	0.651	rs12902948	ENSG00000259362.2	RP11-307C19.1	-4.35	1.51e-05	0.00118	-0.19	-0.13	Type 2 diabetes;	chr15:77556912	chr15:77525540~77534110:+
BRCA	cis	rs875971	0.862	rs11773628	ENSG00000273448.1	RP11-166O4.6	-4.35	1.51e-05	0.00118	-0.12	-0.13	Aortic root size;	chr7:66517644	chr7:67333047~67334383:+
BRCA	cis	rs1009647	0.656	rs10147254	ENSG00000259318.1	RP11-454L9.2	4.35	1.51e-05	0.00118	0.12	0.13	Testicular germ cell tumor;	chr14:55383597	chr14:55394940~55395233:-
BRCA	cis	rs7267979	0.966	rs6037097	ENSG00000125804.12	FAM182A	-4.35	1.51e-05	0.00118	-0.17	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25366585	chr20:26054655~26086917:+
BRCA	cis	rs17684571	0.7	rs13200768	ENSG00000231441.1	RP11-472M19.2	4.35	1.51e-05	0.00118	0.23	0.13	Schizophrenia;	chr6:56786828	chr6:56844002~56864078:+
BRCA	cis	rs17684571	0.7	rs13204466	ENSG00000231441.1	RP11-472M19.2	4.35	1.51e-05	0.00118	0.23	0.13	Schizophrenia;	chr6:56787376	chr6:56844002~56864078:+
BRCA	cis	rs17684571	0.7	rs34612783	ENSG00000231441.1	RP11-472M19.2	4.35	1.51e-05	0.00118	0.23	0.13	Schizophrenia;	chr6:56787851	chr6:56844002~56864078:+
BRCA	cis	rs7267979	0.966	rs3827014	ENSG00000274973.1	RP13-401N8.7	4.35	1.51e-05	0.00118	0.15	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25390923	chr20:25845497~25845862:+
BRCA	cis	rs987360	0.636	rs4863977	ENSG00000248869.4	RP11-138I17.1	4.35	1.51e-05	0.00118	0.14	0.13	Temperament;	chr4:137262509	chr4:136796722~137212799:-
BRCA	cis	rs10448080	0.879	rs240946	ENSG00000259366.1	CTD-2647L4.4	4.35	1.51e-05	0.00118	0.1	0.13	Height;	chr8:28711388	chr8:29055935~29056685:+
BRCA	cis	rs17345786	1	rs11715368	ENSG00000244119.1	PDCL3P4	4.35	1.51e-05	0.00119	0.12	0.13	Colonoscopy-negative controls vs population controls;	chr3:101617536	chr3:101712472~101713191:+
BRCA	cis	rs7474896	0.559	rs10740949	ENSG00000120555.12	SEPT7P9	4.35	1.51e-05	0.00119	0.18	0.13	Obesity (extreme);	chr10:37689507	chr10:38383069~38402916:-
BRCA	cis	rs8040855	0.627	rs72757059	ENSG00000230373.7	GOLGA6L5P	4.35	1.51e-05	0.00119	0.17	0.13	Bulimia nervosa;	chr15:85059918	chr15:84507885~84516814:-
BRCA	cis	rs7647973	1	rs10155014	ENSG00000244380.1	RP11-24C3.2	4.35	1.51e-05	0.00119	0.17	0.13	Menarche (age at onset);	chr3:49394888	chr3:48440352~48446656:-
BRCA	cis	rs3768617	0.51	rs2333621	ENSG00000224468.3	RP11-181K3.4	-4.35	1.51e-05	0.00119	-0.14	-0.13	Fuchs's corneal dystrophy;	chr1:183121616	chr1:183138402~183141282:-
BRCA	cis	rs3768617	0.51	rs6424889	ENSG00000224468.3	RP11-181K3.4	-4.35	1.51e-05	0.00119	-0.14	-0.13	Fuchs's corneal dystrophy;	chr1:183122661	chr1:183138402~183141282:-
BRCA	cis	rs3768617	0.51	rs4652776	ENSG00000224468.3	RP11-181K3.4	-4.35	1.51e-05	0.00119	-0.14	-0.13	Fuchs's corneal dystrophy;	chr1:183122785	chr1:183138402~183141282:-
BRCA	cis	rs3768617	0.51	rs4651139	ENSG00000224468.3	RP11-181K3.4	-4.35	1.51e-05	0.00119	-0.14	-0.13	Fuchs's corneal dystrophy;	chr1:183122828	chr1:183138402~183141282:-
BRCA	cis	rs10911251	0.528	rs4652777	ENSG00000224468.3	RP11-181K3.4	-4.35	1.51e-05	0.00119	-0.14	-0.13	Colorectal cancer;	chr1:183122857	chr1:183138402~183141282:-
BRCA	cis	rs3768617	0.51	rs2296292	ENSG00000224468.3	RP11-181K3.4	-4.35	1.51e-05	0.00119	-0.14	-0.13	Fuchs's corneal dystrophy;	chr1:183117622	chr1:183138402~183141282:-
BRCA	cis	rs3768617	0.51	rs10797846	ENSG00000224468.3	RP11-181K3.4	-4.35	1.51e-05	0.00119	-0.14	-0.13	Fuchs's corneal dystrophy;	chr1:183118350	chr1:183138402~183141282:-
BRCA	cis	rs3768617	0.51	rs1547712	ENSG00000224468.3	RP11-181K3.4	-4.35	1.51e-05	0.00119	-0.14	-0.13	Fuchs's corneal dystrophy;	chr1:183118878	chr1:183138402~183141282:-
BRCA	cis	rs3768617	0.51	rs2027083	ENSG00000224468.3	RP11-181K3.4	-4.35	1.51e-05	0.00119	-0.14	-0.13	Fuchs's corneal dystrophy;	chr1:183119195	chr1:183138402~183141282:-
BRCA	cis	rs3768617	0.51	rs10911254	ENSG00000224468.3	RP11-181K3.4	-4.35	1.51e-05	0.00119	-0.14	-0.13	Fuchs's corneal dystrophy;	chr1:183119492	chr1:183138402~183141282:-
BRCA	cis	rs10911251	0.528	rs10911255	ENSG00000224468.3	RP11-181K3.4	-4.35	1.51e-05	0.00119	-0.14	-0.13	Colorectal cancer;	chr1:183119733	chr1:183138402~183141282:-
BRCA	cis	rs3768617	0.51	rs3768621	ENSG00000224468.3	RP11-181K3.4	-4.35	1.51e-05	0.00119	-0.14	-0.13	Fuchs's corneal dystrophy;	chr1:183120922	chr1:183138402~183141282:-
BRCA	cis	rs3768617	0.51	rs10752902	ENSG00000224468.3	RP11-181K3.4	-4.35	1.51e-05	0.00119	-0.14	-0.13	Fuchs's corneal dystrophy;	chr1:183121130	chr1:183138402~183141282:-
BRCA	cis	rs2243480	1	rs4718270	ENSG00000222364.1	RNU6-96P	-4.35	1.51e-05	0.00119	-0.24	-0.13	Diabetic kidney disease;	chr7:65737415	chr7:66395191~66395286:+
BRCA	cis	rs11098499	0.722	rs7673476	ENSG00000260091.1	RP11-33B1.4	-4.35	1.51e-05	0.00119	-0.11	-0.13	Corneal astigmatism;	chr4:119327528	chr4:119409333~119410233:+
BRCA	cis	rs465969	0.744	rs7758483	ENSG00000230177.1	RP5-1112D6.4	4.35	1.51e-05	0.00119	0.3	0.13	Psoriasis;	chr6:111467945	chr6:111277932~111278742:+
BRCA	cis	rs2832191	0.716	rs2297252	ENSG00000232855.5	AF131217.1	-4.35	1.51e-05	0.00119	-0.16	-0.13	Dental caries;	chr21:29004783	chr21:28439346~28674848:-
BRCA	cis	rs7308116	1	rs11113501	ENSG00000274395.1	RP11-554D14.8	-4.35	1.51e-05	0.00119	-0.14	-0.13	Pelvic organ prolapse (moderate/severe);	chr12:107809960	chr12:107835541~107836555:-
BRCA	cis	rs7308116	1	rs11113502	ENSG00000274395.1	RP11-554D14.8	-4.35	1.51e-05	0.00119	-0.14	-0.13	Pelvic organ prolapse (moderate/severe);	chr12:107809987	chr12:107835541~107836555:-
BRCA	cis	rs2692947	0.727	rs749457	ENSG00000168992.4	OR7E102P	4.35	1.51e-05	0.00119	0.18	0.13	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96130205	chr2:95546531~95547545:+
BRCA	cis	rs6686842	0.56	rs60351276	ENSG00000235358.1	RP11-399E6.1	-4.35	1.51e-05	0.00119	-0.18	-0.13	Height;	chr1:41202879	chr1:41242373~41284861:+
BRCA	cis	rs7267979	0.966	rs2151144	ENSG00000125804.12	FAM182A	4.35	1.51e-05	0.00119	0.17	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25434288	chr20:26054655~26086917:+
BRCA	cis	rs72482608	0.896	rs10737554	ENSG00000271811.1	RP1-79C4.4	4.35	1.51e-05	0.00119	0.14	0.13	Emphysema imaging phenotypes;	chr1:170804380	chr1:170667381~170669425:+
BRCA	cis	rs3824867	0.92	rs7126210	ENSG00000280615.1	Y_RNA	-4.35	1.51e-05	0.00119	-0.16	-0.13	Mean corpuscular hemoglobin;	chr11:47438755	chr11:47614898~47614994:-
BRCA	cis	rs9308731	0.666	rs4849402	ENSG00000230499.1	AC108463.1	-4.35	1.51e-05	0.00119	-0.15	-0.13	Chronic lymphocytic leukemia;	chr2:111116355	chr2:111195963~111206494:+
BRCA	cis	rs2154319	0.609	rs61774718	ENSG00000235358.1	RP11-399E6.1	-4.35	1.51e-05	0.00119	-0.18	-0.13	Height;	chr1:41274060	chr1:41242373~41284861:+
BRCA	cis	rs984222	0.501	rs1325941	ENSG00000231365.4	RP11-418J17.1	-4.35	1.51e-05	0.00119	-0.15	-0.13	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:118941193	chr1:119140396~119275973:+
BRCA	cis	rs10043228	1	rs12522027	ENSG00000271918.1	CTD-2287O16.5	-4.35	1.51e-05	0.00119	-0.19	-0.13	Asthma or chronic obstructive pulmonary disease;	chr5:116280834	chr5:116083807~116085416:-
BRCA	cis	rs9467773	0.844	rs2393669	ENSG00000241549.7	GUSBP2	4.35	1.51e-05	0.00119	0.14	0.13	Intelligence (multi-trait analysis);	chr6:26503645	chr6:26871484~26956554:-
BRCA	cis	rs9467773	1	rs9461259	ENSG00000241549.7	GUSBP2	4.35	1.51e-05	0.00119	0.14	0.13	Intelligence (multi-trait analysis);	chr6:26504607	chr6:26871484~26956554:-
BRCA	cis	rs9467773	1	rs3736781	ENSG00000241549.7	GUSBP2	4.35	1.51e-05	0.00119	0.14	0.13	Intelligence (multi-trait analysis);	chr6:26505134	chr6:26871484~26956554:-
BRCA	cis	rs9467773	1	rs3736782	ENSG00000241549.7	GUSBP2	4.35	1.51e-05	0.00119	0.14	0.13	Intelligence (multi-trait analysis);	chr6:26505175	chr6:26871484~26956554:-
BRCA	cis	rs11779988	0.528	rs208029	ENSG00000253671.1	RP11-806O11.1	-4.35	1.51e-05	0.00119	-0.19	-0.13	Breast cancer;	chr8:17983478	chr8:17808941~17820868:+
BRCA	cis	rs62458065	1	rs10231294	ENSG00000229358.3	DPY19L1P1	-4.35	1.51e-05	0.00119	-0.18	-0.13	Metabolite levels (HVA/MHPG ratio);	chr7:32425745	chr7:32580949~32761787:-
BRCA	cis	rs1910358	0.591	rs12659609	ENSG00000248874.4	C5orf17	-4.35	1.52e-05	0.00119	-0.17	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23974976	chr5:23951348~24178263:+
BRCA	cis	rs6686842	0.536	rs11209720	ENSG00000235358.1	RP11-399E6.1	-4.35	1.52e-05	0.00119	-0.18	-0.13	Height;	chr1:41224745	chr1:41242373~41284861:+
BRCA	cis	rs6686842	0.536	rs11209721	ENSG00000235358.1	RP11-399E6.1	-4.35	1.52e-05	0.00119	-0.18	-0.13	Height;	chr1:41224972	chr1:41242373~41284861:+
BRCA	cis	rs8114671	0.836	rs3746432	ENSG00000126005.14	MMP24-AS1	4.35	1.52e-05	0.00119	0.16	0.13	Height;	chr20:35004960	chr20:35216462~35278131:-
BRCA	cis	rs3764021	0.84	rs12304510	ENSG00000256582.1	RP11-75L1.1	4.35	1.52e-05	0.00119	0.13	0.13	Type 1 diabetes;	chr12:9732930	chr12:9704077~9709350:+
BRCA	cis	rs7267979	1	rs6076339	ENSG00000125804.12	FAM182A	4.35	1.52e-05	0.00119	0.18	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25368076	chr20:26054655~26086917:+
BRCA	cis	rs6121246	0.697	rs7269866	ENSG00000230613.1	HM13-AS1	4.35	1.52e-05	0.00119	0.2	0.13	Mean corpuscular hemoglobin;	chr20:31644701	chr20:31567707~31573263:-
BRCA	cis	rs938554	0.513	rs3733588	ENSG00000250413.1	RP11-448G15.1	4.35	1.52e-05	0.00119	0.18	0.13	Blood metabolite levels;	chr4:9995679	chr4:10006482~10009725:+
BRCA	cis	rs4948275	0.631	rs2606116	ENSG00000237233.2	TMEM26-AS1	-4.35	1.52e-05	0.00119	-0.16	-0.13	Night sleep phenotypes;	chr10:61591316	chr10:61452639~61481956:+
BRCA	cis	rs12887734	0.566	rs3742366	ENSG00000269940.1	RP11-73M18.7	4.35	1.52e-05	0.00119	0.15	0.13	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103732014	chr14:103694560~103695170:+
BRCA	cis	rs2692947	0.74	rs60452119	ENSG00000168992.4	OR7E102P	4.35	1.52e-05	0.00119	0.18	0.13	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95754302	chr2:95546531~95547545:+
BRCA	cis	rs4287000	0.508	rs62573991	ENSG00000227603.1	RP11-165J3.6	-4.35	1.52e-05	0.00119	-0.15	-0.13	Itch intensity from mosquito bite adjusted by bite size;	chr9:93615453	chr9:93435332~93437121:-
BRCA	cis	rs8180040	0.701	rs1079276	ENSG00000276925.1	RP11-708J19.3	-4.35	1.52e-05	0.00119	-0.15	-0.13	Colorectal cancer;	chr3:47004249	chr3:47469777~47469987:+
BRCA	cis	rs853679	1	rs1778508	ENSG00000280107.1	AL022393.9	4.35	1.52e-05	0.00119	0.24	0.13	Depression;	chr6:28262103	chr6:28170845~28172521:+
BRCA	cis	rs12554020	0.681	rs80062429	ENSG00000227603.1	RP11-165J3.6	4.35	1.52e-05	0.00119	0.2	0.13	Schizophrenia;	chr9:93608830	chr9:93435332~93437121:-
BRCA	cis	rs7267979	0.649	rs2500406	ENSG00000277938.1	RP5-965G21.3	-4.35	1.52e-05	0.00119	-0.17	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25421226	chr20:25229150~25231933:+
BRCA	cis	rs7712401	0.755	rs27740	ENSG00000251538.4	RP11-166A12.1	-4.35	1.52e-05	0.00119	-0.14	-0.13	Mean platelet volume;	chr5:122869077	chr5:122628952~122730685:-
BRCA	cis	rs62025270	0.632	rs62023935	ENSG00000259762.1	RP11-158M2.4	-4.35	1.52e-05	0.00119	-0.2	-0.13	Idiopathic pulmonary fibrosis;	chr15:85605604	chr15:85750336~85752901:-
BRCA	cis	rs4578769	0.959	rs11082169	ENSG00000265939.1	UBE2CP2	4.35	1.52e-05	0.00119	0.16	0.13	Eosinophil percentage of white cells;	chr18:22850034	chr18:22900486~22900995:-
BRCA	cis	rs4578769	0.959	rs2100191	ENSG00000265939.1	UBE2CP2	4.35	1.52e-05	0.00119	0.16	0.13	Eosinophil percentage of white cells;	chr18:22851428	chr18:22900486~22900995:-
BRCA	cis	rs4578769	0.959	rs2100190	ENSG00000265939.1	UBE2CP2	4.35	1.52e-05	0.00119	0.16	0.13	Eosinophil percentage of white cells;	chr18:22851857	chr18:22900486~22900995:-
BRCA	cis	rs875971	0.545	rs2460427	ENSG00000273142.1	RP11-458F8.4	-4.35	1.52e-05	0.00119	-0.13	-0.13	Aortic root size;	chr7:66154218	chr7:66902857~66906297:+
BRCA	cis	rs17684571	0.7	rs13194904	ENSG00000231441.1	RP11-472M19.2	4.35	1.52e-05	0.00119	0.22	0.13	Schizophrenia;	chr6:56811443	chr6:56844002~56864078:+
BRCA	cis	rs7131987	0.801	rs6487804	ENSG00000257176.2	RP11-996F15.2	-4.35	1.52e-05	0.00119	-0.16	-0.13	QT interval;	chr12:29302001	chr12:29280418~29317848:-
BRCA	cis	rs11158026	0.567	rs61224609	ENSG00000258413.1	RP11-665C16.6	-4.35	1.52e-05	0.00119	-0.18	-0.13	Parkinson's disease;	chr14:54936490	chr14:55262767~55272075:-
BRCA	cis	rs1993293	0.636	rs2924778	ENSG00000259363.4	CTD-2054N24.2	4.35	1.52e-05	0.00119	0.17	0.13	Coronary artery calcification;	chr15:99758621	chr15:99807023~99877148:+
BRCA	cis	rs78487399	0.908	rs12463527	ENSG00000234936.1	AC010883.5	4.35	1.52e-05	0.00119	0.19	0.13	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43588806	chr2:43229573~43233394:+
BRCA	cis	rs1008375	1	rs7697889	ENSG00000249502.1	AC006160.5	-4.35	1.52e-05	0.00119	-0.15	-0.13	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17616338	chr4:17587467~17614571:-
BRCA	cis	rs6545883	0.524	rs7561697	ENSG00000273302.1	RP11-493E12.2	-4.35	1.52e-05	0.00119	-0.11	-0.13	Tuberculosis;	chr2:61292030	chr2:61199979~61200769:+
BRCA	cis	rs10411936	0.682	rs8103805	ENSG00000280332.1	CTD-2013N17.6	4.35	1.52e-05	0.00119	0.12	0.13	Multiple sclerosis;White blood cell count;	chr19:16487622	chr19:16356329~16358327:-
BRCA	cis	rs7829975	0.567	rs6601273	ENSG00000254153.1	CTA-398F10.2	-4.35	1.52e-05	0.00119	-0.16	-0.13	Mood instability;	chr8:8939009	chr8:8456909~8461337:-
BRCA	cis	rs875971	0.964	rs778735	ENSG00000236529.1	RP13-254B10.1	4.35	1.52e-05	0.00119	0.15	0.13	Aortic root size;	chr7:66349822	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.577	rs34888281	ENSG00000273024.4	INTS4P2	4.35	1.52e-05	0.00119	0.15	0.13	Aortic root size;	chr7:66120784	chr7:65647864~65715661:+
BRCA	cis	rs6738028	0.535	rs744531	ENSG00000227992.1	AC108463.2	-4.35	1.52e-05	0.0012	-0.16	-0.13	Dehydroepiandrosterone sulphate levels;	chr2:111193476	chr2:111203964~111206215:-
BRCA	cis	rs2692947	0.673	rs2692894	ENSG00000168992.4	OR7E102P	-4.35	1.52e-05	0.0012	-0.18	-0.13	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96119195	chr2:95546531~95547545:+
BRCA	cis	rs938554	0.513	rs1014290	ENSG00000250413.1	RP11-448G15.1	-4.35	1.52e-05	0.0012	-0.18	-0.13	Blood metabolite levels;	chr4:10000237	chr4:10006482~10009725:+
BRCA	cis	rs2554380	0.8	rs1544876	ENSG00000230373.7	GOLGA6L5P	-4.35	1.52e-05	0.0012	-0.19	-0.13	Height;	chr15:83707049	chr15:84507885~84516814:-
BRCA	cis	rs2251381	0.565	rs2832279	ENSG00000176054.6	RPL23P2	4.35	1.52e-05	0.0012	0.15	0.13	Selective IgA deficiency;	chr21:29241145	chr21:28997613~28998033:-
BRCA	cis	rs453301	0.606	rs6601279	ENSG00000254153.1	CTA-398F10.2	-4.35	1.52e-05	0.0012	-0.16	-0.13	Joint mobility (Beighton score);	chr8:9050721	chr8:8456909~8461337:-
BRCA	cis	rs453301	0.606	rs6981060	ENSG00000254153.1	CTA-398F10.2	-4.35	1.52e-05	0.0012	-0.16	-0.13	Joint mobility (Beighton score);	chr8:9050725	chr8:8456909~8461337:-
BRCA	cis	rs16846053	0.792	rs72879227	ENSG00000227403.1	AC009299.3	4.35	1.52e-05	0.0012	0.35	0.13	Blood osmolality (transformed sodium);	chr2:161830781	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.792	rs55969921	ENSG00000227403.1	AC009299.3	4.35	1.52e-05	0.0012	0.35	0.13	Blood osmolality (transformed sodium);	chr2:161830899	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.792	rs56299944	ENSG00000227403.1	AC009299.3	4.35	1.52e-05	0.0012	0.35	0.13	Blood osmolality (transformed sodium);	chr2:161830949	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.642	rs72879231	ENSG00000227403.1	AC009299.3	4.35	1.52e-05	0.0012	0.35	0.13	Blood osmolality (transformed sodium);	chr2:161831700	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.792	rs72879233	ENSG00000227403.1	AC009299.3	4.35	1.52e-05	0.0012	0.35	0.13	Blood osmolality (transformed sodium);	chr2:161831789	chr2:161244739~161249050:+
BRCA	cis	rs875971	1	rs1540651	ENSG00000229180.5	GS1-124K5.11	-4.35	1.52e-05	0.0012	-0.12	-0.13	Aortic root size;	chr7:66185134	chr7:66526088~66542624:-
BRCA	cis	rs2255336	0.938	rs9651850	ENSG00000245648.1	RP11-277P12.20	-4.35	1.52e-05	0.0012	-0.22	-0.13	Blood protein levels;	chr12:10490533	chr12:10363769~10398506:+
BRCA	cis	rs8054556	0.787	rs11642612	ENSG00000183604.13	SMG1P5	-4.35	1.53e-05	0.0012	-0.14	-0.13	Autism spectrum disorder or schizophrenia;	chr16:30018874	chr16:30267553~30335374:-
BRCA	cis	rs8054556	0.787	rs11150581	ENSG00000183604.13	SMG1P5	-4.35	1.53e-05	0.0012	-0.14	-0.13	Autism spectrum disorder or schizophrenia;	chr16:30019378	chr16:30267553~30335374:-
BRCA	cis	rs875971	0.66	rs6460308	ENSG00000273142.1	RP11-458F8.4	4.35	1.53e-05	0.0012	0.12	0.13	Aortic root size;	chr7:66619753	chr7:66902857~66906297:+
BRCA	cis	rs10191773	0.522	rs6747639	ENSG00000243389.1	AC012442.5	4.35	1.53e-05	0.0012	0.27	0.13	Yeast infection;	chr2:112209881	chr2:112589040~112614431:+
BRCA	cis	rs4948275	0.693	rs2254096	ENSG00000237233.2	TMEM26-AS1	-4.35	1.53e-05	0.0012	-0.16	-0.13	Night sleep phenotypes;	chr10:61548401	chr10:61452639~61481956:+
BRCA	cis	rs4266144	0.821	rs4325879	ENSG00000241770.1	RP11-555M1.3	-4.35	1.53e-05	0.0012	-0.2	-0.13	Coronary artery disease;	chr3:157134195	chr3:157163452~157169133:+
BRCA	cis	rs10411936	0.712	rs3810198	ENSG00000280332.1	CTD-2013N17.6	4.35	1.53e-05	0.0012	0.12	0.13	Multiple sclerosis;White blood cell count;	chr19:16490383	chr19:16356329~16358327:-
BRCA	cis	rs6860806	0.661	rs6890009	ENSG00000233006.5	AC034220.3	4.35	1.53e-05	0.0012	0.09	0.13	Breast cancer;	chr5:132244340	chr5:132311285~132369916:-
BRCA	cis	rs9308731	0.644	rs4849403	ENSG00000230499.1	AC108463.1	-4.35	1.53e-05	0.0012	-0.15	-0.13	Chronic lymphocytic leukemia;	chr2:111116460	chr2:111195963~111206494:+
BRCA	cis	rs6547741	1	rs6547740	ENSG00000234072.1	AC074117.10	4.35	1.53e-05	0.0012	0.12	0.13	Oral cavity cancer;	chr2:27631502	chr2:27356246~27367622:+
BRCA	cis	rs801193	0.613	rs2659900	ENSG00000236529.1	RP13-254B10.1	4.35	1.53e-05	0.0012	0.15	0.13	Aortic root size;	chr7:66719456	chr7:65840212~65840596:+
BRCA	cis	rs62388641	0.547	rs2317966	ENSG00000218027.2	RP11-157J24.1	4.35	1.53e-05	0.0012	0.15	0.13	Daytime sleep phenotypes;	chr6:1550651	chr6:1513698~1515289:-
BRCA	cis	rs11098499	0.691	rs17009144	ENSG00000260404.2	RP11-384K6.6	-4.35	1.53e-05	0.0012	-0.12	-0.13	Corneal astigmatism;	chr4:119349640	chr4:118591773~118633729:+
BRCA	cis	rs6671200	0.541	rs7555339	ENSG00000226026.4	RP11-57H12.3	-4.35	1.53e-05	0.0012	-0.21	-0.13	Stearic acid (18:0) levels;	chr1:95226023	chr1:95163219~95233982:-
BRCA	cis	rs2136613	0.533	rs1509958	ENSG00000238280.1	RP11-436D10.3	-4.35	1.53e-05	0.0012	-0.17	-0.13	Selective IgA deficiency;	chr10:62856390	chr10:62793562~62805887:-
BRCA	cis	rs2136613	0.533	rs12258444	ENSG00000238280.1	RP11-436D10.3	-4.35	1.53e-05	0.0012	-0.17	-0.13	Selective IgA deficiency;	chr10:62856825	chr10:62793562~62805887:-
BRCA	cis	rs6600671	1	rs10903159	ENSG00000231429.2	RP11-343N15.2	-4.35	1.53e-05	0.0012	-0.16	-0.13	Hip geometry;	chr1:121440138	chr1:121412719~121429274:+
BRCA	cis	rs8040855	0.627	rs17540307	ENSG00000230373.7	GOLGA6L5P	4.35	1.53e-05	0.0012	0.17	0.13	Bulimia nervosa;	chr15:85090614	chr15:84507885~84516814:-
BRCA	cis	rs7267979	1	rs6083844	ENSG00000277938.1	RP5-965G21.3	-4.35	1.53e-05	0.0012	-0.16	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25406196	chr20:25229150~25231933:+
BRCA	cis	rs465969	1	rs463543	ENSG00000230177.1	RP5-1112D6.4	4.35	1.53e-05	0.0012	0.31	0.13	Psoriasis;	chr6:111346349	chr6:111277932~111278742:+
BRCA	cis	rs11742741	0.935	rs72745797	ENSG00000248874.4	C5orf17	-4.35	1.53e-05	0.0012	-0.17	-0.13	Educational attainment;	chr5:24175533	chr5:23951348~24178263:+
BRCA	cis	rs801193	0.935	rs2659899	ENSG00000272831.1	RP11-792A8.4	4.35	1.53e-05	0.0012	0.12	0.13	Aortic root size;	chr7:66721734	chr7:66739829~66740385:-
BRCA	cis	rs467650	0.549	rs2547958	ENSG00000248489.1	CTD-2007H13.3	-4.34	1.53e-05	0.0012	-0.14	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:98658249	chr5:98929171~98995013:+
BRCA	cis	rs6088580	0.634	rs4258875	ENSG00000276073.1	RP5-1125A11.7	4.34	1.53e-05	0.0012	0.15	0.13	Glomerular filtration rate (creatinine);	chr20:34337089	chr20:33985617~33988989:-
BRCA	cis	rs6496932	0.563	rs2344083	ENSG00000218052.5	ADAMTS7P4	-4.34	1.53e-05	0.0012	-0.13	-0.13	Central corneal thickness;Corneal structure;	chr15:85354201	chr15:85255369~85330334:-
BRCA	cis	rs240993	0.812	rs6937734	ENSG00000271789.1	RP5-1112D6.7	4.34	1.53e-05	0.0012	0.17	0.13	Inflammatory skin disease;Psoriasis;	chr6:111415439	chr6:111297126~111298510:+
BRCA	cis	rs651907	0.557	rs17347644	ENSG00000256628.3	ZBTB11-AS1	4.34	1.53e-05	0.0012	0.17	0.13	Colorectal cancer;	chr3:101828889	chr3:101676475~101679217:+
BRCA	cis	rs11892454	0.515	rs6741640	ENSG00000217643.1	PTGES3P2	-4.34	1.53e-05	0.0012	-0.14	-0.13	Heschl's gyrus morphology;	chr2:25845640	chr2:25822469~25822950:+
BRCA	cis	rs2692947	0.763	rs7570074	ENSG00000168992.4	OR7E102P	4.34	1.53e-05	0.0012	0.18	0.13	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95741289	chr2:95546531~95547545:+
BRCA	cis	rs3768617	0.51	rs3768620	ENSG00000224468.3	RP11-181K3.4	-4.34	1.53e-05	0.0012	-0.14	-0.13	Fuchs's corneal dystrophy;	chr1:183123102	chr1:183138402~183141282:-
BRCA	cis	rs7927592	0.763	rs10896340	ENSG00000212093.1	AP000807.1	-4.34	1.53e-05	0.0012	-0.14	-0.13	Total body bone mineral density;	chr11:68545177	chr11:68506083~68506166:-
BRCA	cis	rs2115630	1	rs56074163	ENSG00000259728.4	LINC00933	-4.34	1.53e-05	0.0012	-0.15	-0.13	P wave terminal force;	chr15:84808101	chr15:84570649~84580175:+
BRCA	cis	rs10129255	0.5	rs6576225	ENSG00000211959.2	IGHV4-39	4.34	1.53e-05	0.0012	0.09	0.13	Kawasaki disease;	chr14:106778120	chr14:106421711~106422218:-
BRCA	cis	rs10129255	0.5	rs6576226	ENSG00000211959.2	IGHV4-39	4.34	1.53e-05	0.0012	0.09	0.13	Kawasaki disease;	chr14:106778135	chr14:106421711~106422218:-
BRCA	cis	rs7267979	0.816	rs8115257	ENSG00000274973.1	RP13-401N8.7	-4.34	1.53e-05	0.0012	-0.15	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25227295	chr20:25845497~25845862:+
BRCA	cis	rs1910358	0.53	rs2331686	ENSG00000248874.4	C5orf17	-4.34	1.53e-05	0.0012	-0.17	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23947618	chr5:23951348~24178263:+
BRCA	cis	rs73198271	0.583	rs11781985	ENSG00000254153.1	CTA-398F10.2	4.34	1.53e-05	0.0012	0.18	0.13	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8732273	chr8:8456909~8461337:-
BRCA	cis	rs1910358	0.596	rs7710191	ENSG00000248874.4	C5orf17	-4.34	1.53e-05	0.0012	-0.17	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23997981	chr5:23951348~24178263:+
BRCA	cis	rs6696239	1	rs12123996	ENSG00000227711.2	RP11-275O4.5	-4.34	1.53e-05	0.0012	-0.18	-0.13	Height;	chr1:227557389	chr1:227509028~227520477:-
BRCA	cis	rs2136613	0.533	rs7088066	ENSG00000238280.1	RP11-436D10.3	-4.34	1.53e-05	0.0012	-0.17	-0.13	Selective IgA deficiency;	chr10:62846097	chr10:62793562~62805887:-
BRCA	cis	rs7267979	0.932	rs424487	ENSG00000274973.1	RP13-401N8.7	-4.34	1.53e-05	0.0012	-0.15	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25487495	chr20:25845497~25845862:+
BRCA	cis	rs6441961	0.501	rs6441959	ENSG00000223552.1	RP11-24F11.2	-4.34	1.53e-05	0.0012	-0.16	-0.13	Celiac disease;	chr3:46300938	chr3:46364955~46407059:-
BRCA	cis	rs1005277	0.579	rs2472175	ENSG00000263064.2	RP11-291L22.7	4.34	1.53e-05	0.0012	0.16	0.13	Extrinsic epigenetic age acceleration;	chr10:38093973	chr10:38448689~38448949:+
BRCA	cis	rs1005277	0.579	rs2472176	ENSG00000263064.2	RP11-291L22.7	4.34	1.53e-05	0.0012	0.16	0.13	Extrinsic epigenetic age acceleration;	chr10:38093993	chr10:38448689~38448949:+
BRCA	cis	rs1005277	0.579	rs2983343	ENSG00000263064.2	RP11-291L22.7	4.34	1.53e-05	0.0012	0.16	0.13	Extrinsic epigenetic age acceleration;	chr10:38094404	chr10:38448689~38448949:+
BRCA	cis	rs1005277	0.579	rs2474569	ENSG00000263064.2	RP11-291L22.7	4.34	1.53e-05	0.0012	0.16	0.13	Extrinsic epigenetic age acceleration;	chr10:38094563	chr10:38448689~38448949:+
BRCA	cis	rs1005277	0.602	rs2504142	ENSG00000263064.2	RP11-291L22.7	4.34	1.53e-05	0.0012	0.16	0.13	Extrinsic epigenetic age acceleration;	chr10:38094865	chr10:38448689~38448949:+
BRCA	cis	rs11673344	0.543	rs1818748	ENSG00000226686.6	LINC01535	4.34	1.53e-05	0.0012	0.17	0.13	Obesity-related traits;	chr19:37065416	chr19:37251912~37265535:+
BRCA	cis	rs1075265	0.508	rs12621225	ENSG00000235937.1	AC008280.1	4.34	1.53e-05	0.0012	0.15	0.13	Chronotype;Morning vs. evening chronotype;	chr2:53710040	chr2:54029552~54030682:-
BRCA	cis	rs2242116	0.761	rs6780601	ENSG00000276925.1	RP11-708J19.3	-4.34	1.53e-05	0.0012	-0.16	-0.13	Birth weight;	chr3:46924366	chr3:47469777~47469987:+
BRCA	cis	rs16958440	1	rs62096476	ENSG00000267724.1	RP11-49K24.8	4.34	1.53e-05	0.0012	0.23	0.13	Sitting height ratio;	chr18:47132250	chr18:47105946~47108062:+
BRCA	cis	rs16958440	1	rs62096478	ENSG00000267724.1	RP11-49K24.8	4.34	1.53e-05	0.0012	0.23	0.13	Sitting height ratio;	chr18:47136038	chr18:47105946~47108062:+
BRCA	cis	rs828999	0.583	rs12047398	ENSG00000280186.1	RP11-483I13.6	-4.34	1.53e-05	0.0012	-0.16	-0.13	Monocyte percentage of white cells;	chr1:108150683	chr1:108200413~108202743:+
BRCA	cis	rs6439153	0.933	rs6769662	ENSG00000261159.1	RP11-723O4.9	4.34	1.53e-05	0.0012	0.15	0.13	Pneumococcal bacteremia;	chr3:129002467	chr3:128859716~128860526:-
BRCA	cis	rs2832191	0.671	rs68101501	ENSG00000176054.6	RPL23P2	-4.34	1.54e-05	0.0012	-0.15	-0.13	Dental caries;	chr21:29140908	chr21:28997613~28998033:-
BRCA	cis	rs300890	0.662	rs300903	ENSG00000250326.1	RP11-284M14.1	-4.34	1.54e-05	0.0012	-0.16	-0.13	Nasopharyngeal carcinoma;	chr4:143318649	chr4:142933195~143184861:-
BRCA	cis	rs6545883	0.524	rs12992614	ENSG00000273302.1	RP11-493E12.2	-4.34	1.54e-05	0.0012	-0.12	-0.13	Tuberculosis;	chr2:61365941	chr2:61199979~61200769:+
BRCA	cis	rs2839186	0.934	rs17176520	ENSG00000239415.1	AP001469.9	4.34	1.54e-05	0.0012	0.14	0.13	Testicular germ cell tumor;	chr21:46262167	chr21:46251549~46254133:-
BRCA	cis	rs9921338	0.961	rs7187870	ENSG00000262636.1	CTD-3088G3.4	-4.34	1.54e-05	0.0012	-0.22	-0.13	Vein graft stenosis in coronary artery bypass grafting;	chr16:11338062	chr16:11380859~11381118:-
BRCA	cis	rs10986311	1	rs3758212	ENSG00000227200.1	RP11-121A14.3	-4.34	1.54e-05	0.0012	-0.16	-0.13	Vitiligo;	chr9:124307474	chr9:124262876~124265809:+
BRCA	cis	rs7520050	0.807	rs12025621	ENSG00000234329.1	RP11-767N6.2	-4.34	1.54e-05	0.0012	-0.13	-0.13	Reticulocyte count;Red blood cell count;	chr1:45762719	chr1:45651039~45651826:-
BRCA	cis	rs6012564	0.927	rs932451	ENSG00000227431.4	CSE1L-AS1	-4.34	1.54e-05	0.0012	-0.16	-0.13	Anger;	chr20:48957061	chr20:49040463~49046044:-
BRCA	cis	rs669446	0.561	rs641351	ENSG00000236200.4	KDM4A-AS1	-4.34	1.54e-05	0.0012	-0.17	-0.13	Amyotrophic lateral sclerosis (age of onset);	chr1:43617848	chr1:43699765~43708138:-
BRCA	cis	rs10129255	0.5	rs59939897	ENSG00000211959.2	IGHV4-39	4.34	1.54e-05	0.0012	0.09	0.13	Kawasaki disease;	chr14:106783414	chr14:106421711~106422218:-
BRCA	cis	rs7968440	0.736	rs10783388	ENSG00000272368.2	RP4-605O3.4	4.34	1.54e-05	0.00121	0.13	0.13	Fibrinogen;	chr12:50787916	chr12:50112197~50165618:+
BRCA	cis	rs28374715	0.578	rs17730589	ENSG00000247556.5	OIP5-AS1	4.34	1.54e-05	0.00121	0.15	0.13	Ulcerative colitis;	chr15:41308680	chr15:41283990~41309737:+
BRCA	cis	rs6071166	0.646	rs6071050	ENSG00000224635.1	RP4-564F22.5	-4.34	1.54e-05	0.00121	-0.16	-0.13	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38677429	chr20:38406011~38416797:-
BRCA	cis	rs9952991	0.943	rs9952753	ENSG00000260302.1	RP11-973H7.1	-4.34	1.54e-05	0.00121	-0.22	-0.13	Inflammatory skin disease;	chr18:12780464	chr18:12774651~12775923:-
BRCA	cis	rs2880765	0.835	rs12708553	ENSG00000202081.1	RNU6-1280P	-4.34	1.54e-05	0.00121	-0.15	-0.13	Coronary artery disease;	chr15:85503602	chr15:85651522~85651628:-
BRCA	cis	rs7267979	0.934	rs2261115	ENSG00000125804.12	FAM182A	-4.34	1.54e-05	0.00121	-0.17	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25279171	chr20:26054655~26086917:+
BRCA	cis	rs6460942	0.597	rs4719315	ENSG00000226690.5	AC005281.1	4.34	1.54e-05	0.00121	0.27	0.13	Coronary artery disease;	chr7:12489008	chr7:12496429~12541910:+
BRCA	cis	rs4143844	0.867	rs11631273	ENSG00000259251.2	RP11-643M14.1	4.34	1.54e-05	0.00121	0.32	0.13	Bipolar disorder and schizophrenia;	chr15:61985871	chr15:62060503~62062434:+
BRCA	cis	rs6439153	0.933	rs900381	ENSG00000261159.1	RP11-723O4.9	4.34	1.54e-05	0.00121	0.15	0.13	Pneumococcal bacteremia;	chr3:128994612	chr3:128859716~128860526:-
BRCA	cis	rs2880765	0.835	rs7178991	ENSG00000230373.7	GOLGA6L5P	4.34	1.54e-05	0.00121	0.14	0.13	Coronary artery disease;	chr15:85507713	chr15:84507885~84516814:-
BRCA	cis	rs11742741	0.967	rs72747803	ENSG00000248874.4	C5orf17	-4.34	1.54e-05	0.00121	-0.17	-0.13	Educational attainment;	chr5:24202777	chr5:23951348~24178263:+
BRCA	cis	rs962856	0.756	rs4671799	ENSG00000236780.4	AC078941.1	4.34	1.54e-05	0.00121	0.18	0.13	Pancreatic cancer;	chr2:67395111	chr2:67123357~67215319:-
BRCA	cis	rs962856	0.756	rs4671800	ENSG00000236780.4	AC078941.1	4.34	1.54e-05	0.00121	0.18	0.13	Pancreatic cancer;	chr2:67395216	chr2:67123357~67215319:-
BRCA	cis	rs7701440	0.512	rs2055375	ENSG00000215032.2	GNL3LP1	-4.34	1.54e-05	0.00121	-0.16	-0.13	Educational attainment;	chr5:61235393	chr5:60891935~60893577:-
BRCA	cis	rs780094	0.5	rs12473139	ENSG00000234072.1	AC074117.10	4.34	1.54e-05	0.00121	0.13	0.13	Urate levels in overweight individuals;C-reactive protein;Metabolic syndrome;Red blood cell count;Renal underexcretion gout;Nonalcoholic fatty liver disease;Age-related diseases, mortality and associated endophenotypes;Crohn's disease;Calcium levels;Fasting plasma glucose;Metabolic traits;Fasting blood glucose;Fasting blood insulin;Urate levels in obese individuals;Alcohol consumption (drinks per week);Height;Urate levels;Gondoic acid (20:1n-9) levels;Uric acid levels;Age-related disease endophenotypes;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Homeostasis model assessment of insulin resistance;Alcohol consumption;Fasting blood insulin (BMI interaction);Triglycerides;Fasting blood glucose (BMI interaction);Hypertriglyceridemia;LDL cholesterol;Type 2 diabetes;Triglyceride levels;	chr2:27542720	chr2:27356246~27367622:+
BRCA	cis	rs17270561	0.636	rs2070642	ENSG00000272462.2	U91328.19	-4.34	1.54e-05	0.00121	-0.16	-0.13	Iron status biomarkers;	chr6:25830984	chr6:25992662~26001775:+
BRCA	cis	rs2624839	0.704	rs12632110	ENSG00000228008.1	CTD-2330K9.3	-4.34	1.54e-05	0.00121	-0.13	-0.13	Intelligence (multi-trait analysis);	chr3:50186792	chr3:49903845~49916937:+
BRCA	cis	rs16958440	0.867	rs12326221	ENSG00000267724.1	RP11-49K24.8	4.34	1.54e-05	0.00121	0.27	0.13	Sitting height ratio;	chr18:47156522	chr18:47105946~47108062:+
BRCA	cis	rs1434579	0.966	rs1062093	ENSG00000176761.7	ZNF285B	-4.34	1.54e-05	0.00121	-0.16	-0.13	Tuberculosis;	chr19:44427820	chr19:44467641~44473227:+
BRCA	cis	rs35740288	0.822	rs4843090	ENSG00000202081.1	RNU6-1280P	4.34	1.54e-05	0.00121	0.18	0.13	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85677398	chr15:85651522~85651628:-
BRCA	cis	rs3176789	0.671	rs7953260	ENSG00000256673.1	RP11-599J14.2	4.34	1.54e-05	0.00121	0.15	0.13	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9766067	chr12:9398355~9414851:-
BRCA	cis	rs1371614	0.501	rs6745807	ENSG00000229122.1	AGBL5-IT1	4.34	1.54e-05	0.00121	0.14	0.13	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26962449	chr2:27061038~27061815:+
BRCA	cis	rs11673344	0.523	rs7245520	ENSG00000226686.6	LINC01535	4.34	1.54e-05	0.00121	0.17	0.13	Obesity-related traits;	chr19:37036416	chr19:37251912~37265535:+
BRCA	cis	rs17818399	0.675	rs35949012	ENSG00000279254.1	RP11-536C12.1	-4.34	1.54e-05	0.00121	-0.17	-0.13	Height;	chr2:46633262	chr2:46668870~46670778:+
BRCA	cis	rs17818399	0.815	rs17768018	ENSG00000279254.1	RP11-536C12.1	-4.34	1.54e-05	0.00121	-0.17	-0.13	Height;	chr2:46634872	chr2:46668870~46670778:+
BRCA	cis	rs6599077	1	rs9848462	ENSG00000223797.4	ENTPD3-AS1	-4.34	1.54e-05	0.00121	-0.16	-0.13	Sleep-related phenotypes;	chr3:40055713	chr3:40313802~40453329:-
BRCA	cis	rs832187	0.603	rs7615475	ENSG00000280620.1	SCAANT1	4.34	1.54e-05	0.00121	0.17	0.13	Schizophrenia;	chr3:63940985	chr3:63911518~63911772:-
BRCA	cis	rs3824867	0.959	rs4237544	ENSG00000280615.1	Y_RNA	4.34	1.54e-05	0.00121	0.16	0.13	Mean corpuscular hemoglobin;	chr11:47432720	chr11:47614898~47614994:-
BRCA	cis	rs2243480	1	rs7804223	ENSG00000275400.1	RP4-756H11.5	-4.34	1.54e-05	0.00121	-0.24	-0.13	Diabetic kidney disease;	chr7:66199572	chr7:66553805~66554199:-
BRCA	cis	rs801193	1	rs2420824	ENSG00000229180.5	GS1-124K5.11	-4.34	1.54e-05	0.00121	-0.11	-0.13	Aortic root size;	chr7:66666129	chr7:66526088~66542624:-
BRCA	cis	rs4835473	0.868	rs7683365	ENSG00000249741.2	RP11-673E1.3	4.34	1.54e-05	0.00121	0.15	0.13	Immature fraction of reticulocytes;	chr4:143999443	chr4:143911514~143912053:-
BRCA	cis	rs2880765	0.835	rs4514633	ENSG00000202081.1	RNU6-1280P	4.34	1.54e-05	0.00121	0.15	0.13	Coronary artery disease;	chr15:85497786	chr15:85651522~85651628:-
BRCA	cis	rs3892630	0.878	rs11878394	ENSG00000267475.1	CTD-2538C1.2	-4.34	1.54e-05	0.00121	-0.21	-0.13	Red blood cell traits;	chr19:32714938	chr19:32687089~32691750:-
BRCA	cis	rs7160336	1	rs6574158	ENSG00000259065.1	RP5-1021I20.1	4.34	1.54e-05	0.00121	0.15	0.13	Blood protein levels;	chr14:74045995	chr14:73787360~73803270:+
BRCA	cis	rs13358904	0.955	rs4958029	ENSG00000278921.2	EPB41L4A-AS2	4.34	1.54e-05	0.00121	0.15	0.13	Suicide ideation score in major depressive disorder;	chr5:112261733	chr5:112419583~112420978:+
BRCA	cis	rs17406451	0.743	rs6722806	ENSG00000234936.1	AC010883.5	4.34	1.55e-05	0.00121	0.13	0.13	Mitochondrial DNA levels;	chr2:43400576	chr2:43229573~43233394:+
BRCA	cis	rs11976180	1	rs2961134	ENSG00000244479.5	OR2A1-AS1	4.34	1.55e-05	0.00121	0.18	0.13	Obesity-related traits;	chr7:144073969	chr7:144251264~144356181:-
BRCA	cis	rs6840360	0.642	rs10454251	ENSG00000251611.1	RP11-610P16.1	-4.34	1.55e-05	0.00121	-0.12	-0.13	Intelligence (multi-trait analysis);	chr4:151462810	chr4:151407551~151408835:-
BRCA	cis	rs11009175	0.929	rs11009199	ENSG00000273038.2	RP11-479G22.8	-4.34	1.55e-05	0.00121	-0.23	-0.13	Depression (quantitative trait);	chr10:33053400	chr10:32887255~32889311:-
BRCA	cis	rs7918232	0.891	rs10443987	ENSG00000262412.1	RP11-85G18.6	4.34	1.55e-05	0.00121	0.22	0.13	Breast cancer;	chr10:27086448	chr10:27243130~27250804:+
BRCA	cis	rs559555	0.597	rs502139	ENSG00000272716.1	RP11-563N4.1	4.34	1.55e-05	0.00121	0.15	0.13	Blood metabolite ratios;Blood metabolite levels;	chr2:31586199	chr2:32165046~32165757:-
BRCA	cis	rs9457247	0.534	rs933243	ENSG00000227598.1	RP1-167A14.2	-4.34	1.55e-05	0.00121	-0.14	-0.13	Crohn's disease;	chr6:166990385	chr6:166969626~166999065:-
BRCA	cis	rs2243480	1	rs4718333	ENSG00000275400.1	RP4-756H11.5	-4.34	1.55e-05	0.00121	-0.25	-0.13	Diabetic kidney disease;	chr7:66307771	chr7:66553805~66554199:-
BRCA	cis	rs2243480	1	rs7792391	ENSG00000275400.1	RP4-756H11.5	-4.34	1.55e-05	0.00121	-0.25	-0.13	Diabetic kidney disease;	chr7:66308442	chr7:66553805~66554199:-
BRCA	cis	rs7520050	0.778	rs12404197	ENSG00000234329.1	RP11-767N6.2	-4.34	1.55e-05	0.00121	-0.13	-0.13	Reticulocyte count;Red blood cell count;	chr1:45766748	chr1:45651039~45651826:-
BRCA	cis	rs7520050	0.801	rs6703960	ENSG00000234329.1	RP11-767N6.2	-4.34	1.55e-05	0.00121	-0.13	-0.13	Reticulocyte count;Red blood cell count;	chr1:45767051	chr1:45651039~45651826:-
BRCA	cis	rs9818758	0.545	rs9853352	ENSG00000225399.4	RP11-3B7.1	4.34	1.55e-05	0.00121	0.23	0.13	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49775825	chr3:49260085~49261316:+
BRCA	cis	rs797680	0.789	rs7539307	ENSG00000229635.1	RP4-713B5.2	4.34	1.55e-05	0.00121	0.18	0.13	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93187146	chr1:93384487~93384998:-
BRCA	cis	rs7520050	0.667	rs11211176	ENSG00000234329.1	RP11-767N6.2	-4.34	1.55e-05	0.00121	-0.13	-0.13	Reticulocyte count;Red blood cell count;	chr1:45757414	chr1:45651039~45651826:-
BRCA	cis	rs875971	0.545	rs73148639	ENSG00000232546.1	RP11-458F8.1	4.34	1.55e-05	0.00121	0.13	0.13	Aortic root size;	chr7:66390342	chr7:66848496~66858136:+
BRCA	cis	rs321358	0.848	rs78087740	ENSG00000271390.1	RP11-89C3.3	4.34	1.55e-05	0.00121	0.21	0.13	Body mass index;	chr11:111079016	chr11:111089870~111090368:-
BRCA	cis	rs321358	0.848	rs73015146	ENSG00000271390.1	RP11-89C3.3	4.34	1.55e-05	0.00121	0.21	0.13	Body mass index;	chr11:111079143	chr11:111089870~111090368:-
BRCA	cis	rs930395	0.514	rs13153556	ENSG00000251141.4	RP11-53O19.1	-4.34	1.55e-05	0.00121	-0.13	-0.13	Breast cancer;	chr5:44927999	chr5:44744900~44808777:-
BRCA	cis	rs7048146	0.966	rs4978401	ENSG00000213539.4	YBX1P6	-4.34	1.55e-05	0.00121	-0.15	-0.13	Vascular brain injury;	chr9:109540631	chr9:109532830~109534332:-
BRCA	cis	rs867186	1	rs11906148	ENSG00000126005.14	MMP24-AS1	-4.34	1.55e-05	0.00121	-0.27	-0.13	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35196218	chr20:35216462~35278131:-
BRCA	cis	rs10833905	0.877	rs11026945	ENSG00000246225.5	RP11-17A1.3	-4.34	1.55e-05	0.00121	-0.19	-0.13	Sudden cardiac arrest;	chr11:23053115	chr11:22829380~22945393:+
BRCA	cis	rs13113518	1	rs13133579	ENSG00000272969.1	RP11-528I4.2	4.34	1.55e-05	0.00121	0.15	0.13	Height;	chr4:55459921	chr4:55547112~55547889:+
BRCA	cis	rs2839186	0.681	rs13047198	ENSG00000228137.1	AP001469.7	4.34	1.55e-05	0.00121	0.14	0.13	Testicular germ cell tumor;	chr21:46281921	chr21:46246890~46247682:+
BRCA	cis	rs2337406	0.587	rs10129888	ENSG00000231475.3	IGHV4-31	4.34	1.55e-05	0.00121	0.12	0.13	Alzheimer's disease (late onset);	chr14:106647421	chr14:106349283~106349792:-
BRCA	cis	rs6747488	0.528	rs223630	ENSG00000272716.1	RP11-563N4.1	4.34	1.55e-05	0.00121	0.15	0.13	Interleukin-18 levels;	chr2:31763366	chr2:32165046~32165757:-
BRCA	cis	rs763121	0.853	rs5757193	ENSG00000225450.1	RP3-508I15.14	4.34	1.55e-05	0.00121	0.15	0.13	Menopause (age at onset);	chr22:38638862	chr22:38739003~38749041:+
BRCA	cis	rs2380205	0.967	rs11255577	ENSG00000232807.2	RP11-536K7.3	4.34	1.55e-05	0.00121	0.14	0.13	Breast cancer;	chr10:5856207	chr10:5934270~5945900:-
BRCA	cis	rs2380205	0.967	rs4330991	ENSG00000232807.2	RP11-536K7.3	4.34	1.55e-05	0.00121	0.14	0.13	Breast cancer;	chr10:5856217	chr10:5934270~5945900:-
BRCA	cis	rs721917	0.506	rs2758561	ENSG00000278616.1	BEND3P3	-4.34	1.55e-05	0.00121	-0.12	-0.13	Chronic obstructive pulmonary disease;	chr10:79909718	chr10:79682997~79685436:+
BRCA	cis	rs74161807	1	rs7079075	ENSG00000266200.5	PNLIPRP2	4.34	1.55e-05	0.00121	0.27	0.13	Loneliness;Loneliness (multivariate analysis);	chr10:116610001	chr10:116620953~116645143:+
BRCA	cis	rs7932354	0.583	rs7101374	ENSG00000200376.1	RNU5E-10P	4.34	1.55e-05	0.00121	0.16	0.13	Bone mineral density (hip);Bone mineral density;	chr11:46802691	chr11:47576471~47576588:-
BRCA	cis	rs7833986	0.501	rs72653957	ENSG00000253603.1	CTA-397H3.3	-4.34	1.55e-05	0.00121	-0.19	-0.13	Height;	chr8:56077489	chr8:56074592~56075274:+
BRCA	cis	rs409045	1	rs408815	ENSG00000271874.1	CTD-2024P10.2	-4.34	1.55e-05	0.00121	-0.18	-0.13	Left ventricular mass;	chr5:34633094	chr5:34651457~34651888:-
BRCA	cis	rs409045	1	rs416207	ENSG00000271874.1	CTD-2024P10.2	-4.34	1.55e-05	0.00121	-0.18	-0.13	Left ventricular mass;	chr5:34633104	chr5:34651457~34651888:-
BRCA	cis	rs1345301	0.518	rs1558623	ENSG00000234389.1	AC007278.3	-4.34	1.55e-05	0.00121	-0.12	-0.13	Waist circumference;	chr2:102245942	chr2:102438713~102440475:+
BRCA	cis	rs4869313	0.869	rs3797796	ENSG00000248734.2	CTD-2260A17.1	4.34	1.55e-05	0.00121	0.14	0.13	Pediatric autoimmune diseases;	chr5:96981054	chr5:96784777~96785999:+
BRCA	cis	rs7618915	0.501	rs3733039	ENSG00000243224.1	RP5-1157M23.2	-4.34	1.55e-05	0.00121	-0.14	-0.13	Bipolar disorder;	chr3:52685072	chr3:52239258~52241097:+
BRCA	cis	rs67340775	0.541	rs200966	ENSG00000216901.1	AL022393.7	4.34	1.55e-05	0.00121	0.21	0.13	Lung cancer in ever smokers;	chr6:27894374	chr6:28176188~28176674:+
BRCA	cis	rs7481584	0.581	rs406598	ENSG00000247473.2	CARS-AS1	-4.34	1.55e-05	0.00121	-0.16	-0.13	Calcium levels;	chr11:3055055	chr11:3029009~3041260:+
BRCA	cis	rs7829975	0.606	rs11776838	ENSG00000254153.1	CTA-398F10.2	-4.34	1.55e-05	0.00121	-0.16	-0.13	Mood instability;	chr8:8937291	chr8:8456909~8461337:-
BRCA	cis	rs9788721	0.902	rs951266	ENSG00000261762.1	RP11-650L12.2	-4.34	1.55e-05	0.00121	-0.16	-0.13	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78586199	chr15:78589123~78591276:-
BRCA	cis	rs1665050	0.895	rs8028752	ENSG00000259732.1	RP11-59H7.3	-4.34	1.55e-05	0.00121	-0.17	-0.13	Atopic dermatitis;	chr15:59003803	chr15:59121034~59133250:+
BRCA	cis	rs7267979	1	rs7268053	ENSG00000277938.1	RP5-965G21.3	-4.34	1.55e-05	0.00121	-0.16	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25347650	chr20:25229150~25231933:+
BRCA	cis	rs7267979	1	rs6083809	ENSG00000277938.1	RP5-965G21.3	-4.34	1.55e-05	0.00121	-0.16	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25348673	chr20:25229150~25231933:+
BRCA	cis	rs829883	0.738	rs249846	ENSG00000227825.4	SLC9A7P1	4.34	1.55e-05	0.00121	0.16	0.13	Colorectal adenoma (advanced);	chr12:98474961	chr12:98453835~98457145:-
BRCA	cis	rs10411262	0.935	rs314661	ENSG00000245598.5	DACT3-AS1	-4.34	1.55e-05	0.00122	-0.17	-0.13	Tonsillectomy;	chr19:46669216	chr19:46660364~46677447:+
BRCA	cis	rs490234	0.651	rs13291556	ENSG00000232630.1	PRPS1P2	-4.34	1.55e-05	0.00122	-0.14	-0.13	Mean arterial pressure;	chr9:125478643	chr9:125150653~125151589:+
BRCA	cis	rs708547	0.581	rs6554400	ENSG00000269949.1	RP11-738E22.3	-4.34	1.55e-05	0.00122	-0.16	-0.13	Response to bleomycin (chromatid breaks);	chr4:56939140	chr4:56960927~56961373:-
BRCA	cis	rs6831352	0.703	rs2602854	ENSG00000272777.1	RP11-571L19.8	-4.34	1.55e-05	0.00122	-0.14	-0.13	Alcohol dependence;	chr4:99107500	chr4:99067256~99068125:-
BRCA	cis	rs56322409	0.897	rs10882671	ENSG00000226688.5	ENTPD1-AS1	4.34	1.55e-05	0.00122	0.15	0.13	Blood metabolite levels;	chr10:95824266	chr10:95753206~96090238:-
BRCA	cis	rs7267979	0.966	rs2257233	ENSG00000125804.12	FAM182A	4.34	1.55e-05	0.00122	0.17	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25285348	chr20:26054655~26086917:+
BRCA	cis	rs66887589	0.72	rs11724758	ENSG00000260404.2	RP11-384K6.6	4.34	1.55e-05	0.00122	0.11	0.13	Diastolic blood pressure;	chr4:119318723	chr4:118591773~118633729:+
BRCA	cis	rs6831352	0.734	rs1453872	ENSG00000272777.1	RP11-571L19.8	-4.34	1.56e-05	0.00122	-0.14	-0.13	Alcohol dependence;	chr4:99101331	chr4:99067256~99068125:-
BRCA	cis	rs4835473	0.897	rs62337587	ENSG00000249741.2	RP11-673E1.3	4.34	1.56e-05	0.00122	0.15	0.13	Immature fraction of reticulocytes;	chr4:143725839	chr4:143911514~143912053:-
BRCA	cis	rs8048589	0.559	rs35542345	ENSG00000175604.2	RP11-276H1.3	-4.34	1.56e-05	0.00122	-0.23	-0.13	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);	chr16:12116761	chr16:12086746~12090302:-
BRCA	cis	rs6088580	0.634	rs6059896	ENSG00000276073.1	RP5-1125A11.7	-4.34	1.56e-05	0.00122	-0.14	-0.13	Glomerular filtration rate (creatinine);	chr20:34523978	chr20:33985617~33988989:-
BRCA	cis	rs67766926	0.953	rs10185028	ENSG00000271889.1	RP11-493E12.1	4.34	1.56e-05	0.00122	0.19	0.13	Inflammatory skin disease;	chr2:60891604	chr2:61151433~61162105:-
BRCA	cis	rs7260598	0.792	rs11669171	ENSG00000268442.1	CTD-2027I19.2	4.34	1.56e-05	0.00122	0.22	0.13	Response to taxane treatment (placlitaxel);	chr19:24153957	chr19:24162370~24163425:-
BRCA	cis	rs6430585	0.702	rs73958637	ENSG00000224043.6	CCNT2-AS1	-4.34	1.56e-05	0.00122	-0.22	-0.13	Corneal structure;	chr2:135789357	chr2:134735464~134918710:-
BRCA	cis	rs4907240	0.961	rs12471390	ENSG00000230606.9	AC159540.1	4.34	1.56e-05	0.00122	0.17	0.13	Event-related brain oscillations;	chr2:96657221	chr2:97416165~97433527:-
BRCA	cis	rs7267979	0.932	rs431579	ENSG00000125804.12	FAM182A	-4.34	1.56e-05	0.00122	-0.17	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25489420	chr20:26054655~26086917:+
BRCA	cis	rs2136613	0.533	rs1967747	ENSG00000238280.1	RP11-436D10.3	-4.34	1.56e-05	0.00122	-0.17	-0.13	Selective IgA deficiency;	chr10:62844205	chr10:62793562~62805887:-
BRCA	cis	rs7927592	0.763	rs1193699	ENSG00000212093.1	AP000807.1	4.34	1.56e-05	0.00122	0.14	0.13	Total body bone mineral density;	chr11:68482012	chr11:68506083~68506166:-
BRCA	cis	rs6545883	0.965	rs3771261	ENSG00000270820.4	RP11-355B11.2	4.34	1.56e-05	0.00122	0.15	0.13	Tuberculosis;	chr2:61535026	chr2:61471188~61484130:+
BRCA	cis	rs9914544	0.545	rs4510081	ENSG00000264885.1	RP11-815I9.4	-4.34	1.56e-05	0.00122	-0.12	-0.13	Educational attainment (years of education);	chr17:18895533	chr17:18667629~18669461:-
BRCA	cis	rs4886920	0.775	rs7169661	ENSG00000260776.4	RP11-114H24.2	4.34	1.56e-05	0.00122	0.16	0.13	Neuroticism;	chr15:77854317	chr15:77914217~77926846:-
BRCA	cis	rs6012564	1	rs3092411	ENSG00000227431.4	CSE1L-AS1	-4.34	1.56e-05	0.00122	-0.16	-0.13	Anger;	chr20:49074054	chr20:49040463~49046044:-
BRCA	cis	rs35740288	0.77	rs745191	ENSG00000202081.1	RNU6-1280P	4.34	1.56e-05	0.00122	0.17	0.13	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85579939	chr15:85651522~85651628:-
BRCA	cis	rs7246967	1	rs936525	ENSG00000198153.8	ZNF849P	-4.34	1.56e-05	0.00122	-0.19	-0.13	Bronchopulmonary dysplasia;	chr19:22873387	chr19:22685167~22686732:+
BRCA	cis	rs11098499	0.722	rs17595727	ENSG00000260404.2	RP11-384K6.6	-4.34	1.56e-05	0.00122	-0.12	-0.13	Corneal astigmatism;	chr4:119340919	chr4:118591773~118633729:+
BRCA	cis	rs780094	0.5	rs7570476	ENSG00000234072.1	AC074117.10	4.34	1.56e-05	0.00122	0.13	0.13	Urate levels in overweight individuals;C-reactive protein;Metabolic syndrome;Red blood cell count;Renal underexcretion gout;Nonalcoholic fatty liver disease;Age-related diseases, mortality and associated endophenotypes;Crohn's disease;Calcium levels;Fasting plasma glucose;Metabolic traits;Fasting blood glucose;Fasting blood insulin;Urate levels in obese individuals;Alcohol consumption (drinks per week);Height;Urate levels;Gondoic acid (20:1n-9) levels;Uric acid levels;Age-related disease endophenotypes;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Homeostasis model assessment of insulin resistance;Alcohol consumption;Fasting blood insulin (BMI interaction);Triglycerides;Fasting blood glucose (BMI interaction);Hypertriglyceridemia;LDL cholesterol;Type 2 diabetes;Triglyceride levels;	chr2:27561791	chr2:27356246~27367622:+
BRCA	cis	rs9844666	0.512	rs9870581	ENSG00000273486.1	RP11-731C17.2	4.34	1.56e-05	0.00122	0.16	0.13	Height;	chr3:135922012	chr3:136837338~136839021:-
BRCA	cis	rs1167832	0.645	rs1167829	ENSG00000127957.15	PMS2P3	-4.34	1.56e-05	0.00122	-0.17	-0.13	Ankle injury;	chr7:75535697	chr7:75502930~75528148:-
BRCA	cis	rs13113518	1	rs4864993	ENSG00000272969.1	RP11-528I4.2	4.34	1.56e-05	0.00122	0.15	0.13	Height;	chr4:55450662	chr4:55547112~55547889:+
BRCA	cis	rs13326165	0.76	rs3752819	ENSG00000243224.1	RP5-1157M23.2	-4.34	1.56e-05	0.00122	-0.19	-0.13	HDL cholesterol levels;HDL cholesterol;	chr3:52366724	chr3:52239258~52241097:+
BRCA	cis	rs516805	0.596	rs2606640	ENSG00000279114.1	RP3-425C14.5	-4.34	1.56e-05	0.00122	-0.16	-0.13	Lymphocyte counts;	chr6:122102901	chr6:122471923~122484161:+
BRCA	cis	rs516805	0.63	rs2262318	ENSG00000279114.1	RP3-425C14.5	-4.34	1.56e-05	0.00122	-0.16	-0.13	Lymphocyte counts;	chr6:122102980	chr6:122471923~122484161:+
BRCA	cis	rs801193	1	rs2003301	ENSG00000272831.1	RP11-792A8.4	-4.34	1.56e-05	0.00122	-0.12	-0.13	Aortic root size;	chr7:66682669	chr7:66739829~66740385:-
BRCA	cis	rs7267979	0.789	rs62213729	ENSG00000277938.1	RP5-965G21.3	-4.34	1.56e-05	0.00122	-0.16	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25382790	chr20:25229150~25231933:+
BRCA	cis	rs6088580	0.634	rs6059875	ENSG00000276073.1	RP5-1125A11.7	-4.34	1.56e-05	0.00122	-0.14	-0.13	Glomerular filtration rate (creatinine);	chr20:34498285	chr20:33985617~33988989:-
BRCA	cis	rs6088580	0.634	rs6088512	ENSG00000276073.1	RP5-1125A11.7	-4.34	1.56e-05	0.00122	-0.14	-0.13	Glomerular filtration rate (creatinine);	chr20:34508086	chr20:33985617~33988989:-
BRCA	cis	rs6088580	0.634	rs6058070	ENSG00000276073.1	RP5-1125A11.7	-4.34	1.56e-05	0.00122	-0.14	-0.13	Glomerular filtration rate (creatinine);	chr20:34515716	chr20:33985617~33988989:-
BRCA	cis	rs10735946	1	rs2193038	ENSG00000255733.4	IFNG-AS1	-4.34	1.56e-05	0.00122	-0.12	-0.13	Anti-saccade response;	chr12:68088940	chr12:67989445~68234686:+
BRCA	cis	rs7937890	0.505	rs4403769	ENSG00000254418.1	RP11-21L19.1	4.34	1.56e-05	0.00122	0.16	0.13	Mitochondrial DNA levels;	chr11:14428630	chr11:14262846~14273691:-
BRCA	cis	rs8054556	1	rs9925915	ENSG00000261367.1	RP11-455F5.4	-4.34	1.56e-05	0.00122	-0.15	-0.13	Autism spectrum disorder or schizophrenia;	chr16:29982365	chr16:30107675~30110541:+
BRCA	cis	rs6802315	0.604	rs9863103	ENSG00000272087.1	RP11-379F4.7	-4.34	1.56e-05	0.00122	-0.16	-0.13	Periodontitis (CDC/AAP);	chr3:158746014	chr3:158693120~158693768:-
BRCA	cis	rs216345	0.635	rs12342186	ENSG00000260947.1	RP11-384P7.7	-4.34	1.57e-05	0.00122	-0.14	-0.13	Bipolar disorder;	chr9:34048794	chr9:33697459~33700986:+
BRCA	cis	rs1223397	0.651	rs2439534	ENSG00000215022.6	RP1-257A7.4	4.34	1.57e-05	0.00122	0.16	0.13	Blood pressure;	chr6:13305525	chr6:13264861~13295586:-
BRCA	cis	rs11098499	0.954	rs11729521	ENSG00000260091.1	RP11-33B1.4	-4.34	1.57e-05	0.00122	-0.12	-0.13	Corneal astigmatism;	chr4:119495633	chr4:119409333~119410233:+
BRCA	cis	rs1040	0.873	rs10280	ENSG00000226445.1	XXyac-YX65C7_A.2	-4.34	1.57e-05	0.00122	-0.14	-0.13	Joint mobility (Beighton score);	chr6:169217335	chr6:169213254~169239565:+
BRCA	cis	rs7800418	0.747	rs7788433	ENSG00000214870.7	AC004540.5	4.34	1.57e-05	0.00122	0.17	0.13	Cognitive function;	chr7:26546388	chr7:26398593~26494256:+
BRCA	cis	rs875971	0.545	rs6969224	ENSG00000230295.1	RP11-458F8.2	4.34	1.57e-05	0.00122	0.13	0.13	Aortic root size;	chr7:66370011	chr7:66880708~66882981:+
BRCA	cis	rs490234	0.651	rs13301073	ENSG00000232630.1	PRPS1P2	-4.34	1.57e-05	0.00123	-0.14	-0.13	Mean arterial pressure;	chr9:125522099	chr9:125150653~125151589:+
BRCA	cis	rs12744310	0.832	rs12027990	ENSG00000235358.1	RP11-399E6.1	4.34	1.57e-05	0.00123	0.19	0.13	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41298765	chr1:41242373~41284861:+
BRCA	cis	rs7312933	0.585	rs7969814	ENSG00000257225.1	RP11-328C8.4	-4.34	1.57e-05	0.00123	-0.16	-0.13	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42275855	chr12:42459366~42466128:+
BRCA	cis	rs11742741	0.967	rs1428549	ENSG00000248874.4	C5orf17	-4.34	1.57e-05	0.00123	-0.17	-0.13	Educational attainment;	chr5:24188472	chr5:23951348~24178263:+
BRCA	cis	rs3748682	0.808	rs12728438	ENSG00000222282.1	RNU6-584P	-4.34	1.57e-05	0.00123	-0.17	-0.13	Hypothyroidism;	chr1:37883728	chr1:37885023~37885117:+
BRCA	cis	rs801193	1	rs2659915	ENSG00000272831.1	RP11-792A8.4	4.34	1.57e-05	0.00123	0.12	0.13	Aortic root size;	chr7:66688114	chr7:66739829~66740385:-
BRCA	cis	rs2303319	0.504	rs56965753	ENSG00000227403.1	AC009299.3	4.34	1.57e-05	0.00123	0.31	0.13	Cognitive function;	chr2:161740741	chr2:161244739~161249050:+
BRCA	cis	rs1979679	0.608	rs1581073	ENSG00000278733.1	RP11-425D17.1	-4.34	1.57e-05	0.00123	-0.18	-0.13	Ossification of the posterior longitudinal ligament of the spine;	chr12:28571106	chr12:28185625~28186190:-
BRCA	cis	rs5753037	0.653	rs140129	ENSG00000279159.1	RP3-394A18.1	-4.34	1.57e-05	0.00123	-0.1	-0.13	Type 1 diabetes;	chr22:29754560	chr22:29978950~30028236:-
BRCA	cis	rs886774	0.74	rs10271497	ENSG00000273055.1	CTB-13F3.1	-4.34	1.57e-05	0.00123	-0.13	-0.13	Ulcerative colitis;	chr7:107939229	chr7:107942116~107942740:+
BRCA	cis	rs6430585	0.702	rs2304601	ENSG00000224043.6	CCNT2-AS1	-4.34	1.57e-05	0.00123	-0.23	-0.13	Corneal structure;	chr2:135770464	chr2:134735464~134918710:-
BRCA	cis	rs287982	0.611	rs7568330	ENSG00000269973.1	RP11-95D17.1	-4.34	1.57e-05	0.00123	-0.21	-0.13	Nonsyndromic cleft lip with cleft palate;	chr2:9835428	chr2:9936360~9939590:+
BRCA	cis	rs2839186	0.967	rs2839191	ENSG00000239415.1	AP001469.9	4.34	1.57e-05	0.00123	0.14	0.13	Testicular germ cell tumor;	chr21:46275481	chr21:46251549~46254133:-
BRCA	cis	rs465969	0.744	rs3851228	ENSG00000272356.1	RP5-1112D6.8	-4.34	1.57e-05	0.00123	-0.24	-0.13	Psoriasis;	chr6:111526988	chr6:111309203~111313517:+
BRCA	cis	rs13113518	0.934	rs10866425	ENSG00000273257.1	RP11-177J6.1	4.34	1.57e-05	0.00123	0.17	0.13	Height;	chr4:55582068	chr4:55387949~55388271:+
BRCA	cis	rs7800418	0.723	rs757808	ENSG00000214870.7	AC004540.5	4.34	1.57e-05	0.00123	0.17	0.13	Cognitive function;	chr7:26547115	chr7:26398593~26494256:+
BRCA	cis	rs1005277	0.579	rs2474571	ENSG00000099251.13	HSD17B7P2	4.34	1.57e-05	0.00123	0.15	0.13	Extrinsic epigenetic age acceleration;	chr10:38095711	chr10:38356380~38378505:+
BRCA	cis	rs11098499	0.954	rs67265404	ENSG00000250412.1	KLHL2P1	4.34	1.57e-05	0.00123	0.16	0.13	Corneal astigmatism;	chr4:119438115	chr4:119334329~119378233:+
BRCA	cis	rs2708977	0.549	rs6706734	ENSG00000230606.9	AC159540.1	4.34	1.57e-05	0.00123	0.17	0.13	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96764214	chr2:97416165~97433527:-
BRCA	cis	rs867186	1	rs74626382	ENSG00000126005.14	MMP24-AS1	-4.34	1.57e-05	0.00123	-0.27	-0.13	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35158865	chr20:35216462~35278131:-
BRCA	cis	rs62244186	0.516	rs11922470	ENSG00000233509.2	ZNF197-AS1	4.34	1.57e-05	0.00123	0.17	0.13	Depressive symptoms;	chr3:44736303	chr3:44617128~44624797:-
BRCA	cis	rs516805	0.528	rs2198863	ENSG00000279453.1	RP3-425C14.4	-4.34	1.57e-05	0.00123	-0.18	-0.13	Lymphocyte counts;	chr6:122091576	chr6:122436789~122439223:-
BRCA	cis	rs516805	0.528	rs2684243	ENSG00000279453.1	RP3-425C14.4	-4.34	1.57e-05	0.00123	-0.18	-0.13	Lymphocyte counts;	chr6:122092700	chr6:122436789~122439223:-
BRCA	cis	rs516805	0.528	rs2684244	ENSG00000279453.1	RP3-425C14.4	-4.34	1.57e-05	0.00123	-0.18	-0.13	Lymphocyte counts;	chr6:122092734	chr6:122436789~122439223:-
BRCA	cis	rs516805	0.528	rs2606604	ENSG00000279453.1	RP3-425C14.4	-4.34	1.57e-05	0.00123	-0.18	-0.13	Lymphocyte counts;	chr6:122093150	chr6:122436789~122439223:-
BRCA	cis	rs6747488	0.515	rs599300	ENSG00000272716.1	RP11-563N4.1	4.34	1.57e-05	0.00123	0.15	0.13	Interleukin-18 levels;	chr2:31586237	chr2:32165046~32165757:-
BRCA	cis	rs8040855	0.86	rs7172266	ENSG00000259774.1	RP11-182J1.13	-4.34	1.57e-05	0.00123	-0.17	-0.13	Bulimia nervosa;	chr15:85172982	chr15:84422618~84425882:+
BRCA	cis	rs7647973	0.961	rs7626076	ENSG00000244380.1	RP11-24C3.2	4.34	1.57e-05	0.00123	0.17	0.13	Menarche (age at onset);	chr3:49260706	chr3:48440352~48446656:-
BRCA	cis	rs4787491	0.729	rs8043883	ENSG00000183604.13	SMG1P5	-4.34	1.57e-05	0.00123	-0.13	-0.13	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30033260	chr16:30267553~30335374:-
BRCA	cis	rs9468199	0.505	rs72847381	ENSG00000219392.1	RP1-265C24.5	-4.34	1.57e-05	0.00123	-0.32	-0.13	Parkinson's disease;	chr6:27906153	chr6:28115628~28116551:+
BRCA	cis	rs13326165	0.585	rs7615405	ENSG00000243224.1	RP5-1157M23.2	-4.34	1.57e-05	0.00123	-0.21	-0.13	HDL cholesterol levels;HDL cholesterol;	chr3:52317537	chr3:52239258~52241097:+
BRCA	cis	rs2303319	0.504	rs12467279	ENSG00000227403.1	AC009299.3	4.34	1.57e-05	0.00123	0.33	0.13	Cognitive function;	chr2:161688234	chr2:161244739~161249050:+
BRCA	cis	rs10129255	0.912	rs8011090	ENSG00000274576.2	IGHV2-70	4.34	1.57e-05	0.00123	0.12	0.13	Kawasaki disease;	chr14:106678896	chr14:106770577~106771020:-
BRCA	cis	rs72482608	0.865	rs10919468	ENSG00000271811.1	RP1-79C4.4	4.34	1.57e-05	0.00123	0.14	0.13	Emphysema imaging phenotypes;	chr1:170787116	chr1:170667381~170669425:+
BRCA	cis	rs6432852	0.933	rs6761355	ENSG00000232411.1	AC009495.3	-4.34	1.57e-05	0.00123	-0.15	-0.13	Diabetic kidney disease;	chr2:165895641	chr2:165833048~165839098:-
BRCA	cis	rs10129255	0.536	rs10142951	ENSG00000211959.2	IGHV4-39	4.34	1.57e-05	0.00123	0.09	0.13	Kawasaki disease;	chr14:106782337	chr14:106421711~106422218:-
BRCA	cis	rs651907	0.557	rs7612283	ENSG00000256628.3	ZBTB11-AS1	4.34	1.57e-05	0.00123	0.17	0.13	Colorectal cancer;	chr3:101716075	chr3:101676475~101679217:+
BRCA	cis	rs651907	0.557	rs34457525	ENSG00000256628.3	ZBTB11-AS1	4.34	1.57e-05	0.00123	0.17	0.13	Colorectal cancer;	chr3:101716381	chr3:101676475~101679217:+
BRCA	cis	rs718314	0.507	rs7976877	ENSG00000256894.1	RP11-283G6.3	4.34	1.57e-05	0.00123	0.14	0.13	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Renal cell carcinoma;Waist circumference adjusted for body mass index;	chr12:26331042	chr12:26125155~26126617:-
BRCA	cis	rs8180040	1	rs11714294	ENSG00000276925.1	RP11-708J19.3	4.34	1.57e-05	0.00123	0.15	0.13	Colorectal cancer;	chr3:47298233	chr3:47469777~47469987:+
BRCA	cis	rs867371	1	rs8041868	ENSG00000278603.1	RP13-608F4.5	4.34	1.57e-05	0.00123	0.18	0.13	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82179985	chr15:82472203~82472426:+
BRCA	cis	rs6430585	0.591	rs75223002	ENSG00000224043.6	CCNT2-AS1	-4.34	1.58e-05	0.00123	-0.23	-0.13	Corneal structure;	chr2:135767739	chr2:134735464~134918710:-
BRCA	cis	rs7772486	0.754	rs9390356	ENSG00000270638.1	RP3-466P17.1	-4.34	1.58e-05	0.00123	-0.16	-0.13	Lobe attachment (rater-scored or self-reported);	chr6:145797847	chr6:145735570~145737218:+
BRCA	cis	rs6951245	1	rs80094748	ENSG00000229043.2	AC091729.9	-4.34	1.58e-05	0.00123	-0.24	-0.13	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1064322	chr7:1160374~1165267:+
BRCA	cis	rs7618915	0.501	rs1866268	ENSG00000243224.1	RP5-1157M23.2	-4.34	1.58e-05	0.00123	-0.14	-0.13	Bipolar disorder;	chr3:52685382	chr3:52239258~52241097:+
BRCA	cis	rs2625529	0.652	rs2957734	ENSG00000260037.4	CTD-2524L6.3	4.34	1.58e-05	0.00123	0.17	0.13	Red blood cell count;	chr15:71969044	chr15:71818396~71823384:+
BRCA	cis	rs6545883	0.894	rs778144	ENSG00000270820.4	RP11-355B11.2	-4.34	1.58e-05	0.00123	-0.15	-0.13	Tuberculosis;	chr2:61355993	chr2:61471188~61484130:+
BRCA	cis	rs11098499	0.863	rs13140391	ENSG00000250412.1	KLHL2P1	4.34	1.58e-05	0.00123	0.16	0.13	Corneal astigmatism;	chr4:119582282	chr4:119334329~119378233:+
BRCA	cis	rs11098499	0.863	rs13140409	ENSG00000250412.1	KLHL2P1	4.34	1.58e-05	0.00123	0.16	0.13	Corneal astigmatism;	chr4:119582305	chr4:119334329~119378233:+
BRCA	cis	rs644148	0.781	rs630469	ENSG00000176761.7	ZNF285B	4.34	1.58e-05	0.00123	0.15	0.13	Personality dimensions;	chr19:44465945	chr19:44467641~44473227:+
BRCA	cis	rs7200543	0.583	rs4985149	ENSG00000260872.1	RP11-680G24.5	-4.34	1.58e-05	0.00123	-0.14	-0.13	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15053481	chr16:15018106~15020488:-
BRCA	cis	rs5771242	0.769	rs4838865	ENSG00000273253.2	RP3-402G11.26	-4.34	1.58e-05	0.00123	-0.16	-0.13	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);	chr22:50226183	chr22:50199090~50200837:-
BRCA	cis	rs2018683	0.834	rs733485	ENSG00000233517.1	AC005162.5	-4.34	1.58e-05	0.00123	-0.16	-0.13	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28987069	chr7:28987028~28988899:+
BRCA	cis	rs1005277	0.579	rs2474567	ENSG00000263064.2	RP11-291L22.7	4.34	1.58e-05	0.00123	0.16	0.13	Extrinsic epigenetic age acceleration;	chr10:38093564	chr10:38448689~38448949:+
BRCA	cis	rs2243480	1	rs437889	ENSG00000275400.1	RP4-756H11.5	4.34	1.58e-05	0.00123	0.25	0.13	Diabetic kidney disease;	chr7:66044247	chr7:66553805~66554199:-
BRCA	cis	rs1371614	0.523	rs12468721	ENSG00000229122.1	AGBL5-IT1	-4.34	1.58e-05	0.00123	-0.14	-0.13	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26960883	chr2:27061038~27061815:+
BRCA	cis	rs1371614	0.523	rs12468761	ENSG00000229122.1	AGBL5-IT1	-4.34	1.58e-05	0.00123	-0.14	-0.13	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26960925	chr2:27061038~27061815:+
BRCA	cis	rs13401620	0.843	rs3101946	ENSG00000229326.3	AC069154.4	4.34	1.58e-05	0.00123	0.17	0.13	Breast size;	chr2:119822966	chr2:119698623~119700151:+
BRCA	cis	rs987360	0.775	rs10030128	ENSG00000248869.4	RP11-138I17.1	4.34	1.58e-05	0.00123	0.13	0.13	Temperament;	chr4:137278239	chr4:136796722~137212799:-
BRCA	cis	rs987360	0.745	rs4864401	ENSG00000248869.4	RP11-138I17.1	4.34	1.58e-05	0.00123	0.13	0.13	Temperament;	chr4:137278685	chr4:136796722~137212799:-
BRCA	cis	rs6496044	0.526	rs4291869	ENSG00000230373.7	GOLGA6L5P	4.34	1.58e-05	0.00123	0.14	0.13	Interstitial lung disease;	chr15:85511292	chr15:84507885~84516814:-
BRCA	cis	rs17597773	0.674	rs984676	ENSG00000238078.1	LINC01352	4.34	1.58e-05	0.00123	0.15	0.13	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220835080	chr1:220829255~220832429:+
BRCA	cis	rs1910358	0.614	rs1501940	ENSG00000248874.4	C5orf17	-4.34	1.58e-05	0.00123	-0.17	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23976006	chr5:23951348~24178263:+
BRCA	cis	rs4664293	0.769	rs2729726	ENSG00000230783.1	AC009961.2	-4.34	1.58e-05	0.00123	-0.17	-0.13	Monocyte percentage of white cells;	chr2:159811597	chr2:159689217~159690291:-
BRCA	cis	rs4664293	0.738	rs1549580	ENSG00000230783.1	AC009961.2	-4.34	1.58e-05	0.00123	-0.17	-0.13	Monocyte percentage of white cells;	chr2:159812177	chr2:159689217~159690291:-
BRCA	cis	rs4948275	0.631	rs2814023	ENSG00000237233.2	TMEM26-AS1	-4.34	1.58e-05	0.00123	-0.16	-0.13	Night sleep phenotypes;	chr10:61593649	chr10:61452639~61481956:+
BRCA	cis	rs9527	0.83	rs3740392	ENSG00000236937.2	PTGES3P4	4.34	1.58e-05	0.00123	0.19	0.13	Arsenic metabolism;	chr10:102877098	chr10:102845595~102845950:+
BRCA	cis	rs8054556	1	rs4283241	ENSG00000214725.6	CDIPT-AS1	4.34	1.58e-05	0.00123	0.16	0.13	Autism spectrum disorder or schizophrenia;	chr16:29977028	chr16:29863593~29868053:+
BRCA	cis	rs6968419	1	rs6949241	ENSG00000279086.1	RP11-667F14.1	-4.34	1.58e-05	0.00123	-0.13	-0.13	Intraocular pressure;	chr7:116176318	chr7:116209234~116211511:-
BRCA	cis	rs28829049	0.597	rs12745238	ENSG00000270728.1	RP4-657E11.10	-4.34	1.58e-05	0.00123	-0.13	-0.13	QRS duration in Tripanosoma cruzi seropositivity;	chr1:19067216	chr1:19297080~19297903:+
BRCA	cis	rs17489649	1	rs1008661	ENSG00000271849.1	CTC-332L22.1	4.34	1.58e-05	0.00123	0.17	0.13	Intelligence (multi-trait analysis);	chr5:109799795	chr5:109687802~109688329:-
BRCA	cis	rs3176789	0.914	rs12582052	ENSG00000256673.1	RP11-599J14.2	-4.34	1.58e-05	0.00123	-0.17	-0.13	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9774974	chr12:9398355~9414851:-
BRCA	cis	rs7621025	0.586	rs34553037	ENSG00000239213.4	NCK1-AS1	-4.34	1.58e-05	0.00123	-0.17	-0.13	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136660571	chr3:136841726~136862054:-
BRCA	cis	rs4143844	0.867	rs12916410	ENSG00000259251.2	RP11-643M14.1	4.34	1.58e-05	0.00123	0.32	0.13	Bipolar disorder and schizophrenia;	chr15:62010687	chr15:62060503~62062434:+
BRCA	cis	rs1858037	0.765	rs67404371	ENSG00000237979.1	AC007389.1	4.34	1.58e-05	0.00123	0.17	0.13	Rheumatoid arthritis;	chr2:65370137	chr2:65500993~65502138:-
BRCA	cis	rs2625529	0.529	rs1552133	ENSG00000260037.4	CTD-2524L6.3	4.34	1.58e-05	0.00124	0.17	0.13	Red blood cell count;	chr15:71940556	chr15:71818396~71823384:+
BRCA	cis	rs2625529	0.556	rs1552134	ENSG00000260037.4	CTD-2524L6.3	4.34	1.58e-05	0.00124	0.17	0.13	Red blood cell count;	chr15:71940557	chr15:71818396~71823384:+
BRCA	cis	rs7267979	0.873	rs6037062	ENSG00000204556.4	CTD-2514C3.1	-4.34	1.58e-05	0.00124	-0.18	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25222256	chr20:26018832~26020684:+
BRCA	cis	rs17270561	0.887	rs12201170	ENSG00000272462.2	U91328.19	-4.34	1.58e-05	0.00124	-0.19	-0.13	Iron status biomarkers;	chr6:25866019	chr6:25992662~26001775:+
BRCA	cis	rs11638815	0.603	rs2678448	ENSG00000259429.4	UBE2Q2P2	-4.34	1.58e-05	0.00124	-0.13	-0.13	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82594655	chr15:82355142~82420075:+
BRCA	cis	rs911119	1	rs1010117	ENSG00000270001.1	RP11-218C14.8	-4.34	1.58e-05	0.00124	-0.18	-0.13	Chronic kidney disease;	chr20:23627784	chr20:23631826~23632316:-
BRCA	cis	rs12612619	0.732	rs1078809	ENSG00000272148.1	RP11-195B17.1	4.34	1.58e-05	0.00124	0.15	0.13	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27066047	chr2:27062428~27062907:-
BRCA	cis	rs13113518	1	rs4865013	ENSG00000273257.1	RP11-177J6.1	4.34	1.58e-05	0.00124	0.17	0.13	Height;	chr4:55559957	chr4:55387949~55388271:+
BRCA	cis	rs8099594	0.64	rs1701877	ENSG00000266696.1	RP11-30L3.2	4.34	1.58e-05	0.00124	0.15	0.13	Height;	chr18:49290207	chr18:49205912~49208781:+
BRCA	cis	rs752590	0.806	rs4849174	ENSG00000189223.12	PAX8-AS1	-4.34	1.58e-05	0.00124	-0.2	-0.13	Mucinous ovarian carcinoma;	chr2:113215890	chr2:113211522~113276581:+
BRCA	cis	rs76076331	0.517	rs1734367	ENSG00000271952.1	RP11-245G13.2	4.34	1.58e-05	0.00124	0.16	0.13	Educational attainment (college completion);Educational attainment (years of education);	chr2:10838036	chr2:10878269~10885118:+
BRCA	cis	rs3774749	0.565	rs2518796	ENSG00000228008.1	CTD-2330K9.3	4.34	1.58e-05	0.00124	0.13	0.13	Intelligence (multi-trait analysis);	chr3:50169642	chr3:49903845~49916937:+
BRCA	cis	rs60843830	1	rs55753056	ENSG00000272342.1	RP13-539J13.1	4.34	1.58e-05	0.00124	0.16	0.13	Spherical equivalent (joint analysis main effects and education interaction);	chr2:243929	chr2:739588~740164:-
BRCA	cis	rs5758659	0.652	rs4822084	ENSG00000237037.8	NDUFA6-AS1	4.34	1.58e-05	0.00124	0.15	0.13	Cognitive function;	chr22:42039864	chr22:42090931~42137742:+
BRCA	cis	rs13113518	0.934	rs10866425	ENSG00000272969.1	RP11-528I4.2	4.34	1.58e-05	0.00124	0.15	0.13	Height;	chr4:55582068	chr4:55547112~55547889:+
BRCA	cis	rs2070615	0.545	rs2926804	ENSG00000257964.1	RP11-133N21.10	4.34	1.58e-05	0.00124	0.15	0.13	Bipolar disorder;	chr12:48803595	chr12:49576840~49577505:-
BRCA	cis	rs35146811	0.731	rs2257213	ENSG00000235713.1	RP4-604G5.3	-4.34	1.58e-05	0.00124	-0.16	-0.13	Coronary artery disease;	chr7:100212490	chr7:99992397~99993050:+
BRCA	cis	rs2303319	0.504	rs1006427	ENSG00000227403.1	AC009299.3	4.34	1.59e-05	0.00124	0.31	0.13	Cognitive function;	chr2:161735818	chr2:161244739~161249050:+
BRCA	cis	rs2303319	0.504	rs1006428	ENSG00000227403.1	AC009299.3	4.34	1.59e-05	0.00124	0.31	0.13	Cognitive function;	chr2:161736049	chr2:161244739~161249050:+
BRCA	cis	rs2303319	0.504	rs1023835	ENSG00000227403.1	AC009299.3	4.34	1.59e-05	0.00124	0.31	0.13	Cognitive function;	chr2:161737463	chr2:161244739~161249050:+
BRCA	cis	rs7119	0.651	rs12902898	ENSG00000259362.2	RP11-307C19.1	-4.34	1.59e-05	0.00124	-0.19	-0.13	Type 2 diabetes;	chr15:77556849	chr15:77525540~77534110:+
BRCA	cis	rs801193	0.636	rs10233806	ENSG00000229180.5	GS1-124K5.11	-4.34	1.59e-05	0.00124	-0.12	-0.13	Aortic root size;	chr7:66653261	chr7:66526088~66542624:-
BRCA	cis	rs4907240	0.925	rs11164109	ENSG00000230606.9	AC159540.1	4.34	1.59e-05	0.00124	0.17	0.13	Event-related brain oscillations;	chr2:96635096	chr2:97416165~97433527:-
BRCA	cis	rs801193	1	rs2659909	ENSG00000229180.5	GS1-124K5.11	4.34	1.59e-05	0.00124	0.11	0.13	Aortic root size;	chr7:66695292	chr7:66526088~66542624:-
BRCA	cis	rs5758659	0.714	rs5758574	ENSG00000273366.1	CTA-989H11.1	4.34	1.59e-05	0.00124	0.16	0.13	Cognitive function;	chr22:42085396	chr22:42278188~42278846:+
BRCA	cis	rs10986311	0.832	rs748661	ENSG00000227200.1	RP11-121A14.3	4.34	1.59e-05	0.00124	0.15	0.13	Vitiligo;	chr9:124333295	chr9:124262876~124265809:+
BRCA	cis	rs7267979	0.966	rs2261747	ENSG00000125804.12	FAM182A	-4.34	1.59e-05	0.00124	-0.17	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25281148	chr20:26054655~26086917:+
BRCA	cis	rs6921919	0.525	rs11760133	ENSG00000273712.1	RP5-874C20.7	4.34	1.59e-05	0.00124	0.18	0.13	Autism spectrum disorder or schizophrenia;	chr6:28418962	chr6:28315613~28315883:-
BRCA	cis	rs700651	0.753	rs10207232	ENSG00000231621.1	AC013264.2	-4.34	1.59e-05	0.00124	-0.13	-0.13	Intracranial aneurysm;	chr2:198029089	chr2:197197991~197199273:+
BRCA	cis	rs9341808	0.739	rs4706831	ENSG00000233967.5	RP11-250B2.3	4.34	1.59e-05	0.00124	0.13	0.13	Sitting height ratio;	chr6:80297982	chr6:80443344~80465927:+
BRCA	cis	rs6547741	1	rs10165098	ENSG00000234072.1	AC074117.10	4.34	1.59e-05	0.00124	0.12	0.13	Oral cavity cancer;	chr2:27573659	chr2:27356246~27367622:+
BRCA	cis	rs736408	0.677	rs678	ENSG00000243224.1	RP5-1157M23.2	-4.34	1.59e-05	0.00124	-0.15	-0.13	Bipolar disorder;	chr3:52786965	chr3:52239258~52241097:+
BRCA	cis	rs853679	1	rs1778511	ENSG00000204709.4	LINC01556	-4.34	1.59e-05	0.00124	-0.23	-0.13	Depression;	chr6:28261633	chr6:28943877~28944537:+
BRCA	cis	rs2908197	0.737	rs6465096	ENSG00000186704.9	DTX2P1	4.34	1.59e-05	0.00124	0.16	0.13	3-hydroxypropylmercapturic acid levels in smokers;	chr7:76343555	chr7:76978617~77004308:+
BRCA	cis	rs4819052	1	rs13047688	ENSG00000184274.3	LINC00315	-4.34	1.59e-05	0.00124	-0.19	-0.13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45249375	chr21:45300245~45305257:-
BRCA	cis	rs875971	0.558	rs4433015	ENSG00000273024.4	INTS4P2	4.34	1.59e-05	0.00124	0.15	0.13	Aortic root size;	chr7:66174736	chr7:65647864~65715661:+
BRCA	cis	rs2109514	0.902	rs926197	ENSG00000237813.3	AC002066.1	-4.34	1.59e-05	0.00124	-0.15	-0.13	Prevalent atrial fibrillation;	chr7:116478276	chr7:116238260~116499465:-
BRCA	cis	rs2253762	0.507	rs4752630	ENSG00000226864.1	ATE1-AS1	4.34	1.59e-05	0.00124	0.24	0.13	Breast cancer;	chr10:121991440	chr10:121928312~121951965:+
BRCA	cis	rs7011507	0.535	rs16937921	ENSG00000233858.4	AC026904.1	4.34	1.59e-05	0.00124	0.16	0.13	Inflammatory bowel disease;Ulcerative colitis;	chr8:48579315	chr8:48590401~48594621:+
BRCA	cis	rs2243480	1	rs7456042	ENSG00000222364.1	RNU6-96P	-4.34	1.59e-05	0.00124	-0.24	-0.13	Diabetic kidney disease;	chr7:65834791	chr7:66395191~66395286:+
BRCA	cis	rs2243480	1	rs73142121	ENSG00000222364.1	RNU6-96P	-4.34	1.59e-05	0.00124	-0.24	-0.13	Diabetic kidney disease;	chr7:65846219	chr7:66395191~66395286:+
BRCA	cis	rs2243480	1	rs34702770	ENSG00000222364.1	RNU6-96P	-4.34	1.59e-05	0.00124	-0.24	-0.13	Diabetic kidney disease;	chr7:65879836	chr7:66395191~66395286:+
BRCA	cis	rs2243480	1	rs34637256	ENSG00000222364.1	RNU6-96P	-4.34	1.59e-05	0.00124	-0.24	-0.13	Diabetic kidney disease;	chr7:65895144	chr7:66395191~66395286:+
BRCA	cis	rs7428	0.545	rs4832163	ENSG00000273196.1	RP11-717A5.2	4.34	1.59e-05	0.00124	0.15	0.13	Ear protrusion;	chr2:85313960	chr2:85387074~85387146:-
BRCA	cis	rs11976180	1	rs11975942	ENSG00000244479.5	OR2A1-AS1	4.34	1.59e-05	0.00124	0.18	0.13	Obesity-related traits;	chr7:144043487	chr7:144251264~144356181:-
BRCA	cis	rs4415084	0.834	rs1061310	ENSG00000251141.4	RP11-53O19.1	4.34	1.59e-05	0.00124	0.12	0.13	Breast cancer;	chr5:44820748	chr5:44744900~44808777:-
BRCA	cis	rs67766926	0.953	rs13422089	ENSG00000271889.1	RP11-493E12.1	4.34	1.59e-05	0.00124	0.19	0.13	Inflammatory skin disease;	chr2:60889106	chr2:61151433~61162105:-
BRCA	cis	rs7772486	0.817	rs9386145	ENSG00000270638.1	RP3-466P17.1	4.34	1.59e-05	0.00124	0.15	0.13	Lobe attachment (rater-scored or self-reported);	chr6:146042383	chr6:145735570~145737218:+
BRCA	cis	rs7772486	0.875	rs9390372	ENSG00000270638.1	RP3-466P17.1	4.34	1.59e-05	0.00124	0.15	0.13	Lobe attachment (rater-scored or self-reported);	chr6:146042502	chr6:145735570~145737218:+
BRCA	cis	rs7772486	0.875	rs9373483	ENSG00000270638.1	RP3-466P17.1	4.34	1.59e-05	0.00124	0.15	0.13	Lobe attachment (rater-scored or self-reported);	chr6:146043058	chr6:145735570~145737218:+
BRCA	cis	rs7772486	0.875	rs7766595	ENSG00000270638.1	RP3-466P17.1	4.34	1.59e-05	0.00124	0.15	0.13	Lobe attachment (rater-scored or self-reported);	chr6:146043371	chr6:145735570~145737218:+
BRCA	cis	rs5758511	0.68	rs739147	ENSG00000226450.2	CYP2D8P	4.34	1.59e-05	0.00124	0.15	0.13	Birth weight;	chr22:42275060	chr22:42149886~42155001:-
BRCA	cis	rs10129255	0.518	rs2006284	ENSG00000232216.1	IGHV3-43	4.34	1.59e-05	0.00124	0.1	0.13	Kawasaki disease;	chr14:106676185	chr14:106470264~106470800:-
BRCA	cis	rs801193	0.904	rs4718403	ENSG00000272831.1	RP11-792A8.4	4.34	1.59e-05	0.00124	0.12	0.13	Aortic root size;	chr7:66777742	chr7:66739829~66740385:-
BRCA	cis	rs1656368	0.69	rs73154314	ENSG00000279311.1	RP11-170K4.2	4.34	1.59e-05	0.00124	0.18	0.13	Lobe attachment (rater-scored or self-reported);	chr3:158507728	chr3:158869898~158871821:+
BRCA	cis	rs6452524	0.904	rs10474095	ENSG00000281327.1	LINC01338	4.34	1.59e-05	0.00124	0.16	0.13	Hypertension (SNP x SNP interaction);	chr5:83154887	chr5:82850864~82859836:-
BRCA	cis	rs1075265	0.626	rs805320	ENSG00000235937.1	AC008280.1	4.34	1.59e-05	0.00124	0.15	0.13	Chronotype;Morning vs. evening chronotype;	chr2:53911305	chr2:54029552~54030682:-
BRCA	cis	rs11098499	0.863	rs1383532	ENSG00000250412.1	KLHL2P1	-4.34	1.59e-05	0.00124	-0.16	-0.13	Corneal astigmatism;	chr4:119513249	chr4:119334329~119378233:+
BRCA	cis	rs7520050	0.807	rs6656279	ENSG00000234329.1	RP11-767N6.2	4.34	1.59e-05	0.00124	0.12	0.13	Reticulocyte count;Red blood cell count;	chr1:45658416	chr1:45651039~45651826:-
BRCA	cis	rs7520050	0.807	rs6671802	ENSG00000234329.1	RP11-767N6.2	4.34	1.59e-05	0.00124	0.12	0.13	Reticulocyte count;Red blood cell count;	chr1:45658991	chr1:45651039~45651826:-
BRCA	cis	rs11098499	0.69	rs34818745	ENSG00000225892.3	RP11-384K6.2	4.34	1.6e-05	0.00125	0.13	0.13	Corneal astigmatism;	chr4:119335900	chr4:118632274~118634759:+
BRCA	cis	rs13108904	0.935	rs1732102	ENSG00000196810.4	CTBP1-AS2	-4.34	1.6e-05	0.00125	-0.14	-0.13	Obesity-related traits;	chr4:1284136	chr4:1249300~1288291:+
BRCA	cis	rs17684571	0.7	rs36037734	ENSG00000231441.1	RP11-472M19.2	4.34	1.6e-05	0.00125	0.23	0.13	Schizophrenia;	chr6:56801202	chr6:56844002~56864078:+
BRCA	cis	rs1077773	0.782	rs9969271	ENSG00000237773.4	AC003075.4	-4.34	1.6e-05	0.00125	-0.17	-0.13	Ulcerative colitis;Inflammatory bowel disease;	chr7:17400713	chr7:17279834~17299357:-
BRCA	cis	rs669446	0.561	rs1143701	ENSG00000236200.4	KDM4A-AS1	-4.34	1.6e-05	0.00125	-0.17	-0.13	Amyotrophic lateral sclerosis (age of onset);	chr1:43619068	chr1:43699765~43708138:-
BRCA	cis	rs6095360	1	rs6019547	ENSG00000222365.1	SNORD12B	-4.34	1.6e-05	0.00125	-0.15	-0.13	Intelligence (multi-trait analysis);	chr20:48944554	chr20:49280319~49280409:+
BRCA	cis	rs34792	0.554	rs62039131	ENSG00000260872.1	RP11-680G24.5	-4.34	1.6e-05	0.00125	-0.15	-0.13	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15528701	chr16:15018106~15020488:-
BRCA	cis	rs2243480	1	rs781150	ENSG00000275400.1	RP4-756H11.5	4.34	1.6e-05	0.00125	0.24	0.13	Diabetic kidney disease;	chr7:66015986	chr7:66553805~66554199:-
BRCA	cis	rs2243480	1	rs313798	ENSG00000275400.1	RP4-756H11.5	4.34	1.6e-05	0.00125	0.24	0.13	Diabetic kidney disease;	chr7:66028044	chr7:66553805~66554199:-
BRCA	cis	rs9467773	0.935	rs4573	ENSG00000241549.7	GUSBP2	4.34	1.6e-05	0.00125	0.15	0.13	Intelligence (multi-trait analysis);	chr6:26546580	chr6:26871484~26956554:-
BRCA	cis	rs2880765	0.835	rs2170735	ENSG00000202081.1	RNU6-1280P	4.34	1.6e-05	0.00125	0.15	0.13	Coronary artery disease;	chr15:85500254	chr15:85651522~85651628:-
BRCA	cis	rs11051970	0.879	rs2088806	ENSG00000274964.1	RP11-817I4.1	-4.34	1.6e-05	0.00125	-0.15	-0.13	Response to tocilizumab in rheumatoid arthritis;	chr12:32439191	chr12:32339368~32340724:+
BRCA	cis	rs67981189	0.593	rs9806042	ENSG00000258571.1	PTTG4P	-4.34	1.6e-05	0.00125	-0.14	-0.13	Schizophrenia;	chr14:71064276	chr14:71085482~71085833:-
BRCA	cis	rs10129255	0.5	rs59939897	ENSG00000232216.1	IGHV3-43	4.34	1.6e-05	0.00125	0.1	0.13	Kawasaki disease;	chr14:106783414	chr14:106470264~106470800:-
BRCA	cis	rs875971	0.66	rs10263935	ENSG00000229180.5	GS1-124K5.11	4.33	1.6e-05	0.00125	0.11	0.13	Aortic root size;	chr7:66631041	chr7:66526088~66542624:-
BRCA	cis	rs6968419	0.755	rs3807982	ENSG00000279086.1	RP11-667F14.1	-4.33	1.6e-05	0.00125	-0.15	-0.13	Intraocular pressure;	chr7:116258831	chr7:116209234~116211511:-
BRCA	cis	rs3764021	0.84	rs10743823	ENSG00000256582.1	RP11-75L1.1	4.33	1.6e-05	0.00125	0.13	0.13	Type 1 diabetes;	chr12:9728529	chr12:9704077~9709350:+
BRCA	cis	rs2303319	0.504	rs62189041	ENSG00000227403.1	AC009299.3	4.33	1.6e-05	0.00125	0.31	0.13	Cognitive function;	chr2:161742996	chr2:161244739~161249050:+
BRCA	cis	rs2303319	0.504	rs62189042	ENSG00000227403.1	AC009299.3	4.33	1.6e-05	0.00125	0.31	0.13	Cognitive function;	chr2:161745810	chr2:161244739~161249050:+
BRCA	cis	rs2303319	0.504	rs12467613	ENSG00000227403.1	AC009299.3	4.33	1.6e-05	0.00125	0.31	0.13	Cognitive function;	chr2:161746706	chr2:161244739~161249050:+
BRCA	cis	rs2303319	0.504	rs12467625	ENSG00000227403.1	AC009299.3	4.33	1.6e-05	0.00125	0.31	0.13	Cognitive function;	chr2:161746877	chr2:161244739~161249050:+
BRCA	cis	rs2303319	0.504	rs72877343	ENSG00000227403.1	AC009299.3	4.33	1.6e-05	0.00125	0.31	0.13	Cognitive function;	chr2:161750977	chr2:161244739~161249050:+
BRCA	cis	rs2303319	0.504	rs62189043	ENSG00000227403.1	AC009299.3	4.33	1.6e-05	0.00125	0.31	0.13	Cognitive function;	chr2:161751956	chr2:161244739~161249050:+
BRCA	cis	rs2303319	0.504	rs62189046	ENSG00000227403.1	AC009299.3	4.33	1.6e-05	0.00125	0.31	0.13	Cognitive function;	chr2:161755861	chr2:161244739~161249050:+
BRCA	cis	rs2303319	0.504	rs62189047	ENSG00000227403.1	AC009299.3	4.33	1.6e-05	0.00125	0.31	0.13	Cognitive function;	chr2:161756804	chr2:161244739~161249050:+
BRCA	cis	rs2303319	0.504	rs62189048	ENSG00000227403.1	AC009299.3	4.33	1.6e-05	0.00125	0.31	0.13	Cognitive function;	chr2:161756984	chr2:161244739~161249050:+
BRCA	cis	rs2303319	0.504	rs56026147	ENSG00000227403.1	AC009299.3	4.33	1.6e-05	0.00125	0.31	0.13	Cognitive function;	chr2:161757579	chr2:161244739~161249050:+
BRCA	cis	rs2303319	0.504	rs35304298	ENSG00000227403.1	AC009299.3	4.33	1.6e-05	0.00125	0.31	0.13	Cognitive function;	chr2:161760675	chr2:161244739~161249050:+
BRCA	cis	rs2303319	0.504	rs1449641	ENSG00000227403.1	AC009299.3	4.33	1.6e-05	0.00125	0.31	0.13	Cognitive function;	chr2:161763057	chr2:161244739~161249050:+
BRCA	cis	rs2303319	0.504	rs62189051	ENSG00000227403.1	AC009299.3	4.33	1.6e-05	0.00125	0.31	0.13	Cognitive function;	chr2:161765808	chr2:161244739~161249050:+
BRCA	cis	rs2303319	0.504	rs62189052	ENSG00000227403.1	AC009299.3	4.33	1.6e-05	0.00125	0.31	0.13	Cognitive function;	chr2:161767359	chr2:161244739~161249050:+
BRCA	cis	rs2303319	0.504	rs62189053	ENSG00000227403.1	AC009299.3	4.33	1.6e-05	0.00125	0.31	0.13	Cognitive function;	chr2:161767814	chr2:161244739~161249050:+
BRCA	cis	rs2303319	0.504	rs62189054	ENSG00000227403.1	AC009299.3	4.33	1.6e-05	0.00125	0.31	0.13	Cognitive function;	chr2:161768144	chr2:161244739~161249050:+
BRCA	cis	rs2303319	0.504	rs961421	ENSG00000227403.1	AC009299.3	4.33	1.6e-05	0.00125	0.31	0.13	Cognitive function;	chr2:161769589	chr2:161244739~161249050:+
BRCA	cis	rs453301	0.658	rs6983877	ENSG00000254153.1	CTA-398F10.2	-4.33	1.6e-05	0.00125	-0.16	-0.13	Joint mobility (Beighton score);	chr8:9047129	chr8:8456909~8461337:-
BRCA	cis	rs76076331	0.517	rs1631885	ENSG00000271952.1	RP11-245G13.2	-4.33	1.6e-05	0.00125	-0.16	-0.13	Educational attainment (college completion);Educational attainment (years of education);	chr2:10841805	chr2:10878269~10885118:+
BRCA	cis	rs792448	1	rs1086893	ENSG00000226251.4	RP11-15I11.3	-4.33	1.6e-05	0.00125	-0.18	-0.13	White blood cell count (basophil);	chr1:212389772	chr1:212225278~212238977:-
BRCA	cis	rs7487075	0.93	rs12814298	ENSG00000257261.4	RP11-96H19.1	4.33	1.6e-05	0.00125	0.14	0.13	Itch intensity from mosquito bite;	chr12:46443841	chr12:46383679~46876159:+
BRCA	cis	rs17684571	0.7	rs16888171	ENSG00000231441.1	RP11-472M19.2	4.33	1.6e-05	0.00125	0.19	0.13	Schizophrenia;	chr6:56810369	chr6:56844002~56864078:+
BRCA	cis	rs10129255	0.5	rs4774008	ENSG00000211959.2	IGHV4-39	4.33	1.6e-05	0.00125	0.09	0.13	Kawasaki disease;	chr14:106681273	chr14:106421711~106422218:-
BRCA	cis	rs6921919	0.583	rs7759191	ENSG00000220721.1	OR1F12	4.33	1.6e-05	0.00125	0.16	0.13	Autism spectrum disorder or schizophrenia;	chr6:28385657	chr6:28073316~28074233:+
BRCA	cis	rs6921919	0.583	rs7764737	ENSG00000220721.1	OR1F12	4.33	1.6e-05	0.00125	0.16	0.13	Autism spectrum disorder or schizophrenia;	chr6:28386838	chr6:28073316~28074233:+
BRCA	cis	rs6921919	0.583	rs9461458	ENSG00000220721.1	OR1F12	4.33	1.6e-05	0.00125	0.16	0.13	Autism spectrum disorder or schizophrenia;	chr6:28388098	chr6:28073316~28074233:+
BRCA	cis	rs6921919	0.609	rs9468365	ENSG00000220721.1	OR1F12	4.33	1.6e-05	0.00125	0.16	0.13	Autism spectrum disorder or schizophrenia;	chr6:28390189	chr6:28073316~28074233:+
BRCA	cis	rs6921919	0.583	rs1361385	ENSG00000220721.1	OR1F12	4.33	1.6e-05	0.00125	0.16	0.13	Autism spectrum disorder or schizophrenia;	chr6:28390543	chr6:28073316~28074233:+
BRCA	cis	rs6921919	0.583	rs1416918	ENSG00000220721.1	OR1F12	4.33	1.6e-05	0.00125	0.16	0.13	Autism spectrum disorder or schizophrenia;	chr6:28390558	chr6:28073316~28074233:+
BRCA	cis	rs6921919	0.583	rs9468367	ENSG00000220721.1	OR1F12	4.33	1.6e-05	0.00125	0.16	0.13	Autism spectrum disorder or schizophrenia;	chr6:28392469	chr6:28073316~28074233:+
BRCA	cis	rs12908161	0.96	rs17599989	ENSG00000176700.18	SCAND2P	-4.33	1.6e-05	0.00125	-0.14	-0.13	Schizophrenia;	chr15:84742305	chr15:84631451~84647478:+
BRCA	cis	rs6012564	1	rs2024959	ENSG00000227431.4	CSE1L-AS1	4.33	1.6e-05	0.00125	0.16	0.13	Anger;	chr20:49078854	chr20:49040463~49046044:-
BRCA	cis	rs2832191	0.671	rs73346699	ENSG00000176054.6	RPL23P2	-4.33	1.6e-05	0.00125	-0.15	-0.13	Dental caries;	chr21:29143208	chr21:28997613~28998033:-
BRCA	cis	rs2243480	1	rs2243480	ENSG00000164669.11	INTS4P1	4.33	1.6e-05	0.00125	0.27	0.13	Diabetic kidney disease;	chr7:66134209	chr7:65141225~65234216:+
BRCA	cis	rs7615952	0.546	rs2979333	ENSG00000171084.14	FAM86JP	4.33	1.6e-05	0.00125	0.22	0.13	Blood pressure (smoking interaction);	chr3:125641499	chr3:125916620~125930024:+
BRCA	cis	rs7615952	0.546	rs111812401	ENSG00000171084.14	FAM86JP	4.33	1.6e-05	0.00125	0.22	0.13	Blood pressure (smoking interaction);	chr3:125642651	chr3:125916620~125930024:+
BRCA	cis	rs7615952	0.546	rs2979350	ENSG00000171084.14	FAM86JP	4.33	1.6e-05	0.00125	0.22	0.13	Blood pressure (smoking interaction);	chr3:125643371	chr3:125916620~125930024:+
BRCA	cis	rs28374715	0.532	rs28897479	ENSG00000247556.5	OIP5-AS1	4.33	1.6e-05	0.00125	0.16	0.13	Ulcerative colitis;	chr15:41398653	chr15:41283990~41309737:+
BRCA	cis	rs12073837	0.784	rs35730037	ENSG00000238078.1	LINC01352	-4.33	1.6e-05	0.00125	-0.15	-0.13	F-cell distribution;	chr1:220815403	chr1:220829255~220832429:+
BRCA	cis	rs10938353	0.911	rs1583729	ENSG00000273369.1	RP11-700J17.1	4.33	1.6e-05	0.00125	0.14	0.13	Body mass index;	chr4:44583904	chr4:44693946~44694386:-
BRCA	cis	rs4908769	0.666	rs12123076	ENSG00000270282.1	RP5-1115A15.2	-4.33	1.6e-05	0.00125	-0.16	-0.13	Allergy;	chr1:8778469	chr1:8512653~8513021:+
BRCA	cis	rs11098499	0.954	rs28685688	ENSG00000260091.1	RP11-33B1.4	-4.33	1.6e-05	0.00125	-0.12	-0.13	Corneal astigmatism;	chr4:119499179	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.954	rs7687843	ENSG00000260091.1	RP11-33B1.4	-4.33	1.6e-05	0.00125	-0.12	-0.13	Corneal astigmatism;	chr4:119500056	chr4:119409333~119410233:+
BRCA	cis	rs409045	0.965	rs440827	ENSG00000271874.1	CTD-2024P10.2	-4.33	1.6e-05	0.00125	-0.18	-0.13	Left ventricular mass;	chr5:34629846	chr5:34651457~34651888:-
BRCA	cis	rs56322409	0.865	rs3176895	ENSG00000226688.5	ENTPD1-AS1	4.33	1.6e-05	0.00125	0.15	0.13	Blood metabolite levels;	chr10:95754431	chr10:95753206~96090238:-
BRCA	cis	rs2832191	0.903	rs11700687	ENSG00000236056.1	GAPDHP14	4.33	1.61e-05	0.00125	0.15	0.13	Dental caries;	chr21:29114446	chr21:29222321~29223257:+
BRCA	cis	rs2832191	1	rs2832190	ENSG00000236056.1	GAPDHP14	4.33	1.61e-05	0.00125	0.15	0.13	Dental caries;	chr21:29115905	chr21:29222321~29223257:+
BRCA	cis	rs801193	1	rs2659915	ENSG00000223473.2	GS1-124K5.3	4.33	1.61e-05	0.00125	0.1	0.13	Aortic root size;	chr7:66688114	chr7:66491049~66493566:-
BRCA	cis	rs4908760	0.539	rs6698830	ENSG00000232912.4	RP5-1115A15.1	4.33	1.61e-05	0.00125	0.13	0.13	Vitiligo;	chr1:8794486	chr1:8424645~8434838:+
BRCA	cis	rs35146811	0.961	rs35991721	ENSG00000214313.7	AZGP1P1	4.33	1.61e-05	0.00125	0.14	0.13	Coronary artery disease;	chr7:100131167	chr7:99980762~99987535:+
BRCA	cis	rs6012564	1	rs6125576	ENSG00000227431.4	CSE1L-AS1	4.33	1.61e-05	0.00125	0.17	0.13	Anger;	chr20:49160382	chr20:49040463~49046044:-
BRCA	cis	rs2505998	0.957	rs2435366	ENSG00000273008.1	RP11-351D16.3	-4.33	1.61e-05	0.00125	-0.16	-0.13	Hirschsprung disease;	chr10:43076540	chr10:43136824~43138334:-
BRCA	cis	rs6430538	0.671	rs13390951	ENSG00000224043.6	CCNT2-AS1	-4.33	1.61e-05	0.00125	-0.19	-0.13	Parkinson's disease;	chr2:134824558	chr2:134735464~134918710:-
BRCA	cis	rs11098499	0.954	rs2306455	ENSG00000260091.1	RP11-33B1.4	-4.33	1.61e-05	0.00125	-0.12	-0.13	Corneal astigmatism;	chr4:119500814	chr4:119409333~119410233:+
BRCA	cis	rs2136613	0.533	rs10740087	ENSG00000238280.1	RP11-436D10.3	-4.33	1.61e-05	0.00125	-0.17	-0.13	Selective IgA deficiency;	chr10:62847511	chr10:62793562~62805887:-
BRCA	cis	rs2731006	0.543	rs11181693	ENSG00000257114.2	RP11-25I15.3	4.33	1.61e-05	0.00125	0.2	0.13	Panic disorder;	chr12:42813605	chr12:42692216~42717119:+
BRCA	cis	rs11158026	0.603	rs67571433	ENSG00000258413.1	RP11-665C16.6	-4.33	1.61e-05	0.00125	-0.17	-0.13	Parkinson's disease;	chr14:54981264	chr14:55262767~55272075:-
BRCA	cis	rs13113518	1	rs11133381	ENSG00000272969.1	RP11-528I4.2	4.33	1.61e-05	0.00125	0.15	0.13	Height;	chr4:55450812	chr4:55547112~55547889:+
BRCA	cis	rs13113518	1	rs4864995	ENSG00000272969.1	RP11-528I4.2	4.33	1.61e-05	0.00125	0.15	0.13	Height;	chr4:55452853	chr4:55547112~55547889:+
BRCA	cis	rs10129255	0.518	rs8009612	ENSG00000211959.2	IGHV4-39	4.33	1.61e-05	0.00125	0.09	0.13	Kawasaki disease;	chr14:106777510	chr14:106421711~106422218:-
BRCA	cis	rs11976180	1	rs2951372	ENSG00000244479.5	OR2A1-AS1	4.33	1.61e-05	0.00125	0.17	0.13	Obesity-related traits;	chr7:144052410	chr7:144251264~144356181:-
BRCA	cis	rs8177876	0.822	rs12443549	ENSG00000261061.1	RP11-303E16.2	4.33	1.61e-05	0.00125	0.19	0.13	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81070596	chr16:81030770~81031485:+
BRCA	cis	rs67766926	1	rs13008738	ENSG00000271889.1	RP11-493E12.1	4.33	1.61e-05	0.00125	0.2	0.13	Inflammatory skin disease;	chr2:60851786	chr2:61151433~61162105:-
BRCA	cis	rs7267979	0.966	rs6083817	ENSG00000125804.12	FAM182A	4.33	1.61e-05	0.00125	0.17	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25363362	chr20:26054655~26086917:+
BRCA	cis	rs7267979	1	rs6050564	ENSG00000125804.12	FAM182A	4.33	1.61e-05	0.00125	0.17	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25363595	chr20:26054655~26086917:+
BRCA	cis	rs6545883	0.542	rs2593628	ENSG00000273302.1	RP11-493E12.2	-4.33	1.61e-05	0.00125	-0.12	-0.13	Tuberculosis;	chr2:61346152	chr2:61199979~61200769:+
BRCA	cis	rs4713675	0.584	rs560111	ENSG00000224557.6	HLA-DPB2	-4.33	1.61e-05	0.00125	-0.15	-0.13	Plateletcrit;	chr6:33738500	chr6:33112451~33129084:+
BRCA	cis	rs734999	0.87	rs2147905	ENSG00000238164.5	RP3-395M20.8	4.33	1.61e-05	0.00125	0.11	0.13	Ulcerative colitis;	chr1:2551482	chr1:2549920~2557031:-
BRCA	cis	rs2255336	0.873	rs7397310	ENSG00000245648.1	RP11-277P12.20	4.33	1.61e-05	0.00125	0.19	0.13	Blood protein levels;	chr12:10368394	chr12:10363769~10398506:+
BRCA	cis	rs11673344	0.526	rs17305193	ENSG00000267422.1	CTD-2554C21.1	4.33	1.61e-05	0.00126	0.18	0.13	Obesity-related traits;	chr19:37598764	chr19:37779686~37792865:+
BRCA	cis	rs10129255	0.518	rs11847766	ENSG00000211959.2	IGHV4-39	4.33	1.61e-05	0.00126	0.09	0.13	Kawasaki disease;	chr14:106779186	chr14:106421711~106422218:-
BRCA	cis	rs56174355	1	rs17759603	ENSG00000264513.1	RP11-556O9.2	4.33	1.61e-05	0.00126	0.24	0.13	Diastolic blood pressure;	chr17:62921691	chr17:63117019~63130947:-
BRCA	cis	rs11250098	0.547	rs2409764	ENSG00000154316.13	TDH	-4.33	1.61e-05	0.00126	-0.17	-0.13	Morning vs. evening chronotype;	chr8:11423764	chr8:11339637~11368452:+
BRCA	cis	rs2625529	0.617	rs62023343	ENSG00000260037.4	CTD-2524L6.3	4.33	1.61e-05	0.00126	0.17	0.13	Red blood cell count;	chr15:71882622	chr15:71818396~71823384:+
BRCA	cis	rs2908197	0.843	rs2961041	ENSG00000186704.9	DTX2P1	4.33	1.61e-05	0.00126	0.16	0.13	3-hydroxypropylmercapturic acid levels in smokers;	chr7:76316627	chr7:76978617~77004308:+
BRCA	cis	rs2908197	0.843	rs2908193	ENSG00000186704.9	DTX2P1	4.33	1.61e-05	0.00126	0.16	0.13	3-hydroxypropylmercapturic acid levels in smokers;	chr7:76316628	chr7:76978617~77004308:+
BRCA	cis	rs35740288	0.822	rs1961601	ENSG00000202081.1	RNU6-1280P	4.33	1.61e-05	0.00126	0.18	0.13	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85686375	chr15:85651522~85651628:-
BRCA	cis	rs35740288	0.787	rs727379	ENSG00000202081.1	RNU6-1280P	4.33	1.61e-05	0.00126	0.18	0.13	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85686659	chr15:85651522~85651628:-
BRCA	cis	rs77204473	1	rs17120119	ENSG00000280143.1	AP000892.6	-4.33	1.61e-05	0.00126	-0.22	-0.13	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116876566	chr11:117204967~117210292:+
BRCA	cis	rs56322409	0.861	rs4417206	ENSG00000226688.5	ENTPD1-AS1	4.33	1.61e-05	0.00126	0.15	0.13	Blood metabolite levels;	chr10:95636713	chr10:95753206~96090238:-
BRCA	cis	rs35740288	0.77	rs11634707	ENSG00000202081.1	RNU6-1280P	4.33	1.61e-05	0.00126	0.17	0.13	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85608636	chr15:85651522~85651628:-
BRCA	cis	rs860295	0.702	rs11264375	ENSG00000232093.1	RP11-307C12.11	-4.33	1.61e-05	0.00126	-0.14	-0.13	Body mass index;	chr1:155454274	chr1:155045191~155046118:-
BRCA	cis	rs5758511	0.689	rs5758691	ENSG00000227370.1	RP4-669P10.19	4.33	1.61e-05	0.00126	0.17	0.13	Birth weight;	chr22:42272498	chr22:42132543~42132998:+
BRCA	cis	rs316341	0.723	rs1262184	ENSG00000230438.6	SERPINB9P1	4.33	1.61e-05	0.00126	0.18	0.13	Cerebrospinal fluid AB1-42 levels;	chr6:2834182	chr6:2854657~2881407:-
BRCA	cis	rs7819412	0.522	rs10088853	ENSG00000154316.13	TDH	4.33	1.61e-05	0.00126	0.18	0.13	Triglycerides;	chr8:11130457	chr8:11339637~11368452:+
BRCA	cis	rs6430585	0.759	rs12467770	ENSG00000231890.6	DARS-AS1	-4.33	1.61e-05	0.00126	-0.21	-0.13	Corneal structure;	chr2:135778525	chr2:135985176~136022593:+
BRCA	cis	rs2833693	0.533	rs2833746	ENSG00000261610.1	AP000265.1	4.33	1.61e-05	0.00126	0.16	0.13	Temperament;	chr21:32252556	chr21:32259804~32261585:-
BRCA	cis	rs17228178	1	rs17228178	ENSG00000270055.1	CTD-3092A11.2	-4.33	1.61e-05	0.00126	-0.16	-0.13	Facial depth;Facial morphology (factor 1, breadth of lateral portion of upper face);	chr15:31177725	chr15:30487963~30490313:+
BRCA	cis	rs7487075	0.558	rs7959095	ENSG00000272369.1	RP11-446N19.1	4.33	1.61e-05	0.00126	0.14	0.13	Itch intensity from mosquito bite;	chr12:46239545	chr12:46537502~46652550:+
BRCA	cis	rs6547741	1	rs1528404	ENSG00000234072.1	AC074117.10	-4.33	1.61e-05	0.00126	-0.12	-0.13	Oral cavity cancer;	chr2:27623736	chr2:27356246~27367622:+
BRCA	cis	rs2243480	1	rs313809	ENSG00000275400.1	RP4-756H11.5	4.33	1.61e-05	0.00126	0.24	0.13	Diabetic kidney disease;	chr7:66034996	chr7:66553805~66554199:-
BRCA	cis	rs4415084	0.804	rs4518409	ENSG00000251141.4	RP11-53O19.1	-4.33	1.61e-05	0.00126	-0.12	-0.13	Breast cancer;	chr5:44870750	chr5:44744900~44808777:-
BRCA	cis	rs321358	1	rs321360	ENSG00000271390.1	RP11-89C3.3	4.33	1.61e-05	0.00126	0.21	0.13	Body mass index;	chr11:111125346	chr11:111089870~111090368:-
BRCA	cis	rs2033711	0.503	rs7254299	ENSG00000268307.1	CTD-2619J13.13	4.33	1.61e-05	0.00126	0.15	0.13	Uric acid clearance;	chr19:58373598	chr19:58400221~58400679:+
BRCA	cis	rs7267979	0.816	rs443009	ENSG00000231081.1	RP4-760C5.3	4.33	1.61e-05	0.00126	0.17	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25519181	chr20:26008791~26010531:-
BRCA	cis	rs7160336	0.934	rs7150815	ENSG00000259065.1	RP5-1021I20.1	4.33	1.61e-05	0.00126	0.15	0.13	Blood protein levels;	chr14:74038784	chr14:73787360~73803270:+
BRCA	cis	rs2251301	0.891	rs6990463	ENSG00000154316.13	TDH	4.33	1.61e-05	0.00126	0.22	0.13	Response to antipsychotic therapy (extrapyramidal side effects);	chr8:11263751	chr8:11339637~11368452:+
BRCA	cis	rs7772486	0.875	rs1331639	ENSG00000270638.1	RP3-466P17.1	-4.33	1.61e-05	0.00126	-0.15	-0.13	Lobe attachment (rater-scored or self-reported);	chr6:146110733	chr6:145735570~145737218:+
BRCA	cis	rs8017423	0.647	rs12589952	ENSG00000275198.1	RP11-471B22.3	4.33	1.61e-05	0.00126	0.15	0.13	Mortality in heart failure;	chr14:90355020	chr14:90383365~90387973:+
BRCA	cis	rs867371	0.519	rs1566560	ENSG00000276710.3	CSPG4P8	-4.33	1.61e-05	0.00126	-0.14	-0.13	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82232116	chr15:82459472~82477258:+
BRCA	cis	rs867371	0.519	rs1566559	ENSG00000276710.3	CSPG4P8	-4.33	1.61e-05	0.00126	-0.14	-0.13	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82232120	chr15:82459472~82477258:+
BRCA	cis	rs6012564	1	rs4810909	ENSG00000227431.4	CSE1L-AS1	-4.33	1.61e-05	0.00126	-0.17	-0.13	Anger;	chr20:49004835	chr20:49040463~49046044:-
BRCA	cis	rs12571093	0.571	rs7899387	ENSG00000233590.1	RP11-153K11.3	4.33	1.62e-05	0.00126	0.21	0.13	Optic nerve measurement (disc area);	chr10:68293278	chr10:68233251~68242379:-
BRCA	cis	rs6921919	0.583	rs4254981	ENSG00000220721.1	OR1F12	4.33	1.62e-05	0.00126	0.16	0.13	Autism spectrum disorder or schizophrenia;	chr6:28403625	chr6:28073316~28074233:+
BRCA	cis	rs5758511	0.689	rs56906457	ENSG00000227370.1	RP4-669P10.19	4.33	1.62e-05	0.00126	0.2	0.13	Birth weight;	chr22:42232329	chr22:42132543~42132998:+
BRCA	cis	rs644148	0.967	rs613876	ENSG00000176761.7	ZNF285B	4.33	1.62e-05	0.00126	0.15	0.13	Personality dimensions;	chr19:44464566	chr19:44467641~44473227:+
BRCA	cis	rs690037	1	rs690037	ENSG00000272498.1	RP11-415F23.3	4.33	1.62e-05	0.00126	0.13	0.13	Optic nerve measurement (cup-to-disc ratio);Optic nerve measurement (cup area);	chr3:16354161	chr3:16339308~16339871:+
BRCA	cis	rs2179367	0.959	rs562428	ENSG00000223701.3	RAET1E-AS1	4.33	1.62e-05	0.00126	0.17	0.13	Dupuytren's disease;	chr6:149326389	chr6:149884431~149919508:+
BRCA	cis	rs9467773	0.549	rs9467805	ENSG00000241549.7	GUSBP2	4.33	1.62e-05	0.00126	0.14	0.13	Intelligence (multi-trait analysis);	chr6:26583138	chr6:26871484~26956554:-
BRCA	cis	rs4835473	0.932	rs13152209	ENSG00000249741.2	RP11-673E1.3	-4.33	1.62e-05	0.00126	-0.14	-0.13	Immature fraction of reticulocytes;	chr4:143776088	chr4:143911514~143912053:-
BRCA	cis	rs4948275	0.693	rs2650731	ENSG00000237233.2	TMEM26-AS1	4.33	1.62e-05	0.00126	0.16	0.13	Night sleep phenotypes;	chr10:61579897	chr10:61452639~61481956:+
BRCA	cis	rs11671005	0.779	rs3794971	ENSG00000269600.1	AC016629.3	-4.33	1.62e-05	0.00126	-0.21	-0.13	Mean platelet volume;	chr19:58474499	chr19:58593896~58599355:-
BRCA	cis	rs875971	0.508	rs10258739	ENSG00000273142.1	RP11-458F8.4	4.33	1.62e-05	0.00126	0.11	0.13	Aortic root size;	chr7:66597948	chr7:66902857~66906297:+
BRCA	cis	rs465969	1	rs459048	ENSG00000230177.1	RP5-1112D6.4	4.33	1.62e-05	0.00126	0.31	0.13	Psoriasis;	chr6:111368429	chr6:111277932~111278742:+
BRCA	cis	rs465969	1	rs479343	ENSG00000230177.1	RP5-1112D6.4	4.33	1.62e-05	0.00126	0.31	0.13	Psoriasis;	chr6:111369701	chr6:111277932~111278742:+
BRCA	cis	rs465969	0.744	rs458017	ENSG00000230177.1	RP5-1112D6.4	4.33	1.62e-05	0.00126	0.31	0.13	Psoriasis;	chr6:111374888	chr6:111277932~111278742:+
BRCA	cis	rs465969	1	rs13213522	ENSG00000230177.1	RP5-1112D6.4	4.33	1.62e-05	0.00126	0.31	0.13	Psoriasis;	chr6:111384138	chr6:111277932~111278742:+
BRCA	cis	rs13401620	0.797	rs1046433	ENSG00000229326.3	AC069154.4	-4.33	1.62e-05	0.00126	-0.17	-0.13	Breast size;	chr2:119980249	chr2:119698623~119700151:+
BRCA	cis	rs57221529	0.563	rs4957057	ENSG00000271781.1	CTD-2589H19.6	-4.33	1.62e-05	0.00126	-0.18	-0.13	Lung disease severity in cystic fibrosis;	chr5:569115	chr5:675826~676616:+
BRCA	cis	rs10411936	0.626	rs8113060	ENSG00000280332.1	CTD-2013N17.6	4.33	1.62e-05	0.00126	0.12	0.13	Multiple sclerosis;White blood cell count;	chr19:16485984	chr19:16356329~16358327:-
BRCA	cis	rs2243480	1	rs781142	ENSG00000222364.1	RNU6-96P	-4.33	1.62e-05	0.00126	-0.24	-0.13	Diabetic kidney disease;	chr7:65973791	chr7:66395191~66395286:+
BRCA	cis	rs10129255	0.957	rs10140904	ENSG00000274576.2	IGHV2-70	4.33	1.62e-05	0.00126	0.12	0.13	Kawasaki disease;	chr14:106776558	chr14:106770577~106771020:-
BRCA	cis	rs7267979	1	rs4815406	ENSG00000125804.12	FAM182A	4.33	1.62e-05	0.00126	0.17	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25360680	chr20:26054655~26086917:+
BRCA	cis	rs72843166	0.562	rs17760841	ENSG00000265282.1	RP11-269G24.4	4.33	1.62e-05	0.00126	0.2	0.13	Intelligence (multi-trait analysis);	chr17:63395459	chr17:63430468~63432211:-
BRCA	cis	rs495337	0.735	rs528075	ENSG00000229222.1	KRT18P4	-4.33	1.62e-05	0.00126	-0.17	-0.13	Psoriasis;	chr20:49895107	chr20:49956745~49958032:+
BRCA	cis	rs11098499	0.954	rs6834796	ENSG00000260091.1	RP11-33B1.4	-4.33	1.62e-05	0.00126	-0.12	-0.13	Corneal astigmatism;	chr4:119493538	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.954	rs11734241	ENSG00000260091.1	RP11-33B1.4	-4.33	1.62e-05	0.00126	-0.12	-0.13	Corneal astigmatism;	chr4:119495717	chr4:119409333~119410233:+
BRCA	cis	rs2136613	0.533	rs10740090	ENSG00000238280.1	RP11-436D10.3	-4.33	1.62e-05	0.00126	-0.17	-0.13	Selective IgA deficiency;	chr10:62850027	chr10:62793562~62805887:-
BRCA	cis	rs875971	0.545	rs6460298	ENSG00000230295.1	RP11-458F8.2	4.33	1.62e-05	0.00126	0.13	0.13	Aortic root size;	chr7:66442783	chr7:66880708~66882981:+
BRCA	cis	rs6683071	0.557	rs2378605	ENSG00000225265.1	TAF1A-AS1	4.33	1.62e-05	0.00126	0.23	0.13	Cognitive performance;	chr1:222732211	chr1:222589825~222593032:+
BRCA	cis	rs256438	0.93	rs2434285	ENSG00000251050.1	RP11-168A11.4	-4.33	1.62e-05	0.00126	-0.15	-0.13	Serum thyroid-stimulating hormone levels;	chr5:80095580	chr5:80019609~80019920:+
BRCA	cis	rs7267979	0.528	rs6076366	ENSG00000125804.12	FAM182A	4.33	1.62e-05	0.00126	0.17	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25583990	chr20:26054655~26086917:+
BRCA	cis	rs1043099	0.871	rs9619104	ENSG00000279699.1	RP1-102K2.9	-4.33	1.62e-05	0.00126	-0.21	-0.13	Rheumatoid arthritis;	chr22:30378351	chr22:30275215~30276951:-
BRCA	cis	rs11722228	1	rs4697695	ENSG00000250413.1	RP11-448G15.1	-4.33	1.62e-05	0.00126	-0.18	-0.13	Urate levels;Serum uric acid levels;Gout;	chr4:9914226	chr4:10006482~10009725:+
BRCA	cis	rs10266483	0.774	rs11765812	ENSG00000227986.1	TRIM60P18	4.33	1.62e-05	0.00126	0.15	0.13	Response to statin therapy;	chr7:64385366	chr7:64355078~64356199:+
BRCA	cis	rs812925	0.519	rs967968	ENSG00000270820.4	RP11-355B11.2	-4.33	1.62e-05	0.00126	-0.14	-0.13	Immature fraction of reticulocytes;	chr2:61428921	chr2:61471188~61484130:+
BRCA	cis	rs67340775	0.541	rs200965	ENSG00000216901.1	AL022393.7	4.33	1.62e-05	0.00126	0.22	0.13	Lung cancer in ever smokers;	chr6:27898606	chr6:28176188~28176674:+
BRCA	cis	rs7048146	0.899	rs12550929	ENSG00000213539.4	YBX1P6	4.33	1.62e-05	0.00127	0.15	0.13	Vascular brain injury;	chr9:109541072	chr9:109532830~109534332:-
BRCA	cis	rs930395	0.514	rs4360054	ENSG00000251141.4	RP11-53O19.1	-4.33	1.62e-05	0.00127	-0.13	-0.13	Breast cancer;	chr5:44928902	chr5:44744900~44808777:-
BRCA	cis	rs2227564	0.729	rs2675676	ENSG00000271816.1	BMS1P4	4.33	1.62e-05	0.00127	0.14	0.13	Crohn's disease;Inflammatory bowel disease;	chr10:73888529	chr10:73699151~73730487:-
BRCA	cis	rs3764021	0.87	rs2401395	ENSG00000256582.1	RP11-75L1.1	4.33	1.63e-05	0.00127	0.13	0.13	Type 1 diabetes;	chr12:9726944	chr12:9704077~9709350:+
BRCA	cis	rs2235544	0.565	rs72664114	ENSG00000225183.1	RP4-758J24.4	-4.33	1.63e-05	0.00127	-0.16	-0.13	Thyroid hormone levels;Multiple myeloma (hyperdiploidy);	chr1:54006074	chr1:54089856~54090093:+
BRCA	cis	rs4664293	0.836	rs4516379	ENSG00000226266.5	AC009961.3	-4.33	1.63e-05	0.00127	-0.17	-0.13	Monocyte percentage of white cells;	chr2:159808892	chr2:159670708~159712435:-
BRCA	cis	rs867186	1	rs6060235	ENSG00000126005.14	MMP24-AS1	-4.33	1.63e-05	0.00127	-0.24	-0.13	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35103849	chr20:35216462~35278131:-
BRCA	cis	rs867186	1	rs17319967	ENSG00000126005.14	MMP24-AS1	-4.33	1.63e-05	0.00127	-0.24	-0.13	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35105847	chr20:35216462~35278131:-
BRCA	cis	rs11098499	0.954	rs12499324	ENSG00000260091.1	RP11-33B1.4	-4.33	1.63e-05	0.00127	-0.12	-0.13	Corneal astigmatism;	chr4:119472631	chr4:119409333~119410233:+
BRCA	cis	rs2832191	0.597	rs8127842	ENSG00000176054.6	RPL23P2	-4.33	1.63e-05	0.00127	-0.15	-0.13	Dental caries;	chr21:29144140	chr21:28997613~28998033:-
BRCA	cis	rs12744310	1	rs34190295	ENSG00000235358.1	RP11-399E6.1	4.33	1.63e-05	0.00127	0.19	0.13	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41300207	chr1:41242373~41284861:+
BRCA	cis	rs763121	0.853	rs5750669	ENSG00000225450.1	RP3-508I15.14	-4.33	1.63e-05	0.00127	-0.15	-0.13	Menopause (age at onset);	chr22:38684633	chr22:38739003~38749041:+
BRCA	cis	rs60843830	0.964	rs62114538	ENSG00000272342.1	RP13-539J13.1	4.33	1.63e-05	0.00127	0.16	0.13	Spherical equivalent (joint analysis main effects and education interaction);	chr2:256116	chr2:739588~740164:-
BRCA	cis	rs67981189	0.593	rs7160958	ENSG00000269927.1	RP6-91H8.3	4.33	1.63e-05	0.00127	0.16	0.13	Schizophrenia;	chr14:70975809	chr14:71141125~71143253:-
BRCA	cis	rs11098499	0.909	rs11723839	ENSG00000260404.2	RP11-384K6.6	4.33	1.63e-05	0.00127	0.13	0.13	Corneal astigmatism;	chr4:119378518	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.779	rs7699346	ENSG00000260404.2	RP11-384K6.6	4.33	1.63e-05	0.00127	0.13	0.13	Corneal astigmatism;	chr4:119389387	chr4:118591773~118633729:+
BRCA	cis	rs465969	0.744	rs13220692	ENSG00000230177.1	RP5-1112D6.4	4.33	1.63e-05	0.00127	0.31	0.13	Psoriasis;	chr6:111455836	chr6:111277932~111278742:+
BRCA	cis	rs28374715	0.681	rs28687846	ENSG00000247556.5	OIP5-AS1	4.33	1.63e-05	0.00127	0.15	0.13	Ulcerative colitis;	chr15:41307704	chr15:41283990~41309737:+
BRCA	cis	rs11158026	0.603	rs59323730	ENSG00000233924.1	AL160471.6	-4.33	1.63e-05	0.00127	-0.16	-0.13	Parkinson's disease;	chr14:54972357	chr14:55004813~55005687:-
BRCA	cis	rs11158026	0.603	rs943914	ENSG00000233924.1	AL160471.6	-4.33	1.63e-05	0.00127	-0.16	-0.13	Parkinson's disease;	chr14:54973350	chr14:55004813~55005687:-
BRCA	cis	rs11158026	0.603	rs11846514	ENSG00000233924.1	AL160471.6	-4.33	1.63e-05	0.00127	-0.16	-0.13	Parkinson's disease;	chr14:54973622	chr14:55004813~55005687:-
BRCA	cis	rs6121246	0.697	rs6087716	ENSG00000230613.1	HM13-AS1	4.33	1.63e-05	0.00127	0.2	0.13	Mean corpuscular hemoglobin;	chr20:31641237	chr20:31567707~31573263:-
BRCA	cis	rs7658584	0.624	rs13152371	ENSG00000246375.2	RP11-10L7.1	4.33	1.63e-05	0.00127	0.2	0.13	Squamous cell lung carcinoma;	chr4:88192345	chr4:88284942~88331421:+
BRCA	cis	rs4287000	0.508	rs2254712	ENSG00000227603.1	RP11-165J3.6	-4.33	1.63e-05	0.00127	-0.15	-0.13	Itch intensity from mosquito bite adjusted by bite size;	chr9:93601577	chr9:93435332~93437121:-
BRCA	cis	rs11098499	0.789	rs9991166	ENSG00000225892.3	RP11-384K6.2	4.33	1.63e-05	0.00127	0.13	0.13	Corneal astigmatism;	chr4:119316696	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.708	rs10005237	ENSG00000225892.3	RP11-384K6.2	4.33	1.63e-05	0.00127	0.13	0.13	Corneal astigmatism;	chr4:119316742	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.754	rs10213267	ENSG00000225892.3	RP11-384K6.2	4.33	1.63e-05	0.00127	0.13	0.13	Corneal astigmatism;	chr4:119317919	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.754	rs10212775	ENSG00000225892.3	RP11-384K6.2	4.33	1.63e-05	0.00127	0.13	0.13	Corneal astigmatism;	chr4:119318089	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.754	rs2964	ENSG00000225892.3	RP11-384K6.2	4.33	1.63e-05	0.00127	0.13	0.13	Corneal astigmatism;	chr4:119318976	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.754	rs1511025	ENSG00000225892.3	RP11-384K6.2	4.33	1.63e-05	0.00127	0.13	0.13	Corneal astigmatism;	chr4:119319083	chr4:118632274~118634759:+
BRCA	cis	rs180730	1	rs171069	ENSG00000251609.2	SETP12	-4.33	1.63e-05	0.00127	-0.19	-0.13	Fasting plasma glucose;	chr4:120880210	chr4:120895494~120897083:-
BRCA	cis	rs6600671	0.967	rs4844613	ENSG00000275131.1	CH17-472G23.4	-4.33	1.63e-05	0.00127	-0.12	-0.13	Hip geometry;	chr1:121431913	chr1:120489625~120579190:-
BRCA	cis	rs2835872	0.828	rs2835837	ENSG00000228677.1	TTC3-AS1	-4.33	1.63e-05	0.00127	-0.17	-0.13	Electroencephalographic traits in alcoholism;	chr21:37618141	chr21:37187666~37193926:-
BRCA	cis	rs2242116	0.796	rs2290546	ENSG00000276925.1	RP11-708J19.3	-4.33	1.63e-05	0.00127	-0.16	-0.13	Birth weight;	chr3:46923707	chr3:47469777~47469987:+
BRCA	cis	rs10457838	0.851	rs11759315	ENSG00000236591.1	RP11-162J8.3	-4.33	1.63e-05	0.00127	-0.19	-0.13	Post-traumatic stress disorder;	chr6:149049197	chr6:149027700~149032573:-
BRCA	cis	rs2911132	0.564	rs7356594	ENSG00000272109.1	CTD-2260A17.3	-4.33	1.63e-05	0.00127	-0.19	-0.13	Urate levels (BMI interaction);	chr5:96760485	chr5:96804353~96806105:+
BRCA	cis	rs6968419	0.674	rs4730723	ENSG00000279086.1	RP11-667F14.1	-4.33	1.63e-05	0.00127	-0.14	-0.13	Intraocular pressure;	chr7:116263998	chr7:116209234~116211511:-
BRCA	cis	rs11742741	0.967	rs4554170	ENSG00000248874.4	C5orf17	-4.33	1.63e-05	0.00127	-0.17	-0.13	Educational attainment;	chr5:24229915	chr5:23951348~24178263:+
BRCA	cis	rs10129255	0.53	rs11624912	ENSG00000211959.2	IGHV4-39	4.33	1.63e-05	0.00127	0.09	0.13	Kawasaki disease;	chr14:106673891	chr14:106421711~106422218:-
BRCA	cis	rs465969	1	rs7750803	ENSG00000272356.1	RP5-1112D6.8	-4.33	1.63e-05	0.00127	-0.29	-0.13	Psoriasis;	chr6:111478910	chr6:111309203~111313517:+
BRCA	cis	rs2304003	0.948	rs1432270	ENSG00000235192.1	AC009495.2	4.33	1.63e-05	0.00127	0.16	0.13	Social communication problems;	chr2:165847910	chr2:165794851~165810010:+
BRCA	cis	rs12435908	1	rs57201867	ENSG00000276116.2	FUT8-AS1	-4.33	1.63e-05	0.00127	-0.22	-0.13	Ischemic stroke;	chr14:65627154	chr14:65411170~65412690:-
BRCA	cis	rs281408	0.559	rs281386	ENSG00000232871.7	SEC1P	-4.33	1.63e-05	0.00127	-0.15	-0.13	Urinary metabolites (H-NMR features);	chr19:48714048	chr19:48638071~48682245:+
BRCA	cis	rs9890032	1	rs9890032	ENSG00000263603.1	CTD-2349P21.5	4.33	1.63e-05	0.00127	0.16	0.13	Hip circumference adjusted for BMI;	chr17:30838916	chr17:30729469~30731202:+
BRCA	cis	rs2243480	1	rs431318	ENSG00000275400.1	RP4-756H11.5	4.33	1.63e-05	0.00127	0.25	0.13	Diabetic kidney disease;	chr7:66046610	chr7:66553805~66554199:-
BRCA	cis	rs13113518	1	rs13118237	ENSG00000272969.1	RP11-528I4.2	4.33	1.63e-05	0.00127	0.15	0.13	Height;	chr4:55474259	chr4:55547112~55547889:+
BRCA	cis	rs8031584	0.918	rs61997138	ENSG00000259845.1	HERC2P10	4.33	1.64e-05	0.00127	0.16	0.13	Huntington's disease progression;	chr15:30978573	chr15:30815271~30844153:+
BRCA	cis	rs6921919	0.583	rs7764722	ENSG00000220721.1	OR1F12	4.33	1.64e-05	0.00127	0.16	0.13	Autism spectrum disorder or schizophrenia;	chr6:28386756	chr6:28073316~28074233:+
BRCA	cis	rs7475343	0.501	rs80079690	ENSG00000224034.1	RP11-445P17.8	-4.33	1.64e-05	0.00127	-0.25	-0.13	Intelligence;	chr10:5258474	chr10:5266033~5271236:-
BRCA	cis	rs2908197	0.713	rs2961037	ENSG00000186704.9	DTX2P1	4.33	1.64e-05	0.00127	0.16	0.13	3-hydroxypropylmercapturic acid levels in smokers;	chr7:76322895	chr7:76978617~77004308:+
BRCA	cis	rs7686660	1	rs9991766	ENSG00000250326.1	RP11-284M14.1	-4.33	1.64e-05	0.00127	-0.16	-0.13	Asthma;	chr4:143043992	chr4:142933195~143184861:-
BRCA	cis	rs370915	0.89	rs28610515	ENSG00000250971.1	RP11-696F12.1	4.33	1.64e-05	0.00127	0.15	0.13	Gout;	chr4:186914106	chr4:187060099~187060930:+
BRCA	cis	rs4650943	0.586	rs352312	ENSG00000227740.1	RP11-318C24.2	-4.33	1.64e-05	0.00127	-0.14	-0.13	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in inactive individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr1:176289651	chr1:175904762~175920513:-
BRCA	cis	rs4650943	0.586	rs352309	ENSG00000227740.1	RP11-318C24.2	-4.33	1.64e-05	0.00127	-0.14	-0.13	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in inactive individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr1:176291994	chr1:175904762~175920513:-
BRCA	cis	rs8040855	0.627	rs62019482	ENSG00000230373.7	GOLGA6L5P	4.33	1.64e-05	0.00127	0.17	0.13	Bulimia nervosa;	chr15:85071796	chr15:84507885~84516814:-
BRCA	cis	rs7577599	0.773	rs10206012	ENSG00000224220.1	AC104699.1	4.33	1.64e-05	0.00127	0.11	0.13	Multiple myeloma (IgH translocation);Multiple myeloma;	chr2:25401317	chr2:25421117~25427643:+
BRCA	cis	rs7267979	1	rs4815411	ENSG00000125804.12	FAM182A	4.33	1.64e-05	0.00127	0.17	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25369587	chr20:26054655~26086917:+
BRCA	cis	rs11673344	0.504	rs35579954	ENSG00000276846.1	CTD-3220F14.3	4.33	1.64e-05	0.00127	0.15	0.13	Obesity-related traits;	chr19:37139308	chr19:37314868~37315620:-
BRCA	cis	rs10129255	0.5	rs8006888	ENSG00000211959.2	IGHV4-39	4.33	1.64e-05	0.00127	0.09	0.13	Kawasaki disease;	chr14:106782219	chr14:106421711~106422218:-
BRCA	cis	rs11696739	0.501	rs2243603	ENSG00000242324.1	RP4-576H24.2	4.33	1.64e-05	0.00128	0.18	0.13	Mean platelet volume;	chr20:1566265	chr20:1516759~1557653:-
BRCA	cis	rs2243480	1	rs402418	ENSG00000275400.1	RP4-756H11.5	4.33	1.64e-05	0.00128	0.25	0.13	Diabetic kidney disease;	chr7:66044482	chr7:66553805~66554199:-
BRCA	cis	rs12073837	0.784	rs61830288	ENSG00000238078.1	LINC01352	-4.33	1.64e-05	0.00128	-0.15	-0.13	F-cell distribution;	chr1:220815399	chr1:220829255~220832429:+
BRCA	cis	rs12073837	0.784	rs61830289	ENSG00000238078.1	LINC01352	-4.33	1.64e-05	0.00128	-0.15	-0.13	F-cell distribution;	chr1:220815400	chr1:220829255~220832429:+
BRCA	cis	rs67766926	0.909	rs13420509	ENSG00000271889.1	RP11-493E12.1	4.33	1.64e-05	0.00128	0.19	0.13	Inflammatory skin disease;	chr2:60874753	chr2:61151433~61162105:-
BRCA	cis	rs7267979	1	rs6050561	ENSG00000125804.12	FAM182A	4.33	1.64e-05	0.00128	0.17	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25354219	chr20:26054655~26086917:+
BRCA	cis	rs7267979	1	rs6083813	ENSG00000125804.12	FAM182A	4.33	1.64e-05	0.00128	0.17	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25357035	chr20:26054655~26086917:+
BRCA	cis	rs1832007	0.554	rs75353459	ENSG00000224034.1	RP11-445P17.8	-4.33	1.64e-05	0.00128	-0.21	-0.13	Triglyceride levels;Triglycerides;	chr10:5202899	chr10:5266033~5271236:-
BRCA	cis	rs867371	1	rs1501372	ENSG00000278603.1	RP13-608F4.5	4.33	1.64e-05	0.00128	0.18	0.13	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82176114	chr15:82472203~82472426:+
BRCA	cis	rs1832007	0.554	rs77506074	ENSG00000224034.1	RP11-445P17.8	-4.33	1.64e-05	0.00128	-0.21	-0.13	Triglyceride levels;Triglycerides;	chr10:5202905	chr10:5266033~5271236:-
BRCA	cis	rs10504130	0.935	rs76813841	ENSG00000272024.1	RP11-546K22.3	-4.33	1.64e-05	0.00128	-0.23	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr8:51848253	chr8:51950284~51950690:+
BRCA	cis	rs8048589	0.558	rs35208076	ENSG00000175604.2	RP11-276H1.3	-4.33	1.64e-05	0.00128	-0.22	-0.13	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);	chr16:12134312	chr16:12086746~12090302:-
BRCA	cis	rs1910358	0.614	rs7724548	ENSG00000248874.4	C5orf17	-4.33	1.64e-05	0.00128	-0.17	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23979557	chr5:23951348~24178263:+
BRCA	cis	rs62103177	0.525	rs10438902	ENSG00000278000.1	AC139100.4	-4.33	1.64e-05	0.00128	-0.19	-0.13	Opioid sensitivity;	chr18:79985640	chr18:80161752~80162413:+
BRCA	cis	rs7649643	1	rs7649643	ENSG00000279311.1	RP11-170K4.2	4.33	1.64e-05	0.00128	0.16	0.13	Depressive symptoms;Depressive symptoms (multi-trait analysis);	chr3:158553300	chr3:158869898~158871821:+
BRCA	cis	rs62103177	0.608	rs59300126	ENSG00000278000.1	AC139100.4	4.33	1.64e-05	0.00128	0.22	0.13	Opioid sensitivity;	chr18:79934439	chr18:80161752~80162413:+
BRCA	cis	rs8067545	0.512	rs34726000	ENSG00000261033.1	RP11-209D14.2	-4.33	1.64e-05	0.00128	-0.19	-0.13	Schizophrenia;	chr17:19984508	chr17:20008051~20009234:-
BRCA	cis	rs6840360	0.557	rs1143036	ENSG00000251611.1	RP11-610P16.1	-4.33	1.64e-05	0.00128	-0.12	-0.13	Intelligence (multi-trait analysis);	chr4:151408252	chr4:151407551~151408835:-
BRCA	cis	rs6005807	0.719	rs134547	ENSG00000272858.1	CTA-292E10.8	-4.33	1.64e-05	0.00128	-0.22	-0.13	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28405021	chr22:28814914~28815662:+
BRCA	cis	rs2625529	0.652	rs8027164	ENSG00000260037.4	CTD-2524L6.3	4.33	1.64e-05	0.00128	0.17	0.13	Red blood cell count;	chr15:72115392	chr15:71818396~71823384:+
BRCA	cis	rs6940116	1	rs6940116	ENSG00000216901.1	AL022393.7	4.33	1.64e-05	0.00128	0.22	0.13	Intelligence (multi-trait analysis);Autism spectrum disorder or schizophrenia;	chr6:27740953	chr6:28176188~28176674:+
BRCA	cis	rs6547741	1	rs76784350	ENSG00000234072.1	AC074117.10	4.33	1.64e-05	0.00128	0.12	0.13	Oral cavity cancer;	chr2:27541411	chr2:27356246~27367622:+
BRCA	cis	rs1371614	0.632	rs6738528	ENSG00000229122.1	AGBL5-IT1	-4.33	1.64e-05	0.00128	-0.14	-0.13	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26926390	chr2:27061038~27061815:+
BRCA	cis	rs11098499	0.865	rs11722183	ENSG00000225892.3	RP11-384K6.2	4.33	1.64e-05	0.00128	0.13	0.13	Corneal astigmatism;	chr4:119359442	chr4:118632274~118634759:+
BRCA	cis	rs1048886	0.872	rs9455163	ENSG00000271967.1	RP11-134K13.4	-4.33	1.64e-05	0.00128	-0.18	-0.13	Type 2 diabetes;	chr6:70570054	chr6:70596438~70596980:+
BRCA	cis	rs11892454	0.544	rs34921778	ENSG00000217643.1	PTGES3P2	-4.33	1.64e-05	0.00128	-0.14	-0.13	Heschl's gyrus morphology;	chr2:25788941	chr2:25822469~25822950:+
BRCA	cis	rs2749097	0.609	rs2269241	ENSG00000244256.3	RN7SL130P	-4.33	1.64e-05	0.00128	-0.18	-0.13	Alcohol consumption (transferrin glycosylation);	chr1:63643100	chr1:63655743~63656047:+
BRCA	cis	rs2179367	0.92	rs638407	ENSG00000223701.3	RAET1E-AS1	4.33	1.64e-05	0.00128	0.17	0.13	Dupuytren's disease;	chr6:149417214	chr6:149884431~149919508:+
BRCA	cis	rs11098499	0.863	rs10030660	ENSG00000250412.1	KLHL2P1	4.33	1.64e-05	0.00128	0.16	0.13	Corneal astigmatism;	chr4:119515549	chr4:119334329~119378233:+
BRCA	cis	rs11098499	0.863	rs13149407	ENSG00000250412.1	KLHL2P1	4.33	1.64e-05	0.00128	0.16	0.13	Corneal astigmatism;	chr4:119516670	chr4:119334329~119378233:+
BRCA	cis	rs4948275	0.606	rs2787719	ENSG00000237233.2	TMEM26-AS1	-4.33	1.65e-05	0.00128	-0.16	-0.13	Night sleep phenotypes;	chr10:61573465	chr10:61452639~61481956:+
BRCA	cis	rs860295	0.702	rs12041534	ENSG00000225855.5	RUSC1-AS1	-4.33	1.65e-05	0.00128	-0.1	-0.13	Body mass index;	chr1:155437305	chr1:155316863~155324176:-
BRCA	cis	rs4478858	0.654	rs113490486	ENSG00000223907.1	LINC01226	-4.33	1.65e-05	0.00128	-0.16	-0.13	Alcohol dependence;	chr1:31240016	chr1:31518435~31524245:+
BRCA	cis	rs35146811	0.735	rs1727138	ENSG00000235713.1	RP4-604G5.3	-4.33	1.65e-05	0.00128	-0.15	-0.13	Coronary artery disease;	chr7:100217624	chr7:99992397~99993050:+
BRCA	cis	rs7577599	0.773	rs2384232	ENSG00000224220.1	AC104699.1	4.33	1.65e-05	0.00128	0.11	0.13	Multiple myeloma (IgH translocation);Multiple myeloma;	chr2:25400880	chr2:25421117~25427643:+
BRCA	cis	rs7915131	1	rs10219104	ENSG00000238280.1	RP11-436D10.3	4.33	1.65e-05	0.00128	0.17	0.13	Schizophrenia;	chr10:62661212	chr10:62793562~62805887:-
BRCA	cis	rs516805	0.63	rs2606606	ENSG00000279114.1	RP3-425C14.5	-4.33	1.65e-05	0.00128	-0.17	-0.13	Lymphocyte counts;	chr6:122201126	chr6:122471923~122484161:+
BRCA	cis	rs718433	0.682	rs7150263	ENSG00000256379.1	TRAV8-5	4.33	1.65e-05	0.00128	0.16	0.13	Intraocular pressure;	chr14:21794012	chr14:21903077~21903598:+
BRCA	cis	rs71520386	0.632	rs9654968	ENSG00000226329.2	AC005682.6	-4.33	1.65e-05	0.00128	-0.14	-0.13	Fibrinogen levels;	chr7:22836697	chr7:22863874~22881350:-
BRCA	cis	rs454217	0.521	rs11106512	ENSG00000277851.1	RP11-756G20.1	-4.33	1.65e-05	0.00128	-0.16	-0.13	Smoking quantity;	chr12:92333017	chr12:92247756~92363832:-
BRCA	cis	rs1345301	0.552	rs1558626	ENSG00000234389.1	AC007278.3	-4.33	1.65e-05	0.00128	-0.12	-0.13	Waist circumference;	chr2:102245610	chr2:102438713~102440475:+
BRCA	cis	rs1345301	0.518	rs1558624	ENSG00000234389.1	AC007278.3	-4.33	1.65e-05	0.00128	-0.12	-0.13	Waist circumference;	chr2:102245773	chr2:102438713~102440475:+
BRCA	cis	rs12962334	0.518	rs4800141	ENSG00000273232.1	RP11-370A5.2	4.33	1.65e-05	0.00128	0.17	0.13	Breast cancer;	chr18:22984312	chr18:22882825~22883357:-
BRCA	cis	rs651907	0.506	rs1513118	ENSG00000244119.1	PDCL3P4	4.33	1.65e-05	0.00128	0.11	0.13	Colorectal cancer;	chr3:101942945	chr3:101712472~101713191:+
BRCA	cis	rs7048146	0.966	rs4978824	ENSG00000213539.4	YBX1P6	4.33	1.65e-05	0.00128	0.15	0.13	Vascular brain injury;	chr9:109540112	chr9:109532830~109534332:-
BRCA	cis	rs4494364	0.502	rs1920773	ENSG00000258100.1	RP11-121E16.1	4.33	1.65e-05	0.00128	0.19	0.13	Systolic blood pressure (alcohol consumption interaction);	chr12:91052319	chr12:91362196~91368606:+
BRCA	cis	rs7727544	0.57	rs7701237	ENSG00000233006.5	AC034220.3	4.33	1.65e-05	0.00128	0.1	0.13	Blood metabolite levels;	chr5:132198688	chr5:132311285~132369916:-
BRCA	cis	rs2179367	0.881	rs2744432	ENSG00000223701.3	RAET1E-AS1	-4.33	1.65e-05	0.00128	-0.17	-0.13	Dupuytren's disease;	chr6:149422735	chr6:149884431~149919508:+
BRCA	cis	rs7267979	1	rs6115153	ENSG00000277938.1	RP5-965G21.3	-4.33	1.65e-05	0.00128	-0.16	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25344931	chr20:25229150~25231933:+
BRCA	cis	rs7985	0.523	rs4822768	ENSG00000225783.5	MIAT	-4.33	1.65e-05	0.00128	-0.11	-0.13	Electroencephalogram traits;	chr22:26674786	chr22:26646428~26676475:+
BRCA	cis	rs17270561	1	rs12211184	ENSG00000272462.2	U91328.19	-4.33	1.65e-05	0.00128	-0.19	-0.13	Iron status biomarkers;	chr6:25823546	chr6:25992662~26001775:+
BRCA	cis	rs1910358	0.508	rs10071903	ENSG00000248874.4	C5orf17	-4.33	1.65e-05	0.00128	-0.19	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23771399	chr5:23951348~24178263:+
BRCA	cis	rs867186	1	rs117802529	ENSG00000126005.14	MMP24-AS1	-4.33	1.65e-05	0.00128	-0.26	-0.13	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35198874	chr20:35216462~35278131:-
BRCA	cis	rs1348850	0.651	rs4893821	ENSG00000280374.1	RP11-337N6.3	-4.33	1.65e-05	0.00128	-0.17	-0.13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177364624	chr2:177317715~177318471:-
BRCA	cis	rs2229238	0.868	rs41308419	ENSG00000272030.1	RP1-178F15.4	-4.33	1.65e-05	0.00128	-0.19	-0.13	Coronary heart disease;	chr1:154534721	chr1:153631438~153634397:-
BRCA	cis	rs7312933	0.558	rs2178753	ENSG00000257225.1	RP11-328C8.4	4.33	1.65e-05	0.00129	0.16	0.13	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42339002	chr12:42459366~42466128:+
BRCA	cis	rs2904967	1	rs630055	ENSG00000255200.1	AP003068.18	-4.33	1.65e-05	0.00129	-0.21	-0.13	Mean corpuscular volume;	chr11:65320062	chr11:65174117~65176470:-
BRCA	cis	rs2243480	1	rs313803	ENSG00000275400.1	RP4-756H11.5	4.33	1.65e-05	0.00129	0.25	0.13	Diabetic kidney disease;	chr7:66049744	chr7:66553805~66554199:-
BRCA	cis	rs495337	0.721	rs554263	ENSG00000229222.1	KRT18P4	-4.33	1.65e-05	0.00129	-0.17	-0.13	Psoriasis;	chr20:49897356	chr20:49956745~49958032:+
BRCA	cis	rs17801127	0.636	rs10933118	ENSG00000231969.1	AC144449.1	-4.33	1.65e-05	0.00129	-0.21	-0.13	Liver enzyme levels (alanine transaminase);	chr2:149704914	chr2:149587196~149848233:+
BRCA	cis	rs711830	0.965	rs2857532	ENSG00000226363.3	HAGLROS	-4.33	1.65e-05	0.00129	-0.2	-0.13	Serous invasive ovarian cancer;Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;High-grade serous ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;	chr2:176168555	chr2:176177717~176179008:+
BRCA	cis	rs2839627	0.638	rs9974287	ENSG00000225218.1	AP001628.6	4.33	1.65e-05	0.00129	0.2	0.13	Information processing speed;	chr21:42896893	chr21:42831040~42836477:-
BRCA	cis	rs13113518	1	rs11724094	ENSG00000272969.1	RP11-528I4.2	4.33	1.65e-05	0.00129	0.15	0.13	Height;	chr4:55501479	chr4:55547112~55547889:+
BRCA	cis	rs12612435	0.869	rs67150460	ENSG00000226806.1	AC011893.3	4.33	1.65e-05	0.00129	0.16	0.13	Takotsubo syndrome;	chr2:136370631	chr2:135820191~135823087:+
BRCA	cis	rs11719291	0.833	rs11715835	ENSG00000270441.1	RP11-694I15.7	4.33	1.66e-05	0.00129	0.27	0.13	Cognitive function;	chr3:48733299	chr3:49140086~49160851:-
BRCA	cis	rs2898290	0.592	rs2736342	ENSG00000154316.13	TDH	4.33	1.66e-05	0.00129	0.16	0.13	Systolic blood pressure;	chr8:11489780	chr8:11339637~11368452:+
BRCA	cis	rs409045	1	rs402954	ENSG00000271874.1	CTD-2024P10.2	-4.33	1.66e-05	0.00129	-0.18	-0.13	Left ventricular mass;	chr5:34629926	chr5:34651457~34651888:-
BRCA	cis	rs409045	1	rs436061	ENSG00000271874.1	CTD-2024P10.2	-4.33	1.66e-05	0.00129	-0.18	-0.13	Left ventricular mass;	chr5:34630619	chr5:34651457~34651888:-
BRCA	cis	rs409045	0.965	rs422402	ENSG00000271874.1	CTD-2024P10.2	-4.33	1.66e-05	0.00129	-0.18	-0.13	Left ventricular mass;	chr5:34630746	chr5:34651457~34651888:-
BRCA	cis	rs409045	1	rs457451	ENSG00000271874.1	CTD-2024P10.2	-4.33	1.66e-05	0.00129	-0.18	-0.13	Left ventricular mass;	chr5:34631255	chr5:34651457~34651888:-
BRCA	cis	rs409045	0.965	rs457361	ENSG00000271874.1	CTD-2024P10.2	-4.33	1.66e-05	0.00129	-0.18	-0.13	Left ventricular mass;	chr5:34631573	chr5:34651457~34651888:-
BRCA	cis	rs409045	1	rs467222	ENSG00000271874.1	CTD-2024P10.2	-4.33	1.66e-05	0.00129	-0.18	-0.13	Left ventricular mass;	chr5:34631769	chr5:34651457~34651888:-
BRCA	cis	rs10043775	0.957	rs10060753	ENSG00000251330.3	CTD-2283N19.1	-4.33	1.66e-05	0.00129	-0.17	-0.13	Periodontal microbiota;	chr5:148385452	chr5:148430159~148430807:-
BRCA	cis	rs10129255	0.5	rs6576232	ENSG00000254174.1	IGHV1-12	4.33	1.66e-05	0.00129	0.1	0.13	Kawasaki disease;	chr14:106787090	chr14:106122420~106122709:-
BRCA	cis	rs6831352	0.734	rs3018046	ENSG00000272777.1	RP11-571L19.8	-4.33	1.66e-05	0.00129	-0.14	-0.13	Alcohol dependence;	chr4:99109237	chr4:99067256~99068125:-
BRCA	cis	rs6496044	0.568	rs4842888	ENSG00000202081.1	RNU6-1280P	-4.33	1.66e-05	0.00129	-0.15	-0.13	Interstitial lung disease;	chr15:85519902	chr15:85651522~85651628:-
BRCA	cis	rs2251381	0.606	rs8129515	ENSG00000176054.6	RPL23P2	4.33	1.66e-05	0.00129	0.16	0.13	Selective IgA deficiency;	chr21:29147846	chr21:28997613~28998033:-
BRCA	cis	rs755249	0.567	rs61783376	ENSG00000182109.6	RP11-69E11.4	4.33	1.66e-05	0.00129	0.19	0.13	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39303328	chr1:39522280~39546187:-
BRCA	cis	rs755249	0.567	rs4660636	ENSG00000182109.6	RP11-69E11.4	4.33	1.66e-05	0.00129	0.19	0.13	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39304555	chr1:39522280~39546187:-
BRCA	cis	rs8180040	0.654	rs13078131	ENSG00000276925.1	RP11-708J19.3	-4.33	1.66e-05	0.00129	-0.15	-0.13	Colorectal cancer;	chr3:47163449	chr3:47469777~47469987:+
BRCA	cis	rs801193	1	rs62466794	ENSG00000272831.1	RP11-792A8.4	4.33	1.66e-05	0.00129	0.12	0.13	Aortic root size;	chr7:66726592	chr7:66739829~66740385:-
BRCA	cis	rs13113518	0.841	rs11133400	ENSG00000272969.1	RP11-528I4.2	4.33	1.66e-05	0.00129	0.15	0.13	Height;	chr4:55578787	chr4:55547112~55547889:+
BRCA	cis	rs56322409	0.833	rs10786239	ENSG00000226688.5	ENTPD1-AS1	4.33	1.66e-05	0.00129	0.16	0.13	Blood metabolite levels;	chr10:95886265	chr10:95753206~96090238:-
BRCA	cis	rs17507216	0.718	rs17158403	ENSG00000255769.6	GOLGA2P10	-4.33	1.66e-05	0.00129	-0.19	-0.13	Excessive daytime sleepiness;	chr15:82572478	chr15:82472993~82513950:-
BRCA	cis	rs6545883	0.929	rs7561229	ENSG00000270820.4	RP11-355B11.2	4.33	1.66e-05	0.00129	0.15	0.13	Tuberculosis;	chr2:61510855	chr2:61471188~61484130:+
BRCA	cis	rs7658584	0.592	rs13147650	ENSG00000246375.2	RP11-10L7.1	4.33	1.66e-05	0.00129	0.2	0.13	Squamous cell lung carcinoma;	chr4:88188244	chr4:88284942~88331421:+
BRCA	cis	rs924712	0.545	rs9464148	ENSG00000224984.1	RP11-524H19.2	4.33	1.66e-05	0.00129	0.16	0.13	Breast cancer;	chr6:54840286	chr6:54840118~54840855:-
BRCA	cis	rs17818399	0.815	rs17768132	ENSG00000279254.1	RP11-536C12.1	4.33	1.66e-05	0.00129	0.18	0.13	Height;	chr2:46636110	chr2:46668870~46670778:+
BRCA	cis	rs875971	0.545	rs73148639	ENSG00000230295.1	RP11-458F8.2	4.33	1.66e-05	0.00129	0.13	0.13	Aortic root size;	chr7:66390342	chr7:66880708~66882981:+
BRCA	cis	rs2235544	0.565	rs633315	ENSG00000225183.1	RP4-758J24.4	4.33	1.66e-05	0.00129	0.16	0.13	Thyroid hormone levels;Multiple myeloma (hyperdiploidy);	chr1:54003016	chr1:54089856~54090093:+
BRCA	cis	rs2235544	0.565	rs635509	ENSG00000225183.1	RP4-758J24.4	4.33	1.66e-05	0.00129	0.16	0.13	Thyroid hormone levels;Multiple myeloma (hyperdiploidy);	chr1:54003554	chr1:54089856~54090093:+
BRCA	cis	rs7023329	0.811	rs3928894	ENSG00000265194.1	RP11-70L8.4	4.33	1.66e-05	0.00129	0.14	0.13	Melanoma;	chr9:21818311	chr9:21858910~21861926:-
BRCA	cis	rs7800418	0.784	rs757805	ENSG00000214870.7	AC004540.5	4.33	1.66e-05	0.00129	0.17	0.13	Cognitive function;	chr7:26546952	chr7:26398593~26494256:+
BRCA	cis	rs757081	0.578	rs7109536	ENSG00000184669.7	OR7E14P	-4.33	1.66e-05	0.00129	-0.17	-0.13	Systolic blood pressure;	chr11:17233965	chr11:17013998~17053024:+
BRCA	cis	rs6676180	0.514	rs868675	ENSG00000231365.4	RP11-418J17.1	-4.33	1.66e-05	0.00129	-0.15	-0.13	Monobrow;	chr1:119230973	chr1:119140396~119275973:+
BRCA	cis	rs2278702	0.79	rs11858943	ENSG00000259495.2	RP11-210M15.2	-4.33	1.66e-05	0.00129	-0.19	-0.13	Bipolar disorder;	chr15:80388289	chr15:80344853~80403575:-
BRCA	cis	rs644148	1	rs644148	ENSG00000176761.7	ZNF285B	4.33	1.66e-05	0.00129	0.15	0.13	Personality dimensions;	chr19:44466713	chr19:44467641~44473227:+
BRCA	cis	rs1371614	0.635	rs10196691	ENSG00000272148.1	RP11-195B17.1	-4.33	1.66e-05	0.00129	-0.15	-0.13	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26918491	chr2:27062428~27062907:-
BRCA	cis	rs9291683	0.62	rs4444830	ENSG00000250413.1	RP11-448G15.1	4.33	1.66e-05	0.00129	0.18	0.13	Bone mineral density;	chr4:10123195	chr4:10006482~10009725:+
BRCA	cis	rs4660214	0.666	rs587404	ENSG00000237624.1	OXCT2P1	4.33	1.66e-05	0.00129	0.16	0.13	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39442834	chr1:39514956~39516490:+
BRCA	cis	rs9818758	0.607	rs56004653	ENSG00000270441.1	RP11-694I15.7	4.33	1.66e-05	0.00129	0.33	0.13	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49034795	chr3:49140086~49160851:-
BRCA	cis	rs17065868	0.764	rs9533852	ENSG00000237361.2	TUSC8	-4.33	1.66e-05	0.00129	-0.29	-0.13	Antineutrophil cytoplasmic antibody-associated vasculitis;	chr13:44445782	chr13:44400250~44405984:-
BRCA	cis	rs2191566	0.664	rs7254261	ENSG00000266921.1	RP11-15A1.7	-4.33	1.66e-05	0.00129	-0.17	-0.13	Acute lymphoblastic leukemia (childhood);	chr19:44061274	chr19:43996896~44002836:-
BRCA	cis	rs4664293	0.801	rs6432552	ENSG00000230783.1	AC009961.2	-4.33	1.66e-05	0.00129	-0.17	-0.13	Monocyte percentage of white cells;	chr2:159717613	chr2:159689217~159690291:-
BRCA	cis	rs9818758	0.607	rs67831908	ENSG00000225399.4	RP11-3B7.1	-4.33	1.66e-05	0.00129	-0.22	-0.13	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49276080	chr3:49260085~49261316:+
BRCA	cis	rs4664293	0.801	rs7607143	ENSG00000230783.1	AC009961.2	-4.33	1.66e-05	0.00129	-0.17	-0.13	Monocyte percentage of white cells;	chr2:159728250	chr2:159689217~159690291:-
BRCA	cis	rs4664293	0.833	rs10170336	ENSG00000230783.1	AC009961.2	-4.33	1.66e-05	0.00129	-0.17	-0.13	Monocyte percentage of white cells;	chr2:159732832	chr2:159689217~159690291:-
BRCA	cis	rs875971	0.838	rs2173570	ENSG00000229180.5	GS1-124K5.11	-4.33	1.66e-05	0.00129	-0.11	-0.13	Aortic root size;	chr7:66297976	chr7:66526088~66542624:-
BRCA	cis	rs2839186	0.843	rs17182671	ENSG00000239415.1	AP001469.9	4.33	1.66e-05	0.00129	0.14	0.13	Testicular germ cell tumor;	chr21:46276324	chr21:46251549~46254133:-
BRCA	cis	rs2839186	0.739	rs7282763	ENSG00000239415.1	AP001469.9	4.33	1.66e-05	0.00129	0.14	0.13	Testicular germ cell tumor;	chr21:46276886	chr21:46251549~46254133:-
BRCA	cis	rs5758511	0.68	rs5758698	ENSG00000226450.2	CYP2D8P	4.33	1.66e-05	0.00129	0.15	0.13	Birth weight;	chr22:42288812	chr22:42149886~42155001:-
BRCA	cis	rs1124769	0.5	rs79722088	ENSG00000273674.3	CTD-2378E12.1	-4.33	1.66e-05	0.00129	-0.16	-0.13	Cognitive performance;	chr15:50853702	chr15:50839875~50908599:-
BRCA	cis	rs7592578	0.679	rs62181020	ENSG00000272979.1	RP11-647K16.1	-4.33	1.67e-05	0.00129	-0.21	-0.13	Diastolic blood pressure;	chr2:190460875	chr2:190454092~190454521:-
BRCA	cis	rs13113518	0.966	rs11133387	ENSG00000272969.1	RP11-528I4.2	4.33	1.67e-05	0.00129	0.15	0.13	Height;	chr4:55475130	chr4:55547112~55547889:+
BRCA	cis	rs13113518	1	rs4864999	ENSG00000272969.1	RP11-528I4.2	4.33	1.67e-05	0.00129	0.15	0.13	Height;	chr4:55476736	chr4:55547112~55547889:+
BRCA	cis	rs13113518	0.966	rs10517344	ENSG00000272969.1	RP11-528I4.2	4.33	1.67e-05	0.00129	0.15	0.13	Height;	chr4:55477545	chr4:55547112~55547889:+
BRCA	cis	rs7833986	0.501	rs2953911	ENSG00000253603.1	CTA-397H3.3	-4.33	1.67e-05	0.00129	-0.19	-0.13	Height;	chr8:56035450	chr8:56074592~56075274:+
BRCA	cis	rs6547741	0.717	rs2178197	ENSG00000234072.1	AC074117.10	4.33	1.67e-05	0.00129	0.12	0.13	Oral cavity cancer;	chr2:27637684	chr2:27356246~27367622:+
BRCA	cis	rs7267979	0.789	rs6083820	ENSG00000277938.1	RP5-965G21.3	-4.33	1.67e-05	0.00129	-0.16	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25373542	chr20:25229150~25231933:+
BRCA	cis	rs6596100	0.91	rs62375249	ENSG00000248648.1	RP11-485M7.1	-4.33	1.67e-05	0.00129	-0.18	-0.13	Breast cancer;	chr5:133107787	chr5:133003119~133003365:+
BRCA	cis	rs1048886	0.872	rs9455161	ENSG00000271967.1	RP11-134K13.4	-4.33	1.67e-05	0.00129	-0.18	-0.13	Type 2 diabetes;	chr6:70565476	chr6:70596438~70596980:+
BRCA	cis	rs9921338	0.961	rs57579443	ENSG00000263080.1	RP11-485G7.5	4.33	1.67e-05	0.00129	0.2	0.13	Vein graft stenosis in coronary artery bypass grafting;	chr16:11349140	chr16:11341809~11345211:-
BRCA	cis	rs321358	1	rs321366	ENSG00000271390.1	RP11-89C3.3	4.33	1.67e-05	0.00129	0.21	0.13	Body mass index;	chr11:111128003	chr11:111089870~111090368:-
BRCA	cis	rs62458065	1	rs10250808	ENSG00000229358.3	DPY19L1P1	-4.33	1.67e-05	0.0013	-0.18	-0.13	Metabolite levels (HVA/MHPG ratio);	chr7:32426541	chr7:32580949~32761787:-
BRCA	cis	rs2835872	0.965	rs857946	ENSG00000228677.1	TTC3-AS1	-4.33	1.67e-05	0.0013	-0.17	-0.13	Electroencephalographic traits in alcoholism;	chr21:37637001	chr21:37187666~37193926:-
BRCA	cis	rs10266483	1	rs1960321	ENSG00000228653.2	HNRNPCP7	-4.33	1.67e-05	0.0013	-0.16	-0.13	Response to statin therapy;	chr7:64270906	chr7:64500825~64501729:+
BRCA	cis	rs4869313	0.837	rs13170029	ENSG00000248734.2	CTD-2260A17.1	4.33	1.67e-05	0.0013	0.14	0.13	Pediatric autoimmune diseases;	chr5:96943349	chr5:96784777~96785999:+
BRCA	cis	rs9543976	0.623	rs7982517	ENSG00000261105.4	LMO7-AS1	4.33	1.67e-05	0.0013	0.2	0.13	Diabetic retinopathy;	chr13:75587903	chr13:75604700~75635994:-
BRCA	cis	rs1789	0.706	rs8180240	ENSG00000214846.4	RP11-115L11.1	4.33	1.67e-05	0.0013	0.18	0.13	Blood protein levels;	chr4:15699952	chr4:15730962~15731627:-
BRCA	cis	rs13126694	0.633	rs4406058	ENSG00000251429.1	RP11-597D13.7	4.33	1.67e-05	0.0013	0.13	0.13	Blood osmolality (transformed sodium);	chr4:158083652	chr4:158270378~158278676:+
BRCA	cis	rs4869313	0.905	rs1477364	ENSG00000248734.2	CTD-2260A17.1	4.33	1.67e-05	0.0013	0.14	0.13	Pediatric autoimmune diseases;	chr5:96949188	chr5:96784777~96785999:+
BRCA	cis	rs755249	0.567	rs61779284	ENSG00000182109.6	RP11-69E11.4	4.33	1.67e-05	0.0013	0.19	0.13	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39389505	chr1:39522280~39546187:-
BRCA	cis	rs11892454	0.515	rs10168718	ENSG00000217643.1	PTGES3P2	-4.33	1.67e-05	0.0013	-0.14	-0.13	Heschl's gyrus morphology;	chr2:25830297	chr2:25822469~25822950:+
BRCA	cis	rs11892454	0.543	rs9941574	ENSG00000217643.1	PTGES3P2	-4.33	1.67e-05	0.0013	-0.14	-0.13	Heschl's gyrus morphology;	chr2:25832799	chr2:25822469~25822950:+
BRCA	cis	rs11951515	0.508	rs11958046	ENSG00000248240.1	RP11-159F24.5	-4.33	1.67e-05	0.0013	-0.16	-0.13	Metabolite levels  (X-11787);	chr5:43583287	chr5:43515274~43525310:+
BRCA	cis	rs8040855	0.627	rs11634975	ENSG00000230373.7	GOLGA6L5P	4.33	1.67e-05	0.0013	0.17	0.13	Bulimia nervosa;	chr15:85063247	chr15:84507885~84516814:-
BRCA	cis	rs6430585	0.583	rs58509842	ENSG00000224043.6	CCNT2-AS1	-4.32	1.67e-05	0.0013	-0.22	-0.13	Corneal structure;	chr2:135828457	chr2:134735464~134918710:-
BRCA	cis	rs6430585	0.583	rs3769008	ENSG00000224043.6	CCNT2-AS1	-4.32	1.67e-05	0.0013	-0.22	-0.13	Corneal structure;	chr2:135828613	chr2:134735464~134918710:-
BRCA	cis	rs6430585	0.583	rs12373779	ENSG00000224043.6	CCNT2-AS1	-4.32	1.67e-05	0.0013	-0.22	-0.13	Corneal structure;	chr2:135829270	chr2:134735464~134918710:-
BRCA	cis	rs4374383	0.884	rs1996328	ENSG00000243389.1	AC012442.5	-4.32	1.67e-05	0.0013	-0.17	-0.13	Hepatitis C induced liver fibrosis;	chr2:111923164	chr2:112589040~112614431:+
BRCA	cis	rs160451	0.966	rs28374917	ENSG00000251136.7	RP11-37B2.1	4.32	1.67e-05	0.0013	0.13	0.13	Leprosy;	chr8:89666525	chr8:89609409~89757727:-
BRCA	cis	rs10411936	0.692	rs10413787	ENSG00000280332.1	CTD-2013N17.6	4.32	1.67e-05	0.0013	0.11	0.13	Multiple sclerosis;White blood cell count;	chr19:16484156	chr19:16356329~16358327:-
BRCA	cis	rs13113518	1	rs4864548	ENSG00000272969.1	RP11-528I4.2	-4.32	1.67e-05	0.0013	-0.15	-0.13	Height;	chr4:55547636	chr4:55547112~55547889:+
BRCA	cis	rs9921338	0.961	rs11545336	ENSG00000262703.1	RP11-485G7.6	-4.32	1.67e-05	0.0013	-0.17	-0.13	Vein graft stenosis in coronary artery bypass grafting;	chr16:11345639	chr16:11348143~11349321:-
BRCA	cis	rs11711311	0.955	rs12630791	ENSG00000241529.3	RN7SL767P	4.32	1.67e-05	0.0013	0.16	0.13	IgG glycosylation;	chr3:113668870	chr3:113632704~113632998:+
BRCA	cis	rs17428076	0.751	rs788168	ENSG00000228389.1	AC068039.4	-4.32	1.67e-05	0.0013	-0.19	-0.13	Myopia;	chr2:172053071	chr2:171773482~171775844:+
BRCA	cis	rs2625529	0.73	rs2929528	ENSG00000260037.4	CTD-2524L6.3	4.32	1.67e-05	0.0013	0.17	0.13	Red blood cell count;	chr15:71976996	chr15:71818396~71823384:+
BRCA	cis	rs10946940	0.896	rs12208078	ENSG00000220721.1	OR1F12	-4.32	1.67e-05	0.0013	-0.15	-0.13	Systemic lupus erythematosus;	chr6:27530802	chr6:28073316~28074233:+
BRCA	cis	rs4664293	0.541	rs1425047	ENSG00000230783.1	AC009961.2	4.32	1.67e-05	0.0013	0.16	0.13	Monocyte percentage of white cells;	chr2:159517946	chr2:159689217~159690291:-
BRCA	cis	rs6125597	0.516	rs6019537	ENSG00000227431.4	CSE1L-AS1	-4.32	1.67e-05	0.0013	-0.16	-0.13	Intelligence (multi-trait analysis);	chr20:48927067	chr20:49040463~49046044:-
BRCA	cis	rs8040855	0.627	rs11637512	ENSG00000259774.1	RP11-182J1.13	4.32	1.67e-05	0.0013	0.19	0.13	Bulimia nervosa;	chr15:85105528	chr15:84422618~84425882:+
BRCA	cis	rs4654783	0.627	rs66766977	ENSG00000271428.1	RP1-224A6.8	4.32	1.68e-05	0.0013	0.14	0.13	Endometriosis;	chr1:22104599	chr1:22068340~22068827:-
BRCA	cis	rs2688608	0.53	rs71507081	ENSG00000213731.2	RAB5CP1	-4.32	1.68e-05	0.0013	-0.15	-0.13	Inflammatory bowel disease;	chr10:73733378	chr10:74423435~74424014:-
BRCA	cis	rs9840812	0.769	rs1279425	ENSG00000273486.1	RP11-731C17.2	4.32	1.68e-05	0.0013	0.16	0.13	Fibrinogen levels;	chr3:136288142	chr3:136837338~136839021:-
BRCA	cis	rs409045	1	rs455613	ENSG00000271874.1	CTD-2024P10.2	-4.32	1.68e-05	0.0013	-0.18	-0.13	Left ventricular mass;	chr5:34632561	chr5:34651457~34651888:-
BRCA	cis	rs409045	0.965	rs436961	ENSG00000271874.1	CTD-2024P10.2	-4.32	1.68e-05	0.0013	-0.18	-0.13	Left ventricular mass;	chr5:34633066	chr5:34651457~34651888:-
BRCA	cis	rs4415084	0.662	rs12109710	ENSG00000251141.4	RP11-53O19.1	-4.32	1.68e-05	0.0013	-0.13	-0.13	Breast cancer;	chr5:44929826	chr5:44744900~44808777:-
BRCA	cis	rs10411936	0.626	rs8109817	ENSG00000280332.1	CTD-2013N17.6	4.32	1.68e-05	0.0013	0.11	0.13	Multiple sclerosis;White blood cell count;	chr19:16477078	chr19:16356329~16358327:-
BRCA	cis	rs17489649	0.915	rs6897334	ENSG00000271849.1	CTC-332L22.1	4.32	1.68e-05	0.0013	0.17	0.13	Intelligence (multi-trait analysis);	chr5:109708857	chr5:109687802~109688329:-
BRCA	cis	rs1910358	0.554	rs13356462	ENSG00000248874.4	C5orf17	-4.32	1.68e-05	0.0013	-0.19	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23819849	chr5:23951348~24178263:+
BRCA	cis	rs11157436	0.602	rs11157435	ENSG00000211813.2	TRAV34	4.32	1.68e-05	0.0013	0.14	0.13	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22168888	chr14:22207522~22208129:+
BRCA	cis	rs4835473	0.722	rs7662277	ENSG00000249741.2	RP11-673E1.3	4.32	1.68e-05	0.0013	0.15	0.13	Immature fraction of reticulocytes;	chr4:143999485	chr4:143911514~143912053:-
BRCA	cis	rs739401	0.611	rs417957	ENSG00000183562.3	CTC-343N3.1	-4.32	1.68e-05	0.0013	-0.14	-0.13	Longevity;	chr11:3025001	chr11:2989863~2991344:+
BRCA	cis	rs4443100	0.77	rs6003472	ENSG00000230701.2	FBXW4P1	4.32	1.68e-05	0.0013	0.18	0.13	Serum parathyroid hormone levels;	chr22:23027658	chr22:23262767~23265005:+
BRCA	cis	rs7267979	1	rs6115153	ENSG00000274973.1	RP13-401N8.7	4.32	1.68e-05	0.0013	0.15	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25344931	chr20:25845497~25845862:+
BRCA	cis	rs736408	0.522	rs998909	ENSG00000243224.1	RP5-1157M23.2	-4.32	1.68e-05	0.0013	-0.14	-0.13	Bipolar disorder;	chr3:52771077	chr3:52239258~52241097:+
BRCA	cis	rs7260598	0.792	rs73031013	ENSG00000268442.1	CTD-2027I19.2	4.32	1.68e-05	0.0013	0.22	0.13	Response to taxane treatment (placlitaxel);	chr19:24182049	chr19:24162370~24163425:-
BRCA	cis	rs2554380	0.8	rs2562768	ENSG00000230373.7	GOLGA6L5P	4.32	1.68e-05	0.0013	0.18	0.13	Height;	chr15:83714201	chr15:84507885~84516814:-
BRCA	cis	rs8054556	1	rs3814881	ENSG00000261367.1	RP11-455F5.4	-4.32	1.68e-05	0.0013	-0.15	-0.13	Autism spectrum disorder or schizophrenia;	chr16:29989580	chr16:30107675~30110541:+
BRCA	cis	rs7260598	0.792	rs11669295	ENSG00000268442.1	CTD-2027I19.2	4.32	1.68e-05	0.0013	0.22	0.13	Response to taxane treatment (placlitaxel);	chr19:24154184	chr19:24162370~24163425:-
BRCA	cis	rs7260598	0.792	rs11670299	ENSG00000268442.1	CTD-2027I19.2	4.32	1.68e-05	0.0013	0.22	0.13	Response to taxane treatment (placlitaxel);	chr19:24154959	chr19:24162370~24163425:-
BRCA	cis	rs7267979	1	rs6115168	ENSG00000274973.1	RP13-401N8.7	4.32	1.68e-05	0.0013	0.15	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25392255	chr20:25845497~25845862:+
BRCA	cis	rs58521262	0.546	rs2927368	ENSG00000268105.1	RP11-369G6.2	4.32	1.68e-05	0.0013	0.18	0.13	Testicular germ cell tumor;	chr19:23049683	chr19:23125665~23128543:+
BRCA	cis	rs7475343	0.543	rs117488242	ENSG00000224034.1	RP11-445P17.8	-4.32	1.68e-05	0.0013	-0.27	-0.13	Intelligence;	chr10:5219869	chr10:5266033~5271236:-
BRCA	cis	rs2380205	0.967	rs12784539	ENSG00000232807.2	RP11-536K7.3	4.32	1.68e-05	0.00131	0.14	0.13	Breast cancer;	chr10:5856158	chr10:5934270~5945900:-
BRCA	cis	rs6671200	0.748	rs35051418	ENSG00000235501.4	RP4-639F20.1	-4.32	1.68e-05	0.00131	-0.29	-0.13	Stearic acid (18:0) levels;	chr1:95061405	chr1:94927566~94963270:+
BRCA	cis	rs6095360	0.934	rs2295580	ENSG00000222365.1	SNORD12B	-4.32	1.68e-05	0.00131	-0.14	-0.13	Intelligence (multi-trait analysis);	chr20:49010310	chr20:49280319~49280409:+
BRCA	cis	rs2880765	0.835	rs4360875	ENSG00000202081.1	RNU6-1280P	4.32	1.68e-05	0.00131	0.15	0.13	Coronary artery disease;	chr15:85497163	chr15:85651522~85651628:-
BRCA	cis	rs5765524	0.584	rs8138025	ENSG00000238120.1	CTA-941F9.9	-4.32	1.68e-05	0.00131	-0.14	-0.13	Red blood cell count;	chr22:45578877	chr22:45604432~45605621:-
BRCA	cis	rs7312933	0.558	rs7965743	ENSG00000257225.1	RP11-328C8.4	4.32	1.68e-05	0.00131	0.16	0.13	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42343020	chr12:42459366~42466128:+
BRCA	cis	rs4664293	0.867	rs2114626	ENSG00000226266.5	AC009961.3	4.32	1.68e-05	0.00131	0.17	0.13	Monocyte percentage of white cells;	chr2:159783459	chr2:159670708~159712435:-
BRCA	cis	rs1816213	1	rs34765129	ENSG00000273466.1	RP11-548H3.1	-4.32	1.68e-05	0.00131	-0.28	-0.13	Diastolic blood pressure;	chr2:218703524	chr2:218633256~218634014:-
BRCA	cis	rs2835872	0.965	rs17814920	ENSG00000228677.1	TTC3-AS1	-4.32	1.68e-05	0.00131	-0.17	-0.13	Electroencephalographic traits in alcoholism;	chr21:37643595	chr21:37187666~37193926:-
BRCA	cis	rs6439153	0.933	rs11711812	ENSG00000261159.1	RP11-723O4.9	4.32	1.68e-05	0.00131	0.14	0.13	Pneumococcal bacteremia;	chr3:128989711	chr3:128859716~128860526:-
BRCA	cis	rs6453278	0.559	rs13170206	ENSG00000250802.5	ZBED3-AS1	4.32	1.68e-05	0.00131	0.19	0.13	Autism;	chr5:77099990	chr5:77086740~77166909:+
BRCA	cis	rs2675662	0.525	rs12264025	ENSG00000213731.2	RAB5CP1	-4.32	1.68e-05	0.00131	-0.15	-0.13	Psoriasis vulgaris;Psoriasis;	chr10:73734692	chr10:74423435~74424014:-
BRCA	cis	rs11098499	0.82	rs28394116	ENSG00000250412.1	KLHL2P1	4.32	1.69e-05	0.00131	0.16	0.13	Corneal astigmatism;	chr4:119603128	chr4:119334329~119378233:+
BRCA	cis	rs2839186	0.967	rs17176131	ENSG00000239415.1	AP001469.9	4.32	1.69e-05	0.00131	0.14	0.13	Testicular germ cell tumor;	chr21:46285323	chr21:46251549~46254133:-
BRCA	cis	rs794185	0.517	rs711662	ENSG00000231249.1	ITPR1-AS1	4.32	1.69e-05	0.00131	0.17	0.13	Multiple sclerosis--Brain Glutamate Levels;	chr3:4421324	chr3:4490891~4493163:-
BRCA	cis	rs6547741	0.967	rs4665995	ENSG00000234072.1	AC074117.10	4.32	1.69e-05	0.00131	0.12	0.13	Oral cavity cancer;	chr2:27590960	chr2:27356246~27367622:+
BRCA	cis	rs6547741	0.967	rs4665996	ENSG00000234072.1	AC074117.10	4.32	1.69e-05	0.00131	0.12	0.13	Oral cavity cancer;	chr2:27591476	chr2:27356246~27367622:+
BRCA	cis	rs71636778	0.509	rs34667713	ENSG00000260063.1	RP5-968P14.2	-4.32	1.69e-05	0.00131	-0.3	-0.13	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26966187	chr1:26692132~26694131:-
BRCA	cis	rs801193	1	rs2707856	ENSG00000273142.1	RP11-458F8.4	-4.32	1.69e-05	0.00131	-0.11	-0.13	Aortic root size;	chr7:66746023	chr7:66902857~66906297:+
BRCA	cis	rs6121246	0.697	rs45557936	ENSG00000230613.1	HM13-AS1	4.32	1.69e-05	0.00131	0.2	0.13	Mean corpuscular hemoglobin;	chr20:31638887	chr20:31567707~31573263:-
BRCA	cis	rs7011507	0.617	rs10110839	ENSG00000233858.4	AC026904.1	-4.32	1.69e-05	0.00131	-0.17	-0.13	Inflammatory bowel disease;Ulcerative colitis;	chr8:48469716	chr8:48590401~48594621:+
BRCA	cis	rs721917	0.506	rs927452	ENSG00000278616.1	BEND3P3	-4.32	1.69e-05	0.00131	-0.12	-0.13	Chronic obstructive pulmonary disease;	chr10:79892510	chr10:79682997~79685436:+
BRCA	cis	rs757081	0.667	rs476890	ENSG00000184669.7	OR7E14P	-4.32	1.69e-05	0.00131	-0.2	-0.13	Systolic blood pressure;	chr11:17188415	chr11:17013998~17053024:+
BRCA	cis	rs757081	0.667	rs615424	ENSG00000184669.7	OR7E14P	-4.32	1.69e-05	0.00131	-0.2	-0.13	Systolic blood pressure;	chr11:17188934	chr11:17013998~17053024:+
BRCA	cis	rs7475343	0.501	rs3829125	ENSG00000224034.1	RP11-445P17.8	-4.32	1.69e-05	0.00131	-0.26	-0.13	Intelligence;	chr10:5205821	chr10:5266033~5271236:-
BRCA	cis	rs11673344	0.504	rs2118208	ENSG00000226686.6	LINC01535	4.32	1.69e-05	0.00131	0.17	0.13	Obesity-related traits;	chr19:37135573	chr19:37251912~37265535:+
BRCA	cis	rs11673344	0.504	rs2118209	ENSG00000226686.6	LINC01535	4.32	1.69e-05	0.00131	0.17	0.13	Obesity-related traits;	chr19:37135618	chr19:37251912~37265535:+
BRCA	cis	rs6671200	1	rs34396223	ENSG00000235501.4	RP4-639F20.1	-4.32	1.69e-05	0.00131	-0.32	-0.13	Stearic acid (18:0) levels;	chr1:95232272	chr1:94927566~94963270:+
BRCA	cis	rs911119	1	rs734801	ENSG00000270001.1	RP11-218C14.8	-4.32	1.69e-05	0.00131	-0.18	-0.13	Chronic kidney disease;	chr20:23632154	chr20:23631826~23632316:-
BRCA	cis	rs6840360	0.573	rs7692939	ENSG00000270265.1	RP11-731D1.4	-4.32	1.69e-05	0.00131	-0.15	-0.13	Intelligence (multi-trait analysis);	chr4:151337303	chr4:151333775~151353224:-
BRCA	cis	rs7267979	1	rs3761117	ENSG00000125804.12	FAM182A	4.32	1.69e-05	0.00131	0.17	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25407434	chr20:26054655~26086917:+
BRCA	cis	rs67981189	0.593	rs7154437	ENSG00000269927.1	RP6-91H8.3	4.32	1.69e-05	0.00131	0.16	0.13	Schizophrenia;	chr14:70974668	chr14:71141125~71143253:-
BRCA	cis	rs911119	0.955	rs6114201	ENSG00000270001.1	RP11-218C14.8	-4.32	1.69e-05	0.00131	-0.17	-0.13	Chronic kidney disease;	chr20:23626594	chr20:23631826~23632316:-
BRCA	cis	rs911119	0.955	rs6048952	ENSG00000270001.1	RP11-218C14.8	-4.32	1.69e-05	0.00131	-0.17	-0.13	Chronic kidney disease;	chr20:23626620	chr20:23631826~23632316:-
BRCA	cis	rs6480314	1	rs6480314	ENSG00000233590.1	RP11-153K11.3	4.32	1.69e-05	0.00131	0.21	0.13	Optic nerve measurement (disc area);	chr10:68207690	chr10:68233251~68242379:-
BRCA	cis	rs61931739	0.534	rs7133262	ENSG00000258794.3	DUX4L27	4.32	1.69e-05	0.00131	0.19	0.13	Morning vs. evening chronotype;	chr12:34126509	chr12:34208415~34209675:-
BRCA	cis	rs6547741	0.967	rs4665986	ENSG00000234072.1	AC074117.10	4.32	1.69e-05	0.00131	0.12	0.13	Oral cavity cancer;	chr2:27532301	chr2:27356246~27367622:+
BRCA	cis	rs8064024	0.676	rs56919624	ENSG00000267077.1	RP11-127I20.5	4.32	1.69e-05	0.00131	0.13	0.13	Cancer;	chr16:4827592	chr16:4795265~4796532:-
BRCA	cis	rs6968419	0.788	rs4276607	ENSG00000279086.1	RP11-667F14.1	-4.32	1.69e-05	0.00131	-0.15	-0.13	Intraocular pressure;	chr7:116181554	chr7:116209234~116211511:-
BRCA	cis	rs6968419	0.788	rs67915501	ENSG00000279086.1	RP11-667F14.1	-4.32	1.69e-05	0.00131	-0.15	-0.13	Intraocular pressure;	chr7:116181982	chr7:116209234~116211511:-
BRCA	cis	rs6968419	0.788	rs60671526	ENSG00000279086.1	RP11-667F14.1	-4.32	1.69e-05	0.00131	-0.15	-0.13	Intraocular pressure;	chr7:116183015	chr7:116209234~116211511:-
BRCA	cis	rs4650943	0.586	rs352303	ENSG00000227740.1	RP11-318C24.2	-4.32	1.7e-05	0.00131	-0.13	-0.13	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in inactive individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr1:176286127	chr1:175904762~175920513:-
BRCA	cis	rs7267979	0.565	rs6107060	ENSG00000204556.4	CTD-2514C3.1	-4.32	1.7e-05	0.00131	-0.18	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25611840	chr20:26018832~26020684:+
BRCA	cis	rs6545883	0.794	rs778152	ENSG00000212978.6	AC016747.3	-4.32	1.7e-05	0.00131	-0.18	-0.13	Tuberculosis;	chr2:61381405	chr2:61141592~61144969:-
BRCA	cis	rs6012564	1	rs2869716	ENSG00000227431.4	CSE1L-AS1	4.32	1.7e-05	0.00131	0.17	0.13	Anger;	chr20:49162803	chr20:49040463~49046044:-
BRCA	cis	rs910316	1	rs2098297	ENSG00000259138.1	RP11-950C14.7	-4.32	1.7e-05	0.00131	-0.14	-0.13	Height;	chr14:75152415	chr14:75127153~75136930:+
BRCA	cis	rs644148	0.967	rs2686778	ENSG00000176761.7	ZNF285B	4.32	1.7e-05	0.00131	0.15	0.13	Personality dimensions;	chr19:44468040	chr19:44467641~44473227:+
BRCA	cis	rs62025270	0.632	rs8029034	ENSG00000259762.1	RP11-158M2.4	-4.32	1.7e-05	0.00131	-0.2	-0.13	Idiopathic pulmonary fibrosis;	chr15:85582497	chr15:85750336~85752901:-
BRCA	cis	rs11098499	0.908	rs9995234	ENSG00000260404.2	RP11-384K6.6	4.32	1.7e-05	0.00132	0.13	0.13	Corneal astigmatism;	chr4:119400672	chr4:118591773~118633729:+
BRCA	cis	rs4650943	0.633	rs352296	ENSG00000227740.1	RP11-318C24.2	-4.32	1.7e-05	0.00132	-0.14	-0.13	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in inactive individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr1:176277331	chr1:175904762~175920513:-
BRCA	cis	rs4650943	0.565	rs396432	ENSG00000227740.1	RP11-318C24.2	-4.32	1.7e-05	0.00132	-0.14	-0.13	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in inactive individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr1:176278302	chr1:175904762~175920513:-
BRCA	cis	rs4650943	0.565	rs183033	ENSG00000227740.1	RP11-318C24.2	-4.32	1.7e-05	0.00132	-0.14	-0.13	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in inactive individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr1:176280413	chr1:175904762~175920513:-
BRCA	cis	rs950776	0.714	rs660652	ENSG00000279373.1	RP11-650L12.4	-4.32	1.7e-05	0.00132	-0.16	-0.13	Sudden cardiac arrest;	chr15:78595490	chr15:78537681~78538946:+
BRCA	cis	rs13326165	0.76	rs13075370	ENSG00000243224.1	RP5-1157M23.2	-4.32	1.7e-05	0.00132	-0.19	-0.13	HDL cholesterol levels;HDL cholesterol;	chr3:52365262	chr3:52239258~52241097:+
BRCA	cis	rs13326165	0.715	rs11709658	ENSG00000243224.1	RP5-1157M23.2	-4.32	1.7e-05	0.00132	-0.19	-0.13	HDL cholesterol levels;HDL cholesterol;	chr3:52365611	chr3:52239258~52241097:+
BRCA	cis	rs295490	0.748	rs78069957	ENSG00000272656.1	RP11-219D15.3	4.32	1.7e-05	0.00132	0.33	0.13	PR interval in Tripanosoma cruzi seropositivity;	chr3:139375970	chr3:139349024~139349371:-
BRCA	cis	rs17684571	0.751	rs10498812	ENSG00000231441.1	RP11-472M19.2	4.32	1.7e-05	0.00132	0.23	0.13	Schizophrenia;	chr6:56819412	chr6:56844002~56864078:+
BRCA	cis	rs17684571	0.751	rs13220628	ENSG00000231441.1	RP11-472M19.2	4.32	1.7e-05	0.00132	0.23	0.13	Schizophrenia;	chr6:56819445	chr6:56844002~56864078:+
BRCA	cis	rs2255336	0.873	rs12301897	ENSG00000245648.1	RP11-277P12.20	-4.32	1.7e-05	0.00132	-0.22	-0.13	Blood protein levels;	chr12:10491974	chr12:10363769~10398506:+
BRCA	cis	rs7927592	0.763	rs10896326	ENSG00000212093.1	AP000807.1	4.32	1.7e-05	0.00132	0.14	0.13	Total body bone mineral density;	chr11:68467103	chr11:68506083~68506166:-
BRCA	cis	rs7927592	0.763	rs10896327	ENSG00000212093.1	AP000807.1	4.32	1.7e-05	0.00132	0.14	0.13	Total body bone mineral density;	chr11:68467807	chr11:68506083~68506166:-
BRCA	cis	rs7200543	0.583	rs4985149	ENSG00000275910.1	RP11-680G24.6	-4.32	1.7e-05	0.00132	-0.16	-0.13	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15053481	chr16:15015828~15016390:-
BRCA	cis	rs17784882	0.521	rs11713693	ENSG00000276925.1	RP11-708J19.3	4.32	1.7e-05	0.00132	0.16	0.13	QT interval;	chr3:47033416	chr3:47469777~47469987:+
BRCA	cis	rs10911902	0.866	rs3119331	ENSG00000229739.2	RP11-295K2.3	4.32	1.7e-05	0.00132	0.19	0.13	Schizophrenia;	chr1:186465386	chr1:186435161~186470291:+
BRCA	cis	rs10411936	0.72	rs7252649	ENSG00000280332.1	CTD-2013N17.6	4.32	1.7e-05	0.00132	0.11	0.13	Multiple sclerosis;White blood cell count;	chr19:16471974	chr19:16356329~16358327:-
BRCA	cis	rs7618915	0.501	rs3755798	ENSG00000243224.1	RP5-1157M23.2	-4.32	1.7e-05	0.00132	-0.14	-0.13	Bipolar disorder;	chr3:52707144	chr3:52239258~52241097:+
BRCA	cis	rs78487399	0.808	rs111783562	ENSG00000234936.1	AC010883.5	4.32	1.7e-05	0.00132	0.21	0.13	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43532242	chr2:43229573~43233394:+
BRCA	cis	rs71520386	0.634	rs13240023	ENSG00000226329.2	AC005682.6	-4.32	1.7e-05	0.00132	-0.14	-0.13	Fibrinogen levels;	chr7:22827874	chr7:22863874~22881350:-
BRCA	cis	rs62458065	1	rs10275978	ENSG00000229358.3	DPY19L1P1	-4.32	1.7e-05	0.00132	-0.18	-0.13	Metabolite levels (HVA/MHPG ratio);	chr7:32427107	chr7:32580949~32761787:-
BRCA	cis	rs816535	1	rs816535	ENSG00000274973.1	RP13-401N8.7	-4.32	1.7e-05	0.00132	-0.19	-0.13	Parkinson disease and lewy body pathology;	chr20:26275360	chr20:25845497~25845862:+
BRCA	cis	rs997295	0.713	rs9302245	ENSG00000270964.1	RP11-502I4.3	-4.32	1.7e-05	0.00132	-0.15	-0.13	Motion sickness;	chr15:67728799	chr15:67541072~67542604:-
BRCA	cis	rs3858526	0.917	rs10769386	ENSG00000224295.2	AC087380.14	-4.32	1.7e-05	0.00132	-0.19	-0.13	DNA methylation (variation);	chr11:5952190	chr11:5518441~5524955:-
BRCA	cis	rs2688608	0.592	rs11814282	ENSG00000213731.2	RAB5CP1	-4.32	1.7e-05	0.00132	-0.15	-0.13	Inflammatory bowel disease;	chr10:73730459	chr10:74423435~74424014:-
BRCA	cis	rs8180040	0.726	rs4234465	ENSG00000271161.1	BOLA2P2	4.32	1.7e-05	0.00132	0.14	0.13	Colorectal cancer;	chr3:46985395	chr3:47499841~47500407:+
BRCA	cis	rs1371614	0.611	rs540490	ENSG00000272148.1	RP11-195B17.1	-4.32	1.7e-05	0.00132	-0.15	-0.13	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26909954	chr2:27062428~27062907:-
BRCA	cis	rs10435719	0.902	rs4840599	ENSG00000255495.1	AC145124.2	-4.32	1.7e-05	0.00132	-0.15	-0.13	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11947871	chr8:12194467~12196280:+
BRCA	cis	rs1982963	1	rs753050	ENSG00000277050.1	RP11-102G14.1	-4.32	1.7e-05	0.00132	-0.17	-0.13	Waist-to-hip ratio adjusted for body mass index;	chr14:52038657	chr14:51637348~51637947:-
BRCA	cis	rs7686660	1	rs2322946	ENSG00000250326.1	RP11-284M14.1	-4.32	1.7e-05	0.00132	-0.16	-0.13	Asthma;	chr4:143039406	chr4:142933195~143184861:-
BRCA	cis	rs7686660	1	rs3967122	ENSG00000250326.1	RP11-284M14.1	-4.32	1.7e-05	0.00132	-0.16	-0.13	Asthma;	chr4:143039785	chr4:142933195~143184861:-
BRCA	cis	rs7686660	1	rs12508217	ENSG00000250326.1	RP11-284M14.1	-4.32	1.7e-05	0.00132	-0.16	-0.13	Asthma;	chr4:143041857	chr4:142933195~143184861:-
BRCA	cis	rs7665090	1	rs909349	ENSG00000251288.2	RP11-10L12.2	4.32	1.7e-05	0.00132	0.16	0.13	Primary biliary cholangitis;	chr4:102635159	chr4:102751401~102752641:+
BRCA	cis	rs11083475	1	rs12462270	ENSG00000267892.1	CTD-2540F13.2	4.32	1.7e-05	0.00132	0.15	0.13	Heart rate;	chr19:38710848	chr19:38738284~38739863:+
BRCA	cis	rs11083475	1	rs2279144	ENSG00000267892.1	CTD-2540F13.2	4.32	1.7e-05	0.00132	0.15	0.13	Heart rate;	chr19:38711141	chr19:38738284~38739863:+
BRCA	cis	rs10861342	0.892	rs7966106	ENSG00000257999.1	RP11-61E11.2	4.32	1.71e-05	0.00132	0.26	0.13	IgG glycosylation;	chr12:105221494	chr12:105102472~105107179:-
BRCA	cis	rs7569084	0.663	rs6546150	ENSG00000281920.1	RP11-418H16.1	-4.32	1.71e-05	0.00132	-0.17	-0.13	Sum eosinophil basophil counts;	chr2:65415066	chr2:65623272~65628424:+
BRCA	cis	rs2303319	0.504	rs55841284	ENSG00000227403.1	AC009299.3	4.32	1.71e-05	0.00132	0.31	0.13	Cognitive function;	chr2:161703501	chr2:161244739~161249050:+
BRCA	cis	rs2303319	0.582	rs56315911	ENSG00000227403.1	AC009299.3	4.32	1.71e-05	0.00132	0.31	0.13	Cognitive function;	chr2:161703676	chr2:161244739~161249050:+
BRCA	cis	rs56322409	0.897	rs10509686	ENSG00000226688.5	ENTPD1-AS1	4.32	1.71e-05	0.00132	0.15	0.13	Blood metabolite levels;	chr10:95817989	chr10:95753206~96090238:-
BRCA	cis	rs1510272	0.847	rs6441085	ENSG00000243926.1	TIPARP-AS1	-4.32	1.71e-05	0.00132	-0.15	-0.13	Testicular germ cell tumor;	chr3:156607673	chr3:156671862~156674378:-
BRCA	cis	rs644148	0.836	rs2571112	ENSG00000176761.7	ZNF285B	4.32	1.71e-05	0.00132	0.15	0.13	Personality dimensions;	chr19:44496258	chr19:44467641~44473227:+
BRCA	cis	rs11083475	1	rs3745859	ENSG00000267892.1	CTD-2540F13.2	4.32	1.71e-05	0.00132	0.15	0.13	Heart rate;	chr19:38706105	chr19:38738284~38739863:+
BRCA	cis	rs7267979	0.932	rs446649	ENSG00000277938.1	RP5-965G21.3	4.32	1.71e-05	0.00132	0.16	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25486723	chr20:25229150~25231933:+
BRCA	cis	rs4671400	0.571	rs68020555	ENSG00000273302.1	RP11-493E12.2	-4.32	1.71e-05	0.00132	-0.12	-0.13	3-hydroxypropylmercapturic acid levels in smokers;	chr2:61258647	chr2:61199979~61200769:+
BRCA	cis	rs12144610	0.515	rs61806207	ENSG00000236804.1	RPS3AP12	4.32	1.71e-05	0.00132	0.26	0.13	Lobe attachment (rater-scored or self-reported);	chr1:118953802	chr1:119126539~119127291:-
BRCA	cis	rs6545883	0.894	rs2463102	ENSG00000212978.6	AC016747.3	-4.32	1.71e-05	0.00132	-0.18	-0.13	Tuberculosis;	chr2:61344160	chr2:61141592~61144969:-
BRCA	cis	rs4374383	0.962	rs11683819	ENSG00000243389.1	AC012442.5	4.32	1.71e-05	0.00132	0.17	0.13	Hepatitis C induced liver fibrosis;	chr2:112020864	chr2:112589040~112614431:+
BRCA	cis	rs11098499	0.913	rs10010696	ENSG00000260091.1	RP11-33B1.4	-4.32	1.71e-05	0.00132	-0.12	-0.13	Corneal astigmatism;	chr4:119243148	chr4:119409333~119410233:+
BRCA	cis	rs718433	0.584	rs7142784	ENSG00000256379.1	TRAV8-5	4.32	1.71e-05	0.00132	0.15	0.13	Intraocular pressure;	chr14:21745516	chr14:21903077~21903598:+
BRCA	cis	rs7182948	1	rs1605483	ENSG00000259531.2	RP11-295H24.3	-4.32	1.71e-05	0.00132	-0.19	-0.13	Lung adenocarcinoma;	chr15:49533639	chr15:49365124~49366685:-
BRCA	cis	rs6545883	0.63	rs12998475	ENSG00000273302.1	RP11-493E12.2	-4.32	1.71e-05	0.00132	-0.12	-0.13	Tuberculosis;	chr2:61210352	chr2:61199979~61200769:+
BRCA	cis	rs4143844	1	rs11071644	ENSG00000259251.2	RP11-643M14.1	4.32	1.71e-05	0.00132	0.32	0.13	Bipolar disorder and schizophrenia;	chr15:61969565	chr15:62060503~62062434:+
BRCA	cis	rs7647973	0.922	rs7620024	ENSG00000244380.1	RP11-24C3.2	-4.32	1.71e-05	0.00132	-0.17	-0.13	Menarche (age at onset);	chr3:49414258	chr3:48440352~48446656:-
BRCA	cis	rs1113500	0.547	rs12076264	ENSG00000230489.1	VAV3-AS1	4.32	1.71e-05	0.00132	0.15	0.13	Growth-regulated protein alpha levels;	chr1:108014486	chr1:107964443~107994607:+
BRCA	cis	rs9307551	0.948	rs13112577	ENSG00000250334.4	LINC00989	-4.32	1.71e-05	0.00132	-0.2	-0.13	Refractive error;	chr4:79561246	chr4:79492416~79576460:+
BRCA	cis	rs4908769	0.624	rs1763838	ENSG00000270282.1	RP5-1115A15.2	4.32	1.71e-05	0.00132	0.15	0.13	Allergy;	chr1:8413271	chr1:8512653~8513021:+
BRCA	cis	rs12612435	0.747	rs6728052	ENSG00000226806.1	AC011893.3	4.32	1.71e-05	0.00132	0.15	0.13	Takotsubo syndrome;	chr2:136367471	chr2:135820191~135823087:+
BRCA	cis	rs12612435	0.747	rs1399604	ENSG00000226806.1	AC011893.3	4.32	1.71e-05	0.00132	0.15	0.13	Takotsubo syndrome;	chr2:136373095	chr2:135820191~135823087:+
BRCA	cis	rs7260598	0.792	rs17620072	ENSG00000268442.1	CTD-2027I19.2	4.32	1.71e-05	0.00132	0.22	0.13	Response to taxane treatment (placlitaxel);	chr19:24177850	chr19:24162370~24163425:-
BRCA	cis	rs7260598	0.792	rs73031010	ENSG00000268442.1	CTD-2027I19.2	4.32	1.71e-05	0.00132	0.22	0.13	Response to taxane treatment (placlitaxel);	chr19:24178160	chr19:24162370~24163425:-
BRCA	cis	rs7260598	0.792	rs7260592	ENSG00000268442.1	CTD-2027I19.2	4.32	1.71e-05	0.00132	0.22	0.13	Response to taxane treatment (placlitaxel);	chr19:24178786	chr19:24162370~24163425:-
BRCA	cis	rs12744310	0.887	rs2363810	ENSG00000235358.1	RP11-399E6.1	4.32	1.71e-05	0.00132	0.19	0.13	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41318201	chr1:41242373~41284861:+
BRCA	cis	rs11098499	0.955	rs11931312	ENSG00000250412.1	KLHL2P1	4.32	1.71e-05	0.00132	0.16	0.13	Corneal astigmatism;	chr4:119237868	chr4:119334329~119378233:+
BRCA	cis	rs11892454	0.544	rs7582924	ENSG00000217643.1	PTGES3P2	-4.32	1.71e-05	0.00132	-0.14	-0.13	Heschl's gyrus morphology;	chr2:25774151	chr2:25822469~25822950:+
BRCA	cis	rs11892454	0.544	rs11894959	ENSG00000217643.1	PTGES3P2	-4.32	1.71e-05	0.00132	-0.14	-0.13	Heschl's gyrus morphology;	chr2:25774952	chr2:25822469~25822950:+
BRCA	cis	rs11892454	0.544	rs10490569	ENSG00000217643.1	PTGES3P2	-4.32	1.71e-05	0.00132	-0.14	-0.13	Heschl's gyrus morphology;	chr2:25778558	chr2:25822469~25822950:+
BRCA	cis	rs4415084	0.834	rs7716571	ENSG00000251141.4	RP11-53O19.1	4.32	1.71e-05	0.00133	0.12	0.13	Breast cancer;	chr5:44816882	chr5:44744900~44808777:-
BRCA	cis	rs11673344	0.504	rs11084874	ENSG00000226686.6	LINC01535	4.32	1.71e-05	0.00133	0.17	0.13	Obesity-related traits;	chr19:37096667	chr19:37251912~37265535:+
BRCA	cis	rs4660214	0.671	rs16826012	ENSG00000182109.6	RP11-69E11.4	-4.32	1.71e-05	0.00133	-0.2	-0.13	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39253847	chr1:39522280~39546187:-
BRCA	cis	rs6738627	0.737	rs10184004	ENSG00000223318.1	RNA5SP111	4.32	1.71e-05	0.00133	0.15	0.13	circulating leptin levels adjusted for BMI;Body fat percentage;circulating leptin levels;	chr2:164651879	chr2:164895677~164895777:-
BRCA	cis	rs6430585	0.697	rs1050115	ENSG00000224043.6	CCNT2-AS1	-4.32	1.71e-05	0.00133	-0.23	-0.13	Corneal structure;	chr2:135754247	chr2:134735464~134918710:-
BRCA	cis	rs875971	0.83	rs4718358	ENSG00000229180.5	GS1-124K5.11	4.32	1.71e-05	0.00133	0.11	0.13	Aortic root size;	chr7:66508681	chr7:66526088~66542624:-
BRCA	cis	rs7412746	0.611	rs4970985	ENSG00000231073.1	RP11-316M1.3	-4.32	1.71e-05	0.00133	-0.14	-0.13	Melanoma;	chr1:150914966	chr1:150973123~150975534:+
BRCA	cis	rs38055	0.958	rs251520	ENSG00000247796.2	CTD-2366F13.1	-4.32	1.71e-05	0.00133	-0.16	-0.13	Acne (severe);	chr5:53285842	chr5:53109842~53115126:+
BRCA	cis	rs7267979	0.966	rs6037097	ENSG00000277938.1	RP5-965G21.3	4.32	1.71e-05	0.00133	0.16	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25366585	chr20:25229150~25231933:+
BRCA	cis	rs1223397	1	rs1223397	ENSG00000215022.6	RP1-257A7.4	-4.32	1.71e-05	0.00133	-0.17	-0.13	Blood pressure;	chr6:13270713	chr6:13264861~13295586:-
BRCA	cis	rs934734	0.532	rs7569113	ENSG00000281920.1	RP11-418H16.1	4.32	1.71e-05	0.00133	0.16	0.13	Rheumatoid arthritis;	chr2:65429907	chr2:65623272~65628424:+
BRCA	cis	rs7267979	0.966	rs4815425	ENSG00000277938.1	RP5-965G21.3	-4.32	1.71e-05	0.00133	-0.16	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25418240	chr20:25229150~25231933:+
BRCA	cis	rs11098499	0.754	rs938056	ENSG00000225892.3	RP11-384K6.2	4.32	1.71e-05	0.00133	0.13	0.13	Corneal astigmatism;	chr4:119316298	chr4:118632274~118634759:+
BRCA	cis	rs2625529	0.667	rs16956381	ENSG00000260037.4	CTD-2524L6.3	-4.32	1.71e-05	0.00133	-0.19	-0.13	Red blood cell count;	chr15:71900896	chr15:71818396~71823384:+
BRCA	cis	rs4780355	0.619	rs918737	ENSG00000262703.1	RP11-485G7.6	-4.32	1.71e-05	0.00133	-0.14	-0.13	Crohn's disease and psoriasis;	chr16:11345782	chr16:11348143~11349321:-
BRCA	cis	rs2391285	0.609	rs2107996	ENSG00000214870.7	AC004540.5	4.32	1.71e-05	0.00133	0.2	0.13	Post bronchodilator FEV1/FVC ratio;	chr7:26558871	chr7:26398593~26494256:+
BRCA	cis	rs10849893	0.576	rs7296507	ENSG00000258435.1	RP11-711D18.2	-4.32	1.71e-05	0.00133	-0.14	-0.13	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr12:121409332	chr12:121391962~121399859:+
BRCA	cis	rs2625529	0.652	rs3759820	ENSG00000260037.4	CTD-2524L6.3	4.32	1.71e-05	0.00133	0.17	0.13	Red blood cell count;	chr15:72007690	chr15:71818396~71823384:+
BRCA	cis	rs10995356	0.932	rs10822084	ENSG00000238280.1	RP11-436D10.3	-4.32	1.71e-05	0.00133	-0.18	-0.13	Temperament;	chr10:62918211	chr10:62793562~62805887:-
BRCA	cis	rs644148	0.867	rs2571060	ENSG00000176761.7	ZNF285B	4.32	1.71e-05	0.00133	0.15	0.13	Personality dimensions;	chr19:44467430	chr19:44467641~44473227:+
BRCA	cis	rs2273156	1	rs35797365	ENSG00000226677.3	IGBP1P1	-4.32	1.71e-05	0.00133	-0.2	-0.13	Immunoglobulin light chain (AL) amyloidosis;	chr14:34983553	chr14:34939324~34940332:+
BRCA	cis	rs12612619	0.732	rs6547355	ENSG00000272148.1	RP11-195B17.1	4.32	1.71e-05	0.00133	0.15	0.13	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:26987337	chr2:27062428~27062907:-
BRCA	cis	rs11096990	0.634	rs6531703	ENSG00000249685.1	RP11-360F5.3	-4.32	1.71e-05	0.00133	-0.16	-0.13	Cognitive function;	chr4:39281786	chr4:39133913~39135608:+
BRCA	cis	rs13113518	0.966	rs13144598	ENSG00000272969.1	RP11-528I4.2	4.32	1.71e-05	0.00133	0.15	0.13	Height;	chr4:55570311	chr4:55547112~55547889:+
BRCA	cis	rs7927592	0.763	rs7120876	ENSG00000212093.1	AP000807.1	4.32	1.71e-05	0.00133	0.14	0.13	Total body bone mineral density;	chr11:68493930	chr11:68506083~68506166:-
BRCA	cis	rs4835473	0.868	rs4350958	ENSG00000249741.2	RP11-673E1.3	-4.32	1.72e-05	0.00133	-0.15	-0.13	Immature fraction of reticulocytes;	chr4:143744656	chr4:143911514~143912053:-
BRCA	cis	rs9532580	0.614	rs2180961	ENSG00000168852.11	TPTE2P5	4.32	1.72e-05	0.00133	0.18	0.13	Mean corpuscular hemoglobin;	chr13:40565907	chr13:40822296~40921749:-
BRCA	cis	rs2154319	0.609	rs3899207	ENSG00000235358.1	RP11-399E6.1	-4.32	1.72e-05	0.00133	-0.18	-0.13	Height;	chr1:41256005	chr1:41242373~41284861:+
BRCA	cis	rs867371	1	rs11855089	ENSG00000278603.1	RP13-608F4.5	4.32	1.72e-05	0.00133	0.18	0.13	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82154924	chr15:82472203~82472426:+
BRCA	cis	rs62025270	0.593	rs62022926	ENSG00000259295.5	CSPG4P12	-4.32	1.72e-05	0.00133	-0.21	-0.13	Idiopathic pulmonary fibrosis;	chr15:85696261	chr15:85191438~85213905:+
BRCA	cis	rs6128907	1	rs6128918	ENSG00000224635.1	RP4-564F22.5	4.32	1.72e-05	0.00133	0.21	0.13	Liver fibrosis in pediatric non-alcoholic fatty acid liver disease;	chr20:38762789	chr20:38406011~38416797:-
BRCA	cis	rs2380205	0.967	rs4293038	ENSG00000232807.2	RP11-536K7.3	4.32	1.72e-05	0.00133	0.14	0.13	Breast cancer;	chr10:5856196	chr10:5934270~5945900:-
BRCA	cis	rs6671200	0.607	rs3767313	ENSG00000235501.4	RP4-639F20.1	4.32	1.72e-05	0.00133	0.22	0.13	Stearic acid (18:0) levels;	chr1:95247241	chr1:94927566~94963270:+
BRCA	cis	rs6671200	0.573	rs3820345	ENSG00000235501.4	RP4-639F20.1	4.32	1.72e-05	0.00133	0.22	0.13	Stearic acid (18:0) levels;	chr1:95247619	chr1:94927566~94963270:+
BRCA	cis	rs6671200	0.688	rs4950024	ENSG00000235501.4	RP4-639F20.1	4.32	1.72e-05	0.00133	0.22	0.13	Stearic acid (18:0) levels;	chr1:95247943	chr1:94927566~94963270:+
BRCA	cis	rs8180040	0.726	rs7628747	ENSG00000276925.1	RP11-708J19.3	-4.32	1.72e-05	0.00133	-0.15	-0.13	Colorectal cancer;	chr3:46960500	chr3:47469777~47469987:+
BRCA	cis	rs9844666	0.512	rs4718	ENSG00000273486.1	RP11-731C17.2	4.32	1.72e-05	0.00133	0.16	0.13	Height;	chr3:135925965	chr3:136837338~136839021:-
BRCA	cis	rs12612619	0.695	rs11126806	ENSG00000229122.1	AGBL5-IT1	-4.32	1.72e-05	0.00133	-0.14	-0.13	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27002276	chr2:27061038~27061815:+
BRCA	cis	rs9500256	0.967	rs1012500	ENSG00000272541.1	XXbac-BPGBPG55C20.1	-4.32	1.72e-05	0.00133	-0.14	-0.13	Eosinophilic esophagitis (pediatric);	chr6:57978391	chr6:57855891~57856468:-
BRCA	cis	rs1008375	1	rs28552744	ENSG00000249502.1	AC006160.5	-4.32	1.72e-05	0.00133	-0.15	-0.13	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17618542	chr4:17587467~17614571:-
BRCA	cis	rs7727544	0.716	rs10058655	ENSG00000233006.5	AC034220.3	4.32	1.72e-05	0.00133	0.1	0.13	Blood metabolite levels;	chr5:132235203	chr5:132311285~132369916:-
BRCA	cis	rs970548	0.73	rs61854093	ENSG00000230869.1	CTGLF10P	4.32	1.72e-05	0.00133	0.19	0.13	Total cholesterol levels;HDL cholesterol;HDL cholesterol levels;Cholesterol, total;	chr10:45439433	chr10:45678692~45700532:+
BRCA	cis	rs1075265	0.626	rs805412	ENSG00000235937.1	AC008280.1	4.32	1.72e-05	0.00133	0.15	0.13	Chronotype;Morning vs. evening chronotype;	chr2:53893683	chr2:54029552~54030682:-
BRCA	cis	rs9308731	0.591	rs7569300	ENSG00000230499.1	AC108463.1	-4.32	1.72e-05	0.00133	-0.15	-0.13	Chronic lymphocytic leukemia;	chr2:111187296	chr2:111195963~111206494:+
BRCA	cis	rs9308731	0.569	rs7585054	ENSG00000230499.1	AC108463.1	-4.32	1.72e-05	0.00133	-0.15	-0.13	Chronic lymphocytic leukemia;	chr2:111187350	chr2:111195963~111206494:+
BRCA	cis	rs9308731	0.591	rs7588534	ENSG00000230499.1	AC108463.1	-4.32	1.72e-05	0.00133	-0.15	-0.13	Chronic lymphocytic leukemia;	chr2:111187510	chr2:111195963~111206494:+
BRCA	cis	rs7932354	0.583	rs10769211	ENSG00000200376.1	RNU5E-10P	4.32	1.72e-05	0.00133	0.16	0.13	Bone mineral density (hip);Bone mineral density;	chr11:46851322	chr11:47576471~47576588:-
BRCA	cis	rs2243480	1	rs34193460	ENSG00000222364.1	RNU6-96P	-4.32	1.72e-05	0.00133	-0.24	-0.13	Diabetic kidney disease;	chr7:65928123	chr7:66395191~66395286:+
BRCA	cis	rs7937890	0.535	rs2575857	ENSG00000254418.1	RP11-21L19.1	4.32	1.72e-05	0.00133	0.16	0.13	Mitochondrial DNA levels;	chr11:14479750	chr11:14262846~14273691:-
BRCA	cis	rs4671400	0.602	rs2694623	ENSG00000273302.1	RP11-493E12.2	-4.32	1.72e-05	0.00133	-0.15	-0.13	3-hydroxypropylmercapturic acid levels in smokers;	chr2:61326331	chr2:61199979~61200769:+
BRCA	cis	rs216345	0.705	rs307661	ENSG00000260947.1	RP11-384P7.7	4.32	1.72e-05	0.00133	0.14	0.13	Bipolar disorder;	chr9:33960154	chr9:33697459~33700986:+
BRCA	cis	rs4948275	0.693	rs753246	ENSG00000237233.2	TMEM26-AS1	-4.32	1.72e-05	0.00133	-0.16	-0.13	Night sleep phenotypes;	chr10:61582729	chr10:61452639~61481956:+
BRCA	cis	rs2803122	0.502	rs1854552	ENSG00000272842.1	RP11-513M16.7	4.32	1.72e-05	0.00133	0.15	0.13	Pulse pressure;	chr9:19235049	chr9:19371386~19371945:-
BRCA	cis	rs8054556	1	rs10871451	ENSG00000261367.1	RP11-455F5.4	-4.32	1.72e-05	0.00133	-0.14	-0.13	Autism spectrum disorder or schizophrenia;	chr16:29974884	chr16:30107675~30110541:+
BRCA	cis	rs6600671	1	rs12047116	ENSG00000231429.2	RP11-343N15.2	-4.32	1.72e-05	0.00133	-0.16	-0.13	Hip geometry;	chr1:121443912	chr1:121412719~121429274:+
BRCA	cis	rs6600671	0.967	rs11249347	ENSG00000231429.2	RP11-343N15.2	-4.32	1.72e-05	0.00133	-0.16	-0.13	Hip geometry;	chr1:121446489	chr1:121412719~121429274:+
BRCA	cis	rs7267979	0.789	rs6083841	ENSG00000277938.1	RP5-965G21.3	-4.32	1.72e-05	0.00133	-0.16	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25403928	chr20:25229150~25231933:+
BRCA	cis	rs2613964	1	rs2613964	ENSG00000240057.4	RP11-572M11.4	-4.32	1.72e-05	0.00133	-0.14	-0.13	Pediatric bone mineral content (spine);Pediatric bone mineral density (spine);	chr3:113141933	chr3:113019532~113183301:+
BRCA	cis	rs9818758	0.607	rs73082362	ENSG00000270441.1	RP11-694I15.7	4.32	1.72e-05	0.00133	0.32	0.13	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49076296	chr3:49140086~49160851:-
BRCA	cis	rs2380205	0.967	rs12255077	ENSG00000232807.2	RP11-536K7.3	4.32	1.72e-05	0.00133	0.14	0.13	Breast cancer;	chr10:5856023	chr10:5934270~5945900:-
BRCA	cis	rs17489649	1	rs2301015	ENSG00000271849.1	CTC-332L22.1	4.32	1.72e-05	0.00133	0.17	0.13	Intelligence (multi-trait analysis);	chr5:109807685	chr5:109687802~109688329:-
BRCA	cis	rs9921338	0.668	rs193778	ENSG00000262703.1	RP11-485G7.6	-4.32	1.73e-05	0.00134	-0.17	-0.13	Vein graft stenosis in coronary artery bypass grafting;	chr16:11257354	chr16:11348143~11349321:-
BRCA	cis	rs2255336	0.938	rs7953692	ENSG00000245648.1	RP11-277P12.20	-4.32	1.73e-05	0.00134	-0.21	-0.13	Blood protein levels;	chr12:10482432	chr12:10363769~10398506:+
BRCA	cis	rs6831352	0.734	rs2602857	ENSG00000272777.1	RP11-571L19.8	-4.32	1.73e-05	0.00134	-0.14	-0.13	Alcohol dependence;	chr4:99109167	chr4:99067256~99068125:-
BRCA	cis	rs2243480	1	rs57057549	ENSG00000222364.1	RNU6-96P	-4.32	1.73e-05	0.00134	-0.24	-0.13	Diabetic kidney disease;	chr7:65940751	chr7:66395191~66395286:+
BRCA	cis	rs6071166	0.683	rs6027216	ENSG00000224635.1	RP4-564F22.5	-4.32	1.73e-05	0.00134	-0.16	-0.13	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38678271	chr20:38406011~38416797:-
BRCA	cis	rs6847067	0.672	rs7692223	ENSG00000180769.7	WDFY3-AS2	4.32	1.73e-05	0.00134	0.13	0.13	Oropharynx cancer;	chr4:84971538	chr4:84965682~85011277:+
BRCA	cis	rs1075265	0.901	rs7591194	ENSG00000235937.1	AC008280.1	-4.32	1.73e-05	0.00134	-0.14	-0.13	Chronotype;Morning vs. evening chronotype;	chr2:54086699	chr2:54029552~54030682:-
BRCA	cis	rs1950832	0.689	rs712406	ENSG00000258636.1	CTD-2298J14.2	4.32	1.73e-05	0.00134	0.15	0.13	Urate levels in obese individuals;	chr14:41645115	chr14:41587861~41604856:-
BRCA	cis	rs6547741	1	rs13026621	ENSG00000234072.1	AC074117.10	4.32	1.73e-05	0.00134	0.12	0.13	Oral cavity cancer;	chr2:27584757	chr2:27356246~27367622:+
BRCA	cis	rs7475343	0.501	rs76551580	ENSG00000224034.1	RP11-445P17.8	-4.32	1.73e-05	0.00134	-0.26	-0.13	Intelligence;	chr10:5214871	chr10:5266033~5271236:-
BRCA	cis	rs2839186	0.786	rs7409792	ENSG00000239415.1	AP001469.9	4.32	1.73e-05	0.00134	0.14	0.13	Testicular germ cell tumor;	chr21:46271815	chr21:46251549~46254133:-
BRCA	cis	rs11098499	0.908	rs1002152	ENSG00000260404.2	RP11-384K6.6	4.32	1.73e-05	0.00134	0.13	0.13	Corneal astigmatism;	chr4:119352232	chr4:118591773~118633729:+
BRCA	cis	rs2115630	0.967	rs28595395	ENSG00000259295.5	CSPG4P12	-4.32	1.73e-05	0.00134	-0.16	-0.13	P wave terminal force;	chr15:84791721	chr15:85191438~85213905:+
BRCA	cis	rs757081	0.637	rs34941502	ENSG00000184669.7	OR7E14P	-4.32	1.73e-05	0.00134	-0.2	-0.13	Systolic blood pressure;	chr11:17133885	chr11:17013998~17053024:+
BRCA	cis	rs7267979	0.966	rs2261698	ENSG00000277938.1	RP5-965G21.3	4.32	1.73e-05	0.00134	0.16	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25279274	chr20:25229150~25231933:+
BRCA	cis	rs924712	0.509	rs9475038	ENSG00000224984.1	RP11-524H19.2	4.32	1.73e-05	0.00134	0.16	0.13	Breast cancer;	chr6:54840247	chr6:54840118~54840855:-
BRCA	cis	rs7727544	0.716	rs72793278	ENSG00000233006.5	AC034220.3	4.32	1.73e-05	0.00134	0.1	0.13	Blood metabolite levels;	chr5:132225679	chr5:132311285~132369916:-
BRCA	cis	rs7727544	0.716	rs4705926	ENSG00000233006.5	AC034220.3	4.32	1.73e-05	0.00134	0.1	0.13	Blood metabolite levels;	chr5:132226065	chr5:132311285~132369916:-
BRCA	cis	rs2380205	0.967	rs9663995	ENSG00000232807.2	RP11-536K7.3	4.32	1.73e-05	0.00134	0.14	0.13	Breast cancer;	chr10:5855981	chr10:5934270~5945900:-
BRCA	cis	rs7819412	0.74	rs7844536	ENSG00000154316.13	TDH	4.32	1.73e-05	0.00134	0.17	0.13	Triglycerides;	chr8:11176519	chr8:11339637~11368452:+
BRCA	cis	rs9291683	0.527	rs3822247	ENSG00000250413.1	RP11-448G15.1	4.32	1.73e-05	0.00134	0.18	0.13	Bone mineral density;	chr4:10093047	chr4:10006482~10009725:+
BRCA	cis	rs2657888	0.628	rs7314242	ENSG00000257576.1	RP11-153M3.1	-4.32	1.73e-05	0.00134	-0.16	-0.13	Adiponectin levels;	chr12:56482588	chr12:56511002~56512703:+
BRCA	cis	rs11048434	0.518	rs17730331	ENSG00000256937.1	KRT17P8	-4.32	1.73e-05	0.00134	-0.14	-0.13	Sjögren's syndrome;	chr12:9025836	chr12:9127783~9128645:+
BRCA	cis	rs11048434	0.518	rs1805669	ENSG00000256720.1	RP11-436I9.6	-4.32	1.73e-05	0.00134	-0.13	-0.13	Sjögren's syndrome;	chr12:9027655	chr12:9135084~9135591:+
BRCA	cis	rs2411233	0.967	rs7173881	ENSG00000259278.1	RP11-62C7.2	4.32	1.73e-05	0.00134	0.16	0.13	Platelet count;	chr15:39001096	chr15:39019233~39024918:+
BRCA	cis	rs11096990	0.634	rs17754	ENSG00000249685.1	RP11-360F5.3	4.32	1.73e-05	0.00134	0.17	0.13	Cognitive function;	chr4:39287688	chr4:39133913~39135608:+
BRCA	cis	rs7267979	1	rs3761117	ENSG00000274973.1	RP13-401N8.7	4.32	1.73e-05	0.00134	0.15	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25407434	chr20:25845497~25845862:+
BRCA	cis	rs10181042	0.514	rs1177283	ENSG00000212978.6	AC016747.3	4.32	1.73e-05	0.00134	0.18	0.13	Crohn's disease;	chr2:61121669	chr2:61141592~61144969:-
BRCA	cis	rs875971	0.867	rs1002053	ENSG00000236529.1	RP13-254B10.1	-4.32	1.73e-05	0.00134	-0.14	-0.13	Aortic root size;	chr7:66333558	chr7:65840212~65840596:+
BRCA	cis	rs60843830	1	rs58461606	ENSG00000272342.1	RP13-539J13.1	4.32	1.73e-05	0.00134	0.16	0.13	Spherical equivalent (joint analysis main effects and education interaction);	chr2:267367	chr2:739588~740164:-
BRCA	cis	rs10129255	0.5	rs8006888	ENSG00000232216.1	IGHV3-43	4.32	1.73e-05	0.00134	0.1	0.13	Kawasaki disease;	chr14:106782219	chr14:106470264~106470800:-
BRCA	cis	rs1823874	0.71	rs1840298	ENSG00000182397.13	DNM1P46	-4.32	1.73e-05	0.00134	-0.15	-0.13	IgG glycosylation;	chr15:99821889	chr15:99790156~99806927:-
BRCA	cis	rs9616064	0.74	rs6520049	ENSG00000273145.1	CITF22-92A6.1	-4.32	1.73e-05	0.00134	-0.15	-0.13	Urate levels in obese individuals;	chr22:46600412	chr22:46013606~46015498:+
BRCA	cis	rs216345	0.7	rs307660	ENSG00000260947.1	RP11-384P7.7	4.32	1.73e-05	0.00134	0.14	0.13	Bipolar disorder;	chr9:33942932	chr9:33697459~33700986:+
BRCA	cis	rs9818758	0.556	rs9814987	ENSG00000225399.4	RP11-3B7.1	-4.32	1.73e-05	0.00134	-0.21	-0.13	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49170416	chr3:49260085~49261316:+
BRCA	cis	rs7267979	0.966	rs8123949	ENSG00000125804.12	FAM182A	4.32	1.74e-05	0.00134	0.17	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25407497	chr20:26054655~26086917:+
BRCA	cis	rs7267979	1	rs2184000	ENSG00000125804.12	FAM182A	4.32	1.74e-05	0.00134	0.17	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25415242	chr20:26054655~26086917:+
BRCA	cis	rs4819052	1	rs9306123	ENSG00000184274.3	LINC00315	-4.32	1.74e-05	0.00134	-0.2	-0.13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45290007	chr21:45300245~45305257:-
BRCA	cis	rs16846053	0.579	rs57887363	ENSG00000227403.1	AC009299.3	4.32	1.74e-05	0.00134	0.31	0.13	Blood osmolality (transformed sodium);	chr2:161732210	chr2:161244739~161249050:+
BRCA	cis	rs1553477	0.719	rs62370334	ENSG00000272416.1	CTD-2081C10.7	4.32	1.74e-05	0.00134	0.13	0.13	Monobrow;	chr5:53850363	chr5:53880293~53881051:-
BRCA	cis	rs1510272	1	rs1510273	ENSG00000243926.1	TIPARP-AS1	-4.32	1.74e-05	0.00134	-0.15	-0.13	Testicular germ cell tumor;	chr3:156583033	chr3:156671862~156674378:-
BRCA	cis	rs2439831	0.85	rs10438303	ENSG00000206991.1	RNU6-610P	-4.32	1.74e-05	0.00134	-0.22	-0.13	Lung cancer in ever smokers;	chr15:43724219	chr15:43637632~43637738:-
BRCA	cis	rs8114671	0.804	rs3803936	ENSG00000279253.1	RP4-614O4.13	4.32	1.74e-05	0.00134	0.15	0.13	Height;	chr20:35044972	chr20:35262727~35264187:-
BRCA	cis	rs8114671	0.836	rs13042358	ENSG00000279253.1	RP4-614O4.13	4.32	1.74e-05	0.00134	0.15	0.13	Height;	chr20:35046676	chr20:35262727~35264187:-
BRCA	cis	rs11633886	0.528	rs2460632	ENSG00000273972.1	CTD-2306A12.1	4.32	1.74e-05	0.00134	0.16	0.13	Diisocyanate-induced asthma;	chr15:45803763	chr15:45702640~45703183:+
BRCA	cis	rs6545883	0.894	rs2121661	ENSG00000273302.1	RP11-493E12.2	-4.32	1.74e-05	0.00134	-0.12	-0.13	Tuberculosis;	chr2:61334523	chr2:61199979~61200769:+
BRCA	cis	rs4415084	0.716	rs13154781	ENSG00000251141.4	RP11-53O19.1	4.32	1.74e-05	0.00134	0.13	0.13	Breast cancer;	chr5:44774925	chr5:44744900~44808777:-
BRCA	cis	rs801193	0.967	rs2707841	ENSG00000272831.1	RP11-792A8.4	4.32	1.74e-05	0.00134	0.12	0.13	Aortic root size;	chr7:66692033	chr7:66739829~66740385:-
BRCA	cis	rs801193	1	rs4717310	ENSG00000272831.1	RP11-792A8.4	4.32	1.74e-05	0.00134	0.12	0.13	Aortic root size;	chr7:66696020	chr7:66739829~66740385:-
BRCA	cis	rs875971	0.83	rs427575	ENSG00000229180.5	GS1-124K5.11	4.32	1.74e-05	0.00134	0.12	0.13	Aortic root size;	chr7:66054232	chr7:66526088~66542624:-
BRCA	cis	rs3096299	0.658	rs4785679	ENSG00000261118.1	RP11-104N10.1	4.32	1.74e-05	0.00134	0.14	0.13	Multiple myeloma (IgH translocation);	chr16:89499705	chr16:89492017~89504460:-
BRCA	cis	rs12030196	1	rs932770	ENSG00000230812.4	LINC01358	4.32	1.74e-05	0.00134	0.15	0.13	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr1:59017934	chr1:59020387~59044614:+
BRCA	cis	rs8114671	0.967	rs6142320	ENSG00000279253.1	RP4-614O4.13	4.32	1.74e-05	0.00134	0.15	0.13	Height;	chr20:35200390	chr20:35262727~35264187:-
BRCA	cis	rs8114671	0.967	rs6142321	ENSG00000279253.1	RP4-614O4.13	4.32	1.74e-05	0.00134	0.15	0.13	Height;	chr20:35200671	chr20:35262727~35264187:-
BRCA	cis	rs9467773	1	rs9393728	ENSG00000241549.7	GUSBP2	4.32	1.74e-05	0.00135	0.14	0.13	Intelligence (multi-trait analysis);	chr6:26509102	chr6:26871484~26956554:-
BRCA	cis	rs9467773	1	rs1056667	ENSG00000241549.7	GUSBP2	4.32	1.74e-05	0.00135	0.14	0.13	Intelligence (multi-trait analysis);	chr6:26510336	chr6:26871484~26956554:-
BRCA	cis	rs8180040	1	rs1024037	ENSG00000276925.1	RP11-708J19.3	4.32	1.74e-05	0.00135	0.15	0.13	Colorectal cancer;	chr3:47276959	chr3:47469777~47469987:+
BRCA	cis	rs7771547	0.574	rs11756557	ENSG00000224666.3	RP1-50J22.4	4.32	1.74e-05	0.00135	0.17	0.13	Platelet distribution width;	chr6:36629918	chr6:36386831~36393462:+
BRCA	cis	rs797680	0.856	rs7535628	ENSG00000229635.1	RP4-713B5.2	4.32	1.74e-05	0.00135	0.17	0.13	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93183171	chr1:93384487~93384998:-
BRCA	cis	rs1371614	0.611	rs877272	ENSG00000229122.1	AGBL5-IT1	4.32	1.74e-05	0.00135	0.14	0.13	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26917020	chr2:27061038~27061815:+
BRCA	cis	rs7487075	1	rs10880966	ENSG00000257261.4	RP11-96H19.1	4.32	1.74e-05	0.00135	0.14	0.13	Itch intensity from mosquito bite;	chr12:46407999	chr12:46383679~46876159:+
BRCA	cis	rs6671200	0.748	rs12753842	ENSG00000235501.4	RP4-639F20.1	-4.32	1.74e-05	0.00135	-0.29	-0.13	Stearic acid (18:0) levels;	chr1:95049769	chr1:94927566~94963270:+
BRCA	cis	rs6984305	0.541	rs17716118	ENSG00000253426.4	RP11-10A14.4	4.32	1.74e-05	0.00135	0.25	0.13	Liver enzyme levels (alkaline phosphatase);	chr8:9322624	chr8:9151742~9168136:+
BRCA	cis	rs12681366	0.537	rs2919656	ENSG00000253704.1	RP11-267M23.4	4.32	1.74e-05	0.00135	0.15	0.13	Nonsyndromic cleft lip with cleft palate;	chr8:94460806	chr8:94553722~94569745:+
BRCA	cis	rs738722	0.615	rs743184	ENSG00000279978.1	chr22-38_28785274-29006793.1	-4.32	1.74e-05	0.00135	-0.17	-0.13	Optic cup area;Esophageal cancer and gastric cancer;	chr22:28706979	chr22:28930201~29197572:+
BRCA	cis	rs4664293	0.715	rs13002625	ENSG00000224152.1	AC009506.1	4.32	1.74e-05	0.00135	0.14	0.13	Monocyte percentage of white cells;	chr2:159648114	chr2:159615296~159617082:+
BRCA	cis	rs1910358	0.554	rs4701388	ENSG00000248874.4	C5orf17	-4.32	1.74e-05	0.00135	-0.19	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23738505	chr5:23951348~24178263:+
BRCA	cis	rs58521262	0.685	rs2935443	ENSG00000268105.1	RP11-369G6.2	-4.32	1.74e-05	0.00135	-0.18	-0.13	Testicular germ cell tumor;	chr19:23031847	chr19:23125665~23128543:+
BRCA	cis	rs17684571	0.7	rs35873865	ENSG00000231441.1	RP11-472M19.2	4.32	1.74e-05	0.00135	0.22	0.13	Schizophrenia;	chr6:56790203	chr6:56844002~56864078:+
BRCA	cis	rs1910358	0.596	rs28532124	ENSG00000248874.4	C5orf17	-4.32	1.75e-05	0.00135	-0.17	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23995808	chr5:23951348~24178263:+
BRCA	cis	rs9840812	0.769	rs548288	ENSG00000273486.1	RP11-731C17.2	-4.32	1.75e-05	0.00135	-0.16	-0.13	Fibrinogen levels;	chr3:136250913	chr3:136837338~136839021:-
BRCA	cis	rs11673344	0.583	rs10421436	ENSG00000267422.1	CTD-2554C21.1	-4.32	1.75e-05	0.00135	-0.16	-0.13	Obesity-related traits;	chr19:37394601	chr19:37779686~37792865:+
BRCA	cis	rs2708977	0.667	rs772156	ENSG00000237510.6	AC008268.2	-4.32	1.75e-05	0.00135	-0.17	-0.13	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96364092	chr2:95789654~95800166:+
BRCA	cis	rs7267979	0.966	rs910996	ENSG00000277938.1	RP5-965G21.3	4.32	1.75e-05	0.00135	0.16	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25283560	chr20:25229150~25231933:+
BRCA	cis	rs6012564	0.806	rs4810903	ENSG00000227431.4	CSE1L-AS1	-4.32	1.75e-05	0.00135	-0.16	-0.13	Anger;	chr20:48982668	chr20:49040463~49046044:-
BRCA	cis	rs516805	0.63	rs2816082	ENSG00000279114.1	RP3-425C14.5	-4.32	1.75e-05	0.00135	-0.16	-0.13	Lymphocyte counts;	chr6:122102489	chr6:122471923~122484161:+
BRCA	cis	rs516805	0.63	rs2315814	ENSG00000279114.1	RP3-425C14.5	-4.32	1.75e-05	0.00135	-0.16	-0.13	Lymphocyte counts;	chr6:122102712	chr6:122471923~122484161:+
BRCA	cis	rs67981189	0.574	rs2526884	ENSG00000258571.1	PTTG4P	4.32	1.75e-05	0.00135	0.14	0.13	Schizophrenia;	chr14:70901250	chr14:71085482~71085833:-
BRCA	cis	rs516805	0.667	rs2816078	ENSG00000279114.1	RP3-425C14.5	-4.32	1.75e-05	0.00135	-0.17	-0.13	Lymphocyte counts;	chr6:122201755	chr6:122471923~122484161:+
BRCA	cis	rs62005083	0.5	rs10135300	ENSG00000259065.1	RP5-1021I20.1	-4.32	1.75e-05	0.00135	-0.18	-0.13	Mean corpuscular volume;	chr14:74107858	chr14:73787360~73803270:+
BRCA	cis	rs6012564	1	rs17632	ENSG00000227431.4	CSE1L-AS1	4.32	1.75e-05	0.00135	0.16	0.13	Anger;	chr20:49096526	chr20:49040463~49046044:-
BRCA	cis	rs295490	0.831	rs3772871	ENSG00000272656.1	RP11-219D15.3	-4.32	1.75e-05	0.00135	-0.29	-0.13	PR interval in Tripanosoma cruzi seropositivity;	chr3:139522774	chr3:139349024~139349371:-
BRCA	cis	rs6600671	1	rs4844607	ENSG00000231429.2	RP11-343N15.2	4.32	1.75e-05	0.00135	0.16	0.13	Hip geometry;	chr1:121442201	chr1:121412719~121429274:+
BRCA	cis	rs6870983	0.843	rs247915	ENSG00000247828.6	TMEM161B-AS1	-4.31	1.75e-05	0.00135	-0.17	-0.13	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index;	chr5:88264217	chr5:88268895~88436685:+
BRCA	cis	rs13113518	0.966	rs11942472	ENSG00000273257.1	RP11-177J6.1	4.31	1.75e-05	0.00135	0.17	0.13	Height;	chr4:55574959	chr4:55387949~55388271:+
BRCA	cis	rs11098499	0.954	rs10017543	ENSG00000260091.1	RP11-33B1.4	-4.31	1.75e-05	0.00135	-0.12	-0.13	Corneal astigmatism;	chr4:119400265	chr4:119409333~119410233:+
BRCA	cis	rs6964833	0.872	rs4717903	ENSG00000184616.8	AC004166.6	4.31	1.75e-05	0.00135	0.2	0.13	Menarche (age at onset);	chr7:74653827	chr7:74906673~74913256:-
BRCA	cis	rs6088580	0.619	rs1205335	ENSG00000276073.1	RP5-1125A11.7	4.31	1.75e-05	0.00135	0.15	0.13	Glomerular filtration rate (creatinine);	chr20:34339701	chr20:33985617~33988989:-
BRCA	cis	rs644148	0.836	rs2686776	ENSG00000176761.7	ZNF285B	4.31	1.75e-05	0.00135	0.15	0.13	Personality dimensions;	chr19:44496305	chr19:44467641~44473227:+
BRCA	cis	rs2179367	0.959	rs544947	ENSG00000223701.3	RAET1E-AS1	4.31	1.75e-05	0.00135	0.17	0.13	Dupuytren's disease;	chr6:149402412	chr6:149884431~149919508:+
BRCA	cis	rs13113518	1	rs12651640	ENSG00000272969.1	RP11-528I4.2	4.31	1.75e-05	0.00135	0.15	0.13	Height;	chr4:55454154	chr4:55547112~55547889:+
BRCA	cis	rs13113518	1	rs1554483	ENSG00000272969.1	RP11-528I4.2	4.31	1.75e-05	0.00135	0.15	0.13	Height;	chr4:55455650	chr4:55547112~55547889:+
BRCA	cis	rs13113518	1	rs1464490	ENSG00000272969.1	RP11-528I4.2	4.31	1.75e-05	0.00135	0.15	0.13	Height;	chr4:55456620	chr4:55547112~55547889:+
BRCA	cis	rs13113518	1	rs10517346	ENSG00000272969.1	RP11-528I4.2	4.31	1.75e-05	0.00135	0.15	0.13	Height;	chr4:55457027	chr4:55547112~55547889:+
BRCA	cis	rs13113518	1	rs11133384	ENSG00000272969.1	RP11-528I4.2	4.31	1.75e-05	0.00135	0.15	0.13	Height;	chr4:55457086	chr4:55547112~55547889:+
BRCA	cis	rs875971	0.628	rs6974355	ENSG00000229180.5	GS1-124K5.11	4.31	1.75e-05	0.00135	0.12	0.13	Aortic root size;	chr7:66376994	chr7:66526088~66542624:-
BRCA	cis	rs11673344	0.504	rs10403728	ENSG00000276846.1	CTD-3220F14.3	4.31	1.75e-05	0.00135	0.16	0.13	Obesity-related traits;	chr19:37091569	chr19:37314868~37315620:-
BRCA	cis	rs12216545	0.765	rs1851434	ENSG00000244151.1	RP11-148K1.12	4.31	1.75e-05	0.00135	0.11	0.13	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150532365	chr7:151074742~151076530:-
BRCA	cis	rs9925964	0.933	rs56314408	ENSG00000262766.1	RP11-196G11.4	4.31	1.75e-05	0.00135	0.11	0.13	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31106068	chr16:31118078~31118747:+
BRCA	cis	rs738144	0.502	rs9611034	ENSG00000279833.1	RP4-742C19.13	-4.31	1.75e-05	0.00135	-0.1	-0.13	IgG glycosylation;	chr22:38834879	chr22:39133090~39136760:+
BRCA	cis	rs2108622	1	rs2108622	ENSG00000267218.2	AC005336.5	4.31	1.75e-05	0.00135	0.17	0.13	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15879621	chr19:15902300~15903238:-
BRCA	cis	rs35740288	0.77	rs12898597	ENSG00000202081.1	RNU6-1280P	4.31	1.75e-05	0.00135	0.17	0.13	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85646688	chr15:85651522~85651628:-
BRCA	cis	rs77204473	1	rs12286581	ENSG00000280143.1	AP000892.6	-4.31	1.75e-05	0.00135	-0.25	-0.13	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116878028	chr11:117204967~117210292:+
BRCA	cis	rs853679	0.517	rs2281588	ENSG00000216901.1	AL022393.7	4.31	1.75e-05	0.00135	0.19	0.13	Depression;	chr6:28104824	chr6:28176188~28176674:+
BRCA	cis	rs889312	0.923	rs12697152	ENSG00000271828.1	CTD-2310F14.1	4.31	1.75e-05	0.00136	0.16	0.13	Breast cancer (early onset);Breast cancer;	chr5:56729889	chr5:56927874~56929573:+
BRCA	cis	rs1048886	0.872	rs6911983	ENSG00000271967.1	RP11-134K13.4	-4.31	1.75e-05	0.00136	-0.18	-0.13	Type 2 diabetes;	chr6:70563858	chr6:70596438~70596980:+
BRCA	cis	rs16846053	0.786	rs72877309	ENSG00000227403.1	AC009299.3	4.31	1.76e-05	0.00136	0.31	0.13	Blood osmolality (transformed sodium);	chr2:161731318	chr2:161244739~161249050:+
BRCA	cis	rs11083475	0.967	rs2287729	ENSG00000267892.1	CTD-2540F13.2	4.31	1.76e-05	0.00136	0.15	0.13	Heart rate;	chr19:38704674	chr19:38738284~38739863:+
BRCA	cis	rs9834975	0.967	rs7638180	ENSG00000272758.4	RP11-299J3.8	-4.31	1.76e-05	0.00136	-0.13	-0.13	Diastolic blood pressure;	chr3:122431449	chr3:122416207~122443180:+
BRCA	cis	rs1979679	0.541	rs7956757	ENSG00000278733.1	RP11-425D17.1	-4.31	1.76e-05	0.00136	-0.18	-0.13	Ossification of the posterior longitudinal ligament of the spine;	chr12:28570071	chr12:28185625~28186190:-
BRCA	cis	rs1867631	0.585	rs4655639	ENSG00000248458.2	RP4-598P13.1	4.31	1.76e-05	0.00136	0.14	0.13	Menopause (age at onset);	chr1:66623407	chr1:66665864~66677027:-
BRCA	cis	rs17228178	0.961	rs9920109	ENSG00000215302.7	CTD-3092A11.1	-4.31	1.76e-05	0.00136	-0.17	-0.13	Facial depth;Facial morphology (factor 1, breadth of lateral portion of upper face);	chr15:31177120	chr15:30470779~30507623:+
BRCA	cis	rs1005277	0.579	rs2505194	ENSG00000099251.13	HSD17B7P2	4.31	1.76e-05	0.00136	0.15	0.13	Extrinsic epigenetic age acceleration;	chr10:38104953	chr10:38356380~38378505:+
BRCA	cis	rs2908197	0.737	rs6465097	ENSG00000186704.9	DTX2P1	4.31	1.76e-05	0.00136	0.15	0.13	3-hydroxypropylmercapturic acid levels in smokers;	chr7:76343597	chr7:76978617~77004308:+
BRCA	cis	rs216345	0.615	rs2994032	ENSG00000260947.1	RP11-384P7.7	4.31	1.76e-05	0.00136	0.14	0.13	Bipolar disorder;	chr9:33824587	chr9:33697459~33700986:+
BRCA	cis	rs669446	0.527	rs667676	ENSG00000236200.4	KDM4A-AS1	-4.31	1.76e-05	0.00136	-0.17	-0.13	Amyotrophic lateral sclerosis (age of onset);	chr1:43616545	chr1:43699765~43708138:-
BRCA	cis	rs1014246	1	rs1014246	ENSG00000232767.1	RP11-498B4.5	-4.31	1.76e-05	0.00136	-0.14	-0.13	Age at smoking initiation in chronic obstructive pulmonary disease;	chr10:116706531	chr10:116670103~116672739:+
BRCA	cis	rs1014246	1	rs1014244	ENSG00000232767.1	RP11-498B4.5	-4.31	1.76e-05	0.00136	-0.14	-0.13	Age at smoking initiation in chronic obstructive pulmonary disease;	chr10:116706639	chr10:116670103~116672739:+
BRCA	cis	rs7141336	0.791	rs8003239	ENSG00000258884.1	CTD-3035D6.2	-4.31	1.76e-05	0.00136	-0.17	-0.13	Anxiety disorder;	chr14:90753193	chr14:90822365~90828128:-
BRCA	cis	rs910316	0.967	rs4384542	ENSG00000259138.1	RP11-950C14.7	-4.31	1.76e-05	0.00136	-0.14	-0.13	Height;	chr14:75191310	chr14:75127153~75136930:+
BRCA	cis	rs6430585	0.64	rs6716070	ENSG00000231890.6	DARS-AS1	4.31	1.76e-05	0.00136	0.2	0.13	Corneal structure;	chr2:135787081	chr2:135985176~136022593:+
BRCA	cis	rs4287000	0.508	rs10821177	ENSG00000227603.1	RP11-165J3.6	-4.31	1.76e-05	0.00136	-0.15	-0.13	Itch intensity from mosquito bite adjusted by bite size;	chr9:93605304	chr9:93435332~93437121:-
BRCA	cis	rs4287000	0.508	rs2989752	ENSG00000227603.1	RP11-165J3.6	-4.31	1.76e-05	0.00136	-0.15	-0.13	Itch intensity from mosquito bite adjusted by bite size;	chr9:93605461	chr9:93435332~93437121:-
BRCA	cis	rs12681366	0.623	rs10106494	ENSG00000253704.1	RP11-267M23.4	4.31	1.76e-05	0.00136	0.15	0.13	Nonsyndromic cleft lip with cleft palate;	chr8:94471226	chr8:94553722~94569745:+
BRCA	cis	rs9308731	0.966	rs4849442	ENSG00000230499.1	AC108463.1	-4.31	1.76e-05	0.00136	-0.15	-0.13	Chronic lymphocytic leukemia;	chr2:111176642	chr2:111195963~111206494:+
BRCA	cis	rs7308116	0.53	rs7980811	ENSG00000274395.1	RP11-554D14.8	4.31	1.76e-05	0.00136	0.15	0.13	Pelvic organ prolapse (moderate/severe);	chr12:107903896	chr12:107835541~107836555:-
BRCA	cis	rs6496044	0.547	rs8039929	ENSG00000202081.1	RNU6-1280P	4.31	1.76e-05	0.00136	0.15	0.13	Interstitial lung disease;	chr15:85537731	chr15:85651522~85651628:-
BRCA	cis	rs7772486	0.754	rs702324	ENSG00000270638.1	RP3-466P17.1	-4.31	1.76e-05	0.00136	-0.16	-0.13	Lobe attachment (rater-scored or self-reported);	chr6:145687657	chr6:145735570~145737218:+
BRCA	cis	rs1223397	0.651	rs202019	ENSG00000215022.6	RP1-257A7.4	-4.31	1.76e-05	0.00136	-0.16	-0.13	Blood pressure;	chr6:13301558	chr6:13264861~13295586:-
BRCA	cis	rs7267979	1	rs6115153	ENSG00000125804.12	FAM182A	4.31	1.76e-05	0.00136	0.17	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25344931	chr20:26054655~26086917:+
BRCA	cis	rs7267979	1	rs6050602	ENSG00000277938.1	RP5-965G21.3	-4.31	1.76e-05	0.00136	-0.16	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25420567	chr20:25229150~25231933:+
BRCA	cis	rs2832191	0.671	rs2832212	ENSG00000176054.6	RPL23P2	-4.31	1.76e-05	0.00136	-0.15	-0.13	Dental caries;	chr21:29139096	chr21:28997613~28998033:-
BRCA	cis	rs2832191	0.55	rs66484040	ENSG00000176054.6	RPL23P2	-4.31	1.76e-05	0.00136	-0.15	-0.13	Dental caries;	chr21:29139370	chr21:28997613~28998033:-
BRCA	cis	rs11168351	0.864	rs10875743	ENSG00000257763.1	OR5BK1P	-4.31	1.76e-05	0.00136	-0.14	-0.13	Bipolar disorder and schizophrenia;	chr12:48104630	chr12:48355792~48356614:-
BRCA	cis	rs4449834	0.775	rs7816126	ENSG00000254432.1	RP11-33I11.2	-4.31	1.76e-05	0.00136	-0.16	-0.13	Sum eosinophil basophil counts;	chr8:60749479	chr8:60808735~60809606:-
BRCA	cis	rs6997458	0.806	rs1496532	ENSG00000258256.1	RP11-219B4.5	4.31	1.76e-05	0.00136	0.15	0.13	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85341753	chr8:85222446~85245717:-
BRCA	cis	rs7481584	0.581	rs420127	ENSG00000247473.2	CARS-AS1	-4.31	1.76e-05	0.00136	-0.16	-0.13	Calcium levels;	chr11:3056760	chr11:3029009~3041260:+
BRCA	cis	rs7267979	1	rs6083862	ENSG00000125804.12	FAM182A	4.31	1.76e-05	0.00136	0.17	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25430450	chr20:26054655~26086917:+
BRCA	cis	rs2412819	0.571	rs495880	ENSG00000166763.7	STRCP1	-4.31	1.76e-05	0.00136	-0.18	-0.13	Lung cancer;	chr15:43855067	chr15:43699488~43718184:-
BRCA	cis	rs75804782	0.63	rs75921156	ENSG00000186235.9	AC016757.3	4.31	1.76e-05	0.00136	0.34	0.13	Chronotype;Morning vs. evening chronotype;	chr2:238370992	chr2:238224552~238231677:-
BRCA	cis	rs75804782	0.566	rs56314406	ENSG00000186235.9	AC016757.3	4.31	1.76e-05	0.00136	0.34	0.13	Chronotype;Morning vs. evening chronotype;	chr2:238371736	chr2:238224552~238231677:-
BRCA	cis	rs3113494	1	rs13116978	ENSG00000251411.1	RP11-397E7.4	4.31	1.76e-05	0.00136	0.15	0.13	Amyotrophic lateral sclerosis;	chr4:86911877	chr4:86913266~86914817:-
BRCA	cis	rs1510272	0.961	rs7644461	ENSG00000243926.1	TIPARP-AS1	-4.31	1.76e-05	0.00136	-0.15	-0.13	Testicular germ cell tumor;	chr3:156598903	chr3:156671862~156674378:-
BRCA	cis	rs867371	1	rs8041924	ENSG00000278603.1	RP13-608F4.5	4.31	1.76e-05	0.00136	0.18	0.13	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82181320	chr15:82472203~82472426:+
BRCA	cis	rs9844666	0.512	rs9833699	ENSG00000273486.1	RP11-731C17.2	4.31	1.76e-05	0.00136	0.16	0.13	Height;	chr3:135922442	chr3:136837338~136839021:-
BRCA	cis	rs9844666	0.512	rs9875948	ENSG00000273486.1	RP11-731C17.2	4.31	1.76e-05	0.00136	0.16	0.13	Height;	chr3:135923062	chr3:136837338~136839021:-
BRCA	cis	rs748404	0.518	rs2176870	ENSG00000166763.7	STRCP1	-4.31	1.76e-05	0.00136	-0.17	-0.13	Lung cancer;	chr15:43144212	chr15:43699488~43718184:-
BRCA	cis	rs1910358	0.569	rs56184010	ENSG00000248874.4	C5orf17	-4.31	1.76e-05	0.00136	-0.17	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23954614	chr5:23951348~24178263:+
BRCA	cis	rs853679	0.517	rs9380047	ENSG00000216901.1	AL022393.7	4.31	1.77e-05	0.00136	0.19	0.13	Depression;	chr6:28070115	chr6:28176188~28176674:+
BRCA	cis	rs9921338	0.961	rs7195536	ENSG00000262703.1	RP11-485G7.6	-4.31	1.77e-05	0.00136	-0.17	-0.13	Vein graft stenosis in coronary artery bypass grafting;	chr16:11348171	chr16:11348143~11349321:-
BRCA	cis	rs9921338	0.961	rs7191093	ENSG00000262703.1	RP11-485G7.6	-4.31	1.77e-05	0.00136	-0.17	-0.13	Vein graft stenosis in coronary artery bypass grafting;	chr16:11348422	chr16:11348143~11349321:-
BRCA	cis	rs911119	1	rs6114206	ENSG00000270001.1	RP11-218C14.8	-4.31	1.77e-05	0.00136	-0.18	-0.13	Chronic kidney disease;	chr20:23631152	chr20:23631826~23632316:-
BRCA	cis	rs7226408	0.64	rs1968334	ENSG00000267707.2	RP11-95O2.5	4.31	1.77e-05	0.00136	0.22	0.13	Obesity-related traits;	chr18:36763671	chr18:37243776~37247506:+
BRCA	cis	rs7811142	1	rs60257855	ENSG00000078319.8	PMS2P1	-4.31	1.77e-05	0.00136	-0.21	-0.13	Platelet count;	chr7:100429157	chr7:100320992~100341908:-
BRCA	cis	rs3176789	0.647	rs35143542	ENSG00000256673.1	RP11-599J14.2	4.31	1.77e-05	0.00136	0.15	0.13	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9766925	chr12:9398355~9414851:-
BRCA	cis	rs4415084	0.834	rs7720787	ENSG00000251141.4	RP11-53O19.1	4.31	1.77e-05	0.00136	0.12	0.13	Breast cancer;	chr5:44817207	chr5:44744900~44808777:-
BRCA	cis	rs7824557	0.767	rs3808513	ENSG00000248896.2	CTD-2135J3.3	-4.31	1.77e-05	0.00136	-0.17	-0.13	Retinal vascular caliber;	chr8:11299951	chr8:10729314~10771392:+
BRCA	cis	rs7772486	0.875	rs9399572	ENSG00000270638.1	RP3-466P17.1	4.31	1.77e-05	0.00136	0.15	0.13	Lobe attachment (rater-scored or self-reported);	chr6:146041809	chr6:145735570~145737218:+
BRCA	cis	rs9330264	0.508	rs7364869	ENSG00000160766.13	GBAP1	-4.31	1.77e-05	0.00136	-0.13	-0.13	1,5-anhydroglucitol levels;	chr1:155114712	chr1:155213821~155227422:-
BRCA	cis	rs7572733	0.935	rs771015	ENSG00000231621.1	AC013264.2	-4.31	1.77e-05	0.00136	-0.12	-0.13	Dermatomyositis;	chr2:197803570	chr2:197197991~197199273:+
BRCA	cis	rs7011507	0.562	rs10092171	ENSG00000233858.4	AC026904.1	-4.31	1.77e-05	0.00137	-0.16	-0.13	Inflammatory bowel disease;Ulcerative colitis;	chr8:48514607	chr8:48590401~48594621:+
BRCA	cis	rs1510272	0.924	rs4680284	ENSG00000243926.1	TIPARP-AS1	-4.31	1.77e-05	0.00137	-0.15	-0.13	Testicular germ cell tumor;	chr3:156587852	chr3:156671862~156674378:-
BRCA	cis	rs7200543	1	rs55727637	ENSG00000260872.1	RP11-680G24.5	-4.31	1.77e-05	0.00137	-0.14	-0.13	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15051395	chr16:15018106~15020488:-
BRCA	cis	rs2880765	0.835	rs6497206	ENSG00000202081.1	RNU6-1280P	4.31	1.77e-05	0.00137	0.15	0.13	Coronary artery disease;	chr15:85485994	chr15:85651522~85651628:-
BRCA	cis	rs4578769	0.959	rs9961893	ENSG00000265939.1	UBE2CP2	4.31	1.77e-05	0.00137	0.16	0.13	Eosinophil percentage of white cells;	chr18:22849805	chr18:22900486~22900995:-
BRCA	cis	rs11673344	0.504	rs2385375	ENSG00000276846.1	CTD-3220F14.3	4.31	1.77e-05	0.00137	0.16	0.13	Obesity-related traits;	chr19:37087620	chr19:37314868~37315620:-
BRCA	cis	rs12612435	0.793	rs11899360	ENSG00000226806.1	AC011893.3	4.31	1.77e-05	0.00137	0.15	0.13	Takotsubo syndrome;	chr2:136371354	chr2:135820191~135823087:+
BRCA	cis	rs4072980	0.545	rs16824518	ENSG00000212541.1	RNU6-510P	4.31	1.77e-05	0.00137	0.17	0.13	Coronary artery disease;	chr1:37949643	chr1:37991462~37991569:+
BRCA	cis	rs2625529	0.652	rs2929532	ENSG00000260037.4	CTD-2524L6.3	4.31	1.77e-05	0.00137	0.17	0.13	Red blood cell count;	chr15:72052769	chr15:71818396~71823384:+
BRCA	cis	rs6964833	0.935	rs35735900	ENSG00000184616.8	AC004166.6	4.31	1.77e-05	0.00137	0.2	0.13	Menarche (age at onset);	chr7:74651887	chr7:74906673~74913256:-
BRCA	cis	rs35146811	0.659	rs863450	ENSG00000235713.1	RP4-604G5.3	-4.31	1.77e-05	0.00137	-0.16	-0.13	Coronary artery disease;	chr7:100224062	chr7:99992397~99993050:+
BRCA	cis	rs10938353	0.911	rs2348348	ENSG00000273369.1	RP11-700J17.1	-4.31	1.77e-05	0.00137	-0.15	-0.13	Body mass index;	chr4:44601408	chr4:44693946~44694386:-
BRCA	cis	rs7246657	0.722	rs16958863	ENSG00000226686.6	LINC01535	-4.31	1.77e-05	0.00137	-0.19	-0.13	Coronary artery calcification;	chr19:37633334	chr19:37251912~37265535:+
BRCA	cis	rs700651	0.789	rs10497812	ENSG00000231621.1	AC013264.2	4.31	1.77e-05	0.00137	0.13	0.13	Intracranial aneurysm;	chr2:198046521	chr2:197197991~197199273:+
BRCA	cis	rs12612435	0.784	rs71417594	ENSG00000226806.1	AC011893.3	4.31	1.77e-05	0.00137	0.16	0.13	Takotsubo syndrome;	chr2:136370553	chr2:135820191~135823087:+
BRCA	cis	rs12612435	0.869	rs1515066	ENSG00000226806.1	AC011893.3	4.31	1.77e-05	0.00137	0.16	0.13	Takotsubo syndrome;	chr2:136371888	chr2:135820191~135823087:+
BRCA	cis	rs12612435	0.83	rs1515065	ENSG00000226806.1	AC011893.3	4.31	1.77e-05	0.00137	0.16	0.13	Takotsubo syndrome;	chr2:136373374	chr2:135820191~135823087:+
BRCA	cis	rs12612435	0.83	rs1849874	ENSG00000226806.1	AC011893.3	4.31	1.77e-05	0.00137	0.16	0.13	Takotsubo syndrome;	chr2:136373448	chr2:135820191~135823087:+
BRCA	cis	rs7727544	0.514	rs3846728	ENSG00000233006.5	AC034220.3	4.31	1.77e-05	0.00137	0.1	0.13	Blood metabolite levels;	chr5:132100524	chr5:132311285~132369916:-
BRCA	cis	rs465969	1	rs17090837	ENSG00000230177.1	RP5-1112D6.4	4.31	1.77e-05	0.00137	0.31	0.13	Psoriasis;	chr6:111430650	chr6:111277932~111278742:+
BRCA	cis	rs465969	1	rs35208445	ENSG00000230177.1	RP5-1112D6.4	4.31	1.77e-05	0.00137	0.31	0.13	Psoriasis;	chr6:111434944	chr6:111277932~111278742:+
BRCA	cis	rs465969	1	rs35248830	ENSG00000230177.1	RP5-1112D6.4	4.31	1.77e-05	0.00137	0.31	0.13	Psoriasis;	chr6:111435547	chr6:111277932~111278742:+
BRCA	cis	rs465969	1	rs35151650	ENSG00000230177.1	RP5-1112D6.4	4.31	1.77e-05	0.00137	0.31	0.13	Psoriasis;	chr6:111436524	chr6:111277932~111278742:+
BRCA	cis	rs465969	0.744	rs34089926	ENSG00000230177.1	RP5-1112D6.4	4.31	1.77e-05	0.00137	0.31	0.13	Psoriasis;	chr6:111439043	chr6:111277932~111278742:+
BRCA	cis	rs465969	1	rs4580915	ENSG00000230177.1	RP5-1112D6.4	4.31	1.77e-05	0.00137	0.31	0.13	Psoriasis;	chr6:111439561	chr6:111277932~111278742:+
BRCA	cis	rs12612435	0.747	rs67278654	ENSG00000226806.1	AC011893.3	4.31	1.77e-05	0.00137	0.15	0.13	Takotsubo syndrome;	chr2:136370615	chr2:135820191~135823087:+
BRCA	cis	rs529866	0.5	rs918739	ENSG00000262703.1	RP11-485G7.6	-4.31	1.77e-05	0.00137	-0.14	-0.13	Inflammatory bowel disease;Crohn's disease;	chr16:11345876	chr16:11348143~11349321:-
BRCA	cis	rs8098244	0.516	rs7236486	ENSG00000264745.1	TTC39C-AS1	4.31	1.78e-05	0.00137	0.15	0.13	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23685001	chr18:23994213~24015339:-
BRCA	cis	rs6480314	0.522	rs10762210	ENSG00000233590.1	RP11-153K11.3	4.31	1.78e-05	0.00137	0.2	0.13	Optic nerve measurement (disc area);	chr10:68290860	chr10:68233251~68242379:-
BRCA	cis	rs9527	0.615	rs7096452	ENSG00000213061.2	PFN1P11	4.31	1.78e-05	0.00137	0.18	0.13	Arsenic metabolism;	chr10:102976806	chr10:102838011~102845473:-
BRCA	cis	rs9527	0.615	rs7080462	ENSG00000213061.2	PFN1P11	4.31	1.78e-05	0.00137	0.18	0.13	Arsenic metabolism;	chr10:102976942	chr10:102838011~102845473:-
BRCA	cis	rs11637445	0.677	rs11631864	ENSG00000260657.2	RP11-315D16.4	4.31	1.78e-05	0.00137	0.17	0.13	Posterior cortical atrophy and Alzheimer's disease;	chr15:67775424	chr15:68267792~68277994:-
BRCA	cis	rs6686842	0.56	rs11209361	ENSG00000235358.1	RP11-399E6.1	-4.31	1.78e-05	0.00137	-0.18	-0.13	Height;	chr1:41018279	chr1:41242373~41284861:+
BRCA	cis	rs6964833	0.786	rs35633336	ENSG00000184616.8	AC004166.6	4.31	1.78e-05	0.00137	0.2	0.13	Menarche (age at onset);	chr7:74643961	chr7:74906673~74913256:-
BRCA	cis	rs7267979	0.78	rs2500413	ENSG00000125804.12	FAM182A	-4.31	1.78e-05	0.00137	-0.17	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25260519	chr20:26054655~26086917:+
BRCA	cis	rs7267979	0.714	rs2474763	ENSG00000125804.12	FAM182A	-4.31	1.78e-05	0.00137	-0.17	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25260659	chr20:26054655~26086917:+
BRCA	cis	rs812925	0.512	rs7558954	ENSG00000273302.1	RP11-493E12.2	4.31	1.78e-05	0.00137	0.11	0.13	Immature fraction of reticulocytes;	chr2:61157771	chr2:61199979~61200769:+
BRCA	cis	rs957448	0.507	rs1984711	ENSG00000261437.1	RP11-22C11.2	4.31	1.78e-05	0.00137	0.13	0.13	Nonsyndromic cleft lip with cleft palate;	chr8:94600276	chr8:94637285~94639467:-
BRCA	cis	rs1722133	0.555	rs788770	ENSG00000237471.1	AC073115.6	-4.31	1.78e-05	0.00137	-0.18	-0.13	Sitting height ratio;	chr7:46068825	chr7:45969657~45980191:+
BRCA	cis	rs10129255	0.5	rs8004923	ENSG00000254174.1	IGHV1-12	4.31	1.78e-05	0.00137	0.1	0.13	Kawasaki disease;	chr14:106785926	chr14:106122420~106122709:-
BRCA	cis	rs2235544	0.565	rs12758219	ENSG00000225183.1	RP4-758J24.4	4.31	1.78e-05	0.00137	0.16	0.13	Thyroid hormone levels;Multiple myeloma (hyperdiploidy);	chr1:54000472	chr1:54089856~54090093:+
BRCA	cis	rs6545883	0.562	rs777588	ENSG00000212978.6	AC016747.3	4.31	1.78e-05	0.00137	0.17	0.13	Tuberculosis;	chr2:61199685	chr2:61141592~61144969:-
BRCA	cis	rs11098499	0.955	rs35434465	ENSG00000250412.1	KLHL2P1	4.31	1.78e-05	0.00137	0.16	0.13	Corneal astigmatism;	chr4:119248223	chr4:119334329~119378233:+
BRCA	cis	rs6487679	1	rs1017302	ENSG00000111788.10	RP11-22B23.1	4.31	1.78e-05	0.00137	0.15	0.13	Non-alcoholic fatty liver disease histology (AST);	chr12:9214806	chr12:9277235~9313241:+
BRCA	cis	rs4853525	0.561	rs7597768	ENSG00000235852.1	AC005540.3	4.31	1.78e-05	0.00137	0.17	0.13	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190977153	chr2:190880797~190882059:-
BRCA	cis	rs16846053	0.792	rs62190671	ENSG00000227403.1	AC009299.3	4.31	1.78e-05	0.00137	0.3	0.13	Blood osmolality (transformed sodium);	chr2:161796451	chr2:161244739~161249050:+
BRCA	cis	rs10458771	0.667	rs2588292	ENSG00000227896.2	RP11-77P6.2	4.31	1.78e-05	0.00137	0.21	0.13	Amyotrophic lateral sclerosis (sporadic);	chr10:86536348	chr10:86521945~86525101:+
BRCA	cis	rs7267979	0.773	rs6132821	ENSG00000125804.12	FAM182A	-4.31	1.78e-05	0.00137	-0.17	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25245556	chr20:26054655~26086917:+
BRCA	cis	rs7824557	0.505	rs2736313	ENSG00000255020.1	AF131216.5	-4.31	1.78e-05	0.00137	-0.16	-0.13	Retinal vascular caliber;	chr8:11229433	chr8:11345748~11347502:-
BRCA	cis	rs7918232	0.83	rs7087033	ENSG00000262412.1	RP11-85G18.6	4.31	1.78e-05	0.00137	0.22	0.13	Breast cancer;	chr10:27103593	chr10:27243130~27250804:+
BRCA	cis	rs6585424	1	rs10466226	ENSG00000225484.5	NUTM2B-AS1	4.31	1.78e-05	0.00137	0.25	0.13	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80164299	chr10:79663088~79826594:-
BRCA	cis	rs875971	0.862	rs1167408	ENSG00000271064.1	RP11-792A8.3	4.31	1.78e-05	0.00137	0.16	0.13	Aortic root size;	chr7:66091121	chr7:66748838~66749077:-
BRCA	cis	rs875971	0.83	rs1167406	ENSG00000271064.1	RP11-792A8.3	4.31	1.78e-05	0.00137	0.16	0.13	Aortic root size;	chr7:66091949	chr7:66748838~66749077:-
BRCA	cis	rs875971	0.862	rs1167399	ENSG00000271064.1	RP11-792A8.3	4.31	1.78e-05	0.00137	0.16	0.13	Aortic root size;	chr7:66096890	chr7:66748838~66749077:-
BRCA	cis	rs875971	0.862	rs57866200	ENSG00000271064.1	RP11-792A8.3	4.31	1.78e-05	0.00137	0.16	0.13	Aortic root size;	chr7:66100405	chr7:66748838~66749077:-
BRCA	cis	rs9921338	0.961	rs12934968	ENSG00000262703.1	RP11-485G7.6	4.31	1.78e-05	0.00137	0.16	0.13	Vein graft stenosis in coronary artery bypass grafting;	chr16:11320209	chr16:11348143~11349321:-
BRCA	cis	rs997295	0.638	rs11854197	ENSG00000270964.1	RP11-502I4.3	-4.31	1.78e-05	0.00137	-0.15	-0.13	Motion sickness;	chr15:67685046	chr15:67541072~67542604:-
BRCA	cis	rs6496044	0.568	rs7166642	ENSG00000202081.1	RNU6-1280P	4.31	1.78e-05	0.00137	0.15	0.13	Interstitial lung disease;	chr15:85518040	chr15:85651522~85651628:-
BRCA	cis	rs2115630	0.967	rs7171167	ENSG00000275120.1	RP11-182J1.17	-4.31	1.78e-05	0.00137	-0.15	-0.13	P wave terminal force;	chr15:84695892	chr15:84599434~84606463:-
BRCA	cis	rs6600671	1	rs12145080	ENSG00000231429.2	RP11-343N15.2	4.31	1.78e-05	0.00137	0.16	0.13	Hip geometry;	chr1:121443673	chr1:121412719~121429274:+
BRCA	cis	rs17489649	0.955	rs11241040	ENSG00000271849.1	CTC-332L22.1	4.31	1.78e-05	0.00137	0.17	0.13	Intelligence (multi-trait analysis);	chr5:109843058	chr5:109687802~109688329:-
BRCA	cis	rs13126694	0.633	rs13140039	ENSG00000251429.1	RP11-597D13.7	4.31	1.78e-05	0.00137	0.13	0.13	Blood osmolality (transformed sodium);	chr4:158075041	chr4:158270378~158278676:+
BRCA	cis	rs7811142	1	rs7783550	ENSG00000078319.8	PMS2P1	4.31	1.78e-05	0.00137	0.21	0.13	Platelet count;	chr7:100390182	chr7:100320992~100341908:-
BRCA	cis	rs9844666	0.512	rs9834624	ENSG00000273486.1	RP11-731C17.2	4.31	1.78e-05	0.00137	0.16	0.13	Height;	chr3:135922852	chr3:136837338~136839021:-
BRCA	cis	rs9844666	0.512	rs9854494	ENSG00000273486.1	RP11-731C17.2	4.31	1.78e-05	0.00137	0.16	0.13	Height;	chr3:135922980	chr3:136837338~136839021:-
BRCA	cis	rs4388249	0.651	rs31599	ENSG00000249476.1	CTD-2587M2.1	4.31	1.78e-05	0.00138	0.2	0.13	Schizophrenia;	chr5:109671554	chr5:109237120~109326369:-
BRCA	cis	rs6430585	0.527	rs2289959	ENSG00000231890.6	DARS-AS1	-4.31	1.78e-05	0.00138	-0.2	-0.13	Corneal structure;	chr2:135666334	chr2:135985176~136022593:+
BRCA	cis	rs4834770	1	rs878374	ENSG00000250412.1	KLHL2P1	4.31	1.78e-05	0.00138	0.14	0.13	Blood protein levels;	chr4:119316409	chr4:119334329~119378233:+
BRCA	cis	rs4835473	0.932	rs13129993	ENSG00000249741.2	RP11-673E1.3	4.31	1.79e-05	0.00138	0.15	0.13	Immature fraction of reticulocytes;	chr4:143763076	chr4:143911514~143912053:-
BRCA	cis	rs3812049	0.737	rs1993878	ENSG00000245937.6	LINC01184	4.31	1.79e-05	0.00138	0.18	0.13	Lymphocyte counts;Red cell distribution width;	chr5:128141279	chr5:127940426~128083172:-
BRCA	cis	rs8180040	0.726	rs2061197	ENSG00000276925.1	RP11-708J19.3	4.31	1.79e-05	0.00138	0.15	0.13	Colorectal cancer;	chr3:46959860	chr3:47469777~47469987:+
BRCA	cis	rs13113518	1	rs4864548	ENSG00000249700.7	SRD5A3-AS1	-4.31	1.79e-05	0.00138	-0.16	-0.13	Height;	chr4:55547636	chr4:55363971~55395847:-
BRCA	cis	rs10861342	1	rs10861346	ENSG00000257999.1	RP11-61E11.2	-4.31	1.79e-05	0.00138	-0.27	-0.13	IgG glycosylation;	chr12:105079467	chr12:105102472~105107179:-
BRCA	cis	rs67340775	0.541	rs200973	ENSG00000216901.1	AL022393.7	4.31	1.79e-05	0.00138	0.21	0.13	Lung cancer in ever smokers;	chr6:27890643	chr6:28176188~28176674:+
BRCA	cis	rs11098499	0.644	rs2389880	ENSG00000249244.1	RP11-548H18.2	4.31	1.79e-05	0.00138	0.15	0.13	Corneal astigmatism;	chr4:119638715	chr4:119391831~119395335:-
BRCA	cis	rs12681366	0.623	rs10106494	ENSG00000253175.1	RP11-267M23.6	4.31	1.79e-05	0.00138	0.16	0.13	Nonsyndromic cleft lip with cleft palate;	chr8:94471226	chr8:94565036~94565715:+
BRCA	cis	rs4664293	1	rs12692554	ENSG00000226266.5	AC009961.3	-4.31	1.79e-05	0.00138	-0.16	-0.13	Monocyte percentage of white cells;	chr2:159594777	chr2:159670708~159712435:-
BRCA	cis	rs6545883	0.825	rs7578139	ENSG00000212978.6	AC016747.3	-4.31	1.79e-05	0.00138	-0.18	-0.13	Tuberculosis;	chr2:61336986	chr2:61141592~61144969:-
BRCA	cis	rs12962334	0.518	rs4800141	ENSG00000265939.1	UBE2CP2	4.31	1.79e-05	0.00138	0.15	0.13	Breast cancer;	chr18:22984312	chr18:22900486~22900995:-
BRCA	cis	rs2880765	0.835	rs7180923	ENSG00000230373.7	GOLGA6L5P	4.31	1.79e-05	0.00138	0.14	0.13	Coronary artery disease;	chr15:85507659	chr15:84507885~84516814:-
BRCA	cis	rs11098499	0.575	rs907204	ENSG00000225892.3	RP11-384K6.2	4.31	1.79e-05	0.00138	0.13	0.13	Corneal astigmatism;	chr4:119317499	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.575	rs907205	ENSG00000225892.3	RP11-384K6.2	4.31	1.79e-05	0.00138	0.13	0.13	Corneal astigmatism;	chr4:119317509	chr4:118632274~118634759:+
BRCA	cis	rs10266483	0.515	rs6948710	ENSG00000228653.2	HNRNPCP7	4.31	1.79e-05	0.00138	0.17	0.13	Response to statin therapy;	chr7:64405625	chr7:64500825~64501729:+
BRCA	cis	rs7267979	0.604	rs242130	ENSG00000274973.1	RP13-401N8.7	4.31	1.79e-05	0.00138	0.15	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25613384	chr20:25845497~25845862:+
BRCA	cis	rs2688608	0.592	rs11000757	ENSG00000213731.2	RAB5CP1	-4.31	1.79e-05	0.00138	-0.15	-0.13	Inflammatory bowel disease;	chr10:73727057	chr10:74423435~74424014:-
BRCA	cis	rs26528	0.584	rs153103	ENSG00000251417.2	RP11-1348G14.4	4.31	1.79e-05	0.00138	0.15	0.13	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr16:28517302	chr16:28802743~28817828:+
BRCA	cis	rs2505998	1	rs2435357	ENSG00000273008.1	RP11-351D16.3	-4.31	1.79e-05	0.00138	-0.16	-0.13	Hirschsprung disease;	chr10:43086608	chr10:43136824~43138334:-
BRCA	cis	rs7267979	0.816	rs422148	ENSG00000204556.4	CTD-2514C3.1	-4.31	1.79e-05	0.00138	-0.18	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25531968	chr20:26018832~26020684:+
BRCA	cis	rs9307551	1	rs3109166	ENSG00000250334.4	LINC00989	4.31	1.79e-05	0.00138	0.2	0.13	Refractive error;	chr4:79631045	chr4:79492416~79576460:+
BRCA	cis	rs6847067	0.644	rs1484661	ENSG00000180769.7	WDFY3-AS2	4.31	1.79e-05	0.00138	0.13	0.13	Oropharynx cancer;	chr4:84861079	chr4:84965682~85011277:+
BRCA	cis	rs4578769	0.722	rs4335860	ENSG00000265939.1	UBE2CP2	-4.31	1.79e-05	0.00138	-0.17	-0.13	Eosinophil percentage of white cells;	chr18:22976664	chr18:22900486~22900995:-
BRCA	cis	rs3764021	0.933	rs10492165	ENSG00000256582.1	RP11-75L1.1	4.31	1.79e-05	0.00138	0.13	0.13	Type 1 diabetes;	chr12:9733365	chr12:9704077~9709350:+
BRCA	cis	rs6696239	1	rs12092054	ENSG00000227711.2	RP11-275O4.5	-4.31	1.79e-05	0.00138	-0.18	-0.13	Height;	chr1:227556548	chr1:227509028~227520477:-
BRCA	cis	rs6951245	0.935	rs61910751	ENSG00000229043.2	AC091729.9	-4.31	1.79e-05	0.00138	-0.24	-0.13	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1058259	chr7:1160374~1165267:+
BRCA	cis	rs6951245	0.872	rs77434655	ENSG00000229043.2	AC091729.9	-4.31	1.79e-05	0.00138	-0.24	-0.13	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1058769	chr7:1160374~1165267:+
BRCA	cis	rs6951245	0.872	rs75398423	ENSG00000229043.2	AC091729.9	-4.31	1.79e-05	0.00138	-0.24	-0.13	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1058778	chr7:1160374~1165267:+
BRCA	cis	rs6951245	0.872	rs112309216	ENSG00000229043.2	AC091729.9	-4.31	1.79e-05	0.00138	-0.24	-0.13	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1060660	chr7:1160374~1165267:+
BRCA	cis	rs6951245	0.872	rs76161580	ENSG00000229043.2	AC091729.9	-4.31	1.79e-05	0.00138	-0.24	-0.13	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1060671	chr7:1160374~1165267:+
BRCA	cis	rs6951245	1	rs76388414	ENSG00000229043.2	AC091729.9	-4.31	1.79e-05	0.00138	-0.24	-0.13	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1061058	chr7:1160374~1165267:+
BRCA	cis	rs6951245	1	rs77305932	ENSG00000229043.2	AC091729.9	-4.31	1.79e-05	0.00138	-0.24	-0.13	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1061225	chr7:1160374~1165267:+
BRCA	cis	rs6951245	0.872	rs11768486	ENSG00000229043.2	AC091729.9	-4.31	1.79e-05	0.00138	-0.24	-0.13	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1061654	chr7:1160374~1165267:+
BRCA	cis	rs6951245	1	rs11766526	ENSG00000229043.2	AC091729.9	-4.31	1.79e-05	0.00138	-0.24	-0.13	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1061797	chr7:1160374~1165267:+
BRCA	cis	rs4218	0.648	rs2289895	ENSG00000259732.1	RP11-59H7.3	-4.31	1.79e-05	0.00138	-0.17	-0.13	Social communication problems;	chr15:59089570	chr15:59121034~59133250:+
BRCA	cis	rs10411936	0.682	rs6512113	ENSG00000280332.1	CTD-2013N17.6	4.31	1.79e-05	0.00138	0.11	0.13	Multiple sclerosis;White blood cell count;	chr19:16487458	chr19:16356329~16358327:-
BRCA	cis	rs7819412	0.54	rs2409725	ENSG00000255046.1	RP11-297N6.4	4.31	1.79e-05	0.00138	0.16	0.13	Triglycerides;	chr8:11184152	chr8:11797928~11802568:-
BRCA	cis	rs9650657	0.504	rs10109167	ENSG00000154316.13	TDH	4.31	1.79e-05	0.00138	0.17	0.13	Neuroticism;	chr8:11176016	chr8:11339637~11368452:+
BRCA	cis	rs10129255	1	rs8012033	ENSG00000274576.2	IGHV2-70	4.31	1.79e-05	0.00138	0.12	0.13	Kawasaki disease;	chr14:106678854	chr14:106770577~106771020:-
BRCA	cis	rs13113518	1	rs55699500	ENSG00000272969.1	RP11-528I4.2	4.31	1.79e-05	0.00138	0.15	0.13	Height;	chr4:55540912	chr4:55547112~55547889:+
BRCA	cis	rs862034	0.902	rs862049	ENSG00000270000.1	RP3-449M8.9	4.31	1.79e-05	0.00138	0.16	0.13	Height;	chr14:74515179	chr14:74471930~74472360:-
BRCA	cis	rs4950322	0.518	rs11811023	ENSG00000237188.3	RP11-337C18.8	-4.31	1.79e-05	0.00138	-0.15	-0.13	Protein quantitative trait loci;	chr1:147109536	chr1:147172771~147211568:+
BRCA	cis	rs11098499	0.909	rs79026312	ENSG00000250412.1	KLHL2P1	4.31	1.8e-05	0.00138	0.16	0.13	Corneal astigmatism;	chr4:119519522	chr4:119334329~119378233:+
BRCA	cis	rs11098499	0.909	rs35111518	ENSG00000250412.1	KLHL2P1	4.31	1.8e-05	0.00138	0.16	0.13	Corneal astigmatism;	chr4:119519527	chr4:119334329~119378233:+
BRCA	cis	rs41307935	0.818	rs34339345	ENSG00000260063.1	RP5-968P14.2	-4.31	1.8e-05	0.00138	-0.32	-0.13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26899598	chr1:26692132~26694131:-
BRCA	cis	rs71636778	0.509	rs12739698	ENSG00000260063.1	RP5-968P14.2	-4.31	1.8e-05	0.00138	-0.32	-0.13	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26903542	chr1:26692132~26694131:-
BRCA	cis	rs867371	1	rs6495642	ENSG00000278603.1	RP13-608F4.5	4.31	1.8e-05	0.00138	0.18	0.13	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82165156	chr15:82472203~82472426:+
BRCA	cis	rs875971	0.545	rs6950988	ENSG00000232546.1	RP11-458F8.1	4.31	1.8e-05	0.00138	0.13	0.13	Aortic root size;	chr7:66511428	chr7:66848496~66858136:+
BRCA	cis	rs763121	1	rs1946990	ENSG00000225450.1	RP3-508I15.14	4.31	1.8e-05	0.00138	0.13	0.13	Menopause (age at onset);	chr22:38516766	chr22:38739003~38749041:+
BRCA	cis	rs2562456	0.793	rs627522	ENSG00000240522.1	RPL7AP10	-4.31	1.8e-05	0.00138	-0.14	-0.13	Pain;	chr19:21313002	chr19:21149648~21150438:-
BRCA	cis	rs3617	0.625	rs2240917	ENSG00000242142.1	SERBP1P3	4.31	1.8e-05	0.00138	0.15	0.13	Red blood cell count;Autism spectrum disorder or schizophrenia;	chr3:52817121	chr3:53064283~53065091:-
BRCA	cis	rs9470794	0.92	rs2145887	ENSG00000204110.6	RP1-153P14.8	-4.31	1.8e-05	0.00139	-0.24	-0.13	Type 2 diabetes;	chr6:38129998	chr6:37507348~37535616:+
BRCA	cis	rs1387259	0.619	rs7134565	ENSG00000273765.1	RP11-370I10.11	-4.31	1.8e-05	0.00139	-0.15	-0.13	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48236241	chr12:48360920~48361377:+
BRCA	cis	rs7824557	0.767	rs4559208	ENSG00000154316.13	TDH	-4.31	1.8e-05	0.00139	-0.18	-0.13	Retinal vascular caliber;	chr8:11296416	chr8:11339637~11368452:+
BRCA	cis	rs886774	0.774	rs2108224	ENSG00000273055.1	CTB-13F3.1	4.31	1.8e-05	0.00139	0.13	0.13	Ulcerative colitis;	chr7:107943181	chr7:107942116~107942740:+
BRCA	cis	rs12446632	0.539	rs9941245	ENSG00000261195.1	CTD-2380F24.1	4.31	1.8e-05	0.00139	0.19	0.13	Hip circumference;Body mass index (joint analysis main effects and smoking interaction);BMI in smokers;Menarche (age at onset);Obesity;Childhood body mass index;Waist circumference;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Body mass index;	chr16:19905573	chr16:19761172~19766099:-
BRCA	cis	rs56322409	1	rs7917792	ENSG00000226688.5	ENTPD1-AS1	4.31	1.8e-05	0.00139	0.15	0.13	Blood metabolite levels;	chr10:95605870	chr10:95753206~96090238:-
BRCA	cis	rs4578769	0.681	rs6507450	ENSG00000265939.1	UBE2CP2	4.31	1.8e-05	0.00139	0.17	0.13	Eosinophil percentage of white cells;	chr18:23030584	chr18:22900486~22900995:-
BRCA	cis	rs2304003	1	rs10754968	ENSG00000235192.1	AC009495.2	4.31	1.8e-05	0.00139	0.16	0.13	Social communication problems;	chr2:165845956	chr2:165794851~165810010:+
BRCA	cis	rs10411936	0.72	rs4808513	ENSG00000280332.1	CTD-2013N17.6	4.31	1.8e-05	0.00139	0.11	0.13	Multiple sclerosis;White blood cell count;	chr19:16469687	chr19:16356329~16358327:-
BRCA	cis	rs17711722	0.528	rs73138179	ENSG00000226767.1	RP11-328P23.3	4.31	1.8e-05	0.00139	0.16	0.13	Calcium levels;	chr7:65829495	chr7:65508773~65508944:-
BRCA	cis	rs11098499	0.754	rs2036857	ENSG00000225892.3	RP11-384K6.2	4.31	1.8e-05	0.00139	0.13	0.13	Corneal astigmatism;	chr4:119328085	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.754	rs2036856	ENSG00000225892.3	RP11-384K6.2	4.31	1.8e-05	0.00139	0.13	0.13	Corneal astigmatism;	chr4:119328133	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.754	rs4443261	ENSG00000225892.3	RP11-384K6.2	4.31	1.8e-05	0.00139	0.13	0.13	Corneal astigmatism;	chr4:119328146	chr4:118632274~118634759:+
BRCA	cis	rs10129255	0.957	rs2007467	ENSG00000274576.2	IGHV2-70	-4.31	1.8e-05	0.00139	-0.12	-0.13	Kawasaki disease;	chr14:106771605	chr14:106770577~106771020:-
BRCA	cis	rs644148	0.933	rs565819	ENSG00000176761.7	ZNF285B	-4.31	1.8e-05	0.00139	-0.15	-0.13	Personality dimensions;	chr19:44463492	chr19:44467641~44473227:+
BRCA	cis	rs17428076	0.71	rs62181740	ENSG00000228389.1	AC068039.4	-4.31	1.8e-05	0.00139	-0.23	-0.13	Myopia;	chr2:171683891	chr2:171773482~171775844:+
BRCA	cis	rs4664293	0.769	rs1365798	ENSG00000224152.1	AC009506.1	4.31	1.8e-05	0.00139	0.15	0.13	Monocyte percentage of white cells;	chr2:159795853	chr2:159615296~159617082:+
BRCA	cis	rs6596100	0.915	rs6867581	ENSG00000248648.1	RP11-485M7.1	-4.31	1.8e-05	0.00139	-0.17	-0.13	Breast cancer;	chr5:133053587	chr5:133003119~133003365:+
BRCA	cis	rs6596100	0.956	rs62375202	ENSG00000248648.1	RP11-485M7.1	-4.31	1.8e-05	0.00139	-0.17	-0.13	Breast cancer;	chr5:133054891	chr5:133003119~133003365:+
BRCA	cis	rs6596100	0.91	rs56104944	ENSG00000248648.1	RP11-485M7.1	-4.31	1.8e-05	0.00139	-0.17	-0.13	Breast cancer;	chr5:133069043	chr5:133003119~133003365:+
BRCA	cis	rs11887277	0.741	rs11126734	ENSG00000272148.1	RP11-195B17.1	4.31	1.8e-05	0.00139	0.15	0.13	Obesity-related traits;	chr2:26813110	chr2:27062428~27062907:-
BRCA	cis	rs644148	0.836	rs2686777	ENSG00000176761.7	ZNF285B	4.31	1.8e-05	0.00139	0.15	0.13	Personality dimensions;	chr19:44496325	chr19:44467641~44473227:+
BRCA	cis	rs2018683	0.624	rs1006521	ENSG00000233517.1	AC005162.5	-4.31	1.8e-05	0.00139	-0.16	-0.13	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28956604	chr7:28987028~28988899:+
BRCA	cis	rs12438356	1	rs28640063	ENSG00000259222.2	RP11-809H16.5	-4.31	1.8e-05	0.00139	-0.23	-0.13	CTACK levels;	chr15:69297324	chr15:69080879~69099987:+
BRCA	cis	rs6545883	0.929	rs778154	ENSG00000270820.4	RP11-355B11.2	-4.31	1.8e-05	0.00139	-0.16	-0.13	Tuberculosis;	chr2:61419496	chr2:61471188~61484130:+
BRCA	cis	rs442309	0.807	rs224029	ENSG00000238280.1	RP11-436D10.3	-4.31	1.8e-05	0.00139	-0.17	-0.13	Vogt-Koyanagi-Harada syndrome;	chr10:62759539	chr10:62793562~62805887:-
BRCA	cis	rs2243480	1	rs34970380	ENSG00000222364.1	RNU6-96P	-4.31	1.8e-05	0.00139	-0.24	-0.13	Diabetic kidney disease;	chr7:65966506	chr7:66395191~66395286:+
BRCA	cis	rs9903692	0.954	rs6847	ENSG00000263412.1	RP5-890E16.2	4.31	1.8e-05	0.00139	0.14	0.13	Pulse pressure;	chr17:48070445	chr17:48045141~48048073:-
BRCA	cis	rs2692947	0.832	rs2579519	ENSG00000168992.4	OR7E102P	4.31	1.8e-05	0.00139	0.18	0.13	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96009418	chr2:95546531~95547545:+
BRCA	cis	rs1790761	0.52	rs1551884	ENSG00000231793.4	DOC2GP	-4.31	1.8e-05	0.00139	-0.14	-0.13	Mean corpuscular volume;	chr11:67632130	chr11:67612653~67616257:-
BRCA	cis	rs2235544	0.565	rs650134	ENSG00000225183.1	RP4-758J24.4	4.31	1.8e-05	0.00139	0.16	0.13	Thyroid hormone levels;Multiple myeloma (hyperdiploidy);	chr1:54001669	chr1:54089856~54090093:+
BRCA	cis	rs2235544	0.588	rs662603	ENSG00000225183.1	RP4-758J24.4	4.31	1.8e-05	0.00139	0.16	0.13	Thyroid hormone levels;Multiple myeloma (hyperdiploidy);	chr1:54002094	chr1:54089856~54090093:+
BRCA	cis	rs2235544	0.565	rs664848	ENSG00000225183.1	RP4-758J24.4	4.31	1.8e-05	0.00139	0.16	0.13	Thyroid hormone levels;Multiple myeloma (hyperdiploidy);	chr1:54002648	chr1:54089856~54090093:+
BRCA	cis	rs2235544	0.565	rs633697	ENSG00000225183.1	RP4-758J24.4	4.31	1.8e-05	0.00139	0.16	0.13	Thyroid hormone levels;Multiple myeloma (hyperdiploidy);	chr1:54003087	chr1:54089856~54090093:+
BRCA	cis	rs2235544	0.565	rs677481	ENSG00000225183.1	RP4-758J24.4	4.31	1.8e-05	0.00139	0.16	0.13	Thyroid hormone levels;Multiple myeloma (hyperdiploidy);	chr1:54003164	chr1:54089856~54090093:+
BRCA	cis	rs2235544	0.565	rs635059	ENSG00000225183.1	RP4-758J24.4	4.31	1.8e-05	0.00139	0.16	0.13	Thyroid hormone levels;Multiple myeloma (hyperdiploidy);	chr1:54003447	chr1:54089856~54090093:+
BRCA	cis	rs10788972	0.51	rs665817	ENSG00000225183.1	RP4-758J24.4	4.31	1.8e-05	0.00139	0.16	0.13	Parkinson disease and lewy body pathology;	chr1:54004275	chr1:54089856~54090093:+
BRCA	cis	rs2235544	0.542	rs585269	ENSG00000225183.1	RP4-758J24.4	4.31	1.8e-05	0.00139	0.16	0.13	Thyroid hormone levels;Multiple myeloma (hyperdiploidy);	chr1:54004303	chr1:54089856~54090093:+
BRCA	cis	rs2235544	0.542	rs11206272	ENSG00000225183.1	RP4-758J24.4	4.31	1.8e-05	0.00139	0.16	0.13	Thyroid hormone levels;Multiple myeloma (hyperdiploidy);	chr1:54004362	chr1:54089856~54090093:+
BRCA	cis	rs10129255	0.957	rs10132367	ENSG00000274576.2	IGHV2-70	4.31	1.81e-05	0.00139	0.12	0.13	Kawasaki disease;	chr14:106690981	chr14:106770577~106771020:-
BRCA	cis	rs5742933	0.69	rs16831821	ENSG00000253559.1	OSGEPL1-AS1	-4.31	1.81e-05	0.00139	-0.23	-0.13	Ferritin levels;	chr2:189641087	chr2:189762704~189765556:+
BRCA	cis	rs718433	0.616	rs2222916	ENSG00000256379.1	TRAV8-5	4.31	1.81e-05	0.00139	0.15	0.13	Intraocular pressure;	chr14:21744319	chr14:21903077~21903598:+
BRCA	cis	rs17507216	0.718	rs28587782	ENSG00000259429.4	UBE2Q2P2	-4.31	1.81e-05	0.00139	-0.16	-0.13	Excessive daytime sleepiness;	chr15:82576881	chr15:82355142~82420075:+
BRCA	cis	rs6751744	0.513	rs6738215	ENSG00000226266.5	AC009961.3	-4.31	1.81e-05	0.00139	-0.16	-0.13	Dysphagia;	chr2:159596794	chr2:159670708~159712435:-
BRCA	cis	rs4713118	0.786	rs200503	ENSG00000216901.1	AL022393.7	4.31	1.81e-05	0.00139	0.18	0.13	Parkinson's disease;	chr6:27818104	chr6:28176188~28176674:+
BRCA	cis	rs4713118	0.786	rs200502	ENSG00000216901.1	AL022393.7	4.31	1.81e-05	0.00139	0.18	0.13	Parkinson's disease;	chr6:27820284	chr6:28176188~28176674:+
BRCA	cis	rs3764021	0.87	rs10844622	ENSG00000256582.1	RP11-75L1.1	4.31	1.81e-05	0.00139	0.13	0.13	Type 1 diabetes;	chr12:9732486	chr12:9704077~9709350:+
BRCA	cis	rs11951515	0.508	rs6898866	ENSG00000248240.1	RP11-159F24.5	-4.31	1.81e-05	0.00139	-0.16	-0.13	Metabolite levels  (X-11787);	chr5:43586273	chr5:43515274~43525310:+
BRCA	cis	rs2136613	0.533	rs10761668	ENSG00000238280.1	RP11-436D10.3	-4.31	1.81e-05	0.00139	-0.17	-0.13	Selective IgA deficiency;	chr10:62849983	chr10:62793562~62805887:-
BRCA	cis	rs10995356	0.932	rs10995370	ENSG00000238280.1	RP11-436D10.3	-4.31	1.81e-05	0.00139	-0.17	-0.13	Temperament;	chr10:62926803	chr10:62793562~62805887:-
BRCA	cis	rs9921338	1	rs8049173	ENSG00000262703.1	RP11-485G7.6	-4.31	1.81e-05	0.00139	-0.17	-0.13	Vein graft stenosis in coronary artery bypass grafting;	chr16:11343025	chr16:11348143~11349321:-
BRCA	cis	rs9921338	1	rs8055427	ENSG00000262703.1	RP11-485G7.6	-4.31	1.81e-05	0.00139	-0.17	-0.13	Vein graft stenosis in coronary artery bypass grafting;	chr16:11343026	chr16:11348143~11349321:-
BRCA	cis	rs9921338	0.961	rs9936093	ENSG00000262703.1	RP11-485G7.6	-4.31	1.81e-05	0.00139	-0.17	-0.13	Vein graft stenosis in coronary artery bypass grafting;	chr16:11343459	chr16:11348143~11349321:-
BRCA	cis	rs4916588	0.636	rs60109201	ENSG00000230732.4	AC127904.2	4.31	1.81e-05	0.00139	0.17	0.13	Night sleep phenotypes;	chr3:196888119	chr3:196912646~196914579:+
BRCA	cis	rs6750795	0.746	rs1667301	ENSG00000223198.1	RNU2-22P	-4.31	1.81e-05	0.00139	-0.16	-0.13	Height;	chr2:231559006	chr2:231501990~231502201:-
BRCA	cis	rs17489649	0.956	rs2269210	ENSG00000271849.1	CTC-332L22.1	4.31	1.81e-05	0.00139	0.17	0.13	Intelligence (multi-trait analysis);	chr5:109793064	chr5:109687802~109688329:-
BRCA	cis	rs3748682	0.731	rs9729719	ENSG00000222282.1	RNU6-584P	-4.31	1.81e-05	0.00139	-0.16	-0.13	Hypothyroidism;	chr1:37832535	chr1:37885023~37885117:+
BRCA	cis	rs1661178	0.826	rs1623156	ENSG00000176761.7	ZNF285B	4.31	1.81e-05	0.00139	0.24	0.13	Exploratory eye movement dysfunction in schizophrenia (responsive search score);	chr19:44540600	chr19:44467641~44473227:+
BRCA	cis	rs1440581	0.935	rs6841731	ENSG00000246375.2	RP11-10L7.1	4.31	1.81e-05	0.00139	0.17	0.13	Blood metabolite levels;Metabolite levels;	chr4:88307776	chr4:88284942~88331421:+
BRCA	cis	rs801193	0.548	rs2659904	ENSG00000236529.1	RP13-254B10.1	4.31	1.81e-05	0.00139	0.15	0.13	Aortic root size;	chr7:66713615	chr7:65840212~65840596:+
BRCA	cis	rs1322639	0.614	rs6937001	ENSG00000223485.1	RP11-417E7.1	4.31	1.81e-05	0.00139	0.19	0.13	Pulse pressure;	chr6:169164991	chr6:169158092~169162924:-
BRCA	cis	rs7267979	0.565	rs6076364	ENSG00000125804.12	FAM182A	4.31	1.81e-05	0.00139	0.17	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25576165	chr20:26054655~26086917:+
BRCA	cis	rs34792	0.528	rs222130	ENSG00000207425.1	Y_RNA	-4.31	1.81e-05	0.00139	-0.15	-0.13	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15454453	chr16:14915457~14915556:-
BRCA	cis	rs6545883	0.54	rs11687956	ENSG00000271889.1	RP11-493E12.1	-4.31	1.81e-05	0.00139	-0.17	-0.13	Tuberculosis;	chr2:61624207	chr2:61151433~61162105:-
BRCA	cis	rs13113518	0.545	rs6810483	ENSG00000223305.1	RN7SKP30	4.31	1.81e-05	0.00139	0.17	0.13	Height;	chr4:55424406	chr4:55540502~55540835:-
BRCA	cis	rs875971	0.502	rs1796227	ENSG00000232546.1	RP11-458F8.1	-4.31	1.81e-05	0.00139	-0.13	-0.13	Aortic root size;	chr7:66622032	chr7:66848496~66858136:+
BRCA	cis	rs4143844	1	rs35932993	ENSG00000259251.2	RP11-643M14.1	4.31	1.81e-05	0.00139	0.33	0.13	Bipolar disorder and schizophrenia;	chr15:62069557	chr15:62060503~62062434:+
BRCA	cis	rs11098499	0.754	rs878372	ENSG00000225892.3	RP11-384K6.2	4.31	1.81e-05	0.0014	0.13	0.13	Corneal astigmatism;	chr4:119317625	chr4:118632274~118634759:+
BRCA	cis	rs10129255	0.556	rs6576222	ENSG00000211959.2	IGHV4-39	4.31	1.81e-05	0.0014	0.09	0.13	Kawasaki disease;	chr14:106776442	chr14:106421711~106422218:-
BRCA	cis	rs4489787	1	rs11168638	ENSG00000240399.1	RP1-228P16.1	-4.31	1.81e-05	0.0014	-0.26	-0.13	Prostate cancer (SNP x SNP interaction);	chr12:48559788	chr12:48054813~48055591:-
BRCA	cis	rs321358	1	rs321359	ENSG00000271390.1	RP11-89C3.3	4.31	1.81e-05	0.0014	0.21	0.13	Body mass index;	chr11:111125257	chr11:111089870~111090368:-
BRCA	cis	rs6772849	0.775	rs12486377	ENSG00000242551.2	POU5F1P6	-4.31	1.81e-05	0.0014	-0.17	-0.13	Monocyte percentage of white cells;Monocyte count;	chr3:128696010	chr3:128674735~128677005:-
BRCA	cis	rs6545883	0.794	rs12053388	ENSG00000212978.6	AC016747.3	-4.31	1.81e-05	0.0014	-0.18	-0.13	Tuberculosis;	chr2:61305185	chr2:61141592~61144969:-
BRCA	cis	rs853679	1	rs6901575	ENSG00000280107.1	AL022393.9	-4.31	1.81e-05	0.0014	-0.24	-0.13	Depression;	chr6:28283207	chr6:28170845~28172521:+
BRCA	cis	rs6496044	0.568	rs10468112	ENSG00000202081.1	RNU6-1280P	4.31	1.81e-05	0.0014	0.15	0.13	Interstitial lung disease;	chr15:85530193	chr15:85651522~85651628:-
BRCA	cis	rs6496044	0.568	rs2344436	ENSG00000202081.1	RNU6-1280P	4.31	1.81e-05	0.0014	0.15	0.13	Interstitial lung disease;	chr15:85531675	chr15:85651522~85651628:-
BRCA	cis	rs6496044	0.568	rs6496065	ENSG00000202081.1	RNU6-1280P	4.31	1.81e-05	0.0014	0.15	0.13	Interstitial lung disease;	chr15:85532141	chr15:85651522~85651628:-
BRCA	cis	rs6496044	0.568	rs6496066	ENSG00000202081.1	RNU6-1280P	4.31	1.81e-05	0.0014	0.15	0.13	Interstitial lung disease;	chr15:85532231	chr15:85651522~85651628:-
BRCA	cis	rs4742903	0.904	rs10991167	ENSG00000270332.1	SMC2-AS1	-4.31	1.81e-05	0.0014	-0.14	-0.13	Breast cancer;High-grade serous ovarian cancer;	chr9:104212101	chr9:104080024~104093073:-
BRCA	cis	rs1048886	0.872	rs6913548	ENSG00000271967.1	RP11-134K13.4	-4.31	1.81e-05	0.0014	-0.19	-0.13	Type 2 diabetes;	chr6:70519167	chr6:70596438~70596980:+
BRCA	cis	rs11098499	0.954	rs3733519	ENSG00000260091.1	RP11-33B1.4	-4.31	1.81e-05	0.0014	-0.12	-0.13	Corneal astigmatism;	chr4:119502293	chr4:119409333~119410233:+
BRCA	cis	rs875971	0.545	rs1638724	ENSG00000232546.1	RP11-458F8.1	-4.31	1.81e-05	0.0014	-0.13	-0.13	Aortic root size;	chr7:66575494	chr7:66848496~66858136:+
BRCA	cis	rs9470794	0.831	rs73419487	ENSG00000204110.6	RP1-153P14.8	-4.31	1.81e-05	0.0014	-0.27	-0.13	Type 2 diabetes;	chr6:37917366	chr6:37507348~37535616:+
BRCA	cis	rs9470794	0.915	rs11754247	ENSG00000204110.6	RP1-153P14.8	-4.31	1.81e-05	0.0014	-0.27	-0.13	Type 2 diabetes;	chr6:37921381	chr6:37507348~37535616:+
BRCA	cis	rs9470794	0.915	rs11759486	ENSG00000204110.6	RP1-153P14.8	-4.31	1.81e-05	0.0014	-0.27	-0.13	Type 2 diabetes;	chr6:37931110	chr6:37507348~37535616:+
BRCA	cis	rs1950832	0.657	rs853237	ENSG00000258636.1	CTD-2298J14.2	4.31	1.82e-05	0.0014	0.16	0.13	Urate levels in obese individuals;	chr14:41648025	chr14:41587861~41604856:-
BRCA	cis	rs7267979	0.565	rs4815432	ENSG00000125804.12	FAM182A	4.31	1.82e-05	0.0014	0.17	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25575767	chr20:26054655~26086917:+
BRCA	cis	rs934734	0.532	rs12470883	ENSG00000281920.1	RP11-418H16.1	-4.31	1.82e-05	0.0014	-0.16	-0.13	Rheumatoid arthritis;	chr2:65424717	chr2:65623272~65628424:+
BRCA	cis	rs71636778	0.509	rs17356923	ENSG00000260063.1	RP5-968P14.2	-4.31	1.82e-05	0.0014	-0.29	-0.13	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26956185	chr1:26692132~26694131:-
BRCA	cis	rs71636778	0.509	rs12742376	ENSG00000260063.1	RP5-968P14.2	-4.31	1.82e-05	0.0014	-0.29	-0.13	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26958704	chr1:26692132~26694131:-
BRCA	cis	rs71636778	0.509	rs34514856	ENSG00000260063.1	RP5-968P14.2	-4.31	1.82e-05	0.0014	-0.29	-0.13	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26961069	chr1:26692132~26694131:-
BRCA	cis	rs71636778	0.509	rs60340200	ENSG00000260063.1	RP5-968P14.2	-4.31	1.82e-05	0.0014	-0.29	-0.13	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26961225	chr1:26692132~26694131:-
BRCA	cis	rs17489649	0.955	rs2216555	ENSG00000271849.1	CTC-332L22.1	4.31	1.82e-05	0.0014	0.17	0.13	Intelligence (multi-trait analysis);	chr5:109800930	chr5:109687802~109688329:-
BRCA	cis	rs11098499	0.908	rs7696649	ENSG00000260091.1	RP11-33B1.4	-4.31	1.82e-05	0.0014	-0.12	-0.13	Corneal astigmatism;	chr4:119401022	chr4:119409333~119410233:+
BRCA	cis	rs10129255	0.536	rs10139058	ENSG00000211967.3	IGHV3-53	-4.31	1.82e-05	0.0014	-0.09	-0.13	Kawasaki disease;	chr14:106685899	chr14:106592676~106593347:-
BRCA	cis	rs2136613	0.533	rs10995327	ENSG00000238280.1	RP11-436D10.3	-4.31	1.82e-05	0.0014	-0.17	-0.13	Selective IgA deficiency;	chr10:62842814	chr10:62793562~62805887:-
BRCA	cis	rs409045	1	rs399862	ENSG00000271874.1	CTD-2024P10.2	-4.31	1.82e-05	0.0014	-0.17	-0.13	Left ventricular mass;	chr5:34627728	chr5:34651457~34651888:-
BRCA	cis	rs7927592	0.956	rs11228258	ENSG00000212093.1	AP000807.1	-4.31	1.82e-05	0.0014	-0.15	-0.13	Total body bone mineral density;	chr11:68486860	chr11:68506083~68506166:-
BRCA	cis	rs9863	0.861	rs12301673	ENSG00000270028.1	RP11-380L11.4	4.31	1.82e-05	0.0014	0.16	0.13	White blood cell count;	chr12:123971271	chr12:123925461~123926083:-
BRCA	cis	rs7918232	0.943	rs6482593	ENSG00000262412.1	RP11-85G18.6	4.31	1.82e-05	0.0014	0.21	0.13	Breast cancer;	chr10:27082508	chr10:27243130~27250804:+
BRCA	cis	rs17507216	0.609	rs1431716	ENSG00000259429.4	UBE2Q2P2	-4.31	1.82e-05	0.0014	-0.17	-0.13	Excessive daytime sleepiness;	chr15:82676180	chr15:82355142~82420075:+
BRCA	cis	rs1371614	0.566	rs11902826	ENSG00000272148.1	RP11-195B17.1	-4.31	1.82e-05	0.0014	-0.15	-0.13	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26954677	chr2:27062428~27062907:-
BRCA	cis	rs7572733	0.935	rs6434942	ENSG00000231621.1	AC013264.2	-4.31	1.82e-05	0.0014	-0.12	-0.13	Dermatomyositis;	chr2:197891964	chr2:197197991~197199273:+
BRCA	cis	rs2898681	0.874	rs6852148	ENSG00000248375.1	RP11-177B4.1	-4.31	1.82e-05	0.0014	-0.19	-0.13	Optic nerve measurement (cup area);	chr4:52883835	chr4:52720081~52720831:-
BRCA	cis	rs984222	0.501	rs1779420	ENSG00000231365.4	RP11-418J17.1	-4.31	1.82e-05	0.0014	-0.15	-0.13	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:118943840	chr1:119140396~119275973:+
BRCA	cis	rs8040855	0.627	rs35668291	ENSG00000259774.1	RP11-182J1.13	4.31	1.82e-05	0.0014	0.18	0.13	Bulimia nervosa;	chr15:85109582	chr15:84422618~84425882:+
BRCA	cis	rs516805	0.528	rs2606627	ENSG00000279114.1	RP3-425C14.5	-4.31	1.82e-05	0.0014	-0.16	-0.13	Lymphocyte counts;	chr6:122097129	chr6:122471923~122484161:+
BRCA	cis	rs812925	0.537	rs778146	ENSG00000273302.1	RP11-493E12.2	-4.31	1.82e-05	0.0014	-0.12	-0.13	Immature fraction of reticulocytes;	chr2:61379340	chr2:61199979~61200769:+
BRCA	cis	rs7267979	0.873	rs6132822	ENSG00000125804.12	FAM182A	-4.31	1.82e-05	0.0014	-0.17	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25248059	chr20:26054655~26086917:+
BRCA	cis	rs875971	1	rs709597	ENSG00000229180.5	GS1-124K5.11	-4.31	1.82e-05	0.0014	-0.11	-0.13	Aortic root size;	chr7:66360996	chr7:66526088~66542624:-
BRCA	cis	rs983392	0.868	rs11605427	ENSG00000275344.1	MIR6503	-4.31	1.82e-05	0.0014	-0.14	-0.13	Alzheimer's disease (late onset);	chr11:60161199	chr11:60209071~60209156:-
BRCA	cis	rs2243480	0.908	rs1532573	ENSG00000275400.1	RP4-756H11.5	-4.31	1.82e-05	0.0014	-0.24	-0.13	Diabetic kidney disease;	chr7:66333815	chr7:66553805~66554199:-
BRCA	cis	rs7131987	0.565	rs7976667	ENSG00000275476.1	RP11-996F15.4	4.31	1.82e-05	0.0014	0.14	0.13	QT interval;	chr12:29273098	chr12:29277397~29277882:-
BRCA	cis	rs1910358	0.614	rs10078669	ENSG00000248874.4	C5orf17	-4.31	1.82e-05	0.0014	-0.17	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23951099	chr5:23951348~24178263:+
BRCA	cis	rs10421328	0.784	rs12983292	ENSG00000267419.1	CTC-559E9.6	-4.31	1.82e-05	0.0014	-0.14	-0.13	Parental longevity (combined parental age at death);	chr19:19676958	chr19:19776602~19834927:+
BRCA	cis	rs763121	0.813	rs4821807	ENSG00000225450.1	RP3-508I15.14	-4.31	1.82e-05	0.0014	-0.14	-0.13	Menopause (age at onset);	chr22:38669577	chr22:38739003~38749041:+
BRCA	cis	rs1075265	0.509	rs10178643	ENSG00000233266.1	HMGB1P31	4.31	1.82e-05	0.0014	0.17	0.13	Chronotype;Morning vs. evening chronotype;	chr2:53728341	chr2:54051334~54051760:+
BRCA	cis	rs11168618	0.904	rs7978948	ENSG00000240399.1	RP1-228P16.1	4.31	1.82e-05	0.0014	0.15	0.13	Adiponectin levels;	chr12:48536240	chr12:48054813~48055591:-
BRCA	cis	rs11168618	0.904	rs12366459	ENSG00000240399.1	RP1-228P16.1	4.31	1.82e-05	0.0014	0.15	0.13	Adiponectin levels;	chr12:48537117	chr12:48054813~48055591:-
BRCA	cis	rs13113518	1	rs56362210	ENSG00000272969.1	RP11-528I4.2	4.31	1.82e-05	0.0014	0.15	0.13	Height;	chr4:55540972	chr4:55547112~55547889:+
BRCA	cis	rs8114671	0.933	rs6142327	ENSG00000279253.1	RP4-614O4.13	4.31	1.82e-05	0.0014	0.15	0.13	Height;	chr20:35205344	chr20:35262727~35264187:-
BRCA	cis	rs7927592	0.731	rs643609	ENSG00000212093.1	AP000807.1	4.31	1.82e-05	0.0014	0.14	0.13	Total body bone mineral density;	chr11:68474365	chr11:68506083~68506166:-
BRCA	cis	rs494453	0.922	rs552802	ENSG00000227811.2	FAM212B-AS1	-4.31	1.82e-05	0.0014	-0.17	-0.13	Osteoporosis-related phenotypes;	chr1:111715923	chr1:111739841~111747798:+
BRCA	cis	rs10129255	0.536	rs6576223	ENSG00000211959.2	IGHV4-39	4.31	1.82e-05	0.0014	0.09	0.13	Kawasaki disease;	chr14:106776448	chr14:106421711~106422218:-
BRCA	cis	rs1979679	0.608	rs4931084	ENSG00000278733.1	RP11-425D17.1	-4.31	1.82e-05	0.0014	-0.18	-0.13	Ossification of the posterior longitudinal ligament of the spine;	chr12:28569378	chr12:28185625~28186190:-
BRCA	cis	rs1387259	0.839	rs7486941	ENSG00000257735.1	RP11-370I10.6	-4.31	1.82e-05	0.0014	-0.16	-0.13	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48184848	chr12:48350945~48442411:+
BRCA	cis	rs295490	0.748	rs80175427	ENSG00000272656.1	RP11-219D15.3	4.31	1.82e-05	0.0014	0.29	0.13	PR interval in Tripanosoma cruzi seropositivity;	chr3:139498904	chr3:139349024~139349371:-
BRCA	cis	rs295490	0.748	rs17494482	ENSG00000272656.1	RP11-219D15.3	4.31	1.82e-05	0.0014	0.29	0.13	PR interval in Tripanosoma cruzi seropositivity;	chr3:139499028	chr3:139349024~139349371:-
BRCA	cis	rs295490	0.748	rs2882080	ENSG00000272656.1	RP11-219D15.3	4.31	1.82e-05	0.0014	0.29	0.13	PR interval in Tripanosoma cruzi seropositivity;	chr3:139499109	chr3:139349024~139349371:-
BRCA	cis	rs295490	0.748	rs2882081	ENSG00000272656.1	RP11-219D15.3	4.31	1.82e-05	0.0014	0.29	0.13	PR interval in Tripanosoma cruzi seropositivity;	chr3:139499427	chr3:139349024~139349371:-
BRCA	cis	rs295490	0.748	rs7428398	ENSG00000272656.1	RP11-219D15.3	4.31	1.82e-05	0.0014	0.29	0.13	PR interval in Tripanosoma cruzi seropositivity;	chr3:139499687	chr3:139349024~139349371:-
BRCA	cis	rs295490	0.748	rs77398474	ENSG00000272656.1	RP11-219D15.3	4.31	1.82e-05	0.0014	0.29	0.13	PR interval in Tripanosoma cruzi seropositivity;	chr3:139502307	chr3:139349024~139349371:-
BRCA	cis	rs6600671	0.967	rs12069545	ENSG00000231429.2	RP11-343N15.2	-4.31	1.82e-05	0.0014	-0.16	-0.13	Hip geometry;	chr1:121430343	chr1:121412719~121429274:+
BRCA	cis	rs61931739	0.517	rs4931748	ENSG00000258794.3	DUX4L27	4.31	1.82e-05	0.0014	0.19	0.13	Morning vs. evening chronotype;	chr12:33987892	chr12:34208415~34209675:-
BRCA	cis	rs17711722	0.51	rs11767457	ENSG00000275400.1	RP4-756H11.5	-4.31	1.82e-05	0.0014	-0.16	-0.13	Calcium levels;	chr7:65825628	chr7:66553805~66554199:-
BRCA	cis	rs755249	0.567	rs61779285	ENSG00000182109.6	RP11-69E11.4	4.31	1.82e-05	0.0014	0.19	0.13	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39401383	chr1:39522280~39546187:-
BRCA	cis	rs6545883	0.868	rs7594191	ENSG00000270820.4	RP11-355B11.2	-4.31	1.82e-05	0.0014	-0.15	-0.13	Tuberculosis;	chr2:61612883	chr2:61471188~61484130:+
BRCA	cis	rs6545883	0.56	rs11677776	ENSG00000273302.1	RP11-493E12.2	-4.31	1.82e-05	0.0014	-0.11	-0.13	Tuberculosis;	chr2:61275978	chr2:61199979~61200769:+
BRCA	cis	rs2179367	0.959	rs652807	ENSG00000223701.3	RAET1E-AS1	-4.31	1.83e-05	0.0014	-0.17	-0.13	Dupuytren's disease;	chr6:149416359	chr6:149884431~149919508:+
BRCA	cis	rs1008375	0.932	rs9884565	ENSG00000249502.1	AC006160.5	-4.31	1.83e-05	0.0014	-0.15	-0.13	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17653473	chr4:17587467~17614571:-
BRCA	cis	rs35740288	0.731	rs12898964	ENSG00000202081.1	RNU6-1280P	4.31	1.83e-05	0.0014	0.17	0.13	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85618046	chr15:85651522~85651628:-
BRCA	cis	rs35740288	0.731	rs2344440	ENSG00000202081.1	RNU6-1280P	4.31	1.83e-05	0.0014	0.17	0.13	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85618334	chr15:85651522~85651628:-
BRCA	cis	rs35740288	0.77	rs1157519	ENSG00000202081.1	RNU6-1280P	4.31	1.83e-05	0.0014	0.17	0.13	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85618427	chr15:85651522~85651628:-
BRCA	cis	rs7475343	0.501	rs1889459	ENSG00000224034.1	RP11-445P17.8	-4.31	1.83e-05	0.0014	-0.25	-0.13	Intelligence;	chr10:5272080	chr10:5266033~5271236:-
BRCA	cis	rs11098499	0.955	rs1551	ENSG00000250412.1	KLHL2P1	4.3	1.83e-05	0.00141	0.16	0.13	Corneal astigmatism;	chr4:119237345	chr4:119334329~119378233:+
BRCA	cis	rs2908197	0.737	rs10230188	ENSG00000186704.9	DTX2P1	4.3	1.83e-05	0.00141	0.15	0.13	3-hydroxypropylmercapturic acid levels in smokers;	chr7:76351555	chr7:76978617~77004308:+
BRCA	cis	rs875971	0.545	rs1796222	ENSG00000230295.1	RP11-458F8.2	-4.3	1.83e-05	0.00141	-0.13	-0.13	Aortic root size;	chr7:66592167	chr7:66880708~66882981:+
BRCA	cis	rs7487075	0.558	rs3847985	ENSG00000272369.1	RP11-446N19.1	4.3	1.83e-05	0.00141	0.14	0.13	Itch intensity from mosquito bite;	chr12:46261504	chr12:46537502~46652550:+
BRCA	cis	rs1400816	0.85	rs59414074	ENSG00000228389.1	AC068039.4	-4.3	1.83e-05	0.00141	-0.23	-0.13	Amyotrophic lateral sclerosis (sporadic);	chr2:171678688	chr2:171773482~171775844:+
BRCA	cis	rs794185	0.681	rs711635	ENSG00000231249.1	ITPR1-AS1	-4.3	1.83e-05	0.00141	-0.15	-0.13	Multiple sclerosis--Brain Glutamate Levels;	chr3:4448829	chr3:4490891~4493163:-
BRCA	cis	rs9921338	0.961	rs55707838	ENSG00000262636.1	CTD-3088G3.4	-4.3	1.83e-05	0.00141	-0.21	-0.13	Vein graft stenosis in coronary artery bypass grafting;	chr16:11284218	chr16:11380859~11381118:-
BRCA	cis	rs10504130	0.597	rs4598243	ENSG00000253844.1	RP11-546K22.1	-4.3	1.83e-05	0.00141	-0.19	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr8:51797158	chr8:51961458~52022974:+
BRCA	cis	rs9788721	0.836	rs2009746	ENSG00000261762.1	RP11-650L12.2	-4.3	1.83e-05	0.00141	-0.16	-0.13	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78461760	chr15:78589123~78591276:-
BRCA	cis	rs11239930	0.517	rs2477568	ENSG00000278811.3	LINC00624	-4.3	1.83e-05	0.00141	-0.16	-0.13	AIDS progression;	chr1:147076244	chr1:147258885~147517875:-
BRCA	cis	rs853679	1	rs11965538	ENSG00000280107.1	AL022393.9	-4.3	1.83e-05	0.00141	-0.23	-0.13	Depression;	chr6:28272137	chr6:28170845~28172521:+
BRCA	cis	rs2235544	0.565	rs637590	ENSG00000225183.1	RP4-758J24.4	4.3	1.83e-05	0.00141	0.16	0.13	Thyroid hormone levels;Multiple myeloma (hyperdiploidy);	chr1:53996030	chr1:54089856~54090093:+
BRCA	cis	rs4578769	0.797	rs1010800	ENSG00000265939.1	UBE2CP2	4.3	1.83e-05	0.00141	0.16	0.13	Eosinophil percentage of white cells;	chr18:23027857	chr18:22900486~22900995:-
BRCA	cis	rs721917	0.506	rs7073842	ENSG00000278616.1	BEND3P3	-4.3	1.83e-05	0.00141	-0.12	-0.13	Chronic obstructive pulmonary disease;	chr10:79896644	chr10:79682997~79685436:+
BRCA	cis	rs6708413	0.528	rs7567885	ENSG00000234389.1	AC007278.3	-4.3	1.83e-05	0.00141	-0.13	-0.13	Crohn's disease;Inflammatory bowel disease;	chr2:102492393	chr2:102438713~102440475:+
BRCA	cis	rs2179367	0.959	rs9390677	ENSG00000223701.3	RAET1E-AS1	4.3	1.83e-05	0.00141	0.17	0.13	Dupuytren's disease;	chr6:149389361	chr6:149884431~149919508:+
BRCA	cis	rs2011013	0.6	rs17370572	ENSG00000230373.7	GOLGA6L5P	4.3	1.83e-05	0.00141	0.22	0.13	Sitting height ratio;	chr15:83947961	chr15:84507885~84516814:-
BRCA	cis	rs6121246	0.647	rs6088855	ENSG00000230613.1	HM13-AS1	4.3	1.83e-05	0.00141	0.19	0.13	Mean corpuscular hemoglobin;	chr20:31637989	chr20:31567707~31573263:-
BRCA	cis	rs9308731	0.644	rs1054873	ENSG00000230499.1	AC108463.1	-4.3	1.83e-05	0.00141	-0.15	-0.13	Chronic lymphocytic leukemia;	chr2:111118571	chr2:111195963~111206494:+
BRCA	cis	rs12681366	0.663	rs2919665	ENSG00000253704.1	RP11-267M23.4	4.3	1.84e-05	0.00141	0.14	0.13	Nonsyndromic cleft lip with cleft palate;	chr8:94453147	chr8:94553722~94569745:+
BRCA	cis	rs17684571	0.7	rs13220618	ENSG00000231441.1	RP11-472M19.2	4.3	1.84e-05	0.00141	0.21	0.13	Schizophrenia;	chr6:56819388	chr6:56844002~56864078:+
BRCA	cis	rs13217239	0.608	rs6930508	ENSG00000224843.5	LINC00240	4.3	1.84e-05	0.00141	0.15	0.13	Schizophrenia;	chr6:27085363	chr6:26956992~27023924:+
BRCA	cis	rs13217239	0.646	rs2142685	ENSG00000224843.5	LINC00240	4.3	1.84e-05	0.00141	0.15	0.13	Schizophrenia;	chr6:27086718	chr6:26956992~27023924:+
BRCA	cis	rs6545883	0.894	rs12997538	ENSG00000212978.6	AC016747.3	-4.3	1.84e-05	0.00141	-0.18	-0.13	Tuberculosis;	chr2:61337114	chr2:61141592~61144969:-
BRCA	cis	rs4671400	0.516	rs62152277	ENSG00000273302.1	RP11-493E12.2	-4.3	1.84e-05	0.00141	-0.15	-0.13	3-hydroxypropylmercapturic acid levels in smokers;	chr2:61276269	chr2:61199979~61200769:+
BRCA	cis	rs962856	0.719	rs12713597	ENSG00000236780.4	AC078941.1	4.3	1.84e-05	0.00141	0.18	0.13	Pancreatic cancer;	chr2:67393935	chr2:67123357~67215319:-
BRCA	cis	rs6546324	0.625	rs2861681	ENSG00000236780.4	AC078941.1	4.3	1.84e-05	0.00141	0.23	0.13	Endometriosis;	chr2:67603007	chr2:67123357~67215319:-
BRCA	cis	rs6546324	0.625	rs2902023	ENSG00000236780.4	AC078941.1	4.3	1.84e-05	0.00141	0.23	0.13	Endometriosis;	chr2:67603147	chr2:67123357~67215319:-
BRCA	cis	rs7267979	0.966	rs2261790	ENSG00000125804.12	FAM182A	-4.3	1.84e-05	0.00141	-0.17	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25282153	chr20:26054655~26086917:+
BRCA	cis	rs7267979	0.966	rs2261794	ENSG00000125804.12	FAM182A	-4.3	1.84e-05	0.00141	-0.17	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25282426	chr20:26054655~26086917:+
BRCA	cis	rs7267979	0.966	rs2145126	ENSG00000125804.12	FAM182A	-4.3	1.84e-05	0.00141	-0.17	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25283012	chr20:26054655~26086917:+
BRCA	cis	rs7267979	0.966	rs2257705	ENSG00000125804.12	FAM182A	-4.3	1.84e-05	0.00141	-0.17	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25284028	chr20:26054655~26086917:+
BRCA	cis	rs7267979	0.966	rs2227892	ENSG00000125804.12	FAM182A	-4.3	1.84e-05	0.00141	-0.17	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25284178	chr20:26054655~26086917:+
BRCA	cis	rs7267979	0.966	rs2257712	ENSG00000125804.12	FAM182A	-4.3	1.84e-05	0.00141	-0.17	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25284274	chr20:26054655~26086917:+
BRCA	cis	rs7267979	0.966	rs2257461	ENSG00000125804.12	FAM182A	-4.3	1.84e-05	0.00141	-0.17	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25284918	chr20:26054655~26086917:+
BRCA	cis	rs4143844	1	rs17271291	ENSG00000259251.2	RP11-643M14.1	4.3	1.84e-05	0.00141	0.32	0.13	Bipolar disorder and schizophrenia;	chr15:61982818	chr15:62060503~62062434:+
BRCA	cis	rs8114671	0.869	rs2038503	ENSG00000126005.14	MMP24-AS1	4.3	1.84e-05	0.00141	0.15	0.13	Height;	chr20:35088097	chr20:35216462~35278131:-
BRCA	cis	rs6671200	1	rs10747468	ENSG00000235501.4	RP4-639F20.1	-4.3	1.84e-05	0.00141	-0.26	-0.13	Stearic acid (18:0) levels;	chr1:95220735	chr1:94927566~94963270:+
BRCA	cis	rs516805	0.63	rs2606641	ENSG00000279114.1	RP3-425C14.5	-4.3	1.84e-05	0.00141	-0.16	-0.13	Lymphocyte counts;	chr6:122103704	chr6:122471923~122484161:+
BRCA	cis	rs516805	0.63	rs2606643	ENSG00000279114.1	RP3-425C14.5	-4.3	1.84e-05	0.00141	-0.16	-0.13	Lymphocyte counts;	chr6:122104352	chr6:122471923~122484161:+
BRCA	cis	rs56322409	0.833	rs11188516	ENSG00000226688.5	ENTPD1-AS1	4.3	1.84e-05	0.00141	0.16	0.13	Blood metabolite levels;	chr10:95889688	chr10:95753206~96090238:-
BRCA	cis	rs11168618	0.715	rs35367885	ENSG00000240399.1	RP1-228P16.1	4.3	1.84e-05	0.00141	0.15	0.13	Adiponectin levels;	chr12:48525877	chr12:48054813~48055591:-
BRCA	cis	rs3136202	0.545	rs8055701	ENSG00000242307.1	RPS26P52	4.3	1.84e-05	0.00141	0.17	0.13	Conduct disorder (symptom count);	chr16:13959974	chr16:13922332~13922679:-
BRCA	cis	rs651907	0.557	rs13077925	ENSG00000256628.3	ZBTB11-AS1	4.3	1.84e-05	0.00141	0.17	0.13	Colorectal cancer;	chr3:101769337	chr3:101676475~101679217:+
BRCA	cis	rs703842	1	rs10877019	ENSG00000270039.1	RP11-571M6.17	4.3	1.84e-05	0.00141	0.19	0.13	Multiple sclerosis;	chr12:57779146	chr12:57803838~57804415:+
BRCA	cis	rs3764021	0.87	rs7976584	ENSG00000256582.1	RP11-75L1.1	4.3	1.84e-05	0.00141	0.13	0.13	Type 1 diabetes;	chr12:9726059	chr12:9704077~9709350:+
BRCA	cis	rs13113518	0.902	rs11133386	ENSG00000272969.1	RP11-528I4.2	4.3	1.84e-05	0.00141	0.15	0.13	Height;	chr4:55461320	chr4:55547112~55547889:+
BRCA	cis	rs13113518	0.967	rs4340844	ENSG00000272969.1	RP11-528I4.2	4.3	1.84e-05	0.00141	0.15	0.13	Height;	chr4:55462689	chr4:55547112~55547889:+
BRCA	cis	rs11098499	0.913	rs10010696	ENSG00000250412.1	KLHL2P1	4.3	1.84e-05	0.00141	0.16	0.13	Corneal astigmatism;	chr4:119243148	chr4:119334329~119378233:+
BRCA	cis	rs2573652	0.723	rs2727201	ENSG00000254744.3	CTD-3076O17.1	-4.3	1.84e-05	0.00141	-0.16	-0.13	Height;	chr15:99975106	chr15:99970215~99974010:+
BRCA	cis	rs11168618	0.846	rs11168599	ENSG00000240399.1	RP1-228P16.1	4.3	1.84e-05	0.00141	0.15	0.13	Adiponectin levels;	chr12:48486168	chr12:48054813~48055591:-
BRCA	cis	rs7572733	0.522	rs7573001	ENSG00000231621.1	AC013264.2	-4.3	1.84e-05	0.00141	-0.13	-0.13	Dermatomyositis;	chr2:198065172	chr2:197197991~197199273:+
BRCA	cis	rs6585424	1	rs11202031	ENSG00000225484.5	NUTM2B-AS1	-4.3	1.84e-05	0.00141	-0.26	-0.13	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80184287	chr10:79663088~79826594:-
BRCA	cis	rs9527	0.518	rs11191530	ENSG00000213061.2	PFN1P11	-4.3	1.84e-05	0.00141	-0.25	-0.13	Arsenic metabolism;	chr10:103040287	chr10:102838011~102845473:-
BRCA	cis	rs12681366	0.537	rs2919659	ENSG00000253704.1	RP11-267M23.4	4.3	1.84e-05	0.00141	0.15	0.13	Nonsyndromic cleft lip with cleft palate;	chr8:94459544	chr8:94553722~94569745:+
BRCA	cis	rs2243480	1	rs313807	ENSG00000222364.1	RNU6-96P	-4.3	1.84e-05	0.00142	-0.24	-0.13	Diabetic kidney disease;	chr7:66034494	chr7:66395191~66395286:+
BRCA	cis	rs6964833	1	rs36044436	ENSG00000184616.8	AC004166.6	4.3	1.84e-05	0.00142	0.2	0.13	Menarche (age at onset);	chr7:74675495	chr7:74906673~74913256:-
BRCA	cis	rs2136613	0.533	rs10761663	ENSG00000238280.1	RP11-436D10.3	-4.3	1.84e-05	0.00142	-0.17	-0.13	Selective IgA deficiency;	chr10:62845239	chr10:62793562~62805887:-
BRCA	cis	rs2136613	0.533	rs1475082	ENSG00000238280.1	RP11-436D10.3	-4.3	1.84e-05	0.00142	-0.17	-0.13	Selective IgA deficiency;	chr10:62845621	chr10:62793562~62805887:-
BRCA	cis	rs2136613	0.533	rs1475083	ENSG00000238280.1	RP11-436D10.3	-4.3	1.84e-05	0.00142	-0.17	-0.13	Selective IgA deficiency;	chr10:62845638	chr10:62793562~62805887:-
BRCA	cis	rs2136613	0.533	rs1475084	ENSG00000238280.1	RP11-436D10.3	-4.3	1.84e-05	0.00142	-0.17	-0.13	Selective IgA deficiency;	chr10:62845974	chr10:62793562~62805887:-
BRCA	cis	rs35740288	0.597	rs12900830	ENSG00000259407.1	RP11-158M2.3	-4.3	1.84e-05	0.00142	-0.19	-0.13	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85782923	chr15:85744109~85750281:-
BRCA	cis	rs12612619	0.658	rs112794902	ENSG00000229122.1	AGBL5-IT1	4.3	1.84e-05	0.00142	0.14	0.13	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:26928718	chr2:27061038~27061815:+
BRCA	cis	rs12612619	0.658	rs77920959	ENSG00000229122.1	AGBL5-IT1	4.3	1.84e-05	0.00142	0.14	0.13	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:26928722	chr2:27061038~27061815:+
BRCA	cis	rs7267979	0.966	rs2387882	ENSG00000274973.1	RP13-401N8.7	4.3	1.84e-05	0.00142	0.15	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25398166	chr20:25845497~25845862:+
BRCA	cis	rs7487075	1	rs12832425	ENSG00000257261.4	RP11-96H19.1	4.3	1.84e-05	0.00142	0.14	0.13	Itch intensity from mosquito bite;	chr12:46429035	chr12:46383679~46876159:+
BRCA	cis	rs35851103	0.507	rs6601649	ENSG00000227888.4	FAM66A	-4.3	1.84e-05	0.00142	-0.17	-0.13	Neuroticism;	chr8:11999808	chr8:12362019~12388296:+
BRCA	cis	rs11098499	0.82	rs6829903	ENSG00000250412.1	KLHL2P1	4.3	1.85e-05	0.00142	0.16	0.13	Corneal astigmatism;	chr4:119585729	chr4:119334329~119378233:+
BRCA	cis	rs867371	1	rs7181655	ENSG00000278603.1	RP13-608F4.5	4.3	1.85e-05	0.00142	0.18	0.13	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82163275	chr15:82472203~82472426:+
BRCA	cis	rs17684571	0.751	rs13203148	ENSG00000231441.1	RP11-472M19.2	4.3	1.85e-05	0.00142	0.23	0.13	Schizophrenia;	chr6:56822235	chr6:56844002~56864078:+
BRCA	cis	rs62229266	0.654	rs62230787	ENSG00000214914.3	RPL23AP3	4.3	1.85e-05	0.00142	0.17	0.13	Mitral valve prolapse;	chr21:36004182	chr21:36016079~36016546:-
BRCA	cis	rs8054556	0.967	rs7193532	ENSG00000261367.1	RP11-455F5.4	-4.3	1.85e-05	0.00142	-0.15	-0.13	Autism spectrum disorder or schizophrenia;	chr16:29951481	chr16:30107675~30110541:+
BRCA	cis	rs2229238	0.911	rs60368585	ENSG00000272030.1	RP1-178F15.4	-4.3	1.85e-05	0.00142	-0.19	-0.13	Coronary heart disease;	chr1:154536864	chr1:153631438~153634397:-
BRCA	cis	rs2688608	0.592	rs12253429	ENSG00000213731.2	RAB5CP1	-4.3	1.85e-05	0.00142	-0.15	-0.13	Inflammatory bowel disease;	chr10:73736403	chr10:74423435~74424014:-
BRCA	cis	rs7487075	1	rs12814341	ENSG00000257261.4	RP11-96H19.1	4.3	1.85e-05	0.00142	0.14	0.13	Itch intensity from mosquito bite;	chr12:46429489	chr12:46383679~46876159:+
BRCA	cis	rs7160336	1	rs17782424	ENSG00000259065.1	RP5-1021I20.1	-4.3	1.85e-05	0.00142	-0.15	-0.13	Blood protein levels;	chr14:74194794	chr14:73787360~73803270:+
BRCA	cis	rs2242116	1	rs2168443	ENSG00000276925.1	RP11-708J19.3	4.3	1.85e-05	0.00142	0.15	0.13	Birth weight;	chr3:46905597	chr3:47469777~47469987:+
BRCA	cis	rs7246657	0.509	rs10426093	ENSG00000267470.4	ZNF571-AS1	4.3	1.85e-05	0.00142	0.2	0.13	Coronary artery calcification;	chr19:37124727	chr19:37548914~37587348:+
BRCA	cis	rs2562456	0.793	rs627522	ENSG00000268535.1	RP11-420K14.3	4.3	1.85e-05	0.00142	0.17	0.13	Pain;	chr19:21313002	chr19:21709522~21710191:+
BRCA	cis	rs11098499	0.954	rs9998585	ENSG00000260091.1	RP11-33B1.4	-4.3	1.85e-05	0.00142	-0.12	-0.13	Corneal astigmatism;	chr4:119475647	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.909	rs6842762	ENSG00000260091.1	RP11-33B1.4	-4.3	1.85e-05	0.00142	-0.12	-0.13	Corneal astigmatism;	chr4:119477081	chr4:119409333~119410233:+
BRCA	cis	rs35146811	0.844	rs13223792	ENSG00000214313.7	AZGP1P1	4.3	1.85e-05	0.00142	0.14	0.13	Coronary artery disease;	chr7:100078036	chr7:99980762~99987535:+
BRCA	cis	rs10986311	0.963	rs1024255	ENSG00000227200.1	RP11-121A14.3	-4.3	1.85e-05	0.00142	-0.16	-0.13	Vitiligo;	chr9:124332202	chr9:124262876~124265809:+
BRCA	cis	rs67981189	0.574	rs4467005	ENSG00000269927.1	RP6-91H8.3	4.3	1.85e-05	0.00142	0.16	0.13	Schizophrenia;	chr14:71031939	chr14:71141125~71143253:-
BRCA	cis	rs7824557	0.767	rs17797443	ENSG00000248896.2	CTD-2135J3.3	4.3	1.85e-05	0.00142	0.18	0.13	Retinal vascular caliber;	chr8:11306503	chr8:10729314~10771392:+
BRCA	cis	rs6430585	0.583	rs1435577	ENSG00000224043.6	CCNT2-AS1	-4.3	1.85e-05	0.00142	-0.22	-0.13	Corneal structure;	chr2:135867377	chr2:134735464~134918710:-
BRCA	cis	rs755249	0.529	rs4660732	ENSG00000182109.6	RP11-69E11.4	4.3	1.85e-05	0.00142	0.19	0.13	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39397543	chr1:39522280~39546187:-
BRCA	cis	rs6545883	0.825	rs4672426	ENSG00000270820.4	RP11-355B11.2	-4.3	1.85e-05	0.00142	-0.15	-0.13	Tuberculosis;	chr2:61230013	chr2:61471188~61484130:+
BRCA	cis	rs6545883	0.86	rs4671399	ENSG00000270820.4	RP11-355B11.2	-4.3	1.85e-05	0.00142	-0.15	-0.13	Tuberculosis;	chr2:61231383	chr2:61471188~61484130:+
BRCA	cis	rs2108622	1	rs55744319	ENSG00000267218.2	AC005336.5	4.3	1.85e-05	0.00142	0.17	0.13	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871011	chr19:15902300~15903238:-
BRCA	cis	rs4578769	0.959	rs4800430	ENSG00000265939.1	UBE2CP2	4.3	1.85e-05	0.00142	0.16	0.13	Eosinophil percentage of white cells;	chr18:22803299	chr18:22900486~22900995:-
BRCA	cis	rs7577696	0.924	rs7370704	ENSG00000272716.1	RP11-563N4.1	-4.3	1.85e-05	0.00142	-0.15	-0.13	Inflammatory biomarkers;	chr2:32032648	chr2:32165046~32165757:-
BRCA	cis	rs7267979	0.844	rs6115188	ENSG00000231081.1	RP4-760C5.3	-4.3	1.85e-05	0.00142	-0.17	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25451534	chr20:26008791~26010531:-
BRCA	cis	rs9921338	0.961	rs7626	ENSG00000262636.1	CTD-3088G3.4	-4.3	1.85e-05	0.00142	-0.22	-0.13	Vein graft stenosis in coronary artery bypass grafting;	chr16:11351739	chr16:11380859~11381118:-
BRCA	cis	rs9921338	0.961	rs7193278	ENSG00000262636.1	CTD-3088G3.4	-4.3	1.85e-05	0.00142	-0.22	-0.13	Vein graft stenosis in coronary artery bypass grafting;	chr16:11351974	chr16:11380859~11381118:-
BRCA	cis	rs4415084	0.8	rs930396	ENSG00000251141.4	RP11-53O19.1	-4.3	1.85e-05	0.00142	-0.12	-0.13	Breast cancer;	chr5:44856349	chr5:44744900~44808777:-
BRCA	cis	rs875971	0.545	rs1638724	ENSG00000273142.1	RP11-458F8.4	-4.3	1.85e-05	0.00142	-0.13	-0.13	Aortic root size;	chr7:66575494	chr7:66902857~66906297:+
BRCA	cis	rs1075265	0.68	rs805396	ENSG00000272156.1	RP11-477N3.1	-4.3	1.85e-05	0.00142	-0.14	-0.13	Chronotype;Morning vs. evening chronotype;	chr2:53882314	chr2:54082554~54085066:+
BRCA	cis	rs950169	0.545	rs4354897	ENSG00000275120.1	RP11-182J1.17	4.3	1.85e-05	0.00142	0.2	0.13	Schizophrenia;	chr15:83976219	chr15:84599434~84606463:-
BRCA	cis	rs35740288	0.77	rs11630286	ENSG00000202081.1	RNU6-1280P	4.3	1.85e-05	0.00142	0.17	0.13	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85659298	chr15:85651522~85651628:-
BRCA	cis	rs11098499	0.754	rs878376	ENSG00000225892.3	RP11-384K6.2	4.3	1.85e-05	0.00142	0.13	0.13	Corneal astigmatism;	chr4:119316547	chr4:118632274~118634759:+
BRCA	cis	rs721917	0.525	rs1054053	ENSG00000242600.5	MBL1P	4.3	1.85e-05	0.00142	0.16	0.13	Chronic obstructive pulmonary disease;	chr10:79922889	chr10:79904898~79950336:+
BRCA	cis	rs9921338	0.961	rs7195536	ENSG00000262636.1	CTD-3088G3.4	-4.3	1.85e-05	0.00142	-0.21	-0.13	Vein graft stenosis in coronary artery bypass grafting;	chr16:11348171	chr16:11380859~11381118:-
BRCA	cis	rs9921338	0.961	rs7191093	ENSG00000262636.1	CTD-3088G3.4	-4.3	1.85e-05	0.00142	-0.21	-0.13	Vein graft stenosis in coronary artery bypass grafting;	chr16:11348422	chr16:11380859~11381118:-
BRCA	cis	rs9309473	0.583	rs6705203	ENSG00000163016.8	ALMS1P	4.3	1.85e-05	0.00142	0.16	0.13	Metabolite levels;	chr2:73347472	chr2:73644919~73685576:+
BRCA	cis	rs1124769	0.57	rs2614768	ENSG00000273674.3	CTD-2378E12.1	-4.3	1.85e-05	0.00142	-0.16	-0.13	Cognitive performance;	chr15:50871261	chr15:50839875~50908599:-
BRCA	cis	rs4908760	0.539	rs7513880	ENSG00000232912.4	RP5-1115A15.1	4.3	1.85e-05	0.00142	0.13	0.13	Vitiligo;	chr1:8779241	chr1:8424645~8434838:+
BRCA	cis	rs7011507	0.7	rs55847910	ENSG00000279881.1	RP11-513O13.1	-4.3	1.85e-05	0.00142	-0.21	-0.13	Inflammatory bowel disease;Ulcerative colitis;	chr8:48422172	chr8:48428143~48431041:-
BRCA	cis	rs7011507	0.7	rs72639020	ENSG00000279881.1	RP11-513O13.1	-4.3	1.85e-05	0.00142	-0.21	-0.13	Inflammatory bowel disease;Ulcerative colitis;	chr8:48422306	chr8:48428143~48431041:-
BRCA	cis	rs7011507	0.7	rs55927958	ENSG00000279881.1	RP11-513O13.1	-4.3	1.85e-05	0.00142	-0.21	-0.13	Inflammatory bowel disease;Ulcerative colitis;	chr8:48422714	chr8:48428143~48431041:-
BRCA	cis	rs7011507	0.7	rs55864946	ENSG00000279881.1	RP11-513O13.1	-4.3	1.85e-05	0.00142	-0.21	-0.13	Inflammatory bowel disease;Ulcerative colitis;	chr8:48427958	chr8:48428143~48431041:-
BRCA	cis	rs12744310	0.945	rs1343776	ENSG00000235358.1	RP11-399E6.1	4.3	1.85e-05	0.00142	0.19	0.13	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41292046	chr1:41242373~41284861:+
BRCA	cis	rs12744310	1	rs60552457	ENSG00000235358.1	RP11-399E6.1	4.3	1.85e-05	0.00142	0.19	0.13	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41293827	chr1:41242373~41284861:+
BRCA	cis	rs12744310	1	rs12739950	ENSG00000235358.1	RP11-399E6.1	4.3	1.85e-05	0.00142	0.19	0.13	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41294219	chr1:41242373~41284861:+
BRCA	cis	rs12744310	0.945	rs12740093	ENSG00000235358.1	RP11-399E6.1	4.3	1.85e-05	0.00142	0.19	0.13	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41294329	chr1:41242373~41284861:+
BRCA	cis	rs12744310	1	rs12038894	ENSG00000235358.1	RP11-399E6.1	4.3	1.85e-05	0.00142	0.19	0.13	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41294535	chr1:41242373~41284861:+
BRCA	cis	rs12744310	1	rs12038924	ENSG00000235358.1	RP11-399E6.1	4.3	1.85e-05	0.00142	0.19	0.13	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41294645	chr1:41242373~41284861:+
BRCA	cis	rs12744310	1	rs12032514	ENSG00000235358.1	RP11-399E6.1	4.3	1.85e-05	0.00142	0.19	0.13	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41294890	chr1:41242373~41284861:+
BRCA	cis	rs12744310	1	rs12039767	ENSG00000235358.1	RP11-399E6.1	4.3	1.85e-05	0.00142	0.19	0.13	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41295188	chr1:41242373~41284861:+
BRCA	cis	rs12744310	1	rs12731400	ENSG00000235358.1	RP11-399E6.1	4.3	1.85e-05	0.00142	0.19	0.13	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41295680	chr1:41242373~41284861:+
BRCA	cis	rs12744310	1	rs12032756	ENSG00000235358.1	RP11-399E6.1	4.3	1.85e-05	0.00142	0.19	0.13	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41295757	chr1:41242373~41284861:+
BRCA	cis	rs12744310	1	rs55859000	ENSG00000235358.1	RP11-399E6.1	4.3	1.85e-05	0.00142	0.19	0.13	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41295769	chr1:41242373~41284861:+
BRCA	cis	rs12744310	1	rs12030372	ENSG00000235358.1	RP11-399E6.1	4.3	1.85e-05	0.00142	0.19	0.13	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41296357	chr1:41242373~41284861:+
BRCA	cis	rs12744310	1	rs12032162	ENSG00000235358.1	RP11-399E6.1	4.3	1.85e-05	0.00142	0.19	0.13	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41297263	chr1:41242373~41284861:+
BRCA	cis	rs12744310	1	rs12031417	ENSG00000235358.1	RP11-399E6.1	4.3	1.85e-05	0.00142	0.19	0.13	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41297356	chr1:41242373~41284861:+
BRCA	cis	rs12744310	1	rs12037588	ENSG00000235358.1	RP11-399E6.1	4.3	1.85e-05	0.00142	0.19	0.13	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41298283	chr1:41242373~41284861:+
BRCA	cis	rs6723226	0.699	rs376914	ENSG00000276517.1	AL133243.2	-4.3	1.85e-05	0.00142	-0.17	-0.13	Intelligence (multi-trait analysis);	chr2:32283324	chr2:32526504~32529507:+
BRCA	cis	rs12612435	0.793	rs34821046	ENSG00000226806.1	AC011893.3	4.3	1.86e-05	0.00143	0.15	0.13	Takotsubo syndrome;	chr2:136365850	chr2:135820191~135823087:+
BRCA	cis	rs4218	0.635	rs10431792	ENSG00000259732.1	RP11-59H7.3	-4.3	1.86e-05	0.00143	-0.16	-0.13	Social communication problems;	chr15:59066181	chr15:59121034~59133250:+
BRCA	cis	rs11098499	0.909	rs71614422	ENSG00000250412.1	KLHL2P1	4.3	1.86e-05	0.00143	0.16	0.13	Corneal astigmatism;	chr4:119438185	chr4:119334329~119378233:+
BRCA	cis	rs77204473	1	rs74881320	ENSG00000280143.1	AP000892.6	-4.3	1.86e-05	0.00143	-0.25	-0.13	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116895209	chr11:117204967~117210292:+
BRCA	cis	rs300890	0.664	rs7690761	ENSG00000250326.1	RP11-284M14.1	-4.3	1.86e-05	0.00143	-0.15	-0.13	Nasopharyngeal carcinoma;	chr4:143287609	chr4:142933195~143184861:-
BRCA	cis	rs6600671	1	rs11249351	ENSG00000231429.2	RP11-343N15.2	-4.3	1.86e-05	0.00143	-0.16	-0.13	Hip geometry;	chr1:121430082	chr1:121412719~121429274:+
BRCA	cis	rs2625529	0.617	rs2957365	ENSG00000260037.4	CTD-2524L6.3	4.3	1.86e-05	0.00143	0.17	0.13	Red blood cell count;	chr15:72055765	chr15:71818396~71823384:+
BRCA	cis	rs875971	0.545	rs316306	ENSG00000273142.1	RP11-458F8.4	-4.3	1.86e-05	0.00143	-0.13	-0.13	Aortic root size;	chr7:66153687	chr7:66902857~66906297:+
BRCA	cis	rs11603023	0.874	rs613243	ENSG00000278376.1	RP11-158I9.8	-4.3	1.86e-05	0.00143	-0.12	-0.13	Cholesterol, total;	chr11:118643304	chr11:118791254~118793137:+
BRCA	cis	rs7475343	0.501	rs3750568	ENSG00000224034.1	RP11-445P17.8	-4.3	1.86e-05	0.00143	-0.26	-0.13	Intelligence;	chr10:5205668	chr10:5266033~5271236:-
BRCA	cis	rs7475343	0.501	rs3750567	ENSG00000224034.1	RP11-445P17.8	-4.3	1.86e-05	0.00143	-0.26	-0.13	Intelligence;	chr10:5205671	chr10:5266033~5271236:-
BRCA	cis	rs7487075	0.93	rs6582656	ENSG00000274723.1	RP11-618L22.1	4.3	1.86e-05	0.00143	0.16	0.13	Itch intensity from mosquito bite;	chr12:46449633	chr12:46970504~46972155:+
BRCA	cis	rs6012564	1	rs3092039	ENSG00000227431.4	CSE1L-AS1	-4.3	1.86e-05	0.00143	-0.16	-0.13	Anger;	chr20:49062233	chr20:49040463~49046044:-
BRCA	cis	rs7475343	0.501	rs4339945	ENSG00000224034.1	RP11-445P17.8	-4.3	1.86e-05	0.00143	-0.25	-0.13	Intelligence;	chr10:5264435	chr10:5266033~5271236:-
BRCA	cis	rs2255336	0.938	rs2733840	ENSG00000245648.1	RP11-277P12.20	4.3	1.86e-05	0.00143	0.2	0.13	Blood protein levels;	chr12:10393326	chr12:10363769~10398506:+
BRCA	cis	rs6128907	1	rs6124015	ENSG00000224635.1	RP4-564F22.5	-4.3	1.86e-05	0.00143	-0.2	-0.13	Liver fibrosis in pediatric non-alcoholic fatty acid liver disease;	chr20:38764146	chr20:38406011~38416797:-
BRCA	cis	rs253959	0.545	rs712592	ENSG00000271918.1	CTD-2287O16.5	-4.3	1.86e-05	0.00143	-0.11	-0.13	Bipolar disorder and schizophrenia;	chr5:116321684	chr5:116083807~116085416:-
BRCA	cis	rs253959	0.545	rs712593	ENSG00000271918.1	CTD-2287O16.5	-4.3	1.86e-05	0.00143	-0.11	-0.13	Bipolar disorder and schizophrenia;	chr5:116321700	chr5:116083807~116085416:-
BRCA	cis	rs253959	0.545	rs712594	ENSG00000271918.1	CTD-2287O16.5	-4.3	1.86e-05	0.00143	-0.11	-0.13	Bipolar disorder and schizophrenia;	chr5:116321762	chr5:116083807~116085416:-
BRCA	cis	rs253959	0.545	rs712595	ENSG00000271918.1	CTD-2287O16.5	-4.3	1.86e-05	0.00143	-0.11	-0.13	Bipolar disorder and schizophrenia;	chr5:116321801	chr5:116083807~116085416:-
BRCA	cis	rs7308116	1	rs10861794	ENSG00000274395.1	RP11-554D14.8	-4.3	1.86e-05	0.00143	-0.14	-0.13	Pelvic organ prolapse (moderate/severe);	chr12:107809822	chr12:107835541~107836555:-
BRCA	cis	rs11043280	0.703	rs11043275	ENSG00000212694.7	LINC01089	-4.3	1.86e-05	0.00143	-0.11	-0.13	Mean platelet volume;	chr12:121964817	chr12:121795267~121803906:-
BRCA	cis	rs11048470	0.571	rs10842713	ENSG00000256894.1	RP11-283G6.3	4.3	1.86e-05	0.00143	0.14	0.13	Waist-hip ratio;	chr12:26332706	chr12:26125155~26126617:-
BRCA	cis	rs9470794	0.92	rs11751706	ENSG00000204110.6	RP1-153P14.8	-4.3	1.86e-05	0.00143	-0.27	-0.13	Type 2 diabetes;	chr6:37961653	chr6:37507348~37535616:+
BRCA	cis	rs669446	0.591	rs586339	ENSG00000237950.1	RP11-7O11.3	4.3	1.86e-05	0.00143	0.17	0.13	Amyotrophic lateral sclerosis (age of onset);	chr1:43671586	chr1:43944370~43946551:-
BRCA	cis	rs6547741	0.788	rs7595739	ENSG00000234072.1	AC074117.10	-4.3	1.86e-05	0.00143	-0.13	-0.13	Oral cavity cancer;	chr2:27651696	chr2:27356246~27367622:+
BRCA	cis	rs9926296	0.715	rs467035	ENSG00000274627.1	RP11-104N10.2	-4.3	1.86e-05	0.00143	-0.16	-0.13	Vitiligo;	chr16:89673877	chr16:89516797~89522217:+
BRCA	cis	rs2243480	1	rs7456042	ENSG00000275400.1	RP4-756H11.5	4.3	1.86e-05	0.00143	0.24	0.13	Diabetic kidney disease;	chr7:65834791	chr7:66553805~66554199:-
BRCA	cis	rs2243480	1	rs73142121	ENSG00000275400.1	RP4-756H11.5	4.3	1.86e-05	0.00143	0.24	0.13	Diabetic kidney disease;	chr7:65846219	chr7:66553805~66554199:-
BRCA	cis	rs2243480	1	rs34702770	ENSG00000275400.1	RP4-756H11.5	4.3	1.86e-05	0.00143	0.24	0.13	Diabetic kidney disease;	chr7:65879836	chr7:66553805~66554199:-
BRCA	cis	rs2243480	1	rs34637256	ENSG00000275400.1	RP4-756H11.5	4.3	1.86e-05	0.00143	0.24	0.13	Diabetic kidney disease;	chr7:65895144	chr7:66553805~66554199:-
BRCA	cis	rs6012564	1	rs6012564	ENSG00000222365.1	SNORD12B	4.3	1.86e-05	0.00143	0.14	0.13	Anger;	chr20:48925063	chr20:49280319~49280409:+
BRCA	cis	rs2832191	0.632	rs1984011	ENSG00000232855.5	AF131217.1	4.3	1.86e-05	0.00143	0.16	0.13	Dental caries;	chr21:28965509	chr21:28439346~28674848:-
BRCA	cis	rs62244186	0.52	rs2372828	ENSG00000214820.3	MPRIPP1	-4.3	1.86e-05	0.00143	-0.15	-0.13	Depressive symptoms;	chr3:44743457	chr3:44579938~44581026:-
BRCA	cis	rs950776	0.593	rs481134	ENSG00000279373.1	RP11-650L12.4	4.3	1.86e-05	0.00143	0.16	0.13	Sudden cardiac arrest;	chr15:78585221	chr15:78537681~78538946:+
BRCA	cis	rs11887277	0.902	rs12991828	ENSG00000272148.1	RP11-195B17.1	4.3	1.86e-05	0.00143	0.15	0.13	Obesity-related traits;	chr2:26859691	chr2:27062428~27062907:-
BRCA	cis	rs875971	0.545	rs75577046	ENSG00000230295.1	RP11-458F8.2	4.3	1.86e-05	0.00143	0.13	0.13	Aortic root size;	chr7:66493729	chr7:66880708~66882981:+
BRCA	cis	rs7772486	0.754	rs702319	ENSG00000270638.1	RP3-466P17.1	-4.3	1.86e-05	0.00143	-0.15	-0.13	Lobe attachment (rater-scored or self-reported);	chr6:145684981	chr6:145735570~145737218:+
BRCA	cis	rs1048886	0.872	rs55795712	ENSG00000271967.1	RP11-134K13.4	-4.3	1.86e-05	0.00143	-0.19	-0.13	Type 2 diabetes;	chr6:70570725	chr6:70596438~70596980:+
BRCA	cis	rs7618915	0.501	rs6617	ENSG00000243224.1	RP5-1157M23.2	-4.3	1.86e-05	0.00143	-0.14	-0.13	Bipolar disorder;	chr3:52706166	chr3:52239258~52241097:+
BRCA	cis	rs73242632	1	rs10026915	ENSG00000269949.1	RP11-738E22.3	4.3	1.86e-05	0.00143	0.3	0.13	Congenital heart disease (maternal effect);	chr4:56991605	chr4:56960927~56961373:-
BRCA	cis	rs9470794	1	rs9470784	ENSG00000204110.6	RP1-153P14.8	-4.3	1.86e-05	0.00143	-0.21	-0.13	Type 2 diabetes;	chr6:38115864	chr6:37507348~37535616:+
BRCA	cis	rs7308116	0.935	rs61938594	ENSG00000274395.1	RP11-554D14.8	-4.3	1.87e-05	0.00143	-0.14	-0.13	Pelvic organ prolapse (moderate/severe);	chr12:107810083	chr12:107835541~107836555:-
BRCA	cis	rs1552172	0.853	rs10752826	ENSG00000234367.1	PFN1P3	4.3	1.87e-05	0.00143	0.15	0.13	Breast cancer;	chr1:145832321	chr1:145407772~145408173:+
BRCA	cis	rs2625529	0.503	rs7162299	ENSG00000260037.4	CTD-2524L6.3	4.3	1.87e-05	0.00143	0.17	0.13	Red blood cell count;	chr15:72121724	chr15:71818396~71823384:+
BRCA	cis	rs7475343	0.501	rs7912751	ENSG00000224034.1	RP11-445P17.8	-4.3	1.87e-05	0.00143	-0.26	-0.13	Intelligence;	chr10:5215978	chr10:5266033~5271236:-
BRCA	cis	rs6600671	0.934	rs12131379	ENSG00000231429.2	RP11-343N15.2	-4.3	1.87e-05	0.00143	-0.16	-0.13	Hip geometry;	chr1:121551639	chr1:121412719~121429274:+
BRCA	cis	rs6071166	0.683	rs1830609	ENSG00000224635.1	RP4-564F22.5	-4.3	1.87e-05	0.00143	-0.16	-0.13	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38696382	chr20:38406011~38416797:-
BRCA	cis	rs17489649	1	rs2269207	ENSG00000271849.1	CTC-332L22.1	4.3	1.87e-05	0.00143	0.17	0.13	Intelligence (multi-trait analysis);	chr5:109787042	chr5:109687802~109688329:-
BRCA	cis	rs1048886	0.872	rs76830193	ENSG00000271967.1	RP11-134K13.4	-4.3	1.87e-05	0.00143	-0.2	-0.13	Type 2 diabetes;	chr6:70461113	chr6:70596438~70596980:+
BRCA	cis	rs77956314	0.515	rs12299065	ENSG00000277840.1	RP11-103B5.4	-4.3	1.87e-05	0.00143	-0.21	-0.13	Hippocampal volume;Subcortical brain region volumes;	chr12:117004499	chr12:117002463~117003152:+
BRCA	cis	rs2447097	1	rs2447097	ENSG00000263345.1	RP1-59D14.5	-4.3	1.87e-05	0.00143	-0.1	-0.13	Autism spectrum disorder;	chr17:2374770	chr17:2375061~2379306:-
BRCA	cis	rs10504130	0.696	rs17212214	ENSG00000253844.1	RP11-546K22.1	4.3	1.87e-05	0.00143	0.19	0.13	Venous thromboembolism (SNP x SNP interaction);	chr8:51918582	chr8:51961458~52022974:+
BRCA	cis	rs2136613	0.533	rs7093716	ENSG00000238280.1	RP11-436D10.3	-4.3	1.87e-05	0.00143	-0.17	-0.13	Selective IgA deficiency;	chr10:62847717	chr10:62793562~62805887:-
BRCA	cis	rs2136613	0.533	rs7097383	ENSG00000238280.1	RP11-436D10.3	-4.3	1.87e-05	0.00143	-0.17	-0.13	Selective IgA deficiency;	chr10:62848279	chr10:62793562~62805887:-
BRCA	cis	rs703842	0.963	rs2069506	ENSG00000270039.1	RP11-571M6.17	-4.3	1.87e-05	0.00143	-0.19	-0.13	Multiple sclerosis;	chr12:57749071	chr12:57803838~57804415:+
BRCA	cis	rs1124769	0.57	rs2663528	ENSG00000273674.3	CTD-2378E12.1	-4.3	1.87e-05	0.00143	-0.16	-0.13	Cognitive performance;	chr15:50862707	chr15:50839875~50908599:-
BRCA	cis	rs370915	0.89	rs1425952	ENSG00000250971.1	RP11-696F12.1	4.3	1.87e-05	0.00143	0.15	0.13	Gout;	chr4:186912391	chr4:187060099~187060930:+
BRCA	cis	rs10487112	0.833	rs12704545	ENSG00000235436.9	DPY19L2P4	-4.3	1.87e-05	0.00143	-0.14	-0.13	Perceived unattractiveness to mosquitoes;	chr7:90507751	chr7:90119400~90125600:+
BRCA	cis	rs2243480	1	rs781149	ENSG00000222364.1	RNU6-96P	-4.3	1.87e-05	0.00143	-0.24	-0.13	Diabetic kidney disease;	chr7:66016297	chr7:66395191~66395286:+
BRCA	cis	rs2243480	0.901	rs58207111	ENSG00000222364.1	RNU6-96P	-4.3	1.87e-05	0.00143	-0.24	-0.13	Diabetic kidney disease;	chr7:66021736	chr7:66395191~66395286:+
BRCA	cis	rs6496044	0.568	rs6496039	ENSG00000202081.1	RNU6-1280P	4.3	1.87e-05	0.00143	0.15	0.13	Interstitial lung disease;	chr15:85518732	chr15:85651522~85651628:-
BRCA	cis	rs2908197	0.843	rs2961040	ENSG00000186704.9	DTX2P1	4.3	1.87e-05	0.00143	0.16	0.13	3-hydroxypropylmercapturic acid levels in smokers;	chr7:76317446	chr7:76978617~77004308:+
BRCA	cis	rs17507216	0.681	rs28877110	ENSG00000259429.4	UBE2Q2P2	-4.3	1.87e-05	0.00143	-0.17	-0.13	Excessive daytime sleepiness;	chr15:82672111	chr15:82355142~82420075:+
BRCA	cis	rs763014	0.932	rs2384974	ENSG00000260394.2	LA16c-313D11.9	-4.3	1.87e-05	0.00143	-0.13	-0.13	Height;	chr16:601279	chr16:678504~679777:-
BRCA	cis	rs6547741	1	rs1080060	ENSG00000234072.1	AC074117.10	4.3	1.87e-05	0.00143	0.12	0.13	Oral cavity cancer;	chr2:27545941	chr2:27356246~27367622:+
BRCA	cis	rs875971	0.66	rs12698534	ENSG00000232546.1	RP11-458F8.1	-4.3	1.87e-05	0.00143	-0.11	-0.13	Aortic root size;	chr7:66521858	chr7:66848496~66858136:+
BRCA	cis	rs10911902	0.643	rs17491733	ENSG00000229739.2	RP11-295K2.3	-4.3	1.87e-05	0.00143	-0.2	-0.13	Schizophrenia;	chr1:186402168	chr1:186435161~186470291:+
BRCA	cis	rs644148	0.73	rs2571044	ENSG00000176761.7	ZNF285B	4.3	1.87e-05	0.00144	0.16	0.13	Personality dimensions;	chr19:44481355	chr19:44467641~44473227:+
BRCA	cis	rs7267979	0.844	rs6132824	ENSG00000276952.1	RP5-965G21.6	4.3	1.87e-05	0.00144	0.16	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25257537	chr20:25284915~25285588:-
BRCA	cis	rs7487075	0.808	rs10880961	ENSG00000257261.4	RP11-96H19.1	4.3	1.87e-05	0.00144	0.15	0.13	Itch intensity from mosquito bite;	chr12:46371445	chr12:46383679~46876159:+
BRCA	cis	rs4272720	0.901	rs17773666	ENSG00000228754.1	RP11-534L6.3	-4.3	1.87e-05	0.00144	-0.19	-0.13	Platelet count;Plateletcrit;	chr10:49099202	chr10:48745545~48746128:-
BRCA	cis	rs6870983	0.895	rs33703	ENSG00000247828.6	TMEM161B-AS1	4.3	1.87e-05	0.00144	0.17	0.13	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index;	chr5:88270914	chr5:88268895~88436685:+
BRCA	cis	rs27434	0.607	rs26654	ENSG00000248734.2	CTD-2260A17.1	4.3	1.87e-05	0.00144	0.15	0.13	Ankylosing spondylitis;	chr5:96804664	chr5:96784777~96785999:+
BRCA	cis	rs7833986	0.501	rs2719258	ENSG00000253603.1	CTA-397H3.3	-4.3	1.87e-05	0.00144	-0.19	-0.13	Height;	chr8:56028830	chr8:56074592~56075274:+
BRCA	cis	rs7833986	0.501	rs2719259	ENSG00000253603.1	CTA-397H3.3	-4.3	1.87e-05	0.00144	-0.19	-0.13	Height;	chr8:56029071	chr8:56074592~56075274:+
BRCA	cis	rs2731006	0.64	rs2468321	ENSG00000257114.2	RP11-25I15.3	-4.3	1.87e-05	0.00144	-0.21	-0.13	Panic disorder;	chr12:42803164	chr12:42692216~42717119:+
BRCA	cis	rs11098499	0.954	rs10518328	ENSG00000260091.1	RP11-33B1.4	-4.3	1.87e-05	0.00144	-0.12	-0.13	Corneal astigmatism;	chr4:119480624	chr4:119409333~119410233:+
BRCA	cis	rs4835473	0.868	rs5025156	ENSG00000249741.2	RP11-673E1.3	4.3	1.87e-05	0.00144	0.15	0.13	Immature fraction of reticulocytes;	chr4:143738025	chr4:143911514~143912053:-
BRCA	cis	rs7487075	0.504	rs7312682	ENSG00000272369.1	RP11-446N19.1	4.3	1.87e-05	0.00144	0.14	0.13	Itch intensity from mosquito bite;	chr12:46254215	chr12:46537502~46652550:+
BRCA	cis	rs7487075	0.558	rs12580460	ENSG00000272369.1	RP11-446N19.1	4.3	1.87e-05	0.00144	0.14	0.13	Itch intensity from mosquito bite;	chr12:46255200	chr12:46537502~46652550:+
BRCA	cis	rs6545883	0.894	rs6709441	ENSG00000270820.4	RP11-355B11.2	-4.3	1.88e-05	0.00144	-0.15	-0.13	Tuberculosis;	chr2:61209795	chr2:61471188~61484130:+
BRCA	cis	rs6088590	1	rs6088595	ENSG00000276073.1	RP5-1125A11.7	-4.3	1.88e-05	0.00144	-0.16	-0.13	Coronary artery disease;	chr20:34770696	chr20:33985617~33988989:-
BRCA	cis	rs8180040	0.726	rs7625070	ENSG00000276925.1	RP11-708J19.3	-4.3	1.88e-05	0.00144	-0.15	-0.13	Colorectal cancer;	chr3:47054028	chr3:47469777~47469987:+
BRCA	cis	rs984222	0.501	rs1750333	ENSG00000231365.4	RP11-418J17.1	-4.3	1.88e-05	0.00144	-0.15	-0.13	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:118941315	chr1:119140396~119275973:+
BRCA	cis	rs2235544	0.542	rs679801	ENSG00000225183.1	RP4-758J24.4	4.3	1.88e-05	0.00144	0.16	0.13	Thyroid hormone levels;Multiple myeloma (hyperdiploidy);	chr1:54005084	chr1:54089856~54090093:+
BRCA	cis	rs4908769	0.624	rs1763839	ENSG00000270282.1	RP5-1115A15.2	4.3	1.88e-05	0.00144	0.15	0.13	Allergy;	chr1:8413276	chr1:8512653~8513021:+
BRCA	cis	rs465969	1	rs17510761	ENSG00000230177.1	RP5-1112D6.4	4.3	1.88e-05	0.00144	0.31	0.13	Psoriasis;	chr6:111387380	chr6:111277932~111278742:+
BRCA	cis	rs465969	1	rs78945802	ENSG00000230177.1	RP5-1112D6.4	4.3	1.88e-05	0.00144	0.31	0.13	Psoriasis;	chr6:111407143	chr6:111277932~111278742:+
BRCA	cis	rs465969	1	rs17072683	ENSG00000230177.1	RP5-1112D6.4	4.3	1.88e-05	0.00144	0.31	0.13	Psoriasis;	chr6:111410007	chr6:111277932~111278742:+
BRCA	cis	rs4925540	0.519	rs4971295	ENSG00000215796.3	RP11-551G24.2	-4.3	1.88e-05	0.00144	-0.18	-0.13	Response to taxane treatment (docetaxel);	chr1:247046584	chr1:247042791~247044021:+
BRCA	cis	rs4925540	0.519	rs66643713	ENSG00000215796.3	RP11-551G24.2	-4.3	1.88e-05	0.00144	-0.18	-0.13	Response to taxane treatment (docetaxel);	chr1:247048960	chr1:247042791~247044021:+
BRCA	cis	rs7045881	0.935	rs7023230	ENSG00000254396.1	RP11-56F10.3	4.3	1.88e-05	0.00144	0.21	0.13	Schizophrenia;	chr9:26937270	chr9:27102630~27104728:+
BRCA	cis	rs7267979	1	rs2424704	ENSG00000274973.1	RP13-401N8.7	-4.3	1.88e-05	0.00144	-0.15	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25293293	chr20:25845497~25845862:+
BRCA	cis	rs6596100	0.915	rs72801470	ENSG00000248648.1	RP11-485M7.1	-4.3	1.88e-05	0.00144	-0.17	-0.13	Breast cancer;	chr5:133107719	chr5:133003119~133003365:+
BRCA	cis	rs875971	0.862	rs1981799	ENSG00000229180.5	GS1-124K5.11	4.3	1.88e-05	0.00144	0.11	0.13	Aortic root size;	chr7:66490572	chr7:66526088~66542624:-
BRCA	cis	rs5758511	0.68	rs5758692	ENSG00000227370.1	RP4-669P10.19	4.3	1.88e-05	0.00144	0.18	0.13	Birth weight;	chr22:42273023	chr22:42132543~42132998:+
BRCA	cis	rs867371	0.892	rs4344697	ENSG00000278603.1	RP13-608F4.5	4.3	1.88e-05	0.00144	0.18	0.13	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82252873	chr15:82472203~82472426:+
BRCA	cis	rs875971	1	rs2077593	ENSG00000229180.5	GS1-124K5.11	4.3	1.88e-05	0.00144	0.11	0.13	Aortic root size;	chr7:66427543	chr7:66526088~66542624:-
BRCA	cis	rs875971	0.545	rs35459055	ENSG00000230295.1	RP11-458F8.2	4.3	1.88e-05	0.00144	0.13	0.13	Aortic root size;	chr7:66479399	chr7:66880708~66882981:+
BRCA	cis	rs58521262	0.505	rs457599	ENSG00000268105.1	RP11-369G6.2	4.3	1.88e-05	0.00144	0.18	0.13	Testicular germ cell tumor;	chr19:22949915	chr19:23125665~23128543:+
BRCA	cis	rs12497850	0.931	rs13316620	ENSG00000225399.4	RP11-3B7.1	4.3	1.88e-05	0.00144	0.13	0.13	Parkinson's disease;	chr3:49007922	chr3:49260085~49261316:+
BRCA	cis	rs6723226	0.699	rs376914	ENSG00000276334.1	AL133243.1	4.3	1.88e-05	0.00144	0.17	0.13	Intelligence (multi-trait analysis);	chr2:32283324	chr2:32521927~32523547:+
BRCA	cis	rs4834770	1	rs4336213	ENSG00000178636.7	RP11-455G16.1	-4.3	1.88e-05	0.00144	-0.16	-0.13	Blood protein levels;	chr4:119315314	chr4:119192773~119212644:-
BRCA	cis	rs6545883	0.86	rs6545848	ENSG00000270820.4	RP11-355B11.2	-4.3	1.88e-05	0.00144	-0.15	-0.13	Tuberculosis;	chr2:61234048	chr2:61471188~61484130:+
BRCA	cis	rs61160187	0.582	rs12652878	ENSG00000272308.1	RP11-231G3.1	-4.3	1.88e-05	0.00144	-0.15	-0.13	Educational attainment (years of education);Educational attainment (college completion);	chr5:60868949	chr5:60866457~60866935:-
BRCA	cis	rs61160187	0.548	rs17392014	ENSG00000272308.1	RP11-231G3.1	-4.3	1.88e-05	0.00144	-0.15	-0.13	Educational attainment (years of education);Educational attainment (college completion);	chr5:60869373	chr5:60866457~60866935:-
BRCA	cis	rs11083475	1	rs979972	ENSG00000267892.1	CTD-2540F13.2	4.3	1.88e-05	0.00144	0.15	0.13	Heart rate;	chr19:38653527	chr19:38738284~38739863:+
BRCA	cis	rs4388249	0.651	rs31601	ENSG00000271849.1	CTC-332L22.1	-4.3	1.88e-05	0.00144	-0.24	-0.13	Schizophrenia;	chr5:109669781	chr5:109687802~109688329:-
BRCA	cis	rs516805	0.596	rs2606644	ENSG00000279114.1	RP3-425C14.5	-4.3	1.88e-05	0.00144	-0.16	-0.13	Lymphocyte counts;	chr6:122104734	chr6:122471923~122484161:+
BRCA	cis	rs2243480	1	rs10247526	ENSG00000275400.1	RP4-756H11.5	-4.3	1.88e-05	0.00144	-0.24	-0.13	Diabetic kidney disease;	chr7:66315709	chr7:66553805~66554199:-
BRCA	cis	rs9896933	0.83	rs607544	ENSG00000262663.1	RP11-497H17.1	4.3	1.88e-05	0.00144	0.18	0.13	Bone mineral accretion in asthma (oral corticosteroid dose interaction);	chr17:82810884	chr17:82918282~82918785:+
BRCA	cis	rs58521262	0.585	rs2645877	ENSG00000268105.1	RP11-369G6.2	-4.3	1.89e-05	0.00144	-0.18	-0.13	Testicular germ cell tumor;	chr19:23028009	chr19:23125665~23128543:+
BRCA	cis	rs58521262	0.585	rs2548888	ENSG00000268105.1	RP11-369G6.2	-4.3	1.89e-05	0.00144	-0.18	-0.13	Testicular germ cell tumor;	chr19:23028226	chr19:23125665~23128543:+
BRCA	cis	rs867371	0.502	rs3759800	ENSG00000276710.3	CSPG4P8	4.3	1.89e-05	0.00144	0.13	0.13	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82240622	chr15:82459472~82477258:+
BRCA	cis	rs1910358	0.676	rs6863680	ENSG00000248874.4	C5orf17	-4.3	1.89e-05	0.00145	-0.17	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23996781	chr5:23951348~24178263:+
BRCA	cis	rs56322409	0.507	rs3793747	ENSG00000226688.5	ENTPD1-AS1	4.3	1.89e-05	0.00145	0.15	0.13	Blood metabolite levels;	chr10:95655698	chr10:95753206~96090238:-
BRCA	cis	rs875971	0.66	rs13224319	ENSG00000232546.1	RP11-458F8.1	-4.3	1.89e-05	0.00145	-0.11	-0.13	Aortic root size;	chr7:66542376	chr7:66848496~66858136:+
BRCA	cis	rs875971	0.66	rs801217	ENSG00000232546.1	RP11-458F8.1	4.3	1.89e-05	0.00145	0.11	0.13	Aortic root size;	chr7:66545590	chr7:66848496~66858136:+
BRCA	cis	rs875971	0.638	rs801216	ENSG00000232546.1	RP11-458F8.1	4.3	1.89e-05	0.00145	0.11	0.13	Aortic root size;	chr7:66546680	chr7:66848496~66858136:+
BRCA	cis	rs930395	0.514	rs4391175	ENSG00000251141.4	RP11-53O19.1	-4.3	1.89e-05	0.00145	-0.13	-0.13	Breast cancer;	chr5:44889954	chr5:44744900~44808777:-
BRCA	cis	rs516805	0.667	rs2045354	ENSG00000279114.1	RP3-425C14.5	-4.3	1.89e-05	0.00145	-0.17	-0.13	Lymphocyte counts;	chr6:122209244	chr6:122471923~122484161:+
BRCA	cis	rs2835872	0.965	rs702860	ENSG00000228677.1	TTC3-AS1	4.3	1.89e-05	0.00145	0.17	0.13	Electroencephalographic traits in alcoholism;	chr21:37636327	chr21:37187666~37193926:-
BRCA	cis	rs11098499	0.754	rs1546503	ENSG00000225892.3	RP11-384K6.2	4.3	1.89e-05	0.00145	0.13	0.13	Corneal astigmatism;	chr4:119320012	chr4:118632274~118634759:+
BRCA	cis	rs7937890	0.532	rs2575833	ENSG00000254418.1	RP11-21L19.1	4.3	1.89e-05	0.00145	0.16	0.13	Mitochondrial DNA levels;	chr11:14470959	chr11:14262846~14273691:-
BRCA	cis	rs6840360	0.582	rs2709827	ENSG00000251603.1	RP11-164P12.4	-4.3	1.89e-05	0.00145	-0.12	-0.13	Intelligence (multi-trait analysis);	chr4:151410100	chr4:151667224~151670502:+
BRCA	cis	rs745109	0.816	rs72930340	ENSG00000273080.1	RP11-301O19.1	4.3	1.89e-05	0.00145	0.21	0.13	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86437436	chr2:86195590~86196049:+
BRCA	cis	rs748404	0.666	rs7183708	ENSG00000205771.5	CATSPER2P1	-4.3	1.89e-05	0.00145	-0.2	-0.13	Lung cancer;	chr15:43355226	chr15:43726918~43747094:-
BRCA	cis	rs812925	0.519	rs1186696	ENSG00000270820.4	RP11-355B11.2	4.3	1.89e-05	0.00145	0.14	0.13	Immature fraction of reticulocytes;	chr2:61433348	chr2:61471188~61484130:+
BRCA	cis	rs1430193	0.583	rs1077778	ENSG00000272606.1	RP11-554J4.1	4.3	1.89e-05	0.00145	0.15	0.13	Lung function (forced vital capacity);	chr2:55896196	chr2:55617909~55618373:+
BRCA	cis	rs875971	0.66	rs62465434	ENSG00000232546.1	RP11-458F8.1	-4.3	1.89e-05	0.00145	-0.11	-0.13	Aortic root size;	chr7:66540165	chr7:66848496~66858136:+
BRCA	cis	rs875971	0.545	rs13311962	ENSG00000232559.3	GS1-124K5.12	-4.3	1.89e-05	0.00145	-0.18	-0.13	Aortic root size;	chr7:66603142	chr7:66554588~66576923:-
BRCA	cis	rs2108622	0.711	rs113343664	ENSG00000267218.2	AC005336.5	4.3	1.89e-05	0.00145	0.16	0.13	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15868183	chr19:15902300~15903238:-
BRCA	cis	rs7621331	1	rs13325914	ENSG00000239213.4	NCK1-AS1	4.3	1.89e-05	0.00145	0.16	0.13	Waist circumference adjusted for body mass index;	chr3:135998375	chr3:136841726~136862054:-
BRCA	cis	rs4907240	0.961	rs66727130	ENSG00000230606.9	AC159540.1	4.3	1.89e-05	0.00145	0.17	0.13	Event-related brain oscillations;	chr2:96659254	chr2:97416165~97433527:-
BRCA	cis	rs35740288	0.787	rs2008916	ENSG00000202081.1	RNU6-1280P	4.3	1.89e-05	0.00145	0.18	0.13	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85677959	chr15:85651522~85651628:-
BRCA	cis	rs13326165	0.585	rs6793317	ENSG00000243224.1	RP5-1157M23.2	4.3	1.89e-05	0.00145	0.21	0.13	HDL cholesterol levels;HDL cholesterol;	chr3:52264970	chr3:52239258~52241097:+
BRCA	cis	rs4869313	0.87	rs2548532	ENSG00000248734.2	CTD-2260A17.1	-4.3	1.89e-05	0.00145	-0.14	-0.13	Pediatric autoimmune diseases;	chr5:96902874	chr5:96784777~96785999:+
BRCA	cis	rs4869313	0.869	rs27293	ENSG00000248734.2	CTD-2260A17.1	-4.3	1.89e-05	0.00145	-0.14	-0.13	Pediatric autoimmune diseases;	chr5:97021474	chr5:96784777~96785999:+
BRCA	cis	rs2243480	0.522	rs12698511	ENSG00000229886.1	RP5-1132H15.3	4.3	1.89e-05	0.00145	0.28	0.13	Diabetic kidney disease;	chr7:66009932	chr7:66025126~66031544:-
BRCA	cis	rs3764021	0.87	rs2401394	ENSG00000256582.1	RP11-75L1.1	4.3	1.89e-05	0.00145	0.13	0.13	Type 1 diabetes;	chr12:9726830	chr12:9704077~9709350:+
BRCA	cis	rs3796352	1	rs11718834	ENSG00000242142.1	SERBP1P3	-4.3	1.89e-05	0.00145	-0.25	-0.13	Immune reponse to smallpox (secreted IL-2);	chr3:52929652	chr3:53064283~53065091:-
BRCA	cis	rs1048886	0.872	rs10945231	ENSG00000271967.1	RP11-134K13.4	-4.3	1.89e-05	0.00145	-0.19	-0.13	Type 2 diabetes;	chr6:70588060	chr6:70596438~70596980:+
BRCA	cis	rs6596100	0.868	rs72801445	ENSG00000248648.1	RP11-485M7.1	-4.3	1.89e-05	0.00145	-0.17	-0.13	Breast cancer;	chr5:133053267	chr5:133003119~133003365:+
BRCA	cis	rs77956314	0.515	rs60940473	ENSG00000277840.1	RP11-103B5.4	4.3	1.89e-05	0.00145	0.22	0.13	Hippocampal volume;Subcortical brain region volumes;	chr12:117024777	chr12:117002463~117003152:+
BRCA	cis	rs801193	1	rs1553609	ENSG00000272831.1	RP11-792A8.4	4.3	1.89e-05	0.00145	0.12	0.13	Aortic root size;	chr7:66732152	chr7:66739829~66740385:-
BRCA	cis	rs644148	0.836	rs2686775	ENSG00000176761.7	ZNF285B	4.3	1.89e-05	0.00145	0.15	0.13	Personality dimensions;	chr19:44495998	chr19:44467641~44473227:+
BRCA	cis	rs13326165	0.715	rs11707864	ENSG00000243224.1	RP5-1157M23.2	-4.3	1.89e-05	0.00145	-0.19	-0.13	HDL cholesterol levels;HDL cholesterol;	chr3:52358861	chr3:52239258~52241097:+
BRCA	cis	rs6671200	0.541	rs3738170	ENSG00000235501.4	RP4-639F20.1	4.3	1.89e-05	0.00145	0.22	0.13	Stearic acid (18:0) levels;	chr1:95234048	chr1:94927566~94963270:+
BRCA	cis	rs8048589	0.603	rs2457193	ENSG00000175604.2	RP11-276H1.3	-4.3	1.89e-05	0.00145	-0.19	-0.13	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);	chr16:12084940	chr16:12086746~12090302:-
BRCA	cis	rs1371614	0.566	rs10203050	ENSG00000229122.1	AGBL5-IT1	-4.3	1.89e-05	0.00145	-0.14	-0.13	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26963693	chr2:27061038~27061815:+
BRCA	cis	rs2243480	0.901	rs778687	ENSG00000275400.1	RP4-756H11.5	4.3	1.89e-05	0.00145	0.24	0.13	Diabetic kidney disease;	chr7:66370832	chr7:66553805~66554199:-
BRCA	cis	rs2243480	1	rs778704	ENSG00000275400.1	RP4-756H11.5	4.3	1.89e-05	0.00145	0.24	0.13	Diabetic kidney disease;	chr7:66398480	chr7:66553805~66554199:-
BRCA	cis	rs2243480	0.901	rs778693	ENSG00000275400.1	RP4-756H11.5	4.3	1.89e-05	0.00145	0.24	0.13	Diabetic kidney disease;	chr7:66407358	chr7:66553805~66554199:-
BRCA	cis	rs2243480	1	rs778691	ENSG00000275400.1	RP4-756H11.5	4.3	1.89e-05	0.00145	0.24	0.13	Diabetic kidney disease;	chr7:66408105	chr7:66553805~66554199:-
BRCA	cis	rs2243480	1	rs13235972	ENSG00000275400.1	RP4-756H11.5	4.3	1.89e-05	0.00145	0.24	0.13	Diabetic kidney disease;	chr7:66418618	chr7:66553805~66554199:-
BRCA	cis	rs2243480	1	rs34192067	ENSG00000275400.1	RP4-756H11.5	4.3	1.89e-05	0.00145	0.24	0.13	Diabetic kidney disease;	chr7:66422670	chr7:66553805~66554199:-
BRCA	cis	rs7932354	0.583	rs1007738	ENSG00000200376.1	RNU5E-10P	-4.3	1.89e-05	0.00145	-0.16	-0.13	Bone mineral density (hip);Bone mineral density;	chr11:46827809	chr11:47576471~47576588:-
BRCA	cis	rs2115630	1	rs11854291	ENSG00000275120.1	RP11-182J1.17	-4.3	1.9e-05	0.00145	-0.15	-0.13	P wave terminal force;	chr15:84820477	chr15:84599434~84606463:-
BRCA	cis	rs321358	0.895	rs17457076	ENSG00000271390.1	RP11-89C3.3	4.3	1.9e-05	0.00145	0.21	0.13	Body mass index;	chr11:111081030	chr11:111089870~111090368:-
BRCA	cis	rs8180040	0.654	rs4682831	ENSG00000271161.1	BOLA2P2	-4.3	1.9e-05	0.00145	-0.14	-0.13	Colorectal cancer;	chr3:46985648	chr3:47499841~47500407:+
BRCA	cis	rs56322409	1	rs61871790	ENSG00000226688.5	ENTPD1-AS1	4.3	1.9e-05	0.00145	0.15	0.13	Blood metabolite levels;	chr10:95631466	chr10:95753206~96090238:-
BRCA	cis	rs739496	0.894	rs11065898	ENSG00000234608.6	MAPKAPK5-AS1	4.3	1.9e-05	0.00145	0.16	0.13	Platelet count;	chr12:111424771	chr12:111839764~111842902:-
BRCA	cis	rs7474896	0.583	rs4934898	ENSG00000120555.12	SEPT7P9	4.3	1.9e-05	0.00145	0.18	0.13	Obesity (extreme);	chr10:37701467	chr10:38383069~38402916:-
BRCA	cis	rs4478858	0.647	rs10798836	ENSG00000223907.1	LINC01226	-4.3	1.9e-05	0.00145	-0.16	-0.13	Alcohol dependence;	chr1:31236367	chr1:31518435~31524245:+
BRCA	cis	rs4143844	0.867	rs12915585	ENSG00000259251.2	RP11-643M14.1	4.3	1.9e-05	0.00145	0.32	0.13	Bipolar disorder and schizophrenia;	chr15:61962693	chr15:62060503~62062434:+
BRCA	cis	rs7182948	1	rs8034473	ENSG00000259531.2	RP11-295H24.3	-4.3	1.9e-05	0.00145	-0.19	-0.13	Lung adenocarcinoma;	chr15:49537443	chr15:49365124~49366685:-
BRCA	cis	rs7182948	1	rs967892	ENSG00000259531.2	RP11-295H24.3	-4.3	1.9e-05	0.00145	-0.19	-0.13	Lung adenocarcinoma;	chr15:49540056	chr15:49365124~49366685:-
BRCA	cis	rs7182948	0.958	rs1848286	ENSG00000259531.2	RP11-295H24.3	-4.3	1.9e-05	0.00145	-0.19	-0.13	Lung adenocarcinoma;	chr15:49545346	chr15:49365124~49366685:-
BRCA	cis	rs12530845	0.943	rs11984203	ENSG00000223718.3	AC093107.7	-4.3	1.9e-05	0.00145	-0.2	-0.13	Red blood cell traits;	chr7:135641199	chr7:135660039~135660647:+
BRCA	cis	rs6547741	1	rs6749052	ENSG00000234072.1	AC074117.10	4.3	1.9e-05	0.00145	0.12	0.13	Oral cavity cancer;	chr2:27550012	chr2:27356246~27367622:+
BRCA	cis	rs4415084	0.834	rs6896417	ENSG00000251141.4	RP11-53O19.1	4.3	1.9e-05	0.00145	0.12	0.13	Breast cancer;	chr5:44802536	chr5:44744900~44808777:-
BRCA	cis	rs4415084	0.834	rs13159598	ENSG00000251141.4	RP11-53O19.1	4.3	1.9e-05	0.00145	0.12	0.13	Breast cancer;	chr5:44805824	chr5:44744900~44808777:-
BRCA	cis	rs875971	0.66	rs801211	ENSG00000232546.1	RP11-458F8.1	4.3	1.9e-05	0.00145	0.11	0.13	Aortic root size;	chr7:66550702	chr7:66848496~66858136:+
BRCA	cis	rs875971	0.638	rs801205	ENSG00000232546.1	RP11-458F8.1	4.3	1.9e-05	0.00145	0.11	0.13	Aortic root size;	chr7:66557157	chr7:66848496~66858136:+
BRCA	cis	rs875971	0.617	rs810400	ENSG00000232546.1	RP11-458F8.1	4.3	1.9e-05	0.00145	0.11	0.13	Aortic root size;	chr7:66557902	chr7:66848496~66858136:+
BRCA	cis	rs7475343	0.501	rs7921838	ENSG00000224034.1	RP11-445P17.8	-4.3	1.9e-05	0.00145	-0.26	-0.13	Intelligence;	chr10:5205738	chr10:5266033~5271236:-
BRCA	cis	rs1722133	0.555	rs788770	ENSG00000229628.1	AC073115.7	-4.3	1.9e-05	0.00145	-0.18	-0.13	Sitting height ratio;	chr7:46068825	chr7:45990905~46000898:+
BRCA	cis	rs10771431	0.597	rs7976807	ENSG00000111788.10	RP11-22B23.1	4.3	1.9e-05	0.00145	0.12	0.13	Breast size;	chr12:9199863	chr12:9277235~9313241:+
BRCA	cis	rs2554380	0.943	rs2585052	ENSG00000230373.7	GOLGA6L5P	-4.3	1.9e-05	0.00146	-0.19	-0.13	Height;	chr15:83687238	chr15:84507885~84516814:-
BRCA	cis	rs2554380	0.891	rs2554383	ENSG00000230373.7	GOLGA6L5P	-4.3	1.9e-05	0.00146	-0.19	-0.13	Height;	chr15:83687564	chr15:84507885~84516814:-
BRCA	cis	rs1077773	0.7	rs7797677	ENSG00000237773.4	AC003075.4	-4.3	1.9e-05	0.00146	-0.16	-0.13	Ulcerative colitis;Inflammatory bowel disease;	chr7:17394102	chr7:17279834~17299357:-
BRCA	cis	rs1008375	0.897	rs3733577	ENSG00000249502.1	AC006160.5	-4.3	1.9e-05	0.00146	-0.15	-0.13	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17647610	chr4:17587467~17614571:-
BRCA	cis	rs7927592	0.956	rs11228277	ENSG00000212093.1	AP000807.1	4.3	1.9e-05	0.00146	0.14	0.13	Total body bone mineral density;	chr11:68540856	chr11:68506083~68506166:-
BRCA	cis	rs1910358	0.554	rs3904970	ENSG00000248874.4	C5orf17	-4.3	1.9e-05	0.00146	-0.19	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23737722	chr5:23951348~24178263:+
BRCA	cis	rs360929	0.511	rs360942	ENSG00000245954.5	RP11-18H21.1	4.3	1.9e-05	0.00146	0.13	0.13	Volumetric brain MRI;	chr4:151934255	chr4:152100754~152104720:+
BRCA	cis	rs9393777	0.841	rs34332556	ENSG00000216901.1	AL022393.7	4.3	1.9e-05	0.00146	0.3	0.13	Intelligence (multi-trait analysis);	chr6:27389635	chr6:28176188~28176674:+
BRCA	cis	rs7111546	1	rs16910180	ENSG00000246225.5	RP11-17A1.3	4.3	1.9e-05	0.00146	0.21	0.13	Dialysis-related mortality;	chr11:22800297	chr11:22829380~22945393:+
BRCA	cis	rs2108622	0.727	rs3093193	ENSG00000267218.2	AC005336.5	4.3	1.9e-05	0.00146	0.16	0.13	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15881104	chr19:15902300~15903238:-
BRCA	cis	rs4907240	0.925	rs4907242	ENSG00000230606.9	AC159540.1	4.3	1.9e-05	0.00146	0.17	0.13	Event-related brain oscillations;	chr2:96607376	chr2:97416165~97433527:-
BRCA	cis	rs2446066	0.872	rs3741664	ENSG00000257379.1	RP11-793H13.8	4.3	1.9e-05	0.00146	0.21	0.13	Red blood cell count;	chr12:53428886	chr12:53441741~53467528:+
BRCA	cis	rs4415084	0.834	rs7711136	ENSG00000251141.4	RP11-53O19.1	4.3	1.9e-05	0.00146	0.12	0.13	Breast cancer;	chr5:44822977	chr5:44744900~44808777:-
BRCA	cis	rs4415084	0.834	rs7730841	ENSG00000251141.4	RP11-53O19.1	4.3	1.9e-05	0.00146	0.12	0.13	Breast cancer;	chr5:44823032	chr5:44744900~44808777:-
BRCA	cis	rs4415084	0.834	rs10512865	ENSG00000251141.4	RP11-53O19.1	4.3	1.9e-05	0.00146	0.12	0.13	Breast cancer;	chr5:44823265	chr5:44744900~44808777:-
BRCA	cis	rs4415084	0.834	rs6867533	ENSG00000251141.4	RP11-53O19.1	4.3	1.9e-05	0.00146	0.12	0.13	Breast cancer;	chr5:44827190	chr5:44744900~44808777:-
BRCA	cis	rs13113518	1	rs1522112	ENSG00000272969.1	RP11-528I4.2	4.3	1.9e-05	0.00146	0.15	0.13	Height;	chr4:55463606	chr4:55547112~55547889:+
BRCA	cis	rs13113518	1	rs4864997	ENSG00000272969.1	RP11-528I4.2	4.3	1.9e-05	0.00146	0.15	0.13	Height;	chr4:55466010	chr4:55547112~55547889:+
BRCA	cis	rs13113518	1	rs960152	ENSG00000272969.1	RP11-528I4.2	4.3	1.9e-05	0.00146	0.15	0.13	Height;	chr4:55467308	chr4:55547112~55547889:+
BRCA	cis	rs13113518	0.967	rs12644948	ENSG00000272969.1	RP11-528I4.2	4.3	1.9e-05	0.00146	0.15	0.13	Height;	chr4:55470266	chr4:55547112~55547889:+
BRCA	cis	rs13113518	1	rs3805151	ENSG00000272969.1	RP11-528I4.2	4.3	1.9e-05	0.00146	0.15	0.13	Height;	chr4:55470874	chr4:55547112~55547889:+
BRCA	cis	rs2832191	0.703	rs2853827	ENSG00000215533.7	LINC00189	-4.3	1.9e-05	0.00146	-0.15	-0.13	Dental caries;	chr21:29071275	chr21:29193480~29288205:+
BRCA	cis	rs6490294	0.571	rs11066117	ENSG00000234608.6	MAPKAPK5-AS1	4.3	1.9e-05	0.00146	0.2	0.13	Mean platelet volume;	chr12:111994905	chr12:111839764~111842902:-
BRCA	cis	rs4650943	0.565	rs352297	ENSG00000227740.1	RP11-318C24.2	-4.3	1.9e-05	0.00146	-0.13	-0.13	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in inactive individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr1:176277877	chr1:175904762~175920513:-
BRCA	cis	rs2839186	0.708	rs6518285	ENSG00000239415.1	AP001469.9	4.3	1.9e-05	0.00146	0.14	0.13	Testicular germ cell tumor;	chr21:46224753	chr21:46251549~46254133:-
BRCA	cis	rs4689592	0.523	rs4256224	ENSG00000245468.3	RP11-367J11.3	4.3	1.9e-05	0.00146	0.15	0.13	Monocyte percentage of white cells;	chr4:7072856	chr4:7094571~7103385:-
BRCA	cis	rs1858037	0.867	rs6727013	ENSG00000237979.1	AC007389.1	4.3	1.91e-05	0.00146	0.17	0.13	Rheumatoid arthritis;	chr2:65331241	chr2:65500993~65502138:-
BRCA	cis	rs7937890	0.559	rs2575836	ENSG00000254418.1	RP11-21L19.1	4.3	1.91e-05	0.00146	0.16	0.13	Mitochondrial DNA levels;	chr11:14476318	chr11:14262846~14273691:-
BRCA	cis	rs13113518	1	rs13152173	ENSG00000272969.1	RP11-528I4.2	4.3	1.91e-05	0.00146	0.15	0.13	Height;	chr4:55534788	chr4:55547112~55547889:+
BRCA	cis	rs13113518	1	rs13141049	ENSG00000272969.1	RP11-528I4.2	4.3	1.91e-05	0.00146	0.15	0.13	Height;	chr4:55535489	chr4:55547112~55547889:+
BRCA	cis	rs13113518	0.967	rs12507722	ENSG00000272969.1	RP11-528I4.2	4.3	1.91e-05	0.00146	0.15	0.13	Height;	chr4:55536421	chr4:55547112~55547889:+
BRCA	cis	rs1030420	0.796	rs77801947	ENSG00000200714.1	Y_RNA	-4.3	1.91e-05	0.00146	-0.23	-0.13	Blood metabolite levels;	chr8:66406026	chr8:65592731~65592820:+
BRCA	cis	rs11098499	0.863	rs7669520	ENSG00000250412.1	KLHL2P1	4.3	1.91e-05	0.00146	0.16	0.13	Corneal astigmatism;	chr4:119594123	chr4:119334329~119378233:+
BRCA	cis	rs11098499	0.708	rs1546506	ENSG00000225892.3	RP11-384K6.2	4.3	1.91e-05	0.00146	0.13	0.13	Corneal astigmatism;	chr4:119320085	chr4:118632274~118634759:+
BRCA	cis	rs56322409	1	rs61871792	ENSG00000226688.5	ENTPD1-AS1	4.3	1.91e-05	0.00146	0.15	0.13	Blood metabolite levels;	chr10:95637829	chr10:95753206~96090238:-
BRCA	cis	rs7927592	0.626	rs11228279	ENSG00000212093.1	AP000807.1	-4.3	1.91e-05	0.00146	-0.14	-0.13	Total body bone mineral density;	chr11:68542212	chr11:68506083~68506166:-
BRCA	cis	rs7048146	0.966	rs10816829	ENSG00000213539.4	YBX1P6	4.3	1.91e-05	0.00146	0.15	0.13	Vascular brain injury;	chr9:109536396	chr9:109532830~109534332:-
BRCA	cis	rs6012564	0.929	rs4810898	ENSG00000222365.1	SNORD12B	-4.3	1.91e-05	0.00146	-0.14	-0.13	Anger;	chr20:48937855	chr20:49280319~49280409:+
BRCA	cis	rs1669338	0.588	rs3931974	ENSG00000271870.1	RP11-97C16.1	-4.3	1.91e-05	0.00146	-0.16	-0.13	White matter integrity;	chr3:3145210	chr3:3152942~3153435:+
BRCA	cis	rs9500256	0.967	rs4928431	ENSG00000272541.1	XXbac-BPGBPG55C20.1	4.3	1.91e-05	0.00146	0.14	0.13	Eosinophilic esophagitis (pediatric);	chr6:57979980	chr6:57855891~57856468:-
BRCA	cis	rs78545713	0.649	rs16891464	ENSG00000241549.7	GUSBP2	-4.3	1.91e-05	0.00146	-0.22	-0.13	Iron status biomarkers (total iron binding capacity);	chr6:26235072	chr6:26871484~26956554:-
BRCA	cis	rs10911902	0.643	rs76057663	ENSG00000229739.2	RP11-295K2.3	-4.3	1.91e-05	0.00146	-0.2	-0.13	Schizophrenia;	chr1:186325889	chr1:186435161~186470291:+
BRCA	cis	rs6480314	0.542	rs7894859	ENSG00000233590.1	RP11-153K11.3	-4.29	1.91e-05	0.00146	-0.22	-0.13	Optic nerve measurement (disc area);	chr10:68234620	chr10:68233251~68242379:-
BRCA	cis	rs911119	0.955	rs1011226	ENSG00000270001.1	RP11-218C14.8	4.29	1.91e-05	0.00146	0.16	0.13	Chronic kidney disease;	chr20:23625196	chr20:23631826~23632316:-
BRCA	cis	rs1910358	0.614	rs6452177	ENSG00000248874.4	C5orf17	-4.29	1.91e-05	0.00146	-0.17	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23985984	chr5:23951348~24178263:+
BRCA	cis	rs56322409	1	rs56322409	ENSG00000226688.5	ENTPD1-AS1	4.29	1.91e-05	0.00146	0.15	0.13	Blood metabolite levels;	chr10:95636205	chr10:95753206~96090238:-
BRCA	cis	rs56322409	1	rs11592213	ENSG00000226688.5	ENTPD1-AS1	4.29	1.91e-05	0.00146	0.15	0.13	Blood metabolite levels;	chr10:95636346	chr10:95753206~96090238:-
BRCA	cis	rs11098499	0.954	rs1546505	ENSG00000225892.3	RP11-384K6.2	4.29	1.91e-05	0.00146	0.13	0.13	Corneal astigmatism;	chr4:119320069	chr4:118632274~118634759:+
BRCA	cis	rs6921919	0.583	rs9468370	ENSG00000220721.1	OR1F12	4.29	1.91e-05	0.00146	0.16	0.13	Autism spectrum disorder or schizophrenia;	chr6:28401163	chr6:28073316~28074233:+
BRCA	cis	rs2505998	1	rs2435362	ENSG00000273008.1	RP11-351D16.3	-4.29	1.91e-05	0.00146	-0.16	-0.13	Hirschsprung disease;	chr10:43083331	chr10:43136824~43138334:-
BRCA	cis	rs7048146	0.932	rs1576590	ENSG00000213539.4	YBX1P6	4.29	1.91e-05	0.00146	0.15	0.13	Vascular brain injury;	chr9:109542883	chr9:109532830~109534332:-
BRCA	cis	rs17684571	0.7	rs34520435	ENSG00000231441.1	RP11-472M19.2	4.29	1.91e-05	0.00146	0.2	0.13	Schizophrenia;	chr6:56818319	chr6:56844002~56864078:+
BRCA	cis	rs2280018	1	rs2280017	ENSG00000188599.16	NPIPP1	4.29	1.91e-05	0.00146	0.11	0.13	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15057504	chr16:15104312~15123498:-
BRCA	cis	rs6921919	0.551	rs13201753	ENSG00000273712.1	RP5-874C20.7	4.29	1.91e-05	0.00146	0.18	0.13	Autism spectrum disorder or schizophrenia;	chr6:28363351	chr6:28315613~28315883:-
BRCA	cis	rs4907240	0.961	rs4907241	ENSG00000230606.9	AC159540.1	-4.29	1.91e-05	0.00146	-0.17	-0.13	Event-related brain oscillations;	chr2:96576191	chr2:97416165~97433527:-
BRCA	cis	rs2832191	0.716	rs1543652	ENSG00000215533.7	LINC00189	-4.29	1.91e-05	0.00146	-0.15	-0.13	Dental caries;	chr21:29075679	chr21:29193480~29288205:+
BRCA	cis	rs7481584	0.581	rs420127	ENSG00000236710.1	AC108448.2	4.29	1.91e-05	0.00146	0.18	0.13	Calcium levels;	chr11:3056760	chr11:3084393~3085443:-
BRCA	cis	rs34792	0.528	rs153793	ENSG00000207425.1	Y_RNA	4.29	1.91e-05	0.00146	0.15	0.13	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15448342	chr16:14915457~14915556:-
BRCA	cis	rs7923837	0.663	rs7903302	ENSG00000236493.2	EIF2S2P3	4.29	1.91e-05	0.00146	0.17	0.13	Multiple sclerosis;Body mass index;	chr10:92669754	chr10:92668745~92669743:-
BRCA	cis	rs490234	0.676	rs4838263	ENSG00000232630.1	PRPS1P2	-4.29	1.91e-05	0.00146	-0.14	-0.13	Mean arterial pressure;	chr9:125462920	chr9:125150653~125151589:+
BRCA	cis	rs957448	1	rs60655325	ENSG00000254315.1	RP11-267M23.3	4.29	1.91e-05	0.00146	0.18	0.13	Nonsyndromic cleft lip with cleft palate;	chr8:94552606	chr8:94533628~94534391:+
BRCA	cis	rs6728515	1	rs4665218	ENSG00000232642.1	AC008073.7	4.29	1.91e-05	0.00146	0.23	0.13	Conotruncal heart defects (maternal effects);	chr2:23487294	chr2:24165884~24175005:-
BRCA	cis	rs7800418	0.815	rs757807	ENSG00000214870.7	AC004540.5	4.29	1.91e-05	0.00146	0.17	0.13	Cognitive function;	chr7:26547095	chr7:26398593~26494256:+
BRCA	cis	rs897984	0.542	rs7294	ENSG00000275263.1	RP11-1072A3.4	4.29	1.92e-05	0.00147	0.15	0.13	Dementia with Lewy bodies;	chr16:31091000	chr16:30956872~30957199:-
BRCA	cis	rs1348850	0.608	rs10176632	ENSG00000280374.1	RP11-337N6.3	4.29	1.92e-05	0.00147	0.17	0.13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177361206	chr2:177317715~177318471:-
BRCA	cis	rs240993	0.516	rs1002481	ENSG00000230177.1	RP5-1112D6.4	-4.29	1.92e-05	0.00147	-0.2	-0.13	Inflammatory skin disease;Psoriasis;	chr6:111390819	chr6:111277932~111278742:+
BRCA	cis	rs17270561	0.636	rs9379782	ENSG00000272462.2	U91328.19	-4.29	1.92e-05	0.00147	-0.16	-0.13	Iron status biomarkers;	chr6:25714795	chr6:25992662~26001775:+
BRCA	cis	rs11892454	0.515	rs10208202	ENSG00000217643.1	PTGES3P2	-4.29	1.92e-05	0.00147	-0.14	-0.13	Heschl's gyrus morphology;	chr2:25830707	chr2:25822469~25822950:+
BRCA	cis	rs11096990	0.634	rs1057807	ENSG00000249685.1	RP11-360F5.3	-4.29	1.92e-05	0.00147	-0.16	-0.13	Cognitive function;	chr4:39287853	chr4:39133913~39135608:+
BRCA	cis	rs8098244	0.516	rs2960586	ENSG00000264745.1	TTC39C-AS1	4.29	1.92e-05	0.00147	0.15	0.13	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23690207	chr18:23994213~24015339:-
BRCA	cis	rs58521262	0.53	rs289320	ENSG00000268105.1	RP11-369G6.2	4.29	1.92e-05	0.00147	0.18	0.13	Testicular germ cell tumor;	chr19:22974997	chr19:23125665~23128543:+
BRCA	cis	rs58521262	0.585	rs289302	ENSG00000268105.1	RP11-369G6.2	-4.29	1.92e-05	0.00147	-0.18	-0.13	Testicular germ cell tumor;	chr19:22987152	chr19:23125665~23128543:+
BRCA	cis	rs7937890	0.559	rs2597208	ENSG00000254418.1	RP11-21L19.1	4.29	1.92e-05	0.00147	0.15	0.13	Mitochondrial DNA levels;	chr11:14450783	chr11:14262846~14273691:-
BRCA	cis	rs2073316	0.592	rs72794604	ENSG00000272716.1	RP11-563N4.1	4.29	1.92e-05	0.00147	0.14	0.13	Interleukin-18 levels;	chr2:31454892	chr2:32165046~32165757:-
BRCA	cis	rs11168618	0.846	rs11168599	ENSG00000273765.1	RP11-370I10.11	4.29	1.92e-05	0.00147	0.15	0.13	Adiponectin levels;	chr12:48486168	chr12:48360920~48361377:+
BRCA	cis	rs2243480	1	rs313802	ENSG00000275400.1	RP4-756H11.5	4.29	1.92e-05	0.00147	0.24	0.13	Diabetic kidney disease;	chr7:66051386	chr7:66553805~66554199:-
BRCA	cis	rs2243480	0.803	rs403089	ENSG00000275400.1	RP4-756H11.5	4.29	1.92e-05	0.00147	0.24	0.13	Diabetic kidney disease;	chr7:66052736	chr7:66553805~66554199:-
BRCA	cis	rs2243480	1	rs458291	ENSG00000275400.1	RP4-756H11.5	4.29	1.92e-05	0.00147	0.24	0.13	Diabetic kidney disease;	chr7:66055492	chr7:66553805~66554199:-
BRCA	cis	rs4578769	0.842	rs8093152	ENSG00000265939.1	UBE2CP2	4.29	1.92e-05	0.00147	0.16	0.13	Eosinophil percentage of white cells;	chr18:22867925	chr18:22900486~22900995:-
BRCA	cis	rs875971	0.545	rs11767262	ENSG00000273142.1	RP11-458F8.4	4.29	1.92e-05	0.00147	0.13	0.13	Aortic root size;	chr7:66302237	chr7:66902857~66906297:+
BRCA	cis	rs4650943	0.573	rs352304	ENSG00000227740.1	RP11-318C24.2	-4.29	1.92e-05	0.00147	-0.13	-0.13	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in inactive individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr1:176294389	chr1:175904762~175920513:-
BRCA	cis	rs6547741	0.816	rs10201652	ENSG00000234072.1	AC074117.10	-4.29	1.92e-05	0.00147	-0.13	-0.13	Oral cavity cancer;	chr2:27651465	chr2:27356246~27367622:+
BRCA	cis	rs2186369	1	rs17548631	ENSG00000211683.3	KB-1572G7.3	-4.29	1.92e-05	0.00147	-0.21	-0.13	IgG N-glycosylation phenotypes (multivariate analysis);IgG digalactosylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG glycosylation;IgG fucosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);	chr22:23801938	chr22:23630618~23638941:-
BRCA	cis	rs755249	0.567	rs3768301	ENSG00000182109.6	RP11-69E11.4	4.29	1.92e-05	0.00147	0.19	0.13	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39405121	chr1:39522280~39546187:-
BRCA	cis	rs16944613	0.588	rs6496697	ENSG00000271396.1	RP11-697E2.9	4.29	1.92e-05	0.00147	0.21	0.13	Colorectal cancer;	chr15:90588600	chr15:90284376~90285580:-
BRCA	cis	rs7897654	0.571	rs7920697	ENSG00000213277.3	MARCKSL1P1	4.29	1.92e-05	0.00147	0.17	0.13	Schizophrenia;	chr10:102873580	chr10:103175554~103176094:+
BRCA	cis	rs11168351	0.864	rs12228750	ENSG00000257763.1	OR5BK1P	-4.29	1.92e-05	0.00147	-0.14	-0.13	Bipolar disorder and schizophrenia;	chr12:48103214	chr12:48355792~48356614:-
BRCA	cis	rs9868809	0.505	rs13434258	ENSG00000225399.4	RP11-3B7.1	-4.29	1.92e-05	0.00147	-0.2	-0.13	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48701058	chr3:49260085~49261316:+
BRCA	cis	rs9868809	0.505	rs35064573	ENSG00000225399.4	RP11-3B7.1	-4.29	1.92e-05	0.00147	-0.2	-0.13	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48702847	chr3:49260085~49261316:+
BRCA	cis	rs67981189	0.593	rs7143595	ENSG00000269927.1	RP6-91H8.3	4.29	1.92e-05	0.00147	0.16	0.13	Schizophrenia;	chr14:71055284	chr14:71141125~71143253:-
BRCA	cis	rs11673344	0.523	rs7258438	ENSG00000226686.6	LINC01535	4.29	1.92e-05	0.00147	0.17	0.13	Obesity-related traits;	chr19:37032534	chr19:37251912~37265535:+
BRCA	cis	rs75804782	0.63	rs56354063	ENSG00000186235.9	AC016757.3	4.29	1.92e-05	0.00147	0.34	0.13	Chronotype;Morning vs. evening chronotype;	chr2:238345278	chr2:238224552~238231677:-
BRCA	cis	rs4907240	0.961	rs12469420	ENSG00000230606.9	AC159540.1	-4.29	1.92e-05	0.00147	-0.17	-0.13	Event-related brain oscillations;	chr2:96577568	chr2:97416165~97433527:-
BRCA	cis	rs10129255	0.518	rs12590732	ENSG00000232216.1	IGHV3-43	-4.29	1.92e-05	0.00147	-0.1	-0.13	Kawasaki disease;	chr14:106779612	chr14:106470264~106470800:-
BRCA	cis	rs4650943	0.565	rs352298	ENSG00000227740.1	RP11-318C24.2	-4.29	1.92e-05	0.00147	-0.13	-0.13	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in inactive individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr1:176278383	chr1:175904762~175920513:-
BRCA	cis	rs495337	0.76	rs615868	ENSG00000229222.1	KRT18P4	-4.29	1.92e-05	0.00147	-0.17	-0.13	Psoriasis;	chr20:49902687	chr20:49956745~49958032:+
BRCA	cis	rs1075265	0.933	rs7560947	ENSG00000235937.1	AC008280.1	4.29	1.92e-05	0.00147	0.14	0.13	Chronotype;Morning vs. evening chronotype;	chr2:54087473	chr2:54029552~54030682:-
BRCA	cis	rs516805	0.667	rs2606610	ENSG00000279114.1	RP3-425C14.5	-4.29	1.92e-05	0.00147	-0.17	-0.13	Lymphocyte counts;	chr6:122189959	chr6:122471923~122484161:+
BRCA	cis	rs2108622	0.727	rs3093207	ENSG00000267218.2	AC005336.5	4.29	1.92e-05	0.00147	0.16	0.13	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15877848	chr19:15902300~15903238:-
BRCA	cis	rs983392	0.667	rs631853	ENSG00000275344.1	MIR6503	4.29	1.92e-05	0.00147	0.13	0.13	Alzheimer's disease (late onset);	chr11:60177425	chr11:60209071~60209156:-
BRCA	cis	rs1005277	0.579	rs2474608	ENSG00000272983.1	RP11-508N22.12	4.29	1.92e-05	0.00147	0.14	0.13	Extrinsic epigenetic age acceleration;	chr10:38168181	chr10:38137337~38144399:+
BRCA	cis	rs4218	0.597	rs62002543	ENSG00000259732.1	RP11-59H7.3	-4.29	1.92e-05	0.00147	-0.17	-0.13	Social communication problems;	chr15:59066646	chr15:59121034~59133250:+
BRCA	cis	rs10833905	1	rs12420168	ENSG00000246225.5	RP11-17A1.3	-4.29	1.92e-05	0.00147	-0.19	-0.13	Sudden cardiac arrest;	chr11:23002244	chr11:22829380~22945393:+
BRCA	cis	rs7267979	0.933	rs2261109	ENSG00000277938.1	RP5-965G21.3	4.29	1.93e-05	0.00147	0.16	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25278564	chr20:25229150~25231933:+
BRCA	cis	rs7267979	0.966	rs2261720	ENSG00000277938.1	RP5-965G21.3	4.29	1.93e-05	0.00147	0.16	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25280005	chr20:25229150~25231933:+
BRCA	cis	rs17772222	0.636	rs10484010	ENSG00000258789.1	RP11-507K2.3	-4.29	1.93e-05	0.00147	-0.17	-0.13	Coronary artery calcification;	chr14:88831944	chr14:88551597~88552493:+
BRCA	cis	rs9527	0.615	rs11191489	ENSG00000213061.2	PFN1P11	4.29	1.93e-05	0.00147	0.18	0.13	Arsenic metabolism;	chr10:102980811	chr10:102838011~102845473:-
BRCA	cis	rs38055	0.918	rs37807	ENSG00000247796.2	CTD-2366F13.1	-4.29	1.93e-05	0.00147	-0.16	-0.13	Acne (severe);	chr5:53277913	chr5:53109842~53115126:+
BRCA	cis	rs1005277	0.579	rs2474571	ENSG00000263064.2	RP11-291L22.7	4.29	1.93e-05	0.00147	0.16	0.13	Extrinsic epigenetic age acceleration;	chr10:38095711	chr10:38448689~38448949:+
BRCA	cis	rs4588572	0.644	rs9293751	ENSG00000245556.2	SCAMP1-AS1	-4.29	1.93e-05	0.00147	-0.15	-0.13	Triglycerides;	chr5:78482473	chr5:78342365~78360507:-
BRCA	cis	rs6547741	0.752	rs7562863	ENSG00000234072.1	AC074117.10	-4.29	1.93e-05	0.00147	-0.13	-0.13	Oral cavity cancer;	chr2:27669827	chr2:27356246~27367622:+
BRCA	cis	rs11098499	0.754	rs12506610	ENSG00000225892.3	RP11-384K6.2	4.29	1.93e-05	0.00147	0.13	0.13	Corneal astigmatism;	chr4:119320504	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.743	rs10003567	ENSG00000225892.3	RP11-384K6.2	4.29	1.93e-05	0.00147	0.13	0.13	Corneal astigmatism;	chr4:119320519	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.754	rs10006259	ENSG00000225892.3	RP11-384K6.2	4.29	1.93e-05	0.00147	0.13	0.13	Corneal astigmatism;	chr4:119320990	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.754	rs28652763	ENSG00000225892.3	RP11-384K6.2	4.29	1.93e-05	0.00147	0.13	0.13	Corneal astigmatism;	chr4:119321157	chr4:118632274~118634759:+
BRCA	cis	rs6545883	0.894	rs2694634	ENSG00000270820.4	RP11-355B11.2	-4.29	1.93e-05	0.00147	-0.15	-0.13	Tuberculosis;	chr2:61324300	chr2:61471188~61484130:+
BRCA	cis	rs35146811	0.625	rs2906645	ENSG00000235713.1	RP4-604G5.3	-4.29	1.93e-05	0.00147	-0.16	-0.13	Coronary artery disease;	chr7:100220236	chr7:99992397~99993050:+
BRCA	cis	rs35146811	0.735	rs858506	ENSG00000235713.1	RP4-604G5.3	-4.29	1.93e-05	0.00147	-0.16	-0.13	Coronary artery disease;	chr7:100222427	chr7:99992397~99993050:+
BRCA	cis	rs35146811	0.695	rs858508	ENSG00000235713.1	RP4-604G5.3	-4.29	1.93e-05	0.00147	-0.16	-0.13	Coronary artery disease;	chr7:100223758	chr7:99992397~99993050:+
BRCA	cis	rs6430585	0.583	rs60253740	ENSG00000224043.6	CCNT2-AS1	-4.29	1.93e-05	0.00147	-0.21	-0.13	Corneal structure;	chr2:135814282	chr2:134735464~134918710:-
BRCA	cis	rs6430585	0.583	rs6728946	ENSG00000224043.6	CCNT2-AS1	-4.29	1.93e-05	0.00147	-0.22	-0.13	Corneal structure;	chr2:135877773	chr2:134735464~134918710:-
BRCA	cis	rs875971	0.66	rs1860470	ENSG00000272831.1	RP11-792A8.4	-4.29	1.93e-05	0.00147	-0.12	-0.13	Aortic root size;	chr7:66638707	chr7:66739829~66740385:-
BRCA	cis	rs4415084	0.834	rs1048758	ENSG00000251141.4	RP11-53O19.1	4.29	1.93e-05	0.00148	0.12	0.13	Breast cancer;	chr5:44828492	chr5:44744900~44808777:-
BRCA	cis	rs4415084	0.834	rs7380559	ENSG00000251141.4	RP11-53O19.1	-4.29	1.93e-05	0.00148	-0.12	-0.13	Breast cancer;	chr5:44836908	chr5:44744900~44808777:-
BRCA	cis	rs2832077	1	rs9983229	ENSG00000232855.5	AF131217.1	-4.29	1.93e-05	0.00148	-0.2	-0.13	Cognitive test performance;	chr21:28765352	chr21:28439346~28674848:-
BRCA	cis	rs669446	0.561	rs559575	ENSG00000236200.4	KDM4A-AS1	-4.29	1.93e-05	0.00148	-0.16	-0.13	Amyotrophic lateral sclerosis (age of onset);	chr1:43624269	chr1:43699765~43708138:-
BRCA	cis	rs13160562	0.522	rs26502	ENSG00000248734.2	CTD-2260A17.1	4.29	1.93e-05	0.00148	0.14	0.13	Alcohol dependence;	chr5:96764254	chr5:96784777~96785999:+
BRCA	cis	rs2835345	0.511	rs57583267	ENSG00000279365.1	KB-176G8.1	4.29	1.93e-05	0.00148	0.19	0.13	Pulmonary function;	chr21:36445230	chr21:36485867~36487760:+
BRCA	cis	rs73242632	1	rs28623722	ENSG00000269949.1	RP11-738E22.3	4.29	1.93e-05	0.00148	0.31	0.13	Congenital heart disease (maternal effect);	chr4:57029598	chr4:56960927~56961373:-
BRCA	cis	rs883924	1	rs883924	ENSG00000231107.1	LINC01508	4.29	1.93e-05	0.00148	0.16	0.13	Hepatitis C induced liver fibrosis;	chr9:90419249	chr9:90300902~90433505:-
BRCA	cis	rs10946940	0.965	rs10946935	ENSG00000220721.1	OR1F12	-4.29	1.93e-05	0.00148	-0.15	-0.13	Systemic lupus erythematosus;	chr6:27533566	chr6:28073316~28074233:+
BRCA	cis	rs2731006	0.592	rs2730997	ENSG00000257114.2	RP11-25I15.3	4.29	1.93e-05	0.00148	0.22	0.13	Panic disorder;	chr12:42785916	chr12:42692216~42717119:+
BRCA	cis	rs2731006	0.64	rs2678145	ENSG00000257114.2	RP11-25I15.3	4.29	1.93e-05	0.00148	0.22	0.13	Panic disorder;	chr12:42786534	chr12:42692216~42717119:+
BRCA	cis	rs2731006	0.64	rs2730998	ENSG00000257114.2	RP11-25I15.3	4.29	1.93e-05	0.00148	0.22	0.13	Panic disorder;	chr12:42786603	chr12:42692216~42717119:+
BRCA	cis	rs4648045	0.565	rs11733749	ENSG00000246560.2	RP11-10L12.4	4.29	1.93e-05	0.00148	0.15	0.13	Lymphocyte percentage of white cells;	chr4:102625985	chr4:102828055~102844075:+
BRCA	cis	rs2136613	0.533	rs10995332	ENSG00000238280.1	RP11-436D10.3	-4.29	1.93e-05	0.00148	-0.17	-0.13	Selective IgA deficiency;	chr10:62857905	chr10:62793562~62805887:-
BRCA	cis	rs2136613	0.533	rs10995333	ENSG00000238280.1	RP11-436D10.3	-4.29	1.93e-05	0.00148	-0.17	-0.13	Selective IgA deficiency;	chr10:62858034	chr10:62793562~62805887:-
BRCA	cis	rs10911251	0.527	rs1537520	ENSG00000224468.3	RP11-181K3.4	-4.29	1.93e-05	0.00148	-0.14	-0.13	Colorectal cancer;	chr1:183115094	chr1:183138402~183141282:-
BRCA	cis	rs61160187	0.577	rs34741733	ENSG00000272308.1	RP11-231G3.1	-4.29	1.93e-05	0.00148	-0.15	-0.13	Educational attainment (years of education);Educational attainment (college completion);	chr5:60843721	chr5:60866457~60866935:-
BRCA	cis	rs61160187	0.698	rs72755157	ENSG00000272308.1	RP11-231G3.1	-4.29	1.93e-05	0.00148	-0.15	-0.13	Educational attainment (years of education);Educational attainment (college completion);	chr5:60651559	chr5:60866457~60866935:-
BRCA	cis	rs6547741	1	rs6756238	ENSG00000234072.1	AC074117.10	4.29	1.93e-05	0.00148	0.12	0.13	Oral cavity cancer;	chr2:27618438	chr2:27356246~27367622:+
BRCA	cis	rs11098499	0.909	rs10017335	ENSG00000260091.1	RP11-33B1.4	4.29	1.93e-05	0.00148	0.12	0.13	Corneal astigmatism;	chr4:119460368	chr4:119409333~119410233:+
BRCA	cis	rs11977715	0.538	rs3801916	ENSG00000233942.1	AC004012.1	4.29	1.94e-05	0.00148	0.16	0.13	Middle childhood and early adolescence aggressive behavior;	chr7:95491707	chr7:95471835~95473998:+
BRCA	cis	rs2998286	1	rs2807743	ENSG00000254635.4	WAC-AS1	4.29	1.94e-05	0.00148	0.16	0.13	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28491364	chr10:28522652~28532743:-
BRCA	cis	rs7267979	0.844	rs1555330	ENSG00000276952.1	RP5-965G21.6	4.29	1.94e-05	0.00148	0.16	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25251461	chr20:25284915~25285588:-
BRCA	cis	rs7267979	0.844	rs6107017	ENSG00000276952.1	RP5-965G21.6	4.29	1.94e-05	0.00148	0.16	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25251664	chr20:25284915~25285588:-
BRCA	cis	rs62025270	0.632	rs111906684	ENSG00000259762.1	RP11-158M2.4	-4.29	1.94e-05	0.00148	-0.19	-0.13	Idiopathic pulmonary fibrosis;	chr15:85678705	chr15:85750336~85752901:-
BRCA	cis	rs10861342	1	rs1076	ENSG00000257999.1	RP11-61E11.2	4.29	1.94e-05	0.00148	0.27	0.13	IgG glycosylation;	chr12:105169010	chr12:105102472~105107179:-
BRCA	cis	rs11719291	0.833	rs11713694	ENSG00000270441.1	RP11-694I15.7	4.29	1.94e-05	0.00148	0.28	0.13	Cognitive function;	chr3:48796182	chr3:49140086~49160851:-
BRCA	cis	rs886774	0.74	rs7797759	ENSG00000273055.1	CTB-13F3.1	4.29	1.94e-05	0.00148	0.13	0.13	Ulcerative colitis;	chr7:107924562	chr7:107942116~107942740:+
BRCA	cis	rs7267979	0.527	rs6083891	ENSG00000125804.12	FAM182A	4.29	1.94e-05	0.00148	0.17	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25593636	chr20:26054655~26086917:+
BRCA	cis	rs7772486	0.754	rs9386134	ENSG00000270638.1	RP3-466P17.1	4.29	1.94e-05	0.00148	0.16	0.13	Lobe attachment (rater-scored or self-reported);	chr6:145824372	chr6:145735570~145737218:+
BRCA	cis	rs934734	0.571	rs7572922	ENSG00000281920.1	RP11-418H16.1	-4.29	1.94e-05	0.00148	-0.16	-0.13	Rheumatoid arthritis;	chr2:65425022	chr2:65623272~65628424:+
BRCA	cis	rs2625529	0.816	rs4777467	ENSG00000260037.4	CTD-2524L6.3	-4.29	1.94e-05	0.00148	-0.19	-0.13	Red blood cell count;	chr15:71846137	chr15:71818396~71823384:+
BRCA	cis	rs12681366	0.537	rs3019284	ENSG00000253704.1	RP11-267M23.4	4.29	1.94e-05	0.00148	0.15	0.13	Nonsyndromic cleft lip with cleft palate;	chr8:94460848	chr8:94553722~94569745:+
BRCA	cis	rs62184315	0.536	rs62183651	ENSG00000253559.1	OSGEPL1-AS1	-4.29	1.94e-05	0.00148	-0.23	-0.13	Alcohol dependence (age at onset);	chr2:189647251	chr2:189762704~189765556:+
BRCA	cis	rs62184315	0.536	rs62183652	ENSG00000253559.1	OSGEPL1-AS1	-4.29	1.94e-05	0.00148	-0.23	-0.13	Alcohol dependence (age at onset);	chr2:189648877	chr2:189762704~189765556:+
BRCA	cis	rs62184315	0.536	rs62183653	ENSG00000253559.1	OSGEPL1-AS1	-4.29	1.94e-05	0.00148	-0.23	-0.13	Alcohol dependence (age at onset);	chr2:189650099	chr2:189762704~189765556:+
BRCA	cis	rs62184315	0.536	rs72920421	ENSG00000253559.1	OSGEPL1-AS1	-4.29	1.94e-05	0.00148	-0.23	-0.13	Alcohol dependence (age at onset);	chr2:189650292	chr2:189762704~189765556:+
BRCA	cis	rs1510272	0.847	rs12492935	ENSG00000243926.1	TIPARP-AS1	-4.29	1.94e-05	0.00148	-0.15	-0.13	Testicular germ cell tumor;	chr3:156610164	chr3:156671862~156674378:-
BRCA	cis	rs1510272	0.842	rs2048337	ENSG00000243926.1	TIPARP-AS1	-4.29	1.94e-05	0.00148	-0.15	-0.13	Testicular germ cell tumor;	chr3:156610306	chr3:156671862~156674378:-
BRCA	cis	rs6121246	0.542	rs2376990	ENSG00000230613.1	HM13-AS1	4.29	1.94e-05	0.00148	0.2	0.13	Mean corpuscular hemoglobin;	chr20:31650941	chr20:31567707~31573263:-
BRCA	cis	rs7615952	0.512	rs34085484	ENSG00000241288.6	RP11-379B18.5	-4.29	1.94e-05	0.00148	-0.18	-0.13	Blood pressure (smoking interaction);	chr3:125825343	chr3:125827238~125916384:-
BRCA	cis	rs7615952	0.608	rs35668111	ENSG00000241288.6	RP11-379B18.5	-4.29	1.94e-05	0.00148	-0.18	-0.13	Blood pressure (smoking interaction);	chr3:125825792	chr3:125827238~125916384:-
BRCA	cis	rs17818399	0.815	rs62136873	ENSG00000279254.1	RP11-536C12.1	-4.29	1.94e-05	0.00148	-0.18	-0.13	Height;	chr2:46634098	chr2:46668870~46670778:+
BRCA	cis	rs10129255	0.536	rs17113249	ENSG00000232216.1	IGHV3-43	4.29	1.94e-05	0.00148	0.1	0.13	Kawasaki disease;	chr14:106678273	chr14:106470264~106470800:-
BRCA	cis	rs886774	0.866	rs10267797	ENSG00000273055.1	CTB-13F3.1	-4.29	1.94e-05	0.00148	-0.13	-0.13	Ulcerative colitis;	chr7:107874855	chr7:107942116~107942740:+
BRCA	cis	rs72772090	0.522	rs55804164	ENSG00000248734.2	CTD-2260A17.1	-4.29	1.94e-05	0.00148	-0.3	-0.13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96667371	chr5:96784777~96785999:+
BRCA	cis	rs1387259	0.57	rs12368659	ENSG00000226413.2	OR8T1P	4.29	1.94e-05	0.00148	0.17	0.13	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48168516	chr12:48442030~48442947:-
BRCA	cis	rs1910358	0.554	rs13189504	ENSG00000248874.4	C5orf17	-4.29	1.94e-05	0.00148	-0.19	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23780803	chr5:23951348~24178263:+
BRCA	cis	rs34217772	0.699	rs12432215	ENSG00000258636.1	CTD-2298J14.2	4.29	1.94e-05	0.00148	0.17	0.13	Myopia;	chr14:41843280	chr14:41587861~41604856:-
BRCA	cis	rs2562456	0.874	rs2562408	ENSG00000268535.1	RP11-420K14.3	-4.29	1.94e-05	0.00149	-0.18	-0.13	Pain;	chr19:21527079	chr19:21709522~21710191:+
BRCA	cis	rs9921338	0.923	rs4563054	ENSG00000262636.1	CTD-3088G3.4	-4.29	1.94e-05	0.00149	-0.22	-0.13	Vein graft stenosis in coronary artery bypass grafting;	chr16:11353689	chr16:11380859~11381118:-
BRCA	cis	rs2286503	0.839	rs4722188	ENSG00000226329.2	AC005682.6	4.29	1.94e-05	0.00149	0.12	0.13	Fibrinogen;	chr7:22820592	chr7:22863874~22881350:-
BRCA	cis	rs115575488	0.61	rs12741635	ENSG00000236804.1	RPS3AP12	4.29	1.94e-05	0.00149	0.19	0.13	Lobe attachment (rater-scored or self-reported);	chr1:119051198	chr1:119126539~119127291:-
BRCA	cis	rs6088580	0.634	rs6142157	ENSG00000276073.1	RP5-1125A11.7	4.29	1.94e-05	0.00149	0.14	0.13	Glomerular filtration rate (creatinine);	chr20:34396366	chr20:33985617~33988989:-
BRCA	cis	rs780094	0.5	rs13022873	ENSG00000234072.1	AC074117.10	4.29	1.95e-05	0.00149	0.13	0.13	Urate levels in overweight individuals;C-reactive protein;Metabolic syndrome;Red blood cell count;Renal underexcretion gout;Nonalcoholic fatty liver disease;Age-related diseases, mortality and associated endophenotypes;Crohn's disease;Calcium levels;Fasting plasma glucose;Metabolic traits;Fasting blood glucose;Fasting blood insulin;Urate levels in obese individuals;Alcohol consumption (drinks per week);Height;Urate levels;Gondoic acid (20:1n-9) levels;Uric acid levels;Age-related disease endophenotypes;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Homeostasis model assessment of insulin resistance;Alcohol consumption;Fasting blood insulin (BMI interaction);Triglycerides;Fasting blood glucose (BMI interaction);Hypertriglyceridemia;LDL cholesterol;Type 2 diabetes;Triglyceride levels;	chr2:27592643	chr2:27356246~27367622:+
BRCA	cis	rs9863	0.828	rs7975482	ENSG00000270028.1	RP11-380L11.4	4.29	1.95e-05	0.00149	0.16	0.13	White blood cell count;	chr12:123997143	chr12:123925461~123926083:-
BRCA	cis	rs2403083	0.578	rs7829050	ENSG00000258256.1	RP11-219B4.5	-4.29	1.95e-05	0.00149	-0.16	-0.13	Plasma amyloid beta peptide concentrations (ABx-40);	chr8:85139159	chr8:85222446~85245717:-
BRCA	cis	rs875971	0.66	rs3764903	ENSG00000272831.1	RP11-792A8.4	-4.29	1.95e-05	0.00149	-0.12	-0.13	Aortic root size;	chr7:66633495	chr7:66739829~66740385:-
BRCA	cis	rs893818	1	rs1992314	ENSG00000261801.4	LOXL1-AS1	-4.29	1.95e-05	0.00149	-0.16	-0.13	Exfoliation glaucoma or exfoliation syndrome;	chr15:73931426	chr15:73908071~73928248:-
BRCA	cis	rs2625529	0.652	rs2278987	ENSG00000260037.4	CTD-2524L6.3	4.29	1.95e-05	0.00149	0.16	0.13	Red blood cell count;	chr15:72117428	chr15:71818396~71823384:+
BRCA	cis	rs17027633	0.867	rs12097762	ENSG00000260948.1	RP11-552M11.8	-4.29	1.95e-05	0.00149	-0.25	-0.13	Cerebrospinal fluid t-tau:AB1-42 ratio;	chr1:111418417	chr1:111431046~111433068:-
BRCA	cis	rs9788721	0.836	rs72738736	ENSG00000261762.1	RP11-650L12.2	-4.29	1.95e-05	0.00149	-0.16	-0.13	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78472780	chr15:78589123~78591276:-
BRCA	cis	rs3858526	0.628	rs1840177	ENSG00000224295.2	AC087380.14	-4.29	1.95e-05	0.00149	-0.17	-0.13	DNA methylation (variation);	chr11:5923397	chr11:5518441~5524955:-
BRCA	cis	rs11098499	0.954	rs10017371	ENSG00000260404.2	RP11-384K6.6	4.29	1.95e-05	0.00149	0.13	0.13	Corneal astigmatism;	chr4:119372621	chr4:118591773~118633729:+
BRCA	cis	rs644148	0.77	rs2571113	ENSG00000176761.7	ZNF285B	4.29	1.95e-05	0.00149	0.15	0.13	Personality dimensions;	chr19:44495753	chr19:44467641~44473227:+
BRCA	cis	rs644148	0.836	rs2686774	ENSG00000176761.7	ZNF285B	4.29	1.95e-05	0.00149	0.15	0.13	Personality dimensions;	chr19:44495766	chr19:44467641~44473227:+
BRCA	cis	rs7811142	0.83	rs7341507	ENSG00000078319.8	PMS2P1	-4.29	1.95e-05	0.00149	-0.21	-0.13	Platelet count;	chr7:100353692	chr7:100320992~100341908:-
BRCA	cis	rs4578769	0.959	rs3851816	ENSG00000265939.1	UBE2CP2	4.29	1.95e-05	0.00149	0.16	0.13	Eosinophil percentage of white cells;	chr18:22866880	chr18:22900486~22900995:-
BRCA	cis	rs2236295	0.533	rs931977	ENSG00000238280.1	RP11-436D10.3	4.29	1.95e-05	0.00149	0.17	0.13	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks);	chr10:62898218	chr10:62793562~62805887:-
BRCA	cis	rs3770081	1	rs2241435	ENSG00000273080.1	RP11-301O19.1	-4.29	1.95e-05	0.00149	-0.3	-0.13	Facial emotion recognition (sad faces);	chr2:86133793	chr2:86195590~86196049:+
BRCA	cis	rs11098499	0.909	rs9759478	ENSG00000250412.1	KLHL2P1	4.29	1.95e-05	0.00149	0.16	0.13	Corneal astigmatism;	chr4:119446843	chr4:119334329~119378233:+
BRCA	cis	rs2115630	1	rs4633690	ENSG00000259728.4	LINC00933	-4.29	1.95e-05	0.00149	-0.15	-0.13	P wave terminal force;	chr15:84818729	chr15:84570649~84580175:+
BRCA	cis	rs7771547	0.723	rs2145048	ENSG00000224666.3	RP1-50J22.4	4.29	1.95e-05	0.00149	0.16	0.13	Platelet distribution width;	chr6:36589803	chr6:36386831~36393462:+
BRCA	cis	rs748404	0.666	rs7180812	ENSG00000205771.5	CATSPER2P1	-4.29	1.95e-05	0.00149	-0.2	-0.13	Lung cancer;	chr15:43403033	chr15:43726918~43747094:-
BRCA	cis	rs1005277	0.579	rs2474595	ENSG00000099251.13	HSD17B7P2	-4.29	1.95e-05	0.00149	-0.15	-0.13	Extrinsic epigenetic age acceleration;	chr10:38137854	chr10:38356380~38378505:+
BRCA	cis	rs7937682	0.961	rs7106104	ENSG00000230911.1	PPIHP1	4.29	1.95e-05	0.00149	0.19	0.13	Primary sclerosing cholangitis;	chr11:111764931	chr11:112029858~112030367:-
BRCA	cis	rs10129255	0.957	rs8009073	ENSG00000274576.2	IGHV2-70	4.29	1.95e-05	0.00149	0.12	0.13	Kawasaki disease;	chr14:106777278	chr14:106770577~106771020:-
BRCA	cis	rs6957923	0.659	rs10280508	ENSG00000234286.1	AC006026.13	-4.29	1.95e-05	0.00149	-0.15	-0.13	Height;	chr7:23544439	chr7:23680195~23680786:-
BRCA	cis	rs3113494	1	rs3113494	ENSG00000251411.1	RP11-397E7.4	4.29	1.95e-05	0.00149	0.15	0.13	Amyotrophic lateral sclerosis;	chr4:86911448	chr4:86913266~86914817:-
BRCA	cis	rs3753275	0.628	rs4581300	ENSG00000232912.4	RP5-1115A15.1	-4.29	1.95e-05	0.00149	-0.18	-0.13	Educational attainment;	chr1:8550446	chr1:8424645~8434838:+
BRCA	cis	rs867186	0.92	rs17092456	ENSG00000126005.14	MMP24-AS1	-4.29	1.95e-05	0.00149	-0.23	-0.13	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35208389	chr20:35216462~35278131:-
BRCA	cis	rs11098499	0.739	rs6534130	ENSG00000260404.2	RP11-384K6.6	-4.29	1.95e-05	0.00149	-0.12	-0.13	Corneal astigmatism;	chr4:119210184	chr4:118591773~118633729:+
BRCA	cis	rs1832007	0.809	rs17134604	ENSG00000224034.1	RP11-445P17.8	-4.29	1.95e-05	0.00149	-0.26	-0.13	Triglyceride levels;Triglycerides;	chr10:5219293	chr10:5266033~5271236:-
BRCA	cis	rs2518049	0.519	rs77896903	ENSG00000224034.1	RP11-445P17.8	-4.29	1.95e-05	0.00149	-0.26	-0.13	Metabolic traits;	chr10:5219528	chr10:5266033~5271236:-
BRCA	cis	rs7475343	0.543	rs17134608	ENSG00000224034.1	RP11-445P17.8	-4.29	1.95e-05	0.00149	-0.26	-0.13	Intelligence;	chr10:5220056	chr10:5266033~5271236:-
BRCA	cis	rs6545883	0.894	rs2593633	ENSG00000273302.1	RP11-493E12.2	-4.29	1.95e-05	0.00149	-0.12	-0.13	Tuberculosis;	chr2:61344378	chr2:61199979~61200769:+
BRCA	cis	rs934734	0.532	rs7569257	ENSG00000281920.1	RP11-418H16.1	-4.29	1.95e-05	0.00149	-0.16	-0.13	Rheumatoid arthritis;	chr2:65429842	chr2:65623272~65628424:+
BRCA	cis	rs9467773	0.572	rs62394558	ENSG00000241549.7	GUSBP2	4.29	1.95e-05	0.00149	0.15	0.13	Intelligence (multi-trait analysis);	chr6:26604422	chr6:26871484~26956554:-
BRCA	cis	rs372883	1	rs372883	ENSG00000215533.7	LINC00189	-4.29	1.95e-05	0.00149	-0.14	-0.13	Pancreatic cancer;	chr21:29345416	chr21:29193480~29288205:+
BRCA	cis	rs13287066	0.967	rs10761224	ENSG00000227603.1	RP11-165J3.6	-4.29	1.95e-05	0.00149	-0.13	-0.13	Intelligence (multi-trait analysis);	chr9:93404297	chr9:93435332~93437121:-
BRCA	cis	rs62025270	0.688	rs11073516	ENSG00000259762.1	RP11-158M2.4	-4.29	1.95e-05	0.00149	-0.2	-0.13	Idiopathic pulmonary fibrosis;	chr15:85741996	chr15:85750336~85752901:-
BRCA	cis	rs7727544	0.571	rs12521097	ENSG00000233006.5	AC034220.3	4.29	1.95e-05	0.00149	0.1	0.13	Blood metabolite levels;	chr5:132239645	chr5:132311285~132369916:-
BRCA	cis	rs2243480	0.901	rs1701759	ENSG00000275400.1	RP4-756H11.5	4.29	1.95e-05	0.00149	0.24	0.13	Diabetic kidney disease;	chr7:66005945	chr7:66553805~66554199:-
BRCA	cis	rs7976059	0.824	rs12230839	ENSG00000259887.1	RP11-923I11.5	-4.29	1.95e-05	0.00149	-0.17	-0.13	Urate levels;	chr12:51855621	chr12:51848223~51852729:+
BRCA	cis	rs859767	0.741	rs11898084	ENSG00000224043.6	CCNT2-AS1	4.29	1.95e-05	0.00149	0.18	0.13	Neuroticism;	chr2:134670484	chr2:134735464~134918710:-
BRCA	cis	rs8114671	0.742	rs6058161	ENSG00000126005.14	MMP24-AS1	4.29	1.95e-05	0.00149	0.15	0.13	Height;	chr20:35032223	chr20:35216462~35278131:-
BRCA	cis	rs6452524	1	rs6868817	ENSG00000281327.1	LINC01338	4.29	1.95e-05	0.00149	0.15	0.13	Hypertension (SNP x SNP interaction);	chr5:83142287	chr5:82850864~82859836:-
BRCA	cis	rs6452524	0.967	rs10042018	ENSG00000281327.1	LINC01338	4.29	1.95e-05	0.00149	0.15	0.13	Hypertension (SNP x SNP interaction);	chr5:83142490	chr5:82850864~82859836:-
BRCA	cis	rs6452524	0.967	rs10036418	ENSG00000281327.1	LINC01338	4.29	1.95e-05	0.00149	0.15	0.13	Hypertension (SNP x SNP interaction);	chr5:83142493	chr5:82850864~82859836:-
BRCA	cis	rs6452524	1	rs10055948	ENSG00000281327.1	LINC01338	4.29	1.95e-05	0.00149	0.15	0.13	Hypertension (SNP x SNP interaction);	chr5:83143437	chr5:82850864~82859836:-
BRCA	cis	rs651907	0.588	rs797866	ENSG00000244119.1	PDCL3P4	4.29	1.95e-05	0.00149	0.11	0.13	Colorectal cancer;	chr3:101939187	chr3:101712472~101713191:+
BRCA	cis	rs12705849	0.831	rs2272260	ENSG00000214194.7	LINC00998	4.29	1.95e-05	0.00149	0.16	0.13	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Eosinophil counts;	chr7:113117807	chr7:113116718~113118613:-
BRCA	cis	rs2243480	0.803	rs55700941	ENSG00000275400.1	RP4-756H11.5	4.29	1.95e-05	0.00149	0.24	0.13	Diabetic kidney disease;	chr7:65924813	chr7:66553805~66554199:-
BRCA	cis	rs2625529	0.938	rs2723343	ENSG00000260037.4	CTD-2524L6.3	-4.29	1.95e-05	0.00149	-0.19	-0.13	Red blood cell count;	chr15:71815928	chr15:71818396~71823384:+
BRCA	cis	rs934734	0.532	rs12470883	ENSG00000204929.10	AC074391.1	-4.29	1.95e-05	0.00149	-0.16	-0.13	Rheumatoid arthritis;	chr2:65424717	chr2:65436711~66084639:+
BRCA	cis	rs7267979	0.844	rs1555330	ENSG00000125804.12	FAM182A	-4.29	1.96e-05	0.00149	-0.17	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25251461	chr20:26054655~26086917:+
BRCA	cis	rs7267979	0.844	rs6107017	ENSG00000125804.12	FAM182A	-4.29	1.96e-05	0.00149	-0.17	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25251664	chr20:26054655~26086917:+
BRCA	cis	rs4950322	1	rs4950322	ENSG00000244371.2	PFN1P8	4.29	1.96e-05	0.00149	0.19	0.13	Protein quantitative trait loci;	chr1:147383114	chr1:146957117~146957659:-
BRCA	cis	rs9650657	0.562	rs10090444	ENSG00000255020.1	AF131216.5	-4.29	1.96e-05	0.00149	-0.16	-0.13	Neuroticism;	chr8:10887959	chr8:11345748~11347502:-
BRCA	cis	rs1910358	0.554	rs7706069	ENSG00000248874.4	C5orf17	-4.29	1.96e-05	0.00149	-0.19	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23775243	chr5:23951348~24178263:+
BRCA	cis	rs7572733	0.875	rs771018	ENSG00000231621.1	AC013264.2	-4.29	1.96e-05	0.00149	-0.12	-0.13	Dermatomyositis;	chr2:197785535	chr2:197197991~197199273:+
BRCA	cis	rs13126694	0.633	rs4513617	ENSG00000251429.1	RP11-597D13.7	4.29	1.96e-05	0.00149	0.13	0.13	Blood osmolality (transformed sodium);	chr4:158080045	chr4:158270378~158278676:+
BRCA	cis	rs8180040	0.739	rs12488225	ENSG00000276925.1	RP11-708J19.3	-4.29	1.96e-05	0.00149	-0.15	-0.13	Colorectal cancer;	chr3:47193617	chr3:47469777~47469987:+
BRCA	cis	rs739496	0.579	rs3177647	ENSG00000257624.1	RP1-128M12.3	4.29	1.96e-05	0.00149	0.18	0.13	Platelet count;	chr12:111839772	chr12:112000739~112000985:-
BRCA	cis	rs832540	0.695	rs702686	ENSG00000271828.1	CTD-2310F14.1	4.29	1.96e-05	0.00149	0.16	0.13	Coronary artery disease;	chr5:56905523	chr5:56927874~56929573:+
BRCA	cis	rs11673344	0.504	rs2385374	ENSG00000226686.6	LINC01535	4.29	1.96e-05	0.00149	0.17	0.13	Obesity-related traits;	chr19:37092115	chr19:37251912~37265535:+
BRCA	cis	rs4143844	1	rs62007454	ENSG00000259251.2	RP11-643M14.1	4.29	1.96e-05	0.00149	0.31	0.13	Bipolar disorder and schizophrenia;	chr15:62062496	chr15:62060503~62062434:+
BRCA	cis	rs7267979	1	rs6050559	ENSG00000125804.12	FAM182A	-4.29	1.96e-05	0.0015	-0.17	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25349279	chr20:26054655~26086917:+
BRCA	cis	rs1510272	0.961	rs12696040	ENSG00000243926.1	TIPARP-AS1	-4.29	1.96e-05	0.0015	-0.15	-0.13	Testicular germ cell tumor;	chr3:156587022	chr3:156671862~156674378:-
BRCA	cis	rs1371614	0.611	rs7557229	ENSG00000272148.1	RP11-195B17.1	-4.29	1.96e-05	0.0015	-0.15	-0.13	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26908023	chr2:27062428~27062907:-
BRCA	cis	rs4869313	0.905	rs27712	ENSG00000248734.2	CTD-2260A17.1	4.29	1.96e-05	0.0015	0.14	0.13	Pediatric autoimmune diseases;	chr5:97028359	chr5:96784777~96785999:+
BRCA	cis	rs832540	0.966	rs252925	ENSG00000271828.1	CTD-2310F14.1	-4.29	1.96e-05	0.0015	-0.16	-0.13	Coronary artery disease;	chr5:56907946	chr5:56927874~56929573:+
BRCA	cis	rs7819412	0.521	rs9329238	ENSG00000255046.1	RP11-297N6.4	4.29	1.96e-05	0.0015	0.16	0.13	Triglycerides;	chr8:11176228	chr8:11797928~11802568:-
BRCA	cis	rs4578769	0.918	rs9957390	ENSG00000265939.1	UBE2CP2	4.29	1.96e-05	0.0015	0.16	0.13	Eosinophil percentage of white cells;	chr18:22840421	chr18:22900486~22900995:-
BRCA	cis	rs9818758	0.556	rs11716614	ENSG00000270441.1	RP11-694I15.7	4.29	1.96e-05	0.0015	0.32	0.13	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:48979775	chr3:49140086~49160851:-
BRCA	cis	rs6921919	0.583	rs7759191	ENSG00000273712.1	RP5-874C20.7	4.29	1.96e-05	0.0015	0.17	0.13	Autism spectrum disorder or schizophrenia;	chr6:28385657	chr6:28315613~28315883:-
BRCA	cis	rs6921919	0.583	rs7764737	ENSG00000273712.1	RP5-874C20.7	4.29	1.96e-05	0.0015	0.17	0.13	Autism spectrum disorder or schizophrenia;	chr6:28386838	chr6:28315613~28315883:-
BRCA	cis	rs6921919	0.583	rs9461458	ENSG00000273712.1	RP5-874C20.7	4.29	1.96e-05	0.0015	0.17	0.13	Autism spectrum disorder or schizophrenia;	chr6:28388098	chr6:28315613~28315883:-
BRCA	cis	rs6921919	0.609	rs9468365	ENSG00000273712.1	RP5-874C20.7	4.29	1.96e-05	0.0015	0.17	0.13	Autism spectrum disorder or schizophrenia;	chr6:28390189	chr6:28315613~28315883:-
BRCA	cis	rs6921919	0.583	rs1361385	ENSG00000273712.1	RP5-874C20.7	4.29	1.96e-05	0.0015	0.17	0.13	Autism spectrum disorder or schizophrenia;	chr6:28390543	chr6:28315613~28315883:-
BRCA	cis	rs6921919	0.583	rs1416918	ENSG00000273712.1	RP5-874C20.7	4.29	1.96e-05	0.0015	0.17	0.13	Autism spectrum disorder or schizophrenia;	chr6:28390558	chr6:28315613~28315883:-
BRCA	cis	rs6921919	0.583	rs9468367	ENSG00000273712.1	RP5-874C20.7	4.29	1.96e-05	0.0015	0.17	0.13	Autism spectrum disorder or schizophrenia;	chr6:28392469	chr6:28315613~28315883:-
BRCA	cis	rs16846053	0.605	rs16846179	ENSG00000227403.1	AC009299.3	4.29	1.96e-05	0.0015	0.3	0.13	Blood osmolality (transformed sodium);	chr2:161892546	chr2:161244739~161249050:+
BRCA	cis	rs7312933	0.558	rs11181483	ENSG00000257225.1	RP11-328C8.4	-4.29	1.96e-05	0.0015	-0.16	-0.13	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42404582	chr12:42459366~42466128:+
BRCA	cis	rs6547741	0.935	rs4666005	ENSG00000234072.1	AC074117.10	4.29	1.96e-05	0.0015	0.12	0.13	Oral cavity cancer;	chr2:27632372	chr2:27356246~27367622:+
BRCA	cis	rs669446	0.561	rs641365	ENSG00000236200.4	KDM4A-AS1	-4.29	1.96e-05	0.0015	-0.16	-0.13	Amyotrophic lateral sclerosis (age of onset);	chr1:43617836	chr1:43699765~43708138:-
BRCA	cis	rs13126694	0.599	rs6536297	ENSG00000251429.1	RP11-597D13.7	4.29	1.96e-05	0.0015	0.13	0.13	Blood osmolality (transformed sodium);	chr4:158076205	chr4:158270378~158278676:+
BRCA	cis	rs11098499	0.909	rs10020034	ENSG00000260404.2	RP11-384K6.6	4.29	1.96e-05	0.0015	0.12	0.13	Corneal astigmatism;	chr4:119373176	chr4:118591773~118633729:+
BRCA	cis	rs12531458	0.745	rs2141277	ENSG00000249978.1	TRGV7	4.29	1.96e-05	0.0015	0.11	0.13	Educational attainment (years of education);	chr7:39059578	chr7:38335041~38335514:-
BRCA	cis	rs516805	0.561	rs2684239	ENSG00000279114.1	RP3-425C14.5	-4.29	1.96e-05	0.0015	-0.16	-0.13	Lymphocyte counts;	chr6:122086976	chr6:122471923~122484161:+
BRCA	cis	rs516805	0.561	rs2679640	ENSG00000279114.1	RP3-425C14.5	-4.29	1.96e-05	0.0015	-0.16	-0.13	Lymphocyte counts;	chr6:122087013	chr6:122471923~122484161:+
BRCA	cis	rs9393777	0.668	rs72839449	ENSG00000220721.1	OR1F12	4.29	1.96e-05	0.0015	0.19	0.13	Intelligence (multi-trait analysis);	chr6:27293882	chr6:28073316~28074233:+
BRCA	cis	rs17684571	0.7	rs35886823	ENSG00000231441.1	RP11-472M19.2	4.29	1.96e-05	0.0015	0.19	0.13	Schizophrenia;	chr6:56816682	chr6:56844002~56864078:+
BRCA	cis	rs529866	0.555	rs367569	ENSG00000262636.1	CTD-3088G3.4	4.29	1.96e-05	0.0015	0.19	0.13	Inflammatory bowel disease;Crohn's disease;	chr16:11271643	chr16:11380859~11381118:-
BRCA	cis	rs4374383	0.847	rs1516627	ENSG00000243389.1	AC012442.5	4.29	1.96e-05	0.0015	0.17	0.13	Hepatitis C induced liver fibrosis;	chr2:111946477	chr2:112589040~112614431:+
BRCA	cis	rs7927592	0.763	rs11822059	ENSG00000212093.1	AP000807.1	4.29	1.96e-05	0.0015	0.14	0.13	Total body bone mineral density;	chr11:68533354	chr11:68506083~68506166:-
BRCA	cis	rs4916588	0.636	rs7615073	ENSG00000230732.4	AC127904.2	4.29	1.96e-05	0.0015	0.17	0.13	Night sleep phenotypes;	chr3:196877691	chr3:196912646~196914579:+
BRCA	cis	rs2625529	0.73	rs2957373	ENSG00000260037.4	CTD-2524L6.3	4.29	1.96e-05	0.0015	0.17	0.13	Red blood cell count;	chr15:72048588	chr15:71818396~71823384:+
BRCA	cis	rs9921338	0.924	rs7202024	ENSG00000262636.1	CTD-3088G3.4	-4.29	1.97e-05	0.0015	-0.22	-0.13	Vein graft stenosis in coronary artery bypass grafting;	chr16:11346901	chr16:11380859~11381118:-
BRCA	cis	rs9921338	0.961	rs7206017	ENSG00000262636.1	CTD-3088G3.4	-4.29	1.97e-05	0.0015	-0.22	-0.13	Vein graft stenosis in coronary artery bypass grafting;	chr16:11347004	chr16:11380859~11381118:-
BRCA	cis	rs2738459	0.5	rs11085761	ENSG00000212497.1	RNA5SP465	4.29	1.97e-05	0.0015	0.16	0.13	LDL cholesterol;	chr19:11135944	chr19:12027913~12028021:-
BRCA	cis	rs372883	0.967	rs2832290	ENSG00000215533.7	LINC00189	-4.29	1.97e-05	0.0015	-0.15	-0.13	Pancreatic cancer;	chr21:29356542	chr21:29193480~29288205:+
BRCA	cis	rs2749592	0.55	rs12255038	ENSG00000099251.13	HSD17B7P2	-4.29	1.97e-05	0.0015	-0.15	-0.13	Age-related hearing impairment (SNP x SNP interaction);	chr10:37580404	chr10:38356380~38378505:+
BRCA	cis	rs6671200	1	rs12755552	ENSG00000226026.4	RP11-57H12.3	4.29	1.97e-05	0.0015	0.28	0.13	Stearic acid (18:0) levels;	chr1:95219470	chr1:95163219~95233982:-
BRCA	cis	rs7824557	0.736	rs35392635	ENSG00000248896.2	CTD-2135J3.3	4.29	1.97e-05	0.0015	0.18	0.13	Retinal vascular caliber;	chr8:11306840	chr8:10729314~10771392:+
BRCA	cis	rs11673344	0.502	rs17304703	ENSG00000267422.1	CTD-2554C21.1	4.29	1.97e-05	0.0015	0.18	0.13	Obesity-related traits;	chr19:37582646	chr19:37779686~37792865:+
BRCA	cis	rs73206853	0.563	rs10400410	ENSG00000277299.1	RP11-837J7.4	-4.29	1.97e-05	0.0015	-0.23	-0.13	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr12:110755694	chr12:109948389~109949029:+
BRCA	cis	rs2274273	0.804	rs28428911	ENSG00000259318.1	RP11-454L9.2	4.29	1.97e-05	0.0015	0.11	0.13	Protein biomarker;	chr14:55376878	chr14:55394940~55395233:-
BRCA	cis	rs853679	1	rs1936365	ENSG00000280107.1	AL022393.9	4.29	1.97e-05	0.0015	0.23	0.13	Depression;	chr6:28300675	chr6:28170845~28172521:+
BRCA	cis	rs72634501	0.54	rs16826036	ENSG00000182109.6	RP11-69E11.4	4.29	1.97e-05	0.0015	0.18	0.13	HDL cholesterol;	chr1:39292127	chr1:39522280~39546187:-
BRCA	cis	rs755249	0.567	rs16826038	ENSG00000182109.6	RP11-69E11.4	4.29	1.97e-05	0.0015	0.18	0.13	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39292962	chr1:39522280~39546187:-
BRCA	cis	rs755249	0.567	rs61782157	ENSG00000182109.6	RP11-69E11.4	4.29	1.97e-05	0.0015	0.18	0.13	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39297217	chr1:39522280~39546187:-
BRCA	cis	rs755249	0.567	rs41270803	ENSG00000182109.6	RP11-69E11.4	4.29	1.97e-05	0.0015	0.18	0.13	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39300369	chr1:39522280~39546187:-
BRCA	cis	rs6772849	0.775	rs66822528	ENSG00000242551.2	POU5F1P6	-4.29	1.97e-05	0.0015	-0.17	-0.13	Monocyte percentage of white cells;Monocyte count;	chr3:128696254	chr3:128674735~128677005:-
BRCA	cis	rs7746199	0.736	rs13209332	ENSG00000216901.1	AL022393.7	4.29	1.97e-05	0.0015	0.34	0.13	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27552973	chr6:28176188~28176674:+
BRCA	cis	rs893971	0.674	rs28789746	ENSG00000246375.2	RP11-10L7.1	4.29	1.97e-05	0.0015	0.17	0.13	Conduct disorder (maternal expressed emotions interaction);	chr4:88309350	chr4:88284942~88331421:+
BRCA	cis	rs7618915	0.501	rs34739010	ENSG00000243224.1	RP5-1157M23.2	-4.29	1.97e-05	0.0015	-0.14	-0.13	Bipolar disorder;	chr3:52732106	chr3:52239258~52241097:+
BRCA	cis	rs6968419	0.755	rs2402057	ENSG00000279086.1	RP11-667F14.1	4.29	1.97e-05	0.0015	0.14	0.13	Intraocular pressure;	chr7:116257042	chr7:116209234~116211511:-
BRCA	cis	rs7267979	0.903	rs2474766	ENSG00000125804.12	FAM182A	-4.29	1.97e-05	0.0015	-0.17	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25265517	chr20:26054655~26086917:+
BRCA	cis	rs7267979	0.903	rs2474769	ENSG00000125804.12	FAM182A	-4.29	1.97e-05	0.0015	-0.17	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25268089	chr20:26054655~26086917:+
BRCA	cis	rs7074356	0.525	rs12246441	ENSG00000225484.5	NUTM2B-AS1	4.29	1.97e-05	0.0015	0.22	0.13	Borderline personality disorder;	chr10:80497980	chr10:79663088~79826594:-
BRCA	cis	rs9868809	0.505	rs11706983	ENSG00000225399.4	RP11-3B7.1	-4.29	1.97e-05	0.0015	-0.2	-0.13	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48701245	chr3:49260085~49261316:+
BRCA	cis	rs465969	0.655	rs13203984	ENSG00000230177.1	RP5-1112D6.4	4.29	1.97e-05	0.0015	0.3	0.13	Psoriasis;	chr6:111388538	chr6:111277932~111278742:+
BRCA	cis	rs983392	0.805	rs7933805	ENSG00000275344.1	MIR6503	-4.29	1.97e-05	0.0015	-0.14	-0.13	Alzheimer's disease (late onset);	chr11:60200053	chr11:60209071~60209156:-
BRCA	cis	rs9470794	0.915	rs73419475	ENSG00000204110.6	RP1-153P14.8	-4.29	1.97e-05	0.0015	-0.27	-0.13	Type 2 diabetes;	chr6:37910271	chr6:37507348~37535616:+
BRCA	cis	rs12317459	0.591	rs7133916	ENSG00000213270.5	RPL6P25	-4.29	1.97e-05	0.0015	-0.21	-0.13	Prostate cancer (SNP x SNP interaction);	chr12:82769066	chr12:83151331~83152190:+
BRCA	cis	rs10170310	0.515	rs4954715	ENSG00000241772.2	AC092620.2	4.29	1.97e-05	0.0015	0.22	0.13	Response to antipsychotic treatment;	chr2:138552198	chr2:138569090~138574458:+
BRCA	cis	rs904251	0.62	rs883372	ENSG00000204110.6	RP1-153P14.8	-4.29	1.97e-05	0.0015	-0.17	-0.13	Cognitive performance;	chr6:37509829	chr6:37507348~37535616:+
BRCA	cis	rs10129255	1	rs11627342	ENSG00000232216.1	IGHV3-43	4.29	1.97e-05	0.0015	0.11	0.13	Kawasaki disease;	chr14:106675823	chr14:106470264~106470800:-
BRCA	cis	rs11719291	0.915	rs9834996	ENSG00000225399.4	RP11-3B7.1	-4.29	1.97e-05	0.0015	-0.2	-0.13	Cognitive function;	chr3:48717444	chr3:49260085~49261316:+
BRCA	cis	rs17126232	0.643	rs17126214	ENSG00000253384.1	CTD-2547L16.3	-4.29	1.97e-05	0.0015	-0.27	-0.13	Obesity;	chr8:18091295	chr8:18088569~18089687:-
BRCA	cis	rs2777491	0.54	rs7164684	ENSG00000247556.5	OIP5-AS1	4.29	1.97e-05	0.0015	0.15	0.13	Ulcerative colitis;	chr15:41412810	chr15:41283990~41309737:+
BRCA	cis	rs11098499	0.909	rs1546502	ENSG00000225892.3	RP11-384K6.2	4.29	1.97e-05	0.00151	0.13	0.13	Corneal astigmatism;	chr4:119314743	chr4:118632274~118634759:+
BRCA	cis	rs409045	1	rs450676	ENSG00000271874.1	CTD-2024P10.2	-4.29	1.97e-05	0.00151	-0.18	-0.13	Left ventricular mass;	chr5:34635405	chr5:34651457~34651888:-
BRCA	cis	rs757081	0.667	rs17560341	ENSG00000184669.7	OR7E14P	-4.29	1.97e-05	0.00151	-0.2	-0.13	Systolic blood pressure;	chr11:17085616	chr11:17013998~17053024:+
BRCA	cis	rs812925	0.502	rs6545868	ENSG00000270820.4	RP11-355B11.2	-4.29	1.97e-05	0.00151	-0.14	-0.13	Immature fraction of reticulocytes;	chr2:61428230	chr2:61471188~61484130:+
BRCA	cis	rs7618915	0.501	rs7624716	ENSG00000243224.1	RP5-1157M23.2	-4.29	1.97e-05	0.00151	-0.14	-0.13	Bipolar disorder;	chr3:52717518	chr3:52239258~52241097:+
BRCA	cis	rs7618915	0.501	rs2109634	ENSG00000243224.1	RP5-1157M23.2	-4.29	1.97e-05	0.00151	-0.14	-0.13	Bipolar disorder;	chr3:52718059	chr3:52239258~52241097:+
BRCA	cis	rs2229238	0.911	rs73020232	ENSG00000272030.1	RP1-178F15.4	-4.29	1.97e-05	0.00151	-0.19	-0.13	Coronary heart disease;	chr1:154510193	chr1:153631438~153634397:-
BRCA	cis	rs2692947	0.673	rs2229169	ENSG00000168992.4	OR7E102P	-4.29	1.98e-05	0.00151	-0.18	-0.13	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96114968	chr2:95546531~95547545:+
BRCA	cis	rs10043228	1	rs12332489	ENSG00000271918.1	CTD-2287O16.5	-4.29	1.98e-05	0.00151	-0.17	-0.13	Asthma or chronic obstructive pulmonary disease;	chr5:116243689	chr5:116083807~116085416:-
BRCA	cis	rs10043228	1	rs12332585	ENSG00000271918.1	CTD-2287O16.5	-4.29	1.98e-05	0.00151	-0.17	-0.13	Asthma or chronic obstructive pulmonary disease;	chr5:116245698	chr5:116083807~116085416:-
BRCA	cis	rs2832191	0.679	rs2705659	ENSG00000232855.5	AF131217.1	-4.29	1.98e-05	0.00151	-0.16	-0.13	Dental caries;	chr21:28991587	chr21:28439346~28674848:-
BRCA	cis	rs763121	0.853	rs5757231	ENSG00000225450.1	RP3-508I15.14	4.29	1.98e-05	0.00151	0.14	0.13	Menopause (age at onset);	chr22:38675653	chr22:38739003~38749041:+
BRCA	cis	rs7260598	0.792	rs11672981	ENSG00000268442.1	CTD-2027I19.2	4.29	1.98e-05	0.00151	0.22	0.13	Response to taxane treatment (placlitaxel);	chr19:24144735	chr19:24162370~24163425:-
BRCA	cis	rs6964833	1	rs4717906	ENSG00000184616.8	AC004166.6	4.29	1.98e-05	0.00151	0.19	0.13	Menarche (age at onset);	chr7:74671923	chr7:74906673~74913256:-
BRCA	cis	rs11096990	0.593	rs6531700	ENSG00000249685.1	RP11-360F5.3	-4.29	1.98e-05	0.00151	-0.16	-0.13	Cognitive function;	chr4:39269265	chr4:39133913~39135608:+
BRCA	cis	rs595244	1	rs1678982	ENSG00000259705.1	RP11-227D13.1	-4.29	1.98e-05	0.00151	-0.22	-0.13	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48609223	chr15:48645951~48652016:+
BRCA	cis	rs2832191	0.716	rs9983051	ENSG00000232855.5	AF131217.1	-4.29	1.98e-05	0.00151	-0.16	-0.13	Dental caries;	chr21:28999569	chr21:28439346~28674848:-
BRCA	cis	rs4907240	0.921	rs2278563	ENSG00000230606.9	AC159540.1	4.29	1.98e-05	0.00151	0.17	0.13	Event-related brain oscillations;	chr2:96546956	chr2:97416165~97433527:-
BRCA	cis	rs490234	0.702	rs35129945	ENSG00000232630.1	PRPS1P2	-4.29	1.98e-05	0.00151	-0.14	-0.13	Mean arterial pressure;	chr9:125557855	chr9:125150653~125151589:+
BRCA	cis	rs11098499	0.954	rs12510138	ENSG00000250412.1	KLHL2P1	4.29	1.98e-05	0.00151	0.16	0.13	Corneal astigmatism;	chr4:119502780	chr4:119334329~119378233:+
BRCA	cis	rs10266483	0.739	rs11765764	ENSG00000227986.1	TRIM60P18	4.29	1.98e-05	0.00151	0.15	0.13	Response to statin therapy;	chr7:64368163	chr7:64355078~64356199:+
BRCA	cis	rs4478858	0.775	rs6701861	ENSG00000260386.4	LINC01225	-4.29	1.98e-05	0.00151	-0.15	-0.13	Alcohol dependence;	chr1:31235278	chr1:31500085~31540885:+
BRCA	cis	rs1910358	0.571	rs1501944	ENSG00000248874.4	C5orf17	-4.29	1.98e-05	0.00151	-0.17	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23999291	chr5:23951348~24178263:+
BRCA	cis	rs58521262	0.585	rs2548887	ENSG00000268105.1	RP11-369G6.2	-4.29	1.98e-05	0.00151	-0.18	-0.13	Testicular germ cell tumor;	chr19:23028515	chr19:23125665~23128543:+
BRCA	cis	rs987360	0.745	rs28682384	ENSG00000248869.4	RP11-138I17.1	4.29	1.98e-05	0.00151	0.13	0.13	Temperament;	chr4:137280132	chr4:136796722~137212799:-
BRCA	cis	rs4713118	0.629	rs203887	ENSG00000280107.1	AL022393.9	-4.29	1.98e-05	0.00151	-0.2	-0.13	Parkinson's disease;	chr6:28053491	chr6:28170845~28172521:+
BRCA	cis	rs13326165	0.76	rs2016575	ENSG00000243224.1	RP5-1157M23.2	4.29	1.98e-05	0.00151	0.18	0.13	HDL cholesterol levels;HDL cholesterol;	chr3:52443064	chr3:52239258~52241097:+
BRCA	cis	rs10829156	0.796	rs6482567	ENSG00000240291.1	RP11-499P20.2	4.29	1.98e-05	0.00151	0.15	0.13	Sudden cardiac arrest;	chr10:18625860	chr10:18513115~18545651:-
BRCA	cis	rs8103033	0.786	rs997104	ENSG00000268088.1	AC093063.2	-4.29	1.98e-05	0.00151	-0.14	-0.13	Obesity-related traits;	chr19:39658690	chr19:39693925~39696258:+
BRCA	cis	rs10129255	0.556	rs8010005	ENSG00000211959.2	IGHV4-39	4.29	1.98e-05	0.00151	0.09	0.13	Kawasaki disease;	chr14:106777987	chr14:106421711~106422218:-
BRCA	cis	rs10129255	0.556	rs6576224	ENSG00000211959.2	IGHV4-39	4.29	1.98e-05	0.00151	0.09	0.13	Kawasaki disease;	chr14:106777997	chr14:106421711~106422218:-
BRCA	cis	rs10129255	0.518	rs8010020	ENSG00000211959.2	IGHV4-39	4.29	1.98e-05	0.00151	0.09	0.13	Kawasaki disease;	chr14:106778016	chr14:106421711~106422218:-
BRCA	cis	rs6545883	0.826	rs777590	ENSG00000212978.6	AC016747.3	4.29	1.98e-05	0.00151	0.18	0.13	Tuberculosis;	chr2:61190010	chr2:61141592~61144969:-
BRCA	cis	rs6686842	0.536	rs10493093	ENSG00000235358.1	RP11-399E6.1	-4.29	1.98e-05	0.00151	-0.17	-0.13	Height;	chr1:41236514	chr1:41242373~41284861:+
BRCA	cis	rs7481584	0.624	rs12417389	ENSG00000236710.1	AC108448.2	4.29	1.98e-05	0.00151	0.18	0.13	Calcium levels;	chr11:3014074	chr11:3084393~3085443:-
BRCA	cis	rs4218	0.689	rs60262196	ENSG00000259732.1	RP11-59H7.3	-4.29	1.98e-05	0.00151	-0.17	-0.13	Social communication problems;	chr15:59088853	chr15:59121034~59133250:+
BRCA	cis	rs72634501	0.568	rs590214	ENSG00000237624.1	OXCT2P1	4.29	1.98e-05	0.00151	0.16	0.13	HDL cholesterol;	chr1:39146821	chr1:39514956~39516490:+
BRCA	cis	rs1005277	0.579	rs1780137	ENSG00000099251.13	HSD17B7P2	4.29	1.98e-05	0.00151	0.15	0.13	Extrinsic epigenetic age acceleration;	chr10:38212547	chr10:38356380~38378505:+
BRCA	cis	rs13113518	0.934	rs11133397	ENSG00000272969.1	RP11-528I4.2	4.29	1.98e-05	0.00151	0.15	0.13	Height;	chr4:55534166	chr4:55547112~55547889:+
BRCA	cis	rs13113518	0.934	rs11133398	ENSG00000272969.1	RP11-528I4.2	4.29	1.98e-05	0.00151	0.15	0.13	Height;	chr4:55534180	chr4:55547112~55547889:+
BRCA	cis	rs7932354	0.583	rs10734548	ENSG00000200376.1	RNU5E-10P	4.29	1.98e-05	0.00151	0.16	0.13	Bone mineral density (hip);Bone mineral density;	chr11:46766023	chr11:47576471~47576588:-
BRCA	cis	rs9834975	0.935	rs6771201	ENSG00000272758.4	RP11-299J3.8	-4.29	1.98e-05	0.00151	-0.14	-0.13	Diastolic blood pressure;	chr3:122382874	chr3:122416207~122443180:+
BRCA	cis	rs7618915	0.571	rs2251219	ENSG00000243224.1	RP5-1157M23.2	4.29	1.98e-05	0.00151	0.15	0.13	Bipolar disorder;	chr3:52550771	chr3:52239258~52241097:+
BRCA	cis	rs6545883	0.63	rs12998475	ENSG00000270820.4	RP11-355B11.2	-4.29	1.98e-05	0.00151	-0.15	-0.13	Tuberculosis;	chr2:61210352	chr2:61471188~61484130:+
BRCA	cis	rs6545883	0.894	rs4672431	ENSG00000273302.1	RP11-493E12.2	-4.29	1.98e-05	0.00151	-0.12	-0.13	Tuberculosis;	chr2:61292787	chr2:61199979~61200769:+
BRCA	cis	rs875971	1	rs7792762	ENSG00000236529.1	RP13-254B10.1	4.29	1.98e-05	0.00151	0.14	0.13	Aortic root size;	chr7:66539151	chr7:65840212~65840596:+
BRCA	cis	rs7829975	0.682	rs7013471	ENSG00000233609.3	RP11-62H7.2	-4.29	1.98e-05	0.00151	-0.12	-0.13	Mood instability;	chr8:8829815	chr8:8961200~8979025:+
BRCA	cis	rs10986311	0.747	rs2282085	ENSG00000227200.1	RP11-121A14.3	-4.29	1.98e-05	0.00151	-0.16	-0.13	Vitiligo;	chr9:124262761	chr9:124262876~124265809:+
BRCA	cis	rs62103177	0.608	rs551643	ENSG00000278000.1	AC139100.4	-4.29	1.98e-05	0.00151	-0.2	-0.13	Opioid sensitivity;	chr18:80081068	chr18:80161752~80162413:+
BRCA	cis	rs4664293	0.801	rs7590595	ENSG00000230783.1	AC009961.2	-4.29	1.98e-05	0.00151	-0.17	-0.13	Monocyte percentage of white cells;	chr2:159715198	chr2:159689217~159690291:-
BRCA	cis	rs4950322	0.57	rs72692917	ENSG00000237188.3	RP11-337C18.8	4.29	1.99e-05	0.00151	0.17	0.13	Protein quantitative trait loci;	chr1:147304389	chr1:147172771~147211568:+
BRCA	cis	rs4950322	0.57	rs66580541	ENSG00000237188.3	RP11-337C18.8	4.29	1.99e-05	0.00151	0.17	0.13	Protein quantitative trait loci;	chr1:147308828	chr1:147172771~147211568:+
BRCA	cis	rs4950322	0.57	rs945742	ENSG00000237188.3	RP11-337C18.8	4.29	1.99e-05	0.00151	0.17	0.13	Protein quantitative trait loci;	chr1:147313437	chr1:147172771~147211568:+
BRCA	cis	rs10938353	0.911	rs7698806	ENSG00000273369.1	RP11-700J17.1	-4.29	1.99e-05	0.00151	-0.15	-0.13	Body mass index;	chr4:44592146	chr4:44693946~44694386:-
BRCA	cis	rs7267979	1	rs6050573	ENSG00000274973.1	RP13-401N8.7	-4.29	1.99e-05	0.00151	-0.15	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25385429	chr20:25845497~25845862:+
BRCA	cis	rs2526882	0.541	rs2526859	ENSG00000258571.1	PTTG4P	4.29	1.99e-05	0.00151	0.14	0.13	Schizophrenia;	chr14:70945490	chr14:71085482~71085833:-
BRCA	cis	rs6015450	1	rs6026729	ENSG00000228340.4	MIR646HG	4.29	1.99e-05	0.00151	0.26	0.13	Hypertension;Blood pressure;Systolic blood pressure;Diastolic blood pressure;	chr20:59153214	chr20:60087840~60527458:+
BRCA	cis	rs34421088	0.548	rs2618443	ENSG00000255046.1	RP11-297N6.4	4.29	1.99e-05	0.00151	0.15	0.13	Neuroticism;	chr8:11527047	chr8:11797928~11802568:-
BRCA	cis	rs17489649	1	rs35547924	ENSG00000271849.1	CTC-332L22.1	4.29	1.99e-05	0.00151	0.17	0.13	Intelligence (multi-trait analysis);	chr5:109820955	chr5:109687802~109688329:-
BRCA	cis	rs67981189	0.593	rs7143595	ENSG00000258571.1	PTTG4P	-4.29	1.99e-05	0.00151	-0.14	-0.13	Schizophrenia;	chr14:71055284	chr14:71085482~71085833:-
BRCA	cis	rs2235544	0.565	rs605182	ENSG00000225183.1	RP4-758J24.4	4.29	1.99e-05	0.00151	0.16	0.13	Thyroid hormone levels;Multiple myeloma (hyperdiploidy);	chr1:54001283	chr1:54089856~54090093:+
BRCA	cis	rs2235544	0.554	rs605272	ENSG00000225183.1	RP4-758J24.4	4.29	1.99e-05	0.00151	0.16	0.13	Thyroid hormone levels;Multiple myeloma (hyperdiploidy);	chr1:54001353	chr1:54089856~54090093:+
BRCA	cis	rs801193	1	rs3778909	ENSG00000272831.1	RP11-792A8.4	4.29	1.99e-05	0.00152	0.12	0.13	Aortic root size;	chr7:66790659	chr7:66739829~66740385:-
BRCA	cis	rs60843830	1	rs7566279	ENSG00000272342.1	RP13-539J13.1	4.29	1.99e-05	0.00152	0.16	0.13	Spherical equivalent (joint analysis main effects and education interaction);	chr2:281178	chr2:739588~740164:-
BRCA	cis	rs7617773	0.963	rs6800730	ENSG00000199476.1	Y_RNA	-4.29	1.99e-05	0.00152	-0.17	-0.13	Coronary artery disease;	chr3:48132720	chr3:48288587~48288694:+
BRCA	cis	rs4434138	0.568	rs6414569	ENSG00000243224.1	RP5-1157M23.2	-4.29	1.99e-05	0.00152	-0.14	-0.13	Intelligence (multi-trait analysis);	chr3:52674059	chr3:52239258~52241097:+
BRCA	cis	rs9952991	0.882	rs2847274	ENSG00000260302.1	RP11-973H7.1	-4.29	1.99e-05	0.00152	-0.21	-0.13	Inflammatory skin disease;	chr18:12777604	chr18:12774651~12775923:-
BRCA	cis	rs10266483	0.774	rs7796802	ENSG00000227986.1	TRIM60P18	4.29	1.99e-05	0.00152	0.14	0.13	Response to statin therapy;	chr7:64323744	chr7:64355078~64356199:+
BRCA	cis	rs17597773	0.674	rs903319	ENSG00000238078.1	LINC01352	-4.29	1.99e-05	0.00152	-0.16	-0.13	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220812469	chr1:220829255~220832429:+
BRCA	cis	rs7487075	0.964	rs2408497	ENSG00000257261.4	RP11-96H19.1	4.29	1.99e-05	0.00152	0.14	0.13	Itch intensity from mosquito bite;	chr12:46402968	chr12:46383679~46876159:+
BRCA	cis	rs875971	0.964	rs778723	ENSG00000229180.5	GS1-124K5.11	4.29	1.99e-05	0.00152	0.11	0.13	Aortic root size;	chr7:66364510	chr7:66526088~66542624:-
BRCA	cis	rs10129255	0.5	rs11628999	ENSG00000254174.1	IGHV1-12	4.29	1.99e-05	0.00152	0.1	0.13	Kawasaki disease;	chr14:106800208	chr14:106122420~106122709:-
BRCA	cis	rs10833905	1	rs11026893	ENSG00000246225.5	RP11-17A1.3	-4.29	1.99e-05	0.00152	-0.19	-0.13	Sudden cardiac arrest;	chr11:23002690	chr11:22829380~22945393:+
BRCA	cis	rs13217239	0.646	rs7451149	ENSG00000224843.5	LINC00240	4.29	1.99e-05	0.00152	0.15	0.13	Schizophrenia;	chr6:27089739	chr6:26956992~27023924:+
BRCA	cis	rs875971	1	rs778726	ENSG00000229180.5	GS1-124K5.11	4.29	1.99e-05	0.00152	0.11	0.13	Aortic root size;	chr7:66363744	chr7:66526088~66542624:-
BRCA	cis	rs875971	0.767	rs1695815	ENSG00000229180.5	GS1-124K5.11	4.29	1.99e-05	0.00152	0.11	0.13	Aortic root size;	chr7:66366357	chr7:66526088~66542624:-
BRCA	cis	rs875971	1	rs778685	ENSG00000229180.5	GS1-124K5.11	4.29	1.99e-05	0.00152	0.11	0.13	Aortic root size;	chr7:66371189	chr7:66526088~66542624:-
BRCA	cis	rs875971	0.929	rs778682	ENSG00000229180.5	GS1-124K5.11	4.29	1.99e-05	0.00152	0.11	0.13	Aortic root size;	chr7:66372947	chr7:66526088~66542624:-
BRCA	cis	rs875971	0.964	rs11765965	ENSG00000229180.5	GS1-124K5.11	4.29	1.99e-05	0.00152	0.11	0.13	Aortic root size;	chr7:66377234	chr7:66526088~66542624:-
BRCA	cis	rs72772090	0.522	rs112272517	ENSG00000248734.2	CTD-2260A17.1	-4.29	1.99e-05	0.00152	-0.31	-0.13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96651542	chr5:96784777~96785999:+
BRCA	cis	rs72772090	0.522	rs76961889	ENSG00000248734.2	CTD-2260A17.1	-4.29	1.99e-05	0.00152	-0.31	-0.13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96652228	chr5:96784777~96785999:+
BRCA	cis	rs859767	0.741	rs4954159	ENSG00000224043.6	CCNT2-AS1	4.29	1.99e-05	0.00152	0.18	0.13	Neuroticism;	chr2:134669212	chr2:134735464~134918710:-
BRCA	cis	rs2731006	0.64	rs991703	ENSG00000257114.2	RP11-25I15.3	-4.29	2e-05	0.00152	-0.21	-0.13	Panic disorder;	chr12:42801910	chr12:42692216~42717119:+
BRCA	cis	rs11148252	0.846	rs7985262	ENSG00000198384.8	TPTE2P3	4.29	2e-05	0.00152	0.15	0.13	Lewy body disease;	chr13:52423026	chr13:52522632~52586906:+
BRCA	cis	rs754466	0.605	rs10824578	ENSG00000213514.2	RP11-428P16.2	4.29	2e-05	0.00152	0.17	0.13	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77818486	chr10:77730766~77734769:+
BRCA	cis	rs9527	0.59	rs7087459	ENSG00000213061.2	PFN1P11	4.28	2e-05	0.00152	0.18	0.13	Arsenic metabolism;	chr10:103031242	chr10:102838011~102845473:-
BRCA	cis	rs9527	0.59	rs7088200	ENSG00000213061.2	PFN1P11	4.28	2e-05	0.00152	0.18	0.13	Arsenic metabolism;	chr10:103033478	chr10:102838011~102845473:-
BRCA	cis	rs2073316	0.662	rs1978639	ENSG00000272716.1	RP11-563N4.1	4.28	2e-05	0.00152	0.14	0.13	Interleukin-18 levels;	chr2:31410090	chr2:32165046~32165757:-
BRCA	cis	rs11098499	0.955	rs1511015	ENSG00000260091.1	RP11-33B1.4	-4.28	2e-05	0.00152	-0.12	-0.13	Corneal astigmatism;	chr4:119249318	chr4:119409333~119410233:+
BRCA	cis	rs6128907	1	rs1535431	ENSG00000224635.1	RP4-564F22.5	4.28	2e-05	0.00152	0.2	0.13	Liver fibrosis in pediatric non-alcoholic fatty acid liver disease;	chr20:38775776	chr20:38406011~38416797:-
BRCA	cis	rs9868809	0.505	rs9877685	ENSG00000225399.4	RP11-3B7.1	-4.28	2e-05	0.00152	-0.2	-0.13	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48711155	chr3:49260085~49261316:+
BRCA	cis	rs9868809	0.505	rs13063223	ENSG00000225399.4	RP11-3B7.1	-4.28	2e-05	0.00152	-0.2	-0.13	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48712907	chr3:49260085~49261316:+
BRCA	cis	rs853679	0.76	rs11962305	ENSG00000204709.4	LINC01556	4.28	2e-05	0.00152	0.21	0.13	Depression;	chr6:28232159	chr6:28943877~28944537:+
BRCA	cis	rs2235544	0.55	rs12075159	ENSG00000225183.1	RP4-758J24.4	4.28	2e-05	0.00152	0.16	0.13	Thyroid hormone levels;Multiple myeloma (hyperdiploidy);	chr1:54004561	chr1:54089856~54090093:+
BRCA	cis	rs6921919	0.583	rs9461459	ENSG00000273712.1	RP5-874C20.7	4.28	2e-05	0.00152	0.17	0.13	Autism spectrum disorder or schizophrenia;	chr6:28394139	chr6:28315613~28315883:-
BRCA	cis	rs6921919	0.583	rs28360638	ENSG00000273712.1	RP5-874C20.7	4.28	2e-05	0.00152	0.17	0.13	Autism spectrum disorder or schizophrenia;	chr6:28394552	chr6:28315613~28315883:-
BRCA	cis	rs6921919	0.583	rs9468368	ENSG00000273712.1	RP5-874C20.7	4.28	2e-05	0.00152	0.17	0.13	Autism spectrum disorder or schizophrenia;	chr6:28397172	chr6:28315613~28315883:-
BRCA	cis	rs875971	0.638	rs6960778	ENSG00000273142.1	RP11-458F8.4	4.28	2e-05	0.00152	0.11	0.13	Aortic root size;	chr7:66606610	chr7:66902857~66906297:+
BRCA	cis	rs11711311	1	rs10212375	ENSG00000241529.3	RN7SL767P	-4.28	2e-05	0.00152	-0.15	-0.13	IgG glycosylation;	chr3:113752489	chr3:113632704~113632998:+
BRCA	cis	rs11711311	1	rs7622515	ENSG00000241529.3	RN7SL767P	-4.28	2e-05	0.00152	-0.15	-0.13	IgG glycosylation;	chr3:113753691	chr3:113632704~113632998:+
BRCA	cis	rs12999542	0.706	rs11465623	ENSG00000234389.1	AC007278.3	4.28	2e-05	0.00152	0.21	0.13	Serum protein levels (sST2);	chr2:102376579	chr2:102438713~102440475:+
BRCA	cis	rs987360	0.775	rs4864404	ENSG00000248869.4	RP11-138I17.1	4.28	2e-05	0.00152	0.13	0.13	Temperament;	chr4:137283667	chr4:136796722~137212799:-
BRCA	cis	rs987360	0.717	rs10016706	ENSG00000248869.4	RP11-138I17.1	4.28	2e-05	0.00152	0.13	0.13	Temperament;	chr4:137284032	chr4:136796722~137212799:-
BRCA	cis	rs11088226	0.598	rs79634586	ENSG00000186842.4	LINC00846	-4.28	2e-05	0.00152	-0.22	-0.13	Gastritis;	chr21:32587053	chr21:32572238~32575881:-
BRCA	cis	rs745109	0.832	rs80354140	ENSG00000273080.1	RP11-301O19.1	4.28	2e-05	0.00152	0.21	0.13	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86446090	chr2:86195590~86196049:+
BRCA	cis	rs7260598	0.792	rs73021467	ENSG00000268442.1	CTD-2027I19.2	4.28	2e-05	0.00152	0.22	0.13	Response to taxane treatment (placlitaxel);	chr19:24142863	chr19:24162370~24163425:-
BRCA	cis	rs7260598	0.792	rs4019979	ENSG00000268442.1	CTD-2027I19.2	4.28	2e-05	0.00152	0.22	0.13	Response to taxane treatment (placlitaxel);	chr19:24143881	chr19:24162370~24163425:-
BRCA	cis	rs6012564	0.964	rs6063371	ENSG00000227431.4	CSE1L-AS1	4.28	2e-05	0.00152	0.17	0.13	Anger;	chr20:49202768	chr20:49040463~49046044:-
BRCA	cis	rs11633886	0.585	rs12915664	ENSG00000273972.1	CTD-2306A12.1	4.28	2e-05	0.00152	0.15	0.13	Diisocyanate-induced asthma;	chr15:45787855	chr15:45702640~45703183:+
BRCA	cis	rs1910358	0.614	rs1393226	ENSG00000248874.4	C5orf17	-4.28	2e-05	0.00152	-0.17	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23956667	chr5:23951348~24178263:+
BRCA	cis	rs1910358	0.659	rs10076648	ENSG00000248874.4	C5orf17	-4.28	2e-05	0.00152	-0.17	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23958998	chr5:23951348~24178263:+
BRCA	cis	rs6496044	0.568	rs3743321	ENSG00000202081.1	RNU6-1280P	4.28	2e-05	0.00152	0.15	0.13	Interstitial lung disease;	chr15:85521737	chr15:85651522~85651628:-
BRCA	cis	rs17801127	0.748	rs57536657	ENSG00000231969.1	AC144449.1	4.28	2e-05	0.00152	0.23	0.13	Liver enzyme levels (alanine transaminase);	chr2:149665638	chr2:149587196~149848233:+
BRCA	cis	rs17065868	1	rs9525971	ENSG00000237361.2	TUSC8	-4.28	2e-05	0.00152	-0.27	-0.13	Antineutrophil cytoplasmic antibody-associated vasculitis;	chr13:44521208	chr13:44400250~44405984:-
BRCA	cis	rs2832191	0.646	rs2832210	ENSG00000176054.6	RPL23P2	-4.28	2e-05	0.00153	-0.15	-0.13	Dental caries;	chr21:29136402	chr21:28997613~28998033:-
BRCA	cis	rs2444217	0.872	rs2531977	ENSG00000262888.1	RP11-462G12.2	-4.28	2e-05	0.00153	-0.15	-0.13	Body mass index;	chr16:3993700	chr16:3931217~3946305:-
BRCA	cis	rs2074409	0.509	rs853219	ENSG00000276054.1	RP11-378E13.3	-4.28	2e-05	0.00153	-0.15	-0.13	Response to angiotensin II receptor blocker therapy;	chr17:37427296	chr17:37386886~37387926:+
BRCA	cis	rs71520386	0.898	rs12536091	ENSG00000230658.1	KLHL7-AS1	4.28	2e-05	0.00153	0.23	0.13	Fibrinogen levels;	chr7:22788581	chr7:23101228~23105703:-
BRCA	cis	rs6860806	0.695	rs6867282	ENSG00000233006.5	AC034220.3	4.28	2.01e-05	0.00153	0.09	0.13	Breast cancer;	chr5:132247427	chr5:132311285~132369916:-
BRCA	cis	rs11696845	0.966	rs6073535	ENSG00000276223.1	RP4-781B1.5	-4.28	2.01e-05	0.00153	-0.14	-0.13	Obesity-related traits;	chr20:44745218	chr20:44746642~44747201:+
BRCA	cis	rs516805	0.528	rs2198863	ENSG00000279114.1	RP3-425C14.5	-4.28	2.01e-05	0.00153	-0.16	-0.13	Lymphocyte counts;	chr6:122091576	chr6:122471923~122484161:+
BRCA	cis	rs516805	0.528	rs2684243	ENSG00000279114.1	RP3-425C14.5	-4.28	2.01e-05	0.00153	-0.16	-0.13	Lymphocyte counts;	chr6:122092700	chr6:122471923~122484161:+
BRCA	cis	rs516805	0.528	rs2684244	ENSG00000279114.1	RP3-425C14.5	-4.28	2.01e-05	0.00153	-0.16	-0.13	Lymphocyte counts;	chr6:122092734	chr6:122471923~122484161:+
BRCA	cis	rs516805	0.528	rs2606604	ENSG00000279114.1	RP3-425C14.5	-4.28	2.01e-05	0.00153	-0.16	-0.13	Lymphocyte counts;	chr6:122093150	chr6:122471923~122484161:+
BRCA	cis	rs9470794	0.831	rs77272813	ENSG00000204110.6	RP1-153P14.8	-4.28	2.01e-05	0.00153	-0.27	-0.13	Type 2 diabetes;	chr6:37912980	chr6:37507348~37535616:+
BRCA	cis	rs9470794	0.831	rs11752567	ENSG00000204110.6	RP1-153P14.8	-4.28	2.01e-05	0.00153	-0.27	-0.13	Type 2 diabetes;	chr6:37913669	chr6:37507348~37535616:+
BRCA	cis	rs930395	0.514	rs4323241	ENSG00000251141.4	RP11-53O19.1	-4.28	2.01e-05	0.00153	-0.13	-0.13	Breast cancer;	chr5:44929054	chr5:44744900~44808777:-
BRCA	cis	rs4950322	0.542	rs12046706	ENSG00000237188.3	RP11-337C18.8	4.28	2.01e-05	0.00153	0.15	0.13	Protein quantitative trait loci;	chr1:147189758	chr1:147172771~147211568:+
BRCA	cis	rs867371	1	rs2088858	ENSG00000278603.1	RP13-608F4.5	4.28	2.01e-05	0.00153	0.18	0.13	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82182408	chr15:82472203~82472426:+
BRCA	cis	rs867371	1	rs4778982	ENSG00000278603.1	RP13-608F4.5	4.28	2.01e-05	0.00153	0.18	0.13	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82182931	chr15:82472203~82472426:+
BRCA	cis	rs867371	1	rs2867579	ENSG00000278603.1	RP13-608F4.5	4.28	2.01e-05	0.00153	0.18	0.13	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82183043	chr15:82472203~82472426:+
BRCA	cis	rs867371	1	rs881308	ENSG00000278603.1	RP13-608F4.5	4.28	2.01e-05	0.00153	0.18	0.13	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82183456	chr15:82472203~82472426:+
BRCA	cis	rs4713675	0.624	rs482786	ENSG00000224557.6	HLA-DPB2	4.28	2.01e-05	0.00153	0.17	0.13	Plateletcrit;	chr6:33739822	chr6:33112451~33129084:+
BRCA	cis	rs6439153	0.967	rs12695513	ENSG00000261159.1	RP11-723O4.9	4.28	2.01e-05	0.00153	0.14	0.13	Pneumococcal bacteremia;	chr3:129003469	chr3:128859716~128860526:-
BRCA	cis	rs2731006	0.64	rs2468325	ENSG00000257114.2	RP11-25I15.3	4.28	2.01e-05	0.00153	0.22	0.13	Panic disorder;	chr12:42785706	chr12:42692216~42717119:+
BRCA	cis	rs950776	0.714	rs472054	ENSG00000279373.1	RP11-650L12.4	-4.28	2.01e-05	0.00153	-0.16	-0.13	Sudden cardiac arrest;	chr15:78595652	chr15:78537681~78538946:+
BRCA	cis	rs2018683	0.834	rs733485	ENSG00000228421.2	AC005013.5	4.28	2.01e-05	0.00153	0.16	0.13	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28987069	chr7:28957667~28959345:+
BRCA	cis	rs4700393	0.52	rs286158	ENSG00000215032.2	GNL3LP1	4.28	2.01e-05	0.00153	0.18	0.13	Intelligence (multi-trait analysis);	chr5:60638426	chr5:60891935~60893577:-
BRCA	cis	rs12531458	0.78	rs6462892	ENSG00000249978.1	TRGV7	4.28	2.01e-05	0.00153	0.11	0.13	Educational attainment (years of education);	chr7:39061259	chr7:38335041~38335514:-
BRCA	cis	rs875971	0.964	rs1643388	ENSG00000236529.1	RP13-254B10.1	4.28	2.01e-05	0.00153	0.14	0.13	Aortic root size;	chr7:66379575	chr7:65840212~65840596:+
BRCA	cis	rs875971	1	rs778722	ENSG00000236529.1	RP13-254B10.1	4.28	2.01e-05	0.00153	0.14	0.13	Aortic root size;	chr7:66379841	chr7:65840212~65840596:+
BRCA	cis	rs5758511	0.633	rs5751258	ENSG00000226450.2	CYP2D8P	4.28	2.01e-05	0.00153	0.15	0.13	Birth weight;	chr22:42267865	chr22:42149886~42155001:-
BRCA	cis	rs9368481	0.761	rs12661756	ENSG00000224843.5	LINC00240	-4.28	2.01e-05	0.00153	-0.15	-0.13	Autism spectrum disorder or schizophrenia;	chr6:27035704	chr6:26956992~27023924:+
BRCA	cis	rs797680	0.786	rs7532195	ENSG00000229635.1	RP4-713B5.2	4.28	2.01e-05	0.00153	0.17	0.13	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93151846	chr1:93384487~93384998:-
BRCA	cis	rs2562456	0.833	rs2650801	ENSG00000268535.1	RP11-420K14.3	4.28	2.01e-05	0.00153	0.18	0.13	Pain;	chr19:21452553	chr19:21709522~21710191:+
BRCA	cis	rs11048434	0.518	rs1805669	ENSG00000256937.1	KRT17P8	-4.28	2.01e-05	0.00153	-0.15	-0.13	Sjögren's syndrome;	chr12:9027655	chr12:9127783~9128645:+
BRCA	cis	rs516805	0.528	rs2606611	ENSG00000279114.1	RP3-425C14.5	-4.28	2.01e-05	0.00153	-0.16	-0.13	Lymphocyte counts;	chr6:122094502	chr6:122471923~122484161:+
BRCA	cis	rs516805	0.528	rs1402537	ENSG00000279114.1	RP3-425C14.5	-4.28	2.01e-05	0.00153	-0.16	-0.13	Lymphocyte counts;	chr6:122094962	chr6:122471923~122484161:+
BRCA	cis	rs516805	0.528	rs2606622	ENSG00000279114.1	RP3-425C14.5	-4.28	2.01e-05	0.00153	-0.16	-0.13	Lymphocyte counts;	chr6:122096367	chr6:122471923~122484161:+
BRCA	cis	rs10129255	0.5	rs8022547	ENSG00000211959.2	IGHV4-39	4.28	2.01e-05	0.00153	0.09	0.13	Kawasaki disease;	chr14:106781985	chr14:106421711~106422218:-
BRCA	cis	rs7618915	0.501	rs13079063	ENSG00000243224.1	RP5-1157M23.2	-4.28	2.01e-05	0.00153	-0.14	-0.13	Bipolar disorder;	chr3:52710444	chr3:52239258~52241097:+
BRCA	cis	rs12612619	0.732	rs4665366	ENSG00000272148.1	RP11-195B17.1	-4.28	2.01e-05	0.00153	-0.14	-0.13	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:26989728	chr2:27062428~27062907:-
BRCA	cis	rs12317459	0.591	rs11115400	ENSG00000213270.5	RPL6P25	-4.28	2.01e-05	0.00153	-0.22	-0.13	Prostate cancer (SNP x SNP interaction);	chr12:82770681	chr12:83151331~83152190:+
BRCA	cis	rs10129255	0.5	rs10131875	ENSG00000254174.1	IGHV1-12	4.28	2.01e-05	0.00153	0.1	0.13	Kawasaki disease;	chr14:106792798	chr14:106122420~106122709:-
BRCA	cis	rs4489787	0.803	rs2705158	ENSG00000240399.1	RP1-228P16.1	4.28	2.01e-05	0.00153	0.2	0.13	Prostate cancer (SNP x SNP interaction);	chr12:48511092	chr12:48054813~48055591:-
BRCA	cis	rs12571093	0.656	rs3858147	ENSG00000233590.1	RP11-153K11.3	-4.28	2.01e-05	0.00153	-0.21	-0.13	Optic nerve measurement (disc area);	chr10:68253507	chr10:68233251~68242379:-
BRCA	cis	rs7932354	0.583	rs6485692	ENSG00000200376.1	RNU5E-10P	4.28	2.01e-05	0.00153	0.16	0.13	Bone mineral density (hip);Bone mineral density;	chr11:46783033	chr11:47576471~47576588:-
BRCA	cis	rs739496	0.947	rs2283358	ENSG00000234608.6	MAPKAPK5-AS1	4.28	2.01e-05	0.00153	0.16	0.13	Platelet count;	chr12:111427761	chr12:111839764~111842902:-
BRCA	cis	rs115575488	0.85	rs10494221	ENSG00000236804.1	RPS3AP12	4.28	2.01e-05	0.00153	0.24	0.13	Lobe attachment (rater-scored or self-reported);	chr1:119091601	chr1:119126539~119127291:-
BRCA	cis	rs997295	0.675	rs17242605	ENSG00000270964.1	RP11-502I4.3	-4.28	2.01e-05	0.00153	-0.15	-0.13	Motion sickness;	chr15:67671098	chr15:67541072~67542604:-
BRCA	cis	rs997295	0.675	rs12912974	ENSG00000270964.1	RP11-502I4.3	-4.28	2.01e-05	0.00153	-0.15	-0.13	Motion sickness;	chr15:67682041	chr15:67541072~67542604:-
BRCA	cis	rs6452524	1	rs6452526	ENSG00000281327.1	LINC01338	4.28	2.01e-05	0.00153	0.15	0.13	Hypertension (SNP x SNP interaction);	chr5:83140992	chr5:82850864~82859836:-
BRCA	cis	rs6452524	1	rs6452527	ENSG00000281327.1	LINC01338	4.28	2.01e-05	0.00153	0.15	0.13	Hypertension (SNP x SNP interaction);	chr5:83141021	chr5:82850864~82859836:-
BRCA	cis	rs6452524	1	rs10055844	ENSG00000281327.1	LINC01338	4.28	2.01e-05	0.00153	0.15	0.13	Hypertension (SNP x SNP interaction);	chr5:83141276	chr5:82850864~82859836:-
BRCA	cis	rs6452524	1	rs10077862	ENSG00000281327.1	LINC01338	4.28	2.01e-05	0.00153	0.15	0.13	Hypertension (SNP x SNP interaction);	chr5:83141322	chr5:82850864~82859836:-
BRCA	cis	rs6128907	0.898	rs9636527	ENSG00000224635.1	RP4-564F22.5	4.28	2.01e-05	0.00153	0.21	0.13	Liver fibrosis in pediatric non-alcoholic fatty acid liver disease;	chr20:38774270	chr20:38406011~38416797:-
BRCA	cis	rs67766926	0.953	rs72807480	ENSG00000271889.1	RP11-493E12.1	4.28	2.01e-05	0.00153	0.19	0.13	Inflammatory skin disease;	chr2:60907629	chr2:61151433~61162105:-
BRCA	cis	rs17428076	0.749	rs62181741	ENSG00000228389.1	AC068039.4	-4.28	2.02e-05	0.00153	-0.23	-0.13	Myopia;	chr2:171684565	chr2:171773482~171775844:+
BRCA	cis	rs7246967	1	rs7257127	ENSG00000198153.8	ZNF849P	-4.28	2.02e-05	0.00153	-0.18	-0.13	Bronchopulmonary dysplasia;	chr19:22873897	chr19:22685167~22686732:+
BRCA	cis	rs10411936	0.72	rs2885706	ENSG00000280332.1	CTD-2013N17.6	4.28	2.02e-05	0.00153	0.11	0.13	Multiple sclerosis;White blood cell count;	chr19:16472126	chr19:16356329~16358327:-
BRCA	cis	rs1722141	0.501	rs12532079	ENSG00000237471.1	AC073115.6	-4.28	2.02e-05	0.00153	-0.18	-0.13	Sitting height ratio;	chr7:46119144	chr7:45969657~45980191:+
BRCA	cis	rs13113518	1	rs13108499	ENSG00000272969.1	RP11-528I4.2	4.28	2.02e-05	0.00153	0.15	0.13	Height;	chr4:55526514	chr4:55547112~55547889:+
BRCA	cis	rs6968419	1	rs6977233	ENSG00000279086.1	RP11-667F14.1	-4.28	2.02e-05	0.00153	-0.13	-0.13	Intraocular pressure;	chr7:116174688	chr7:116209234~116211511:-
BRCA	cis	rs11098499	0.954	rs6849561	ENSG00000260404.2	RP11-384K6.6	-4.28	2.02e-05	0.00153	-0.13	-0.13	Corneal astigmatism;	chr4:119488539	chr4:118591773~118633729:+
BRCA	cis	rs35740288	0.822	rs2306225	ENSG00000202081.1	RNU6-1280P	4.28	2.02e-05	0.00153	0.18	0.13	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85684721	chr15:85651522~85651628:-
BRCA	cis	rs35740288	0.929	rs11556865	ENSG00000202081.1	RNU6-1280P	4.28	2.02e-05	0.00153	0.18	0.13	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85759949	chr15:85651522~85651628:-
BRCA	cis	rs7618915	0.501	rs1468638	ENSG00000243224.1	RP5-1157M23.2	-4.28	2.02e-05	0.00153	-0.14	-0.13	Bipolar disorder;	chr3:52714042	chr3:52239258~52241097:+
BRCA	cis	rs736408	0.522	rs11716747	ENSG00000243224.1	RP5-1157M23.2	-4.28	2.02e-05	0.00153	-0.14	-0.13	Bipolar disorder;	chr3:52714841	chr3:52239258~52241097:+
BRCA	cis	rs7618915	0.501	rs35526119	ENSG00000243224.1	RP5-1157M23.2	-4.28	2.02e-05	0.00153	-0.14	-0.13	Bipolar disorder;	chr3:52715318	chr3:52239258~52241097:+
BRCA	cis	rs3764021	0.87	rs2192437	ENSG00000256582.1	RP11-75L1.1	4.28	2.02e-05	0.00153	0.13	0.13	Type 1 diabetes;	chr12:9726639	chr12:9704077~9709350:+
BRCA	cis	rs3764021	0.87	rs10844617	ENSG00000256582.1	RP11-75L1.1	4.28	2.02e-05	0.00153	0.13	0.13	Type 1 diabetes;	chr12:9726772	chr12:9704077~9709350:+
BRCA	cis	rs867371	1	rs1846911	ENSG00000278603.1	RP13-608F4.5	4.28	2.02e-05	0.00153	0.18	0.13	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82176309	chr15:82472203~82472426:+
BRCA	cis	rs7727544	0.716	rs11955347	ENSG00000233006.5	AC034220.3	4.28	2.02e-05	0.00153	0.1	0.13	Blood metabolite levels;	chr5:132232231	chr5:132311285~132369916:-
BRCA	cis	rs2898290	0.5	rs11998678	ENSG00000250794.2	ALG1L12P	4.28	2.02e-05	0.00153	0.17	0.13	Systolic blood pressure;	chr8:11972641	chr8:12421032~12425000:+
BRCA	cis	rs409045	1	rs460836	ENSG00000271874.1	CTD-2024P10.2	-4.28	2.02e-05	0.00153	-0.17	-0.13	Left ventricular mass;	chr5:34634888	chr5:34651457~34651888:-
BRCA	cis	rs10043228	0.826	rs62384461	ENSG00000271918.1	CTD-2287O16.5	-4.28	2.02e-05	0.00153	-0.17	-0.13	Asthma or chronic obstructive pulmonary disease;	chr5:116283659	chr5:116083807~116085416:-
BRCA	cis	rs797680	0.856	rs4847235	ENSG00000229635.1	RP4-713B5.2	4.28	2.02e-05	0.00153	0.17	0.13	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93162170	chr1:93384487~93384998:-
BRCA	cis	rs797680	0.856	rs11164876	ENSG00000229635.1	RP4-713B5.2	4.28	2.02e-05	0.00153	0.17	0.13	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93164953	chr1:93384487~93384998:-
BRCA	cis	rs797680	0.856	rs12044657	ENSG00000229635.1	RP4-713B5.2	4.28	2.02e-05	0.00153	0.17	0.13	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93174039	chr1:93384487~93384998:-
BRCA	cis	rs11098499	0.618	rs28491261	ENSG00000225892.3	RP11-384K6.2	4.28	2.02e-05	0.00154	0.13	0.13	Corneal astigmatism;	chr4:119373745	chr4:118632274~118634759:+
BRCA	cis	rs17169635	0.765	rs1015350	ENSG00000272941.1	RP11-134L10.1	4.28	2.02e-05	0.00154	0.15	0.13	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);	chr7:134890504	chr7:135168403~135169547:+
BRCA	cis	rs7960884	0.754	rs7961839	ENSG00000226472.6	RP11-551L14.4	4.28	2.02e-05	0.00154	0.17	0.13	Systolic blood pressure response to hydrochlorothiazide in hypertension;	chr12:31225394	chr12:30978308~31006010:-
BRCA	cis	rs868036	0.56	rs12443086	ENSG00000270964.1	RP11-502I4.3	4.28	2.02e-05	0.00154	0.14	0.13	Restless legs syndrome;	chr15:67788116	chr15:67541072~67542604:-
BRCA	cis	rs9818758	0.607	rs73084135	ENSG00000225399.4	RP11-3B7.1	-4.28	2.02e-05	0.00154	-0.24	-0.13	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49234785	chr3:49260085~49261316:+
BRCA	cis	rs7267979	1	rs2257991	ENSG00000125804.12	FAM182A	4.28	2.02e-05	0.00154	0.17	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25289703	chr20:26054655~26086917:+
BRCA	cis	rs2408955	0.568	rs12099462	ENSG00000257763.1	OR5BK1P	-4.28	2.02e-05	0.00154	-0.14	-0.13	Glycated hemoglobin levels;	chr12:48109321	chr12:48355792~48356614:-
BRCA	cis	rs9527	0.568	rs12772775	ENSG00000213061.2	PFN1P11	4.28	2.02e-05	0.00154	0.18	0.13	Arsenic metabolism;	chr10:102943242	chr10:102838011~102845473:-
BRCA	cis	rs1124769	0.57	rs17702978	ENSG00000273674.3	CTD-2378E12.1	4.28	2.02e-05	0.00154	0.16	0.13	Cognitive performance;	chr15:50868358	chr15:50839875~50908599:-
BRCA	cis	rs11098499	0.954	rs7681544	ENSG00000260091.1	RP11-33B1.4	-4.28	2.02e-05	0.00154	-0.12	-0.13	Corneal astigmatism;	chr4:119490100	chr4:119409333~119410233:+
BRCA	cis	rs10510102	0.516	rs11200300	ENSG00000226864.1	ATE1-AS1	4.28	2.02e-05	0.00154	0.26	0.13	Breast cancer;	chr10:121977489	chr10:121928312~121951965:+
BRCA	cis	rs7520050	0.778	rs3013597	ENSG00000281133.1	AL355480.3	-4.28	2.02e-05	0.00154	-0.15	-0.13	Reticulocyte count;Red blood cell count;	chr1:45662684	chr1:45580892~45580996:-
BRCA	cis	rs1722141	0.633	rs788717	ENSG00000237471.1	AC073115.6	4.28	2.02e-05	0.00154	0.18	0.13	Sitting height ratio;	chr7:45964897	chr7:45969657~45980191:+
BRCA	cis	rs2179367	0.959	rs536203	ENSG00000223701.3	RAET1E-AS1	4.28	2.02e-05	0.00154	0.17	0.13	Dupuytren's disease;	chr6:149330128	chr6:149884431~149919508:+
BRCA	cis	rs6012564	0.793	rs6067007	ENSG00000227431.4	CSE1L-AS1	4.28	2.02e-05	0.00154	0.17	0.13	Anger;	chr20:49204492	chr20:49040463~49046044:-
BRCA	cis	rs6480314	0.522	rs10733841	ENSG00000233590.1	RP11-153K11.3	4.28	2.02e-05	0.00154	0.2	0.13	Optic nerve measurement (disc area);	chr10:68293520	chr10:68233251~68242379:-
BRCA	cis	rs950169	0.58	rs11634322	ENSG00000229212.6	RP11-561C5.4	-4.28	2.02e-05	0.00154	-0.17	-0.13	Schizophrenia;	chr15:84628978	chr15:85205440~85234795:-
BRCA	cis	rs6480314	0.522	rs10762212	ENSG00000233590.1	RP11-153K11.3	4.28	2.02e-05	0.00154	0.2	0.13	Optic nerve measurement (disc area);	chr10:68295190	chr10:68233251~68242379:-
BRCA	cis	rs2039553	0.574	rs2783085	ENSG00000227354.5	RBM26-AS1	4.28	2.02e-05	0.00154	0.15	0.13	Pancreatic cancer;	chr13:79747029	chr13:79406309~79424328:+
BRCA	cis	rs7267979	1	rs6115168	ENSG00000125804.12	FAM182A	4.28	2.03e-05	0.00154	0.17	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25392255	chr20:26054655~26086917:+
BRCA	cis	rs853679	1	rs7740487	ENSG00000280107.1	AL022393.9	-4.28	2.03e-05	0.00154	-0.24	-0.13	Depression;	chr6:28248708	chr6:28170845~28172521:+
BRCA	cis	rs7727544	0.582	rs10478998	ENSG00000233006.5	AC034220.3	4.28	2.03e-05	0.00154	0.1	0.13	Blood metabolite levels;	chr5:132180838	chr5:132311285~132369916:-
BRCA	cis	rs58521262	0.585	rs2548898	ENSG00000268105.1	RP11-369G6.2	-4.28	2.03e-05	0.00154	-0.18	-0.13	Testicular germ cell tumor;	chr19:23030131	chr19:23125665~23128543:+
BRCA	cis	rs17597773	0.638	rs12129004	ENSG00000238078.1	LINC01352	-4.28	2.03e-05	0.00154	-0.15	-0.13	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220812173	chr1:220829255~220832429:+
BRCA	cis	rs644148	0.73	rs2117383	ENSG00000176761.7	ZNF285B	-4.28	2.03e-05	0.00154	-0.16	-0.13	Personality dimensions;	chr19:44474081	chr19:44467641~44473227:+
BRCA	cis	rs10504130	1	rs12678680	ENSG00000272024.1	RP11-546K22.3	-4.28	2.03e-05	0.00154	-0.24	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr8:51755889	chr8:51950284~51950690:+
BRCA	cis	rs72772090	0.522	rs17477045	ENSG00000248734.2	CTD-2260A17.1	4.28	2.03e-05	0.00154	0.29	0.13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96652280	chr5:96784777~96785999:+
BRCA	cis	rs859767	0.741	rs7571113	ENSG00000224043.6	CCNT2-AS1	4.28	2.03e-05	0.00154	0.18	0.13	Neuroticism;	chr2:134669822	chr2:134735464~134918710:-
BRCA	cis	rs495337	0.76	rs2769975	ENSG00000229222.1	KRT18P4	-4.28	2.03e-05	0.00154	-0.17	-0.13	Psoriasis;	chr20:49899974	chr20:49956745~49958032:+
BRCA	cis	rs2243480	1	rs34703416	ENSG00000222364.1	RNU6-96P	-4.28	2.03e-05	0.00154	-0.24	-0.13	Diabetic kidney disease;	chr7:65835655	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.545	rs75840613	ENSG00000232546.1	RP11-458F8.1	4.28	2.03e-05	0.00154	0.13	0.13	Aortic root size;	chr7:66376399	chr7:66848496~66858136:+
BRCA	cis	rs755249	0.567	rs6668369	ENSG00000182109.6	RP11-69E11.4	4.28	2.03e-05	0.00154	0.19	0.13	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39382675	chr1:39522280~39546187:-
BRCA	cis	rs2908197	0.737	rs6978009	ENSG00000186704.9	DTX2P1	-4.28	2.03e-05	0.00154	-0.15	-0.13	3-hydroxypropylmercapturic acid levels in smokers;	chr7:76362917	chr7:76978617~77004308:+
BRCA	cis	rs797680	0.856	rs6685271	ENSG00000229635.1	RP4-713B5.2	4.28	2.03e-05	0.00154	0.17	0.13	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93169033	chr1:93384487~93384998:-
BRCA	cis	rs11098499	0.863	rs1552095	ENSG00000260404.2	RP11-384K6.6	4.28	2.03e-05	0.00154	0.13	0.13	Corneal astigmatism;	chr4:119539151	chr4:118591773~118633729:+
BRCA	cis	rs7520050	0.771	rs4660882	ENSG00000281133.1	AL355480.3	-4.28	2.03e-05	0.00154	-0.15	-0.13	Reticulocyte count;Red blood cell count;	chr1:45650620	chr1:45580892~45580996:-
BRCA	cis	rs10266483	1	rs10266483	ENSG00000228653.2	HNRNPCP7	-4.28	2.03e-05	0.00154	-0.15	-0.13	Response to statin therapy;	chr7:64272953	chr7:64500825~64501729:+
BRCA	cis	rs7800418	0.784	rs757806	ENSG00000214870.7	AC004540.5	4.28	2.03e-05	0.00154	0.17	0.13	Cognitive function;	chr7:26547048	chr7:26398593~26494256:+
BRCA	cis	rs6963495	0.818	rs73190155	ENSG00000223886.3	RP11-251G23.2	4.28	2.03e-05	0.00154	0.2	0.13	Bipolar disorder (body mass index interaction);	chr7:105513088	chr7:105530209~105530671:+
BRCA	cis	rs6963495	0.818	rs73190156	ENSG00000223886.3	RP11-251G23.2	4.28	2.03e-05	0.00154	0.2	0.13	Bipolar disorder (body mass index interaction);	chr7:105513120	chr7:105530209~105530671:+
BRCA	cis	rs6963495	0.818	rs73190158	ENSG00000223886.3	RP11-251G23.2	4.28	2.03e-05	0.00154	0.2	0.13	Bipolar disorder (body mass index interaction);	chr7:105513496	chr7:105530209~105530671:+
BRCA	cis	rs1555322	1	rs2425041	ENSG00000261582.1	RP4-614O4.11	-4.28	2.03e-05	0.00154	-0.19	-0.13	Attention deficit hyperactivity disorder;	chr20:35271210	chr20:35267885~35280043:-
BRCA	cis	rs7727544	0.557	rs2897096	ENSG00000233006.5	AC034220.3	4.28	2.03e-05	0.00154	0.1	0.13	Blood metabolite levels;	chr5:132150591	chr5:132311285~132369916:-
BRCA	cis	rs4666002	0.871	rs10208529	ENSG00000234072.1	AC074117.10	4.28	2.03e-05	0.00154	0.13	0.13	Phospholipid levels (plasma);	chr2:27563321	chr2:27356246~27367622:+
BRCA	cis	rs1218582	0.774	rs12036859	ENSG00000270361.1	RP11-307C12.13	4.28	2.03e-05	0.00154	0.15	0.13	Prostate cancer;	chr1:154887464	chr1:154937370~154938059:+
BRCA	cis	rs3617	0.598	rs56214994	ENSG00000279144.1	RP11-894J14.2	-4.28	2.03e-05	0.00155	-0.17	-0.13	Red blood cell count;Autism spectrum disorder or schizophrenia;	chr3:52844584	chr3:52848085~52848553:-
BRCA	cis	rs2108622	0.958	rs56340170	ENSG00000267218.2	AC005336.5	4.28	2.03e-05	0.00155	0.17	0.13	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871067	chr19:15902300~15903238:-
BRCA	cis	rs4835473	0.897	rs11728121	ENSG00000249741.2	RP11-673E1.3	-4.28	2.03e-05	0.00155	-0.15	-0.13	Immature fraction of reticulocytes;	chr4:143707079	chr4:143911514~143912053:-
BRCA	cis	rs9650657	0.504	rs10108347	ENSG00000154316.13	TDH	4.28	2.03e-05	0.00155	0.17	0.13	Neuroticism;	chr8:11176008	chr8:11339637~11368452:+
BRCA	cis	rs2109514	0.84	rs2402080	ENSG00000237813.3	AC002066.1	4.28	2.03e-05	0.00155	0.16	0.13	Prevalent atrial fibrillation;	chr7:116494962	chr7:116238260~116499465:-
BRCA	cis	rs7647973	0.925	rs4955439	ENSG00000244380.1	RP11-24C3.2	-4.28	2.03e-05	0.00155	-0.17	-0.13	Menarche (age at onset);	chr3:49208212	chr3:48440352~48446656:-
BRCA	cis	rs3812762	0.871	rs10734637	ENSG00000254860.4	TMEM9B-AS1	-4.28	2.04e-05	0.00155	-0.12	-0.13	Hypospadias;	chr11:8766678	chr11:8964675~8977527:+
BRCA	cis	rs7932354	0.536	rs10838620	ENSG00000200376.1	RNU5E-10P	4.28	2.04e-05	0.00155	0.16	0.13	Bone mineral density (hip);Bone mineral density;	chr11:46796548	chr11:47576471~47576588:-
BRCA	cis	rs1371614	0.611	rs3910615	ENSG00000272148.1	RP11-195B17.1	-4.28	2.04e-05	0.00155	-0.15	-0.13	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26908154	chr2:27062428~27062907:-
BRCA	cis	rs2227564	0.729	rs2633306	ENSG00000279689.1	RP11-574K11.32	-4.28	2.04e-05	0.00155	-0.14	-0.13	Crohn's disease;Inflammatory bowel disease;	chr10:73892689	chr10:73769264~73772862:-
BRCA	cis	rs7811142	0.83	rs6965458	ENSG00000078319.8	PMS2P1	-4.28	2.04e-05	0.00155	-0.23	-0.13	Platelet count;	chr7:100375779	chr7:100320992~100341908:-
BRCA	cis	rs13256369	1	rs4841017	ENSG00000233609.3	RP11-62H7.2	4.28	2.04e-05	0.00155	0.14	0.13	Obesity-related traits;	chr8:8719583	chr8:8961200~8979025:+
BRCA	cis	rs6430538	0.621	rs4953933	ENSG00000224043.6	CCNT2-AS1	-4.28	2.04e-05	0.00155	-0.19	-0.13	Parkinson's disease;	chr2:134786014	chr2:134735464~134918710:-
BRCA	cis	rs5758511	0.573	rs5996074	ENSG00000215771.2	LRRC37A14P	4.28	2.04e-05	0.00155	0.17	0.13	Birth weight;	chr22:41840333	chr22:41189727~41190188:-
BRCA	cis	rs4930561	0.765	rs10896304	ENSG00000184795.9	UNC93B5	-4.28	2.04e-05	0.00155	-0.15	-0.13	Breast cancer in childhood cancer survivors;IgG glycosylation;	chr11:68214247	chr11:67711702~67716005:-
BRCA	cis	rs11758351	0.789	rs2069020	ENSG00000241549.7	GUSBP2	-4.28	2.04e-05	0.00155	-0.19	-0.13	Renal underexcretion gout;Gout;	chr6:26205272	chr6:26871484~26956554:-
BRCA	cis	rs6452524	1	rs7710900	ENSG00000281327.1	LINC01338	4.28	2.04e-05	0.00155	0.15	0.13	Hypertension (SNP x SNP interaction);	chr5:83137201	chr5:82850864~82859836:-
BRCA	cis	rs13113518	0.902	rs12642716	ENSG00000272969.1	RP11-528I4.2	4.28	2.04e-05	0.00155	0.15	0.13	Height;	chr4:55479996	chr4:55547112~55547889:+
BRCA	cis	rs35740288	1	rs11637212	ENSG00000202081.1	RNU6-1280P	-4.28	2.04e-05	0.00155	-0.18	-0.13	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85749866	chr15:85651522~85651628:-
BRCA	cis	rs11048434	0.518	rs34651717	ENSG00000256720.1	RP11-436I9.6	-4.28	2.04e-05	0.00155	-0.13	-0.13	Sjögren's syndrome;	chr12:9025154	chr12:9135084~9135591:+
BRCA	cis	rs11048434	0.518	rs35176717	ENSG00000256720.1	RP11-436I9.6	-4.28	2.04e-05	0.00155	-0.13	-0.13	Sjögren's syndrome;	chr12:9025170	chr12:9135084~9135591:+
BRCA	cis	rs11048434	0.518	rs34533518	ENSG00000256720.1	RP11-436I9.6	-4.28	2.04e-05	0.00155	-0.13	-0.13	Sjögren's syndrome;	chr12:9025302	chr12:9135084~9135591:+
BRCA	cis	rs7572733	0.935	rs938929	ENSG00000231621.1	AC013264.2	4.28	2.04e-05	0.00155	0.12	0.13	Dermatomyositis;	chr2:197916136	chr2:197197991~197199273:+
BRCA	cis	rs6977955	1	rs740122	ENSG00000234336.5	JAZF1-AS1	-4.28	2.04e-05	0.00155	-0.18	-0.13	Allergic disease (asthma, hay fever or eczema);	chr7:28126823	chr7:28180322~28243917:+
BRCA	cis	rs7100689	0.524	rs7902460	ENSG00000226659.1	RP11-137H2.4	-4.28	2.04e-05	0.00155	-0.17	-0.13	Post bronchodilator FEV1;	chr10:80439507	chr10:80529597~80535942:-
BRCA	cis	rs1823874	0.71	rs4965543	ENSG00000182397.13	DNM1P46	-4.28	2.04e-05	0.00155	-0.15	-0.13	IgG glycosylation;	chr15:99821050	chr15:99790156~99806927:-
BRCA	cis	rs4366055	1	rs4366055	ENSG00000254315.1	RP11-267M23.3	4.28	2.04e-05	0.00155	0.17	0.13	Body mass index;	chr8:94495100	chr8:94533628~94534391:+
BRCA	cis	rs7045881	0.935	rs62544361	ENSG00000254396.1	RP11-56F10.3	4.28	2.04e-05	0.00155	0.23	0.13	Schizophrenia;	chr9:26797816	chr9:27102630~27104728:+
BRCA	cis	rs7045881	0.935	rs62544362	ENSG00000254396.1	RP11-56F10.3	4.28	2.04e-05	0.00155	0.23	0.13	Schizophrenia;	chr9:26797830	chr9:27102630~27104728:+
BRCA	cis	rs12534093	0.67	rs13229167	ENSG00000234286.1	AC006026.13	-4.28	2.04e-05	0.00155	-0.18	-0.13	Infant length;Height;	chr7:23552243	chr7:23680195~23680786:-
BRCA	cis	rs2625529	0.652	rs2957736	ENSG00000260037.4	CTD-2524L6.3	4.28	2.04e-05	0.00155	0.17	0.13	Red blood cell count;	chr15:71973003	chr15:71818396~71823384:+
BRCA	cis	rs1982963	1	rs753051	ENSG00000277050.1	RP11-102G14.1	-4.28	2.04e-05	0.00155	-0.17	-0.13	Waist-to-hip ratio adjusted for body mass index;	chr14:52038642	chr14:51637348~51637947:-
BRCA	cis	rs6012564	1	rs3092720	ENSG00000227431.4	CSE1L-AS1	-4.28	2.04e-05	0.00155	-0.16	-0.13	Anger;	chr20:49023929	chr20:49040463~49046044:-
BRCA	cis	rs721917	0.506	rs2493722	ENSG00000278616.1	BEND3P3	-4.28	2.04e-05	0.00155	-0.12	-0.13	Chronic obstructive pulmonary disease;	chr10:79896989	chr10:79682997~79685436:+
BRCA	cis	rs721917	0.545	rs2758542	ENSG00000278616.1	BEND3P3	-4.28	2.04e-05	0.00155	-0.12	-0.13	Chronic obstructive pulmonary disease;	chr10:79897946	chr10:79682997~79685436:+
BRCA	cis	rs721917	0.506	rs7914360	ENSG00000278616.1	BEND3P3	-4.28	2.04e-05	0.00155	-0.12	-0.13	Chronic obstructive pulmonary disease;	chr10:79898002	chr10:79682997~79685436:+
BRCA	cis	rs721917	0.506	rs2254025	ENSG00000278616.1	BEND3P3	-4.28	2.04e-05	0.00155	-0.12	-0.13	Chronic obstructive pulmonary disease;	chr10:79898457	chr10:79682997~79685436:+
BRCA	cis	rs721917	0.525	rs2254017	ENSG00000278616.1	BEND3P3	-4.28	2.04e-05	0.00155	-0.12	-0.13	Chronic obstructive pulmonary disease;	chr10:79898635	chr10:79682997~79685436:+
BRCA	cis	rs721917	0.506	rs2254013	ENSG00000278616.1	BEND3P3	-4.28	2.04e-05	0.00155	-0.12	-0.13	Chronic obstructive pulmonary disease;	chr10:79898692	chr10:79682997~79685436:+
BRCA	cis	rs721917	0.506	rs2253875	ENSG00000278616.1	BEND3P3	-4.28	2.04e-05	0.00155	-0.12	-0.13	Chronic obstructive pulmonary disease;	chr10:79899446	chr10:79682997~79685436:+
BRCA	cis	rs721917	0.544	rs9325567	ENSG00000278616.1	BEND3P3	-4.28	2.04e-05	0.00155	-0.12	-0.13	Chronic obstructive pulmonary disease;	chr10:79899822	chr10:79682997~79685436:+
BRCA	cis	rs10829156	0.945	rs8181345	ENSG00000240291.1	RP11-499P20.2	4.28	2.04e-05	0.00155	0.16	0.13	Sudden cardiac arrest;	chr10:18678689	chr10:18513115~18545651:-
BRCA	cis	rs8062405	0.754	rs28410083	ENSG00000261766.1	RP11-22P6.2	4.28	2.04e-05	0.00155	0.13	0.13	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620039	chr16:28862166~28863340:-
BRCA	cis	rs8062405	0.789	rs1968751	ENSG00000261766.1	RP11-22P6.2	4.28	2.04e-05	0.00155	0.13	0.13	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620438	chr16:28862166~28863340:-
BRCA	cis	rs2108622	0.727	rs55954696	ENSG00000267218.2	AC005336.5	4.28	2.05e-05	0.00155	0.16	0.13	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15870995	chr19:15902300~15903238:-
BRCA	cis	rs2154319	0.666	rs3856251	ENSG00000235358.1	RP11-399E6.1	-4.28	2.05e-05	0.00155	-0.18	-0.13	Height;	chr1:41250375	chr1:41242373~41284861:+
BRCA	cis	rs568617	0.953	rs583887	ENSG00000254510.1	RP11-867G23.10	-4.28	2.05e-05	0.00155	-0.16	-0.13	Crohn's disease;	chr11:65876556	chr11:66409158~66417137:+
BRCA	cis	rs7937890	0.559	rs2597197	ENSG00000254418.1	RP11-21L19.1	4.28	2.05e-05	0.00155	0.15	0.13	Mitochondrial DNA levels;	chr11:14468286	chr11:14262846~14273691:-
BRCA	cis	rs58521262	0.585	rs463879	ENSG00000268105.1	RP11-369G6.2	4.28	2.05e-05	0.00155	0.18	0.13	Testicular germ cell tumor;	chr19:22948181	chr19:23125665~23128543:+
BRCA	cis	rs58521262	0.585	rs466772	ENSG00000268105.1	RP11-369G6.2	4.28	2.05e-05	0.00155	0.18	0.13	Testicular germ cell tumor;	chr19:22948182	chr19:23125665~23128543:+
BRCA	cis	rs58521262	0.649	rs464598	ENSG00000268105.1	RP11-369G6.2	4.28	2.05e-05	0.00155	0.18	0.13	Testicular germ cell tumor;	chr19:22948265	chr19:23125665~23128543:+
BRCA	cis	rs11719291	0.833	rs34037363	ENSG00000270441.1	RP11-694I15.7	4.28	2.05e-05	0.00156	0.28	0.13	Cognitive function;	chr3:48783603	chr3:49140086~49160851:-
BRCA	cis	rs11187837	0.803	rs752140	ENSG00000273450.1	RP11-76P2.4	4.28	2.05e-05	0.00156	0.28	0.13	Sudden cardiac arrest;	chr10:94311639	chr10:94314907~94315327:-
BRCA	cis	rs7481584	0.564	rs432585	ENSG00000247473.2	CARS-AS1	-4.28	2.05e-05	0.00156	-0.16	-0.13	Calcium levels;	chr11:3063673	chr11:3029009~3041260:+
BRCA	cis	rs7647973	1	rs1464569	ENSG00000244380.1	RP11-24C3.2	4.28	2.05e-05	0.00156	0.17	0.13	Menarche (age at onset);	chr3:49422917	chr3:48440352~48446656:-
BRCA	cis	rs4835473	0.722	rs7666296	ENSG00000249741.2	RP11-673E1.3	4.28	2.05e-05	0.00156	0.14	0.13	Immature fraction of reticulocytes;	chr4:143999004	chr4:143911514~143912053:-
BRCA	cis	rs7819412	0.521	rs10110684	ENSG00000255046.1	RP11-297N6.4	4.28	2.05e-05	0.00156	0.16	0.13	Triglycerides;	chr8:11181650	chr8:11797928~11802568:-
BRCA	cis	rs7160336	1	rs7146708	ENSG00000259065.1	RP5-1021I20.1	4.28	2.05e-05	0.00156	0.15	0.13	Blood protein levels;	chr14:74094337	chr14:73787360~73803270:+
BRCA	cis	rs7160336	1	rs2300194	ENSG00000259065.1	RP5-1021I20.1	4.28	2.05e-05	0.00156	0.15	0.13	Blood protein levels;	chr14:74100785	chr14:73787360~73803270:+
BRCA	cis	rs10510102	0.623	rs10159856	ENSG00000226864.1	ATE1-AS1	4.28	2.05e-05	0.00156	0.25	0.13	Breast cancer;	chr10:121988292	chr10:121928312~121951965:+
BRCA	cis	rs6088580	0.634	rs6142159	ENSG00000276073.1	RP5-1125A11.7	4.28	2.05e-05	0.00156	0.14	0.13	Glomerular filtration rate (creatinine);	chr20:34405229	chr20:33985617~33988989:-
BRCA	cis	rs2832191	0.692	rs2245517	ENSG00000215533.7	LINC00189	-4.28	2.05e-05	0.00156	-0.15	-0.13	Dental caries;	chr21:28985647	chr21:29193480~29288205:+
BRCA	cis	rs62025270	0.576	rs62022947	ENSG00000259762.1	RP11-158M2.4	-4.28	2.05e-05	0.00156	-0.19	-0.13	Idiopathic pulmonary fibrosis;	chr15:85728091	chr15:85750336~85752901:-
BRCA	cis	rs11124272	0.504	rs4952220	ENSG00000272716.1	RP11-563N4.1	4.28	2.05e-05	0.00156	0.14	0.13	Interleukin-18 levels;	chr2:31540486	chr2:32165046~32165757:-
BRCA	cis	rs739496	0.895	rs7977752	ENSG00000234608.6	MAPKAPK5-AS1	4.28	2.05e-05	0.00156	0.16	0.13	Platelet count;	chr12:111412426	chr12:111839764~111842902:-
BRCA	cis	rs1823874	0.677	rs2100447	ENSG00000182397.13	DNM1P46	-4.28	2.05e-05	0.00156	-0.15	-0.13	IgG glycosylation;	chr15:99820188	chr15:99790156~99806927:-
BRCA	cis	rs7267979	1	rs4815424	ENSG00000125804.12	FAM182A	4.28	2.05e-05	0.00156	0.17	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25409648	chr20:26054655~26086917:+
BRCA	cis	rs875971	1	rs11971949	ENSG00000229180.5	GS1-124K5.11	-4.28	2.05e-05	0.00156	-0.11	-0.13	Aortic root size;	chr7:66161027	chr7:66526088~66542624:-
BRCA	cis	rs7267979	0.873	rs6037062	ENSG00000125804.12	FAM182A	-4.28	2.05e-05	0.00156	-0.17	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25222256	chr20:26054655~26086917:+
BRCA	cis	rs2832191	0.692	rs8134627	ENSG00000232855.5	AF131217.1	4.28	2.05e-05	0.00156	0.16	0.13	Dental caries;	chr21:28976747	chr21:28439346~28674848:-
BRCA	cis	rs11719291	0.833	rs11709246	ENSG00000270441.1	RP11-694I15.7	4.28	2.05e-05	0.00156	0.27	0.13	Cognitive function;	chr3:48822065	chr3:49140086~49160851:-
BRCA	cis	rs11719291	0.504	rs71324924	ENSG00000270441.1	RP11-694I15.7	4.28	2.05e-05	0.00156	0.27	0.13	Cognitive function;	chr3:48828011	chr3:49140086~49160851:-
BRCA	cis	rs4443100	0.67	rs9612225	ENSG00000230701.2	FBXW4P1	4.28	2.05e-05	0.00156	0.18	0.13	Serum parathyroid hormone levels;	chr22:23064441	chr22:23262767~23265005:+
BRCA	cis	rs733175	0.953	rs4485819	ENSG00000250413.1	RP11-448G15.1	-4.28	2.06e-05	0.00156	-0.2	-0.13	Psychosis and Alzheimer's disease;	chr4:10035769	chr4:10006482~10009725:+
BRCA	cis	rs11779988	0.545	rs454692	ENSG00000253671.1	RP11-806O11.1	-4.28	2.06e-05	0.00156	-0.19	-0.13	Breast cancer;	chr8:17931789	chr8:17808941~17820868:+
BRCA	cis	rs7011507	0.513	rs10087276	ENSG00000233858.4	AC026904.1	-4.28	2.06e-05	0.00156	-0.15	-0.13	Inflammatory bowel disease;Ulcerative colitis;	chr8:48518124	chr8:48590401~48594621:+
BRCA	cis	rs2466254	0.657	rs2203834	ENSG00000251468.2	RP11-369K16.1	-4.28	2.06e-05	0.00156	-0.22	-0.13	Pneumonia;	chr8:12967384	chr8:12958387~12962200:+
BRCA	cis	rs71636778	0.509	rs78581866	ENSG00000260063.1	RP5-968P14.2	-4.28	2.06e-05	0.00156	-0.31	-0.13	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26921075	chr1:26692132~26694131:-
BRCA	cis	rs71636778	0.509	rs11538549	ENSG00000260063.1	RP5-968P14.2	-4.28	2.06e-05	0.00156	-0.31	-0.13	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26921792	chr1:26692132~26694131:-
BRCA	cis	rs6430585	0.527	rs6753232	ENSG00000224043.6	CCNT2-AS1	4.28	2.06e-05	0.00156	0.21	0.13	Corneal structure;	chr2:135678747	chr2:134735464~134918710:-
BRCA	cis	rs2832191	0.74	rs2853830	ENSG00000215533.7	LINC00189	-4.28	2.06e-05	0.00156	-0.15	-0.13	Dental caries;	chr21:29044503	chr21:29193480~29288205:+
BRCA	cis	rs11098499	0.954	rs6848389	ENSG00000260091.1	RP11-33B1.4	-4.28	2.06e-05	0.00156	-0.12	-0.13	Corneal astigmatism;	chr4:119481467	chr4:119409333~119410233:+
BRCA	cis	rs3768617	0.74	rs28533496	ENSG00000224468.3	RP11-181K3.4	-4.28	2.06e-05	0.00156	-0.15	-0.13	Fuchs's corneal dystrophy;	chr1:183050750	chr1:183138402~183141282:-
BRCA	cis	rs3768617	0.782	rs10911211	ENSG00000224468.3	RP11-181K3.4	-4.28	2.06e-05	0.00156	-0.15	-0.13	Fuchs's corneal dystrophy;	chr1:183053164	chr1:183138402~183141282:-
BRCA	cis	rs12900463	0.813	rs187316	ENSG00000259728.4	LINC00933	4.28	2.06e-05	0.00156	0.18	0.13	Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine);	chr15:84862764	chr15:84570649~84580175:+
BRCA	cis	rs6772849	0.775	rs9828414	ENSG00000242551.2	POU5F1P6	-4.28	2.06e-05	0.00156	-0.17	-0.13	Monocyte percentage of white cells;Monocyte count;	chr3:128693874	chr3:128674735~128677005:-
BRCA	cis	rs11098499	0.954	rs10008392	ENSG00000260091.1	RP11-33B1.4	-4.28	2.06e-05	0.00156	-0.12	-0.13	Corneal astigmatism;	chr4:119397684	chr4:119409333~119410233:+
BRCA	cis	rs7160336	1	rs8003543	ENSG00000259065.1	RP5-1021I20.1	-4.28	2.06e-05	0.00156	-0.15	-0.13	Blood protein levels;	chr14:74188571	chr14:73787360~73803270:+
BRCA	cis	rs11955398	0.522	rs34643	ENSG00000272308.1	RP11-231G3.1	-4.28	2.06e-05	0.00156	-0.15	-0.13	Intelligence (multi-trait analysis);	chr5:61048750	chr5:60866457~60866935:-
BRCA	cis	rs11098499	0.754	rs4107728	ENSG00000225892.3	RP11-384K6.2	4.28	2.06e-05	0.00156	0.13	0.13	Corneal astigmatism;	chr4:119332755	chr4:118632274~118634759:+
BRCA	cis	rs10129255	0.957	rs10136560	ENSG00000211974.3	IGHV2-70	4.28	2.06e-05	0.00156	0.14	0.13	Kawasaki disease;	chr14:106787630	chr14:106723574~106724093:-
BRCA	cis	rs12368653	0.616	rs1027315	ENSG00000257159.1	RP11-58A17.3	-4.28	2.06e-05	0.00156	-0.15	-0.13	Multiple sclerosis;	chr12:57640409	chr12:57967058~57968399:+
BRCA	cis	rs10946940	0.93	rs12215012	ENSG00000220721.1	OR1F12	-4.28	2.06e-05	0.00157	-0.15	-0.13	Systemic lupus erythematosus;	chr6:27539715	chr6:28073316~28074233:+
BRCA	cis	rs6452524	1	rs62374373	ENSG00000281327.1	LINC01338	4.28	2.06e-05	0.00157	0.15	0.13	Hypertension (SNP x SNP interaction);	chr5:83137389	chr5:82850864~82859836:-
BRCA	cis	rs8062405	0.69	rs6498089	ENSG00000261766.1	RP11-22P6.2	4.28	2.06e-05	0.00157	0.13	0.13	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28617979	chr16:28862166~28863340:-
BRCA	cis	rs9840812	0.598	rs33999043	ENSG00000239213.4	NCK1-AS1	4.28	2.06e-05	0.00157	0.19	0.13	Fibrinogen levels;	chr3:136381198	chr3:136841726~136862054:-
BRCA	cis	rs516805	0.63	rs2606596	ENSG00000279114.1	RP3-425C14.5	-4.28	2.06e-05	0.00157	-0.17	-0.13	Lymphocyte counts;	chr6:122211597	chr6:122471923~122484161:+
BRCA	cis	rs4664293	0.867	rs7606046	ENSG00000226266.5	AC009961.3	-4.28	2.06e-05	0.00157	-0.16	-0.13	Monocyte percentage of white cells;	chr2:159719647	chr2:159670708~159712435:-
BRCA	cis	rs6545883	0.507	rs6545855	ENSG00000273302.1	RP11-493E12.2	-4.28	2.06e-05	0.00157	-0.11	-0.13	Tuberculosis;	chr2:61305725	chr2:61199979~61200769:+
BRCA	cis	rs2625529	1	rs2625529	ENSG00000260037.4	CTD-2524L6.3	4.28	2.06e-05	0.00157	0.17	0.13	Red blood cell count;	chr15:71826436	chr15:71818396~71823384:+
BRCA	cis	rs2880765	0.835	rs56406982	ENSG00000202081.1	RNU6-1280P	4.28	2.06e-05	0.00157	0.15	0.13	Coronary artery disease;	chr15:85493148	chr15:85651522~85651628:-
BRCA	cis	rs2279168	0.737	rs7178054	ENSG00000259407.1	RP11-158M2.3	-4.28	2.07e-05	0.00157	-0.25	-0.13	Response to platinum-based chemotherapy (carboplatin);	chr15:85440272	chr15:85744109~85750281:-
BRCA	cis	rs559555	0.553	rs806645	ENSG00000276334.1	AL133243.1	-4.28	2.07e-05	0.00157	-0.16	-0.13	Blood metabolite ratios;Blood metabolite levels;	chr2:31582871	chr2:32521927~32523547:+
BRCA	cis	rs6545883	0.655	rs11893880	ENSG00000212978.6	AC016747.3	4.28	2.07e-05	0.00157	0.17	0.13	Tuberculosis;	chr2:61194884	chr2:61141592~61144969:-
BRCA	cis	rs875971	0.66	rs10215132	ENSG00000273142.1	RP11-458F8.4	4.28	2.07e-05	0.00157	0.11	0.13	Aortic root size;	chr7:66589419	chr7:66902857~66906297:+
BRCA	cis	rs4725617	0.822	rs7792901	ENSG00000229153.4	EPHA1-AS1	4.28	2.07e-05	0.00157	0.28	0.13	Blood protein levels;	chr7:143410226	chr7:143407813~143523449:+
BRCA	cis	rs2980439	0.525	rs2980508	ENSG00000233609.3	RP11-62H7.2	4.28	2.07e-05	0.00157	0.12	0.13	Neuroticism;	chr8:8314210	chr8:8961200~8979025:+
BRCA	cis	rs9818758	0.607	rs67060340	ENSG00000225399.4	RP11-3B7.1	-4.28	2.07e-05	0.00157	-0.23	-0.13	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:48877888	chr3:49260085~49261316:+
BRCA	cis	rs8180040	0.966	rs34634681	ENSG00000276925.1	RP11-708J19.3	4.28	2.07e-05	0.00157	0.16	0.13	Colorectal cancer;	chr3:47537612	chr3:47469777~47469987:+
BRCA	cis	rs867186	1	rs6060236	ENSG00000126005.14	MMP24-AS1	-4.28	2.07e-05	0.00157	-0.24	-0.13	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35104815	chr20:35216462~35278131:-
BRCA	cis	rs6968419	1	rs12536669	ENSG00000279086.1	RP11-667F14.1	-4.28	2.07e-05	0.00157	-0.13	-0.13	Intraocular pressure;	chr7:116173624	chr7:116209234~116211511:-
BRCA	cis	rs6071166	0.683	rs6015631	ENSG00000224635.1	RP4-564F22.5	4.28	2.07e-05	0.00157	0.16	0.13	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38688270	chr20:38406011~38416797:-
BRCA	cis	rs1993293	0.636	rs749516	ENSG00000259363.4	CTD-2054N24.2	4.28	2.07e-05	0.00157	0.16	0.13	Coronary artery calcification;	chr15:99754345	chr15:99807023~99877148:+
BRCA	cis	rs2391285	0.609	rs4722610	ENSG00000214870.7	AC004540.5	-4.28	2.07e-05	0.00157	-0.2	-0.13	Post bronchodilator FEV1/FVC ratio;	chr7:26558412	chr7:26398593~26494256:+
BRCA	cis	rs2243480	1	rs73142166	ENSG00000275400.1	RP4-756H11.5	4.28	2.07e-05	0.00157	0.24	0.13	Diabetic kidney disease;	chr7:65910845	chr7:66553805~66554199:-
BRCA	cis	rs4388249	0.651	rs31599	ENSG00000271849.1	CTC-332L22.1	-4.28	2.07e-05	0.00157	-0.24	-0.13	Schizophrenia;	chr5:109671554	chr5:109687802~109688329:-
BRCA	cis	rs4835473	0.932	rs4383567	ENSG00000249741.2	RP11-673E1.3	-4.28	2.07e-05	0.00157	-0.13	-0.13	Immature fraction of reticulocytes;	chr4:143788873	chr4:143911514~143912053:-
BRCA	cis	rs16958440	0.867	rs2117373	ENSG00000280212.1	RP11-49K24.3	4.28	2.07e-05	0.00157	0.28	0.13	Sitting height ratio;	chr18:47145463	chr18:47076117~47076594:+
BRCA	cis	rs2832191	0.692	rs2245517	ENSG00000232855.5	AF131217.1	-4.28	2.07e-05	0.00157	-0.16	-0.13	Dental caries;	chr21:28985647	chr21:28439346~28674848:-
BRCA	cis	rs6496667	0.532	rs2601207	ENSG00000259262.1	NDUFA3P4	-4.28	2.07e-05	0.00157	-0.15	-0.13	Rheumatoid arthritis;	chr15:90420310	chr15:90385814~90386063:+
BRCA	cis	rs1005277	0.579	rs2505237	ENSG00000272983.1	RP11-508N22.12	4.28	2.07e-05	0.00157	0.14	0.13	Extrinsic epigenetic age acceleration;	chr10:38149970	chr10:38137337~38144399:+
BRCA	cis	rs1005277	0.579	rs2474599	ENSG00000272983.1	RP11-508N22.12	4.28	2.07e-05	0.00157	0.14	0.13	Extrinsic epigenetic age acceleration;	chr10:38150011	chr10:38137337~38144399:+
BRCA	cis	rs7927592	0.956	rs7104877	ENSG00000212093.1	AP000807.1	-4.28	2.07e-05	0.00157	-0.14	-0.13	Total body bone mineral density;	chr11:68610134	chr11:68506083~68506166:-
BRCA	cis	rs2227564	0.761	rs2227552	ENSG00000271816.1	BMS1P4	4.28	2.07e-05	0.00157	0.15	0.13	Crohn's disease;Inflammatory bowel disease;	chr10:73909561	chr10:73699151~73730487:-
BRCA	cis	rs35740288	0.929	rs3858927	ENSG00000202081.1	RNU6-1280P	4.28	2.07e-05	0.00157	0.18	0.13	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85758385	chr15:85651522~85651628:-
BRCA	cis	rs4948275	0.74	rs2787699	ENSG00000237233.2	TMEM26-AS1	-4.28	2.07e-05	0.00157	-0.16	-0.13	Night sleep phenotypes;	chr10:61539102	chr10:61452639~61481956:+
BRCA	cis	rs2243480	1	rs73150014	ENSG00000275400.1	RP4-756H11.5	4.28	2.07e-05	0.00157	0.24	0.13	Diabetic kidney disease;	chr7:65985932	chr7:66553805~66554199:-
BRCA	cis	rs7819412	0.502	rs11777918	ENSG00000248896.2	CTD-2135J3.3	4.28	2.08e-05	0.00157	0.16	0.13	Triglycerides;	chr8:11179410	chr8:10729314~10771392:+
BRCA	cis	rs2243480	1	rs3885839	ENSG00000222364.1	RNU6-96P	-4.28	2.08e-05	0.00157	-0.24	-0.13	Diabetic kidney disease;	chr7:65825416	chr7:66395191~66395286:+
BRCA	cis	rs2518049	0.563	rs75811842	ENSG00000224034.1	RP11-445P17.8	-4.28	2.08e-05	0.00157	-0.26	-0.13	Metabolic traits;	chr10:5219138	chr10:5266033~5271236:-
BRCA	cis	rs7475343	0.501	rs76494948	ENSG00000224034.1	RP11-445P17.8	-4.28	2.08e-05	0.00157	-0.26	-0.13	Intelligence;	chr10:5219148	chr10:5266033~5271236:-
BRCA	cis	rs7771547	0.603	rs10947615	ENSG00000224666.3	RP1-50J22.4	4.28	2.08e-05	0.00157	0.17	0.13	Platelet distribution width;	chr6:36631819	chr6:36386831~36393462:+
BRCA	cis	rs13113518	1	rs12501636	ENSG00000272969.1	RP11-528I4.2	4.28	2.08e-05	0.00157	0.15	0.13	Height;	chr4:55482317	chr4:55547112~55547889:+
BRCA	cis	rs13217239	0.646	rs9393789	ENSG00000224843.5	LINC00240	4.28	2.08e-05	0.00157	0.15	0.13	Schizophrenia;	chr6:27099249	chr6:26956992~27023924:+
BRCA	cis	rs2243480	1	rs73142122	ENSG00000222364.1	RNU6-96P	-4.28	2.08e-05	0.00157	-0.24	-0.13	Diabetic kidney disease;	chr7:65846311	chr7:66395191~66395286:+
BRCA	cis	rs2243480	0.901	rs73142137	ENSG00000222364.1	RNU6-96P	-4.28	2.08e-05	0.00157	-0.24	-0.13	Diabetic kidney disease;	chr7:65878455	chr7:66395191~66395286:+
BRCA	cis	rs2243480	1	rs13247184	ENSG00000222364.1	RNU6-96P	-4.28	2.08e-05	0.00157	-0.24	-0.13	Diabetic kidney disease;	chr7:65893941	chr7:66395191~66395286:+
BRCA	cis	rs2243480	1	rs35283677	ENSG00000222364.1	RNU6-96P	-4.28	2.08e-05	0.00157	-0.24	-0.13	Diabetic kidney disease;	chr7:65894246	chr7:66395191~66395286:+
BRCA	cis	rs2243480	1	rs35421653	ENSG00000222364.1	RNU6-96P	-4.28	2.08e-05	0.00157	-0.24	-0.13	Diabetic kidney disease;	chr7:65898442	chr7:66395191~66395286:+
BRCA	cis	rs372883	0.901	rs733610	ENSG00000176054.6	RPL23P2	-4.28	2.08e-05	0.00158	-0.14	-0.13	Pancreatic cancer;	chr21:29283878	chr21:28997613~28998033:-
BRCA	cis	rs669446	0.561	rs664728	ENSG00000236200.4	KDM4A-AS1	-4.28	2.08e-05	0.00158	-0.16	-0.13	Amyotrophic lateral sclerosis (age of onset);	chr1:43636043	chr1:43699765~43708138:-
BRCA	cis	rs669446	0.561	rs664336	ENSG00000236200.4	KDM4A-AS1	-4.28	2.08e-05	0.00158	-0.16	-0.13	Amyotrophic lateral sclerosis (age of onset);	chr1:43636129	chr1:43699765~43708138:-
BRCA	cis	rs13217239	0.572	rs9379958	ENSG00000224843.5	LINC00240	4.28	2.08e-05	0.00158	0.15	0.13	Schizophrenia;	chr6:27098384	chr6:26956992~27023924:+
BRCA	cis	rs6893300	1	rs6893300	ENSG00000250999.1	RP11-1379J22.5	4.28	2.08e-05	0.00158	0.18	0.13	Resting heart rate;	chr5:179708814	chr5:179657762~179664432:+
BRCA	cis	rs2229238	0.911	rs73020246	ENSG00000272030.1	RP1-178F15.4	-4.28	2.08e-05	0.00158	-0.18	-0.13	Coronary heart disease;	chr1:154513164	chr1:153631438~153634397:-
BRCA	cis	rs2229238	0.911	rs6674171	ENSG00000272030.1	RP1-178F15.4	-4.28	2.08e-05	0.00158	-0.18	-0.13	Coronary heart disease;	chr1:154519207	chr1:153631438~153634397:-
BRCA	cis	rs34217772	1	rs2023562	ENSG00000258636.1	CTD-2298J14.2	4.28	2.08e-05	0.00158	0.17	0.13	Myopia;	chr14:41801713	chr14:41587861~41604856:-
BRCA	cis	rs10129255	0.957	rs17113284	ENSG00000232216.1	IGHV3-43	-4.28	2.08e-05	0.00158	-0.11	-0.13	Kawasaki disease;	chr14:106684476	chr14:106470264~106470800:-
BRCA	cis	rs11098499	0.955	rs1511019	ENSG00000250412.1	KLHL2P1	4.28	2.08e-05	0.00158	0.16	0.13	Corneal astigmatism;	chr4:119244852	chr4:119334329~119378233:+
BRCA	cis	rs12210905	1	rs9368494	ENSG00000216901.1	AL022393.7	4.28	2.08e-05	0.00158	0.24	0.13	Hip circumference adjusted for BMI;	chr6:27269522	chr6:28176188~28176674:+
BRCA	cis	rs875971	0.638	rs10249404	ENSG00000232546.1	RP11-458F8.1	4.28	2.08e-05	0.00158	0.11	0.13	Aortic root size;	chr7:66581737	chr7:66848496~66858136:+
BRCA	cis	rs1218582	0.772	rs6683557	ENSG00000270361.1	RP11-307C12.13	-4.28	2.08e-05	0.00158	-0.15	-0.13	Prostate cancer;	chr1:154879831	chr1:154937370~154938059:+
BRCA	cis	rs10129255	0.5	rs34326748	ENSG00000232216.1	IGHV3-43	4.28	2.08e-05	0.00158	0.1	0.13	Kawasaki disease;	chr14:106782523	chr14:106470264~106470800:-
BRCA	cis	rs10129255	0.5	rs10143385	ENSG00000232216.1	IGHV3-43	4.28	2.08e-05	0.00158	0.1	0.13	Kawasaki disease;	chr14:106782559	chr14:106470264~106470800:-
BRCA	cis	rs875971	0.964	rs778721	ENSG00000236529.1	RP13-254B10.1	4.28	2.08e-05	0.00158	0.14	0.13	Aortic root size;	chr7:66380410	chr7:65840212~65840596:+
BRCA	cis	rs12049351	0.774	rs16849844	ENSG00000229367.1	HMGN2P19	-4.28	2.08e-05	0.00158	-0.19	-0.13	Circulating myeloperoxidase levels (plasma);	chr1:229484649	chr1:229570532~229570796:+
BRCA	cis	rs6683071	0.557	rs4240934	ENSG00000225265.1	TAF1A-AS1	-4.28	2.08e-05	0.00158	-0.22	-0.13	Cognitive performance;	chr1:222730956	chr1:222589825~222593032:+
BRCA	cis	rs2834288	0.5	rs7280837	ENSG00000237945.6	LINC00649	4.28	2.08e-05	0.00158	0.15	0.13	Gut microbiota (bacterial taxa);	chr21:33951533	chr21:33915534~33977691:+
BRCA	cis	rs2834288	0.5	rs4817602	ENSG00000237945.6	LINC00649	4.28	2.08e-05	0.00158	0.15	0.13	Gut microbiota (bacterial taxa);	chr21:33952354	chr21:33915534~33977691:+
BRCA	cis	rs6430585	0.583	rs78364332	ENSG00000224043.6	CCNT2-AS1	-4.28	2.08e-05	0.00158	-0.22	-0.13	Corneal structure;	chr2:135882531	chr2:134735464~134918710:-
BRCA	cis	rs442309	0.846	rs224049	ENSG00000238280.1	RP11-436D10.3	-4.28	2.08e-05	0.00158	-0.17	-0.13	Vogt-Koyanagi-Harada syndrome;	chr10:62732673	chr10:62793562~62805887:-
BRCA	cis	rs6439153	0.933	rs7648877	ENSG00000261159.1	RP11-723O4.9	4.28	2.08e-05	0.00158	0.14	0.13	Pneumococcal bacteremia;	chr3:128991137	chr3:128859716~128860526:-
BRCA	cis	rs2554380	0.76	rs1946367	ENSG00000230373.7	GOLGA6L5P	-4.28	2.08e-05	0.00158	-0.18	-0.13	Height;	chr15:83756511	chr15:84507885~84516814:-
BRCA	cis	rs7771547	0.692	rs9380580	ENSG00000224666.3	RP1-50J22.4	4.28	2.08e-05	0.00158	0.16	0.13	Platelet distribution width;	chr6:36583619	chr6:36386831~36393462:+
BRCA	cis	rs7771547	0.723	rs7759778	ENSG00000224666.3	RP1-50J22.4	4.28	2.08e-05	0.00158	0.16	0.13	Platelet distribution width;	chr6:36584490	chr6:36386831~36393462:+
BRCA	cis	rs7771547	0.723	rs7741888	ENSG00000224666.3	RP1-50J22.4	4.28	2.08e-05	0.00158	0.16	0.13	Platelet distribution width;	chr6:36584527	chr6:36386831~36393462:+
BRCA	cis	rs7771547	0.723	rs7760766	ENSG00000224666.3	RP1-50J22.4	4.28	2.08e-05	0.00158	0.16	0.13	Platelet distribution width;	chr6:36584908	chr6:36386831~36393462:+
BRCA	cis	rs7771547	0.692	rs9366909	ENSG00000224666.3	RP1-50J22.4	4.28	2.08e-05	0.00158	0.16	0.13	Platelet distribution width;	chr6:36585092	chr6:36386831~36393462:+
BRCA	cis	rs7246657	0.551	rs4806413	ENSG00000267470.4	ZNF571-AS1	4.28	2.08e-05	0.00158	0.2	0.13	Coronary artery calcification;	chr19:37126814	chr19:37548914~37587348:+
BRCA	cis	rs11098499	0.863	rs1010739	ENSG00000250412.1	KLHL2P1	4.28	2.08e-05	0.00158	0.16	0.13	Corneal astigmatism;	chr4:119542316	chr4:119334329~119378233:+
BRCA	cis	rs490234	0.812	rs12341150	ENSG00000232630.1	PRPS1P2	-4.28	2.08e-05	0.00158	-0.13	-0.13	Mean arterial pressure;	chr9:125578491	chr9:125150653~125151589:+
BRCA	cis	rs11637445	0.677	rs3784713	ENSG00000260657.2	RP11-315D16.4	-4.28	2.08e-05	0.00158	-0.16	-0.13	Posterior cortical atrophy and Alzheimer's disease;	chr15:67780675	chr15:68267792~68277994:-
BRCA	cis	rs7771547	0.723	rs56144242	ENSG00000224666.3	RP1-50J22.4	4.28	2.08e-05	0.00158	0.16	0.13	Platelet distribution width;	chr6:36585432	chr6:36386831~36393462:+
BRCA	cis	rs7771547	0.723	rs61211228	ENSG00000224666.3	RP1-50J22.4	4.28	2.08e-05	0.00158	0.16	0.13	Platelet distribution width;	chr6:36585639	chr6:36386831~36393462:+
BRCA	cis	rs2337406	0.925	rs76288499	ENSG00000223648.3	IGHV3-64	4.28	2.08e-05	0.00158	0.15	0.13	Alzheimer's disease (late onset);	chr14:106686309	chr14:106643132~106658258:-
BRCA	cis	rs7160336	1	rs7160336	ENSG00000259065.1	RP5-1021I20.1	4.28	2.08e-05	0.00158	0.14	0.13	Blood protein levels;	chr14:74105657	chr14:73787360~73803270:+
BRCA	cis	rs62025270	0.522	rs16943120	ENSG00000259762.1	RP11-158M2.4	-4.28	2.08e-05	0.00158	-0.19	-0.13	Idiopathic pulmonary fibrosis;	chr15:85683066	chr15:85750336~85752901:-
BRCA	cis	rs6545883	0.894	rs2593633	ENSG00000270820.4	RP11-355B11.2	-4.28	2.08e-05	0.00158	-0.15	-0.13	Tuberculosis;	chr2:61344378	chr2:61471188~61484130:+
BRCA	cis	rs867186	0.925	rs6060257	ENSG00000126005.14	MMP24-AS1	-4.28	2.08e-05	0.00158	-0.21	-0.13	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35132354	chr20:35216462~35278131:-
BRCA	cis	rs8054556	1	rs3814880	ENSG00000261367.1	RP11-455F5.4	-4.28	2.09e-05	0.00158	-0.15	-0.13	Autism spectrum disorder or schizophrenia;	chr16:30006574	chr16:30107675~30110541:+
BRCA	cis	rs11711311	0.955	rs10934247	ENSG00000241529.3	RN7SL767P	-4.28	2.09e-05	0.00158	-0.16	-0.13	IgG glycosylation;	chr3:113816094	chr3:113632704~113632998:+
BRCA	cis	rs189798	0.807	rs9949	ENSG00000254340.1	RP11-10A14.3	4.28	2.09e-05	0.00158	0.19	0.13	Myopia (pathological);	chr8:9137002	chr8:9141424~9145435:+
BRCA	cis	rs8054556	0.74	rs4609871	ENSG00000183604.13	SMG1P5	4.28	2.09e-05	0.00158	0.12	0.13	Autism spectrum disorder or schizophrenia;	chr16:29920743	chr16:30267553~30335374:-
BRCA	cis	rs2880765	0.835	rs4281668	ENSG00000202081.1	RNU6-1280P	4.28	2.09e-05	0.00158	0.16	0.13	Coronary artery disease;	chr15:85504055	chr15:85651522~85651628:-
BRCA	cis	rs6728642	0.561	rs62152901	ENSG00000273265.1	RP11-353K11.1	4.28	2.09e-05	0.00158	0.2	0.13	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:96899161	chr2:96812239~96813657:-
BRCA	cis	rs875971	1	rs1167612	ENSG00000229180.5	GS1-124K5.11	-4.27	2.09e-05	0.00158	-0.11	-0.13	Aortic root size;	chr7:66102989	chr7:66526088~66542624:-
BRCA	cis	rs4925114	0.568	rs4925109	ENSG00000281749.1	Y_RNA	-4.27	2.09e-05	0.00158	-0.15	-0.13	Body mass index;	chr17:17758488	chr17:18001101~18001195:-
BRCA	cis	rs12025262	0.546	rs10754539	ENSG00000215795.2	RP11-488L18.3	4.27	2.09e-05	0.00158	0.13	0.13	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr1:247202128	chr1:247183813~247185482:-
BRCA	cis	rs6596100	0.915	rs56306291	ENSG00000248648.1	RP11-485M7.1	-4.27	2.09e-05	0.00158	-0.17	-0.13	Breast cancer;	chr5:133069255	chr5:133003119~133003365:+
BRCA	cis	rs11892454	0.544	rs7599961	ENSG00000217643.1	PTGES3P2	-4.27	2.09e-05	0.00158	-0.14	-0.13	Heschl's gyrus morphology;	chr2:25783610	chr2:25822469~25822950:+
BRCA	cis	rs7260598	0.792	rs11672468	ENSG00000268442.1	CTD-2027I19.2	4.27	2.09e-05	0.00158	0.22	0.13	Response to taxane treatment (placlitaxel);	chr19:24119770	chr19:24162370~24163425:-
BRCA	cis	rs3768617	0.811	rs11590958	ENSG00000224468.3	RP11-181K3.4	-4.27	2.09e-05	0.00158	-0.15	-0.13	Fuchs's corneal dystrophy;	chr1:183054501	chr1:183138402~183141282:-
BRCA	cis	rs7572733	0.935	rs771010	ENSG00000231621.1	AC013264.2	4.27	2.09e-05	0.00158	0.12	0.13	Dermatomyositis;	chr2:197826282	chr2:197197991~197199273:+
BRCA	cis	rs1005277	0.579	rs2505241	ENSG00000272983.1	RP11-508N22.12	4.27	2.09e-05	0.00158	0.14	0.13	Extrinsic epigenetic age acceleration;	chr10:38153493	chr10:38137337~38144399:+
BRCA	cis	rs11098499	0.618	rs28491261	ENSG00000260404.2	RP11-384K6.6	4.27	2.09e-05	0.00158	0.12	0.13	Corneal astigmatism;	chr4:119373745	chr4:118591773~118633729:+
BRCA	cis	rs516805	0.63	rs699405	ENSG00000279114.1	RP3-425C14.5	-4.27	2.09e-05	0.00158	-0.16	-0.13	Lymphocyte counts;	chr6:122274145	chr6:122471923~122484161:+
BRCA	cis	rs516805	0.596	rs225088	ENSG00000279114.1	RP3-425C14.5	-4.27	2.09e-05	0.00158	-0.16	-0.13	Lymphocyte counts;	chr6:122277898	chr6:122471923~122484161:+
BRCA	cis	rs6847067	0.672	rs66965560	ENSG00000180769.7	WDFY3-AS2	4.27	2.09e-05	0.00158	0.13	0.13	Oropharynx cancer;	chr4:85040707	chr4:84965682~85011277:+
BRCA	cis	rs669446	0.561	rs531459	ENSG00000236200.4	KDM4A-AS1	-4.27	2.09e-05	0.00158	-0.16	-0.13	Amyotrophic lateral sclerosis (age of onset);	chr1:43625004	chr1:43699765~43708138:-
BRCA	cis	rs669446	0.561	rs628342	ENSG00000236200.4	KDM4A-AS1	-4.27	2.09e-05	0.00158	-0.16	-0.13	Amyotrophic lateral sclerosis (age of onset);	chr1:43625065	chr1:43699765~43708138:-
BRCA	cis	rs539096	0.781	rs2916568	ENSG00000236200.4	KDM4A-AS1	-4.27	2.09e-05	0.00158	-0.16	-0.13	Intelligence (multi-trait analysis);	chr1:43625603	chr1:43699765~43708138:-
BRCA	cis	rs2625529	0.529	rs7183055	ENSG00000260037.4	CTD-2524L6.3	4.27	2.09e-05	0.00158	0.16	0.13	Red blood cell count;	chr15:72084707	chr15:71818396~71823384:+
BRCA	cis	rs409045	1	rs372550	ENSG00000271874.1	CTD-2024P10.2	-4.27	2.09e-05	0.00158	-0.17	-0.13	Left ventricular mass;	chr5:34638318	chr5:34651457~34651888:-
BRCA	cis	rs875971	0.83	rs587360	ENSG00000229180.5	GS1-124K5.11	4.27	2.09e-05	0.00158	0.11	0.13	Aortic root size;	chr7:66057711	chr7:66526088~66542624:-
BRCA	cis	rs7267979	0.78	rs6050679	ENSG00000125804.12	FAM182A	-4.27	2.09e-05	0.00158	-0.17	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25557191	chr20:26054655~26086917:+
BRCA	cis	rs1218582	0.774	rs4845679	ENSG00000270361.1	RP11-307C12.13	-4.27	2.09e-05	0.00158	-0.15	-0.13	Prostate cancer;	chr1:154888711	chr1:154937370~154938059:+
BRCA	cis	rs4538475	0.79	rs11934811	ENSG00000214846.4	RP11-115L11.1	-4.27	2.09e-05	0.00159	-0.22	-0.13	Parkinson's disease;	chr4:15736630	chr4:15730962~15731627:-
BRCA	cis	rs7572733	0.935	rs11679040	ENSG00000231621.1	AC013264.2	-4.27	2.09e-05	0.00159	-0.12	-0.13	Dermatomyositis;	chr2:197942105	chr2:197197991~197199273:+
BRCA	cis	rs875971	1	rs6963646	ENSG00000229180.5	GS1-124K5.11	-4.27	2.09e-05	0.00159	-0.11	-0.13	Aortic root size;	chr7:66220780	chr7:66526088~66542624:-
BRCA	cis	rs6547741	1	rs2384654	ENSG00000234072.1	AC074117.10	4.27	2.09e-05	0.00159	0.12	0.13	Oral cavity cancer;	chr2:27624497	chr2:27356246~27367622:+
BRCA	cis	rs2274273	0.805	rs28660594	ENSG00000259318.1	RP11-454L9.2	4.27	2.09e-05	0.00159	0.11	0.13	Protein biomarker;	chr14:55379456	chr14:55394940~55395233:-
BRCA	cis	rs7481584	0.624	rs1077335	ENSG00000236710.1	AC108448.2	4.27	2.09e-05	0.00159	0.18	0.13	Calcium levels;	chr11:3009294	chr11:3084393~3085443:-
BRCA	cis	rs2346177	0.605	rs7598712	ENSG00000279254.1	RP11-536C12.1	-4.27	2.09e-05	0.00159	-0.15	-0.13	HDL cholesterol;	chr2:46433313	chr2:46668870~46670778:+
BRCA	cis	rs1656368	0.726	rs73154307	ENSG00000279311.1	RP11-170K4.2	4.27	2.09e-05	0.00159	0.17	0.13	Lobe attachment (rater-scored or self-reported);	chr3:158494752	chr3:158869898~158871821:+
BRCA	cis	rs1018697	0.518	rs284846	ENSG00000236937.2	PTGES3P4	-4.27	2.09e-05	0.00159	-0.2	-0.13	Colorectal adenoma (advanced);	chr10:102797533	chr10:102845595~102845950:+
BRCA	cis	rs886774	0.866	rs2108230	ENSG00000273055.1	CTB-13F3.1	4.27	2.09e-05	0.00159	0.13	0.13	Ulcerative colitis;	chr7:107875079	chr7:107942116~107942740:+
BRCA	cis	rs1823874	0.677	rs2100446	ENSG00000182397.13	DNM1P46	-4.27	2.1e-05	0.00159	-0.15	-0.13	IgG glycosylation;	chr15:99820169	chr15:99790156~99806927:-
BRCA	cis	rs983392	0.667	rs624663	ENSG00000275344.1	MIR6503	4.27	2.1e-05	0.00159	0.13	0.13	Alzheimer's disease (late onset);	chr11:60177592	chr11:60209071~60209156:-
BRCA	cis	rs9863	0.828	rs35099862	ENSG00000270028.1	RP11-380L11.4	4.27	2.1e-05	0.00159	0.16	0.13	White blood cell count;	chr12:123982657	chr12:123925461~123926083:-
BRCA	cis	rs11673344	0.504	rs8109501	ENSG00000226686.6	LINC01535	4.27	2.1e-05	0.00159	0.17	0.13	Obesity-related traits;	chr19:37102194	chr19:37251912~37265535:+
BRCA	cis	rs7937890	0.559	rs2597206	ENSG00000254418.1	RP11-21L19.1	4.27	2.1e-05	0.00159	0.15	0.13	Mitochondrial DNA levels;	chr11:14455992	chr11:14262846~14273691:-
BRCA	cis	rs11098499	0.909	rs28714195	ENSG00000260091.1	RP11-33B1.4	-4.27	2.1e-05	0.00159	-0.12	-0.13	Corneal astigmatism;	chr4:119395795	chr4:119409333~119410233:+
BRCA	cis	rs6452524	0.868	rs1564379	ENSG00000281327.1	LINC01338	4.27	2.1e-05	0.00159	0.15	0.13	Hypertension (SNP x SNP interaction);	chr5:83082143	chr5:82850864~82859836:-
BRCA	cis	rs7267979	0.873	rs6115093	ENSG00000125804.12	FAM182A	-4.27	2.1e-05	0.00159	-0.18	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25230094	chr20:26054655~26086917:+
BRCA	cis	rs6831352	0.734	rs3100630	ENSG00000272777.1	RP11-571L19.8	-4.27	2.1e-05	0.00159	-0.14	-0.13	Alcohol dependence;	chr4:99110564	chr4:99067256~99068125:-
BRCA	cis	rs6831352	0.703	rs3133152	ENSG00000272777.1	RP11-571L19.8	-4.27	2.1e-05	0.00159	-0.14	-0.13	Alcohol dependence;	chr4:99110570	chr4:99067256~99068125:-
BRCA	cis	rs9925964	0.933	rs8050894	ENSG00000260911.2	RP11-196G11.2	-4.27	2.1e-05	0.00159	-0.12	-0.13	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31093188	chr16:31043150~31049868:+
BRCA	cis	rs4713118	0.587	rs9393899	ENSG00000216901.1	AL022393.7	4.27	2.1e-05	0.00159	0.19	0.13	Parkinson's disease;	chr6:28165750	chr6:28176188~28176674:+
BRCA	cis	rs1075265	0.669	rs805330	ENSG00000235937.1	AC008280.1	4.27	2.1e-05	0.00159	0.15	0.13	Chronotype;Morning vs. evening chronotype;	chr2:53921194	chr2:54029552~54030682:-
BRCA	cis	rs3812762	0.871	rs3862352	ENSG00000254860.4	TMEM9B-AS1	4.27	2.1e-05	0.00159	0.13	0.13	Hypospadias;	chr11:8796473	chr11:8964675~8977527:+
BRCA	cis	rs4650994	1	rs10913568	ENSG00000273384.1	RP5-1098D14.1	4.27	2.1e-05	0.00159	0.16	0.13	HDL cholesterol;HDL cholesterol levels;	chr1:178544276	chr1:178651706~178652282:+
BRCA	cis	rs6439153	0.967	rs12695512	ENSG00000261159.1	RP11-723O4.9	4.27	2.1e-05	0.00159	0.14	0.13	Pneumococcal bacteremia;	chr3:129003239	chr3:128859716~128860526:-
BRCA	cis	rs6490294	0.571	rs11066120	ENSG00000234608.6	MAPKAPK5-AS1	4.27	2.1e-05	0.00159	0.2	0.13	Mean platelet volume;	chr12:111998391	chr12:111839764~111842902:-
BRCA	cis	rs6490294	0.571	rs7312472	ENSG00000234608.6	MAPKAPK5-AS1	4.27	2.1e-05	0.00159	0.2	0.13	Mean platelet volume;	chr12:112000966	chr12:111839764~111842902:-
BRCA	cis	rs6490294	0.571	rs57439171	ENSG00000234608.6	MAPKAPK5-AS1	4.27	2.1e-05	0.00159	0.2	0.13	Mean platelet volume;	chr12:112001483	chr12:111839764~111842902:-
BRCA	cis	rs6490294	0.571	rs7316650	ENSG00000234608.6	MAPKAPK5-AS1	4.27	2.1e-05	0.00159	0.2	0.13	Mean platelet volume;	chr12:112001860	chr12:111839764~111842902:-
BRCA	cis	rs6490294	0.571	rs7313773	ENSG00000234608.6	MAPKAPK5-AS1	4.27	2.1e-05	0.00159	0.2	0.13	Mean platelet volume;	chr12:112003884	chr12:111839764~111842902:-
BRCA	cis	rs6686842	0.56	rs7534059	ENSG00000235358.1	RP11-399E6.1	-4.27	2.1e-05	0.00159	-0.18	-0.13	Height;	chr1:41015223	chr1:41242373~41284861:+
BRCA	cis	rs748404	0.629	rs34657657	ENSG00000166763.7	STRCP1	4.27	2.1e-05	0.00159	0.2	0.13	Lung cancer;	chr15:43315763	chr15:43699488~43718184:-
BRCA	cis	rs748404	0.626	rs62019432	ENSG00000166763.7	STRCP1	4.27	2.1e-05	0.00159	0.2	0.13	Lung cancer;	chr15:43316482	chr15:43699488~43718184:-
BRCA	cis	rs7160336	1	rs12434078	ENSG00000259065.1	RP5-1021I20.1	-4.27	2.1e-05	0.00159	-0.15	-0.13	Blood protein levels;	chr14:74184411	chr14:73787360~73803270:+
BRCA	cis	rs984222	0.617	rs12123458	ENSG00000231365.4	RP11-418J17.1	4.27	2.1e-05	0.00159	0.16	0.13	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119211635	chr1:119140396~119275973:+
BRCA	cis	rs2281558	0.833	rs6115202	ENSG00000274414.1	RP5-965G21.4	4.27	2.1e-05	0.00159	0.17	0.13	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25516902	chr20:25239007~25245229:-
BRCA	cis	rs11098499	0.863	rs12508173	ENSG00000260091.1	RP11-33B1.4	-4.27	2.1e-05	0.00159	-0.12	-0.13	Corneal astigmatism;	chr4:119397371	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.908	rs12504149	ENSG00000260091.1	RP11-33B1.4	-4.27	2.1e-05	0.00159	-0.12	-0.13	Corneal astigmatism;	chr4:119397422	chr4:119409333~119410233:+
BRCA	cis	rs7267979	1	rs6050590	ENSG00000125804.12	FAM182A	4.27	2.1e-05	0.00159	0.17	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25404358	chr20:26054655~26086917:+
BRCA	cis	rs7267979	1	rs4813566	ENSG00000125804.12	FAM182A	4.27	2.1e-05	0.00159	0.17	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25405829	chr20:26054655~26086917:+
BRCA	cis	rs7267979	1	rs4815421	ENSG00000125804.12	FAM182A	4.27	2.1e-05	0.00159	0.17	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25405873	chr20:26054655~26086917:+
BRCA	cis	rs9527	0.59	rs7920868	ENSG00000213061.2	PFN1P11	4.27	2.1e-05	0.00159	0.18	0.13	Arsenic metabolism;	chr10:103035652	chr10:102838011~102845473:-
BRCA	cis	rs4699052	0.625	rs4481237	ENSG00000248740.4	RP11-328K4.1	4.27	2.1e-05	0.00159	0.15	0.13	Testicular germ cell tumor;	chr4:103332852	chr4:103256159~103453658:+
BRCA	cis	rs875971	1	rs6979382	ENSG00000236529.1	RP13-254B10.1	4.27	2.1e-05	0.00159	0.14	0.13	Aortic root size;	chr7:66421388	chr7:65840212~65840596:+
BRCA	cis	rs875971	1	rs6961990	ENSG00000236529.1	RP13-254B10.1	4.27	2.1e-05	0.00159	0.14	0.13	Aortic root size;	chr7:66423583	chr7:65840212~65840596:+
BRCA	cis	rs1048886	0.872	rs9455162	ENSG00000271967.1	RP11-134K13.4	-4.27	2.1e-05	0.00159	-0.18	-0.13	Type 2 diabetes;	chr6:70568398	chr6:70596438~70596980:+
BRCA	cis	rs721917	0.506	rs2758558	ENSG00000242600.5	MBL1P	4.27	2.1e-05	0.00159	0.16	0.13	Chronic obstructive pulmonary disease;	chr10:79923822	chr10:79904898~79950336:+
BRCA	cis	rs2164068	0.57	rs34608683	ENSG00000231621.1	AC013264.2	4.27	2.1e-05	0.00159	0.13	0.13	Allergy;	chr2:197870988	chr2:197197991~197199273:+
BRCA	cis	rs7572733	0.555	rs2164071	ENSG00000231621.1	AC013264.2	-4.27	2.1e-05	0.00159	-0.13	-0.13	Dermatomyositis;	chr2:198050743	chr2:197197991~197199273:+
BRCA	cis	rs867371	1	rs7180584	ENSG00000278603.1	RP13-608F4.5	4.27	2.1e-05	0.00159	0.18	0.13	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82163493	chr15:82472203~82472426:+
BRCA	cis	rs6840360	0.681	rs9968292	ENSG00000251603.1	RP11-164P12.4	-4.27	2.1e-05	0.00159	-0.12	-0.13	Intelligence (multi-trait analysis);	chr4:151376216	chr4:151667224~151670502:+
BRCA	cis	rs739496	0.947	rs11608565	ENSG00000234608.6	MAPKAPK5-AS1	4.27	2.1e-05	0.00159	0.16	0.13	Platelet count;	chr12:111484122	chr12:111839764~111842902:-
BRCA	cis	rs10129255	0.5	rs1024350	ENSG00000232216.1	IGHV3-43	4.27	2.11e-05	0.00159	0.1	0.13	Kawasaki disease;	chr14:106685105	chr14:106470264~106470800:-
BRCA	cis	rs6671200	1	rs71654419	ENSG00000226026.4	RP11-57H12.3	4.27	2.11e-05	0.00159	0.28	0.13	Stearic acid (18:0) levels;	chr1:95198941	chr1:95163219~95233982:-
BRCA	cis	rs1707322	1	rs1613296	ENSG00000234329.1	RP11-767N6.2	-4.27	2.11e-05	0.00159	-0.13	-0.13	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46081180	chr1:45651039~45651826:-
BRCA	cis	rs4784227	1	rs4784227	ENSG00000249231.6	CASC16	-4.27	2.11e-05	0.00159	-0.17	-0.13	Breast cancer (estrogen-receptor negative);Breast cancer;Parkinson's disease;	chr16:52565276	chr16:52552090~52652105:-
BRCA	cis	rs4699052	0.625	rs10212959	ENSG00000248740.4	RP11-328K4.1	-4.27	2.11e-05	0.00159	-0.15	-0.13	Testicular germ cell tumor;	chr4:103379778	chr4:103256159~103453658:+
BRCA	cis	rs1823874	0.71	rs3919790	ENSG00000182397.13	DNM1P46	-4.27	2.11e-05	0.00159	-0.15	-0.13	IgG glycosylation;	chr15:99821130	chr15:99790156~99806927:-
BRCA	cis	rs7260598	0.792	rs73021454	ENSG00000268442.1	CTD-2027I19.2	4.27	2.11e-05	0.00159	0.22	0.13	Response to taxane treatment (placlitaxel);	chr19:24133074	chr19:24162370~24163425:-
BRCA	cis	rs7260598	0.792	rs11671960	ENSG00000268442.1	CTD-2027I19.2	4.27	2.11e-05	0.00159	0.22	0.13	Response to taxane treatment (placlitaxel);	chr19:24135019	chr19:24162370~24163425:-
BRCA	cis	rs7260598	0.792	rs59756985	ENSG00000268442.1	CTD-2027I19.2	4.27	2.11e-05	0.00159	0.22	0.13	Response to taxane treatment (placlitaxel);	chr19:24141664	chr19:24162370~24163425:-
BRCA	cis	rs2337406	0.538	rs10141701	ENSG00000211970.3	IGHV4-61	4.27	2.11e-05	0.00159	0.11	0.13	Alzheimer's disease (late onset);	chr14:106633467	chr14:106639119~106639657:-
BRCA	cis	rs1910358	0.591	rs62347241	ENSG00000248874.4	C5orf17	-4.27	2.11e-05	0.00159	-0.17	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23987494	chr5:23951348~24178263:+
BRCA	cis	rs1910358	0.614	rs62347242	ENSG00000248874.4	C5orf17	-4.27	2.11e-05	0.00159	-0.17	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23987566	chr5:23951348~24178263:+
BRCA	cis	rs1910358	0.614	rs1847062	ENSG00000248874.4	C5orf17	-4.27	2.11e-05	0.00159	-0.17	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23988479	chr5:23951348~24178263:+
BRCA	cis	rs9921338	0.961	rs7200667	ENSG00000262636.1	CTD-3088G3.4	-4.27	2.11e-05	0.00159	-0.22	-0.13	Vein graft stenosis in coronary artery bypass grafting;	chr16:11346547	chr16:11380859~11381118:-
BRCA	cis	rs62458065	0.85	rs7785659	ENSG00000273014.1	RP11-225B17.2	-4.27	2.11e-05	0.0016	-0.2	-0.13	Metabolite levels (HVA/MHPG ratio);	chr7:32421403	chr7:32758882~32759353:+
BRCA	cis	rs9863	0.828	rs75989601	ENSG00000270028.1	RP11-380L11.4	4.27	2.11e-05	0.0016	0.16	0.13	White blood cell count;	chr12:123982176	chr12:123925461~123926083:-
BRCA	cis	rs11048434	0.518	rs2377678	ENSG00000256937.1	KRT17P8	-4.27	2.11e-05	0.0016	-0.14	-0.13	Sjögren's syndrome;	chr12:9021562	chr12:9127783~9128645:+
BRCA	cis	rs11673344	0.504	rs4806409	ENSG00000226686.6	LINC01535	4.27	2.11e-05	0.0016	0.17	0.13	Obesity-related traits;	chr19:37097923	chr19:37251912~37265535:+
BRCA	cis	rs2832191	0.933	rs2832236	ENSG00000232855.5	AF131217.1	4.27	2.11e-05	0.0016	0.16	0.13	Dental caries;	chr21:29175281	chr21:28439346~28674848:-
BRCA	cis	rs11098499	0.863	rs2291185	ENSG00000250412.1	KLHL2P1	4.27	2.11e-05	0.0016	0.16	0.13	Corneal astigmatism;	chr4:119513678	chr4:119334329~119378233:+
BRCA	cis	rs7267979	0.934	rs2257464	ENSG00000125804.12	FAM182A	-4.27	2.11e-05	0.0016	-0.17	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25285236	chr20:26054655~26086917:+
BRCA	cis	rs755249	0.567	rs72661961	ENSG00000182109.6	RP11-69E11.4	4.27	2.11e-05	0.0016	0.18	0.13	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39366096	chr1:39522280~39546187:-
BRCA	cis	rs755249	0.532	rs61779277	ENSG00000182109.6	RP11-69E11.4	4.27	2.11e-05	0.0016	0.18	0.13	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39367863	chr1:39522280~39546187:-
BRCA	cis	rs755249	0.532	rs61779278	ENSG00000182109.6	RP11-69E11.4	4.27	2.11e-05	0.0016	0.18	0.13	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39368945	chr1:39522280~39546187:-
BRCA	cis	rs755249	0.567	rs2296172	ENSG00000182109.6	RP11-69E11.4	4.27	2.11e-05	0.0016	0.18	0.13	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39370145	chr1:39522280~39546187:-
BRCA	cis	rs755249	0.567	rs61779279	ENSG00000182109.6	RP11-69E11.4	4.27	2.11e-05	0.0016	0.18	0.13	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39371430	chr1:39522280~39546187:-
BRCA	cis	rs3748682	0.861	rs28420383	ENSG00000222282.1	RNU6-584P	-4.27	2.11e-05	0.0016	-0.17	-0.13	Hypothyroidism;	chr1:37880733	chr1:37885023~37885117:+
BRCA	cis	rs739496	0.579	rs10849984	ENSG00000257624.1	RP1-128M12.3	4.27	2.11e-05	0.0016	0.18	0.13	Platelet count;	chr12:111909924	chr12:112000739~112000985:-
BRCA	cis	rs739496	0.579	rs10849985	ENSG00000257624.1	RP1-128M12.3	4.27	2.11e-05	0.0016	0.18	0.13	Platelet count;	chr12:111909950	chr12:112000739~112000985:-
BRCA	cis	rs4718428	1	rs1830070	ENSG00000230295.1	RP11-458F8.2	-4.27	2.11e-05	0.0016	-0.11	-0.13	Corneal structure;	chr7:66884684	chr7:66880708~66882981:+
BRCA	cis	rs7160336	1	rs17098083	ENSG00000259065.1	RP5-1021I20.1	-4.27	2.11e-05	0.0016	-0.15	-0.13	Blood protein levels;	chr14:74188955	chr14:73787360~73803270:+
BRCA	cis	rs73242632	1	rs115267736	ENSG00000269949.1	RP11-738E22.3	4.27	2.11e-05	0.0016	0.31	0.13	Congenital heart disease (maternal effect);	chr4:56900757	chr4:56960927~56961373:-
BRCA	cis	rs7897654	0.571	rs12764049	ENSG00000213277.3	MARCKSL1P1	4.27	2.11e-05	0.0016	0.17	0.13	Schizophrenia;	chr10:102875199	chr10:103175554~103176094:+
BRCA	cis	rs875971	1	rs709595	ENSG00000236529.1	RP13-254B10.1	4.27	2.11e-05	0.0016	0.14	0.13	Aortic root size;	chr7:66352346	chr7:65840212~65840596:+
BRCA	cis	rs875971	1	rs811880	ENSG00000236529.1	RP13-254B10.1	4.27	2.11e-05	0.0016	0.14	0.13	Aortic root size;	chr7:66353659	chr7:65840212~65840596:+
BRCA	cis	rs2842346	0.549	rs1859302	ENSG00000258623.1	CTD-2325P2.3	-4.27	2.11e-05	0.0016	-0.17	-0.13	Breast cancer;	chr14:68539468	chr14:68683411~68685565:-
BRCA	cis	rs686320	1	rs1194758	ENSG00000245532.5	NEAT1	-4.27	2.11e-05	0.0016	-0.15	-0.13	Hip circumference adjusted for BMI;	chr11:65470614	chr11:65422774~65445540:+
BRCA	cis	rs2505998	1	rs1864410	ENSG00000273008.1	RP11-351D16.3	-4.27	2.11e-05	0.0016	-0.16	-0.13	Hirschsprung disease;	chr10:43080177	chr10:43136824~43138334:-
BRCA	cis	rs2505998	0.957	rs1864408	ENSG00000273008.1	RP11-351D16.3	-4.27	2.11e-05	0.0016	-0.16	-0.13	Hirschsprung disease;	chr10:43080435	chr10:43136824~43138334:-
BRCA	cis	rs8180040	0.805	rs17410853	ENSG00000276925.1	RP11-708J19.3	4.27	2.11e-05	0.0016	0.15	0.13	Colorectal cancer;	chr3:47322481	chr3:47469777~47469987:+
BRCA	cis	rs1005277	0.54	rs2474598	ENSG00000272983.1	RP11-508N22.12	-4.27	2.11e-05	0.0016	-0.14	-0.13	Extrinsic epigenetic age acceleration;	chr10:38141368	chr10:38137337~38144399:+
BRCA	cis	rs2108622	0.649	rs113055956	ENSG00000267218.2	AC005336.5	4.27	2.11e-05	0.0016	0.16	0.13	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15866502	chr19:15902300~15903238:-
BRCA	cis	rs6012564	0.806	rs4810903	ENSG00000222365.1	SNORD12B	-4.27	2.11e-05	0.0016	-0.14	-0.13	Anger;	chr20:48982668	chr20:49280319~49280409:+
BRCA	cis	rs7897654	0.571	rs12767543	ENSG00000213277.3	MARCKSL1P1	4.27	2.11e-05	0.0016	0.17	0.13	Schizophrenia;	chr10:102871906	chr10:103175554~103176094:+
BRCA	cis	rs4948275	0.693	rs2606104	ENSG00000237233.2	TMEM26-AS1	-4.27	2.11e-05	0.0016	-0.15	-0.13	Night sleep phenotypes;	chr10:61583103	chr10:61452639~61481956:+
BRCA	cis	rs4948275	0.693	rs2606105	ENSG00000237233.2	TMEM26-AS1	-4.27	2.11e-05	0.0016	-0.15	-0.13	Night sleep phenotypes;	chr10:61583174	chr10:61452639~61481956:+
BRCA	cis	rs78487399	0.808	rs112387154	ENSG00000234936.1	AC010883.5	4.27	2.11e-05	0.0016	0.21	0.13	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43536092	chr2:43229573~43233394:+
BRCA	cis	rs9818758	0.607	rs9311439	ENSG00000225399.4	RP11-3B7.1	-4.27	2.11e-05	0.0016	-0.21	-0.13	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49272975	chr3:49260085~49261316:+
BRCA	cis	rs9921338	0.961	rs7206749	ENSG00000262636.1	CTD-3088G3.4	-4.27	2.11e-05	0.0016	-0.21	-0.13	Vein graft stenosis in coronary artery bypass grafting;	chr16:11283065	chr16:11380859~11381118:-
BRCA	cis	rs11673344	0.526	rs17244769	ENSG00000267422.1	CTD-2554C21.1	4.27	2.12e-05	0.0016	0.18	0.13	Obesity-related traits;	chr19:37562031	chr19:37779686~37792865:+
BRCA	cis	rs6921919	0.583	rs2041230	ENSG00000273712.1	RP5-874C20.7	4.27	2.12e-05	0.0016	0.17	0.13	Autism spectrum disorder or schizophrenia;	chr6:28397738	chr6:28315613~28315883:-
BRCA	cis	rs7260598	0.685	rs73021424	ENSG00000268442.1	CTD-2027I19.2	4.27	2.12e-05	0.0016	0.22	0.13	Response to taxane treatment (placlitaxel);	chr19:24090897	chr19:24162370~24163425:-
BRCA	cis	rs7260598	0.685	rs11667970	ENSG00000268442.1	CTD-2027I19.2	4.27	2.12e-05	0.0016	0.22	0.13	Response to taxane treatment (placlitaxel);	chr19:24094893	chr19:24162370~24163425:-
BRCA	cis	rs7260598	0.581	rs73021432	ENSG00000268442.1	CTD-2027I19.2	4.27	2.12e-05	0.0016	0.22	0.13	Response to taxane treatment (placlitaxel);	chr19:24101827	chr19:24162370~24163425:-
BRCA	cis	rs2439831	0.85	rs28595038	ENSG00000206991.1	RNU6-610P	-4.27	2.12e-05	0.0016	-0.21	-0.13	Lung cancer in ever smokers;	chr15:43752661	chr15:43637632~43637738:-
BRCA	cis	rs11764932	0.632	rs4532497	ENSG00000229108.1	MEOX2-AS1	-4.27	2.12e-05	0.0016	-0.16	-0.13	Kidney function decline traits;	chr7:15673227	chr7:15688378~15695491:+
BRCA	cis	rs7577696	0.888	rs652978	ENSG00000272716.1	RP11-563N4.1	-4.27	2.12e-05	0.0016	-0.14	-0.13	Inflammatory biomarkers;	chr2:32061342	chr2:32165046~32165757:-
BRCA	cis	rs10986311	0.862	rs2416924	ENSG00000227200.1	RP11-121A14.3	4.27	2.12e-05	0.0016	0.15	0.13	Vitiligo;	chr9:124345867	chr9:124262876~124265809:+
BRCA	cis	rs17345786	1	rs3762729	ENSG00000244119.1	PDCL3P4	4.27	2.12e-05	0.0016	0.12	0.13	Colonoscopy-negative controls vs population controls;	chr3:101590030	chr3:101712472~101713191:+
BRCA	cis	rs12612619	0.685	rs4665937	ENSG00000272148.1	RP11-195B17.1	-4.27	2.12e-05	0.0016	-0.15	-0.13	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27018927	chr2:27062428~27062907:-
BRCA	cis	rs9527	0.521	rs12259163	ENSG00000213061.2	PFN1P11	4.27	2.12e-05	0.0016	0.18	0.13	Arsenic metabolism;	chr10:103201720	chr10:102838011~102845473:-
BRCA	cis	rs10864907	0.614	rs12468164	ENSG00000231747.1	AC079922.2	4.27	2.12e-05	0.0016	0.12	0.13	Pulmonary function;	chr2:112955206	chr2:112621809~112622167:-
BRCA	cis	rs34656763	0.666	rs616030	ENSG00000198468.6	FLVCR1-AS1	-4.27	2.12e-05	0.0016	-0.19	-0.13	Loneliness;Loneliness (multivariate analysis);Loneliness (linear analysis);	chr1:212522883	chr1:212852108~212858088:-
BRCA	cis	rs2243480	0.711	rs2460426	ENSG00000275400.1	RP4-756H11.5	-4.27	2.12e-05	0.0016	-0.24	-0.13	Diabetic kidney disease;	chr7:66158142	chr7:66553805~66554199:-
BRCA	cis	rs1910358	0.554	rs4701390	ENSG00000248874.4	C5orf17	-4.27	2.12e-05	0.0016	-0.19	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23742369	chr5:23951348~24178263:+
BRCA	cis	rs1198430	1	rs1198432	ENSG00000271420.1	RP5-1057J7.7	-4.27	2.12e-05	0.0016	-0.17	-0.13	Total cholesterol levels;	chr1:23429662	chr1:23378380~23379029:-
BRCA	cis	rs12612619	0.732	rs13020526	ENSG00000229122.1	AGBL5-IT1	4.27	2.12e-05	0.0016	0.14	0.13	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:26981782	chr2:27061038~27061815:+
BRCA	cis	rs8040855	0.627	rs12900012	ENSG00000230373.7	GOLGA6L5P	4.27	2.12e-05	0.0016	0.17	0.13	Bulimia nervosa;	chr15:85046955	chr15:84507885~84516814:-
BRCA	cis	rs11742741	0.774	rs1469416	ENSG00000248874.4	C5orf17	-4.27	2.12e-05	0.0016	-0.17	-0.13	Educational attainment;	chr5:24117673	chr5:23951348~24178263:+
BRCA	cis	rs7833790	0.929	rs10958048	ENSG00000254689.1	RP11-354A14.1	-4.27	2.12e-05	0.0016	-0.19	-0.13	Diastolic blood pressure;	chr8:81880679	chr8:81885377~81923193:+
BRCA	cis	rs35740288	0.742	rs4843087	ENSG00000202081.1	RNU6-1280P	4.27	2.12e-05	0.0016	0.17	0.13	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85629624	chr15:85651522~85651628:-
BRCA	cis	rs9304861	1	rs9304861	ENSG00000248830.1	ZNF807	4.27	2.12e-05	0.00161	0.24	0.13	Alzheimer disease and age of onset;	chr19:34780984	chr19:34542462~34545395:-
BRCA	cis	rs801193	0.967	rs2707853	ENSG00000272831.1	RP11-792A8.4	4.27	2.12e-05	0.00161	0.12	0.13	Aortic root size;	chr7:66749023	chr7:66739829~66740385:-
BRCA	cis	rs2439831	0.85	rs60883262	ENSG00000206991.1	RNU6-610P	-4.27	2.12e-05	0.00161	-0.21	-0.13	Lung cancer in ever smokers;	chr15:43784305	chr15:43637632~43637738:-
BRCA	cis	rs6015450	1	rs6026732	ENSG00000228340.4	MIR646HG	4.27	2.12e-05	0.00161	0.26	0.13	Hypertension;Blood pressure;Systolic blood pressure;Diastolic blood pressure;	chr20:59154304	chr20:60087840~60527458:+
BRCA	cis	rs7771547	0.723	rs35707365	ENSG00000224666.3	RP1-50J22.4	4.27	2.12e-05	0.00161	0.16	0.13	Platelet distribution width;	chr6:36588857	chr6:36386831~36393462:+
BRCA	cis	rs7771547	0.723	rs9380582	ENSG00000224666.3	RP1-50J22.4	4.27	2.12e-05	0.00161	0.16	0.13	Platelet distribution width;	chr6:36588953	chr6:36386831~36393462:+
BRCA	cis	rs9921338	0.887	rs6498183	ENSG00000262636.1	CTD-3088G3.4	-4.27	2.12e-05	0.00161	-0.22	-0.13	Vein graft stenosis in coronary artery bypass grafting;	chr16:11337051	chr16:11380859~11381118:-
BRCA	cis	rs875971	1	rs10215948	ENSG00000236529.1	RP13-254B10.1	-4.27	2.12e-05	0.00161	-0.14	-0.13	Aortic root size;	chr7:66282799	chr7:65840212~65840596:+
BRCA	cis	rs35740288	0.929	rs11635081	ENSG00000202081.1	RNU6-1280P	4.27	2.13e-05	0.00161	0.18	0.13	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85761029	chr15:85651522~85651628:-
BRCA	cis	rs1383484	0.606	rs9329364	ENSG00000225151.9	GOLGA2P7	4.27	2.13e-05	0.00161	0.16	0.13	Height;	chr15:83974490	chr15:84199311~84230136:-
BRCA	cis	rs116095464	0.558	rs9312978	ENSG00000248925.1	CTD-2083E4.6	4.27	2.13e-05	0.00161	0.26	0.13	Breast cancer;	chr5:221815	chr5:269858~271516:-
BRCA	cis	rs116095464	0.558	rs9312979	ENSG00000248925.1	CTD-2083E4.6	4.27	2.13e-05	0.00161	0.26	0.13	Breast cancer;	chr5:221942	chr5:269858~271516:-
BRCA	cis	rs720475	1	rs720475	ENSG00000228960.5	OR2A9P	-4.27	2.13e-05	0.00161	-0.19	-0.13	Breast cancer;	chr7:144377836	chr7:144294480~144300934:+
BRCA	cis	rs11711311	1	rs62268168	ENSG00000241529.3	RN7SL767P	-4.27	2.13e-05	0.00161	-0.15	-0.13	IgG glycosylation;	chr3:113770600	chr3:113632704~113632998:+
BRCA	cis	rs1075265	0.68	rs805396	ENSG00000235937.1	AC008280.1	4.27	2.13e-05	0.00161	0.14	0.13	Chronotype;Morning vs. evening chronotype;	chr2:53882314	chr2:54029552~54030682:-
BRCA	cis	rs651907	0.514	rs55654108	ENSG00000256628.3	ZBTB11-AS1	4.27	2.13e-05	0.00161	0.17	0.13	Colorectal cancer;	chr3:101706859	chr3:101676475~101679217:+
BRCA	cis	rs6964833	0.935	rs13238996	ENSG00000184616.8	AC004166.6	4.27	2.13e-05	0.00161	0.2	0.13	Menarche (age at onset);	chr7:74655318	chr7:74906673~74913256:-
BRCA	cis	rs7267979	0.932	rs367666	ENSG00000274973.1	RP13-401N8.7	-4.27	2.13e-05	0.00161	-0.15	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25469182	chr20:25845497~25845862:+
BRCA	cis	rs67766926	0.953	rs6545835	ENSG00000271889.1	RP11-493E12.1	4.27	2.13e-05	0.00161	0.19	0.13	Inflammatory skin disease;	chr2:60885417	chr2:61151433~61162105:-
BRCA	cis	rs2243480	1	rs35820085	ENSG00000222364.1	RNU6-96P	-4.27	2.13e-05	0.00161	-0.24	-0.13	Diabetic kidney disease;	chr7:65977771	chr7:66395191~66395286:+
BRCA	cis	rs6728642	0.908	rs7588921	ENSG00000230606.9	AC159540.1	4.27	2.13e-05	0.00161	0.23	0.13	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:97352698	chr2:97416165~97433527:-
BRCA	cis	rs35740288	0.895	rs3743332	ENSG00000202081.1	RNU6-1280P	4.27	2.13e-05	0.00161	0.18	0.13	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85760520	chr15:85651522~85651628:-
BRCA	cis	rs745109	0.882	rs74959393	ENSG00000273080.1	RP11-301O19.1	4.27	2.13e-05	0.00161	0.21	0.13	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86433692	chr2:86195590~86196049:+
BRCA	cis	rs1018697	0.518	rs284843	ENSG00000236937.2	PTGES3P4	-4.27	2.13e-05	0.00161	-0.2	-0.13	Colorectal adenoma (advanced);	chr10:102793809	chr10:102845595~102845950:+
BRCA	cis	rs6545883	0.894	rs2600672	ENSG00000273302.1	RP11-493E12.2	4.27	2.13e-05	0.00161	0.12	0.13	Tuberculosis;	chr2:61309605	chr2:61199979~61200769:+
BRCA	cis	rs7267979	0.966	rs2263204	ENSG00000276952.1	RP5-965G21.6	-4.27	2.13e-05	0.00161	-0.16	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25397052	chr20:25284915~25285588:-
BRCA	cis	rs1008375	0.897	rs2315554	ENSG00000249502.1	AC006160.5	-4.27	2.13e-05	0.00161	-0.16	-0.13	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17658784	chr4:17587467~17614571:-
BRCA	cis	rs6121246	0.697	rs6120970	ENSG00000230613.1	HM13-AS1	4.27	2.13e-05	0.00161	0.19	0.13	Mean corpuscular hemoglobin;	chr20:31644649	chr20:31567707~31573263:-
BRCA	cis	rs8114671	0.836	rs6120778	ENSG00000279253.1	RP4-614O4.13	-4.27	2.13e-05	0.00161	-0.15	-0.13	Height;	chr20:34977366	chr20:35262727~35264187:-
BRCA	cis	rs739496	0.947	rs7299849	ENSG00000234608.6	MAPKAPK5-AS1	4.27	2.13e-05	0.00161	0.16	0.13	Platelet count;	chr12:111417657	chr12:111839764~111842902:-
BRCA	cis	rs9818758	0.607	rs71324929	ENSG00000225399.4	RP11-3B7.1	-4.27	2.13e-05	0.00161	-0.25	-0.13	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49007280	chr3:49260085~49261316:+
BRCA	cis	rs6545883	0.929	rs12617911	ENSG00000270820.4	RP11-355B11.2	4.27	2.13e-05	0.00161	0.15	0.13	Tuberculosis;	chr2:61513690	chr2:61471188~61484130:+
BRCA	cis	rs6596100	0.91	rs1131809	ENSG00000248648.1	RP11-485M7.1	-4.27	2.13e-05	0.00161	-0.17	-0.13	Breast cancer;	chr5:133101839	chr5:133003119~133003365:+
BRCA	cis	rs6596100	0.956	rs56083805	ENSG00000248648.1	RP11-485M7.1	-4.27	2.13e-05	0.00161	-0.17	-0.13	Breast cancer;	chr5:133106571	chr5:133003119~133003365:+
BRCA	cis	rs2835872	0.896	rs721014	ENSG00000228677.1	TTC3-AS1	4.27	2.13e-05	0.00161	0.17	0.13	Electroencephalographic traits in alcoholism;	chr21:37635807	chr21:37187666~37193926:-
BRCA	cis	rs2835872	0.965	rs857947	ENSG00000228677.1	TTC3-AS1	4.27	2.13e-05	0.00161	0.17	0.13	Electroencephalographic traits in alcoholism;	chr21:37636237	chr21:37187666~37193926:-
BRCA	cis	rs11088226	0.681	rs2833926	ENSG00000186842.4	LINC00846	-4.27	2.13e-05	0.00161	-0.22	-0.13	Gastritis;	chr21:32602969	chr21:32572238~32575881:-
BRCA	cis	rs11603691	1	rs11606862	ENSG00000254662.1	RP11-872D17.4	4.27	2.13e-05	0.00161	0.31	0.13	Low high density lipoprotein cholesterol levels;	chr11:57245268	chr11:57325603~57327958:+
BRCA	cis	rs7267979	0.966	rs2261784	ENSG00000277938.1	RP5-965G21.3	4.27	2.13e-05	0.00161	0.16	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25281760	chr20:25229150~25231933:+
BRCA	cis	rs7267979	0.966	rs2261785	ENSG00000277938.1	RP5-965G21.3	4.27	2.13e-05	0.00161	0.16	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25281767	chr20:25229150~25231933:+
BRCA	cis	rs4218	0.528	rs57557135	ENSG00000259732.1	RP11-59H7.3	-4.27	2.13e-05	0.00161	-0.16	-0.13	Social communication problems;	chr15:59054018	chr15:59121034~59133250:+
BRCA	cis	rs7937890	0.559	rs2597201	ENSG00000254418.1	RP11-21L19.1	4.27	2.13e-05	0.00161	0.15	0.13	Mitochondrial DNA levels;	chr11:14463858	chr11:14262846~14273691:-
BRCA	cis	rs7937890	0.532	rs2575832	ENSG00000254418.1	RP11-21L19.1	4.27	2.13e-05	0.00161	0.15	0.13	Mitochondrial DNA levels;	chr11:14467264	chr11:14262846~14273691:-
BRCA	cis	rs4143844	0.867	rs35559361	ENSG00000259251.2	RP11-643M14.1	4.27	2.13e-05	0.00161	0.32	0.13	Bipolar disorder and schizophrenia;	chr15:61891318	chr15:62060503~62062434:+
BRCA	cis	rs1910358	0.53	rs6452158	ENSG00000248874.4	C5orf17	-4.27	2.13e-05	0.00161	-0.19	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23769071	chr5:23951348~24178263:+
BRCA	cis	rs13113518	0.678	rs13149568	ENSG00000272969.1	RP11-528I4.2	4.27	2.13e-05	0.00161	0.15	0.13	Height;	chr4:55370412	chr4:55547112~55547889:+
BRCA	cis	rs4415084	0.932	rs2218080	ENSG00000251141.4	RP11-53O19.1	4.27	2.14e-05	0.00161	0.12	0.13	Breast cancer;	chr5:44714228	chr5:44744900~44808777:-
BRCA	cis	rs7119	0.689	rs8040318	ENSG00000259362.2	RP11-307C19.1	-4.27	2.14e-05	0.00161	-0.18	-0.13	Type 2 diabetes;	chr15:77511318	chr15:77525540~77534110:+
BRCA	cis	rs1193	0.651	rs4832048	ENSG00000231259.4	AC125232.1	-4.27	2.14e-05	0.00161	-0.16	-0.13	High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;High light scatter reticulocyte count;	chr2:86680567	chr2:87031815~87053069:-
BRCA	cis	rs1953600	1	rs1953600	ENSG00000226659.1	RP11-137H2.4	4.27	2.14e-05	0.00162	0.17	0.13	Sarcoidosis;	chr10:80151969	chr10:80529597~80535942:-
BRCA	cis	rs2625529	0.938	rs4238447	ENSG00000260037.4	CTD-2524L6.3	-4.27	2.14e-05	0.00162	-0.19	-0.13	Red blood cell count;	chr15:71839539	chr15:71818396~71823384:+
BRCA	cis	rs9527	0.59	rs12246739	ENSG00000213061.2	PFN1P11	-4.27	2.14e-05	0.00162	-0.18	-0.13	Arsenic metabolism;	chr10:103027262	chr10:102838011~102845473:-
BRCA	cis	rs60843830	1	rs60149603	ENSG00000272342.1	RP13-539J13.1	4.27	2.14e-05	0.00162	0.17	0.13	Spherical equivalent (joint analysis main effects and education interaction);	chr2:285421	chr2:739588~740164:-
BRCA	cis	rs4869313	0.837	rs7726445	ENSG00000248734.2	CTD-2260A17.1	4.27	2.14e-05	0.00162	0.13	0.13	Pediatric autoimmune diseases;	chr5:96945339	chr5:96784777~96785999:+
BRCA	cis	rs6546324	0.625	rs2861687	ENSG00000236780.4	AC078941.1	4.27	2.14e-05	0.00162	0.23	0.13	Endometriosis;	chr2:67611052	chr2:67123357~67215319:-
BRCA	cis	rs9652601	0.691	rs12928726	ENSG00000274038.1	RP11-66H6.4	-4.27	2.14e-05	0.00162	-0.14	-0.13	Systemic lupus erythematosus;	chr16:11097715	chr16:11056556~11057034:+
BRCA	cis	rs10829156	0.66	rs10828901	ENSG00000225527.1	RP11-383B4.4	-4.27	2.14e-05	0.00162	-0.17	-0.13	Sudden cardiac arrest;	chr10:18552161	chr10:18531849~18533336:-
BRCA	cis	rs801193	1	rs3778909	ENSG00000223473.2	GS1-124K5.3	4.27	2.14e-05	0.00162	0.1	0.13	Aortic root size;	chr7:66790659	chr7:66491049~66493566:-
BRCA	cis	rs4787491	0.729	rs11150584	ENSG00000183604.13	SMG1P5	-4.27	2.14e-05	0.00162	-0.13	-0.13	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30028357	chr16:30267553~30335374:-
BRCA	cis	rs11098499	0.863	rs1383533	ENSG00000250412.1	KLHL2P1	4.27	2.14e-05	0.00162	0.16	0.13	Corneal astigmatism;	chr4:119513421	chr4:119334329~119378233:+
BRCA	cis	rs62103177	0.525	rs612913	ENSG00000278000.1	AC139100.4	-4.27	2.14e-05	0.00162	-0.2	-0.13	Opioid sensitivity;	chr18:80087974	chr18:80161752~80162413:+
BRCA	cis	rs745109	0.882	rs72930315	ENSG00000273080.1	RP11-301O19.1	4.27	2.14e-05	0.00162	0.21	0.13	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86427428	chr2:86195590~86196049:+
BRCA	cis	rs7267979	0.565	rs13040726	ENSG00000204556.4	CTD-2514C3.1	4.27	2.14e-05	0.00162	0.18	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25579245	chr20:26018832~26020684:+
BRCA	cis	rs6452524	0.935	rs6896953	ENSG00000281327.1	LINC01338	-4.27	2.14e-05	0.00162	-0.15	-0.13	Hypertension (SNP x SNP interaction);	chr5:83089284	chr5:82850864~82859836:-
BRCA	cis	rs4671400	0.571	rs2421116	ENSG00000273302.1	RP11-493E12.2	-4.27	2.14e-05	0.00162	-0.14	-0.13	3-hydroxypropylmercapturic acid levels in smokers;	chr2:61261276	chr2:61199979~61200769:+
BRCA	cis	rs1979679	0.801	rs7979524	ENSG00000278733.1	RP11-425D17.1	-4.27	2.14e-05	0.00162	-0.17	-0.13	Ossification of the posterior longitudinal ligament of the spine;	chr12:28550900	chr12:28185625~28186190:-
BRCA	cis	rs7811142	1	rs7803454	ENSG00000078319.8	PMS2P1	-4.27	2.14e-05	0.00162	-0.23	-0.13	Platelet count;	chr7:100393925	chr7:100320992~100341908:-
BRCA	cis	rs7811142	0.943	rs11769886	ENSG00000078319.8	PMS2P1	-4.27	2.14e-05	0.00162	-0.23	-0.13	Platelet count;	chr7:100400984	chr7:100320992~100341908:-
BRCA	cis	rs409045	1	rs461277	ENSG00000271874.1	CTD-2024P10.2	-4.27	2.14e-05	0.00162	-0.17	-0.13	Left ventricular mass;	chr5:34633480	chr5:34651457~34651888:-
BRCA	cis	rs17685	0.712	rs9800948	ENSG00000280388.1	RP11-229D13.3	-4.27	2.14e-05	0.00162	-0.13	-0.13	Coffee consumption (cups per day);Coffee consumption;	chr7:76181155	chr7:76043977~76045963:-
BRCA	cis	rs911119	1	rs3088162	ENSG00000270001.1	RP11-218C14.8	-4.27	2.14e-05	0.00162	-0.17	-0.13	Chronic kidney disease;	chr20:23627115	chr20:23631826~23632316:-
BRCA	cis	rs409045	1	rs462076	ENSG00000271874.1	CTD-2024P10.2	-4.27	2.14e-05	0.00162	-0.17	-0.13	Left ventricular mass;	chr5:34633853	chr5:34651457~34651888:-
BRCA	cis	rs6921919	0.515	rs1558205	ENSG00000273712.1	RP5-874C20.7	-4.27	2.14e-05	0.00162	-0.17	-0.13	Autism spectrum disorder or schizophrenia;	chr6:28414485	chr6:28315613~28315883:-
BRCA	cis	rs6545883	0.894	rs2694643	ENSG00000273302.1	RP11-493E12.2	4.27	2.14e-05	0.00162	0.12	0.13	Tuberculosis;	chr2:61377248	chr2:61199979~61200769:+
BRCA	cis	rs4578769	0.642	rs9957007	ENSG00000265939.1	UBE2CP2	4.27	2.14e-05	0.00162	0.17	0.13	Eosinophil percentage of white cells;	chr18:23037065	chr18:22900486~22900995:-
BRCA	cis	rs4835473	0.932	rs13117421	ENSG00000249741.2	RP11-673E1.3	4.27	2.14e-05	0.00162	0.15	0.13	Immature fraction of reticulocytes;	chr4:143769405	chr4:143911514~143912053:-
BRCA	cis	rs9840812	0.655	rs696516	ENSG00000239213.4	NCK1-AS1	4.27	2.14e-05	0.00162	0.16	0.13	Fibrinogen levels;	chr3:136348936	chr3:136841726~136862054:-
BRCA	cis	rs12612619	0.732	rs12613822	ENSG00000272148.1	RP11-195B17.1	4.27	2.14e-05	0.00162	0.15	0.13	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:26994234	chr2:27062428~27062907:-
BRCA	cis	rs1730008	1	rs827162	ENSG00000279311.1	RP11-170K4.2	-4.27	2.14e-05	0.00162	-0.15	-0.13	Lobe attachment (rater-scored or self-reported);	chr3:158305298	chr3:158869898~158871821:+
BRCA	cis	rs7811142	0.83	rs75636500	ENSG00000078319.8	PMS2P1	-4.27	2.14e-05	0.00162	-0.23	-0.13	Platelet count;	chr7:100350034	chr7:100320992~100341908:-
BRCA	cis	rs801193	0.967	rs34356500	ENSG00000273142.1	RP11-458F8.4	-4.27	2.14e-05	0.00162	-0.11	-0.13	Aortic root size;	chr7:66771620	chr7:66902857~66906297:+
BRCA	cis	rs4664293	1	rs10204535	ENSG00000226266.5	AC009961.3	-4.27	2.15e-05	0.00162	-0.16	-0.13	Monocyte percentage of white cells;	chr2:159607181	chr2:159670708~159712435:-
BRCA	cis	rs718314	1	rs1027087	ENSG00000256894.1	RP11-283G6.3	4.27	2.15e-05	0.00162	0.15	0.13	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Renal cell carcinoma;Waist circumference adjusted for body mass index;	chr12:26317917	chr12:26125155~26126617:-
BRCA	cis	rs6012564	0.964	rs2064853	ENSG00000227431.4	CSE1L-AS1	-4.27	2.15e-05	0.00162	-0.16	-0.13	Anger;	chr20:49058639	chr20:49040463~49046044:-
BRCA	cis	rs7177699	0.557	rs8027833	ENSG00000261143.1	ADAMTS7P3	-4.27	2.15e-05	0.00162	-0.16	-0.13	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78820495	chr15:77976042~77993057:+
BRCA	cis	rs11098499	1	rs10029750	ENSG00000260091.1	RP11-33B1.4	-4.27	2.15e-05	0.00162	-0.12	-0.13	Corneal astigmatism;	chr4:119251388	chr4:119409333~119410233:+
BRCA	cis	rs2832191	0.692	rs2254872	ENSG00000215533.7	LINC00189	-4.27	2.15e-05	0.00162	-0.15	-0.13	Dental caries;	chr21:29042403	chr21:29193480~29288205:+
BRCA	cis	rs28374715	0.783	rs11630656	ENSG00000247556.5	OIP5-AS1	4.27	2.15e-05	0.00162	0.16	0.13	Ulcerative colitis;	chr15:41278711	chr15:41283990~41309737:+
BRCA	cis	rs7267979	1	rs4815420	ENSG00000277938.1	RP5-965G21.3	-4.27	2.15e-05	0.00162	-0.16	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25403343	chr20:25229150~25231933:+
BRCA	cis	rs875971	0.545	rs11770063	ENSG00000230295.1	RP11-458F8.2	4.27	2.15e-05	0.00162	0.13	0.13	Aortic root size;	chr7:66318029	chr7:66880708~66882981:+
BRCA	cis	rs745109	0.751	rs1518808	ENSG00000273080.1	RP11-301O19.1	4.27	2.15e-05	0.00162	0.21	0.13	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86419070	chr2:86195590~86196049:+
BRCA	cis	rs4489787	1	rs61995742	ENSG00000240399.1	RP1-228P16.1	-4.27	2.15e-05	0.00162	-0.26	-0.13	Prostate cancer (SNP x SNP interaction);	chr12:48560247	chr12:48054813~48055591:-
BRCA	cis	rs6545883	0.542	rs10177225	ENSG00000270820.4	RP11-355B11.2	-4.27	2.15e-05	0.00163	-0.14	-0.13	Tuberculosis;	chr2:61367363	chr2:61471188~61484130:+
BRCA	cis	rs73242632	1	rs3755901	ENSG00000269949.1	RP11-738E22.3	4.27	2.15e-05	0.00163	0.31	0.13	Congenital heart disease (maternal effect);	chr4:56909830	chr4:56960927~56961373:-
BRCA	cis	rs1832007	0.58	rs72772226	ENSG00000224034.1	RP11-445P17.8	-4.27	2.15e-05	0.00163	-0.21	-0.13	Triglyceride levels;Triglycerides;	chr10:5203048	chr10:5266033~5271236:-
BRCA	cis	rs6012564	0.963	rs6125590	ENSG00000227431.4	CSE1L-AS1	4.27	2.15e-05	0.00163	0.17	0.13	Anger;	chr20:49204089	chr20:49040463~49046044:-
BRCA	cis	rs9925964	0.933	rs2303222	ENSG00000260911.2	RP11-196G11.2	-4.27	2.15e-05	0.00163	-0.12	-0.13	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31074149	chr16:31043150~31049868:+
BRCA	cis	rs13217239	0.646	rs12527111	ENSG00000224843.5	LINC00240	-4.27	2.15e-05	0.00163	-0.15	-0.13	Schizophrenia;	chr6:27038696	chr6:26956992~27023924:+
BRCA	cis	rs3176789	0.647	rs9971740	ENSG00000256673.1	RP11-599J14.2	4.27	2.15e-05	0.00163	0.15	0.13	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9768931	chr12:9398355~9414851:-
BRCA	cis	rs3176789	0.647	rs10772127	ENSG00000256673.1	RP11-599J14.2	4.27	2.15e-05	0.00163	0.15	0.13	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9769194	chr12:9398355~9414851:-
BRCA	cis	rs997295	0.713	rs9302246	ENSG00000270964.1	RP11-502I4.3	-4.27	2.15e-05	0.00163	-0.15	-0.13	Motion sickness;	chr15:67728942	chr15:67541072~67542604:-
BRCA	cis	rs2880765	0.835	rs4842887	ENSG00000202081.1	RNU6-1280P	4.27	2.15e-05	0.00163	0.15	0.13	Coronary artery disease;	chr15:85492579	chr15:85651522~85651628:-
BRCA	cis	rs2688608	0.592	rs11000760	ENSG00000213731.2	RAB5CP1	-4.27	2.15e-05	0.00163	-0.15	-0.13	Inflammatory bowel disease;	chr10:73733976	chr10:74423435~74424014:-
BRCA	cis	rs11742741	1	rs35670153	ENSG00000248874.4	C5orf17	-4.27	2.15e-05	0.00163	-0.17	-0.13	Educational attainment;	chr5:24176102	chr5:23951348~24178263:+
BRCA	cis	rs718314	0.64	rs1049376	ENSG00000256894.1	RP11-283G6.3	4.27	2.15e-05	0.00163	0.15	0.13	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Renal cell carcinoma;Waist circumference adjusted for body mass index;	chr12:26338542	chr12:26125155~26126617:-
BRCA	cis	rs9393777	0.841	rs13191474	ENSG00000216901.1	AL022393.7	4.27	2.15e-05	0.00163	0.31	0.13	Intelligence (multi-trait analysis);	chr6:27445566	chr6:28176188~28176674:+
BRCA	cis	rs7829975	0.688	rs7827182	ENSG00000173295.6	FAM86B3P	4.27	2.15e-05	0.00163	0.13	0.13	Mood instability;	chr8:8522961	chr8:8228595~8244865:+
BRCA	cis	rs61931739	0.534	rs4931783	ENSG00000258794.3	DUX4L27	4.27	2.15e-05	0.00163	0.19	0.13	Morning vs. evening chronotype;	chr12:33962387	chr12:34208415~34209675:-
BRCA	cis	rs7824557	0.767	rs11775635	ENSG00000248896.2	CTD-2135J3.3	4.27	2.16e-05	0.00163	0.18	0.13	Retinal vascular caliber;	chr8:11307356	chr8:10729314~10771392:+
BRCA	cis	rs11168618	0.846	rs7974213	ENSG00000240399.1	RP1-228P16.1	-4.27	2.16e-05	0.00163	-0.15	-0.13	Adiponectin levels;	chr12:48487709	chr12:48054813~48055591:-
BRCA	cis	rs1941184	0.5	rs8094212	ENSG00000266521.1	RP11-650P15.1	-4.27	2.16e-05	0.00163	-0.18	-0.13	Parkinson's disease (age of onset);	chr18:31454341	chr18:31496645~31497195:-
BRCA	cis	rs6545883	0.894	rs35292974	ENSG00000270820.4	RP11-355B11.2	-4.27	2.16e-05	0.00163	-0.15	-0.13	Tuberculosis;	chr2:61294912	chr2:61471188~61484130:+
BRCA	cis	rs11633886	0.565	rs1356881	ENSG00000273972.1	CTD-2306A12.1	4.27	2.16e-05	0.00163	0.15	0.13	Diisocyanate-induced asthma;	chr15:45781261	chr15:45702640~45703183:+
BRCA	cis	rs13401620	0.843	rs3768914	ENSG00000229326.3	AC069154.4	-4.27	2.16e-05	0.00163	-0.17	-0.13	Breast size;	chr2:119877629	chr2:119698623~119700151:+
BRCA	cis	rs7119	0.717	rs12916973	ENSG00000259362.2	RP11-307C19.1	4.27	2.16e-05	0.00163	0.18	0.13	Type 2 diabetes;	chr15:77515757	chr15:77525540~77534110:+
BRCA	cis	rs2243480	1	rs73142162	ENSG00000275400.1	RP4-756H11.5	4.27	2.16e-05	0.00163	0.24	0.13	Diabetic kidney disease;	chr7:65909309	chr7:66553805~66554199:-
BRCA	cis	rs16846053	0.792	rs2084545	ENSG00000227403.1	AC009299.3	4.27	2.16e-05	0.00163	0.34	0.13	Blood osmolality (transformed sodium);	chr2:161831980	chr2:161244739~161249050:+
BRCA	cis	rs7686660	1	rs4234884	ENSG00000250326.1	RP11-284M14.1	4.27	2.16e-05	0.00163	0.15	0.13	Asthma;	chr4:143060087	chr4:142933195~143184861:-
BRCA	cis	rs8180040	0.726	rs10461018	ENSG00000276925.1	RP11-708J19.3	4.27	2.16e-05	0.00163	0.15	0.13	Colorectal cancer;	chr3:46953752	chr3:47469777~47469987:+
BRCA	cis	rs13236243	0.673	rs11764350	ENSG00000237773.4	AC003075.4	4.27	2.16e-05	0.00163	0.17	0.13	Sensory disturbances after bilateral sagittal split ramus osteotomy;	chr7:17382489	chr7:17279834~17299357:-
BRCA	cis	rs10043228	1	rs12515308	ENSG00000271918.1	CTD-2287O16.5	-4.27	2.16e-05	0.00163	-0.16	-0.13	Asthma or chronic obstructive pulmonary disease;	chr5:116114744	chr5:116083807~116085416:-
BRCA	cis	rs6452524	1	rs2126988	ENSG00000281327.1	LINC01338	4.27	2.16e-05	0.00163	0.15	0.13	Hypertension (SNP x SNP interaction);	chr5:83146496	chr5:82850864~82859836:-
BRCA	cis	rs5758511	0.689	rs5758691	ENSG00000226450.2	CYP2D8P	4.27	2.16e-05	0.00163	0.15	0.13	Birth weight;	chr22:42272498	chr22:42149886~42155001:-
BRCA	cis	rs6736093	0.966	rs11682629	ENSG00000236307.2	EEF1E1P1	-4.27	2.16e-05	0.00163	-0.17	-0.13	Coronary artery disease;	chr2:111986722	chr2:111887914~111888741:+
BRCA	cis	rs6736093	0.966	rs11685190	ENSG00000236307.2	EEF1E1P1	-4.27	2.16e-05	0.00163	-0.17	-0.13	Coronary artery disease;	chr2:111991127	chr2:111887914~111888741:+
BRCA	cis	rs13401620	0.763	rs3106241	ENSG00000229326.3	AC069154.4	-4.27	2.16e-05	0.00163	-0.17	-0.13	Breast size;	chr2:119900567	chr2:119698623~119700151:+
BRCA	cis	rs67340775	0.541	rs200979	ENSG00000216901.1	AL022393.7	4.27	2.16e-05	0.00163	0.21	0.13	Lung cancer in ever smokers;	chr6:27884579	chr6:28176188~28176674:+
BRCA	cis	rs91731	1	rs268732	ENSG00000249572.1	CTD-2203K17.1	4.27	2.16e-05	0.00163	0.28	0.13	Lung function (FVC);	chr5:33384414	chr5:33424025~33440619:-
BRCA	cis	rs9840812	0.69	rs1618069	ENSG00000273486.1	RP11-731C17.2	4.27	2.16e-05	0.00163	0.16	0.13	Fibrinogen levels;	chr3:136308303	chr3:136837338~136839021:-
BRCA	cis	rs370915	0.564	rs10027461	ENSG00000250971.1	RP11-696F12.1	4.27	2.16e-05	0.00163	0.13	0.13	Gout;	chr4:186916454	chr4:187060099~187060930:+
BRCA	cis	rs2274273	0.624	rs3783651	ENSG00000259318.1	RP11-454L9.2	4.27	2.16e-05	0.00163	0.12	0.13	Protein biomarker;	chr14:55384255	chr14:55394940~55395233:-
BRCA	cis	rs7833986	0.501	rs2719261	ENSG00000253603.1	CTA-397H3.3	-4.27	2.16e-05	0.00163	-0.18	-0.13	Height;	chr8:56029423	chr8:56074592~56075274:+
BRCA	cis	rs8114671	0.836	rs62213676	ENSG00000126005.14	MMP24-AS1	4.27	2.16e-05	0.00163	0.15	0.13	Height;	chr20:35024873	chr20:35216462~35278131:-
BRCA	cis	rs2333021	1	rs4899453	ENSG00000259015.1	RP11-109N23.6	-4.27	2.16e-05	0.00163	-0.13	-0.13	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:73021883	chr14:72960595~72961993:+
BRCA	cis	rs6012564	1	rs2252259	ENSG00000227431.4	CSE1L-AS1	-4.27	2.16e-05	0.00163	-0.16	-0.13	Anger;	chr20:49046286	chr20:49040463~49046044:-
BRCA	cis	rs7011507	0.7	rs72639010	ENSG00000279881.1	RP11-513O13.1	-4.27	2.16e-05	0.00163	-0.2	-0.13	Inflammatory bowel disease;Ulcerative colitis;	chr8:48417761	chr8:48428143~48431041:-
BRCA	cis	rs2136613	0.533	rs10740088	ENSG00000238280.1	RP11-436D10.3	-4.27	2.16e-05	0.00163	-0.17	-0.13	Selective IgA deficiency;	chr10:62849651	chr10:62793562~62805887:-
BRCA	cis	rs2136613	0.533	rs10740089	ENSG00000238280.1	RP11-436D10.3	-4.27	2.16e-05	0.00163	-0.17	-0.13	Selective IgA deficiency;	chr10:62849674	chr10:62793562~62805887:-
BRCA	cis	rs7267979	0.549	rs6138537	ENSG00000276952.1	RP5-965G21.6	4.27	2.16e-05	0.00163	0.16	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25203830	chr20:25284915~25285588:-
BRCA	cis	rs3748682	1	rs3748682	ENSG00000222282.1	RNU6-584P	4.27	2.16e-05	0.00163	0.16	0.13	Hypothyroidism;	chr1:37814315	chr1:37885023~37885117:+
BRCA	cis	rs1910358	0.554	rs4701387	ENSG00000248874.4	C5orf17	-4.27	2.16e-05	0.00163	-0.19	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23733123	chr5:23951348~24178263:+
BRCA	cis	rs1910358	0.554	rs10076847	ENSG00000248874.4	C5orf17	-4.27	2.16e-05	0.00163	-0.19	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23734083	chr5:23951348~24178263:+
BRCA	cis	rs10458771	0.667	rs73346400	ENSG00000227896.2	RP11-77P6.2	4.27	2.16e-05	0.00163	0.21	0.13	Amyotrophic lateral sclerosis (sporadic);	chr10:86420211	chr10:86521945~86525101:+
BRCA	cis	rs6921919	0.583	rs7764722	ENSG00000273712.1	RP5-874C20.7	4.27	2.16e-05	0.00163	0.17	0.13	Autism spectrum disorder or schizophrenia;	chr6:28386756	chr6:28315613~28315883:-
BRCA	cis	rs6088580	0.634	rs11700221	ENSG00000276073.1	RP5-1125A11.7	4.27	2.16e-05	0.00163	0.14	0.13	Glomerular filtration rate (creatinine);	chr20:34352514	chr20:33985617~33988989:-
BRCA	cis	rs9818758	0.607	rs34784192	ENSG00000225399.4	RP11-3B7.1	-4.27	2.16e-05	0.00163	-0.2	-0.13	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49237390	chr3:49260085~49261316:+
BRCA	cis	rs739496	0.793	rs73199895	ENSG00000234608.6	MAPKAPK5-AS1	4.27	2.16e-05	0.00163	0.16	0.13	Platelet count;	chr12:111428283	chr12:111839764~111842902:-
BRCA	cis	rs9650657	0.801	rs4841437	ENSG00000154316.13	TDH	4.27	2.16e-05	0.00163	0.17	0.13	Neuroticism;	chr8:10739285	chr8:11339637~11368452:+
BRCA	cis	rs56174355	0.915	rs7225370	ENSG00000264513.1	RP11-556O9.2	4.27	2.16e-05	0.00163	0.2	0.13	Diastolic blood pressure;	chr17:62957020	chr17:63117019~63130947:-
BRCA	cis	rs11673344	0.523	rs7256380	ENSG00000226686.6	LINC01535	4.27	2.17e-05	0.00163	0.17	0.13	Obesity-related traits;	chr19:37041178	chr19:37251912~37265535:+
BRCA	cis	rs896854	0.738	rs1713669	ENSG00000245080.5	RP11-320N21.1	4.27	2.17e-05	0.00163	0.16	0.13	Type 2 diabetes;	chr8:94946409	chr8:95066808~95073182:-
BRCA	cis	rs10895275	0.625	rs10791569	ENSG00000277459.1	RP11-732A21.3	-4.27	2.17e-05	0.00164	-0.13	-0.13	Migraine;	chr11:102217604	chr11:102109827~102110457:-
BRCA	cis	rs13113518	1	rs4864546	ENSG00000272969.1	RP11-528I4.2	4.27	2.17e-05	0.00164	0.15	0.13	Height;	chr4:55537960	chr4:55547112~55547889:+
BRCA	cis	rs4302906	0.689	rs13300085	ENSG00000187984.11	ANKRD19P	-4.27	2.17e-05	0.00164	-0.12	-0.13	Lobe attachment (rater-scored or self-reported);	chr9:93005798	chr9:92809388~92888693:+
BRCA	cis	rs7572733	0.84	rs700648	ENSG00000231621.1	AC013264.2	-4.27	2.17e-05	0.00164	-0.12	-0.13	Dermatomyositis;	chr2:197757912	chr2:197197991~197199273:+
BRCA	cis	rs7572733	0.84	rs700649	ENSG00000231621.1	AC013264.2	-4.27	2.17e-05	0.00164	-0.12	-0.13	Dermatomyositis;	chr2:197758028	chr2:197197991~197199273:+
BRCA	cis	rs7572733	0.84	rs700650	ENSG00000231621.1	AC013264.2	-4.27	2.17e-05	0.00164	-0.12	-0.13	Dermatomyositis;	chr2:197759561	chr2:197197991~197199273:+
BRCA	cis	rs7572733	0.811	rs771013	ENSG00000231621.1	AC013264.2	-4.27	2.17e-05	0.00164	-0.12	-0.13	Dermatomyositis;	chr2:197760513	chr2:197197991~197199273:+
BRCA	cis	rs7572733	0.84	rs1065949	ENSG00000231621.1	AC013264.2	-4.27	2.17e-05	0.00164	-0.12	-0.13	Dermatomyositis;	chr2:197762331	chr2:197197991~197199273:+
BRCA	cis	rs7572733	0.84	rs700653	ENSG00000231621.1	AC013264.2	-4.27	2.17e-05	0.00164	-0.12	-0.13	Dermatomyositis;	chr2:197772709	chr2:197197991~197199273:+
BRCA	cis	rs7572733	0.84	rs700654	ENSG00000231621.1	AC013264.2	-4.27	2.17e-05	0.00164	-0.12	-0.13	Dermatomyositis;	chr2:197778697	chr2:197197991~197199273:+
BRCA	cis	rs10129255	0.536	rs3944157	ENSG00000211967.3	IGHV3-53	-4.27	2.17e-05	0.00164	-0.09	-0.13	Kawasaki disease;	chr14:106682286	chr14:106592676~106593347:-
BRCA	cis	rs7824557	0.603	rs2249804	ENSG00000255046.1	RP11-297N6.4	-4.27	2.17e-05	0.00164	-0.15	-0.13	Retinal vascular caliber;	chr8:11358108	chr8:11797928~11802568:-
BRCA	cis	rs2599510	0.744	rs2254106	ENSG00000276517.1	AL133243.2	-4.27	2.17e-05	0.00164	-0.16	-0.13	Interleukin-18 levels;	chr2:32543730	chr2:32526504~32529507:+
BRCA	cis	rs893818	1	rs67173550	ENSG00000261801.4	LOXL1-AS1	4.27	2.17e-05	0.00164	0.16	0.13	Exfoliation glaucoma or exfoliation syndrome;	chr15:73937136	chr15:73908071~73928248:-
BRCA	cis	rs9470794	0.831	rs73419457	ENSG00000204110.6	RP1-153P14.8	-4.27	2.17e-05	0.00164	-0.26	-0.13	Type 2 diabetes;	chr6:37898013	chr6:37507348~37535616:+
BRCA	cis	rs10895987	0.955	rs7113761	ENSG00000255200.1	AP003068.18	4.27	2.17e-05	0.00164	0.18	0.13	Blood protein levels;	chr11:65159251	chr11:65174117~65176470:-
BRCA	cis	rs9840812	0.861	rs687339	ENSG00000273486.1	RP11-731C17.2	4.27	2.17e-05	0.00164	0.17	0.13	Fibrinogen levels;	chr3:136213517	chr3:136837338~136839021:-
BRCA	cis	rs4415084	0.68	rs4495192	ENSG00000251141.4	RP11-53O19.1	-4.27	2.17e-05	0.00164	-0.13	-0.13	Breast cancer;	chr5:44929075	chr5:44744900~44808777:-
BRCA	cis	rs8099594	0.666	rs573978	ENSG00000266696.1	RP11-30L3.2	4.27	2.17e-05	0.00164	0.15	0.13	Height;	chr18:49300942	chr18:49205912~49208781:+
BRCA	cis	rs2243480	1	rs1701758	ENSG00000275400.1	RP4-756H11.5	4.27	2.17e-05	0.00164	0.24	0.13	Diabetic kidney disease;	chr7:66005214	chr7:66553805~66554199:-
BRCA	cis	rs10129255	0.5	rs1024350	ENSG00000211959.2	IGHV4-39	4.27	2.17e-05	0.00164	0.09	0.13	Kawasaki disease;	chr14:106685105	chr14:106421711~106422218:-
BRCA	cis	rs11977715	0.538	rs43067	ENSG00000233942.1	AC004012.1	-4.27	2.17e-05	0.00164	-0.16	-0.13	Middle childhood and early adolescence aggressive behavior;	chr7:95485392	chr7:95471835~95473998:+
BRCA	cis	rs490234	0.586	rs12553548	ENSG00000232630.1	PRPS1P2	-4.27	2.17e-05	0.00164	-0.13	-0.13	Mean arterial pressure;	chr9:125392982	chr9:125150653~125151589:+
BRCA	cis	rs6012564	1	rs3091866	ENSG00000227431.4	CSE1L-AS1	-4.27	2.17e-05	0.00164	-0.16	-0.13	Anger;	chr20:49031816	chr20:49040463~49046044:-
BRCA	cis	rs62388641	0.547	rs4513844	ENSG00000272279.1	RP11-157J24.2	-4.27	2.17e-05	0.00164	-0.16	-0.13	Daytime sleep phenotypes;	chr6:1551747	chr6:1528364~1528911:-
BRCA	cis	rs10829156	0.945	rs10829199	ENSG00000240291.1	RP11-499P20.2	4.27	2.17e-05	0.00164	0.15	0.13	Sudden cardiac arrest;	chr10:18679012	chr10:18513115~18545651:-
BRCA	cis	rs11673344	0.523	rs10406110	ENSG00000276846.1	CTD-3220F14.3	4.27	2.17e-05	0.00164	0.16	0.13	Obesity-related traits;	chr19:37160027	chr19:37314868~37315620:-
BRCA	cis	rs5758511	0.68	rs56111723	ENSG00000227370.1	RP4-669P10.19	4.27	2.17e-05	0.00164	0.17	0.13	Birth weight;	chr22:42268877	chr22:42132543~42132998:+
BRCA	cis	rs11098499	0.955	rs6815725	ENSG00000250412.1	KLHL2P1	4.27	2.17e-05	0.00164	0.16	0.13	Corneal astigmatism;	chr4:119237255	chr4:119334329~119378233:+
BRCA	cis	rs748404	0.666	rs7177146	ENSG00000205771.5	CATSPER2P1	-4.27	2.17e-05	0.00164	-0.2	-0.13	Lung cancer;	chr15:43506110	chr15:43726918~43747094:-
BRCA	cis	rs9652601	0.649	rs12599402	ENSG00000274038.1	RP11-66H6.4	-4.27	2.17e-05	0.00164	-0.14	-0.13	Systemic lupus erythematosus;	chr16:11096031	chr16:11056556~11057034:+
BRCA	cis	rs6686842	0.536	rs61774707	ENSG00000235358.1	RP11-399E6.1	-4.27	2.17e-05	0.00164	-0.18	-0.13	Height;	chr1:41247552	chr1:41242373~41284861:+
BRCA	cis	rs1865760	0.929	rs9358896	ENSG00000272462.2	U91328.19	-4.27	2.17e-05	0.00164	-0.16	-0.13	Height;	chr6:25942969	chr6:25992662~26001775:+
BRCA	cis	rs2136613	0.505	rs10761674	ENSG00000238280.1	RP11-436D10.3	-4.27	2.18e-05	0.00164	-0.17	-0.13	Selective IgA deficiency;	chr10:62858580	chr10:62793562~62805887:-
BRCA	cis	rs1858037	0.806	rs12612780	ENSG00000281920.1	RP11-418H16.1	4.27	2.18e-05	0.00164	0.17	0.13	Rheumatoid arthritis;	chr2:65355967	chr2:65623272~65628424:+
BRCA	cis	rs6736093	0.966	rs13020304	ENSG00000236307.2	EEF1E1P1	-4.27	2.18e-05	0.00164	-0.17	-0.13	Coronary artery disease;	chr2:111983958	chr2:111887914~111888741:+
BRCA	cis	rs8114671	0.967	rs1577924	ENSG00000279253.1	RP4-614O4.13	4.27	2.18e-05	0.00164	0.15	0.13	Height;	chr20:35196485	chr20:35262727~35264187:-
BRCA	cis	rs17801127	0.901	rs16827309	ENSG00000231969.1	AC144449.1	4.27	2.18e-05	0.00164	0.24	0.13	Liver enzyme levels (alanine transaminase);	chr2:149666098	chr2:149587196~149848233:+
BRCA	cis	rs4415084	0.744	rs1371023	ENSG00000251141.4	RP11-53O19.1	-4.27	2.18e-05	0.00164	-0.12	-0.13	Breast cancer;	chr5:44846473	chr5:44744900~44808777:-
BRCA	cis	rs7267979	1	rs2500436	ENSG00000276952.1	RP5-965G21.6	-4.27	2.18e-05	0.00164	-0.16	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25425730	chr20:25284915~25285588:-
BRCA	cis	rs8114671	0.836	rs6141526	ENSG00000126005.14	MMP24-AS1	4.27	2.18e-05	0.00164	0.15	0.13	Height;	chr20:35027452	chr20:35216462~35278131:-
BRCA	cis	rs2489715	1	rs2246565	ENSG00000185904.10	LINC00839	-4.27	2.18e-05	0.00164	-0.17	-0.13	Helix rolling;	chr10:42402200	chr10:42475543~42495336:+
BRCA	cis	rs12786942	1	rs12793746	ENSG00000254506.1	RP11-748H22.1	4.27	2.18e-05	0.00164	0.23	0.13	Facial depth;	chr11:101497254	chr11:101584295~101595156:+
BRCA	cis	rs7267979	0.706	rs6037069	ENSG00000204556.4	CTD-2514C3.1	-4.27	2.18e-05	0.00164	-0.18	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25253530	chr20:26018832~26020684:+
BRCA	cis	rs6546324	0.625	rs6546317	ENSG00000236780.4	AC078941.1	4.26	2.18e-05	0.00164	0.23	0.13	Endometriosis;	chr2:67601661	chr2:67123357~67215319:-
BRCA	cis	rs698833	0.501	rs10194161	ENSG00000223658.6	AC011242.6	-4.26	2.18e-05	0.00164	-0.16	-0.13	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr2:44280074	chr2:43675380~43676322:-
BRCA	cis	rs13034020	0.522	rs4564760	ENSG00000271889.1	RP11-493E12.1	-4.26	2.18e-05	0.00164	-0.19	-0.13	Hodgkin's lymphoma;	chr2:61021440	chr2:61151433~61162105:-
BRCA	cis	rs8054556	1	rs9925915	ENSG00000214725.6	CDIPT-AS1	-4.26	2.18e-05	0.00164	-0.16	-0.13	Autism spectrum disorder or schizophrenia;	chr16:29982365	chr16:29863593~29868053:+
BRCA	cis	rs7208859	0.623	rs122898	ENSG00000276250.1	CTD-2349P21.12	4.26	2.18e-05	0.00164	0.21	0.13	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30578236	chr17:30803654~30804077:+
BRCA	cis	rs2380205	0.538	rs1976655	ENSG00000232807.2	RP11-536K7.3	4.26	2.18e-05	0.00165	0.14	0.13	Breast cancer;	chr10:5880766	chr10:5934270~5945900:-
BRCA	cis	rs6860806	0.695	rs11952099	ENSG00000233006.5	AC034220.3	4.26	2.18e-05	0.00165	0.09	0.13	Breast cancer;	chr5:132241079	chr5:132311285~132369916:-
BRCA	cis	rs11096990	0.656	rs3733284	ENSG00000249685.1	RP11-360F5.3	-4.26	2.18e-05	0.00165	-0.16	-0.13	Cognitive function;	chr4:39299714	chr4:39133913~39135608:+
BRCA	cis	rs11779988	0.545	rs411531	ENSG00000253671.1	RP11-806O11.1	-4.26	2.18e-05	0.00165	-0.19	-0.13	Breast cancer;	chr8:17938425	chr8:17808941~17820868:+
BRCA	cis	rs6585424	1	rs12268619	ENSG00000225484.5	NUTM2B-AS1	-4.26	2.18e-05	0.00165	-0.25	-0.13	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80160904	chr10:79663088~79826594:-
BRCA	cis	rs7591472	1	rs7591472	ENSG00000201499.1	RNU6-312P	-4.26	2.18e-05	0.00165	-0.18	-0.13	Triptolide cytotoxicity;	chr2:201025028	chr2:200881715~200881821:-
BRCA	cis	rs7833986	0.501	rs72653941	ENSG00000253603.1	CTA-397H3.3	-4.26	2.18e-05	0.00165	-0.18	-0.13	Height;	chr8:56029688	chr8:56074592~56075274:+
BRCA	cis	rs62458065	0.85	rs7785659	ENSG00000229358.3	DPY19L1P1	-4.26	2.18e-05	0.00165	-0.18	-0.13	Metabolite levels (HVA/MHPG ratio);	chr7:32421403	chr7:32580949~32761787:-
BRCA	cis	rs875971	0.789	rs28815324	ENSG00000230295.1	RP11-458F8.2	-4.26	2.18e-05	0.00165	-0.13	-0.13	Aortic root size;	chr7:66100789	chr7:66880708~66882981:+
BRCA	cis	rs1832007	0.554	rs11596429	ENSG00000224034.1	RP11-445P17.8	-4.26	2.18e-05	0.00165	-0.21	-0.13	Triglyceride levels;Triglycerides;	chr10:5203345	chr10:5266033~5271236:-
BRCA	cis	rs9573567	0.881	rs6562897	ENSG00000261553.4	RP11-29G8.3	4.26	2.18e-05	0.00165	0.28	0.13	Red blood cell count;Mean corpuscular volume;	chr13:75502157	chr13:75549773~75807120:+
BRCA	cis	rs9573567	1	rs4242961	ENSG00000261553.4	RP11-29G8.3	4.26	2.18e-05	0.00165	0.28	0.13	Red blood cell count;Mean corpuscular volume;	chr13:75503772	chr13:75549773~75807120:+
BRCA	cis	rs6928977	0.5	rs3734213	ENSG00000234084.1	RP3-388E23.2	-4.26	2.19e-05	0.00165	-0.13	-0.13	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135620170	chr6:135301568~135307158:+
BRCA	cis	rs853679	0.567	rs13209596	ENSG00000220721.1	OR1F12	4.26	2.19e-05	0.00165	0.17	0.13	Depression;	chr6:28428413	chr6:28073316~28074233:+
BRCA	cis	rs10851478	0.802	rs7178146	ENSG00000259531.2	RP11-295H24.3	-4.26	2.19e-05	0.00165	-0.18	-0.13	Oral cavity cancer;	chr15:49712620	chr15:49365124~49366685:-
BRCA	cis	rs893818	1	rs4886785	ENSG00000261801.4	LOXL1-AS1	4.26	2.19e-05	0.00165	0.16	0.13	Exfoliation glaucoma or exfoliation syndrome;	chr15:73937450	chr15:73908071~73928248:-
BRCA	cis	rs7771547	0.723	rs12153820	ENSG00000224666.3	RP1-50J22.4	4.26	2.19e-05	0.00165	0.16	0.13	Platelet distribution width;	chr6:36586253	chr6:36386831~36393462:+
BRCA	cis	rs2108622	1	rs62107762	ENSG00000267218.2	AC005336.5	4.26	2.19e-05	0.00165	0.17	0.13	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871728	chr19:15902300~15903238:-
BRCA	cis	rs1858037	0.765	rs67404371	ENSG00000281920.1	RP11-418H16.1	4.26	2.19e-05	0.00165	0.17	0.13	Rheumatoid arthritis;	chr2:65370137	chr2:65623272~65628424:+
BRCA	cis	rs6439153	0.933	rs6799008	ENSG00000261159.1	RP11-723O4.9	4.26	2.19e-05	0.00165	0.14	0.13	Pneumococcal bacteremia;	chr3:128998544	chr3:128859716~128860526:-
BRCA	cis	rs4489787	0.892	rs2705159	ENSG00000240399.1	RP1-228P16.1	4.26	2.19e-05	0.00165	0.2	0.13	Prostate cancer (SNP x SNP interaction);	chr12:48508409	chr12:48054813~48055591:-
BRCA	cis	rs10266483	0.739	rs55747800	ENSG00000228653.2	HNRNPCP7	4.26	2.19e-05	0.00165	0.17	0.13	Response to statin therapy;	chr7:64410105	chr7:64500825~64501729:+
BRCA	cis	rs10266483	0.774	rs56055804	ENSG00000228653.2	HNRNPCP7	4.26	2.19e-05	0.00165	0.17	0.13	Response to statin therapy;	chr7:64410423	chr7:64500825~64501729:+
BRCA	cis	rs6545883	0.965	rs2305155	ENSG00000270820.4	RP11-355B11.2	4.26	2.19e-05	0.00165	0.15	0.13	Tuberculosis;	chr2:61502123	chr2:61471188~61484130:+
BRCA	cis	rs783540	0.609	rs803686	ENSG00000255769.6	GOLGA2P10	4.26	2.19e-05	0.00165	0.17	0.13	Schizophrenia;	chr15:82550590	chr15:82472993~82513950:-
BRCA	cis	rs2832191	0.692	rs8134627	ENSG00000215533.7	LINC00189	4.26	2.19e-05	0.00165	0.15	0.13	Dental caries;	chr21:28976747	chr21:29193480~29288205:+
BRCA	cis	rs7260598	0.642	rs10403746	ENSG00000268442.1	CTD-2027I19.2	4.26	2.19e-05	0.00165	0.2	0.13	Response to taxane treatment (placlitaxel);	chr19:23924452	chr19:24162370~24163425:-
BRCA	cis	rs11098499	0.619	rs28502463	ENSG00000225892.3	RP11-384K6.2	4.26	2.19e-05	0.00165	0.13	0.13	Corneal astigmatism;	chr4:119335868	chr4:118632274~118634759:+
BRCA	cis	rs17489649	1	rs2042165	ENSG00000271849.1	CTC-332L22.1	4.26	2.19e-05	0.00165	0.17	0.13	Intelligence (multi-trait analysis);	chr5:109801619	chr5:109687802~109688329:-
BRCA	cis	rs3768617	0.782	rs12146099	ENSG00000224468.3	RP11-181K3.4	-4.26	2.19e-05	0.00165	-0.15	-0.13	Fuchs's corneal dystrophy;	chr1:182998944	chr1:183138402~183141282:-
BRCA	cis	rs1124609	1	rs111705530	ENSG00000244879.4	GABPB1-AS1	4.26	2.19e-05	0.00165	0.27	0.13	Subjective well-being;	chr15:50186235	chr15:50354959~50372202:+
BRCA	cis	rs12681366	0.564	rs2165405	ENSG00000253175.1	RP11-267M23.6	4.26	2.19e-05	0.00165	0.16	0.13	Nonsyndromic cleft lip with cleft palate;	chr8:94442079	chr8:94565036~94565715:+
BRCA	cis	rs9818758	0.607	rs13077498	ENSG00000270441.1	RP11-694I15.7	4.26	2.19e-05	0.00165	0.26	0.13	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49276545	chr3:49140086~49160851:-
BRCA	cis	rs1722141	0.601	rs2464927	ENSG00000229628.1	AC073115.7	-4.26	2.19e-05	0.00165	-0.18	-0.13	Sitting height ratio;	chr7:46036579	chr7:45990905~46000898:+
BRCA	cis	rs2486012	1	rs2485991	ENSG00000237950.1	RP11-7O11.3	4.26	2.19e-05	0.00165	0.2	0.13	Intelligence (multi-trait analysis);	chr1:43926050	chr1:43944370~43946551:-
BRCA	cis	rs853679	0.517	rs9368556	ENSG00000216901.1	AL022393.7	4.26	2.19e-05	0.00165	0.19	0.13	Depression;	chr6:28163375	chr6:28176188~28176674:+
BRCA	cis	rs853679	0.517	rs9368557	ENSG00000216901.1	AL022393.7	4.26	2.19e-05	0.00165	0.19	0.13	Depression;	chr6:28163759	chr6:28176188~28176674:+
BRCA	cis	rs853679	0.517	rs9380059	ENSG00000216901.1	AL022393.7	4.26	2.19e-05	0.00165	0.19	0.13	Depression;	chr6:28164580	chr6:28176188~28176674:+
BRCA	cis	rs853679	0.517	rs9380060	ENSG00000216901.1	AL022393.7	4.26	2.19e-05	0.00165	0.19	0.13	Depression;	chr6:28164825	chr6:28176188~28176674:+
BRCA	cis	rs853679	0.517	rs35227624	ENSG00000216901.1	AL022393.7	4.26	2.19e-05	0.00165	0.19	0.13	Depression;	chr6:28164948	chr6:28176188~28176674:+
BRCA	cis	rs853679	0.517	rs9380061	ENSG00000216901.1	AL022393.7	4.26	2.19e-05	0.00165	0.19	0.13	Depression;	chr6:28165025	chr6:28176188~28176674:+
BRCA	cis	rs853679	0.517	rs9368558	ENSG00000216901.1	AL022393.7	4.26	2.19e-05	0.00165	0.19	0.13	Depression;	chr6:28165528	chr6:28176188~28176674:+
BRCA	cis	rs7200543	1	rs34614532	ENSG00000207425.1	Y_RNA	-4.26	2.19e-05	0.00165	-0.16	-0.13	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15039051	chr16:14915457~14915556:-
BRCA	cis	rs6545883	0.894	rs35292974	ENSG00000212978.6	AC016747.3	-4.26	2.19e-05	0.00165	-0.17	-0.13	Tuberculosis;	chr2:61294912	chr2:61141592~61144969:-
BRCA	cis	rs7800418	0.784	rs757809	ENSG00000214870.7	AC004540.5	4.26	2.19e-05	0.00165	0.17	0.13	Cognitive function;	chr7:26547637	chr7:26398593~26494256:+
BRCA	cis	rs4948275	0.631	rs2650743	ENSG00000237233.2	TMEM26-AS1	-4.26	2.19e-05	0.00165	-0.15	-0.13	Night sleep phenotypes;	chr10:61590160	chr10:61452639~61481956:+
BRCA	cis	rs7011507	0.7	rs72639011	ENSG00000279881.1	RP11-513O13.1	-4.26	2.19e-05	0.00165	-0.2	-0.13	Inflammatory bowel disease;Ulcerative colitis;	chr8:48419755	chr8:48428143~48431041:-
BRCA	cis	rs7011507	0.7	rs72639012	ENSG00000279881.1	RP11-513O13.1	-4.26	2.19e-05	0.00165	-0.2	-0.13	Inflammatory bowel disease;Ulcerative colitis;	chr8:48419869	chr8:48428143~48431041:-
BRCA	cis	rs7011507	0.7	rs72639013	ENSG00000279881.1	RP11-513O13.1	-4.26	2.19e-05	0.00165	-0.2	-0.13	Inflammatory bowel disease;Ulcerative colitis;	chr8:48420070	chr8:48428143~48431041:-
BRCA	cis	rs1910358	0.554	rs11957643	ENSG00000248874.4	C5orf17	-4.26	2.19e-05	0.00165	-0.19	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23731916	chr5:23951348~24178263:+
BRCA	cis	rs7572733	0.555	rs2342558	ENSG00000231621.1	AC013264.2	-4.26	2.19e-05	0.00165	-0.13	-0.13	Dermatomyositis;	chr2:198055418	chr2:197197991~197199273:+
BRCA	cis	rs6121246	0.865	rs6058421	ENSG00000230613.1	HM13-AS1	4.26	2.19e-05	0.00165	0.19	0.13	Mean corpuscular hemoglobin;	chr20:31707210	chr20:31567707~31573263:-
BRCA	cis	rs801193	0.66	rs1962050	ENSG00000236529.1	RP13-254B10.1	-4.26	2.2e-05	0.00165	-0.14	-0.13	Aortic root size;	chr7:66775021	chr7:65840212~65840596:+
BRCA	cis	rs7520050	0.898	rs4660885	ENSG00000281133.1	AL355480.3	4.26	2.2e-05	0.00165	0.15	0.13	Reticulocyte count;Red blood cell count;	chr1:45778084	chr1:45580892~45580996:-
BRCA	cis	rs56116382	0.604	rs9858428	ENSG00000225399.4	RP11-3B7.1	-4.26	2.2e-05	0.00165	-0.24	-0.13	High light scatter reticulocyte count;Intelligence (multi-trait analysis);	chr3:49840152	chr3:49260085~49261316:+
BRCA	cis	rs11098499	0.908	rs11098527	ENSG00000260091.1	RP11-33B1.4	-4.26	2.2e-05	0.00165	-0.12	-0.13	Corneal astigmatism;	chr4:119478751	chr4:119409333~119410233:+
BRCA	cis	rs10829156	0.699	rs6482516	ENSG00000225527.1	RP11-383B4.4	-4.26	2.2e-05	0.00166	-0.17	-0.13	Sudden cardiac arrest;	chr10:18550421	chr10:18531849~18533336:-
BRCA	cis	rs6921919	0.583	rs11755942	ENSG00000273712.1	RP5-874C20.7	4.26	2.2e-05	0.00166	0.17	0.13	Autism spectrum disorder or schizophrenia;	chr6:28401760	chr6:28315613~28315883:-
BRCA	cis	rs12435908	1	rs2152375	ENSG00000276116.2	FUT8-AS1	-4.26	2.2e-05	0.00166	-0.22	-0.13	Ischemic stroke;	chr14:65449060	chr14:65411170~65412690:-
BRCA	cis	rs7927592	0.956	rs11228278	ENSG00000212093.1	AP000807.1	4.26	2.2e-05	0.00166	0.14	0.13	Total body bone mineral density;	chr11:68541062	chr11:68506083~68506166:-
BRCA	cis	rs6570726	0.935	rs392014	ENSG00000270638.1	RP3-466P17.1	4.26	2.2e-05	0.00166	0.14	0.13	Lobe attachment (rater-scored or self-reported);	chr6:145522555	chr6:145735570~145737218:+
BRCA	cis	rs12681366	0.537	rs2197004	ENSG00000253175.1	RP11-267M23.6	4.26	2.2e-05	0.00166	0.16	0.13	Nonsyndromic cleft lip with cleft palate;	chr8:94444748	chr8:94565036~94565715:+
BRCA	cis	rs7789940	0.904	rs73140040	ENSG00000186704.9	DTX2P1	4.26	2.2e-05	0.00166	0.16	0.13	Multiple sclerosis;	chr7:76306923	chr7:76978617~77004308:+
BRCA	cis	rs8181477	0.764	rs11014484	ENSG00000240291.1	RP11-499P20.2	-4.26	2.2e-05	0.00166	-0.13	-0.13	Obesity-related traits;	chr10:18490395	chr10:18513115~18545651:-
BRCA	cis	rs6963495	0.818	rs55922564	ENSG00000223886.3	RP11-251G23.2	4.26	2.2e-05	0.00166	0.2	0.13	Bipolar disorder (body mass index interaction);	chr7:105515443	chr7:105530209~105530671:+
BRCA	cis	rs6963495	0.818	rs73190161	ENSG00000223886.3	RP11-251G23.2	4.26	2.2e-05	0.00166	0.2	0.13	Bipolar disorder (body mass index interaction);	chr7:105516424	chr7:105530209~105530671:+
BRCA	cis	rs6963495	0.818	rs73190163	ENSG00000223886.3	RP11-251G23.2	4.26	2.2e-05	0.00166	0.2	0.13	Bipolar disorder (body mass index interaction);	chr7:105516847	chr7:105530209~105530671:+
BRCA	cis	rs6963495	0.872	rs1569134	ENSG00000223886.3	RP11-251G23.2	4.26	2.2e-05	0.00166	0.2	0.13	Bipolar disorder (body mass index interaction);	chr7:105517781	chr7:105530209~105530671:+
BRCA	cis	rs6963495	0.818	rs114865717	ENSG00000223886.3	RP11-251G23.2	4.26	2.2e-05	0.00166	0.2	0.13	Bipolar disorder (body mass index interaction);	chr7:105518079	chr7:105530209~105530671:+
BRCA	cis	rs6963495	0.818	rs55740553	ENSG00000223886.3	RP11-251G23.2	4.26	2.2e-05	0.00166	0.2	0.13	Bipolar disorder (body mass index interaction);	chr7:105519104	chr7:105530209~105530671:+
BRCA	cis	rs6963495	0.818	rs73190166	ENSG00000223886.3	RP11-251G23.2	4.26	2.2e-05	0.00166	0.2	0.13	Bipolar disorder (body mass index interaction);	chr7:105519508	chr7:105530209~105530671:+
BRCA	cis	rs6963495	0.818	rs75116202	ENSG00000223886.3	RP11-251G23.2	4.26	2.2e-05	0.00166	0.2	0.13	Bipolar disorder (body mass index interaction);	chr7:105519612	chr7:105530209~105530671:+
BRCA	cis	rs6963495	0.818	rs73190167	ENSG00000223886.3	RP11-251G23.2	4.26	2.2e-05	0.00166	0.2	0.13	Bipolar disorder (body mass index interaction);	chr7:105519971	chr7:105530209~105530671:+
BRCA	cis	rs6963495	0.745	rs73190169	ENSG00000223886.3	RP11-251G23.2	4.26	2.2e-05	0.00166	0.2	0.13	Bipolar disorder (body mass index interaction);	chr7:105520053	chr7:105530209~105530671:+
BRCA	cis	rs4218	0.681	rs1867757	ENSG00000259732.1	RP11-59H7.3	-4.26	2.2e-05	0.00166	-0.16	-0.13	Social communication problems;	chr15:59072315	chr15:59121034~59133250:+
BRCA	cis	rs2991971	1	rs667626	ENSG00000280836.1	AL355480.1	4.26	2.2e-05	0.00166	0.15	0.13	High light scatter reticulocyte count;	chr1:45554879	chr1:45581219~45581321:-
BRCA	cis	rs6480314	0.522	rs2120900	ENSG00000233590.1	RP11-153K11.3	4.26	2.2e-05	0.00166	0.2	0.13	Optic nerve measurement (disc area);	chr10:68296052	chr10:68233251~68242379:-
BRCA	cis	rs721917	0.506	rs2254016	ENSG00000278616.1	BEND3P3	-4.26	2.2e-05	0.00166	-0.12	-0.13	Chronic obstructive pulmonary disease;	chr10:79898668	chr10:79682997~79685436:+
BRCA	cis	rs17406451	1	rs17406451	ENSG00000234936.1	AC010883.5	4.26	2.2e-05	0.00166	0.14	0.13	Mitochondrial DNA levels;	chr2:43405337	chr2:43229573~43233394:+
BRCA	cis	rs7200543	1	rs1135999	ENSG00000207425.1	Y_RNA	-4.26	2.2e-05	0.00166	-0.16	-0.13	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15038105	chr16:14915457~14915556:-
BRCA	cis	rs11955398	0.716	rs10939862	ENSG00000215032.2	GNL3LP1	-4.26	2.2e-05	0.00166	-0.16	-0.13	Intelligence (multi-trait analysis);	chr5:60705817	chr5:60891935~60893577:-
BRCA	cis	rs10029851	0.645	rs893036	ENSG00000234492.4	RPL34-AS1	-4.26	2.2e-05	0.00166	-0.15	-0.13	Amyotrophic lateral sclerosis (sporadic);	chr4:108702194	chr4:108538190~108620460:-
BRCA	cis	rs2253762	0.54	rs11200324	ENSG00000226864.1	ATE1-AS1	-4.26	2.2e-05	0.00166	-0.24	-0.13	Breast cancer;	chr10:122009999	chr10:121928312~121951965:+
BRCA	cis	rs12435908	1	rs60942639	ENSG00000276116.2	FUT8-AS1	-4.26	2.2e-05	0.00166	-0.22	-0.13	Ischemic stroke;	chr14:65640918	chr14:65411170~65412690:-
BRCA	cis	rs4835473	0.932	rs9685306	ENSG00000249741.2	RP11-673E1.3	4.26	2.2e-05	0.00166	0.15	0.13	Immature fraction of reticulocytes;	chr4:143748843	chr4:143911514~143912053:-
BRCA	cis	rs7011507	0.589	rs16937564	ENSG00000233858.4	AC026904.1	-4.26	2.2e-05	0.00166	-0.16	-0.13	Inflammatory bowel disease;Ulcerative colitis;	chr8:48510971	chr8:48590401~48594621:+
BRCA	cis	rs35146811	0.735	rs1727140	ENSG00000235713.1	RP4-604G5.3	-4.26	2.2e-05	0.00166	-0.15	-0.13	Coronary artery disease;	chr7:100217776	chr7:99992397~99993050:+
BRCA	cis	rs8180040	0.603	rs9854790	ENSG00000271161.1	BOLA2P2	4.26	2.2e-05	0.00166	0.14	0.13	Colorectal cancer;	chr3:47059816	chr3:47499841~47500407:+
BRCA	cis	rs4869313	0.869	rs27295	ENSG00000248734.2	CTD-2260A17.1	-4.26	2.2e-05	0.00166	-0.13	-0.13	Pediatric autoimmune diseases;	chr5:97022983	chr5:96784777~96785999:+
BRCA	cis	rs1005277	0.603	rs1998062	ENSG00000272983.1	RP11-508N22.12	4.26	2.2e-05	0.00166	0.14	0.13	Extrinsic epigenetic age acceleration;	chr10:38168724	chr10:38137337~38144399:+
BRCA	cis	rs4907240	0.925	rs7575254	ENSG00000230606.9	AC159540.1	4.26	2.2e-05	0.00166	0.17	0.13	Event-related brain oscillations;	chr2:96610023	chr2:97416165~97433527:-
BRCA	cis	rs4218	0.531	rs12101733	ENSG00000259732.1	RP11-59H7.3	-4.26	2.2e-05	0.00166	-0.15	-0.13	Social communication problems;	chr15:59047566	chr15:59121034~59133250:+
BRCA	cis	rs35740288	0.545	rs12916187	ENSG00000259407.1	RP11-158M2.3	-4.26	2.2e-05	0.00166	-0.19	-0.13	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85782893	chr15:85744109~85750281:-
BRCA	cis	rs721917	0.506	rs927452	ENSG00000242600.5	MBL1P	4.26	2.21e-05	0.00166	0.16	0.13	Chronic obstructive pulmonary disease;	chr10:79892510	chr10:79904898~79950336:+
BRCA	cis	rs6545883	0.826	rs777593	ENSG00000270820.4	RP11-355B11.2	4.26	2.21e-05	0.00166	0.15	0.13	Tuberculosis;	chr2:61191968	chr2:61471188~61484130:+
BRCA	cis	rs27434	0.561	rs35134	ENSG00000248734.2	CTD-2260A17.1	4.26	2.21e-05	0.00166	0.15	0.13	Ankylosing spondylitis;	chr5:96823820	chr5:96784777~96785999:+
BRCA	cis	rs17489649	0.956	rs2301013	ENSG00000271849.1	CTC-332L22.1	4.26	2.21e-05	0.00166	0.17	0.13	Intelligence (multi-trait analysis);	chr5:109802219	chr5:109687802~109688329:-
BRCA	cis	rs9914544	0.545	rs8067882	ENSG00000264885.1	RP11-815I9.4	-4.26	2.21e-05	0.00166	-0.13	-0.13	Educational attainment (years of education);	chr17:18903818	chr17:18667629~18669461:-
BRCA	cis	rs1979679	0.578	rs1993936	ENSG00000278733.1	RP11-425D17.1	4.26	2.21e-05	0.00166	0.16	0.13	Ossification of the posterior longitudinal ligament of the spine;	chr12:28120979	chr12:28185625~28186190:-
BRCA	cis	rs4474465	1	rs6592779	ENSG00000251323.2	RP11-452H21.4	4.26	2.21e-05	0.00166	0.18	0.13	Alzheimer's disease (survival time);	chr11:78486237	chr11:78423982~78429836:-
BRCA	cis	rs7267979	0.844	rs8184820	ENSG00000276952.1	RP5-965G21.6	-4.26	2.21e-05	0.00166	-0.16	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25269941	chr20:25284915~25285588:-
BRCA	cis	rs4689592	0.546	rs10937784	ENSG00000245468.3	RP11-367J11.3	4.26	2.21e-05	0.00166	0.14	0.13	Monocyte percentage of white cells;	chr4:7059208	chr4:7094571~7103385:-
BRCA	cis	rs3745567	0.622	rs11569470	ENSG00000276980.1	CTD-3128G10.7	4.26	2.21e-05	0.00166	0.21	0.13	Complement C3 and C4 levels;	chr19:6698443	chr19:6716386~6717742:-
BRCA	cis	rs9840812	0.769	rs576771	ENSG00000273486.1	RP11-731C17.2	4.26	2.21e-05	0.00166	0.16	0.13	Fibrinogen levels;	chr3:136270450	chr3:136837338~136839021:-
BRCA	cis	rs867186	1	rs74599371	ENSG00000126005.14	MMP24-AS1	-4.26	2.21e-05	0.00166	-0.24	-0.13	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:34973692	chr20:35216462~35278131:-
BRCA	cis	rs867186	1	rs79197732	ENSG00000126005.14	MMP24-AS1	-4.26	2.21e-05	0.00166	-0.24	-0.13	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:34974673	chr20:35216462~35278131:-
BRCA	cis	rs2832191	0.791	rs2251517	ENSG00000215533.7	LINC00189	-4.26	2.21e-05	0.00166	-0.15	-0.13	Dental caries;	chr21:29159630	chr21:29193480~29288205:+
BRCA	cis	rs794185	0.592	rs304039	ENSG00000231249.1	ITPR1-AS1	4.26	2.21e-05	0.00166	0.15	0.13	Multiple sclerosis--Brain Glutamate Levels;	chr3:4510742	chr3:4490891~4493163:-
BRCA	cis	rs8040855	0.579	rs4843029	ENSG00000259762.1	RP11-158M2.4	-4.26	2.21e-05	0.00166	-0.15	-0.13	Bulimia nervosa;	chr15:85182164	chr15:85750336~85752901:-
BRCA	cis	rs4664293	0.967	rs1346325	ENSG00000224152.1	AC009506.1	-4.26	2.21e-05	0.00166	-0.15	-0.13	Monocyte percentage of white cells;	chr2:159685995	chr2:159615296~159617082:+
BRCA	cis	rs1910358	0.676	rs10942018	ENSG00000248874.4	C5orf17	4.26	2.21e-05	0.00166	0.17	0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23997045	chr5:23951348~24178263:+
BRCA	cis	rs794185	0.564	rs304080	ENSG00000231249.1	ITPR1-AS1	-4.26	2.21e-05	0.00166	-0.14	-0.13	Multiple sclerosis--Brain Glutamate Levels;	chr3:4490262	chr3:4490891~4493163:-
BRCA	cis	rs7937890	0.504	rs2575847	ENSG00000254418.1	RP11-21L19.1	4.26	2.21e-05	0.00166	0.15	0.13	Mitochondrial DNA levels;	chr11:14449626	chr11:14262846~14273691:-
BRCA	cis	rs7937890	0.559	rs2575825	ENSG00000254418.1	RP11-21L19.1	4.26	2.21e-05	0.00166	0.15	0.13	Mitochondrial DNA levels;	chr11:14450550	chr11:14262846~14273691:-
BRCA	cis	rs11098499	1	rs35643470	ENSG00000250412.1	KLHL2P1	4.26	2.21e-05	0.00166	0.16	0.13	Corneal astigmatism;	chr4:119263793	chr4:119334329~119378233:+
BRCA	cis	rs9527	0.615	rs36045108	ENSG00000213061.2	PFN1P11	4.26	2.21e-05	0.00167	0.18	0.13	Arsenic metabolism;	chr10:102938172	chr10:102838011~102845473:-
BRCA	cis	rs7267979	1	rs4815418	ENSG00000125804.12	FAM182A	4.26	2.21e-05	0.00167	0.17	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25401575	chr20:26054655~26086917:+
BRCA	cis	rs4415084	0.804	rs9292913	ENSG00000251141.4	RP11-53O19.1	-4.26	2.21e-05	0.00167	-0.12	-0.13	Breast cancer;	chr5:44870777	chr5:44744900~44808777:-
BRCA	cis	rs17092148	0.636	rs2295096	ENSG00000126005.14	MMP24-AS1	-4.26	2.21e-05	0.00167	-0.17	-0.13	Neuroticism;	chr20:34876907	chr20:35216462~35278131:-
BRCA	cis	rs6772849	0.804	rs9832430	ENSG00000242551.2	POU5F1P6	-4.26	2.21e-05	0.00167	-0.17	-0.13	Monocyte percentage of white cells;Monocyte count;	chr3:128694054	chr3:128674735~128677005:-
BRCA	cis	rs12681366	0.511	rs2919670	ENSG00000253175.1	RP11-267M23.6	4.26	2.21e-05	0.00167	0.16	0.13	Nonsyndromic cleft lip with cleft palate;	chr8:94444390	chr8:94565036~94565715:+
BRCA	cis	rs9595908	0.9	rs1324414	ENSG00000281026.1	N4BP2L2-IT2	-4.26	2.21e-05	0.00167	-0.11	-0.13	Body mass index;	chr13:32600088	chr13:32504506~32509395:-
BRCA	cis	rs34217772	0.83	rs36024104	ENSG00000258636.1	CTD-2298J14.2	4.26	2.21e-05	0.00167	0.18	0.13	Myopia;	chr14:41825790	chr14:41587861~41604856:-
BRCA	cis	rs6001482	0.679	rs5750786	ENSG00000279278.1	CH17-264L24.1	4.26	2.21e-05	0.00167	0.11	0.13	Diastolic blood pressure;	chr22:22235358	chr22:22264601~22273020:+
BRCA	cis	rs12497850	0.931	rs1134591	ENSG00000225399.4	RP11-3B7.1	4.26	2.22e-05	0.00167	0.13	0.13	Parkinson's disease;	chr3:48935459	chr3:49260085~49261316:+
BRCA	cis	rs9921338	0.961	rs77552156	ENSG00000262636.1	CTD-3088G3.4	-4.26	2.22e-05	0.00167	-0.22	-0.13	Vein graft stenosis in coronary artery bypass grafting;	chr16:11332542	chr16:11380859~11381118:-
BRCA	cis	rs11673344	0.504	rs4806408	ENSG00000276846.1	CTD-3220F14.3	4.26	2.22e-05	0.00167	0.15	0.13	Obesity-related traits;	chr19:37097875	chr19:37314868~37315620:-
BRCA	cis	rs35176054	0.73	rs11596085	ENSG00000280693.1	SH3PXD2A-AS1	-4.26	2.22e-05	0.00167	-0.24	-0.13	Atrial fibrillation;	chr10:103769902	chr10:103745966~103755423:+
BRCA	cis	rs61160187	0.549	rs12518404	ENSG00000272308.1	RP11-231G3.1	-4.26	2.22e-05	0.00167	-0.15	-0.13	Educational attainment (years of education);Educational attainment (college completion);	chr5:61046169	chr5:60866457~60866935:-
BRCA	cis	rs4302906	0.729	rs4424328	ENSG00000187984.11	ANKRD19P	-4.26	2.22e-05	0.00167	-0.12	-0.13	Lobe attachment (rater-scored or self-reported);	chr9:92973192	chr9:92809388~92888693:+
BRCA	cis	rs875971	0.545	rs12670811	ENSG00000232546.1	RP11-458F8.1	4.26	2.22e-05	0.00167	0.12	0.13	Aortic root size;	chr7:66358032	chr7:66848496~66858136:+
BRCA	cis	rs2229238	0.911	rs59838898	ENSG00000272030.1	RP1-178F15.4	-4.26	2.22e-05	0.00167	-0.18	-0.13	Coronary heart disease;	chr1:154493825	chr1:153631438~153634397:-
BRCA	cis	rs2229238	0.911	rs10047079	ENSG00000272030.1	RP1-178F15.4	-4.26	2.22e-05	0.00167	-0.18	-0.13	Coronary heart disease;	chr1:154495659	chr1:153631438~153634397:-
BRCA	cis	rs56313388	0.505	rs4783932	ENSG00000246379.5	RP11-461O7.1	4.26	2.22e-05	0.00167	0.14	0.13	Pulse pressure;	chr16:56240589	chr16:56092987~56191094:-
BRCA	cis	rs8180040	0.966	rs11710322	ENSG00000276925.1	RP11-708J19.3	4.26	2.22e-05	0.00167	0.15	0.13	Colorectal cancer;	chr3:47289646	chr3:47469777~47469987:+
BRCA	cis	rs180730	1	rs343198	ENSG00000251609.2	SETP12	-4.26	2.22e-05	0.00167	-0.19	-0.13	Fasting plasma glucose;	chr4:120877031	chr4:120895494~120897083:-
BRCA	cis	rs79390637	1	rs79390637	ENSG00000280615.1	Y_RNA	-4.26	2.22e-05	0.00167	-0.16	-0.13	Intraocular pressure;	chr11:47435316	chr11:47614898~47614994:-
BRCA	cis	rs6671200	0.607	rs10874908	ENSG00000235501.4	RP4-639F20.1	4.26	2.22e-05	0.00167	0.22	0.13	Stearic acid (18:0) levels;	chr1:95238595	chr1:94927566~94963270:+
BRCA	cis	rs2236231	0.55	rs4902496	ENSG00000259648.1	RP11-643G16.4	-4.26	2.22e-05	0.00167	-0.19	-0.13	Plasma kynurenine levels in major depressive disorder;	chr14:67588896	chr14:67614929~67616626:+
BRCA	cis	rs1910358	0.53	rs10064523	ENSG00000248874.4	C5orf17	-4.26	2.22e-05	0.00167	-0.19	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23757193	chr5:23951348~24178263:+
BRCA	cis	rs73186030	0.92	rs17265703	ENSG00000272758.4	RP11-299J3.8	-4.26	2.22e-05	0.00167	-0.2	-0.13	Serum parathyroid hormone levels;	chr3:122329797	chr3:122416207~122443180:+
BRCA	cis	rs2255336	0.938	rs12578507	ENSG00000245648.1	RP11-277P12.20	-4.26	2.22e-05	0.00167	-0.21	-0.13	Blood protein levels;	chr12:10470396	chr12:10363769~10398506:+
BRCA	cis	rs73186030	0.623	rs16832958	ENSG00000272758.4	RP11-299J3.8	4.26	2.22e-05	0.00167	0.16	0.13	Serum parathyroid hormone levels;	chr3:122299646	chr3:122416207~122443180:+
BRCA	cis	rs1371614	0.55	rs2384508	ENSG00000272148.1	RP11-195B17.1	4.26	2.22e-05	0.00167	0.14	0.13	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26920188	chr2:27062428~27062907:-
BRCA	cis	rs2320614	0.679	rs10857352	ENSG00000250027.1	RP11-563E2.2	-4.26	2.22e-05	0.00167	-0.14	-0.13	Lung adenocarcinoma;	chr4:163180330	chr4:163108785~163119965:+
BRCA	cis	rs2320614	0.679	rs10001148	ENSG00000250027.1	RP11-563E2.2	-4.26	2.22e-05	0.00167	-0.14	-0.13	Lung adenocarcinoma;	chr4:163180462	chr4:163108785~163119965:+
BRCA	cis	rs757081	0.648	rs214923	ENSG00000184669.7	OR7E14P	-4.26	2.22e-05	0.00167	-0.17	-0.13	Systolic blood pressure;	chr11:17215533	chr11:17013998~17053024:+
BRCA	cis	rs8177876	0.642	rs4454990	ENSG00000245059.2	RP11-303E16.7	-4.26	2.22e-05	0.00167	-0.26	-0.13	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81106550	chr16:81077319~81078861:+
BRCA	cis	rs7107174	1	rs4492844	ENSG00000251323.2	RP11-452H21.4	4.26	2.22e-05	0.00167	0.19	0.13	Testicular germ cell tumor;	chr11:78315470	chr11:78423982~78429836:-
BRCA	cis	rs13113518	1	rs13116194	ENSG00000272969.1	RP11-528I4.2	4.26	2.22e-05	0.00167	0.15	0.13	Height;	chr4:55531150	chr4:55547112~55547889:+
BRCA	cis	rs13113518	1	rs13117836	ENSG00000272969.1	RP11-528I4.2	4.26	2.22e-05	0.00167	0.15	0.13	Height;	chr4:55531218	chr4:55547112~55547889:+
BRCA	cis	rs13113518	0.966	rs7668429	ENSG00000272969.1	RP11-528I4.2	4.26	2.22e-05	0.00167	0.15	0.13	Height;	chr4:55531811	chr4:55547112~55547889:+
BRCA	cis	rs4143844	0.867	rs77585482	ENSG00000259251.2	RP11-643M14.1	4.26	2.22e-05	0.00167	0.32	0.13	Bipolar disorder and schizophrenia;	chr15:61925442	chr15:62060503~62062434:+
BRCA	cis	rs4671400	0.571	rs28480287	ENSG00000273302.1	RP11-493E12.2	-4.26	2.22e-05	0.00167	-0.14	-0.13	3-hydroxypropylmercapturic acid levels in smokers;	chr2:61262154	chr2:61199979~61200769:+
BRCA	cis	rs4650994	1	rs35810840	ENSG00000273384.1	RP5-1098D14.1	4.26	2.23e-05	0.00167	0.16	0.13	HDL cholesterol;HDL cholesterol levels;	chr1:178553507	chr1:178651706~178652282:+
BRCA	cis	rs2179367	0.959	rs540538	ENSG00000223701.3	RAET1E-AS1	4.26	2.23e-05	0.00167	0.17	0.13	Dupuytren's disease;	chr6:149326808	chr6:149884431~149919508:+
BRCA	cis	rs9859260	0.744	rs539816	ENSG00000207650.1	MIR570	-4.26	2.23e-05	0.00167	-0.15	-0.13	Mean corpuscular volume;	chr3:196057205	chr3:195699401~195699497:+
BRCA	cis	rs9859260	0.744	rs492349	ENSG00000207650.1	MIR570	-4.26	2.23e-05	0.00167	-0.15	-0.13	Mean corpuscular volume;	chr3:196057321	chr3:195699401~195699497:+
BRCA	cis	rs9859260	0.744	rs492288	ENSG00000207650.1	MIR570	-4.26	2.23e-05	0.00167	-0.15	-0.13	Mean corpuscular volume;	chr3:196057339	chr3:195699401~195699497:+
BRCA	cis	rs2839186	0.771	rs2839155	ENSG00000239415.1	AP001469.9	4.26	2.23e-05	0.00167	0.14	0.13	Testicular germ cell tumor;	chr21:46220078	chr21:46251549~46254133:-
BRCA	cis	rs4950322	0.57	rs72691102	ENSG00000237188.3	RP11-337C18.8	4.26	2.23e-05	0.00167	0.17	0.13	Protein quantitative trait loci;	chr1:147301189	chr1:147172771~147211568:+
BRCA	cis	rs4950322	0.57	rs72692904	ENSG00000237188.3	RP11-337C18.8	4.26	2.23e-05	0.00167	0.17	0.13	Protein quantitative trait loci;	chr1:147301437	chr1:147172771~147211568:+
BRCA	cis	rs4950322	0.57	rs72692905	ENSG00000237188.3	RP11-337C18.8	4.26	2.23e-05	0.00167	0.17	0.13	Protein quantitative trait loci;	chr1:147301560	chr1:147172771~147211568:+
BRCA	cis	rs745109	0.816	rs74443614	ENSG00000273080.1	RP11-301O19.1	4.26	2.23e-05	0.00168	0.22	0.13	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86618386	chr2:86195590~86196049:+
BRCA	cis	rs4449834	0.816	rs11993480	ENSG00000254432.1	RP11-33I11.2	-4.26	2.23e-05	0.00168	-0.16	-0.13	Sum eosinophil basophil counts;	chr8:60744514	chr8:60808735~60809606:-
BRCA	cis	rs7071275	0.6	rs11200052	ENSG00000226864.1	ATE1-AS1	4.26	2.23e-05	0.00168	0.25	0.13	Dupuytren's disease;	chr10:121642723	chr10:121928312~121951965:+
BRCA	cis	rs11686241	0.872	rs16856226	ENSG00000241520.1	AC098820.4	4.26	2.23e-05	0.00168	0.19	0.13	Cancer;	chr2:216484954	chr2:216483032~216487196:-
BRCA	cis	rs9308731	0.644	rs3789064	ENSG00000230499.1	AC108463.1	-4.26	2.23e-05	0.00168	-0.15	-0.13	Chronic lymphocytic leukemia;	chr2:111157745	chr2:111195963~111206494:+
BRCA	cis	rs5758511	0.634	rs1001587	ENSG00000226450.2	CYP2D8P	4.26	2.23e-05	0.00168	0.15	0.13	Birth weight;	chr22:42274105	chr22:42149886~42155001:-
BRCA	cis	rs62458065	0.925	rs10243243	ENSG00000229358.3	DPY19L1P1	-4.26	2.23e-05	0.00168	-0.17	-0.13	Metabolite levels (HVA/MHPG ratio);	chr7:32421097	chr7:32580949~32761787:-
BRCA	cis	rs6439153	0.933	rs34193129	ENSG00000261159.1	RP11-723O4.9	4.26	2.23e-05	0.00168	0.14	0.13	Pneumococcal bacteremia;	chr3:128972564	chr3:128859716~128860526:-
BRCA	cis	rs7833986	0.501	rs2668007	ENSG00000253603.1	CTA-397H3.3	-4.26	2.23e-05	0.00168	-0.19	-0.13	Height;	chr8:56031552	chr8:56074592~56075274:+
BRCA	cis	rs1348850	0.958	rs11689550	ENSG00000280374.1	RP11-337N6.3	4.26	2.23e-05	0.00168	0.18	0.13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177591570	chr2:177317715~177318471:-
BRCA	cis	rs875971	0.66	rs3764903	ENSG00000229180.5	GS1-124K5.11	-4.26	2.23e-05	0.00168	-0.11	-0.13	Aortic root size;	chr7:66633495	chr7:66526088~66542624:-
BRCA	cis	rs7771547	0.632	rs79102826	ENSG00000224666.3	RP1-50J22.4	4.26	2.23e-05	0.00168	0.16	0.13	Platelet distribution width;	chr6:36588037	chr6:36386831~36393462:+
BRCA	cis	rs7771547	0.723	rs10807169	ENSG00000224666.3	RP1-50J22.4	4.26	2.23e-05	0.00168	0.16	0.13	Platelet distribution width;	chr6:36588792	chr6:36386831~36393462:+
BRCA	cis	rs10129255	1	rs11627342	ENSG00000274576.2	IGHV2-70	4.26	2.23e-05	0.00168	0.12	0.13	Kawasaki disease;	chr14:106675823	chr14:106770577~106771020:-
BRCA	cis	rs1979679	0.608	rs4931082	ENSG00000278733.1	RP11-425D17.1	-4.26	2.23e-05	0.00168	-0.18	-0.13	Ossification of the posterior longitudinal ligament of the spine;	chr12:28567087	chr12:28185625~28186190:-
BRCA	cis	rs1167832	1	rs1167832	ENSG00000278416.1	PMS2L2	4.26	2.23e-05	0.00168	0.23	0.13	Ankle injury;	chr7:75537904	chr7:75344015~75359550:-
BRCA	cis	rs2380205	0.967	rs10905316	ENSG00000232807.2	RP11-536K7.3	4.26	2.23e-05	0.00168	0.14	0.13	Breast cancer;	chr10:5856777	chr10:5934270~5945900:-
BRCA	cis	rs875971	1	rs937495	ENSG00000236529.1	RP13-254B10.1	-4.26	2.23e-05	0.00168	-0.14	-0.13	Aortic root size;	chr7:66314811	chr7:65840212~65840596:+
BRCA	cis	rs875971	1	rs2036264	ENSG00000236529.1	RP13-254B10.1	-4.26	2.23e-05	0.00168	-0.14	-0.13	Aortic root size;	chr7:66334917	chr7:65840212~65840596:+
BRCA	cis	rs875971	1	rs7783613	ENSG00000236529.1	RP13-254B10.1	-4.26	2.23e-05	0.00168	-0.14	-0.13	Aortic root size;	chr7:66340274	chr7:65840212~65840596:+
BRCA	cis	rs2235544	0.565	rs665421	ENSG00000225183.1	RP4-758J24.4	4.26	2.23e-05	0.00168	0.16	0.13	Thyroid hormone levels;Multiple myeloma (hyperdiploidy);	chr1:54004210	chr1:54089856~54090093:+
BRCA	cis	rs2274273	0.624	rs72717738	ENSG00000259318.1	RP11-454L9.2	4.26	2.23e-05	0.00168	0.12	0.13	Protein biomarker;	chr14:55376043	chr14:55394940~55395233:-
BRCA	cis	rs4143844	0.867	rs11629741	ENSG00000259251.2	RP11-643M14.1	4.26	2.23e-05	0.00168	0.31	0.13	Bipolar disorder and schizophrenia;	chr15:61892783	chr15:62060503~62062434:+
BRCA	cis	rs4143844	0.867	rs34796280	ENSG00000259251.2	RP11-643M14.1	4.26	2.23e-05	0.00168	0.31	0.13	Bipolar disorder and schizophrenia;	chr15:61893680	chr15:62060503~62062434:+
BRCA	cis	rs12682352	0.652	rs1567398	ENSG00000254153.1	CTA-398F10.2	-4.26	2.23e-05	0.00168	-0.15	-0.13	Neuroticism;	chr8:8869294	chr8:8456909~8461337:-
BRCA	cis	rs2243480	1	rs937108	ENSG00000226002.1	RP11-460N20.5	-4.26	2.23e-05	0.00168	-0.21	-0.13	Diabetic kidney disease;	chr7:65963465	chr7:65084103~65100232:+
BRCA	cis	rs7246967	1	rs8113312	ENSG00000198153.8	ZNF849P	-4.26	2.23e-05	0.00168	-0.19	-0.13	Bronchopulmonary dysplasia;	chr19:22878380	chr19:22685167~22686732:+
BRCA	cis	rs11742741	0.87	rs62350773	ENSG00000248874.4	C5orf17	-4.26	2.23e-05	0.00168	-0.17	-0.13	Educational attainment;	chr5:24098745	chr5:23951348~24178263:+
BRCA	cis	rs7412746	0.611	rs10888398	ENSG00000231073.1	RP11-316M1.3	-4.26	2.23e-05	0.00168	-0.14	-0.13	Melanoma;	chr1:150914306	chr1:150973123~150975534:+
BRCA	cis	rs1008375	0.966	rs2315553	ENSG00000249502.1	AC006160.5	-4.26	2.23e-05	0.00168	-0.15	-0.13	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17625709	chr4:17587467~17614571:-
BRCA	cis	rs6870983	0.636	rs11948659	ENSG00000247828.6	TMEM161B-AS1	4.26	2.23e-05	0.00168	0.16	0.13	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index;	chr5:88144680	chr5:88268895~88436685:+
BRCA	cis	rs7267979	1	rs4815420	ENSG00000125804.12	FAM182A	4.26	2.23e-05	0.00168	0.17	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25403343	chr20:26054655~26086917:+
BRCA	cis	rs409045	1	rs367167	ENSG00000271874.1	CTD-2024P10.2	-4.26	2.23e-05	0.00168	-0.17	-0.13	Left ventricular mass;	chr5:34633287	chr5:34651457~34651888:-
BRCA	cis	rs409045	1	rs466261	ENSG00000271874.1	CTD-2024P10.2	-4.26	2.23e-05	0.00168	-0.17	-0.13	Left ventricular mass;	chr5:34633650	chr5:34651457~34651888:-
BRCA	cis	rs409045	1	rs458995	ENSG00000271874.1	CTD-2024P10.2	-4.26	2.23e-05	0.00168	-0.17	-0.13	Left ventricular mass;	chr5:34633804	chr5:34651457~34651888:-
BRCA	cis	rs4780355	1	rs4780355	ENSG00000262703.1	RP11-485G7.6	4.26	2.24e-05	0.00168	0.14	0.13	Crohn's disease and psoriasis;	chr16:11254001	chr16:11348143~11349321:-
BRCA	cis	rs11951515	0.508	rs7705166	ENSG00000248240.1	RP11-159F24.5	-4.26	2.24e-05	0.00168	-0.16	-0.13	Metabolite levels  (X-11787);	chr5:43587346	chr5:43515274~43525310:+
BRCA	cis	rs9470794	1	rs78606940	ENSG00000204110.6	RP1-153P14.8	-4.26	2.24e-05	0.00168	-0.26	-0.13	Type 2 diabetes;	chr6:37955320	chr6:37507348~37535616:+
BRCA	cis	rs9470794	1	rs73421427	ENSG00000204110.6	RP1-153P14.8	-4.26	2.24e-05	0.00168	-0.26	-0.13	Type 2 diabetes;	chr6:37956329	chr6:37507348~37535616:+
BRCA	cis	rs6921919	0.609	rs1005127	ENSG00000273712.1	RP5-874C20.7	4.26	2.24e-05	0.00168	0.17	0.13	Autism spectrum disorder or schizophrenia;	chr6:28399881	chr6:28315613~28315883:-
BRCA	cis	rs853679	0.515	rs4580862	ENSG00000273712.1	RP5-874C20.7	4.26	2.24e-05	0.00168	0.17	0.13	Depression;	chr6:28399886	chr6:28315613~28315883:-
BRCA	cis	rs6921919	0.583	rs4357130	ENSG00000273712.1	RP5-874C20.7	4.26	2.24e-05	0.00168	0.17	0.13	Autism spectrum disorder or schizophrenia;	chr6:28399906	chr6:28315613~28315883:-
BRCA	cis	rs10129255	0.5	rs34326748	ENSG00000211967.3	IGHV3-53	-4.26	2.24e-05	0.00168	-0.09	-0.13	Kawasaki disease;	chr14:106782523	chr14:106592676~106593347:-
BRCA	cis	rs10129255	0.5	rs10143385	ENSG00000211967.3	IGHV3-53	-4.26	2.24e-05	0.00168	-0.09	-0.13	Kawasaki disease;	chr14:106782559	chr14:106592676~106593347:-
BRCA	cis	rs2962370	0.842	rs2929710	ENSG00000215196.4	AC091878.1	4.26	2.24e-05	0.00168	0.16	0.13	Bipolar disorder with mood-incongruent psychosis;	chr5:17213256	chr5:17130028~17217047:-
BRCA	cis	rs10829156	0.66	rs11014830	ENSG00000225527.1	RP11-383B4.4	-4.26	2.24e-05	0.00168	-0.17	-0.13	Sudden cardiac arrest;	chr10:18551504	chr10:18531849~18533336:-
BRCA	cis	rs745109	0.882	rs58361202	ENSG00000273080.1	RP11-301O19.1	4.26	2.24e-05	0.00168	0.21	0.13	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86448108	chr2:86195590~86196049:+
BRCA	cis	rs745109	0.882	rs76258845	ENSG00000273080.1	RP11-301O19.1	4.26	2.24e-05	0.00168	0.21	0.13	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86450151	chr2:86195590~86196049:+
BRCA	cis	rs745109	0.751	rs72930364	ENSG00000273080.1	RP11-301O19.1	4.26	2.24e-05	0.00168	0.21	0.13	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86454498	chr2:86195590~86196049:+
BRCA	cis	rs745109	0.882	rs59183618	ENSG00000273080.1	RP11-301O19.1	4.26	2.24e-05	0.00168	0.21	0.13	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86465649	chr2:86195590~86196049:+
BRCA	cis	rs745109	0.882	rs57836876	ENSG00000273080.1	RP11-301O19.1	4.26	2.24e-05	0.00168	0.21	0.13	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86466094	chr2:86195590~86196049:+
BRCA	cis	rs745109	0.882	rs34605051	ENSG00000273080.1	RP11-301O19.1	4.26	2.24e-05	0.00168	0.21	0.13	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86466703	chr2:86195590~86196049:+
BRCA	cis	rs745109	0.882	rs72930385	ENSG00000273080.1	RP11-301O19.1	4.26	2.24e-05	0.00168	0.21	0.13	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86467669	chr2:86195590~86196049:+
BRCA	cis	rs2073316	0.592	rs1114962	ENSG00000272716.1	RP11-563N4.1	4.26	2.24e-05	0.00168	0.14	0.13	Interleukin-18 levels;	chr2:31452382	chr2:32165046~32165757:-
BRCA	cis	rs2839186	0.872	rs13052233	ENSG00000239415.1	AP001469.9	4.26	2.24e-05	0.00168	0.14	0.13	Testicular germ cell tumor;	chr21:46287370	chr21:46251549~46254133:-
BRCA	cis	rs4950322	0.57	rs72692920	ENSG00000237188.3	RP11-337C18.8	4.26	2.24e-05	0.00168	0.17	0.13	Protein quantitative trait loci;	chr1:147308501	chr1:147172771~147211568:+
BRCA	cis	rs1910358	0.548	rs1910066	ENSG00000248874.4	C5orf17	-4.26	2.24e-05	0.00168	-0.17	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:24010087	chr5:23951348~24178263:+
BRCA	cis	rs7932354	0.583	rs6485695	ENSG00000200376.1	RNU5E-10P	4.26	2.24e-05	0.00168	0.16	0.13	Bone mineral density (hip);Bone mineral density;	chr11:46814615	chr11:47576471~47576588:-
BRCA	cis	rs875971	0.66	rs1860470	ENSG00000229180.5	GS1-124K5.11	-4.26	2.24e-05	0.00168	-0.11	-0.13	Aortic root size;	chr7:66638707	chr7:66526088~66542624:-
BRCA	cis	rs11711311	0.955	rs9881563	ENSG00000241529.3	RN7SL767P	4.26	2.24e-05	0.00168	0.15	0.13	IgG glycosylation;	chr3:113695184	chr3:113632704~113632998:+
BRCA	cis	rs7577696	0.545	rs2300700	ENSG00000272716.1	RP11-563N4.1	-4.26	2.24e-05	0.00168	-0.14	-0.13	Inflammatory biomarkers;	chr2:31561922	chr2:32165046~32165757:-
BRCA	cis	rs1023500	0.505	rs134887	ENSG00000182057.4	OGFRP1	4.26	2.24e-05	0.00168	0.15	0.13	Schizophrenia;	chr22:42278233	chr22:42269753~42275196:+
BRCA	cis	rs3768617	0.811	rs12043805	ENSG00000224468.3	RP11-181K3.4	-4.26	2.24e-05	0.00168	-0.15	-0.13	Fuchs's corneal dystrophy;	chr1:183039015	chr1:183138402~183141282:-
BRCA	cis	rs3768617	0.811	rs10911205	ENSG00000224468.3	RP11-181K3.4	-4.26	2.24e-05	0.00168	-0.15	-0.13	Fuchs's corneal dystrophy;	chr1:183040142	chr1:183138402~183141282:-
BRCA	cis	rs9400467	0.6	rs4521634	ENSG00000255389.1	C6orf3	-4.26	2.24e-05	0.00168	-0.15	-0.13	Amino acid levels;Blood metabolite levels;	chr6:111523908	chr6:111599875~111602295:+
BRCA	cis	rs4713118	0.699	rs200978	ENSG00000280107.1	AL022393.9	-4.26	2.24e-05	0.00169	-0.2	-0.13	Parkinson's disease;	chr6:27885390	chr6:28170845~28172521:+
BRCA	cis	rs6067053	0.671	rs1130146	ENSG00000227431.4	CSE1L-AS1	4.26	2.24e-05	0.00169	0.17	0.13	Intelligence (multi-trait analysis);	chr20:49242680	chr20:49040463~49046044:-
BRCA	cis	rs11148252	0.744	rs4884354	ENSG00000198384.8	TPTE2P3	4.26	2.24e-05	0.00169	0.15	0.13	Lewy body disease;	chr13:52443339	chr13:52522632~52586906:+
BRCA	cis	rs2108622	0.727	rs62106157	ENSG00000267218.2	AC005336.5	4.26	2.24e-05	0.00169	0.16	0.13	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15869638	chr19:15902300~15903238:-
BRCA	cis	rs2108622	0.727	rs62106158	ENSG00000267218.2	AC005336.5	4.26	2.24e-05	0.00169	0.16	0.13	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15869682	chr19:15902300~15903238:-
BRCA	cis	rs17507216	0.667	rs13379724	ENSG00000259429.4	UBE2Q2P2	-4.26	2.24e-05	0.00169	-0.15	-0.13	Excessive daytime sleepiness;	chr15:82619892	chr15:82355142~82420075:+
BRCA	cis	rs28829049	0.57	rs12060125	ENSG00000270728.1	RP4-657E11.10	4.26	2.24e-05	0.00169	0.13	0.13	QRS duration in Tripanosoma cruzi seropositivity;	chr1:19064614	chr1:19297080~19297903:+
BRCA	cis	rs7569084	1	rs13385171	ENSG00000237979.1	AC007389.1	-4.26	2.24e-05	0.00169	-0.15	-0.13	Sum eosinophil basophil counts;	chr2:65434709	chr2:65500993~65502138:-
BRCA	cis	rs6088580	0.634	rs2378134	ENSG00000276073.1	RP5-1125A11.7	4.26	2.24e-05	0.00169	0.14	0.13	Glomerular filtration rate (creatinine);	chr20:34350279	chr20:33985617~33988989:-
BRCA	cis	rs9921338	0.961	rs4781069	ENSG00000262636.1	CTD-3088G3.4	-4.26	2.24e-05	0.00169	-0.22	-0.13	Vein graft stenosis in coronary artery bypass grafting;	chr16:11334905	chr16:11380859~11381118:-
BRCA	cis	rs8030379	1	rs4842924	ENSG00000176700.18	SCAND2P	4.26	2.25e-05	0.00169	0.12	0.13	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83918855	chr15:84631451~84647478:+
BRCA	cis	rs2880765	0.835	rs4842886	ENSG00000202081.1	RNU6-1280P	4.26	2.25e-05	0.00169	0.15	0.13	Coronary artery disease;	chr15:85492542	chr15:85651522~85651628:-
BRCA	cis	rs853679	0.517	rs6922063	ENSG00000261839.1	RP1-265C24.8	4.26	2.25e-05	0.00169	0.18	0.13	Depression;	chr6:28126588	chr6:28136849~28139678:+
BRCA	cis	rs853679	0.517	rs2275508	ENSG00000261839.1	RP1-265C24.8	4.26	2.25e-05	0.00169	0.18	0.13	Depression;	chr6:28126953	chr6:28136849~28139678:+
BRCA	cis	rs1555322	1	rs1555322	ENSG00000279253.1	RP4-614O4.13	-4.26	2.25e-05	0.00169	-0.21	-0.13	Attention deficit hyperactivity disorder;	chr20:35261376	chr20:35262727~35264187:-
BRCA	cis	rs7308116	0.935	rs12299334	ENSG00000274395.1	RP11-554D14.8	-4.26	2.25e-05	0.00169	-0.14	-0.13	Pelvic organ prolapse (moderate/severe);	chr12:107810231	chr12:107835541~107836555:-
BRCA	cis	rs7308116	0.904	rs79943104	ENSG00000274395.1	RP11-554D14.8	-4.26	2.25e-05	0.00169	-0.14	-0.13	Pelvic organ prolapse (moderate/severe);	chr12:107810235	chr12:107835541~107836555:-
BRCA	cis	rs7308116	0.904	rs12306400	ENSG00000274395.1	RP11-554D14.8	-4.26	2.25e-05	0.00169	-0.14	-0.13	Pelvic organ prolapse (moderate/severe);	chr12:107810240	chr12:107835541~107836555:-
BRCA	cis	rs4578769	0.765	rs12455548	ENSG00000265939.1	UBE2CP2	-4.26	2.25e-05	0.00169	-0.17	-0.13	Eosinophil percentage of white cells;	chr18:22831514	chr18:22900486~22900995:-
BRCA	cis	rs11098499	1	rs13116504	ENSG00000250412.1	KLHL2P1	4.26	2.25e-05	0.00169	0.16	0.13	Corneal astigmatism;	chr4:119288257	chr4:119334329~119378233:+
BRCA	cis	rs1510272	1	rs4679778	ENSG00000243926.1	TIPARP-AS1	-4.26	2.25e-05	0.00169	-0.15	-0.13	Testicular germ cell tumor;	chr3:156578150	chr3:156671862~156674378:-
BRCA	cis	rs1048886	0.872	rs2207423	ENSG00000271967.1	RP11-134K13.4	-4.26	2.25e-05	0.00169	-0.18	-0.13	Type 2 diabetes;	chr6:70537682	chr6:70596438~70596980:+
BRCA	cis	rs1552172	0.853	rs10752826	ENSG00000234222.5	RP11-315I20.1	4.26	2.25e-05	0.00169	0.16	0.13	Breast cancer;	chr1:145832321	chr1:145926590~145959179:+
BRCA	cis	rs1555321	0.523	rs12411679	ENSG00000273038.2	RP11-479G22.8	4.26	2.25e-05	0.00169	0.16	0.13	Coronary artery disease;	chr10:33227749	chr10:32887255~32889311:-
BRCA	cis	rs11711311	0.826	rs13077644	ENSG00000241529.3	RN7SL767P	-4.26	2.25e-05	0.00169	-0.15	-0.13	IgG glycosylation;	chr3:113748930	chr3:113632704~113632998:+
BRCA	cis	rs7308116	1	rs12299329	ENSG00000274395.1	RP11-554D14.8	-4.26	2.25e-05	0.00169	-0.14	-0.13	Pelvic organ prolapse (moderate/severe);	chr12:107810173	chr12:107835541~107836555:-
BRCA	cis	rs7308116	1	rs7960155	ENSG00000274395.1	RP11-554D14.8	-4.26	2.25e-05	0.00169	-0.14	-0.13	Pelvic organ prolapse (moderate/severe);	chr12:107810598	chr12:107835541~107836555:-
BRCA	cis	rs6012564	1	rs17632	ENSG00000222365.1	SNORD12B	4.26	2.25e-05	0.00169	0.14	0.13	Anger;	chr20:49096526	chr20:49280319~49280409:+
BRCA	cis	rs12234571	0.557	rs11977422	ENSG00000214293.7	APTR	4.26	2.25e-05	0.00169	0.22	0.13	Obesity-related traits;	chr7:77814598	chr7:77657660~77696265:-
BRCA	cis	rs7932354	0.583	rs7943866	ENSG00000200376.1	RNU5E-10P	4.26	2.25e-05	0.00169	0.16	0.13	Bone mineral density (hip);Bone mineral density;	chr11:46860403	chr11:47576471~47576588:-
BRCA	cis	rs4950322	0.57	rs72691093	ENSG00000237188.3	RP11-337C18.8	4.26	2.25e-05	0.00169	0.17	0.13	Protein quantitative trait loci;	chr1:147297977	chr1:147172771~147211568:+
BRCA	cis	rs4950322	0.57	rs76236344	ENSG00000237188.3	RP11-337C18.8	4.26	2.25e-05	0.00169	0.17	0.13	Protein quantitative trait loci;	chr1:147297989	chr1:147172771~147211568:+
BRCA	cis	rs2505998	1	rs2505998	ENSG00000273008.1	RP11-351D16.3	-4.26	2.25e-05	0.00169	-0.16	-0.13	Hirschsprung disease;	chr10:43075477	chr10:43136824~43138334:-
BRCA	cis	rs11098499	0.913	rs11098496	ENSG00000260091.1	RP11-33B1.4	-4.26	2.25e-05	0.00169	-0.12	-0.13	Corneal astigmatism;	chr4:119246311	chr4:119409333~119410233:+
BRCA	cis	rs6547741	1	rs6737921	ENSG00000234072.1	AC074117.10	4.26	2.25e-05	0.00169	0.12	0.13	Oral cavity cancer;	chr2:27616240	chr2:27356246~27367622:+
BRCA	cis	rs61931739	0.534	rs12372721	ENSG00000258794.3	DUX4L27	4.26	2.25e-05	0.00169	0.19	0.13	Morning vs. evening chronotype;	chr12:34022366	chr12:34208415~34209675:-
BRCA	cis	rs4478858	0.647	rs6425720	ENSG00000260386.4	LINC01225	-4.26	2.25e-05	0.00169	-0.16	-0.13	Alcohol dependence;	chr1:31236708	chr1:31500085~31540885:+
BRCA	cis	rs6963495	0.818	rs73190149	ENSG00000223886.3	RP11-251G23.2	4.26	2.25e-05	0.00169	0.2	0.13	Bipolar disorder (body mass index interaction);	chr7:105512346	chr7:105530209~105530671:+
BRCA	cis	rs3740713	1	rs73440615	ENSG00000256361.1	RP11-613F22.6	4.26	2.25e-05	0.00169	0.2	0.13	Amyotrophic lateral sclerosis (sporadic);	chr11:18445736	chr11:18511043~18511475:-
BRCA	cis	rs745109	0.882	rs34633268	ENSG00000273080.1	RP11-301O19.1	4.26	2.25e-05	0.00169	0.21	0.13	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86439178	chr2:86195590~86196049:+
BRCA	cis	rs745109	0.882	rs111226991	ENSG00000273080.1	RP11-301O19.1	4.26	2.25e-05	0.00169	0.21	0.13	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86441699	chr2:86195590~86196049:+
BRCA	cis	rs1865760	0.865	rs9467650	ENSG00000272462.2	U91328.19	-4.26	2.25e-05	0.00169	-0.16	-0.13	Height;	chr6:25958007	chr6:25992662~26001775:+
BRCA	cis	rs7267979	1	rs6083856	ENSG00000276952.1	RP5-965G21.6	-4.26	2.25e-05	0.00169	-0.16	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25426949	chr20:25284915~25285588:-
BRCA	cis	rs950776	0.593	rs6495306	ENSG00000279373.1	RP11-650L12.4	-4.26	2.25e-05	0.00169	-0.16	-0.13	Sudden cardiac arrest;	chr15:78573551	chr15:78537681~78538946:+
BRCA	cis	rs8114671	0.836	rs734308	ENSG00000126005.14	MMP24-AS1	4.26	2.25e-05	0.00169	0.15	0.13	Height;	chr20:34984293	chr20:35216462~35278131:-
BRCA	cis	rs4671400	0.571	rs4672428	ENSG00000273302.1	RP11-493E12.2	-4.26	2.26e-05	0.00169	-0.15	-0.13	3-hydroxypropylmercapturic acid levels in smokers;	chr2:61251362	chr2:61199979~61200769:+
BRCA	cis	rs1008375	1	rs10027755	ENSG00000249502.1	AC006160.5	-4.26	2.26e-05	0.00169	-0.15	-0.13	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17614331	chr4:17587467~17614571:-
BRCA	cis	rs4869313	0.905	rs2617447	ENSG00000248734.2	CTD-2260A17.1	4.26	2.26e-05	0.0017	0.14	0.13	Pediatric autoimmune diseases;	chr5:96931951	chr5:96784777~96785999:+
BRCA	cis	rs7412746	0.611	rs10788794	ENSG00000231073.1	RP11-316M1.3	4.26	2.26e-05	0.0017	0.14	0.13	Melanoma;	chr1:150756200	chr1:150973123~150975534:+
BRCA	cis	rs9308731	0.644	rs3789068	ENSG00000230499.1	AC108463.1	-4.26	2.26e-05	0.0017	-0.15	-0.13	Chronic lymphocytic leukemia;	chr2:111151670	chr2:111195963~111206494:+
BRCA	cis	rs860295	0.702	rs2025669	ENSG00000225855.5	RUSC1-AS1	4.26	2.26e-05	0.0017	0.11	0.13	Body mass index;	chr1:155387818	chr1:155316863~155324176:-
BRCA	cis	rs6600671	1	rs4844380	ENSG00000231429.2	RP11-343N15.2	-4.26	2.26e-05	0.0017	-0.16	-0.13	Hip geometry;	chr1:121451764	chr1:121412719~121429274:+
BRCA	cis	rs1910358	0.53	rs10462248	ENSG00000248874.4	C5orf17	-4.26	2.26e-05	0.0017	-0.19	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23737497	chr5:23951348~24178263:+
BRCA	cis	rs2880765	0.835	rs11638498	ENSG00000202081.1	RNU6-1280P	4.26	2.26e-05	0.0017	0.15	0.13	Coronary artery disease;	chr15:85479787	chr15:85651522~85651628:-
BRCA	cis	rs860295	0.702	rs10908465	ENSG00000225855.5	RUSC1-AS1	4.26	2.26e-05	0.0017	0.11	0.13	Body mass index;	chr1:155419897	chr1:155316863~155324176:-
BRCA	cis	rs6671200	0.831	rs12742928	ENSG00000235501.4	RP4-639F20.1	-4.26	2.26e-05	0.0017	-0.3	-0.13	Stearic acid (18:0) levels;	chr1:95142839	chr1:94927566~94963270:+
BRCA	cis	rs983392	0.805	rs7926729	ENSG00000275344.1	MIR6503	-4.26	2.26e-05	0.0017	-0.14	-0.13	Alzheimer's disease (late onset);	chr11:60194313	chr11:60209071~60209156:-
BRCA	cis	rs6012564	1	rs2024959	ENSG00000222365.1	SNORD12B	4.26	2.26e-05	0.0017	0.14	0.13	Anger;	chr20:49078854	chr20:49280319~49280409:+
BRCA	cis	rs6600671	0.934	rs11249348	ENSG00000231429.2	RP11-343N15.2	-4.26	2.26e-05	0.0017	-0.15	-0.13	Hip geometry;	chr1:121446444	chr1:121412719~121429274:+
BRCA	cis	rs4218	0.648	rs12915899	ENSG00000259732.1	RP11-59H7.3	-4.26	2.26e-05	0.0017	-0.16	-0.13	Social communication problems;	chr15:59084332	chr15:59121034~59133250:+
BRCA	cis	rs17684571	0.7	rs61601344	ENSG00000231441.1	RP11-472M19.2	4.26	2.26e-05	0.0017	0.19	0.13	Schizophrenia;	chr6:56797356	chr6:56844002~56864078:+
BRCA	cis	rs2731006	0.64	rs2056196	ENSG00000257114.2	RP11-25I15.3	4.26	2.26e-05	0.0017	0.19	0.13	Panic disorder;	chr12:42809340	chr12:42692216~42717119:+
BRCA	cis	rs6995541	0.583	rs17152305	ENSG00000246477.3	AF131216.6	4.26	2.26e-05	0.0017	0.13	0.13	Triglyceride levels;	chr8:10762594	chr8:11315859~11325429:-
BRCA	cis	rs2304003	1	rs4667844	ENSG00000235192.1	AC009495.2	4.26	2.26e-05	0.0017	0.15	0.13	Social communication problems;	chr2:165844614	chr2:165794851~165810010:+
BRCA	cis	rs9818758	0.607	rs113186424	ENSG00000225399.4	RP11-3B7.1	-4.26	2.26e-05	0.0017	-0.2	-0.13	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49235293	chr3:49260085~49261316:+
BRCA	cis	rs12594515	0.6	rs12903858	ENSG00000259200.1	RP11-718O11.1	-4.26	2.26e-05	0.0017	-0.14	-0.13	Weight;Waist circumference;	chr15:45679968	chr15:45705078~45931069:+
BRCA	cis	rs2880765	0.566	rs17553249	ENSG00000259630.2	CTD-2262B20.1	-4.26	2.26e-05	0.0017	-0.16	-0.13	Coronary artery disease;	chr15:85463463	chr15:85415228~85415633:+
BRCA	cis	rs62025270	0.747	rs17639314	ENSG00000259295.5	CSPG4P12	-4.26	2.26e-05	0.0017	-0.21	-0.13	Idiopathic pulmonary fibrosis;	chr15:85766678	chr15:85191438~85213905:+
BRCA	cis	rs11098499	0.909	rs2127821	ENSG00000260404.2	RP11-384K6.6	4.26	2.26e-05	0.0017	0.12	0.13	Corneal astigmatism;	chr4:119473380	chr4:118591773~118633729:+
BRCA	cis	rs2562456	0.52	rs25760	ENSG00000240522.1	RPL7AP10	-4.26	2.26e-05	0.0017	-0.16	-0.13	Pain;	chr19:21211375	chr19:21149648~21150438:-
BRCA	cis	rs2411233	0.967	rs10851377	ENSG00000259278.1	RP11-62C7.2	4.26	2.26e-05	0.0017	0.15	0.13	Platelet count;	chr15:38994531	chr15:39019233~39024918:+
BRCA	cis	rs6012564	0.927	rs6019570	ENSG00000222365.1	SNORD12B	-4.26	2.26e-05	0.0017	-0.14	-0.13	Anger;	chr20:48983153	chr20:49280319~49280409:+
BRCA	cis	rs6452524	0.692	rs1382367	ENSG00000281327.1	LINC01338	-4.26	2.26e-05	0.0017	-0.16	-0.13	Hypertension (SNP x SNP interaction);	chr5:83155393	chr5:82850864~82859836:-
BRCA	cis	rs465969	0.744	rs13220692	ENSG00000272356.1	RP5-1112D6.8	4.26	2.26e-05	0.0017	0.28	0.13	Psoriasis;	chr6:111455836	chr6:111309203~111313517:+
BRCA	cis	rs6067053	0.646	rs3818066	ENSG00000227431.4	CSE1L-AS1	4.26	2.27e-05	0.0017	0.17	0.13	Intelligence (multi-trait analysis);	chr20:49278429	chr20:49040463~49046044:-
BRCA	cis	rs11051970	0.877	rs2651360	ENSG00000274964.1	RP11-817I4.1	-4.26	2.27e-05	0.0017	-0.15	-0.13	Response to tocilizumab in rheumatoid arthritis;	chr12:32435986	chr12:32339368~32340724:+
BRCA	cis	rs4835473	0.932	rs1842484	ENSG00000249741.2	RP11-673E1.3	-4.26	2.27e-05	0.0017	-0.13	-0.13	Immature fraction of reticulocytes;	chr4:143793829	chr4:143911514~143912053:-
BRCA	cis	rs703842	0.616	rs870392	ENSG00000270039.1	RP11-571M6.17	-4.26	2.27e-05	0.0017	-0.2	-0.13	Multiple sclerosis;	chr12:57825390	chr12:57803838~57804415:+
BRCA	cis	rs10911902	0.643	rs75906210	ENSG00000229739.2	RP11-295K2.3	-4.26	2.27e-05	0.0017	-0.19	-0.13	Schizophrenia;	chr1:186365092	chr1:186435161~186470291:+
BRCA	cis	rs950169	0.58	rs2271431	ENSG00000229212.6	RP11-561C5.4	-4.26	2.27e-05	0.0017	-0.17	-0.13	Schizophrenia;	chr15:84646233	chr15:85205440~85234795:-
BRCA	cis	rs61931739	0.534	rs10844774	ENSG00000258794.3	DUX4L27	4.26	2.27e-05	0.0017	0.19	0.13	Morning vs. evening chronotype;	chr12:34013829	chr12:34208415~34209675:-
BRCA	cis	rs10861342	1	rs12229846	ENSG00000257999.1	RP11-61E11.2	-4.26	2.27e-05	0.0017	-0.27	-0.13	IgG glycosylation;	chr12:105159288	chr12:105102472~105107179:-
BRCA	cis	rs4218	0.689	rs35066133	ENSG00000259732.1	RP11-59H7.3	-4.26	2.27e-05	0.0017	-0.16	-0.13	Social communication problems;	chr15:59081917	chr15:59121034~59133250:+
BRCA	cis	rs539096	0.56	rs56201009	ENSG00000236200.4	KDM4A-AS1	-4.26	2.27e-05	0.0017	-0.16	-0.13	Intelligence (multi-trait analysis);	chr1:43633075	chr1:43699765~43708138:-
BRCA	cis	rs17818399	0.815	rs17768138	ENSG00000279254.1	RP11-536C12.1	-4.26	2.27e-05	0.0017	-0.17	-0.13	Height;	chr2:46641078	chr2:46668870~46670778:+
BRCA	cis	rs875971	0.545	rs1796222	ENSG00000273142.1	RP11-458F8.4	-4.26	2.27e-05	0.0017	-0.13	-0.13	Aortic root size;	chr7:66592167	chr7:66902857~66906297:+
BRCA	cis	rs1048886	0.745	rs12524814	ENSG00000271967.1	RP11-134K13.4	-4.26	2.27e-05	0.0017	-0.2	-0.13	Type 2 diabetes;	chr6:70519449	chr6:70596438~70596980:+
BRCA	cis	rs7800418	0.753	rs757810	ENSG00000214870.7	AC004540.5	4.26	2.27e-05	0.00171	0.17	0.13	Cognitive function;	chr7:26547780	chr7:26398593~26494256:+
BRCA	cis	rs7800418	0.753	rs757811	ENSG00000214870.7	AC004540.5	4.26	2.27e-05	0.00171	0.17	0.13	Cognitive function;	chr7:26547784	chr7:26398593~26494256:+
BRCA	cis	rs7800418	0.753	rs2391300	ENSG00000214870.7	AC004540.5	4.26	2.27e-05	0.00171	0.17	0.13	Cognitive function;	chr7:26547801	chr7:26398593~26494256:+
BRCA	cis	rs7800418	0.715	rs757812	ENSG00000214870.7	AC004540.5	4.26	2.27e-05	0.00171	0.17	0.13	Cognitive function;	chr7:26547867	chr7:26398593~26494256:+
BRCA	cis	rs7800418	0.784	rs10231724	ENSG00000214870.7	AC004540.5	4.26	2.27e-05	0.00171	0.17	0.13	Cognitive function;	chr7:26548053	chr7:26398593~26494256:+
BRCA	cis	rs7520050	0.807	rs3013594	ENSG00000234329.1	RP11-767N6.2	4.26	2.27e-05	0.00171	0.12	0.13	Reticulocyte count;Red blood cell count;	chr1:45672328	chr1:45651039~45651826:-
BRCA	cis	rs739401	0.611	rs2239900	ENSG00000183562.3	CTC-343N3.1	-4.26	2.27e-05	0.00171	-0.14	-0.13	Longevity;	chr11:3009762	chr11:2989863~2991344:+
BRCA	cis	rs2073316	0.592	rs17545483	ENSG00000272716.1	RP11-563N4.1	4.26	2.27e-05	0.00171	0.14	0.13	Interleukin-18 levels;	chr2:31440937	chr2:32165046~32165757:-
BRCA	cis	rs6963495	0.818	rs73190151	ENSG00000223886.3	RP11-251G23.2	4.26	2.27e-05	0.00171	0.2	0.13	Bipolar disorder (body mass index interaction);	chr7:105512440	chr7:105530209~105530671:+
BRCA	cis	rs3750082	0.632	rs35165932	ENSG00000231952.3	DPY19L1P2	4.26	2.27e-05	0.00171	0.17	0.13	Glomerular filtration rate (creatinine);	chr7:32886648	chr7:32812757~32838570:+
BRCA	cis	rs3750082	0.692	rs10248993	ENSG00000231952.3	DPY19L1P2	4.26	2.27e-05	0.00171	0.17	0.13	Glomerular filtration rate (creatinine);	chr7:32887535	chr7:32812757~32838570:+
BRCA	cis	rs17597773	0.674	rs12117818	ENSG00000238078.1	LINC01352	-4.26	2.27e-05	0.00171	-0.16	-0.13	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220828141	chr1:220829255~220832429:+
BRCA	cis	rs6452524	1	rs10080123	ENSG00000281327.1	LINC01338	-4.26	2.27e-05	0.00171	-0.16	-0.13	Hypertension (SNP x SNP interaction);	chr5:83165447	chr5:82850864~82859836:-
BRCA	cis	rs4650994	0.625	rs6681348	ENSG00000273384.1	RP5-1098D14.1	4.26	2.27e-05	0.00171	0.16	0.13	HDL cholesterol;HDL cholesterol levels;	chr1:178557136	chr1:178651706~178652282:+
BRCA	cis	rs4650994	0.625	rs6681354	ENSG00000273384.1	RP5-1098D14.1	4.26	2.27e-05	0.00171	0.16	0.13	HDL cholesterol;HDL cholesterol levels;	chr1:178557144	chr1:178651706~178652282:+
BRCA	cis	rs10129255	0.518	rs10150460	ENSG00000211959.2	IGHV4-39	-4.26	2.28e-05	0.00171	-0.09	-0.13	Kawasaki disease;	chr14:106677179	chr14:106421711~106422218:-
BRCA	cis	rs6570726	0.516	rs10457779	ENSG00000235652.6	RP11-545I5.3	4.26	2.28e-05	0.00171	0.13	0.13	Lobe attachment (rater-scored or self-reported);	chr6:145415527	chr6:145799409~145886585:+
BRCA	cis	rs11719291	0.833	rs13074318	ENSG00000270441.1	RP11-694I15.7	4.26	2.28e-05	0.00171	0.29	0.13	Cognitive function;	chr3:48779292	chr3:49140086~49160851:-
BRCA	cis	rs61160187	0.582	rs4647150	ENSG00000272308.1	RP11-231G3.1	-4.26	2.28e-05	0.00171	-0.15	-0.13	Educational attainment (years of education);Educational attainment (college completion);	chr5:60874778	chr5:60866457~60866935:-
BRCA	cis	rs875971	0.66	rs7807930	ENSG00000273142.1	RP11-458F8.4	4.26	2.28e-05	0.00171	0.11	0.13	Aortic root size;	chr7:66622178	chr7:66902857~66906297:+
BRCA	cis	rs748404	0.518	rs2176870	ENSG00000249839.1	AC011330.5	4.26	2.28e-05	0.00171	0.17	0.13	Lung cancer;	chr15:43144212	chr15:43663654~43684339:-
BRCA	cis	rs875971	1	rs778726	ENSG00000236529.1	RP13-254B10.1	4.26	2.28e-05	0.00171	0.14	0.13	Aortic root size;	chr7:66363744	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.767	rs1695815	ENSG00000236529.1	RP13-254B10.1	4.26	2.28e-05	0.00171	0.14	0.13	Aortic root size;	chr7:66366357	chr7:65840212~65840596:+
BRCA	cis	rs875971	1	rs778685	ENSG00000236529.1	RP13-254B10.1	4.26	2.28e-05	0.00171	0.14	0.13	Aortic root size;	chr7:66371189	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.929	rs778682	ENSG00000236529.1	RP13-254B10.1	4.26	2.28e-05	0.00171	0.14	0.13	Aortic root size;	chr7:66372947	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.964	rs11765965	ENSG00000236529.1	RP13-254B10.1	4.26	2.28e-05	0.00171	0.14	0.13	Aortic root size;	chr7:66377234	chr7:65840212~65840596:+
BRCA	cis	rs61542988	0.532	rs12673996	ENSG00000228649.7	AC005682.5	4.26	2.28e-05	0.00171	0.12	0.13	Fibrinogen levels;	chr7:22793781	chr7:22854178~22861579:+
BRCA	cis	rs801193	0.548	rs6975044	ENSG00000236529.1	RP13-254B10.1	4.26	2.28e-05	0.00171	0.14	0.13	Aortic root size;	chr7:66762495	chr7:65840212~65840596:+
BRCA	cis	rs2274273	0.624	rs8014540	ENSG00000259318.1	RP11-454L9.2	4.26	2.28e-05	0.00171	0.12	0.13	Protein biomarker;	chr14:55374970	chr14:55394940~55395233:-
BRCA	cis	rs935334	1	rs4304957	ENSG00000258454.1	RP11-361H10.3	4.26	2.28e-05	0.00171	0.21	0.13	Blood pressure;	chr14:76181229	chr14:76235817~76263474:+
BRCA	cis	rs935334	0.825	rs4389088	ENSG00000258454.1	RP11-361H10.3	4.26	2.28e-05	0.00171	0.21	0.13	Blood pressure;	chr14:76181254	chr14:76235817~76263474:+
BRCA	cis	rs7647973	1	rs13088309	ENSG00000244380.1	RP11-24C3.2	4.26	2.28e-05	0.00171	0.17	0.13	Menarche (age at onset);	chr3:49330884	chr3:48440352~48446656:-
BRCA	cis	rs80028505	1	rs7770183	ENSG00000271304.1	DPRXP2	4.26	2.28e-05	0.00171	0.26	0.13	Foot ulcer in diabetes and neuropathy;	chr6:36114796	chr6:35989515~35990436:-
BRCA	cis	rs80028505	0.908	rs56044978	ENSG00000271304.1	DPRXP2	4.26	2.28e-05	0.00171	0.26	0.13	Foot ulcer in diabetes and neuropathy;	chr6:36115327	chr6:35989515~35990436:-
BRCA	cis	rs875971	0.545	rs12671152	ENSG00000232559.3	GS1-124K5.12	4.26	2.28e-05	0.00171	0.18	0.13	Aortic root size;	chr7:66311140	chr7:66554588~66576923:-
BRCA	cis	rs425277	0.958	rs262687	ENSG00000269227.1	RP11-345P4.6	4.26	2.28e-05	0.00171	0.14	0.13	Height;	chr1:2185716	chr1:1673275~1674397:+
BRCA	cis	rs9470794	1	rs57040650	ENSG00000204110.6	RP1-153P14.8	-4.25	2.28e-05	0.00171	-0.26	-0.13	Type 2 diabetes;	chr6:37958983	chr6:37507348~37535616:+
BRCA	cis	rs9470794	1	rs73421433	ENSG00000204110.6	RP1-153P14.8	-4.25	2.28e-05	0.00171	-0.26	-0.13	Type 2 diabetes;	chr6:37964786	chr6:37507348~37535616:+
BRCA	cis	rs8048589	0.558	rs34565142	ENSG00000175604.2	RP11-276H1.3	-4.25	2.28e-05	0.00171	-0.21	-0.13	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);	chr16:12137490	chr16:12086746~12090302:-
BRCA	cis	rs4718428	1	rs12534637	ENSG00000230295.1	RP11-458F8.2	-4.25	2.28e-05	0.00171	-0.11	-0.13	Corneal structure;	chr7:66862667	chr7:66880708~66882981:+
BRCA	cis	rs7727544	0.654	rs4705849	ENSG00000233006.5	AC034220.3	4.25	2.28e-05	0.00171	0.1	0.13	Blood metabolite levels;	chr5:132223506	chr5:132311285~132369916:-
BRCA	cis	rs934734	0.571	rs7565437	ENSG00000281920.1	RP11-418H16.1	-4.25	2.28e-05	0.00171	-0.16	-0.13	Rheumatoid arthritis;	chr2:65419832	chr2:65623272~65628424:+
BRCA	cis	rs11673344	0.523	rs6510585	ENSG00000226686.6	LINC01535	4.25	2.28e-05	0.00171	0.17	0.13	Obesity-related traits;	chr19:37063081	chr19:37251912~37265535:+
BRCA	cis	rs4374383	0.884	rs4468823	ENSG00000243389.1	AC012442.5	-4.25	2.28e-05	0.00171	-0.17	-0.13	Hepatitis C induced liver fibrosis;	chr2:111926794	chr2:112589040~112614431:+
BRCA	cis	rs8103278	1	rs7252126	ENSG00000267395.4	AC074212.6	4.25	2.28e-05	0.00171	0.13	0.13	Coronary artery disease;	chr19:45799116	chr19:45767796~45772504:+
BRCA	cis	rs3764021	0.87	rs7970116	ENSG00000256582.1	RP11-75L1.1	-4.25	2.28e-05	0.00171	-0.13	-0.13	Type 1 diabetes;	chr12:9727518	chr12:9704077~9709350:+
BRCA	cis	rs1371614	0.589	rs935018	ENSG00000272148.1	RP11-195B17.1	-4.25	2.28e-05	0.00171	-0.15	-0.13	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26883757	chr2:27062428~27062907:-
BRCA	cis	rs2625529	0.824	rs16956328	ENSG00000260037.4	CTD-2524L6.3	-4.25	2.28e-05	0.00171	-0.19	-0.13	Red blood cell count;	chr15:71851514	chr15:71818396~71823384:+
BRCA	cis	rs2834288	0.5	rs766425	ENSG00000237945.6	LINC00649	4.25	2.28e-05	0.00171	0.15	0.13	Gut microbiota (bacterial taxa);	chr21:33962264	chr21:33915534~33977691:+
BRCA	cis	rs7824557	0.767	rs28507159	ENSG00000248896.2	CTD-2135J3.3	4.25	2.28e-05	0.00171	0.18	0.13	Retinal vascular caliber;	chr8:11308567	chr8:10729314~10771392:+
BRCA	cis	rs58521262	0.556	rs289338	ENSG00000268105.1	RP11-369G6.2	4.25	2.28e-05	0.00171	0.18	0.13	Testicular germ cell tumor;	chr19:22968623	chr19:23125665~23128543:+
BRCA	cis	rs7267979	0.816	rs405822	ENSG00000231081.1	RP4-760C5.3	-4.25	2.28e-05	0.00171	-0.16	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25520678	chr20:26008791~26010531:-
BRCA	cis	rs7267979	0.816	rs409853	ENSG00000231081.1	RP4-760C5.3	-4.25	2.28e-05	0.00171	-0.16	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25525431	chr20:26008791~26010531:-
BRCA	cis	rs12935418	0.616	rs12446053	ENSG00000261061.1	RP11-303E16.2	4.25	2.28e-05	0.00171	0.13	0.13	Mean corpuscular volume;	chr16:80930234	chr16:81030770~81031485:+
BRCA	cis	rs893971	0.646	rs1595910	ENSG00000246375.2	RP11-10L7.1	4.25	2.28e-05	0.00171	0.17	0.13	Conduct disorder (maternal expressed emotions interaction);	chr4:88311420	chr4:88284942~88331421:+
BRCA	cis	rs10847980	1	rs10847980	ENSG00000256092.2	RP13-942N8.1	4.25	2.28e-05	0.00171	0.19	0.13	Adiponectin levels;	chr12:122903375	chr12:123363868~123366113:+
BRCA	cis	rs8058578	1	rs7204278	ENSG00000260911.2	RP11-196G11.2	4.25	2.28e-05	0.00171	0.13	0.13	Multiple myeloma;	chr16:30718953	chr16:31043150~31049868:+
BRCA	cis	rs11083475	1	rs10415219	ENSG00000267892.1	CTD-2540F13.2	4.25	2.28e-05	0.00171	0.15	0.13	Heart rate;	chr19:38659595	chr19:38738284~38739863:+
BRCA	cis	rs4561483	0.801	rs33660	ENSG00000261216.1	RP11-166B2.5	-4.25	2.29e-05	0.00171	-0.15	-0.13	Testicular germ cell tumor;	chr16:11868001	chr16:11908208~11908916:+
BRCA	cis	rs911119	0.955	rs4815224	ENSG00000270001.1	RP11-218C14.8	-4.25	2.29e-05	0.00171	-0.18	-0.13	Chronic kidney disease;	chr20:23613475	chr20:23631826~23632316:-
BRCA	cis	rs7475343	0.501	rs17134592	ENSG00000224034.1	RP11-445P17.8	-4.25	2.29e-05	0.00171	-0.25	-0.13	Intelligence;	chr10:5218719	chr10:5266033~5271236:-
BRCA	cis	rs687432	0.847	rs12790525	ENSG00000265566.2	RN7SL605P	-4.25	2.29e-05	0.00171	-0.19	-0.13	Parkinson's disease;	chr11:58054978	chr11:57528085~57528365:-
BRCA	cis	rs687432	0.885	rs61904024	ENSG00000265566.2	RN7SL605P	-4.25	2.29e-05	0.00171	-0.19	-0.13	Parkinson's disease;	chr11:58055283	chr11:57528085~57528365:-
BRCA	cis	rs6963495	0.818	rs117845382	ENSG00000223886.3	RP11-251G23.2	4.25	2.29e-05	0.00172	0.2	0.13	Bipolar disorder (body mass index interaction);	chr7:105511593	chr7:105530209~105530671:+
BRCA	cis	rs6963495	0.818	rs116457537	ENSG00000223886.3	RP11-251G23.2	4.25	2.29e-05	0.00172	0.2	0.13	Bipolar disorder (body mass index interaction);	chr7:105511625	chr7:105530209~105530671:+
BRCA	cis	rs875971	0.8	rs427557	ENSG00000229180.5	GS1-124K5.11	4.25	2.29e-05	0.00172	0.11	0.13	Aortic root size;	chr7:66054263	chr7:66526088~66542624:-
BRCA	cis	rs10129255	0.5	rs2105991	ENSG00000232216.1	IGHV3-43	4.25	2.29e-05	0.00172	0.1	0.13	Kawasaki disease;	chr14:106682022	chr14:106470264~106470800:-
BRCA	cis	rs8022179	0.58	rs6575979	ENSG00000244691.1	RPL10AP1	-4.25	2.29e-05	0.00172	-0.18	-0.13	Monocyte count;	chr14:103374681	chr14:103412119~103412761:-
BRCA	cis	rs1823874	0.71	rs56160817	ENSG00000182397.13	DNM1P46	-4.25	2.29e-05	0.00172	-0.15	-0.13	IgG glycosylation;	chr15:99820472	chr15:99790156~99806927:-
BRCA	cis	rs721917	0.525	rs2250652	ENSG00000278616.1	BEND3P3	-4.25	2.29e-05	0.00172	-0.12	-0.13	Chronic obstructive pulmonary disease;	chr10:79902893	chr10:79682997~79685436:+
BRCA	cis	rs875971	0.929	rs4122249	ENSG00000265600.1	AC006480.1	-4.25	2.29e-05	0.00172	-0.15	-0.13	Aortic root size;	chr7:66455949	chr7:67356680~67356779:+
BRCA	cis	rs2243480	0.901	rs2900904	ENSG00000222364.1	RNU6-96P	-4.25	2.29e-05	0.00172	-0.24	-0.13	Diabetic kidney disease;	chr7:65739282	chr7:66395191~66395286:+
BRCA	cis	rs2739330	0.796	rs2154594	ENSG00000228039.3	KB-1125A3.10	-4.25	2.29e-05	0.00172	-0.15	-0.13	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23963780~23964374:+
BRCA	cis	rs739496	0.895	rs2283357	ENSG00000234608.6	MAPKAPK5-AS1	4.25	2.29e-05	0.00172	0.16	0.13	Platelet count;	chr12:111459575	chr12:111839764~111842902:-
BRCA	cis	rs11158026	0.603	rs17832269	ENSG00000258413.1	RP11-665C16.6	-4.25	2.29e-05	0.00172	-0.18	-0.13	Parkinson's disease;	chr14:54965373	chr14:55262767~55272075:-
BRCA	cis	rs801193	0.613	rs2659900	ENSG00000272831.1	RP11-792A8.4	4.25	2.29e-05	0.00172	0.12	0.13	Aortic root size;	chr7:66719456	chr7:66739829~66740385:-
BRCA	cis	rs2304003	1	rs9973895	ENSG00000235192.1	AC009495.2	4.25	2.29e-05	0.00172	0.16	0.13	Social communication problems;	chr2:165860936	chr2:165794851~165810010:+
BRCA	cis	rs2625529	0.652	rs2929518	ENSG00000260037.4	CTD-2524L6.3	4.25	2.29e-05	0.00172	0.16	0.13	Red blood cell count;	chr15:72040407	chr15:71818396~71823384:+
BRCA	cis	rs17270561	0.666	rs9356988	ENSG00000272462.2	U91328.19	-4.25	2.29e-05	0.00172	-0.16	-0.13	Iron status biomarkers;	chr6:25777253	chr6:25992662~26001775:+
BRCA	cis	rs6480314	0.636	rs34888891	ENSG00000233590.1	RP11-153K11.3	-4.25	2.29e-05	0.00172	-0.22	-0.13	Optic nerve measurement (disc area);	chr10:68242351	chr10:68233251~68242379:-
BRCA	cis	rs720475	0.732	rs17195725	ENSG00000228960.5	OR2A9P	4.25	2.29e-05	0.00172	0.2	0.13	Breast cancer;	chr7:144440044	chr7:144294480~144300934:+
BRCA	cis	rs853679	0.517	rs17711344	ENSG00000261839.1	RP1-265C24.8	-4.25	2.29e-05	0.00172	-0.18	-0.13	Depression;	chr6:28109824	chr6:28136849~28139678:+
BRCA	cis	rs321358	1	rs321368	ENSG00000271390.1	RP11-89C3.3	4.25	2.3e-05	0.00172	0.21	0.13	Body mass index;	chr11:111129033	chr11:111089870~111090368:-
BRCA	cis	rs321358	1	rs321369	ENSG00000271390.1	RP11-89C3.3	4.25	2.3e-05	0.00172	0.21	0.13	Body mass index;	chr11:111129797	chr11:111089870~111090368:-
BRCA	cis	rs321358	1	rs321370	ENSG00000271390.1	RP11-89C3.3	4.25	2.3e-05	0.00172	0.21	0.13	Body mass index;	chr11:111129959	chr11:111089870~111090368:-
BRCA	cis	rs7011507	0.617	rs10110147	ENSG00000233858.4	AC026904.1	-4.25	2.3e-05	0.00172	-0.16	-0.13	Inflammatory bowel disease;Ulcerative colitis;	chr8:48469851	chr8:48590401~48594621:+
BRCA	cis	rs7011507	0.617	rs931764	ENSG00000233858.4	AC026904.1	-4.25	2.3e-05	0.00172	-0.16	-0.13	Inflammatory bowel disease;Ulcerative colitis;	chr8:48471994	chr8:48590401~48594621:+
BRCA	cis	rs6012564	0.927	rs6019570	ENSG00000227431.4	CSE1L-AS1	-4.25	2.3e-05	0.00172	-0.16	-0.13	Anger;	chr20:48983153	chr20:49040463~49046044:-
BRCA	cis	rs12477438	0.834	rs11903311	ENSG00000231822.1	AC019097.7	-4.25	2.3e-05	0.00172	-0.14	-0.13	Chronic sinus infection;	chr2:99085344	chr2:99102018~99102752:+
BRCA	cis	rs4948275	0.631	rs2606114	ENSG00000237233.2	TMEM26-AS1	-4.25	2.3e-05	0.00172	-0.15	-0.13	Night sleep phenotypes;	chr10:61589393	chr10:61452639~61481956:+
BRCA	cis	rs4787491	0.729	rs11544328	ENSG00000183604.13	SMG1P5	-4.25	2.3e-05	0.00172	-0.12	-0.13	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30025807	chr16:30267553~30335374:-
BRCA	cis	rs7811142	0.775	rs6946768	ENSG00000078319.8	PMS2P1	-4.25	2.3e-05	0.00172	-0.22	-0.13	Platelet count;	chr7:100356770	chr7:100320992~100341908:-
BRCA	cis	rs812925	0.537	rs2593620	ENSG00000270820.4	RP11-355B11.2	-4.25	2.3e-05	0.00172	-0.14	-0.13	Immature fraction of reticulocytes;	chr2:61386126	chr2:61471188~61484130:+
BRCA	cis	rs11671005	0.611	rs56026876	ENSG00000269600.1	AC016629.3	-4.25	2.3e-05	0.00172	-0.21	-0.13	Mean platelet volume;	chr19:58494790	chr19:58593896~58599355:-
BRCA	cis	rs12439619	0.846	rs28470877	ENSG00000259429.4	UBE2Q2P2	-4.25	2.3e-05	0.00172	-0.16	-0.13	Intelligence (multi-trait analysis);	chr15:82245797	chr15:82355142~82420075:+
BRCA	cis	rs3176789	0.647	rs7309767	ENSG00000256673.1	RP11-599J14.2	4.25	2.3e-05	0.00172	0.15	0.13	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9768303	chr12:9398355~9414851:-
BRCA	cis	rs35146811	0.844	rs4424195	ENSG00000214313.7	AZGP1P1	4.25	2.3e-05	0.00172	0.13	0.13	Coronary artery disease;	chr7:100045122	chr7:99980762~99987535:+
BRCA	cis	rs6012564	0.893	rs6012579	ENSG00000222365.1	SNORD12B	-4.25	2.3e-05	0.00172	-0.14	-0.13	Anger;	chr20:49006883	chr20:49280319~49280409:+
BRCA	cis	rs16944613	0.541	rs7494949	ENSG00000271396.1	RP11-697E2.9	-4.25	2.3e-05	0.00172	-0.21	-0.13	Colorectal cancer;	chr15:90547162	chr15:90284376~90285580:-
BRCA	cis	rs651907	0.535	rs11919389	ENSG00000256628.3	ZBTB11-AS1	4.25	2.3e-05	0.00172	0.16	0.13	Colorectal cancer;	chr3:101705614	chr3:101676475~101679217:+
BRCA	cis	rs1538970	0.781	rs34768551	ENSG00000281133.1	AL355480.3	-4.25	2.3e-05	0.00173	-0.19	-0.13	Platelet count;	chr1:45554736	chr1:45580892~45580996:-
BRCA	cis	rs7267979	1	rs4815408	ENSG00000125804.12	FAM182A	4.25	2.3e-05	0.00173	0.17	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25366042	chr20:26054655~26086917:+
BRCA	cis	rs6596100	0.823	rs11745702	ENSG00000248648.1	RP11-485M7.1	-4.25	2.3e-05	0.00173	-0.17	-0.13	Breast cancer;	chr5:133108609	chr5:133003119~133003365:+
BRCA	cis	rs6921919	0.583	rs6907950	ENSG00000273712.1	RP5-874C20.7	4.25	2.3e-05	0.00173	0.17	0.13	Autism spectrum disorder or schizophrenia;	chr6:28402469	chr6:28315613~28315883:-
BRCA	cis	rs72772090	0.522	rs76590269	ENSG00000248734.2	CTD-2260A17.1	-4.25	2.3e-05	0.00173	-0.31	-0.13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96660706	chr5:96784777~96785999:+
BRCA	cis	rs6545883	0.507	rs62149712	ENSG00000270820.4	RP11-355B11.2	-4.25	2.3e-05	0.00173	-0.14	-0.13	Tuberculosis;	chr2:61374137	chr2:61471188~61484130:+
BRCA	cis	rs7200543	0.666	rs34955778	ENSG00000258354.1	MIR3180-1	-4.25	2.3e-05	0.00173	-0.16	-0.13	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15045737	chr16:14909887~14911345:-
BRCA	cis	rs17406451	0.704	rs2172169	ENSG00000234936.1	AC010883.5	4.25	2.3e-05	0.00173	0.13	0.13	Mitochondrial DNA levels;	chr2:43530726	chr2:43229573~43233394:+
BRCA	cis	rs2692947	0.759	rs11687113	ENSG00000232931.4	LINC00342	4.25	2.3e-05	0.00173	0.13	0.13	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95992840	chr2:95807118~95816215:-
BRCA	cis	rs8180040	0.676	rs11130114	ENSG00000276925.1	RP11-708J19.3	-4.25	2.3e-05	0.00173	-0.15	-0.13	Colorectal cancer;	chr3:47113161	chr3:47469777~47469987:+
BRCA	cis	rs2163813	0.788	rs247774	ENSG00000275540.1	CTC-559E9.12	-4.25	2.31e-05	0.00173	-0.18	-0.13	Toenail selenium levels;	chr19:19732742	chr19:19740884~19750127:+
BRCA	cis	rs9859260	0.744	rs3933	ENSG00000207650.1	MIR570	-4.25	2.31e-05	0.00173	-0.15	-0.13	Mean corpuscular volume;	chr3:196058126	chr3:195699401~195699497:+
BRCA	cis	rs12468226	0.938	rs4675274	ENSG00000272966.1	RP11-686O6.1	-4.25	2.31e-05	0.00173	-0.21	-0.13	Urate levels;	chr2:202243145	chr2:202336739~202337200:+
BRCA	cis	rs62025270	0.547	rs416916	ENSG00000259295.5	CSPG4P12	-4.25	2.31e-05	0.00173	-0.17	-0.13	Idiopathic pulmonary fibrosis;	chr15:85649185	chr15:85191438~85213905:+
BRCA	cis	rs4650943	0.565	rs352329	ENSG00000227740.1	RP11-318C24.2	-4.25	2.31e-05	0.00173	-0.13	-0.13	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in inactive individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr1:176273954	chr1:175904762~175920513:-
BRCA	cis	rs34217772	1	rs17781427	ENSG00000258636.1	CTD-2298J14.2	4.25	2.31e-05	0.00173	0.17	0.13	Myopia;	chr14:41802022	chr14:41587861~41604856:-
BRCA	cis	rs10504130	0.569	rs11784869	ENSG00000253844.1	RP11-546K22.1	-4.25	2.31e-05	0.00173	-0.19	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr8:51906951	chr8:51961458~52022974:+
BRCA	cis	rs6870983	0.802	rs10074877	ENSG00000247828.6	TMEM161B-AS1	-4.25	2.31e-05	0.00173	-0.16	-0.13	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index;	chr5:88449565	chr5:88268895~88436685:+
BRCA	cis	rs442309	0.967	rs224031	ENSG00000238280.1	RP11-436D10.3	-4.25	2.31e-05	0.00173	-0.17	-0.13	Vogt-Koyanagi-Harada syndrome;	chr10:62761596	chr10:62793562~62805887:-
BRCA	cis	rs6600671	0.899	rs2319971	ENSG00000275538.1	RNVU1-19	4.25	2.31e-05	0.00173	0.16	0.13	Hip geometry;	chr1:121485184	chr1:120850819~120850985:-
BRCA	cis	rs4578769	0.765	rs67551099	ENSG00000265939.1	UBE2CP2	-4.25	2.31e-05	0.00173	-0.16	-0.13	Eosinophil percentage of white cells;	chr18:22831167	chr18:22900486~22900995:-
BRCA	cis	rs875971	0.638	rs3898855	ENSG00000232546.1	RP11-458F8.1	4.25	2.31e-05	0.00173	0.11	0.13	Aortic root size;	chr7:66571411	chr7:66848496~66858136:+
BRCA	cis	rs875971	0.638	rs10278816	ENSG00000232546.1	RP11-458F8.1	4.25	2.31e-05	0.00173	0.11	0.13	Aortic root size;	chr7:66572000	chr7:66848496~66858136:+
BRCA	cis	rs875971	0.66	rs10281080	ENSG00000232546.1	RP11-458F8.1	4.25	2.31e-05	0.00173	0.11	0.13	Aortic root size;	chr7:66577454	chr7:66848496~66858136:+
BRCA	cis	rs875971	0.66	rs10950044	ENSG00000232546.1	RP11-458F8.1	4.25	2.31e-05	0.00173	0.11	0.13	Aortic root size;	chr7:66577989	chr7:66848496~66858136:+
BRCA	cis	rs9467773	0.595	rs12525810	ENSG00000241549.7	GUSBP2	4.25	2.31e-05	0.00173	0.14	0.13	Intelligence (multi-trait analysis);	chr6:26623283	chr6:26871484~26956554:-
BRCA	cis	rs651907	0.514	rs10936744	ENSG00000256628.3	ZBTB11-AS1	4.25	2.31e-05	0.00173	0.16	0.13	Colorectal cancer;	chr3:101714596	chr3:101676475~101679217:+
BRCA	cis	rs6496044	0.547	rs1564719	ENSG00000202081.1	RNU6-1280P	4.25	2.31e-05	0.00173	0.15	0.13	Interstitial lung disease;	chr15:85511035	chr15:85651522~85651628:-
BRCA	cis	rs7937890	0.559	rs2575831	ENSG00000254418.1	RP11-21L19.1	4.25	2.31e-05	0.00173	0.15	0.13	Mitochondrial DNA levels;	chr11:14464648	chr11:14262846~14273691:-
BRCA	cis	rs11673344	0.518	rs73033134	ENSG00000267422.1	CTD-2554C21.1	4.25	2.31e-05	0.00173	0.18	0.13	Obesity-related traits;	chr19:37596046	chr19:37779686~37792865:+
BRCA	cis	rs4295623	0.531	rs2898295	ENSG00000251402.3	FAM90A25P	-4.25	2.31e-05	0.00173	-0.15	-0.13	Morning vs. evening chronotype;	chr8:11738460	chr8:12415080~12418090:-
BRCA	cis	rs11098499	0.754	rs17049949	ENSG00000225892.3	RP11-384K6.2	4.25	2.31e-05	0.00173	0.13	0.13	Corneal astigmatism;	chr4:119334135	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.754	rs7689729	ENSG00000225892.3	RP11-384K6.2	4.25	2.31e-05	0.00173	0.13	0.13	Corneal astigmatism;	chr4:119335037	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.865	rs3956464	ENSG00000225892.3	RP11-384K6.2	4.25	2.31e-05	0.00173	0.13	0.13	Corneal astigmatism;	chr4:119335609	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.648	rs2002047	ENSG00000225892.3	RP11-384K6.2	4.25	2.31e-05	0.00173	0.13	0.13	Corneal astigmatism;	chr4:119336073	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.775	rs2002049	ENSG00000225892.3	RP11-384K6.2	4.25	2.31e-05	0.00173	0.13	0.13	Corneal astigmatism;	chr4:119336262	chr4:118632274~118634759:+
BRCA	cis	rs4415084	0.661	rs10462080	ENSG00000251141.4	RP11-53O19.1	4.25	2.31e-05	0.00173	0.12	0.13	Breast cancer;	chr5:44798950	chr5:44744900~44808777:-
BRCA	cis	rs3748682	1	rs3748682	ENSG00000252448.1	SNORA63	4.25	2.31e-05	0.00173	0.16	0.13	Hypothyroidism;	chr1:37814315	chr1:37884237~37884317:+
BRCA	cis	rs7429990	0.932	rs6803741	ENSG00000228638.1	FCF1P2	4.25	2.31e-05	0.00173	0.13	0.13	Educational attainment (years of education);	chr3:48082050	chr3:48290793~48291375:-
BRCA	cis	rs7572733	0.555	rs35563720	ENSG00000231621.1	AC013264.2	-4.25	2.31e-05	0.00173	-0.13	-0.13	Dermatomyositis;	chr2:198058351	chr2:197197991~197199273:+
BRCA	cis	rs1440410	0.83	rs10519678	ENSG00000250326.1	RP11-284M14.1	-4.25	2.32e-05	0.00173	-0.14	-0.13	Ischemic stroke;	chr4:143260920	chr4:142933195~143184861:-
BRCA	cis	rs7475343	0.543	rs77353068	ENSG00000224034.1	RP11-445P17.8	-4.25	2.32e-05	0.00173	-0.25	-0.13	Intelligence;	chr10:5219263	chr10:5266033~5271236:-
BRCA	cis	rs7475343	0.543	rs80264034	ENSG00000224034.1	RP11-445P17.8	-4.25	2.32e-05	0.00173	-0.25	-0.13	Intelligence;	chr10:5219613	chr10:5266033~5271236:-
BRCA	cis	rs7475343	0.543	rs74404998	ENSG00000224034.1	RP11-445P17.8	-4.25	2.32e-05	0.00173	-0.25	-0.13	Intelligence;	chr10:5219720	chr10:5266033~5271236:-
BRCA	cis	rs7475343	0.543	rs17134607	ENSG00000224034.1	RP11-445P17.8	-4.25	2.32e-05	0.00173	-0.25	-0.13	Intelligence;	chr10:5219947	chr10:5266033~5271236:-
BRCA	cis	rs875971	1	rs778696	ENSG00000229180.5	GS1-124K5.11	4.25	2.32e-05	0.00173	0.11	0.13	Aortic root size;	chr7:66405826	chr7:66526088~66542624:-
BRCA	cis	rs875971	1	rs778694	ENSG00000229180.5	GS1-124K5.11	4.25	2.32e-05	0.00173	0.11	0.13	Aortic root size;	chr7:66406571	chr7:66526088~66542624:-
BRCA	cis	rs875971	1	rs4718344	ENSG00000229180.5	GS1-124K5.11	4.25	2.32e-05	0.00173	0.11	0.13	Aortic root size;	chr7:66409394	chr7:66526088~66542624:-
BRCA	cis	rs875971	0.737	rs7803424	ENSG00000229180.5	GS1-124K5.11	4.25	2.32e-05	0.00173	0.11	0.13	Aortic root size;	chr7:66415618	chr7:66526088~66542624:-
BRCA	cis	rs875971	0.83	rs7799834	ENSG00000229180.5	GS1-124K5.11	4.25	2.32e-05	0.00173	0.11	0.13	Aortic root size;	chr7:66415707	chr7:66526088~66542624:-
BRCA	cis	rs853679	0.567	rs9969098	ENSG00000220721.1	OR1F12	4.25	2.32e-05	0.00173	0.17	0.13	Depression;	chr6:28430971	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.567	rs16894106	ENSG00000220721.1	OR1F12	4.25	2.32e-05	0.00173	0.17	0.13	Depression;	chr6:28432562	chr6:28073316~28074233:+
BRCA	cis	rs2243480	1	rs1723270	ENSG00000222364.1	RNU6-96P	-4.25	2.32e-05	0.00173	-0.24	-0.13	Diabetic kidney disease;	chr7:66004843	chr7:66395191~66395286:+
BRCA	cis	rs4950322	0.57	rs72692907	ENSG00000237188.3	RP11-337C18.8	4.25	2.32e-05	0.00174	0.17	0.13	Protein quantitative trait loci;	chr1:147301921	chr1:147172771~147211568:+
BRCA	cis	rs4950322	0.57	rs72692914	ENSG00000237188.3	RP11-337C18.8	4.25	2.32e-05	0.00174	0.17	0.13	Protein quantitative trait loci;	chr1:147302946	chr1:147172771~147211568:+
BRCA	cis	rs2446066	0.872	rs7309494	ENSG00000257379.1	RP11-793H13.8	4.25	2.32e-05	0.00174	0.21	0.13	Red blood cell count;	chr12:53432209	chr12:53441741~53467528:+
BRCA	cis	rs736408	0.527	rs2577831	ENSG00000243224.1	RP5-1157M23.2	-4.25	2.32e-05	0.00174	-0.14	-0.13	Bipolar disorder;	chr3:52594040	chr3:52239258~52241097:+
BRCA	cis	rs10911902	0.643	rs75008037	ENSG00000229739.2	RP11-295K2.3	-4.25	2.32e-05	0.00174	-0.19	-0.13	Schizophrenia;	chr1:186371380	chr1:186435161~186470291:+
BRCA	cis	rs10911902	0.643	rs76554103	ENSG00000229739.2	RP11-295K2.3	-4.25	2.32e-05	0.00174	-0.19	-0.13	Schizophrenia;	chr1:186371402	chr1:186435161~186470291:+
BRCA	cis	rs10911902	0.643	rs7514615	ENSG00000229739.2	RP11-295K2.3	-4.25	2.32e-05	0.00174	-0.19	-0.13	Schizophrenia;	chr1:186373191	chr1:186435161~186470291:+
BRCA	cis	rs875971	0.66	rs7807944	ENSG00000273142.1	RP11-458F8.4	4.25	2.32e-05	0.00174	0.11	0.13	Aortic root size;	chr7:66622208	chr7:66902857~66906297:+
BRCA	cis	rs8114671	0.933	rs2103971	ENSG00000279253.1	RP4-614O4.13	4.25	2.32e-05	0.00174	0.15	0.13	Height;	chr20:35198453	chr20:35262727~35264187:-
BRCA	cis	rs10043228	1	rs17138884	ENSG00000271918.1	CTD-2287O16.5	-4.25	2.32e-05	0.00174	-0.16	-0.13	Asthma or chronic obstructive pulmonary disease;	chr5:116089931	chr5:116083807~116085416:-
BRCA	cis	rs7789940	0.809	rs12533836	ENSG00000280388.1	RP11-229D13.3	-4.25	2.32e-05	0.00174	-0.14	-0.13	Multiple sclerosis;	chr7:76306305	chr7:76043977~76045963:-
BRCA	cis	rs2243480	0.901	rs3813708	ENSG00000226002.1	RP11-460N20.5	-4.25	2.32e-05	0.00174	-0.22	-0.13	Diabetic kidney disease;	chr7:65840645	chr7:65084103~65100232:+
BRCA	cis	rs2039553	0.591	rs7984156	ENSG00000227354.5	RBM26-AS1	-4.25	2.32e-05	0.00174	-0.15	-0.13	Pancreatic cancer;	chr13:79800402	chr13:79406309~79424328:+
BRCA	cis	rs875971	0.929	rs778692	ENSG00000229180.5	GS1-124K5.11	4.25	2.32e-05	0.00174	0.11	0.13	Aortic root size;	chr7:66407462	chr7:66526088~66542624:-
BRCA	cis	rs875971	1	rs4718343	ENSG00000229180.5	GS1-124K5.11	4.25	2.32e-05	0.00174	0.11	0.13	Aortic root size;	chr7:66409301	chr7:66526088~66542624:-
BRCA	cis	rs875971	1	rs1968225	ENSG00000229180.5	GS1-124K5.11	4.25	2.32e-05	0.00174	0.11	0.13	Aortic root size;	chr7:66409786	chr7:66526088~66542624:-
BRCA	cis	rs875971	1	rs6460295	ENSG00000229180.5	GS1-124K5.11	4.25	2.32e-05	0.00174	0.11	0.13	Aortic root size;	chr7:66417741	chr7:66526088~66542624:-
BRCA	cis	rs875971	0.964	rs6978721	ENSG00000229180.5	GS1-124K5.11	4.25	2.32e-05	0.00174	0.11	0.13	Aortic root size;	chr7:66418217	chr7:66526088~66542624:-
BRCA	cis	rs2243480	1	rs1167613	ENSG00000222364.1	RNU6-96P	-4.25	2.32e-05	0.00174	-0.24	-0.13	Diabetic kidney disease;	chr7:66022452	chr7:66395191~66395286:+
BRCA	cis	rs2243480	1	rs313799	ENSG00000222364.1	RNU6-96P	-4.25	2.32e-05	0.00174	-0.24	-0.13	Diabetic kidney disease;	chr7:66029343	chr7:66395191~66395286:+
BRCA	cis	rs709400	0.93	rs10149249	ENSG00000258851.1	RP11-894P9.2	-4.25	2.32e-05	0.00174	-0.16	-0.13	Body mass index;	chr14:103581420	chr14:103553421~103561877:+
BRCA	cis	rs7932354	0.536	rs1551744	ENSG00000200376.1	RNU5E-10P	4.25	2.32e-05	0.00174	0.16	0.13	Bone mineral density (hip);Bone mineral density;	chr11:46843449	chr11:47576471~47576588:-
BRCA	cis	rs12612619	0.732	rs2304681	ENSG00000272148.1	RP11-195B17.1	-4.25	2.32e-05	0.00174	-0.15	-0.13	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27092384	chr2:27062428~27062907:-
BRCA	cis	rs8180040	0.62	rs9845728	ENSG00000271161.1	BOLA2P2	4.25	2.32e-05	0.00174	0.14	0.13	Colorectal cancer;	chr3:47061886	chr3:47499841~47500407:+
BRCA	cis	rs8180040	0.62	rs9844122	ENSG00000271161.1	BOLA2P2	4.25	2.32e-05	0.00174	0.14	0.13	Colorectal cancer;	chr3:47066840	chr3:47499841~47500407:+
BRCA	cis	rs983392	0.805	rs10897011	ENSG00000275344.1	MIR6503	-4.25	2.32e-05	0.00174	-0.14	-0.13	Alzheimer's disease (late onset);	chr11:60193954	chr11:60209071~60209156:-
BRCA	cis	rs4713118	0.662	rs464312	ENSG00000216901.1	AL022393.7	4.25	2.32e-05	0.00174	0.18	0.13	Parkinson's disease;	chr6:27999813	chr6:28176188~28176674:+
BRCA	cis	rs4713118	0.662	rs469228	ENSG00000216901.1	AL022393.7	4.25	2.32e-05	0.00174	0.18	0.13	Parkinson's disease;	chr6:28002926	chr6:28176188~28176674:+
BRCA	cis	rs4713118	0.54	rs469227	ENSG00000216901.1	AL022393.7	4.25	2.32e-05	0.00174	0.18	0.13	Parkinson's disease;	chr6:28002927	chr6:28176188~28176674:+
BRCA	cis	rs4713118	0.662	rs149948	ENSG00000216901.1	AL022393.7	4.25	2.32e-05	0.00174	0.18	0.13	Parkinson's disease;	chr6:28007039	chr6:28176188~28176674:+
BRCA	cis	rs9982086	0.793	rs79926245	ENSG00000260583.1	AP000223.42	-4.25	2.32e-05	0.00174	-0.32	-0.13	Carboplatin disposition in epthelial ovarian cancer;	chr21:25609354	chr21:25582770~25583326:-
BRCA	cis	rs2243480	0.901	rs2900904	ENSG00000275400.1	RP4-756H11.5	4.25	2.32e-05	0.00174	0.23	0.13	Diabetic kidney disease;	chr7:65739282	chr7:66553805~66554199:-
BRCA	cis	rs1910358	0.53	rs1520978	ENSG00000248874.4	C5orf17	-4.25	2.32e-05	0.00174	-0.18	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23753388	chr5:23951348~24178263:+
BRCA	cis	rs1910358	0.554	rs13153859	ENSG00000248874.4	C5orf17	-4.25	2.32e-05	0.00174	-0.18	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23754900	chr5:23951348~24178263:+
BRCA	cis	rs75804782	0.63	rs56108200	ENSG00000186235.9	AC016757.3	4.25	2.32e-05	0.00174	0.33	0.13	Chronotype;Morning vs. evening chronotype;	chr2:238368247	chr2:238224552~238231677:-
BRCA	cis	rs7209700	0.644	rs7214468	ENSG00000228782.6	CTD-2026D20.3	-4.25	2.32e-05	0.00174	-0.15	-0.13	IgG glycosylation;	chr17:47293400	chr17:47450568~47492492:-
BRCA	cis	rs4302906	0.964	rs10992561	ENSG00000187984.11	ANKRD19P	-4.25	2.32e-05	0.00174	-0.12	-0.13	Lobe attachment (rater-scored or self-reported);	chr9:92976101	chr9:92809388~92888693:+
BRCA	cis	rs58521262	0.585	rs462900	ENSG00000268105.1	RP11-369G6.2	4.25	2.32e-05	0.00174	0.18	0.13	Testicular germ cell tumor;	chr19:22940861	chr19:23125665~23128543:+
BRCA	cis	rs6968419	0.674	rs7459355	ENSG00000279086.1	RP11-667F14.1	-4.25	2.32e-05	0.00174	-0.14	-0.13	Intraocular pressure;	chr7:116266721	chr7:116209234~116211511:-
BRCA	cis	rs11764932	0.931	rs740567	ENSG00000229108.1	MEOX2-AS1	-4.25	2.32e-05	0.00174	-0.15	-0.13	Kidney function decline traits;	chr7:15687704	chr7:15688378~15695491:+
BRCA	cis	rs7200786	0.583	rs7185202	ENSG00000274038.1	RP11-66H6.4	-4.25	2.32e-05	0.00174	-0.15	-0.13	Systemic lupus erythematosus;Multiple sclerosis;	chr16:11041207	chr16:11056556~11057034:+
BRCA	cis	rs58521262	0.556	rs289318	ENSG00000268105.1	RP11-369G6.2	-4.25	2.32e-05	0.00174	-0.18	-0.13	Testicular germ cell tumor;	chr19:22976684	chr19:23125665~23128543:+
BRCA	cis	rs67981189	0.593	rs8007425	ENSG00000258571.1	PTTG4P	-4.25	2.32e-05	0.00174	-0.14	-0.13	Schizophrenia;	chr14:71041483	chr14:71085482~71085833:-
BRCA	cis	rs2562456	0.876	rs7252585	ENSG00000268555.1	RP11-678G14.3	-4.25	2.32e-05	0.00174	-0.16	-0.13	Pain;	chr19:21475141	chr19:21570822~21587322:-
BRCA	cis	rs6546324	0.625	rs2861686	ENSG00000236780.4	AC078941.1	4.25	2.33e-05	0.00174	0.23	0.13	Endometriosis;	chr2:67610919	chr2:67123357~67215319:-
BRCA	cis	rs372883	0.967	rs1153280	ENSG00000176054.6	RPL23P2	4.25	2.33e-05	0.00174	0.13	0.13	Pancreatic cancer;	chr21:29305751	chr21:28997613~28998033:-
BRCA	cis	rs780094	0.5	rs74175068	ENSG00000234072.1	AC074117.10	4.25	2.33e-05	0.00174	0.13	0.13	Urate levels in overweight individuals;C-reactive protein;Metabolic syndrome;Red blood cell count;Renal underexcretion gout;Nonalcoholic fatty liver disease;Age-related diseases, mortality and associated endophenotypes;Crohn's disease;Calcium levels;Fasting plasma glucose;Metabolic traits;Fasting blood glucose;Fasting blood insulin;Urate levels in obese individuals;Alcohol consumption (drinks per week);Height;Urate levels;Gondoic acid (20:1n-9) levels;Uric acid levels;Age-related disease endophenotypes;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Homeostasis model assessment of insulin resistance;Alcohol consumption;Fasting blood insulin (BMI interaction);Triglycerides;Fasting blood glucose (BMI interaction);Hypertriglyceridemia;LDL cholesterol;Type 2 diabetes;Triglyceride levels;	chr2:27610635	chr2:27356246~27367622:+
BRCA	cis	rs1910358	0.53	rs7732119	ENSG00000248874.4	C5orf17	-4.25	2.33e-05	0.00174	-0.19	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23731563	chr5:23951348~24178263:+
BRCA	cis	rs5758511	0.68	rs5758692	ENSG00000226450.2	CYP2D8P	4.25	2.33e-05	0.00174	0.15	0.13	Birth weight;	chr22:42273023	chr22:42149886~42155001:-
BRCA	cis	rs9834975	0.9	rs9878861	ENSG00000272758.4	RP11-299J3.8	-4.25	2.33e-05	0.00174	-0.13	-0.13	Diastolic blood pressure;	chr3:122394139	chr3:122416207~122443180:+
BRCA	cis	rs9834975	0.967	rs9841311	ENSG00000272758.4	RP11-299J3.8	-4.25	2.33e-05	0.00174	-0.13	-0.13	Diastolic blood pressure;	chr3:122394494	chr3:122416207~122443180:+
BRCA	cis	rs4948275	0.641	rs1378887	ENSG00000237233.2	TMEM26-AS1	-4.25	2.33e-05	0.00174	-0.15	-0.13	Night sleep phenotypes;	chr10:61561613	chr10:61452639~61481956:+
BRCA	cis	rs1008375	1	rs3933453	ENSG00000249502.1	AC006160.5	-4.25	2.33e-05	0.00174	-0.15	-0.13	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17634696	chr4:17587467~17614571:-
BRCA	cis	rs78487399	0.808	rs13414140	ENSG00000234936.1	AC010883.5	4.25	2.33e-05	0.00174	0.18	0.13	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43444037	chr2:43229573~43233394:+
BRCA	cis	rs3774749	0.565	rs1005678	ENSG00000228008.1	CTD-2330K9.3	4.25	2.33e-05	0.00174	0.13	0.13	Intelligence (multi-trait analysis);	chr3:50172856	chr3:49903845~49916937:+
BRCA	cis	rs465969	1	rs34382476	ENSG00000230177.1	RP5-1112D6.4	4.25	2.33e-05	0.00175	0.31	0.13	Psoriasis;	chr6:111423551	chr6:111277932~111278742:+
BRCA	cis	rs886774	1	rs6949033	ENSG00000273055.1	CTB-13F3.1	4.25	2.33e-05	0.00175	0.13	0.13	Ulcerative colitis;	chr7:107854772	chr7:107942116~107942740:+
BRCA	cis	rs66887589	0.616	rs13113885	ENSG00000249244.1	RP11-548H18.2	4.25	2.33e-05	0.00175	0.15	0.13	Diastolic blood pressure;	chr4:119300021	chr4:119391831~119395335:-
BRCA	cis	rs13113518	1	rs13122619	ENSG00000272969.1	RP11-528I4.2	4.25	2.33e-05	0.00175	0.15	0.13	Height;	chr4:55479339	chr4:55547112~55547889:+
BRCA	cis	rs10947428	0.522	rs2967	ENSG00000224557.6	HLA-DPB2	4.25	2.33e-05	0.00175	0.16	0.13	Allergic disease (asthma, hay fever or eczema);	chr6:33721757	chr6:33112451~33129084:+
BRCA	cis	rs62388641	0.547	rs2317966	ENSG00000272279.1	RP11-157J24.2	-4.25	2.33e-05	0.00175	-0.15	-0.13	Daytime sleep phenotypes;	chr6:1550651	chr6:1528364~1528911:-
BRCA	cis	rs2832191	1	rs2832185	ENSG00000236056.1	GAPDHP14	4.25	2.34e-05	0.00175	0.14	0.13	Dental caries;	chr21:29111440	chr21:29222321~29223257:+
BRCA	cis	rs12317459	0.591	rs7296213	ENSG00000213270.5	RPL6P25	-4.25	2.34e-05	0.00175	-0.22	-0.13	Prostate cancer (SNP x SNP interaction);	chr12:82768241	chr12:83151331~83152190:+
BRCA	cis	rs12317459	0.591	rs7315215	ENSG00000213270.5	RPL6P25	-4.25	2.34e-05	0.00175	-0.22	-0.13	Prostate cancer (SNP x SNP interaction);	chr12:82768259	chr12:83151331~83152190:+
BRCA	cis	rs11098499	0.739	rs951570	ENSG00000260404.2	RP11-384K6.6	-4.25	2.34e-05	0.00175	-0.12	-0.13	Corneal astigmatism;	chr4:119229312	chr4:118591773~118633729:+
BRCA	cis	rs17345786	0.953	rs78645744	ENSG00000244119.1	PDCL3P4	4.25	2.34e-05	0.00175	0.11	0.13	Colonoscopy-negative controls vs population controls;	chr3:101608945	chr3:101712472~101713191:+
BRCA	cis	rs6674176	0.551	rs72684780	ENSG00000237950.1	RP11-7O11.3	-4.25	2.34e-05	0.00175	-0.27	-0.13	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43964491	chr1:43944370~43946551:-
BRCA	cis	rs6893300	0.826	rs7709723	ENSG00000225051.5	HMGB3P22	4.25	2.34e-05	0.00175	0.16	0.13	Resting heart rate;	chr5:179717262	chr5:179679032~179694768:+
BRCA	cis	rs801193	1	rs4717319	ENSG00000272831.1	RP11-792A8.4	4.25	2.34e-05	0.00175	0.12	0.13	Aortic root size;	chr7:66777606	chr7:66739829~66740385:-
BRCA	cis	rs11096990	0.634	rs6829064	ENSG00000249685.1	RP11-360F5.3	-4.25	2.34e-05	0.00175	-0.16	-0.13	Cognitive function;	chr4:39290192	chr4:39133913~39135608:+
BRCA	cis	rs10129255	0.5	rs7157975	ENSG00000254174.1	IGHV1-12	4.25	2.34e-05	0.00175	0.1	0.13	Kawasaki disease;	chr14:106804049	chr14:106122420~106122709:-
BRCA	cis	rs2243480	0.901	rs2456483	ENSG00000275400.1	RP4-756H11.5	4.25	2.34e-05	0.00175	0.23	0.13	Diabetic kidney disease;	chr7:65996588	chr7:66553805~66554199:-
BRCA	cis	rs2243480	1	rs1701750	ENSG00000275400.1	RP4-756H11.5	4.25	2.34e-05	0.00175	0.23	0.13	Diabetic kidney disease;	chr7:66002158	chr7:66553805~66554199:-
BRCA	cis	rs4374383	0.884	rs10207820	ENSG00000243389.1	AC012442.5	-4.25	2.34e-05	0.00175	-0.17	-0.13	Hepatitis C induced liver fibrosis;	chr2:111941773	chr2:112589040~112614431:+
BRCA	cis	rs3745567	0.622	rs10408682	ENSG00000276980.1	CTD-3128G10.7	4.25	2.34e-05	0.00175	0.21	0.13	Complement C3 and C4 levels;	chr19:6699319	chr19:6716386~6717742:-
BRCA	cis	rs6831352	0.703	rs2602862	ENSG00000272777.1	RP11-571L19.8	-4.25	2.34e-05	0.00175	-0.14	-0.13	Alcohol dependence;	chr4:99112070	chr4:99067256~99068125:-
BRCA	cis	rs910316	0.934	rs7141705	ENSG00000259138.1	RP11-950C14.7	-4.25	2.34e-05	0.00175	-0.14	-0.13	Height;	chr14:75188649	chr14:75127153~75136930:+
BRCA	cis	rs72627123	1	rs59363432	ENSG00000259065.1	RP5-1021I20.1	-4.25	2.34e-05	0.00175	-0.21	-0.13	Morning vs. evening chronotype;	chr14:73930842	chr14:73787360~73803270:+
BRCA	cis	rs2839186	0.867	rs13050387	ENSG00000239415.1	AP001469.9	4.25	2.34e-05	0.00175	0.14	0.13	Testicular germ cell tumor;	chr21:46281509	chr21:46251549~46254133:-
BRCA	cis	rs2839186	0.872	rs13046834	ENSG00000239415.1	AP001469.9	4.25	2.34e-05	0.00175	0.14	0.13	Testicular germ cell tumor;	chr21:46281571	chr21:46251549~46254133:-
BRCA	cis	rs2839186	0.721	rs13051200	ENSG00000239415.1	AP001469.9	4.25	2.34e-05	0.00175	0.14	0.13	Testicular germ cell tumor;	chr21:46281779	chr21:46251549~46254133:-
BRCA	cis	rs7771547	0.574	rs9366907	ENSG00000224666.3	RP1-50J22.4	4.25	2.34e-05	0.00175	0.16	0.13	Platelet distribution width;	chr6:36581777	chr6:36386831~36393462:+
BRCA	cis	rs7771547	0.723	rs9368938	ENSG00000224666.3	RP1-50J22.4	4.25	2.34e-05	0.00175	0.16	0.13	Platelet distribution width;	chr6:36581975	chr6:36386831~36393462:+
BRCA	cis	rs7771547	0.692	rs9380578	ENSG00000224666.3	RP1-50J22.4	4.25	2.34e-05	0.00175	0.16	0.13	Platelet distribution width;	chr6:36582510	chr6:36386831~36393462:+
BRCA	cis	rs7771547	0.723	rs9394360	ENSG00000224666.3	RP1-50J22.4	4.25	2.34e-05	0.00175	0.16	0.13	Platelet distribution width;	chr6:36582593	chr6:36386831~36393462:+
BRCA	cis	rs7771547	0.723	rs9366908	ENSG00000224666.3	RP1-50J22.4	4.25	2.34e-05	0.00175	0.16	0.13	Platelet distribution width;	chr6:36582711	chr6:36386831~36393462:+
BRCA	cis	rs9381040	0.61	rs2057002	ENSG00000161912.16	ADCY10P1	4.25	2.34e-05	0.00175	0.14	0.13	Alzheimer's disease (late onset);	chr6:41055223	chr6:41101022~41140835:+
BRCA	cis	rs6802315	0.575	rs1864508	ENSG00000272087.1	RP11-379F4.7	4.25	2.34e-05	0.00175	0.15	0.13	Periodontitis (CDC/AAP);	chr3:158765024	chr3:158693120~158693768:-
BRCA	cis	rs6545883	0.929	rs6545873	ENSG00000270820.4	RP11-355B11.2	4.25	2.34e-05	0.00175	0.15	0.13	Tuberculosis;	chr2:61505877	chr2:61471188~61484130:+
BRCA	cis	rs1979679	0.573	rs6487693	ENSG00000278733.1	RP11-425D17.1	-4.25	2.34e-05	0.00175	-0.17	-0.13	Ossification of the posterior longitudinal ligament of the spine;	chr12:28574158	chr12:28185625~28186190:-
BRCA	cis	rs1979679	0.573	rs6487694	ENSG00000278733.1	RP11-425D17.1	-4.25	2.34e-05	0.00175	-0.17	-0.13	Ossification of the posterior longitudinal ligament of the spine;	chr12:28574801	chr12:28185625~28186190:-
BRCA	cis	rs7226835	0.63	rs525985	ENSG00000267374.1	RP11-244M2.1	-4.25	2.34e-05	0.00175	-0.19	-0.13	Obesity-related traits;	chr18:39697060	chr18:39206924~39800318:-
BRCA	cis	rs2243480	1	rs35396113	ENSG00000275400.1	RP4-756H11.5	4.25	2.34e-05	0.00175	0.24	0.13	Diabetic kidney disease;	chr7:66030474	chr7:66553805~66554199:-
BRCA	cis	rs9987353	0.518	rs4841110	ENSG00000248538.5	RP11-10A14.5	-4.25	2.34e-05	0.00175	-0.13	-0.13	Recombination measurement;	chr8:9228513	chr8:9189011~9202854:+
BRCA	cis	rs1383484	1	rs7176613	ENSG00000230373.7	GOLGA6L5P	-4.25	2.34e-05	0.00175	-0.15	-0.13	Height;	chr15:83834450	chr15:84507885~84516814:-
BRCA	cis	rs6071166	0.683	rs6027333	ENSG00000224635.1	RP4-564F22.5	-4.25	2.34e-05	0.00175	-0.16	-0.13	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38694620	chr20:38406011~38416797:-
BRCA	cis	rs12612619	0.732	rs13032059	ENSG00000272148.1	RP11-195B17.1	4.25	2.34e-05	0.00175	0.14	0.13	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27010921	chr2:27062428~27062907:-
BRCA	cis	rs12612619	0.732	rs13032100	ENSG00000272148.1	RP11-195B17.1	4.25	2.34e-05	0.00175	0.14	0.13	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27010991	chr2:27062428~27062907:-
BRCA	cis	rs7800418	0.888	rs10244803	ENSG00000214870.7	AC004540.5	4.25	2.34e-05	0.00175	0.17	0.13	Cognitive function;	chr7:26551387	chr7:26398593~26494256:+
BRCA	cis	rs4664293	1	rs6432540	ENSG00000226266.5	AC009961.3	-4.25	2.34e-05	0.00175	-0.16	-0.13	Monocyte percentage of white cells;	chr2:159594192	chr2:159670708~159712435:-
BRCA	cis	rs2408955	0.5	rs12816820	ENSG00000226413.2	OR8T1P	4.25	2.34e-05	0.00175	0.17	0.13	Glycated hemoglobin levels;	chr12:48164542	chr12:48442030~48442947:-
BRCA	cis	rs202072	1	rs202073	ENSG00000272379.1	RP1-257A7.5	-4.25	2.34e-05	0.00175	-0.18	-0.13	HIV-1 viral setpoint;	chr6:13268373	chr6:13290018~13290490:-
BRCA	cis	rs1150668	0.83	rs2531831	ENSG00000270326.1	RP5-874C20.6	-4.25	2.34e-05	0.00175	-0.16	-0.13	Pubertal anthropometrics;	chr6:28420988	chr6:28319660~28319852:-
BRCA	cis	rs10266483	0.739	rs11765764	ENSG00000228653.2	HNRNPCP7	4.25	2.34e-05	0.00175	0.16	0.13	Response to statin therapy;	chr7:64368163	chr7:64500825~64501729:+
BRCA	cis	rs4835473	0.932	rs11736609	ENSG00000249741.2	RP11-673E1.3	4.25	2.35e-05	0.00175	0.15	0.13	Immature fraction of reticulocytes;	chr4:143832876	chr4:143911514~143912053:-
BRCA	cis	rs867371	1	rs13380317	ENSG00000278603.1	RP13-608F4.5	-4.25	2.35e-05	0.00175	-0.17	-0.13	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82214449	chr15:82472203~82472426:+
BRCA	cis	rs78487399	0.908	rs17031079	ENSG00000234936.1	AC010883.5	4.25	2.35e-05	0.00176	0.18	0.13	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43577794	chr2:43229573~43233394:+
BRCA	cis	rs7555523	0.832	rs7524755	ENSG00000224358.1	RP11-466F5.8	-4.25	2.35e-05	0.00176	-0.21	-0.13	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165725660	chr1:165768929~165775176:+
BRCA	cis	rs7520050	0.807	rs28844317	ENSG00000234329.1	RP11-767N6.2	4.25	2.35e-05	0.00176	0.12	0.13	Reticulocyte count;Red blood cell count;	chr1:45743535	chr1:45651039~45651826:-
BRCA	cis	rs7520050	0.807	rs6429576	ENSG00000234329.1	RP11-767N6.2	4.25	2.35e-05	0.00176	0.12	0.13	Reticulocyte count;Red blood cell count;	chr1:45750903	chr1:45651039~45651826:-
BRCA	cis	rs4835473	0.838	rs34521499	ENSG00000249741.2	RP11-673E1.3	4.25	2.35e-05	0.00176	0.15	0.13	Immature fraction of reticulocytes;	chr4:143777628	chr4:143911514~143912053:-
BRCA	cis	rs4835473	0.9	rs34264936	ENSG00000249741.2	RP11-673E1.3	4.25	2.35e-05	0.00176	0.15	0.13	Immature fraction of reticulocytes;	chr4:143780294	chr4:143911514~143912053:-
BRCA	cis	rs4835473	0.9	rs13140028	ENSG00000249741.2	RP11-673E1.3	4.25	2.35e-05	0.00176	0.15	0.13	Immature fraction of reticulocytes;	chr4:143782195	chr4:143911514~143912053:-
BRCA	cis	rs6480314	0.522	rs17231602	ENSG00000233590.1	RP11-153K11.3	-4.25	2.35e-05	0.00176	-0.24	-0.13	Optic nerve measurement (disc area);	chr10:68252532	chr10:68233251~68242379:-
BRCA	cis	rs12682352	0.715	rs332039	ENSG00000233609.3	RP11-62H7.2	4.25	2.35e-05	0.00176	0.13	0.13	Neuroticism;	chr8:8866141	chr8:8961200~8979025:+
BRCA	cis	rs7475343	0.543	rs77355283	ENSG00000224034.1	RP11-445P17.8	-4.25	2.35e-05	0.00176	-0.25	-0.13	Intelligence;	chr10:5220173	chr10:5266033~5271236:-
BRCA	cis	rs860295	0.702	rs12081067	ENSG00000225855.5	RUSC1-AS1	4.25	2.35e-05	0.00176	0.11	0.13	Body mass index;	chr1:155389191	chr1:155316863~155324176:-
BRCA	cis	rs9990333	0.687	rs62285383	ENSG00000207650.1	MIR570	4.25	2.35e-05	0.00176	0.15	0.13	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196087052	chr3:195699401~195699497:+
BRCA	cis	rs984222	0.501	rs1419289	ENSG00000231365.4	RP11-418J17.1	-4.25	2.35e-05	0.00176	-0.15	-0.13	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:118944613	chr1:119140396~119275973:+
BRCA	cis	rs4907240	0.961	rs7580048	ENSG00000230606.9	AC159540.1	4.25	2.35e-05	0.00176	0.17	0.13	Event-related brain oscillations;	chr2:96638443	chr2:97416165~97433527:-
BRCA	cis	rs442309	1	rs224139	ENSG00000238280.1	RP11-436D10.3	-4.25	2.35e-05	0.00176	-0.18	-0.13	Vogt-Koyanagi-Harada syndrome;	chr10:62713956	chr10:62793562~62805887:-
BRCA	cis	rs12435908	0.867	rs73268557	ENSG00000276116.2	FUT8-AS1	-4.25	2.35e-05	0.00176	-0.2	-0.13	Ischemic stroke;	chr14:65654835	chr14:65411170~65412690:-
BRCA	cis	rs9308731	0.644	rs1837366	ENSG00000230499.1	AC108463.1	-4.25	2.35e-05	0.00176	-0.15	-0.13	Chronic lymphocytic leukemia;	chr2:111117052	chr2:111195963~111206494:+
BRCA	cis	rs2839186	0.934	rs2839194	ENSG00000239415.1	AP001469.9	4.25	2.35e-05	0.00176	0.14	0.13	Testicular germ cell tumor;	chr21:46279523	chr21:46251549~46254133:-
BRCA	cis	rs13098911	0.54	rs71325098	ENSG00000223552.1	RP11-24F11.2	-4.25	2.35e-05	0.00176	-0.22	-0.13	Celiac disease;	chr3:45970899	chr3:46364955~46407059:-
BRCA	cis	rs1722133	0.555	rs62450964	ENSG00000237471.1	AC073115.6	-4.25	2.35e-05	0.00176	-0.18	-0.13	Sitting height ratio;	chr7:46085526	chr7:45969657~45980191:+
BRCA	cis	rs17027633	1	rs10489791	ENSG00000260948.1	RP11-552M11.8	-4.25	2.35e-05	0.00176	-0.24	-0.13	Cerebrospinal fluid t-tau:AB1-42 ratio;	chr1:111416263	chr1:111431046~111433068:-
BRCA	cis	rs1075265	0.509	rs10201938	ENSG00000235937.1	AC008280.1	4.25	2.35e-05	0.00176	0.15	0.13	Chronotype;Morning vs. evening chronotype;	chr2:53728352	chr2:54029552~54030682:-
BRCA	cis	rs7647973	0.925	rs7429661	ENSG00000244380.1	RP11-24C3.2	4.25	2.35e-05	0.00176	0.17	0.13	Menarche (age at onset);	chr3:49191367	chr3:48440352~48446656:-
BRCA	cis	rs6600671	1	rs10903161	ENSG00000275538.1	RNVU1-19	4.25	2.35e-05	0.00176	0.15	0.13	Hip geometry;	chr1:121436882	chr1:120850819~120850985:-
BRCA	cis	rs4869313	0.967	rs1559359	ENSG00000248734.2	CTD-2260A17.1	-4.25	2.36e-05	0.00176	-0.13	-0.13	Pediatric autoimmune diseases;	chr5:96891574	chr5:96784777~96785999:+
BRCA	cis	rs1982963	0.906	rs2029976	ENSG00000277050.1	RP11-102G14.1	-4.25	2.36e-05	0.00176	-0.16	-0.13	Waist-to-hip ratio adjusted for body mass index;	chr14:52039093	chr14:51637348~51637947:-
BRCA	cis	rs1982963	1	rs2029975	ENSG00000277050.1	RP11-102G14.1	-4.25	2.36e-05	0.00176	-0.16	-0.13	Waist-to-hip ratio adjusted for body mass index;	chr14:52039352	chr14:51637348~51637947:-
BRCA	cis	rs1982963	1	rs10139288	ENSG00000277050.1	RP11-102G14.1	-4.25	2.36e-05	0.00176	-0.16	-0.13	Waist-to-hip ratio adjusted for body mass index;	chr14:52039768	chr14:51637348~51637947:-
BRCA	cis	rs4478858	0.647	rs10798836	ENSG00000260386.4	LINC01225	-4.25	2.36e-05	0.00176	-0.15	-0.13	Alcohol dependence;	chr1:31236367	chr1:31500085~31540885:+
BRCA	cis	rs6547741	1	rs4665381	ENSG00000234072.1	AC074117.10	4.25	2.36e-05	0.00176	0.12	0.13	Oral cavity cancer;	chr2:27534283	chr2:27356246~27367622:+
BRCA	cis	rs4143844	0.867	rs36056548	ENSG00000259251.2	RP11-643M14.1	4.25	2.36e-05	0.00176	0.32	0.13	Bipolar disorder and schizophrenia;	chr15:61904187	chr15:62060503~62062434:+
BRCA	cis	rs9840812	0.725	rs3821445	ENSG00000239213.4	NCK1-AS1	-4.25	2.36e-05	0.00176	-0.19	-0.13	Fibrinogen levels;	chr3:136283967	chr3:136841726~136862054:-
BRCA	cis	rs2108622	0.727	rs2158511	ENSG00000267218.2	AC005336.5	4.25	2.36e-05	0.00176	0.16	0.13	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15875837	chr19:15902300~15903238:-
BRCA	cis	rs4869313	0.905	rs27307	ENSG00000248734.2	CTD-2260A17.1	4.25	2.36e-05	0.00176	0.14	0.13	Pediatric autoimmune diseases;	chr5:97002801	chr5:96784777~96785999:+
BRCA	cis	rs801193	1	rs2659889	ENSG00000272831.1	RP11-792A8.4	4.25	2.36e-05	0.00176	0.12	0.13	Aortic root size;	chr7:66752125	chr7:66739829~66740385:-
BRCA	cis	rs181553	0.961	rs1288812	ENSG00000266696.1	RP11-30L3.2	4.25	2.36e-05	0.00176	0.15	0.13	Hip circumference adjusted for BMI;	chr18:49041111	chr18:49205912~49208781:+
BRCA	cis	rs6951245	0.608	rs10252234	ENSG00000229043.2	AC091729.9	-4.25	2.36e-05	0.00176	-0.18	-0.13	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1074745	chr7:1160374~1165267:+
BRCA	cis	rs75804782	0.572	rs56330821	ENSG00000186235.9	AC016757.3	4.25	2.36e-05	0.00176	0.33	0.13	Chronotype;Morning vs. evening chronotype;	chr2:238365308	chr2:238224552~238231677:-
BRCA	cis	rs35740288	0.77	rs11631386	ENSG00000202081.1	RNU6-1280P	4.25	2.36e-05	0.00176	0.17	0.13	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85648764	chr15:85651522~85651628:-
BRCA	cis	rs7412746	0.621	rs11204749	ENSG00000231073.1	RP11-316M1.3	4.25	2.36e-05	0.00176	0.14	0.13	Melanoma;	chr1:150957087	chr1:150973123~150975534:+
BRCA	cis	rs3748682	0.821	rs71642605	ENSG00000222282.1	RNU6-584P	-4.25	2.36e-05	0.00176	-0.17	-0.13	Hypothyroidism;	chr1:37790755	chr1:37885023~37885117:+
BRCA	cis	rs7569084	0.663	rs10190233	ENSG00000281920.1	RP11-418H16.1	-4.25	2.36e-05	0.00176	-0.16	-0.13	Sum eosinophil basophil counts;	chr2:65413095	chr2:65623272~65628424:+
BRCA	cis	rs4648045	0.565	rs4698863	ENSG00000251288.2	RP11-10L12.2	-4.25	2.36e-05	0.00176	-0.17	-0.13	Lymphocyte percentage of white cells;	chr4:102624691	chr4:102751401~102752641:+
BRCA	cis	rs2274459	0.749	rs2281831	ENSG00000249346.5	LINC01016	4.25	2.36e-05	0.00176	0.16	0.13	Obesity (extreme);	chr6:33728038	chr6:33867506~33896914:-
BRCA	cis	rs4930561	0.739	rs10896303	ENSG00000184795.9	UNC93B5	-4.25	2.36e-05	0.00176	-0.15	-0.13	Breast cancer in childhood cancer survivors;IgG glycosylation;	chr11:68206825	chr11:67711702~67716005:-
BRCA	cis	rs610932	0.517	rs688460	ENSG00000275344.1	MIR6503	4.25	2.36e-05	0.00176	0.13	0.13	Alzheimer's disease;	chr11:60219237	chr11:60209071~60209156:-
BRCA	cis	rs4950322	0.512	rs10736839	ENSG00000244371.2	PFN1P8	4.25	2.36e-05	0.00176	0.15	0.13	Protein quantitative trait loci;	chr1:147370431	chr1:146957117~146957659:-
BRCA	cis	rs12612619	0.732	rs722911	ENSG00000272148.1	RP11-195B17.1	4.25	2.36e-05	0.00176	0.14	0.13	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:26988344	chr2:27062428~27062907:-
BRCA	cis	rs7487075	0.558	rs4768692	ENSG00000272369.1	RP11-446N19.1	4.25	2.36e-05	0.00176	0.14	0.13	Itch intensity from mosquito bite;	chr12:46245852	chr12:46537502~46652550:+
BRCA	cis	rs17756712	0.528	rs2073007	ENSG00000271911.1	RP11-532F6.5	4.25	2.36e-05	0.00177	0.19	0.13	Vertical cup-disc ratio;	chr6:638267	chr6:761675~780648:+
BRCA	cis	rs11673344	0.526	rs55909413	ENSG00000267422.1	CTD-2554C21.1	4.25	2.36e-05	0.00177	0.18	0.13	Obesity-related traits;	chr19:37578663	chr19:37779686~37792865:+
BRCA	cis	rs11673344	0.526	rs73033122	ENSG00000267422.1	CTD-2554C21.1	4.25	2.36e-05	0.00177	0.18	0.13	Obesity-related traits;	chr19:37586006	chr19:37779686~37792865:+
BRCA	cis	rs739496	0.947	rs2339816	ENSG00000234608.6	MAPKAPK5-AS1	4.25	2.36e-05	0.00177	0.16	0.13	Platelet count;	chr12:111474384	chr12:111839764~111842902:-
BRCA	cis	rs4842666	0.915	rs12579302	ENSG00000270344.2	RP11-734K2.4	-4.25	2.36e-05	0.00177	-0.16	-0.13	Blood pressure;	chr12:89656726	chr12:89525654~89548005:+
BRCA	cis	rs4263408	1	rs7687557	ENSG00000224097.5	RP11-472B18.1	4.25	2.36e-05	0.00177	0.15	0.13	Plasma amyloid beta peptide concentrations (ABx-40);	chr4:39767640	chr4:39480255~39481905:+
BRCA	cis	rs875971	0.838	rs2173570	ENSG00000236529.1	RP13-254B10.1	-4.25	2.36e-05	0.00177	-0.14	-0.13	Aortic root size;	chr7:66297976	chr7:65840212~65840596:+
BRCA	cis	rs16846053	0.792	rs2100213	ENSG00000227403.1	AC009299.3	4.25	2.36e-05	0.00177	0.34	0.13	Blood osmolality (transformed sodium);	chr2:161832308	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.685	rs56027511	ENSG00000227403.1	AC009299.3	4.25	2.36e-05	0.00177	0.34	0.13	Blood osmolality (transformed sodium);	chr2:161833006	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.685	rs56091742	ENSG00000227403.1	AC009299.3	4.25	2.36e-05	0.00177	0.34	0.13	Blood osmolality (transformed sodium);	chr2:161833015	chr2:161244739~161249050:+
BRCA	cis	rs4302906	0.86	rs7030160	ENSG00000187984.11	ANKRD19P	-4.25	2.36e-05	0.00177	-0.12	-0.13	Lobe attachment (rater-scored or self-reported);	chr9:92977373	chr9:92809388~92888693:+
BRCA	cis	rs6121246	0.697	rs6088857	ENSG00000230613.1	HM13-AS1	4.25	2.36e-05	0.00177	0.19	0.13	Mean corpuscular hemoglobin;	chr20:31638961	chr20:31567707~31573263:-
BRCA	cis	rs4700393	0.52	rs5012862	ENSG00000215032.2	GNL3LP1	4.25	2.36e-05	0.00177	0.17	0.13	Intelligence (multi-trait analysis);	chr5:60588926	chr5:60891935~60893577:-
BRCA	cis	rs7520050	0.807	rs28378621	ENSG00000234329.1	RP11-767N6.2	4.25	2.36e-05	0.00177	0.12	0.13	Reticulocyte count;Red blood cell count;	chr1:45723882	chr1:45651039~45651826:-
BRCA	cis	rs7937890	0.531	rs2575859	ENSG00000254418.1	RP11-21L19.1	4.25	2.36e-05	0.00177	0.15	0.13	Mitochondrial DNA levels;	chr11:14489190	chr11:14262846~14273691:-
BRCA	cis	rs7200543	1	rs4985154	ENSG00000207425.1	Y_RNA	-4.25	2.36e-05	0.00177	-0.16	-0.13	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15037785	chr16:14915457~14915556:-
BRCA	cis	rs11758351	0.866	rs77205516	ENSG00000241549.7	GUSBP2	-4.25	2.37e-05	0.00177	-0.19	-0.13	Renal underexcretion gout;Gout;	chr6:26205128	chr6:26871484~26956554:-
BRCA	cis	rs11758351	0.866	rs2069019	ENSG00000241549.7	GUSBP2	-4.25	2.37e-05	0.00177	-0.19	-0.13	Renal underexcretion gout;Gout;	chr6:26205376	chr6:26871484~26956554:-
BRCA	cis	rs9308731	0.644	rs10189015	ENSG00000230499.1	AC108463.1	-4.25	2.37e-05	0.00177	-0.15	-0.13	Chronic lymphocytic leukemia;	chr2:111160895	chr2:111195963~111206494:+
BRCA	cis	rs2408955	0.542	rs7975632	ENSG00000226413.2	OR8T1P	4.25	2.37e-05	0.00177	0.18	0.13	Glycated hemoglobin levels;	chr12:48049265	chr12:48442030~48442947:-
BRCA	cis	rs11673344	0.526	rs55865869	ENSG00000267422.1	CTD-2554C21.1	4.25	2.37e-05	0.00177	0.18	0.13	Obesity-related traits;	chr19:37578683	chr19:37779686~37792865:+
BRCA	cis	rs6452524	1	rs6452524	ENSG00000281327.1	LINC01338	-4.25	2.37e-05	0.00177	-0.15	-0.13	Hypertension (SNP x SNP interaction);	chr5:83137962	chr5:82850864~82859836:-
BRCA	cis	rs3845817	0.843	rs6705904	ENSG00000237979.1	AC007389.1	-4.25	2.37e-05	0.00177	-0.15	-0.13	Bipolar disorder;	chr2:65542897	chr2:65500993~65502138:-
BRCA	cis	rs1048886	0.872	rs12216376	ENSG00000271967.1	RP11-134K13.4	4.25	2.37e-05	0.00177	0.19	0.13	Type 2 diabetes;	chr6:70568521	chr6:70596438~70596980:+
BRCA	cis	rs1124769	0.57	rs2574757	ENSG00000273674.3	CTD-2378E12.1	4.25	2.37e-05	0.00177	0.16	0.13	Cognitive performance;	chr15:50846263	chr15:50839875~50908599:-
BRCA	cis	rs2832191	1	rs2832191	ENSG00000236056.1	GAPDHP14	4.25	2.37e-05	0.00177	0.14	0.13	Dental caries;	chr21:29116979	chr21:29222321~29223257:+
BRCA	cis	rs2136613	0.533	rs1412554	ENSG00000238280.1	RP11-436D10.3	4.25	2.37e-05	0.00177	0.16	0.13	Selective IgA deficiency;	chr10:62850180	chr10:62793562~62805887:-
BRCA	cis	rs4869313	0.869	rs3909451	ENSG00000248734.2	CTD-2260A17.1	-4.25	2.37e-05	0.00177	-0.14	-0.13	Pediatric autoimmune diseases;	chr5:96959417	chr5:96784777~96785999:+
BRCA	cis	rs56322409	1	rs11188398	ENSG00000226688.5	ENTPD1-AS1	4.25	2.37e-05	0.00177	0.15	0.13	Blood metabolite levels;	chr10:95609336	chr10:95753206~96090238:-
BRCA	cis	rs4287000	0.508	rs2989756	ENSG00000227603.1	RP11-165J3.6	-4.25	2.37e-05	0.00177	-0.15	-0.13	Itch intensity from mosquito bite adjusted by bite size;	chr9:93616328	chr9:93435332~93437121:-
BRCA	cis	rs7771547	0.519	rs72852340	ENSG00000224666.3	RP1-50J22.4	4.25	2.37e-05	0.00177	0.17	0.13	Platelet distribution width;	chr6:36587027	chr6:36386831~36393462:+
BRCA	cis	rs7771547	0.723	rs73423325	ENSG00000224666.3	RP1-50J22.4	4.25	2.37e-05	0.00177	0.16	0.13	Platelet distribution width;	chr6:36586512	chr6:36386831~36393462:+
BRCA	cis	rs651907	0.514	rs12636047	ENSG00000256628.3	ZBTB11-AS1	4.25	2.37e-05	0.00177	0.16	0.13	Colorectal cancer;	chr3:101715605	chr3:101676475~101679217:+
BRCA	cis	rs9868809	0.505	rs28567949	ENSG00000225399.4	RP11-3B7.1	-4.25	2.37e-05	0.00177	-0.19	-0.13	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48707127	chr3:49260085~49261316:+
BRCA	cis	rs6545883	0.826	rs777591	ENSG00000212978.6	AC016747.3	4.25	2.37e-05	0.00177	0.18	0.13	Tuberculosis;	chr2:61190482	chr2:61141592~61144969:-
BRCA	cis	rs1005277	0.579	rs1740737	ENSG00000099251.13	HSD17B7P2	4.25	2.37e-05	0.00177	0.14	0.13	Extrinsic epigenetic age acceleration;	chr10:38210437	chr10:38356380~38378505:+
BRCA	cis	rs669446	0.561	rs517849	ENSG00000236200.4	KDM4A-AS1	-4.25	2.37e-05	0.00177	-0.16	-0.13	Amyotrophic lateral sclerosis (age of onset);	chr1:43616202	chr1:43699765~43708138:-
BRCA	cis	rs2555155	0.602	rs2555143	ENSG00000254595.1	CTD-2010I16.1	-4.25	2.37e-05	0.00177	-0.15	-0.13	DNA methylation (variation);	chr11:6520350	chr11:6488186~6489377:-
BRCA	cis	rs11098499	0.863	rs1010739	ENSG00000260091.1	RP11-33B1.4	-4.25	2.37e-05	0.00177	-0.12	-0.13	Corneal astigmatism;	chr4:119542316	chr4:119409333~119410233:+
BRCA	cis	rs2281558	0.583	rs7260957	ENSG00000230772.1	VN1R108P	-4.25	2.37e-05	0.00177	-0.19	-0.13	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25741826	chr20:25734264~25735093:+
BRCA	cis	rs7703051	1	rs17244834	ENSG00000271815.1	CTD-2235C13.3	-4.25	2.37e-05	0.00177	-0.17	-0.13	Age-related diseases, mortality and associated endophenotypes;LDL cholesterol;Age-related disease endophenotypes;	chr5:75347023	chr5:75363760~75364242:+
BRCA	cis	rs7267979	1	rs3002702	ENSG00000125804.12	FAM182A	-4.25	2.37e-05	0.00177	-0.17	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25288284	chr20:26054655~26086917:+
BRCA	cis	rs7487075	0.754	rs10880962	ENSG00000274723.1	RP11-618L22.1	4.25	2.37e-05	0.00177	0.15	0.13	Itch intensity from mosquito bite;	chr12:46379661	chr12:46970504~46972155:+
BRCA	cis	rs6546324	0.625	rs4671812	ENSG00000236780.4	AC078941.1	4.25	2.37e-05	0.00177	0.23	0.13	Endometriosis;	chr2:67605354	chr2:67123357~67215319:-
BRCA	cis	rs35146811	0.735	rs1727139	ENSG00000235713.1	RP4-604G5.3	-4.25	2.37e-05	0.00177	-0.15	-0.13	Coronary artery disease;	chr7:100217744	chr7:99992397~99993050:+
BRCA	cis	rs34792	0.853	rs153807	ENSG00000258354.1	MIR3180-1	4.25	2.37e-05	0.00177	0.16	0.13	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15462646	chr16:14909887~14911345:-
BRCA	cis	rs8017423	0.647	rs12587362	ENSG00000275198.1	RP11-471B22.3	4.25	2.37e-05	0.00177	0.15	0.13	Mortality in heart failure;	chr14:90354883	chr14:90383365~90387973:+
BRCA	cis	rs12681366	0.563	rs6999103	ENSG00000253175.1	RP11-267M23.6	4.25	2.37e-05	0.00177	0.15	0.13	Nonsyndromic cleft lip with cleft palate;	chr8:94470309	chr8:94565036~94565715:+
BRCA	cis	rs1832007	0.554	rs11594428	ENSG00000224034.1	RP11-445P17.8	-4.25	2.37e-05	0.00177	-0.21	-0.13	Triglyceride levels;Triglycerides;	chr10:5203006	chr10:5266033~5271236:-
BRCA	cis	rs6545883	0.759	rs777585	ENSG00000270820.4	RP11-355B11.2	-4.25	2.37e-05	0.00177	-0.15	-0.13	Tuberculosis;	chr2:61185424	chr2:61471188~61484130:+
BRCA	cis	rs2898290	0.5	rs11998678	ENSG00000270154.1	RP11-419I17.1	-4.25	2.37e-05	0.00177	-0.15	-0.13	Systolic blood pressure;	chr8:11972641	chr8:12476462~12477122:+
BRCA	cis	rs539096	0.781	rs2970609	ENSG00000236200.4	KDM4A-AS1	-4.25	2.38e-05	0.00177	-0.16	-0.13	Intelligence (multi-trait analysis);	chr1:43631843	chr1:43699765~43708138:-
BRCA	cis	rs11673344	0.523	rs1402468	ENSG00000276846.1	CTD-3220F14.3	4.25	2.38e-05	0.00177	0.15	0.13	Obesity-related traits;	chr19:37129346	chr19:37314868~37315620:-
BRCA	cis	rs7937890	0.559	rs2167160	ENSG00000254418.1	RP11-21L19.1	4.25	2.38e-05	0.00177	0.15	0.13	Mitochondrial DNA levels;	chr11:14485903	chr11:14262846~14273691:-
BRCA	cis	rs6479891	0.63	rs10995447	ENSG00000232075.1	MRPL35P2	4.25	2.38e-05	0.00177	0.21	0.13	Arthritis (juvenile idiopathic);	chr10:63119761	chr10:63634317~63634827:-
BRCA	cis	rs6918586	1	rs6918586	ENSG00000272810.1	U91328.22	4.25	2.38e-05	0.00178	0.15	0.13	Schizophrenia;	chr6:26097156	chr6:26013241~26013757:+
BRCA	cis	rs2243480	1	rs73142166	ENSG00000226002.1	RP11-460N20.5	-4.25	2.38e-05	0.00178	-0.22	-0.13	Diabetic kidney disease;	chr7:65910845	chr7:65084103~65100232:+
BRCA	cis	rs1910358	0.554	rs6452154	ENSG00000248874.4	C5orf17	-4.25	2.38e-05	0.00178	-0.19	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23749718	chr5:23951348~24178263:+
BRCA	cis	rs7937890	0.532	rs2575827	ENSG00000254418.1	RP11-21L19.1	4.25	2.38e-05	0.00178	0.15	0.13	Mitochondrial DNA levels;	chr11:14453969	chr11:14262846~14273691:-
BRCA	cis	rs6736093	0.966	rs74182850	ENSG00000236307.2	EEF1E1P1	-4.25	2.38e-05	0.00178	-0.17	-0.13	Coronary artery disease;	chr2:111923760	chr2:111887914~111888741:+
BRCA	cis	rs6736093	0.966	rs11686647	ENSG00000236307.2	EEF1E1P1	-4.25	2.38e-05	0.00178	-0.17	-0.13	Coronary artery disease;	chr2:111926820	chr2:111887914~111888741:+
BRCA	cis	rs6736093	0.966	rs13013340	ENSG00000236307.2	EEF1E1P1	-4.25	2.38e-05	0.00178	-0.17	-0.13	Coronary artery disease;	chr2:111937411	chr2:111887914~111888741:+
BRCA	cis	rs6736093	0.966	rs71414616	ENSG00000236307.2	EEF1E1P1	-4.25	2.38e-05	0.00178	-0.17	-0.13	Coronary artery disease;	chr2:111939107	chr2:111887914~111888741:+
BRCA	cis	rs6736093	0.966	rs13033393	ENSG00000236307.2	EEF1E1P1	-4.25	2.38e-05	0.00178	-0.17	-0.13	Coronary artery disease;	chr2:111940055	chr2:111887914~111888741:+
BRCA	cis	rs6736093	0.966	rs11674226	ENSG00000236307.2	EEF1E1P1	-4.25	2.38e-05	0.00178	-0.17	-0.13	Coronary artery disease;	chr2:111940811	chr2:111887914~111888741:+
BRCA	cis	rs812925	0.512	rs1729674	ENSG00000273302.1	RP11-493E12.2	4.25	2.38e-05	0.00178	0.11	0.13	Immature fraction of reticulocytes;	chr2:61162602	chr2:61199979~61200769:+
BRCA	cis	rs7182948	0.957	rs17483139	ENSG00000259531.2	RP11-295H24.3	4.25	2.38e-05	0.00178	0.21	0.13	Lung adenocarcinoma;	chr15:49712315	chr15:49365124~49366685:-
BRCA	cis	rs4561483	0.624	rs2215928	ENSG00000261216.1	RP11-166B2.5	-4.25	2.38e-05	0.00178	-0.15	-0.13	Testicular germ cell tumor;	chr16:11834061	chr16:11908208~11908916:+
BRCA	cis	rs12744310	1	rs12029950	ENSG00000235358.1	RP11-399E6.1	4.25	2.38e-05	0.00178	0.19	0.13	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41287493	chr1:41242373~41284861:+
BRCA	cis	rs12744310	0.943	rs12027685	ENSG00000235358.1	RP11-399E6.1	4.25	2.38e-05	0.00178	0.19	0.13	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41290626	chr1:41242373~41284861:+
BRCA	cis	rs12744310	1	rs12024413	ENSG00000235358.1	RP11-399E6.1	4.25	2.38e-05	0.00178	0.19	0.13	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41290744	chr1:41242373~41284861:+
BRCA	cis	rs12744310	1	rs34027267	ENSG00000235358.1	RP11-399E6.1	4.25	2.38e-05	0.00178	0.19	0.13	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41291005	chr1:41242373~41284861:+
BRCA	cis	rs12744310	1	rs12722758	ENSG00000235358.1	RP11-399E6.1	4.25	2.38e-05	0.00178	0.19	0.13	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41291343	chr1:41242373~41284861:+
BRCA	cis	rs12744310	1	rs12723893	ENSG00000235358.1	RP11-399E6.1	4.25	2.38e-05	0.00178	0.19	0.13	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41291368	chr1:41242373~41284861:+
BRCA	cis	rs17489649	1	rs12518625	ENSG00000271849.1	CTC-332L22.1	4.25	2.38e-05	0.00178	0.17	0.13	Intelligence (multi-trait analysis);	chr5:109836474	chr5:109687802~109688329:-
BRCA	cis	rs10208649	1	rs13387291	ENSG00000233266.1	HMGB1P31	4.25	2.38e-05	0.00178	0.29	0.13	Body mass index;	chr2:53808114	chr2:54051334~54051760:+
BRCA	cis	rs2524005	1	rs2524005	ENSG00000231130.1	HLA-T	-4.25	2.38e-05	0.00178	-0.21	-0.13	Bipolar disorder and schizophrenia;	chr6:29931900	chr6:29896654~29897786:+
BRCA	cis	rs13160562	0.527	rs27525	ENSG00000248734.2	CTD-2260A17.1	4.25	2.38e-05	0.00178	0.14	0.13	Alcohol dependence;	chr5:96766255	chr5:96784777~96785999:+
BRCA	cis	rs2460905	1	rs2460903	ENSG00000251468.2	RP11-369K16.1	4.25	2.38e-05	0.00178	0.25	0.13	Post-traumatic stress disorder;	chr8:12976116	chr8:12958387~12962200:+
BRCA	cis	rs1383484	0.545	rs9329363	ENSG00000225151.9	GOLGA2P7	4.25	2.38e-05	0.00178	0.16	0.13	Height;	chr15:83974382	chr15:84199311~84230136:-
BRCA	cis	rs7927592	0.83	rs7120635	ENSG00000212093.1	AP000807.1	4.24	2.38e-05	0.00178	0.14	0.13	Total body bone mineral density;	chr11:68493825	chr11:68506083~68506166:-
BRCA	cis	rs7896471	0.546	rs11815640	ENSG00000227695.4	DNMBP-AS1	-4.24	2.38e-05	0.00178	-0.27	-0.13	Blood protein levels;	chr10:99978482	chr10:99927010~99958381:+
BRCA	cis	rs6600671	1	rs4844616	ENSG00000231429.2	RP11-343N15.2	-4.24	2.38e-05	0.00178	-0.16	-0.13	Hip geometry;	chr1:121429348	chr1:121412719~121429274:+
BRCA	cis	rs2108622	0.727	rs62106155	ENSG00000267218.2	AC005336.5	4.24	2.38e-05	0.00178	0.16	0.13	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15869550	chr19:15902300~15903238:-
BRCA	cis	rs202072	0.872	rs413120	ENSG00000215022.6	RP1-257A7.4	4.24	2.38e-05	0.00178	0.16	0.13	HIV-1 viral setpoint;	chr6:13280409	chr6:13264861~13295586:-
BRCA	cis	rs11098499	0.754	rs1980025	ENSG00000260404.2	RP11-384K6.6	-4.24	2.38e-05	0.00178	-0.12	-0.13	Corneal astigmatism;	chr4:119331651	chr4:118591773~118633729:+
BRCA	cis	rs16940212	0.505	rs16940168	ENSG00000259771.1	RP11-429D19.1	4.24	2.38e-05	0.00178	0.23	0.13	HDL cholesterol;HDL cholesterol levels;	chr15:58391955	chr15:59266720~59271162:-
BRCA	cis	rs62103177	0.608	rs34383580	ENSG00000278000.1	AC139100.4	-4.24	2.38e-05	0.00178	-0.2	-0.13	Opioid sensitivity;	chr18:80074960	chr18:80161752~80162413:+
BRCA	cis	rs2662776	1	rs10753609	ENSG00000232995.6	RGS5	-4.24	2.39e-05	0.00178	-0.13	-0.13	Lead levels in blood;	chr1:163190547	chr1:163244505~163321894:-
BRCA	cis	rs875971	0.965	rs9969301	ENSG00000236529.1	RP13-254B10.1	-4.24	2.39e-05	0.00178	-0.14	-0.13	Aortic root size;	chr7:66316668	chr7:65840212~65840596:+
BRCA	cis	rs6870983	0.584	rs10053933	ENSG00000247828.6	TMEM161B-AS1	-4.24	2.39e-05	0.00178	-0.16	-0.13	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index;	chr5:88145364	chr5:88268895~88436685:+
BRCA	cis	rs7267979	1	rs6076345	ENSG00000125804.12	FAM182A	4.24	2.39e-05	0.00178	0.17	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25401259	chr20:26054655~26086917:+
BRCA	cis	rs6449502	0.536	rs10471505	ENSG00000251279.1	CTC-436P18.1	4.24	2.39e-05	0.00178	0.27	0.13	Mean platelet volume;	chr5:61192023	chr5:61162070~61232040:+
BRCA	cis	rs7246967	0.673	rs55638152	ENSG00000198153.8	ZNF849P	-4.24	2.39e-05	0.00178	-0.18	-0.13	Bronchopulmonary dysplasia;	chr19:22872492	chr19:22685167~22686732:+
BRCA	cis	rs2832191	0.74	rs2832177	ENSG00000232855.5	AF131217.1	4.24	2.39e-05	0.00178	0.16	0.13	Dental caries;	chr21:29106032	chr21:28439346~28674848:-
BRCA	cis	rs8054556	0.787	rs3814877	ENSG00000261367.1	RP11-455F5.4	-4.24	2.39e-05	0.00178	-0.14	-0.13	Autism spectrum disorder or schizophrenia;	chr16:30031356	chr16:30107675~30110541:+
BRCA	cis	rs1555321	0.571	rs10763918	ENSG00000273038.2	RP11-479G22.8	4.24	2.39e-05	0.00178	0.16	0.13	Coronary artery disease;	chr10:33227086	chr10:32887255~32889311:-
BRCA	cis	rs2312236	0.714	rs11808386	ENSG00000225171.2	DUTP6	4.24	2.39e-05	0.00178	0.18	0.13	Post-traumatic stress disorder;	chr1:166753153	chr1:166868748~166869209:+
BRCA	cis	rs867371	0.929	rs7176075	ENSG00000278603.1	RP13-608F4.5	4.24	2.39e-05	0.00178	0.17	0.13	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82178998	chr15:82472203~82472426:+
BRCA	cis	rs6893300	0.857	rs6860716	ENSG00000250999.1	RP11-1379J22.5	4.24	2.39e-05	0.00178	0.17	0.13	Resting heart rate;	chr5:179735839	chr5:179657762~179664432:+
BRCA	cis	rs6671200	0.666	rs12724474	ENSG00000235501.4	RP4-639F20.1	-4.24	2.39e-05	0.00178	-0.29	-0.13	Stearic acid (18:0) levels;	chr1:95046277	chr1:94927566~94963270:+
BRCA	cis	rs6547741	1	rs11127071	ENSG00000234072.1	AC074117.10	4.24	2.39e-05	0.00178	0.12	0.13	Oral cavity cancer;	chr2:27615191	chr2:27356246~27367622:+
BRCA	cis	rs1421334	0.781	rs11778607	ENSG00000279041.1	CTD-2373N4.3	4.24	2.39e-05	0.00179	0.13	0.13	Intelligence (multi-trait analysis);	chr8:30982052	chr8:30552345~30553766:+
BRCA	cis	rs10411936	0.962	rs10402422	ENSG00000280332.1	CTD-2013N17.6	4.24	2.39e-05	0.00179	0.11	0.13	Multiple sclerosis;White blood cell count;	chr19:16364577	chr19:16356329~16358327:-
BRCA	cis	rs17489649	1	rs7726343	ENSG00000271849.1	CTC-332L22.1	4.24	2.39e-05	0.00179	0.17	0.13	Intelligence (multi-trait analysis);	chr5:109816233	chr5:109687802~109688329:-
BRCA	cis	rs9868809	0.505	rs13316551	ENSG00000225399.4	RP11-3B7.1	-4.24	2.39e-05	0.00179	-0.19	-0.13	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48707734	chr3:49260085~49261316:+
BRCA	cis	rs7829975	0.688	rs6995407	ENSG00000233609.3	RP11-62H7.2	4.24	2.39e-05	0.00179	0.12	0.13	Mood instability;	chr8:8527137	chr8:8961200~8979025:+
BRCA	cis	rs957448	0.561	rs58663902	ENSG00000261437.1	RP11-22C11.2	4.24	2.39e-05	0.00179	0.12	0.13	Nonsyndromic cleft lip with cleft palate;	chr8:94610177	chr8:94637285~94639467:-
BRCA	cis	rs11098499	0.955	rs35197422	ENSG00000260091.1	RP11-33B1.4	-4.24	2.39e-05	0.00179	-0.12	-0.13	Corneal astigmatism;	chr4:119248159	chr4:119409333~119410233:+
BRCA	cis	rs181553	0.664	rs948789	ENSG00000266696.1	RP11-30L3.2	-4.24	2.4e-05	0.00179	-0.15	-0.13	Hip circumference adjusted for BMI;	chr18:49174326	chr18:49205912~49208781:+
BRCA	cis	rs7671266	0.532	rs28730480	ENSG00000250413.1	RP11-448G15.1	-4.24	2.4e-05	0.00179	-0.21	-0.13	Cardiovascular disease risk factors;	chr4:10047243	chr4:10006482~10009725:+
BRCA	cis	rs4865762	0.514	rs30088	ENSG00000247796.2	CTD-2366F13.1	4.24	2.4e-05	0.00179	0.14	0.13	Intraocular pressure;	chr5:53130011	chr5:53109842~53115126:+
BRCA	cis	rs6088580	0.608	rs1205342	ENSG00000276073.1	RP5-1125A11.7	4.24	2.4e-05	0.00179	0.14	0.13	Glomerular filtration rate (creatinine);	chr20:34334036	chr20:33985617~33988989:-
BRCA	cis	rs11742741	0.905	rs57590048	ENSG00000248874.4	C5orf17	-4.24	2.4e-05	0.00179	-0.17	-0.13	Educational attainment;	chr5:24106579	chr5:23951348~24178263:+
BRCA	cis	rs4287000	0.508	rs4743929	ENSG00000227603.1	RP11-165J3.6	-4.24	2.4e-05	0.00179	-0.15	-0.13	Itch intensity from mosquito bite adjusted by bite size;	chr9:93606355	chr9:93435332~93437121:-
BRCA	cis	rs13113518	0.966	rs12506788	ENSG00000272969.1	RP11-528I4.2	4.24	2.4e-05	0.00179	0.15	0.13	Height;	chr4:55477426	chr4:55547112~55547889:+
BRCA	cis	rs7182948	1	rs967893	ENSG00000259531.2	RP11-295H24.3	-4.24	2.4e-05	0.00179	-0.18	-0.13	Lung adenocarcinoma;	chr15:49540071	chr15:49365124~49366685:-
BRCA	cis	rs848490	0.889	rs17156320	ENSG00000214293.7	APTR	-4.24	2.4e-05	0.00179	-0.16	-0.13	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77670793	chr7:77657660~77696265:-
BRCA	cis	rs58521262	0.585	rs1645767	ENSG00000268105.1	RP11-369G6.2	-4.24	2.4e-05	0.00179	-0.18	-0.13	Testicular germ cell tumor;	chr19:23026435	chr19:23125665~23128543:+
BRCA	cis	rs1982963	1	rs904061	ENSG00000277050.1	RP11-102G14.1	-4.24	2.4e-05	0.00179	-0.16	-0.13	Waist-to-hip ratio adjusted for body mass index;	chr14:52037906	chr14:51637348~51637947:-
BRCA	cis	rs28829049	0.597	rs2313509	ENSG00000270728.1	RP4-657E11.10	-4.24	2.4e-05	0.00179	-0.13	-0.13	QRS duration in Tripanosoma cruzi seropositivity;	chr1:19111366	chr1:19297080~19297903:+
BRCA	cis	rs4919687	0.55	rs12783444	ENSG00000213061.2	PFN1P11	4.24	2.4e-05	0.00179	0.18	0.13	Colorectal cancer;	chr10:102720902	chr10:102838011~102845473:-
BRCA	cis	rs7819412	0.595	rs10503416	ENSG00000154316.13	TDH	-4.24	2.4e-05	0.00179	-0.17	-0.13	Triglycerides;	chr8:11130043	chr8:11339637~11368452:+
BRCA	cis	rs58521262	0.556	rs289324	ENSG00000268105.1	RP11-369G6.2	4.24	2.4e-05	0.00179	0.18	0.13	Testicular germ cell tumor;	chr19:22974103	chr19:23125665~23128543:+
BRCA	cis	rs6430585	0.528	rs6750549	ENSG00000231890.6	DARS-AS1	-4.24	2.4e-05	0.00179	-0.21	-0.13	Corneal structure;	chr2:135949910	chr2:135985176~136022593:+
BRCA	cis	rs2243480	0.706	rs6460257	ENSG00000222364.1	RNU6-96P	-4.24	2.4e-05	0.00179	-0.2	-0.13	Diabetic kidney disease;	chr7:65731813	chr7:66395191~66395286:+
BRCA	cis	rs2243480	0.831	rs57294491	ENSG00000275400.1	RP4-756H11.5	-4.24	2.4e-05	0.00179	-0.24	-0.13	Diabetic kidney disease;	chr7:66219914	chr7:66553805~66554199:-
BRCA	cis	rs10458771	0.667	rs11817847	ENSG00000227896.2	RP11-77P6.2	4.24	2.4e-05	0.00179	0.21	0.13	Amyotrophic lateral sclerosis (sporadic);	chr10:86510491	chr10:86521945~86525101:+
BRCA	cis	rs7267979	0.966	rs2482918	ENSG00000276952.1	RP5-965G21.6	-4.24	2.4e-05	0.00179	-0.16	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25431499	chr20:25284915~25285588:-
BRCA	cis	rs9425766	0.64	rs9660881	ENSG00000200674.1	RN7SKP160	4.24	2.4e-05	0.00179	0.21	0.13	Life satisfaction;	chr1:173867378	chr1:173791548~173791887:+
BRCA	cis	rs9425766	0.678	rs55829688	ENSG00000200674.1	RN7SKP160	4.24	2.4e-05	0.00179	0.21	0.13	Life satisfaction;	chr1:173868168	chr1:173791548~173791887:+
BRCA	cis	rs6088580	0.668	rs1205337	ENSG00000276073.1	RP5-1125A11.7	4.24	2.4e-05	0.00179	0.14	0.13	Glomerular filtration rate (creatinine);	chr20:34338235	chr20:33985617~33988989:-
BRCA	cis	rs2073316	0.527	rs72790682	ENSG00000272716.1	RP11-563N4.1	4.24	2.4e-05	0.00179	0.14	0.13	Interleukin-18 levels;	chr2:31434795	chr2:32165046~32165757:-
BRCA	cis	rs6751744	0.924	rs13386318	ENSG00000226266.5	AC009961.3	-4.24	2.4e-05	0.00179	-0.18	-0.13	Dysphagia;	chr2:159541846	chr2:159670708~159712435:-
BRCA	cis	rs7260598	0.685	rs11671000	ENSG00000268442.1	CTD-2027I19.2	4.24	2.4e-05	0.00179	0.22	0.13	Response to taxane treatment (placlitaxel);	chr19:24110025	chr19:24162370~24163425:-
BRCA	cis	rs7260598	0.792	rs73021445	ENSG00000268442.1	CTD-2027I19.2	4.24	2.4e-05	0.00179	0.22	0.13	Response to taxane treatment (placlitaxel);	chr19:24121306	chr19:24162370~24163425:-
BRCA	cis	rs7260598	0.792	rs7252836	ENSG00000268442.1	CTD-2027I19.2	4.24	2.4e-05	0.00179	0.22	0.13	Response to taxane treatment (placlitaxel);	chr19:24122787	chr19:24162370~24163425:-
BRCA	cis	rs7260598	0.792	rs61737180	ENSG00000268442.1	CTD-2027I19.2	4.24	2.4e-05	0.00179	0.22	0.13	Response to taxane treatment (placlitaxel);	chr19:24127230	chr19:24162370~24163425:-
BRCA	cis	rs62458065	0.85	rs6462362	ENSG00000229358.3	DPY19L1P1	-4.24	2.4e-05	0.00179	-0.18	-0.13	Metabolite levels (HVA/MHPG ratio);	chr7:32425121	chr7:32580949~32761787:-
BRCA	cis	rs6840360	0.573	rs4696080	ENSG00000270265.1	RP11-731D1.4	-4.24	2.4e-05	0.00179	-0.15	-0.13	Intelligence (multi-trait analysis);	chr4:151355313	chr4:151333775~151353224:-
BRCA	cis	rs1005277	0.557	rs2983338	ENSG00000276805.1	RP11-291L22.6	4.24	2.41e-05	0.00179	0.14	0.13	Extrinsic epigenetic age acceleration;	chr10:38261806	chr10:38451030~38451785:+
BRCA	cis	rs2832191	0.671	rs2832213	ENSG00000176054.6	RPL23P2	-4.24	2.41e-05	0.00179	-0.15	-0.13	Dental caries;	chr21:29140593	chr21:28997613~28998033:-
BRCA	cis	rs875971	0.619	rs12533585	ENSG00000232546.1	RP11-458F8.1	-4.24	2.41e-05	0.00179	-0.11	-0.13	Aortic root size;	chr7:66519618	chr7:66848496~66858136:+
BRCA	cis	rs2908197	0.713	rs2961038	ENSG00000186704.9	DTX2P1	4.24	2.41e-05	0.00179	0.15	0.13	3-hydroxypropylmercapturic acid levels in smokers;	chr7:76322753	chr7:76978617~77004308:+
BRCA	cis	rs7772486	0.875	rs6913797	ENSG00000270638.1	RP3-466P17.1	4.24	2.41e-05	0.00179	0.15	0.13	Lobe attachment (rater-scored or self-reported);	chr6:146092622	chr6:145735570~145737218:+
BRCA	cis	rs4073054	0.564	rs4564157	ENSG00000232879.2	RP11-544M22.3	-4.24	2.41e-05	0.0018	-0.14	-0.13	Blood metabolite levels;	chr1:161208365	chr1:161034834~161035006:+
BRCA	cis	rs4835473	0.797	rs34585546	ENSG00000249741.2	RP11-673E1.3	4.24	2.41e-05	0.0018	0.15	0.13	Immature fraction of reticulocytes;	chr4:143680693	chr4:143911514~143912053:-
BRCA	cis	rs6546324	0.625	rs4260227	ENSG00000236780.4	AC078941.1	4.24	2.41e-05	0.0018	0.22	0.13	Endometriosis;	chr2:67616405	chr2:67123357~67215319:-
BRCA	cis	rs7572733	0.555	rs7600269	ENSG00000231621.1	AC013264.2	-4.24	2.41e-05	0.0018	-0.13	-0.13	Dermatomyositis;	chr2:198058744	chr2:197197991~197199273:+
BRCA	cis	rs2243480	1	rs1723269	ENSG00000275400.1	RP4-756H11.5	4.24	2.41e-05	0.0018	0.24	0.13	Diabetic kidney disease;	chr7:66007799	chr7:66553805~66554199:-
BRCA	cis	rs9341808	0.754	rs3805885	ENSG00000233967.5	RP11-250B2.3	-4.24	2.41e-05	0.0018	-0.13	-0.13	Sitting height ratio;	chr6:80287034	chr6:80443344~80465927:+
BRCA	cis	rs7267979	1	rs2387884	ENSG00000125804.12	FAM182A	4.24	2.41e-05	0.0018	0.17	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25398433	chr20:26054655~26086917:+
BRCA	cis	rs875971	0.965	rs28682868	ENSG00000229180.5	GS1-124K5.11	-4.24	2.41e-05	0.0018	-0.11	-0.13	Aortic root size;	chr7:66224822	chr7:66526088~66542624:-
BRCA	cis	rs2692947	0.673	rs4907299	ENSG00000168992.4	OR7E102P	4.24	2.41e-05	0.0018	0.18	0.13	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96114374	chr2:95546531~95547545:+
BRCA	cis	rs4869313	0.905	rs2910793	ENSG00000248734.2	CTD-2260A17.1	-4.24	2.41e-05	0.0018	-0.13	-0.13	Pediatric autoimmune diseases;	chr5:96911730	chr5:96784777~96785999:+
BRCA	cis	rs4869313	0.87	rs2859491	ENSG00000248734.2	CTD-2260A17.1	-4.24	2.41e-05	0.0018	-0.13	-0.13	Pediatric autoimmune diseases;	chr5:96913944	chr5:96784777~96785999:+
BRCA	cis	rs9527	0.59	rs10883818	ENSG00000213061.2	PFN1P11	4.24	2.41e-05	0.0018	0.18	0.13	Arsenic metabolism;	chr10:102999829	chr10:102838011~102845473:-
BRCA	cis	rs71520386	0.632	rs10254365	ENSG00000226329.2	AC005682.6	-4.24	2.41e-05	0.0018	-0.14	-0.13	Fibrinogen levels;	chr7:22825135	chr7:22863874~22881350:-
BRCA	cis	rs9952991	0.941	rs2542149	ENSG00000260302.1	RP11-973H7.1	-4.24	2.41e-05	0.0018	-0.21	-0.13	Inflammatory skin disease;	chr18:12779019	chr18:12774651~12775923:-
BRCA	cis	rs9952991	0.941	rs2542150	ENSG00000260302.1	RP11-973H7.1	-4.24	2.41e-05	0.0018	-0.21	-0.13	Inflammatory skin disease;	chr18:12779764	chr18:12774651~12775923:-
BRCA	cis	rs6545883	0.965	rs766447	ENSG00000270820.4	RP11-355B11.2	4.24	2.41e-05	0.0018	0.15	0.13	Tuberculosis;	chr2:61508434	chr2:61471188~61484130:+
BRCA	cis	rs4578769	0.729	rs12456875	ENSG00000265939.1	UBE2CP2	-4.24	2.41e-05	0.0018	-0.16	-0.13	Eosinophil percentage of white cells;	chr18:22830208	chr18:22900486~22900995:-
BRCA	cis	rs8180040	0.932	rs62246474	ENSG00000271161.1	BOLA2P2	-4.24	2.41e-05	0.0018	-0.14	-0.13	Colorectal cancer;	chr3:47356640	chr3:47499841~47500407:+
BRCA	cis	rs2832191	0.671	rs2409332	ENSG00000176054.6	RPL23P2	-4.24	2.41e-05	0.0018	-0.15	-0.13	Dental caries;	chr21:29140458	chr21:28997613~28998033:-
BRCA	cis	rs2018683	0.624	rs2286219	ENSG00000233517.1	AC005162.5	-4.24	2.41e-05	0.0018	-0.16	-0.13	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28959047	chr7:28987028~28988899:+
BRCA	cis	rs9527	0.518	rs11191487	ENSG00000213061.2	PFN1P11	4.24	2.42e-05	0.0018	0.25	0.13	Arsenic metabolism;	chr10:102974866	chr10:102838011~102845473:-
BRCA	cis	rs308403	0.509	rs13122636	ENSG00000224786.1	CETN4P	4.24	2.42e-05	0.0018	0.17	0.13	Blood protein levels;	chr4:122749890	chr4:122730548~122732193:-
BRCA	cis	rs2832191	0.755	rs2832192	ENSG00000236056.1	GAPDHP14	4.24	2.42e-05	0.0018	0.14	0.13	Dental caries;	chr21:29118852	chr21:29222321~29223257:+
BRCA	cis	rs745109	0.882	rs72930396	ENSG00000273080.1	RP11-301O19.1	4.24	2.42e-05	0.0018	0.21	0.13	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86475396	chr2:86195590~86196049:+
BRCA	cis	rs2518049	0.563	rs17134724	ENSG00000224034.1	RP11-445P17.8	-4.24	2.42e-05	0.0018	-0.24	-0.13	Metabolic traits;	chr10:5276549	chr10:5266033~5271236:-
BRCA	cis	rs2882667	0.964	rs11739351	ENSG00000242683.1	CTB-46B19.1	4.24	2.42e-05	0.0018	0.15	0.13	Age-related hearing impairment (SNP x SNP interaction);	chr5:138976053	chr5:139035148~139035987:-
BRCA	cis	rs2904967	0.929	rs2904980	ENSG00000254614.2	AP003068.23	-4.24	2.42e-05	0.0018	-0.22	-0.13	Mean corpuscular volume;	chr11:65234208	chr11:65177606~65181834:-
BRCA	cis	rs11098499	0.644	rs17517414	ENSG00000260404.2	RP11-384K6.6	4.24	2.42e-05	0.0018	0.12	0.13	Corneal astigmatism;	chr4:119340946	chr4:118591773~118633729:+
BRCA	cis	rs11642862	1	rs111954099	ENSG00000280211.1	RP11-2C24.3	-4.24	2.42e-05	0.0018	-0.2	-0.13	Tonsillectomy;	chr16:30778302	chr16:30773532~30776033:-
BRCA	cis	rs7011507	0.589	rs10098707	ENSG00000233858.4	AC026904.1	4.24	2.42e-05	0.0018	0.16	0.13	Inflammatory bowel disease;Ulcerative colitis;	chr8:48511700	chr8:48590401~48594621:+
BRCA	cis	rs7011507	0.582	rs72637607	ENSG00000279881.1	RP11-513O13.1	-4.24	2.42e-05	0.0018	-0.22	-0.13	Inflammatory bowel disease;Ulcerative colitis;	chr8:48327076	chr8:48428143~48431041:-
BRCA	cis	rs11742741	0.605	rs28594809	ENSG00000248874.4	C5orf17	-4.24	2.42e-05	0.0018	-0.17	-0.13	Educational attainment;	chr5:24057825	chr5:23951348~24178263:+
BRCA	cis	rs801193	1	rs2003301	ENSG00000223473.2	GS1-124K5.3	-4.24	2.42e-05	0.0018	-0.1	-0.13	Aortic root size;	chr7:66682669	chr7:66491049~66493566:-
BRCA	cis	rs4835473	0.932	rs34917094	ENSG00000249741.2	RP11-673E1.3	4.24	2.42e-05	0.0018	0.15	0.13	Immature fraction of reticulocytes;	chr4:143832003	chr4:143911514~143912053:-
BRCA	cis	rs8114671	0.836	rs4911461	ENSG00000126005.14	MMP24-AS1	4.24	2.42e-05	0.0018	0.15	0.13	Height;	chr20:35042190	chr20:35216462~35278131:-
BRCA	cis	rs4930561	0.739	rs12225316	ENSG00000184795.9	UNC93B5	-4.24	2.42e-05	0.00181	-0.15	-0.13	Breast cancer in childhood cancer survivors;IgG glycosylation;	chr11:68208536	chr11:67711702~67716005:-
BRCA	cis	rs875971	0.619	rs2302918	ENSG00000273142.1	RP11-458F8.4	-4.24	2.42e-05	0.00181	-0.11	-0.13	Aortic root size;	chr7:66535945	chr7:66902857~66906297:+
BRCA	cis	rs7246657	0.524	rs10411251	ENSG00000276846.1	CTD-3220F14.3	4.24	2.42e-05	0.00181	0.19	0.13	Coronary artery calcification;	chr19:36937853	chr19:37314868~37315620:-
BRCA	cis	rs2832191	0.692	rs2245734	ENSG00000232855.5	AF131217.1	-4.24	2.42e-05	0.00181	-0.16	-0.13	Dental caries;	chr21:28987644	chr21:28439346~28674848:-
BRCA	cis	rs7475343	0.501	rs7909379	ENSG00000224034.1	RP11-445P17.8	-4.24	2.42e-05	0.00181	-0.25	-0.13	Intelligence;	chr10:5209851	chr10:5266033~5271236:-
BRCA	cis	rs7475343	0.501	rs7909380	ENSG00000224034.1	RP11-445P17.8	-4.24	2.42e-05	0.00181	-0.25	-0.13	Intelligence;	chr10:5209852	chr10:5266033~5271236:-
BRCA	cis	rs7475343	0.501	rs117310669	ENSG00000224034.1	RP11-445P17.8	-4.24	2.42e-05	0.00181	-0.25	-0.13	Intelligence;	chr10:5210050	chr10:5266033~5271236:-
BRCA	cis	rs7475343	0.501	rs4424574	ENSG00000224034.1	RP11-445P17.8	-4.24	2.42e-05	0.00181	-0.25	-0.13	Intelligence;	chr10:5210114	chr10:5266033~5271236:-
BRCA	cis	rs7475343	0.501	rs7475279	ENSG00000224034.1	RP11-445P17.8	-4.24	2.42e-05	0.00181	-0.25	-0.13	Intelligence;	chr10:5210903	chr10:5266033~5271236:-
BRCA	cis	rs7475343	0.501	rs7475281	ENSG00000224034.1	RP11-445P17.8	-4.24	2.42e-05	0.00181	-0.25	-0.13	Intelligence;	chr10:5210939	chr10:5266033~5271236:-
BRCA	cis	rs7475343	0.501	rs7078211	ENSG00000224034.1	RP11-445P17.8	-4.24	2.42e-05	0.00181	-0.25	-0.13	Intelligence;	chr10:5211675	chr10:5266033~5271236:-
BRCA	cis	rs7475343	0.501	rs6601927	ENSG00000224034.1	RP11-445P17.8	-4.24	2.42e-05	0.00181	-0.25	-0.13	Intelligence;	chr10:5212183	chr10:5266033~5271236:-
BRCA	cis	rs7475343	0.501	rs7897431	ENSG00000224034.1	RP11-445P17.8	-4.24	2.42e-05	0.00181	-0.25	-0.13	Intelligence;	chr10:5212225	chr10:5266033~5271236:-
BRCA	cis	rs7475343	0.501	rs1831977	ENSG00000224034.1	RP11-445P17.8	-4.24	2.42e-05	0.00181	-0.25	-0.13	Intelligence;	chr10:5212858	chr10:5266033~5271236:-
BRCA	cis	rs7475343	0.501	rs1832007	ENSG00000224034.1	RP11-445P17.8	-4.24	2.42e-05	0.00181	-0.25	-0.13	Intelligence;	chr10:5212884	chr10:5266033~5271236:-
BRCA	cis	rs7475343	0.501	rs17134585	ENSG00000224034.1	RP11-445P17.8	-4.24	2.42e-05	0.00181	-0.25	-0.13	Intelligence;	chr10:5214309	chr10:5266033~5271236:-
BRCA	cis	rs7475343	0.501	rs17134588	ENSG00000224034.1	RP11-445P17.8	-4.24	2.42e-05	0.00181	-0.25	-0.13	Intelligence;	chr10:5214534	chr10:5266033~5271236:-
BRCA	cis	rs7475343	0.501	rs77503049	ENSG00000224034.1	RP11-445P17.8	-4.24	2.42e-05	0.00181	-0.25	-0.13	Intelligence;	chr10:5214795	chr10:5266033~5271236:-
BRCA	cis	rs7475343	0.501	rs78585347	ENSG00000224034.1	RP11-445P17.8	-4.24	2.42e-05	0.00181	-0.25	-0.13	Intelligence;	chr10:5215134	chr10:5266033~5271236:-
BRCA	cis	rs7475343	0.501	rs78686304	ENSG00000224034.1	RP11-445P17.8	-4.24	2.42e-05	0.00181	-0.25	-0.13	Intelligence;	chr10:5215834	chr10:5266033~5271236:-
BRCA	cis	rs2243480	1	rs35058610	ENSG00000226002.1	RP11-460N20.5	-4.24	2.42e-05	0.00181	-0.21	-0.13	Diabetic kidney disease;	chr7:65925938	chr7:65084103~65100232:+
BRCA	cis	rs6439153	0.933	rs810952	ENSG00000261159.1	RP11-723O4.9	4.24	2.42e-05	0.00181	0.14	0.13	Pneumococcal bacteremia;	chr3:128967062	chr3:128859716~128860526:-
BRCA	cis	rs11992162	1	rs7460395	ENSG00000251402.3	FAM90A25P	4.24	2.42e-05	0.00181	0.16	0.13	Monocyte count;	chr8:11977866	chr8:12415080~12418090:-
BRCA	cis	rs8114671	0.836	rs6142284	ENSG00000126005.14	MMP24-AS1	4.24	2.43e-05	0.00181	0.15	0.13	Height;	chr20:35053564	chr20:35216462~35278131:-
BRCA	cis	rs875971	0.545	rs73146609	ENSG00000273142.1	RP11-458F8.4	4.24	2.43e-05	0.00181	0.13	0.13	Aortic root size;	chr7:66302477	chr7:66902857~66906297:+
BRCA	cis	rs875971	0.545	rs2173571	ENSG00000273142.1	RP11-458F8.4	4.24	2.43e-05	0.00181	0.13	0.13	Aortic root size;	chr7:66305392	chr7:66902857~66906297:+
BRCA	cis	rs6686842	0.56	rs213765	ENSG00000235358.1	RP11-399E6.1	4.24	2.43e-05	0.00181	0.18	0.13	Height;	chr1:41116334	chr1:41242373~41284861:+
BRCA	cis	rs2243480	0.803	rs35480979	ENSG00000275400.1	RP4-756H11.5	4.24	2.43e-05	0.00181	0.23	0.13	Diabetic kidney disease;	chr7:65892097	chr7:66553805~66554199:-
BRCA	cis	rs2243480	1	rs35391607	ENSG00000275400.1	RP4-756H11.5	4.24	2.43e-05	0.00181	0.23	0.13	Diabetic kidney disease;	chr7:65895842	chr7:66553805~66554199:-
BRCA	cis	rs2243480	1	rs13220979	ENSG00000275400.1	RP4-756H11.5	4.24	2.43e-05	0.00181	0.23	0.13	Diabetic kidney disease;	chr7:65898217	chr7:66553805~66554199:-
BRCA	cis	rs2243480	1	rs34974928	ENSG00000275400.1	RP4-756H11.5	4.24	2.43e-05	0.00181	0.23	0.13	Diabetic kidney disease;	chr7:65899019	chr7:66553805~66554199:-
BRCA	cis	rs6545883	0.894	rs2463102	ENSG00000273302.1	RP11-493E12.2	-4.24	2.43e-05	0.00181	-0.12	-0.13	Tuberculosis;	chr2:61344160	chr2:61199979~61200769:+
BRCA	cis	rs6071166	0.683	rs7344456	ENSG00000224635.1	RP4-564F22.5	-4.24	2.43e-05	0.00181	-0.15	-0.13	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38678651	chr20:38406011~38416797:-
BRCA	cis	rs983392	1	rs4939312	ENSG00000275344.1	MIR6503	4.24	2.43e-05	0.00181	0.14	0.13	Alzheimer's disease (late onset);	chr11:60132633	chr11:60209071~60209156:-
BRCA	cis	rs952623	0.611	rs10435033	ENSG00000211694.2	TRGV10	4.24	2.43e-05	0.00181	0.11	0.13	Intelligence (multi-trait analysis);	chr7:39015237	chr7:38299811~38300322:-
BRCA	cis	rs75804782	0.63	rs113725999	ENSG00000186235.9	AC016757.3	4.24	2.43e-05	0.00181	0.33	0.13	Chronotype;Morning vs. evening chronotype;	chr2:238379010	chr2:238224552~238231677:-
BRCA	cis	rs75804782	0.515	rs75251934	ENSG00000186235.9	AC016757.3	4.24	2.43e-05	0.00181	0.33	0.13	Chronotype;Morning vs. evening chronotype;	chr2:238379746	chr2:238224552~238231677:-
BRCA	cis	rs2243480	0.901	rs3813708	ENSG00000222364.1	RNU6-96P	-4.24	2.43e-05	0.00181	-0.24	-0.13	Diabetic kidney disease;	chr7:65840645	chr7:66395191~66395286:+
BRCA	cis	rs6921919	0.583	rs4254981	ENSG00000273712.1	RP5-874C20.7	4.24	2.43e-05	0.00181	0.17	0.13	Autism spectrum disorder or schizophrenia;	chr6:28403625	chr6:28315613~28315883:-
BRCA	cis	rs6870983	0.895	rs13157159	ENSG00000247828.6	TMEM161B-AS1	4.24	2.43e-05	0.00181	0.17	0.13	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index;	chr5:88366503	chr5:88268895~88436685:+
BRCA	cis	rs1823874	0.71	rs55947799	ENSG00000182397.13	DNM1P46	-4.24	2.43e-05	0.00181	-0.15	-0.13	IgG glycosylation;	chr15:99820700	chr15:99790156~99806927:-
BRCA	cis	rs7267979	0.932	rs367666	ENSG00000125804.12	FAM182A	-4.24	2.43e-05	0.00181	-0.17	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25469182	chr20:26054655~26086917:+
BRCA	cis	rs4948275	0.605	rs2650746	ENSG00000237233.2	TMEM26-AS1	-4.24	2.43e-05	0.00181	-0.15	-0.13	Night sleep phenotypes;	chr10:61587436	chr10:61452639~61481956:+
BRCA	cis	rs62025270	0.547	rs8035496	ENSG00000259295.5	CSPG4P12	-4.24	2.43e-05	0.00181	-0.17	-0.13	Idiopathic pulmonary fibrosis;	chr15:85591101	chr15:85191438~85213905:+
BRCA	cis	rs6480314	0.522	rs10047388	ENSG00000233590.1	RP11-153K11.3	4.24	2.43e-05	0.00181	0.2	0.13	Optic nerve measurement (disc area);	chr10:68300456	chr10:68233251~68242379:-
BRCA	cis	rs983392	1	rs2165525	ENSG00000275344.1	MIR6503	-4.24	2.43e-05	0.00181	-0.14	-0.13	Alzheimer's disease (late onset);	chr11:60139319	chr11:60209071~60209156:-
BRCA	cis	rs12691307	1	rs12691307	ENSG00000183604.13	SMG1P5	-4.24	2.43e-05	0.00181	-0.12	-0.13	Schizophrenia;	chr16:29928556	chr16:30267553~30335374:-
BRCA	cis	rs4650943	0.561	rs4147204	ENSG00000227740.1	RP11-318C24.2	-4.24	2.43e-05	0.00181	-0.14	-0.13	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in inactive individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr1:176381808	chr1:175904762~175920513:-
BRCA	cis	rs6870983	0.697	rs6884773	ENSG00000247828.6	TMEM161B-AS1	-4.24	2.44e-05	0.00181	-0.16	-0.13	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index;	chr5:88419648	chr5:88268895~88436685:+
BRCA	cis	rs7590268	0.895	rs35114568	ENSG00000279873.2	LINC01126	4.24	2.44e-05	0.00181	0.17	0.13	Orofacial clefts;	chr2:43448153	chr2:43227210~43228855:+
BRCA	cis	rs11098499	0.691	rs10010355	ENSG00000260404.2	RP11-384K6.6	4.24	2.44e-05	0.00182	0.12	0.13	Corneal astigmatism;	chr4:119339888	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.691	rs9307471	ENSG00000260404.2	RP11-384K6.6	4.24	2.44e-05	0.00182	0.12	0.13	Corneal astigmatism;	chr4:119340107	chr4:118591773~118633729:+
BRCA	cis	rs2115630	1	rs7183401	ENSG00000259728.4	LINC00933	-4.24	2.44e-05	0.00182	-0.14	-0.13	P wave terminal force;	chr15:84828713	chr15:84570649~84580175:+
BRCA	cis	rs875971	0.66	rs28698552	ENSG00000232546.1	RP11-458F8.1	-4.24	2.44e-05	0.00182	-0.11	-0.13	Aortic root size;	chr7:66540031	chr7:66848496~66858136:+
BRCA	cis	rs12144610	0.515	rs61806235	ENSG00000236804.1	RPS3AP12	4.24	2.44e-05	0.00182	0.26	0.13	Lobe attachment (rater-scored or self-reported);	chr1:118973782	chr1:119126539~119127291:-
BRCA	cis	rs10504130	0.569	rs10958305	ENSG00000253844.1	RP11-546K22.1	-4.24	2.44e-05	0.00182	-0.19	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr8:51906464	chr8:51961458~52022974:+
BRCA	cis	rs651907	0.535	rs34648996	ENSG00000256628.3	ZBTB11-AS1	4.24	2.44e-05	0.00182	0.17	0.13	Colorectal cancer;	chr3:101792358	chr3:101676475~101679217:+
BRCA	cis	rs7727544	0.631	rs13357280	ENSG00000233006.5	AC034220.3	4.24	2.44e-05	0.00182	0.1	0.13	Blood metabolite levels;	chr5:132264494	chr5:132311285~132369916:-
BRCA	cis	rs7011507	0.662	rs56348830	ENSG00000279881.1	RP11-513O13.1	-4.24	2.44e-05	0.00182	-0.2	-0.13	Inflammatory bowel disease;Ulcerative colitis;	chr8:48429435	chr8:48428143~48431041:-
BRCA	cis	rs77686669	1	rs77686669	ENSG00000214313.7	AZGP1P1	-4.24	2.44e-05	0.00182	-0.14	-0.13	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr7:100146949	chr7:99980762~99987535:+
BRCA	cis	rs910316	0.967	rs4899551	ENSG00000259138.1	RP11-950C14.7	-4.24	2.44e-05	0.00182	-0.14	-0.13	Height;	chr14:75193543	chr14:75127153~75136930:+
BRCA	cis	rs3812762	0.868	rs7934519	ENSG00000254860.4	TMEM9B-AS1	-4.24	2.44e-05	0.00182	-0.12	-0.13	Hypospadias;	chr11:8770434	chr11:8964675~8977527:+
BRCA	cis	rs7944584	0.502	rs10769256	ENSG00000280615.1	Y_RNA	4.24	2.44e-05	0.00182	0.15	0.13	Fasting blood glucose;Fasting blood glucose (BMI interaction);	chr11:47356845	chr11:47614898~47614994:-
BRCA	cis	rs1950832	0.723	rs1447579	ENSG00000258636.1	CTD-2298J14.2	-4.24	2.44e-05	0.00182	-0.15	-0.13	Urate levels in obese individuals;	chr14:41656478	chr14:41587861~41604856:-
BRCA	cis	rs202072	0.585	rs1512414	ENSG00000272379.1	RP1-257A7.5	4.24	2.44e-05	0.00182	0.17	0.13	HIV-1 viral setpoint;	chr6:13276183	chr6:13290018~13290490:-
BRCA	cis	rs10129255	0.5	rs6576232	ENSG00000232216.1	IGHV3-43	4.24	2.44e-05	0.00182	0.1	0.13	Kawasaki disease;	chr14:106787090	chr14:106470264~106470800:-
BRCA	cis	rs7267979	0.844	rs4423675	ENSG00000231081.1	RP4-760C5.3	4.24	2.44e-05	0.00182	0.17	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25422142	chr20:26008791~26010531:-
BRCA	cis	rs2243480	1	rs6460260	ENSG00000275400.1	RP4-756H11.5	-4.24	2.44e-05	0.00182	-0.23	-0.13	Diabetic kidney disease;	chr7:65750468	chr7:66553805~66554199:-
BRCA	cis	rs2243480	1	rs6460261	ENSG00000275400.1	RP4-756H11.5	-4.24	2.44e-05	0.00182	-0.23	-0.13	Diabetic kidney disease;	chr7:65750593	chr7:66553805~66554199:-
BRCA	cis	rs7475343	0.501	rs7893850	ENSG00000224034.1	RP11-445P17.8	-4.24	2.44e-05	0.00182	-0.25	-0.13	Intelligence;	chr10:5209519	chr10:5266033~5271236:-
BRCA	cis	rs1008375	0.932	rs13127157	ENSG00000249502.1	AC006160.5	4.24	2.44e-05	0.00182	0.16	0.13	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17616426	chr4:17587467~17614571:-
BRCA	cis	rs56322409	1	rs11188396	ENSG00000226688.5	ENTPD1-AS1	4.24	2.44e-05	0.00182	0.15	0.13	Blood metabolite levels;	chr10:95607753	chr10:95753206~96090238:-
BRCA	cis	rs9470794	1	rs9470796	ENSG00000204110.6	RP1-153P14.8	-4.24	2.45e-05	0.00182	-0.2	-0.13	Type 2 diabetes;	chr6:38142063	chr6:37507348~37535616:+
BRCA	cis	rs4865762	0.967	rs1363919	ENSG00000247796.2	CTD-2366F13.1	-4.24	2.45e-05	0.00182	-0.14	-0.13	Intraocular pressure;	chr5:53330023	chr5:53109842~53115126:+
BRCA	cis	rs6088580	0.634	rs6141465	ENSG00000276073.1	RP5-1125A11.7	4.24	2.45e-05	0.00182	0.14	0.13	Glomerular filtration rate (creatinine);	chr20:34379508	chr20:33985617~33988989:-
BRCA	cis	rs7312933	0.558	rs7305397	ENSG00000257225.1	RP11-328C8.4	-4.24	2.45e-05	0.00182	-0.16	-0.13	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42456256	chr12:42459366~42466128:+
BRCA	cis	rs3617	0.625	rs2240915	ENSG00000279144.1	RP11-894J14.2	4.24	2.45e-05	0.00182	0.16	0.13	Red blood cell count;Autism spectrum disorder or schizophrenia;	chr3:52825510	chr3:52848085~52848553:-
BRCA	cis	rs3617	0.625	rs2245647	ENSG00000279144.1	RP11-894J14.2	4.24	2.45e-05	0.00182	0.16	0.13	Red blood cell count;Autism spectrum disorder or schizophrenia;	chr3:52828737	chr3:52848085~52848553:-
BRCA	cis	rs12681366	0.919	rs13248829	ENSG00000253175.1	RP11-267M23.6	4.24	2.45e-05	0.00182	0.15	0.13	Nonsyndromic cleft lip with cleft palate;	chr8:94476750	chr8:94565036~94565715:+
BRCA	cis	rs7615952	0.575	rs35949599	ENSG00000241288.6	RP11-379B18.5	-4.24	2.45e-05	0.00182	-0.17	-0.13	Blood pressure (smoking interaction);	chr3:125825359	chr3:125827238~125916384:-
BRCA	cis	rs8048589	0.604	rs11642033	ENSG00000175604.2	RP11-276H1.3	-4.24	2.45e-05	0.00182	-0.22	-0.13	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);	chr16:12114133	chr16:12086746~12090302:-
BRCA	cis	rs6547741	1	rs6547734	ENSG00000234072.1	AC074117.10	4.24	2.45e-05	0.00182	0.12	0.13	Oral cavity cancer;	chr2:27608123	chr2:27356246~27367622:+
BRCA	cis	rs8180040	0.966	rs17784882	ENSG00000271161.1	BOLA2P2	-4.24	2.45e-05	0.00182	-0.14	-0.13	Colorectal cancer;	chr3:47502513	chr3:47499841~47500407:+
BRCA	cis	rs7897654	0.571	rs12765002	ENSG00000213277.3	MARCKSL1P1	4.24	2.45e-05	0.00182	0.17	0.13	Schizophrenia;	chr10:102875591	chr10:103175554~103176094:+
BRCA	cis	rs924712	0.545	rs12195438	ENSG00000261116.1	RP3-523K23.2	4.24	2.45e-05	0.00182	0.15	0.13	Breast cancer;	chr6:54845232	chr6:54943167~54945099:+
BRCA	cis	rs10129255	0.5	rs6576230	ENSG00000211959.2	IGHV4-39	4.24	2.45e-05	0.00182	0.09	0.13	Kawasaki disease;	chr14:106778539	chr14:106421711~106422218:-
BRCA	cis	rs11098499	0.954	rs13145352	ENSG00000250950.1	RP11-33B1.3	4.24	2.45e-05	0.00182	0.16	0.13	Corneal astigmatism;	chr4:119488808	chr4:119456350~119457277:+
BRCA	cis	rs6840360	0.582	rs4473638	ENSG00000251603.1	RP11-164P12.4	-4.24	2.45e-05	0.00182	-0.12	-0.13	Intelligence (multi-trait analysis);	chr4:151400994	chr4:151667224~151670502:+
BRCA	cis	rs6840360	0.548	rs4254751	ENSG00000251603.1	RP11-164P12.4	-4.24	2.45e-05	0.00182	-0.12	-0.13	Intelligence (multi-trait analysis);	chr4:151401419	chr4:151667224~151670502:+
BRCA	cis	rs812925	0.515	rs1177308	ENSG00000273302.1	RP11-493E12.2	4.24	2.45e-05	0.00182	0.11	0.13	Immature fraction of reticulocytes;	chr2:61160119	chr2:61199979~61200769:+
BRCA	cis	rs812925	0.553	rs1177307	ENSG00000273302.1	RP11-493E12.2	4.24	2.45e-05	0.00182	0.11	0.13	Immature fraction of reticulocytes;	chr2:61160253	chr2:61199979~61200769:+
BRCA	cis	rs1730008	1	rs827130	ENSG00000279311.1	RP11-170K4.2	-4.24	2.45e-05	0.00182	-0.15	-0.13	Lobe attachment (rater-scored or self-reported);	chr3:158295491	chr3:158869898~158871821:+
BRCA	cis	rs35146811	0.735	rs7811662	ENSG00000235713.1	RP4-604G5.3	4.24	2.45e-05	0.00182	0.15	0.13	Coronary artery disease;	chr7:100194985	chr7:99992397~99993050:+
BRCA	cis	rs1371614	0.531	rs77562583	ENSG00000272148.1	RP11-195B17.1	4.24	2.45e-05	0.00183	0.14	0.13	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26928775	chr2:27062428~27062907:-
BRCA	cis	rs7246967	0.866	rs35177997	ENSG00000198153.8	ZNF849P	-4.24	2.45e-05	0.00183	-0.18	-0.13	Bronchopulmonary dysplasia;	chr19:22877425	chr19:22685167~22686732:+
BRCA	cis	rs58521262	0.556	rs291774	ENSG00000268105.1	RP11-369G6.2	-4.24	2.45e-05	0.00183	-0.18	-0.13	Testicular germ cell tumor;	chr19:23026398	chr19:23125665~23128543:+
BRCA	cis	rs11673344	0.503	rs1829603	ENSG00000226686.6	LINC01535	4.24	2.45e-05	0.00183	0.17	0.13	Obesity-related traits;	chr19:37065396	chr19:37251912~37265535:+
BRCA	cis	rs61160187	0.582	rs62372134	ENSG00000272308.1	RP11-231G3.1	-4.24	2.45e-05	0.00183	-0.15	-0.13	Educational attainment (years of education);Educational attainment (college completion);	chr5:60906420	chr5:60866457~60866935:-
BRCA	cis	rs7620503	0.721	rs6769488	ENSG00000228561.2	RP11-114M1.1	4.24	2.45e-05	0.00183	0.17	0.13	Corneal structure;	chr3:177590370	chr3:177683627~177691250:+
BRCA	cis	rs4671400	0.543	rs10178135	ENSG00000273302.1	RP11-493E12.2	-4.24	2.45e-05	0.00183	-0.14	-0.13	3-hydroxypropylmercapturic acid levels in smokers;	chr2:61258132	chr2:61199979~61200769:+
BRCA	cis	rs9868809	0.505	rs11706203	ENSG00000225399.4	RP11-3B7.1	-4.24	2.45e-05	0.00183	-0.19	-0.13	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48708806	chr3:49260085~49261316:+
BRCA	cis	rs6912958	0.559	rs242267	ENSG00000272008.1	RP11-393I2.4	4.24	2.45e-05	0.00183	0.14	0.13	Monocyte percentage of white cells;	chr6:87352119	chr6:87151159~87155285:-
BRCA	cis	rs2243480	1	rs34815098	ENSG00000275400.1	RP4-756H11.5	4.24	2.45e-05	0.00183	0.23	0.13	Diabetic kidney disease;	chr7:65827267	chr7:66553805~66554199:-
BRCA	cis	rs2243480	1	rs35735127	ENSG00000275400.1	RP4-756H11.5	4.24	2.45e-05	0.00183	0.23	0.13	Diabetic kidney disease;	chr7:65835436	chr7:66553805~66554199:-
BRCA	cis	rs2243480	0.901	rs35256305	ENSG00000275400.1	RP4-756H11.5	4.24	2.45e-05	0.00183	0.23	0.13	Diabetic kidney disease;	chr7:65841418	chr7:66553805~66554199:-
BRCA	cis	rs2243480	0.803	rs34004500	ENSG00000275400.1	RP4-756H11.5	4.24	2.45e-05	0.00183	0.23	0.13	Diabetic kidney disease;	chr7:65847191	chr7:66553805~66554199:-
BRCA	cis	rs2243480	1	rs35825738	ENSG00000275400.1	RP4-756H11.5	4.24	2.45e-05	0.00183	0.23	0.13	Diabetic kidney disease;	chr7:65853040	chr7:66553805~66554199:-
BRCA	cis	rs6012564	1	rs2426106	ENSG00000227431.4	CSE1L-AS1	-4.24	2.45e-05	0.00183	-0.16	-0.13	Anger;	chr20:49022927	chr20:49040463~49046044:-
BRCA	cis	rs4948275	0.693	rs2814033	ENSG00000237233.2	TMEM26-AS1	4.24	2.46e-05	0.00183	0.15	0.13	Night sleep phenotypes;	chr10:61571836	chr10:61452639~61481956:+
BRCA	cis	rs2574985	0.738	rs3011770	ENSG00000231345.3	BEND3P1	-4.24	2.46e-05	0.00183	-0.21	-0.13	Subjective well-being;	chr10:50511625	chr10:50655967~50660472:+
BRCA	cis	rs853679	0.76	rs11967137	ENSG00000204709.4	LINC01556	4.24	2.46e-05	0.00183	0.21	0.13	Depression;	chr6:28231986	chr6:28943877~28944537:+
BRCA	cis	rs3768617	0.61	rs10911228	ENSG00000224468.3	RP11-181K3.4	-4.24	2.46e-05	0.00183	-0.15	-0.13	Fuchs's corneal dystrophy;	chr1:183080657	chr1:183138402~183141282:-
BRCA	cis	rs75804782	0.63	rs55708222	ENSG00000186235.9	AC016757.3	4.24	2.46e-05	0.00183	0.33	0.13	Chronotype;Morning vs. evening chronotype;	chr2:238379052	chr2:238224552~238231677:-
BRCA	cis	rs56322409	1	rs11188400	ENSG00000226688.5	ENTPD1-AS1	4.24	2.46e-05	0.00183	0.15	0.13	Blood metabolite levels;	chr10:95611570	chr10:95753206~96090238:-
BRCA	cis	rs11098499	0.863	rs1010740	ENSG00000250412.1	KLHL2P1	-4.24	2.46e-05	0.00183	-0.16	-0.13	Corneal astigmatism;	chr4:119542254	chr4:119334329~119378233:+
BRCA	cis	rs11098499	0.909	rs11723839	ENSG00000250412.1	KLHL2P1	4.24	2.46e-05	0.00183	0.16	0.13	Corneal astigmatism;	chr4:119378518	chr4:119334329~119378233:+
BRCA	cis	rs11098499	0.779	rs7699346	ENSG00000250412.1	KLHL2P1	4.24	2.46e-05	0.00183	0.16	0.13	Corneal astigmatism;	chr4:119389387	chr4:119334329~119378233:+
BRCA	cis	rs7177699	0.525	rs7166770	ENSG00000261143.1	ADAMTS7P3	-4.24	2.46e-05	0.00183	-0.16	-0.13	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78821226	chr15:77976042~77993057:+
BRCA	cis	rs4650994	0.905	rs12753251	ENSG00000273384.1	RP5-1098D14.1	4.24	2.46e-05	0.00183	0.16	0.13	HDL cholesterol;HDL cholesterol levels;	chr1:178560763	chr1:178651706~178652282:+
BRCA	cis	rs4237845	0.537	rs11172367	ENSG00000257159.1	RP11-58A17.3	4.24	2.46e-05	0.00183	0.16	0.13	Intelligence (multi-trait analysis);	chr12:57878703	chr12:57967058~57968399:+
BRCA	cis	rs997295	0.554	rs28568344	ENSG00000270964.1	RP11-502I4.3	4.24	2.46e-05	0.00183	0.14	0.13	Motion sickness;	chr15:67804189	chr15:67541072~67542604:-
BRCA	cis	rs950776	0.616	rs647041	ENSG00000279373.1	RP11-650L12.4	-4.24	2.46e-05	0.00183	-0.16	-0.13	Sudden cardiac arrest;	chr15:78588139	chr15:78537681~78538946:+
BRCA	cis	rs7811142	0.83	rs705866	ENSG00000078319.8	PMS2P1	-4.24	2.46e-05	0.00183	-0.22	-0.13	Platelet count;	chr7:100367662	chr7:100320992~100341908:-
BRCA	cis	rs6928977	0.5	rs6941629	ENSG00000234084.1	RP3-388E23.2	-4.24	2.46e-05	0.00183	-0.13	-0.13	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135621634	chr6:135301568~135307158:+
BRCA	cis	rs875971	0.545	rs316305	ENSG00000273142.1	RP11-458F8.4	-4.24	2.46e-05	0.00183	-0.13	-0.13	Aortic root size;	chr7:66152984	chr7:66902857~66906297:+
BRCA	cis	rs12612619	0.732	rs2053385	ENSG00000272148.1	RP11-195B17.1	4.24	2.46e-05	0.00183	0.14	0.13	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27008277	chr2:27062428~27062907:-
BRCA	cis	rs62458065	0.713	rs921406	ENSG00000229358.3	DPY19L1P1	-4.24	2.46e-05	0.00183	-0.18	-0.13	Metabolite levels (HVA/MHPG ratio);	chr7:32446593	chr7:32580949~32761787:-
BRCA	cis	rs11098499	0.955	rs11931312	ENSG00000260091.1	RP11-33B1.4	-4.24	2.46e-05	0.00183	-0.12	-0.13	Corneal astigmatism;	chr4:119237868	chr4:119409333~119410233:+
BRCA	cis	rs4460629	0.65	rs11264319	ENSG00000160766.13	GBAP1	-4.24	2.46e-05	0.00183	-0.13	-0.13	Serum magnesium levels;	chr1:155111466	chr1:155213821~155227422:-
BRCA	cis	rs2243480	1	rs6958420	ENSG00000275400.1	RP4-756H11.5	-4.24	2.46e-05	0.00183	-0.24	-0.13	Diabetic kidney disease;	chr7:66286184	chr7:66553805~66554199:-
BRCA	cis	rs2243480	1	rs1392104	ENSG00000275400.1	RP4-756H11.5	-4.24	2.46e-05	0.00183	-0.24	-0.13	Diabetic kidney disease;	chr7:66294120	chr7:66553805~66554199:-
BRCA	cis	rs12497850	1	rs12493578	ENSG00000225399.4	RP11-3B7.1	-4.24	2.46e-05	0.00183	-0.13	-0.13	Parkinson's disease;	chr3:48692683	chr3:49260085~49261316:+
BRCA	cis	rs792448	1	rs792448	ENSG00000226251.4	RP11-15I11.3	4.24	2.46e-05	0.00183	0.17	0.13	White blood cell count (basophil);	chr1:212385055	chr1:212225278~212238977:-
BRCA	cis	rs9733	0.596	rs12403255	ENSG00000231073.1	RP11-316M1.3	4.24	2.46e-05	0.00183	0.14	0.13	Tonsillectomy;	chr1:150687936	chr1:150973123~150975534:+
BRCA	cis	rs2255336	0.938	rs12298043	ENSG00000245648.1	RP11-277P12.20	-4.24	2.46e-05	0.00183	-0.21	-0.13	Blood protein levels;	chr12:10456883	chr12:10363769~10398506:+
BRCA	cis	rs4950322	0.58	rs17359629	ENSG00000237188.3	RP11-337C18.8	4.24	2.46e-05	0.00183	0.15	0.13	Protein quantitative trait loci;	chr1:147121537	chr1:147172771~147211568:+
BRCA	cis	rs2832191	0.646	rs2832214	ENSG00000176054.6	RPL23P2	-4.24	2.47e-05	0.00183	-0.15	-0.13	Dental caries;	chr21:29144806	chr21:28997613~28998033:-
BRCA	cis	rs812925	0.537	rs778153	ENSG00000273302.1	RP11-493E12.2	-4.24	2.47e-05	0.00183	-0.11	-0.13	Immature fraction of reticulocytes;	chr2:61381517	chr2:61199979~61200769:+
BRCA	cis	rs6671200	0.607	rs7528790	ENSG00000235501.4	RP4-639F20.1	4.24	2.47e-05	0.00183	0.22	0.13	Stearic acid (18:0) levels;	chr1:95243518	chr1:94927566~94963270:+
BRCA	cis	rs6088580	0.634	rs13041646	ENSG00000276073.1	RP5-1125A11.7	-4.24	2.47e-05	0.00184	-0.14	-0.13	Glomerular filtration rate (creatinine);	chr20:34495076	chr20:33985617~33988989:-
BRCA	cis	rs1048886	0.872	rs12209965	ENSG00000271967.1	RP11-134K13.4	-4.24	2.47e-05	0.00184	-0.18	-0.13	Type 2 diabetes;	chr6:70568193	chr6:70596438~70596980:+
BRCA	cis	rs7267979	0.816	rs6138593	ENSG00000231081.1	RP4-760C5.3	-4.24	2.47e-05	0.00184	-0.16	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25523856	chr20:26008791~26010531:-
BRCA	cis	rs4713118	0.662	rs149901	ENSG00000216901.1	AL022393.7	4.24	2.47e-05	0.00184	0.18	0.13	Parkinson's disease;	chr6:27997725	chr6:28176188~28176674:+
BRCA	cis	rs4578769	0.802	rs66816194	ENSG00000265939.1	UBE2CP2	-4.24	2.47e-05	0.00184	-0.17	-0.13	Eosinophil percentage of white cells;	chr18:22895554	chr18:22900486~22900995:-
BRCA	cis	rs1910358	0.879	rs6863146	ENSG00000248874.4	C5orf17	-4.24	2.47e-05	0.00184	-0.2	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23929060	chr5:23951348~24178263:+
BRCA	cis	rs1143633	0.53	rs2723163	ENSG00000231747.1	AC079922.2	-4.24	2.47e-05	0.00184	-0.12	-0.13	Allergic disease (asthma, hay fever or eczema);	chr2:112936762	chr2:112621809~112622167:-
BRCA	cis	rs10769966	0.515	rs2568069	ENSG00000254860.4	TMEM9B-AS1	4.24	2.47e-05	0.00184	0.12	0.13	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;	chr11:8956160	chr11:8964675~8977527:+
BRCA	cis	rs62025270	0.688	rs17575870	ENSG00000259295.5	CSPG4P12	-4.24	2.47e-05	0.00184	-0.2	-0.13	Idiopathic pulmonary fibrosis;	chr15:85713926	chr15:85191438~85213905:+
BRCA	cis	rs6570726	0.935	rs386344	ENSG00000270638.1	RP3-466P17.1	4.24	2.47e-05	0.00184	0.14	0.13	Lobe attachment (rater-scored or self-reported);	chr6:145534486	chr6:145735570~145737218:+
BRCA	cis	rs7927592	0.763	rs7129248	ENSG00000212093.1	AP000807.1	4.24	2.47e-05	0.00184	0.14	0.13	Total body bone mineral density;	chr11:68495808	chr11:68506083~68506166:-
BRCA	cis	rs610932	0.517	rs584469	ENSG00000275344.1	MIR6503	4.24	2.47e-05	0.00184	0.13	0.13	Alzheimer's disease;	chr11:60221389	chr11:60209071~60209156:-
BRCA	cis	rs12681366	0.571	rs2930959	ENSG00000253704.1	RP11-267M23.4	4.24	2.47e-05	0.00184	0.13	0.13	Nonsyndromic cleft lip with cleft palate;	chr8:94461930	chr8:94553722~94569745:+
BRCA	cis	rs17489649	1	rs3753174	ENSG00000271849.1	CTC-332L22.1	4.24	2.47e-05	0.00184	0.17	0.13	Intelligence (multi-trait analysis);	chr5:109772236	chr5:109687802~109688329:-
BRCA	cis	rs8037818	1	rs4643284	ENSG00000261064.1	RP11-1000B6.3	-4.24	2.47e-05	0.00184	-0.16	-0.13	Obesity-related traits;	chr15:32639897	chr15:32536047~32587613:+
BRCA	cis	rs495337	0.735	rs636987	ENSG00000229222.1	KRT18P4	-4.24	2.47e-05	0.00184	-0.16	-0.13	Psoriasis;	chr20:49907751	chr20:49956745~49958032:+
BRCA	cis	rs703842	0.963	rs2291617	ENSG00000270039.1	RP11-571M6.17	-4.24	2.47e-05	0.00184	-0.18	-0.13	Multiple sclerosis;	chr12:57772620	chr12:57803838~57804415:+
BRCA	cis	rs10829156	0.66	rs4338439	ENSG00000225527.1	RP11-383B4.4	-4.24	2.47e-05	0.00184	-0.19	-0.13	Sudden cardiac arrest;	chr10:18594220	chr10:18531849~18533336:-
BRCA	cis	rs2991971	0.903	rs2991973	ENSG00000280836.1	AL355480.1	4.24	2.47e-05	0.00184	0.15	0.13	High light scatter reticulocyte count;	chr1:45554960	chr1:45581219~45581321:-
BRCA	cis	rs9818758	0.607	rs34566463	ENSG00000225399.4	RP11-3B7.1	-4.24	2.47e-05	0.00184	-0.2	-0.13	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49207644	chr3:49260085~49261316:+
BRCA	cis	rs4604234	0.901	rs6907326	ENSG00000272129.1	RP11-250B2.6	-4.24	2.48e-05	0.00184	-0.31	-0.13	Cancer;	chr6:80395748	chr6:80355424~80356859:+
BRCA	cis	rs11098499	0.644	rs3806808	ENSG00000249244.1	RP11-548H18.2	4.24	2.48e-05	0.00184	0.15	0.13	Corneal astigmatism;	chr4:119629930	chr4:119391831~119395335:-
BRCA	cis	rs58521262	0.53	rs460681	ENSG00000268105.1	RP11-369G6.2	4.24	2.48e-05	0.00184	0.18	0.13	Testicular germ cell tumor;	chr19:22957743	chr19:23125665~23128543:+
BRCA	cis	rs58521262	0.505	rs457741	ENSG00000268105.1	RP11-369G6.2	4.24	2.48e-05	0.00184	0.18	0.13	Testicular germ cell tumor;	chr19:22957777	chr19:23125665~23128543:+
BRCA	cis	rs58521262	0.53	rs462713	ENSG00000268105.1	RP11-369G6.2	4.24	2.48e-05	0.00184	0.18	0.13	Testicular germ cell tumor;	chr19:22957903	chr19:23125665~23128543:+
BRCA	cis	rs58521262	0.53	rs289356	ENSG00000268105.1	RP11-369G6.2	4.24	2.48e-05	0.00184	0.18	0.13	Testicular germ cell tumor;	chr19:22961532	chr19:23125665~23128543:+
BRCA	cis	rs58521262	0.53	rs289353	ENSG00000268105.1	RP11-369G6.2	4.24	2.48e-05	0.00184	0.18	0.13	Testicular germ cell tumor;	chr19:22961787	chr19:23125665~23128543:+
BRCA	cis	rs58521262	0.556	rs289351	ENSG00000268105.1	RP11-369G6.2	4.24	2.48e-05	0.00184	0.18	0.13	Testicular germ cell tumor;	chr19:22962536	chr19:23125665~23128543:+
BRCA	cis	rs58521262	0.505	rs289348	ENSG00000268105.1	RP11-369G6.2	4.24	2.48e-05	0.00184	0.18	0.13	Testicular germ cell tumor;	chr19:22964638	chr19:23125665~23128543:+
BRCA	cis	rs58521262	0.53	rs289346	ENSG00000268105.1	RP11-369G6.2	4.24	2.48e-05	0.00184	0.18	0.13	Testicular germ cell tumor;	chr19:22965198	chr19:23125665~23128543:+
BRCA	cis	rs58521262	0.556	rs289345	ENSG00000268105.1	RP11-369G6.2	4.24	2.48e-05	0.00184	0.18	0.13	Testicular germ cell tumor;	chr19:22966079	chr19:23125665~23128543:+
BRCA	cis	rs7932354	0.583	rs7107778	ENSG00000200376.1	RNU5E-10P	4.24	2.48e-05	0.00184	0.16	0.13	Bone mineral density (hip);Bone mineral density;	chr11:46839304	chr11:47576471~47576588:-
BRCA	cis	rs934734	0.509	rs12185577	ENSG00000281920.1	RP11-418H16.1	-4.24	2.48e-05	0.00184	-0.16	-0.13	Rheumatoid arthritis;	chr2:65432354	chr2:65623272~65628424:+
BRCA	cis	rs62458065	0.513	rs7788809	ENSG00000229358.3	DPY19L1P1	-4.24	2.48e-05	0.00184	-0.18	-0.13	Metabolite levels (HVA/MHPG ratio);	chr7:32513010	chr7:32580949~32761787:-
BRCA	cis	rs3748682	0.821	rs12030690	ENSG00000222282.1	RNU6-584P	-4.24	2.48e-05	0.00184	-0.17	-0.13	Hypothyroidism;	chr1:37792335	chr1:37885023~37885117:+
BRCA	cis	rs2243480	1	rs1039664	ENSG00000222364.1	RNU6-96P	-4.24	2.48e-05	0.00185	-0.23	-0.13	Diabetic kidney disease;	chr7:65984729	chr7:66395191~66395286:+
BRCA	cis	rs9573567	0.881	rs6562898	ENSG00000261553.4	RP11-29G8.3	-4.24	2.48e-05	0.00185	-0.27	-0.13	Red blood cell count;Mean corpuscular volume;	chr13:75502232	chr13:75549773~75807120:+
BRCA	cis	rs17345786	0.954	rs17508319	ENSG00000244119.1	PDCL3P4	4.24	2.48e-05	0.00185	0.11	0.13	Colonoscopy-negative controls vs population controls;	chr3:101600059	chr3:101712472~101713191:+
BRCA	cis	rs7428	0.545	rs9248	ENSG00000273196.1	RP11-717A5.2	4.24	2.48e-05	0.00185	0.15	0.13	Ear protrusion;	chr2:85310189	chr2:85387074~85387146:-
BRCA	cis	rs4512344	0.509	rs2409784	ENSG00000227888.4	FAM66A	-4.24	2.48e-05	0.00185	-0.16	-0.13	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:11539347	chr8:12362019~12388296:+
BRCA	cis	rs897984	0.553	rs2335013	ENSG00000274678.1	RP11-2C24.7	-4.24	2.48e-05	0.00185	-0.16	-0.13	Dementia with Lewy bodies;	chr16:30866025	chr16:30821338~30821884:+
BRCA	cis	rs6847067	0.672	rs4590017	ENSG00000180769.7	WDFY3-AS2	4.24	2.48e-05	0.00185	0.13	0.13	Oropharynx cancer;	chr4:84977588	chr4:84965682~85011277:+
BRCA	cis	rs9834975	0.967	rs12487598	ENSG00000272758.4	RP11-299J3.8	-4.24	2.48e-05	0.00185	-0.13	-0.13	Diastolic blood pressure;	chr3:122459755	chr3:122416207~122443180:+
BRCA	cis	rs9834975	0.967	rs6771095	ENSG00000272758.4	RP11-299J3.8	-4.24	2.48e-05	0.00185	-0.13	-0.13	Diastolic blood pressure;	chr3:122472888	chr3:122416207~122443180:+
BRCA	cis	rs9834975	0.901	rs10934600	ENSG00000272758.4	RP11-299J3.8	-4.24	2.48e-05	0.00185	-0.13	-0.13	Diastolic blood pressure;	chr3:122477270	chr3:122416207~122443180:+
BRCA	cis	rs9834975	0.967	rs7642161	ENSG00000272758.4	RP11-299J3.8	-4.24	2.48e-05	0.00185	-0.13	-0.13	Diastolic blood pressure;	chr3:122480385	chr3:122416207~122443180:+
BRCA	cis	rs1910358	0.554	rs7708067	ENSG00000248874.4	C5orf17	-4.24	2.48e-05	0.00185	-0.18	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23751604	chr5:23951348~24178263:+
BRCA	cis	rs1910358	0.53	rs6872880	ENSG00000248874.4	C5orf17	-4.24	2.48e-05	0.00185	-0.18	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23752517	chr5:23951348~24178263:+
BRCA	cis	rs1910358	0.554	rs1915473	ENSG00000248874.4	C5orf17	-4.24	2.48e-05	0.00185	-0.18	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23752895	chr5:23951348~24178263:+
BRCA	cis	rs9500256	0.655	rs12209098	ENSG00000272316.1	XXbac-BPGBPG55C20.2	-4.24	2.49e-05	0.00185	-0.12	-0.13	Eosinophilic esophagitis (pediatric);	chr6:58014194	chr6:57908560~57913911:-
BRCA	cis	rs11711311	0.868	rs13091621	ENSG00000241529.3	RN7SL767P	-4.24	2.49e-05	0.00185	-0.15	-0.13	IgG glycosylation;	chr3:113763130	chr3:113632704~113632998:+
BRCA	cis	rs9925964	0.967	rs749767	ENSG00000232748.3	RP11-196G11.6	-4.24	2.49e-05	0.00185	-0.16	-0.13	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31113086	chr16:31056460~31062803:+
BRCA	cis	rs2439831	0.85	rs3862142	ENSG00000206991.1	RNU6-610P	-4.24	2.49e-05	0.00185	-0.21	-0.13	Lung cancer in ever smokers;	chr15:43772608	chr15:43637632~43637738:-
BRCA	cis	rs2439831	0.85	rs2277531	ENSG00000206991.1	RNU6-610P	-4.24	2.49e-05	0.00185	-0.21	-0.13	Lung cancer in ever smokers;	chr15:43776871	chr15:43637632~43637738:-
BRCA	cis	rs3733585	0.566	rs35955619	ENSG00000250413.1	RP11-448G15.1	4.24	2.49e-05	0.00185	0.17	0.13	Cleft plate (environmental tobacco smoke interaction);	chr4:9917362	chr4:10006482~10009725:+
BRCA	cis	rs875971	0.895	rs4145009	ENSG00000273024.4	INTS4P2	4.23	2.49e-05	0.00185	0.15	0.13	Aortic root size;	chr7:66261628	chr7:65647864~65715661:+
BRCA	cis	rs28374715	0.532	rs28703570	ENSG00000247556.5	OIP5-AS1	4.23	2.49e-05	0.00185	0.15	0.13	Ulcerative colitis;	chr15:41387294	chr15:41283990~41309737:+
BRCA	cis	rs2708977	0.965	rs12717781	ENSG00000237510.6	AC008268.2	4.23	2.49e-05	0.00185	0.17	0.13	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96583405	chr2:95789654~95800166:+
BRCA	cis	rs2692947	0.759	rs11687113	ENSG00000168992.4	OR7E102P	4.23	2.49e-05	0.00185	0.17	0.13	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95992840	chr2:95546531~95547545:+
BRCA	cis	rs10129255	0.5	rs8004923	ENSG00000232216.1	IGHV3-43	4.23	2.49e-05	0.00185	0.1	0.13	Kawasaki disease;	chr14:106785926	chr14:106470264~106470800:-
BRCA	cis	rs964611	1	rs964611	ENSG00000259488.2	RP11-154J22.1	-4.23	2.49e-05	0.00185	-0.17	-0.13	Metabolite levels (Pyroglutamine);	chr15:48305317	chr15:48312353~48331856:-
BRCA	cis	rs7487075	0.78	rs12296120	ENSG00000272369.1	RP11-446N19.1	4.23	2.49e-05	0.00185	0.14	0.13	Itch intensity from mosquito bite;	chr12:46343808	chr12:46537502~46652550:+
BRCA	cis	rs58521262	0.556	rs1908942	ENSG00000268105.1	RP11-369G6.2	-4.23	2.49e-05	0.00185	-0.18	-0.13	Testicular germ cell tumor;	chr19:23001307	chr19:23125665~23128543:+
BRCA	cis	rs17507216	0.718	rs17158403	ENSG00000259429.4	UBE2Q2P2	-4.23	2.49e-05	0.00185	-0.16	-0.13	Excessive daytime sleepiness;	chr15:82572478	chr15:82355142~82420075:+
BRCA	cis	rs559555	1	rs559555	ENSG00000272716.1	RP11-563N4.1	4.23	2.49e-05	0.00185	0.14	0.13	Blood metabolite ratios;Blood metabolite levels;	chr2:31585905	chr2:32165046~32165757:-
BRCA	cis	rs7308116	1	rs7308116	ENSG00000274395.1	RP11-554D14.8	-4.23	2.49e-05	0.00185	-0.14	-0.13	Pelvic organ prolapse (moderate/severe);	chr12:107806819	chr12:107835541~107836555:-
BRCA	cis	rs9527	0.545	rs10218853	ENSG00000213061.2	PFN1P11	4.23	2.49e-05	0.00185	0.18	0.13	Arsenic metabolism;	chr10:103037030	chr10:102838011~102845473:-
BRCA	cis	rs10510102	0.516	rs3936070	ENSG00000226864.1	ATE1-AS1	4.23	2.49e-05	0.00185	0.26	0.13	Breast cancer;	chr10:121974440	chr10:121928312~121951965:+
BRCA	cis	rs13358904	0.868	rs28620667	ENSG00000278921.2	EPB41L4A-AS2	4.23	2.49e-05	0.00185	0.15	0.13	Suicide ideation score in major depressive disorder;	chr5:112260048	chr5:112419583~112420978:+
BRCA	cis	rs35146811	0.844	rs34031156	ENSG00000214313.7	AZGP1P1	4.23	2.49e-05	0.00185	0.14	0.13	Coronary artery disease;	chr7:100080294	chr7:99980762~99987535:+
BRCA	cis	rs3892630	0.5	rs6510301	ENSG00000267567.1	CTD-2538C1.3	4.23	2.5e-05	0.00185	0.2	0.13	Red blood cell traits;	chr19:32868885	chr19:32718298~32719595:-
BRCA	cis	rs11711311	0.955	rs12634241	ENSG00000241529.3	RN7SL767P	-4.23	2.5e-05	0.00185	-0.15	-0.13	IgG glycosylation;	chr3:113678838	chr3:113632704~113632998:+
BRCA	cis	rs4388249	0.659	rs10065099	ENSG00000271849.1	CTC-332L22.1	-4.23	2.5e-05	0.00185	-0.17	-0.13	Schizophrenia;	chr5:109841677	chr5:109687802~109688329:-
BRCA	cis	rs78487399	0.71	rs79625619	ENSG00000234936.1	AC010883.5	4.23	2.5e-05	0.00185	0.19	0.13	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43367344	chr2:43229573~43233394:+
BRCA	cis	rs700651	0.685	rs976180	ENSG00000231621.1	AC013264.2	4.23	2.5e-05	0.00185	0.13	0.13	Intracranial aneurysm;	chr2:198015719	chr2:197197991~197199273:+
BRCA	cis	rs739496	0.615	rs4648328	ENSG00000226469.1	ADAM1B	4.23	2.5e-05	0.00186	0.18	0.13	Platelet count;	chr12:111784984	chr12:111927018~111929017:+
BRCA	cis	rs801193	0.66	rs10950049	ENSG00000265600.1	AC006480.1	-4.23	2.5e-05	0.00186	-0.15	-0.13	Aortic root size;	chr7:66765873	chr7:67356680~67356779:+
BRCA	cis	rs11887277	0.651	rs34736994	ENSG00000272148.1	RP11-195B17.1	-4.23	2.5e-05	0.00186	-0.15	-0.13	Obesity-related traits;	chr2:26808217	chr2:27062428~27062907:-
BRCA	cis	rs11977715	0.521	rs1476516	ENSG00000233942.1	AC004012.1	-4.23	2.5e-05	0.00186	-0.16	-0.13	Middle childhood and early adolescence aggressive behavior;	chr7:95489898	chr7:95471835~95473998:+
BRCA	cis	rs12936587	0.595	rs9911672	ENSG00000223979.2	SMCR2	-4.23	2.5e-05	0.00186	-0.15	-0.13	Coronary heart disease;Coronary artery disease or large artery stroke;Coronary artery disease;Hip circumference;	chr17:17625356	chr17:17674026~17677688:-
BRCA	cis	rs216345	0.7	rs2196	ENSG00000260947.1	RP11-384P7.7	4.23	2.5e-05	0.00186	0.14	0.13	Bipolar disorder;	chr9:33914310	chr9:33697459~33700986:+
BRCA	cis	rs62103177	0.564	rs2115996	ENSG00000278000.1	AC139100.4	4.23	2.5e-05	0.00186	0.23	0.13	Opioid sensitivity;	chr18:79941007	chr18:80161752~80162413:+
BRCA	cis	rs73222236	0.787	rs6783337	ENSG00000239213.4	NCK1-AS1	4.23	2.5e-05	0.00186	0.15	0.13	Coronary artery disease;	chr3:136333895	chr3:136841726~136862054:-
BRCA	cis	rs8070463	0.515	rs11655943	ENSG00000263293.2	RP11-290H9.4	4.23	2.5e-05	0.00186	0.15	0.13	Multiple sclerosis;Ankylosing spondylitis;	chr17:47308274	chr17:47303460~47323613:-
BRCA	cis	rs6547741	1	rs10205364	ENSG00000234072.1	AC074117.10	4.23	2.5e-05	0.00186	0.12	0.13	Oral cavity cancer;	chr2:27571366	chr2:27356246~27367622:+
BRCA	cis	rs6547741	1	rs1919125	ENSG00000234072.1	AC074117.10	4.23	2.5e-05	0.00186	0.12	0.13	Oral cavity cancer;	chr2:27578536	chr2:27356246~27367622:+
BRCA	cis	rs6547741	1	rs1919126	ENSG00000234072.1	AC074117.10	4.23	2.5e-05	0.00186	0.12	0.13	Oral cavity cancer;	chr2:27578551	chr2:27356246~27367622:+
BRCA	cis	rs6545883	0.894	rs7602859	ENSG00000273302.1	RP11-493E12.2	-4.23	2.5e-05	0.00186	-0.12	-0.13	Tuberculosis;	chr2:61231071	chr2:61199979~61200769:+
BRCA	cis	rs6545883	0.542	rs7584500	ENSG00000270820.4	RP11-355B11.2	4.23	2.5e-05	0.00186	0.14	0.13	Tuberculosis;	chr2:61464980	chr2:61471188~61484130:+
BRCA	cis	rs6460942	0.597	rs7808537	ENSG00000226690.5	AC005281.1	4.23	2.5e-05	0.00186	0.26	0.13	Coronary artery disease;	chr7:12481287	chr7:12496429~12541910:+
BRCA	cis	rs58521262	0.556	rs291769	ENSG00000268105.1	RP11-369G6.2	-4.23	2.5e-05	0.00186	-0.18	-0.13	Testicular germ cell tumor;	chr19:23001139	chr19:23125665~23128543:+
BRCA	cis	rs6540731	0.521	rs10779572	ENSG00000226251.4	RP11-15I11.3	4.23	2.5e-05	0.00186	0.16	0.13	Intelligence (childhood);	chr1:212181070	chr1:212225278~212238977:-
BRCA	cis	rs2554380	0.891	rs2244838	ENSG00000230373.7	GOLGA6L5P	-4.23	2.5e-05	0.00186	-0.18	-0.13	Height;	chr15:83629846	chr15:84507885~84516814:-
BRCA	cis	rs938554	0.513	rs4529048	ENSG00000250413.1	RP11-448G15.1	-4.23	2.5e-05	0.00186	-0.18	-0.13	Blood metabolite levels;	chr4:9995488	chr4:10006482~10009725:+
BRCA	cis	rs12701220	0.689	rs12536282	ENSG00000229043.2	AC091729.9	-4.23	2.5e-05	0.00186	-0.22	-0.13	Bronchopulmonary dysplasia;	chr7:1076014	chr7:1160374~1165267:+
BRCA	cis	rs62025270	0.632	rs17571078	ENSG00000259762.1	RP11-158M2.4	-4.23	2.5e-05	0.00186	-0.19	-0.13	Idiopathic pulmonary fibrosis;	chr15:85597248	chr15:85750336~85752901:-
BRCA	cis	rs11098499	0.954	rs28572238	ENSG00000260091.1	RP11-33B1.4	-4.23	2.5e-05	0.00186	-0.11	-0.13	Corneal astigmatism;	chr4:119395531	chr4:119409333~119410233:+
BRCA	cis	rs875971	1	rs6460296	ENSG00000229180.5	GS1-124K5.11	4.23	2.51e-05	0.00186	0.11	0.13	Aortic root size;	chr7:66430152	chr7:66526088~66542624:-
BRCA	cis	rs2235544	0.565	rs620907	ENSG00000225183.1	RP4-758J24.4	4.23	2.51e-05	0.00186	0.16	0.13	Thyroid hormone levels;Multiple myeloma (hyperdiploidy);	chr1:54002493	chr1:54089856~54090093:+
BRCA	cis	rs7226408	0.842	rs1863615	ENSG00000267707.2	RP11-95O2.5	4.23	2.51e-05	0.00186	0.19	0.13	Obesity-related traits;	chr18:36768212	chr18:37243776~37247506:+
BRCA	cis	rs3617	0.572	rs2245538	ENSG00000242142.1	SERBP1P3	4.23	2.51e-05	0.00186	0.15	0.13	Red blood cell count;Autism spectrum disorder or schizophrenia;	chr3:52818044	chr3:53064283~53065091:-
BRCA	cis	rs853679	1	rs1778511	ENSG00000280107.1	AL022393.9	4.23	2.51e-05	0.00186	0.23	0.13	Depression;	chr6:28261633	chr6:28170845~28172521:+
BRCA	cis	rs12612619	0.659	rs12997235	ENSG00000272148.1	RP11-195B17.1	-4.23	2.51e-05	0.00186	-0.14	-0.13	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27006211	chr2:27062428~27062907:-
BRCA	cis	rs748404	0.666	rs12905220	ENSG00000205771.5	CATSPER2P1	-4.23	2.51e-05	0.00186	-0.19	-0.13	Lung cancer;	chr15:43465641	chr15:43726918~43747094:-
BRCA	cis	rs875971	0.545	rs73146609	ENSG00000232546.1	RP11-458F8.1	4.23	2.51e-05	0.00186	0.13	0.13	Aortic root size;	chr7:66302477	chr7:66848496~66858136:+
BRCA	cis	rs875971	0.545	rs2173571	ENSG00000232546.1	RP11-458F8.1	4.23	2.51e-05	0.00186	0.13	0.13	Aortic root size;	chr7:66305392	chr7:66848496~66858136:+
BRCA	cis	rs7412746	0.658	rs7526489	ENSG00000231073.1	RP11-316M1.3	4.23	2.51e-05	0.00186	0.14	0.13	Melanoma;	chr1:150753762	chr1:150973123~150975534:+
BRCA	cis	rs1387259	0.619	rs2130095	ENSG00000273765.1	RP11-370I10.11	-4.23	2.51e-05	0.00186	-0.14	-0.13	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48244972	chr12:48360920~48361377:+
BRCA	cis	rs13401620	0.81	rs2292361	ENSG00000229326.3	AC069154.4	4.23	2.51e-05	0.00186	0.16	0.13	Breast size;	chr2:119932329	chr2:119698623~119700151:+
BRCA	cis	rs11711311	0.955	rs34458493	ENSG00000241529.3	RN7SL767P	-4.23	2.51e-05	0.00186	-0.15	-0.13	IgG glycosylation;	chr3:113677626	chr3:113632704~113632998:+
BRCA	cis	rs10986311	0.962	rs10818943	ENSG00000227200.1	RP11-121A14.3	-4.23	2.51e-05	0.00186	-0.16	-0.13	Vitiligo;	chr9:124325461	chr9:124262876~124265809:+
BRCA	cis	rs61931739	0.517	rs11612493	ENSG00000258794.3	DUX4L27	4.23	2.51e-05	0.00186	0.19	0.13	Morning vs. evening chronotype;	chr12:33961337	chr12:34208415~34209675:-
BRCA	cis	rs875971	1	rs4717292	ENSG00000229180.5	GS1-124K5.11	4.23	2.51e-05	0.00186	0.11	0.13	Aortic root size;	chr7:66430611	chr7:66526088~66542624:-
BRCA	cis	rs875971	1	rs35149210	ENSG00000229180.5	GS1-124K5.11	4.23	2.51e-05	0.00186	0.11	0.13	Aortic root size;	chr7:66464938	chr7:66526088~66542624:-
BRCA	cis	rs4650994	1	rs10913570	ENSG00000273384.1	RP5-1098D14.1	4.23	2.51e-05	0.00186	0.16	0.13	HDL cholesterol;HDL cholesterol levels;	chr1:178553991	chr1:178651706~178652282:+
BRCA	cis	rs3768617	1	rs2027077	ENSG00000224468.3	RP11-181K3.4	-4.23	2.51e-05	0.00186	-0.15	-0.13	Fuchs's corneal dystrophy;	chr1:183104318	chr1:183138402~183141282:-
BRCA	cis	rs7487075	0.897	rs2897968	ENSG00000257261.4	RP11-96H19.1	4.23	2.51e-05	0.00186	0.15	0.13	Itch intensity from mosquito bite;	chr12:46369903	chr12:46383679~46876159:+
BRCA	cis	rs7111546	0.943	rs16910194	ENSG00000246225.5	RP11-17A1.3	4.23	2.51e-05	0.00186	0.21	0.13	Dialysis-related mortality;	chr11:22807366	chr11:22829380~22945393:+
BRCA	cis	rs7172118	1	rs7172118	ENSG00000261762.1	RP11-650L12.2	-4.23	2.51e-05	0.00187	-0.16	-0.13	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1/FVC ratio in COPD;	chr15:78570111	chr15:78589123~78591276:-
BRCA	cis	rs2505998	0.957	rs2435359	ENSG00000273008.1	RP11-351D16.3	-4.23	2.51e-05	0.00187	-0.16	-0.13	Hirschsprung disease;	chr10:43084567	chr10:43136824~43138334:-
BRCA	cis	rs7932354	0.55	rs10769208	ENSG00000200376.1	RNU5E-10P	4.23	2.51e-05	0.00187	0.16	0.13	Bone mineral density (hip);Bone mineral density;	chr11:46800690	chr11:47576471~47576588:-
BRCA	cis	rs6981523	0.553	rs11783890	ENSG00000255046.1	RP11-297N6.4	4.23	2.51e-05	0.00187	0.17	0.13	Neuroticism;	chr8:11198879	chr8:11797928~11802568:-
BRCA	cis	rs984222	0.617	rs4659152	ENSG00000231365.4	RP11-418J17.1	4.23	2.51e-05	0.00187	0.16	0.13	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119216235	chr1:119140396~119275973:+
BRCA	cis	rs2880765	0.835	rs7169429	ENSG00000202081.1	RNU6-1280P	4.23	2.51e-05	0.00187	0.15	0.13	Coronary artery disease;	chr15:85493417	chr15:85651522~85651628:-
BRCA	cis	rs9784649	0.891	rs57355285	ENSG00000245662.2	RP11-184E9.1	4.23	2.52e-05	0.00187	0.19	0.13	Peripheral arterial disease (traffic-related air pollution interaction);	chr5:25016275	chr5:25190682~25306172:+
BRCA	cis	rs1153858	1	rs16952714	ENSG00000275672.1	GATM-AS1	-4.23	2.52e-05	0.00187	-0.17	-0.13	Homoarginine levels;	chr15:45358160	chr15:45378700~45380123:+
BRCA	cis	rs8098244	0.516	rs1711451	ENSG00000264745.1	TTC39C-AS1	4.23	2.52e-05	0.00187	0.15	0.13	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23690470	chr18:23994213~24015339:-
BRCA	cis	rs6439153	0.901	rs2630263	ENSG00000261159.1	RP11-723O4.9	4.23	2.52e-05	0.00187	0.14	0.13	Pneumococcal bacteremia;	chr3:128969475	chr3:128859716~128860526:-
BRCA	cis	rs8099594	0.601	rs7504446	ENSG00000266696.1	RP11-30L3.2	4.23	2.52e-05	0.00187	0.15	0.13	Height;	chr18:49390750	chr18:49205912~49208781:+
BRCA	cis	rs10129255	0.5	rs4774008	ENSG00000254174.1	IGHV1-12	4.23	2.52e-05	0.00187	0.1	0.13	Kawasaki disease;	chr14:106681273	chr14:106122420~106122709:-
BRCA	cis	rs7267979	1	rs6050598	ENSG00000125804.12	FAM182A	-4.23	2.52e-05	0.00187	-0.17	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25416621	chr20:26054655~26086917:+
BRCA	cis	rs962856	0.897	rs644055	ENSG00000236605.1	AC023115.4	4.23	2.52e-05	0.00187	0.15	0.13	Pancreatic cancer;	chr2:67432539	chr2:67324627~67325304:+
BRCA	cis	rs6430538	0.621	rs12465725	ENSG00000224043.6	CCNT2-AS1	-4.23	2.52e-05	0.00187	-0.18	-0.13	Parkinson's disease;	chr2:134792516	chr2:134735464~134918710:-
BRCA	cis	rs8054556	0.633	rs12928610	ENSG00000261367.1	RP11-455F5.4	-4.23	2.52e-05	0.00187	-0.14	-0.13	Autism spectrum disorder or schizophrenia;	chr16:30004701	chr16:30107675~30110541:+
BRCA	cis	rs6012564	0.964	rs73266241	ENSG00000227431.4	CSE1L-AS1	4.23	2.52e-05	0.00187	0.16	0.13	Anger;	chr20:49043748	chr20:49040463~49046044:-
BRCA	cis	rs6012564	0.964	rs3092302	ENSG00000227431.4	CSE1L-AS1	-4.23	2.52e-05	0.00187	-0.16	-0.13	Anger;	chr20:49037721	chr20:49040463~49046044:-
BRCA	cis	rs12285276	0.75	rs4756024	ENSG00000205106.4	DKFZp779M0652	4.23	2.52e-05	0.00187	0.18	0.13	Visceral fat;	chr11:45789727	chr11:45771432~45772358:+
BRCA	cis	rs755249	0.567	rs16825939	ENSG00000182109.6	RP11-69E11.4	4.23	2.52e-05	0.00187	0.18	0.13	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39196836	chr1:39522280~39546187:-
BRCA	cis	rs755249	0.567	rs16825942	ENSG00000182109.6	RP11-69E11.4	4.23	2.52e-05	0.00187	0.18	0.13	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39196946	chr1:39522280~39546187:-
BRCA	cis	rs755249	0.567	rs67020650	ENSG00000182109.6	RP11-69E11.4	4.23	2.52e-05	0.00187	0.18	0.13	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39202343	chr1:39522280~39546187:-
BRCA	cis	rs755249	0.567	rs72661925	ENSG00000182109.6	RP11-69E11.4	4.23	2.52e-05	0.00187	0.18	0.13	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39203865	chr1:39522280~39546187:-
BRCA	cis	rs755249	0.567	rs72661927	ENSG00000182109.6	RP11-69E11.4	4.23	2.52e-05	0.00187	0.18	0.13	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39209650	chr1:39522280~39546187:-
BRCA	cis	rs6449502	0.536	rs28409386	ENSG00000251279.1	CTC-436P18.1	4.23	2.52e-05	0.00187	0.27	0.13	Mean platelet volume;	chr5:61190761	chr5:61162070~61232040:+
BRCA	cis	rs7772486	0.743	rs1292339	ENSG00000270638.1	RP3-466P17.1	-4.23	2.52e-05	0.00187	-0.15	-0.13	Lobe attachment (rater-scored or self-reported);	chr6:145645950	chr6:145735570~145737218:+
BRCA	cis	rs11711311	1	rs13070720	ENSG00000241529.3	RN7SL767P	-4.23	2.52e-05	0.00187	-0.15	-0.13	IgG glycosylation;	chr3:113754907	chr3:113632704~113632998:+
BRCA	cis	rs7267979	1	rs6076339	ENSG00000274973.1	RP13-401N8.7	4.23	2.52e-05	0.00187	0.15	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25368076	chr20:25845497~25845862:+
BRCA	cis	rs11887277	0.741	rs66661970	ENSG00000272148.1	RP11-195B17.1	-4.23	2.52e-05	0.00187	-0.15	-0.13	Obesity-related traits;	chr2:26811688	chr2:27062428~27062907:-
BRCA	cis	rs11887277	0.771	rs11126733	ENSG00000272148.1	RP11-195B17.1	-4.23	2.52e-05	0.00187	-0.15	-0.13	Obesity-related traits;	chr2:26812827	chr2:27062428~27062907:-
BRCA	cis	rs11887277	0.708	rs11890002	ENSG00000272148.1	RP11-195B17.1	-4.23	2.52e-05	0.00187	-0.15	-0.13	Obesity-related traits;	chr2:26813624	chr2:27062428~27062907:-
BRCA	cis	rs7155454	0.935	rs11620955	ENSG00000272158.1	RP11-840I19.5	-4.23	2.52e-05	0.00187	-0.16	-0.13	Mean corpuscular volume;Mean corpuscular hemoglobin;Red blood cell traits;	chr14:65024537	chr14:65003325~65003767:-
BRCA	cis	rs3812762	0.957	rs6484008	ENSG00000254860.4	TMEM9B-AS1	-4.23	2.52e-05	0.00187	-0.12	-0.13	Hypospadias;	chr11:8732601	chr11:8964675~8977527:+
BRCA	cis	rs7308116	1	rs7976734	ENSG00000274395.1	RP11-554D14.8	-4.23	2.52e-05	0.00187	-0.14	-0.13	Pelvic organ prolapse (moderate/severe);	chr12:107807941	chr12:107835541~107836555:-
BRCA	cis	rs7267979	1	rs4815407	ENSG00000125804.12	FAM182A	4.23	2.52e-05	0.00187	0.17	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25360842	chr20:26054655~26086917:+
BRCA	cis	rs2486012	0.737	rs11210928	ENSG00000237950.1	RP11-7O11.3	4.23	2.52e-05	0.00187	0.23	0.13	Intelligence (multi-trait analysis);	chr1:43802548	chr1:43944370~43946551:-
BRCA	cis	rs7267979	1	rs7268053	ENSG00000125804.12	FAM182A	4.23	2.53e-05	0.00187	0.17	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25347650	chr20:26054655~26086917:+
BRCA	cis	rs7267979	1	rs6083809	ENSG00000125804.12	FAM182A	4.23	2.53e-05	0.00187	0.17	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25348673	chr20:26054655~26086917:+
BRCA	cis	rs7412746	0.611	rs11204748	ENSG00000231073.1	RP11-316M1.3	4.23	2.53e-05	0.00187	0.14	0.13	Melanoma;	chr1:150954893	chr1:150973123~150975534:+
BRCA	cis	rs11070836	0.935	rs2141278	ENSG00000259378.1	DCAF13P3	-4.23	2.53e-05	0.00187	-0.17	-0.13	Airway wall thickness;	chr15:51124263	chr15:50944663~50945996:+
BRCA	cis	rs1434579	0.897	rs2037903	ENSG00000176761.7	ZNF285B	-4.23	2.53e-05	0.00187	-0.15	-0.13	Tuberculosis;	chr19:44440953	chr19:44467641~44473227:+
BRCA	cis	rs9393692	0.645	rs766407	ENSG00000241549.7	GUSBP2	-4.23	2.53e-05	0.00188	-0.16	-0.13	Educational attainment;	chr6:26319306	chr6:26871484~26956554:-
BRCA	cis	rs9393692	0.645	rs11756673	ENSG00000241549.7	GUSBP2	-4.23	2.53e-05	0.00188	-0.16	-0.13	Educational attainment;	chr6:26323277	chr6:26871484~26956554:-
BRCA	cis	rs11098499	1	rs6837898	ENSG00000250412.1	KLHL2P1	4.23	2.53e-05	0.00188	0.16	0.13	Corneal astigmatism;	chr4:119257999	chr4:119334329~119378233:+
BRCA	cis	rs924712	0.545	rs9475034	ENSG00000224984.1	RP11-524H19.2	4.23	2.53e-05	0.00188	0.15	0.13	Breast cancer;	chr6:54837491	chr6:54840118~54840855:-
BRCA	cis	rs61160187	0.518	rs62372133	ENSG00000272308.1	RP11-231G3.1	-4.23	2.53e-05	0.00188	-0.15	-0.13	Educational attainment (years of education);Educational attainment (college completion);	chr5:60906350	chr5:60866457~60866935:-
BRCA	cis	rs58521262	0.556	rs1676468	ENSG00000268105.1	RP11-369G6.2	-4.23	2.53e-05	0.00188	-0.18	-0.13	Testicular germ cell tumor;	chr19:23030632	chr19:23125665~23128543:+
BRCA	cis	rs7487075	0.688	rs12227156	ENSG00000257261.4	RP11-96H19.1	4.23	2.53e-05	0.00188	0.14	0.13	Itch intensity from mosquito bite;	chr12:46615645	chr12:46383679~46876159:+
BRCA	cis	rs875971	0.528	rs801213	ENSG00000232546.1	RP11-458F8.1	-4.23	2.53e-05	0.00188	-0.12	-0.13	Aortic root size;	chr7:66549931	chr7:66848496~66858136:+
BRCA	cis	rs875971	0.545	rs801212	ENSG00000232546.1	RP11-458F8.1	-4.23	2.53e-05	0.00188	-0.12	-0.13	Aortic root size;	chr7:66550643	chr7:66848496~66858136:+
BRCA	cis	rs6012564	1	rs56131635	ENSG00000227431.4	CSE1L-AS1	4.23	2.53e-05	0.00188	0.16	0.13	Anger;	chr20:49157806	chr20:49040463~49046044:-
BRCA	cis	rs4787491	0.729	rs4788215	ENSG00000183604.13	SMG1P5	-4.23	2.53e-05	0.00188	-0.12	-0.13	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30036609	chr16:30267553~30335374:-
BRCA	cis	rs12303914	0.802	rs7135494	ENSG00000256682.2	TAS2R12	-4.23	2.53e-05	0.00188	-0.15	-0.13	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr12:10317494	chr12:10894943~10896952:-
BRCA	cis	rs1048886	0.872	rs76911285	ENSG00000271967.1	RP11-134K13.4	-4.23	2.53e-05	0.00188	-0.18	-0.13	Type 2 diabetes;	chr6:70572479	chr6:70596438~70596980:+
BRCA	cis	rs490234	0.588	rs35278449	ENSG00000232630.1	PRPS1P2	-4.23	2.53e-05	0.00188	-0.14	-0.13	Mean arterial pressure;	chr9:125410684	chr9:125150653~125151589:+
BRCA	cis	rs11098499	0.662	rs13108589	ENSG00000260404.2	RP11-384K6.6	4.23	2.53e-05	0.00188	0.12	0.13	Corneal astigmatism;	chr4:119346947	chr4:118591773~118633729:+
BRCA	cis	rs1910358	0.554	rs3857312	ENSG00000248874.4	C5orf17	-4.23	2.54e-05	0.00188	-0.19	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23745721	chr5:23951348~24178263:+
BRCA	cis	rs6596100	0.956	rs12173082	ENSG00000248648.1	RP11-485M7.1	-4.23	2.54e-05	0.00188	-0.17	-0.13	Breast cancer;	chr5:133053995	chr5:133003119~133003365:+
BRCA	cis	rs6596100	0.956	rs62375205	ENSG00000248648.1	RP11-485M7.1	-4.23	2.54e-05	0.00188	-0.17	-0.13	Breast cancer;	chr5:133057697	chr5:133003119~133003365:+
BRCA	cis	rs6596100	0.956	rs72801450	ENSG00000248648.1	RP11-485M7.1	-4.23	2.54e-05	0.00188	-0.17	-0.13	Breast cancer;	chr5:133064067	chr5:133003119~133003365:+
BRCA	cis	rs6921919	0.609	rs9461455	ENSG00000273712.1	RP5-874C20.7	4.23	2.54e-05	0.00188	0.17	0.13	Autism spectrum disorder or schizophrenia;	chr6:28361954	chr6:28315613~28315883:-
BRCA	cis	rs2108622	0.559	rs7252638	ENSG00000267218.2	AC005336.5	4.23	2.54e-05	0.00188	0.16	0.13	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15870215	chr19:15902300~15903238:-
BRCA	cis	rs2108622	0.727	rs7253684	ENSG00000267218.2	AC005336.5	4.23	2.54e-05	0.00188	0.16	0.13	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15870316	chr19:15902300~15903238:-
BRCA	cis	rs6452524	0.87	rs2174976	ENSG00000281327.1	LINC01338	4.23	2.54e-05	0.00188	0.16	0.13	Hypertension (SNP x SNP interaction);	chr5:83197136	chr5:82850864~82859836:-
BRCA	cis	rs7487075	0.93	rs4076484	ENSG00000272369.1	RP11-446N19.1	4.23	2.54e-05	0.00188	0.14	0.13	Itch intensity from mosquito bite;	chr12:46440129	chr12:46537502~46652550:+
BRCA	cis	rs7487075	0.823	rs34472481	ENSG00000272369.1	RP11-446N19.1	4.23	2.54e-05	0.00188	0.14	0.13	Itch intensity from mosquito bite;	chr12:46442565	chr12:46537502~46652550:+
BRCA	cis	rs3824867	0.804	rs12419342	ENSG00000280615.1	Y_RNA	-4.23	2.54e-05	0.00188	-0.16	-0.13	Mean corpuscular hemoglobin;	chr11:47446993	chr11:47614898~47614994:-
BRCA	cis	rs853679	1	rs1419183	ENSG00000204709.4	LINC01556	4.23	2.54e-05	0.00188	0.23	0.13	Depression;	chr6:28275017	chr6:28943877~28944537:+
BRCA	cis	rs7671266	0.532	rs7349721	ENSG00000250413.1	RP11-448G15.1	-4.23	2.54e-05	0.00188	-0.2	-0.13	Cardiovascular disease risk factors;	chr4:10040938	chr4:10006482~10009725:+
BRCA	cis	rs11673344	0.526	rs17244713	ENSG00000267422.1	CTD-2554C21.1	4.23	2.54e-05	0.00188	0.18	0.13	Obesity-related traits;	chr19:37559938	chr19:37779686~37792865:+
BRCA	cis	rs11955398	0.502	rs10052649	ENSG00000272308.1	RP11-231G3.1	4.23	2.54e-05	0.00188	0.15	0.13	Intelligence (multi-trait analysis);	chr5:60859157	chr5:60866457~60866935:-
BRCA	cis	rs62458065	0.85	rs10273165	ENSG00000273014.1	RP11-225B17.2	-4.23	2.54e-05	0.00188	-0.2	-0.13	Metabolite levels (HVA/MHPG ratio);	chr7:32421228	chr7:32758882~32759353:+
BRCA	cis	rs6596100	0.956	rs62375235	ENSG00000248648.1	RP11-485M7.1	-4.23	2.54e-05	0.00188	-0.17	-0.13	Breast cancer;	chr5:133074175	chr5:133003119~133003365:+
BRCA	cis	rs656900	0.647	rs898436	ENSG00000261229.4	MTHFS	4.23	2.54e-05	0.00188	0.13	0.13	Cerebrospinal P-tau181p levels;	chr15:79824790	chr15:79843547~79897285:-
BRCA	cis	rs2227564	0.7	rs12413039	ENSG00000271816.1	BMS1P4	-4.23	2.54e-05	0.00188	-0.14	-0.13	Crohn's disease;Inflammatory bowel disease;	chr10:73765001	chr10:73699151~73730487:-
BRCA	cis	rs9393777	0.547	rs2893910	ENSG00000220721.1	OR1F12	4.23	2.54e-05	0.00188	0.19	0.13	Intelligence (multi-trait analysis);	chr6:27315475	chr6:28073316~28074233:+
BRCA	cis	rs7308116	1	rs7959929	ENSG00000274395.1	RP11-554D14.8	-4.23	2.54e-05	0.00188	-0.14	-0.13	Pelvic organ prolapse (moderate/severe);	chr12:107810479	chr12:107835541~107836555:-
BRCA	cis	rs11098499	0.754	rs2036860	ENSG00000225892.3	RP11-384K6.2	4.23	2.54e-05	0.00188	0.13	0.13	Corneal astigmatism;	chr4:119327779	chr4:118632274~118634759:+
BRCA	cis	rs2749097	0.696	rs2013012	ENSG00000244256.3	RN7SL130P	4.23	2.54e-05	0.00188	0.17	0.13	Alcohol consumption (transferrin glycosylation);	chr1:63662538	chr1:63655743~63656047:+
BRCA	cis	rs2243480	1	rs2465120	ENSG00000275400.1	RP4-756H11.5	4.23	2.54e-05	0.00188	0.24	0.13	Diabetic kidney disease;	chr7:66155987	chr7:66553805~66554199:-
BRCA	cis	rs2243480	0.908	rs2460431	ENSG00000275400.1	RP4-756H11.5	-4.23	2.54e-05	0.00188	-0.24	-0.13	Diabetic kidney disease;	chr7:66157859	chr7:66553805~66554199:-
BRCA	cis	rs2243480	1	rs4718309	ENSG00000275400.1	RP4-756H11.5	-4.23	2.54e-05	0.00188	-0.24	-0.13	Diabetic kidney disease;	chr7:66162777	chr7:66553805~66554199:-
BRCA	cis	rs2243480	1	rs6460274	ENSG00000275400.1	RP4-756H11.5	-4.23	2.54e-05	0.00188	-0.24	-0.13	Diabetic kidney disease;	chr7:66163497	chr7:66553805~66554199:-
BRCA	cis	rs2243480	1	rs7787230	ENSG00000275400.1	RP4-756H11.5	-4.23	2.54e-05	0.00188	-0.24	-0.13	Diabetic kidney disease;	chr7:66164112	chr7:66553805~66554199:-
BRCA	cis	rs763121	0.853	rs138702	ENSG00000273076.1	RP3-508I15.22	-4.23	2.54e-05	0.00188	-0.14	-0.13	Menopause (age at onset);	chr22:38736596	chr22:38743495~38743910:+
BRCA	cis	rs875971	0.964	rs778723	ENSG00000236529.1	RP13-254B10.1	4.23	2.54e-05	0.00188	0.14	0.13	Aortic root size;	chr7:66364510	chr7:65840212~65840596:+
BRCA	cis	rs11098499	0.618	rs28491261	ENSG00000260091.1	RP11-33B1.4	-4.23	2.54e-05	0.00188	-0.12	-0.13	Corneal astigmatism;	chr4:119373745	chr4:119409333~119410233:+
BRCA	cis	rs8114671	0.967	rs6142323	ENSG00000279253.1	RP4-614O4.13	4.23	2.54e-05	0.00188	0.15	0.13	Height;	chr20:35201180	chr20:35262727~35264187:-
BRCA	cis	rs10266483	0.739	rs12538943	ENSG00000228653.2	HNRNPCP7	4.23	2.54e-05	0.00189	0.17	0.13	Response to statin therapy;	chr7:64395990	chr7:64500825~64501729:+
BRCA	cis	rs7647973	0.925	rs6446257	ENSG00000244380.1	RP11-24C3.2	-4.23	2.54e-05	0.00189	-0.17	-0.13	Menarche (age at onset);	chr3:49216059	chr3:48440352~48446656:-
BRCA	cis	rs6480314	0.522	rs4746756	ENSG00000233590.1	RP11-153K11.3	4.23	2.54e-05	0.00189	0.2	0.13	Optic nerve measurement (disc area);	chr10:68301188	chr10:68233251~68242379:-
BRCA	cis	rs6480314	0.522	rs4363487	ENSG00000233590.1	RP11-153K11.3	4.23	2.54e-05	0.00189	0.2	0.13	Optic nerve measurement (disc area);	chr10:68301809	chr10:68233251~68242379:-
BRCA	cis	rs6480314	0.522	rs10762214	ENSG00000233590.1	RP11-153K11.3	4.23	2.54e-05	0.00189	0.2	0.13	Optic nerve measurement (disc area);	chr10:68302555	chr10:68233251~68242379:-
BRCA	cis	rs6480314	0.522	rs12769008	ENSG00000233590.1	RP11-153K11.3	4.23	2.54e-05	0.00189	0.2	0.13	Optic nerve measurement (disc area);	chr10:68302836	chr10:68233251~68242379:-
BRCA	cis	rs6480314	0.522	rs61857263	ENSG00000233590.1	RP11-153K11.3	4.23	2.54e-05	0.00189	0.2	0.13	Optic nerve measurement (disc area);	chr10:68303370	chr10:68233251~68242379:-
BRCA	cis	rs12571093	0.571	rs4517412	ENSG00000233590.1	RP11-153K11.3	4.23	2.54e-05	0.00189	0.2	0.13	Optic nerve measurement (disc area);	chr10:68303779	chr10:68233251~68242379:-
BRCA	cis	rs12571093	0.571	rs7097498	ENSG00000233590.1	RP11-153K11.3	4.23	2.54e-05	0.00189	0.2	0.13	Optic nerve measurement (disc area);	chr10:68303780	chr10:68233251~68242379:-
BRCA	cis	rs6480314	0.614	rs7067601	ENSG00000233590.1	RP11-153K11.3	4.23	2.54e-05	0.00189	0.2	0.13	Optic nerve measurement (disc area);	chr10:68304213	chr10:68233251~68242379:-
BRCA	cis	rs6480314	0.522	rs10733843	ENSG00000233590.1	RP11-153K11.3	4.23	2.54e-05	0.00189	0.2	0.13	Optic nerve measurement (disc area);	chr10:68304752	chr10:68233251~68242379:-
BRCA	cis	rs6480314	0.522	rs4746760	ENSG00000233590.1	RP11-153K11.3	4.23	2.54e-05	0.00189	0.2	0.13	Optic nerve measurement (disc area);	chr10:68306122	chr10:68233251~68242379:-
BRCA	cis	rs1387259	0.839	rs7486941	ENSG00000226413.2	OR8T1P	-4.23	2.54e-05	0.00189	-0.16	-0.13	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48184848	chr12:48442030~48442947:-
BRCA	cis	rs10504130	0.569	rs34073804	ENSG00000253844.1	RP11-546K22.1	-4.23	2.55e-05	0.00189	-0.19	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr8:51776808	chr8:51961458~52022974:+
BRCA	cis	rs721917	0.506	rs2758558	ENSG00000278616.1	BEND3P3	-4.23	2.55e-05	0.00189	-0.12	-0.13	Chronic obstructive pulmonary disease;	chr10:79923822	chr10:79682997~79685436:+
BRCA	cis	rs11098499	0.739	rs4833612	ENSG00000260404.2	RP11-384K6.6	-4.23	2.55e-05	0.00189	-0.12	-0.13	Corneal astigmatism;	chr4:119226441	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.739	rs10013032	ENSG00000260404.2	RP11-384K6.6	-4.23	2.55e-05	0.00189	-0.12	-0.13	Corneal astigmatism;	chr4:119228264	chr4:118591773~118633729:+
BRCA	cis	rs16846053	0.792	rs62187703	ENSG00000227403.1	AC009299.3	4.23	2.55e-05	0.00189	0.33	0.13	Blood osmolality (transformed sodium);	chr2:161829705	chr2:161244739~161249050:+
BRCA	cis	rs67766926	0.951	rs10174032	ENSG00000271889.1	RP11-493E12.1	4.23	2.55e-05	0.00189	0.19	0.13	Inflammatory skin disease;	chr2:60951790	chr2:61151433~61162105:-
BRCA	cis	rs7267979	0.565	rs4815437	ENSG00000125804.12	FAM182A	4.23	2.55e-05	0.00189	0.17	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25604152	chr20:26054655~26086917:+
BRCA	cis	rs2562456	0.793	rs62110424	ENSG00000268658.4	LINC00664	4.23	2.55e-05	0.00189	0.22	0.13	Pain;	chr19:21416835	chr19:21483374~21503238:+
BRCA	cis	rs854765	0.647	rs4426402	ENSG00000281749.1	Y_RNA	-4.23	2.55e-05	0.00189	-0.15	-0.13	Total body bone mineral density;	chr17:18074612	chr17:18001101~18001195:-
BRCA	cis	rs1910358	0.554	rs1520980	ENSG00000248874.4	C5orf17	-4.23	2.55e-05	0.00189	-0.18	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23755438	chr5:23951348~24178263:+
BRCA	cis	rs1910358	0.554	rs4701233	ENSG00000248874.4	C5orf17	-4.23	2.55e-05	0.00189	-0.18	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23756054	chr5:23951348~24178263:+
BRCA	cis	rs2286503	0.78	rs2286506	ENSG00000226329.2	AC005682.6	4.23	2.55e-05	0.00189	0.12	0.13	Fibrinogen;	chr7:22815196	chr7:22863874~22881350:-
BRCA	cis	rs4907240	1	rs4907240	ENSG00000230606.9	AC159540.1	4.23	2.55e-05	0.00189	0.17	0.13	Event-related brain oscillations;	chr2:96562302	chr2:97416165~97433527:-
BRCA	cis	rs420259	0.727	rs523422	ENSG00000260136.4	CTD-2270L9.4	4.23	2.55e-05	0.00189	0.12	0.13	Bipolar disorder;	chr16:23649888	chr16:23452758~23457606:+
BRCA	cis	rs6496044	0.527	rs7163068	ENSG00000202081.1	RNU6-1280P	4.23	2.55e-05	0.00189	0.15	0.13	Interstitial lung disease;	chr15:85529235	chr15:85651522~85651628:-
BRCA	cis	rs61160187	0.582	rs1382917	ENSG00000272308.1	RP11-231G3.1	-4.23	2.55e-05	0.00189	-0.15	-0.13	Educational attainment (years of education);Educational attainment (college completion);	chr5:60956668	chr5:60866457~60866935:-
BRCA	cis	rs9308731	0.591	rs7565473	ENSG00000230499.1	AC108463.1	-4.23	2.55e-05	0.00189	-0.15	-0.13	Chronic lymphocytic leukemia;	chr2:111186213	chr2:111195963~111206494:+
BRCA	cis	rs7772486	0.774	rs2247571	ENSG00000270638.1	RP3-466P17.1	4.23	2.55e-05	0.00189	0.15	0.13	Lobe attachment (rater-scored or self-reported);	chr6:145898397	chr6:145735570~145737218:+
BRCA	cis	rs7338174	0.655	rs9316535	ENSG00000236778.6	INTS6-AS1	4.23	2.55e-05	0.00189	0.29	0.13	Mitochondrial DNA levels;	chr13:51329329	chr13:51452367~51552364:+
BRCA	cis	rs7811142	0.83	rs11765869	ENSG00000078319.8	PMS2P1	-4.23	2.55e-05	0.00189	-0.22	-0.13	Platelet count;	chr7:100367166	chr7:100320992~100341908:-
BRCA	cis	rs7481584	0.581	rs406598	ENSG00000236710.1	AC108448.2	4.23	2.55e-05	0.00189	0.18	0.13	Calcium levels;	chr11:3055055	chr11:3084393~3085443:-
BRCA	cis	rs7475343	0.501	rs79849481	ENSG00000224034.1	RP11-445P17.8	-4.23	2.55e-05	0.00189	-0.25	-0.13	Intelligence;	chr10:5220133	chr10:5266033~5271236:-
BRCA	cis	rs16846053	0.792	rs62187711	ENSG00000227403.1	AC009299.3	4.23	2.55e-05	0.00189	0.34	0.13	Blood osmolality (transformed sodium);	chr2:161834551	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.792	rs72879248	ENSG00000227403.1	AC009299.3	4.23	2.55e-05	0.00189	0.34	0.13	Blood osmolality (transformed sodium);	chr2:161834856	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.792	rs72879250	ENSG00000227403.1	AC009299.3	4.23	2.55e-05	0.00189	0.34	0.13	Blood osmolality (transformed sodium);	chr2:161834857	chr2:161244739~161249050:+
BRCA	cis	rs9527	0.59	rs7087040	ENSG00000213061.2	PFN1P11	4.23	2.55e-05	0.00189	0.18	0.13	Arsenic metabolism;	chr10:103039911	chr10:102838011~102845473:-
BRCA	cis	rs9818758	0.607	rs9880088	ENSG00000225399.4	RP11-3B7.1	-4.23	2.55e-05	0.00189	-0.22	-0.13	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49141557	chr3:49260085~49261316:+
BRCA	cis	rs3768617	0.565	rs10752898	ENSG00000224468.3	RP11-181K3.4	-4.23	2.55e-05	0.00189	-0.14	-0.13	Fuchs's corneal dystrophy;	chr1:183108761	chr1:183138402~183141282:-
BRCA	cis	rs721917	0.506	rs4320898	ENSG00000278616.1	BEND3P3	-4.23	2.55e-05	0.00189	-0.12	-0.13	Chronic obstructive pulmonary disease;	chr10:79891322	chr10:79682997~79685436:+
BRCA	cis	rs721917	0.506	rs4322333	ENSG00000278616.1	BEND3P3	-4.23	2.55e-05	0.00189	-0.12	-0.13	Chronic obstructive pulmonary disease;	chr10:79891340	chr10:79682997~79685436:+
BRCA	cis	rs875971	0.545	rs73152714	ENSG00000232546.1	RP11-458F8.1	4.23	2.55e-05	0.00189	0.12	0.13	Aortic root size;	chr7:66534641	chr7:66848496~66858136:+
BRCA	cis	rs875971	0.545	rs4718364	ENSG00000232546.1	RP11-458F8.1	4.23	2.55e-05	0.00189	0.12	0.13	Aortic root size;	chr7:66536353	chr7:66848496~66858136:+
BRCA	cis	rs875971	0.545	rs801199	ENSG00000232546.1	RP11-458F8.1	-4.23	2.55e-05	0.00189	-0.12	-0.13	Aortic root size;	chr7:66560286	chr7:66848496~66858136:+
BRCA	cis	rs465969	0.744	rs9400477	ENSG00000230177.1	RP5-1112D6.4	-4.23	2.55e-05	0.00189	-0.3	-0.13	Psoriasis;	chr6:111469440	chr6:111277932~111278742:+
BRCA	cis	rs11673344	0.526	rs8111790	ENSG00000267422.1	CTD-2554C21.1	4.23	2.55e-05	0.00189	0.18	0.13	Obesity-related traits;	chr19:37565861	chr19:37779686~37792865:+
BRCA	cis	rs28374715	0.681	rs28728213	ENSG00000247556.5	OIP5-AS1	4.23	2.55e-05	0.00189	0.14	0.13	Ulcerative colitis;	chr15:41361404	chr15:41283990~41309737:+
BRCA	cis	rs7572733	0.935	rs696814	ENSG00000231621.1	AC013264.2	-4.23	2.56e-05	0.00189	-0.12	-0.13	Dermatomyositis;	chr2:197823175	chr2:197197991~197199273:+
BRCA	cis	rs1371614	0.545	rs3769137	ENSG00000272148.1	RP11-195B17.1	-4.23	2.56e-05	0.00189	-0.14	-0.13	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26946622	chr2:27062428~27062907:-
BRCA	cis	rs6968419	0.788	rs1317791	ENSG00000279086.1	RP11-667F14.1	-4.23	2.56e-05	0.00189	-0.14	-0.13	Intraocular pressure;	chr7:116199667	chr7:116209234~116211511:-
BRCA	cis	rs490234	0.616	rs2648318	ENSG00000232630.1	PRPS1P2	-4.23	2.56e-05	0.00189	-0.13	-0.13	Mean arterial pressure;	chr9:125401168	chr9:125150653~125151589:+
BRCA	cis	rs2439831	0.85	rs11070408	ENSG00000206991.1	RNU6-610P	-4.23	2.56e-05	0.00189	-0.21	-0.13	Lung cancer in ever smokers;	chr15:43742590	chr15:43637632~43637738:-
BRCA	cis	rs11742741	0.806	rs1032758	ENSG00000248874.4	C5orf17	-4.23	2.56e-05	0.00189	-0.17	-0.13	Educational attainment;	chr5:24017488	chr5:23951348~24178263:+
BRCA	cis	rs890448	0.796	rs10007821	ENSG00000254531.1	FLJ20021	4.23	2.56e-05	0.00189	0.15	0.13	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101414887	chr4:101347780~101348883:+
BRCA	cis	rs115575488	0.85	rs17185989	ENSG00000236804.1	RPS3AP12	4.23	2.56e-05	0.0019	0.24	0.13	Lobe attachment (rater-scored or self-reported);	chr1:119035302	chr1:119126539~119127291:-
BRCA	cis	rs11098499	0.955	rs1397608	ENSG00000260091.1	RP11-33B1.4	-4.23	2.56e-05	0.0019	-0.12	-0.13	Corneal astigmatism;	chr4:119240589	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.955	rs7685268	ENSG00000260091.1	RP11-33B1.4	-4.23	2.56e-05	0.0019	-0.12	-0.13	Corneal astigmatism;	chr4:119241033	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.955	rs7684942	ENSG00000260091.1	RP11-33B1.4	-4.23	2.56e-05	0.0019	-0.12	-0.13	Corneal astigmatism;	chr4:119241046	chr4:119409333~119410233:+
BRCA	cis	rs2411233	0.967	rs1865281	ENSG00000259278.1	RP11-62C7.2	4.23	2.56e-05	0.0019	0.15	0.13	Platelet count;	chr15:39000089	chr15:39019233~39024918:+
BRCA	cis	rs2411233	0.967	rs2411237	ENSG00000259278.1	RP11-62C7.2	4.23	2.56e-05	0.0019	0.15	0.13	Platelet count;	chr15:39000523	chr15:39019233~39024918:+
BRCA	cis	rs8114671	0.562	rs6087643	ENSG00000126005.14	MMP24-AS1	-4.23	2.56e-05	0.0019	-0.15	-0.13	Height;	chr20:34886659	chr20:35216462~35278131:-
BRCA	cis	rs7520050	0.807	rs5021934	ENSG00000234329.1	RP11-767N6.2	-4.23	2.56e-05	0.0019	-0.12	-0.13	Reticulocyte count;Red blood cell count;	chr1:45643632	chr1:45651039~45651826:-
BRCA	cis	rs6596100	0.868	rs4128344	ENSG00000248648.1	RP11-485M7.1	-4.23	2.56e-05	0.0019	-0.17	-0.13	Breast cancer;	chr5:133082388	chr5:133003119~133003365:+
BRCA	cis	rs6600671	0.966	rs6600664	ENSG00000231429.2	RP11-343N15.2	-4.23	2.56e-05	0.0019	-0.16	-0.13	Hip geometry;	chr1:121480638	chr1:121412719~121429274:+
BRCA	cis	rs6600671	0.932	rs6600663	ENSG00000231429.2	RP11-343N15.2	-4.23	2.56e-05	0.0019	-0.16	-0.13	Hip geometry;	chr1:121480639	chr1:121412719~121429274:+
BRCA	cis	rs10129255	1	rs11627342	ENSG00000211967.3	IGHV3-53	-4.23	2.56e-05	0.0019	-0.1	-0.13	Kawasaki disease;	chr14:106675823	chr14:106592676~106593347:-
BRCA	cis	rs5758659	0.714	rs2284087	ENSG00000273366.1	CTA-989H11.1	4.23	2.56e-05	0.0019	0.15	0.13	Cognitive function;	chr22:42089667	chr22:42278188~42278846:+
BRCA	cis	rs11048434	0.518	rs1805707	ENSG00000256720.1	RP11-436I9.6	-4.23	2.56e-05	0.0019	-0.13	-0.13	Sjögren's syndrome;	chr12:9029110	chr12:9135084~9135591:+
BRCA	cis	rs4906332	0.811	rs2756138	ENSG00000244691.1	RPL10AP1	4.23	2.56e-05	0.0019	0.18	0.13	Coronary artery disease;	chr14:103530396	chr14:103412119~103412761:-
BRCA	cis	rs3733585	0.605	rs4697926	ENSG00000250413.1	RP11-448G15.1	-4.23	2.56e-05	0.0019	-0.17	-0.13	Cleft plate (environmental tobacco smoke interaction);	chr4:10122943	chr4:10006482~10009725:+
BRCA	cis	rs4784227	0.627	rs12922061	ENSG00000260963.1	RP11-297L17.2	-4.23	2.56e-05	0.0019	-0.17	-0.13	Breast cancer (estrogen-receptor negative);Breast cancer;Parkinson's disease;	chr16:52601088	chr16:52607349~52613908:+
BRCA	cis	rs1865760	0.519	rs4360119	ENSG00000272462.2	U91328.19	-4.23	2.56e-05	0.0019	-0.16	-0.13	Height;	chr6:25814846	chr6:25992662~26001775:+
BRCA	cis	rs11742741	0.774	rs1428204	ENSG00000248874.4	C5orf17	-4.23	2.56e-05	0.0019	-0.17	-0.13	Educational attainment;	chr5:24081270	chr5:23951348~24178263:+
BRCA	cis	rs17345786	0.911	rs10936707	ENSG00000244119.1	PDCL3P4	4.23	2.56e-05	0.0019	0.12	0.13	Colonoscopy-negative controls vs population controls;	chr3:101605219	chr3:101712472~101713191:+
BRCA	cis	rs4761470	0.577	rs4761602	ENSG00000258365.1	RP11-1105G2.3	-4.23	2.56e-05	0.0019	-0.17	-0.13	Estradiol plasma levels (breast cancer);	chr12:94291262	chr12:94277758~94282844:-
BRCA	cis	rs91731	1	rs91731	ENSG00000249572.1	CTD-2203K17.1	-4.23	2.56e-05	0.0019	-0.26	-0.13	Lung function (FVC);	chr5:33334206	chr5:33424025~33440619:-
BRCA	cis	rs7246657	0.678	rs2927740	ENSG00000226686.6	LINC01535	4.23	2.56e-05	0.0019	0.19	0.13	Coronary artery calcification;	chr19:37650065	chr19:37251912~37265535:+
BRCA	cis	rs72819225	0.616	rs72819249	ENSG00000228701.1	TNKS2-AS1	4.23	2.56e-05	0.0019	0.18	0.13	Yeast infection;	chr10:91568730	chr10:91782839~91798291:-
BRCA	cis	rs6545883	0.507	rs12478192	ENSG00000273302.1	RP11-493E12.2	-4.23	2.56e-05	0.0019	-0.11	-0.13	Tuberculosis;	chr2:61364040	chr2:61199979~61200769:+
BRCA	cis	rs568617	1	rs687672	ENSG00000254510.1	RP11-867G23.10	-4.23	2.56e-05	0.0019	-0.16	-0.13	Crohn's disease;	chr11:65882513	chr11:66409158~66417137:+
BRCA	cis	rs8180040	1	rs7613282	ENSG00000271161.1	BOLA2P2	-4.23	2.57e-05	0.0019	-0.14	-0.13	Colorectal cancer;	chr3:47347919	chr3:47499841~47500407:+
BRCA	cis	rs61931739	0.517	rs34760282	ENSG00000258794.3	DUX4L27	4.23	2.57e-05	0.0019	0.19	0.13	Morning vs. evening chronotype;	chr12:34000776	chr12:34208415~34209675:-
BRCA	cis	rs1722133	0.555	rs788764	ENSG00000229628.1	AC073115.7	4.23	2.57e-05	0.0019	0.18	0.13	Sitting height ratio;	chr7:46103295	chr7:45990905~46000898:+
BRCA	cis	rs1722133	0.555	rs788762	ENSG00000229628.1	AC073115.7	4.23	2.57e-05	0.0019	0.18	0.13	Sitting height ratio;	chr7:46104921	chr7:45990905~46000898:+
BRCA	cis	rs1722133	0.515	rs788760	ENSG00000229628.1	AC073115.7	4.23	2.57e-05	0.0019	0.18	0.13	Sitting height ratio;	chr7:46105307	chr7:45990905~46000898:+
BRCA	cis	rs886774	0.615	rs881177	ENSG00000273055.1	CTB-13F3.1	-4.23	2.57e-05	0.0019	-0.13	-0.13	Ulcerative colitis;	chr7:107932823	chr7:107942116~107942740:+
BRCA	cis	rs4974559	0.947	rs10000012	ENSG00000253399.1	AC078852.2	-4.23	2.57e-05	0.0019	-0.18	-0.13	Systolic blood pressure;	chr4:1363537	chr4:1358479~1359461:+
BRCA	cis	rs2562456	0.917	rs2650793	ENSG00000213976.4	CTD-2561J22.2	4.23	2.57e-05	0.0019	0.15	0.13	Pain;	chr19:21493313	chr19:21382865~21387177:+
BRCA	cis	rs4478858	0.647	rs12752761	ENSG00000260386.4	LINC01225	-4.23	2.57e-05	0.0019	-0.15	-0.13	Alcohol dependence;	chr1:31238041	chr1:31500085~31540885:+
BRCA	cis	rs2573652	0.723	rs4577068	ENSG00000254744.3	CTD-3076O17.1	-4.23	2.57e-05	0.0019	-0.16	-0.13	Height;	chr15:99975754	chr15:99970215~99974010:+
BRCA	cis	rs6545883	0.929	rs2252662	ENSG00000212978.6	AC016747.3	4.23	2.57e-05	0.0019	0.18	0.13	Tuberculosis;	chr2:61443596	chr2:61141592~61144969:-
BRCA	cis	rs71520386	0.632	rs9691076	ENSG00000226329.2	AC005682.6	-4.23	2.57e-05	0.0019	-0.13	-0.13	Fibrinogen levels;	chr7:22829742	chr7:22863874~22881350:-
BRCA	cis	rs10849893	0.595	rs10444490	ENSG00000258435.1	RP11-711D18.2	-4.23	2.57e-05	0.0019	-0.14	-0.13	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr12:121438582	chr12:121391962~121399859:+
BRCA	cis	rs490234	0.702	rs4838274	ENSG00000232630.1	PRPS1P2	-4.23	2.57e-05	0.0019	-0.14	-0.13	Mean arterial pressure;	chr9:125583715	chr9:125150653~125151589:+
BRCA	cis	rs9921338	0.961	rs56010295	ENSG00000262636.1	CTD-3088G3.4	-4.23	2.57e-05	0.0019	-0.21	-0.13	Vein graft stenosis in coronary artery bypass grafting;	chr16:11285050	chr16:11380859~11381118:-
BRCA	cis	rs6968419	0.642	rs67251819	ENSG00000279086.1	RP11-667F14.1	-4.23	2.57e-05	0.0019	-0.14	-0.13	Intraocular pressure;	chr7:116265532	chr7:116209234~116211511:-
BRCA	cis	rs893818	1	rs893818	ENSG00000261801.4	LOXL1-AS1	4.23	2.57e-05	0.0019	0.16	0.13	Exfoliation glaucoma or exfoliation syndrome;	chr15:73936854	chr15:73908071~73928248:-
BRCA	cis	rs58521262	0.53	rs289352	ENSG00000268105.1	RP11-369G6.2	4.23	2.57e-05	0.0019	0.18	0.13	Testicular germ cell tumor;	chr19:22962468	chr19:23125665~23128543:+
BRCA	cis	rs12681366	0.663	rs3099398	ENSG00000253704.1	RP11-267M23.4	4.23	2.57e-05	0.0019	0.13	0.13	Nonsyndromic cleft lip with cleft palate;	chr8:94467651	chr8:94553722~94569745:+
BRCA	cis	rs2179367	0.919	rs577001	ENSG00000223701.3	RAET1E-AS1	4.23	2.57e-05	0.0019	0.17	0.13	Dupuytren's disease;	chr6:149325172	chr6:149884431~149919508:+
BRCA	cis	rs11098499	0.754	rs7672594	ENSG00000225892.3	RP11-384K6.2	4.23	2.57e-05	0.00191	0.13	0.13	Corneal astigmatism;	chr4:119327388	chr4:118632274~118634759:+
BRCA	cis	rs17507216	0.671	rs28582623	ENSG00000255769.6	GOLGA2P10	-4.23	2.57e-05	0.00191	-0.18	-0.13	Excessive daytime sleepiness;	chr15:82577381	chr15:82472993~82513950:-
BRCA	cis	rs1345301	0.518	rs12468355	ENSG00000234389.1	AC007278.3	-4.23	2.57e-05	0.00191	-0.12	-0.13	Waist circumference;	chr2:102244790	chr2:102438713~102440475:+
BRCA	cis	rs6128907	1	rs62202485	ENSG00000224635.1	RP4-564F22.5	4.23	2.57e-05	0.00191	0.2	0.13	Liver fibrosis in pediatric non-alcoholic fatty acid liver disease;	chr20:38779925	chr20:38406011~38416797:-
BRCA	cis	rs7071275	0.891	rs10510099	ENSG00000226864.1	ATE1-AS1	4.23	2.58e-05	0.00191	0.21	0.13	Dupuytren's disease;	chr10:121672332	chr10:121928312~121951965:+
BRCA	cis	rs9470794	1	rs9470782	ENSG00000204110.6	RP1-153P14.8	-4.23	2.58e-05	0.00191	-0.21	-0.13	Type 2 diabetes;	chr6:38114834	chr6:37507348~37535616:+
BRCA	cis	rs11742741	0.748	rs1428195	ENSG00000248874.4	C5orf17	-4.23	2.58e-05	0.00191	-0.17	-0.13	Educational attainment;	chr5:24128739	chr5:23951348~24178263:+
BRCA	cis	rs11764932	0.756	rs1050290	ENSG00000229108.1	MEOX2-AS1	4.23	2.58e-05	0.00191	0.15	0.13	Kidney function decline traits;	chr7:15686441	chr7:15688378~15695491:+
BRCA	cis	rs2286492	0.655	rs117841439	ENSG00000228649.7	AC005682.5	-4.23	2.58e-05	0.00191	-0.2	-0.13	Bipolar disorder;	chr7:22870922	chr7:22854178~22861579:+
BRCA	cis	rs58521262	0.556	rs2935441	ENSG00000268105.1	RP11-369G6.2	-4.23	2.58e-05	0.00191	-0.18	-0.13	Testicular germ cell tumor;	chr19:23028393	chr19:23125665~23128543:+
BRCA	cis	rs58521262	0.615	rs2088374	ENSG00000268105.1	RP11-369G6.2	-4.23	2.58e-05	0.00191	-0.18	-0.13	Testicular germ cell tumor;	chr19:23029760	chr19:23125665~23128543:+
BRCA	cis	rs911119	1	rs3787498	ENSG00000270001.1	RP11-218C14.8	-4.23	2.58e-05	0.00191	-0.18	-0.13	Chronic kidney disease;	chr20:23636144	chr20:23631826~23632316:-
BRCA	cis	rs7897654	0.571	rs12771681	ENSG00000213277.3	MARCKSL1P1	4.23	2.58e-05	0.00191	0.17	0.13	Schizophrenia;	chr10:102875863	chr10:103175554~103176094:+
BRCA	cis	rs4689592	0.523	rs6446565	ENSG00000245468.3	RP11-367J11.3	4.23	2.58e-05	0.00191	0.14	0.13	Monocyte percentage of white cells;	chr4:7072300	chr4:7094571~7103385:-
BRCA	cis	rs1223397	0.589	rs364493	ENSG00000215022.6	RP1-257A7.4	4.23	2.58e-05	0.00191	0.17	0.13	Blood pressure;	chr6:13296788	chr6:13264861~13295586:-
BRCA	cis	rs7267979	1	rs6037095	ENSG00000125804.12	FAM182A	4.23	2.58e-05	0.00191	0.17	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25355051	chr20:26054655~26086917:+
BRCA	cis	rs7267979	1	rs6050562	ENSG00000125804.12	FAM182A	4.23	2.58e-05	0.00191	0.17	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25355550	chr20:26054655~26086917:+
BRCA	cis	rs3096299	0.838	rs4785561	ENSG00000261118.1	RP11-104N10.1	4.23	2.58e-05	0.00191	0.14	0.13	Multiple myeloma (IgH translocation);	chr16:89362644	chr16:89492017~89504460:-
BRCA	cis	rs9818758	0.607	rs9862483	ENSG00000225399.4	RP11-3B7.1	-4.23	2.58e-05	0.00191	-0.22	-0.13	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49158008	chr3:49260085~49261316:+
BRCA	cis	rs9527	0.83	rs12249194	ENSG00000236937.2	PTGES3P4	4.23	2.58e-05	0.00191	0.18	0.13	Arsenic metabolism;	chr10:102883941	chr10:102845595~102845950:+
BRCA	cis	rs2286503	0.752	rs2286504	ENSG00000226329.2	AC005682.6	4.23	2.58e-05	0.00191	0.12	0.13	Fibrinogen;	chr7:22815228	chr7:22863874~22881350:-
BRCA	cis	rs6546324	0.58	rs4362541	ENSG00000236780.4	AC078941.1	4.23	2.58e-05	0.00191	0.22	0.13	Endometriosis;	chr2:67615734	chr2:67123357~67215319:-
BRCA	cis	rs875971	0.619	rs10278371	ENSG00000273142.1	RP11-458F8.4	4.23	2.58e-05	0.00191	0.11	0.13	Aortic root size;	chr7:66586553	chr7:66902857~66906297:+
BRCA	cis	rs7937890	0.559	rs2575838	ENSG00000254418.1	RP11-21L19.1	4.23	2.58e-05	0.00191	0.15	0.13	Mitochondrial DNA levels;	chr11:14476675	chr11:14262846~14273691:-
BRCA	cis	rs13401620	0.917	rs6542549	ENSG00000229326.3	AC069154.4	-4.23	2.58e-05	0.00191	-0.17	-0.13	Breast size;	chr2:119769256	chr2:119698623~119700151:+
BRCA	cis	rs16846053	0.792	rs62187712	ENSG00000227403.1	AC009299.3	4.23	2.58e-05	0.00191	0.34	0.13	Blood osmolality (transformed sodium);	chr2:161835383	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.792	rs62187713	ENSG00000227403.1	AC009299.3	4.23	2.58e-05	0.00191	0.34	0.13	Blood osmolality (transformed sodium);	chr2:161835607	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.792	rs2892796	ENSG00000227403.1	AC009299.3	4.23	2.58e-05	0.00191	0.34	0.13	Blood osmolality (transformed sodium);	chr2:161836100	chr2:161244739~161249050:+
BRCA	cis	rs934734	0.532	rs2860773	ENSG00000281920.1	RP11-418H16.1	-4.23	2.58e-05	0.00191	-0.15	-0.13	Rheumatoid arthritis;	chr2:65438507	chr2:65623272~65628424:+
BRCA	cis	rs6545883	0.894	rs7572603	ENSG00000270820.4	RP11-355B11.2	-4.23	2.58e-05	0.00191	-0.15	-0.13	Tuberculosis;	chr2:61325010	chr2:61471188~61484130:+
BRCA	cis	rs3930017	0.513	rs3930018	ENSG00000233448.2	PMS2P9	4.23	2.58e-05	0.00191	0.17	0.13	Body mass index;	chr7:77091318	chr7:77039944~77043776:+
BRCA	cis	rs2251381	0.75	rs2255055	ENSG00000232855.5	AF131217.1	-4.23	2.58e-05	0.00191	-0.17	-0.13	Selective IgA deficiency;	chr21:29164724	chr21:28439346~28674848:-
BRCA	cis	rs409045	1	rs379727	ENSG00000271874.1	CTD-2024P10.2	4.23	2.58e-05	0.00191	0.17	0.13	Left ventricular mass;	chr5:34639005	chr5:34651457~34651888:-
BRCA	cis	rs7771547	0.723	rs9368940	ENSG00000224666.3	RP1-50J22.4	4.23	2.58e-05	0.00191	0.16	0.13	Platelet distribution width;	chr6:36590923	chr6:36386831~36393462:+
BRCA	cis	rs2243480	1	rs34136756	ENSG00000226002.1	RP11-460N20.5	-4.23	2.58e-05	0.00191	-0.21	-0.13	Diabetic kidney disease;	chr7:65916269	chr7:65084103~65100232:+
BRCA	cis	rs2446066	0.872	rs36065378	ENSG00000257379.1	RP11-793H13.8	4.23	2.58e-05	0.00191	0.2	0.13	Red blood cell count;	chr12:53380995	chr12:53441741~53467528:+
BRCA	cis	rs752590	0.806	rs4849174	ENSG00000274877.1	RP11-65I12.1	-4.23	2.58e-05	0.00191	-0.19	-0.13	Mucinous ovarian carcinoma;	chr2:113215890	chr2:113237595~113240825:+
BRCA	cis	rs6452524	1	rs4591730	ENSG00000281327.1	LINC01338	4.23	2.58e-05	0.00191	0.15	0.13	Hypertension (SNP x SNP interaction);	chr5:83151983	chr5:82850864~82859836:-
BRCA	cis	rs10504130	0.569	rs12680128	ENSG00000253844.1	RP11-546K22.1	-4.23	2.58e-05	0.00191	-0.19	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr8:51766683	chr8:51961458~52022974:+
BRCA	cis	rs1823874	0.71	rs56186545	ENSG00000182397.13	DNM1P46	-4.23	2.58e-05	0.00191	-0.15	-0.13	IgG glycosylation;	chr15:99820554	chr15:99790156~99806927:-
BRCA	cis	rs4415084	0.804	rs9790896	ENSG00000251141.4	RP11-53O19.1	4.23	2.58e-05	0.00191	0.12	0.13	Breast cancer;	chr5:44899989	chr5:44744900~44808777:-
BRCA	cis	rs7011507	0.535	rs28689821	ENSG00000233858.4	AC026904.1	-4.23	2.59e-05	0.00191	-0.16	-0.13	Inflammatory bowel disease;Ulcerative colitis;	chr8:48541213	chr8:48590401~48594621:+
BRCA	cis	rs7111546	1	rs73484234	ENSG00000246225.5	RP11-17A1.3	4.23	2.59e-05	0.00191	0.21	0.13	Dialysis-related mortality;	chr11:22800665	chr11:22829380~22945393:+
BRCA	cis	rs983392	0.805	rs1834550	ENSG00000275344.1	MIR6503	-4.23	2.59e-05	0.00191	-0.14	-0.13	Alzheimer's disease (late onset);	chr11:60192370	chr11:60209071~60209156:-
BRCA	cis	rs6802315	0.604	rs9881462	ENSG00000272087.1	RP11-379F4.7	4.23	2.59e-05	0.00191	0.15	0.13	Periodontitis (CDC/AAP);	chr3:158763333	chr3:158693120~158693768:-
BRCA	cis	rs1048886	0.872	rs74586626	ENSG00000271967.1	RP11-134K13.4	-4.23	2.59e-05	0.00191	-0.2	-0.13	Type 2 diabetes;	chr6:70514387	chr6:70596438~70596980:+
BRCA	cis	rs1048886	0.872	rs17635446	ENSG00000271967.1	RP11-134K13.4	-4.23	2.59e-05	0.00191	-0.2	-0.13	Type 2 diabetes;	chr6:70516453	chr6:70596438~70596980:+
BRCA	cis	rs721917	0.506	rs2819113	ENSG00000278616.1	BEND3P3	-4.23	2.59e-05	0.00191	-0.12	-0.13	Chronic obstructive pulmonary disease;	chr10:79890987	chr10:79682997~79685436:+
BRCA	cis	rs651907	0.535	rs4342086	ENSG00000256628.3	ZBTB11-AS1	4.23	2.59e-05	0.00191	0.17	0.13	Colorectal cancer;	chr3:101784921	chr3:101676475~101679217:+
BRCA	cis	rs7475343	0.501	rs3750571	ENSG00000224034.1	RP11-445P17.8	4.23	2.59e-05	0.00191	0.25	0.13	Intelligence;	chr10:5205471	chr10:5266033~5271236:-
BRCA	cis	rs748404	0.626	rs62021176	ENSG00000205771.5	CATSPER2P1	-4.23	2.59e-05	0.00191	-0.19	-0.13	Lung cancer;	chr15:43388014	chr15:43726918~43747094:-
BRCA	cis	rs6570726	1	rs436066	ENSG00000270638.1	RP3-466P17.1	4.23	2.59e-05	0.00191	0.14	0.13	Lobe attachment (rater-scored or self-reported);	chr6:145525991	chr6:145735570~145737218:+
BRCA	cis	rs11098499	0.697	rs35280960	ENSG00000225892.3	RP11-384K6.2	4.23	2.59e-05	0.00191	0.13	0.13	Corneal astigmatism;	chr4:119335904	chr4:118632274~118634759:+
BRCA	cis	rs8114671	0.836	rs6060165	ENSG00000279253.1	RP4-614O4.13	4.23	2.59e-05	0.00192	0.15	0.13	Height;	chr20:35031677	chr20:35262727~35264187:-
BRCA	cis	rs10995356	0.932	rs7902607	ENSG00000238280.1	RP11-436D10.3	-4.23	2.59e-05	0.00192	-0.17	-0.13	Temperament;	chr10:62914708	chr10:62793562~62805887:-
BRCA	cis	rs853679	0.882	rs2743555	ENSG00000280107.1	AL022393.9	-4.23	2.59e-05	0.00192	-0.23	-0.13	Depression;	chr6:28273304	chr6:28170845~28172521:+
BRCA	cis	rs10411936	0.962	rs10404046	ENSG00000280332.1	CTD-2013N17.6	4.23	2.59e-05	0.00192	0.11	0.13	Multiple sclerosis;White blood cell count;	chr19:16366444	chr19:16356329~16358327:-
BRCA	cis	rs12446632	0.941	rs7204864	ENSG00000261195.1	CTD-2380F24.1	-4.23	2.59e-05	0.00192	-0.21	-0.13	Hip circumference;Body mass index (joint analysis main effects and smoking interaction);BMI in smokers;Menarche (age at onset);Obesity;Childhood body mass index;Waist circumference;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Body mass index;	chr16:19931605	chr16:19761172~19766099:-
BRCA	cis	rs11250097	0.507	rs2409779	ENSG00000154316.13	TDH	4.23	2.59e-05	0.00192	0.18	0.13	Neuroticism;	chr8:11453831	chr8:11339637~11368452:+
BRCA	cis	rs2839186	0.771	rs2280959	ENSG00000239415.1	AP001469.9	4.23	2.59e-05	0.00192	0.14	0.13	Testicular germ cell tumor;	chr21:46222082	chr21:46251549~46254133:-
BRCA	cis	rs2839186	0.739	rs2280958	ENSG00000239415.1	AP001469.9	4.23	2.59e-05	0.00192	0.14	0.13	Testicular germ cell tumor;	chr21:46222102	chr21:46251549~46254133:-
BRCA	cis	rs6736093	0.966	rs35189728	ENSG00000236307.2	EEF1E1P1	-4.23	2.59e-05	0.00192	-0.17	-0.13	Coronary artery disease;	chr2:111962651	chr2:111887914~111888741:+
BRCA	cis	rs13217239	0.574	rs9366680	ENSG00000224843.5	LINC00240	-4.23	2.59e-05	0.00192	-0.15	-0.13	Schizophrenia;	chr6:27038344	chr6:26956992~27023924:+
BRCA	cis	rs9425766	0.64	rs3791020	ENSG00000200674.1	RN7SKP160	-4.23	2.59e-05	0.00192	-0.2	-0.13	Life satisfaction;	chr1:173844059	chr1:173791548~173791887:+
BRCA	cis	rs4780355	0.843	rs413024	ENSG00000262636.1	CTD-3088G3.4	4.23	2.6e-05	0.00192	0.19	0.13	Crohn's disease and psoriasis;	chr16:11260234	chr16:11380859~11381118:-
BRCA	cis	rs2191566	0.664	rs6509138	ENSG00000266921.1	RP11-15A1.7	-4.23	2.6e-05	0.00192	-0.16	-0.13	Acute lymphoblastic leukemia (childhood);	chr19:44066240	chr19:43996896~44002836:-
BRCA	cis	rs62458065	0.85	rs10273165	ENSG00000229358.3	DPY19L1P1	-4.23	2.6e-05	0.00192	-0.18	-0.13	Metabolite levels (HVA/MHPG ratio);	chr7:32421228	chr7:32580949~32761787:-
BRCA	cis	rs875971	0.545	rs3735147	ENSG00000230295.1	RP11-458F8.2	4.23	2.6e-05	0.00192	0.12	0.13	Aortic root size;	chr7:66505541	chr7:66880708~66882981:+
BRCA	cis	rs7833787	1	rs7002237	ENSG00000254054.2	RP11-156K13.3	-4.23	2.6e-05	0.00192	-0.15	-0.13	Obesity-related traits;	chr8:18847004	chr8:17905756~17907887:+
BRCA	cis	rs2243480	0.831	rs7806717	ENSG00000226002.1	RP11-460N20.5	4.23	2.6e-05	0.00192	0.21	0.13	Diabetic kidney disease;	chr7:65928187	chr7:65084103~65100232:+
BRCA	cis	rs2243480	1	rs34933526	ENSG00000226002.1	RP11-460N20.5	-4.23	2.6e-05	0.00192	-0.21	-0.13	Diabetic kidney disease;	chr7:65918212	chr7:65084103~65100232:+
BRCA	cis	rs2243480	1	rs6949812	ENSG00000226002.1	RP11-460N20.5	-4.23	2.6e-05	0.00192	-0.21	-0.13	Diabetic kidney disease;	chr7:65922114	chr7:65084103~65100232:+
BRCA	cis	rs2243480	1	rs6970243	ENSG00000226002.1	RP11-460N20.5	-4.23	2.6e-05	0.00192	-0.21	-0.13	Diabetic kidney disease;	chr7:65923503	chr7:65084103~65100232:+
BRCA	cis	rs2243480	0.708	rs35310401	ENSG00000226002.1	RP11-460N20.5	-4.23	2.6e-05	0.00192	-0.21	-0.13	Diabetic kidney disease;	chr7:65925372	chr7:65084103~65100232:+
BRCA	cis	rs6736093	0.83	rs11680463	ENSG00000236307.2	EEF1E1P1	-4.23	2.6e-05	0.00192	-0.16	-0.13	Coronary artery disease;	chr2:112018034	chr2:111887914~111888741:+
BRCA	cis	rs10504130	0.53	rs4292674	ENSG00000253844.1	RP11-546K22.1	-4.23	2.6e-05	0.00192	-0.19	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr8:51767212	chr8:51961458~52022974:+
BRCA	cis	rs10504130	0.569	rs4292675	ENSG00000253844.1	RP11-546K22.1	-4.23	2.6e-05	0.00192	-0.19	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr8:51767414	chr8:51961458~52022974:+
BRCA	cis	rs10504130	0.569	rs76746661	ENSG00000253844.1	RP11-546K22.1	-4.23	2.6e-05	0.00192	-0.19	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr8:51769206	chr8:51961458~52022974:+
BRCA	cis	rs10504130	0.66	rs79691523	ENSG00000253844.1	RP11-546K22.1	-4.23	2.6e-05	0.00192	-0.19	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr8:51772173	chr8:51961458~52022974:+
BRCA	cis	rs3768617	0.811	rs10797828	ENSG00000224468.3	RP11-181K3.4	-4.23	2.6e-05	0.00192	-0.15	-0.13	Fuchs's corneal dystrophy;	chr1:183059295	chr1:183138402~183141282:-
BRCA	cis	rs10191773	0.535	rs56048537	ENSG00000243389.1	AC012442.5	4.22	2.6e-05	0.00192	0.24	0.13	Yeast infection;	chr2:112320890	chr2:112589040~112614431:+
BRCA	cis	rs78487399	0.808	rs6728106	ENSG00000234936.1	AC010883.5	4.22	2.6e-05	0.00192	0.18	0.13	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43456746	chr2:43229573~43233394:+
BRCA	cis	rs78487399	0.808	rs10203174	ENSG00000234936.1	AC010883.5	4.22	2.6e-05	0.00192	0.18	0.13	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43462891	chr2:43229573~43233394:+
BRCA	cis	rs10849893	0.576	rs889970	ENSG00000258435.1	RP11-711D18.2	-4.22	2.6e-05	0.00192	-0.14	-0.13	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr12:121418414	chr12:121391962~121399859:+
BRCA	cis	rs6439153	0.933	rs1871951	ENSG00000261159.1	RP11-723O4.9	4.22	2.6e-05	0.00192	0.14	0.13	Pneumococcal bacteremia;	chr3:129001644	chr3:128859716~128860526:-
BRCA	cis	rs875971	1	rs875971	ENSG00000236529.1	RP13-254B10.1	-4.22	2.6e-05	0.00192	-0.14	-0.13	Aortic root size;	chr7:66152608	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.965	rs10267430	ENSG00000236529.1	RP13-254B10.1	-4.22	2.6e-05	0.00192	-0.14	-0.13	Aortic root size;	chr7:66278036	chr7:65840212~65840596:+
BRCA	cis	rs950776	0.593	rs555018	ENSG00000279373.1	RP11-650L12.4	-4.22	2.6e-05	0.00192	-0.16	-0.13	Sudden cardiac arrest;	chr15:78586900	chr15:78537681~78538946:+
BRCA	cis	rs7621331	0.963	rs9808979	ENSG00000239213.4	NCK1-AS1	4.22	2.6e-05	0.00192	0.15	0.13	Waist circumference adjusted for body mass index;	chr3:136000456	chr3:136841726~136862054:-
BRCA	cis	rs7621331	1	rs9872542	ENSG00000239213.4	NCK1-AS1	4.22	2.6e-05	0.00192	0.15	0.13	Waist circumference adjusted for body mass index;	chr3:136001831	chr3:136841726~136862054:-
BRCA	cis	rs1910358	0.554	rs1568454	ENSG00000248874.4	C5orf17	-4.22	2.6e-05	0.00192	-0.19	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23756760	chr5:23951348~24178263:+
BRCA	cis	rs1910358	0.554	rs1568455	ENSG00000248874.4	C5orf17	-4.22	2.6e-05	0.00192	-0.19	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23756769	chr5:23951348~24178263:+
BRCA	cis	rs2243480	1	rs67728539	ENSG00000222364.1	RNU6-96P	-4.22	2.6e-05	0.00193	-0.23	-0.13	Diabetic kidney disease;	chr7:65913137	chr7:66395191~66395286:+
BRCA	cis	rs7932354	0.55	rs10734549	ENSG00000200376.1	RNU5E-10P	4.22	2.6e-05	0.00193	0.16	0.13	Bone mineral density (hip);Bone mineral density;	chr11:46801136	chr11:47576471~47576588:-
BRCA	cis	rs745109	0.832	rs72932364	ENSG00000273080.1	RP11-301O19.1	4.22	2.6e-05	0.00193	0.2	0.13	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86524227	chr2:86195590~86196049:+
BRCA	cis	rs1876905	0.68	rs395564	ENSG00000255389.1	C6orf3	4.22	2.61e-05	0.00193	0.16	0.13	Mean corpuscular hemoglobin;	chr6:111176176	chr6:111599875~111602295:+
BRCA	cis	rs4489787	1	rs80211218	ENSG00000240399.1	RP1-228P16.1	-4.22	2.61e-05	0.00193	-0.25	-0.13	Prostate cancer (SNP x SNP interaction);	chr12:48558266	chr12:48054813~48055591:-
BRCA	cis	rs2243480	1	rs35046236	ENSG00000226002.1	RP11-460N20.5	-4.22	2.61e-05	0.00193	-0.21	-0.13	Diabetic kidney disease;	chr7:65943626	chr7:65084103~65100232:+
BRCA	cis	rs2243480	1	rs36068983	ENSG00000226002.1	RP11-460N20.5	-4.22	2.61e-05	0.00193	-0.21	-0.13	Diabetic kidney disease;	chr7:65944004	chr7:65084103~65100232:+
BRCA	cis	rs2243480	1	rs68189316	ENSG00000226002.1	RP11-460N20.5	-4.22	2.61e-05	0.00193	-0.21	-0.13	Diabetic kidney disease;	chr7:65944182	chr7:65084103~65100232:+
BRCA	cis	rs9393777	0.623	rs13211166	ENSG00000220721.1	OR1F12	4.22	2.61e-05	0.00193	0.19	0.13	Intelligence (multi-trait analysis);	chr6:27298161	chr6:28073316~28074233:+
BRCA	cis	rs7727544	0.582	rs3805683	ENSG00000233006.5	AC034220.3	4.22	2.61e-05	0.00193	0.1	0.13	Blood metabolite levels;	chr5:132199432	chr5:132311285~132369916:-
BRCA	cis	rs13098911	0.54	rs71327021	ENSG00000223552.1	RP11-24F11.2	-4.22	2.61e-05	0.00193	-0.22	-0.13	Celiac disease;	chr3:46079025	chr3:46364955~46407059:-
BRCA	cis	rs4494364	0.502	rs1920778	ENSG00000258100.1	RP11-121E16.1	4.22	2.61e-05	0.00193	0.18	0.13	Systolic blood pressure (alcohol consumption interaction);	chr12:91034255	chr12:91362196~91368606:+
BRCA	cis	rs4237845	0.537	rs12312955	ENSG00000270039.1	RP11-571M6.17	-4.22	2.61e-05	0.00193	-0.18	-0.13	Intelligence (multi-trait analysis);	chr12:57871440	chr12:57803838~57804415:+
BRCA	cis	rs2880765	0.835	rs7161880	ENSG00000202081.1	RNU6-1280P	4.22	2.61e-05	0.00193	0.15	0.13	Coronary artery disease;	chr15:85475515	chr15:85651522~85651628:-
BRCA	cis	rs10771431	0.782	rs10771415	ENSG00000256427.1	RP11-118B22.4	4.22	2.61e-05	0.00193	0.13	0.13	Breast size;	chr12:9205627	chr12:9246497~9257960:+
BRCA	cis	rs62025270	0.848	rs2554	ENSG00000259762.1	RP11-158M2.4	-4.22	2.61e-05	0.00193	-0.19	-0.13	Idiopathic pulmonary fibrosis;	chr15:85759412	chr15:85750336~85752901:-
BRCA	cis	rs74665712	0.591	rs4609105	ENSG00000232400.1	RAD17P1	4.22	2.61e-05	0.00193	0.14	0.13	Residual cognition;	chr7:16918049	chr7:16864267~16866308:-
BRCA	cis	rs74665712	0.591	rs12532502	ENSG00000232400.1	RAD17P1	4.22	2.61e-05	0.00193	0.14	0.13	Residual cognition;	chr7:16918062	chr7:16864267~16866308:-
BRCA	cis	rs7429990	0.965	rs7651237	ENSG00000199476.1	Y_RNA	4.22	2.61e-05	0.00193	0.19	0.13	Educational attainment (years of education);	chr3:48064038	chr3:48288587~48288694:+
BRCA	cis	rs7772486	0.774	rs6930181	ENSG00000270638.1	RP3-466P17.1	-4.22	2.61e-05	0.00193	-0.14	-0.13	Lobe attachment (rater-scored or self-reported);	chr6:145859838	chr6:145735570~145737218:+
BRCA	cis	rs610932	0.517	rs666555	ENSG00000275344.1	MIR6503	4.22	2.61e-05	0.00193	0.13	0.13	Alzheimer's disease;	chr11:60203511	chr11:60209071~60209156:-
BRCA	cis	rs375066	0.935	rs10406290	ENSG00000267191.1	RP11-15A1.2	-4.22	2.61e-05	0.00193	-0.17	-0.13	Breast cancer;	chr19:43874725	chr19:43902001~43926545:+
BRCA	cis	rs957448	1	rs72674852	ENSG00000254315.1	RP11-267M23.3	4.22	2.61e-05	0.00193	0.18	0.13	Nonsyndromic cleft lip with cleft palate;	chr8:94536523	chr8:94533628~94534391:+
BRCA	cis	rs8040855	0.557	rs9744503	ENSG00000259762.1	RP11-158M2.4	-4.22	2.61e-05	0.00193	-0.15	-0.13	Bulimia nervosa;	chr15:85180986	chr15:85750336~85752901:-
BRCA	cis	rs1048886	0.808	rs2293297	ENSG00000271967.1	RP11-134K13.4	-4.22	2.61e-05	0.00193	-0.18	-0.13	Type 2 diabetes;	chr6:70567100	chr6:70596438~70596980:+
BRCA	cis	rs10829156	0.947	rs10764661	ENSG00000240291.1	RP11-499P20.2	4.22	2.61e-05	0.00193	0.15	0.13	Sudden cardiac arrest;	chr10:18659018	chr10:18513115~18545651:-
BRCA	cis	rs11673344	0.526	rs17303902	ENSG00000267422.1	CTD-2554C21.1	4.22	2.62e-05	0.00193	0.18	0.13	Obesity-related traits;	chr19:37551912	chr19:37779686~37792865:+
BRCA	cis	rs11673344	0.526	rs55754546	ENSG00000267422.1	CTD-2554C21.1	4.22	2.62e-05	0.00193	0.18	0.13	Obesity-related traits;	chr19:37552860	chr19:37779686~37792865:+
BRCA	cis	rs6585424	1	rs6585454	ENSG00000225484.5	NUTM2B-AS1	4.22	2.62e-05	0.00193	0.25	0.13	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80180945	chr10:79663088~79826594:-
BRCA	cis	rs62064224	0.589	rs2344976	ENSG00000279781.1	RP11-466A19.7	4.22	2.62e-05	0.00193	0.16	0.13	Schizophrenia;	chr17:32358916	chr17:32518322~32518934:-
BRCA	cis	rs11051970	0.659	rs904917	ENSG00000274964.1	RP11-817I4.1	-4.22	2.62e-05	0.00193	-0.16	-0.13	Response to tocilizumab in rheumatoid arthritis;	chr12:32438368	chr12:32339368~32340724:+
BRCA	cis	rs7246657	0.551	rs12972146	ENSG00000267470.4	ZNF571-AS1	4.22	2.62e-05	0.00193	0.2	0.13	Coronary artery calcification;	chr19:37135193	chr19:37548914~37587348:+
BRCA	cis	rs12681366	0.553	rs2930967	ENSG00000253704.1	RP11-267M23.4	-4.22	2.62e-05	0.00193	-0.14	-0.13	Nonsyndromic cleft lip with cleft palate;	chr8:94450371	chr8:94553722~94569745:+
BRCA	cis	rs11083475	1	rs979971	ENSG00000267892.1	CTD-2540F13.2	4.22	2.62e-05	0.00193	0.15	0.13	Heart rate;	chr19:38653604	chr19:38738284~38739863:+
BRCA	cis	rs748404	0.666	rs16957680	ENSG00000205771.5	CATSPER2P1	-4.22	2.62e-05	0.00193	-0.19	-0.13	Lung cancer;	chr15:43396207	chr15:43726918~43747094:-
BRCA	cis	rs2380205	0.967	rs713588	ENSG00000232807.2	RP11-536K7.3	4.22	2.62e-05	0.00193	0.13	0.13	Breast cancer;	chr10:5844999	chr10:5934270~5945900:-
BRCA	cis	rs2108622	0.727	rs7253873	ENSG00000267218.2	AC005336.5	4.22	2.62e-05	0.00193	0.15	0.13	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15870090	chr19:15902300~15903238:-
BRCA	cis	rs7260598	0.642	rs8101310	ENSG00000268442.1	CTD-2027I19.2	4.22	2.62e-05	0.00193	0.2	0.13	Response to taxane treatment (placlitaxel);	chr19:23961137	chr19:24162370~24163425:-
BRCA	cis	rs9788721	0.836	rs72738732	ENSG00000261762.1	RP11-650L12.2	-4.22	2.62e-05	0.00194	-0.17	-0.13	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78459846	chr15:78589123~78591276:-
BRCA	cis	rs6496044	0.611	rs6496055	ENSG00000202081.1	RNU6-1280P	4.22	2.62e-05	0.00194	0.15	0.13	Interstitial lung disease;	chr15:85527457	chr15:85651522~85651628:-
BRCA	cis	rs6751744	0.513	rs7563368	ENSG00000226266.5	AC009961.3	4.22	2.62e-05	0.00194	0.16	0.13	Dysphagia;	chr2:159600564	chr2:159670708~159712435:-
BRCA	cis	rs71520386	0.846	rs13243243	ENSG00000230658.1	KLHL7-AS1	-4.22	2.62e-05	0.00194	-0.22	-0.13	Fibrinogen levels;	chr7:22781400	chr7:23101228~23105703:-
BRCA	cis	rs7142002	0.881	rs1904298	ENSG00000271780.1	RP11-1017G21.5	4.22	2.62e-05	0.00194	0.17	0.13	Autism;	chr14:101890138	chr14:101948347~101949425:+
BRCA	cis	rs2243480	1	rs73142162	ENSG00000222364.1	RNU6-96P	-4.22	2.62e-05	0.00194	-0.24	-0.13	Diabetic kidney disease;	chr7:65909309	chr7:66395191~66395286:+
BRCA	cis	rs7267979	1	rs6083844	ENSG00000125804.12	FAM182A	4.22	2.62e-05	0.00194	0.17	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25406196	chr20:26054655~26086917:+
BRCA	cis	rs4835473	0.801	rs999049	ENSG00000249741.2	RP11-673E1.3	4.22	2.63e-05	0.00194	0.15	0.13	Immature fraction of reticulocytes;	chr4:143715440	chr4:143911514~143912053:-
BRCA	cis	rs11633886	0.528	rs2899383	ENSG00000273972.1	CTD-2306A12.1	4.22	2.63e-05	0.00194	0.15	0.13	Diisocyanate-induced asthma;	chr15:45804853	chr15:45702640~45703183:+
BRCA	cis	rs7727544	0.582	rs3792894	ENSG00000233006.5	AC034220.3	4.22	2.63e-05	0.00194	0.09	0.13	Blood metabolite levels;	chr5:132211578	chr5:132311285~132369916:-
BRCA	cis	rs11662586	0.517	rs7228070	ENSG00000261126.6	RP11-795F19.1	4.22	2.63e-05	0.00194	0.12	0.13	Exploratory eye movement dysfunction in schizophrenia (responsive search score);	chr18:79938967	chr18:80046900~80095482:+
BRCA	cis	rs11098499	0.954	rs3733520	ENSG00000250412.1	KLHL2P1	4.22	2.63e-05	0.00194	0.15	0.13	Corneal astigmatism;	chr4:119502325	chr4:119334329~119378233:+
BRCA	cis	rs2625529	0.652	rs2957735	ENSG00000260037.4	CTD-2524L6.3	4.22	2.63e-05	0.00194	0.16	0.13	Red blood cell count;	chr15:71972832	chr15:71818396~71823384:+
BRCA	cis	rs875971	0.862	rs709609	ENSG00000271064.1	RP11-792A8.3	4.22	2.63e-05	0.00194	0.16	0.13	Aortic root size;	chr7:66095574	chr7:66748838~66749077:-
BRCA	cis	rs10043228	1	rs10079394	ENSG00000271918.1	CTD-2287O16.5	-4.22	2.63e-05	0.00194	-0.17	-0.13	Asthma or chronic obstructive pulmonary disease;	chr5:116265222	chr5:116083807~116085416:-
BRCA	cis	rs2255336	0.938	rs2734561	ENSG00000245648.1	RP11-277P12.20	4.22	2.63e-05	0.00194	0.19	0.13	Blood protein levels;	chr12:10402386	chr12:10363769~10398506:+
BRCA	cis	rs11096990	0.656	rs3796513	ENSG00000249685.1	RP11-360F5.3	-4.22	2.63e-05	0.00194	-0.16	-0.13	Cognitive function;	chr4:39289462	chr4:39133913~39135608:+
BRCA	cis	rs11096990	0.634	rs10029074	ENSG00000249685.1	RP11-360F5.3	-4.22	2.63e-05	0.00194	-0.16	-0.13	Cognitive function;	chr4:39290882	chr4:39133913~39135608:+
BRCA	cis	rs11096990	0.634	rs1564710	ENSG00000249685.1	RP11-360F5.3	-4.22	2.63e-05	0.00194	-0.16	-0.13	Cognitive function;	chr4:39291178	chr4:39133913~39135608:+
BRCA	cis	rs4950322	0.512	rs4625342	ENSG00000244371.2	PFN1P8	4.22	2.63e-05	0.00194	0.15	0.13	Protein quantitative trait loci;	chr1:147369887	chr1:146957117~146957659:-
BRCA	cis	rs8180040	1	rs1076394	ENSG00000276925.1	RP11-708J19.3	4.22	2.63e-05	0.00194	0.15	0.13	Colorectal cancer;	chr3:47281291	chr3:47469777~47469987:+
BRCA	cis	rs8180040	0.966	rs17476234	ENSG00000276925.1	RP11-708J19.3	4.22	2.63e-05	0.00194	0.15	0.13	Colorectal cancer;	chr3:47284808	chr3:47469777~47469987:+
BRCA	cis	rs10181042	0.514	rs1177288	ENSG00000212978.6	AC016747.3	4.22	2.63e-05	0.00194	0.17	0.13	Crohn's disease;	chr2:61125850	chr2:61141592~61144969:-
BRCA	cis	rs792448	0.743	rs2516331	ENSG00000229983.1	RP11-15I11.2	4.22	2.63e-05	0.00194	0.16	0.13	White blood cell count (basophil);	chr1:212243647	chr1:212168207~212190259:+
BRCA	cis	rs321358	0.895	rs73015151	ENSG00000271390.1	RP11-89C3.3	4.22	2.63e-05	0.00194	0.19	0.13	Body mass index;	chr11:111084669	chr11:111089870~111090368:-
BRCA	cis	rs321358	0.895	rs17535886	ENSG00000271390.1	RP11-89C3.3	4.22	2.63e-05	0.00194	0.19	0.13	Body mass index;	chr11:111084852	chr11:111089870~111090368:-
BRCA	cis	rs2191566	0.639	rs7260075	ENSG00000266921.1	RP11-15A1.7	-4.22	2.63e-05	0.00194	-0.16	-0.13	Acute lymphoblastic leukemia (childhood);	chr19:44062613	chr19:43996896~44002836:-
BRCA	cis	rs4819052	0.851	rs2838831	ENSG00000215447.6	BX322557.10	-4.22	2.63e-05	0.00194	-0.13	-0.13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244860	chr21:45288052~45291738:+
BRCA	cis	rs6547741	1	rs7604798	ENSG00000234072.1	AC074117.10	4.22	2.63e-05	0.00194	0.12	0.13	Oral cavity cancer;	chr2:27602073	chr2:27356246~27367622:+
BRCA	cis	rs7771547	0.574	rs9349001	ENSG00000224666.3	RP1-50J22.4	4.22	2.63e-05	0.00194	0.16	0.13	Platelet distribution width;	chr6:36582904	chr6:36386831~36393462:+
BRCA	cis	rs17092148	1	rs17092148	ENSG00000202150.1	RNU6-407P	4.22	2.63e-05	0.00194	0.19	0.13	Neuroticism;	chr20:34847358	chr20:35030317~35030420:-
BRCA	cis	rs9840812	0.728	rs12630999	ENSG00000273486.1	RP11-731C17.2	4.22	2.63e-05	0.00194	0.16	0.13	Fibrinogen levels;	chr3:136582085	chr3:136837338~136839021:-
BRCA	cis	rs1048886	0.872	rs7757026	ENSG00000271967.1	RP11-134K13.4	-4.22	2.63e-05	0.00194	-0.18	-0.13	Type 2 diabetes;	chr6:70570891	chr6:70596438~70596980:+
BRCA	cis	rs1048886	0.872	rs12197942	ENSG00000271967.1	RP11-134K13.4	-4.22	2.63e-05	0.00194	-0.18	-0.13	Type 2 diabetes;	chr6:70571649	chr6:70596438~70596980:+
BRCA	cis	rs1048886	0.872	rs12197963	ENSG00000271967.1	RP11-134K13.4	-4.22	2.63e-05	0.00194	-0.18	-0.13	Type 2 diabetes;	chr6:70571718	chr6:70596438~70596980:+
BRCA	cis	rs1048886	0.872	rs73480275	ENSG00000271967.1	RP11-134K13.4	-4.22	2.63e-05	0.00194	-0.18	-0.13	Type 2 diabetes;	chr6:70572421	chr6:70596438~70596980:+
BRCA	cis	rs8113308	0.81	rs17695737	ENSG00000269483.1	AC006272.1	4.22	2.63e-05	0.00194	0.24	0.13	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51942283	chr19:51839924~51843324:-
BRCA	cis	rs9921338	0.961	rs7199821	ENSG00000262636.1	CTD-3088G3.4	-4.22	2.63e-05	0.00194	-0.21	-0.13	Vein graft stenosis in coronary artery bypass grafting;	chr16:11331154	chr16:11380859~11381118:-
BRCA	cis	rs28374715	0.733	rs7167706	ENSG00000247556.5	OIP5-AS1	4.22	2.63e-05	0.00194	0.15	0.13	Ulcerative colitis;	chr15:41277446	chr15:41283990~41309737:+
BRCA	cis	rs12477438	0.765	rs10193039	ENSG00000231822.1	AC019097.7	-4.22	2.63e-05	0.00194	-0.14	-0.13	Chronic sinus infection;	chr2:99075910	chr2:99102018~99102752:+
BRCA	cis	rs7116495	0.609	rs2503	ENSG00000248671.6	ALG1L9P	4.22	2.63e-05	0.00194	0.31	0.13	Severe influenza A (H1N1) infection;	chr11:72008357	chr11:71794363~71818238:-
BRCA	cis	rs7267979	0.932	rs446649	ENSG00000125804.12	FAM182A	-4.22	2.63e-05	0.00194	-0.17	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25486723	chr20:26054655~26086917:+
BRCA	cis	rs7267979	0.873	rs6132822	ENSG00000276952.1	RP5-965G21.6	4.22	2.63e-05	0.00194	0.16	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25248059	chr20:25284915~25285588:-
BRCA	cis	rs1910358	0.554	rs7735359	ENSG00000248874.4	C5orf17	-4.22	2.63e-05	0.00195	-0.18	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23757806	chr5:23951348~24178263:+
BRCA	cis	rs465969	1	rs17090837	ENSG00000272356.1	RP5-1112D6.8	4.22	2.64e-05	0.00195	0.28	0.13	Psoriasis;	chr6:111430650	chr6:111309203~111313517:+
BRCA	cis	rs465969	1	rs35208445	ENSG00000272356.1	RP5-1112D6.8	4.22	2.64e-05	0.00195	0.28	0.13	Psoriasis;	chr6:111434944	chr6:111309203~111313517:+
BRCA	cis	rs465969	1	rs35248830	ENSG00000272356.1	RP5-1112D6.8	4.22	2.64e-05	0.00195	0.28	0.13	Psoriasis;	chr6:111435547	chr6:111309203~111313517:+
BRCA	cis	rs465969	1	rs35151650	ENSG00000272356.1	RP5-1112D6.8	4.22	2.64e-05	0.00195	0.28	0.13	Psoriasis;	chr6:111436524	chr6:111309203~111313517:+
BRCA	cis	rs465969	0.744	rs34089926	ENSG00000272356.1	RP5-1112D6.8	4.22	2.64e-05	0.00195	0.28	0.13	Psoriasis;	chr6:111439043	chr6:111309203~111313517:+
BRCA	cis	rs465969	1	rs4580915	ENSG00000272356.1	RP5-1112D6.8	4.22	2.64e-05	0.00195	0.28	0.13	Psoriasis;	chr6:111439561	chr6:111309203~111313517:+
BRCA	cis	rs11603691	1	rs2155233	ENSG00000254662.1	RP11-872D17.4	-4.22	2.64e-05	0.00195	-0.29	-0.13	Low high density lipoprotein cholesterol levels;	chr11:57274518	chr11:57325603~57327958:+
BRCA	cis	rs7481584	0.564	rs432585	ENSG00000236710.1	AC108448.2	4.22	2.64e-05	0.00195	0.18	0.13	Calcium levels;	chr11:3063673	chr11:3084393~3085443:-
BRCA	cis	rs35306767	0.909	rs12264390	ENSG00000229869.1	RP11-363N22.2	-4.22	2.64e-05	0.00195	-0.19	-0.13	Eosinophil percentage of granulocytes;	chr10:913171	chr10:933026~942743:+
BRCA	cis	rs7267979	1	rs11087520	ENSG00000274414.1	RP5-965G21.4	-4.22	2.64e-05	0.00195	-0.15	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25456191	chr20:25239007~25245229:-
BRCA	cis	rs11742741	0.805	rs62349713	ENSG00000248874.4	C5orf17	-4.22	2.64e-05	0.00195	-0.17	-0.13	Educational attainment;	chr5:24026836	chr5:23951348~24178263:+
BRCA	cis	rs2109514	0.84	rs10228178	ENSG00000237813.3	AC002066.1	4.22	2.64e-05	0.00195	0.16	0.13	Prevalent atrial fibrillation;	chr7:116492157	chr7:116238260~116499465:-
BRCA	cis	rs409045	1	rs456108	ENSG00000271874.1	CTD-2024P10.2	-4.22	2.64e-05	0.00195	-0.17	-0.13	Left ventricular mass;	chr5:34636885	chr5:34651457~34651888:-
BRCA	cis	rs8180040	0.676	rs13098228	ENSG00000276925.1	RP11-708J19.3	-4.22	2.64e-05	0.00195	-0.15	-0.13	Colorectal cancer;	chr3:47096763	chr3:47469777~47469987:+
BRCA	cis	rs61160187	0.517	rs6884966	ENSG00000272308.1	RP11-231G3.1	-4.22	2.64e-05	0.00195	-0.15	-0.13	Educational attainment (years of education);Educational attainment (college completion);	chr5:60897512	chr5:60866457~60866935:-
BRCA	cis	rs12612619	0.667	rs7605526	ENSG00000272148.1	RP11-195B17.1	4.22	2.64e-05	0.00195	0.15	0.13	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27122616	chr2:27062428~27062907:-
BRCA	cis	rs9952991	0.883	rs2542148	ENSG00000260302.1	RP11-973H7.1	-4.22	2.64e-05	0.00195	-0.21	-0.13	Inflammatory skin disease;	chr18:12777574	chr18:12774651~12775923:-
BRCA	cis	rs332034	0.591	rs7017739	ENSG00000253893.2	FAM85B	4.22	2.64e-05	0.00195	0.23	0.13	Conduct disorder (maternal expressed emotions interaction);	chr8:8850129	chr8:8167819~8226614:-
BRCA	cis	rs6840360	0.582	rs2724555	ENSG00000251603.1	RP11-164P12.4	-4.22	2.64e-05	0.00195	-0.12	-0.13	Intelligence (multi-trait analysis);	chr4:151420726	chr4:151667224~151670502:+
BRCA	cis	rs3753275	0.69	rs6577500	ENSG00000232912.4	RP5-1115A15.1	4.22	2.64e-05	0.00195	0.16	0.13	Educational attainment;	chr1:8554512	chr1:8424645~8434838:+
BRCA	cis	rs55780018	0.675	rs10932201	ENSG00000224137.1	AC079767.4	4.22	2.64e-05	0.00195	0.11	0.13	Systolic blood pressure;	chr2:207561533	chr2:207662375~207667024:+
BRCA	cis	rs3930017	0.513	rs3930018	ENSG00000265479.4	DTX2P1-UPK3BP1-PMS2P11	4.22	2.64e-05	0.00195	0.16	0.13	Body mass index;	chr7:77091318	chr7:76980949~77043775:+
BRCA	cis	rs2243480	1	rs1723270	ENSG00000275400.1	RP4-756H11.5	4.22	2.64e-05	0.00195	0.23	0.13	Diabetic kidney disease;	chr7:66004843	chr7:66553805~66554199:-
BRCA	cis	rs73201462	0.901	rs17282209	ENSG00000242551.2	POU5F1P6	4.22	2.64e-05	0.00195	0.24	0.13	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:127996353	chr3:128674735~128677005:-
BRCA	cis	rs7772486	0.875	rs7739371	ENSG00000270638.1	RP3-466P17.1	4.22	2.64e-05	0.00195	0.15	0.13	Lobe attachment (rater-scored or self-reported);	chr6:146103217	chr6:145735570~145737218:+
BRCA	cis	rs6893300	0.826	rs7734102	ENSG00000225051.5	HMGB3P22	-4.22	2.64e-05	0.00195	-0.16	-0.13	Resting heart rate;	chr5:179726796	chr5:179679032~179694768:+
BRCA	cis	rs78487399	0.808	rs17031001	ENSG00000234936.1	AC010883.5	4.22	2.64e-05	0.00195	0.19	0.13	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43534079	chr2:43229573~43233394:+
BRCA	cis	rs11098499	0.954	rs4577559	ENSG00000260091.1	RP11-33B1.4	-4.22	2.64e-05	0.00195	-0.12	-0.13	Corneal astigmatism;	chr4:119482888	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.954	rs7656252	ENSG00000260091.1	RP11-33B1.4	-4.22	2.64e-05	0.00195	-0.12	-0.13	Corneal astigmatism;	chr4:119483113	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.865	rs28845498	ENSG00000260091.1	RP11-33B1.4	-4.22	2.64e-05	0.00195	-0.12	-0.13	Corneal astigmatism;	chr4:119484031	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.954	rs56270433	ENSG00000260091.1	RP11-33B1.4	-4.22	2.64e-05	0.00195	-0.12	-0.13	Corneal astigmatism;	chr4:119484875	chr4:119409333~119410233:+
BRCA	cis	rs10844706	0.666	rs10844609	ENSG00000256673.1	RP11-599J14.2	-4.22	2.64e-05	0.00195	-0.16	-0.13	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9723909	chr12:9398355~9414851:-
BRCA	cis	rs737008	0.96	rs11640295	ENSG00000262636.1	CTD-3088G3.4	4.22	2.64e-05	0.00195	0.18	0.13	Obesity-related traits;	chr16:11296871	chr16:11380859~11381118:-
BRCA	cis	rs8114671	0.662	rs6088664	ENSG00000126005.14	MMP24-AS1	-4.22	2.64e-05	0.00195	-0.15	-0.13	Height;	chr20:34963297	chr20:35216462~35278131:-
BRCA	cis	rs950776	0.684	rs692780	ENSG00000279373.1	RP11-650L12.4	-4.22	2.64e-05	0.00195	-0.16	-0.13	Sudden cardiac arrest;	chr15:78584163	chr15:78537681~78538946:+
BRCA	cis	rs6490294	0.571	rs7316563	ENSG00000234608.6	MAPKAPK5-AS1	4.22	2.64e-05	0.00195	0.19	0.13	Mean platelet volume;	chr12:112015831	chr12:111839764~111842902:-
BRCA	cis	rs4143844	0.867	rs71411468	ENSG00000259251.2	RP11-643M14.1	4.22	2.64e-05	0.00195	0.32	0.13	Bipolar disorder and schizophrenia;	chr15:61894514	chr15:62060503~62062434:+
BRCA	cis	rs7923837	0.616	rs12219514	ENSG00000236493.2	EIF2S2P3	4.22	2.64e-05	0.00195	0.17	0.13	Multiple sclerosis;Body mass index;	chr10:92706682	chr10:92668745~92669743:-
BRCA	cis	rs801193	1	rs7785213	ENSG00000223473.2	GS1-124K5.3	-4.22	2.64e-05	0.00195	-0.1	-0.13	Aortic root size;	chr7:66673991	chr7:66491049~66493566:-
BRCA	cis	rs2832191	0.716	rs1888439	ENSG00000232855.5	AF131217.1	-4.22	2.64e-05	0.00195	-0.16	-0.13	Dental caries;	chr21:29082136	chr21:28439346~28674848:-
BRCA	cis	rs494453	0.922	rs531083	ENSG00000227811.2	FAM212B-AS1	-4.22	2.65e-05	0.00195	-0.17	-0.13	Osteoporosis-related phenotypes;	chr1:111680532	chr1:111739841~111747798:+
BRCA	cis	rs11098499	0.865	rs11098513	ENSG00000260091.1	RP11-33B1.4	-4.22	2.65e-05	0.00195	-0.11	-0.13	Corneal astigmatism;	chr4:119394920	chr4:119409333~119410233:+
BRCA	cis	rs3764021	0.87	rs7956831	ENSG00000256582.1	RP11-75L1.1	-4.22	2.65e-05	0.00195	-0.13	-0.13	Type 1 diabetes;	chr12:9736561	chr12:9704077~9709350:+
BRCA	cis	rs13217239	0.646	rs6456767	ENSG00000224843.5	LINC00240	4.22	2.65e-05	0.00195	0.15	0.13	Schizophrenia;	chr6:27102764	chr6:26956992~27023924:+
BRCA	cis	rs490234	0.588	rs34983978	ENSG00000232630.1	PRPS1P2	-4.22	2.65e-05	0.00195	-0.14	-0.13	Mean arterial pressure;	chr9:125406891	chr9:125150653~125151589:+
BRCA	cis	rs11168187	0.506	rs12812960	ENSG00000257433.4	RP1-197B17.3	4.22	2.65e-05	0.00195	0.16	0.13	Vertical cup-disc ratio;	chr12:47729395	chr12:47706085~47742294:+
BRCA	cis	rs997295	0.713	rs10518739	ENSG00000270964.1	RP11-502I4.3	4.22	2.65e-05	0.00195	0.15	0.13	Motion sickness;	chr15:67722633	chr15:67541072~67542604:-
BRCA	cis	rs2562456	0.558	rs62108173	ENSG00000240522.1	RPL7AP10	-4.22	2.65e-05	0.00196	-0.16	-0.13	Pain;	chr19:21244386	chr19:21149648~21150438:-
BRCA	cis	rs7824557	0.707	rs3808519	ENSG00000154316.13	TDH	-4.22	2.65e-05	0.00196	-0.17	-0.13	Retinal vascular caliber;	chr8:11285461	chr8:11339637~11368452:+
BRCA	cis	rs6596100	0.956	rs13718	ENSG00000248648.1	RP11-485M7.1	-4.22	2.65e-05	0.00196	-0.17	-0.13	Breast cancer;	chr5:133105610	chr5:133003119~133003365:+
BRCA	cis	rs2688608	0.592	rs7923045	ENSG00000272140.2	RP11-574K11.29	4.22	2.65e-05	0.00196	0.12	0.13	Inflammatory bowel disease;	chr10:73727740	chr10:73703735~73713581:-
BRCA	cis	rs3812762	0.912	rs10769953	ENSG00000254860.4	TMEM9B-AS1	-4.22	2.65e-05	0.00196	-0.12	-0.13	Hypospadias;	chr11:8756805	chr11:8964675~8977527:+
BRCA	cis	rs7267979	0.966	rs2387882	ENSG00000125804.12	FAM182A	4.22	2.65e-05	0.00196	0.17	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25398166	chr20:26054655~26086917:+
BRCA	cis	rs2304003	1	rs1560595	ENSG00000235192.1	AC009495.2	-4.22	2.65e-05	0.00196	-0.15	-0.13	Social communication problems;	chr2:165843358	chr2:165794851~165810010:+
BRCA	cis	rs2439831	0.85	rs28504496	ENSG00000206991.1	RNU6-610P	-4.22	2.65e-05	0.00196	-0.21	-0.13	Lung cancer in ever smokers;	chr15:43724685	chr15:43637632~43637738:-
BRCA	cis	rs1974653	0.567	rs7284822	ENSG00000236540.6	AC006547.13	-4.22	2.65e-05	0.00196	-0.16	-0.13	Schizophrenia;	chr22:20069555	chr22:20058030~20070569:-
BRCA	cis	rs4494364	0.502	rs1920780	ENSG00000258100.1	RP11-121E16.1	4.22	2.65e-05	0.00196	0.18	0.13	Systolic blood pressure (alcohol consumption interaction);	chr12:91034193	chr12:91362196~91368606:+
BRCA	cis	rs7932354	0.583	rs7480140	ENSG00000200376.1	RNU5E-10P	4.22	2.65e-05	0.00196	0.16	0.13	Bone mineral density (hip);Bone mineral density;	chr11:46834784	chr11:47576471~47576588:-
BRCA	cis	rs2253762	0.609	rs10887057	ENSG00000276742.1	RP11-500G22.4	4.22	2.65e-05	0.00196	0.2	0.13	Breast cancer;	chr10:122043799	chr10:121956782~121957098:+
BRCA	cis	rs2243480	0.808	rs12698508	ENSG00000222364.1	RNU6-96P	-4.22	2.65e-05	0.00196	-0.24	-0.13	Diabetic kidney disease;	chr7:65946971	chr7:66395191~66395286:+
BRCA	cis	rs224278	0.584	rs752602	ENSG00000238280.1	RP11-436D10.3	-4.22	2.66e-05	0.00196	-0.17	-0.13	Ewing sarcoma;	chr10:62831797	chr10:62793562~62805887:-
BRCA	cis	rs2692947	0.702	rs7604842	ENSG00000168992.4	OR7E102P	-4.22	2.66e-05	0.00196	-0.18	-0.13	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96111592	chr2:95546531~95547545:+
BRCA	cis	rs2108622	0.527	rs67617968	ENSG00000267218.2	AC005336.5	4.22	2.66e-05	0.00196	0.15	0.13	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15866755	chr19:15902300~15903238:-
BRCA	cis	rs10833905	1	rs876092	ENSG00000246225.5	RP11-17A1.3	-4.22	2.66e-05	0.00196	-0.18	-0.13	Sudden cardiac arrest;	chr11:23021075	chr11:22829380~22945393:+
BRCA	cis	rs9921338	0.923	rs72771877	ENSG00000262636.1	CTD-3088G3.4	-4.22	2.66e-05	0.00196	-0.21	-0.13	Vein graft stenosis in coronary artery bypass grafting;	chr16:11274759	chr16:11380859~11381118:-
BRCA	cis	rs1910358	0.676	rs2088921	ENSG00000248874.4	C5orf17	-4.22	2.66e-05	0.00196	-0.17	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:24008312	chr5:23951348~24178263:+
BRCA	cis	rs745109	0.882	rs58829418	ENSG00000273080.1	RP11-301O19.1	4.22	2.66e-05	0.00196	0.21	0.13	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86472593	chr2:86195590~86196049:+
BRCA	cis	rs6828577	0.862	rs298992	ENSG00000281731.1	RP11-384K6.8	4.22	2.66e-05	0.00196	0.15	0.13	Perioperative myocardial infarction in coronary artery bypass surgery;	chr4:118720786	chr4:118664087~118685341:-
BRCA	cis	rs9470794	0.915	rs11757359	ENSG00000204110.6	RP1-153P14.8	-4.22	2.66e-05	0.00196	-0.26	-0.13	Type 2 diabetes;	chr6:37938275	chr6:37507348~37535616:+
BRCA	cis	rs1665050	0.901	rs1665051	ENSG00000259732.1	RP11-59H7.3	-4.22	2.66e-05	0.00196	-0.15	-0.13	Atopic dermatitis;	chr15:59003025	chr15:59121034~59133250:+
BRCA	cis	rs4302906	0.893	rs10821049	ENSG00000187984.11	ANKRD19P	-4.22	2.66e-05	0.00196	-0.12	-0.13	Lobe attachment (rater-scored or self-reported);	chr9:92978490	chr9:92809388~92888693:+
BRCA	cis	rs832540	0.931	rs832536	ENSG00000271828.1	CTD-2310F14.1	-4.22	2.66e-05	0.00196	-0.16	-0.13	Coronary artery disease;	chr5:56916768	chr5:56927874~56929573:+
BRCA	cis	rs10028773	0.7	rs7690338	ENSG00000225892.3	RP11-384K6.2	4.22	2.66e-05	0.00196	0.13	0.13	Educational attainment;	chr4:119335313	chr4:118632274~118634759:+
BRCA	cis	rs2115630	0.967	rs10438428	ENSG00000275120.1	RP11-182J1.17	-4.22	2.66e-05	0.00196	-0.15	-0.13	P wave terminal force;	chr15:84787514	chr15:84599434~84606463:-
BRCA	cis	rs875971	1	rs1544549	ENSG00000229180.5	GS1-124K5.11	-4.22	2.66e-05	0.00196	-0.11	-0.13	Aortic root size;	chr7:66625676	chr7:66526088~66542624:-
BRCA	cis	rs170183	1	rs170183	ENSG00000233818.1	AP000695.4	4.22	2.66e-05	0.00196	0.13	0.13	Bone mineral density;	chr21:36476036	chr21:36445731~36532408:+
BRCA	cis	rs853679	0.517	rs1947862	ENSG00000216901.1	AL022393.7	4.22	2.66e-05	0.00196	0.19	0.13	Depression;	chr6:28137418	chr6:28176188~28176674:+
BRCA	cis	rs9844666	0.512	rs9864775	ENSG00000273486.1	RP11-731C17.2	4.22	2.66e-05	0.00196	0.16	0.13	Height;	chr3:135924726	chr3:136837338~136839021:-
BRCA	cis	rs11098499	0.954	rs6822679	ENSG00000260091.1	RP11-33B1.4	-4.22	2.66e-05	0.00196	-0.12	-0.13	Corneal astigmatism;	chr4:119481547	chr4:119409333~119410233:+
BRCA	cis	rs7165170	0.507	rs4932352	ENSG00000245479.2	LINC01585	4.22	2.66e-05	0.00196	0.15	0.13	Crohn's disease;Inflammatory bowel disease;	chr15:90602568	chr15:90660234~90664967:+
BRCA	cis	rs7182948	1	rs12902107	ENSG00000259531.2	RP11-295H24.3	-4.22	2.66e-05	0.00196	-0.18	-0.13	Lung adenocarcinoma;	chr15:49575126	chr15:49365124~49366685:-
BRCA	cis	rs11089937	0.616	rs12484496	ENSG00000211638.2	IGLV8-61	4.22	2.66e-05	0.00196	0.12	0.13	Periodontitis (PAL4Q3);	chr22:22180296	chr22:22098700~22099212:+
BRCA	cis	rs10129255	0.556	rs9324093	ENSG00000211967.3	IGHV3-53	-4.22	2.66e-05	0.00196	-0.09	-0.13	Kawasaki disease;	chr14:106683893	chr14:106592676~106593347:-
BRCA	cis	rs11098499	0.739	rs7441137	ENSG00000260404.2	RP11-384K6.6	-4.22	2.66e-05	0.00196	-0.12	-0.13	Corneal astigmatism;	chr4:119212066	chr4:118591773~118633729:+
BRCA	cis	rs1979679	0.608	rs1581075	ENSG00000278733.1	RP11-425D17.1	-4.22	2.66e-05	0.00196	-0.18	-0.13	Ossification of the posterior longitudinal ligament of the spine;	chr12:28570992	chr12:28185625~28186190:-
BRCA	cis	rs2991971	0.81	rs781058	ENSG00000280836.1	AL355480.1	-4.22	2.66e-05	0.00196	-0.15	-0.13	High light scatter reticulocyte count;	chr1:45469384	chr1:45581219~45581321:-
BRCA	cis	rs13098911	0.54	rs17215008	ENSG00000223552.1	RP11-24F11.2	-4.22	2.66e-05	0.00196	-0.22	-0.13	Celiac disease;	chr3:45970787	chr3:46364955~46407059:-
BRCA	cis	rs2274459	0.841	rs12203688	ENSG00000249346.5	LINC01016	-4.22	2.66e-05	0.00196	-0.17	-0.13	Obesity (extreme);	chr6:33725847	chr6:33867506~33896914:-
BRCA	cis	rs4218	0.681	rs12913177	ENSG00000259732.1	RP11-59H7.3	4.22	2.66e-05	0.00196	0.16	0.13	Social communication problems;	chr15:59066273	chr15:59121034~59133250:+
BRCA	cis	rs828999	0.688	rs6693028	ENSG00000280186.1	RP11-483I13.6	-4.22	2.66e-05	0.00196	-0.14	-0.13	Monocyte percentage of white cells;	chr1:108151747	chr1:108200413~108202743:+
BRCA	cis	rs853679	1	rs2799077	ENSG00000204709.4	LINC01556	4.22	2.66e-05	0.00196	0.23	0.13	Depression;	chr6:28266819	chr6:28943877~28944537:+
BRCA	cis	rs6671200	0.607	rs3767315	ENSG00000235501.4	RP4-639F20.1	4.22	2.66e-05	0.00196	0.22	0.13	Stearic acid (18:0) levels;	chr1:95240416	chr1:94927566~94963270:+
BRCA	cis	rs7267979	0.932	rs417130	ENSG00000274414.1	RP5-965G21.4	-4.22	2.66e-05	0.00197	-0.15	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25477684	chr20:25239007~25245229:-
BRCA	cis	rs7267979	0.932	rs372678	ENSG00000274414.1	RP5-965G21.4	-4.22	2.66e-05	0.00197	-0.15	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25484612	chr20:25239007~25245229:-
BRCA	cis	rs17489649	1	rs2284988	ENSG00000271849.1	CTC-332L22.1	4.22	2.66e-05	0.00197	0.17	0.13	Intelligence (multi-trait analysis);	chr5:109705607	chr5:109687802~109688329:-
BRCA	cis	rs12612619	0.732	rs12616092	ENSG00000272148.1	RP11-195B17.1	4.22	2.67e-05	0.00197	0.14	0.13	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:26994360	chr2:27062428~27062907:-
BRCA	cis	rs6012564	0.749	rs8120015	ENSG00000227431.4	CSE1L-AS1	4.22	2.67e-05	0.00197	0.16	0.13	Anger;	chr20:49128772	chr20:49040463~49046044:-
BRCA	cis	rs1538970	0.781	rs11211139	ENSG00000281133.1	AL355480.3	-4.22	2.67e-05	0.00197	-0.19	-0.13	Platelet count;	chr1:45550079	chr1:45580892~45580996:-
BRCA	cis	rs7576126	0.563	rs1807337	ENSG00000281920.1	RP11-418H16.1	-4.22	2.67e-05	0.00197	-0.16	-0.13	Severe influenza A (H1N1) infection;	chr2:65436033	chr2:65623272~65628424:+
BRCA	cis	rs17684571	0.7	rs35609883	ENSG00000231441.1	RP11-472M19.2	4.22	2.67e-05	0.00197	0.19	0.13	Schizophrenia;	chr6:56807034	chr6:56844002~56864078:+
BRCA	cis	rs1371614	0.655	rs509047	ENSG00000229122.1	AGBL5-IT1	-4.22	2.67e-05	0.00197	-0.14	-0.13	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26905661	chr2:27061038~27061815:+
BRCA	cis	rs2562456	0.833	rs56179986	ENSG00000268658.4	LINC00664	4.22	2.67e-05	0.00197	0.22	0.13	Pain;	chr19:21337882	chr19:21483374~21503238:+
BRCA	cis	rs1048886	0.872	rs56074506	ENSG00000271967.1	RP11-134K13.4	-4.22	2.67e-05	0.00197	-0.18	-0.13	Type 2 diabetes;	chr6:70558066	chr6:70596438~70596980:+
BRCA	cis	rs1048886	0.808	rs6941595	ENSG00000271967.1	RP11-134K13.4	-4.22	2.67e-05	0.00197	-0.18	-0.13	Type 2 diabetes;	chr6:70558710	chr6:70596438~70596980:+
BRCA	cis	rs7772486	0.712	rs6570726	ENSG00000270638.1	RP3-466P17.1	4.22	2.67e-05	0.00197	0.15	0.13	Lobe attachment (rater-scored or self-reported);	chr6:145838324	chr6:145735570~145737218:+
BRCA	cis	rs12468226	0.817	rs6722588	ENSG00000272966.1	RP11-686O6.1	-4.22	2.67e-05	0.00197	-0.22	-0.13	Urate levels;	chr2:202187163	chr2:202336739~202337200:+
BRCA	cis	rs1910358	0.705	rs6861036	ENSG00000248874.4	C5orf17	-4.22	2.67e-05	0.00197	-0.17	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:24005009	chr5:23951348~24178263:+
BRCA	cis	rs7475343	0.501	rs3750572	ENSG00000224034.1	RP11-445P17.8	-4.22	2.67e-05	0.00197	-0.25	-0.13	Intelligence;	chr10:5205413	chr10:5266033~5271236:-
BRCA	cis	rs13401620	0.81	rs11688028	ENSG00000229326.3	AC069154.4	4.22	2.67e-05	0.00197	0.16	0.13	Breast size;	chr2:119938079	chr2:119698623~119700151:+
BRCA	cis	rs13401620	0.81	rs12991183	ENSG00000229326.3	AC069154.4	4.22	2.67e-05	0.00197	0.16	0.13	Breast size;	chr2:119949029	chr2:119698623~119700151:+
BRCA	cis	rs13098911	0.54	rs3851346	ENSG00000223552.1	RP11-24F11.2	-4.22	2.67e-05	0.00197	-0.21	-0.13	Celiac disease;	chr3:46012089	chr3:46364955~46407059:-
BRCA	cis	rs41307935	0.818	rs35576939	ENSG00000260063.1	RP5-968P14.2	-4.22	2.67e-05	0.00197	-0.29	-0.13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26947604	chr1:26692132~26694131:-
BRCA	cis	rs17489649	0.915	rs6892181	ENSG00000271849.1	CTC-332L22.1	4.22	2.67e-05	0.00197	0.17	0.13	Intelligence (multi-trait analysis);	chr5:109707981	chr5:109687802~109688329:-
BRCA	cis	rs2832191	0.692	rs2254872	ENSG00000232855.5	AF131217.1	-4.22	2.67e-05	0.00197	-0.16	-0.13	Dental caries;	chr21:29042403	chr21:28439346~28674848:-
BRCA	cis	rs7833790	0.929	rs28464834	ENSG00000254689.1	RP11-354A14.1	-4.22	2.67e-05	0.00197	-0.19	-0.13	Diastolic blood pressure;	chr8:81885121	chr8:81885377~81923193:+
BRCA	cis	rs1823874	0.677	rs8042705	ENSG00000182397.13	DNM1P46	-4.22	2.67e-05	0.00197	-0.14	-0.13	IgG glycosylation;	chr15:99824501	chr15:99790156~99806927:-
BRCA	cis	rs13401620	0.843	rs28852693	ENSG00000229326.3	AC069154.4	-4.22	2.67e-05	0.00197	-0.16	-0.13	Breast size;	chr2:119890084	chr2:119698623~119700151:+
BRCA	cis	rs2439831	0.85	rs12441861	ENSG00000206991.1	RNU6-610P	-4.22	2.67e-05	0.00197	-0.21	-0.13	Lung cancer in ever smokers;	chr15:43768685	chr15:43637632~43637738:-
BRCA	cis	rs7246967	0.935	rs8112754	ENSG00000198153.8	ZNF849P	-4.22	2.67e-05	0.00197	-0.18	-0.13	Bronchopulmonary dysplasia;	chr19:22878068	chr19:22685167~22686732:+
BRCA	cis	rs654950	0.875	rs689076	ENSG00000230638.4	RP11-486B10.4	-4.22	2.67e-05	0.00197	-0.17	-0.13	Airway imaging phenotypes;	chr1:41533456	chr1:41542069~41544310:+
BRCA	cis	rs12900463	0.813	rs186266	ENSG00000259728.4	LINC00933	4.22	2.68e-05	0.00197	0.18	0.13	Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine);	chr15:84859564	chr15:84570649~84580175:+
BRCA	cis	rs2243480	1	rs316331	ENSG00000237026.1	RP11-328P23.2	-4.22	2.68e-05	0.00197	-0.24	-0.13	Diabetic kidney disease;	chr7:66139635	chr7:65235790~65236723:-
BRCA	cis	rs11098499	0.754	rs28643450	ENSG00000225892.3	RP11-384K6.2	4.22	2.68e-05	0.00197	0.13	0.13	Corneal astigmatism;	chr4:119324087	chr4:118632274~118634759:+
BRCA	cis	rs4218	0.532	rs17236369	ENSG00000259732.1	RP11-59H7.3	-4.22	2.68e-05	0.00197	-0.15	-0.13	Social communication problems;	chr15:59021656	chr15:59121034~59133250:+
BRCA	cis	rs875971	0.638	rs7793569	ENSG00000223473.2	GS1-124K5.3	-4.22	2.68e-05	0.00197	-0.1	-0.13	Aortic root size;	chr7:66651646	chr7:66491049~66493566:-
BRCA	cis	rs801193	1	rs3857688	ENSG00000223473.2	GS1-124K5.3	-4.22	2.68e-05	0.00197	-0.1	-0.13	Aortic root size;	chr7:66662819	chr7:66491049~66493566:-
BRCA	cis	rs801193	1	rs2286684	ENSG00000223473.2	GS1-124K5.3	-4.22	2.68e-05	0.00197	-0.1	-0.13	Aortic root size;	chr7:66664843	chr7:66491049~66493566:-
BRCA	cis	rs801193	0.935	rs2286683	ENSG00000223473.2	GS1-124K5.3	-4.22	2.68e-05	0.00197	-0.1	-0.13	Aortic root size;	chr7:66664856	chr7:66491049~66493566:-
BRCA	cis	rs801193	1	rs10274773	ENSG00000223473.2	GS1-124K5.3	-4.22	2.68e-05	0.00197	-0.1	-0.13	Aortic root size;	chr7:66668591	chr7:66491049~66493566:-
BRCA	cis	rs10129255	0.518	rs8009594	ENSG00000211959.2	IGHV4-39	4.22	2.68e-05	0.00197	0.09	0.13	Kawasaki disease;	chr14:106777494	chr14:106421711~106422218:-
BRCA	cis	rs57221529	0.709	rs4957056	ENSG00000225138.6	CTD-2228K2.7	4.22	2.68e-05	0.00197	0.19	0.13	Lung disease severity in cystic fibrosis;	chr5:569990	chr5:473236~480884:+
BRCA	cis	rs4950322	0.518	rs4950305	ENSG00000244371.2	PFN1P8	-4.22	2.68e-05	0.00197	-0.17	-0.13	Protein quantitative trait loci;	chr1:147117711	chr1:146957117~146957659:-
BRCA	cis	rs651907	0.535	rs34743741	ENSG00000256628.3	ZBTB11-AS1	4.22	2.68e-05	0.00197	0.17	0.13	Colorectal cancer;	chr3:101813604	chr3:101676475~101679217:+
BRCA	cis	rs12681366	0.571	rs2919654	ENSG00000253704.1	RP11-267M23.4	4.22	2.68e-05	0.00197	0.13	0.13	Nonsyndromic cleft lip with cleft palate;	chr8:94464045	chr8:94553722~94569745:+
BRCA	cis	rs9309473	0.607	rs12478346	ENSG00000163016.8	ALMS1P	4.22	2.68e-05	0.00197	0.16	0.13	Metabolite levels;	chr2:73357232	chr2:73644919~73685576:+
BRCA	cis	rs11673344	0.523	rs17206540	ENSG00000226686.6	LINC01535	4.22	2.68e-05	0.00197	0.17	0.13	Obesity-related traits;	chr19:37069009	chr19:37251912~37265535:+
BRCA	cis	rs11098499	0.865	rs11722183	ENSG00000260404.2	RP11-384K6.6	4.22	2.68e-05	0.00197	0.12	0.13	Corneal astigmatism;	chr4:119359442	chr4:118591773~118633729:+
BRCA	cis	rs4237845	0.636	rs11172371	ENSG00000257159.1	RP11-58A17.3	4.22	2.68e-05	0.00198	0.16	0.13	Intelligence (multi-trait analysis);	chr12:57892405	chr12:57967058~57968399:+
BRCA	cis	rs6088580	0.634	rs6087580	ENSG00000275784.1	RP5-1125A11.6	4.22	2.68e-05	0.00198	0.14	0.13	Glomerular filtration rate (creatinine);	chr20:34404786	chr20:33989480~33991818:-
BRCA	cis	rs739496	0.793	rs76604970	ENSG00000234608.6	MAPKAPK5-AS1	4.22	2.68e-05	0.00198	0.16	0.13	Platelet count;	chr12:111529351	chr12:111839764~111842902:-
BRCA	cis	rs7481584	0.626	rs2071103	ENSG00000236710.1	AC108448.2	4.22	2.68e-05	0.00198	0.17	0.13	Calcium levels;	chr11:3018857	chr11:3084393~3085443:-
BRCA	cis	rs9925964	0.967	rs749767	ENSG00000260911.2	RP11-196G11.2	4.22	2.68e-05	0.00198	0.12	0.13	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31113086	chr16:31043150~31049868:+
BRCA	cis	rs9308731	0.644	rs3789061	ENSG00000230499.1	AC108463.1	-4.22	2.68e-05	0.00198	-0.15	-0.13	Chronic lymphocytic leukemia;	chr2:111160653	chr2:111195963~111206494:+
BRCA	cis	rs409045	0.932	rs409601	ENSG00000271874.1	CTD-2024P10.2	-4.22	2.68e-05	0.00198	-0.17	-0.13	Left ventricular mass;	chr5:34628749	chr5:34651457~34651888:-
BRCA	cis	rs180730	1	rs1450472	ENSG00000251609.2	SETP12	4.22	2.68e-05	0.00198	0.19	0.13	Fasting plasma glucose;	chr4:120882137	chr4:120895494~120897083:-
BRCA	cis	rs11673344	0.503	rs10414520	ENSG00000226686.6	LINC01535	4.22	2.68e-05	0.00198	0.17	0.13	Obesity-related traits;	chr19:37057279	chr19:37251912~37265535:+
BRCA	cis	rs1348850	0.874	rs4893822	ENSG00000280374.1	RP11-337N6.3	4.22	2.68e-05	0.00198	0.18	0.13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177420999	chr2:177317715~177318471:-
BRCA	cis	rs6545883	0.524	rs17482440	ENSG00000273302.1	RP11-493E12.2	-4.22	2.68e-05	0.00198	-0.11	-0.13	Tuberculosis;	chr2:61321722	chr2:61199979~61200769:+
BRCA	cis	rs1040	0.727	rs7382431	ENSG00000226445.1	XXyac-YX65C7_A.2	-4.22	2.68e-05	0.00198	-0.15	-0.13	Joint mobility (Beighton score);	chr6:169221734	chr6:169213254~169239565:+
BRCA	cis	rs6686842	1	rs6686842	ENSG00000235358.1	RP11-399E6.1	4.22	2.68e-05	0.00198	0.16	0.13	Height;	chr1:41065199	chr1:41242373~41284861:+
BRCA	cis	rs2835872	0.965	rs717859	ENSG00000228677.1	TTC3-AS1	4.22	2.68e-05	0.00198	0.17	0.13	Electroencephalographic traits in alcoholism;	chr21:37640500	chr21:37187666~37193926:-
BRCA	cis	rs11083475	1	rs3786845	ENSG00000267892.1	CTD-2540F13.2	4.22	2.68e-05	0.00198	0.14	0.13	Heart rate;	chr19:38704443	chr19:38738284~38739863:+
BRCA	cis	rs4835473	0.897	rs2323194	ENSG00000249741.2	RP11-673E1.3	4.22	2.68e-05	0.00198	0.15	0.13	Immature fraction of reticulocytes;	chr4:143752879	chr4:143911514~143912053:-
BRCA	cis	rs8180040	0.764	rs62246375	ENSG00000276925.1	RP11-708J19.3	4.22	2.69e-05	0.00198	0.15	0.13	Colorectal cancer;	chr3:46972974	chr3:47469777~47469987:+
BRCA	cis	rs10463316	0.817	rs1810083	ENSG00000260581.1	CTB-113P19.4	-4.22	2.69e-05	0.00198	-0.15	-0.13	Metabolite levels (Pyroglutamine);	chr5:151397246	chr5:151652275~151655449:+
BRCA	cis	rs10129255	0.5	rs8022547	ENSG00000211967.3	IGHV3-53	-4.22	2.69e-05	0.00198	-0.09	-0.13	Kawasaki disease;	chr14:106781985	chr14:106592676~106593347:-
BRCA	cis	rs61931739	0.517	rs12367881	ENSG00000258794.3	DUX4L27	4.22	2.69e-05	0.00198	0.19	0.13	Morning vs. evening chronotype;	chr12:34022573	chr12:34208415~34209675:-
BRCA	cis	rs465969	0.793	rs7752225	ENSG00000272356.1	RP5-1112D6.8	-4.22	2.69e-05	0.00198	-0.28	-0.13	Psoriasis;	chr6:111459412	chr6:111309203~111313517:+
BRCA	cis	rs7312933	0.558	rs11181466	ENSG00000257225.1	RP11-328C8.4	-4.22	2.69e-05	0.00198	-0.16	-0.13	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42371379	chr12:42459366~42466128:+
BRCA	cis	rs7312933	0.558	rs11181467	ENSG00000257225.1	RP11-328C8.4	-4.22	2.69e-05	0.00198	-0.16	-0.13	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42371448	chr12:42459366~42466128:+
BRCA	cis	rs6545883	0.524	rs2694619	ENSG00000273302.1	RP11-493E12.2	-4.22	2.69e-05	0.00198	-0.11	-0.13	Tuberculosis;	chr2:61309766	chr2:61199979~61200769:+
BRCA	cis	rs10040989	1	rs10040989	ENSG00000253404.1	AC034243.1	-4.22	2.69e-05	0.00198	-0.24	-0.13	QT interval;	chr5:138238036	chr5:138744434~138753309:-
BRCA	cis	rs6545883	0.894	rs778157	ENSG00000273302.1	RP11-493E12.2	4.22	2.69e-05	0.00198	0.12	0.13	Tuberculosis;	chr2:61327154	chr2:61199979~61200769:+
BRCA	cis	rs6088580	0.634	rs6058041	ENSG00000276073.1	RP5-1125A11.7	-4.22	2.69e-05	0.00198	-0.14	-0.13	Glomerular filtration rate (creatinine);	chr20:34430202	chr20:33985617~33988989:-
BRCA	cis	rs7246967	1	rs11879853	ENSG00000198153.8	ZNF849P	4.22	2.69e-05	0.00198	0.18	0.13	Bronchopulmonary dysplasia;	chr19:22846632	chr19:22685167~22686732:+
BRCA	cis	rs651907	0.535	rs61396602	ENSG00000256628.3	ZBTB11-AS1	4.22	2.69e-05	0.00198	0.17	0.13	Colorectal cancer;	chr3:101790202	chr3:101676475~101679217:+
BRCA	cis	rs12435908	1	rs2268958	ENSG00000276116.2	FUT8-AS1	-4.22	2.69e-05	0.00198	-0.22	-0.13	Ischemic stroke;	chr14:65661520	chr14:65411170~65412690:-
BRCA	cis	rs7937682	0.961	rs4936682	ENSG00000230911.1	PPIHP1	4.22	2.69e-05	0.00198	0.18	0.13	Primary sclerosing cholangitis;	chr11:111759019	chr11:112029858~112030367:-
BRCA	cis	rs1018697	0.518	rs2790914	ENSG00000236937.2	PTGES3P4	-4.22	2.69e-05	0.00198	-0.19	-0.13	Colorectal adenoma (advanced);	chr10:102808261	chr10:102845595~102845950:+
BRCA	cis	rs6565180	0.926	rs12446288	ENSG00000183604.13	SMG1P5	4.22	2.69e-05	0.00198	0.13	0.13	Tonsillectomy;	chr16:30377388	chr16:30267553~30335374:-
BRCA	cis	rs9788721	0.836	rs7181486	ENSG00000261762.1	RP11-650L12.2	4.22	2.69e-05	0.00198	0.15	0.13	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78449276	chr15:78589123~78591276:-
BRCA	cis	rs71636778	0.509	rs35969145	ENSG00000260063.1	RP5-968P14.2	-4.22	2.69e-05	0.00198	-0.29	-0.13	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26932901	chr1:26692132~26694131:-
BRCA	cis	rs11711311	1	rs7633832	ENSG00000241529.3	RN7SL767P	-4.22	2.69e-05	0.00198	-0.15	-0.13	IgG glycosylation;	chr3:113753445	chr3:113632704~113632998:+
BRCA	cis	rs10986311	0.928	rs12349571	ENSG00000227200.1	RP11-121A14.3	4.22	2.69e-05	0.00198	0.15	0.13	Vitiligo;	chr9:124331464	chr9:124262876~124265809:+
BRCA	cis	rs10986311	0.928	rs10986319	ENSG00000227200.1	RP11-121A14.3	4.22	2.69e-05	0.00198	0.15	0.13	Vitiligo;	chr9:124331544	chr9:124262876~124265809:+
BRCA	cis	rs10986311	0.894	rs10986320	ENSG00000227200.1	RP11-121A14.3	4.22	2.69e-05	0.00198	0.15	0.13	Vitiligo;	chr9:124331623	chr9:124262876~124265809:+
BRCA	cis	rs77106637	0.86	rs1552224	ENSG00000245148.2	ARAP1-AS2	-4.22	2.69e-05	0.00198	-0.18	-0.13	Type 2 diabetes;	chr11:72722053	chr11:72700474~72705607:+
BRCA	cis	rs875971	0.642	rs35526611	ENSG00000273142.1	RP11-458F8.4	4.22	2.69e-05	0.00198	0.11	0.13	Aortic root size;	chr7:66629021	chr7:66902857~66906297:+
BRCA	cis	rs718314	0.956	rs11048454	ENSG00000256894.1	RP11-283G6.3	4.22	2.69e-05	0.00198	0.16	0.13	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Renal cell carcinoma;Waist circumference adjusted for body mass index;	chr12:26307112	chr12:26125155~26126617:-
BRCA	cis	rs875971	0.706	rs1643374	ENSG00000273024.4	INTS4P2	-4.22	2.69e-05	0.00198	-0.14	-0.13	Aortic root size;	chr7:66407695	chr7:65647864~65715661:+
BRCA	cis	rs7267979	1	rs13038834	ENSG00000276952.1	RP5-965G21.6	4.22	2.69e-05	0.00198	0.16	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25460797	chr20:25284915~25285588:-
BRCA	cis	rs7686660	1	rs4690760	ENSG00000250326.1	RP11-284M14.1	-4.22	2.69e-05	0.00198	-0.15	-0.13	Asthma;	chr4:143051592	chr4:142933195~143184861:-
BRCA	cis	rs1910358	0.554	rs4505918	ENSG00000248874.4	C5orf17	-4.22	2.69e-05	0.00198	-0.19	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23744604	chr5:23951348~24178263:+
BRCA	cis	rs6545883	0.868	rs28749199	ENSG00000212978.6	AC016747.3	4.22	2.69e-05	0.00198	0.18	0.13	Tuberculosis;	chr2:61599917	chr2:61141592~61144969:-
BRCA	cis	rs4415084	0.652	rs10070928	ENSG00000251141.4	RP11-53O19.1	-4.22	2.69e-05	0.00198	-0.12	-0.13	Breast cancer;	chr5:44888455	chr5:44744900~44808777:-
BRCA	cis	rs1910358	0.554	rs10055162	ENSG00000248874.4	C5orf17	-4.22	2.69e-05	0.00198	-0.18	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23757915	chr5:23951348~24178263:+
BRCA	cis	rs10129255	0.5	rs7157975	ENSG00000232216.1	IGHV3-43	4.22	2.69e-05	0.00198	0.1	0.13	Kawasaki disease;	chr14:106804049	chr14:106470264~106470800:-
BRCA	cis	rs11992162	0.591	rs4240678	ENSG00000255046.1	RP11-297N6.4	4.22	2.69e-05	0.00198	0.15	0.13	Monocyte count;	chr8:11944917	chr8:11797928~11802568:-
BRCA	cis	rs9788721	0.836	rs17484235	ENSG00000261762.1	RP11-650L12.2	-4.22	2.69e-05	0.00198	-0.17	-0.13	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78469072	chr15:78589123~78591276:-
BRCA	cis	rs957448	1	rs7829886	ENSG00000254315.1	RP11-267M23.3	4.22	2.69e-05	0.00198	0.16	0.13	Nonsyndromic cleft lip with cleft palate;	chr8:94485160	chr8:94533628~94534391:+
BRCA	cis	rs2832077	0.943	rs2832091	ENSG00000232855.5	AF131217.1	4.22	2.69e-05	0.00198	0.2	0.13	Cognitive test performance;	chr21:28790533	chr21:28439346~28674848:-
BRCA	cis	rs11742741	1	rs4701426	ENSG00000248874.4	C5orf17	-4.22	2.7e-05	0.00198	-0.17	-0.13	Educational attainment;	chr5:24177655	chr5:23951348~24178263:+
BRCA	cis	rs4886920	0.894	rs4587942	ENSG00000260776.4	RP11-114H24.2	-4.22	2.7e-05	0.00198	-0.15	-0.13	Neuroticism;	chr15:77827003	chr15:77914217~77926846:-
BRCA	cis	rs11088226	0.681	rs8131384	ENSG00000186842.4	LINC00846	-4.22	2.7e-05	0.00198	-0.22	-0.13	Gastritis;	chr21:32571817	chr21:32572238~32575881:-
BRCA	cis	rs7267979	0.773	rs6132821	ENSG00000276952.1	RP5-965G21.6	4.22	2.7e-05	0.00198	0.16	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25245556	chr20:25284915~25285588:-
BRCA	cis	rs801193	1	rs2659915	ENSG00000229180.5	GS1-124K5.11	4.22	2.7e-05	0.00199	0.11	0.13	Aortic root size;	chr7:66688114	chr7:66526088~66542624:-
BRCA	cis	rs7267979	0.932	rs449370	ENSG00000125804.12	FAM182A	4.22	2.7e-05	0.00199	0.17	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25470544	chr20:26054655~26086917:+
BRCA	cis	rs7011507	0.51	rs72639064	ENSG00000233858.4	AC026904.1	-4.22	2.7e-05	0.00199	-0.16	-0.13	Inflammatory bowel disease;Ulcerative colitis;	chr8:48563306	chr8:48590401~48594621:+
BRCA	cis	rs4489787	1	rs12230448	ENSG00000240399.1	RP1-228P16.1	-4.22	2.7e-05	0.00199	-0.25	-0.13	Prostate cancer (SNP x SNP interaction);	chr12:48557155	chr12:48054813~48055591:-
BRCA	cis	rs4489787	1	rs12230471	ENSG00000240399.1	RP1-228P16.1	-4.22	2.7e-05	0.00199	-0.25	-0.13	Prostate cancer (SNP x SNP interaction);	chr12:48557406	chr12:48054813~48055591:-
BRCA	cis	rs4489787	1	rs11168633	ENSG00000240399.1	RP1-228P16.1	-4.22	2.7e-05	0.00199	-0.25	-0.13	Prostate cancer (SNP x SNP interaction);	chr12:48557441	chr12:48054813~48055591:-
BRCA	cis	rs4489787	1	rs11168634	ENSG00000240399.1	RP1-228P16.1	-4.22	2.7e-05	0.00199	-0.25	-0.13	Prostate cancer (SNP x SNP interaction);	chr12:48557810	chr12:48054813~48055591:-
BRCA	cis	rs4489787	1	rs11168636	ENSG00000240399.1	RP1-228P16.1	-4.22	2.7e-05	0.00199	-0.25	-0.13	Prostate cancer (SNP x SNP interaction);	chr12:48558057	chr12:48054813~48055591:-
BRCA	cis	rs1910358	0.554	rs1879480	ENSG00000248874.4	C5orf17	-4.22	2.7e-05	0.00199	-0.19	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23729932	chr5:23951348~24178263:+
BRCA	cis	rs1348850	0.651	rs1901824	ENSG00000280374.1	RP11-337N6.3	4.22	2.7e-05	0.00199	0.17	0.13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177360738	chr2:177317715~177318471:-
BRCA	cis	rs4699052	0.625	rs7695593	ENSG00000248740.4	RP11-328K4.1	4.22	2.7e-05	0.00199	0.15	0.13	Testicular germ cell tumor;	chr4:103342626	chr4:103256159~103453658:+
BRCA	cis	rs1144713	0.6	rs2683489	ENSG00000274964.1	RP11-817I4.1	-4.22	2.7e-05	0.00199	-0.14	-0.13	Obesity-related traits;	chr12:32098247	chr12:32339368~32340724:+
BRCA	cis	rs2380205	0.967	rs7894083	ENSG00000232807.2	RP11-536K7.3	4.22	2.7e-05	0.00199	0.13	0.13	Breast cancer;	chr10:5851305	chr10:5934270~5945900:-
BRCA	cis	rs61931739	0.534	rs11053049	ENSG00000258794.3	DUX4L27	4.22	2.7e-05	0.00199	0.19	0.13	Morning vs. evening chronotype;	chr12:34011602	chr12:34208415~34209675:-
BRCA	cis	rs17818399	0.781	rs34449783	ENSG00000279254.1	RP11-536C12.1	-4.22	2.7e-05	0.00199	-0.17	-0.13	Height;	chr2:46636416	chr2:46668870~46670778:+
BRCA	cis	rs8180040	0.62	rs6442055	ENSG00000271161.1	BOLA2P2	4.22	2.7e-05	0.00199	0.14	0.13	Colorectal cancer;	chr3:47069232	chr3:47499841~47500407:+
BRCA	cis	rs13113518	1	rs4864547	ENSG00000272969.1	RP11-528I4.2	4.22	2.7e-05	0.00199	0.15	0.13	Height;	chr4:55538228	chr4:55547112~55547889:+
BRCA	cis	rs7829975	0.714	rs11784052	ENSG00000253981.4	ALG1L13P	4.22	2.7e-05	0.00199	0.14	0.13	Mood instability;	chr8:8814452	chr8:8236003~8244667:-
BRCA	cis	rs4835473	0.897	rs11735341	ENSG00000249741.2	RP11-673E1.3	4.22	2.7e-05	0.00199	0.15	0.13	Immature fraction of reticulocytes;	chr4:143716030	chr4:143911514~143912053:-
BRCA	cis	rs10911902	0.643	rs6425027	ENSG00000229739.2	RP11-295K2.3	-4.22	2.7e-05	0.00199	-0.19	-0.13	Schizophrenia;	chr1:186376034	chr1:186435161~186470291:+
BRCA	cis	rs10911902	0.643	rs6425028	ENSG00000229739.2	RP11-295K2.3	-4.22	2.7e-05	0.00199	-0.19	-0.13	Schizophrenia;	chr1:186376149	chr1:186435161~186470291:+
BRCA	cis	rs9650657	0.529	rs6601521	ENSG00000154316.13	TDH	4.22	2.7e-05	0.00199	0.15	0.13	Neuroticism;	chr8:10771437	chr8:11339637~11368452:+
BRCA	cis	rs425277	0.958	rs262688	ENSG00000269227.1	RP11-345P4.6	4.22	2.71e-05	0.00199	0.14	0.13	Height;	chr1:2182126	chr1:1673275~1674397:+
BRCA	cis	rs6545883	0.524	rs2694618	ENSG00000273302.1	RP11-493E12.2	4.22	2.71e-05	0.00199	0.11	0.13	Tuberculosis;	chr2:61309849	chr2:61199979~61200769:+
BRCA	cis	rs2109514	0.902	rs6980387	ENSG00000237813.3	AC002066.1	4.22	2.71e-05	0.00199	0.15	0.13	Prevalent atrial fibrillation;	chr7:116486828	chr7:116238260~116499465:-
BRCA	cis	rs78487399	0.614	rs7600657	ENSG00000234936.1	AC010883.5	4.22	2.71e-05	0.00199	0.18	0.13	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43483305	chr2:43229573~43233394:+
BRCA	cis	rs78487399	0.808	rs7601093	ENSG00000234936.1	AC010883.5	4.22	2.71e-05	0.00199	0.18	0.13	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43483668	chr2:43229573~43233394:+
BRCA	cis	rs913672	0.637	rs6125965	ENSG00000224397.4	LINC01272	4.22	2.71e-05	0.00199	0.15	0.13	Monocyte count;	chr20:50282076	chr20:50267486~50279795:+
BRCA	cis	rs1348850	0.608	rs2364845	ENSG00000280374.1	RP11-337N6.3	4.22	2.71e-05	0.00199	0.17	0.13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177361512	chr2:177317715~177318471:-
BRCA	cis	rs728616	0.867	rs61860039	ENSG00000242600.5	MBL1P	4.22	2.71e-05	0.00199	0.32	0.13	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80180150	chr10:79904898~79950336:+
BRCA	cis	rs6496932	0.865	rs4843049	ENSG00000259774.1	RP11-182J1.13	4.22	2.71e-05	0.00199	0.2	0.13	Central corneal thickness;Corneal structure;	chr15:85331141	chr15:84422618~84425882:+
BRCA	cis	rs1910358	0.554	rs3904973	ENSG00000248874.4	C5orf17	-4.22	2.71e-05	0.00199	-0.18	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23743761	chr5:23951348~24178263:+
BRCA	cis	rs1910358	0.554	rs7731307	ENSG00000248874.4	C5orf17	-4.22	2.71e-05	0.00199	-0.18	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23744215	chr5:23951348~24178263:+
BRCA	cis	rs1910358	0.554	rs3915663	ENSG00000248874.4	C5orf17	-4.22	2.71e-05	0.00199	-0.18	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23744678	chr5:23951348~24178263:+
BRCA	cis	rs1910358	0.596	rs3915664	ENSG00000248874.4	C5orf17	-4.22	2.71e-05	0.00199	-0.18	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23744897	chr5:23951348~24178263:+
BRCA	cis	rs1910358	0.554	rs3915665	ENSG00000248874.4	C5orf17	-4.22	2.71e-05	0.00199	-0.18	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23744979	chr5:23951348~24178263:+
BRCA	cis	rs1910358	0.554	rs3857313	ENSG00000248874.4	C5orf17	-4.22	2.71e-05	0.00199	-0.18	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23745846	chr5:23951348~24178263:+
BRCA	cis	rs1910358	0.554	rs4701391	ENSG00000248874.4	C5orf17	-4.22	2.71e-05	0.00199	-0.18	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23746041	chr5:23951348~24178263:+
BRCA	cis	rs1910358	0.554	rs3908936	ENSG00000248874.4	C5orf17	-4.22	2.71e-05	0.00199	-0.18	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23746051	chr5:23951348~24178263:+
BRCA	cis	rs1910358	0.554	rs4701392	ENSG00000248874.4	C5orf17	-4.22	2.71e-05	0.00199	-0.18	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23746109	chr5:23951348~24178263:+
BRCA	cis	rs1910358	0.554	rs3904972	ENSG00000248874.4	C5orf17	-4.22	2.71e-05	0.00199	-0.18	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23747287	chr5:23951348~24178263:+
BRCA	cis	rs1910358	0.53	rs2343380	ENSG00000248874.4	C5orf17	-4.22	2.71e-05	0.00199	-0.18	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23747683	chr5:23951348~24178263:+
BRCA	cis	rs3824867	0.92	rs4282946	ENSG00000280615.1	Y_RNA	-4.22	2.71e-05	0.00199	-0.16	-0.13	Mean corpuscular hemoglobin;	chr11:47434651	chr11:47614898~47614994:-
BRCA	cis	rs3824867	0.879	rs10742806	ENSG00000280615.1	Y_RNA	-4.22	2.71e-05	0.00199	-0.16	-0.13	Mean corpuscular hemoglobin;	chr11:47434675	chr11:47614898~47614994:-
BRCA	cis	rs11892454	0.515	rs4063544	ENSG00000217643.1	PTGES3P2	-4.22	2.71e-05	0.00199	-0.14	-0.13	Heschl's gyrus morphology;	chr2:25819646	chr2:25822469~25822950:+
BRCA	cis	rs867186	1	rs112777695	ENSG00000126005.14	MMP24-AS1	-4.22	2.71e-05	0.00199	-0.24	-0.13	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35105374	chr20:35216462~35278131:-
BRCA	cis	rs871012	0.502	rs2112691	ENSG00000248544.2	CTB-47B11.3	-4.22	2.71e-05	0.00199	-0.17	-0.13	IgG glycosylation;	chr5:157456328	chr5:157375741~157384950:-
BRCA	cis	rs7200786	0.593	rs1700819	ENSG00000274038.1	RP11-66H6.4	-4.22	2.71e-05	0.002	-0.15	-0.13	Systemic lupus erythematosus;Multiple sclerosis;	chr16:10963066	chr16:11056556~11057034:+
BRCA	cis	rs9859260	0.614	rs493661	ENSG00000207650.1	MIR570	-4.22	2.71e-05	0.002	-0.15	-0.13	Mean corpuscular volume;	chr3:196059618	chr3:195699401~195699497:+
BRCA	cis	rs2108622	0.727	rs62107770	ENSG00000267218.2	AC005336.5	4.22	2.71e-05	0.002	0.16	0.13	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15874615	chr19:15902300~15903238:-
BRCA	cis	rs91731	0.92	rs268723	ENSG00000249572.1	CTD-2203K17.1	-4.22	2.71e-05	0.002	-0.25	-0.13	Lung function (FVC);	chr5:33355167	chr5:33424025~33440619:-
BRCA	cis	rs1865760	0.786	rs1436308	ENSG00000272462.2	U91328.19	-4.22	2.71e-05	0.002	-0.16	-0.13	Height;	chr6:25939339	chr6:25992662~26001775:+
BRCA	cis	rs9914544	0.689	rs11078421	ENSG00000264885.1	RP11-815I9.4	-4.21	2.72e-05	0.002	-0.12	-0.13	Educational attainment (years of education);	chr17:18901072	chr17:18667629~18669461:-
BRCA	cis	rs1910358	0.554	rs10064553	ENSG00000248874.4	C5orf17	-4.21	2.72e-05	0.002	-0.18	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23757265	chr5:23951348~24178263:+
BRCA	cis	rs7727544	0.548	rs35696821	ENSG00000233006.5	AC034220.3	4.21	2.72e-05	0.002	0.1	0.13	Blood metabolite levels;	chr5:132172324	chr5:132311285~132369916:-
BRCA	cis	rs1005277	0.505	rs1208689	ENSG00000226578.1	RP11-258F22.1	-4.21	2.72e-05	0.002	-0.14	-0.13	Extrinsic epigenetic age acceleration;	chr10:37808847	chr10:37775371~37784131:-
BRCA	cis	rs8114671	0.562	rs6087642	ENSG00000126005.14	MMP24-AS1	-4.21	2.72e-05	0.002	-0.15	-0.13	Height;	chr20:34880503	chr20:35216462~35278131:-
BRCA	cis	rs875971	0.638	rs35986979	ENSG00000273142.1	RP11-458F8.4	4.21	2.72e-05	0.002	0.11	0.13	Aortic root size;	chr7:66624003	chr7:66902857~66906297:+
BRCA	cis	rs8054556	1	rs11642046	ENSG00000214725.6	CDIPT-AS1	-4.21	2.72e-05	0.002	-0.15	-0.13	Autism spectrum disorder or schizophrenia;	chr16:29981787	chr16:29863593~29868053:+
BRCA	cis	rs1722133	0.515	rs788713	ENSG00000237471.1	AC073115.6	4.21	2.72e-05	0.002	0.18	0.13	Sitting height ratio;	chr7:46097051	chr7:45969657~45980191:+
BRCA	cis	rs8098244	0.737	rs1258152	ENSG00000265752.2	RP11-403A21.1	-4.21	2.72e-05	0.002	-0.18	-0.13	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23948377	chr18:23957754~23982556:-
BRCA	cis	rs1910358	0.554	rs4701237	ENSG00000248874.4	C5orf17	-4.21	2.72e-05	0.002	-0.19	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23770311	chr5:23951348~24178263:+
BRCA	cis	rs4671400	0.516	rs1809028	ENSG00000273302.1	RP11-493E12.2	4.21	2.72e-05	0.002	0.15	0.13	3-hydroxypropylmercapturic acid levels in smokers;	chr2:61186588	chr2:61199979~61200769:+
BRCA	cis	rs16944613	0.51	rs11636571	ENSG00000245479.2	LINC01585	4.21	2.72e-05	0.002	0.15	0.13	Colorectal cancer;	chr15:90600625	chr15:90660234~90664967:+
BRCA	cis	rs6479874	0.92	rs2339681	ENSG00000223502.1	RP11-96B5.3	-4.21	2.72e-05	0.002	-0.24	-0.13	Migraine;	chr10:51032739	chr10:51062579~51068553:-
BRCA	cis	rs8017423	0.608	rs12589866	ENSG00000275198.1	RP11-471B22.3	4.21	2.72e-05	0.002	0.15	0.13	Mortality in heart failure;	chr14:90354633	chr14:90383365~90387973:+
BRCA	cis	rs6125597	0.516	rs6019537	ENSG00000222365.1	SNORD12B	-4.21	2.72e-05	0.002	-0.14	-0.13	Intelligence (multi-trait analysis);	chr20:48927067	chr20:49280319~49280409:+
BRCA	cis	rs1670533	0.615	rs59985183	ENSG00000251639.2	RP11-20I20.1	4.21	2.72e-05	0.002	0.19	0.13	Recombination rate (females);	chr4:1093383	chr4:1100016~1101558:-
BRCA	cis	rs7267979	0.866	rs437635	ENSG00000277938.1	RP5-965G21.3	4.21	2.72e-05	0.002	0.15	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25476252	chr20:25229150~25231933:+
BRCA	cis	rs7267979	0.932	rs417110	ENSG00000277938.1	RP5-965G21.3	4.21	2.72e-05	0.002	0.15	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25477661	chr20:25229150~25231933:+
BRCA	cis	rs7267979	0.932	rs449703	ENSG00000277938.1	RP5-965G21.3	4.21	2.72e-05	0.002	0.15	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25477923	chr20:25229150~25231933:+
BRCA	cis	rs2832191	0.791	rs2251517	ENSG00000232855.5	AF131217.1	-4.21	2.72e-05	0.002	-0.15	-0.13	Dental caries;	chr21:29159630	chr21:28439346~28674848:-
BRCA	cis	rs7412746	0.611	rs10888391	ENSG00000231073.1	RP11-316M1.3	4.21	2.72e-05	0.002	0.14	0.13	Melanoma;	chr1:150757507	chr1:150973123~150975534:+
BRCA	cis	rs2911132	0.564	rs17401719	ENSG00000272109.1	CTD-2260A17.3	4.21	2.72e-05	0.002	0.18	0.13	Urate levels (BMI interaction);	chr5:96753342	chr5:96804353~96806105:+
BRCA	cis	rs8180040	0.701	rs62248439	ENSG00000276925.1	RP11-708J19.3	4.21	2.72e-05	0.002	0.15	0.13	Colorectal cancer;	chr3:46954958	chr3:47469777~47469987:+
BRCA	cis	rs58785573	0.57	rs1824652	ENSG00000231160.8	KLF3-AS1	-4.21	2.72e-05	0.002	-0.13	-0.13	Lymphocyte percentage of white cells;	chr4:38642976	chr4:38612701~38664883:-
BRCA	cis	rs4715166	1	rs4715166	ENSG00000272379.1	RP1-257A7.5	-4.21	2.72e-05	0.002	-0.15	-0.13	Hip geometry;	chr6:13215826	chr6:13290018~13290490:-
BRCA	cis	rs7267979	1	rs6138572	ENSG00000276952.1	RP5-965G21.6	4.21	2.72e-05	0.002	0.16	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25455298	chr20:25284915~25285588:-
BRCA	cis	rs7267979	1	rs6138575	ENSG00000276952.1	RP5-965G21.6	4.21	2.72e-05	0.002	0.16	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25458316	chr20:25284915~25285588:-
BRCA	cis	rs6472235	0.586	rs62507386	ENSG00000272010.1	CTD-3025N20.3	-4.21	2.72e-05	0.002	-0.16	-0.13	Plateletcrit;Myopia (pathological);	chr8:66012724	chr8:65591850~65592472:-
BRCA	cis	rs2408955	0.501	rs8716	ENSG00000226413.2	OR8T1P	4.21	2.73e-05	0.002	0.17	0.13	Glycated hemoglobin levels;	chr12:48145699	chr12:48442030~48442947:-
BRCA	cis	rs6088590	0.648	rs6058105	ENSG00000276073.1	RP5-1125A11.7	-4.21	2.73e-05	0.002	-0.14	-0.13	Coronary artery disease;	chr20:34683915	chr20:33985617~33988989:-
BRCA	cis	rs9470794	1	rs11753267	ENSG00000204110.6	RP1-153P14.8	4.21	2.73e-05	0.00201	0.25	0.13	Type 2 diabetes;	chr6:37965545	chr6:37507348~37535616:+
BRCA	cis	rs10487112	0.833	rs12704547	ENSG00000235436.9	DPY19L2P4	-4.21	2.73e-05	0.00201	-0.14	-0.13	Perceived unattractiveness to mosquitoes;	chr7:90512589	chr7:90119400~90125600:+
BRCA	cis	rs2010672	0.5	rs4932351	ENSG00000245479.2	LINC01585	4.21	2.73e-05	0.00201	0.15	0.13	Eosinophil counts;Sum eosinophil basophil counts;Eosinophil percentage of white cells;	chr15:90600488	chr15:90660234~90664967:+
BRCA	cis	rs2010672	0.5	rs11631439	ENSG00000245479.2	LINC01585	4.21	2.73e-05	0.00201	0.15	0.13	Eosinophil counts;Sum eosinophil basophil counts;Eosinophil percentage of white cells;	chr15:90600573	chr15:90660234~90664967:+
BRCA	cis	rs6968419	0.674	rs6466571	ENSG00000279086.1	RP11-667F14.1	4.21	2.73e-05	0.00201	0.14	0.13	Intraocular pressure;	chr7:116269991	chr7:116209234~116211511:-
BRCA	cis	rs801193	0.904	rs4718403	ENSG00000223473.2	GS1-124K5.3	4.21	2.73e-05	0.00201	0.1	0.13	Aortic root size;	chr7:66777742	chr7:66491049~66493566:-
BRCA	cis	rs13326165	0.585	rs17052051	ENSG00000243224.1	RP5-1157M23.2	-4.21	2.73e-05	0.00201	-0.21	-0.13	HDL cholesterol levels;HDL cholesterol;	chr3:52297250	chr3:52239258~52241097:+
BRCA	cis	rs7572733	0.901	rs6734096	ENSG00000231621.1	AC013264.2	-4.21	2.73e-05	0.00201	-0.12	-0.13	Dermatomyositis;	chr2:197891735	chr2:197197991~197199273:+
BRCA	cis	rs2486012	1	rs1636877	ENSG00000237950.1	RP11-7O11.3	-4.21	2.73e-05	0.00201	-0.23	-0.13	Intelligence (multi-trait analysis);	chr1:43921953	chr1:43944370~43946551:-
BRCA	cis	rs4494364	0.502	rs2160117	ENSG00000258100.1	RP11-121E16.1	4.21	2.73e-05	0.00201	0.18	0.13	Systolic blood pressure (alcohol consumption interaction);	chr12:91028284	chr12:91362196~91368606:+
BRCA	cis	rs2657888	0.628	rs3809122	ENSG00000257576.1	RP11-153M3.1	-4.21	2.73e-05	0.00201	-0.16	-0.13	Adiponectin levels;	chr12:56488926	chr12:56511002~56512703:+
BRCA	cis	rs11098499	0.697	rs4560394	ENSG00000260404.2	RP11-384K6.6	4.21	2.73e-05	0.00201	0.12	0.13	Corneal astigmatism;	chr4:119392280	chr4:118591773~118633729:+
BRCA	cis	rs35612822	0.723	rs12694388	ENSG00000232485.2	AC098820.3	-4.21	2.73e-05	0.00201	-0.16	-0.13	Kidney disease (early stage) in type 1 diabetes;	chr2:216396598	chr2:216479030~216498761:-
BRCA	cis	rs7312933	0.558	rs1051453	ENSG00000257225.1	RP11-328C8.4	-4.21	2.73e-05	0.00201	-0.16	-0.13	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42458415	chr12:42459366~42466128:+
BRCA	cis	rs2554380	0.943	rs2562776	ENSG00000230373.7	GOLGA6L5P	-4.21	2.73e-05	0.00201	-0.19	-0.13	Height;	chr15:83699411	chr15:84507885~84516814:-
BRCA	cis	rs7481584	0.624	rs2106229	ENSG00000236710.1	AC108448.2	4.21	2.73e-05	0.00201	0.17	0.13	Calcium levels;	chr11:3019965	chr11:3084393~3085443:-
BRCA	cis	rs10129255	0.5	rs8004923	ENSG00000211967.3	IGHV3-53	-4.21	2.73e-05	0.00201	-0.08	-0.13	Kawasaki disease;	chr14:106785926	chr14:106592676~106593347:-
BRCA	cis	rs1910358	0.53	rs7732852	ENSG00000248874.4	C5orf17	-4.21	2.73e-05	0.00201	-0.19	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23780287	chr5:23951348~24178263:+
BRCA	cis	rs4474465	1	rs11237520	ENSG00000251323.2	RP11-452H21.4	4.21	2.74e-05	0.00201	0.17	0.13	Alzheimer's disease (survival time);	chr11:78490155	chr11:78423982~78429836:-
BRCA	cis	rs1971762	0.527	rs7311902	ENSG00000270175.1	RP11-793H13.11	-4.21	2.74e-05	0.00201	-0.11	-0.13	Height;	chr12:53621452	chr12:53500162~53500936:-
BRCA	cis	rs7833790	1	rs7834808	ENSG00000254689.1	RP11-354A14.1	4.21	2.74e-05	0.00201	0.19	0.13	Diastolic blood pressure;	chr8:81792761	chr8:81885377~81923193:+
BRCA	cis	rs9527	0.59	rs12415388	ENSG00000213061.2	PFN1P11	4.21	2.74e-05	0.00201	0.18	0.13	Arsenic metabolism;	chr10:103036588	chr10:102838011~102845473:-
BRCA	cis	rs763121	1	rs1946990	ENSG00000228274.3	RP3-508I15.9	4.21	2.74e-05	0.00201	0.13	0.13	Menopause (age at onset);	chr22:38516766	chr22:38667585~38681820:-
BRCA	cis	rs10504130	0.569	rs4418329	ENSG00000253844.1	RP11-546K22.1	-4.21	2.74e-05	0.00201	-0.19	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr8:51758554	chr8:51961458~52022974:+
BRCA	cis	rs10504130	0.569	rs4442134	ENSG00000253844.1	RP11-546K22.1	-4.21	2.74e-05	0.00201	-0.19	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr8:51758584	chr8:51961458~52022974:+
BRCA	cis	rs7824557	0.701	rs2060465	ENSG00000248896.2	CTD-2135J3.3	4.21	2.74e-05	0.00201	0.17	0.13	Retinal vascular caliber;	chr8:11305100	chr8:10729314~10771392:+
BRCA	cis	rs12303914	0.802	rs12829155	ENSG00000256682.2	TAS2R12	-4.21	2.74e-05	0.00201	-0.15	-0.13	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr12:10315655	chr12:10894943~10896952:-
BRCA	cis	rs11098499	0.954	rs10006706	ENSG00000260091.1	RP11-33B1.4	-4.21	2.74e-05	0.00201	-0.12	-0.13	Corneal astigmatism;	chr4:119487997	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.754	rs1511017	ENSG00000225892.3	RP11-384K6.2	4.21	2.74e-05	0.00201	0.12	0.13	Corneal astigmatism;	chr4:119329650	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.789	rs12498994	ENSG00000225892.3	RP11-384K6.2	4.21	2.74e-05	0.00201	0.12	0.13	Corneal astigmatism;	chr4:119329663	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.754	rs12507565	ENSG00000225892.3	RP11-384K6.2	4.21	2.74e-05	0.00201	0.12	0.13	Corneal astigmatism;	chr4:119329966	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.826	rs12511640	ENSG00000225892.3	RP11-384K6.2	4.21	2.74e-05	0.00201	0.12	0.13	Corneal astigmatism;	chr4:119330093	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.754	rs1980026	ENSG00000225892.3	RP11-384K6.2	4.21	2.74e-05	0.00201	0.12	0.13	Corneal astigmatism;	chr4:119330488	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.743	rs11098501	ENSG00000225892.3	RP11-384K6.2	4.21	2.74e-05	0.00201	0.12	0.13	Corneal astigmatism;	chr4:119330862	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.754	rs11098502	ENSG00000225892.3	RP11-384K6.2	4.21	2.74e-05	0.00201	0.12	0.13	Corneal astigmatism;	chr4:119330908	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.708	rs11732686	ENSG00000225892.3	RP11-384K6.2	4.21	2.74e-05	0.00201	0.12	0.13	Corneal astigmatism;	chr4:119331175	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.754	rs11724409	ENSG00000225892.3	RP11-384K6.2	4.21	2.74e-05	0.00201	0.12	0.13	Corneal astigmatism;	chr4:119331206	chr4:118632274~118634759:+
BRCA	cis	rs9402743	0.634	rs2327647	ENSG00000234084.1	RP3-388E23.2	4.21	2.74e-05	0.00201	0.13	0.13	Systemic lupus erythematosus;	chr6:135597296	chr6:135301568~135307158:+
BRCA	cis	rs13326165	0.585	rs6445385	ENSG00000243224.1	RP5-1157M23.2	-4.21	2.74e-05	0.00201	-0.21	-0.13	HDL cholesterol levels;HDL cholesterol;	chr3:52311443	chr3:52239258~52241097:+
BRCA	cis	rs465969	1	rs34382476	ENSG00000272356.1	RP5-1112D6.8	4.21	2.74e-05	0.00201	0.28	0.13	Psoriasis;	chr6:111423551	chr6:111309203~111313517:+
BRCA	cis	rs7267979	0.899	rs442834	ENSG00000277938.1	RP5-965G21.3	4.21	2.74e-05	0.00201	0.15	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25477460	chr20:25229150~25231933:+
BRCA	cis	rs4287000	0.508	rs9409477	ENSG00000227603.1	RP11-165J3.6	-4.21	2.74e-05	0.00201	-0.15	-0.13	Itch intensity from mosquito bite adjusted by bite size;	chr9:93606481	chr9:93435332~93437121:-
BRCA	cis	rs4287000	0.508	rs2265574	ENSG00000227603.1	RP11-165J3.6	-4.21	2.74e-05	0.00201	-0.15	-0.13	Itch intensity from mosquito bite adjusted by bite size;	chr9:93608493	chr9:93435332~93437121:-
BRCA	cis	rs11098499	0.954	rs4309825	ENSG00000260091.1	RP11-33B1.4	4.21	2.74e-05	0.00201	0.11	0.13	Corneal astigmatism;	chr4:119393726	chr4:119409333~119410233:+
BRCA	cis	rs78487399	0.908	rs76501189	ENSG00000234936.1	AC010883.5	4.21	2.74e-05	0.00202	0.19	0.13	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43579214	chr2:43229573~43233394:+
BRCA	cis	rs9921338	0.632	rs80945	ENSG00000262703.1	RP11-485G7.6	-4.21	2.74e-05	0.00202	-0.17	-0.13	Vein graft stenosis in coronary artery bypass grafting;	chr16:11249263	chr16:11348143~11349321:-
BRCA	cis	rs757081	0.669	rs542274	ENSG00000184669.7	OR7E14P	-4.21	2.74e-05	0.00202	-0.17	-0.13	Systolic blood pressure;	chr11:17185886	chr11:17013998~17053024:+
BRCA	cis	rs4722166	0.63	rs7808457	ENSG00000225541.1	AC002480.5	4.21	2.74e-05	0.00202	0.14	0.13	Lung cancer;	chr7:22758646	chr7:22571607~22661792:-
BRCA	cis	rs853679	0.723	rs9366718	ENSG00000204709.4	LINC01556	4.21	2.74e-05	0.00202	0.21	0.13	Depression;	chr6:28237724	chr6:28943877~28944537:+
BRCA	cis	rs7336933	1	rs7336933	ENSG00000231530.1	RP11-187A9.3	4.21	2.74e-05	0.00202	0.19	0.13	Calcium levels;	chr13:41984940	chr13:42043727~42044247:-
BRCA	cis	rs295490	0.748	rs58234450	ENSG00000272656.1	RP11-219D15.3	4.21	2.75e-05	0.00202	0.28	0.13	PR interval in Tripanosoma cruzi seropositivity;	chr3:139481465	chr3:139349024~139349371:-
BRCA	cis	rs875971	0.545	rs316316	ENSG00000273142.1	RP11-458F8.4	-4.21	2.75e-05	0.00202	-0.13	-0.13	Aortic root size;	chr7:66149270	chr7:66902857~66906297:+
BRCA	cis	rs7267979	0.966	rs6050567	ENSG00000125804.12	FAM182A	4.21	2.75e-05	0.00202	0.17	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25373925	chr20:26054655~26086917:+
BRCA	cis	rs7182948	1	rs12901416	ENSG00000259531.2	RP11-295H24.3	-4.21	2.75e-05	0.00202	-0.18	-0.13	Lung adenocarcinoma;	chr15:49574925	chr15:49365124~49366685:-
BRCA	cis	rs9368481	0.761	rs9357030	ENSG00000224843.5	LINC00240	4.21	2.75e-05	0.00202	0.15	0.13	Autism spectrum disorder or schizophrenia;	chr6:27017247	chr6:26956992~27023924:+
BRCA	cis	rs2304003	0.528	rs1023708	ENSG00000235192.1	AC009495.2	4.21	2.75e-05	0.00202	0.14	0.13	Social communication problems;	chr2:165863084	chr2:165794851~165810010:+
BRCA	cis	rs11098499	0.754	rs12513083	ENSG00000225892.3	RP11-384K6.2	4.21	2.75e-05	0.00202	0.12	0.13	Corneal astigmatism;	chr4:119328457	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.754	rs12509621	ENSG00000225892.3	RP11-384K6.2	4.21	2.75e-05	0.00202	0.12	0.13	Corneal astigmatism;	chr4:119328505	chr4:118632274~118634759:+
BRCA	cis	rs7819412	0.521	rs9329238	ENSG00000154316.13	TDH	4.21	2.75e-05	0.00202	0.17	0.13	Triglycerides;	chr8:11176228	chr8:11339637~11368452:+
BRCA	cis	rs17695224	0.545	rs4802875	ENSG00000269483.1	AC006272.1	4.21	2.75e-05	0.00202	0.15	0.13	HDL cholesterol;HDL cholesterol levels;	chr19:51827056	chr19:51839924~51843324:-
BRCA	cis	rs6545883	0.86	rs6545847	ENSG00000212978.6	AC016747.3	-4.21	2.75e-05	0.00202	-0.17	-0.13	Tuberculosis;	chr2:61218198	chr2:61141592~61144969:-
BRCA	cis	rs934734	0.532	rs55792977	ENSG00000281920.1	RP11-418H16.1	-4.21	2.75e-05	0.00202	-0.15	-0.13	Rheumatoid arthritis;	chr2:65423730	chr2:65623272~65628424:+
BRCA	cis	rs875971	1	rs778710	ENSG00000229180.5	GS1-124K5.11	4.21	2.75e-05	0.00202	0.11	0.13	Aortic root size;	chr7:66389847	chr7:66526088~66542624:-
BRCA	cis	rs7932354	0.583	rs2306026	ENSG00000200376.1	RNU5E-10P	4.21	2.75e-05	0.00202	0.16	0.13	Bone mineral density (hip);Bone mineral density;	chr11:46868162	chr11:47576471~47576588:-
BRCA	cis	rs7932354	0.537	rs3816614	ENSG00000200376.1	RNU5E-10P	4.21	2.75e-05	0.00202	0.16	0.13	Bone mineral density (hip);Bone mineral density;	chr11:46868614	chr11:47576471~47576588:-
BRCA	cis	rs2301573	0.68	rs80042323	ENSG00000271270.4	TMCC1-AS1	-4.21	2.75e-05	0.00202	-0.28	-0.13	Hip circumference;	chr3:129735813	chr3:129893871~129918575:+
BRCA	cis	rs7267979	0.565	rs958075	ENSG00000231081.1	RP4-760C5.3	4.21	2.75e-05	0.00202	0.16	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25614487	chr20:26008791~26010531:-
BRCA	cis	rs2380205	0.967	rs11255558	ENSG00000232807.2	RP11-536K7.3	4.21	2.75e-05	0.00202	0.13	0.13	Breast cancer;	chr10:5854429	chr10:5934270~5945900:-
BRCA	cis	rs4865762	0.904	rs254198	ENSG00000247796.2	CTD-2366F13.1	4.21	2.75e-05	0.00202	0.14	0.13	Intraocular pressure;	chr5:53204982	chr5:53109842~53115126:+
BRCA	cis	rs1396626	0.821	rs1509183	ENSG00000235501.4	RP4-639F20.1	-4.21	2.75e-05	0.00202	-0.17	-0.13	Diabetic kidney disease;	chr1:95550383	chr1:94927566~94963270:+
BRCA	cis	rs11098499	0.754	rs1814813	ENSG00000260404.2	RP11-384K6.6	-4.21	2.75e-05	0.00202	-0.11	-0.13	Corneal astigmatism;	chr4:119337052	chr4:118591773~118633729:+
BRCA	cis	rs62103177	0.525	rs4799117	ENSG00000278000.1	AC139100.4	-4.21	2.75e-05	0.00202	-0.18	-0.13	Opioid sensitivity;	chr18:79996604	chr18:80161752~80162413:+
BRCA	cis	rs62103177	0.525	rs4283293	ENSG00000278000.1	AC139100.4	-4.21	2.75e-05	0.00202	-0.18	-0.13	Opioid sensitivity;	chr18:79999582	chr18:80161752~80162413:+
BRCA	cis	rs2834288	1	rs2834288	ENSG00000273102.1	AP000569.9	4.21	2.75e-05	0.00202	0.14	0.13	Gut microbiota (bacterial taxa);	chr21:33892093	chr21:33967101~33968573:-
BRCA	cis	rs4489787	1	rs2705155	ENSG00000240399.1	RP1-228P16.1	4.21	2.75e-05	0.00202	0.2	0.13	Prostate cancer (SNP x SNP interaction);	chr12:48513307	chr12:48054813~48055591:-
BRCA	cis	rs7260598	0.685	rs73524177	ENSG00000268442.1	CTD-2027I19.2	4.21	2.76e-05	0.00202	0.21	0.13	Response to taxane treatment (placlitaxel);	chr19:24156376	chr19:24162370~24163425:-
BRCA	cis	rs11098499	0.955	rs1551	ENSG00000260091.1	RP11-33B1.4	-4.21	2.76e-05	0.00202	-0.12	-0.13	Corneal astigmatism;	chr4:119237345	chr4:119409333~119410233:+
BRCA	cis	rs6490294	0.904	rs12423126	ENSG00000257624.1	RP1-128M12.3	4.21	2.76e-05	0.00202	0.18	0.13	Mean platelet volume;	chr12:111991665	chr12:112000739~112000985:-
BRCA	cis	rs9840812	0.953	rs61791721	ENSG00000239213.4	NCK1-AS1	-4.21	2.76e-05	0.00202	-0.16	-0.13	Fibrinogen levels;	chr3:136085708	chr3:136841726~136862054:-
BRCA	cis	rs3796352	1	rs10510761	ENSG00000242142.1	SERBP1P3	4.21	2.76e-05	0.00203	0.24	0.13	Immune reponse to smallpox (secreted IL-2);	chr3:52931239	chr3:53064283~53065091:-
BRCA	cis	rs6067053	0.671	rs6067035	ENSG00000227431.4	CSE1L-AS1	4.21	2.76e-05	0.00203	0.16	0.13	Intelligence (multi-trait analysis);	chr20:49291253	chr20:49040463~49046044:-
BRCA	cis	rs683250	0.598	rs578842	ENSG00000254551.1	RP11-727A23.7	4.21	2.76e-05	0.00203	0.17	0.13	Subcortical brain region volumes;	chr11:83263868	chr11:83209431~83213379:-
BRCA	cis	rs35146811	0.735	rs858512	ENSG00000235713.1	RP4-604G5.3	-4.21	2.76e-05	0.00203	-0.15	-0.13	Coronary artery disease;	chr7:100226830	chr7:99992397~99993050:+
BRCA	cis	rs35146811	0.7	rs858513	ENSG00000235713.1	RP4-604G5.3	-4.21	2.76e-05	0.00203	-0.15	-0.13	Coronary artery disease;	chr7:100227935	chr7:99992397~99993050:+
BRCA	cis	rs745109	0.765	rs56055358	ENSG00000273080.1	RP11-301O19.1	4.21	2.76e-05	0.00203	0.21	0.13	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86471430	chr2:86195590~86196049:+
BRCA	cis	rs864745	0.571	rs849139	ENSG00000234336.5	JAZF1-AS1	-4.21	2.76e-05	0.00203	-0.16	-0.13	Crohn's disease;Type 2 diabetes;	chr7:28139777	chr7:28180322~28243917:+
BRCA	cis	rs2505998	0.879	rs2435358	ENSG00000273008.1	RP11-351D16.3	-4.21	2.76e-05	0.00203	-0.16	-0.13	Hirschsprung disease;	chr10:43084767	chr10:43136824~43138334:-
BRCA	cis	rs797680	0.856	rs11164880	ENSG00000229635.1	RP4-713B5.2	4.21	2.76e-05	0.00203	0.17	0.13	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93192539	chr1:93384487~93384998:-
BRCA	cis	rs797680	0.856	rs7513705	ENSG00000229635.1	RP4-713B5.2	4.21	2.76e-05	0.00203	0.17	0.13	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93200792	chr1:93384487~93384998:-
BRCA	cis	rs7932354	0.536	rs7929294	ENSG00000200376.1	RNU5E-10P	4.21	2.76e-05	0.00203	0.16	0.13	Bone mineral density (hip);Bone mineral density;	chr11:46754626	chr11:47576471~47576588:-
BRCA	cis	rs6840360	0.571	rs718800	ENSG00000278978.1	RP11-164P12.5	4.21	2.76e-05	0.00203	0.16	0.13	Intelligence (multi-trait analysis);	chr4:151628155	chr4:151669786~151670503:+
BRCA	cis	rs7267979	0.966	rs6107031	ENSG00000125804.12	FAM182A	4.21	2.76e-05	0.00203	0.17	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25370041	chr20:26054655~26086917:+
BRCA	cis	rs7267979	1	rs6115159	ENSG00000125804.12	FAM182A	4.21	2.76e-05	0.00203	0.17	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25370308	chr20:26054655~26086917:+
BRCA	cis	rs7267979	1	rs4813562	ENSG00000125804.12	FAM182A	4.21	2.76e-05	0.00203	0.17	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25371952	chr20:26054655~26086917:+
BRCA	cis	rs10504130	0.569	rs12679983	ENSG00000253844.1	RP11-546K22.1	-4.21	2.76e-05	0.00203	-0.19	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr8:51765596	chr8:51961458~52022974:+
BRCA	cis	rs4950322	0.542	rs17159924	ENSG00000237188.3	RP11-337C18.8	4.21	2.76e-05	0.00203	0.16	0.13	Protein quantitative trait loci;	chr1:147199463	chr1:147172771~147211568:+
BRCA	cis	rs2243480	1	rs781156	ENSG00000275400.1	RP4-756H11.5	4.21	2.76e-05	0.00203	0.23	0.13	Diabetic kidney disease;	chr7:66014154	chr7:66553805~66554199:-
BRCA	cis	rs2243480	1	rs451396	ENSG00000275400.1	RP4-756H11.5	4.21	2.76e-05	0.00203	0.23	0.13	Diabetic kidney disease;	chr7:66019087	chr7:66553805~66554199:-
BRCA	cis	rs2243480	1	rs1715235	ENSG00000275400.1	RP4-756H11.5	4.21	2.76e-05	0.00203	0.23	0.13	Diabetic kidney disease;	chr7:66023407	chr7:66553805~66554199:-
BRCA	cis	rs10129255	0.5	rs1024350	ENSG00000254174.1	IGHV1-12	4.21	2.76e-05	0.00203	0.1	0.13	Kawasaki disease;	chr14:106685105	chr14:106122420~106122709:-
BRCA	cis	rs465969	0.744	rs6939657	ENSG00000272356.1	RP5-1112D6.8	4.21	2.76e-05	0.00203	0.25	0.13	Psoriasis;	chr6:111521822	chr6:111309203~111313517:+
BRCA	cis	rs6600671	0.693	rs1853731	ENSG00000275538.1	RNVU1-19	4.21	2.76e-05	0.00203	0.16	0.13	Hip geometry;	chr1:121510262	chr1:120850819~120850985:-
BRCA	cis	rs12999542	1	rs11465597	ENSG00000234389.1	AC007278.3	4.21	2.76e-05	0.00203	0.18	0.13	Serum protein levels (sST2);	chr2:102370753	chr2:102438713~102440475:+
BRCA	cis	rs2731006	0.64	rs2678105	ENSG00000257114.2	RP11-25I15.3	4.21	2.76e-05	0.00203	0.21	0.13	Panic disorder;	chr12:42770547	chr12:42692216~42717119:+
BRCA	cis	rs962856	0.822	rs6546307	ENSG00000236605.1	AC023115.4	4.21	2.76e-05	0.00203	0.15	0.13	Pancreatic cancer;	chr2:67416921	chr2:67324627~67325304:+
BRCA	cis	rs6772849	0.804	rs4857920	ENSG00000242551.2	POU5F1P6	-4.21	2.76e-05	0.00203	-0.17	-0.13	Monocyte percentage of white cells;Monocyte count;	chr3:128688780	chr3:128674735~128677005:-
BRCA	cis	rs875971	0.571	rs160641	ENSG00000273142.1	RP11-458F8.4	-4.21	2.76e-05	0.00203	-0.13	-0.13	Aortic root size;	chr7:66112359	chr7:66902857~66906297:+
BRCA	cis	rs875971	0.964	rs55748098	ENSG00000236529.1	RP13-254B10.1	-4.21	2.76e-05	0.00203	-0.14	-0.13	Aortic root size;	chr7:66298631	chr7:65840212~65840596:+
BRCA	cis	rs12030196	1	rs11207368	ENSG00000230812.4	LINC01358	4.21	2.76e-05	0.00203	0.14	0.13	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr1:59019388	chr1:59020387~59044614:+
BRCA	cis	rs10266483	0.656	rs670966	ENSG00000271550.1	BNIP3P11	4.21	2.77e-05	0.00203	0.17	0.13	Response to statin therapy;	chr7:64302521	chr7:64678954~64687393:-
BRCA	cis	rs2731006	0.64	rs2468326	ENSG00000257114.2	RP11-25I15.3	4.21	2.77e-05	0.00203	0.21	0.13	Panic disorder;	chr12:42785698	chr12:42692216~42717119:+
BRCA	cis	rs2229238	0.911	rs112394421	ENSG00000272030.1	RP1-178F15.4	-4.21	2.77e-05	0.00203	-0.18	-0.13	Coronary heart disease;	chr1:154539532	chr1:153631438~153634397:-
BRCA	cis	rs57221529	0.766	rs17563576	ENSG00000225138.6	CTD-2228K2.7	4.21	2.77e-05	0.00203	0.19	0.13	Lung disease severity in cystic fibrosis;	chr5:560361	chr5:473236~480884:+
BRCA	cis	rs8180040	0.967	rs4858890	ENSG00000271161.1	BOLA2P2	-4.21	2.77e-05	0.00203	-0.14	-0.13	Colorectal cancer;	chr3:47363966	chr3:47499841~47500407:+
BRCA	cis	rs11048434	0.518	rs7136274	ENSG00000256720.1	RP11-436I9.6	4.21	2.77e-05	0.00203	0.13	0.13	Sjögren's syndrome;	chr12:9022360	chr12:9135084~9135591:+
BRCA	cis	rs4925540	0.962	rs61498462	ENSG00000215796.3	RP11-551G24.2	-4.21	2.77e-05	0.00203	-0.15	-0.13	Response to taxane treatment (docetaxel);	chr1:247045378	chr1:247042791~247044021:+
BRCA	cis	rs78487399	0.808	rs7591387	ENSG00000234936.1	AC010883.5	4.21	2.77e-05	0.00203	0.2	0.13	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43528893	chr2:43229573~43233394:+
BRCA	cis	rs983392	1	rs2847666	ENSG00000275344.1	MIR6503	-4.21	2.77e-05	0.00203	-0.14	-0.13	Alzheimer's disease (late onset);	chr11:60092103	chr11:60209071~60209156:-
BRCA	cis	rs1549118	0.669	rs11621178	ENSG00000239272.1	RPL21P10	4.21	2.77e-05	0.00203	0.15	0.13	Resting heart rate;	chr14:77908885	chr14:77683202~77683989:-
BRCA	cis	rs11035577	0.632	rs7114328	ENSG00000279675.1	RP11-454H19.2	4.21	2.77e-05	0.00203	0.19	0.13	Temperament (bipolar disorder);	chr11:39782804	chr11:40107244~40112599:-
BRCA	cis	rs1005277	0.579	rs1614236	ENSG00000099251.13	HSD17B7P2	4.21	2.77e-05	0.00203	0.14	0.13	Extrinsic epigenetic age acceleration;	chr10:38214068	chr10:38356380~38378505:+
BRCA	cis	rs1005277	0.579	rs2749616	ENSG00000099251.13	HSD17B7P2	4.21	2.77e-05	0.00203	0.14	0.13	Extrinsic epigenetic age acceleration;	chr10:38222065	chr10:38356380~38378505:+
BRCA	cis	rs372883	0.554	rs10154065	ENSG00000176054.6	RPL23P2	4.21	2.77e-05	0.00203	0.15	0.13	Pancreatic cancer;	chr21:29377160	chr21:28997613~28998033:-
BRCA	cis	rs6490294	0.898	rs57646770	ENSG00000257624.1	RP1-128M12.3	4.21	2.77e-05	0.00203	0.18	0.13	Mean platelet volume;	chr12:111993408	chr12:112000739~112000985:-
BRCA	cis	rs7200543	1	rs4500751	ENSG00000260872.1	RP11-680G24.5	-4.21	2.77e-05	0.00203	-0.14	-0.13	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15046354	chr16:15018106~15020488:-
BRCA	cis	rs2880765	0.743	rs11630410	ENSG00000202081.1	RNU6-1280P	4.21	2.77e-05	0.00203	0.15	0.13	Coronary artery disease;	chr15:85461510	chr15:85651522~85651628:-
BRCA	cis	rs2880765	0.71	rs11630457	ENSG00000202081.1	RNU6-1280P	4.21	2.77e-05	0.00203	0.15	0.13	Coronary artery disease;	chr15:85461570	chr15:85651522~85651628:-
BRCA	cis	rs4664293	0.625	rs7590617	ENSG00000224152.1	AC009506.1	4.21	2.77e-05	0.00203	0.13	0.13	Monocyte percentage of white cells;	chr2:159775437	chr2:159615296~159617082:+
BRCA	cis	rs4664293	0.625	rs7564585	ENSG00000224152.1	AC009506.1	4.21	2.77e-05	0.00203	0.13	0.13	Monocyte percentage of white cells;	chr2:159775582	chr2:159615296~159617082:+
BRCA	cis	rs4664293	0.546	rs7564399	ENSG00000224152.1	AC009506.1	4.21	2.77e-05	0.00203	0.13	0.13	Monocyte percentage of white cells;	chr2:159775608	chr2:159615296~159617082:+
BRCA	cis	rs6671200	0.79	rs259357	ENSG00000235501.4	RP4-639F20.1	4.21	2.77e-05	0.00203	0.27	0.13	Stearic acid (18:0) levels;	chr1:95245922	chr1:94927566~94963270:+
BRCA	cis	rs467650	0.549	rs720859	ENSG00000248489.1	CTD-2007H13.3	-4.21	2.77e-05	0.00203	-0.14	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:98659713	chr5:98929171~98995013:+
BRCA	cis	rs465969	1	rs35856111	ENSG00000272356.1	RP5-1112D6.8	4.21	2.77e-05	0.00203	0.28	0.13	Psoriasis;	chr6:111452265	chr6:111309203~111313517:+
BRCA	cis	rs9527	0.59	rs10883820	ENSG00000213061.2	PFN1P11	-4.21	2.77e-05	0.00203	-0.17	-0.13	Arsenic metabolism;	chr10:103004904	chr10:102838011~102845473:-
BRCA	cis	rs1910358	0.636	rs7717072	ENSG00000248874.4	C5orf17	-4.21	2.77e-05	0.00203	-0.17	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23949421	chr5:23951348~24178263:+
BRCA	cis	rs7577696	0.525	rs9752651	ENSG00000272716.1	RP11-563N4.1	4.21	2.77e-05	0.00203	0.14	0.13	Inflammatory biomarkers;	chr2:31983380	chr2:32165046~32165757:-
BRCA	cis	rs9818758	0.607	rs12715434	ENSG00000225399.4	RP11-3B7.1	-4.21	2.77e-05	0.00203	-0.2	-0.13	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49257592	chr3:49260085~49261316:+
BRCA	cis	rs4835473	0.897	rs13144504	ENSG00000249741.2	RP11-673E1.3	4.21	2.77e-05	0.00203	0.15	0.13	Immature fraction of reticulocytes;	chr4:143707402	chr4:143911514~143912053:-
BRCA	cis	rs490234	0.841	rs10114882	ENSG00000232630.1	PRPS1P2	-4.21	2.77e-05	0.00203	-0.13	-0.13	Mean arterial pressure;	chr9:125541146	chr9:125150653~125151589:+
BRCA	cis	rs4664293	0.625	rs35481084	ENSG00000224152.1	AC009506.1	4.21	2.77e-05	0.00203	0.13	0.13	Monocyte percentage of white cells;	chr2:159777729	chr2:159615296~159617082:+
BRCA	cis	rs4664293	0.625	rs10460300	ENSG00000224152.1	AC009506.1	4.21	2.77e-05	0.00203	0.13	0.13	Monocyte percentage of white cells;	chr2:159778210	chr2:159615296~159617082:+
BRCA	cis	rs7412746	0.611	rs11204747	ENSG00000231073.1	RP11-316M1.3	-4.21	2.77e-05	0.00203	-0.13	-0.13	Melanoma;	chr1:150954676	chr1:150973123~150975534:+
BRCA	cis	rs4143844	0.867	rs17303915	ENSG00000259251.2	RP11-643M14.1	4.21	2.77e-05	0.00203	0.32	0.13	Bipolar disorder and schizophrenia;	chr15:61882695	chr15:62060503~62062434:+
BRCA	cis	rs2243480	1	rs316321	ENSG00000237026.1	RP11-328P23.2	4.21	2.77e-05	0.00203	0.24	0.13	Diabetic kidney disease;	chr7:66146626	chr7:65235790~65236723:-
BRCA	cis	rs2243480	1	rs316318	ENSG00000237026.1	RP11-328P23.2	4.21	2.77e-05	0.00203	0.24	0.13	Diabetic kidney disease;	chr7:66147917	chr7:65235790~65236723:-
BRCA	cis	rs2243480	1	rs316317	ENSG00000237026.1	RP11-328P23.2	4.21	2.77e-05	0.00203	0.24	0.13	Diabetic kidney disease;	chr7:66148650	chr7:65235790~65236723:-
BRCA	cis	rs2243480	1	rs316304	ENSG00000237026.1	RP11-328P23.2	4.21	2.77e-05	0.00203	0.24	0.13	Diabetic kidney disease;	chr7:66151907	chr7:65235790~65236723:-
BRCA	cis	rs3858526	0.883	rs10769320	ENSG00000224295.2	AC087380.14	4.21	2.77e-05	0.00204	0.18	0.13	DNA methylation (variation);	chr11:5911601	chr11:5518441~5524955:-
BRCA	cis	rs7932354	0.583	rs3829940	ENSG00000200376.1	RNU5E-10P	4.21	2.77e-05	0.00204	0.16	0.13	Bone mineral density (hip);Bone mineral density;	chr11:46858422	chr11:47576471~47576588:-
BRCA	cis	rs6545883	0.507	rs59981505	ENSG00000270820.4	RP11-355B11.2	-4.21	2.77e-05	0.00204	-0.14	-0.13	Tuberculosis;	chr2:61353394	chr2:61471188~61484130:+
BRCA	cis	rs2243480	0.901	rs35087093	ENSG00000226002.1	RP11-460N20.5	-4.21	2.77e-05	0.00204	-0.21	-0.13	Diabetic kidney disease;	chr7:65940221	chr7:65084103~65100232:+
BRCA	cis	rs6547741	1	rs1972669	ENSG00000234072.1	AC074117.10	4.21	2.78e-05	0.00204	0.12	0.13	Oral cavity cancer;	chr2:27544240	chr2:27356246~27367622:+
BRCA	cis	rs1348850	0.651	rs1901826	ENSG00000280374.1	RP11-337N6.3	4.21	2.78e-05	0.00204	0.17	0.13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177360538	chr2:177317715~177318471:-
BRCA	cis	rs4443100	0.67	rs13054331	ENSG00000230701.2	FBXW4P1	4.21	2.78e-05	0.00204	0.18	0.13	Serum parathyroid hormone levels;	chr22:23064885	chr22:23262767~23265005:+
BRCA	cis	rs4443100	0.67	rs13056137	ENSG00000230701.2	FBXW4P1	4.21	2.78e-05	0.00204	0.18	0.13	Serum parathyroid hormone levels;	chr22:23065083	chr22:23262767~23265005:+
BRCA	cis	rs10266483	0.739	rs2692099	ENSG00000271550.1	BNIP3P11	4.21	2.78e-05	0.00204	0.17	0.13	Response to statin therapy;	chr7:64307384	chr7:64678954~64687393:-
BRCA	cis	rs1910358	0.596	rs7707467	ENSG00000248874.4	C5orf17	-4.21	2.78e-05	0.00204	-0.18	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23751286	chr5:23951348~24178263:+
BRCA	cis	rs7267979	0.789	rs6083810	ENSG00000277938.1	RP5-965G21.3	-4.21	2.78e-05	0.00204	-0.16	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25349123	chr20:25229150~25231933:+
BRCA	cis	rs6928977	0.538	rs9494290	ENSG00000234084.1	RP3-388E23.2	-4.21	2.78e-05	0.00204	-0.13	-0.13	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135596407	chr6:135301568~135307158:+
BRCA	cis	rs10129255	0.5	rs988134	ENSG00000211959.2	IGHV4-39	4.21	2.78e-05	0.00204	0.09	0.13	Kawasaki disease;	chr14:106776698	chr14:106421711~106422218:-
BRCA	cis	rs10129255	0.5	rs988133	ENSG00000211959.2	IGHV4-39	4.21	2.78e-05	0.00204	0.09	0.13	Kawasaki disease;	chr14:106776724	chr14:106421711~106422218:-
BRCA	cis	rs17065868	1	rs9533890	ENSG00000237361.2	TUSC8	-4.21	2.78e-05	0.00204	-0.28	-0.13	Antineutrophil cytoplasmic antibody-associated vasculitis;	chr13:44524538	chr13:44400250~44405984:-
BRCA	cis	rs13326165	0.76	rs9844183	ENSG00000243224.1	RP5-1157M23.2	-4.21	2.78e-05	0.00204	-0.18	-0.13	HDL cholesterol levels;HDL cholesterol;	chr3:52281176	chr3:52239258~52241097:+
BRCA	cis	rs3892630	0.878	rs114224536	ENSG00000267475.1	CTD-2538C1.2	-4.21	2.78e-05	0.00204	-0.2	-0.13	Red blood cell traits;	chr19:32720326	chr19:32687089~32691750:-
BRCA	cis	rs7267979	1	rs6037099	ENSG00000125804.12	FAM182A	4.21	2.78e-05	0.00204	0.17	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25376240	chr20:26054655~26086917:+
BRCA	cis	rs7267979	0.966	rs4815414	ENSG00000125804.12	FAM182A	4.21	2.78e-05	0.00204	0.17	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25381065	chr20:26054655~26086917:+
BRCA	cis	rs7267979	1	rs6083825	ENSG00000125804.12	FAM182A	4.21	2.78e-05	0.00204	0.17	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25385788	chr20:26054655~26086917:+
BRCA	cis	rs7267979	1	rs34645895	ENSG00000125804.12	FAM182A	4.21	2.78e-05	0.00204	0.17	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25387737	chr20:26054655~26086917:+
BRCA	cis	rs7267979	1	rs6037105	ENSG00000125804.12	FAM182A	4.21	2.78e-05	0.00204	0.17	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25393563	chr20:26054655~26086917:+
BRCA	cis	rs2625529	0.689	rs12161990	ENSG00000260037.4	CTD-2524L6.3	4.21	2.78e-05	0.00204	0.17	0.13	Red blood cell count;	chr15:71910099	chr15:71818396~71823384:+
BRCA	cis	rs739496	0.843	rs10774629	ENSG00000234608.6	MAPKAPK5-AS1	-4.21	2.78e-05	0.00204	-0.16	-0.13	Platelet count;	chr12:111582410	chr12:111839764~111842902:-
BRCA	cis	rs875971	1	rs10257427	ENSG00000236529.1	RP13-254B10.1	-4.21	2.78e-05	0.00204	-0.14	-0.13	Aortic root size;	chr7:66278221	chr7:65840212~65840596:+
BRCA	cis	rs4925386	1	rs4925386	ENSG00000275437.1	RP5-908M14.10	4.21	2.78e-05	0.00204	0.13	0.13	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62345988	chr20:62402236~62405935:-
BRCA	cis	rs656900	0.647	rs600671	ENSG00000261229.4	MTHFS	-4.21	2.78e-05	0.00204	-0.13	-0.13	Cerebrospinal P-tau181p levels;	chr15:79824890	chr15:79843547~79897285:-
BRCA	cis	rs718433	0.585	rs4982491	ENSG00000256379.1	TRAV8-5	4.21	2.78e-05	0.00204	0.15	0.13	Intraocular pressure;	chr14:21742958	chr14:21903077~21903598:+
BRCA	cis	rs34792	0.554	rs62039130	ENSG00000260872.1	RP11-680G24.5	-4.21	2.78e-05	0.00204	-0.15	-0.13	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15518277	chr16:15018106~15020488:-
BRCA	cis	rs2274459	1	rs35445446	ENSG00000249346.5	LINC01016	4.21	2.78e-05	0.00204	0.17	0.13	Obesity (extreme);	chr6:33748968	chr6:33867506~33896914:-
BRCA	cis	rs13113518	0.966	rs11942472	ENSG00000272969.1	RP11-528I4.2	4.21	2.78e-05	0.00204	0.15	0.13	Height;	chr4:55574959	chr4:55547112~55547889:+
BRCA	cis	rs7937890	0.559	rs2034480	ENSG00000254418.1	RP11-21L19.1	4.21	2.78e-05	0.00204	0.15	0.13	Mitochondrial DNA levels;	chr11:14445377	chr11:14262846~14273691:-
BRCA	cis	rs6840360	0.642	rs2724577	ENSG00000251603.1	RP11-164P12.4	-4.21	2.78e-05	0.00204	-0.13	-0.13	Intelligence (multi-trait analysis);	chr4:151433753	chr4:151667224~151670502:+
BRCA	cis	rs1005277	0.579	rs2505248	ENSG00000272983.1	RP11-508N22.12	4.21	2.78e-05	0.00204	0.14	0.13	Extrinsic epigenetic age acceleration;	chr10:38170169	chr10:38137337~38144399:+
BRCA	cis	rs4218	0.505	rs6494064	ENSG00000259732.1	RP11-59H7.3	4.21	2.78e-05	0.00204	0.15	0.13	Social communication problems;	chr15:59053192	chr15:59121034~59133250:+
BRCA	cis	rs10504130	0.569	rs13275967	ENSG00000253844.1	RP11-546K22.1	-4.21	2.78e-05	0.00204	-0.19	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr8:51761316	chr8:51961458~52022974:+
BRCA	cis	rs10504130	0.569	rs13274159	ENSG00000253844.1	RP11-546K22.1	-4.21	2.78e-05	0.00204	-0.19	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr8:51761450	chr8:51961458~52022974:+
BRCA	cis	rs10504130	0.569	rs4436115	ENSG00000253844.1	RP11-546K22.1	-4.21	2.78e-05	0.00204	-0.19	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr8:51761932	chr8:51961458~52022974:+
BRCA	cis	rs10504130	0.569	rs4573262	ENSG00000253844.1	RP11-546K22.1	-4.21	2.78e-05	0.00204	-0.19	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr8:51762249	chr8:51961458~52022974:+
BRCA	cis	rs2115630	1	rs1030863	ENSG00000275120.1	RP11-182J1.17	-4.21	2.79e-05	0.00204	-0.15	-0.13	P wave terminal force;	chr15:84739404	chr15:84599434~84606463:-
BRCA	cis	rs1910358	0.53	rs3846543	ENSG00000248874.4	C5orf17	-4.21	2.79e-05	0.00204	-0.18	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23748073	chr5:23951348~24178263:+
BRCA	cis	rs17772222	0.837	rs1864748	ENSG00000258789.1	RP11-507K2.3	-4.21	2.79e-05	0.00204	-0.16	-0.13	Coronary artery calcification;	chr14:88488847	chr14:88551597~88552493:+
BRCA	cis	rs1005277	0.522	rs11011343	ENSG00000226578.1	RP11-258F22.1	-4.21	2.79e-05	0.00204	-0.14	-0.13	Extrinsic epigenetic age acceleration;	chr10:37713770	chr10:37775371~37784131:-
BRCA	cis	rs595244	1	rs59343375	ENSG00000259705.1	RP11-227D13.1	4.21	2.79e-05	0.00204	0.2	0.13	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48526928	chr15:48645951~48652016:+
BRCA	cis	rs11098499	0.954	rs17006190	ENSG00000260091.1	RP11-33B1.4	-4.21	2.79e-05	0.00204	-0.12	-0.13	Corneal astigmatism;	chr4:119497683	chr4:119409333~119410233:+
BRCA	cis	rs5742933	0.69	rs6726636	ENSG00000253559.1	OSGEPL1-AS1	-4.21	2.79e-05	0.00204	-0.2	-0.13	Ferritin levels;	chr2:189653095	chr2:189762704~189765556:+
BRCA	cis	rs9628987	0.5	rs56812469	ENSG00000270282.1	RP5-1115A15.2	-4.21	2.79e-05	0.00205	-0.18	-0.13	Breast cancer;	chr1:8384170	chr1:8512653~8513021:+
BRCA	cis	rs6865582	0.87	rs11741352	ENSG00000213757.3	CTC-451P13.1	4.21	2.79e-05	0.00205	0.13	0.13	Blood protein levels;	chr5:78890735	chr5:79284132~79284918:-
BRCA	cis	rs12900463	0.813	rs306198	ENSG00000259728.4	LINC00933	-4.21	2.79e-05	0.00205	-0.17	-0.13	Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine);	chr15:84862138	chr15:84570649~84580175:+
BRCA	cis	rs752590	0.806	rs874898	ENSG00000189223.12	PAX8-AS1	-4.21	2.79e-05	0.00205	-0.2	-0.13	Mucinous ovarian carcinoma;	chr2:113216619	chr2:113211522~113276581:+
BRCA	cis	rs17270561	0.639	rs9356989	ENSG00000272462.2	U91328.19	-4.21	2.79e-05	0.00205	-0.16	-0.13	Iron status biomarkers;	chr6:25781722	chr6:25992662~26001775:+
BRCA	cis	rs7561149	1	rs7600330	ENSG00000270574.1	RP11-171I2.2	-4.21	2.79e-05	0.00205	-0.17	-0.13	QT interval;	chr2:178825258	chr2:178578790~178580906:+
BRCA	cis	rs518600	1	rs518600	ENSG00000272716.1	RP11-563N4.1	4.21	2.79e-05	0.00205	0.14	0.13	Interleukin-18 levels;	chr2:31629385	chr2:32165046~32165757:-
BRCA	cis	rs2115630	0.967	rs12595786	ENSG00000275120.1	RP11-182J1.17	-4.21	2.79e-05	0.00205	-0.15	-0.13	P wave terminal force;	chr15:84793439	chr15:84599434~84606463:-
BRCA	cis	rs4474465	1	rs7927722	ENSG00000251323.2	RP11-452H21.4	-4.21	2.79e-05	0.00205	-0.18	-0.13	Alzheimer's disease (survival time);	chr11:78499847	chr11:78423982~78429836:-
BRCA	cis	rs6088580	0.634	rs6059905	ENSG00000275784.1	RP5-1125A11.6	-4.21	2.79e-05	0.00205	-0.14	-0.13	Glomerular filtration rate (creatinine);	chr20:34539142	chr20:33989480~33991818:-
BRCA	cis	rs9926296	0.715	rs467035	ENSG00000261118.1	RP11-104N10.1	-4.21	2.79e-05	0.00205	-0.15	-0.13	Vitiligo;	chr16:89673877	chr16:89492017~89504460:-
BRCA	cis	rs6686842	0.536	rs17358157	ENSG00000235358.1	RP11-399E6.1	-4.21	2.79e-05	0.00205	-0.17	-0.13	Height;	chr1:41233850	chr1:41242373~41284861:+
BRCA	cis	rs3764021	0.506	rs11052372	ENSG00000256673.1	RP11-599J14.2	-4.21	2.79e-05	0.00205	-0.16	-0.13	Type 1 diabetes;	chr12:9679363	chr12:9398355~9414851:-
BRCA	cis	rs4767841	0.552	rs2893796	ENSG00000248636.5	RP11-768F21.1	-4.21	2.79e-05	0.00205	-0.17	-0.13	Urgency urinary incontinence;	chr12:119613464	chr12:119387987~119668079:-
BRCA	cis	rs4218	0.56	rs8039514	ENSG00000259732.1	RP11-59H7.3	-4.21	2.79e-05	0.00205	-0.15	-0.13	Social communication problems;	chr15:59114382	chr15:59121034~59133250:+
BRCA	cis	rs4374383	0.884	rs6726639	ENSG00000243389.1	AC012442.5	-4.21	2.8e-05	0.00205	-0.17	-0.13	Hepatitis C induced liver fibrosis;	chr2:111995520	chr2:112589040~112614431:+
BRCA	cis	rs9868809	0.505	rs28793701	ENSG00000225399.4	RP11-3B7.1	-4.21	2.8e-05	0.00205	-0.2	-0.13	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48725250	chr3:49260085~49261316:+
BRCA	cis	rs409045	0.932	rs375449	ENSG00000271874.1	CTD-2024P10.2	-4.21	2.8e-05	0.00205	-0.17	-0.13	Left ventricular mass;	chr5:34626990	chr5:34651457~34651888:-
BRCA	cis	rs3768617	0.51	rs3768622	ENSG00000224468.3	RP11-181K3.4	-4.21	2.8e-05	0.00205	-0.14	-0.13	Fuchs's corneal dystrophy;	chr1:183120876	chr1:183138402~183141282:-
BRCA	cis	rs12073837	0.5	rs4143772	ENSG00000257551.1	HLX-AS1	-4.21	2.8e-05	0.00205	-0.13	-0.13	F-cell distribution;	chr1:220815004	chr1:220832763~220880140:-
BRCA	cis	rs6012564	0.826	rs6012570	ENSG00000227431.4	CSE1L-AS1	-4.21	2.8e-05	0.00205	-0.17	-0.13	Anger;	chr20:48952121	chr20:49040463~49046044:-
BRCA	cis	rs2834288	0.5	rs2834304	ENSG00000237945.6	LINC00649	4.21	2.8e-05	0.00205	0.15	0.13	Gut microbiota (bacterial taxa);	chr21:33949550	chr21:33915534~33977691:+
BRCA	cis	rs7824557	1	rs7824557	ENSG00000255020.1	AF131216.5	4.21	2.8e-05	0.00205	0.16	0.13	Retinal vascular caliber;	chr8:11246602	chr8:11345748~11347502:-
BRCA	cis	rs12681366	0.614	rs2919663	ENSG00000253704.1	RP11-267M23.4	4.21	2.8e-05	0.00205	0.13	0.13	Nonsyndromic cleft lip with cleft palate;	chr8:94457918	chr8:94553722~94569745:+
BRCA	cis	rs8040855	0.825	rs3964197	ENSG00000259774.1	RP11-182J1.13	4.21	2.8e-05	0.00205	0.16	0.13	Bulimia nervosa;	chr15:85178681	chr15:84422618~84425882:+
BRCA	cis	rs875971	0.545	rs6961853	ENSG00000232546.1	RP11-458F8.1	4.21	2.8e-05	0.00205	0.12	0.13	Aortic root size;	chr7:66537035	chr7:66848496~66858136:+
BRCA	cis	rs10129255	0.536	rs8004835	ENSG00000211967.3	IGHV3-53	-4.21	2.8e-05	0.00205	-0.09	-0.13	Kawasaki disease;	chr14:106686361	chr14:106592676~106593347:-
BRCA	cis	rs13325613	0.915	rs11919884	ENSG00000223552.1	RP11-24F11.2	-4.21	2.8e-05	0.00205	-0.23	-0.13	Monocyte count;	chr3:46259932	chr3:46364955~46407059:-
BRCA	cis	rs875971	0.666	rs13242072	ENSG00000273024.4	INTS4P2	4.21	2.8e-05	0.00205	0.14	0.13	Aortic root size;	chr7:66301001	chr7:65647864~65715661:+
BRCA	cis	rs17489649	0.824	rs724783	ENSG00000271849.1	CTC-332L22.1	4.21	2.8e-05	0.00205	0.16	0.13	Intelligence (multi-trait analysis);	chr5:109717759	chr5:109687802~109688329:-
BRCA	cis	rs465969	0.546	rs7772141	ENSG00000230177.1	RP5-1112D6.4	-4.21	2.8e-05	0.00206	-0.3	-0.13	Psoriasis;	chr6:111472358	chr6:111277932~111278742:+
BRCA	cis	rs465969	0.793	rs7776047	ENSG00000230177.1	RP5-1112D6.4	-4.21	2.8e-05	0.00206	-0.3	-0.13	Psoriasis;	chr6:111472391	chr6:111277932~111278742:+
BRCA	cis	rs2835872	0.828	rs2835840	ENSG00000228677.1	TTC3-AS1	-4.21	2.8e-05	0.00206	-0.17	-0.13	Electroencephalographic traits in alcoholism;	chr21:37619019	chr21:37187666~37193926:-
BRCA	cis	rs4869313	0.905	rs1216566	ENSG00000248734.2	CTD-2260A17.1	4.21	2.81e-05	0.00206	0.13	0.13	Pediatric autoimmune diseases;	chr5:96928352	chr5:96784777~96785999:+
BRCA	cis	rs34787248	1	rs34787248	ENSG00000204709.4	LINC01556	4.21	2.81e-05	0.00206	0.21	0.13	Autism spectrum disorder or schizophrenia;	chr6:28230108	chr6:28943877~28944537:+
BRCA	cis	rs16944613	0.51	rs7163773	ENSG00000245479.2	LINC01585	4.21	2.81e-05	0.00206	0.15	0.13	Colorectal cancer;	chr15:90601254	chr15:90660234~90664967:+
BRCA	cis	rs10029851	0.617	rs6852328	ENSG00000234492.4	RPL34-AS1	4.21	2.81e-05	0.00206	0.15	0.13	Amyotrophic lateral sclerosis (sporadic);	chr4:108692792	chr4:108538190~108620460:-
BRCA	cis	rs1910358	0.554	rs7711725	ENSG00000248874.4	C5orf17	-4.21	2.81e-05	0.00206	-0.18	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23757580	chr5:23951348~24178263:+
BRCA	cis	rs11098499	0.697	rs4560394	ENSG00000225892.3	RP11-384K6.2	4.21	2.81e-05	0.00206	0.13	0.13	Corneal astigmatism;	chr4:119392280	chr4:118632274~118634759:+
BRCA	cis	rs3617	0.625	rs2239548	ENSG00000242142.1	SERBP1P3	4.21	2.81e-05	0.00206	0.14	0.13	Red blood cell count;Autism spectrum disorder or schizophrenia;	chr3:52820170	chr3:53064283~53065091:-
BRCA	cis	rs1867631	0.585	rs12062570	ENSG00000248458.2	RP4-598P13.1	4.21	2.81e-05	0.00206	0.13	0.13	Menopause (age at onset);	chr1:66620602	chr1:66665864~66677027:-
BRCA	cis	rs420259	0.689	rs26765	ENSG00000260136.4	CTD-2270L9.4	4.21	2.81e-05	0.00206	0.12	0.13	Bipolar disorder;	chr16:23688945	chr16:23452758~23457606:+
BRCA	cis	rs11098499	0.78	rs12504773	ENSG00000250412.1	KLHL2P1	4.21	2.81e-05	0.00206	0.16	0.13	Corneal astigmatism;	chr4:119640994	chr4:119334329~119378233:+
BRCA	cis	rs7819412	0.54	rs2409726	ENSG00000255046.1	RP11-297N6.4	4.21	2.81e-05	0.00206	0.16	0.13	Triglycerides;	chr8:11185629	chr8:11797928~11802568:-
BRCA	cis	rs2832077	1	rs2832065	ENSG00000232855.5	AF131217.1	4.21	2.81e-05	0.00206	0.2	0.13	Cognitive test performance;	chr21:28763040	chr21:28439346~28674848:-
BRCA	cis	rs91731	1	rs268710	ENSG00000249572.1	CTD-2203K17.1	-4.21	2.81e-05	0.00206	-0.26	-0.13	Lung function (FVC);	chr5:33369717	chr5:33424025~33440619:-
BRCA	cis	rs6452524	0.868	rs2386235	ENSG00000281327.1	LINC01338	4.21	2.81e-05	0.00206	0.16	0.13	Hypertension (SNP x SNP interaction);	chr5:83101452	chr5:82850864~82859836:-
BRCA	cis	rs7615952	0.932	rs13065725	ENSG00000248787.1	RP11-666A20.4	-4.21	2.81e-05	0.00206	-0.22	-0.13	Blood pressure (smoking interaction);	chr3:125913446	chr3:125908005~125910272:-
BRCA	cis	rs7686660	0.865	rs72615966	ENSG00000250326.1	RP11-284M14.1	-4.21	2.81e-05	0.00206	-0.15	-0.13	Asthma;	chr4:143093140	chr4:142933195~143184861:-
BRCA	cis	rs11711311	1	rs12632983	ENSG00000241529.3	RN7SL767P	-4.21	2.81e-05	0.00206	-0.15	-0.13	IgG glycosylation;	chr3:113763066	chr3:113632704~113632998:+
BRCA	cis	rs4950322	0.57	rs72691095	ENSG00000237188.3	RP11-337C18.8	4.21	2.81e-05	0.00206	0.17	0.13	Protein quantitative trait loci;	chr1:147298305	chr1:147172771~147211568:+
BRCA	cis	rs74665712	0.591	rs12532530	ENSG00000232400.1	RAD17P1	4.21	2.81e-05	0.00206	0.15	0.13	Residual cognition;	chr7:16918018	chr7:16864267~16866308:-
BRCA	cis	rs4648045	0.565	rs4698860	ENSG00000251288.2	RP11-10L12.2	-4.21	2.81e-05	0.00206	-0.16	-0.13	Lymphocyte percentage of white cells;	chr4:102624170	chr4:102751401~102752641:+
BRCA	cis	rs11098499	0.865	rs11722183	ENSG00000250412.1	KLHL2P1	4.21	2.81e-05	0.00206	0.15	0.13	Corneal astigmatism;	chr4:119359442	chr4:119334329~119378233:+
BRCA	cis	rs7577696	0.741	rs2300702	ENSG00000272716.1	RP11-563N4.1	4.21	2.81e-05	0.00206	0.14	0.13	Inflammatory biomarkers;	chr2:31562948	chr2:32165046~32165757:-
BRCA	cis	rs1865760	0.892	rs9379806	ENSG00000272462.2	U91328.19	-4.21	2.81e-05	0.00206	-0.16	-0.13	Height;	chr6:25940730	chr6:25992662~26001775:+
BRCA	cis	rs875971	0.545	rs7783889	ENSG00000232559.3	GS1-124K5.12	4.21	2.81e-05	0.00206	0.18	0.13	Aortic root size;	chr7:66283366	chr7:66554588~66576923:-
BRCA	cis	rs8114671	0.562	rs6088640	ENSG00000126005.14	MMP24-AS1	-4.21	2.81e-05	0.00206	-0.15	-0.13	Height;	chr20:34884706	chr20:35216462~35278131:-
BRCA	cis	rs1823874	0.71	rs2085087	ENSG00000182397.13	DNM1P46	-4.21	2.81e-05	0.00206	-0.14	-0.13	IgG glycosylation;	chr15:99819938	chr15:99790156~99806927:-
BRCA	cis	rs7432375	0.566	rs835636	ENSG00000273486.1	RP11-731C17.2	4.21	2.81e-05	0.00206	0.14	0.13	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136955658	chr3:136837338~136839021:-
BRCA	cis	rs2243480	1	rs2961102	ENSG00000222364.1	RNU6-96P	-4.21	2.81e-05	0.00206	-0.24	-0.13	Diabetic kidney disease;	chr7:65959671	chr7:66395191~66395286:+
BRCA	cis	rs4835473	0.9	rs10032963	ENSG00000249741.2	RP11-673E1.3	-4.21	2.81e-05	0.00206	-0.13	-0.13	Immature fraction of reticulocytes;	chr4:143733068	chr4:143911514~143912053:-
BRCA	cis	rs10129255	0.518	rs10136903	ENSG00000211959.2	IGHV4-39	4.21	2.81e-05	0.00206	0.09	0.13	Kawasaki disease;	chr14:106778866	chr14:106421711~106422218:-
BRCA	cis	rs9470794	1	rs9462389	ENSG00000204110.6	RP1-153P14.8	-4.21	2.81e-05	0.00206	-0.2	-0.13	Type 2 diabetes;	chr6:38145647	chr6:37507348~37535616:+
BRCA	cis	rs8180040	0.577	rs12493425	ENSG00000271161.1	BOLA2P2	4.21	2.81e-05	0.00206	0.14	0.13	Colorectal cancer;	chr3:47135456	chr3:47499841~47500407:+
BRCA	cis	rs8040855	0.756	rs2342118	ENSG00000230373.7	GOLGA6L5P	-4.21	2.82e-05	0.00206	-0.16	-0.13	Bulimia nervosa;	chr15:85149785	chr15:84507885~84516814:-
BRCA	cis	rs7267979	0.844	rs6083851	ENSG00000231081.1	RP4-760C5.3	4.21	2.82e-05	0.00206	0.16	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25420599	chr20:26008791~26010531:-
BRCA	cis	rs9500256	0.903	rs726783	ENSG00000272541.1	XXbac-BPGBPG55C20.1	-4.21	2.82e-05	0.00206	-0.14	-0.13	Eosinophilic esophagitis (pediatric);	chr6:58006583	chr6:57855891~57856468:-
BRCA	cis	rs10911902	0.602	rs3736595	ENSG00000229739.2	RP11-295K2.3	-4.21	2.82e-05	0.00206	-0.21	-0.13	Schizophrenia;	chr1:186331745	chr1:186435161~186470291:+
BRCA	cis	rs2574985	0.813	rs1203411	ENSG00000231345.3	BEND3P1	-4.21	2.82e-05	0.00206	-0.22	-0.13	Subjective well-being;	chr10:50434498	chr10:50655967~50660472:+
BRCA	cis	rs748404	0.666	rs34633582	ENSG00000205771.5	CATSPER2P1	-4.21	2.82e-05	0.00206	-0.19	-0.13	Lung cancer;	chr15:43462683	chr15:43726918~43747094:-
BRCA	cis	rs2115630	1	rs6496441	ENSG00000275120.1	RP11-182J1.17	-4.21	2.82e-05	0.00206	-0.15	-0.13	P wave terminal force;	chr15:84820117	chr15:84599434~84606463:-
BRCA	cis	rs801193	1	rs6975195	ENSG00000223473.2	GS1-124K5.3	-4.21	2.82e-05	0.00206	-0.1	-0.13	Aortic root size;	chr7:66659787	chr7:66491049~66493566:-
BRCA	cis	rs180730	1	rs3114955	ENSG00000251609.2	SETP12	-4.21	2.82e-05	0.00206	-0.19	-0.13	Fasting plasma glucose;	chr4:120884835	chr4:120895494~120897083:-
BRCA	cis	rs7727544	0.647	rs7721882	ENSG00000233006.5	AC034220.3	4.21	2.82e-05	0.00207	0.1	0.13	Blood metabolite levels;	chr5:132083255	chr5:132311285~132369916:-
BRCA	cis	rs1005277	0.579	rs1780145	ENSG00000099251.13	HSD17B7P2	4.21	2.82e-05	0.00207	0.14	0.13	Extrinsic epigenetic age acceleration;	chr10:38248142	chr10:38356380~38378505:+
BRCA	cis	rs2554380	0.8	rs8032414	ENSG00000230373.7	GOLGA6L5P	-4.21	2.82e-05	0.00207	-0.18	-0.13	Height;	chr15:83727217	chr15:84507885~84516814:-
BRCA	cis	rs1005277	0.579	rs2474587	ENSG00000272983.1	RP11-508N22.12	4.21	2.82e-05	0.00207	0.14	0.13	Extrinsic epigenetic age acceleration;	chr10:38131738	chr10:38137337~38144399:+
BRCA	cis	rs1005277	0.579	rs2474588	ENSG00000272983.1	RP11-508N22.12	4.21	2.82e-05	0.00207	0.14	0.13	Extrinsic epigenetic age acceleration;	chr10:38131942	chr10:38137337~38144399:+
BRCA	cis	rs6751744	0.824	rs10205689	ENSG00000230783.1	AC009961.2	-4.21	2.82e-05	0.00207	-0.17	-0.13	Dysphagia;	chr2:159507158	chr2:159689217~159690291:-
BRCA	cis	rs2880765	0.835	rs6497202	ENSG00000202081.1	RNU6-1280P	4.21	2.82e-05	0.00207	0.15	0.13	Coronary artery disease;	chr15:85478144	chr15:85651522~85651628:-
BRCA	cis	rs4919687	0.55	rs10437480	ENSG00000213061.2	PFN1P11	4.21	2.82e-05	0.00207	0.18	0.13	Colorectal cancer;	chr10:102693267	chr10:102838011~102845473:-
BRCA	cis	rs4919687	0.55	rs4264100	ENSG00000213061.2	PFN1P11	4.21	2.82e-05	0.00207	0.18	0.13	Colorectal cancer;	chr10:102694356	chr10:102838011~102845473:-
BRCA	cis	rs1124769	0.619	rs7170036	ENSG00000273674.3	CTD-2378E12.1	4.21	2.82e-05	0.00207	0.15	0.13	Cognitive performance;	chr15:50956106	chr15:50839875~50908599:-
BRCA	cis	rs4879656	0.525	rs13300152	ENSG00000236184.1	TCEA1P4	4.21	2.82e-05	0.00207	0.17	0.13	Menopause (age at onset);	chr9:33097998	chr9:32979560~32980403:-
BRCA	cis	rs853679	0.517	rs4713146	ENSG00000216901.1	AL022393.7	4.21	2.82e-05	0.00207	0.19	0.13	Depression;	chr6:28143758	chr6:28176188~28176674:+
BRCA	cis	rs853679	0.517	rs9393894	ENSG00000216901.1	AL022393.7	4.21	2.82e-05	0.00207	0.19	0.13	Depression;	chr6:28144784	chr6:28176188~28176674:+
BRCA	cis	rs13325613	0.834	rs10510749	ENSG00000223552.1	RP11-24F11.2	4.21	2.83e-05	0.00207	0.23	0.13	Monocyte count;	chr3:46138924	chr3:46364955~46407059:-
BRCA	cis	rs3892630	0.824	rs7247264	ENSG00000267475.1	CTD-2538C1.2	-4.21	2.83e-05	0.00207	-0.2	-0.13	Red blood cell traits;	chr19:32748940	chr19:32687089~32691750:-
BRCA	cis	rs3892630	0.824	rs34748593	ENSG00000267475.1	CTD-2538C1.2	-4.21	2.83e-05	0.00207	-0.2	-0.13	Red blood cell traits;	chr19:32749541	chr19:32687089~32691750:-
BRCA	cis	rs7267979	0.789	rs1983974	ENSG00000231081.1	RP4-760C5.3	4.21	2.83e-05	0.00207	0.16	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25549983	chr20:26008791~26010531:-
BRCA	cis	rs7119	0.717	rs12904254	ENSG00000259362.2	RP11-307C19.1	-4.21	2.83e-05	0.00207	-0.18	-0.13	Type 2 diabetes;	chr15:77510243	chr15:77525540~77534110:+
BRCA	cis	rs9733	0.596	rs12089989	ENSG00000231073.1	RP11-316M1.3	4.21	2.83e-05	0.00207	0.13	0.13	Tonsillectomy;	chr1:150743306	chr1:150973123~150975534:+
BRCA	cis	rs7267979	1	rs6050555	ENSG00000274973.1	RP13-401N8.7	4.21	2.83e-05	0.00207	0.15	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25347907	chr20:25845497~25845862:+
BRCA	cis	rs1115240	0.704	rs1955850	ENSG00000262119.1	RP11-483C6.1	4.21	2.83e-05	0.00207	0.14	0.13	Educational attainment (years of education);	chr14:26654208	chr14:26592747~26594517:-
BRCA	cis	rs11673344	0.526	rs2306201	ENSG00000267422.1	CTD-2554C21.1	4.21	2.83e-05	0.00207	0.18	0.13	Obesity-related traits;	chr19:37586573	chr19:37779686~37792865:+
BRCA	cis	rs11673344	0.526	rs2291001	ENSG00000267422.1	CTD-2554C21.1	4.21	2.83e-05	0.00207	0.18	0.13	Obesity-related traits;	chr19:37594431	chr19:37779686~37792865:+
BRCA	cis	rs1043099	0.912	rs4820831	ENSG00000279699.1	RP1-102K2.9	4.21	2.83e-05	0.00207	0.22	0.13	Rheumatoid arthritis;	chr22:30315454	chr22:30275215~30276951:-
BRCA	cis	rs1005277	0.579	rs1780130	ENSG00000272983.1	RP11-508N22.12	4.21	2.83e-05	0.00207	0.14	0.13	Extrinsic epigenetic age acceleration;	chr10:38196450	chr10:38137337~38144399:+
BRCA	cis	rs4835473	0.897	rs1817027	ENSG00000249741.2	RP11-673E1.3	4.21	2.83e-05	0.00207	0.15	0.13	Immature fraction of reticulocytes;	chr4:143713336	chr4:143911514~143912053:-
BRCA	cis	rs12744310	1	rs12034357	ENSG00000235358.1	RP11-399E6.1	4.21	2.83e-05	0.00207	0.19	0.13	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41302557	chr1:41242373~41284861:+
BRCA	cis	rs12744310	1	rs7553908	ENSG00000235358.1	RP11-399E6.1	4.21	2.83e-05	0.00207	0.19	0.13	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41302569	chr1:41242373~41284861:+
BRCA	cis	rs1823874	0.71	rs2902472	ENSG00000182397.13	DNM1P46	-4.21	2.83e-05	0.00207	-0.14	-0.13	IgG glycosylation;	chr15:99824257	chr15:99790156~99806927:-
BRCA	cis	rs1005277	0.579	rs1985707	ENSG00000272983.1	RP11-508N22.12	4.21	2.83e-05	0.00207	0.14	0.13	Extrinsic epigenetic age acceleration;	chr10:38145170	chr10:38137337~38144399:+
BRCA	cis	rs853679	0.517	rs9295761	ENSG00000216901.1	AL022393.7	4.21	2.83e-05	0.00207	0.19	0.13	Depression;	chr6:28180209	chr6:28176188~28176674:+
BRCA	cis	rs721917	0.506	rs2819102	ENSG00000242600.5	MBL1P	4.21	2.83e-05	0.00207	0.16	0.13	Chronic obstructive pulmonary disease;	chr10:79928914	chr10:79904898~79950336:+
BRCA	cis	rs997295	0.713	rs8042567	ENSG00000270964.1	RP11-502I4.3	-4.21	2.83e-05	0.00207	-0.14	-0.13	Motion sickness;	chr15:67683261	chr15:67541072~67542604:-
BRCA	cis	rs10761482	1	rs10761482	ENSG00000254271.1	RP11-131N11.4	-4.21	2.83e-05	0.00207	-0.18	-0.13	Schizophrenia;	chr10:60325579	chr10:60734342~60741828:+
BRCA	cis	rs9788721	0.9	rs72740964	ENSG00000261762.1	RP11-650L12.2	-4.21	2.83e-05	0.00207	-0.16	-0.13	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78576294	chr15:78589123~78591276:-
BRCA	cis	rs7727544	0.647	rs6898270	ENSG00000233006.5	AC034220.3	4.21	2.83e-05	0.00207	0.1	0.13	Blood metabolite levels;	chr5:132085497	chr5:132311285~132369916:-
BRCA	cis	rs4713118	0.699	rs200969	ENSG00000280107.1	AL022393.9	-4.21	2.83e-05	0.00207	-0.19	-0.13	Parkinson's disease;	chr6:27891675	chr6:28170845~28172521:+
BRCA	cis	rs1048886	0.872	rs12527634	ENSG00000271967.1	RP11-134K13.4	-4.21	2.83e-05	0.00207	-0.18	-0.13	Type 2 diabetes;	chr6:70510304	chr6:70596438~70596980:+
BRCA	cis	rs10266483	0.739	rs682662	ENSG00000271550.1	BNIP3P11	4.21	2.83e-05	0.00207	0.17	0.13	Response to statin therapy;	chr7:64306107	chr7:64678954~64687393:-
BRCA	cis	rs10266483	0.739	rs679966	ENSG00000271550.1	BNIP3P11	4.21	2.83e-05	0.00207	0.17	0.13	Response to statin therapy;	chr7:64306688	chr7:64678954~64687393:-
BRCA	cis	rs875971	0.545	rs35459055	ENSG00000232546.1	RP11-458F8.1	4.21	2.83e-05	0.00207	0.12	0.13	Aortic root size;	chr7:66479399	chr7:66848496~66858136:+
BRCA	cis	rs2731006	0.591	rs908658	ENSG00000257114.2	RP11-25I15.3	-4.21	2.83e-05	0.00207	-0.21	-0.13	Panic disorder;	chr12:42774929	chr12:42692216~42717119:+
BRCA	cis	rs28374715	0.578	rs7169543	ENSG00000247556.5	OIP5-AS1	4.21	2.83e-05	0.00207	0.15	0.13	Ulcerative colitis;	chr15:41328207	chr15:41283990~41309737:+
BRCA	cis	rs28374715	0.528	rs28492932	ENSG00000247556.5	OIP5-AS1	4.21	2.83e-05	0.00207	0.15	0.13	Ulcerative colitis;	chr15:41332199	chr15:41283990~41309737:+
BRCA	cis	rs3176789	0.624	rs11052978	ENSG00000256673.1	RP11-599J14.2	4.21	2.83e-05	0.00207	0.15	0.13	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9767882	chr12:9398355~9414851:-
BRCA	cis	rs875971	0.545	rs12670811	ENSG00000230295.1	RP11-458F8.2	4.21	2.83e-05	0.00207	0.12	0.13	Aortic root size;	chr7:66358032	chr7:66880708~66882981:+
BRCA	cis	rs11098499	1	rs28374891	ENSG00000260091.1	RP11-33B1.4	-4.21	2.83e-05	0.00207	-0.12	-0.13	Corneal astigmatism;	chr4:119262395	chr4:119409333~119410233:+
BRCA	cis	rs7771547	0.723	rs9394363	ENSG00000224666.3	RP1-50J22.4	4.2	2.84e-05	0.00208	0.15	0.13	Platelet distribution width;	chr6:36591187	chr6:36386831~36393462:+
BRCA	cis	rs757081	0.658	rs190046	ENSG00000184669.7	OR7E14P	-4.2	2.84e-05	0.00208	-0.17	-0.13	Systolic blood pressure;	chr11:17271809	chr11:17013998~17053024:+
BRCA	cis	rs757110	0.524	rs214095	ENSG00000184669.7	OR7E14P	-4.2	2.84e-05	0.00208	-0.17	-0.13	Type 2 diabetes;	chr11:17271915	chr11:17013998~17053024:+
BRCA	cis	rs10761482	0.859	rs1599166	ENSG00000254271.1	RP11-131N11.4	4.2	2.84e-05	0.00208	0.18	0.13	Schizophrenia;	chr10:60403971	chr10:60734342~60741828:+
BRCA	cis	rs72482608	0.865	rs7523880	ENSG00000271811.1	RP1-79C4.4	4.2	2.84e-05	0.00208	0.14	0.13	Emphysema imaging phenotypes;	chr1:170800838	chr1:170667381~170669425:+
BRCA	cis	rs6545883	0.929	rs1838978	ENSG00000212978.6	AC016747.3	-4.2	2.84e-05	0.00208	-0.18	-0.13	Tuberculosis;	chr2:61313788	chr2:61141592~61144969:-
BRCA	cis	rs4819052	1	rs13053002	ENSG00000184274.3	LINC00315	-4.2	2.84e-05	0.00208	-0.19	-0.13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45257939	chr21:45300245~45305257:-
BRCA	cis	rs7267979	0.528	rs2387976	ENSG00000231081.1	RP4-760C5.3	4.2	2.84e-05	0.00208	0.17	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25618924	chr20:26008791~26010531:-
BRCA	cis	rs2625529	0.824	rs7170754	ENSG00000260037.4	CTD-2524L6.3	-4.2	2.84e-05	0.00208	-0.19	-0.13	Red blood cell count;	chr15:71926253	chr15:71818396~71823384:+
BRCA	cis	rs2625529	0.824	rs7170461	ENSG00000260037.4	CTD-2524L6.3	-4.2	2.84e-05	0.00208	-0.19	-0.13	Red blood cell count;	chr15:71926258	chr15:71818396~71823384:+
BRCA	cis	rs2164068	0.57	rs700677	ENSG00000231621.1	AC013264.2	4.2	2.84e-05	0.00208	0.13	0.13	Allergy;	chr2:197837700	chr2:197197991~197199273:+
BRCA	cis	rs10129255	0.5	rs10131875	ENSG00000232216.1	IGHV3-43	4.2	2.84e-05	0.00208	0.09	0.13	Kawasaki disease;	chr14:106792798	chr14:106470264~106470800:-
BRCA	cis	rs10129255	0.5	rs6576232	ENSG00000211967.3	IGHV3-53	-4.2	2.84e-05	0.00208	-0.08	-0.13	Kawasaki disease;	chr14:106787090	chr14:106592676~106593347:-
BRCA	cis	rs957448	0.561	rs4735302	ENSG00000261437.1	RP11-22C11.2	-4.2	2.84e-05	0.00208	-0.12	-0.13	Nonsyndromic cleft lip with cleft palate;	chr8:94604752	chr8:94637285~94639467:-
BRCA	cis	rs7572733	0.84	rs1065953	ENSG00000231621.1	AC013264.2	-4.2	2.84e-05	0.00208	-0.12	-0.13	Dermatomyositis;	chr2:197749888	chr2:197197991~197199273:+
BRCA	cis	rs7727544	0.582	rs4361509	ENSG00000233006.5	AC034220.3	-4.2	2.84e-05	0.00208	-0.1	-0.13	Blood metabolite levels;	chr5:132201060	chr5:132311285~132369916:-
BRCA	cis	rs11096990	0.6	rs6835337	ENSG00000249685.1	RP11-360F5.3	-4.2	2.84e-05	0.00208	-0.16	-0.13	Cognitive function;	chr4:39281189	chr4:39133913~39135608:+
BRCA	cis	rs7267979	0.844	rs6107027	ENSG00000231081.1	RP4-760C5.3	-4.2	2.84e-05	0.00208	-0.16	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25307996	chr20:26008791~26010531:-
BRCA	cis	rs6585424	1	rs35497678	ENSG00000225484.5	NUTM2B-AS1	-4.2	2.84e-05	0.00208	-0.25	-0.13	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80161322	chr10:79663088~79826594:-
BRCA	cis	rs6585424	1	rs2304410	ENSG00000225484.5	NUTM2B-AS1	-4.2	2.84e-05	0.00208	-0.25	-0.13	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80162054	chr10:79663088~79826594:-
BRCA	cis	rs6585424	0.778	rs12257082	ENSG00000225484.5	NUTM2B-AS1	-4.2	2.84e-05	0.00208	-0.25	-0.13	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80162365	chr10:79663088~79826594:-
BRCA	cis	rs6585424	1	rs34100029	ENSG00000225484.5	NUTM2B-AS1	-4.2	2.84e-05	0.00208	-0.25	-0.13	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80163842	chr10:79663088~79826594:-
BRCA	cis	rs115769866	0.618	rs7759252	ENSG00000216901.1	AL022393.7	4.2	2.84e-05	0.00208	0.19	0.13	Bipolar disorder;	chr6:28501645	chr6:28176188~28176674:+
BRCA	cis	rs6012564	1	rs6125539	ENSG00000227431.4	CSE1L-AS1	4.2	2.84e-05	0.00208	0.16	0.13	Anger;	chr20:49087273	chr20:49040463~49046044:-
BRCA	cis	rs256438	0.93	rs2438635	ENSG00000251050.1	RP11-168A11.4	-4.2	2.84e-05	0.00208	-0.15	-0.13	Serum thyroid-stimulating hormone levels;	chr5:80095582	chr5:80019609~80019920:+
BRCA	cis	rs13108904	0.901	rs6826029	ENSG00000253399.1	AC078852.2	-4.2	2.84e-05	0.00208	-0.14	-0.13	Obesity-related traits;	chr4:1313901	chr4:1358479~1359461:+
BRCA	cis	rs6671200	0.748	rs11586384	ENSG00000235501.4	RP4-639F20.1	-4.2	2.84e-05	0.00208	-0.28	-0.13	Stearic acid (18:0) levels;	chr1:95006185	chr1:94927566~94963270:+
BRCA	cis	rs6671200	0.667	rs12739445	ENSG00000235501.4	RP4-639F20.1	-4.2	2.84e-05	0.00208	-0.28	-0.13	Stearic acid (18:0) levels;	chr1:95007082	chr1:94927566~94963270:+
BRCA	cis	rs2255336	0.938	rs10161486	ENSG00000245648.1	RP11-277P12.20	-4.2	2.84e-05	0.00208	-0.2	-0.13	Blood protein levels;	chr12:10457167	chr12:10363769~10398506:+
BRCA	cis	rs2255336	0.938	rs73070924	ENSG00000245648.1	RP11-277P12.20	-4.2	2.84e-05	0.00208	-0.2	-0.13	Blood protein levels;	chr12:10457386	chr12:10363769~10398506:+
BRCA	cis	rs11887277	0.718	rs12992179	ENSG00000272148.1	RP11-195B17.1	-4.2	2.84e-05	0.00208	-0.15	-0.13	Obesity-related traits;	chr2:26808403	chr2:27062428~27062907:-
BRCA	cis	rs1008375	0.966	rs11733730	ENSG00000249502.1	AC006160.5	-4.2	2.84e-05	0.00208	-0.15	-0.13	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17623586	chr4:17587467~17614571:-
BRCA	cis	rs11892454	0.515	rs2176181	ENSG00000217643.1	PTGES3P2	-4.2	2.84e-05	0.00208	-0.13	-0.13	Heschl's gyrus morphology;	chr2:25807470	chr2:25822469~25822950:+
BRCA	cis	rs11892454	0.515	rs2176180	ENSG00000217643.1	PTGES3P2	-4.2	2.84e-05	0.00208	-0.13	-0.13	Heschl's gyrus morphology;	chr2:25807499	chr2:25822469~25822950:+
BRCA	cis	rs28829049	0.597	rs12563386	ENSG00000270728.1	RP4-657E11.10	-4.2	2.84e-05	0.00208	-0.13	-0.13	QRS duration in Tripanosoma cruzi seropositivity;	chr1:19128711	chr1:19297080~19297903:+
BRCA	cis	rs568617	0.859	rs1204650	ENSG00000254510.1	RP11-867G23.10	-4.2	2.84e-05	0.00208	-0.16	-0.13	Crohn's disease;	chr11:65878109	chr11:66409158~66417137:+
BRCA	cis	rs568617	0.953	rs1151519	ENSG00000254510.1	RP11-867G23.10	-4.2	2.84e-05	0.00208	-0.16	-0.13	Crohn's disease;	chr11:65878360	chr11:66409158~66417137:+
BRCA	cis	rs568617	0.903	rs601863	ENSG00000254510.1	RP11-867G23.10	-4.2	2.84e-05	0.00208	-0.16	-0.13	Crohn's disease;	chr11:65879086	chr11:66409158~66417137:+
BRCA	cis	rs6088580	0.602	rs6058064	ENSG00000276073.1	RP5-1125A11.7	-4.2	2.85e-05	0.00208	-0.14	-0.13	Glomerular filtration rate (creatinine);	chr20:34498817	chr20:33985617~33988989:-
BRCA	cis	rs4660214	0.666	rs7554206	ENSG00000237624.1	OXCT2P1	-4.2	2.85e-05	0.00208	-0.16	-0.13	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39463568	chr1:39514956~39516490:+
BRCA	cis	rs38055	0.837	rs574790	ENSG00000247796.2	CTD-2366F13.1	-4.2	2.85e-05	0.00208	-0.15	-0.13	Acne (severe);	chr5:53330469	chr5:53109842~53115126:+
BRCA	cis	rs6001482	0.679	rs1894238	ENSG00000279278.1	CH17-264L24.1	4.2	2.85e-05	0.00208	0.11	0.13	Diastolic blood pressure;	chr22:22235704	chr22:22264601~22273020:+
BRCA	cis	rs4650943	0.565	rs352334	ENSG00000227740.1	RP11-318C24.2	-4.2	2.85e-05	0.00208	-0.13	-0.13	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in inactive individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr1:176268934	chr1:175904762~175920513:-
BRCA	cis	rs2380205	0.967	rs9663697	ENSG00000232807.2	RP11-536K7.3	4.2	2.85e-05	0.00208	0.13	0.13	Breast cancer;	chr10:5855943	chr10:5934270~5945900:-
BRCA	cis	rs78487399	0.808	rs10200815	ENSG00000234936.1	AC010883.5	4.2	2.85e-05	0.00208	0.18	0.13	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43446134	chr2:43229573~43233394:+
BRCA	cis	rs71636778	0.509	rs17340509	ENSG00000260063.1	RP5-968P14.2	-4.2	2.85e-05	0.00208	-0.29	-0.13	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26948209	chr1:26692132~26694131:-
BRCA	cis	rs71636778	0.509	rs17360994	ENSG00000260063.1	RP5-968P14.2	-4.2	2.85e-05	0.00208	-0.29	-0.13	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26952082	chr1:26692132~26694131:-
BRCA	cis	rs6067053	0.621	rs11696801	ENSG00000227431.4	CSE1L-AS1	4.2	2.85e-05	0.00208	0.16	0.13	Intelligence (multi-trait analysis);	chr20:49251062	chr20:49040463~49046044:-
BRCA	cis	rs2446066	0.872	rs11170555	ENSG00000257379.1	RP11-793H13.8	4.2	2.85e-05	0.00208	0.21	0.13	Red blood cell count;	chr12:53430359	chr12:53441741~53467528:+
BRCA	cis	rs2446066	0.872	rs17099205	ENSG00000257379.1	RP11-793H13.8	4.2	2.85e-05	0.00208	0.21	0.13	Red blood cell count;	chr12:53430798	chr12:53441741~53467528:+
BRCA	cis	rs2446066	0.872	rs12368222	ENSG00000257379.1	RP11-793H13.8	4.2	2.85e-05	0.00208	0.21	0.13	Red blood cell count;	chr12:53430960	chr12:53441741~53467528:+
BRCA	cis	rs4415084	0.768	rs9292915	ENSG00000251141.4	RP11-53O19.1	-4.2	2.85e-05	0.00208	-0.12	-0.13	Breast cancer;	chr5:44871555	chr5:44744900~44808777:-
BRCA	cis	rs6671200	0.607	rs2147587	ENSG00000235501.4	RP4-639F20.1	4.2	2.85e-05	0.00208	0.21	0.13	Stearic acid (18:0) levels;	chr1:95249328	chr1:94927566~94963270:+
BRCA	cis	rs4950322	0.518	rs55697094	ENSG00000237188.3	RP11-337C18.8	4.2	2.85e-05	0.00208	0.16	0.13	Protein quantitative trait loci;	chr1:147121205	chr1:147172771~147211568:+
BRCA	cis	rs875971	0.545	rs2279757	ENSG00000230295.1	RP11-458F8.2	4.2	2.85e-05	0.00208	0.13	0.13	Aortic root size;	chr7:66363676	chr7:66880708~66882981:+
BRCA	cis	rs875971	0.545	rs11766183	ENSG00000230295.1	RP11-458F8.2	4.2	2.85e-05	0.00208	0.13	0.13	Aortic root size;	chr7:66374173	chr7:66880708~66882981:+
BRCA	cis	rs875971	0.545	rs1065265	ENSG00000230295.1	RP11-458F8.2	4.2	2.85e-05	0.00208	0.13	0.13	Aortic root size;	chr7:66376216	chr7:66880708~66882981:+
BRCA	cis	rs67766926	0.761	rs10179897	ENSG00000271889.1	RP11-493E12.1	4.2	2.85e-05	0.00208	0.19	0.13	Inflammatory skin disease;	chr2:60877700	chr2:61151433~61162105:-
BRCA	cis	rs875971	1	rs7789554	ENSG00000229180.5	GS1-124K5.11	4.2	2.85e-05	0.00208	0.11	0.13	Aortic root size;	chr7:66481051	chr7:66526088~66542624:-
BRCA	cis	rs875971	1	rs4717300	ENSG00000229180.5	GS1-124K5.11	4.2	2.85e-05	0.00208	0.11	0.13	Aortic root size;	chr7:66482393	chr7:66526088~66542624:-
BRCA	cis	rs875971	0.895	rs1974769	ENSG00000229180.5	GS1-124K5.11	4.2	2.85e-05	0.00208	0.11	0.13	Aortic root size;	chr7:66485627	chr7:66526088~66542624:-
BRCA	cis	rs875971	0.895	rs6460300	ENSG00000229180.5	GS1-124K5.11	4.2	2.85e-05	0.00208	0.11	0.13	Aortic root size;	chr7:66487937	chr7:66526088~66542624:-
BRCA	cis	rs875971	0.862	rs7803416	ENSG00000229180.5	GS1-124K5.11	4.2	2.85e-05	0.00208	0.11	0.13	Aortic root size;	chr7:66489212	chr7:66526088~66542624:-
BRCA	cis	rs875971	0.964	rs2277911	ENSG00000229180.5	GS1-124K5.11	4.2	2.85e-05	0.00208	0.11	0.13	Aortic root size;	chr7:66493638	chr7:66526088~66542624:-
BRCA	cis	rs801193	0.967	rs2707849	ENSG00000223473.2	GS1-124K5.3	4.2	2.85e-05	0.00208	0.1	0.13	Aortic root size;	chr7:66687725	chr7:66491049~66493566:-
BRCA	cis	rs6012564	1	rs3092374	ENSG00000230758.1	SNAP23P	-4.2	2.85e-05	0.00208	-0.15	-0.13	Anger;	chr20:49047407	chr20:49038357~49038602:-
BRCA	cis	rs7267979	0.932	rs431579	ENSG00000277938.1	RP5-965G21.3	4.2	2.85e-05	0.00208	0.15	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25489420	chr20:25229150~25231933:+
BRCA	cis	rs12554020	0.892	rs75625893	ENSG00000227603.1	RP11-165J3.6	4.2	2.85e-05	0.00209	0.19	0.13	Schizophrenia;	chr9:93605006	chr9:93435332~93437121:-
BRCA	cis	rs321358	0.895	rs7950087	ENSG00000271390.1	RP11-89C3.3	-4.2	2.85e-05	0.00209	-0.2	-0.13	Body mass index;	chr11:111082536	chr11:111089870~111090368:-
BRCA	cis	rs2136613	0.533	rs1509956	ENSG00000238280.1	RP11-436D10.3	-4.2	2.85e-05	0.00209	-0.16	-0.13	Selective IgA deficiency;	chr10:62843574	chr10:62793562~62805887:-
BRCA	cis	rs9549260	0.753	rs9532563	ENSG00000168852.11	TPTE2P5	4.2	2.85e-05	0.00209	0.14	0.13	Red blood cell count;	chr13:40586133	chr13:40822296~40921749:-
BRCA	cis	rs11673344	0.523	rs2082010	ENSG00000226686.6	LINC01535	4.2	2.85e-05	0.00209	0.17	0.13	Obesity-related traits;	chr19:37039874	chr19:37251912~37265535:+
BRCA	cis	rs11098499	0.954	rs59394118	ENSG00000225892.3	RP11-384K6.2	4.2	2.85e-05	0.00209	0.13	0.13	Corneal astigmatism;	chr4:119374396	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.865	rs9996417	ENSG00000225892.3	RP11-384K6.2	4.2	2.85e-05	0.00209	0.13	0.13	Corneal astigmatism;	chr4:119374707	chr4:118632274~118634759:+
BRCA	cis	rs4787491	0.704	rs35605010	ENSG00000183604.13	SMG1P5	-4.2	2.85e-05	0.00209	-0.12	-0.13	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30022107	chr16:30267553~30335374:-
BRCA	cis	rs4143844	0.867	rs11071640	ENSG00000259251.2	RP11-643M14.1	4.2	2.85e-05	0.00209	0.32	0.13	Bipolar disorder and schizophrenia;	chr15:61918305	chr15:62060503~62062434:+
BRCA	cis	rs4143844	0.867	rs12907567	ENSG00000259251.2	RP11-643M14.1	4.2	2.85e-05	0.00209	0.32	0.13	Bipolar disorder and schizophrenia;	chr15:61922408	chr15:62060503~62062434:+
BRCA	cis	rs4143844	0.867	rs34853395	ENSG00000259251.2	RP11-643M14.1	4.2	2.85e-05	0.00209	0.32	0.13	Bipolar disorder and schizophrenia;	chr15:61923024	chr15:62060503~62062434:+
BRCA	cis	rs8020289	0.56	rs4903492	ENSG00000258569.1	RP11-99E15.2	4.2	2.85e-05	0.00209	0.15	0.13	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks);	chr14:76798185	chr14:76710658~76761388:-
BRCA	cis	rs10129255	0.5	rs11628999	ENSG00000232216.1	IGHV3-43	4.2	2.85e-05	0.00209	0.09	0.13	Kawasaki disease;	chr14:106800208	chr14:106470264~106470800:-
BRCA	cis	rs9308731	0.591	rs9308742	ENSG00000230499.1	AC108463.1	-4.2	2.86e-05	0.00209	-0.15	-0.13	Chronic lymphocytic leukemia;	chr2:111186044	chr2:111195963~111206494:+
BRCA	cis	rs6430585	0.527	rs7592050	ENSG00000224043.6	CCNT2-AS1	4.2	2.86e-05	0.00209	0.21	0.13	Corneal structure;	chr2:135701657	chr2:134735464~134918710:-
BRCA	cis	rs11083475	1	rs883433	ENSG00000267892.1	CTD-2540F13.2	-4.2	2.86e-05	0.00209	-0.14	-0.13	Heart rate;	chr19:38715648	chr19:38738284~38739863:+
BRCA	cis	rs11098499	1	rs58601355	ENSG00000250412.1	KLHL2P1	4.2	2.86e-05	0.00209	0.16	0.13	Corneal astigmatism;	chr4:119265212	chr4:119334329~119378233:+
BRCA	cis	rs7811142	0.945	rs6955362	ENSG00000078319.8	PMS2P1	-4.2	2.86e-05	0.00209	-0.21	-0.13	Platelet count;	chr7:100458543	chr7:100320992~100341908:-
BRCA	cis	rs7811142	1	rs6975514	ENSG00000078319.8	PMS2P1	-4.2	2.86e-05	0.00209	-0.21	-0.13	Platelet count;	chr7:100458597	chr7:100320992~100341908:-
BRCA	cis	rs1555321	0.571	rs1331316	ENSG00000273038.2	RP11-479G22.8	4.2	2.86e-05	0.00209	0.16	0.13	Coronary artery disease;	chr10:33228923	chr10:32887255~32889311:-
BRCA	cis	rs12681366	0.537	rs2381886	ENSG00000253175.1	RP11-267M23.6	4.2	2.86e-05	0.00209	0.15	0.13	Nonsyndromic cleft lip with cleft palate;	chr8:94464825	chr8:94565036~94565715:+
BRCA	cis	rs7200543	1	rs1136001	ENSG00000207425.1	Y_RNA	-4.2	2.86e-05	0.00209	-0.16	-0.13	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15038117	chr16:14915457~14915556:-
BRCA	cis	rs7475343	0.501	rs7908297	ENSG00000224034.1	RP11-445P17.8	-4.2	2.86e-05	0.00209	-0.25	-0.13	Intelligence;	chr10:5209739	chr10:5266033~5271236:-
BRCA	cis	rs9818758	0.556	rs9813813	ENSG00000225399.4	RP11-3B7.1	-4.2	2.86e-05	0.00209	-0.24	-0.13	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49169660	chr3:49260085~49261316:+
BRCA	cis	rs6452524	1	rs10037872	ENSG00000281327.1	LINC01338	4.2	2.86e-05	0.00209	0.15	0.13	Hypertension (SNP x SNP interaction);	chr5:83144101	chr5:82850864~82859836:-
BRCA	cis	rs9733	0.596	rs72702585	ENSG00000231073.1	RP11-316M1.3	4.2	2.86e-05	0.00209	0.13	0.13	Tonsillectomy;	chr1:150723951	chr1:150973123~150975534:+
BRCA	cis	rs8058578	0.832	rs7500719	ENSG00000280211.1	RP11-2C24.3	4.2	2.86e-05	0.00209	0.13	0.13	Multiple myeloma;	chr16:30829556	chr16:30773532~30776033:-
BRCA	cis	rs6596100	0.868	rs3935119	ENSG00000248648.1	RP11-485M7.1	-4.2	2.87e-05	0.00209	-0.17	-0.13	Breast cancer;	chr5:133057648	chr5:133003119~133003365:+
BRCA	cis	rs6596100	0.956	rs62375211	ENSG00000248648.1	RP11-485M7.1	-4.2	2.87e-05	0.00209	-0.17	-0.13	Breast cancer;	chr5:133067046	chr5:133003119~133003365:+
BRCA	cis	rs2625529	0.73	rs1481861	ENSG00000260037.4	CTD-2524L6.3	4.2	2.87e-05	0.00209	0.17	0.13	Red blood cell count;	chr15:71947788	chr15:71818396~71823384:+
BRCA	cis	rs7267979	0.903	rs2500400	ENSG00000276952.1	RP5-965G21.6	-4.2	2.87e-05	0.00209	-0.16	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25374069	chr20:25284915~25285588:-
BRCA	cis	rs3768617	1	rs1360704	ENSG00000224468.3	RP11-181K3.4	4.2	2.87e-05	0.00209	0.15	0.13	Fuchs's corneal dystrophy;	chr1:183130245	chr1:183138402~183141282:-
BRCA	cis	rs1865760	0.865	rs9467647	ENSG00000272462.2	U91328.19	-4.2	2.87e-05	0.0021	-0.15	-0.13	Height;	chr6:25957414	chr6:25992662~26001775:+
BRCA	cis	rs1865760	0.865	rs10946800	ENSG00000272462.2	U91328.19	-4.2	2.87e-05	0.0021	-0.15	-0.13	Height;	chr6:25957545	chr6:25992662~26001775:+
BRCA	cis	rs1865760	0.865	rs9467648	ENSG00000272462.2	U91328.19	-4.2	2.87e-05	0.0021	-0.15	-0.13	Height;	chr6:25957705	chr6:25992662~26001775:+
BRCA	cis	rs1865760	0.865	rs9467651	ENSG00000272462.2	U91328.19	-4.2	2.87e-05	0.0021	-0.15	-0.13	Height;	chr6:25958029	chr6:25992662~26001775:+
BRCA	cis	rs1865760	0.865	rs9467652	ENSG00000272462.2	U91328.19	-4.2	2.87e-05	0.0021	-0.15	-0.13	Height;	chr6:25958899	chr6:25992662~26001775:+
BRCA	cis	rs1865760	0.827	rs9461227	ENSG00000272462.2	U91328.19	-4.2	2.87e-05	0.0021	-0.15	-0.13	Height;	chr6:25960587	chr6:25992662~26001775:+
BRCA	cis	rs2073316	0.592	rs67830899	ENSG00000272716.1	RP11-563N4.1	4.2	2.87e-05	0.0021	0.14	0.13	Interleukin-18 levels;	chr2:31434714	chr2:32165046~32165757:-
BRCA	cis	rs651907	0.535	rs11707250	ENSG00000256628.3	ZBTB11-AS1	-4.2	2.87e-05	0.0021	-0.17	-0.13	Colorectal cancer;	chr3:101790527	chr3:101676475~101679217:+
BRCA	cis	rs2108622	0.683	rs56228205	ENSG00000267218.2	AC005336.5	4.2	2.87e-05	0.0021	0.15	0.13	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871163	chr19:15902300~15903238:-
BRCA	cis	rs6860806	0.661	rs1588263	ENSG00000233006.5	AC034220.3	4.2	2.87e-05	0.0021	0.09	0.13	Breast cancer;	chr5:132241465	chr5:132311285~132369916:-
BRCA	cis	rs700641	1	rs700641	ENSG00000231621.1	AC013264.2	-4.2	2.87e-05	0.0021	-0.12	-0.13	Morning vs. evening chronotype;	chr2:197734509	chr2:197197991~197199273:+
BRCA	cis	rs1008375	0.933	rs6847966	ENSG00000249502.1	AC006160.5	-4.2	2.87e-05	0.0021	-0.15	-0.13	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17632632	chr4:17587467~17614571:-
BRCA	cis	rs1008375	1	rs6848360	ENSG00000249502.1	AC006160.5	-4.2	2.87e-05	0.0021	-0.15	-0.13	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17632819	chr4:17587467~17614571:-
BRCA	cis	rs1008375	1	rs7659718	ENSG00000249502.1	AC006160.5	-4.2	2.87e-05	0.0021	-0.15	-0.13	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17636397	chr4:17587467~17614571:-
BRCA	cis	rs2842346	0.568	rs2247048	ENSG00000258623.1	CTD-2325P2.3	-4.2	2.87e-05	0.0021	-0.17	-0.13	Breast cancer;	chr14:68531603	chr14:68683411~68685565:-
BRCA	cis	rs11719291	0.915	rs11557629	ENSG00000225399.4	RP11-3B7.1	-4.2	2.87e-05	0.0021	-0.18	-0.13	Cognitive function;	chr3:48694790	chr3:49260085~49261316:+
BRCA	cis	rs10986311	0.713	rs10986292	ENSG00000227200.1	RP11-121A14.3	-4.2	2.87e-05	0.0021	-0.16	-0.13	Vitiligo;	chr9:124254597	chr9:124262876~124265809:+
BRCA	cis	rs13113518	1	rs10462032	ENSG00000272969.1	RP11-528I4.2	4.2	2.87e-05	0.0021	0.15	0.13	Height;	chr4:55479069	chr4:55547112~55547889:+
BRCA	cis	rs8180040	0.726	rs1463393	ENSG00000276925.1	RP11-708J19.3	4.2	2.87e-05	0.0021	0.15	0.13	Colorectal cancer;	chr3:46953497	chr3:47469777~47469987:+
BRCA	cis	rs9467773	0.609	rs12663780	ENSG00000124549.13	BTN2A3P	-4.2	2.87e-05	0.0021	-0.14	-0.13	Intelligence (multi-trait analysis);	chr6:26397345	chr6:26421391~26432383:+
BRCA	cis	rs2562456	0.917	rs11085463	ENSG00000268555.1	RP11-678G14.3	4.2	2.87e-05	0.0021	0.16	0.13	Pain;	chr19:21568500	chr19:21570822~21587322:-
BRCA	cis	rs863750	0.507	rs10846604	ENSG00000275389.1	RP11-214K3.24	-4.2	2.87e-05	0.0021	-0.18	-0.13	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-hip ratio;	chr12:124110948	chr12:124085761~124088598:+
BRCA	cis	rs651907	0.64	rs1091664	ENSG00000244119.1	PDCL3P4	4.2	2.87e-05	0.0021	0.11	0.13	Colorectal cancer;	chr3:101899846	chr3:101712472~101713191:+
BRCA	cis	rs7119	0.651	rs34607443	ENSG00000259362.2	RP11-307C19.1	-4.2	2.87e-05	0.0021	-0.18	-0.13	Type 2 diabetes;	chr15:77555550	chr15:77525540~77534110:+
BRCA	cis	rs28829049	0.597	rs12740975	ENSG00000270728.1	RP4-657E11.10	-4.2	2.87e-05	0.0021	-0.13	-0.13	QRS duration in Tripanosoma cruzi seropositivity;	chr1:19111429	chr1:19297080~19297903:+
BRCA	cis	rs997295	0.554	rs7180312	ENSG00000270964.1	RP11-502I4.3	4.2	2.87e-05	0.0021	0.14	0.13	Motion sickness;	chr15:67812918	chr15:67541072~67542604:-
BRCA	cis	rs62025270	0.632	rs80036674	ENSG00000259762.1	RP11-158M2.4	-4.2	2.87e-05	0.0021	-0.19	-0.13	Idiopathic pulmonary fibrosis;	chr15:85571217	chr15:85750336~85752901:-
BRCA	cis	rs2253762	0.645	rs11200366	ENSG00000276742.1	RP11-500G22.4	-4.2	2.87e-05	0.0021	-0.2	-0.13	Breast cancer;	chr10:122044170	chr10:121956782~121957098:+
BRCA	cis	rs859767	0.679	rs1104801	ENSG00000224043.6	CCNT2-AS1	4.2	2.87e-05	0.0021	0.18	0.13	Neuroticism;	chr2:134679031	chr2:134735464~134918710:-
BRCA	cis	rs72843506	0.722	rs9908418	ENSG00000270091.1	RP11-78O7.2	-4.2	2.87e-05	0.0021	-0.2	-0.13	Schizophrenia;	chr17:20311252	chr17:19896590~19897287:-
BRCA	cis	rs9308731	0.591	rs7572367	ENSG00000230499.1	AC108463.1	-4.2	2.87e-05	0.0021	-0.15	-0.13	Chronic lymphocytic leukemia;	chr2:111185394	chr2:111195963~111206494:+
BRCA	cis	rs8114671	0.836	rs2425006	ENSG00000279253.1	RP4-614O4.13	4.2	2.87e-05	0.0021	0.15	0.13	Height;	chr20:34983425	chr20:35262727~35264187:-
BRCA	cis	rs853679	0.517	rs4713135	ENSG00000216901.1	AL022393.7	4.2	2.87e-05	0.0021	0.18	0.13	Depression;	chr6:28071808	chr6:28176188~28176674:+
BRCA	cis	rs4950322	0.58	rs4950308	ENSG00000244371.2	PFN1P8	-4.2	2.88e-05	0.0021	-0.17	-0.13	Protein quantitative trait loci;	chr1:147120092	chr1:146957117~146957659:-
BRCA	cis	rs6545883	1	rs778762	ENSG00000270820.4	RP11-355B11.2	4.2	2.88e-05	0.0021	0.15	0.13	Tuberculosis;	chr2:61555786	chr2:61471188~61484130:+
BRCA	cis	rs10411936	0.785	rs2363120	ENSG00000280332.1	CTD-2013N17.6	-4.2	2.88e-05	0.0021	-0.11	-0.13	Multiple sclerosis;White blood cell count;	chr19:16409060	chr19:16356329~16358327:-
BRCA	cis	rs7937890	0.531	rs2575828	ENSG00000254418.1	RP11-21L19.1	4.2	2.88e-05	0.0021	0.15	0.13	Mitochondrial DNA levels;	chr11:14462646	chr11:14262846~14273691:-
BRCA	cis	rs7937890	0.559	rs2575829	ENSG00000254418.1	RP11-21L19.1	4.2	2.88e-05	0.0021	0.15	0.13	Mitochondrial DNA levels;	chr11:14463475	chr11:14262846~14273691:-
BRCA	cis	rs7937890	0.559	rs2597200	ENSG00000254418.1	RP11-21L19.1	4.2	2.88e-05	0.0021	0.15	0.13	Mitochondrial DNA levels;	chr11:14464054	chr11:14262846~14273691:-
BRCA	cis	rs7937890	0.559	rs2575830	ENSG00000254418.1	RP11-21L19.1	4.2	2.88e-05	0.0021	0.15	0.13	Mitochondrial DNA levels;	chr11:14464056	chr11:14262846~14273691:-
BRCA	cis	rs6545883	0.929	rs1186711	ENSG00000270820.4	RP11-355B11.2	4.2	2.88e-05	0.0021	0.16	0.13	Tuberculosis;	chr2:61461370	chr2:61471188~61484130:+
BRCA	cis	rs9467773	0.583	rs2498380	ENSG00000241549.7	GUSBP2	-4.2	2.88e-05	0.0021	-0.14	-0.13	Intelligence (multi-trait analysis);	chr6:26643768	chr6:26871484~26956554:-
BRCA	cis	rs9308731	0.591	rs9808225	ENSG00000230499.1	AC108463.1	-4.2	2.88e-05	0.0021	-0.15	-0.13	Chronic lymphocytic leukemia;	chr2:111185937	chr2:111195963~111206494:+
BRCA	cis	rs6831352	0.734	rs2851259	ENSG00000272777.1	RP11-571L19.8	-4.2	2.88e-05	0.0021	-0.14	-0.13	Alcohol dependence;	chr4:99112835	chr4:99067256~99068125:-
BRCA	cis	rs6831352	0.703	rs4235435	ENSG00000272777.1	RP11-571L19.8	-4.2	2.88e-05	0.0021	-0.14	-0.13	Alcohol dependence;	chr4:99118427	chr4:99067256~99068125:-
BRCA	cis	rs3816183	1	rs3816181	ENSG00000226491.1	FTOP1	-4.2	2.88e-05	0.0021	-0.16	-0.13	Hypospadias;	chr2:42788472	chr2:42797225~42798712:-
BRCA	cis	rs17818399	0.502	rs1451152	ENSG00000279254.1	RP11-536C12.1	-4.2	2.88e-05	0.0021	-0.15	-0.13	Height;	chr2:46573011	chr2:46668870~46670778:+
BRCA	cis	rs409045	1	rs440678	ENSG00000271874.1	CTD-2024P10.2	-4.2	2.88e-05	0.0021	-0.17	-0.13	Left ventricular mass;	chr5:34629828	chr5:34651457~34651888:-
BRCA	cis	rs5758511	0.773	rs12167978	ENSG00000226450.2	CYP2D8P	4.2	2.88e-05	0.0021	0.14	0.13	Birth weight;	chr22:41950471	chr22:42149886~42155001:-
BRCA	cis	rs4831760	0.748	rs13253915	ENSG00000250483.1	PPM1AP1	4.2	2.88e-05	0.0021	0.19	0.13	Pulmonary function decline;	chr8:15564538	chr8:15806149~15807283:-
BRCA	cis	rs875971	0.895	rs778700	ENSG00000236529.1	RP13-254B10.1	4.2	2.88e-05	0.0021	0.14	0.13	Aortic root size;	chr7:66401463	chr7:65840212~65840596:+
BRCA	cis	rs875971	1	rs778699	ENSG00000236529.1	RP13-254B10.1	4.2	2.88e-05	0.0021	0.14	0.13	Aortic root size;	chr7:66403303	chr7:65840212~65840596:+
BRCA	cis	rs56322409	1	rs11188407	ENSG00000226688.5	ENTPD1-AS1	4.2	2.88e-05	0.0021	0.15	0.13	Blood metabolite levels;	chr10:95630776	chr10:95753206~96090238:-
BRCA	cis	rs721917	0.526	rs2256574	ENSG00000242600.5	MBL1P	4.2	2.88e-05	0.0021	0.16	0.13	Chronic obstructive pulmonary disease;	chr10:79925283	chr10:79904898~79950336:+
BRCA	cis	rs4819052	1	rs733738	ENSG00000184274.3	LINC00315	4.2	2.88e-05	0.0021	0.18	0.13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45246481	chr21:45300245~45305257:-
BRCA	cis	rs871012	0.502	rs11951889	ENSG00000248544.2	CTB-47B11.3	-4.2	2.88e-05	0.0021	-0.17	-0.13	IgG glycosylation;	chr5:157449776	chr5:157375741~157384950:-
BRCA	cis	rs10504130	0.569	rs11785467	ENSG00000253844.1	RP11-546K22.1	-4.2	2.88e-05	0.0021	-0.19	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr8:51763108	chr8:51961458~52022974:+
BRCA	cis	rs7777677	0.925	rs4726540	ENSG00000232869.2	TRBV29-1	-4.2	2.88e-05	0.0021	-0.1	-0.13	Alcoholic chronic pancreatitis;	chr7:142658771	chr7:142740206~142740894:+
BRCA	cis	rs755249	0.532	rs2296173	ENSG00000182109.6	RP11-69E11.4	4.2	2.88e-05	0.0021	0.18	0.13	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39447679	chr1:39522280~39546187:-
BRCA	cis	rs755249	0.567	rs3118014	ENSG00000182109.6	RP11-69E11.4	4.2	2.88e-05	0.0021	0.18	0.13	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39448418	chr1:39522280~39546187:-
BRCA	cis	rs4476553	0.935	rs12696704	ENSG00000247708.6	STX18-AS1	4.2	2.88e-05	0.0021	0.13	0.13	Response to amphetamines;	chr4:4709483	chr4:4542131~4710938:+
BRCA	cis	rs4287000	0.508	rs928368	ENSG00000227603.1	RP11-165J3.6	-4.2	2.88e-05	0.00211	-0.15	-0.13	Itch intensity from mosquito bite adjusted by bite size;	chr9:93610202	chr9:93435332~93437121:-
BRCA	cis	rs754466	0.58	rs11002289	ENSG00000213514.2	RP11-428P16.2	4.2	2.88e-05	0.00211	0.18	0.13	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77772822	chr10:77730766~77734769:+
BRCA	cis	rs4650994	0.623	rs35854525	ENSG00000273062.1	RP11-428K3.1	-4.2	2.88e-05	0.00211	-0.13	-0.13	HDL cholesterol;HDL cholesterol levels;	chr1:178649469	chr1:178724306~178726285:-
BRCA	cis	rs7727544	0.594	rs10479000	ENSG00000233006.5	AC034220.3	4.2	2.88e-05	0.00211	0.1	0.13	Blood metabolite levels;	chr5:132271709	chr5:132311285~132369916:-
BRCA	cis	rs9341808	0.556	rs10455370	ENSG00000279022.1	RP11-250B2.4	-4.2	2.88e-05	0.00211	-0.15	-0.13	Sitting height ratio;	chr6:80331150	chr6:80440730~80441172:+
BRCA	cis	rs77633900	0.772	rs284898	ENSG00000196274.5	Metazoa_SRP	4.2	2.88e-05	0.00211	0.22	0.13	Glioma;Non-glioblastoma glioma;	chr15:76458354	chr15:76230048~76230390:-
BRCA	cis	rs6012564	0.783	rs6125575	ENSG00000227431.4	CSE1L-AS1	4.2	2.88e-05	0.00211	0.16	0.13	Anger;	chr20:49159159	chr20:49040463~49046044:-
BRCA	cis	rs10761482	0.861	rs7909961	ENSG00000254271.1	RP11-131N11.4	4.2	2.88e-05	0.00211	0.18	0.13	Schizophrenia;	chr10:60405820	chr10:60734342~60741828:+
BRCA	cis	rs17489649	1	rs1438660	ENSG00000271849.1	CTC-332L22.1	4.2	2.89e-05	0.00211	0.17	0.13	Intelligence (multi-trait analysis);	chr5:109722893	chr5:109687802~109688329:-
BRCA	cis	rs13126694	0.65	rs10028808	ENSG00000251429.1	RP11-597D13.7	4.2	2.89e-05	0.00211	0.12	0.13	Blood osmolality (transformed sodium);	chr4:157939488	chr4:158270378~158278676:+
BRCA	cis	rs4664293	0.836	rs4665118	ENSG00000226266.5	AC009961.3	-4.2	2.89e-05	0.00211	-0.17	-0.13	Monocyte percentage of white cells;	chr2:159802938	chr2:159670708~159712435:-
BRCA	cis	rs11098499	0.954	rs7437420	ENSG00000260404.2	RP11-384K6.6	4.2	2.89e-05	0.00211	0.12	0.13	Corneal astigmatism;	chr4:119391748	chr4:118591773~118633729:+
BRCA	cis	rs1577917	0.56	rs9450288	ENSG00000220563.1	PKMP3	4.2	2.89e-05	0.00211	0.13	0.13	Response to antipsychotic treatment;	chr6:85511868	chr6:85659892~85660606:-
BRCA	cis	rs7646881	0.504	rs67305172	ENSG00000240207.5	RP11-379F4.4	-4.2	2.89e-05	0.00211	-0.18	-0.13	Tetralogy of Fallot;	chr3:158746485	chr3:158732263~158784070:+
BRCA	cis	rs10911902	0.643	rs79080293	ENSG00000229739.2	RP11-295K2.3	-4.2	2.89e-05	0.00211	-0.19	-0.13	Schizophrenia;	chr1:186379546	chr1:186435161~186470291:+
BRCA	cis	rs2243480	0.901	rs57126451	ENSG00000226002.1	RP11-460N20.5	-4.2	2.89e-05	0.00211	-0.21	-0.13	Diabetic kidney disease;	chr7:65951319	chr7:65084103~65100232:+
BRCA	cis	rs952623	0.649	rs6974522	ENSG00000211694.2	TRGV10	4.2	2.89e-05	0.00211	0.11	0.13	Intelligence (multi-trait analysis);	chr7:39033772	chr7:38299811~38300322:-
BRCA	cis	rs6736093	0.965	rs4264571	ENSG00000236307.2	EEF1E1P1	-4.2	2.89e-05	0.00211	-0.17	-0.13	Coronary artery disease;	chr2:111916572	chr2:111887914~111888741:+
BRCA	cis	rs1876905	0.764	rs4947106	ENSG00000255389.1	C6orf3	-4.2	2.89e-05	0.00211	-0.16	-0.13	Mean corpuscular hemoglobin;	chr6:111100163	chr6:111599875~111602295:+
BRCA	cis	rs13034020	0.594	rs10496090	ENSG00000271889.1	RP11-493E12.1	-4.2	2.89e-05	0.00211	-0.23	-0.13	Hodgkin's lymphoma;	chr2:61026898	chr2:61151433~61162105:-
BRCA	cis	rs10804591	0.666	rs4688807	ENSG00000206417.7	H1FX-AS1	-4.2	2.89e-05	0.00211	-0.12	-0.13	Waist-hip ratio;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Hip circumference adjusted for BMI;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;	chr3:129590420	chr3:129315392~129326225:+
BRCA	cis	rs7561149	1	rs7561149	ENSG00000270574.1	RP11-171I2.2	-4.2	2.89e-05	0.00211	-0.17	-0.13	QT interval;	chr2:178825129	chr2:178578790~178580906:+
BRCA	cis	rs11148252	0.74	rs7981050	ENSG00000198384.8	TPTE2P3	4.2	2.89e-05	0.00211	0.15	0.13	Lewy body disease;	chr13:52181014	chr13:52522632~52586906:+
BRCA	cis	rs11711311	1	rs9288983	ENSG00000241529.3	RN7SL767P	-4.2	2.89e-05	0.00211	-0.15	-0.13	IgG glycosylation;	chr3:113769852	chr3:113632704~113632998:+
BRCA	cis	rs10080237	0.564	rs2490232	ENSG00000272129.1	RP11-250B2.6	-4.2	2.89e-05	0.00211	-0.16	-0.13	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;	chr6:80105085	chr6:80355424~80356859:+
BRCA	cis	rs9739640	1	rs9739640	ENSG00000257379.1	RP11-793H13.8	4.2	2.89e-05	0.00211	0.19	0.13	Reticulocyte count;	chr12:53389390	chr12:53441741~53467528:+
BRCA	cis	rs17270561	0.553	rs9379784	ENSG00000272462.2	U91328.19	-4.2	2.89e-05	0.00211	-0.16	-0.13	Iron status biomarkers;	chr6:25725278	chr6:25992662~26001775:+
BRCA	cis	rs757081	0.667	rs12420958	ENSG00000184669.7	OR7E14P	-4.2	2.89e-05	0.00211	-0.19	-0.13	Systolic blood pressure;	chr11:17078885	chr11:17013998~17053024:+
BRCA	cis	rs9921338	0.961	rs8043692	ENSG00000262636.1	CTD-3088G3.4	-4.2	2.89e-05	0.00211	-0.2	-0.13	Vein graft stenosis in coronary artery bypass grafting;	chr16:11333100	chr16:11380859~11381118:-
BRCA	cis	rs9921338	0.923	rs6498181	ENSG00000262636.1	CTD-3088G3.4	-4.2	2.89e-05	0.00211	-0.2	-0.13	Vein graft stenosis in coronary artery bypass grafting;	chr16:11333336	chr16:11380859~11381118:-
BRCA	cis	rs11931598	1	rs11931598	ENSG00000245468.3	RP11-367J11.3	4.2	2.89e-05	0.00211	0.12	0.13	Sum basophil neutrophil counts;Neutrophil count;Granulocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;	chr4:7045375	chr4:7094571~7103385:-
BRCA	cis	rs7833790	0.963	rs7836040	ENSG00000254689.1	RP11-354A14.1	4.2	2.89e-05	0.00211	0.18	0.13	Diastolic blood pressure;	chr8:81786093	chr8:81885377~81923193:+
BRCA	cis	rs9527	0.535	rs4917999	ENSG00000213061.2	PFN1P11	-4.2	2.89e-05	0.00211	-0.18	-0.13	Arsenic metabolism;	chr10:103203294	chr10:102838011~102845473:-
BRCA	cis	rs1005277	0.54	rs2224248	ENSG00000272983.1	RP11-508N22.12	4.2	2.89e-05	0.00211	0.14	0.13	Extrinsic epigenetic age acceleration;	chr10:38162958	chr10:38137337~38144399:+
BRCA	cis	rs952623	0.649	rs12538487	ENSG00000211694.2	TRGV10	4.2	2.89e-05	0.00211	0.11	0.13	Intelligence (multi-trait analysis);	chr7:39035780	chr7:38299811~38300322:-
BRCA	cis	rs10761482	0.601	rs7074460	ENSG00000254271.1	RP11-131N11.4	4.2	2.89e-05	0.00211	0.18	0.13	Schizophrenia;	chr10:60425085	chr10:60734342~60741828:+
BRCA	cis	rs4650994	1	rs10798615	ENSG00000273384.1	RP5-1098D14.1	4.2	2.89e-05	0.00211	0.16	0.13	HDL cholesterol;HDL cholesterol levels;	chr1:178544760	chr1:178651706~178652282:+
BRCA	cis	rs875971	0.564	rs313804	ENSG00000229180.5	GS1-124K5.11	4.2	2.89e-05	0.00211	0.11	0.13	Aortic root size;	chr7:66049635	chr7:66526088~66542624:-
BRCA	cis	rs875971	0.662	rs448725	ENSG00000229180.5	GS1-124K5.11	4.2	2.89e-05	0.00211	0.11	0.13	Aortic root size;	chr7:66049641	chr7:66526088~66542624:-
BRCA	cis	rs733175	0.904	rs3775944	ENSG00000250413.1	RP11-448G15.1	-4.2	2.9e-05	0.00211	-0.2	-0.13	Psychosis and Alzheimer's disease;	chr4:10018350	chr4:10006482~10009725:+
BRCA	cis	rs763121	0.889	rs4820335	ENSG00000225450.1	RP3-508I15.14	4.2	2.9e-05	0.00211	0.13	0.13	Menopause (age at onset);	chr22:38539922	chr22:38739003~38749041:+
BRCA	cis	rs832540	0.931	rs33318	ENSG00000271828.1	CTD-2310F14.1	-4.2	2.9e-05	0.00211	-0.16	-0.13	Coronary artery disease;	chr5:56912587	chr5:56927874~56929573:+
BRCA	cis	rs6570726	0.516	rs9376932	ENSG00000235652.6	RP11-545I5.3	4.2	2.9e-05	0.00211	0.13	0.13	Lobe attachment (rater-scored or self-reported);	chr6:145408354	chr6:145799409~145886585:+
BRCA	cis	rs930395	0.514	rs10069220	ENSG00000251141.4	RP11-53O19.1	-4.2	2.9e-05	0.00211	-0.12	-0.13	Breast cancer;	chr5:44881876	chr5:44744900~44808777:-
BRCA	cis	rs7824557	0.872	rs1347410	ENSG00000154316.13	TDH	4.2	2.9e-05	0.00211	0.17	0.13	Retinal vascular caliber;	chr8:11253733	chr8:11339637~11368452:+
BRCA	cis	rs7267979	0.932	rs6037125	ENSG00000277938.1	RP5-965G21.3	4.2	2.9e-05	0.00211	0.15	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25482746	chr20:25229150~25231933:+
BRCA	cis	rs7829975	0.564	rs2976855	ENSG00000233609.3	RP11-62H7.2	4.2	2.9e-05	0.00211	0.12	0.13	Mood instability;	chr8:8444284	chr8:8961200~8979025:+
BRCA	cis	rs17801127	0.748	rs2192896	ENSG00000231969.1	AC144449.1	4.2	2.9e-05	0.00211	0.23	0.13	Liver enzyme levels (alanine transaminase);	chr2:149659554	chr2:149587196~149848233:+
BRCA	cis	rs2115630	1	rs6496452	ENSG00000275120.1	RP11-182J1.17	-4.2	2.9e-05	0.00212	-0.15	-0.13	P wave terminal force;	chr15:84829414	chr15:84599434~84606463:-
BRCA	cis	rs5762752	0.509	rs5752746	ENSG00000235954.5	TTC28-AS1	-4.2	2.9e-05	0.00212	-0.14	-0.13	Optic disc area;	chr22:28450592	chr22:27919376~28008581:+
BRCA	cis	rs6747488	0.515	rs599300	ENSG00000276334.1	AL133243.1	4.2	2.9e-05	0.00212	0.16	0.13	Interleukin-18 levels;	chr2:31586237	chr2:32521927~32523547:+
BRCA	cis	rs11098499	0.691	rs12502524	ENSG00000260404.2	RP11-384K6.6	4.2	2.9e-05	0.00212	0.12	0.13	Corneal astigmatism;	chr4:119350259	chr4:118591773~118633729:+
BRCA	cis	rs4499344	0.73	rs614361	ENSG00000267475.1	CTD-2538C1.2	4.2	2.9e-05	0.00212	0.16	0.13	Mean platelet volume;	chr19:32615481	chr19:32687089~32691750:-
BRCA	cis	rs4499344	0.73	rs614370	ENSG00000267475.1	CTD-2538C1.2	4.2	2.9e-05	0.00212	0.16	0.13	Mean platelet volume;	chr19:32615484	chr19:32687089~32691750:-
BRCA	cis	rs8114671	0.562	rs6088636	ENSG00000126005.14	MMP24-AS1	-4.2	2.9e-05	0.00212	-0.15	-0.13	Height;	chr20:34881943	chr20:35216462~35278131:-
BRCA	cis	rs10992797	0.504	rs2989755	ENSG00000227603.1	RP11-165J3.6	-4.2	2.9e-05	0.00212	-0.15	-0.13	Intelligence (multi-trait analysis);	chr9:93613971	chr9:93435332~93437121:-
BRCA	cis	rs5758511	0.689	rs55906806	ENSG00000227370.1	RP4-669P10.19	4.2	2.9e-05	0.00212	0.2	0.13	Birth weight;	chr22:42248465	chr22:42132543~42132998:+
BRCA	cis	rs983392	0.709	rs11601689	ENSG00000275344.1	MIR6503	-4.2	2.9e-05	0.00212	-0.13	-0.13	Alzheimer's disease (late onset);	chr11:60228793	chr11:60209071~60209156:-
BRCA	cis	rs2625529	0.586	rs59975112	ENSG00000260037.4	CTD-2524L6.3	4.2	2.9e-05	0.00212	0.16	0.13	Red blood cell count;	chr15:72131369	chr15:71818396~71823384:+
BRCA	cis	rs755249	0.567	rs76111861	ENSG00000182109.6	RP11-69E11.4	4.2	2.9e-05	0.00212	0.18	0.13	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39377018	chr1:39522280~39546187:-
BRCA	cis	rs755249	0.567	rs72661965	ENSG00000182109.6	RP11-69E11.4	4.2	2.9e-05	0.00212	0.18	0.13	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39380918	chr1:39522280~39546187:-
BRCA	cis	rs9834975	0.967	rs12152463	ENSG00000272758.4	RP11-299J3.8	-4.2	2.9e-05	0.00212	-0.13	-0.13	Diastolic blood pressure;	chr3:122381600	chr3:122416207~122443180:+
BRCA	cis	rs58521262	0.585	rs291772	ENSG00000268105.1	RP11-369G6.2	-4.2	2.9e-05	0.00212	-0.17	-0.13	Testicular germ cell tumor;	chr19:23024584	chr19:23125665~23128543:+
BRCA	cis	rs7000551	0.532	rs4872486	ENSG00000254272.1	RP11-382J24.2	-4.2	2.9e-05	0.00212	-0.17	-0.13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr8:22398846	chr8:22492631~22493044:+
BRCA	cis	rs6671200	0.748	rs11589700	ENSG00000235501.4	RP4-639F20.1	-4.2	2.9e-05	0.00212	-0.28	-0.13	Stearic acid (18:0) levels;	chr1:95007885	chr1:94927566~94963270:+
BRCA	cis	rs7116495	0.609	rs4387373	ENSG00000248671.6	ALG1L9P	-4.2	2.9e-05	0.00212	-0.33	-0.13	Severe influenza A (H1N1) infection;	chr11:72063862	chr11:71794363~71818238:-
BRCA	cis	rs7116495	0.609	rs674319	ENSG00000248671.6	ALG1L9P	-4.2	2.9e-05	0.00212	-0.33	-0.13	Severe influenza A (H1N1) infection;	chr11:72064345	chr11:71794363~71818238:-
BRCA	cis	rs748404	0.666	rs34178146	ENSG00000205771.5	CATSPER2P1	-4.2	2.9e-05	0.00212	-0.19	-0.13	Lung cancer;	chr15:43384406	chr15:43726918~43747094:-
BRCA	cis	rs11719291	0.831	rs11715177	ENSG00000225399.4	RP11-3B7.1	-4.2	2.9e-05	0.00212	-0.2	-0.13	Cognitive function;	chr3:48726461	chr3:49260085~49261316:+
BRCA	cis	rs4713118	0.699	rs200978	ENSG00000216901.1	AL022393.7	4.2	2.9e-05	0.00212	0.19	0.13	Parkinson's disease;	chr6:27885390	chr6:28176188~28176674:+
BRCA	cis	rs27434	0.583	rs26653	ENSG00000248734.2	CTD-2260A17.1	4.2	2.9e-05	0.00212	0.14	0.13	Ankylosing spondylitis;	chr5:96803547	chr5:96784777~96785999:+
BRCA	cis	rs875971	0.545	rs1796222	ENSG00000232546.1	RP11-458F8.1	-4.2	2.9e-05	0.00212	-0.12	-0.13	Aortic root size;	chr7:66592167	chr7:66848496~66858136:+
BRCA	cis	rs4845570	1	rs3790514	ENSG00000203288.3	RP11-98D18.9	-4.2	2.9e-05	0.00212	-0.22	-0.13	Coronary artery disease;	chr1:151771692	chr1:151790804~151794402:+
BRCA	cis	rs11955398	0.522	rs12522154	ENSG00000272308.1	RP11-231G3.1	4.2	2.9e-05	0.00212	0.15	0.13	Intelligence (multi-trait analysis);	chr5:60885673	chr5:60866457~60866935:-
BRCA	cis	rs4831760	0.783	rs11775286	ENSG00000250483.1	PPM1AP1	4.2	2.9e-05	0.00212	0.18	0.13	Pulmonary function decline;	chr8:15565761	chr8:15806149~15807283:-
BRCA	cis	rs739496	0.843	rs688812	ENSG00000234608.6	MAPKAPK5-AS1	4.2	2.9e-05	0.00212	0.16	0.13	Platelet count;	chr12:111524777	chr12:111839764~111842902:-
BRCA	cis	rs9393692	0.645	rs4145910	ENSG00000241549.7	GUSBP2	-4.2	2.91e-05	0.00212	-0.15	-0.13	Educational attainment;	chr6:26313077	chr6:26871484~26956554:-
BRCA	cis	rs4950322	0.518	rs4950304	ENSG00000244371.2	PFN1P8	-4.2	2.91e-05	0.00212	-0.17	-0.13	Protein quantitative trait loci;	chr1:147116685	chr1:146957117~146957659:-
BRCA	cis	rs11009175	0.746	rs11009203	ENSG00000273038.2	RP11-479G22.8	-4.2	2.91e-05	0.00212	-0.21	-0.13	Depression (quantitative trait);	chr10:33059205	chr10:32887255~32889311:-
BRCA	cis	rs11098499	0.754	rs1980027	ENSG00000260091.1	RP11-33B1.4	-4.2	2.91e-05	0.00212	-0.11	-0.13	Corneal astigmatism;	chr4:119330422	chr4:119409333~119410233:+
BRCA	cis	rs7267979	1	rs2424710	ENSG00000276952.1	RP5-965G21.6	4.2	2.91e-05	0.00212	0.16	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25303250	chr20:25284915~25285588:-
BRCA	cis	rs8177876	0.658	rs2316730	ENSG00000261838.4	RP11-303E16.6	4.2	2.91e-05	0.00212	0.27	0.13	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81106035	chr16:81069854~81076598:+
BRCA	cis	rs11098499	0.754	rs10213554	ENSG00000225892.3	RP11-384K6.2	-4.2	2.91e-05	0.00212	-0.13	-0.13	Corneal astigmatism;	chr4:119339630	chr4:118632274~118634759:+
BRCA	cis	rs35100037	0.803	rs13166431	ENSG00000249421.1	ADAMTS19-AS1	-4.2	2.91e-05	0.00212	-0.22	-0.13	Ankle injury;	chr5:129308262	chr5:129459559~129460689:-
BRCA	cis	rs1910358	0.69	rs10066987	ENSG00000248874.4	C5orf17	-4.2	2.91e-05	0.00212	-0.17	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23970584	chr5:23951348~24178263:+
BRCA	cis	rs1910358	0.664	rs4554168	ENSG00000248874.4	C5orf17	-4.2	2.91e-05	0.00212	-0.17	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23973867	chr5:23951348~24178263:+
BRCA	cis	rs9868809	0.772	rs28452701	ENSG00000225399.4	RP11-3B7.1	-4.2	2.91e-05	0.00212	-0.2	-0.13	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48671142	chr3:49260085~49261316:+
BRCA	cis	rs4650943	0.544	rs2504473	ENSG00000227740.1	RP11-318C24.2	-4.2	2.91e-05	0.00212	-0.13	-0.13	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in inactive individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr1:176307916	chr1:175904762~175920513:-
BRCA	cis	rs7267979	0.932	rs6037125	ENSG00000274414.1	RP5-965G21.4	-4.2	2.91e-05	0.00212	-0.15	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25482746	chr20:25239007~25245229:-
BRCA	cis	rs897984	0.568	rs67264578	ENSG00000260911.2	RP11-196G11.2	4.2	2.91e-05	0.00212	0.13	0.13	Dementia with Lewy bodies;	chr16:30868074	chr16:31043150~31049868:+
BRCA	cis	rs8062405	0.789	rs28676837	ENSG00000261766.1	RP11-22P6.2	4.2	2.91e-05	0.00212	0.13	0.13	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28615742	chr16:28862166~28863340:-
BRCA	cis	rs7105310	1	rs7106095	ENSG00000255062.1	RP11-712L6.5	4.2	2.91e-05	0.00212	0.22	0.13	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;	chr11:126176388	chr11:126294298~126304318:-
BRCA	cis	rs495337	0.735	rs2281217	ENSG00000229222.1	KRT18P4	-4.2	2.91e-05	0.00212	-0.16	-0.13	Psoriasis;	chr20:49951518	chr20:49956745~49958032:+
BRCA	cis	rs7011507	0.532	rs56250422	ENSG00000279881.1	RP11-513O13.1	-4.2	2.91e-05	0.00212	-0.22	-0.13	Inflammatory bowel disease;Ulcerative colitis;	chr8:48311920	chr8:48428143~48431041:-
BRCA	cis	rs375066	0.901	rs1978723	ENSG00000267191.1	RP11-15A1.2	4.2	2.91e-05	0.00212	0.16	0.13	Breast cancer;	chr19:43879648	chr19:43902001~43926545:+
BRCA	cis	rs36563	0.631	rs17108910	ENSG00000258571.1	PTTG4P	-4.2	2.91e-05	0.00212	-0.2	-0.13	Alcohol dependence;	chr14:71030982	chr14:71085482~71085833:-
BRCA	cis	rs6840360	0.573	rs2407171	ENSG00000270265.1	RP11-731D1.4	-4.2	2.91e-05	0.00213	-0.14	-0.13	Intelligence (multi-trait analysis);	chr4:151335630	chr4:151333775~151353224:-
BRCA	cis	rs10938353	0.911	rs6833262	ENSG00000273369.1	RP11-700J17.1	-4.2	2.91e-05	0.00213	-0.14	-0.13	Body mass index;	chr4:44583130	chr4:44693946~44694386:-
BRCA	cis	rs2832191	0.72	rs7277028	ENSG00000236056.1	GAPDHP14	4.2	2.91e-05	0.00213	0.14	0.13	Dental caries;	chr21:29122283	chr21:29222321~29223257:+
BRCA	cis	rs4478858	0.735	rs7523438	ENSG00000223907.1	LINC01226	4.2	2.92e-05	0.00213	0.16	0.13	Alcohol dependence;	chr1:31315466	chr1:31518435~31524245:+
BRCA	cis	rs7829975	0.624	rs7823056	ENSG00000233609.3	RP11-62H7.2	4.2	2.92e-05	0.00213	0.12	0.13	Mood instability;	chr8:8525195	chr8:8961200~8979025:+
BRCA	cis	rs1910358	0.614	rs6452179	ENSG00000248874.4	C5orf17	-4.2	2.92e-05	0.00213	-0.17	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23986096	chr5:23951348~24178263:+
BRCA	cis	rs1910358	0.614	rs9293107	ENSG00000248874.4	C5orf17	-4.2	2.92e-05	0.00213	-0.17	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23989893	chr5:23951348~24178263:+
BRCA	cis	rs1910358	0.569	rs10085082	ENSG00000248874.4	C5orf17	-4.2	2.92e-05	0.00213	-0.17	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23990060	chr5:23951348~24178263:+
BRCA	cis	rs1910358	0.614	rs62347244	ENSG00000248874.4	C5orf17	-4.2	2.92e-05	0.00213	-0.17	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23993787	chr5:23951348~24178263:+
BRCA	cis	rs10911902	0.913	rs61810323	ENSG00000229739.2	RP11-295K2.3	-4.2	2.92e-05	0.00213	-0.18	-0.13	Schizophrenia;	chr1:186525919	chr1:186435161~186470291:+
BRCA	cis	rs7727544	0.582	rs10052046	ENSG00000233006.5	AC034220.3	4.2	2.92e-05	0.00213	0.09	0.13	Blood metabolite levels;	chr5:132208773	chr5:132311285~132369916:-
BRCA	cis	rs6125597	0.533	rs6122778	ENSG00000227431.4	CSE1L-AS1	4.2	2.92e-05	0.00213	0.16	0.13	Intelligence (multi-trait analysis);	chr20:49267405	chr20:49040463~49046044:-
BRCA	cis	rs739496	0.843	rs583140	ENSG00000234608.6	MAPKAPK5-AS1	4.2	2.92e-05	0.00213	0.16	0.13	Platelet count;	chr12:111548150	chr12:111839764~111842902:-
BRCA	cis	rs10829156	0.786	rs7077786	ENSG00000225527.1	RP11-383B4.4	-4.2	2.92e-05	0.00213	-0.18	-0.13	Sudden cardiac arrest;	chr10:18603453	chr10:18531849~18533336:-
BRCA	cis	rs61160187	0.582	rs1021005	ENSG00000272308.1	RP11-231G3.1	-4.2	2.92e-05	0.00213	-0.15	-0.13	Educational attainment (years of education);Educational attainment (college completion);	chr5:60895633	chr5:60866457~60866935:-
BRCA	cis	rs28374715	0.528	rs7178360	ENSG00000247556.5	OIP5-AS1	4.2	2.92e-05	0.00213	0.15	0.13	Ulcerative colitis;	chr15:41338977	chr15:41283990~41309737:+
BRCA	cis	rs28374715	0.578	rs7165914	ENSG00000247556.5	OIP5-AS1	4.2	2.92e-05	0.00213	0.15	0.13	Ulcerative colitis;	chr15:41340253	chr15:41283990~41309737:+
BRCA	cis	rs11098499	0.505	rs75122014	ENSG00000260404.2	RP11-384K6.6	4.2	2.92e-05	0.00213	0.12	0.13	Corneal astigmatism;	chr4:119441271	chr4:118591773~118633729:+
BRCA	cis	rs6430585	0.583	rs79176913	ENSG00000224043.6	CCNT2-AS1	-4.2	2.92e-05	0.00213	-0.22	-0.13	Corneal structure;	chr2:135880543	chr2:134735464~134918710:-
BRCA	cis	rs7572733	0.935	rs700679	ENSG00000231621.1	AC013264.2	-4.2	2.92e-05	0.00213	-0.12	-0.13	Dermatomyositis;	chr2:197842192	chr2:197197991~197199273:+
BRCA	cis	rs875971	1	rs12698523	ENSG00000229180.5	GS1-124K5.11	4.2	2.92e-05	0.00213	0.11	0.13	Aortic root size;	chr7:66503126	chr7:66526088~66542624:-
BRCA	cis	rs6964587	1	rs12530646	ENSG00000188693.7	CYP51A1-AS1	4.2	2.92e-05	0.00213	0.14	0.13	Breast cancer;	chr7:91958722	chr7:92134604~92180725:+
BRCA	cis	rs11711311	0.955	rs12636536	ENSG00000241529.3	RN7SL767P	-4.2	2.92e-05	0.00213	-0.15	-0.13	IgG glycosylation;	chr3:113755379	chr3:113632704~113632998:+
BRCA	cis	rs3176789	0.647	rs7295897	ENSG00000256673.1	RP11-599J14.2	4.2	2.92e-05	0.00213	0.15	0.13	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9768280	chr12:9398355~9414851:-
BRCA	cis	rs2562456	0.55	rs4809143	ENSG00000268658.4	LINC00664	4.2	2.92e-05	0.00213	0.22	0.13	Pain;	chr19:21589926	chr19:21483374~21503238:+
BRCA	cis	rs2562456	0.583	rs4809144	ENSG00000268658.4	LINC00664	4.2	2.92e-05	0.00213	0.22	0.13	Pain;	chr19:21589928	chr19:21483374~21503238:+
BRCA	cis	rs12586478	0.538	rs2221451	ENSG00000205562.2	RP11-497E19.1	4.2	2.92e-05	0.00213	0.12	0.13	Post bronchodilator FEV1;	chr14:86322665	chr14:85524432~85529988:-
BRCA	cis	rs812925	0.537	rs10208769	ENSG00000270820.4	RP11-355B11.2	-4.2	2.92e-05	0.00213	-0.14	-0.13	Immature fraction of reticulocytes;	chr2:61378479	chr2:61471188~61484130:+
BRCA	cis	rs240993	0.516	rs414763	ENSG00000230177.1	RP5-1112D6.4	-4.2	2.92e-05	0.00213	-0.2	-0.13	Inflammatory skin disease;Psoriasis;	chr6:111324561	chr6:111277932~111278742:+
BRCA	cis	rs6012564	0.964	rs6125577	ENSG00000227431.4	CSE1L-AS1	4.2	2.92e-05	0.00213	0.16	0.13	Anger;	chr20:49166558	chr20:49040463~49046044:-
BRCA	cis	rs516805	0.631	rs2606647	ENSG00000279114.1	RP3-425C14.5	-4.2	2.92e-05	0.00213	-0.16	-0.13	Lymphocyte counts;	chr6:122118967	chr6:122471923~122484161:+
BRCA	cis	rs801193	1	rs7782320	ENSG00000272831.1	RP11-792A8.4	4.2	2.92e-05	0.00213	0.12	0.13	Aortic root size;	chr7:66712111	chr7:66739829~66740385:-
BRCA	cis	rs853679	0.542	rs9393892	ENSG00000261839.1	RP1-265C24.8	4.2	2.93e-05	0.00213	0.18	0.13	Depression;	chr6:28113616	chr6:28136849~28139678:+
BRCA	cis	rs9393692	0.645	rs28446029	ENSG00000241549.7	GUSBP2	-4.2	2.93e-05	0.00213	-0.15	-0.13	Educational attainment;	chr6:26305573	chr6:26871484~26956554:-
BRCA	cis	rs11098499	0.863	rs12508173	ENSG00000260404.2	RP11-384K6.6	4.2	2.93e-05	0.00213	0.12	0.13	Corneal astigmatism;	chr4:119397371	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.908	rs12504149	ENSG00000260404.2	RP11-384K6.6	4.2	2.93e-05	0.00213	0.12	0.13	Corneal astigmatism;	chr4:119397422	chr4:118591773~118633729:+
BRCA	cis	rs2625529	0.652	rs1481862	ENSG00000260037.4	CTD-2524L6.3	4.2	2.93e-05	0.00213	0.16	0.13	Red blood cell count;	chr15:71953307	chr15:71818396~71823384:+
BRCA	cis	rs7267979	1	rs2387880	ENSG00000125804.12	FAM182A	4.2	2.93e-05	0.00213	0.17	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25397151	chr20:26054655~26086917:+
BRCA	cis	rs1656368	0.726	rs6788907	ENSG00000279311.1	RP11-170K4.2	4.2	2.93e-05	0.00213	0.17	0.13	Lobe attachment (rater-scored or self-reported);	chr3:158495034	chr3:158869898~158871821:+
BRCA	cis	rs6546537	0.955	rs1396798	ENSG00000231024.1	AC092431.3	4.2	2.93e-05	0.00213	0.18	0.13	Serum thyroid-stimulating hormone levels;	chr2:69660705	chr2:69700192~69713847:-
BRCA	cis	rs7818688	1	rs112529587	ENSG00000245080.5	RP11-320N21.1	-4.2	2.93e-05	0.00213	-0.23	-0.13	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95047807	chr8:95066808~95073182:-
BRCA	cis	rs11673344	0.542	rs2562598	ENSG00000276846.1	CTD-3220F14.3	4.2	2.93e-05	0.00213	0.15	0.13	Obesity-related traits;	chr19:37025318	chr19:37314868~37315620:-
BRCA	cis	rs6545883	0.862	rs11691734	ENSG00000212978.6	AC016747.3	4.2	2.93e-05	0.00213	0.17	0.13	Tuberculosis;	chr2:61475331	chr2:61141592~61144969:-
BRCA	cis	rs8114671	0.562	rs1013677	ENSG00000126005.14	MMP24-AS1	-4.2	2.93e-05	0.00213	-0.15	-0.13	Height;	chr20:34880990	chr20:35216462~35278131:-
BRCA	cis	rs10844706	0.699	rs10844615	ENSG00000256673.1	RP11-599J14.2	-4.2	2.93e-05	0.00214	-0.16	-0.13	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9725646	chr12:9398355~9414851:-
BRCA	cis	rs12760731	0.843	rs12033565	ENSG00000213057.5	C1orf220	-4.2	2.93e-05	0.00214	-0.16	-0.13	Obesity-related traits;	chr1:178522831	chr1:178542752~178548889:+
BRCA	cis	rs77204473	1	rs12292278	ENSG00000280143.1	AP000892.6	4.2	2.93e-05	0.00214	0.24	0.13	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116887977	chr11:117204967~117210292:+
BRCA	cis	rs36051895	0.502	rs12347799	ENSG00000236254.1	MTND4P14	-4.2	2.93e-05	0.00214	-0.15	-0.13	Pediatric autoimmune diseases;	chr9:5215954	chr9:5107937~5109290:+
BRCA	cis	rs2143950	0.512	rs79000843	ENSG00000226677.3	IGBP1P1	-4.2	2.93e-05	0.00214	-0.18	-0.13	Atopic dermatitis;	chr14:35041694	chr14:34939324~34940332:+
BRCA	cis	rs7727544	0.582	rs6896703	ENSG00000233006.5	AC034220.3	-4.2	2.93e-05	0.00214	-0.1	-0.13	Blood metabolite levels;	chr5:132185602	chr5:132311285~132369916:-
BRCA	cis	rs2302465	0.86	rs16892232	ENSG00000273133.1	RP11-799M12.2	-4.2	2.93e-05	0.00214	-0.24	-0.13	Blood protein levels;	chr4:15656013	chr4:15563698~15564253:-
BRCA	cis	rs2880765	0.566	rs12911430	ENSG00000259630.2	CTD-2262B20.1	-4.2	2.93e-05	0.00214	-0.16	-0.13	Coronary artery disease;	chr15:85468033	chr15:85415228~85415633:+
BRCA	cis	rs2179367	0.959	rs514839	ENSG00000223701.3	RAET1E-AS1	4.2	2.93e-05	0.00214	0.16	0.13	Dupuytren's disease;	chr6:149327304	chr6:149884431~149919508:+
BRCA	cis	rs9341808	0.754	rs3805885	ENSG00000279022.1	RP11-250B2.4	-4.2	2.93e-05	0.00214	-0.15	-0.13	Sitting height ratio;	chr6:80287034	chr6:80440730~80441172:+
BRCA	cis	rs35146811	0.735	rs1636975	ENSG00000235713.1	RP4-604G5.3	-4.2	2.93e-05	0.00214	-0.15	-0.13	Coronary artery disease;	chr7:100214466	chr7:99992397~99993050:+
BRCA	cis	rs7267979	1	rs2257432	ENSG00000125804.12	FAM182A	-4.2	2.93e-05	0.00214	-0.17	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25290450	chr20:26054655~26086917:+
BRCA	cis	rs7267979	1	rs2258066	ENSG00000125804.12	FAM182A	-4.2	2.93e-05	0.00214	-0.17	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25290690	chr20:26054655~26086917:+
BRCA	cis	rs7267979	1	rs2258135	ENSG00000125804.12	FAM182A	-4.2	2.93e-05	0.00214	-0.17	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25291687	chr20:26054655~26086917:+
BRCA	cis	rs7395581	0.877	rs10838691	ENSG00000280615.1	Y_RNA	4.2	2.93e-05	0.00214	0.15	0.13	HDL cholesterol;	chr11:47320178	chr11:47614898~47614994:-
BRCA	cis	rs34792	0.554	rs62039131	ENSG00000275910.1	RP11-680G24.6	-4.2	2.93e-05	0.00214	-0.16	-0.13	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15528701	chr16:15015828~15016390:-
BRCA	cis	rs9733	0.65	rs11204680	ENSG00000203804.4	ADAMTSL4-AS1	-4.2	2.93e-05	0.00214	-0.14	-0.13	Tonsillectomy;	chr1:150614664	chr1:150560202~150574552:-
BRCA	cis	rs4869313	0.905	rs27660	ENSG00000248734.2	CTD-2260A17.1	-4.2	2.93e-05	0.00214	-0.14	-0.13	Pediatric autoimmune diseases;	chr5:97012071	chr5:96784777~96785999:+
BRCA	cis	rs739401	0.572	rs739400	ENSG00000183562.3	CTC-343N3.1	-4.2	2.93e-05	0.00214	-0.14	-0.13	Longevity;	chr11:2995290	chr11:2989863~2991344:+
BRCA	cis	rs11098499	0.954	rs59394118	ENSG00000260404.2	RP11-384K6.6	4.2	2.94e-05	0.00214	0.12	0.13	Corneal astigmatism;	chr4:119374396	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.865	rs9996417	ENSG00000260404.2	RP11-384K6.6	4.2	2.94e-05	0.00214	0.12	0.13	Corneal astigmatism;	chr4:119374707	chr4:118591773~118633729:+
BRCA	cis	rs10129255	0.518	rs10150460	ENSG00000232216.1	IGHV3-43	-4.2	2.94e-05	0.00214	-0.1	-0.13	Kawasaki disease;	chr14:106677179	chr14:106470264~106470800:-
BRCA	cis	rs911119	0.908	rs8114619	ENSG00000270001.1	RP11-218C14.8	-4.2	2.94e-05	0.00214	-0.16	-0.13	Chronic kidney disease;	chr20:23621176	chr20:23631826~23632316:-
BRCA	cis	rs9308731	0.966	rs4849442	ENSG00000227992.1	AC108463.2	-4.2	2.94e-05	0.00214	-0.15	-0.13	Chronic lymphocytic leukemia;	chr2:111176642	chr2:111203964~111206215:-
BRCA	cis	rs7577696	0.671	rs55877106	ENSG00000272716.1	RP11-563N4.1	4.2	2.94e-05	0.00214	0.14	0.13	Inflammatory biomarkers;	chr2:32205732	chr2:32165046~32165757:-
BRCA	cis	rs4660214	0.724	rs2484751	ENSG00000237624.1	OXCT2P1	-4.2	2.94e-05	0.00214	-0.16	-0.13	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39282867	chr1:39514956~39516490:+
BRCA	cis	rs568617	0.716	rs111953392	ENSG00000254510.1	RP11-867G23.10	4.2	2.94e-05	0.00214	0.2	0.13	Crohn's disease;	chr11:65828226	chr11:66409158~66417137:+
BRCA	cis	rs2242663	0.529	rs1785640	ENSG00000255517.5	CTD-3074O7.5	4.2	2.94e-05	0.00214	0.15	0.13	Bipolar disorder;	chr11:66455687	chr11:66473490~66480233:-
BRCA	cis	rs8073765	0.661	rs9915975	ENSG00000266744.1	RP11-131K5.1	4.2	2.94e-05	0.00214	0.16	0.13	Verbal memory performance (immediate recall change);	chr17:13728451	chr17:13957748~13966952:-
BRCA	cis	rs72766638	0.848	rs11789898	ENSG00000235106.7	LINC00094	-4.2	2.94e-05	0.00214	-0.16	-0.13	Mosquito bite size;	chr9:134060541	chr9:134025439~134034666:+
BRCA	cis	rs6671200	1	rs6671200	ENSG00000226026.4	RP11-57H12.3	-4.2	2.94e-05	0.00214	-0.24	-0.13	Stearic acid (18:0) levels;	chr1:95231973	chr1:95163219~95233982:-
BRCA	cis	rs2436845	0.627	rs1897787	ENSG00000253669.3	KB-1732A1.1	4.2	2.94e-05	0.00214	0.16	0.13	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102850195	chr8:102805517~102809971:+
BRCA	cis	rs7937890	0.559	rs2597188	ENSG00000254418.1	RP11-21L19.1	4.2	2.94e-05	0.00215	0.15	0.13	Mitochondrial DNA levels;	chr11:14495360	chr11:14262846~14273691:-
BRCA	cis	rs7937890	0.559	rs2597187	ENSG00000254418.1	RP11-21L19.1	4.2	2.94e-05	0.00215	0.15	0.13	Mitochondrial DNA levels;	chr11:14495473	chr11:14262846~14273691:-
BRCA	cis	rs62103177	0.608	rs613847	ENSG00000278000.1	AC139100.4	-4.2	2.95e-05	0.00215	-0.2	-0.13	Opioid sensitivity;	chr18:80087736	chr18:80161752~80162413:+
BRCA	cis	rs11887277	0.588	rs7590170	ENSG00000272148.1	RP11-195B17.1	-4.2	2.95e-05	0.00215	-0.15	-0.13	Obesity-related traits;	chr2:26806266	chr2:27062428~27062907:-
BRCA	cis	rs28472312	0.832	rs28433345	ENSG00000259982.1	CDC37P1	4.2	2.95e-05	0.00215	0.16	0.13	Intelligence (multi-trait analysis);	chr16:28872006	chr16:28700294~28701540:-
BRCA	cis	rs8113308	0.515	rs56343029	ENSG00000269483.1	AC006272.1	4.2	2.95e-05	0.00215	0.3	0.13	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51960184	chr19:51839924~51843324:-
BRCA	cis	rs891378	1	rs1858001	ENSG00000274245.1	RP11-357P18.2	4.2	2.95e-05	0.00215	0.17	0.13	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207314659	chr1:207372559~207373252:+
BRCA	cis	rs4664293	0.836	rs73967923	ENSG00000226266.5	AC009961.3	-4.2	2.95e-05	0.00215	-0.17	-0.13	Monocyte percentage of white cells;	chr2:159801754	chr2:159670708~159712435:-
BRCA	cis	rs669446	0.561	rs516790	ENSG00000236200.4	KDM4A-AS1	4.2	2.95e-05	0.00215	0.16	0.13	Amyotrophic lateral sclerosis (age of onset);	chr1:43616041	chr1:43699765~43708138:-
BRCA	cis	rs9525927	0.67	rs2246499	ENSG00000227258.4	SMIM2-AS1	-4.2	2.95e-05	0.00215	-0.19	-0.13	Dupuytren's disease;	chr13:44255900	chr13:44110451~44240517:+
BRCA	cis	rs1434579	0.865	rs12978546	ENSG00000176761.7	ZNF285B	-4.2	2.95e-05	0.00215	-0.15	-0.13	Tuberculosis;	chr19:44441764	chr19:44467641~44473227:+
BRCA	cis	rs1865760	0.929	rs1436307	ENSG00000272462.2	U91328.19	-4.2	2.95e-05	0.00215	-0.16	-0.13	Height;	chr6:25939495	chr6:25992662~26001775:+
BRCA	cis	rs4950322	0.547	rs61838945	ENSG00000244371.2	PFN1P8	-4.2	2.95e-05	0.00215	-0.17	-0.13	Protein quantitative trait loci;	chr1:147111477	chr1:146957117~146957659:-
BRCA	cis	rs11742741	0.806	rs62349712	ENSG00000248874.4	C5orf17	-4.2	2.95e-05	0.00215	-0.17	-0.13	Educational attainment;	chr5:24026757	chr5:23951348~24178263:+
BRCA	cis	rs11742741	0.712	rs72745716	ENSG00000248874.4	C5orf17	-4.2	2.95e-05	0.00215	-0.17	-0.13	Educational attainment;	chr5:24027368	chr5:23951348~24178263:+
BRCA	cis	rs2108622	0.727	rs7256877	ENSG00000267218.2	AC005336.5	4.2	2.95e-05	0.00215	0.15	0.13	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15869873	chr19:15902300~15903238:-
BRCA	cis	rs875971	0.545	rs3936065	ENSG00000230295.1	RP11-458F8.2	4.2	2.95e-05	0.00215	0.12	0.13	Aortic root size;	chr7:66325577	chr7:66880708~66882981:+
BRCA	cis	rs875971	0.545	rs4718335	ENSG00000230295.1	RP11-458F8.2	4.2	2.95e-05	0.00215	0.12	0.13	Aortic root size;	chr7:66339619	chr7:66880708~66882981:+
BRCA	cis	rs9467773	0.529	rs7356988	ENSG00000124549.13	BTN2A3P	-4.2	2.95e-05	0.00215	-0.14	-0.13	Intelligence (multi-trait analysis);	chr6:26396499	chr6:26421391~26432383:+
BRCA	cis	rs11673344	0.504	rs35162188	ENSG00000276846.1	CTD-3220F14.3	4.2	2.95e-05	0.00215	0.15	0.13	Obesity-related traits;	chr19:37088908	chr19:37314868~37315620:-
BRCA	cis	rs8180040	0.729	rs11720439	ENSG00000276925.1	RP11-708J19.3	4.2	2.95e-05	0.00215	0.15	0.13	Colorectal cancer;	chr3:47305513	chr3:47469777~47469987:+
BRCA	cis	rs2625529	0.689	rs4526973	ENSG00000260037.4	CTD-2524L6.3	-4.2	2.95e-05	0.00215	-0.16	-0.13	Red blood cell count;	chr15:71846378	chr15:71818396~71823384:+
BRCA	cis	rs6686842	1	rs213742	ENSG00000235358.1	RP11-399E6.1	-4.2	2.95e-05	0.00215	-0.16	-0.13	Height;	chr1:41155455	chr1:41242373~41284861:+
BRCA	cis	rs2692947	0.537	rs11685849	ENSG00000168992.4	OR7E102P	4.2	2.95e-05	0.00215	0.19	0.13	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95578056	chr2:95546531~95547545:+
BRCA	cis	rs2692947	0.537	rs11688045	ENSG00000168992.4	OR7E102P	4.2	2.95e-05	0.00215	0.19	0.13	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95578057	chr2:95546531~95547545:+
BRCA	cis	rs2243480	0.901	rs73148097	ENSG00000222364.1	RNU6-96P	-4.2	2.95e-05	0.00215	-0.23	-0.13	Diabetic kidney disease;	chr7:65966800	chr7:66395191~66395286:+
BRCA	cis	rs2243480	1	rs906134	ENSG00000222364.1	RNU6-96P	-4.2	2.95e-05	0.00215	-0.23	-0.13	Diabetic kidney disease;	chr7:65979301	chr7:66395191~66395286:+
BRCA	cis	rs763121	0.819	rs4560233	ENSG00000225450.1	RP3-508I15.14	-4.2	2.95e-05	0.00215	-0.14	-0.13	Menopause (age at onset);	chr22:38586437	chr22:38739003~38749041:+
BRCA	cis	rs4478858	0.684	rs10753245	ENSG00000260386.4	LINC01225	-4.2	2.95e-05	0.00215	-0.15	-0.13	Alcohol dependence;	chr1:31258361	chr1:31500085~31540885:+
BRCA	cis	rs875971	0.545	rs2420612	ENSG00000230295.1	RP11-458F8.2	4.2	2.95e-05	0.00215	0.13	0.13	Aortic root size;	chr7:66536825	chr7:66880708~66882981:+
BRCA	cis	rs2688608	0.592	rs11000758	ENSG00000213731.2	RAB5CP1	-4.2	2.95e-05	0.00215	-0.14	-0.13	Inflammatory bowel disease;	chr10:73733852	chr10:74423435~74424014:-
BRCA	cis	rs338389	0.516	rs7359201	ENSG00000260657.2	RP11-315D16.4	-4.2	2.95e-05	0.00215	-0.15	-0.13	Survival in rectal cancer;	chr15:68021411	chr15:68267792~68277994:-
BRCA	cis	rs755249	0.567	rs4660546	ENSG00000182109.6	RP11-69E11.4	4.2	2.96e-05	0.00215	0.18	0.13	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39213730	chr1:39522280~39546187:-
BRCA	cis	rs748404	1	rs66651343	ENSG00000205771.5	CATSPER2P1	-4.2	2.96e-05	0.00215	-0.19	-0.13	Lung cancer;	chr15:43265806	chr15:43726918~43747094:-
BRCA	cis	rs17581137	0.591	rs2397804	ENSG00000247809.6	NR2F2-AS1	-4.2	2.96e-05	0.00215	-0.15	-0.13	Coronary artery disease;	chr15:95635794	chr15:96110040~96327361:-
BRCA	cis	rs721917	0.506	rs2265961	ENSG00000278616.1	BEND3P3	-4.2	2.96e-05	0.00215	-0.12	-0.13	Chronic obstructive pulmonary disease;	chr10:79886101	chr10:79682997~79685436:+
BRCA	cis	rs721917	0.506	rs7088752	ENSG00000278616.1	BEND3P3	-4.2	2.96e-05	0.00215	-0.12	-0.13	Chronic obstructive pulmonary disease;	chr10:79886704	chr10:79682997~79685436:+
BRCA	cis	rs721917	0.506	rs7078242	ENSG00000278616.1	BEND3P3	-4.2	2.96e-05	0.00215	-0.12	-0.13	Chronic obstructive pulmonary disease;	chr10:79886885	chr10:79682997~79685436:+
BRCA	cis	rs721917	0.525	rs2244001	ENSG00000278616.1	BEND3P3	-4.2	2.96e-05	0.00215	-0.12	-0.13	Chronic obstructive pulmonary disease;	chr10:79888813	chr10:79682997~79685436:+
BRCA	cis	rs721917	0.506	rs1811886	ENSG00000278616.1	BEND3P3	-4.2	2.96e-05	0.00215	-0.12	-0.13	Chronic obstructive pulmonary disease;	chr10:79889812	chr10:79682997~79685436:+
BRCA	cis	rs330048	0.525	rs10112237	ENSG00000253981.4	ALG1L13P	-4.2	2.96e-05	0.00215	-0.14	-0.13	Systemic lupus erythematosus;	chr8:9215219	chr8:8236003~8244667:-
BRCA	cis	rs10266483	0.739	rs55747800	ENSG00000227986.1	TRIM60P18	4.2	2.96e-05	0.00215	0.15	0.13	Response to statin therapy;	chr7:64410105	chr7:64355078~64356199:+
BRCA	cis	rs10266483	0.774	rs56055804	ENSG00000227986.1	TRIM60P18	4.2	2.96e-05	0.00215	0.15	0.13	Response to statin therapy;	chr7:64410423	chr7:64355078~64356199:+
BRCA	cis	rs1129187	0.967	rs9462857	ENSG00000220614.1	RP11-480N24.4	4.2	2.96e-05	0.00215	0.14	0.13	Alzheimer's disease in APOE e4+ carriers;	chr6:42975360	chr6:43328134~43328476:+
BRCA	cis	rs11892454	0.515	rs13413825	ENSG00000217643.1	PTGES3P2	-4.2	2.96e-05	0.00215	-0.13	-0.13	Heschl's gyrus morphology;	chr2:25801581	chr2:25822469~25822950:+
BRCA	cis	rs1910358	0.554	rs4395602	ENSG00000248874.4	C5orf17	-4.2	2.96e-05	0.00215	-0.18	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23749327	chr5:23951348~24178263:+
BRCA	cis	rs1910358	0.507	rs6876256	ENSG00000248874.4	C5orf17	-4.2	2.96e-05	0.00215	-0.18	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23749390	chr5:23951348~24178263:+
BRCA	cis	rs1910358	0.53	rs6880584	ENSG00000248874.4	C5orf17	-4.2	2.96e-05	0.00215	-0.18	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23749396	chr5:23951348~24178263:+
BRCA	cis	rs2243480	1	rs313814	ENSG00000234585.5	CCT6P3	-4.2	2.96e-05	0.00215	-0.2	-0.13	Diabetic kidney disease;	chr7:66038306	chr7:65038354~65074713:+
BRCA	cis	rs7267979	0.528	rs34485039	ENSG00000125804.12	FAM182A	4.2	2.96e-05	0.00215	0.17	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25603127	chr20:26054655~26086917:+
BRCA	cis	rs409045	0.93	rs382782	ENSG00000271874.1	CTD-2024P10.2	4.2	2.96e-05	0.00215	0.17	0.13	Left ventricular mass;	chr5:34626236	chr5:34651457~34651888:-
BRCA	cis	rs34792	0.554	rs62039131	ENSG00000258354.1	MIR3180-1	-4.2	2.96e-05	0.00215	-0.18	-0.13	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15528701	chr16:14909887~14911345:-
BRCA	cis	rs4578769	0.691	rs28594790	ENSG00000273232.1	RP11-370A5.2	-4.2	2.96e-05	0.00215	-0.16	-0.13	Eosinophil percentage of white cells;	chr18:22985463	chr18:22882825~22883357:-
BRCA	cis	rs7937890	0.532	rs2256884	ENSG00000254418.1	RP11-21L19.1	4.2	2.96e-05	0.00215	0.15	0.13	Mitochondrial DNA levels;	chr11:14454856	chr11:14262846~14273691:-
BRCA	cis	rs12428035	0.656	rs9525079	ENSG00000247400.3	DNAJC3-AS1	4.2	2.96e-05	0.00216	0.2	0.13	Glomerular filtration rate (cystatin C);Response to statins (LDL cholesterol change);	chr13:95906202	chr13:95648733~95676925:-
BRCA	cis	rs2408955	0.501	rs8716	ENSG00000257735.1	RP11-370I10.6	4.19	2.96e-05	0.00216	0.16	0.13	Glycated hemoglobin levels;	chr12:48145699	chr12:48350945~48442411:+
BRCA	cis	rs875971	0.66	rs801192	ENSG00000232546.1	RP11-458F8.1	4.19	2.96e-05	0.00216	0.11	0.13	Aortic root size;	chr7:66566965	chr7:66848496~66858136:+
BRCA	cis	rs875971	0.66	rs801190	ENSG00000232546.1	RP11-458F8.1	4.19	2.96e-05	0.00216	0.11	0.13	Aortic root size;	chr7:66568046	chr7:66848496~66858136:+
BRCA	cis	rs875971	0.66	rs3857686	ENSG00000232546.1	RP11-458F8.1	4.19	2.96e-05	0.00216	0.11	0.13	Aortic root size;	chr7:66571204	chr7:66848496~66858136:+
BRCA	cis	rs4907240	0.961	rs11682934	ENSG00000230606.9	AC159540.1	4.19	2.96e-05	0.00216	0.17	0.13	Event-related brain oscillations;	chr2:96571416	chr2:97416165~97433527:-
BRCA	cis	rs1048886	0.872	rs73474966	ENSG00000271967.1	RP11-134K13.4	-4.19	2.96e-05	0.00216	-0.17	-0.13	Type 2 diabetes;	chr6:70427988	chr6:70596438~70596980:+
BRCA	cis	rs1048886	0.938	rs9455104	ENSG00000271967.1	RP11-134K13.4	-4.19	2.96e-05	0.00216	-0.17	-0.13	Type 2 diabetes;	chr6:70433762	chr6:70596438~70596980:+
BRCA	cis	rs6452524	0.868	rs10057303	ENSG00000281327.1	LINC01338	4.19	2.96e-05	0.00216	0.16	0.13	Hypertension (SNP x SNP interaction);	chr5:83098564	chr5:82850864~82859836:-
BRCA	cis	rs62025270	0.632	rs78572940	ENSG00000259295.5	CSPG4P12	-4.19	2.96e-05	0.00216	-0.2	-0.13	Idiopathic pulmonary fibrosis;	chr15:85696539	chr15:85191438~85213905:+
BRCA	cis	rs673253	0.581	rs11210860	ENSG00000229431.1	RP1-92O14.6	4.19	2.96e-05	0.00216	0.13	0.13	Intelligence (multi-trait analysis);	chr1:43516856	chr1:43385113~43389155:+
BRCA	cis	rs9584850	0.834	rs17574378	ENSG00000231194.1	FARP1-AS1	4.19	2.96e-05	0.00216	0.17	0.13	Neuroticism;	chr13:98464130	chr13:98435405~98435840:-
BRCA	cis	rs2839186	0.771	rs13046451	ENSG00000239415.1	AP001469.9	-4.19	2.96e-05	0.00216	-0.14	-0.13	Testicular germ cell tumor;	chr21:46221459	chr21:46251549~46254133:-
BRCA	cis	rs13113518	1	rs34648901	ENSG00000272969.1	RP11-528I4.2	4.19	2.96e-05	0.00216	0.15	0.13	Height;	chr4:55541259	chr4:55547112~55547889:+
BRCA	cis	rs7937890	0.559	rs2575837	ENSG00000254418.1	RP11-21L19.1	4.19	2.97e-05	0.00216	0.15	0.13	Mitochondrial DNA levels;	chr11:14476455	chr11:14262846~14273691:-
BRCA	cis	rs6596100	0.956	rs62375244	ENSG00000248648.1	RP11-485M7.1	-4.19	2.97e-05	0.00216	-0.17	-0.13	Breast cancer;	chr5:133100527	chr5:133003119~133003365:+
BRCA	cis	rs7586673	0.725	rs6715870	ENSG00000235724.7	AC009299.2	-4.19	2.97e-05	0.00216	-0.15	-0.13	Intelligence (multi-trait analysis);	chr2:161038275	chr2:161222785~161308303:-
BRCA	cis	rs11098499	0.663	rs9996501	ENSG00000260091.1	RP11-33B1.4	-4.19	2.97e-05	0.00216	-0.11	-0.13	Corneal astigmatism;	chr4:119317763	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.697	rs28458294	ENSG00000260091.1	RP11-33B1.4	-4.19	2.97e-05	0.00216	-0.11	-0.13	Corneal astigmatism;	chr4:119317769	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.663	rs28369503	ENSG00000260091.1	RP11-33B1.4	-4.19	2.97e-05	0.00216	-0.11	-0.13	Corneal astigmatism;	chr4:119317770	chr4:119409333~119410233:+
BRCA	cis	rs10487112	0.803	rs2374265	ENSG00000235436.9	DPY19L2P4	-4.19	2.97e-05	0.00216	-0.14	-0.13	Perceived unattractiveness to mosquitoes;	chr7:90486827	chr7:90119400~90125600:+
BRCA	cis	rs10487112	0.803	rs2374266	ENSG00000235436.9	DPY19L2P4	-4.19	2.97e-05	0.00216	-0.14	-0.13	Perceived unattractiveness to mosquitoes;	chr7:90486828	chr7:90119400~90125600:+
BRCA	cis	rs3812049	0.693	rs9327468	ENSG00000245937.6	LINC01184	4.19	2.97e-05	0.00216	0.18	0.13	Lymphocyte counts;Red cell distribution width;	chr5:128106169	chr5:127940426~128083172:-
BRCA	cis	rs930395	0.514	rs13187933	ENSG00000251141.4	RP11-53O19.1	-4.19	2.97e-05	0.00216	-0.12	-0.13	Breast cancer;	chr5:44883141	chr5:44744900~44808777:-
BRCA	cis	rs4415084	0.652	rs11948387	ENSG00000251141.4	RP11-53O19.1	-4.19	2.97e-05	0.00216	-0.12	-0.13	Breast cancer;	chr5:44884139	chr5:44744900~44808777:-
BRCA	cis	rs2562456	0.652	rs62110214	ENSG00000268658.4	LINC00664	4.19	2.97e-05	0.00216	0.22	0.13	Pain;	chr19:21592406	chr19:21483374~21503238:+
BRCA	cis	rs13434995	0.513	rs6851971	ENSG00000273257.1	RP11-177J6.1	4.19	2.97e-05	0.00216	0.19	0.13	Adiponectin levels;	chr4:55561897	chr4:55387949~55388271:+
BRCA	cis	rs7267979	0.932	rs424487	ENSG00000125804.12	FAM182A	-4.19	2.97e-05	0.00216	-0.17	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25487495	chr20:26054655~26086917:+
BRCA	cis	rs2243480	1	rs73142162	ENSG00000226002.1	RP11-460N20.5	-4.19	2.97e-05	0.00216	-0.22	-0.13	Diabetic kidney disease;	chr7:65909309	chr7:65084103~65100232:+
BRCA	cis	rs9291683	0.61	rs993173	ENSG00000250413.1	RP11-448G15.1	4.19	2.97e-05	0.00216	0.16	0.13	Bone mineral density;	chr4:10322311	chr4:10006482~10009725:+
BRCA	cis	rs465969	1	rs463543	ENSG00000272356.1	RP5-1112D6.8	4.19	2.97e-05	0.00216	0.28	0.13	Psoriasis;	chr6:111346349	chr6:111309203~111313517:+
BRCA	cis	rs853679	0.517	rs12332979	ENSG00000216901.1	AL022393.7	4.19	2.97e-05	0.00216	0.19	0.13	Depression;	chr6:28173770	chr6:28176188~28176674:+
BRCA	cis	rs853679	0.517	rs67878650	ENSG00000216901.1	AL022393.7	4.19	2.97e-05	0.00216	0.19	0.13	Depression;	chr6:28174809	chr6:28176188~28176674:+
BRCA	cis	rs853679	0.569	rs9348798	ENSG00000216901.1	AL022393.7	4.19	2.97e-05	0.00216	0.19	0.13	Depression;	chr6:28175233	chr6:28176188~28176674:+
BRCA	cis	rs853679	0.517	rs9380065	ENSG00000216901.1	AL022393.7	4.19	2.97e-05	0.00216	0.19	0.13	Depression;	chr6:28176973	chr6:28176188~28176674:+
BRCA	cis	rs6671200	1	rs259359	ENSG00000235501.4	RP4-639F20.1	4.19	2.97e-05	0.00216	0.27	0.13	Stearic acid (18:0) levels;	chr1:95243483	chr1:94927566~94963270:+
BRCA	cis	rs11742741	0.87	rs12186522	ENSG00000248874.4	C5orf17	-4.19	2.97e-05	0.00216	-0.17	-0.13	Educational attainment;	chr5:24082800	chr5:23951348~24178263:+
BRCA	cis	rs910316	0.967	rs8007539	ENSG00000259138.1	RP11-950C14.7	-4.19	2.97e-05	0.00216	-0.13	-0.13	Height;	chr14:75198250	chr14:75127153~75136930:+
BRCA	cis	rs783540	0.5	rs7178459	ENSG00000276710.3	CSPG4P8	-4.19	2.97e-05	0.00216	-0.16	-0.13	Schizophrenia;	chr15:82729632	chr15:82459472~82477258:+
BRCA	cis	rs2834288	0.5	rs2834305	ENSG00000237945.6	LINC00649	4.19	2.98e-05	0.00216	0.15	0.13	Gut microbiota (bacterial taxa);	chr21:33955321	chr21:33915534~33977691:+
BRCA	cis	rs6736093	0.966	rs13027171	ENSG00000236307.2	EEF1E1P1	-4.19	2.98e-05	0.00216	-0.17	-0.13	Coronary artery disease;	chr2:111929411	chr2:111887914~111888741:+
BRCA	cis	rs6452524	1	rs9293332	ENSG00000281327.1	LINC01338	4.19	2.98e-05	0.00217	0.15	0.13	Hypertension (SNP x SNP interaction);	chr5:83141546	chr5:82850864~82859836:-
BRCA	cis	rs7267979	0.844	rs2424703	ENSG00000231081.1	RP4-760C5.3	-4.19	2.98e-05	0.00217	-0.16	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25289488	chr20:26008791~26010531:-
BRCA	cis	rs13113518	0.967	rs7696832	ENSG00000272969.1	RP11-528I4.2	4.19	2.98e-05	0.00217	0.15	0.13	Height;	chr4:55537080	chr4:55547112~55547889:+
BRCA	cis	rs8180040	0.967	rs17411375	ENSG00000271161.1	BOLA2P2	-4.19	2.98e-05	0.00217	-0.14	-0.13	Colorectal cancer;	chr3:47353645	chr3:47499841~47500407:+
BRCA	cis	rs7332672	0.962	rs2182885	ENSG00000218502.3	H2AFZP3	4.19	2.98e-05	0.00217	0.14	0.13	Eosinophil counts;	chr13:99202870	chr13:99215372~99215758:-
BRCA	cis	rs11098499	0.954	rs17009122	ENSG00000260404.2	RP11-384K6.6	4.19	2.98e-05	0.00217	0.12	0.13	Corneal astigmatism;	chr4:119441248	chr4:118591773~118633729:+
BRCA	cis	rs7727544	0.625	rs3864277	ENSG00000233006.5	AC034220.3	4.19	2.98e-05	0.00217	0.1	0.13	Blood metabolite levels;	chr5:132084556	chr5:132311285~132369916:-
BRCA	cis	rs7177699	0.557	rs6495333	ENSG00000261143.1	ADAMTS7P3	-4.19	2.98e-05	0.00217	-0.15	-0.13	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78820873	chr15:77976042~77993057:+
BRCA	cis	rs7177699	0.557	rs9920493	ENSG00000261143.1	ADAMTS7P3	-4.19	2.98e-05	0.00217	-0.15	-0.13	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78821504	chr15:77976042~77993057:+
BRCA	cis	rs4845570	0.85	rs4618976	ENSG00000203288.3	RP11-98D18.9	4.19	2.98e-05	0.00217	0.21	0.13	Coronary artery disease;	chr1:151794112	chr1:151790804~151794402:+
BRCA	cis	rs7735319	0.546	rs6450949	ENSG00000249572.1	CTD-2203K17.1	-4.19	2.98e-05	0.00217	-0.16	-0.13	Systolic blood pressure;	chr5:33170210	chr5:33424025~33440619:-
BRCA	cis	rs1048886	0.872	rs9455105	ENSG00000271967.1	RP11-134K13.4	-4.19	2.98e-05	0.00217	-0.17	-0.13	Type 2 diabetes;	chr6:70433778	chr6:70596438~70596980:+
BRCA	cis	rs11098499	0.954	rs6857105	ENSG00000225892.3	RP11-384K6.2	4.19	2.98e-05	0.00217	0.13	0.13	Corneal astigmatism;	chr4:119301143	chr4:118632274~118634759:+
BRCA	cis	rs55780018	0.644	rs4675682	ENSG00000224137.1	AC079767.4	4.19	2.98e-05	0.00217	0.11	0.13	Systolic blood pressure;	chr2:207538026	chr2:207662375~207667024:+
BRCA	cis	rs2243480	1	rs1964692	ENSG00000222364.1	RNU6-96P	-4.19	2.98e-05	0.00217	-0.23	-0.13	Diabetic kidney disease;	chr7:65989196	chr7:66395191~66395286:+
BRCA	cis	rs6452524	0.935	rs10474081	ENSG00000281327.1	LINC01338	4.19	2.98e-05	0.00217	0.16	0.13	Hypertension (SNP x SNP interaction);	chr5:83095064	chr5:82850864~82859836:-
BRCA	cis	rs7712401	0.791	rs6872932	ENSG00000251538.4	RP11-166A12.1	4.19	2.98e-05	0.00217	0.14	0.13	Mean platelet volume;	chr5:122809941	chr5:122628952~122730685:-
BRCA	cis	rs7267979	0.966	rs3827014	ENSG00000125804.12	FAM182A	4.19	2.98e-05	0.00217	0.17	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25390923	chr20:26054655~26086917:+
BRCA	cis	rs1730008	0.556	rs1656369	ENSG00000279311.1	RP11-170K4.2	4.19	2.98e-05	0.00217	0.15	0.13	Lobe attachment (rater-scored or self-reported);	chr3:158562296	chr3:158869898~158871821:+
BRCA	cis	rs35740288	0.822	rs34734963	ENSG00000202081.1	RNU6-1280P	4.19	2.98e-05	0.00217	0.18	0.13	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85674413	chr15:85651522~85651628:-
BRCA	cis	rs7260598	0.792	rs73021416	ENSG00000268442.1	CTD-2027I19.2	4.19	2.98e-05	0.00217	0.21	0.13	Response to taxane treatment (placlitaxel);	chr19:24081849	chr19:24162370~24163425:-
BRCA	cis	rs372883	0.869	rs2027605	ENSG00000215533.7	LINC00189	4.19	2.98e-05	0.00217	0.14	0.13	Pancreatic cancer;	chr21:29354452	chr21:29193480~29288205:+
BRCA	cis	rs875971	0.597	rs11763224	ENSG00000230295.1	RP11-458F8.2	4.19	2.99e-05	0.00217	0.12	0.13	Aortic root size;	chr7:66518628	chr7:66880708~66882981:+
BRCA	cis	rs867186	1	rs79341738	ENSG00000126005.14	MMP24-AS1	-4.19	2.99e-05	0.00217	-0.24	-0.13	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35114301	chr20:35216462~35278131:-
BRCA	cis	rs559555	0.626	rs499362	ENSG00000276334.1	AL133243.1	4.19	2.99e-05	0.00217	0.16	0.13	Blood metabolite ratios;Blood metabolite levels;	chr2:31586503	chr2:32521927~32523547:+
BRCA	cis	rs1005277	0.563	rs2800550	ENSG00000272983.1	RP11-508N22.12	4.19	2.99e-05	0.00217	0.14	0.13	Extrinsic epigenetic age acceleration;	chr10:38194001	chr10:38137337~38144399:+
BRCA	cis	rs8114671	0.836	rs2425006	ENSG00000126005.14	MMP24-AS1	4.19	2.99e-05	0.00217	0.15	0.13	Height;	chr20:34983425	chr20:35216462~35278131:-
BRCA	cis	rs9650657	0.74	rs7002282	ENSG00000154316.13	TDH	4.19	2.99e-05	0.00217	0.16	0.13	Neuroticism;	chr8:10809483	chr8:11339637~11368452:+
BRCA	cis	rs11096990	0.634	rs2839765	ENSG00000249685.1	RP11-360F5.3	-4.19	2.99e-05	0.00217	-0.16	-0.13	Cognitive function;	chr4:39293933	chr4:39133913~39135608:+
BRCA	cis	rs6496932	0.663	rs12915663	ENSG00000218052.5	ADAMTS7P4	-4.19	2.99e-05	0.00217	-0.14	-0.13	Central corneal thickness;Corneal structure;	chr15:85362249	chr15:85255369~85330334:-
BRCA	cis	rs853679	0.882	rs2743555	ENSG00000204709.4	LINC01556	4.19	2.99e-05	0.00217	0.23	0.13	Depression;	chr6:28273304	chr6:28943877~28944537:+
BRCA	cis	rs78773383	0.505	rs13123782	ENSG00000249685.1	RP11-360F5.3	-4.19	2.99e-05	0.00217	-0.16	-0.13	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr4:39375785	chr4:39133913~39135608:+
BRCA	cis	rs6547741	0.967	rs4665999	ENSG00000234072.1	AC074117.10	4.19	2.99e-05	0.00217	0.12	0.13	Oral cavity cancer;	chr2:27611577	chr2:27356246~27367622:+
BRCA	cis	rs1223397	0.651	rs202021	ENSG00000215022.6	RP1-257A7.4	-4.19	2.99e-05	0.00217	-0.15	-0.13	Blood pressure;	chr6:13302609	chr6:13264861~13295586:-
BRCA	cis	rs11098499	0.865	rs10213221	ENSG00000225892.3	RP11-384K6.2	4.19	2.99e-05	0.00217	0.12	0.13	Corneal astigmatism;	chr4:119334771	chr4:118632274~118634759:+
BRCA	cis	rs7520050	0.807	rs28378621	ENSG00000281133.1	AL355480.3	-4.19	2.99e-05	0.00217	-0.15	-0.13	Reticulocyte count;Red blood cell count;	chr1:45723882	chr1:45580892~45580996:-
BRCA	cis	rs2115630	1	rs10220733	ENSG00000275120.1	RP11-182J1.17	-4.19	2.99e-05	0.00217	-0.15	-0.13	P wave terminal force;	chr15:84737633	chr15:84599434~84606463:-
BRCA	cis	rs1910358	0.554	rs1520984	ENSG00000248874.4	C5orf17	-4.19	2.99e-05	0.00217	-0.18	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23758447	chr5:23951348~24178263:+
BRCA	cis	rs1910358	0.554	rs1520986	ENSG00000248874.4	C5orf17	-4.19	2.99e-05	0.00217	-0.18	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23758939	chr5:23951348~24178263:+
BRCA	cis	rs1910358	0.554	rs1520987	ENSG00000248874.4	C5orf17	-4.19	2.99e-05	0.00217	-0.18	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23758946	chr5:23951348~24178263:+
BRCA	cis	rs66887589	0.616	rs11732621	ENSG00000250412.1	KLHL2P1	4.19	2.99e-05	0.00217	0.14	0.13	Diastolic blood pressure;	chr4:119291728	chr4:119334329~119378233:+
BRCA	cis	rs4950322	0.58	rs1813002	ENSG00000244371.2	PFN1P8	-4.19	2.99e-05	0.00217	-0.17	-0.13	Protein quantitative trait loci;	chr1:147112579	chr1:146957117~146957659:-
BRCA	cis	rs17608059	0.524	rs9897978	ENSG00000266709.1	RP11-214O1.2	4.19	2.99e-05	0.00217	0.14	0.13	Temperament;	chr17:13996939	chr17:14303854~14305505:+
BRCA	cis	rs6012564	1	rs2426112	ENSG00000222365.1	SNORD12B	-4.19	2.99e-05	0.00218	-0.13	-0.13	Anger;	chr20:49073602	chr20:49280319~49280409:+
BRCA	cis	rs6012564	1	rs2426113	ENSG00000222365.1	SNORD12B	-4.19	2.99e-05	0.00218	-0.13	-0.13	Anger;	chr20:49073652	chr20:49280319~49280409:+
BRCA	cis	rs6012564	0.929	rs2426114	ENSG00000222365.1	SNORD12B	-4.19	2.99e-05	0.00218	-0.13	-0.13	Anger;	chr20:49075855	chr20:49280319~49280409:+
BRCA	cis	rs6012564	1	rs2426116	ENSG00000222365.1	SNORD12B	-4.19	2.99e-05	0.00218	-0.13	-0.13	Anger;	chr20:49076510	chr20:49280319~49280409:+
BRCA	cis	rs490234	0.702	rs12553311	ENSG00000232630.1	PRPS1P2	-4.19	2.99e-05	0.00218	-0.13	-0.13	Mean arterial pressure;	chr9:125636717	chr9:125150653~125151589:+
BRCA	cis	rs2704588	1	rs1458553	ENSG00000270720.1	RP11-84C13.2	-4.19	2.99e-05	0.00218	-0.18	-0.13	Longevity;	chr4:88914840	chr4:89119284~89119871:+
BRCA	cis	rs2832191	1	rs6516891	ENSG00000236056.1	GAPDHP14	4.19	2.99e-05	0.00218	0.14	0.13	Dental caries;	chr21:29110749	chr21:29222321~29223257:+
BRCA	cis	rs2832191	1	rs2832184	ENSG00000236056.1	GAPDHP14	4.19	2.99e-05	0.00218	0.14	0.13	Dental caries;	chr21:29110944	chr21:29222321~29223257:+
BRCA	cis	rs875971	0.83	rs4718358	ENSG00000236529.1	RP13-254B10.1	4.19	2.99e-05	0.00218	0.14	0.13	Aortic root size;	chr7:66508681	chr7:65840212~65840596:+
BRCA	cis	rs1910358	0.554	rs3857311	ENSG00000248874.4	C5orf17	-4.19	2.99e-05	0.00218	-0.18	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23745715	chr5:23951348~24178263:+
BRCA	cis	rs9527	0.641	rs10786732	ENSG00000213061.2	PFN1P11	4.19	2.99e-05	0.00218	0.17	0.13	Arsenic metabolism;	chr10:103002778	chr10:102838011~102845473:-
BRCA	cis	rs7267979	1	rs6115140	ENSG00000276952.1	RP5-965G21.6	4.19	2.99e-05	0.00218	0.16	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25304871	chr20:25284915~25285588:-
BRCA	cis	rs875971	1	rs778706	ENSG00000229180.5	GS1-124K5.11	4.19	2.99e-05	0.00218	0.11	0.13	Aortic root size;	chr7:66395437	chr7:66526088~66542624:-
BRCA	cis	rs17801127	0.818	rs16827307	ENSG00000231969.1	AC144449.1	-4.19	3e-05	0.00218	-0.23	-0.13	Liver enzyme levels (alanine transaminase);	chr2:149663444	chr2:149587196~149848233:+
BRCA	cis	rs2832077	0.506	rs2832081	ENSG00000215533.7	LINC00189	-4.19	3e-05	0.00218	-0.15	-0.13	Cognitive test performance;	chr21:28780670	chr21:29193480~29288205:+
BRCA	cis	rs9470794	1	rs7760452	ENSG00000204110.6	RP1-153P14.8	-4.19	3e-05	0.00218	-0.2	-0.13	Type 2 diabetes;	chr6:38140553	chr6:37507348~37535616:+
BRCA	cis	rs6452524	0.935	rs1478480	ENSG00000281327.1	LINC01338	4.19	3e-05	0.00218	0.15	0.13	Hypertension (SNP x SNP interaction);	chr5:83112117	chr5:82850864~82859836:-
BRCA	cis	rs12439619	0.705	rs17354185	ENSG00000255769.6	GOLGA2P10	4.19	3e-05	0.00218	0.19	0.13	Intelligence (multi-trait analysis);	chr15:82133829	chr15:82472993~82513950:-
BRCA	cis	rs1005277	0.557	rs1854563	ENSG00000272983.1	RP11-508N22.12	4.19	3e-05	0.00218	0.14	0.13	Extrinsic epigenetic age acceleration;	chr10:38146033	chr10:38137337~38144399:+
BRCA	cis	rs1005277	0.579	rs2505240	ENSG00000272983.1	RP11-508N22.12	4.19	3e-05	0.00218	0.14	0.13	Extrinsic epigenetic age acceleration;	chr10:38153491	chr10:38137337~38144399:+
BRCA	cis	rs4835473	0.932	rs13152443	ENSG00000249741.2	RP11-673E1.3	4.19	3e-05	0.00218	0.14	0.13	Immature fraction of reticulocytes;	chr4:143742492	chr4:143911514~143912053:-
BRCA	cis	rs11096990	0.634	rs2276888	ENSG00000249685.1	RP11-360F5.3	-4.19	3e-05	0.00218	-0.16	-0.13	Cognitive function;	chr4:39278287	chr4:39133913~39135608:+
BRCA	cis	rs7771547	0.603	rs72852338	ENSG00000224666.3	RP1-50J22.4	4.19	3e-05	0.00218	0.17	0.13	Platelet distribution width;	chr6:36586463	chr6:36386831~36393462:+
BRCA	cis	rs568617	0.953	rs658524	ENSG00000254510.1	RP11-867G23.10	-4.19	3e-05	0.00218	-0.16	-0.13	Crohn's disease;	chr11:65879789	chr11:66409158~66417137:+
BRCA	cis	rs911555	0.511	rs8007489	ENSG00000269910.1	RP11-73M18.10	-4.19	3e-05	0.00218	-0.12	-0.13	Intelligence (multi-trait analysis);	chr14:103588235	chr14:103694516~103695050:-
BRCA	cis	rs6828577	0.817	rs298996	ENSG00000281731.1	RP11-384K6.8	-4.19	3e-05	0.00218	-0.15	-0.13	Perioperative myocardial infarction in coronary artery bypass surgery;	chr4:118703590	chr4:118664087~118685341:-
BRCA	cis	rs1129187	0.934	rs9471974	ENSG00000220614.1	RP11-480N24.4	4.19	3e-05	0.00218	0.14	0.13	Alzheimer's disease in APOE e4+ carriers;	chr6:42951246	chr6:43328134~43328476:+
BRCA	cis	rs3892630	0.619	rs61062732	ENSG00000267475.1	CTD-2538C1.2	-4.19	3e-05	0.00218	-0.18	-0.13	Red blood cell traits;	chr19:32813811	chr19:32687089~32691750:-
BRCA	cis	rs11098499	1	rs3749591	ENSG00000225892.3	RP11-384K6.2	4.19	3e-05	0.00218	0.14	0.13	Corneal astigmatism;	chr4:119292875	chr4:118632274~118634759:+
BRCA	cis	rs10995356	0.966	rs7915640	ENSG00000238280.1	RP11-436D10.3	-4.19	3e-05	0.00218	-0.17	-0.13	Temperament;	chr10:62910533	chr10:62793562~62805887:-
BRCA	cis	rs11742741	0.774	rs4701418	ENSG00000248874.4	C5orf17	-4.19	3e-05	0.00218	-0.17	-0.13	Educational attainment;	chr5:24025283	chr5:23951348~24178263:+
BRCA	cis	rs6600671	0.764	rs6600673	ENSG00000270231.3	NBPF8P	4.19	3e-05	0.00218	0.14	0.13	Hip geometry;	chr1:121426988	chr1:120436353~120467739:+
BRCA	cis	rs78487399	0.908	rs12469695	ENSG00000234936.1	AC010883.5	4.19	3e-05	0.00218	0.18	0.13	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43606119	chr2:43229573~43233394:+
BRCA	cis	rs853679	0.517	rs9393887	ENSG00000216901.1	AL022393.7	4.19	3e-05	0.00218	0.18	0.13	Depression;	chr6:28091242	chr6:28176188~28176674:+
BRCA	cis	rs1005277	0.579	rs1780116	ENSG00000099251.13	HSD17B7P2	4.19	3e-05	0.00218	0.14	0.13	Extrinsic epigenetic age acceleration;	chr10:38237693	chr10:38356380~38378505:+
BRCA	cis	rs1005277	0.579	rs1780121	ENSG00000099251.13	HSD17B7P2	4.19	3e-05	0.00218	0.14	0.13	Extrinsic epigenetic age acceleration;	chr10:38240509	chr10:38356380~38378505:+
BRCA	cis	rs6452524	1	rs1031902	ENSG00000281327.1	LINC01338	4.19	3e-05	0.00218	0.15	0.13	Hypertension (SNP x SNP interaction);	chr5:83152308	chr5:82850864~82859836:-
BRCA	cis	rs4971059	0.654	rs12028043	ENSG00000160766.13	GBAP1	-4.19	3e-05	0.00218	-0.13	-0.13	Breast cancer;	chr1:155160360	chr1:155213821~155227422:-
BRCA	cis	rs2380205	1	rs7098372	ENSG00000232807.2	RP11-536K7.3	4.19	3.01e-05	0.00218	0.13	0.13	Breast cancer;	chr10:5844186	chr10:5934270~5945900:-
BRCA	cis	rs4919687	0.55	rs7904252	ENSG00000213061.2	PFN1P11	-4.19	3.01e-05	0.00218	-0.18	-0.13	Colorectal cancer;	chr10:102696968	chr10:102838011~102845473:-
BRCA	cis	rs6121246	0.909	rs6060812	ENSG00000230613.1	HM13-AS1	4.19	3.01e-05	0.00218	0.19	0.13	Mean corpuscular hemoglobin;	chr20:31705000	chr20:31567707~31573263:-
BRCA	cis	rs1953600	0.837	rs2819946	ENSG00000226659.1	RP11-137H2.4	4.19	3.01e-05	0.00218	0.17	0.13	Sarcoidosis;	chr10:80191879	chr10:80529597~80535942:-
BRCA	cis	rs6918586	1	rs198811	ENSG00000272810.1	U91328.22	4.19	3.01e-05	0.00218	0.14	0.13	Schizophrenia;	chr6:26128218	chr6:26013241~26013757:+
BRCA	cis	rs28374715	0.528	rs7181982	ENSG00000247556.5	OIP5-AS1	4.19	3.01e-05	0.00218	0.15	0.13	Ulcerative colitis;	chr15:41330822	chr15:41283990~41309737:+
BRCA	cis	rs28374715	0.578	rs8036026	ENSG00000247556.5	OIP5-AS1	4.19	3.01e-05	0.00218	0.15	0.13	Ulcerative colitis;	chr15:41338301	chr15:41283990~41309737:+
BRCA	cis	rs13113518	1	rs4864994	ENSG00000272969.1	RP11-528I4.2	4.19	3.01e-05	0.00218	0.15	0.13	Height;	chr4:55451955	chr4:55547112~55547889:+
BRCA	cis	rs6088580	0.634	rs6088475	ENSG00000276073.1	RP5-1125A11.7	4.19	3.01e-05	0.00219	0.14	0.13	Glomerular filtration rate (creatinine);	chr20:34377181	chr20:33985617~33988989:-
BRCA	cis	rs12549025	0.536	rs9644075	ENSG00000253390.1	CTC-756D1.2	-4.19	3.01e-05	0.00219	-0.22	-0.13	Reticulocyte fraction of red cells;	chr8:23502448	chr8:23458601~23484971:+
BRCA	cis	rs12744310	1	rs12035913	ENSG00000235358.1	RP11-399E6.1	-4.19	3.01e-05	0.00219	-0.19	-0.13	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41291385	chr1:41242373~41284861:+
BRCA	cis	rs2880765	0.835	rs4842884	ENSG00000202081.1	RNU6-1280P	4.19	3.01e-05	0.00219	0.15	0.13	Coronary artery disease;	chr15:85491943	chr15:85651522~85651628:-
BRCA	cis	rs11098499	0.863	rs3775845	ENSG00000250412.1	KLHL2P1	4.19	3.01e-05	0.00219	0.16	0.13	Corneal astigmatism;	chr4:119511292	chr4:119334329~119378233:+
BRCA	cis	rs6547741	1	rs6706610	ENSG00000234072.1	AC074117.10	4.19	3.01e-05	0.00219	0.12	0.13	Oral cavity cancer;	chr2:27555224	chr2:27356246~27367622:+
BRCA	cis	rs60843830	1	rs4497901	ENSG00000272342.1	RP13-539J13.1	4.19	3.01e-05	0.00219	0.16	0.13	Spherical equivalent (joint analysis main effects and education interaction);	chr2:239969	chr2:739588~740164:-
BRCA	cis	rs2243480	1	rs160634	ENSG00000275400.1	RP4-756H11.5	-4.19	3.01e-05	0.00219	-0.22	-0.13	Diabetic kidney disease;	chr7:66063677	chr7:66553805~66554199:-
BRCA	cis	rs6430585	0.583	rs59213715	ENSG00000224043.6	CCNT2-AS1	-4.19	3.01e-05	0.00219	-0.22	-0.13	Corneal structure;	chr2:135889012	chr2:134735464~134918710:-
BRCA	cis	rs4835473	0.932	rs34324222	ENSG00000249741.2	RP11-673E1.3	4.19	3.01e-05	0.00219	0.15	0.13	Immature fraction of reticulocytes;	chr4:143784572	chr4:143911514~143912053:-
BRCA	cis	rs11051970	0.559	rs11051991	ENSG00000274964.1	RP11-817I4.1	4.19	3.01e-05	0.00219	0.18	0.13	Response to tocilizumab in rheumatoid arthritis;	chr12:32410998	chr12:32339368~32340724:+
BRCA	cis	rs1008375	0.897	rs1006723	ENSG00000249502.1	AC006160.5	-4.19	3.01e-05	0.00219	-0.15	-0.13	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17616901	chr4:17587467~17614571:-
BRCA	cis	rs4499344	0.696	rs2868154	ENSG00000267475.1	CTD-2538C1.2	4.19	3.01e-05	0.00219	0.16	0.13	Mean platelet volume;	chr19:32608399	chr19:32687089~32691750:-
BRCA	cis	rs453301	0.606	rs7462373	ENSG00000233609.3	RP11-62H7.2	-4.19	3.01e-05	0.00219	-0.12	-0.13	Joint mobility (Beighton score);	chr8:9041808	chr8:8961200~8979025:+
BRCA	cis	rs4478858	0.684	rs10798837	ENSG00000223907.1	LINC01226	-4.19	3.01e-05	0.00219	-0.15	-0.13	Alcohol dependence;	chr1:31246493	chr1:31518435~31524245:+
BRCA	cis	rs4478858	0.684	rs10798838	ENSG00000223907.1	LINC01226	-4.19	3.01e-05	0.00219	-0.15	-0.13	Alcohol dependence;	chr1:31246603	chr1:31518435~31524245:+
BRCA	cis	rs11098499	0.954	rs3733524	ENSG00000260404.2	RP11-384K6.6	4.19	3.01e-05	0.00219	0.13	0.13	Corneal astigmatism;	chr4:119502574	chr4:118591773~118633729:+
BRCA	cis	rs1910358	0.554	rs9790918	ENSG00000248874.4	C5orf17	-4.19	3.01e-05	0.00219	-0.18	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23759799	chr5:23951348~24178263:+
BRCA	cis	rs1836229	0.874	rs1434254	ENSG00000225706.1	PTPRD-AS1	4.19	3.01e-05	0.00219	0.14	0.13	Restless legs syndrome;	chr9:8826278	chr9:8858130~8862255:+
BRCA	cis	rs12612619	0.732	rs1866655	ENSG00000229122.1	AGBL5-IT1	-4.19	3.01e-05	0.00219	-0.14	-0.13	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:26985999	chr2:27061038~27061815:+
BRCA	cis	rs863750	1	rs863750	ENSG00000275389.1	RP11-214K3.24	4.19	3.01e-05	0.00219	0.16	0.13	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-hip ratio;	chr12:124020897	chr12:124085761~124088598:+
BRCA	cis	rs2073316	0.559	rs4952236	ENSG00000272716.1	RP11-563N4.1	4.19	3.01e-05	0.00219	0.14	0.13	Interleukin-18 levels;	chr2:31422073	chr2:32165046~32165757:-
BRCA	cis	rs875971	0.964	rs1643388	ENSG00000229180.5	GS1-124K5.11	4.19	3.01e-05	0.00219	0.11	0.13	Aortic root size;	chr7:66379575	chr7:66526088~66542624:-
BRCA	cis	rs875971	1	rs778722	ENSG00000229180.5	GS1-124K5.11	4.19	3.01e-05	0.00219	0.11	0.13	Aortic root size;	chr7:66379841	chr7:66526088~66542624:-
BRCA	cis	rs35146811	0.695	rs1618851	ENSG00000235713.1	RP4-604G5.3	-4.19	3.01e-05	0.00219	-0.15	-0.13	Coronary artery disease;	chr7:100213020	chr7:99992397~99993050:+
BRCA	cis	rs35146811	0.735	rs1727130	ENSG00000235713.1	RP4-604G5.3	-4.19	3.01e-05	0.00219	-0.15	-0.13	Coronary artery disease;	chr7:100213841	chr7:99992397~99993050:+
BRCA	cis	rs35146811	0.695	rs1727132	ENSG00000235713.1	RP4-604G5.3	-4.19	3.01e-05	0.00219	-0.15	-0.13	Coronary artery disease;	chr7:100214674	chr7:99992397~99993050:+
BRCA	cis	rs35146811	0.735	rs1727133	ENSG00000235713.1	RP4-604G5.3	-4.19	3.01e-05	0.00219	-0.15	-0.13	Coronary artery disease;	chr7:100215247	chr7:99992397~99993050:+
BRCA	cis	rs7475343	0.538	rs4330990	ENSG00000224034.1	RP11-445P17.8	-4.19	3.01e-05	0.00219	-0.24	-0.13	Intelligence;	chr10:5164222	chr10:5266033~5271236:-
BRCA	cis	rs3176789	0.624	rs12427030	ENSG00000256673.1	RP11-599J14.2	4.19	3.01e-05	0.00219	0.15	0.13	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9767776	chr12:9398355~9414851:-
BRCA	cis	rs300890	0.56	rs9308170	ENSG00000250326.1	RP11-284M14.1	-4.19	3.02e-05	0.00219	-0.15	-0.13	Nasopharyngeal carcinoma;	chr4:143263660	chr4:142933195~143184861:-
BRCA	cis	rs8180040	1	rs8180040	ENSG00000271161.1	BOLA2P2	4.19	3.02e-05	0.00219	0.14	0.13	Colorectal cancer;	chr3:47347457	chr3:47499841~47500407:+
BRCA	cis	rs9784649	1	rs7702197	ENSG00000245662.2	RP11-184E9.1	-4.19	3.02e-05	0.00219	-0.19	-0.13	Peripheral arterial disease (traffic-related air pollution interaction);	chr5:24975669	chr5:25190682~25306172:+
BRCA	cis	rs6545883	0.826	rs2694617	ENSG00000273302.1	RP11-493E12.2	-4.19	3.02e-05	0.00219	-0.12	-0.13	Tuberculosis;	chr2:61310079	chr2:61199979~61200769:+
BRCA	cis	rs7267979	1	rs2424700	ENSG00000125804.12	FAM182A	-4.19	3.02e-05	0.00219	-0.17	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25285877	chr20:26054655~26086917:+
BRCA	cis	rs11051970	0.659	rs950082	ENSG00000274964.1	RP11-817I4.1	-4.19	3.02e-05	0.00219	-0.16	-0.13	Response to tocilizumab in rheumatoid arthritis;	chr12:32435480	chr12:32339368~32340724:+
BRCA	cis	rs11051970	0.659	rs950081	ENSG00000274964.1	RP11-817I4.1	-4.19	3.02e-05	0.00219	-0.16	-0.13	Response to tocilizumab in rheumatoid arthritis;	chr12:32435554	chr12:32339368~32340724:+
BRCA	cis	rs4835473	0.669	rs75704080	ENSG00000249741.2	RP11-673E1.3	4.19	3.02e-05	0.00219	0.14	0.13	Immature fraction of reticulocytes;	chr4:143779066	chr4:143911514~143912053:-
BRCA	cis	rs867186	1	rs117249133	ENSG00000126005.14	MMP24-AS1	-4.19	3.02e-05	0.00219	-0.26	-0.13	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35185827	chr20:35216462~35278131:-
BRCA	cis	rs11742741	0.905	rs1428550	ENSG00000248874.4	C5orf17	-4.19	3.02e-05	0.00219	-0.17	-0.13	Educational attainment;	chr5:24107016	chr5:23951348~24178263:+
BRCA	cis	rs7771547	0.788	rs10214849	ENSG00000224666.3	RP1-50J22.4	4.19	3.02e-05	0.00219	0.15	0.13	Platelet distribution width;	chr6:36633668	chr6:36386831~36393462:+
BRCA	cis	rs6026584	1	rs15754	ENSG00000270951.1	RP1-309F20.4	-4.19	3.02e-05	0.00219	-0.16	-0.13	Renal function-related traits (BUN);	chr20:58894172	chr20:58876592~58876981:-
BRCA	cis	rs4671400	0.571	rs4672429	ENSG00000273302.1	RP11-493E12.2	-4.19	3.02e-05	0.00219	-0.14	-0.13	3-hydroxypropylmercapturic acid levels in smokers;	chr2:61268334	chr2:61199979~61200769:+
BRCA	cis	rs754466	0.58	rs1344966	ENSG00000213514.2	RP11-428P16.2	4.19	3.02e-05	0.00219	0.18	0.13	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77774769	chr10:77730766~77734769:+
BRCA	cis	rs7572733	0.905	rs6718039	ENSG00000231621.1	AC013264.2	-4.19	3.02e-05	0.00219	-0.12	-0.13	Dermatomyositis;	chr2:197896918	chr2:197197991~197199273:+
BRCA	cis	rs1005277	0.579	rs1780122	ENSG00000099251.13	HSD17B7P2	4.19	3.02e-05	0.00219	0.14	0.13	Extrinsic epigenetic age acceleration;	chr10:38240581	chr10:38356380~38378505:+
BRCA	cis	rs748404	0.589	rs62020616	ENSG00000205771.5	CATSPER2P1	-4.19	3.02e-05	0.00219	-0.19	-0.13	Lung cancer;	chr15:43558554	chr15:43726918~43747094:-
BRCA	cis	rs748404	0.626	rs60367691	ENSG00000205771.5	CATSPER2P1	-4.19	3.02e-05	0.00219	-0.19	-0.13	Lung cancer;	chr15:43559201	chr15:43726918~43747094:-
BRCA	cis	rs11239930	0.517	rs535827	ENSG00000237188.3	RP11-337C18.8	4.19	3.02e-05	0.00219	0.14	0.13	AIDS progression;	chr1:147076642	chr1:147172771~147211568:+
BRCA	cis	rs853679	0.517	rs2273564	ENSG00000216901.1	AL022393.7	4.19	3.02e-05	0.00219	0.18	0.13	Depression;	chr6:28089816	chr6:28176188~28176674:+
BRCA	cis	rs853679	0.517	rs1853097	ENSG00000216901.1	AL022393.7	4.19	3.02e-05	0.00219	0.18	0.13	Depression;	chr6:28090857	chr6:28176188~28176674:+
BRCA	cis	rs853679	0.517	rs9393888	ENSG00000216901.1	AL022393.7	4.19	3.02e-05	0.00219	0.18	0.13	Depression;	chr6:28091439	chr6:28176188~28176674:+
BRCA	cis	rs853679	0.517	rs3734573	ENSG00000216901.1	AL022393.7	4.19	3.02e-05	0.00219	0.18	0.13	Depression;	chr6:28091659	chr6:28176188~28176674:+
BRCA	cis	rs853679	0.517	rs3823180	ENSG00000216901.1	AL022393.7	4.19	3.02e-05	0.00219	0.18	0.13	Depression;	chr6:28093966	chr6:28176188~28176674:+
BRCA	cis	rs853679	0.517	rs9368551	ENSG00000216901.1	AL022393.7	4.19	3.02e-05	0.00219	0.18	0.13	Depression;	chr6:28094014	chr6:28176188~28176674:+
BRCA	cis	rs703842	1	rs2069502	ENSG00000270039.1	RP11-571M6.17	4.19	3.02e-05	0.00219	0.18	0.13	Multiple sclerosis;	chr12:57750882	chr12:57803838~57804415:+
BRCA	cis	rs9307551	0.948	rs1837645	ENSG00000250334.4	LINC00989	-4.19	3.02e-05	0.00219	-0.2	-0.13	Refractive error;	chr4:79560081	chr4:79492416~79576460:+
BRCA	cis	rs2832191	1	rs2832183	ENSG00000232855.5	AF131217.1	4.19	3.02e-05	0.0022	0.15	0.13	Dental caries;	chr21:29109829	chr21:28439346~28674848:-
BRCA	cis	rs2731006	0.64	rs2730970	ENSG00000257114.2	RP11-25I15.3	-4.19	3.02e-05	0.0022	-0.21	-0.13	Panic disorder;	chr12:42793077	chr12:42692216~42717119:+
BRCA	cis	rs11148252	0.74	rs9536052	ENSG00000272281.5	TPTE2P2	4.19	3.02e-05	0.0022	0.12	0.13	Lewy body disease;	chr13:52386574	chr13:52219344~52334277:-
BRCA	cis	rs7182948	1	rs11070707	ENSG00000259531.2	RP11-295H24.3	-4.19	3.02e-05	0.0022	-0.18	-0.13	Lung adenocarcinoma;	chr15:49567438	chr15:49365124~49366685:-
BRCA	cis	rs8016982	0.963	rs2099108	ENSG00000258999.1	RP11-114N19.3	4.19	3.03e-05	0.0022	0.16	0.13	Schizophrenia;	chr14:81209076	chr14:81107033~81170414:-
BRCA	cis	rs11098499	0.874	rs28452522	ENSG00000225892.3	RP11-384K6.2	4.19	3.03e-05	0.0022	0.14	0.13	Corneal astigmatism;	chr4:119189629	chr4:118632274~118634759:+
BRCA	cis	rs2408955	0.521	rs7301003	ENSG00000226413.2	OR8T1P	4.19	3.03e-05	0.0022	0.17	0.13	Glycated hemoglobin levels;	chr12:48156444	chr12:48442030~48442947:-
BRCA	cis	rs11742741	0.681	rs4602584	ENSG00000248874.4	C5orf17	-4.19	3.03e-05	0.0022	-0.17	-0.13	Educational attainment;	chr5:24028963	chr5:23951348~24178263:+
BRCA	cis	rs11098499	0.954	rs10006706	ENSG00000260404.2	RP11-384K6.6	4.19	3.03e-05	0.0022	0.12	0.13	Corneal astigmatism;	chr4:119487997	chr4:118591773~118633729:+
BRCA	cis	rs2380205	0.967	rs7898042	ENSG00000232807.2	RP11-536K7.3	4.19	3.03e-05	0.0022	0.13	0.13	Breast cancer;	chr10:5851439	chr10:5934270~5945900:-
BRCA	cis	rs9818758	0.556	rs116432667	ENSG00000225399.4	RP11-3B7.1	-4.19	3.03e-05	0.0022	-0.23	-0.13	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:48910156	chr3:49260085~49261316:+
BRCA	cis	rs9818758	0.607	rs13087930	ENSG00000225399.4	RP11-3B7.1	-4.19	3.03e-05	0.0022	-0.23	-0.13	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:48924293	chr3:49260085~49261316:+
BRCA	cis	rs6496932	0.663	rs4843051	ENSG00000218052.5	ADAMTS7P4	-4.19	3.03e-05	0.0022	-0.14	-0.13	Central corneal thickness;Corneal structure;	chr15:85360907	chr15:85255369~85330334:-
BRCA	cis	rs983392	1	rs2847667	ENSG00000275344.1	MIR6503	-4.19	3.03e-05	0.0022	-0.14	-0.13	Alzheimer's disease (late onset);	chr11:60092136	chr11:60209071~60209156:-
BRCA	cis	rs17767294	1	rs17767294	ENSG00000204709.4	LINC01556	4.19	3.03e-05	0.0022	0.27	0.13	Parkinson's disease;	chr6:28086420	chr6:28943877~28944537:+
BRCA	cis	rs7932354	0.583	rs7940578	ENSG00000200376.1	RNU5E-10P	4.19	3.03e-05	0.0022	0.16	0.13	Bone mineral density (hip);Bone mineral density;	chr11:46790677	chr11:47576471~47576588:-
BRCA	cis	rs7200543	1	rs1121	ENSG00000207425.1	Y_RNA	-4.19	3.03e-05	0.0022	-0.16	-0.13	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15037219	chr16:14915457~14915556:-
BRCA	cis	rs2108622	0.727	rs62106156	ENSG00000267218.2	AC005336.5	4.19	3.03e-05	0.0022	0.15	0.13	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15869614	chr19:15902300~15903238:-
BRCA	cis	rs78487399	0.71	rs7572923	ENSG00000234936.1	AC010883.5	4.19	3.03e-05	0.0022	0.2	0.13	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43457970	chr2:43229573~43233394:+
BRCA	cis	rs78487399	0.808	rs7599799	ENSG00000234936.1	AC010883.5	4.19	3.03e-05	0.0022	0.2	0.13	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43458354	chr2:43229573~43233394:+
BRCA	cis	rs78487399	0.808	rs7573500	ENSG00000234936.1	AC010883.5	4.19	3.03e-05	0.0022	0.2	0.13	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43458486	chr2:43229573~43233394:+
BRCA	cis	rs78487399	0.808	rs79955955	ENSG00000234936.1	AC010883.5	4.19	3.03e-05	0.0022	0.2	0.13	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43459846	chr2:43229573~43233394:+
BRCA	cis	rs409045	0.93	rs381126	ENSG00000271874.1	CTD-2024P10.2	-4.19	3.03e-05	0.0022	-0.17	-0.13	Left ventricular mass;	chr5:34626151	chr5:34651457~34651888:-
BRCA	cis	rs7726839	0.561	rs4957050	ENSG00000225138.6	CTD-2228K2.7	4.19	3.03e-05	0.0022	0.18	0.13	Obesity-related traits;	chr5:578951	chr5:473236~480884:+
BRCA	cis	rs7726839	0.561	rs4957049	ENSG00000225138.6	CTD-2228K2.7	4.19	3.03e-05	0.0022	0.18	0.13	Obesity-related traits;	chr5:578965	chr5:473236~480884:+
BRCA	cis	rs7726839	0.561	rs72703044	ENSG00000225138.6	CTD-2228K2.7	4.19	3.03e-05	0.0022	0.18	0.13	Obesity-related traits;	chr5:579622	chr5:473236~480884:+
BRCA	cis	rs465969	1	rs7750803	ENSG00000230177.1	RP5-1112D6.4	-4.19	3.03e-05	0.0022	-0.3	-0.13	Psoriasis;	chr6:111478910	chr6:111277932~111278742:+
BRCA	cis	rs7267979	1	rs910997	ENSG00000125804.12	FAM182A	-4.19	3.03e-05	0.0022	-0.17	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25286665	chr20:26054655~26086917:+
BRCA	cis	rs6860540	0.796	rs10404	ENSG00000251405.2	CTB-109A12.1	-4.19	3.03e-05	0.0022	-0.18	-0.13	Inflammatory skin disease;	chr5:157477625	chr5:157362615~157460078:-
BRCA	cis	rs11098499	0.909	rs10026736	ENSG00000250412.1	KLHL2P1	4.19	3.03e-05	0.0022	0.16	0.13	Corneal astigmatism;	chr4:119463167	chr4:119334329~119378233:+
BRCA	cis	rs4747241	0.515	rs4554797	ENSG00000226701.1	RP11-570G20.1	4.19	3.03e-05	0.0022	0.14	0.13	Heschl's gyrus morphology;	chr10:72228506	chr10:72189941~72190576:+
BRCA	cis	rs728616	0.764	rs117833443	ENSG00000242600.5	MBL1P	4.19	3.03e-05	0.0022	0.32	0.13	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79978380	chr10:79904898~79950336:+
BRCA	cis	rs728616	0.867	rs116994688	ENSG00000242600.5	MBL1P	4.19	3.03e-05	0.0022	0.32	0.13	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79978381	chr10:79904898~79950336:+
BRCA	cis	rs7811142	1	rs4472444	ENSG00000078319.8	PMS2P1	-4.19	3.04e-05	0.0022	-0.2	-0.13	Platelet count;	chr7:100473135	chr7:100320992~100341908:-
BRCA	cis	rs7811142	1	rs7809801	ENSG00000078319.8	PMS2P1	-4.19	3.04e-05	0.0022	-0.2	-0.13	Platelet count;	chr7:100474408	chr7:100320992~100341908:-
BRCA	cis	rs4648045	0.565	rs4698863	ENSG00000246560.2	RP11-10L12.4	4.19	3.04e-05	0.0022	0.15	0.13	Lymphocyte percentage of white cells;	chr4:102624691	chr4:102828055~102844075:+
BRCA	cis	rs1048886	0.872	rs9294876	ENSG00000271967.1	RP11-134K13.4	-4.19	3.04e-05	0.0022	-0.17	-0.13	Type 2 diabetes;	chr6:70541718	chr6:70596438~70596980:+
BRCA	cis	rs2625529	0.775	rs12913042	ENSG00000260037.4	CTD-2524L6.3	-4.19	3.04e-05	0.0022	-0.19	-0.13	Red blood cell count;	chr15:71909968	chr15:71818396~71823384:+
BRCA	cis	rs853679	1	rs11965538	ENSG00000204709.4	LINC01556	4.19	3.04e-05	0.0022	0.23	0.13	Depression;	chr6:28272137	chr6:28943877~28944537:+
BRCA	cis	rs4835473	0.932	rs28796049	ENSG00000249741.2	RP11-673E1.3	-4.19	3.04e-05	0.0022	-0.13	-0.13	Immature fraction of reticulocytes;	chr4:143733990	chr4:143911514~143912053:-
BRCA	cis	rs7572733	0.504	rs72928581	ENSG00000231621.1	AC013264.2	-4.19	3.04e-05	0.0022	-0.13	-0.13	Dermatomyositis;	chr2:198001896	chr2:197197991~197199273:+
BRCA	cis	rs321358	1	rs321358	ENSG00000271390.1	RP11-89C3.3	4.19	3.04e-05	0.0022	0.2	0.13	Body mass index;	chr11:111125247	chr11:111089870~111090368:-
BRCA	cis	rs7927592	0.717	rs7126451	ENSG00000212093.1	AP000807.1	-4.19	3.04e-05	0.0022	-0.14	-0.13	Total body bone mineral density;	chr11:68489918	chr11:68506083~68506166:-
BRCA	cis	rs115575488	0.85	rs114544572	ENSG00000236804.1	RPS3AP12	4.19	3.04e-05	0.00221	0.24	0.13	Lobe attachment (rater-scored or self-reported);	chr1:119046840	chr1:119126539~119127291:-
BRCA	cis	rs875971	0.965	rs7794930	ENSG00000236529.1	RP13-254B10.1	-4.19	3.04e-05	0.00221	-0.14	-0.13	Aortic root size;	chr7:66313559	chr7:65840212~65840596:+
BRCA	cis	rs8048589	0.615	rs34598762	ENSG00000175604.2	RP11-276H1.3	-4.19	3.04e-05	0.00221	-0.23	-0.13	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);	chr16:12141101	chr16:12086746~12090302:-
BRCA	cis	rs7824557	0.767	rs2164272	ENSG00000248896.2	CTD-2135J3.3	4.19	3.04e-05	0.00221	0.17	0.13	Retinal vascular caliber;	chr8:11304987	chr8:10729314~10771392:+
BRCA	cis	rs2731006	0.64	rs2731003	ENSG00000257114.2	RP11-25I15.3	4.19	3.04e-05	0.00221	0.21	0.13	Panic disorder;	chr12:42790527	chr12:42692216~42717119:+
BRCA	cis	rs2731006	0.64	rs1400814	ENSG00000257114.2	RP11-25I15.3	4.19	3.04e-05	0.00221	0.21	0.13	Panic disorder;	chr12:42790753	chr12:42692216~42717119:+
BRCA	cis	rs2731006	0.64	rs1517666	ENSG00000257114.2	RP11-25I15.3	4.19	3.04e-05	0.00221	0.21	0.13	Panic disorder;	chr12:42791526	chr12:42692216~42717119:+
BRCA	cis	rs2731006	0.64	rs2037238	ENSG00000257114.2	RP11-25I15.3	4.19	3.04e-05	0.00221	0.21	0.13	Panic disorder;	chr12:42791547	chr12:42692216~42717119:+
BRCA	cis	rs2731006	0.64	rs2678134	ENSG00000257114.2	RP11-25I15.3	4.19	3.04e-05	0.00221	0.21	0.13	Panic disorder;	chr12:42792190	chr12:42692216~42717119:+
BRCA	cis	rs2731006	0.64	rs2731004	ENSG00000257114.2	RP11-25I15.3	4.19	3.04e-05	0.00221	0.21	0.13	Panic disorder;	chr12:42792304	chr12:42692216~42717119:+
BRCA	cis	rs2731006	0.64	rs2678136	ENSG00000257114.2	RP11-25I15.3	4.19	3.04e-05	0.00221	0.21	0.13	Panic disorder;	chr12:42794230	chr12:42692216~42717119:+
BRCA	cis	rs2731006	0.592	rs2678137	ENSG00000257114.2	RP11-25I15.3	4.19	3.04e-05	0.00221	0.21	0.13	Panic disorder;	chr12:42795453	chr12:42692216~42717119:+
BRCA	cis	rs2731006	0.64	rs2730968	ENSG00000257114.2	RP11-25I15.3	4.19	3.04e-05	0.00221	0.21	0.13	Panic disorder;	chr12:42795866	chr12:42692216~42717119:+
BRCA	cis	rs2731006	0.592	rs2678144	ENSG00000257114.2	RP11-25I15.3	4.19	3.04e-05	0.00221	0.21	0.13	Panic disorder;	chr12:42796621	chr12:42692216~42717119:+
BRCA	cis	rs2731006	0.64	rs2678143	ENSG00000257114.2	RP11-25I15.3	4.19	3.04e-05	0.00221	0.21	0.13	Panic disorder;	chr12:42796757	chr12:42692216~42717119:+
BRCA	cis	rs2731006	0.64	rs1517667	ENSG00000257114.2	RP11-25I15.3	4.19	3.04e-05	0.00221	0.21	0.13	Panic disorder;	chr12:42797115	chr12:42692216~42717119:+
BRCA	cis	rs2731006	0.64	rs7314719	ENSG00000257114.2	RP11-25I15.3	4.19	3.04e-05	0.00221	0.21	0.13	Panic disorder;	chr12:42797832	chr12:42692216~42717119:+
BRCA	cis	rs2731006	0.64	rs2459741	ENSG00000257114.2	RP11-25I15.3	4.19	3.04e-05	0.00221	0.21	0.13	Panic disorder;	chr12:42797900	chr12:42692216~42717119:+
BRCA	cis	rs2731006	0.64	rs1607249	ENSG00000257114.2	RP11-25I15.3	4.19	3.04e-05	0.00221	0.21	0.13	Panic disorder;	chr12:42801577	chr12:42692216~42717119:+
BRCA	cis	rs2731006	0.64	rs2730980	ENSG00000257114.2	RP11-25I15.3	4.19	3.04e-05	0.00221	0.21	0.13	Panic disorder;	chr12:42801771	chr12:42692216~42717119:+
BRCA	cis	rs11096990	0.634	rs6815855	ENSG00000249685.1	RP11-360F5.3	-4.19	3.04e-05	0.00221	-0.16	-0.13	Cognitive function;	chr4:39294926	chr4:39133913~39135608:+
BRCA	cis	rs13064773	0.718	rs13065107	ENSG00000272247.1	RP11-379F4.9	4.19	3.04e-05	0.00221	0.15	0.13	Response to abacavir-containing treatment in HIV-1 infection (virologic failure);Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr3:158865848	chr3:158801257~158801935:-
BRCA	cis	rs6012564	1	rs3091529	ENSG00000227431.4	CSE1L-AS1	-4.19	3.04e-05	0.00221	-0.16	-0.13	Anger;	chr20:49030531	chr20:49040463~49046044:-
BRCA	cis	rs6012564	1	rs1022687	ENSG00000227431.4	CSE1L-AS1	-4.19	3.04e-05	0.00221	-0.16	-0.13	Anger;	chr20:49032317	chr20:49040463~49046044:-
BRCA	cis	rs2030746	0.521	rs9784140	ENSG00000237614.1	AC073257.2	4.19	3.04e-05	0.00221	0.16	0.13	LDL cholesterol;Total cholesterol levels;LDL cholesterol levels;	chr2:120568547	chr2:120542909~120544326:-
BRCA	cis	rs875971	1	rs6958271	ENSG00000229180.5	GS1-124K5.11	4.19	3.04e-05	0.00221	0.11	0.13	Aortic root size;	chr7:66514344	chr7:66526088~66542624:-
BRCA	cis	rs875971	1	rs6958277	ENSG00000229180.5	GS1-124K5.11	4.19	3.04e-05	0.00221	0.11	0.13	Aortic root size;	chr7:66514362	chr7:66526088~66542624:-
BRCA	cis	rs4449834	0.816	rs6471897	ENSG00000254432.1	RP11-33I11.2	-4.19	3.04e-05	0.00221	-0.16	-0.13	Sum eosinophil basophil counts;	chr8:60745528	chr8:60808735~60809606:-
BRCA	cis	rs987724	0.519	rs9818684	ENSG00000240875.4	LINC00886	4.19	3.04e-05	0.00221	0.15	0.13	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156806431	chr3:156747346~156817062:-
BRCA	cis	rs7811142	1	rs7811142	ENSG00000078319.8	PMS2P1	-4.19	3.05e-05	0.00221	-0.21	-0.13	Platelet count;	chr7:100467820	chr7:100320992~100341908:-
BRCA	cis	rs1538970	0.816	rs4633317	ENSG00000281133.1	AL355480.3	-4.19	3.05e-05	0.00221	-0.18	-0.13	Platelet count;	chr1:45519485	chr1:45580892~45580996:-
BRCA	cis	rs11083475	1	rs10406778	ENSG00000267892.1	CTD-2540F13.2	4.19	3.05e-05	0.00221	0.15	0.13	Heart rate;	chr19:38679833	chr19:38738284~38739863:+
BRCA	cis	rs867371	1	rs7173339	ENSG00000278603.1	RP13-608F4.5	4.19	3.05e-05	0.00221	0.17	0.13	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82175253	chr15:82472203~82472426:+
BRCA	cis	rs3845817	0.703	rs702941	ENSG00000237979.1	AC007389.1	4.19	3.05e-05	0.00221	0.15	0.13	Bipolar disorder;	chr2:65521864	chr2:65500993~65502138:-
BRCA	cis	rs9307551	0.6	rs11098778	ENSG00000250334.4	LINC00989	-4.19	3.05e-05	0.00221	-0.16	-0.13	Refractive error;	chr4:79617847	chr4:79492416~79576460:+
BRCA	cis	rs10080237	0.564	rs2490224	ENSG00000272129.1	RP11-250B2.6	4.19	3.05e-05	0.00221	0.16	0.13	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;	chr6:80100116	chr6:80355424~80356859:+
BRCA	cis	rs8114671	0.904	rs6060197	ENSG00000279253.1	RP4-614O4.13	4.19	3.05e-05	0.00221	0.15	0.13	Height;	chr20:35066512	chr20:35262727~35264187:-
BRCA	cis	rs8114671	0.839	rs6142290	ENSG00000279253.1	RP4-614O4.13	4.19	3.05e-05	0.00221	0.15	0.13	Height;	chr20:35066869	chr20:35262727~35264187:-
BRCA	cis	rs8114671	0.869	rs6060199	ENSG00000279253.1	RP4-614O4.13	4.19	3.05e-05	0.00221	0.15	0.13	Height;	chr20:35066970	chr20:35262727~35264187:-
BRCA	cis	rs9308731	0.623	rs11674517	ENSG00000230499.1	AC108463.1	-4.19	3.05e-05	0.00221	-0.15	-0.13	Chronic lymphocytic leukemia;	chr2:111146255	chr2:111195963~111206494:+
BRCA	cis	rs875971	0.619	rs10278371	ENSG00000223473.2	GS1-124K5.3	-4.19	3.05e-05	0.00221	-0.1	-0.13	Aortic root size;	chr7:66586553	chr7:66491049~66493566:-
BRCA	cis	rs5758659	0.679	rs134870	ENSG00000231261.1	HMGN2P10	4.19	3.05e-05	0.00221	0.14	0.13	Cognitive function;	chr22:42256311	chr22:41709225~41709489:-
BRCA	cis	rs495337	0.76	rs471054	ENSG00000229222.1	KRT18P4	-4.19	3.05e-05	0.00221	-0.16	-0.13	Psoriasis;	chr20:49896699	chr20:49956745~49958032:+
BRCA	cis	rs10421328	0.797	rs919778	ENSG00000267419.1	CTC-559E9.6	4.19	3.05e-05	0.00221	0.16	0.13	Parental longevity (combined parental age at death);	chr19:19661913	chr19:19776602~19834927:+
BRCA	cis	rs699371	0.525	rs7156302	ENSG00000259005.1	RP3-449M8.6	4.19	3.05e-05	0.00221	0.15	0.13	Height;	chr14:74428260	chr14:74474007~74474864:-
BRCA	cis	rs7267979	1	rs2257982	ENSG00000125804.12	FAM182A	-4.19	3.05e-05	0.00221	-0.17	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25288994	chr20:26054655~26086917:+
BRCA	cis	rs7267979	1	rs2257985	ENSG00000125804.12	FAM182A	-4.19	3.05e-05	0.00221	-0.17	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25289107	chr20:26054655~26086917:+
BRCA	cis	rs7267979	1	rs2257988	ENSG00000125804.12	FAM182A	-4.19	3.05e-05	0.00221	-0.17	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25289367	chr20:26054655~26086917:+
BRCA	cis	rs950776	0.593	rs588765	ENSG00000279373.1	RP11-650L12.4	-4.19	3.05e-05	0.00221	-0.15	-0.13	Sudden cardiac arrest;	chr15:78573083	chr15:78537681~78538946:+
BRCA	cis	rs35740288	0.597	rs12900830	ENSG00000202081.1	RNU6-1280P	4.19	3.05e-05	0.00221	0.19	0.13	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85782923	chr15:85651522~85651628:-
BRCA	cis	rs6012564	0.928	rs6095396	ENSG00000222365.1	SNORD12B	-4.19	3.05e-05	0.00221	-0.14	-0.13	Anger;	chr20:49010633	chr20:49280319~49280409:+
BRCA	cis	rs465969	1	rs459048	ENSG00000272356.1	RP5-1112D6.8	4.19	3.05e-05	0.00221	0.28	0.13	Psoriasis;	chr6:111368429	chr6:111309203~111313517:+
BRCA	cis	rs465969	1	rs479343	ENSG00000272356.1	RP5-1112D6.8	4.19	3.05e-05	0.00221	0.28	0.13	Psoriasis;	chr6:111369701	chr6:111309203~111313517:+
BRCA	cis	rs465969	0.744	rs458017	ENSG00000272356.1	RP5-1112D6.8	4.19	3.05e-05	0.00221	0.28	0.13	Psoriasis;	chr6:111374888	chr6:111309203~111313517:+
BRCA	cis	rs465969	1	rs13213522	ENSG00000272356.1	RP5-1112D6.8	4.19	3.05e-05	0.00221	0.28	0.13	Psoriasis;	chr6:111384138	chr6:111309203~111313517:+
BRCA	cis	rs711830	0.931	rs717852	ENSG00000226363.3	HAGLROS	-4.19	3.05e-05	0.00221	-0.19	-0.13	Serous invasive ovarian cancer;Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;High-grade serous ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;	chr2:176166895	chr2:176177717~176179008:+
BRCA	cis	rs2625529	0.652	rs2899776	ENSG00000260037.4	CTD-2524L6.3	4.19	3.05e-05	0.00221	0.16	0.13	Red blood cell count;	chr15:71976024	chr15:71818396~71823384:+
BRCA	cis	rs4664293	0.747	rs7600347	ENSG00000226266.5	AC009961.3	-4.19	3.05e-05	0.00222	-0.17	-0.13	Monocyte percentage of white cells;	chr2:159800981	chr2:159670708~159712435:-
BRCA	cis	rs6600671	1	rs1856572	ENSG00000275131.1	CH17-472G23.4	-4.19	3.06e-05	0.00222	-0.12	-0.13	Hip geometry;	chr1:121427719	chr1:120489625~120579190:-
BRCA	cis	rs256438	0.524	rs1438737	ENSG00000251050.1	RP11-168A11.4	-4.19	3.06e-05	0.00222	-0.14	-0.13	Serum thyroid-stimulating hormone levels;	chr5:80053582	chr5:80019609~80019920:+
BRCA	cis	rs8114671	0.836	rs6060140	ENSG00000279253.1	RP4-614O4.13	-4.19	3.06e-05	0.00222	-0.15	-0.13	Height;	chr20:34978704	chr20:35262727~35264187:-
BRCA	cis	rs8114671	0.836	rs745849	ENSG00000126005.14	MMP24-AS1	4.19	3.06e-05	0.00222	0.15	0.13	Height;	chr20:34984375	chr20:35216462~35278131:-
BRCA	cis	rs6968419	0.714	rs1048508	ENSG00000279086.1	RP11-667F14.1	4.19	3.06e-05	0.00222	0.14	0.13	Intraocular pressure;	chr7:116252596	chr7:116209234~116211511:-
BRCA	cis	rs77204473	1	rs12294191	ENSG00000280143.1	AP000892.6	-4.19	3.06e-05	0.00222	-0.22	-0.13	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116889108	chr11:117204967~117210292:+
BRCA	cis	rs6671200	0.607	rs3753872	ENSG00000235501.4	RP4-639F20.1	4.19	3.06e-05	0.00222	0.21	0.13	Stearic acid (18:0) levels;	chr1:95233628	chr1:94927566~94963270:+
BRCA	cis	rs7267979	1	rs404394	ENSG00000274973.1	RP13-401N8.7	-4.19	3.06e-05	0.00222	-0.15	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25467260	chr20:25845497~25845862:+
BRCA	cis	rs2243480	1	rs1723267	ENSG00000222364.1	RNU6-96P	-4.19	3.06e-05	0.00222	-0.23	-0.13	Diabetic kidney disease;	chr7:66008327	chr7:66395191~66395286:+
BRCA	cis	rs6570726	0.935	rs371744	ENSG00000270638.1	RP3-466P17.1	4.19	3.06e-05	0.00222	0.14	0.13	Lobe attachment (rater-scored or self-reported);	chr6:145519888	chr6:145735570~145737218:+
BRCA	cis	rs7267979	1	rs6083828	ENSG00000274973.1	RP13-401N8.7	4.19	3.06e-05	0.00222	0.15	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25389282	chr20:25845497~25845862:+
BRCA	cis	rs17092148	0.636	rs59030726	ENSG00000126005.14	MMP24-AS1	-4.19	3.06e-05	0.00222	-0.17	-0.13	Neuroticism;	chr20:34866314	chr20:35216462~35278131:-
BRCA	cis	rs7177699	0.557	rs7165902	ENSG00000261143.1	ADAMTS7P3	-4.19	3.06e-05	0.00222	-0.15	-0.13	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78823530	chr15:77976042~77993057:+
BRCA	cis	rs7177699	0.557	rs7165075	ENSG00000261143.1	ADAMTS7P3	-4.19	3.06e-05	0.00222	-0.15	-0.13	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78823623	chr15:77976042~77993057:+
BRCA	cis	rs7177699	0.557	rs6495335	ENSG00000261143.1	ADAMTS7P3	-4.19	3.06e-05	0.00222	-0.15	-0.13	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78824791	chr15:77976042~77993057:+
BRCA	cis	rs7177699	0.557	rs12442476	ENSG00000261143.1	ADAMTS7P3	-4.19	3.06e-05	0.00222	-0.15	-0.13	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78825514	chr15:77976042~77993057:+
BRCA	cis	rs73242632	0.867	rs73242634	ENSG00000269949.1	RP11-738E22.3	4.19	3.06e-05	0.00222	0.34	0.13	Congenital heart disease (maternal effect);	chr4:57069355	chr4:56960927~56961373:-
BRCA	cis	rs853679	1	rs1679732	ENSG00000204709.4	LINC01556	-4.19	3.06e-05	0.00222	-0.22	-0.13	Depression;	chr6:28253486	chr6:28943877~28944537:+
BRCA	cis	rs6908034	0.607	rs12525152	ENSG00000228412.5	RP4-625H18.2	4.19	3.06e-05	0.00222	0.28	0.13	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19809193	chr6:19802164~19804752:-
BRCA	cis	rs4218	0.638	rs12437587	ENSG00000259732.1	RP11-59H7.3	-4.19	3.06e-05	0.00222	-0.16	-0.13	Social communication problems;	chr15:59072785	chr15:59121034~59133250:+
BRCA	cis	rs9341808	0.538	rs620147	ENSG00000233967.5	RP11-250B2.3	-4.19	3.06e-05	0.00222	-0.13	-0.13	Sitting height ratio;	chr6:80282373	chr6:80443344~80465927:+
BRCA	cis	rs6430585	0.702	rs2304601	ENSG00000231890.6	DARS-AS1	-4.19	3.06e-05	0.00222	-0.2	-0.13	Corneal structure;	chr2:135770464	chr2:135985176~136022593:+
BRCA	cis	rs10129255	0.509	rs756583	ENSG00000211967.3	IGHV3-53	-4.19	3.06e-05	0.00222	-0.09	-0.13	Kawasaki disease;	chr14:106680002	chr14:106592676~106593347:-
BRCA	cis	rs420259	0.861	rs450787	ENSG00000260136.4	CTD-2270L9.4	4.19	3.06e-05	0.00222	0.12	0.13	Bipolar disorder;	chr16:23625382	chr16:23452758~23457606:+
BRCA	cis	rs13421350	0.579	rs10207640	ENSG00000225205.4	AC093818.1	4.19	3.06e-05	0.00222	0.23	0.13	Diabetic kidney disease;	chr2:172442998	chr2:172480840~172556596:-
BRCA	cis	rs6545883	0.602	rs11125871	ENSG00000212978.6	AC016747.3	-4.19	3.06e-05	0.00222	-0.17	-0.13	Tuberculosis;	chr2:61242991	chr2:61141592~61144969:-
BRCA	cis	rs10992471	0.56	rs10992513	ENSG00000275318.1	RP11-526D8.11	-4.19	3.06e-05	0.00222	-0.12	-0.13	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr9:92890818	chr9:92840955~92841688:-
BRCA	cis	rs73186030	0.92	rs2001548	ENSG00000272758.4	RP11-299J3.8	4.19	3.07e-05	0.00222	0.19	0.13	Serum parathyroid hormone levels;	chr3:122313942	chr3:122416207~122443180:+
BRCA	cis	rs3768617	0.966	rs6669796	ENSG00000224468.3	RP11-181K3.4	-4.19	3.07e-05	0.00222	-0.14	-0.13	Fuchs's corneal dystrophy;	chr1:183113690	chr1:183138402~183141282:-
BRCA	cis	rs180730	1	rs1901136	ENSG00000251609.2	SETP12	-4.19	3.07e-05	0.00222	-0.19	-0.13	Fasting plasma glucose;	chr4:120881574	chr4:120895494~120897083:-
BRCA	cis	rs597539	0.521	rs7943745	ENSG00000250508.1	RP11-757G1.6	-4.19	3.07e-05	0.00222	-0.16	-0.13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68838360	chr11:68870664~68874542:+
BRCA	cis	rs11051970	0.659	rs1809913	ENSG00000274964.1	RP11-817I4.1	-4.19	3.07e-05	0.00222	-0.16	-0.13	Response to tocilizumab in rheumatoid arthritis;	chr12:32438692	chr12:32339368~32340724:+
BRCA	cis	rs9393777	0.92	rs35716472	ENSG00000216901.1	AL022393.7	4.19	3.07e-05	0.00222	0.3	0.13	Intelligence (multi-trait analysis);	chr6:27438828	chr6:28176188~28176674:+
BRCA	cis	rs2337406	0.587	rs10150642	ENSG00000211972.2	IGHV3-66	-4.19	3.07e-05	0.00222	-0.11	-0.13	Alzheimer's disease (late onset);	chr14:106647269	chr14:106675017~106675544:-
BRCA	cis	rs2018683	1	rs4719963	ENSG00000233517.1	AC005162.5	4.19	3.07e-05	0.00222	0.15	0.13	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28971448	chr7:28987028~28988899:+
BRCA	cis	rs2243480	1	rs4548056	ENSG00000275400.1	RP4-756H11.5	4.19	3.07e-05	0.00222	0.23	0.13	Diabetic kidney disease;	chr7:65833886	chr7:66553805~66554199:-
BRCA	cis	rs8114671	0.869	rs1407202	ENSG00000279253.1	RP4-614O4.13	4.19	3.07e-05	0.00222	0.15	0.13	Height;	chr20:35064164	chr20:35262727~35264187:-
BRCA	cis	rs6601450	0.547	rs10105843	ENSG00000154316.13	TDH	-4.19	3.07e-05	0.00222	-0.17	-0.13	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;	chr8:10340353	chr8:11339637~11368452:+
BRCA	cis	rs11892454	0.515	rs10198667	ENSG00000217643.1	PTGES3P2	-4.19	3.07e-05	0.00222	-0.14	-0.13	Heschl's gyrus morphology;	chr2:25798007	chr2:25822469~25822950:+
BRCA	cis	rs559555	0.523	rs490457	ENSG00000272716.1	RP11-563N4.1	4.19	3.07e-05	0.00222	0.15	0.13	Blood metabolite ratios;Blood metabolite levels;	chr2:31614037	chr2:32165046~32165757:-
BRCA	cis	rs853679	0.598	rs9380054	ENSG00000216901.1	AL022393.7	4.19	3.07e-05	0.00222	0.18	0.13	Depression;	chr6:28099759	chr6:28176188~28176674:+
BRCA	cis	rs4713118	0.547	rs2116981	ENSG00000216901.1	AL022393.7	4.19	3.07e-05	0.00222	0.18	0.13	Parkinson's disease;	chr6:28100173	chr6:28176188~28176674:+
BRCA	cis	rs853679	0.517	rs9368552	ENSG00000216901.1	AL022393.7	4.19	3.07e-05	0.00222	0.18	0.13	Depression;	chr6:28100648	chr6:28176188~28176674:+
BRCA	cis	rs853679	0.542	rs34131763	ENSG00000216901.1	AL022393.7	4.19	3.07e-05	0.00222	0.18	0.13	Depression;	chr6:28107222	chr6:28176188~28176674:+
BRCA	cis	rs748404	0.666	rs72709850	ENSG00000205771.5	CATSPER2P1	-4.19	3.07e-05	0.00223	-0.19	-0.13	Lung cancer;	chr15:43462486	chr15:43726918~43747094:-
BRCA	cis	rs964611	0.882	rs75094472	ENSG00000259488.2	RP11-154J22.1	-4.19	3.07e-05	0.00223	-0.16	-0.13	Metabolite levels (Pyroglutamine);	chr15:48351917	chr15:48312353~48331856:-
BRCA	cis	rs73242632	1	rs2271806	ENSG00000269949.1	RP11-738E22.3	4.19	3.07e-05	0.00223	0.3	0.13	Congenital heart disease (maternal effect);	chr4:57020984	chr4:56960927~56961373:-
BRCA	cis	rs61931739	0.5	rs10844789	ENSG00000258794.3	DUX4L27	4.19	3.07e-05	0.00223	0.19	0.13	Morning vs. evening chronotype;	chr12:34049344	chr12:34208415~34209675:-
BRCA	cis	rs61931739	0.534	rs11053072	ENSG00000258794.3	DUX4L27	4.19	3.07e-05	0.00223	0.19	0.13	Morning vs. evening chronotype;	chr12:34049464	chr12:34208415~34209675:-
BRCA	cis	rs61931739	0.534	rs11053073	ENSG00000258794.3	DUX4L27	4.19	3.07e-05	0.00223	0.19	0.13	Morning vs. evening chronotype;	chr12:34049477	chr12:34208415~34209675:-
BRCA	cis	rs7011507	0.535	rs6998738	ENSG00000233858.4	AC026904.1	-4.19	3.07e-05	0.00223	-0.16	-0.13	Inflammatory bowel disease;Ulcerative colitis;	chr8:48553490	chr8:48590401~48594621:+
BRCA	cis	rs7824557	0.767	rs3808509	ENSG00000248896.2	CTD-2135J3.3	4.19	3.07e-05	0.00223	0.17	0.13	Retinal vascular caliber;	chr8:11305747	chr8:10729314~10771392:+
BRCA	cis	rs1005277	0.54	rs2145487	ENSG00000226578.1	RP11-258F22.1	-4.19	3.07e-05	0.00223	-0.14	-0.13	Extrinsic epigenetic age acceleration;	chr10:37721149	chr10:37775371~37784131:-
BRCA	cis	rs1048886	0.872	rs6933150	ENSG00000271967.1	RP11-134K13.4	-4.19	3.07e-05	0.00223	-0.18	-0.13	Type 2 diabetes;	chr6:70519176	chr6:70596438~70596980:+
BRCA	cis	rs4950322	0.57	rs80270233	ENSG00000237188.3	RP11-337C18.8	4.19	3.07e-05	0.00223	0.16	0.13	Protein quantitative trait loci;	chr1:147263320	chr1:147172771~147211568:+
BRCA	cis	rs4287000	0.508	rs2265575	ENSG00000227603.1	RP11-165J3.6	-4.19	3.07e-05	0.00223	-0.15	-0.13	Itch intensity from mosquito bite adjusted by bite size;	chr9:93609482	chr9:93435332~93437121:-
BRCA	cis	rs748404	0.666	rs514438	ENSG00000205771.5	CATSPER2P1	-4.19	3.07e-05	0.00223	-0.19	-0.13	Lung cancer;	chr15:43328245	chr15:43726918~43747094:-
BRCA	cis	rs11085466	1	rs2292986	ENSG00000268081.1	RP11-678G14.2	4.19	3.08e-05	0.00223	0.2	0.13	Colorectal or endometrial cancer;	chr19:21593530	chr19:21554640~21569237:-
BRCA	cis	rs4143844	0.867	rs12901055	ENSG00000259251.2	RP11-643M14.1	4.19	3.08e-05	0.00223	0.32	0.13	Bipolar disorder and schizophrenia;	chr15:61880708	chr15:62060503~62062434:+
BRCA	cis	rs957448	1	rs28817653	ENSG00000254315.1	RP11-267M23.3	4.19	3.08e-05	0.00223	0.17	0.13	Nonsyndromic cleft lip with cleft palate;	chr8:94557822	chr8:94533628~94534391:+
BRCA	cis	rs6600671	0.899	rs11249432	ENSG00000231429.2	RP11-343N15.2	-4.19	3.08e-05	0.00223	-0.15	-0.13	Hip geometry;	chr1:121541678	chr1:121412719~121429274:+
BRCA	cis	rs875971	0.638	rs7793569	ENSG00000272831.1	RP11-792A8.4	-4.19	3.08e-05	0.00223	-0.12	-0.13	Aortic root size;	chr7:66651646	chr7:66739829~66740385:-
BRCA	cis	rs801193	1	rs3857688	ENSG00000272831.1	RP11-792A8.4	-4.19	3.08e-05	0.00223	-0.12	-0.13	Aortic root size;	chr7:66662819	chr7:66739829~66740385:-
BRCA	cis	rs801193	1	rs2286684	ENSG00000272831.1	RP11-792A8.4	-4.19	3.08e-05	0.00223	-0.12	-0.13	Aortic root size;	chr7:66664843	chr7:66739829~66740385:-
BRCA	cis	rs801193	0.935	rs2286683	ENSG00000272831.1	RP11-792A8.4	-4.19	3.08e-05	0.00223	-0.12	-0.13	Aortic root size;	chr7:66664856	chr7:66739829~66740385:-
BRCA	cis	rs801193	1	rs10274773	ENSG00000272831.1	RP11-792A8.4	-4.19	3.08e-05	0.00223	-0.12	-0.13	Aortic root size;	chr7:66668591	chr7:66739829~66740385:-
BRCA	cis	rs7771547	0.547	rs1076931	ENSG00000224666.3	RP1-50J22.4	4.19	3.08e-05	0.00223	0.16	0.13	Platelet distribution width;	chr6:36594244	chr6:36386831~36393462:+
BRCA	cis	rs10761482	0.639	rs2067612	ENSG00000254271.1	RP11-131N11.4	4.19	3.08e-05	0.00223	0.18	0.13	Schizophrenia;	chr10:60452576	chr10:60734342~60741828:+
BRCA	cis	rs13326165	0.715	rs11718125	ENSG00000243224.1	RP5-1157M23.2	-4.19	3.08e-05	0.00223	-0.18	-0.13	HDL cholesterol levels;HDL cholesterol;	chr3:52345404	chr3:52239258~52241097:+
BRCA	cis	rs7267979	1	rs4815417	ENSG00000125804.12	FAM182A	4.19	3.08e-05	0.00223	0.17	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25398890	chr20:26054655~26086917:+
BRCA	cis	rs6671200	0.748	rs79375907	ENSG00000235501.4	RP4-639F20.1	-4.19	3.08e-05	0.00223	-0.28	-0.13	Stearic acid (18:0) levels;	chr1:95074005	chr1:94927566~94963270:+
BRCA	cis	rs1198430	0.929	rs1210852	ENSG00000271420.1	RP5-1057J7.7	4.19	3.08e-05	0.00223	0.17	0.13	Total cholesterol levels;	chr1:23427040	chr1:23378380~23379029:-
BRCA	cis	rs13108904	0.521	rs4974609	ENSG00000253399.1	AC078852.2	4.19	3.08e-05	0.00223	0.14	0.13	Obesity-related traits;	chr4:1363136	chr4:1358479~1359461:+
BRCA	cis	rs4415084	0.716	rs12518851	ENSG00000251141.4	RP11-53O19.1	4.19	3.08e-05	0.00223	0.12	0.13	Breast cancer;	chr5:44828129	chr5:44744900~44808777:-
BRCA	cis	rs4415084	0.716	rs13155698	ENSG00000251141.4	RP11-53O19.1	4.19	3.08e-05	0.00223	0.12	0.13	Breast cancer;	chr5:44828579	chr5:44744900~44808777:-
BRCA	cis	rs4415084	0.716	rs10038562	ENSG00000251141.4	RP11-53O19.1	-4.19	3.08e-05	0.00223	-0.12	-0.13	Breast cancer;	chr5:44832124	chr5:44744900~44808777:-
BRCA	cis	rs4415084	0.716	rs6896350	ENSG00000251141.4	RP11-53O19.1	-4.19	3.08e-05	0.00223	-0.12	-0.13	Breast cancer;	chr5:44832469	chr5:44744900~44808777:-
BRCA	cis	rs4415084	0.68	rs1371025	ENSG00000251141.4	RP11-53O19.1	-4.19	3.08e-05	0.00223	-0.12	-0.13	Breast cancer;	chr5:44834131	chr5:44744900~44808777:-
BRCA	cis	rs4415084	0.716	rs2330620	ENSG00000251141.4	RP11-53O19.1	-4.19	3.08e-05	0.00223	-0.12	-0.13	Breast cancer;	chr5:44839720	chr5:44744900~44808777:-
BRCA	cis	rs4415084	0.716	rs2083243	ENSG00000251141.4	RP11-53O19.1	-4.19	3.08e-05	0.00223	-0.12	-0.13	Breast cancer;	chr5:44840045	chr5:44744900~44808777:-
BRCA	cis	rs4415084	0.716	rs729599	ENSG00000251141.4	RP11-53O19.1	-4.19	3.08e-05	0.00223	-0.12	-0.13	Breast cancer;	chr5:44842158	chr5:44744900~44808777:-
BRCA	cis	rs4415084	0.716	rs1371024	ENSG00000251141.4	RP11-53O19.1	-4.19	3.08e-05	0.00223	-0.12	-0.13	Breast cancer;	chr5:44843488	chr5:44744900~44808777:-
BRCA	cis	rs2229238	0.868	rs73018293	ENSG00000272030.1	RP1-178F15.4	-4.19	3.08e-05	0.00223	-0.18	-0.13	Coronary heart disease;	chr1:154493101	chr1:153631438~153634397:-
BRCA	cis	rs7520050	0.833	rs1085242	ENSG00000281133.1	AL355480.3	4.19	3.08e-05	0.00223	0.15	0.13	Reticulocyte count;Red blood cell count;	chr1:46078552	chr1:45580892~45580996:-
BRCA	cis	rs6545883	0.859	rs7561672	ENSG00000273302.1	RP11-493E12.2	-4.19	3.08e-05	0.00223	-0.12	-0.13	Tuberculosis;	chr2:61291959	chr2:61199979~61200769:+
BRCA	cis	rs3768617	0.811	rs6424883	ENSG00000224468.3	RP11-181K3.4	-4.19	3.09e-05	0.00223	-0.15	-0.13	Fuchs's corneal dystrophy;	chr1:183068560	chr1:183138402~183141282:-
BRCA	cis	rs3768617	0.811	rs12563494	ENSG00000224468.3	RP11-181K3.4	-4.19	3.09e-05	0.00223	-0.15	-0.13	Fuchs's corneal dystrophy;	chr1:183070563	chr1:183138402~183141282:-
BRCA	cis	rs4478858	0.735	rs4949393	ENSG00000223907.1	LINC01226	-4.19	3.09e-05	0.00224	-0.16	-0.13	Alcohol dependence;	chr1:31379028	chr1:31518435~31524245:+
BRCA	cis	rs4869313	0.905	rs1046395	ENSG00000248734.2	CTD-2260A17.1	4.19	3.09e-05	0.00224	0.13	0.13	Pediatric autoimmune diseases;	chr5:96937476	chr5:96784777~96785999:+
BRCA	cis	rs13098911	0.54	rs71327017	ENSG00000223552.1	RP11-24F11.2	-4.19	3.09e-05	0.00224	-0.22	-0.13	Celiac disease;	chr3:46069721	chr3:46364955~46407059:-
BRCA	cis	rs12285276	0.75	rs7116816	ENSG00000205106.4	DKFZp779M0652	4.19	3.09e-05	0.00224	0.18	0.13	Visceral fat;	chr11:45783444	chr11:45771432~45772358:+
BRCA	cis	rs12285276	0.711	rs12274152	ENSG00000205106.4	DKFZp779M0652	4.19	3.09e-05	0.00224	0.18	0.13	Visceral fat;	chr11:45786272	chr11:45771432~45772358:+
BRCA	cis	rs7911264	0.791	rs9420589	ENSG00000232709.1	MARK2P9	4.19	3.09e-05	0.00224	0.17	0.13	Inflammatory bowel disease;	chr10:92690476	chr10:92418667~92420875:+
BRCA	cis	rs9834975	0.815	rs9874163	ENSG00000272758.4	RP11-299J3.8	-4.19	3.09e-05	0.00224	-0.13	-0.13	Diastolic blood pressure;	chr3:122386581	chr3:122416207~122443180:+
BRCA	cis	rs11098499	0.954	rs6822679	ENSG00000260404.2	RP11-384K6.6	4.19	3.09e-05	0.00224	0.12	0.13	Corneal astigmatism;	chr4:119481547	chr4:118591773~118633729:+
BRCA	cis	rs2274273	0.624	rs10132453	ENSG00000259318.1	RP11-454L9.2	4.19	3.09e-05	0.00224	0.12	0.13	Protein biomarker;	chr14:55374133	chr14:55394940~55395233:-
BRCA	cis	rs2243480	1	rs316330	ENSG00000237026.1	RP11-328P23.2	4.19	3.09e-05	0.00224	0.24	0.13	Diabetic kidney disease;	chr7:66140385	chr7:65235790~65236723:-
BRCA	cis	rs12922040	0.701	rs12149912	ENSG00000207425.1	Y_RNA	4.19	3.09e-05	0.00224	0.15	0.13	Serum uric acid levels in response to allopurinol in gout;	chr16:15774798	chr16:14915457~14915556:-
BRCA	cis	rs4143844	0.867	rs35607089	ENSG00000259251.2	RP11-643M14.1	4.19	3.09e-05	0.00224	0.3	0.13	Bipolar disorder and schizophrenia;	chr15:61909573	chr15:62060503~62062434:+
BRCA	cis	rs9784649	0.76	rs72755820	ENSG00000245662.2	RP11-184E9.1	4.19	3.09e-05	0.00224	0.19	0.13	Peripheral arterial disease (traffic-related air pollution interaction);	chr5:25066072	chr5:25190682~25306172:+
BRCA	cis	rs11711311	1	rs2305546	ENSG00000241529.3	RN7SL767P	-4.19	3.09e-05	0.00224	-0.15	-0.13	IgG glycosylation;	chr3:113784507	chr3:113632704~113632998:+
BRCA	cis	rs11051970	0.614	rs2728684	ENSG00000274964.1	RP11-817I4.1	-4.19	3.09e-05	0.00224	-0.16	-0.13	Response to tocilizumab in rheumatoid arthritis;	chr12:32422731	chr12:32339368~32340724:+
BRCA	cis	rs8180040	0.966	rs11710322	ENSG00000271161.1	BOLA2P2	-4.19	3.09e-05	0.00224	-0.14	-0.13	Colorectal cancer;	chr3:47289646	chr3:47499841~47500407:+
BRCA	cis	rs34773007	1	rs17377483	ENSG00000232709.1	MARK2P9	4.18	3.09e-05	0.00224	0.22	0.13	Type 2 diabetes;	chr10:92900376	chr10:92418667~92420875:+
BRCA	cis	rs7119	0.623	rs12905318	ENSG00000259362.2	RP11-307C19.1	-4.18	3.09e-05	0.00224	-0.18	-0.13	Type 2 diabetes;	chr15:77553531	chr15:77525540~77534110:+
BRCA	cis	rs7119	0.651	rs12904200	ENSG00000259362.2	RP11-307C19.1	-4.18	3.09e-05	0.00224	-0.18	-0.13	Type 2 diabetes;	chr15:77553560	chr15:77525540~77534110:+
BRCA	cis	rs7119	0.651	rs12904208	ENSG00000259362.2	RP11-307C19.1	-4.18	3.09e-05	0.00224	-0.18	-0.13	Type 2 diabetes;	chr15:77553569	chr15:77525540~77534110:+
BRCA	cis	rs7119	0.651	rs12905044	ENSG00000259362.2	RP11-307C19.1	-4.18	3.09e-05	0.00224	-0.18	-0.13	Type 2 diabetes;	chr15:77553873	chr15:77525540~77534110:+
BRCA	cis	rs1910358	0.554	rs1832642	ENSG00000248874.4	C5orf17	-4.18	3.09e-05	0.00224	-0.18	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23747045	chr5:23951348~24178263:+
BRCA	cis	rs6480314	0.636	rs61854782	ENSG00000233590.1	RP11-153K11.3	-4.18	3.09e-05	0.00224	-0.21	-0.13	Optic nerve measurement (disc area);	chr10:68231992	chr10:68233251~68242379:-
BRCA	cis	rs7267979	1	rs6050566	ENSG00000125804.12	FAM182A	4.18	3.09e-05	0.00224	0.17	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25370435	chr20:26054655~26086917:+
BRCA	cis	rs2380205	0.967	rs4256891	ENSG00000232807.2	RP11-536K7.3	4.18	3.09e-05	0.00224	0.13	0.13	Breast cancer;	chr10:5846095	chr10:5934270~5945900:-
BRCA	cis	rs2380205	0.935	rs3954757	ENSG00000232807.2	RP11-536K7.3	4.18	3.09e-05	0.00224	0.13	0.13	Breast cancer;	chr10:5846103	chr10:5934270~5945900:-
BRCA	cis	rs34421088	0.548	rs2618443	ENSG00000270154.1	RP11-419I17.1	-4.18	3.1e-05	0.00224	-0.15	-0.13	Neuroticism;	chr8:11527047	chr8:12476462~12477122:+
BRCA	cis	rs6963495	0.769	rs73192134	ENSG00000223886.3	RP11-251G23.2	4.18	3.1e-05	0.00224	0.2	0.13	Bipolar disorder (body mass index interaction);	chr7:105548891	chr7:105530209~105530671:+
BRCA	cis	rs651907	0.535	rs13084113	ENSG00000256628.3	ZBTB11-AS1	4.18	3.1e-05	0.00224	0.17	0.13	Colorectal cancer;	chr3:101815195	chr3:101676475~101679217:+
BRCA	cis	rs7200543	0.848	rs62039480	ENSG00000275910.1	RP11-680G24.6	-4.18	3.1e-05	0.00224	-0.14	-0.13	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15043593	chr16:15015828~15016390:-
BRCA	cis	rs1371614	0.531	rs77562583	ENSG00000229122.1	AGBL5-IT1	4.18	3.1e-05	0.00224	0.14	0.13	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26928775	chr2:27061038~27061815:+
BRCA	cis	rs9834975	0.935	rs6798997	ENSG00000272758.4	RP11-299J3.8	-4.18	3.1e-05	0.00224	-0.13	-0.13	Diastolic blood pressure;	chr3:122355857	chr3:122416207~122443180:+
BRCA	cis	rs2073316	0.662	rs61706447	ENSG00000272716.1	RP11-563N4.1	4.18	3.1e-05	0.00224	0.14	0.13	Interleukin-18 levels;	chr2:31410572	chr2:32165046~32165757:-
BRCA	cis	rs9527	0.518	rs7899608	ENSG00000213061.2	PFN1P11	4.18	3.1e-05	0.00224	0.24	0.13	Arsenic metabolism;	chr10:102967547	chr10:102838011~102845473:-
BRCA	cis	rs2243480	1	rs781149	ENSG00000275400.1	RP4-756H11.5	4.18	3.1e-05	0.00224	0.23	0.13	Diabetic kidney disease;	chr7:66016297	chr7:66553805~66554199:-
BRCA	cis	rs2243480	0.901	rs58207111	ENSG00000275400.1	RP4-756H11.5	4.18	3.1e-05	0.00224	0.23	0.13	Diabetic kidney disease;	chr7:66021736	chr7:66553805~66554199:-
BRCA	cis	rs4650943	0.586	rs2455738	ENSG00000227740.1	RP11-318C24.2	-4.18	3.1e-05	0.00224	-0.13	-0.13	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in inactive individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr1:176322567	chr1:175904762~175920513:-
BRCA	cis	rs8031584	0.918	rs11639169	ENSG00000259845.1	HERC2P10	4.18	3.1e-05	0.00224	0.15	0.13	Huntington's disease progression;	chr15:30963235	chr15:30815271~30844153:+
BRCA	cis	rs1005277	0.579	rs2505257	ENSG00000272983.1	RP11-508N22.12	4.18	3.1e-05	0.00224	0.14	0.13	Extrinsic epigenetic age acceleration;	chr10:38083736	chr10:38137337~38144399:+
BRCA	cis	rs10911902	0.56	rs76317001	ENSG00000229739.2	RP11-295K2.3	-4.18	3.1e-05	0.00224	-0.2	-0.13	Schizophrenia;	chr1:186303357	chr1:186435161~186470291:+
BRCA	cis	rs13096357	0.52	rs17080319	ENSG00000225399.4	RP11-3B7.1	-4.18	3.1e-05	0.00224	-0.19	-0.13	Cognitive ability (multi-trait analysis);	chr3:48695047	chr3:49260085~49261316:+
BRCA	cis	rs957448	1	rs957447	ENSG00000254315.1	RP11-267M23.3	4.18	3.1e-05	0.00224	0.17	0.13	Nonsyndromic cleft lip with cleft palate;	chr8:94528995	chr8:94533628~94534391:+
BRCA	cis	rs4237845	0.537	rs1599931	ENSG00000270039.1	RP11-571M6.17	-4.18	3.1e-05	0.00224	-0.19	-0.13	Intelligence (multi-trait analysis);	chr12:57865067	chr12:57803838~57804415:+
BRCA	cis	rs4950322	0.57	rs72691097	ENSG00000237188.3	RP11-337C18.8	4.18	3.1e-05	0.00224	0.16	0.13	Protein quantitative trait loci;	chr1:147299711	chr1:147172771~147211568:+
BRCA	cis	rs4950322	0.57	rs72691098	ENSG00000237188.3	RP11-337C18.8	4.18	3.1e-05	0.00224	0.16	0.13	Protein quantitative trait loci;	chr1:147300142	chr1:147172771~147211568:+
BRCA	cis	rs62458065	0.513	rs10268803	ENSG00000229358.3	DPY19L1P1	-4.18	3.1e-05	0.00225	-0.18	-0.13	Metabolite levels (HVA/MHPG ratio);	chr7:32508223	chr7:32580949~32761787:-
BRCA	cis	rs6545883	0.894	rs778158	ENSG00000212978.6	AC016747.3	-4.18	3.1e-05	0.00225	-0.17	-0.13	Tuberculosis;	chr2:61328286	chr2:61141592~61144969:-
BRCA	cis	rs6088590	0.582	rs6059909	ENSG00000275784.1	RP5-1125A11.6	-4.18	3.1e-05	0.00225	-0.14	-0.13	Coronary artery disease;	chr20:34551887	chr20:33989480~33991818:-
BRCA	cis	rs12036718	0.511	rs11205444	ENSG00000272491.1	RP5-1024N4.4	-4.18	3.1e-05	0.00225	-0.2	-0.13	Yu-Zhi constitution type in type 2 diabetes;	chr1:48139025	chr1:48227888~48229561:-
BRCA	cis	rs7267979	0.753	rs400357	ENSG00000274414.1	RP5-965G21.4	-4.18	3.1e-05	0.00225	-0.15	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25498422	chr20:25239007~25245229:-
BRCA	cis	rs7811142	0.943	rs66958101	ENSG00000078319.8	PMS2P1	-4.18	3.1e-05	0.00225	-0.21	-0.13	Platelet count;	chr7:100476397	chr7:100320992~100341908:-
BRCA	cis	rs4776970	0.632	rs12592101	ENSG00000270964.1	RP11-502I4.3	-4.18	3.1e-05	0.00225	-0.14	-0.13	Body mass index;Waist circumference;	chr15:67737232	chr15:67541072~67542604:-
BRCA	cis	rs1005277	0.54	rs4934907	ENSG00000226578.1	RP11-258F22.1	-4.18	3.1e-05	0.00225	-0.14	-0.13	Extrinsic epigenetic age acceleration;	chr10:37726302	chr10:37775371~37784131:-
BRCA	cis	rs1005277	0.54	rs11011351	ENSG00000226578.1	RP11-258F22.1	-4.18	3.1e-05	0.00225	-0.14	-0.13	Extrinsic epigenetic age acceleration;	chr10:37741597	chr10:37775371~37784131:-
BRCA	cis	rs6963495	0.818	rs6961233	ENSG00000223886.3	RP11-251G23.2	4.18	3.1e-05	0.00225	0.2	0.13	Bipolar disorder (body mass index interaction);	chr7:105510022	chr7:105530209~105530671:+
BRCA	cis	rs736408	0.924	rs2535629	ENSG00000239557.1	RP11-168J18.6	4.18	3.1e-05	0.00225	0.16	0.13	Bipolar disorder;	chr3:52799203	chr3:52373652~52374882:+
BRCA	cis	rs10761482	0.645	rs10761498	ENSG00000254271.1	RP11-131N11.4	4.18	3.1e-05	0.00225	0.18	0.13	Schizophrenia;	chr10:60423627	chr10:60734342~60741828:+
BRCA	cis	rs6430585	0.527	rs2254780	ENSG00000231890.6	DARS-AS1	-4.18	3.1e-05	0.00225	-0.19	-0.13	Corneal structure;	chr2:135677956	chr2:135985176~136022593:+
BRCA	cis	rs4948275	0.693	rs2606115	ENSG00000237233.2	TMEM26-AS1	-4.18	3.11e-05	0.00225	-0.15	-0.13	Night sleep phenotypes;	chr10:61556771	chr10:61452639~61481956:+
BRCA	cis	rs669446	0.527	rs585711	ENSG00000236200.4	KDM4A-AS1	-4.18	3.11e-05	0.00225	-0.16	-0.13	Amyotrophic lateral sclerosis (age of onset);	chr1:43634192	chr1:43699765~43708138:-
BRCA	cis	rs669446	0.561	rs585652	ENSG00000236200.4	KDM4A-AS1	-4.18	3.11e-05	0.00225	-0.16	-0.13	Amyotrophic lateral sclerosis (age of onset);	chr1:43634239	chr1:43699765~43708138:-
BRCA	cis	rs4787491	0.704	rs67218159	ENSG00000183604.13	SMG1P5	-4.18	3.11e-05	0.00225	-0.12	-0.13	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30039184	chr16:30267553~30335374:-
BRCA	cis	rs6430538	0.621	rs6430540	ENSG00000224043.6	CCNT2-AS1	-4.18	3.11e-05	0.00225	-0.18	-0.13	Parkinson's disease;	chr2:134793993	chr2:134735464~134918710:-
BRCA	cis	rs10181042	0.612	rs1177282	ENSG00000273302.1	RP11-493E12.2	4.18	3.11e-05	0.00225	0.11	0.13	Crohn's disease;	chr2:61130642	chr2:61199979~61200769:+
BRCA	cis	rs180730	0.898	rs343200	ENSG00000251609.2	SETP12	-4.18	3.11e-05	0.00225	-0.19	-0.13	Fasting plasma glucose;	chr4:120876657	chr4:120895494~120897083:-
BRCA	cis	rs3764021	0.87	rs10844597	ENSG00000256582.1	RP11-75L1.1	4.18	3.11e-05	0.00225	0.13	0.13	Type 1 diabetes;	chr12:9722303	chr12:9704077~9709350:+
BRCA	cis	rs9309473	0.583	rs6705203	ENSG00000230002.2	ALMS1-IT1	4.18	3.11e-05	0.00225	0.15	0.13	Metabolite levels;	chr2:73347472	chr2:73456764~73459484:+
BRCA	cis	rs748404	0.666	rs12900259	ENSG00000205771.5	CATSPER2P1	-4.18	3.11e-05	0.00225	-0.19	-0.13	Lung cancer;	chr15:43427369	chr15:43726918~43747094:-
BRCA	cis	rs748404	0.666	rs34921640	ENSG00000205771.5	CATSPER2P1	-4.18	3.11e-05	0.00225	-0.19	-0.13	Lung cancer;	chr15:43429187	chr15:43726918~43747094:-
BRCA	cis	rs748404	0.666	rs62020574	ENSG00000205771.5	CATSPER2P1	-4.18	3.11e-05	0.00225	-0.19	-0.13	Lung cancer;	chr15:43429380	chr15:43726918~43747094:-
BRCA	cis	rs4143844	0.867	rs12185103	ENSG00000259251.2	RP11-643M14.1	4.18	3.11e-05	0.00225	0.31	0.13	Bipolar disorder and schizophrenia;	chr15:61889092	chr15:62060503~62062434:+
BRCA	cis	rs6494488	0.5	rs79866634	ENSG00000248415.1	GAPDHP61	-4.18	3.11e-05	0.00225	-0.26	-0.13	Coronary artery disease;	chr15:64526422	chr15:64528667~64529671:-
BRCA	cis	rs1722141	0.601	rs1722144	ENSG00000229628.1	AC073115.7	4.18	3.11e-05	0.00225	0.17	0.13	Sitting height ratio;	chr7:46033701	chr7:45990905~46000898:+
BRCA	cis	rs7903456	0.648	rs9421561	ENSG00000224914.2	LINC00863	4.18	3.11e-05	0.00225	0.16	0.13	Gout;Renal underexcretion gout;	chr10:87039315	chr10:87342736~87357882:+
BRCA	cis	rs1005277	0.522	rs1208767	ENSG00000226578.1	RP11-258F22.1	-4.18	3.11e-05	0.00225	-0.14	-0.13	Extrinsic epigenetic age acceleration;	chr10:37753367	chr10:37775371~37784131:-
BRCA	cis	rs11098499	0.691	rs12510133	ENSG00000260404.2	RP11-384K6.6	4.18	3.11e-05	0.00225	0.11	0.13	Corneal astigmatism;	chr4:119350189	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.754	rs12506487	ENSG00000260404.2	RP11-384K6.6	4.18	3.11e-05	0.00225	0.11	0.13	Corneal astigmatism;	chr4:119350206	chr4:118591773~118633729:+
BRCA	cis	rs6545883	0.894	rs778157	ENSG00000212978.6	AC016747.3	4.18	3.11e-05	0.00225	0.17	0.13	Tuberculosis;	chr2:61327154	chr2:61141592~61144969:-
BRCA	cis	rs6968419	0.674	rs57756655	ENSG00000279086.1	RP11-667F14.1	-4.18	3.11e-05	0.00225	-0.14	-0.13	Intraocular pressure;	chr7:116287114	chr7:116209234~116211511:-
BRCA	cis	rs721917	0.506	rs2493725	ENSG00000278616.1	BEND3P3	-4.18	3.11e-05	0.00225	-0.12	-0.13	Chronic obstructive pulmonary disease;	chr10:79898126	chr10:79682997~79685436:+
BRCA	cis	rs7475343	0.538	rs61854684	ENSG00000224034.1	RP11-445P17.8	-4.18	3.11e-05	0.00225	-0.24	-0.13	Intelligence;	chr10:5165720	chr10:5266033~5271236:-
BRCA	cis	rs7475343	0.538	rs61854687	ENSG00000224034.1	RP11-445P17.8	-4.18	3.11e-05	0.00225	-0.24	-0.13	Intelligence;	chr10:5171289	chr10:5266033~5271236:-
BRCA	cis	rs7475343	0.573	rs61854697	ENSG00000224034.1	RP11-445P17.8	-4.18	3.11e-05	0.00225	-0.24	-0.13	Intelligence;	chr10:5172504	chr10:5266033~5271236:-
BRCA	cis	rs6750047	0.649	rs4670231	ENSG00000235848.3	RMDN2-AS1	-4.18	3.11e-05	0.00225	-0.17	-0.13	Cutaneous malignant melanoma;Melanoma;	chr2:38040693	chr2:37949911~38067041:-
BRCA	cis	rs7267979	0.718	rs2983489	ENSG00000231081.1	RP4-760C5.3	-4.18	3.11e-05	0.00225	-0.17	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25263484	chr20:26008791~26010531:-
BRCA	cis	rs4664293	0.541	rs1863218	ENSG00000230783.1	AC009961.2	4.18	3.11e-05	0.00225	0.15	0.13	Monocyte percentage of white cells;	chr2:159512276	chr2:159689217~159690291:-
BRCA	cis	rs4650994	1	rs4354501	ENSG00000273384.1	RP5-1098D14.1	4.18	3.11e-05	0.00225	0.16	0.13	HDL cholesterol;HDL cholesterol levels;	chr1:178555461	chr1:178651706~178652282:+
BRCA	cis	rs10457838	0.783	rs10872631	ENSG00000236591.1	RP11-162J8.3	-4.18	3.11e-05	0.00225	-0.18	-0.13	Post-traumatic stress disorder;	chr6:149067559	chr6:149027700~149032573:-
BRCA	cis	rs17801127	0.748	rs78209888	ENSG00000231969.1	AC144449.1	4.18	3.11e-05	0.00225	0.23	0.13	Liver enzyme levels (alanine transaminase);	chr2:149668565	chr2:149587196~149848233:+
BRCA	cis	rs1005277	0.579	rs2008449	ENSG00000272983.1	RP11-508N22.12	-4.18	3.11e-05	0.00225	-0.14	-0.13	Extrinsic epigenetic age acceleration;	chr10:38125276	chr10:38137337~38144399:+
BRCA	cis	rs10829156	0.732	rs7075678	ENSG00000225527.1	RP11-383B4.4	-4.18	3.11e-05	0.00225	-0.18	-0.13	Sudden cardiac arrest;	chr10:18585174	chr10:18531849~18533336:-
BRCA	cis	rs11170468	1	rs11170489	ENSG00000257718.1	RP11-396F22.1	4.18	3.11e-05	0.00225	0.17	0.13	Body mass index;	chr12:39040175	chr12:38906451~38909592:+
BRCA	cis	rs897984	0.568	rs56083427	ENSG00000260911.2	RP11-196G11.2	4.18	3.11e-05	0.00225	0.13	0.13	Dementia with Lewy bodies;	chr16:30869977	chr16:31043150~31049868:+
BRCA	cis	rs7621331	1	rs17197552	ENSG00000239213.4	NCK1-AS1	4.18	3.12e-05	0.00225	0.15	0.13	Waist circumference adjusted for body mass index;	chr3:136003422	chr3:136841726~136862054:-
BRCA	cis	rs875971	0.545	rs11770063	ENSG00000232546.1	RP11-458F8.1	4.18	3.12e-05	0.00225	0.12	0.13	Aortic root size;	chr7:66318029	chr7:66848496~66858136:+
BRCA	cis	rs7772486	0.875	rs1125461	ENSG00000270638.1	RP3-466P17.1	4.18	3.12e-05	0.00226	0.15	0.13	Lobe attachment (rater-scored or self-reported);	chr6:146096517	chr6:145735570~145737218:+
BRCA	cis	rs983392	0.805	rs7116190	ENSG00000275344.1	MIR6503	-4.18	3.12e-05	0.00226	-0.13	-0.13	Alzheimer's disease (late onset);	chr11:60197519	chr11:60209071~60209156:-
BRCA	cis	rs7267979	1	rs7019	ENSG00000276952.1	RP5-965G21.6	4.18	3.12e-05	0.00226	0.16	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25297642	chr20:25284915~25285588:-
BRCA	cis	rs3812762	0.871	rs3844100	ENSG00000254860.4	TMEM9B-AS1	-4.18	3.12e-05	0.00226	-0.12	-0.13	Hypospadias;	chr11:8796261	chr11:8964675~8977527:+
BRCA	cis	rs9381040	0.655	rs2294696	ENSG00000161912.16	ADCY10P1	-4.18	3.12e-05	0.00226	-0.14	-0.13	Alzheimer's disease (late onset);	chr6:41069249	chr6:41101022~41140835:+
BRCA	cis	rs7308116	0.967	rs6539363	ENSG00000274395.1	RP11-554D14.8	-4.18	3.12e-05	0.00226	-0.14	-0.13	Pelvic organ prolapse (moderate/severe);	chr12:107807493	chr12:107835541~107836555:-
BRCA	cis	rs7267979	0.932	rs417130	ENSG00000277938.1	RP5-965G21.3	4.18	3.12e-05	0.00226	0.15	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25477684	chr20:25229150~25231933:+
BRCA	cis	rs7267979	0.932	rs372678	ENSG00000277938.1	RP5-965G21.3	4.18	3.12e-05	0.00226	0.15	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25484612	chr20:25229150~25231933:+
BRCA	cis	rs757081	0.648	rs214102	ENSG00000184669.7	OR7E14P	-4.18	3.12e-05	0.00226	-0.17	-0.13	Systolic blood pressure;	chr11:17266751	chr11:17013998~17053024:+
BRCA	cis	rs12571093	0.571	rs10823175	ENSG00000233590.1	RP11-153K11.3	4.18	3.12e-05	0.00226	0.2	0.13	Optic nerve measurement (disc area);	chr10:68306024	chr10:68233251~68242379:-
BRCA	cis	rs6480314	0.522	rs4746759	ENSG00000233590.1	RP11-153K11.3	4.18	3.12e-05	0.00226	0.2	0.13	Optic nerve measurement (disc area);	chr10:68306040	chr10:68233251~68242379:-
BRCA	cis	rs4650994	0.967	rs6681043	ENSG00000273384.1	RP5-1098D14.1	4.18	3.12e-05	0.00226	0.16	0.13	HDL cholesterol;HDL cholesterol levels;	chr1:178556822	chr1:178651706~178652282:+
BRCA	cis	rs8058578	1	rs3747481	ENSG00000260911.2	RP11-196G11.2	4.18	3.12e-05	0.00226	0.13	0.13	Multiple myeloma;	chr16:30655046	chr16:31043150~31049868:+
BRCA	cis	rs12887734	0.566	rs3742366	ENSG00000269910.1	RP11-73M18.10	4.18	3.12e-05	0.00226	0.14	0.13	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103732014	chr14:103694516~103695050:-
BRCA	cis	rs2625529	0.617	rs2306576	ENSG00000260037.4	CTD-2524L6.3	4.18	3.12e-05	0.00226	0.16	0.13	Red blood cell count;	chr15:71878345	chr15:71818396~71823384:+
BRCA	cis	rs10958369	0.836	rs2376145	ENSG00000260484.1	RP11-1081M5.2	4.18	3.12e-05	0.00226	0.14	0.13	Response to antineoplastic agents;	chr8:53486783	chr8:53388701~53390872:-
BRCA	cis	rs2625529	0.652	rs2930069	ENSG00000260037.4	CTD-2524L6.3	4.18	3.13e-05	0.00226	0.16	0.13	Red blood cell count;	chr15:71934636	chr15:71818396~71823384:+
BRCA	cis	rs1656368	0.726	rs55765541	ENSG00000279311.1	RP11-170K4.2	4.18	3.13e-05	0.00226	0.17	0.13	Lobe attachment (rater-scored or self-reported);	chr3:158495758	chr3:158869898~158871821:+
BRCA	cis	rs62244186	0.566	rs55852922	ENSG00000233509.2	ZNF197-AS1	4.18	3.13e-05	0.00226	0.16	0.13	Depressive symptoms;	chr3:44784696	chr3:44617128~44624797:-
BRCA	cis	rs62244186	0.566	rs55901755	ENSG00000233509.2	ZNF197-AS1	4.18	3.13e-05	0.00226	0.16	0.13	Depressive symptoms;	chr3:44793215	chr3:44617128~44624797:-
BRCA	cis	rs6686842	1	rs6663565	ENSG00000235358.1	RP11-399E6.1	-4.18	3.13e-05	0.00226	-0.16	-0.13	Height;	chr1:41098016	chr1:41242373~41284861:+
BRCA	cis	rs1077773	0.531	rs11766278	ENSG00000237773.4	AC003075.4	-4.18	3.13e-05	0.00226	-0.17	-0.13	Ulcerative colitis;Inflammatory bowel disease;	chr7:17410907	chr7:17279834~17299357:-
BRCA	cis	rs6671200	0.79	rs640527	ENSG00000235501.4	RP4-639F20.1	4.18	3.13e-05	0.00226	0.27	0.13	Stearic acid (18:0) levels;	chr1:95240059	chr1:94927566~94963270:+
BRCA	cis	rs1722141	0.535	rs788773	ENSG00000229628.1	AC073115.7	4.18	3.13e-05	0.00226	0.17	0.13	Sitting height ratio;	chr7:46012657	chr7:45990905~46000898:+
BRCA	cis	rs6430585	0.527	rs62168836	ENSG00000224043.6	CCNT2-AS1	-4.18	3.13e-05	0.00226	-0.22	-0.13	Corneal structure;	chr2:135705547	chr2:134735464~134918710:-
BRCA	cis	rs4560672	0.627	rs1744170	ENSG00000218226.1	TATDN2P2	-4.18	3.13e-05	0.00226	-0.19	-0.13	Smoking quantity;	chr6:158086808	chr6:158609706~158621636:-
BRCA	cis	rs3892630	0.62	rs10413279	ENSG00000267567.1	CTD-2538C1.3	4.18	3.13e-05	0.00226	0.18	0.13	Red blood cell traits;	chr19:32691840	chr19:32718298~32719595:-
BRCA	cis	rs11633958	1	rs11633958	ENSG00000261762.1	RP11-650L12.2	-4.18	3.13e-05	0.00226	-0.16	-0.13	Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78569722	chr15:78589123~78591276:-
BRCA	cis	rs2835345	0.563	rs12482140	ENSG00000233818.1	AP000695.4	4.18	3.13e-05	0.00226	0.14	0.13	Pulmonary function;	chr21:36451735	chr21:36445731~36532408:+
BRCA	cis	rs2835345	0.528	rs73204243	ENSG00000233818.1	AP000695.4	4.18	3.13e-05	0.00226	0.14	0.13	Pulmonary function;	chr21:36451776	chr21:36445731~36532408:+
BRCA	cis	rs2835345	0.595	rs78237434	ENSG00000233818.1	AP000695.4	4.18	3.13e-05	0.00226	0.14	0.13	Pulmonary function;	chr21:36451826	chr21:36445731~36532408:+
BRCA	cis	rs1371614	0.566	rs10184824	ENSG00000272148.1	RP11-195B17.1	-4.18	3.13e-05	0.00226	-0.14	-0.13	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26955084	chr2:27062428~27062907:-
BRCA	cis	rs7267979	0.727	rs2474765	ENSG00000231081.1	RP4-760C5.3	-4.18	3.13e-05	0.00227	-0.17	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25265314	chr20:26008791~26010531:-
BRCA	cis	rs853679	0.517	rs9357063	ENSG00000216901.1	AL022393.7	4.18	3.13e-05	0.00227	0.18	0.13	Depression;	chr6:28092227	chr6:28176188~28176674:+
BRCA	cis	rs875971	0.964	rs778721	ENSG00000229180.5	GS1-124K5.11	4.18	3.13e-05	0.00227	0.11	0.13	Aortic root size;	chr7:66380410	chr7:66526088~66542624:-
BRCA	cis	rs11239930	0.517	rs590286	ENSG00000278811.3	LINC00624	4.18	3.13e-05	0.00227	0.15	0.13	AIDS progression;	chr1:147074056	chr1:147258885~147517875:-
BRCA	cis	rs7267979	1	rs4813563	ENSG00000125804.12	FAM182A	4.18	3.13e-05	0.00227	0.17	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25384704	chr20:26054655~26086917:+
BRCA	cis	rs7267979	0.966	rs6037103	ENSG00000125804.12	FAM182A	4.18	3.13e-05	0.00227	0.17	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25388459	chr20:26054655~26086917:+
BRCA	cis	rs4143844	0.867	rs12901735	ENSG00000259251.2	RP11-643M14.1	4.18	3.13e-05	0.00227	0.32	0.13	Bipolar disorder and schizophrenia;	chr15:61951360	chr15:62060503~62062434:+
BRCA	cis	rs11098499	0.909	rs28668716	ENSG00000260404.2	RP11-384K6.6	4.18	3.13e-05	0.00227	0.12	0.13	Corneal astigmatism;	chr4:119388720	chr4:118591773~118633729:+
BRCA	cis	rs7119	0.623	rs11637932	ENSG00000259362.2	RP11-307C19.1	-4.18	3.13e-05	0.00227	-0.18	-0.13	Type 2 diabetes;	chr15:77555011	chr15:77525540~77534110:+
BRCA	cis	rs4925386	0.681	rs2427295	ENSG00000275437.1	RP5-908M14.10	4.18	3.13e-05	0.00227	0.14	0.13	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62352375	chr20:62402236~62405935:-
BRCA	cis	rs9982086	0.793	rs74335692	ENSG00000260583.1	AP000223.42	-4.18	3.13e-05	0.00227	-0.32	-0.13	Carboplatin disposition in epthelial ovarian cancer;	chr21:25619097	chr21:25582770~25583326:-
BRCA	cis	rs2274273	1	rs8011834	ENSG00000259318.1	RP11-454L9.2	4.18	3.14e-05	0.00227	0.11	0.13	Protein biomarker;	chr14:55159259	chr14:55394940~55395233:-
BRCA	cis	rs4478858	0.698	rs10914370	ENSG00000223907.1	LINC01226	-4.18	3.14e-05	0.00227	-0.16	-0.13	Alcohol dependence;	chr1:31382108	chr1:31518435~31524245:+
BRCA	cis	rs4143844	0.867	rs62009109	ENSG00000259251.2	RP11-643M14.1	4.18	3.14e-05	0.00227	0.32	0.13	Bipolar disorder and schizophrenia;	chr15:61927032	chr15:62060503~62062434:+
BRCA	cis	rs7520050	0.933	rs6680211	ENSG00000234329.1	RP11-767N6.2	-4.18	3.14e-05	0.00227	-0.12	-0.13	Reticulocyte count;Red blood cell count;	chr1:45849335	chr1:45651039~45651826:-
BRCA	cis	rs10191773	0.589	rs72833410	ENSG00000243389.1	AC012442.5	4.18	3.14e-05	0.00227	0.25	0.13	Yeast infection;	chr2:112296542	chr2:112589040~112614431:+
BRCA	cis	rs7267979	1	rs6050609	ENSG00000277938.1	RP5-965G21.3	-4.18	3.14e-05	0.00227	-0.15	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25431115	chr20:25229150~25231933:+
BRCA	cis	rs10208649	1	rs10188834	ENSG00000233266.1	HMGB1P31	4.18	3.14e-05	0.00227	0.3	0.13	Body mass index;	chr2:53937236	chr2:54051334~54051760:+
BRCA	cis	rs13118159	0.801	rs13147602	ENSG00000254094.1	AC078852.1	-4.18	3.14e-05	0.00227	-0.14	-0.13	Longevity;	chr4:1338387	chr4:1356581~1358075:+
BRCA	cis	rs7260598	0.642	rs10425299	ENSG00000268442.1	CTD-2027I19.2	4.18	3.14e-05	0.00227	0.2	0.13	Response to taxane treatment (placlitaxel);	chr19:23995757	chr19:24162370~24163425:-
BRCA	cis	rs4218	0.597	rs12438208	ENSG00000259732.1	RP11-59H7.3	-4.18	3.14e-05	0.00227	-0.16	-0.13	Social communication problems;	chr15:59057715	chr15:59121034~59133250:+
BRCA	cis	rs2411233	1	rs7166250	ENSG00000259278.1	RP11-62C7.2	4.18	3.14e-05	0.00227	0.15	0.13	Platelet count;	chr15:38990900	chr15:39019233~39024918:+
BRCA	cis	rs1865760	0.929	rs1816546	ENSG00000272462.2	U91328.19	-4.18	3.14e-05	0.00227	-0.16	-0.13	Height;	chr6:25938024	chr6:25992662~26001775:+
BRCA	cis	rs6545883	0.524	rs811871	ENSG00000273302.1	RP11-493E12.2	-4.18	3.14e-05	0.00227	-0.11	-0.13	Tuberculosis;	chr2:61350814	chr2:61199979~61200769:+
BRCA	cis	rs4787491	0.765	rs4788216	ENSG00000183604.13	SMG1P5	-4.18	3.14e-05	0.00227	-0.12	-0.13	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30036756	chr16:30267553~30335374:-
BRCA	cis	rs2243480	1	rs34815098	ENSG00000222364.1	RNU6-96P	-4.18	3.14e-05	0.00227	-0.23	-0.13	Diabetic kidney disease;	chr7:65827267	chr7:66395191~66395286:+
BRCA	cis	rs2243480	1	rs35735127	ENSG00000222364.1	RNU6-96P	-4.18	3.14e-05	0.00227	-0.23	-0.13	Diabetic kidney disease;	chr7:65835436	chr7:66395191~66395286:+
BRCA	cis	rs2243480	0.901	rs35256305	ENSG00000222364.1	RNU6-96P	-4.18	3.14e-05	0.00227	-0.23	-0.13	Diabetic kidney disease;	chr7:65841418	chr7:66395191~66395286:+
BRCA	cis	rs2243480	0.803	rs34004500	ENSG00000222364.1	RNU6-96P	-4.18	3.14e-05	0.00227	-0.23	-0.13	Diabetic kidney disease;	chr7:65847191	chr7:66395191~66395286:+
BRCA	cis	rs2243480	1	rs35825738	ENSG00000222364.1	RNU6-96P	-4.18	3.14e-05	0.00227	-0.23	-0.13	Diabetic kidney disease;	chr7:65853040	chr7:66395191~66395286:+
BRCA	cis	rs6067053	0.671	rs6125600	ENSG00000227431.4	CSE1L-AS1	4.18	3.14e-05	0.00227	0.16	0.13	Intelligence (multi-trait analysis);	chr20:49256363	chr20:49040463~49046044:-
BRCA	cis	rs3113494	0.902	rs3113493	ENSG00000251411.1	RP11-397E7.4	4.18	3.14e-05	0.00227	0.14	0.13	Amyotrophic lateral sclerosis;	chr4:86911018	chr4:86913266~86914817:-
BRCA	cis	rs9840812	0.769	rs489398	ENSG00000239213.4	NCK1-AS1	4.18	3.14e-05	0.00227	0.18	0.13	Fibrinogen levels;	chr3:136276656	chr3:136841726~136862054:-
BRCA	cis	rs1722141	0.571	rs788771	ENSG00000229628.1	AC073115.7	4.18	3.14e-05	0.00227	0.17	0.13	Sitting height ratio;	chr7:46015281	chr7:45990905~46000898:+
BRCA	cis	rs7826238	0.539	rs2945891	ENSG00000233609.3	RP11-62H7.2	4.18	3.15e-05	0.00227	0.12	0.13	Systolic blood pressure;	chr8:8297953	chr8:8961200~8979025:+
BRCA	cis	rs6012564	1	rs3092411	ENSG00000222365.1	SNORD12B	-4.18	3.15e-05	0.00227	-0.13	-0.13	Anger;	chr20:49074054	chr20:49280319~49280409:+
BRCA	cis	rs7308116	1	rs6539366	ENSG00000274395.1	RP11-554D14.8	-4.18	3.15e-05	0.00227	-0.14	-0.13	Pelvic organ prolapse (moderate/severe);	chr12:107807799	chr12:107835541~107836555:-
BRCA	cis	rs1667255	1	rs7243588	ENSG00000266521.1	RP11-650P15.1	4.18	3.15e-05	0.00228	0.15	0.13	Retinol levels;	chr18:31580649	chr18:31496645~31497195:-
BRCA	cis	rs372883	0.648	rs382732	ENSG00000176054.6	RPL23P2	4.18	3.15e-05	0.00228	0.14	0.13	Pancreatic cancer;	chr21:29346689	chr21:28997613~28998033:-
BRCA	cis	rs875971	0.545	rs73376394	ENSG00000232559.3	GS1-124K5.12	4.18	3.15e-05	0.00228	0.17	0.13	Aortic root size;	chr7:66172694	chr7:66554588~66576923:-
BRCA	cis	rs6088580	0.634	rs1205345	ENSG00000276073.1	RP5-1125A11.7	4.18	3.15e-05	0.00228	0.14	0.13	Glomerular filtration rate (creatinine);	chr20:34326893	chr20:33985617~33988989:-
BRCA	cis	rs8180040	0.764	rs4683324	ENSG00000276925.1	RP11-708J19.3	-4.18	3.15e-05	0.00228	-0.14	-0.13	Colorectal cancer;	chr3:47209794	chr3:47469777~47469987:+
BRCA	cis	rs6545883	0.965	rs7591345	ENSG00000270820.4	RP11-355B11.2	4.18	3.15e-05	0.00228	0.15	0.13	Tuberculosis;	chr2:61502506	chr2:61471188~61484130:+
BRCA	cis	rs853679	0.517	rs4711164	ENSG00000216901.1	AL022393.7	4.18	3.15e-05	0.00228	0.19	0.13	Depression;	chr6:28147378	chr6:28176188~28176674:+
BRCA	cis	rs853679	0.517	rs4711165	ENSG00000216901.1	AL022393.7	4.18	3.15e-05	0.00228	0.19	0.13	Depression;	chr6:28147406	chr6:28176188~28176674:+
BRCA	cis	rs853679	0.517	rs4713148	ENSG00000216901.1	AL022393.7	4.18	3.15e-05	0.00228	0.19	0.13	Depression;	chr6:28148143	chr6:28176188~28176674:+
BRCA	cis	rs853679	0.517	rs9348794	ENSG00000216901.1	AL022393.7	4.18	3.15e-05	0.00228	0.19	0.13	Depression;	chr6:28149979	chr6:28176188~28176674:+
BRCA	cis	rs853679	0.517	rs9295758	ENSG00000216901.1	AL022393.7	4.18	3.15e-05	0.00228	0.19	0.13	Depression;	chr6:28152885	chr6:28176188~28176674:+
BRCA	cis	rs853679	0.517	rs17774663	ENSG00000216901.1	AL022393.7	4.18	3.15e-05	0.00228	0.19	0.13	Depression;	chr6:28153120	chr6:28176188~28176674:+
BRCA	cis	rs794185	0.625	rs304088	ENSG00000231249.1	ITPR1-AS1	-4.18	3.15e-05	0.00228	-0.14	-0.13	Multiple sclerosis--Brain Glutamate Levels;	chr3:4479513	chr3:4490891~4493163:-
BRCA	cis	rs11633886	0.528	rs2247958	ENSG00000273972.1	CTD-2306A12.1	4.18	3.15e-05	0.00228	0.15	0.13	Diisocyanate-induced asthma;	chr15:45807336	chr15:45702640~45703183:+
BRCA	cis	rs4237845	0.513	rs7134797	ENSG00000257159.1	RP11-58A17.3	4.18	3.15e-05	0.00228	0.16	0.13	Intelligence (multi-trait analysis);	chr12:57870069	chr12:57967058~57968399:+
BRCA	cis	rs748404	0.666	rs7176923	ENSG00000166763.7	STRCP1	4.18	3.15e-05	0.00228	0.19	0.13	Lung cancer;	chr15:43317679	chr15:43699488~43718184:-
BRCA	cis	rs12908161	0.515	rs12907646	ENSG00000259295.5	CSPG4P12	4.18	3.15e-05	0.00228	0.19	0.13	Schizophrenia;	chr15:84860265	chr15:85191438~85213905:+
BRCA	cis	rs6545883	0.868	rs6752938	ENSG00000270820.4	RP11-355B11.2	4.18	3.16e-05	0.00228	0.15	0.13	Tuberculosis;	chr2:61614453	chr2:61471188~61484130:+
BRCA	cis	rs7177699	0.557	rs8026598	ENSG00000261143.1	ADAMTS7P3	-4.18	3.16e-05	0.00228	-0.15	-0.13	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78820596	chr15:77976042~77993057:+
BRCA	cis	rs1048886	0.872	rs17634272	ENSG00000271967.1	RP11-134K13.4	-4.18	3.16e-05	0.00228	-0.19	-0.13	Type 2 diabetes;	chr6:70436792	chr6:70596438~70596980:+
BRCA	cis	rs1048886	0.872	rs76730904	ENSG00000271967.1	RP11-134K13.4	-4.18	3.16e-05	0.00228	-0.19	-0.13	Type 2 diabetes;	chr6:70440983	chr6:70596438~70596980:+
BRCA	cis	rs1048886	0.872	rs76917369	ENSG00000271967.1	RP11-134K13.4	-4.18	3.16e-05	0.00228	-0.19	-0.13	Type 2 diabetes;	chr6:70443516	chr6:70596438~70596980:+
BRCA	cis	rs1048886	0.938	rs12528385	ENSG00000271967.1	RP11-134K13.4	-4.18	3.16e-05	0.00228	-0.19	-0.13	Type 2 diabetes;	chr6:70448582	chr6:70596438~70596980:+
BRCA	cis	rs1048886	0.808	rs76320501	ENSG00000271967.1	RP11-134K13.4	-4.18	3.16e-05	0.00228	-0.19	-0.13	Type 2 diabetes;	chr6:70449586	chr6:70596438~70596980:+
BRCA	cis	rs17772222	0.876	rs12436982	ENSG00000258789.1	RP11-507K2.3	-4.18	3.16e-05	0.00228	-0.16	-0.13	Coronary artery calcification;	chr14:88689862	chr14:88551597~88552493:+
BRCA	cis	rs2835345	0.511	rs2835356	ENSG00000279365.1	KB-176G8.1	4.18	3.16e-05	0.00228	0.18	0.13	Pulmonary function;	chr21:36444900	chr21:36485867~36487760:+
BRCA	cis	rs950776	0.684	rs11637635	ENSG00000279373.1	RP11-650L12.4	-4.18	3.16e-05	0.00228	-0.16	-0.13	Sudden cardiac arrest;	chr15:78584808	chr15:78537681~78538946:+
BRCA	cis	rs4907240	0.961	rs6759099	ENSG00000230606.9	AC159540.1	4.18	3.16e-05	0.00228	0.16	0.13	Event-related brain oscillations;	chr2:96601523	chr2:97416165~97433527:-
BRCA	cis	rs4907240	0.961	rs6749159	ENSG00000230606.9	AC159540.1	4.18	3.16e-05	0.00228	0.16	0.13	Event-related brain oscillations;	chr2:96601556	chr2:97416165~97433527:-
BRCA	cis	rs4907240	0.961	rs62154845	ENSG00000230606.9	AC159540.1	4.18	3.16e-05	0.00228	0.16	0.13	Event-related brain oscillations;	chr2:96601907	chr2:97416165~97433527:-
BRCA	cis	rs3845817	0.843	rs11678288	ENSG00000237979.1	AC007389.1	4.18	3.16e-05	0.00228	0.15	0.13	Bipolar disorder;	chr2:65547553	chr2:65500993~65502138:-
BRCA	cis	rs67981189	0.574	rs2526848	ENSG00000258571.1	PTTG4P	4.18	3.16e-05	0.00229	0.14	0.13	Schizophrenia;	chr14:70953025	chr14:71085482~71085833:-
BRCA	cis	rs7771547	0.603	rs7344	ENSG00000224666.3	RP1-50J22.4	4.18	3.16e-05	0.00229	0.16	0.13	Platelet distribution width;	chr6:36602589	chr6:36386831~36393462:+
BRCA	cis	rs875971	0.502	rs2946580	ENSG00000273142.1	RP11-458F8.4	-4.18	3.17e-05	0.00229	-0.13	-0.13	Aortic root size;	chr7:66066855	chr7:66902857~66906297:+
BRCA	cis	rs4664293	0.967	rs2357526	ENSG00000226266.5	AC009961.3	4.18	3.17e-05	0.00229	0.16	0.13	Monocyte percentage of white cells;	chr2:159668085	chr2:159670708~159712435:-
BRCA	cis	rs12681366	0.537	rs6999976	ENSG00000253175.1	RP11-267M23.6	4.18	3.17e-05	0.00229	0.15	0.13	Nonsyndromic cleft lip with cleft palate;	chr8:94470194	chr8:94565036~94565715:+
BRCA	cis	rs8114671	0.562	rs6058120	ENSG00000126005.14	MMP24-AS1	-4.18	3.17e-05	0.00229	-0.15	-0.13	Height;	chr20:34815026	chr20:35216462~35278131:-
BRCA	cis	rs1167827	1	rs1167827	ENSG00000205583.12	STAG3L1	4.18	3.17e-05	0.00229	0.15	0.13	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75533848	chr7:75359194~75395383:+
BRCA	cis	rs6723162	0.51	rs959053	ENSG00000237751.2	LINC01143	-4.18	3.17e-05	0.00229	-0.18	-0.13	Neurocognitive impairment in HIV-1 infection (dichotomous);	chr2:70928442	chr2:70887871~70889959:+
BRCA	cis	rs4499344	0.73	rs434020	ENSG00000267475.1	CTD-2538C1.2	4.18	3.17e-05	0.00229	0.16	0.13	Mean platelet volume;	chr19:32613164	chr19:32687089~32691750:-
BRCA	cis	rs4499344	0.696	rs398990	ENSG00000267475.1	CTD-2538C1.2	4.18	3.17e-05	0.00229	0.16	0.13	Mean platelet volume;	chr19:32613338	chr19:32687089~32691750:-
BRCA	cis	rs4499344	0.73	rs369859	ENSG00000267475.1	CTD-2538C1.2	4.18	3.17e-05	0.00229	0.16	0.13	Mean platelet volume;	chr19:32613399	chr19:32687089~32691750:-
BRCA	cis	rs9467773	0.572	rs13213953	ENSG00000241549.7	GUSBP2	4.18	3.17e-05	0.00229	0.15	0.13	Intelligence (multi-trait analysis);	chr6:26594306	chr6:26871484~26956554:-
BRCA	cis	rs3824867	0.92	rs10742805	ENSG00000280615.1	Y_RNA	-4.18	3.17e-05	0.00229	-0.16	-0.13	Mean corpuscular hemoglobin;	chr11:47433150	chr11:47614898~47614994:-
BRCA	cis	rs8113308	0.515	rs55866828	ENSG00000269483.1	AC006272.1	4.18	3.17e-05	0.00229	0.3	0.13	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51938332	chr19:51839924~51843324:-
BRCA	cis	rs4499344	0.768	rs10411319	ENSG00000267475.1	CTD-2538C1.2	4.18	3.17e-05	0.00229	0.16	0.13	Mean platelet volume;	chr19:32611899	chr19:32687089~32691750:-
BRCA	cis	rs9308731	0.64	rs10204044	ENSG00000230499.1	AC108463.1	4.18	3.17e-05	0.00229	0.17	0.13	Chronic lymphocytic leukemia;	chr2:111137967	chr2:111195963~111206494:+
BRCA	cis	rs1910358	0.69	rs4701407	ENSG00000248874.4	C5orf17	-4.18	3.17e-05	0.00229	-0.17	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23933763	chr5:23951348~24178263:+
BRCA	cis	rs1910358	0.69	rs10052352	ENSG00000248874.4	C5orf17	-4.18	3.17e-05	0.00229	-0.17	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23946440	chr5:23951348~24178263:+
BRCA	cis	rs11098499	0.955	rs11944880	ENSG00000260091.1	RP11-33B1.4	4.18	3.17e-05	0.00229	0.11	0.13	Corneal astigmatism;	chr4:119238179	chr4:119409333~119410233:+
BRCA	cis	rs875971	0.658	rs432667	ENSG00000229180.5	GS1-124K5.11	4.18	3.17e-05	0.00229	0.11	0.13	Aortic root size;	chr7:66049646	chr7:66526088~66542624:-
BRCA	cis	rs10504130	1	rs16916865	ENSG00000253844.1	RP11-546K22.1	-4.18	3.17e-05	0.00229	-0.21	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr8:51833290	chr8:51961458~52022974:+
BRCA	cis	rs2562456	0.754	rs112195516	ENSG00000268658.4	LINC00664	4.18	3.17e-05	0.00229	0.22	0.13	Pain;	chr19:21410849	chr19:21483374~21503238:+
BRCA	cis	rs12612619	0.732	rs10865461	ENSG00000272148.1	RP11-195B17.1	4.18	3.17e-05	0.00229	0.14	0.13	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27069783	chr2:27062428~27062907:-
BRCA	cis	rs17597773	0.638	rs4143773	ENSG00000257551.1	HLX-AS1	-4.18	3.17e-05	0.00229	-0.15	-0.13	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220814900	chr1:220832763~220880140:-
BRCA	cis	rs6449502	0.541	rs9291707	ENSG00000251279.1	CTC-436P18.1	4.18	3.17e-05	0.00229	0.26	0.13	Mean platelet volume;	chr5:61180399	chr5:61162070~61232040:+
BRCA	cis	rs1153858	0.943	rs4774580	ENSG00000275672.1	GATM-AS1	-4.18	3.17e-05	0.00229	-0.16	-0.13	Homoarginine levels;	chr15:45359888	chr15:45378700~45380123:+
BRCA	cis	rs1008375	0.932	rs6449321	ENSG00000249502.1	AC006160.5	-4.18	3.17e-05	0.00229	-0.15	-0.13	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17642849	chr4:17587467~17614571:-
BRCA	cis	rs516805	0.667	rs2606609	ENSG00000279114.1	RP3-425C14.5	4.18	3.17e-05	0.00229	0.16	0.13	Lymphocyte counts;	chr6:122190346	chr6:122471923~122484161:+
BRCA	cis	rs9307551	0.576	rs13104474	ENSG00000250334.4	LINC00989	-4.18	3.17e-05	0.00229	-0.16	-0.13	Refractive error;	chr4:79618576	chr4:79492416~79576460:+
BRCA	cis	rs2243480	1	rs4718270	ENSG00000275400.1	RP4-756H11.5	4.18	3.18e-05	0.00229	0.23	0.13	Diabetic kidney disease;	chr7:65737415	chr7:66553805~66554199:-
BRCA	cis	rs8180040	0.764	rs62246375	ENSG00000280667.1	Y_RNA	-4.18	3.18e-05	0.00229	-0.14	-0.13	Colorectal cancer;	chr3:46972974	chr3:47501083~47501182:+
BRCA	cis	rs2242116	0.796	rs9852082	ENSG00000276925.1	RP11-708J19.3	-4.18	3.18e-05	0.00229	-0.16	-0.13	Birth weight;	chr3:46930887	chr3:47469777~47469987:+
BRCA	cis	rs56322409	1	rs2296691	ENSG00000226688.5	ENTPD1-AS1	4.18	3.18e-05	0.00229	0.15	0.13	Blood metabolite levels;	chr10:95611232	chr10:95753206~96090238:-
BRCA	cis	rs11098499	0.754	rs1849457	ENSG00000225892.3	RP11-384K6.2	4.18	3.18e-05	0.00229	0.13	0.13	Corneal astigmatism;	chr4:119333200	chr4:118632274~118634759:+
BRCA	cis	rs2554380	0.843	rs2562783	ENSG00000230373.7	GOLGA6L5P	-4.18	3.18e-05	0.00229	-0.18	-0.13	Height;	chr15:83719174	chr15:84507885~84516814:-
BRCA	cis	rs2439831	0.85	rs7168158	ENSG00000206991.1	RNU6-610P	-4.18	3.18e-05	0.00229	-0.21	-0.13	Lung cancer in ever smokers;	chr15:43758178	chr15:43637632~43637738:-
BRCA	cis	rs4950322	0.542	rs28381210	ENSG00000237188.3	RP11-337C18.8	4.18	3.18e-05	0.00229	0.16	0.13	Protein quantitative trait loci;	chr1:147201925	chr1:147172771~147211568:+
BRCA	cis	rs1048886	0.872	rs7756774	ENSG00000271967.1	RP11-134K13.4	-4.18	3.18e-05	0.00229	-0.18	-0.13	Type 2 diabetes;	chr6:70543057	chr6:70596438~70596980:+
BRCA	cis	rs4718428	1	rs1830070	ENSG00000222364.1	RNU6-96P	-4.18	3.18e-05	0.00229	-0.15	-0.13	Corneal structure;	chr7:66884684	chr7:66395191~66395286:+
BRCA	cis	rs11742741	0.837	rs72745762	ENSG00000248874.4	C5orf17	-4.18	3.18e-05	0.0023	-0.17	-0.13	Educational attainment;	chr5:24117377	chr5:23951348~24178263:+
BRCA	cis	rs1910358	0.554	rs2357121	ENSG00000248874.4	C5orf17	-4.18	3.18e-05	0.0023	-0.18	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23749853	chr5:23951348~24178263:+
BRCA	cis	rs1910358	0.554	rs2357122	ENSG00000248874.4	C5orf17	-4.18	3.18e-05	0.0023	-0.18	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23749951	chr5:23951348~24178263:+
BRCA	cis	rs1910358	0.554	rs1851145	ENSG00000248874.4	C5orf17	-4.18	3.18e-05	0.0023	-0.18	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23750291	chr5:23951348~24178263:+
BRCA	cis	rs4925540	0.962	rs4971315	ENSG00000215796.3	RP11-551G24.2	-4.18	3.18e-05	0.0023	-0.15	-0.13	Response to taxane treatment (docetaxel);	chr1:247046674	chr1:247042791~247044021:+
BRCA	cis	rs4925540	1	rs61852630	ENSG00000215796.3	RP11-551G24.2	-4.18	3.18e-05	0.0023	-0.15	-0.13	Response to taxane treatment (docetaxel);	chr1:247046891	chr1:247042791~247044021:+
BRCA	cis	rs4925540	1	rs4971316	ENSG00000215796.3	RP11-551G24.2	-4.18	3.18e-05	0.0023	-0.15	-0.13	Response to taxane treatment (docetaxel);	chr1:247047601	chr1:247042791~247044021:+
BRCA	cis	rs4925540	0.963	rs61852631	ENSG00000215796.3	RP11-551G24.2	-4.18	3.18e-05	0.0023	-0.15	-0.13	Response to taxane treatment (docetaxel);	chr1:247047665	chr1:247042791~247044021:+
BRCA	cis	rs4925540	1	rs4971319	ENSG00000215796.3	RP11-551G24.2	-4.18	3.18e-05	0.0023	-0.15	-0.13	Response to taxane treatment (docetaxel);	chr1:247048263	chr1:247042791~247044021:+
BRCA	cis	rs6997458	0.576	rs1995057	ENSG00000258256.1	RP11-219B4.5	4.18	3.18e-05	0.0023	0.15	0.13	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85336076	chr8:85222446~85245717:-
BRCA	cis	rs7520050	0.933	rs6666743	ENSG00000234329.1	RP11-767N6.2	-4.18	3.18e-05	0.0023	-0.12	-0.13	Reticulocyte count;Red blood cell count;	chr1:45845603	chr1:45651039~45651826:-
BRCA	cis	rs4650943	0.565	rs352333	ENSG00000227740.1	RP11-318C24.2	-4.18	3.18e-05	0.0023	-0.13	-0.13	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in inactive individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr1:176269197	chr1:175904762~175920513:-
BRCA	cis	rs4650943	0.565	rs352331	ENSG00000227740.1	RP11-318C24.2	-4.18	3.18e-05	0.0023	-0.13	-0.13	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in inactive individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr1:176270393	chr1:175904762~175920513:-
BRCA	cis	rs36051895	0.559	rs7850228	ENSG00000236254.1	MTND4P14	4.18	3.18e-05	0.0023	0.15	0.13	Pediatric autoimmune diseases;	chr9:5210671	chr9:5107937~5109290:+
BRCA	cis	rs7267979	1	rs6107033	ENSG00000125804.12	FAM182A	4.18	3.18e-05	0.0023	0.17	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25382955	chr20:26054655~26086917:+
BRCA	cis	rs140330585	1	rs140330585	ENSG00000261762.1	RP11-650L12.2	-4.18	3.18e-05	0.0023	-0.16	-0.13	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1/FVC ratio in COPD;	chr15:78574103	chr15:78589123~78591276:-
BRCA	cis	rs7260598	0.685	rs73021422	ENSG00000268442.1	CTD-2027I19.2	4.18	3.18e-05	0.0023	0.21	0.13	Response to taxane treatment (placlitaxel);	chr19:24082919	chr19:24162370~24163425:-
BRCA	cis	rs4356203	0.905	rs10832733	ENSG00000272034.1	SNORD14A	-4.18	3.18e-05	0.0023	-0.13	-0.13	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17089725	chr11:17074654~17074744:-
BRCA	cis	rs6496044	0.548	rs7163032	ENSG00000202081.1	RNU6-1280P	4.18	3.18e-05	0.0023	0.15	0.13	Interstitial lung disease;	chr15:85529188	chr15:85651522~85651628:-
BRCA	cis	rs2070615	0.833	rs6580695	ENSG00000258017.1	RP11-386G11.10	-4.18	3.19e-05	0.0023	-0.16	-0.13	Bipolar disorder;	chr12:48807424	chr12:49127782~49147869:+
BRCA	cis	rs7561149	0.966	rs12471428	ENSG00000270574.1	RP11-171I2.2	4.18	3.19e-05	0.0023	0.17	0.13	QT interval;	chr2:178822792	chr2:178578790~178580906:+
BRCA	cis	rs8040855	0.599	rs6496800	ENSG00000259762.1	RP11-158M2.4	-4.18	3.19e-05	0.0023	-0.15	-0.13	Bulimia nervosa;	chr15:85185055	chr15:85750336~85752901:-
BRCA	cis	rs721917	0.506	rs2758556	ENSG00000242600.5	MBL1P	-4.18	3.19e-05	0.0023	-0.16	-0.13	Chronic obstructive pulmonary disease;	chr10:79931229	chr10:79904898~79950336:+
BRCA	cis	rs9818758	0.545	rs11717978	ENSG00000225399.4	RP11-3B7.1	-4.18	3.19e-05	0.0023	-0.23	-0.13	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:48931603	chr3:49260085~49261316:+
BRCA	cis	rs9818758	0.556	rs13086240	ENSG00000225399.4	RP11-3B7.1	-4.18	3.19e-05	0.0023	-0.23	-0.13	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:48963976	chr3:49260085~49261316:+
BRCA	cis	rs6700559	0.679	rs7520407	ENSG00000260088.1	RP11-92G12.3	4.18	3.19e-05	0.0023	0.16	0.13	Coronary artery disease;	chr1:200686600	chr1:200669507~200694250:+
BRCA	cis	rs6700559	0.679	rs12076946	ENSG00000260088.1	RP11-92G12.3	4.18	3.19e-05	0.0023	0.16	0.13	Coronary artery disease;	chr1:200693707	chr1:200669507~200694250:+
BRCA	cis	rs1910358	0.664	rs7721658	ENSG00000248874.4	C5orf17	-4.18	3.19e-05	0.0023	-0.17	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23935565	chr5:23951348~24178263:+
BRCA	cis	rs7520050	0.966	rs10789475	ENSG00000234329.1	RP11-767N6.2	-4.18	3.19e-05	0.0023	-0.12	-0.13	Reticulocyte count;Red blood cell count;	chr1:45838505	chr1:45651039~45651826:-
BRCA	cis	rs6546847	0.531	rs2567601	ENSG00000163016.8	ALMS1P	4.18	3.19e-05	0.0023	0.23	0.13	Urinary metabolites (H-NMR features);	chr2:73758040	chr2:73644919~73685576:+
BRCA	cis	rs801193	0.66	rs2659914	ENSG00000229180.5	GS1-124K5.11	4.18	3.19e-05	0.0023	0.11	0.13	Aortic root size;	chr7:66691927	chr7:66526088~66542624:-
BRCA	cis	rs801193	0.591	rs2707839	ENSG00000229180.5	GS1-124K5.11	4.18	3.19e-05	0.0023	0.11	0.13	Aortic root size;	chr7:66728097	chr7:66526088~66542624:-
BRCA	cis	rs4143844	0.867	rs34486946	ENSG00000259251.2	RP11-643M14.1	4.18	3.19e-05	0.0023	0.32	0.13	Bipolar disorder and schizophrenia;	chr15:61929355	chr15:62060503~62062434:+
BRCA	cis	rs16846053	0.792	rs62190660	ENSG00000227403.1	AC009299.3	4.18	3.19e-05	0.0023	0.33	0.13	Blood osmolality (transformed sodium);	chr2:161777194	chr2:161244739~161249050:+
BRCA	cis	rs4237845	0.636	rs11172371	ENSG00000270039.1	RP11-571M6.17	-4.18	3.19e-05	0.0023	-0.19	-0.13	Intelligence (multi-trait analysis);	chr12:57892405	chr12:57803838~57804415:+
BRCA	cis	rs4415084	0.68	rs7715731	ENSG00000251141.4	RP11-53O19.1	-4.18	3.19e-05	0.0023	-0.12	-0.13	Breast cancer;	chr5:44846742	chr5:44744900~44808777:-
BRCA	cis	rs6067053	0.671	rs6067024	ENSG00000227431.4	CSE1L-AS1	4.18	3.19e-05	0.0023	0.16	0.13	Intelligence (multi-trait analysis);	chr20:49226609	chr20:49040463~49046044:-
BRCA	cis	rs7927592	0.731	rs2840367	ENSG00000212093.1	AP000807.1	-4.18	3.19e-05	0.0023	-0.13	-0.13	Total body bone mineral density;	chr11:68534633	chr11:68506083~68506166:-
BRCA	cis	rs812925	0.537	rs2463097	ENSG00000273302.1	RP11-493E12.2	-4.18	3.19e-05	0.0023	-0.11	-0.13	Immature fraction of reticulocytes;	chr2:61387166	chr2:61199979~61200769:+
BRCA	cis	rs61931739	0.517	rs11053063	ENSG00000258794.3	DUX4L27	4.18	3.19e-05	0.0023	0.19	0.13	Morning vs. evening chronotype;	chr12:34028076	chr12:34208415~34209675:-
BRCA	cis	rs61931739	0.5	rs11053066	ENSG00000258794.3	DUX4L27	4.18	3.19e-05	0.0023	0.19	0.13	Morning vs. evening chronotype;	chr12:34032383	chr12:34208415~34209675:-
BRCA	cis	rs61931739	0.517	rs10772139	ENSG00000258794.3	DUX4L27	4.18	3.19e-05	0.0023	0.19	0.13	Morning vs. evening chronotype;	chr12:34033243	chr12:34208415~34209675:-
BRCA	cis	rs61931739	0.534	rs28548399	ENSG00000258794.3	DUX4L27	4.18	3.19e-05	0.0023	0.19	0.13	Morning vs. evening chronotype;	chr12:34035216	chr12:34208415~34209675:-
BRCA	cis	rs61931739	0.517	rs11053067	ENSG00000258794.3	DUX4L27	4.18	3.19e-05	0.0023	0.19	0.13	Morning vs. evening chronotype;	chr12:34038456	chr12:34208415~34209675:-
BRCA	cis	rs4650943	0.586	rs2102197	ENSG00000227740.1	RP11-318C24.2	-4.18	3.19e-05	0.00231	-0.13	-0.13	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in inactive individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr1:176403351	chr1:175904762~175920513:-
BRCA	cis	rs2380205	0.967	rs12774966	ENSG00000232807.2	RP11-536K7.3	4.18	3.2e-05	0.00231	0.13	0.13	Breast cancer;	chr10:5856135	chr10:5934270~5945900:-
BRCA	cis	rs875971	1	rs10257427	ENSG00000229180.5	GS1-124K5.11	-4.18	3.2e-05	0.00231	-0.11	-0.13	Aortic root size;	chr7:66278221	chr7:66526088~66542624:-
BRCA	cis	rs7267979	1	rs453329	ENSG00000274414.1	RP5-965G21.4	-4.18	3.2e-05	0.00231	-0.15	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25459957	chr20:25239007~25245229:-
BRCA	cis	rs911119	1	rs13039536	ENSG00000270001.1	RP11-218C14.8	-4.18	3.2e-05	0.00231	-0.17	-0.13	Chronic kidney disease;	chr20:23631668	chr20:23631826~23632316:-
BRCA	cis	rs763121	0.853	rs5757187	ENSG00000225450.1	RP3-508I15.14	4.18	3.2e-05	0.00231	0.14	0.13	Menopause (age at onset);	chr22:38625517	chr22:38739003~38749041:+
BRCA	cis	rs875971	0.545	rs313830	ENSG00000273142.1	RP11-458F8.4	-4.18	3.2e-05	0.00231	-0.13	-0.13	Aortic root size;	chr7:66086944	chr7:66902857~66906297:+
BRCA	cis	rs721917	0.506	rs2475756	ENSG00000278616.1	BEND3P3	-4.18	3.2e-05	0.00231	-0.12	-0.13	Chronic obstructive pulmonary disease;	chr10:79897010	chr10:79682997~79685436:+
BRCA	cis	rs7176093	1	rs7176093	ENSG00000259295.5	CSPG4P12	4.18	3.2e-05	0.00231	0.17	0.13	Aging traits;	chr15:85826199	chr15:85191438~85213905:+
BRCA	cis	rs1910358	0.554	rs3857314	ENSG00000248874.4	C5orf17	-4.18	3.2e-05	0.00231	-0.18	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23746773	chr5:23951348~24178263:+
BRCA	cis	rs7746199	0.736	rs13195636	ENSG00000216901.1	AL022393.7	4.18	3.2e-05	0.00231	0.33	0.13	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27541714	chr6:28176188~28176674:+
BRCA	cis	rs9467773	0.566	rs66972160	ENSG00000124549.13	BTN2A3P	-4.18	3.2e-05	0.00231	-0.13	-0.13	Intelligence (multi-trait analysis);	chr6:26359078	chr6:26421391~26432383:+
BRCA	cis	rs9467773	0.526	rs9348710	ENSG00000124549.13	BTN2A3P	-4.18	3.2e-05	0.00231	-0.13	-0.13	Intelligence (multi-trait analysis);	chr6:26360258	chr6:26421391~26432383:+
BRCA	cis	rs7487075	1	rs12827740	ENSG00000274723.1	RP11-618L22.1	4.18	3.2e-05	0.00231	0.15	0.13	Itch intensity from mosquito bite;	chr12:46454332	chr12:46970504~46972155:+
BRCA	cis	rs17695224	0.519	rs2159654	ENSG00000269483.1	AC006272.1	4.18	3.2e-05	0.00231	0.15	0.13	HDL cholesterol;HDL cholesterol levels;	chr19:51834004	chr19:51839924~51843324:-
BRCA	cis	rs17695224	0.5	rs2159655	ENSG00000269483.1	AC006272.1	4.18	3.2e-05	0.00231	0.15	0.13	HDL cholesterol;HDL cholesterol levels;	chr19:51834006	chr19:51839924~51843324:-
BRCA	cis	rs1598856	0.966	rs11097788	ENSG00000246560.2	RP11-10L12.4	4.18	3.2e-05	0.00231	0.14	0.13	Primary biliary cholangitis;	chr4:102486271	chr4:102828055~102844075:+
BRCA	cis	rs12887734	0.566	rs8548	ENSG00000269910.1	RP11-73M18.10	4.18	3.2e-05	0.00231	0.14	0.13	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103733243	chr14:103694516~103695050:-
BRCA	cis	rs12210905	1	rs67310631	ENSG00000216901.1	AL022393.7	4.18	3.2e-05	0.00231	0.23	0.13	Hip circumference adjusted for BMI;	chr6:27265464	chr6:28176188~28176674:+
BRCA	cis	rs12210905	1	rs9379967	ENSG00000216901.1	AL022393.7	4.18	3.2e-05	0.00231	0.23	0.13	Hip circumference adjusted for BMI;	chr6:27265648	chr6:28176188~28176674:+
BRCA	cis	rs1005277	0.602	rs1831315	ENSG00000272983.1	RP11-508N22.12	4.18	3.2e-05	0.00231	0.14	0.13	Extrinsic epigenetic age acceleration;	chr10:38184425	chr10:38137337~38144399:+
BRCA	cis	rs17270561	0.666	rs4712971	ENSG00000272462.2	U91328.19	-4.18	3.2e-05	0.00231	-0.16	-0.13	Iron status biomarkers;	chr6:25771672	chr6:25992662~26001775:+
BRCA	cis	rs10829156	0.66	rs7918933	ENSG00000225527.1	RP11-383B4.4	-4.18	3.2e-05	0.00231	-0.18	-0.13	Sudden cardiac arrest;	chr10:18517434	chr10:18531849~18533336:-
BRCA	cis	rs7520050	0.933	rs9787208	ENSG00000234329.1	RP11-767N6.2	-4.18	3.2e-05	0.00231	-0.12	-0.13	Reticulocyte count;Red blood cell count;	chr1:45848944	chr1:45651039~45651826:-
BRCA	cis	rs11098499	0.954	rs59866101	ENSG00000260404.2	RP11-384K6.6	4.18	3.2e-05	0.00231	0.12	0.13	Corneal astigmatism;	chr4:119375436	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.618	rs6858383	ENSG00000260404.2	RP11-384K6.6	4.18	3.2e-05	0.00231	0.12	0.13	Corneal astigmatism;	chr4:119375617	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.697	rs6832410	ENSG00000260404.2	RP11-384K6.6	4.18	3.2e-05	0.00231	0.12	0.13	Corneal astigmatism;	chr4:119375645	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.865	rs1112817	ENSG00000260404.2	RP11-384K6.6	4.18	3.2e-05	0.00231	0.12	0.13	Corneal astigmatism;	chr4:119376645	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.779	rs10016060	ENSG00000260404.2	RP11-384K6.6	4.18	3.2e-05	0.00231	0.12	0.13	Corneal astigmatism;	chr4:119377257	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.954	rs10005644	ENSG00000260404.2	RP11-384K6.6	4.18	3.2e-05	0.00231	0.12	0.13	Corneal astigmatism;	chr4:119377322	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.697	rs10016448	ENSG00000260404.2	RP11-384K6.6	4.18	3.2e-05	0.00231	0.12	0.13	Corneal astigmatism;	chr4:119377690	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.657	rs9996569	ENSG00000260404.2	RP11-384K6.6	4.18	3.2e-05	0.00231	0.12	0.13	Corneal astigmatism;	chr4:119377849	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.908	rs11729050	ENSG00000260404.2	RP11-384K6.6	4.18	3.2e-05	0.00231	0.12	0.13	Corneal astigmatism;	chr4:119378911	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.954	rs28429722	ENSG00000260404.2	RP11-384K6.6	4.18	3.2e-05	0.00231	0.12	0.13	Corneal astigmatism;	chr4:119378938	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.954	rs10014845	ENSG00000260404.2	RP11-384K6.6	4.18	3.2e-05	0.00231	0.12	0.13	Corneal astigmatism;	chr4:119379922	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.779	rs7674500	ENSG00000260404.2	RP11-384K6.6	4.18	3.2e-05	0.00231	0.12	0.13	Corneal astigmatism;	chr4:119382438	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.909	rs28884220	ENSG00000260404.2	RP11-384K6.6	4.18	3.2e-05	0.00231	0.12	0.13	Corneal astigmatism;	chr4:119386056	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.909	rs28793658	ENSG00000260404.2	RP11-384K6.6	4.18	3.2e-05	0.00231	0.12	0.13	Corneal astigmatism;	chr4:119386059	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.697	rs4373140	ENSG00000260404.2	RP11-384K6.6	4.18	3.2e-05	0.00231	0.12	0.13	Corneal astigmatism;	chr4:119386543	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.954	rs13113483	ENSG00000260404.2	RP11-384K6.6	4.18	3.2e-05	0.00231	0.12	0.13	Corneal astigmatism;	chr4:119387884	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.542	rs10440343	ENSG00000260404.2	RP11-384K6.6	4.18	3.2e-05	0.00231	0.12	0.13	Corneal astigmatism;	chr4:119388632	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.779	rs10011097	ENSG00000260404.2	RP11-384K6.6	4.18	3.2e-05	0.00231	0.12	0.13	Corneal astigmatism;	chr4:119389204	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.542	rs7677836	ENSG00000260404.2	RP11-384K6.6	4.18	3.2e-05	0.00231	0.12	0.13	Corneal astigmatism;	chr4:119389483	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.909	rs10002083	ENSG00000260404.2	RP11-384K6.6	4.18	3.2e-05	0.00231	0.12	0.13	Corneal astigmatism;	chr4:119389997	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.954	rs10024844	ENSG00000260404.2	RP11-384K6.6	4.18	3.2e-05	0.00231	0.12	0.13	Corneal astigmatism;	chr4:119390373	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.954	rs4345162	ENSG00000260404.2	RP11-384K6.6	4.18	3.2e-05	0.00231	0.12	0.13	Corneal astigmatism;	chr4:119391804	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.657	rs4463052	ENSG00000260404.2	RP11-384K6.6	4.18	3.2e-05	0.00231	0.12	0.13	Corneal astigmatism;	chr4:119392103	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.954	rs13151285	ENSG00000260404.2	RP11-384K6.6	4.18	3.2e-05	0.00231	0.12	0.13	Corneal astigmatism;	chr4:119393586	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.739	rs9884728	ENSG00000260404.2	RP11-384K6.6	-4.18	3.2e-05	0.00231	-0.12	-0.13	Corneal astigmatism;	chr4:119205924	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.863	rs11098532	ENSG00000260091.1	RP11-33B1.4	-4.18	3.2e-05	0.00231	-0.12	-0.13	Corneal astigmatism;	chr4:119569571	chr4:119409333~119410233:+
BRCA	cis	rs8180040	0.62	rs6414435	ENSG00000271161.1	BOLA2P2	4.18	3.2e-05	0.00231	0.14	0.13	Colorectal cancer;	chr3:47079650	chr3:47499841~47500407:+
BRCA	cis	rs4578769	0.681	rs4456613	ENSG00000265939.1	UBE2CP2	-4.18	3.2e-05	0.00231	-0.16	-0.13	Eosinophil percentage of white cells;	chr18:22987266	chr18:22900486~22900995:-
BRCA	cis	rs2108622	0.701	rs3093209	ENSG00000214049.6	UCA1	4.18	3.2e-05	0.00231	0.18	0.13	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15877610	chr19:15828961~15836320:+
BRCA	cis	rs71520386	0.625	rs10265548	ENSG00000230658.1	KLHL7-AS1	4.18	3.2e-05	0.00231	0.18	0.13	Fibrinogen levels;	chr7:22772959	chr7:23101228~23105703:-
BRCA	cis	rs8180040	0.783	rs11710121	ENSG00000276925.1	RP11-708J19.3	4.18	3.2e-05	0.00231	0.15	0.13	Colorectal cancer;	chr3:47310011	chr3:47469777~47469987:+
BRCA	cis	rs16944613	0.51	rs17180057	ENSG00000245479.2	LINC01585	4.18	3.2e-05	0.00231	0.16	0.13	Colorectal cancer;	chr15:90612602	chr15:90660234~90664967:+
BRCA	cis	rs2298450	0.55	rs113779114	ENSG00000231106.2	LINC01436	4.18	3.2e-05	0.00231	0.14	0.13	Schizophrenia;	chr21:36285774	chr21:36005338~36007838:+
BRCA	cis	rs11098499	0.865	rs28753180	ENSG00000260091.1	RP11-33B1.4	-4.18	3.2e-05	0.00231	-0.11	-0.13	Corneal astigmatism;	chr4:119484212	chr4:119409333~119410233:+
BRCA	cis	rs4664293	0.625	rs4665102	ENSG00000224152.1	AC009506.1	4.18	3.2e-05	0.00231	0.14	0.13	Monocyte percentage of white cells;	chr2:159666076	chr2:159615296~159617082:+
BRCA	cis	rs765787	0.53	rs12323957	ENSG00000259539.1	CTD-2651B20.1	-4.18	3.2e-05	0.00231	-0.16	-0.13	Uric acid levels;	chr15:45198575	chr15:45152664~45167526:-
BRCA	cis	rs2842346	0.568	rs2525523	ENSG00000258623.1	CTD-2325P2.3	-4.18	3.2e-05	0.00231	-0.17	-0.13	Breast cancer;	chr14:68540196	chr14:68683411~68685565:-
BRCA	cis	rs2842346	0.568	rs2525524	ENSG00000258623.1	CTD-2325P2.3	-4.18	3.2e-05	0.00231	-0.17	-0.13	Breast cancer;	chr14:68540205	chr14:68683411~68685565:-
BRCA	cis	rs8180040	0.62	rs9858443	ENSG00000271161.1	BOLA2P2	4.18	3.21e-05	0.00231	0.14	0.13	Colorectal cancer;	chr3:47044558	chr3:47499841~47500407:+
BRCA	cis	rs8180040	0.62	rs4683322	ENSG00000271161.1	BOLA2P2	4.18	3.21e-05	0.00231	0.14	0.13	Colorectal cancer;	chr3:47051699	chr3:47499841~47500407:+
BRCA	cis	rs16846053	0.792	rs62187739	ENSG00000227403.1	AC009299.3	4.18	3.21e-05	0.00231	0.34	0.13	Blood osmolality (transformed sodium);	chr2:161837917	chr2:161244739~161249050:+
BRCA	cis	rs683250	0.629	rs524441	ENSG00000254551.1	RP11-727A23.7	4.18	3.21e-05	0.00231	0.16	0.13	Subcortical brain region volumes;	chr11:83250016	chr11:83209431~83213379:-
BRCA	cis	rs1437396	0.657	rs2576715	ENSG00000203327.2	AC012358.7	-4.18	3.21e-05	0.00231	-0.13	-0.13	Alcohol dependence;	chr2:55335556	chr2:55214387~55216126:-
BRCA	cis	rs2731006	0.64	rs2468322	ENSG00000257114.2	RP11-25I15.3	4.18	3.21e-05	0.00231	0.21	0.13	Panic disorder;	chr12:42800781	chr12:42692216~42717119:+
BRCA	cis	rs11719291	0.667	rs9877542	ENSG00000225399.4	RP11-3B7.1	-4.18	3.21e-05	0.00231	-0.19	-0.13	Cognitive function;	chr3:48711112	chr3:49260085~49261316:+
BRCA	cis	rs7665090	0.806	rs434644	ENSG00000251288.2	RP11-10L12.2	4.18	3.21e-05	0.00231	0.15	0.13	Primary biliary cholangitis;	chr4:102662032	chr4:102751401~102752641:+
BRCA	cis	rs2880765	0.743	rs7168345	ENSG00000202081.1	RNU6-1280P	-4.18	3.21e-05	0.00231	-0.15	-0.13	Coronary artery disease;	chr15:85470370	chr15:85651522~85651628:-
BRCA	cis	rs1858037	0.867	rs4671658	ENSG00000281920.1	RP11-418H16.1	-4.18	3.21e-05	0.00231	-0.16	-0.13	Rheumatoid arthritis;	chr2:65334258	chr2:65623272~65628424:+
BRCA	cis	rs7811142	0.943	rs111493473	ENSG00000078319.8	PMS2P1	-4.18	3.21e-05	0.00231	-0.2	-0.13	Platelet count;	chr7:100452119	chr7:100320992~100341908:-
BRCA	cis	rs56322409	1	rs10882644	ENSG00000226688.5	ENTPD1-AS1	4.18	3.21e-05	0.00231	0.15	0.13	Blood metabolite levels;	chr10:95628822	chr10:95753206~96090238:-
BRCA	cis	rs56322409	1	rs11188406	ENSG00000226688.5	ENTPD1-AS1	4.18	3.21e-05	0.00231	0.15	0.13	Blood metabolite levels;	chr10:95630438	chr10:95753206~96090238:-
BRCA	cis	rs11711311	1	rs6792447	ENSG00000241529.3	RN7SL767P	-4.18	3.21e-05	0.00231	-0.15	-0.13	IgG glycosylation;	chr3:113789488	chr3:113632704~113632998:+
BRCA	cis	rs6431644	0.731	rs887062	ENSG00000224287.2	MSL3P1	-4.18	3.21e-05	0.00232	-0.16	-0.13	Left atrial antero-posterior diameter;	chr2:233855851	chr2:233865437~233868444:-
BRCA	cis	rs11096990	0.679	rs6531707	ENSG00000249685.1	RP11-360F5.3	-4.18	3.21e-05	0.00232	-0.16	-0.13	Cognitive function;	chr4:39296064	chr4:39133913~39135608:+
BRCA	cis	rs77204473	1	rs11216186	ENSG00000280143.1	AP000892.6	-4.18	3.21e-05	0.00232	-0.25	-0.13	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116913976	chr11:117204967~117210292:+
BRCA	cis	rs6012564	0.826	rs2869715	ENSG00000222365.1	SNORD12B	4.18	3.21e-05	0.00232	0.13	0.13	Anger;	chr20:49143463	chr20:49280319~49280409:+
BRCA	cis	rs6012564	0.793	rs6066979	ENSG00000222365.1	SNORD12B	4.18	3.21e-05	0.00232	0.13	0.13	Anger;	chr20:49144319	chr20:49280319~49280409:+
BRCA	cis	rs6012564	0.762	rs6066980	ENSG00000222365.1	SNORD12B	4.18	3.21e-05	0.00232	0.13	0.13	Anger;	chr20:49144320	chr20:49280319~49280409:+
BRCA	cis	rs7129556	1	rs7129556	ENSG00000241782.1	RP11-91P24.1	-4.18	3.21e-05	0.00232	-0.18	-0.13	Weight loss (gastric bypass surgery);	chr11:77589003	chr11:77868722~77869195:-
BRCA	cis	rs6430585	0.702	rs746857	ENSG00000231890.6	DARS-AS1	4.18	3.21e-05	0.00232	0.19	0.13	Corneal structure;	chr2:135797320	chr2:135985176~136022593:+
BRCA	cis	rs6893300	0.857	rs62406181	ENSG00000250999.1	RP11-1379J22.5	4.18	3.22e-05	0.00232	0.17	0.13	Resting heart rate;	chr5:179744802	chr5:179657762~179664432:+
BRCA	cis	rs7131987	0.644	rs6487817	ENSG00000257176.2	RP11-996F15.2	4.18	3.22e-05	0.00232	0.16	0.13	QT interval;	chr12:29395277	chr12:29280418~29317848:-
BRCA	cis	rs10129255	0.536	rs10139058	ENSG00000274576.2	IGHV2-70	-4.18	3.22e-05	0.00232	-0.1	-0.13	Kawasaki disease;	chr14:106685899	chr14:106770577~106771020:-
BRCA	cis	rs17801127	0.748	rs71413657	ENSG00000231969.1	AC144449.1	4.18	3.22e-05	0.00232	0.23	0.13	Liver enzyme levels (alanine transaminase);	chr2:149656807	chr2:149587196~149848233:+
BRCA	cis	rs1910358	0.554	rs13177260	ENSG00000248874.4	C5orf17	4.18	3.22e-05	0.00232	0.18	0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23754865	chr5:23951348~24178263:+
BRCA	cis	rs138544659	1	rs138544659	ENSG00000261762.1	RP11-650L12.2	-4.18	3.22e-05	0.00232	-0.15	-0.13	Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78608359	chr15:78589123~78591276:-
BRCA	cis	rs9527	0.59	rs11191544	ENSG00000213061.2	PFN1P11	4.18	3.22e-05	0.00232	0.17	0.13	Arsenic metabolism;	chr10:103067441	chr10:102838011~102845473:-
BRCA	cis	rs16944613	0.51	rs10520692	ENSG00000245479.2	LINC01585	4.18	3.22e-05	0.00232	0.15	0.13	Colorectal cancer;	chr15:90611239	chr15:90660234~90664967:+
BRCA	cis	rs409045	1	rs456329	ENSG00000271874.1	CTD-2024P10.2	-4.18	3.22e-05	0.00232	-0.17	-0.13	Left ventricular mass;	chr5:34632496	chr5:34651457~34651888:-
BRCA	cis	rs2274273	0.774	rs9323278	ENSG00000233924.1	AL160471.6	-4.18	3.22e-05	0.00232	-0.15	-0.13	Protein biomarker;	chr14:55074856	chr14:55004813~55005687:-
BRCA	cis	rs35740288	0.77	rs10520592	ENSG00000202081.1	RNU6-1280P	4.18	3.22e-05	0.00232	0.17	0.13	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85570911	chr15:85651522~85651628:-
BRCA	cis	rs13325613	0.517	rs13091868	ENSG00000223552.1	RP11-24F11.2	-4.18	3.22e-05	0.00232	-0.22	-0.13	Monocyte count;	chr3:46081551	chr3:46364955~46407059:-
BRCA	cis	rs13325613	0.585	rs13092030	ENSG00000223552.1	RP11-24F11.2	-4.18	3.22e-05	0.00232	-0.22	-0.13	Monocyte count;	chr3:46081563	chr3:46364955~46407059:-
BRCA	cis	rs11098499	0.909	rs73842633	ENSG00000260404.2	RP11-384K6.6	4.18	3.22e-05	0.00232	0.12	0.13	Corneal astigmatism;	chr4:119454309	chr4:118591773~118633729:+
BRCA	cis	rs12438356	1	rs76907455	ENSG00000259222.2	RP11-809H16.5	-4.18	3.22e-05	0.00232	-0.22	-0.13	CTACK levels;	chr15:69288481	chr15:69080879~69099987:+
BRCA	cis	rs875971	0.545	rs66594357	ENSG00000273142.1	RP11-458F8.4	4.18	3.22e-05	0.00232	0.13	0.13	Aortic root size;	chr7:66327797	chr7:66902857~66906297:+
BRCA	cis	rs875971	0.964	rs55748098	ENSG00000229180.5	GS1-124K5.11	-4.18	3.22e-05	0.00232	-0.11	-0.13	Aortic root size;	chr7:66298631	chr7:66526088~66542624:-
BRCA	cis	rs1153858	0.945	rs16943246	ENSG00000275672.1	GATM-AS1	-4.18	3.22e-05	0.00232	-0.17	-0.13	Homoarginine levels;	chr15:45428399	chr15:45378700~45380123:+
BRCA	cis	rs6500602	0.702	rs6500605	ENSG00000280063.1	RP11-295D4.3	4.18	3.22e-05	0.00232	0.09	0.13	Schizophrenia;	chr16:4452409	chr16:4346694~4348648:-
BRCA	cis	rs6545883	0.525	rs1729662	ENSG00000273302.1	RP11-493E12.2	4.18	3.22e-05	0.00232	0.12	0.13	Tuberculosis;	chr2:61164170	chr2:61199979~61200769:+
BRCA	cis	rs73222236	0.825	rs9858457	ENSG00000239213.4	NCK1-AS1	4.18	3.22e-05	0.00232	0.14	0.13	Coronary artery disease;	chr3:136530735	chr3:136841726~136862054:-
BRCA	cis	rs1910358	0.554	rs4701393	ENSG00000248874.4	C5orf17	-4.18	3.23e-05	0.00232	-0.18	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23755590	chr5:23951348~24178263:+
BRCA	cis	rs11098499	0.754	rs12510269	ENSG00000260091.1	RP11-33B1.4	-4.18	3.23e-05	0.00232	-0.11	-0.13	Corneal astigmatism;	chr4:119320491	chr4:119409333~119410233:+
BRCA	cis	rs10849893	0.576	rs7134248	ENSG00000258435.1	RP11-711D18.2	-4.18	3.23e-05	0.00232	-0.14	-0.13	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr12:121459249	chr12:121391962~121399859:+
BRCA	cis	rs3733585	0.631	rs4697924	ENSG00000250413.1	RP11-448G15.1	4.18	3.23e-05	0.00233	0.18	0.13	Cleft plate (environmental tobacco smoke interaction);	chr4:10122615	chr4:10006482~10009725:+
BRCA	cis	rs4143844	0.867	rs12907534	ENSG00000259251.2	RP11-643M14.1	4.18	3.23e-05	0.00233	0.31	0.13	Bipolar disorder and schizophrenia;	chr15:61908396	chr15:62060503~62062434:+
BRCA	cis	rs2274273	0.6	rs10131730	ENSG00000259318.1	RP11-454L9.2	4.18	3.23e-05	0.00233	0.12	0.13	Protein biomarker;	chr14:55373374	chr14:55394940~55395233:-
BRCA	cis	rs2274273	0.624	rs12050123	ENSG00000259318.1	RP11-454L9.2	4.18	3.23e-05	0.00233	0.12	0.13	Protein biomarker;	chr14:55373668	chr14:55394940~55395233:-
BRCA	cis	rs983392	0.805	rs7926344	ENSG00000275344.1	MIR6503	-4.18	3.23e-05	0.00233	-0.13	-0.13	Alzheimer's disease (late onset);	chr11:60194693	chr11:60209071~60209156:-
BRCA	cis	rs875971	0.929	rs10950041	ENSG00000229180.5	GS1-124K5.11	4.18	3.23e-05	0.00233	0.11	0.13	Aortic root size;	chr7:66508888	chr7:66526088~66542624:-
BRCA	cis	rs853679	0.517	rs3757185	ENSG00000216901.1	AL022393.7	4.17	3.23e-05	0.00233	0.19	0.13	Depression;	chr6:28139998	chr6:28176188~28176674:+
BRCA	cis	rs728616	0.867	rs118134654	ENSG00000242600.5	MBL1P	4.17	3.23e-05	0.00233	0.32	0.13	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79984625	chr10:79904898~79950336:+
BRCA	cis	rs61160187	0.582	rs4647132	ENSG00000272308.1	RP11-231G3.1	-4.17	3.23e-05	0.00233	-0.15	-0.13	Educational attainment (years of education);Educational attainment (college completion);	chr5:60886893	chr5:60866457~60866935:-
BRCA	cis	rs6831352	0.693	rs2602875	ENSG00000272777.1	RP11-571L19.8	-4.17	3.23e-05	0.00233	-0.14	-0.13	Alcohol dependence;	chr4:99118344	chr4:99067256~99068125:-
BRCA	cis	rs812925	0.512	rs1177309	ENSG00000273302.1	RP11-493E12.2	4.17	3.23e-05	0.00233	0.11	0.13	Immature fraction of reticulocytes;	chr2:61158113	chr2:61199979~61200769:+
BRCA	cis	rs6545883	0.929	rs10193666	ENSG00000212978.6	AC016747.3	-4.17	3.23e-05	0.00233	-0.18	-0.13	Tuberculosis;	chr2:61402273	chr2:61141592~61144969:-
BRCA	cis	rs11992162	1	rs7460395	ENSG00000255495.1	AC145124.2	4.17	3.23e-05	0.00233	0.15	0.13	Monocyte count;	chr8:11977866	chr8:12194467~12196280:+
BRCA	cis	rs4561483	0.734	rs33655	ENSG00000261216.1	RP11-166B2.5	-4.17	3.23e-05	0.00233	-0.15	-0.13	Testicular germ cell tumor;	chr16:11876524	chr16:11908208~11908916:+
BRCA	cis	rs728616	0.867	rs12412226	ENSG00000242600.5	MBL1P	4.17	3.23e-05	0.00233	0.32	0.13	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79975532	chr10:79904898~79950336:+
BRCA	cis	rs728616	0.867	rs4387301	ENSG00000242600.5	MBL1P	4.17	3.23e-05	0.00233	0.32	0.13	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79976643	chr10:79904898~79950336:+
BRCA	cis	rs728616	0.867	rs61860420	ENSG00000242600.5	MBL1P	4.17	3.23e-05	0.00233	0.32	0.13	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79979623	chr10:79904898~79950336:+
BRCA	cis	rs728616	0.867	rs75447386	ENSG00000242600.5	MBL1P	4.17	3.23e-05	0.00233	0.32	0.13	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79979891	chr10:79904898~79950336:+
BRCA	cis	rs728616	0.867	rs4520539	ENSG00000242600.5	MBL1P	4.17	3.23e-05	0.00233	0.32	0.13	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79980773	chr10:79904898~79950336:+
BRCA	cis	rs728616	0.867	rs61860421	ENSG00000242600.5	MBL1P	4.17	3.23e-05	0.00233	0.32	0.13	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79983643	chr10:79904898~79950336:+
BRCA	cis	rs2835872	0.965	rs73222309	ENSG00000228677.1	TTC3-AS1	-4.17	3.23e-05	0.00233	-0.17	-0.13	Electroencephalographic traits in alcoholism;	chr21:37641384	chr21:37187666~37193926:-
BRCA	cis	rs11098499	0.754	rs7672778	ENSG00000225892.3	RP11-384K6.2	4.17	3.23e-05	0.00233	0.12	0.13	Corneal astigmatism;	chr4:119327430	chr4:118632274~118634759:+
BRCA	cis	rs13401620	0.81	rs7573792	ENSG00000229326.3	AC069154.4	-4.17	3.23e-05	0.00233	-0.16	-0.13	Breast size;	chr2:119904529	chr2:119698623~119700151:+
BRCA	cis	rs9423406	0.752	rs34390260	ENSG00000215267.7	AKR1C7P	-4.17	3.24e-05	0.00233	-0.24	-0.13	Intelligence;	chr10:5262995	chr10:5275173~5288470:-
BRCA	cis	rs9423406	0.752	rs35426646	ENSG00000215267.7	AKR1C7P	-4.17	3.24e-05	0.00233	-0.24	-0.13	Intelligence;	chr10:5264082	chr10:5275173~5288470:-
BRCA	cis	rs10129255	0.5	rs11628999	ENSG00000211967.3	IGHV3-53	-4.17	3.24e-05	0.00233	-0.08	-0.13	Kawasaki disease;	chr14:106800208	chr14:106592676~106593347:-
BRCA	cis	rs4916588	0.636	rs4916571	ENSG00000230732.4	AC127904.2	4.17	3.24e-05	0.00233	0.16	0.13	Night sleep phenotypes;	chr3:196874193	chr3:196912646~196914579:+
BRCA	cis	rs875971	0.929	rs6970860	ENSG00000229180.5	GS1-124K5.11	4.17	3.24e-05	0.00233	0.11	0.13	Aortic root size;	chr7:66511647	chr7:66526088~66542624:-
BRCA	cis	rs7226408	0.842	rs1609426	ENSG00000267707.2	RP11-95O2.5	4.17	3.24e-05	0.00233	0.2	0.13	Obesity-related traits;	chr18:36765624	chr18:37243776~37247506:+
BRCA	cis	rs757081	0.667	rs3950680	ENSG00000184669.7	OR7E14P	-4.17	3.24e-05	0.00233	-0.19	-0.13	Systolic blood pressure;	chr11:17117119	chr11:17013998~17053024:+
BRCA	cis	rs875971	0.522	rs1968127	ENSG00000232546.1	RP11-458F8.1	4.17	3.24e-05	0.00233	0.11	0.13	Aortic root size;	chr7:66591816	chr7:66848496~66858136:+
BRCA	cis	rs3858526	0.883	rs7481923	ENSG00000224295.2	AC087380.14	4.17	3.24e-05	0.00233	0.18	0.13	DNA methylation (variation);	chr11:5912112	chr11:5518441~5524955:-
BRCA	cis	rs7267979	0.844	rs35735333	ENSG00000231081.1	RP4-760C5.3	4.17	3.24e-05	0.00233	0.16	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25356569	chr20:26008791~26010531:-
BRCA	cis	rs871012	0.502	rs17599812	ENSG00000248544.2	CTB-47B11.3	-4.17	3.24e-05	0.00233	-0.17	-0.13	IgG glycosylation;	chr5:157450982	chr5:157375741~157384950:-
BRCA	cis	rs6671200	0.573	rs6666528	ENSG00000235501.4	RP4-639F20.1	4.17	3.24e-05	0.00233	0.21	0.13	Stearic acid (18:0) levels;	chr1:95231934	chr1:94927566~94963270:+
BRCA	cis	rs703842	1	rs703842	ENSG00000270039.1	RP11-571M6.17	4.17	3.24e-05	0.00233	0.17	0.13	Multiple sclerosis;	chr12:57768956	chr12:57803838~57804415:+
BRCA	cis	rs7811142	1	rs11766752	ENSG00000078319.8	PMS2P1	-4.17	3.24e-05	0.00233	-0.2	-0.13	Platelet count;	chr7:100475669	chr7:100320992~100341908:-
BRCA	cis	rs13326165	0.715	rs11716017	ENSG00000243224.1	RP5-1157M23.2	-4.17	3.24e-05	0.00234	-0.18	-0.13	HDL cholesterol levels;HDL cholesterol;	chr3:52346975	chr3:52239258~52241097:+
BRCA	cis	rs7308116	1	rs6539365	ENSG00000274395.1	RP11-554D14.8	-4.17	3.24e-05	0.00234	-0.14	-0.13	Pelvic organ prolapse (moderate/severe);	chr12:107807742	chr12:107835541~107836555:-
BRCA	cis	rs490234	0.702	rs2416964	ENSG00000232630.1	PRPS1P2	-4.17	3.24e-05	0.00234	-0.13	-0.13	Mean arterial pressure;	chr9:125598134	chr9:125150653~125151589:+
BRCA	cis	rs1048886	0.808	rs16869340	ENSG00000271967.1	RP11-134K13.4	-4.17	3.24e-05	0.00234	-0.17	-0.13	Type 2 diabetes;	chr6:70540063	chr6:70596438~70596980:+
BRCA	cis	rs61931739	0.5	rs7955247	ENSG00000258794.3	DUX4L27	4.17	3.24e-05	0.00234	0.19	0.13	Morning vs. evening chronotype;	chr12:33973645	chr12:34208415~34209675:-
BRCA	cis	rs61931739	0.534	rs1490113	ENSG00000258794.3	DUX4L27	4.17	3.24e-05	0.00234	0.19	0.13	Morning vs. evening chronotype;	chr12:33979459	chr12:34208415~34209675:-
BRCA	cis	rs10040989	0.748	rs2231472	ENSG00000253404.1	AC034243.1	-4.17	3.24e-05	0.00234	-0.26	-0.13	QT interval;	chr5:138213120	chr5:138744434~138753309:-
BRCA	cis	rs2924679	1	rs3019587	ENSG00000160172.9	FAM86C2P	4.17	3.25e-05	0.00234	0.3	0.13	Obesity-related traits;	chr11:68802174	chr11:67791648~67805336:-
BRCA	cis	rs6452524	1	rs6887846	ENSG00000281327.1	LINC01338	-4.17	3.25e-05	0.00234	-0.15	-0.13	Hypertension (SNP x SNP interaction);	chr5:83140542	chr5:82850864~82859836:-
BRCA	cis	rs2243480	1	rs781142	ENSG00000226002.1	RP11-460N20.5	-4.17	3.25e-05	0.00234	-0.21	-0.13	Diabetic kidney disease;	chr7:65973791	chr7:65084103~65100232:+
BRCA	cis	rs4865762	0.837	rs192262	ENSG00000247796.2	CTD-2366F13.1	4.17	3.25e-05	0.00234	0.14	0.13	Intraocular pressure;	chr5:53202440	chr5:53109842~53115126:+
BRCA	cis	rs17695224	0.545	rs7252508	ENSG00000269483.1	AC006272.1	4.17	3.25e-05	0.00234	0.15	0.13	HDL cholesterol;HDL cholesterol levels;	chr19:51831530	chr19:51839924~51843324:-
BRCA	cis	rs78487399	0.808	rs17030835	ENSG00000234936.1	AC010883.5	4.17	3.25e-05	0.00234	0.2	0.13	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43459106	chr2:43229573~43233394:+
BRCA	cis	rs875971	0.929	rs778712	ENSG00000236529.1	RP13-254B10.1	4.17	3.25e-05	0.00234	0.14	0.13	Aortic root size;	chr7:66384991	chr7:65840212~65840596:+
BRCA	cis	rs6570726	0.905	rs421032	ENSG00000270638.1	RP3-466P17.1	4.17	3.25e-05	0.00234	0.14	0.13	Lobe attachment (rater-scored or self-reported);	chr6:145506635	chr6:145735570~145737218:+
BRCA	cis	rs6570726	0.935	rs9390329	ENSG00000270638.1	RP3-466P17.1	4.17	3.25e-05	0.00234	0.14	0.13	Lobe attachment (rater-scored or self-reported);	chr6:145506890	chr6:145735570~145737218:+
BRCA	cis	rs6570726	0.902	rs406979	ENSG00000270638.1	RP3-466P17.1	4.17	3.25e-05	0.00234	0.14	0.13	Lobe attachment (rater-scored or self-reported);	chr6:145517847	chr6:145735570~145737218:+
BRCA	cis	rs8040855	0.627	rs12905036	ENSG00000259774.1	RP11-182J1.13	4.17	3.25e-05	0.00234	0.18	0.13	Bulimia nervosa;	chr15:85094557	chr15:84422618~84425882:+
BRCA	cis	rs7727544	0.582	rs2301579	ENSG00000233006.5	AC034220.3	4.17	3.25e-05	0.00234	0.09	0.13	Blood metabolite levels;	chr5:132217647	chr5:132311285~132369916:-
BRCA	cis	rs1858037	0.867	rs6727013	ENSG00000281920.1	RP11-418H16.1	4.17	3.25e-05	0.00234	0.17	0.13	Rheumatoid arthritis;	chr2:65331241	chr2:65623272~65628424:+
BRCA	cis	rs6430585	0.527	rs62168792	ENSG00000224043.6	CCNT2-AS1	-4.17	3.25e-05	0.00234	-0.21	-0.13	Corneal structure;	chr2:135657647	chr2:134735464~134918710:-
BRCA	cis	rs11673344	0.543	rs8108429	ENSG00000276846.1	CTD-3220F14.3	4.17	3.25e-05	0.00234	0.15	0.13	Obesity-related traits;	chr19:37145874	chr19:37314868~37315620:-
BRCA	cis	rs4865762	0.774	rs7737693	ENSG00000247796.2	CTD-2366F13.1	-4.17	3.25e-05	0.00234	-0.13	-0.13	Intraocular pressure;	chr5:53307111	chr5:53109842~53115126:+
BRCA	cis	rs6600671	1	rs1591882	ENSG00000275131.1	CH17-472G23.4	-4.17	3.25e-05	0.00234	-0.12	-0.13	Hip geometry;	chr1:121441455	chr1:120489625~120579190:-
BRCA	cis	rs11742741	0.875	rs1582946	ENSG00000248874.4	C5orf17	-4.17	3.25e-05	0.00234	-0.17	-0.13	Educational attainment;	chr5:24122900	chr5:23951348~24178263:+
BRCA	cis	rs11742741	0.777	rs62350792	ENSG00000248874.4	C5orf17	-4.17	3.25e-05	0.00234	-0.17	-0.13	Educational attainment;	chr5:24123069	chr5:23951348~24178263:+
BRCA	cis	rs1371614	0.566	rs11695406	ENSG00000272148.1	RP11-195B17.1	-4.17	3.25e-05	0.00234	-0.14	-0.13	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26955261	chr2:27062428~27062907:-
BRCA	cis	rs1910358	0.664	rs7721740	ENSG00000248874.4	C5orf17	-4.17	3.25e-05	0.00234	-0.17	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23983851	chr5:23951348~24178263:+
BRCA	cis	rs1910358	0.69	rs7702818	ENSG00000248874.4	C5orf17	-4.17	3.25e-05	0.00234	-0.17	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23984118	chr5:23951348~24178263:+
BRCA	cis	rs801193	0.66	rs1016265	ENSG00000265600.1	AC006480.1	-4.17	3.25e-05	0.00234	-0.15	-0.13	Aortic root size;	chr7:66749580	chr7:67356680~67356779:+
BRCA	cis	rs801193	0.66	rs4610622	ENSG00000265600.1	AC006480.1	-4.17	3.25e-05	0.00234	-0.15	-0.13	Aortic root size;	chr7:66759510	chr7:67356680~67356779:+
BRCA	cis	rs9937943	0.721	rs8059315	ENSG00000262904.1	TMPOP2	-4.17	3.25e-05	0.00234	-0.17	-0.13	Neutrophil percentage of white cells;	chr16:74472549	chr16:74667506~74668706:+
BRCA	cis	rs757081	0.648	rs10766382	ENSG00000184669.7	OR7E14P	-4.17	3.25e-05	0.00234	-0.17	-0.13	Systolic blood pressure;	chr11:17252894	chr11:17013998~17053024:+
BRCA	cis	rs757081	0.547	rs11024220	ENSG00000184669.7	OR7E14P	-4.17	3.25e-05	0.00234	-0.17	-0.13	Systolic blood pressure;	chr11:17252987	chr11:17013998~17053024:+
BRCA	cis	rs757081	0.579	rs11024221	ENSG00000184669.7	OR7E14P	-4.17	3.25e-05	0.00234	-0.17	-0.13	Systolic blood pressure;	chr11:17253003	chr11:17013998~17053024:+
BRCA	cis	rs4869313	0.869	rs2161548	ENSG00000248734.2	CTD-2260A17.1	4.17	3.25e-05	0.00234	0.13	0.13	Pediatric autoimmune diseases;	chr5:96982441	chr5:96784777~96785999:+
BRCA	cis	rs4819052	0.918	rs34886433	ENSG00000184274.3	LINC00315	-4.17	3.25e-05	0.00234	-0.2	-0.13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260623	chr21:45300245~45305257:-
BRCA	cis	rs3742264	0.656	rs4941537	ENSG00000235903.6	CPB2-AS1	4.17	3.25e-05	0.00234	0.16	0.13	Blood protein levels;	chr13:45968441	chr13:46052806~46113332:+
BRCA	cis	rs801193	0.66	rs2659914	ENSG00000272831.1	RP11-792A8.4	4.17	3.25e-05	0.00234	0.12	0.13	Aortic root size;	chr7:66691927	chr7:66739829~66740385:-
BRCA	cis	rs801193	0.591	rs2707839	ENSG00000272831.1	RP11-792A8.4	4.17	3.25e-05	0.00234	0.12	0.13	Aortic root size;	chr7:66728097	chr7:66739829~66740385:-
BRCA	cis	rs4578769	0.722	rs4265922	ENSG00000265939.1	UBE2CP2	-4.17	3.25e-05	0.00234	-0.16	-0.13	Eosinophil percentage of white cells;	chr18:22983169	chr18:22900486~22900995:-
BRCA	cis	rs9818758	0.607	rs66991555	ENSG00000225399.4	RP11-3B7.1	-4.17	3.26e-05	0.00234	-0.2	-0.13	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49191210	chr3:49260085~49261316:+
BRCA	cis	rs875971	0.929	rs778692	ENSG00000236529.1	RP13-254B10.1	4.17	3.26e-05	0.00234	0.14	0.13	Aortic root size;	chr7:66407462	chr7:65840212~65840596:+
BRCA	cis	rs875971	1	rs4718343	ENSG00000236529.1	RP13-254B10.1	4.17	3.26e-05	0.00234	0.14	0.13	Aortic root size;	chr7:66409301	chr7:65840212~65840596:+
BRCA	cis	rs875971	1	rs1968225	ENSG00000236529.1	RP13-254B10.1	4.17	3.26e-05	0.00234	0.14	0.13	Aortic root size;	chr7:66409786	chr7:65840212~65840596:+
BRCA	cis	rs875971	1	rs6460295	ENSG00000236529.1	RP13-254B10.1	4.17	3.26e-05	0.00234	0.14	0.13	Aortic root size;	chr7:66417741	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.964	rs6978721	ENSG00000236529.1	RP13-254B10.1	4.17	3.26e-05	0.00234	0.14	0.13	Aortic root size;	chr7:66418217	chr7:65840212~65840596:+
BRCA	cis	rs2625529	0.652	rs2957750	ENSG00000260037.4	CTD-2524L6.3	4.17	3.26e-05	0.00234	0.16	0.13	Red blood cell count;	chr15:72039917	chr15:71818396~71823384:+
BRCA	cis	rs11955398	0.502	rs158922	ENSG00000272308.1	RP11-231G3.1	-4.17	3.26e-05	0.00234	-0.15	-0.13	Intelligence (multi-trait analysis);	chr5:60945159	chr5:60866457~60866935:-
BRCA	cis	rs721917	0.525	rs2819106	ENSG00000242600.5	MBL1P	4.17	3.26e-05	0.00234	0.16	0.13	Chronic obstructive pulmonary disease;	chr10:79926324	chr10:79904898~79950336:+
BRCA	cis	rs3820068	0.581	rs6669417	ENSG00000237301.1	RP4-680D5.2	-4.17	3.26e-05	0.00234	-0.16	-0.13	Systolic blood pressure;	chr1:15595876	chr1:15586136~15603626:-
BRCA	cis	rs1077773	0.585	rs7800734	ENSG00000237773.4	AC003075.4	-4.17	3.26e-05	0.00235	-0.16	-0.13	Ulcerative colitis;Inflammatory bowel disease;	chr7:17399847	chr7:17279834~17299357:-
BRCA	cis	rs6964587	0.967	rs13233496	ENSG00000188693.7	CYP51A1-AS1	-4.17	3.26e-05	0.00235	-0.14	-0.13	Breast cancer;	chr7:92183721	chr7:92134604~92180725:+
BRCA	cis	rs728616	0.867	rs117139504	ENSG00000242600.5	MBL1P	4.17	3.26e-05	0.00235	0.32	0.13	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79974451	chr10:79904898~79950336:+
BRCA	cis	rs7686660	1	rs13126432	ENSG00000250326.1	RP11-284M14.1	-4.17	3.26e-05	0.00235	-0.15	-0.13	Asthma;	chr4:143047041	chr4:142933195~143184861:-
BRCA	cis	rs488400	0.571	rs518213	ENSG00000270265.1	RP11-731D1.4	-4.17	3.26e-05	0.00235	-0.15	-0.13	Trans fatty acid levels;	chr4:151892080	chr4:151333775~151353224:-
BRCA	cis	rs72634258	0.945	rs28624	ENSG00000238290.1	RP11-431K24.1	4.17	3.26e-05	0.00235	0.18	0.13	Inflammatory bowel disease;	chr1:8024295	chr1:8026738~8122702:+
BRCA	cis	rs755249	0.501	rs2484749	ENSG00000237624.1	OXCT2P1	-4.17	3.26e-05	0.00235	-0.16	-0.13	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39293283	chr1:39514956~39516490:+
BRCA	cis	rs11085466	1	rs4399664	ENSG00000268081.1	RP11-678G14.2	-4.17	3.26e-05	0.00235	-0.2	-0.13	Colorectal or endometrial cancer;	chr19:21595224	chr19:21554640~21569237:-
BRCA	cis	rs755249	0.567	rs3754346	ENSG00000182109.6	RP11-69E11.4	4.17	3.26e-05	0.00235	0.18	0.13	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39349288	chr1:39522280~39546187:-
BRCA	cis	rs755249	0.567	rs16826093	ENSG00000182109.6	RP11-69E11.4	4.17	3.26e-05	0.00235	0.18	0.13	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39349471	chr1:39522280~39546187:-
BRCA	cis	rs755249	0.567	rs17264671	ENSG00000182109.6	RP11-69E11.4	4.17	3.26e-05	0.00235	0.18	0.13	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39352380	chr1:39522280~39546187:-
BRCA	cis	rs755249	0.567	rs4660690	ENSG00000182109.6	RP11-69E11.4	4.17	3.26e-05	0.00235	0.18	0.13	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39353831	chr1:39522280~39546187:-
BRCA	cis	rs748404	0.666	rs12907870	ENSG00000205771.5	CATSPER2P1	-4.17	3.26e-05	0.00235	-0.19	-0.13	Lung cancer;	chr15:43453971	chr15:43726918~43747094:-
BRCA	cis	rs1371614	0.632	rs6718978	ENSG00000229122.1	AGBL5-IT1	4.17	3.26e-05	0.00235	0.13	0.13	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26938723	chr2:27061038~27061815:+
BRCA	cis	rs7787531	1	rs6467244	ENSG00000281896.1	RP11-274B21.13	4.17	3.26e-05	0.00235	0.12	0.13	Tuberculosis;	chr7:129409666	chr7:128617865~128625905:+
BRCA	cis	rs7671266	0.532	rs733175	ENSG00000250413.1	RP11-448G15.1	-4.17	3.26e-05	0.00235	-0.2	-0.13	Cardiovascular disease risk factors;	chr4:10048517	chr4:10006482~10009725:+
BRCA	cis	rs35146811	0.735	rs2272345	ENSG00000235713.1	RP4-604G5.3	4.17	3.26e-05	0.00235	0.15	0.13	Coronary artery disease;	chr7:100199408	chr7:99992397~99993050:+
BRCA	cis	rs4835473	0.932	rs62337619	ENSG00000249741.2	RP11-673E1.3	4.17	3.26e-05	0.00235	0.15	0.13	Immature fraction of reticulocytes;	chr4:143742083	chr4:143911514~143912053:-
BRCA	cis	rs7267979	1	rs6132835	ENSG00000274973.1	RP13-401N8.7	-4.17	3.26e-05	0.00235	-0.15	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25454031	chr20:25845497~25845862:+
BRCA	cis	rs7267979	0.933	rs11699203	ENSG00000274973.1	RP13-401N8.7	-4.17	3.26e-05	0.00235	-0.15	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25454533	chr20:25845497~25845862:+
BRCA	cis	rs7267979	0.933	rs6138571	ENSG00000274973.1	RP13-401N8.7	-4.17	3.26e-05	0.00235	-0.15	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25454752	chr20:25845497~25845862:+
BRCA	cis	rs7267979	0.966	rs416745	ENSG00000274973.1	RP13-401N8.7	-4.17	3.26e-05	0.00235	-0.15	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25458232	chr20:25845497~25845862:+
BRCA	cis	rs7267979	1	rs447722	ENSG00000274973.1	RP13-401N8.7	-4.17	3.26e-05	0.00235	-0.15	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25462874	chr20:25845497~25845862:+
BRCA	cis	rs7267979	1	rs422424	ENSG00000274973.1	RP13-401N8.7	-4.17	3.26e-05	0.00235	-0.15	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25464810	chr20:25845497~25845862:+
BRCA	cis	rs7267979	1	rs422844	ENSG00000274973.1	RP13-401N8.7	-4.17	3.26e-05	0.00235	-0.15	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25464955	chr20:25845497~25845862:+
BRCA	cis	rs7267979	1	rs401166	ENSG00000274973.1	RP13-401N8.7	-4.17	3.26e-05	0.00235	-0.15	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25465672	chr20:25845497~25845862:+
BRCA	cis	rs4787491	0.729	rs4238960	ENSG00000183604.13	SMG1P5	-4.17	3.27e-05	0.00235	-0.12	-0.13	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30027327	chr16:30267553~30335374:-
BRCA	cis	rs2554380	0.8	rs2585068	ENSG00000230373.7	GOLGA6L5P	-4.17	3.27e-05	0.00235	-0.17	-0.13	Height;	chr15:83735705	chr15:84507885~84516814:-
BRCA	cis	rs1048886	0.745	rs9283835	ENSG00000271967.1	RP11-134K13.4	-4.17	3.27e-05	0.00235	-0.17	-0.13	Type 2 diabetes;	chr6:70533649	chr6:70596438~70596980:+
BRCA	cis	rs7918232	0.505	rs788221	ENSG00000262412.1	RP11-85G18.6	-4.17	3.27e-05	0.00235	-0.25	-0.13	Breast cancer;	chr10:27153318	chr10:27243130~27250804:+
BRCA	cis	rs360929	0.935	rs360927	ENSG00000245954.5	RP11-18H21.1	-4.17	3.27e-05	0.00235	-0.15	-0.13	Volumetric brain MRI;	chr4:151985693	chr4:152100754~152104720:+
BRCA	cis	rs9470794	1	rs79287562	ENSG00000204110.6	RP1-153P14.8	-4.17	3.27e-05	0.00235	-0.23	-0.13	Type 2 diabetes;	chr6:38128181	chr6:37507348~37535616:+
BRCA	cis	rs2380205	0.875	rs10795593	ENSG00000232807.2	RP11-536K7.3	4.17	3.27e-05	0.00235	0.13	0.13	Breast cancer;	chr10:5853793	chr10:5934270~5945900:-
BRCA	cis	rs6545883	0.929	rs10200055	ENSG00000212978.6	AC016747.3	-4.17	3.27e-05	0.00235	-0.17	-0.13	Tuberculosis;	chr2:61400882	chr2:61141592~61144969:-
BRCA	cis	rs11098499	0.754	rs12711071	ENSG00000260091.1	RP11-33B1.4	-4.17	3.27e-05	0.00235	-0.11	-0.13	Corneal astigmatism;	chr4:119319779	chr4:119409333~119410233:+
BRCA	cis	rs2708977	0.965	rs13019986	ENSG00000237510.6	AC008268.2	4.17	3.27e-05	0.00235	0.17	0.13	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96577321	chr2:95789654~95800166:+
BRCA	cis	rs4835473	0.808	rs1984810	ENSG00000249741.2	RP11-673E1.3	-4.17	3.27e-05	0.00235	-0.13	-0.13	Immature fraction of reticulocytes;	chr4:143824970	chr4:143911514~143912053:-
BRCA	cis	rs853679	0.517	rs12174753	ENSG00000216901.1	AL022393.7	4.17	3.27e-05	0.00235	0.18	0.13	Depression;	chr6:28074687	chr6:28176188~28176674:+
BRCA	cis	rs4237845	0.537	rs10877031	ENSG00000270039.1	RP11-571M6.17	-4.17	3.27e-05	0.00235	-0.18	-0.13	Intelligence (multi-trait analysis);	chr12:57872912	chr12:57803838~57804415:+
BRCA	cis	rs6452524	1	rs62374374	ENSG00000281327.1	LINC01338	4.17	3.27e-05	0.00235	0.15	0.13	Hypertension (SNP x SNP interaction);	chr5:83144838	chr5:82850864~82859836:-
BRCA	cis	rs6452524	1	rs1382372	ENSG00000281327.1	LINC01338	4.17	3.27e-05	0.00235	0.15	0.13	Hypertension (SNP x SNP interaction);	chr5:83145237	chr5:82850864~82859836:-
BRCA	cis	rs6452524	1	rs1382371	ENSG00000281327.1	LINC01338	4.17	3.27e-05	0.00235	0.15	0.13	Hypertension (SNP x SNP interaction);	chr5:83145300	chr5:82850864~82859836:-
BRCA	cis	rs6452524	1	rs1382369	ENSG00000281327.1	LINC01338	4.17	3.27e-05	0.00235	0.15	0.13	Hypertension (SNP x SNP interaction);	chr5:83145610	chr5:82850864~82859836:-
BRCA	cis	rs6452524	1	rs2386240	ENSG00000281327.1	LINC01338	4.17	3.27e-05	0.00235	0.15	0.13	Hypertension (SNP x SNP interaction);	chr5:83147192	chr5:82850864~82859836:-
BRCA	cis	rs6452524	1	rs9986131	ENSG00000281327.1	LINC01338	4.17	3.27e-05	0.00235	0.15	0.13	Hypertension (SNP x SNP interaction);	chr5:83149037	chr5:82850864~82859836:-
BRCA	cis	rs853679	0.567	rs7740429	ENSG00000220721.1	OR1F12	4.17	3.27e-05	0.00235	0.17	0.13	Depression;	chr6:28431469	chr6:28073316~28074233:+
BRCA	cis	rs3858526	0.883	rs1453429	ENSG00000224295.2	AC087380.14	4.17	3.27e-05	0.00235	0.18	0.13	DNA methylation (variation);	chr11:5912248	chr11:5518441~5524955:-
BRCA	cis	rs1008375	1	rs1974624	ENSG00000249502.1	AC006160.5	-4.17	3.27e-05	0.00235	-0.15	-0.13	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17648658	chr4:17587467~17614571:-
BRCA	cis	rs1008375	0.902	rs6844984	ENSG00000249502.1	AC006160.5	-4.17	3.27e-05	0.00235	-0.15	-0.13	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17649681	chr4:17587467~17614571:-
BRCA	cis	rs9733	0.593	rs10888384	ENSG00000203804.4	ADAMTSL4-AS1	-4.17	3.27e-05	0.00235	-0.14	-0.13	Tonsillectomy;	chr1:150601780	chr1:150560202~150574552:-
BRCA	cis	rs72615157	0.634	rs74774557	ENSG00000242294.5	STAG3L5P	4.17	3.27e-05	0.00235	0.12	0.13	Lung function (FEV1/FVC);	chr7:100212802	chr7:100336079~100351900:+
BRCA	cis	rs5758511	0.731	rs58302269	ENSG00000226450.2	CYP2D8P	4.17	3.27e-05	0.00235	0.14	0.13	Birth weight;	chr22:41955305	chr22:42149886~42155001:-
BRCA	cis	rs3816183	1	rs6717616	ENSG00000226491.1	FTOP1	-4.17	3.27e-05	0.00236	-0.16	-0.13	Hypospadias;	chr2:42786197	chr2:42797225~42798712:-
BRCA	cis	rs9840812	0.637	rs698270	ENSG00000273486.1	RP11-731C17.2	4.17	3.27e-05	0.00236	0.16	0.13	Fibrinogen levels;	chr3:136390670	chr3:136837338~136839021:-
BRCA	cis	rs728616	0.681	rs12412762	ENSG00000225484.5	NUTM2B-AS1	4.17	3.27e-05	0.00236	0.29	0.13	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80147714	chr10:79663088~79826594:-
BRCA	cis	rs11098499	0.691	rs28396837	ENSG00000260404.2	RP11-384K6.6	4.17	3.27e-05	0.00236	0.11	0.13	Corneal astigmatism;	chr4:119350386	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.629	rs28369518	ENSG00000260404.2	RP11-384K6.6	4.17	3.27e-05	0.00236	0.11	0.13	Corneal astigmatism;	chr4:119350475	chr4:118591773~118633729:+
BRCA	cis	rs4650994	1	rs10913571	ENSG00000273384.1	RP5-1098D14.1	4.17	3.28e-05	0.00236	0.16	0.13	HDL cholesterol;HDL cholesterol levels;	chr1:178557513	chr1:178651706~178652282:+
BRCA	cis	rs4650994	1	rs10913572	ENSG00000273384.1	RP5-1098D14.1	4.17	3.28e-05	0.00236	0.16	0.13	HDL cholesterol;HDL cholesterol levels;	chr1:178557583	chr1:178651706~178652282:+
BRCA	cis	rs1660895	0.576	rs17049280	ENSG00000227632.2	AC018804.6	4.17	3.28e-05	0.00236	0.17	0.13	Alcohol dependence (age at onset);	chr2:129250882	chr2:130202312~130212628:+
BRCA	cis	rs7308116	0.874	rs6419396	ENSG00000274395.1	RP11-554D14.8	-4.17	3.28e-05	0.00236	-0.14	-0.13	Pelvic organ prolapse (moderate/severe);	chr12:107807321	chr12:107835541~107836555:-
BRCA	cis	rs7308116	0.874	rs6539362	ENSG00000274395.1	RP11-554D14.8	-4.17	3.28e-05	0.00236	-0.14	-0.13	Pelvic organ prolapse (moderate/severe);	chr12:107807334	chr12:107835541~107836555:-
BRCA	cis	rs1836229	0.869	rs7864663	ENSG00000225706.1	PTPRD-AS1	-4.17	3.28e-05	0.00236	-0.14	-0.13	Restless legs syndrome;	chr9:8824417	chr9:8858130~8862255:+
BRCA	cis	rs11719291	0.833	rs11713694	ENSG00000225399.4	RP11-3B7.1	-4.17	3.28e-05	0.00236	-0.23	-0.13	Cognitive function;	chr3:48796182	chr3:49260085~49261316:+
BRCA	cis	rs9470794	1	rs11758095	ENSG00000204110.6	RP1-153P14.8	-4.17	3.28e-05	0.00236	-0.23	-0.13	Type 2 diabetes;	chr6:38117673	chr6:37507348~37535616:+
BRCA	cis	rs2998286	0.862	rs2807728	ENSG00000237128.1	RP11-351M16.3	-4.17	3.28e-05	0.00236	-0.16	-0.13	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28526504	chr10:28433008~28495813:-
BRCA	cis	rs875971	1	rs6957199	ENSG00000229180.5	GS1-124K5.11	4.17	3.28e-05	0.00236	0.11	0.13	Aortic root size;	chr7:66513532	chr7:66526088~66542624:-
BRCA	cis	rs2832191	0.791	rs9983651	ENSG00000236056.1	GAPDHP14	4.17	3.28e-05	0.00236	0.14	0.13	Dental caries;	chr21:29118906	chr21:29222321~29223257:+
BRCA	cis	rs2832191	0.755	rs55671430	ENSG00000236056.1	GAPDHP14	4.17	3.28e-05	0.00236	0.14	0.13	Dental caries;	chr21:29120100	chr21:29222321~29223257:+
BRCA	cis	rs2832191	0.72	rs2832194	ENSG00000236056.1	GAPDHP14	4.17	3.28e-05	0.00236	0.14	0.13	Dental caries;	chr21:29121929	chr21:29222321~29223257:+
BRCA	cis	rs5751614	0.537	rs7288846	ENSG00000240160.3	RN7SL263P	-4.17	3.28e-05	0.00236	-0.17	-0.13	Height;	chr22:23281097	chr22:23261782~23262071:-
BRCA	cis	rs11719291	0.833	rs11709246	ENSG00000225399.4	RP11-3B7.1	-4.17	3.28e-05	0.00236	-0.23	-0.13	Cognitive function;	chr3:48822065	chr3:49260085~49261316:+
BRCA	cis	rs11719291	0.504	rs71324924	ENSG00000225399.4	RP11-3B7.1	-4.17	3.28e-05	0.00236	-0.23	-0.13	Cognitive function;	chr3:48828011	chr3:49260085~49261316:+
BRCA	cis	rs757081	0.667	rs17641418	ENSG00000184669.7	OR7E14P	-4.17	3.28e-05	0.00236	-0.19	-0.13	Systolic blood pressure;	chr11:17139794	chr11:17013998~17053024:+
BRCA	cis	rs7200543	1	rs7200543	ENSG00000207425.1	Y_RNA	4.17	3.28e-05	0.00236	0.15	0.13	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15036113	chr16:14915457~14915556:-
BRCA	cis	rs7592578	0.766	rs35818159	ENSG00000272979.1	RP11-647K16.1	-4.17	3.28e-05	0.00236	-0.23	-0.13	Diastolic blood pressure;	chr2:190544890	chr2:190454092~190454521:-
BRCA	cis	rs11098499	0.865	rs4507344	ENSG00000260404.2	RP11-384K6.6	4.17	3.28e-05	0.00236	0.12	0.13	Corneal astigmatism;	chr4:119386330	chr4:118591773~118633729:+
BRCA	cis	rs8180040	0.726	rs2305634	ENSG00000276925.1	RP11-708J19.3	4.17	3.28e-05	0.00236	0.15	0.13	Colorectal cancer;	chr3:47002048	chr3:47469777~47469987:+
BRCA	cis	rs11168351	0.833	rs6580652	ENSG00000257735.1	RP11-370I10.6	-4.17	3.28e-05	0.00236	-0.16	-0.13	Bipolar disorder and schizophrenia;	chr12:48053322	chr12:48350945~48442411:+
BRCA	cis	rs983392	1	rs11230155	ENSG00000275344.1	MIR6503	-4.17	3.28e-05	0.00236	-0.13	-0.13	Alzheimer's disease (late onset);	chr11:60137486	chr11:60209071~60209156:-
BRCA	cis	rs1348850	0.651	rs4893936	ENSG00000280374.1	RP11-337N6.3	4.17	3.28e-05	0.00236	0.16	0.13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177375948	chr2:177317715~177318471:-
BRCA	cis	rs1865760	0.865	rs1115920	ENSG00000272462.2	U91328.19	-4.17	3.28e-05	0.00236	-0.15	-0.13	Height;	chr6:25953799	chr6:25992662~26001775:+
BRCA	cis	rs7412746	0.658	rs12068264	ENSG00000231073.1	RP11-316M1.3	4.17	3.28e-05	0.00236	0.14	0.13	Melanoma;	chr1:150754853	chr1:150973123~150975534:+
BRCA	cis	rs9527	0.59	rs10883843	ENSG00000213061.2	PFN1P11	4.17	3.28e-05	0.00236	0.18	0.13	Arsenic metabolism;	chr10:103187736	chr10:102838011~102845473:-
BRCA	cis	rs4819052	1	rs2838847	ENSG00000184274.3	LINC00315	-4.17	3.28e-05	0.00236	-0.18	-0.13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251043	chr21:45300245~45305257:-
BRCA	cis	rs2731006	0.64	rs2731010	ENSG00000257114.2	RP11-25I15.3	4.17	3.28e-05	0.00236	0.21	0.13	Panic disorder;	chr12:42767686	chr12:42692216~42717119:+
BRCA	cis	rs2731006	0.64	rs17091886	ENSG00000257114.2	RP11-25I15.3	4.17	3.28e-05	0.00236	0.21	0.13	Panic disorder;	chr12:42767786	chr12:42692216~42717119:+
BRCA	cis	rs2731006	0.64	rs2731015	ENSG00000257114.2	RP11-25I15.3	4.17	3.28e-05	0.00236	0.21	0.13	Panic disorder;	chr12:42767818	chr12:42692216~42717119:+
BRCA	cis	rs2731006	0.64	rs2731016	ENSG00000257114.2	RP11-25I15.3	4.17	3.28e-05	0.00236	0.21	0.13	Panic disorder;	chr12:42768032	chr12:42692216~42717119:+
BRCA	cis	rs2731006	0.64	rs2678112	ENSG00000257114.2	RP11-25I15.3	4.17	3.28e-05	0.00236	0.21	0.13	Panic disorder;	chr12:42768061	chr12:42692216~42717119:+
BRCA	cis	rs17711722	0.565	rs73372653	ENSG00000226002.1	RP11-460N20.5	4.17	3.28e-05	0.00236	0.14	0.13	Calcium levels;	chr7:65977808	chr7:65084103~65100232:+
BRCA	cis	rs9635963	1	rs8091699	ENSG00000264924.1	RP11-799B12.2	-4.17	3.28e-05	0.00236	-0.15	-0.13	Protein quantitative trait loci;	chr18:24144281	chr18:24113637~24121003:-
BRCA	cis	rs983392	1	rs55847558	ENSG00000275344.1	MIR6503	-4.17	3.28e-05	0.00236	-0.13	-0.13	Alzheimer's disease (late onset);	chr11:60136320	chr11:60209071~60209156:-
BRCA	cis	rs4415084	0.804	rs4329028	ENSG00000251141.4	RP11-53O19.1	4.17	3.28e-05	0.00236	0.12	0.13	Breast cancer;	chr5:44872251	chr5:44744900~44808777:-
BRCA	cis	rs11122895	0.61	rs13397902	ENSG00000236307.2	EEF1E1P1	4.17	3.28e-05	0.00236	0.14	0.13	Allergic sensitization;	chr2:111849928	chr2:111887914~111888741:+
BRCA	cis	rs4578769	0.765	rs10432158	ENSG00000265939.1	UBE2CP2	-4.17	3.28e-05	0.00236	-0.16	-0.13	Eosinophil percentage of white cells;	chr18:22826406	chr18:22900486~22900995:-
BRCA	cis	rs4578769	0.765	rs10432159	ENSG00000265939.1	UBE2CP2	-4.17	3.28e-05	0.00236	-0.16	-0.13	Eosinophil percentage of white cells;	chr18:22826596	chr18:22900486~22900995:-
BRCA	cis	rs4578769	0.765	rs16972382	ENSG00000265939.1	UBE2CP2	-4.17	3.28e-05	0.00236	-0.16	-0.13	Eosinophil percentage of white cells;	chr18:22831403	chr18:22900486~22900995:-
BRCA	cis	rs8180040	1	rs1076394	ENSG00000271161.1	BOLA2P2	-4.17	3.28e-05	0.00236	-0.14	-0.13	Colorectal cancer;	chr3:47281291	chr3:47499841~47500407:+
BRCA	cis	rs8180040	0.966	rs17476234	ENSG00000271161.1	BOLA2P2	-4.17	3.28e-05	0.00236	-0.14	-0.13	Colorectal cancer;	chr3:47284808	chr3:47499841~47500407:+
BRCA	cis	rs2625529	0.701	rs12911154	ENSG00000260037.4	CTD-2524L6.3	-4.17	3.28e-05	0.00236	-0.19	-0.13	Red blood cell count;	chr15:71920312	chr15:71818396~71823384:+
BRCA	cis	rs9818758	0.545	rs9853352	ENSG00000270441.1	RP11-694I15.7	-4.17	3.29e-05	0.00236	-0.26	-0.13	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49775825	chr3:49140086~49160851:-
BRCA	cis	rs56077333	1	rs56077333	ENSG00000261762.1	RP11-650L12.2	-4.17	3.29e-05	0.00236	-0.15	-0.13	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio in COPD;	chr15:78606661	chr15:78589123~78591276:-
BRCA	cis	rs66887589	0.616	rs6843509	ENSG00000250412.1	KLHL2P1	4.17	3.29e-05	0.00236	0.14	0.13	Diastolic blood pressure;	chr4:119299041	chr4:119334329~119378233:+
BRCA	cis	rs10792665	0.686	rs1904428	ENSG00000246067.6	RAB30-AS1	4.17	3.29e-05	0.00236	0.13	0.13	Obesity-related traits;	chr11:83007210	chr11:83072066~83106719:+
BRCA	cis	rs1322639	0.571	rs13204417	ENSG00000223485.1	RP11-417E7.1	4.17	3.29e-05	0.00236	0.14	0.13	Pulse pressure;	chr6:169175260	chr6:169158092~169162924:-
BRCA	cis	rs10411936	1	rs16995422	ENSG00000280332.1	CTD-2013N17.6	-4.17	3.29e-05	0.00236	-0.11	-0.13	Multiple sclerosis;White blood cell count;	chr19:16408234	chr19:16356329~16358327:-
BRCA	cis	rs7918232	0.943	rs4747584	ENSG00000262412.1	RP11-85G18.6	4.17	3.29e-05	0.00236	0.21	0.13	Breast cancer;	chr10:27084404	chr10:27243130~27250804:+
BRCA	cis	rs3816183	1	rs893730	ENSG00000226491.1	FTOP1	-4.17	3.29e-05	0.00236	-0.16	-0.13	Hypospadias;	chr2:42788226	chr2:42797225~42798712:-
BRCA	cis	rs58521262	0.53	rs289344	ENSG00000268105.1	RP11-369G6.2	4.17	3.29e-05	0.00236	0.17	0.13	Testicular germ cell tumor;	chr19:22966868	chr19:23125665~23128543:+
BRCA	cis	rs58521262	0.505	rs289343	ENSG00000268105.1	RP11-369G6.2	4.17	3.29e-05	0.00236	0.17	0.13	Testicular germ cell tumor;	chr19:22967394	chr19:23125665~23128543:+
BRCA	cis	rs58521262	0.556	rs289342	ENSG00000268105.1	RP11-369G6.2	4.17	3.29e-05	0.00236	0.17	0.13	Testicular germ cell tumor;	chr19:22967587	chr19:23125665~23128543:+
BRCA	cis	rs58521262	0.556	rs289339	ENSG00000268105.1	RP11-369G6.2	4.17	3.29e-05	0.00236	0.17	0.13	Testicular germ cell tumor;	chr19:22968097	chr19:23125665~23128543:+
BRCA	cis	rs4478858	0.684	rs10798837	ENSG00000260386.4	LINC01225	-4.17	3.29e-05	0.00236	-0.15	-0.13	Alcohol dependence;	chr1:31246493	chr1:31500085~31540885:+
BRCA	cis	rs4478858	0.684	rs10798838	ENSG00000260386.4	LINC01225	-4.17	3.29e-05	0.00236	-0.15	-0.13	Alcohol dependence;	chr1:31246603	chr1:31500085~31540885:+
BRCA	cis	rs7590268	0.806	rs7596480	ENSG00000279873.2	LINC01126	-4.17	3.29e-05	0.00237	-0.15	-0.13	Orofacial clefts;	chr2:43394023	chr2:43227210~43228855:+
BRCA	cis	rs2625529	0.938	rs2625530	ENSG00000260037.4	CTD-2524L6.3	-4.17	3.29e-05	0.00237	-0.18	-0.13	Red blood cell count;	chr15:71833693	chr15:71818396~71823384:+
BRCA	cis	rs9467773	0.62	rs1027203	ENSG00000241549.7	GUSBP2	4.17	3.29e-05	0.00237	0.14	0.13	Intelligence (multi-trait analysis);	chr6:26639104	chr6:26871484~26956554:-
BRCA	cis	rs9467773	0.595	rs2172007	ENSG00000241549.7	GUSBP2	4.17	3.29e-05	0.00237	0.14	0.13	Intelligence (multi-trait analysis);	chr6:26639549	chr6:26871484~26956554:-
BRCA	cis	rs7267979	0.966	rs6083855	ENSG00000277938.1	RP5-965G21.3	-4.17	3.29e-05	0.00237	-0.15	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25424482	chr20:25229150~25231933:+
BRCA	cis	rs7267979	1	rs4815426	ENSG00000277938.1	RP5-965G21.3	-4.17	3.29e-05	0.00237	-0.15	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25424550	chr20:25229150~25231933:+
BRCA	cis	rs10129255	0.5	rs10131875	ENSG00000211967.3	IGHV3-53	-4.17	3.29e-05	0.00237	-0.08	-0.13	Kawasaki disease;	chr14:106792798	chr14:106592676~106593347:-
BRCA	cis	rs4648045	0.565	rs4698862	ENSG00000246560.2	RP11-10L12.4	4.17	3.29e-05	0.00237	0.15	0.13	Lymphocyte percentage of white cells;	chr4:102624640	chr4:102828055~102844075:+
BRCA	cis	rs1065852	0.526	rs9607869	ENSG00000205702.9	CYP2D7	4.17	3.29e-05	0.00237	0.12	0.13	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42022106	chr22:42140203~42144577:-
BRCA	cis	rs6671200	1	rs259354	ENSG00000226026.4	RP11-57H12.3	-4.17	3.29e-05	0.00237	-0.24	-0.13	Stearic acid (18:0) levels;	chr1:95252649	chr1:95163219~95233982:-
BRCA	cis	rs4272720	0.901	rs72785044	ENSG00000228754.1	RP11-534L6.3	-4.17	3.29e-05	0.00237	-0.19	-0.13	Platelet count;Plateletcrit;	chr10:49101804	chr10:48745545~48746128:-
BRCA	cis	rs7412746	0.658	rs2272214	ENSG00000231073.1	RP11-316M1.3	4.17	3.29e-05	0.00237	0.13	0.13	Melanoma;	chr1:150958986	chr1:150973123~150975534:+
BRCA	cis	rs875971	1	rs10244498	ENSG00000272831.1	RP11-792A8.4	4.17	3.29e-05	0.00237	0.12	0.13	Aortic root size;	chr7:66651069	chr7:66739829~66740385:-
BRCA	cis	rs597539	0.652	rs646586	ENSG00000255741.1	RP11-757G1.5	4.17	3.29e-05	0.00237	0.18	0.13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68914185	chr11:68941503~68942852:-
BRCA	cis	rs7917772	0.503	rs11191347	ENSG00000213061.2	PFN1P11	-4.17	3.29e-05	0.00237	-0.17	-0.13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;	chr10:102591860	chr10:102838011~102845473:-
BRCA	cis	rs6430585	0.697	rs7607174	ENSG00000224043.6	CCNT2-AS1	-4.17	3.29e-05	0.00237	-0.22	-0.13	Corneal structure;	chr2:135756100	chr2:134735464~134918710:-
BRCA	cis	rs6430585	0.697	rs115944351	ENSG00000224043.6	CCNT2-AS1	-4.17	3.29e-05	0.00237	-0.22	-0.13	Corneal structure;	chr2:135757888	chr2:134735464~134918710:-
BRCA	cis	rs2243480	0.908	rs4718273	ENSG00000275400.1	RP4-756H11.5	-4.17	3.29e-05	0.00237	-0.23	-0.13	Diabetic kidney disease;	chr7:65751112	chr7:66553805~66554199:-
BRCA	cis	rs591584	0.802	rs6483346	ENSG00000255893.1	RP11-685N10.1	-4.17	3.3e-05	0.00237	-0.14	-0.13	Macrophage Migration Inhibitory Factor levels;	chr11:94555485	chr11:94472908~94473570:-
BRCA	cis	rs6490294	0.851	rs1016079	ENSG00000257624.1	RP1-128M12.3	-4.17	3.3e-05	0.00237	-0.17	-0.13	Mean platelet volume;	chr12:111972382	chr12:112000739~112000985:-
BRCA	cis	rs7512898	0.9	rs6427848	ENSG00000260088.1	RP11-92G12.3	-4.17	3.3e-05	0.00237	-0.15	-0.13	Electrocardiographic conduction measures;	chr1:200701253	chr1:200669507~200694250:+
BRCA	cis	rs11098499	0.863	rs6835635	ENSG00000250412.1	KLHL2P1	4.17	3.3e-05	0.00237	0.16	0.13	Corneal astigmatism;	chr4:119537712	chr4:119334329~119378233:+
BRCA	cis	rs2243480	1	rs1167613	ENSG00000275400.1	RP4-756H11.5	4.17	3.3e-05	0.00237	0.23	0.13	Diabetic kidney disease;	chr7:66022452	chr7:66553805~66554199:-
BRCA	cis	rs2243480	1	rs313799	ENSG00000275400.1	RP4-756H11.5	4.17	3.3e-05	0.00237	0.23	0.13	Diabetic kidney disease;	chr7:66029343	chr7:66553805~66554199:-
BRCA	cis	rs12887734	0.524	rs4906363	ENSG00000269940.1	RP11-73M18.7	4.17	3.3e-05	0.00237	0.14	0.13	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103743902	chr14:103694560~103695170:+
BRCA	cis	rs4578769	0.765	rs11662489	ENSG00000265939.1	UBE2CP2	-4.17	3.3e-05	0.00237	-0.16	-0.13	Eosinophil percentage of white cells;	chr18:22816959	chr18:22900486~22900995:-
BRCA	cis	rs1979679	0.578	rs2127316	ENSG00000278733.1	RP11-425D17.1	4.17	3.3e-05	0.00237	0.16	0.13	Ossification of the posterior longitudinal ligament of the spine;	chr12:28121472	chr12:28185625~28186190:-
BRCA	cis	rs4948275	0.631	rs2787720	ENSG00000237233.2	TMEM26-AS1	-4.17	3.3e-05	0.00237	-0.15	-0.13	Night sleep phenotypes;	chr10:61588707	chr10:61452639~61481956:+
BRCA	cis	rs4948275	0.631	rs2606112	ENSG00000237233.2	TMEM26-AS1	-4.17	3.3e-05	0.00237	-0.15	-0.13	Night sleep phenotypes;	chr10:61588746	chr10:61452639~61481956:+
BRCA	cis	rs4948275	0.631	rs2650744	ENSG00000237233.2	TMEM26-AS1	-4.17	3.3e-05	0.00237	-0.15	-0.13	Night sleep phenotypes;	chr10:61588800	chr10:61452639~61481956:+
BRCA	cis	rs4948275	0.597	rs2606113	ENSG00000237233.2	TMEM26-AS1	-4.17	3.3e-05	0.00237	-0.15	-0.13	Night sleep phenotypes;	chr10:61589204	chr10:61452639~61481956:+
BRCA	cis	rs9467773	1	rs1321479	ENSG00000241549.7	GUSBP2	-4.17	3.3e-05	0.00237	-0.13	-0.13	Intelligence (multi-trait analysis);	chr6:26501669	chr6:26871484~26956554:-
BRCA	cis	rs7182948	1	rs12902794	ENSG00000259531.2	RP11-295H24.3	-4.17	3.3e-05	0.00237	-0.18	-0.13	Lung adenocarcinoma;	chr15:49574951	chr15:49365124~49366685:-
BRCA	cis	rs2333021	1	rs2333021	ENSG00000259015.1	RP11-109N23.6	4.17	3.3e-05	0.00237	0.13	0.13	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:73017676	chr14:72960595~72961993:+
BRCA	cis	rs6599077	1	rs6768659	ENSG00000223797.4	ENTPD3-AS1	4.17	3.3e-05	0.00237	0.16	0.13	Sleep-related phenotypes;	chr3:40055510	chr3:40313802~40453329:-
BRCA	cis	rs6963495	0.818	rs17343556	ENSG00000223886.3	RP11-251G23.2	4.17	3.3e-05	0.00237	0.2	0.13	Bipolar disorder (body mass index interaction);	chr7:105510825	chr7:105530209~105530671:+
BRCA	cis	rs8098244	0.557	rs11082712	ENSG00000265752.2	RP11-403A21.1	4.17	3.3e-05	0.00237	0.14	0.13	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23718286	chr18:23957754~23982556:-
BRCA	cis	rs61160187	0.582	rs1460961	ENSG00000272308.1	RP11-231G3.1	-4.17	3.3e-05	0.00237	-0.15	-0.13	Educational attainment (years of education);Educational attainment (college completion);	chr5:61116005	chr5:60866457~60866935:-
BRCA	cis	rs34217772	0.68	rs61990336	ENSG00000258636.1	CTD-2298J14.2	4.17	3.3e-05	0.00237	0.17	0.13	Myopia;	chr14:41712728	chr14:41587861~41604856:-
BRCA	cis	rs812925	0.502	rs2084318	ENSG00000270820.4	RP11-355B11.2	-4.17	3.3e-05	0.00237	-0.14	-0.13	Immature fraction of reticulocytes;	chr2:61425466	chr2:61471188~61484130:+
BRCA	cis	rs6546324	0.592	rs2861648	ENSG00000236780.4	AC078941.1	4.17	3.3e-05	0.00237	0.22	0.13	Endometriosis;	chr2:67576776	chr2:67123357~67215319:-
BRCA	cis	rs9470794	0.915	rs73419461	ENSG00000204110.6	RP1-153P14.8	-4.17	3.3e-05	0.00237	-0.26	-0.13	Type 2 diabetes;	chr6:37900118	chr6:37507348~37535616:+
BRCA	cis	rs9470794	0.915	rs73419465	ENSG00000204110.6	RP1-153P14.8	-4.17	3.3e-05	0.00237	-0.26	-0.13	Type 2 diabetes;	chr6:37900982	chr6:37507348~37535616:+
BRCA	cis	rs6940638	0.662	rs6915678	ENSG00000124549.13	BTN2A3P	-4.17	3.3e-05	0.00237	-0.13	-0.13	Intelligence (multi-trait analysis);	chr6:27268087	chr6:26421391~26432383:+
BRCA	cis	rs6921919	0.525	rs16894095	ENSG00000220721.1	OR1F12	4.17	3.3e-05	0.00237	0.16	0.13	Autism spectrum disorder or schizophrenia;	chr6:28422453	chr6:28073316~28074233:+
BRCA	cis	rs11098499	0.722	rs1814814	ENSG00000249244.1	RP11-548H18.2	4.17	3.3e-05	0.00237	0.14	0.13	Corneal astigmatism;	chr4:119336969	chr4:119391831~119395335:-
BRCA	cis	rs4950322	0.542	rs4950384	ENSG00000237188.3	RP11-337C18.8	4.17	3.3e-05	0.00237	0.16	0.13	Protein quantitative trait loci;	chr1:147177310	chr1:147172771~147211568:+
BRCA	cis	rs9926296	0.715	rs467035	ENSG00000223959.7	AFG3L1P	-4.17	3.3e-05	0.00237	-0.13	-0.13	Vitiligo;	chr16:89673877	chr16:89972586~90002161:+
BRCA	cis	rs11671005	0.572	rs11669127	ENSG00000269600.1	AC016629.3	4.17	3.31e-05	0.00238	0.21	0.13	Mean platelet volume;	chr19:58492463	chr19:58593896~58599355:-
BRCA	cis	rs6452524	1	rs6882220	ENSG00000281327.1	LINC01338	4.17	3.31e-05	0.00238	0.15	0.13	Hypertension (SNP x SNP interaction);	chr5:83139715	chr5:82850864~82859836:-
BRCA	cis	rs7119	0.651	rs12915057	ENSG00000259362.2	RP11-307C19.1	-4.17	3.31e-05	0.00238	-0.18	-0.13	Type 2 diabetes;	chr15:77555403	chr15:77525540~77534110:+
BRCA	cis	rs7119	0.679	rs34075648	ENSG00000259362.2	RP11-307C19.1	-4.17	3.31e-05	0.00238	-0.18	-0.13	Type 2 diabetes;	chr15:77555460	chr15:77525540~77534110:+
BRCA	cis	rs7119	0.651	rs35657172	ENSG00000259362.2	RP11-307C19.1	-4.17	3.31e-05	0.00238	-0.18	-0.13	Type 2 diabetes;	chr15:77555471	chr15:77525540~77534110:+
BRCA	cis	rs11098499	0.954	rs7437420	ENSG00000225892.3	RP11-384K6.2	4.17	3.31e-05	0.00238	0.13	0.13	Corneal astigmatism;	chr4:119391748	chr4:118632274~118634759:+
BRCA	cis	rs2832191	0.74	rs2853830	ENSG00000232855.5	AF131217.1	-4.17	3.31e-05	0.00238	-0.16	-0.13	Dental caries;	chr21:29044503	chr21:28439346~28674848:-
BRCA	cis	rs7267979	1	rs12428	ENSG00000274414.1	RP5-965G21.4	4.17	3.31e-05	0.00238	0.15	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25453185	chr20:25239007~25245229:-
BRCA	cis	rs7923609	0.502	rs7896910	ENSG00000232075.1	MRPL35P2	-4.17	3.31e-05	0.00238	-0.19	-0.13	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63256961	chr10:63634317~63634827:-
BRCA	cis	rs2574985	0.887	rs2339402	ENSG00000231345.3	BEND3P1	4.17	3.31e-05	0.00238	0.2	0.13	Subjective well-being;	chr10:50394027	chr10:50655967~50660472:+
BRCA	cis	rs6847067	0.636	rs4383611	ENSG00000180769.7	WDFY3-AS2	4.17	3.31e-05	0.00238	0.13	0.13	Oropharynx cancer;	chr4:84996655	chr4:84965682~85011277:+
BRCA	cis	rs4831760	0.783	rs4831341	ENSG00000250483.1	PPM1AP1	4.17	3.31e-05	0.00238	0.19	0.13	Pulmonary function decline;	chr8:15565984	chr8:15806149~15807283:-
BRCA	cis	rs6452524	0.935	rs3901654	ENSG00000281327.1	LINC01338	4.17	3.31e-05	0.00238	0.15	0.13	Hypertension (SNP x SNP interaction);	chr5:83110519	chr5:82850864~82859836:-
BRCA	cis	rs4835473	0.9	rs35670120	ENSG00000249741.2	RP11-673E1.3	4.17	3.31e-05	0.00238	0.14	0.13	Immature fraction of reticulocytes;	chr4:143787041	chr4:143911514~143912053:-
BRCA	cis	rs4950322	0.57	rs17356184	ENSG00000237188.3	RP11-337C18.8	4.17	3.31e-05	0.00238	0.16	0.13	Protein quantitative trait loci;	chr1:147262943	chr1:147172771~147211568:+
BRCA	cis	rs4950322	0.57	rs4950392	ENSG00000237188.3	RP11-337C18.8	4.17	3.31e-05	0.00238	0.16	0.13	Protein quantitative trait loci;	chr1:147264889	chr1:147172771~147211568:+
BRCA	cis	rs934734	0.935	rs6711791	ENSG00000281920.1	RP11-418H16.1	4.17	3.31e-05	0.00238	0.15	0.13	Rheumatoid arthritis;	chr2:65352094	chr2:65623272~65628424:+
BRCA	cis	rs10266483	0.774	rs7796802	ENSG00000271550.1	BNIP3P11	-4.17	3.31e-05	0.00238	-0.17	-0.13	Response to statin therapy;	chr7:64323744	chr7:64678954~64687393:-
BRCA	cis	rs896854	0.738	rs481887	ENSG00000245080.5	RP11-320N21.1	-4.17	3.31e-05	0.00238	-0.16	-0.13	Type 2 diabetes;	chr8:94955610	chr8:95066808~95073182:-
BRCA	cis	rs61931739	0.534	rs11053047	ENSG00000258794.3	DUX4L27	4.17	3.31e-05	0.00238	0.19	0.13	Morning vs. evening chronotype;	chr12:34008149	chr12:34208415~34209675:-
BRCA	cis	rs11051970	0.879	rs2467065	ENSG00000274964.1	RP11-817I4.1	-4.17	3.31e-05	0.00238	-0.15	-0.13	Response to tocilizumab in rheumatoid arthritis;	chr12:32433131	chr12:32339368~32340724:+
BRCA	cis	rs7226408	0.842	rs1609425	ENSG00000267707.2	RP11-95O2.5	-4.17	3.31e-05	0.00238	-0.21	-0.13	Obesity-related traits;	chr18:36765721	chr18:37243776~37247506:+
BRCA	cis	rs12591650	0.556	rs746241	ENSG00000259591.1	RP11-554D20.1	-4.17	3.31e-05	0.00238	-0.21	-0.13	Subcutaneous adipose tissue;	chr15:60785832	chr15:60763906~60765625:+
BRCA	cis	rs1910358	0.554	rs3904974	ENSG00000248874.4	C5orf17	4.17	3.31e-05	0.00238	0.18	0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23743683	chr5:23951348~24178263:+
BRCA	cis	rs6128907	0.615	rs116490114	ENSG00000224635.1	RP4-564F22.5	4.17	3.31e-05	0.00238	0.2	0.13	Liver fibrosis in pediatric non-alcoholic fatty acid liver disease;	chr20:38779527	chr20:38406011~38416797:-
BRCA	cis	rs7771547	0.755	rs6937430	ENSG00000224666.3	RP1-50J22.4	4.17	3.31e-05	0.00238	0.15	0.13	Platelet distribution width;	chr6:36634120	chr6:36386831~36393462:+
BRCA	cis	rs801193	1	rs7782320	ENSG00000223473.2	GS1-124K5.3	4.17	3.32e-05	0.00238	0.1	0.13	Aortic root size;	chr7:66712111	chr7:66491049~66493566:-
BRCA	cis	rs61160187	0.549	rs56031340	ENSG00000272308.1	RP11-231G3.1	-4.17	3.32e-05	0.00238	-0.15	-0.13	Educational attainment (years of education);Educational attainment (college completion);	chr5:60958043	chr5:60866457~60866935:-
BRCA	cis	rs4415084	0.716	rs4457089	ENSG00000251141.4	RP11-53O19.1	4.17	3.32e-05	0.00238	0.12	0.13	Breast cancer;	chr5:44821634	chr5:44744900~44808777:-
BRCA	cis	rs11931598	0.513	rs3857170	ENSG00000245468.3	RP11-367J11.3	4.17	3.32e-05	0.00238	0.12	0.13	Sum basophil neutrophil counts;Neutrophil count;Granulocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;	chr4:7001639	chr4:7094571~7103385:-
BRCA	cis	rs1009077	0.68	rs62319609	ENSG00000245958.5	RP11-33B1.1	4.17	3.32e-05	0.00238	0.16	0.13	Endometriosis;	chr4:119570485	chr4:119454791~119552025:+
BRCA	cis	rs757081	0.667	rs12577388	ENSG00000184669.7	OR7E14P	-4.17	3.32e-05	0.00238	-0.19	-0.13	Systolic blood pressure;	chr11:17079608	chr11:17013998~17053024:+
BRCA	cis	rs9995093	0.881	rs12641788	ENSG00000246375.2	RP11-10L7.1	-4.17	3.32e-05	0.00238	-0.25	-0.13	Bipolar disorder;	chr4:88301012	chr4:88284942~88331421:+
BRCA	cis	rs728616	0.558	rs61859793	ENSG00000225484.5	NUTM2B-AS1	-4.17	3.32e-05	0.00238	-0.28	-0.13	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79927007	chr10:79663088~79826594:-
BRCA	cis	rs792448	0.743	rs351386	ENSG00000229983.1	RP11-15I11.2	4.17	3.32e-05	0.00238	0.16	0.13	White blood cell count (basophil);	chr1:212248429	chr1:212168207~212190259:+
BRCA	cis	rs11124272	0.55	rs607294	ENSG00000272716.1	RP11-563N4.1	4.17	3.32e-05	0.00238	0.15	0.13	Interleukin-18 levels;	chr2:31607738	chr2:32165046~32165757:-
BRCA	cis	rs9733	0.65	rs2048558	ENSG00000203804.4	ADAMTSL4-AS1	-4.17	3.32e-05	0.00238	-0.14	-0.13	Tonsillectomy;	chr1:150599254	chr1:150560202~150574552:-
BRCA	cis	rs8054556	0.967	rs11150576	ENSG00000261367.1	RP11-455F5.4	-4.17	3.32e-05	0.00238	-0.15	-0.13	Autism spectrum disorder or schizophrenia;	chr16:29954175	chr16:30107675~30110541:+
BRCA	cis	rs983392	0.68	rs11230201	ENSG00000275344.1	MIR6503	-4.17	3.32e-05	0.00239	-0.13	-0.13	Alzheimer's disease (late onset);	chr11:60229521	chr11:60209071~60209156:-
BRCA	cis	rs1005277	0.579	rs2749612	ENSG00000272983.1	RP11-508N22.12	4.17	3.32e-05	0.00239	0.14	0.13	Extrinsic epigenetic age acceleration;	chr10:38199682	chr10:38137337~38144399:+
BRCA	cis	rs875971	0.545	rs7811204	ENSG00000230295.1	RP11-458F8.2	4.17	3.32e-05	0.00239	0.12	0.13	Aortic root size;	chr7:66387213	chr7:66880708~66882981:+
BRCA	cis	rs875971	1	rs778706	ENSG00000236529.1	RP13-254B10.1	4.17	3.32e-05	0.00239	0.14	0.13	Aortic root size;	chr7:66395437	chr7:65840212~65840596:+
BRCA	cis	rs2243480	1	rs313807	ENSG00000275400.1	RP4-756H11.5	4.17	3.32e-05	0.00239	0.23	0.13	Diabetic kidney disease;	chr7:66034494	chr7:66553805~66554199:-
BRCA	cis	rs1949733	0.628	rs1543246	ENSG00000205959.3	RP11-689P11.2	-4.17	3.32e-05	0.00239	-0.12	-0.13	Response to antineoplastic agents;	chr4:8503182	chr4:8482270~8512610:+
BRCA	cis	rs875971	0.964	rs778708	ENSG00000236529.1	RP13-254B10.1	4.17	3.33e-05	0.00239	0.14	0.13	Aortic root size;	chr7:66391332	chr7:65840212~65840596:+
BRCA	cis	rs35146811	0.731	rs2257213	ENSG00000214313.7	AZGP1P1	-4.17	3.33e-05	0.00239	-0.14	-0.13	Coronary artery disease;	chr7:100212490	chr7:99980762~99987535:+
BRCA	cis	rs983392	0.709	rs2015475	ENSG00000275344.1	MIR6503	-4.17	3.33e-05	0.00239	-0.13	-0.13	Alzheimer's disease (late onset);	chr11:60231490	chr11:60209071~60209156:-
BRCA	cis	rs7160336	1	rs11159063	ENSG00000259065.1	RP5-1021I20.1	-4.17	3.33e-05	0.00239	-0.14	-0.13	Blood protein levels;	chr14:74147863	chr14:73787360~73803270:+
BRCA	cis	rs12073837	0.572	rs883847	ENSG00000272823.1	RP11-295M18.6	-4.17	3.33e-05	0.00239	-0.14	-0.13	F-cell distribution;	chr1:220798986	chr1:220828676~220829211:-
BRCA	cis	rs1005277	0.563	rs2505216	ENSG00000272983.1	RP11-508N22.12	4.17	3.33e-05	0.00239	0.14	0.13	Extrinsic epigenetic age acceleration;	chr10:38193902	chr10:38137337~38144399:+
BRCA	cis	rs2242330	0.651	rs7692528	ENSG00000250075.4	RP11-584P21.2	4.17	3.33e-05	0.00239	0.16	0.13	Parkinson's disease;	chr4:67589584	chr4:67417305~67468251:-
BRCA	cis	rs11098499	0.863	rs7699064	ENSG00000260404.2	RP11-384K6.6	-4.17	3.33e-05	0.00239	-0.12	-0.13	Corneal astigmatism;	chr4:119507154	chr4:118591773~118633729:+
BRCA	cis	rs875971	0.619	rs10278371	ENSG00000229180.5	GS1-124K5.11	-4.17	3.33e-05	0.00239	-0.11	-0.13	Aortic root size;	chr7:66586553	chr7:66526088~66542624:-
BRCA	cis	rs61931739	0.534	rs11053029	ENSG00000258794.3	DUX4L27	4.17	3.33e-05	0.00239	0.19	0.13	Morning vs. evening chronotype;	chr12:33978831	chr12:34208415~34209675:-
BRCA	cis	rs9788721	0.836	rs17484524	ENSG00000261762.1	RP11-650L12.2	-4.17	3.33e-05	0.00239	-0.16	-0.13	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78480334	chr15:78589123~78591276:-
BRCA	cis	rs3136202	0.684	rs7189139	ENSG00000242307.1	RPS26P52	-4.17	3.33e-05	0.00239	-0.16	-0.13	Conduct disorder (symptom count);	chr16:13962808	chr16:13922332~13922679:-
BRCA	cis	rs6840360	0.582	rs11732918	ENSG00000251611.1	RP11-610P16.1	-4.17	3.33e-05	0.00239	-0.11	-0.13	Intelligence (multi-trait analysis);	chr4:151397893	chr4:151407551~151408835:-
BRCA	cis	rs721917	0.506	rs2244451	ENSG00000278616.1	BEND3P3	-4.17	3.33e-05	0.00239	-0.12	-0.13	Chronic obstructive pulmonary disease;	chr10:79885234	chr10:79682997~79685436:+
BRCA	cis	rs2880765	0.743	rs16940052	ENSG00000202081.1	RNU6-1280P	4.17	3.34e-05	0.00239	0.15	0.13	Coronary artery disease;	chr15:85463443	chr15:85651522~85651628:-
BRCA	cis	rs6490294	0.8	rs78783055	ENSG00000226469.1	ADAM1B	4.17	3.34e-05	0.00239	0.17	0.13	Mean platelet volume;	chr12:111795691	chr12:111927018~111929017:+
BRCA	cis	rs7267979	1	rs448396	ENSG00000274973.1	RP13-401N8.7	-4.17	3.34e-05	0.0024	-0.15	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25459633	chr20:25845497~25845862:+
BRCA	cis	rs875971	1	rs709597	ENSG00000236529.1	RP13-254B10.1	-4.17	3.34e-05	0.0024	-0.14	-0.13	Aortic root size;	chr7:66360996	chr7:65840212~65840596:+
BRCA	cis	rs853679	0.517	rs9283884	ENSG00000216901.1	AL022393.7	-4.17	3.34e-05	0.0024	-0.18	-0.13	Depression;	chr6:28167882	chr6:28176188~28176674:+
BRCA	cis	rs17507216	0.628	rs28737193	ENSG00000259429.4	UBE2Q2P2	-4.17	3.34e-05	0.0024	-0.16	-0.13	Excessive daytime sleepiness;	chr15:82701318	chr15:82355142~82420075:+
BRCA	cis	rs7621331	0.963	rs9289503	ENSG00000239213.4	NCK1-AS1	4.17	3.34e-05	0.0024	0.15	0.13	Waist circumference adjusted for body mass index;	chr3:136020499	chr3:136841726~136862054:-
BRCA	cis	rs2832191	0.791	rs2832196	ENSG00000236056.1	GAPDHP14	4.17	3.34e-05	0.0024	0.14	0.13	Dental caries;	chr21:29125091	chr21:29222321~29223257:+
BRCA	cis	rs2243480	1	rs1964692	ENSG00000275400.1	RP4-756H11.5	4.17	3.34e-05	0.0024	0.23	0.13	Diabetic kidney disease;	chr7:65989196	chr7:66553805~66554199:-
BRCA	cis	rs721917	0.525	rs1054053	ENSG00000278616.1	BEND3P3	-4.17	3.34e-05	0.0024	-0.12	-0.13	Chronic obstructive pulmonary disease;	chr10:79922889	chr10:79682997~79685436:+
BRCA	cis	rs8180040	0.629	rs7426969	ENSG00000271161.1	BOLA2P2	4.17	3.35e-05	0.0024	0.14	0.13	Colorectal cancer;	chr3:47049865	chr3:47499841~47500407:+
BRCA	cis	rs6490294	0.904	rs11066112	ENSG00000257624.1	RP1-128M12.3	4.17	3.35e-05	0.0024	0.17	0.13	Mean platelet volume;	chr12:111978782	chr12:112000739~112000985:-
BRCA	cis	rs11098499	0.954	rs10034623	ENSG00000250412.1	KLHL2P1	4.17	3.35e-05	0.0024	0.15	0.13	Corneal astigmatism;	chr4:119476674	chr4:119334329~119378233:+
BRCA	cis	rs3096299	0.685	rs12935112	ENSG00000261118.1	RP11-104N10.1	-4.17	3.35e-05	0.0024	-0.13	-0.13	Multiple myeloma (IgH translocation);	chr16:89476450	chr16:89492017~89504460:-
BRCA	cis	rs6463739	0.581	rs6965873	ENSG00000219545.8	UMAD1	4.17	3.35e-05	0.0024	0.14	0.13	Small cell lung carcinoma;	chr7:7861612	chr7:7640711~8004059:+
BRCA	cis	rs2243480	0.803	rs35480979	ENSG00000222364.1	RNU6-96P	-4.17	3.35e-05	0.0024	-0.23	-0.13	Diabetic kidney disease;	chr7:65892097	chr7:66395191~66395286:+
BRCA	cis	rs2243480	1	rs35391607	ENSG00000222364.1	RNU6-96P	-4.17	3.35e-05	0.0024	-0.23	-0.13	Diabetic kidney disease;	chr7:65895842	chr7:66395191~66395286:+
BRCA	cis	rs2243480	1	rs13220979	ENSG00000222364.1	RNU6-96P	-4.17	3.35e-05	0.0024	-0.23	-0.13	Diabetic kidney disease;	chr7:65898217	chr7:66395191~66395286:+
BRCA	cis	rs2243480	1	rs34974928	ENSG00000222364.1	RNU6-96P	-4.17	3.35e-05	0.0024	-0.23	-0.13	Diabetic kidney disease;	chr7:65899019	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.965	rs10267430	ENSG00000229180.5	GS1-124K5.11	-4.17	3.35e-05	0.0024	-0.11	-0.13	Aortic root size;	chr7:66278036	chr7:66526088~66542624:-
BRCA	cis	rs2835345	0.563	rs12627167	ENSG00000233818.1	AP000695.4	4.17	3.35e-05	0.0024	0.13	0.13	Pulmonary function;	chr21:36449855	chr21:36445731~36532408:+
BRCA	cis	rs6585424	0.929	rs12256429	ENSG00000225484.5	NUTM2B-AS1	-4.17	3.35e-05	0.0024	-0.25	-0.13	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80178876	chr10:79663088~79826594:-
BRCA	cis	rs11158026	0.603	rs34988865	ENSG00000258413.1	RP11-665C16.6	-4.17	3.35e-05	0.0024	-0.17	-0.13	Parkinson's disease;	chr14:55008131	chr14:55262767~55272075:-
BRCA	cis	rs4835473	0.831	rs1984809	ENSG00000249741.2	RP11-673E1.3	-4.17	3.35e-05	0.0024	-0.13	-0.13	Immature fraction of reticulocytes;	chr4:143825018	chr4:143911514~143912053:-
BRCA	cis	rs9818758	0.607	rs11710247	ENSG00000225399.4	RP11-3B7.1	-4.17	3.35e-05	0.0024	-0.2	-0.13	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49212367	chr3:49260085~49261316:+
BRCA	cis	rs7615952	0.932	rs9841157	ENSG00000248787.1	RP11-666A20.4	-4.17	3.35e-05	0.0024	-0.22	-0.13	Blood pressure (smoking interaction);	chr3:125916812	chr3:125908005~125910272:-
BRCA	cis	rs7615952	0.551	rs12695470	ENSG00000248787.1	RP11-666A20.4	-4.17	3.35e-05	0.0024	-0.22	-0.13	Blood pressure (smoking interaction);	chr3:125916875	chr3:125908005~125910272:-
BRCA	cis	rs465969	1	rs17510761	ENSG00000272356.1	RP5-1112D6.8	4.17	3.35e-05	0.0024	0.28	0.13	Psoriasis;	chr6:111387380	chr6:111309203~111313517:+
BRCA	cis	rs465969	1	rs78945802	ENSG00000272356.1	RP5-1112D6.8	4.17	3.35e-05	0.0024	0.28	0.13	Psoriasis;	chr6:111407143	chr6:111309203~111313517:+
BRCA	cis	rs465969	1	rs17072683	ENSG00000272356.1	RP5-1112D6.8	4.17	3.35e-05	0.0024	0.28	0.13	Psoriasis;	chr6:111410007	chr6:111309203~111313517:+
BRCA	cis	rs6860540	0.796	rs57229403	ENSG00000251405.2	CTB-109A12.1	-4.17	3.35e-05	0.0024	-0.18	-0.13	Inflammatory skin disease;	chr5:157489634	chr5:157362615~157460078:-
BRCA	cis	rs875971	1	rs778696	ENSG00000265600.1	AC006480.1	-4.17	3.35e-05	0.00241	-0.15	-0.13	Aortic root size;	chr7:66405826	chr7:67356680~67356779:+
BRCA	cis	rs875971	1	rs778694	ENSG00000265600.1	AC006480.1	-4.17	3.35e-05	0.00241	-0.15	-0.13	Aortic root size;	chr7:66406571	chr7:67356680~67356779:+
BRCA	cis	rs875971	1	rs4718344	ENSG00000265600.1	AC006480.1	-4.17	3.35e-05	0.00241	-0.15	-0.13	Aortic root size;	chr7:66409394	chr7:67356680~67356779:+
BRCA	cis	rs875971	0.737	rs7803424	ENSG00000265600.1	AC006480.1	-4.17	3.35e-05	0.00241	-0.15	-0.13	Aortic root size;	chr7:66415618	chr7:67356680~67356779:+
BRCA	cis	rs875971	0.83	rs7799834	ENSG00000265600.1	AC006480.1	-4.17	3.35e-05	0.00241	-0.15	-0.13	Aortic root size;	chr7:66415707	chr7:67356680~67356779:+
BRCA	cis	rs4499344	0.73	rs2903755	ENSG00000267475.1	CTD-2538C1.2	4.17	3.35e-05	0.00241	0.16	0.13	Mean platelet volume;	chr19:32607964	chr19:32687089~32691750:-
BRCA	cis	rs4499344	0.73	rs2868150	ENSG00000267475.1	CTD-2538C1.2	4.17	3.35e-05	0.00241	0.16	0.13	Mean platelet volume;	chr19:32607969	chr19:32687089~32691750:-
BRCA	cis	rs4499344	0.73	rs28402742	ENSG00000267475.1	CTD-2538C1.2	4.17	3.35e-05	0.00241	0.16	0.13	Mean platelet volume;	chr19:32608828	chr19:32687089~32691750:-
BRCA	cis	rs4499344	0.73	rs28416849	ENSG00000267475.1	CTD-2538C1.2	4.17	3.35e-05	0.00241	0.16	0.13	Mean platelet volume;	chr19:32608852	chr19:32687089~32691750:-
BRCA	cis	rs3096299	0.582	rs12935119	ENSG00000261118.1	RP11-104N10.1	4.17	3.35e-05	0.00241	0.13	0.13	Multiple myeloma (IgH translocation);	chr16:89476466	chr16:89492017~89504460:-
BRCA	cis	rs9859260	0.744	rs557527	ENSG00000207650.1	MIR570	-4.17	3.35e-05	0.00241	-0.15	-0.13	Mean corpuscular volume;	chr3:196053838	chr3:195699401~195699497:+
BRCA	cis	rs6547741	1	rs4666009	ENSG00000234072.1	AC074117.10	4.17	3.35e-05	0.00241	0.12	0.13	Oral cavity cancer;	chr2:27635125	chr2:27356246~27367622:+
BRCA	cis	rs77956314	0.515	rs4767490	ENSG00000277840.1	RP11-103B5.4	-4.17	3.36e-05	0.00241	-0.21	-0.13	Hippocampal volume;Subcortical brain region volumes;	chr12:116997211	chr12:117002463~117003152:+
BRCA	cis	rs41357746	0.525	rs57030473	ENSG00000270964.1	RP11-502I4.3	-4.17	3.36e-05	0.00241	-0.14	-0.13	Total body bone mineral density;	chr15:67484340	chr15:67541072~67542604:-
BRCA	cis	rs1538970	0.884	rs1771551	ENSG00000281133.1	AL355480.3	-4.17	3.36e-05	0.00241	-0.17	-0.13	Platelet count;	chr1:45417971	chr1:45580892~45580996:-
BRCA	cis	rs2108622	0.727	rs7254940	ENSG00000267218.2	AC005336.5	4.17	3.36e-05	0.00241	0.15	0.13	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15873698	chr19:15902300~15903238:-
BRCA	cis	rs6736093	0.931	rs34974369	ENSG00000236307.2	EEF1E1P1	-4.17	3.36e-05	0.00241	-0.16	-0.13	Coronary artery disease;	chr2:111925813	chr2:111887914~111888741:+
BRCA	cis	rs372883	0.901	rs13048365	ENSG00000215533.7	LINC00189	4.17	3.36e-05	0.00241	0.14	0.13	Pancreatic cancer;	chr21:29368073	chr21:29193480~29288205:+
BRCA	cis	rs2731006	0.64	rs2730969	ENSG00000257114.2	RP11-25I15.3	4.17	3.36e-05	0.00241	0.21	0.13	Panic disorder;	chr12:42794918	chr12:42692216~42717119:+
BRCA	cis	rs6671200	0.79	rs259357	ENSG00000226026.4	RP11-57H12.3	-4.17	3.36e-05	0.00241	-0.24	-0.13	Stearic acid (18:0) levels;	chr1:95245922	chr1:95163219~95233982:-
BRCA	cis	rs1823874	0.71	rs2085086	ENSG00000182397.13	DNM1P46	-4.17	3.36e-05	0.00241	-0.14	-0.13	IgG glycosylation;	chr15:99819887	chr15:99790156~99806927:-
BRCA	cis	rs10819861	0.967	rs10989287	ENSG00000175611.10	LINC00476	4.17	3.36e-05	0.00241	0.13	0.13	Electrocardiographic traits;	chr9:96105566	chr9:95759231~95875977:-
BRCA	cis	rs2243480	1	rs35396113	ENSG00000222364.1	RNU6-96P	-4.17	3.36e-05	0.00241	-0.23	-0.13	Diabetic kidney disease;	chr7:66030474	chr7:66395191~66395286:+
BRCA	cis	rs35146811	0.735	rs1138417	ENSG00000214313.7	AZGP1P1	-4.17	3.36e-05	0.00241	-0.14	-0.13	Coronary artery disease;	chr7:100209523	chr7:99980762~99987535:+
BRCA	cis	rs256438	0.524	rs445471	ENSG00000251050.1	RP11-168A11.4	-4.17	3.36e-05	0.00241	-0.14	-0.13	Serum thyroid-stimulating hormone levels;	chr5:80052606	chr5:80019609~80019920:+
BRCA	cis	rs755249	0.501	rs621807	ENSG00000237624.1	OXCT2P1	4.17	3.36e-05	0.00241	0.16	0.13	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39376771	chr1:39514956~39516490:+
BRCA	cis	rs8031584	0.679	rs34017474	ENSG00000270055.1	CTD-3092A11.2	-4.17	3.36e-05	0.00241	-0.15	-0.13	Huntington's disease progression;	chr15:30938408	chr15:30487963~30490313:+
BRCA	cis	rs6071166	0.646	rs6027244	ENSG00000224635.1	RP4-564F22.5	-4.17	3.36e-05	0.00241	-0.15	-0.13	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38683366	chr20:38406011~38416797:-
BRCA	cis	rs1910358	0.554	rs955885	ENSG00000248874.4	C5orf17	-4.17	3.36e-05	0.00241	-0.18	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23759293	chr5:23951348~24178263:+
BRCA	cis	rs67340775	0.541	rs200964	ENSG00000216901.1	AL022393.7	4.17	3.36e-05	0.00241	0.21	0.13	Lung cancer in ever smokers;	chr6:27899165	chr6:28176188~28176674:+
BRCA	cis	rs62025270	0.688	rs62022939	ENSG00000259295.5	CSPG4P12	-4.17	3.36e-05	0.00241	-0.2	-0.13	Idiopathic pulmonary fibrosis;	chr15:85707651	chr15:85191438~85213905:+
BRCA	cis	rs2242330	0.651	rs10050076	ENSG00000250075.4	RP11-584P21.2	-4.17	3.36e-05	0.00241	-0.16	-0.13	Parkinson's disease;	chr4:67589682	chr4:67417305~67468251:-
BRCA	cis	rs10986311	0.862	rs912353	ENSG00000227200.1	RP11-121A14.3	4.17	3.36e-05	0.00241	0.15	0.13	Vitiligo;	chr9:124357077	chr9:124262876~124265809:+
BRCA	cis	rs2439831	0.85	rs10163054	ENSG00000206991.1	RNU6-610P	-4.17	3.36e-05	0.00241	-0.21	-0.13	Lung cancer in ever smokers;	chr15:43755440	chr15:43637632~43637738:-
BRCA	cis	rs2732480	0.967	rs2732469	ENSG00000257763.1	OR5BK1P	4.17	3.36e-05	0.00241	0.13	0.13	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48319149	chr12:48355792~48356614:-
BRCA	cis	rs739496	0.602	rs79209359	ENSG00000234608.6	MAPKAPK5-AS1	4.17	3.36e-05	0.00241	0.16	0.13	Platelet count;	chr12:111529357	chr12:111839764~111842902:-
BRCA	cis	rs896854	0.738	rs509594	ENSG00000245080.5	RP11-320N21.1	-4.17	3.36e-05	0.00241	-0.16	-0.13	Type 2 diabetes;	chr8:94954928	chr8:95066808~95073182:-
BRCA	cis	rs11098499	0.954	rs10008392	ENSG00000260404.2	RP11-384K6.6	4.17	3.36e-05	0.00241	0.12	0.13	Corneal astigmatism;	chr4:119397684	chr4:118591773~118633729:+
BRCA	cis	rs860295	0.812	rs10908481	ENSG00000225855.5	RUSC1-AS1	4.17	3.36e-05	0.00241	0.1	0.13	Body mass index;	chr1:155743859	chr1:155316863~155324176:-
BRCA	cis	rs9859260	0.71	rs41298097	ENSG00000207650.1	MIR570	-4.17	3.37e-05	0.00241	-0.15	-0.13	Mean corpuscular volume;	chr3:196052284	chr3:195699401~195699497:+
BRCA	cis	rs9859260	0.71	rs34906439	ENSG00000207650.1	MIR570	-4.17	3.37e-05	0.00241	-0.15	-0.13	Mean corpuscular volume;	chr3:196052835	chr3:195699401~195699497:+
BRCA	cis	rs6708331	0.938	rs36025045	ENSG00000231024.1	AC092431.3	-4.17	3.37e-05	0.00241	-0.18	-0.13	Obesity-related traits;	chr2:70121829	chr2:69700192~69713847:-
BRCA	cis	rs4835473	0.932	rs13107719	ENSG00000249741.2	RP11-673E1.3	4.17	3.37e-05	0.00241	0.14	0.13	Immature fraction of reticulocytes;	chr4:143752034	chr4:143911514~143912053:-
BRCA	cis	rs10844706	0.699	rs11052717	ENSG00000256673.1	RP11-599J14.2	-4.17	3.37e-05	0.00241	-0.16	-0.13	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9726217	chr12:9398355~9414851:-
BRCA	cis	rs17507216	1	rs17507216	ENSG00000259429.4	UBE2Q2P2	4.17	3.37e-05	0.00241	0.15	0.13	Excessive daytime sleepiness;	chr15:82558175	chr15:82355142~82420075:+
BRCA	cis	rs4919694	0.615	rs78384860	ENSG00000236937.2	PTGES3P4	4.17	3.37e-05	0.00242	0.28	0.13	Arsenic metabolism;	chr10:103243262	chr10:102845595~102845950:+
BRCA	cis	rs4664293	0.867	rs3771719	ENSG00000224152.1	AC009506.1	4.17	3.37e-05	0.00242	0.13	0.13	Monocyte percentage of white cells;	chr2:159774453	chr2:159615296~159617082:+
BRCA	cis	rs7561149	1	rs7591782	ENSG00000270574.1	RP11-171I2.2	-4.17	3.37e-05	0.00242	-0.17	-0.13	QT interval;	chr2:178828286	chr2:178578790~178580906:+
BRCA	cis	rs6840360	0.642	rs56301462	ENSG00000251611.1	RP11-610P16.1	-4.17	3.37e-05	0.00242	-0.11	-0.13	Intelligence (multi-trait analysis);	chr4:151530976	chr4:151407551~151408835:-
BRCA	cis	rs372883	0.6	rs407712	ENSG00000176054.6	RPL23P2	-4.17	3.37e-05	0.00242	-0.15	-0.13	Pancreatic cancer;	chr21:29350210	chr21:28997613~28998033:-
BRCA	cis	rs9733	0.621	rs12746899	ENSG00000203804.4	ADAMTSL4-AS1	-4.16	3.37e-05	0.00242	-0.14	-0.13	Tonsillectomy;	chr1:150607202	chr1:150560202~150574552:-
BRCA	cis	rs7772486	0.875	rs6570736	ENSG00000270638.1	RP3-466P17.1	4.16	3.37e-05	0.00242	0.15	0.13	Lobe attachment (rater-scored or self-reported);	chr6:146067184	chr6:145735570~145737218:+
BRCA	cis	rs7182948	1	rs11070705	ENSG00000259531.2	RP11-295H24.3	-4.16	3.37e-05	0.00242	-0.18	-0.13	Lung adenocarcinoma;	chr15:49551454	chr15:49365124~49366685:-
BRCA	cis	rs7182948	1	rs2413963	ENSG00000259531.2	RP11-295H24.3	-4.16	3.37e-05	0.00242	-0.18	-0.13	Lung adenocarcinoma;	chr15:49555934	chr15:49365124~49366685:-
BRCA	cis	rs7182948	1	rs1395900	ENSG00000259531.2	RP11-295H24.3	-4.16	3.37e-05	0.00242	-0.18	-0.13	Lung adenocarcinoma;	chr15:49557400	chr15:49365124~49366685:-
BRCA	cis	rs801193	0.967	rs2420827	ENSG00000229180.5	GS1-124K5.11	-4.16	3.37e-05	0.00242	-0.11	-0.13	Aortic root size;	chr7:66682114	chr7:66526088~66542624:-
BRCA	cis	rs739496	0.579	rs16941759	ENSG00000257624.1	RP1-128M12.3	-4.16	3.37e-05	0.00242	-0.17	-0.13	Platelet count;	chr12:111930117	chr12:112000739~112000985:-
BRCA	cis	rs7819412	0.521	rs2409720	ENSG00000255046.1	RP11-297N6.4	4.16	3.37e-05	0.00242	0.15	0.13	Triglycerides;	chr8:11180394	chr8:11797928~11802568:-
BRCA	cis	rs73198271	0.653	rs10099808	ENSG00000253893.2	FAM85B	-4.16	3.37e-05	0.00242	-0.16	-0.13	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8802363	chr8:8167819~8226614:-
BRCA	cis	rs957448	0.539	rs9643346	ENSG00000261437.1	RP11-22C11.2	4.16	3.37e-05	0.00242	0.12	0.13	Nonsyndromic cleft lip with cleft palate;	chr8:94601587	chr8:94637285~94639467:-
BRCA	cis	rs9733	0.596	rs72702536	ENSG00000231073.1	RP11-316M1.3	4.16	3.37e-05	0.00242	0.13	0.13	Tonsillectomy;	chr1:150690098	chr1:150973123~150975534:+
BRCA	cis	rs739496	0.579	rs7975437	ENSG00000257624.1	RP1-128M12.3	4.16	3.38e-05	0.00242	0.17	0.13	Platelet count;	chr12:111939145	chr12:112000739~112000985:-
BRCA	cis	rs829883	0.932	rs249840	ENSG00000227825.4	SLC9A7P1	4.16	3.38e-05	0.00242	0.16	0.13	Colorectal adenoma (advanced);	chr12:98478215	chr12:98453835~98457145:-
BRCA	cis	rs61160187	0.582	rs12655603	ENSG00000272308.1	RP11-231G3.1	-4.16	3.38e-05	0.00242	-0.15	-0.13	Educational attainment (years of education);Educational attainment (college completion);	chr5:60908769	chr5:60866457~60866935:-
BRCA	cis	rs12744310	1	rs12041533	ENSG00000235358.1	RP11-399E6.1	4.16	3.38e-05	0.00242	0.19	0.13	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41302599	chr1:41242373~41284861:+
BRCA	cis	rs12744310	1	rs12032215	ENSG00000235358.1	RP11-399E6.1	4.16	3.38e-05	0.00242	0.19	0.13	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41303662	chr1:41242373~41284861:+
BRCA	cis	rs12744310	1	rs12035353	ENSG00000235358.1	RP11-399E6.1	4.16	3.38e-05	0.00242	0.19	0.13	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41303665	chr1:41242373~41284861:+
BRCA	cis	rs10129255	0.5	rs8006888	ENSG00000211967.3	IGHV3-53	-4.16	3.38e-05	0.00242	-0.08	-0.13	Kawasaki disease;	chr14:106782219	chr14:106592676~106593347:-
BRCA	cis	rs12317459	0.591	rs7312288	ENSG00000213270.5	RPL6P25	-4.16	3.38e-05	0.00242	-0.21	-0.13	Prostate cancer (SNP x SNP interaction);	chr12:82772076	chr12:83151331~83152190:+
BRCA	cis	rs295490	0.748	rs74846775	ENSG00000272656.1	RP11-219D15.3	4.16	3.38e-05	0.00242	0.32	0.13	PR interval in Tripanosoma cruzi seropositivity;	chr3:139354736	chr3:139349024~139349371:-
BRCA	cis	rs11719291	0.833	rs34037363	ENSG00000225399.4	RP11-3B7.1	-4.16	3.38e-05	0.00242	-0.23	-0.13	Cognitive function;	chr3:48783603	chr3:49260085~49261316:+
BRCA	cis	rs7487075	0.93	rs7308910	ENSG00000274723.1	RP11-618L22.1	4.16	3.38e-05	0.00242	0.15	0.13	Itch intensity from mosquito bite;	chr12:46444459	chr12:46970504~46972155:+
BRCA	cis	rs11098499	0.909	rs11723757	ENSG00000260404.2	RP11-384K6.6	4.16	3.38e-05	0.00242	0.12	0.13	Corneal astigmatism;	chr4:119378514	chr4:118591773~118633729:+
BRCA	cis	rs6479874	0.646	rs7101068	ENSG00000223502.1	RP11-96B5.3	-4.16	3.38e-05	0.00242	-0.23	-0.13	Migraine;	chr10:50998744	chr10:51062579~51068553:-
BRCA	cis	rs7572733	0.555	rs6745726	ENSG00000231621.1	AC013264.2	-4.16	3.38e-05	0.00242	-0.13	-0.13	Dermatomyositis;	chr2:198069356	chr2:197197991~197199273:+
BRCA	cis	rs6452524	1	rs10043018	ENSG00000281327.1	LINC01338	4.16	3.38e-05	0.00242	0.15	0.13	Hypertension (SNP x SNP interaction);	chr5:83138498	chr5:82850864~82859836:-
BRCA	cis	rs6452524	0.935	rs10037501	ENSG00000281327.1	LINC01338	4.16	3.38e-05	0.00242	0.15	0.13	Hypertension (SNP x SNP interaction);	chr5:83138722	chr5:82850864~82859836:-
BRCA	cis	rs6452524	0.904	rs6452525	ENSG00000281327.1	LINC01338	4.16	3.38e-05	0.00242	0.15	0.13	Hypertension (SNP x SNP interaction);	chr5:83138752	chr5:82850864~82859836:-
BRCA	cis	rs6452524	1	rs7716931	ENSG00000281327.1	LINC01338	4.16	3.38e-05	0.00242	0.15	0.13	Hypertension (SNP x SNP interaction);	chr5:83138856	chr5:82850864~82859836:-
BRCA	cis	rs6452524	1	rs7721416	ENSG00000281327.1	LINC01338	4.16	3.38e-05	0.00242	0.15	0.13	Hypertension (SNP x SNP interaction);	chr5:83139174	chr5:82850864~82859836:-
BRCA	cis	rs801193	1	rs6975195	ENSG00000272831.1	RP11-792A8.4	-4.16	3.38e-05	0.00242	-0.11	-0.13	Aortic root size;	chr7:66659787	chr7:66739829~66740385:-
BRCA	cis	rs11098499	0.954	rs12499324	ENSG00000260404.2	RP11-384K6.6	4.16	3.38e-05	0.00242	0.12	0.13	Corneal astigmatism;	chr4:119472631	chr4:118591773~118633729:+
BRCA	cis	rs801193	1	rs10234018	ENSG00000273142.1	RP11-458F8.4	4.16	3.38e-05	0.00242	0.11	0.13	Aortic root size;	chr7:66681297	chr7:66902857~66906297:+
BRCA	cis	rs1656368	0.726	rs73154309	ENSG00000279311.1	RP11-170K4.2	4.16	3.38e-05	0.00242	0.17	0.13	Lobe attachment (rater-scored or self-reported);	chr3:158496832	chr3:158869898~158871821:+
BRCA	cis	rs1552244	0.572	rs3843008	ENSG00000232901.1	CYCSP10	4.16	3.38e-05	0.00242	0.22	0.13	Alzheimer's disease;	chr3:10132058	chr3:10000647~10000940:-
BRCA	cis	rs853679	1	rs1679732	ENSG00000280107.1	AL022393.9	4.16	3.38e-05	0.00242	0.22	0.13	Depression;	chr6:28253486	chr6:28170845~28172521:+
BRCA	cis	rs6963495	0.818	rs55691539	ENSG00000223886.3	RP11-251G23.2	4.16	3.38e-05	0.00242	0.2	0.13	Bipolar disorder (body mass index interaction);	chr7:105525327	chr7:105530209~105530671:+
BRCA	cis	rs9818758	0.607	rs34326553	ENSG00000225399.4	RP11-3B7.1	-4.16	3.38e-05	0.00243	-0.23	-0.13	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49096996	chr3:49260085~49261316:+
BRCA	cis	rs2243480	0.711	rs1626926	ENSG00000226002.1	RP11-460N20.5	-4.16	3.38e-05	0.00243	-0.21	-0.13	Diabetic kidney disease;	chr7:65970805	chr7:65084103~65100232:+
BRCA	cis	rs875971	0.508	rs6947808	ENSG00000273142.1	RP11-458F8.4	4.16	3.38e-05	0.00243	0.11	0.13	Aortic root size;	chr7:66580095	chr7:66902857~66906297:+
BRCA	cis	rs4499344	0.73	rs2545357	ENSG00000267475.1	CTD-2538C1.2	4.16	3.39e-05	0.00243	0.16	0.13	Mean platelet volume;	chr19:32613704	chr19:32687089~32691750:-
BRCA	cis	rs4478858	0.654	rs113490486	ENSG00000260386.4	LINC01225	-4.16	3.39e-05	0.00243	-0.15	-0.13	Alcohol dependence;	chr1:31240016	chr1:31500085~31540885:+
BRCA	cis	rs10504130	0.569	rs34213209	ENSG00000253844.1	RP11-546K22.1	-4.16	3.39e-05	0.00243	-0.19	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr8:51773341	chr8:51961458~52022974:+
BRCA	cis	rs16944613	0.51	rs8030781	ENSG00000245479.2	LINC01585	4.16	3.39e-05	0.00243	0.15	0.13	Colorectal cancer;	chr15:90599840	chr15:90660234~90664967:+
BRCA	cis	rs853679	0.517	rs9468297	ENSG00000216901.1	AL022393.7	4.16	3.39e-05	0.00243	0.19	0.13	Depression;	chr6:28151096	chr6:28176188~28176674:+
BRCA	cis	rs875971	0.895	rs7788984	ENSG00000236529.1	RP13-254B10.1	4.16	3.39e-05	0.00243	0.14	0.13	Aortic root size;	chr7:66450629	chr7:65840212~65840596:+
BRCA	cis	rs72482608	0.835	rs10733057	ENSG00000271811.1	RP1-79C4.4	4.16	3.39e-05	0.00243	0.14	0.13	Emphysema imaging phenotypes;	chr1:170779135	chr1:170667381~170669425:+
BRCA	cis	rs11673344	0.504	rs8099987	ENSG00000276846.1	CTD-3220F14.3	4.16	3.39e-05	0.00243	0.15	0.13	Obesity-related traits;	chr19:37132570	chr19:37314868~37315620:-
BRCA	cis	rs11673344	0.504	rs8110796	ENSG00000276846.1	CTD-3220F14.3	4.16	3.39e-05	0.00243	0.15	0.13	Obesity-related traits;	chr19:37132682	chr19:37314868~37315620:-
BRCA	cis	rs11673344	0.504	rs8111285	ENSG00000276846.1	CTD-3220F14.3	4.16	3.39e-05	0.00243	0.15	0.13	Obesity-related traits;	chr19:37132747	chr19:37314868~37315620:-
BRCA	cis	rs11673344	0.504	rs6510591	ENSG00000276846.1	CTD-3220F14.3	4.16	3.39e-05	0.00243	0.15	0.13	Obesity-related traits;	chr19:37133186	chr19:37314868~37315620:-
BRCA	cis	rs935334	0.866	rs12587652	ENSG00000258454.1	RP11-361H10.3	-4.16	3.39e-05	0.00243	-0.2	-0.13	Blood pressure;	chr14:76222270	chr14:76235817~76263474:+
BRCA	cis	rs2835872	0.965	rs857973	ENSG00000228677.1	TTC3-AS1	4.16	3.39e-05	0.00243	0.17	0.13	Electroencephalographic traits in alcoholism;	chr21:37635196	chr21:37187666~37193926:-
BRCA	cis	rs783540	0.521	rs28719490	ENSG00000276710.3	CSPG4P8	-4.16	3.39e-05	0.00243	-0.16	-0.13	Schizophrenia;	chr15:82720688	chr15:82459472~82477258:+
BRCA	cis	rs11673344	0.504	rs6510592	ENSG00000276846.1	CTD-3220F14.3	4.16	3.39e-05	0.00243	0.15	0.13	Obesity-related traits;	chr19:37133430	chr19:37314868~37315620:-
BRCA	cis	rs13401620	0.833	rs13386365	ENSG00000229326.3	AC069154.4	-4.16	3.39e-05	0.00243	-0.16	-0.13	Breast size;	chr2:119845849	chr2:119698623~119700151:+
BRCA	cis	rs2562456	0.833	rs2650776	ENSG00000268658.4	LINC00664	4.16	3.39e-05	0.00243	0.21	0.13	Pain;	chr19:21430595	chr19:21483374~21503238:+
BRCA	cis	rs11098499	0.697	rs35280960	ENSG00000260091.1	RP11-33B1.4	-4.16	3.39e-05	0.00243	-0.11	-0.13	Corneal astigmatism;	chr4:119335904	chr4:119409333~119410233:+
BRCA	cis	rs16944613	0.51	rs11636695	ENSG00000245479.2	LINC01585	-4.16	3.39e-05	0.00243	-0.15	-0.13	Colorectal cancer;	chr15:90609679	chr15:90660234~90664967:+
BRCA	cis	rs1048886	0.872	rs76513668	ENSG00000271967.1	RP11-134K13.4	-4.16	3.39e-05	0.00243	-0.19	-0.13	Type 2 diabetes;	chr6:70465172	chr6:70596438~70596980:+
BRCA	cis	rs1048886	0.872	rs79485742	ENSG00000271967.1	RP11-134K13.4	-4.16	3.39e-05	0.00243	-0.19	-0.13	Type 2 diabetes;	chr6:70465305	chr6:70596438~70596980:+
BRCA	cis	rs1048886	0.872	rs74749095	ENSG00000271967.1	RP11-134K13.4	-4.16	3.39e-05	0.00243	-0.19	-0.13	Type 2 diabetes;	chr6:70467165	chr6:70596438~70596980:+
BRCA	cis	rs1048886	0.872	rs76309923	ENSG00000271967.1	RP11-134K13.4	-4.16	3.39e-05	0.00243	-0.19	-0.13	Type 2 diabetes;	chr6:70471257	chr6:70596438~70596980:+
BRCA	cis	rs17772222	0.876	rs12587528	ENSG00000258789.1	RP11-507K2.3	-4.16	3.39e-05	0.00243	-0.16	-0.13	Coronary artery calcification;	chr14:88487652	chr14:88551597~88552493:+
BRCA	cis	rs8114671	0.836	rs6120778	ENSG00000126005.14	MMP24-AS1	-4.16	3.39e-05	0.00243	-0.15	-0.13	Height;	chr20:34977366	chr20:35216462~35278131:-
BRCA	cis	rs739496	0.527	rs61612992	ENSG00000257624.1	RP1-128M12.3	4.16	3.39e-05	0.00243	0.17	0.13	Platelet count;	chr12:111920260	chr12:112000739~112000985:-
BRCA	cis	rs739496	0.527	rs7300320	ENSG00000257624.1	RP1-128M12.3	4.16	3.39e-05	0.00243	0.17	0.13	Platelet count;	chr12:111922364	chr12:112000739~112000985:-
BRCA	cis	rs739496	0.527	rs11066089	ENSG00000257624.1	RP1-128M12.3	4.16	3.39e-05	0.00243	0.17	0.13	Platelet count;	chr12:111925463	chr12:112000739~112000985:-
BRCA	cis	rs2243480	0.908	rs55876148	ENSG00000222364.1	RNU6-96P	-4.16	3.39e-05	0.00243	-0.24	-0.13	Diabetic kidney disease;	chr7:65914813	chr7:66395191~66395286:+
BRCA	cis	rs6686842	0.56	rs3738368	ENSG00000235358.1	RP11-399E6.1	-4.16	3.39e-05	0.00243	-0.18	-0.13	Height;	chr1:41020230	chr1:41242373~41284861:+
BRCA	cis	rs4499344	0.696	rs10402929	ENSG00000267475.1	CTD-2538C1.2	4.16	3.39e-05	0.00243	0.16	0.13	Mean platelet volume;	chr19:32609339	chr19:32687089~32691750:-
BRCA	cis	rs4499344	0.73	rs7250272	ENSG00000267475.1	CTD-2538C1.2	4.16	3.39e-05	0.00243	0.16	0.13	Mean platelet volume;	chr19:32609432	chr19:32687089~32691750:-
BRCA	cis	rs4499344	0.664	rs4286210	ENSG00000267475.1	CTD-2538C1.2	4.16	3.39e-05	0.00243	0.16	0.13	Mean platelet volume;	chr19:32610315	chr19:32687089~32691750:-
BRCA	cis	rs4835473	0.932	rs6828935	ENSG00000249741.2	RP11-673E1.3	-4.16	3.39e-05	0.00243	-0.13	-0.13	Immature fraction of reticulocytes;	chr4:143829113	chr4:143911514~143912053:-
BRCA	cis	rs1696803	1	rs2935717	ENSG00000276742.1	RP11-500G22.4	-4.16	3.4e-05	0.00243	-0.2	-0.13	Breast cancer;	chr10:121676732	chr10:121956782~121957098:+
BRCA	cis	rs8114671	0.804	rs6088666	ENSG00000279253.1	RP4-614O4.13	-4.16	3.4e-05	0.00243	-0.15	-0.13	Height;	chr20:34976767	chr20:35262727~35264187:-
BRCA	cis	rs983392	0.651	rs718376	ENSG00000275344.1	MIR6503	-4.16	3.4e-05	0.00243	-0.13	-0.13	Alzheimer's disease (late onset);	chr11:60235462	chr11:60209071~60209156:-
BRCA	cis	rs62025270	0.688	rs10163064	ENSG00000259762.1	RP11-158M2.4	-4.16	3.4e-05	0.00243	-0.19	-0.13	Idiopathic pulmonary fibrosis;	chr15:85734289	chr15:85750336~85752901:-
BRCA	cis	rs17801127	0.818	rs16827301	ENSG00000231969.1	AC144449.1	4.16	3.4e-05	0.00243	0.23	0.13	Liver enzyme levels (alanine transaminase);	chr2:149654608	chr2:149587196~149848233:+
BRCA	cis	rs17801127	0.818	rs17496121	ENSG00000231969.1	AC144449.1	4.16	3.4e-05	0.00243	0.23	0.13	Liver enzyme levels (alanine transaminase);	chr2:149654906	chr2:149587196~149848233:+
BRCA	cis	rs7267979	1	rs2257808	ENSG00000125804.12	FAM182A	-4.16	3.4e-05	0.00243	-0.17	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25285814	chr20:26054655~26086917:+
BRCA	cis	rs7267979	1	rs2257809	ENSG00000125804.12	FAM182A	-4.16	3.4e-05	0.00243	-0.17	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25285840	chr20:26054655~26086917:+
BRCA	cis	rs12030196	0.871	rs11207361	ENSG00000230812.4	LINC01358	4.16	3.4e-05	0.00243	0.14	0.13	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr1:58991131	chr1:59020387~59044614:+
BRCA	cis	rs11887277	0.741	rs12471783	ENSG00000272148.1	RP11-195B17.1	-4.16	3.4e-05	0.00243	-0.15	-0.13	Obesity-related traits;	chr2:26817051	chr2:27062428~27062907:-
BRCA	cis	rs7620503	0.721	rs11709335	ENSG00000228561.2	RP11-114M1.1	4.16	3.4e-05	0.00243	0.16	0.13	Corneal structure;	chr3:177591101	chr3:177683627~177691250:+
BRCA	cis	rs875971	0.964	rs60193905	ENSG00000265600.1	AC006480.1	-4.16	3.4e-05	0.00243	-0.15	-0.13	Aortic root size;	chr7:66506273	chr7:67356680~67356779:+
BRCA	cis	rs6452524	0.935	rs7736296	ENSG00000281327.1	LINC01338	-4.16	3.4e-05	0.00243	-0.15	-0.13	Hypertension (SNP x SNP interaction);	chr5:83082421	chr5:82850864~82859836:-
BRCA	cis	rs61931739	0.534	rs11053020	ENSG00000258794.3	DUX4L27	4.16	3.4e-05	0.00243	0.18	0.13	Morning vs. evening chronotype;	chr12:33958157	chr12:34208415~34209675:-
BRCA	cis	rs61931739	0.534	rs11053021	ENSG00000258794.3	DUX4L27	4.16	3.4e-05	0.00243	0.18	0.13	Morning vs. evening chronotype;	chr12:33958222	chr12:34208415~34209675:-
BRCA	cis	rs4302906	0.964	rs11788120	ENSG00000187984.11	ANKRD19P	-4.16	3.4e-05	0.00243	-0.12	-0.13	Lobe attachment (rater-scored or self-reported);	chr9:92985992	chr9:92809388~92888693:+
BRCA	cis	rs17818399	0.788	rs17818315	ENSG00000279254.1	RP11-536C12.1	-4.16	3.4e-05	0.00243	-0.17	-0.13	Height;	chr2:46591853	chr2:46668870~46670778:+
BRCA	cis	rs17264034	0.5	rs1508800	ENSG00000250786.1	SNHG18	-4.16	3.4e-05	0.00244	-0.15	-0.13	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9556349	chr5:9546200~9550609:+
BRCA	cis	rs7267979	0.844	rs6083845	ENSG00000231081.1	RP4-760C5.3	4.16	3.4e-05	0.00244	0.16	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25407454	chr20:26008791~26010531:-
BRCA	cis	rs718314	1	rs10743579	ENSG00000256894.1	RP11-283G6.3	4.16	3.4e-05	0.00244	0.15	0.13	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Renal cell carcinoma;Waist circumference adjusted for body mass index;	chr12:26308212	chr12:26125155~26126617:-
BRCA	cis	rs13434995	0.513	rs13134079	ENSG00000239040.1	Y_RNA	-4.16	3.4e-05	0.00244	-0.15	-0.13	Adiponectin levels;	chr4:55542021	chr4:55412636~55412738:+
BRCA	cis	rs1722141	0.601	rs2464927	ENSG00000237471.1	AC073115.6	-4.16	3.4e-05	0.00244	-0.17	-0.13	Sitting height ratio;	chr7:46036579	chr7:45969657~45980191:+
BRCA	cis	rs1348850	0.539	rs1453371	ENSG00000280374.1	RP11-337N6.3	4.16	3.41e-05	0.00244	0.17	0.13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177363134	chr2:177317715~177318471:-
BRCA	cis	rs9788721	0.902	rs17486195	ENSG00000261762.1	RP11-650L12.2	-4.16	3.41e-05	0.00244	-0.16	-0.13	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78572855	chr15:78589123~78591276:-
BRCA	cis	rs6452524	0.905	rs10040244	ENSG00000281327.1	LINC01338	4.16	3.41e-05	0.00244	0.15	0.13	Hypertension (SNP x SNP interaction);	chr5:83089242	chr5:82850864~82859836:-
BRCA	cis	rs10457838	0.751	rs6932386	ENSG00000236591.1	RP11-162J8.3	-4.16	3.41e-05	0.00244	-0.18	-0.13	Post-traumatic stress disorder;	chr6:149064375	chr6:149027700~149032573:-
BRCA	cis	rs9859260	0.689	rs3817672	ENSG00000271662.1	RP11-141C7.3	-4.16	3.41e-05	0.00244	-0.16	-0.13	Mean corpuscular volume;	chr3:196073940	chr3:195650146~195651472:-
BRCA	cis	rs897984	0.542	rs7294	ENSG00000232748.3	RP11-196G11.6	4.16	3.41e-05	0.00244	0.15	0.13	Dementia with Lewy bodies;	chr16:31091000	chr16:31056460~31062803:+
BRCA	cis	rs2842346	0.568	rs2842331	ENSG00000258623.1	CTD-2325P2.3	-4.16	3.41e-05	0.00244	-0.17	-0.13	Breast cancer;	chr14:68543973	chr14:68683411~68685565:-
BRCA	cis	rs11098499	0.954	rs2389803	ENSG00000260404.2	RP11-384K6.6	-4.16	3.41e-05	0.00244	-0.12	-0.13	Corneal astigmatism;	chr4:119472356	chr4:118591773~118633729:+
BRCA	cis	rs17345786	1	rs3804778	ENSG00000244119.1	PDCL3P4	4.16	3.41e-05	0.00244	0.12	0.13	Colonoscopy-negative controls vs population controls;	chr3:101575728	chr3:101712472~101713191:+
BRCA	cis	rs875971	0.895	rs3857684	ENSG00000236529.1	RP13-254B10.1	4.16	3.41e-05	0.00244	0.14	0.13	Aortic root size;	chr7:66473171	chr7:65840212~65840596:+
BRCA	cis	rs8180040	0.654	rs6791062	ENSG00000271161.1	BOLA2P2	4.16	3.41e-05	0.00244	0.14	0.13	Colorectal cancer;	chr3:47132853	chr3:47499841~47500407:+
BRCA	cis	rs10040989	0.915	rs17171780	ENSG00000253404.1	AC034243.1	-4.16	3.41e-05	0.00244	-0.25	-0.13	QT interval;	chr5:138205127	chr5:138744434~138753309:-
BRCA	cis	rs7267979	0.789	rs4815429	ENSG00000231081.1	RP4-760C5.3	4.16	3.41e-05	0.00244	0.16	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25540975	chr20:26008791~26010531:-
BRCA	cis	rs11098499	0.722	rs28713555	ENSG00000225892.3	RP11-384K6.2	4.16	3.41e-05	0.00244	0.12	0.13	Corneal astigmatism;	chr4:119330840	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.863	rs7664986	ENSG00000250412.1	KLHL2P1	4.16	3.41e-05	0.00244	0.16	0.13	Corneal astigmatism;	chr4:119508797	chr4:119334329~119378233:+
BRCA	cis	rs11098499	0.818	rs10008791	ENSG00000250412.1	KLHL2P1	4.16	3.41e-05	0.00244	0.16	0.13	Corneal astigmatism;	chr4:119510314	chr4:119334329~119378233:+
BRCA	cis	rs11098499	0.863	rs11736416	ENSG00000250412.1	KLHL2P1	4.16	3.41e-05	0.00244	0.16	0.13	Corneal astigmatism;	chr4:119510506	chr4:119334329~119378233:+
BRCA	cis	rs7561149	1	rs12992014	ENSG00000270574.1	RP11-171I2.2	-4.16	3.41e-05	0.00244	-0.17	-0.13	QT interval;	chr2:178826558	chr2:178578790~178580906:+
BRCA	cis	rs38055	0.668	rs62357407	ENSG00000247796.2	CTD-2366F13.1	4.16	3.41e-05	0.00244	0.17	0.13	Acne (severe);	chr5:53200622	chr5:53109842~53115126:+
BRCA	cis	rs7107174	1	rs10899467	ENSG00000251323.2	RP11-452H21.4	4.16	3.41e-05	0.00244	0.19	0.13	Testicular germ cell tumor;	chr11:78303011	chr11:78423982~78429836:-
BRCA	cis	rs7833986	0.501	rs2667999	ENSG00000253603.1	CTA-397H3.3	-4.16	3.41e-05	0.00244	-0.18	-0.13	Height;	chr8:56037915	chr8:56074592~56075274:+
BRCA	cis	rs736801	0.808	rs2522057	ENSG00000233006.5	AC034220.3	4.16	3.41e-05	0.00244	0.1	0.13	Mosquito bite size;Breast cancer;	chr5:132466255	chr5:132311285~132369916:-
BRCA	cis	rs7267979	1	rs1888997	ENSG00000276952.1	RP5-965G21.6	-4.16	3.41e-05	0.00244	-0.16	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25318352	chr20:25284915~25285588:-
BRCA	cis	rs4927850	0.709	rs6783079	ENSG00000207650.1	MIR570	4.16	3.42e-05	0.00244	0.18	0.13	Pancreatic cancer;	chr3:195925837	chr3:195699401~195699497:+
BRCA	cis	rs4927850	0.709	rs6765762	ENSG00000207650.1	MIR570	4.16	3.42e-05	0.00244	0.18	0.13	Pancreatic cancer;	chr3:195925980	chr3:195699401~195699497:+
BRCA	cis	rs61160187	0.582	rs62367872	ENSG00000272308.1	RP11-231G3.1	-4.16	3.42e-05	0.00245	-0.15	-0.13	Educational attainment (years of education);Educational attainment (college completion);	chr5:60976943	chr5:60866457~60866935:-
BRCA	cis	rs61160187	0.556	rs55738840	ENSG00000272308.1	RP11-231G3.1	-4.16	3.42e-05	0.00245	-0.15	-0.13	Educational attainment (years of education);Educational attainment (college completion);	chr5:60977587	chr5:60866457~60866935:-
BRCA	cis	rs61160187	0.582	rs58646987	ENSG00000272308.1	RP11-231G3.1	-4.16	3.42e-05	0.00245	-0.15	-0.13	Educational attainment (years of education);Educational attainment (college completion);	chr5:60979867	chr5:60866457~60866935:-
BRCA	cis	rs61160187	0.582	rs11739952	ENSG00000272308.1	RP11-231G3.1	-4.16	3.42e-05	0.00245	-0.15	-0.13	Educational attainment (years of education);Educational attainment (college completion);	chr5:60980150	chr5:60866457~60866935:-
BRCA	cis	rs2274459	1	rs34139049	ENSG00000249346.5	LINC01016	4.16	3.42e-05	0.00245	0.17	0.13	Obesity (extreme);	chr6:33749007	chr6:33867506~33896914:-
BRCA	cis	rs2274459	1	rs35274562	ENSG00000249346.5	LINC01016	4.16	3.42e-05	0.00245	0.17	0.13	Obesity (extreme);	chr6:33749054	chr6:33867506~33896914:-
BRCA	cis	rs792448	0.743	rs351379	ENSG00000229983.1	RP11-15I11.2	4.16	3.42e-05	0.00245	0.16	0.13	White blood cell count (basophil);	chr1:212250447	chr1:212168207~212190259:+
BRCA	cis	rs4143844	0.867	rs62007764	ENSG00000259251.2	RP11-643M14.1	4.16	3.42e-05	0.00245	0.31	0.13	Bipolar disorder and schizophrenia;	chr15:61948855	chr15:62060503~62062434:+
BRCA	cis	rs911119	0.908	rs12624424	ENSG00000270001.1	RP11-218C14.8	-4.16	3.42e-05	0.00245	-0.17	-0.13	Chronic kidney disease;	chr20:23621241	chr20:23631826~23632316:-
BRCA	cis	rs748404	0.666	rs34515241	ENSG00000205771.5	CATSPER2P1	-4.16	3.42e-05	0.00245	-0.19	-0.13	Lung cancer;	chr15:43342011	chr15:43726918~43747094:-
BRCA	cis	rs17507216	0.718	rs72751675	ENSG00000259429.4	UBE2Q2P2	-4.16	3.42e-05	0.00245	-0.17	-0.13	Excessive daytime sleepiness;	chr15:82630452	chr15:82355142~82420075:+
BRCA	cis	rs2302465	0.86	rs73239182	ENSG00000273133.1	RP11-799M12.2	-4.16	3.42e-05	0.00245	-0.24	-0.13	Blood protein levels;	chr4:15614559	chr4:15563698~15564253:-
BRCA	cis	rs10129255	0.518	rs12590732	ENSG00000211959.2	IGHV4-39	-4.16	3.42e-05	0.00245	-0.09	-0.13	Kawasaki disease;	chr14:106779612	chr14:106421711~106422218:-
BRCA	cis	rs13434995	0.513	rs6554285	ENSG00000239040.1	Y_RNA	-4.16	3.42e-05	0.00245	-0.15	-0.13	Adiponectin levels;	chr4:55533953	chr4:55412636~55412738:+
BRCA	cis	rs13434995	0.513	rs7660668	ENSG00000239040.1	Y_RNA	-4.16	3.42e-05	0.00245	-0.15	-0.13	Adiponectin levels;	chr4:55535530	chr4:55412636~55412738:+
BRCA	cis	rs2554380	0.843	rs2554386	ENSG00000230373.7	GOLGA6L5P	-4.16	3.42e-05	0.00245	-0.18	-0.13	Height;	chr15:83734770	chr15:84507885~84516814:-
BRCA	cis	rs642803	1	rs557675	ENSG00000255557.1	RP11-770G2.2	4.16	3.42e-05	0.00245	0.15	0.13	Urate levels;	chr11:65799248	chr11:65745729~65771585:+
BRCA	cis	rs490234	0.783	rs10119855	ENSG00000232630.1	PRPS1P2	-4.16	3.42e-05	0.00245	-0.13	-0.13	Mean arterial pressure;	chr9:125508844	chr9:125150653~125151589:+
BRCA	cis	rs11098499	0.955	rs35197422	ENSG00000250412.1	KLHL2P1	4.16	3.42e-05	0.00245	0.15	0.13	Corneal astigmatism;	chr4:119248159	chr4:119334329~119378233:+
BRCA	cis	rs9638182	0.636	rs6968170	ENSG00000274080.1	CTA-315H11.2	4.16	3.42e-05	0.00245	0.19	0.13	Triglycerides;	chr7:73606346	chr7:73609262~73611502:-
BRCA	cis	rs4908760	0.516	rs11121232	ENSG00000232912.4	RP5-1115A15.1	4.16	3.43e-05	0.00245	0.12	0.13	Vitiligo;	chr1:8790650	chr1:8424645~8434838:+
BRCA	cis	rs4869313	0.905	rs38031	ENSG00000248734.2	CTD-2260A17.1	-4.16	3.43e-05	0.00245	-0.13	-0.13	Pediatric autoimmune diseases;	chr5:97019744	chr5:96784777~96785999:+
BRCA	cis	rs16846053	0.792	rs62189059	ENSG00000227403.1	AC009299.3	4.16	3.43e-05	0.00245	0.33	0.13	Blood osmolality (transformed sodium);	chr2:161775657	chr2:161244739~161249050:+
BRCA	cis	rs4835473	0.932	rs10857413	ENSG00000249741.2	RP11-673E1.3	-4.16	3.43e-05	0.00245	-0.13	-0.13	Immature fraction of reticulocytes;	chr4:143827752	chr4:143911514~143912053:-
BRCA	cis	rs1371614	0.632	rs3739088	ENSG00000272148.1	RP11-195B17.1	-4.16	3.43e-05	0.00245	-0.14	-0.13	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26944916	chr2:27062428~27062907:-
BRCA	cis	rs1371614	0.632	rs3769135	ENSG00000272148.1	RP11-195B17.1	-4.16	3.43e-05	0.00245	-0.14	-0.13	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26945543	chr2:27062428~27062907:-
BRCA	cis	rs950169	0.512	rs4374136	ENSG00000275120.1	RP11-182J1.17	4.16	3.43e-05	0.00245	0.2	0.13	Schizophrenia;	chr15:83976255	chr15:84599434~84606463:-
BRCA	cis	rs12368653	0.584	rs7295422	ENSG00000257159.1	RP11-58A17.3	-4.16	3.43e-05	0.00245	-0.15	-0.13	Multiple sclerosis;	chr12:57705953	chr12:57967058~57968399:+
BRCA	cis	rs2408955	0.521	rs10875753	ENSG00000226413.2	OR8T1P	4.16	3.43e-05	0.00245	0.17	0.13	Glycated hemoglobin levels;	chr12:48163358	chr12:48442030~48442947:-
BRCA	cis	rs875971	0.706	rs1643374	ENSG00000229180.5	GS1-124K5.11	4.16	3.43e-05	0.00245	0.11	0.13	Aortic root size;	chr7:66407695	chr7:66526088~66542624:-
BRCA	cis	rs911119	0.955	rs35610040	ENSG00000270001.1	RP11-218C14.8	-4.16	3.43e-05	0.00245	-0.17	-0.13	Chronic kidney disease;	chr20:23635832	chr20:23631826~23632316:-
BRCA	cis	rs911119	1	rs3787499	ENSG00000270001.1	RP11-218C14.8	-4.16	3.43e-05	0.00245	-0.17	-0.13	Chronic kidney disease;	chr20:23636170	chr20:23631826~23632316:-
BRCA	cis	rs911119	1	rs3827142	ENSG00000270001.1	RP11-218C14.8	-4.16	3.43e-05	0.00245	-0.17	-0.13	Chronic kidney disease;	chr20:23636370	chr20:23631826~23632316:-
BRCA	cis	rs35740288	0.77	rs11630968	ENSG00000202081.1	RNU6-1280P	4.16	3.43e-05	0.00245	0.17	0.13	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85574770	chr15:85651522~85651628:-
BRCA	cis	rs4578769	0.765	rs16972427	ENSG00000265939.1	UBE2CP2	-4.16	3.43e-05	0.00245	-0.16	-0.13	Eosinophil percentage of white cells;	chr18:22833393	chr18:22900486~22900995:-
BRCA	cis	rs1910358	0.69	rs4701412	ENSG00000248874.4	C5orf17	-4.16	3.43e-05	0.00245	-0.17	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23963130	chr5:23951348~24178263:+
BRCA	cis	rs2243480	0.522	rs431168	ENSG00000226002.1	RP11-460N20.5	-4.16	3.43e-05	0.00245	-0.26	-0.13	Diabetic kidney disease;	chr7:66046617	chr7:65084103~65100232:+
BRCA	cis	rs35740288	0.77	rs67253156	ENSG00000202081.1	RNU6-1280P	4.16	3.43e-05	0.00245	0.16	0.13	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85561814	chr15:85651522~85651628:-
BRCA	cis	rs812925	0.502	rs13028833	ENSG00000270820.4	RP11-355B11.2	-4.16	3.43e-05	0.00246	-0.14	-0.13	Immature fraction of reticulocytes;	chr2:61417194	chr2:61471188~61484130:+
BRCA	cis	rs9733	0.621	rs6669122	ENSG00000203804.4	ADAMTSL4-AS1	-4.16	3.43e-05	0.00246	-0.14	-0.13	Tonsillectomy;	chr1:150619256	chr1:150560202~150574552:-
BRCA	cis	rs2380205	0.538	rs11255698	ENSG00000232807.2	RP11-536K7.3	4.16	3.43e-05	0.00246	0.14	0.13	Breast cancer;	chr10:5878930	chr10:5934270~5945900:-
BRCA	cis	rs748404	0.626	rs72707530	ENSG00000205771.5	CATSPER2P1	-4.16	3.43e-05	0.00246	-0.19	-0.13	Lung cancer;	chr15:43353622	chr15:43726918~43747094:-
BRCA	cis	rs11098499	0.863	rs13140391	ENSG00000260091.1	RP11-33B1.4	-4.16	3.43e-05	0.00246	-0.12	-0.13	Corneal astigmatism;	chr4:119582282	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.863	rs13140409	ENSG00000260091.1	RP11-33B1.4	-4.16	3.43e-05	0.00246	-0.12	-0.13	Corneal astigmatism;	chr4:119582305	chr4:119409333~119410233:+
BRCA	cis	rs957448	1	rs16916881	ENSG00000254315.1	RP11-267M23.3	4.16	3.43e-05	0.00246	0.17	0.13	Nonsyndromic cleft lip with cleft palate;	chr8:94554042	chr8:94533628~94534391:+
BRCA	cis	rs13108904	0.967	rs62293658	ENSG00000253399.1	AC078852.2	4.16	3.43e-05	0.00246	0.14	0.13	Obesity-related traits;	chr4:1282628	chr4:1358479~1359461:+
BRCA	cis	rs2832077	1	rs2832077	ENSG00000232855.5	AF131217.1	4.16	3.44e-05	0.00246	0.19	0.13	Cognitive test performance;	chr21:28768699	chr21:28439346~28674848:-
BRCA	cis	rs4869313	0.837	rs2432142	ENSG00000248734.2	CTD-2260A17.1	4.16	3.44e-05	0.00246	0.13	0.13	Pediatric autoimmune diseases;	chr5:96939497	chr5:96784777~96785999:+
BRCA	cis	rs11673344	0.523	rs2562609	ENSG00000276846.1	CTD-3220F14.3	4.16	3.44e-05	0.00246	0.15	0.13	Obesity-related traits;	chr19:37036255	chr19:37314868~37315620:-
BRCA	cis	rs7620503	0.613	rs11707809	ENSG00000228221.4	LINC00578	4.16	3.44e-05	0.00246	0.16	0.13	Corneal structure;	chr3:177567542	chr3:177441921~177752305:+
BRCA	cis	rs34975555	0.568	rs17692021	ENSG00000254054.2	RP11-156K13.3	-4.16	3.44e-05	0.00246	-0.18	-0.13	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:17976976	chr8:17905756~17907887:+
BRCA	cis	rs1005277	0.563	rs2505215	ENSG00000272983.1	RP11-508N22.12	4.16	3.44e-05	0.00246	0.14	0.13	Extrinsic epigenetic age acceleration;	chr10:38192345	chr10:38137337~38144399:+
BRCA	cis	rs4578769	0.959	rs9947011	ENSG00000265939.1	UBE2CP2	-4.16	3.44e-05	0.00246	-0.15	-0.13	Eosinophil percentage of white cells;	chr18:22840446	chr18:22900486~22900995:-
BRCA	cis	rs848490	0.928	rs62460675	ENSG00000214293.7	APTR	4.16	3.44e-05	0.00246	0.16	0.13	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77678027	chr7:77657660~77696265:-
BRCA	cis	rs7487075	0.558	rs56988021	ENSG00000272369.1	RP11-446N19.1	4.16	3.44e-05	0.00246	0.14	0.13	Itch intensity from mosquito bite;	chr12:46243568	chr12:46537502~46652550:+
BRCA	cis	rs4819052	0.851	rs8134392	ENSG00000215447.6	BX322557.10	4.16	3.44e-05	0.00246	0.13	0.13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45243875	chr21:45288052~45291738:+
BRCA	cis	rs2243480	1	rs34703416	ENSG00000226002.1	RP11-460N20.5	-4.16	3.44e-05	0.00246	-0.21	-0.13	Diabetic kidney disease;	chr7:65835655	chr7:65084103~65100232:+
BRCA	cis	rs801193	0.967	rs2707841	ENSG00000223473.2	GS1-124K5.3	4.16	3.44e-05	0.00246	0.1	0.13	Aortic root size;	chr7:66692033	chr7:66491049~66493566:-
BRCA	cis	rs801193	1	rs4717310	ENSG00000223473.2	GS1-124K5.3	4.16	3.44e-05	0.00246	0.1	0.13	Aortic root size;	chr7:66696020	chr7:66491049~66493566:-
BRCA	cis	rs9907295	0.901	rs4796119	ENSG00000271013.1	AC015849.15	4.16	3.44e-05	0.00246	0.2	0.13	Fibroblast growth factor basic levels;	chr17:35866084	chr17:35912635~35918010:-
BRCA	cis	rs5762752	0.647	rs9625533	ENSG00000279978.1	chr22-38_28785274-29006793.1	4.16	3.44e-05	0.00246	0.17	0.13	Optic disc area;	chr22:28692602	chr22:28930201~29197572:+
BRCA	cis	rs4835473	0.932	rs6851999	ENSG00000249741.2	RP11-673E1.3	-4.16	3.44e-05	0.00246	-0.13	-0.13	Immature fraction of reticulocytes;	chr4:143742567	chr4:143911514~143912053:-
BRCA	cis	rs910316	0.967	rs4903293	ENSG00000259138.1	RP11-950C14.7	-4.16	3.44e-05	0.00246	-0.13	-0.13	Height;	chr14:75189865	chr14:75127153~75136930:+
BRCA	cis	rs17772222	0.917	rs1998670	ENSG00000258789.1	RP11-507K2.3	-4.16	3.44e-05	0.00246	-0.16	-0.13	Coronary artery calcification;	chr14:88504581	chr14:88551597~88552493:+
BRCA	cis	rs4919694	0.808	rs80020194	ENSG00000236937.2	PTGES3P4	4.16	3.44e-05	0.00246	0.28	0.13	Arsenic metabolism;	chr10:103276197	chr10:102845595~102845950:+
BRCA	cis	rs8114671	0.628	rs6060130	ENSG00000126005.14	MMP24-AS1	-4.16	3.44e-05	0.00246	-0.15	-0.13	Height;	chr20:34961516	chr20:35216462~35278131:-
BRCA	cis	rs4648045	0.565	rs4698862	ENSG00000251288.2	RP11-10L12.2	-4.16	3.45e-05	0.00246	-0.16	-0.13	Lymphocyte percentage of white cells;	chr4:102624640	chr4:102751401~102752641:+
BRCA	cis	rs1555322	1	rs2425037	ENSG00000261582.1	RP4-614O4.11	4.16	3.45e-05	0.00246	0.17	0.13	Attention deficit hyperactivity disorder;	chr20:35268626	chr20:35267885~35280043:-
BRCA	cis	rs9733	0.596	rs6587518	ENSG00000231073.1	RP11-316M1.3	4.16	3.45e-05	0.00246	0.13	0.13	Tonsillectomy;	chr1:150689311	chr1:150973123~150975534:+
BRCA	cis	rs2055375	0.56	rs7446842	ENSG00000272308.1	RP11-231G3.1	-4.16	3.45e-05	0.00247	-0.15	-0.13	Intelligence (multi-trait analysis);	chr5:61237688	chr5:60866457~60866935:-
BRCA	cis	rs7474896	0.583	rs34185758	ENSG00000120555.12	SEPT7P9	4.16	3.45e-05	0.00247	0.19	0.13	Obesity (extreme);	chr10:37701926	chr10:38383069~38402916:-
BRCA	cis	rs7746199	0.736	rs34573979	ENSG00000216901.1	AL022393.7	4.16	3.45e-05	0.00247	0.33	0.13	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27512747	chr6:28176188~28176674:+
BRCA	cis	rs35740288	0.822	rs10520599	ENSG00000259407.1	RP11-158M2.3	-4.16	3.45e-05	0.00247	-0.17	-0.13	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85679866	chr15:85744109~85750281:-
BRCA	cis	rs2071426	0.622	rs7097166	ENSG00000273450.1	RP11-76P2.4	4.16	3.45e-05	0.00247	0.17	0.13	Blood metabolite levels;	chr10:95017122	chr10:94314907~94315327:-
BRCA	cis	rs7474896	0.561	rs2474603	ENSG00000263064.2	RP11-291L22.7	4.16	3.45e-05	0.00247	0.2	0.13	Obesity (extreme);	chr10:38156754	chr10:38448689~38448949:+
BRCA	cis	rs7772486	0.875	rs9390377	ENSG00000270638.1	RP3-466P17.1	4.16	3.45e-05	0.00247	0.15	0.13	Lobe attachment (rater-scored or self-reported);	chr6:146065796	chr6:145735570~145737218:+
BRCA	cis	rs6088590	0.561	rs2295444	ENSG00000275784.1	RP5-1125A11.6	-4.16	3.45e-05	0.00247	-0.14	-0.13	Coronary artery disease;	chr20:34586079	chr20:33989480~33991818:-
BRCA	cis	rs2991971	0.934	rs2991974	ENSG00000280836.1	AL355480.1	4.16	3.45e-05	0.00247	0.15	0.13	High light scatter reticulocyte count;	chr1:45554982	chr1:45581219~45581321:-
BRCA	cis	rs2731006	0.64	rs2678135	ENSG00000257114.2	RP11-25I15.3	4.16	3.46e-05	0.00247	0.21	0.13	Panic disorder;	chr12:42794158	chr12:42692216~42717119:+
BRCA	cis	rs9868809	0.772	rs34096717	ENSG00000225399.4	RP11-3B7.1	-4.16	3.46e-05	0.00247	-0.2	-0.13	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48682020	chr3:49260085~49261316:+
BRCA	cis	rs1987511	1	rs7900903	ENSG00000224034.1	RP11-445P17.8	-4.16	3.46e-05	0.00247	-0.17	-0.13	Intelligence;	chr10:5313497	chr10:5266033~5271236:-
BRCA	cis	rs1129187	0.935	rs9986447	ENSG00000220614.1	RP11-480N24.4	-4.16	3.46e-05	0.00247	-0.15	-0.13	Alzheimer's disease in APOE e4+ carriers;	chr6:42975041	chr6:43328134~43328476:+
BRCA	cis	rs1722133	0.555	rs62450964	ENSG00000229628.1	AC073115.7	-4.16	3.46e-05	0.00247	-0.18	-0.13	Sitting height ratio;	chr7:46085526	chr7:45990905~46000898:+
BRCA	cis	rs72627123	0.881	rs28548133	ENSG00000259065.1	RP5-1021I20.1	4.16	3.46e-05	0.00247	0.2	0.13	Morning vs. evening chronotype;	chr14:73842451	chr14:73787360~73803270:+
BRCA	cis	rs7918232	0.607	rs1755401	ENSG00000262412.1	RP11-85G18.6	4.16	3.46e-05	0.00247	0.24	0.13	Breast cancer;	chr10:27116834	chr10:27243130~27250804:+
BRCA	cis	rs4950322	0.563	rs6686480	ENSG00000244371.2	PFN1P8	-4.16	3.46e-05	0.00247	-0.17	-0.13	Protein quantitative trait loci;	chr1:147111986	chr1:146957117~146957659:-
BRCA	cis	rs6756513	0.5	rs7596535	ENSG00000231024.1	AC092431.3	-4.16	3.46e-05	0.00247	-0.17	-0.13	Breast cancer;Platelet count;	chr2:69858829	chr2:69700192~69713847:-
BRCA	cis	rs7267979	0.844	rs2257649	ENSG00000231081.1	RP4-760C5.3	-4.16	3.46e-05	0.00247	-0.16	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25282821	chr20:26008791~26010531:-
BRCA	cis	rs72482608	0.835	rs1029320	ENSG00000271811.1	RP1-79C4.4	-4.16	3.46e-05	0.00247	-0.14	-0.13	Emphysema imaging phenotypes;	chr1:170773087	chr1:170667381~170669425:+
BRCA	cis	rs6001482	0.702	rs7286018	ENSG00000279278.1	CH17-264L24.1	4.16	3.46e-05	0.00247	0.11	0.13	Diastolic blood pressure;	chr22:22236464	chr22:22264601~22273020:+
BRCA	cis	rs256438	0.524	rs166270	ENSG00000251050.1	RP11-168A11.4	-4.16	3.46e-05	0.00247	-0.14	-0.13	Serum thyroid-stimulating hormone levels;	chr5:80044756	chr5:80019609~80019920:+
BRCA	cis	rs11204677	1	rs11204677	ENSG00000203804.4	ADAMTSL4-AS1	-4.16	3.46e-05	0.00247	-0.14	-0.13	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:150602219	chr1:150560202~150574552:-
BRCA	cis	rs6546324	0.615	rs7598280	ENSG00000236780.4	AC078941.1	4.16	3.46e-05	0.00248	0.22	0.13	Endometriosis;	chr2:67588181	chr2:67123357~67215319:-
BRCA	cis	rs8040855	0.627	rs1532776	ENSG00000259774.1	RP11-182J1.13	4.16	3.46e-05	0.00248	0.18	0.13	Bulimia nervosa;	chr15:85081383	chr15:84422618~84425882:+
BRCA	cis	rs6671200	0.607	rs2296308	ENSG00000235501.4	RP4-639F20.1	-4.16	3.46e-05	0.00248	-0.21	-0.13	Stearic acid (18:0) levels;	chr1:95244383	chr1:94927566~94963270:+
BRCA	cis	rs757081	0.667	rs17561348	ENSG00000184669.7	OR7E14P	4.16	3.47e-05	0.00248	0.19	0.13	Systolic blood pressure;	chr11:17140068	chr11:17013998~17053024:+
BRCA	cis	rs964611	0.882	rs56308793	ENSG00000259488.2	RP11-154J22.1	-4.16	3.47e-05	0.00248	-0.16	-0.13	Metabolite levels (Pyroglutamine);	chr15:48350611	chr15:48312353~48331856:-
BRCA	cis	rs7487075	0.502	rs12299843	ENSG00000272369.1	RP11-446N19.1	4.16	3.47e-05	0.00248	0.14	0.13	Itch intensity from mosquito bite;	chr12:46242227	chr12:46537502~46652550:+
BRCA	cis	rs7221109	0.71	rs4890093	ENSG00000229028.2	KRT223P	4.16	3.47e-05	0.00248	0.15	0.13	Type 1 diabetes;	chr17:40639691	chr17:40717235~40721932:-
BRCA	cis	rs10487112	0.901	rs12704540	ENSG00000235436.9	DPY19L2P4	-4.16	3.47e-05	0.00248	-0.14	-0.13	Perceived unattractiveness to mosquitoes;	chr7:90456902	chr7:90119400~90125600:+
BRCA	cis	rs1153858	1	rs11070453	ENSG00000275672.1	GATM-AS1	-4.16	3.47e-05	0.00248	-0.17	-0.13	Homoarginine levels;	chr15:45352956	chr15:45378700~45380123:+
BRCA	cis	rs1153858	1	rs12593230	ENSG00000275672.1	GATM-AS1	-4.16	3.47e-05	0.00248	-0.17	-0.13	Homoarginine levels;	chr15:45354770	chr15:45378700~45380123:+
BRCA	cis	rs4987094	0.634	rs11214592	ENSG00000270179.1	RP11-159N11.4	4.16	3.47e-05	0.00248	0.19	0.13	Schizophrenia;	chr11:113379751	chr11:113368478~113369117:+
BRCA	cis	rs13113518	1	rs4864548	ENSG00000273257.1	RP11-177J6.1	-4.16	3.47e-05	0.00248	-0.16	-0.13	Height;	chr4:55547636	chr4:55387949~55388271:+
BRCA	cis	rs739496	0.843	rs10774631	ENSG00000234608.6	MAPKAPK5-AS1	-4.16	3.47e-05	0.00248	-0.16	-0.13	Platelet count;	chr12:111585197	chr12:111839764~111842902:-
BRCA	cis	rs4650943	0.565	rs4442332	ENSG00000227740.1	RP11-318C24.2	-4.16	3.47e-05	0.00248	-0.13	-0.13	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in inactive individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr1:176247141	chr1:175904762~175920513:-
BRCA	cis	rs4650943	0.565	rs4652156	ENSG00000227740.1	RP11-318C24.2	-4.16	3.47e-05	0.00248	-0.13	-0.13	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in inactive individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr1:176247794	chr1:175904762~175920513:-
BRCA	cis	rs4650943	0.565	rs1858181	ENSG00000227740.1	RP11-318C24.2	-4.16	3.47e-05	0.00248	-0.13	-0.13	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in inactive individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr1:176249499	chr1:175904762~175920513:-
BRCA	cis	rs4650943	0.528	rs7538600	ENSG00000227740.1	RP11-318C24.2	-4.16	3.47e-05	0.00248	-0.13	-0.13	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in inactive individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr1:176253823	chr1:175904762~175920513:-
BRCA	cis	rs4650943	0.565	rs7340050	ENSG00000227740.1	RP11-318C24.2	-4.16	3.47e-05	0.00248	-0.13	-0.13	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in inactive individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr1:176255610	chr1:175904762~175920513:-
BRCA	cis	rs2117029	0.5	rs3741619	ENSG00000258017.1	RP11-386G11.10	4.16	3.47e-05	0.00248	0.17	0.13	Intelligence (multi-trait analysis);	chr12:48995693	chr12:49127782~49147869:+
BRCA	cis	rs4835473	0.864	rs57648439	ENSG00000249741.2	RP11-673E1.3	4.16	3.47e-05	0.00248	0.14	0.13	Immature fraction of reticulocytes;	chr4:143691519	chr4:143911514~143912053:-
BRCA	cis	rs78487399	0.71	rs17031000	ENSG00000234936.1	AC010883.5	4.16	3.47e-05	0.00248	0.2	0.13	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43531486	chr2:43229573~43233394:+
BRCA	cis	rs11696845	1	rs1467472	ENSG00000276223.1	RP4-781B1.5	-4.16	3.47e-05	0.00248	-0.13	-0.13	Obesity-related traits;	chr20:44742910	chr20:44746642~44747201:+
BRCA	cis	rs6430585	0.527	rs60966546	ENSG00000224043.6	CCNT2-AS1	-4.16	3.47e-05	0.00248	-0.21	-0.13	Corneal structure;	chr2:135644273	chr2:134735464~134918710:-
BRCA	cis	rs938554	0.513	rs11943372	ENSG00000250413.1	RP11-448G15.1	-4.16	3.47e-05	0.00248	-0.18	-0.13	Blood metabolite levels;	chr4:9997722	chr4:10006482~10009725:+
BRCA	cis	rs7647973	1	rs3448	ENSG00000244380.1	RP11-24C3.2	4.16	3.47e-05	0.00248	0.16	0.13	Menarche (age at onset);	chr3:49359318	chr3:48440352~48446656:-
BRCA	cis	rs7647973	1	rs11130190	ENSG00000244380.1	RP11-24C3.2	4.16	3.47e-05	0.00248	0.16	0.13	Menarche (age at onset);	chr3:49364704	chr3:48440352~48446656:-
BRCA	cis	rs1005277	0.54	rs1814077	ENSG00000226578.1	RP11-258F22.1	-4.16	3.48e-05	0.00248	-0.14	-0.13	Extrinsic epigenetic age acceleration;	chr10:37703090	chr10:37775371~37784131:-
BRCA	cis	rs2115630	0.967	rs11073702	ENSG00000275120.1	RP11-182J1.17	-4.16	3.48e-05	0.00248	-0.15	-0.13	P wave terminal force;	chr15:84766840	chr15:84599434~84606463:-
BRCA	cis	rs4869313	0.905	rs71654350	ENSG00000248734.2	CTD-2260A17.1	4.16	3.48e-05	0.00248	0.13	0.13	Pediatric autoimmune diseases;	chr5:96943244	chr5:96784777~96785999:+
BRCA	cis	rs4869313	0.87	rs7733312	ENSG00000248734.2	CTD-2260A17.1	4.16	3.48e-05	0.00248	0.13	0.13	Pediatric autoimmune diseases;	chr5:96950117	chr5:96784777~96785999:+
BRCA	cis	rs409045	0.965	rs462352	ENSG00000271874.1	CTD-2024P10.2	-4.16	3.48e-05	0.00248	-0.17	-0.13	Left ventricular mass;	chr5:34635891	chr5:34651457~34651888:-
BRCA	cis	rs9287719	0.639	rs2357649	ENSG00000234818.1	AC092687.5	-4.16	3.48e-05	0.00248	-0.15	-0.13	Prostate cancer;	chr2:10556662	chr2:10589166~10604830:+
BRCA	cis	rs6496044	0.611	rs8026938	ENSG00000202081.1	RNU6-1280P	-4.16	3.48e-05	0.00248	-0.15	-0.13	Interstitial lung disease;	chr15:85525887	chr15:85651522~85651628:-
BRCA	cis	rs13113518	1	rs4865007	ENSG00000272969.1	RP11-528I4.2	-4.16	3.48e-05	0.00248	-0.15	-0.13	Height;	chr4:55537550	chr4:55547112~55547889:+
BRCA	cis	rs17270561	0.609	rs9348692	ENSG00000272462.2	U91328.19	-4.16	3.48e-05	0.00249	-0.16	-0.13	Iron status biomarkers;	chr6:25720584	chr6:25992662~26001775:+
BRCA	cis	rs7621331	0.963	rs6771997	ENSG00000273486.1	RP11-731C17.2	-4.16	3.48e-05	0.00249	-0.15	-0.13	Waist circumference adjusted for body mass index;	chr3:136012472	chr3:136837338~136839021:-
BRCA	cis	rs8180040	1	rs1024037	ENSG00000271161.1	BOLA2P2	-4.16	3.48e-05	0.00249	-0.14	-0.13	Colorectal cancer;	chr3:47276959	chr3:47499841~47500407:+
BRCA	cis	rs896854	0.738	rs2515226	ENSG00000245080.5	RP11-320N21.1	-4.16	3.48e-05	0.00249	-0.16	-0.13	Type 2 diabetes;	chr8:94953515	chr8:95066808~95073182:-
BRCA	cis	rs1885120	0.773	rs2425025	ENSG00000250917.1	RP4-785G19.5	4.16	3.48e-05	0.00249	0.37	0.13	Melanoma;	chr20:35259351	chr20:34234840~34281173:-
BRCA	cis	rs6088590	0.561	rs6059926	ENSG00000275784.1	RP5-1125A11.6	-4.16	3.48e-05	0.00249	-0.14	-0.13	Coronary artery disease;	chr20:34577000	chr20:33989480~33991818:-
BRCA	cis	rs10986311	0.851	rs7853472	ENSG00000227200.1	RP11-121A14.3	-4.16	3.48e-05	0.00249	-0.15	-0.13	Vitiligo;	chr9:124274388	chr9:124262876~124265809:+
BRCA	cis	rs12681366	0.537	rs2919667	ENSG00000253175.1	RP11-267M23.6	4.16	3.48e-05	0.00249	0.15	0.13	Nonsyndromic cleft lip with cleft palate;	chr8:94452974	chr8:94565036~94565715:+
BRCA	cis	rs2991971	1	rs2934859	ENSG00000280836.1	AL355480.1	4.16	3.48e-05	0.00249	0.15	0.13	High light scatter reticulocyte count;	chr1:45552164	chr1:45581219~45581321:-
BRCA	cis	rs860295	1	rs822490	ENSG00000203761.5	MSTO2P	-4.16	3.48e-05	0.00249	-0.1	-0.13	Body mass index;	chr1:155853180	chr1:155745829~155750137:+
BRCA	cis	rs3892630	0.529	rs35300319	ENSG00000267567.1	CTD-2538C1.3	4.16	3.48e-05	0.00249	0.19	0.13	Red blood cell traits;	chr19:32919042	chr19:32718298~32719595:-
BRCA	cis	rs11673344	0.526	rs35153242	ENSG00000267422.1	CTD-2554C21.1	-4.16	3.48e-05	0.00249	-0.17	-0.13	Obesity-related traits;	chr19:37660841	chr19:37779686~37792865:+
BRCA	cis	rs490234	0.702	rs4838279	ENSG00000232630.1	PRPS1P2	-4.16	3.48e-05	0.00249	-0.13	-0.13	Mean arterial pressure;	chr9:125649447	chr9:125150653~125151589:+
BRCA	cis	rs875971	0.66	rs10263935	ENSG00000223473.2	GS1-124K5.3	4.16	3.48e-05	0.00249	0.1	0.13	Aortic root size;	chr7:66631041	chr7:66491049~66493566:-
BRCA	cis	rs58521262	0.556	rs289337	ENSG00000268105.1	RP11-369G6.2	-4.16	3.49e-05	0.00249	-0.17	-0.13	Testicular germ cell tumor;	chr19:22968988	chr19:23125665~23128543:+
BRCA	cis	rs6480314	0.831	rs11813125	ENSG00000233590.1	RP11-153K11.3	4.16	3.49e-05	0.00249	0.2	0.13	Optic nerve measurement (disc area);	chr10:68215276	chr10:68233251~68242379:-
BRCA	cis	rs7592578	0.882	rs7569128	ENSG00000272979.1	RP11-647K16.1	4.16	3.49e-05	0.00249	0.22	0.13	Diastolic blood pressure;	chr2:190581965	chr2:190454092~190454521:-
BRCA	cis	rs853679	0.882	rs9468287	ENSG00000216901.1	AL022393.7	4.16	3.49e-05	0.00249	0.26	0.13	Depression;	chr6:28111963	chr6:28176188~28176674:+
BRCA	cis	rs2243480	1	rs73142166	ENSG00000222364.1	RNU6-96P	-4.16	3.49e-05	0.00249	-0.23	-0.13	Diabetic kidney disease;	chr7:65910845	chr7:66395191~66395286:+
BRCA	cis	rs2908197	0.765	rs2098205	ENSG00000186704.9	DTX2P1	4.16	3.49e-05	0.00249	0.15	0.13	3-hydroxypropylmercapturic acid levels in smokers;	chr7:76309571	chr7:76978617~77004308:+
BRCA	cis	rs12435908	1	rs17246042	ENSG00000276116.2	FUT8-AS1	-4.16	3.49e-05	0.00249	-0.2	-0.13	Ischemic stroke;	chr14:65407612	chr14:65411170~65412690:-
BRCA	cis	rs853679	0.517	rs56310871	ENSG00000216901.1	AL022393.7	4.16	3.49e-05	0.00249	0.18	0.13	Depression;	chr6:28076704	chr6:28176188~28176674:+
BRCA	cis	rs6893300	0.961	rs11738269	ENSG00000250999.1	RP11-1379J22.5	-4.16	3.49e-05	0.00249	-0.18	-0.13	Resting heart rate;	chr5:179782058	chr5:179657762~179664432:+
BRCA	cis	rs875971	0.66	rs10272357	ENSG00000232546.1	RP11-458F8.1	4.16	3.49e-05	0.00249	0.11	0.13	Aortic root size;	chr7:66598087	chr7:66848496~66858136:+
BRCA	cis	rs180730	1	rs2667175	ENSG00000251609.2	SETP12	-4.16	3.49e-05	0.00249	-0.19	-0.13	Fasting plasma glucose;	chr4:120882099	chr4:120895494~120897083:-
BRCA	cis	rs8180040	0.701	rs12491473	ENSG00000276925.1	RP11-708J19.3	4.16	3.49e-05	0.00249	0.15	0.13	Colorectal cancer;	chr3:46948414	chr3:47469777~47469987:+
BRCA	cis	rs801193	1	rs2659889	ENSG00000223473.2	GS1-124K5.3	4.16	3.49e-05	0.00249	0.1	0.13	Aortic root size;	chr7:66752125	chr7:66491049~66493566:-
BRCA	cis	rs6430585	0.697	rs6724569	ENSG00000224043.6	CCNT2-AS1	-4.16	3.49e-05	0.00249	-0.22	-0.13	Corneal structure;	chr2:135759400	chr2:134735464~134918710:-
BRCA	cis	rs2962370	0.842	rs2929709	ENSG00000215196.4	AC091878.1	4.16	3.49e-05	0.00249	0.16	0.13	Bipolar disorder with mood-incongruent psychosis;	chr5:17213098	chr5:17130028~17217047:-
BRCA	cis	rs2243480	1	rs316329	ENSG00000237026.1	RP11-328P23.2	4.16	3.49e-05	0.00249	0.23	0.13	Diabetic kidney disease;	chr7:66143429	chr7:65235790~65236723:-
BRCA	cis	rs4218	0.597	rs12438111	ENSG00000259732.1	RP11-59H7.3	-4.16	3.49e-05	0.00249	-0.16	-0.13	Social communication problems;	chr15:59057540	chr15:59121034~59133250:+
BRCA	cis	rs7267979	0.932	rs6107052	ENSG00000277938.1	RP5-965G21.3	4.16	3.49e-05	0.00249	0.15	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25550202	chr20:25229150~25231933:+
BRCA	cis	rs7572733	0.935	rs6742782	ENSG00000231621.1	AC013264.2	-4.16	3.49e-05	0.00249	-0.12	-0.13	Dermatomyositis;	chr2:197890297	chr2:197197991~197199273:+
BRCA	cis	rs9527	0.59	rs7067663	ENSG00000213061.2	PFN1P11	4.16	3.49e-05	0.0025	0.17	0.13	Arsenic metabolism;	chr10:103123893	chr10:102838011~102845473:-
BRCA	cis	rs17489649	1	rs13187428	ENSG00000271849.1	CTC-332L22.1	4.16	3.49e-05	0.0025	0.16	0.13	Intelligence (multi-trait analysis);	chr5:109759844	chr5:109687802~109688329:-
BRCA	cis	rs2991971	1	rs9147	ENSG00000280836.1	AL355480.1	4.16	3.49e-05	0.0025	0.15	0.13	High light scatter reticulocyte count;	chr1:45551015	chr1:45581219~45581321:-
BRCA	cis	rs4865762	0.904	rs4865764	ENSG00000247796.2	CTD-2366F13.1	-4.16	3.49e-05	0.0025	-0.13	-0.13	Intraocular pressure;	chr5:53314938	chr5:53109842~53115126:+
BRCA	cis	rs683250	0.598	rs7933220	ENSG00000254551.1	RP11-727A23.7	4.16	3.5e-05	0.0025	0.16	0.13	Subcortical brain region volumes;	chr11:83307732	chr11:83209431~83213379:-
BRCA	cis	rs1005277	0.579	rs2474568	ENSG00000272983.1	RP11-508N22.12	4.16	3.5e-05	0.0025	0.14	0.13	Extrinsic epigenetic age acceleration;	chr10:38094219	chr10:38137337~38144399:+
BRCA	cis	rs11096990	0.634	rs6531706	ENSG00000249685.1	RP11-360F5.3	-4.16	3.5e-05	0.0025	-0.16	-0.13	Cognitive function;	chr4:39294547	chr4:39133913~39135608:+
BRCA	cis	rs1910358	0.53	rs1520982	ENSG00000248874.4	C5orf17	-4.16	3.5e-05	0.0025	-0.18	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23758273	chr5:23951348~24178263:+
BRCA	cis	rs1910358	0.554	rs1520985	ENSG00000248874.4	C5orf17	-4.16	3.5e-05	0.0025	-0.18	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23758769	chr5:23951348~24178263:+
BRCA	cis	rs875971	0.895	rs778700	ENSG00000229180.5	GS1-124K5.11	4.16	3.5e-05	0.0025	0.11	0.13	Aortic root size;	chr7:66401463	chr7:66526088~66542624:-
BRCA	cis	rs875971	1	rs778699	ENSG00000229180.5	GS1-124K5.11	4.16	3.5e-05	0.0025	0.11	0.13	Aortic root size;	chr7:66403303	chr7:66526088~66542624:-
BRCA	cis	rs7937682	0.961	rs4935790	ENSG00000230911.1	PPIHP1	4.16	3.5e-05	0.0025	0.18	0.13	Primary sclerosing cholangitis;	chr11:111762290	chr11:112029858~112030367:-
BRCA	cis	rs875971	1	rs778710	ENSG00000265600.1	AC006480.1	-4.16	3.5e-05	0.0025	-0.15	-0.13	Aortic root size;	chr7:66389847	chr7:67356680~67356779:+
BRCA	cis	rs748404	0.666	rs34591748	ENSG00000205771.5	CATSPER2P1	-4.16	3.5e-05	0.0025	-0.19	-0.13	Lung cancer;	chr15:43334917	chr15:43726918~43747094:-
BRCA	cis	rs420259	0.727	rs249869	ENSG00000260136.4	CTD-2270L9.4	4.16	3.5e-05	0.0025	0.12	0.13	Bipolar disorder;	chr16:23655236	chr16:23452758~23457606:+
BRCA	cis	rs420259	0.681	rs249868	ENSG00000260136.4	CTD-2270L9.4	4.16	3.5e-05	0.0025	0.12	0.13	Bipolar disorder;	chr16:23655476	chr16:23452758~23457606:+
BRCA	cis	rs4415084	0.646	rs13183209	ENSG00000251141.4	RP11-53O19.1	4.16	3.5e-05	0.0025	0.12	0.13	Breast cancer;	chr5:44803647	chr5:44744900~44808777:-
BRCA	cis	rs763121	0.853	rs2235230	ENSG00000225450.1	RP3-508I15.14	4.16	3.5e-05	0.0025	0.15	0.13	Menopause (age at onset);	chr22:38728462	chr22:38739003~38749041:+
BRCA	cis	rs2688608	0.587	rs2894040	ENSG00000213731.2	RAB5CP1	-4.16	3.5e-05	0.0025	-0.14	-0.13	Inflammatory bowel disease;	chr10:73718401	chr10:74423435~74424014:-
BRCA	cis	rs2688608	0.592	rs3849967	ENSG00000213731.2	RAB5CP1	-4.16	3.5e-05	0.0025	-0.14	-0.13	Inflammatory bowel disease;	chr10:73723608	chr10:74423435~74424014:-
BRCA	cis	rs61931739	0.517	rs10844802	ENSG00000258794.3	DUX4L27	4.16	3.5e-05	0.0025	0.18	0.13	Morning vs. evening chronotype;	chr12:34078066	chr12:34208415~34209675:-
BRCA	cis	rs61931739	0.534	rs10506120	ENSG00000258794.3	DUX4L27	4.16	3.5e-05	0.0025	0.18	0.13	Morning vs. evening chronotype;	chr12:34082668	chr12:34208415~34209675:-
BRCA	cis	rs4143844	0.867	rs12912477	ENSG00000259251.2	RP11-643M14.1	4.16	3.5e-05	0.0025	0.31	0.13	Bipolar disorder and schizophrenia;	chr15:61949909	chr15:62060503~62062434:+
BRCA	cis	rs4578769	0.765	rs11082147	ENSG00000265939.1	UBE2CP2	-4.16	3.5e-05	0.0025	-0.16	-0.13	Eosinophil percentage of white cells;	chr18:22806559	chr18:22900486~22900995:-
BRCA	cis	rs11098499	0.754	rs17595608	ENSG00000260091.1	RP11-33B1.4	-4.16	3.5e-05	0.0025	-0.11	-0.13	Corneal astigmatism;	chr4:119329351	chr4:119409333~119410233:+
BRCA	cis	rs4916588	0.636	rs4916566	ENSG00000230732.4	AC127904.2	-4.16	3.5e-05	0.0025	-0.16	-0.13	Night sleep phenotypes;	chr3:196872053	chr3:196912646~196914579:+
BRCA	cis	rs62025270	0.547	rs338536	ENSG00000259295.5	CSPG4P12	-4.16	3.5e-05	0.0025	-0.17	-0.13	Idiopathic pulmonary fibrosis;	chr15:85654009	chr15:85191438~85213905:+
BRCA	cis	rs7833790	1	rs1463259	ENSG00000254689.1	RP11-354A14.1	4.16	3.5e-05	0.0025	0.18	0.13	Diastolic blood pressure;	chr8:81825510	chr8:81885377~81923193:+
BRCA	cis	rs755249	0.762	rs1775654	ENSG00000237624.1	OXCT2P1	4.16	3.5e-05	0.0025	0.16	0.13	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39484408	chr1:39514956~39516490:+
BRCA	cis	rs4499344	0.696	rs2868153	ENSG00000267475.1	CTD-2538C1.2	4.16	3.5e-05	0.0025	0.16	0.13	Mean platelet volume;	chr19:32608371	chr19:32687089~32691750:-
BRCA	cis	rs75504410	0.579	rs2637713	ENSG00000231160.8	KLF3-AS1	4.16	3.51e-05	0.0025	0.18	0.13	Sum eosinophil basophil counts;Eosinophil counts;	chr4:38625716	chr4:38612701~38664883:-
BRCA	cis	rs17680741	0.697	rs2343550	ENSG00000226659.1	RP11-137H2.4	4.16	3.51e-05	0.0025	0.22	0.13	Coronary artery disease;	chr10:80504667	chr10:80529597~80535942:-
BRCA	cis	rs3742597	0.84	rs10138052	ENSG00000276116.2	FUT8-AS1	-4.16	3.51e-05	0.0025	-0.15	-0.13	N-glycan levels;	chr14:65366722	chr14:65411170~65412690:-
BRCA	cis	rs7475343	0.561	rs1781930	ENSG00000224034.1	RP11-445P17.8	4.16	3.51e-05	0.0025	0.24	0.13	Intelligence;	chr10:5154078	chr10:5266033~5271236:-
BRCA	cis	rs295490	0.748	rs75634125	ENSG00000272656.1	RP11-219D15.3	4.16	3.51e-05	0.0025	0.32	0.13	PR interval in Tripanosoma cruzi seropositivity;	chr3:139371639	chr3:139349024~139349371:-
BRCA	cis	rs295490	0.748	rs80249265	ENSG00000272656.1	RP11-219D15.3	4.16	3.51e-05	0.0025	0.32	0.13	PR interval in Tripanosoma cruzi seropositivity;	chr3:139371856	chr3:139349024~139349371:-
BRCA	cis	rs6081541	1	rs6081544	ENSG00000179447.2	RP5-1027G4.3	-4.16	3.51e-05	0.0025	-0.18	-0.13	Psychosis (atypical);	chr20:19236132	chr20:19242302~19284596:-
BRCA	cis	rs6596100	0.915	rs62375245	ENSG00000248648.1	RP11-485M7.1	-4.16	3.51e-05	0.0025	-0.16	-0.13	Breast cancer;	chr5:133102666	chr5:133003119~133003365:+
BRCA	cis	rs6596100	0.956	rs62375247	ENSG00000248648.1	RP11-485M7.1	-4.16	3.51e-05	0.0025	-0.16	-0.13	Breast cancer;	chr5:133103336	chr5:133003119~133003365:+
BRCA	cis	rs6596100	0.915	rs56076449	ENSG00000248648.1	RP11-485M7.1	-4.16	3.51e-05	0.0025	-0.16	-0.13	Breast cancer;	chr5:133106498	chr5:133003119~133003365:+
BRCA	cis	rs957448	1	rs16916874	ENSG00000254315.1	RP11-267M23.3	4.16	3.51e-05	0.0025	0.17	0.13	Nonsyndromic cleft lip with cleft palate;	chr8:94537749	chr8:94533628~94534391:+
BRCA	cis	rs409045	0.932	rs457371	ENSG00000271874.1	CTD-2024P10.2	-4.16	3.51e-05	0.0025	-0.17	-0.13	Left ventricular mass;	chr5:34637103	chr5:34651457~34651888:-
BRCA	cis	rs7960884	0.712	rs11051331	ENSG00000226472.6	RP11-551L14.4	4.16	3.51e-05	0.00251	0.17	0.13	Systolic blood pressure response to hydrochlorothiazide in hypertension;	chr12:31220687	chr12:30978308~31006010:-
BRCA	cis	rs875971	0.545	rs6950988	ENSG00000273142.1	RP11-458F8.4	4.16	3.51e-05	0.00251	0.13	0.13	Aortic root size;	chr7:66511428	chr7:66902857~66906297:+
BRCA	cis	rs745109	0.882	rs78926831	ENSG00000273080.1	RP11-301O19.1	4.16	3.51e-05	0.00251	0.2	0.13	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86433537	chr2:86195590~86196049:+
BRCA	cis	rs12893668	0.703	rs2403197	ENSG00000269940.1	RP11-73M18.7	4.16	3.51e-05	0.00251	0.15	0.13	Reticulocyte count;	chr14:103587427	chr14:103694560~103695170:+
BRCA	cis	rs7267979	0.933	rs2261109	ENSG00000125804.12	FAM182A	-4.16	3.51e-05	0.00251	-0.17	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25278564	chr20:26054655~26086917:+
BRCA	cis	rs7267979	0.966	rs2261720	ENSG00000125804.12	FAM182A	-4.16	3.51e-05	0.00251	-0.17	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25280005	chr20:26054655~26086917:+
BRCA	cis	rs8180040	0.62	rs11917361	ENSG00000271161.1	BOLA2P2	-4.16	3.51e-05	0.00251	-0.14	-0.13	Colorectal cancer;	chr3:47029007	chr3:47499841~47500407:+
BRCA	cis	rs763121	0.853	rs4821812	ENSG00000225450.1	RP3-508I15.14	-4.16	3.51e-05	0.00251	-0.14	-0.13	Menopause (age at onset);	chr22:38679230	chr22:38739003~38749041:+
BRCA	cis	rs7267979	1	rs4815412	ENSG00000277938.1	RP5-965G21.3	4.16	3.51e-05	0.00251	0.15	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25369689	chr20:25229150~25231933:+
BRCA	cis	rs739496	0.843	rs610769	ENSG00000234608.6	MAPKAPK5-AS1	4.16	3.51e-05	0.00251	0.16	0.13	Platelet count;	chr12:111561766	chr12:111839764~111842902:-
BRCA	cis	rs739496	0.843	rs595529	ENSG00000234608.6	MAPKAPK5-AS1	4.16	3.51e-05	0.00251	0.16	0.13	Platelet count;	chr12:111562844	chr12:111839764~111842902:-
BRCA	cis	rs1371614	0.545	rs3769138	ENSG00000229122.1	AGBL5-IT1	4.16	3.51e-05	0.00251	0.14	0.13	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26946672	chr2:27061038~27061815:+
BRCA	cis	rs4869313	0.935	rs1544777	ENSG00000248734.2	CTD-2260A17.1	4.16	3.52e-05	0.00251	0.13	0.13	Pediatric autoimmune diseases;	chr5:96978526	chr5:96784777~96785999:+
BRCA	cis	rs12317459	0.591	rs7310087	ENSG00000213270.5	RPL6P25	-4.16	3.52e-05	0.00251	-0.21	-0.13	Prostate cancer (SNP x SNP interaction);	chr12:82771952	chr12:83151331~83152190:+
BRCA	cis	rs886774	0.899	rs4404839	ENSG00000273055.1	CTB-13F3.1	-4.16	3.52e-05	0.00251	-0.13	-0.13	Ulcerative colitis;	chr7:107860052	chr7:107942116~107942740:+
BRCA	cis	rs983392	0.967	rs2847664	ENSG00000275344.1	MIR6503	-4.16	3.52e-05	0.00251	-0.14	-0.13	Alzheimer's disease (late onset);	chr11:60091024	chr11:60209071~60209156:-
BRCA	cis	rs875971	0.895	rs12698520	ENSG00000236529.1	RP13-254B10.1	4.16	3.52e-05	0.00251	0.14	0.13	Aortic root size;	chr7:66453720	chr7:65840212~65840596:+
BRCA	cis	rs2274273	0.712	rs9806049	ENSG00000233924.1	AL160471.6	-4.16	3.52e-05	0.00251	-0.15	-0.13	Protein biomarker;	chr14:55058871	chr14:55004813~55005687:-
BRCA	cis	rs38055	0.958	rs435548	ENSG00000247796.2	CTD-2366F13.1	-4.16	3.52e-05	0.00251	-0.15	-0.13	Acne (severe);	chr5:53283161	chr5:53109842~53115126:+
BRCA	cis	rs11239930	0.538	rs4950361	ENSG00000278811.3	LINC00624	-4.16	3.52e-05	0.00251	-0.15	-0.13	AIDS progression;	chr1:147087618	chr1:147258885~147517875:-
BRCA	cis	rs2832191	0.545	rs2251381	ENSG00000176054.6	RPL23P2	4.16	3.52e-05	0.00251	0.14	0.13	Dental caries;	chr21:29158371	chr21:28997613~28998033:-
BRCA	cis	rs62244186	0.52	rs2372828	ENSG00000233509.2	ZNF197-AS1	-4.16	3.52e-05	0.00251	-0.16	-0.13	Depressive symptoms;	chr3:44743457	chr3:44617128~44624797:-
BRCA	cis	rs4218	0.648	rs8042896	ENSG00000259732.1	RP11-59H7.3	-4.16	3.52e-05	0.00251	-0.16	-0.13	Social communication problems;	chr15:59067727	chr15:59121034~59133250:+
BRCA	cis	rs6452524	1	rs7738033	ENSG00000281327.1	LINC01338	4.16	3.52e-05	0.00251	0.15	0.13	Hypertension (SNP x SNP interaction);	chr5:83135470	chr5:82850864~82859836:-
BRCA	cis	rs6452524	1	rs6860239	ENSG00000281327.1	LINC01338	4.16	3.52e-05	0.00251	0.15	0.13	Hypertension (SNP x SNP interaction);	chr5:83136022	chr5:82850864~82859836:-
BRCA	cis	rs67981189	0.513	rs7154395	ENSG00000258571.1	PTTG4P	-4.15	3.52e-05	0.00251	-0.14	-0.13	Schizophrenia;	chr14:71099583	chr14:71085482~71085833:-
BRCA	cis	rs651907	0.535	rs9830943	ENSG00000256628.3	ZBTB11-AS1	4.15	3.52e-05	0.00251	0.16	0.13	Colorectal cancer;	chr3:101710055	chr3:101676475~101679217:+
BRCA	cis	rs490234	0.702	rs1339499	ENSG00000232630.1	PRPS1P2	-4.15	3.52e-05	0.00251	-0.13	-0.13	Mean arterial pressure;	chr9:125644174	chr9:125150653~125151589:+
BRCA	cis	rs2832191	0.791	rs2832197	ENSG00000236056.1	GAPDHP14	4.15	3.52e-05	0.00251	0.14	0.13	Dental caries;	chr21:29125469	chr21:29222321~29223257:+
BRCA	cis	rs2832191	0.791	rs57721945	ENSG00000236056.1	GAPDHP14	4.15	3.52e-05	0.00251	0.14	0.13	Dental caries;	chr21:29126423	chr21:29222321~29223257:+
BRCA	cis	rs11098499	0.909	rs1809406	ENSG00000250412.1	KLHL2P1	4.15	3.52e-05	0.00251	0.15	0.13	Corneal astigmatism;	chr4:119455967	chr4:119334329~119378233:+
BRCA	cis	rs11098499	0.865	rs2389809	ENSG00000250412.1	KLHL2P1	4.15	3.52e-05	0.00251	0.15	0.13	Corneal astigmatism;	chr4:119456244	chr4:119334329~119378233:+
BRCA	cis	rs11098499	0.909	rs9994810	ENSG00000250412.1	KLHL2P1	4.15	3.52e-05	0.00251	0.15	0.13	Corneal astigmatism;	chr4:119460435	chr4:119334329~119378233:+
BRCA	cis	rs11098499	0.697	rs10020027	ENSG00000250412.1	KLHL2P1	4.15	3.52e-05	0.00251	0.15	0.13	Corneal astigmatism;	chr4:119460724	chr4:119334329~119378233:+
BRCA	cis	rs11098499	0.779	rs7356491	ENSG00000250412.1	KLHL2P1	4.15	3.52e-05	0.00251	0.15	0.13	Corneal astigmatism;	chr4:119460819	chr4:119334329~119378233:+
BRCA	cis	rs2832191	0.72	rs2832200	ENSG00000236056.1	GAPDHP14	4.15	3.52e-05	0.00251	0.14	0.13	Dental caries;	chr21:29126844	chr21:29222321~29223257:+
BRCA	cis	rs2832191	0.791	rs28633762	ENSG00000236056.1	GAPDHP14	4.15	3.52e-05	0.00251	0.14	0.13	Dental caries;	chr21:29127749	chr21:29222321~29223257:+
BRCA	cis	rs13434995	0.842	rs9790448	ENSG00000273257.1	RP11-177J6.1	-4.15	3.52e-05	0.00251	-0.2	-0.13	Adiponectin levels;	chr4:55592918	chr4:55387949~55388271:+
BRCA	cis	rs2832191	0.632	rs2246777	ENSG00000215533.7	LINC00189	4.15	3.52e-05	0.00251	0.15	0.13	Dental caries;	chr21:28937264	chr21:29193480~29288205:+
BRCA	cis	rs1075265	0.509	rs10188142	ENSG00000235937.1	AC008280.1	-4.15	3.52e-05	0.00251	-0.14	-0.13	Chronotype;Morning vs. evening chronotype;	chr2:53730999	chr2:54029552~54030682:-
BRCA	cis	rs755249	0.567	rs41270807	ENSG00000182109.6	RP11-69E11.4	4.15	3.53e-05	0.00251	0.18	0.13	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39336143	chr1:39522280~39546187:-
BRCA	cis	rs755249	0.53	rs16826087	ENSG00000182109.6	RP11-69E11.4	4.15	3.53e-05	0.00251	0.18	0.13	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39346846	chr1:39522280~39546187:-
BRCA	cis	rs755249	0.567	rs41270811	ENSG00000182109.6	RP11-69E11.4	4.15	3.53e-05	0.00251	0.18	0.13	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39349672	chr1:39522280~39546187:-
BRCA	cis	rs755249	0.567	rs61779274	ENSG00000182109.6	RP11-69E11.4	4.15	3.53e-05	0.00251	0.18	0.13	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39351269	chr1:39522280~39546187:-
BRCA	cis	rs1730008	1	rs1193511	ENSG00000279311.1	RP11-170K4.2	-4.15	3.53e-05	0.00252	-0.15	-0.13	Lobe attachment (rater-scored or self-reported);	chr3:158312308	chr3:158869898~158871821:+
BRCA	cis	rs757081	0.637	rs586785	ENSG00000184669.7	OR7E14P	-4.15	3.53e-05	0.00252	-0.19	-0.13	Systolic blood pressure;	chr11:17187167	chr11:17013998~17053024:+
BRCA	cis	rs6870983	0.857	rs10473915	ENSG00000247828.6	TMEM161B-AS1	-4.15	3.53e-05	0.00252	-0.16	-0.13	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index;	chr5:88449160	chr5:88268895~88436685:+
BRCA	cis	rs11931598	0.514	rs10937779	ENSG00000245468.3	RP11-367J11.3	4.15	3.53e-05	0.00252	0.12	0.13	Sum basophil neutrophil counts;Neutrophil count;Granulocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;	chr4:7037599	chr4:7094571~7103385:-
BRCA	cis	rs4747241	0.515	rs11000212	ENSG00000226701.1	RP11-570G20.1	4.15	3.53e-05	0.00252	0.14	0.13	Heschl's gyrus morphology;	chr10:72195894	chr10:72189941~72190576:+
BRCA	cis	rs3812762	0.912	rs10769954	ENSG00000254860.4	TMEM9B-AS1	-4.15	3.53e-05	0.00252	-0.12	-0.13	Hypospadias;	chr11:8762166	chr11:8964675~8977527:+
BRCA	cis	rs9859260	0.744	rs406271	ENSG00000207650.1	MIR570	-4.15	3.53e-05	0.00252	-0.15	-0.13	Mean corpuscular volume;	chr3:196050105	chr3:195699401~195699497:+
BRCA	cis	rs58521262	0.585	rs457149	ENSG00000268105.1	RP11-369G6.2	4.15	3.53e-05	0.00252	0.17	0.13	Testicular germ cell tumor;	chr19:22947311	chr19:23125665~23128543:+
BRCA	cis	rs6599077	1	rs9866108	ENSG00000223797.4	ENTPD3-AS1	4.15	3.53e-05	0.00252	0.16	0.13	Sleep-related phenotypes;	chr3:40055800	chr3:40313802~40453329:-
BRCA	cis	rs71520386	0.607	rs28660425	ENSG00000226329.2	AC005682.6	-4.15	3.53e-05	0.00252	-0.13	-0.13	Fibrinogen levels;	chr7:22818532	chr7:22863874~22881350:-
BRCA	cis	rs11098499	0.78	rs7680914	ENSG00000250412.1	KLHL2P1	4.15	3.53e-05	0.00252	0.16	0.13	Corneal astigmatism;	chr4:119641898	chr4:119334329~119378233:+
BRCA	cis	rs7267979	1	rs6107033	ENSG00000274973.1	RP13-401N8.7	4.15	3.53e-05	0.00252	0.15	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25382955	chr20:25845497~25845862:+
BRCA	cis	rs11098499	0.754	rs1849457	ENSG00000260091.1	RP11-33B1.4	-4.15	3.53e-05	0.00252	-0.11	-0.13	Corneal astigmatism;	chr4:119333200	chr4:119409333~119410233:+
BRCA	cis	rs10457838	0.638	rs12203658	ENSG00000236591.1	RP11-162J8.3	4.15	3.53e-05	0.00252	0.18	0.13	Post-traumatic stress disorder;	chr6:148996111	chr6:149027700~149032573:-
BRCA	cis	rs930395	0.514	rs7718354	ENSG00000251141.4	RP11-53O19.1	-4.15	3.53e-05	0.00252	-0.12	-0.13	Breast cancer;	chr5:44890912	chr5:44744900~44808777:-
BRCA	cis	rs6570726	0.533	rs1832374	ENSG00000235652.6	RP11-545I5.3	4.15	3.53e-05	0.00252	0.13	0.13	Lobe attachment (rater-scored or self-reported);	chr6:145396616	chr6:145799409~145886585:+
BRCA	cis	rs871012	0.502	rs62388483	ENSG00000248544.2	CTB-47B11.3	-4.15	3.53e-05	0.00252	-0.16	-0.13	IgG glycosylation;	chr5:157456829	chr5:157375741~157384950:-
BRCA	cis	rs56322409	0.503	rs4325250	ENSG00000226688.5	ENTPD1-AS1	4.15	3.53e-05	0.00252	0.14	0.13	Blood metabolite levels;	chr10:95915562	chr10:95753206~96090238:-
BRCA	cis	rs38055	0.793	rs37776	ENSG00000247796.2	CTD-2366F13.1	-4.15	3.53e-05	0.00252	-0.15	-0.13	Acne (severe);	chr5:53332300	chr5:53109842~53115126:+
BRCA	cis	rs5758511	0.633	rs5751258	ENSG00000227370.1	RP4-669P10.19	4.15	3.53e-05	0.00252	0.17	0.13	Birth weight;	chr22:42267865	chr22:42132543~42132998:+
BRCA	cis	rs4415084	0.716	rs10462081	ENSG00000251141.4	RP11-53O19.1	4.15	3.53e-05	0.00252	0.12	0.13	Breast cancer;	chr5:44800563	chr5:44744900~44808777:-
BRCA	cis	rs875971	0.964	rs778708	ENSG00000265600.1	AC006480.1	-4.15	3.53e-05	0.00252	-0.15	-0.13	Aortic root size;	chr7:66391332	chr7:67356680~67356779:+
BRCA	cis	rs6545883	0.862	rs1880866	ENSG00000212978.6	AC016747.3	4.15	3.53e-05	0.00252	0.17	0.13	Tuberculosis;	chr2:61471837	chr2:61141592~61144969:-
BRCA	cis	rs875971	0.522	rs1968127	ENSG00000229180.5	GS1-124K5.11	-4.15	3.53e-05	0.00252	-0.11	-0.13	Aortic root size;	chr7:66591816	chr7:66526088~66542624:-
BRCA	cis	rs8177876	0.658	rs2316730	ENSG00000261141.1	RP11-303E16.5	4.15	3.53e-05	0.00252	0.23	0.13	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81106035	chr16:81055301~81056426:+
BRCA	cis	rs2274273	0.713	rs56725788	ENSG00000233924.1	AL160471.6	-4.15	3.53e-05	0.00252	-0.14	-0.13	Protein biomarker;	chr14:55073383	chr14:55004813~55005687:-
BRCA	cis	rs2274273	0.743	rs13379159	ENSG00000233924.1	AL160471.6	-4.15	3.53e-05	0.00252	-0.14	-0.13	Protein biomarker;	chr14:55074083	chr14:55004813~55005687:-
BRCA	cis	rs7177699	0.557	rs8035093	ENSG00000261143.1	ADAMTS7P3	-4.15	3.53e-05	0.00252	-0.15	-0.13	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78828328	chr15:77976042~77993057:+
BRCA	cis	rs739401	0.572	rs12276060	ENSG00000183562.3	CTC-343N3.1	-4.15	3.53e-05	0.00252	-0.14	-0.13	Longevity;	chr11:2994342	chr11:2989863~2991344:+
BRCA	cis	rs745109	0.882	rs72930323	ENSG00000273080.1	RP11-301O19.1	4.15	3.53e-05	0.00252	0.2	0.13	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86428739	chr2:86195590~86196049:+
BRCA	cis	rs11098499	0.71	rs6851130	ENSG00000260404.2	RP11-384K6.6	-4.15	3.53e-05	0.00252	-0.12	-0.13	Corneal astigmatism;	chr4:119212557	chr4:118591773~118633729:+
BRCA	cis	rs748404	0.666	rs7181634	ENSG00000205771.5	CATSPER2P1	-4.15	3.53e-05	0.00252	-0.19	-0.13	Lung cancer;	chr15:43351703	chr15:43726918~43747094:-
BRCA	cis	rs6963495	0.818	rs56251768	ENSG00000223886.3	RP11-251G23.2	4.15	3.54e-05	0.00252	0.2	0.13	Bipolar disorder (body mass index interaction);	chr7:105525144	chr7:105530209~105530671:+
BRCA	cis	rs6963495	0.818	rs56177071	ENSG00000223886.3	RP11-251G23.2	4.15	3.54e-05	0.00252	0.2	0.13	Bipolar disorder (body mass index interaction);	chr7:105525201	chr7:105530209~105530671:+
BRCA	cis	rs6963495	0.818	rs55794529	ENSG00000223886.3	RP11-251G23.2	4.15	3.54e-05	0.00252	0.2	0.13	Bipolar disorder (body mass index interaction);	chr7:105525300	chr7:105530209~105530671:+
BRCA	cis	rs6963495	0.818	rs73190200	ENSG00000223886.3	RP11-251G23.2	4.15	3.54e-05	0.00252	0.2	0.13	Bipolar disorder (body mass index interaction);	chr7:105525409	chr7:105530209~105530671:+
BRCA	cis	rs6963495	0.799	rs73190201	ENSG00000223886.3	RP11-251G23.2	4.15	3.54e-05	0.00252	0.2	0.13	Bipolar disorder (body mass index interaction);	chr7:105525444	chr7:105530209~105530671:+
BRCA	cis	rs6963495	0.818	rs73190202	ENSG00000223886.3	RP11-251G23.2	4.15	3.54e-05	0.00252	0.2	0.13	Bipolar disorder (body mass index interaction);	chr7:105526063	chr7:105530209~105530671:+
BRCA	cis	rs6963495	0.769	rs117986187	ENSG00000223886.3	RP11-251G23.2	4.15	3.54e-05	0.00252	0.2	0.13	Bipolar disorder (body mass index interaction);	chr7:105526864	chr7:105530209~105530671:+
BRCA	cis	rs7395581	0.797	rs10742801	ENSG00000280615.1	Y_RNA	4.15	3.54e-05	0.00252	0.15	0.13	HDL cholesterol;	chr11:47320669	chr11:47614898~47614994:-
BRCA	cis	rs801193	0.761	rs2659888	ENSG00000223473.2	GS1-124K5.3	4.15	3.54e-05	0.00252	0.1	0.13	Aortic root size;	chr7:66765184	chr7:66491049~66493566:-
BRCA	cis	rs2731006	0.64	rs2678104	ENSG00000257114.2	RP11-25I15.3	-4.15	3.54e-05	0.00252	-0.21	-0.13	Panic disorder;	chr12:42770808	chr12:42692216~42717119:+
BRCA	cis	rs7267979	0.744	rs6050464	ENSG00000277938.1	RP5-965G21.3	4.15	3.54e-05	0.00252	0.15	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25228663	chr20:25229150~25231933:+
BRCA	cis	rs2998286	0.666	rs2491251	ENSG00000237128.1	RP11-351M16.3	4.15	3.54e-05	0.00252	0.15	0.13	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28525363	chr10:28433008~28495813:-
BRCA	cis	rs11098499	0.954	rs59394118	ENSG00000260091.1	RP11-33B1.4	-4.15	3.54e-05	0.00252	-0.11	-0.13	Corneal astigmatism;	chr4:119374396	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.865	rs9996417	ENSG00000260091.1	RP11-33B1.4	-4.15	3.54e-05	0.00252	-0.11	-0.13	Corneal astigmatism;	chr4:119374707	chr4:119409333~119410233:+
BRCA	cis	rs16846053	0.792	rs62187736	ENSG00000227403.1	AC009299.3	4.15	3.54e-05	0.00252	0.34	0.13	Blood osmolality (transformed sodium);	chr2:161836778	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.792	rs55970269	ENSG00000227403.1	AC009299.3	4.15	3.54e-05	0.00252	0.34	0.13	Blood osmolality (transformed sodium);	chr2:161837044	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.792	rs55658092	ENSG00000227403.1	AC009299.3	4.15	3.54e-05	0.00252	0.34	0.13	Blood osmolality (transformed sodium);	chr2:161837049	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.792	rs55764479	ENSG00000227403.1	AC009299.3	4.15	3.54e-05	0.00252	0.34	0.13	Blood osmolality (transformed sodium);	chr2:161837228	chr2:161244739~161249050:+
BRCA	cis	rs2562456	0.617	rs34203148	ENSG00000240522.1	RPL7AP10	-4.15	3.54e-05	0.00252	-0.14	-0.13	Pain;	chr19:21590743	chr19:21149648~21150438:-
BRCA	cis	rs6600671	1	rs4844381	ENSG00000231429.2	RP11-343N15.2	-4.15	3.54e-05	0.00252	-0.15	-0.13	Hip geometry;	chr1:121443040	chr1:121412719~121429274:+
BRCA	cis	rs2688608	0.592	rs7909802	ENSG00000213731.2	RAB5CP1	-4.15	3.54e-05	0.00252	-0.14	-0.13	Inflammatory bowel disease;	chr10:73724428	chr10:74423435~74424014:-
BRCA	cis	rs7932354	0.583	rs7934421	ENSG00000200376.1	RNU5E-10P	4.15	3.54e-05	0.00252	0.16	0.13	Bone mineral density (hip);Bone mineral density;	chr11:46831202	chr11:47576471~47576588:-
BRCA	cis	rs748404	0.666	rs55748552	ENSG00000205771.5	CATSPER2P1	-4.15	3.54e-05	0.00252	-0.19	-0.13	Lung cancer;	chr15:43359428	chr15:43726918~43747094:-
BRCA	cis	rs748404	0.63	rs35278805	ENSG00000205771.5	CATSPER2P1	-4.15	3.54e-05	0.00252	-0.19	-0.13	Lung cancer;	chr15:43361124	chr15:43726918~43747094:-
BRCA	cis	rs4143844	0.609	rs34234705	ENSG00000259251.2	RP11-643M14.1	4.15	3.54e-05	0.00252	0.31	0.13	Bipolar disorder and schizophrenia;	chr15:61938475	chr15:62060503~62062434:+
BRCA	cis	rs801193	0.935	rs2659899	ENSG00000223473.2	GS1-124K5.3	4.15	3.54e-05	0.00252	0.1	0.13	Aortic root size;	chr7:66721734	chr7:66491049~66493566:-
BRCA	cis	rs4950322	0.58	rs17359629	ENSG00000244371.2	PFN1P8	-4.15	3.54e-05	0.00252	-0.16	-0.13	Protein quantitative trait loci;	chr1:147121537	chr1:146957117~146957659:-
BRCA	cis	rs6088580	0.634	rs6059824	ENSG00000276073.1	RP5-1125A11.7	-4.15	3.54e-05	0.00252	-0.14	-0.13	Glomerular filtration rate (creatinine);	chr20:34426737	chr20:33985617~33988989:-
BRCA	cis	rs2274273	0.529	rs7149965	ENSG00000258413.1	RP11-665C16.6	-4.15	3.54e-05	0.00252	-0.16	-0.13	Protein biomarker;	chr14:55041473	chr14:55262767~55272075:-
BRCA	cis	rs6546324	0.625	rs2902007	ENSG00000236780.4	AC078941.1	4.15	3.54e-05	0.00252	0.21	0.13	Endometriosis;	chr2:67568330	chr2:67123357~67215319:-
BRCA	cis	rs757081	0.667	rs7108067	ENSG00000184669.7	OR7E14P	-4.15	3.54e-05	0.00252	-0.19	-0.13	Systolic blood pressure;	chr11:17178673	chr11:17013998~17053024:+
BRCA	cis	rs757081	0.606	rs679201	ENSG00000184669.7	OR7E14P	-4.15	3.54e-05	0.00252	-0.19	-0.13	Systolic blood pressure;	chr11:17179344	chr11:17013998~17053024:+
BRCA	cis	rs13401620	0.843	rs4404280	ENSG00000229326.3	AC069154.4	4.15	3.54e-05	0.00252	0.16	0.13	Breast size;	chr2:119929271	chr2:119698623~119700151:+
BRCA	cis	rs34421088	0.576	rs2572432	ENSG00000154316.13	TDH	4.15	3.54e-05	0.00252	0.17	0.13	Neuroticism;	chr8:11244214	chr8:11339637~11368452:+
BRCA	cis	rs3768617	0.782	rs10752893	ENSG00000224468.3	RP11-181K3.4	-4.15	3.54e-05	0.00253	-0.15	-0.13	Fuchs's corneal dystrophy;	chr1:183077126	chr1:183138402~183141282:-
BRCA	cis	rs875971	0.66	rs10215132	ENSG00000229180.5	GS1-124K5.11	-4.15	3.54e-05	0.00253	-0.11	-0.13	Aortic root size;	chr7:66589419	chr7:66526088~66542624:-
BRCA	cis	rs7690839	1	rs7690839	ENSG00000270720.1	RP11-84C13.2	4.15	3.54e-05	0.00253	0.14	0.13	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr4:88898173	chr4:89119284~89119871:+
BRCA	cis	rs3617	0.625	rs2240915	ENSG00000242142.1	SERBP1P3	4.15	3.54e-05	0.00253	0.14	0.13	Red blood cell count;Autism spectrum disorder or schizophrenia;	chr3:52825510	chr3:53064283~53065091:-
BRCA	cis	rs3617	0.625	rs2245647	ENSG00000242142.1	SERBP1P3	4.15	3.54e-05	0.00253	0.14	0.13	Red blood cell count;Autism spectrum disorder or schizophrenia;	chr3:52828737	chr3:53064283~53065091:-
BRCA	cis	rs13098911	0.54	rs36122610	ENSG00000223552.1	RP11-24F11.2	-4.15	3.55e-05	0.00253	-0.21	-0.13	Celiac disease;	chr3:45981341	chr3:46364955~46407059:-
BRCA	cis	rs13098911	0.54	rs34442130	ENSG00000223552.1	RP11-24F11.2	-4.15	3.55e-05	0.00253	-0.21	-0.13	Celiac disease;	chr3:45983037	chr3:46364955~46407059:-
BRCA	cis	rs13098911	0.54	rs13075758	ENSG00000223552.1	RP11-24F11.2	-4.15	3.55e-05	0.00253	-0.21	-0.13	Celiac disease;	chr3:45983556	chr3:46364955~46407059:-
BRCA	cis	rs875971	0.964	rs60193905	ENSG00000236529.1	RP13-254B10.1	4.15	3.55e-05	0.00253	0.14	0.13	Aortic root size;	chr7:66506273	chr7:65840212~65840596:+
BRCA	cis	rs28374715	0.681	rs7168307	ENSG00000247556.5	OIP5-AS1	4.15	3.55e-05	0.00253	0.13	0.13	Ulcerative colitis;	chr15:41328336	chr15:41283990~41309737:+
BRCA	cis	rs733592	0.524	rs10875741	ENSG00000257763.1	OR5BK1P	-4.15	3.55e-05	0.00253	-0.12	-0.13	Plateletcrit;	chr12:48099139	chr12:48355792~48356614:-
BRCA	cis	rs4499344	0.73	rs10413061	ENSG00000267475.1	CTD-2538C1.2	4.15	3.55e-05	0.00253	0.16	0.13	Mean platelet volume;	chr19:32612372	chr19:32687089~32691750:-
BRCA	cis	rs4499344	0.73	rs10410888	ENSG00000267475.1	CTD-2538C1.2	4.15	3.55e-05	0.00253	0.16	0.13	Mean platelet volume;	chr19:32612422	chr19:32687089~32691750:-
BRCA	cis	rs4499344	0.73	rs35098593	ENSG00000267475.1	CTD-2538C1.2	4.15	3.55e-05	0.00253	0.16	0.13	Mean platelet volume;	chr19:32613033	chr19:32687089~32691750:-
BRCA	cis	rs4499344	0.73	rs34270210	ENSG00000267475.1	CTD-2538C1.2	4.15	3.55e-05	0.00253	0.16	0.13	Mean platelet volume;	chr19:32613039	chr19:32687089~32691750:-
BRCA	cis	rs12368653	0.583	rs7952989	ENSG00000257159.1	RP11-58A17.3	-4.15	3.55e-05	0.00253	-0.15	-0.13	Multiple sclerosis;	chr12:57702206	chr12:57967058~57968399:+
BRCA	cis	rs3096299	0.967	rs2965932	ENSG00000261546.1	CTD-2555A7.3	4.15	3.55e-05	0.00253	0.14	0.13	Multiple myeloma (IgH translocation);	chr16:89410643	chr16:89113175~89115279:-
BRCA	cis	rs6545883	0.894	rs10496092	ENSG00000273302.1	RP11-493E12.2	-4.15	3.55e-05	0.00253	-0.12	-0.13	Tuberculosis;	chr2:61297544	chr2:61199979~61200769:+
BRCA	cis	rs801193	0.935	rs2659916	ENSG00000223473.2	GS1-124K5.3	4.15	3.55e-05	0.00253	0.1	0.13	Aortic root size;	chr7:66686365	chr7:66491049~66493566:-
BRCA	cis	rs3176789	0.601	rs12427278	ENSG00000256673.1	RP11-599J14.2	4.15	3.55e-05	0.00253	0.14	0.13	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9767525	chr12:9398355~9414851:-
BRCA	cis	rs13326165	0.585	rs10460962	ENSG00000243224.1	RP5-1157M23.2	-4.15	3.55e-05	0.00253	-0.21	-0.13	HDL cholesterol levels;HDL cholesterol;	chr3:52309663	chr3:52239258~52241097:+
BRCA	cis	rs6430585	0.527	rs76622824	ENSG00000224043.6	CCNT2-AS1	-4.15	3.55e-05	0.00253	-0.21	-0.13	Corneal structure;	chr2:135654309	chr2:134735464~134918710:-
BRCA	cis	rs17772222	0.917	rs61986670	ENSG00000258789.1	RP11-507K2.3	-4.15	3.55e-05	0.00253	-0.16	-0.13	Coronary artery calcification;	chr14:88730875	chr14:88551597~88552493:+
BRCA	cis	rs481331	0.741	rs683538	ENSG00000273008.1	RP11-351D16.3	4.15	3.55e-05	0.00253	0.16	0.13	Systemic juvenile idiopathic arthritis;	chr10:42653406	chr10:43136824~43138334:-
BRCA	cis	rs6460942	0.659	rs6969309	ENSG00000226690.5	AC005281.1	4.15	3.55e-05	0.00253	0.26	0.13	Coronary artery disease;	chr7:12476221	chr7:12496429~12541910:+
BRCA	cis	rs6460942	0.597	rs7811374	ENSG00000226690.5	AC005281.1	4.15	3.55e-05	0.00253	0.26	0.13	Coronary artery disease;	chr7:12477811	chr7:12496429~12541910:+
BRCA	cis	rs409045	0.932	rs442403	ENSG00000271874.1	CTD-2024P10.2	-4.15	3.55e-05	0.00253	-0.16	-0.13	Left ventricular mass;	chr5:34629785	chr5:34651457~34651888:-
BRCA	cis	rs4869313	0.905	rs2927609	ENSG00000248734.2	CTD-2260A17.1	4.15	3.55e-05	0.00253	0.13	0.13	Pediatric autoimmune diseases;	chr5:96916375	chr5:96784777~96785999:+
BRCA	cis	rs4869313	0.905	rs1363907	ENSG00000248734.2	CTD-2260A17.1	4.15	3.55e-05	0.00253	0.13	0.13	Pediatric autoimmune diseases;	chr5:96917099	chr5:96784777~96785999:+
BRCA	cis	rs4869313	0.87	rs1820148	ENSG00000248734.2	CTD-2260A17.1	4.15	3.55e-05	0.00253	0.13	0.13	Pediatric autoimmune diseases;	chr5:96917294	chr5:96784777~96785999:+
BRCA	cis	rs4869313	0.905	rs1363908	ENSG00000248734.2	CTD-2260A17.1	4.15	3.55e-05	0.00253	0.13	0.13	Pediatric autoimmune diseases;	chr5:96917400	chr5:96784777~96785999:+
BRCA	cis	rs7267979	0.966	rs2227890	ENSG00000125804.12	FAM182A	-4.15	3.55e-05	0.00253	-0.17	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25280295	chr20:26054655~26086917:+
BRCA	cis	rs6001482	0.679	rs5995706	ENSG00000279278.1	CH17-264L24.1	4.15	3.55e-05	0.00253	0.11	0.13	Diastolic blood pressure;	chr22:22236371	chr22:22264601~22273020:+
BRCA	cis	rs1478897	0.804	rs9329246	ENSG00000154316.13	TDH	-4.15	3.55e-05	0.00253	-0.16	-0.13	Systemic lupus erythematosus;	chr8:11535371	chr8:11339637~11368452:+
BRCA	cis	rs6545883	0.894	rs4672436	ENSG00000273302.1	RP11-493E12.2	-4.15	3.55e-05	0.00253	-0.12	-0.13	Tuberculosis;	chr2:61376222	chr2:61199979~61200769:+
BRCA	cis	rs6545883	0.859	rs35760550	ENSG00000273302.1	RP11-493E12.2	-4.15	3.55e-05	0.00253	-0.12	-0.13	Tuberculosis;	chr2:61376730	chr2:61199979~61200769:+
BRCA	cis	rs6545883	0.859	rs62149714	ENSG00000273302.1	RP11-493E12.2	-4.15	3.55e-05	0.00253	-0.12	-0.13	Tuberculosis;	chr2:61376734	chr2:61199979~61200769:+
BRCA	cis	rs35740288	0.787	rs2291047	ENSG00000202081.1	RNU6-1280P	4.15	3.56e-05	0.00253	0.17	0.13	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85682574	chr15:85651522~85651628:-
BRCA	cis	rs897984	0.683	rs8050330	ENSG00000275263.1	RP11-1072A3.4	-4.15	3.56e-05	0.00253	-0.15	-0.13	Dementia with Lewy bodies;	chr16:30813649	chr16:30956872~30957199:-
BRCA	cis	rs4478858	0.602	rs6425723	ENSG00000223907.1	LINC01226	-4.15	3.56e-05	0.00253	-0.15	-0.13	Alcohol dependence;	chr1:31242357	chr1:31518435~31524245:+
BRCA	cis	rs4671400	0.571	rs6738482	ENSG00000273302.1	RP11-493E12.2	-4.15	3.56e-05	0.00253	-0.14	-0.13	3-hydroxypropylmercapturic acid levels in smokers;	chr2:61267766	chr2:61199979~61200769:+
BRCA	cis	rs11098499	0.913	rs11098496	ENSG00000250412.1	KLHL2P1	4.15	3.56e-05	0.00253	0.15	0.13	Corneal astigmatism;	chr4:119246311	chr4:119334329~119378233:+
BRCA	cis	rs9392653	1	rs9378932	ENSG00000220685.3	RP11-530A18.1	-4.15	3.56e-05	0.00253	-0.18	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr6:5070964	chr6:5065795~5066982:-
BRCA	cis	rs11098499	0.644	rs10012252	ENSG00000249244.1	RP11-548H18.2	4.15	3.56e-05	0.00254	0.15	0.13	Corneal astigmatism;	chr4:119637984	chr4:119391831~119395335:-
BRCA	cis	rs10129255	0.5	rs2105989	ENSG00000254174.1	IGHV1-12	4.15	3.56e-05	0.00254	0.1	0.13	Kawasaki disease;	chr14:106682199	chr14:106122420~106122709:-
BRCA	cis	rs952623	0.649	rs6462886	ENSG00000211694.2	TRGV10	-4.15	3.56e-05	0.00254	-0.11	-0.13	Intelligence (multi-trait analysis);	chr7:39026967	chr7:38299811~38300322:-
BRCA	cis	rs7487075	0.78	rs12307969	ENSG00000274723.1	RP11-618L22.1	4.15	3.56e-05	0.00254	0.15	0.13	Itch intensity from mosquito bite;	chr12:46365274	chr12:46970504~46972155:+
BRCA	cis	rs1156327	0.655	rs4782224	ENSG00000188477.11	AC003003.5	-4.15	3.56e-05	0.00254	-0.33	-0.13	Periodontal disease-related phenotypes;	chr16:19314698	chr16:19285783~19310947:+
BRCA	cis	rs739496	0.579	rs1981517	ENSG00000234608.6	MAPKAPK5-AS1	4.15	3.56e-05	0.00254	0.15	0.13	Platelet count;	chr12:111885778	chr12:111839764~111842902:-
BRCA	cis	rs10208649	0.908	rs10199995	ENSG00000272156.1	RP11-477N3.1	4.15	3.56e-05	0.00254	0.27	0.13	Body mass index;	chr2:53981138	chr2:54082554~54085066:+
BRCA	cis	rs62458065	0.85	rs10239812	ENSG00000273014.1	RP11-225B17.2	-4.15	3.56e-05	0.00254	-0.2	-0.13	Metabolite levels (HVA/MHPG ratio);	chr7:32420736	chr7:32758882~32759353:+
BRCA	cis	rs1015362	0.581	rs4911373	ENSG00000275784.1	RP5-1125A11.6	-4.15	3.56e-05	0.00254	-0.18	-0.13	Freckles;Red vs. non-red hair color;Skin sensitivity to sun;Burning and freckling;	chr20:33920952	chr20:33989480~33991818:-
BRCA	cis	rs9650657	0.537	rs7016385	ENSG00000255020.1	AF131216.5	-4.15	3.56e-05	0.00254	-0.15	-0.13	Neuroticism;	chr8:10921962	chr8:11345748~11347502:-
BRCA	cis	rs7647973	1	rs6785045	ENSG00000244380.1	RP11-24C3.2	-4.15	3.56e-05	0.00254	-0.16	-0.13	Menarche (age at onset);	chr3:49397810	chr3:48440352~48446656:-
BRCA	cis	rs7647973	1	rs7648995	ENSG00000244380.1	RP11-24C3.2	-4.15	3.56e-05	0.00254	-0.16	-0.13	Menarche (age at onset);	chr3:49401370	chr3:48440352~48446656:-
BRCA	cis	rs7647973	1	rs2140270	ENSG00000244380.1	RP11-24C3.2	-4.15	3.56e-05	0.00254	-0.16	-0.13	Menarche (age at onset);	chr3:49402007	chr3:48440352~48446656:-
BRCA	cis	rs7647973	1	rs2177268	ENSG00000244380.1	RP11-24C3.2	-4.15	3.56e-05	0.00254	-0.16	-0.13	Menarche (age at onset);	chr3:49402292	chr3:48440352~48446656:-
BRCA	cis	rs8058578	1	rs13338946	ENSG00000260911.2	RP11-196G11.2	4.15	3.56e-05	0.00254	0.12	0.13	Multiple myeloma;	chr16:30689537	chr16:31043150~31049868:+
BRCA	cis	rs1910358	0.554	rs62348285	ENSG00000248874.4	C5orf17	-4.15	3.57e-05	0.00254	-0.18	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23734408	chr5:23951348~24178263:+
BRCA	cis	rs8114671	0.836	rs6142294	ENSG00000279253.1	RP4-614O4.13	4.15	3.57e-05	0.00254	0.15	0.13	Height;	chr20:35083694	chr20:35262727~35264187:-
BRCA	cis	rs4073582	0.595	rs1151540	ENSG00000255320.1	RP11-755F10.1	-4.15	3.57e-05	0.00254	-0.16	-0.13	Gout;	chr11:66274336	chr11:66244840~66246239:-
BRCA	cis	rs1865760	0.865	rs9467645	ENSG00000272462.2	U91328.19	-4.15	3.57e-05	0.00254	-0.15	-0.13	Height;	chr6:25954948	chr6:25992662~26001775:+
BRCA	cis	rs739496	0.579	rs3741998	ENSG00000257624.1	RP1-128M12.3	4.15	3.57e-05	0.00254	0.17	0.13	Platelet count;	chr12:111902039	chr12:112000739~112000985:-
BRCA	cis	rs739496	0.527	rs12319165	ENSG00000257624.1	RP1-128M12.3	4.15	3.57e-05	0.00254	0.17	0.13	Platelet count;	chr12:111902930	chr12:112000739~112000985:-
BRCA	cis	rs739496	0.579	rs73426310	ENSG00000257624.1	RP1-128M12.3	4.15	3.57e-05	0.00254	0.17	0.13	Platelet count;	chr12:111904606	chr12:112000739~112000985:-
BRCA	cis	rs739496	0.527	rs12427012	ENSG00000257624.1	RP1-128M12.3	4.15	3.57e-05	0.00254	0.17	0.13	Platelet count;	chr12:111905570	chr12:112000739~112000985:-
BRCA	cis	rs739496	0.579	rs12316525	ENSG00000257624.1	RP1-128M12.3	4.15	3.57e-05	0.00254	0.17	0.13	Platelet count;	chr12:111906315	chr12:112000739~112000985:-
BRCA	cis	rs739496	0.579	rs73426314	ENSG00000257624.1	RP1-128M12.3	4.15	3.57e-05	0.00254	0.17	0.13	Platelet count;	chr12:111907252	chr12:112000739~112000985:-
BRCA	cis	rs739496	0.579	rs12582302	ENSG00000257624.1	RP1-128M12.3	4.15	3.57e-05	0.00254	0.17	0.13	Platelet count;	chr12:111907830	chr12:112000739~112000985:-
BRCA	cis	rs739496	0.579	rs11066077	ENSG00000257624.1	RP1-128M12.3	4.15	3.57e-05	0.00254	0.17	0.13	Platelet count;	chr12:111908857	chr12:112000739~112000985:-
BRCA	cis	rs9959145	1	rs9989546	ENSG00000267108.1	RP11-861E21.1	4.15	3.57e-05	0.00254	0.23	0.13	Immune response to smallpox vaccine (IL-6);	chr18:12562538	chr18:12432897~12437635:+
BRCA	cis	rs11098499	0.955	rs11944880	ENSG00000250412.1	KLHL2P1	-4.15	3.57e-05	0.00254	-0.15	-0.13	Corneal astigmatism;	chr4:119238179	chr4:119334329~119378233:+
BRCA	cis	rs2486012	1	rs2486012	ENSG00000237950.1	RP11-7O11.3	-4.15	3.57e-05	0.00254	-0.23	-0.13	Intelligence (multi-trait analysis);	chr1:43907737	chr1:43944370~43946551:-
BRCA	cis	rs1434579	0.897	rs2037904	ENSG00000176761.7	ZNF285B	-4.15	3.57e-05	0.00254	-0.15	-0.13	Tuberculosis;	chr19:44440908	chr19:44467641~44473227:+
BRCA	cis	rs8114671	0.562	rs6120758	ENSG00000126005.14	MMP24-AS1	-4.15	3.57e-05	0.00254	-0.15	-0.13	Height;	chr20:34904720	chr20:35216462~35278131:-
BRCA	cis	rs9368481	0.761	rs9348746	ENSG00000224843.5	LINC00240	4.15	3.57e-05	0.00254	0.15	0.13	Autism spectrum disorder or schizophrenia;	chr6:27002578	chr6:26956992~27023924:+
BRCA	cis	rs957448	1	rs72674861	ENSG00000254315.1	RP11-267M23.3	4.15	3.57e-05	0.00254	0.17	0.13	Nonsyndromic cleft lip with cleft palate;	chr8:94550051	chr8:94533628~94534391:+
BRCA	cis	rs11098499	0.754	rs10518300	ENSG00000225892.3	RP11-384K6.2	-4.15	3.57e-05	0.00254	-0.12	-0.13	Corneal astigmatism;	chr4:119328344	chr4:118632274~118634759:+
BRCA	cis	rs17495987	0.75	rs2159830	ENSG00000219545.8	UMAD1	-4.15	3.57e-05	0.00254	-0.16	-0.13	Tonsillectomy;	chr7:7866894	chr7:7640711~8004059:+
BRCA	cis	rs10911902	0.643	rs16825201	ENSG00000229739.2	RP11-295K2.3	-4.15	3.57e-05	0.00254	-0.19	-0.13	Schizophrenia;	chr1:186344698	chr1:186435161~186470291:+
BRCA	cis	rs9900280	1	rs559972	ENSG00000264808.1	RP11-802D6.1	4.15	3.57e-05	0.00254	0.15	0.13	Mean platelet volume;	chr17:29487478	chr17:29369717~29390777:-
BRCA	cis	rs11098499	1	rs35643470	ENSG00000260091.1	RP11-33B1.4	-4.15	3.57e-05	0.00254	-0.11	-0.13	Corneal astigmatism;	chr4:119263793	chr4:119409333~119410233:+
BRCA	cis	rs4415084	0.716	rs727305	ENSG00000251141.4	RP11-53O19.1	4.15	3.57e-05	0.00254	0.12	0.13	Breast cancer;	chr5:44795940	chr5:44744900~44808777:-
BRCA	cis	rs4869313	0.87	rs6859168	ENSG00000248734.2	CTD-2260A17.1	-4.15	3.57e-05	0.00254	-0.13	-0.13	Pediatric autoimmune diseases;	chr5:96898611	chr5:96784777~96785999:+
BRCA	cis	rs56322409	1	rs2152916	ENSG00000226688.5	ENTPD1-AS1	4.15	3.57e-05	0.00255	0.15	0.13	Blood metabolite levels;	chr10:95632508	chr10:95753206~96090238:-
BRCA	cis	rs2692947	0.637	rs72492201	ENSG00000232931.4	LINC00342	4.15	3.57e-05	0.00255	0.14	0.13	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95964453	chr2:95807118~95816215:-
BRCA	cis	rs11742741	0.806	rs62349710	ENSG00000248874.4	C5orf17	-4.15	3.58e-05	0.00255	-0.16	-0.13	Educational attainment;	chr5:24022214	chr5:23951348~24178263:+
BRCA	cis	rs11742741	0.806	rs62349711	ENSG00000248874.4	C5orf17	-4.15	3.58e-05	0.00255	-0.16	-0.13	Educational attainment;	chr5:24022405	chr5:23951348~24178263:+
BRCA	cis	rs11742741	0.806	rs1948769	ENSG00000248874.4	C5orf17	-4.15	3.58e-05	0.00255	-0.16	-0.13	Educational attainment;	chr5:24023000	chr5:23951348~24178263:+
BRCA	cis	rs16846053	0.792	rs12053256	ENSG00000227403.1	AC009299.3	4.15	3.58e-05	0.00255	0.33	0.13	Blood osmolality (transformed sodium);	chr2:161783488	chr2:161244739~161249050:+
BRCA	cis	rs8114671	0.869	rs2145559	ENSG00000279253.1	RP4-614O4.13	4.15	3.58e-05	0.00255	0.15	0.13	Height;	chr20:35063922	chr20:35262727~35264187:-
BRCA	cis	rs11070836	0.935	rs35975557	ENSG00000259378.1	DCAF13P3	4.15	3.58e-05	0.00255	0.17	0.13	Airway wall thickness;	chr15:51133230	chr15:50944663~50945996:+
BRCA	cis	rs600550	0.889	rs1365247	ENSG00000275344.1	MIR6503	4.15	3.58e-05	0.00255	0.13	0.13	Lipoprotein-associated phospholipase A2 activity and mass;	chr11:60259836	chr11:60209071~60209156:-
BRCA	cis	rs1529102	0.899	rs1358624	ENSG00000225889.6	AC074289.1	4.15	3.58e-05	0.00255	0.11	0.13	Breast size;	chr2:64259365	chr2:64143239~64252859:+
BRCA	cis	rs6963495	0.818	rs117887993	ENSG00000223886.3	RP11-251G23.2	4.15	3.58e-05	0.00255	0.2	0.13	Bipolar disorder (body mass index interaction);	chr7:105553390	chr7:105530209~105530671:+
BRCA	cis	rs2486012	1	rs783301	ENSG00000237950.1	RP11-7O11.3	-4.15	3.58e-05	0.00255	-0.23	-0.13	Intelligence (multi-trait analysis);	chr1:43903337	chr1:43944370~43946551:-
BRCA	cis	rs2486012	1	rs2485995	ENSG00000237950.1	RP11-7O11.3	-4.15	3.58e-05	0.00255	-0.23	-0.13	Intelligence (multi-trait analysis);	chr1:43903928	chr1:43944370~43946551:-
BRCA	cis	rs4218	0.648	rs1074702	ENSG00000259732.1	RP11-59H7.3	-4.15	3.58e-05	0.00255	-0.16	-0.13	Social communication problems;	chr15:59073900	chr15:59121034~59133250:+
BRCA	cis	rs17818399	0.89	rs34752561	ENSG00000279254.1	RP11-536C12.1	-4.15	3.58e-05	0.00255	-0.17	-0.13	Height;	chr2:46623011	chr2:46668870~46670778:+
BRCA	cis	rs3768617	0.706	rs10797801	ENSG00000224468.3	RP11-181K3.4	-4.15	3.58e-05	0.00255	-0.14	-0.13	Fuchs's corneal dystrophy;	chr1:183002830	chr1:183138402~183141282:-
BRCA	cis	rs7260598	0.642	rs8104784	ENSG00000268442.1	CTD-2027I19.2	4.15	3.58e-05	0.00255	0.2	0.13	Response to taxane treatment (placlitaxel);	chr19:23961732	chr19:24162370~24163425:-
BRCA	cis	rs11742741	0.742	rs72745713	ENSG00000248874.4	C5orf17	-4.15	3.58e-05	0.00255	-0.17	-0.13	Educational attainment;	chr5:24025495	chr5:23951348~24178263:+
BRCA	cis	rs7665090	1	rs735403	ENSG00000251288.2	RP11-10L12.2	4.15	3.58e-05	0.00255	0.15	0.13	Primary biliary cholangitis;	chr4:102632386	chr4:102751401~102752641:+
BRCA	cis	rs13401620	0.843	rs2968773	ENSG00000229326.3	AC069154.4	-4.15	3.58e-05	0.00255	-0.16	-0.13	Breast size;	chr2:119848575	chr2:119698623~119700151:+
BRCA	cis	rs11742741	0.806	rs2134237	ENSG00000248874.4	C5orf17	-4.15	3.58e-05	0.00255	-0.17	-0.13	Educational attainment;	chr5:24056641	chr5:23951348~24178263:+
BRCA	cis	rs6964587	0.967	rs12531966	ENSG00000188693.7	CYP51A1-AS1	-4.15	3.58e-05	0.00255	-0.14	-0.13	Breast cancer;	chr7:92136526	chr7:92134604~92180725:+
BRCA	cis	rs10761482	0.813	rs12776510	ENSG00000254271.1	RP11-131N11.4	4.15	3.58e-05	0.00255	0.18	0.13	Schizophrenia;	chr10:60408170	chr10:60734342~60741828:+
BRCA	cis	rs12049351	0.665	rs6663689	ENSG00000229367.1	HMGN2P19	4.15	3.58e-05	0.00255	0.17	0.13	Circulating myeloperoxidase levels (plasma);	chr1:229494416	chr1:229570532~229570796:+
BRCA	cis	rs11098499	0.722	rs10025925	ENSG00000260404.2	RP11-384K6.6	4.15	3.58e-05	0.00255	0.11	0.13	Corneal astigmatism;	chr4:119350589	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.731	rs10015579	ENSG00000260404.2	RP11-384K6.6	4.15	3.58e-05	0.00255	0.11	0.13	Corneal astigmatism;	chr4:119350647	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.908	rs11098527	ENSG00000260404.2	RP11-384K6.6	4.15	3.58e-05	0.00255	0.12	0.13	Corneal astigmatism;	chr4:119478751	chr4:118591773~118633729:+
BRCA	cis	rs875971	1	rs1565531	ENSG00000229180.5	GS1-124K5.11	-4.15	3.58e-05	0.00255	-0.11	-0.13	Aortic root size;	chr7:66198126	chr7:66526088~66542624:-
BRCA	cis	rs3176789	0.671	rs35559880	ENSG00000256673.1	RP11-599J14.2	4.15	3.58e-05	0.00255	0.15	0.13	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9766965	chr12:9398355~9414851:-
BRCA	cis	rs13326165	0.585	rs17052054	ENSG00000243224.1	RP5-1157M23.2	-4.15	3.58e-05	0.00255	-0.21	-0.13	HDL cholesterol levels;HDL cholesterol;	chr3:52303738	chr3:52239258~52241097:+
BRCA	cis	rs2108622	0.727	rs3093216	ENSG00000214049.6	UCA1	4.15	3.58e-05	0.00255	0.18	0.13	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15876927	chr19:15828961~15836320:+
BRCA	cis	rs8098244	0.737	rs1258148	ENSG00000265752.2	RP11-403A21.1	-4.15	3.58e-05	0.00255	-0.18	-0.13	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23940216	chr18:23957754~23982556:-
BRCA	cis	rs4698412	0.561	rs6815296	ENSG00000273133.1	RP11-799M12.2	-4.15	3.59e-05	0.00255	-0.15	-0.13	Parkinson's disease;	chr4:15690513	chr4:15563698~15564253:-
BRCA	cis	rs60843830	1	rs56321614	ENSG00000272342.1	RP13-539J13.1	4.15	3.59e-05	0.00255	0.16	0.13	Spherical equivalent (joint analysis main effects and education interaction);	chr2:268191	chr2:739588~740164:-
BRCA	cis	rs11098499	0.754	rs66900435	ENSG00000260091.1	RP11-33B1.4	-4.15	3.59e-05	0.00255	-0.11	-0.13	Corneal astigmatism;	chr4:119328270	chr4:119409333~119410233:+
BRCA	cis	rs72482608	0.896	rs2143109	ENSG00000271811.1	RP1-79C4.4	4.15	3.59e-05	0.00255	0.14	0.13	Emphysema imaging phenotypes;	chr1:170803890	chr1:170667381~170669425:+
BRCA	cis	rs11098499	0.954	rs9998585	ENSG00000260404.2	RP11-384K6.6	4.15	3.59e-05	0.00255	0.12	0.13	Corneal astigmatism;	chr4:119475647	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.909	rs6842762	ENSG00000260404.2	RP11-384K6.6	4.15	3.59e-05	0.00255	0.12	0.13	Corneal astigmatism;	chr4:119477081	chr4:118591773~118633729:+
BRCA	cis	rs6431644	0.895	rs7594626	ENSG00000224287.2	MSL3P1	4.15	3.59e-05	0.00255	0.15	0.13	Left atrial antero-posterior diameter;	chr2:233891278	chr2:233865437~233868444:-
BRCA	cis	rs7572733	0.935	rs12995110	ENSG00000231621.1	AC013264.2	4.15	3.59e-05	0.00256	0.12	0.13	Dermatomyositis;	chr2:197924289	chr2:197197991~197199273:+
BRCA	cis	rs7572733	0.935	rs4850816	ENSG00000231621.1	AC013264.2	4.15	3.59e-05	0.00256	0.12	0.13	Dermatomyositis;	chr2:197925041	chr2:197197991~197199273:+
BRCA	cis	rs34792	0.626	rs153784	ENSG00000275910.1	RP11-680G24.6	-4.15	3.59e-05	0.00256	-0.16	-0.13	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15508734	chr16:15015828~15016390:-
BRCA	cis	rs9307551	0.697	rs9993773	ENSG00000250334.4	LINC00989	-4.15	3.59e-05	0.00256	-0.19	-0.13	Refractive error;	chr4:79513450	chr4:79492416~79576460:+
BRCA	cis	rs9990333	0.87	rs58758084	ENSG00000231464.1	AC024937.4	-4.15	3.59e-05	0.00256	-0.16	-0.13	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196086110	chr3:195996738~195998233:+
BRCA	cis	rs6430585	0.528	rs75667274	ENSG00000231890.6	DARS-AS1	-4.15	3.59e-05	0.00256	-0.22	-0.13	Corneal structure;	chr2:135924916	chr2:135985176~136022593:+
BRCA	cis	rs10129255	0.5	rs2027902	ENSG00000232216.1	IGHV3-43	4.15	3.59e-05	0.00256	0.09	0.13	Kawasaki disease;	chr14:106807157	chr14:106470264~106470800:-
BRCA	cis	rs1008375	0.863	rs4698632	ENSG00000249502.1	AC006160.5	-4.15	3.59e-05	0.00256	-0.15	-0.13	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17613271	chr4:17587467~17614571:-
BRCA	cis	rs11098499	0.865	rs4507344	ENSG00000260091.1	RP11-33B1.4	-4.15	3.59e-05	0.00256	-0.11	-0.13	Corneal astigmatism;	chr4:119386330	chr4:119409333~119410233:+
BRCA	cis	rs2880765	0.835	rs7180213	ENSG00000202081.1	RNU6-1280P	4.15	3.59e-05	0.00256	0.15	0.13	Coronary artery disease;	chr15:85477956	chr15:85651522~85651628:-
BRCA	cis	rs4287000	0.508	rs2265576	ENSG00000227603.1	RP11-165J3.6	-4.15	3.59e-05	0.00256	-0.14	-0.13	Itch intensity from mosquito bite adjusted by bite size;	chr9:93609519	chr9:93435332~93437121:-
BRCA	cis	rs4415084	0.652	rs6883465	ENSG00000251141.4	RP11-53O19.1	-4.15	3.59e-05	0.00256	-0.12	-0.13	Breast cancer;	chr5:44891518	chr5:44744900~44808777:-
BRCA	cis	rs930395	0.514	rs7734331	ENSG00000251141.4	RP11-53O19.1	-4.15	3.59e-05	0.00256	-0.12	-0.13	Breast cancer;	chr5:44895486	chr5:44744900~44808777:-
BRCA	cis	rs8040855	0.599	rs6496792	ENSG00000259762.1	RP11-158M2.4	-4.15	3.59e-05	0.00256	-0.15	-0.13	Bulimia nervosa;	chr15:85182514	chr15:85750336~85752901:-
BRCA	cis	rs8040855	0.599	rs6496793	ENSG00000259762.1	RP11-158M2.4	-4.15	3.59e-05	0.00256	-0.15	-0.13	Bulimia nervosa;	chr15:85182515	chr15:85750336~85752901:-
BRCA	cis	rs8040855	0.599	rs6496795	ENSG00000259762.1	RP11-158M2.4	-4.15	3.59e-05	0.00256	-0.15	-0.13	Bulimia nervosa;	chr15:85182622	chr15:85750336~85752901:-
BRCA	cis	rs3749237	0.595	rs1050088	ENSG00000226913.1	BSN-AS2	4.15	3.59e-05	0.00256	0.13	0.13	Resting heart rate;	chr3:49533449	chr3:49549306~49554366:-
BRCA	cis	rs7620503	0.959	rs7627379	ENSG00000228561.2	RP11-114M1.1	4.15	3.59e-05	0.00256	0.15	0.13	Corneal structure;	chr3:177569158	chr3:177683627~177691250:+
BRCA	cis	rs62458065	0.513	rs787216	ENSG00000229358.3	DPY19L1P1	-4.15	3.59e-05	0.00256	-0.17	-0.13	Metabolite levels (HVA/MHPG ratio);	chr7:32539279	chr7:32580949~32761787:-
BRCA	cis	rs62458065	0.513	rs702831	ENSG00000229358.3	DPY19L1P1	-4.15	3.59e-05	0.00256	-0.17	-0.13	Metabolite levels (HVA/MHPG ratio);	chr7:32540103	chr7:32580949~32761787:-
BRCA	cis	rs62458065	0.513	rs787220	ENSG00000229358.3	DPY19L1P1	-4.15	3.59e-05	0.00256	-0.17	-0.13	Metabolite levels (HVA/MHPG ratio);	chr7:32541527	chr7:32580949~32761787:-
BRCA	cis	rs6545883	0.826	rs777590	ENSG00000273302.1	RP11-493E12.2	4.15	3.6e-05	0.00256	0.12	0.13	Tuberculosis;	chr2:61190010	chr2:61199979~61200769:+
BRCA	cis	rs3748682	0.861	rs28625842	ENSG00000222282.1	RNU6-584P	-4.15	3.6e-05	0.00256	-0.16	-0.13	Hypothyroidism;	chr1:37845114	chr1:37885023~37885117:+
BRCA	cis	rs4835473	0.932	rs7356305	ENSG00000249741.2	RP11-673E1.3	-4.15	3.6e-05	0.00256	-0.13	-0.13	Immature fraction of reticulocytes;	chr4:143737850	chr4:143911514~143912053:-
BRCA	cis	rs2320614	0.648	rs1382661	ENSG00000250027.1	RP11-563E2.2	-4.15	3.6e-05	0.00256	-0.14	-0.13	Lung adenocarcinoma;	chr4:163182938	chr4:163108785~163119965:+
BRCA	cis	rs4650943	0.581	rs4652161	ENSG00000227740.1	RP11-318C24.2	4.15	3.6e-05	0.00256	0.13	0.13	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in inactive individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr1:176292067	chr1:175904762~175920513:-
BRCA	cis	rs812925	0.537	rs778139	ENSG00000273302.1	RP11-493E12.2	-4.15	3.6e-05	0.00256	-0.11	-0.13	Immature fraction of reticulocytes;	chr2:61457429	chr2:61199979~61200769:+
BRCA	cis	rs61931739	0.534	rs10844800	ENSG00000258794.3	DUX4L27	4.15	3.6e-05	0.00256	0.18	0.13	Morning vs. evening chronotype;	chr12:34077799	chr12:34208415~34209675:-
BRCA	cis	rs6071166	0.683	rs6027218	ENSG00000224635.1	RP4-564F22.5	-4.15	3.6e-05	0.00256	-0.15	-0.13	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38678619	chr20:38406011~38416797:-
BRCA	cis	rs6570726	0.526	rs7755237	ENSG00000270638.1	RP3-466P17.1	-4.15	3.6e-05	0.00256	-0.14	-0.13	Lobe attachment (rater-scored or self-reported);	chr6:145410716	chr6:145735570~145737218:+
BRCA	cis	rs62025270	0.747	rs12324721	ENSG00000259762.1	RP11-158M2.4	-4.15	3.6e-05	0.00256	-0.19	-0.13	Idiopathic pulmonary fibrosis;	chr15:85767741	chr15:85750336~85752901:-
BRCA	cis	rs2380205	0.967	rs4009521	ENSG00000232807.2	RP11-536K7.3	4.15	3.6e-05	0.00256	0.13	0.13	Breast cancer;	chr10:5846127	chr10:5934270~5945900:-
BRCA	cis	rs7123876	0.83	rs57614870	ENSG00000256633.1	RP11-169D4.2	4.15	3.6e-05	0.00256	0.14	0.13	Body mass index;	chr11:72724938	chr11:72584572~72587979:+
BRCA	cis	rs7123876	0.83	rs59311588	ENSG00000256633.1	RP11-169D4.2	4.15	3.6e-05	0.00256	0.14	0.13	Body mass index;	chr11:72724951	chr11:72584572~72587979:+
BRCA	cis	rs853679	0.542	rs6934769	ENSG00000261839.1	RP1-265C24.8	4.15	3.6e-05	0.00256	0.17	0.13	Depression;	chr6:28123153	chr6:28136849~28139678:+
BRCA	cis	rs853679	0.517	rs17711801	ENSG00000261839.1	RP1-265C24.8	4.15	3.6e-05	0.00256	0.17	0.13	Depression;	chr6:28124529	chr6:28136849~28139678:+
BRCA	cis	rs4713118	0.527	rs9461433	ENSG00000261839.1	RP1-265C24.8	4.15	3.6e-05	0.00256	0.17	0.13	Parkinson's disease;	chr6:28127394	chr6:28136849~28139678:+
BRCA	cis	rs853679	0.517	rs9468292	ENSG00000261839.1	RP1-265C24.8	4.15	3.6e-05	0.00256	0.17	0.13	Depression;	chr6:28127577	chr6:28136849~28139678:+
BRCA	cis	rs9402743	0.634	rs9494294	ENSG00000234084.1	RP3-388E23.2	-4.15	3.6e-05	0.00256	-0.13	-0.13	Systemic lupus erythematosus;	chr6:135603460	chr6:135301568~135307158:+
BRCA	cis	rs7572733	0.84	rs770666	ENSG00000231621.1	AC013264.2	-4.15	3.6e-05	0.00256	-0.12	-0.13	Dermatomyositis;	chr2:197747173	chr2:197197991~197199273:+
BRCA	cis	rs7809799	1	rs10254104	ENSG00000242798.1	RP11-506M12.1	4.15	3.6e-05	0.00256	0.22	0.13	Ulcerative colitis;	chr7:99171665	chr7:100115214~100127139:-
BRCA	cis	rs10129255	0.536	rs10142951	ENSG00000211967.3	IGHV3-53	-4.15	3.6e-05	0.00256	-0.08	-0.13	Kawasaki disease;	chr14:106782337	chr14:106592676~106593347:-
BRCA	cis	rs7267979	0.74	rs2259961	ENSG00000231081.1	RP4-760C5.3	-4.15	3.6e-05	0.00256	-0.16	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25301990	chr20:26008791~26010531:-
BRCA	cis	rs2380205	0.875	rs10795592	ENSG00000232807.2	RP11-536K7.3	4.15	3.61e-05	0.00256	0.13	0.13	Breast cancer;	chr10:5853792	chr10:5934270~5945900:-
BRCA	cis	rs2251381	0.722	rs2251278	ENSG00000232855.5	AF131217.1	-4.15	3.61e-05	0.00256	-0.17	-0.13	Selective IgA deficiency;	chr21:29156913	chr21:28439346~28674848:-
BRCA	cis	rs1371614	0.632	rs6708148	ENSG00000272148.1	RP11-195B17.1	4.15	3.61e-05	0.00256	0.14	0.13	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26944452	chr2:27062428~27062907:-
BRCA	cis	rs13118159	0.872	rs1882105	ENSG00000254094.1	AC078852.1	-4.15	3.61e-05	0.00257	-0.14	-0.13	Longevity;	chr4:1352168	chr4:1356581~1358075:+
BRCA	cis	rs801193	1	rs7782320	ENSG00000229180.5	GS1-124K5.11	4.15	3.61e-05	0.00257	0.11	0.13	Aortic root size;	chr7:66712111	chr7:66526088~66542624:-
BRCA	cis	rs886774	0.866	rs6466201	ENSG00000273055.1	CTB-13F3.1	-4.15	3.61e-05	0.00257	-0.13	-0.13	Ulcerative colitis;	chr7:107872165	chr7:107942116~107942740:+
BRCA	cis	rs8064024	0.676	rs9938805	ENSG00000267077.1	RP11-127I20.5	-4.15	3.61e-05	0.00257	-0.13	-0.13	Cancer;	chr16:4827552	chr16:4795265~4796532:-
BRCA	cis	rs1976403	0.633	rs1697422	ENSG00000186543.7	CROCCP5	-4.15	3.61e-05	0.00257	-0.15	-0.13	Liver enzyme levels (alkaline phosphatase);	chr1:21495404	chr1:21434318~21437558:+
BRCA	cis	rs6121246	0.909	rs6060793	ENSG00000230613.1	HM13-AS1	4.15	3.61e-05	0.00257	0.19	0.13	Mean corpuscular hemoglobin;	chr20:31701027	chr20:31567707~31573263:-
BRCA	cis	rs2998286	0.862	rs2185293	ENSG00000237128.1	RP11-351M16.3	4.15	3.61e-05	0.00257	0.15	0.13	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28519170	chr10:28433008~28495813:-
BRCA	cis	rs2562456	0.52	rs250001	ENSG00000240522.1	RPL7AP10	-4.15	3.61e-05	0.00257	-0.16	-0.13	Pain;	chr19:21225387	chr19:21149648~21150438:-
BRCA	cis	rs2554380	0.8	rs8034055	ENSG00000230373.7	GOLGA6L5P	-4.15	3.61e-05	0.00257	-0.17	-0.13	Height;	chr15:83743143	chr15:84507885~84516814:-
BRCA	cis	rs7260598	0.585	rs8112076	ENSG00000268442.1	CTD-2027I19.2	4.15	3.61e-05	0.00257	0.2	0.13	Response to taxane treatment (placlitaxel);	chr19:23956561	chr19:24162370~24163425:-
BRCA	cis	rs2486012	1	rs2428963	ENSG00000237950.1	RP11-7O11.3	-4.15	3.61e-05	0.00257	-0.23	-0.13	Intelligence (multi-trait analysis);	chr1:43907767	chr1:43944370~43946551:-
BRCA	cis	rs4578769	0.759	rs1982565	ENSG00000265939.1	UBE2CP2	-4.15	3.61e-05	0.00257	-0.16	-0.13	Eosinophil percentage of white cells;	chr18:22994861	chr18:22900486~22900995:-
BRCA	cis	rs875971	0.545	rs316324	ENSG00000273142.1	RP11-458F8.4	-4.15	3.61e-05	0.00257	-0.12	-0.13	Aortic root size;	chr7:66145627	chr7:66902857~66906297:+
BRCA	cis	rs875971	0.545	rs316323	ENSG00000273142.1	RP11-458F8.4	-4.15	3.61e-05	0.00257	-0.12	-0.13	Aortic root size;	chr7:66146002	chr7:66902857~66906297:+
BRCA	cis	rs2380205	0.967	rs4287254	ENSG00000232807.2	RP11-536K7.3	4.15	3.61e-05	0.00257	0.13	0.13	Breast cancer;	chr10:5846178	chr10:5934270~5945900:-
BRCA	cis	rs2380205	0.967	rs7897260	ENSG00000232807.2	RP11-536K7.3	4.15	3.61e-05	0.00257	0.13	0.13	Breast cancer;	chr10:5846464	chr10:5934270~5945900:-
BRCA	cis	rs2380205	0.967	rs7907795	ENSG00000232807.2	RP11-536K7.3	4.15	3.61e-05	0.00257	0.13	0.13	Breast cancer;	chr10:5846817	chr10:5934270~5945900:-
BRCA	cis	rs2380205	0.967	rs7903875	ENSG00000232807.2	RP11-536K7.3	4.15	3.61e-05	0.00257	0.13	0.13	Breast cancer;	chr10:5846822	chr10:5934270~5945900:-
BRCA	cis	rs2380205	0.967	rs7898059	ENSG00000232807.2	RP11-536K7.3	4.15	3.61e-05	0.00257	0.13	0.13	Breast cancer;	chr10:5847075	chr10:5934270~5945900:-
BRCA	cis	rs2380205	0.967	rs10795590	ENSG00000232807.2	RP11-536K7.3	4.15	3.61e-05	0.00257	0.13	0.13	Breast cancer;	chr10:5847123	chr10:5934270~5945900:-
BRCA	cis	rs420259	0.861	rs249954	ENSG00000260136.4	CTD-2270L9.4	4.15	3.61e-05	0.00257	0.12	0.13	Bipolar disorder;	chr16:23629146	chr16:23452758~23457606:+
BRCA	cis	rs2243480	1	rs2420171	ENSG00000237026.1	RP11-328P23.2	-4.15	3.61e-05	0.00257	-0.24	-0.13	Diabetic kidney disease;	chr7:66172773	chr7:65235790~65236723:-
BRCA	cis	rs3760982	0.967	rs3760984	ENSG00000267191.1	RP11-15A1.2	-4.15	3.62e-05	0.00257	-0.16	-0.13	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43782610	chr19:43902001~43926545:+
BRCA	cis	rs2243480	1	rs4548056	ENSG00000222364.1	RNU6-96P	-4.15	3.62e-05	0.00257	-0.23	-0.13	Diabetic kidney disease;	chr7:65833886	chr7:66395191~66395286:+
BRCA	cis	rs7572733	0.84	rs770667	ENSG00000231621.1	AC013264.2	-4.15	3.62e-05	0.00257	-0.12	-0.13	Dermatomyositis;	chr2:197748584	chr2:197197991~197199273:+
BRCA	cis	rs7177699	0.557	rs34372090	ENSG00000261143.1	ADAMTS7P3	4.15	3.62e-05	0.00257	0.16	0.13	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78818393	chr15:77976042~77993057:+
BRCA	cis	rs9952991	0.941	rs2847278	ENSG00000260302.1	RP11-973H7.1	-4.15	3.62e-05	0.00257	-0.21	-0.13	Inflammatory skin disease;	chr18:12778716	chr18:12774651~12775923:-
BRCA	cis	rs1153858	0.943	rs8038342	ENSG00000275672.1	GATM-AS1	-4.15	3.62e-05	0.00257	-0.16	-0.13	Homoarginine levels;	chr15:45359339	chr15:45378700~45380123:+
BRCA	cis	rs1153858	1	rs4774579	ENSG00000275672.1	GATM-AS1	-4.15	3.62e-05	0.00257	-0.16	-0.13	Homoarginine levels;	chr15:45359605	chr15:45378700~45380123:+
BRCA	cis	rs710913	0.618	rs6587	ENSG00000228060.1	RP11-69E11.8	-4.15	3.62e-05	0.00257	-0.13	-0.13	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39624273	chr1:39565160~39573203:+
BRCA	cis	rs2136613	0.651	rs16917768	ENSG00000238280.1	RP11-436D10.3	-4.15	3.62e-05	0.00257	-0.16	-0.13	Selective IgA deficiency;	chr10:62864705	chr10:62793562~62805887:-
BRCA	cis	rs3850699	0.666	rs7905481	ENSG00000213061.2	PFN1P11	4.15	3.62e-05	0.00257	0.18	0.13	Prostate cancer;	chr10:102716535	chr10:102838011~102845473:-
BRCA	cis	rs539514	0.516	rs9318377	ENSG00000261105.4	LMO7-AS1	-4.15	3.62e-05	0.00257	-0.15	-0.13	Type 1 diabetes;	chr13:75835882	chr13:75604700~75635994:-
BRCA	cis	rs1355223	0.902	rs1453380	ENSG00000271369.1	RP11-350D17.3	-4.15	3.62e-05	0.00257	-0.15	-0.13	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34682135	chr11:34709600~34710161:+
BRCA	cis	rs7487075	0.93	rs4076484	ENSG00000274723.1	RP11-618L22.1	4.15	3.62e-05	0.00257	0.16	0.13	Itch intensity from mosquito bite;	chr12:46440129	chr12:46970504~46972155:+
BRCA	cis	rs7487075	0.823	rs34472481	ENSG00000274723.1	RP11-618L22.1	4.15	3.62e-05	0.00257	0.16	0.13	Itch intensity from mosquito bite;	chr12:46442565	chr12:46970504~46972155:+
BRCA	cis	rs2408955	0.5	rs12816820	ENSG00000257735.1	RP11-370I10.6	4.15	3.62e-05	0.00257	0.16	0.13	Glycated hemoglobin levels;	chr12:48164542	chr12:48350945~48442411:+
BRCA	cis	rs875971	1	rs778696	ENSG00000236529.1	RP13-254B10.1	4.15	3.62e-05	0.00258	0.14	0.13	Aortic root size;	chr7:66405826	chr7:65840212~65840596:+
BRCA	cis	rs875971	1	rs778694	ENSG00000236529.1	RP13-254B10.1	4.15	3.62e-05	0.00258	0.14	0.13	Aortic root size;	chr7:66406571	chr7:65840212~65840596:+
BRCA	cis	rs875971	1	rs4718344	ENSG00000236529.1	RP13-254B10.1	4.15	3.62e-05	0.00258	0.14	0.13	Aortic root size;	chr7:66409394	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.737	rs7803424	ENSG00000236529.1	RP13-254B10.1	4.15	3.62e-05	0.00258	0.14	0.13	Aortic root size;	chr7:66415618	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.83	rs7799834	ENSG00000236529.1	RP13-254B10.1	4.15	3.62e-05	0.00258	0.14	0.13	Aortic root size;	chr7:66415707	chr7:65840212~65840596:+
BRCA	cis	rs7267979	0.844	rs2474780	ENSG00000231081.1	RP4-760C5.3	-4.15	3.62e-05	0.00258	-0.16	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25305199	chr20:26008791~26010531:-
BRCA	cis	rs11098499	0.954	rs10008459	ENSG00000260404.2	RP11-384K6.6	4.15	3.62e-05	0.00258	0.12	0.13	Corneal astigmatism;	chr4:119473076	chr4:118591773~118633729:+
BRCA	cis	rs8040855	0.627	rs17540307	ENSG00000259774.1	RP11-182J1.13	4.15	3.62e-05	0.00258	0.18	0.13	Bulimia nervosa;	chr15:85090614	chr15:84422618~84425882:+
BRCA	cis	rs10857712	0.95	rs10857711	ENSG00000214279.11	SCART1	-4.15	3.62e-05	0.00258	-0.14	-0.13	Systemic lupus erythematosus;	chr10:133410555	chr10:133453928~133523558:+
BRCA	cis	rs295490	0.748	rs77423224	ENSG00000272656.1	RP11-219D15.3	4.15	3.62e-05	0.00258	0.32	0.13	PR interval in Tripanosoma cruzi seropositivity;	chr3:139384020	chr3:139349024~139349371:-
BRCA	cis	rs4919687	0.55	rs12780827	ENSG00000213061.2	PFN1P11	4.15	3.63e-05	0.00258	0.18	0.13	Colorectal cancer;	chr10:102708197	chr10:102838011~102845473:-
BRCA	cis	rs2731006	0.64	rs2678111	ENSG00000257114.2	RP11-25I15.3	4.15	3.63e-05	0.00258	0.21	0.13	Panic disorder;	chr12:42768511	chr12:42692216~42717119:+
BRCA	cis	rs2731006	0.64	rs2678110	ENSG00000257114.2	RP11-25I15.3	4.15	3.63e-05	0.00258	0.21	0.13	Panic disorder;	chr12:42768786	chr12:42692216~42717119:+
BRCA	cis	rs2731006	0.64	rs2731017	ENSG00000257114.2	RP11-25I15.3	4.15	3.63e-05	0.00258	0.21	0.13	Panic disorder;	chr12:42769196	chr12:42692216~42717119:+
BRCA	cis	rs2731006	0.64	rs2678109	ENSG00000257114.2	RP11-25I15.3	4.15	3.63e-05	0.00258	0.21	0.13	Panic disorder;	chr12:42769320	chr12:42692216~42717119:+
BRCA	cis	rs2731006	0.64	rs2678108	ENSG00000257114.2	RP11-25I15.3	4.15	3.63e-05	0.00258	0.21	0.13	Panic disorder;	chr12:42769775	chr12:42692216~42717119:+
BRCA	cis	rs2731006	0.64	rs2407112	ENSG00000257114.2	RP11-25I15.3	4.15	3.63e-05	0.00258	0.21	0.13	Panic disorder;	chr12:42769893	chr12:42692216~42717119:+
BRCA	cis	rs2731006	0.64	rs1878580	ENSG00000257114.2	RP11-25I15.3	4.15	3.63e-05	0.00258	0.21	0.13	Panic disorder;	chr12:42770039	chr12:42692216~42717119:+
BRCA	cis	rs2731006	0.64	rs1878579	ENSG00000257114.2	RP11-25I15.3	4.15	3.63e-05	0.00258	0.21	0.13	Panic disorder;	chr12:42770246	chr12:42692216~42717119:+
BRCA	cis	rs4578769	0.765	rs12456384	ENSG00000265939.1	UBE2CP2	-4.15	3.63e-05	0.00258	-0.16	-0.13	Eosinophil percentage of white cells;	chr18:22841032	chr18:22900486~22900995:-
BRCA	cis	rs2243480	0.901	rs313808	ENSG00000275400.1	RP4-756H11.5	4.15	3.63e-05	0.00258	0.23	0.13	Diabetic kidney disease;	chr7:66034886	chr7:66553805~66554199:-
BRCA	cis	rs9859260	0.71	rs419068	ENSG00000207650.1	MIR570	-4.15	3.63e-05	0.00258	-0.15	-0.13	Mean corpuscular volume;	chr3:196055305	chr3:195699401~195699497:+
BRCA	cis	rs9859260	0.71	rs366268	ENSG00000207650.1	MIR570	-4.15	3.63e-05	0.00258	-0.15	-0.13	Mean corpuscular volume;	chr3:196055306	chr3:195699401~195699497:+
BRCA	cis	rs9859260	0.744	rs419059	ENSG00000207650.1	MIR570	-4.15	3.63e-05	0.00258	-0.15	-0.13	Mean corpuscular volume;	chr3:196055313	chr3:195699401~195699497:+
BRCA	cis	rs801193	0.901	rs4273746	ENSG00000265600.1	AC006480.1	4.15	3.63e-05	0.00258	0.15	0.13	Aortic root size;	chr7:66836124	chr7:67356680~67356779:+
BRCA	cis	rs739496	0.527	rs16941703	ENSG00000257624.1	RP1-128M12.3	4.15	3.63e-05	0.00258	0.17	0.13	Platelet count;	chr12:111880930	chr12:112000739~112000985:-
BRCA	cis	rs739496	0.527	rs61440627	ENSG00000257624.1	RP1-128M12.3	4.15	3.63e-05	0.00258	0.17	0.13	Platelet count;	chr12:111881193	chr12:112000739~112000985:-
BRCA	cis	rs35740288	0.77	rs11630112	ENSG00000202081.1	RNU6-1280P	4.15	3.63e-05	0.00258	0.16	0.13	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85577015	chr15:85651522~85651628:-
BRCA	cis	rs10266483	0.739	rs2692104	ENSG00000271550.1	BNIP3P11	4.15	3.63e-05	0.00258	0.17	0.13	Response to statin therapy;	chr7:64300577	chr7:64678954~64687393:-
BRCA	cis	rs4266144	1	rs4561781	ENSG00000241770.1	RP11-555M1.3	4.15	3.63e-05	0.00258	0.16	0.13	Coronary artery disease;	chr3:157135154	chr3:157163452~157169133:+
BRCA	cis	rs28829049	0.597	rs12566296	ENSG00000270728.1	RP4-657E11.10	-4.15	3.63e-05	0.00258	-0.13	-0.13	QRS duration in Tripanosoma cruzi seropositivity;	chr1:19171949	chr1:19297080~19297903:+
BRCA	cis	rs28829049	0.597	rs1009806	ENSG00000270728.1	RP4-657E11.10	-4.15	3.63e-05	0.00258	-0.13	-0.13	QRS duration in Tripanosoma cruzi seropositivity;	chr1:19174057	chr1:19297080~19297903:+
BRCA	cis	rs7896471	0.546	rs7904171	ENSG00000227695.4	DNMBP-AS1	-4.15	3.63e-05	0.00258	-0.29	-0.13	Blood protein levels;	chr10:99985803	chr10:99927010~99958381:+
BRCA	cis	rs7177699	0.557	rs9920968	ENSG00000261143.1	ADAMTS7P3	-4.15	3.63e-05	0.00258	-0.15	-0.13	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78826405	chr15:77976042~77993057:+
BRCA	cis	rs10761482	0.566	rs7092863	ENSG00000254271.1	RP11-131N11.4	4.15	3.63e-05	0.00258	0.18	0.13	Schizophrenia;	chr10:60421124	chr10:60734342~60741828:+
BRCA	cis	rs2554380	0.843	rs2098904	ENSG00000230373.7	GOLGA6L5P	-4.15	3.63e-05	0.00258	-0.17	-0.13	Height;	chr15:83737503	chr15:84507885~84516814:-
BRCA	cis	rs7824557	0.628	rs7841394	ENSG00000154316.13	TDH	-4.15	3.63e-05	0.00258	-0.16	-0.13	Retinal vascular caliber;	chr8:11328162	chr8:11339637~11368452:+
BRCA	cis	rs875971	0.545	rs313828	ENSG00000273142.1	RP11-458F8.4	-4.15	3.63e-05	0.00258	-0.13	-0.13	Aortic root size;	chr7:66087627	chr7:66902857~66906297:+
BRCA	cis	rs16846053	0.792	rs62187704	ENSG00000227403.1	AC009299.3	4.15	3.63e-05	0.00258	0.33	0.13	Blood osmolality (transformed sodium);	chr2:161829817	chr2:161244739~161249050:+
BRCA	cis	rs11673344	0.542	rs2562585	ENSG00000276846.1	CTD-3220F14.3	4.15	3.63e-05	0.00258	0.15	0.13	Obesity-related traits;	chr19:37018321	chr19:37314868~37315620:-
BRCA	cis	rs991427	0.554	rs4360756	ENSG00000258100.1	RP11-121E16.1	-4.15	3.63e-05	0.00258	-0.19	-0.13	Systolic blood pressure (alcohol consumption interaction);	chr12:90940828	chr12:91362196~91368606:+
BRCA	cis	rs9402743	0.634	rs6570018	ENSG00000234084.1	RP3-388E23.2	-4.15	3.63e-05	0.00258	-0.13	-0.13	Systemic lupus erythematosus;	chr6:135602218	chr6:135301568~135307158:+
BRCA	cis	rs7267979	0.966	rs2261698	ENSG00000125804.12	FAM182A	-4.15	3.63e-05	0.00258	-0.17	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25279274	chr20:26054655~26086917:+
BRCA	cis	rs8040855	0.603	rs10520585	ENSG00000230373.7	GOLGA6L5P	-4.15	3.63e-05	0.00258	-0.17	-0.13	Bulimia nervosa;	chr15:85118275	chr15:84507885~84516814:-
BRCA	cis	rs35146811	0.659	rs863450	ENSG00000214313.7	AZGP1P1	-4.15	3.63e-05	0.00258	-0.14	-0.13	Coronary artery disease;	chr7:100224062	chr7:99980762~99987535:+
BRCA	cis	rs1075265	0.901	rs1058320	ENSG00000235937.1	AC008280.1	4.15	3.63e-05	0.00258	0.14	0.13	Chronotype;Morning vs. evening chronotype;	chr2:54085016	chr2:54029552~54030682:-
BRCA	cis	rs6088590	0.561	rs6059934	ENSG00000275784.1	RP5-1125A11.6	-4.15	3.63e-05	0.00258	-0.14	-0.13	Coronary artery disease;	chr20:34590520	chr20:33989480~33991818:-
BRCA	cis	rs115575488	0.632	rs78527560	ENSG00000236804.1	RPS3AP12	4.15	3.63e-05	0.00258	0.24	0.13	Lobe attachment (rater-scored or self-reported);	chr1:119043653	chr1:119126539~119127291:-
BRCA	cis	rs4950322	0.512	rs2353974	ENSG00000244371.2	PFN1P8	4.15	3.64e-05	0.00258	0.15	0.13	Protein quantitative trait loci;	chr1:147384534	chr1:146957117~146957659:-
BRCA	cis	rs11187837	0.901	rs7100626	ENSG00000273450.1	RP11-76P2.4	4.15	3.64e-05	0.00258	0.28	0.13	Sudden cardiac arrest;	chr10:94309917	chr10:94314907~94315327:-
BRCA	cis	rs1722141	0.57	rs788728	ENSG00000229628.1	AC073115.7	4.15	3.64e-05	0.00258	0.17	0.13	Sitting height ratio;	chr7:46034169	chr7:45990905~46000898:+
BRCA	cis	rs10995356	0.966	rs10740096	ENSG00000238280.1	RP11-436D10.3	-4.15	3.64e-05	0.00258	-0.17	-0.13	Temperament;	chr10:62915331	chr10:62793562~62805887:-
BRCA	cis	rs9818758	0.607	rs11716445	ENSG00000225399.4	RP11-3B7.1	-4.15	3.64e-05	0.00258	-0.25	-0.13	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49368662	chr3:49260085~49261316:+
BRCA	cis	rs2919009	0.709	rs55710400	ENSG00000271670.1	RP11-95I16.4	4.15	3.64e-05	0.00258	0.18	0.13	Obesity-related traits;	chr10:120802676	chr10:120879256~120880667:-
BRCA	cis	rs10829156	0.945	rs10741131	ENSG00000240291.1	RP11-499P20.2	4.15	3.64e-05	0.00259	0.15	0.13	Sudden cardiac arrest;	chr10:18683130	chr10:18513115~18545651:-
BRCA	cis	rs2143950	0.512	rs62625038	ENSG00000226677.3	IGBP1P1	-4.15	3.64e-05	0.00259	-0.17	-0.13	Atopic dermatitis;	chr14:35047811	chr14:34939324~34940332:+
BRCA	cis	rs737008	0.922	rs2070923	ENSG00000262703.1	RP11-485G7.6	4.15	3.64e-05	0.00259	0.14	0.13	Obesity-related traits;	chr16:11275998	chr16:11348143~11349321:-
BRCA	cis	rs7267979	1	rs398036	ENSG00000274414.1	RP5-965G21.4	-4.15	3.64e-05	0.00259	-0.15	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25459214	chr20:25239007~25245229:-
BRCA	cis	rs7267979	1	rs397119	ENSG00000274414.1	RP5-965G21.4	-4.15	3.64e-05	0.00259	-0.15	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25459551	chr20:25239007~25245229:-
BRCA	cis	rs60843830	0.964	rs7584915	ENSG00000272342.1	RP13-539J13.1	4.15	3.64e-05	0.00259	0.16	0.13	Spherical equivalent (joint analysis main effects and education interaction);	chr2:264227	chr2:739588~740164:-
BRCA	cis	rs10170310	0.515	rs12990836	ENSG00000241772.2	AC092620.2	4.15	3.64e-05	0.00259	0.24	0.13	Response to antipsychotic treatment;	chr2:138590282	chr2:138569090~138574458:+
BRCA	cis	rs911119	0.908	rs8121147	ENSG00000270001.1	RP11-218C14.8	-4.15	3.64e-05	0.00259	-0.16	-0.13	Chronic kidney disease;	chr20:23621071	chr20:23631826~23632316:-
BRCA	cis	rs911119	0.955	rs6048945	ENSG00000270001.1	RP11-218C14.8	-4.15	3.64e-05	0.00259	-0.16	-0.13	Chronic kidney disease;	chr20:23621591	chr20:23631826~23632316:-
BRCA	cis	rs911119	0.955	rs6048946	ENSG00000270001.1	RP11-218C14.8	-4.15	3.64e-05	0.00259	-0.16	-0.13	Chronic kidney disease;	chr20:23621670	chr20:23631826~23632316:-
BRCA	cis	rs6088580	0.634	rs4142007	ENSG00000276073.1	RP5-1125A11.7	4.15	3.64e-05	0.00259	0.14	0.13	Glomerular filtration rate (creatinine);	chr20:34402244	chr20:33985617~33988989:-
BRCA	cis	rs755249	0.567	rs1126313	ENSG00000182109.6	RP11-69E11.4	-4.15	3.64e-05	0.00259	-0.18	-0.13	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39174072	chr1:39522280~39546187:-
BRCA	cis	rs739496	0.615	rs4646777	ENSG00000226469.1	ADAM1B	4.15	3.64e-05	0.00259	0.17	0.13	Platelet count;	chr12:111792232	chr12:111927018~111929017:+
BRCA	cis	rs11250097	0.549	rs11784897	ENSG00000154316.13	TDH	4.15	3.64e-05	0.00259	0.17	0.13	Neuroticism;	chr8:11452933	chr8:11339637~11368452:+
BRCA	cis	rs2880765	0.545	rs17553734	ENSG00000259630.2	CTD-2262B20.1	4.15	3.64e-05	0.00259	0.16	0.13	Coronary artery disease;	chr15:85469828	chr15:85415228~85415633:+
BRCA	cis	rs11098499	0.954	rs11722872	ENSG00000260404.2	RP11-384K6.6	4.15	3.64e-05	0.00259	0.12	0.13	Corneal astigmatism;	chr4:119311875	chr4:118591773~118633729:+
BRCA	cis	rs7520050	0.933	rs12565042	ENSG00000234329.1	RP11-767N6.2	-4.15	3.64e-05	0.00259	-0.12	-0.13	Reticulocyte count;Red blood cell count;	chr1:45833438	chr1:45651039~45651826:-
BRCA	cis	rs1670533	1	rs633556	ENSG00000251639.2	RP11-20I20.1	4.15	3.64e-05	0.00259	0.19	0.13	Recombination rate (females);	chr4:1098617	chr4:1100016~1101558:-
BRCA	cis	rs181553	0.664	rs4567802	ENSG00000266696.1	RP11-30L3.2	4.15	3.64e-05	0.00259	0.14	0.13	Hip circumference adjusted for BMI;	chr18:49170994	chr18:49205912~49208781:+
BRCA	cis	rs494459	0.838	rs555649	ENSG00000255435.5	RP11-770J1.3	4.15	3.65e-05	0.00259	0.13	0.13	Height;	chr11:118781100	chr11:118511911~118531094:-
BRCA	cis	rs875971	1	rs12533997	ENSG00000229180.5	GS1-124K5.11	4.15	3.65e-05	0.00259	0.11	0.13	Aortic root size;	chr7:66500390	chr7:66526088~66542624:-
BRCA	cis	rs6802315	0.604	rs9861938	ENSG00000272087.1	RP11-379F4.7	4.15	3.65e-05	0.00259	0.15	0.13	Periodontitis (CDC/AAP);	chr3:158745257	chr3:158693120~158693768:-
BRCA	cis	rs5758511	0.773	rs62240999	ENSG00000226450.2	CYP2D8P	4.15	3.65e-05	0.00259	0.14	0.13	Birth weight;	chr22:41959559	chr22:42149886~42155001:-
BRCA	cis	rs875971	1	rs1981798	ENSG00000236529.1	RP13-254B10.1	4.15	3.65e-05	0.00259	0.14	0.13	Aortic root size;	chr7:66489916	chr7:65840212~65840596:+
BRCA	cis	rs3096299	0.967	rs2965827	ENSG00000261546.1	CTD-2555A7.3	4.15	3.65e-05	0.00259	0.14	0.13	Multiple myeloma (IgH translocation);	chr16:89390942	chr16:89113175~89115279:-
BRCA	cis	rs11673344	0.563	rs55825113	ENSG00000276846.1	CTD-3220F14.3	4.15	3.65e-05	0.00259	0.15	0.13	Obesity-related traits;	chr19:37191523	chr19:37314868~37315620:-
BRCA	cis	rs6500602	0.893	rs6500598	ENSG00000280063.1	RP11-295D4.3	4.15	3.65e-05	0.00259	0.1	0.13	Schizophrenia;	chr16:4420963	chr16:4346694~4348648:-
BRCA	cis	rs875971	0.666	rs13242072	ENSG00000229180.5	GS1-124K5.11	-4.15	3.65e-05	0.00259	-0.11	-0.13	Aortic root size;	chr7:66301001	chr7:66526088~66542624:-
BRCA	cis	rs6496044	0.526	rs4291869	ENSG00000202081.1	RNU6-1280P	4.15	3.65e-05	0.00259	0.15	0.13	Interstitial lung disease;	chr15:85511292	chr15:85651522~85651628:-
BRCA	cis	rs7267979	0.934	rs2261753	ENSG00000125804.12	FAM182A	-4.15	3.65e-05	0.00259	-0.17	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25281655	chr20:26054655~26086917:+
BRCA	cis	rs9527	0.59	rs11191547	ENSG00000213061.2	PFN1P11	4.15	3.65e-05	0.00259	0.17	0.13	Arsenic metabolism;	chr10:103083391	chr10:102838011~102845473:-
BRCA	cis	rs1048886	0.938	rs7759464	ENSG00000271967.1	RP11-134K13.4	-4.15	3.65e-05	0.00259	-0.17	-0.13	Type 2 diabetes;	chr6:70422469	chr6:70596438~70596980:+
BRCA	cis	rs1077773	0.509	rs6461315	ENSG00000237773.4	AC003075.4	-4.15	3.65e-05	0.00259	-0.18	-0.13	Ulcerative colitis;Inflammatory bowel disease;	chr7:17408820	chr7:17279834~17299357:-
BRCA	cis	rs8114671	0.805	rs4616	ENSG00000126005.14	MMP24-AS1	4.15	3.65e-05	0.00259	0.15	0.13	Height;	chr20:35002555	chr20:35216462~35278131:-
BRCA	cis	rs28829049	0.597	rs71645438	ENSG00000270728.1	RP4-657E11.10	-4.15	3.65e-05	0.00259	-0.13	-0.13	QRS duration in Tripanosoma cruzi seropositivity;	chr1:19175855	chr1:19297080~19297903:+
BRCA	cis	rs28829049	0.597	rs34219832	ENSG00000270728.1	RP4-657E11.10	-4.15	3.65e-05	0.00259	-0.13	-0.13	QRS duration in Tripanosoma cruzi seropositivity;	chr1:19175938	chr1:19297080~19297903:+
BRCA	cis	rs3764563	0.935	rs1654592	ENSG00000267594.5	CYP4F24P	4.15	3.65e-05	0.00259	0.24	0.13	Inflammatory biomarkers;	chr19:15579485	chr19:15760241~15779909:-
BRCA	cis	rs12501370	0.568	rs2661656	ENSG00000201736.1	RNA5SP160	4.15	3.65e-05	0.00259	0.17	0.13	Iris color (L* coordinate);	chr4:41118868	chr4:40990154~40990273:+
BRCA	cis	rs9308731	0.623	rs6708784	ENSG00000230499.1	AC108463.1	-4.15	3.65e-05	0.00259	-0.15	-0.13	Chronic lymphocytic leukemia;	chr2:111169802	chr2:111195963~111206494:+
BRCA	cis	rs7520050	0.966	rs1085243	ENSG00000281133.1	AL355480.3	4.15	3.65e-05	0.00259	0.15	0.13	Reticulocyte count;Red blood cell count;	chr1:46079096	chr1:45580892~45580996:-
BRCA	cis	rs2835872	0.965	rs2835852	ENSG00000228677.1	TTC3-AS1	4.15	3.65e-05	0.0026	0.17	0.13	Electroencephalographic traits in alcoholism;	chr21:37641826	chr21:37187666~37193926:-
BRCA	cis	rs8062405	1	rs7187776	ENSG00000261766.1	RP11-22P6.2	-4.15	3.65e-05	0.0026	-0.12	-0.13	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28846324	chr16:28862166~28863340:-
BRCA	cis	rs983392	1	rs4939314	ENSG00000275344.1	MIR6503	-4.15	3.66e-05	0.0026	-0.13	-0.13	Alzheimer's disease (late onset);	chr11:60133102	chr11:60209071~60209156:-
BRCA	cis	rs7267979	1	rs10966	ENSG00000125804.12	FAM182A	-4.15	3.66e-05	0.0026	-0.17	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25302308	chr20:26054655~26086917:+
BRCA	cis	rs10043228	1	rs10079394	ENSG00000250015.1	CTC-339F2.2	4.15	3.66e-05	0.0026	0.17	0.13	Asthma or chronic obstructive pulmonary disease;	chr5:116265222	chr5:116302354~116304134:-
BRCA	cis	rs6547741	0.904	rs2384628	ENSG00000234072.1	AC074117.10	4.15	3.66e-05	0.0026	0.12	0.13	Oral cavity cancer;	chr2:27551835	chr2:27356246~27367622:+
BRCA	cis	rs58521262	0.585	rs461390	ENSG00000268105.1	RP11-369G6.2	4.15	3.66e-05	0.0026	0.17	0.13	Testicular germ cell tumor;	chr19:22947617	chr19:23125665~23128543:+
BRCA	cis	rs58521262	0.556	rs465723	ENSG00000268105.1	RP11-369G6.2	4.15	3.66e-05	0.0026	0.17	0.13	Testicular germ cell tumor;	chr19:22948661	chr19:23125665~23128543:+
BRCA	cis	rs58521262	0.556	rs459820	ENSG00000268105.1	RP11-369G6.2	4.15	3.66e-05	0.0026	0.17	0.13	Testicular germ cell tumor;	chr19:22948981	chr19:23125665~23128543:+
BRCA	cis	rs7475343	0.573	rs76848149	ENSG00000224034.1	RP11-445P17.8	-4.15	3.66e-05	0.0026	-0.25	-0.13	Intelligence;	chr10:5192443	chr10:5266033~5271236:-
BRCA	cis	rs9392653	0.96	rs9405256	ENSG00000220685.3	RP11-530A18.1	-4.15	3.66e-05	0.0026	-0.18	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr6:5070065	chr6:5065795~5066982:-
BRCA	cis	rs875971	0.545	rs73152714	ENSG00000273142.1	RP11-458F8.4	4.15	3.66e-05	0.0026	0.13	0.13	Aortic root size;	chr7:66534641	chr7:66902857~66906297:+
BRCA	cis	rs875971	0.545	rs4718364	ENSG00000273142.1	RP11-458F8.4	4.15	3.66e-05	0.0026	0.13	0.13	Aortic root size;	chr7:66536353	chr7:66902857~66906297:+
BRCA	cis	rs875971	0.545	rs801199	ENSG00000273142.1	RP11-458F8.4	-4.15	3.66e-05	0.0026	-0.13	-0.13	Aortic root size;	chr7:66560286	chr7:66902857~66906297:+
BRCA	cis	rs6012564	1	rs6125540	ENSG00000222365.1	SNORD12B	4.15	3.66e-05	0.0026	0.13	0.13	Anger;	chr20:49087502	chr20:49280319~49280409:+
BRCA	cis	rs10895987	1	rs11227126	ENSG00000255200.1	AP003068.18	4.15	3.66e-05	0.0026	0.18	0.13	Blood protein levels;	chr11:65140591	chr11:65174117~65176470:-
BRCA	cis	rs2834288	0.5	rs7277248	ENSG00000237945.6	LINC00649	4.15	3.66e-05	0.0026	0.15	0.13	Gut microbiota (bacterial taxa);	chr21:33957948	chr21:33915534~33977691:+
BRCA	cis	rs11887277	0.741	rs4665352	ENSG00000272148.1	RP11-195B17.1	-4.15	3.66e-05	0.0026	-0.14	-0.13	Obesity-related traits;	chr2:26816574	chr2:27062428~27062907:-
BRCA	cis	rs72482608	0.835	rs6679313	ENSG00000271811.1	RP1-79C4.4	4.15	3.66e-05	0.0026	0.14	0.13	Emphysema imaging phenotypes;	chr1:170745969	chr1:170667381~170669425:+
BRCA	cis	rs6545883	0.929	rs3821222	ENSG00000270820.4	RP11-355B11.2	4.15	3.66e-05	0.0026	0.15	0.13	Tuberculosis;	chr2:61486391	chr2:61471188~61484130:+
BRCA	cis	rs3176789	0.671	rs12425365	ENSG00000256673.1	RP11-599J14.2	4.15	3.66e-05	0.0026	0.14	0.13	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9767422	chr12:9398355~9414851:-
BRCA	cis	rs34792	0.853	rs1684546	ENSG00000207425.1	Y_RNA	4.15	3.66e-05	0.0026	0.14	0.13	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15466568	chr16:14915457~14915556:-
BRCA	cis	rs11742741	0.902	rs56392095	ENSG00000248874.4	C5orf17	-4.15	3.66e-05	0.0026	-0.17	-0.13	Educational attainment;	chr5:24234492	chr5:23951348~24178263:+
BRCA	cis	rs11742741	0.934	rs58713722	ENSG00000248874.4	C5orf17	-4.15	3.66e-05	0.0026	-0.17	-0.13	Educational attainment;	chr5:24236801	chr5:23951348~24178263:+
BRCA	cis	rs12681366	0.663	rs2919666	ENSG00000253704.1	RP11-267M23.4	4.15	3.66e-05	0.0026	0.13	0.13	Nonsyndromic cleft lip with cleft palate;	chr8:94453059	chr8:94553722~94569745:+
BRCA	cis	rs1910358	0.69	rs1948768	ENSG00000248874.4	C5orf17	-4.15	3.66e-05	0.0026	-0.17	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23953216	chr5:23951348~24178263:+
BRCA	cis	rs853679	0.517	rs9393884	ENSG00000216901.1	AL022393.7	4.15	3.66e-05	0.0026	0.18	0.13	Depression;	chr6:28079011	chr6:28176188~28176674:+
BRCA	cis	rs948562	0.681	rs10792180	ENSG00000255299.4	RP11-655C2.3	-4.15	3.66e-05	0.0026	-0.15	-0.13	Lymphoma;	chr11:58660116	chr11:58497888~58505758:-
BRCA	cis	rs757081	0.648	rs7108315	ENSG00000184669.7	OR7E14P	-4.15	3.66e-05	0.0026	-0.17	-0.13	Systolic blood pressure;	chr11:17245617	chr11:17013998~17053024:+
BRCA	cis	rs875971	0.929	rs12535036	ENSG00000229180.5	GS1-124K5.11	4.15	3.66e-05	0.0026	0.11	0.13	Aortic root size;	chr7:66499076	chr7:66526088~66542624:-
BRCA	cis	rs875971	1	rs6970030	ENSG00000229180.5	GS1-124K5.11	4.15	3.66e-05	0.0026	0.11	0.13	Aortic root size;	chr7:66503692	chr7:66526088~66542624:-
BRCA	cis	rs875971	0.928	rs6970357	ENSG00000229180.5	GS1-124K5.11	4.15	3.66e-05	0.0026	0.11	0.13	Aortic root size;	chr7:66503891	chr7:66526088~66542624:-
BRCA	cis	rs875971	0.638	rs6460305	ENSG00000229180.5	GS1-124K5.11	-4.15	3.66e-05	0.0026	-0.11	-0.13	Aortic root size;	chr7:66595421	chr7:66526088~66542624:-
BRCA	cis	rs58785573	0.57	rs4833078	ENSG00000231160.8	KLF3-AS1	-4.15	3.67e-05	0.0026	-0.12	-0.13	Lymphocyte percentage of white cells;	chr4:38644855	chr4:38612701~38664883:-
BRCA	cis	rs875971	0.964	rs12668936	ENSG00000229180.5	GS1-124K5.11	4.15	3.67e-05	0.0026	0.11	0.13	Aortic root size;	chr7:66449417	chr7:66526088~66542624:-
BRCA	cis	rs11096990	0.656	rs2123027	ENSG00000249685.1	RP11-360F5.3	-4.15	3.67e-05	0.0026	-0.16	-0.13	Cognitive function;	chr4:39289493	chr4:39133913~39135608:+
BRCA	cis	rs801193	0.636	rs2659895	ENSG00000272831.1	RP11-792A8.4	4.15	3.67e-05	0.0026	0.12	0.13	Aortic root size;	chr7:66731484	chr7:66739829~66740385:-
BRCA	cis	rs4374383	0.715	rs2871922	ENSG00000243389.1	AC012442.5	-4.15	3.67e-05	0.0026	-0.16	-0.13	Hepatitis C induced liver fibrosis;	chr2:111961854	chr2:112589040~112614431:+
BRCA	cis	rs4374383	0.884	rs7579906	ENSG00000243389.1	AC012442.5	-4.15	3.67e-05	0.0026	-0.16	-0.13	Hepatitis C induced liver fibrosis;	chr2:111965789	chr2:112589040~112614431:+
BRCA	cis	rs812925	0.533	rs35507645	ENSG00000273302.1	RP11-493E12.2	4.15	3.67e-05	0.0026	0.11	0.13	Immature fraction of reticulocytes;	chr2:61169631	chr2:61199979~61200769:+
BRCA	cis	rs8114671	0.836	rs2038504	ENSG00000126005.14	MMP24-AS1	4.15	3.67e-05	0.0026	0.15	0.13	Height;	chr20:35060384	chr20:35216462~35278131:-
BRCA	cis	rs8114671	0.836	rs2104083	ENSG00000126005.14	MMP24-AS1	4.15	3.67e-05	0.0026	0.15	0.13	Height;	chr20:35061330	chr20:35216462~35278131:-
BRCA	cis	rs8114671	0.839	rs2104084	ENSG00000126005.14	MMP24-AS1	4.15	3.67e-05	0.0026	0.15	0.13	Height;	chr20:35061414	chr20:35216462~35278131:-
BRCA	cis	rs8114671	0.528	rs6119542	ENSG00000126005.14	MMP24-AS1	-4.15	3.67e-05	0.0026	-0.15	-0.13	Height;	chr20:34896742	chr20:35216462~35278131:-
BRCA	cis	rs1124769	0.619	rs7177664	ENSG00000273674.3	CTD-2378E12.1	-4.15	3.67e-05	0.0026	-0.15	-0.13	Cognitive performance;	chr15:51093137	chr15:50839875~50908599:-
BRCA	cis	rs9914544	1	rs1037036	ENSG00000273018.4	CTD-2303H24.2	-4.15	3.67e-05	0.00261	-0.17	-0.13	Educational attainment (years of education);	chr17:18860764	chr17:18511221~18551705:-
BRCA	cis	rs801193	1	rs1553609	ENSG00000223473.2	GS1-124K5.3	4.15	3.67e-05	0.00261	0.1	0.13	Aortic root size;	chr7:66732152	chr7:66491049~66493566:-
BRCA	cis	rs13326165	0.715	rs34355561	ENSG00000243224.1	RP5-1157M23.2	-4.15	3.67e-05	0.00261	-0.18	-0.13	HDL cholesterol levels;HDL cholesterol;	chr3:52349104	chr3:52239258~52241097:+
BRCA	cis	rs4834770	0.792	rs7676969	ENSG00000248280.1	RP11-33B1.2	4.15	3.67e-05	0.00261	0.12	0.13	Blood protein levels;	chr4:119252569	chr4:119440561~119450157:-
BRCA	cis	rs4834770	0.685	rs4496567	ENSG00000248280.1	RP11-33B1.2	4.15	3.67e-05	0.00261	0.12	0.13	Blood protein levels;	chr4:119254470	chr4:119440561~119450157:-
BRCA	cis	rs4834770	0.792	rs6823331	ENSG00000248280.1	RP11-33B1.2	4.15	3.67e-05	0.00261	0.12	0.13	Blood protein levels;	chr4:119259635	chr4:119440561~119450157:-
BRCA	cis	rs9392653	0.847	rs9392649	ENSG00000220685.3	RP11-530A18.1	-4.15	3.67e-05	0.00261	-0.17	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr6:5063805	chr6:5065795~5066982:-
BRCA	cis	rs853679	0.517	rs9393890	ENSG00000216901.1	AL022393.7	4.15	3.67e-05	0.00261	0.18	0.13	Depression;	chr6:28096077	chr6:28176188~28176674:+
BRCA	cis	rs853679	0.517	rs9366715	ENSG00000216901.1	AL022393.7	4.15	3.67e-05	0.00261	0.18	0.13	Depression;	chr6:28096855	chr6:28176188~28176674:+
BRCA	cis	rs7658584	0.592	rs56892189	ENSG00000246375.2	RP11-10L7.1	4.15	3.67e-05	0.00261	0.19	0.13	Squamous cell lung carcinoma;	chr4:88188491	chr4:88284942~88331421:+
BRCA	cis	rs11673344	0.543	rs12980849	ENSG00000276846.1	CTD-3220F14.3	4.14	3.67e-05	0.00261	0.15	0.13	Obesity-related traits;	chr19:37160812	chr19:37314868~37315620:-
BRCA	cis	rs7474896	0.583	rs10764144	ENSG00000120555.12	SEPT7P9	4.14	3.67e-05	0.00261	0.17	0.13	Obesity (extreme);	chr10:37686804	chr10:38383069~38402916:-
BRCA	cis	rs4835473	0.932	rs35055653	ENSG00000249741.2	RP11-673E1.3	4.14	3.68e-05	0.00261	0.14	0.13	Immature fraction of reticulocytes;	chr4:143754836	chr4:143911514~143912053:-
BRCA	cis	rs12744310	0.943	rs35972058	ENSG00000235358.1	RP11-399E6.1	4.14	3.68e-05	0.00261	0.19	0.13	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41303474	chr1:41242373~41284861:+
BRCA	cis	rs12744310	0.943	rs12032906	ENSG00000235358.1	RP11-399E6.1	4.14	3.68e-05	0.00261	0.19	0.13	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41303486	chr1:41242373~41284861:+
BRCA	cis	rs12744310	1	rs34315814	ENSG00000235358.1	RP11-399E6.1	4.14	3.68e-05	0.00261	0.19	0.13	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41303500	chr1:41242373~41284861:+
BRCA	cis	rs2018683	0.523	rs4513881	ENSG00000228421.2	AC005013.5	-4.14	3.68e-05	0.00261	-0.16	-0.13	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28985794	chr7:28957667~28959345:+
BRCA	cis	rs4415084	0.716	rs727304	ENSG00000251141.4	RP11-53O19.1	4.14	3.68e-05	0.00261	0.12	0.13	Breast cancer;	chr5:44796188	chr5:44744900~44808777:-
BRCA	cis	rs12049351	0.774	rs12033236	ENSG00000229367.1	HMGN2P19	4.14	3.68e-05	0.00261	0.17	0.13	Circulating myeloperoxidase levels (plasma);	chr1:229504724	chr1:229570532~229570796:+
BRCA	cis	rs703842	0.616	rs7489290	ENSG00000257159.1	RP11-58A17.3	4.14	3.68e-05	0.00261	0.16	0.13	Multiple sclerosis;	chr12:57834805	chr12:57967058~57968399:+
BRCA	cis	rs7647973	1	rs56127630	ENSG00000244380.1	RP11-24C3.2	-4.14	3.68e-05	0.00261	-0.16	-0.13	Menarche (age at onset);	chr3:49400603	chr3:48440352~48446656:-
BRCA	cis	rs6921919	0.583	rs6908137	ENSG00000273712.1	RP5-874C20.7	4.14	3.68e-05	0.00261	0.17	0.13	Autism spectrum disorder or schizophrenia;	chr6:28402616	chr6:28315613~28315883:-
BRCA	cis	rs7726839	0.561	rs72703046	ENSG00000271781.1	CTD-2589H19.6	-4.14	3.68e-05	0.00261	-0.18	-0.13	Obesity-related traits;	chr5:580014	chr5:675826~676616:+
BRCA	cis	rs651907	0.557	rs34947019	ENSG00000256628.3	ZBTB11-AS1	4.14	3.68e-05	0.00261	0.16	0.13	Colorectal cancer;	chr3:101813391	chr3:101676475~101679217:+
BRCA	cis	rs4499344	0.73	rs7247597	ENSG00000267475.1	CTD-2538C1.2	4.14	3.68e-05	0.00261	0.16	0.13	Mean platelet volume;	chr19:32611351	chr19:32687089~32691750:-
BRCA	cis	rs6847067	0.672	rs6531783	ENSG00000180769.7	WDFY3-AS2	4.14	3.68e-05	0.00261	0.13	0.13	Oropharynx cancer;	chr4:85011190	chr4:84965682~85011277:+
BRCA	cis	rs2486012	1	rs2428960	ENSG00000237950.1	RP11-7O11.3	-4.14	3.68e-05	0.00261	-0.23	-0.13	Intelligence (multi-trait analysis);	chr1:43927474	chr1:43944370~43946551:-
BRCA	cis	rs875971	0.545	rs75577046	ENSG00000232546.1	RP11-458F8.1	4.14	3.68e-05	0.00261	0.12	0.13	Aortic root size;	chr7:66493729	chr7:66848496~66858136:+
BRCA	cis	rs745109	0.882	rs72930361	ENSG00000273080.1	RP11-301O19.1	4.14	3.68e-05	0.00261	0.2	0.13	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86453230	chr2:86195590~86196049:+
BRCA	cis	rs745109	0.882	rs55866634	ENSG00000273080.1	RP11-301O19.1	4.14	3.68e-05	0.00261	0.2	0.13	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86458999	chr2:86195590~86196049:+
BRCA	cis	rs745109	0.832	rs56169889	ENSG00000273080.1	RP11-301O19.1	4.14	3.68e-05	0.00261	0.2	0.13	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86459162	chr2:86195590~86196049:+
BRCA	cis	rs745109	0.882	rs72930369	ENSG00000273080.1	RP11-301O19.1	4.14	3.68e-05	0.00261	0.2	0.13	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86460260	chr2:86195590~86196049:+
BRCA	cis	rs745109	0.882	rs72930387	ENSG00000273080.1	RP11-301O19.1	4.14	3.68e-05	0.00261	0.2	0.13	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86468062	chr2:86195590~86196049:+
BRCA	cis	rs1910358	0.554	rs3843469	ENSG00000248874.4	C5orf17	-4.14	3.68e-05	0.00261	-0.18	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23738856	chr5:23951348~24178263:+
BRCA	cis	rs1910358	0.554	rs3846541	ENSG00000248874.4	C5orf17	-4.14	3.68e-05	0.00261	-0.18	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23739200	chr5:23951348~24178263:+
BRCA	cis	rs71520386	0.632	rs1029738	ENSG00000226329.2	AC005682.6	-4.14	3.68e-05	0.00261	-0.13	-0.13	Fibrinogen levels;	chr7:22834428	chr7:22863874~22881350:-
BRCA	cis	rs35146811	0.961	rs11771139	ENSG00000214313.7	AZGP1P1	4.14	3.68e-05	0.00261	0.14	0.13	Coronary artery disease;	chr7:100138436	chr7:99980762~99987535:+
BRCA	cis	rs72819225	0.616	rs4933669	ENSG00000228701.1	TNKS2-AS1	4.14	3.68e-05	0.00261	0.17	0.13	Yeast infection;	chr10:91569949	chr10:91782839~91798291:-
BRCA	cis	rs853679	0.517	rs7755442	ENSG00000216901.1	AL022393.7	4.14	3.69e-05	0.00261	0.18	0.13	Depression;	chr6:28071237	chr6:28176188~28176674:+
BRCA	cis	rs853679	0.517	rs55747925	ENSG00000216901.1	AL022393.7	4.14	3.69e-05	0.00261	0.18	0.13	Depression;	chr6:28076559	chr6:28176188~28176674:+
BRCA	cis	rs853679	0.517	rs34716816	ENSG00000216901.1	AL022393.7	4.14	3.69e-05	0.00261	0.18	0.13	Depression;	chr6:28078391	chr6:28176188~28176674:+
BRCA	cis	rs853679	0.517	rs9380049	ENSG00000216901.1	AL022393.7	4.14	3.69e-05	0.00261	0.18	0.13	Depression;	chr6:28080757	chr6:28176188~28176674:+
BRCA	cis	rs853679	0.517	rs9380050	ENSG00000216901.1	AL022393.7	4.14	3.69e-05	0.00261	0.18	0.13	Depression;	chr6:28080760	chr6:28176188~28176674:+
BRCA	cis	rs801193	1	rs62466794	ENSG00000223473.2	GS1-124K5.3	4.14	3.69e-05	0.00261	0.1	0.13	Aortic root size;	chr7:66726592	chr7:66491049~66493566:-
BRCA	cis	rs9840812	0.591	rs1291921	ENSG00000273486.1	RP11-731C17.2	4.14	3.69e-05	0.00262	0.15	0.13	Fibrinogen levels;	chr3:136317384	chr3:136837338~136839021:-
BRCA	cis	rs516805	0.63	rs1379098	ENSG00000279114.1	RP3-425C14.5	-4.14	3.69e-05	0.00262	-0.16	-0.13	Lymphocyte counts;	chr6:122121672	chr6:122471923~122484161:+
BRCA	cis	rs7932354	0.583	rs10769212	ENSG00000200376.1	RNU5E-10P	4.14	3.69e-05	0.00262	0.16	0.13	Bone mineral density (hip);Bone mineral density;	chr11:46871947	chr11:47576471~47576588:-
BRCA	cis	rs5758659	0.819	rs134871	ENSG00000270083.1	RP1-257I20.14	4.14	3.69e-05	0.00262	0.14	0.13	Cognitive function;	chr22:42256710	chr22:42089630~42090028:-
BRCA	cis	rs7824557	0.707	rs3808518	ENSG00000154316.13	TDH	4.14	3.69e-05	0.00262	0.17	0.13	Retinal vascular caliber;	chr8:11285763	chr8:11339637~11368452:+
BRCA	cis	rs2832191	0.74	rs2012645	ENSG00000215533.7	LINC00189	-4.14	3.69e-05	0.00262	-0.15	-0.13	Dental caries;	chr21:29073640	chr21:29193480~29288205:+
BRCA	cis	rs2832191	0.716	rs2692625	ENSG00000215533.7	LINC00189	-4.14	3.69e-05	0.00262	-0.15	-0.13	Dental caries;	chr21:29074039	chr21:29193480~29288205:+
BRCA	cis	rs4776970	0.632	rs8030996	ENSG00000270964.1	RP11-502I4.3	-4.14	3.69e-05	0.00262	-0.14	-0.13	Body mass index;Waist circumference;	chr15:67739068	chr15:67541072~67542604:-
BRCA	cis	rs11250097	0.549	rs11778177	ENSG00000154316.13	TDH	4.14	3.69e-05	0.00262	0.17	0.13	Neuroticism;	chr8:11452853	chr8:11339637~11368452:+
BRCA	cis	rs71520386	0.579	rs4394299	ENSG00000226329.2	AC005682.6	-4.14	3.69e-05	0.00262	-0.13	-0.13	Fibrinogen levels;	chr7:22825763	chr7:22863874~22881350:-
BRCA	cis	rs11662586	0.517	rs7230837	ENSG00000261126.6	RP11-795F19.1	4.14	3.69e-05	0.00262	0.12	0.13	Exploratory eye movement dysfunction in schizophrenia (responsive search score);	chr18:79935384	chr18:80046900~80095482:+
BRCA	cis	rs11711311	1	rs62268169	ENSG00000241529.3	RN7SL767P	-4.14	3.69e-05	0.00262	-0.15	-0.13	IgG glycosylation;	chr3:113775013	chr3:113632704~113632998:+
BRCA	cis	rs13434995	0.513	rs7698022	ENSG00000239040.1	Y_RNA	-4.14	3.69e-05	0.00262	-0.15	-0.13	Adiponectin levels;	chr4:55541180	chr4:55412636~55412738:+
BRCA	cis	rs2765539	0.59	rs4659137	ENSG00000231365.4	RP11-418J17.1	-4.14	3.69e-05	0.00262	-0.18	-0.13	Waist-hip ratio;	chr1:118978171	chr1:119140396~119275973:+
BRCA	cis	rs6545883	0.894	rs2694639	ENSG00000273302.1	RP11-493E12.2	-4.14	3.7e-05	0.00262	-0.12	-0.13	Tuberculosis;	chr2:61368156	chr2:61199979~61200769:+
BRCA	cis	rs757081	0.636	rs214934	ENSG00000184669.7	OR7E14P	-4.14	3.7e-05	0.00262	-0.19	-0.13	Systolic blood pressure;	chr11:17171928	chr11:17013998~17053024:+
BRCA	cis	rs2391285	0.609	rs2286177	ENSG00000214870.7	AC004540.5	4.14	3.7e-05	0.00262	0.19	0.13	Post bronchodilator FEV1/FVC ratio;	chr7:26556504	chr7:26398593~26494256:+
BRCA	cis	rs2018683	0.7	rs13227954	ENSG00000228421.2	AC005013.5	-4.14	3.7e-05	0.00262	-0.16	-0.13	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28977572	chr7:28957667~28959345:+
BRCA	cis	rs7267979	0.932	rs1985737	ENSG00000125804.12	FAM182A	-4.14	3.7e-05	0.00262	-0.16	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25610832	chr20:26054655~26086917:+
BRCA	cis	rs2625529	0.618	rs6494992	ENSG00000260037.4	CTD-2524L6.3	4.14	3.7e-05	0.00262	0.16	0.13	Red blood cell count;	chr15:72128409	chr15:71818396~71823384:+
BRCA	cis	rs13434995	0.513	rs1021307	ENSG00000239040.1	Y_RNA	-4.14	3.7e-05	0.00262	-0.15	-0.13	Adiponectin levels;	chr4:55529547	chr4:55412636~55412738:+
BRCA	cis	rs13434995	0.513	rs1021306	ENSG00000239040.1	Y_RNA	-4.14	3.7e-05	0.00262	-0.15	-0.13	Adiponectin levels;	chr4:55529777	chr4:55412636~55412738:+
BRCA	cis	rs11158026	0.526	rs11626210	ENSG00000258413.1	RP11-665C16.6	-4.14	3.7e-05	0.00262	-0.2	-0.13	Parkinson's disease;	chr14:54882831	chr14:55262767~55272075:-
BRCA	cis	rs7520050	0.931	rs1707333	ENSG00000281133.1	AL355480.3	4.14	3.7e-05	0.00262	0.15	0.13	Reticulocyte count;Red blood cell count;	chr1:46081363	chr1:45580892~45580996:-
BRCA	cis	rs4970988	0.787	rs1532770	ENSG00000231073.1	RP11-316M1.3	4.14	3.7e-05	0.00262	0.14	0.13	Urate levels;	chr1:150752859	chr1:150973123~150975534:+
BRCA	cis	rs3176789	0.647	rs12824297	ENSG00000256673.1	RP11-599J14.2	4.14	3.7e-05	0.00262	0.14	0.13	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9767068	chr12:9398355~9414851:-
BRCA	cis	rs3176789	0.647	rs12824308	ENSG00000256673.1	RP11-599J14.2	4.14	3.7e-05	0.00262	0.14	0.13	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9767088	chr12:9398355~9414851:-
BRCA	cis	rs3176789	0.647	rs12817268	ENSG00000256673.1	RP11-599J14.2	4.14	3.7e-05	0.00262	0.14	0.13	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9767157	chr12:9398355~9414851:-
BRCA	cis	rs3176789	0.647	rs12422685	ENSG00000256673.1	RP11-599J14.2	4.14	3.7e-05	0.00262	0.14	0.13	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9767376	chr12:9398355~9414851:-
BRCA	cis	rs7260598	0.642	rs8112289	ENSG00000268442.1	CTD-2027I19.2	4.14	3.7e-05	0.00262	0.2	0.13	Response to taxane treatment (placlitaxel);	chr19:23956571	chr19:24162370~24163425:-
BRCA	cis	rs9392653	1	rs9392651	ENSG00000220685.3	RP11-530A18.1	-4.14	3.7e-05	0.00262	-0.18	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr6:5070825	chr6:5065795~5066982:-
BRCA	cis	rs16944613	0.541	rs4566137	ENSG00000259212.1	CTD-3065B20.2	4.14	3.7e-05	0.00262	0.19	0.13	Colorectal cancer;	chr15:90554732	chr15:90595840~90596447:-
BRCA	cis	rs4664293	0.867	rs13432	ENSG00000224152.1	AC009506.1	-4.14	3.7e-05	0.00262	-0.15	-0.13	Monocyte percentage of white cells;	chr2:159769216	chr2:159615296~159617082:+
BRCA	cis	rs7726839	0.561	rs72703046	ENSG00000225138.6	CTD-2228K2.7	4.14	3.7e-05	0.00263	0.18	0.13	Obesity-related traits;	chr5:580014	chr5:473236~480884:+
BRCA	cis	rs2562456	0.526	rs950504	ENSG00000268658.4	LINC00664	4.14	3.7e-05	0.00263	0.19	0.13	Pain;	chr19:21601193	chr19:21483374~21503238:+
BRCA	cis	rs801193	1	rs6958520	ENSG00000223473.2	GS1-124K5.3	4.14	3.7e-05	0.00263	0.1	0.13	Aortic root size;	chr7:66686466	chr7:66491049~66493566:-
BRCA	cis	rs1910358	0.53	rs4612026	ENSG00000248874.4	C5orf17	-4.14	3.71e-05	0.00263	-0.18	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23760219	chr5:23951348~24178263:+
BRCA	cis	rs1910358	0.554	rs5010439	ENSG00000248874.4	C5orf17	-4.14	3.71e-05	0.00263	-0.18	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23760419	chr5:23951348~24178263:+
BRCA	cis	rs1910358	0.554	rs4518347	ENSG00000248874.4	C5orf17	-4.14	3.71e-05	0.00263	-0.18	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23760448	chr5:23951348~24178263:+
BRCA	cis	rs1910358	0.554	rs10061955	ENSG00000248874.4	C5orf17	-4.14	3.71e-05	0.00263	-0.18	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23761469	chr5:23951348~24178263:+
BRCA	cis	rs1635	0.655	rs60698636	ENSG00000216901.1	AL022393.7	4.14	3.71e-05	0.00263	0.3	0.13	Schizophrenia;	chr6:28348268	chr6:28176188~28176674:+
BRCA	cis	rs703842	1	rs3782130	ENSG00000270039.1	RP11-571M6.17	-4.14	3.71e-05	0.00263	-0.18	-0.13	Multiple sclerosis;	chr12:57768115	chr12:57803838~57804415:+
BRCA	cis	rs62458065	0.513	rs10265319	ENSG00000229358.3	DPY19L1P1	-4.14	3.71e-05	0.00263	-0.17	-0.13	Metabolite levels (HVA/MHPG ratio);	chr7:32531952	chr7:32580949~32761787:-
BRCA	cis	rs1005277	0.579	rs1780137	ENSG00000272983.1	RP11-508N22.12	4.14	3.71e-05	0.00263	0.14	0.13	Extrinsic epigenetic age acceleration;	chr10:38212547	chr10:38137337~38144399:+
BRCA	cis	rs745109	0.882	rs57291816	ENSG00000273080.1	RP11-301O19.1	4.14	3.71e-05	0.00263	0.2	0.13	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86444745	chr2:86195590~86196049:+
BRCA	cis	rs4908769	0.624	rs2708632	ENSG00000270282.1	RP5-1115A15.2	-4.14	3.71e-05	0.00263	-0.15	-0.13	Allergy;	chr1:8404449	chr1:8512653~8513021:+
BRCA	cis	rs721917	0.507	rs2819101	ENSG00000242600.5	MBL1P	4.14	3.71e-05	0.00263	0.16	0.13	Chronic obstructive pulmonary disease;	chr10:79936986	chr10:79904898~79950336:+
BRCA	cis	rs28530618	0.515	rs6579027	ENSG00000198547.7	C20orf203	-4.14	3.71e-05	0.00263	-0.14	-0.13	Birth weight;	chr20:32651223	chr20:32631652~32673941:-
BRCA	cis	rs10129255	0.5	rs7161740	ENSG00000211959.2	IGHV4-39	4.14	3.71e-05	0.00263	0.09	0.13	Kawasaki disease;	chr14:106776119	chr14:106421711~106422218:-
BRCA	cis	rs17345786	0.817	rs11720560	ENSG00000244119.1	PDCL3P4	4.14	3.71e-05	0.00263	0.11	0.13	Colonoscopy-negative controls vs population controls;	chr3:101609640	chr3:101712472~101713191:+
BRCA	cis	rs1223397	0.617	rs202032	ENSG00000215022.6	RP1-257A7.4	-4.14	3.71e-05	0.00263	-0.17	-0.13	Blood pressure;	chr6:13291844	chr6:13264861~13295586:-
BRCA	cis	rs11637445	0.627	rs4776988	ENSG00000260657.2	RP11-315D16.4	-4.14	3.71e-05	0.00263	-0.15	-0.13	Posterior cortical atrophy and Alzheimer's disease;	chr15:67831813	chr15:68267792~68277994:-
BRCA	cis	rs62560775	0.541	rs12352425	ENSG00000279670.1	RP11-70L8.5	4.14	3.71e-05	0.00263	0.21	0.13	Lung cancer;Lung adenocarcinoma;	chr9:22042087	chr9:21892188~21893857:+
BRCA	cis	rs911119	0.955	rs6036474	ENSG00000270001.1	RP11-218C14.8	-4.14	3.71e-05	0.00263	-0.17	-0.13	Chronic kidney disease;	chr20:23623777	chr20:23631826~23632316:-
BRCA	cis	rs10986311	0.962	rs2068165	ENSG00000227200.1	RP11-121A14.3	-4.14	3.71e-05	0.00263	-0.15	-0.13	Vitiligo;	chr9:124326071	chr9:124262876~124265809:+
BRCA	cis	rs4132699	0.62	rs11265913	ENSG00000225460.1	RP13-93L13.1	-4.14	3.71e-05	0.00263	-0.14	-0.13	Nonsyndromic cleft lip with or without cleft palate;Orofacial clefts;	chr9:89483114	chr9:89472237~89472692:+
BRCA	cis	rs739496	0.579	rs9971746	ENSG00000234608.6	MAPKAPK5-AS1	-4.14	3.72e-05	0.00263	-0.16	-0.13	Platelet count;	chr12:111899558	chr12:111839764~111842902:-
BRCA	cis	rs7246657	0.508	rs1644702	ENSG00000226686.6	LINC01535	-4.14	3.72e-05	0.00263	-0.22	-0.13	Coronary artery calcification;	chr19:37001005	chr19:37251912~37265535:+
BRCA	cis	rs7772486	0.875	rs2777482	ENSG00000270638.1	RP3-466P17.1	4.14	3.72e-05	0.00263	0.15	0.13	Lobe attachment (rater-scored or self-reported);	chr6:145999205	chr6:145735570~145737218:+
BRCA	cis	rs11719291	0.504	rs34571182	ENSG00000225399.4	RP11-3B7.1	-4.14	3.72e-05	0.00263	-0.21	-0.13	Cognitive function;	chr3:49171624	chr3:49260085~49261316:+
BRCA	cis	rs10844706	0.669	rs10772108	ENSG00000278635.1	CTD-2318O12.1	-4.14	3.72e-05	0.00263	-0.14	-0.13	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9746454	chr12:9415641~9416718:+
BRCA	cis	rs8180040	0.62	rs6767907	ENSG00000271161.1	BOLA2P2	-4.14	3.72e-05	0.00263	-0.14	-0.13	Colorectal cancer;	chr3:47121171	chr3:47499841~47500407:+
BRCA	cis	rs4388249	0.651	rs253245	ENSG00000271849.1	CTC-332L22.1	-4.14	3.72e-05	0.00264	-0.23	-0.13	Schizophrenia;	chr5:109668499	chr5:109687802~109688329:-
BRCA	cis	rs1538970	0.847	rs781230	ENSG00000281133.1	AL355480.3	4.14	3.72e-05	0.00264	0.17	0.13	Platelet count;	chr1:45415079	chr1:45580892~45580996:-
BRCA	cis	rs34421088	0.564	rs6983129	ENSG00000255046.1	RP11-297N6.4	-4.14	3.72e-05	0.00264	-0.15	-0.13	Neuroticism;	chr8:11733627	chr8:11797928~11802568:-
BRCA	cis	rs739401	0.572	rs739399	ENSG00000183562.3	CTC-343N3.1	-4.14	3.72e-05	0.00264	-0.13	-0.13	Longevity;	chr11:2995222	chr11:2989863~2991344:+
BRCA	cis	rs17406451	0.788	rs11124937	ENSG00000234936.1	AC010883.5	4.14	3.72e-05	0.00264	0.12	0.13	Mitochondrial DNA levels;	chr2:43469076	chr2:43229573~43233394:+
BRCA	cis	rs4948275	0.631	rs1947520	ENSG00000237233.2	TMEM26-AS1	-4.14	3.72e-05	0.00264	-0.15	-0.13	Night sleep phenotypes;	chr10:61588334	chr10:61452639~61481956:+
BRCA	cis	rs983392	0.709	rs1349667	ENSG00000275344.1	MIR6503	-4.14	3.72e-05	0.00264	-0.13	-0.13	Alzheimer's disease (late onset);	chr11:60225873	chr11:60209071~60209156:-
BRCA	cis	rs17756712	0.666	rs1099773	ENSG00000271727.1	RP11-532F6.4	-4.14	3.72e-05	0.00264	-0.16	-0.13	Vertical cup-disc ratio;	chr6:646076	chr6:711533~750729:+
BRCA	cis	rs6480314	0.522	rs7902936	ENSG00000233590.1	RP11-153K11.3	4.14	3.72e-05	0.00264	0.2	0.13	Optic nerve measurement (disc area);	chr10:68299584	chr10:68233251~68242379:-
BRCA	cis	rs12571093	0.571	rs7903251	ENSG00000233590.1	RP11-153K11.3	4.14	3.72e-05	0.00264	0.2	0.13	Optic nerve measurement (disc area);	chr10:68299969	chr10:68233251~68242379:-
BRCA	cis	rs7260598	0.606	rs72483177	ENSG00000268442.1	CTD-2027I19.2	4.14	3.72e-05	0.00264	0.2	0.13	Response to taxane treatment (placlitaxel);	chr19:23970913	chr19:24162370~24163425:-
BRCA	cis	rs11096990	0.656	rs4580661	ENSG00000249685.1	RP11-360F5.3	-4.14	3.72e-05	0.00264	-0.16	-0.13	Cognitive function;	chr4:39294730	chr4:39133913~39135608:+
BRCA	cis	rs7267979	0.966	rs6050611	ENSG00000274973.1	RP13-401N8.7	-4.14	3.72e-05	0.00264	-0.15	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25433783	chr20:25845497~25845862:+
BRCA	cis	rs6430585	0.64	rs3816155	ENSG00000224043.6	CCNT2-AS1	4.14	3.72e-05	0.00264	0.21	0.13	Corneal structure;	chr2:135794956	chr2:134735464~134918710:-
BRCA	cis	rs11742741	0.805	rs12186963	ENSG00000248874.4	C5orf17	-4.14	3.72e-05	0.00264	-0.17	-0.13	Educational attainment;	chr5:24090136	chr5:23951348~24178263:+
BRCA	cis	rs853679	0.517	rs9393884	ENSG00000261839.1	RP1-265C24.8	4.14	3.72e-05	0.00264	0.17	0.13	Depression;	chr6:28079011	chr6:28136849~28139678:+
BRCA	cis	rs17270561	0.609	rs1892248	ENSG00000272462.2	U91328.19	-4.14	3.73e-05	0.00264	-0.16	-0.13	Iron status biomarkers;	chr6:25768686	chr6:25992662~26001775:+
BRCA	cis	rs10129255	0.556	rs9324093	ENSG00000274576.2	IGHV2-70	-4.14	3.73e-05	0.00264	-0.1	-0.13	Kawasaki disease;	chr14:106683893	chr14:106770577~106771020:-
BRCA	cis	rs2251381	0.75	rs2251186	ENSG00000232855.5	AF131217.1	-4.14	3.73e-05	0.00264	-0.17	-0.13	Selective IgA deficiency;	chr21:29156559	chr21:28439346~28674848:-
BRCA	cis	rs4415084	0.716	rs13189120	ENSG00000251141.4	RP11-53O19.1	4.14	3.73e-05	0.00264	0.12	0.13	Breast cancer;	chr5:44822181	chr5:44744900~44808777:-
BRCA	cis	rs6088580	0.634	rs4277599	ENSG00000276073.1	RP5-1125A11.7	4.14	3.73e-05	0.00264	0.14	0.13	Glomerular filtration rate (creatinine);	chr20:34421099	chr20:33985617~33988989:-
BRCA	cis	rs6600671	1	rs12047116	ENSG00000275131.1	CH17-472G23.4	-4.14	3.73e-05	0.00264	-0.12	-0.13	Hip geometry;	chr1:121443912	chr1:120489625~120579190:-
BRCA	cis	rs6600671	0.967	rs11249347	ENSG00000275131.1	CH17-472G23.4	-4.14	3.73e-05	0.00264	-0.12	-0.13	Hip geometry;	chr1:121446489	chr1:120489625~120579190:-
BRCA	cis	rs6921919	0.525	rs16894095	ENSG00000273712.1	RP5-874C20.7	4.14	3.73e-05	0.00264	0.17	0.13	Autism spectrum disorder or schizophrenia;	chr6:28422453	chr6:28315613~28315883:-
BRCA	cis	rs801193	1	rs11773829	ENSG00000229180.5	GS1-124K5.11	-4.14	3.73e-05	0.00264	-0.11	-0.13	Aortic root size;	chr7:66676087	chr7:66526088~66542624:-
BRCA	cis	rs10829156	0.699	rs10828879	ENSG00000225527.1	RP11-383B4.4	-4.14	3.73e-05	0.00264	-0.16	-0.13	Sudden cardiac arrest;	chr10:18546425	chr10:18531849~18533336:-
BRCA	cis	rs718314	0.869	rs2129869	ENSG00000256894.1	RP11-283G6.3	4.14	3.73e-05	0.00264	0.16	0.13	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Renal cell carcinoma;Waist circumference adjusted for body mass index;	chr12:26304717	chr12:26125155~26126617:-
BRCA	cis	rs8040855	0.756	rs12909477	ENSG00000230373.7	GOLGA6L5P	-4.14	3.73e-05	0.00264	-0.16	-0.13	Bulimia nervosa;	chr15:85146644	chr15:84507885~84516814:-
BRCA	cis	rs2880765	0.835	rs11074276	ENSG00000202081.1	RNU6-1280P	4.14	3.73e-05	0.00264	0.15	0.13	Coronary artery disease;	chr15:85487132	chr15:85651522~85651628:-
BRCA	cis	rs2880765	0.835	rs7164106	ENSG00000202081.1	RNU6-1280P	4.14	3.73e-05	0.00264	0.15	0.13	Coronary artery disease;	chr15:85489359	chr15:85651522~85651628:-
BRCA	cis	rs2880765	0.835	rs1872074	ENSG00000202081.1	RNU6-1280P	4.14	3.73e-05	0.00264	0.15	0.13	Coronary artery disease;	chr15:85489953	chr15:85651522~85651628:-
BRCA	cis	rs2834188	0.557	rs3171425	ENSG00000272659.1	AP000295.10	-4.14	3.73e-05	0.00264	-0.17	-0.13	Narcolepsy;	chr21:33296442	chr21:33309491~33310181:+
BRCA	cis	rs7111546	1	rs113330537	ENSG00000246225.5	RP11-17A1.3	4.14	3.73e-05	0.00264	0.23	0.13	Dialysis-related mortality;	chr11:22797185	chr11:22829380~22945393:+
BRCA	cis	rs12744310	1	rs35318047	ENSG00000235358.1	RP11-399E6.1	4.14	3.73e-05	0.00264	0.18	0.13	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41289494	chr1:41242373~41284861:+
BRCA	cis	rs12744310	0.943	rs35493284	ENSG00000235358.1	RP11-399E6.1	4.14	3.73e-05	0.00264	0.18	0.13	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41289517	chr1:41242373~41284861:+
BRCA	cis	rs12744310	1	rs12025254	ENSG00000235358.1	RP11-399E6.1	4.14	3.73e-05	0.00264	0.18	0.13	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41291234	chr1:41242373~41284861:+
BRCA	cis	rs2032366	0.63	rs7235404	ENSG00000267279.1	RP11-879F14.2	4.14	3.73e-05	0.00264	0.18	0.13	Obesity-related traits;	chr18:61628753	chr18:61585746~61606916:-
BRCA	cis	rs6600671	1	rs4844607	ENSG00000275131.1	CH17-472G23.4	4.14	3.73e-05	0.00264	0.12	0.13	Hip geometry;	chr1:121442201	chr1:120489625~120579190:-
BRCA	cis	rs952623	0.622	rs12667652	ENSG00000211694.2	TRGV10	4.14	3.73e-05	0.00264	0.11	0.13	Intelligence (multi-trait analysis);	chr7:39034972	chr7:38299811~38300322:-
BRCA	cis	rs11742741	0.837	rs6888084	ENSG00000248874.4	C5orf17	-4.14	3.73e-05	0.00264	-0.17	-0.13	Educational attainment;	chr5:24126959	chr5:23951348~24178263:+
BRCA	cis	rs3930017	0.513	rs3930018	ENSG00000242435.1	UPK3BP1	4.14	3.73e-05	0.00264	0.16	0.13	Body mass index;	chr7:77091318	chr7:77004662~77005774:+
BRCA	cis	rs9982086	0.793	rs75137825	ENSG00000260583.1	AP000223.42	-4.14	3.73e-05	0.00264	-0.32	-0.13	Carboplatin disposition in epthelial ovarian cancer;	chr21:25621385	chr21:25582770~25583326:-
BRCA	cis	rs4578769	0.722	rs12458865	ENSG00000265939.1	UBE2CP2	-4.14	3.73e-05	0.00264	-0.16	-0.13	Eosinophil percentage of white cells;	chr18:22954677	chr18:22900486~22900995:-
BRCA	cis	rs3768617	0.706	rs11588675	ENSG00000224468.3	RP11-181K3.4	-4.14	3.73e-05	0.00264	-0.14	-0.13	Fuchs's corneal dystrophy;	chr1:183018917	chr1:183138402~183141282:-
BRCA	cis	rs11096990	0.634	rs746678	ENSG00000249685.1	RP11-360F5.3	-4.14	3.73e-05	0.00264	-0.15	-0.13	Cognitive function;	chr4:39279035	chr4:39133913~39135608:+
BRCA	cis	rs6012564	0.963	rs2075679	ENSG00000222365.1	SNORD12B	4.14	3.73e-05	0.00264	0.13	0.13	Anger;	chr20:49085052	chr20:49280319~49280409:+
BRCA	cis	rs2554380	0.943	rs2585042	ENSG00000230373.7	GOLGA6L5P	-4.14	3.73e-05	0.00264	-0.18	-0.13	Height;	chr15:83672996	chr15:84507885~84516814:-
BRCA	cis	rs12317459	0.591	rs12307933	ENSG00000213270.5	RPL6P25	-4.14	3.73e-05	0.00265	-0.21	-0.13	Prostate cancer (SNP x SNP interaction);	chr12:82772409	chr12:83151331~83152190:+
BRCA	cis	rs72627123	0.5	rs67852564	ENSG00000259065.1	RP5-1021I20.1	-4.14	3.73e-05	0.00265	-0.17	-0.13	Morning vs. evening chronotype;	chr14:74093217	chr14:73787360~73803270:+
BRCA	cis	rs7615952	0.551	rs6438945	ENSG00000248787.1	RP11-666A20.4	-4.14	3.73e-05	0.00265	-0.22	-0.13	Blood pressure (smoking interaction);	chr3:125915630	chr3:125908005~125910272:-
BRCA	cis	rs752010	0.841	rs6661784	ENSG00000230638.4	RP11-486B10.4	-4.14	3.74e-05	0.00265	-0.15	-0.13	Lupus nephritis in systemic lupus erythematosus;	chr1:41614641	chr1:41542069~41544310:+
BRCA	cis	rs2251381	0.75	rs8129616	ENSG00000232855.5	AF131217.1	4.14	3.74e-05	0.00265	0.16	0.13	Selective IgA deficiency;	chr21:29147764	chr21:28439346~28674848:-
BRCA	cis	rs7615952	0.673	rs7632557	ENSG00000248787.1	RP11-666A20.4	-4.14	3.74e-05	0.00265	-0.22	-0.13	Blood pressure (smoking interaction);	chr3:125916038	chr3:125908005~125910272:-
BRCA	cis	rs875971	0.929	rs34406470	ENSG00000229180.5	GS1-124K5.11	4.14	3.74e-05	0.00265	0.11	0.13	Aortic root size;	chr7:66464969	chr7:66526088~66542624:-
BRCA	cis	rs12368653	0.641	rs7311632	ENSG00000257159.1	RP11-58A17.3	-4.14	3.74e-05	0.00265	-0.15	-0.13	Multiple sclerosis;	chr12:57692557	chr12:57967058~57968399:+
BRCA	cis	rs1005277	0.579	rs1548255	ENSG00000272983.1	RP11-508N22.12	4.14	3.74e-05	0.00265	0.14	0.13	Extrinsic epigenetic age acceleration;	chr10:38128265	chr10:38137337~38144399:+
BRCA	cis	rs897984	0.52	rs4889536	ENSG00000274678.1	RP11-2C24.7	-4.14	3.74e-05	0.00265	-0.16	-0.13	Dementia with Lewy bodies;	chr16:30860434	chr16:30821338~30821884:+
BRCA	cis	rs4925540	1	rs7511962	ENSG00000215796.3	RP11-551G24.2	-4.14	3.74e-05	0.00265	-0.15	-0.13	Response to taxane treatment (docetaxel);	chr1:247048820	chr1:247042791~247044021:+
BRCA	cis	rs4925540	1	rs7519795	ENSG00000215796.3	RP11-551G24.2	-4.14	3.74e-05	0.00265	-0.15	-0.13	Response to taxane treatment (docetaxel);	chr1:247048824	chr1:247042791~247044021:+
BRCA	cis	rs867186	1	rs8117100	ENSG00000126005.14	MMP24-AS1	-4.14	3.74e-05	0.00265	-0.23	-0.13	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35104458	chr20:35216462~35278131:-
BRCA	cis	rs7520050	0.933	rs6694340	ENSG00000234329.1	RP11-767N6.2	-4.14	3.74e-05	0.00265	-0.12	-0.13	Reticulocyte count;Red blood cell count;	chr1:45823744	chr1:45651039~45651826:-
BRCA	cis	rs9863	0.861	rs11057399	ENSG00000270028.1	RP11-380L11.4	4.14	3.74e-05	0.00265	0.16	0.13	White blood cell count;	chr12:123940531	chr12:123925461~123926083:-
BRCA	cis	rs7772486	0.817	rs12198065	ENSG00000270638.1	RP3-466P17.1	4.14	3.74e-05	0.00265	0.15	0.13	Lobe attachment (rater-scored or self-reported);	chr6:146064150	chr6:145735570~145737218:+
BRCA	cis	rs6430585	0.527	rs2278731	ENSG00000224043.6	CCNT2-AS1	-4.14	3.74e-05	0.00265	-0.21	-0.13	Corneal structure;	chr2:135638730	chr2:134735464~134918710:-
BRCA	cis	rs700651	0.624	rs12105927	ENSG00000231621.1	AC013264.2	-4.14	3.74e-05	0.00265	-0.13	-0.13	Intracranial aneurysm;	chr2:198072534	chr2:197197991~197199273:+
BRCA	cis	rs4869313	0.905	rs716848	ENSG00000248734.2	CTD-2260A17.1	4.14	3.74e-05	0.00265	0.13	0.13	Pediatric autoimmune diseases;	chr5:96929296	chr5:96784777~96785999:+
BRCA	cis	rs56313388	0.505	rs9302680	ENSG00000246379.5	RP11-461O7.1	-4.14	3.74e-05	0.00265	-0.14	-0.13	Pulse pressure;	chr16:56235980	chr16:56092987~56191094:-
BRCA	cis	rs7930295	1	rs10893380	ENSG00000255062.1	RP11-712L6.5	4.14	3.74e-05	0.00265	0.19	0.13	Schizophrenia;	chr11:125441778	chr11:126294298~126304318:-
BRCA	cis	rs10911902	0.643	rs3766699	ENSG00000229739.2	RP11-295K2.3	-4.14	3.74e-05	0.00265	-0.19	-0.13	Schizophrenia;	chr1:186381179	chr1:186435161~186470291:+
BRCA	cis	rs847649	0.732	rs56269620	ENSG00000239969.4	RP11-163E9.2	-4.14	3.74e-05	0.00265	-0.16	-0.13	Morning vs. evening chronotype;	chr7:102849009	chr7:102364162~102380633:+
BRCA	cis	rs10080237	0.564	rs2490230	ENSG00000272129.1	RP11-250B2.6	4.14	3.74e-05	0.00265	0.16	0.13	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;	chr6:80102747	chr6:80355424~80356859:+
BRCA	cis	rs11098499	0.754	rs714899	ENSG00000260091.1	RP11-33B1.4	-4.14	3.74e-05	0.00265	-0.11	-0.13	Corneal astigmatism;	chr4:119321880	chr4:119409333~119410233:+
BRCA	cis	rs2243480	1	rs1039664	ENSG00000275400.1	RP4-756H11.5	4.14	3.74e-05	0.00265	0.23	0.13	Diabetic kidney disease;	chr7:65984729	chr7:66553805~66554199:-
BRCA	cis	rs2243480	0.901	rs1701759	ENSG00000222364.1	RNU6-96P	-4.14	3.74e-05	0.00265	-0.23	-0.13	Diabetic kidney disease;	chr7:66005945	chr7:66395191~66395286:+
BRCA	cis	rs711830	1	rs1051929	ENSG00000226363.3	HAGLROS	-4.14	3.74e-05	0.00265	-0.19	-0.13	Serous invasive ovarian cancer;Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;High-grade serous ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;	chr2:176172026	chr2:176177717~176179008:+
BRCA	cis	rs930421	0.544	rs4953653	ENSG00000226491.1	FTOP1	-4.14	3.74e-05	0.00265	-0.15	-0.13	Attention deficit hyperactivity disorder;	chr2:42762019	chr2:42797225~42798712:-
BRCA	cis	rs6545883	0.718	rs2694624	ENSG00000212978.6	AC016747.3	4.14	3.74e-05	0.00265	0.17	0.13	Tuberculosis;	chr2:61445178	chr2:61141592~61144969:-
BRCA	cis	rs6545883	0.503	rs1665272	ENSG00000273302.1	RP11-493E12.2	4.14	3.74e-05	0.00265	0.11	0.13	Tuberculosis;	chr2:61152151	chr2:61199979~61200769:+
BRCA	cis	rs4803480	0.572	rs17710743	ENSG00000270164.1	LINC01480	4.14	3.74e-05	0.00265	0.26	0.13	Schizophrenia;	chr19:41569079	chr19:41535183~41536904:+
BRCA	cis	rs2554380	0.843	rs1426162	ENSG00000230373.7	GOLGA6L5P	-4.14	3.75e-05	0.00265	-0.17	-0.13	Height;	chr15:83717251	chr15:84507885~84516814:-
BRCA	cis	rs7572733	0.935	rs10198606	ENSG00000231621.1	AC013264.2	4.14	3.75e-05	0.00265	0.12	0.13	Dermatomyositis;	chr2:197905015	chr2:197197991~197199273:+
BRCA	cis	rs1008375	1	rs1006722	ENSG00000249502.1	AC006160.5	4.14	3.75e-05	0.00265	0.15	0.13	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17617090	chr4:17587467~17614571:-
BRCA	cis	rs4950322	0.518	rs61838938	ENSG00000244371.2	PFN1P8	-4.14	3.75e-05	0.00265	-0.16	-0.13	Protein quantitative trait loci;	chr1:147105943	chr1:146957117~146957659:-
BRCA	cis	rs4950322	0.529	rs11809327	ENSG00000244371.2	PFN1P8	-4.14	3.75e-05	0.00265	-0.16	-0.13	Protein quantitative trait loci;	chr1:147106679	chr1:146957117~146957659:-
BRCA	cis	rs4950322	0.563	rs11809328	ENSG00000244371.2	PFN1P8	-4.14	3.75e-05	0.00265	-0.16	-0.13	Protein quantitative trait loci;	chr1:147106681	chr1:146957117~146957659:-
BRCA	cis	rs71520386	0.632	rs10279864	ENSG00000226329.2	AC005682.6	-4.14	3.75e-05	0.00265	-0.13	-0.13	Fibrinogen levels;	chr7:22824205	chr7:22863874~22881350:-
BRCA	cis	rs71520386	0.632	rs10253651	ENSG00000226329.2	AC005682.6	-4.14	3.75e-05	0.00265	-0.13	-0.13	Fibrinogen levels;	chr7:22830564	chr7:22863874~22881350:-
BRCA	cis	rs7474896	0.507	rs2474555	ENSG00000263064.2	RP11-291L22.7	4.14	3.75e-05	0.00265	0.2	0.13	Obesity (extreme);	chr10:38176292	chr10:38448689~38448949:+
BRCA	cis	rs10170310	0.515	rs4954937	ENSG00000241772.2	AC092620.2	4.14	3.75e-05	0.00265	0.24	0.13	Response to antipsychotic treatment;	chr2:138573096	chr2:138569090~138574458:+
BRCA	cis	rs12744310	0.943	rs34862272	ENSG00000235358.1	RP11-399E6.1	4.14	3.75e-05	0.00265	0.19	0.13	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41302981	chr1:41242373~41284861:+
BRCA	cis	rs12744310	1	rs34796305	ENSG00000235358.1	RP11-399E6.1	4.14	3.75e-05	0.00265	0.19	0.13	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41303373	chr1:41242373~41284861:+
BRCA	cis	rs12744310	1	rs12032191	ENSG00000235358.1	RP11-399E6.1	4.14	3.75e-05	0.00265	0.19	0.13	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41303546	chr1:41242373~41284861:+
BRCA	cis	rs2229238	0.868	rs12408461	ENSG00000272030.1	RP1-178F15.4	-4.14	3.75e-05	0.00265	-0.18	-0.13	Coronary heart disease;	chr1:154540234	chr1:153631438~153634397:-
BRCA	cis	rs6847067	0.683	rs12640811	ENSG00000180769.7	WDFY3-AS2	4.14	3.75e-05	0.00265	0.12	0.13	Oropharynx cancer;	chr4:85011514	chr4:84965682~85011277:+
BRCA	cis	rs4499344	0.664	rs7258278	ENSG00000267475.1	CTD-2538C1.2	4.14	3.75e-05	0.00266	0.16	0.13	Mean platelet volume;	chr19:32608617	chr19:32687089~32691750:-
BRCA	cis	rs75422866	0.51	rs73105803	ENSG00000280054.1	RP1-197B17.7	4.14	3.75e-05	0.00266	0.3	0.13	Pneumonia;	chr12:47722135	chr12:47728151~47730598:-
BRCA	cis	rs75422866	0.51	rs73105812	ENSG00000280054.1	RP1-197B17.7	4.14	3.75e-05	0.00266	0.3	0.13	Pneumonia;	chr12:47724404	chr12:47728151~47730598:-
BRCA	cis	rs75422866	0.51	rs74733564	ENSG00000280054.1	RP1-197B17.7	4.14	3.75e-05	0.00266	0.3	0.13	Pneumonia;	chr12:47724644	chr12:47728151~47730598:-
BRCA	cis	rs75422866	0.51	rs73105814	ENSG00000280054.1	RP1-197B17.7	4.14	3.75e-05	0.00266	0.3	0.13	Pneumonia;	chr12:47725817	chr12:47728151~47730598:-
BRCA	cis	rs11096990	0.634	rs2086752	ENSG00000249685.1	RP11-360F5.3	-4.14	3.75e-05	0.00266	-0.15	-0.13	Cognitive function;	chr4:39280486	chr4:39133913~39135608:+
BRCA	cis	rs950776	0.714	rs514743	ENSG00000279373.1	RP11-650L12.4	-4.14	3.75e-05	0.00266	-0.16	-0.13	Sudden cardiac arrest;	chr15:78591885	chr15:78537681~78538946:+
BRCA	cis	rs2286503	1	rs17724311	ENSG00000226329.2	AC005682.6	4.14	3.75e-05	0.00266	0.12	0.13	Fibrinogen;	chr7:22837174	chr7:22863874~22881350:-
BRCA	cis	rs875971	0.964	rs6978429	ENSG00000229180.5	GS1-124K5.11	4.14	3.75e-05	0.00266	0.11	0.13	Aortic root size;	chr7:66494889	chr7:66526088~66542624:-
BRCA	cis	rs875971	1	rs4718357	ENSG00000229180.5	GS1-124K5.11	4.14	3.75e-05	0.00266	0.11	0.13	Aortic root size;	chr7:66495891	chr7:66526088~66542624:-
BRCA	cis	rs10043228	1	rs78362565	ENSG00000250015.1	CTC-339F2.2	4.14	3.76e-05	0.00266	0.17	0.13	Asthma or chronic obstructive pulmonary disease;	chr5:116228596	chr5:116302354~116304134:-
BRCA	cis	rs4578769	0.765	rs57308197	ENSG00000265939.1	UBE2CP2	-4.14	3.76e-05	0.00266	-0.16	-0.13	Eosinophil percentage of white cells;	chr18:22874272	chr18:22900486~22900995:-
BRCA	cis	rs12285276	0.673	rs12283175	ENSG00000205106.4	DKFZp779M0652	4.14	3.76e-05	0.00266	0.18	0.13	Visceral fat;	chr11:45781619	chr11:45771432~45772358:+
BRCA	cis	rs875971	1	rs778710	ENSG00000236529.1	RP13-254B10.1	4.14	3.76e-05	0.00266	0.14	0.13	Aortic root size;	chr7:66389847	chr7:65840212~65840596:+
BRCA	cis	rs721917	0.506	rs2758555	ENSG00000242600.5	MBL1P	4.14	3.76e-05	0.00266	0.16	0.13	Chronic obstructive pulmonary disease;	chr10:79931278	chr10:79904898~79950336:+
BRCA	cis	rs6870983	0.749	rs10074764	ENSG00000247828.6	TMEM161B-AS1	-4.14	3.76e-05	0.00266	-0.16	-0.13	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index;	chr5:88181931	chr5:88268895~88436685:+
BRCA	cis	rs7620503	1	rs34332266	ENSG00000277241.1	RP11-114M1.3	4.14	3.76e-05	0.00266	0.14	0.13	Corneal structure;	chr3:177581273	chr3:177700346~177701072:-
BRCA	cis	rs853679	0.517	rs4713141	ENSG00000216901.1	AL022393.7	4.14	3.76e-05	0.00266	0.18	0.13	Depression;	chr6:28133900	chr6:28176188~28176674:+
BRCA	cis	rs11096990	0.634	rs7654501	ENSG00000249685.1	RP11-360F5.3	-4.14	3.76e-05	0.00266	-0.15	-0.13	Cognitive function;	chr4:39282364	chr4:39133913~39135608:+
BRCA	cis	rs2304003	1	rs1560594	ENSG00000235192.1	AC009495.2	4.14	3.76e-05	0.00266	0.15	0.13	Social communication problems;	chr2:165843288	chr2:165794851~165810010:+
BRCA	cis	rs34217772	0.64	rs58373729	ENSG00000258636.1	CTD-2298J14.2	4.14	3.76e-05	0.00266	0.16	0.13	Myopia;	chr14:41729765	chr14:41587861~41604856:-
BRCA	cis	rs11018904	0.906	rs55685917	ENSG00000280367.1	RP11-121L10.2	4.14	3.76e-05	0.00266	0.2	0.13	Intelligence (multi-trait analysis);	chr11:90231197	chr11:90223153~90226538:+
BRCA	cis	rs11018904	0.906	rs35286339	ENSG00000280367.1	RP11-121L10.2	4.14	3.76e-05	0.00266	0.2	0.13	Intelligence (multi-trait analysis);	chr11:90232511	chr11:90223153~90226538:+
BRCA	cis	rs728616	0.867	rs61860034	ENSG00000242600.5	MBL1P	4.14	3.76e-05	0.00266	0.31	0.13	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80172092	chr10:79904898~79950336:+
BRCA	cis	rs11096990	0.634	rs745642	ENSG00000249685.1	RP11-360F5.3	-4.14	3.76e-05	0.00266	-0.15	-0.13	Cognitive function;	chr4:39279642	chr4:39133913~39135608:+
BRCA	cis	rs10761482	0.813	rs7087726	ENSG00000254271.1	RP11-131N11.4	4.14	3.76e-05	0.00266	0.18	0.13	Schizophrenia;	chr10:60402824	chr10:60734342~60741828:+
BRCA	cis	rs4948275	0.693	rs2606106	ENSG00000237233.2	TMEM26-AS1	-4.14	3.76e-05	0.00266	-0.15	-0.13	Night sleep phenotypes;	chr10:61584791	chr10:61452639~61481956:+
BRCA	cis	rs4948275	0.693	rs1598574	ENSG00000237233.2	TMEM26-AS1	-4.14	3.76e-05	0.00266	-0.15	-0.13	Night sleep phenotypes;	chr10:61584954	chr10:61452639~61481956:+
BRCA	cis	rs755249	0.567	rs41270821	ENSG00000182109.6	RP11-69E11.4	4.14	3.76e-05	0.00266	0.18	0.13	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39458060	chr1:39522280~39546187:-
BRCA	cis	rs755249	0.567	rs2296175	ENSG00000182109.6	RP11-69E11.4	4.14	3.76e-05	0.00266	0.18	0.13	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39458726	chr1:39522280~39546187:-
BRCA	cis	rs847649	0.692	rs7800548	ENSG00000239969.4	RP11-163E9.2	4.14	3.76e-05	0.00266	0.16	0.13	Morning vs. evening chronotype;	chr7:102841395	chr7:102364162~102380633:+
BRCA	cis	rs875971	0.895	rs4718349	ENSG00000229180.5	GS1-124K5.11	4.14	3.76e-05	0.00266	0.11	0.13	Aortic root size;	chr7:66444024	chr7:66526088~66542624:-
BRCA	cis	rs875971	1	rs2042133	ENSG00000229180.5	GS1-124K5.11	4.14	3.76e-05	0.00266	0.11	0.13	Aortic root size;	chr7:66466935	chr7:66526088~66542624:-
BRCA	cis	rs875971	0.964	rs2161065	ENSG00000229180.5	GS1-124K5.11	4.14	3.76e-05	0.00266	0.11	0.13	Aortic root size;	chr7:66467918	chr7:66526088~66542624:-
BRCA	cis	rs875971	0.862	rs12698521	ENSG00000229180.5	GS1-124K5.11	4.14	3.76e-05	0.00266	0.11	0.13	Aortic root size;	chr7:66474502	chr7:66526088~66542624:-
BRCA	cis	rs3176789	0.697	rs12422688	ENSG00000256673.1	RP11-599J14.2	4.14	3.76e-05	0.00266	0.14	0.13	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9767426	chr12:9398355~9414851:-
BRCA	cis	rs3176789	0.647	rs12422955	ENSG00000256673.1	RP11-599J14.2	4.14	3.76e-05	0.00266	0.14	0.13	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9767494	chr12:9398355~9414851:-
BRCA	cis	rs2839186	0.771	rs13049175	ENSG00000239415.1	AP001469.9	-4.14	3.76e-05	0.00266	-0.14	-0.13	Testicular germ cell tumor;	chr21:46221412	chr21:46251549~46254133:-
BRCA	cis	rs11018904	0.906	rs10501713	ENSG00000280367.1	RP11-121L10.2	4.14	3.76e-05	0.00266	0.21	0.13	Intelligence (multi-trait analysis);	chr11:90219845	chr11:90223153~90226538:+
BRCA	cis	rs7089973	0.932	rs17794346	ENSG00000236799.1	RP11-383C6.2	4.14	3.77e-05	0.00266	0.17	0.13	Bipolar disorder or attention deficit hyperactivity disorder;	chr10:114883336	chr10:114994657~114996593:+
BRCA	cis	rs17270561	0.666	rs1141034	ENSG00000272462.2	U91328.19	-4.14	3.77e-05	0.00266	-0.16	-0.13	Iron status biomarkers;	chr6:25780104	chr6:25992662~26001775:+
BRCA	cis	rs6071166	0.683	rs6015611	ENSG00000224635.1	RP4-564F22.5	-4.14	3.77e-05	0.00266	-0.15	-0.13	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38679658	chr20:38406011~38416797:-
BRCA	cis	rs4725617	0.584	rs7792781	ENSG00000229153.4	EPHA1-AS1	-4.14	3.77e-05	0.00267	-0.28	-0.13	Blood protein levels;	chr7:143409933	chr7:143407813~143523449:+
BRCA	cis	rs11671005	0.779	rs11670125	ENSG00000269600.1	AC016629.3	-4.14	3.77e-05	0.00267	-0.21	-0.13	Mean platelet volume;	chr19:58476023	chr19:58593896~58599355:-
BRCA	cis	rs6490294	0.799	rs73424286	ENSG00000234608.6	MAPKAPK5-AS1	4.14	3.77e-05	0.00267	0.15	0.13	Mean platelet volume;	chr12:111889338	chr12:111839764~111842902:-
BRCA	cis	rs6430585	0.527	rs1446586	ENSG00000224043.6	CCNT2-AS1	4.14	3.77e-05	0.00267	0.21	0.13	Corneal structure;	chr2:135649875	chr2:134735464~134918710:-
BRCA	cis	rs420259	0.636	rs34513	ENSG00000260136.4	CTD-2270L9.4	4.14	3.77e-05	0.00267	0.12	0.13	Bipolar disorder;	chr16:23660671	chr16:23452758~23457606:+
BRCA	cis	rs11098499	0.909	rs11723839	ENSG00000225892.3	RP11-384K6.2	4.14	3.77e-05	0.00267	0.13	0.13	Corneal astigmatism;	chr4:119378518	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.779	rs7699346	ENSG00000225892.3	RP11-384K6.2	4.14	3.77e-05	0.00267	0.13	0.13	Corneal astigmatism;	chr4:119389387	chr4:118632274~118634759:+
BRCA	cis	rs36051895	0.559	rs7868706	ENSG00000236254.1	MTND4P14	-4.14	3.77e-05	0.00267	-0.15	-0.13	Pediatric autoimmune diseases;	chr9:5210936	chr9:5107937~5109290:+
BRCA	cis	rs754466	0.58	rs10824571	ENSG00000213514.2	RP11-428P16.2	4.14	3.77e-05	0.00267	0.18	0.13	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77772173	chr10:77730766~77734769:+
BRCA	cis	rs1876905	0.68	rs395564	ENSG00000230177.1	RP5-1112D6.4	-4.14	3.77e-05	0.00267	-0.18	-0.13	Mean corpuscular hemoglobin;	chr6:111176176	chr6:111277932~111278742:+
BRCA	cis	rs4415084	0.716	rs2330619	ENSG00000251141.4	RP11-53O19.1	4.14	3.77e-05	0.00267	0.12	0.13	Breast cancer;	chr5:44795960	chr5:44744900~44808777:-
BRCA	cis	rs4415084	0.716	rs1438819	ENSG00000251141.4	RP11-53O19.1	4.14	3.77e-05	0.00267	0.12	0.13	Breast cancer;	chr5:44797744	chr5:44744900~44808777:-
BRCA	cis	rs9527	0.59	rs7898770	ENSG00000213061.2	PFN1P11	-4.14	3.77e-05	0.00267	-0.17	-0.13	Arsenic metabolism;	chr10:102996879	chr10:102838011~102845473:-
BRCA	cis	rs7520050	0.771	rs4660882	ENSG00000234329.1	RP11-767N6.2	4.14	3.77e-05	0.00267	0.12	0.13	Reticulocyte count;Red blood cell count;	chr1:45650620	chr1:45651039~45651826:-
BRCA	cis	rs2391285	0.609	rs2040944	ENSG00000214870.7	AC004540.5	4.14	3.77e-05	0.00267	0.19	0.13	Post bronchodilator FEV1/FVC ratio;	chr7:26557532	chr7:26398593~26494256:+
BRCA	cis	rs7520050	0.778	rs3013597	ENSG00000234329.1	RP11-767N6.2	4.14	3.77e-05	0.00267	0.12	0.13	Reticulocyte count;Red blood cell count;	chr1:45662684	chr1:45651039~45651826:-
BRCA	cis	rs4415084	0.716	rs6451774	ENSG00000251141.4	RP11-53O19.1	4.14	3.77e-05	0.00267	0.12	0.13	Breast cancer;	chr5:44793882	chr5:44744900~44808777:-
BRCA	cis	rs6840360	0.582	rs4696259	ENSG00000251603.1	RP11-164P12.4	-4.14	3.77e-05	0.00267	-0.12	-0.13	Intelligence (multi-trait analysis);	chr4:151389636	chr4:151667224~151670502:+
BRCA	cis	rs1538970	0.884	rs781232	ENSG00000281133.1	AL355480.3	4.14	3.78e-05	0.00267	0.17	0.13	Platelet count;	chr1:45424727	chr1:45580892~45580996:-
BRCA	cis	rs11977670	0.583	rs17161443	ENSG00000260231.1	JHDM1D-AS1	-4.14	3.78e-05	0.00267	-0.14	-0.13	Breast cancer;	chr7:140239403	chr7:140177261~140179640:+
BRCA	cis	rs6738028	0.504	rs11123406	ENSG00000227992.1	AC108463.2	4.14	3.78e-05	0.00267	0.15	0.13	Dehydroepiandrosterone sulphate levels;	chr2:111192964	chr2:111203964~111206215:-
BRCA	cis	rs875971	1	rs10215948	ENSG00000229180.5	GS1-124K5.11	-4.14	3.78e-05	0.00267	-0.11	-0.13	Aortic root size;	chr7:66282799	chr7:66526088~66542624:-
BRCA	cis	rs11158026	0.603	rs3783646	ENSG00000233924.1	AL160471.6	-4.14	3.78e-05	0.00267	-0.15	-0.13	Parkinson's disease;	chr14:55005169	chr14:55004813~55005687:-
BRCA	cis	rs7475343	0.538	rs1761603	ENSG00000224034.1	RP11-445P17.8	4.14	3.78e-05	0.00267	0.24	0.13	Intelligence;	chr10:5157010	chr10:5266033~5271236:-
BRCA	cis	rs4561483	0.801	rs40311	ENSG00000261216.1	RP11-166B2.5	4.14	3.78e-05	0.00267	0.15	0.13	Testicular germ cell tumor;	chr16:11869333	chr16:11908208~11908916:+
BRCA	cis	rs1048886	0.938	rs55968813	ENSG00000271967.1	RP11-134K13.4	-4.14	3.78e-05	0.00267	-0.18	-0.13	Type 2 diabetes;	chr6:70514521	chr6:70596438~70596980:+
BRCA	cis	rs11098499	0.954	rs59866101	ENSG00000225892.3	RP11-384K6.2	4.14	3.78e-05	0.00267	0.13	0.13	Corneal astigmatism;	chr4:119375436	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.618	rs6858383	ENSG00000225892.3	RP11-384K6.2	4.14	3.78e-05	0.00267	0.13	0.13	Corneal astigmatism;	chr4:119375617	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.697	rs6832410	ENSG00000225892.3	RP11-384K6.2	4.14	3.78e-05	0.00267	0.13	0.13	Corneal astigmatism;	chr4:119375645	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.865	rs1112817	ENSG00000225892.3	RP11-384K6.2	4.14	3.78e-05	0.00267	0.13	0.13	Corneal astigmatism;	chr4:119376645	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.779	rs10016060	ENSG00000225892.3	RP11-384K6.2	4.14	3.78e-05	0.00267	0.13	0.13	Corneal astigmatism;	chr4:119377257	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.954	rs10005644	ENSG00000225892.3	RP11-384K6.2	4.14	3.78e-05	0.00267	0.13	0.13	Corneal astigmatism;	chr4:119377322	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.697	rs10016448	ENSG00000225892.3	RP11-384K6.2	4.14	3.78e-05	0.00267	0.13	0.13	Corneal astigmatism;	chr4:119377690	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.657	rs9996569	ENSG00000225892.3	RP11-384K6.2	4.14	3.78e-05	0.00267	0.13	0.13	Corneal astigmatism;	chr4:119377849	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.908	rs11729050	ENSG00000225892.3	RP11-384K6.2	4.14	3.78e-05	0.00267	0.13	0.13	Corneal astigmatism;	chr4:119378911	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.954	rs28429722	ENSG00000225892.3	RP11-384K6.2	4.14	3.78e-05	0.00267	0.13	0.13	Corneal astigmatism;	chr4:119378938	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.954	rs10014845	ENSG00000225892.3	RP11-384K6.2	4.14	3.78e-05	0.00267	0.13	0.13	Corneal astigmatism;	chr4:119379922	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.779	rs7674500	ENSG00000225892.3	RP11-384K6.2	4.14	3.78e-05	0.00267	0.13	0.13	Corneal astigmatism;	chr4:119382438	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.909	rs28884220	ENSG00000225892.3	RP11-384K6.2	4.14	3.78e-05	0.00267	0.13	0.13	Corneal astigmatism;	chr4:119386056	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.909	rs28793658	ENSG00000225892.3	RP11-384K6.2	4.14	3.78e-05	0.00267	0.13	0.13	Corneal astigmatism;	chr4:119386059	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.697	rs4373140	ENSG00000225892.3	RP11-384K6.2	4.14	3.78e-05	0.00267	0.13	0.13	Corneal astigmatism;	chr4:119386543	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.954	rs13113483	ENSG00000225892.3	RP11-384K6.2	4.14	3.78e-05	0.00267	0.13	0.13	Corneal astigmatism;	chr4:119387884	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.542	rs10440343	ENSG00000225892.3	RP11-384K6.2	4.14	3.78e-05	0.00267	0.13	0.13	Corneal astigmatism;	chr4:119388632	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.779	rs10011097	ENSG00000225892.3	RP11-384K6.2	4.14	3.78e-05	0.00267	0.13	0.13	Corneal astigmatism;	chr4:119389204	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.542	rs7677836	ENSG00000225892.3	RP11-384K6.2	4.14	3.78e-05	0.00267	0.13	0.13	Corneal astigmatism;	chr4:119389483	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.909	rs10002083	ENSG00000225892.3	RP11-384K6.2	4.14	3.78e-05	0.00267	0.13	0.13	Corneal astigmatism;	chr4:119389997	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.954	rs10024844	ENSG00000225892.3	RP11-384K6.2	4.14	3.78e-05	0.00267	0.13	0.13	Corneal astigmatism;	chr4:119390373	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.954	rs4345162	ENSG00000225892.3	RP11-384K6.2	4.14	3.78e-05	0.00267	0.13	0.13	Corneal astigmatism;	chr4:119391804	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.657	rs4463052	ENSG00000225892.3	RP11-384K6.2	4.14	3.78e-05	0.00267	0.13	0.13	Corneal astigmatism;	chr4:119392103	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.954	rs13151285	ENSG00000225892.3	RP11-384K6.2	4.14	3.78e-05	0.00267	0.13	0.13	Corneal astigmatism;	chr4:119393586	chr4:118632274~118634759:+
BRCA	cis	rs11096990	0.634	rs6531704	ENSG00000249685.1	RP11-360F5.3	-4.14	3.78e-05	0.00267	-0.15	-0.13	Cognitive function;	chr4:39282126	chr4:39133913~39135608:+
BRCA	cis	rs875971	0.545	rs75840613	ENSG00000273142.1	RP11-458F8.4	4.14	3.78e-05	0.00267	0.13	0.13	Aortic root size;	chr7:66376399	chr7:66902857~66906297:+
BRCA	cis	rs60843830	1	rs59937473	ENSG00000272342.1	RP13-539J13.1	4.14	3.78e-05	0.00267	0.16	0.13	Spherical equivalent (joint analysis main effects and education interaction);	chr2:271797	chr2:739588~740164:-
BRCA	cis	rs7141336	0.8	rs1570114	ENSG00000258884.1	CTD-3035D6.2	4.14	3.78e-05	0.00267	0.17	0.13	Anxiety disorder;	chr14:90821190	chr14:90822365~90828128:-
BRCA	cis	rs875971	0.895	rs10755833	ENSG00000229180.5	GS1-124K5.11	4.14	3.78e-05	0.00267	0.11	0.13	Aortic root size;	chr7:66448930	chr7:66526088~66542624:-
BRCA	cis	rs875971	0.895	rs1833495	ENSG00000229180.5	GS1-124K5.11	4.14	3.78e-05	0.00267	0.11	0.13	Aortic root size;	chr7:66456608	chr7:66526088~66542624:-
BRCA	cis	rs875971	0.964	rs6945032	ENSG00000229180.5	GS1-124K5.11	4.14	3.78e-05	0.00267	0.11	0.13	Aortic root size;	chr7:66457499	chr7:66526088~66542624:-
BRCA	cis	rs875971	0.929	rs12673810	ENSG00000229180.5	GS1-124K5.11	4.14	3.78e-05	0.00267	0.11	0.13	Aortic root size;	chr7:66458866	chr7:66526088~66542624:-
BRCA	cis	rs875971	1	rs6961155	ENSG00000229180.5	GS1-124K5.11	4.14	3.78e-05	0.00267	0.11	0.13	Aortic root size;	chr7:66468308	chr7:66526088~66542624:-
BRCA	cis	rs875971	1	rs7789768	ENSG00000229180.5	GS1-124K5.11	4.14	3.78e-05	0.00267	0.11	0.13	Aortic root size;	chr7:66473993	chr7:66526088~66542624:-
BRCA	cis	rs875971	1	rs1363055	ENSG00000229180.5	GS1-124K5.11	4.14	3.78e-05	0.00267	0.11	0.13	Aortic root size;	chr7:66478288	chr7:66526088~66542624:-
BRCA	cis	rs875971	0.964	rs9691480	ENSG00000229180.5	GS1-124K5.11	4.14	3.78e-05	0.00267	0.11	0.13	Aortic root size;	chr7:66479319	chr7:66526088~66542624:-
BRCA	cis	rs11096990	0.594	rs2381373	ENSG00000249685.1	RP11-360F5.3	-4.14	3.78e-05	0.00267	-0.15	-0.13	Cognitive function;	chr4:39280683	chr4:39133913~39135608:+
BRCA	cis	rs6088590	0.561	rs6059918	ENSG00000275784.1	RP5-1125A11.6	-4.14	3.78e-05	0.00267	-0.14	-0.13	Coronary artery disease;	chr20:34562699	chr20:33989480~33991818:-
BRCA	cis	rs2835345	0.528	rs12483650	ENSG00000233818.1	AP000695.4	4.14	3.78e-05	0.00267	0.13	0.13	Pulmonary function;	chr21:36450778	chr21:36445731~36532408:+
BRCA	cis	rs2835345	0.563	rs12483621	ENSG00000233818.1	AP000695.4	4.14	3.78e-05	0.00267	0.13	0.13	Pulmonary function;	chr21:36450798	chr21:36445731~36532408:+
BRCA	cis	rs67981189	0.593	rs12896829	ENSG00000258571.1	PTTG4P	-4.14	3.78e-05	0.00267	-0.13	-0.13	Schizophrenia;	chr14:70996959	chr14:71085482~71085833:-
BRCA	cis	rs11098499	1	rs10029750	ENSG00000250412.1	KLHL2P1	4.14	3.78e-05	0.00267	0.15	0.13	Corneal astigmatism;	chr4:119251388	chr4:119334329~119378233:+
BRCA	cis	rs62458065	0.513	rs7805536	ENSG00000229358.3	DPY19L1P1	-4.14	3.78e-05	0.00267	-0.17	-0.13	Metabolite levels (HVA/MHPG ratio);	chr7:32533958	chr7:32580949~32761787:-
BRCA	cis	rs62458065	0.513	rs10268149	ENSG00000229358.3	DPY19L1P1	-4.14	3.78e-05	0.00267	-0.17	-0.13	Metabolite levels (HVA/MHPG ratio);	chr7:32535887	chr7:32580949~32761787:-
BRCA	cis	rs10487112	0.833	rs2374267	ENSG00000235436.9	DPY19L2P4	-4.14	3.78e-05	0.00268	-0.14	-0.13	Perceived unattractiveness to mosquitoes;	chr7:90505255	chr7:90119400~90125600:+
BRCA	cis	rs6480314	0.522	rs10740294	ENSG00000233590.1	RP11-153K11.3	4.14	3.78e-05	0.00268	0.19	0.13	Optic nerve measurement (disc area);	chr10:68301595	chr10:68233251~68242379:-
BRCA	cis	rs12428035	0.656	rs1854758	ENSG00000247400.3	DNAJC3-AS1	4.14	3.79e-05	0.00268	0.2	0.13	Glomerular filtration rate (cystatin C);Response to statins (LDL cholesterol change);	chr13:95889295	chr13:95648733~95676925:-
BRCA	cis	rs6430585	0.527	rs12467569	ENSG00000224043.6	CCNT2-AS1	-4.14	3.79e-05	0.00268	-0.21	-0.13	Corneal structure;	chr2:135656277	chr2:134735464~134918710:-
BRCA	cis	rs61160187	0.582	rs12654306	ENSG00000272308.1	RP11-231G3.1	-4.14	3.79e-05	0.00268	-0.14	-0.13	Educational attainment (years of education);Educational attainment (college completion);	chr5:60889029	chr5:60866457~60866935:-
BRCA	cis	rs897984	0.52	rs4889622	ENSG00000274678.1	RP11-2C24.7	-4.14	3.79e-05	0.00268	-0.16	-0.13	Dementia with Lewy bodies;	chr16:30859636	chr16:30821338~30821884:+
BRCA	cis	rs6671200	1	rs259346	ENSG00000226026.4	RP11-57H12.3	4.14	3.79e-05	0.00268	0.24	0.13	Stearic acid (18:0) levels;	chr1:95263190	chr1:95163219~95233982:-
BRCA	cis	rs3858526	0.917	rs9284148	ENSG00000224295.2	AC087380.14	4.14	3.79e-05	0.00268	0.18	0.13	DNA methylation (variation);	chr11:5951955	chr11:5518441~5524955:-
BRCA	cis	rs13401620	0.843	rs6738565	ENSG00000229326.3	AC069154.4	-4.14	3.79e-05	0.00268	-0.16	-0.13	Breast size;	chr2:119853484	chr2:119698623~119700151:+
BRCA	cis	rs10129255	0.536	rs17113249	ENSG00000211959.2	IGHV4-39	4.14	3.79e-05	0.00268	0.09	0.13	Kawasaki disease;	chr14:106678273	chr14:106421711~106422218:-
BRCA	cis	rs10457838	0.783	rs2879862	ENSG00000236591.1	RP11-162J8.3	-4.14	3.79e-05	0.00268	-0.17	-0.13	Post-traumatic stress disorder;	chr6:149068617	chr6:149027700~149032573:-
BRCA	cis	rs4787491	0.729	rs3814878	ENSG00000183604.13	SMG1P5	-4.14	3.79e-05	0.00268	-0.12	-0.13	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30030645	chr16:30267553~30335374:-
BRCA	cis	rs8040855	0.599	rs8037195	ENSG00000259762.1	RP11-158M2.4	-4.14	3.79e-05	0.00268	-0.15	-0.13	Bulimia nervosa;	chr15:85181455	chr15:85750336~85752901:-
BRCA	cis	rs9402743	0.634	rs66513771	ENSG00000234084.1	RP3-388E23.2	-4.14	3.79e-05	0.00268	-0.13	-0.13	Systemic lupus erythematosus;	chr6:135603885	chr6:135301568~135307158:+
BRCA	cis	rs9402743	0.634	rs7774974	ENSG00000234084.1	RP3-388E23.2	-4.14	3.79e-05	0.00268	-0.13	-0.13	Systemic lupus erythematosus;	chr6:135604248	chr6:135301568~135307158:+
BRCA	cis	rs6928977	0.538	rs6570019	ENSG00000234084.1	RP3-388E23.2	-4.14	3.79e-05	0.00268	-0.13	-0.13	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135604595	chr6:135301568~135307158:+
BRCA	cis	rs9402743	0.564	rs6570020	ENSG00000234084.1	RP3-388E23.2	-4.14	3.79e-05	0.00268	-0.13	-0.13	Systemic lupus erythematosus;	chr6:135604607	chr6:135301568~135307158:+
BRCA	cis	rs739496	0.579	rs2879603	ENSG00000257624.1	RP1-128M12.3	4.14	3.79e-05	0.00268	0.17	0.13	Platelet count;	chr12:111840221	chr12:112000739~112000985:-
BRCA	cis	rs11098499	0.954	rs10518328	ENSG00000260404.2	RP11-384K6.6	4.14	3.79e-05	0.00268	0.12	0.13	Corneal astigmatism;	chr4:119480624	chr4:118591773~118633729:+
BRCA	cis	rs2836974	0.604	rs2854727	ENSG00000255568.3	BRWD1-AS2	4.14	3.79e-05	0.00268	0.12	0.13	Cognitive function;	chr21:39341861	chr21:39313935~39314962:+
BRCA	cis	rs11098499	0.739	rs2203039	ENSG00000260404.2	RP11-384K6.6	-4.14	3.79e-05	0.00268	-0.12	-0.13	Corneal astigmatism;	chr4:119211192	chr4:118591773~118633729:+
BRCA	cis	rs7267979	0.966	rs2261698	ENSG00000274973.1	RP13-401N8.7	-4.14	3.8e-05	0.00268	-0.15	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25279274	chr20:25845497~25845862:+
BRCA	cis	rs61160187	0.61	rs4700399	ENSG00000272308.1	RP11-231G3.1	-4.14	3.8e-05	0.00268	-0.15	-0.13	Educational attainment (years of education);Educational attainment (college completion);	chr5:60840627	chr5:60866457~60866935:-
BRCA	cis	rs1559040	0.79	rs11687470	ENSG00000272156.1	RP11-477N3.1	-4.14	3.8e-05	0.00268	-0.24	-0.13	Sudden cardiac arrest;	chr2:54009666	chr2:54082554~54085066:+
BRCA	cis	rs11098499	0.954	rs3733524	ENSG00000260091.1	RP11-33B1.4	-4.14	3.8e-05	0.00268	-0.12	-0.13	Corneal astigmatism;	chr4:119502574	chr4:119409333~119410233:+
BRCA	cis	rs10129255	0.5	rs59939897	ENSG00000211967.3	IGHV3-53	-4.14	3.8e-05	0.00268	-0.08	-0.13	Kawasaki disease;	chr14:106783414	chr14:106592676~106593347:-
BRCA	cis	rs11673344	0.504	rs7258360	ENSG00000226686.6	LINC01535	4.14	3.8e-05	0.00268	0.16	0.13	Obesity-related traits;	chr19:37115015	chr19:37251912~37265535:+
BRCA	cis	rs2274459	0.841	rs13204162	ENSG00000249346.5	LINC01016	4.14	3.8e-05	0.00268	0.16	0.13	Obesity (extreme);	chr6:33728354	chr6:33867506~33896914:-
BRCA	cis	rs853679	0.513	rs9468296	ENSG00000216901.1	AL022393.7	4.14	3.8e-05	0.00268	0.18	0.13	Depression;	chr6:28145952	chr6:28176188~28176674:+
BRCA	cis	rs7819412	0.505	rs17782554	ENSG00000154316.13	TDH	4.14	3.8e-05	0.00269	0.17	0.13	Triglycerides;	chr8:11164596	chr8:11339637~11368452:+
BRCA	cis	rs7267979	0.764	rs2474767	ENSG00000231081.1	RP4-760C5.3	-4.14	3.8e-05	0.00269	-0.16	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25266097	chr20:26008791~26010531:-
BRCA	cis	rs6012564	1	rs6066968	ENSG00000222365.1	SNORD12B	4.14	3.8e-05	0.00269	0.13	0.13	Anger;	chr20:49110804	chr20:49280319~49280409:+
BRCA	cis	rs860295	0.812	rs12407800	ENSG00000160766.13	GBAP1	-4.14	3.8e-05	0.00269	-0.13	-0.13	Body mass index;	chr1:155790951	chr1:155213821~155227422:-
BRCA	cis	rs256438	0.731	rs9293800	ENSG00000251050.1	RP11-168A11.4	-4.14	3.8e-05	0.00269	-0.15	-0.13	Serum thyroid-stimulating hormone levels;	chr5:80067450	chr5:80019609~80019920:+
BRCA	cis	rs6012564	0.793	rs6125552	ENSG00000222365.1	SNORD12B	4.14	3.8e-05	0.00269	0.13	0.13	Anger;	chr20:49107788	chr20:49280319~49280409:+
BRCA	cis	rs7618915	1	rs7618915	ENSG00000239557.1	RP11-168J18.6	4.14	3.8e-05	0.00269	0.17	0.13	Bipolar disorder;	chr3:52245578	chr3:52373652~52374882:+
BRCA	cis	rs11048434	0.518	rs7136274	ENSG00000111788.10	RP11-22B23.1	-4.14	3.8e-05	0.00269	-0.12	-0.13	Sjögren's syndrome;	chr12:9022360	chr12:9277235~9313241:+
BRCA	cis	rs11098499	0.865	rs28753180	ENSG00000260404.2	RP11-384K6.6	4.14	3.8e-05	0.00269	0.12	0.13	Corneal astigmatism;	chr4:119484212	chr4:118591773~118633729:+
BRCA	cis	rs7267979	1	rs2500443	ENSG00000276952.1	RP5-965G21.6	-4.14	3.8e-05	0.00269	-0.16	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25350806	chr20:25284915~25285588:-
BRCA	cis	rs67981189	0.593	rs221924	ENSG00000258571.1	PTTG4P	4.14	3.8e-05	0.00269	0.14	0.13	Schizophrenia;	chr14:71114061	chr14:71085482~71085833:-
BRCA	cis	rs721917	0.506	rs1923538	ENSG00000242600.5	MBL1P	4.14	3.8e-05	0.00269	0.16	0.13	Chronic obstructive pulmonary disease;	chr10:79935276	chr10:79904898~79950336:+
BRCA	cis	rs875971	0.638	rs6960778	ENSG00000229180.5	GS1-124K5.11	-4.14	3.8e-05	0.00269	-0.11	-0.13	Aortic root size;	chr7:66606610	chr7:66526088~66542624:-
BRCA	cis	rs9470794	1	rs9462395	ENSG00000204110.6	RP1-153P14.8	-4.14	3.8e-05	0.00269	-0.2	-0.13	Type 2 diabetes;	chr6:38159710	chr6:37507348~37535616:+
BRCA	cis	rs11098499	0.863	rs3775854	ENSG00000250412.1	KLHL2P1	4.14	3.81e-05	0.00269	0.15	0.13	Corneal astigmatism;	chr4:119550816	chr4:119334329~119378233:+
BRCA	cis	rs11098499	0.863	rs6853998	ENSG00000250412.1	KLHL2P1	4.14	3.81e-05	0.00269	0.15	0.13	Corneal astigmatism;	chr4:119554705	chr4:119334329~119378233:+
BRCA	cis	rs11098499	0.863	rs6858777	ENSG00000250412.1	KLHL2P1	4.14	3.81e-05	0.00269	0.15	0.13	Corneal astigmatism;	chr4:119554811	chr4:119334329~119378233:+
BRCA	cis	rs11098499	0.863	rs11731756	ENSG00000250412.1	KLHL2P1	4.14	3.81e-05	0.00269	0.15	0.13	Corneal astigmatism;	chr4:119557541	chr4:119334329~119378233:+
BRCA	cis	rs11098499	0.863	rs34308924	ENSG00000250412.1	KLHL2P1	4.14	3.81e-05	0.00269	0.15	0.13	Corneal astigmatism;	chr4:119560276	chr4:119334329~119378233:+
BRCA	cis	rs11098499	0.863	rs2170276	ENSG00000250412.1	KLHL2P1	4.14	3.81e-05	0.00269	0.15	0.13	Corneal astigmatism;	chr4:119564669	chr4:119334329~119378233:+
BRCA	cis	rs3764021	0.87	rs10772085	ENSG00000256582.1	RP11-75L1.1	4.14	3.81e-05	0.00269	0.13	0.13	Type 1 diabetes;	chr12:9724281	chr12:9704077~9709350:+
BRCA	cis	rs3812762	0.871	rs11603335	ENSG00000254860.4	TMEM9B-AS1	-4.14	3.81e-05	0.00269	-0.12	-0.13	Hypospadias;	chr11:8788297	chr11:8964675~8977527:+
BRCA	cis	rs72482608	0.835	rs7528424	ENSG00000271811.1	RP1-79C4.4	4.14	3.81e-05	0.00269	0.14	0.13	Emphysema imaging phenotypes;	chr1:170747319	chr1:170667381~170669425:+
BRCA	cis	rs11098499	0.789	rs10212719	ENSG00000225892.3	RP11-384K6.2	4.14	3.81e-05	0.00269	0.12	0.13	Corneal astigmatism;	chr4:119333282	chr4:118632274~118634759:+
BRCA	cis	rs801193	1	rs11773829	ENSG00000223473.2	GS1-124K5.3	-4.14	3.81e-05	0.00269	-0.1	-0.13	Aortic root size;	chr7:66676087	chr7:66491049~66493566:-
BRCA	cis	rs11096990	0.634	rs17431358	ENSG00000249685.1	RP11-360F5.3	-4.14	3.81e-05	0.00269	-0.15	-0.13	Cognitive function;	chr4:39275676	chr4:39133913~39135608:+
BRCA	cis	rs3176789	0.624	rs12427301	ENSG00000256673.1	RP11-599J14.2	4.14	3.81e-05	0.00269	0.14	0.13	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9767695	chr12:9398355~9414851:-
BRCA	cis	rs11098499	0.863	rs3736115	ENSG00000250412.1	KLHL2P1	-4.14	3.81e-05	0.00269	-0.15	-0.13	Corneal astigmatism;	chr4:119567548	chr4:119334329~119378233:+
BRCA	cis	rs321358	1	rs429803	ENSG00000271390.1	RP11-89C3.3	4.14	3.81e-05	0.00269	0.21	0.13	Body mass index;	chr11:111132263	chr11:111089870~111090368:-
BRCA	cis	rs7475343	0.573	rs61854731	ENSG00000224034.1	RP11-445P17.8	-4.14	3.81e-05	0.00269	-0.25	-0.13	Intelligence;	chr10:5192198	chr10:5266033~5271236:-
BRCA	cis	rs2439831	0.702	rs2467402	ENSG00000206991.1	RNU6-610P	4.14	3.81e-05	0.00269	0.19	0.13	Lung cancer in ever smokers;	chr15:43732292	chr15:43637632~43637738:-
BRCA	cis	rs7811142	1	rs11773661	ENSG00000078319.8	PMS2P1	-4.14	3.81e-05	0.00269	-0.2	-0.13	Platelet count;	chr7:100475446	chr7:100320992~100341908:-
BRCA	cis	rs4650943	0.565	rs352313	ENSG00000227740.1	RP11-318C24.2	-4.14	3.81e-05	0.00269	-0.13	-0.13	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in inactive individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr1:176266920	chr1:175904762~175920513:-
BRCA	cis	rs1348850	0.626	rs1901825	ENSG00000280374.1	RP11-337N6.3	4.14	3.81e-05	0.00269	0.16	0.13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177360603	chr2:177317715~177318471:-
BRCA	cis	rs698833	0.501	rs12473699	ENSG00000223658.6	AC011242.6	4.14	3.81e-05	0.00269	0.15	0.13	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr2:44280534	chr2:43675380~43676322:-
BRCA	cis	rs13358904	0.868	rs34819608	ENSG00000278921.2	EPB41L4A-AS2	4.14	3.82e-05	0.0027	0.15	0.13	Suicide ideation score in major depressive disorder;	chr5:112254712	chr5:112419583~112420978:+
BRCA	cis	rs755249	0.51	rs599892	ENSG00000237624.1	OXCT2P1	4.14	3.82e-05	0.0027	0.16	0.13	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39457212	chr1:39514956~39516490:+
BRCA	cis	rs7177699	0.557	rs12898712	ENSG00000261143.1	ADAMTS7P3	-4.14	3.82e-05	0.0027	-0.15	-0.13	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78820280	chr15:77976042~77993057:+
BRCA	cis	rs7177699	0.557	rs12898452	ENSG00000261143.1	ADAMTS7P3	-4.14	3.82e-05	0.0027	-0.15	-0.13	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78820286	chr15:77976042~77993057:+
BRCA	cis	rs2749592	0.55	rs10764135	ENSG00000099251.13	HSD17B7P2	-4.14	3.82e-05	0.0027	-0.14	-0.13	Age-related hearing impairment (SNP x SNP interaction);	chr10:37577917	chr10:38356380~38378505:+
BRCA	cis	rs853679	0.517	rs1947863	ENSG00000216901.1	AL022393.7	4.14	3.82e-05	0.0027	0.18	0.13	Depression;	chr6:28131566	chr6:28176188~28176674:+
BRCA	cis	rs7208859	0.673	rs9889755	ENSG00000266490.1	CTD-2349P21.9	-4.14	3.82e-05	0.0027	-0.17	-0.13	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30907487	chr17:30792372~30792833:+
BRCA	cis	rs7209700	0.6	rs7218632	ENSG00000228782.6	CTD-2026D20.3	-4.14	3.82e-05	0.0027	-0.15	-0.13	IgG glycosylation;	chr17:47287787	chr17:47450568~47492492:-
BRCA	cis	rs6012564	1	rs911411	ENSG00000222365.1	SNORD12B	4.14	3.82e-05	0.0027	0.13	0.13	Anger;	chr20:49101894	chr20:49280319~49280409:+
BRCA	cis	rs6012564	1	rs6063352	ENSG00000222365.1	SNORD12B	4.14	3.82e-05	0.0027	0.13	0.13	Anger;	chr20:49102057	chr20:49280319~49280409:+
BRCA	cis	rs6012564	1	rs6063353	ENSG00000222365.1	SNORD12B	4.14	3.82e-05	0.0027	0.13	0.13	Anger;	chr20:49103273	chr20:49280319~49280409:+
BRCA	cis	rs6012564	1	rs6063354	ENSG00000222365.1	SNORD12B	4.14	3.82e-05	0.0027	0.13	0.13	Anger;	chr20:49103412	chr20:49280319~49280409:+
BRCA	cis	rs829883	0.898	rs249834	ENSG00000227825.4	SLC9A7P1	-4.14	3.82e-05	0.0027	-0.16	-0.13	Colorectal adenoma (advanced);	chr12:98433766	chr12:98453835~98457145:-
BRCA	cis	rs11098499	0.909	rs28668716	ENSG00000225892.3	RP11-384K6.2	4.14	3.82e-05	0.0027	0.13	0.13	Corneal astigmatism;	chr4:119388720	chr4:118632274~118634759:+
BRCA	cis	rs2108622	0.727	rs3093193	ENSG00000214049.6	UCA1	4.14	3.82e-05	0.0027	0.18	0.13	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15881104	chr19:15828961~15836320:+
BRCA	cis	rs2832191	1	rs8131214	ENSG00000236056.1	GAPDHP14	4.14	3.82e-05	0.0027	0.14	0.13	Dental caries;	chr21:29111065	chr21:29222321~29223257:+
BRCA	cis	rs17684571	0.751	rs10498813	ENSG00000231441.1	RP11-472M19.2	4.14	3.82e-05	0.0027	0.2	0.13	Schizophrenia;	chr6:56819921	chr6:56844002~56864078:+
BRCA	cis	rs748404	0.666	rs36078097	ENSG00000205771.5	CATSPER2P1	-4.14	3.82e-05	0.0027	-0.19	-0.13	Lung cancer;	chr15:43466209	chr15:43726918~43747094:-
BRCA	cis	rs748404	0.666	rs7181783	ENSG00000205771.5	CATSPER2P1	-4.14	3.82e-05	0.0027	-0.19	-0.13	Lung cancer;	chr15:43469723	chr15:43726918~43747094:-
BRCA	cis	rs748404	0.666	rs35903301	ENSG00000205771.5	CATSPER2P1	-4.14	3.82e-05	0.0027	-0.19	-0.13	Lung cancer;	chr15:43472332	chr15:43726918~43747094:-
BRCA	cis	rs748404	0.666	rs34002293	ENSG00000205771.5	CATSPER2P1	-4.14	3.82e-05	0.0027	-0.19	-0.13	Lung cancer;	chr15:43472401	chr15:43726918~43747094:-
BRCA	cis	rs748404	0.666	rs34181131	ENSG00000205771.5	CATSPER2P1	-4.14	3.82e-05	0.0027	-0.19	-0.13	Lung cancer;	chr15:43478527	chr15:43726918~43747094:-
BRCA	cis	rs748404	0.666	rs7173383	ENSG00000205771.5	CATSPER2P1	-4.14	3.82e-05	0.0027	-0.19	-0.13	Lung cancer;	chr15:43480838	chr15:43726918~43747094:-
BRCA	cis	rs748404	0.666	rs55801120	ENSG00000205771.5	CATSPER2P1	-4.14	3.82e-05	0.0027	-0.19	-0.13	Lung cancer;	chr15:43495042	chr15:43726918~43747094:-
BRCA	cis	rs748404	0.666	rs12911740	ENSG00000205771.5	CATSPER2P1	-4.14	3.82e-05	0.0027	-0.19	-0.13	Lung cancer;	chr15:43498254	chr15:43726918~43747094:-
BRCA	cis	rs11098499	0.863	rs3822195	ENSG00000250412.1	KLHL2P1	4.14	3.82e-05	0.0027	0.15	0.13	Corneal astigmatism;	chr4:119550505	chr4:119334329~119378233:+
BRCA	cis	rs5758511	0.633	rs5758689	ENSG00000226450.2	CYP2D8P	4.14	3.82e-05	0.0027	0.15	0.13	Birth weight;	chr22:42268966	chr22:42149886~42155001:-
BRCA	cis	rs4835473	0.932	rs35017645	ENSG00000249741.2	RP11-673E1.3	4.14	3.82e-05	0.0027	0.14	0.13	Immature fraction of reticulocytes;	chr4:143760196	chr4:143911514~143912053:-
BRCA	cis	rs875971	1	rs12532998	ENSG00000229180.5	GS1-124K5.11	4.14	3.82e-05	0.0027	0.11	0.13	Aortic root size;	chr7:66502472	chr7:66526088~66542624:-
BRCA	cis	rs1865760	0.519	rs2275904	ENSG00000272462.2	U91328.19	-4.14	3.82e-05	0.0027	-0.16	-0.13	Height;	chr6:25767857	chr6:25992662~26001775:+
BRCA	cis	rs1048886	0.872	rs6942012	ENSG00000271967.1	RP11-134K13.4	-4.14	3.82e-05	0.0027	-0.17	-0.13	Type 2 diabetes;	chr6:70543769	chr6:70596438~70596980:+
BRCA	cis	rs17489649	0.915	rs759809	ENSG00000271849.1	CTC-332L22.1	4.14	3.83e-05	0.0027	0.16	0.13	Intelligence (multi-trait analysis);	chr5:109830083	chr5:109687802~109688329:-
BRCA	cis	rs9818758	0.607	rs3923475	ENSG00000225399.4	RP11-3B7.1	-4.14	3.83e-05	0.0027	-0.23	-0.13	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49018355	chr3:49260085~49261316:+
BRCA	cis	rs9818758	0.607	rs11706052	ENSG00000225399.4	RP11-3B7.1	-4.14	3.83e-05	0.0027	-0.23	-0.13	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49026677	chr3:49260085~49261316:+
BRCA	cis	rs11719291	0.584	rs13080725	ENSG00000225399.4	RP11-3B7.1	-4.14	3.83e-05	0.0027	-0.23	-0.13	Cognitive function;	chr3:49038659	chr3:49260085~49261316:+
BRCA	cis	rs9818758	0.607	rs35108630	ENSG00000225399.4	RP11-3B7.1	-4.14	3.83e-05	0.0027	-0.23	-0.13	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49050923	chr3:49260085~49261316:+
BRCA	cis	rs12681366	0.564	rs10808669	ENSG00000253175.1	RP11-267M23.6	4.14	3.83e-05	0.0027	0.15	0.13	Nonsyndromic cleft lip with cleft palate;	chr8:94468833	chr8:94565036~94565715:+
BRCA	cis	rs7005380	1	rs10955943	ENSG00000245330.4	KB-1471A8.1	-4.14	3.83e-05	0.0027	-0.17	-0.13	Interstitial lung disease;	chr8:119931903	chr8:119867419~119874488:-
BRCA	cis	rs739496	0.527	rs7136469	ENSG00000257624.1	RP1-128M12.3	4.14	3.83e-05	0.0027	0.17	0.13	Platelet count;	chr12:111910387	chr12:112000739~112000985:-
BRCA	cis	rs6490294	0.799	rs11066082	ENSG00000257624.1	RP1-128M12.3	4.14	3.83e-05	0.0027	0.17	0.13	Mean platelet volume;	chr12:111913544	chr12:112000739~112000985:-
BRCA	cis	rs9818758	0.607	rs11719220	ENSG00000225399.4	RP11-3B7.1	-4.14	3.83e-05	0.0027	-0.21	-0.13	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49207768	chr3:49260085~49261316:+
BRCA	cis	rs4650994	0.935	rs4652306	ENSG00000273384.1	RP5-1098D14.1	4.14	3.83e-05	0.0027	0.16	0.13	HDL cholesterol;HDL cholesterol levels;	chr1:178559071	chr1:178651706~178652282:+
BRCA	cis	rs4650994	1	rs6660445	ENSG00000273384.1	RP5-1098D14.1	4.14	3.83e-05	0.0027	0.16	0.13	HDL cholesterol;HDL cholesterol levels;	chr1:178559736	chr1:178651706~178652282:+
BRCA	cis	rs875971	1	rs2077593	ENSG00000236529.1	RP13-254B10.1	4.14	3.83e-05	0.0027	0.14	0.13	Aortic root size;	chr7:66427543	chr7:65840212~65840596:+
BRCA	cis	rs11096990	0.634	rs12648082	ENSG00000249685.1	RP11-360F5.3	-4.14	3.83e-05	0.0027	-0.15	-0.13	Cognitive function;	chr4:39278104	chr4:39133913~39135608:+
BRCA	cis	rs6088580	0.713	rs1884669	ENSG00000275784.1	RP5-1125A11.6	-4.14	3.83e-05	0.00271	-0.14	-0.13	Glomerular filtration rate (creatinine);	chr20:34583483	chr20:33989480~33991818:-
BRCA	cis	rs7927592	0.956	rs6591341	ENSG00000212093.1	AP000807.1	4.14	3.83e-05	0.00271	0.14	0.13	Total body bone mineral density;	chr11:68568010	chr11:68506083~68506166:-
BRCA	cis	rs6088580	0.634	rs6142164	ENSG00000276073.1	RP5-1125A11.7	4.14	3.83e-05	0.00271	0.14	0.13	Glomerular filtration rate (creatinine);	chr20:34418791	chr20:33985617~33988989:-
BRCA	cis	rs9532580	0.614	rs17446614	ENSG00000168852.11	TPTE2P5	-4.14	3.83e-05	0.00271	-0.16	-0.13	Mean corpuscular hemoglobin;	chr13:40565740	chr13:40822296~40921749:-
BRCA	cis	rs1910358	0.554	rs955886	ENSG00000248874.4	C5orf17	-4.14	3.83e-05	0.00271	-0.18	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23759393	chr5:23951348~24178263:+
BRCA	cis	rs1910358	0.554	rs955887	ENSG00000248874.4	C5orf17	-4.14	3.83e-05	0.00271	-0.18	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23759403	chr5:23951348~24178263:+
BRCA	cis	rs687432	0.885	rs12792435	ENSG00000265566.2	RN7SL605P	-4.14	3.83e-05	0.00271	-0.18	-0.13	Parkinson's disease;	chr11:58034260	chr11:57528085~57528365:-
BRCA	cis	rs687432	0.885	rs61903966	ENSG00000265566.2	RN7SL605P	-4.14	3.83e-05	0.00271	-0.18	-0.13	Parkinson's disease;	chr11:58034455	chr11:57528085~57528365:-
BRCA	cis	rs687432	0.885	rs61903967	ENSG00000265566.2	RN7SL605P	-4.14	3.83e-05	0.00271	-0.18	-0.13	Parkinson's disease;	chr11:58034917	chr11:57528085~57528365:-
BRCA	cis	rs687432	0.885	rs36071925	ENSG00000265566.2	RN7SL605P	-4.14	3.83e-05	0.00271	-0.18	-0.13	Parkinson's disease;	chr11:58036955	chr11:57528085~57528365:-
BRCA	cis	rs687432	0.885	rs61904009	ENSG00000265566.2	RN7SL605P	-4.14	3.83e-05	0.00271	-0.18	-0.13	Parkinson's disease;	chr11:58040141	chr11:57528085~57528365:-
BRCA	cis	rs687432	0.885	rs11607308	ENSG00000265566.2	RN7SL605P	-4.14	3.83e-05	0.00271	-0.18	-0.13	Parkinson's disease;	chr11:58041482	chr11:57528085~57528365:-
BRCA	cis	rs6545883	0.86	rs6545847	ENSG00000270820.4	RP11-355B11.2	-4.14	3.83e-05	0.00271	-0.14	-0.13	Tuberculosis;	chr2:61218198	chr2:61471188~61484130:+
BRCA	cis	rs10043228	1	rs10066259	ENSG00000271918.1	CTD-2287O16.5	-4.13	3.84e-05	0.00271	-0.17	-0.13	Asthma or chronic obstructive pulmonary disease;	chr5:116116195	chr5:116083807~116085416:-
BRCA	cis	rs651907	0.565	rs2925323	ENSG00000244119.1	PDCL3P4	4.13	3.84e-05	0.00271	0.1	0.13	Colorectal cancer;	chr3:101940082	chr3:101712472~101713191:+
BRCA	cis	rs6672530	0.518	rs1495847	ENSG00000227711.2	RP11-275O4.5	4.13	3.84e-05	0.00271	0.15	0.13	Hip circumference adjusted for BMI;	chr1:227546608	chr1:227509028~227520477:-
BRCA	cis	rs6490294	0.528	rs12423572	ENSG00000226469.1	ADAM1B	4.13	3.84e-05	0.00271	0.23	0.13	Mean platelet volume;	chr12:112178115	chr12:111927018~111929017:+
BRCA	cis	rs7800418	0.784	rs882540	ENSG00000214870.7	AC004540.5	4.13	3.84e-05	0.00271	0.16	0.13	Cognitive function;	chr7:26550270	chr7:26398593~26494256:+
BRCA	cis	rs7475343	0.501	rs77697233	ENSG00000224034.1	RP11-445P17.8	-4.13	3.84e-05	0.00271	-0.25	-0.13	Intelligence;	chr10:5204162	chr10:5266033~5271236:-
BRCA	cis	rs1865760	0.927	rs6915834	ENSG00000272462.2	U91328.19	-4.13	3.84e-05	0.00271	-0.15	-0.13	Height;	chr6:25935199	chr6:25992662~26001775:+
BRCA	cis	rs12586478	0.561	rs1505188	ENSG00000205562.2	RP11-497E19.1	-4.13	3.84e-05	0.00271	-0.12	-0.13	Post bronchodilator FEV1;	chr14:86326014	chr14:85524432~85529988:-
BRCA	cis	rs875971	1	rs3735148	ENSG00000236529.1	RP13-254B10.1	4.13	3.84e-05	0.00271	0.14	0.13	Aortic root size;	chr7:66506022	chr7:65840212~65840596:+
BRCA	cis	rs812925	0.533	rs60997156	ENSG00000273302.1	RP11-493E12.2	4.13	3.84e-05	0.00271	0.11	0.13	Immature fraction of reticulocytes;	chr2:61169404	chr2:61199979~61200769:+
BRCA	cis	rs7665090	0.806	rs413967	ENSG00000251288.2	RP11-10L12.2	4.13	3.84e-05	0.00271	0.15	0.13	Primary biliary cholangitis;	chr4:102662039	chr4:102751401~102752641:+
BRCA	cis	rs7665090	0.806	rs404574	ENSG00000251288.2	RP11-10L12.2	4.13	3.84e-05	0.00271	0.15	0.13	Primary biliary cholangitis;	chr4:102662051	chr4:102751401~102752641:+
BRCA	cis	rs853679	0.542	rs6934769	ENSG00000216901.1	AL022393.7	4.13	3.84e-05	0.00271	0.18	0.13	Depression;	chr6:28123153	chr6:28176188~28176674:+
BRCA	cis	rs853679	0.517	rs17711801	ENSG00000216901.1	AL022393.7	4.13	3.84e-05	0.00271	0.18	0.13	Depression;	chr6:28124529	chr6:28176188~28176674:+
BRCA	cis	rs4713118	0.527	rs9461433	ENSG00000216901.1	AL022393.7	4.13	3.84e-05	0.00271	0.18	0.13	Parkinson's disease;	chr6:28127394	chr6:28176188~28176674:+
BRCA	cis	rs853679	0.517	rs9468292	ENSG00000216901.1	AL022393.7	4.13	3.84e-05	0.00271	0.18	0.13	Depression;	chr6:28127577	chr6:28176188~28176674:+
BRCA	cis	rs9818758	0.607	rs35283189	ENSG00000225399.4	RP11-3B7.1	-4.13	3.84e-05	0.00271	-0.23	-0.13	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49076235	chr3:49260085~49261316:+
BRCA	cis	rs9818758	0.607	rs34580506	ENSG00000225399.4	RP11-3B7.1	-4.13	3.84e-05	0.00271	-0.23	-0.13	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49076280	chr3:49260085~49261316:+
BRCA	cis	rs2278170	0.67	rs2641405	ENSG00000225101.4	OR52K3P	4.13	3.84e-05	0.00271	0.17	0.13	Amyotrophic lateral sclerosis;	chr11:4554849	chr11:4474813~4475755:+
BRCA	cis	rs748404	1	rs748404	ENSG00000205771.5	CATSPER2P1	-4.13	3.84e-05	0.00271	-0.19	-0.13	Lung cancer;	chr15:43267033	chr15:43726918~43747094:-
BRCA	cis	rs6545883	0.929	rs3732171	ENSG00000270820.4	RP11-355B11.2	4.13	3.84e-05	0.00271	0.14	0.13	Tuberculosis;	chr2:61522555	chr2:61471188~61484130:+
BRCA	cis	rs7045881	0.877	rs17755607	ENSG00000254396.1	RP11-56F10.3	-4.13	3.84e-05	0.00271	-0.23	-0.13	Schizophrenia;	chr9:26785736	chr9:27102630~27104728:+
BRCA	cis	rs6565180	1	rs11863150	ENSG00000183604.13	SMG1P5	4.13	3.84e-05	0.00271	0.13	0.13	Tonsillectomy;	chr16:30374182	chr16:30267553~30335374:-
BRCA	cis	rs997295	0.554	rs4261477	ENSG00000270964.1	RP11-502I4.3	4.13	3.85e-05	0.00271	0.14	0.13	Motion sickness;	chr15:67781630	chr15:67541072~67542604:-
BRCA	cis	rs490234	0.702	rs4838277	ENSG00000232630.1	PRPS1P2	-4.13	3.85e-05	0.00271	-0.13	-0.13	Mean arterial pressure;	chr9:125605607	chr9:125150653~125151589:+
BRCA	cis	rs875971	0.66	rs6460308	ENSG00000229180.5	GS1-124K5.11	-4.13	3.85e-05	0.00272	-0.11	-0.13	Aortic root size;	chr7:66619753	chr7:66526088~66542624:-
BRCA	cis	rs875971	0.597	rs11763224	ENSG00000232546.1	RP11-458F8.1	4.13	3.85e-05	0.00272	0.12	0.13	Aortic root size;	chr7:66518628	chr7:66848496~66858136:+
BRCA	cis	rs3748682	0.731	rs3891572	ENSG00000222282.1	RNU6-584P	-4.13	3.85e-05	0.00272	-0.16	-0.13	Hypothyroidism;	chr1:37833204	chr1:37885023~37885117:+
BRCA	cis	rs1993293	0.636	rs1993294	ENSG00000259363.4	CTD-2054N24.2	-4.13	3.85e-05	0.00272	-0.17	-0.13	Coronary artery calcification;	chr15:99757486	chr15:99807023~99877148:+
BRCA	cis	rs867186	1	rs2069940	ENSG00000126005.14	MMP24-AS1	-4.13	3.85e-05	0.00272	-0.25	-0.13	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35171469	chr20:35216462~35278131:-
BRCA	cis	rs35520189	0.961	rs13008855	ENSG00000189223.12	PAX8-AS1	4.13	3.85e-05	0.00272	0.2	0.13	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:112851991	chr2:113211522~113276581:+
BRCA	cis	rs4835473	0.897	rs13135627	ENSG00000249741.2	RP11-673E1.3	4.13	3.85e-05	0.00272	0.15	0.13	Immature fraction of reticulocytes;	chr4:143691099	chr4:143911514~143912053:-
BRCA	cis	rs7617773	0.963	rs12495221	ENSG00000199476.1	Y_RNA	4.13	3.85e-05	0.00272	0.16	0.13	Coronary artery disease;	chr3:48137688	chr3:48288587~48288694:+
BRCA	cis	rs34421088	0.623	rs2572433	ENSG00000154316.13	TDH	-4.13	3.85e-05	0.00272	-0.17	-0.13	Neuroticism;	chr8:11243532	chr8:11339637~11368452:+
BRCA	cis	rs11098499	0.954	rs4577559	ENSG00000260404.2	RP11-384K6.6	4.13	3.85e-05	0.00272	0.12	0.13	Corneal astigmatism;	chr4:119482888	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.954	rs7656252	ENSG00000260404.2	RP11-384K6.6	4.13	3.85e-05	0.00272	0.12	0.13	Corneal astigmatism;	chr4:119483113	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.865	rs28845498	ENSG00000260404.2	RP11-384K6.6	4.13	3.85e-05	0.00272	0.12	0.13	Corneal astigmatism;	chr4:119484031	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.954	rs56270433	ENSG00000260404.2	RP11-384K6.6	4.13	3.85e-05	0.00272	0.12	0.13	Corneal astigmatism;	chr4:119484875	chr4:118591773~118633729:+
BRCA	cis	rs12477438	0.834	rs1563106	ENSG00000231822.1	AC019097.7	-4.13	3.85e-05	0.00272	-0.14	-0.13	Chronic sinus infection;	chr2:99084918	chr2:99102018~99102752:+
BRCA	cis	rs6015450	0.85	rs6026731	ENSG00000228340.4	MIR646HG	4.13	3.85e-05	0.00272	0.25	0.13	Hypertension;Blood pressure;Systolic blood pressure;Diastolic blood pressure;	chr20:59154160	chr20:60087840~60527458:+
BRCA	cis	rs7824557	0.591	rs2736282	ENSG00000255020.1	AF131216.5	-4.13	3.85e-05	0.00272	-0.15	-0.13	Retinal vascular caliber;	chr8:11367971	chr8:11345748~11347502:-
BRCA	cis	rs4648045	0.565	rs11733293	ENSG00000246560.2	RP11-10L12.4	-4.13	3.85e-05	0.00272	-0.14	-0.13	Lymphocyte percentage of white cells;	chr4:102624096	chr4:102828055~102844075:+
BRCA	cis	rs4950322	0.515	rs72691016	ENSG00000237188.3	RP11-337C18.8	4.13	3.86e-05	0.00272	0.15	0.13	Protein quantitative trait loci;	chr1:147245375	chr1:147172771~147211568:+
BRCA	cis	rs2640806	0.505	rs28830572	ENSG00000253105.4	KB-1448A5.1	4.13	3.86e-05	0.00272	0.15	0.13	Obesity-related traits;	chr8:96351869	chr8:96371865~96387438:-
BRCA	cis	rs1950832	0.723	rs853239	ENSG00000258636.1	CTD-2298J14.2	4.13	3.86e-05	0.00272	0.15	0.13	Urate levels in obese individuals;	chr14:41646463	chr14:41587861~41604856:-
BRCA	cis	rs911119	1	rs6114209	ENSG00000270001.1	RP11-218C14.8	-4.13	3.86e-05	0.00272	-0.17	-0.13	Chronic kidney disease;	chr20:23641629	chr20:23631826~23632316:-
BRCA	cis	rs860818	1	rs858238	ENSG00000230658.1	KLHL7-AS1	-4.13	3.86e-05	0.00272	-0.31	-0.13	Initial pursuit acceleration;	chr7:23199514	chr7:23101228~23105703:-
BRCA	cis	rs4648045	0.565	rs4698860	ENSG00000246560.2	RP11-10L12.4	4.13	3.86e-05	0.00272	0.14	0.13	Lymphocyte percentage of white cells;	chr4:102624170	chr4:102828055~102844075:+
BRCA	cis	rs1400816	0.85	rs1878583	ENSG00000228389.1	AC068039.4	-4.13	3.86e-05	0.00272	-0.23	-0.13	Amyotrophic lateral sclerosis (sporadic);	chr2:171868791	chr2:171773482~171775844:+
BRCA	cis	rs1007738	0.58	rs61897844	ENSG00000200376.1	RNU5E-10P	-4.13	3.86e-05	0.00272	-0.17	-0.13	Bone mineral density (hip);	chr11:47169309	chr11:47576471~47576588:-
BRCA	cis	rs6671200	0.748	rs12751061	ENSG00000235501.4	RP4-639F20.1	-4.13	3.86e-05	0.00272	-0.28	-0.13	Stearic acid (18:0) levels;	chr1:95065035	chr1:94927566~94963270:+
BRCA	cis	rs6452524	0.935	rs1382376	ENSG00000281327.1	LINC01338	4.13	3.86e-05	0.00272	0.14	0.13	Hypertension (SNP x SNP interaction);	chr5:83095418	chr5:82850864~82859836:-
BRCA	cis	rs6452524	0.935	rs12109517	ENSG00000281327.1	LINC01338	4.13	3.86e-05	0.00272	0.14	0.13	Hypertension (SNP x SNP interaction);	chr5:83095947	chr5:82850864~82859836:-
BRCA	cis	rs6452524	0.935	rs12109514	ENSG00000281327.1	LINC01338	4.13	3.86e-05	0.00272	0.14	0.13	Hypertension (SNP x SNP interaction);	chr5:83095965	chr5:82850864~82859836:-
BRCA	cis	rs1124769	0.619	rs8182062	ENSG00000273674.3	CTD-2378E12.1	4.13	3.86e-05	0.00273	0.15	0.13	Cognitive performance;	chr15:50962305	chr15:50839875~50908599:-
BRCA	cis	rs321358	0.943	rs402820	ENSG00000271390.1	RP11-89C3.3	4.13	3.87e-05	0.00273	0.21	0.13	Body mass index;	chr11:111132480	chr11:111089870~111090368:-
BRCA	cis	rs651907	0.535	rs13085776	ENSG00000256628.3	ZBTB11-AS1	4.13	3.87e-05	0.00273	0.17	0.13	Colorectal cancer;	chr3:101786663	chr3:101676475~101679217:+
BRCA	cis	rs4950322	0.57	rs72691054	ENSG00000237188.3	RP11-337C18.8	4.13	3.87e-05	0.00273	0.16	0.13	Protein quantitative trait loci;	chr1:147277942	chr1:147172771~147211568:+
BRCA	cis	rs11039131	0.787	rs326217	ENSG00000280615.1	Y_RNA	-4.13	3.87e-05	0.00273	-0.16	-0.13	Schizophrenia;	chr11:47281724	chr11:47614898~47614994:-
BRCA	cis	rs4499344	0.693	rs8106944	ENSG00000267475.1	CTD-2538C1.2	4.13	3.87e-05	0.00273	0.16	0.13	Mean platelet volume;	chr19:32606877	chr19:32687089~32691750:-
BRCA	cis	rs4499344	0.693	rs8106502	ENSG00000267475.1	CTD-2538C1.2	4.13	3.87e-05	0.00273	0.16	0.13	Mean platelet volume;	chr19:32606890	chr19:32687089~32691750:-
BRCA	cis	rs13098911	0.54	rs35477280	ENSG00000223552.1	RP11-24F11.2	-4.13	3.87e-05	0.00273	-0.21	-0.13	Celiac disease;	chr3:45932600	chr3:46364955~46407059:-
BRCA	cis	rs13098911	0.54	rs13066516	ENSG00000223552.1	RP11-24F11.2	-4.13	3.87e-05	0.00273	-0.21	-0.13	Celiac disease;	chr3:45933951	chr3:46364955~46407059:-
BRCA	cis	rs13063635	0.915	rs77902290	ENSG00000223552.1	RP11-24F11.2	-4.13	3.87e-05	0.00273	-0.21	-0.13	Eosinophil percentage of granulocytes;	chr3:45935170	chr3:46364955~46407059:-
BRCA	cis	rs6015450	1	rs6026728	ENSG00000228340.4	MIR646HG	-4.13	3.87e-05	0.00273	-0.24	-0.13	Hypertension;Blood pressure;Systolic blood pressure;Diastolic blood pressure;	chr20:59148075	chr20:60087840~60527458:+
BRCA	cis	rs7487075	0.78	rs1873793	ENSG00000274723.1	RP11-618L22.1	-4.13	3.87e-05	0.00273	-0.15	-0.13	Itch intensity from mosquito bite;	chr12:46367541	chr12:46970504~46972155:+
BRCA	cis	rs11098499	0.697	rs4560394	ENSG00000260091.1	RP11-33B1.4	-4.13	3.87e-05	0.00273	-0.11	-0.13	Corneal astigmatism;	chr4:119392280	chr4:119409333~119410233:+
BRCA	cis	rs412658	0.668	rs7253490	ENSG00000269345.1	VN1R85P	-4.13	3.87e-05	0.00273	-0.15	-0.13	Telomere length;	chr19:22110904	chr19:22174766~22175191:-
BRCA	cis	rs7572733	0.555	rs6434953	ENSG00000231621.1	AC013264.2	-4.13	3.87e-05	0.00273	-0.12	-0.13	Dermatomyositis;	chr2:198064969	chr2:197197991~197199273:+
BRCA	cis	rs3816183	1	rs893729	ENSG00000226491.1	FTOP1	-4.13	3.87e-05	0.00273	-0.16	-0.13	Hypospadias;	chr2:42788084	chr2:42797225~42798712:-
BRCA	cis	rs4218	0.543	rs4775110	ENSG00000259732.1	RP11-59H7.3	-4.13	3.87e-05	0.00273	-0.15	-0.13	Social communication problems;	chr15:59023685	chr15:59121034~59133250:+
BRCA	cis	rs7824557	1	rs2736371	ENSG00000255020.1	AF131216.5	4.13	3.87e-05	0.00273	0.16	0.13	Retinal vascular caliber;	chr8:11248020	chr8:11345748~11347502:-
BRCA	cis	rs952623	0.649	rs6952464	ENSG00000211694.2	TRGV10	4.13	3.87e-05	0.00273	0.11	0.13	Intelligence (multi-trait analysis);	chr7:39036727	chr7:38299811~38300322:-
BRCA	cis	rs9470794	1	rs11759483	ENSG00000204110.6	RP1-153P14.8	-4.13	3.87e-05	0.00273	-0.23	-0.13	Type 2 diabetes;	chr6:38119903	chr6:37507348~37535616:+
BRCA	cis	rs34217772	0.581	rs61990346	ENSG00000258636.1	CTD-2298J14.2	4.13	3.87e-05	0.00273	0.16	0.13	Myopia;	chr14:41728950	chr14:41587861~41604856:-
BRCA	cis	rs6750047	0.747	rs2116229	ENSG00000235848.3	RMDN2-AS1	-4.13	3.88e-05	0.00273	-0.16	-0.13	Cutaneous malignant melanoma;Melanoma;	chr2:38043347	chr2:37949911~38067041:-
BRCA	cis	rs6088590	0.561	rs3891369	ENSG00000275784.1	RP5-1125A11.6	-4.13	3.88e-05	0.00273	-0.14	-0.13	Coronary artery disease;	chr20:34573323	chr20:33989480~33991818:-
BRCA	cis	rs12435908	1	rs73286173	ENSG00000276116.2	FUT8-AS1	-4.13	3.88e-05	0.00273	-0.19	-0.13	Ischemic stroke;	chr14:65612822	chr14:65411170~65412690:-
BRCA	cis	rs12435908	1	rs73268512	ENSG00000276116.2	FUT8-AS1	-4.13	3.88e-05	0.00273	-0.19	-0.13	Ischemic stroke;	chr14:65622187	chr14:65411170~65412690:-
BRCA	cis	rs35146811	0.657	rs36019559	ENSG00000235713.1	RP4-604G5.3	-4.13	3.88e-05	0.00273	-0.15	-0.13	Coronary artery disease;	chr7:100216963	chr7:99992397~99993050:+
BRCA	cis	rs853679	0.76	rs2299029	ENSG00000204709.4	LINC01556	4.13	3.88e-05	0.00274	0.2	0.13	Depression;	chr6:28231053	chr6:28943877~28944537:+
BRCA	cis	rs11098499	0.82	rs13122709	ENSG00000250412.1	KLHL2P1	4.13	3.88e-05	0.00274	0.15	0.13	Corneal astigmatism;	chr4:119634201	chr4:119334329~119378233:+
BRCA	cis	rs6121246	0.909	rs6089071	ENSG00000230613.1	HM13-AS1	4.13	3.88e-05	0.00274	0.19	0.13	Mean corpuscular hemoglobin;	chr20:31790581	chr20:31567707~31573263:-
BRCA	cis	rs1722141	0.601	rs2690723	ENSG00000229628.1	AC073115.7	4.13	3.88e-05	0.00274	0.17	0.13	Sitting height ratio;	chr7:46031071	chr7:45990905~46000898:+
BRCA	cis	rs495337	0.76	rs492702	ENSG00000229222.1	KRT18P4	-4.13	3.88e-05	0.00274	-0.16	-0.13	Psoriasis;	chr20:49906048	chr20:49956745~49958032:+
BRCA	cis	rs13401620	0.797	rs66977029	ENSG00000229326.3	AC069154.4	-4.13	3.88e-05	0.00274	-0.16	-0.13	Breast size;	chr2:119923575	chr2:119698623~119700151:+
BRCA	cis	rs7267979	0.565	rs3752273	ENSG00000231081.1	RP4-760C5.3	4.13	3.88e-05	0.00274	0.16	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25614147	chr20:26008791~26010531:-
BRCA	cis	rs4869313	0.774	rs2548530	ENSG00000248734.2	CTD-2260A17.1	-4.13	3.88e-05	0.00274	-0.13	-0.13	Pediatric autoimmune diseases;	chr5:96904223	chr5:96784777~96785999:+
BRCA	cis	rs911119	0.955	rs8121283	ENSG00000270001.1	RP11-218C14.8	-4.13	3.88e-05	0.00274	-0.16	-0.13	Chronic kidney disease;	chr20:23624365	chr20:23631826~23632316:-
BRCA	cis	rs911119	0.955	rs8115417	ENSG00000270001.1	RP11-218C14.8	-4.13	3.88e-05	0.00274	-0.16	-0.13	Chronic kidney disease;	chr20:23624586	chr20:23631826~23632316:-
BRCA	cis	rs911119	0.955	rs8121405	ENSG00000270001.1	RP11-218C14.8	-4.13	3.88e-05	0.00274	-0.16	-0.13	Chronic kidney disease;	chr20:23624589	chr20:23631826~23632316:-
BRCA	cis	rs911119	0.955	rs8115423	ENSG00000270001.1	RP11-218C14.8	-4.13	3.88e-05	0.00274	-0.16	-0.13	Chronic kidney disease;	chr20:23624616	chr20:23631826~23632316:-
BRCA	cis	rs1005277	0.579	rs1780146	ENSG00000099251.13	HSD17B7P2	4.13	3.88e-05	0.00274	0.14	0.13	Extrinsic epigenetic age acceleration;	chr10:38228946	chr10:38356380~38378505:+
BRCA	cis	rs77633900	0.772	rs387321	ENSG00000196274.5	Metazoa_SRP	4.13	3.88e-05	0.00274	0.22	0.13	Glioma;Non-glioblastoma glioma;	chr15:76451224	chr15:76230048~76230390:-
BRCA	cis	rs7592578	0.766	rs12472081	ENSG00000272979.1	RP11-647K16.1	-4.13	3.89e-05	0.00274	-0.23	-0.13	Diastolic blood pressure;	chr2:190533819	chr2:190454092~190454521:-
BRCA	cis	rs495337	0.76	rs515686	ENSG00000229222.1	KRT18P4	-4.13	3.89e-05	0.00274	-0.16	-0.13	Psoriasis;	chr20:49899252	chr20:49956745~49958032:+
BRCA	cis	rs1153858	1	rs12437887	ENSG00000275672.1	GATM-AS1	-4.13	3.89e-05	0.00274	-0.16	-0.13	Homoarginine levels;	chr15:45376896	chr15:45378700~45380123:+
BRCA	cis	rs13098911	0.54	rs35516580	ENSG00000223552.1	RP11-24F11.2	-4.13	3.89e-05	0.00274	-0.21	-0.13	Celiac disease;	chr3:46066006	chr3:46364955~46407059:-
BRCA	cis	rs9527	0.615	rs4917991	ENSG00000213061.2	PFN1P11	4.13	3.89e-05	0.00274	0.17	0.13	Arsenic metabolism;	chr10:103024076	chr10:102838011~102845473:-
BRCA	cis	rs4819052	1	rs2297284	ENSG00000184274.3	LINC00315	-4.13	3.89e-05	0.00274	-0.19	-0.13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45285430	chr21:45300245~45305257:-
BRCA	cis	rs7267979	1	rs4815424	ENSG00000276952.1	RP5-965G21.6	-4.13	3.89e-05	0.00274	-0.15	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25409648	chr20:25284915~25285588:-
BRCA	cis	rs4834770	0.746	rs2389747	ENSG00000250412.1	KLHL2P1	4.13	3.89e-05	0.00274	0.14	0.13	Blood protein levels;	chr4:119314947	chr4:119334329~119378233:+
BRCA	cis	rs4834770	0.717	rs1022146	ENSG00000250412.1	KLHL2P1	4.13	3.89e-05	0.00274	0.14	0.13	Blood protein levels;	chr4:119314948	chr4:119334329~119378233:+
BRCA	cis	rs2108622	0.727	rs76984410	ENSG00000267218.2	AC005336.5	4.13	3.89e-05	0.00274	0.15	0.13	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871890	chr19:15902300~15903238:-
BRCA	cis	rs2108622	0.727	rs77780918	ENSG00000267218.2	AC005336.5	4.13	3.89e-05	0.00274	0.15	0.13	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871897	chr19:15902300~15903238:-
BRCA	cis	rs10129255	1	rs9324091	ENSG00000274576.2	IGHV2-70	4.13	3.89e-05	0.00274	0.12	0.13	Kawasaki disease;	chr14:106676625	chr14:106770577~106771020:-
BRCA	cis	rs16944613	0.51	rs4932350	ENSG00000245479.2	LINC01585	4.13	3.89e-05	0.00274	0.15	0.13	Colorectal cancer;	chr15:90600206	chr15:90660234~90664967:+
BRCA	cis	rs6545883	0.929	rs2593625	ENSG00000212978.6	AC016747.3	4.13	3.89e-05	0.00274	0.17	0.13	Tuberculosis;	chr2:61441634	chr2:61141592~61144969:-
BRCA	cis	rs2554380	0.843	rs2562779	ENSG00000230373.7	GOLGA6L5P	-4.13	3.89e-05	0.00274	-0.18	-0.13	Height;	chr15:83722223	chr15:84507885~84516814:-
BRCA	cis	rs11187837	0.803	rs11187866	ENSG00000273450.1	RP11-76P2.4	4.13	3.89e-05	0.00274	0.26	0.13	Sudden cardiac arrest;	chr10:94326234	chr10:94314907~94315327:-
BRCA	cis	rs2832191	1	rs6516891	ENSG00000232855.5	AF131217.1	4.13	3.89e-05	0.00274	0.15	0.13	Dental caries;	chr21:29110749	chr21:28439346~28674848:-
BRCA	cis	rs2832191	1	rs2832184	ENSG00000232855.5	AF131217.1	4.13	3.89e-05	0.00274	0.15	0.13	Dental caries;	chr21:29110944	chr21:28439346~28674848:-
BRCA	cis	rs875971	1	rs3735148	ENSG00000229180.5	GS1-124K5.11	4.13	3.89e-05	0.00274	0.11	0.13	Aortic root size;	chr7:66506022	chr7:66526088~66542624:-
BRCA	cis	rs853679	0.517	rs3757187	ENSG00000216901.1	AL022393.7	4.13	3.89e-05	0.00274	0.18	0.13	Depression;	chr6:28139876	chr6:28176188~28176674:+
BRCA	cis	rs718433	0.585	rs7154789	ENSG00000256379.1	TRAV8-5	-4.13	3.89e-05	0.00274	-0.17	-0.13	Intraocular pressure;	chr14:21835377	chr14:21903077~21903598:+
BRCA	cis	rs1048886	0.872	rs55990831	ENSG00000271967.1	RP11-134K13.4	-4.13	3.89e-05	0.00274	-0.19	-0.13	Type 2 diabetes;	chr6:70457679	chr6:70596438~70596980:+
BRCA	cis	rs12073837	0.5	rs2807845	ENSG00000257551.1	HLX-AS1	-4.13	3.89e-05	0.00274	-0.13	-0.13	F-cell distribution;	chr1:220822945	chr1:220832763~220880140:-
BRCA	cis	rs5758511	0.68	rs5758681	ENSG00000226450.2	CYP2D8P	4.13	3.89e-05	0.00274	0.14	0.13	Birth weight;	chr22:42249085	chr22:42149886~42155001:-
BRCA	cis	rs875971	0.558	rs4433015	ENSG00000229180.5	GS1-124K5.11	-4.13	3.89e-05	0.00274	-0.11	-0.13	Aortic root size;	chr7:66174736	chr7:66526088~66542624:-
BRCA	cis	rs6472235	0.586	rs4565445	ENSG00000272010.1	CTD-3025N20.3	4.13	3.89e-05	0.00274	0.16	0.13	Plateletcrit;Myopia (pathological);	chr8:66005841	chr8:65591850~65592472:-
BRCA	cis	rs10844706	0.669	rs10844682	ENSG00000256673.1	RP11-599J14.2	4.13	3.89e-05	0.00274	0.16	0.13	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9747028	chr12:9398355~9414851:-
BRCA	cis	rs875971	0.545	rs6460298	ENSG00000232546.1	RP11-458F8.1	4.13	3.89e-05	0.00274	0.12	0.13	Aortic root size;	chr7:66442783	chr7:66848496~66858136:+
BRCA	cis	rs7308116	0.791	rs57210198	ENSG00000274395.1	RP11-554D14.8	-4.13	3.89e-05	0.00274	-0.14	-0.13	Pelvic organ prolapse (moderate/severe);	chr12:107811963	chr12:107835541~107836555:-
BRCA	cis	rs56046484	0.871	rs7177110	ENSG00000230373.7	GOLGA6L5P	4.13	3.89e-05	0.00274	0.18	0.13	Testicular germ cell tumor;	chr15:85128524	chr15:84507885~84516814:-
BRCA	cis	rs6840360	0.558	rs2709821	ENSG00000251611.1	RP11-610P16.1	-4.13	3.89e-05	0.00274	-0.11	-0.13	Intelligence (multi-trait analysis);	chr4:151421038	chr4:151407551~151408835:-
BRCA	cis	rs2625529	0.73	rs1481860	ENSG00000260037.4	CTD-2524L6.3	4.13	3.89e-05	0.00274	0.16	0.13	Red blood cell count;	chr15:71949516	chr15:71818396~71823384:+
BRCA	cis	rs12562037	0.673	rs16851653	ENSG00000272510.1	RP4-680D5.8	4.13	3.9e-05	0.00274	0.22	0.13	Alcoholic chronic pancreatitis;	chr1:15452618	chr1:15565611~15565956:-
BRCA	cis	rs3816183	0.958	rs7583085	ENSG00000226491.1	FTOP1	4.13	3.9e-05	0.00275	0.16	0.13	Hypospadias;	chr2:42795828	chr2:42797225~42798712:-
BRCA	cis	rs6545883	0.894	rs6739427	ENSG00000273302.1	RP11-493E12.2	-4.13	3.9e-05	0.00275	-0.12	-0.13	Tuberculosis;	chr2:61225744	chr2:61199979~61200769:+
BRCA	cis	rs6545883	0.86	rs777589	ENSG00000212978.6	AC016747.3	4.13	3.9e-05	0.00275	0.17	0.13	Tuberculosis;	chr2:61198486	chr2:61141592~61144969:-
BRCA	cis	rs6545883	0.894	rs2694632	ENSG00000273302.1	RP11-493E12.2	-4.13	3.9e-05	0.00275	-0.12	-0.13	Tuberculosis;	chr2:61331547	chr2:61199979~61200769:+
BRCA	cis	rs58521262	0.556	rs289300	ENSG00000268105.1	RP11-369G6.2	-4.13	3.9e-05	0.00275	-0.17	-0.13	Testicular germ cell tumor;	chr19:22992528	chr19:23125665~23128543:+
BRCA	cis	rs58521262	0.556	rs289298	ENSG00000268105.1	RP11-369G6.2	-4.13	3.9e-05	0.00275	-0.17	-0.13	Testicular germ cell tumor;	chr19:22993143	chr19:23125665~23128543:+
BRCA	cis	rs58521262	0.556	rs289297	ENSG00000268105.1	RP11-369G6.2	-4.13	3.9e-05	0.00275	-0.17	-0.13	Testicular germ cell tumor;	chr19:22993338	chr19:23125665~23128543:+
BRCA	cis	rs58521262	0.556	rs289294	ENSG00000268105.1	RP11-369G6.2	-4.13	3.9e-05	0.00275	-0.17	-0.13	Testicular germ cell tumor;	chr19:22993971	chr19:23125665~23128543:+
BRCA	cis	rs58521262	0.685	rs289291	ENSG00000268105.1	RP11-369G6.2	-4.13	3.9e-05	0.00275	-0.17	-0.13	Testicular germ cell tumor;	chr19:22995087	chr19:23125665~23128543:+
BRCA	cis	rs58521262	0.585	rs289290	ENSG00000268105.1	RP11-369G6.2	-4.13	3.9e-05	0.00275	-0.17	-0.13	Testicular germ cell tumor;	chr19:22996071	chr19:23125665~23128543:+
BRCA	cis	rs58521262	0.556	rs399132	ENSG00000268105.1	RP11-369G6.2	-4.13	3.9e-05	0.00275	-0.17	-0.13	Testicular germ cell tumor;	chr19:22997898	chr19:23125665~23128543:+
BRCA	cis	rs38055	0.837	rs37777	ENSG00000247796.2	CTD-2366F13.1	-4.13	3.9e-05	0.00275	-0.15	-0.13	Acne (severe);	chr5:53332520	chr5:53109842~53115126:+
BRCA	cis	rs11764932	0.8	rs3807879	ENSG00000229108.1	MEOX2-AS1	-4.13	3.9e-05	0.00275	-0.14	-0.13	Kidney function decline traits;	chr7:15688386	chr7:15688378~15695491:+
BRCA	cis	rs2554380	0.843	rs1365198	ENSG00000230373.7	GOLGA6L5P	-4.13	3.9e-05	0.00275	-0.17	-0.13	Height;	chr15:83730151	chr15:84507885~84516814:-
BRCA	cis	rs1910358	0.664	rs1604458	ENSG00000248874.4	C5orf17	-4.13	3.9e-05	0.00275	-0.17	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23955527	chr5:23951348~24178263:+
BRCA	cis	rs2976388	1	rs1045574	ENSG00000253196.1	RP11-706C16.7	-4.13	3.9e-05	0.00275	-0.12	-0.13	Urinary tract infection frequency;	chr8:142682540	chr8:142763116~142766427:+
BRCA	cis	rs2625529	0.652	rs2899775	ENSG00000260037.4	CTD-2524L6.3	4.13	3.91e-05	0.00275	0.16	0.13	Red blood cell count;	chr15:71976013	chr15:71818396~71823384:+
BRCA	cis	rs801193	0.967	rs2707853	ENSG00000223473.2	GS1-124K5.3	4.13	3.91e-05	0.00275	0.1	0.13	Aortic root size;	chr7:66749023	chr7:66491049~66493566:-
BRCA	cis	rs7932354	0.583	rs4294527	ENSG00000200376.1	RNU5E-10P	4.13	3.91e-05	0.00275	0.16	0.13	Bone mineral density (hip);Bone mineral density;	chr11:46807249	chr11:47576471~47576588:-
BRCA	cis	rs2243480	1	rs1723269	ENSG00000222364.1	RNU6-96P	-4.13	3.91e-05	0.00275	-0.23	-0.13	Diabetic kidney disease;	chr7:66007799	chr7:66395191~66395286:+
BRCA	cis	rs12428035	0.764	rs1330556	ENSG00000247400.3	DNAJC3-AS1	4.13	3.91e-05	0.00275	0.2	0.13	Glomerular filtration rate (cystatin C);Response to statins (LDL cholesterol change);	chr13:95889589	chr13:95648733~95676925:-
BRCA	cis	rs801193	0.935	rs11772264	ENSG00000223473.2	GS1-124K5.3	4.13	3.91e-05	0.00275	0.1	0.13	Aortic root size;	chr7:66711400	chr7:66491049~66493566:-
BRCA	cis	rs875971	0.545	rs2707851	ENSG00000232559.3	GS1-124K5.12	-4.13	3.91e-05	0.00275	-0.17	-0.13	Aortic root size;	chr7:66624178	chr7:66554588~66576923:-
BRCA	cis	rs7572733	0.555	rs10202569	ENSG00000231621.1	AC013264.2	-4.13	3.91e-05	0.00275	-0.12	-0.13	Dermatomyositis;	chr2:198070002	chr2:197197991~197199273:+
BRCA	cis	rs7085104	0.727	rs12773892	ENSG00000213277.3	MARCKSL1P1	4.13	3.91e-05	0.00275	0.16	0.13	Immature fraction of reticulocytes;Schizophrenia;	chr10:102871420	chr10:103175554~103176094:+
BRCA	cis	rs6831352	0.918	rs13107558	ENSG00000272777.1	RP11-571L19.8	4.13	3.91e-05	0.00275	0.14	0.13	Alcohol dependence;	chr4:99129049	chr4:99067256~99068125:-
BRCA	cis	rs1019173	0.816	rs7808913	ENSG00000261455.1	LINC01003	4.13	3.91e-05	0.00275	0.14	0.13	Kidney function decline traits;	chr7:152019364	chr7:152463786~152465549:+
BRCA	cis	rs8180040	0.967	rs17411375	ENSG00000276925.1	RP11-708J19.3	4.13	3.91e-05	0.00275	0.14	0.13	Colorectal cancer;	chr3:47353645	chr3:47469777~47469987:+
BRCA	cis	rs4561483	0.801	rs33623	ENSG00000261216.1	RP11-166B2.5	4.13	3.91e-05	0.00275	0.15	0.13	Testicular germ cell tumor;	chr16:11913578	chr16:11908208~11908916:+
BRCA	cis	rs4499344	0.73	rs421607	ENSG00000267475.1	CTD-2538C1.2	4.13	3.91e-05	0.00275	0.16	0.13	Mean platelet volume;	chr19:32614045	chr19:32687089~32691750:-
BRCA	cis	rs11892454	0.515	rs3731638	ENSG00000217643.1	PTGES3P2	-4.13	3.91e-05	0.00275	-0.13	-0.13	Heschl's gyrus morphology;	chr2:25823976	chr2:25822469~25822950:+
BRCA	cis	rs2243480	0.901	rs313808	ENSG00000226002.1	RP11-460N20.5	-4.13	3.91e-05	0.00276	-0.21	-0.13	Diabetic kidney disease;	chr7:66034886	chr7:65084103~65100232:+
BRCA	cis	rs67766926	0.951	rs10208137	ENSG00000271889.1	RP11-493E12.1	4.13	3.91e-05	0.00276	0.18	0.13	Inflammatory skin disease;	chr2:60951036	chr2:61151433~61162105:-
BRCA	cis	rs2408955	0.504	rs11168441	ENSG00000226413.2	OR8T1P	4.13	3.91e-05	0.00276	0.17	0.13	Glycated hemoglobin levels;	chr12:48182271	chr12:48442030~48442947:-
BRCA	cis	rs2243480	0.803	rs55700941	ENSG00000226002.1	RP11-460N20.5	-4.13	3.92e-05	0.00276	-0.21	-0.13	Diabetic kidney disease;	chr7:65924813	chr7:65084103~65100232:+
BRCA	cis	rs739401	0.611	rs450817	ENSG00000247473.2	CARS-AS1	4.13	3.92e-05	0.00276	0.14	0.13	Longevity;	chr11:3035482	chr11:3029009~3041260:+
BRCA	cis	rs11673344	0.523	rs2562594	ENSG00000276846.1	CTD-3220F14.3	4.13	3.92e-05	0.00276	0.15	0.13	Obesity-related traits;	chr19:37023783	chr19:37314868~37315620:-
BRCA	cis	rs11673344	0.523	rs8101392	ENSG00000276846.1	CTD-3220F14.3	4.13	3.92e-05	0.00276	0.15	0.13	Obesity-related traits;	chr19:37024416	chr19:37314868~37315620:-
BRCA	cis	rs4869313	0.837	rs38034	ENSG00000248734.2	CTD-2260A17.1	4.13	3.92e-05	0.00276	0.13	0.13	Pediatric autoimmune diseases;	chr5:96986715	chr5:96784777~96785999:+
BRCA	cis	rs1048886	0.938	rs9294868	ENSG00000271967.1	RP11-134K13.4	-4.13	3.92e-05	0.00276	-0.17	-0.13	Type 2 diabetes;	chr6:70415806	chr6:70596438~70596980:+
BRCA	cis	rs2625529	0.818	rs16956241	ENSG00000260037.4	CTD-2524L6.3	-4.13	3.92e-05	0.00276	-0.18	-0.13	Red blood cell count;	chr15:71819347	chr15:71818396~71823384:+
BRCA	cis	rs748404	0.666	rs35326382	ENSG00000205771.5	CATSPER2P1	-4.13	3.92e-05	0.00276	-0.19	-0.13	Lung cancer;	chr15:43338686	chr15:43726918~43747094:-
BRCA	cis	rs7772486	0.846	rs7755440	ENSG00000270638.1	RP3-466P17.1	4.13	3.92e-05	0.00276	0.15	0.13	Lobe attachment (rater-scored or self-reported);	chr6:146054770	chr6:145735570~145737218:+
BRCA	cis	rs2439831	0.702	rs2788	ENSG00000206991.1	RNU6-610P	-4.13	3.92e-05	0.00276	-0.21	-0.13	Lung cancer in ever smokers;	chr15:43772688	chr15:43637632~43637738:-
BRCA	cis	rs2439831	0.85	rs28891769	ENSG00000206991.1	RNU6-610P	-4.13	3.92e-05	0.00276	-0.21	-0.13	Lung cancer in ever smokers;	chr15:43780662	chr15:43637632~43637738:-
BRCA	cis	rs2439831	0.85	rs28578398	ENSG00000206991.1	RNU6-610P	-4.13	3.92e-05	0.00276	-0.21	-0.13	Lung cancer in ever smokers;	chr15:43782848	chr15:43637632~43637738:-
BRCA	cis	rs1143633	0.615	rs4364030	ENSG00000231747.1	AC079922.2	4.13	3.92e-05	0.00276	0.13	0.13	Allergic disease (asthma, hay fever or eczema);	chr2:112906832	chr2:112621809~112622167:-
BRCA	cis	rs2070615	0.545	rs10875877	ENSG00000257964.1	RP11-133N21.10	-4.13	3.92e-05	0.00276	-0.14	-0.13	Bipolar disorder;	chr12:48804156	chr12:49576840~49577505:-
BRCA	cis	rs2625529	0.556	rs55679065	ENSG00000260037.4	CTD-2524L6.3	4.13	3.92e-05	0.00276	0.16	0.13	Red blood cell count;	chr15:72141054	chr15:71818396~71823384:+
BRCA	cis	rs8060686	0.545	rs8056649	ENSG00000280214.1	CTD-2012K14.5	4.13	3.92e-05	0.00276	0.19	0.13	HDL cholesterol;Metabolic syndrome;	chr16:68226180	chr16:67550815~67552935:-
BRCA	cis	rs11671005	0.571	rs56243535	ENSG00000269600.1	AC016629.3	-4.13	3.92e-05	0.00276	-0.21	-0.13	Mean platelet volume;	chr19:58494783	chr19:58593896~58599355:-
BRCA	cis	rs8114671	0.869	rs1407202	ENSG00000126005.14	MMP24-AS1	4.13	3.92e-05	0.00276	0.15	0.13	Height;	chr20:35064164	chr20:35216462~35278131:-
BRCA	cis	rs9959145	0.925	rs78425322	ENSG00000267108.1	RP11-861E21.1	4.13	3.92e-05	0.00276	0.23	0.13	Immune response to smallpox vaccine (IL-6);	chr18:12725105	chr18:12432897~12437635:+
BRCA	cis	rs2408955	0.504	rs11168441	ENSG00000257735.1	RP11-370I10.6	4.13	3.92e-05	0.00276	0.16	0.13	Glycated hemoglobin levels;	chr12:48182271	chr12:48350945~48442411:+
BRCA	cis	rs7824557	0.592	rs920044	ENSG00000255020.1	AF131216.5	-4.13	3.92e-05	0.00276	-0.15	-0.13	Retinal vascular caliber;	chr8:11366804	chr8:11345748~11347502:-
BRCA	cis	rs11083475	1	rs10403540	ENSG00000267892.1	CTD-2540F13.2	4.13	3.92e-05	0.00276	0.14	0.13	Heart rate;	chr19:38714206	chr19:38738284~38739863:+
BRCA	cis	rs13217239	0.646	rs10456351	ENSG00000124549.13	BTN2A3P	4.13	3.92e-05	0.00276	0.13	0.13	Schizophrenia;	chr6:27019013	chr6:26421391~26432383:+
BRCA	cis	rs9309473	0.718	rs6546829	ENSG00000163016.8	ALMS1P	4.13	3.92e-05	0.00276	0.15	0.13	Metabolite levels;	chr2:73386661	chr2:73644919~73685576:+
BRCA	cis	rs10266483	0.562	rs10949887	ENSG00000227986.1	TRIM60P18	-4.13	3.92e-05	0.00276	-0.15	-0.13	Response to statin therapy;	chr7:64291702	chr7:64355078~64356199:+
BRCA	cis	rs12681366	0.537	rs9297939	ENSG00000253175.1	RP11-267M23.6	4.13	3.92e-05	0.00276	0.15	0.13	Nonsyndromic cleft lip with cleft palate;	chr8:94467961	chr8:94565036~94565715:+
BRCA	cis	rs58521262	0.556	rs289317	ENSG00000268105.1	RP11-369G6.2	-4.13	3.92e-05	0.00276	-0.17	-0.13	Testicular germ cell tumor;	chr19:22978495	chr19:23125665~23128543:+
BRCA	cis	rs58521262	0.53	rs289315	ENSG00000268105.1	RP11-369G6.2	-4.13	3.92e-05	0.00276	-0.17	-0.13	Testicular germ cell tumor;	chr19:22979171	chr19:23125665~23128543:+
BRCA	cis	rs58521262	0.53	rs289310	ENSG00000268105.1	RP11-369G6.2	-4.13	3.92e-05	0.00276	-0.17	-0.13	Testicular germ cell tumor;	chr19:22982612	chr19:23125665~23128543:+
BRCA	cis	rs58521262	0.585	rs289307	ENSG00000268105.1	RP11-369G6.2	-4.13	3.92e-05	0.00276	-0.17	-0.13	Testicular germ cell tumor;	chr19:22984154	chr19:23125665~23128543:+
BRCA	cis	rs58521262	0.585	rs176456	ENSG00000268105.1	RP11-369G6.2	-4.13	3.92e-05	0.00276	-0.17	-0.13	Testicular germ cell tumor;	chr19:22984164	chr19:23125665~23128543:+
BRCA	cis	rs58521262	0.556	rs289303	ENSG00000268105.1	RP11-369G6.2	-4.13	3.92e-05	0.00276	-0.17	-0.13	Testicular germ cell tumor;	chr19:22986213	chr19:23125665~23128543:+
BRCA	cis	rs58521262	0.556	rs289329	ENSG00000268105.1	RP11-369G6.2	4.13	3.92e-05	0.00276	0.17	0.13	Testicular germ cell tumor;	chr19:22972365	chr19:23125665~23128543:+
BRCA	cis	rs58521262	0.556	rs289323	ENSG00000268105.1	RP11-369G6.2	4.13	3.92e-05	0.00276	0.17	0.13	Testicular germ cell tumor;	chr19:22974413	chr19:23125665~23128543:+
BRCA	cis	rs58521262	0.556	rs289321	ENSG00000268105.1	RP11-369G6.2	4.13	3.92e-05	0.00276	0.17	0.13	Testicular germ cell tumor;	chr19:22974479	chr19:23125665~23128543:+
BRCA	cis	rs6500602	0.627	rs2270363	ENSG00000280063.1	RP11-295D4.3	4.13	3.93e-05	0.00276	0.1	0.13	Schizophrenia;	chr16:4476291	chr16:4346694~4348648:-
BRCA	cis	rs11603691	0.901	rs11228997	ENSG00000254662.1	RP11-872D17.4	-4.13	3.93e-05	0.00276	-0.26	-0.13	Low high density lipoprotein cholesterol levels;	chr11:57316555	chr11:57325603~57327958:+
BRCA	cis	rs490234	0.902	rs7853181	ENSG00000232630.1	PRPS1P2	4.13	3.93e-05	0.00276	0.12	0.13	Mean arterial pressure;	chr9:125460745	chr9:125150653~125151589:+
BRCA	cis	rs9368481	0.761	rs9379952	ENSG00000224843.5	LINC00240	4.13	3.93e-05	0.00276	0.15	0.13	Autism spectrum disorder or schizophrenia;	chr6:27020121	chr6:26956992~27023924:+
BRCA	cis	rs9473147	0.586	rs7740538	ENSG00000270761.1	RP11-385F7.1	-4.13	3.93e-05	0.00276	-0.15	-0.13	Platelet distribution width;Mean platelet volume;	chr6:47665362	chr6:47477243~47477572:-
BRCA	cis	rs6671200	1	rs6671200	ENSG00000235501.4	RP4-639F20.1	4.13	3.93e-05	0.00277	0.26	0.13	Stearic acid (18:0) levels;	chr1:95231973	chr1:94927566~94963270:+
BRCA	cis	rs5758511	0.773	rs9623482	ENSG00000226450.2	CYP2D8P	4.13	3.93e-05	0.00277	0.14	0.13	Birth weight;	chr22:41964570	chr22:42149886~42155001:-
BRCA	cis	rs7896471	0.546	rs7910239	ENSG00000227695.4	DNMBP-AS1	-4.13	3.93e-05	0.00277	-0.29	-0.13	Blood protein levels;	chr10:99983799	chr10:99927010~99958381:+
BRCA	cis	rs8098244	0.737	rs948432	ENSG00000265752.2	RP11-403A21.1	-4.13	3.93e-05	0.00277	-0.18	-0.13	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23959998	chr18:23957754~23982556:-
BRCA	cis	rs7474896	0.616	rs2474561	ENSG00000120555.12	SEPT7P9	4.13	3.93e-05	0.00277	0.19	0.13	Obesity (extreme);	chr10:38084616	chr10:38383069~38402916:-
BRCA	cis	rs4835473	0.932	rs17763107	ENSG00000249741.2	RP11-673E1.3	4.13	3.93e-05	0.00277	0.14	0.13	Immature fraction of reticulocytes;	chr4:143828512	chr4:143911514~143912053:-
BRCA	cis	rs6460942	0.597	rs13221702	ENSG00000226690.5	AC005281.1	-4.13	3.93e-05	0.00277	-0.25	-0.13	Coronary artery disease;	chr7:12479450	chr7:12496429~12541910:+
BRCA	cis	rs4948275	0.597	rs2251482	ENSG00000237233.2	TMEM26-AS1	4.13	3.94e-05	0.00277	0.15	0.13	Night sleep phenotypes;	chr10:61606156	chr10:61452639~61481956:+
BRCA	cis	rs690037	0.528	rs568833	ENSG00000272529.1	RP11-415F23.4	4.13	3.94e-05	0.00277	0.11	0.13	Optic nerve measurement (cup-to-disc ratio);Optic nerve measurement (cup area);	chr3:16326329	chr3:16345126~16346440:+
BRCA	cis	rs11673344	0.562	rs7250507	ENSG00000276846.1	CTD-3220F14.3	4.13	3.94e-05	0.00277	0.15	0.13	Obesity-related traits;	chr19:37095772	chr19:37314868~37315620:-
BRCA	cis	rs2380205	0.935	rs7901964	ENSG00000232807.2	RP11-536K7.3	4.13	3.94e-05	0.00277	0.13	0.13	Breast cancer;	chr10:5854938	chr10:5934270~5945900:-
BRCA	cis	rs372883	0.6	rs2832293	ENSG00000176054.6	RPL23P2	4.13	3.94e-05	0.00277	0.14	0.13	Pancreatic cancer;	chr21:29366551	chr21:28997613~28998033:-
BRCA	cis	rs259282	0.813	rs259250	ENSG00000267475.1	CTD-2538C1.2	4.13	3.94e-05	0.00277	0.16	0.13	Schizophrenia;	chr19:32658310	chr19:32687089~32691750:-
BRCA	cis	rs2692947	1	rs2692947	ENSG00000168992.4	OR7E102P	4.13	3.94e-05	0.00277	0.17	0.13	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96008368	chr2:95546531~95547545:+
BRCA	cis	rs983392	0.709	rs1426250	ENSG00000275344.1	MIR6503	-4.13	3.94e-05	0.00277	-0.13	-0.13	Alzheimer's disease (late onset);	chr11:60233852	chr11:60209071~60209156:-
BRCA	cis	rs4415084	0.688	rs67274820	ENSG00000251141.4	RP11-53O19.1	4.13	3.94e-05	0.00277	0.12	0.13	Breast cancer;	chr5:44782193	chr5:44744900~44808777:-
BRCA	cis	rs4415084	0.716	rs16901963	ENSG00000251141.4	RP11-53O19.1	4.13	3.94e-05	0.00277	0.12	0.13	Breast cancer;	chr5:44783000	chr5:44744900~44808777:-
BRCA	cis	rs4415084	0.716	rs16901965	ENSG00000251141.4	RP11-53O19.1	4.13	3.94e-05	0.00277	0.12	0.13	Breast cancer;	chr5:44783256	chr5:44744900~44808777:-
BRCA	cis	rs4415084	0.716	rs6875933	ENSG00000251141.4	RP11-53O19.1	4.13	3.94e-05	0.00277	0.12	0.13	Breast cancer;	chr5:44786594	chr5:44744900~44808777:-
BRCA	cis	rs6012564	1	rs755587	ENSG00000222365.1	SNORD12B	4.13	3.94e-05	0.00277	0.13	0.13	Anger;	chr20:49104420	chr20:49280319~49280409:+
BRCA	cis	rs853679	1	rs6905391	ENSG00000280107.1	AL022393.9	-4.13	3.94e-05	0.00277	-0.22	-0.13	Depression;	chr6:28294909	chr6:28170845~28172521:+
BRCA	cis	rs10129255	0.957	rs12590667	ENSG00000211967.3	IGHV3-53	4.13	3.94e-05	0.00277	0.09	0.13	Kawasaki disease;	chr14:106779223	chr14:106592676~106593347:-
BRCA	cis	rs17345786	1	rs997739	ENSG00000244119.1	PDCL3P4	4.13	3.94e-05	0.00277	0.11	0.13	Colonoscopy-negative controls vs population controls;	chr3:101595096	chr3:101712472~101713191:+
BRCA	cis	rs12908161	0.959	rs17598603	ENSG00000229212.6	RP11-561C5.4	4.13	3.94e-05	0.00277	0.16	0.13	Schizophrenia;	chr15:84656980	chr15:85205440~85234795:-
BRCA	cis	rs7267979	0.932	rs431579	ENSG00000274414.1	RP5-965G21.4	-4.13	3.95e-05	0.00278	-0.15	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25489420	chr20:25239007~25245229:-
BRCA	cis	rs801193	0.901	rs4273746	ENSG00000229180.5	GS1-124K5.11	-4.13	3.95e-05	0.00278	-0.11	-0.13	Aortic root size;	chr7:66836124	chr7:66526088~66542624:-
BRCA	cis	rs4930561	0.765	rs1894204	ENSG00000184795.9	UNC93B5	-4.13	3.95e-05	0.00278	-0.14	-0.13	Breast cancer in childhood cancer survivors;IgG glycosylation;	chr11:68162204	chr11:67711702~67716005:-
BRCA	cis	rs2439831	0.702	rs7171750	ENSG00000206991.1	RNU6-610P	-4.13	3.95e-05	0.00278	-0.21	-0.13	Lung cancer in ever smokers;	chr15:43733660	chr15:43637632~43637738:-
BRCA	cis	rs6012564	1	rs2252259	ENSG00000222365.1	SNORD12B	-4.13	3.95e-05	0.00278	-0.13	-0.13	Anger;	chr20:49046286	chr20:49280319~49280409:+
BRCA	cis	rs62025270	1	rs62025270	ENSG00000202081.1	RNU6-1280P	-4.13	3.95e-05	0.00278	-0.19	-0.13	Idiopathic pulmonary fibrosis;	chr15:85756967	chr15:85651522~85651628:-
BRCA	cis	rs8105895	0.935	rs28374572	ENSG00000269345.1	VN1R85P	4.13	3.95e-05	0.00278	0.18	0.13	Body mass index (change over time);	chr19:22093676	chr19:22174766~22175191:-
BRCA	cis	rs11696845	1	rs1555299	ENSG00000276223.1	RP4-781B1.5	-4.13	3.95e-05	0.00278	-0.13	-0.13	Obesity-related traits;	chr20:44741465	chr20:44746642~44747201:+
BRCA	cis	rs11696845	1	rs13038016	ENSG00000276223.1	RP4-781B1.5	-4.13	3.95e-05	0.00278	-0.13	-0.13	Obesity-related traits;	chr20:44741856	chr20:44746642~44747201:+
BRCA	cis	rs11696845	1	rs13037759	ENSG00000276223.1	RP4-781B1.5	-4.13	3.95e-05	0.00278	-0.13	-0.13	Obesity-related traits;	chr20:44742051	chr20:44746642~44747201:+
BRCA	cis	rs11696845	0.965	rs13038381	ENSG00000276223.1	RP4-781B1.5	-4.13	3.95e-05	0.00278	-0.13	-0.13	Obesity-related traits;	chr20:44742106	chr20:44746642~44747201:+
BRCA	cis	rs4699052	0.662	rs1516731	ENSG00000248740.4	RP11-328K4.1	4.13	3.95e-05	0.00278	0.14	0.13	Testicular germ cell tumor;	chr4:103331537	chr4:103256159~103453658:+
BRCA	cis	rs1865760	0.892	rs2328903	ENSG00000272462.2	U91328.19	-4.13	3.95e-05	0.00278	-0.15	-0.13	Height;	chr6:25935537	chr6:25992662~26001775:+
BRCA	cis	rs1865760	0.892	rs6456705	ENSG00000272462.2	U91328.19	-4.13	3.95e-05	0.00278	-0.15	-0.13	Height;	chr6:25935828	chr6:25992662~26001775:+
BRCA	cis	rs7572733	0.935	rs1369511	ENSG00000231621.1	AC013264.2	-4.13	3.95e-05	0.00278	-0.12	-0.13	Dermatomyositis;	chr2:197881391	chr2:197197991~197199273:+
BRCA	cis	rs2832191	0.655	rs2247110	ENSG00000232855.5	AF131217.1	4.13	3.95e-05	0.00278	0.15	0.13	Dental caries;	chr21:28951566	chr21:28439346~28674848:-
BRCA	cis	rs11722228	1	rs11722228	ENSG00000250413.1	RP11-448G15.1	-4.13	3.95e-05	0.00278	-0.17	-0.13	Urate levels;Serum uric acid levels;Gout;	chr4:9914117	chr4:10006482~10009725:+
BRCA	cis	rs2739330	0.828	rs4820572	ENSG00000228039.3	KB-1125A3.10	4.13	3.95e-05	0.00278	0.15	0.13	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23963780~23964374:+
BRCA	cis	rs7927592	0.763	rs10791982	ENSG00000212093.1	AP000807.1	-4.13	3.95e-05	0.00278	-0.13	-0.13	Total body bone mineral density;	chr11:68570196	chr11:68506083~68506166:-
BRCA	cis	rs7475343	0.505	rs1781929	ENSG00000224034.1	RP11-445P17.8	4.13	3.95e-05	0.00278	0.24	0.13	Intelligence;	chr10:5153924	chr10:5266033~5271236:-
BRCA	cis	rs6600671	1	rs6600669	ENSG00000223345.3	HIST2H2BA	4.13	3.95e-05	0.00278	0.15	0.13	Hip geometry;	chr1:121471785	chr1:121108210~121117257:-
BRCA	cis	rs4950322	0.57	rs17356219	ENSG00000237188.3	RP11-337C18.8	4.13	3.95e-05	0.00278	0.16	0.13	Protein quantitative trait loci;	chr1:147265684	chr1:147172771~147211568:+
BRCA	cis	rs4950322	0.57	rs17356233	ENSG00000237188.3	RP11-337C18.8	4.13	3.95e-05	0.00278	0.16	0.13	Protein quantitative trait loci;	chr1:147268843	chr1:147172771~147211568:+
BRCA	cis	rs2071426	0.622	rs2901826	ENSG00000273450.1	RP11-76P2.4	4.13	3.95e-05	0.00278	0.17	0.13	Blood metabolite levels;	chr10:95009322	chr10:94314907~94315327:-
BRCA	cis	rs1387259	0.57	rs12368659	ENSG00000257735.1	RP11-370I10.6	4.13	3.95e-05	0.00278	0.16	0.13	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48168516	chr12:48350945~48442411:+
BRCA	cis	rs853679	0.517	rs6922063	ENSG00000216901.1	AL022393.7	4.13	3.95e-05	0.00278	0.18	0.13	Depression;	chr6:28126588	chr6:28176188~28176674:+
BRCA	cis	rs853679	0.517	rs2275508	ENSG00000216901.1	AL022393.7	4.13	3.95e-05	0.00278	0.18	0.13	Depression;	chr6:28126953	chr6:28176188~28176674:+
BRCA	cis	rs12612619	0.732	rs1053609	ENSG00000272148.1	RP11-195B17.1	4.13	3.96e-05	0.00278	0.14	0.13	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27070282	chr2:27062428~27062907:-
BRCA	cis	rs7647973	1	rs9842132	ENSG00000244380.1	RP11-24C3.2	-4.13	3.96e-05	0.00278	-0.16	-0.13	Menarche (age at onset);	chr3:49390500	chr3:48440352~48446656:-
BRCA	cis	rs8098244	0.603	rs2337186	ENSG00000265752.2	RP11-403A21.1	4.13	3.96e-05	0.00278	0.14	0.13	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23732088	chr18:23957754~23982556:-
BRCA	cis	rs10266483	0.774	rs10239221	ENSG00000271550.1	BNIP3P11	-4.13	3.96e-05	0.00278	-0.17	-0.13	Response to statin therapy;	chr7:64352852	chr7:64678954~64687393:-
BRCA	cis	rs1161098	0.71	rs7304063	ENSG00000256037.1	MRPL40P1	-4.13	3.96e-05	0.00278	-0.16	-0.13	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr12:67418684	chr12:67351436~67352039:+
BRCA	cis	rs72819225	0.616	rs12256726	ENSG00000228701.1	TNKS2-AS1	4.13	3.96e-05	0.00278	0.17	0.13	Yeast infection;	chr10:91569370	chr10:91782839~91798291:-
BRCA	cis	rs7412746	0.658	rs2230061	ENSG00000231073.1	RP11-316M1.3	4.13	3.96e-05	0.00278	0.14	0.13	Melanoma;	chr1:150755063	chr1:150973123~150975534:+
BRCA	cis	rs61931739	0.517	rs7958755	ENSG00000258794.3	DUX4L27	4.13	3.96e-05	0.00278	0.18	0.13	Morning vs. evening chronotype;	chr12:34141764	chr12:34208415~34209675:-
BRCA	cis	rs61931739	0.517	rs7958856	ENSG00000258794.3	DUX4L27	4.13	3.96e-05	0.00278	0.18	0.13	Morning vs. evening chronotype;	chr12:34141802	chr12:34208415~34209675:-
BRCA	cis	rs875971	0.508	rs10242423	ENSG00000273142.1	RP11-458F8.4	4.13	3.96e-05	0.00278	0.11	0.13	Aortic root size;	chr7:66594188	chr7:66902857~66906297:+
BRCA	cis	rs875971	0.508	rs10253883	ENSG00000273142.1	RP11-458F8.4	4.13	3.96e-05	0.00278	0.11	0.13	Aortic root size;	chr7:66596151	chr7:66902857~66906297:+
BRCA	cis	rs12049351	0.774	rs6668018	ENSG00000229367.1	HMGN2P19	4.13	3.96e-05	0.00278	0.18	0.13	Circulating myeloperoxidase levels (plasma);	chr1:229493306	chr1:229570532~229570796:+
BRCA	cis	rs4930561	0.765	rs4930564	ENSG00000184795.9	UNC93B5	4.13	3.96e-05	0.00278	0.14	0.13	Breast cancer in childhood cancer survivors;IgG glycosylation;	chr11:68215814	chr11:67711702~67716005:-
BRCA	cis	rs13126694	0.633	rs4326059	ENSG00000251429.1	RP11-597D13.7	-4.13	3.96e-05	0.00278	-0.13	-0.13	Blood osmolality (transformed sodium);	chr4:158075315	chr4:158270378~158278676:+
BRCA	cis	rs6012564	0.964	rs2064853	ENSG00000222365.1	SNORD12B	-4.13	3.96e-05	0.00279	-0.13	-0.13	Anger;	chr20:49058639	chr20:49280319~49280409:+
BRCA	cis	rs13401620	0.843	rs6726490	ENSG00000229326.3	AC069154.4	-4.13	3.96e-05	0.00279	-0.16	-0.13	Breast size;	chr2:119850555	chr2:119698623~119700151:+
BRCA	cis	rs720475	0.732	rs17172978	ENSG00000228960.5	OR2A9P	-4.13	3.96e-05	0.00279	-0.19	-0.13	Breast cancer;	chr7:144429551	chr7:144294480~144300934:+
BRCA	cis	rs893818	1	rs4886776	ENSG00000261801.4	LOXL1-AS1	4.13	3.96e-05	0.00279	0.16	0.13	Exfoliation glaucoma or exfoliation syndrome;	chr15:73932655	chr15:73908071~73928248:-
BRCA	cis	rs754466	0.58	rs2579176	ENSG00000213514.2	RP11-428P16.2	4.13	3.96e-05	0.00279	0.18	0.13	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77769592	chr10:77730766~77734769:+
BRCA	cis	rs2380205	0.967	rs10905303	ENSG00000232807.2	RP11-536K7.3	4.13	3.96e-05	0.00279	0.13	0.13	Breast cancer;	chr10:5852217	chr10:5934270~5945900:-
BRCA	cis	rs1371614	0.635	rs34803465	ENSG00000229122.1	AGBL5-IT1	-4.13	3.97e-05	0.00279	-0.13	-0.13	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26915417	chr2:27061038~27061815:+
BRCA	cis	rs6044112	0.948	rs17743285	ENSG00000273998.1	RP4-777L9.2	4.13	3.97e-05	0.00279	0.23	0.13	Response to taxane treatment (docetaxel);	chr20:16559079	chr20:16576068~16579615:+
BRCA	cis	rs9527	0.544	rs11191549	ENSG00000213061.2	PFN1P11	4.13	3.97e-05	0.00279	0.17	0.13	Arsenic metabolism;	chr10:103087040	chr10:102838011~102845473:-
BRCA	cis	rs721917	0.525	rs2758541	ENSG00000278616.1	BEND3P3	-4.13	3.97e-05	0.00279	-0.12	-0.13	Chronic obstructive pulmonary disease;	chr10:79895801	chr10:79682997~79685436:+
BRCA	cis	rs2031532	0.589	rs4941643	ENSG00000236577.1	SNRPGP14	4.13	3.97e-05	0.00279	0.14	0.13	Cardiac hypertrophy;	chr13:49494251	chr13:49488970~49489364:+
BRCA	cis	rs4713118	0.587	rs9393899	ENSG00000261839.1	RP1-265C24.8	4.13	3.97e-05	0.00279	0.18	0.13	Parkinson's disease;	chr6:28165750	chr6:28136849~28139678:+
BRCA	cis	rs7003550	1	rs7003550	ENSG00000254028.1	AC083843.2	4.13	3.97e-05	0.00279	0.17	0.13	Bone mineral accretion in asthma (oral corticosteroid dose interaction);	chr8:134838655	chr8:134832747~134834482:+
BRCA	cis	rs875971	1	rs10244498	ENSG00000229180.5	GS1-124K5.11	4.13	3.97e-05	0.00279	0.11	0.13	Aortic root size;	chr7:66651069	chr7:66526088~66542624:-
BRCA	cis	rs4919687	0.55	rs11191372	ENSG00000213061.2	PFN1P11	4.13	3.97e-05	0.00279	0.18	0.13	Colorectal cancer;	chr10:102702430	chr10:102838011~102845473:-
BRCA	cis	rs721917	0.506	rs2758547	ENSG00000242600.5	MBL1P	4.13	3.97e-05	0.00279	0.16	0.13	Chronic obstructive pulmonary disease;	chr10:79937368	chr10:79904898~79950336:+
BRCA	cis	rs2599510	0.783	rs2568464	ENSG00000276517.1	AL133243.2	4.13	3.97e-05	0.00279	0.15	0.13	Interleukin-18 levels;	chr2:32623591	chr2:32526504~32529507:+
BRCA	cis	rs1476679	1	rs1476679	ENSG00000235713.1	RP4-604G5.3	-4.13	3.97e-05	0.00279	-0.15	-0.13	Alzheimer's disease (late onset);	chr7:100406823	chr7:99992397~99993050:+
BRCA	cis	rs952623	0.649	rs6462887	ENSG00000211694.2	TRGV10	4.13	3.97e-05	0.00279	0.11	0.13	Intelligence (multi-trait analysis);	chr7:39028036	chr7:38299811~38300322:-
BRCA	cis	rs4218	0.543	rs12050865	ENSG00000259732.1	RP11-59H7.3	-4.13	3.98e-05	0.00279	-0.15	-0.13	Social communication problems;	chr15:59020689	chr15:59121034~59133250:+
BRCA	cis	rs11098499	0.909	rs28668716	ENSG00000260091.1	RP11-33B1.4	-4.13	3.98e-05	0.00279	-0.11	-0.13	Corneal astigmatism;	chr4:119388720	chr4:119409333~119410233:+
BRCA	cis	rs465969	1	rs17510733	ENSG00000272356.1	RP5-1112D6.8	4.13	3.98e-05	0.00279	0.28	0.13	Psoriasis;	chr6:111389715	chr6:111309203~111313517:+
BRCA	cis	rs2243480	1	rs1723267	ENSG00000275400.1	RP4-756H11.5	4.13	3.98e-05	0.0028	0.23	0.13	Diabetic kidney disease;	chr7:66008327	chr7:66553805~66554199:-
BRCA	cis	rs4835473	0.868	rs35809032	ENSG00000249741.2	RP11-673E1.3	4.13	3.98e-05	0.0028	0.14	0.13	Immature fraction of reticulocytes;	chr4:143824797	chr4:143911514~143912053:-
BRCA	cis	rs853679	0.517	rs9393896	ENSG00000216901.1	AL022393.7	4.13	3.98e-05	0.0028	0.18	0.13	Depression;	chr6:28159925	chr6:28176188~28176674:+
BRCA	cis	rs853679	0.517	rs9393897	ENSG00000216901.1	AL022393.7	4.13	3.98e-05	0.0028	0.18	0.13	Depression;	chr6:28159932	chr6:28176188~28176674:+
BRCA	cis	rs2439831	0.702	rs7175032	ENSG00000206991.1	RNU6-610P	-4.13	3.98e-05	0.0028	-0.21	-0.13	Lung cancer in ever smokers;	chr15:43768038	chr15:43637632~43637738:-
BRCA	cis	rs13434995	0.513	rs972446	ENSG00000239040.1	Y_RNA	-4.13	3.98e-05	0.0028	-0.15	-0.13	Adiponectin levels;	chr4:55569581	chr4:55412636~55412738:+
BRCA	cis	rs13434995	0.513	rs11732481	ENSG00000239040.1	Y_RNA	-4.13	3.98e-05	0.0028	-0.15	-0.13	Adiponectin levels;	chr4:55570212	chr4:55412636~55412738:+
BRCA	cis	rs4415084	0.646	rs969679	ENSG00000251141.4	RP11-53O19.1	4.13	3.98e-05	0.0028	0.12	0.13	Breast cancer;	chr5:44803950	chr5:44744900~44808777:-
BRCA	cis	rs4415084	0.716	rs7717459	ENSG00000251141.4	RP11-53O19.1	4.13	3.98e-05	0.0028	0.12	0.13	Breast cancer;	chr5:44804423	chr5:44744900~44808777:-
BRCA	cis	rs4415084	0.662	rs3761649	ENSG00000251141.4	RP11-53O19.1	4.13	3.98e-05	0.0028	0.12	0.13	Breast cancer;	chr5:44808062	chr5:44744900~44808777:-
BRCA	cis	rs4415084	0.716	rs3761650	ENSG00000251141.4	RP11-53O19.1	4.13	3.98e-05	0.0028	0.12	0.13	Breast cancer;	chr5:44808254	chr5:44744900~44808777:-
BRCA	cis	rs4415084	0.716	rs3747479	ENSG00000251141.4	RP11-53O19.1	4.13	3.98e-05	0.0028	0.12	0.13	Breast cancer;	chr5:44809060	chr5:44744900~44808777:-
BRCA	cis	rs4415084	0.716	rs1866406	ENSG00000251141.4	RP11-53O19.1	4.13	3.98e-05	0.0028	0.12	0.13	Breast cancer;	chr5:44809843	chr5:44744900~44808777:-
BRCA	cis	rs4415084	0.716	rs11746506	ENSG00000251141.4	RP11-53O19.1	4.13	3.98e-05	0.0028	0.12	0.13	Breast cancer;	chr5:44812464	chr5:44744900~44808777:-
BRCA	cis	rs875971	0.66	rs79009421	ENSG00000229180.5	GS1-124K5.11	-4.13	3.98e-05	0.0028	-0.11	-0.13	Aortic root size;	chr7:66603522	chr7:66526088~66542624:-
BRCA	cis	rs7829975	0.742	rs1533059	ENSG00000253981.4	ALG1L13P	-4.13	3.98e-05	0.0028	-0.14	-0.13	Mood instability;	chr8:8827443	chr8:8236003~8244667:-
BRCA	cis	rs13326165	0.715	rs34908451	ENSG00000243224.1	RP5-1157M23.2	-4.13	3.98e-05	0.0028	-0.18	-0.13	HDL cholesterol levels;HDL cholesterol;	chr3:52351099	chr3:52239258~52241097:+
BRCA	cis	rs660899	0.857	rs56352978	ENSG00000229431.1	RP1-92O14.6	-4.13	3.98e-05	0.0028	-0.14	-0.13	Hypertension risk in short sleep duration;	chr1:43765809	chr1:43385113~43389155:+
BRCA	cis	rs6828577	0.779	rs419292	ENSG00000281731.1	RP11-384K6.8	-4.13	3.99e-05	0.0028	-0.14	-0.13	Perioperative myocardial infarction in coronary artery bypass surgery;	chr4:118712975	chr4:118664087~118685341:-
BRCA	cis	rs6828577	0.819	rs368669	ENSG00000281731.1	RP11-384K6.8	-4.13	3.99e-05	0.0028	-0.14	-0.13	Perioperative myocardial infarction in coronary artery bypass surgery;	chr4:118713120	chr4:118664087~118685341:-
BRCA	cis	rs6828577	0.862	rs298974	ENSG00000281731.1	RP11-384K6.8	-4.13	3.99e-05	0.0028	-0.14	-0.13	Perioperative myocardial infarction in coronary artery bypass surgery;	chr4:118714879	chr4:118664087~118685341:-
BRCA	cis	rs6128907	0.8	rs6129020	ENSG00000224635.1	RP4-564F22.5	-4.13	3.99e-05	0.0028	-0.22	-0.13	Liver fibrosis in pediatric non-alcoholic fatty acid liver disease;	chr20:38786294	chr20:38406011~38416797:-
BRCA	cis	rs10266483	0.843	rs10272639	ENSG00000227986.1	TRIM60P18	-4.13	3.99e-05	0.0028	-0.13	-0.13	Response to statin therapy;	chr7:64278944	chr7:64355078~64356199:+
BRCA	cis	rs11098499	0.754	rs10212714	ENSG00000260091.1	RP11-33B1.4	-4.13	3.99e-05	0.0028	-0.11	-0.13	Corneal astigmatism;	chr4:119333147	chr4:119409333~119410233:+
BRCA	cis	rs911119	0.955	rs6048933	ENSG00000270001.1	RP11-218C14.8	-4.13	3.99e-05	0.0028	-0.17	-0.13	Chronic kidney disease;	chr20:23615000	chr20:23631826~23632316:-
BRCA	cis	rs911119	0.908	rs6048949	ENSG00000270001.1	RP11-218C14.8	-4.13	3.99e-05	0.0028	-0.16	-0.13	Chronic kidney disease;	chr20:23622562	chr20:23631826~23632316:-
BRCA	cis	rs911119	0.908	rs6048950	ENSG00000270001.1	RP11-218C14.8	-4.13	3.99e-05	0.0028	-0.16	-0.13	Chronic kidney disease;	chr20:23622615	chr20:23631826~23632316:-
BRCA	cis	rs9470794	0.588	rs11757143	ENSG00000204110.6	RP1-153P14.8	-4.13	3.99e-05	0.0028	-0.21	-0.13	Type 2 diabetes;	chr6:38098294	chr6:37507348~37535616:+
BRCA	cis	rs495337	0.76	rs6067282	ENSG00000229222.1	KRT18P4	-4.13	3.99e-05	0.0028	-0.16	-0.13	Psoriasis;	chr20:49952741	chr20:49956745~49958032:+
BRCA	cis	rs17684571	0.687	rs17752213	ENSG00000231441.1	RP11-472M19.2	4.13	3.99e-05	0.0028	0.21	0.13	Schizophrenia;	chr6:56864627	chr6:56844002~56864078:+
BRCA	cis	rs2835872	0.965	rs73222314	ENSG00000228677.1	TTC3-AS1	-4.13	3.99e-05	0.0028	-0.17	-0.13	Electroencephalographic traits in alcoholism;	chr21:37642500	chr21:37187666~37193926:-
BRCA	cis	rs2835872	0.965	rs2835853	ENSG00000228677.1	TTC3-AS1	-4.13	3.99e-05	0.0028	-0.17	-0.13	Electroencephalographic traits in alcoholism;	chr21:37642590	chr21:37187666~37193926:-
BRCA	cis	rs2229238	0.911	rs57783436	ENSG00000272030.1	RP1-178F15.4	-4.13	3.99e-05	0.0028	-0.18	-0.13	Coronary heart disease;	chr1:154539233	chr1:153631438~153634397:-
BRCA	cis	rs2229238	0.911	rs73023346	ENSG00000272030.1	RP1-178F15.4	-4.13	3.99e-05	0.0028	-0.18	-0.13	Coronary heart disease;	chr1:154539601	chr1:153631438~153634397:-
BRCA	cis	rs2229238	0.868	rs73023348	ENSG00000272030.1	RP1-178F15.4	-4.13	3.99e-05	0.0028	-0.18	-0.13	Coronary heart disease;	chr1:154540942	chr1:153631438~153634397:-
BRCA	cis	rs2229238	0.868	rs72999419	ENSG00000272030.1	RP1-178F15.4	-4.13	3.99e-05	0.0028	-0.18	-0.13	Coronary heart disease;	chr1:154541616	chr1:153631438~153634397:-
BRCA	cis	rs2229238	0.911	rs41313910	ENSG00000272030.1	RP1-178F15.4	-4.13	3.99e-05	0.0028	-0.18	-0.13	Coronary heart disease;	chr1:154541727	chr1:153631438~153634397:-
BRCA	cis	rs7308116	0.546	rs2374728	ENSG00000274395.1	RP11-554D14.8	-4.13	3.99e-05	0.0028	-0.15	-0.13	Pelvic organ prolapse (moderate/severe);	chr12:107833522	chr12:107835541~107836555:-
BRCA	cis	rs6439699	0.825	rs66527272	ENSG00000273486.1	RP11-731C17.2	4.13	3.99e-05	0.0028	0.18	0.13	Intelligence (multi-trait analysis);	chr3:137352185	chr3:136837338~136839021:-
BRCA	cis	rs9423406	0.66	rs113394930	ENSG00000215267.7	AKR1C7P	-4.13	3.99e-05	0.0028	-0.24	-0.13	Intelligence;	chr10:5254040	chr10:5275173~5288470:-
BRCA	cis	rs7590268	0.789	rs6751298	ENSG00000279873.2	LINC01126	4.13	3.99e-05	0.0028	0.15	0.13	Orofacial clefts;	chr2:43400521	chr2:43227210~43228855:+
BRCA	cis	rs853679	1	rs6901575	ENSG00000204709.4	LINC01556	4.13	3.99e-05	0.0028	0.22	0.13	Depression;	chr6:28283207	chr6:28943877~28944537:+
BRCA	cis	rs4143844	0.867	rs11637606	ENSG00000259251.2	RP11-643M14.1	-4.13	3.99e-05	0.00281	-0.29	-0.13	Bipolar disorder and schizophrenia;	chr15:61912515	chr15:62060503~62062434:+
BRCA	cis	rs2911132	0.568	rs3797814	ENSG00000272109.1	CTD-2260A17.3	-4.13	3.99e-05	0.00281	-0.18	-0.13	Urate levels (BMI interaction);	chr5:96756222	chr5:96804353~96806105:+
BRCA	cis	rs2835345	0.563	rs12627161	ENSG00000233818.1	AP000695.4	4.13	4e-05	0.00281	0.13	0.13	Pulmonary function;	chr21:36449649	chr21:36445731~36532408:+
BRCA	cis	rs2835345	0.563	rs12627241	ENSG00000233818.1	AP000695.4	4.13	4e-05	0.00281	0.13	0.13	Pulmonary function;	chr21:36449689	chr21:36445731~36532408:+
BRCA	cis	rs2835345	0.563	rs12627173	ENSG00000233818.1	AP000695.4	4.13	4e-05	0.00281	0.13	0.13	Pulmonary function;	chr21:36449715	chr21:36445731~36532408:+
BRCA	cis	rs1910358	0.648	rs1910064	ENSG00000248874.4	C5orf17	-4.13	4e-05	0.00281	-0.17	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:24007008	chr5:23951348~24178263:+
BRCA	cis	rs7811142	1	rs11761725	ENSG00000078319.8	PMS2P1	-4.13	4e-05	0.00281	-0.22	-0.13	Platelet count;	chr7:100442192	chr7:100320992~100341908:-
BRCA	cis	rs2486012	0.737	rs37457	ENSG00000237950.1	RP11-7O11.3	4.13	4e-05	0.00281	0.23	0.13	Intelligence (multi-trait analysis);	chr1:43825519	chr1:43944370~43946551:-
BRCA	cis	rs4907240	0.922	rs4907246	ENSG00000230606.9	AC159540.1	4.13	4e-05	0.00281	0.16	0.13	Event-related brain oscillations;	chr2:96660549	chr2:97416165~97433527:-
BRCA	cis	rs4713118	0.621	rs9295755	ENSG00000272009.1	RP1-313I6.12	4.13	4e-05	0.00281	0.19	0.13	Parkinson's disease;	chr6:28065396	chr6:28078792~28081130:-
BRCA	cis	rs6921919	0.583	rs9468355	ENSG00000220721.1	OR1F12	4.13	4e-05	0.00281	0.15	0.13	Autism spectrum disorder or schizophrenia;	chr6:28374100	chr6:28073316~28074233:+
BRCA	cis	rs4578769	0.685	rs6507432	ENSG00000265939.1	UBE2CP2	4.13	4e-05	0.00281	0.16	0.13	Eosinophil percentage of white cells;	chr18:23010884	chr18:22900486~22900995:-
BRCA	cis	rs11892454	0.515	rs13405775	ENSG00000217643.1	PTGES3P2	-4.13	4e-05	0.00281	-0.13	-0.13	Heschl's gyrus morphology;	chr2:25804117	chr2:25822469~25822950:+
BRCA	cis	rs300890	0.664	rs13137362	ENSG00000250326.1	RP11-284M14.1	-4.13	4e-05	0.00281	-0.14	-0.13	Nasopharyngeal carcinoma;	chr4:143278821	chr4:142933195~143184861:-
BRCA	cis	rs13434995	0.513	rs6846764	ENSG00000239040.1	Y_RNA	-4.13	4e-05	0.00281	-0.15	-0.13	Adiponectin levels;	chr4:55557322	chr4:55412636~55412738:+
BRCA	cis	rs13434995	0.513	rs6853506	ENSG00000239040.1	Y_RNA	-4.13	4e-05	0.00281	-0.15	-0.13	Adiponectin levels;	chr4:55558207	chr4:55412636~55412738:+
BRCA	cis	rs1008375	1	rs1558378	ENSG00000249502.1	AC006160.5	-4.13	4e-05	0.00281	-0.14	-0.13	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17648728	chr4:17587467~17614571:-
BRCA	cis	rs1008375	1	rs1558377	ENSG00000249502.1	AC006160.5	-4.13	4e-05	0.00281	-0.14	-0.13	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17649135	chr4:17587467~17614571:-
BRCA	cis	rs1008375	0.966	rs2872957	ENSG00000249502.1	AC006160.5	-4.13	4e-05	0.00281	-0.14	-0.13	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17650134	chr4:17587467~17614571:-
BRCA	cis	rs80226907	0.539	rs8015252	ENSG00000186615.9	KTN1-AS1	4.13	4e-05	0.00281	0.22	0.13	Mean platelet volume;	chr14:55448675	chr14:55499278~55580110:-
BRCA	cis	rs11098499	0.954	rs6849171	ENSG00000250412.1	KLHL2P1	4.12	4e-05	0.00281	0.15	0.13	Corneal astigmatism;	chr4:119488394	chr4:119334329~119378233:+
BRCA	cis	rs3812049	0.826	rs2409110	ENSG00000245937.6	LINC01184	4.12	4e-05	0.00281	0.17	0.13	Lymphocyte counts;Red cell distribution width;	chr5:128097355	chr5:127940426~128083172:-
BRCA	cis	rs1065852	0.526	rs739296	ENSG00000205702.9	CYP2D7	-4.12	4e-05	0.00281	-0.11	-0.13	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:41993944	chr22:42140203~42144577:-
BRCA	cis	rs13113518	0.678	rs7663650	ENSG00000272969.1	RP11-528I4.2	-4.12	4e-05	0.00281	-0.15	-0.13	Height;	chr4:55364952	chr4:55547112~55547889:+
BRCA	cis	rs703842	0.739	rs701008	ENSG00000270039.1	RP11-571M6.17	-4.12	4.01e-05	0.00281	-0.17	-0.13	Multiple sclerosis;	chr12:57723862	chr12:57803838~57804415:+
BRCA	cis	rs853679	0.713	rs200991	ENSG00000216901.1	AL022393.7	-4.12	4.01e-05	0.00281	-0.21	-0.13	Depression;	chr6:27847716	chr6:28176188~28176674:+
BRCA	cis	rs13434995	0.513	rs2130040	ENSG00000239040.1	Y_RNA	-4.12	4.01e-05	0.00281	-0.15	-0.13	Adiponectin levels;	chr4:55564036	chr4:55412636~55412738:+
BRCA	cis	rs2839186	0.934	rs4819221	ENSG00000239415.1	AP001469.9	-4.12	4.01e-05	0.00281	-0.13	-0.13	Testicular germ cell tumor;	chr21:46275503	chr21:46251549~46254133:-
BRCA	cis	rs11098499	0.955	rs1511015	ENSG00000250412.1	KLHL2P1	4.12	4.01e-05	0.00281	0.15	0.13	Corneal astigmatism;	chr4:119249318	chr4:119334329~119378233:+
BRCA	cis	rs6088580	0.609	rs6059844	ENSG00000275784.1	RP5-1125A11.6	-4.12	4.01e-05	0.00281	-0.13	-0.13	Glomerular filtration rate (creatinine);	chr20:34448677	chr20:33989480~33991818:-
BRCA	cis	rs6963495	0.818	rs56268110	ENSG00000223886.3	RP11-251G23.2	4.12	4.01e-05	0.00281	0.2	0.13	Bipolar disorder (body mass index interaction);	chr7:105526265	chr7:105530209~105530671:+
BRCA	cis	rs6963495	0.818	rs55825845	ENSG00000223886.3	RP11-251G23.2	4.12	4.01e-05	0.00281	0.2	0.13	Bipolar disorder (body mass index interaction);	chr7:105526266	chr7:105530209~105530671:+
BRCA	cis	rs2486012	0.85	rs246774	ENSG00000237950.1	RP11-7O11.3	4.12	4.01e-05	0.00281	0.24	0.13	Intelligence (multi-trait analysis);	chr1:43834023	chr1:43944370~43946551:-
BRCA	cis	rs6456156	0.819	rs9457273	ENSG00000272549.1	RP11-351J23.2	4.12	4.01e-05	0.00281	0.13	0.13	Primary biliary cholangitis;	chr6:167107261	chr6:167666840~167679270:-
BRCA	cis	rs7523050	0.908	rs67425757	ENSG00000203897.3	SPATA42	-4.12	4.01e-05	0.00281	-0.22	-0.13	Fat distribution (HIV);	chr1:108856034	chr1:108857217~108858524:+
BRCA	cis	rs78487399	0.808	rs72865297	ENSG00000234936.1	AC010883.5	4.12	4.01e-05	0.00281	0.18	0.13	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43516109	chr2:43229573~43233394:+
BRCA	cis	rs17345786	1	rs73863360	ENSG00000244119.1	PDCL3P4	4.12	4.01e-05	0.00281	0.11	0.13	Colonoscopy-negative controls vs population controls;	chr3:101597993	chr3:101712472~101713191:+
BRCA	cis	rs2904967	0.631	rs650056	ENSG00000255200.1	AP003068.18	-4.12	4.01e-05	0.00281	-0.26	-0.13	Mean corpuscular volume;	chr11:65257635	chr11:65174117~65176470:-
BRCA	cis	rs739496	0.947	rs55851737	ENSG00000234608.6	MAPKAPK5-AS1	4.12	4.01e-05	0.00282	0.15	0.13	Platelet count;	chr12:111499034	chr12:111839764~111842902:-
BRCA	cis	rs4374383	0.884	rs1554214	ENSG00000243389.1	AC012442.5	4.12	4.01e-05	0.00282	0.16	0.13	Hepatitis C induced liver fibrosis;	chr2:111986340	chr2:112589040~112614431:+
BRCA	cis	rs964611	0.938	rs8032357	ENSG00000259488.2	RP11-154J22.1	-4.12	4.01e-05	0.00282	-0.16	-0.13	Metabolite levels (Pyroglutamine);	chr15:48326622	chr15:48312353~48331856:-
BRCA	cis	rs9959145	1	rs9946557	ENSG00000267108.1	RP11-861E21.1	4.12	4.01e-05	0.00282	0.23	0.13	Immune response to smallpox vaccine (IL-6);	chr18:12563862	chr18:12432897~12437635:+
BRCA	cis	rs1577917	0.655	rs9359658	ENSG00000220563.1	PKMP3	4.12	4.01e-05	0.00282	0.13	0.13	Response to antipsychotic treatment;	chr6:85596051	chr6:85659892~85660606:-
BRCA	cis	rs801193	1	rs7788576	ENSG00000223473.2	GS1-124K5.3	-4.12	4.01e-05	0.00282	-0.1	-0.13	Aortic root size;	chr7:66683315	chr7:66491049~66493566:-
BRCA	cis	rs7246657	0.722	rs2972438	ENSG00000226686.6	LINC01535	-4.12	4.01e-05	0.00282	-0.19	-0.13	Coronary artery calcification;	chr19:37719946	chr19:37251912~37265535:+
BRCA	cis	rs2380205	0.967	rs10905307	ENSG00000232807.2	RP11-536K7.3	4.12	4.01e-05	0.00282	0.13	0.13	Breast cancer;	chr10:5852537	chr10:5934270~5945900:-
BRCA	cis	rs2380205	0.935	rs2380200	ENSG00000232807.2	RP11-536K7.3	4.12	4.01e-05	0.00282	0.13	0.13	Breast cancer;	chr10:5852976	chr10:5934270~5945900:-
BRCA	cis	rs2380205	0.967	rs9732607	ENSG00000232807.2	RP11-536K7.3	4.12	4.01e-05	0.00282	0.13	0.13	Breast cancer;	chr10:5853138	chr10:5934270~5945900:-
BRCA	cis	rs2380205	0.967	rs11255555	ENSG00000232807.2	RP11-536K7.3	4.12	4.01e-05	0.00282	0.13	0.13	Breast cancer;	chr10:5853398	chr10:5934270~5945900:-
BRCA	cis	rs10857712	0.754	rs2297031	ENSG00000273336.1	OR7M1P	-4.12	4.01e-05	0.00282	-0.18	-0.13	Systemic lupus erythematosus;	chr10:133419150	chr10:133481238~133481770:+
BRCA	cis	rs7572733	0.905	rs6735214	ENSG00000231621.1	AC013264.2	-4.12	4.01e-05	0.00282	-0.12	-0.13	Dermatomyositis;	chr2:197895783	chr2:197197991~197199273:+
BRCA	cis	rs11168351	1	rs11168351	ENSG00000273765.1	RP11-370I10.11	4.12	4.01e-05	0.00282	0.15	0.13	Bipolar disorder and schizophrenia;	chr12:48009982	chr12:48360920~48361377:+
BRCA	cis	rs4664293	0.764	rs10195287	ENSG00000226266.5	AC009961.3	-4.12	4.01e-05	0.00282	-0.15	-0.13	Monocyte percentage of white cells;	chr2:159604967	chr2:159670708~159712435:-
BRCA	cis	rs58521262	0.556	rs289333	ENSG00000268105.1	RP11-369G6.2	4.12	4.02e-05	0.00282	0.17	0.13	Testicular germ cell tumor;	chr19:22970240	chr19:23125665~23128543:+
BRCA	cis	rs58521262	0.556	rs289331	ENSG00000268105.1	RP11-369G6.2	4.12	4.02e-05	0.00282	0.17	0.13	Testicular germ cell tumor;	chr19:22971634	chr19:23125665~23128543:+
BRCA	cis	rs801193	0.967	rs34356500	ENSG00000272831.1	RP11-792A8.4	4.12	4.02e-05	0.00282	0.11	0.13	Aortic root size;	chr7:66771620	chr7:66739829~66740385:-
BRCA	cis	rs1371614	0.635	rs12612520	ENSG00000229122.1	AGBL5-IT1	-4.12	4.02e-05	0.00282	-0.13	-0.13	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26914439	chr2:27061038~27061815:+
BRCA	cis	rs7267979	1	rs6050565	ENSG00000274414.1	RP5-965G21.4	4.12	4.02e-05	0.00282	0.15	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25366927	chr20:25239007~25245229:-
BRCA	cis	rs8054556	0.692	rs4788199	ENSG00000261367.1	RP11-455F5.4	-4.12	4.02e-05	0.00282	-0.14	-0.13	Autism spectrum disorder or schizophrenia;	chr16:29959536	chr16:30107675~30110541:+
BRCA	cis	rs375066	0.935	rs421512	ENSG00000267191.1	RP11-15A1.2	-4.12	4.02e-05	0.00282	-0.17	-0.13	Breast cancer;	chr19:43911428	chr19:43902001~43926545:+
BRCA	cis	rs2243480	1	rs34703416	ENSG00000275400.1	RP4-756H11.5	4.12	4.02e-05	0.00282	0.23	0.13	Diabetic kidney disease;	chr7:65835655	chr7:66553805~66554199:-
BRCA	cis	rs321358	1	rs419633	ENSG00000271390.1	RP11-89C3.3	4.12	4.02e-05	0.00282	0.21	0.13	Body mass index;	chr11:111132187	chr11:111089870~111090368:-
BRCA	cis	rs6088580	0.634	rs6059878	ENSG00000275784.1	RP5-1125A11.6	-4.12	4.02e-05	0.00282	-0.14	-0.13	Glomerular filtration rate (creatinine);	chr20:34499361	chr20:33989480~33991818:-
BRCA	cis	rs6088580	0.601	rs6120668	ENSG00000275784.1	RP5-1125A11.6	-4.12	4.02e-05	0.00282	-0.14	-0.13	Glomerular filtration rate (creatinine);	chr20:34511988	chr20:33989480~33991818:-
BRCA	cis	rs6088580	0.634	rs6059887	ENSG00000275784.1	RP5-1125A11.6	-4.12	4.02e-05	0.00282	-0.14	-0.13	Glomerular filtration rate (creatinine);	chr20:34513297	chr20:33989480~33991818:-
BRCA	cis	rs6088580	0.634	rs6059892	ENSG00000275784.1	RP5-1125A11.6	-4.12	4.02e-05	0.00282	-0.14	-0.13	Glomerular filtration rate (creatinine);	chr20:34517961	chr20:33989480~33991818:-
BRCA	cis	rs6088580	0.609	rs2378205	ENSG00000275784.1	RP5-1125A11.6	-4.12	4.02e-05	0.00282	-0.14	-0.13	Glomerular filtration rate (creatinine);	chr20:34522998	chr20:33989480~33991818:-
BRCA	cis	rs11154801	0.634	rs6941396	ENSG00000234084.1	RP3-388E23.2	-4.12	4.02e-05	0.00282	-0.13	-0.13	Multiple sclerosis;	chr6:135606388	chr6:135301568~135307158:+
BRCA	cis	rs10487112	0.87	rs10953008	ENSG00000235436.9	DPY19L2P4	-4.12	4.02e-05	0.00282	-0.14	-0.13	Perceived unattractiveness to mosquitoes;	chr7:90463594	chr7:90119400~90125600:+
BRCA	cis	rs4560672	0.627	rs350291	ENSG00000218226.1	TATDN2P2	-4.12	4.02e-05	0.00282	-0.19	-0.13	Smoking quantity;	chr6:158087926	chr6:158609706~158621636:-
BRCA	cis	rs886774	0.587	rs35814593	ENSG00000273055.1	CTB-13F3.1	-4.12	4.03e-05	0.00282	-0.13	-0.13	Ulcerative colitis;	chr7:107940670	chr7:107942116~107942740:+
BRCA	cis	rs256438	0.502	rs2434277	ENSG00000251050.1	RP11-168A11.4	-4.12	4.03e-05	0.00282	-0.14	-0.13	Serum thyroid-stimulating hormone levels;	chr5:80051513	chr5:80019609~80019920:+
BRCA	cis	rs256438	0.524	rs2438649	ENSG00000251050.1	RP11-168A11.4	-4.12	4.03e-05	0.00282	-0.14	-0.13	Serum thyroid-stimulating hormone levels;	chr5:80051816	chr5:80019609~80019920:+
BRCA	cis	rs256438	0.524	rs689879	ENSG00000251050.1	RP11-168A11.4	-4.12	4.03e-05	0.00282	-0.14	-0.13	Serum thyroid-stimulating hormone levels;	chr5:80051934	chr5:80019609~80019920:+
BRCA	cis	rs763121	0.853	rs5750668	ENSG00000225450.1	RP3-508I15.14	-4.12	4.03e-05	0.00282	-0.14	-0.13	Menopause (age at onset);	chr22:38683959	chr22:38739003~38749041:+
BRCA	cis	rs12612619	0.732	rs1440044	ENSG00000272148.1	RP11-195B17.1	4.12	4.03e-05	0.00283	0.14	0.13	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27004086	chr2:27062428~27062907:-
BRCA	cis	rs860818	1	rs858242	ENSG00000230658.1	KLHL7-AS1	-4.12	4.03e-05	0.00283	-0.32	-0.13	Initial pursuit acceleration;	chr7:23185723	chr7:23101228~23105703:-
BRCA	cis	rs860818	1	rs1637220	ENSG00000230658.1	KLHL7-AS1	-4.12	4.03e-05	0.00283	-0.32	-0.13	Initial pursuit acceleration;	chr7:23193232	chr7:23101228~23105703:-
BRCA	cis	rs860818	1	rs6955117	ENSG00000230658.1	KLHL7-AS1	-4.12	4.03e-05	0.00283	-0.32	-0.13	Initial pursuit acceleration;	chr7:23194521	chr7:23101228~23105703:-
BRCA	cis	rs4950322	0.512	rs2353981	ENSG00000244371.2	PFN1P8	4.12	4.03e-05	0.00283	0.15	0.13	Protein quantitative trait loci;	chr1:147368365	chr1:146957117~146957659:-
BRCA	cis	rs10761482	0.566	rs4505011	ENSG00000254271.1	RP11-131N11.4	4.12	4.03e-05	0.00283	0.18	0.13	Schizophrenia;	chr10:60440550	chr10:60734342~60741828:+
BRCA	cis	rs61160187	0.61	rs4700397	ENSG00000272308.1	RP11-231G3.1	4.12	4.03e-05	0.00283	0.14	0.13	Educational attainment (years of education);Educational attainment (college completion);	chr5:60840135	chr5:60866457~60866935:-
BRCA	cis	rs801193	1	rs17566701	ENSG00000229180.5	GS1-124K5.11	4.12	4.03e-05	0.00283	0.11	0.13	Aortic root size;	chr7:66728196	chr7:66526088~66542624:-
BRCA	cis	rs6496932	0.503	rs8037726	ENSG00000259630.2	CTD-2262B20.1	-4.12	4.03e-05	0.00283	-0.18	-0.13	Central corneal thickness;Corneal structure;	chr15:85408154	chr15:85415228~85415633:+
BRCA	cis	rs10411161	0.702	rs8110531	ENSG00000269483.1	AC006272.1	4.12	4.03e-05	0.00283	0.2	0.13	Breast cancer;	chr19:51880257	chr19:51839924~51843324:-
BRCA	cis	rs7177699	0.557	rs62011002	ENSG00000261143.1	ADAMTS7P3	-4.12	4.03e-05	0.00283	-0.15	-0.13	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78828236	chr15:77976042~77993057:+
BRCA	cis	rs251253	0.827	rs370164	ENSG00000253959.1	CTB-43E15.1	4.12	4.03e-05	0.00283	0.11	0.13	PR interval;	chr5:173088640	chr5:173642519~173658194:+
BRCA	cis	rs853679	0.517	rs4713141	ENSG00000261839.1	RP1-265C24.8	4.12	4.03e-05	0.00283	0.17	0.13	Depression;	chr6:28133900	chr6:28136849~28139678:+
BRCA	cis	rs9863	0.828	rs71458830	ENSG00000270028.1	RP11-380L11.4	4.12	4.03e-05	0.00283	0.16	0.13	White blood cell count;	chr12:123992014	chr12:123925461~123926083:-
BRCA	cis	rs721917	0.525	rs2246111	ENSG00000242600.5	MBL1P	4.12	4.03e-05	0.00283	0.15	0.13	Chronic obstructive pulmonary disease;	chr10:79929985	chr10:79904898~79950336:+
BRCA	cis	rs61931739	0.534	rs7965503	ENSG00000258794.3	DUX4L27	4.12	4.03e-05	0.00283	0.18	0.13	Morning vs. evening chronotype;	chr12:34046414	chr12:34208415~34209675:-
BRCA	cis	rs2439831	0.85	rs7169988	ENSG00000206991.1	RNU6-610P	-4.12	4.03e-05	0.00283	-0.21	-0.13	Lung cancer in ever smokers;	chr15:43768237	chr15:43637632~43637738:-
BRCA	cis	rs7267979	1	rs6050573	ENSG00000277938.1	RP5-965G21.3	4.12	4.04e-05	0.00283	0.15	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25385429	chr20:25229150~25231933:+
BRCA	cis	rs3816183	1	rs11124892	ENSG00000226491.1	FTOP1	-4.12	4.04e-05	0.00283	-0.16	-0.13	Hypospadias;	chr2:42787164	chr2:42797225~42798712:-
BRCA	cis	rs7819412	0.668	rs2409714	ENSG00000154316.13	TDH	4.12	4.04e-05	0.00283	0.16	0.13	Triglycerides;	chr8:11152608	chr8:11339637~11368452:+
BRCA	cis	rs1153858	1	rs12594857	ENSG00000275672.1	GATM-AS1	-4.12	4.04e-05	0.00283	-0.16	-0.13	Homoarginine levels;	chr15:45374980	chr15:45378700~45380123:+
BRCA	cis	rs4869313	0.869	rs27290	ENSG00000248734.2	CTD-2260A17.1	4.12	4.04e-05	0.00283	0.13	0.13	Pediatric autoimmune diseases;	chr5:97014384	chr5:96784777~96785999:+
BRCA	cis	rs38055	0.813	rs565253	ENSG00000247796.2	CTD-2366F13.1	-4.12	4.04e-05	0.00283	-0.15	-0.13	Acne (severe);	chr5:53283382	chr5:53109842~53115126:+
BRCA	cis	rs6545883	0.895	rs2177961	ENSG00000212978.6	AC016747.3	-4.12	4.04e-05	0.00283	-0.17	-0.13	Tuberculosis;	chr2:61333129	chr2:61141592~61144969:-
BRCA	cis	rs78487399	0.908	rs7568901	ENSG00000234936.1	AC010883.5	4.12	4.04e-05	0.00283	0.18	0.13	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43587845	chr2:43229573~43233394:+
BRCA	cis	rs1865760	1	rs1865760	ENSG00000272462.2	U91328.19	-4.12	4.04e-05	0.00283	-0.15	-0.13	Height;	chr6:25916751	chr6:25992662~26001775:+
BRCA	cis	rs7592578	0.766	rs62182865	ENSG00000272979.1	RP11-647K16.1	-4.12	4.04e-05	0.00283	-0.23	-0.13	Diastolic blood pressure;	chr2:190569454	chr2:190454092~190454521:-
BRCA	cis	rs73607972	0.501	rs4784317	ENSG00000275191.1	RP11-36I17.2	-4.12	4.04e-05	0.00283	-0.2	-0.13	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53552273	chr16:53628256~53628816:-
BRCA	cis	rs10504130	0.569	rs34319820	ENSG00000253844.1	RP11-546K22.1	-4.12	4.04e-05	0.00283	-0.18	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr8:51777314	chr8:51961458~52022974:+
BRCA	cis	rs3892630	0.588	rs7248798	ENSG00000267475.1	CTD-2538C1.2	-4.12	4.04e-05	0.00283	-0.18	-0.13	Red blood cell traits;	chr19:32812778	chr19:32687089~32691750:-
BRCA	cis	rs7771547	0.723	rs9357219	ENSG00000224666.3	RP1-50J22.4	-4.12	4.04e-05	0.00283	-0.15	-0.13	Platelet distribution width;	chr6:36589906	chr6:36386831~36393462:+
BRCA	cis	rs4699052	0.625	rs11734836	ENSG00000248740.4	RP11-328K4.1	4.12	4.04e-05	0.00283	0.14	0.13	Testicular germ cell tumor;	chr4:103332046	chr4:103256159~103453658:+
BRCA	cis	rs2227564	0.7	rs2675677	ENSG00000271816.1	BMS1P4	4.12	4.04e-05	0.00284	0.14	0.13	Crohn's disease;Inflammatory bowel disease;	chr10:73888491	chr10:73699151~73730487:-
BRCA	cis	rs11098499	0.954	rs2389803	ENSG00000260091.1	RP11-33B1.4	4.12	4.04e-05	0.00284	0.11	0.13	Corneal astigmatism;	chr4:119472356	chr4:119409333~119410233:+
BRCA	cis	rs11250097	0.549	rs11784897	ENSG00000255046.1	RP11-297N6.4	4.12	4.04e-05	0.00284	0.16	0.13	Neuroticism;	chr8:11452933	chr8:11797928~11802568:-
BRCA	cis	rs13217239	0.646	rs9379956	ENSG00000224843.5	LINC00240	4.12	4.04e-05	0.00284	0.14	0.13	Schizophrenia;	chr6:27065956	chr6:26956992~27023924:+
BRCA	cis	rs56322409	0.564	rs4391761	ENSG00000226688.5	ENTPD1-AS1	4.12	4.04e-05	0.00284	0.14	0.13	Blood metabolite levels;	chr10:95921204	chr10:95753206~96090238:-
BRCA	cis	rs7481584	0.603	rs399467	ENSG00000236710.1	AC108448.2	4.12	4.05e-05	0.00284	0.17	0.13	Calcium levels;	chr11:3051118	chr11:3084393~3085443:-
BRCA	cis	rs875971	1	rs12532998	ENSG00000236529.1	RP13-254B10.1	4.12	4.05e-05	0.00284	0.14	0.13	Aortic root size;	chr7:66502472	chr7:65840212~65840596:+
BRCA	cis	rs2439831	0.85	rs28718261	ENSG00000206991.1	RNU6-610P	-4.12	4.05e-05	0.00284	-0.21	-0.13	Lung cancer in ever smokers;	chr15:43751595	chr15:43637632~43637738:-
BRCA	cis	rs6546324	0.625	rs4533457	ENSG00000236780.4	AC078941.1	4.12	4.05e-05	0.00284	0.22	0.13	Endometriosis;	chr2:67560216	chr2:67123357~67215319:-
BRCA	cis	rs2486012	0.737	rs556667	ENSG00000237950.1	RP11-7O11.3	4.12	4.05e-05	0.00284	0.21	0.13	Intelligence (multi-trait analysis);	chr1:43821742	chr1:43944370~43946551:-
BRCA	cis	rs801193	1	rs2707836	ENSG00000223473.2	GS1-124K5.3	4.12	4.05e-05	0.00284	0.1	0.13	Aortic root size;	chr7:66695448	chr7:66491049~66493566:-
BRCA	cis	rs801193	0.844	rs7779971	ENSG00000223473.2	GS1-124K5.3	4.12	4.05e-05	0.00284	0.1	0.13	Aortic root size;	chr7:66696803	chr7:66491049~66493566:-
BRCA	cis	rs7267979	0.966	rs6050611	ENSG00000274414.1	RP5-965G21.4	-4.12	4.05e-05	0.00284	-0.15	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25433783	chr20:25239007~25245229:-
BRCA	cis	rs739496	0.579	rs3213628	ENSG00000257624.1	RP1-128M12.3	4.12	4.05e-05	0.00284	0.17	0.13	Platelet count;	chr12:111842969	chr12:112000739~112000985:-
BRCA	cis	rs10191773	0.535	rs11685514	ENSG00000243389.1	AC012442.5	4.12	4.05e-05	0.00284	0.25	0.13	Yeast infection;	chr2:112342437	chr2:112589040~112614431:+
BRCA	cis	rs180730	0.948	rs3115312	ENSG00000251609.2	SETP12	-4.12	4.05e-05	0.00284	-0.19	-0.13	Fasting plasma glucose;	chr4:120882651	chr4:120895494~120897083:-
BRCA	cis	rs10946940	0.896	rs12208078	ENSG00000219392.1	RP1-265C24.5	4.12	4.05e-05	0.00284	0.17	0.13	Systemic lupus erythematosus;	chr6:27530802	chr6:28115628~28116551:+
BRCA	cis	rs11098499	0.863	rs13134665	ENSG00000250412.1	KLHL2P1	4.12	4.05e-05	0.00284	0.15	0.13	Corneal astigmatism;	chr4:119505275	chr4:119334329~119378233:+
BRCA	cis	rs2179367	0.959	rs521845	ENSG00000223701.3	RAET1E-AS1	-4.12	4.05e-05	0.00284	-0.16	-0.13	Dupuytren's disease;	chr6:149350562	chr6:149884431~149919508:+
BRCA	cis	rs9393777	0.668	rs3800318	ENSG00000220721.1	OR1F12	4.12	4.05e-05	0.00284	0.18	0.13	Intelligence (multi-trait analysis);	chr6:27295862	chr6:28073316~28074233:+
BRCA	cis	rs3768617	0.706	rs9943067	ENSG00000224468.3	RP11-181K3.4	-4.12	4.05e-05	0.00284	-0.14	-0.13	Fuchs's corneal dystrophy;	chr1:183005967	chr1:183138402~183141282:-
BRCA	cis	rs750460	0.808	rs2165241	ENSG00000261801.4	LOXL1-AS1	4.12	4.05e-05	0.00284	0.14	0.13	Height;	chr15:73929861	chr15:73908071~73928248:-
BRCA	cis	rs4295623	0.531	rs2898295	ENSG00000270154.1	RP11-419I17.1	-4.12	4.05e-05	0.00284	-0.14	-0.13	Morning vs. evening chronotype;	chr8:11738460	chr8:12476462~12477122:+
BRCA	cis	rs300890	0.689	rs300953	ENSG00000250326.1	RP11-284M14.1	-4.12	4.06e-05	0.00284	-0.15	-0.13	Nasopharyngeal carcinoma;	chr4:143280506	chr4:142933195~143184861:-
BRCA	cis	rs2554380	0.783	rs2554385	ENSG00000230373.7	GOLGA6L5P	-4.12	4.06e-05	0.00284	-0.17	-0.13	Height;	chr15:83737835	chr15:84507885~84516814:-
BRCA	cis	rs6964587	0.967	rs12538325	ENSG00000188693.7	CYP51A1-AS1	-4.12	4.06e-05	0.00284	-0.14	-0.13	Breast cancer;	chr7:92128165	chr7:92134604~92180725:+
BRCA	cis	rs11098499	0.754	rs1511017	ENSG00000260091.1	RP11-33B1.4	-4.12	4.06e-05	0.00284	-0.11	-0.13	Corneal astigmatism;	chr4:119329650	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.789	rs12498994	ENSG00000260091.1	RP11-33B1.4	-4.12	4.06e-05	0.00284	-0.11	-0.13	Corneal astigmatism;	chr4:119329663	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.754	rs12507565	ENSG00000260091.1	RP11-33B1.4	-4.12	4.06e-05	0.00284	-0.11	-0.13	Corneal astigmatism;	chr4:119329966	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.826	rs12511640	ENSG00000260091.1	RP11-33B1.4	-4.12	4.06e-05	0.00284	-0.11	-0.13	Corneal astigmatism;	chr4:119330093	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.754	rs1980026	ENSG00000260091.1	RP11-33B1.4	-4.12	4.06e-05	0.00284	-0.11	-0.13	Corneal astigmatism;	chr4:119330488	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.743	rs11098501	ENSG00000260091.1	RP11-33B1.4	-4.12	4.06e-05	0.00284	-0.11	-0.13	Corneal astigmatism;	chr4:119330862	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.754	rs11098502	ENSG00000260091.1	RP11-33B1.4	-4.12	4.06e-05	0.00284	-0.11	-0.13	Corneal astigmatism;	chr4:119330908	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.708	rs11732686	ENSG00000260091.1	RP11-33B1.4	-4.12	4.06e-05	0.00284	-0.11	-0.13	Corneal astigmatism;	chr4:119331175	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.754	rs11724409	ENSG00000260091.1	RP11-33B1.4	-4.12	4.06e-05	0.00284	-0.11	-0.13	Corneal astigmatism;	chr4:119331206	chr4:119409333~119410233:+
BRCA	cis	rs6490294	0.904	rs11066111	ENSG00000257624.1	RP1-128M12.3	4.12	4.06e-05	0.00284	0.17	0.13	Mean platelet volume;	chr12:111977375	chr12:112000739~112000985:-
BRCA	cis	rs2243480	1	rs34970380	ENSG00000226002.1	RP11-460N20.5	-4.12	4.06e-05	0.00284	-0.21	-0.13	Diabetic kidney disease;	chr7:65966506	chr7:65084103~65100232:+
BRCA	cis	rs2243480	1	rs781156	ENSG00000222364.1	RNU6-96P	-4.12	4.06e-05	0.00284	-0.23	-0.13	Diabetic kidney disease;	chr7:66014154	chr7:66395191~66395286:+
BRCA	cis	rs2243480	1	rs451396	ENSG00000222364.1	RNU6-96P	-4.12	4.06e-05	0.00284	-0.23	-0.13	Diabetic kidney disease;	chr7:66019087	chr7:66395191~66395286:+
BRCA	cis	rs2243480	1	rs1715235	ENSG00000222364.1	RNU6-96P	-4.12	4.06e-05	0.00284	-0.23	-0.13	Diabetic kidney disease;	chr7:66023407	chr7:66395191~66395286:+
BRCA	cis	rs7246967	0.866	rs438972	ENSG00000198153.8	ZNF849P	-4.12	4.06e-05	0.00284	-0.18	-0.13	Bronchopulmonary dysplasia;	chr19:22837025	chr19:22685167~22686732:+
BRCA	cis	rs7487075	1	rs12832425	ENSG00000274723.1	RP11-618L22.1	4.12	4.06e-05	0.00285	0.15	0.13	Itch intensity from mosquito bite;	chr12:46429035	chr12:46970504~46972155:+
BRCA	cis	rs1549733	0.577	rs13029785	ENSG00000229754.1	CXCR2P1	4.12	4.06e-05	0.00285	0.12	0.13	Optic disc area;	chr2:217558071	chr2:218059155~218065729:-
BRCA	cis	rs9393692	0.645	rs766406	ENSG00000241549.7	GUSBP2	-4.12	4.06e-05	0.00285	-0.15	-0.13	Educational attainment;	chr6:26319360	chr6:26871484~26956554:-
BRCA	cis	rs7520050	0.743	rs61789988	ENSG00000234329.1	RP11-767N6.2	-4.12	4.06e-05	0.00285	-0.12	-0.13	Reticulocyte count;Red blood cell count;	chr1:45619570	chr1:45651039~45651826:-
BRCA	cis	rs3764563	0.935	rs585680	ENSG00000267594.5	CYP4F24P	4.12	4.06e-05	0.00285	0.23	0.13	Inflammatory biomarkers;	chr19:15576991	chr19:15760241~15779909:-
BRCA	cis	rs9467773	1	rs9467779	ENSG00000241549.7	GUSBP2	-4.12	4.06e-05	0.00285	-0.14	-0.13	Intelligence (multi-trait analysis);	chr6:26536459	chr6:26871484~26956554:-
BRCA	cis	rs6593122	0.71	rs6944290	ENSG00000235454.1	HAUS6P3	-4.12	4.06e-05	0.00285	-0.17	-0.13	Vaccine-related adverse events;	chr7:54132445	chr7:53862233~53863339:+
BRCA	cis	rs6593122	0.755	rs6957670	ENSG00000235454.1	HAUS6P3	-4.12	4.06e-05	0.00285	-0.17	-0.13	Vaccine-related adverse events;	chr7:54132453	chr7:53862233~53863339:+
BRCA	cis	rs1865760	1	rs2071299	ENSG00000272462.2	U91328.19	-4.12	4.06e-05	0.00285	-0.15	-0.13	Height;	chr6:25914573	chr6:25992662~26001775:+
BRCA	cis	rs1865760	1	rs2071298	ENSG00000272462.2	U91328.19	-4.12	4.06e-05	0.00285	-0.15	-0.13	Height;	chr6:25914673	chr6:25992662~26001775:+
BRCA	cis	rs1865760	0.964	rs1324084	ENSG00000272462.2	U91328.19	-4.12	4.06e-05	0.00285	-0.15	-0.13	Height;	chr6:25914906	chr6:25992662~26001775:+
BRCA	cis	rs12438356	1	rs74860015	ENSG00000259222.2	RP11-809H16.5	-4.12	4.06e-05	0.00285	-0.22	-0.13	CTACK levels;	chr15:69295071	chr15:69080879~69099987:+
BRCA	cis	rs61160187	0.673	rs3958943	ENSG00000272308.1	RP11-231G3.1	4.12	4.07e-05	0.00285	0.14	0.13	Educational attainment (years of education);Educational attainment (college completion);	chr5:60580922	chr5:60866457~60866935:-
BRCA	cis	rs10129255	0.5	rs12101190	ENSG00000211967.3	IGHV3-53	-4.12	4.07e-05	0.00285	-0.08	-0.13	Kawasaki disease;	chr14:106784149	chr14:106592676~106593347:-
BRCA	cis	rs10129255	0.518	rs8004895	ENSG00000211967.3	IGHV3-53	-4.12	4.07e-05	0.00285	-0.08	-0.13	Kawasaki disease;	chr14:106785139	chr14:106592676~106593347:-
BRCA	cis	rs7177699	0.557	rs12898292	ENSG00000261143.1	ADAMTS7P3	-4.12	4.07e-05	0.00285	-0.15	-0.13	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78820261	chr15:77976042~77993057:+
BRCA	cis	rs1161098	1	rs1161174	ENSG00000256037.1	MRPL40P1	-4.12	4.07e-05	0.00285	-0.19	-0.13	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr12:67465743	chr12:67351436~67352039:+
BRCA	cis	rs2832191	0.74	rs2832175	ENSG00000215533.7	LINC00189	4.12	4.07e-05	0.00285	0.14	0.13	Dental caries;	chr21:29103285	chr21:29193480~29288205:+
BRCA	cis	rs7508	0.511	rs208025	ENSG00000253671.1	RP11-806O11.1	-4.12	4.07e-05	0.00285	-0.17	-0.13	Atrial fibrillation;	chr8:18020661	chr8:17808941~17820868:+
BRCA	cis	rs4761470	0.577	rs57925369	ENSG00000258365.1	RP11-1105G2.3	-4.12	4.07e-05	0.00285	-0.16	-0.13	Estradiol plasma levels (breast cancer);	chr12:94295732	chr12:94277758~94282844:-
BRCA	cis	rs983392	0.642	rs636147	ENSG00000275344.1	MIR6503	4.12	4.07e-05	0.00285	0.13	0.13	Alzheimer's disease (late onset);	chr11:60189619	chr11:60209071~60209156:-
BRCA	cis	rs9863	0.896	rs12829951	ENSG00000270028.1	RP11-380L11.4	4.12	4.07e-05	0.00285	0.16	0.13	White blood cell count;	chr12:123941294	chr12:123925461~123926083:-
BRCA	cis	rs739496	0.843	rs621899	ENSG00000234608.6	MAPKAPK5-AS1	4.12	4.07e-05	0.00285	0.15	0.13	Platelet count;	chr12:111547047	chr12:111839764~111842902:-
BRCA	cis	rs739496	0.843	rs625093	ENSG00000234608.6	MAPKAPK5-AS1	4.12	4.07e-05	0.00285	0.15	0.13	Platelet count;	chr12:111550628	chr12:111839764~111842902:-
BRCA	cis	rs739496	0.843	rs638791	ENSG00000234608.6	MAPKAPK5-AS1	4.12	4.07e-05	0.00285	0.15	0.13	Platelet count;	chr12:111551432	chr12:111839764~111842902:-
BRCA	cis	rs948562	0.523	rs11827480	ENSG00000255299.4	RP11-655C2.3	-4.12	4.07e-05	0.00285	-0.15	-0.13	Lymphoma;	chr11:58665251	chr11:58497888~58505758:-
BRCA	cis	rs9879311	0.966	rs7619385	ENSG00000240288.6	GHRLOS	4.12	4.07e-05	0.00285	0.14	0.13	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr3:10373225	chr3:10285754~10293449:+
BRCA	cis	rs950169	0.58	rs17598114	ENSG00000229212.6	RP11-561C5.4	-4.12	4.07e-05	0.00285	-0.16	-0.13	Schizophrenia;	chr15:84628086	chr15:85205440~85234795:-
BRCA	cis	rs6893300	0.961	rs62406219	ENSG00000250999.1	RP11-1379J22.5	4.12	4.07e-05	0.00285	0.17	0.13	Resting heart rate;	chr5:179784628	chr5:179657762~179664432:+
BRCA	cis	rs1549733	0.552	rs16857862	ENSG00000229754.1	CXCR2P1	-4.12	4.07e-05	0.00285	-0.12	-0.13	Optic disc area;	chr2:217555754	chr2:218059155~218065729:-
BRCA	cis	rs4650943	0.572	rs2455753	ENSG00000227740.1	RP11-318C24.2	-4.12	4.07e-05	0.00285	-0.13	-0.13	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in inactive individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr1:176319560	chr1:175904762~175920513:-
BRCA	cis	rs17270561	0.609	rs4711094	ENSG00000272462.2	U91328.19	-4.12	4.07e-05	0.00285	-0.15	-0.13	Iron status biomarkers;	chr6:25705946	chr6:25992662~26001775:+
BRCA	cis	rs6940638	0.662	rs7759694	ENSG00000124549.13	BTN2A3P	-4.12	4.07e-05	0.00286	-0.13	-0.13	Intelligence (multi-trait analysis);	chr6:27273177	chr6:26421391~26432383:+
BRCA	cis	rs17027633	1	rs17027633	ENSG00000260948.1	RP11-552M11.8	-4.12	4.08e-05	0.00286	-0.29	-0.13	Cerebrospinal fluid t-tau:AB1-42 ratio;	chr1:111419634	chr1:111431046~111433068:-
BRCA	cis	rs17027633	1	rs2275794	ENSG00000260948.1	RP11-552M11.8	-4.12	4.08e-05	0.00286	-0.29	-0.13	Cerebrospinal fluid t-tau:AB1-42 ratio;	chr1:111421640	chr1:111431046~111433068:-
BRCA	cis	rs17027633	1	rs17027642	ENSG00000260948.1	RP11-552M11.8	-4.12	4.08e-05	0.00286	-0.29	-0.13	Cerebrospinal fluid t-tau:AB1-42 ratio;	chr1:111422023	chr1:111431046~111433068:-
BRCA	cis	rs13434995	0.513	rs13133077	ENSG00000239040.1	Y_RNA	-4.12	4.08e-05	0.00286	-0.15	-0.13	Adiponectin levels;	chr4:55577642	chr4:55412636~55412738:+
BRCA	cis	rs13434995	0.513	rs7665286	ENSG00000239040.1	Y_RNA	-4.12	4.08e-05	0.00286	-0.15	-0.13	Adiponectin levels;	chr4:55578765	chr4:55412636~55412738:+
BRCA	cis	rs13434995	0.513	rs7683997	ENSG00000239040.1	Y_RNA	-4.12	4.08e-05	0.00286	-0.15	-0.13	Adiponectin levels;	chr4:55581272	chr4:55412636~55412738:+
BRCA	cis	rs8180040	0.726	rs4234465	ENSG00000276925.1	RP11-708J19.3	-4.12	4.08e-05	0.00286	-0.14	-0.13	Colorectal cancer;	chr3:46985395	chr3:47469777~47469987:+
BRCA	cis	rs7746199	0.673	rs72845046	ENSG00000216901.1	AL022393.7	4.12	4.08e-05	0.00286	0.33	0.13	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27607489	chr6:28176188~28176674:+
BRCA	cis	rs10509586	1	rs11185978	ENSG00000232110.6	RP11-149I23.3	-4.12	4.08e-05	0.00286	-0.34	-0.13	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);	chr10:90029031	chr10:89283765~89292125:+
BRCA	cis	rs6565180	0.962	rs6565183	ENSG00000183604.13	SMG1P5	-4.12	4.08e-05	0.00286	-0.13	-0.13	Tonsillectomy;	chr16:30371434	chr16:30267553~30335374:-
BRCA	cis	rs1865760	1	rs7770139	ENSG00000272462.2	U91328.19	-4.12	4.08e-05	0.00286	-0.15	-0.13	Height;	chr6:25925595	chr6:25992662~26001775:+
BRCA	cis	rs8022179	0.566	rs959083	ENSG00000259775.1	RP11-45P15.4	-4.12	4.08e-05	0.00286	-0.17	-0.13	Monocyte count;	chr14:103356350	chr14:103331674~103332367:-
BRCA	cis	rs6738627	1	rs6712203	ENSG00000223318.1	RNA5SP111	4.12	4.08e-05	0.00286	0.14	0.13	circulating leptin levels adjusted for BMI;Body fat percentage;circulating leptin levels;	chr2:164700808	chr2:164895677~164895777:-
BRCA	cis	rs875971	0.66	rs1860468	ENSG00000265600.1	AC006480.1	4.12	4.08e-05	0.00286	0.15	0.13	Aortic root size;	chr7:66642265	chr7:67356680~67356779:+
BRCA	cis	rs6430585	0.591	rs75223002	ENSG00000231890.6	DARS-AS1	-4.12	4.08e-05	0.00286	-0.2	-0.13	Corneal structure;	chr2:135767739	chr2:135985176~136022593:+
BRCA	cis	rs9308731	0.666	rs724710	ENSG00000230499.1	AC108463.1	4.12	4.08e-05	0.00286	0.15	0.13	Chronic lymphocytic leukemia;	chr2:111150114	chr2:111195963~111206494:+
BRCA	cis	rs17228178	0.961	rs7172386	ENSG00000215302.7	CTD-3092A11.1	-4.12	4.08e-05	0.00286	-0.16	-0.13	Facial depth;Facial morphology (factor 1, breadth of lateral portion of upper face);	chr15:31175149	chr15:30470779~30507623:+
BRCA	cis	rs4388249	0.651	rs31608	ENSG00000271849.1	CTC-332L22.1	-4.12	4.08e-05	0.00286	-0.22	-0.13	Schizophrenia;	chr5:109663811	chr5:109687802~109688329:-
BRCA	cis	rs34217772	0.941	rs34009991	ENSG00000258636.1	CTD-2298J14.2	4.12	4.08e-05	0.00286	0.18	0.13	Myopia;	chr14:41783923	chr14:41587861~41604856:-
BRCA	cis	rs752590	0.65	rs6751201	ENSG00000274877.1	RP11-65I12.1	4.12	4.08e-05	0.00286	0.18	0.13	Mucinous ovarian carcinoma;	chr2:113195122	chr2:113237595~113240825:+
BRCA	cis	rs13401620	0.843	rs2086400	ENSG00000229326.3	AC069154.4	-4.12	4.08e-05	0.00286	-0.16	-0.13	Breast size;	chr2:119837405	chr2:119698623~119700151:+
BRCA	cis	rs2243480	1	rs2243480	ENSG00000222364.1	RNU6-96P	-4.12	4.08e-05	0.00286	-0.24	-0.13	Diabetic kidney disease;	chr7:66134209	chr7:66395191~66395286:+
BRCA	cis	rs739496	0.579	rs1981517	ENSG00000257624.1	RP1-128M12.3	4.12	4.08e-05	0.00286	0.17	0.13	Platelet count;	chr12:111885778	chr12:112000739~112000985:-
BRCA	cis	rs11098499	1	rs12506395	ENSG00000260091.1	RP11-33B1.4	-4.12	4.09e-05	0.00286	-0.11	-0.13	Corneal astigmatism;	chr4:119263939	chr4:119409333~119410233:+
BRCA	cis	rs453301	0.658	rs12114954	ENSG00000233609.3	RP11-62H7.2	-4.12	4.09e-05	0.00286	-0.12	-0.13	Joint mobility (Beighton score);	chr8:9047352	chr8:8961200~8979025:+
BRCA	cis	rs848490	0.722	rs4729772	ENSG00000214293.7	APTR	4.12	4.09e-05	0.00286	0.14	0.13	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77826582	chr7:77657660~77696265:-
BRCA	cis	rs1555322	1	rs6058219	ENSG00000126005.14	MMP24-AS1	-4.12	4.09e-05	0.00286	-0.21	-0.13	Attention deficit hyperactivity disorder;	chr20:35271441	chr20:35216462~35278131:-
BRCA	cis	rs4415084	0.716	rs1438822	ENSG00000251141.4	RP11-53O19.1	-4.12	4.09e-05	0.00286	-0.12	-0.13	Breast cancer;	chr5:44859070	chr5:44744900~44808777:-
BRCA	cis	rs7656342	0.964	rs13148356	ENSG00000250342.1	SNRPCP16	-4.12	4.09e-05	0.00286	-0.15	-0.13	Gut microbiota (bacterial taxa);	chr4:9815446	chr4:9051842~9052051:-
BRCA	cis	rs9341808	0.754	rs9352808	ENSG00000233967.5	RP11-250B2.3	4.12	4.09e-05	0.00286	0.13	0.13	Sitting height ratio;	chr6:80287625	chr6:80443344~80465927:+
BRCA	cis	rs2842346	0.568	rs2525526	ENSG00000258623.1	CTD-2325P2.3	-4.12	4.09e-05	0.00286	-0.17	-0.13	Breast cancer;	chr14:68542449	chr14:68683411~68685565:-
BRCA	cis	rs9650657	0.538	rs11250093	ENSG00000154316.13	TDH	-4.12	4.09e-05	0.00286	-0.16	-0.13	Neuroticism;	chr8:10941318	chr8:11339637~11368452:+
BRCA	cis	rs957448	0.529	rs9642928	ENSG00000261437.1	RP11-22C11.2	4.12	4.09e-05	0.00286	0.12	0.13	Nonsyndromic cleft lip with cleft palate;	chr8:94601698	chr8:94637285~94639467:-
BRCA	cis	rs7937890	0.559	rs6486197	ENSG00000254418.1	RP11-21L19.1	4.12	4.09e-05	0.00286	0.15	0.13	Mitochondrial DNA levels;	chr11:14508328	chr11:14262846~14273691:-
BRCA	cis	rs11098499	1	rs28374891	ENSG00000250412.1	KLHL2P1	4.12	4.09e-05	0.00286	0.15	0.13	Corneal astigmatism;	chr4:119262395	chr4:119334329~119378233:+
BRCA	cis	rs2108622	0.727	rs12609900	ENSG00000267218.2	AC005336.5	4.12	4.09e-05	0.00287	0.15	0.13	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871604	chr19:15902300~15903238:-
BRCA	cis	rs2108622	0.727	rs62107763	ENSG00000267218.2	AC005336.5	4.12	4.09e-05	0.00287	0.15	0.13	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871788	chr19:15902300~15903238:-
BRCA	cis	rs2108622	0.727	rs62107764	ENSG00000267218.2	AC005336.5	4.12	4.09e-05	0.00287	0.15	0.13	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871848	chr19:15902300~15903238:-
BRCA	cis	rs2108622	0.727	rs8101038	ENSG00000267218.2	AC005336.5	4.12	4.09e-05	0.00287	0.15	0.13	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15872054	chr19:15902300~15903238:-
BRCA	cis	rs7474896	0.616	rs2505239	ENSG00000263064.2	RP11-291L22.7	4.12	4.09e-05	0.00287	0.2	0.13	Obesity (extreme);	chr10:38151837	chr10:38448689~38448949:+
BRCA	cis	rs801193	1	rs11773829	ENSG00000272831.1	RP11-792A8.4	-4.12	4.09e-05	0.00287	-0.11	-0.13	Aortic root size;	chr7:66676087	chr7:66739829~66740385:-
BRCA	cis	rs8114671	0.804	rs6088666	ENSG00000126005.14	MMP24-AS1	-4.12	4.09e-05	0.00287	-0.15	-0.13	Height;	chr20:34976767	chr20:35216462~35278131:-
BRCA	cis	rs893818	1	rs893816	ENSG00000261801.4	LOXL1-AS1	4.12	4.09e-05	0.00287	0.16	0.13	Exfoliation glaucoma or exfoliation syndrome;	chr15:73936123	chr15:73908071~73928248:-
BRCA	cis	rs875971	0.66	rs7807930	ENSG00000229180.5	GS1-124K5.11	-4.12	4.09e-05	0.00287	-0.11	-0.13	Aortic root size;	chr7:66622178	chr7:66526088~66542624:-
BRCA	cis	rs6964833	1	rs4717907	ENSG00000184616.8	AC004166.6	4.12	4.09e-05	0.00287	0.18	0.13	Menarche (age at onset);	chr7:74672169	chr7:74906673~74913256:-
BRCA	cis	rs7829975	0.593	rs2921061	ENSG00000233609.3	RP11-62H7.2	4.12	4.09e-05	0.00287	0.12	0.13	Mood instability;	chr8:8460105	chr8:8961200~8979025:+
BRCA	cis	rs7927592	0.731	rs488381	ENSG00000212093.1	AP000807.1	-4.12	4.09e-05	0.00287	-0.13	-0.13	Total body bone mineral density;	chr11:68524225	chr11:68506083~68506166:-
BRCA	cis	rs73242632	1	rs2227902	ENSG00000269949.1	RP11-738E22.3	4.12	4.1e-05	0.00287	0.3	0.13	Congenital heart disease (maternal effect);	chr4:56930934	chr4:56960927~56961373:-
BRCA	cis	rs4950322	0.57	rs72691041	ENSG00000237188.3	RP11-337C18.8	4.12	4.1e-05	0.00287	0.16	0.13	Protein quantitative trait loci;	chr1:147267084	chr1:147172771~147211568:+
BRCA	cis	rs11098499	0.954	rs7437420	ENSG00000260091.1	RP11-33B1.4	-4.12	4.1e-05	0.00287	-0.11	-0.13	Corneal astigmatism;	chr4:119391748	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.874	rs28452522	ENSG00000260404.2	RP11-384K6.6	4.12	4.1e-05	0.00287	0.13	0.13	Corneal astigmatism;	chr4:119189629	chr4:118591773~118633729:+
BRCA	cis	rs7481584	0.624	rs440130	ENSG00000236710.1	AC108448.2	4.12	4.1e-05	0.00287	0.17	0.13	Calcium levels;	chr11:3030246	chr11:3084393~3085443:-
BRCA	cis	rs2835345	0.63	rs55681268	ENSG00000233818.1	AP000695.4	4.12	4.1e-05	0.00287	0.13	0.13	Pulmonary function;	chr21:36449419	chr21:36445731~36532408:+
BRCA	cis	rs11098499	0.754	rs9999724	ENSG00000260091.1	RP11-33B1.4	-4.12	4.1e-05	0.00287	-0.11	-0.13	Corneal astigmatism;	chr4:119318789	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.739	rs10031033	ENSG00000260404.2	RP11-384K6.6	4.12	4.1e-05	0.00287	0.12	0.13	Corneal astigmatism;	chr4:119230297	chr4:118591773~118633729:+
BRCA	cis	rs7746199	0.736	rs67652222	ENSG00000216901.1	AL022393.7	4.12	4.1e-05	0.00287	0.33	0.13	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27618441	chr6:28176188~28176674:+
BRCA	cis	rs10191773	0.589	rs72831634	ENSG00000243389.1	AC012442.5	4.12	4.1e-05	0.00287	0.26	0.13	Yeast infection;	chr2:112189219	chr2:112589040~112614431:+
BRCA	cis	rs2731006	0.64	rs1878577	ENSG00000257114.2	RP11-25I15.3	-4.12	4.1e-05	0.00287	-0.2	-0.13	Panic disorder;	chr12:42770327	chr12:42692216~42717119:+
BRCA	cis	rs1910358	0.554	rs3932337	ENSG00000248874.4	C5orf17	-4.12	4.1e-05	0.00287	-0.18	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23742776	chr5:23951348~24178263:+
BRCA	cis	rs10911902	0.643	rs3766705	ENSG00000229739.2	RP11-295K2.3	-4.12	4.1e-05	0.00287	-0.19	-0.13	Schizophrenia;	chr1:186342680	chr1:186435161~186470291:+
BRCA	cis	rs11158026	0.826	rs10136545	ENSG00000258413.1	RP11-665C16.6	-4.12	4.1e-05	0.00287	-0.16	-0.13	Parkinson's disease;	chr14:54886145	chr14:55262767~55272075:-
BRCA	cis	rs4478858	0.684	rs7515988	ENSG00000223907.1	LINC01226	4.12	4.1e-05	0.00287	0.15	0.13	Alcohol dependence;	chr1:31258214	chr1:31518435~31524245:+
BRCA	cis	rs7937890	0.874	rs2303972	ENSG00000254418.1	RP11-21L19.1	-4.12	4.1e-05	0.00287	-0.15	-0.13	Mitochondrial DNA levels;	chr11:14281736	chr11:14262846~14273691:-
BRCA	cis	rs11742741	0.806	rs1501950	ENSG00000248874.4	C5orf17	-4.12	4.1e-05	0.00287	-0.16	-0.13	Educational attainment;	chr5:24020200	chr5:23951348~24178263:+
BRCA	cis	rs38055	0.668	rs17241927	ENSG00000247796.2	CTD-2366F13.1	4.12	4.11e-05	0.00287	0.17	0.13	Acne (severe);	chr5:53197103	chr5:53109842~53115126:+
BRCA	cis	rs11671005	0.736	rs11668201	ENSG00000269600.1	AC016629.3	-4.12	4.11e-05	0.00287	-0.2	-0.13	Mean platelet volume;	chr19:58492265	chr19:58593896~58599355:-
BRCA	cis	rs2242116	0.796	rs7645278	ENSG00000276925.1	RP11-708J19.3	-4.12	4.11e-05	0.00287	-0.15	-0.13	Birth weight;	chr3:46932610	chr3:47469777~47469987:+
BRCA	cis	rs3020264	1	rs3020264	ENSG00000249898.6	CTD-2541M15.1	4.12	4.11e-05	0.00288	0.17	0.13	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 24 weeks);	chr8:6631056	chr8:6618475~6708209:-
BRCA	cis	rs6963495	0.818	rs6973263	ENSG00000223886.3	RP11-251G23.2	4.12	4.11e-05	0.00288	0.2	0.13	Bipolar disorder (body mass index interaction);	chr7:105529846	chr7:105530209~105530671:+
BRCA	cis	rs6963495	0.818	rs6955796	ENSG00000223886.3	RP11-251G23.2	4.12	4.11e-05	0.00288	0.2	0.13	Bipolar disorder (body mass index interaction);	chr7:105529874	chr7:105530209~105530671:+
BRCA	cis	rs6963495	0.818	rs6973974	ENSG00000223886.3	RP11-251G23.2	4.12	4.11e-05	0.00288	0.2	0.13	Bipolar disorder (body mass index interaction);	chr7:105530182	chr7:105530209~105530671:+
BRCA	cis	rs6963495	0.818	rs55983796	ENSG00000223886.3	RP11-251G23.2	4.12	4.11e-05	0.00288	0.2	0.13	Bipolar disorder (body mass index interaction);	chr7:105530494	chr7:105530209~105530671:+
BRCA	cis	rs6963495	0.818	rs73192120	ENSG00000223886.3	RP11-251G23.2	4.12	4.11e-05	0.00288	0.2	0.13	Bipolar disorder (body mass index interaction);	chr7:105530709	chr7:105530209~105530671:+
BRCA	cis	rs6963495	0.818	rs73192126	ENSG00000223886.3	RP11-251G23.2	4.12	4.11e-05	0.00288	0.2	0.13	Bipolar disorder (body mass index interaction);	chr7:105534968	chr7:105530209~105530671:+
BRCA	cis	rs73198271	0.628	rs11783707	ENSG00000253893.2	FAM85B	4.12	4.11e-05	0.00288	0.22	0.13	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8732099	chr8:8167819~8226614:-
BRCA	cis	rs17772222	0.958	rs59136503	ENSG00000258789.1	RP11-507K2.3	-4.12	4.11e-05	0.00288	-0.16	-0.13	Coronary artery calcification;	chr14:88501921	chr14:88551597~88552493:+
BRCA	cis	rs6940729	1	rs6940729	ENSG00000270761.1	RP11-385F7.1	-4.12	4.11e-05	0.00288	-0.12	-0.13	Plasma homocysteine levels;	chr6:47585184	chr6:47477243~47477572:-
BRCA	cis	rs1048886	0.872	rs16869353	ENSG00000271967.1	RP11-134K13.4	-4.12	4.11e-05	0.00288	-0.18	-0.13	Type 2 diabetes;	chr6:70545730	chr6:70596438~70596980:+
BRCA	cis	rs7267979	0.966	rs2261790	ENSG00000274973.1	RP13-401N8.7	-4.12	4.11e-05	0.00288	-0.14	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25282153	chr20:25845497~25845862:+
BRCA	cis	rs7267979	0.966	rs2261794	ENSG00000274973.1	RP13-401N8.7	-4.12	4.11e-05	0.00288	-0.14	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25282426	chr20:25845497~25845862:+
BRCA	cis	rs7267979	0.966	rs2145126	ENSG00000274973.1	RP13-401N8.7	-4.12	4.11e-05	0.00288	-0.14	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25283012	chr20:25845497~25845862:+
BRCA	cis	rs7267979	0.966	rs2257705	ENSG00000274973.1	RP13-401N8.7	-4.12	4.11e-05	0.00288	-0.14	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25284028	chr20:25845497~25845862:+
BRCA	cis	rs7267979	0.966	rs2227892	ENSG00000274973.1	RP13-401N8.7	-4.12	4.11e-05	0.00288	-0.14	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25284178	chr20:25845497~25845862:+
BRCA	cis	rs7267979	0.966	rs2257712	ENSG00000274973.1	RP13-401N8.7	-4.12	4.11e-05	0.00288	-0.14	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25284274	chr20:25845497~25845862:+
BRCA	cis	rs7267979	0.966	rs2257461	ENSG00000274973.1	RP13-401N8.7	-4.12	4.11e-05	0.00288	-0.14	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25284918	chr20:25845497~25845862:+
BRCA	cis	rs34792	0.554	rs62039130	ENSG00000275910.1	RP11-680G24.6	-4.12	4.11e-05	0.00288	-0.16	-0.13	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15518277	chr16:15015828~15016390:-
BRCA	cis	rs911119	0.955	rs12625716	ENSG00000270001.1	RP11-218C14.8	4.12	4.11e-05	0.00288	0.17	0.13	Chronic kidney disease;	chr20:23626208	chr20:23631826~23632316:-
BRCA	cis	rs71386921	1	rs71386921	ENSG00000262412.1	RP11-85G18.6	4.12	4.11e-05	0.00288	0.2	0.13	Breast cancer;	chr10:27189786	chr10:27243130~27250804:+
BRCA	cis	rs7267979	0.744	rs6050463	ENSG00000274414.1	RP5-965G21.4	-4.12	4.11e-05	0.00288	-0.15	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25228354	chr20:25239007~25245229:-
BRCA	cis	rs7771547	0.603	rs9357218	ENSG00000224666.3	RP1-50J22.4	4.12	4.11e-05	0.00288	0.16	0.13	Platelet distribution width;	chr6:36582081	chr6:36386831~36393462:+
BRCA	cis	rs4302906	0.964	rs10821051	ENSG00000187984.11	ANKRD19P	-4.12	4.11e-05	0.00288	-0.11	-0.13	Lobe attachment (rater-scored or self-reported);	chr9:92985770	chr9:92809388~92888693:+
BRCA	cis	rs12887734	0.524	rs12888002	ENSG00000269940.1	RP11-73M18.7	4.12	4.11e-05	0.00288	0.14	0.13	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103772310	chr14:103694560~103695170:+
BRCA	cis	rs2880765	0.525	rs35899940	ENSG00000230373.7	GOLGA6L5P	4.12	4.11e-05	0.00288	0.15	0.13	Coronary artery disease;	chr15:85510466	chr15:84507885~84516814:-
BRCA	cis	rs651907	0.535	rs35810977	ENSG00000256628.3	ZBTB11-AS1	4.12	4.11e-05	0.00288	0.16	0.13	Colorectal cancer;	chr3:101812536	chr3:101676475~101679217:+
BRCA	cis	rs17489649	0.869	rs2043831	ENSG00000271849.1	CTC-332L22.1	4.12	4.12e-05	0.00288	0.16	0.13	Intelligence (multi-trait analysis);	chr5:109721127	chr5:109687802~109688329:-
BRCA	cis	rs1048886	0.808	rs9455158	ENSG00000271967.1	RP11-134K13.4	-4.12	4.12e-05	0.00288	-0.17	-0.13	Type 2 diabetes;	chr6:70561176	chr6:70596438~70596980:+
BRCA	cis	rs3096299	0.933	rs2965823	ENSG00000259877.2	RP11-46C24.7	-4.12	4.12e-05	0.00288	-0.12	-0.13	Multiple myeloma (IgH translocation);	chr16:89388516	chr16:89215211~89217653:-
BRCA	cis	rs7243790	1	rs10502990	ENSG00000277324.1	RP11-850A17.1	4.12	4.12e-05	0.00288	0.14	0.13	Diastolic blood pressure;	chr18:54438168	chr18:54268346~54270028:-
BRCA	cis	rs8114671	0.804	rs3803936	ENSG00000126005.14	MMP24-AS1	4.12	4.12e-05	0.00288	0.15	0.13	Height;	chr20:35044972	chr20:35216462~35278131:-
BRCA	cis	rs8114671	0.836	rs13042358	ENSG00000126005.14	MMP24-AS1	4.12	4.12e-05	0.00288	0.15	0.13	Height;	chr20:35046676	chr20:35216462~35278131:-
BRCA	cis	rs7267979	0.549	rs6138537	ENSG00000277938.1	RP5-965G21.3	4.12	4.12e-05	0.00288	0.15	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25203830	chr20:25229150~25231933:+
BRCA	cis	rs9341808	0.727	rs9352809	ENSG00000233967.5	RP11-250B2.3	4.12	4.12e-05	0.00288	0.13	0.13	Sitting height ratio;	chr6:80289599	chr6:80443344~80465927:+
BRCA	cis	rs4845570	1	rs6659705	ENSG00000203288.3	RP11-98D18.9	-4.12	4.12e-05	0.00288	-0.21	-0.13	Coronary artery disease;	chr1:151797274	chr1:151790804~151794402:+
BRCA	cis	rs875971	0.545	rs11770063	ENSG00000273142.1	RP11-458F8.4	4.12	4.12e-05	0.00288	0.13	0.13	Aortic root size;	chr7:66318029	chr7:66902857~66906297:+
BRCA	cis	rs1836229	0.874	rs10120450	ENSG00000225706.1	PTPRD-AS1	-4.12	4.12e-05	0.00288	-0.14	-0.13	Restless legs syndrome;	chr9:8826588	chr9:8858130~8862255:+
BRCA	cis	rs9863	0.861	rs4930725	ENSG00000270028.1	RP11-380L11.4	4.12	4.12e-05	0.00288	0.16	0.13	White blood cell count;	chr12:123943615	chr12:123925461~123926083:-
BRCA	cis	rs9527	0.544	rs1572578	ENSG00000213061.2	PFN1P11	4.12	4.12e-05	0.00288	0.17	0.13	Arsenic metabolism;	chr10:103062674	chr10:102838011~102845473:-
BRCA	cis	rs11098499	0.954	rs13107475	ENSG00000250412.1	KLHL2P1	4.12	4.12e-05	0.00288	0.15	0.13	Corneal astigmatism;	chr4:119471856	chr4:119334329~119378233:+
BRCA	cis	rs6570726	0.935	rs400968	ENSG00000270638.1	RP3-466P17.1	4.12	4.12e-05	0.00288	0.14	0.13	Lobe attachment (rater-scored or self-reported);	chr6:145498582	chr6:145735570~145737218:+
BRCA	cis	rs6570726	0.935	rs391820	ENSG00000270638.1	RP3-466P17.1	4.12	4.12e-05	0.00288	0.14	0.13	Lobe attachment (rater-scored or self-reported);	chr6:145500148	chr6:145735570~145737218:+
BRCA	cis	rs6570726	0.875	rs1883407	ENSG00000270638.1	RP3-466P17.1	4.12	4.12e-05	0.00288	0.14	0.13	Lobe attachment (rater-scored or self-reported);	chr6:145502296	chr6:145735570~145737218:+
BRCA	cis	rs757081	0.648	rs12276859	ENSG00000184669.7	OR7E14P	-4.12	4.12e-05	0.00288	-0.17	-0.13	Systolic blood pressure;	chr11:17255418	chr11:17013998~17053024:+
BRCA	cis	rs9341808	0.538	rs9343980	ENSG00000233967.5	RP11-250B2.3	-4.12	4.12e-05	0.00288	-0.13	-0.13	Sitting height ratio;	chr6:80313715	chr6:80443344~80465927:+
BRCA	cis	rs1665650	0.789	rs11197806	ENSG00000232767.1	RP11-498B4.5	-4.12	4.12e-05	0.00288	-0.14	-0.13	Colorectal cancer;	chr10:116722255	chr10:116670103~116672739:+
BRCA	cis	rs1371614	0.632	rs3769134	ENSG00000272148.1	RP11-195B17.1	4.12	4.12e-05	0.00288	0.14	0.13	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26928023	chr2:27062428~27062907:-
BRCA	cis	rs4664293	0.605	rs6745815	ENSG00000226266.5	AC009961.3	4.12	4.12e-05	0.00288	0.15	0.13	Monocyte percentage of white cells;	chr2:159693558	chr2:159670708~159712435:-
BRCA	cis	rs4664293	0.551	rs11898293	ENSG00000226266.5	AC009961.3	4.12	4.12e-05	0.00288	0.15	0.13	Monocyte percentage of white cells;	chr2:159696082	chr2:159670708~159712435:-
BRCA	cis	rs875971	0.964	rs778708	ENSG00000229180.5	GS1-124K5.11	4.12	4.12e-05	0.00288	0.11	0.13	Aortic root size;	chr7:66391332	chr7:66526088~66542624:-
BRCA	cis	rs9309473	0.687	rs11693531	ENSG00000230002.2	ALMS1-IT1	4.12	4.12e-05	0.00288	0.15	0.13	Metabolite levels;	chr2:73381486	chr2:73456764~73459484:+
BRCA	cis	rs12612619	0.732	rs6547401	ENSG00000272148.1	RP11-195B17.1	4.12	4.12e-05	0.00289	0.14	0.13	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27061977	chr2:27062428~27062907:-
BRCA	cis	rs9788721	0.902	rs7180002	ENSG00000261762.1	RP11-650L12.2	-4.12	4.12e-05	0.00289	-0.16	-0.13	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78581651	chr15:78589123~78591276:-
BRCA	cis	rs7267979	0.932	rs2260997	ENSG00000274973.1	RP13-401N8.7	4.12	4.12e-05	0.00289	0.14	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25275630	chr20:25845497~25845862:+
BRCA	cis	rs748404	0.626	rs35992154	ENSG00000205771.5	CATSPER2P1	-4.12	4.13e-05	0.00289	-0.19	-0.13	Lung cancer;	chr15:43345669	chr15:43726918~43747094:-
BRCA	cis	rs61931739	0.534	rs7302688	ENSG00000258794.3	DUX4L27	4.12	4.13e-05	0.00289	0.18	0.13	Morning vs. evening chronotype;	chr12:34082129	chr12:34208415~34209675:-
BRCA	cis	rs984222	0.617	rs2003365	ENSG00000231365.4	RP11-418J17.1	4.12	4.13e-05	0.00289	0.15	0.13	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119219414	chr1:119140396~119275973:+
BRCA	cis	rs771767	0.539	rs708232	ENSG00000244119.1	PDCL3P4	4.12	4.13e-05	0.00289	0.13	0.13	Multiple sclerosis;	chr3:102035538	chr3:101712472~101713191:+
BRCA	cis	rs4950322	0.515	rs76327075	ENSG00000237188.3	RP11-337C18.8	4.12	4.13e-05	0.00289	0.15	0.13	Protein quantitative trait loci;	chr1:147246319	chr1:147172771~147211568:+
BRCA	cis	rs6963495	0.818	rs73192107	ENSG00000223886.3	RP11-251G23.2	4.12	4.13e-05	0.00289	0.2	0.13	Bipolar disorder (body mass index interaction);	chr7:105527648	chr7:105530209~105530671:+
BRCA	cis	rs6963495	0.818	rs73192113	ENSG00000223886.3	RP11-251G23.2	4.12	4.13e-05	0.00289	0.2	0.13	Bipolar disorder (body mass index interaction);	chr7:105529156	chr7:105530209~105530671:+
BRCA	cis	rs6963495	0.818	rs73192115	ENSG00000223886.3	RP11-251G23.2	4.12	4.13e-05	0.00289	0.2	0.13	Bipolar disorder (body mass index interaction);	chr7:105529158	chr7:105530209~105530671:+
BRCA	cis	rs35740288	0.929	rs11636821	ENSG00000202081.1	RNU6-1280P	4.12	4.13e-05	0.00289	0.17	0.13	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85762774	chr15:85651522~85651628:-
BRCA	cis	rs35740288	0.929	rs11630684	ENSG00000202081.1	RNU6-1280P	4.12	4.13e-05	0.00289	0.17	0.13	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85763025	chr15:85651522~85651628:-
BRCA	cis	rs11148252	0.669	rs4884320	ENSG00000278238.1	RP11-245D16.4	-4.12	4.13e-05	0.00289	-0.14	-0.13	Lewy body disease;	chr13:52432779	chr13:52454775~52455331:-
BRCA	cis	rs6593122	0.755	rs1404203	ENSG00000235454.1	HAUS6P3	-4.12	4.13e-05	0.00289	-0.17	-0.13	Vaccine-related adverse events;	chr7:54132285	chr7:53862233~53863339:+
BRCA	cis	rs1371614	0.635	rs12618836	ENSG00000229122.1	AGBL5-IT1	4.12	4.13e-05	0.00289	0.13	0.13	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26914748	chr2:27061038~27061815:+
BRCA	cis	rs875971	0.638	rs6460305	ENSG00000232546.1	RP11-458F8.1	4.12	4.13e-05	0.00289	0.11	0.13	Aortic root size;	chr7:66595421	chr7:66848496~66858136:+
BRCA	cis	rs27434	0.605	rs2351012	ENSG00000272109.1	CTD-2260A17.3	-4.12	4.13e-05	0.00289	-0.2	-0.13	Ankylosing spondylitis;	chr5:96856044	chr5:96804353~96806105:+
BRCA	cis	rs1665650	1	rs1665650	ENSG00000232767.1	RP11-498B4.5	-4.12	4.13e-05	0.00289	-0.13	-0.13	Colorectal cancer;	chr10:116727589	chr10:116670103~116672739:+
BRCA	cis	rs2243480	1	rs1701758	ENSG00000222364.1	RNU6-96P	-4.12	4.13e-05	0.00289	-0.23	-0.13	Diabetic kidney disease;	chr7:66005214	chr7:66395191~66395286:+
BRCA	cis	rs2904967	1	rs509303	ENSG00000255200.1	AP003068.18	-4.12	4.13e-05	0.00289	-0.2	-0.13	Mean corpuscular volume;	chr11:65325719	chr11:65174117~65176470:-
BRCA	cis	rs718314	0.719	rs11048447	ENSG00000256894.1	RP11-283G6.3	4.12	4.14e-05	0.00289	0.14	0.13	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Renal cell carcinoma;Waist circumference adjusted for body mass index;	chr12:26291164	chr12:26125155~26126617:-
BRCA	cis	rs8114671	0.935	rs35193912	ENSG00000279253.1	RP4-614O4.13	4.12	4.14e-05	0.00289	0.14	0.13	Height;	chr20:35197247	chr20:35262727~35264187:-
BRCA	cis	rs8114671	0.967	rs34515766	ENSG00000279253.1	RP4-614O4.13	4.12	4.14e-05	0.00289	0.14	0.13	Height;	chr20:35197418	chr20:35262727~35264187:-
BRCA	cis	rs7267979	1	rs2424704	ENSG00000125804.12	FAM182A	-4.12	4.14e-05	0.00289	-0.16	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25293293	chr20:26054655~26086917:+
BRCA	cis	rs300890	0.689	rs300946	ENSG00000250326.1	RP11-284M14.1	-4.12	4.14e-05	0.00289	-0.15	-0.13	Nasopharyngeal carcinoma;	chr4:143288265	chr4:142933195~143184861:-
BRCA	cis	rs12612619	0.732	rs893790	ENSG00000229122.1	AGBL5-IT1	-4.12	4.14e-05	0.00289	-0.13	-0.13	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:26978989	chr2:27061038~27061815:+
BRCA	cis	rs8113308	0.515	rs113082012	ENSG00000269483.1	AC006272.1	4.12	4.14e-05	0.00289	0.3	0.13	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51960980	chr19:51839924~51843324:-
BRCA	cis	rs8114671	1	rs8114671	ENSG00000279253.1	RP4-614O4.13	4.12	4.14e-05	0.00289	0.15	0.13	Height;	chr20:35201339	chr20:35262727~35264187:-
BRCA	cis	rs11098499	0.909	rs10017335	ENSG00000225892.3	RP11-384K6.2	-4.12	4.14e-05	0.00289	-0.13	-0.13	Corneal astigmatism;	chr4:119460368	chr4:118632274~118634759:+
BRCA	cis	rs2242116	0.727	rs4683298	ENSG00000276925.1	RP11-708J19.3	-4.12	4.14e-05	0.00289	-0.15	-0.13	Birth weight;	chr3:46924897	chr3:47469777~47469987:+
BRCA	cis	rs9921338	0.887	rs9926136	ENSG00000262703.1	RP11-485G7.6	-4.12	4.14e-05	0.00289	-0.16	-0.13	Vein graft stenosis in coronary artery bypass grafting;	chr16:11343418	chr16:11348143~11349321:-
BRCA	cis	rs9925964	0.967	rs1978487	ENSG00000260911.2	RP11-196G11.2	4.12	4.14e-05	0.00289	0.12	0.13	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31118621	chr16:31043150~31049868:+
BRCA	cis	rs35146811	0.625	rs2906645	ENSG00000214313.7	AZGP1P1	-4.12	4.14e-05	0.00289	-0.14	-0.13	Coronary artery disease;	chr7:100220236	chr7:99980762~99987535:+
BRCA	cis	rs35146811	0.735	rs858506	ENSG00000214313.7	AZGP1P1	-4.12	4.14e-05	0.00289	-0.14	-0.13	Coronary artery disease;	chr7:100222427	chr7:99980762~99987535:+
BRCA	cis	rs35146811	0.695	rs858508	ENSG00000214313.7	AZGP1P1	-4.12	4.14e-05	0.00289	-0.14	-0.13	Coronary artery disease;	chr7:100223758	chr7:99980762~99987535:+
BRCA	cis	rs4664293	0.625	rs11899419	ENSG00000226266.5	AC009961.3	4.12	4.14e-05	0.00289	0.15	0.13	Monocyte percentage of white cells;	chr2:159688858	chr2:159670708~159712435:-
BRCA	cis	rs61160187	0.556	rs4647052	ENSG00000272308.1	RP11-231G3.1	-4.12	4.14e-05	0.00289	-0.14	-0.13	Educational attainment (years of education);Educational attainment (college completion);	chr5:60939656	chr5:60866457~60866935:-
BRCA	cis	rs7260598	0.792	rs4635459	ENSG00000268442.1	CTD-2027I19.2	4.12	4.14e-05	0.0029	0.2	0.13	Response to taxane treatment (placlitaxel);	chr19:23999020	chr19:24162370~24163425:-
BRCA	cis	rs9527	0.83	rs11191442	ENSG00000236937.2	PTGES3P4	4.12	4.14e-05	0.0029	0.18	0.13	Arsenic metabolism;	chr10:102883839	chr10:102845595~102845950:+
BRCA	cis	rs2835345	0.563	rs12483690	ENSG00000233818.1	AP000695.4	4.12	4.14e-05	0.0029	0.13	0.13	Pulmonary function;	chr21:36451265	chr21:36445731~36532408:+
BRCA	cis	rs2835345	0.596	rs12482097	ENSG00000233818.1	AP000695.4	4.12	4.14e-05	0.0029	0.13	0.13	Pulmonary function;	chr21:36451592	chr21:36445731~36532408:+
BRCA	cis	rs2835345	0.596	rs12482138	ENSG00000233818.1	AP000695.4	4.12	4.14e-05	0.0029	0.13	0.13	Pulmonary function;	chr21:36451608	chr21:36445731~36532408:+
BRCA	cis	rs2835345	0.563	rs12482257	ENSG00000233818.1	AP000695.4	4.12	4.14e-05	0.0029	0.13	0.13	Pulmonary function;	chr21:36451660	chr21:36445731~36532408:+
BRCA	cis	rs1075265	0.811	rs805322	ENSG00000272156.1	RP11-477N3.1	4.12	4.14e-05	0.0029	0.13	0.13	Chronotype;Morning vs. evening chronotype;	chr2:53912758	chr2:54082554~54085066:+
BRCA	cis	rs11098499	0.955	rs6815725	ENSG00000260091.1	RP11-33B1.4	-4.12	4.14e-05	0.0029	-0.11	-0.13	Corneal astigmatism;	chr4:119237255	chr4:119409333~119410233:+
BRCA	cis	rs1371614	0.632	rs3739085	ENSG00000272148.1	RP11-195B17.1	4.12	4.14e-05	0.0029	0.14	0.13	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26940176	chr2:27062428~27062907:-
BRCA	cis	rs6952407	1	rs6952407	ENSG00000265600.1	AC006480.1	4.12	4.14e-05	0.0029	0.15	0.13	Cotinine glucuronidation;	chr7:66580525	chr7:67356680~67356779:+
BRCA	cis	rs9527	0.59	rs11191540	ENSG00000213061.2	PFN1P11	4.12	4.14e-05	0.0029	0.17	0.13	Arsenic metabolism;	chr10:103063052	chr10:102838011~102845473:-
BRCA	cis	rs9527	0.59	rs7092029	ENSG00000213061.2	PFN1P11	4.12	4.14e-05	0.0029	0.17	0.13	Arsenic metabolism;	chr10:103064152	chr10:102838011~102845473:-
BRCA	cis	rs9527	0.59	rs943039	ENSG00000213061.2	PFN1P11	4.12	4.14e-05	0.0029	0.17	0.13	Arsenic metabolism;	chr10:103065375	chr10:102838011~102845473:-
BRCA	cis	rs11711311	1	rs3732793	ENSG00000241529.3	RN7SL767P	-4.12	4.14e-05	0.0029	-0.15	-0.13	IgG glycosylation;	chr3:113723351	chr3:113632704~113632998:+
BRCA	cis	rs301801	0.803	rs2661863	ENSG00000270282.1	RP5-1115A15.2	-4.12	4.14e-05	0.0029	-0.15	-0.13	Optic cup area;Vertical cup-disc ratio;	chr1:8392665	chr1:8512653~8513021:+
BRCA	cis	rs7811142	0.83	rs76798830	ENSG00000078319.8	PMS2P1	-4.12	4.14e-05	0.0029	-0.22	-0.13	Platelet count;	chr7:100355205	chr7:100320992~100341908:-
BRCA	cis	rs6840360	0.582	rs6535796	ENSG00000251611.1	RP11-610P16.1	-4.12	4.14e-05	0.0029	-0.11	-0.13	Intelligence (multi-trait analysis);	chr4:151383576	chr4:151407551~151408835:-
BRCA	cis	rs11742741	0.87	rs1428207	ENSG00000248874.4	C5orf17	-4.12	4.15e-05	0.0029	-0.16	-0.13	Educational attainment;	chr5:24094910	chr5:23951348~24178263:+
BRCA	cis	rs952623	0.649	rs7801660	ENSG00000211694.2	TRGV10	4.12	4.15e-05	0.0029	0.11	0.13	Intelligence (multi-trait analysis);	chr7:39032873	chr7:38299811~38300322:-
BRCA	cis	rs6570726	0.935	rs367612	ENSG00000270638.1	RP3-466P17.1	4.12	4.15e-05	0.0029	0.14	0.13	Lobe attachment (rater-scored or self-reported);	chr6:145507851	chr6:145735570~145737218:+
BRCA	cis	rs6570726	0.905	rs375692	ENSG00000270638.1	RP3-466P17.1	4.12	4.15e-05	0.0029	0.14	0.13	Lobe attachment (rater-scored or self-reported);	chr6:145519232	chr6:145735570~145737218:+
BRCA	cis	rs683250	0.66	rs520291	ENSG00000254551.1	RP11-727A23.7	4.12	4.15e-05	0.0029	0.16	0.13	Subcortical brain region volumes;	chr11:83246990	chr11:83209431~83213379:-
BRCA	cis	rs11098499	0.909	rs11723757	ENSG00000260091.1	RP11-33B1.4	-4.12	4.15e-05	0.0029	-0.11	-0.13	Corneal astigmatism;	chr4:119378514	chr4:119409333~119410233:+
BRCA	cis	rs2446066	0.872	rs7955418	ENSG00000257379.1	RP11-793H13.8	4.12	4.15e-05	0.0029	0.19	0.13	Red blood cell count;	chr12:53397846	chr12:53441741~53467528:+
BRCA	cis	rs7829975	0.533	rs13274028	ENSG00000254153.1	CTA-398F10.2	4.12	4.15e-05	0.0029	0.16	0.13	Mood instability;	chr8:8871683	chr8:8456909~8461337:-
BRCA	cis	rs9527	0.59	rs10509764	ENSG00000213061.2	PFN1P11	4.12	4.15e-05	0.0029	0.17	0.13	Arsenic metabolism;	chr10:103016718	chr10:102838011~102845473:-
BRCA	cis	rs9527	0.59	rs6584537	ENSG00000213061.2	PFN1P11	4.12	4.15e-05	0.0029	0.17	0.13	Arsenic metabolism;	chr10:103018510	chr10:102838011~102845473:-
BRCA	cis	rs9527	0.569	rs78193706	ENSG00000213061.2	PFN1P11	4.12	4.15e-05	0.0029	0.17	0.13	Arsenic metabolism;	chr10:103020807	chr10:102838011~102845473:-
BRCA	cis	rs8114671	0.836	rs734308	ENSG00000279253.1	RP4-614O4.13	4.12	4.15e-05	0.0029	0.15	0.13	Height;	chr20:34984293	chr20:35262727~35264187:-
BRCA	cis	rs875971	0.66	rs10272357	ENSG00000229180.5	GS1-124K5.11	-4.12	4.15e-05	0.0029	-0.11	-0.13	Aortic root size;	chr7:66598087	chr7:66526088~66542624:-
BRCA	cis	rs1005277	0.579	rs176838	ENSG00000272983.1	RP11-508N22.12	-4.12	4.15e-05	0.0029	-0.13	-0.13	Extrinsic epigenetic age acceleration;	chr10:38082971	chr10:38137337~38144399:+
BRCA	cis	rs7727544	0.582	rs3805681	ENSG00000233006.5	AC034220.3	4.12	4.15e-05	0.0029	0.09	0.13	Blood metabolite levels;	chr5:132202167	chr5:132311285~132369916:-
BRCA	cis	rs10266483	0.774	rs1404678	ENSG00000271550.1	BNIP3P11	-4.12	4.15e-05	0.0029	-0.17	-0.13	Response to statin therapy;	chr7:64342138	chr7:64678954~64687393:-
BRCA	cis	rs9788721	0.802	rs56219465	ENSG00000261762.1	RP11-650L12.2	-4.12	4.15e-05	0.0029	-0.15	-0.13	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78450237	chr15:78589123~78591276:-
BRCA	cis	rs6893300	1	rs62406178	ENSG00000250999.1	RP11-1379J22.5	4.12	4.15e-05	0.0029	0.18	0.13	Resting heart rate;	chr5:179737217	chr5:179657762~179664432:+
BRCA	cis	rs1065852	0.503	rs9620006	ENSG00000205702.9	CYP2D7	4.12	4.15e-05	0.0029	0.12	0.13	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42003543	chr22:42140203~42144577:-
BRCA	cis	rs859767	0.812	rs842358	ENSG00000224043.6	CCNT2-AS1	-4.12	4.15e-05	0.0029	-0.18	-0.13	Neuroticism;	chr2:134587539	chr2:134735464~134918710:-
BRCA	cis	rs35740288	0.731	rs11638407	ENSG00000202081.1	RNU6-1280P	4.12	4.15e-05	0.0029	0.16	0.13	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85551424	chr15:85651522~85651628:-
BRCA	cis	rs58521262	0.556	rs390911	ENSG00000268105.1	RP11-369G6.2	4.12	4.15e-05	0.0029	0.17	0.13	Testicular germ cell tumor;	chr19:22941943	chr19:23125665~23128543:+
BRCA	cis	rs58521262	0.556	rs465933	ENSG00000268105.1	RP11-369G6.2	4.12	4.15e-05	0.0029	0.17	0.13	Testicular germ cell tumor;	chr19:22945401	chr19:23125665~23128543:+
BRCA	cis	rs11098499	0.865	rs4507344	ENSG00000225892.3	RP11-384K6.2	4.12	4.15e-05	0.0029	0.13	0.13	Corneal astigmatism;	chr4:119386330	chr4:118632274~118634759:+
BRCA	cis	rs875971	0.66	rs1860468	ENSG00000229180.5	GS1-124K5.11	-4.12	4.15e-05	0.0029	-0.11	-0.13	Aortic root size;	chr7:66642265	chr7:66526088~66542624:-
BRCA	cis	rs7267979	0.565	rs6107059	ENSG00000125804.12	FAM182A	4.12	4.16e-05	0.0029	0.16	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25611795	chr20:26054655~26086917:+
BRCA	cis	rs2562456	0.55	rs4809143	ENSG00000240522.1	RPL7AP10	-4.12	4.16e-05	0.00291	-0.15	-0.13	Pain;	chr19:21589926	chr19:21149648~21150438:-
BRCA	cis	rs2562456	0.583	rs4809144	ENSG00000240522.1	RPL7AP10	-4.12	4.16e-05	0.00291	-0.15	-0.13	Pain;	chr19:21589928	chr19:21149648~21150438:-
BRCA	cis	rs9527	0.59	rs12355120	ENSG00000213061.2	PFN1P11	4.12	4.16e-05	0.00291	0.17	0.13	Arsenic metabolism;	chr10:103092409	chr10:102838011~102845473:-
BRCA	cis	rs9467773	0.62	rs2101582	ENSG00000241549.7	GUSBP2	4.12	4.16e-05	0.00291	0.13	0.13	Intelligence (multi-trait analysis);	chr6:26622506	chr6:26871484~26956554:-
BRCA	cis	rs13108904	0.935	rs3755920	ENSG00000196810.4	CTBP1-AS2	4.12	4.16e-05	0.00291	0.14	0.13	Obesity-related traits;	chr4:1249829	chr4:1249300~1288291:+
BRCA	cis	rs860818	1	rs858253	ENSG00000230658.1	KLHL7-AS1	-4.12	4.16e-05	0.00291	-0.32	-0.13	Initial pursuit acceleration;	chr7:23178101	chr7:23101228~23105703:-
BRCA	cis	rs930395	0.514	rs6871052	ENSG00000251141.4	RP11-53O19.1	-4.12	4.16e-05	0.00291	-0.12	-0.13	Breast cancer;	chr5:44863215	chr5:44744900~44808777:-
BRCA	cis	rs930395	0.514	rs6893319	ENSG00000251141.4	RP11-53O19.1	-4.12	4.16e-05	0.00291	-0.12	-0.13	Breast cancer;	chr5:44863627	chr5:44744900~44808777:-
BRCA	cis	rs4415084	0.652	rs10053247	ENSG00000251141.4	RP11-53O19.1	-4.12	4.16e-05	0.00291	-0.12	-0.13	Breast cancer;	chr5:44863857	chr5:44744900~44808777:-
BRCA	cis	rs930395	0.514	rs10065638	ENSG00000251141.4	RP11-53O19.1	-4.12	4.16e-05	0.00291	-0.12	-0.13	Breast cancer;	chr5:44866060	chr5:44744900~44808777:-
BRCA	cis	rs930395	0.514	rs6894324	ENSG00000251141.4	RP11-53O19.1	-4.12	4.16e-05	0.00291	-0.12	-0.13	Breast cancer;	chr5:44867234	chr5:44744900~44808777:-
BRCA	cis	rs2905347	0.737	rs2010437	ENSG00000179428.2	AC073072.5	-4.12	4.16e-05	0.00291	-0.14	-0.13	Major depression and alcohol dependence;	chr7:22591561	chr7:22725395~22727620:-
BRCA	cis	rs763121	0.853	rs3827357	ENSG00000225450.1	RP3-508I15.14	-4.12	4.16e-05	0.00291	-0.14	-0.13	Menopause (age at onset);	chr22:38683408	chr22:38739003~38749041:+
BRCA	cis	rs7312933	0.567	rs11181399	ENSG00000257225.1	RP11-328C8.4	-4.12	4.16e-05	0.00291	-0.15	-0.13	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42272610	chr12:42459366~42466128:+
BRCA	cis	rs9879311	1	rs9879311	ENSG00000240288.6	GHRLOS	4.12	4.16e-05	0.00291	0.14	0.13	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr3:10373659	chr3:10285754~10293449:+
BRCA	cis	rs4272720	0.855	rs11817325	ENSG00000228754.1	RP11-534L6.3	-4.12	4.16e-05	0.00291	-0.18	-0.13	Platelet count;Plateletcrit;	chr10:49029739	chr10:48745545~48746128:-
BRCA	cis	rs669446	0.561	rs530201	ENSG00000236200.4	KDM4A-AS1	-4.12	4.16e-05	0.00291	-0.16	-0.13	Amyotrophic lateral sclerosis (age of onset);	chr1:43636586	chr1:43699765~43708138:-
BRCA	cis	rs7577599	0.812	rs17046986	ENSG00000224220.1	AC104699.1	4.12	4.16e-05	0.00291	0.11	0.13	Multiple myeloma (IgH translocation);Multiple myeloma;	chr2:25398031	chr2:25421117~25427643:+
BRCA	cis	rs875971	0.929	rs778712	ENSG00000265600.1	AC006480.1	-4.12	4.17e-05	0.00291	-0.15	-0.13	Aortic root size;	chr7:66384991	chr7:67356680~67356779:+
BRCA	cis	rs9952991	0.883	rs2847293	ENSG00000260302.1	RP11-973H7.1	-4.12	4.17e-05	0.00291	-0.2	-0.13	Inflammatory skin disease;	chr18:12782449	chr18:12774651~12775923:-
BRCA	cis	rs875971	0.929	rs12535036	ENSG00000236529.1	RP13-254B10.1	4.12	4.17e-05	0.00291	0.14	0.13	Aortic root size;	chr7:66499076	chr7:65840212~65840596:+
BRCA	cis	rs875971	1	rs6970030	ENSG00000236529.1	RP13-254B10.1	4.12	4.17e-05	0.00291	0.14	0.13	Aortic root size;	chr7:66503692	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.928	rs6970357	ENSG00000236529.1	RP13-254B10.1	4.12	4.17e-05	0.00291	0.14	0.13	Aortic root size;	chr7:66503891	chr7:65840212~65840596:+
BRCA	cis	rs7487075	0.558	rs12303214	ENSG00000272369.1	RP11-446N19.1	4.12	4.17e-05	0.00291	0.14	0.13	Itch intensity from mosquito bite;	chr12:46255745	chr12:46537502~46652550:+
BRCA	cis	rs4478858	0.735	rs4494186	ENSG00000260386.4	LINC01225	4.12	4.17e-05	0.00291	0.15	0.13	Alcohol dependence;	chr1:31385000	chr1:31500085~31540885:+
BRCA	cis	rs2251381	0.741	rs2735966	ENSG00000232855.5	AF131217.1	-4.12	4.17e-05	0.00291	-0.16	-0.13	Selective IgA deficiency;	chr21:29165853	chr21:28439346~28674848:-
BRCA	cis	rs11051970	0.879	rs2088807	ENSG00000274964.1	RP11-817I4.1	-4.12	4.17e-05	0.00291	-0.15	-0.13	Response to tocilizumab in rheumatoid arthritis;	chr12:32439167	chr12:32339368~32340724:+
BRCA	cis	rs6431644	0.64	rs887061	ENSG00000224287.2	MSL3P1	4.12	4.17e-05	0.00291	0.14	0.13	Left atrial antero-posterior diameter;	chr2:233855972	chr2:233865437~233868444:-
BRCA	cis	rs6754311	0.731	rs1470457	ENSG00000231890.6	DARS-AS1	-4.12	4.17e-05	0.00291	-0.16	-0.13	Mosquito bite size;	chr2:135824278	chr2:135985176~136022593:+
BRCA	cis	rs7937890	0.559	rs2575853	ENSG00000254418.1	RP11-21L19.1	4.12	4.17e-05	0.00291	0.15	0.13	Mitochondrial DNA levels;	chr11:14512417	chr11:14262846~14273691:-
BRCA	cis	rs6723226	0.572	rs176404	ENSG00000276517.1	AL133243.2	4.12	4.17e-05	0.00291	0.15	0.13	Intelligence (multi-trait analysis);	chr2:32413778	chr2:32526504~32529507:+
BRCA	cis	rs4925540	0.962	rs1565897	ENSG00000215796.3	RP11-551G24.2	-4.12	4.17e-05	0.00292	-0.15	-0.13	Response to taxane treatment (docetaxel);	chr1:247042384	chr1:247042791~247044021:+
BRCA	cis	rs10986311	0.832	rs10818952	ENSG00000227200.1	RP11-121A14.3	-4.12	4.17e-05	0.00292	-0.15	-0.13	Vitiligo;	chr9:124375524	chr9:124262876~124265809:+
BRCA	cis	rs1371614	0.632	rs6759548	ENSG00000272148.1	RP11-195B17.1	4.12	4.17e-05	0.00292	0.14	0.13	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26938192	chr2:27062428~27062907:-
BRCA	cis	rs38055	1	rs454737	ENSG00000247796.2	CTD-2366F13.1	-4.12	4.17e-05	0.00292	-0.15	-0.13	Acne (severe);	chr5:53275193	chr5:53109842~53115126:+
BRCA	cis	rs1876905	0.539	rs240987	ENSG00000255389.1	C6orf3	4.12	4.17e-05	0.00292	0.17	0.13	Mean corpuscular hemoglobin;	chr6:111268552	chr6:111599875~111602295:+
BRCA	cis	rs4374383	0.772	rs66477683	ENSG00000243389.1	AC012442.5	-4.12	4.17e-05	0.00292	-0.16	-0.13	Hepatitis C induced liver fibrosis;	chr2:111976120	chr2:112589040~112614431:+
BRCA	cis	rs4374383	0.884	rs68087924	ENSG00000243389.1	AC012442.5	-4.12	4.17e-05	0.00292	-0.16	-0.13	Hepatitis C induced liver fibrosis;	chr2:111976140	chr2:112589040~112614431:+
BRCA	cis	rs4374383	0.812	rs66486378	ENSG00000243389.1	AC012442.5	-4.12	4.17e-05	0.00292	-0.16	-0.13	Hepatitis C induced liver fibrosis;	chr2:111976403	chr2:112589040~112614431:+
BRCA	cis	rs4374383	0.884	rs1607059	ENSG00000243389.1	AC012442.5	-4.12	4.17e-05	0.00292	-0.16	-0.13	Hepatitis C induced liver fibrosis;	chr2:111976935	chr2:112589040~112614431:+
BRCA	cis	rs4374383	0.884	rs10199083	ENSG00000243389.1	AC012442.5	-4.12	4.17e-05	0.00292	-0.16	-0.13	Hepatitis C induced liver fibrosis;	chr2:111979065	chr2:112589040~112614431:+
BRCA	cis	rs4374383	0.884	rs10166564	ENSG00000243389.1	AC012442.5	-4.12	4.17e-05	0.00292	-0.16	-0.13	Hepatitis C induced liver fibrosis;	chr2:111979146	chr2:112589040~112614431:+
BRCA	cis	rs4374383	0.884	rs10199616	ENSG00000243389.1	AC012442.5	-4.12	4.17e-05	0.00292	-0.16	-0.13	Hepatitis C induced liver fibrosis;	chr2:111979608	chr2:112589040~112614431:+
BRCA	cis	rs4374383	0.847	rs10177803	ENSG00000243389.1	AC012442.5	-4.12	4.17e-05	0.00292	-0.16	-0.13	Hepatitis C induced liver fibrosis;	chr2:111979715	chr2:112589040~112614431:+
BRCA	cis	rs4374383	0.811	rs6725192	ENSG00000243389.1	AC012442.5	-4.12	4.17e-05	0.00292	-0.16	-0.13	Hepatitis C induced liver fibrosis;	chr2:111980985	chr2:112589040~112614431:+
BRCA	cis	rs9733	0.65	rs6698495	ENSG00000203804.4	ADAMTSL4-AS1	-4.12	4.17e-05	0.00292	-0.14	-0.13	Tonsillectomy;	chr1:150592000	chr1:150560202~150574552:-
BRCA	cis	rs987724	0.519	rs12492968	ENSG00000240875.4	LINC00886	-4.12	4.18e-05	0.00292	-0.15	-0.13	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156824048	chr3:156747346~156817062:-
BRCA	cis	rs4143844	0.609	rs62007453	ENSG00000259251.2	RP11-643M14.1	4.12	4.18e-05	0.00292	0.32	0.13	Bipolar disorder and schizophrenia;	chr15:62062061	chr15:62060503~62062434:+
BRCA	cis	rs61160187	0.582	rs976631	ENSG00000272308.1	RP11-231G3.1	-4.12	4.18e-05	0.00292	-0.14	-0.13	Educational attainment (years of education);Educational attainment (college completion);	chr5:60920216	chr5:60866457~60866935:-
BRCA	cis	rs17345786	1	rs7641261	ENSG00000244119.1	PDCL3P4	4.12	4.18e-05	0.00292	0.11	0.13	Colonoscopy-negative controls vs population controls;	chr3:101560162	chr3:101712472~101713191:+
BRCA	cis	rs721917	0.525	rs2258874	ENSG00000278616.1	BEND3P3	-4.11	4.18e-05	0.00292	-0.12	-0.13	Chronic obstructive pulmonary disease;	chr10:79919400	chr10:79682997~79685436:+
BRCA	cis	rs752590	0.806	rs874898	ENSG00000274877.1	RP11-65I12.1	-4.11	4.18e-05	0.00292	-0.18	-0.13	Mucinous ovarian carcinoma;	chr2:113216619	chr2:113237595~113240825:+
BRCA	cis	rs737008	0.922	rs376374	ENSG00000262703.1	RP11-485G7.6	-4.11	4.18e-05	0.00292	-0.14	-0.13	Obesity-related traits;	chr16:11276759	chr16:11348143~11349321:-
BRCA	cis	rs9470794	1	rs78680078	ENSG00000204110.6	RP1-153P14.8	-4.11	4.18e-05	0.00292	-0.22	-0.13	Type 2 diabetes;	chr6:38140256	chr6:37507348~37535616:+
BRCA	cis	rs9470794	1	rs12662543	ENSG00000204110.6	RP1-153P14.8	-4.11	4.18e-05	0.00292	-0.22	-0.13	Type 2 diabetes;	chr6:38142234	chr6:37507348~37535616:+
BRCA	cis	rs2880765	0.545	rs11631739	ENSG00000259630.2	CTD-2262B20.1	-4.11	4.18e-05	0.00292	-0.16	-0.13	Coronary artery disease;	chr15:85469347	chr15:85415228~85415633:+
BRCA	cis	rs3755605	0.635	rs7643249	ENSG00000242578.1	RP11-469J4.3	4.11	4.18e-05	0.00292	0.15	0.13	Testicular germ cell tumor;	chr3:170095552	chr3:170410512~170418615:+
BRCA	cis	rs10829156	0.786	rs7093907	ENSG00000225527.1	RP11-383B4.4	-4.11	4.18e-05	0.00292	-0.18	-0.13	Sudden cardiac arrest;	chr10:18587225	chr10:18531849~18533336:-
BRCA	cis	rs2274459	1	rs35721478	ENSG00000249346.5	LINC01016	4.11	4.18e-05	0.00292	0.17	0.13	Obesity (extreme);	chr6:33757352	chr6:33867506~33896914:-
BRCA	cis	rs1048886	0.872	rs16869373	ENSG00000271967.1	RP11-134K13.4	-4.11	4.18e-05	0.00292	-0.18	-0.13	Type 2 diabetes;	chr6:70559929	chr6:70596438~70596980:+
BRCA	cis	rs860818	1	rs2529002	ENSG00000230658.1	KLHL7-AS1	-4.11	4.18e-05	0.00292	-0.32	-0.13	Initial pursuit acceleration;	chr7:23193704	chr7:23101228~23105703:-
BRCA	cis	rs2411233	0.674	rs10851378	ENSG00000259278.1	RP11-62C7.2	-4.11	4.18e-05	0.00292	-0.15	-0.13	Platelet count;	chr15:39030221	chr15:39019233~39024918:+
BRCA	cis	rs6546324	0.625	rs6717863	ENSG00000236780.4	AC078941.1	4.11	4.18e-05	0.00292	0.22	0.13	Endometriosis;	chr2:67617667	chr2:67123357~67215319:-
BRCA	cis	rs763121	0.853	rs9607566	ENSG00000225450.1	RP3-508I15.14	-4.11	4.18e-05	0.00292	-0.14	-0.13	Menopause (age at onset);	chr22:38679429	chr22:38739003~38749041:+
BRCA	cis	rs7119038	0.818	rs6589684	ENSG00000255422.1	AP002954.4	-4.11	4.18e-05	0.00292	-0.17	-0.13	Sjögren's syndrome;	chr11:118740248	chr11:118704607~118750263:+
BRCA	cis	rs2731006	0.591	rs73130905	ENSG00000257114.2	RP11-25I15.3	4.11	4.19e-05	0.00292	0.21	0.13	Panic disorder;	chr12:42811200	chr12:42692216~42717119:+
BRCA	cis	rs739496	0.615	rs4646778	ENSG00000226469.1	ADAM1B	4.11	4.19e-05	0.00292	0.17	0.13	Platelet count;	chr12:111797979	chr12:111927018~111929017:+
BRCA	cis	rs77633900	0.772	rs284897	ENSG00000196274.5	Metazoa_SRP	4.11	4.19e-05	0.00292	0.22	0.13	Glioma;Non-glioblastoma glioma;	chr15:76458381	chr15:76230048~76230390:-
BRCA	cis	rs71520386	0.632	rs9692432	ENSG00000226329.2	AC005682.6	-4.11	4.19e-05	0.00292	-0.13	-0.13	Fibrinogen levels;	chr7:22829244	chr7:22863874~22881350:-
BRCA	cis	rs71520386	0.632	rs71520387	ENSG00000226329.2	AC005682.6	-4.11	4.19e-05	0.00292	-0.13	-0.13	Fibrinogen levels;	chr7:22830057	chr7:22863874~22881350:-
BRCA	cis	rs71520386	0.632	rs10224244	ENSG00000226329.2	AC005682.6	-4.11	4.19e-05	0.00292	-0.13	-0.13	Fibrinogen levels;	chr7:22830455	chr7:22863874~22881350:-
BRCA	cis	rs6490294	0.528	rs11066126	ENSG00000234608.6	MAPKAPK5-AS1	4.11	4.19e-05	0.00292	0.19	0.13	Mean platelet volume;	chr12:112007087	chr12:111839764~111842902:-
BRCA	cis	rs7160336	1	rs10150366	ENSG00000259065.1	RP5-1021I20.1	-4.11	4.19e-05	0.00292	-0.14	-0.13	Blood protein levels;	chr14:74175586	chr14:73787360~73803270:+
BRCA	cis	rs28374715	0.635	rs8023530	ENSG00000247556.5	OIP5-AS1	4.11	4.19e-05	0.00292	0.13	0.13	Ulcerative colitis;	chr15:41355577	chr15:41283990~41309737:+
BRCA	cis	rs2304003	0.583	rs1023706	ENSG00000235192.1	AC009495.2	4.11	4.19e-05	0.00293	0.14	0.13	Social communication problems;	chr2:165863636	chr2:165794851~165810010:+
BRCA	cis	rs5771225	0.544	rs1555048	ENSG00000279182.1	XX-C00717C00720L.1	4.11	4.19e-05	0.00293	0.13	0.13	Late-onset Alzheimer's disease;	chr22:50249919	chr22:50316035~50317025:+
BRCA	cis	rs8180040	1	rs2159400	ENSG00000271161.1	BOLA2P2	-4.11	4.19e-05	0.00293	-0.14	-0.13	Colorectal cancer;	chr3:47334400	chr3:47499841~47500407:+
BRCA	cis	rs7177699	0.557	rs7176187	ENSG00000261143.1	ADAMTS7P3	-4.11	4.19e-05	0.00293	-0.15	-0.13	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78829031	chr15:77976042~77993057:+
BRCA	cis	rs2905347	0.737	rs756879	ENSG00000179428.2	AC073072.5	4.11	4.19e-05	0.00293	0.13	0.13	Major depression and alcohol dependence;	chr7:22594386	chr7:22725395~22727620:-
BRCA	cis	rs78487399	0.808	rs17030998	ENSG00000234936.1	AC010883.5	4.11	4.19e-05	0.00293	0.2	0.13	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43531060	chr2:43229573~43233394:+
BRCA	cis	rs2998286	0.862	rs2807732	ENSG00000237128.1	RP11-351M16.3	4.11	4.19e-05	0.00293	0.15	0.13	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28520318	chr10:28433008~28495813:-
BRCA	cis	rs2243480	1	rs73150014	ENSG00000222364.1	RNU6-96P	-4.11	4.19e-05	0.00293	-0.23	-0.13	Diabetic kidney disease;	chr7:65985932	chr7:66395191~66395286:+
BRCA	cis	rs4950322	0.518	rs56151278	ENSG00000227242.3	NBPF13P	-4.11	4.19e-05	0.00293	-0.18	-0.13	Protein quantitative trait loci;	chr1:147117421	chr1:147021320~147124525:-
BRCA	cis	rs4415084	0.716	rs3761648	ENSG00000251141.4	RP11-53O19.1	4.11	4.19e-05	0.00293	0.12	0.13	Breast cancer;	chr5:44807977	chr5:44744900~44808777:-
BRCA	cis	rs1865760	1	rs6905887	ENSG00000272462.2	U91328.19	-4.11	4.19e-05	0.00293	-0.15	-0.13	Height;	chr6:25911875	chr6:25992662~26001775:+
BRCA	cis	rs10487112	0.833	rs7796253	ENSG00000235436.9	DPY19L2P4	-4.11	4.19e-05	0.00293	-0.14	-0.13	Perceived unattractiveness to mosquitoes;	chr7:90516630	chr7:90119400~90125600:+
BRCA	cis	rs739496	0.579	rs73422318	ENSG00000257624.1	RP1-128M12.3	4.11	4.19e-05	0.00293	0.17	0.13	Platelet count;	chr12:111838169	chr12:112000739~112000985:-
BRCA	cis	rs739496	0.579	rs7314870	ENSG00000257624.1	RP1-128M12.3	4.11	4.19e-05	0.00293	0.17	0.13	Platelet count;	chr12:111838660	chr12:112000739~112000985:-
BRCA	cis	rs748404	0.666	rs12911569	ENSG00000166763.7	STRCP1	4.11	4.19e-05	0.00293	0.19	0.13	Lung cancer;	chr15:43305099	chr15:43699488~43718184:-
BRCA	cis	rs4415084	0.635	rs7736952	ENSG00000251141.4	RP11-53O19.1	4.11	4.19e-05	0.00293	0.12	0.13	Breast cancer;	chr5:44790277	chr5:44744900~44808777:-
BRCA	cis	rs1478897	0.575	rs12679960	ENSG00000270154.1	RP11-419I17.1	4.11	4.19e-05	0.00293	0.16	0.13	Systemic lupus erythematosus;	chr8:11573481	chr8:12476462~12477122:+
BRCA	cis	rs6736093	0.704	rs11684476	ENSG00000236307.2	EEF1E1P1	-4.11	4.2e-05	0.00293	-0.15	-0.13	Coronary artery disease;	chr2:112036404	chr2:111887914~111888741:+
BRCA	cis	rs61931739	0.534	rs10844801	ENSG00000258794.3	DUX4L27	4.11	4.2e-05	0.00293	0.18	0.13	Morning vs. evening chronotype;	chr12:34078005	chr12:34208415~34209675:-
BRCA	cis	rs7789940	1	rs76024966	ENSG00000280388.1	RP11-229D13.3	-4.11	4.2e-05	0.00293	-0.14	-0.13	Multiple sclerosis;	chr7:76365704	chr7:76043977~76045963:-
BRCA	cis	rs875971	0.862	rs6460282	ENSG00000273024.4	INTS4P2	4.11	4.2e-05	0.00293	0.14	0.13	Aortic root size;	chr7:66226259	chr7:65647864~65715661:+
BRCA	cis	rs1122401	1	rs1122401	ENSG00000280159.1	CTD-2591A1.1	4.11	4.2e-05	0.00293	0.16	0.13	Smoking initiation;	chr5:54580152	chr5:54643557~54645987:+
BRCA	cis	rs4650943	0.586	rs12096584	ENSG00000227740.1	RP11-318C24.2	-4.11	4.2e-05	0.00293	-0.13	-0.13	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in inactive individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr1:176320408	chr1:175904762~175920513:-
BRCA	cis	rs964611	0.882	rs4775749	ENSG00000259488.2	RP11-154J22.1	4.11	4.2e-05	0.00293	0.16	0.13	Metabolite levels (Pyroglutamine);	chr15:48350064	chr15:48312353~48331856:-
BRCA	cis	rs3748682	0.861	rs28411034	ENSG00000222282.1	RNU6-584P	-4.11	4.2e-05	0.00293	-0.16	-0.13	Hypothyroidism;	chr1:37811325	chr1:37885023~37885117:+
BRCA	cis	rs757081	0.608	rs214938	ENSG00000184669.7	OR7E14P	-4.11	4.2e-05	0.00293	-0.19	-0.13	Systolic blood pressure;	chr11:17166969	chr11:17013998~17053024:+
BRCA	cis	rs4578769	0.765	rs55762801	ENSG00000265939.1	UBE2CP2	-4.11	4.2e-05	0.00293	-0.16	-0.13	Eosinophil percentage of white cells;	chr18:22807096	chr18:22900486~22900995:-
BRCA	cis	rs9818758	0.607	rs35060561	ENSG00000225399.4	RP11-3B7.1	-4.11	4.2e-05	0.00293	-0.21	-0.13	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49218070	chr3:49260085~49261316:+
BRCA	cis	rs4664293	0.625	rs2114625	ENSG00000226266.5	AC009961.3	-4.11	4.2e-05	0.00293	-0.15	-0.13	Monocyte percentage of white cells;	chr2:159687297	chr2:159670708~159712435:-
BRCA	cis	rs2370759	1	rs7910776	ENSG00000227253.3	RP11-166N17.1	-4.11	4.2e-05	0.00293	-0.2	-0.13	Sexual dysfunction (female);	chr10:32350165	chr10:32266289~32269474:+
BRCA	cis	rs3805389	0.504	rs10026315	ENSG00000249700.7	SRD5A3-AS1	-4.11	4.2e-05	0.00294	-0.2	-0.13	Waist-to-hip ratio adjusted for body mass index;	chr4:55612195	chr4:55363971~55395847:-
BRCA	cis	rs1976403	0.659	rs10799700	ENSG00000186543.7	CROCCP5	-4.11	4.21e-05	0.00294	-0.15	-0.13	Liver enzyme levels (alkaline phosphatase);	chr1:21494475	chr1:21434318~21437558:+
BRCA	cis	rs17695224	0.545	rs8111469	ENSG00000269483.1	AC006272.1	4.11	4.21e-05	0.00294	0.15	0.13	HDL cholesterol;HDL cholesterol levels;	chr19:51829272	chr19:51839924~51843324:-
BRCA	cis	rs11098499	0.954	rs59866101	ENSG00000260091.1	RP11-33B1.4	-4.11	4.21e-05	0.00294	-0.11	-0.13	Corneal astigmatism;	chr4:119375436	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.618	rs6858383	ENSG00000260091.1	RP11-33B1.4	-4.11	4.21e-05	0.00294	-0.11	-0.13	Corneal astigmatism;	chr4:119375617	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.697	rs6832410	ENSG00000260091.1	RP11-33B1.4	-4.11	4.21e-05	0.00294	-0.11	-0.13	Corneal astigmatism;	chr4:119375645	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.865	rs1112817	ENSG00000260091.1	RP11-33B1.4	-4.11	4.21e-05	0.00294	-0.11	-0.13	Corneal astigmatism;	chr4:119376645	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.779	rs10016060	ENSG00000260091.1	RP11-33B1.4	-4.11	4.21e-05	0.00294	-0.11	-0.13	Corneal astigmatism;	chr4:119377257	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.954	rs10005644	ENSG00000260091.1	RP11-33B1.4	-4.11	4.21e-05	0.00294	-0.11	-0.13	Corneal astigmatism;	chr4:119377322	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.697	rs10016448	ENSG00000260091.1	RP11-33B1.4	-4.11	4.21e-05	0.00294	-0.11	-0.13	Corneal astigmatism;	chr4:119377690	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.657	rs9996569	ENSG00000260091.1	RP11-33B1.4	-4.11	4.21e-05	0.00294	-0.11	-0.13	Corneal astigmatism;	chr4:119377849	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.908	rs11729050	ENSG00000260091.1	RP11-33B1.4	-4.11	4.21e-05	0.00294	-0.11	-0.13	Corneal astigmatism;	chr4:119378911	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.954	rs28429722	ENSG00000260091.1	RP11-33B1.4	-4.11	4.21e-05	0.00294	-0.11	-0.13	Corneal astigmatism;	chr4:119378938	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.954	rs10014845	ENSG00000260091.1	RP11-33B1.4	-4.11	4.21e-05	0.00294	-0.11	-0.13	Corneal astigmatism;	chr4:119379922	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.779	rs7674500	ENSG00000260091.1	RP11-33B1.4	-4.11	4.21e-05	0.00294	-0.11	-0.13	Corneal astigmatism;	chr4:119382438	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.909	rs28884220	ENSG00000260091.1	RP11-33B1.4	-4.11	4.21e-05	0.00294	-0.11	-0.13	Corneal astigmatism;	chr4:119386056	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.909	rs28793658	ENSG00000260091.1	RP11-33B1.4	-4.11	4.21e-05	0.00294	-0.11	-0.13	Corneal astigmatism;	chr4:119386059	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.697	rs4373140	ENSG00000260091.1	RP11-33B1.4	-4.11	4.21e-05	0.00294	-0.11	-0.13	Corneal astigmatism;	chr4:119386543	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.954	rs13113483	ENSG00000260091.1	RP11-33B1.4	-4.11	4.21e-05	0.00294	-0.11	-0.13	Corneal astigmatism;	chr4:119387884	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.542	rs10440343	ENSG00000260091.1	RP11-33B1.4	-4.11	4.21e-05	0.00294	-0.11	-0.13	Corneal astigmatism;	chr4:119388632	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.779	rs10011097	ENSG00000260091.1	RP11-33B1.4	-4.11	4.21e-05	0.00294	-0.11	-0.13	Corneal astigmatism;	chr4:119389204	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.542	rs7677836	ENSG00000260091.1	RP11-33B1.4	-4.11	4.21e-05	0.00294	-0.11	-0.13	Corneal astigmatism;	chr4:119389483	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.909	rs10002083	ENSG00000260091.1	RP11-33B1.4	-4.11	4.21e-05	0.00294	-0.11	-0.13	Corneal astigmatism;	chr4:119389997	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.954	rs10024844	ENSG00000260091.1	RP11-33B1.4	-4.11	4.21e-05	0.00294	-0.11	-0.13	Corneal astigmatism;	chr4:119390373	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.954	rs4345162	ENSG00000260091.1	RP11-33B1.4	-4.11	4.21e-05	0.00294	-0.11	-0.13	Corneal astigmatism;	chr4:119391804	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.657	rs4463052	ENSG00000260091.1	RP11-33B1.4	-4.11	4.21e-05	0.00294	-0.11	-0.13	Corneal astigmatism;	chr4:119392103	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.954	rs13151285	ENSG00000260091.1	RP11-33B1.4	-4.11	4.21e-05	0.00294	-0.11	-0.13	Corneal astigmatism;	chr4:119393586	chr4:119409333~119410233:+
BRCA	cis	rs11168618	0.74	rs7299323	ENSG00000240399.1	RP1-228P16.1	4.11	4.21e-05	0.00294	0.13	0.13	Adiponectin levels;	chr12:48527750	chr12:48054813~48055591:-
BRCA	cis	rs4073582	0.516	rs1151539	ENSG00000255320.1	RP11-755F10.1	-4.11	4.21e-05	0.00294	-0.16	-0.13	Gout;	chr11:66264189	chr11:66244840~66246239:-
BRCA	cis	rs4073582	0.595	rs528842	ENSG00000255320.1	RP11-755F10.1	-4.11	4.21e-05	0.00294	-0.16	-0.13	Gout;	chr11:66264919	chr11:66244840~66246239:-
BRCA	cis	rs4073582	0.595	rs474005	ENSG00000255320.1	RP11-755F10.1	-4.11	4.21e-05	0.00294	-0.16	-0.13	Gout;	chr11:66265830	chr11:66244840~66246239:-
BRCA	cis	rs4073582	0.595	rs2508657	ENSG00000255320.1	RP11-755F10.1	-4.11	4.21e-05	0.00294	-0.16	-0.13	Gout;	chr11:66276427	chr11:66244840~66246239:-
BRCA	cis	rs812925	0.537	rs10865324	ENSG00000273302.1	RP11-493E12.2	-4.11	4.21e-05	0.00294	-0.11	-0.13	Immature fraction of reticulocytes;	chr2:61394172	chr2:61199979~61200769:+
BRCA	cis	rs11098499	0.954	rs7436506	ENSG00000260404.2	RP11-384K6.6	4.11	4.21e-05	0.00294	0.12	0.13	Corneal astigmatism;	chr4:119472614	chr4:118591773~118633729:+
BRCA	cis	rs12612619	0.732	rs11679681	ENSG00000272148.1	RP11-195B17.1	4.11	4.21e-05	0.00294	0.14	0.13	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27075611	chr2:27062428~27062907:-
BRCA	cis	rs8094794	0.744	rs56373654	ENSG00000267707.2	RP11-95O2.5	4.11	4.21e-05	0.00294	0.2	0.13	Periodontal disease-related phenotypes;	chr18:36715968	chr18:37243776~37247506:+
BRCA	cis	rs2346177	0.777	rs7587138	ENSG00000279254.1	RP11-536C12.1	4.11	4.21e-05	0.00294	0.15	0.13	HDL cholesterol;	chr2:46429950	chr2:46668870~46670778:+
BRCA	cis	rs757081	0.667	rs12577418	ENSG00000184669.7	OR7E14P	-4.11	4.21e-05	0.00294	-0.19	-0.13	Systolic blood pressure;	chr11:17080007	chr11:17013998~17053024:+
BRCA	cis	rs11098499	0.863	rs12498539	ENSG00000250412.1	KLHL2P1	4.11	4.21e-05	0.00294	0.15	0.13	Corneal astigmatism;	chr4:119547215	chr4:119334329~119378233:+
BRCA	cis	rs11098499	0.863	rs3822194	ENSG00000250412.1	KLHL2P1	4.11	4.21e-05	0.00294	0.15	0.13	Corneal astigmatism;	chr4:119550493	chr4:119334329~119378233:+
BRCA	cis	rs11096990	0.656	rs7686161	ENSG00000249685.1	RP11-360F5.3	-4.11	4.21e-05	0.00294	-0.15	-0.13	Cognitive function;	chr4:39283201	chr4:39133913~39135608:+
BRCA	cis	rs7772486	0.754	rs13214277	ENSG00000270638.1	RP3-466P17.1	4.11	4.21e-05	0.00294	0.15	0.13	Lobe attachment (rater-scored or self-reported);	chr6:145814989	chr6:145735570~145737218:+
BRCA	cis	rs801193	0.967	rs34356500	ENSG00000223473.2	GS1-124K5.3	4.11	4.21e-05	0.00294	0.1	0.13	Aortic root size;	chr7:66771620	chr7:66491049~66493566:-
BRCA	cis	rs9392653	0.96	rs9392071	ENSG00000220685.3	RP11-530A18.1	-4.11	4.21e-05	0.00294	-0.18	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr6:5072477	chr6:5065795~5066982:-
BRCA	cis	rs1722133	0.555	rs788724	ENSG00000237471.1	AC073115.6	-4.11	4.21e-05	0.00294	-0.17	-0.13	Sitting height ratio;	chr7:46049548	chr7:45969657~45980191:+
BRCA	cis	rs896854	0.714	rs572547	ENSG00000245080.5	RP11-320N21.1	-4.11	4.21e-05	0.00294	-0.15	-0.13	Type 2 diabetes;	chr8:94954058	chr8:95066808~95073182:-
BRCA	cis	rs2243480	1	rs56016656	ENSG00000226002.1	RP11-460N20.5	-4.11	4.21e-05	0.00294	-0.21	-0.13	Diabetic kidney disease;	chr7:65918494	chr7:65084103~65100232:+
BRCA	cis	rs2243480	1	rs56291018	ENSG00000226002.1	RP11-460N20.5	-4.11	4.21e-05	0.00294	-0.21	-0.13	Diabetic kidney disease;	chr7:65925352	chr7:65084103~65100232:+
BRCA	cis	rs2243480	1	rs36033484	ENSG00000226002.1	RP11-460N20.5	-4.11	4.21e-05	0.00294	-0.21	-0.13	Diabetic kidney disease;	chr7:65925571	chr7:65084103~65100232:+
BRCA	cis	rs7267979	0.528	rs2387976	ENSG00000125804.12	FAM182A	4.11	4.21e-05	0.00294	0.17	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25618924	chr20:26054655~26086917:+
BRCA	cis	rs7954584	0.813	rs1523261	ENSG00000274292.1	RP11-347I19.7	-4.11	4.21e-05	0.00294	-0.1	-0.13	Mean corpuscular volume;	chr12:122024971	chr12:121800797~121803403:+
BRCA	cis	rs2439831	0.85	rs16977798	ENSG00000206991.1	RNU6-610P	-4.11	4.22e-05	0.00294	-0.2	-0.13	Lung cancer in ever smokers;	chr15:43859750	chr15:43637632~43637738:-
BRCA	cis	rs9402743	0.634	rs7765113	ENSG00000234084.1	RP3-388E23.2	-4.11	4.22e-05	0.00294	-0.13	-0.13	Systemic lupus erythematosus;	chr6:135598935	chr6:135301568~135307158:+
BRCA	cis	rs6460942	0.597	rs62449509	ENSG00000226690.5	AC005281.1	4.11	4.22e-05	0.00294	0.26	0.13	Coronary artery disease;	chr7:12475387	chr7:12496429~12541910:+
BRCA	cis	rs6565180	0.926	rs8046445	ENSG00000183604.13	SMG1P5	-4.11	4.22e-05	0.00294	-0.13	-0.13	Tonsillectomy;	chr16:30374941	chr16:30267553~30335374:-
BRCA	cis	rs1320333	0.772	rs17786111	ENSG00000272342.1	RP13-539J13.1	-4.11	4.22e-05	0.00294	-0.22	-0.13	Obesity-related traits;	chr2:700562	chr2:739588~740164:-
BRCA	cis	rs4650943	0.61	rs1912243	ENSG00000227740.1	RP11-318C24.2	-4.11	4.22e-05	0.00294	-0.13	-0.13	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in inactive individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr1:176247204	chr1:175904762~175920513:-
BRCA	cis	rs4650943	0.565	rs1553770	ENSG00000227740.1	RP11-318C24.2	-4.11	4.22e-05	0.00294	-0.13	-0.13	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in inactive individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr1:176250302	chr1:175904762~175920513:-
BRCA	cis	rs13434995	0.513	rs62305264	ENSG00000239040.1	Y_RNA	4.11	4.22e-05	0.00294	0.15	0.13	Adiponectin levels;	chr4:55502968	chr4:55412636~55412738:+
BRCA	cis	rs7267979	0.932	rs2387891	ENSG00000277938.1	RP5-965G21.3	4.11	4.22e-05	0.00294	0.15	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25489692	chr20:25229150~25231933:+
BRCA	cis	rs2446066	0.872	rs7300593	ENSG00000257379.1	RP11-793H13.8	4.11	4.22e-05	0.00294	0.19	0.13	Red blood cell count;	chr12:53396666	chr12:53441741~53467528:+
BRCA	cis	rs2115630	0.967	rs11073731	ENSG00000275120.1	RP11-182J1.17	-4.11	4.22e-05	0.00295	-0.15	-0.13	P wave terminal force;	chr15:84811882	chr15:84599434~84606463:-
BRCA	cis	rs745109	0.816	rs72930349	ENSG00000273080.1	RP11-301O19.1	4.11	4.22e-05	0.00295	0.2	0.13	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86444481	chr2:86195590~86196049:+
BRCA	cis	rs12534093	0.67	rs11773115	ENSG00000234286.1	AC006026.13	-4.11	4.22e-05	0.00295	-0.19	-0.13	Infant length;Height;	chr7:23549423	chr7:23680195~23680786:-
BRCA	cis	rs9393692	0.645	rs9467703	ENSG00000241549.7	GUSBP2	-4.11	4.22e-05	0.00295	-0.15	-0.13	Educational attainment;	chr6:26318675	chr6:26871484~26956554:-
BRCA	cis	rs4664293	0.625	rs6760931	ENSG00000226266.5	AC009961.3	4.11	4.22e-05	0.00295	0.15	0.13	Monocyte percentage of white cells;	chr2:159702600	chr2:159670708~159712435:-
BRCA	cis	rs801193	0.904	rs4718403	ENSG00000265600.1	AC006480.1	-4.11	4.22e-05	0.00295	-0.15	-0.13	Aortic root size;	chr7:66777742	chr7:67356680~67356779:+
BRCA	cis	rs853679	0.825	rs8180562	ENSG00000216901.1	AL022393.7	4.11	4.22e-05	0.00295	0.25	0.13	Depression;	chr6:28173682	chr6:28176188~28176674:+
BRCA	cis	rs853679	0.882	rs9380064	ENSG00000216901.1	AL022393.7	4.11	4.22e-05	0.00295	0.25	0.13	Depression;	chr6:28175340	chr6:28176188~28176674:+
BRCA	cis	rs11742741	0.744	rs72745737	ENSG00000248874.4	C5orf17	-4.11	4.22e-05	0.00295	-0.16	-0.13	Educational attainment;	chr5:24074073	chr5:23951348~24178263:+
BRCA	cis	rs755249	0.567	rs2036463	ENSG00000182109.6	RP11-69E11.4	4.11	4.22e-05	0.00295	0.17	0.13	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39222403	chr1:39522280~39546187:-
BRCA	cis	rs755249	0.567	rs2036464	ENSG00000182109.6	RP11-69E11.4	4.11	4.22e-05	0.00295	0.17	0.13	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39222570	chr1:39522280~39546187:-
BRCA	cis	rs755249	0.567	rs905381	ENSG00000182109.6	RP11-69E11.4	4.11	4.22e-05	0.00295	0.17	0.13	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39222880	chr1:39522280~39546187:-
BRCA	cis	rs11098499	0.908	rs7696649	ENSG00000260404.2	RP11-384K6.6	4.11	4.22e-05	0.00295	0.12	0.13	Corneal astigmatism;	chr4:119401022	chr4:118591773~118633729:+
BRCA	cis	rs459571	0.92	rs460154	ENSG00000235106.7	LINC00094	4.11	4.22e-05	0.00295	0.13	0.13	Platelet distribution width;	chr9:134044187	chr9:134025439~134034666:+
BRCA	cis	rs6893300	0.785	rs11738720	ENSG00000250999.1	RP11-1379J22.5	4.11	4.23e-05	0.00295	0.17	0.13	Resting heart rate;	chr5:179727997	chr5:179657762~179664432:+
BRCA	cis	rs1722141	0.669	rs1722122	ENSG00000229628.1	AC073115.7	-4.11	4.23e-05	0.00295	-0.17	-0.13	Sitting height ratio;	chr7:45989247	chr7:45990905~46000898:+
BRCA	cis	rs6570726	1	rs374464	ENSG00000270638.1	RP3-466P17.1	4.11	4.23e-05	0.00295	0.14	0.13	Lobe attachment (rater-scored or self-reported);	chr6:145525543	chr6:145735570~145737218:+
BRCA	cis	rs6570726	1	rs450076	ENSG00000270638.1	RP3-466P17.1	4.11	4.23e-05	0.00295	0.14	0.13	Lobe attachment (rater-scored or self-reported);	chr6:145526519	chr6:145735570~145737218:+
BRCA	cis	rs2692947	0.673	rs2917662	ENSG00000168992.4	OR7E102P	4.11	4.23e-05	0.00295	0.17	0.13	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96129218	chr2:95546531~95547545:+
BRCA	cis	rs6696239	0.513	rs7542685	ENSG00000227711.2	RP11-275O4.5	4.11	4.23e-05	0.00295	0.15	0.13	Height;	chr1:227542752	chr1:227509028~227520477:-
BRCA	cis	rs11673344	0.523	rs7255724	ENSG00000276846.1	CTD-3220F14.3	4.11	4.23e-05	0.00295	0.15	0.13	Obesity-related traits;	chr19:37158675	chr19:37314868~37315620:-
BRCA	cis	rs9510787	0.538	rs1575666	ENSG00000205861.10	C1QTNF9B-AS1	-4.11	4.23e-05	0.00295	-0.19	-0.13	Nasopharyngeal carcinoma;	chr13:23648549	chr13:23888889~23897263:+
BRCA	cis	rs6964587	0.967	rs34040612	ENSG00000188693.7	CYP51A1-AS1	-4.11	4.23e-05	0.00295	-0.14	-0.13	Breast cancer;	chr7:92169602	chr7:92134604~92180725:+
BRCA	cis	rs7267979	0.932	rs4280527	ENSG00000277938.1	RP5-965G21.3	4.11	4.23e-05	0.00295	0.15	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25563378	chr20:25229150~25231933:+
BRCA	cis	rs17680741	0.657	rs12246432	ENSG00000226659.1	RP11-137H2.4	4.11	4.23e-05	0.00295	0.21	0.13	Coronary artery disease;	chr10:80510462	chr10:80529597~80535942:-
BRCA	cis	rs11098499	0.863	rs2306456	ENSG00000260091.1	RP11-33B1.4	-4.11	4.23e-05	0.00295	-0.11	-0.13	Corneal astigmatism;	chr4:119551267	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.863	rs11947234	ENSG00000260091.1	RP11-33B1.4	-4.11	4.23e-05	0.00295	-0.11	-0.13	Corneal astigmatism;	chr4:119553704	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.863	rs11933966	ENSG00000260091.1	RP11-33B1.4	-4.11	4.23e-05	0.00295	-0.11	-0.13	Corneal astigmatism;	chr4:119555560	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.863	rs36040693	ENSG00000260091.1	RP11-33B1.4	-4.11	4.23e-05	0.00295	-0.11	-0.13	Corneal astigmatism;	chr4:119556461	chr4:119409333~119410233:+
BRCA	cis	rs6095360	0.615	rs17445665	ENSG00000222365.1	SNORD12B	4.11	4.23e-05	0.00295	0.16	0.13	Intelligence (multi-trait analysis);	chr20:48893954	chr20:49280319~49280409:+
BRCA	cis	rs4415084	0.966	rs4479849	ENSG00000248779.1	RP11-53O19.2	-4.11	4.23e-05	0.00295	-0.12	-0.13	Breast cancer;	chr5:44643904	chr5:44752949~44765744:+
BRCA	cis	rs8040855	0.627	rs4980357	ENSG00000259774.1	RP11-182J1.13	4.11	4.23e-05	0.00295	0.17	0.13	Bulimia nervosa;	chr15:85064878	chr15:84422618~84425882:+
BRCA	cis	rs8040855	0.627	rs4980356	ENSG00000259774.1	RP11-182J1.13	4.11	4.23e-05	0.00295	0.17	0.13	Bulimia nervosa;	chr15:85064901	chr15:84422618~84425882:+
BRCA	cis	rs6545883	0.859	rs2694644	ENSG00000273302.1	RP11-493E12.2	-4.11	4.23e-05	0.00295	-0.12	-0.13	Tuberculosis;	chr2:61377721	chr2:61199979~61200769:+
BRCA	cis	rs2071426	0.622	rs1934975	ENSG00000273450.1	RP11-76P2.4	4.11	4.23e-05	0.00295	0.16	0.13	Blood metabolite levels;	chr10:95010012	chr10:94314907~94315327:-
BRCA	cis	rs2243480	1	rs466983	ENSG00000237026.1	RP11-328P23.2	4.11	4.23e-05	0.00295	0.24	0.13	Diabetic kidney disease;	chr7:66055509	chr7:65235790~65236723:-
BRCA	cis	rs739496	0.579	rs7980569	ENSG00000257624.1	RP1-128M12.3	4.11	4.23e-05	0.00295	0.17	0.13	Platelet count;	chr12:111843580	chr12:112000739~112000985:-
BRCA	cis	rs739496	0.579	rs7970847	ENSG00000257624.1	RP1-128M12.3	4.11	4.23e-05	0.00295	0.17	0.13	Platelet count;	chr12:111843689	chr12:112000739~112000985:-
BRCA	cis	rs38055	0.958	rs251519	ENSG00000247796.2	CTD-2366F13.1	-4.11	4.23e-05	0.00295	-0.15	-0.13	Acne (severe);	chr5:53285299	chr5:53109842~53115126:+
BRCA	cis	rs739496	0.527	rs2269801	ENSG00000234608.6	MAPKAPK5-AS1	4.11	4.23e-05	0.00295	0.15	0.13	Platelet count;	chr12:111888319	chr12:111839764~111842902:-
BRCA	cis	rs6490294	0.748	rs2269802	ENSG00000234608.6	MAPKAPK5-AS1	4.11	4.23e-05	0.00295	0.15	0.13	Mean platelet volume;	chr12:111888334	chr12:111839764~111842902:-
BRCA	cis	rs2286503	0.78	rs12113458	ENSG00000226329.2	AC005682.6	4.11	4.23e-05	0.00295	0.12	0.13	Fibrinogen;	chr7:22816009	chr7:22863874~22881350:-
BRCA	cis	rs7267979	0.565	rs6107060	ENSG00000125804.12	FAM182A	-4.11	4.24e-05	0.00295	-0.16	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25611840	chr20:26054655~26086917:+
BRCA	cis	rs875971	0.66	rs79009421	ENSG00000232546.1	RP11-458F8.1	4.11	4.24e-05	0.00295	0.11	0.13	Aortic root size;	chr7:66603522	chr7:66848496~66858136:+
BRCA	cis	rs10129255	1	rs9324091	ENSG00000232216.1	IGHV3-43	4.11	4.24e-05	0.00296	0.11	0.13	Kawasaki disease;	chr14:106676625	chr14:106470264~106470800:-
BRCA	cis	rs11673344	0.526	rs73035160	ENSG00000267422.1	CTD-2554C21.1	4.11	4.24e-05	0.00296	0.17	0.13	Obesity-related traits;	chr19:37655135	chr19:37779686~37792865:+
BRCA	cis	rs8180040	1	rs11130127	ENSG00000271161.1	BOLA2P2	-4.11	4.24e-05	0.00296	-0.13	-0.13	Colorectal cancer;	chr3:47357303	chr3:47499841~47500407:+
BRCA	cis	rs6430585	0.527	rs961360	ENSG00000224043.6	CCNT2-AS1	-4.11	4.24e-05	0.00296	-0.21	-0.13	Corneal structure;	chr2:135636088	chr2:134735464~134918710:-
BRCA	cis	rs711830	1	rs2249131	ENSG00000226363.3	HAGLROS	-4.11	4.24e-05	0.00296	-0.19	-0.13	Serous invasive ovarian cancer;Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;High-grade serous ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;	chr2:176167367	chr2:176177717~176179008:+
BRCA	cis	rs1850744	1	rs1878275	ENSG00000163612.10	FAM86KP	-4.11	4.24e-05	0.00296	-0.33	-0.13	Economic and political preferences;	chr4:9775777	chr4:9153296~9165451:+
BRCA	cis	rs1850744	1	rs9685502	ENSG00000163612.10	FAM86KP	-4.11	4.24e-05	0.00296	-0.33	-0.13	Economic and political preferences;	chr4:9778012	chr4:9153296~9165451:+
BRCA	cis	rs875971	0.964	rs6978429	ENSG00000236529.1	RP13-254B10.1	4.11	4.24e-05	0.00296	0.14	0.13	Aortic root size;	chr7:66494889	chr7:65840212~65840596:+
BRCA	cis	rs875971	1	rs4718357	ENSG00000236529.1	RP13-254B10.1	4.11	4.24e-05	0.00296	0.14	0.13	Aortic root size;	chr7:66495891	chr7:65840212~65840596:+
BRCA	cis	rs11711311	1	rs3806641	ENSG00000241529.3	RN7SL767P	-4.11	4.24e-05	0.00296	-0.15	-0.13	IgG glycosylation;	chr3:113746914	chr3:113632704~113632998:+
BRCA	cis	rs2278170	0.926	rs2278172	ENSG00000225101.4	OR52K3P	-4.11	4.24e-05	0.00296	-0.17	-0.13	Amyotrophic lateral sclerosis;	chr11:4475731	chr11:4474813~4475755:+
BRCA	cis	rs694419	0.602	rs1473980	ENSG00000278017.1	RP11-120K19.4	-4.11	4.24e-05	0.00296	-0.15	-0.13	Serum albumin level;	chr18:62539443	chr18:62525919~62526325:-
BRCA	cis	rs2243480	0.522	rs431168	ENSG00000237026.1	RP11-328P23.2	4.11	4.24e-05	0.00296	0.29	0.13	Diabetic kidney disease;	chr7:66046617	chr7:65235790~65236723:-
BRCA	cis	rs77956314	0.515	rs10850741	ENSG00000277840.1	RP11-103B5.4	-4.11	4.25e-05	0.00296	-0.2	-0.13	Hippocampal volume;Subcortical brain region volumes;	chr12:116994199	chr12:117002463~117003152:+
BRCA	cis	rs4218	0.543	rs35658945	ENSG00000259732.1	RP11-59H7.3	-4.11	4.25e-05	0.00296	-0.15	-0.13	Social communication problems;	chr15:59018053	chr15:59121034~59133250:+
BRCA	cis	rs9291683	0.935	rs1860911	ENSG00000250413.1	RP11-448G15.1	-4.11	4.25e-05	0.00296	-0.16	-0.13	Bone mineral density;	chr4:10273433	chr4:10006482~10009725:+
BRCA	cis	rs13434995	0.513	rs6554282	ENSG00000239040.1	Y_RNA	-4.11	4.25e-05	0.00296	-0.15	-0.13	Adiponectin levels;	chr4:55519812	chr4:55412636~55412738:+
BRCA	cis	rs13434995	0.513	rs6554283	ENSG00000239040.1	Y_RNA	-4.11	4.25e-05	0.00296	-0.15	-0.13	Adiponectin levels;	chr4:55521053	chr4:55412636~55412738:+
BRCA	cis	rs13434995	0.513	rs1546004	ENSG00000239040.1	Y_RNA	-4.11	4.25e-05	0.00296	-0.15	-0.13	Adiponectin levels;	chr4:55521612	chr4:55412636~55412738:+
BRCA	cis	rs13434995	0.513	rs4865006	ENSG00000239040.1	Y_RNA	-4.11	4.25e-05	0.00296	-0.15	-0.13	Adiponectin levels;	chr4:55526112	chr4:55412636~55412738:+
BRCA	cis	rs2835872	0.965	rs2835849	ENSG00000228677.1	TTC3-AS1	-4.11	4.25e-05	0.00296	-0.17	-0.13	Electroencephalographic traits in alcoholism;	chr21:37639222	chr21:37187666~37193926:-
BRCA	cis	rs3748682	0.821	rs12751325	ENSG00000222282.1	RNU6-584P	-4.11	4.25e-05	0.00296	-0.16	-0.13	Hypothyroidism;	chr1:37823711	chr1:37885023~37885117:+
BRCA	cis	rs73201462	1	rs2811523	ENSG00000242551.2	POU5F1P6	4.11	4.25e-05	0.00296	0.2	0.13	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128292554	chr3:128674735~128677005:-
BRCA	cis	rs4950322	0.57	rs2354428	ENSG00000237188.3	RP11-337C18.8	4.11	4.25e-05	0.00296	0.16	0.13	Protein quantitative trait loci;	chr1:147277512	chr1:147172771~147211568:+
BRCA	cis	rs7308116	1	rs7302313	ENSG00000274395.1	RP11-554D14.8	-4.11	4.25e-05	0.00296	-0.14	-0.13	Pelvic organ prolapse (moderate/severe);	chr12:107812158	chr12:107835541~107836555:-
BRCA	cis	rs7590268	0.848	rs7600177	ENSG00000279873.2	LINC01126	4.11	4.25e-05	0.00296	0.15	0.13	Orofacial clefts;	chr2:43400916	chr2:43227210~43228855:+
BRCA	cis	rs718433	0.616	rs7142911	ENSG00000256379.1	TRAV8-5	4.11	4.25e-05	0.00296	0.15	0.13	Intraocular pressure;	chr14:21745252	chr14:21903077~21903598:+
BRCA	cis	rs11083475	0.967	rs13343794	ENSG00000267892.1	CTD-2540F13.2	4.11	4.25e-05	0.00296	0.14	0.13	Heart rate;	chr19:38688631	chr19:38738284~38739863:+
BRCA	cis	rs1048886	0.938	rs73478819	ENSG00000271967.1	RP11-134K13.4	-4.11	4.25e-05	0.00296	-0.17	-0.13	Type 2 diabetes;	chr6:70473382	chr6:70596438~70596980:+
BRCA	cis	rs1048886	0.938	rs73482554	ENSG00000271967.1	RP11-134K13.4	-4.11	4.25e-05	0.00296	-0.17	-0.13	Type 2 diabetes;	chr6:70473706	chr6:70596438~70596980:+
BRCA	cis	rs2229238	0.911	rs73023349	ENSG00000272030.1	RP1-178F15.4	-4.11	4.25e-05	0.00296	-0.18	-0.13	Coronary heart disease;	chr1:154540964	chr1:153631438~153634397:-
BRCA	cis	rs849141	0.925	rs520161	ENSG00000234336.5	JAZF1-AS1	-4.11	4.25e-05	0.00296	-0.17	-0.13	Height;Hip circumference adjusted for BMI;	chr7:28171041	chr7:28180322~28243917:+
BRCA	cis	rs6545883	0.894	rs2167566	ENSG00000212978.6	AC016747.3	4.11	4.25e-05	0.00296	0.17	0.13	Tuberculosis;	chr2:61292273	chr2:61141592~61144969:-
BRCA	cis	rs4950322	0.57	rs17356240	ENSG00000237188.3	RP11-337C18.8	4.11	4.25e-05	0.00296	0.16	0.13	Protein quantitative trait loci;	chr1:147269877	chr1:147172771~147211568:+
BRCA	cis	rs4950322	0.57	rs1999820	ENSG00000237188.3	RP11-337C18.8	4.11	4.25e-05	0.00296	0.16	0.13	Protein quantitative trait loci;	chr1:147270329	chr1:147172771~147211568:+
BRCA	cis	rs4950322	0.57	rs4950316	ENSG00000237188.3	RP11-337C18.8	4.11	4.25e-05	0.00296	0.16	0.13	Protein quantitative trait loci;	chr1:147273712	chr1:147172771~147211568:+
BRCA	cis	rs7267979	1	rs2482930	ENSG00000276952.1	RP5-965G21.6	-4.11	4.25e-05	0.00297	-0.16	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25353479	chr20:25284915~25285588:-
BRCA	cis	rs2411233	1	rs1824493	ENSG00000259278.1	RP11-62C7.2	4.11	4.25e-05	0.00297	0.15	0.13	Platelet count;	chr15:38992462	chr15:39019233~39024918:+
BRCA	cis	rs8180040	0.545	rs9311403	ENSG00000271161.1	BOLA2P2	4.11	4.26e-05	0.00297	0.14	0.13	Colorectal cancer;	chr3:47097388	chr3:47499841~47500407:+
BRCA	cis	rs7772486	0.754	rs12199362	ENSG00000270638.1	RP3-466P17.1	4.11	4.26e-05	0.00297	0.15	0.13	Lobe attachment (rater-scored or self-reported);	chr6:145797089	chr6:145735570~145737218:+
BRCA	cis	rs875971	0.545	rs6961853	ENSG00000273142.1	RP11-458F8.4	4.11	4.26e-05	0.00297	0.12	0.13	Aortic root size;	chr7:66537035	chr7:66902857~66906297:+
BRCA	cis	rs7267979	0.866	rs437635	ENSG00000274414.1	RP5-965G21.4	-4.11	4.26e-05	0.00297	-0.15	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25476252	chr20:25239007~25245229:-
BRCA	cis	rs7267979	0.932	rs417110	ENSG00000274414.1	RP5-965G21.4	-4.11	4.26e-05	0.00297	-0.15	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25477661	chr20:25239007~25245229:-
BRCA	cis	rs7267979	0.932	rs449703	ENSG00000274414.1	RP5-965G21.4	-4.11	4.26e-05	0.00297	-0.15	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25477923	chr20:25239007~25245229:-
BRCA	cis	rs9921338	1	rs8049173	ENSG00000262636.1	CTD-3088G3.4	-4.11	4.26e-05	0.00297	-0.21	-0.13	Vein graft stenosis in coronary artery bypass grafting;	chr16:11343025	chr16:11380859~11381118:-
BRCA	cis	rs9921338	1	rs8055427	ENSG00000262636.1	CTD-3088G3.4	-4.11	4.26e-05	0.00297	-0.21	-0.13	Vein graft stenosis in coronary artery bypass grafting;	chr16:11343026	chr16:11380859~11381118:-
BRCA	cis	rs9921338	0.961	rs9936093	ENSG00000262636.1	CTD-3088G3.4	-4.11	4.26e-05	0.00297	-0.21	-0.13	Vein graft stenosis in coronary artery bypass grafting;	chr16:11343459	chr16:11380859~11381118:-
BRCA	cis	rs991427	0.915	rs11105987	ENSG00000258100.1	RP11-121E16.1	-4.11	4.26e-05	0.00297	-0.16	-0.13	Systolic blood pressure (alcohol consumption interaction);	chr12:91100420	chr12:91362196~91368606:+
BRCA	cis	rs7260598	0.642	rs56977104	ENSG00000268442.1	CTD-2027I19.2	4.11	4.26e-05	0.00297	0.2	0.13	Response to taxane treatment (placlitaxel);	chr19:23956560	chr19:24162370~24163425:-
BRCA	cis	rs739496	0.579	rs7980569	ENSG00000234608.6	MAPKAPK5-AS1	4.11	4.26e-05	0.00297	0.15	0.13	Platelet count;	chr12:111843580	chr12:111839764~111842902:-
BRCA	cis	rs739496	0.579	rs7970847	ENSG00000234608.6	MAPKAPK5-AS1	4.11	4.26e-05	0.00297	0.15	0.13	Platelet count;	chr12:111843689	chr12:111839764~111842902:-
BRCA	cis	rs1836229	0.805	rs10815964	ENSG00000225706.1	PTPRD-AS1	-4.11	4.26e-05	0.00297	-0.14	-0.13	Restless legs syndrome;	chr9:8826108	chr9:8858130~8862255:+
BRCA	cis	rs7487075	1	rs12827740	ENSG00000257261.4	RP11-96H19.1	4.11	4.26e-05	0.00297	0.14	0.13	Itch intensity from mosquito bite;	chr12:46454332	chr12:46383679~46876159:+
BRCA	cis	rs6600671	0.934	rs11249429	ENSG00000231429.2	RP11-343N15.2	4.11	4.26e-05	0.00297	0.15	0.13	Hip geometry;	chr1:121549282	chr1:121412719~121429274:+
BRCA	cis	rs7561149	1	rs12464151	ENSG00000270574.1	RP11-171I2.2	-4.11	4.26e-05	0.00297	-0.17	-0.13	QT interval;	chr2:178826182	chr2:178578790~178580906:+
BRCA	cis	rs7487075	1	rs12813763	ENSG00000274723.1	RP11-618L22.1	-4.11	4.26e-05	0.00297	-0.15	-0.13	Itch intensity from mosquito bite;	chr12:46429121	chr12:46970504~46972155:+
BRCA	cis	rs9393777	0.668	rs16897515	ENSG00000220721.1	OR1F12	-4.11	4.27e-05	0.00297	-0.18	-0.13	Intelligence (multi-trait analysis);	chr6:27310241	chr6:28073316~28074233:+
BRCA	cis	rs950169	0.544	rs62021193	ENSG00000229212.6	RP11-561C5.4	-4.11	4.27e-05	0.00297	-0.16	-0.13	Schizophrenia;	chr15:84627352	chr15:85205440~85234795:-
BRCA	cis	rs2991971	0.933	rs666720	ENSG00000280836.1	AL355480.1	4.11	4.27e-05	0.00297	0.15	0.13	High light scatter reticulocyte count;	chr1:45555123	chr1:45581219~45581321:-
BRCA	cis	rs7259811	0.812	rs62133209	ENSG00000268266.1	AC003005.2	4.11	4.27e-05	0.00297	0.18	0.13	Western dietary pattern;	chr19:56714717	chr19:57477649~57482996:+
BRCA	cis	rs829883	1	rs249839	ENSG00000227825.4	SLC9A7P1	4.11	4.27e-05	0.00297	0.16	0.13	Colorectal adenoma (advanced);	chr12:98478586	chr12:98453835~98457145:-
BRCA	cis	rs6430585	0.702	rs1042712	ENSG00000224043.6	CCNT2-AS1	4.11	4.27e-05	0.00297	0.2	0.13	Corneal structure;	chr2:135788274	chr2:134735464~134918710:-
BRCA	cis	rs12681366	0.537	rs2919664	ENSG00000253175.1	RP11-267M23.6	4.11	4.27e-05	0.00297	0.15	0.13	Nonsyndromic cleft lip with cleft palate;	chr8:94456485	chr8:94565036~94565715:+
BRCA	cis	rs78487399	0.665	rs72867023	ENSG00000234936.1	AC010883.5	4.11	4.27e-05	0.00297	0.17	0.13	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43536027	chr2:43229573~43233394:+
BRCA	cis	rs10844706	0.699	rs11052750	ENSG00000256673.1	RP11-599J14.2	-4.11	4.27e-05	0.00297	-0.15	-0.13	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9735090	chr12:9398355~9414851:-
BRCA	cis	rs6686842	0.513	rs11579483	ENSG00000235358.1	RP11-399E6.1	-4.11	4.27e-05	0.00298	-0.17	-0.13	Height;	chr1:41014192	chr1:41242373~41284861:+
BRCA	cis	rs3748682	0.861	rs28625842	ENSG00000252448.1	SNORA63	-4.11	4.27e-05	0.00298	-0.16	-0.13	Hypothyroidism;	chr1:37845114	chr1:37884237~37884317:+
BRCA	cis	rs7267979	1	rs2482928	ENSG00000276952.1	RP5-965G21.6	-4.11	4.27e-05	0.00298	-0.16	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25350894	chr20:25284915~25285588:-
BRCA	cis	rs10043228	1	rs7727882	ENSG00000271918.1	CTD-2287O16.5	-4.11	4.27e-05	0.00298	-0.16	-0.13	Asthma or chronic obstructive pulmonary disease;	chr5:116278810	chr5:116083807~116085416:-
BRCA	cis	rs11673344	0.504	rs10403975	ENSG00000276846.1	CTD-3220F14.3	4.11	4.27e-05	0.00298	0.15	0.13	Obesity-related traits;	chr19:37082172	chr19:37314868~37315620:-
BRCA	cis	rs1005277	0.579	rs1780133	ENSG00000276805.1	RP11-291L22.6	4.11	4.27e-05	0.00298	0.14	0.13	Extrinsic epigenetic age acceleration;	chr10:38210581	chr10:38451030~38451785:+
BRCA	cis	rs7520050	0.966	rs1768803	ENSG00000281133.1	AL355480.3	4.11	4.27e-05	0.00298	0.15	0.13	Reticulocyte count;Red blood cell count;	chr1:46080536	chr1:45580892~45580996:-
BRCA	cis	rs9959145	0.778	rs77764901	ENSG00000267108.1	RP11-861E21.1	4.11	4.28e-05	0.00298	0.23	0.13	Immune response to smallpox vaccine (IL-6);	chr18:12567459	chr18:12432897~12437635:+
BRCA	cis	rs6545883	0.868	rs7574631	ENSG00000270820.4	RP11-355B11.2	4.11	4.28e-05	0.00298	0.14	0.13	Tuberculosis;	chr2:61598007	chr2:61471188~61484130:+
BRCA	cis	rs983392	0.679	rs655231	ENSG00000275344.1	MIR6503	-4.11	4.28e-05	0.00298	-0.13	-0.13	Alzheimer's disease (late onset);	chr11:60246384	chr11:60209071~60209156:-
BRCA	cis	rs875971	0.638	rs35986979	ENSG00000229180.5	GS1-124K5.11	-4.11	4.28e-05	0.00298	-0.11	-0.13	Aortic root size;	chr7:66624003	chr7:66526088~66542624:-
BRCA	cis	rs7226408	0.948	rs11661681	ENSG00000267707.2	RP11-95O2.5	-4.11	4.28e-05	0.00298	-0.2	-0.13	Obesity-related traits;	chr18:36815577	chr18:37243776~37247506:+
BRCA	cis	rs9527	0.59	rs10883830	ENSG00000213061.2	PFN1P11	4.11	4.28e-05	0.00298	0.17	0.13	Arsenic metabolism;	chr10:103091528	chr10:102838011~102845473:-
BRCA	cis	rs490234	0.812	rs13288963	ENSG00000232630.1	PRPS1P2	-4.11	4.28e-05	0.00298	-0.13	-0.13	Mean arterial pressure;	chr9:125532919	chr9:125150653~125151589:+
BRCA	cis	rs66887589	0.592	rs2175383	ENSG00000250412.1	KLHL2P1	4.11	4.28e-05	0.00298	0.14	0.13	Diastolic blood pressure;	chr4:119294681	chr4:119334329~119378233:+
BRCA	cis	rs875971	0.545	rs3936065	ENSG00000232546.1	RP11-458F8.1	4.11	4.28e-05	0.00298	0.12	0.13	Aortic root size;	chr7:66325577	chr7:66848496~66858136:+
BRCA	cis	rs875971	0.545	rs4718335	ENSG00000232546.1	RP11-458F8.1	4.11	4.28e-05	0.00298	0.12	0.13	Aortic root size;	chr7:66339619	chr7:66848496~66858136:+
BRCA	cis	rs1005277	0.579	rs2472183	ENSG00000272983.1	RP11-508N22.12	4.11	4.28e-05	0.00298	0.13	0.13	Extrinsic epigenetic age acceleration;	chr10:38103567	chr10:38137337~38144399:+
BRCA	cis	rs4494364	0.502	rs1861129	ENSG00000258100.1	RP11-121E16.1	4.11	4.28e-05	0.00298	0.18	0.13	Systolic blood pressure (alcohol consumption interaction);	chr12:91044441	chr12:91362196~91368606:+
BRCA	cis	rs11096990	0.634	rs7659894	ENSG00000249685.1	RP11-360F5.3	-4.11	4.28e-05	0.00298	-0.15	-0.13	Cognitive function;	chr4:39282815	chr4:39133913~39135608:+
BRCA	cis	rs6049003	0.594	rs4073754	ENSG00000232645.4	LINC01431	4.11	4.28e-05	0.00298	0.14	0.13	Cerebrospinal fluid biomarker levels;	chr20:23735600	chr20:23356594~23358116:-
BRCA	cis	rs2243480	0.522	rs431168	ENSG00000229886.1	RP5-1132H15.3	4.11	4.28e-05	0.00298	0.27	0.13	Diabetic kidney disease;	chr7:66046617	chr7:66025126~66031544:-
BRCA	cis	rs7267979	0.933	rs2258728	ENSG00000274973.1	RP13-401N8.7	-4.11	4.28e-05	0.00298	-0.14	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25295707	chr20:25845497~25845862:+
BRCA	cis	rs17684571	0.687	rs13214893	ENSG00000231441.1	RP11-472M19.2	4.11	4.28e-05	0.00298	0.22	0.13	Schizophrenia;	chr6:56865425	chr6:56844002~56864078:+
BRCA	cis	rs10761482	0.601	rs1954117	ENSG00000254271.1	RP11-131N11.4	4.11	4.28e-05	0.00298	0.18	0.13	Schizophrenia;	chr10:60450830	chr10:60734342~60741828:+
BRCA	cis	rs952623	0.649	rs13242896	ENSG00000211694.2	TRGV10	4.11	4.28e-05	0.00298	0.11	0.13	Intelligence (multi-trait analysis);	chr7:39030462	chr7:38299811~38300322:-
BRCA	cis	rs7620503	0.765	rs2133594	ENSG00000228221.4	LINC00578	-4.11	4.28e-05	0.00298	-0.16	-0.13	Corneal structure;	chr3:177584329	chr3:177441921~177752305:+
BRCA	cis	rs2243480	0.901	rs2949697	ENSG00000275400.1	RP4-756H11.5	4.11	4.28e-05	0.00298	0.23	0.13	Diabetic kidney disease;	chr7:65999249	chr7:66553805~66554199:-
BRCA	cis	rs9527	0.545	rs7100369	ENSG00000213061.2	PFN1P11	4.11	4.29e-05	0.00298	0.17	0.13	Arsenic metabolism;	chr10:103196461	chr10:102838011~102845473:-
BRCA	cis	rs9527	0.545	rs12784384	ENSG00000213061.2	PFN1P11	4.11	4.29e-05	0.00298	0.17	0.13	Arsenic metabolism;	chr10:103197837	chr10:102838011~102845473:-
BRCA	cis	rs9527	0.545	rs10883847	ENSG00000213061.2	PFN1P11	4.11	4.29e-05	0.00298	0.17	0.13	Arsenic metabolism;	chr10:103198527	chr10:102838011~102845473:-
BRCA	cis	rs4443100	0.916	rs8139695	ENSG00000230701.2	FBXW4P1	-4.11	4.29e-05	0.00298	-0.16	-0.13	Serum parathyroid hormone levels;	chr22:23031726	chr22:23262767~23265005:+
BRCA	cis	rs6545883	0.859	rs2600661	ENSG00000270820.4	RP11-355B11.2	-4.11	4.29e-05	0.00298	-0.14	-0.13	Tuberculosis;	chr2:61315946	chr2:61471188~61484130:+
BRCA	cis	rs10266483	0.774	rs10949901	ENSG00000271550.1	BNIP3P11	-4.11	4.29e-05	0.00299	-0.17	-0.13	Response to statin therapy;	chr7:64352396	chr7:64678954~64687393:-
BRCA	cis	rs58521262	0.556	rs435715	ENSG00000268105.1	RP11-369G6.2	4.11	4.29e-05	0.00299	0.17	0.13	Testicular germ cell tumor;	chr19:22943284	chr19:23125665~23128543:+
BRCA	cis	rs950776	0.714	rs615470	ENSG00000279373.1	RP11-650L12.4	-4.11	4.29e-05	0.00299	-0.15	-0.13	Sudden cardiac arrest;	chr15:78593646	chr15:78537681~78538946:+
BRCA	cis	rs4950322	0.563	rs6700783	ENSG00000244371.2	PFN1P8	-4.11	4.29e-05	0.00299	-0.17	-0.13	Protein quantitative trait loci;	chr1:147111987	chr1:146957117~146957659:-
BRCA	cis	rs4302906	0.72	rs3936099	ENSG00000187984.11	ANKRD19P	4.11	4.29e-05	0.00299	0.12	0.13	Lobe attachment (rater-scored or self-reported);	chr9:92949362	chr9:92809388~92888693:+
BRCA	cis	rs7267979	0.899	rs442834	ENSG00000274414.1	RP5-965G21.4	-4.11	4.29e-05	0.00299	-0.15	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25477460	chr20:25239007~25245229:-
BRCA	cis	rs2408955	0.541	rs11168428	ENSG00000226413.2	OR8T1P	-4.11	4.29e-05	0.00299	-0.17	-0.13	Glycated hemoglobin levels;	chr12:48153345	chr12:48442030~48442947:-
BRCA	cis	rs875971	0.638	rs6960778	ENSG00000232546.1	RP11-458F8.1	4.11	4.29e-05	0.00299	0.11	0.13	Aortic root size;	chr7:66606610	chr7:66848496~66858136:+
BRCA	cis	rs1950832	0.689	rs1101391	ENSG00000258636.1	CTD-2298J14.2	4.11	4.29e-05	0.00299	0.15	0.13	Urate levels in obese individuals;	chr14:41635561	chr14:41587861~41604856:-
BRCA	cis	rs9876781	0.624	rs12491849	ENSG00000229759.1	MRPS18AP1	4.11	4.29e-05	0.00299	0.16	0.13	Longevity;	chr3:48489975	chr3:48256350~48256938:-
BRCA	cis	rs1429524	0.885	rs55646004	ENSG00000243144.5	RP11-115N4.1	4.11	4.29e-05	0.00299	0.16	0.13	Ejection fraction in Tripanosoma cruzi seropositivity;	chr7:91311582	chr7:91311368~91515409:+
BRCA	cis	rs7520050	0.966	rs4660910	ENSG00000281133.1	AL355480.3	4.11	4.29e-05	0.00299	0.15	0.13	Reticulocyte count;Red blood cell count;	chr1:46082730	chr1:45580892~45580996:-
BRCA	cis	rs7267979	1	rs6050544	ENSG00000125804.12	FAM182A	4.11	4.29e-05	0.00299	0.16	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25339592	chr20:26054655~26086917:+
BRCA	cis	rs38055	0.837	rs37778	ENSG00000247796.2	CTD-2366F13.1	-4.11	4.29e-05	0.00299	-0.15	-0.13	Acne (severe);	chr5:53333400	chr5:53109842~53115126:+
BRCA	cis	rs867186	1	rs11907011	ENSG00000126005.14	MMP24-AS1	-4.11	4.3e-05	0.00299	-0.25	-0.13	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35179967	chr20:35216462~35278131:-
BRCA	cis	rs7746199	0.736	rs34105070	ENSG00000216901.1	AL022393.7	4.11	4.3e-05	0.00299	0.32	0.13	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27593026	chr6:28176188~28176674:+
BRCA	cis	rs4950322	0.57	rs7554833	ENSG00000227242.3	NBPF13P	4.11	4.3e-05	0.00299	0.19	0.13	Protein quantitative trait loci;	chr1:147289362	chr1:147021320~147124525:-
BRCA	cis	rs11233413	0.874	rs1943340	ENSG00000246067.6	RAB30-AS1	4.11	4.3e-05	0.00299	0.16	0.13	Economic and political preferences (feminism/equality);	chr11:83055613	chr11:83072066~83106719:+
BRCA	cis	rs6993270	0.779	rs7814126	ENSG00000245330.4	KB-1471A8.1	-4.11	4.3e-05	0.00299	-0.2	-0.13	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr8:119896996	chr8:119867419~119874488:-
BRCA	cis	rs4073582	0.555	rs521109	ENSG00000255320.1	RP11-755F10.1	-4.11	4.3e-05	0.00299	-0.16	-0.13	Gout;	chr11:66263477	chr11:66244840~66246239:-
BRCA	cis	rs256438	0.524	rs404375	ENSG00000251050.1	RP11-168A11.4	-4.11	4.3e-05	0.003	-0.13	-0.13	Serum thyroid-stimulating hormone levels;	chr5:80052936	chr5:80019609~80019920:+
BRCA	cis	rs1008375	0.966	rs6833808	ENSG00000249502.1	AC006160.5	-4.11	4.3e-05	0.003	-0.14	-0.13	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17650903	chr4:17587467~17614571:-
BRCA	cis	rs6545883	0.507	rs4672427	ENSG00000273302.1	RP11-493E12.2	-4.11	4.31e-05	0.003	-0.11	-0.13	Tuberculosis;	chr2:61242115	chr2:61199979~61200769:+
BRCA	cis	rs62458065	0.713	rs28421905	ENSG00000281332.1	LINC00997	-4.11	4.31e-05	0.003	-0.19	-0.13	Metabolite levels (HVA/MHPG ratio);	chr7:32449889	chr7:32760279~32762924:+
BRCA	cis	rs181553	0.664	rs1838963	ENSG00000266696.1	RP11-30L3.2	4.11	4.31e-05	0.003	0.14	0.13	Hip circumference adjusted for BMI;	chr18:49153498	chr18:49205912~49208781:+
BRCA	cis	rs559406	0.501	rs2847298	ENSG00000260302.1	RP11-973H7.1	-4.11	4.31e-05	0.003	-0.16	-0.13	Psoriasis;	chr18:12800121	chr18:12774651~12775923:-
BRCA	cis	rs3812762	0.879	rs1079452	ENSG00000254860.4	TMEM9B-AS1	4.11	4.31e-05	0.003	0.11	0.13	Hypospadias;	chr11:8757625	chr11:8964675~8977527:+
BRCA	cis	rs9527	0.59	rs7906754	ENSG00000213061.2	PFN1P11	4.11	4.31e-05	0.003	0.17	0.13	Arsenic metabolism;	chr10:103022800	chr10:102838011~102845473:-
BRCA	cis	rs1865760	0.964	rs6932113	ENSG00000272462.2	U91328.19	-4.11	4.31e-05	0.003	-0.15	-0.13	Height;	chr6:25912870	chr6:25992662~26001775:+
BRCA	cis	rs10864907	0.553	rs7578034	ENSG00000231747.1	AC079922.2	-4.11	4.31e-05	0.003	-0.12	-0.13	Pulmonary function;	chr2:112960500	chr2:112621809~112622167:-
BRCA	cis	rs10864907	0.553	rs7580877	ENSG00000231747.1	AC079922.2	-4.11	4.31e-05	0.003	-0.12	-0.13	Pulmonary function;	chr2:112960733	chr2:112621809~112622167:-
BRCA	cis	rs71520386	0.632	rs10269414	ENSG00000226329.2	AC005682.6	-4.11	4.31e-05	0.003	-0.13	-0.13	Fibrinogen levels;	chr7:22816674	chr7:22863874~22881350:-
BRCA	cis	rs71520386	0.632	rs2286500	ENSG00000226329.2	AC005682.6	-4.11	4.31e-05	0.003	-0.13	-0.13	Fibrinogen levels;	chr7:22817185	chr7:22863874~22881350:-
BRCA	cis	rs737008	0.922	rs376374	ENSG00000262636.1	CTD-3088G3.4	-4.11	4.31e-05	0.003	-0.18	-0.13	Obesity-related traits;	chr16:11276759	chr16:11380859~11381118:-
BRCA	cis	rs4869313	0.869	rs27289	ENSG00000248734.2	CTD-2260A17.1	-4.11	4.31e-05	0.003	-0.13	-0.13	Pediatric autoimmune diseases;	chr5:97010574	chr5:96784777~96785999:+
BRCA	cis	rs2411233	0.967	rs7161833	ENSG00000259278.1	RP11-62C7.2	4.11	4.31e-05	0.003	0.15	0.13	Platelet count;	chr15:38993434	chr15:39019233~39024918:+
BRCA	cis	rs11098499	0.754	rs12711071	ENSG00000225892.3	RP11-384K6.2	4.11	4.31e-05	0.003	0.12	0.13	Corneal astigmatism;	chr4:119319779	chr4:118632274~118634759:+
BRCA	cis	rs9628987	0.53	rs301793	ENSG00000270282.1	RP5-1115A15.2	4.11	4.31e-05	0.003	0.18	0.13	Breast cancer;	chr1:8407474	chr1:8512653~8513021:+
BRCA	cis	rs801193	1	rs1553610	ENSG00000223473.2	GS1-124K5.3	4.11	4.31e-05	0.003	0.1	0.13	Aortic root size;	chr7:66732246	chr7:66491049~66493566:-
BRCA	cis	rs801193	1	rs2707845	ENSG00000223473.2	GS1-124K5.3	4.11	4.31e-05	0.003	0.1	0.13	Aortic root size;	chr7:66733811	chr7:66491049~66493566:-
BRCA	cis	rs801193	1	rs2707850	ENSG00000223473.2	GS1-124K5.3	4.11	4.31e-05	0.003	0.1	0.13	Aortic root size;	chr7:66738883	chr7:66491049~66493566:-
BRCA	cis	rs801193	0.967	rs1110414	ENSG00000223473.2	GS1-124K5.3	4.11	4.31e-05	0.003	0.1	0.13	Aortic root size;	chr7:66740595	chr7:66491049~66493566:-
BRCA	cis	rs801193	1	rs7783924	ENSG00000223473.2	GS1-124K5.3	4.11	4.31e-05	0.003	0.1	0.13	Aortic root size;	chr7:66744070	chr7:66491049~66493566:-
BRCA	cis	rs801193	1	rs7789184	ENSG00000223473.2	GS1-124K5.3	4.11	4.31e-05	0.003	0.1	0.13	Aortic root size;	chr7:66745208	chr7:66491049~66493566:-
BRCA	cis	rs801193	1	rs2707854	ENSG00000223473.2	GS1-124K5.3	4.11	4.31e-05	0.003	0.1	0.13	Aortic root size;	chr7:66747610	chr7:66491049~66493566:-
BRCA	cis	rs1371614	0.635	rs12612619	ENSG00000229122.1	AGBL5-IT1	-4.11	4.31e-05	0.003	-0.13	-0.13	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26914803	chr2:27061038~27061815:+
BRCA	cis	rs7200543	1	rs6498540	ENSG00000207425.1	Y_RNA	-4.11	4.31e-05	0.003	-0.16	-0.13	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15036737	chr16:14915457~14915556:-
BRCA	cis	rs10129255	0.872	rs1858683	ENSG00000274576.2	IGHV2-70	4.11	4.31e-05	0.003	0.12	0.13	Kawasaki disease;	chr14:106670217	chr14:106770577~106771020:-
BRCA	cis	rs7937890	0.504	rs2575822	ENSG00000254418.1	RP11-21L19.1	4.11	4.32e-05	0.003	0.15	0.13	Mitochondrial DNA levels;	chr11:14498305	chr11:14262846~14273691:-
BRCA	cis	rs7937890	0.559	rs2575823	ENSG00000254418.1	RP11-21L19.1	4.11	4.32e-05	0.003	0.15	0.13	Mitochondrial DNA levels;	chr11:14499808	chr11:14262846~14273691:-
BRCA	cis	rs7937890	0.559	rs2597221	ENSG00000254418.1	RP11-21L19.1	4.11	4.32e-05	0.003	0.15	0.13	Mitochondrial DNA levels;	chr11:14505529	chr11:14262846~14273691:-
BRCA	cis	rs6593122	0.755	rs2877185	ENSG00000235454.1	HAUS6P3	-4.11	4.32e-05	0.00301	-0.17	-0.13	Vaccine-related adverse events;	chr7:54129355	chr7:53862233~53863339:+
BRCA	cis	rs6088580	0.601	rs6059827	ENSG00000275784.1	RP5-1125A11.6	-4.11	4.32e-05	0.00301	-0.14	-0.13	Glomerular filtration rate (creatinine);	chr20:34428552	chr20:33989480~33991818:-
BRCA	cis	rs6545883	0.894	rs2694634	ENSG00000212978.6	AC016747.3	-4.11	4.32e-05	0.00301	-0.17	-0.13	Tuberculosis;	chr2:61324300	chr2:61141592~61144969:-
BRCA	cis	rs7621331	1	rs6810223	ENSG00000239213.4	NCK1-AS1	4.11	4.32e-05	0.00301	0.14	0.13	Waist circumference adjusted for body mass index;	chr3:135975662	chr3:136841726~136862054:-
BRCA	cis	rs17801127	0.818	rs16827316	ENSG00000231969.1	AC144449.1	4.11	4.32e-05	0.00301	0.22	0.13	Liver enzyme levels (alanine transaminase);	chr2:149674565	chr2:149587196~149848233:+
BRCA	cis	rs6671200	1	rs259346	ENSG00000235501.4	RP4-639F20.1	-4.11	4.32e-05	0.00301	-0.26	-0.13	Stearic acid (18:0) levels;	chr1:95263190	chr1:94927566~94963270:+
BRCA	cis	rs11242704	0.632	rs57995235	ENSG00000218027.2	RP11-157J24.1	4.11	4.32e-05	0.00301	0.17	0.13	Response to hepatitis C treatment;	chr6:1530716	chr6:1513698~1515289:-
BRCA	cis	rs4950322	0.748	rs17360812	ENSG00000237188.3	RP11-337C18.8	-4.11	4.32e-05	0.00301	-0.16	-0.13	Protein quantitative trait loci;	chr1:147355010	chr1:147172771~147211568:+
BRCA	cis	rs6964587	1	rs12537846	ENSG00000188693.7	CYP51A1-AS1	4.11	4.32e-05	0.00301	0.13	0.13	Breast cancer;	chr7:92092267	chr7:92134604~92180725:+
BRCA	cis	rs9470794	0.748	rs11752863	ENSG00000204110.6	RP1-153P14.8	-4.11	4.32e-05	0.00301	-0.23	-0.13	Type 2 diabetes;	chr6:37968730	chr6:37507348~37535616:+
BRCA	cis	rs244293	0.76	rs4794547	ENSG00000275710.1	RP11-257O5.4	4.11	4.32e-05	0.00301	0.14	0.13	Menarche (age at onset);	chr17:54933811	chr17:54964474~54964679:+
BRCA	cis	rs10849893	0.557	rs10849890	ENSG00000258435.1	RP11-711D18.2	-4.11	4.32e-05	0.00301	-0.14	-0.13	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr12:121464922	chr12:121391962~121399859:+
BRCA	cis	rs1153858	1	rs2066090	ENSG00000275672.1	GATM-AS1	-4.11	4.32e-05	0.00301	-0.16	-0.13	Homoarginine levels;	chr15:45357820	chr15:45378700~45380123:+
BRCA	cis	rs3768617	0.51	rs12086466	ENSG00000224468.3	RP11-181K3.4	4.11	4.33e-05	0.00301	0.13	0.13	Fuchs's corneal dystrophy;	chr1:183106643	chr1:183138402~183141282:-
BRCA	cis	rs4835473	0.897	rs2060654	ENSG00000246448.2	RP13-578N3.3	-4.11	4.33e-05	0.00301	-0.14	-0.13	Immature fraction of reticulocytes;	chr4:143739155	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.932	rs2060655	ENSG00000246448.2	RP13-578N3.3	-4.11	4.33e-05	0.00301	-0.14	-0.13	Immature fraction of reticulocytes;	chr4:143739159	chr4:143700257~143865072:+
BRCA	cis	rs8130944	1	rs2269149	ENSG00000225731.1	AP001627.1	4.11	4.33e-05	0.00301	0.14	0.13	Perceived unattractiveness to mosquitoes;	chr21:42721247	chr21:42733594~42741758:-
BRCA	cis	rs11711311	0.955	rs12636240	ENSG00000241529.3	RN7SL767P	-4.11	4.33e-05	0.00301	-0.15	-0.13	IgG glycosylation;	chr3:113672435	chr3:113632704~113632998:+
BRCA	cis	rs7267979	1	rs6115182	ENSG00000277938.1	RP5-965G21.3	-4.11	4.33e-05	0.00301	-0.15	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25429623	chr20:25229150~25231933:+
BRCA	cis	rs35740288	0.929	rs11630585	ENSG00000202081.1	RNU6-1280P	4.11	4.33e-05	0.00301	0.17	0.13	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85762773	chr15:85651522~85651628:-
BRCA	cis	rs4449834	0.851	rs11993896	ENSG00000254432.1	RP11-33I11.2	-4.11	4.33e-05	0.00301	-0.16	-0.13	Sum eosinophil basophil counts;	chr8:60790370	chr8:60808735~60809606:-
BRCA	cis	rs11098499	0.738	rs28408407	ENSG00000250412.1	KLHL2P1	4.11	4.33e-05	0.00301	0.15	0.13	Corneal astigmatism;	chr4:119454875	chr4:119334329~119378233:+
BRCA	cis	rs11098499	0.863	rs9884402	ENSG00000260091.1	RP11-33B1.4	-4.11	4.33e-05	0.00301	-0.11	-0.13	Corneal astigmatism;	chr4:119568827	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.731	rs9995026	ENSG00000260091.1	RP11-33B1.4	-4.11	4.33e-05	0.00301	-0.11	-0.13	Corneal astigmatism;	chr4:119569344	chr4:119409333~119410233:+
BRCA	cis	rs6121246	0.909	rs1994250	ENSG00000230613.1	HM13-AS1	4.11	4.33e-05	0.00301	0.19	0.13	Mean corpuscular hemoglobin;	chr20:31699691	chr20:31567707~31573263:-
BRCA	cis	rs6121246	0.909	rs1994249	ENSG00000230613.1	HM13-AS1	4.11	4.33e-05	0.00301	0.19	0.13	Mean corpuscular hemoglobin;	chr20:31699790	chr20:31567707~31573263:-
BRCA	cis	rs950776	0.648	rs57945453	ENSG00000279373.1	RP11-650L12.4	4.11	4.33e-05	0.00301	0.16	0.13	Sudden cardiac arrest;	chr15:78570503	chr15:78537681~78538946:+
BRCA	cis	rs11098499	0.863	rs9884402	ENSG00000250412.1	KLHL2P1	4.11	4.33e-05	0.00301	0.15	0.13	Corneal astigmatism;	chr4:119568827	chr4:119334329~119378233:+
BRCA	cis	rs11098499	0.731	rs9995026	ENSG00000250412.1	KLHL2P1	4.11	4.33e-05	0.00301	0.15	0.13	Corneal astigmatism;	chr4:119569344	chr4:119334329~119378233:+
BRCA	cis	rs801193	1	rs62466793	ENSG00000223473.2	GS1-124K5.3	4.11	4.33e-05	0.00301	0.1	0.13	Aortic root size;	chr7:66726530	chr7:66491049~66493566:-
BRCA	cis	rs1865760	1	rs2071297	ENSG00000272462.2	U91328.19	4.11	4.33e-05	0.00301	0.15	0.13	Height;	chr6:25924285	chr6:25992662~26001775:+
BRCA	cis	rs747650	0.504	rs11601798	ENSG00000200376.1	RNU5E-10P	-4.11	4.33e-05	0.00301	-0.17	-0.13	Acne (severe);	chr11:47136841	chr11:47576471~47576588:-
BRCA	cis	rs4561483	0.801	rs154148	ENSG00000261216.1	RP11-166B2.5	-4.11	4.33e-05	0.00301	-0.15	-0.13	Testicular germ cell tumor;	chr16:11862621	chr16:11908208~11908916:+
BRCA	cis	rs3750082	0.692	rs34737146	ENSG00000231952.3	DPY19L1P2	4.11	4.34e-05	0.00302	0.17	0.13	Glomerular filtration rate (creatinine);	chr7:32896314	chr7:32812757~32838570:+
BRCA	cis	rs4713118	0.662	rs9393881	ENSG00000216901.1	AL022393.7	4.11	4.34e-05	0.00302	0.18	0.13	Parkinson's disease;	chr6:28055973	chr6:28176188~28176674:+
BRCA	cis	rs2274273	0.624	rs7150763	ENSG00000259318.1	RP11-454L9.2	4.11	4.34e-05	0.00302	0.11	0.13	Protein biomarker;	chr14:55373083	chr14:55394940~55395233:-
BRCA	cis	rs11742741	0.616	rs17501795	ENSG00000248874.4	C5orf17	-4.11	4.34e-05	0.00302	-0.16	-0.13	Educational attainment;	chr5:24066127	chr5:23951348~24178263:+
BRCA	cis	rs1153858	0.943	rs11070454	ENSG00000275672.1	GATM-AS1	-4.11	4.34e-05	0.00302	-0.16	-0.13	Homoarginine levels;	chr15:45388054	chr15:45378700~45380123:+
BRCA	cis	rs5758511	0.68	rs5758688	ENSG00000226450.2	CYP2D8P	4.11	4.34e-05	0.00302	0.15	0.13	Birth weight;	chr22:42266495	chr22:42149886~42155001:-
BRCA	cis	rs6840360	0.533	rs11099829	ENSG00000270265.1	RP11-731D1.4	4.11	4.34e-05	0.00302	0.15	0.13	Intelligence (multi-trait analysis);	chr4:151806147	chr4:151333775~151353224:-
BRCA	cis	rs2109514	0.65	rs12531767	ENSG00000237813.3	AC002066.1	4.11	4.34e-05	0.00302	0.15	0.13	Prevalent atrial fibrillation;	chr7:116488951	chr7:116238260~116499465:-
BRCA	cis	rs4698412	0.561	rs17405811	ENSG00000273133.1	RP11-799M12.2	-4.11	4.34e-05	0.00302	-0.15	-0.13	Parkinson's disease;	chr4:15684182	chr4:15563698~15564253:-
BRCA	cis	rs6772849	0.93	rs12487604	ENSG00000242551.2	POU5F1P6	-4.11	4.34e-05	0.00302	-0.17	-0.13	Monocyte percentage of white cells;Monocyte count;	chr3:128618232	chr3:128674735~128677005:-
BRCA	cis	rs71520386	0.632	rs12532938	ENSG00000226329.2	AC005682.6	-4.11	4.34e-05	0.00302	-0.13	-0.13	Fibrinogen levels;	chr7:22820876	chr7:22863874~22881350:-
BRCA	cis	rs2109514	0.84	rs6953982	ENSG00000237813.3	AC002066.1	4.11	4.34e-05	0.00302	0.15	0.13	Prevalent atrial fibrillation;	chr7:116489236	chr7:116238260~116499465:-
BRCA	cis	rs17406451	1	rs6544653	ENSG00000234936.1	AC010883.5	4.11	4.34e-05	0.00302	0.13	0.13	Mitochondrial DNA levels;	chr2:43405811	chr2:43229573~43233394:+
BRCA	cis	rs1910358	0.554	rs6452157	ENSG00000248874.4	C5orf17	-4.11	4.34e-05	0.00302	-0.18	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23760601	chr5:23951348~24178263:+
BRCA	cis	rs875971	0.66	rs7807944	ENSG00000229180.5	GS1-124K5.11	-4.11	4.34e-05	0.00302	-0.11	-0.13	Aortic root size;	chr7:66622208	chr7:66526088~66542624:-
BRCA	cis	rs4908760	0.827	rs7556169	ENSG00000232912.4	RP5-1115A15.1	-4.11	4.34e-05	0.00302	-0.12	-0.13	Vitiligo;	chr1:8681342	chr1:8424645~8434838:+
BRCA	cis	rs12724450	0.655	rs11801190	ENSG00000228126.1	FALEC	4.11	4.34e-05	0.00302	0.23	0.13	Blood protein levels;	chr1:150511528	chr1:150515757~150518032:+
BRCA	cis	rs1075265	0.509	rs10188142	ENSG00000233266.1	HMGB1P31	-4.11	4.35e-05	0.00302	-0.16	-0.13	Chronotype;Morning vs. evening chronotype;	chr2:53730999	chr2:54051334~54051760:+
BRCA	cis	rs160451	0.934	rs34036322	ENSG00000251136.7	RP11-37B2.1	4.11	4.35e-05	0.00302	0.12	0.13	Leprosy;	chr8:89654670	chr8:89609409~89757727:-
BRCA	cis	rs853679	1	rs10456362	ENSG00000280107.1	AL022393.9	4.11	4.35e-05	0.00302	0.21	0.13	Depression;	chr6:28254038	chr6:28170845~28172521:+
BRCA	cis	rs1865760	0.865	rs4478388	ENSG00000272462.2	U91328.19	-4.11	4.35e-05	0.00302	-0.15	-0.13	Height;	chr6:25953405	chr6:25992662~26001775:+
BRCA	cis	rs1371614	0.632	rs3739088	ENSG00000229122.1	AGBL5-IT1	-4.11	4.35e-05	0.00302	-0.13	-0.13	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26944916	chr2:27061038~27061815:+
BRCA	cis	rs1371614	0.632	rs3769135	ENSG00000229122.1	AGBL5-IT1	-4.11	4.35e-05	0.00302	-0.13	-0.13	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26945543	chr2:27061038~27061815:+
BRCA	cis	rs2395128	0.519	rs10762651	ENSG00000213731.2	RAB5CP1	4.11	4.35e-05	0.00302	0.21	0.13	Ulcerative colitis;Inflammatory bowel disease;	chr10:75062359	chr10:74423435~74424014:-
BRCA	cis	rs8180040	0.966	rs1872164	ENSG00000280667.1	Y_RNA	-4.11	4.35e-05	0.00302	-0.14	-0.13	Colorectal cancer;	chr3:47373610	chr3:47501083~47501182:+
BRCA	cis	rs886774	0.899	rs6947045	ENSG00000273055.1	CTB-13F3.1	-4.11	4.35e-05	0.00302	-0.13	-0.13	Ulcerative colitis;	chr7:107859502	chr7:107942116~107942740:+
BRCA	cis	rs853679	0.517	rs9368556	ENSG00000261839.1	RP1-265C24.8	4.11	4.35e-05	0.00302	0.18	0.13	Depression;	chr6:28163375	chr6:28136849~28139678:+
BRCA	cis	rs853679	0.517	rs9368557	ENSG00000261839.1	RP1-265C24.8	4.11	4.35e-05	0.00302	0.18	0.13	Depression;	chr6:28163759	chr6:28136849~28139678:+
BRCA	cis	rs853679	0.517	rs9380059	ENSG00000261839.1	RP1-265C24.8	4.11	4.35e-05	0.00302	0.18	0.13	Depression;	chr6:28164580	chr6:28136849~28139678:+
BRCA	cis	rs853679	0.517	rs9380060	ENSG00000261839.1	RP1-265C24.8	4.11	4.35e-05	0.00302	0.18	0.13	Depression;	chr6:28164825	chr6:28136849~28139678:+
BRCA	cis	rs853679	0.517	rs35227624	ENSG00000261839.1	RP1-265C24.8	4.11	4.35e-05	0.00302	0.18	0.13	Depression;	chr6:28164948	chr6:28136849~28139678:+
BRCA	cis	rs853679	0.517	rs9380061	ENSG00000261839.1	RP1-265C24.8	4.11	4.35e-05	0.00302	0.18	0.13	Depression;	chr6:28165025	chr6:28136849~28139678:+
BRCA	cis	rs853679	0.517	rs9368558	ENSG00000261839.1	RP1-265C24.8	4.11	4.35e-05	0.00302	0.18	0.13	Depression;	chr6:28165528	chr6:28136849~28139678:+
BRCA	cis	rs6500602	0.855	rs1139652	ENSG00000280063.1	RP11-295D4.3	4.11	4.35e-05	0.00302	0.1	0.13	Schizophrenia;	chr16:4426088	chr16:4346694~4348648:-
BRCA	cis	rs2749592	0.531	rs1208559	ENSG00000099251.13	HSD17B7P2	-4.11	4.35e-05	0.00302	-0.15	-0.13	Age-related hearing impairment (SNP x SNP interaction);	chr10:37932442	chr10:38356380~38378505:+
BRCA	cis	rs2832191	1	rs2832183	ENSG00000236056.1	GAPDHP14	4.11	4.35e-05	0.00302	0.14	0.13	Dental caries;	chr21:29109829	chr21:29222321~29223257:+
BRCA	cis	rs651907	0.817	rs675779	ENSG00000244119.1	PDCL3P4	4.11	4.35e-05	0.00302	0.1	0.13	Colorectal cancer;	chr3:101880175	chr3:101712472~101713191:+
BRCA	cis	rs11098499	0.789	rs10212719	ENSG00000260091.1	RP11-33B1.4	-4.11	4.35e-05	0.00303	-0.11	-0.13	Corneal astigmatism;	chr4:119333282	chr4:119409333~119410233:+
BRCA	cis	rs9868809	0.505	rs28657585	ENSG00000225399.4	RP11-3B7.1	-4.11	4.35e-05	0.00303	-0.18	-0.13	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48698783	chr3:49260085~49261316:+
BRCA	cis	rs219780	0.898	rs219785	ENSG00000233818.1	AP000695.4	4.11	4.36e-05	0.00303	0.15	0.13	Kidney stones;	chr21:36459562	chr21:36445731~36532408:+
BRCA	cis	rs13401620	0.843	rs3106244	ENSG00000229326.3	AC069154.4	-4.11	4.36e-05	0.00303	-0.16	-0.13	Breast size;	chr2:119889606	chr2:119698623~119700151:+
BRCA	cis	rs8054556	0.656	rs4420550	ENSG00000183604.13	SMG1P5	-4.11	4.36e-05	0.00303	-0.12	-0.13	Autism spectrum disorder or schizophrenia;	chr16:29927499	chr16:30267553~30335374:-
BRCA	cis	rs253959	0.545	rs712588	ENSG00000271918.1	CTD-2287O16.5	-4.11	4.36e-05	0.00303	-0.1	-0.13	Bipolar disorder and schizophrenia;	chr5:116318908	chr5:116083807~116085416:-
BRCA	cis	rs1322639	0.614	rs9689800	ENSG00000223485.1	RP11-417E7.1	4.11	4.36e-05	0.00303	0.13	0.13	Pulse pressure;	chr6:169172850	chr6:169158092~169162924:-
BRCA	cis	rs6546324	0.625	rs11900280	ENSG00000236780.4	AC078941.1	4.11	4.36e-05	0.00303	0.22	0.13	Endometriosis;	chr2:67613269	chr2:67123357~67215319:-
BRCA	cis	rs6546324	0.625	rs2902025	ENSG00000236780.4	AC078941.1	4.11	4.36e-05	0.00303	0.22	0.13	Endometriosis;	chr2:67615292	chr2:67123357~67215319:-
BRCA	cis	rs13217239	0.646	rs7747454	ENSG00000224843.5	LINC00240	4.1	4.36e-05	0.00303	0.14	0.13	Schizophrenia;	chr6:27066474	chr6:26956992~27023924:+
BRCA	cis	rs10129255	0.5	rs12101190	ENSG00000254174.1	IGHV1-12	4.1	4.36e-05	0.00303	0.1	0.13	Kawasaki disease;	chr14:106784149	chr14:106122420~106122709:-
BRCA	cis	rs10129255	0.518	rs8004895	ENSG00000254174.1	IGHV1-12	4.1	4.36e-05	0.00303	0.1	0.13	Kawasaki disease;	chr14:106785139	chr14:106122420~106122709:-
BRCA	cis	rs10986311	0.609	rs10118498	ENSG00000227200.1	RP11-121A14.3	4.1	4.36e-05	0.00303	0.14	0.13	Vitiligo;	chr9:124297845	chr9:124262876~124265809:+
BRCA	cis	rs1538970	0.81	rs12067642	ENSG00000281133.1	AL355480.3	-4.1	4.36e-05	0.00303	-0.17	-0.13	Platelet count;	chr1:45461845	chr1:45580892~45580996:-
BRCA	cis	rs6088580	0.634	rs6088508	ENSG00000275784.1	RP5-1125A11.6	-4.1	4.36e-05	0.00303	-0.14	-0.13	Glomerular filtration rate (creatinine);	chr20:34472276	chr20:33989480~33991818:-
BRCA	cis	rs2243480	1	rs313809	ENSG00000222364.1	RNU6-96P	-4.1	4.36e-05	0.00303	-0.23	-0.13	Diabetic kidney disease;	chr7:66034996	chr7:66395191~66395286:+
BRCA	cis	rs1865760	1	rs6910174	ENSG00000272462.2	U91328.19	-4.1	4.36e-05	0.00303	-0.15	-0.13	Height;	chr6:25904186	chr6:25992662~26001775:+
BRCA	cis	rs2962370	0.842	rs2929726	ENSG00000215196.4	AC091878.1	-4.1	4.36e-05	0.00303	-0.15	-0.13	Bipolar disorder with mood-incongruent psychosis;	chr5:17211540	chr5:17130028~17217047:-
BRCA	cis	rs10761482	0.861	rs10740027	ENSG00000254271.1	RP11-131N11.4	4.1	4.36e-05	0.00303	0.18	0.13	Schizophrenia;	chr10:60399903	chr10:60734342~60741828:+
BRCA	cis	rs4698412	0.561	rs11729955	ENSG00000273133.1	RP11-799M12.2	4.1	4.37e-05	0.00303	0.15	0.13	Parkinson's disease;	chr4:15688009	chr4:15563698~15564253:-
BRCA	cis	rs308403	0.608	rs309362	ENSG00000224786.1	CETN4P	4.1	4.37e-05	0.00303	0.19	0.13	Blood protein levels;	chr4:122736999	chr4:122730548~122732193:-
BRCA	cis	rs2070615	0.525	rs10875876	ENSG00000257964.1	RP11-133N21.10	-4.1	4.37e-05	0.00304	-0.14	-0.13	Bipolar disorder;	chr12:48801606	chr12:49576840~49577505:-
BRCA	cis	rs2998286	0.862	rs1339704	ENSG00000237128.1	RP11-351M16.3	4.1	4.37e-05	0.00304	0.15	0.13	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28527400	chr10:28433008~28495813:-
BRCA	cis	rs7894407	0.594	rs1163238	ENSG00000213061.2	PFN1P11	-4.1	4.37e-05	0.00304	-0.17	-0.13	White matter hyperintensity burden;	chr10:103184236	chr10:102838011~102845473:-
BRCA	cis	rs1371614	0.545	rs3769136	ENSG00000272148.1	RP11-195B17.1	4.1	4.37e-05	0.00304	0.14	0.13	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26945875	chr2:27062428~27062907:-
BRCA	cis	rs11098499	0.863	rs59732491	ENSG00000250412.1	KLHL2P1	4.1	4.37e-05	0.00304	0.15	0.13	Corneal astigmatism;	chr4:119568433	chr4:119334329~119378233:+
BRCA	cis	rs11098499	0.863	rs11723090	ENSG00000250412.1	KLHL2P1	4.1	4.37e-05	0.00304	0.15	0.13	Corneal astigmatism;	chr4:119569437	chr4:119334329~119378233:+
BRCA	cis	rs7824557	0.569	rs35418978	ENSG00000255046.1	RP11-297N6.4	-4.1	4.37e-05	0.00304	-0.15	-0.13	Retinal vascular caliber;	chr8:11328944	chr8:11797928~11802568:-
BRCA	cis	rs7395581	0.918	rs326214	ENSG00000280615.1	Y_RNA	-4.1	4.37e-05	0.00304	-0.15	-0.13	HDL cholesterol;	chr11:47276809	chr11:47614898~47614994:-
BRCA	cis	rs7312933	0.592	rs1551210	ENSG00000257225.1	RP11-328C8.4	-4.1	4.37e-05	0.00304	-0.15	-0.13	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42472072	chr12:42459366~42466128:+
BRCA	cis	rs6546324	0.625	rs11126138	ENSG00000236780.4	AC078941.1	4.1	4.37e-05	0.00304	0.21	0.13	Endometriosis;	chr2:67567344	chr2:67123357~67215319:-
BRCA	cis	rs6546324	0.625	rs2861640	ENSG00000236780.4	AC078941.1	4.1	4.37e-05	0.00304	0.21	0.13	Endometriosis;	chr2:67567457	chr2:67123357~67215319:-
BRCA	cis	rs739401	0.588	rs10219272	ENSG00000183562.3	CTC-343N3.1	-4.1	4.37e-05	0.00304	-0.13	-0.13	Longevity;	chr11:2999559	chr11:2989863~2991344:+
BRCA	cis	rs739496	0.947	rs2285520	ENSG00000234608.6	MAPKAPK5-AS1	4.1	4.37e-05	0.00304	0.16	0.13	Platelet count;	chr12:111429683	chr12:111839764~111842902:-
BRCA	cis	rs4950322	0.518	rs4950306	ENSG00000227242.3	NBPF13P	-4.1	4.37e-05	0.00304	-0.18	-0.13	Protein quantitative trait loci;	chr1:147117838	chr1:147021320~147124525:-
BRCA	cis	rs2303319	0.504	rs58622044	ENSG00000227403.1	AC009299.3	4.1	4.37e-05	0.00304	0.3	0.13	Cognitive function;	chr2:161739777	chr2:161244739~161249050:+
BRCA	cis	rs2303319	0.504	rs56009150	ENSG00000227403.1	AC009299.3	4.1	4.37e-05	0.00304	0.3	0.13	Cognitive function;	chr2:161742072	chr2:161244739~161249050:+
BRCA	cis	rs2303319	0.504	rs62189055	ENSG00000227403.1	AC009299.3	4.1	4.37e-05	0.00304	0.3	0.13	Cognitive function;	chr2:161769239	chr2:161244739~161249050:+
BRCA	cis	rs11098499	0.908	rs1002152	ENSG00000225892.3	RP11-384K6.2	4.1	4.37e-05	0.00304	0.13	0.13	Corneal astigmatism;	chr4:119352232	chr4:118632274~118634759:+
BRCA	cis	rs11098403	0.833	rs4461585	ENSG00000225892.3	RP11-384K6.2	4.1	4.38e-05	0.00304	0.12	0.13	Schizophrenia;	chr4:117783765	chr4:118632274~118634759:+
BRCA	cis	rs1722141	0.601	rs788744	ENSG00000229628.1	AC073115.7	4.1	4.38e-05	0.00304	0.16	0.13	Sitting height ratio;	chr7:46028849	chr7:45990905~46000898:+
BRCA	cis	rs6480314	0.831	rs11813170	ENSG00000233590.1	RP11-153K11.3	-4.1	4.38e-05	0.00304	-0.21	-0.13	Optic nerve measurement (disc area);	chr10:68215366	chr10:68233251~68242379:-
BRCA	cis	rs10946940	0.965	rs10946935	ENSG00000219392.1	RP1-265C24.5	4.1	4.38e-05	0.00304	0.17	0.13	Systemic lupus erythematosus;	chr6:27533566	chr6:28115628~28116551:+
BRCA	cis	rs801193	1	rs3778909	ENSG00000265600.1	AC006480.1	-4.1	4.38e-05	0.00304	-0.15	-0.13	Aortic root size;	chr7:66790659	chr7:67356680~67356779:+
BRCA	cis	rs9381040	0.61	rs6941090	ENSG00000161912.16	ADCY10P1	4.1	4.38e-05	0.00304	0.14	0.13	Alzheimer's disease (late onset);	chr6:41075726	chr6:41101022~41140835:+
BRCA	cis	rs9381040	0.655	rs9381031	ENSG00000161912.16	ADCY10P1	4.1	4.38e-05	0.00304	0.14	0.13	Alzheimer's disease (late onset);	chr6:41077218	chr6:41101022~41140835:+
BRCA	cis	rs9381040	0.61	rs717883	ENSG00000161912.16	ADCY10P1	4.1	4.38e-05	0.00304	0.14	0.13	Alzheimer's disease (late onset);	chr6:41077531	chr6:41101022~41140835:+
BRCA	cis	rs9381040	0.61	rs2294694	ENSG00000161912.16	ADCY10P1	4.1	4.38e-05	0.00304	0.14	0.13	Alzheimer's disease (late onset);	chr6:41078438	chr6:41101022~41140835:+
BRCA	cis	rs3753275	0.628	rs4581300	ENSG00000270282.1	RP5-1115A15.2	-4.1	4.38e-05	0.00304	-0.19	-0.13	Educational attainment;	chr1:8550446	chr1:8512653~8513021:+
BRCA	cis	rs3812049	0.784	rs6889311	ENSG00000245937.6	LINC01184	4.1	4.38e-05	0.00304	0.17	0.13	Lymphocyte counts;Red cell distribution width;	chr5:128095593	chr5:127940426~128083172:-
BRCA	cis	rs983392	1	rs983392	ENSG00000275344.1	MIR6503	-4.1	4.38e-05	0.00304	-0.14	-0.13	Alzheimer's disease (late onset);	chr11:60156035	chr11:60209071~60209156:-
BRCA	cis	rs2243480	0.901	rs2456483	ENSG00000222364.1	RNU6-96P	-4.1	4.38e-05	0.00304	-0.23	-0.13	Diabetic kidney disease;	chr7:65996588	chr7:66395191~66395286:+
BRCA	cis	rs2243480	1	rs1701750	ENSG00000222364.1	RNU6-96P	-4.1	4.38e-05	0.00304	-0.23	-0.13	Diabetic kidney disease;	chr7:66002158	chr7:66395191~66395286:+
BRCA	cis	rs801193	1	rs2659906	ENSG00000223473.2	GS1-124K5.3	4.1	4.38e-05	0.00304	0.1	0.13	Aortic root size;	chr7:66700323	chr7:66491049~66493566:-
BRCA	cis	rs2731006	0.64	rs973001	ENSG00000257114.2	RP11-25I15.3	4.1	4.38e-05	0.00304	0.2	0.13	Panic disorder;	chr12:42786388	chr12:42692216~42717119:+
BRCA	cis	rs1153858	1	rs61365925	ENSG00000275672.1	GATM-AS1	-4.1	4.38e-05	0.00304	-0.16	-0.13	Homoarginine levels;	chr15:45358113	chr15:45378700~45380123:+
BRCA	cis	rs2115630	0.967	rs28595395	ENSG00000259728.4	LINC00933	-4.1	4.38e-05	0.00304	-0.14	-0.13	P wave terminal force;	chr15:84791721	chr15:84570649~84580175:+
BRCA	cis	rs6452524	0.836	rs10041617	ENSG00000281327.1	LINC01338	4.1	4.38e-05	0.00304	0.14	0.13	Hypertension (SNP x SNP interaction);	chr5:83096535	chr5:82850864~82859836:-
BRCA	cis	rs160451	0.966	rs12216864	ENSG00000251136.7	RP11-37B2.1	4.1	4.38e-05	0.00304	0.12	0.13	Leprosy;	chr8:89665895	chr8:89609409~89757727:-
BRCA	cis	rs10457838	0.783	rs10872630	ENSG00000236591.1	RP11-162J8.3	-4.1	4.38e-05	0.00305	-0.18	-0.13	Post-traumatic stress disorder;	chr6:149065820	chr6:149027700~149032573:-
BRCA	cis	rs970548	0.954	rs11239549	ENSG00000230869.1	CTGLF10P	4.1	4.38e-05	0.00305	0.15	0.13	Total cholesterol levels;HDL cholesterol;HDL cholesterol levels;Cholesterol, total;	chr10:45523383	chr10:45678692~45700532:+
BRCA	cis	rs11168618	0.875	rs11458	ENSG00000273765.1	RP11-370I10.11	4.1	4.39e-05	0.00305	0.15	0.13	Adiponectin levels;	chr12:48494811	chr12:48360920~48361377:+
BRCA	cis	rs1865760	1	rs3799372	ENSG00000272462.2	U91328.19	-4.1	4.39e-05	0.00305	-0.15	-0.13	Height;	chr6:25922083	chr6:25992662~26001775:+
BRCA	cis	rs1865760	0.963	rs1540273	ENSG00000272462.2	U91328.19	-4.1	4.39e-05	0.00305	-0.15	-0.13	Height;	chr6:25923930	chr6:25992662~26001775:+
BRCA	cis	rs1865760	1	rs9358895	ENSG00000272462.2	U91328.19	-4.1	4.39e-05	0.00305	-0.15	-0.13	Height;	chr6:25924427	chr6:25992662~26001775:+
BRCA	cis	rs875971	1	rs6957199	ENSG00000236529.1	RP13-254B10.1	4.1	4.39e-05	0.00305	0.14	0.13	Aortic root size;	chr7:66513532	chr7:65840212~65840596:+
BRCA	cis	rs17489649	1	rs6894052	ENSG00000271849.1	CTC-332L22.1	4.1	4.39e-05	0.00305	0.16	0.13	Intelligence (multi-trait analysis);	chr5:109844056	chr5:109687802~109688329:-
BRCA	cis	rs7475343	0.501	rs76669111	ENSG00000224034.1	RP11-445P17.8	-4.1	4.39e-05	0.00305	-0.24	-0.13	Intelligence;	chr10:5203817	chr10:5266033~5271236:-
BRCA	cis	rs13098911	0.54	rs34863575	ENSG00000223552.1	RP11-24F11.2	-4.1	4.39e-05	0.00305	-0.22	-0.13	Celiac disease;	chr3:46052571	chr3:46364955~46407059:-
BRCA	cis	rs911119	0.955	rs7265178	ENSG00000270001.1	RP11-218C14.8	-4.1	4.39e-05	0.00305	-0.16	-0.13	Chronic kidney disease;	chr20:23622745	chr20:23631826~23632316:-
BRCA	cis	rs890448	0.796	rs1549516	ENSG00000254531.1	FLJ20021	4.1	4.39e-05	0.00305	0.15	0.13	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101417585	chr4:101347780~101348883:+
BRCA	cis	rs2880765	0.805	rs11858817	ENSG00000202081.1	RNU6-1280P	4.1	4.39e-05	0.00305	0.14	0.13	Coronary artery disease;	chr15:85488029	chr15:85651522~85651628:-
BRCA	cis	rs2880765	0.835	rs28874135	ENSG00000202081.1	RNU6-1280P	4.1	4.39e-05	0.00305	0.14	0.13	Coronary artery disease;	chr15:85488272	chr15:85651522~85651628:-
BRCA	cis	rs2880765	0.835	rs11633604	ENSG00000202081.1	RNU6-1280P	4.1	4.39e-05	0.00305	0.14	0.13	Coronary artery disease;	chr15:85488348	chr15:85651522~85651628:-
BRCA	cis	rs56313388	0.505	rs11076146	ENSG00000246379.5	RP11-461O7.1	-4.1	4.39e-05	0.00305	-0.14	-0.13	Pulse pressure;	chr16:56227517	chr16:56092987~56191094:-
BRCA	cis	rs2911132	0.564	rs28580505	ENSG00000272109.1	CTD-2260A17.3	-4.1	4.39e-05	0.00305	-0.18	-0.13	Urate levels (BMI interaction);	chr5:96765516	chr5:96804353~96806105:+
BRCA	cis	rs736408	0.677	rs1042779	ENSG00000243224.1	RP5-1157M23.2	-4.1	4.39e-05	0.00305	-0.14	-0.13	Bipolar disorder;	chr3:52786995	chr3:52239258~52241097:+
BRCA	cis	rs12786942	1	rs36111323	ENSG00000254506.1	RP11-748H22.1	4.1	4.39e-05	0.00305	0.23	0.13	Facial depth;	chr11:101489019	chr11:101584295~101595156:+
BRCA	cis	rs7011507	0.563	rs10094801	ENSG00000233858.4	AC026904.1	-4.1	4.39e-05	0.00305	-0.16	-0.13	Inflammatory bowel disease;Ulcerative colitis;	chr8:48548032	chr8:48590401~48594621:+
BRCA	cis	rs4950322	0.58	rs7515160	ENSG00000237188.3	RP11-337C18.8	4.1	4.4e-05	0.00305	0.15	0.13	Protein quantitative trait loci;	chr1:147120714	chr1:147172771~147211568:+
BRCA	cis	rs6121246	0.738	rs2376996	ENSG00000230613.1	HM13-AS1	4.1	4.4e-05	0.00305	0.19	0.13	Mean corpuscular hemoglobin;	chr20:31728864	chr20:31567707~31573263:-
BRCA	cis	rs6121246	0.821	rs7265413	ENSG00000230613.1	HM13-AS1	4.1	4.4e-05	0.00305	0.19	0.13	Mean corpuscular hemoglobin;	chr20:31730120	chr20:31567707~31573263:-
BRCA	cis	rs2880765	0.566	rs11630381	ENSG00000259630.2	CTD-2262B20.1	-4.1	4.4e-05	0.00305	-0.16	-0.13	Coronary artery disease;	chr15:85469272	chr15:85415228~85415633:+
BRCA	cis	rs10800309	0.71	rs6427595	ENSG00000225217.1	HSPA7	4.1	4.4e-05	0.00305	0.15	0.13	Inflammatory bowel disease;Ulcerative colitis;	chr1:161493708	chr1:161606291~161608217:+
BRCA	cis	rs873549	0.959	rs10779467	ENSG00000227925.1	RP11-191N8.2	-4.1	4.4e-05	0.00305	-0.15	-0.13	Keloid;	chr1:222092288	chr1:221827666~221840666:-
BRCA	cis	rs11098499	1	rs13435802	ENSG00000250412.1	KLHL2P1	-4.1	4.4e-05	0.00306	-0.15	-0.13	Corneal astigmatism;	chr4:119256805	chr4:119334329~119378233:+
BRCA	cis	rs6686842	0.56	rs2802549	ENSG00000235358.1	RP11-399E6.1	4.1	4.4e-05	0.00306	0.17	0.13	Height;	chr1:41034874	chr1:41242373~41284861:+
BRCA	cis	rs7621331	1	rs13098245	ENSG00000239213.4	NCK1-AS1	4.1	4.4e-05	0.00306	0.14	0.13	Waist circumference adjusted for body mass index;	chr3:135994792	chr3:136841726~136862054:-
BRCA	cis	rs875971	1	rs2420591	ENSG00000236529.1	RP13-254B10.1	4.1	4.4e-05	0.00306	0.14	0.13	Aortic root size;	chr7:66447394	chr7:65840212~65840596:+
BRCA	cis	rs7267979	0.565	rs958075	ENSG00000277938.1	RP5-965G21.3	-4.1	4.4e-05	0.00306	-0.15	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25614487	chr20:25229150~25231933:+
BRCA	cis	rs7481584	0.624	rs412149	ENSG00000236710.1	AC108448.2	4.1	4.41e-05	0.00306	0.17	0.13	Calcium levels;	chr11:3048713	chr11:3084393~3085443:-
BRCA	cis	rs6964587	0.867	rs12704637	ENSG00000188693.7	CYP51A1-AS1	-4.1	4.41e-05	0.00306	-0.15	-0.13	Breast cancer;	chr7:92245372	chr7:92134604~92180725:+
BRCA	cis	rs12744310	0.83	rs12028010	ENSG00000235358.1	RP11-399E6.1	4.1	4.41e-05	0.00306	0.18	0.13	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41298799	chr1:41242373~41284861:+
BRCA	cis	rs752010	0.841	rs7519983	ENSG00000230638.4	RP11-486B10.4	-4.1	4.41e-05	0.00306	-0.15	-0.13	Lupus nephritis in systemic lupus erythematosus;	chr1:41617698	chr1:41542069~41544310:+
BRCA	cis	rs375066	0.935	rs429027	ENSG00000267191.1	RP11-15A1.2	-4.1	4.41e-05	0.00306	-0.16	-0.13	Breast cancer;	chr19:43891337	chr19:43902001~43926545:+
BRCA	cis	rs17695224	0.606	rs10411054	ENSG00000269483.1	AC006272.1	4.1	4.41e-05	0.00306	0.15	0.13	HDL cholesterol;HDL cholesterol levels;	chr19:51831208	chr19:51839924~51843324:-
BRCA	cis	rs748404	0.666	rs72709879	ENSG00000205771.5	CATSPER2P1	-4.1	4.41e-05	0.00306	-0.19	-0.13	Lung cancer;	chr15:43507777	chr15:43726918~43747094:-
BRCA	cis	rs8040855	0.599	rs2342123	ENSG00000259762.1	RP11-158M2.4	4.1	4.41e-05	0.00306	0.14	0.13	Bulimia nervosa;	chr15:85181918	chr15:85750336~85752901:-
BRCA	cis	rs61931739	0.534	rs10844791	ENSG00000258794.3	DUX4L27	4.1	4.41e-05	0.00306	0.18	0.13	Morning vs. evening chronotype;	chr12:34058724	chr12:34208415~34209675:-
BRCA	cis	rs2911132	0.506	rs1862609	ENSG00000272109.1	CTD-2260A17.3	-4.1	4.41e-05	0.00306	-0.18	-0.13	Urate levels (BMI interaction);	chr5:96750986	chr5:96804353~96806105:+
BRCA	cis	rs948562	0.681	rs78570565	ENSG00000255299.4	RP11-655C2.3	-4.1	4.41e-05	0.00306	-0.15	-0.13	Lymphoma;	chr11:58664597	chr11:58497888~58505758:-
BRCA	cis	rs7833790	0.963	rs2400473	ENSG00000254689.1	RP11-354A14.1	4.1	4.41e-05	0.00306	0.18	0.13	Diastolic blood pressure;	chr8:81791168	chr8:81885377~81923193:+
BRCA	cis	rs7577696	0.925	rs212695	ENSG00000276334.1	AL133243.1	4.1	4.41e-05	0.00306	0.16	0.13	Inflammatory biomarkers;	chr2:32215799	chr2:32521927~32523547:+
BRCA	cis	rs7267979	1	rs2500446	ENSG00000276952.1	RP5-965G21.6	-4.1	4.41e-05	0.00306	-0.16	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25359028	chr20:25284915~25285588:-
BRCA	cis	rs1005277	0.579	rs2800485	ENSG00000276805.1	RP11-291L22.6	4.1	4.41e-05	0.00306	0.14	0.13	Extrinsic epigenetic age acceleration;	chr10:38253660	chr10:38451030~38451785:+
BRCA	cis	rs2274459	0.841	rs3818532	ENSG00000249346.5	LINC01016	-4.1	4.41e-05	0.00306	-0.16	-0.13	Obesity (extreme);	chr6:33712030	chr6:33867506~33896914:-
BRCA	cis	rs453301	0.658	rs6983877	ENSG00000233609.3	RP11-62H7.2	-4.1	4.41e-05	0.00306	-0.12	-0.13	Joint mobility (Beighton score);	chr8:9047129	chr8:8961200~8979025:+
BRCA	cis	rs4143844	0.867	rs35168171	ENSG00000259251.2	RP11-643M14.1	4.1	4.41e-05	0.00306	0.31	0.13	Bipolar disorder and schizophrenia;	chr15:62060759	chr15:62060503~62062434:+
BRCA	cis	rs61931739	0.534	rs10844816	ENSG00000258794.3	DUX4L27	4.1	4.42e-05	0.00306	0.18	0.13	Morning vs. evening chronotype;	chr12:34095598	chr12:34208415~34209675:-
BRCA	cis	rs7267979	0.966	rs3002698	ENSG00000276952.1	RP5-965G21.6	-4.1	4.42e-05	0.00306	-0.15	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25322743	chr20:25284915~25285588:-
BRCA	cis	rs1722141	0.669	rs788732	ENSG00000229628.1	AC073115.7	4.1	4.42e-05	0.00306	0.17	0.13	Sitting height ratio;	chr7:45995450	chr7:45990905~46000898:+
BRCA	cis	rs6496932	0.563	rs2344083	ENSG00000259774.1	RP11-182J1.13	-4.1	4.42e-05	0.00307	-0.14	-0.13	Central corneal thickness;Corneal structure;	chr15:85354201	chr15:84422618~84425882:+
BRCA	cis	rs6490294	0.528	rs12422941	ENSG00000226469.1	ADAM1B	-4.1	4.42e-05	0.00307	-0.21	-0.13	Mean platelet volume;	chr12:112099934	chr12:111927018~111929017:+
BRCA	cis	rs6088580	0.634	rs6142153	ENSG00000276073.1	RP5-1125A11.7	4.1	4.42e-05	0.00307	0.14	0.13	Glomerular filtration rate (creatinine);	chr20:34380941	chr20:33985617~33988989:-
BRCA	cis	rs11742741	0.806	rs4701417	ENSG00000248874.4	C5orf17	-4.1	4.42e-05	0.00307	-0.16	-0.13	Educational attainment;	chr5:24013458	chr5:23951348~24178263:+
BRCA	cis	rs7746199	0.736	rs13212093	ENSG00000216901.1	AL022393.7	4.1	4.42e-05	0.00307	0.32	0.13	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27638937	chr6:28176188~28176674:+
BRCA	cis	rs7746199	0.736	rs34038546	ENSG00000216901.1	AL022393.7	4.1	4.42e-05	0.00307	0.32	0.13	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27639881	chr6:28176188~28176674:+
BRCA	cis	rs141342723	1	rs141342723	ENSG00000216901.1	AL022393.7	4.1	4.42e-05	0.00307	0.32	0.13	Autism spectrum disorder or schizophrenia;	chr6:27654305	chr6:28176188~28176674:+
BRCA	cis	rs7746199	0.736	rs34543938	ENSG00000216901.1	AL022393.7	4.1	4.42e-05	0.00307	0.32	0.13	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27656861	chr6:28176188~28176674:+
BRCA	cis	rs7746199	0.736	rs56405707	ENSG00000216901.1	AL022393.7	4.1	4.42e-05	0.00307	0.32	0.13	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27672467	chr6:28176188~28176674:+
BRCA	cis	rs10463316	0.823	rs7700340	ENSG00000260581.1	CTB-113P19.4	4.1	4.42e-05	0.00307	0.15	0.13	Metabolite levels (Pyroglutamine);	chr5:151396759	chr5:151652275~151655449:+
BRCA	cis	rs1008375	1	rs12507142	ENSG00000249502.1	AC006160.5	-4.1	4.42e-05	0.00307	-0.14	-0.13	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17654480	chr4:17587467~17614571:-
BRCA	cis	rs6847067	0.794	rs6531782	ENSG00000180769.7	WDFY3-AS2	-4.1	4.42e-05	0.00307	-0.11	-0.13	Oropharynx cancer;	chr4:85007246	chr4:84965682~85011277:+
BRCA	cis	rs2832191	1	rs2832189	ENSG00000232855.5	AF131217.1	4.1	4.42e-05	0.00307	0.15	0.13	Dental caries;	chr21:29115093	chr21:28439346~28674848:-
BRCA	cis	rs9921338	0.961	rs57579443	ENSG00000262703.1	RP11-485G7.6	-4.1	4.42e-05	0.00307	-0.15	-0.13	Vein graft stenosis in coronary artery bypass grafting;	chr16:11349140	chr16:11348143~11349321:-
BRCA	cis	rs10266483	0.774	rs642909	ENSG00000271550.1	BNIP3P11	4.1	4.42e-05	0.00307	0.17	0.13	Response to statin therapy;	chr7:64309943	chr7:64678954~64687393:-
BRCA	cis	rs801193	1	rs3800812	ENSG00000223473.2	GS1-124K5.3	4.1	4.42e-05	0.00307	0.1	0.13	Aortic root size;	chr7:66758474	chr7:66491049~66493566:-
BRCA	cis	rs801193	1	rs4279493	ENSG00000223473.2	GS1-124K5.3	4.1	4.42e-05	0.00307	0.1	0.13	Aortic root size;	chr7:66761633	chr7:66491049~66493566:-
BRCA	cis	rs875971	0.66	rs6460308	ENSG00000232546.1	RP11-458F8.1	4.1	4.42e-05	0.00307	0.11	0.13	Aortic root size;	chr7:66619753	chr7:66848496~66858136:+
BRCA	cis	rs10458771	0.667	rs79680561	ENSG00000227896.2	RP11-77P6.2	4.1	4.42e-05	0.00307	0.2	0.13	Amyotrophic lateral sclerosis (sporadic);	chr10:86453968	chr10:86521945~86525101:+
BRCA	cis	rs4664293	1	rs12692554	ENSG00000224152.1	AC009506.1	-4.1	4.42e-05	0.00307	-0.14	-0.13	Monocyte percentage of white cells;	chr2:159594777	chr2:159615296~159617082:+
BRCA	cis	rs9650657	0.537	rs11250092	ENSG00000255020.1	AF131216.5	-4.1	4.42e-05	0.00307	-0.15	-0.13	Neuroticism;	chr8:10929033	chr8:11345748~11347502:-
BRCA	cis	rs9992667	0.829	rs337628	ENSG00000231160.8	KLF3-AS1	4.1	4.42e-05	0.00307	0.14	0.13	Eosinophil percentage of granulocytes;	chr4:38633523	chr4:38612701~38664883:-
BRCA	cis	rs10181042	0.535	rs2441465	ENSG00000273302.1	RP11-493E12.2	4.1	4.42e-05	0.00307	0.11	0.13	Crohn's disease;	chr2:61084052	chr2:61199979~61200769:+
BRCA	cis	rs11035577	0.632	rs991293	ENSG00000279675.1	RP11-454H19.2	4.1	4.42e-05	0.00307	0.2	0.13	Temperament (bipolar disorder);	chr11:39778522	chr11:40107244~40112599:-
BRCA	cis	rs3748682	0.861	rs2291297	ENSG00000252448.1	SNORA63	-4.1	4.42e-05	0.00307	-0.16	-0.13	Hypothyroidism;	chr1:37806988	chr1:37884237~37884317:+
BRCA	cis	rs61931739	0.517	rs10844815	ENSG00000258794.3	DUX4L27	4.1	4.43e-05	0.00307	0.18	0.13	Morning vs. evening chronotype;	chr12:34092215	chr12:34208415~34209675:-
BRCA	cis	rs7208859	0.673	rs9889755	ENSG00000214719.10	AC005562.1	4.1	4.43e-05	0.00307	0.21	0.13	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30907487	chr17:30576464~30672789:+
BRCA	cis	rs875971	1	rs2420168	ENSG00000229180.5	GS1-124K5.11	-4.1	4.43e-05	0.00307	-0.11	-0.13	Aortic root size;	chr7:66165644	chr7:66526088~66542624:-
BRCA	cis	rs17695224	0.565	rs61681419	ENSG00000269483.1	AC006272.1	4.1	4.43e-05	0.00307	0.15	0.13	HDL cholesterol;HDL cholesterol levels;	chr19:51830726	chr19:51839924~51843324:-
BRCA	cis	rs17695224	0.545	rs13346095	ENSG00000269483.1	AC006272.1	4.1	4.43e-05	0.00307	0.15	0.13	HDL cholesterol;HDL cholesterol levels;	chr19:51831092	chr19:51839924~51843324:-
BRCA	cis	rs1371614	0.592	rs12613534	ENSG00000229122.1	AGBL5-IT1	-4.1	4.43e-05	0.00307	-0.13	-0.13	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26915726	chr2:27061038~27061815:+
BRCA	cis	rs8040855	0.658	rs11634877	ENSG00000259774.1	RP11-182J1.13	4.1	4.43e-05	0.00307	0.17	0.13	Bulimia nervosa;	chr15:85068246	chr15:84422618~84425882:+
BRCA	cis	rs8040855	0.627	rs11632175	ENSG00000259774.1	RP11-182J1.13	4.1	4.43e-05	0.00307	0.17	0.13	Bulimia nervosa;	chr15:85068449	chr15:84422618~84425882:+
BRCA	cis	rs7267979	1	rs2482937	ENSG00000276952.1	RP5-965G21.6	-4.1	4.43e-05	0.00307	-0.16	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25360150	chr20:25284915~25285588:-
BRCA	cis	rs2412819	0.571	rs7174260	ENSG00000166763.7	STRCP1	4.1	4.43e-05	0.00307	0.19	0.13	Lung cancer;	chr15:43751988	chr15:43699488~43718184:-
BRCA	cis	rs7656342	0.93	rs1829413	ENSG00000250342.1	SNRPCP16	-4.1	4.43e-05	0.00307	-0.15	-0.13	Gut microbiota (bacterial taxa);	chr4:9790715	chr4:9051842~9052051:-
BRCA	cis	rs57221529	0.655	rs11948381	ENSG00000225138.6	CTD-2228K2.7	4.1	4.43e-05	0.00307	0.18	0.13	Lung disease severity in cystic fibrosis;	chr5:568298	chr5:473236~480884:+
BRCA	cis	rs1040	0.646	rs6422750	ENSG00000226445.1	XXyac-YX65C7_A.2	-4.1	4.43e-05	0.00308	-0.13	-0.13	Joint mobility (Beighton score);	chr6:169206088	chr6:169213254~169239565:+
BRCA	cis	rs4664293	0.625	rs4665102	ENSG00000226266.5	AC009961.3	4.1	4.43e-05	0.00308	0.15	0.13	Monocyte percentage of white cells;	chr2:159666076	chr2:159670708~159712435:-
BRCA	cis	rs733592	0.931	rs765260	ENSG00000273765.1	RP11-370I10.11	-4.1	4.43e-05	0.00308	-0.14	-0.13	Plateletcrit;	chr12:48038153	chr12:48360920~48361377:+
BRCA	cis	rs7267979	0.903	rs2474766	ENSG00000276952.1	RP5-965G21.6	4.1	4.43e-05	0.00308	0.15	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25265517	chr20:25284915~25285588:-
BRCA	cis	rs7267979	0.903	rs2474769	ENSG00000276952.1	RP5-965G21.6	4.1	4.43e-05	0.00308	0.15	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25268089	chr20:25284915~25285588:-
BRCA	cis	rs34217772	0.699	rs12432265	ENSG00000258636.1	CTD-2298J14.2	4.1	4.44e-05	0.00308	0.17	0.13	Myopia;	chr14:41843491	chr14:41587861~41604856:-
BRCA	cis	rs875971	0.929	rs10950041	ENSG00000265600.1	AC006480.1	-4.1	4.44e-05	0.00308	-0.15	-0.13	Aortic root size;	chr7:66508888	chr7:67356680~67356779:+
BRCA	cis	rs886774	0.967	rs1017056	ENSG00000273055.1	CTB-13F3.1	-4.1	4.44e-05	0.00308	-0.13	-0.13	Ulcerative colitis;	chr7:107853538	chr7:107942116~107942740:+
BRCA	cis	rs11051970	0.879	rs10844201	ENSG00000274964.1	RP11-817I4.1	-4.1	4.44e-05	0.00308	-0.15	-0.13	Response to tocilizumab in rheumatoid arthritis;	chr12:32422095	chr12:32339368~32340724:+
BRCA	cis	rs8180040	0.726	rs7610636	ENSG00000260236.1	RP11-708J19.1	-4.1	4.44e-05	0.00308	-0.11	-0.13	Colorectal cancer;	chr3:47022946	chr3:47379089~47380999:-
BRCA	cis	rs17027633	1	rs75755924	ENSG00000260948.1	RP11-552M11.8	-4.1	4.44e-05	0.00308	-0.29	-0.13	Cerebrospinal fluid t-tau:AB1-42 ratio;	chr1:111406197	chr1:111431046~111433068:-
BRCA	cis	rs2624839	0.704	rs2624838	ENSG00000228008.1	CTD-2330K9.3	4.1	4.44e-05	0.00308	0.13	0.13	Intelligence (multi-trait analysis);	chr3:50168209	chr3:49903845~49916937:+
BRCA	cis	rs7620503	0.625	rs7620805	ENSG00000228221.4	LINC00578	4.1	4.44e-05	0.00308	0.16	0.13	Corneal structure;	chr3:177586637	chr3:177441921~177752305:+
BRCA	cis	rs721917	0.506	rs2819100	ENSG00000242600.5	MBL1P	4.1	4.44e-05	0.00308	0.15	0.13	Chronic obstructive pulmonary disease;	chr10:79937163	chr10:79904898~79950336:+
BRCA	cis	rs7572733	0.935	rs1401093	ENSG00000231621.1	AC013264.2	4.1	4.44e-05	0.00308	0.12	0.13	Dermatomyositis;	chr2:197915115	chr2:197197991~197199273:+
BRCA	cis	rs7572733	0.935	rs1401094	ENSG00000231621.1	AC013264.2	4.1	4.44e-05	0.00308	0.12	0.13	Dermatomyositis;	chr2:197915125	chr2:197197991~197199273:+
BRCA	cis	rs4869313	0.905	rs251341	ENSG00000248734.2	CTD-2260A17.1	-4.1	4.44e-05	0.00308	-0.13	-0.13	Pediatric autoimmune diseases;	chr5:96900916	chr5:96784777~96785999:+
BRCA	cis	rs7011507	0.589	rs72639043	ENSG00000233858.4	AC026904.1	-4.1	4.44e-05	0.00308	-0.16	-0.13	Inflammatory bowel disease;Ulcerative colitis;	chr8:48481877	chr8:48590401~48594621:+
BRCA	cis	rs7011507	0.589	rs7817656	ENSG00000233858.4	AC026904.1	-4.1	4.44e-05	0.00308	-0.16	-0.13	Inflammatory bowel disease;Ulcerative colitis;	chr8:48482993	chr8:48590401~48594621:+
BRCA	cis	rs7011507	0.589	rs11774421	ENSG00000233858.4	AC026904.1	-4.1	4.44e-05	0.00308	-0.16	-0.13	Inflammatory bowel disease;Ulcerative colitis;	chr8:48483428	chr8:48590401~48594621:+
BRCA	cis	rs4834770	1	rs10034579	ENSG00000250412.1	KLHL2P1	4.1	4.44e-05	0.00308	0.14	0.13	Blood protein levels;	chr4:119322874	chr4:119334329~119378233:+
BRCA	cis	rs721917	0.525	rs10788338	ENSG00000278616.1	BEND3P3	-4.1	4.44e-05	0.00308	-0.12	-0.13	Chronic obstructive pulmonary disease;	chr10:79973266	chr10:79682997~79685436:+
BRCA	cis	rs6547741	1	rs6750943	ENSG00000234072.1	AC074117.10	4.1	4.44e-05	0.00308	0.12	0.13	Oral cavity cancer;	chr2:27555037	chr2:27356246~27367622:+
BRCA	cis	rs7746199	0.736	rs58616630	ENSG00000216901.1	AL022393.7	4.1	4.45e-05	0.00308	0.32	0.13	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27506936	chr6:28176188~28176674:+
BRCA	cis	rs860295	0.756	rs7546258	ENSG00000225855.5	RUSC1-AS1	4.1	4.45e-05	0.00308	0.1	0.13	Body mass index;	chr1:155728854	chr1:155316863~155324176:-
BRCA	cis	rs4561483	0.801	rs33631	ENSG00000261216.1	RP11-166B2.5	-4.1	4.45e-05	0.00308	-0.15	-0.13	Testicular germ cell tumor;	chr16:11901530	chr16:11908208~11908916:+
BRCA	cis	rs10129255	0.5	rs6576225	ENSG00000254174.1	IGHV1-12	4.1	4.45e-05	0.00308	0.1	0.13	Kawasaki disease;	chr14:106778120	chr14:106122420~106122709:-
BRCA	cis	rs10129255	0.5	rs6576226	ENSG00000254174.1	IGHV1-12	4.1	4.45e-05	0.00308	0.1	0.13	Kawasaki disease;	chr14:106778135	chr14:106122420~106122709:-
BRCA	cis	rs8180040	0.593	rs4018905	ENSG00000271161.1	BOLA2P2	4.1	4.45e-05	0.00308	0.13	0.13	Colorectal cancer;	chr3:47096680	chr3:47499841~47500407:+
BRCA	cis	rs748404	0.666	rs17780417	ENSG00000205771.5	CATSPER2P1	-4.1	4.45e-05	0.00308	-0.19	-0.13	Lung cancer;	chr15:43347264	chr15:43726918~43747094:-
BRCA	cis	rs10129255	0.5	rs34326748	ENSG00000254174.1	IGHV1-12	4.1	4.45e-05	0.00308	0.1	0.13	Kawasaki disease;	chr14:106782523	chr14:106122420~106122709:-
BRCA	cis	rs10129255	0.5	rs10143385	ENSG00000254174.1	IGHV1-12	4.1	4.45e-05	0.00308	0.1	0.13	Kawasaki disease;	chr14:106782559	chr14:106122420~106122709:-
BRCA	cis	rs9291059	1	rs9291059	ENSG00000236297.1	RP11-175P19.2	4.1	4.45e-05	0.00308	0.26	0.13	Depressive symptoms (multi-trait analysis);	chr3:193627166	chr3:193578812~193593090:-
BRCA	cis	rs911119	1	rs911119	ENSG00000270001.1	RP11-218C14.8	4.1	4.45e-05	0.00308	0.16	0.13	Chronic kidney disease;	chr20:23632100	chr20:23631826~23632316:-
BRCA	cis	rs739496	0.947	rs12580300	ENSG00000234608.6	MAPKAPK5-AS1	4.1	4.45e-05	0.00308	0.15	0.13	Platelet count;	chr12:111411467	chr12:111839764~111842902:-
BRCA	cis	rs739496	0.947	rs7973120	ENSG00000234608.6	MAPKAPK5-AS1	4.1	4.45e-05	0.00308	0.15	0.13	Platelet count;	chr12:111418934	chr12:111839764~111842902:-
BRCA	cis	rs11098499	0.722	rs28713555	ENSG00000260091.1	RP11-33B1.4	-4.1	4.45e-05	0.00309	-0.11	-0.13	Corneal astigmatism;	chr4:119330840	chr4:119409333~119410233:+
BRCA	cis	rs7656342	0.964	rs56139970	ENSG00000250342.1	SNRPCP16	-4.1	4.45e-05	0.00309	-0.15	-0.13	Gut microbiota (bacterial taxa);	chr4:9800648	chr4:9051842~9052051:-
BRCA	cis	rs6546324	0.625	rs2902024	ENSG00000236780.4	AC078941.1	4.1	4.45e-05	0.00309	0.2	0.13	Endometriosis;	chr2:67609586	chr2:67123357~67215319:-
BRCA	cis	rs6546324	0.58	rs2861684	ENSG00000236780.4	AC078941.1	4.1	4.45e-05	0.00309	0.2	0.13	Endometriosis;	chr2:67610248	chr2:67123357~67215319:-
BRCA	cis	rs739496	0.947	rs28362508	ENSG00000234608.6	MAPKAPK5-AS1	4.1	4.45e-05	0.00309	0.16	0.13	Platelet count;	chr12:111446611	chr12:111839764~111842902:-
BRCA	cis	rs4237845	0.537	rs7312623	ENSG00000257159.1	RP11-58A17.3	4.1	4.45e-05	0.00309	0.16	0.13	Intelligence (multi-trait analysis);	chr12:57868740	chr12:57967058~57968399:+
BRCA	cis	rs9733	0.818	rs7520022	ENSG00000203804.4	ADAMTSL4-AS1	-4.1	4.45e-05	0.00309	-0.13	-0.13	Tonsillectomy;	chr1:150686697	chr1:150560202~150574552:-
BRCA	cis	rs11742741	0.806	rs72745711	ENSG00000248874.4	C5orf17	-4.1	4.45e-05	0.00309	-0.16	-0.13	Educational attainment;	chr5:24019430	chr5:23951348~24178263:+
BRCA	cis	rs11742741	0.806	rs62349708	ENSG00000248874.4	C5orf17	-4.1	4.45e-05	0.00309	-0.16	-0.13	Educational attainment;	chr5:24019528	chr5:23951348~24178263:+
BRCA	cis	rs8054556	0.692	rs4424923	ENSG00000183604.13	SMG1P5	-4.1	4.45e-05	0.00309	-0.12	-0.13	Autism spectrum disorder or schizophrenia;	chr16:29927972	chr16:30267553~30335374:-
BRCA	cis	rs2227564	0.678	rs2242256	ENSG00000242288.9	RP11-464F9.1	-4.1	4.45e-05	0.00309	-0.17	-0.13	Crohn's disease;Inflammatory bowel disease;	chr10:73837788	chr10:73674295~73730466:-
BRCA	cis	rs2227564	0.678	rs2242257	ENSG00000242288.9	RP11-464F9.1	-4.1	4.45e-05	0.00309	-0.17	-0.13	Crohn's disease;Inflammatory bowel disease;	chr10:73837847	chr10:73674295~73730466:-
BRCA	cis	rs9513627	0.915	rs7327204	ENSG00000228889.5	UBAC2-AS1	-4.1	4.45e-05	0.00309	-0.23	-0.13	Obesity-related traits;	chr13:99474698	chr13:99196377~99200710:-
BRCA	cis	rs7412746	0.611	rs2256355	ENSG00000231073.1	RP11-316M1.3	4.1	4.45e-05	0.00309	0.13	0.13	Melanoma;	chr1:150839318	chr1:150973123~150975534:+
BRCA	cis	rs7915131	1	rs7086136	ENSG00000238280.1	RP11-436D10.3	4.1	4.45e-05	0.00309	0.16	0.13	Schizophrenia;	chr10:62650312	chr10:62793562~62805887:-
BRCA	cis	rs7915131	1	rs7068361	ENSG00000238280.1	RP11-436D10.3	4.1	4.45e-05	0.00309	0.16	0.13	Schizophrenia;	chr10:62648607	chr10:62793562~62805887:-
BRCA	cis	rs2832191	0.74	rs2832177	ENSG00000215533.7	LINC00189	4.1	4.46e-05	0.00309	0.14	0.13	Dental caries;	chr21:29106032	chr21:29193480~29288205:+
BRCA	cis	rs5758659	0.652	rs129857	ENSG00000182057.4	OGFRP1	-4.1	4.46e-05	0.00309	-0.14	-0.13	Cognitive function;	chr22:42003682	chr22:42269753~42275196:+
BRCA	cis	rs9308731	0.591	rs55878194	ENSG00000230499.1	AC108463.1	-4.1	4.46e-05	0.00309	-0.14	-0.13	Chronic lymphocytic leukemia;	chr2:111182897	chr2:111195963~111206494:+
BRCA	cis	rs2505998	0.871	rs2505990	ENSG00000273008.1	RP11-351D16.3	-4.1	4.46e-05	0.00309	-0.16	-0.13	Hirschsprung disease;	chr10:43069900	chr10:43136824~43138334:-
BRCA	cis	rs6686842	0.798	rs12037263	ENSG00000235358.1	RP11-399E6.1	4.1	4.46e-05	0.00309	0.16	0.13	Height;	chr1:41016828	chr1:41242373~41284861:+
BRCA	cis	rs934734	0.532	rs55792977	ENSG00000204929.10	AC074391.1	-4.1	4.46e-05	0.00309	-0.15	-0.13	Rheumatoid arthritis;	chr2:65423730	chr2:65436711~66084639:+
BRCA	cis	rs11098499	0.955	rs13113112	ENSG00000250412.1	KLHL2P1	4.1	4.46e-05	0.00309	0.15	0.13	Corneal astigmatism;	chr4:119234885	chr4:119334329~119378233:+
BRCA	cis	rs10129255	0.5	rs6576231	ENSG00000254174.1	IGHV1-12	4.1	4.46e-05	0.00309	0.1	0.13	Kawasaki disease;	chr14:106783693	chr14:106122420~106122709:-
BRCA	cis	rs17027633	1	rs1343349	ENSG00000260948.1	RP11-552M11.8	-4.1	4.46e-05	0.00309	-0.29	-0.13	Cerebrospinal fluid t-tau:AB1-42 ratio;	chr1:111406665	chr1:111431046~111433068:-
BRCA	cis	rs11098499	0.908	rs28559989	ENSG00000260404.2	RP11-384K6.6	4.1	4.46e-05	0.00309	0.12	0.13	Corneal astigmatism;	chr4:119465472	chr4:118591773~118633729:+
BRCA	cis	rs12571093	0.571	rs10740295	ENSG00000233590.1	RP11-153K11.3	4.1	4.46e-05	0.00309	0.19	0.13	Optic nerve measurement (disc area);	chr10:68304313	chr10:68233251~68242379:-
BRCA	cis	rs3845817	0.703	rs702888	ENSG00000237979.1	AC007389.1	4.1	4.46e-05	0.00309	0.15	0.13	Bipolar disorder;	chr2:65527905	chr2:65500993~65502138:-
BRCA	cis	rs2039553	0.574	rs2248413	ENSG00000227354.5	RBM26-AS1	4.1	4.46e-05	0.00309	0.14	0.13	Pancreatic cancer;	chr13:79746028	chr13:79406309~79424328:+
BRCA	cis	rs875971	0.964	rs778723	ENSG00000265600.1	AC006480.1	-4.1	4.46e-05	0.00309	-0.15	-0.13	Aortic root size;	chr7:66364510	chr7:67356680~67356779:+
BRCA	cis	rs6496932	1	rs35796484	ENSG00000259295.5	CSPG4P12	4.1	4.46e-05	0.00309	0.2	0.13	Central corneal thickness;Corneal structure;	chr15:85282019	chr15:85191438~85213905:+
BRCA	cis	rs4494364	0.502	rs887920	ENSG00000258100.1	RP11-121E16.1	4.1	4.46e-05	0.00309	0.18	0.13	Systolic blood pressure (alcohol consumption interaction);	chr12:91035105	chr12:91362196~91368606:+
BRCA	cis	rs10777288	0.561	rs7312958	ENSG00000258100.1	RP11-121E16.1	4.1	4.46e-05	0.00309	0.18	0.13	Pulmonary function (smoking interaction);	chr12:91035165	chr12:91362196~91368606:+
BRCA	cis	rs4767841	0.935	rs2285595	ENSG00000248636.5	RP11-768F21.1	4.1	4.46e-05	0.00309	0.16	0.13	Urgency urinary incontinence;	chr12:119718603	chr12:119387987~119668079:-
BRCA	cis	rs8114671	0.967	rs6142322	ENSG00000279253.1	RP4-614O4.13	4.1	4.46e-05	0.00309	0.14	0.13	Height;	chr20:35200735	chr20:35262727~35264187:-
BRCA	cis	rs911119	0.818	rs12625182	ENSG00000270001.1	RP11-218C14.8	-4.1	4.47e-05	0.00309	-0.16	-0.13	Chronic kidney disease;	chr20:23623386	chr20:23631826~23632316:-
BRCA	cis	rs2839186	0.706	rs2839188	ENSG00000228137.1	AP001469.7	4.1	4.47e-05	0.00309	0.13	0.13	Testicular germ cell tumor;	chr21:46272884	chr21:46246890~46247682:+
BRCA	cis	rs2749592	0.531	rs1208559	ENSG00000263064.2	RP11-291L22.7	-4.1	4.47e-05	0.00309	-0.16	-0.13	Age-related hearing impairment (SNP x SNP interaction);	chr10:37932442	chr10:38448689~38448949:+
BRCA	cis	rs7800418	0.784	rs2190188	ENSG00000214870.7	AC004540.5	-4.1	4.47e-05	0.0031	-0.16	-0.13	Cognitive function;	chr7:26546250	chr7:26398593~26494256:+
BRCA	cis	rs6570726	0.935	rs449377	ENSG00000270638.1	RP3-466P17.1	4.1	4.47e-05	0.0031	0.14	0.13	Lobe attachment (rater-scored or self-reported);	chr6:145531301	chr6:145735570~145737218:+
BRCA	cis	rs72843506	0.528	rs73981803	ENSG00000270091.1	RP11-78O7.2	-4.1	4.47e-05	0.0031	-0.19	-0.13	Schizophrenia;	chr17:20088952	chr17:19896590~19897287:-
BRCA	cis	rs890448	0.796	rs2433311	ENSG00000254531.1	FLJ20021	4.1	4.47e-05	0.0031	0.15	0.13	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101434778	chr4:101347780~101348883:+
BRCA	cis	rs2391285	0.609	rs1859601	ENSG00000280255.1	RP5-1007F24.1	4.1	4.47e-05	0.0031	0.17	0.13	Post bronchodilator FEV1/FVC ratio;	chr7:26551238	chr7:26538378~26541048:+
BRCA	cis	rs3764563	1	rs681417	ENSG00000267594.5	CYP4F24P	4.1	4.47e-05	0.0031	0.24	0.13	Inflammatory biomarkers;	chr19:15583991	chr19:15760241~15779909:-
BRCA	cis	rs897984	0.683	rs72799316	ENSG00000275263.1	RP11-1072A3.4	-4.1	4.47e-05	0.0031	-0.15	-0.13	Dementia with Lewy bodies;	chr16:30815884	chr16:30956872~30957199:-
BRCA	cis	rs11168618	0.904	rs10875829	ENSG00000273765.1	RP11-370I10.11	4.1	4.47e-05	0.0031	0.14	0.13	Adiponectin levels;	chr12:48533414	chr12:48360920~48361377:+
BRCA	cis	rs6593122	0.755	rs61553944	ENSG00000235454.1	HAUS6P3	-4.1	4.47e-05	0.0031	-0.17	-0.13	Vaccine-related adverse events;	chr7:54131734	chr7:53862233~53863339:+
BRCA	cis	rs2688608	0.592	rs10762560	ENSG00000213731.2	RAB5CP1	-4.1	4.47e-05	0.0031	-0.14	-0.13	Inflammatory bowel disease;	chr10:73735647	chr10:74423435~74424014:-
BRCA	cis	rs6496932	1	rs11638110	ENSG00000259774.1	RP11-182J1.13	4.1	4.47e-05	0.0031	0.19	0.13	Central corneal thickness;Corneal structure;	chr15:85279653	chr15:84422618~84425882:+
BRCA	cis	rs1670533	0.872	rs10017931	ENSG00000251639.2	RP11-20I20.1	4.1	4.47e-05	0.0031	0.19	0.13	Recombination rate (females);	chr4:1066959	chr4:1100016~1101558:-
BRCA	cis	rs1429524	1	rs1429524	ENSG00000243144.5	RP11-115N4.1	-4.1	4.47e-05	0.0031	-0.16	-0.13	Ejection fraction in Tripanosoma cruzi seropositivity;	chr7:91314953	chr7:91311368~91515409:+
BRCA	cis	rs12612619	0.732	rs1465881	ENSG00000272148.1	RP11-195B17.1	4.1	4.47e-05	0.0031	0.14	0.13	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27014746	chr2:27062428~27062907:-
BRCA	cis	rs8016982	0.855	rs10149681	ENSG00000258999.1	RP11-114N19.3	4.1	4.47e-05	0.0031	0.16	0.13	Schizophrenia;	chr14:81219975	chr14:81107033~81170414:-
BRCA	cis	rs6545883	0.965	rs1992765	ENSG00000270820.4	RP11-355B11.2	4.1	4.47e-05	0.0031	0.14	0.13	Tuberculosis;	chr2:61524198	chr2:61471188~61484130:+
BRCA	cis	rs7011507	0.589	rs1910252	ENSG00000233858.4	AC026904.1	-4.1	4.47e-05	0.0031	-0.16	-0.13	Inflammatory bowel disease;Ulcerative colitis;	chr8:48494802	chr8:48590401~48594621:+
BRCA	cis	rs739496	0.579	rs3782885	ENSG00000257624.1	RP1-128M12.3	4.1	4.47e-05	0.0031	0.17	0.13	Platelet count;	chr12:111844779	chr12:112000739~112000985:-
BRCA	cis	rs739496	0.579	rs11066046	ENSG00000257624.1	RP1-128M12.3	4.1	4.47e-05	0.0031	0.17	0.13	Platelet count;	chr12:111846077	chr12:112000739~112000985:-
BRCA	cis	rs739496	0.579	rs2158030	ENSG00000257624.1	RP1-128M12.3	4.1	4.47e-05	0.0031	0.17	0.13	Platelet count;	chr12:111847787	chr12:112000739~112000985:-
BRCA	cis	rs6490294	0.799	rs7315642	ENSG00000257624.1	RP1-128M12.3	4.1	4.47e-05	0.0031	0.17	0.13	Mean platelet volume;	chr12:111848992	chr12:112000739~112000985:-
BRCA	cis	rs739496	0.579	rs12302040	ENSG00000257624.1	RP1-128M12.3	4.1	4.47e-05	0.0031	0.17	0.13	Platelet count;	chr12:111850375	chr12:112000739~112000985:-
BRCA	cis	rs739496	0.579	rs12322899	ENSG00000257624.1	RP1-128M12.3	4.1	4.47e-05	0.0031	0.17	0.13	Platelet count;	chr12:111850398	chr12:112000739~112000985:-
BRCA	cis	rs739496	0.579	rs12307192	ENSG00000257624.1	RP1-128M12.3	4.1	4.47e-05	0.0031	0.17	0.13	Platelet count;	chr12:111852542	chr12:112000739~112000985:-
BRCA	cis	rs739496	0.579	rs12307365	ENSG00000257624.1	RP1-128M12.3	4.1	4.47e-05	0.0031	0.17	0.13	Platelet count;	chr12:111852847	chr12:112000739~112000985:-
BRCA	cis	rs739496	0.579	rs6489817	ENSG00000257624.1	RP1-128M12.3	4.1	4.47e-05	0.0031	0.17	0.13	Platelet count;	chr12:111853438	chr12:112000739~112000985:-
BRCA	cis	rs739496	0.579	rs7296199	ENSG00000257624.1	RP1-128M12.3	4.1	4.47e-05	0.0031	0.17	0.13	Platelet count;	chr12:111854040	chr12:112000739~112000985:-
BRCA	cis	rs739496	0.579	rs12313385	ENSG00000257624.1	RP1-128M12.3	4.1	4.47e-05	0.0031	0.17	0.13	Platelet count;	chr12:111854343	chr12:112000739~112000985:-
BRCA	cis	rs739496	0.579	rs7310605	ENSG00000257624.1	RP1-128M12.3	4.1	4.47e-05	0.0031	0.17	0.13	Platelet count;	chr12:111854666	chr12:112000739~112000985:-
BRCA	cis	rs739496	0.579	rs57427612	ENSG00000257624.1	RP1-128M12.3	4.1	4.47e-05	0.0031	0.17	0.13	Platelet count;	chr12:111856192	chr12:112000739~112000985:-
BRCA	cis	rs739496	0.579	rs7976557	ENSG00000257624.1	RP1-128M12.3	4.1	4.47e-05	0.0031	0.17	0.13	Platelet count;	chr12:111862976	chr12:112000739~112000985:-
BRCA	cis	rs739496	0.579	rs11066054	ENSG00000257624.1	RP1-128M12.3	4.1	4.47e-05	0.0031	0.17	0.13	Platelet count;	chr12:111868361	chr12:112000739~112000985:-
BRCA	cis	rs739496	0.579	rs7297760	ENSG00000257624.1	RP1-128M12.3	4.1	4.47e-05	0.0031	0.17	0.13	Platelet count;	chr12:111875884	chr12:112000739~112000985:-
BRCA	cis	rs6490294	0.799	rs12426566	ENSG00000257624.1	RP1-128M12.3	4.1	4.47e-05	0.0031	0.17	0.13	Mean platelet volume;	chr12:111877368	chr12:112000739~112000985:-
BRCA	cis	rs739496	0.527	rs2097701	ENSG00000257624.1	RP1-128M12.3	4.1	4.47e-05	0.0031	0.17	0.13	Platelet count;	chr12:111878970	chr12:112000739~112000985:-
BRCA	cis	rs739496	0.579	rs7294623	ENSG00000257624.1	RP1-128M12.3	4.1	4.47e-05	0.0031	0.17	0.13	Platelet count;	chr12:111879292	chr12:112000739~112000985:-
BRCA	cis	rs11098499	0.954	rs10017371	ENSG00000225892.3	RP11-384K6.2	4.1	4.47e-05	0.0031	0.13	0.13	Corneal astigmatism;	chr4:119372621	chr4:118632274~118634759:+
BRCA	cis	rs6012564	1	rs2273653	ENSG00000227431.4	CSE1L-AS1	4.1	4.48e-05	0.0031	0.16	0.13	Anger;	chr20:49154219	chr20:49040463~49046044:-
BRCA	cis	rs1008375	0.8	rs62296338	ENSG00000249502.1	AC006160.5	-4.1	4.48e-05	0.0031	-0.15	-0.13	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17611802	chr4:17587467~17614571:-
BRCA	cis	rs1910358	0.554	rs1568457	ENSG00000248874.4	C5orf17	4.1	4.48e-05	0.0031	0.18	0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23756914	chr5:23951348~24178263:+
BRCA	cis	rs74233809	1	rs3740390	ENSG00000236937.2	PTGES3P4	4.1	4.48e-05	0.0031	0.26	0.13	Birth weight;	chr10:102878723	chr10:102845595~102845950:+
BRCA	cis	rs1153858	1	rs12437840	ENSG00000275672.1	GATM-AS1	-4.1	4.48e-05	0.0031	-0.16	-0.13	Homoarginine levels;	chr15:45376857	chr15:45378700~45380123:+
BRCA	cis	rs56322409	1	rs61871793	ENSG00000226688.5	ENTPD1-AS1	4.1	4.48e-05	0.0031	0.15	0.13	Blood metabolite levels;	chr10:95647981	chr10:95753206~96090238:-
BRCA	cis	rs8040855	0.547	rs17611171	ENSG00000230373.7	GOLGA6L5P	4.1	4.48e-05	0.0031	0.16	0.13	Bulimia nervosa;	chr15:85029468	chr15:84507885~84516814:-
BRCA	cis	rs9863	0.861	rs4405410	ENSG00000270028.1	RP11-380L11.4	4.1	4.48e-05	0.0031	0.16	0.13	White blood cell count;	chr12:123951241	chr12:123925461~123926083:-
BRCA	cis	rs2562456	0.917	rs10420016	ENSG00000268119.4	CTD-2561J22.5	-4.1	4.48e-05	0.0031	-0.19	-0.13	Pain;	chr19:21505800	chr19:21444241~21463908:-
BRCA	cis	rs372883	0.6	rs2832294	ENSG00000176054.6	RPL23P2	4.1	4.48e-05	0.00311	0.14	0.13	Pancreatic cancer;	chr21:29367350	chr21:28997613~28998033:-
BRCA	cis	rs372883	0.6	rs2832295	ENSG00000176054.6	RPL23P2	4.1	4.48e-05	0.00311	0.14	0.13	Pancreatic cancer;	chr21:29367522	chr21:28997613~28998033:-
BRCA	cis	rs7005380	0.965	rs11988434	ENSG00000245330.4	KB-1471A8.1	-4.1	4.48e-05	0.00311	-0.17	-0.13	Interstitial lung disease;	chr8:119932982	chr8:119867419~119874488:-
BRCA	cis	rs7005380	1	rs11995536	ENSG00000245330.4	KB-1471A8.1	-4.1	4.48e-05	0.00311	-0.17	-0.13	Interstitial lung disease;	chr8:119933028	chr8:119867419~119874488:-
BRCA	cis	rs4699052	0.739	rs6836157	ENSG00000248740.4	RP11-328K4.1	4.1	4.48e-05	0.00311	0.14	0.13	Testicular germ cell tumor;	chr4:103321833	chr4:103256159~103453658:+
BRCA	cis	rs11951515	0.508	rs10059993	ENSG00000248240.1	RP11-159F24.5	-4.1	4.48e-05	0.00311	-0.15	-0.13	Metabolite levels  (X-11787);	chr5:43598250	chr5:43515274~43525310:+
BRCA	cis	rs6751744	0.924	rs13386318	ENSG00000224152.1	AC009506.1	-4.1	4.48e-05	0.00311	-0.15	-0.13	Dysphagia;	chr2:159541846	chr2:159615296~159617082:+
BRCA	cis	rs7487075	0.93	rs4768121	ENSG00000274723.1	RP11-618L22.1	4.1	4.48e-05	0.00311	0.15	0.13	Itch intensity from mosquito bite;	chr12:46436069	chr12:46970504~46972155:+
BRCA	cis	rs75422866	0.867	rs7304743	ENSG00000280054.1	RP1-197B17.7	-4.1	4.49e-05	0.00311	-0.27	-0.13	Pneumonia;	chr12:47683658	chr12:47728151~47730598:-
BRCA	cis	rs2640806	0.505	rs11996832	ENSG00000253105.4	KB-1448A5.1	4.1	4.49e-05	0.00311	0.15	0.13	Obesity-related traits;	chr8:96353584	chr8:96371865~96387438:-
BRCA	cis	rs6991838	0.612	rs7842162	ENSG00000272155.1	RP11-707M3.3	-4.1	4.49e-05	0.00311	-0.12	-0.13	Intelligence (multi-trait analysis);	chr8:65644057	chr8:65714334~65714778:-
BRCA	cis	rs890448	0.796	rs7690316	ENSG00000254531.1	FLJ20021	4.1	4.49e-05	0.00311	0.15	0.13	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101417949	chr4:101347780~101348883:+
BRCA	cis	rs875971	1	rs7781698	ENSG00000265600.1	AC006480.1	-4.1	4.49e-05	0.00311	-0.15	-0.13	Aortic root size;	chr7:66431325	chr7:67356680~67356779:+
BRCA	cis	rs6545883	0.859	rs2600661	ENSG00000212978.6	AC016747.3	-4.1	4.49e-05	0.00311	-0.17	-0.13	Tuberculosis;	chr2:61315946	chr2:61141592~61144969:-
BRCA	cis	rs2243480	1	rs34560516	ENSG00000226002.1	RP11-460N20.5	-4.1	4.49e-05	0.00311	-0.21	-0.13	Diabetic kidney disease;	chr7:65939105	chr7:65084103~65100232:+
BRCA	cis	rs9921338	0.887	rs7189044	ENSG00000262703.1	RP11-485G7.6	-4.1	4.49e-05	0.00311	-0.15	-0.13	Vein graft stenosis in coronary artery bypass grafting;	chr16:11348339	chr16:11348143~11349321:-
BRCA	cis	rs2562456	0.652	rs62110214	ENSG00000240522.1	RPL7AP10	-4.1	4.49e-05	0.00311	-0.15	-0.13	Pain;	chr19:21592406	chr19:21149648~21150438:-
BRCA	cis	rs853679	0.517	rs36078605	ENSG00000261839.1	RP1-265C24.8	4.1	4.49e-05	0.00311	0.17	0.13	Depression;	chr6:28110254	chr6:28136849~28139678:+
BRCA	cis	rs6593122	0.71	rs961809	ENSG00000235454.1	HAUS6P3	-4.1	4.49e-05	0.00311	-0.17	-0.13	Vaccine-related adverse events;	chr7:54131392	chr7:53862233~53863339:+
BRCA	cis	rs2911132	0.621	rs28432918	ENSG00000272109.1	CTD-2260A17.3	-4.1	4.49e-05	0.00311	-0.18	-0.13	Urate levels (BMI interaction);	chr5:96765522	chr5:96804353~96806105:+
BRCA	cis	rs11098499	0.58	rs12509234	ENSG00000260404.2	RP11-384K6.6	4.1	4.49e-05	0.00311	0.12	0.13	Corneal astigmatism;	chr4:119398279	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.909	rs10014719	ENSG00000260404.2	RP11-384K6.6	4.1	4.49e-05	0.00311	0.12	0.13	Corneal astigmatism;	chr4:119399560	chr4:118591773~118633729:+
BRCA	cis	rs7267979	1	rs6083805	ENSG00000125804.12	FAM182A	4.1	4.49e-05	0.00311	0.16	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25336720	chr20:26054655~26086917:+
BRCA	cis	rs745109	0.882	rs55828608	ENSG00000273080.1	RP11-301O19.1	4.1	4.49e-05	0.00311	0.2	0.13	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86452421	chr2:86195590~86196049:+
BRCA	cis	rs745109	0.882	rs72930362	ENSG00000273080.1	RP11-301O19.1	4.1	4.49e-05	0.00311	0.2	0.13	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86453739	chr2:86195590~86196049:+
BRCA	cis	rs7474896	0.513	rs12357232	ENSG00000272983.1	RP11-508N22.12	4.1	4.49e-05	0.00311	0.23	0.13	Obesity (extreme);	chr10:37553520	chr10:38137337~38144399:+
BRCA	cis	rs75422866	0.867	rs7303895	ENSG00000280054.1	RP1-197B17.7	4.1	4.49e-05	0.00311	0.28	0.13	Pneumonia;	chr12:47683290	chr12:47728151~47730598:-
BRCA	cis	rs6867032	0.527	rs4246752	ENSG00000248994.1	RP11-259O2.1	-4.1	4.49e-05	0.00311	-0.18	-0.13	Gut microbiome composition (winter);	chr5:1975461	chr5:1933863~1959176:+
BRCA	cis	rs853679	0.882	rs9380069	ENSG00000280107.1	AL022393.9	-4.1	4.49e-05	0.00311	-0.24	-0.13	Depression;	chr6:28235522	chr6:28170845~28172521:+
BRCA	cis	rs9307551	0.6	rs1440857	ENSG00000250334.4	LINC00989	-4.1	4.49e-05	0.00311	-0.16	-0.13	Refractive error;	chr4:79616866	chr4:79492416~79576460:+
BRCA	cis	rs516805	0.528	rs2816088	ENSG00000279114.1	RP3-425C14.5	-4.1	4.49e-05	0.00311	-0.15	-0.13	Lymphocyte counts;	chr6:122081706	chr6:122471923~122484161:+
BRCA	cis	rs1048886	0.872	rs55639214	ENSG00000271967.1	RP11-134K13.4	-4.1	4.5e-05	0.00311	-0.19	-0.13	Type 2 diabetes;	chr6:70577494	chr6:70596438~70596980:+
BRCA	cis	rs1048886	0.872	rs56114703	ENSG00000271967.1	RP11-134K13.4	-4.1	4.5e-05	0.00311	-0.19	-0.13	Type 2 diabetes;	chr6:70577594	chr6:70596438~70596980:+
BRCA	cis	rs10266483	0.774	rs10949894	ENSG00000271550.1	BNIP3P11	-4.1	4.5e-05	0.00311	-0.17	-0.13	Response to statin therapy;	chr7:64340143	chr7:64678954~64687393:-
BRCA	cis	rs73201462	1	rs11706908	ENSG00000242551.2	POU5F1P6	4.1	4.5e-05	0.00311	0.21	0.13	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128314205	chr3:128674735~128677005:-
BRCA	cis	rs7829975	0.624	rs7823056	ENSG00000253981.4	ALG1L13P	4.1	4.5e-05	0.00311	0.14	0.13	Mood instability;	chr8:8525195	chr8:8236003~8244667:-
BRCA	cis	rs6545883	0.894	rs7572603	ENSG00000212978.6	AC016747.3	-4.1	4.5e-05	0.00311	-0.17	-0.13	Tuberculosis;	chr2:61325010	chr2:61141592~61144969:-
BRCA	cis	rs4302906	0.964	rs7875497	ENSG00000187984.11	ANKRD19P	-4.1	4.5e-05	0.00311	-0.11	-0.13	Lobe attachment (rater-scored or self-reported);	chr9:92986535	chr9:92809388~92888693:+
BRCA	cis	rs6545883	0.825	rs4672426	ENSG00000273302.1	RP11-493E12.2	-4.1	4.5e-05	0.00312	-0.12	-0.13	Tuberculosis;	chr2:61230013	chr2:61199979~61200769:+
BRCA	cis	rs6545883	0.86	rs4671399	ENSG00000273302.1	RP11-493E12.2	-4.1	4.5e-05	0.00312	-0.12	-0.13	Tuberculosis;	chr2:61231383	chr2:61199979~61200769:+
BRCA	cis	rs1440410	0.735	rs893929	ENSG00000250326.1	RP11-284M14.1	-4.1	4.5e-05	0.00312	-0.14	-0.13	Ischemic stroke;	chr4:143266227	chr4:142933195~143184861:-
BRCA	cis	rs7592578	0.64	rs56127319	ENSG00000272979.1	RP11-647K16.1	-4.1	4.5e-05	0.00312	-0.2	-0.13	Diastolic blood pressure;	chr2:190431703	chr2:190454092~190454521:-
BRCA	cis	rs1730008	1	rs1193513	ENSG00000279311.1	RP11-170K4.2	-4.1	4.5e-05	0.00312	-0.15	-0.13	Lobe attachment (rater-scored or self-reported);	chr3:158307596	chr3:158869898~158871821:+
BRCA	cis	rs2880765	0.743	rs6497194	ENSG00000202081.1	RNU6-1280P	4.1	4.5e-05	0.00312	0.15	0.13	Coronary artery disease;	chr15:85470885	chr15:85651522~85651628:-
BRCA	cis	rs748404	1	rs12911132	ENSG00000205771.5	CATSPER2P1	-4.1	4.5e-05	0.00312	-0.18	-0.13	Lung cancer;	chr15:43268238	chr15:43726918~43747094:-
BRCA	cis	rs7395581	0.918	rs10838693	ENSG00000280615.1	Y_RNA	4.1	4.5e-05	0.00312	0.15	0.13	HDL cholesterol;	chr11:47329002	chr11:47614898~47614994:-
BRCA	cis	rs300703	0.542	rs300691	ENSG00000228643.1	AC079779.4	-4.1	4.5e-05	0.00312	-0.2	-0.13	Blood protein levels;	chr2:180171	chr2:286419~301515:+
BRCA	cis	rs9840812	0.639	rs610860	ENSG00000273486.1	RP11-731C17.2	4.1	4.5e-05	0.00312	0.18	0.13	Fibrinogen levels;	chr3:136333974	chr3:136837338~136839021:-
BRCA	cis	rs4925540	0.962	rs7547915	ENSG00000215796.3	RP11-551G24.2	-4.1	4.51e-05	0.00312	-0.15	-0.13	Response to taxane treatment (docetaxel);	chr1:247040304	chr1:247042791~247044021:+
BRCA	cis	rs2662776	1	rs2999967	ENSG00000232995.6	RGS5	-4.1	4.51e-05	0.00312	-0.13	-0.13	Lead levels in blood;	chr1:163196886	chr1:163244505~163321894:-
BRCA	cis	rs61160187	0.582	rs4642318	ENSG00000272308.1	RP11-231G3.1	-4.1	4.51e-05	0.00312	-0.14	-0.13	Educational attainment (years of education);Educational attainment (college completion);	chr5:60996931	chr5:60866457~60866935:-
BRCA	cis	rs1075265	0.62	rs10192626	ENSG00000272156.1	RP11-477N3.1	-4.1	4.51e-05	0.00312	-0.13	-0.13	Chronotype;Morning vs. evening chronotype;	chr2:53760885	chr2:54082554~54085066:+
BRCA	cis	rs6452524	0.935	rs10045744	ENSG00000281327.1	LINC01338	4.1	4.51e-05	0.00312	0.14	0.13	Hypertension (SNP x SNP interaction);	chr5:83113688	chr5:82850864~82859836:-
BRCA	cis	rs875971	0.545	rs221986	ENSG00000273142.1	RP11-458F8.4	-4.1	4.51e-05	0.00312	-0.13	-0.13	Aortic root size;	chr7:66105323	chr7:66902857~66906297:+
BRCA	cis	rs1008375	1	rs17507481	ENSG00000249502.1	AC006160.5	-4.1	4.51e-05	0.00312	-0.14	-0.13	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17618443	chr4:17587467~17614571:-
BRCA	cis	rs7811142	0.72	rs112622797	ENSG00000078319.8	PMS2P1	-4.1	4.51e-05	0.00312	-0.22	-0.13	Platelet count;	chr7:100319793	chr7:100320992~100341908:-
BRCA	cis	rs304029	0.512	rs11130036	ENSG00000231249.1	ITPR1-AS1	4.1	4.51e-05	0.00312	0.16	0.13	Diabetic kidney disease;	chr3:4501779	chr3:4490891~4493163:-
BRCA	cis	rs4834770	0.718	rs4833618	ENSG00000248280.1	RP11-33B1.2	-4.1	4.51e-05	0.00312	-0.12	-0.13	Blood protein levels;	chr4:119388345	chr4:119440561~119450157:-
BRCA	cis	rs274567	0.599	rs11242110	ENSG00000233006.5	AC034220.3	-4.1	4.51e-05	0.00312	-0.09	-0.13	Blood metabolite levels;	chr5:132408085	chr5:132311285~132369916:-
BRCA	cis	rs4478858	0.684	rs4949369	ENSG00000260386.4	LINC01225	-4.1	4.51e-05	0.00312	-0.15	-0.13	Alcohol dependence;	chr1:31250998	chr1:31500085~31540885:+
BRCA	cis	rs17772222	0.958	rs12436326	ENSG00000258789.1	RP11-507K2.3	-4.1	4.52e-05	0.00313	-0.15	-0.13	Coronary artery calcification;	chr14:88533632	chr14:88551597~88552493:+
BRCA	cis	rs6840360	0.582	rs1372976	ENSG00000251611.1	RP11-610P16.1	-4.1	4.52e-05	0.00313	-0.11	-0.13	Intelligence (multi-trait analysis);	chr4:151530301	chr4:151407551~151408835:-
BRCA	cis	rs739496	0.579	rs7488629	ENSG00000257624.1	RP1-128M12.3	4.1	4.52e-05	0.00313	0.17	0.13	Platelet count;	chr12:111835696	chr12:112000739~112000985:-
BRCA	cis	rs6490294	0.748	rs73422316	ENSG00000257624.1	RP1-128M12.3	4.1	4.52e-05	0.00313	0.17	0.13	Mean platelet volume;	chr12:111835870	chr12:112000739~112000985:-
BRCA	cis	rs4699052	0.625	rs1850321	ENSG00000248740.4	RP11-328K4.1	4.1	4.52e-05	0.00313	0.14	0.13	Testicular germ cell tumor;	chr4:103331608	chr4:103256159~103453658:+
BRCA	cis	rs1910358	0.554	rs10472507	ENSG00000248874.4	C5orf17	-4.1	4.52e-05	0.00313	-0.18	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr5:23751209	chr5:23951348~24178263:+
BRCA	cis	rs34773007	0.542	rs66536955	ENSG00000232709.1	MARK2P9	4.1	4.52e-05	0.00313	0.17	0.13	Type 2 diabetes;	chr10:92977910	chr10:92418667~92420875:+
BRCA	cis	rs4143844	0.867	rs36004142	ENSG00000259251.2	RP11-643M14.1	4.1	4.52e-05	0.00313	0.31	0.13	Bipolar disorder and schizophrenia;	chr15:61940042	chr15:62060503~62062434:+
BRCA	cis	rs4143844	0.867	rs12905103	ENSG00000259251.2	RP11-643M14.1	4.1	4.52e-05	0.00313	0.31	0.13	Bipolar disorder and schizophrenia;	chr15:61940083	chr15:62060503~62062434:+
BRCA	cis	rs4143844	0.867	rs12905403	ENSG00000259251.2	RP11-643M14.1	4.1	4.52e-05	0.00313	0.31	0.13	Bipolar disorder and schizophrenia;	chr15:61940109	chr15:62060503~62062434:+
BRCA	cis	rs801193	1	rs2659912	ENSG00000223473.2	GS1-124K5.3	4.1	4.52e-05	0.00313	0.1	0.13	Aortic root size;	chr7:66693012	chr7:66491049~66493566:-
BRCA	cis	rs8130944	1	rs2269148	ENSG00000225731.1	AP001627.1	4.1	4.52e-05	0.00313	0.14	0.13	Perceived unattractiveness to mosquitoes;	chr21:42721144	chr21:42733594~42741758:-
BRCA	cis	rs17489649	1	rs2300989	ENSG00000271849.1	CTC-332L22.1	4.1	4.52e-05	0.00313	0.16	0.13	Intelligence (multi-trait analysis);	chr5:109697123	chr5:109687802~109688329:-
BRCA	cis	rs703842	1	rs10877012	ENSG00000270039.1	RP11-571M6.17	-4.1	4.52e-05	0.00313	-0.18	-0.13	Multiple sclerosis;	chr12:57768302	chr12:57803838~57804415:+
BRCA	cis	rs6545883	0.524	rs2463101	ENSG00000270820.4	RP11-355B11.2	-4.1	4.52e-05	0.00313	-0.14	-0.13	Tuberculosis;	chr2:61347287	chr2:61471188~61484130:+
BRCA	cis	rs78487399	0.808	rs74608713	ENSG00000234936.1	AC010883.5	4.1	4.52e-05	0.00313	0.18	0.13	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43536400	chr2:43229573~43233394:+
BRCA	cis	rs8130944	0.856	rs4919998	ENSG00000225731.1	AP001627.1	4.1	4.52e-05	0.00313	0.14	0.13	Perceived unattractiveness to mosquitoes;	chr21:42721490	chr21:42733594~42741758:-
BRCA	cis	rs11098499	0.908	rs28499576	ENSG00000250412.1	KLHL2P1	4.1	4.52e-05	0.00313	0.15	0.13	Corneal astigmatism;	chr4:119465522	chr4:119334329~119378233:+
BRCA	cis	rs8114671	0.836	rs6142294	ENSG00000126005.14	MMP24-AS1	4.1	4.52e-05	0.00313	0.15	0.13	Height;	chr20:35083694	chr20:35216462~35278131:-
BRCA	cis	rs6496932	0.503	rs7170085	ENSG00000259630.2	CTD-2262B20.1	-4.1	4.52e-05	0.00313	-0.18	-0.13	Central corneal thickness;Corneal structure;	chr15:85403879	chr15:85415228~85415633:+
BRCA	cis	rs4589258	1	rs10741371	ENSG00000280367.1	RP11-121L10.2	4.1	4.52e-05	0.00313	0.15	0.13	Intelligence (multi-trait analysis);	chr11:90766985	chr11:90223153~90226538:+
BRCA	cis	rs6759004	1	rs6759004	ENSG00000238829.1	RNU7-45P	-4.1	4.53e-05	0.00313	-0.19	-0.13	Triptolide cytotoxicity;	chr2:201139953	chr2:201141904~201141966:+
BRCA	cis	rs2625529	0.652	rs2957740	ENSG00000260037.4	CTD-2524L6.3	4.1	4.53e-05	0.00313	0.16	0.13	Red blood cell count;	chr15:72015350	chr15:71818396~71823384:+
BRCA	cis	rs11955398	0.502	rs290513	ENSG00000272308.1	RP11-231G3.1	-4.1	4.53e-05	0.00313	-0.15	-0.13	Intelligence (multi-trait analysis);	chr5:61014936	chr5:60866457~60866935:-
BRCA	cis	rs11955398	0.502	rs248688	ENSG00000272308.1	RP11-231G3.1	-4.1	4.53e-05	0.00313	-0.15	-0.13	Intelligence (multi-trait analysis);	chr5:61021606	chr5:60866457~60866935:-
BRCA	cis	rs7267979	0.934	rs2257464	ENSG00000274973.1	RP13-401N8.7	-4.1	4.53e-05	0.00313	-0.14	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25285236	chr20:25845497~25845862:+
BRCA	cis	rs6431644	0.725	rs12692249	ENSG00000224287.2	MSL3P1	4.1	4.53e-05	0.00313	0.15	0.13	Left atrial antero-posterior diameter;	chr2:233863084	chr2:233865437~233868444:-
BRCA	cis	rs6600671	1	rs10794671	ENSG00000275131.1	CH17-472G23.4	-4.1	4.53e-05	0.00313	-0.12	-0.13	Hip geometry;	chr1:121426382	chr1:120489625~120579190:-
BRCA	cis	rs9309473	0.528	rs7573275	ENSG00000163016.8	ALMS1P	4.1	4.53e-05	0.00314	0.16	0.13	Metabolite levels;	chr2:73325414	chr2:73644919~73685576:+
BRCA	cis	rs1430193	0.543	rs934273	ENSG00000272606.1	RP11-554J4.1	4.1	4.53e-05	0.00314	0.14	0.13	Lung function (forced vital capacity);	chr2:55897149	chr2:55617909~55618373:+
BRCA	cis	rs7267979	1	rs8125868	ENSG00000125804.12	FAM182A	4.1	4.53e-05	0.00314	0.16	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25343774	chr20:26054655~26086917:+
BRCA	cis	rs6545883	0.86	rs6545848	ENSG00000273302.1	RP11-493E12.2	-4.1	4.53e-05	0.00314	-0.12	-0.13	Tuberculosis;	chr2:61234048	chr2:61199979~61200769:+
BRCA	cis	rs728616	0.867	rs4633405	ENSG00000242600.5	MBL1P	4.1	4.53e-05	0.00314	0.3	0.13	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80167690	chr10:79904898~79950336:+
BRCA	cis	rs12049351	0.774	rs34551512	ENSG00000229367.1	HMGN2P19	4.1	4.53e-05	0.00314	0.19	0.13	Circulating myeloperoxidase levels (plasma);	chr1:229483141	chr1:229570532~229570796:+
BRCA	cis	rs957448	0.561	rs34471170	ENSG00000261437.1	RP11-22C11.2	4.1	4.53e-05	0.00314	0.12	0.13	Nonsyndromic cleft lip with cleft palate;	chr8:94601135	chr8:94637285~94639467:-
BRCA	cis	rs957448	0.561	rs9642927	ENSG00000261437.1	RP11-22C11.2	4.1	4.53e-05	0.00314	0.12	0.13	Nonsyndromic cleft lip with cleft palate;	chr8:94601414	chr8:94637285~94639467:-
BRCA	cis	rs2243480	1	rs1167613	ENSG00000226002.1	RP11-460N20.5	-4.1	4.53e-05	0.00314	-0.21	-0.13	Diabetic kidney disease;	chr7:66022452	chr7:65084103~65100232:+
BRCA	cis	rs2243480	1	rs313799	ENSG00000226002.1	RP11-460N20.5	-4.1	4.53e-05	0.00314	-0.21	-0.13	Diabetic kidney disease;	chr7:66029343	chr7:65084103~65100232:+
BRCA	cis	rs490234	0.702	rs13284551	ENSG00000232630.1	PRPS1P2	-4.1	4.53e-05	0.00314	-0.13	-0.13	Mean arterial pressure;	chr9:125649690	chr9:125150653~125151589:+
BRCA	cis	rs73201462	1	rs16844002	ENSG00000242551.2	POU5F1P6	4.1	4.53e-05	0.00314	0.2	0.13	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128334644	chr3:128674735~128677005:-
BRCA	cis	rs6452524	1	rs11740478	ENSG00000281327.1	LINC01338	4.1	4.53e-05	0.00314	0.14	0.13	Hypertension (SNP x SNP interaction);	chr5:83150567	chr5:82850864~82859836:-
BRCA	cis	rs8048589	0.604	rs11646584	ENSG00000175604.2	RP11-276H1.3	-4.1	4.53e-05	0.00314	-0.21	-0.13	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);	chr16:12114118	chr16:12086746~12090302:-
BRCA	cis	rs875971	1	rs6945843	ENSG00000236529.1	RP13-254B10.1	-4.1	4.54e-05	0.00314	-0.14	-0.13	Aortic root size;	chr7:66269796	chr7:65840212~65840596:+
BRCA	cis	rs2749592	0.505	rs7915670	ENSG00000099251.13	HSD17B7P2	-4.1	4.54e-05	0.00314	-0.14	-0.13	Age-related hearing impairment (SNP x SNP interaction);	chr10:37581284	chr10:38356380~38378505:+
BRCA	cis	rs3750552	0.66	rs6559472	ENSG00000278910.2	BANCR	-4.1	4.54e-05	0.00314	-0.18	-0.13	Bipolar disorder;	chr9:69330960	chr9:69296682~69306977:-
BRCA	cis	rs2108622	0.727	rs8104311	ENSG00000267218.2	AC005336.5	4.1	4.54e-05	0.00314	0.15	0.13	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871950	chr19:15902300~15903238:-
BRCA	cis	rs375066	0.935	rs373168	ENSG00000267191.1	RP11-15A1.2	-4.1	4.54e-05	0.00314	-0.16	-0.13	Breast cancer;	chr19:43926717	chr19:43902001~43926545:+
BRCA	cis	rs4664293	0.625	rs11899419	ENSG00000224152.1	AC009506.1	4.1	4.54e-05	0.00314	0.13	0.13	Monocyte percentage of white cells;	chr2:159688858	chr2:159615296~159617082:+
BRCA	cis	rs2243480	1	rs313807	ENSG00000226002.1	RP11-460N20.5	-4.1	4.54e-05	0.00314	-0.21	-0.13	Diabetic kidney disease;	chr7:66034494	chr7:65084103~65100232:+
BRCA	cis	rs1549733	0.577	rs2373081	ENSG00000229754.1	CXCR2P1	-4.1	4.54e-05	0.00314	-0.12	-0.13	Optic disc area;	chr2:217560579	chr2:218059155~218065729:-
BRCA	cis	rs2243480	1	rs35432774	ENSG00000226002.1	RP11-460N20.5	-4.1	4.54e-05	0.00314	-0.2	-0.13	Diabetic kidney disease;	chr7:65928032	chr7:65084103~65100232:+
BRCA	cis	rs1005277	0.579	rs176886	ENSG00000272983.1	RP11-508N22.12	4.1	4.54e-05	0.00314	0.13	0.13	Extrinsic epigenetic age acceleration;	chr10:38115046	chr10:38137337~38144399:+
BRCA	cis	rs1005277	0.557	rs176887	ENSG00000272983.1	RP11-508N22.12	4.1	4.54e-05	0.00314	0.13	0.13	Extrinsic epigenetic age acceleration;	chr10:38117166	chr10:38137337~38144399:+
BRCA	cis	rs4578769	0.765	rs60721147	ENSG00000265939.1	UBE2CP2	-4.1	4.54e-05	0.00314	-0.16	-0.13	Eosinophil percentage of white cells;	chr18:22848569	chr18:22900486~22900995:-
BRCA	cis	rs6546324	0.625	rs6746394	ENSG00000236780.4	AC078941.1	4.1	4.54e-05	0.00314	0.22	0.13	Endometriosis;	chr2:67617889	chr2:67123357~67215319:-
BRCA	cis	rs7572733	0.935	rs2217837	ENSG00000231621.1	AC013264.2	-4.1	4.54e-05	0.00314	-0.12	-0.13	Dermatomyositis;	chr2:197881535	chr2:197197991~197199273:+
BRCA	cis	rs4664293	0.669	rs2042778	ENSG00000226266.5	AC009961.3	4.1	4.54e-05	0.00314	0.15	0.13	Monocyte percentage of white cells;	chr2:159672119	chr2:159670708~159712435:-
BRCA	cis	rs4664293	0.625	rs62171654	ENSG00000226266.5	AC009961.3	4.1	4.54e-05	0.00314	0.15	0.13	Monocyte percentage of white cells;	chr2:159675107	chr2:159670708~159712435:-
BRCA	cis	rs4664293	0.625	rs11903816	ENSG00000226266.5	AC009961.3	4.1	4.54e-05	0.00314	0.15	0.13	Monocyte percentage of white cells;	chr2:159675347	chr2:159670708~159712435:-
BRCA	cis	rs4664293	0.625	rs6738523	ENSG00000226266.5	AC009961.3	4.1	4.54e-05	0.00314	0.15	0.13	Monocyte percentage of white cells;	chr2:159681203	chr2:159670708~159712435:-
BRCA	cis	rs4664293	0.585	rs11893106	ENSG00000226266.5	AC009961.3	4.1	4.54e-05	0.00314	0.15	0.13	Monocyte percentage of white cells;	chr2:159684294	chr2:159670708~159712435:-
BRCA	cis	rs6600671	0.899	rs2319971	ENSG00000275131.1	CH17-472G23.4	-4.1	4.54e-05	0.00314	-0.12	-0.13	Hip geometry;	chr1:121485184	chr1:120489625~120579190:-
BRCA	cis	rs66887589	0.616	rs1052633	ENSG00000250412.1	KLHL2P1	4.1	4.54e-05	0.00314	0.14	0.13	Diastolic blood pressure;	chr4:119294159	chr4:119334329~119378233:+
BRCA	cis	rs875971	0.66	rs10215132	ENSG00000223473.2	GS1-124K5.3	-4.1	4.55e-05	0.00314	-0.1	-0.13	Aortic root size;	chr7:66589419	chr7:66491049~66493566:-
BRCA	cis	rs739496	0.615	rs11609628	ENSG00000226469.1	ADAM1B	4.1	4.55e-05	0.00314	0.17	0.13	Platelet count;	chr12:111779404	chr12:111927018~111929017:+
BRCA	cis	rs10833905	1	rs112686297	ENSG00000246225.5	RP11-17A1.3	-4.1	4.55e-05	0.00314	-0.18	-0.13	Sudden cardiac arrest;	chr11:23001448	chr11:22829380~22945393:+
BRCA	cis	rs4819052	0.851	rs8127834	ENSG00000215447.6	BX322557.10	-4.09	4.55e-05	0.00315	-0.13	-0.13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45276194	chr21:45288052~45291738:+
BRCA	cis	rs6012564	1	rs2426109	ENSG00000227431.4	CSE1L-AS1	-4.09	4.55e-05	0.00315	-0.15	-0.13	Anger;	chr20:49046090	chr20:49040463~49046044:-
BRCA	cis	rs17772222	0.958	rs74074098	ENSG00000258789.1	RP11-507K2.3	-4.09	4.55e-05	0.00315	-0.16	-0.13	Coronary artery calcification;	chr14:88484213	chr14:88551597~88552493:+
BRCA	cis	rs10050311	0.685	rs7678571	ENSG00000251411.1	RP11-397E7.4	-4.09	4.55e-05	0.00315	-0.16	-0.13	Insulin-related traits;	chr4:86833560	chr4:86913266~86914817:-
BRCA	cis	rs13098911	0.54	rs33910087	ENSG00000223552.1	RP11-24F11.2	-4.09	4.55e-05	0.00315	-0.21	-0.13	Celiac disease;	chr3:45967995	chr3:46364955~46407059:-
BRCA	cis	rs12497850	0.931	rs6442130	ENSG00000229759.1	MRPS18AP1	4.09	4.55e-05	0.00315	0.15	0.13	Parkinson's disease;	chr3:48740594	chr3:48256350~48256938:-
BRCA	cis	rs10457838	0.783	rs62426156	ENSG00000236591.1	RP11-162J8.3	-4.09	4.55e-05	0.00315	-0.18	-0.13	Post-traumatic stress disorder;	chr6:149071697	chr6:149027700~149032573:-
BRCA	cis	rs4664293	0.642	rs6732598	ENSG00000226266.5	AC009961.3	4.09	4.55e-05	0.00315	0.15	0.13	Monocyte percentage of white cells;	chr2:159790370	chr2:159670708~159712435:-
BRCA	cis	rs10861342	0.515	rs7134351	ENSG00000257999.1	RP11-61E11.2	4.09	4.56e-05	0.00315	0.18	0.13	IgG glycosylation;	chr12:105061439	chr12:105102472~105107179:-
BRCA	cis	rs6840360	0.642	rs56301462	ENSG00000251603.1	RP11-164P12.4	-4.09	4.56e-05	0.00315	-0.12	-0.13	Intelligence (multi-trait analysis);	chr4:151530976	chr4:151667224~151670502:+
BRCA	cis	rs9926296	0.744	rs164746	ENSG00000274627.1	RP11-104N10.2	4.09	4.56e-05	0.00315	0.16	0.13	Vitiligo;	chr16:89642611	chr16:89516797~89522217:+
BRCA	cis	rs6088580	0.634	rs2378133	ENSG00000276073.1	RP5-1125A11.7	4.09	4.56e-05	0.00315	0.14	0.13	Glomerular filtration rate (creatinine);	chr20:34331699	chr20:33985617~33988989:-
BRCA	cis	rs2904967	0.703	rs2957111	ENSG00000255200.1	AP003068.18	-4.09	4.56e-05	0.00315	-0.26	-0.13	Mean corpuscular volume;	chr11:65235976	chr11:65174117~65176470:-
BRCA	cis	rs17092148	1	rs60789653	ENSG00000202150.1	RNU6-407P	-4.09	4.56e-05	0.00315	-0.19	-0.13	Neuroticism;	chr20:34859359	chr20:35030317~35030420:-
BRCA	cis	rs453301	0.658	rs3855900	ENSG00000233609.3	RP11-62H7.2	-4.09	4.56e-05	0.00315	-0.12	-0.13	Joint mobility (Beighton score);	chr8:9044411	chr8:8961200~8979025:+
BRCA	cis	rs875971	1	rs11974219	ENSG00000229180.5	GS1-124K5.11	-4.09	4.56e-05	0.00315	-0.11	-0.13	Aortic root size;	chr7:66182423	chr7:66526088~66542624:-
BRCA	cis	rs9573567	0.541	rs2328945	ENSG00000261553.4	RP11-29G8.3	4.09	4.56e-05	0.00315	0.27	0.13	Red blood cell count;Mean corpuscular volume;	chr13:75501017	chr13:75549773~75807120:+
BRCA	cis	rs9573567	0.881	rs2328946	ENSG00000261553.4	RP11-29G8.3	4.09	4.56e-05	0.00315	0.27	0.13	Red blood cell count;Mean corpuscular volume;	chr13:75501096	chr13:75549773~75807120:+
BRCA	cis	rs9573567	0.881	rs2328947	ENSG00000261553.4	RP11-29G8.3	4.09	4.56e-05	0.00315	0.27	0.13	Red blood cell count;Mean corpuscular volume;	chr13:75501191	chr13:75549773~75807120:+
BRCA	cis	rs9573567	0.881	rs7318786	ENSG00000261553.4	RP11-29G8.3	4.09	4.56e-05	0.00315	0.27	0.13	Red blood cell count;Mean corpuscular volume;	chr13:75501461	chr13:75549773~75807120:+
BRCA	cis	rs9573567	0.881	rs6562896	ENSG00000261553.4	RP11-29G8.3	4.09	4.56e-05	0.00315	0.27	0.13	Red blood cell count;Mean corpuscular volume;	chr13:75501794	chr13:75549773~75807120:+
BRCA	cis	rs4869313	0.869	rs3849749	ENSG00000248734.2	CTD-2260A17.1	-4.09	4.56e-05	0.00315	-0.13	-0.13	Pediatric autoimmune diseases;	chr5:96898829	chr5:96784777~96785999:+
BRCA	cis	rs7985	0.901	rs6005133	ENSG00000244625.4	MIATNB	4.09	4.56e-05	0.00315	0.14	0.13	Electroencephalogram traits;	chr22:26681021	chr22:26672767~26780207:+
BRCA	cis	rs6452524	0.935	rs7703318	ENSG00000281327.1	LINC01338	4.09	4.56e-05	0.00315	0.14	0.13	Hypertension (SNP x SNP interaction);	chr5:83118234	chr5:82850864~82859836:-
BRCA	cis	rs490234	0.702	rs4838275	ENSG00000232630.1	PRPS1P2	-4.09	4.57e-05	0.00316	-0.13	-0.13	Mean arterial pressure;	chr9:125590506	chr9:125150653~125151589:+
BRCA	cis	rs8180040	1	rs11714294	ENSG00000271161.1	BOLA2P2	-4.09	4.57e-05	0.00316	-0.13	-0.13	Colorectal cancer;	chr3:47298233	chr3:47499841~47500407:+
BRCA	cis	rs453301	0.686	rs3989373	ENSG00000233609.3	RP11-62H7.2	-4.09	4.57e-05	0.00316	-0.12	-0.13	Joint mobility (Beighton score);	chr8:9053798	chr8:8961200~8979025:+
BRCA	cis	rs2411233	0.935	rs7180259	ENSG00000259278.1	RP11-62C7.2	4.09	4.57e-05	0.00316	0.15	0.13	Platelet count;	chr15:39010523	chr15:39019233~39024918:+
BRCA	cis	rs2243480	0.901	rs3813708	ENSG00000275400.1	RP4-756H11.5	4.09	4.57e-05	0.00316	0.23	0.13	Diabetic kidney disease;	chr7:65840645	chr7:66553805~66554199:-
BRCA	cis	rs4415084	0.716	rs6451781	ENSG00000251141.4	RP11-53O19.1	-4.09	4.57e-05	0.00316	-0.12	-0.13	Breast cancer;	chr5:44860404	chr5:44744900~44808777:-
BRCA	cis	rs375066	0.935	rs367283	ENSG00000267191.1	RP11-15A1.2	-4.09	4.57e-05	0.00316	-0.16	-0.13	Breast cancer;	chr19:43901975	chr19:43902001~43926545:+
BRCA	cis	rs733592	0.507	rs56129148	ENSG00000257763.1	OR5BK1P	-4.09	4.57e-05	0.00316	-0.12	-0.13	Plateletcrit;	chr12:48091747	chr12:48355792~48356614:-
BRCA	cis	rs1555322	1	rs2425037	ENSG00000279253.1	RP4-614O4.13	4.09	4.57e-05	0.00316	0.2	0.13	Attention deficit hyperactivity disorder;	chr20:35268626	chr20:35262727~35264187:-
BRCA	cis	rs7200543	1	rs14347	ENSG00000207425.1	Y_RNA	-4.09	4.57e-05	0.00316	-0.15	-0.13	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15040032	chr16:14915457~14915556:-
BRCA	cis	rs6452524	0.569	rs7720588	ENSG00000281327.1	LINC01338	4.09	4.57e-05	0.00316	0.15	0.13	Hypertension (SNP x SNP interaction);	chr5:83081107	chr5:82850864~82859836:-
BRCA	cis	rs2835872	0.965	rs2835848	ENSG00000228677.1	TTC3-AS1	-4.09	4.57e-05	0.00316	-0.17	-0.13	Electroencephalographic traits in alcoholism;	chr21:37638771	chr21:37187666~37193926:-
BRCA	cis	rs2835872	0.965	rs73222307	ENSG00000228677.1	TTC3-AS1	-4.09	4.57e-05	0.00316	-0.17	-0.13	Electroencephalographic traits in alcoholism;	chr21:37639923	chr21:37187666~37193926:-
BRCA	cis	rs886774	0.932	rs722691	ENSG00000273055.1	CTB-13F3.1	-4.09	4.58e-05	0.00316	-0.13	-0.13	Ulcerative colitis;	chr7:107859739	chr7:107942116~107942740:+
BRCA	cis	rs853679	0.556	rs45509595	ENSG00000216901.1	AL022393.7	4.09	4.58e-05	0.00316	0.33	0.13	Depression;	chr6:27873148	chr6:28176188~28176674:+
BRCA	cis	rs2243480	1	rs781157	ENSG00000275400.1	RP4-756H11.5	4.09	4.58e-05	0.00316	0.22	0.13	Diabetic kidney disease;	chr7:66013324	chr7:66553805~66554199:-
BRCA	cis	rs6600671	1	rs10903159	ENSG00000275131.1	CH17-472G23.4	-4.09	4.58e-05	0.00316	-0.12	-0.13	Hip geometry;	chr1:121440138	chr1:120489625~120579190:-
BRCA	cis	rs7772486	0.84	rs11155451	ENSG00000270638.1	RP3-466P17.1	4.09	4.58e-05	0.00316	0.15	0.13	Lobe attachment (rater-scored or self-reported);	chr6:146101388	chr6:145735570~145737218:+
BRCA	cis	rs12612435	0.83	rs6714949	ENSG00000226806.1	AC011893.3	4.09	4.58e-05	0.00316	0.14	0.13	Takotsubo syndrome;	chr2:136367456	chr2:135820191~135823087:+
BRCA	cis	rs4664293	0.605	rs6741498	ENSG00000226266.5	AC009961.3	4.09	4.58e-05	0.00317	0.15	0.13	Monocyte percentage of white cells;	chr2:159698111	chr2:159670708~159712435:-
BRCA	cis	rs10864907	0.71	rs11674086	ENSG00000231747.1	AC079922.2	-4.09	4.58e-05	0.00317	-0.12	-0.13	Pulmonary function;	chr2:112961805	chr2:112621809~112622167:-
BRCA	cis	rs8130944	1	rs4920140	ENSG00000225731.1	AP001627.1	4.09	4.58e-05	0.00317	0.14	0.13	Perceived unattractiveness to mosquitoes;	chr21:42720525	chr21:42733594~42741758:-
BRCA	cis	rs6751744	0.889	rs12692553	ENSG00000226266.5	AC009961.3	-4.09	4.58e-05	0.00317	-0.17	-0.13	Dysphagia;	chr2:159534337	chr2:159670708~159712435:-
BRCA	cis	rs6600671	1	rs11249350	ENSG00000275131.1	CH17-472G23.4	-4.09	4.58e-05	0.00317	-0.12	-0.13	Hip geometry;	chr1:121436587	chr1:120489625~120579190:-
BRCA	cis	rs516805	0.528	rs2684230	ENSG00000279114.1	RP3-425C14.5	-4.09	4.59e-05	0.00317	-0.15	-0.13	Lymphocyte counts;	chr6:122078062	chr6:122471923~122484161:+
BRCA	cis	rs17065868	1	rs9525962	ENSG00000237361.2	TUSC8	-4.09	4.59e-05	0.00317	-0.24	-0.13	Antineutrophil cytoplasmic antibody-associated vasculitis;	chr13:44491255	chr13:44400250~44405984:-
BRCA	cis	rs6860540	0.796	rs10475585	ENSG00000251405.2	CTB-109A12.1	-4.09	4.59e-05	0.00317	-0.17	-0.13	Inflammatory skin disease;	chr5:157488080	chr5:157362615~157460078:-
BRCA	cis	rs1198430	1	rs1198431	ENSG00000271420.1	RP5-1057J7.7	-4.09	4.59e-05	0.00317	-0.17	-0.13	Total cholesterol levels;	chr1:23429223	chr1:23378380~23379029:-
BRCA	cis	rs9470794	0.915	rs9470772	ENSG00000204110.6	RP1-153P14.8	-4.09	4.59e-05	0.00317	-0.2	-0.13	Type 2 diabetes;	chr6:38095294	chr6:37507348~37535616:+
BRCA	cis	rs700651	0.789	rs5007118	ENSG00000231621.1	AC013264.2	-4.09	4.59e-05	0.00317	-0.12	-0.13	Intracranial aneurysm;	chr2:198045014	chr2:197197991~197199273:+
BRCA	cis	rs7592578	0.882	rs61117285	ENSG00000272979.1	RP11-647K16.1	-4.09	4.59e-05	0.00317	-0.21	-0.13	Diastolic blood pressure;	chr2:190604260	chr2:190454092~190454521:-
BRCA	cis	rs7592578	0.882	rs58568707	ENSG00000272979.1	RP11-647K16.1	-4.09	4.59e-05	0.00317	-0.21	-0.13	Diastolic blood pressure;	chr2:190604261	chr2:190454092~190454521:-
BRCA	cis	rs12681366	0.708	rs1011249	ENSG00000253175.1	RP11-267M23.6	4.09	4.59e-05	0.00317	0.14	0.13	Nonsyndromic cleft lip with cleft palate;	chr8:94425833	chr8:94565036~94565715:+
BRCA	cis	rs7824557	0.606	rs2736264	ENSG00000255046.1	RP11-297N6.4	-4.09	4.59e-05	0.00317	-0.15	-0.13	Retinal vascular caliber;	chr8:11329130	chr8:11797928~11802568:-
BRCA	cis	rs4835473	0.932	rs5016159	ENSG00000246448.2	RP13-578N3.3	4.09	4.59e-05	0.00317	0.14	0.13	Immature fraction of reticulocytes;	chr4:143738362	chr4:143700257~143865072:+
BRCA	cis	rs875971	0.54	rs4717275	ENSG00000223473.2	GS1-124K5.3	-4.09	4.59e-05	0.00317	-0.1	-0.13	Aortic root size;	chr7:65800193	chr7:66491049~66493566:-
BRCA	cis	rs34217772	1	rs12434724	ENSG00000258636.1	CTD-2298J14.2	-4.09	4.59e-05	0.00317	-0.16	-0.13	Myopia;	chr14:41801994	chr14:41587861~41604856:-
BRCA	cis	rs465969	0.546	rs7772141	ENSG00000272356.1	RP5-1112D6.8	-4.09	4.59e-05	0.00317	-0.27	-0.13	Psoriasis;	chr6:111472358	chr6:111309203~111313517:+
BRCA	cis	rs465969	0.793	rs7776047	ENSG00000272356.1	RP5-1112D6.8	-4.09	4.59e-05	0.00317	-0.27	-0.13	Psoriasis;	chr6:111472391	chr6:111309203~111313517:+
BRCA	cis	rs739496	0.947	rs2239195	ENSG00000234608.6	MAPKAPK5-AS1	4.09	4.59e-05	0.00317	0.15	0.13	Platelet count;	chr12:111443505	chr12:111839764~111842902:-
BRCA	cis	rs4650943	0.586	rs10798448	ENSG00000227740.1	RP11-318C24.2	-4.09	4.59e-05	0.00317	-0.13	-0.13	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in inactive individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr1:176231787	chr1:175904762~175920513:-
BRCA	cis	rs9970334	0.596	rs709209	ENSG00000225077.2	LINC00337	-4.09	4.59e-05	0.00317	-0.15	-0.13	Resting heart rate;	chr1:6218354	chr1:6236240~6239444:+
BRCA	cis	rs10761482	0.906	rs7911934	ENSG00000254271.1	RP11-131N11.4	4.09	4.59e-05	0.00317	0.17	0.13	Schizophrenia;	chr10:60332332	chr10:60734342~60741828:+
BRCA	cis	rs867186	1	rs11167260	ENSG00000126005.14	MMP24-AS1	-4.09	4.59e-05	0.00317	-0.25	-0.13	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35187397	chr20:35216462~35278131:-
BRCA	cis	rs11977715	0.538	rs43063	ENSG00000233942.1	AC004012.1	-4.09	4.59e-05	0.00317	-0.15	-0.13	Middle childhood and early adolescence aggressive behavior;	chr7:95480475	chr7:95471835~95473998:+
BRCA	cis	rs2271404	0.506	rs12989775	ENSG00000227992.1	AC108463.2	4.09	4.6e-05	0.00317	0.16	0.13	Atopic dermatitis;	chr2:111241250	chr2:111203964~111206215:-
BRCA	cis	rs801193	0.66	rs2659897	ENSG00000272831.1	RP11-792A8.4	-4.09	4.6e-05	0.00317	-0.11	-0.13	Aortic root size;	chr7:66722728	chr7:66739829~66740385:-
BRCA	cis	rs13434995	0.513	rs9993599	ENSG00000239040.1	Y_RNA	-4.09	4.6e-05	0.00317	-0.15	-0.13	Adiponectin levels;	chr4:55586798	chr4:55412636~55412738:+
BRCA	cis	rs9291683	0.61	rs993172	ENSG00000250413.1	RP11-448G15.1	-4.09	4.6e-05	0.00317	-0.16	-0.13	Bone mineral density;	chr4:10322737	chr4:10006482~10009725:+
BRCA	cis	rs2832191	1	rs2832191	ENSG00000232855.5	AF131217.1	4.09	4.6e-05	0.00317	0.15	0.13	Dental caries;	chr21:29116979	chr21:28439346~28674848:-
BRCA	cis	rs853679	0.517	rs9380056	ENSG00000216901.1	AL022393.7	4.09	4.6e-05	0.00317	0.18	0.13	Depression;	chr6:28136698	chr6:28176188~28176674:+
BRCA	cis	rs853679	0.517	rs9380057	ENSG00000216901.1	AL022393.7	4.09	4.6e-05	0.00317	0.18	0.13	Depression;	chr6:28136856	chr6:28176188~28176674:+
BRCA	cis	rs853679	0.517	rs6941992	ENSG00000216901.1	AL022393.7	4.09	4.6e-05	0.00317	0.18	0.13	Depression;	chr6:28138363	chr6:28176188~28176674:+
BRCA	cis	rs4713118	0.516	rs4713142	ENSG00000216901.1	AL022393.7	4.09	4.6e-05	0.00317	0.18	0.13	Parkinson's disease;	chr6:28138569	chr6:28176188~28176674:+
BRCA	cis	rs853679	0.517	rs4713143	ENSG00000216901.1	AL022393.7	4.09	4.6e-05	0.00317	0.18	0.13	Depression;	chr6:28138981	chr6:28176188~28176674:+
BRCA	cis	rs853679	0.517	rs4713144	ENSG00000216901.1	AL022393.7	4.09	4.6e-05	0.00317	0.18	0.13	Depression;	chr6:28139012	chr6:28176188~28176674:+
BRCA	cis	rs2835345	0.563	rs78113480	ENSG00000233818.1	AP000695.4	4.09	4.6e-05	0.00317	0.13	0.13	Pulmonary function;	chr21:36452022	chr21:36445731~36532408:+
BRCA	cis	rs2835345	0.563	rs4378885	ENSG00000233818.1	AP000695.4	4.09	4.6e-05	0.00317	0.13	0.13	Pulmonary function;	chr21:36452613	chr21:36445731~36532408:+
BRCA	cis	rs2835345	0.563	rs4481073	ENSG00000233818.1	AP000695.4	4.09	4.6e-05	0.00317	0.13	0.13	Pulmonary function;	chr21:36452657	chr21:36445731~36532408:+
BRCA	cis	rs2835345	0.563	rs2835361	ENSG00000233818.1	AP000695.4	4.09	4.6e-05	0.00317	0.13	0.13	Pulmonary function;	chr21:36452699	chr21:36445731~36532408:+
BRCA	cis	rs7592578	0.882	rs2192010	ENSG00000272979.1	RP11-647K16.1	-4.09	4.6e-05	0.00318	-0.21	-0.13	Diastolic blood pressure;	chr2:190597407	chr2:190454092~190454521:-
BRCA	cis	rs75920871	0.589	rs2075547	ENSG00000254851.1	RP11-109L13.1	-4.09	4.6e-05	0.00318	-0.21	-0.13	Subjective well-being;	chr11:117197818	chr11:117135528~117138582:+
BRCA	cis	rs632111	0.519	rs281380	ENSG00000232871.7	SEC1P	-4.09	4.6e-05	0.00318	-0.14	-0.13	Serum lipase activity;	chr19:48711213	chr19:48638071~48682245:+
BRCA	cis	rs2274273	0.84	rs10136596	ENSG00000259318.1	RP11-454L9.2	4.09	4.6e-05	0.00318	0.11	0.13	Protein biomarker;	chr14:55370055	chr14:55394940~55395233:-
BRCA	cis	rs7429990	0.965	rs7651237	ENSG00000228638.1	FCF1P2	4.09	4.6e-05	0.00318	0.14	0.13	Educational attainment (years of education);	chr3:48064038	chr3:48290793~48291375:-
BRCA	cis	rs7577696	0.706	rs2268796	ENSG00000272716.1	RP11-563N4.1	4.09	4.6e-05	0.00318	0.14	0.13	Inflammatory biomarkers;	chr2:31557210	chr2:32165046~32165757:-
BRCA	cis	rs1129187	0.935	rs4987173	ENSG00000220614.1	RP11-480N24.4	4.09	4.6e-05	0.00318	0.14	0.13	Alzheimer's disease in APOE e4+ carriers;	chr6:42963486	chr6:43328134~43328476:+
BRCA	cis	rs911555	0.511	rs2296483	ENSG00000269940.1	RP11-73M18.7	4.09	4.6e-05	0.00318	0.13	0.13	Intelligence (multi-trait analysis);	chr14:103563455	chr14:103694560~103695170:+
BRCA	cis	rs6968419	0.609	rs73716708	ENSG00000279086.1	RP11-667F14.1	-4.09	4.6e-05	0.00318	-0.14	-0.13	Intraocular pressure;	chr7:116265689	chr7:116209234~116211511:-
BRCA	cis	rs6968419	0.609	rs73716710	ENSG00000279086.1	RP11-667F14.1	-4.09	4.6e-05	0.00318	-0.14	-0.13	Intraocular pressure;	chr7:116265690	chr7:116209234~116211511:-
BRCA	cis	rs2115630	1	rs4633690	ENSG00000275120.1	RP11-182J1.17	-4.09	4.6e-05	0.00318	-0.14	-0.13	P wave terminal force;	chr15:84818729	chr15:84599434~84606463:-
BRCA	cis	rs703842	0.616	rs4760171	ENSG00000270039.1	RP11-571M6.17	-4.09	4.6e-05	0.00318	-0.18	-0.13	Multiple sclerosis;	chr12:57832121	chr12:57803838~57804415:+
BRCA	cis	rs17684571	0.683	rs13215883	ENSG00000231441.1	RP11-472M19.2	4.09	4.6e-05	0.00318	0.22	0.13	Schizophrenia;	chr6:56858927	chr6:56844002~56864078:+
BRCA	cis	rs2908197	0.699	rs2908191	ENSG00000186704.9	DTX2P1	4.09	4.6e-05	0.00318	0.14	0.13	3-hydroxypropylmercapturic acid levels in smokers;	chr7:76333005	chr7:76978617~77004308:+
BRCA	cis	rs4578769	0.759	rs7243797	ENSG00000265939.1	UBE2CP2	4.09	4.61e-05	0.00318	0.15	0.13	Eosinophil percentage of white cells;	chr18:23014467	chr18:22900486~22900995:-
BRCA	cis	rs4578769	0.802	rs7230571	ENSG00000265939.1	UBE2CP2	4.09	4.61e-05	0.00318	0.15	0.13	Eosinophil percentage of white cells;	chr18:23014493	chr18:22900486~22900995:-
BRCA	cis	rs2835872	0.965	rs2835855	ENSG00000228677.1	TTC3-AS1	-4.09	4.61e-05	0.00318	-0.17	-0.13	Electroencephalographic traits in alcoholism;	chr21:37643452	chr21:37187666~37193926:-
BRCA	cis	rs747650	0.532	rs10838658	ENSG00000200376.1	RNU5E-10P	-4.09	4.61e-05	0.00318	-0.17	-0.13	Acne (severe);	chr11:47109227	chr11:47576471~47576588:-
BRCA	cis	rs10266483	0.741	rs10254313	ENSG00000227986.1	TRIM60P18	-4.09	4.61e-05	0.00318	-0.13	-0.13	Response to statin therapy;	chr7:64278935	chr7:64355078~64356199:+
BRCA	cis	rs10266483	0.741	rs35244017	ENSG00000227986.1	TRIM60P18	-4.09	4.61e-05	0.00318	-0.13	-0.13	Response to statin therapy;	chr7:64278939	chr7:64355078~64356199:+
BRCA	cis	rs875971	0.964	rs6945019	ENSG00000236529.1	RP13-254B10.1	4.09	4.61e-05	0.00318	0.14	0.13	Aortic root size;	chr7:66457471	chr7:65840212~65840596:+
BRCA	cis	rs13434995	0.513	rs1979605	ENSG00000239040.1	Y_RNA	-4.09	4.61e-05	0.00318	-0.15	-0.13	Adiponectin levels;	chr4:55552706	chr4:55412636~55412738:+
BRCA	cis	rs7267979	1	rs6083828	ENSG00000274414.1	RP5-965G21.4	4.09	4.61e-05	0.00318	0.15	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25389282	chr20:25239007~25245229:-
BRCA	cis	rs10129255	0.5	rs6576231	ENSG00000211967.3	IGHV3-53	-4.09	4.61e-05	0.00318	-0.08	-0.13	Kawasaki disease;	chr14:106783693	chr14:106592676~106593347:-
BRCA	cis	rs801193	0.761	rs2659888	ENSG00000272831.1	RP11-792A8.4	4.09	4.61e-05	0.00318	0.11	0.13	Aortic root size;	chr7:66765184	chr7:66739829~66740385:-
BRCA	cis	rs7572733	0.84	rs4850808	ENSG00000231621.1	AC013264.2	-4.09	4.61e-05	0.00318	-0.11	-0.13	Dermatomyositis;	chr2:197711418	chr2:197197991~197199273:+
BRCA	cis	rs1371614	0.635	rs4316900	ENSG00000229122.1	AGBL5-IT1	-4.09	4.61e-05	0.00318	-0.13	-0.13	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26917474	chr2:27061038~27061815:+
BRCA	cis	rs181553	0.664	rs1965843	ENSG00000266696.1	RP11-30L3.2	4.09	4.61e-05	0.00319	0.14	0.13	Hip circumference adjusted for BMI;	chr18:49155947	chr18:49205912~49208781:+
BRCA	cis	rs1153858	1	rs67831559	ENSG00000275672.1	GATM-AS1	-4.09	4.61e-05	0.00319	-0.16	-0.13	Homoarginine levels;	chr15:45357109	chr15:45378700~45380123:+
BRCA	cis	rs71566846	0.649	rs6906645	ENSG00000272541.1	XXbac-BPGBPG55C20.1	-4.09	4.62e-05	0.00319	-0.19	-0.13	Coronary artery disease;	chr6:57265776	chr6:57855891~57856468:-
BRCA	cis	rs1823874	0.71	rs4246297	ENSG00000182397.13	DNM1P46	-4.09	4.62e-05	0.00319	-0.14	-0.13	IgG glycosylation;	chr15:99826723	chr15:99790156~99806927:-
BRCA	cis	rs6413860	0.667	rs10924809	ENSG00000235021.1	RP11-439E19.7	4.09	4.62e-05	0.00319	0.18	0.13	Gut microbiome composition (summer);	chr1:246699286	chr1:246690047~246691821:+
BRCA	cis	rs7903456	0.648	rs9420431	ENSG00000200253.1	RNU6-529P	4.09	4.62e-05	0.00319	0.16	0.13	Gout;Renal underexcretion gout;	chr10:87067639	chr10:87041238~87041341:-
BRCA	cis	rs2662776	1	rs2999965	ENSG00000232995.6	RGS5	-4.09	4.62e-05	0.00319	-0.13	-0.13	Lead levels in blood;	chr1:163198509	chr1:163244505~163321894:-
BRCA	cis	rs2274459	0.908	rs12204620	ENSG00000249346.5	LINC01016	4.09	4.62e-05	0.00319	0.17	0.13	Obesity (extreme);	chr6:33773286	chr6:33867506~33896914:-
BRCA	cis	rs2274459	1	rs12204992	ENSG00000249346.5	LINC01016	4.09	4.62e-05	0.00319	0.17	0.13	Obesity (extreme);	chr6:33773947	chr6:33867506~33896914:-
BRCA	cis	rs739496	0.579	rs12296574	ENSG00000234608.6	MAPKAPK5-AS1	4.09	4.62e-05	0.00319	0.15	0.13	Platelet count;	chr12:111884973	chr12:111839764~111842902:-
BRCA	cis	rs745109	0.882	rs1518810	ENSG00000273080.1	RP11-301O19.1	-4.09	4.62e-05	0.00319	-0.2	-0.13	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86422310	chr2:86195590~86196049:+
BRCA	cis	rs875971	1	rs12533997	ENSG00000236529.1	RP13-254B10.1	4.09	4.62e-05	0.00319	0.14	0.13	Aortic root size;	chr7:66500390	chr7:65840212~65840596:+
BRCA	cis	rs17301013	0.9	rs1754351	ENSG00000234741.6	GAS5	-4.09	4.62e-05	0.00319	-0.12	-0.13	Systemic lupus erythematosus;	chr1:174762458	chr1:173863900~173868882:-
BRCA	cis	rs1153858	1	rs16942568	ENSG00000275672.1	GATM-AS1	-4.09	4.62e-05	0.00319	-0.16	-0.13	Homoarginine levels;	chr15:45385192	chr15:45378700~45380123:+
BRCA	cis	rs757081	0.667	rs34724588	ENSG00000184669.7	OR7E14P	-4.09	4.62e-05	0.00319	-0.19	-0.13	Systolic blood pressure;	chr11:17116034	chr11:17013998~17053024:+
BRCA	cis	rs160451	0.966	rs1603289	ENSG00000251136.7	RP11-37B2.1	4.09	4.62e-05	0.00319	0.12	0.13	Leprosy;	chr8:89655405	chr8:89609409~89757727:-
BRCA	cis	rs11098499	0.82	rs28578366	ENSG00000250412.1	KLHL2P1	-4.09	4.62e-05	0.00319	-0.15	-0.13	Corneal astigmatism;	chr4:119615750	chr4:119334329~119378233:+
BRCA	cis	rs6860540	0.687	rs6871720	ENSG00000248544.2	CTB-47B11.3	-4.09	4.63e-05	0.00319	-0.17	-0.13	Inflammatory skin disease;	chr5:157447457	chr5:157375741~157384950:-
BRCA	cis	rs9733	0.65	rs61820165	ENSG00000203804.4	ADAMTSL4-AS1	-4.09	4.63e-05	0.00319	-0.14	-0.13	Tonsillectomy;	chr1:150583511	chr1:150560202~150574552:-
BRCA	cis	rs801193	0.935	rs11772264	ENSG00000229180.5	GS1-124K5.11	4.09	4.63e-05	0.00319	0.11	0.13	Aortic root size;	chr7:66711400	chr7:66526088~66542624:-
BRCA	cis	rs10129255	0.957	rs8005468	ENSG00000211967.3	IGHV3-53	-4.09	4.63e-05	0.00319	-0.09	-0.13	Kawasaki disease;	chr14:106686431	chr14:106592676~106593347:-
BRCA	cis	rs11098499	0.863	rs3822192	ENSG00000260404.2	RP11-384K6.6	4.09	4.63e-05	0.00319	0.12	0.13	Corneal astigmatism;	chr4:119524565	chr4:118591773~118633729:+
BRCA	cis	rs7267979	1	rs6107033	ENSG00000276952.1	RP5-965G21.6	-4.09	4.63e-05	0.00319	-0.15	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25382955	chr20:25284915~25285588:-
BRCA	cis	rs4927850	0.501	rs9881504	ENSG00000242086.7	LINC00969	4.09	4.63e-05	0.00319	0.15	0.13	Pancreatic cancer;	chr3:195929743	chr3:195658062~195739964:+
BRCA	cis	rs9733	0.596	rs7529998	ENSG00000231073.1	RP11-316M1.3	4.09	4.63e-05	0.00319	0.13	0.13	Tonsillectomy;	chr1:150690055	chr1:150973123~150975534:+
BRCA	cis	rs9733	0.596	rs11803569	ENSG00000231073.1	RP11-316M1.3	4.09	4.63e-05	0.00319	0.13	0.13	Tonsillectomy;	chr1:150691601	chr1:150973123~150975534:+
BRCA	cis	rs7615952	0.611	rs35321002	ENSG00000250012.1	RP11-124N2.1	-4.09	4.63e-05	0.0032	-0.21	-0.13	Blood pressure (smoking interaction);	chr3:125893222	chr3:126084220~126095349:+
BRCA	cis	rs6121246	0.909	rs6060870	ENSG00000230613.1	HM13-AS1	4.09	4.63e-05	0.0032	0.19	0.13	Mean corpuscular hemoglobin;	chr20:31715496	chr20:31567707~31573263:-
BRCA	cis	rs2337406	0.925	rs76288499	ENSG00000280411.1	IGHV1-69-2	-4.09	4.63e-05	0.0032	-0.12	-0.13	Alzheimer's disease (late onset);	chr14:106686309	chr14:106762092~106762588:-
BRCA	cis	rs6088580	0.634	rs62212172	ENSG00000276073.1	RP5-1125A11.7	4.09	4.63e-05	0.0032	0.14	0.13	Glomerular filtration rate (creatinine);	chr20:34399899	chr20:33985617~33988989:-
BRCA	cis	rs10028773	0.666	rs12498657	ENSG00000260404.2	RP11-384K6.6	4.09	4.63e-05	0.0032	0.11	0.13	Educational attainment;	chr4:119341711	chr4:118591773~118633729:+
BRCA	cis	rs2708977	0.698	rs772160	ENSG00000237510.6	AC008268.2	-4.09	4.63e-05	0.0032	-0.19	-0.13	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96373928	chr2:95789654~95800166:+
BRCA	cis	rs12612619	0.732	rs3754734	ENSG00000272148.1	RP11-195B17.1	4.09	4.63e-05	0.0032	0.14	0.13	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27076730	chr2:27062428~27062907:-
BRCA	cis	rs13434995	0.513	rs4336288	ENSG00000239040.1	Y_RNA	-4.09	4.63e-05	0.0032	-0.15	-0.13	Adiponectin levels;	chr4:55584088	chr4:55412636~55412738:+
BRCA	cis	rs7771547	0.574	rs9368943	ENSG00000224666.3	RP1-50J22.4	4.09	4.64e-05	0.0032	0.16	0.13	Platelet distribution width;	chr6:36598798	chr6:36386831~36393462:+
BRCA	cis	rs5758659	0.652	rs6519301	ENSG00000182057.4	OGFRP1	4.09	4.64e-05	0.0032	0.14	0.13	Cognitive function;	chr22:41989963	chr22:42269753~42275196:+
BRCA	cis	rs9527	0.59	rs763914	ENSG00000213061.2	PFN1P11	4.09	4.64e-05	0.0032	0.17	0.13	Arsenic metabolism;	chr10:103081830	chr10:102838011~102845473:-
BRCA	cis	rs7487075	1	rs7301001	ENSG00000274723.1	RP11-618L22.1	4.09	4.64e-05	0.0032	0.15	0.13	Itch intensity from mosquito bite;	chr12:46437058	chr12:46970504~46972155:+
BRCA	cis	rs3781264	0.848	rs7099485	ENSG00000268894.5	PLCE1-AS1	-4.09	4.64e-05	0.0032	-0.16	-0.13	Esophageal cancer and gastric cancer;	chr10:94305937	chr10:94279277~94287478:-
BRCA	cis	rs17772222	0.917	rs1956406	ENSG00000258789.1	RP11-507K2.3	-4.09	4.64e-05	0.0032	-0.15	-0.13	Coronary artery calcification;	chr14:88749711	chr14:88551597~88552493:+
BRCA	cis	rs3764021	0.509	rs10844569	ENSG00000278635.1	CTD-2318O12.1	-4.09	4.64e-05	0.0032	-0.14	-0.13	Type 1 diabetes;	chr12:9717756	chr12:9415641~9416718:+
BRCA	cis	rs7160336	1	rs10140966	ENSG00000259065.1	RP5-1021I20.1	-4.09	4.64e-05	0.0032	-0.14	-0.13	Blood protein levels;	chr14:74180219	chr14:73787360~73803270:+
BRCA	cis	rs983392	0.792	rs504272	ENSG00000275344.1	MIR6503	-4.09	4.64e-05	0.0032	-0.13	-0.13	Alzheimer's disease (late onset);	chr11:60139003	chr11:60209071~60209156:-
BRCA	cis	rs17507216	0.588	rs28864981	ENSG00000259429.4	UBE2Q2P2	-4.09	4.64e-05	0.0032	-0.16	-0.13	Excessive daytime sleepiness;	chr15:82695420	chr15:82355142~82420075:+
BRCA	cis	rs17507216	0.628	rs8032321	ENSG00000259429.4	UBE2Q2P2	-4.09	4.64e-05	0.0032	-0.16	-0.13	Excessive daytime sleepiness;	chr15:82698956	chr15:82355142~82420075:+
BRCA	cis	rs17507216	0.628	rs8040488	ENSG00000259429.4	UBE2Q2P2	-4.09	4.64e-05	0.0032	-0.16	-0.13	Excessive daytime sleepiness;	chr15:82699081	chr15:82355142~82420075:+
BRCA	cis	rs8062405	0.964	rs62036614	ENSG00000261766.1	RP11-22P6.2	-4.09	4.64e-05	0.0032	-0.13	-0.13	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28813364	chr16:28862166~28863340:-
BRCA	cis	rs74665712	0.591	rs35784161	ENSG00000232400.1	RAD17P1	4.09	4.64e-05	0.0032	0.14	0.13	Residual cognition;	chr7:16913065	chr7:16864267~16866308:-
BRCA	cis	rs801193	0.967	rs2707853	ENSG00000273142.1	RP11-458F8.4	-4.09	4.64e-05	0.0032	-0.11	-0.13	Aortic root size;	chr7:66749023	chr7:66902857~66906297:+
BRCA	cis	rs1538970	0.774	rs67683090	ENSG00000281133.1	AL355480.3	-4.09	4.64e-05	0.0032	-0.17	-0.13	Platelet count;	chr1:45512131	chr1:45580892~45580996:-
BRCA	cis	rs875971	0.895	rs10755833	ENSG00000236529.1	RP13-254B10.1	4.09	4.64e-05	0.0032	0.14	0.13	Aortic root size;	chr7:66448930	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.895	rs1833495	ENSG00000236529.1	RP13-254B10.1	4.09	4.64e-05	0.0032	0.14	0.13	Aortic root size;	chr7:66456608	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.964	rs6945032	ENSG00000236529.1	RP13-254B10.1	4.09	4.64e-05	0.0032	0.14	0.13	Aortic root size;	chr7:66457499	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.929	rs12673810	ENSG00000236529.1	RP13-254B10.1	4.09	4.64e-05	0.0032	0.14	0.13	Aortic root size;	chr7:66458866	chr7:65840212~65840596:+
BRCA	cis	rs875971	1	rs6961155	ENSG00000236529.1	RP13-254B10.1	4.09	4.64e-05	0.0032	0.14	0.13	Aortic root size;	chr7:66468308	chr7:65840212~65840596:+
BRCA	cis	rs875971	1	rs7789768	ENSG00000236529.1	RP13-254B10.1	4.09	4.64e-05	0.0032	0.14	0.13	Aortic root size;	chr7:66473993	chr7:65840212~65840596:+
BRCA	cis	rs875971	1	rs1363055	ENSG00000236529.1	RP13-254B10.1	4.09	4.64e-05	0.0032	0.14	0.13	Aortic root size;	chr7:66478288	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.964	rs9691480	ENSG00000236529.1	RP13-254B10.1	4.09	4.64e-05	0.0032	0.14	0.13	Aortic root size;	chr7:66479319	chr7:65840212~65840596:+
BRCA	cis	rs1153858	1	rs12101539	ENSG00000275672.1	GATM-AS1	-4.09	4.64e-05	0.0032	-0.16	-0.13	Homoarginine levels;	chr15:45358468	chr15:45378700~45380123:+
BRCA	cis	rs875971	1	rs12698523	ENSG00000236529.1	RP13-254B10.1	4.09	4.65e-05	0.00321	0.14	0.13	Aortic root size;	chr7:66503126	chr7:65840212~65840596:+
BRCA	cis	rs73195822	0.614	rs17683336	ENSG00000277299.1	RP11-837J7.4	-4.09	4.65e-05	0.00321	-0.21	-0.13	Itch intensity from mosquito bite;	chr12:110774907	chr12:109948389~109949029:+
BRCA	cis	rs11673344	0.526	rs1871196	ENSG00000267422.1	CTD-2554C21.1	4.09	4.65e-05	0.00321	0.17	0.13	Obesity-related traits;	chr19:37656022	chr19:37779686~37792865:+
BRCA	cis	rs6071166	0.683	rs1885461	ENSG00000224635.1	RP4-564F22.5	-4.09	4.65e-05	0.00321	-0.15	-0.13	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38685539	chr20:38406011~38416797:-
BRCA	cis	rs718433	0.584	rs7142784	ENSG00000211778.2	TRAV4	-4.09	4.65e-05	0.00321	-0.09	-0.13	Intraocular pressure;	chr14:21745516	chr14:21736152~21736982:+
BRCA	cis	rs2089162	1	rs2089162	ENSG00000261762.1	RP11-650L12.2	-4.09	4.65e-05	0.00321	-0.16	-0.13	Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78447421	chr15:78589123~78591276:-
BRCA	cis	rs12612435	0.736	rs6756808	ENSG00000226806.1	AC011893.3	-4.09	4.65e-05	0.00321	-0.15	-0.13	Takotsubo syndrome;	chr2:136382119	chr2:135820191~135823087:+
BRCA	cis	rs2304003	0.583	rs962501	ENSG00000235192.1	AC009495.2	4.09	4.65e-05	0.00321	0.14	0.13	Social communication problems;	chr2:165864741	chr2:165794851~165810010:+
BRCA	cis	rs801193	1	rs2659912	ENSG00000272831.1	RP11-792A8.4	4.09	4.65e-05	0.00321	0.11	0.13	Aortic root size;	chr7:66693012	chr7:66739829~66740385:-
BRCA	cis	rs2998286	0.862	rs2993989	ENSG00000237128.1	RP11-351M16.3	4.09	4.65e-05	0.00321	0.15	0.13	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28512986	chr10:28433008~28495813:-
BRCA	cis	rs11098499	0.82	rs11737395	ENSG00000250412.1	KLHL2P1	4.09	4.65e-05	0.00321	0.15	0.13	Corneal astigmatism;	chr4:119599549	chr4:119334329~119378233:+
BRCA	cis	rs11742741	0.806	rs60154129	ENSG00000248874.4	C5orf17	-4.09	4.65e-05	0.00321	-0.16	-0.13	Educational attainment;	chr5:24029596	chr5:23951348~24178263:+
BRCA	cis	rs10043228	1	rs12152964	ENSG00000271918.1	CTD-2287O16.5	-4.09	4.65e-05	0.00321	-0.18	-0.13	Asthma or chronic obstructive pulmonary disease;	chr5:116274268	chr5:116083807~116085416:-
BRCA	cis	rs2573652	0.723	rs2573655	ENSG00000254744.3	CTD-3076O17.1	-4.09	4.65e-05	0.00321	-0.16	-0.13	Height;	chr15:99975504	chr15:99970215~99974010:+
BRCA	cis	rs3764021	0.87	rs11052710	ENSG00000256582.1	RP11-75L1.1	4.09	4.66e-05	0.00321	0.13	0.13	Type 1 diabetes;	chr12:9723754	chr12:9704077~9709350:+
BRCA	cis	rs7985	1	rs5761672	ENSG00000244625.4	MIATNB	4.09	4.66e-05	0.00321	0.14	0.13	Electroencephalogram traits;	chr22:26673476	chr22:26672767~26780207:+
BRCA	cis	rs6121246	0.909	rs6058450	ENSG00000230613.1	HM13-AS1	4.09	4.66e-05	0.00321	0.18	0.13	Mean corpuscular hemoglobin;	chr20:31756108	chr20:31567707~31573263:-
BRCA	cis	rs6121246	0.909	rs6060929	ENSG00000230613.1	HM13-AS1	4.09	4.66e-05	0.00321	0.18	0.13	Mean corpuscular hemoglobin;	chr20:31758111	chr20:31567707~31573263:-
BRCA	cis	rs6121246	0.909	rs6119720	ENSG00000230613.1	HM13-AS1	4.09	4.66e-05	0.00321	0.18	0.13	Mean corpuscular hemoglobin;	chr20:31759765	chr20:31567707~31573263:-
BRCA	cis	rs28829049	0.535	rs12565185	ENSG00000270728.1	RP4-657E11.10	-4.09	4.66e-05	0.00321	-0.13	-0.13	QRS duration in Tripanosoma cruzi seropositivity;	chr1:19171815	chr1:19297080~19297903:+
BRCA	cis	rs4699052	0.599	rs11938459	ENSG00000248740.4	RP11-328K4.1	4.09	4.66e-05	0.00321	0.14	0.13	Testicular germ cell tumor;	chr4:103312832	chr4:103256159~103453658:+
BRCA	cis	rs11170468	0.945	rs11170493	ENSG00000257718.1	RP11-396F22.1	-4.09	4.66e-05	0.00321	-0.16	-0.13	Body mass index;	chr12:39041871	chr12:38906451~38909592:+
BRCA	cis	rs783540	0.609	rs803686	ENSG00000276710.3	CSPG4P8	4.09	4.66e-05	0.00321	0.15	0.13	Schizophrenia;	chr15:82550590	chr15:82459472~82477258:+
BRCA	cis	rs180730	1	rs3106313	ENSG00000251609.2	SETP12	-4.09	4.66e-05	0.00321	-0.19	-0.13	Fasting plasma glucose;	chr4:120882815	chr4:120895494~120897083:-
BRCA	cis	rs8054556	0.787	rs3814877	ENSG00000183604.13	SMG1P5	-4.09	4.66e-05	0.00321	-0.12	-0.13	Autism spectrum disorder or schizophrenia;	chr16:30031356	chr16:30267553~30335374:-
BRCA	cis	rs3816183	1	rs3816183	ENSG00000226491.1	FTOP1	4.09	4.66e-05	0.00321	0.16	0.13	Hypospadias;	chr2:42788579	chr2:42797225~42798712:-
BRCA	cis	rs16944613	0.541	rs13313427	ENSG00000271396.1	RP11-697E2.9	-4.09	4.66e-05	0.00321	-0.2	-0.13	Colorectal cancer;	chr15:90547536	chr15:90284376~90285580:-
BRCA	cis	rs56390833	1	rs56390833	ENSG00000261762.1	RP11-650L12.2	-4.09	4.66e-05	0.00321	-0.15	-0.13	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio in COPD;	chr15:78585039	chr15:78589123~78591276:-
BRCA	cis	rs7267979	0.966	rs3002698	ENSG00000274414.1	RP5-965G21.4	4.09	4.66e-05	0.00321	0.15	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25322743	chr20:25239007~25245229:-
BRCA	cis	rs6832769	0.767	rs6850524	ENSG00000272969.1	RP11-528I4.2	4.09	4.66e-05	0.00321	0.15	0.13	Personality dimensions;	chr4:55515830	chr4:55547112~55547889:+
BRCA	cis	rs6832769	0.767	rs11133394	ENSG00000272969.1	RP11-528I4.2	4.09	4.66e-05	0.00321	0.15	0.13	Personality dimensions;	chr4:55517071	chr4:55547112~55547889:+
BRCA	cis	rs875971	1	rs875971	ENSG00000229180.5	GS1-124K5.11	-4.09	4.66e-05	0.00321	-0.11	-0.13	Aortic root size;	chr7:66152608	chr7:66526088~66542624:-
BRCA	cis	rs6490294	0.851	rs56814171	ENSG00000257624.1	RP1-128M12.3	4.09	4.66e-05	0.00321	0.17	0.13	Mean platelet volume;	chr12:111965146	chr12:112000739~112000985:-
BRCA	cis	rs7267979	0.816	rs422148	ENSG00000231081.1	RP4-760C5.3	-4.09	4.66e-05	0.00322	-0.16	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25531968	chr20:26008791~26010531:-
BRCA	cis	rs1322639	0.531	rs11751421	ENSG00000223485.1	RP11-417E7.1	4.09	4.66e-05	0.00322	0.13	0.13	Pulse pressure;	chr6:169174898	chr6:169158092~169162924:-
BRCA	cis	rs8014204	0.604	rs2159906	ENSG00000279594.1	RP11-950C14.10	4.09	4.66e-05	0.00322	0.15	0.13	Caffeine consumption;	chr14:74924209	chr14:75011269~75012851:-
BRCA	cis	rs7312933	0.703	rs12371615	ENSG00000257225.1	RP11-328C8.4	-4.09	4.66e-05	0.00322	-0.15	-0.13	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42170187	chr12:42459366~42466128:+
BRCA	cis	rs5758659	0.729	rs134866	ENSG00000231261.1	HMGN2P10	4.09	4.66e-05	0.00322	0.14	0.13	Cognitive function;	chr22:42254657	chr22:41709225~41709489:-
BRCA	cis	rs4664293	0.625	rs6713600	ENSG00000226266.5	AC009961.3	4.09	4.66e-05	0.00322	0.15	0.13	Monocyte percentage of white cells;	chr2:159706559	chr2:159670708~159712435:-
BRCA	cis	rs4664293	0.625	rs7607394	ENSG00000226266.5	AC009961.3	4.09	4.66e-05	0.00322	0.15	0.13	Monocyte percentage of white cells;	chr2:159707286	chr2:159670708~159712435:-
BRCA	cis	rs11992162	0.636	rs11250182	ENSG00000154316.13	TDH	4.09	4.67e-05	0.00322	0.15	0.13	Monocyte count;	chr8:11950067	chr8:11339637~11368452:+
BRCA	cis	rs2408955	0.522	rs4760679	ENSG00000257735.1	RP11-370I10.6	-4.09	4.67e-05	0.00322	-0.15	-0.13	Glycated hemoglobin levels;	chr12:48067852	chr12:48350945~48442411:+
BRCA	cis	rs13401620	0.665	rs13414110	ENSG00000229326.3	AC069154.4	-4.09	4.67e-05	0.00322	-0.16	-0.13	Breast size;	chr2:119901443	chr2:119698623~119700151:+
BRCA	cis	rs10761482	0.861	rs9988785	ENSG00000254271.1	RP11-131N11.4	4.09	4.67e-05	0.00322	0.17	0.13	Schizophrenia;	chr10:60349234	chr10:60734342~60741828:+
BRCA	cis	rs4650943	0.586	rs74561013	ENSG00000227740.1	RP11-318C24.2	-4.09	4.67e-05	0.00322	-0.13	-0.13	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in inactive individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr1:176232578	chr1:175904762~175920513:-
BRCA	cis	rs244293	0.7	rs12939352	ENSG00000275710.1	RP11-257O5.4	4.09	4.67e-05	0.00322	0.13	0.13	Menarche (age at onset);	chr17:54930294	chr17:54964474~54964679:+
BRCA	cis	rs10200159	0.793	rs10496054	ENSG00000272606.1	RP11-554J4.1	-4.09	4.67e-05	0.00322	-0.27	-0.13	Vitiligo;	chr2:55761735	chr2:55617909~55618373:+
BRCA	cis	rs1953600	0.87	rs2573356	ENSG00000226659.1	RP11-137H2.4	4.09	4.67e-05	0.00322	0.17	0.13	Sarcoidosis;	chr10:80189607	chr10:80529597~80535942:-
BRCA	cis	rs6696239	0.956	rs11581704	ENSG00000215812.5	ZNF847P	4.09	4.67e-05	0.00322	0.18	0.13	Height;	chr1:227621033	chr1:227696892~227706699:-
BRCA	cis	rs1510272	1	rs1510272	ENSG00000243926.1	TIPARP-AS1	-4.09	4.67e-05	0.00322	-0.14	-0.13	Testicular germ cell tumor;	chr3:156582935	chr3:156671862~156674378:-
BRCA	cis	rs29784	0.526	rs29795	ENSG00000253959.1	CTB-43E15.1	-4.09	4.67e-05	0.00322	-0.11	-0.13	Infantile hypertrophic pyloric stenosis;	chr5:173150400	chr5:173642519~173658194:+
BRCA	cis	rs12612619	0.704	rs10185736	ENSG00000272148.1	RP11-195B17.1	-4.09	4.67e-05	0.00322	-0.14	-0.13	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27098356	chr2:27062428~27062907:-
BRCA	cis	rs7577696	0.744	rs2268797	ENSG00000272716.1	RP11-563N4.1	4.09	4.67e-05	0.00322	0.14	0.13	Inflammatory biomarkers;	chr2:31558682	chr2:32165046~32165757:-
BRCA	cis	rs7481584	0.624	rs369461	ENSG00000236710.1	AC108448.2	4.09	4.67e-05	0.00322	0.17	0.13	Calcium levels;	chr11:3040762	chr11:3084393~3085443:-
BRCA	cis	rs651907	0.535	rs36060163	ENSG00000256628.3	ZBTB11-AS1	4.09	4.67e-05	0.00322	0.16	0.13	Colorectal cancer;	chr3:101642119	chr3:101676475~101679217:+
BRCA	cis	rs12786942	0.932	rs12801419	ENSG00000254506.1	RP11-748H22.1	4.09	4.67e-05	0.00322	0.23	0.13	Facial depth;	chr11:101485398	chr11:101584295~101595156:+
BRCA	cis	rs12786942	1	rs12806241	ENSG00000254506.1	RP11-748H22.1	4.09	4.67e-05	0.00322	0.23	0.13	Facial depth;	chr11:101490297	chr11:101584295~101595156:+
BRCA	cis	rs516805	0.667	rs1456706	ENSG00000279114.1	RP3-425C14.5	-4.09	4.67e-05	0.00322	-0.16	-0.13	Lymphocyte counts;	chr6:122134801	chr6:122471923~122484161:+
BRCA	cis	rs516805	0.667	rs2606651	ENSG00000279114.1	RP3-425C14.5	-4.09	4.67e-05	0.00322	-0.16	-0.13	Lymphocyte counts;	chr6:122136475	chr6:122471923~122484161:+
BRCA	cis	rs1371614	0.635	rs12714002	ENSG00000229122.1	AGBL5-IT1	-4.09	4.67e-05	0.00322	-0.13	-0.13	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26912057	chr2:27061038~27061815:+
BRCA	cis	rs8017423	0.615	rs12586761	ENSG00000275198.1	RP11-471B22.3	4.09	4.67e-05	0.00322	0.15	0.13	Mortality in heart failure;	chr14:90354553	chr14:90383365~90387973:+
BRCA	cis	rs11098499	0.82	rs6829903	ENSG00000260091.1	RP11-33B1.4	-4.09	4.67e-05	0.00322	-0.11	-0.13	Corneal astigmatism;	chr4:119585729	chr4:119409333~119410233:+
BRCA	cis	rs8114671	0.562	rs34837802	ENSG00000261582.1	RP4-614O4.11	-4.09	4.67e-05	0.00322	-0.12	-0.13	Height;	chr20:34837105	chr20:35267885~35280043:-
BRCA	cis	rs6026584	0.823	rs6026574	ENSG00000270951.1	RP1-309F20.4	-4.09	4.67e-05	0.00322	-0.16	-0.13	Renal function-related traits (BUN);	chr20:58881440	chr20:58876592~58876981:-
BRCA	cis	rs801193	1	rs1553609	ENSG00000273142.1	RP11-458F8.4	-4.09	4.67e-05	0.00322	-0.11	-0.13	Aortic root size;	chr7:66732152	chr7:66902857~66906297:+
BRCA	cis	rs6431644	0.64	rs917432	ENSG00000224287.2	MSL3P1	4.09	4.68e-05	0.00322	0.15	0.13	Left atrial antero-posterior diameter;	chr2:233854278	chr2:233865437~233868444:-
BRCA	cis	rs4699052	0.739	rs6855777	ENSG00000248740.4	RP11-328K4.1	-4.09	4.68e-05	0.00322	-0.14	-0.13	Testicular germ cell tumor;	chr4:103321207	chr4:103256159~103453658:+
BRCA	cis	rs2839186	0.596	rs4819217	ENSG00000223901.2	AP001469.5	4.09	4.68e-05	0.00322	0.13	0.13	Testicular germ cell tumor;	chr21:46224178	chr21:46220269~46225364:+
BRCA	cis	rs4919694	1	rs11191545	ENSG00000236937.2	PTGES3P4	4.09	4.68e-05	0.00322	0.25	0.13	Arsenic metabolism;	chr10:103070036	chr10:102845595~102845950:+
BRCA	cis	rs11098499	0.863	rs7669520	ENSG00000260091.1	RP11-33B1.4	-4.09	4.68e-05	0.00322	-0.11	-0.13	Corneal astigmatism;	chr4:119594123	chr4:119409333~119410233:+
BRCA	cis	rs4415084	0.716	rs6451778	ENSG00000251141.4	RP11-53O19.1	-4.09	4.68e-05	0.00322	-0.12	-0.13	Breast cancer;	chr5:44857886	chr5:44744900~44808777:-
BRCA	cis	rs17489649	0.868	rs13185070	ENSG00000271849.1	CTC-332L22.1	4.09	4.68e-05	0.00323	0.16	0.13	Intelligence (multi-trait analysis);	chr5:109818161	chr5:109687802~109688329:-
BRCA	cis	rs6088590	0.561	rs11167239	ENSG00000275784.1	RP5-1125A11.6	-4.09	4.68e-05	0.00323	-0.14	-0.13	Coronary artery disease;	chr20:34552668	chr20:33989480~33991818:-
BRCA	cis	rs9952991	0.941	rs2014857	ENSG00000260302.1	RP11-973H7.1	-4.09	4.68e-05	0.00323	-0.2	-0.13	Inflammatory skin disease;	chr18:12774327	chr18:12774651~12775923:-
BRCA	cis	rs10911902	0.602	rs6425025	ENSG00000229739.2	RP11-295K2.3	-4.09	4.68e-05	0.00323	-0.19	-0.13	Schizophrenia;	chr1:186305025	chr1:186435161~186470291:+
BRCA	cis	rs7937890	0.559	rs2597219	ENSG00000254418.1	RP11-21L19.1	4.09	4.68e-05	0.00323	0.15	0.13	Mitochondrial DNA levels;	chr11:14509320	chr11:14262846~14273691:-
BRCA	cis	rs7937890	0.559	rs2575852	ENSG00000254418.1	RP11-21L19.1	4.09	4.68e-05	0.00323	0.15	0.13	Mitochondrial DNA levels;	chr11:14511822	chr11:14262846~14273691:-
BRCA	cis	rs7937890	0.531	rs2597216	ENSG00000254418.1	RP11-21L19.1	4.09	4.68e-05	0.00323	0.15	0.13	Mitochondrial DNA levels;	chr11:14512370	chr11:14262846~14273691:-
BRCA	cis	rs7937890	0.559	rs1548074	ENSG00000254418.1	RP11-21L19.1	4.09	4.68e-05	0.00323	0.15	0.13	Mitochondrial DNA levels;	chr11:14513279	chr11:14262846~14273691:-
BRCA	cis	rs718433	0.599	rs1014478	ENSG00000256379.1	TRAV8-5	4.09	4.68e-05	0.00323	0.16	0.13	Intraocular pressure;	chr14:21849523	chr14:21903077~21903598:+
BRCA	cis	rs957448	0.561	rs1808488	ENSG00000261437.1	RP11-22C11.2	4.09	4.68e-05	0.00323	0.12	0.13	Nonsyndromic cleft lip with cleft palate;	chr8:94602636	chr8:94637285~94639467:-
BRCA	cis	rs957448	0.583	rs754275	ENSG00000261437.1	RP11-22C11.2	4.09	4.68e-05	0.00323	0.12	0.13	Nonsyndromic cleft lip with cleft palate;	chr8:94602741	chr8:94637285~94639467:-
BRCA	cis	rs957448	0.561	rs1426172	ENSG00000261437.1	RP11-22C11.2	4.09	4.68e-05	0.00323	0.12	0.13	Nonsyndromic cleft lip with cleft palate;	chr8:94602988	chr8:94637285~94639467:-
BRCA	cis	rs1387259	0.64	rs10783243	ENSG00000273765.1	RP11-370I10.11	-4.09	4.68e-05	0.00323	-0.14	-0.13	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48259220	chr12:48360920~48361377:+
BRCA	cis	rs9921338	0.961	rs66555362	ENSG00000262636.1	CTD-3088G3.4	-4.09	4.68e-05	0.00323	-0.2	-0.13	Vein graft stenosis in coronary artery bypass grafting;	chr16:11294976	chr16:11380859~11381118:-
BRCA	cis	rs2924679	1	rs3019587	ENSG00000255741.1	RP11-757G1.5	4.09	4.68e-05	0.00323	0.33	0.13	Obesity-related traits;	chr11:68802174	chr11:68941503~68942852:-
BRCA	cis	rs875971	0.545	rs10950036	ENSG00000273142.1	RP11-458F8.4	4.09	4.69e-05	0.00323	0.12	0.13	Aortic root size;	chr7:66353241	chr7:66902857~66906297:+
BRCA	cis	rs7260598	0.642	rs67799720	ENSG00000268442.1	CTD-2027I19.2	4.09	4.69e-05	0.00323	0.2	0.13	Response to taxane treatment (placlitaxel);	chr19:23981347	chr19:24162370~24163425:-
BRCA	cis	rs2411233	1	rs12910064	ENSG00000259278.1	RP11-62C7.2	4.09	4.69e-05	0.00323	0.15	0.13	Platelet count;	chr15:38991535	chr15:39019233~39024918:+
BRCA	cis	rs9470794	0.915	rs11758035	ENSG00000204110.6	RP1-153P14.8	-4.09	4.69e-05	0.00323	-0.26	-0.13	Type 2 diabetes;	chr6:37872337	chr6:37507348~37535616:+
BRCA	cis	rs1876905	0.68	rs7767302	ENSG00000271789.1	RP5-1112D6.7	4.09	4.69e-05	0.00323	0.19	0.13	Mean corpuscular hemoglobin;	chr6:111143942	chr6:111297126~111298510:+
BRCA	cis	rs9309473	0.607	rs6716776	ENSG00000230002.2	ALMS1-IT1	4.09	4.69e-05	0.00323	0.15	0.13	Metabolite levels;	chr2:73360585	chr2:73456764~73459484:+
BRCA	cis	rs11098499	0.754	rs12510269	ENSG00000225892.3	RP11-384K6.2	4.09	4.69e-05	0.00323	0.12	0.13	Corneal astigmatism;	chr4:119320491	chr4:118632274~118634759:+
BRCA	cis	rs10895275	0.649	rs1895916	ENSG00000277459.1	RP11-732A21.3	4.09	4.69e-05	0.00323	0.12	0.13	Migraine;	chr11:102221938	chr11:102109827~102110457:-
BRCA	cis	rs56313388	0.505	rs11076145	ENSG00000246379.5	RP11-461O7.1	-4.09	4.69e-05	0.00323	-0.14	-0.13	Pulse pressure;	chr16:56215975	chr16:56092987~56191094:-
BRCA	cis	rs9467773	0.572	rs2076029	ENSG00000124549.13	BTN2A3P	-4.09	4.69e-05	0.00323	-0.13	-0.13	Intelligence (multi-trait analysis);	chr6:26390602	chr6:26421391~26432383:+
BRCA	cis	rs2403083	0.584	rs4150942	ENSG00000258256.1	RP11-219B4.5	-4.09	4.69e-05	0.00323	-0.15	-0.13	Plasma amyloid beta peptide concentrations (ABx-40);	chr8:85203451	chr8:85222446~85245717:-
BRCA	cis	rs10129255	0.5	rs11627315	ENSG00000211967.3	IGHV3-53	-4.09	4.69e-05	0.00323	-0.08	-0.13	Kawasaki disease;	chr14:106802182	chr14:106592676~106593347:-
BRCA	cis	rs6893300	0.785	rs6887507	ENSG00000225051.5	HMGB3P22	4.09	4.69e-05	0.00323	0.16	0.13	Resting heart rate;	chr5:179759236	chr5:179679032~179694768:+
BRCA	cis	rs9818758	0.607	rs80170003	ENSG00000225399.4	RP11-3B7.1	-4.09	4.7e-05	0.00323	-0.23	-0.13	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:48914207	chr3:49260085~49261316:+
BRCA	cis	rs6600671	0.691	rs6600662	ENSG00000275538.1	RNVU1-19	4.09	4.7e-05	0.00323	0.16	0.13	Hip geometry;	chr1:121488992	chr1:120850819~120850985:-
BRCA	cis	rs7312933	0.618	rs6582394	ENSG00000257225.1	RP11-328C8.4	-4.09	4.7e-05	0.00324	-0.15	-0.13	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42292387	chr12:42459366~42466128:+
BRCA	cis	rs8105895	0.733	rs10423457	ENSG00000269345.1	VN1R85P	4.09	4.7e-05	0.00324	0.18	0.13	Body mass index (change over time);	chr19:22096465	chr19:22174766~22175191:-
BRCA	cis	rs11742741	0.742	rs6452183	ENSG00000248874.4	C5orf17	-4.09	4.7e-05	0.00324	-0.16	-0.13	Educational attainment;	chr5:24053567	chr5:23951348~24178263:+
BRCA	cis	rs11742741	0.806	rs1604456	ENSG00000248874.4	C5orf17	-4.09	4.7e-05	0.00324	-0.16	-0.13	Educational attainment;	chr5:24053734	chr5:23951348~24178263:+
BRCA	cis	rs1941184	0.5	rs11873153	ENSG00000266521.1	RP11-650P15.1	-4.09	4.7e-05	0.00324	-0.17	-0.13	Parkinson's disease (age of onset);	chr18:31432005	chr18:31496645~31497195:-
BRCA	cis	rs983392	0.805	rs2123314	ENSG00000275344.1	MIR6503	4.09	4.7e-05	0.00324	0.13	0.13	Alzheimer's disease (late onset);	chr11:60198822	chr11:60209071~60209156:-
BRCA	cis	rs11083475	1	rs3786848	ENSG00000267892.1	CTD-2540F13.2	4.09	4.7e-05	0.00324	0.14	0.13	Heart rate;	chr19:38716689	chr19:38738284~38739863:+
BRCA	cis	rs6496932	0.802	rs2063442	ENSG00000218052.5	ADAMTS7P4	4.09	4.7e-05	0.00324	0.14	0.13	Central corneal thickness;Corneal structure;	chr15:85314813	chr15:85255369~85330334:-
BRCA	cis	rs9467773	0.62	rs2504600	ENSG00000224843.5	LINC00240	-4.09	4.7e-05	0.00324	-0.14	-0.13	Intelligence (multi-trait analysis);	chr6:26648106	chr6:26956992~27023924:+
BRCA	cis	rs9467773	0.62	rs2130657	ENSG00000224843.5	LINC00240	-4.09	4.7e-05	0.00324	-0.14	-0.13	Intelligence (multi-trait analysis);	chr6:26650598	chr6:26956992~27023924:+
BRCA	cis	rs9467773	0.62	rs2498351	ENSG00000224843.5	LINC00240	-4.09	4.7e-05	0.00324	-0.14	-0.13	Intelligence (multi-trait analysis);	chr6:26659414	chr6:26956992~27023924:+
BRCA	cis	rs9467773	0.62	rs2504566	ENSG00000224843.5	LINC00240	-4.09	4.7e-05	0.00324	-0.14	-0.13	Intelligence (multi-trait analysis);	chr6:26660260	chr6:26956992~27023924:+
BRCA	cis	rs10504130	0.569	rs11775611	ENSG00000253844.1	RP11-546K22.1	-4.09	4.7e-05	0.00324	-0.18	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr8:51907714	chr8:51961458~52022974:+
BRCA	cis	rs3816183	1	rs10174617	ENSG00000226491.1	FTOP1	-4.09	4.7e-05	0.00324	-0.16	-0.13	Hypospadias;	chr2:42788925	chr2:42797225~42798712:-
BRCA	cis	rs61160187	0.582	rs72757187	ENSG00000272308.1	RP11-231G3.1	-4.09	4.7e-05	0.00324	-0.14	-0.13	Educational attainment (years of education);Educational attainment (college completion);	chr5:60967939	chr5:60866457~60866935:-
BRCA	cis	rs6951245	0.935	rs112554101	ENSG00000229043.2	AC091729.9	-4.09	4.7e-05	0.00324	-0.2	-0.13	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1025899	chr7:1160374~1165267:+
BRCA	cis	rs12435908	1	rs59117465	ENSG00000276116.2	FUT8-AS1	-4.09	4.7e-05	0.00324	-0.21	-0.13	Ischemic stroke;	chr14:65585754	chr14:65411170~65412690:-
BRCA	cis	rs7020830	0.789	rs17408112	ENSG00000260100.1	RP11-220I1.5	-4.09	4.7e-05	0.00324	-0.15	-0.13	Schizophrenia;	chr9:37114068	chr9:37078813~37079776:-
BRCA	cis	rs6546324	0.625	rs2861689	ENSG00000236780.4	AC078941.1	4.09	4.7e-05	0.00324	0.21	0.13	Endometriosis;	chr2:67611472	chr2:67123357~67215319:-
BRCA	cis	rs7772486	0.875	rs6934467	ENSG00000270638.1	RP3-466P17.1	4.09	4.7e-05	0.00324	0.15	0.13	Lobe attachment (rater-scored or self-reported);	chr6:146089393	chr6:145735570~145737218:+
BRCA	cis	rs7481584	0.962	rs2001006	ENSG00000247473.2	CARS-AS1	-4.09	4.71e-05	0.00324	-0.15	-0.13	Calcium levels;	chr11:2953682	chr11:3029009~3041260:+
BRCA	cis	rs1153858	1	rs4534782	ENSG00000275672.1	GATM-AS1	-4.09	4.71e-05	0.00324	-0.16	-0.13	Homoarginine levels;	chr15:45360735	chr15:45378700~45380123:+
BRCA	cis	rs748404	0.666	rs16957730	ENSG00000205771.5	CATSPER2P1	-4.09	4.71e-05	0.00324	-0.19	-0.13	Lung cancer;	chr15:43438288	chr15:43726918~43747094:-
BRCA	cis	rs17489649	1	rs11747338	ENSG00000271849.1	CTC-332L22.1	4.09	4.71e-05	0.00324	0.16	0.13	Intelligence (multi-trait analysis);	chr5:109815030	chr5:109687802~109688329:-
BRCA	cis	rs3764563	0.935	rs643442	ENSG00000267594.5	CYP4F24P	4.09	4.71e-05	0.00324	0.23	0.13	Inflammatory biomarkers;	chr19:15573276	chr19:15760241~15779909:-
BRCA	cis	rs2243480	1	rs781156	ENSG00000226002.1	RP11-460N20.5	-4.09	4.71e-05	0.00324	-0.21	-0.13	Diabetic kidney disease;	chr7:66014154	chr7:65084103~65100232:+
BRCA	cis	rs2243480	1	rs451396	ENSG00000226002.1	RP11-460N20.5	-4.09	4.71e-05	0.00324	-0.21	-0.13	Diabetic kidney disease;	chr7:66019087	chr7:65084103~65100232:+
BRCA	cis	rs2243480	1	rs1715235	ENSG00000226002.1	RP11-460N20.5	-4.09	4.71e-05	0.00324	-0.21	-0.13	Diabetic kidney disease;	chr7:66023407	chr7:65084103~65100232:+
BRCA	cis	rs12435908	1	rs60554055	ENSG00000276116.2	FUT8-AS1	-4.09	4.71e-05	0.00324	-0.19	-0.13	Ischemic stroke;	chr14:65601567	chr14:65411170~65412690:-
BRCA	cis	rs2486012	1	rs2485990	ENSG00000237950.1	RP11-7O11.3	-4.09	4.71e-05	0.00324	-0.23	-0.13	Intelligence (multi-trait analysis);	chr1:43931118	chr1:43944370~43946551:-
BRCA	cis	rs17684571	0.687	rs34083827	ENSG00000231441.1	RP11-472M19.2	4.09	4.71e-05	0.00324	0.21	0.13	Schizophrenia;	chr6:56866498	chr6:56844002~56864078:+
BRCA	cis	rs11098403	0.833	rs4569817	ENSG00000225892.3	RP11-384K6.2	4.09	4.71e-05	0.00324	0.12	0.13	Schizophrenia;	chr4:117776753	chr4:118632274~118634759:+
BRCA	cis	rs7267979	0.899	rs6115213	ENSG00000276952.1	RP5-965G21.6	4.09	4.71e-05	0.00325	0.15	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25569736	chr20:25284915~25285588:-
BRCA	cis	rs4835473	0.932	rs17695238	ENSG00000249741.2	RP11-673E1.3	4.09	4.71e-05	0.00325	0.14	0.13	Immature fraction of reticulocytes;	chr4:143820720	chr4:143911514~143912053:-
BRCA	cis	rs11098499	0.954	rs10017543	ENSG00000260404.2	RP11-384K6.6	4.09	4.71e-05	0.00325	0.12	0.13	Corneal astigmatism;	chr4:119400265	chr4:118591773~118633729:+
BRCA	cis	rs6593122	0.785	rs10242612	ENSG00000235454.1	HAUS6P3	-4.09	4.71e-05	0.00325	-0.17	-0.13	Vaccine-related adverse events;	chr7:54126112	chr7:53862233~53863339:+
BRCA	cis	rs6593122	0.755	rs4947872	ENSG00000235454.1	HAUS6P3	-4.09	4.71e-05	0.00325	-0.17	-0.13	Vaccine-related adverse events;	chr7:54127962	chr7:53862233~53863339:+
BRCA	cis	rs6593122	0.755	rs4947454	ENSG00000235454.1	HAUS6P3	-4.09	4.71e-05	0.00325	-0.17	-0.13	Vaccine-related adverse events;	chr7:54128008	chr7:53862233~53863339:+
BRCA	cis	rs6593122	0.755	rs12667707	ENSG00000235454.1	HAUS6P3	-4.09	4.71e-05	0.00325	-0.17	-0.13	Vaccine-related adverse events;	chr7:54128298	chr7:53862233~53863339:+
BRCA	cis	rs7267979	1	rs4815412	ENSG00000125804.12	FAM182A	-4.09	4.71e-05	0.00325	-0.16	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25369689	chr20:26054655~26086917:+
BRCA	cis	rs10844706	0.699	rs10844636	ENSG00000214776.8	RP11-726G1.1	-4.09	4.71e-05	0.00325	-0.15	-0.13	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9735420	chr12:9467552~9576275:+
BRCA	cis	rs747650	0.504	rs4752816	ENSG00000200376.1	RNU5E-10P	4.09	4.72e-05	0.00325	0.17	0.13	Acne (severe);	chr11:46957472	chr11:47576471~47576588:-
BRCA	cis	rs2832191	0.791	rs7283853	ENSG00000236056.1	GAPDHP14	4.09	4.72e-05	0.00325	0.14	0.13	Dental caries;	chr21:29126194	chr21:29222321~29223257:+
BRCA	cis	rs11035577	0.57	rs991295	ENSG00000279675.1	RP11-454H19.2	-4.09	4.72e-05	0.00325	-0.2	-0.13	Temperament (bipolar disorder);	chr11:39778558	chr11:40107244~40112599:-
BRCA	cis	rs6736093	0.763	rs4848973	ENSG00000236307.2	EEF1E1P1	-4.09	4.72e-05	0.00325	-0.16	-0.13	Coronary artery disease;	chr2:112032985	chr2:111887914~111888741:+
BRCA	cis	rs7772486	0.754	rs9386132	ENSG00000270638.1	RP3-466P17.1	4.09	4.72e-05	0.00325	0.15	0.13	Lobe attachment (rater-scored or self-reported);	chr6:145819615	chr6:145735570~145737218:+
BRCA	cis	rs1005277	0.579	rs2474584	ENSG00000272983.1	RP11-508N22.12	4.09	4.72e-05	0.00325	0.13	0.13	Extrinsic epigenetic age acceleration;	chr10:38127461	chr10:38137337~38144399:+
BRCA	cis	rs1005277	0.579	rs2474586	ENSG00000272983.1	RP11-508N22.12	4.09	4.72e-05	0.00325	0.13	0.13	Extrinsic epigenetic age acceleration;	chr10:38129954	chr10:38137337~38144399:+
BRCA	cis	rs4415084	0.688	rs10462083	ENSG00000251141.4	RP11-53O19.1	4.09	4.72e-05	0.00325	0.12	0.13	Breast cancer;	chr5:44806635	chr5:44744900~44808777:-
BRCA	cis	rs2274459	1	rs35646598	ENSG00000249346.5	LINC01016	4.09	4.72e-05	0.00325	0.17	0.13	Obesity (extreme);	chr6:33749639	chr6:33867506~33896914:-
BRCA	cis	rs13108904	0.935	rs13148614	ENSG00000253399.1	AC078852.2	-4.09	4.72e-05	0.00325	-0.14	-0.13	Obesity-related traits;	chr4:1254569	chr4:1358479~1359461:+
BRCA	cis	rs875971	0.545	rs1638735	ENSG00000232559.3	GS1-124K5.12	4.09	4.72e-05	0.00325	0.17	0.13	Aortic root size;	chr7:66630751	chr7:66554588~66576923:-
BRCA	cis	rs8099594	0.565	rs4939846	ENSG00000266696.1	RP11-30L3.2	-4.09	4.72e-05	0.00325	-0.14	-0.13	Height;	chr18:49189715	chr18:49205912~49208781:+
BRCA	cis	rs4302906	0.964	rs10283714	ENSG00000187984.11	ANKRD19P	-4.09	4.72e-05	0.00325	-0.12	-0.13	Lobe attachment (rater-scored or self-reported);	chr9:92987075	chr9:92809388~92888693:+
BRCA	cis	rs755249	0.501	rs2490945	ENSG00000237624.1	OXCT2P1	4.09	4.72e-05	0.00325	0.16	0.13	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39371672	chr1:39514956~39516490:+
BRCA	cis	rs8114671	0.836	rs6060140	ENSG00000126005.14	MMP24-AS1	-4.09	4.72e-05	0.00325	-0.15	-0.13	Height;	chr20:34978704	chr20:35216462~35278131:-
BRCA	cis	rs7474896	0.513	rs10827797	ENSG00000272983.1	RP11-508N22.12	4.09	4.72e-05	0.00325	0.23	0.13	Obesity (extreme);	chr10:37548585	chr10:38137337~38144399:+
BRCA	cis	rs7474896	0.513	rs11011246	ENSG00000272983.1	RP11-508N22.12	4.09	4.72e-05	0.00325	0.23	0.13	Obesity (extreme);	chr10:37550355	chr10:38137337~38144399:+
BRCA	cis	rs7119	0.604	rs2682924	ENSG00000259362.2	RP11-307C19.1	-4.09	4.72e-05	0.00325	-0.17	-0.13	Type 2 diabetes;	chr15:77571378	chr15:77525540~77534110:+
BRCA	cis	rs1065852	0.526	rs59993856	ENSG00000205702.9	CYP2D7	4.09	4.72e-05	0.00325	0.11	0.13	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42007976	chr22:42140203~42144577:-
BRCA	cis	rs9952980	0.752	rs12455117	ENSG00000266968.2	RP11-116O18.1	-4.09	4.72e-05	0.00325	-0.15	-0.13	Breast cancer;	chr18:45304061	chr18:45646153~45647937:+
BRCA	cis	rs10829156	0.699	rs7911922	ENSG00000225527.1	RP11-383B4.4	-4.09	4.72e-05	0.00325	-0.17	-0.13	Sudden cardiac arrest;	chr10:18542768	chr10:18531849~18533336:-
BRCA	cis	rs4650943	0.55	rs2938149	ENSG00000227740.1	RP11-318C24.2	-4.09	4.72e-05	0.00325	-0.13	-0.13	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in inactive individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr1:176325165	chr1:175904762~175920513:-
BRCA	cis	rs752010	0.543	rs1570355	ENSG00000230638.4	RP11-486B10.4	-4.09	4.72e-05	0.00325	-0.15	-0.13	Lupus nephritis in systemic lupus erythematosus;	chr1:41576646	chr1:41542069~41544310:+
BRCA	cis	rs7267979	0.714	rs6132825	ENSG00000276952.1	RP5-965G21.6	4.09	4.73e-05	0.00325	0.15	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25257673	chr20:25284915~25285588:-
BRCA	cis	rs9470794	0.915	rs77803369	ENSG00000204110.6	RP1-153P14.8	-4.09	4.73e-05	0.00325	-0.26	-0.13	Type 2 diabetes;	chr6:37867857	chr6:37507348~37535616:+
BRCA	cis	rs5758511	0.731	rs5751186	ENSG00000226450.2	CYP2D8P	-4.09	4.73e-05	0.00325	-0.14	-0.13	Birth weight;	chr22:41953706	chr22:42149886~42155001:-
BRCA	cis	rs561341	1	rs7214017	ENSG00000277511.1	CTD-2095E4.5	4.09	4.73e-05	0.00325	0.17	0.13	Hip circumference adjusted for BMI;	chr17:32005201	chr17:32127595~32128454:+
BRCA	cis	rs4648045	0.594	rs62327180	ENSG00000246560.2	RP11-10L12.4	4.09	4.73e-05	0.00325	0.15	0.13	Lymphocyte percentage of white cells;	chr4:102619605	chr4:102828055~102844075:+
BRCA	cis	rs4499344	0.73	rs453804	ENSG00000267475.1	CTD-2538C1.2	4.09	4.73e-05	0.00325	0.16	0.13	Mean platelet volume;	chr19:32614706	chr19:32687089~32691750:-
BRCA	cis	rs4499344	0.73	rs392332	ENSG00000267475.1	CTD-2538C1.2	4.09	4.73e-05	0.00325	0.16	0.13	Mean platelet volume;	chr19:32614837	chr19:32687089~32691750:-
BRCA	cis	rs73201462	1	rs2999089	ENSG00000242551.2	POU5F1P6	-4.09	4.73e-05	0.00326	-0.23	-0.13	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128216316	chr3:128674735~128677005:-
BRCA	cis	rs17489649	1	rs3797681	ENSG00000271849.1	CTC-332L22.1	4.09	4.73e-05	0.00326	0.16	0.13	Intelligence (multi-trait analysis);	chr5:109824123	chr5:109687802~109688329:-
BRCA	cis	rs9921338	0.924	rs7193645	ENSG00000262636.1	CTD-3088G3.4	-4.09	4.73e-05	0.00326	-0.2	-0.13	Vein graft stenosis in coronary artery bypass grafting;	chr16:11287179	chr16:11380859~11381118:-
BRCA	cis	rs1153858	1	rs4775937	ENSG00000275672.1	GATM-AS1	-4.09	4.73e-05	0.00326	-0.16	-0.13	Homoarginine levels;	chr15:45386416	chr15:45378700~45380123:+
BRCA	cis	rs897984	0.52	rs4889614	ENSG00000274678.1	RP11-2C24.7	-4.09	4.73e-05	0.00326	-0.16	-0.13	Dementia with Lewy bodies;	chr16:30850814	chr16:30821338~30821884:+
BRCA	cis	rs1048886	0.808	rs6455369	ENSG00000271967.1	RP11-134K13.4	-4.09	4.74e-05	0.00326	-0.17	-0.13	Type 2 diabetes;	chr6:70528850	chr6:70596438~70596980:+
BRCA	cis	rs7561149	1	rs12469367	ENSG00000270574.1	RP11-171I2.2	-4.09	4.74e-05	0.00326	-0.17	-0.13	QT interval;	chr2:178826943	chr2:178578790~178580906:+
BRCA	cis	rs7200543	1	rs2740	ENSG00000207425.1	Y_RNA	-4.09	4.74e-05	0.00326	-0.15	-0.13	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15038251	chr16:14915457~14915556:-
BRCA	cis	rs1953600	0.87	rs2789695	ENSG00000226659.1	RP11-137H2.4	4.09	4.74e-05	0.00326	0.17	0.13	Sarcoidosis;	chr10:80187084	chr10:80529597~80535942:-
BRCA	cis	rs1953600	0.87	rs2573370	ENSG00000226659.1	RP11-137H2.4	4.09	4.74e-05	0.00326	0.17	0.13	Sarcoidosis;	chr10:80191610	chr10:80529597~80535942:-
BRCA	cis	rs1953600	0.837	rs3098105	ENSG00000226659.1	RP11-137H2.4	4.09	4.74e-05	0.00326	0.17	0.13	Sarcoidosis;	chr10:80193510	chr10:80529597~80535942:-
BRCA	cis	rs6490294	0.651	rs440	ENSG00000226469.1	ADAM1B	4.09	4.74e-05	0.00326	0.17	0.13	Mean platelet volume;	chr12:111790910	chr12:111927018~111929017:+
BRCA	cis	rs6545883	0.894	rs6545867	ENSG00000212978.6	AC016747.3	-4.09	4.74e-05	0.00326	-0.17	-0.13	Tuberculosis;	chr2:61423892	chr2:61141592~61144969:-
BRCA	cis	rs2299587	0.585	rs2285304	ENSG00000253671.1	RP11-806O11.1	-4.09	4.74e-05	0.00326	-0.17	-0.13	Economic and political preferences;	chr8:17940422	chr8:17808941~17820868:+
BRCA	cis	rs7267979	0.868	rs6138550	ENSG00000277938.1	RP5-965G21.3	4.09	4.74e-05	0.00326	0.15	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25242794	chr20:25229150~25231933:+
BRCA	cis	rs4237845	0.537	rs10877031	ENSG00000257159.1	RP11-58A17.3	4.09	4.74e-05	0.00326	0.16	0.13	Intelligence (multi-trait analysis);	chr12:57872912	chr12:57967058~57968399:+
BRCA	cis	rs1430193	0.583	rs1077779	ENSG00000272606.1	RP11-554J4.1	4.09	4.74e-05	0.00326	0.14	0.13	Lung function (forced vital capacity);	chr2:55896231	chr2:55617909~55618373:+
BRCA	cis	rs2286503	0.752	rs59538378	ENSG00000226329.2	AC005682.6	4.09	4.74e-05	0.00326	0.12	0.13	Fibrinogen;	chr7:22837478	chr7:22863874~22881350:-
BRCA	cis	rs7771547	0.519	rs4713973	ENSG00000224666.3	RP1-50J22.4	4.09	4.74e-05	0.00326	0.15	0.13	Platelet distribution width;	chr6:36414267	chr6:36386831~36393462:+
BRCA	cis	rs1015362	0.54	rs2378026	ENSG00000275784.1	RP5-1125A11.6	-4.09	4.74e-05	0.00326	-0.18	-0.13	Freckles;Red vs. non-red hair color;Skin sensitivity to sun;Burning and freckling;	chr20:33921845	chr20:33989480~33991818:-
BRCA	cis	rs6857303	0.965	rs6857262	ENSG00000251600.4	RP11-673E1.1	4.09	4.74e-05	0.00326	0.15	0.13	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:144104897	chr4:143912331~143982454:+
BRCA	cis	rs11098499	0.955	rs13114751	ENSG00000250412.1	KLHL2P1	4.09	4.74e-05	0.00326	0.15	0.13	Corneal astigmatism;	chr4:119235462	chr4:119334329~119378233:+
BRCA	cis	rs7119	0.634	rs11635634	ENSG00000259362.2	RP11-307C19.1	4.09	4.74e-05	0.00326	0.17	0.13	Type 2 diabetes;	chr15:77571070	chr15:77525540~77534110:+
BRCA	cis	rs7617773	0.963	rs9822496	ENSG00000199476.1	Y_RNA	-4.09	4.74e-05	0.00326	-0.16	-0.13	Coronary artery disease;	chr3:48139843	chr3:48288587~48288694:+
BRCA	cis	rs1005277	0.579	rs2474594	ENSG00000272983.1	RP11-508N22.12	4.09	4.74e-05	0.00326	0.13	0.13	Extrinsic epigenetic age acceleration;	chr10:38137733	chr10:38137337~38144399:+
BRCA	cis	rs1005277	0.579	rs11011461	ENSG00000272983.1	RP11-508N22.12	4.09	4.74e-05	0.00326	0.13	0.13	Extrinsic epigenetic age acceleration;	chr10:38142499	chr10:38137337~38144399:+
BRCA	cis	rs6964587	1	rs11772102	ENSG00000188693.7	CYP51A1-AS1	4.09	4.74e-05	0.00326	0.14	0.13	Breast cancer;	chr7:91929012	chr7:92134604~92180725:+
BRCA	cis	rs6964587	1	rs9969198	ENSG00000188693.7	CYP51A1-AS1	4.09	4.74e-05	0.00326	0.14	0.13	Breast cancer;	chr7:91938178	chr7:92134604~92180725:+
BRCA	cis	rs58521262	0.556	rs289299	ENSG00000268105.1	RP11-369G6.2	-4.09	4.74e-05	0.00326	-0.17	-0.13	Testicular germ cell tumor;	chr19:22992949	chr19:23125665~23128543:+
BRCA	cis	rs1008375	0.966	rs28750296	ENSG00000249502.1	AC006160.5	-4.09	4.74e-05	0.00326	-0.14	-0.13	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17684203	chr4:17587467~17614571:-
BRCA	cis	rs35740288	0.731	rs12913556	ENSG00000202081.1	RNU6-1280P	4.09	4.74e-05	0.00327	0.16	0.13	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85558965	chr15:85651522~85651628:-
BRCA	cis	rs35740288	0.731	rs35085180	ENSG00000202081.1	RNU6-1280P	4.09	4.74e-05	0.00327	0.16	0.13	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85559381	chr15:85651522~85651628:-
BRCA	cis	rs256438	0.602	rs1866389	ENSG00000251050.1	RP11-168A11.4	4.09	4.75e-05	0.00327	0.17	0.13	Serum thyroid-stimulating hormone levels;	chr5:80065442	chr5:80019609~80019920:+
BRCA	cis	rs10504130	0.569	rs12676345	ENSG00000253844.1	RP11-546K22.1	-4.09	4.75e-05	0.00327	-0.18	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr8:51773249	chr8:51961458~52022974:+
BRCA	cis	rs897984	0.52	rs4889534	ENSG00000274678.1	RP11-2C24.7	-4.08	4.75e-05	0.00327	-0.16	-0.13	Dementia with Lewy bodies;	chr16:30854119	chr16:30821338~30821884:+
BRCA	cis	rs9926296	0.744	rs164746	ENSG00000261118.1	RP11-104N10.1	4.08	4.75e-05	0.00327	0.16	0.13	Vitiligo;	chr16:89642611	chr16:89492017~89504460:-
BRCA	cis	rs9402743	0.597	rs9385729	ENSG00000234084.1	RP3-388E23.2	-4.08	4.75e-05	0.00327	-0.12	-0.13	Systemic lupus erythematosus;	chr6:135600001	chr6:135301568~135307158:+
BRCA	cis	rs6545883	0.894	rs2600660	ENSG00000273302.1	RP11-493E12.2	-4.08	4.75e-05	0.00327	-0.12	-0.13	Tuberculosis;	chr2:61322465	chr2:61199979~61200769:+
BRCA	cis	rs11250097	0.549	rs11778177	ENSG00000255046.1	RP11-297N6.4	4.08	4.75e-05	0.00327	0.16	0.13	Neuroticism;	chr8:11452853	chr8:11797928~11802568:-
BRCA	cis	rs11048470	0.614	rs8311	ENSG00000256894.1	RP11-283G6.3	-4.08	4.75e-05	0.00327	-0.13	-0.13	Waist-hip ratio;	chr12:26337157	chr12:26125155~26126617:-
BRCA	cis	rs8037818	1	rs4544214	ENSG00000261064.1	RP11-1000B6.3	4.08	4.75e-05	0.00327	0.16	0.13	Obesity-related traits;	chr15:32639703	chr15:32536047~32587613:+
BRCA	cis	rs2304003	1	rs4667847	ENSG00000235192.1	AC009495.2	4.08	4.75e-05	0.00327	0.15	0.13	Social communication problems;	chr2:165858696	chr2:165794851~165810010:+
BRCA	cis	rs597539	0.652	rs611046	ENSG00000261625.1	RP11-554A11.4	-4.08	4.75e-05	0.00327	-0.12	-0.13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68864236	chr11:69000765~69002048:-
BRCA	cis	rs886774	0.866	rs6949753	ENSG00000273055.1	CTB-13F3.1	-4.08	4.75e-05	0.00327	-0.13	-0.13	Ulcerative colitis;	chr7:107872050	chr7:107942116~107942740:+
BRCA	cis	rs1836229	0.874	rs2053125	ENSG00000225706.1	PTPRD-AS1	-4.08	4.75e-05	0.00327	-0.14	-0.13	Restless legs syndrome;	chr9:8831162	chr9:8858130~8862255:+
BRCA	cis	rs10028773	0.7	rs7690338	ENSG00000260091.1	RP11-33B1.4	-4.08	4.75e-05	0.00327	-0.11	-0.13	Educational attainment;	chr4:119335313	chr4:119409333~119410233:+
BRCA	cis	rs8114671	0.869	rs2145559	ENSG00000126005.14	MMP24-AS1	4.08	4.75e-05	0.00327	0.15	0.13	Height;	chr20:35063922	chr20:35216462~35278131:-
BRCA	cis	rs564309	1	rs505129	ENSG00000183929.7	DUSP5P1	4.08	4.75e-05	0.00327	0.23	0.13	Hip circumference (psychosocial stress interaction);	chr1:228399128	chr1:228650241~228651379:+
BRCA	cis	rs6840360	0.555	rs4554052	ENSG00000270265.1	RP11-731D1.4	4.08	4.75e-05	0.00327	0.15	0.13	Intelligence (multi-trait analysis);	chr4:151805458	chr4:151333775~151353224:-
BRCA	cis	rs17772222	0.876	rs12587598	ENSG00000258789.1	RP11-507K2.3	-4.08	4.75e-05	0.00327	-0.15	-0.13	Coronary artery calcification;	chr14:88729474	chr14:88551597~88552493:+
BRCA	cis	rs6840360	0.582	rs11733820	ENSG00000251603.1	RP11-164P12.4	-4.08	4.75e-05	0.00327	-0.12	-0.13	Intelligence (multi-trait analysis);	chr4:151394987	chr4:151667224~151670502:+
BRCA	cis	rs3096299	0.933	rs28608022	ENSG00000259877.2	RP11-46C24.7	-4.08	4.75e-05	0.00327	-0.12	-0.13	Multiple myeloma (IgH translocation);	chr16:89387884	chr16:89215211~89217653:-
BRCA	cis	rs6593122	0.755	rs1987272	ENSG00000235454.1	HAUS6P3	-4.08	4.75e-05	0.00327	-0.17	-0.13	Vaccine-related adverse events;	chr7:54127177	chr7:53862233~53863339:+
BRCA	cis	rs739401	0.572	rs7111857	ENSG00000247473.2	CARS-AS1	-4.08	4.76e-05	0.00327	-0.14	-0.13	Longevity;	chr11:3046876	chr11:3029009~3041260:+
BRCA	cis	rs7937890	0.561	rs2575849	ENSG00000254418.1	RP11-21L19.1	4.08	4.76e-05	0.00327	0.15	0.13	Mitochondrial DNA levels;	chr11:14518093	chr11:14262846~14273691:-
BRCA	cis	rs6545883	0.929	rs2421203	ENSG00000212978.6	AC016747.3	4.08	4.76e-05	0.00327	0.17	0.13	Tuberculosis;	chr2:61442113	chr2:61141592~61144969:-
BRCA	cis	rs5758511	0.68	rs739146	ENSG00000226450.2	CYP2D8P	4.08	4.76e-05	0.00327	0.14	0.13	Birth weight;	chr22:42264408	chr22:42149886~42155001:-
BRCA	cis	rs17027633	1	rs17027601	ENSG00000260948.1	RP11-552M11.8	-4.08	4.76e-05	0.00327	-0.29	-0.13	Cerebrospinal fluid t-tau:AB1-42 ratio;	chr1:111413650	chr1:111431046~111433068:-
BRCA	cis	rs2562456	0.833	rs55790393	ENSG00000240522.1	RPL7AP10	-4.08	4.76e-05	0.00328	-0.15	-0.13	Pain;	chr19:21323382	chr19:21149648~21150438:-
BRCA	cis	rs2562456	0.793	rs11672341	ENSG00000240522.1	RPL7AP10	-4.08	4.76e-05	0.00328	-0.15	-0.13	Pain;	chr19:21324502	chr19:21149648~21150438:-
BRCA	cis	rs765787	0.505	rs12593605	ENSG00000259539.1	CTD-2651B20.1	-4.08	4.76e-05	0.00328	-0.16	-0.13	Uric acid levels;	chr15:45205250	chr15:45152664~45167526:-
BRCA	cis	rs1949733	0.656	rs6845969	ENSG00000251615.3	RP11-774O3.3	-4.08	4.76e-05	0.00328	-0.13	-0.13	Response to antineoplastic agents;	chr4:8400738	chr4:8355090~8358338:-
BRCA	cis	rs11098499	0.789	rs1980024	ENSG00000260091.1	RP11-33B1.4	-4.08	4.76e-05	0.00328	-0.11	-0.13	Corneal astigmatism;	chr4:119331892	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.754	rs34425882	ENSG00000260091.1	RP11-33B1.4	-4.08	4.76e-05	0.00328	-0.11	-0.13	Corneal astigmatism;	chr4:119332022	chr4:119409333~119410233:+
BRCA	cis	rs952623	0.649	rs17171519	ENSG00000211694.2	TRGV10	4.08	4.76e-05	0.00328	0.1	0.13	Intelligence (multi-trait analysis);	chr7:39020712	chr7:38299811~38300322:-
BRCA	cis	rs5758511	0.689	rs11913578	ENSG00000226450.2	CYP2D8P	4.08	4.76e-05	0.00328	0.14	0.13	Birth weight;	chr22:41951387	chr22:42149886~42155001:-
BRCA	cis	rs13434995	0.513	rs1979604	ENSG00000239040.1	Y_RNA	-4.08	4.76e-05	0.00328	-0.15	-0.13	Adiponectin levels;	chr4:55552588	chr4:55412636~55412738:+
BRCA	cis	rs13434995	0.537	rs4865012	ENSG00000239040.1	Y_RNA	-4.08	4.76e-05	0.00328	-0.15	-0.13	Adiponectin levels;	chr4:55554619	chr4:55412636~55412738:+
BRCA	cis	rs409045	0.965	rs367892	ENSG00000271874.1	CTD-2024P10.2	-4.08	4.76e-05	0.00328	-0.17	-0.13	Left ventricular mass;	chr5:34638969	chr5:34651457~34651888:-
BRCA	cis	rs7246967	0.932	rs1478457	ENSG00000198153.8	ZNF849P	-4.08	4.77e-05	0.00328	-0.18	-0.13	Bronchopulmonary dysplasia;	chr19:22882467	chr19:22685167~22686732:+
BRCA	cis	rs11098499	0.754	rs11732087	ENSG00000260091.1	RP11-33B1.4	-4.08	4.77e-05	0.00328	-0.11	-0.13	Corneal astigmatism;	chr4:119318676	chr4:119409333~119410233:+
BRCA	cis	rs8040855	0.599	rs4577058	ENSG00000259762.1	RP11-158M2.4	-4.08	4.77e-05	0.00328	-0.14	-0.13	Bulimia nervosa;	chr15:85183227	chr15:85750336~85752901:-
BRCA	cis	rs8060686	0.516	rs7193701	ENSG00000259804.1	CTD-2012K14.7	4.08	4.77e-05	0.00328	0.17	0.13	HDL cholesterol;Metabolic syndrome;	chr16:68151257	chr16:67561411~67562309:-
BRCA	cis	rs9921338	0.887	rs7189044	ENSG00000263080.1	RP11-485G7.5	4.08	4.77e-05	0.00328	0.19	0.13	Vein graft stenosis in coronary artery bypass grafting;	chr16:11348339	chr16:11341809~11345211:-
BRCA	cis	rs8114671	0.967	rs6142324	ENSG00000279253.1	RP4-614O4.13	4.08	4.77e-05	0.00328	0.14	0.13	Height;	chr20:35201240	chr20:35262727~35264187:-
BRCA	cis	rs4489787	1	rs17237198	ENSG00000240399.1	RP1-228P16.1	4.08	4.77e-05	0.00328	0.22	0.13	Prostate cancer (SNP x SNP interaction);	chr12:48560149	chr12:48054813~48055591:-
BRCA	cis	rs875971	0.545	rs73378304	ENSG00000232546.1	RP11-458F8.1	4.08	4.77e-05	0.00328	0.12	0.13	Aortic root size;	chr7:66175760	chr7:66848496~66858136:+
BRCA	cis	rs7520050	0.807	rs3013594	ENSG00000281133.1	AL355480.3	-4.08	4.77e-05	0.00328	-0.15	-0.13	Reticulocyte count;Red blood cell count;	chr1:45672328	chr1:45580892~45580996:-
BRCA	cis	rs1048886	0.938	rs7769582	ENSG00000271967.1	RP11-134K13.4	4.08	4.77e-05	0.00328	0.16	0.13	Type 2 diabetes;	chr6:70519956	chr6:70596438~70596980:+
BRCA	cis	rs6071166	0.683	rs6027265	ENSG00000224635.1	RP4-564F22.5	-4.08	4.77e-05	0.00328	-0.15	-0.13	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38687350	chr20:38406011~38416797:-
BRCA	cis	rs6071166	0.683	rs6027270	ENSG00000224635.1	RP4-564F22.5	-4.08	4.77e-05	0.00328	-0.15	-0.13	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38687750	chr20:38406011~38416797:-
BRCA	cis	rs6071166	0.683	rs1154702	ENSG00000224635.1	RP4-564F22.5	-4.08	4.77e-05	0.00328	-0.15	-0.13	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38687958	chr20:38406011~38416797:-
BRCA	cis	rs6071166	0.683	rs6027274	ENSG00000224635.1	RP4-564F22.5	-4.08	4.77e-05	0.00328	-0.15	-0.13	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38688536	chr20:38406011~38416797:-
BRCA	cis	rs6071166	0.708	rs6027284	ENSG00000224635.1	RP4-564F22.5	-4.08	4.77e-05	0.00328	-0.15	-0.13	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38689716	chr20:38406011~38416797:-
BRCA	cis	rs4869313	0.869	rs38033	ENSG00000248734.2	CTD-2260A17.1	4.08	4.77e-05	0.00328	0.13	0.13	Pediatric autoimmune diseases;	chr5:96986432	chr5:96784777~96785999:+
BRCA	cis	rs739496	0.579	rs7974772	ENSG00000234608.6	MAPKAPK5-AS1	4.08	4.77e-05	0.00328	0.15	0.13	Platelet count;	chr12:111894479	chr12:111839764~111842902:-
BRCA	cis	rs739496	0.579	rs10849982	ENSG00000234608.6	MAPKAPK5-AS1	4.08	4.77e-05	0.00328	0.15	0.13	Platelet count;	chr12:111897735	chr12:111839764~111842902:-
BRCA	cis	rs853679	0.517	rs9393890	ENSG00000261839.1	RP1-265C24.8	4.08	4.78e-05	0.00328	0.17	0.13	Depression;	chr6:28096077	chr6:28136849~28139678:+
BRCA	cis	rs853679	0.517	rs9366715	ENSG00000261839.1	RP1-265C24.8	4.08	4.78e-05	0.00328	0.17	0.13	Depression;	chr6:28096855	chr6:28136849~28139678:+
BRCA	cis	rs9527	0.641	rs34130454	ENSG00000213061.2	PFN1P11	4.08	4.78e-05	0.00328	0.17	0.13	Arsenic metabolism;	chr10:103143881	chr10:102838011~102845473:-
BRCA	cis	rs2518049	1	rs2518047	ENSG00000224034.1	RP11-445P17.8	4.08	4.78e-05	0.00328	0.23	0.13	Metabolic traits;	chr10:5094168	chr10:5266033~5271236:-
BRCA	cis	rs6545883	0.894	rs6739427	ENSG00000270820.4	RP11-355B11.2	-4.08	4.78e-05	0.00329	-0.14	-0.13	Tuberculosis;	chr2:61225744	chr2:61471188~61484130:+
BRCA	cis	rs853679	0.598	rs9380054	ENSG00000261839.1	RP1-265C24.8	4.08	4.78e-05	0.00329	0.17	0.13	Depression;	chr6:28099759	chr6:28136849~28139678:+
BRCA	cis	rs4713118	0.547	rs2116981	ENSG00000261839.1	RP1-265C24.8	4.08	4.78e-05	0.00329	0.17	0.13	Parkinson's disease;	chr6:28100173	chr6:28136849~28139678:+
BRCA	cis	rs853679	0.517	rs9368552	ENSG00000261839.1	RP1-265C24.8	4.08	4.78e-05	0.00329	0.17	0.13	Depression;	chr6:28100648	chr6:28136849~28139678:+
BRCA	cis	rs853679	0.542	rs34131763	ENSG00000261839.1	RP1-265C24.8	4.08	4.78e-05	0.00329	0.17	0.13	Depression;	chr6:28107222	chr6:28136849~28139678:+
BRCA	cis	rs8114671	0.562	rs34837802	ENSG00000279253.1	RP4-614O4.13	-4.08	4.78e-05	0.00329	-0.14	-0.13	Height;	chr20:34837105	chr20:35262727~35264187:-
BRCA	cis	rs11098499	0.909	rs11723839	ENSG00000260091.1	RP11-33B1.4	-4.08	4.78e-05	0.00329	-0.11	-0.13	Corneal astigmatism;	chr4:119378518	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.779	rs7699346	ENSG00000260091.1	RP11-33B1.4	-4.08	4.78e-05	0.00329	-0.11	-0.13	Corneal astigmatism;	chr4:119389387	chr4:119409333~119410233:+
BRCA	cis	rs8012947	0.651	rs8008129	ENSG00000257621.6	PSMA3-AS1	4.08	4.78e-05	0.00329	0.11	0.13	Alcohol consumption in current drinkers;	chr14:58362314	chr14:58265365~58298134:-
BRCA	cis	rs321358	0.731	rs1900556	ENSG00000271390.1	RP11-89C3.3	4.08	4.78e-05	0.00329	0.19	0.13	Body mass index;	chr11:111148276	chr11:111089870~111090368:-
BRCA	cis	rs853679	0.517	rs9393887	ENSG00000261839.1	RP1-265C24.8	4.08	4.78e-05	0.00329	0.17	0.13	Depression;	chr6:28091242	chr6:28136849~28139678:+
BRCA	cis	rs801193	1	rs4717319	ENSG00000223473.2	GS1-124K5.3	4.08	4.78e-05	0.00329	0.1	0.13	Aortic root size;	chr7:66777606	chr7:66491049~66493566:-
BRCA	cis	rs3796619	0.503	rs1466216	ENSG00000254094.1	AC078852.1	4.08	4.78e-05	0.00329	0.14	0.13	Recombination rate (males);	chr4:1078119	chr4:1356581~1358075:+
BRCA	cis	rs35520189	0.557	rs12617864	ENSG00000231747.1	AC079922.2	4.08	4.78e-05	0.00329	0.13	0.13	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:112957399	chr2:112621809~112622167:-
BRCA	cis	rs6802315	0.604	rs9861938	ENSG00000272247.1	RP11-379F4.9	-4.08	4.78e-05	0.00329	-0.14	-0.13	Periodontitis (CDC/AAP);	chr3:158745257	chr3:158801257~158801935:-
BRCA	cis	rs7011507	0.535	rs1976450	ENSG00000233858.4	AC026904.1	-4.08	4.78e-05	0.00329	-0.15	-0.13	Inflammatory bowel disease;Ulcerative colitis;	chr8:48544382	chr8:48590401~48594621:+
BRCA	cis	rs6750047	0.719	rs1583171	ENSG00000235848.3	RMDN2-AS1	-4.08	4.78e-05	0.00329	-0.16	-0.13	Cutaneous malignant melanoma;Melanoma;	chr2:38042964	chr2:37949911~38067041:-
BRCA	cis	rs4886920	0.862	rs34549121	ENSG00000260776.4	RP11-114H24.2	-4.08	4.78e-05	0.00329	-0.15	-0.13	Neuroticism;	chr15:77831644	chr15:77914217~77926846:-
BRCA	cis	rs10958369	0.871	rs2126793	ENSG00000260484.1	RP11-1081M5.2	4.08	4.78e-05	0.00329	0.14	0.13	Response to antineoplastic agents;	chr8:53486479	chr8:53388701~53390872:-
BRCA	cis	rs1077514	0.515	rs1767141	ENSG00000232482.2	RP4-654C18.1	4.08	4.79e-05	0.00329	0.2	0.13	Cholesterol, total;	chr1:23407857	chr1:23410832~23412146:+
BRCA	cis	rs1008375	0.932	rs9283698	ENSG00000249502.1	AC006160.5	-4.08	4.79e-05	0.00329	-0.15	-0.13	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17660848	chr4:17587467~17614571:-
BRCA	cis	rs2446066	0.872	rs114075368	ENSG00000257379.1	RP11-793H13.8	4.08	4.79e-05	0.00329	0.19	0.13	Red blood cell count;	chr12:53407960	chr12:53441741~53467528:+
BRCA	cis	rs17270561	0.609	rs4712968	ENSG00000272462.2	U91328.19	-4.08	4.79e-05	0.00329	-0.15	-0.13	Iron status biomarkers;	chr6:25760116	chr6:25992662~26001775:+
BRCA	cis	rs17270561	0.609	rs7769908	ENSG00000272462.2	U91328.19	-4.08	4.79e-05	0.00329	-0.15	-0.13	Iron status biomarkers;	chr6:25760311	chr6:25992662~26001775:+
BRCA	cis	rs17270561	0.609	rs7770037	ENSG00000272462.2	U91328.19	-4.08	4.79e-05	0.00329	-0.15	-0.13	Iron status biomarkers;	chr6:25760363	chr6:25992662~26001775:+
BRCA	cis	rs17270561	0.609	rs9348695	ENSG00000272462.2	U91328.19	-4.08	4.79e-05	0.00329	-0.15	-0.13	Iron status biomarkers;	chr6:25762782	chr6:25992662~26001775:+
BRCA	cis	rs17270561	0.609	rs2000350	ENSG00000272462.2	U91328.19	-4.08	4.79e-05	0.00329	-0.15	-0.13	Iron status biomarkers;	chr6:25762926	chr6:25992662~26001775:+
BRCA	cis	rs17270561	0.609	rs1318016	ENSG00000272462.2	U91328.19	-4.08	4.79e-05	0.00329	-0.15	-0.13	Iron status biomarkers;	chr6:25764476	chr6:25992662~26001775:+
BRCA	cis	rs17270561	0.609	rs1892245	ENSG00000272462.2	U91328.19	-4.08	4.79e-05	0.00329	-0.15	-0.13	Iron status biomarkers;	chr6:25764605	chr6:25992662~26001775:+
BRCA	cis	rs17270561	0.583	rs6937800	ENSG00000272462.2	U91328.19	-4.08	4.79e-05	0.00329	-0.15	-0.13	Iron status biomarkers;	chr6:25765715	chr6:25992662~26001775:+
BRCA	cis	rs17270561	0.609	rs3778272	ENSG00000272462.2	U91328.19	-4.08	4.79e-05	0.00329	-0.15	-0.13	Iron status biomarkers;	chr6:25767433	chr6:25992662~26001775:+
BRCA	cis	rs17270561	0.609	rs2275905	ENSG00000272462.2	U91328.19	-4.08	4.79e-05	0.00329	-0.15	-0.13	Iron status biomarkers;	chr6:25767878	chr6:25992662~26001775:+
BRCA	cis	rs10946940	0.93	rs12215012	ENSG00000219392.1	RP1-265C24.5	4.08	4.79e-05	0.00329	0.16	0.13	Systemic lupus erythematosus;	chr6:27539715	chr6:28115628~28116551:+
BRCA	cis	rs180730	1	rs343195	ENSG00000251609.2	SETP12	-4.08	4.79e-05	0.00329	-0.19	-0.13	Fasting plasma glucose;	chr4:120879311	chr4:120895494~120897083:-
BRCA	cis	rs180730	1	rs180730	ENSG00000251609.2	SETP12	-4.08	4.79e-05	0.00329	-0.19	-0.13	Fasting plasma glucose;	chr4:120880635	chr4:120895494~120897083:-
BRCA	cis	rs1429524	0.922	rs10265137	ENSG00000243144.5	RP11-115N4.1	-4.08	4.79e-05	0.00329	-0.16	-0.13	Ejection fraction in Tripanosoma cruzi seropositivity;	chr7:91307142	chr7:91311368~91515409:+
BRCA	cis	rs1009077	0.61	rs2389864	ENSG00000245958.5	RP11-33B1.1	-4.08	4.79e-05	0.00329	-0.14	-0.13	Endometriosis;	chr4:119589595	chr4:119454791~119552025:+
BRCA	cis	rs77204473	0.744	rs17120523	ENSG00000280143.1	AP000892.6	-4.08	4.79e-05	0.00329	-0.25	-0.13	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117223875	chr11:117204967~117210292:+
BRCA	cis	rs853679	0.517	rs56364346	ENSG00000216901.1	AL022393.7	4.08	4.79e-05	0.00329	0.18	0.13	Depression;	chr6:28082984	chr6:28176188~28176674:+
BRCA	cis	rs853679	0.517	rs9357061	ENSG00000216901.1	AL022393.7	4.08	4.79e-05	0.00329	0.18	0.13	Depression;	chr6:28083994	chr6:28176188~28176674:+
BRCA	cis	rs853679	0.517	rs9368550	ENSG00000216901.1	AL022393.7	4.08	4.79e-05	0.00329	0.18	0.13	Depression;	chr6:28084025	chr6:28176188~28176674:+
BRCA	cis	rs853679	0.542	rs2295594	ENSG00000216901.1	AL022393.7	4.08	4.79e-05	0.00329	0.18	0.13	Depression;	chr6:28085319	chr6:28176188~28176674:+
BRCA	cis	rs6445967	0.966	rs9857570	ENSG00000272182.1	RP11-802O23.3	4.08	4.79e-05	0.00329	0.14	0.13	Platelet count;	chr3:58294963	chr3:58428255~58428815:+
BRCA	cis	rs12220238	1	rs11000930	ENSG00000213731.2	RAB5CP1	4.08	4.79e-05	0.00329	0.21	0.13	Soluble interleukin-2 receptor subunit alpha;	chr10:74223224	chr10:74423435~74424014:-
BRCA	cis	rs8040855	0.575	rs12912860	ENSG00000230373.7	GOLGA6L5P	4.08	4.79e-05	0.00329	0.16	0.13	Bulimia nervosa;	chr15:85030267	chr15:84507885~84516814:-
BRCA	cis	rs6599077	0.951	rs9860449	ENSG00000223797.4	ENTPD3-AS1	4.08	4.79e-05	0.00329	0.15	0.13	Sleep-related phenotypes;	chr3:40052542	chr3:40313802~40453329:-
BRCA	cis	rs1865760	1	rs3752421	ENSG00000272462.2	U91328.19	-4.08	4.79e-05	0.00329	-0.15	-0.13	Height;	chr6:25918460	chr6:25992662~26001775:+
BRCA	cis	rs739496	0.947	rs739497	ENSG00000234608.6	MAPKAPK5-AS1	4.08	4.79e-05	0.00329	0.15	0.13	Platelet count;	chr12:111420282	chr12:111839764~111842902:-
BRCA	cis	rs9392556	0.626	rs626080	ENSG00000230648.1	RP3-406P24.3	-4.08	4.79e-05	0.0033	-0.14	-0.13	Blood metabolite levels;	chr6:4101333	chr6:4018843~4021215:-
BRCA	cis	rs757081	0.643	rs665311	ENSG00000184669.7	OR7E14P	-4.08	4.79e-05	0.0033	-0.19	-0.13	Systolic blood pressure;	chr11:17185193	chr11:17013998~17053024:+
BRCA	cis	rs757081	0.667	rs569780	ENSG00000184669.7	OR7E14P	-4.08	4.79e-05	0.0033	-0.19	-0.13	Systolic blood pressure;	chr11:17185198	chr11:17013998~17053024:+
BRCA	cis	rs9470794	0.831	rs74479294	ENSG00000204110.6	RP1-153P14.8	-4.08	4.79e-05	0.0033	-0.26	-0.13	Type 2 diabetes;	chr6:37935497	chr6:37507348~37535616:+
BRCA	cis	rs687432	0.885	rs34300518	ENSG00000265566.2	RN7SL605P	-4.08	4.8e-05	0.0033	-0.18	-0.13	Parkinson's disease;	chr11:58048424	chr11:57528085~57528365:-
BRCA	cis	rs4835473	0.932	rs17695782	ENSG00000249741.2	RP11-673E1.3	4.08	4.8e-05	0.0033	0.14	0.13	Immature fraction of reticulocytes;	chr4:143830311	chr4:143911514~143912053:-
BRCA	cis	rs9527	0.545	rs12247514	ENSG00000213061.2	PFN1P11	4.08	4.8e-05	0.0033	0.17	0.13	Arsenic metabolism;	chr10:103198309	chr10:102838011~102845473:-
BRCA	cis	rs757081	0.658	rs190046	ENSG00000272034.1	SNORD14A	-4.08	4.8e-05	0.0033	-0.13	-0.13	Systolic blood pressure;	chr11:17271809	chr11:17074654~17074744:-
BRCA	cis	rs757110	0.524	rs214095	ENSG00000272034.1	SNORD14A	-4.08	4.8e-05	0.0033	-0.13	-0.13	Type 2 diabetes;	chr11:17271915	chr11:17074654~17074744:-
BRCA	cis	rs4671400	0.571	rs62152275	ENSG00000273302.1	RP11-493E12.2	-4.08	4.8e-05	0.0033	-0.14	-0.13	3-hydroxypropylmercapturic acid levels in smokers;	chr2:61275103	chr2:61199979~61200769:+
BRCA	cis	rs11764932	0.825	rs917441	ENSG00000229108.1	MEOX2-AS1	-4.08	4.8e-05	0.0033	-0.14	-0.13	Kidney function decline traits;	chr7:15686748	chr7:15688378~15695491:+
BRCA	cis	rs1153858	1	rs9788780	ENSG00000275672.1	GATM-AS1	-4.08	4.8e-05	0.0033	-0.16	-0.13	Homoarginine levels;	chr15:45393289	chr15:45378700~45380123:+
BRCA	cis	rs1722141	0.669	rs1722122	ENSG00000237471.1	AC073115.6	-4.08	4.8e-05	0.0033	-0.17	-0.13	Sitting height ratio;	chr7:45989247	chr7:45969657~45980191:+
BRCA	cis	rs8058578	0.943	rs35629860	ENSG00000274678.1	RP11-2C24.7	4.08	4.8e-05	0.0033	0.16	0.13	Multiple myeloma;	chr16:30660211	chr16:30821338~30821884:+
BRCA	cis	rs977987	0.788	rs7184525	ENSG00000280152.1	RP11-331F4.5	-4.08	4.8e-05	0.0033	-0.13	-0.13	Dupuytren's disease;	chr16:75403288	chr16:75245994~75250077:-
BRCA	cis	rs739496	0.579	rs12321677	ENSG00000257624.1	RP1-128M12.3	-4.08	4.8e-05	0.0033	-0.17	-0.13	Platelet count;	chr12:111901211	chr12:112000739~112000985:-
BRCA	cis	rs11098499	0.863	rs6833334	ENSG00000250412.1	KLHL2P1	4.08	4.8e-05	0.0033	0.15	0.13	Corneal astigmatism;	chr4:119583072	chr4:119334329~119378233:+
BRCA	cis	rs2274459	0.915	rs77577915	ENSG00000249346.5	LINC01016	4.08	4.8e-05	0.0033	0.17	0.13	Obesity (extreme);	chr6:33765027	chr6:33867506~33896914:-
BRCA	cis	rs13108904	0.935	rs4974575	ENSG00000253399.1	AC078852.2	-4.08	4.8e-05	0.0033	-0.14	-0.13	Obesity-related traits;	chr4:1258240	chr4:1358479~1359461:+
BRCA	cis	rs7412746	0.611	rs3768018	ENSG00000231073.1	RP11-316M1.3	4.08	4.8e-05	0.0033	0.14	0.13	Melanoma;	chr1:150751271	chr1:150973123~150975534:+
BRCA	cis	rs11696845	0.965	rs34485448	ENSG00000276223.1	RP4-781B1.5	-4.08	4.8e-05	0.0033	-0.13	-0.13	Obesity-related traits;	chr20:44741878	chr20:44746642~44747201:+
BRCA	cis	rs720475	0.732	rs73159066	ENSG00000228960.5	OR2A9P	-4.08	4.8e-05	0.0033	-0.19	-0.13	Breast cancer;	chr7:144426495	chr7:144294480~144300934:+
BRCA	cis	rs17027633	1	rs1343350	ENSG00000260948.1	RP11-552M11.8	-4.08	4.81e-05	0.0033	-0.28	-0.13	Cerebrospinal fluid t-tau:AB1-42 ratio;	chr1:111406901	chr1:111431046~111433068:-
BRCA	cis	rs17027633	1	rs76876038	ENSG00000260948.1	RP11-552M11.8	-4.08	4.81e-05	0.0033	-0.28	-0.13	Cerebrospinal fluid t-tau:AB1-42 ratio;	chr1:111407235	chr1:111431046~111433068:-
BRCA	cis	rs11098499	0.644	rs7676296	ENSG00000260091.1	RP11-33B1.4	-4.08	4.81e-05	0.0033	-0.11	-0.13	Corneal astigmatism;	chr4:119634532	chr4:119409333~119410233:+
BRCA	cis	rs944990	0.855	rs1055710	ENSG00000227603.1	RP11-165J3.6	4.08	4.81e-05	0.0033	0.14	0.13	Body mass index;	chr9:93452646	chr9:93435332~93437121:-
BRCA	cis	rs4845570	1	rs1054479	ENSG00000203288.3	RP11-98D18.9	-4.08	4.81e-05	0.0033	-0.21	-0.13	Coronary artery disease;	chr1:151773603	chr1:151790804~151794402:+
BRCA	cis	rs4845570	1	rs6683364	ENSG00000203288.3	RP11-98D18.9	-4.08	4.81e-05	0.0033	-0.21	-0.13	Coronary artery disease;	chr1:151773726	chr1:151790804~151794402:+
BRCA	cis	rs10849893	0.595	rs7980819	ENSG00000258435.1	RP11-711D18.2	-4.08	4.81e-05	0.0033	-0.14	-0.13	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr12:121449391	chr12:121391962~121399859:+
BRCA	cis	rs4950322	0.517	rs114823926	ENSG00000237188.3	RP11-337C18.8	4.08	4.81e-05	0.0033	0.16	0.13	Protein quantitative trait loci;	chr1:147281805	chr1:147172771~147211568:+
BRCA	cis	rs703842	1	rs10877015	ENSG00000270039.1	RP11-571M6.17	-4.08	4.81e-05	0.0033	-0.17	-0.13	Multiple sclerosis;	chr12:57774005	chr12:57803838~57804415:+
BRCA	cis	rs875971	0.577	rs34888281	ENSG00000229180.5	GS1-124K5.11	-4.08	4.81e-05	0.0033	-0.11	-0.13	Aortic root size;	chr7:66120784	chr7:66526088~66542624:-
BRCA	cis	rs8180040	0.654	rs6773521	ENSG00000271161.1	BOLA2P2	-4.08	4.81e-05	0.0033	-0.13	-0.13	Colorectal cancer;	chr3:47192929	chr3:47499841~47500407:+
BRCA	cis	rs17489649	0.956	rs6881643	ENSG00000271849.1	CTC-332L22.1	4.08	4.81e-05	0.00331	0.16	0.13	Intelligence (multi-trait analysis);	chr5:109818683	chr5:109687802~109688329:-
BRCA	cis	rs1861628	0.512	rs10932677	ENSG00000229352.1	AC007563.3	-4.08	4.81e-05	0.00331	-0.2	-0.13	Serum thyroid-stimulating hormone levels;Hypothyroidism;	chr2:216762427	chr2:216799608~216805335:+
BRCA	cis	rs2227564	0.7	rs2688613	ENSG00000271816.1	BMS1P4	4.08	4.81e-05	0.00331	0.13	0.13	Crohn's disease;Inflammatory bowel disease;	chr10:73893287	chr10:73699151~73730487:-
BRCA	cis	rs2446066	0.872	rs34148420	ENSG00000257379.1	RP11-793H13.8	4.08	4.81e-05	0.00331	0.19	0.13	Red blood cell count;	chr12:53405024	chr12:53441741~53467528:+
BRCA	cis	rs3796619	0.503	rs13147452	ENSG00000254094.1	AC078852.1	-4.08	4.81e-05	0.00331	-0.14	-0.13	Recombination rate (males);	chr4:1084336	chr4:1356581~1358075:+
BRCA	cis	rs7267979	1	rs4815404	ENSG00000125804.12	FAM182A	4.08	4.81e-05	0.00331	0.16	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25321209	chr20:26054655~26086917:+
BRCA	cis	rs10819861	0.934	rs7019587	ENSG00000175611.10	LINC00476	4.08	4.82e-05	0.00331	0.13	0.13	Electrocardiographic traits;	chr9:96095986	chr9:95759231~95875977:-
BRCA	cis	rs886774	0.866	rs2395933	ENSG00000273055.1	CTB-13F3.1	-4.08	4.82e-05	0.00331	-0.13	-0.13	Ulcerative colitis;	chr7:107869207	chr7:107942116~107942740:+
BRCA	cis	rs9921338	0.961	rs6498185	ENSG00000262636.1	CTD-3088G3.4	-4.08	4.82e-05	0.00331	-0.19	-0.13	Vein graft stenosis in coronary artery bypass grafting;	chr16:11350869	chr16:11380859~11381118:-
BRCA	cis	rs7267979	1	rs6115146	ENSG00000125804.12	FAM182A	4.08	4.82e-05	0.00331	0.16	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25323871	chr20:26054655~26086917:+
BRCA	cis	rs7267979	0.934	rs6037085	ENSG00000125804.12	FAM182A	4.08	4.82e-05	0.00331	0.16	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25324566	chr20:26054655~26086917:+
BRCA	cis	rs8099594	0.565	rs1942999	ENSG00000266696.1	RP11-30L3.2	4.08	4.82e-05	0.00331	0.14	0.13	Height;	chr18:49186458	chr18:49205912~49208781:+
BRCA	cis	rs35146811	0.735	rs858512	ENSG00000214313.7	AZGP1P1	-4.08	4.82e-05	0.00331	-0.14	-0.13	Coronary artery disease;	chr7:100226830	chr7:99980762~99987535:+
BRCA	cis	rs35146811	0.7	rs858513	ENSG00000214313.7	AZGP1P1	-4.08	4.82e-05	0.00331	-0.14	-0.13	Coronary artery disease;	chr7:100227935	chr7:99980762~99987535:+
BRCA	cis	rs9400180	1	rs1913	ENSG00000271734.1	RP1-111B22.3	-4.08	4.82e-05	0.00331	-0.15	-0.13	Major depressive disorder;	chr6:108030793	chr6:108030249~108030718:-
BRCA	cis	rs10504130	0.569	rs2069119	ENSG00000253844.1	RP11-546K22.1	-4.08	4.82e-05	0.00331	-0.18	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr8:51773876	chr8:51961458~52022974:+
BRCA	cis	rs10504130	0.569	rs35603537	ENSG00000253844.1	RP11-546K22.1	-4.08	4.82e-05	0.00331	-0.18	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr8:51773899	chr8:51961458~52022974:+
BRCA	cis	rs10504130	0.502	rs71513552	ENSG00000253844.1	RP11-546K22.1	-4.08	4.82e-05	0.00331	-0.18	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr8:51776662	chr8:51961458~52022974:+
BRCA	cis	rs4650943	0.609	rs1503121	ENSG00000227740.1	RP11-318C24.2	-4.08	4.82e-05	0.00331	-0.13	-0.13	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in inactive individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr1:176316245	chr1:175904762~175920513:-
BRCA	cis	rs7020830	0.861	rs2291589	ENSG00000260100.1	RP11-220I1.5	-4.08	4.82e-05	0.00331	-0.15	-0.13	Schizophrenia;	chr9:37079664	chr9:37078813~37079776:-
BRCA	cis	rs9818758	0.607	rs61729488	ENSG00000225399.4	RP11-3B7.1	-4.08	4.83e-05	0.00331	-0.24	-0.13	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49030471	chr3:49260085~49261316:+
BRCA	cis	rs11603020	0.95	rs28362949	ENSG00000265566.2	RN7SL605P	-4.08	4.83e-05	0.00332	-0.18	-0.13	Blood protein levels;	chr11:57604438	chr11:57528085~57528365:-
BRCA	cis	rs11711311	1	rs11711311	ENSG00000241529.3	RN7SL767P	-4.08	4.83e-05	0.00332	-0.15	-0.13	IgG glycosylation;	chr3:113711752	chr3:113632704~113632998:+
BRCA	cis	rs2446066	0.872	rs10876449	ENSG00000257379.1	RP11-793H13.8	4.08	4.83e-05	0.00332	0.19	0.13	Red blood cell count;	chr12:53385991	chr12:53441741~53467528:+
BRCA	cis	rs2446066	0.872	rs11170525	ENSG00000257379.1	RP11-793H13.8	4.08	4.83e-05	0.00332	0.19	0.13	Red blood cell count;	chr12:53388844	chr12:53441741~53467528:+
BRCA	cis	rs2446066	0.818	rs7315782	ENSG00000257379.1	RP11-793H13.8	4.08	4.83e-05	0.00332	0.19	0.13	Red blood cell count;	chr12:53391129	chr12:53441741~53467528:+
BRCA	cis	rs12612619	0.658	rs112794902	ENSG00000272148.1	RP11-195B17.1	4.08	4.83e-05	0.00332	0.14	0.13	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:26928718	chr2:27062428~27062907:-
BRCA	cis	rs12612619	0.658	rs77920959	ENSG00000272148.1	RP11-195B17.1	4.08	4.83e-05	0.00332	0.14	0.13	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:26928722	chr2:27062428~27062907:-
BRCA	cis	rs7312933	0.618	rs7315968	ENSG00000257225.1	RP11-328C8.4	-4.08	4.83e-05	0.00332	-0.15	-0.13	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42243284	chr12:42459366~42466128:+
BRCA	cis	rs853679	0.517	rs1947863	ENSG00000261839.1	RP1-265C24.8	4.08	4.83e-05	0.00332	0.17	0.13	Depression;	chr6:28131566	chr6:28136849~28139678:+
BRCA	cis	rs13434995	0.513	rs7665846	ENSG00000239040.1	Y_RNA	-4.08	4.83e-05	0.00332	-0.15	-0.13	Adiponectin levels;	chr4:55573078	chr4:55412636~55412738:+
BRCA	cis	rs2243480	1	rs35396113	ENSG00000226002.1	RP11-460N20.5	-4.08	4.83e-05	0.00332	-0.21	-0.13	Diabetic kidney disease;	chr7:66030474	chr7:65084103~65100232:+
BRCA	cis	rs11822910	0.737	rs2729389	ENSG00000265566.2	RN7SL605P	-4.08	4.83e-05	0.00332	-0.16	-0.13	Platelet distribution width;	chr11:57444173	chr11:57528085~57528365:-
BRCA	cis	rs2274273	0.84	rs11626751	ENSG00000259318.1	RP11-454L9.2	4.08	4.83e-05	0.00332	0.11	0.13	Protein biomarker;	chr14:55368509	chr14:55394940~55395233:-
BRCA	cis	rs17772222	0.958	rs76559451	ENSG00000258789.1	RP11-507K2.3	-4.08	4.83e-05	0.00332	-0.15	-0.13	Coronary artery calcification;	chr14:88523193	chr14:88551597~88552493:+
BRCA	cis	rs6452524	0.967	rs1564211	ENSG00000281327.1	LINC01338	4.08	4.83e-05	0.00332	0.14	0.13	Hypertension (SNP x SNP interaction);	chr5:83117014	chr5:82850864~82859836:-
BRCA	cis	rs1971762	0.712	rs7302232	ENSG00000270175.1	RP11-793H13.11	-4.08	4.83e-05	0.00332	-0.11	-0.13	Height;	chr12:53571639	chr12:53500162~53500936:-
BRCA	cis	rs17684571	0.751	rs35225175	ENSG00000231441.1	RP11-472M19.2	4.08	4.83e-05	0.00332	0.22	0.13	Schizophrenia;	chr6:56822783	chr6:56844002~56864078:+
BRCA	cis	rs801193	1	rs7785213	ENSG00000229180.5	GS1-124K5.11	-4.08	4.83e-05	0.00332	-0.11	-0.13	Aortic root size;	chr7:66673991	chr7:66526088~66542624:-
BRCA	cis	rs8040855	0.627	rs12909971	ENSG00000230373.7	GOLGA6L5P	4.08	4.83e-05	0.00332	0.15	0.13	Bulimia nervosa;	chr15:85045767	chr15:84507885~84516814:-
BRCA	cis	rs812925	0.502	rs2053750	ENSG00000270820.4	RP11-355B11.2	-4.08	4.83e-05	0.00332	-0.14	-0.13	Immature fraction of reticulocytes;	chr2:61429138	chr2:61471188~61484130:+
BRCA	cis	rs11764932	0.965	rs740566	ENSG00000229108.1	MEOX2-AS1	4.08	4.83e-05	0.00332	0.14	0.13	Kidney function decline traits;	chr7:15687577	chr7:15688378~15695491:+
BRCA	cis	rs9467773	0.62	rs9461276	ENSG00000224843.5	LINC00240	-4.08	4.84e-05	0.00332	-0.14	-0.13	Intelligence (multi-trait analysis);	chr6:26594940	chr6:26956992~27023924:+
BRCA	cis	rs4927850	0.752	rs7618864	ENSG00000224769.1	AC069213.1	4.08	4.84e-05	0.00332	0.18	0.13	Pancreatic cancer;	chr3:196022690	chr3:195614947~195620233:+
BRCA	cis	rs75504410	0.579	rs2637712	ENSG00000231160.8	KLF3-AS1	-4.08	4.84e-05	0.00332	-0.17	-0.13	Sum eosinophil basophil counts;Eosinophil counts;	chr4:38624896	chr4:38612701~38664883:-
BRCA	cis	rs6545883	0.894	rs2694649	ENSG00000273302.1	RP11-493E12.2	-4.08	4.84e-05	0.00332	-0.12	-0.13	Tuberculosis;	chr2:61346691	chr2:61199979~61200769:+
BRCA	cis	rs10844706	0.669	rs10772102	ENSG00000256673.1	RP11-599J14.2	-4.08	4.84e-05	0.00332	-0.16	-0.13	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9744357	chr12:9398355~9414851:-
BRCA	cis	rs3764563	0.935	rs646816	ENSG00000267594.5	CYP4F24P	4.08	4.84e-05	0.00332	0.24	0.13	Inflammatory biomarkers;	chr19:15584290	chr19:15760241~15779909:-
BRCA	cis	rs6893300	0.961	rs11744616	ENSG00000250999.1	RP11-1379J22.5	4.08	4.84e-05	0.00332	0.18	0.13	Resting heart rate;	chr5:179782112	chr5:179657762~179664432:+
BRCA	cis	rs6088590	0.561	rs6088527	ENSG00000275784.1	RP5-1125A11.6	-4.08	4.84e-05	0.00332	-0.14	-0.13	Coronary artery disease;	chr20:34568037	chr20:33989480~33991818:-
BRCA	cis	rs11668609	1	rs919812	ENSG00000268058.1	BNIP3P40	-4.08	4.84e-05	0.00332	-0.15	-0.13	Response to taxane treatment (docetaxel);	chr19:24163425	chr19:24098425~24098980:-
BRCA	cis	rs7818688	1	rs77257477	ENSG00000253528.2	RP11-347C18.4	-4.08	4.84e-05	0.00332	-0.2	-0.13	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95033171	chr8:94974573~94974853:-
BRCA	cis	rs7818688	0.79	rs74395342	ENSG00000253528.2	RP11-347C18.4	-4.08	4.84e-05	0.00332	-0.2	-0.13	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95034723	chr8:94974573~94974853:-
BRCA	cis	rs7818688	1	rs6651271	ENSG00000253528.2	RP11-347C18.4	-4.08	4.84e-05	0.00332	-0.2	-0.13	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95035393	chr8:94974573~94974853:-
BRCA	cis	rs11638352	1	rs2412854	ENSG00000205771.5	CATSPER2P1	4.08	4.84e-05	0.00332	0.26	0.13	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44002274	chr15:43726918~43747094:-
BRCA	cis	rs6545883	0.868	rs7608483	ENSG00000270820.4	RP11-355B11.2	4.08	4.84e-05	0.00332	0.14	0.13	Tuberculosis;	chr2:61609100	chr2:61471188~61484130:+
BRCA	cis	rs7267979	1	rs6050598	ENSG00000276952.1	RP5-965G21.6	4.08	4.84e-05	0.00332	0.15	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25416621	chr20:25284915~25285588:-
BRCA	cis	rs372883	0.6	rs1312254	ENSG00000176054.6	RPL23P2	-4.08	4.84e-05	0.00332	-0.14	-0.13	Pancreatic cancer;	chr21:29323080	chr21:28997613~28998033:-
BRCA	cis	rs42490	0.528	rs1040327	ENSG00000251136.7	RP11-37B2.1	4.08	4.84e-05	0.00333	0.12	0.13	Leprosy;	chr8:89669585	chr8:89609409~89757727:-
BRCA	cis	rs2274459	1	rs12211554	ENSG00000249346.5	LINC01016	4.08	4.84e-05	0.00333	0.17	0.13	Obesity (extreme);	chr6:33758011	chr6:33867506~33896914:-
BRCA	cis	rs6452524	0.935	rs1542539	ENSG00000281327.1	LINC01338	4.08	4.84e-05	0.00333	0.14	0.13	Hypertension (SNP x SNP interaction);	chr5:83116033	chr5:82850864~82859836:-
BRCA	cis	rs6452524	0.935	rs1543847	ENSG00000281327.1	LINC01338	4.08	4.84e-05	0.00333	0.14	0.13	Hypertension (SNP x SNP interaction);	chr5:83116044	chr5:82850864~82859836:-
BRCA	cis	rs4908760	0.827	rs10864362	ENSG00000232912.4	RP5-1115A15.1	4.08	4.85e-05	0.00333	0.12	0.13	Vitiligo;	chr1:8672395	chr1:8424645~8434838:+
BRCA	cis	rs7726839	0.561	rs4957050	ENSG00000271781.1	CTD-2589H19.6	-4.08	4.85e-05	0.00333	-0.18	-0.13	Obesity-related traits;	chr5:578951	chr5:675826~676616:+
BRCA	cis	rs7726839	0.561	rs4957049	ENSG00000271781.1	CTD-2589H19.6	-4.08	4.85e-05	0.00333	-0.18	-0.13	Obesity-related traits;	chr5:578965	chr5:675826~676616:+
BRCA	cis	rs7726839	0.561	rs72703044	ENSG00000271781.1	CTD-2589H19.6	-4.08	4.85e-05	0.00333	-0.18	-0.13	Obesity-related traits;	chr5:579622	chr5:675826~676616:+
BRCA	cis	rs6545883	0.868	rs6545887	ENSG00000270820.4	RP11-355B11.2	4.08	4.85e-05	0.00333	0.14	0.13	Tuberculosis;	chr2:61601683	chr2:61471188~61484130:+
BRCA	cis	rs6964587	0.933	rs6465350	ENSG00000188693.7	CYP51A1-AS1	-4.08	4.85e-05	0.00333	-0.14	-0.13	Breast cancer;	chr7:92139301	chr7:92134604~92180725:+
BRCA	cis	rs867371	0.656	rs2665103	ENSG00000259429.4	UBE2Q2P2	4.08	4.85e-05	0.00333	0.12	0.13	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82140374	chr15:82355142~82420075:+
BRCA	cis	rs7267979	0.966	rs2261790	ENSG00000277938.1	RP5-965G21.3	4.08	4.85e-05	0.00333	0.15	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25282153	chr20:25229150~25231933:+
BRCA	cis	rs7267979	0.966	rs2261794	ENSG00000277938.1	RP5-965G21.3	4.08	4.85e-05	0.00333	0.15	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25282426	chr20:25229150~25231933:+
BRCA	cis	rs7267979	0.966	rs2145126	ENSG00000277938.1	RP5-965G21.3	4.08	4.85e-05	0.00333	0.15	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25283012	chr20:25229150~25231933:+
BRCA	cis	rs7267979	0.966	rs2257705	ENSG00000277938.1	RP5-965G21.3	4.08	4.85e-05	0.00333	0.15	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25284028	chr20:25229150~25231933:+
BRCA	cis	rs7267979	0.966	rs2227892	ENSG00000277938.1	RP5-965G21.3	4.08	4.85e-05	0.00333	0.15	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25284178	chr20:25229150~25231933:+
BRCA	cis	rs7267979	0.966	rs2257712	ENSG00000277938.1	RP5-965G21.3	4.08	4.85e-05	0.00333	0.15	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25284274	chr20:25229150~25231933:+
BRCA	cis	rs7267979	0.966	rs2257461	ENSG00000277938.1	RP5-965G21.3	4.08	4.85e-05	0.00333	0.15	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25284918	chr20:25229150~25231933:+
BRCA	cis	rs7267979	0.816	rs6037158	ENSG00000231081.1	RP4-760C5.3	-4.08	4.85e-05	0.00333	-0.16	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25614830	chr20:26008791~26010531:-
BRCA	cis	rs7267979	0.933	rs2261109	ENSG00000274973.1	RP13-401N8.7	-4.08	4.85e-05	0.00333	-0.14	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25278564	chr20:25845497~25845862:+
BRCA	cis	rs7267979	0.966	rs2261720	ENSG00000274973.1	RP13-401N8.7	-4.08	4.85e-05	0.00333	-0.14	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25280005	chr20:25845497~25845862:+
BRCA	cis	rs7246967	0.866	rs35105042	ENSG00000198153.8	ZNF849P	-4.08	4.85e-05	0.00333	-0.18	-0.13	Bronchopulmonary dysplasia;	chr19:22865550	chr19:22685167~22686732:+
BRCA	cis	rs7246967	0.932	rs62120788	ENSG00000198153.8	ZNF849P	-4.08	4.85e-05	0.00333	-0.18	-0.13	Bronchopulmonary dysplasia;	chr19:22868210	chr19:22685167~22686732:+
BRCA	cis	rs7246967	0.932	rs4932799	ENSG00000198153.8	ZNF849P	-4.08	4.85e-05	0.00333	-0.18	-0.13	Bronchopulmonary dysplasia;	chr19:22868779	chr19:22685167~22686732:+
BRCA	cis	rs61160187	0.582	rs67490467	ENSG00000272308.1	RP11-231G3.1	-4.08	4.85e-05	0.00333	-0.14	-0.13	Educational attainment (years of education);Educational attainment (college completion);	chr5:60967991	chr5:60866457~60866935:-
BRCA	cis	rs13098911	0.54	rs34000569	ENSG00000223552.1	RP11-24F11.2	-4.08	4.85e-05	0.00333	-0.21	-0.13	Celiac disease;	chr3:45957717	chr3:46364955~46407059:-
BRCA	cis	rs13098911	0.54	rs34324101	ENSG00000223552.1	RP11-24F11.2	-4.08	4.85e-05	0.00333	-0.21	-0.13	Celiac disease;	chr3:45959236	chr3:46364955~46407059:-
BRCA	cis	rs13098911	0.54	rs13069079	ENSG00000223552.1	RP11-24F11.2	-4.08	4.85e-05	0.00333	-0.21	-0.13	Celiac disease;	chr3:45959378	chr3:46364955~46407059:-
BRCA	cis	rs13098911	0.54	rs34849862	ENSG00000223552.1	RP11-24F11.2	-4.08	4.85e-05	0.00333	-0.21	-0.13	Celiac disease;	chr3:45959875	chr3:46364955~46407059:-
BRCA	cis	rs2625529	0.617	rs7175792	ENSG00000260037.4	CTD-2524L6.3	-4.08	4.85e-05	0.00333	-0.16	-0.13	Red blood cell count;	chr15:72139542	chr15:71818396~71823384:+
BRCA	cis	rs9467773	0.595	rs2451736	ENSG00000224843.5	LINC00240	-4.08	4.85e-05	0.00333	-0.14	-0.13	Intelligence (multi-trait analysis);	chr6:26620316	chr6:26956992~27023924:+
BRCA	cis	rs718314	1	rs1398676	ENSG00000256894.1	RP11-283G6.3	4.08	4.86e-05	0.00333	0.15	0.13	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Renal cell carcinoma;Waist circumference adjusted for body mass index;	chr12:26306487	chr12:26125155~26126617:-
BRCA	cis	rs6751744	0.513	rs6738215	ENSG00000224152.1	AC009506.1	-4.08	4.86e-05	0.00333	-0.14	-0.13	Dysphagia;	chr2:159596794	chr2:159615296~159617082:+
BRCA	cis	rs10504130	0.569	rs13265006	ENSG00000253844.1	RP11-546K22.1	-4.08	4.86e-05	0.00333	-0.18	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr8:51877963	chr8:51961458~52022974:+
BRCA	cis	rs10504130	0.597	rs34058697	ENSG00000253844.1	RP11-546K22.1	-4.08	4.86e-05	0.00333	-0.18	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr8:51882392	chr8:51961458~52022974:+
BRCA	cis	rs61931739	0.534	rs11053075	ENSG00000258794.3	DUX4L27	-4.08	4.86e-05	0.00333	-0.18	-0.13	Morning vs. evening chronotype;	chr12:34054074	chr12:34208415~34209675:-
BRCA	cis	rs1048886	0.938	rs2346890	ENSG00000271967.1	RP11-134K13.4	-4.08	4.86e-05	0.00333	-0.18	-0.13	Type 2 diabetes;	chr6:70508055	chr6:70596438~70596980:+
BRCA	cis	rs10129255	0.5	rs59939897	ENSG00000254174.1	IGHV1-12	4.08	4.86e-05	0.00333	0.1	0.13	Kawasaki disease;	chr14:106783414	chr14:106122420~106122709:-
BRCA	cis	rs4664293	0.769	rs2729726	ENSG00000224152.1	AC009506.1	-4.08	4.86e-05	0.00333	-0.14	-0.13	Monocyte percentage of white cells;	chr2:159811597	chr2:159615296~159617082:+
BRCA	cis	rs4664293	0.738	rs1549580	ENSG00000224152.1	AC009506.1	-4.08	4.86e-05	0.00333	-0.14	-0.13	Monocyte percentage of white cells;	chr2:159812177	chr2:159615296~159617082:+
BRCA	cis	rs10463316	0.894	rs6579875	ENSG00000260581.1	CTB-113P19.4	4.08	4.86e-05	0.00333	0.14	0.13	Metabolite levels (Pyroglutamine);	chr5:151403013	chr5:151652275~151655449:+
BRCA	cis	rs4302906	0.93	rs10992565	ENSG00000187984.11	ANKRD19P	-4.08	4.86e-05	0.00333	-0.11	-0.13	Lobe attachment (rater-scored or self-reported);	chr9:92988448	chr9:92809388~92888693:+
BRCA	cis	rs752590	0.65	rs6751201	ENSG00000189223.12	PAX8-AS1	4.08	4.86e-05	0.00333	0.19	0.13	Mucinous ovarian carcinoma;	chr2:113195122	chr2:113211522~113276581:+
BRCA	cis	rs7267979	0.844	rs869358	ENSG00000231081.1	RP4-760C5.3	4.08	4.86e-05	0.00333	0.16	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25394038	chr20:26008791~26010531:-
BRCA	cis	rs2109514	0.774	rs6954077	ENSG00000237813.3	AC002066.1	4.08	4.86e-05	0.00334	0.15	0.13	Prevalent atrial fibrillation;	chr7:116489099	chr7:116238260~116499465:-
BRCA	cis	rs4671400	0.571	rs12615222	ENSG00000273302.1	RP11-493E12.2	-4.08	4.86e-05	0.00334	-0.14	-0.13	3-hydroxypropylmercapturic acid levels in smokers;	chr2:61267760	chr2:61199979~61200769:+
BRCA	cis	rs6964587	0.839	rs17731846	ENSG00000188693.7	CYP51A1-AS1	-4.08	4.86e-05	0.00334	-0.14	-0.13	Breast cancer;	chr7:91811028	chr7:92134604~92180725:+
BRCA	cis	rs12681366	0.663	rs10216902	ENSG00000253704.1	RP11-267M23.4	4.08	4.86e-05	0.00334	0.13	0.13	Nonsyndromic cleft lip with cleft palate;	chr8:94467750	chr8:94553722~94569745:+
BRCA	cis	rs1048886	0.938	rs79421004	ENSG00000271967.1	RP11-134K13.4	-4.08	4.86e-05	0.00334	-0.19	-0.13	Type 2 diabetes;	chr6:70478869	chr6:70596438~70596980:+
BRCA	cis	rs1048886	0.872	rs17713105	ENSG00000271967.1	RP11-134K13.4	-4.08	4.86e-05	0.00334	-0.19	-0.13	Type 2 diabetes;	chr6:70484097	chr6:70596438~70596980:+
BRCA	cis	rs5758511	0.773	rs1894714	ENSG00000226450.2	CYP2D8P	-4.08	4.86e-05	0.00334	-0.14	-0.13	Birth weight;	chr22:41953130	chr22:42149886~42155001:-
BRCA	cis	rs728616	0.717	rs17098169	ENSG00000242600.5	MBL1P	-4.08	4.86e-05	0.00334	-0.26	-0.13	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80056378	chr10:79904898~79950336:+
BRCA	cis	rs11098499	0.754	rs17049949	ENSG00000260091.1	RP11-33B1.4	-4.08	4.86e-05	0.00334	-0.11	-0.13	Corneal astigmatism;	chr4:119334135	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.754	rs7689729	ENSG00000260091.1	RP11-33B1.4	-4.08	4.86e-05	0.00334	-0.11	-0.13	Corneal astigmatism;	chr4:119335037	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.865	rs3956464	ENSG00000260091.1	RP11-33B1.4	-4.08	4.86e-05	0.00334	-0.11	-0.13	Corneal astigmatism;	chr4:119335609	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.648	rs2002047	ENSG00000260091.1	RP11-33B1.4	-4.08	4.86e-05	0.00334	-0.11	-0.13	Corneal astigmatism;	chr4:119336073	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.775	rs2002049	ENSG00000260091.1	RP11-33B1.4	-4.08	4.86e-05	0.00334	-0.11	-0.13	Corneal astigmatism;	chr4:119336262	chr4:119409333~119410233:+
BRCA	cis	rs12439619	0.81	rs28876157	ENSG00000259429.4	UBE2Q2P2	-4.08	4.86e-05	0.00334	-0.15	-0.13	Intelligence (multi-trait analysis);	chr15:82216708	chr15:82355142~82420075:+
BRCA	cis	rs4925540	0.962	rs10924897	ENSG00000215796.3	RP11-551G24.2	-4.08	4.87e-05	0.00334	-0.15	-0.13	Response to taxane treatment (docetaxel);	chr1:247038730	chr1:247042791~247044021:+
BRCA	cis	rs8049367	0.684	rs2238423	ENSG00000267077.1	RP11-127I20.5	4.08	4.87e-05	0.00334	0.13	0.13	Nonsyndromic cleft lip with or without cleft palate;	chr16:3921391	chr16:4795265~4796532:-
BRCA	cis	rs739496	0.579	rs12296574	ENSG00000257624.1	RP1-128M12.3	4.08	4.87e-05	0.00334	0.17	0.13	Platelet count;	chr12:111884973	chr12:112000739~112000985:-
BRCA	cis	rs2302465	0.86	rs55784324	ENSG00000273133.1	RP11-799M12.2	-4.08	4.87e-05	0.00334	-0.25	-0.13	Blood protein levels;	chr4:15620026	chr4:15563698~15564253:-
BRCA	cis	rs9467773	0.62	rs9461275	ENSG00000224843.5	LINC00240	-4.08	4.87e-05	0.00334	-0.14	-0.13	Intelligence (multi-trait analysis);	chr6:26590573	chr6:26956992~27023924:+
BRCA	cis	rs6977955	1	rs917117	ENSG00000234336.5	JAZF1-AS1	-4.08	4.87e-05	0.00334	-0.17	-0.13	Allergic disease (asthma, hay fever or eczema);	chr7:28136686	chr7:28180322~28243917:+
BRCA	cis	rs4907240	0.961	rs10460601	ENSG00000230606.9	AC159540.1	4.08	4.87e-05	0.00334	0.16	0.13	Event-related brain oscillations;	chr2:96586707	chr2:97416165~97433527:-
BRCA	cis	rs6496044	0.568	rs1982743	ENSG00000202081.1	RNU6-1280P	4.08	4.87e-05	0.00334	0.14	0.13	Interstitial lung disease;	chr15:85525528	chr15:85651522~85651628:-
BRCA	cis	rs2625529	0.73	rs12912771	ENSG00000260037.4	CTD-2524L6.3	-4.08	4.87e-05	0.00334	-0.16	-0.13	Red blood cell count;	chr15:71870587	chr15:71818396~71823384:+
BRCA	cis	rs7824557	0.806	rs10503418	ENSG00000255046.1	RP11-297N6.4	4.08	4.87e-05	0.00334	0.16	0.13	Retinal vascular caliber;	chr8:11261474	chr8:11797928~11802568:-
BRCA	cis	rs11098499	0.863	rs2306457	ENSG00000250412.1	KLHL2P1	4.08	4.87e-05	0.00334	0.15	0.13	Corneal astigmatism;	chr4:119551684	chr4:119334329~119378233:+
BRCA	cis	rs13098911	0.54	rs13079869	ENSG00000223552.1	RP11-24F11.2	-4.08	4.87e-05	0.00334	-0.21	-0.13	Celiac disease;	chr3:45966595	chr3:46364955~46407059:-
BRCA	cis	rs6088580	0.561	rs3761147	ENSG00000275784.1	RP5-1125A11.6	4.08	4.87e-05	0.00334	0.14	0.13	Glomerular filtration rate (creatinine);	chr20:34408883	chr20:33989480~33991818:-
BRCA	cis	rs745109	0.882	rs59895355	ENSG00000273080.1	RP11-301O19.1	4.08	4.87e-05	0.00334	0.2	0.13	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86574412	chr2:86195590~86196049:+
BRCA	cis	rs1479090	0.901	rs6835785	ENSG00000250027.1	RP11-563E2.2	-4.08	4.87e-05	0.00334	-0.18	-0.13	Lung cancer;	chr4:163134850	chr4:163108785~163119965:+
BRCA	cis	rs6545883	0.894	rs6760075	ENSG00000212978.6	AC016747.3	-4.08	4.88e-05	0.00334	-0.17	-0.13	Tuberculosis;	chr2:61385746	chr2:61141592~61144969:-
BRCA	cis	rs6088580	0.543	rs13042351	ENSG00000279253.1	RP4-614O4.13	4.08	4.88e-05	0.00334	0.14	0.13	Glomerular filtration rate (creatinine);	chr20:34650769	chr20:35262727~35264187:-
BRCA	cis	rs2115630	1	rs8037423	ENSG00000275120.1	RP11-182J1.17	-4.08	4.88e-05	0.00335	-0.15	-0.13	P wave terminal force;	chr15:84812263	chr15:84599434~84606463:-
BRCA	cis	rs4143844	0.867	rs11629900	ENSG00000259251.2	RP11-643M14.1	4.08	4.88e-05	0.00335	0.31	0.13	Bipolar disorder and schizophrenia;	chr15:61954938	chr15:62060503~62062434:+
BRCA	cis	rs539514	0.516	rs2273996	ENSG00000261105.4	LMO7-AS1	-4.08	4.88e-05	0.00335	-0.15	-0.13	Type 1 diabetes;	chr13:75836589	chr13:75604700~75635994:-
BRCA	cis	rs875971	0.929	rs778692	ENSG00000265600.1	AC006480.1	-4.08	4.88e-05	0.00335	-0.15	-0.13	Aortic root size;	chr7:66407462	chr7:67356680~67356779:+
BRCA	cis	rs875971	1	rs4718343	ENSG00000265600.1	AC006480.1	-4.08	4.88e-05	0.00335	-0.15	-0.13	Aortic root size;	chr7:66409301	chr7:67356680~67356779:+
BRCA	cis	rs875971	1	rs1968225	ENSG00000265600.1	AC006480.1	-4.08	4.88e-05	0.00335	-0.15	-0.13	Aortic root size;	chr7:66409786	chr7:67356680~67356779:+
BRCA	cis	rs875971	1	rs6460295	ENSG00000265600.1	AC006480.1	-4.08	4.88e-05	0.00335	-0.15	-0.13	Aortic root size;	chr7:66417741	chr7:67356680~67356779:+
BRCA	cis	rs875971	0.964	rs6978721	ENSG00000265600.1	AC006480.1	-4.08	4.88e-05	0.00335	-0.15	-0.13	Aortic root size;	chr7:66418217	chr7:67356680~67356779:+
BRCA	cis	rs9527	0.59	rs11191578	ENSG00000213061.2	PFN1P11	4.08	4.88e-05	0.00335	0.17	0.13	Arsenic metabolism;	chr10:103142580	chr10:102838011~102845473:-
BRCA	cis	rs8040855	0.627	rs11632658	ENSG00000259774.1	RP11-182J1.13	-4.08	4.88e-05	0.00335	-0.17	-0.13	Bulimia nervosa;	chr15:85062982	chr15:84422618~84425882:+
BRCA	cis	rs1479090	0.805	rs2320615	ENSG00000250027.1	RP11-563E2.2	-4.08	4.88e-05	0.00335	-0.17	-0.13	Lung cancer;	chr4:163148797	chr4:163108785~163119965:+
BRCA	cis	rs921968	0.643	rs62191565	ENSG00000273466.1	RP11-548H3.1	4.08	4.88e-05	0.00335	0.13	0.13	Mean corpuscular hemoglobin concentration;	chr2:218617294	chr2:218633256~218634014:-
BRCA	cis	rs38055	0.918	rs251522	ENSG00000247796.2	CTD-2366F13.1	-4.08	4.88e-05	0.00335	-0.15	-0.13	Acne (severe);	chr5:53287330	chr5:53109842~53115126:+
BRCA	cis	rs2243480	1	rs73142122	ENSG00000275400.1	RP4-756H11.5	4.08	4.89e-05	0.00335	0.23	0.13	Diabetic kidney disease;	chr7:65846311	chr7:66553805~66554199:-
BRCA	cis	rs2243480	0.901	rs73142137	ENSG00000275400.1	RP4-756H11.5	4.08	4.89e-05	0.00335	0.23	0.13	Diabetic kidney disease;	chr7:65878455	chr7:66553805~66554199:-
BRCA	cis	rs2243480	1	rs13247184	ENSG00000275400.1	RP4-756H11.5	4.08	4.89e-05	0.00335	0.23	0.13	Diabetic kidney disease;	chr7:65893941	chr7:66553805~66554199:-
BRCA	cis	rs2243480	1	rs35283677	ENSG00000275400.1	RP4-756H11.5	4.08	4.89e-05	0.00335	0.23	0.13	Diabetic kidney disease;	chr7:65894246	chr7:66553805~66554199:-
BRCA	cis	rs2243480	1	rs35421653	ENSG00000275400.1	RP4-756H11.5	4.08	4.89e-05	0.00335	0.23	0.13	Diabetic kidney disease;	chr7:65898442	chr7:66553805~66554199:-
BRCA	cis	rs9733	0.596	rs1336898	ENSG00000231073.1	RP11-316M1.3	4.08	4.89e-05	0.00335	0.13	0.13	Tonsillectomy;	chr1:150692574	chr1:150973123~150975534:+
BRCA	cis	rs4919694	1	rs11191439	ENSG00000236937.2	PTGES3P4	-4.08	4.89e-05	0.00335	-0.25	-0.13	Arsenic metabolism;	chr10:102878966	chr10:102845595~102845950:+
BRCA	cis	rs10129255	0.5	rs8011115	ENSG00000232216.1	IGHV3-43	4.08	4.89e-05	0.00335	0.09	0.13	Kawasaki disease;	chr14:106786292	chr14:106470264~106470800:-
BRCA	cis	rs72759215	1	rs72759215	ENSG00000272308.1	RP11-231G3.1	-4.08	4.89e-05	0.00335	-0.14	-0.13	Intelligence (multi-trait analysis);	chr5:61056756	chr5:60866457~60866935:-
BRCA	cis	rs10129255	0.5	rs7157975	ENSG00000211967.3	IGHV3-53	-4.08	4.89e-05	0.00335	-0.08	-0.13	Kawasaki disease;	chr14:106804049	chr14:106592676~106593347:-
BRCA	cis	rs6121246	0.909	rs6087778	ENSG00000230613.1	HM13-AS1	4.08	4.89e-05	0.00335	0.18	0.13	Mean corpuscular hemoglobin;	chr20:31766339	chr20:31567707~31573263:-
BRCA	cis	rs4787491	0.679	rs12933575	ENSG00000183604.13	SMG1P5	-4.08	4.89e-05	0.00335	-0.12	-0.13	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30011243	chr16:30267553~30335374:-
BRCA	cis	rs11098499	0.863	rs3775843	ENSG00000250412.1	KLHL2P1	4.08	4.89e-05	0.00335	0.15	0.13	Corneal astigmatism;	chr4:119506689	chr4:119334329~119378233:+
BRCA	cis	rs11098499	0.863	rs3775844	ENSG00000250412.1	KLHL2P1	4.08	4.89e-05	0.00335	0.15	0.13	Corneal astigmatism;	chr4:119506878	chr4:119334329~119378233:+
BRCA	cis	rs7037266	0.927	rs7046665	ENSG00000232946.1	RP11-390F4.2	-4.08	4.89e-05	0.00335	-0.15	-0.13	Menarche (age at onset);	chr9:6947484	chr9:6675284~6675614:+
BRCA	cis	rs6088580	0.634	rs6120669	ENSG00000275784.1	RP5-1125A11.6	-4.08	4.89e-05	0.00335	-0.14	-0.13	Glomerular filtration rate (creatinine);	chr20:34517223	chr20:33989480~33991818:-
BRCA	cis	rs7267979	0.714	rs1555329	ENSG00000125804.12	FAM182A	-4.08	4.89e-05	0.00335	-0.16	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25251222	chr20:26054655~26086917:+
BRCA	cis	rs7772486	0.79	rs2250387	ENSG00000270638.1	RP3-466P17.1	4.08	4.89e-05	0.00335	0.15	0.13	Lobe attachment (rater-scored or self-reported);	chr6:145884097	chr6:145735570~145737218:+
BRCA	cis	rs8040855	0.627	rs12913859	ENSG00000259774.1	RP11-182J1.13	4.08	4.89e-05	0.00335	0.18	0.13	Bulimia nervosa;	chr15:85095187	chr15:84422618~84425882:+
BRCA	cis	rs2408955	0.561	rs9971924	ENSG00000226413.2	OR8T1P	-4.08	4.89e-05	0.00336	-0.16	-0.13	Glycated hemoglobin levels;	chr12:48086049	chr12:48442030~48442947:-
BRCA	cis	rs1865760	0.786	rs2164487	ENSG00000272462.2	U91328.19	-4.08	4.89e-05	0.00336	-0.15	-0.13	Height;	chr6:25950572	chr6:25992662~26001775:+
BRCA	cis	rs1865760	0.865	rs6929805	ENSG00000272462.2	U91328.19	-4.08	4.89e-05	0.00336	-0.15	-0.13	Height;	chr6:25950606	chr6:25992662~26001775:+
BRCA	cis	rs938554	0.542	rs7678287	ENSG00000250413.1	RP11-448G15.1	-4.08	4.9e-05	0.00336	-0.19	-0.13	Blood metabolite levels;	chr4:9998877	chr4:10006482~10009725:+
BRCA	cis	rs771767	0.539	rs771778	ENSG00000244119.1	PDCL3P4	4.08	4.9e-05	0.00336	0.13	0.13	Multiple sclerosis;	chr3:102034124	chr3:101712472~101713191:+
BRCA	cis	rs771767	0.539	rs771777	ENSG00000244119.1	PDCL3P4	4.08	4.9e-05	0.00336	0.13	0.13	Multiple sclerosis;	chr3:102034140	chr3:101712472~101713191:+
BRCA	cis	rs853679	0.517	rs9368555	ENSG00000216901.1	AL022393.7	4.08	4.9e-05	0.00336	0.18	0.13	Depression;	chr6:28141189	chr6:28176188~28176674:+
BRCA	cis	rs853679	0.517	rs9393893	ENSG00000216901.1	AL022393.7	4.08	4.9e-05	0.00336	0.18	0.13	Depression;	chr6:28141484	chr6:28176188~28176674:+
BRCA	cis	rs757081	0.667	rs1987694	ENSG00000184669.7	OR7E14P	-4.08	4.9e-05	0.00336	-0.19	-0.13	Systolic blood pressure;	chr11:17086101	chr11:17013998~17053024:+
BRCA	cis	rs6964587	1	rs10488512	ENSG00000188693.7	CYP51A1-AS1	-4.08	4.9e-05	0.00336	-0.14	-0.13	Breast cancer;	chr7:92124265	chr7:92134604~92180725:+
BRCA	cis	rs375066	0.935	rs448823	ENSG00000267191.1	RP11-15A1.2	-4.08	4.9e-05	0.00336	-0.16	-0.13	Breast cancer;	chr19:43902139	chr19:43902001~43926545:+
BRCA	cis	rs375066	0.868	rs448829	ENSG00000267191.1	RP11-15A1.2	-4.08	4.9e-05	0.00336	-0.16	-0.13	Breast cancer;	chr19:43902169	chr19:43902001~43926545:+
BRCA	cis	rs3739034	1	rs4953925	ENSG00000224043.6	CCNT2-AS1	-4.08	4.9e-05	0.00336	-0.21	-0.13	Gut microbiome composition (winter);	chr2:134713720	chr2:134735464~134918710:-
BRCA	cis	rs6593122	0.71	rs56127030	ENSG00000235454.1	HAUS6P3	-4.08	4.9e-05	0.00336	-0.17	-0.13	Vaccine-related adverse events;	chr7:54131742	chr7:53862233~53863339:+
BRCA	cis	rs6593122	0.755	rs10249172	ENSG00000235454.1	HAUS6P3	-4.08	4.9e-05	0.00336	-0.17	-0.13	Vaccine-related adverse events;	chr7:54131784	chr7:53862233~53863339:+
BRCA	cis	rs6593122	0.755	rs1404202	ENSG00000235454.1	HAUS6P3	-4.08	4.9e-05	0.00336	-0.17	-0.13	Vaccine-related adverse events;	chr7:54132174	chr7:53862233~53863339:+
BRCA	cis	rs6593122	0.755	rs13438560	ENSG00000235454.1	HAUS6P3	-4.08	4.9e-05	0.00336	-0.17	-0.13	Vaccine-related adverse events;	chr7:54132673	chr7:53862233~53863339:+
BRCA	cis	rs6593122	0.755	rs13438496	ENSG00000235454.1	HAUS6P3	-4.08	4.9e-05	0.00336	-0.17	-0.13	Vaccine-related adverse events;	chr7:54132706	chr7:53862233~53863339:+
BRCA	cis	rs6593122	0.755	rs13438502	ENSG00000235454.1	HAUS6P3	-4.08	4.9e-05	0.00336	-0.17	-0.13	Vaccine-related adverse events;	chr7:54132764	chr7:53862233~53863339:+
BRCA	cis	rs6593122	0.755	rs13438200	ENSG00000235454.1	HAUS6P3	-4.08	4.9e-05	0.00336	-0.17	-0.13	Vaccine-related adverse events;	chr7:54132890	chr7:53862233~53863339:+
BRCA	cis	rs6593122	0.755	rs10271778	ENSG00000235454.1	HAUS6P3	-4.08	4.9e-05	0.00336	-0.17	-0.13	Vaccine-related adverse events;	chr7:54132920	chr7:53862233~53863339:+
BRCA	cis	rs6593122	0.727	rs4574802	ENSG00000235454.1	HAUS6P3	-4.08	4.9e-05	0.00336	-0.17	-0.13	Vaccine-related adverse events;	chr7:54133194	chr7:53862233~53863339:+
BRCA	cis	rs6593122	0.755	rs6955817	ENSG00000235454.1	HAUS6P3	-4.08	4.9e-05	0.00336	-0.17	-0.13	Vaccine-related adverse events;	chr7:54133758	chr7:53862233~53863339:+
BRCA	cis	rs6593122	0.755	rs6977371	ENSG00000235454.1	HAUS6P3	-4.08	4.9e-05	0.00336	-0.17	-0.13	Vaccine-related adverse events;	chr7:54134187	chr7:53862233~53863339:+
BRCA	cis	rs6593122	0.755	rs4947456	ENSG00000235454.1	HAUS6P3	-4.08	4.9e-05	0.00336	-0.17	-0.13	Vaccine-related adverse events;	chr7:54134628	chr7:53862233~53863339:+
BRCA	cis	rs9368481	0.554	rs2754603	ENSG00000224843.5	LINC00240	4.08	4.9e-05	0.00336	0.15	0.13	Autism spectrum disorder or schizophrenia;	chr6:26997360	chr6:26956992~27023924:+
BRCA	cis	rs10504130	0.569	rs71513549	ENSG00000253844.1	RP11-546K22.1	-4.08	4.9e-05	0.00336	-0.18	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr8:51770326	chr8:51961458~52022974:+
BRCA	cis	rs10504130	0.502	rs4321994	ENSG00000253844.1	RP11-546K22.1	-4.08	4.9e-05	0.00336	-0.18	-0.13	Venous thromboembolism (SNP x SNP interaction);	chr8:51771680	chr8:51961458~52022974:+
BRCA	cis	rs853679	0.769	rs17720293	ENSG00000280107.1	AL022393.9	-4.08	4.9e-05	0.00336	-0.29	-0.13	Depression;	chr6:28246920	chr6:28170845~28172521:+
BRCA	cis	rs10043228	1	rs1876674	ENSG00000271918.1	CTD-2287O16.5	-4.08	4.9e-05	0.00336	-0.15	-0.13	Asthma or chronic obstructive pulmonary disease;	chr5:116115272	chr5:116083807~116085416:-
BRCA	cis	rs10043228	0.826	rs12521815	ENSG00000271918.1	CTD-2287O16.5	-4.08	4.9e-05	0.00336	-0.15	-0.13	Asthma or chronic obstructive pulmonary disease;	chr5:116116625	chr5:116083807~116085416:-
BRCA	cis	rs10043228	0.826	rs10478277	ENSG00000271918.1	CTD-2287O16.5	-4.08	4.9e-05	0.00336	-0.15	-0.13	Asthma or chronic obstructive pulmonary disease;	chr5:116116872	chr5:116083807~116085416:-
BRCA	cis	rs10043228	1	rs10478278	ENSG00000271918.1	CTD-2287O16.5	-4.08	4.9e-05	0.00336	-0.15	-0.13	Asthma or chronic obstructive pulmonary disease;	chr5:116117061	chr5:116083807~116085416:-
BRCA	cis	rs2662776	1	rs2814372	ENSG00000232995.6	RGS5	-4.08	4.9e-05	0.00336	-0.13	-0.13	Lead levels in blood;	chr1:163194834	chr1:163244505~163321894:-
BRCA	cis	rs17801127	0.636	rs4667408	ENSG00000231969.1	AC144449.1	-4.08	4.9e-05	0.00336	-0.19	-0.13	Liver enzyme levels (alanine transaminase);	chr2:149694352	chr2:149587196~149848233:+
BRCA	cis	rs6496932	0.802	rs12442399	ENSG00000218052.5	ADAMTS7P4	4.08	4.91e-05	0.00336	0.13	0.13	Central corneal thickness;Corneal structure;	chr15:85311619	chr15:85255369~85330334:-
BRCA	cis	rs180730	1	rs2667176	ENSG00000251609.2	SETP12	-4.08	4.91e-05	0.00336	-0.18	-0.13	Fasting plasma glucose;	chr4:120881498	chr4:120895494~120897083:-
BRCA	cis	rs6430585	0.527	rs1446586	ENSG00000231890.6	DARS-AS1	4.08	4.91e-05	0.00336	0.19	0.13	Corneal structure;	chr2:135649875	chr2:135985176~136022593:+
BRCA	cis	rs1371614	0.55	rs2384508	ENSG00000229122.1	AGBL5-IT1	4.08	4.91e-05	0.00336	0.13	0.13	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26920188	chr2:27061038~27061815:+
BRCA	cis	rs6121246	0.909	rs3203770	ENSG00000230613.1	HM13-AS1	4.08	4.91e-05	0.00336	0.18	0.13	Mean corpuscular hemoglobin;	chr20:31794512	chr20:31567707~31573263:-
BRCA	cis	rs6121246	0.909	rs6119725	ENSG00000230613.1	HM13-AS1	4.08	4.91e-05	0.00336	0.18	0.13	Mean corpuscular hemoglobin;	chr20:31797754	chr20:31567707~31573263:-
BRCA	cis	rs6121246	0.909	rs1075698	ENSG00000230613.1	HM13-AS1	4.08	4.91e-05	0.00336	0.18	0.13	Mean corpuscular hemoglobin;	chr20:31800189	chr20:31567707~31573263:-
BRCA	cis	rs35306767	0.903	rs4522091	ENSG00000229869.1	RP11-363N22.2	-4.08	4.91e-05	0.00337	-0.19	-0.13	Eosinophil percentage of granulocytes;	chr10:828176	chr10:933026~942743:+
BRCA	cis	rs7824557	0.767	rs2060463	ENSG00000248896.2	CTD-2135J3.3	4.08	4.91e-05	0.00337	0.17	0.13	Retinal vascular caliber;	chr8:11304101	chr8:10729314~10771392:+
BRCA	cis	rs10043228	0.826	rs62384693	ENSG00000271918.1	CTD-2287O16.5	-4.08	4.91e-05	0.00337	-0.16	-0.13	Asthma or chronic obstructive pulmonary disease;	chr5:116097784	chr5:116083807~116085416:-
BRCA	cis	rs10043228	1	rs62384697	ENSG00000271918.1	CTD-2287O16.5	-4.08	4.91e-05	0.00337	-0.16	-0.13	Asthma or chronic obstructive pulmonary disease;	chr5:116102587	chr5:116083807~116085416:-
BRCA	cis	rs4790333	0.967	rs2002863	ENSG00000262333.1	HNRNPA1P16	-4.08	4.91e-05	0.00337	-0.13	-0.13	Proinsulin levels;	chr17:2366475	chr17:2306761~2307715:+
BRCA	cis	rs1865760	0.964	rs9379802	ENSG00000272462.2	U91328.19	-4.08	4.91e-05	0.00337	-0.15	-0.13	Height;	chr6:25933670	chr6:25992662~26001775:+
BRCA	cis	rs7111546	1	rs80216128	ENSG00000246225.5	RP11-17A1.3	4.08	4.91e-05	0.00337	0.22	0.13	Dialysis-related mortality;	chr11:22801324	chr11:22829380~22945393:+
BRCA	cis	rs300890	0.689	rs300951	ENSG00000250326.1	RP11-284M14.1	-4.08	4.92e-05	0.00337	-0.14	-0.13	Nasopharyngeal carcinoma;	chr4:143280230	chr4:142933195~143184861:-
BRCA	cis	rs875971	0.964	rs12668936	ENSG00000236529.1	RP13-254B10.1	4.08	4.92e-05	0.00337	0.14	0.13	Aortic root size;	chr7:66449417	chr7:65840212~65840596:+
BRCA	cis	rs62025270	0.632	rs55981798	ENSG00000259762.1	RP11-158M2.4	-4.08	4.92e-05	0.00337	-0.18	-0.13	Idiopathic pulmonary fibrosis;	chr15:85600869	chr15:85750336~85752901:-
BRCA	cis	rs62025270	0.576	rs17633959	ENSG00000259762.1	RP11-158M2.4	-4.08	4.92e-05	0.00337	-0.18	-0.13	Idiopathic pulmonary fibrosis;	chr15:85600950	chr15:85750336~85752901:-
BRCA	cis	rs4415084	0.716	rs4492119	ENSG00000251141.4	RP11-53O19.1	-4.08	4.92e-05	0.00337	-0.12	-0.13	Breast cancer;	chr5:44855512	chr5:44744900~44808777:-
BRCA	cis	rs739496	0.579	rs2238152	ENSG00000226469.1	ADAM1B	4.08	4.92e-05	0.00337	0.17	0.13	Platelet count;	chr12:111776655	chr12:111927018~111929017:+
BRCA	cis	rs6736093	0.966	rs11679801	ENSG00000236307.2	EEF1E1P1	-4.08	4.92e-05	0.00337	-0.16	-0.13	Coronary artery disease;	chr2:111955258	chr2:111887914~111888741:+
BRCA	cis	rs7829975	0.806	rs2428	ENSG00000253981.4	ALG1L13P	4.08	4.92e-05	0.00337	0.14	0.13	Mood instability;	chr8:8783635	chr8:8236003~8244667:-
BRCA	cis	rs9467773	0.62	rs6925087	ENSG00000224843.5	LINC00240	-4.08	4.92e-05	0.00337	-0.14	-0.13	Intelligence (multi-trait analysis);	chr6:26592625	chr6:26956992~27023924:+
BRCA	cis	rs9467773	0.62	rs4368798	ENSG00000224843.5	LINC00240	-4.08	4.92e-05	0.00337	-0.14	-0.13	Intelligence (multi-trait analysis);	chr6:26593243	chr6:26956992~27023924:+
BRCA	cis	rs1865760	0.865	rs2164485	ENSG00000272462.2	U91328.19	-4.08	4.92e-05	0.00337	-0.15	-0.13	Height;	chr6:25951878	chr6:25992662~26001775:+
BRCA	cis	rs6121246	0.821	rs3181073	ENSG00000230613.1	HM13-AS1	-4.08	4.92e-05	0.00337	-0.18	-0.13	Mean corpuscular hemoglobin;	chr20:31719396	chr20:31567707~31573263:-
BRCA	cis	rs13434995	0.513	rs12509047	ENSG00000239040.1	Y_RNA	-4.08	4.92e-05	0.00337	-0.15	-0.13	Adiponectin levels;	chr4:55545245	chr4:55412636~55412738:+
BRCA	cis	rs9470794	1	rs12662940	ENSG00000204110.6	RP1-153P14.8	-4.08	4.92e-05	0.00337	-0.22	-0.13	Type 2 diabetes;	chr6:38143159	chr6:37507348~37535616:+
BRCA	cis	rs9952991	0.883	rs2847260	ENSG00000260302.1	RP11-973H7.1	-4.08	4.92e-05	0.00337	-0.2	-0.13	Inflammatory skin disease;	chr18:12775592	chr18:12774651~12775923:-
BRCA	cis	rs9952991	0.883	rs2542147	ENSG00000260302.1	RP11-973H7.1	-4.08	4.92e-05	0.00337	-0.2	-0.13	Inflammatory skin disease;	chr18:12775852	chr18:12774651~12775923:-
BRCA	cis	rs7119	0.604	rs2682927	ENSG00000259362.2	RP11-307C19.1	4.08	4.92e-05	0.00337	0.17	0.13	Type 2 diabetes;	chr15:77566826	chr15:77525540~77534110:+
BRCA	cis	rs28829049	0.536	rs2073105	ENSG00000270728.1	RP4-657E11.10	-4.08	4.92e-05	0.00337	-0.13	-0.13	QRS duration in Tripanosoma cruzi seropositivity;	chr1:19223370	chr1:19297080~19297903:+
BRCA	cis	rs2274273	0.588	rs17675223	ENSG00000259318.1	RP11-454L9.2	4.08	4.92e-05	0.00337	0.11	0.13	Protein biomarker;	chr14:55395518	chr14:55394940~55395233:-
BRCA	cis	rs2242330	0.705	rs7670716	ENSG00000250075.4	RP11-584P21.2	4.08	4.92e-05	0.00337	0.16	0.13	Parkinson's disease;	chr4:67582656	chr4:67417305~67468251:-
BRCA	cis	rs739496	0.579	rs16941759	ENSG00000234608.6	MAPKAPK5-AS1	-4.08	4.92e-05	0.00337	-0.15	-0.13	Platelet count;	chr12:111930117	chr12:111839764~111842902:-
BRCA	cis	rs2227564	0.794	rs2688607	ENSG00000271816.1	BMS1P4	-4.08	4.92e-05	0.00337	-0.14	-0.13	Crohn's disease;Inflammatory bowel disease;	chr10:73903978	chr10:73699151~73730487:-
BRCA	cis	rs11098499	0.954	rs12506546	ENSG00000225892.3	RP11-384K6.2	4.08	4.93e-05	0.00337	0.13	0.13	Corneal astigmatism;	chr4:119380463	chr4:118632274~118634759:+
BRCA	cis	rs9533799	1	rs11620543	ENSG00000227258.4	SMIM2-AS1	-4.08	4.93e-05	0.00337	-0.16	-0.13	Amyotrophic lateral sclerosis;	chr13:44224235	chr13:44110451~44240517:+
BRCA	cis	rs409045	0.932	rs457649	ENSG00000271874.1	CTD-2024P10.2	-4.08	4.93e-05	0.00337	-0.16	-0.13	Left ventricular mass;	chr5:34631129	chr5:34651457~34651888:-
BRCA	cis	rs801193	1	rs1553610	ENSG00000273142.1	RP11-458F8.4	-4.08	4.93e-05	0.00337	-0.11	-0.13	Aortic root size;	chr7:66732246	chr7:66902857~66906297:+
BRCA	cis	rs801193	1	rs2707845	ENSG00000273142.1	RP11-458F8.4	-4.08	4.93e-05	0.00337	-0.11	-0.13	Aortic root size;	chr7:66733811	chr7:66902857~66906297:+
BRCA	cis	rs801193	1	rs2707850	ENSG00000273142.1	RP11-458F8.4	-4.08	4.93e-05	0.00337	-0.11	-0.13	Aortic root size;	chr7:66738883	chr7:66902857~66906297:+
BRCA	cis	rs801193	0.967	rs1110414	ENSG00000273142.1	RP11-458F8.4	-4.08	4.93e-05	0.00337	-0.11	-0.13	Aortic root size;	chr7:66740595	chr7:66902857~66906297:+
BRCA	cis	rs801193	1	rs7783924	ENSG00000273142.1	RP11-458F8.4	-4.08	4.93e-05	0.00337	-0.11	-0.13	Aortic root size;	chr7:66744070	chr7:66902857~66906297:+
BRCA	cis	rs801193	1	rs7789184	ENSG00000273142.1	RP11-458F8.4	-4.08	4.93e-05	0.00337	-0.11	-0.13	Aortic root size;	chr7:66745208	chr7:66902857~66906297:+
BRCA	cis	rs801193	1	rs2707854	ENSG00000273142.1	RP11-458F8.4	-4.08	4.93e-05	0.00337	-0.11	-0.13	Aortic root size;	chr7:66747610	chr7:66902857~66906297:+
BRCA	cis	rs970548	0.909	rs55665473	ENSG00000230869.1	CTGLF10P	4.08	4.93e-05	0.00337	0.16	0.13	Total cholesterol levels;HDL cholesterol;HDL cholesterol levels;Cholesterol, total;	chr10:45526557	chr10:45678692~45700532:+
BRCA	cis	rs12612619	0.732	rs2289360	ENSG00000272148.1	RP11-195B17.1	4.08	4.93e-05	0.00337	0.14	0.13	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27079297	chr2:27062428~27062907:-
BRCA	cis	rs9527	0.59	rs1046411	ENSG00000213061.2	PFN1P11	4.08	4.93e-05	0.00337	0.17	0.13	Arsenic metabolism;	chr10:103078059	chr10:102838011~102845473:-
BRCA	cis	rs17772222	0.958	rs17203789	ENSG00000258789.1	RP11-507K2.3	-4.08	4.93e-05	0.00337	-0.15	-0.13	Coronary artery calcification;	chr14:88541362	chr14:88551597~88552493:+
BRCA	cis	rs295490	0.748	rs75256094	ENSG00000272656.1	RP11-219D15.3	4.08	4.93e-05	0.00338	0.32	0.13	PR interval in Tripanosoma cruzi seropositivity;	chr3:139349504	chr3:139349024~139349371:-
BRCA	cis	rs71520386	0.632	rs2286509	ENSG00000226329.2	AC005682.6	-4.08	4.93e-05	0.00338	-0.13	-0.13	Fibrinogen levels;	chr7:22814832	chr7:22863874~22881350:-
BRCA	cis	rs4415084	0.716	rs2165008	ENSG00000251141.4	RP11-53O19.1	4.08	4.93e-05	0.00338	0.12	0.13	Breast cancer;	chr5:44821577	chr5:44744900~44808777:-
BRCA	cis	rs6545883	0.894	rs4672423	ENSG00000212978.6	AC016747.3	-4.08	4.93e-05	0.00338	-0.17	-0.13	Tuberculosis;	chr2:61208140	chr2:61141592~61144969:-
BRCA	cis	rs2286503	0.752	rs6461669	ENSG00000226329.2	AC005682.6	4.08	4.93e-05	0.00338	0.12	0.13	Fibrinogen;	chr7:22818447	chr7:22863874~22881350:-
BRCA	cis	rs9368481	0.729	rs9379950	ENSG00000224843.5	LINC00240	4.08	4.93e-05	0.00338	0.15	0.13	Autism spectrum disorder or schizophrenia;	chr6:26993769	chr6:26956992~27023924:+
BRCA	cis	rs1008375	0.931	rs6813374	ENSG00000249502.1	AC006160.5	-4.08	4.93e-05	0.00338	-0.14	-0.13	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17647871	chr4:17587467~17614571:-
BRCA	cis	rs1008375	0.966	rs6813375	ENSG00000249502.1	AC006160.5	-4.08	4.93e-05	0.00338	-0.14	-0.13	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17647876	chr4:17587467~17614571:-
BRCA	cis	rs812925	0.555	rs12616433	ENSG00000270820.4	RP11-355B11.2	4.08	4.93e-05	0.00338	0.14	0.13	Immature fraction of reticulocytes;	chr2:61469353	chr2:61471188~61484130:+
BRCA	cis	rs7260598	0.792	rs73021412	ENSG00000268442.1	CTD-2027I19.2	4.08	4.93e-05	0.00338	0.21	0.13	Response to taxane treatment (placlitaxel);	chr19:24070755	chr19:24162370~24163425:-
BRCA	cis	rs34217772	0.64	rs61990337	ENSG00000258636.1	CTD-2298J14.2	4.08	4.93e-05	0.00338	0.16	0.13	Myopia;	chr14:41715214	chr14:41587861~41604856:-
BRCA	cis	rs2411233	1	rs2117207	ENSG00000259278.1	RP11-62C7.2	4.08	4.93e-05	0.00338	0.15	0.13	Platelet count;	chr15:38997053	chr15:39019233~39024918:+
BRCA	cis	rs10129255	0.5	rs8014529	ENSG00000254174.1	IGHV1-12	4.08	4.93e-05	0.00338	0.1	0.13	Kawasaki disease;	chr14:106784065	chr14:106122420~106122709:-
BRCA	cis	rs459571	0.959	rs416390	ENSG00000235106.7	LINC00094	-4.08	4.93e-05	0.00338	-0.13	-0.13	Platelet distribution width;	chr9:134043427	chr9:134025439~134034666:+
BRCA	cis	rs7176093	1	rs72757332	ENSG00000259295.5	CSPG4P12	-4.08	4.93e-05	0.00338	-0.17	-0.13	Aging traits;	chr15:85825819	chr15:85191438~85213905:+
BRCA	cis	rs28735056	0.572	rs4799100	ENSG00000261126.6	RP11-795F19.1	-4.08	4.93e-05	0.00338	-0.12	-0.13	Schizophrenia;	chr18:79880207	chr18:80046900~80095482:+
BRCA	cis	rs875971	0.895	rs778700	ENSG00000265600.1	AC006480.1	-4.08	4.93e-05	0.00338	-0.15	-0.13	Aortic root size;	chr7:66401463	chr7:67356680~67356779:+
BRCA	cis	rs875971	1	rs778699	ENSG00000265600.1	AC006480.1	-4.08	4.93e-05	0.00338	-0.15	-0.13	Aortic root size;	chr7:66403303	chr7:67356680~67356779:+
BRCA	cis	rs7487075	0.964	rs2408497	ENSG00000274723.1	RP11-618L22.1	4.08	4.93e-05	0.00338	0.15	0.13	Itch intensity from mosquito bite;	chr12:46402968	chr12:46970504~46972155:+
BRCA	cis	rs7487075	0.504	rs1000405	ENSG00000272369.1	RP11-446N19.1	4.08	4.93e-05	0.00338	0.14	0.13	Itch intensity from mosquito bite;	chr12:46262739	chr12:46537502~46652550:+
BRCA	cis	rs2281558	0.833	rs55792313	ENSG00000274414.1	RP5-965G21.4	-4.08	4.94e-05	0.00338	-0.17	-0.13	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25540619	chr20:25239007~25245229:-
BRCA	cis	rs6964587	0.933	rs13230837	ENSG00000188693.7	CYP51A1-AS1	-4.08	4.94e-05	0.00338	-0.14	-0.13	Breast cancer;	chr7:92149703	chr7:92134604~92180725:+
BRCA	cis	rs1836229	0.874	rs10119815	ENSG00000225706.1	PTPRD-AS1	-4.08	4.94e-05	0.00338	-0.14	-0.13	Restless legs syndrome;	chr9:8826783	chr9:8858130~8862255:+
BRCA	cis	rs1836229	0.839	rs10116689	ENSG00000225706.1	PTPRD-AS1	-4.08	4.94e-05	0.00338	-0.14	-0.13	Restless legs syndrome;	chr9:8826788	chr9:8858130~8862255:+
BRCA	cis	rs4886920	0.894	rs6495252	ENSG00000260776.4	RP11-114H24.2	4.08	4.94e-05	0.00338	0.15	0.13	Neuroticism;	chr15:77825343	chr15:77914217~77926846:-
BRCA	cis	rs256438	0.524	rs428279	ENSG00000251050.1	RP11-168A11.4	-4.08	4.94e-05	0.00338	-0.13	-0.13	Serum thyroid-stimulating hormone levels;	chr5:80049987	chr5:80019609~80019920:+
BRCA	cis	rs62244186	0.566	rs2135531	ENSG00000214820.3	MPRIPP1	4.08	4.94e-05	0.00338	0.14	0.13	Depressive symptoms;	chr3:44839666	chr3:44579938~44581026:-
BRCA	cis	rs2555155	0.87	rs2723652	ENSG00000254595.1	CTD-2010I16.1	-4.08	4.94e-05	0.00338	-0.14	-0.13	DNA methylation (variation);	chr11:6512851	chr11:6488186~6489377:-
BRCA	cis	rs6847067	0.672	rs1838038	ENSG00000180769.7	WDFY3-AS2	4.08	4.94e-05	0.00338	0.12	0.13	Oropharynx cancer;	chr4:84649211	chr4:84965682~85011277:+
BRCA	cis	rs516805	0.63	rs2606656	ENSG00000279114.1	RP3-425C14.5	-4.08	4.94e-05	0.00338	-0.16	-0.13	Lymphocyte counts;	chr6:122153088	chr6:122471923~122484161:+
BRCA	cis	rs160451	0.774	rs4961159	ENSG00000251136.7	RP11-37B2.1	4.08	4.94e-05	0.00338	0.12	0.13	Leprosy;	chr8:89691677	chr8:89609409~89757727:-
BRCA	cis	rs11711311	1	rs9855613	ENSG00000241529.3	RN7SL767P	-4.08	4.94e-05	0.00338	-0.15	-0.13	IgG glycosylation;	chr3:113729608	chr3:113632704~113632998:+
BRCA	cis	rs13401620	0.879	rs28897386	ENSG00000229326.3	AC069154.4	-4.08	4.94e-05	0.00339	-0.16	-0.13	Breast size;	chr2:119847807	chr2:119698623~119700151:+
BRCA	cis	rs853679	0.517	rs35193936	ENSG00000261839.1	RP1-265C24.8	4.08	4.94e-05	0.00339	0.17	0.13	Depression;	chr6:28108492	chr6:28136849~28139678:+
BRCA	cis	rs6792584	0.889	rs7628838	ENSG00000241316.5	SUCLG2-AS1	-4.08	4.94e-05	0.00339	-0.14	-0.13	Corneal astigmatism;	chr3:67455474	chr3:67654697~67947713:+
BRCA	cis	rs8113308	0.81	rs11880193	ENSG00000269483.1	AC006272.1	4.08	4.95e-05	0.00339	0.22	0.13	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51945416	chr19:51839924~51843324:-
BRCA	cis	rs9818758	0.607	rs11706189	ENSG00000225399.4	RP11-3B7.1	-4.08	4.95e-05	0.00339	-0.21	-0.13	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49173400	chr3:49260085~49261316:+
BRCA	cis	rs7927592	0.763	rs596494	ENSG00000212093.1	AP000807.1	4.08	4.95e-05	0.00339	0.13	0.13	Total body bone mineral density;	chr11:68483586	chr11:68506083~68506166:-
BRCA	cis	rs11098499	0.954	rs1022145	ENSG00000260404.2	RP11-384K6.6	4.08	4.95e-05	0.00339	0.12	0.13	Corneal astigmatism;	chr4:119309824	chr4:118591773~118633729:+
BRCA	cis	rs739496	0.501	rs441	ENSG00000226469.1	ADAM1B	4.08	4.95e-05	0.00339	0.17	0.13	Platelet count;	chr12:111791045	chr12:111927018~111929017:+
BRCA	cis	rs2692947	0.537	rs2320170	ENSG00000168992.4	OR7E102P	-4.08	4.95e-05	0.00339	-0.17	-0.13	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95574025	chr2:95546531~95547545:+
BRCA	cis	rs1348850	0.793	rs13027299	ENSG00000280374.1	RP11-337N6.3	4.08	4.95e-05	0.00339	0.17	0.13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177590773	chr2:177317715~177318471:-
BRCA	cis	rs9308731	0.644	rs7577824	ENSG00000230499.1	AC108463.1	-4.08	4.95e-05	0.00339	-0.15	-0.13	Chronic lymphocytic leukemia;	chr2:111119186	chr2:111195963~111206494:+
BRCA	cis	rs853679	0.882	rs9468300	ENSG00000216901.1	AL022393.7	4.08	4.95e-05	0.00339	0.25	0.13	Depression;	chr6:28159062	chr6:28176188~28176674:+
BRCA	cis	rs6593122	0.755	rs6954339	ENSG00000235454.1	HAUS6P3	4.08	4.95e-05	0.00339	0.17	0.13	Vaccine-related adverse events;	chr7:54139932	chr7:53862233~53863339:+
BRCA	cis	rs11098499	0.909	rs11723757	ENSG00000225892.3	RP11-384K6.2	4.08	4.95e-05	0.00339	0.12	0.13	Corneal astigmatism;	chr4:119378514	chr4:118632274~118634759:+
BRCA	cis	rs2880765	0.835	rs4526974	ENSG00000202081.1	RNU6-1280P	4.08	4.95e-05	0.00339	0.14	0.13	Coronary artery disease;	chr15:85481053	chr15:85651522~85651628:-
BRCA	cis	rs11098499	0.789	rs1980024	ENSG00000225892.3	RP11-384K6.2	4.08	4.95e-05	0.00339	0.12	0.13	Corneal astigmatism;	chr4:119331892	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.754	rs34425882	ENSG00000225892.3	RP11-384K6.2	4.08	4.95e-05	0.00339	0.12	0.13	Corneal astigmatism;	chr4:119332022	chr4:118632274~118634759:+
BRCA	cis	rs4218	0.543	rs2414618	ENSG00000259732.1	RP11-59H7.3	-4.07	4.95e-05	0.00339	-0.15	-0.13	Social communication problems;	chr15:59019684	chr15:59121034~59133250:+
BRCA	cis	rs10463316	0.817	rs7701271	ENSG00000260581.1	CTB-113P19.4	-4.07	4.95e-05	0.00339	-0.14	-0.13	Metabolite levels (Pyroglutamine);	chr5:151397147	chr5:151652275~151655449:+
BRCA	cis	rs7267979	0.727	rs4815431	ENSG00000125804.12	FAM182A	4.07	4.95e-05	0.00339	0.16	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25551769	chr20:26054655~26086917:+
BRCA	cis	rs3816183	1	rs3816179	ENSG00000226491.1	FTOP1	-4.07	4.95e-05	0.00339	-0.16	-0.13	Hypospadias;	chr2:42788261	chr2:42797225~42798712:-
BRCA	cis	rs11168618	0.87	rs7302209	ENSG00000273765.1	RP11-370I10.11	4.07	4.95e-05	0.00339	0.15	0.13	Adiponectin levels;	chr12:48501601	chr12:48360920~48361377:+
BRCA	cis	rs911119	1	rs67567111	ENSG00000270001.1	RP11-218C14.8	-4.07	4.95e-05	0.00339	-0.17	-0.13	Chronic kidney disease;	chr20:23638438	chr20:23631826~23632316:-
BRCA	cis	rs7975161	0.938	rs10400561	ENSG00000257681.1	RP11-341G23.4	-4.07	4.95e-05	0.00339	-0.18	-0.13	Toenail selenium levels;	chr12:104247142	chr12:103746315~103768858:-
BRCA	cis	rs17489649	1	rs3776933	ENSG00000271849.1	CTC-332L22.1	4.07	4.96e-05	0.00339	0.16	0.13	Intelligence (multi-trait analysis);	chr5:109805922	chr5:109687802~109688329:-
BRCA	cis	rs5771225	0.544	rs1555048	ENSG00000184319.14	RPL23AP82	4.07	4.96e-05	0.00339	0.17	0.13	Late-onset Alzheimer's disease;	chr22:50249919	chr22:50756948~50801309:+
BRCA	cis	rs911119	0.818	rs67862677	ENSG00000270001.1	RP11-218C14.8	-4.07	4.96e-05	0.00339	-0.17	-0.13	Chronic kidney disease;	chr20:23610449	chr20:23631826~23632316:-
BRCA	cis	rs516805	0.667	rs2045352	ENSG00000279114.1	RP3-425C14.5	-4.07	4.96e-05	0.00339	-0.15	-0.13	Lymphocyte counts;	chr6:122119694	chr6:122471923~122484161:+
BRCA	cis	rs9733	0.525	rs11584184	ENSG00000231073.1	RP11-316M1.3	4.07	4.96e-05	0.00339	0.13	0.13	Tonsillectomy;	chr1:150723213	chr1:150973123~150975534:+
BRCA	cis	rs9733	0.596	rs6669369	ENSG00000231073.1	RP11-316M1.3	4.07	4.96e-05	0.00339	0.13	0.13	Tonsillectomy;	chr1:150723416	chr1:150973123~150975534:+
BRCA	cis	rs9733	0.596	rs6681990	ENSG00000231073.1	RP11-316M1.3	4.07	4.96e-05	0.00339	0.13	0.13	Tonsillectomy;	chr1:150723453	chr1:150973123~150975534:+
BRCA	cis	rs9733	0.596	rs6692960	ENSG00000231073.1	RP11-316M1.3	4.07	4.96e-05	0.00339	0.13	0.13	Tonsillectomy;	chr1:150723489	chr1:150973123~150975534:+
BRCA	cis	rs9733	0.596	rs12086472	ENSG00000231073.1	RP11-316M1.3	4.07	4.96e-05	0.00339	0.13	0.13	Tonsillectomy;	chr1:150725234	chr1:150973123~150975534:+
BRCA	cis	rs9733	0.628	rs7540874	ENSG00000231073.1	RP11-316M1.3	4.07	4.96e-05	0.00339	0.13	0.13	Tonsillectomy;	chr1:150730187	chr1:150973123~150975534:+
BRCA	cis	rs9733	0.596	rs1136808	ENSG00000231073.1	RP11-316M1.3	4.07	4.96e-05	0.00339	0.13	0.13	Tonsillectomy;	chr1:150730241	chr1:150973123~150975534:+
BRCA	cis	rs853679	0.517	rs4713150	ENSG00000261839.1	RP1-265C24.8	4.07	4.96e-05	0.00339	0.17	0.13	Depression;	chr6:28168434	chr6:28136849~28139678:+
BRCA	cis	rs4713118	0.527	rs4713151	ENSG00000261839.1	RP1-265C24.8	4.07	4.96e-05	0.00339	0.17	0.13	Parkinson's disease;	chr6:28168578	chr6:28136849~28139678:+
BRCA	cis	rs853679	0.517	rs9393901	ENSG00000261839.1	RP1-265C24.8	4.07	4.96e-05	0.00339	0.17	0.13	Depression;	chr6:28169019	chr6:28136849~28139678:+
BRCA	cis	rs853679	0.517	rs3173443	ENSG00000261839.1	RP1-265C24.8	4.07	4.96e-05	0.00339	0.17	0.13	Depression;	chr6:28169249	chr6:28136849~28139678:+
BRCA	cis	rs853679	0.517	rs4713152	ENSG00000261839.1	RP1-265C24.8	4.07	4.96e-05	0.00339	0.17	0.13	Depression;	chr6:28169676	chr6:28136849~28139678:+
BRCA	cis	rs853679	0.517	rs9348797	ENSG00000261839.1	RP1-265C24.8	4.07	4.96e-05	0.00339	0.17	0.13	Depression;	chr6:28169755	chr6:28136849~28139678:+
BRCA	cis	rs853679	0.517	rs9380062	ENSG00000261839.1	RP1-265C24.8	4.07	4.96e-05	0.00339	0.17	0.13	Depression;	chr6:28169791	chr6:28136849~28139678:+
BRCA	cis	rs853679	0.542	rs9380063	ENSG00000261839.1	RP1-265C24.8	4.07	4.96e-05	0.00339	0.17	0.13	Depression;	chr6:28170075	chr6:28136849~28139678:+
BRCA	cis	rs8114671	0.967	rs4911478	ENSG00000279253.1	RP4-614O4.13	4.07	4.96e-05	0.0034	0.14	0.13	Height;	chr20:35194822	chr20:35262727~35264187:-
BRCA	cis	rs9527	0.545	rs11191602	ENSG00000213061.2	PFN1P11	4.07	4.96e-05	0.0034	0.17	0.13	Arsenic metabolism;	chr10:103194462	chr10:102838011~102845473:-
BRCA	cis	rs9527	0.545	rs7095304	ENSG00000213061.2	PFN1P11	4.07	4.96e-05	0.0034	0.17	0.13	Arsenic metabolism;	chr10:103195038	chr10:102838011~102845473:-
BRCA	cis	rs875971	0.528	rs801213	ENSG00000273142.1	RP11-458F8.4	-4.07	4.96e-05	0.0034	-0.12	-0.13	Aortic root size;	chr7:66549931	chr7:66902857~66906297:+
BRCA	cis	rs875971	0.545	rs801212	ENSG00000273142.1	RP11-458F8.4	-4.07	4.96e-05	0.0034	-0.12	-0.13	Aortic root size;	chr7:66550643	chr7:66902857~66906297:+
BRCA	cis	rs2835872	0.965	rs1787330	ENSG00000228677.1	TTC3-AS1	4.07	4.96e-05	0.0034	0.17	0.13	Electroencephalographic traits in alcoholism;	chr21:37630485	chr21:37187666~37193926:-
BRCA	cis	rs2243480	1	rs3885839	ENSG00000275400.1	RP4-756H11.5	4.07	4.96e-05	0.0034	0.23	0.13	Diabetic kidney disease;	chr7:65825416	chr7:66553805~66554199:-
BRCA	cis	rs4589258	0.933	rs10830574	ENSG00000280367.1	RP11-121L10.2	-4.07	4.96e-05	0.0034	-0.15	-0.13	Intelligence (multi-trait analysis);	chr11:90774393	chr11:90223153~90226538:+
BRCA	cis	rs983392	0.68	rs56357056	ENSG00000275344.1	MIR6503	-4.07	4.96e-05	0.0034	-0.13	-0.13	Alzheimer's disease (late onset);	chr11:60219344	chr11:60209071~60209156:-
BRCA	cis	rs75422866	0.51	rs35784744	ENSG00000280054.1	RP1-197B17.7	4.07	4.96e-05	0.0034	0.3	0.13	Pneumonia;	chr12:47729646	chr12:47728151~47730598:-
BRCA	cis	rs12428035	0.764	rs9525077	ENSG00000247400.3	DNAJC3-AS1	4.07	4.97e-05	0.0034	0.2	0.13	Glomerular filtration rate (cystatin C);Response to statins (LDL cholesterol change);	chr13:95888539	chr13:95648733~95676925:-
BRCA	cis	rs9527	0.622	rs12779263	ENSG00000213061.2	PFN1P11	4.07	4.97e-05	0.0034	0.17	0.13	Arsenic metabolism;	chr10:103126776	chr10:102838011~102845473:-
BRCA	cis	rs74665712	0.591	rs10487587	ENSG00000232400.1	RAD17P1	4.07	4.97e-05	0.0034	0.14	0.13	Residual cognition;	chr7:16915163	chr7:16864267~16866308:-
BRCA	cis	rs11098499	0.644	rs34835603	ENSG00000225892.3	RP11-384K6.2	4.07	4.97e-05	0.0034	0.12	0.13	Corneal astigmatism;	chr4:119632273	chr4:118632274~118634759:+
BRCA	cis	rs6088580	0.601	rs6059872	ENSG00000275784.1	RP5-1125A11.6	-4.07	4.97e-05	0.0034	-0.14	-0.13	Glomerular filtration rate (creatinine);	chr20:34494970	chr20:33989480~33991818:-
BRCA	cis	rs115575488	0.632	rs78527560	ENSG00000231365.4	RP11-418J17.1	4.07	4.97e-05	0.0034	0.24	0.13	Lobe attachment (rater-scored or self-reported);	chr1:119043653	chr1:119140396~119275973:+
BRCA	cis	rs6751744	0.855	rs10206214	ENSG00000230783.1	AC009961.2	-4.07	4.97e-05	0.0034	-0.17	-0.13	Dysphagia;	chr2:159507781	chr2:159689217~159690291:-
BRCA	cis	rs6751744	0.855	rs1425045	ENSG00000230783.1	AC009961.2	-4.07	4.97e-05	0.0034	-0.17	-0.13	Dysphagia;	chr2:159508236	chr2:159689217~159690291:-
BRCA	cis	rs860295	0.702	rs11264380	ENSG00000232093.1	RP11-307C12.11	4.07	4.97e-05	0.0034	0.13	0.13	Body mass index;	chr1:155550353	chr1:155045191~155046118:-
BRCA	cis	rs4561483	0.801	rs33619	ENSG00000261216.1	RP11-166B2.5	-4.07	4.97e-05	0.0034	-0.15	-0.13	Testicular germ cell tumor;	chr16:11915084	chr16:11908208~11908916:+
BRCA	cis	rs8040855	0.627	rs11631548	ENSG00000259774.1	RP11-182J1.13	4.07	4.97e-05	0.0034	0.17	0.13	Bulimia nervosa;	chr15:85076017	chr15:84422618~84425882:+
BRCA	cis	rs13098911	0.54	rs2373087	ENSG00000223552.1	RP11-24F11.2	-4.07	4.97e-05	0.0034	-0.21	-0.13	Celiac disease;	chr3:45926551	chr3:46364955~46407059:-
BRCA	cis	rs13098911	0.54	rs13099120	ENSG00000223552.1	RP11-24F11.2	-4.07	4.97e-05	0.0034	-0.21	-0.13	Celiac disease;	chr3:45929452	chr3:46364955~46407059:-
BRCA	cis	rs4499344	0.73	rs8103269	ENSG00000267475.1	CTD-2538C1.2	4.07	4.97e-05	0.0034	0.16	0.13	Mean platelet volume;	chr19:32606597	chr19:32687089~32691750:-
BRCA	cis	rs2486012	1	rs2906461	ENSG00000237950.1	RP11-7O11.3	4.07	4.97e-05	0.0034	0.23	0.13	Intelligence (multi-trait analysis);	chr1:43868556	chr1:43944370~43946551:-
BRCA	cis	rs983392	0.792	rs534273	ENSG00000275344.1	MIR6503	-4.07	4.97e-05	0.0034	-0.13	-0.13	Alzheimer's disease (late onset);	chr11:60139926	chr11:60209071~60209156:-
BRCA	cis	rs6472235	0.586	rs17306183	ENSG00000272010.1	CTD-3025N20.3	-4.07	4.97e-05	0.0034	-0.15	-0.13	Plateletcrit;Myopia (pathological);	chr8:65992140	chr8:65591850~65592472:-
BRCA	cis	rs3617	0.625	rs56019197	ENSG00000242142.1	SERBP1P3	-4.07	4.97e-05	0.0034	-0.14	-0.13	Red blood cell count;Autism spectrum disorder or schizophrenia;	chr3:52840737	chr3:53064283~53065091:-
BRCA	cis	rs9527	0.59	rs7897663	ENSG00000213061.2	PFN1P11	4.07	4.98e-05	0.0034	0.17	0.13	Arsenic metabolism;	chr10:103145847	chr10:102838011~102845473:-
BRCA	cis	rs3748682	0.861	rs12563037	ENSG00000222282.1	RNU6-584P	4.07	4.98e-05	0.0034	0.16	0.13	Hypothyroidism;	chr1:37792972	chr1:37885023~37885117:+
BRCA	cis	rs6596100	0.91	rs62375203	ENSG00000248648.1	RP11-485M7.1	-4.07	4.98e-05	0.0034	-0.17	-0.13	Breast cancer;	chr5:133055730	chr5:133003119~133003365:+
BRCA	cis	rs745109	0.882	rs56242451	ENSG00000273080.1	RP11-301O19.1	4.07	4.98e-05	0.0034	0.2	0.13	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86462933	chr2:86195590~86196049:+
BRCA	cis	rs8054556	1	rs4788204	ENSG00000214725.6	CDIPT-AS1	-4.07	4.98e-05	0.0034	-0.15	-0.13	Autism spectrum disorder or schizophrenia;	chr16:29983897	chr16:29863593~29868053:+
BRCA	cis	rs962856	0.964	rs1486133	ENSG00000236605.1	AC023115.4	-4.07	4.98e-05	0.0034	-0.14	-0.13	Pancreatic cancer;	chr2:67414889	chr2:67324627~67325304:+
BRCA	cis	rs2115630	1	rs2115630	ENSG00000259728.4	LINC00933	-4.07	4.98e-05	0.0034	-0.14	-0.13	P wave terminal force;	chr15:84821285	chr15:84570649~84580175:+
BRCA	cis	rs11098499	0.575	rs907204	ENSG00000260091.1	RP11-33B1.4	-4.07	4.98e-05	0.0034	-0.11	-0.13	Corneal astigmatism;	chr4:119317499	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.575	rs907205	ENSG00000260091.1	RP11-33B1.4	-4.07	4.98e-05	0.0034	-0.11	-0.13	Corneal astigmatism;	chr4:119317509	chr4:119409333~119410233:+
BRCA	cis	rs4650943	0.55	rs10458350	ENSG00000227740.1	RP11-318C24.2	-4.07	4.98e-05	0.00341	-0.13	-0.13	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in inactive individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr1:176223486	chr1:175904762~175920513:-
BRCA	cis	rs6964833	0.935	rs34762099	ENSG00000184616.8	AC004166.6	4.07	4.98e-05	0.00341	0.19	0.13	Menarche (age at onset);	chr7:74636378	chr7:74906673~74913256:-
BRCA	cis	rs256438	0.524	rs2434278	ENSG00000251050.1	RP11-168A11.4	-4.07	4.98e-05	0.00341	-0.13	-0.13	Serum thyroid-stimulating hormone levels;	chr5:80051057	chr5:80019609~80019920:+
BRCA	cis	rs13434995	0.513	rs2412658	ENSG00000239040.1	Y_RNA	-4.07	4.98e-05	0.00341	-0.15	-0.13	Adiponectin levels;	chr4:55577050	chr4:55412636~55412738:+
BRCA	cis	rs4578769	0.765	rs1609463	ENSG00000265939.1	UBE2CP2	-4.07	4.98e-05	0.00341	-0.16	-0.13	Eosinophil percentage of white cells;	chr18:22824144	chr18:22900486~22900995:-
BRCA	cis	rs4869313	0.869	rs430827	ENSG00000248734.2	CTD-2260A17.1	-4.07	4.98e-05	0.00341	-0.13	-0.13	Pediatric autoimmune diseases;	chr5:96995667	chr5:96784777~96785999:+
BRCA	cis	rs6596100	0.956	rs7730125	ENSG00000248648.1	RP11-485M7.1	-4.07	4.98e-05	0.00341	-0.16	-0.13	Breast cancer;	chr5:133050531	chr5:133003119~133003365:+
BRCA	cis	rs2439831	0.85	rs7174208	ENSG00000206991.1	RNU6-610P	-4.07	4.98e-05	0.00341	-0.2	-0.13	Lung cancer in ever smokers;	chr15:43760484	chr15:43637632~43637738:-
BRCA	cis	rs2439831	0.85	rs12101756	ENSG00000206991.1	RNU6-610P	-4.07	4.98e-05	0.00341	-0.2	-0.13	Lung cancer in ever smokers;	chr15:43761689	chr15:43637632~43637738:-
BRCA	cis	rs6546324	0.625	rs1430790	ENSG00000236780.4	AC078941.1	-4.07	4.98e-05	0.00341	-0.21	-0.13	Endometriosis;	chr2:67637780	chr2:67123357~67215319:-
BRCA	cis	rs9467773	0.62	rs2494696	ENSG00000224843.5	LINC00240	-4.07	4.99e-05	0.00341	-0.14	-0.13	Intelligence (multi-trait analysis);	chr6:26620666	chr6:26956992~27023924:+
BRCA	cis	rs6452524	0.905	rs7736289	ENSG00000281327.1	LINC01338	4.07	4.99e-05	0.00341	0.14	0.13	Hypertension (SNP x SNP interaction);	chr5:83082401	chr5:82850864~82859836:-
BRCA	cis	rs9527	0.59	rs3781282	ENSG00000213061.2	PFN1P11	-4.07	4.99e-05	0.00341	-0.17	-0.13	Arsenic metabolism;	chr10:103092662	chr10:102838011~102845473:-
BRCA	cis	rs739496	0.579	rs3752631	ENSG00000257624.1	RP1-128M12.3	4.07	4.99e-05	0.00341	0.17	0.13	Platelet count;	chr12:111938353	chr12:112000739~112000985:-
BRCA	cis	rs739496	0.579	rs7959619	ENSG00000257624.1	RP1-128M12.3	4.07	4.99e-05	0.00341	0.17	0.13	Platelet count;	chr12:111938793	chr12:112000739~112000985:-
BRCA	cis	rs7267979	0.844	rs6076343	ENSG00000231081.1	RP4-760C5.3	4.07	4.99e-05	0.00341	0.16	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25396027	chr20:26008791~26010531:-
BRCA	cis	rs4499344	0.73	rs12460624	ENSG00000267475.1	CTD-2538C1.2	4.07	4.99e-05	0.00341	0.16	0.13	Mean platelet volume;	chr19:32607136	chr19:32687089~32691750:-
BRCA	cis	rs875971	1	rs7789554	ENSG00000236529.1	RP13-254B10.1	4.07	4.99e-05	0.00341	0.14	0.13	Aortic root size;	chr7:66481051	chr7:65840212~65840596:+
BRCA	cis	rs875971	1	rs4717300	ENSG00000236529.1	RP13-254B10.1	4.07	4.99e-05	0.00341	0.14	0.13	Aortic root size;	chr7:66482393	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.895	rs1974769	ENSG00000236529.1	RP13-254B10.1	4.07	4.99e-05	0.00341	0.14	0.13	Aortic root size;	chr7:66485627	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.895	rs6460300	ENSG00000236529.1	RP13-254B10.1	4.07	4.99e-05	0.00341	0.14	0.13	Aortic root size;	chr7:66487937	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.862	rs7803416	ENSG00000236529.1	RP13-254B10.1	4.07	4.99e-05	0.00341	0.14	0.13	Aortic root size;	chr7:66489212	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.964	rs2277911	ENSG00000236529.1	RP13-254B10.1	4.07	4.99e-05	0.00341	0.14	0.13	Aortic root size;	chr7:66493638	chr7:65840212~65840596:+
BRCA	cis	rs11098499	0.754	rs12513083	ENSG00000260091.1	RP11-33B1.4	-4.07	4.99e-05	0.00341	-0.11	-0.13	Corneal astigmatism;	chr4:119328457	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.754	rs12509621	ENSG00000260091.1	RP11-33B1.4	-4.07	4.99e-05	0.00341	-0.11	-0.13	Corneal astigmatism;	chr4:119328505	chr4:119409333~119410233:+
BRCA	cis	rs847649	0.842	rs7789252	ENSG00000239969.4	RP11-163E9.2	-4.07	4.99e-05	0.00341	-0.16	-0.13	Morning vs. evening chronotype;	chr7:102983780	chr7:102364162~102380633:+
BRCA	cis	rs6545883	0.825	rs7578139	ENSG00000273302.1	RP11-493E12.2	-4.07	4.99e-05	0.00341	-0.12	-0.13	Tuberculosis;	chr2:61336986	chr2:61199979~61200769:+
BRCA	cis	rs3096299	0.658	rs3934737	ENSG00000261118.1	RP11-104N10.1	4.07	4.99e-05	0.00341	0.13	0.13	Multiple myeloma (IgH translocation);	chr16:89493801	chr16:89492017~89504460:-
BRCA	cis	rs1005277	0.579	rs176880	ENSG00000272983.1	RP11-508N22.12	-4.07	4.99e-05	0.00341	-0.13	-0.13	Extrinsic epigenetic age acceleration;	chr10:38112489	chr10:38137337~38144399:+
BRCA	cis	rs853679	0.517	rs9380056	ENSG00000261839.1	RP1-265C24.8	4.07	4.99e-05	0.00341	0.17	0.13	Depression;	chr6:28136698	chr6:28136849~28139678:+
BRCA	cis	rs853679	0.517	rs9380057	ENSG00000261839.1	RP1-265C24.8	4.07	4.99e-05	0.00341	0.17	0.13	Depression;	chr6:28136856	chr6:28136849~28139678:+
BRCA	cis	rs853679	0.517	rs6941992	ENSG00000261839.1	RP1-265C24.8	4.07	4.99e-05	0.00341	0.17	0.13	Depression;	chr6:28138363	chr6:28136849~28139678:+
BRCA	cis	rs4713118	0.516	rs4713142	ENSG00000261839.1	RP1-265C24.8	4.07	4.99e-05	0.00341	0.17	0.13	Parkinson's disease;	chr6:28138569	chr6:28136849~28139678:+
BRCA	cis	rs853679	0.517	rs4713143	ENSG00000261839.1	RP1-265C24.8	4.07	4.99e-05	0.00341	0.17	0.13	Depression;	chr6:28138981	chr6:28136849~28139678:+
BRCA	cis	rs853679	0.517	rs4713144	ENSG00000261839.1	RP1-265C24.8	4.07	4.99e-05	0.00341	0.17	0.13	Depression;	chr6:28139012	chr6:28136849~28139678:+
BRCA	cis	rs34217772	1	rs17181699	ENSG00000258636.1	CTD-2298J14.2	4.07	4.99e-05	0.00341	0.17	0.13	Myopia;	chr14:41791465	chr14:41587861~41604856:-
BRCA	cis	rs4143844	0.737	rs35984535	ENSG00000259251.2	RP11-643M14.1	4.07	4.99e-05	0.00342	0.3	0.13	Bipolar disorder and schizophrenia;	chr15:61912747	chr15:62060503~62062434:+
BRCA	cis	rs12210905	1	rs6938397	ENSG00000216901.1	AL022393.7	4.07	4.99e-05	0.00342	0.23	0.13	Hip circumference adjusted for BMI;	chr6:27263445	chr6:28176188~28176674:+
BRCA	cis	rs4970988	0.501	rs11204713	ENSG00000231073.1	RP11-316M1.3	4.07	5e-05	0.00342	0.13	0.13	Urate levels;	chr1:150722147	chr1:150973123~150975534:+
BRCA	cis	rs2625529	0.775	rs2723342	ENSG00000260037.4	CTD-2524L6.3	-4.07	5e-05	0.00342	-0.18	-0.13	Red blood cell count;	chr15:71815358	chr15:71818396~71823384:+
BRCA	cis	rs10266483	0.739	rs2692099	ENSG00000228653.2	HNRNPCP7	-4.07	5e-05	0.00342	-0.15	-0.13	Response to statin therapy;	chr7:64307384	chr7:64500825~64501729:+
BRCA	cis	rs1008375	1	rs6449319	ENSG00000249502.1	AC006160.5	-4.07	5e-05	0.00342	-0.14	-0.13	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17638660	chr4:17587467~17614571:-
BRCA	cis	rs6600671	0.899	rs6674392	ENSG00000231429.2	RP11-343N15.2	-4.07	5e-05	0.00342	-0.15	-0.13	Hip geometry;	chr1:121518864	chr1:121412719~121429274:+
BRCA	cis	rs11098499	0.863	rs3822190	ENSG00000260091.1	RP11-33B1.4	-4.07	5e-05	0.00342	-0.11	-0.13	Corneal astigmatism;	chr4:119506943	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.863	rs3822191	ENSG00000260091.1	RP11-33B1.4	-4.07	5e-05	0.00342	-0.11	-0.13	Corneal astigmatism;	chr4:119506946	chr4:119409333~119410233:+
BRCA	cis	rs3169166	0.546	rs4887027	ENSG00000259562.2	RP11-762H8.2	4.07	5e-05	0.00342	0.1	0.13	Reticulocyte fraction of red cells;Reticulocyte count;	chr15:78287599	chr15:78290527~78291221:-
BRCA	cis	rs4561483	0.801	rs33637	ENSG00000261216.1	RP11-166B2.5	-4.07	5e-05	0.00342	-0.15	-0.13	Testicular germ cell tumor;	chr16:11896018	chr16:11908208~11908916:+
BRCA	cis	rs11098499	0.908	rs7695996	ENSG00000260404.2	RP11-384K6.6	4.07	5e-05	0.00342	0.12	0.13	Corneal astigmatism;	chr4:119400878	chr4:118591773~118633729:+
BRCA	cis	rs11711311	1	rs9863050	ENSG00000241529.3	RN7SL767P	-4.07	5e-05	0.00342	-0.15	-0.13	IgG glycosylation;	chr3:113790041	chr3:113632704~113632998:+
BRCA	cis	rs9959145	1	rs77321492	ENSG00000267108.1	RP11-861E21.1	4.07	5e-05	0.00342	0.23	0.13	Immune response to smallpox vaccine (IL-6);	chr18:12552124	chr18:12432897~12437635:+
BRCA	cis	rs9467773	0.62	rs2101581	ENSG00000224843.5	LINC00240	-4.07	5e-05	0.00342	-0.14	-0.13	Intelligence (multi-trait analysis);	chr6:26622541	chr6:26956992~27023924:+
BRCA	cis	rs2136613	0.751	rs224308	ENSG00000238280.1	RP11-436D10.3	4.07	5e-05	0.00342	0.16	0.13	Selective IgA deficiency;	chr10:62843007	chr10:62793562~62805887:-
BRCA	cis	rs10871290	0.881	rs7498574	ENSG00000262904.1	TMPOP2	4.07	5.01e-05	0.00342	0.13	0.13	Breast cancer;	chr16:74438763	chr16:74667506~74668706:+
BRCA	cis	rs17684571	0.751	rs6934714	ENSG00000231441.1	RP11-472M19.2	4.07	5.01e-05	0.00342	0.18	0.13	Schizophrenia;	chr6:56821811	chr6:56844002~56864078:+
BRCA	cis	rs17680741	0.697	rs12269333	ENSG00000226659.1	RP11-137H2.4	4.07	5.01e-05	0.00342	0.21	0.13	Coronary artery disease;	chr10:80507049	chr10:80529597~80535942:-
BRCA	cis	rs17772222	0.917	rs61986671	ENSG00000258789.1	RP11-507K2.3	-4.07	5.01e-05	0.00342	-0.15	-0.13	Coronary artery calcification;	chr14:88732917	chr14:88551597~88552493:+
BRCA	cis	rs801193	1	rs3800812	ENSG00000265600.1	AC006480.1	-4.07	5.01e-05	0.00342	-0.15	-0.13	Aortic root size;	chr7:66758474	chr7:67356680~67356779:+
BRCA	cis	rs801193	1	rs4279493	ENSG00000265600.1	AC006480.1	-4.07	5.01e-05	0.00342	-0.15	-0.13	Aortic root size;	chr7:66761633	chr7:67356680~67356779:+
BRCA	cis	rs7177699	0.557	rs4389113	ENSG00000261143.1	ADAMTS7P3	4.07	5.01e-05	0.00342	0.16	0.13	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78829397	chr15:77976042~77993057:+
BRCA	cis	rs6592362	0.54	rs2226628	ENSG00000254748.1	HNRNPCP8	-4.07	5.01e-05	0.00342	-0.17	-0.13	Inflammatory bowel disease;	chr11:87380803	chr11:87024583~87025777:+
BRCA	cis	rs6867032	0.527	rs1017924	ENSG00000248994.1	RP11-259O2.1	4.07	5.01e-05	0.00342	0.17	0.13	Gut microbiome composition (winter);	chr5:1976073	chr5:1933863~1959176:+
BRCA	cis	rs7160336	1	rs4903186	ENSG00000259065.1	RP5-1021I20.1	4.07	5.01e-05	0.00342	0.14	0.13	Blood protein levels;	chr14:74116004	chr14:73787360~73803270:+
BRCA	cis	rs875971	1	rs2420820	ENSG00000229180.5	GS1-124K5.11	-4.07	5.01e-05	0.00343	-0.11	-0.13	Aortic root size;	chr7:66626920	chr7:66526088~66542624:-
BRCA	cis	rs1218582	0.711	rs4845677	ENSG00000270361.1	RP11-307C12.13	-4.07	5.01e-05	0.00343	-0.14	-0.13	Prostate cancer;	chr1:154865574	chr1:154937370~154938059:+
BRCA	cis	rs495337	0.76	rs13040201	ENSG00000229222.1	KRT18P4	-4.07	5.01e-05	0.00343	-0.16	-0.13	Psoriasis;	chr20:49919812	chr20:49956745~49958032:+
BRCA	cis	rs495337	0.72	rs2869937	ENSG00000229222.1	KRT18P4	-4.07	5.01e-05	0.00343	-0.16	-0.13	Psoriasis;	chr20:49920081	chr20:49956745~49958032:+
BRCA	cis	rs495337	0.76	rs6067270	ENSG00000229222.1	KRT18P4	-4.07	5.01e-05	0.00343	-0.16	-0.13	Psoriasis;	chr20:49920717	chr20:49956745~49958032:+
BRCA	cis	rs7487075	1	rs10880966	ENSG00000274723.1	RP11-618L22.1	4.07	5.02e-05	0.00343	0.15	0.13	Itch intensity from mosquito bite;	chr12:46407999	chr12:46970504~46972155:+
BRCA	cis	rs6921919	0.583	rs9468370	ENSG00000273712.1	RP5-874C20.7	4.07	5.02e-05	0.00343	0.16	0.13	Autism spectrum disorder or schizophrenia;	chr6:28401163	chr6:28315613~28315883:-
BRCA	cis	rs911119	0.954	rs35966482	ENSG00000270001.1	RP11-218C14.8	-4.07	5.02e-05	0.00343	-0.17	-0.13	Chronic kidney disease;	chr20:23640079	chr20:23631826~23632316:-
BRCA	cis	rs875971	0.638	rs7793569	ENSG00000229180.5	GS1-124K5.11	-4.07	5.02e-05	0.00343	-0.11	-0.13	Aortic root size;	chr7:66651646	chr7:66526088~66542624:-
BRCA	cis	rs801193	1	rs3857688	ENSG00000229180.5	GS1-124K5.11	-4.07	5.02e-05	0.00343	-0.11	-0.13	Aortic root size;	chr7:66662819	chr7:66526088~66542624:-
BRCA	cis	rs801193	1	rs2286684	ENSG00000229180.5	GS1-124K5.11	-4.07	5.02e-05	0.00343	-0.11	-0.13	Aortic root size;	chr7:66664843	chr7:66526088~66542624:-
BRCA	cis	rs801193	0.935	rs2286683	ENSG00000229180.5	GS1-124K5.11	-4.07	5.02e-05	0.00343	-0.11	-0.13	Aortic root size;	chr7:66664856	chr7:66526088~66542624:-
BRCA	cis	rs801193	1	rs10274773	ENSG00000229180.5	GS1-124K5.11	-4.07	5.02e-05	0.00343	-0.11	-0.13	Aortic root size;	chr7:66668591	chr7:66526088~66542624:-
BRCA	cis	rs1005277	0.579	rs1780136	ENSG00000276805.1	RP11-291L22.6	4.07	5.02e-05	0.00343	0.14	0.13	Extrinsic epigenetic age acceleration;	chr10:38212525	chr10:38451030~38451785:+
BRCA	cis	rs1005277	0.579	rs1780138	ENSG00000276805.1	RP11-291L22.6	4.07	5.02e-05	0.00343	0.14	0.13	Extrinsic epigenetic age acceleration;	chr10:38212726	chr10:38451030~38451785:+
BRCA	cis	rs1005277	0.579	rs1780139	ENSG00000276805.1	RP11-291L22.6	4.07	5.02e-05	0.00343	0.14	0.13	Extrinsic epigenetic age acceleration;	chr10:38214090	chr10:38451030~38451785:+
BRCA	cis	rs1005277	0.602	rs1780141	ENSG00000276805.1	RP11-291L22.6	4.07	5.02e-05	0.00343	0.14	0.13	Extrinsic epigenetic age acceleration;	chr10:38215371	chr10:38451030~38451785:+
BRCA	cis	rs1555322	1	rs1555322	ENSG00000261582.1	RP4-614O4.11	-4.07	5.02e-05	0.00343	-0.17	-0.13	Attention deficit hyperactivity disorder;	chr20:35261376	chr20:35267885~35280043:-
BRCA	cis	rs7338174	0.655	rs4942995	ENSG00000236778.6	INTS6-AS1	4.07	5.02e-05	0.00343	0.29	0.13	Mitochondrial DNA levels;	chr13:51355168	chr13:51452367~51552364:+
BRCA	cis	rs6964587	1	rs7784248	ENSG00000188693.7	CYP51A1-AS1	-4.07	5.02e-05	0.00343	-0.14	-0.13	Breast cancer;	chr7:92128797	chr7:92134604~92180725:+
BRCA	cis	rs4561483	0.801	rs33640	ENSG00000261216.1	RP11-166B2.5	-4.07	5.02e-05	0.00343	-0.15	-0.13	Testicular germ cell tumor;	chr16:11893017	chr16:11908208~11908916:+
BRCA	cis	rs1371614	0.588	rs11126784	ENSG00000272148.1	RP11-195B17.1	4.07	5.02e-05	0.00343	0.14	0.13	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26946974	chr2:27062428~27062907:-
BRCA	cis	rs8113308	0.688	rs7259507	ENSG00000269483.1	AC006272.1	4.07	5.02e-05	0.00343	0.22	0.13	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51942475	chr19:51839924~51843324:-
BRCA	cis	rs8113308	0.81	rs7259622	ENSG00000269483.1	AC006272.1	4.07	5.02e-05	0.00343	0.22	0.13	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51942484	chr19:51839924~51843324:-
BRCA	cis	rs2204008	0.583	rs12307593	ENSG00000257718.1	RP11-396F22.1	4.07	5.02e-05	0.00343	0.13	0.13	Bladder cancer;	chr12:37924001	chr12:38906451~38909592:+
BRCA	cis	rs9840812	0.68	rs17252498	ENSG00000239213.4	NCK1-AS1	-4.07	5.02e-05	0.00343	-0.18	-0.13	Fibrinogen levels;	chr3:136295356	chr3:136841726~136862054:-
BRCA	cis	rs67981189	0.572	rs2810077	ENSG00000269927.1	RP6-91H8.3	-4.07	5.02e-05	0.00343	-0.15	-0.13	Schizophrenia;	chr14:70897097	chr14:71141125~71143253:-
BRCA	cis	rs4908760	0.539	rs6690928	ENSG00000232912.4	RP5-1115A15.1	4.07	5.02e-05	0.00343	0.12	0.13	Vitiligo;	chr1:8799432	chr1:8424645~8434838:+
BRCA	cis	rs448720	0.554	rs2127162	ENSG00000260657.2	RP11-315D16.4	4.07	5.02e-05	0.00343	0.15	0.13	Cognitive performance;	chr15:67798486	chr15:68267792~68277994:-
BRCA	cis	rs651907	0.513	rs34963630	ENSG00000256628.3	ZBTB11-AS1	4.07	5.02e-05	0.00343	0.16	0.13	Colorectal cancer;	chr3:101785973	chr3:101676475~101679217:+
BRCA	cis	rs6928977	0.896	rs2614287	ENSG00000234084.1	RP3-388E23.2	4.07	5.02e-05	0.00343	0.12	0.13	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135371709	chr6:135301568~135307158:+
BRCA	cis	rs10463316	0.784	rs906678	ENSG00000260581.1	CTB-113P19.4	4.07	5.02e-05	0.00343	0.14	0.13	Metabolite levels (Pyroglutamine);	chr5:151399479	chr5:151652275~151655449:+
BRCA	cis	rs13434995	0.513	rs62303726	ENSG00000239040.1	Y_RNA	4.07	5.02e-05	0.00343	0.15	0.13	Adiponectin levels;	chr4:55490415	chr4:55412636~55412738:+
BRCA	cis	rs13434995	0.513	rs55729020	ENSG00000239040.1	Y_RNA	4.07	5.02e-05	0.00343	0.15	0.13	Adiponectin levels;	chr4:55491681	chr4:55412636~55412738:+
BRCA	cis	rs13434995	0.513	rs3805156	ENSG00000239040.1	Y_RNA	4.07	5.02e-05	0.00343	0.15	0.13	Adiponectin levels;	chr4:55497925	chr4:55412636~55412738:+
BRCA	cis	rs13434995	0.513	rs62303731	ENSG00000239040.1	Y_RNA	4.07	5.02e-05	0.00343	0.15	0.13	Adiponectin levels;	chr4:55499667	chr4:55412636~55412738:+
BRCA	cis	rs13434995	0.513	rs62303732	ENSG00000239040.1	Y_RNA	4.07	5.02e-05	0.00343	0.15	0.13	Adiponectin levels;	chr4:55499868	chr4:55412636~55412738:+
BRCA	cis	rs13434995	0.513	rs56196624	ENSG00000239040.1	Y_RNA	4.07	5.02e-05	0.00343	0.15	0.13	Adiponectin levels;	chr4:55500340	chr4:55412636~55412738:+
BRCA	cis	rs13434995	0.513	rs62305265	ENSG00000239040.1	Y_RNA	4.07	5.02e-05	0.00343	0.15	0.13	Adiponectin levels;	chr4:55503474	chr4:55412636~55412738:+
BRCA	cis	rs1971762	0.527	rs4019971	ENSG00000270175.1	RP11-793H13.11	-4.07	5.03e-05	0.00343	-0.11	-0.13	Height;	chr12:53584931	chr12:53500162~53500936:-
BRCA	cis	rs4578769	0.765	rs11082172	ENSG00000265939.1	UBE2CP2	-4.07	5.03e-05	0.00343	-0.16	-0.13	Eosinophil percentage of white cells;	chr18:22857866	chr18:22900486~22900995:-
BRCA	cis	rs9467773	0.62	rs1490488	ENSG00000224843.5	LINC00240	-4.07	5.03e-05	0.00343	-0.14	-0.13	Intelligence (multi-trait analysis);	chr6:26614580	chr6:26956992~27023924:+
BRCA	cis	rs9467773	0.62	rs2494692	ENSG00000224843.5	LINC00240	-4.07	5.03e-05	0.00343	-0.14	-0.13	Intelligence (multi-trait analysis);	chr6:26614995	chr6:26956992~27023924:+
BRCA	cis	rs10844706	0.699	rs11052751	ENSG00000256673.1	RP11-599J14.2	-4.07	5.03e-05	0.00344	-0.15	-0.13	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9735136	chr12:9398355~9414851:-
BRCA	cis	rs983392	0.709	rs56273223	ENSG00000275344.1	MIR6503	-4.07	5.03e-05	0.00344	-0.13	-0.13	Alzheimer's disease (late onset);	chr11:60217203	chr11:60209071~60209156:-
BRCA	cis	rs181553	0.699	rs8092003	ENSG00000266696.1	RP11-30L3.2	4.07	5.03e-05	0.00344	0.14	0.13	Hip circumference adjusted for BMI;	chr18:49165560	chr18:49205912~49208781:+
BRCA	cis	rs9470794	1	rs11758540	ENSG00000204110.6	RP1-153P14.8	4.07	5.03e-05	0.00344	0.24	0.13	Type 2 diabetes;	chr6:37982585	chr6:37507348~37535616:+
BRCA	cis	rs17270561	0.609	rs7772382	ENSG00000272462.2	U91328.19	-4.07	5.03e-05	0.00344	-0.15	-0.13	Iron status biomarkers;	chr6:25707888	chr6:25992662~26001775:+
BRCA	cis	rs11098499	0.619	rs28502463	ENSG00000260091.1	RP11-33B1.4	-4.07	5.03e-05	0.00344	-0.11	-0.13	Corneal astigmatism;	chr4:119335868	chr4:119409333~119410233:+
BRCA	cis	rs529866	0.519	rs4451969	ENSG00000262703.1	RP11-485G7.6	-4.07	5.03e-05	0.00344	-0.13	-0.13	Inflammatory bowel disease;Crohn's disease;	chr16:11289662	chr16:11348143~11349321:-
BRCA	cis	rs7182948	0.768	rs17482833	ENSG00000259531.2	RP11-295H24.3	-4.07	5.03e-05	0.00344	-0.18	-0.13	Lung adenocarcinoma;	chr15:49679298	chr15:49365124~49366685:-
BRCA	cis	rs516805	0.667	rs2606617	ENSG00000279114.1	RP3-425C14.5	-4.07	5.03e-05	0.00344	-0.16	-0.13	Lymphocyte counts;	chr6:122182619	chr6:122471923~122484161:+
BRCA	cis	rs1048886	0.872	rs12203089	ENSG00000271967.1	RP11-134K13.4	-4.07	5.03e-05	0.00344	-0.19	-0.13	Type 2 diabetes;	chr6:70578956	chr6:70596438~70596980:+
BRCA	cis	rs2411233	0.935	rs2164011	ENSG00000259278.1	RP11-62C7.2	4.07	5.03e-05	0.00344	0.15	0.13	Platelet count;	chr15:38996828	chr15:39019233~39024918:+
BRCA	cis	rs1015213	1	rs7816406	ENSG00000253475.1	RP11-110G21.2	4.07	5.03e-05	0.00344	0.23	0.13	Glaucoma (primary angle closure);	chr8:51978116	chr8:51895957~51896374:-
BRCA	cis	rs1015213	0.737	rs7817432	ENSG00000253475.1	RP11-110G21.2	4.07	5.03e-05	0.00344	0.23	0.13	Glaucoma (primary angle closure);	chr8:51978123	chr8:51895957~51896374:-
BRCA	cis	rs28829049	0.597	rs2066002	ENSG00000270728.1	RP4-657E11.10	-4.07	5.03e-05	0.00344	-0.13	-0.13	QRS duration in Tripanosoma cruzi seropositivity;	chr1:19177806	chr1:19297080~19297903:+
BRCA	cis	rs11233413	1	rs11233405	ENSG00000246067.6	RAB30-AS1	-4.07	5.04e-05	0.00344	-0.15	-0.13	Economic and political preferences (feminism/equality);	chr11:82998588	chr11:83072066~83106719:+
BRCA	cis	rs875971	0.545	rs73136346	ENSG00000273142.1	RP11-458F8.4	-4.07	5.04e-05	0.00344	-0.13	-0.13	Aortic root size;	chr7:66101095	chr7:66902857~66906297:+
BRCA	cis	rs513088	0.681	rs558843	ENSG00000225171.2	DUTP6	4.07	5.04e-05	0.00344	0.18	0.13	Schizophrenia;	chr1:166664979	chr1:166868748~166869209:+
BRCA	cis	rs2952768	1	rs2952768	ENSG00000224137.1	AC079767.4	-4.07	5.04e-05	0.00344	-0.11	-0.13	Opioid sensitivity;	chr2:207629510	chr2:207662375~207667024:+
BRCA	cis	rs801193	0.66	rs10950049	ENSG00000229180.5	GS1-124K5.11	4.07	5.04e-05	0.00344	0.11	0.13	Aortic root size;	chr7:66765873	chr7:66526088~66542624:-
BRCA	cis	rs12216125	0.801	rs56107510	ENSG00000272462.2	U91328.19	-4.07	5.04e-05	0.00344	-0.16	-0.13	Iron status biomarkers;	chr6:25987208	chr6:25992662~26001775:+
BRCA	cis	rs687432	0.885	rs7930102	ENSG00000265566.2	RN7SL605P	-4.07	5.04e-05	0.00344	-0.18	-0.13	Parkinson's disease;	chr11:58047287	chr11:57528085~57528365:-
BRCA	cis	rs6452524	0.935	rs10076059	ENSG00000281327.1	LINC01338	4.07	5.04e-05	0.00344	0.14	0.13	Hypertension (SNP x SNP interaction);	chr5:83105698	chr5:82850864~82859836:-
BRCA	cis	rs6452524	0.935	rs7736783	ENSG00000281327.1	LINC01338	4.07	5.04e-05	0.00344	0.14	0.13	Hypertension (SNP x SNP interaction);	chr5:83107050	chr5:82850864~82859836:-
BRCA	cis	rs6452524	0.935	rs11951257	ENSG00000281327.1	LINC01338	4.07	5.04e-05	0.00344	0.14	0.13	Hypertension (SNP x SNP interaction);	chr5:83107492	chr5:82850864~82859836:-
BRCA	cis	rs10129255	0.536	rs10142951	ENSG00000254174.1	IGHV1-12	4.07	5.04e-05	0.00344	0.1	0.13	Kawasaki disease;	chr14:106782337	chr14:106122420~106122709:-
BRCA	cis	rs6049003	0.622	rs4303784	ENSG00000232645.4	LINC01431	4.07	5.04e-05	0.00345	0.13	0.13	Cerebrospinal fluid biomarker levels;	chr20:23734183	chr20:23356594~23358116:-
BRCA	cis	rs4916588	0.636	rs6797560	ENSG00000230732.4	AC127904.2	4.07	5.04e-05	0.00345	0.16	0.13	Night sleep phenotypes;	chr3:196893423	chr3:196912646~196914579:+
BRCA	cis	rs4916588	0.636	rs60110595	ENSG00000230732.4	AC127904.2	4.07	5.04e-05	0.00345	0.16	0.13	Night sleep phenotypes;	chr3:196894898	chr3:196912646~196914579:+
BRCA	cis	rs4916588	0.608	rs4916581	ENSG00000230732.4	AC127904.2	4.07	5.04e-05	0.00345	0.16	0.13	Night sleep phenotypes;	chr3:196909683	chr3:196912646~196914579:+
BRCA	cis	rs4916588	0.636	rs11922178	ENSG00000230732.4	AC127904.2	4.07	5.04e-05	0.00345	0.16	0.13	Night sleep phenotypes;	chr3:196913250	chr3:196912646~196914579:+
BRCA	cis	rs7412746	0.553	rs59337856	ENSG00000231073.1	RP11-316M1.3	4.07	5.04e-05	0.00345	0.13	0.13	Melanoma;	chr1:150773930	chr1:150973123~150975534:+
BRCA	cis	rs7412746	0.611	rs10888394	ENSG00000231073.1	RP11-316M1.3	4.07	5.04e-05	0.00345	0.13	0.13	Melanoma;	chr1:150777437	chr1:150973123~150975534:+
BRCA	cis	rs11098499	0.913	rs35271032	ENSG00000250412.1	KLHL2P1	4.07	5.05e-05	0.00345	0.15	0.13	Corneal astigmatism;	chr4:119235504	chr4:119334329~119378233:+
BRCA	cis	rs6700559	0.692	rs4915447	ENSG00000260088.1	RP11-92G12.3	4.07	5.05e-05	0.00345	0.15	0.13	Coronary artery disease;	chr1:200624340	chr1:200669507~200694250:+
BRCA	cis	rs3764021	0.87	rs10492166	ENSG00000256582.1	RP11-75L1.1	4.07	5.05e-05	0.00345	0.12	0.13	Type 1 diabetes;	chr12:9733403	chr12:9704077~9709350:+
BRCA	cis	rs8054556	0.539	rs12596543	ENSG00000183604.13	SMG1P5	-4.07	5.05e-05	0.00345	-0.12	-0.13	Autism spectrum disorder or schizophrenia;	chr16:30017814	chr16:30267553~30335374:-
BRCA	cis	rs12681366	0.708	rs2930958	ENSG00000253175.1	RP11-267M23.6	4.07	5.05e-05	0.00345	0.14	0.13	Nonsyndromic cleft lip with cleft palate;	chr8:94428325	chr8:94565036~94565715:+
BRCA	cis	rs73198271	1	rs73198279	ENSG00000253893.2	FAM85B	4.07	5.05e-05	0.00345	0.19	0.13	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8750994	chr8:8167819~8226614:-
BRCA	cis	rs8180040	1	rs7613282	ENSG00000276925.1	RP11-708J19.3	4.07	5.05e-05	0.00345	0.14	0.13	Colorectal cancer;	chr3:47347919	chr3:47469777~47469987:+
BRCA	cis	rs11098499	0.863	rs1383532	ENSG00000260404.2	RP11-384K6.6	-4.07	5.05e-05	0.00345	-0.12	-0.13	Corneal astigmatism;	chr4:119513249	chr4:118591773~118633729:+
BRCA	cis	rs7572733	0.935	rs9288281	ENSG00000231621.1	AC013264.2	-4.07	5.05e-05	0.00345	-0.11	-0.13	Dermatomyositis;	chr2:197879642	chr2:197197991~197199273:+
BRCA	cis	rs10266483	0.739	rs682662	ENSG00000228653.2	HNRNPCP7	-4.07	5.05e-05	0.00345	-0.15	-0.13	Response to statin therapy;	chr7:64306107	chr7:64500825~64501729:+
BRCA	cis	rs10266483	0.739	rs679966	ENSG00000228653.2	HNRNPCP7	-4.07	5.05e-05	0.00345	-0.15	-0.13	Response to statin therapy;	chr7:64306688	chr7:64500825~64501729:+
BRCA	cis	rs2408955	0.521	rs10875753	ENSG00000257735.1	RP11-370I10.6	4.07	5.05e-05	0.00345	0.15	0.13	Glycated hemoglobin levels;	chr12:48163358	chr12:48350945~48442411:+
BRCA	cis	rs2446066	0.872	rs11170532	ENSG00000257379.1	RP11-793H13.8	4.07	5.05e-05	0.00345	0.19	0.13	Red blood cell count;	chr12:53394551	chr12:53441741~53467528:+
BRCA	cis	rs6472235	0.681	rs34174890	ENSG00000272010.1	CTD-3025N20.3	-4.07	5.05e-05	0.00345	-0.15	-0.13	Plateletcrit;Myopia (pathological);	chr8:65954892	chr8:65591850~65592472:-
BRCA	cis	rs11742741	0.806	rs58960681	ENSG00000248874.4	C5orf17	-4.07	5.05e-05	0.00345	-0.16	-0.13	Educational attainment;	chr5:24030874	chr5:23951348~24178263:+
BRCA	cis	rs11098499	0.955	rs56386062	ENSG00000250412.1	KLHL2P1	4.07	5.06e-05	0.00345	0.15	0.13	Corneal astigmatism;	chr4:119233980	chr4:119334329~119378233:+
BRCA	cis	rs7520050	0.966	rs785464	ENSG00000281133.1	AL355480.3	4.07	5.06e-05	0.00345	0.14	0.13	Reticulocyte count;Red blood cell count;	chr1:46057417	chr1:45580892~45580996:-
BRCA	cis	rs1730008	1	rs10470472	ENSG00000279311.1	RP11-170K4.2	-4.07	5.06e-05	0.00345	-0.14	-0.13	Lobe attachment (rater-scored or self-reported);	chr3:158297631	chr3:158869898~158871821:+
BRCA	cis	rs10844706	0.699	rs10844635	ENSG00000256673.1	RP11-599J14.2	-4.07	5.06e-05	0.00345	-0.15	-0.13	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9735313	chr12:9398355~9414851:-
BRCA	cis	rs10844706	0.699	rs10844637	ENSG00000256673.1	RP11-599J14.2	-4.07	5.06e-05	0.00345	-0.15	-0.13	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9735495	chr12:9398355~9414851:-
BRCA	cis	rs10844706	0.699	rs10844638	ENSG00000256673.1	RP11-599J14.2	-4.07	5.06e-05	0.00345	-0.15	-0.13	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9735800	chr12:9398355~9414851:-
BRCA	cis	rs2227564	0.62	rs11000765	ENSG00000242288.9	RP11-464F9.1	4.07	5.06e-05	0.00345	0.16	0.13	Crohn's disease;Inflammatory bowel disease;	chr10:73752694	chr10:73674295~73730466:-
BRCA	cis	rs7520050	1	rs785511	ENSG00000281133.1	AL355480.3	4.07	5.06e-05	0.00345	0.14	0.13	Reticulocyte count;Red blood cell count;	chr1:46068826	chr1:45580892~45580996:-
BRCA	cis	rs7520050	0.966	rs809775	ENSG00000281133.1	AL355480.3	4.07	5.06e-05	0.00345	0.14	0.13	Reticulocyte count;Red blood cell count;	chr1:46072368	chr1:45580892~45580996:-
BRCA	cis	rs3764563	0.935	rs667386	ENSG00000267594.5	CYP4F24P	4.07	5.06e-05	0.00345	0.23	0.13	Inflammatory biomarkers;	chr19:15584806	chr19:15760241~15779909:-
BRCA	cis	rs2281558	0.876	rs2274890	ENSG00000274414.1	RP5-965G21.4	-4.07	5.06e-05	0.00345	-0.17	-0.13	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25320386	chr20:25239007~25245229:-
BRCA	cis	rs11098499	0.82	rs11737395	ENSG00000260091.1	RP11-33B1.4	-4.07	5.06e-05	0.00345	-0.11	-0.13	Corneal astigmatism;	chr4:119599549	chr4:119409333~119410233:+
BRCA	cis	rs703842	0.616	rs871871	ENSG00000270039.1	RP11-571M6.17	-4.07	5.06e-05	0.00345	-0.18	-0.13	Multiple sclerosis;	chr12:57825898	chr12:57803838~57804415:+
BRCA	cis	rs17695224	0.5	rs4802877	ENSG00000269483.1	AC006272.1	4.07	5.06e-05	0.00346	0.15	0.13	HDL cholesterol;HDL cholesterol levels;	chr19:51831991	chr19:51839924~51843324:-
BRCA	cis	rs17695224	0.52	rs4801898	ENSG00000269483.1	AC006272.1	4.07	5.06e-05	0.00346	0.15	0.13	HDL cholesterol;HDL cholesterol levels;	chr19:51832064	chr19:51839924~51843324:-
BRCA	cis	rs17695224	0.545	rs17761960	ENSG00000269483.1	AC006272.1	4.07	5.06e-05	0.00346	0.15	0.13	HDL cholesterol;HDL cholesterol levels;	chr19:51832275	chr19:51839924~51843324:-
BRCA	cis	rs17695224	0.565	rs7248523	ENSG00000269483.1	AC006272.1	4.07	5.06e-05	0.00346	0.15	0.13	HDL cholesterol;HDL cholesterol levels;	chr19:51833888	chr19:51839924~51843324:-
BRCA	cis	rs17695224	0.585	rs10406893	ENSG00000269483.1	AC006272.1	4.07	5.06e-05	0.00346	0.15	0.13	HDL cholesterol;HDL cholesterol levels;	chr19:51833901	chr19:51839924~51843324:-
BRCA	cis	rs17695224	0.545	rs10406732	ENSG00000269483.1	AC006272.1	4.07	5.06e-05	0.00346	0.15	0.13	HDL cholesterol;HDL cholesterol levels;	chr19:51833974	chr19:51839924~51843324:-
BRCA	cis	rs17695224	0.527	rs2903546	ENSG00000269483.1	AC006272.1	4.07	5.06e-05	0.00346	0.15	0.13	HDL cholesterol;HDL cholesterol levels;	chr19:51834082	chr19:51839924~51843324:-
BRCA	cis	rs6723226	0.75	rs3769597	ENSG00000276517.1	AL133243.2	-4.07	5.06e-05	0.00346	-0.15	-0.13	Intelligence (multi-trait analysis);	chr2:32466332	chr2:32526504~32529507:+
BRCA	cis	rs11168618	0.904	rs11495273	ENSG00000273765.1	RP11-370I10.11	4.07	5.06e-05	0.00346	0.14	0.13	Adiponectin levels;	chr12:48535407	chr12:48360920~48361377:+
BRCA	cis	rs495337	0.76	rs2745078	ENSG00000229222.1	KRT18P4	-4.07	5.06e-05	0.00346	-0.16	-0.13	Psoriasis;	chr20:49908923	chr20:49956745~49958032:+
BRCA	cis	rs1008375	0.9	rs4698622	ENSG00000249502.1	AC006160.5	-4.07	5.06e-05	0.00346	-0.15	-0.13	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17587934	chr4:17587467~17614571:-
BRCA	cis	rs5758511	0.68	rs5758687	ENSG00000226450.2	CYP2D8P	4.07	5.06e-05	0.00346	0.14	0.13	Birth weight;	chr22:42260582	chr22:42149886~42155001:-
BRCA	cis	rs7636293	0.86	rs55862617	ENSG00000270773.1	RP13-685P2.7	4.07	5.07e-05	0.00346	0.14	0.13	Height;	chr3:129330693	chr3:129345411~129346164:+
BRCA	cis	rs7636293	0.86	rs55894447	ENSG00000270773.1	RP13-685P2.7	4.07	5.07e-05	0.00346	0.14	0.13	Height;	chr3:129330694	chr3:129345411~129346164:+
BRCA	cis	rs7636293	0.86	rs55893559	ENSG00000270773.1	RP13-685P2.7	4.07	5.07e-05	0.00346	0.14	0.13	Height;	chr3:129330695	chr3:129345411~129346164:+
BRCA	cis	rs755249	0.567	rs4660603	ENSG00000182109.6	RP11-69E11.4	-4.07	5.07e-05	0.00346	-0.17	-0.13	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39270662	chr1:39522280~39546187:-
BRCA	cis	rs6430585	0.583	rs7561565	ENSG00000224043.6	CCNT2-AS1	-4.07	5.07e-05	0.00346	-0.21	-0.13	Corneal structure;	chr2:135883217	chr2:134735464~134918710:-
BRCA	cis	rs8054556	1	rs4788200	ENSG00000214725.6	CDIPT-AS1	-4.07	5.07e-05	0.00346	-0.15	-0.13	Autism spectrum disorder or schizophrenia;	chr16:29959944	chr16:29863593~29868053:+
BRCA	cis	rs12237653	0.929	rs10812239	ENSG00000236404.7	VLDLR-AS1	4.07	5.07e-05	0.00346	0.19	0.13	Gambling;	chr9:2551136	chr9:2422702~2643359:-
BRCA	cis	rs6504622	0.755	rs4074249	ENSG00000263142.4	LRRC37A17P	-4.07	5.07e-05	0.00346	-0.1	-0.13	Orofacial clefts;	chr17:47072043	chr17:46978481~47054569:+
BRCA	cis	rs2832191	0.967	rs3787660	ENSG00000176054.6	RPL23P2	4.07	5.07e-05	0.00346	0.13	0.13	Dental caries;	chr21:29148586	chr21:28997613~28998033:-
BRCA	cis	rs4415084	0.716	rs4440370	ENSG00000251141.4	RP11-53O19.1	-4.07	5.07e-05	0.00346	-0.12	-0.13	Breast cancer;	chr5:44853250	chr5:44744900~44808777:-
BRCA	cis	rs10895987	1	rs12280510	ENSG00000255200.1	AP003068.18	4.07	5.07e-05	0.00346	0.18	0.13	Blood protein levels;	chr11:65147076	chr11:65174117~65176470:-
BRCA	cis	rs6545883	0.895	rs2256617	ENSG00000212978.6	AC016747.3	4.07	5.07e-05	0.00346	0.17	0.13	Tuberculosis;	chr2:61452789	chr2:61141592~61144969:-
BRCA	cis	rs2191566	1	rs2191566	ENSG00000266921.1	RP11-15A1.7	4.07	5.07e-05	0.00346	0.16	0.13	Acute lymphoblastic leukemia (childhood);	chr19:44007237	chr19:43996896~44002836:-
BRCA	cis	rs801193	0.904	rs4718405	ENSG00000272831.1	RP11-792A8.4	4.07	5.07e-05	0.00346	0.11	0.13	Aortic root size;	chr7:66789659	chr7:66739829~66740385:-
BRCA	cis	rs6758001	1	rs6758001	ENSG00000230838.1	AC093850.2	-4.07	5.07e-05	0.00346	-0.24	-0.13	Cerebrospinal fluid clusterin levels;	chr2:215750203	chr2:215718043~215719424:+
BRCA	cis	rs375066	0.868	rs368079	ENSG00000267191.1	RP11-15A1.2	-4.07	5.07e-05	0.00346	-0.16	-0.13	Breast cancer;	chr19:43889204	chr19:43902001~43926545:+
BRCA	cis	rs651907	0.535	rs2290859	ENSG00000256628.3	ZBTB11-AS1	4.07	5.07e-05	0.00346	0.16	0.13	Colorectal cancer;	chr3:101806781	chr3:101676475~101679217:+
BRCA	cis	rs6738028	0.504	rs11123406	ENSG00000230499.1	AC108463.1	4.07	5.08e-05	0.00346	0.15	0.13	Dehydroepiandrosterone sulphate levels;	chr2:111192964	chr2:111195963~111206494:+
BRCA	cis	rs7824557	0.564	rs13260727	ENSG00000255495.1	AC145124.2	4.07	5.08e-05	0.00346	0.15	0.13	Retinal vascular caliber;	chr8:11375351	chr8:12194467~12196280:+
BRCA	cis	rs2243480	1	rs316322	ENSG00000237026.1	RP11-328P23.2	4.07	5.08e-05	0.00346	0.23	0.13	Diabetic kidney disease;	chr7:66146246	chr7:65235790~65236723:-
BRCA	cis	rs2191566	1	rs367499	ENSG00000266921.1	RP11-15A1.7	4.07	5.08e-05	0.00346	0.16	0.13	Acute lymphoblastic leukemia (childhood);	chr19:44000829	chr19:43996896~44002836:-
BRCA	cis	rs1005277	0.579	rs2472175	ENSG00000272983.1	RP11-508N22.12	4.07	5.08e-05	0.00346	0.13	0.13	Extrinsic epigenetic age acceleration;	chr10:38093973	chr10:38137337~38144399:+
BRCA	cis	rs1005277	0.579	rs2472176	ENSG00000272983.1	RP11-508N22.12	4.07	5.08e-05	0.00346	0.13	0.13	Extrinsic epigenetic age acceleration;	chr10:38093993	chr10:38137337~38144399:+
BRCA	cis	rs1005277	0.579	rs2983343	ENSG00000272983.1	RP11-508N22.12	4.07	5.08e-05	0.00346	0.13	0.13	Extrinsic epigenetic age acceleration;	chr10:38094404	chr10:38137337~38144399:+
BRCA	cis	rs1005277	0.579	rs2474569	ENSG00000272983.1	RP11-508N22.12	4.07	5.08e-05	0.00346	0.13	0.13	Extrinsic epigenetic age acceleration;	chr10:38094563	chr10:38137337~38144399:+
BRCA	cis	rs1005277	0.602	rs2504142	ENSG00000272983.1	RP11-508N22.12	4.07	5.08e-05	0.00346	0.13	0.13	Extrinsic epigenetic age acceleration;	chr10:38094865	chr10:38137337~38144399:+
BRCA	cis	rs6893300	1	rs55975622	ENSG00000250999.1	RP11-1379J22.5	4.07	5.08e-05	0.00346	0.18	0.13	Resting heart rate;	chr5:179740704	chr5:179657762~179664432:+
BRCA	cis	rs6893300	1	rs17617068	ENSG00000250999.1	RP11-1379J22.5	4.07	5.08e-05	0.00346	0.18	0.13	Resting heart rate;	chr5:179741096	chr5:179657762~179664432:+
BRCA	cis	rs6496044	0.568	rs12899946	ENSG00000202081.1	RNU6-1280P	4.07	5.08e-05	0.00346	0.14	0.13	Interstitial lung disease;	chr15:85522851	chr15:85651522~85651628:-
BRCA	cis	rs6496044	0.568	rs12898783	ENSG00000202081.1	RNU6-1280P	4.07	5.08e-05	0.00346	0.14	0.13	Interstitial lung disease;	chr15:85522869	chr15:85651522~85651628:-
BRCA	cis	rs6496044	0.568	rs11855789	ENSG00000202081.1	RNU6-1280P	4.07	5.08e-05	0.00346	0.14	0.13	Interstitial lung disease;	chr15:85523172	chr15:85651522~85651628:-
BRCA	cis	rs11168618	0.875	rs11168606	ENSG00000273765.1	RP11-370I10.11	4.07	5.08e-05	0.00347	0.15	0.13	Adiponectin levels;	chr12:48498906	chr12:48360920~48361377:+
BRCA	cis	rs6088580	0.634	rs6120666	ENSG00000275784.1	RP5-1125A11.6	-4.07	5.08e-05	0.00347	-0.14	-0.13	Glomerular filtration rate (creatinine);	chr20:34502913	chr20:33989480~33991818:-
BRCA	cis	rs9527	0.59	rs10883829	ENSG00000213061.2	PFN1P11	4.07	5.08e-05	0.00347	0.17	0.13	Arsenic metabolism;	chr10:103080878	chr10:102838011~102845473:-
BRCA	cis	rs7819412	0.594	rs7460507	ENSG00000255020.1	AF131216.5	4.07	5.08e-05	0.00347	0.15	0.13	Triglycerides;	chr8:11111565	chr8:11345748~11347502:-
BRCA	cis	rs2486012	1	rs61770287	ENSG00000237950.1	RP11-7O11.3	-4.07	5.08e-05	0.00347	-0.23	-0.13	Intelligence (multi-trait analysis);	chr1:43893533	chr1:43944370~43946551:-
BRCA	cis	rs9905704	0.633	rs4793588	ENSG00000265148.4	BZRAP1-AS1	-4.07	5.08e-05	0.00347	-0.16	-0.13	Testicular germ cell tumor;	chr17:58393690	chr17:58325450~58415766:+
BRCA	cis	rs7615952	0.932	rs11922218	ENSG00000241288.6	RP11-379B18.5	-4.07	5.08e-05	0.00347	-0.18	-0.13	Blood pressure (smoking interaction);	chr3:125912446	chr3:125827238~125916384:-
BRCA	cis	rs7615952	0.866	rs11922276	ENSG00000241288.6	RP11-379B18.5	-4.07	5.08e-05	0.00347	-0.18	-0.13	Blood pressure (smoking interaction);	chr3:125912483	chr3:125827238~125916384:-
BRCA	cis	rs4713118	0.525	rs9357042	ENSG00000219392.1	RP1-265C24.5	-4.07	5.08e-05	0.00347	-0.16	-0.13	Parkinson's disease;	chr6:27615016	chr6:28115628~28116551:+
BRCA	cis	rs7160336	0.875	rs1966402	ENSG00000259065.1	RP5-1021I20.1	-4.07	5.08e-05	0.00347	-0.14	-0.13	Blood protein levels;	chr14:74179374	chr14:73787360~73803270:+
BRCA	cis	rs1371614	0.61	rs6547317	ENSG00000272148.1	RP11-195B17.1	4.07	5.09e-05	0.00347	0.14	0.13	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26929051	chr2:27062428~27062907:-
BRCA	cis	rs7267979	0.966	rs2261784	ENSG00000125804.12	FAM182A	-4.07	5.09e-05	0.00347	-0.17	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25281760	chr20:26054655~26086917:+
BRCA	cis	rs7267979	0.966	rs2261785	ENSG00000125804.12	FAM182A	-4.07	5.09e-05	0.00347	-0.17	-0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25281767	chr20:26054655~26086917:+
BRCA	cis	rs13434995	0.513	rs62305268	ENSG00000239040.1	Y_RNA	4.07	5.09e-05	0.00347	0.15	0.13	Adiponectin levels;	chr4:55506991	chr4:55412636~55412738:+
BRCA	cis	rs13434995	0.513	rs62305270	ENSG00000239040.1	Y_RNA	4.07	5.09e-05	0.00347	0.15	0.13	Adiponectin levels;	chr4:55507842	chr4:55412636~55412738:+
BRCA	cis	rs13434995	0.513	rs7681414	ENSG00000239040.1	Y_RNA	4.07	5.09e-05	0.00347	0.15	0.13	Adiponectin levels;	chr4:55508890	chr4:55412636~55412738:+
BRCA	cis	rs13434995	0.513	rs62305271	ENSG00000239040.1	Y_RNA	4.07	5.09e-05	0.00347	0.15	0.13	Adiponectin levels;	chr4:55509715	chr4:55412636~55412738:+
BRCA	cis	rs13434995	0.513	rs10462033	ENSG00000239040.1	Y_RNA	4.07	5.09e-05	0.00347	0.15	0.13	Adiponectin levels;	chr4:55511552	chr4:55412636~55412738:+
BRCA	cis	rs13434995	0.513	rs1915905	ENSG00000239040.1	Y_RNA	4.07	5.09e-05	0.00347	0.15	0.13	Adiponectin levels;	chr4:55512381	chr4:55412636~55412738:+
BRCA	cis	rs13434995	0.513	rs1522109	ENSG00000239040.1	Y_RNA	4.07	5.09e-05	0.00347	0.15	0.13	Adiponectin levels;	chr4:55514403	chr4:55412636~55412738:+
BRCA	cis	rs2243480	0.901	rs12530490	ENSG00000237026.1	RP11-328P23.2	-4.07	5.09e-05	0.00347	-0.23	-0.13	Diabetic kidney disease;	chr7:66226660	chr7:65235790~65236723:-
BRCA	cis	rs2243480	1	rs7778911	ENSG00000237026.1	RP11-328P23.2	-4.07	5.09e-05	0.00347	-0.23	-0.13	Diabetic kidney disease;	chr7:66229519	chr7:65235790~65236723:-
BRCA	cis	rs6546324	0.625	rs2902008	ENSG00000236780.4	AC078941.1	4.07	5.09e-05	0.00347	0.22	0.13	Endometriosis;	chr2:67575818	chr2:67123357~67215319:-
BRCA	cis	rs4143844	0.867	rs11629598	ENSG00000259251.2	RP11-643M14.1	4.07	5.09e-05	0.00347	0.31	0.13	Bipolar disorder and schizophrenia;	chr15:61950998	chr15:62060503~62062434:+
BRCA	cis	rs6490294	0.571	rs11066119	ENSG00000234608.6	MAPKAPK5-AS1	4.07	5.09e-05	0.00347	0.18	0.13	Mean platelet volume;	chr12:111996700	chr12:111839764~111842902:-
BRCA	cis	rs9381040	0.655	rs9394756	ENSG00000161912.16	ADCY10P1	4.07	5.09e-05	0.00347	0.14	0.13	Alzheimer's disease (late onset);	chr6:41048444	chr6:41101022~41140835:+
BRCA	cis	rs6088813	0.663	rs2425056	ENSG00000126005.14	MMP24-AS1	-4.07	5.09e-05	0.00347	-0.15	-0.13	Height;	chr20:35321442	chr20:35216462~35278131:-
BRCA	cis	rs9467773	0.596	rs2451750	ENSG00000224843.5	LINC00240	-4.07	5.09e-05	0.00347	-0.14	-0.13	Intelligence (multi-trait analysis);	chr6:26646351	chr6:26956992~27023924:+
BRCA	cis	rs9467773	0.596	rs2451751	ENSG00000224843.5	LINC00240	-4.07	5.09e-05	0.00347	-0.14	-0.13	Intelligence (multi-trait analysis);	chr6:26646486	chr6:26956992~27023924:+
BRCA	cis	rs1048886	0.938	rs55990553	ENSG00000271967.1	RP11-134K13.4	-4.07	5.1e-05	0.00348	-0.17	-0.13	Type 2 diabetes;	chr6:70436610	chr6:70596438~70596980:+
BRCA	cis	rs1048886	0.938	rs77691649	ENSG00000271967.1	RP11-134K13.4	-4.07	5.1e-05	0.00348	-0.17	-0.13	Type 2 diabetes;	chr6:70438815	chr6:70596438~70596980:+
BRCA	cis	rs1048886	0.938	rs9455113	ENSG00000271967.1	RP11-134K13.4	-4.07	5.1e-05	0.00348	-0.17	-0.13	Type 2 diabetes;	chr6:70447967	chr6:70596438~70596980:+
BRCA	cis	rs983392	1	rs2847655	ENSG00000275344.1	MIR6503	-4.07	5.1e-05	0.00348	-0.14	-0.13	Alzheimer's disease (late onset);	chr11:60098198	chr11:60209071~60209156:-
BRCA	cis	rs1129187	0.967	rs3805952	ENSG00000220614.1	RP11-480N24.4	4.07	5.1e-05	0.00348	0.14	0.13	Alzheimer's disease in APOE e4+ carriers;	chr6:42969388	chr6:43328134~43328476:+
BRCA	cis	rs1129187	0.967	rs3805951	ENSG00000220614.1	RP11-480N24.4	4.07	5.1e-05	0.00348	0.14	0.13	Alzheimer's disease in APOE e4+ carriers;	chr6:42969438	chr6:43328134~43328476:+
BRCA	cis	rs17489649	1	rs2269206	ENSG00000271849.1	CTC-332L22.1	4.07	5.1e-05	0.00348	0.16	0.13	Intelligence (multi-trait analysis);	chr5:109786985	chr5:109687802~109688329:-
BRCA	cis	rs2574985	0.924	rs1916567	ENSG00000231345.3	BEND3P1	4.07	5.1e-05	0.00348	0.21	0.13	Subjective well-being;	chr10:50398623	chr10:50655967~50660472:+
BRCA	cis	rs7647973	0.506	rs11920251	ENSG00000226913.1	BSN-AS2	-4.07	5.1e-05	0.00348	-0.13	-0.13	Menarche (age at onset);	chr3:49319238	chr3:49549306~49554366:-
BRCA	cis	rs1048886	0.938	rs12528866	ENSG00000271967.1	RP11-134K13.4	-4.07	5.1e-05	0.00348	-0.17	-0.13	Type 2 diabetes;	chr6:70478144	chr6:70596438~70596980:+
BRCA	cis	rs1005277	0.579	rs1621040	ENSG00000276805.1	RP11-291L22.6	4.07	5.1e-05	0.00348	0.14	0.13	Extrinsic epigenetic age acceleration;	chr10:38208304	chr10:38451030~38451785:+
BRCA	cis	rs17027633	1	rs79891093	ENSG00000260948.1	RP11-552M11.8	-4.07	5.1e-05	0.00348	-0.29	-0.13	Cerebrospinal fluid t-tau:AB1-42 ratio;	chr1:111423955	chr1:111431046~111433068:-
BRCA	cis	rs867186	1	rs7263203	ENSG00000126005.14	MMP24-AS1	-4.07	5.1e-05	0.00348	-0.24	-0.13	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35185572	chr20:35216462~35278131:-
BRCA	cis	rs875971	0.929	rs6970860	ENSG00000236529.1	RP13-254B10.1	4.07	5.1e-05	0.00348	0.14	0.13	Aortic root size;	chr7:66511647	chr7:65840212~65840596:+
BRCA	cis	rs957448	1	rs72674843	ENSG00000254315.1	RP11-267M23.3	4.07	5.1e-05	0.00348	0.17	0.13	Nonsyndromic cleft lip with cleft palate;	chr8:94520772	chr8:94533628~94534391:+
BRCA	cis	rs3753275	0.579	rs10779703	ENSG00000270282.1	RP5-1115A15.2	4.07	5.1e-05	0.00348	0.17	0.13	Educational attainment;	chr1:8536123	chr1:8512653~8513021:+
BRCA	cis	rs61931739	0.534	rs7310499	ENSG00000258794.3	DUX4L27	4.07	5.1e-05	0.00348	0.18	0.13	Morning vs. evening chronotype;	chr12:34059177	chr12:34208415~34209675:-
BRCA	cis	rs4835473	0.808	rs6836630	ENSG00000249741.2	RP11-673E1.3	4.07	5.1e-05	0.00348	0.14	0.13	Immature fraction of reticulocytes;	chr4:143801068	chr4:143911514~143912053:-
BRCA	cis	rs4835473	0.932	rs13101541	ENSG00000249741.2	RP11-673E1.3	4.07	5.1e-05	0.00348	0.14	0.13	Immature fraction of reticulocytes;	chr4:143806590	chr4:143911514~143912053:-
BRCA	cis	rs7976059	0.895	rs12367434	ENSG00000259887.1	RP11-923I11.5	-4.07	5.1e-05	0.00348	-0.16	-0.13	Urate levels;	chr12:51854131	chr12:51848223~51852729:+
BRCA	cis	rs7487075	0.554	rs7960819	ENSG00000272369.1	RP11-446N19.1	4.07	5.1e-05	0.00348	0.13	0.13	Itch intensity from mosquito bite;	chr12:46234999	chr12:46537502~46652550:+
BRCA	cis	rs7487075	0.554	rs7957777	ENSG00000272369.1	RP11-446N19.1	4.07	5.1e-05	0.00348	0.13	0.13	Itch intensity from mosquito bite;	chr12:46235006	chr12:46537502~46652550:+
BRCA	cis	rs4650943	0.586	rs2455739	ENSG00000227740.1	RP11-318C24.2	-4.07	5.11e-05	0.00348	-0.13	-0.13	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in inactive individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr1:176321314	chr1:175904762~175920513:-
BRCA	cis	rs853679	0.517	rs56310871	ENSG00000261839.1	RP1-265C24.8	4.07	5.11e-05	0.00348	0.17	0.13	Depression;	chr6:28076704	chr6:28136849~28139678:+
BRCA	cis	rs2115630	0.791	rs2008262	ENSG00000259295.5	CSPG4P12	-4.07	5.11e-05	0.00348	-0.15	-0.13	P wave terminal force;	chr15:84762039	chr15:85191438~85213905:+
BRCA	cis	rs745109	0.882	rs56347930	ENSG00000273080.1	RP11-301O19.1	4.07	5.11e-05	0.00348	0.2	0.13	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86456778	chr2:86195590~86196049:+
BRCA	cis	rs7646881	0.504	rs4264773	ENSG00000240207.5	RP11-379F4.4	-4.07	5.11e-05	0.00348	-0.17	-0.13	Tetralogy of Fallot;	chr3:158745436	chr3:158732263~158784070:+
BRCA	cis	rs12612619	0.732	rs13020526	ENSG00000272148.1	RP11-195B17.1	4.07	5.11e-05	0.00348	0.14	0.13	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:26981782	chr2:27062428~27062907:-
BRCA	cis	rs9733	0.596	rs1415148	ENSG00000231073.1	RP11-316M1.3	4.07	5.11e-05	0.00348	0.13	0.13	Tonsillectomy;	chr1:150733279	chr1:150973123~150975534:+
BRCA	cis	rs11711311	0.955	rs9813630	ENSG00000241529.3	RN7SL767P	-4.07	5.11e-05	0.00349	-0.15	-0.13	IgG glycosylation;	chr3:113658514	chr3:113632704~113632998:+
BRCA	cis	rs6546847	0.531	rs2567602	ENSG00000163016.8	ALMS1P	4.07	5.11e-05	0.00349	0.22	0.13	Urinary metabolites (H-NMR features);	chr2:73758409	chr2:73644919~73685576:+
BRCA	cis	rs4654783	1	rs4654783	ENSG00000218510.5	LINC00339	4.07	5.11e-05	0.00349	0.16	0.13	Endometriosis;	chr1:22113027	chr1:22025188~22031223:+
BRCA	cis	rs6790105	1	rs6790105	ENSG00000244380.1	RP11-24C3.2	4.07	5.11e-05	0.00349	0.16	0.13	Childhood ear infection;	chr3:49355976	chr3:48440352~48446656:-
BRCA	cis	rs1346	0.58	rs11227234	ENSG00000245532.5	NEAT1	-4.07	5.11e-05	0.00349	-0.13	-0.13	Vertical cup-disc ratio;Optic cup area;	chr11:65597700	chr11:65422774~65445540:+
BRCA	cis	rs7267979	1	rs6050555	ENSG00000125804.12	FAM182A	4.07	5.11e-05	0.00349	0.17	0.13	Liver enzyme levels (alkaline phosphatase);	chr20:25347907	chr20:26054655~26086917:+
BRCA	cis	rs6088580	0.634	rs6059850	ENSG00000275784.1	RP5-1125A11.6	-4.07	5.12e-05	0.00349	-0.14	-0.13	Glomerular filtration rate (creatinine);	chr20:34456979	chr20:33989480~33991818:-
BRCA	cis	rs4650943	0.586	rs2455735	ENSG00000227740.1	RP11-318C24.2	-4.07	5.12e-05	0.00349	-0.13	-0.13	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in inactive individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr1:176323099	chr1:175904762~175920513:-
BRCA	cis	rs7260598	0.642	rs11667910	ENSG00000268442.1	CTD-2027I19.2	4.07	5.12e-05	0.00349	0.2	0.13	Response to taxane treatment (placlitaxel);	chr19:23976911	chr19:24162370~24163425:-
BRCA	cis	rs683250	0.66	rs645169	ENSG00000254551.1	RP11-727A23.7	4.07	5.12e-05	0.00349	0.16	0.13	Subcortical brain region volumes;	chr11:83264440	chr11:83209431~83213379:-
BRCA	cis	rs9470794	1	rs11755190	ENSG00000204110.6	RP1-153P14.8	-4.07	5.12e-05	0.00349	-0.19	-0.13	Type 2 diabetes;	chr6:38160467	chr6:37507348~37535616:+
BRCA	cis	rs6700559	0.565	rs2809341	ENSG00000260088.1	RP11-92G12.3	-4.07	5.12e-05	0.00349	-0.15	-0.13	Coronary artery disease;	chr1:200628560	chr1:200669507~200694250:+
BRCA	cis	rs11892454	0.712	rs13409567	ENSG00000217643.1	PTGES3P2	-4.07	5.12e-05	0.00349	-0.14	-0.13	Heschl's gyrus morphology;	chr2:25719381	chr2:25822469~25822950:+
BRCA	cis	rs1371614	0.545	rs13035643	ENSG00000272148.1	RP11-195B17.1	-4.07	5.12e-05	0.00349	-0.14	-0.13	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26950473	chr2:27062428~27062907:-
BRCA	cis	rs1371614	0.545	rs4665930	ENSG00000272148.1	RP11-195B17.1	-4.07	5.12e-05	0.00349	-0.14	-0.13	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26950652	chr2:27062428~27062907:-
BRCA	cis	rs930395	0.514	rs4866783	ENSG00000251141.4	RP11-53O19.1	-4.07	5.12e-05	0.00349	-0.12	-0.13	Breast cancer;	chr5:44876405	chr5:44744900~44808777:-
BRCA	cis	rs853679	0.517	rs9393891	ENSG00000261839.1	RP1-265C24.8	4.07	5.12e-05	0.00349	0.17	0.13	Depression;	chr6:28111382	chr6:28136849~28139678:+
BRCA	cis	rs853679	0.517	rs9468286	ENSG00000261839.1	RP1-265C24.8	4.07	5.12e-05	0.00349	0.17	0.13	Depression;	chr6:28111650	chr6:28136849~28139678:+
BRCA	cis	rs853679	0.517	rs9380055	ENSG00000261839.1	RP1-265C24.8	4.07	5.12e-05	0.00349	0.17	0.13	Depression;	chr6:28113851	chr6:28136849~28139678:+
BRCA	cis	rs853679	0.517	rs9368553	ENSG00000261839.1	RP1-265C24.8	4.07	5.12e-05	0.00349	0.17	0.13	Depression;	chr6:28114487	chr6:28136849~28139678:+
BRCA	cis	rs853679	0.517	rs9368554	ENSG00000261839.1	RP1-265C24.8	4.07	5.12e-05	0.00349	0.17	0.13	Depression;	chr6:28114933	chr6:28136849~28139678:+
BRCA	cis	rs853679	0.517	rs4713137	ENSG00000261839.1	RP1-265C24.8	4.07	5.12e-05	0.00349	0.17	0.13	Depression;	chr6:28115743	chr6:28136849~28139678:+
BRCA	cis	rs853679	0.517	rs9348793	ENSG00000261839.1	RP1-265C24.8	4.07	5.12e-05	0.00349	0.17	0.13	Depression;	chr6:28116411	chr6:28136849~28139678:+
BRCA	cis	rs4713118	0.586	rs6905516	ENSG00000261839.1	RP1-265C24.8	4.07	5.12e-05	0.00349	0.17	0.13	Parkinson's disease;	chr6:28118700	chr6:28136849~28139678:+
BRCA	cis	rs4713118	0.586	rs6905522	ENSG00000261839.1	RP1-265C24.8	4.07	5.12e-05	0.00349	0.17	0.13	Parkinson's disease;	chr6:28118701	chr6:28136849~28139678:+
BRCA	cis	rs4713118	0.586	rs9468290	ENSG00000261839.1	RP1-265C24.8	4.07	5.12e-05	0.00349	0.17	0.13	Parkinson's disease;	chr6:28119896	chr6:28136849~28139678:+
BRCA	cis	rs9527	0.83	rs10883790	ENSG00000236937.2	PTGES3P4	4.07	5.12e-05	0.00349	0.17	0.13	Arsenic metabolism;	chr10:102881198	chr10:102845595~102845950:+
BRCA	cis	rs9527	0.83	rs11191440	ENSG00000236937.2	PTGES3P4	4.07	5.12e-05	0.00349	0.17	0.13	Arsenic metabolism;	chr10:102881754	chr10:102845595~102845950:+
BRCA	cis	rs17695224	0.527	rs7250063	ENSG00000269483.1	AC006272.1	4.07	5.12e-05	0.00349	0.15	0.12	HDL cholesterol;HDL cholesterol levels;	chr19:51834447	chr19:51839924~51843324:-
BRCA	cis	rs2518049	0.654	rs76656738	ENSG00000224034.1	RP11-445P17.8	-4.07	5.12e-05	0.00349	-0.24	-0.12	Metabolic traits;	chr10:5196057	chr10:5266033~5271236:-
BRCA	cis	rs2518049	0.654	rs3812617	ENSG00000224034.1	RP11-445P17.8	-4.07	5.12e-05	0.00349	-0.24	-0.12	Metabolic traits;	chr10:5196320	chr10:5266033~5271236:-
BRCA	cis	rs1005277	0.579	rs2505198	ENSG00000272983.1	RP11-508N22.12	4.07	5.12e-05	0.00349	0.13	0.12	Extrinsic epigenetic age acceleration;	chr10:38104255	chr10:38137337~38144399:+
BRCA	cis	rs17684571	0.751	rs34896026	ENSG00000231441.1	RP11-472M19.2	4.07	5.12e-05	0.00349	0.21	0.12	Schizophrenia;	chr6:56829383	chr6:56844002~56864078:+
BRCA	cis	rs8054556	1	rs6565173	ENSG00000214725.6	CDIPT-AS1	-4.07	5.12e-05	0.00349	-0.15	-0.12	Autism spectrum disorder or schizophrenia;	chr16:29962846	chr16:29863593~29868053:+
BRCA	cis	rs2904967	0.631	rs650056	ENSG00000254614.2	AP003068.23	-4.07	5.12e-05	0.00349	-0.28	-0.12	Mean corpuscular volume;	chr11:65257635	chr11:65177606~65181834:-
BRCA	cis	rs1549733	0.577	rs16857851	ENSG00000229754.1	CXCR2P1	-4.07	5.13e-05	0.00349	-0.12	-0.12	Optic disc area;	chr2:217553627	chr2:218059155~218065729:-
BRCA	cis	rs38055	0.881	rs40230	ENSG00000247796.2	CTD-2366F13.1	-4.07	5.13e-05	0.00349	-0.15	-0.12	Acne (severe);	chr5:53296267	chr5:53109842~53115126:+
BRCA	cis	rs9381040	0.655	rs9381029	ENSG00000161912.16	ADCY10P1	4.07	5.13e-05	0.00349	0.14	0.12	Alzheimer's disease (late onset);	chr6:41058714	chr6:41101022~41140835:+
BRCA	cis	rs9381040	0.61	rs2268191	ENSG00000161912.16	ADCY10P1	4.07	5.13e-05	0.00349	0.14	0.12	Alzheimer's disease (late onset);	chr6:41059914	chr6:41101022~41140835:+
BRCA	cis	rs801193	0.967	rs3800823	ENSG00000223473.2	GS1-124K5.3	-4.07	5.13e-05	0.00349	-0.1	-0.12	Aortic root size;	chr7:66682123	chr7:66491049~66493566:-
BRCA	cis	rs4538475	0.539	rs73241111	ENSG00000273133.1	RP11-799M12.2	-4.07	5.13e-05	0.00349	-0.25	-0.12	Parkinson's disease;	chr4:15629132	chr4:15563698~15564253:-
BRCA	cis	rs875971	0.545	rs7811204	ENSG00000232546.1	RP11-458F8.1	4.07	5.13e-05	0.00349	0.12	0.12	Aortic root size;	chr7:66387213	chr7:66848496~66858136:+
BRCA	cis	rs3096299	0.967	rs2965932	ENSG00000259877.2	RP11-46C24.7	4.07	5.13e-05	0.00349	0.12	0.12	Multiple myeloma (IgH translocation);	chr16:89410643	chr16:89215211~89217653:-
BRCA	cis	rs17292804	0.527	rs12887734	ENSG00000269940.1	RP11-73M18.7	4.07	5.13e-05	0.0035	0.14	0.12	Autism spectrum disorder or schizophrenia;	chr14:103580497	chr14:103694560~103695170:+
BRCA	cis	rs763121	0.853	rs1043441	ENSG00000225450.1	RP3-508I15.14	-4.07	5.13e-05	0.0035	-0.14	-0.12	Menopause (age at onset);	chr22:38734959	chr22:38739003~38749041:+
BRCA	cis	rs7615952	0.604	rs9837847	ENSG00000248787.1	RP11-666A20.4	-4.07	5.13e-05	0.0035	-0.25	-0.12	Blood pressure (smoking interaction);	chr3:125905076	chr3:125908005~125910272:-
BRCA	cis	rs9959145	1	rs1940973	ENSG00000267108.1	RP11-861E21.1	4.07	5.13e-05	0.0035	0.23	0.12	Immune response to smallpox vaccine (IL-6);	chr18:12550748	chr18:12432897~12437635:+
BRCA	cis	rs9959145	1	rs79785672	ENSG00000267108.1	RP11-861E21.1	4.07	5.13e-05	0.0035	0.23	0.12	Immune response to smallpox vaccine (IL-6);	chr18:12552110	chr18:12432897~12437635:+
BRCA	cis	rs7772486	0.875	rs9373485	ENSG00000270638.1	RP3-466P17.1	4.07	5.13e-05	0.0035	0.14	0.12	Lobe attachment (rater-scored or self-reported);	chr6:146080293	chr6:145735570~145737218:+
BRCA	cis	rs2274273	0.87	rs2016931	ENSG00000259318.1	RP11-454L9.2	4.07	5.13e-05	0.0035	0.1	0.12	Protein biomarker;	chr14:55375614	chr14:55394940~55395233:-
BRCA	cis	rs2562456	0.833	rs11666525	ENSG00000268658.4	LINC00664	4.07	5.13e-05	0.0035	0.22	0.12	Pain;	chr19:21416503	chr19:21483374~21503238:+
BRCA	cis	rs6893300	0.826	rs7734102	ENSG00000250999.1	RP11-1379J22.5	-4.07	5.13e-05	0.0035	-0.16	-0.12	Resting heart rate;	chr5:179726796	chr5:179657762~179664432:+
BRCA	cis	rs7412746	0.611	rs11204726	ENSG00000231073.1	RP11-316M1.3	4.07	5.13e-05	0.0035	0.13	0.12	Melanoma;	chr1:150771016	chr1:150973123~150975534:+
BRCA	cis	rs1876905	0.68	rs7767302	ENSG00000230177.1	RP5-1112D6.4	4.07	5.13e-05	0.0035	0.19	0.12	Mean corpuscular hemoglobin;	chr6:111143942	chr6:111277932~111278742:+
BRCA	cis	rs875971	1	rs2077593	ENSG00000265600.1	AC006480.1	-4.07	5.13e-05	0.0035	-0.15	-0.12	Aortic root size;	chr7:66427543	chr7:67356680~67356779:+
BRCA	cis	rs875971	1	rs2420591	ENSG00000229180.5	GS1-124K5.11	4.07	5.13e-05	0.0035	0.11	0.12	Aortic root size;	chr7:66447394	chr7:66526088~66542624:-
BRCA	cis	rs7267979	0.816	rs376742	ENSG00000231081.1	RP4-760C5.3	-4.07	5.13e-05	0.0035	-0.16	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25506781	chr20:26008791~26010531:-
BRCA	cis	rs11668609	1	rs7260280	ENSG00000268058.1	BNIP3P40	-4.07	5.13e-05	0.0035	-0.15	-0.12	Response to taxane treatment (docetaxel);	chr19:24140020	chr19:24098425~24098980:-
BRCA	cis	rs2301573	0.584	rs12494774	ENSG00000271270.4	TMCC1-AS1	4.07	5.13e-05	0.0035	0.26	0.12	Hip circumference;	chr3:129890314	chr3:129893871~129918575:+
BRCA	cis	rs4908769	0.66	rs302714	ENSG00000270282.1	RP5-1115A15.2	4.07	5.13e-05	0.0035	0.15	0.12	Allergy;	chr1:8426071	chr1:8512653~8513021:+
BRCA	cis	rs6870983	0.749	rs13360207	ENSG00000247828.6	TMEM161B-AS1	-4.07	5.13e-05	0.0035	-0.16	-0.12	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index;	chr5:88185757	chr5:88268895~88436685:+
BRCA	cis	rs9959145	1	rs79998152	ENSG00000267108.1	RP11-861E21.1	4.07	5.14e-05	0.0035	0.22	0.12	Immune response to smallpox vaccine (IL-6);	chr18:12567413	chr18:12432897~12437635:+
BRCA	cis	rs516805	0.665	rs2606648	ENSG00000279114.1	RP3-425C14.5	-4.07	5.14e-05	0.0035	-0.16	-0.12	Lymphocyte counts;	chr6:122119554	chr6:122471923~122484161:+
BRCA	cis	rs8177876	0.749	rs10459871	ENSG00000245059.2	RP11-303E16.7	4.07	5.14e-05	0.0035	0.27	0.12	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81059462	chr16:81077319~81078861:+
BRCA	cis	rs6546324	0.615	rs4233939	ENSG00000236780.4	AC078941.1	4.07	5.14e-05	0.0035	0.21	0.12	Endometriosis;	chr2:67555603	chr2:67123357~67215319:-
BRCA	cis	rs1472147	1	rs4323418	ENSG00000272899.2	RP11-309L24.4	-4.07	5.14e-05	0.0035	-0.16	-0.12	Calcium levels;	chr7:128866916	chr7:128866579~128872044:+
BRCA	cis	rs1048886	0.808	rs4496758	ENSG00000271967.1	RP11-134K13.4	-4.07	5.14e-05	0.0035	-0.17	-0.12	Type 2 diabetes;	chr6:70530390	chr6:70596438~70596980:+
BRCA	cis	rs1048886	0.938	rs2273210	ENSG00000271967.1	RP11-134K13.4	-4.07	5.14e-05	0.0035	-0.17	-0.12	Type 2 diabetes;	chr6:70480874	chr6:70596438~70596980:+
BRCA	cis	rs8180040	1	rs2302278	ENSG00000271161.1	BOLA2P2	-4.07	5.14e-05	0.0035	-0.13	-0.12	Colorectal cancer;	chr3:47319592	chr3:47499841~47500407:+
BRCA	cis	rs7577696	0.708	rs610758	ENSG00000272716.1	RP11-563N4.1	4.07	5.14e-05	0.0035	0.14	0.12	Inflammatory biomarkers;	chr2:31608492	chr2:32165046~32165757:-
BRCA	cis	rs3020264	0.586	rs3020265	ENSG00000246089.3	RP11-115C21.2	4.07	5.14e-05	0.0035	0.14	0.12	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 24 weeks);	chr8:6631400	chr8:6403551~6407142:-
BRCA	cis	rs9863	0.861	rs7131882	ENSG00000270028.1	RP11-380L11.4	4.07	5.14e-05	0.0035	0.16	0.12	White blood cell count;	chr12:123942189	chr12:123925461~123926083:-
BRCA	cis	rs7267979	1	rs2257808	ENSG00000277938.1	RP5-965G21.3	4.07	5.14e-05	0.0035	0.15	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25285814	chr20:25229150~25231933:+
BRCA	cis	rs7267979	1	rs2257809	ENSG00000277938.1	RP5-965G21.3	4.07	5.14e-05	0.0035	0.15	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25285840	chr20:25229150~25231933:+
BRCA	cis	rs7267979	0.932	rs449370	ENSG00000274973.1	RP13-401N8.7	4.07	5.14e-05	0.0035	0.14	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25470544	chr20:25845497~25845862:+
BRCA	cis	rs957448	1	rs72674855	ENSG00000254315.1	RP11-267M23.3	4.07	5.14e-05	0.0035	0.16	0.12	Nonsyndromic cleft lip with cleft palate;	chr8:94536706	chr8:94533628~94534391:+
BRCA	cis	rs875971	0.545	rs1267814	ENSG00000232559.3	GS1-124K5.12	-4.07	5.14e-05	0.0035	-0.17	-0.12	Aortic root size;	chr7:66579422	chr7:66554588~66576923:-
BRCA	cis	rs2777491	0.507	rs11854081	ENSG00000247556.5	OIP5-AS1	4.07	5.14e-05	0.00351	0.14	0.12	Ulcerative colitis;	chr15:41354200	chr15:41283990~41309737:+
BRCA	cis	rs17695224	0.5	rs4802876	ENSG00000269483.1	AC006272.1	4.07	5.15e-05	0.00351	0.15	0.12	HDL cholesterol;HDL cholesterol levels;	chr19:51831964	chr19:51839924~51843324:-
BRCA	cis	rs875971	0.895	rs4718349	ENSG00000236529.1	RP13-254B10.1	4.07	5.15e-05	0.00351	0.14	0.12	Aortic root size;	chr7:66444024	chr7:65840212~65840596:+
BRCA	cis	rs875971	1	rs2042133	ENSG00000236529.1	RP13-254B10.1	4.07	5.15e-05	0.00351	0.14	0.12	Aortic root size;	chr7:66466935	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.964	rs2161065	ENSG00000236529.1	RP13-254B10.1	4.07	5.15e-05	0.00351	0.14	0.12	Aortic root size;	chr7:66467918	chr7:65840212~65840596:+
BRCA	cis	rs875971	0.862	rs12698521	ENSG00000236529.1	RP13-254B10.1	4.07	5.15e-05	0.00351	0.14	0.12	Aortic root size;	chr7:66474502	chr7:65840212~65840596:+
BRCA	cis	rs2486012	1	rs17474535	ENSG00000237950.1	RP11-7O11.3	-4.07	5.15e-05	0.00351	-0.23	-0.12	Intelligence (multi-trait analysis);	chr1:43887412	chr1:43944370~43946551:-
BRCA	cis	rs34217772	0.64	rs1597050	ENSG00000258636.1	CTD-2298J14.2	4.07	5.15e-05	0.00351	0.16	0.12	Myopia;	chr14:41731692	chr14:41587861~41604856:-
BRCA	cis	rs61931739	0.571	rs4001689	ENSG00000258794.3	DUX4L27	4.07	5.15e-05	0.00351	0.18	0.12	Morning vs. evening chronotype;	chr12:34090336	chr12:34208415~34209675:-
BRCA	cis	rs73108077	1	rs73105971	ENSG00000277112.2	RP11-755J8.1	-4.07	5.15e-05	0.00351	-0.21	-0.12	Red blood cell density in sickle cell anemia;	chr20:31369934	chr20:30681825~30723932:-
BRCA	cis	rs7686660	1	rs66633688	ENSG00000250326.1	RP11-284M14.1	-4.07	5.15e-05	0.00351	-0.15	-0.12	Asthma;	chr4:143058486	chr4:142933195~143184861:-
BRCA	cis	rs3781913	0.874	rs12363065	ENSG00000202522.1	Y_RNA	4.07	5.15e-05	0.00351	0.11	0.12	Rheumatoid arthritis;	chr11:72659855	chr11:72766004~72766116:+
BRCA	cis	rs9307551	0.697	rs1992367	ENSG00000250334.4	LINC00989	-4.07	5.15e-05	0.00351	-0.2	-0.12	Refractive error;	chr4:79528495	chr4:79492416~79576460:+
BRCA	cis	rs2380205	0.875	rs4282898	ENSG00000232807.2	RP11-536K7.3	4.07	5.15e-05	0.00351	0.13	0.12	Breast cancer;	chr10:5857324	chr10:5934270~5945900:-
BRCA	cis	rs1153858	0.943	rs7402632	ENSG00000275672.1	GATM-AS1	-4.07	5.15e-05	0.00351	-0.17	-0.12	Homoarginine levels;	chr15:45409715	chr15:45378700~45380123:+
BRCA	cis	rs875971	0.862	rs6947339	ENSG00000273024.4	INTS4P2	-4.07	5.16e-05	0.00351	-0.14	-0.12	Aortic root size;	chr7:66423483	chr7:65647864~65715661:+
BRCA	cis	rs375066	0.901	rs368316	ENSG00000267191.1	RP11-15A1.2	-4.07	5.16e-05	0.00351	-0.16	-0.12	Breast cancer;	chr19:43927742	chr19:43902001~43926545:+
BRCA	cis	rs9437689	0.833	rs1146461	ENSG00000235501.4	RP4-639F20.1	-4.07	5.16e-05	0.00351	-0.16	-0.12	Phospholipid levels (plasma);	chr1:94942936	chr1:94927566~94963270:+
BRCA	cis	rs2486012	0.826	rs17533707	ENSG00000237950.1	RP11-7O11.3	-4.07	5.16e-05	0.00351	-0.23	-0.12	Intelligence (multi-trait analysis);	chr1:43895861	chr1:43944370~43946551:-
BRCA	cis	rs2692947	0.696	rs2576437	ENSG00000168992.4	OR7E102P	4.07	5.16e-05	0.00351	0.17	0.12	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96134678	chr2:95546531~95547545:+
BRCA	cis	rs3858526	0.92	rs11039548	ENSG00000224295.2	AC087380.14	4.07	5.16e-05	0.00351	0.18	0.12	DNA methylation (variation);	chr11:5909053	chr11:5518441~5524955:-
BRCA	cis	rs11742741	0.806	rs59100515	ENSG00000248874.4	C5orf17	-4.07	5.16e-05	0.00351	-0.16	-0.12	Educational attainment;	chr5:24055649	chr5:23951348~24178263:+
BRCA	cis	rs7819412	0.54	rs2409725	ENSG00000154316.13	TDH	4.07	5.16e-05	0.00352	0.17	0.12	Triglycerides;	chr8:11184152	chr8:11339637~11368452:+
BRCA	cis	rs11742741	0.837	rs11743115	ENSG00000248874.4	C5orf17	-4.07	5.16e-05	0.00352	-0.16	-0.12	Educational attainment;	chr5:24093238	chr5:23951348~24178263:+
BRCA	cis	rs7819412	0.645	rs10156356	ENSG00000154316.13	TDH	4.07	5.16e-05	0.00352	0.16	0.12	Triglycerides;	chr8:11188700	chr8:11339637~11368452:+
BRCA	cis	rs938554	0.513	rs10939650	ENSG00000250413.1	RP11-448G15.1	-4.07	5.16e-05	0.00352	-0.17	-0.12	Blood metabolite levels;	chr4:9996816	chr4:10006482~10009725:+
BRCA	cis	rs970548	0.954	rs11239549	ENSG00000237840.5	FAM21FP	4.07	5.16e-05	0.00352	0.16	0.12	Total cholesterol levels;HDL cholesterol;HDL cholesterol levels;Cholesterol, total;	chr10:45523383	chr10:45706431~45727231:-
BRCA	cis	rs7011507	0.589	rs11995181	ENSG00000233858.4	AC026904.1	-4.07	5.16e-05	0.00352	-0.15	-0.12	Inflammatory bowel disease;Ulcerative colitis;	chr8:48491731	chr8:48590401~48594621:+
BRCA	cis	rs7011507	0.589	rs115105539	ENSG00000233858.4	AC026904.1	-4.07	5.16e-05	0.00352	-0.15	-0.12	Inflammatory bowel disease;Ulcerative colitis;	chr8:48496936	chr8:48590401~48594621:+
BRCA	cis	rs7267979	1	rs2474777	ENSG00000276952.1	RP5-965G21.6	4.07	5.16e-05	0.00352	0.15	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25291997	chr20:25284915~25285588:-
BRCA	cis	rs10129255	0.518	rs7143784	ENSG00000232216.1	IGHV3-43	4.06	5.17e-05	0.00352	0.09	0.12	Kawasaki disease;	chr14:106687277	chr14:106470264~106470800:-
BRCA	cis	rs2625529	0.775	rs4777489	ENSG00000260037.4	CTD-2524L6.3	4.06	5.17e-05	0.00352	0.18	0.12	Red blood cell count;	chr15:72138093	chr15:71818396~71823384:+
BRCA	cis	rs6452524	0.534	rs10061690	ENSG00000281327.1	LINC01338	4.06	5.17e-05	0.00352	0.15	0.12	Hypertension (SNP x SNP interaction);	chr5:83063226	chr5:82850864~82859836:-
BRCA	cis	rs6545883	0.895	rs2421192	ENSG00000212978.6	AC016747.3	-4.06	5.17e-05	0.00352	-0.17	-0.12	Tuberculosis;	chr2:61416496	chr2:61141592~61144969:-
BRCA	cis	rs801193	0.761	rs2659888	ENSG00000265600.1	AC006480.1	-4.06	5.17e-05	0.00352	-0.15	-0.12	Aortic root size;	chr7:66765184	chr7:67356680~67356779:+
BRCA	cis	rs957448	1	rs957448	ENSG00000254315.1	RP11-267M23.3	4.06	5.17e-05	0.00352	0.16	0.12	Nonsyndromic cleft lip with cleft palate;	chr8:94529074	chr8:94533628~94534391:+
BRCA	cis	rs801193	1	rs2659909	ENSG00000223473.2	GS1-124K5.3	4.06	5.17e-05	0.00352	0.09	0.12	Aortic root size;	chr7:66695292	chr7:66491049~66493566:-
BRCA	cis	rs490049	1	rs490049	ENSG00000236581.7	STARD13-AS	4.06	5.17e-05	0.00352	0.28	0.12	Diabetic kidney disease;	chr13:32990725	chr13:33180401~33281584:+
BRCA	cis	rs1167832	0.645	rs1167828	ENSG00000127957.15	PMS2P3	-4.06	5.17e-05	0.00352	-0.16	-0.12	Ankle injury;	chr7:75534076	chr7:75502930~75528148:-
BRCA	cis	rs11673344	0.563	rs4805199	ENSG00000276846.1	CTD-3220F14.3	4.06	5.17e-05	0.00352	0.15	0.12	Obesity-related traits;	chr19:37115527	chr19:37314868~37315620:-
BRCA	cis	rs875971	0.545	rs6460298	ENSG00000273142.1	RP11-458F8.4	4.06	5.17e-05	0.00352	0.12	0.12	Aortic root size;	chr7:66442783	chr7:66902857~66906297:+
BRCA	cis	rs2255336	0.938	rs12315123	ENSG00000245648.1	RP11-277P12.20	-4.06	5.17e-05	0.00352	-0.2	-0.12	Blood protein levels;	chr12:10481540	chr12:10363769~10398506:+
BRCA	cis	rs2243480	1	rs1546059	ENSG00000237026.1	RP11-328P23.2	-4.06	5.17e-05	0.00352	-0.23	-0.12	Diabetic kidney disease;	chr7:66189722	chr7:65235790~65236723:-
BRCA	cis	rs2243480	1	rs2420170	ENSG00000237026.1	RP11-328P23.2	-4.06	5.17e-05	0.00352	-0.23	-0.12	Diabetic kidney disease;	chr7:66191066	chr7:65235790~65236723:-
BRCA	cis	rs8130944	1	rs2269151	ENSG00000225731.1	AP001627.1	4.06	5.17e-05	0.00352	0.14	0.12	Perceived unattractiveness to mosquitoes;	chr21:42721370	chr21:42733594~42741758:-
BRCA	cis	rs10844706	0.699	rs10844636	ENSG00000256673.1	RP11-599J14.2	4.06	5.17e-05	0.00352	0.15	0.12	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9735420	chr12:9398355~9414851:-
BRCA	cis	rs2574985	1	rs2574985	ENSG00000231345.3	BEND3P1	-4.06	5.17e-05	0.00352	-0.21	-0.12	Subjective well-being;	chr10:50369726	chr10:50655967~50660472:+
BRCA	cis	rs930395	0.514	rs4129642	ENSG00000251141.4	RP11-53O19.1	-4.06	5.17e-05	0.00352	-0.12	-0.12	Breast cancer;	chr5:44898027	chr5:44744900~44808777:-
BRCA	cis	rs853679	0.517	rs35193936	ENSG00000216901.1	AL022393.7	4.06	5.18e-05	0.00352	0.18	0.12	Depression;	chr6:28108492	chr6:28176188~28176674:+
BRCA	cis	rs875971	0.545	rs3735147	ENSG00000232546.1	RP11-458F8.1	4.06	5.18e-05	0.00352	0.12	0.12	Aortic root size;	chr7:66505541	chr7:66848496~66858136:+
BRCA	cis	rs7771547	0.603	rs9296193	ENSG00000224666.3	RP1-50J22.4	-4.06	5.18e-05	0.00352	-0.16	-0.12	Platelet distribution width;	chr6:36633679	chr6:36386831~36393462:+
BRCA	cis	rs2832077	0.943	rs2832100	ENSG00000232855.5	AF131217.1	4.06	5.18e-05	0.00352	0.19	0.12	Cognitive test performance;	chr21:28803305	chr21:28439346~28674848:-
BRCA	cis	rs6545883	0.894	rs2600672	ENSG00000212978.6	AC016747.3	4.06	5.18e-05	0.00352	0.17	0.12	Tuberculosis;	chr2:61309605	chr2:61141592~61144969:-
BRCA	cis	rs1065852	0.526	rs8138080	ENSG00000205702.9	CYP2D7	-4.06	5.18e-05	0.00353	-0.12	-0.12	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42000367	chr22:42140203~42144577:-
BRCA	cis	rs4218	0.689	rs34338282	ENSG00000259732.1	RP11-59H7.3	-4.06	5.18e-05	0.00353	-0.16	-0.12	Social communication problems;	chr15:59096897	chr15:59121034~59133250:+
BRCA	cis	rs564309	1	rs474600	ENSG00000183929.7	DUSP5P1	4.06	5.18e-05	0.00353	0.22	0.12	Hip circumference (psychosocial stress interaction);	chr1:228398136	chr1:228650241~228651379:+
BRCA	cis	rs1910358	0.554	rs4701389	ENSG00000248874.4	C5orf17	-4.06	5.18e-05	0.00353	-0.18	-0.12	Venous thromboembolism (SNP x SNP interaction);	chr5:23742287	chr5:23951348~24178263:+
BRCA	cis	rs2408955	0.522	rs7139330	ENSG00000257735.1	RP11-370I10.6	-4.06	5.18e-05	0.00353	-0.15	-0.12	Glycated hemoglobin levels;	chr12:48089701	chr12:48350945~48442411:+
BRCA	cis	rs9784649	1	rs55924805	ENSG00000245662.2	RP11-184E9.1	4.06	5.18e-05	0.00353	0.2	0.12	Peripheral arterial disease (traffic-related air pollution interaction);	chr5:24999647	chr5:25190682~25306172:+
BRCA	cis	rs17772222	0.917	rs12434935	ENSG00000258789.1	RP11-507K2.3	-4.06	5.18e-05	0.00353	-0.15	-0.12	Coronary artery calcification;	chr14:88645449	chr14:88551597~88552493:+
BRCA	cis	rs6893300	1	rs62406177	ENSG00000250999.1	RP11-1379J22.5	4.06	5.18e-05	0.00353	0.18	0.12	Resting heart rate;	chr5:179737208	chr5:179657762~179664432:+
BRCA	cis	rs875971	1	rs6460296	ENSG00000265600.1	AC006480.1	-4.06	5.18e-05	0.00353	-0.15	-0.12	Aortic root size;	chr7:66430152	chr7:67356680~67356779:+
BRCA	cis	rs12612435	0.83	rs11891276	ENSG00000226806.1	AC011893.3	4.06	5.18e-05	0.00353	0.15	0.12	Takotsubo syndrome;	chr2:136364967	chr2:135820191~135823087:+
BRCA	cis	rs12612435	0.83	rs11895020	ENSG00000226806.1	AC011893.3	4.06	5.18e-05	0.00353	0.15	0.12	Takotsubo syndrome;	chr2:136364982	chr2:135820191~135823087:+
BRCA	cis	rs1005277	0.579	rs2472181	ENSG00000272983.1	RP11-508N22.12	4.06	5.18e-05	0.00353	0.13	0.12	Extrinsic epigenetic age acceleration;	chr10:38097836	chr10:38137337~38144399:+
BRCA	cis	rs1005277	0.579	rs2474574	ENSG00000272983.1	RP11-508N22.12	4.06	5.18e-05	0.00353	0.13	0.12	Extrinsic epigenetic age acceleration;	chr10:38098367	chr10:38137337~38144399:+
BRCA	cis	rs1005277	0.579	rs2504140	ENSG00000272983.1	RP11-508N22.12	4.06	5.18e-05	0.00353	0.13	0.12	Extrinsic epigenetic age acceleration;	chr10:38098651	chr10:38137337~38144399:+
BRCA	cis	rs1005277	0.579	rs2472182	ENSG00000272983.1	RP11-508N22.12	4.06	5.18e-05	0.00353	0.13	0.12	Extrinsic epigenetic age acceleration;	chr10:38099937	chr10:38137337~38144399:+
BRCA	cis	rs1005277	0.579	rs2021649	ENSG00000272983.1	RP11-508N22.12	4.06	5.18e-05	0.00353	0.13	0.12	Extrinsic epigenetic age acceleration;	chr10:38103194	chr10:38137337~38144399:+
BRCA	cis	rs1005277	0.579	rs2505197	ENSG00000272983.1	RP11-508N22.12	4.06	5.18e-05	0.00353	0.13	0.12	Extrinsic epigenetic age acceleration;	chr10:38104382	chr10:38137337~38144399:+
BRCA	cis	rs1005277	0.579	rs2505196	ENSG00000272983.1	RP11-508N22.12	4.06	5.18e-05	0.00353	0.13	0.12	Extrinsic epigenetic age acceleration;	chr10:38104635	chr10:38137337~38144399:+
BRCA	cis	rs2898290	0.592	rs2736342	ENSG00000255495.1	AC145124.2	-4.06	5.18e-05	0.00353	-0.14	-0.12	Systolic blood pressure;	chr8:11489780	chr8:12194467~12196280:+
BRCA	cis	rs7131987	0.903	rs7308125	ENSG00000273680.1	RP11-996F15.6	4.06	5.19e-05	0.00353	0.16	0.12	QT interval;	chr12:29272278	chr12:29332733~29333383:-
BRCA	cis	rs875971	0.545	rs6969224	ENSG00000232546.1	RP11-458F8.1	4.06	5.19e-05	0.00353	0.12	0.12	Aortic root size;	chr7:66370011	chr7:66848496~66858136:+
BRCA	cis	rs9733	0.596	rs56058687	ENSG00000231073.1	RP11-316M1.3	4.06	5.19e-05	0.00353	0.13	0.12	Tonsillectomy;	chr1:150662590	chr1:150973123~150975534:+
BRCA	cis	rs2692947	0.637	rs1168967	ENSG00000168992.4	OR7E102P	4.06	5.19e-05	0.00353	0.17	0.12	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96160278	chr2:95546531~95547545:+
BRCA	cis	rs10266483	0.739	rs2692104	ENSG00000228653.2	HNRNPCP7	-4.06	5.19e-05	0.00353	-0.15	-0.12	Response to statin therapy;	chr7:64300577	chr7:64500825~64501729:+
BRCA	cis	rs6802315	0.604	rs9861938	ENSG00000272440.1	RP11-379F4.6	4.06	5.19e-05	0.00353	0.15	0.12	Periodontitis (CDC/AAP);	chr3:158745257	chr3:158695367~158695581:+
BRCA	cis	rs4869313	0.905	rs10058476	ENSG00000248734.2	CTD-2260A17.1	4.06	5.19e-05	0.00353	0.13	0.12	Pediatric autoimmune diseases;	chr5:96961823	chr5:96784777~96785999:+
BRCA	cis	rs4478858	0.839	rs10798834	ENSG00000229447.2	RP11-490K7.4	-4.06	5.19e-05	0.00353	-0.12	-0.12	Alcohol dependence;	chr1:31236130	chr1:31263245~31263681:-
BRCA	cis	rs465969	1	rs17510733	ENSG00000230177.1	RP5-1112D6.4	4.06	5.19e-05	0.00353	0.29	0.12	Psoriasis;	chr6:111389715	chr6:111277932~111278742:+
BRCA	cis	rs8177876	0.642	rs4454990	ENSG00000261061.1	RP11-303E16.2	4.06	5.19e-05	0.00353	0.16	0.12	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81106550	chr16:81030770~81031485:+
BRCA	cis	rs4713118	0.516	rs7739216	ENSG00000261839.1	RP1-265C24.8	4.06	5.19e-05	0.00353	0.17	0.12	Parkinson's disease;	chr6:28112168	chr6:28136849~28139678:+
BRCA	cis	rs853679	0.517	rs35512245	ENSG00000261839.1	RP1-265C24.8	4.06	5.19e-05	0.00353	0.17	0.12	Depression;	chr6:28112175	chr6:28136849~28139678:+
BRCA	cis	rs1077514	0.515	rs1767141	ENSG00000271420.1	RP5-1057J7.7	-4.06	5.19e-05	0.00353	-0.18	-0.12	Cholesterol, total;	chr1:23407857	chr1:23378380~23379029:-
BRCA	cis	rs17406451	0.819	rs12465064	ENSG00000234936.1	AC010883.5	4.06	5.19e-05	0.00353	0.12	0.12	Mitochondrial DNA levels;	chr2:43419000	chr2:43229573~43233394:+
BRCA	cis	rs11742741	0.806	rs60920330	ENSG00000248874.4	C5orf17	-4.06	5.19e-05	0.00353	-0.16	-0.12	Educational attainment;	chr5:24047350	chr5:23951348~24178263:+
BRCA	cis	rs9665626	1	rs9665626	ENSG00000213277.3	MARCKSL1P1	-4.06	5.19e-05	0.00353	-0.21	-0.12	Schizophrenia;	chr10:102540881	chr10:103175554~103176094:+
BRCA	cis	rs9402743	0.634	rs9483853	ENSG00000234084.1	RP3-388E23.2	-4.06	5.19e-05	0.00353	-0.12	-0.12	Systemic lupus erythematosus;	chr6:135595767	chr6:135301568~135307158:+
BRCA	cis	rs9402743	0.634	rs4394233	ENSG00000234084.1	RP3-388E23.2	-4.06	5.19e-05	0.00353	-0.12	-0.12	Systemic lupus erythematosus;	chr6:135596752	chr6:135301568~135307158:+
BRCA	cis	rs11168618	0.74	rs10875826	ENSG00000240399.1	RP1-228P16.1	4.06	5.19e-05	0.00353	0.13	0.12	Adiponectin levels;	chr12:48527377	chr12:48054813~48055591:-
BRCA	cis	rs10895275	0.886	rs11605954	ENSG00000277459.1	RP11-732A21.3	4.06	5.19e-05	0.00353	0.13	0.12	Migraine;	chr11:102178490	chr11:102109827~102110457:-
BRCA	cis	rs4415084	0.716	rs7708213	ENSG00000251141.4	RP11-53O19.1	-4.06	5.19e-05	0.00354	-0.12	-0.12	Breast cancer;	chr5:44848299	chr5:44744900~44808777:-
BRCA	cis	rs1348850	0.872	rs12991272	ENSG00000280374.1	RP11-337N6.3	4.06	5.2e-05	0.00354	0.17	0.12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177592611	chr2:177317715~177318471:-
BRCA	cis	rs12467847	0.931	rs2708931	ENSG00000231747.1	AC079922.2	4.06	5.2e-05	0.00354	0.12	0.12	Response to amphetamines;	chr2:112936301	chr2:112621809~112622167:-
BRCA	cis	rs2486012	1	rs61770286	ENSG00000237950.1	RP11-7O11.3	-4.06	5.2e-05	0.00354	-0.23	-0.12	Intelligence (multi-trait analysis);	chr1:43890937	chr1:43944370~43946551:-
BRCA	cis	rs7283707	0.581	rs373173	ENSG00000270071.1	AP001172.2	4.06	5.2e-05	0.00354	0.16	0.12	QRS complex (12-leadsum);	chr21:15924059	chr21:16291791~16308133:-
BRCA	cis	rs1371614	0.632	rs6718978	ENSG00000272148.1	RP11-195B17.1	4.06	5.2e-05	0.00354	0.14	0.12	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26938723	chr2:27062428~27062907:-
BRCA	cis	rs6545883	0.86	rs6749226	ENSG00000273302.1	RP11-493E12.2	-4.06	5.2e-05	0.00354	-0.12	-0.12	Tuberculosis;	chr2:61282648	chr2:61199979~61200769:+
BRCA	cis	rs409045	1	rs437465	ENSG00000271874.1	CTD-2024P10.2	-4.06	5.2e-05	0.00354	-0.16	-0.12	Left ventricular mass;	chr5:34638763	chr5:34651457~34651888:-
BRCA	cis	rs11098499	0.754	rs12506610	ENSG00000260091.1	RP11-33B1.4	-4.06	5.2e-05	0.00354	-0.11	-0.12	Corneal astigmatism;	chr4:119320504	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.743	rs10003567	ENSG00000260091.1	RP11-33B1.4	-4.06	5.2e-05	0.00354	-0.11	-0.12	Corneal astigmatism;	chr4:119320519	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.754	rs10006259	ENSG00000260091.1	RP11-33B1.4	-4.06	5.2e-05	0.00354	-0.11	-0.12	Corneal astigmatism;	chr4:119320990	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.754	rs28652763	ENSG00000260091.1	RP11-33B1.4	-4.06	5.2e-05	0.00354	-0.11	-0.12	Corneal astigmatism;	chr4:119321157	chr4:119409333~119410233:+
BRCA	cis	rs38055	0.801	rs629725	ENSG00000247796.2	CTD-2366F13.1	-4.06	5.2e-05	0.00354	-0.15	-0.12	Acne (severe);	chr5:53335237	chr5:53109842~53115126:+
BRCA	cis	rs7847628	0.587	rs12684934	ENSG00000238181.2	AHCYP2	-4.06	5.2e-05	0.00354	-0.16	-0.12	Birth weight;	chr9:120830881	chr9:120720673~120721972:+
BRCA	cis	rs801193	0.935	rs3800820	ENSG00000229180.5	GS1-124K5.11	-4.06	5.2e-05	0.00354	-0.11	-0.12	Aortic root size;	chr7:66682191	chr7:66526088~66542624:-
BRCA	cis	rs495337	0.76	rs6125813	ENSG00000229222.1	KRT18P4	-4.06	5.2e-05	0.00354	-0.15	-0.12	Psoriasis;	chr20:49924646	chr20:49956745~49958032:+
BRCA	cis	rs2018683	0.649	rs12536605	ENSG00000233517.1	AC005162.5	-4.06	5.2e-05	0.00354	-0.15	-0.12	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28930883	chr7:28987028~28988899:+
BRCA	cis	rs13230714	1	rs13230714	ENSG00000170356.8	OR2A20P	4.06	5.2e-05	0.00354	0.18	0.12	Breast cancer;	chr7:144477198	chr7:144250045~144252957:-
BRCA	cis	rs12324805	0.532	rs6495638	ENSG00000255769.6	GOLGA2P10	-4.06	5.2e-05	0.00354	-0.15	-0.12	Body mass index;	chr15:82030912	chr15:82472993~82513950:-
BRCA	cis	rs6893300	0.785	rs58386410	ENSG00000250999.1	RP11-1379J22.5	4.06	5.2e-05	0.00354	0.17	0.12	Resting heart rate;	chr5:179778703	chr5:179657762~179664432:+
BRCA	cis	rs6893300	0.785	rs17617710	ENSG00000250999.1	RP11-1379J22.5	4.06	5.2e-05	0.00354	0.17	0.12	Resting heart rate;	chr5:179779106	chr5:179657762~179664432:+
BRCA	cis	rs6545883	0.826	rs2694651	ENSG00000273302.1	RP11-493E12.2	-4.06	5.2e-05	0.00354	-0.12	-0.12	Tuberculosis;	chr2:61361507	chr2:61199979~61200769:+
BRCA	cis	rs11168351	0.927	rs7971880	ENSG00000273765.1	RP11-370I10.11	4.06	5.2e-05	0.00354	0.15	0.12	Bipolar disorder and schizophrenia;	chr12:47997272	chr12:48360920~48361377:+
BRCA	cis	rs17123764	0.892	rs9805063	ENSG00000257464.1	RP11-161H23.8	-4.06	5.2e-05	0.00354	-0.22	-0.12	Intelligence (multi-trait analysis);	chr12:49747381	chr12:49442424~49442652:-
BRCA	cis	rs17123764	0.892	rs1012874	ENSG00000257464.1	RP11-161H23.8	-4.06	5.2e-05	0.00354	-0.22	-0.12	Intelligence (multi-trait analysis);	chr12:49753167	chr12:49442424~49442652:-
BRCA	cis	rs9925964	0.748	rs4889603	ENSG00000260911.2	RP11-196G11.2	4.06	5.2e-05	0.00354	0.12	0.12	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:30970904	chr16:31043150~31049868:+
BRCA	cis	rs7829975	0.623	rs10092965	ENSG00000253981.4	ALG1L13P	4.06	5.21e-05	0.00354	0.14	0.12	Mood instability;	chr8:8515975	chr8:8236003~8244667:-
BRCA	cis	rs11098499	0.818	rs55825515	ENSG00000260091.1	RP11-33B1.4	-4.06	5.21e-05	0.00354	-0.11	-0.12	Corneal astigmatism;	chr4:119565247	chr4:119409333~119410233:+
BRCA	cis	rs7940866	1	rs7940866	ENSG00000255455.2	RP11-890B15.3	4.06	5.21e-05	0.00354	0.13	0.12	Schizophrenia;	chr11:130947684	chr11:130866254~130870247:-
BRCA	cis	rs2274273	0.712	rs17832311	ENSG00000233924.1	AL160471.6	-4.06	5.21e-05	0.00354	-0.14	-0.12	Protein biomarker;	chr14:55067748	chr14:55004813~55005687:-
BRCA	cis	rs875971	0.545	rs2279757	ENSG00000232546.1	RP11-458F8.1	4.06	5.21e-05	0.00354	0.12	0.12	Aortic root size;	chr7:66363676	chr7:66848496~66858136:+
BRCA	cis	rs875971	0.545	rs11766183	ENSG00000232546.1	RP11-458F8.1	4.06	5.21e-05	0.00354	0.12	0.12	Aortic root size;	chr7:66374173	chr7:66848496~66858136:+
BRCA	cis	rs875971	0.545	rs1065265	ENSG00000232546.1	RP11-458F8.1	4.06	5.21e-05	0.00354	0.12	0.12	Aortic root size;	chr7:66376216	chr7:66848496~66858136:+
BRCA	cis	rs256438	0.524	rs256445	ENSG00000251050.1	RP11-168A11.4	-4.06	5.21e-05	0.00354	-0.13	-0.12	Serum thyroid-stimulating hormone levels;	chr5:80044942	chr5:80019609~80019920:+
BRCA	cis	rs1005277	0.541	rs2505193	ENSG00000272983.1	RP11-508N22.12	4.06	5.21e-05	0.00354	0.13	0.12	Extrinsic epigenetic age acceleration;	chr10:38105710	chr10:38137337~38144399:+
BRCA	cis	rs10829156	0.538	rs61840846	ENSG00000225527.1	RP11-383B4.4	-4.06	5.21e-05	0.00354	-0.18	-0.12	Sudden cardiac arrest;	chr10:18606393	chr10:18531849~18533336:-
BRCA	cis	rs6918586	1	rs198806	ENSG00000272810.1	U91328.22	-4.06	5.21e-05	0.00354	-0.14	-0.12	Schizophrenia;	chr6:26133388	chr6:26013241~26013757:+
BRCA	cis	rs11098499	0.863	rs11098531	ENSG00000260091.1	RP11-33B1.4	-4.06	5.21e-05	0.00354	-0.11	-0.12	Corneal astigmatism;	chr4:119543846	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.863	rs28718422	ENSG00000260091.1	RP11-33B1.4	-4.06	5.21e-05	0.00354	-0.11	-0.12	Corneal astigmatism;	chr4:119545149	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.818	rs12498599	ENSG00000260091.1	RP11-33B1.4	-4.06	5.21e-05	0.00354	-0.11	-0.12	Corneal astigmatism;	chr4:119547348	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.863	rs10009626	ENSG00000260091.1	RP11-33B1.4	-4.06	5.21e-05	0.00354	-0.11	-0.12	Corneal astigmatism;	chr4:119548850	chr4:119409333~119410233:+
BRCA	cis	rs9990333	0.562	rs12632706	ENSG00000207650.1	MIR570	4.06	5.21e-05	0.00354	0.15	0.12	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196088723	chr3:195699401~195699497:+
BRCA	cis	rs9840812	0.773	rs61789601	ENSG00000239213.4	NCK1-AS1	-4.06	5.21e-05	0.00354	-0.18	-0.12	Fibrinogen levels;	chr3:136236137	chr3:136841726~136862054:-
BRCA	cis	rs4478858	0.735	rs4949393	ENSG00000260386.4	LINC01225	-4.06	5.21e-05	0.00354	-0.15	-0.12	Alcohol dependence;	chr1:31379028	chr1:31500085~31540885:+
BRCA	cis	rs4478858	0.735	rs4494186	ENSG00000223907.1	LINC01226	4.06	5.21e-05	0.00355	0.15	0.12	Alcohol dependence;	chr1:31385000	chr1:31518435~31524245:+
BRCA	cis	rs7487075	1	rs12814341	ENSG00000274723.1	RP11-618L22.1	4.06	5.21e-05	0.00355	0.15	0.12	Itch intensity from mosquito bite;	chr12:46429489	chr12:46970504~46972155:+
BRCA	cis	rs4948275	0.631	rs2606111	ENSG00000237233.2	TMEM26-AS1	-4.06	5.21e-05	0.00355	-0.15	-0.12	Night sleep phenotypes;	chr10:61588695	chr10:61452639~61481956:+
BRCA	cis	rs12073837	0.5	rs11118610	ENSG00000257551.1	HLX-AS1	-4.06	5.21e-05	0.00355	-0.13	-0.12	F-cell distribution;	chr1:220816744	chr1:220832763~220880140:-
BRCA	cis	rs757081	0.648	rs10766382	ENSG00000272034.1	SNORD14A	-4.06	5.22e-05	0.00355	-0.13	-0.12	Systolic blood pressure;	chr11:17252894	chr11:17074654~17074744:-
BRCA	cis	rs757081	0.547	rs11024220	ENSG00000272034.1	SNORD14A	-4.06	5.22e-05	0.00355	-0.13	-0.12	Systolic blood pressure;	chr11:17252987	chr11:17074654~17074744:-
BRCA	cis	rs757081	0.579	rs11024221	ENSG00000272034.1	SNORD14A	-4.06	5.22e-05	0.00355	-0.13	-0.12	Systolic blood pressure;	chr11:17253003	chr11:17074654~17074744:-
BRCA	cis	rs13113518	1	rs7691799	ENSG00000272969.1	RP11-528I4.2	4.06	5.22e-05	0.00355	0.14	0.12	Height;	chr4:55545574	chr4:55547112~55547889:+
BRCA	cis	rs4671400	0.543	rs62152274	ENSG00000273302.1	RP11-493E12.2	-4.06	5.22e-05	0.00355	-0.14	-0.12	3-hydroxypropylmercapturic acid levels in smokers;	chr2:61272453	chr2:61199979~61200769:+
BRCA	cis	rs6496932	0.802	rs8038403	ENSG00000218052.5	ADAMTS7P4	4.06	5.22e-05	0.00355	0.13	0.12	Central corneal thickness;Corneal structure;	chr15:85313364	chr15:85255369~85330334:-
BRCA	cis	rs55863869	1	rs12465449	ENSG00000271401.1	RP11-171I2.3	-4.06	5.22e-05	0.00355	-0.24	-0.12	QT interval;	chr2:178817087	chr2:178644717~178645179:+
BRCA	cis	rs1048886	0.872	rs9294872	ENSG00000271967.1	RP11-134K13.4	-4.06	5.22e-05	0.00355	-0.17	-0.12	Type 2 diabetes;	chr6:70463567	chr6:70596438~70596980:+
BRCA	cis	rs17027633	1	rs3767604	ENSG00000234020.1	CHIAP3	4.06	5.22e-05	0.00355	0.29	0.12	Cerebrospinal fluid t-tau:AB1-42 ratio;	chr1:111424855	chr1:111353275~111367409:-
BRCA	cis	rs8040855	0.627	rs11630697	ENSG00000259774.1	RP11-182J1.13	4.06	5.22e-05	0.00355	0.17	0.12	Bulimia nervosa;	chr15:85063214	chr15:84422618~84425882:+
BRCA	cis	rs8030379	1	rs1480823	ENSG00000176700.18	SCAND2P	-4.06	5.22e-05	0.00355	-0.11	-0.12	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83916994	chr15:84631451~84647478:+
BRCA	cis	rs6545883	0.894	rs6734628	ENSG00000273302.1	RP11-493E12.2	-4.06	5.22e-05	0.00355	-0.12	-0.12	Tuberculosis;	chr2:61224125	chr2:61199979~61200769:+
BRCA	cis	rs72819225	0.616	rs4933668	ENSG00000228701.1	TNKS2-AS1	4.06	5.22e-05	0.00355	0.17	0.12	Yeast infection;	chr10:91569525	chr10:91782839~91798291:-
BRCA	cis	rs4869313	0.905	rs38039	ENSG00000248734.2	CTD-2260A17.1	-4.06	5.22e-05	0.00355	-0.13	-0.12	Pediatric autoimmune diseases;	chr5:96991585	chr5:96784777~96785999:+
BRCA	cis	rs4834272	0.58	rs9884682	ENSG00000249509.1	RP11-402J6.1	4.06	5.22e-05	0.00355	0.14	0.12	Body mass index;	chr4:112381483	chr4:112515385~112546881:+
BRCA	cis	rs11892454	0.674	rs6706535	ENSG00000217643.1	PTGES3P2	-4.06	5.22e-05	0.00355	-0.14	-0.12	Heschl's gyrus morphology;	chr2:25721802	chr2:25822469~25822950:+
BRCA	cis	rs6723226	0.803	rs387780	ENSG00000276517.1	AL133243.2	-4.06	5.22e-05	0.00355	-0.16	-0.12	Intelligence (multi-trait analysis);	chr2:32277426	chr2:32526504~32529507:+
BRCA	cis	rs853679	0.517	rs9393895	ENSG00000216901.1	AL022393.7	4.06	5.22e-05	0.00355	0.18	0.12	Depression;	chr6:28159843	chr6:28176188~28176674:+
BRCA	cis	rs801193	0.636	rs2659895	ENSG00000229180.5	GS1-124K5.11	4.06	5.22e-05	0.00355	0.11	0.12	Aortic root size;	chr7:66731484	chr7:66526088~66542624:-
BRCA	cis	rs6088590	0.561	rs6087600	ENSG00000275784.1	RP5-1125A11.6	-4.06	5.23e-05	0.00355	-0.14	-0.12	Coronary artery disease;	chr20:34569413	chr20:33989480~33991818:-
BRCA	cis	rs12900463	0.752	rs12904777	ENSG00000225151.9	GOLGA2P7	-4.06	5.23e-05	0.00355	-0.15	-0.12	Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine);	chr15:84872514	chr15:84199311~84230136:-
BRCA	cis	rs7771547	0.574	rs9394361	ENSG00000224666.3	RP1-50J22.4	4.06	5.23e-05	0.00356	0.16	0.12	Platelet distribution width;	chr6:36583593	chr6:36386831~36393462:+
BRCA	cis	rs875971	1	rs4717292	ENSG00000236529.1	RP13-254B10.1	4.06	5.23e-05	0.00356	0.14	0.12	Aortic root size;	chr7:66430611	chr7:65840212~65840596:+
BRCA	cis	rs875971	1	rs35149210	ENSG00000236529.1	RP13-254B10.1	4.06	5.23e-05	0.00356	0.14	0.12	Aortic root size;	chr7:66464938	chr7:65840212~65840596:+
BRCA	cis	rs4272720	0.855	rs11816318	ENSG00000228754.1	RP11-534L6.3	-4.06	5.23e-05	0.00356	-0.18	-0.12	Platelet count;Plateletcrit;	chr10:49028323	chr10:48745545~48746128:-
BRCA	cis	rs12586478	0.519	rs4904314	ENSG00000205562.2	RP11-497E19.1	4.06	5.23e-05	0.00356	0.12	0.12	Post bronchodilator FEV1;	chr14:86329430	chr14:85524432~85529988:-
BRCA	cis	rs763121	0.853	rs6519120	ENSG00000225450.1	RP3-508I15.14	4.06	5.23e-05	0.00356	0.13	0.12	Menopause (age at onset);	chr22:38595388	chr22:38739003~38749041:+
BRCA	cis	rs7824557	0.701	rs4568582	ENSG00000248896.2	CTD-2135J3.3	4.06	5.23e-05	0.00356	0.17	0.12	Retinal vascular caliber;	chr8:11302986	chr8:10729314~10771392:+
BRCA	cis	rs7107174	0.901	rs10899500	ENSG00000251323.2	RP11-452H21.4	4.06	5.23e-05	0.00356	0.17	0.12	Testicular germ cell tumor;	chr11:78414200	chr11:78423982~78429836:-
BRCA	cis	rs62246343	0.605	rs34665459	ENSG00000214041.4	PGAM1P4	4.06	5.23e-05	0.00356	0.16	0.12	Fibrinogen levels;	chr3:9423041	chr3:9348443~9349192:+
BRCA	cis	rs875971	0.895	rs4718349	ENSG00000265600.1	AC006480.1	-4.06	5.23e-05	0.00356	-0.15	-0.12	Aortic root size;	chr7:66444024	chr7:67356680~67356779:+
BRCA	cis	rs875971	1	rs2042133	ENSG00000265600.1	AC006480.1	-4.06	5.23e-05	0.00356	-0.15	-0.12	Aortic root size;	chr7:66466935	chr7:67356680~67356779:+
BRCA	cis	rs875971	0.964	rs2161065	ENSG00000265600.1	AC006480.1	-4.06	5.23e-05	0.00356	-0.15	-0.12	Aortic root size;	chr7:66467918	chr7:67356680~67356779:+
BRCA	cis	rs875971	0.862	rs12698521	ENSG00000265600.1	AC006480.1	-4.06	5.23e-05	0.00356	-0.15	-0.12	Aortic root size;	chr7:66474502	chr7:67356680~67356779:+
BRCA	cis	rs7671266	0.532	rs4608811	ENSG00000250413.1	RP11-448G15.1	-4.06	5.23e-05	0.00356	-0.2	-0.12	Cardiovascular disease risk factors;	chr4:10048051	chr4:10006482~10009725:+
BRCA	cis	rs10043228	1	rs10062350	ENSG00000271918.1	CTD-2287O16.5	-4.06	5.24e-05	0.00356	-0.17	-0.12	Asthma or chronic obstructive pulmonary disease;	chr5:116117800	chr5:116083807~116085416:-
BRCA	cis	rs2243480	0.803	rs423187	ENSG00000237026.1	RP11-328P23.2	4.06	5.24e-05	0.00356	0.24	0.12	Diabetic kidney disease;	chr7:66044512	chr7:65235790~65236723:-
BRCA	cis	rs62103177	0.564	rs7228971	ENSG00000267270.4	PARD6G-AS1	-4.06	5.24e-05	0.00356	-0.21	-0.12	Opioid sensitivity;	chr18:79978025	chr18:80147924~80178432:+
BRCA	cis	rs875971	0.825	rs6951503	ENSG00000273024.4	INTS4P2	4.06	5.24e-05	0.00356	0.14	0.12	Aortic root size;	chr7:66253949	chr7:65647864~65715661:+
BRCA	cis	rs2274273	0.712	rs7144652	ENSG00000233924.1	AL160471.6	-4.06	5.24e-05	0.00356	-0.14	-0.12	Protein biomarker;	chr14:55071000	chr14:55004813~55005687:-
BRCA	cis	rs11098499	0.754	rs10212714	ENSG00000225892.3	RP11-384K6.2	4.06	5.24e-05	0.00356	0.12	0.12	Corneal astigmatism;	chr4:119333147	chr4:118632274~118634759:+
BRCA	cis	rs35740288	0.787	rs11637768	ENSG00000202081.1	RNU6-1280P	4.06	5.24e-05	0.00356	0.17	0.12	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85680179	chr15:85651522~85651628:-
BRCA	cis	rs11098499	0.754	rs1546503	ENSG00000260091.1	RP11-33B1.4	-4.06	5.24e-05	0.00356	-0.11	-0.12	Corneal astigmatism;	chr4:119320012	chr4:119409333~119410233:+
BRCA	cis	rs7267979	1	rs3002702	ENSG00000274973.1	RP13-401N8.7	-4.06	5.25e-05	0.00357	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25288284	chr20:25845497~25845862:+
BRCA	cis	rs9470794	1	rs73421439	ENSG00000204110.6	RP1-153P14.8	-4.06	5.25e-05	0.00357	-0.23	-0.12	Type 2 diabetes;	chr6:37970495	chr6:37507348~37535616:+
BRCA	cis	rs733175	0.857	rs3796838	ENSG00000250413.1	RP11-448G15.1	-4.06	5.25e-05	0.00357	-0.19	-0.12	Psychosis and Alzheimer's disease;	chr4:10009406	chr4:10006482~10009725:+
BRCA	cis	rs853679	0.882	rs9393908	ENSG00000204709.4	LINC01556	4.06	5.25e-05	0.00357	0.26	0.12	Depression;	chr6:28223052	chr6:28943877~28944537:+
BRCA	cis	rs853679	0.882	rs9366717	ENSG00000204709.4	LINC01556	4.06	5.25e-05	0.00357	0.26	0.12	Depression;	chr6:28223279	chr6:28943877~28944537:+
BRCA	cis	rs2251381	0.778	rs2245021	ENSG00000232855.5	AF131217.1	-4.06	5.25e-05	0.00357	-0.16	-0.12	Selective IgA deficiency;	chr21:29174520	chr21:28439346~28674848:-
BRCA	cis	rs71520386	0.607	rs28617621	ENSG00000226329.2	AC005682.6	-4.06	5.25e-05	0.00357	-0.13	-0.12	Fibrinogen levels;	chr7:22818063	chr7:22863874~22881350:-
BRCA	cis	rs11168618	0.904	rs7978948	ENSG00000273765.1	RP11-370I10.11	4.06	5.25e-05	0.00357	0.14	0.12	Adiponectin levels;	chr12:48536240	chr12:48360920~48361377:+
BRCA	cis	rs11168618	0.904	rs12366459	ENSG00000273765.1	RP11-370I10.11	4.06	5.25e-05	0.00357	0.14	0.12	Adiponectin levels;	chr12:48537117	chr12:48360920~48361377:+
BRCA	cis	rs4538475	0.559	rs17405797	ENSG00000273133.1	RP11-799M12.2	-4.06	5.25e-05	0.00357	-0.26	-0.12	Parkinson's disease;	chr4:15684153	chr4:15563698~15564253:-
BRCA	cis	rs11009175	0.929	rs11009198	ENSG00000273038.2	RP11-479G22.8	-4.06	5.25e-05	0.00357	-0.22	-0.12	Depression (quantitative trait);	chr10:33053379	chr10:32887255~32889311:-
BRCA	cis	rs11009175	0.929	rs11009200	ENSG00000273038.2	RP11-479G22.8	-4.06	5.25e-05	0.00357	-0.22	-0.12	Depression (quantitative trait);	chr10:33053456	chr10:32887255~32889311:-
BRCA	cis	rs748404	0.666	rs35160541	ENSG00000205771.5	CATSPER2P1	-4.06	5.25e-05	0.00357	-0.19	-0.12	Lung cancer;	chr15:43365601	chr15:43726918~43747094:-
BRCA	cis	rs3617	0.598	rs56214994	ENSG00000242142.1	SERBP1P3	-4.06	5.25e-05	0.00357	-0.14	-0.12	Red blood cell count;Autism spectrum disorder or schizophrenia;	chr3:52844584	chr3:53064283~53065091:-
BRCA	cis	rs13326165	0.709	rs2159607	ENSG00000243224.1	RP5-1157M23.2	4.06	5.25e-05	0.00357	0.18	0.12	HDL cholesterol levels;HDL cholesterol;	chr3:52467435	chr3:52239258~52241097:+
BRCA	cis	rs17428076	0.629	rs72892859	ENSG00000228389.1	AC068039.4	-4.06	5.25e-05	0.00357	-0.19	-0.12	Myopia;	chr2:172039980	chr2:171773482~171775844:+
BRCA	cis	rs2255336	0.938	rs61917723	ENSG00000245648.1	RP11-277P12.20	-4.06	5.26e-05	0.00357	-0.2	-0.12	Blood protein levels;	chr12:10472728	chr12:10363769~10398506:+
BRCA	cis	rs7487075	0.797	rs10785630	ENSG00000257261.4	RP11-96H19.1	4.06	5.26e-05	0.00357	0.14	0.12	Itch intensity from mosquito bite;	chr12:46486597	chr12:46383679~46876159:+
BRCA	cis	rs10458771	0.667	rs11814255	ENSG00000227896.2	RP11-77P6.2	4.06	5.26e-05	0.00357	0.2	0.12	Amyotrophic lateral sclerosis (sporadic);	chr10:86463630	chr10:86521945~86525101:+
BRCA	cis	rs7520050	0.966	rs1707340	ENSG00000281133.1	AL355480.3	4.06	5.26e-05	0.00357	0.14	0.12	Reticulocyte count;Red blood cell count;	chr1:46049270	chr1:45580892~45580996:-
BRCA	cis	rs7520050	1	rs785473	ENSG00000281133.1	AL355480.3	4.06	5.26e-05	0.00357	0.14	0.12	Reticulocyte count;Red blood cell count;	chr1:46051191	chr1:45580892~45580996:-
BRCA	cis	rs7520050	0.931	rs785472	ENSG00000281133.1	AL355480.3	4.06	5.26e-05	0.00357	0.14	0.12	Reticulocyte count;Red blood cell count;	chr1:46052616	chr1:45580892~45580996:-
BRCA	cis	rs832540	0.966	rs33321	ENSG00000271828.1	CTD-2310F14.1	-4.06	5.26e-05	0.00357	-0.15	-0.12	Coronary artery disease;	chr5:56910246	chr5:56927874~56929573:+
BRCA	cis	rs7267979	0.966	rs910996	ENSG00000274414.1	RP5-965G21.4	-4.06	5.26e-05	0.00357	-0.15	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25283560	chr20:25239007~25245229:-
BRCA	cis	rs7520050	0.807	rs5021934	ENSG00000281133.1	AL355480.3	4.06	5.26e-05	0.00357	0.14	0.12	Reticulocyte count;Red blood cell count;	chr1:45643632	chr1:45580892~45580996:-
BRCA	cis	rs2243480	0.908	rs4718273	ENSG00000226002.1	RP11-460N20.5	4.06	5.26e-05	0.00357	0.21	0.12	Diabetic kidney disease;	chr7:65751112	chr7:65084103~65100232:+
BRCA	cis	rs11695541	0.826	rs749296	ENSG00000270820.4	RP11-355B11.2	4.06	5.26e-05	0.00357	0.31	0.12	Methadone dose in opioid dependence;	chr2:60640670	chr2:61471188~61484130:+
BRCA	cis	rs465969	0.655	rs13203984	ENSG00000272356.1	RP5-1112D6.8	4.06	5.26e-05	0.00357	0.27	0.12	Psoriasis;	chr6:111388538	chr6:111309203~111313517:+
BRCA	cis	rs1348850	0.914	rs1975544	ENSG00000280374.1	RP11-337N6.3	4.06	5.26e-05	0.00357	0.18	0.12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177600695	chr2:177317715~177318471:-
BRCA	cis	rs6496932	0.865	rs4843049	ENSG00000259295.5	CSPG4P12	4.06	5.26e-05	0.00357	0.2	0.12	Central corneal thickness;Corneal structure;	chr15:85331141	chr15:85191438~85213905:+
BRCA	cis	rs1555322	1	rs2425034	ENSG00000261582.1	RP4-614O4.11	-4.06	5.26e-05	0.00357	-0.17	-0.12	Attention deficit hyperactivity disorder;	chr20:35268011	chr20:35267885~35280043:-
BRCA	cis	rs1555322	0.858	rs2425035	ENSG00000261582.1	RP4-614O4.11	-4.06	5.26e-05	0.00357	-0.17	-0.12	Attention deficit hyperactivity disorder;	chr20:35268016	chr20:35267885~35280043:-
BRCA	cis	rs1371614	0.566	rs11887401	ENSG00000272148.1	RP11-195B17.1	4.06	5.26e-05	0.00357	0.13	0.12	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26958244	chr2:27062428~27062907:-
BRCA	cis	rs983392	0.709	rs7932740	ENSG00000275344.1	MIR6503	-4.06	5.26e-05	0.00357	-0.13	-0.12	Alzheimer's disease (late onset);	chr11:60208638	chr11:60209071~60209156:-
BRCA	cis	rs75504410	0.579	rs2087661	ENSG00000231160.8	KLF3-AS1	-4.06	5.26e-05	0.00358	-0.17	-0.12	Sum eosinophil basophil counts;Eosinophil counts;	chr4:38626309	chr4:38612701~38664883:-
BRCA	cis	rs10266483	0.656	rs670966	ENSG00000228653.2	HNRNPCP7	-4.06	5.26e-05	0.00358	-0.15	-0.12	Response to statin therapy;	chr7:64302521	chr7:64500825~64501729:+
BRCA	cis	rs6840360	0.87	rs1372978	ENSG00000251611.1	RP11-610P16.1	-4.06	5.26e-05	0.00358	-0.11	-0.12	Intelligence (multi-trait analysis);	chr4:151535028	chr4:151407551~151408835:-
BRCA	cis	rs9402743	0.671	rs6934889	ENSG00000234084.1	RP3-388E23.2	4.06	5.26e-05	0.00358	0.13	0.12	Systemic lupus erythematosus;	chr6:135629542	chr6:135301568~135307158:+
BRCA	cis	rs4950322	0.58	rs17355474	ENSG00000237188.3	RP11-337C18.8	4.06	5.26e-05	0.00358	0.16	0.12	Protein quantitative trait loci;	chr1:147120541	chr1:147172771~147211568:+
BRCA	cis	rs7777677	0.925	rs6956269	ENSG00000232869.2	TRBV29-1	-4.06	5.26e-05	0.00358	-0.1	-0.12	Alcoholic chronic pancreatitis;	chr7:142661303	chr7:142740206~142740894:+
BRCA	cis	rs1153858	1	rs1890565	ENSG00000275672.1	GATM-AS1	-4.06	5.27e-05	0.00358	-0.16	-0.12	Homoarginine levels;	chr15:45371101	chr15:45378700~45380123:+
BRCA	cis	rs8062405	1	rs62037364	ENSG00000261766.1	RP11-22P6.2	-4.06	5.27e-05	0.00358	-0.12	-0.12	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28857374	chr16:28862166~28863340:-
BRCA	cis	rs9467773	0.62	rs2451737	ENSG00000224843.5	LINC00240	-4.06	5.27e-05	0.00358	-0.14	-0.12	Intelligence (multi-trait analysis);	chr6:26618813	chr6:26956992~27023924:+
BRCA	cis	rs9467773	0.596	rs2494693	ENSG00000224843.5	LINC00240	-4.06	5.27e-05	0.00358	-0.14	-0.12	Intelligence (multi-trait analysis);	chr6:26618998	chr6:26956992~27023924:+
BRCA	cis	rs9467773	0.62	rs2494694	ENSG00000224843.5	LINC00240	-4.06	5.27e-05	0.00358	-0.14	-0.12	Intelligence (multi-trait analysis);	chr6:26619100	chr6:26956992~27023924:+
BRCA	cis	rs4374383	0.884	rs10171174	ENSG00000243389.1	AC012442.5	-4.06	5.27e-05	0.00358	-0.16	-0.12	Hepatitis C induced liver fibrosis;	chr2:111981485	chr2:112589040~112614431:+
BRCA	cis	rs2243480	1	rs410128	ENSG00000275400.1	RP4-756H11.5	4.06	5.27e-05	0.00358	0.24	0.12	Diabetic kidney disease;	chr7:66138186	chr7:66553805~66554199:-
BRCA	cis	rs516805	0.561	rs9490494	ENSG00000279114.1	RP3-425C14.5	4.06	5.27e-05	0.00358	0.18	0.12	Lymphocyte counts;	chr6:122612860	chr6:122471923~122484161:+
BRCA	cis	rs516805	0.561	rs9490495	ENSG00000279114.1	RP3-425C14.5	4.06	5.27e-05	0.00358	0.18	0.12	Lymphocyte counts;	chr6:122613043	chr6:122471923~122484161:+
BRCA	cis	rs4460629	0.742	rs11264314	ENSG00000160766.13	GBAP1	-4.06	5.27e-05	0.00358	-0.12	-0.12	Serum magnesium levels;	chr1:155105947	chr1:155213821~155227422:-
BRCA	cis	rs11168618	0.692	rs4760707	ENSG00000240399.1	RP1-228P16.1	4.06	5.27e-05	0.00358	0.13	0.12	Adiponectin levels;	chr12:48454857	chr12:48054813~48055591:-
BRCA	cis	rs7267979	0.706	rs6138542	ENSG00000125804.12	FAM182A	-4.06	5.27e-05	0.00358	-0.17	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25227137	chr20:26054655~26086917:+
BRCA	cis	rs2562456	0.754	rs11666213	ENSG00000268658.4	LINC00664	4.06	5.27e-05	0.00358	0.21	0.12	Pain;	chr19:21422843	chr19:21483374~21503238:+
BRCA	cis	rs11098499	0.722	rs10006192	ENSG00000260404.2	RP11-384K6.6	4.06	5.28e-05	0.00358	0.11	0.12	Corneal astigmatism;	chr4:119341867	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.615	rs28551750	ENSG00000260404.2	RP11-384K6.6	4.06	5.28e-05	0.00358	0.11	0.12	Corneal astigmatism;	chr4:119343746	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.691	rs9995716	ENSG00000260404.2	RP11-384K6.6	4.06	5.28e-05	0.00358	0.11	0.12	Corneal astigmatism;	chr4:119343841	chr4:118591773~118633729:+
BRCA	cis	rs62458065	0.85	rs28693551	ENSG00000229358.3	DPY19L1P1	-4.06	5.28e-05	0.00358	-0.17	-0.12	Metabolite levels (HVA/MHPG ratio);	chr7:32429775	chr7:32580949~32761787:-
BRCA	cis	rs4950322	0.57	rs3737855	ENSG00000237188.3	RP11-337C18.8	4.06	5.28e-05	0.00358	0.16	0.12	Protein quantitative trait loci;	chr1:147271257	chr1:147172771~147211568:+
BRCA	cis	rs1865760	0.964	rs3799373	ENSG00000272462.2	U91328.19	-4.06	5.28e-05	0.00358	-0.15	-0.12	Height;	chr6:25928945	chr6:25992662~26001775:+
BRCA	cis	rs2446066	0.872	rs12368491	ENSG00000257379.1	RP11-793H13.8	4.06	5.28e-05	0.00358	0.19	0.12	Red blood cell count;	chr12:53389175	chr12:53441741~53467528:+
BRCA	cis	rs4869313	0.869	rs10038651	ENSG00000248734.2	CTD-2260A17.1	4.06	5.28e-05	0.00358	0.13	0.12	Pediatric autoimmune diseases;	chr5:96984707	chr5:96784777~96785999:+
BRCA	cis	rs7923609	0.54	rs10995455	ENSG00000232075.1	MRPL35P2	-4.06	5.28e-05	0.00359	-0.18	-0.12	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63176601	chr10:63634317~63634827:-
BRCA	cis	rs2625529	0.652	rs8036307	ENSG00000260037.4	CTD-2524L6.3	4.06	5.28e-05	0.00359	0.16	0.12	Red blood cell count;	chr15:71882779	chr15:71818396~71823384:+
BRCA	cis	rs4648045	0.624	rs1609798	ENSG00000246560.2	RP11-10L12.4	4.06	5.28e-05	0.00359	0.15	0.12	Lymphocyte percentage of white cells;	chr4:102616285	chr4:102828055~102844075:+
BRCA	cis	rs1371614	0.523	rs11904656	ENSG00000272148.1	RP11-195B17.1	4.06	5.28e-05	0.00359	0.14	0.12	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26950381	chr2:27062428~27062907:-
BRCA	cis	rs4908769	0.624	rs301796	ENSG00000270282.1	RP5-1115A15.2	4.06	5.28e-05	0.00359	0.15	0.12	Allergy;	chr1:8406670	chr1:8512653~8513021:+
BRCA	cis	rs4908769	0.587	rs301795	ENSG00000270282.1	RP5-1115A15.2	4.06	5.28e-05	0.00359	0.15	0.12	Allergy;	chr1:8407293	chr1:8512653~8513021:+
BRCA	cis	rs4908769	0.624	rs301789	ENSG00000270282.1	RP5-1115A15.2	4.06	5.28e-05	0.00359	0.15	0.12	Allergy;	chr1:8409277	chr1:8512653~8513021:+
BRCA	cis	rs73222236	0.963	rs9875207	ENSG00000273486.1	RP11-731C17.2	4.06	5.28e-05	0.00359	0.14	0.12	Coronary artery disease;	chr3:136111296	chr3:136837338~136839021:-
BRCA	cis	rs6840360	0.726	rs6816292	ENSG00000278978.1	RP11-164P12.5	4.06	5.28e-05	0.00359	0.14	0.12	Intelligence (multi-trait analysis);	chr4:151809391	chr4:151669786~151670503:+
BRCA	cis	rs1355223	0.872	rs12802798	ENSG00000271369.1	RP11-350D17.3	-4.06	5.28e-05	0.00359	-0.14	-0.12	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34725887	chr11:34709600~34710161:+
BRCA	cis	rs1355223	0.872	rs7116409	ENSG00000271369.1	RP11-350D17.3	-4.06	5.28e-05	0.00359	-0.14	-0.12	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34729460	chr11:34709600~34710161:+
BRCA	cis	rs10129255	1	rs61997605	ENSG00000274576.2	IGHV2-70	4.06	5.29e-05	0.00359	0.11	0.12	Kawasaki disease;	chr14:106678368	chr14:106770577~106771020:-
BRCA	cis	rs11098499	0.954	rs28572238	ENSG00000260404.2	RP11-384K6.6	4.06	5.29e-05	0.00359	0.12	0.12	Corneal astigmatism;	chr4:119395531	chr4:118591773~118633729:+
BRCA	cis	rs6121246	0.909	rs2376992	ENSG00000230613.1	HM13-AS1	4.06	5.29e-05	0.00359	0.19	0.12	Mean corpuscular hemoglobin;	chr20:31675615	chr20:31567707~31573263:-
BRCA	cis	rs11711311	1	rs10934243	ENSG00000241529.3	RN7SL767P	-4.06	5.29e-05	0.00359	-0.15	-0.12	IgG glycosylation;	chr3:113711392	chr3:113632704~113632998:+
BRCA	cis	rs2408955	0.521	rs10875749	ENSG00000226413.2	OR8T1P	-4.06	5.29e-05	0.00359	-0.16	-0.12	Glycated hemoglobin levels;	chr12:48138134	chr12:48442030~48442947:-
BRCA	cis	rs2408955	0.522	rs7139330	ENSG00000226413.2	OR8T1P	-4.06	5.29e-05	0.00359	-0.16	-0.12	Glycated hemoglobin levels;	chr12:48089701	chr12:48442030~48442947:-
BRCA	cis	rs7976059	0.895	rs73109568	ENSG00000259887.1	RP11-923I11.5	-4.06	5.29e-05	0.00359	-0.16	-0.12	Urate levels;	chr12:51855219	chr12:51848223~51852729:+
BRCA	cis	rs2839186	0.708	rs6518285	ENSG00000223901.2	AP001469.5	4.06	5.29e-05	0.00359	0.12	0.12	Testicular germ cell tumor;	chr21:46224753	chr21:46220269~46225364:+
BRCA	cis	rs6545883	0.525	rs1621048	ENSG00000273302.1	RP11-493E12.2	-4.06	5.29e-05	0.00359	-0.11	-0.12	Tuberculosis;	chr2:61137081	chr2:61199979~61200769:+
BRCA	cis	rs1153858	1	rs12595087	ENSG00000275672.1	GATM-AS1	-4.06	5.29e-05	0.00359	-0.16	-0.12	Homoarginine levels;	chr15:45363034	chr15:45378700~45380123:+
BRCA	cis	rs35520189	0.845	rs2723152	ENSG00000274877.1	RP11-65I12.1	4.06	5.29e-05	0.00359	0.17	0.12	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:112888113	chr2:113237595~113240825:+
BRCA	cis	rs568617	1	rs641018	ENSG00000254510.1	RP11-867G23.10	4.06	5.29e-05	0.00359	0.15	0.12	Crohn's disease;	chr11:65887922	chr11:66409158~66417137:+
BRCA	cis	rs8114671	0.804	rs6060139	ENSG00000126005.14	MMP24-AS1	-4.06	5.29e-05	0.00359	-0.15	-0.12	Height;	chr20:34978696	chr20:35216462~35278131:-
BRCA	cis	rs4374383	0.926	rs4643544	ENSG00000243389.1	AC012442.5	-4.06	5.29e-05	0.00359	-0.16	-0.12	Hepatitis C induced liver fibrosis;	chr2:112021136	chr2:112589040~112614431:+
BRCA	cis	rs3749237	0.595	rs1050088	ENSG00000225399.4	RP11-3B7.1	-4.06	5.29e-05	0.00359	-0.12	-0.12	Resting heart rate;	chr3:49533449	chr3:49260085~49261316:+
BRCA	cis	rs11098499	1	rs6849889	ENSG00000250412.1	KLHL2P1	4.06	5.29e-05	0.0036	0.15	0.12	Corneal astigmatism;	chr4:119265193	chr4:119334329~119378233:+
BRCA	cis	rs568617	0.953	rs645900	ENSG00000254510.1	RP11-867G23.10	-4.06	5.29e-05	0.0036	-0.15	-0.12	Crohn's disease;	chr11:65880664	chr11:66409158~66417137:+
BRCA	cis	rs2836974	0.545	rs3167757	ENSG00000255568.3	BRWD1-AS2	4.06	5.3e-05	0.0036	0.12	0.12	Cognitive function;	chr21:39342552	chr21:39313935~39314962:+
BRCA	cis	rs1910358	0.676	rs1354166	ENSG00000248874.4	C5orf17	-4.06	5.3e-05	0.0036	-0.16	-0.12	Venous thromboembolism (SNP x SNP interaction);	chr5:24000800	chr5:23951348~24178263:+
BRCA	cis	rs6593122	0.71	rs73126226	ENSG00000235454.1	HAUS6P3	-4.06	5.3e-05	0.0036	-0.17	-0.12	Vaccine-related adverse events;	chr7:54126569	chr7:53862233~53863339:+
BRCA	cis	rs6593122	0.755	rs6964662	ENSG00000235454.1	HAUS6P3	-4.06	5.3e-05	0.0036	-0.17	-0.12	Vaccine-related adverse events;	chr7:54126596	chr7:53862233~53863339:+
BRCA	cis	rs9381040	0.655	rs9381032	ENSG00000161912.16	ADCY10P1	4.06	5.3e-05	0.0036	0.14	0.12	Alzheimer's disease (late onset);	chr6:41077247	chr6:41101022~41140835:+
BRCA	cis	rs8098244	0.557	rs11662720	ENSG00000265752.2	RP11-403A21.1	-4.06	5.3e-05	0.0036	-0.13	-0.12	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23722127	chr18:23957754~23982556:-
BRCA	cis	rs1538970	0.962	rs2487442	ENSG00000281133.1	AL355480.3	4.06	5.3e-05	0.0036	0.16	0.12	Platelet count;	chr1:45391504	chr1:45580892~45580996:-
BRCA	cis	rs848490	0.855	rs67745553	ENSG00000214293.7	APTR	4.06	5.3e-05	0.0036	0.16	0.12	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77674781	chr7:77657660~77696265:-
BRCA	cis	rs7520050	0.966	rs9429183	ENSG00000281133.1	AL355480.3	4.06	5.3e-05	0.0036	0.14	0.12	Reticulocyte count;Red blood cell count;	chr1:46058910	chr1:45580892~45580996:-
BRCA	cis	rs2243480	1	rs4718315	ENSG00000237026.1	RP11-328P23.2	-4.06	5.3e-05	0.0036	-0.23	-0.12	Diabetic kidney disease;	chr7:66183554	chr7:65235790~65236723:-
BRCA	cis	rs2243480	1	rs4718316	ENSG00000237026.1	RP11-328P23.2	-4.06	5.3e-05	0.0036	-0.23	-0.12	Diabetic kidney disease;	chr7:66183744	chr7:65235790~65236723:-
BRCA	cis	rs2408955	0.561	rs9971924	ENSG00000257735.1	RP11-370I10.6	-4.06	5.3e-05	0.0036	-0.15	-0.12	Glycated hemoglobin levels;	chr12:48086049	chr12:48350945~48442411:+
BRCA	cis	rs2880765	0.835	rs4843062	ENSG00000230373.7	GOLGA6L5P	4.06	5.3e-05	0.0036	0.13	0.12	Coronary artery disease;	chr15:85496906	chr15:84507885~84516814:-
BRCA	cis	rs860295	0.812	rs4278368	ENSG00000225855.5	RUSC1-AS1	4.06	5.3e-05	0.0036	0.1	0.12	Body mass index;	chr1:155752766	chr1:155316863~155324176:-
BRCA	cis	rs11083475	1	rs11083475	ENSG00000267892.1	CTD-2540F13.2	4.06	5.3e-05	0.0036	0.14	0.12	Heart rate;	chr19:38697472	chr19:38738284~38739863:+
BRCA	cis	rs7927592	0.673	rs498782	ENSG00000212093.1	AP000807.1	4.06	5.3e-05	0.0036	0.13	0.12	Total body bone mineral density;	chr11:68508383	chr11:68506083~68506166:-
BRCA	cis	rs6452524	0.901	rs17284211	ENSG00000281327.1	LINC01338	4.06	5.3e-05	0.0036	0.14	0.12	Hypertension (SNP x SNP interaction);	chr5:83098706	chr5:82850864~82859836:-
BRCA	cis	rs6452524	0.935	rs1382374	ENSG00000281327.1	LINC01338	4.06	5.3e-05	0.0036	0.14	0.12	Hypertension (SNP x SNP interaction);	chr5:83101010	chr5:82850864~82859836:-
BRCA	cis	rs13401620	0.745	rs13432018	ENSG00000229326.3	AC069154.4	-4.06	5.3e-05	0.0036	-0.16	-0.12	Breast size;	chr2:119876940	chr2:119698623~119700151:+
BRCA	cis	rs886774	0.932	rs2007425	ENSG00000273055.1	CTB-13F3.1	-4.06	5.3e-05	0.0036	-0.13	-0.12	Ulcerative colitis;	chr7:107859685	chr7:107942116~107942740:+
BRCA	cis	rs2236231	0.55	rs12897715	ENSG00000259648.1	RP11-643G16.4	-4.06	5.3e-05	0.0036	-0.18	-0.12	Plasma kynurenine levels in major depressive disorder;	chr14:67593117	chr14:67614929~67616626:+
BRCA	cis	rs2243480	1	rs958550	ENSG00000275400.1	RP4-756H11.5	-4.06	5.3e-05	0.0036	-0.22	-0.12	Diabetic kidney disease;	chr7:66170692	chr7:66553805~66554199:-
BRCA	cis	rs801193	0.66	rs1016265	ENSG00000229180.5	GS1-124K5.11	4.06	5.31e-05	0.0036	0.11	0.12	Aortic root size;	chr7:66749580	chr7:66526088~66542624:-
BRCA	cis	rs801193	0.66	rs4610622	ENSG00000229180.5	GS1-124K5.11	4.06	5.31e-05	0.0036	0.11	0.12	Aortic root size;	chr7:66759510	chr7:66526088~66542624:-
BRCA	cis	rs10735946	1	rs2870956	ENSG00000255733.4	IFNG-AS1	-4.06	5.31e-05	0.0036	-0.11	-0.12	Anti-saccade response;	chr12:68092998	chr12:67989445~68234686:+
BRCA	cis	rs860295	0.702	rs10796943	ENSG00000232093.1	RP11-307C12.11	4.06	5.31e-05	0.0036	0.14	0.12	Body mass index;	chr1:155444938	chr1:155045191~155046118:-
BRCA	cis	rs2518049	0.654	rs7087111	ENSG00000224034.1	RP11-445P17.8	-4.06	5.31e-05	0.0036	-0.24	-0.12	Metabolic traits;	chr10:5197861	chr10:5266033~5271236:-
BRCA	cis	rs6772849	0.775	rs67105978	ENSG00000242551.2	POU5F1P6	-4.06	5.31e-05	0.0036	-0.16	-0.12	Monocyte percentage of white cells;Monocyte count;	chr3:128696337	chr3:128674735~128677005:-
BRCA	cis	rs875971	0.66	rs7807944	ENSG00000232546.1	RP11-458F8.1	4.06	5.31e-05	0.0036	0.1	0.12	Aortic root size;	chr7:66622208	chr7:66848496~66858136:+
BRCA	cis	rs2518049	1	rs1937848	ENSG00000224034.1	RP11-445P17.8	4.06	5.31e-05	0.0036	0.23	0.12	Metabolic traits;	chr10:5091851	chr10:5266033~5271236:-
BRCA	cis	rs11098499	0.754	rs7672778	ENSG00000260091.1	RP11-33B1.4	-4.06	5.31e-05	0.0036	-0.11	-0.12	Corneal astigmatism;	chr4:119327430	chr4:119409333~119410233:+
BRCA	cis	rs4538475	0.539	rs73241112	ENSG00000273133.1	RP11-799M12.2	-4.06	5.31e-05	0.0036	-0.25	-0.12	Parkinson's disease;	chr4:15629219	chr4:15563698~15564253:-
BRCA	cis	rs2302465	0.86	rs3822258	ENSG00000273133.1	RP11-799M12.2	-4.06	5.31e-05	0.0036	-0.25	-0.12	Blood protein levels;	chr4:15630370	chr4:15563698~15564253:-
BRCA	cis	rs7651446	0.649	rs12497720	ENSG00000240875.4	LINC00886	4.06	5.31e-05	0.0036	0.23	0.12	Ovarian cancer;Epithelial ovarian cancer;	chr3:156646047	chr3:156747346~156817062:-
BRCA	cis	rs12122100	0.862	rs6689542	ENSG00000244371.2	PFN1P8	4.06	5.31e-05	0.0036	0.16	0.12	HIV-1 control;	chr1:147035327	chr1:146957117~146957659:-
BRCA	cis	rs490234	0.719	rs13287525	ENSG00000232630.1	PRPS1P2	-4.06	5.31e-05	0.0036	-0.12	-0.12	Mean arterial pressure;	chr9:125456901	chr9:125150653~125151589:+
BRCA	cis	rs10510102	0.516	rs12242799	ENSG00000226864.1	ATE1-AS1	4.06	5.31e-05	0.00361	0.25	0.12	Breast cancer;	chr10:121980067	chr10:121928312~121951965:+
BRCA	cis	rs711830	1	rs1318778	ENSG00000226363.3	HAGLROS	-4.06	5.31e-05	0.00361	-0.18	-0.12	Serous invasive ovarian cancer;Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;High-grade serous ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;	chr2:176173103	chr2:176177717~176179008:+
BRCA	cis	rs11742741	0.87	rs4701421	ENSG00000248874.4	C5orf17	-4.06	5.31e-05	0.00361	-0.16	-0.12	Educational attainment;	chr5:24088888	chr5:23951348~24178263:+
BRCA	cis	rs490234	0.812	rs12553699	ENSG00000232630.1	PRPS1P2	-4.06	5.31e-05	0.00361	-0.13	-0.12	Mean arterial pressure;	chr9:125532247	chr9:125150653~125151589:+
BRCA	cis	rs1005277	0.541	rs2263163	ENSG00000272983.1	RP11-508N22.12	4.06	5.32e-05	0.00361	0.13	0.12	Extrinsic epigenetic age acceleration;	chr10:38100959	chr10:38137337~38144399:+
BRCA	cis	rs950169	0.58	rs17532346	ENSG00000229212.6	RP11-561C5.4	-4.06	5.32e-05	0.00361	-0.16	-0.12	Schizophrenia;	chr15:84628264	chr15:85205440~85234795:-
BRCA	cis	rs7267979	0.966	rs454723	ENSG00000274973.1	RP13-401N8.7	-4.06	5.32e-05	0.00361	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25458292	chr20:25845497~25845862:+
BRCA	cis	rs11158026	0.501	rs67620272	ENSG00000258413.1	RP11-665C16.6	-4.06	5.32e-05	0.00361	-0.2	-0.12	Parkinson's disease;	chr14:54884861	chr14:55262767~55272075:-
BRCA	cis	rs9868809	0.505	rs9882549	ENSG00000225399.4	RP11-3B7.1	-4.06	5.32e-05	0.00361	-0.18	-0.12	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48711925	chr3:49260085~49261316:+
BRCA	cis	rs9840812	0.769	rs489398	ENSG00000273486.1	RP11-731C17.2	4.06	5.32e-05	0.00361	0.17	0.12	Fibrinogen levels;	chr3:136276656	chr3:136837338~136839021:-
BRCA	cis	rs7011507	0.51	rs57846507	ENSG00000233858.4	AC026904.1	-4.06	5.32e-05	0.00361	-0.15	-0.12	Inflammatory bowel disease;Ulcerative colitis;	chr8:48543835	chr8:48590401~48594621:+
BRCA	cis	rs6081541	1	rs62201127	ENSG00000179447.2	RP5-1027G4.3	-4.06	5.32e-05	0.00361	-0.17	-0.12	Psychosis (atypical);	chr20:19245192	chr20:19242302~19284596:-
BRCA	cis	rs1005277	0.579	rs2472173	ENSG00000272983.1	RP11-508N22.12	4.06	5.32e-05	0.00361	0.13	0.12	Extrinsic epigenetic age acceleration;	chr10:38085710	chr10:38137337~38144399:+
BRCA	cis	rs1005277	0.579	rs2472174	ENSG00000272983.1	RP11-508N22.12	4.06	5.32e-05	0.00361	0.13	0.12	Extrinsic epigenetic age acceleration;	chr10:38086454	chr10:38137337~38144399:+
BRCA	cis	rs6696239	0.513	rs1021554	ENSG00000227711.2	RP11-275O4.5	4.06	5.32e-05	0.00361	0.15	0.12	Height;	chr1:227556250	chr1:227509028~227520477:-
BRCA	cis	rs6696239	0.513	rs1021553	ENSG00000227711.2	RP11-275O4.5	4.06	5.32e-05	0.00361	0.15	0.12	Height;	chr1:227556286	chr1:227509028~227520477:-
BRCA	cis	rs2625529	0.761	rs972029	ENSG00000260037.4	CTD-2524L6.3	-4.06	5.32e-05	0.00361	-0.17	-0.12	Red blood cell count;	chr15:71880645	chr15:71818396~71823384:+
BRCA	cis	rs9309473	0.687	rs6706235	ENSG00000163016.8	ALMS1P	4.06	5.32e-05	0.00361	0.15	0.12	Metabolite levels;	chr2:73386430	chr2:73644919~73685576:+
BRCA	cis	rs7520050	0.807	rs4660312	ENSG00000281133.1	AL355480.3	-4.06	5.32e-05	0.00361	-0.14	-0.12	Reticulocyte count;Red blood cell count;	chr1:45644900	chr1:45580892~45580996:-
BRCA	cis	rs2070074	0.591	rs3739882	ENSG00000261215.1	RP11-195F19.30	4.06	5.32e-05	0.00361	0.28	0.12	CTACK levels;	chr9:34653112	chr9:34661903~34666029:-
BRCA	cis	rs2880765	0.706	rs7172006	ENSG00000259630.2	CTD-2262B20.1	-4.06	5.32e-05	0.00361	-0.16	-0.12	Coronary artery disease;	chr15:85510128	chr15:85415228~85415633:+
BRCA	cis	rs801193	1	rs2055682	ENSG00000272831.1	RP11-792A8.4	4.06	5.32e-05	0.00361	0.11	0.12	Aortic root size;	chr7:66795302	chr7:66739829~66740385:-
BRCA	cis	rs1865760	1	rs3830057	ENSG00000272462.2	U91328.19	-4.06	5.33e-05	0.00361	-0.15	-0.12	Height;	chr6:25918282	chr6:25992662~26001775:+
BRCA	cis	rs4698412	0.561	rs11722300	ENSG00000273133.1	RP11-799M12.2	-4.06	5.33e-05	0.00361	-0.15	-0.12	Parkinson's disease;	chr4:15683428	chr4:15563698~15564253:-
BRCA	cis	rs7572733	0.901	rs13011918	ENSG00000231621.1	AC013264.2	4.06	5.33e-05	0.00361	0.11	0.12	Dermatomyositis;	chr2:197914359	chr2:197197991~197199273:+
BRCA	cis	rs2274273	0.967	rs10147667	ENSG00000259318.1	RP11-454L9.2	-4.06	5.33e-05	0.00361	-0.1	-0.12	Protein biomarker;	chr14:55104131	chr14:55394940~55395233:-
BRCA	cis	rs10771431	0.81	rs10771418	ENSG00000256427.1	RP11-118B22.4	4.06	5.33e-05	0.00361	0.13	0.12	Breast size;	chr12:9206399	chr12:9246497~9257960:+
BRCA	cis	rs62458065	0.85	rs10239812	ENSG00000229358.3	DPY19L1P1	-4.06	5.33e-05	0.00361	-0.18	-0.12	Metabolite levels (HVA/MHPG ratio);	chr7:32420736	chr7:32580949~32761787:-
BRCA	cis	rs1910358	0.579	rs7730970	ENSG00000248874.4	C5orf17	-4.06	5.33e-05	0.00361	-0.18	-0.12	Venous thromboembolism (SNP x SNP interaction);	chr5:23757455	chr5:23951348~24178263:+
BRCA	cis	rs6593122	0.755	rs12670947	ENSG00000235454.1	HAUS6P3	-4.06	5.33e-05	0.00362	-0.17	-0.12	Vaccine-related adverse events;	chr7:54135315	chr7:53862233~53863339:+
BRCA	cis	rs6593122	0.755	rs9718891	ENSG00000235454.1	HAUS6P3	-4.06	5.33e-05	0.00362	-0.17	-0.12	Vaccine-related adverse events;	chr7:54135382	chr7:53862233~53863339:+
BRCA	cis	rs61931739	0.517	rs12815556	ENSG00000258794.3	DUX4L27	4.06	5.33e-05	0.00362	0.18	0.12	Morning vs. evening chronotype;	chr12:34166735	chr12:34208415~34209675:-
BRCA	cis	rs6088580	0.634	rs3736762	ENSG00000275784.1	RP5-1125A11.6	-4.06	5.33e-05	0.00362	-0.14	-0.12	Glomerular filtration rate (creatinine);	chr20:34449531	chr20:33989480~33991818:-
BRCA	cis	rs6088580	0.634	rs6058051	ENSG00000275784.1	RP5-1125A11.6	-4.06	5.33e-05	0.00362	-0.14	-0.12	Glomerular filtration rate (creatinine);	chr20:34457057	chr20:33989480~33991818:-
BRCA	cis	rs62025270	0.51	rs76204898	ENSG00000259762.1	RP11-158M2.4	-4.06	5.33e-05	0.00362	-0.22	-0.12	Idiopathic pulmonary fibrosis;	chr15:85750895	chr15:85750336~85752901:-
BRCA	cis	rs8114671	0.562	rs2076667	ENSG00000126005.14	MMP24-AS1	-4.06	5.33e-05	0.00362	-0.14	-0.12	Height;	chr20:34919161	chr20:35216462~35278131:-
BRCA	cis	rs17027633	1	rs76261890	ENSG00000260948.1	RP11-552M11.8	-4.06	5.33e-05	0.00362	-0.28	-0.12	Cerebrospinal fluid t-tau:AB1-42 ratio;	chr1:111416225	chr1:111431046~111433068:-
BRCA	cis	rs10129255	0.5	rs8006888	ENSG00000254174.1	IGHV1-12	4.06	5.33e-05	0.00362	0.1	0.12	Kawasaki disease;	chr14:106782219	chr14:106122420~106122709:-
BRCA	cis	rs11098499	0.955	rs4145951	ENSG00000250412.1	KLHL2P1	4.06	5.33e-05	0.00362	0.15	0.12	Corneal astigmatism;	chr4:119234662	chr4:119334329~119378233:+
BRCA	cis	rs11098499	0.955	rs35916640	ENSG00000250412.1	KLHL2P1	4.06	5.33e-05	0.00362	0.15	0.12	Corneal astigmatism;	chr4:119234697	chr4:119334329~119378233:+
BRCA	cis	rs62229266	0.771	rs62230790	ENSG00000214914.3	RPL23AP3	4.06	5.34e-05	0.00362	0.15	0.12	Mitral valve prolapse;	chr21:36016613	chr21:36016079~36016546:-
BRCA	cis	rs6070116	0.789	rs6064552	ENSG00000124097.7	HMGB1P1	4.06	5.34e-05	0.00362	0.17	0.12	Response to statin therapy;	chr20:57467810	chr20:57488392~57489027:-
BRCA	cis	rs2486012	0.737	rs246773	ENSG00000237950.1	RP11-7O11.3	4.06	5.34e-05	0.00362	0.23	0.12	Intelligence (multi-trait analysis);	chr1:43834577	chr1:43944370~43946551:-
BRCA	cis	rs8113308	0.81	rs73582180	ENSG00000269483.1	AC006272.1	4.06	5.34e-05	0.00362	0.22	0.12	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51943284	chr19:51839924~51843324:-
BRCA	cis	rs8113308	0.81	rs8105910	ENSG00000269483.1	AC006272.1	4.06	5.34e-05	0.00362	0.22	0.12	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51943815	chr19:51839924~51843324:-
BRCA	cis	rs8054556	1	rs4788201	ENSG00000214725.6	CDIPT-AS1	-4.06	5.34e-05	0.00362	-0.15	-0.12	Autism spectrum disorder or schizophrenia;	chr16:29961369	chr16:29863593~29868053:+
BRCA	cis	rs4302906	0.964	rs10821050	ENSG00000187984.11	ANKRD19P	-4.06	5.34e-05	0.00362	-0.11	-0.12	Lobe attachment (rater-scored or self-reported);	chr9:92982633	chr9:92809388~92888693:+
BRCA	cis	rs6593122	0.755	rs6973036	ENSG00000235454.1	HAUS6P3	-4.06	5.34e-05	0.00362	-0.17	-0.12	Vaccine-related adverse events;	chr7:54133189	chr7:53862233~53863339:+
BRCA	cis	rs801193	0.66	rs974239	ENSG00000229180.5	GS1-124K5.11	4.06	5.34e-05	0.00362	0.11	0.12	Aortic root size;	chr7:66748504	chr7:66526088~66542624:-
BRCA	cis	rs801193	1	rs7788576	ENSG00000229180.5	GS1-124K5.11	-4.06	5.34e-05	0.00362	-0.11	-0.12	Aortic root size;	chr7:66683315	chr7:66526088~66542624:-
BRCA	cis	rs2880765	0.743	rs12906308	ENSG00000202081.1	RNU6-1280P	-4.06	5.34e-05	0.00362	-0.15	-0.12	Coronary artery disease;	chr15:85464828	chr15:85651522~85651628:-
BRCA	cis	rs2880765	0.743	rs8039049	ENSG00000202081.1	RNU6-1280P	4.06	5.34e-05	0.00362	0.15	0.12	Coronary artery disease;	chr15:85464398	chr15:85651522~85651628:-
BRCA	cis	rs2880765	0.743	rs8039631	ENSG00000202081.1	RNU6-1280P	4.06	5.34e-05	0.00362	0.15	0.12	Coronary artery disease;	chr15:85464700	chr15:85651522~85651628:-
BRCA	cis	rs2976388	0.669	rs2976391	ENSG00000253196.1	RP11-706C16.7	4.06	5.34e-05	0.00362	0.12	0.12	Urinary tract infection frequency;	chr8:142681306	chr8:142763116~142766427:+
BRCA	cis	rs721917	0.506	rs2819098	ENSG00000242600.5	MBL1P	4.06	5.34e-05	0.00362	0.15	0.12	Chronic obstructive pulmonary disease;	chr10:79938341	chr10:79904898~79950336:+
BRCA	cis	rs8098244	0.737	rs1154243	ENSG00000265752.2	RP11-403A21.1	-4.06	5.34e-05	0.00362	-0.17	-0.12	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23963824	chr18:23957754~23982556:-
BRCA	cis	rs8098244	0.708	rs1154245	ENSG00000265752.2	RP11-403A21.1	-4.06	5.34e-05	0.00362	-0.17	-0.12	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23964250	chr18:23957754~23982556:-
BRCA	cis	rs3845817	0.843	rs3911862	ENSG00000237979.1	AC007389.1	-4.06	5.34e-05	0.00362	-0.14	-0.12	Bipolar disorder;	chr2:65532537	chr2:65500993~65502138:-
BRCA	cis	rs1910358	0.554	rs6861302	ENSG00000248874.4	C5orf17	-4.06	5.34e-05	0.00362	-0.18	-0.12	Venous thromboembolism (SNP x SNP interaction);	chr5:23728272	chr5:23951348~24178263:+
BRCA	cis	rs6001482	0.533	rs12484704	ENSG00000279278.1	CH17-264L24.1	4.06	5.34e-05	0.00362	0.13	0.12	Diastolic blood pressure;	chr22:22228856	chr22:22264601~22273020:+
BRCA	cis	rs6088580	0.634	rs1890002	ENSG00000276073.1	RP5-1125A11.7	4.06	5.34e-05	0.00362	0.14	0.12	Glomerular filtration rate (creatinine);	chr20:34331413	chr20:33985617~33988989:-
BRCA	cis	rs1008375	1	rs3815413	ENSG00000249502.1	AC006160.5	-4.06	5.34e-05	0.00363	-0.14	-0.12	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17653025	chr4:17587467~17614571:-
BRCA	cis	rs7048146	0.899	rs1330846	ENSG00000213539.4	YBX1P6	-4.06	5.35e-05	0.00363	-0.14	-0.12	Vascular brain injury;	chr9:109574668	chr9:109532830~109534332:-
BRCA	cis	rs6570726	0.516	rs9322025	ENSG00000235652.6	RP11-545I5.3	4.06	5.35e-05	0.00363	0.12	0.12	Lobe attachment (rater-scored or self-reported);	chr6:145408060	chr6:145799409~145886585:+
BRCA	cis	rs9921338	0.887	rs13330151	ENSG00000262636.1	CTD-3088G3.4	-4.06	5.35e-05	0.00363	-0.21	-0.12	Vein graft stenosis in coronary artery bypass grafting;	chr16:11308542	chr16:11380859~11381118:-
BRCA	cis	rs875971	0.577	rs34888281	ENSG00000223473.2	GS1-124K5.3	-4.06	5.35e-05	0.00363	-0.1	-0.12	Aortic root size;	chr7:66120784	chr7:66491049~66493566:-
BRCA	cis	rs1040	1	rs10945405	ENSG00000226445.1	XXyac-YX65C7_A.2	4.06	5.35e-05	0.00363	0.13	0.12	Joint mobility (Beighton score);	chr6:169221041	chr6:169213254~169239565:+
BRCA	cis	rs11048470	0.569	rs4654	ENSG00000256894.1	RP11-283G6.3	-4.06	5.35e-05	0.00363	-0.13	-0.12	Waist-hip ratio;	chr12:26337222	chr12:26125155~26126617:-
BRCA	cis	rs801193	1	rs2659889	ENSG00000273142.1	RP11-458F8.4	-4.06	5.35e-05	0.00363	-0.11	-0.12	Aortic root size;	chr7:66752125	chr7:66902857~66906297:+
BRCA	cis	rs7487075	0.78	rs10785620	ENSG00000272369.1	RP11-446N19.1	4.06	5.35e-05	0.00363	0.14	0.12	Itch intensity from mosquito bite;	chr12:46343469	chr12:46537502~46652550:+
BRCA	cis	rs62025270	0.632	rs80036674	ENSG00000259367.1	RP11-815J21.4	4.06	5.35e-05	0.00363	0.12	0.12	Idiopathic pulmonary fibrosis;	chr15:85571217	chr15:85619623~85670948:-
BRCA	cis	rs13098911	0.54	rs2171531	ENSG00000223552.1	RP11-24F11.2	-4.06	5.35e-05	0.00363	-0.21	-0.12	Celiac disease;	chr3:45939679	chr3:46364955~46407059:-
BRCA	cis	rs6452524	0.905	rs1478482	ENSG00000281327.1	LINC01338	4.06	5.35e-05	0.00363	0.14	0.12	Hypertension (SNP x SNP interaction);	chr5:83111279	chr5:82850864~82859836:-
BRCA	cis	rs1865760	1	rs7757666	ENSG00000272462.2	U91328.19	-4.06	5.35e-05	0.00363	-0.15	-0.12	Height;	chr6:25902398	chr6:25992662~26001775:+
BRCA	cis	rs1865760	1	rs6910138	ENSG00000272462.2	U91328.19	-4.06	5.35e-05	0.00363	-0.15	-0.12	Height;	chr6:25904124	chr6:25992662~26001775:+
BRCA	cis	rs4713118	0.621	rs10484403	ENSG00000272009.1	RP1-313I6.12	-4.06	5.35e-05	0.00363	-0.18	-0.12	Parkinson's disease;	chr6:28065745	chr6:28078792~28081130:-
BRCA	cis	rs516805	0.667	rs9320856	ENSG00000279114.1	RP3-425C14.5	-4.06	5.35e-05	0.00363	-0.16	-0.12	Lymphocyte counts;	chr6:122219888	chr6:122471923~122484161:+
BRCA	cis	rs28374715	0.783	rs11635269	ENSG00000247556.5	OIP5-AS1	4.06	5.35e-05	0.00363	0.14	0.12	Ulcerative colitis;	chr15:41278512	chr15:41283990~41309737:+
BRCA	cis	rs7267979	0.932	rs4280527	ENSG00000274414.1	RP5-965G21.4	-4.06	5.35e-05	0.00363	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25563378	chr20:25239007~25245229:-
BRCA	cis	rs3748022	1	rs12124627	ENSG00000261000.1	RP11-534L20.5	4.06	5.35e-05	0.00363	0.18	0.12	Lymphocyte counts;	chr1:206513930	chr1:206503948~206504456:+
BRCA	cis	rs2832270	0.525	rs73192156	ENSG00000176054.6	RPL23P2	-4.06	5.35e-05	0.00363	-0.18	-0.12	Response to mTOR inhibitor (everolimus);	chr21:29085205	chr21:28997613~28998033:-
BRCA	cis	rs730566	1	rs4858819	ENSG00000244380.1	RP11-24C3.2	-4.06	5.35e-05	0.00363	-0.17	-0.12	Prion diseases;	chr3:48436678	chr3:48440352~48446656:-
BRCA	cis	rs10911902	0.643	rs74842753	ENSG00000229739.2	RP11-295K2.3	-4.06	5.35e-05	0.00363	-0.19	-0.12	Schizophrenia;	chr1:186390059	chr1:186435161~186470291:+
BRCA	cis	rs62229266	0.682	rs2835224	ENSG00000214914.3	RPL23AP3	4.06	5.36e-05	0.00363	0.16	0.12	Mitral valve prolapse;	chr21:35997732	chr21:36016079~36016546:-
BRCA	cis	rs2692947	0.759	rs2949885	ENSG00000232931.4	LINC00342	4.06	5.36e-05	0.00363	0.13	0.12	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95996667	chr2:95807118~95816215:-
BRCA	cis	rs2115536	0.704	rs2163005	ENSG00000278600.1	RP11-81A1.6	-4.06	5.36e-05	0.00363	-0.11	-0.12	Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Eosinophil counts;Neutrophil percentage of granulocytes;	chr15:79902138	chr15:79920195~79922455:-
BRCA	cis	rs6088580	0.634	rs6058052	ENSG00000275784.1	RP5-1125A11.6	-4.06	5.36e-05	0.00363	-0.13	-0.12	Glomerular filtration rate (creatinine);	chr20:34459279	chr20:33989480~33991818:-
BRCA	cis	rs6088580	0.634	rs6087588	ENSG00000275784.1	RP5-1125A11.6	-4.06	5.36e-05	0.00363	-0.13	-0.12	Glomerular filtration rate (creatinine);	chr20:34478564	chr20:33989480~33991818:-
BRCA	cis	rs853679	1	rs1679709	ENSG00000280107.1	AL022393.9	4.06	5.36e-05	0.00363	0.22	0.12	Depression;	chr6:28260564	chr6:28170845~28172521:+
BRCA	cis	rs7572733	0.935	rs6734561	ENSG00000231621.1	AC013264.2	-4.06	5.36e-05	0.00363	-0.11	-0.12	Dermatomyositis;	chr2:197860352	chr2:197197991~197199273:+
BRCA	cis	rs7572733	0.901	rs700689	ENSG00000231621.1	AC013264.2	-4.06	5.36e-05	0.00363	-0.11	-0.12	Dermatomyositis;	chr2:197861925	chr2:197197991~197199273:+
BRCA	cis	rs7572733	0.935	rs700691	ENSG00000231621.1	AC013264.2	-4.06	5.36e-05	0.00363	-0.11	-0.12	Dermatomyositis;	chr2:197863128	chr2:197197991~197199273:+
BRCA	cis	rs7572733	0.905	rs700693	ENSG00000231621.1	AC013264.2	-4.06	5.36e-05	0.00363	-0.11	-0.12	Dermatomyositis;	chr2:197865291	chr2:197197991~197199273:+
BRCA	cis	rs6452524	0.935	rs6868416	ENSG00000281327.1	LINC01338	4.06	5.36e-05	0.00363	0.14	0.12	Hypertension (SNP x SNP interaction);	chr5:83084320	chr5:82850864~82859836:-
BRCA	cis	rs9381040	0.61	rs4140580	ENSG00000161912.16	ADCY10P1	4.06	5.36e-05	0.00363	0.14	0.12	Alzheimer's disease (late onset);	chr6:41074003	chr6:41101022~41140835:+
BRCA	cis	rs9381040	0.61	rs4140579	ENSG00000161912.16	ADCY10P1	4.06	5.36e-05	0.00363	0.14	0.12	Alzheimer's disease (late onset);	chr6:41074013	chr6:41101022~41140835:+
BRCA	cis	rs9381040	0.655	rs2268188	ENSG00000161912.16	ADCY10P1	4.06	5.36e-05	0.00363	0.14	0.12	Alzheimer's disease (late onset);	chr6:41074851	chr6:41101022~41140835:+
BRCA	cis	rs9402743	0.634	rs7767072	ENSG00000234084.1	RP3-388E23.2	-4.06	5.36e-05	0.00363	-0.12	-0.12	Systemic lupus erythematosus;	chr6:135593899	chr6:135301568~135307158:+
BRCA	cis	rs28735056	0.903	rs56185453	ENSG00000261126.6	RP11-795F19.1	-4.06	5.36e-05	0.00363	-0.12	-0.12	Schizophrenia;	chr18:79878297	chr18:80046900~80095482:+
BRCA	cis	rs2302465	0.652	rs113796811	ENSG00000273133.1	RP11-799M12.2	-4.06	5.36e-05	0.00364	-0.25	-0.12	Blood protein levels;	chr4:15639152	chr4:15563698~15564253:-
BRCA	cis	rs2302465	0.789	rs73241120	ENSG00000273133.1	RP11-799M12.2	-4.06	5.36e-05	0.00364	-0.25	-0.12	Blood protein levels;	chr4:15639850	chr4:15563698~15564253:-
BRCA	cis	rs2302465	0.86	rs56149419	ENSG00000273133.1	RP11-799M12.2	-4.06	5.36e-05	0.00364	-0.25	-0.12	Blood protein levels;	chr4:15643853	chr4:15563698~15564253:-
BRCA	cis	rs2302465	0.86	rs55963737	ENSG00000273133.1	RP11-799M12.2	-4.06	5.36e-05	0.00364	-0.25	-0.12	Blood protein levels;	chr4:15644272	chr4:15563698~15564253:-
BRCA	cis	rs2302465	0.86	rs73241185	ENSG00000273133.1	RP11-799M12.2	-4.06	5.36e-05	0.00364	-0.25	-0.12	Blood protein levels;	chr4:15648299	chr4:15563698~15564253:-
BRCA	cis	rs2302465	0.86	rs73241190	ENSG00000273133.1	RP11-799M12.2	-4.06	5.36e-05	0.00364	-0.25	-0.12	Blood protein levels;	chr4:15649740	chr4:15563698~15564253:-
BRCA	cis	rs2302465	0.86	rs73241191	ENSG00000273133.1	RP11-799M12.2	-4.06	5.36e-05	0.00364	-0.25	-0.12	Blood protein levels;	chr4:15652682	chr4:15563698~15564253:-
BRCA	cis	rs2302465	0.86	rs73241198	ENSG00000273133.1	RP11-799M12.2	-4.06	5.36e-05	0.00364	-0.25	-0.12	Blood protein levels;	chr4:15654589	chr4:15563698~15564253:-
BRCA	cis	rs747650	0.532	rs3922684	ENSG00000200376.1	RNU5E-10P	-4.06	5.36e-05	0.00364	-0.16	-0.12	Acne (severe);	chr11:47099625	chr11:47576471~47576588:-
BRCA	cis	rs11098499	0.644	rs10050092	ENSG00000260091.1	RP11-33B1.4	-4.06	5.36e-05	0.00364	-0.11	-0.12	Corneal astigmatism;	chr4:119610930	chr4:119409333~119410233:+
BRCA	cis	rs1008375	1	rs1860596	ENSG00000249502.1	AC006160.5	-4.06	5.37e-05	0.00364	-0.14	-0.12	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17658459	chr4:17587467~17614571:-
BRCA	cis	rs7267979	1	rs910997	ENSG00000274973.1	RP13-401N8.7	-4.06	5.37e-05	0.00364	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25286665	chr20:25845497~25845862:+
BRCA	cis	rs4478858	0.684	rs10798839	ENSG00000260386.4	LINC01225	-4.06	5.37e-05	0.00364	-0.15	-0.12	Alcohol dependence;	chr1:31258911	chr1:31500085~31540885:+
BRCA	cis	rs8054556	1	rs7190185	ENSG00000214725.6	CDIPT-AS1	-4.06	5.37e-05	0.00364	-0.15	-0.12	Autism spectrum disorder or schizophrenia;	chr16:29951031	chr16:29863593~29868053:+
BRCA	cis	rs7260598	0.581	rs17311328	ENSG00000268442.1	CTD-2027I19.2	4.06	5.37e-05	0.00364	0.22	0.12	Response to taxane treatment (placlitaxel);	chr19:24186640	chr19:24162370~24163425:-
BRCA	cis	rs9470794	1	rs9470765	ENSG00000204110.6	RP1-153P14.8	-4.06	5.37e-05	0.00364	-0.21	-0.12	Type 2 diabetes;	chr6:38085146	chr6:37507348~37535616:+
BRCA	cis	rs9840812	0.69	rs7628146	ENSG00000273486.1	RP11-731C17.2	4.06	5.37e-05	0.00364	0.15	0.12	Fibrinogen levels;	chr3:136279611	chr3:136837338~136839021:-
BRCA	cis	rs2243480	1	rs2243480	ENSG00000237026.1	RP11-328P23.2	4.06	5.37e-05	0.00364	0.24	0.12	Diabetic kidney disease;	chr7:66134209	chr7:65235790~65236723:-
BRCA	cis	rs1008375	1	rs4698641	ENSG00000249502.1	AC006160.5	-4.06	5.37e-05	0.00364	-0.14	-0.12	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17641007	chr4:17587467~17614571:-
BRCA	cis	rs1005277	0.579	rs9418322	ENSG00000272983.1	RP11-508N22.12	4.06	5.37e-05	0.00364	0.13	0.12	Extrinsic epigenetic age acceleration;	chr10:38088368	chr10:38137337~38144399:+
BRCA	cis	rs9308731	0.591	rs938095	ENSG00000230499.1	AC108463.1	4.06	5.37e-05	0.00364	0.14	0.12	Chronic lymphocytic leukemia;	chr2:111191232	chr2:111195963~111206494:+
BRCA	cis	rs4218	0.681	rs34977427	ENSG00000259732.1	RP11-59H7.3	-4.06	5.37e-05	0.00364	-0.16	-0.12	Social communication problems;	chr15:59098172	chr15:59121034~59133250:+
BRCA	cis	rs6121246	0.909	rs6060633	ENSG00000230613.1	HM13-AS1	4.06	5.37e-05	0.00364	0.18	0.12	Mean corpuscular hemoglobin;	chr20:31675514	chr20:31567707~31573263:-
BRCA	cis	rs6121246	0.909	rs6060644	ENSG00000230613.1	HM13-AS1	4.06	5.37e-05	0.00364	0.18	0.12	Mean corpuscular hemoglobin;	chr20:31677849	chr20:31567707~31573263:-
BRCA	cis	rs7267979	1	rs6050598	ENSG00000274973.1	RP13-401N8.7	-4.06	5.37e-05	0.00364	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25416621	chr20:25845497~25845862:+
BRCA	cis	rs12712135	0.709	rs55664618	ENSG00000234389.1	AC007278.3	-4.06	5.37e-05	0.00364	-0.11	-0.12	Blood protein levels;	chr2:102399756	chr2:102438713~102440475:+
BRCA	cis	rs860295	0.557	rs11264371	ENSG00000225855.5	RUSC1-AS1	4.06	5.37e-05	0.00364	0.1	0.12	Body mass index;	chr1:155442246	chr1:155316863~155324176:-
BRCA	cis	rs4906332	0.834	rs12882130	ENSG00000259775.1	RP11-45P15.4	-4.06	5.37e-05	0.00364	-0.14	-0.12	Coronary artery disease;	chr14:103412437	chr14:103331674~103332367:-
BRCA	cis	rs17123764	0.892	rs17123927	ENSG00000257464.1	RP11-161H23.8	-4.06	5.37e-05	0.00364	-0.22	-0.12	Intelligence (multi-trait analysis);	chr12:49755564	chr12:49442424~49442652:-
BRCA	cis	rs875971	0.642	rs35526611	ENSG00000232546.1	RP11-458F8.1	4.06	5.37e-05	0.00364	0.1	0.12	Aortic root size;	chr7:66629021	chr7:66848496~66858136:+
BRCA	cis	rs2832077	0.943	rs2832094	ENSG00000232855.5	AF131217.1	4.06	5.37e-05	0.00364	0.19	0.12	Cognitive test performance;	chr21:28793588	chr21:28439346~28674848:-
BRCA	cis	rs875971	0.929	rs778712	ENSG00000229180.5	GS1-124K5.11	4.06	5.38e-05	0.00364	0.11	0.12	Aortic root size;	chr7:66384991	chr7:66526088~66542624:-
BRCA	cis	rs11603020	0.95	rs28362950	ENSG00000265566.2	RN7SL605P	-4.06	5.38e-05	0.00364	-0.18	-0.12	Blood protein levels;	chr11:57604445	chr11:57528085~57528365:-
BRCA	cis	rs6593122	0.755	rs2877184	ENSG00000235454.1	HAUS6P3	-4.06	5.38e-05	0.00364	-0.17	-0.12	Vaccine-related adverse events;	chr7:54125289	chr7:53862233~53863339:+
BRCA	cis	rs8098244	0.737	rs1786046	ENSG00000265752.2	RP11-403A21.1	-4.06	5.38e-05	0.00365	-0.18	-0.12	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23955801	chr18:23957754~23982556:-
BRCA	cis	rs4865762	0.514	rs251335	ENSG00000247796.2	CTD-2366F13.1	4.06	5.38e-05	0.00365	0.14	0.12	Intraocular pressure;	chr5:53135806	chr5:53109842~53115126:+
BRCA	cis	rs9467773	1	rs9357010	ENSG00000241549.7	GUSBP2	4.06	5.38e-05	0.00365	0.13	0.12	Intelligence (multi-trait analysis);	chr6:26527717	chr6:26871484~26956554:-
BRCA	cis	rs6088580	0.634	rs1205338	ENSG00000276073.1	RP5-1125A11.7	4.06	5.38e-05	0.00365	0.14	0.12	Glomerular filtration rate (creatinine);	chr20:34337819	chr20:33985617~33988989:-
BRCA	cis	rs73201462	1	rs2999068	ENSG00000242551.2	POU5F1P6	-4.06	5.38e-05	0.00365	-0.2	-0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128259135	chr3:128674735~128677005:-
BRCA	cis	rs73201462	1	rs2955099	ENSG00000242551.2	POU5F1P6	-4.06	5.38e-05	0.00365	-0.2	-0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128260811	chr3:128674735~128677005:-
BRCA	cis	rs73201462	1	rs2999066	ENSG00000242551.2	POU5F1P6	-4.06	5.38e-05	0.00365	-0.2	-0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128261443	chr3:128674735~128677005:-
BRCA	cis	rs73201462	1	rs2999065	ENSG00000242551.2	POU5F1P6	-4.06	5.38e-05	0.00365	-0.2	-0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128262595	chr3:128674735~128677005:-
BRCA	cis	rs73201462	1	rs2811545	ENSG00000242551.2	POU5F1P6	-4.06	5.38e-05	0.00365	-0.2	-0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128264305	chr3:128674735~128677005:-
BRCA	cis	rs794185	0.561	rs304028	ENSG00000231249.1	ITPR1-AS1	-4.06	5.38e-05	0.00365	-0.14	-0.12	Multiple sclerosis--Brain Glutamate Levels;	chr3:4504076	chr3:4490891~4493163:-
BRCA	cis	rs73201462	1	rs2811537	ENSG00000242551.2	POU5F1P6	4.06	5.38e-05	0.00365	0.21	0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128269081	chr3:128674735~128677005:-
BRCA	cis	rs3753275	0.69	rs11121197	ENSG00000270282.1	RP5-1115A15.2	4.06	5.38e-05	0.00365	0.18	0.12	Educational attainment;	chr1:8526274	chr1:8512653~8513021:+
BRCA	cis	rs7267979	1	rs6083804	ENSG00000274973.1	RP13-401N8.7	4.06	5.38e-05	0.00365	0.14	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25336424	chr20:25845497~25845862:+
BRCA	cis	rs7267979	1	rs4815405	ENSG00000274973.1	RP13-401N8.7	4.06	5.38e-05	0.00365	0.14	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25336856	chr20:25845497~25845862:+
BRCA	cis	rs7267979	1	rs6050542	ENSG00000274973.1	RP13-401N8.7	4.06	5.38e-05	0.00365	0.14	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25338243	chr20:25845497~25845862:+
BRCA	cis	rs6496932	0.865	rs4842874	ENSG00000259774.1	RP11-182J1.13	4.06	5.39e-05	0.00365	0.19	0.12	Central corneal thickness;Corneal structure;	chr15:85323464	chr15:84422618~84425882:+
BRCA	cis	rs73201462	1	rs6765233	ENSG00000242551.2	POU5F1P6	-4.06	5.39e-05	0.00365	-0.21	-0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128284007	chr3:128674735~128677005:-
BRCA	cis	rs875971	0.545	rs3936065	ENSG00000273142.1	RP11-458F8.4	4.06	5.39e-05	0.00365	0.13	0.12	Aortic root size;	chr7:66325577	chr7:66902857~66906297:+
BRCA	cis	rs875971	0.545	rs4718335	ENSG00000273142.1	RP11-458F8.4	4.06	5.39e-05	0.00365	0.13	0.12	Aortic root size;	chr7:66339619	chr7:66902857~66906297:+
BRCA	cis	rs911119	0.954	rs2424582	ENSG00000270001.1	RP11-218C14.8	-4.05	5.39e-05	0.00365	-0.16	-0.12	Chronic kidney disease;	chr20:23641913	chr20:23631826~23632316:-
BRCA	cis	rs651907	0.535	rs1460097	ENSG00000256628.3	ZBTB11-AS1	4.05	5.39e-05	0.00365	0.16	0.12	Colorectal cancer;	chr3:101778725	chr3:101676475~101679217:+
BRCA	cis	rs801193	1	rs2659906	ENSG00000229180.5	GS1-124K5.11	4.05	5.39e-05	0.00365	0.11	0.12	Aortic root size;	chr7:66700323	chr7:66526088~66542624:-
BRCA	cis	rs7246967	0.932	rs35446354	ENSG00000198153.8	ZNF849P	-4.05	5.39e-05	0.00365	-0.17	-0.12	Bronchopulmonary dysplasia;	chr19:22844522	chr19:22685167~22686732:+
BRCA	cis	rs2562456	0.917	rs2681392	ENSG00000268119.4	CTD-2561J22.5	-4.05	5.39e-05	0.00365	-0.19	-0.12	Pain;	chr19:21513185	chr19:21444241~21463908:-
BRCA	cis	rs4869313	0.837	rs38038	ENSG00000248734.2	CTD-2260A17.1	-4.05	5.39e-05	0.00365	-0.13	-0.12	Pediatric autoimmune diseases;	chr5:96991434	chr5:96784777~96785999:+
BRCA	cis	rs4869313	0.837	rs27436	ENSG00000248734.2	CTD-2260A17.1	-4.05	5.39e-05	0.00365	-0.13	-0.12	Pediatric autoimmune diseases;	chr5:96995262	chr5:96784777~96785999:+
BRCA	cis	rs4869313	0.869	rs10044354	ENSG00000248734.2	CTD-2260A17.1	4.05	5.39e-05	0.00365	0.13	0.12	Pediatric autoimmune diseases;	chr5:96984791	chr5:96784777~96785999:+
BRCA	cis	rs4869313	0.869	rs9314181	ENSG00000248734.2	CTD-2260A17.1	4.05	5.39e-05	0.00365	0.13	0.12	Pediatric autoimmune diseases;	chr5:96984882	chr5:96784777~96785999:+
BRCA	cis	rs893818	1	rs58270968	ENSG00000261801.4	LOXL1-AS1	4.05	5.39e-05	0.00365	0.16	0.12	Exfoliation glaucoma or exfoliation syndrome;	chr15:73933804	chr15:73908071~73928248:-
BRCA	cis	rs2486012	0.826	rs2993621	ENSG00000237950.1	RP11-7O11.3	-4.05	5.39e-05	0.00365	-0.23	-0.12	Intelligence (multi-trait analysis);	chr1:43906619	chr1:43944370~43946551:-
BRCA	cis	rs783540	0.521	rs1259176	ENSG00000276710.3	CSPG4P8	4.05	5.4e-05	0.00366	0.15	0.12	Schizophrenia;	chr15:82602149	chr15:82459472~82477258:+
BRCA	cis	rs3820068	0.581	rs61056912	ENSG00000237301.1	RP4-680D5.2	-4.05	5.4e-05	0.00366	-0.16	-0.12	Systolic blood pressure;	chr1:15599801	chr1:15586136~15603626:-
BRCA	cis	rs11098499	0.863	rs1010740	ENSG00000260404.2	RP11-384K6.6	-4.05	5.4e-05	0.00366	-0.12	-0.12	Corneal astigmatism;	chr4:119542254	chr4:118591773~118633729:+
BRCA	cis	rs8180040	0.966	rs6800271	ENSG00000276925.1	RP11-708J19.3	4.05	5.4e-05	0.00366	0.14	0.12	Colorectal cancer;	chr3:47429297	chr3:47469777~47469987:+
BRCA	cis	rs853679	0.517	rs9468298	ENSG00000216901.1	AL022393.7	4.05	5.4e-05	0.00366	0.18	0.12	Depression;	chr6:28154567	chr6:28176188~28176674:+
BRCA	cis	rs853679	0.517	rs9295759	ENSG00000216901.1	AL022393.7	4.05	5.4e-05	0.00366	0.18	0.12	Depression;	chr6:28156691	chr6:28176188~28176674:+
BRCA	cis	rs853679	0.517	rs9348796	ENSG00000216901.1	AL022393.7	4.05	5.4e-05	0.00366	0.18	0.12	Depression;	chr6:28158424	chr6:28176188~28176674:+
BRCA	cis	rs853679	0.517	rs11552219	ENSG00000216901.1	AL022393.7	4.05	5.4e-05	0.00366	0.18	0.12	Depression;	chr6:28159056	chr6:28176188~28176674:+
BRCA	cis	rs853679	0.517	rs9357066	ENSG00000216901.1	AL022393.7	4.05	5.4e-05	0.00366	0.18	0.12	Depression;	chr6:28162053	chr6:28176188~28176674:+
BRCA	cis	rs875971	0.929	rs34406470	ENSG00000265600.1	AC006480.1	-4.05	5.4e-05	0.00366	-0.15	-0.12	Aortic root size;	chr7:66464969	chr7:67356680~67356779:+
BRCA	cis	rs1635	0.655	rs73742541	ENSG00000216901.1	AL022393.7	4.05	5.4e-05	0.00366	0.29	0.12	Schizophrenia;	chr6:28342838	chr6:28176188~28176674:+
BRCA	cis	rs11098499	0.708	rs1546506	ENSG00000260091.1	RP11-33B1.4	-4.05	5.4e-05	0.00366	-0.11	-0.12	Corneal astigmatism;	chr4:119320085	chr4:119409333~119410233:+
BRCA	cis	rs4478858	0.684	rs4949369	ENSG00000223907.1	LINC01226	-4.05	5.4e-05	0.00366	-0.15	-0.12	Alcohol dependence;	chr1:31250998	chr1:31518435~31524245:+
BRCA	cis	rs6546847	0.531	rs2567603	ENSG00000163016.8	ALMS1P	4.05	5.4e-05	0.00366	0.21	0.12	Urinary metabolites (H-NMR features);	chr2:73758998	chr2:73644919~73685576:+
BRCA	cis	rs7267979	0.868	rs6138546	ENSG00000277938.1	RP5-965G21.3	4.05	5.4e-05	0.00366	0.15	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25235898	chr20:25229150~25231933:+
BRCA	cis	rs7267979	1	rs7018	ENSG00000125804.12	FAM182A	-4.05	5.4e-05	0.00366	-0.16	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25297625	chr20:26054655~26086917:+
BRCA	cis	rs2486012	0.655	rs2906598	ENSG00000237950.1	RP11-7O11.3	-4.05	5.4e-05	0.00366	-0.23	-0.12	Intelligence (multi-trait analysis);	chr1:43906618	chr1:43944370~43946551:-
BRCA	cis	rs4919687	0.55	rs7904252	ENSG00000236937.2	PTGES3P4	-4.05	5.4e-05	0.00366	-0.17	-0.12	Colorectal cancer;	chr10:102696968	chr10:102845595~102845950:+
BRCA	cis	rs3764563	1	rs602300	ENSG00000267594.5	CYP4F24P	4.05	5.4e-05	0.00366	0.23	0.12	Inflammatory biomarkers;	chr19:15582230	chr19:15760241~15779909:-
BRCA	cis	rs3764563	1	rs601410	ENSG00000267594.5	CYP4F24P	4.05	5.4e-05	0.00366	0.23	0.12	Inflammatory biomarkers;	chr19:15582436	chr19:15760241~15779909:-
BRCA	cis	rs2229238	0.868	rs72999415	ENSG00000272030.1	RP1-178F15.4	-4.05	5.4e-05	0.00366	-0.18	-0.12	Coronary heart disease;	chr1:154541236	chr1:153631438~153634397:-
BRCA	cis	rs62229266	0.804	rs62230788	ENSG00000214914.3	RPL23AP3	4.05	5.4e-05	0.00366	0.16	0.12	Mitral valve prolapse;	chr21:36008039	chr21:36016079~36016546:-
BRCA	cis	rs1161098	0.723	rs1161178	ENSG00000203585.3	RP11-542B15.1	4.05	5.41e-05	0.00366	0.18	0.12	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr12:67428952	chr12:67519829~67567126:+
BRCA	cis	rs2408955	0.522	rs4760679	ENSG00000226413.2	OR8T1P	-4.05	5.41e-05	0.00366	-0.16	-0.12	Glycated hemoglobin levels;	chr12:48067852	chr12:48442030~48442947:-
BRCA	cis	rs9309473	0.607	rs1851546	ENSG00000163016.8	ALMS1P	4.05	5.41e-05	0.00366	0.15	0.12	Metabolite levels;	chr2:73363999	chr2:73644919~73685576:+
BRCA	cis	rs7267979	1	rs6076336	ENSG00000274973.1	RP13-401N8.7	4.05	5.41e-05	0.00366	0.14	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25338576	chr20:25845497~25845862:+
BRCA	cis	rs6088580	0.634	rs6120650	ENSG00000275784.1	RP5-1125A11.6	-4.05	5.41e-05	0.00366	-0.14	-0.12	Glomerular filtration rate (creatinine);	chr20:34452168	chr20:33989480~33991818:-
BRCA	cis	rs2302465	0.86	rs73239191	ENSG00000273133.1	RP11-799M12.2	-4.05	5.41e-05	0.00366	-0.25	-0.12	Blood protein levels;	chr4:15621374	chr4:15563698~15564253:-
BRCA	cis	rs9818758	0.607	rs11552724	ENSG00000225399.4	RP11-3B7.1	-4.05	5.41e-05	0.00367	-0.22	-0.12	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49119040	chr3:49260085~49261316:+
BRCA	cis	rs115575488	0.85	rs78664615	ENSG00000236804.1	RPS3AP12	4.05	5.41e-05	0.00367	0.23	0.12	Lobe attachment (rater-scored or self-reported);	chr1:119102543	chr1:119126539~119127291:-
BRCA	cis	rs1005277	0.579	rs2474567	ENSG00000272983.1	RP11-508N22.12	4.05	5.41e-05	0.00367	0.13	0.12	Extrinsic epigenetic age acceleration;	chr10:38093564	chr10:38137337~38144399:+
BRCA	cis	rs6600671	1	rs2185281	ENSG00000275131.1	CH17-472G23.4	-4.05	5.41e-05	0.00367	-0.12	-0.12	Hip geometry;	chr1:121438132	chr1:120489625~120579190:-
BRCA	cis	rs4869313	0.869	rs444309	ENSG00000248734.2	CTD-2260A17.1	-4.05	5.42e-05	0.00367	-0.13	-0.12	Pediatric autoimmune diseases;	chr5:96995665	chr5:96784777~96785999:+
BRCA	cis	rs35522438	1	rs35522438	ENSG00000188693.7	CYP51A1-AS1	-4.05	5.42e-05	0.00367	-0.14	-0.12	Breast cancer;	chr7:92243558	chr7:92134604~92180725:+
BRCA	cis	rs7523050	0.908	rs12405585	ENSG00000203897.3	SPATA42	-4.05	5.42e-05	0.00367	-0.21	-0.12	Fat distribution (HIV);	chr1:108854607	chr1:108857217~108858524:+
BRCA	cis	rs2562456	0.793	rs3853837	ENSG00000268658.4	LINC00664	4.05	5.42e-05	0.00367	0.21	0.12	Pain;	chr19:21419172	chr19:21483374~21503238:+
BRCA	cis	rs2562456	0.793	rs3853838	ENSG00000268658.4	LINC00664	4.05	5.42e-05	0.00367	0.21	0.12	Pain;	chr19:21419192	chr19:21483374~21503238:+
BRCA	cis	rs2562456	0.833	rs62110426	ENSG00000268658.4	LINC00664	4.05	5.42e-05	0.00367	0.21	0.12	Pain;	chr19:21420124	chr19:21483374~21503238:+
BRCA	cis	rs7267979	0.816	rs6076358	ENSG00000231081.1	RP4-760C5.3	4.05	5.42e-05	0.00367	0.16	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25538767	chr20:26008791~26010531:-
BRCA	cis	rs10129255	0.518	rs8009612	ENSG00000254174.1	IGHV1-12	4.05	5.42e-05	0.00367	0.1	0.12	Kawasaki disease;	chr14:106777510	chr14:106122420~106122709:-
BRCA	cis	rs11686241	0.935	rs909330	ENSG00000241520.1	AC098820.4	4.05	5.42e-05	0.00367	0.19	0.12	Cancer;	chr2:216480367	chr2:216483032~216487196:-
BRCA	cis	rs62025270	0.688	rs17577869	ENSG00000259762.1	RP11-158M2.4	-4.05	5.42e-05	0.00367	-0.18	-0.12	Idiopathic pulmonary fibrosis;	chr15:85771142	chr15:85750336~85752901:-
BRCA	cis	rs35740288	1	rs35740288	ENSG00000259407.1	RP11-158M2.3	-4.05	5.42e-05	0.00367	-0.16	-0.12	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85753854	chr15:85744109~85750281:-
BRCA	cis	rs35740288	1	rs17577449	ENSG00000259407.1	RP11-158M2.3	-4.05	5.42e-05	0.00367	-0.16	-0.12	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85753954	chr15:85744109~85750281:-
BRCA	cis	rs739496	0.579	rs11066095	ENSG00000257624.1	RP1-128M12.3	4.05	5.42e-05	0.00367	0.17	0.12	Platelet count;	chr12:111939733	chr12:112000739~112000985:-
BRCA	cis	rs739496	0.579	rs7133881	ENSG00000257624.1	RP1-128M12.3	4.05	5.42e-05	0.00367	0.17	0.12	Platelet count;	chr12:111940964	chr12:112000739~112000985:-
BRCA	cis	rs6490294	0.748	rs7295665	ENSG00000257624.1	RP1-128M12.3	4.05	5.42e-05	0.00367	0.17	0.12	Mean platelet volume;	chr12:111941467	chr12:112000739~112000985:-
BRCA	cis	rs739496	0.614	rs7137889	ENSG00000257624.1	RP1-128M12.3	4.05	5.42e-05	0.00367	0.17	0.12	Platelet count;	chr12:111941783	chr12:112000739~112000985:-
BRCA	cis	rs6490294	0.904	rs12579298	ENSG00000257624.1	RP1-128M12.3	4.05	5.42e-05	0.00367	0.17	0.12	Mean platelet volume;	chr12:111956218	chr12:112000739~112000985:-
BRCA	cis	rs6490294	0.904	rs12306814	ENSG00000257624.1	RP1-128M12.3	4.05	5.42e-05	0.00367	0.17	0.12	Mean platelet volume;	chr12:111966009	chr12:112000739~112000985:-
BRCA	cis	rs2625529	0.652	rs2034879	ENSG00000260037.4	CTD-2524L6.3	-4.05	5.42e-05	0.00367	-0.16	-0.12	Red blood cell count;	chr15:72137648	chr15:71818396~71823384:+
BRCA	cis	rs8130944	1	rs10154056	ENSG00000225731.1	AP001627.1	4.05	5.42e-05	0.00367	0.14	0.12	Perceived unattractiveness to mosquitoes;	chr21:42717774	chr21:42733594~42741758:-
BRCA	cis	rs8130944	0.897	rs4919996	ENSG00000225731.1	AP001627.1	4.05	5.42e-05	0.00367	0.14	0.12	Perceived unattractiveness to mosquitoes;	chr21:42717943	chr21:42733594~42741758:-
BRCA	cis	rs8130944	0.808	rs4919997	ENSG00000225731.1	AP001627.1	4.05	5.42e-05	0.00367	0.14	0.12	Perceived unattractiveness to mosquitoes;	chr21:42718065	chr21:42733594~42741758:-
BRCA	cis	rs8130944	1	rs7281614	ENSG00000225731.1	AP001627.1	4.05	5.42e-05	0.00367	0.14	0.12	Perceived unattractiveness to mosquitoes;	chr21:42718374	chr21:42733594~42741758:-
BRCA	cis	rs8130944	0.93	rs7278005	ENSG00000225731.1	AP001627.1	4.05	5.42e-05	0.00367	0.14	0.12	Perceived unattractiveness to mosquitoes;	chr21:42718510	chr21:42733594~42741758:-
BRCA	cis	rs733592	0.524	rs10875741	ENSG00000273765.1	RP11-370I10.11	-4.05	5.42e-05	0.00367	-0.14	-0.12	Plateletcrit;	chr12:48099139	chr12:48360920~48361377:+
BRCA	cis	rs6751744	0.924	rs13386318	ENSG00000230783.1	AC009961.2	-4.05	5.42e-05	0.00367	-0.17	-0.12	Dysphagia;	chr2:159541846	chr2:159689217~159690291:-
BRCA	cis	rs9527	0.545	rs7894588	ENSG00000213061.2	PFN1P11	4.05	5.42e-05	0.00367	0.17	0.12	Arsenic metabolism;	chr10:102996273	chr10:102838011~102845473:-
BRCA	cis	rs6452524	0.935	rs1478485	ENSG00000281327.1	LINC01338	4.05	5.42e-05	0.00367	0.14	0.12	Hypertension (SNP x SNP interaction);	chr5:83084708	chr5:82850864~82859836:-
BRCA	cis	rs11098499	0.909	rs10026736	ENSG00000260091.1	RP11-33B1.4	-4.05	5.43e-05	0.00367	-0.11	-0.12	Corneal astigmatism;	chr4:119463167	chr4:119409333~119410233:+
BRCA	cis	rs28735056	0.587	rs8093548	ENSG00000261126.6	RP11-795F19.1	-4.05	5.43e-05	0.00367	-0.12	-0.12	Schizophrenia;	chr18:79876451	chr18:80046900~80095482:+
BRCA	cis	rs1048886	0.938	rs17713212	ENSG00000271967.1	RP11-134K13.4	-4.05	5.43e-05	0.00367	-0.19	-0.12	Type 2 diabetes;	chr6:70489129	chr6:70596438~70596980:+
BRCA	cis	rs1048886	0.872	rs55761717	ENSG00000271967.1	RP11-134K13.4	-4.05	5.43e-05	0.00367	-0.19	-0.12	Type 2 diabetes;	chr6:70489778	chr6:70596438~70596980:+
BRCA	cis	rs62025270	0.848	rs62025269	ENSG00000259762.1	RP11-158M2.4	-4.05	5.43e-05	0.00368	-0.18	-0.12	Idiopathic pulmonary fibrosis;	chr15:85756859	chr15:85750336~85752901:-
BRCA	cis	rs801193	0.967	rs2707849	ENSG00000229180.5	GS1-124K5.11	4.05	5.43e-05	0.00368	0.11	0.12	Aortic root size;	chr7:66687725	chr7:66526088~66542624:-
BRCA	cis	rs7824557	0.767	rs6985460	ENSG00000248896.2	CTD-2135J3.3	4.05	5.43e-05	0.00368	0.16	0.12	Retinal vascular caliber;	chr8:11313578	chr8:10729314~10771392:+
BRCA	cis	rs921968	0.643	rs832801	ENSG00000273466.1	RP11-548H3.1	4.05	5.43e-05	0.00368	0.13	0.12	Mean corpuscular hemoglobin concentration;	chr2:218623975	chr2:218633256~218634014:-
BRCA	cis	rs921968	0.643	rs832799	ENSG00000273466.1	RP11-548H3.1	4.05	5.43e-05	0.00368	0.13	0.12	Mean corpuscular hemoglobin concentration;	chr2:218625388	chr2:218633256~218634014:-
BRCA	cis	rs13217239	0.646	rs35691005	ENSG00000124549.13	BTN2A3P	4.05	5.43e-05	0.00368	0.13	0.12	Schizophrenia;	chr6:27004291	chr6:26421391~26432383:+
BRCA	cis	rs13217239	0.646	rs10946891	ENSG00000124549.13	BTN2A3P	4.05	5.43e-05	0.00368	0.13	0.12	Schizophrenia;	chr6:27005436	chr6:26421391~26432383:+
BRCA	cis	rs13217239	0.646	rs12201393	ENSG00000124549.13	BTN2A3P	4.05	5.43e-05	0.00368	0.13	0.12	Schizophrenia;	chr6:27007911	chr6:26421391~26432383:+
BRCA	cis	rs2271404	0.506	rs12329287	ENSG00000227992.1	AC108463.2	4.05	5.43e-05	0.00368	0.16	0.12	Atopic dermatitis;	chr2:111237710	chr2:111203964~111206215:-
BRCA	cis	rs2243480	1	rs4718270	ENSG00000226002.1	RP11-460N20.5	-4.05	5.43e-05	0.00368	-0.21	-0.12	Diabetic kidney disease;	chr7:65737415	chr7:65084103~65100232:+
BRCA	cis	rs6545883	0.791	rs2600665	ENSG00000273302.1	RP11-493E12.2	4.05	5.43e-05	0.00368	0.12	0.12	Tuberculosis;	chr2:61178660	chr2:61199979~61200769:+
BRCA	cis	rs9470794	1	rs73421436	ENSG00000204110.6	RP1-153P14.8	-4.05	5.43e-05	0.00368	-0.23	-0.12	Type 2 diabetes;	chr6:37969498	chr6:37507348~37535616:+
BRCA	cis	rs875971	0.545	rs73148639	ENSG00000273142.1	RP11-458F8.4	4.05	5.44e-05	0.00368	0.12	0.12	Aortic root size;	chr7:66390342	chr7:66902857~66906297:+
BRCA	cis	rs13256369	1	rs9329166	ENSG00000254153.1	CTA-398F10.2	4.05	5.44e-05	0.00368	0.17	0.12	Obesity-related traits;	chr8:8719145	chr8:8456909~8461337:-
BRCA	cis	rs73201462	0.901	rs16843876	ENSG00000242551.2	POU5F1P6	4.05	5.44e-05	0.00368	0.2	0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128313697	chr3:128674735~128677005:-
BRCA	cis	rs1005277	0.579	rs9299760	ENSG00000272983.1	RP11-508N22.12	4.05	5.44e-05	0.00368	0.13	0.12	Extrinsic epigenetic age acceleration;	chr10:38088992	chr10:38137337~38144399:+
BRCA	cis	rs1005277	0.579	rs2023351	ENSG00000272983.1	RP11-508N22.12	4.05	5.44e-05	0.00368	0.13	0.12	Extrinsic epigenetic age acceleration;	chr10:38089886	chr10:38137337~38144399:+
BRCA	cis	rs442309	0.875	rs192004	ENSG00000238280.1	RP11-436D10.3	-4.05	5.44e-05	0.00368	-0.16	-0.12	Vogt-Koyanagi-Harada syndrome;	chr10:62745965	chr10:62793562~62805887:-
BRCA	cis	rs7809799	0.571	rs11978582	ENSG00000244219.5	GS1-259H13.2	4.05	5.44e-05	0.00368	0.26	0.12	Ulcerative colitis;	chr7:99318335	chr7:99598066~99610813:+
BRCA	cis	rs7267979	1	rs2424712	ENSG00000277938.1	RP5-965G21.3	4.05	5.44e-05	0.00368	0.15	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25436306	chr20:25229150~25231933:+
BRCA	cis	rs7267979	0.966	rs2424714	ENSG00000277938.1	RP5-965G21.3	4.05	5.44e-05	0.00368	0.15	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25438045	chr20:25229150~25231933:+
BRCA	cis	rs7267979	0.966	rs2424715	ENSG00000277938.1	RP5-965G21.3	4.05	5.44e-05	0.00368	0.15	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25439441	chr20:25229150~25231933:+
BRCA	cis	rs6599077	0.95	rs9863906	ENSG00000223797.4	ENTPD3-AS1	4.05	5.44e-05	0.00368	0.15	0.12	Sleep-related phenotypes;	chr3:40058399	chr3:40313802~40453329:-
BRCA	cis	rs2243480	1	rs781150	ENSG00000222364.1	RNU6-96P	-4.05	5.44e-05	0.00368	-0.23	-0.12	Diabetic kidney disease;	chr7:66015986	chr7:66395191~66395286:+
BRCA	cis	rs2243480	1	rs313798	ENSG00000222364.1	RNU6-96P	-4.05	5.44e-05	0.00368	-0.23	-0.12	Diabetic kidney disease;	chr7:66028044	chr7:66395191~66395286:+
BRCA	cis	rs73222236	0.746	rs28889583	ENSG00000273486.1	RP11-731C17.2	4.05	5.44e-05	0.00368	0.15	0.12	Coronary artery disease;	chr3:136460690	chr3:136837338~136839021:-
BRCA	cis	rs12122100	0.526	rs12122534	ENSG00000227242.3	NBPF13P	4.05	5.44e-05	0.00368	0.15	0.12	HIV-1 control;	chr1:147032846	chr1:147021320~147124525:-
BRCA	cis	rs757081	0.648	rs12276859	ENSG00000272034.1	SNORD14A	-4.05	5.44e-05	0.00368	-0.13	-0.12	Systolic blood pressure;	chr11:17255418	chr11:17074654~17074744:-
BRCA	cis	rs4907240	0.961	rs11691670	ENSG00000230606.9	AC159540.1	4.05	5.44e-05	0.00368	0.16	0.12	Event-related brain oscillations;	chr2:96573033	chr2:97416165~97433527:-
BRCA	cis	rs1790761	0.52	rs7124513	ENSG00000255318.1	RP11-655M14.13	-4.05	5.44e-05	0.00368	-0.15	-0.12	Mean corpuscular volume;	chr11:67628243	chr11:67618279~67627304:-
BRCA	cis	rs10504130	0.569	rs34004633	ENSG00000253844.1	RP11-546K22.1	-4.05	5.44e-05	0.00368	-0.18	-0.12	Venous thromboembolism (SNP x SNP interaction);	chr8:51764279	chr8:51961458~52022974:+
BRCA	cis	rs853679	0.517	rs4713145	ENSG00000216901.1	AL022393.7	4.05	5.44e-05	0.00368	0.18	0.12	Depression;	chr6:28139049	chr6:28176188~28176674:+
BRCA	cis	rs17092148	1	rs6088579	ENSG00000202150.1	RNU6-407P	4.05	5.45e-05	0.00369	0.19	0.12	Neuroticism;	chr20:34696820	chr20:35030317~35030420:-
BRCA	cis	rs7267979	0.868	rs6138546	ENSG00000276952.1	RP5-965G21.6	4.05	5.45e-05	0.00369	0.15	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25235898	chr20:25284915~25285588:-
BRCA	cis	rs983392	1	rs4939311	ENSG00000275344.1	MIR6503	-4.05	5.45e-05	0.00369	-0.13	-0.12	Alzheimer's disease (late onset);	chr11:60110494	chr11:60209071~60209156:-
BRCA	cis	rs995000	0.64	rs6679002	ENSG00000235545.1	RP11-230B22.1	-4.05	5.45e-05	0.00369	-0.14	-0.12	Triglyceride levels;	chr1:62734265	chr1:62688482~62710694:+
BRCA	cis	rs2731006	0.64	rs2730967	ENSG00000257114.2	RP11-25I15.3	-4.05	5.45e-05	0.00369	-0.2	-0.12	Panic disorder;	chr12:42781195	chr12:42692216~42717119:+
BRCA	cis	rs8113308	0.81	rs11879040	ENSG00000269483.1	AC006272.1	4.05	5.45e-05	0.00369	0.21	0.12	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51946856	chr19:51839924~51843324:-
BRCA	cis	rs2034650	0.904	rs59424629	ENSG00000223313.1	RNU6-516P	4.05	5.46e-05	0.00369	0.15	0.12	Interstitial lung disease;	chr15:40428343	chr15:40529570~40529673:+
BRCA	cis	rs2034650	0.904	rs61661087	ENSG00000223313.1	RNU6-516P	4.05	5.46e-05	0.00369	0.15	0.12	Interstitial lung disease;	chr15:40428344	chr15:40529570~40529673:+
BRCA	cis	rs801193	0.636	rs10233806	ENSG00000272831.1	RP11-792A8.4	-4.05	5.46e-05	0.00369	-0.11	-0.12	Aortic root size;	chr7:66653261	chr7:66739829~66740385:-
BRCA	cis	rs17270561	0.609	rs2000351	ENSG00000272462.2	U91328.19	-4.05	5.46e-05	0.00369	-0.15	-0.12	Iron status biomarkers;	chr6:25759555	chr6:25992662~26001775:+
BRCA	cis	rs17489649	0.911	rs2269205	ENSG00000271849.1	CTC-332L22.1	4.05	5.46e-05	0.00369	0.16	0.12	Intelligence (multi-trait analysis);	chr5:109786878	chr5:109687802~109688329:-
BRCA	cis	rs13126694	0.65	rs13103614	ENSG00000251429.1	RP11-597D13.7	4.05	5.46e-05	0.00369	0.12	0.12	Blood osmolality (transformed sodium);	chr4:157938359	chr4:158270378~158278676:+
BRCA	cis	rs34217772	0.64	rs58844543	ENSG00000258636.1	CTD-2298J14.2	4.05	5.46e-05	0.00369	0.16	0.12	Myopia;	chr14:41725427	chr14:41587861~41604856:-
BRCA	cis	rs7260598	0.792	rs17620029	ENSG00000268442.1	CTD-2027I19.2	4.05	5.46e-05	0.00369	0.2	0.12	Response to taxane treatment (placlitaxel);	chr19:24171510	chr19:24162370~24163425:-
BRCA	cis	rs983392	0.709	rs11230194	ENSG00000275344.1	MIR6503	-4.05	5.46e-05	0.00369	-0.13	-0.12	Alzheimer's disease (late onset);	chr11:60212842	chr11:60209071~60209156:-
BRCA	cis	rs6893300	0.961	rs11741570	ENSG00000250999.1	RP11-1379J22.5	4.05	5.46e-05	0.00369	0.18	0.12	Resting heart rate;	chr5:179781909	chr5:179657762~179664432:+
BRCA	cis	rs2446066	0.872	rs7133236	ENSG00000257379.1	RP11-793H13.8	4.05	5.46e-05	0.00369	0.19	0.12	Red blood cell count;	chr12:53397201	chr12:53441741~53467528:+
BRCA	cis	rs2446066	0.872	rs74090765	ENSG00000257379.1	RP11-793H13.8	4.05	5.46e-05	0.00369	0.19	0.12	Red blood cell count;	chr12:53399130	chr12:53441741~53467528:+
BRCA	cis	rs13108904	0.652	rs2878539	ENSG00000253399.1	AC078852.2	-4.05	5.46e-05	0.00369	-0.14	-0.12	Obesity-related traits;	chr4:1250089	chr4:1358479~1359461:+
BRCA	cis	rs17772222	0.874	rs78077739	ENSG00000258789.1	RP11-507K2.3	-4.05	5.46e-05	0.00369	-0.15	-0.12	Coronary artery calcification;	chr14:88741176	chr14:88551597~88552493:+
BRCA	cis	rs8058578	0.832	rs35969813	ENSG00000260911.2	RP11-196G11.2	4.05	5.46e-05	0.00369	0.12	0.12	Multiple myeloma;	chr16:30703096	chr16:31043150~31049868:+
BRCA	cis	rs801193	1	rs3800812	ENSG00000273142.1	RP11-458F8.4	-4.05	5.46e-05	0.00369	-0.11	-0.12	Aortic root size;	chr7:66758474	chr7:66902857~66906297:+
BRCA	cis	rs801193	1	rs4279493	ENSG00000273142.1	RP11-458F8.4	-4.05	5.46e-05	0.00369	-0.11	-0.12	Aortic root size;	chr7:66761633	chr7:66902857~66906297:+
BRCA	cis	rs11711311	1	rs12695295	ENSG00000241529.3	RN7SL767P	-4.05	5.46e-05	0.00369	-0.14	-0.12	IgG glycosylation;	chr3:113756019	chr3:113632704~113632998:+
BRCA	cis	rs2832077	0.943	rs2832106	ENSG00000232855.5	AF131217.1	4.05	5.46e-05	0.0037	0.19	0.12	Cognitive test performance;	chr21:28819445	chr21:28439346~28674848:-
BRCA	cis	rs9921338	0.961	rs9936328	ENSG00000262636.1	CTD-3088G3.4	-4.05	5.46e-05	0.0037	-0.2	-0.12	Vein graft stenosis in coronary artery bypass grafting;	chr16:11344364	chr16:11380859~11381118:-
BRCA	cis	rs9470794	1	rs9470794	ENSG00000204110.6	RP1-153P14.8	-4.05	5.46e-05	0.0037	-0.19	-0.12	Type 2 diabetes;	chr6:38139068	chr6:37507348~37535616:+
BRCA	cis	rs6751744	0.889	rs12692553	ENSG00000224152.1	AC009506.1	-4.05	5.46e-05	0.0037	-0.15	-0.12	Dysphagia;	chr2:159534337	chr2:159615296~159617082:+
BRCA	cis	rs11098403	0.833	rs1023892	ENSG00000225892.3	RP11-384K6.2	4.05	5.47e-05	0.0037	0.12	0.12	Schizophrenia;	chr4:117780197	chr4:118632274~118634759:+
BRCA	cis	rs860295	0.812	rs12081192	ENSG00000225855.5	RUSC1-AS1	4.05	5.47e-05	0.0037	0.1	0.12	Body mass index;	chr1:155768253	chr1:155316863~155324176:-
BRCA	cis	rs7572733	0.935	rs10048735	ENSG00000231621.1	AC013264.2	-4.05	5.47e-05	0.0037	-0.11	-0.12	Dermatomyositis;	chr2:197877801	chr2:197197991~197199273:+
BRCA	cis	rs739496	0.527	rs10849981	ENSG00000257624.1	RP1-128M12.3	4.05	5.47e-05	0.0037	0.17	0.12	Platelet count;	chr12:111897413	chr12:112000739~112000985:-
BRCA	cis	rs860295	0.702	rs11264366	ENSG00000232093.1	RP11-307C12.11	4.05	5.47e-05	0.0037	0.14	0.12	Body mass index;	chr1:155365620	chr1:155045191~155046118:-
BRCA	cis	rs495337	0.76	rs2254930	ENSG00000229222.1	KRT18P4	-4.05	5.47e-05	0.0037	-0.15	-0.12	Psoriasis;	chr20:49910570	chr20:49956745~49958032:+
BRCA	cis	rs495337	0.76	rs2769977	ENSG00000229222.1	KRT18P4	-4.05	5.47e-05	0.0037	-0.15	-0.12	Psoriasis;	chr20:49910927	chr20:49956745~49958032:+
BRCA	cis	rs495337	0.646	rs6067267	ENSG00000229222.1	KRT18P4	-4.05	5.47e-05	0.0037	-0.15	-0.12	Psoriasis;	chr20:49911700	chr20:49956745~49958032:+
BRCA	cis	rs78487399	0.808	rs114563746	ENSG00000234936.1	AC010883.5	4.05	5.47e-05	0.0037	0.2	0.12	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43533741	chr2:43229573~43233394:+
BRCA	cis	rs2274459	0.818	rs13206228	ENSG00000249346.5	LINC01016	4.05	5.47e-05	0.0037	0.17	0.12	Obesity (extreme);	chr6:33751606	chr6:33867506~33896914:-
BRCA	cis	rs660899	0.857	rs3791044	ENSG00000229431.1	RP1-92O14.6	-4.05	5.47e-05	0.0037	-0.13	-0.12	Hypertension risk in short sleep duration;	chr1:43754262	chr1:43385113~43389155:+
BRCA	cis	rs1008375	1	rs60178264	ENSG00000249502.1	AC006160.5	-4.05	5.47e-05	0.0037	-0.14	-0.12	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17683685	chr4:17587467~17614571:-
BRCA	cis	rs1008375	1	rs28497813	ENSG00000249502.1	AC006160.5	-4.05	5.47e-05	0.0037	-0.14	-0.12	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17683880	chr4:17587467~17614571:-
BRCA	cis	rs6968419	0.761	rs7808705	ENSG00000279086.1	RP11-667F14.1	-4.05	5.47e-05	0.0037	-0.12	-0.12	Intraocular pressure;	chr7:116144284	chr7:116209234~116211511:-
BRCA	cis	rs4561483	0.801	rs33643	ENSG00000261216.1	RP11-166B2.5	-4.05	5.47e-05	0.0037	-0.15	-0.12	Testicular germ cell tumor;	chr16:11892292	chr16:11908208~11908916:+
BRCA	cis	rs7621331	0.963	rs6809006	ENSG00000239213.4	NCK1-AS1	4.05	5.47e-05	0.0037	0.14	0.12	Waist circumference adjusted for body mass index;	chr3:136012398	chr3:136841726~136862054:-
BRCA	cis	rs13063635	0.831	rs35209528	ENSG00000223552.1	RP11-24F11.2	-4.05	5.47e-05	0.0037	-0.21	-0.12	Eosinophil percentage of granulocytes;	chr3:45962004	chr3:46364955~46407059:-
BRCA	cis	rs2554380	0.843	rs1019665	ENSG00000230373.7	GOLGA6L5P	-4.05	5.48e-05	0.0037	-0.17	-0.12	Height;	chr15:83711867	chr15:84507885~84516814:-
BRCA	cis	rs2554380	0.843	rs1019667	ENSG00000230373.7	GOLGA6L5P	-4.05	5.48e-05	0.0037	-0.17	-0.12	Height;	chr15:83712097	chr15:84507885~84516814:-
BRCA	cis	rs2243480	1	rs316326	ENSG00000237026.1	RP11-328P23.2	4.05	5.48e-05	0.0037	0.23	0.12	Diabetic kidney disease;	chr7:66144466	chr7:65235790~65236723:-
BRCA	cis	rs2243480	1	rs316325	ENSG00000237026.1	RP11-328P23.2	4.05	5.48e-05	0.0037	0.23	0.12	Diabetic kidney disease;	chr7:66144531	chr7:65235790~65236723:-
BRCA	cis	rs17270561	0.609	rs4132072	ENSG00000272462.2	U91328.19	-4.05	5.48e-05	0.0037	-0.15	-0.12	Iron status biomarkers;	chr6:25717615	chr6:25992662~26001775:+
BRCA	cis	rs1345301	0.518	rs1035131	ENSG00000234389.1	AC007278.3	-4.05	5.48e-05	0.00371	-0.11	-0.12	Waist circumference;	chr2:102246181	chr2:102438713~102440475:+
BRCA	cis	rs3816183	0.959	rs893733	ENSG00000226491.1	FTOP1	-4.05	5.48e-05	0.00371	-0.16	-0.12	Hypospadias;	chr2:42789698	chr2:42797225~42798712:-
BRCA	cis	rs1528472	0.868	rs2899576	ENSG00000276533.1	RP11-139H15.5	-4.05	5.48e-05	0.00371	-0.14	-0.12	Urinary albumin-to-creatinine ratio;Urinary albumin-to-creatinine ratio in non-diabetics;	chr15:55028419	chr15:55288849~55289346:-
BRCA	cis	rs739496	0.793	rs655107	ENSG00000234608.6	MAPKAPK5-AS1	4.05	5.48e-05	0.00371	0.15	0.12	Platelet count;	chr12:111558753	chr12:111839764~111842902:-
BRCA	cis	rs739496	0.843	rs642536	ENSG00000234608.6	MAPKAPK5-AS1	4.05	5.48e-05	0.00371	0.15	0.12	Platelet count;	chr12:111559219	chr12:111839764~111842902:-
BRCA	cis	rs739496	0.843	rs848129	ENSG00000234608.6	MAPKAPK5-AS1	4.05	5.48e-05	0.00371	0.15	0.12	Platelet count;	chr12:111559698	chr12:111839764~111842902:-
BRCA	cis	rs7690839	1	rs4693974	ENSG00000270720.1	RP11-84C13.2	4.05	5.48e-05	0.00371	0.14	0.12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr4:88889244	chr4:89119284~89119871:+
BRCA	cis	rs6012564	0.964	rs3092302	ENSG00000222365.1	SNORD12B	-4.05	5.48e-05	0.00371	-0.13	-0.12	Anger;	chr20:49037721	chr20:49280319~49280409:+
BRCA	cis	rs6012564	0.964	rs73266241	ENSG00000222365.1	SNORD12B	4.05	5.48e-05	0.00371	0.13	0.12	Anger;	chr20:49043748	chr20:49280319~49280409:+
BRCA	cis	rs1538970	0.847	rs1771550	ENSG00000281133.1	AL355480.3	4.05	5.49e-05	0.00371	0.16	0.12	Platelet count;	chr1:45417893	chr1:45580892~45580996:-
BRCA	cis	rs7267979	1	rs453329	ENSG00000274973.1	RP13-401N8.7	-4.05	5.49e-05	0.00371	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25459957	chr20:25845497~25845862:+
BRCA	cis	rs9926296	0.744	rs164746	ENSG00000260259.1	RP11-368I7.4	4.05	5.49e-05	0.00371	0.17	0.12	Vitiligo;	chr16:89642611	chr16:89682620~89686569:-
BRCA	cis	rs3764563	1	rs586608	ENSG00000267594.5	CYP4F24P	4.05	5.49e-05	0.00371	0.23	0.12	Inflammatory biomarkers;	chr19:15583357	chr19:15760241~15779909:-
BRCA	cis	rs2143950	0.512	rs77772792	ENSG00000226677.3	IGBP1P1	-4.05	5.49e-05	0.00371	-0.17	-0.12	Atopic dermatitis;	chr14:35050921	chr14:34939324~34940332:+
BRCA	cis	rs6671200	0.748	rs34254763	ENSG00000235501.4	RP4-639F20.1	-4.05	5.49e-05	0.00371	-0.28	-0.12	Stearic acid (18:0) levels;	chr1:95075405	chr1:94927566~94963270:+
BRCA	cis	rs10799445	0.55	rs7512348	ENSG00000227711.2	RP11-275O4.5	4.05	5.49e-05	0.00371	0.15	0.12	Height;	chr1:227552571	chr1:227509028~227520477:-
BRCA	cis	rs11098499	0.754	rs28643450	ENSG00000260091.1	RP11-33B1.4	-4.05	5.49e-05	0.00371	-0.11	-0.12	Corneal astigmatism;	chr4:119324087	chr4:119409333~119410233:+
BRCA	cis	rs91731	1	rs272750	ENSG00000249572.1	CTD-2203K17.1	-4.05	5.49e-05	0.00371	-0.24	-0.12	Lung function (FVC);	chr5:33345974	chr5:33424025~33440619:-
BRCA	cis	rs1153858	0.621	rs12913645	ENSG00000275672.1	GATM-AS1	4.05	5.49e-05	0.00371	0.17	0.12	Homoarginine levels;	chr15:45262868	chr15:45378700~45380123:+
BRCA	cis	rs9425766	0.679	rs4650990	ENSG00000200674.1	RN7SKP160	4.05	5.49e-05	0.00371	0.16	0.12	Life satisfaction;	chr1:174289943	chr1:173791548~173791887:+
BRCA	cis	rs6723108	0.66	rs655472	ENSG00000224043.6	CCNT2-AS1	-4.05	5.49e-05	0.00371	-0.17	-0.12	Type 2 diabetes;	chr2:134532650	chr2:134735464~134918710:-
BRCA	cis	rs2243480	1	rs6974723	ENSG00000237026.1	RP11-328P23.2	-4.05	5.49e-05	0.00371	-0.23	-0.12	Diabetic kidney disease;	chr7:66172952	chr7:65235790~65236723:-
BRCA	cis	rs2243480	1	rs9769882	ENSG00000237026.1	RP11-328P23.2	-4.05	5.49e-05	0.00371	-0.23	-0.12	Diabetic kidney disease;	chr7:66177938	chr7:65235790~65236723:-
BRCA	cis	rs2243480	1	rs6966322	ENSG00000237026.1	RP11-328P23.2	-4.05	5.49e-05	0.00371	-0.23	-0.12	Diabetic kidney disease;	chr7:66181767	chr7:65235790~65236723:-
BRCA	cis	rs2243480	1	rs4145008	ENSG00000237026.1	RP11-328P23.2	-4.05	5.49e-05	0.00371	-0.23	-0.12	Diabetic kidney disease;	chr7:66182524	chr7:65235790~65236723:-
BRCA	cis	rs11742741	0.806	rs1354168	ENSG00000248874.4	C5orf17	-4.05	5.49e-05	0.00371	-0.16	-0.12	Educational attainment;	chr5:24047867	chr5:23951348~24178263:+
BRCA	cis	rs442309	0.967	rs224032	ENSG00000238280.1	RP11-436D10.3	-4.05	5.49e-05	0.00371	-0.16	-0.12	Vogt-Koyanagi-Harada syndrome;	chr10:62762069	chr10:62793562~62805887:-
BRCA	cis	rs853679	0.517	rs868987	ENSG00000216901.1	AL022393.7	-4.05	5.49e-05	0.00371	-0.18	-0.12	Depression;	chr6:28142370	chr6:28176188~28176674:+
BRCA	cis	rs6968419	0.674	rs4730726	ENSG00000279086.1	RP11-667F14.1	-4.05	5.5e-05	0.00371	-0.13	-0.12	Intraocular pressure;	chr7:116273282	chr7:116209234~116211511:-
BRCA	cis	rs1048886	0.872	rs9455121	ENSG00000271967.1	RP11-134K13.4	-4.05	5.5e-05	0.00371	-0.17	-0.12	Type 2 diabetes;	chr6:70460144	chr6:70596438~70596980:+
BRCA	cis	rs28374715	0.578	rs72739630	ENSG00000247556.5	OIP5-AS1	4.05	5.5e-05	0.00372	0.15	0.12	Ulcerative colitis;	chr15:41338866	chr15:41283990~41309737:+
BRCA	cis	rs728616	0.558	rs2880599	ENSG00000225484.5	NUTM2B-AS1	-4.05	5.5e-05	0.00372	-0.26	-0.12	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80404679	chr10:79663088~79826594:-
BRCA	cis	rs897984	0.553	rs2125293	ENSG00000274678.1	RP11-2C24.7	-4.05	5.5e-05	0.00372	-0.16	-0.12	Dementia with Lewy bodies;	chr16:30852554	chr16:30821338~30821884:+
BRCA	cis	rs4948275	0.631	rs2606110	ENSG00000237233.2	TMEM26-AS1	-4.05	5.5e-05	0.00372	-0.15	-0.12	Night sleep phenotypes;	chr10:61587581	chr10:61452639~61481956:+
BRCA	cis	rs6494488	0.5	rs7172505	ENSG00000248415.1	GAPDHP61	-4.05	5.5e-05	0.00372	-0.25	-0.12	Coronary artery disease;	chr15:64524718	chr15:64528667~64529671:-
BRCA	cis	rs875971	0.66	rs7807930	ENSG00000232546.1	RP11-458F8.1	4.05	5.5e-05	0.00372	0.1	0.12	Aortic root size;	chr7:66622178	chr7:66848496~66858136:+
BRCA	cis	rs17270561	0.609	rs9393655	ENSG00000272462.2	U91328.19	-4.05	5.5e-05	0.00372	-0.15	-0.12	Iron status biomarkers;	chr6:25711110	chr6:25992662~26001775:+
BRCA	cis	rs7267979	1	rs2257432	ENSG00000277938.1	RP5-965G21.3	4.05	5.51e-05	0.00372	0.15	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25290450	chr20:25229150~25231933:+
BRCA	cis	rs7267979	1	rs2258066	ENSG00000277938.1	RP5-965G21.3	4.05	5.51e-05	0.00372	0.15	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25290690	chr20:25229150~25231933:+
BRCA	cis	rs7267979	1	rs2258135	ENSG00000277938.1	RP5-965G21.3	4.05	5.51e-05	0.00372	0.15	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25291687	chr20:25229150~25231933:+
BRCA	cis	rs1065852	0.526	rs4822079	ENSG00000205702.9	CYP2D7	4.05	5.51e-05	0.00372	0.11	0.12	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:41998608	chr22:42140203~42144577:-
BRCA	cis	rs78487399	0.808	rs13413856	ENSG00000234936.1	AC010883.5	4.05	5.51e-05	0.00372	0.19	0.12	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43537686	chr2:43229573~43233394:+
BRCA	cis	rs4494364	0.502	rs1920742	ENSG00000258100.1	RP11-121E16.1	4.05	5.51e-05	0.00372	0.17	0.12	Systolic blood pressure (alcohol consumption interaction);	chr12:91011489	chr12:91362196~91368606:+
BRCA	cis	rs875971	0.666	rs13242072	ENSG00000223473.2	GS1-124K5.3	-4.05	5.51e-05	0.00372	-0.1	-0.12	Aortic root size;	chr7:66301001	chr7:66491049~66493566:-
BRCA	cis	rs7520050	0.807	rs72688483	ENSG00000281133.1	AL355480.3	-4.05	5.51e-05	0.00372	-0.14	-0.12	Reticulocyte count;Red blood cell count;	chr1:45683537	chr1:45580892~45580996:-
BRCA	cis	rs6545883	0.894	rs4672423	ENSG00000273302.1	RP11-493E12.2	-4.05	5.51e-05	0.00372	-0.12	-0.12	Tuberculosis;	chr2:61208140	chr2:61199979~61200769:+
BRCA	cis	rs11633886	0.528	rs2248216	ENSG00000273972.1	CTD-2306A12.1	4.05	5.51e-05	0.00372	0.14	0.12	Diisocyanate-induced asthma;	chr15:45809383	chr15:45702640~45703183:+
BRCA	cis	rs38055	0.881	rs408393	ENSG00000247796.2	CTD-2366F13.1	-4.05	5.51e-05	0.00372	-0.15	-0.12	Acne (severe);	chr5:53317725	chr5:53109842~53115126:+
BRCA	cis	rs7772486	0.79	rs9403749	ENSG00000270638.1	RP3-466P17.1	4.05	5.51e-05	0.00372	0.14	0.12	Lobe attachment (rater-scored or self-reported);	chr6:145841103	chr6:145735570~145737218:+
BRCA	cis	rs6893300	0.776	rs55868831	ENSG00000250999.1	RP11-1379J22.5	4.05	5.51e-05	0.00372	0.16	0.12	Resting heart rate;	chr5:179730295	chr5:179657762~179664432:+
BRCA	cis	rs6893300	0.776	rs56396231	ENSG00000250999.1	RP11-1379J22.5	4.05	5.51e-05	0.00372	0.16	0.12	Resting heart rate;	chr5:179730297	chr5:179657762~179664432:+
BRCA	cis	rs6545883	0.86	rs6545847	ENSG00000273302.1	RP11-493E12.2	-4.05	5.51e-05	0.00372	-0.12	-0.12	Tuberculosis;	chr2:61218198	chr2:61199979~61200769:+
BRCA	cis	rs3764021	0.509	rs10772073	ENSG00000278635.1	CTD-2318O12.1	-4.05	5.51e-05	0.00372	-0.14	-0.12	Type 1 diabetes;	chr12:9717428	chr12:9415641~9416718:+
BRCA	cis	rs3764021	0.509	rs10772074	ENSG00000278635.1	CTD-2318O12.1	-4.05	5.51e-05	0.00372	-0.14	-0.12	Type 1 diabetes;	chr12:9717686	chr12:9415641~9416718:+
BRCA	cis	rs2439831	0.85	rs12442129	ENSG00000206991.1	RNU6-610P	-4.05	5.51e-05	0.00372	-0.2	-0.12	Lung cancer in ever smokers;	chr15:43763658	chr15:43637632~43637738:-
BRCA	cis	rs4689592	0.503	rs11945642	ENSG00000245468.3	RP11-367J11.3	-4.05	5.51e-05	0.00373	-0.14	-0.12	Monocyte percentage of white cells;	chr4:7049338	chr4:7094571~7103385:-
BRCA	cis	rs11742741	0.87	rs2877428	ENSG00000248874.4	C5orf17	-4.05	5.51e-05	0.00373	-0.16	-0.12	Educational attainment;	chr5:24090575	chr5:23951348~24178263:+
BRCA	cis	rs950169	0.519	rs7237	ENSG00000176700.18	SCAND2P	-4.05	5.52e-05	0.00373	-0.13	-0.12	Schizophrenia;	chr15:84643346	chr15:84631451~84647478:+
BRCA	cis	rs6088580	0.634	rs6059860	ENSG00000275784.1	RP5-1125A11.6	-4.05	5.52e-05	0.00373	-0.14	-0.12	Glomerular filtration rate (creatinine);	chr20:34476025	chr20:33989480~33991818:-
BRCA	cis	rs738722	0.539	rs2346397	ENSG00000279978.1	chr22-38_28785274-29006793.1	4.05	5.52e-05	0.00373	0.16	0.12	Optic cup area;Esophageal cancer and gastric cancer;	chr22:28490817	chr22:28930201~29197572:+
BRCA	cis	rs7267979	0.565	rs3752273	ENSG00000277938.1	RP5-965G21.3	-4.05	5.52e-05	0.00373	-0.15	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25614147	chr20:25229150~25231933:+
BRCA	cis	rs1040	0.69	rs9393165	ENSG00000226445.1	XXyac-YX65C7_A.2	-4.05	5.52e-05	0.00373	-0.14	-0.12	Joint mobility (Beighton score);	chr6:169220152	chr6:169213254~169239565:+
BRCA	cis	rs2625529	0.668	rs12914070	ENSG00000260037.4	CTD-2524L6.3	-4.05	5.52e-05	0.00373	-0.18	-0.12	Red blood cell count;	chr15:72041938	chr15:71818396~71823384:+
BRCA	cis	rs10191773	0.589	rs72831636	ENSG00000243389.1	AC012442.5	4.05	5.52e-05	0.00373	0.26	0.12	Yeast infection;	chr2:112190671	chr2:112589040~112614431:+
BRCA	cis	rs853679	0.517	rs4713135	ENSG00000261839.1	RP1-265C24.8	4.05	5.52e-05	0.00373	0.17	0.12	Depression;	chr6:28071808	chr6:28136849~28139678:+
BRCA	cis	rs2662776	1	rs10753607	ENSG00000232995.6	RGS5	4.05	5.52e-05	0.00373	0.13	0.12	Lead levels in blood;	chr1:163189038	chr1:163244505~163321894:-
BRCA	cis	rs11168618	0.904	rs7136845	ENSG00000273765.1	RP11-370I10.11	4.05	5.52e-05	0.00373	0.15	0.12	Adiponectin levels;	chr12:48513246	chr12:48360920~48361377:+
BRCA	cis	rs9952991	0.941	rs888270	ENSG00000260302.1	RP11-973H7.1	4.05	5.52e-05	0.00373	0.21	0.12	Inflammatory skin disease;	chr18:12774895	chr18:12774651~12775923:-
BRCA	cis	rs1129187	0.967	rs11752813	ENSG00000220614.1	RP11-480N24.4	4.05	5.52e-05	0.00373	0.14	0.12	Alzheimer's disease in APOE e4+ carriers;	chr6:42960279	chr6:43328134~43328476:+
BRCA	cis	rs3739034	0.877	rs4954164	ENSG00000224043.6	CCNT2-AS1	-4.05	5.53e-05	0.00373	-0.25	-0.12	Gut microbiome composition (winter);	chr2:134700495	chr2:134735464~134918710:-
BRCA	cis	rs2298450	0.55	rs3827184	ENSG00000231106.2	LINC01436	4.05	5.53e-05	0.00373	0.13	0.12	Schizophrenia;	chr21:36289388	chr21:36005338~36007838:+
BRCA	cis	rs9921338	0.961	rs9302459	ENSG00000262636.1	CTD-3088G3.4	4.05	5.53e-05	0.00373	0.2	0.12	Vein graft stenosis in coronary artery bypass grafting;	chr16:11326482	chr16:11380859~11381118:-
BRCA	cis	rs7267979	1	rs2257982	ENSG00000277938.1	RP5-965G21.3	4.05	5.53e-05	0.00373	0.15	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25288994	chr20:25229150~25231933:+
BRCA	cis	rs7267979	1	rs2257985	ENSG00000277938.1	RP5-965G21.3	4.05	5.53e-05	0.00373	0.15	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25289107	chr20:25229150~25231933:+
BRCA	cis	rs7267979	1	rs2257988	ENSG00000277938.1	RP5-965G21.3	4.05	5.53e-05	0.00373	0.15	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25289367	chr20:25229150~25231933:+
BRCA	cis	rs9402743	0.632	rs9389329	ENSG00000231028.7	LINC00271	4.05	5.53e-05	0.00373	0.13	0.12	Systemic lupus erythematosus;	chr6:135777966	chr6:135497801~135716055:+
BRCA	cis	rs7020830	0.898	rs506981	ENSG00000230188.1	RP11-405L18.4	4.05	5.53e-05	0.00373	0.15	0.12	Schizophrenia;	chr9:37351351	chr9:37490421~37490893:-
BRCA	cis	rs2736345	0.755	rs2736340	ENSG00000270154.1	RP11-419I17.1	4.05	5.53e-05	0.00373	0.17	0.12	Systemic lupus erythematosus;Sjögren's syndrome;	chr8:11486464	chr8:12476462~12477122:+
BRCA	cis	rs4834770	0.765	rs1511016	ENSG00000245958.5	RP11-33B1.1	-4.05	5.53e-05	0.00373	-0.11	-0.12	Blood protein levels;	chr4:119249200	chr4:119454791~119552025:+
BRCA	cis	rs2518049	0.654	rs7074004	ENSG00000224034.1	RP11-445P17.8	-4.05	5.53e-05	0.00374	-0.24	-0.12	Metabolic traits;	chr10:5197743	chr10:5266033~5271236:-
BRCA	cis	rs10761482	0.813	rs3808942	ENSG00000254271.1	RP11-131N11.4	4.05	5.53e-05	0.00374	0.17	0.12	Schizophrenia;	chr10:60391090	chr10:60734342~60741828:+
BRCA	cis	rs4907240	0.883	rs11678174	ENSG00000230606.9	AC159540.1	4.05	5.53e-05	0.00374	0.16	0.12	Event-related brain oscillations;	chr2:96583366	chr2:97416165~97433527:-
BRCA	cis	rs11158026	0.603	rs67571433	ENSG00000233924.1	AL160471.6	-4.05	5.53e-05	0.00374	-0.15	-0.12	Parkinson's disease;	chr14:54981264	chr14:55004813~55005687:-
BRCA	cis	rs4689592	0.554	rs3822270	ENSG00000245468.3	RP11-367J11.3	4.05	5.53e-05	0.00374	0.13	0.12	Monocyte percentage of white cells;	chr4:7068077	chr4:7094571~7103385:-
BRCA	cis	rs6452790	0.627	rs10514297	ENSG00000247828.6	TMEM161B-AS1	4.05	5.53e-05	0.00374	0.17	0.12	Cognitive function;	chr5:88139669	chr5:88268895~88436685:+
BRCA	cis	rs17597773	0.638	rs12129004	ENSG00000257551.1	HLX-AS1	-4.05	5.53e-05	0.00374	-0.14	-0.12	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220812173	chr1:220832763~220880140:-
BRCA	cis	rs853679	0.766	rs9368561	ENSG00000216901.1	AL022393.7	4.05	5.53e-05	0.00374	0.25	0.12	Depression;	chr6:28200565	chr6:28176188~28176674:+
BRCA	cis	rs7204230	1	rs2287078	ENSG00000261291.1	RP11-295M3.2	-4.05	5.53e-05	0.00374	-0.15	-0.12	Fibrinogen;	chr16:53292948	chr16:53168522~53169450:+
BRCA	cis	rs4073416	0.707	rs1054218	ENSG00000276116.2	FUT8-AS1	-4.05	5.53e-05	0.00374	-0.13	-0.12	N-glycan levels;	chr14:65742472	chr14:65411170~65412690:-
BRCA	cis	rs17772222	0.876	rs58655091	ENSG00000258789.1	RP11-507K2.3	-4.05	5.53e-05	0.00374	-0.15	-0.12	Coronary artery calcification;	chr14:88748567	chr14:88551597~88552493:+
BRCA	cis	rs11098499	0.865	rs10213221	ENSG00000260091.1	RP11-33B1.4	-4.05	5.53e-05	0.00374	-0.11	-0.12	Corneal astigmatism;	chr4:119334771	chr4:119409333~119410233:+
BRCA	cis	rs6088580	0.567	rs6088520	ENSG00000275784.1	RP5-1125A11.6	4.05	5.54e-05	0.00374	0.14	0.12	Glomerular filtration rate (creatinine);	chr20:34544560	chr20:33989480~33991818:-
BRCA	cis	rs801193	0.66	rs974239	ENSG00000272831.1	RP11-792A8.4	4.05	5.54e-05	0.00374	0.11	0.12	Aortic root size;	chr7:66748504	chr7:66739829~66740385:-
BRCA	cis	rs9527	0.59	rs7901197	ENSG00000213061.2	PFN1P11	4.05	5.54e-05	0.00374	0.17	0.12	Arsenic metabolism;	chr10:103080676	chr10:102838011~102845473:-
BRCA	cis	rs10463316	0.817	rs6880228	ENSG00000260581.1	CTB-113P19.4	-4.05	5.54e-05	0.00374	-0.14	-0.12	Metabolite levels (Pyroglutamine);	chr5:151398584	chr5:151652275~151655449:+
BRCA	cis	rs875971	0.508	rs10950045	ENSG00000273142.1	RP11-458F8.4	4.05	5.54e-05	0.00374	0.11	0.12	Aortic root size;	chr7:66601386	chr7:66902857~66906297:+
BRCA	cis	rs801193	0.839	rs6968619	ENSG00000273142.1	RP11-458F8.4	4.05	5.54e-05	0.00374	0.11	0.12	Aortic root size;	chr7:66603880	chr7:66902857~66906297:+
BRCA	cis	rs801193	0.805	rs12532355	ENSG00000273142.1	RP11-458F8.4	4.05	5.54e-05	0.00374	0.11	0.12	Aortic root size;	chr7:66605597	chr7:66902857~66906297:+
BRCA	cis	rs11098499	0.826	rs4472123	ENSG00000260091.1	RP11-33B1.4	-4.05	5.54e-05	0.00374	-0.11	-0.12	Corneal astigmatism;	chr4:119315475	chr4:119409333~119410233:+
BRCA	cis	rs739496	0.579	rs7974772	ENSG00000257624.1	RP1-128M12.3	4.05	5.54e-05	0.00374	0.17	0.12	Platelet count;	chr12:111894479	chr12:112000739~112000985:-
BRCA	cis	rs739496	0.579	rs10849982	ENSG00000257624.1	RP1-128M12.3	4.05	5.54e-05	0.00374	0.17	0.12	Platelet count;	chr12:111897735	chr12:112000739~112000985:-
BRCA	cis	rs6593122	0.755	rs34598583	ENSG00000235454.1	HAUS6P3	-4.05	5.54e-05	0.00374	-0.17	-0.12	Vaccine-related adverse events;	chr7:54130260	chr7:53862233~53863339:+
BRCA	cis	rs1009077	0.68	rs3775850	ENSG00000245958.5	RP11-33B1.1	4.05	5.54e-05	0.00374	0.16	0.12	Endometriosis;	chr4:119529863	chr4:119454791~119552025:+
BRCA	cis	rs11168618	0.904	rs11495273	ENSG00000240399.1	RP1-228P16.1	4.05	5.54e-05	0.00374	0.13	0.12	Adiponectin levels;	chr12:48535407	chr12:48054813~48055591:-
BRCA	cis	rs4374383	0.847	rs4848918	ENSG00000243389.1	AC012442.5	-4.05	5.54e-05	0.00374	-0.16	-0.12	Hepatitis C induced liver fibrosis;	chr2:111981905	chr2:112589040~112614431:+
BRCA	cis	rs28374715	0.578	rs13313520	ENSG00000247556.5	OIP5-AS1	4.05	5.54e-05	0.00374	0.14	0.12	Ulcerative colitis;	chr15:41336929	chr15:41283990~41309737:+
BRCA	cis	rs4478858	0.684	rs10753245	ENSG00000223907.1	LINC01226	-4.05	5.54e-05	0.00374	-0.15	-0.12	Alcohol dependence;	chr1:31258361	chr1:31518435~31524245:+
BRCA	cis	rs6545883	0.894	rs778158	ENSG00000273302.1	RP11-493E12.2	-4.05	5.54e-05	0.00374	-0.11	-0.12	Tuberculosis;	chr2:61328286	chr2:61199979~61200769:+
BRCA	cis	rs2301573	0.584	rs62265568	ENSG00000271270.4	TMCC1-AS1	-4.05	5.55e-05	0.00374	-0.27	-0.12	Hip circumference;	chr3:129774158	chr3:129893871~129918575:+
BRCA	cis	rs853679	0.517	rs9393885	ENSG00000216901.1	AL022393.7	4.05	5.55e-05	0.00375	0.18	0.12	Depression;	chr6:28082231	chr6:28176188~28176674:+
BRCA	cis	rs853679	0.517	rs9393886	ENSG00000216901.1	AL022393.7	4.05	5.55e-05	0.00375	0.18	0.12	Depression;	chr6:28082261	chr6:28176188~28176674:+
BRCA	cis	rs4713118	0.515	rs9368549	ENSG00000216901.1	AL022393.7	4.05	5.55e-05	0.00375	0.18	0.12	Parkinson's disease;	chr6:28082269	chr6:28176188~28176674:+
BRCA	cis	rs6993270	0.725	rs7814482	ENSG00000245330.4	KB-1471A8.1	-4.05	5.55e-05	0.00375	-0.19	-0.12	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr8:119897263	chr8:119867419~119874488:-
BRCA	cis	rs1730008	1	rs827168	ENSG00000279311.1	RP11-170K4.2	-4.05	5.55e-05	0.00375	-0.14	-0.12	Lobe attachment (rater-scored or self-reported);	chr3:158301060	chr3:158869898~158871821:+
BRCA	cis	rs1730008	0.964	rs827167	ENSG00000279311.1	RP11-170K4.2	-4.05	5.55e-05	0.00375	-0.14	-0.12	Lobe attachment (rater-scored or self-reported);	chr3:158301458	chr3:158869898~158871821:+
BRCA	cis	rs7267979	1	rs6050547	ENSG00000274973.1	RP13-401N8.7	4.05	5.55e-05	0.00375	0.14	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25345376	chr20:25845497~25845862:+
BRCA	cis	rs2518049	0.654	rs17134523	ENSG00000224034.1	RP11-445P17.8	-4.05	5.55e-05	0.00375	-0.24	-0.12	Metabolic traits;	chr10:5197337	chr10:5266033~5271236:-
BRCA	cis	rs6452790	0.627	rs1816739	ENSG00000247828.6	TMEM161B-AS1	-4.05	5.55e-05	0.00375	-0.17	-0.12	Cognitive function;	chr5:88138237	chr5:88268895~88436685:+
BRCA	cis	rs7267979	0.873	rs7453	ENSG00000125804.12	FAM182A	-4.05	5.55e-05	0.00375	-0.17	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25226438	chr20:26054655~26086917:+
BRCA	cis	rs2839186	0.77	rs2280956	ENSG00000228137.1	AP001469.7	-4.05	5.55e-05	0.00375	-0.13	-0.12	Testicular germ cell tumor;	chr21:46222409	chr21:46246890~46247682:+
BRCA	cis	rs1005277	0.579	rs2504143	ENSG00000272983.1	RP11-508N22.12	4.05	5.55e-05	0.00375	0.13	0.12	Extrinsic epigenetic age acceleration;	chr10:38094778	chr10:38137337~38144399:+
BRCA	cis	rs1005277	0.579	rs2474575	ENSG00000272983.1	RP11-508N22.12	4.05	5.55e-05	0.00375	0.13	0.12	Extrinsic epigenetic age acceleration;	chr10:38098973	chr10:38137337~38144399:+
BRCA	cis	rs6463739	0.765	rs7808111	ENSG00000219545.8	UMAD1	4.05	5.56e-05	0.00375	0.13	0.12	Small cell lung carcinoma;	chr7:7853735	chr7:7640711~8004059:+
BRCA	cis	rs7267979	1	rs6050617	ENSG00000277938.1	RP5-965G21.3	4.05	5.56e-05	0.00375	0.15	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25441012	chr20:25229150~25231933:+
BRCA	cis	rs7267979	0.933	rs2387887	ENSG00000277938.1	RP5-965G21.3	4.05	5.56e-05	0.00375	0.15	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25446445	chr20:25229150~25231933:+
BRCA	cis	rs7267979	1	rs6037121	ENSG00000277938.1	RP5-965G21.3	4.05	5.56e-05	0.00375	0.15	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25447675	chr20:25229150~25231933:+
BRCA	cis	rs7267979	1	rs1047171	ENSG00000277938.1	RP5-965G21.3	4.05	5.56e-05	0.00375	0.15	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25448150	chr20:25229150~25231933:+
BRCA	cis	rs7267979	1	rs6050629	ENSG00000277938.1	RP5-965G21.3	4.05	5.56e-05	0.00375	0.15	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25450044	chr20:25229150~25231933:+
BRCA	cis	rs7267979	1	rs6050630	ENSG00000277938.1	RP5-965G21.3	4.05	5.56e-05	0.00375	0.15	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25450109	chr20:25229150~25231933:+
BRCA	cis	rs2493298	1	rs6670123	ENSG00000227372.9	TP73-AS1	4.05	5.56e-05	0.00375	0.14	0.12	Coronary artery disease;	chr1:3410232	chr1:3735601~3747336:-
BRCA	cis	rs9834975	0.935	rs6438724	ENSG00000272758.4	RP11-299J3.8	-4.05	5.56e-05	0.00375	-0.13	-0.12	Diastolic blood pressure;	chr3:122364841	chr3:122416207~122443180:+
BRCA	cis	rs970548	0.908	rs10900229	ENSG00000230869.1	CTGLF10P	4.05	5.56e-05	0.00375	0.16	0.12	Total cholesterol levels;HDL cholesterol;HDL cholesterol levels;Cholesterol, total;	chr10:45625598	chr10:45678692~45700532:+
BRCA	cis	rs11955398	0.502	rs3101879	ENSG00000272308.1	RP11-231G3.1	-4.05	5.56e-05	0.00375	-0.15	-0.12	Intelligence (multi-trait analysis);	chr5:60971048	chr5:60866457~60866935:-
BRCA	cis	rs9549260	0.753	rs9532562	ENSG00000168852.11	TPTE2P5	4.05	5.56e-05	0.00376	0.14	0.12	Red blood cell count;	chr13:40579448	chr13:40822296~40921749:-
BRCA	cis	rs2708977	0.965	rs2314109	ENSG00000237510.6	AC008268.2	-4.05	5.56e-05	0.00376	-0.17	-0.12	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96577795	chr2:95789654~95800166:+
BRCA	cis	rs4073416	0.691	rs10483785	ENSG00000276116.2	FUT8-AS1	4.05	5.56e-05	0.00376	0.13	0.12	N-glycan levels;	chr14:65752799	chr14:65411170~65412690:-
BRCA	cis	rs28374715	0.635	rs28557159	ENSG00000247556.5	OIP5-AS1	4.05	5.56e-05	0.00376	0.13	0.12	Ulcerative colitis;	chr15:41365155	chr15:41283990~41309737:+
BRCA	cis	rs6686842	0.536	rs12128359	ENSG00000235358.1	RP11-399E6.1	-4.05	5.56e-05	0.00376	-0.17	-0.12	Height;	chr1:41243240	chr1:41242373~41284861:+
BRCA	cis	rs6686842	0.536	rs59911668	ENSG00000235358.1	RP11-399E6.1	-4.05	5.56e-05	0.00376	-0.17	-0.12	Height;	chr1:41243803	chr1:41242373~41284861:+
BRCA	cis	rs853679	0.517	rs9393885	ENSG00000261839.1	RP1-265C24.8	4.05	5.56e-05	0.00376	0.17	0.12	Depression;	chr6:28082231	chr6:28136849~28139678:+
BRCA	cis	rs853679	0.517	rs9393886	ENSG00000261839.1	RP1-265C24.8	4.05	5.56e-05	0.00376	0.17	0.12	Depression;	chr6:28082261	chr6:28136849~28139678:+
BRCA	cis	rs4713118	0.515	rs9368549	ENSG00000261839.1	RP1-265C24.8	4.05	5.56e-05	0.00376	0.17	0.12	Parkinson's disease;	chr6:28082269	chr6:28136849~28139678:+
BRCA	cis	rs7246967	0.604	rs12981846	ENSG00000198153.8	ZNF849P	-4.05	5.57e-05	0.00376	-0.17	-0.12	Bronchopulmonary dysplasia;	chr19:22838557	chr19:22685167~22686732:+
BRCA	cis	rs16944613	0.588	rs6416553	ENSG00000271396.1	RP11-697E2.9	4.05	5.57e-05	0.00376	0.21	0.12	Colorectal cancer;	chr15:90592179	chr15:90284376~90285580:-
BRCA	cis	rs3892630	0.824	rs35654350	ENSG00000267475.1	CTD-2538C1.2	-4.05	5.57e-05	0.00376	-0.19	-0.12	Red blood cell traits;	chr19:32732860	chr19:32687089~32691750:-
BRCA	cis	rs2640806	0.505	rs6997446	ENSG00000253105.4	KB-1448A5.1	4.05	5.57e-05	0.00376	0.14	0.12	Obesity-related traits;	chr8:96354230	chr8:96371865~96387438:-
BRCA	cis	rs7339483	0.702	rs13344859	ENSG00000268442.1	CTD-2027I19.2	4.05	5.57e-05	0.00376	0.26	0.12	Discordance in emotional problems in monozygotic twins;	chr19:24187286	chr19:24162370~24163425:-
BRCA	cis	rs1949733	0.656	rs2631762	ENSG00000251615.3	RP11-774O3.3	-4.05	5.57e-05	0.00376	-0.13	-0.12	Response to antineoplastic agents;	chr4:8421395	chr4:8355090~8358338:-
BRCA	cis	rs11098499	0.754	rs7672594	ENSG00000260091.1	RP11-33B1.4	-4.05	5.57e-05	0.00376	-0.11	-0.12	Corneal astigmatism;	chr4:119327388	chr4:119409333~119410233:+
BRCA	cis	rs6088590	1	rs6088615	ENSG00000276073.1	RP5-1125A11.7	4.05	5.57e-05	0.00376	0.14	0.12	Coronary artery disease;	chr20:34812671	chr20:33985617~33988989:-
BRCA	cis	rs9346455	0.614	rs2273888	ENSG00000279289.1	RP3-331H24.6	-4.05	5.58e-05	0.00376	-0.18	-0.12	Antipsychotic drug-induced weight gain;Antipsychotic drug-induced weight gain (time interaction);	chr6:71296809	chr6:71386852~71390829:-
BRCA	cis	rs78487399	0.808	rs17030845	ENSG00000234936.1	AC010883.5	4.05	5.58e-05	0.00376	0.19	0.12	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43460740	chr2:43229573~43233394:+
BRCA	cis	rs970548	0.955	rs11239551	ENSG00000237840.5	FAM21FP	4.05	5.58e-05	0.00376	0.17	0.12	Total cholesterol levels;HDL cholesterol;HDL cholesterol levels;Cholesterol, total;	chr10:45530659	chr10:45706431~45727231:-
BRCA	cis	rs516805	0.528	rs1379094	ENSG00000279114.1	RP3-425C14.5	4.05	5.58e-05	0.00376	0.15	0.12	Lymphocyte counts;	chr6:122098054	chr6:122471923~122484161:+
BRCA	cis	rs728616	0.681	rs12769764	ENSG00000225484.5	NUTM2B-AS1	-4.05	5.58e-05	0.00377	-0.17	-0.12	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80157357	chr10:79663088~79826594:-
BRCA	cis	rs11892454	0.604	rs6711346	ENSG00000217643.1	PTGES3P2	-4.05	5.58e-05	0.00377	-0.14	-0.12	Heschl's gyrus morphology;	chr2:25710129	chr2:25822469~25822950:+
BRCA	cis	rs7686660	1	rs4690758	ENSG00000250326.1	RP11-284M14.1	-4.05	5.58e-05	0.00377	-0.15	-0.12	Asthma;	chr4:143047663	chr4:142933195~143184861:-
BRCA	cis	rs683250	0.629	rs513468	ENSG00000254551.1	RP11-727A23.7	-4.05	5.58e-05	0.00377	-0.16	-0.12	Subcortical brain region volumes;	chr11:83222507	chr11:83209431~83213379:-
BRCA	cis	rs875971	0.545	rs75577046	ENSG00000273142.1	RP11-458F8.4	4.05	5.58e-05	0.00377	0.12	0.12	Aortic root size;	chr7:66493729	chr7:66902857~66906297:+
BRCA	cis	rs7116495	0.609	rs1894004	ENSG00000248671.6	ALG1L9P	-4.05	5.58e-05	0.00377	-0.32	-0.12	Severe influenza A (H1N1) infection;	chr11:72048771	chr11:71794363~71818238:-
BRCA	cis	rs7116495	0.867	rs4378421	ENSG00000248671.6	ALG1L9P	-4.05	5.58e-05	0.00377	-0.32	-0.12	Severe influenza A (H1N1) infection;	chr11:72050950	chr11:71794363~71818238:-
BRCA	cis	rs930395	0.514	rs9791059	ENSG00000251141.4	RP11-53O19.1	-4.05	5.58e-05	0.00377	-0.12	-0.12	Breast cancer;	chr5:44900345	chr5:44744900~44808777:-
BRCA	cis	rs930395	0.514	rs4457088	ENSG00000251141.4	RP11-53O19.1	-4.05	5.58e-05	0.00377	-0.12	-0.12	Breast cancer;	chr5:44900852	chr5:44744900~44808777:-
BRCA	cis	rs812925	0.519	rs2922089	ENSG00000273302.1	RP11-493E12.2	-4.05	5.58e-05	0.00377	-0.11	-0.12	Immature fraction of reticulocytes;	chr2:61397994	chr2:61199979~61200769:+
BRCA	cis	rs11051970	0.879	rs2651362	ENSG00000274964.1	RP11-817I4.1	-4.05	5.58e-05	0.00377	-0.14	-0.12	Response to tocilizumab in rheumatoid arthritis;	chr12:32434917	chr12:32339368~32340724:+
BRCA	cis	rs11051970	0.879	rs950080	ENSG00000274964.1	RP11-817I4.1	-4.05	5.58e-05	0.00377	-0.14	-0.12	Response to tocilizumab in rheumatoid arthritis;	chr12:32435569	chr12:32339368~32340724:+
BRCA	cis	rs11051970	0.879	rs950079	ENSG00000274964.1	RP11-817I4.1	-4.05	5.58e-05	0.00377	-0.14	-0.12	Response to tocilizumab in rheumatoid arthritis;	chr12:32435686	chr12:32339368~32340724:+
BRCA	cis	rs11051970	0.877	rs2728671	ENSG00000274964.1	RP11-817I4.1	-4.05	5.58e-05	0.00377	-0.14	-0.12	Response to tocilizumab in rheumatoid arthritis;	chr12:32436781	chr12:32339368~32340724:+
BRCA	cis	rs11711311	1	rs12736	ENSG00000241529.3	RN7SL767P	-4.05	5.59e-05	0.00377	-0.15	-0.12	IgG glycosylation;	chr3:113811364	chr3:113632704~113632998:+
BRCA	cis	rs256438	0.524	rs690325	ENSG00000251050.1	RP11-168A11.4	-4.05	5.59e-05	0.00377	-0.13	-0.12	Serum thyroid-stimulating hormone levels;	chr5:80047979	chr5:80019609~80019920:+
BRCA	cis	rs10911902	0.913	rs12137128	ENSG00000229739.2	RP11-295K2.3	-4.05	5.59e-05	0.00377	-0.18	-0.12	Schizophrenia;	chr1:186550622	chr1:186435161~186470291:+
BRCA	cis	rs10208649	1	rs6545369	ENSG00000233266.1	HMGB1P31	4.05	5.59e-05	0.00377	0.3	0.12	Body mass index;	chr2:53828006	chr2:54051334~54051760:+
BRCA	cis	rs6545883	0.929	rs10190332	ENSG00000212978.6	AC016747.3	-4.05	5.59e-05	0.00377	-0.17	-0.12	Tuberculosis;	chr2:61392132	chr2:61141592~61144969:-
BRCA	cis	rs6545883	0.895	rs7588814	ENSG00000212978.6	AC016747.3	4.05	5.59e-05	0.00377	0.17	0.12	Tuberculosis;	chr2:61468454	chr2:61141592~61144969:-
BRCA	cis	rs733592	1	rs733592	ENSG00000273765.1	RP11-370I10.11	-4.05	5.59e-05	0.00377	-0.14	-0.12	Plateletcrit;	chr12:48035993	chr12:48360920~48361377:+
BRCA	cis	rs9470794	0.915	rs79946740	ENSG00000204110.6	RP1-153P14.8	-4.05	5.59e-05	0.00377	-0.25	-0.12	Type 2 diabetes;	chr6:37873580	chr6:37507348~37535616:+
BRCA	cis	rs9470794	0.915	rs73419436	ENSG00000204110.6	RP1-153P14.8	-4.05	5.59e-05	0.00377	-0.25	-0.12	Type 2 diabetes;	chr6:37875064	chr6:37507348~37535616:+
BRCA	cis	rs6067053	0.558	rs79274472	ENSG00000227431.4	CSE1L-AS1	4.05	5.59e-05	0.00377	0.16	0.12	Intelligence (multi-trait analysis);	chr20:49297643	chr20:49040463~49046044:-
BRCA	cis	rs4218	0.597	rs10431762	ENSG00000259732.1	RP11-59H7.3	-4.05	5.59e-05	0.00377	-0.16	-0.12	Social communication problems;	chr15:59066330	chr15:59121034~59133250:+
BRCA	cis	rs7312933	0.566	rs11181454	ENSG00000257225.1	RP11-328C8.4	4.05	5.59e-05	0.00377	0.15	0.12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42352684	chr12:42459366~42466128:+
BRCA	cis	rs1865760	0.964	rs9295677	ENSG00000272462.2	U91328.19	-4.05	5.59e-05	0.00377	-0.15	-0.12	Height;	chr6:25933484	chr6:25992662~26001775:+
BRCA	cis	rs6908034	0.607	rs76413455	ENSG00000228412.5	RP4-625H18.2	4.05	5.59e-05	0.00377	0.27	0.12	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19808733	chr6:19802164~19804752:-
BRCA	cis	rs6908034	0.607	rs76525593	ENSG00000228412.5	RP4-625H18.2	4.05	5.59e-05	0.00377	0.27	0.12	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19808939	chr6:19802164~19804752:-
BRCA	cis	rs568617	1	rs656980	ENSG00000254510.1	RP11-867G23.10	4.05	5.59e-05	0.00377	0.15	0.12	Crohn's disease;	chr11:65888811	chr11:66409158~66417137:+
BRCA	cis	rs957448	0.561	rs7459558	ENSG00000261437.1	RP11-22C11.2	4.05	5.59e-05	0.00377	0.12	0.12	Nonsyndromic cleft lip with cleft palate;	chr8:94598618	chr8:94637285~94639467:-
BRCA	cis	rs539096	0.671	rs513862	ENSG00000236200.4	KDM4A-AS1	-4.05	5.59e-05	0.00377	-0.16	-0.12	Intelligence (multi-trait analysis);	chr1:43648734	chr1:43699765~43708138:-
BRCA	cis	rs11098499	0.754	rs4107728	ENSG00000260091.1	RP11-33B1.4	-4.05	5.59e-05	0.00377	-0.11	-0.12	Corneal astigmatism;	chr4:119332755	chr4:119409333~119410233:+
BRCA	cis	rs7177699	0.557	rs7403714	ENSG00000261143.1	ADAMTS7P3	4.05	5.59e-05	0.00377	0.16	0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78826308	chr15:77976042~77993057:+
BRCA	cis	rs6545883	0.894	rs6709441	ENSG00000273302.1	RP11-493E12.2	-4.05	5.59e-05	0.00377	-0.12	-0.12	Tuberculosis;	chr2:61209795	chr2:61199979~61200769:+
BRCA	cis	rs6736093	0.704	rs34593596	ENSG00000236307.2	EEF1E1P1	-4.05	5.59e-05	0.00377	-0.14	-0.12	Coronary artery disease;	chr2:112039292	chr2:111887914~111888741:+
BRCA	cis	rs1865760	0.827	rs9295680	ENSG00000272462.2	U91328.19	-4.05	5.6e-05	0.00377	-0.15	-0.12	Height;	chr6:25943875	chr6:25992662~26001775:+
BRCA	cis	rs1865760	0.827	rs9295681	ENSG00000272462.2	U91328.19	-4.05	5.6e-05	0.00377	-0.15	-0.12	Height;	chr6:25943889	chr6:25992662~26001775:+
BRCA	cis	rs983392	0.805	rs11230183	ENSG00000275344.1	MIR6503	-4.05	5.6e-05	0.00377	-0.13	-0.12	Alzheimer's disease (late onset);	chr11:60198252	chr11:60209071~60209156:-
BRCA	cis	rs721917	0.525	rs11201011	ENSG00000225484.5	NUTM2B-AS1	-4.05	5.6e-05	0.00378	-0.17	-0.12	Chronic obstructive pulmonary disease;	chr10:79980164	chr10:79663088~79826594:-
BRCA	cis	rs2274459	1	rs68168863	ENSG00000249346.5	LINC01016	4.05	5.6e-05	0.00378	0.17	0.12	Obesity (extreme);	chr6:33790461	chr6:33867506~33896914:-
BRCA	cis	rs875971	0.862	rs778724	ENSG00000273024.4	INTS4P2	-4.05	5.6e-05	0.00378	-0.14	-0.12	Aortic root size;	chr7:66364304	chr7:65647864~65715661:+
BRCA	cis	rs875971	0.66	rs801193	ENSG00000223473.2	GS1-124K5.3	-4.05	5.6e-05	0.00378	-0.1	-0.12	Aortic root size;	chr7:66565625	chr7:66491049~66493566:-
BRCA	cis	rs2662776	1	rs2662776	ENSG00000232995.6	RGS5	-4.05	5.6e-05	0.00378	-0.13	-0.12	Lead levels in blood;	chr1:163195239	chr1:163244505~163321894:-
BRCA	cis	rs91731	0.92	rs972465	ENSG00000249572.1	CTD-2203K17.1	4.05	5.6e-05	0.00378	0.22	0.12	Lung function (FVC);	chr5:33255350	chr5:33424025~33440619:-
BRCA	cis	rs11764932	0.699	rs3801423	ENSG00000229108.1	MEOX2-AS1	-4.05	5.6e-05	0.00378	-0.15	-0.12	Kidney function decline traits;	chr7:15679721	chr7:15688378~15695491:+
BRCA	cis	rs2411233	0.967	rs1824494	ENSG00000259278.1	RP11-62C7.2	4.05	5.6e-05	0.00378	0.15	0.12	Platelet count;	chr15:38992562	chr15:39019233~39024918:+
BRCA	cis	rs9844666	0.512	rs9839259	ENSG00000273486.1	RP11-731C17.2	-4.05	5.6e-05	0.00378	-0.14	-0.12	Height;	chr3:135923495	chr3:136837338~136839021:-
BRCA	cis	rs11098499	0.866	rs11098506	ENSG00000260404.2	RP11-384K6.6	4.05	5.6e-05	0.00378	0.11	0.12	Corneal astigmatism;	chr4:119363816	chr4:118591773~118633729:+
BRCA	cis	rs73222236	0.963	rs9837224	ENSG00000273486.1	RP11-731C17.2	4.05	5.6e-05	0.00378	0.14	0.12	Coronary artery disease;	chr3:136111385	chr3:136837338~136839021:-
BRCA	cis	rs739496	0.579	rs3752630	ENSG00000257624.1	RP1-128M12.3	4.05	5.6e-05	0.00378	0.17	0.12	Platelet count;	chr12:111938186	chr12:112000739~112000985:-
BRCA	cis	rs737008	0.96	rs11640295	ENSG00000262703.1	RP11-485G7.6	4.05	5.61e-05	0.00378	0.13	0.12	Obesity-related traits;	chr16:11296871	chr16:11348143~11349321:-
BRCA	cis	rs4660456	0.556	rs823674	ENSG00000238287.1	RP11-656D10.3	-4.05	5.61e-05	0.00378	-0.15	-0.12	Platelet count;	chr1:40774799	chr1:40493157~40508661:-
BRCA	cis	rs2274459	1	rs751095	ENSG00000249346.5	LINC01016	4.05	5.61e-05	0.00378	0.16	0.12	Obesity (extreme);	chr6:33774941	chr6:33867506~33896914:-
BRCA	cis	rs6430585	0.702	rs3213890	ENSG00000231890.6	DARS-AS1	-4.05	5.61e-05	0.00378	-0.19	-0.12	Corneal structure;	chr2:135794618	chr2:135985176~136022593:+
BRCA	cis	rs6430585	0.536	rs3213892	ENSG00000231890.6	DARS-AS1	-4.05	5.61e-05	0.00378	-0.19	-0.12	Corneal structure;	chr2:135794947	chr2:135985176~136022593:+
BRCA	cis	rs559406	0.54	rs11663472	ENSG00000260302.1	RP11-973H7.1	-4.05	5.61e-05	0.00378	-0.16	-0.12	Psoriasis;	chr18:12810472	chr18:12774651~12775923:-
BRCA	cis	rs10458771	0.667	rs34565590	ENSG00000227896.2	RP11-77P6.2	4.05	5.61e-05	0.00378	0.18	0.12	Amyotrophic lateral sclerosis (sporadic);	chr10:86424915	chr10:86521945~86525101:+
BRCA	cis	rs9467773	0.572	rs9467737	ENSG00000124549.13	BTN2A3P	-4.05	5.61e-05	0.00378	-0.13	-0.12	Intelligence (multi-trait analysis);	chr6:26381402	chr6:26421391~26432383:+
BRCA	cis	rs6545883	0.894	rs12615783	ENSG00000273302.1	RP11-493E12.2	-4.05	5.61e-05	0.00378	-0.12	-0.12	Tuberculosis;	chr2:61213812	chr2:61199979~61200769:+
BRCA	cis	rs2286492	0.655	rs117841439	ENSG00000179428.2	AC073072.5	4.05	5.61e-05	0.00379	0.23	0.12	Bipolar disorder;	chr7:22870922	chr7:22725395~22727620:-
BRCA	cis	rs10829156	0.741	rs9731044	ENSG00000225527.1	RP11-383B4.4	-4.05	5.62e-05	0.00379	-0.18	-0.12	Sudden cardiac arrest;	chr10:18605356	chr10:18531849~18533336:-
BRCA	cis	rs10129255	1	rs61997605	ENSG00000232216.1	IGHV3-43	4.05	5.62e-05	0.00379	0.11	0.12	Kawasaki disease;	chr14:106678368	chr14:106470264~106470800:-
BRCA	cis	rs11098499	0.863	rs13136462	ENSG00000250412.1	KLHL2P1	4.05	5.62e-05	0.00379	0.15	0.12	Corneal astigmatism;	chr4:119622018	chr4:119334329~119378233:+
BRCA	cis	rs6993270	0.725	rs76299830	ENSG00000245330.4	KB-1471A8.1	-4.05	5.62e-05	0.00379	-0.19	-0.12	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr8:119905727	chr8:119867419~119874488:-
BRCA	cis	rs4578769	0.879	rs7243408	ENSG00000273232.1	RP11-370A5.2	4.05	5.62e-05	0.00379	0.17	0.12	Eosinophil percentage of white cells;	chr18:22861647	chr18:22882825~22883357:-
BRCA	cis	rs875971	0.862	rs1981799	ENSG00000236529.1	RP13-254B10.1	4.05	5.62e-05	0.00379	0.14	0.12	Aortic root size;	chr7:66490572	chr7:65840212~65840596:+
BRCA	cis	rs11711311	1	rs16861312	ENSG00000241529.3	RN7SL767P	-4.04	5.62e-05	0.00379	-0.15	-0.12	IgG glycosylation;	chr3:113773555	chr3:113632704~113632998:+
BRCA	cis	rs8113308	0.81	rs11881650	ENSG00000269483.1	AC006272.1	-4.04	5.62e-05	0.00379	-0.22	-0.12	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51946886	chr19:51839924~51843324:-
BRCA	cis	rs62025270	0.806	rs62025266	ENSG00000259762.1	RP11-158M2.4	-4.04	5.62e-05	0.00379	-0.18	-0.12	Idiopathic pulmonary fibrosis;	chr15:85755217	chr15:85750336~85752901:-
BRCA	cis	rs8180040	0.966	rs56351005	ENSG00000280667.1	Y_RNA	-4.04	5.62e-05	0.00379	-0.14	-0.12	Colorectal cancer;	chr3:47388696	chr3:47501083~47501182:+
BRCA	cis	rs5758511	0.773	rs11913631	ENSG00000226450.2	CYP2D8P	4.04	5.62e-05	0.00379	0.13	0.12	Birth weight;	chr22:41951367	chr22:42149886~42155001:-
BRCA	cis	rs2908197	0.866	rs2961048	ENSG00000186704.9	DTX2P1	4.04	5.62e-05	0.00379	0.15	0.12	3-hydroxypropylmercapturic acid levels in smokers;	chr7:76305691	chr7:76978617~77004308:+
BRCA	cis	rs7818688	1	rs11786380	ENSG00000245080.5	RP11-320N21.1	-4.04	5.62e-05	0.00379	-0.21	-0.12	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95015908	chr8:95066808~95073182:-
BRCA	cis	rs6840360	0.642	rs10454251	ENSG00000251603.1	RP11-164P12.4	-4.04	5.62e-05	0.00379	-0.11	-0.12	Intelligence (multi-trait analysis);	chr4:151462810	chr4:151667224~151670502:+
BRCA	cis	rs12893668	0.703	rs2403197	ENSG00000244691.1	RPL10AP1	-4.04	5.62e-05	0.00379	-0.17	-0.12	Reticulocyte count;	chr14:103587427	chr14:103412119~103412761:-
BRCA	cis	rs7833986	0.534	rs17814089	ENSG00000253603.1	CTA-397H3.3	4.04	5.62e-05	0.00379	0.18	0.12	Height;	chr8:56053004	chr8:56074592~56075274:+
BRCA	cis	rs12612619	0.732	rs7560595	ENSG00000272148.1	RP11-195B17.1	4.04	5.62e-05	0.00379	0.14	0.12	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27006504	chr2:27062428~27062907:-
BRCA	cis	rs721917	0.506	rs2819097	ENSG00000242600.5	MBL1P	4.04	5.63e-05	0.00379	0.15	0.12	Chronic obstructive pulmonary disease;	chr10:79940225	chr10:79904898~79950336:+
BRCA	cis	rs6840360	0.533	rs4696297	ENSG00000270265.1	RP11-731D1.4	4.04	5.63e-05	0.00379	0.14	0.12	Intelligence (multi-trait analysis);	chr4:151804686	chr4:151333775~151353224:-
BRCA	cis	rs2243480	1	rs7456042	ENSG00000226002.1	RP11-460N20.5	-4.04	5.63e-05	0.00379	-0.2	-0.12	Diabetic kidney disease;	chr7:65834791	chr7:65084103~65100232:+
BRCA	cis	rs2243480	1	rs73142121	ENSG00000226002.1	RP11-460N20.5	-4.04	5.63e-05	0.00379	-0.2	-0.12	Diabetic kidney disease;	chr7:65846219	chr7:65084103~65100232:+
BRCA	cis	rs2243480	1	rs34702770	ENSG00000226002.1	RP11-460N20.5	-4.04	5.63e-05	0.00379	-0.2	-0.12	Diabetic kidney disease;	chr7:65879836	chr7:65084103~65100232:+
BRCA	cis	rs2243480	1	rs34637256	ENSG00000226002.1	RP11-460N20.5	-4.04	5.63e-05	0.00379	-0.2	-0.12	Diabetic kidney disease;	chr7:65895144	chr7:65084103~65100232:+
BRCA	cis	rs10266483	0.774	rs28580000	ENSG00000271550.1	BNIP3P11	-4.04	5.63e-05	0.00379	-0.17	-0.12	Response to statin therapy;	chr7:64341531	chr7:64678954~64687393:-
BRCA	cis	rs4950322	0.547	rs56864370	ENSG00000244371.2	PFN1P8	-4.04	5.63e-05	0.00379	-0.16	-0.12	Protein quantitative trait loci;	chr1:147111847	chr1:146957117~146957659:-
BRCA	cis	rs4218	0.573	rs16940998	ENSG00000259732.1	RP11-59H7.3	4.04	5.63e-05	0.00379	0.15	0.12	Social communication problems;	chr15:59086095	chr15:59121034~59133250:+
BRCA	cis	rs2274459	0.778	rs9296097	ENSG00000249346.5	LINC01016	4.04	5.63e-05	0.00379	0.15	0.12	Obesity (extreme);	chr6:33692366	chr6:33867506~33896914:-
BRCA	cis	rs2832191	1	rs8131214	ENSG00000232855.5	AF131217.1	4.04	5.63e-05	0.0038	0.15	0.12	Dental caries;	chr21:29111065	chr21:28439346~28674848:-
BRCA	cis	rs539096	0.918	rs519669	ENSG00000236200.4	KDM4A-AS1	-4.04	5.63e-05	0.0038	-0.16	-0.12	Intelligence (multi-trait analysis);	chr1:43609834	chr1:43699765~43708138:-
BRCA	cis	rs73198271	1	rs11776513	ENSG00000253893.2	FAM85B	4.04	5.63e-05	0.0038	0.19	0.12	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8751547	chr8:8167819~8226614:-
BRCA	cis	rs853679	0.517	rs1904840	ENSG00000216901.1	AL022393.7	4.04	5.63e-05	0.0038	0.18	0.12	Depression;	chr6:28140454	chr6:28176188~28176674:+
BRCA	cis	rs6545883	0.894	rs778144	ENSG00000273302.1	RP11-493E12.2	-4.04	5.63e-05	0.0038	-0.12	-0.12	Tuberculosis;	chr2:61355993	chr2:61199979~61200769:+
BRCA	cis	rs8040855	0.627	rs62019482	ENSG00000259774.1	RP11-182J1.13	4.04	5.63e-05	0.0038	0.17	0.12	Bulimia nervosa;	chr15:85071796	chr15:84422618~84425882:+
BRCA	cis	rs1910358	0.664	rs9293105	ENSG00000248874.4	C5orf17	-4.04	5.63e-05	0.0038	-0.16	-0.12	Venous thromboembolism (SNP x SNP interaction);	chr5:23948435	chr5:23951348~24178263:+
BRCA	cis	rs4835473	0.932	rs35164917	ENSG00000249741.2	RP11-673E1.3	-4.04	5.63e-05	0.0038	-0.13	-0.12	Immature fraction of reticulocytes;	chr4:143748891	chr4:143911514~143912053:-
BRCA	cis	rs2108622	0.727	rs9305069	ENSG00000267218.2	AC005336.5	4.04	5.64e-05	0.0038	0.15	0.12	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15872576	chr19:15902300~15903238:-
BRCA	cis	rs1005277	0.577	rs4934906	ENSG00000226578.1	RP11-258F22.1	-4.04	5.64e-05	0.0038	-0.13	-0.12	Extrinsic epigenetic age acceleration;	chr10:37726100	chr10:37775371~37784131:-
BRCA	cis	rs12505749	0.542	rs6849183	ENSG00000270147.1	RP11-646I6.6	4.04	5.64e-05	0.0038	0.14	0.12	Airflow obstruction;	chr4:56463770	chr4:56396312~56396871:+
BRCA	cis	rs13401620	0.797	rs3106250	ENSG00000229326.3	AC069154.4	-4.04	5.64e-05	0.0038	-0.16	-0.12	Breast size;	chr2:119854953	chr2:119698623~119700151:+
BRCA	cis	rs754466	0.561	rs11002344	ENSG00000204049.1	RP11-126H7.4	4.04	5.64e-05	0.0038	0.2	0.12	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77949967	chr10:77866875~77869610:+
BRCA	cis	rs1982963	1	rs1982963	ENSG00000277050.1	RP11-102G14.1	-4.04	5.64e-05	0.0038	-0.15	-0.12	Waist-to-hip ratio adjusted for body mass index;	chr14:52042383	chr14:51637348~51637947:-
BRCA	cis	rs4761470	0.577	rs3803070	ENSG00000258172.1	RP11-1105G2.4	-4.04	5.64e-05	0.0038	-0.17	-0.12	Estradiol plasma levels (breast cancer);	chr12:94294912	chr12:94272150~94277195:-
BRCA	cis	rs2625529	0.824	rs4776581	ENSG00000260037.4	CTD-2524L6.3	-4.04	5.64e-05	0.0038	-0.18	-0.12	Red blood cell count;	chr15:71914730	chr15:71818396~71823384:+
BRCA	cis	rs2625529	0.824	rs4777470	ENSG00000260037.4	CTD-2524L6.3	-4.04	5.64e-05	0.0038	-0.18	-0.12	Red blood cell count;	chr15:71915177	chr15:71818396~71823384:+
BRCA	cis	rs2625529	0.761	rs4776582	ENSG00000260037.4	CTD-2524L6.3	-4.04	5.64e-05	0.0038	-0.18	-0.12	Red blood cell count;	chr15:71915179	chr15:71818396~71823384:+
BRCA	cis	rs4916588	0.636	rs34533379	ENSG00000230732.4	AC127904.2	4.04	5.64e-05	0.0038	0.16	0.12	Night sleep phenotypes;	chr3:196886204	chr3:196912646~196914579:+
BRCA	cis	rs1979679	0.842	rs3741760	ENSG00000278733.1	RP11-425D17.1	-4.04	5.64e-05	0.0038	-0.15	-0.12	Ossification of the posterior longitudinal ligament of the spine;	chr12:28391531	chr12:28185625~28186190:-
BRCA	cis	rs6977955	1	rs10951192	ENSG00000234336.5	JAZF1-AS1	4.04	5.64e-05	0.0038	0.17	0.12	Allergic disease (asthma, hay fever or eczema);	chr7:28121414	chr7:28180322~28243917:+
BRCA	cis	rs4819052	0.684	rs914216	ENSG00000215447.6	BX322557.10	-4.04	5.64e-05	0.0038	-0.13	-0.12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45278383	chr21:45288052~45291738:+
BRCA	cis	rs9470794	1	rs56106114	ENSG00000204110.6	RP1-153P14.8	-4.04	5.64e-05	0.0038	-0.25	-0.12	Type 2 diabetes;	chr6:37967274	chr6:37507348~37535616:+
BRCA	cis	rs1048886	0.938	rs73482585	ENSG00000271967.1	RP11-134K13.4	-4.04	5.64e-05	0.0038	-0.17	-0.12	Type 2 diabetes;	chr6:70493160	chr6:70596438~70596980:+
BRCA	cis	rs6736093	0.966	rs11692445	ENSG00000236307.2	EEF1E1P1	-4.04	5.64e-05	0.0038	-0.16	-0.12	Coronary artery disease;	chr2:111946456	chr2:111887914~111888741:+
BRCA	cis	rs875971	0.929	rs10950041	ENSG00000236529.1	RP13-254B10.1	4.04	5.64e-05	0.0038	0.13	0.12	Aortic root size;	chr7:66508888	chr7:65840212~65840596:+
BRCA	cis	rs6490294	0.799	rs73424286	ENSG00000257624.1	RP1-128M12.3	4.04	5.64e-05	0.0038	0.17	0.12	Mean platelet volume;	chr12:111889338	chr12:112000739~112000985:-
BRCA	cis	rs11098499	0.863	rs1552092	ENSG00000260091.1	RP11-33B1.4	-4.04	5.64e-05	0.0038	-0.11	-0.12	Corneal astigmatism;	chr4:119567341	chr4:119409333~119410233:+
BRCA	cis	rs4218	0.513	rs17302142	ENSG00000259732.1	RP11-59H7.3	-4.04	5.64e-05	0.0038	-0.15	-0.12	Social communication problems;	chr15:59053813	chr15:59121034~59133250:+
BRCA	cis	rs983392	0.709	rs1820428	ENSG00000275344.1	MIR6503	-4.04	5.64e-05	0.0038	-0.13	-0.12	Alzheimer's disease (late onset);	chr11:60218860	chr11:60209071~60209156:-
BRCA	cis	rs983392	0.709	rs4492839	ENSG00000275344.1	MIR6503	-4.04	5.64e-05	0.0038	-0.13	-0.12	Alzheimer's disease (late onset);	chr11:60218926	chr11:60209071~60209156:-
BRCA	cis	rs10129255	0.536	rs8004835	ENSG00000274576.2	IGHV2-70	-4.04	5.64e-05	0.0038	-0.1	-0.12	Kawasaki disease;	chr14:106686361	chr14:106770577~106771020:-
BRCA	cis	rs73198271	1	rs11775821	ENSG00000253893.2	FAM85B	4.04	5.64e-05	0.0038	0.19	0.12	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8751643	chr8:8167819~8226614:-
BRCA	cis	rs4650943	0.586	rs2455752	ENSG00000227740.1	RP11-318C24.2	-4.04	5.65e-05	0.0038	-0.13	-0.12	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in inactive individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr1:176319795	chr1:175904762~175920513:-
BRCA	cis	rs78487399	0.908	rs80075345	ENSG00000234936.1	AC010883.5	4.04	5.65e-05	0.0038	0.17	0.12	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43583559	chr2:43229573~43233394:+
BRCA	cis	rs1696803	1	rs2935717	ENSG00000226864.1	ATE1-AS1	-4.04	5.65e-05	0.00381	-0.2	-0.12	Breast cancer;	chr10:121676732	chr10:121928312~121951965:+
BRCA	cis	rs11603691	0.901	rs7111339	ENSG00000254662.1	RP11-872D17.4	-4.04	5.65e-05	0.00381	-0.26	-0.12	Low high density lipoprotein cholesterol levels;	chr11:57323498	chr11:57325603~57327958:+
BRCA	cis	rs6088580	0.634	rs7271970	ENSG00000276073.1	RP5-1125A11.7	4.04	5.65e-05	0.00381	0.13	0.12	Glomerular filtration rate (creatinine);	chr20:34399860	chr20:33985617~33988989:-
BRCA	cis	rs1153858	1	rs56850226	ENSG00000275672.1	GATM-AS1	-4.04	5.65e-05	0.00381	-0.16	-0.12	Homoarginine levels;	chr15:45340920	chr15:45378700~45380123:+
BRCA	cis	rs11098499	0.863	rs59732491	ENSG00000260091.1	RP11-33B1.4	-4.04	5.65e-05	0.00381	-0.11	-0.12	Corneal astigmatism;	chr4:119568433	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.863	rs11723090	ENSG00000260091.1	RP11-33B1.4	-4.04	5.65e-05	0.00381	-0.11	-0.12	Corneal astigmatism;	chr4:119569437	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.909	rs28714195	ENSG00000260404.2	RP11-384K6.6	4.04	5.65e-05	0.00381	0.12	0.12	Corneal astigmatism;	chr4:119395795	chr4:118591773~118633729:+
BRCA	cis	rs7246967	0.736	rs2546463	ENSG00000198153.8	ZNF849P	-4.04	5.65e-05	0.00381	-0.19	-0.12	Bronchopulmonary dysplasia;	chr19:22811804	chr19:22685167~22686732:+
BRCA	cis	rs11187837	0.901	rs11187870	ENSG00000273450.1	RP11-76P2.4	4.04	5.65e-05	0.00381	0.27	0.12	Sudden cardiac arrest;	chr10:94328109	chr10:94314907~94315327:-
BRCA	cis	rs763121	0.962	rs2071887	ENSG00000225450.1	RP3-508I15.14	-4.04	5.65e-05	0.00381	-0.13	-0.12	Menopause (age at onset);	chr22:38483005	chr22:38739003~38749041:+
BRCA	cis	rs3768617	0.811	rs12066082	ENSG00000224468.3	RP11-181K3.4	-4.04	5.66e-05	0.00381	-0.14	-0.12	Fuchs's corneal dystrophy;	chr1:183085728	chr1:183138402~183141282:-
BRCA	cis	rs73242632	1	rs12511480	ENSG00000269949.1	RP11-738E22.3	-4.04	5.66e-05	0.00381	-0.25	-0.12	Congenital heart disease (maternal effect);	chr4:56881977	chr4:56960927~56961373:-
BRCA	cis	rs7100689	0.542	rs7096715	ENSG00000226659.1	RP11-137H2.4	-4.04	5.66e-05	0.00381	-0.17	-0.12	Post bronchodilator FEV1;	chr10:80436193	chr10:80529597~80535942:-
BRCA	cis	rs9467773	0.595	rs7767847	ENSG00000224843.5	LINC00240	-4.04	5.66e-05	0.00381	-0.14	-0.12	Intelligence (multi-trait analysis);	chr6:26597665	chr6:26956992~27023924:+
BRCA	cis	rs11098499	0.789	rs9991166	ENSG00000260091.1	RP11-33B1.4	-4.04	5.66e-05	0.00381	-0.11	-0.12	Corneal astigmatism;	chr4:119316696	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.708	rs10005237	ENSG00000260091.1	RP11-33B1.4	-4.04	5.66e-05	0.00381	-0.11	-0.12	Corneal astigmatism;	chr4:119316742	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.754	rs10213267	ENSG00000260091.1	RP11-33B1.4	-4.04	5.66e-05	0.00381	-0.11	-0.12	Corneal astigmatism;	chr4:119317919	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.754	rs10212775	ENSG00000260091.1	RP11-33B1.4	-4.04	5.66e-05	0.00381	-0.11	-0.12	Corneal astigmatism;	chr4:119318089	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.754	rs2964	ENSG00000260091.1	RP11-33B1.4	-4.04	5.66e-05	0.00381	-0.11	-0.12	Corneal astigmatism;	chr4:119318976	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.754	rs1511025	ENSG00000260091.1	RP11-33B1.4	-4.04	5.66e-05	0.00381	-0.11	-0.12	Corneal astigmatism;	chr4:119319083	chr4:119409333~119410233:+
BRCA	cis	rs4243971	0.516	rs6141659	ENSG00000275576.1	RP5-836N17.4	4.04	5.66e-05	0.00381	0.13	0.12	Inflammatory bowel disease;Crohn's disease;	chr20:32284466	chr20:32116171~32116629:+
BRCA	cis	rs7267979	0.903	rs6050482	ENSG00000125804.12	FAM182A	-4.04	5.66e-05	0.00381	-0.16	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25245691	chr20:26054655~26086917:+
BRCA	cis	rs7819412	0.595	rs4841500	ENSG00000154316.13	TDH	4.04	5.66e-05	0.00381	0.16	0.12	Triglycerides;	chr8:11130765	chr8:11339637~11368452:+
BRCA	cis	rs513088	0.681	rs494467	ENSG00000225171.2	DUTP6	4.04	5.66e-05	0.00381	0.18	0.12	Schizophrenia;	chr1:166692954	chr1:166868748~166869209:+
BRCA	cis	rs2243480	0.711	rs2460426	ENSG00000237026.1	RP11-328P23.2	-4.04	5.66e-05	0.00381	-0.23	-0.12	Diabetic kidney disease;	chr7:66158142	chr7:65235790~65236723:-
BRCA	cis	rs1008375	1	rs28480159	ENSG00000249502.1	AC006160.5	-4.04	5.66e-05	0.00381	-0.14	-0.12	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17684084	chr4:17587467~17614571:-
BRCA	cis	rs7045881	0.935	rs7851339	ENSG00000254396.1	RP11-56F10.3	4.04	5.66e-05	0.00381	0.2	0.12	Schizophrenia;	chr9:26930066	chr9:27102630~27104728:+
BRCA	cis	rs6600671	0.967	rs4844613	ENSG00000270392.2	PFN1P2	4.04	5.66e-05	0.00381	0.14	0.12	Hip geometry;	chr1:121431913	chr1:120432204~120434052:-
BRCA	cis	rs17772222	0.917	rs17260415	ENSG00000258789.1	RP11-507K2.3	-4.04	5.66e-05	0.00382	-0.15	-0.12	Coronary artery calcification;	chr14:88745629	chr14:88551597~88552493:+
BRCA	cis	rs6585424	0.925	rs11201964	ENSG00000225484.5	NUTM2B-AS1	-4.04	5.66e-05	0.00382	-0.24	-0.12	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80171611	chr10:79663088~79826594:-
BRCA	cis	rs6585424	1	rs11201966	ENSG00000225484.5	NUTM2B-AS1	-4.04	5.66e-05	0.00382	-0.24	-0.12	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80172024	chr10:79663088~79826594:-
BRCA	cis	rs7246967	1	rs12983770	ENSG00000198153.8	ZNF849P	-4.04	5.66e-05	0.00382	-0.17	-0.12	Bronchopulmonary dysplasia;	chr19:22840812	chr19:22685167~22686732:+
BRCA	cis	rs709400	0.859	rs7154948	ENSG00000258851.1	RP11-894P9.2	-4.04	5.66e-05	0.00382	-0.15	-0.12	Body mass index;	chr14:103556607	chr14:103553421~103561877:+
BRCA	cis	rs4934494	0.525	rs10881611	ENSG00000240996.1	RP11-80H5.7	-4.04	5.67e-05	0.00382	-0.15	-0.12	Red blood cell count;	chr10:89623664	chr10:89694295~89697928:-
BRCA	cis	rs12468226	0.938	rs12463937	ENSG00000272966.1	RP11-686O6.1	4.04	5.67e-05	0.00382	0.21	0.12	Urate levels;	chr2:202246543	chr2:202336739~202337200:+
BRCA	cis	rs9921338	0.961	rs4780358	ENSG00000262636.1	CTD-3088G3.4	-4.04	5.67e-05	0.00382	-0.2	-0.12	Vein graft stenosis in coronary artery bypass grafting;	chr16:11280355	chr16:11380859~11381118:-
BRCA	cis	rs2186369	0.948	rs12167679	ENSG00000272733.1	KB-208E9.1	-4.04	5.67e-05	0.00382	-0.17	-0.12	IgG N-glycosylation phenotypes (multivariate analysis);IgG digalactosylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG glycosylation;IgG fucosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);	chr22:23799503	chr22:23580880~23583859:-
BRCA	cis	rs12586478	0.568	rs17122114	ENSG00000205562.2	RP11-497E19.1	4.04	5.67e-05	0.00382	0.12	0.12	Post bronchodilator FEV1;	chr14:86322561	chr14:85524432~85529988:-
BRCA	cis	rs12439619	0.846	rs62012056	ENSG00000259429.4	UBE2Q2P2	-4.04	5.67e-05	0.00382	-0.15	-0.12	Intelligence (multi-trait analysis);	chr15:82247278	chr15:82355142~82420075:+
BRCA	cis	rs801193	0.935	rs3800820	ENSG00000223473.2	GS1-124K5.3	-4.04	5.67e-05	0.00382	-0.1	-0.12	Aortic root size;	chr7:66682191	chr7:66491049~66493566:-
BRCA	cis	rs35146811	0.624	rs1727134	ENSG00000214313.7	AZGP1P1	-4.04	5.67e-05	0.00382	-0.14	-0.12	Coronary artery disease;	chr7:100216049	chr7:99980762~99987535:+
BRCA	cis	rs35146811	0.735	rs1636978	ENSG00000214313.7	AZGP1P1	-4.04	5.67e-05	0.00382	-0.14	-0.12	Coronary artery disease;	chr7:100216289	chr7:99980762~99987535:+
BRCA	cis	rs1910358	0.69	rs7724487	ENSG00000248874.4	C5orf17	-4.04	5.67e-05	0.00382	-0.16	-0.12	Venous thromboembolism (SNP x SNP interaction);	chr5:23948162	chr5:23951348~24178263:+
BRCA	cis	rs7020830	0.522	rs10814509	ENSG00000260100.1	RP11-220I1.5	-4.04	5.67e-05	0.00382	-0.15	-0.12	Schizophrenia;	chr9:37111060	chr9:37078813~37079776:-
BRCA	cis	rs10819861	0.934	rs7041071	ENSG00000175611.10	LINC00476	4.04	5.67e-05	0.00382	0.13	0.12	Electrocardiographic traits;	chr9:96098699	chr9:95759231~95875977:-
BRCA	cis	rs875971	0.545	rs3735147	ENSG00000273142.1	RP11-458F8.4	4.04	5.67e-05	0.00382	0.12	0.12	Aortic root size;	chr7:66505541	chr7:66902857~66906297:+
BRCA	cis	rs7412746	0.658	rs11204723	ENSG00000231073.1	RP11-316M1.3	4.04	5.67e-05	0.00382	0.13	0.12	Melanoma;	chr1:150759142	chr1:150973123~150975534:+
BRCA	cis	rs38055	0.881	rs370753	ENSG00000247796.2	CTD-2366F13.1	-4.04	5.67e-05	0.00382	-0.15	-0.12	Acne (severe);	chr5:53324826	chr5:53109842~53115126:+
BRCA	cis	rs34034104	1	rs34034104	ENSG00000223313.1	RNU6-516P	4.04	5.67e-05	0.00382	0.18	0.12	Itch intensity from mosquito bite;Itch intensity from mosquito bite adjusted by bite size;	chr15:40432834	chr15:40529570~40529673:+
BRCA	cis	rs11098499	0.954	rs12506546	ENSG00000250412.1	KLHL2P1	4.04	5.67e-05	0.00382	0.15	0.12	Corneal astigmatism;	chr4:119380463	chr4:119334329~119378233:+
BRCA	cis	rs9308731	0.644	rs1837368	ENSG00000230499.1	AC108463.1	-4.04	5.67e-05	0.00382	-0.14	-0.12	Chronic lymphocytic leukemia;	chr2:111116931	chr2:111195963~111206494:+
BRCA	cis	rs6993270	0.725	rs7823167	ENSG00000245330.4	KB-1471A8.1	-4.04	5.67e-05	0.00382	-0.19	-0.12	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr8:119898806	chr8:119867419~119874488:-
BRCA	cis	rs6993270	0.779	rs7461618	ENSG00000245330.4	KB-1471A8.1	-4.04	5.67e-05	0.00382	-0.19	-0.12	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr8:119899415	chr8:119867419~119874488:-
BRCA	cis	rs6993270	0.779	rs11995595	ENSG00000245330.4	KB-1471A8.1	-4.04	5.67e-05	0.00382	-0.19	-0.12	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr8:119903122	chr8:119867419~119874488:-
BRCA	cis	rs6993270	0.779	rs59865322	ENSG00000245330.4	KB-1471A8.1	-4.04	5.67e-05	0.00382	-0.19	-0.12	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr8:119903649	chr8:119867419~119874488:-
BRCA	cis	rs10761482	0.813	rs4948409	ENSG00000254271.1	RP11-131N11.4	4.04	5.68e-05	0.00382	0.17	0.12	Schizophrenia;	chr10:60356062	chr10:60734342~60741828:+
BRCA	cis	rs853679	0.517	rs9357065	ENSG00000216901.1	AL022393.7	4.04	5.68e-05	0.00382	0.18	0.12	Depression;	chr6:28161802	chr6:28176188~28176674:+
BRCA	cis	rs3743266	0.613	rs10851681	ENSG00000245534.5	RORA-AS1	-4.04	5.68e-05	0.00382	-0.14	-0.12	Menarche (age at onset);	chr15:60439939	chr15:60479178~60630637:+
BRCA	cis	rs7520050	0.807	rs4468203	ENSG00000281133.1	AL355480.3	-4.04	5.68e-05	0.00382	-0.14	-0.12	Reticulocyte count;Red blood cell count;	chr1:45647600	chr1:45580892~45580996:-
BRCA	cis	rs10504130	0.569	rs60153173	ENSG00000253844.1	RP11-546K22.1	-4.04	5.68e-05	0.00382	-0.18	-0.12	Venous thromboembolism (SNP x SNP interaction);	chr8:51778064	chr8:51961458~52022974:+
BRCA	cis	rs6452524	0.868	rs10071617	ENSG00000281327.1	LINC01338	4.04	5.68e-05	0.00382	0.14	0.12	Hypertension (SNP x SNP interaction);	chr5:83103207	chr5:82850864~82859836:-
BRCA	cis	rs10504130	0.569	rs4534123	ENSG00000253844.1	RP11-546K22.1	4.04	5.68e-05	0.00382	0.18	0.12	Venous thromboembolism (SNP x SNP interaction);	chr8:51765297	chr8:51961458~52022974:+
BRCA	cis	rs757081	0.648	rs11024223	ENSG00000272034.1	SNORD14A	4.04	5.68e-05	0.00382	0.13	0.12	Systolic blood pressure;	chr11:17256146	chr11:17074654~17074744:-
BRCA	cis	rs5751168	0.646	rs362139	ENSG00000211654.2	IGLV5-37	4.04	5.68e-05	0.00383	0.16	0.12	Prostate cancer (SNP x SNP interaction);	chr22:22507208	chr22:22427540~22428035:+
BRCA	cis	rs6545883	0.894	rs10177303	ENSG00000273302.1	RP11-493E12.2	-4.04	5.68e-05	0.00383	-0.12	-0.12	Tuberculosis;	chr2:61367324	chr2:61199979~61200769:+
BRCA	cis	rs1005277	0.522	rs7090858	ENSG00000226578.1	RP11-258F22.1	4.04	5.68e-05	0.00383	0.13	0.12	Extrinsic epigenetic age acceleration;	chr10:37714742	chr10:37775371~37784131:-
BRCA	cis	rs970548	0.688	rs2082110	ENSG00000230869.1	CTGLF10P	4.04	5.68e-05	0.00383	0.18	0.12	Total cholesterol levels;HDL cholesterol;HDL cholesterol levels;Cholesterol, total;	chr10:45435622	chr10:45678692~45700532:+
BRCA	cis	rs970548	0.688	rs2082109	ENSG00000230869.1	CTGLF10P	4.04	5.68e-05	0.00383	0.18	0.12	Total cholesterol levels;HDL cholesterol;HDL cholesterol levels;Cholesterol, total;	chr10:45435654	chr10:45678692~45700532:+
BRCA	cis	rs6012564	1	rs11696870	ENSG00000222365.1	SNORD12B	4.04	5.68e-05	0.00383	0.13	0.12	Anger;	chr20:49109070	chr20:49280319~49280409:+
BRCA	cis	rs6012564	0.963	rs6063355	ENSG00000222365.1	SNORD12B	4.04	5.68e-05	0.00383	0.13	0.12	Anger;	chr20:49109592	chr20:49280319~49280409:+
BRCA	cis	rs4302906	0.729	rs6479442	ENSG00000187984.11	ANKRD19P	-4.04	5.69e-05	0.00383	-0.11	-0.12	Lobe attachment (rater-scored or self-reported);	chr9:92953435	chr9:92809388~92888693:+
BRCA	cis	rs11673344	0.504	rs4806407	ENSG00000226686.6	LINC01535	-4.04	5.69e-05	0.00383	-0.16	-0.12	Obesity-related traits;	chr19:37097849	chr19:37251912~37265535:+
BRCA	cis	rs6121246	0.821	rs6121209	ENSG00000230613.1	HM13-AS1	4.04	5.69e-05	0.00383	0.19	0.12	Mean corpuscular hemoglobin;	chr20:31723455	chr20:31567707~31573263:-
BRCA	cis	rs61542988	0.57	rs10950919	ENSG00000228649.7	AC005682.5	4.04	5.69e-05	0.00383	0.13	0.12	Fibrinogen levels;	chr7:22794202	chr7:22854178~22861579:+
BRCA	cis	rs983392	0.679	rs764859	ENSG00000275344.1	MIR6503	-4.04	5.69e-05	0.00383	-0.13	-0.12	Alzheimer's disease (late onset);	chr11:60210782	chr11:60209071~60209156:-
BRCA	cis	rs568617	1	rs568617	ENSG00000254510.1	RP11-867G23.10	4.04	5.69e-05	0.00383	0.15	0.12	Crohn's disease;	chr11:65885771	chr11:66409158~66417137:+
BRCA	cis	rs568617	1	rs693824	ENSG00000254510.1	RP11-867G23.10	4.04	5.69e-05	0.00383	0.15	0.12	Crohn's disease;	chr11:65887312	chr11:66409158~66417137:+
BRCA	cis	rs801193	0.901	rs4273746	ENSG00000223473.2	GS1-124K5.3	-4.04	5.69e-05	0.00383	-0.1	-0.12	Aortic root size;	chr7:66836124	chr7:66491049~66493566:-
BRCA	cis	rs930395	0.514	rs34501299	ENSG00000251141.4	RP11-53O19.1	-4.04	5.69e-05	0.00383	-0.12	-0.12	Breast cancer;	chr5:44912977	chr5:44744900~44808777:-
BRCA	cis	rs9674544	0.757	rs4410130	ENSG00000248278.1	SUMO2P17	4.04	5.69e-05	0.00383	0.15	0.12	Primary tooth development (number of teeth);Primary tooth development (time to first tooth eruption);	chr17:49045580	chr17:48874860~48908983:-
BRCA	cis	rs875971	0.545	rs2420612	ENSG00000273142.1	RP11-458F8.4	4.04	5.69e-05	0.00383	0.13	0.12	Aortic root size;	chr7:66536825	chr7:66902857~66906297:+
BRCA	cis	rs17684571	0.938	rs10498811	ENSG00000231441.1	RP11-472M19.2	4.04	5.69e-05	0.00383	0.2	0.12	Schizophrenia;	chr6:56696475	chr6:56844002~56864078:+
BRCA	cis	rs757081	0.702	rs522619	ENSG00000184669.7	OR7E14P	-4.04	5.69e-05	0.00383	-0.18	-0.12	Systolic blood pressure;	chr11:17182901	chr11:17013998~17053024:+
BRCA	cis	rs4478858	0.698	rs10914370	ENSG00000260386.4	LINC01225	-4.04	5.69e-05	0.00383	-0.15	-0.12	Alcohol dependence;	chr1:31382108	chr1:31500085~31540885:+
BRCA	cis	rs10411161	0.702	rs8110546	ENSG00000269483.1	AC006272.1	4.04	5.69e-05	0.00383	0.2	0.12	Breast cancer;	chr19:51880303	chr19:51839924~51843324:-
BRCA	cis	rs10411161	0.702	rs8110461	ENSG00000269483.1	AC006272.1	4.04	5.69e-05	0.00383	0.2	0.12	Breast cancer;	chr19:51880316	chr19:51839924~51843324:-
BRCA	cis	rs11742741	0.806	rs11745873	ENSG00000248874.4	C5orf17	-4.04	5.7e-05	0.00383	-0.16	-0.12	Educational attainment;	chr5:24074812	chr5:23951348~24178263:+
BRCA	cis	rs17772222	0.917	rs17260380	ENSG00000258789.1	RP11-507K2.3	-4.04	5.7e-05	0.00383	-0.15	-0.12	Coronary artery calcification;	chr14:88682142	chr14:88551597~88552493:+
BRCA	cis	rs72772090	0.522	rs17477471	ENSG00000248734.2	CTD-2260A17.1	4.04	5.7e-05	0.00384	0.29	0.12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96677415	chr5:96784777~96785999:+
BRCA	cis	rs35146811	0.735	rs1061230	ENSG00000235713.1	RP4-604G5.3	-4.04	5.7e-05	0.00384	-0.14	-0.12	Coronary artery disease;	chr7:100209642	chr7:99992397~99993050:+
BRCA	cis	rs7819412	0.522	rs3021495	ENSG00000154316.13	TDH	4.04	5.7e-05	0.00384	0.18	0.12	Triglycerides;	chr8:11137233	chr8:11339637~11368452:+
BRCA	cis	rs2411233	1	rs7165634	ENSG00000259278.1	RP11-62C7.2	4.04	5.7e-05	0.00384	0.14	0.12	Platelet count;	chr15:38990447	chr15:39019233~39024918:+
BRCA	cis	rs6968419	0.761	rs6964941	ENSG00000279086.1	RP11-667F14.1	-4.04	5.7e-05	0.00384	-0.12	-0.12	Intraocular pressure;	chr7:116145742	chr7:116209234~116211511:-
BRCA	cis	rs9733	0.536	rs10888385	ENSG00000203804.4	ADAMTSL4-AS1	-4.04	5.7e-05	0.00384	-0.13	-0.12	Tonsillectomy;	chr1:150601826	chr1:150560202~150574552:-
BRCA	cis	rs12468226	0.938	rs12471060	ENSG00000272966.1	RP11-686O6.1	4.04	5.7e-05	0.00384	0.21	0.12	Urate levels;	chr2:202309597	chr2:202336739~202337200:+
BRCA	cis	rs925550	0.932	rs17006039	ENSG00000224786.1	CETN4P	-4.04	5.71e-05	0.00384	-0.21	-0.12	Primary biliary cholangitis;	chr4:122684588	chr4:122730548~122732193:-
BRCA	cis	rs7260598	0.792	rs11670331	ENSG00000268442.1	CTD-2027I19.2	4.04	5.71e-05	0.00384	0.21	0.12	Response to taxane treatment (placlitaxel);	chr19:24155040	chr19:24162370~24163425:-
BRCA	cis	rs6964587	0.967	rs410	ENSG00000188693.7	CYP51A1-AS1	4.04	5.71e-05	0.00384	0.14	0.12	Breast cancer;	chr7:91928111	chr7:92134604~92180725:+
BRCA	cis	rs2243480	1	rs160643	ENSG00000275400.1	RP4-756H11.5	4.04	5.71e-05	0.00384	0.21	0.12	Diabetic kidney disease;	chr7:66093235	chr7:66553805~66554199:-
BRCA	cis	rs9733	0.818	rs4970924	ENSG00000203804.4	ADAMTSL4-AS1	-4.04	5.71e-05	0.00384	-0.13	-0.12	Tonsillectomy;	chr1:150660603	chr1:150560202~150574552:-
BRCA	cis	rs4665809	0.759	rs62128394	ENSG00000231655.1	AC011742.3	-4.04	5.71e-05	0.00384	-0.21	-0.12	Gut microbiome composition (summer);	chr2:26141157	chr2:26140263~26141264:-
BRCA	cis	rs4650943	0.586	rs1948816	ENSG00000227740.1	RP11-318C24.2	-4.04	5.71e-05	0.00384	-0.13	-0.12	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in inactive individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr1:176324257	chr1:175904762~175920513:-
BRCA	cis	rs34792	0.554	rs62039130	ENSG00000258354.1	MIR3180-1	-4.04	5.71e-05	0.00384	-0.17	-0.12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15518277	chr16:14909887~14911345:-
BRCA	cis	rs7474896	1	rs11011344	ENSG00000272983.1	RP11-508N22.12	4.04	5.71e-05	0.00384	0.19	0.12	Obesity (extreme);	chr10:37715918	chr10:38137337~38144399:+
BRCA	cis	rs990171	0.538	rs4851599	ENSG00000234389.1	AC007278.3	4.04	5.71e-05	0.00384	0.12	0.12	Lymphocyte counts;	chr2:102499561	chr2:102438713~102440475:+
BRCA	cis	rs990171	0.511	rs4851013	ENSG00000234389.1	AC007278.3	4.04	5.71e-05	0.00384	0.12	0.12	Lymphocyte counts;	chr2:102499676	chr2:102438713~102440475:+
BRCA	cis	rs1005277	0.579	rs1780122	ENSG00000272983.1	RP11-508N22.12	4.04	5.71e-05	0.00384	0.13	0.12	Extrinsic epigenetic age acceleration;	chr10:38240581	chr10:38137337~38144399:+
BRCA	cis	rs4664293	0.647	rs7587700	ENSG00000224152.1	AC009506.1	-4.04	5.71e-05	0.00384	-0.13	-0.12	Monocyte percentage of white cells;	chr2:159587809	chr2:159615296~159617082:+
BRCA	cis	rs4835473	0.897	rs6537167	ENSG00000249741.2	RP11-673E1.3	-4.04	5.71e-05	0.00384	-0.13	-0.12	Immature fraction of reticulocytes;	chr4:143691323	chr4:143911514~143912053:-
BRCA	cis	rs6545883	0.826	rs777590	ENSG00000270820.4	RP11-355B11.2	4.04	5.71e-05	0.00384	0.14	0.12	Tuberculosis;	chr2:61190010	chr2:61471188~61484130:+
BRCA	cis	rs2109514	1	rs2270188	ENSG00000237813.3	AC002066.1	4.04	5.71e-05	0.00384	0.15	0.12	Prevalent atrial fibrillation;	chr7:116500470	chr7:116238260~116499465:-
BRCA	cis	rs807669	0.586	rs5746671	ENSG00000260924.2	LINC01311	-4.04	5.71e-05	0.00384	-0.1	-0.12	Metabolite levels;	chr22:19173386	chr22:19171395~19172839:+
BRCA	cis	rs465969	0.744	rs9400477	ENSG00000272356.1	RP5-1112D6.8	-4.04	5.71e-05	0.00384	-0.27	-0.12	Psoriasis;	chr6:111469440	chr6:111309203~111313517:+
BRCA	cis	rs1665050	0.571	rs1446238	ENSG00000259732.1	RP11-59H7.3	-4.04	5.71e-05	0.00384	-0.15	-0.12	Atopic dermatitis;	chr15:59055558	chr15:59121034~59133250:+
BRCA	cis	rs539096	0.706	rs618369	ENSG00000236200.4	KDM4A-AS1	-4.04	5.71e-05	0.00384	-0.14	-0.12	Intelligence (multi-trait analysis);	chr1:43606125	chr1:43699765~43708138:-
BRCA	cis	rs9381040	0.61	rs2268195	ENSG00000161912.16	ADCY10P1	4.04	5.71e-05	0.00384	0.14	0.12	Alzheimer's disease (late onset);	chr6:41056601	chr6:41101022~41140835:+
BRCA	cis	rs9381040	0.61	rs9381028	ENSG00000161912.16	ADCY10P1	4.04	5.71e-05	0.00384	0.14	0.12	Alzheimer's disease (late onset);	chr6:41057342	chr6:41101022~41140835:+
BRCA	cis	rs9381040	0.61	rs9357345	ENSG00000161912.16	ADCY10P1	4.04	5.71e-05	0.00384	0.14	0.12	Alzheimer's disease (late onset);	chr6:41057379	chr6:41101022~41140835:+
BRCA	cis	rs28374715	0.532	rs28584379	ENSG00000247556.5	OIP5-AS1	4.04	5.71e-05	0.00384	0.15	0.12	Ulcerative colitis;	chr15:41378210	chr15:41283990~41309737:+
BRCA	cis	rs495337	0.76	rs6122844	ENSG00000229222.1	KRT18P4	-4.04	5.72e-05	0.00385	-0.15	-0.12	Psoriasis;	chr20:49925008	chr20:49956745~49958032:+
BRCA	cis	rs495337	0.72	rs6067271	ENSG00000229222.1	KRT18P4	-4.04	5.72e-05	0.00385	-0.15	-0.12	Psoriasis;	chr20:49925126	chr20:49956745~49958032:+
BRCA	cis	rs4886920	0.894	rs4886930	ENSG00000260776.4	RP11-114H24.2	-4.04	5.72e-05	0.00385	-0.15	-0.12	Neuroticism;	chr15:77835064	chr15:77914217~77926846:-
BRCA	cis	rs1371614	0.632	rs6738528	ENSG00000272148.1	RP11-195B17.1	-4.04	5.72e-05	0.00385	-0.14	-0.12	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26926390	chr2:27062428~27062907:-
BRCA	cis	rs17428076	0.751	rs1008152	ENSG00000228389.1	AC068039.4	-4.04	5.72e-05	0.00385	-0.19	-0.12	Myopia;	chr2:172047362	chr2:171773482~171775844:+
BRCA	cis	rs57221529	0.563	rs4957057	ENSG00000225138.6	CTD-2228K2.7	4.04	5.72e-05	0.00385	0.17	0.12	Lung disease severity in cystic fibrosis;	chr5:569115	chr5:473236~480884:+
BRCA	cis	rs3858526	1	rs3858526	ENSG00000224295.2	AC087380.14	4.04	5.72e-05	0.00385	0.17	0.12	DNA methylation (variation);	chr11:5938527	chr11:5518441~5524955:-
BRCA	cis	rs683250	0.629	rs657324	ENSG00000254551.1	RP11-727A23.7	4.04	5.72e-05	0.00385	0.16	0.12	Subcortical brain region volumes;	chr11:83264088	chr11:83209431~83213379:-
BRCA	cis	rs7777677	0.925	rs4726547	ENSG00000232869.2	TRBV29-1	-4.04	5.72e-05	0.00385	-0.1	-0.12	Alcoholic chronic pancreatitis;	chr7:142662750	chr7:142740206~142740894:+
BRCA	cis	rs10923574	0.597	rs10754378	ENSG00000231365.4	RP11-418J17.1	-4.04	5.72e-05	0.00385	-0.15	-0.12	Breast cancer;Folding of antihelix;	chr1:118501291	chr1:119140396~119275973:+
BRCA	cis	rs2274459	1	rs12190954	ENSG00000249346.5	LINC01016	4.04	5.72e-05	0.00385	0.17	0.12	Obesity (extreme);	chr6:33778841	chr6:33867506~33896914:-
BRCA	cis	rs2301573	0.516	rs36016814	ENSG00000271270.4	TMCC1-AS1	-4.04	5.72e-05	0.00385	-0.27	-0.12	Hip circumference;	chr3:129879046	chr3:129893871~129918575:+
BRCA	cis	rs13401620	0.871	rs949529	ENSG00000229326.3	AC069154.4	-4.04	5.72e-05	0.00385	-0.16	-0.12	Breast size;	chr2:119859969	chr2:119698623~119700151:+
BRCA	cis	rs5758511	0.773	rs10154700	ENSG00000226450.2	CYP2D8P	4.04	5.72e-05	0.00385	0.14	0.12	Birth weight;	chr22:41969069	chr22:42149886~42155001:-
BRCA	cis	rs17711722	0.523	rs365896	ENSG00000226002.1	RP11-460N20.5	-4.04	5.72e-05	0.00385	-0.13	-0.12	Calcium levels;	chr7:66045710	chr7:65084103~65100232:+
BRCA	cis	rs5758511	0.773	rs73165164	ENSG00000226450.2	CYP2D8P	4.04	5.73e-05	0.00385	0.14	0.12	Birth weight;	chr22:41959545	chr22:42149886~42155001:-
BRCA	cis	rs2251381	0.722	rs2776252	ENSG00000232855.5	AF131217.1	-4.04	5.73e-05	0.00385	-0.16	-0.12	Selective IgA deficiency;	chr21:29159384	chr21:28439346~28674848:-
BRCA	cis	rs8026198	0.929	rs7179709	ENSG00000260571.1	BNIP3P5	-4.04	5.73e-05	0.00385	-0.21	-0.12	Fibrinogen levels;	chr15:42354999	chr15:42313687~42314386:+
BRCA	cis	rs3764021	0.87	rs10743819	ENSG00000256582.1	RP11-75L1.1	4.04	5.73e-05	0.00385	0.13	0.12	Type 1 diabetes;	chr12:9724172	chr12:9704077~9709350:+
BRCA	cis	rs6088580	0.634	rs6059866	ENSG00000276073.1	RP5-1125A11.7	-4.04	5.73e-05	0.00385	-0.13	-0.12	Glomerular filtration rate (creatinine);	chr20:34488005	chr20:33985617~33988989:-
BRCA	cis	rs2662776	1	rs10753608	ENSG00000232995.6	RGS5	4.04	5.73e-05	0.00385	0.13	0.12	Lead levels in blood;	chr1:163190261	chr1:163244505~163321894:-
BRCA	cis	rs55940216	0.527	rs7844251	ENSG00000253384.1	CTD-2547L16.3	-4.04	5.73e-05	0.00385	-0.27	-0.12	Facial morphology (factor 14, intercanthal width);	chr8:18107050	chr8:18088569~18089687:-
BRCA	cis	rs6545883	0.86	rs777589	ENSG00000273302.1	RP11-493E12.2	4.04	5.73e-05	0.00385	0.12	0.12	Tuberculosis;	chr2:61198486	chr2:61199979~61200769:+
BRCA	cis	rs8056446	0.837	rs4888748	ENSG00000280274.1	RP11-556H2.1	-4.04	5.73e-05	0.00385	-0.13	-0.12	Pulmonary function (smoking interaction);	chr16:78139257	chr16:79016136~79017429:+
BRCA	cis	rs6049003	0.622	rs6049010	ENSG00000232645.4	LINC01431	4.04	5.73e-05	0.00385	0.13	0.12	Cerebrospinal fluid biomarker levels;	chr20:23712282	chr20:23356594~23358116:-
BRCA	cis	rs9733	0.596	rs6686525	ENSG00000231073.1	RP11-316M1.3	4.04	5.73e-05	0.00385	0.13	0.12	Tonsillectomy;	chr1:150663335	chr1:150973123~150975534:+
BRCA	cis	rs372883	0.613	rs1153289	ENSG00000176054.6	RPL23P2	-4.04	5.73e-05	0.00385	-0.14	-0.12	Pancreatic cancer;	chr21:29313891	chr21:28997613~28998033:-
BRCA	cis	rs11098499	0.954	rs12508504	ENSG00000225892.3	RP11-384K6.2	4.04	5.73e-05	0.00385	0.13	0.12	Corneal astigmatism;	chr4:119489452	chr4:118632274~118634759:+
BRCA	cis	rs2625529	0.824	rs12906711	ENSG00000260037.4	CTD-2524L6.3	-4.04	5.73e-05	0.00385	-0.18	-0.12	Red blood cell count;	chr15:71922724	chr15:71818396~71823384:+
BRCA	cis	rs8098244	0.737	rs1154241	ENSG00000265752.2	RP11-403A21.1	-4.04	5.73e-05	0.00385	-0.17	-0.12	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23944675	chr18:23957754~23982556:-
BRCA	cis	rs2136613	0.751	rs1571921	ENSG00000238280.1	RP11-436D10.3	4.04	5.73e-05	0.00385	0.15	0.12	Selective IgA deficiency;	chr10:62850893	chr10:62793562~62805887:-
BRCA	cis	rs1910358	0.69	rs1354165	ENSG00000248874.4	C5orf17	-4.04	5.73e-05	0.00386	-0.16	-0.12	Venous thromboembolism (SNP x SNP interaction);	chr5:23948625	chr5:23951348~24178263:+
BRCA	cis	rs4950322	0.518	rs61838951	ENSG00000227242.3	NBPF13P	-4.04	5.73e-05	0.00386	-0.17	-0.12	Protein quantitative trait loci;	chr1:147116081	chr1:147021320~147124525:-
BRCA	cis	rs962856	0.964	rs601827	ENSG00000236605.1	AC023115.4	4.04	5.73e-05	0.00386	0.14	0.12	Pancreatic cancer;	chr2:67435398	chr2:67324627~67325304:+
BRCA	cis	rs45509595	0.841	rs200485	ENSG00000216901.1	AL022393.7	4.04	5.74e-05	0.00386	0.23	0.12	Breast cancer;	chr6:27807919	chr6:28176188~28176674:+
BRCA	cis	rs6479874	0.646	rs7083536	ENSG00000223502.1	RP11-96B5.3	-4.04	5.74e-05	0.00386	-0.22	-0.12	Migraine;	chr10:50995929	chr10:51062579~51068553:-
BRCA	cis	rs1538970	0.781	rs713358	ENSG00000281133.1	AL355480.3	-4.04	5.74e-05	0.00386	-0.17	-0.12	Platelet count;	chr1:45522595	chr1:45580892~45580996:-
BRCA	cis	rs4664293	0.647	rs6756502	ENSG00000226266.5	AC009961.3	4.04	5.74e-05	0.00386	0.15	0.12	Monocyte percentage of white cells;	chr2:159698072	chr2:159670708~159712435:-
BRCA	cis	rs875971	0.66	rs12698534	ENSG00000229180.5	GS1-124K5.11	4.04	5.74e-05	0.00386	0.11	0.12	Aortic root size;	chr7:66521858	chr7:66526088~66542624:-
BRCA	cis	rs73201462	0.908	rs2955092	ENSG00000242551.2	POU5F1P6	-4.04	5.74e-05	0.00386	-0.2	-0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128253685	chr3:128674735~128677005:-
BRCA	cis	rs73201462	0.908	rs2955094	ENSG00000242551.2	POU5F1P6	-4.04	5.74e-05	0.00386	-0.2	-0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128258080	chr3:128674735~128677005:-
BRCA	cis	rs11239930	0.538	rs4950361	ENSG00000230832.3	RP11-325P15.2	4.04	5.74e-05	0.00386	0.17	0.12	AIDS progression;	chr1:147087618	chr1:147082338~147083578:-
BRCA	cis	rs7267979	1	rs2258201	ENSG00000125804.12	FAM182A	-4.04	5.74e-05	0.00386	-0.16	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25291854	chr20:26054655~26086917:+
BRCA	cis	rs2229238	0.868	rs72999422	ENSG00000272030.1	RP1-178F15.4	-4.04	5.74e-05	0.00386	-0.18	-0.12	Coronary heart disease;	chr1:154542466	chr1:153631438~153634397:-
BRCA	cis	rs2229238	0.911	rs58881140	ENSG00000272030.1	RP1-178F15.4	-4.04	5.74e-05	0.00386	-0.18	-0.12	Coronary heart disease;	chr1:154542717	chr1:153631438~153634397:-
BRCA	cis	rs17684571	0.751	rs13190854	ENSG00000231441.1	RP11-472M19.2	4.04	5.74e-05	0.00386	0.2	0.12	Schizophrenia;	chr6:56827020	chr6:56844002~56864078:+
BRCA	cis	rs7191700	0.509	rs416603	ENSG00000262703.1	RP11-485G7.6	-4.04	5.74e-05	0.00386	-0.12	-0.12	Multiple sclerosis;	chr16:11270222	chr16:11348143~11349321:-
BRCA	cis	rs9959145	0.778	rs2186906	ENSG00000267108.1	RP11-861E21.1	4.04	5.74e-05	0.00386	0.22	0.12	Immune response to smallpox vaccine (IL-6);	chr18:12572196	chr18:12432897~12437635:+
BRCA	cis	rs6963495	0.719	rs73190172	ENSG00000223886.3	RP11-251G23.2	4.04	5.74e-05	0.00386	0.19	0.12	Bipolar disorder (body mass index interaction);	chr7:105520763	chr7:105530209~105530671:+
BRCA	cis	rs6963495	0.719	rs73190174	ENSG00000223886.3	RP11-251G23.2	4.04	5.74e-05	0.00386	0.19	0.12	Bipolar disorder (body mass index interaction);	chr7:105520769	chr7:105530209~105530671:+
BRCA	cis	rs6963495	0.818	rs118134111	ENSG00000223886.3	RP11-251G23.2	4.04	5.74e-05	0.00386	0.19	0.12	Bipolar disorder (body mass index interaction);	chr7:105520782	chr7:105530209~105530671:+
BRCA	cis	rs6963495	0.818	rs117028299	ENSG00000223886.3	RP11-251G23.2	4.04	5.74e-05	0.00386	0.19	0.12	Bipolar disorder (body mass index interaction);	chr7:105521863	chr7:105530209~105530671:+
BRCA	cis	rs6963495	0.745	rs73190179	ENSG00000223886.3	RP11-251G23.2	4.04	5.74e-05	0.00386	0.19	0.12	Bipolar disorder (body mass index interaction);	chr7:105522365	chr7:105530209~105530671:+
BRCA	cis	rs6963495	0.745	rs75805443	ENSG00000223886.3	RP11-251G23.2	4.04	5.74e-05	0.00386	0.19	0.12	Bipolar disorder (body mass index interaction);	chr7:105522381	chr7:105530209~105530671:+
BRCA	cis	rs6963495	0.818	rs73190181	ENSG00000223886.3	RP11-251G23.2	4.04	5.74e-05	0.00386	0.19	0.12	Bipolar disorder (body mass index interaction);	chr7:105522460	chr7:105530209~105530671:+
BRCA	cis	rs6963495	0.818	rs73190183	ENSG00000223886.3	RP11-251G23.2	4.04	5.74e-05	0.00386	0.19	0.12	Bipolar disorder (body mass index interaction);	chr7:105522575	chr7:105530209~105530671:+
BRCA	cis	rs6963495	0.818	rs9769403	ENSG00000223886.3	RP11-251G23.2	4.04	5.74e-05	0.00386	0.19	0.12	Bipolar disorder (body mass index interaction);	chr7:105522644	chr7:105530209~105530671:+
BRCA	cis	rs6963495	0.818	rs56055535	ENSG00000223886.3	RP11-251G23.2	4.04	5.74e-05	0.00386	0.19	0.12	Bipolar disorder (body mass index interaction);	chr7:105523127	chr7:105530209~105530671:+
BRCA	cis	rs6963495	0.538	rs55967123	ENSG00000223886.3	RP11-251G23.2	4.04	5.74e-05	0.00386	0.19	0.12	Bipolar disorder (body mass index interaction);	chr7:105523231	chr7:105530209~105530671:+
BRCA	cis	rs6963495	0.818	rs115609508	ENSG00000223886.3	RP11-251G23.2	4.04	5.74e-05	0.00386	0.19	0.12	Bipolar disorder (body mass index interaction);	chr7:105523269	chr7:105530209~105530671:+
BRCA	cis	rs6963495	0.818	rs73190184	ENSG00000223886.3	RP11-251G23.2	4.04	5.74e-05	0.00386	0.19	0.12	Bipolar disorder (body mass index interaction);	chr7:105523289	chr7:105530209~105530671:+
BRCA	cis	rs6963495	0.674	rs75880756	ENSG00000223886.3	RP11-251G23.2	4.04	5.74e-05	0.00386	0.19	0.12	Bipolar disorder (body mass index interaction);	chr7:105523374	chr7:105530209~105530671:+
BRCA	cis	rs6963495	0.818	rs73190186	ENSG00000223886.3	RP11-251G23.2	4.04	5.74e-05	0.00386	0.19	0.12	Bipolar disorder (body mass index interaction);	chr7:105523921	chr7:105530209~105530671:+
BRCA	cis	rs6963495	0.818	rs73190187	ENSG00000223886.3	RP11-251G23.2	4.04	5.74e-05	0.00386	0.19	0.12	Bipolar disorder (body mass index interaction);	chr7:105523954	chr7:105530209~105530671:+
BRCA	cis	rs6963495	0.818	rs73190189	ENSG00000223886.3	RP11-251G23.2	4.04	5.74e-05	0.00386	0.19	0.12	Bipolar disorder (body mass index interaction);	chr7:105524005	chr7:105530209~105530671:+
BRCA	cis	rs6963495	0.872	rs73190193	ENSG00000223886.3	RP11-251G23.2	4.04	5.74e-05	0.00386	0.19	0.12	Bipolar disorder (body mass index interaction);	chr7:105524405	chr7:105530209~105530671:+
BRCA	cis	rs116979167	0.63	rs56230603	ENSG00000223886.3	RP11-251G23.2	4.04	5.74e-05	0.00386	0.19	0.12	Bipolar disorder (body mass index interaction);	chr7:105524821	chr7:105530209~105530671:+
BRCA	cis	rs6963495	0.745	rs56239334	ENSG00000223886.3	RP11-251G23.2	4.04	5.74e-05	0.00386	0.19	0.12	Bipolar disorder (body mass index interaction);	chr7:105524904	chr7:105530209~105530671:+
BRCA	cis	rs6963495	0.745	rs55906043	ENSG00000223886.3	RP11-251G23.2	4.04	5.74e-05	0.00386	0.19	0.12	Bipolar disorder (body mass index interaction);	chr7:105524920	chr7:105530209~105530671:+
BRCA	cis	rs4689592	0.503	rs2292461	ENSG00000245468.3	RP11-367J11.3	4.04	5.74e-05	0.00386	0.14	0.12	Monocyte percentage of white cells;	chr4:7056746	chr4:7094571~7103385:-
BRCA	cis	rs9527	0.59	rs11191553	ENSG00000213061.2	PFN1P11	4.04	5.74e-05	0.00386	0.17	0.12	Arsenic metabolism;	chr10:103091639	chr10:102838011~102845473:-
BRCA	cis	rs11158026	0.526	rs3783639	ENSG00000258413.1	RP11-665C16.6	-4.04	5.74e-05	0.00386	-0.2	-0.12	Parkinson's disease;	chr14:54881948	chr14:55262767~55272075:-
BRCA	cis	rs1005277	0.579	rs1780116	ENSG00000272983.1	RP11-508N22.12	4.04	5.74e-05	0.00386	0.13	0.12	Extrinsic epigenetic age acceleration;	chr10:38237693	chr10:38137337~38144399:+
BRCA	cis	rs1005277	0.579	rs1780121	ENSG00000272983.1	RP11-508N22.12	4.04	5.74e-05	0.00386	0.13	0.12	Extrinsic epigenetic age acceleration;	chr10:38240509	chr10:38137337~38144399:+
BRCA	cis	rs962856	0.964	rs2171175	ENSG00000236605.1	AC023115.4	4.04	5.75e-05	0.00386	0.14	0.12	Pancreatic cancer;	chr2:67413595	chr2:67324627~67325304:+
BRCA	cis	rs739496	0.527	rs10849981	ENSG00000234608.6	MAPKAPK5-AS1	4.04	5.75e-05	0.00386	0.15	0.12	Platelet count;	chr12:111897413	chr12:111839764~111842902:-
BRCA	cis	rs6964587	0.967	rs10231350	ENSG00000188693.7	CYP51A1-AS1	-4.04	5.75e-05	0.00386	-0.14	-0.12	Breast cancer;	chr7:92179185	chr7:92134604~92180725:+
BRCA	cis	rs11711311	1	rs2242108	ENSG00000241529.3	RN7SL767P	-4.04	5.75e-05	0.00386	-0.15	-0.12	IgG glycosylation;	chr3:113715056	chr3:113632704~113632998:+
BRCA	cis	rs11098499	0.863	rs6534139	ENSG00000225892.3	RP11-384K6.2	-4.04	5.75e-05	0.00387	-0.13	-0.12	Corneal astigmatism;	chr4:119528301	chr4:118632274~118634759:+
BRCA	cis	rs6696239	0.513	rs10495276	ENSG00000227711.2	RP11-275O4.5	4.04	5.75e-05	0.00387	0.15	0.12	Height;	chr1:227549245	chr1:227509028~227520477:-
BRCA	cis	rs6445975	1	rs7653734	ENSG00000272182.1	RP11-802O23.3	4.04	5.75e-05	0.00387	0.14	0.12	Systemic lupus erythematosus;	chr3:58387158	chr3:58428255~58428815:+
BRCA	cis	rs11671005	0.779	rs731259	ENSG00000265272.2	RN7SL693P	4.04	5.75e-05	0.00387	0.2	0.12	Mean platelet volume;	chr19:58478057	chr19:58490797~58491075:+
BRCA	cis	rs6012564	0.893	rs6012579	ENSG00000227431.4	CSE1L-AS1	-4.04	5.75e-05	0.00387	-0.15	-0.12	Anger;	chr20:49006883	chr20:49040463~49046044:-
BRCA	cis	rs80028505	0.908	rs16884919	ENSG00000271304.1	DPRXP2	-4.04	5.75e-05	0.00387	-0.24	-0.12	Foot ulcer in diabetes and neuropathy;	chr6:36103740	chr6:35989515~35990436:-
BRCA	cis	rs9368481	1	rs9368481	ENSG00000224843.5	LINC00240	4.04	5.76e-05	0.00387	0.15	0.12	Autism spectrum disorder or schizophrenia;	chr6:26993982	chr6:26956992~27023924:+
BRCA	cis	rs12289961	0.681	rs2186405	ENSG00000265566.2	RN7SL605P	4.04	5.76e-05	0.00387	0.21	0.12	Lymphoma;	chr11:58268706	chr11:57528085~57528365:-
BRCA	cis	rs12289961	0.681	rs10896734	ENSG00000265566.2	RN7SL605P	4.04	5.76e-05	0.00387	0.21	0.12	Lymphoma;	chr11:58268933	chr11:57528085~57528365:-
BRCA	cis	rs12289961	0.681	rs11229328	ENSG00000265566.2	RN7SL605P	4.04	5.76e-05	0.00387	0.21	0.12	Lymphoma;	chr11:58270761	chr11:57528085~57528365:-
BRCA	cis	rs4835473	0.932	rs1450235	ENSG00000249741.2	RP11-673E1.3	-4.04	5.76e-05	0.00387	-0.14	-0.12	Immature fraction of reticulocytes;	chr4:143782927	chr4:143911514~143912053:-
BRCA	cis	rs67981189	0.593	rs7160958	ENSG00000258571.1	PTTG4P	-4.04	5.76e-05	0.00387	-0.13	-0.12	Schizophrenia;	chr14:70975809	chr14:71085482~71085833:-
BRCA	cis	rs3768617	0.706	rs6678517	ENSG00000224468.3	RP11-181K3.4	-4.04	5.76e-05	0.00387	-0.14	-0.12	Fuchs's corneal dystrophy;	chr1:183033504	chr1:183138402~183141282:-
BRCA	cis	rs9341808	0.754	rs9352808	ENSG00000279022.1	RP11-250B2.4	4.04	5.76e-05	0.00387	0.14	0.12	Sitting height ratio;	chr6:80287625	chr6:80440730~80441172:+
BRCA	cis	rs11955398	0.522	rs329624	ENSG00000272308.1	RP11-231G3.1	-4.04	5.76e-05	0.00387	-0.15	-0.12	Intelligence (multi-trait analysis);	chr5:60989310	chr5:60866457~60866935:-
BRCA	cis	rs9467773	0.62	rs2504540	ENSG00000224843.5	LINC00240	-4.04	5.76e-05	0.00387	-0.14	-0.12	Intelligence (multi-trait analysis);	chr6:26641398	chr6:26956992~27023924:+
BRCA	cis	rs9291059	0.737	rs12494647	ENSG00000236297.1	RP11-175P19.2	4.04	5.76e-05	0.00387	0.27	0.12	Depressive symptoms (multi-trait analysis);	chr3:193668868	chr3:193578812~193593090:-
BRCA	cis	rs11098499	0.863	rs12508173	ENSG00000225892.3	RP11-384K6.2	4.04	5.76e-05	0.00387	0.12	0.12	Corneal astigmatism;	chr4:119397371	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.908	rs12504149	ENSG00000225892.3	RP11-384K6.2	4.04	5.76e-05	0.00387	0.12	0.12	Corneal astigmatism;	chr4:119397422	chr4:118632274~118634759:+
BRCA	cis	rs8130944	0.897	rs7277424	ENSG00000225731.1	AP001627.1	4.04	5.76e-05	0.00387	0.14	0.12	Perceived unattractiveness to mosquitoes;	chr21:42721777	chr21:42733594~42741758:-
BRCA	cis	rs4374383	0.884	rs10188640	ENSG00000243389.1	AC012442.5	-4.04	5.76e-05	0.00387	-0.16	-0.12	Hepatitis C induced liver fibrosis;	chr2:111983520	chr2:112589040~112614431:+
BRCA	cis	rs4374383	0.884	rs10188642	ENSG00000243389.1	AC012442.5	-4.04	5.76e-05	0.00387	-0.16	-0.12	Hepatitis C induced liver fibrosis;	chr2:111983522	chr2:112589040~112614431:+
BRCA	cis	rs4950322	0.57	rs17356492	ENSG00000237188.3	RP11-337C18.8	4.04	5.76e-05	0.00387	0.16	0.12	Protein quantitative trait loci;	chr1:147296089	chr1:147172771~147211568:+
BRCA	cis	rs28374715	0.532	rs11070328	ENSG00000247556.5	OIP5-AS1	4.04	5.77e-05	0.00387	0.14	0.12	Ulcerative colitis;	chr15:41359371	chr15:41283990~41309737:+
BRCA	cis	rs28374715	0.532	rs28535540	ENSG00000247556.5	OIP5-AS1	4.04	5.77e-05	0.00387	0.14	0.12	Ulcerative colitis;	chr15:41367079	chr15:41283990~41309737:+
BRCA	cis	rs9959145	0.929	rs113231666	ENSG00000267108.1	RP11-861E21.1	4.04	5.77e-05	0.00387	0.22	0.12	Immune response to smallpox vaccine (IL-6);	chr18:12574011	chr18:12432897~12437635:+
BRCA	cis	rs720475	0.732	rs62483106	ENSG00000228960.5	OR2A9P	-4.04	5.77e-05	0.00388	-0.19	-0.12	Breast cancer;	chr7:144439533	chr7:144294480~144300934:+
BRCA	cis	rs7267979	1	rs6050632	ENSG00000277938.1	RP5-965G21.3	4.04	5.77e-05	0.00388	0.15	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25451965	chr20:25229150~25231933:+
BRCA	cis	rs27434	0.583	rs151953	ENSG00000248734.2	CTD-2260A17.1	4.04	5.77e-05	0.00388	0.14	0.12	Ankylosing spondylitis;	chr5:96821945	chr5:96784777~96785999:+
BRCA	cis	rs948562	0.793	rs79869893	ENSG00000280010.1	AP001350.4	4.04	5.77e-05	0.00388	0.25	0.12	Lymphoma;	chr11:58514409	chr11:58627435~58628528:+
BRCA	cis	rs3816183	1	rs7422835	ENSG00000226491.1	FTOP1	-4.04	5.77e-05	0.00388	-0.16	-0.12	Hypospadias;	chr2:42788867	chr2:42797225~42798712:-
BRCA	cis	rs1971762	0.545	rs10876466	ENSG00000270175.1	RP11-793H13.11	-4.04	5.77e-05	0.00388	-0.11	-0.12	Height;	chr12:53587642	chr12:53500162~53500936:-
BRCA	cis	rs1865760	1	rs9467636	ENSG00000272462.2	U91328.19	-4.04	5.77e-05	0.00388	-0.15	-0.12	Height;	chr6:25919321	chr6:25992662~26001775:+
BRCA	cis	rs1865760	1	rs9358893	ENSG00000272462.2	U91328.19	-4.04	5.77e-05	0.00388	-0.15	-0.12	Height;	chr6:25921533	chr6:25992662~26001775:+
BRCA	cis	rs12303914	0.762	rs2537752	ENSG00000256682.2	TAS2R12	4.04	5.77e-05	0.00388	0.14	0.12	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr12:10314934	chr12:10894943~10896952:-
BRCA	cis	rs7818688	1	rs28477467	ENSG00000245080.5	RP11-320N21.1	-4.04	5.78e-05	0.00388	-0.21	-0.12	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95020677	chr8:95066808~95073182:-
BRCA	cis	rs4302906	1	rs4302906	ENSG00000187984.11	ANKRD19P	-4.04	5.78e-05	0.00388	-0.11	-0.12	Lobe attachment (rater-scored or self-reported);	chr9:92972425	chr9:92809388~92888693:+
BRCA	cis	rs873549	0.959	rs10779467	ENSG00000238042.4	RP11-815M8.1	-4.04	5.78e-05	0.00388	-0.15	-0.12	Keloid;	chr1:222092288	chr1:221880981~221978523:-
BRCA	cis	rs7267979	0.934	rs2261753	ENSG00000277938.1	RP5-965G21.3	4.04	5.78e-05	0.00388	0.15	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25281655	chr20:25229150~25231933:+
BRCA	cis	rs7520050	0.966	rs1768816	ENSG00000281133.1	AL355480.3	4.04	5.78e-05	0.00388	0.14	0.12	Reticulocyte count;Red blood cell count;	chr1:46062927	chr1:45580892~45580996:-
BRCA	cis	rs4266144	0.821	rs56237906	ENSG00000241770.1	RP11-555M1.3	-4.04	5.78e-05	0.00388	-0.18	-0.12	Coronary artery disease;	chr3:157134684	chr3:157163452~157169133:+
BRCA	cis	rs13108904	0.901	rs12509700	ENSG00000253399.1	AC078852.2	-4.04	5.78e-05	0.00388	-0.14	-0.12	Obesity-related traits;	chr4:1302533	chr4:1358479~1359461:+
BRCA	cis	rs4449834	0.851	rs11986742	ENSG00000254432.1	RP11-33I11.2	-4.04	5.78e-05	0.00388	-0.16	-0.12	Sum eosinophil basophil counts;	chr8:60790284	chr8:60808735~60809606:-
BRCA	cis	rs4865762	0.874	rs2548321	ENSG00000247796.2	CTD-2366F13.1	-4.04	5.78e-05	0.00388	-0.13	-0.12	Intraocular pressure;	chr5:53206696	chr5:53109842~53115126:+
BRCA	cis	rs8114671	0.869	rs66535333	ENSG00000126005.14	MMP24-AS1	4.04	5.78e-05	0.00388	0.15	0.12	Height;	chr20:35068863	chr20:35216462~35278131:-
BRCA	cis	rs8114671	0.869	rs1544047	ENSG00000126005.14	MMP24-AS1	4.04	5.78e-05	0.00388	0.15	0.12	Height;	chr20:35082950	chr20:35216462~35278131:-
BRCA	cis	rs8114671	0.836	rs17404569	ENSG00000126005.14	MMP24-AS1	4.04	5.78e-05	0.00388	0.15	0.12	Height;	chr20:35086274	chr20:35216462~35278131:-
BRCA	cis	rs2302465	0.86	rs73241109	ENSG00000273133.1	RP11-799M12.2	-4.04	5.78e-05	0.00388	-0.25	-0.12	Blood protein levels;	chr4:15628805	chr4:15563698~15564253:-
BRCA	cis	rs7111546	0.565	rs79085089	ENSG00000246225.5	RP11-17A1.3	4.04	5.78e-05	0.00389	0.21	0.12	Dialysis-related mortality;	chr11:22940163	chr11:22829380~22945393:+
BRCA	cis	rs711830	1	rs1549334	ENSG00000226363.3	HAGLROS	-4.04	5.78e-05	0.00389	-0.18	-0.12	Serous invasive ovarian cancer;Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;High-grade serous ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;	chr2:176174469	chr2:176177717~176179008:+
BRCA	cis	rs11603020	0.95	rs3824988	ENSG00000265566.2	RN7SL605P	4.04	5.78e-05	0.00389	0.18	0.12	Blood protein levels;	chr11:57610495	chr11:57528085~57528365:-
BRCA	cis	rs4409675	0.871	rs10902678	ENSG00000227050.1	RP11-460I13.2	4.04	5.79e-05	0.00389	0.16	0.12	Corneal astigmatism;	chr1:27942062	chr1:27938875~27960193:-
BRCA	cis	rs1560104	0.709	rs6498334	ENSG00000259876.1	CTD-3037G24.4	4.04	5.79e-05	0.00389	0.13	0.12	Obesity-related traits;	chr16:12602789	chr16:12556353~12557694:-
BRCA	cis	rs11098499	0.863	rs3775854	ENSG00000260091.1	RP11-33B1.4	-4.04	5.79e-05	0.00389	-0.11	-0.12	Corneal astigmatism;	chr4:119550816	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.863	rs6853998	ENSG00000260091.1	RP11-33B1.4	-4.04	5.79e-05	0.00389	-0.11	-0.12	Corneal astigmatism;	chr4:119554705	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.863	rs6858777	ENSG00000260091.1	RP11-33B1.4	-4.04	5.79e-05	0.00389	-0.11	-0.12	Corneal astigmatism;	chr4:119554811	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.863	rs11731756	ENSG00000260091.1	RP11-33B1.4	-4.04	5.79e-05	0.00389	-0.11	-0.12	Corneal astigmatism;	chr4:119557541	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.863	rs34308924	ENSG00000260091.1	RP11-33B1.4	-4.04	5.79e-05	0.00389	-0.11	-0.12	Corneal astigmatism;	chr4:119560276	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.863	rs2170276	ENSG00000260091.1	RP11-33B1.4	-4.04	5.79e-05	0.00389	-0.11	-0.12	Corneal astigmatism;	chr4:119564669	chr4:119409333~119410233:+
BRCA	cis	rs8180040	0.966	rs2062278	ENSG00000280667.1	Y_RNA	4.04	5.79e-05	0.00389	0.14	0.12	Colorectal cancer;	chr3:47375271	chr3:47501083~47501182:+
BRCA	cis	rs35306767	0.855	rs56222464	ENSG00000229869.1	RP11-363N22.2	-4.04	5.79e-05	0.00389	-0.21	-0.12	Eosinophil percentage of granulocytes;	chr10:821595	chr10:933026~942743:+
BRCA	cis	rs35306767	0.855	rs34251037	ENSG00000229869.1	RP11-363N22.2	-4.04	5.79e-05	0.00389	-0.21	-0.12	Eosinophil percentage of granulocytes;	chr10:821944	chr10:933026~942743:+
BRCA	cis	rs11051970	0.879	rs2728682	ENSG00000274964.1	RP11-817I4.1	-4.04	5.79e-05	0.00389	-0.14	-0.12	Response to tocilizumab in rheumatoid arthritis;	chr12:32427259	chr12:32339368~32340724:+
BRCA	cis	rs5997397	1	rs5997397	ENSG00000226471.5	CTA-292E10.6	-4.04	5.79e-05	0.00389	-0.14	-0.12	Red cell distribution width;	chr22:28758467	chr22:28800683~28848559:+
BRCA	cis	rs6736093	0.67	rs72829613	ENSG00000236307.2	EEF1E1P1	-4.04	5.79e-05	0.00389	-0.14	-0.12	Coronary artery disease;	chr2:112037055	chr2:111887914~111888741:+
BRCA	cis	rs6736093	0.704	rs11897014	ENSG00000236307.2	EEF1E1P1	-4.04	5.79e-05	0.00389	-0.14	-0.12	Coronary artery disease;	chr2:112038331	chr2:111887914~111888741:+
BRCA	cis	rs4561483	0.801	rs33649	ENSG00000261216.1	RP11-166B2.5	-4.04	5.79e-05	0.00389	-0.15	-0.12	Testicular germ cell tumor;	chr16:11885751	chr16:11908208~11908916:+
BRCA	cis	rs10911902	0.643	rs6678193	ENSG00000229739.2	RP11-295K2.3	-4.04	5.79e-05	0.00389	-0.19	-0.12	Schizophrenia;	chr1:186413607	chr1:186435161~186470291:+
BRCA	cis	rs875971	1	rs6460296	ENSG00000236529.1	RP13-254B10.1	4.04	5.79e-05	0.00389	0.13	0.12	Aortic root size;	chr7:66430152	chr7:65840212~65840596:+
BRCA	cis	rs1479090	0.851	rs1463555	ENSG00000250027.1	RP11-563E2.2	-4.04	5.79e-05	0.00389	-0.18	-0.12	Lung cancer;	chr4:163128296	chr4:163108785~163119965:+
BRCA	cis	rs11158026	0.603	rs66769866	ENSG00000233924.1	AL160471.6	-4.04	5.79e-05	0.00389	-0.15	-0.12	Parkinson's disease;	chr14:54979435	chr14:55004813~55005687:-
BRCA	cis	rs11158026	0.603	rs7151670	ENSG00000233924.1	AL160471.6	-4.04	5.79e-05	0.00389	-0.15	-0.12	Parkinson's disease;	chr14:54986041	chr14:55004813~55005687:-
BRCA	cis	rs739496	0.527	rs2269801	ENSG00000257624.1	RP1-128M12.3	4.04	5.8e-05	0.00389	0.17	0.12	Platelet count;	chr12:111888319	chr12:112000739~112000985:-
BRCA	cis	rs6490294	0.748	rs2269802	ENSG00000257624.1	RP1-128M12.3	4.04	5.8e-05	0.00389	0.17	0.12	Mean platelet volume;	chr12:111888334	chr12:112000739~112000985:-
BRCA	cis	rs4218	0.517	rs71480503	ENSG00000259732.1	RP11-59H7.3	-4.04	5.8e-05	0.00389	-0.16	-0.12	Social communication problems;	chr15:59098246	chr15:59121034~59133250:+
BRCA	cis	rs7772486	0.875	rs11755334	ENSG00000270638.1	RP3-466P17.1	4.04	5.8e-05	0.00389	0.14	0.12	Lobe attachment (rater-scored or self-reported);	chr6:146078161	chr6:145735570~145737218:+
BRCA	cis	rs2835345	0.962	rs2835344	ENSG00000230479.1	AP000695.6	4.04	5.8e-05	0.0039	0.13	0.12	Pulmonary function;	chr21:36429047	chr21:36430360~36481070:+
BRCA	cis	rs17169635	0.84	rs3800746	ENSG00000272941.1	RP11-134L10.1	-4.04	5.8e-05	0.0039	-0.14	-0.12	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);	chr7:134865335	chr7:135168403~135169547:+
BRCA	cis	rs11096990	0.634	rs10019594	ENSG00000249685.1	RP11-360F5.3	-4.04	5.8e-05	0.0039	-0.15	-0.12	Cognitive function;	chr4:39287127	chr4:39133913~39135608:+
BRCA	cis	rs7116495	0.609	rs501308	ENSG00000248671.6	ALG1L9P	4.04	5.8e-05	0.0039	0.29	0.12	Severe influenza A (H1N1) infection;	chr11:71870279	chr11:71794363~71818238:-
BRCA	cis	rs4767841	0.552	rs12827937	ENSG00000248636.5	RP11-768F21.1	-4.04	5.8e-05	0.0039	-0.16	-0.12	Urgency urinary incontinence;	chr12:119612444	chr12:119387987~119668079:-
BRCA	cis	rs924712	0.547	rs239794	ENSG00000261116.1	RP3-523K23.2	4.04	5.81e-05	0.0039	0.16	0.12	Breast cancer;	chr6:54937577	chr6:54943167~54945099:+
BRCA	cis	rs11098499	1	rs12506395	ENSG00000250412.1	KLHL2P1	4.04	5.81e-05	0.0039	0.15	0.12	Corneal astigmatism;	chr4:119263939	chr4:119334329~119378233:+
BRCA	cis	rs6736093	0.796	rs4848971	ENSG00000236307.2	EEF1E1P1	-4.04	5.81e-05	0.0039	-0.16	-0.12	Coronary artery disease;	chr2:112032869	chr2:111887914~111888741:+
BRCA	cis	rs7246657	0.551	rs10419174	ENSG00000267470.4	ZNF571-AS1	4.04	5.81e-05	0.0039	0.19	0.12	Coronary artery calcification;	chr19:37114439	chr19:37548914~37587348:+
BRCA	cis	rs11711311	1	rs9826465	ENSG00000241529.3	RN7SL767P	-4.04	5.81e-05	0.0039	-0.14	-0.12	IgG glycosylation;	chr3:113713407	chr3:113632704~113632998:+
BRCA	cis	rs1484642	0.881	rs7005350	ENSG00000253649.2	PRSS51	-4.04	5.81e-05	0.0039	-0.23	-0.12	Bipolar disorder and schizophrenia;	chr8:10132588	chr8:10482878~10547585:-
BRCA	cis	rs7726839	0.561	rs3915384	ENSG00000225138.6	CTD-2228K2.7	4.04	5.81e-05	0.0039	0.17	0.12	Obesity-related traits;	chr5:573280	chr5:473236~480884:+
BRCA	cis	rs4478858	0.709	rs937786	ENSG00000260386.4	LINC01225	4.04	5.81e-05	0.0039	0.15	0.12	Alcohol dependence;	chr1:31385022	chr1:31500085~31540885:+
BRCA	cis	rs795484	0.683	rs514826	ENSG00000275409.1	RP11-131L12.4	4.04	5.81e-05	0.0039	0.14	0.12	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;	chr12:118371498	chr12:118430147~118430699:+
BRCA	cis	rs11711311	0.911	rs28577577	ENSG00000241529.3	RN7SL767P	-4.04	5.81e-05	0.0039	-0.15	-0.12	IgG glycosylation;	chr3:113728429	chr3:113632704~113632998:+
BRCA	cis	rs11711311	1	rs13073843	ENSG00000241529.3	RN7SL767P	-4.04	5.81e-05	0.0039	-0.15	-0.12	IgG glycosylation;	chr3:113730303	chr3:113632704~113632998:+
BRCA	cis	rs11711311	1	rs9865435	ENSG00000241529.3	RN7SL767P	-4.04	5.81e-05	0.0039	-0.15	-0.12	IgG glycosylation;	chr3:113731199	chr3:113632704~113632998:+
BRCA	cis	rs11711311	1	rs9865965	ENSG00000241529.3	RN7SL767P	-4.04	5.81e-05	0.0039	-0.15	-0.12	IgG glycosylation;	chr3:113731648	chr3:113632704~113632998:+
BRCA	cis	rs11711311	1	rs9826808	ENSG00000241529.3	RN7SL767P	-4.04	5.81e-05	0.0039	-0.15	-0.12	IgG glycosylation;	chr3:113736797	chr3:113632704~113632998:+
BRCA	cis	rs11711311	1	rs9830978	ENSG00000241529.3	RN7SL767P	-4.04	5.81e-05	0.0039	-0.15	-0.12	IgG glycosylation;	chr3:113737093	chr3:113632704~113632998:+
BRCA	cis	rs9921338	0.887	rs9926136	ENSG00000263080.1	RP11-485G7.5	4.04	5.81e-05	0.0039	0.19	0.12	Vein graft stenosis in coronary artery bypass grafting;	chr16:11343418	chr16:11341809~11345211:-
BRCA	cis	rs853679	0.517	rs4713145	ENSG00000261839.1	RP1-265C24.8	4.04	5.81e-05	0.0039	0.17	0.12	Depression;	chr6:28139049	chr6:28136849~28139678:+
BRCA	cis	rs2562456	0.754	rs11673234	ENSG00000240522.1	RPL7AP10	-4.04	5.81e-05	0.0039	-0.15	-0.12	Pain;	chr19:21324800	chr19:21149648~21150438:-
BRCA	cis	rs2562456	0.754	rs11673320	ENSG00000240522.1	RPL7AP10	-4.04	5.81e-05	0.0039	-0.15	-0.12	Pain;	chr19:21324801	chr19:21149648~21150438:-
BRCA	cis	rs7800418	0.723	rs4555996	ENSG00000214870.7	AC004540.5	4.04	5.81e-05	0.0039	0.16	0.12	Cognitive function;	chr7:26550208	chr7:26398593~26494256:+
BRCA	cis	rs13034020	0.522	rs62150978	ENSG00000271889.1	RP11-493E12.1	-4.04	5.81e-05	0.0039	-0.19	-0.12	Hodgkin's lymphoma;	chr2:61029087	chr2:61151433~61162105:-
BRCA	cis	rs73201462	1	rs2999067	ENSG00000242551.2	POU5F1P6	-4.04	5.81e-05	0.0039	-0.2	-0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128259688	chr3:128674735~128677005:-
BRCA	cis	rs2625529	0.775	rs62023342	ENSG00000260037.4	CTD-2524L6.3	-4.04	5.81e-05	0.0039	-0.18	-0.12	Red blood cell count;	chr15:71868964	chr15:71818396~71823384:+
BRCA	cis	rs4819052	0.851	rs9754134	ENSG00000215447.6	BX322557.10	-4.04	5.81e-05	0.0039	-0.13	-0.12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45241836	chr21:45288052~45291738:+
BRCA	cis	rs4865762	0.783	rs1423422	ENSG00000247796.2	CTD-2366F13.1	4.04	5.82e-05	0.0039	0.13	0.12	Intraocular pressure;	chr5:53335677	chr5:53109842~53115126:+
BRCA	cis	rs6570726	1	rs441477	ENSG00000270638.1	RP3-466P17.1	4.04	5.82e-05	0.0039	0.14	0.12	Lobe attachment (rater-scored or self-reported);	chr6:145527107	chr6:145735570~145737218:+
BRCA	cis	rs11673344	0.566	rs8109103	ENSG00000267422.1	CTD-2554C21.1	4.04	5.82e-05	0.0039	0.16	0.12	Obesity-related traits;	chr19:37503209	chr19:37779686~37792865:+
BRCA	cis	rs11686241	0.935	rs3108223	ENSG00000241520.1	AC098820.4	-4.04	5.82e-05	0.0039	-0.18	-0.12	Cancer;	chr2:216502272	chr2:216483032~216487196:-
BRCA	cis	rs73201462	1	rs2811522	ENSG00000242551.2	POU5F1P6	-4.04	5.82e-05	0.0039	-0.2	-0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128292580	chr3:128674735~128677005:-
BRCA	cis	rs427691	0.625	rs370575	ENSG00000271849.1	CTC-332L22.1	-4.04	5.82e-05	0.0039	-0.2	-0.12	Autism spectrum disorder or schizophrenia;	chr5:109675587	chr5:109687802~109688329:-
BRCA	cis	rs160451	0.966	rs2101854	ENSG00000251136.7	RP11-37B2.1	4.04	5.82e-05	0.00391	0.12	0.12	Leprosy;	chr8:89663517	chr8:89609409~89757727:-
BRCA	cis	rs12505749	0.542	rs66858948	ENSG00000270147.1	RP11-646I6.6	-4.04	5.82e-05	0.00391	-0.14	-0.12	Airflow obstruction;	chr4:56467976	chr4:56396312~56396871:+
BRCA	cis	rs9733	0.628	rs72700895	ENSG00000231073.1	RP11-316M1.3	4.04	5.82e-05	0.00391	0.13	0.12	Tonsillectomy;	chr1:150653553	chr1:150973123~150975534:+
BRCA	cis	rs13315871	1	rs4362735	ENSG00000272182.1	RP11-802O23.3	4.04	5.82e-05	0.00391	0.23	0.12	Cholesterol, total;	chr3:58444166	chr3:58428255~58428815:+
BRCA	cis	rs7204230	0.538	rs3815548	ENSG00000261291.1	RP11-295M3.2	4.04	5.82e-05	0.00391	0.15	0.12	Fibrinogen;	chr16:53287822	chr16:53168522~53169450:+
BRCA	cis	rs11098499	0.691	rs9996644	ENSG00000225892.3	RP11-384K6.2	4.04	5.82e-05	0.00391	0.12	0.12	Corneal astigmatism;	chr4:119317722	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.691	rs9996494	ENSG00000225892.3	RP11-384K6.2	4.04	5.82e-05	0.00391	0.12	0.12	Corneal astigmatism;	chr4:119317725	chr4:118632274~118634759:+
BRCA	cis	rs10938353	0.861	rs11943007	ENSG00000273369.1	RP11-700J17.1	4.04	5.82e-05	0.00391	0.15	0.12	Body mass index;	chr4:44588886	chr4:44693946~44694386:-
BRCA	cis	rs2835345	0.563	rs60727080	ENSG00000233818.1	AP000695.4	4.04	5.82e-05	0.00391	0.13	0.12	Pulmonary function;	chr21:36454876	chr21:36445731~36532408:+
BRCA	cis	rs1008375	0.932	rs9291660	ENSG00000249502.1	AC006160.5	-4.04	5.82e-05	0.00391	-0.15	-0.12	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17661791	chr4:17587467~17614571:-
BRCA	cis	rs10792665	0.649	rs11233432	ENSG00000246067.6	RAB30-AS1	-4.04	5.82e-05	0.00391	-0.13	-0.12	Obesity-related traits;	chr11:83028711	chr11:83072066~83106719:+
BRCA	cis	rs853679	0.517	rs9380058	ENSG00000216901.1	AL022393.7	4.04	5.82e-05	0.00391	0.18	0.12	Depression;	chr6:28159666	chr6:28176188~28176674:+
BRCA	cis	rs853679	0.517	rs9393898	ENSG00000216901.1	AL022393.7	4.04	5.82e-05	0.00391	0.18	0.12	Depression;	chr6:28162598	chr6:28176188~28176674:+
BRCA	cis	rs5758511	0.773	rs62240997	ENSG00000226450.2	CYP2D8P	4.04	5.82e-05	0.00391	0.14	0.12	Birth weight;	chr22:41958563	chr22:42149886~42155001:-
BRCA	cis	rs6545883	0.558	rs7587389	ENSG00000270820.4	RP11-355B11.2	-4.04	5.82e-05	0.00391	-0.13	-0.12	Tuberculosis;	chr2:61422656	chr2:61471188~61484130:+
BRCA	cis	rs8180040	0.966	rs922957	ENSG00000280667.1	Y_RNA	-4.04	5.83e-05	0.00391	-0.14	-0.12	Colorectal cancer;	chr3:47380662	chr3:47501083~47501182:+
BRCA	cis	rs2411233	0.967	rs2035061	ENSG00000259278.1	RP11-62C7.2	4.04	5.83e-05	0.00391	0.15	0.12	Platelet count;	chr15:38995085	chr15:39019233~39024918:+
BRCA	cis	rs875971	0.929	rs4122249	ENSG00000229180.5	GS1-124K5.11	4.04	5.83e-05	0.00391	0.11	0.12	Aortic root size;	chr7:66455949	chr7:66526088~66542624:-
BRCA	cis	rs1555322	1	rs2425036	ENSG00000261582.1	RP4-614O4.11	-4.04	5.83e-05	0.00391	-0.17	-0.12	Attention deficit hyperactivity disorder;	chr20:35268178	chr20:35267885~35280043:-
BRCA	cis	rs983392	0.709	rs7939882	ENSG00000275344.1	MIR6503	-4.04	5.83e-05	0.00391	-0.13	-0.12	Alzheimer's disease (late onset);	chr11:60206456	chr11:60209071~60209156:-
BRCA	cis	rs7267979	0.966	rs2227890	ENSG00000277938.1	RP5-965G21.3	4.04	5.83e-05	0.00391	0.15	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25280295	chr20:25229150~25231933:+
BRCA	cis	rs6993270	0.725	rs59559961	ENSG00000245330.4	KB-1471A8.1	-4.04	5.83e-05	0.00391	-0.19	-0.12	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr8:119907410	chr8:119867419~119874488:-
BRCA	cis	rs9863	0.861	rs4930723	ENSG00000270028.1	RP11-380L11.4	4.04	5.83e-05	0.00391	0.16	0.12	White blood cell count;	chr12:123939053	chr12:123925461~123926083:-
BRCA	cis	rs11098499	0.754	rs2036860	ENSG00000260091.1	RP11-33B1.4	-4.04	5.83e-05	0.00391	-0.11	-0.12	Corneal astigmatism;	chr4:119327779	chr4:119409333~119410233:+
BRCA	cis	rs10946940	0.965	rs4713112	ENSG00000219392.1	RP1-265C24.5	4.04	5.83e-05	0.00391	0.16	0.12	Systemic lupus erythematosus;	chr6:27549054	chr6:28115628~28116551:+
BRCA	cis	rs13416342	0.681	rs6730274	ENSG00000236259.1	AC017083.2	-4.04	5.83e-05	0.00391	-0.14	-0.12	Breast cancer;	chr2:67861383	chr2:68125265~68125747:+
BRCA	cis	rs3764021	0.87	rs10466829	ENSG00000256582.1	RP11-75L1.1	4.04	5.83e-05	0.00391	0.13	0.12	Type 1 diabetes;	chr12:9723495	chr12:9704077~9709350:+
BRCA	cis	rs11098499	0.863	rs2306457	ENSG00000260091.1	RP11-33B1.4	-4.04	5.83e-05	0.00391	-0.11	-0.12	Corneal astigmatism;	chr4:119551684	chr4:119409333~119410233:+
BRCA	cis	rs6508941	0.61	rs814530	ENSG00000277453.1	CTC-492K19.7	4.04	5.83e-05	0.00391	0.13	0.12	Antibody level in response to infection;	chr19:40510665	chr19:40426115~40426702:+
BRCA	cis	rs4374383	0.884	rs908518	ENSG00000243389.1	AC012442.5	4.04	5.83e-05	0.00391	0.16	0.12	Hepatitis C induced liver fibrosis;	chr2:111920049	chr2:112589040~112614431:+
BRCA	cis	rs12289961	0.681	rs73479886	ENSG00000265566.2	RN7SL605P	4.04	5.83e-05	0.00391	0.21	0.12	Lymphoma;	chr11:58273736	chr11:57528085~57528365:-
BRCA	cis	rs2229238	0.911	rs11490956	ENSG00000272030.1	RP1-178F15.4	-4.04	5.83e-05	0.00391	-0.17	-0.12	Coronary heart disease;	chr1:154514782	chr1:153631438~153634397:-
BRCA	cis	rs2229238	0.911	rs111600849	ENSG00000272030.1	RP1-178F15.4	-4.04	5.83e-05	0.00391	-0.17	-0.12	Coronary heart disease;	chr1:154515013	chr1:153631438~153634397:-
BRCA	cis	rs9393813	0.626	rs2393926	ENSG00000241549.7	GUSBP2	4.04	5.83e-05	0.00392	0.13	0.12	Bipolar disorder;	chr6:27352965	chr6:26871484~26956554:-
BRCA	cis	rs4415084	0.804	rs7705343	ENSG00000248779.1	RP11-53O19.2	4.04	5.84e-05	0.00392	0.11	0.12	Breast cancer;	chr5:44879475	chr5:44752949~44765744:+
BRCA	cis	rs911555	0.755	rs2756122	ENSG00000269910.1	RP11-73M18.10	4.04	5.84e-05	0.00392	0.13	0.12	Intelligence (multi-trait analysis);	chr14:103516696	chr14:103694516~103695050:-
BRCA	cis	rs38055	0.629	rs62357405	ENSG00000247796.2	CTD-2366F13.1	4.04	5.84e-05	0.00392	0.17	0.12	Acne (severe);	chr5:53199127	chr5:53109842~53115126:+
BRCA	cis	rs1722133	0.515	rs788713	ENSG00000229628.1	AC073115.7	4.04	5.84e-05	0.00392	0.17	0.12	Sitting height ratio;	chr7:46097051	chr7:45990905~46000898:+
BRCA	cis	rs2562456	0.917	rs2681389	ENSG00000268119.4	CTD-2561J22.5	-4.04	5.84e-05	0.00392	-0.19	-0.12	Pain;	chr19:21509773	chr19:21444241~21463908:-
BRCA	cis	rs7267979	1	rs2856	ENSG00000277938.1	RP5-965G21.3	4.04	5.84e-05	0.00392	0.15	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25452900	chr20:25229150~25231933:+
BRCA	cis	rs6480314	1	rs3814184	ENSG00000233590.1	RP11-153K11.3	-4.04	5.84e-05	0.00392	-0.2	-0.12	Optic nerve measurement (disc area);	chr10:68206494	chr10:68233251~68242379:-
BRCA	cis	rs990171	0.538	rs4851017	ENSG00000234389.1	AC007278.3	4.04	5.84e-05	0.00392	0.12	0.12	Lymphocyte counts;	chr2:102504310	chr2:102438713~102440475:+
BRCA	cis	rs7577696	0.8	rs216544	ENSG00000272716.1	RP11-563N4.1	-4.04	5.84e-05	0.00392	-0.14	-0.12	Inflammatory biomarkers;	chr2:32093737	chr2:32165046~32165757:-
BRCA	cis	rs2832077	1	rs12329875	ENSG00000232855.5	AF131217.1	4.04	5.84e-05	0.00392	0.19	0.12	Cognitive test performance;	chr21:28765474	chr21:28439346~28674848:-
BRCA	cis	rs6593122	0.755	rs6960759	ENSG00000235454.1	HAUS6P3	-4.04	5.84e-05	0.00392	-0.17	-0.12	Vaccine-related adverse events;	chr7:54138058	chr7:53862233~53863339:+
BRCA	cis	rs6593122	0.755	rs6961929	ENSG00000235454.1	HAUS6P3	-4.04	5.84e-05	0.00392	-0.17	-0.12	Vaccine-related adverse events;	chr7:54138111	chr7:53862233~53863339:+
BRCA	cis	rs6593122	0.701	rs10270899	ENSG00000235454.1	HAUS6P3	-4.04	5.84e-05	0.00392	-0.17	-0.12	Vaccine-related adverse events;	chr7:54138411	chr7:53862233~53863339:+
BRCA	cis	rs6593122	0.727	rs10255773	ENSG00000235454.1	HAUS6P3	-4.04	5.84e-05	0.00392	-0.17	-0.12	Vaccine-related adverse events;	chr7:54138454	chr7:53862233~53863339:+
BRCA	cis	rs6593122	0.755	rs2049410	ENSG00000235454.1	HAUS6P3	-4.04	5.84e-05	0.00392	-0.17	-0.12	Vaccine-related adverse events;	chr7:54138863	chr7:53862233~53863339:+
BRCA	cis	rs6593122	0.755	rs7786411	ENSG00000235454.1	HAUS6P3	-4.04	5.84e-05	0.00392	-0.17	-0.12	Vaccine-related adverse events;	chr7:54139197	chr7:53862233~53863339:+
BRCA	cis	rs6593122	0.785	rs10156183	ENSG00000235454.1	HAUS6P3	-4.04	5.84e-05	0.00392	-0.17	-0.12	Vaccine-related adverse events;	chr7:54139267	chr7:53862233~53863339:+
BRCA	cis	rs17772222	0.917	rs17188046	ENSG00000258789.1	RP11-507K2.3	-4.04	5.84e-05	0.00392	-0.15	-0.12	Coronary artery calcification;	chr14:88624417	chr14:88551597~88552493:+
BRCA	cis	rs2229238	0.911	rs6681207	ENSG00000272030.1	RP1-178F15.4	-4.04	5.84e-05	0.00392	-0.18	-0.12	Coronary heart disease;	chr1:154544741	chr1:153631438~153634397:-
BRCA	cis	rs11992162	0.591	rs35657308	ENSG00000254866.2	DEFB109P3	4.04	5.84e-05	0.00392	0.16	0.12	Monocyte count;	chr8:11946893	chr8:12150895~12151134:-
BRCA	cis	rs2444217	0.872	rs2531977	ENSG00000262185.1	RP11-462G12.1	-4.04	5.85e-05	0.00392	-0.15	-0.12	Body mass index;	chr16:3993700	chr16:3947609~3950444:-
BRCA	cis	rs2039553	0.607	rs10507900	ENSG00000227354.5	RBM26-AS1	-4.04	5.85e-05	0.00392	-0.14	-0.12	Pancreatic cancer;	chr13:79769398	chr13:79406309~79424328:+
BRCA	cis	rs11668609	0.81	rs8105851	ENSG00000268058.1	BNIP3P40	-4.04	5.85e-05	0.00392	-0.15	-0.12	Response to taxane treatment (docetaxel);	chr19:24080533	chr19:24098425~24098980:-
BRCA	cis	rs61931739	0.5	rs12829125	ENSG00000258794.3	DUX4L27	4.04	5.85e-05	0.00392	0.18	0.12	Morning vs. evening chronotype;	chr12:34161854	chr12:34208415~34209675:-
BRCA	cis	rs61931739	0.5	rs11053140	ENSG00000258794.3	DUX4L27	4.04	5.85e-05	0.00392	0.18	0.12	Morning vs. evening chronotype;	chr12:34163187	chr12:34208415~34209675:-
BRCA	cis	rs7260598	0.642	rs10407805	ENSG00000268442.1	CTD-2027I19.2	4.04	5.85e-05	0.00392	0.19	0.12	Response to taxane treatment (placlitaxel);	chr19:23982903	chr19:24162370~24163425:-
BRCA	cis	rs13326165	0.76	rs123602	ENSG00000275956.1	RP5-966M1.7	-4.04	5.85e-05	0.00392	-0.18	-0.12	HDL cholesterol levels;HDL cholesterol;	chr3:52408338	chr3:52732547~52733867:+
BRCA	cis	rs72799341	1	rs72799341	ENSG00000280211.1	RP11-2C24.3	4.04	5.85e-05	0.00392	0.14	0.12	Diastolic blood pressure;	chr16:30925422	chr16:30773532~30776033:-
BRCA	cis	rs13126694	0.778	rs4691454	ENSG00000251073.1	NUDT19P5	4.04	5.85e-05	0.00393	0.12	0.12	Blood osmolality (transformed sodium);	chr4:158117101	chr4:158182825~158183393:+
BRCA	cis	rs9393813	0.626	rs7772739	ENSG00000241549.7	GUSBP2	4.04	5.85e-05	0.00393	0.13	0.12	Bipolar disorder;	chr6:27351069	chr6:26871484~26956554:-
BRCA	cis	rs490234	0.676	rs13293034	ENSG00000232630.1	PRPS1P2	-4.04	5.85e-05	0.00393	-0.13	-0.12	Mean arterial pressure;	chr9:125494672	chr9:125150653~125151589:+
BRCA	cis	rs490234	0.702	rs13284572	ENSG00000232630.1	PRPS1P2	-4.04	5.85e-05	0.00393	-0.13	-0.12	Mean arterial pressure;	chr9:125495991	chr9:125150653~125151589:+
BRCA	cis	rs490234	0.702	rs1891035	ENSG00000232630.1	PRPS1P2	-4.04	5.85e-05	0.00393	-0.13	-0.12	Mean arterial pressure;	chr9:125496405	chr9:125150653~125151589:+
BRCA	cis	rs7260598	0.642	rs10424894	ENSG00000268442.1	CTD-2027I19.2	4.04	5.86e-05	0.00393	0.19	0.12	Response to taxane treatment (placlitaxel);	chr19:23978053	chr19:24162370~24163425:-
BRCA	cis	rs7260598	0.642	rs10423626	ENSG00000268442.1	CTD-2027I19.2	4.04	5.86e-05	0.00393	0.19	0.12	Response to taxane treatment (placlitaxel);	chr19:23978229	chr19:24162370~24163425:-
BRCA	cis	rs2058059	0.636	rs2961005	ENSG00000205578.5	POM121B	4.04	5.86e-05	0.00393	0.2	0.12	Subcutaneous adipose tissue;	chr7:72675517	chr7:73293497~73301161:+
BRCA	cis	rs7572733	0.935	rs10192466	ENSG00000231621.1	AC013264.2	-4.03	5.86e-05	0.00393	-0.11	-0.12	Dermatomyositis;	chr2:197873295	chr2:197197991~197199273:+
BRCA	cis	rs6964587	1	rs12533199	ENSG00000188693.7	CYP51A1-AS1	-4.03	5.86e-05	0.00393	-0.13	-0.12	Breast cancer;	chr7:92128079	chr7:92134604~92180725:+
BRCA	cis	rs983392	0.709	rs2081547	ENSG00000275344.1	MIR6503	-4.03	5.86e-05	0.00393	-0.13	-0.12	Alzheimer's disease (late onset);	chr11:60221957	chr11:60209071~60209156:-
BRCA	cis	rs11239930	0.517	rs584107	ENSG00000237188.3	RP11-337C18.8	-4.03	5.86e-05	0.00393	-0.14	-0.12	AIDS progression;	chr1:147075862	chr1:147172771~147211568:+
BRCA	cis	rs801193	0.761	rs2659888	ENSG00000229180.5	GS1-124K5.11	4.03	5.86e-05	0.00393	0.11	0.12	Aortic root size;	chr7:66765184	chr7:66526088~66542624:-
BRCA	cis	rs7819412	0.54	rs11777355	ENSG00000255046.1	RP11-297N6.4	4.03	5.86e-05	0.00393	0.15	0.12	Triglycerides;	chr8:11187180	chr8:11797928~11802568:-
BRCA	cis	rs7267979	1	rs2258879	ENSG00000277938.1	RP5-965G21.3	4.03	5.87e-05	0.00393	0.15	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25298577	chr20:25229150~25231933:+
BRCA	cis	rs7267979	1	rs2257496	ENSG00000277938.1	RP5-965G21.3	4.03	5.87e-05	0.00393	0.15	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25298679	chr20:25229150~25231933:+
BRCA	cis	rs7267979	1	rs2258884	ENSG00000277938.1	RP5-965G21.3	4.03	5.87e-05	0.00393	0.15	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25298903	chr20:25229150~25231933:+
BRCA	cis	rs7267979	1	rs2259837	ENSG00000277938.1	RP5-965G21.3	4.03	5.87e-05	0.00393	0.15	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25299569	chr20:25229150~25231933:+
BRCA	cis	rs7267979	1	rs2259873	ENSG00000277938.1	RP5-965G21.3	4.03	5.87e-05	0.00393	0.15	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25300145	chr20:25229150~25231933:+
BRCA	cis	rs694419	0.654	rs625400	ENSG00000278017.1	RP11-120K19.4	-4.03	5.87e-05	0.00393	-0.15	-0.12	Serum albumin level;	chr18:62490672	chr18:62525919~62526325:-
BRCA	cis	rs6452524	0.935	rs1017794	ENSG00000281327.1	LINC01338	4.03	5.87e-05	0.00394	0.14	0.12	Hypertension (SNP x SNP interaction);	chr5:83086236	chr5:82850864~82859836:-
BRCA	cis	rs6585424	1	rs3851055	ENSG00000225484.5	NUTM2B-AS1	-4.03	5.87e-05	0.00394	-0.24	-0.12	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80178340	chr10:79663088~79826594:-
BRCA	cis	rs9788721	0.934	rs16969968	ENSG00000261762.1	RP11-650L12.2	-4.03	5.87e-05	0.00394	-0.16	-0.12	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78590583	chr15:78589123~78591276:-
BRCA	cis	rs3858526	1	rs3858527	ENSG00000224295.2	AC087380.14	4.03	5.87e-05	0.00394	0.17	0.12	DNA methylation (variation);	chr11:5938618	chr11:5518441~5524955:-
BRCA	cis	rs11168618	0.904	rs4359253	ENSG00000273765.1	RP11-370I10.11	4.03	5.87e-05	0.00394	0.14	0.12	Adiponectin levels;	chr12:48533925	chr12:48360920~48361377:+
BRCA	cis	rs7412746	0.658	rs897815	ENSG00000231073.1	RP11-316M1.3	-4.03	5.87e-05	0.00394	-0.13	-0.12	Melanoma;	chr1:150906625	chr1:150973123~150975534:+
BRCA	cis	rs9982086	0.793	rs11087965	ENSG00000260583.1	AP000223.42	-4.03	5.87e-05	0.00394	-0.28	-0.12	Carboplatin disposition in epthelial ovarian cancer;	chr21:25557717	chr21:25582770~25583326:-
BRCA	cis	rs9982086	0.793	rs36059302	ENSG00000260583.1	AP000223.42	-4.03	5.87e-05	0.00394	-0.28	-0.12	Carboplatin disposition in epthelial ovarian cancer;	chr21:25563201	chr21:25582770~25583326:-
BRCA	cis	rs687432	0.885	rs7123727	ENSG00000265566.2	RN7SL605P	-4.03	5.87e-05	0.00394	-0.18	-0.12	Parkinson's disease;	chr11:58031711	chr11:57528085~57528365:-
BRCA	cis	rs2924679	1	rs3019587	ENSG00000260895.1	RP11-554A11.7	4.03	5.87e-05	0.00394	0.33	0.12	Obesity-related traits;	chr11:68802174	chr11:69103493~69109094:+
BRCA	cis	rs17695224	0.545	rs10500309	ENSG00000269483.1	AC006272.1	4.03	5.87e-05	0.00394	0.15	0.12	HDL cholesterol;HDL cholesterol levels;	chr19:51829123	chr19:51839924~51843324:-
BRCA	cis	rs7011507	0.535	rs1160606	ENSG00000233858.4	AC026904.1	-4.03	5.87e-05	0.00394	-0.15	-0.12	Inflammatory bowel disease;Ulcerative colitis;	chr8:48545336	chr8:48590401~48594621:+
BRCA	cis	rs7011507	0.535	rs5001149	ENSG00000233858.4	AC026904.1	-4.03	5.87e-05	0.00394	-0.15	-0.12	Inflammatory bowel disease;Ulcerative colitis;	chr8:48550394	chr8:48590401~48594621:+
BRCA	cis	rs7267979	1	rs2258201	ENSG00000274973.1	RP13-401N8.7	-4.03	5.87e-05	0.00394	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25291854	chr20:25845497~25845862:+
BRCA	cis	rs7487075	1	rs7976280	ENSG00000274723.1	RP11-618L22.1	4.03	5.87e-05	0.00394	0.15	0.12	Itch intensity from mosquito bite;	chr12:46407042	chr12:46970504~46972155:+
BRCA	cis	rs9425766	0.962	rs9425430	ENSG00000200674.1	RN7SKP160	4.03	5.87e-05	0.00394	0.17	0.12	Life satisfaction;	chr1:173888145	chr1:173791548~173791887:+
BRCA	cis	rs10911902	0.913	rs6666680	ENSG00000229739.2	RP11-295K2.3	-4.03	5.87e-05	0.00394	-0.18	-0.12	Schizophrenia;	chr1:186551203	chr1:186435161~186470291:+
BRCA	cis	rs9381040	0.655	rs2268187	ENSG00000161912.16	ADCY10P1	4.03	5.88e-05	0.00394	0.14	0.12	Alzheimer's disease (late onset);	chr6:41075254	chr6:41101022~41140835:+
BRCA	cis	rs11168618	1	rs12815544	ENSG00000273765.1	RP11-370I10.11	4.03	5.88e-05	0.00394	0.14	0.12	Adiponectin levels;	chr12:48555825	chr12:48360920~48361377:+
BRCA	cis	rs4302906	0.964	rs9942903	ENSG00000187984.11	ANKRD19P	-4.03	5.88e-05	0.00394	-0.11	-0.12	Lobe attachment (rater-scored or self-reported);	chr9:92975463	chr9:92809388~92888693:+
BRCA	cis	rs4302906	0.893	rs3802381	ENSG00000187984.11	ANKRD19P	-4.03	5.88e-05	0.00394	-0.11	-0.12	Lobe attachment (rater-scored or self-reported);	chr9:92976499	chr9:92809388~92888693:+
BRCA	cis	rs5758511	0.68	rs1107553	ENSG00000226450.2	CYP2D8P	4.03	5.88e-05	0.00394	0.14	0.12	Birth weight;	chr22:42271467	chr22:42149886~42155001:-
BRCA	cis	rs11671005	0.779	rs731259	ENSG00000269600.1	AC016629.3	-4.03	5.88e-05	0.00394	-0.2	-0.12	Mean platelet volume;	chr19:58478057	chr19:58593896~58599355:-
BRCA	cis	rs1560104	0.709	rs7200211	ENSG00000259876.1	CTD-3037G24.4	4.03	5.88e-05	0.00394	0.14	0.12	Obesity-related traits;	chr16:12605083	chr16:12556353~12557694:-
BRCA	cis	rs801193	0.66	rs2659897	ENSG00000265600.1	AC006480.1	4.03	5.88e-05	0.00394	0.15	0.12	Aortic root size;	chr7:66722728	chr7:67356680~67356779:+
BRCA	cis	rs10938353	0.859	rs13115873	ENSG00000273369.1	RP11-700J17.1	-4.03	5.89e-05	0.00394	-0.15	-0.12	Body mass index;	chr4:44587577	chr4:44693946~44694386:-
BRCA	cis	rs11098499	0.954	rs11098526	ENSG00000260404.2	RP11-384K6.6	4.03	5.89e-05	0.00395	0.12	0.12	Corneal astigmatism;	chr4:119469204	chr4:118591773~118633729:+
BRCA	cis	rs1429524	1	rs747236	ENSG00000243144.5	RP11-115N4.1	4.03	5.89e-05	0.00395	0.16	0.12	Ejection fraction in Tripanosoma cruzi seropositivity;	chr7:91314249	chr7:91311368~91515409:+
BRCA	cis	rs739496	0.579	rs3782885	ENSG00000234608.6	MAPKAPK5-AS1	4.03	5.89e-05	0.00395	0.15	0.12	Platelet count;	chr12:111844779	chr12:111839764~111842902:-
BRCA	cis	rs739496	0.579	rs11066046	ENSG00000234608.6	MAPKAPK5-AS1	4.03	5.89e-05	0.00395	0.15	0.12	Platelet count;	chr12:111846077	chr12:111839764~111842902:-
BRCA	cis	rs739496	0.579	rs2158030	ENSG00000234608.6	MAPKAPK5-AS1	4.03	5.89e-05	0.00395	0.15	0.12	Platelet count;	chr12:111847787	chr12:111839764~111842902:-
BRCA	cis	rs6490294	0.799	rs7315642	ENSG00000234608.6	MAPKAPK5-AS1	4.03	5.89e-05	0.00395	0.15	0.12	Mean platelet volume;	chr12:111848992	chr12:111839764~111842902:-
BRCA	cis	rs739496	0.579	rs12302040	ENSG00000234608.6	MAPKAPK5-AS1	4.03	5.89e-05	0.00395	0.15	0.12	Platelet count;	chr12:111850375	chr12:111839764~111842902:-
BRCA	cis	rs739496	0.579	rs12322899	ENSG00000234608.6	MAPKAPK5-AS1	4.03	5.89e-05	0.00395	0.15	0.12	Platelet count;	chr12:111850398	chr12:111839764~111842902:-
BRCA	cis	rs739496	0.579	rs12307192	ENSG00000234608.6	MAPKAPK5-AS1	4.03	5.89e-05	0.00395	0.15	0.12	Platelet count;	chr12:111852542	chr12:111839764~111842902:-
BRCA	cis	rs739496	0.579	rs12307365	ENSG00000234608.6	MAPKAPK5-AS1	4.03	5.89e-05	0.00395	0.15	0.12	Platelet count;	chr12:111852847	chr12:111839764~111842902:-
BRCA	cis	rs739496	0.579	rs6489817	ENSG00000234608.6	MAPKAPK5-AS1	4.03	5.89e-05	0.00395	0.15	0.12	Platelet count;	chr12:111853438	chr12:111839764~111842902:-
BRCA	cis	rs739496	0.579	rs7296199	ENSG00000234608.6	MAPKAPK5-AS1	4.03	5.89e-05	0.00395	0.15	0.12	Platelet count;	chr12:111854040	chr12:111839764~111842902:-
BRCA	cis	rs739496	0.579	rs12313385	ENSG00000234608.6	MAPKAPK5-AS1	4.03	5.89e-05	0.00395	0.15	0.12	Platelet count;	chr12:111854343	chr12:111839764~111842902:-
BRCA	cis	rs739496	0.579	rs7310605	ENSG00000234608.6	MAPKAPK5-AS1	4.03	5.89e-05	0.00395	0.15	0.12	Platelet count;	chr12:111854666	chr12:111839764~111842902:-
BRCA	cis	rs739496	0.579	rs57427612	ENSG00000234608.6	MAPKAPK5-AS1	4.03	5.89e-05	0.00395	0.15	0.12	Platelet count;	chr12:111856192	chr12:111839764~111842902:-
BRCA	cis	rs739496	0.579	rs7976557	ENSG00000234608.6	MAPKAPK5-AS1	4.03	5.89e-05	0.00395	0.15	0.12	Platelet count;	chr12:111862976	chr12:111839764~111842902:-
BRCA	cis	rs739496	0.579	rs11066054	ENSG00000234608.6	MAPKAPK5-AS1	4.03	5.89e-05	0.00395	0.15	0.12	Platelet count;	chr12:111868361	chr12:111839764~111842902:-
BRCA	cis	rs739496	0.579	rs7297760	ENSG00000234608.6	MAPKAPK5-AS1	4.03	5.89e-05	0.00395	0.15	0.12	Platelet count;	chr12:111875884	chr12:111839764~111842902:-
BRCA	cis	rs6490294	0.799	rs12426566	ENSG00000234608.6	MAPKAPK5-AS1	4.03	5.89e-05	0.00395	0.15	0.12	Mean platelet volume;	chr12:111877368	chr12:111839764~111842902:-
BRCA	cis	rs739496	0.527	rs2097701	ENSG00000234608.6	MAPKAPK5-AS1	4.03	5.89e-05	0.00395	0.15	0.12	Platelet count;	chr12:111878970	chr12:111839764~111842902:-
BRCA	cis	rs739496	0.579	rs7294623	ENSG00000234608.6	MAPKAPK5-AS1	4.03	5.89e-05	0.00395	0.15	0.12	Platelet count;	chr12:111879292	chr12:111839764~111842902:-
BRCA	cis	rs718314	0.692	rs12829457	ENSG00000256894.1	RP11-283G6.3	-4.03	5.89e-05	0.00395	-0.13	-0.12	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Renal cell carcinoma;Waist circumference adjusted for body mass index;	chr12:26296546	chr12:26125155~26126617:-
BRCA	cis	rs17406451	1	rs34175409	ENSG00000234936.1	AC010883.5	4.03	5.89e-05	0.00395	0.13	0.12	Mitochondrial DNA levels;	chr2:43416175	chr2:43229573~43233394:+
BRCA	cis	rs6964587	1	rs2282974	ENSG00000188693.7	CYP51A1-AS1	-4.03	5.89e-05	0.00395	-0.13	-0.12	Breast cancer;	chr7:92132303	chr7:92134604~92180725:+
BRCA	cis	rs6964587	0.967	rs55801687	ENSG00000188693.7	CYP51A1-AS1	-4.03	5.89e-05	0.00395	-0.13	-0.12	Breast cancer;	chr7:92133315	chr7:92134604~92180725:+
BRCA	cis	rs11098499	0.866	rs3756156	ENSG00000250412.1	KLHL2P1	4.03	5.89e-05	0.00395	0.15	0.12	Corneal astigmatism;	chr4:119603686	chr4:119334329~119378233:+
BRCA	cis	rs2749592	0.513	rs1208708	ENSG00000263064.2	RP11-291L22.7	4.03	5.89e-05	0.00395	0.16	0.12	Age-related hearing impairment (SNP x SNP interaction);	chr10:37796648	chr10:38448689~38448949:+
BRCA	cis	rs2274459	0.841	rs10947432	ENSG00000249346.5	LINC01016	-4.03	5.89e-05	0.00395	-0.16	-0.12	Obesity (extreme);	chr6:33708779	chr6:33867506~33896914:-
BRCA	cis	rs2108622	0.701	rs118144071	ENSG00000214049.6	UCA1	4.03	5.89e-05	0.00395	0.18	0.12	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15868384	chr19:15828961~15836320:+
BRCA	cis	rs3808502	0.549	rs7831039	ENSG00000227888.4	FAM66A	-4.03	5.89e-05	0.00395	-0.16	-0.12	Neuroticism;	chr8:11570128	chr8:12362019~12388296:+
BRCA	cis	rs2030746	0.521	rs13415147	ENSG00000237614.1	AC073257.2	4.03	5.89e-05	0.00395	0.15	0.12	LDL cholesterol;Total cholesterol levels;LDL cholesterol levels;	chr2:120572192	chr2:120542909~120544326:-
BRCA	cis	rs11668609	0.748	rs8112938	ENSG00000268058.1	BNIP3P40	-4.03	5.89e-05	0.00395	-0.15	-0.12	Response to taxane treatment (docetaxel);	chr19:24169654	chr19:24098425~24098980:-
BRCA	cis	rs1665650	0.957	rs1665641	ENSG00000232767.1	RP11-498B4.5	-4.03	5.9e-05	0.00395	-0.13	-0.12	Colorectal cancer;	chr10:116735426	chr10:116670103~116672739:+
BRCA	cis	rs2302465	0.86	rs73239174	ENSG00000273133.1	RP11-799M12.2	-4.03	5.9e-05	0.00395	-0.25	-0.12	Blood protein levels;	chr4:15611859	chr4:15563698~15564253:-
BRCA	cis	rs4538475	0.539	rs73239175	ENSG00000273133.1	RP11-799M12.2	-4.03	5.9e-05	0.00395	-0.25	-0.12	Parkinson's disease;	chr4:15612556	chr4:15563698~15564253:-
BRCA	cis	rs2302465	0.86	rs115494850	ENSG00000273133.1	RP11-799M12.2	-4.03	5.9e-05	0.00395	-0.25	-0.12	Blood protein levels;	chr4:15614042	chr4:15563698~15564253:-
BRCA	cis	rs2832077	0.943	rs11702320	ENSG00000232855.5	AF131217.1	4.03	5.9e-05	0.00395	0.19	0.12	Cognitive test performance;	chr21:28822929	chr21:28439346~28674848:-
BRCA	cis	rs6430538	0.55	rs11902999	ENSG00000224043.6	CCNT2-AS1	-4.03	5.9e-05	0.00395	-0.17	-0.12	Parkinson's disease;	chr2:134809581	chr2:134735464~134918710:-
BRCA	cis	rs2562456	0.792	rs2562398	ENSG00000213976.4	CTD-2561J22.2	4.03	5.9e-05	0.00395	0.15	0.12	Pain;	chr19:21540147	chr19:21382865~21387177:+
BRCA	cis	rs1914816	0.941	rs2460146	ENSG00000196274.5	Metazoa_SRP	4.03	5.9e-05	0.00395	0.16	0.12	Response to tocilizumab in rheumatoid arthritis;	chr15:76262414	chr15:76230048~76230390:-
BRCA	cis	rs256438	0.542	rs17885391	ENSG00000251050.1	RP11-168A11.4	-4.03	5.9e-05	0.00395	-0.13	-0.12	Serum thyroid-stimulating hormone levels;	chr5:80051342	chr5:80019609~80019920:+
BRCA	cis	rs7523050	0.908	rs12404382	ENSG00000203897.3	SPATA42	-4.03	5.9e-05	0.00395	-0.21	-0.12	Fat distribution (HIV);	chr1:108854507	chr1:108857217~108858524:+
BRCA	cis	rs13256369	0.802	rs11249885	ENSG00000272267.2	RP11-375N15.2	-4.03	5.9e-05	0.00395	-0.16	-0.12	Obesity-related traits;	chr8:8704498	chr8:9555144~9556520:-
BRCA	cis	rs757081	0.648	rs7108316	ENSG00000272034.1	SNORD14A	-4.03	5.9e-05	0.00395	-0.13	-0.12	Systolic blood pressure;	chr11:17253488	chr11:17074654~17074744:-
BRCA	cis	rs13217239	0.646	rs12209886	ENSG00000124549.13	BTN2A3P	4.03	5.9e-05	0.00395	0.13	0.12	Schizophrenia;	chr6:27016978	chr6:26421391~26432383:+
BRCA	cis	rs6940638	0.531	rs12211984	ENSG00000124549.13	BTN2A3P	4.03	5.9e-05	0.00395	0.13	0.12	Intelligence (multi-trait analysis);	chr6:27018275	chr6:26421391~26432383:+
BRCA	cis	rs9595908	0.785	rs7331393	ENSG00000281026.1	N4BP2L2-IT2	4.03	5.9e-05	0.00395	0.11	0.12	Body mass index;	chr13:32647065	chr13:32504506~32509395:-
BRCA	cis	rs10735946	1	rs7310291	ENSG00000255733.4	IFNG-AS1	-4.03	5.9e-05	0.00395	-0.11	-0.12	Anti-saccade response;	chr12:68086733	chr12:67989445~68234686:+
BRCA	cis	rs11098499	0.863	rs3822195	ENSG00000260091.1	RP11-33B1.4	-4.03	5.9e-05	0.00395	-0.11	-0.12	Corneal astigmatism;	chr4:119550505	chr4:119409333~119410233:+
BRCA	cis	rs9863	0.828	rs11057409	ENSG00000270028.1	RP11-380L11.4	-4.03	5.9e-05	0.00395	-0.15	-0.12	White blood cell count;	chr12:123994784	chr12:123925461~123926083:-
BRCA	cis	rs875971	0.619	rs12533585	ENSG00000229180.5	GS1-124K5.11	4.03	5.9e-05	0.00395	0.11	0.12	Aortic root size;	chr7:66519618	chr7:66526088~66542624:-
BRCA	cis	rs67766926	0.953	rs9752570	ENSG00000271889.1	RP11-493E12.1	4.03	5.9e-05	0.00396	0.18	0.12	Inflammatory skin disease;	chr2:60904894	chr2:61151433~61162105:-
BRCA	cis	rs9868809	0.505	rs56735597	ENSG00000225399.4	RP11-3B7.1	-4.03	5.9e-05	0.00396	-0.19	-0.12	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48727735	chr3:49260085~49261316:+
BRCA	cis	rs7246967	0.8	rs2362131	ENSG00000198153.8	ZNF849P	-4.03	5.9e-05	0.00396	-0.17	-0.12	Bronchopulmonary dysplasia;	chr19:22839634	chr19:22685167~22686732:+
BRCA	cis	rs6736093	0.966	rs3811634	ENSG00000236307.2	EEF1E1P1	-4.03	5.91e-05	0.00396	-0.15	-0.12	Coronary artery disease;	chr2:111997366	chr2:111887914~111888741:+
BRCA	cis	rs875971	0.66	rs801211	ENSG00000229180.5	GS1-124K5.11	-4.03	5.91e-05	0.00396	-0.11	-0.12	Aortic root size;	chr7:66550702	chr7:66526088~66542624:-
BRCA	cis	rs875971	0.638	rs801205	ENSG00000229180.5	GS1-124K5.11	-4.03	5.91e-05	0.00396	-0.11	-0.12	Aortic root size;	chr7:66557157	chr7:66526088~66542624:-
BRCA	cis	rs875971	0.617	rs810400	ENSG00000229180.5	GS1-124K5.11	-4.03	5.91e-05	0.00396	-0.11	-0.12	Aortic root size;	chr7:66557902	chr7:66526088~66542624:-
BRCA	cis	rs2991971	0.81	rs2036021	ENSG00000280836.1	AL355480.1	4.03	5.91e-05	0.00396	0.15	0.12	High light scatter reticulocyte count;	chr1:45435698	chr1:45581219~45581321:-
BRCA	cis	rs1153858	1	rs4774577	ENSG00000275672.1	GATM-AS1	-4.03	5.91e-05	0.00396	-0.16	-0.12	Homoarginine levels;	chr15:45352487	chr15:45378700~45380123:+
BRCA	cis	rs1153858	1	rs4774578	ENSG00000275672.1	GATM-AS1	-4.03	5.91e-05	0.00396	-0.16	-0.12	Homoarginine levels;	chr15:45353853	chr15:45378700~45380123:+
BRCA	cis	rs61524473	1	rs61524473	ENSG00000275672.1	GATM-AS1	-4.03	5.91e-05	0.00396	-0.16	-0.12	Metabolite levels (small molecules and protein measures);	chr15:45354085	chr15:45378700~45380123:+
BRCA	cis	rs1153858	1	rs10444821	ENSG00000275672.1	GATM-AS1	-4.03	5.91e-05	0.00396	-0.16	-0.12	Homoarginine levels;	chr15:45355038	chr15:45378700~45380123:+
BRCA	cis	rs1153858	1	rs72623915	ENSG00000275672.1	GATM-AS1	-4.03	5.91e-05	0.00396	-0.16	-0.12	Homoarginine levels;	chr15:45355235	chr15:45378700~45380123:+
BRCA	cis	rs1153858	1	rs66714503	ENSG00000275672.1	GATM-AS1	-4.03	5.91e-05	0.00396	-0.16	-0.12	Homoarginine levels;	chr15:45355840	chr15:45378700~45380123:+
BRCA	cis	rs1009077	0.716	rs34601943	ENSG00000245958.5	RP11-33B1.1	4.03	5.91e-05	0.00396	0.18	0.12	Endometriosis;	chr4:119607869	chr4:119454791~119552025:+
BRCA	cis	rs930395	0.514	rs11951760	ENSG00000251141.4	RP11-53O19.1	-4.03	5.91e-05	0.00396	-0.12	-0.12	Breast cancer;	chr5:44872070	chr5:44744900~44808777:-
BRCA	cis	rs9844666	0.512	rs870812	ENSG00000273486.1	RP11-731C17.2	4.03	5.91e-05	0.00396	0.15	0.12	Height;	chr3:135928225	chr3:136837338~136839021:-
BRCA	cis	rs9844666	0.512	rs908825	ENSG00000273486.1	RP11-731C17.2	4.03	5.91e-05	0.00396	0.15	0.12	Height;	chr3:135928695	chr3:136837338~136839021:-
BRCA	cis	rs2625529	0.824	rs2415130	ENSG00000260037.4	CTD-2524L6.3	-4.03	5.91e-05	0.00396	-0.17	-0.12	Red blood cell count;	chr15:71950213	chr15:71818396~71823384:+
BRCA	cis	rs721917	0.506	rs1923540	ENSG00000242600.5	MBL1P	4.03	5.91e-05	0.00396	0.15	0.12	Chronic obstructive pulmonary disease;	chr10:79930616	chr10:79904898~79950336:+
BRCA	cis	rs17270561	0.609	rs4712970	ENSG00000272462.2	U91328.19	-4.03	5.91e-05	0.00396	-0.15	-0.12	Iron status biomarkers;	chr6:25770479	chr6:25992662~26001775:+
BRCA	cis	rs3743162	0.553	rs12915656	ENSG00000259295.5	CSPG4P12	4.03	5.91e-05	0.00396	0.19	0.12	Alzheimer's disease (age of onset);	chr15:84872349	chr15:85191438~85213905:+
BRCA	cis	rs62229266	0.771	rs11701590	ENSG00000214914.3	RPL23AP3	4.03	5.91e-05	0.00396	0.15	0.12	Mitral valve prolapse;	chr21:36012432	chr21:36016079~36016546:-
BRCA	cis	rs4869313	0.869	rs27659	ENSG00000248734.2	CTD-2260A17.1	-4.03	5.91e-05	0.00396	-0.13	-0.12	Pediatric autoimmune diseases;	chr5:97007848	chr5:96784777~96785999:+
BRCA	cis	rs7829975	0.667	rs1877119	ENSG00000253981.4	ALG1L13P	4.03	5.91e-05	0.00396	0.14	0.12	Mood instability;	chr8:8849687	chr8:8236003~8244667:-
BRCA	cis	rs11711311	1	rs2242109	ENSG00000241529.3	RN7SL767P	-4.03	5.91e-05	0.00396	-0.15	-0.12	IgG glycosylation;	chr3:113715253	chr3:113632704~113632998:+
BRCA	cis	rs6708413	0.52	rs6543151	ENSG00000234389.1	AC007278.3	4.03	5.92e-05	0.00396	0.12	0.12	Crohn's disease;Inflammatory bowel disease;	chr2:102497582	chr2:102438713~102440475:+
BRCA	cis	rs6802315	1	rs6802315	ENSG00000272087.1	RP11-379F4.7	4.03	5.92e-05	0.00396	0.15	0.12	Periodontitis (CDC/AAP);	chr3:158796571	chr3:158693120~158693768:-
BRCA	cis	rs6490294	0.904	rs9971871	ENSG00000257624.1	RP1-128M12.3	4.03	5.92e-05	0.00396	0.17	0.12	Mean platelet volume;	chr12:111970572	chr12:112000739~112000985:-
BRCA	cis	rs875971	0.66	rs13224319	ENSG00000229180.5	GS1-124K5.11	4.03	5.92e-05	0.00396	0.11	0.12	Aortic root size;	chr7:66542376	chr7:66526088~66542624:-
BRCA	cis	rs875971	0.66	rs801217	ENSG00000229180.5	GS1-124K5.11	-4.03	5.92e-05	0.00396	-0.11	-0.12	Aortic root size;	chr7:66545590	chr7:66526088~66542624:-
BRCA	cis	rs875971	0.638	rs801216	ENSG00000229180.5	GS1-124K5.11	-4.03	5.92e-05	0.00396	-0.11	-0.12	Aortic root size;	chr7:66546680	chr7:66526088~66542624:-
BRCA	cis	rs516805	0.667	rs2606650	ENSG00000279114.1	RP3-425C14.5	-4.03	5.92e-05	0.00396	-0.15	-0.12	Lymphocyte counts;	chr6:122123443	chr6:122471923~122484161:+
BRCA	cis	rs516805	0.562	rs2816156	ENSG00000279114.1	RP3-425C14.5	-4.03	5.92e-05	0.00396	-0.15	-0.12	Lymphocyte counts;	chr6:122124569	chr6:122471923~122484161:+
BRCA	cis	rs409045	0.869	rs457350	ENSG00000271874.1	CTD-2024P10.2	-4.03	5.92e-05	0.00396	-0.16	-0.12	Left ventricular mass;	chr5:34649996	chr5:34651457~34651888:-
BRCA	cis	rs259282	0.605	rs36107586	ENSG00000267475.1	CTD-2538C1.2	4.03	5.92e-05	0.00397	0.15	0.12	Schizophrenia;	chr19:32618768	chr19:32687089~32691750:-
BRCA	cis	rs10986311	0.832	rs9695388	ENSG00000227200.1	RP11-121A14.3	-4.03	5.92e-05	0.00397	-0.14	-0.12	Vitiligo;	chr9:124379448	chr9:124262876~124265809:+
BRCA	cis	rs9368481	0.743	rs9368480	ENSG00000224843.5	LINC00240	-4.03	5.92e-05	0.00397	-0.15	-0.12	Autism spectrum disorder or schizophrenia;	chr6:26987971	chr6:26956992~27023924:+
BRCA	cis	rs935334	1	rs1900125	ENSG00000258454.1	RP11-361H10.3	-4.03	5.92e-05	0.00397	-0.2	-0.12	Blood pressure;	chr14:76191127	chr14:76235817~76263474:+
BRCA	cis	rs11955398	0.502	rs158914	ENSG00000272308.1	RP11-231G3.1	4.03	5.92e-05	0.00397	0.15	0.12	Intelligence (multi-trait analysis);	chr5:60950582	chr5:60866457~60866935:-
BRCA	cis	rs372883	0.967	rs2832292	ENSG00000215533.7	LINC00189	4.03	5.93e-05	0.00397	0.14	0.12	Pancreatic cancer;	chr21:29366439	chr21:29193480~29288205:+
BRCA	cis	rs7267979	1	rs2257420	ENSG00000277938.1	RP5-965G21.3	4.03	5.93e-05	0.00397	0.15	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25295254	chr20:25229150~25231933:+
BRCA	cis	rs9768139	0.524	rs7779175	ENSG00000225365.1	AC078942.1	4.03	5.93e-05	0.00397	0.16	0.12	Calcium levels;	chr7:158344226	chr7:158537495~158539879:+
BRCA	cis	rs3749237	1	rs2307021	ENSG00000225399.4	RP11-3B7.1	4.03	5.93e-05	0.00397	0.12	0.12	Resting heart rate;	chr3:49728050	chr3:49260085~49261316:+
BRCA	cis	rs6490294	0.904	rs1016078	ENSG00000257624.1	RP1-128M12.3	4.03	5.93e-05	0.00397	0.17	0.12	Mean platelet volume;	chr12:111972273	chr12:112000739~112000985:-
BRCA	cis	rs8054556	1	rs11901	ENSG00000214725.6	CDIPT-AS1	-4.03	5.93e-05	0.00397	-0.15	-0.12	Autism spectrum disorder or schizophrenia;	chr16:29972749	chr16:29863593~29868053:+
BRCA	cis	rs9309473	0.687	rs11693531	ENSG00000163016.8	ALMS1P	4.03	5.93e-05	0.00397	0.15	0.12	Metabolite levels;	chr2:73381486	chr2:73644919~73685576:+
BRCA	cis	rs11098499	0.954	rs1022145	ENSG00000225892.3	RP11-384K6.2	4.03	5.93e-05	0.00397	0.13	0.12	Corneal astigmatism;	chr4:119309824	chr4:118632274~118634759:+
BRCA	cis	rs17772222	0.837	rs57118463	ENSG00000258789.1	RP11-507K2.3	-4.03	5.93e-05	0.00397	-0.15	-0.12	Coronary artery calcification;	chr14:88665822	chr14:88551597~88552493:+
BRCA	cis	rs7735319	0.546	rs6872111	ENSG00000249572.1	CTD-2203K17.1	4.03	5.93e-05	0.00397	0.16	0.12	Systolic blood pressure;	chr5:33105003	chr5:33424025~33440619:-
BRCA	cis	rs890448	0.796	rs4452435	ENSG00000254531.1	FLJ20021	-4.03	5.93e-05	0.00397	-0.14	-0.12	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101416549	chr4:101347780~101348883:+
BRCA	cis	rs11719291	0.833	rs13074318	ENSG00000225399.4	RP11-3B7.1	-4.03	5.93e-05	0.00397	-0.23	-0.12	Cognitive function;	chr3:48779292	chr3:49260085~49261316:+
BRCA	cis	rs12612435	0.869	rs67789205	ENSG00000226806.1	AC011893.3	4.03	5.93e-05	0.00397	0.15	0.12	Takotsubo syndrome;	chr2:136363558	chr2:135820191~135823087:+
BRCA	cis	rs2281558	0.833	rs12480853	ENSG00000274414.1	RP5-965G21.4	-4.03	5.93e-05	0.00397	-0.16	-0.12	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25542323	chr20:25239007~25245229:-
BRCA	cis	rs7267979	1	rs2257808	ENSG00000274973.1	RP13-401N8.7	-4.03	5.93e-05	0.00397	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25285814	chr20:25845497~25845862:+
BRCA	cis	rs7267979	1	rs2257809	ENSG00000274973.1	RP13-401N8.7	-4.03	5.93e-05	0.00397	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25285840	chr20:25845497~25845862:+
BRCA	cis	rs6545883	0.894	rs6545845	ENSG00000212978.6	AC016747.3	-4.03	5.93e-05	0.00397	-0.17	-0.12	Tuberculosis;	chr2:61209909	chr2:61141592~61144969:-
BRCA	cis	rs4561483	0.801	rs33620	ENSG00000261216.1	RP11-166B2.5	-4.03	5.94e-05	0.00397	-0.15	-0.12	Testicular germ cell tumor;	chr16:11914689	chr16:11908208~11908916:+
BRCA	cis	rs10191773	0.535	rs11123133	ENSG00000243389.1	AC012442.5	4.03	5.94e-05	0.00397	0.25	0.12	Yeast infection;	chr2:112207446	chr2:112589040~112614431:+
BRCA	cis	rs10129255	0.5	rs8014529	ENSG00000211967.3	IGHV3-53	-4.03	5.94e-05	0.00397	-0.08	-0.12	Kawasaki disease;	chr14:106784065	chr14:106592676~106593347:-
BRCA	cis	rs4925386	0.759	rs2427293	ENSG00000275437.1	RP5-908M14.10	-4.03	5.94e-05	0.00397	-0.14	-0.12	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62350803	chr20:62402236~62405935:-
BRCA	cis	rs4664293	0.625	rs6722715	ENSG00000226266.5	AC009961.3	4.03	5.94e-05	0.00398	0.15	0.12	Monocyte percentage of white cells;	chr2:159668515	chr2:159670708~159712435:-
BRCA	cis	rs11018874	0.597	rs4268468	ENSG00000280385.1	AP000648.5	4.03	5.94e-05	0.00398	0.16	0.12	White blood cell types;	chr11:90153116	chr11:90193614~90198120:+
BRCA	cis	rs6546324	0.625	rs4671813	ENSG00000236780.4	AC078941.1	4.03	5.94e-05	0.00398	0.21	0.12	Endometriosis;	chr2:67614703	chr2:67123357~67215319:-
BRCA	cis	rs6546324	0.539	rs4671192	ENSG00000236780.4	AC078941.1	4.03	5.94e-05	0.00398	0.21	0.12	Endometriosis;	chr2:67614723	chr2:67123357~67215319:-
BRCA	cis	rs739496	0.615	rs56884502	ENSG00000226469.1	ADAM1B	4.03	5.94e-05	0.00398	0.17	0.12	Platelet count;	chr12:111769496	chr12:111927018~111929017:+
BRCA	cis	rs739496	0.642	rs74849450	ENSG00000226469.1	ADAM1B	4.03	5.94e-05	0.00398	0.17	0.12	Platelet count;	chr12:111771034	chr12:111927018~111929017:+
BRCA	cis	rs9315786	0.924	rs7323436	ENSG00000168852.11	TPTE2P5	-4.03	5.94e-05	0.00398	-0.12	-0.12	Neutrophil percentage of granulocytes;	chr13:40776843	chr13:40822296~40921749:-
BRCA	cis	rs17597773	0.638	rs881995	ENSG00000238078.1	LINC01352	-4.03	5.94e-05	0.00398	-0.14	-0.12	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220811152	chr1:220829255~220832429:+
BRCA	cis	rs11098499	0.863	rs7678400	ENSG00000260091.1	RP11-33B1.4	-4.03	5.94e-05	0.00398	-0.11	-0.12	Corneal astigmatism;	chr4:119540802	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.863	rs1480936	ENSG00000260091.1	RP11-33B1.4	-4.03	5.94e-05	0.00398	-0.11	-0.12	Corneal astigmatism;	chr4:119541706	chr4:119409333~119410233:+
BRCA	cis	rs2408955	0.522	rs973398	ENSG00000226413.2	OR8T1P	-4.03	5.94e-05	0.00398	-0.16	-0.12	Glycated hemoglobin levels;	chr12:48097265	chr12:48442030~48442947:-
BRCA	cis	rs6993270	0.779	rs112325385	ENSG00000245330.4	KB-1471A8.1	-4.03	5.94e-05	0.00398	-0.19	-0.12	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr8:119904415	chr8:119867419~119874488:-
BRCA	cis	rs62025270	0.547	rs386346	ENSG00000259295.5	CSPG4P12	-4.03	5.94e-05	0.00398	-0.16	-0.12	Idiopathic pulmonary fibrosis;	chr15:85651328	chr15:85191438~85213905:+
BRCA	cis	rs4664293	0.605	rs12474082	ENSG00000226266.5	AC009961.3	4.03	5.94e-05	0.00398	0.15	0.12	Monocyte percentage of white cells;	chr2:159657403	chr2:159670708~159712435:-
BRCA	cis	rs4664293	0.585	rs1991372	ENSG00000226266.5	AC009961.3	4.03	5.94e-05	0.00398	0.15	0.12	Monocyte percentage of white cells;	chr2:159659556	chr2:159670708~159712435:-
BRCA	cis	rs4664293	0.546	rs1991373	ENSG00000226266.5	AC009961.3	4.03	5.94e-05	0.00398	0.15	0.12	Monocyte percentage of white cells;	chr2:159659714	chr2:159670708~159712435:-
BRCA	cis	rs4664293	0.625	rs6707985	ENSG00000226266.5	AC009961.3	4.03	5.94e-05	0.00398	0.15	0.12	Monocyte percentage of white cells;	chr2:159659877	chr2:159670708~159712435:-
BRCA	cis	rs4664293	0.625	rs62171641	ENSG00000226266.5	AC009961.3	4.03	5.94e-05	0.00398	0.15	0.12	Monocyte percentage of white cells;	chr2:159659994	chr2:159670708~159712435:-
BRCA	cis	rs4664293	0.585	rs35293435	ENSG00000226266.5	AC009961.3	4.03	5.94e-05	0.00398	0.15	0.12	Monocyte percentage of white cells;	chr2:159662396	chr2:159670708~159712435:-
BRCA	cis	rs4664293	0.625	rs62171646	ENSG00000226266.5	AC009961.3	4.03	5.94e-05	0.00398	0.15	0.12	Monocyte percentage of white cells;	chr2:159662563	chr2:159670708~159712435:-
BRCA	cis	rs4664293	0.625	rs4664295	ENSG00000226266.5	AC009961.3	4.03	5.94e-05	0.00398	0.15	0.12	Monocyte percentage of white cells;	chr2:159663807	chr2:159670708~159712435:-
BRCA	cis	rs1371614	0.502	rs4572551	ENSG00000272148.1	RP11-195B17.1	4.03	5.95e-05	0.00398	0.14	0.12	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26971145	chr2:27062428~27062907:-
BRCA	cis	rs7267979	1	rs2258617	ENSG00000277938.1	RP5-965G21.3	4.03	5.95e-05	0.00398	0.15	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25293682	chr20:25229150~25231933:+
BRCA	cis	rs911119	1	rs5030707	ENSG00000270001.1	RP11-218C14.8	-4.03	5.95e-05	0.00398	-0.17	-0.12	Chronic kidney disease;	chr20:23638019	chr20:23631826~23632316:-
BRCA	cis	rs911119	0.909	rs111360484	ENSG00000270001.1	RP11-218C14.8	-4.03	5.95e-05	0.00398	-0.17	-0.12	Chronic kidney disease;	chr20:23638347	chr20:23631826~23632316:-
BRCA	cis	rs875971	0.66	rs62465434	ENSG00000229180.5	GS1-124K5.11	4.03	5.95e-05	0.00398	0.11	0.12	Aortic root size;	chr7:66540165	chr7:66526088~66542624:-
BRCA	cis	rs1048886	0.938	rs58085250	ENSG00000271967.1	RP11-134K13.4	-4.03	5.95e-05	0.00398	-0.18	-0.12	Type 2 diabetes;	chr6:70508878	chr6:70596438~70596980:+
BRCA	cis	rs683250	0.629	rs1151243	ENSG00000254551.1	RP11-727A23.7	4.03	5.95e-05	0.00398	0.15	0.12	Subcortical brain region volumes;	chr11:83265369	chr11:83209431~83213379:-
BRCA	cis	rs962856	0.964	rs600388	ENSG00000236605.1	AC023115.4	4.03	5.95e-05	0.00398	0.15	0.12	Pancreatic cancer;	chr2:67429677	chr2:67324627~67325304:+
BRCA	cis	rs10911902	0.913	rs80040530	ENSG00000229739.2	RP11-295K2.3	-4.03	5.95e-05	0.00398	-0.18	-0.12	Schizophrenia;	chr1:186603052	chr1:186435161~186470291:+
BRCA	cis	rs12188164	0.582	rs80273890	ENSG00000188242.4	PP7080	4.03	5.95e-05	0.00398	0.18	0.12	Cystic fibrosis severity;	chr5:482942	chr5:466124~473098:-
BRCA	cis	rs12428035	0.656	rs7339059	ENSG00000247400.3	DNAJC3-AS1	4.03	5.95e-05	0.00398	0.19	0.12	Glomerular filtration rate (cystatin C);Response to statins (LDL cholesterol change);	chr13:95902223	chr13:95648733~95676925:-
BRCA	cis	rs12428035	0.656	rs7334320	ENSG00000247400.3	DNAJC3-AS1	4.03	5.95e-05	0.00398	0.19	0.12	Glomerular filtration rate (cystatin C);Response to statins (LDL cholesterol change);	chr13:95902673	chr13:95648733~95676925:-
BRCA	cis	rs6121246	0.909	rs6058463	ENSG00000230613.1	HM13-AS1	4.03	5.95e-05	0.00398	0.18	0.12	Mean corpuscular hemoglobin;	chr20:31797389	chr20:31567707~31573263:-
BRCA	cis	rs911119	1	rs1064039	ENSG00000270001.1	RP11-218C14.8	-4.03	5.95e-05	0.00398	-0.17	-0.12	Chronic kidney disease;	chr20:23637790	chr20:23631826~23632316:-
BRCA	cis	rs12701220	0.894	rs12701348	ENSG00000224079.1	AC091729.7	4.03	5.95e-05	0.00398	0.19	0.12	Bronchopulmonary dysplasia;	chr7:999821	chr7:1074450~1078036:+
BRCA	cis	rs11711311	0.955	rs1048892	ENSG00000241529.3	RN7SL767P	-4.03	5.95e-05	0.00398	-0.15	-0.12	IgG glycosylation;	chr3:113746012	chr3:113632704~113632998:+
BRCA	cis	rs10487112	0.833	rs12704542	ENSG00000235436.9	DPY19L2P4	-4.03	5.95e-05	0.00398	-0.14	-0.12	Perceived unattractiveness to mosquitoes;	chr7:90493318	chr7:90119400~90125600:+
BRCA	cis	rs2115630	1	rs11854313	ENSG00000275120.1	RP11-182J1.17	-4.03	5.95e-05	0.00399	-0.14	-0.12	P wave terminal force;	chr15:84760817	chr15:84599434~84606463:-
BRCA	cis	rs1005277	0.579	rs1780145	ENSG00000272983.1	RP11-508N22.12	4.03	5.96e-05	0.00399	0.13	0.12	Extrinsic epigenetic age acceleration;	chr10:38248142	chr10:38137337~38144399:+
BRCA	cis	rs9788682	0.747	rs8042059	ENSG00000261143.1	ADAMTS7P3	-4.03	5.96e-05	0.00399	-0.16	-0.12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78615517	chr15:77976042~77993057:+
BRCA	cis	rs17270561	0.636	rs3922681	ENSG00000272462.2	U91328.19	-4.03	5.96e-05	0.00399	-0.15	-0.12	Iron status biomarkers;	chr6:25698253	chr6:25992662~26001775:+
BRCA	cis	rs2880765	0.835	rs6496027	ENSG00000230373.7	GOLGA6L5P	4.03	5.96e-05	0.00399	0.13	0.12	Coronary artery disease;	chr15:85506757	chr15:84507885~84516814:-
BRCA	cis	rs6049003	0.622	rs6138047	ENSG00000232645.4	LINC01431	4.03	5.96e-05	0.00399	0.13	0.12	Cerebrospinal fluid biomarker levels;	chr20:23727080	chr20:23356594~23358116:-
BRCA	cis	rs1075265	0.783	rs805359	ENSG00000272156.1	RP11-477N3.1	-4.03	5.96e-05	0.00399	-0.13	-0.12	Chronotype;Morning vs. evening chronotype;	chr2:53935317	chr2:54082554~54085066:+
BRCA	cis	rs38055	1	rs40232	ENSG00000247796.2	CTD-2366F13.1	-4.03	5.96e-05	0.00399	-0.15	-0.12	Acne (severe);	chr5:53265155	chr5:53109842~53115126:+
BRCA	cis	rs9381040	0.655	rs6939989	ENSG00000161912.16	ADCY10P1	4.03	5.96e-05	0.00399	0.14	0.12	Alzheimer's disease (late onset);	chr6:41052466	chr6:41101022~41140835:+
BRCA	cis	rs6479874	0.915	rs4935212	ENSG00000223502.1	RP11-96B5.3	4.03	5.96e-05	0.00399	0.22	0.12	Migraine;	chr10:51012717	chr10:51062579~51068553:-
BRCA	cis	rs9402743	0.634	rs2327646	ENSG00000234084.1	RP3-388E23.2	-4.03	5.96e-05	0.00399	-0.12	-0.12	Systemic lupus erythematosus;	chr6:135597186	chr6:135301568~135307158:+
BRCA	cis	rs7267979	1	rs2258201	ENSG00000277938.1	RP5-965G21.3	4.03	5.97e-05	0.00399	0.15	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25291854	chr20:25229150~25231933:+
BRCA	cis	rs801193	1	rs6958520	ENSG00000272831.1	RP11-792A8.4	4.03	5.97e-05	0.00399	0.11	0.12	Aortic root size;	chr7:66686466	chr7:66739829~66740385:-
BRCA	cis	rs3760982	1	rs10421887	ENSG00000267191.1	RP11-15A1.2	4.03	5.97e-05	0.00399	0.15	0.12	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43790697	chr19:43902001~43926545:+
BRCA	cis	rs7937890	0.507	rs4463820	ENSG00000254418.1	RP11-21L19.1	4.03	5.97e-05	0.00399	0.15	0.12	Mitochondrial DNA levels;	chr11:14534796	chr11:14262846~14273691:-
BRCA	cis	rs7818688	1	rs73276417	ENSG00000245080.5	RP11-320N21.1	-4.03	5.97e-05	0.00399	-0.21	-0.12	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95014084	chr8:95066808~95073182:-
BRCA	cis	rs7818688	1	rs28440026	ENSG00000245080.5	RP11-320N21.1	-4.03	5.97e-05	0.00399	-0.21	-0.12	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95014516	chr8:95066808~95073182:-
BRCA	cis	rs7818688	1	rs28712702	ENSG00000245080.5	RP11-320N21.1	-4.03	5.97e-05	0.00399	-0.21	-0.12	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95014752	chr8:95066808~95073182:-
BRCA	cis	rs7818688	1	rs28363725	ENSG00000245080.5	RP11-320N21.1	-4.03	5.97e-05	0.00399	-0.21	-0.12	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95014880	chr8:95066808~95073182:-
BRCA	cis	rs7818688	1	rs28378156	ENSG00000245080.5	RP11-320N21.1	-4.03	5.97e-05	0.00399	-0.21	-0.12	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95014899	chr8:95066808~95073182:-
BRCA	cis	rs7818688	1	rs6989862	ENSG00000245080.5	RP11-320N21.1	-4.03	5.97e-05	0.00399	-0.21	-0.12	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95015340	chr8:95066808~95073182:-
BRCA	cis	rs7818688	1	rs6985880	ENSG00000245080.5	RP11-320N21.1	-4.03	5.97e-05	0.00399	-0.21	-0.12	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95015371	chr8:95066808~95073182:-
BRCA	cis	rs7818688	1	rs7008542	ENSG00000245080.5	RP11-320N21.1	-4.03	5.97e-05	0.00399	-0.21	-0.12	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95015635	chr8:95066808~95073182:-
BRCA	cis	rs7818688	0.932	rs6471505	ENSG00000245080.5	RP11-320N21.1	-4.03	5.97e-05	0.00399	-0.21	-0.12	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95016397	chr8:95066808~95073182:-
BRCA	cis	rs7818688	0.932	rs6471506	ENSG00000245080.5	RP11-320N21.1	-4.03	5.97e-05	0.00399	-0.21	-0.12	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95016472	chr8:95066808~95073182:-
BRCA	cis	rs7818688	0.858	rs7826196	ENSG00000245080.5	RP11-320N21.1	-4.03	5.97e-05	0.00399	-0.21	-0.12	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95016774	chr8:95066808~95073182:-
BRCA	cis	rs7267979	0.932	rs6115214	ENSG00000274414.1	RP5-965G21.4	4.03	5.97e-05	0.00399	0.15	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25576790	chr20:25239007~25245229:-
BRCA	cis	rs8180040	0.681	rs9818382	ENSG00000271161.1	BOLA2P2	4.03	5.97e-05	0.00399	0.13	0.12	Colorectal cancer;	chr3:47151544	chr3:47499841~47500407:+
BRCA	cis	rs36051895	0.559	rs1590268	ENSG00000236254.1	MTND4P14	-4.03	5.97e-05	0.00399	-0.14	-0.12	Pediatric autoimmune diseases;	chr9:5209433	chr9:5107937~5109290:+
BRCA	cis	rs11098403	0.764	rs4377657	ENSG00000225892.3	RP11-384K6.2	4.03	5.97e-05	0.00399	0.12	0.12	Schizophrenia;	chr4:117800878	chr4:118632274~118634759:+
BRCA	cis	rs2243480	1	rs410128	ENSG00000237026.1	RP11-328P23.2	4.03	5.97e-05	0.00399	0.24	0.12	Diabetic kidney disease;	chr7:66138186	chr7:65235790~65236723:-
BRCA	cis	rs6121246	0.909	rs6119651	ENSG00000230613.1	HM13-AS1	4.03	5.97e-05	0.004	0.18	0.12	Mean corpuscular hemoglobin;	chr20:31671443	chr20:31567707~31573263:-
BRCA	cis	rs4650943	0.658	rs1503124	ENSG00000227740.1	RP11-318C24.2	-4.03	5.97e-05	0.004	-0.13	-0.12	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in inactive individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr1:176384990	chr1:175904762~175920513:-
BRCA	cis	rs2514805	0.803	rs2513786	ENSG00000253585.1	KB-1184D12.1	4.03	5.97e-05	0.004	0.23	0.12	Diisocyanate-induced asthma;	chr8:94114660	chr8:94097764~94104322:-
BRCA	cis	rs11742741	0.806	rs11750284	ENSG00000248874.4	C5orf17	-4.03	5.97e-05	0.004	-0.16	-0.12	Educational attainment;	chr5:24041380	chr5:23951348~24178263:+
BRCA	cis	rs10276381	0.579	rs11520706	ENSG00000234336.5	JAZF1-AS1	4.03	5.98e-05	0.004	0.28	0.12	Crohn's disease;	chr7:28163129	chr7:28180322~28243917:+
BRCA	cis	rs8180040	0.62	rs2278963	ENSG00000271161.1	BOLA2P2	-4.03	5.98e-05	0.004	-0.14	-0.12	Colorectal cancer;	chr3:47013379	chr3:47499841~47500407:+
BRCA	cis	rs35306767	0.855	rs61830900	ENSG00000229869.1	RP11-363N22.2	-4.03	5.98e-05	0.004	-0.21	-0.12	Eosinophil percentage of granulocytes;	chr10:825541	chr10:933026~942743:+
BRCA	cis	rs891378	0.958	rs10746462	ENSG00000274245.1	RP11-357P18.2	-4.03	5.98e-05	0.004	-0.16	-0.12	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207337203	chr1:207372559~207373252:+
BRCA	cis	rs853679	0.517	rs36078605	ENSG00000216901.1	AL022393.7	4.03	5.98e-05	0.004	0.18	0.12	Depression;	chr6:28110254	chr6:28176188~28176674:+
BRCA	cis	rs7267979	1	rs910997	ENSG00000277938.1	RP5-965G21.3	4.03	5.98e-05	0.004	0.15	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25286665	chr20:25229150~25231933:+
BRCA	cis	rs10090774	0.965	rs4961300	ENSG00000280303.2	ERICD	4.03	5.98e-05	0.004	0.15	0.12	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140900768	chr8:140636281~140638283:+
BRCA	cis	rs957448	1	rs2381885	ENSG00000254315.1	RP11-267M23.3	4.03	5.98e-05	0.004	0.17	0.12	Nonsyndromic cleft lip with cleft palate;	chr8:94499974	chr8:94533628~94534391:+
BRCA	cis	rs6964587	1	rs7811873	ENSG00000188693.7	CYP51A1-AS1	-4.03	5.98e-05	0.004	-0.13	-0.12	Breast cancer;	chr7:92121806	chr7:92134604~92180725:+
BRCA	cis	rs6964587	1	rs2269727	ENSG00000188693.7	CYP51A1-AS1	-4.03	5.98e-05	0.004	-0.13	-0.12	Breast cancer;	chr7:92123376	chr7:92134604~92180725:+
BRCA	cis	rs11083475	0.967	rs7254100	ENSG00000267892.1	CTD-2540F13.2	4.03	5.98e-05	0.004	0.14	0.12	Heart rate;	chr19:38682846	chr19:38738284~38739863:+
BRCA	cis	rs8040855	0.52	rs11629963	ENSG00000259774.1	RP11-182J1.13	-4.03	5.98e-05	0.004	-0.18	-0.12	Bulimia nervosa;	chr15:84986808	chr15:84422618~84425882:+
BRCA	cis	rs67340775	0.541	rs169287	ENSG00000216901.1	AL022393.7	4.03	5.98e-05	0.004	0.2	0.12	Lung cancer in ever smokers;	chr6:27886982	chr6:28176188~28176674:+
BRCA	cis	rs1950832	0.723	rs8022751	ENSG00000258636.1	CTD-2298J14.2	-4.03	5.99e-05	0.004	-0.15	-0.12	Urate levels in obese individuals;	chr14:41657545	chr14:41587861~41604856:-
BRCA	cis	rs924712	0.514	rs421957	ENSG00000261116.1	RP3-523K23.2	-4.03	5.99e-05	0.004	-0.16	-0.12	Breast cancer;	chr6:54930937	chr6:54943167~54945099:+
BRCA	cis	rs7210837	1	rs1964555	ENSG00000175061.16	LRRC75A-AS1	4.03	5.99e-05	0.004	0.16	0.12	Response to platinum-based chemotherapy (cisplatin);	chr17:16860241	chr17:16438822~16478678:+
BRCA	cis	rs6893300	0.785	rs3797762	ENSG00000250999.1	RP11-1379J22.5	4.03	5.99e-05	0.004	0.17	0.12	Resting heart rate;	chr5:179775687	chr5:179657762~179664432:+
BRCA	cis	rs10129255	0.744	rs28517388	ENSG00000274576.2	IGHV2-70	4.03	5.99e-05	0.004	0.12	0.12	Kawasaki disease;	chr14:106704323	chr14:106770577~106771020:-
BRCA	cis	rs848490	0.722	rs6976860	ENSG00000214293.7	APTR	4.03	5.99e-05	0.004	0.14	0.12	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77822829	chr7:77657660~77696265:-
BRCA	cis	rs80226907	0.634	rs713473	ENSG00000186615.9	KTN1-AS1	-4.03	5.99e-05	0.004	-0.25	-0.12	Mean platelet volume;	chr14:55437978	chr14:55499278~55580110:-
BRCA	cis	rs6772849	0.768	rs9820741	ENSG00000242551.2	POU5F1P6	-4.03	5.99e-05	0.00401	-0.16	-0.12	Monocyte percentage of white cells;Monocyte count;	chr3:128697237	chr3:128674735~128677005:-
BRCA	cis	rs1971762	0.527	rs6580953	ENSG00000270175.1	RP11-793H13.11	-4.03	5.99e-05	0.00401	-0.11	-0.12	Height;	chr12:53627354	chr12:53500162~53500936:-
BRCA	cis	rs3735485	0.738	rs11771107	ENSG00000201772.1	SNORA5C	4.03	5.99e-05	0.00401	0.16	0.12	White blood cell count;Sum basophil neutrophil counts;Neutrophil count;Granulocyte percentage of myeloid white cells;Monocyte percentage of white cells;Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Lymphocyte counts;	chr7:45094536	chr7:45104906~45105042:-
BRCA	cis	rs9844666	0.512	rs1568350	ENSG00000273486.1	RP11-731C17.2	4.03	5.99e-05	0.00401	0.15	0.12	Height;	chr3:135929843	chr3:136837338~136839021:-
BRCA	cis	rs2692947	0.537	rs1834135	ENSG00000168992.4	OR7E102P	4.03	5.99e-05	0.00401	0.17	0.12	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95578477	chr2:95546531~95547545:+
BRCA	cis	rs6545883	0.965	rs778752	ENSG00000270820.4	RP11-355B11.2	4.03	5.99e-05	0.00401	0.14	0.12	Tuberculosis;	chr2:61549767	chr2:61471188~61484130:+
BRCA	cis	rs16846053	0.792	rs72877400	ENSG00000227403.1	AC009299.3	4.03	5.99e-05	0.00401	0.31	0.12	Blood osmolality (transformed sodium);	chr2:161820181	chr2:161244739~161249050:+
BRCA	cis	rs61931739	0.5	rs10844829	ENSG00000258794.3	DUX4L27	4.03	5.99e-05	0.00401	0.18	0.12	Morning vs. evening chronotype;	chr12:34151981	chr12:34208415~34209675:-
BRCA	cis	rs984222	0.838	rs6428789	ENSG00000231365.4	RP11-418J17.1	-4.03	6e-05	0.00401	-0.15	-0.12	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119007857	chr1:119140396~119275973:+
BRCA	cis	rs6452524	0.935	rs1011979	ENSG00000281327.1	LINC01338	4.03	6e-05	0.00401	0.14	0.12	Hypertension (SNP x SNP interaction);	chr5:83097431	chr5:82850864~82859836:-
BRCA	cis	rs7267979	1	rs2297497	ENSG00000274973.1	RP13-401N8.7	4.03	6e-05	0.00401	0.14	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25317273	chr20:25845497~25845862:+
BRCA	cis	rs12681366	0.959	rs58826082	ENSG00000253175.1	RP11-267M23.6	4.03	6e-05	0.00401	0.14	0.12	Nonsyndromic cleft lip with cleft palate;	chr8:94351487	chr8:94565036~94565715:+
BRCA	cis	rs4713118	0.911	rs9461406	ENSG00000219392.1	RP1-265C24.5	4.03	6e-05	0.00401	0.18	0.12	Parkinson's disease;	chr6:27751985	chr6:28115628~28116551:+
BRCA	cis	rs7800418	0.963	rs13223498	ENSG00000214870.7	AC004540.5	-4.03	6e-05	0.00401	-0.16	-0.12	Cognitive function;	chr7:26566603	chr7:26398593~26494256:+
BRCA	cis	rs6472235	0.586	rs34464051	ENSG00000272010.1	CTD-3025N20.3	-4.03	6e-05	0.00401	-0.15	-0.12	Plateletcrit;Myopia (pathological);	chr8:65989769	chr8:65591850~65592472:-
BRCA	cis	rs6012564	0.928	rs8118105	ENSG00000227431.4	CSE1L-AS1	4.03	6e-05	0.00401	0.15	0.12	Anger;	chr20:49182127	chr20:49040463~49046044:-
BRCA	cis	rs2625529	0.761	rs8028532	ENSG00000260037.4	CTD-2524L6.3	-4.03	6e-05	0.00402	-0.18	-0.12	Red blood cell count;	chr15:72055713	chr15:71818396~71823384:+
BRCA	cis	rs875971	1	rs6958271	ENSG00000236529.1	RP13-254B10.1	4.03	6.01e-05	0.00402	0.14	0.12	Aortic root size;	chr7:66514344	chr7:65840212~65840596:+
BRCA	cis	rs875971	1	rs6958277	ENSG00000236529.1	RP13-254B10.1	4.03	6.01e-05	0.00402	0.14	0.12	Aortic root size;	chr7:66514362	chr7:65840212~65840596:+
BRCA	cis	rs11051970	0.879	rs2171373	ENSG00000274964.1	RP11-817I4.1	-4.03	6.01e-05	0.00402	-0.14	-0.12	Response to tocilizumab in rheumatoid arthritis;	chr12:32422843	chr12:32339368~32340724:+
BRCA	cis	rs11051970	0.879	rs2243815	ENSG00000274964.1	RP11-817I4.1	-4.03	6.01e-05	0.00402	-0.14	-0.12	Response to tocilizumab in rheumatoid arthritis;	chr12:32423224	chr12:32339368~32340724:+
BRCA	cis	rs7103648	0.966	rs10838702	ENSG00000280615.1	Y_RNA	4.03	6.01e-05	0.00402	0.14	0.12	Systolic blood pressure;Diastolic blood pressure;	chr11:47389337	chr11:47614898~47614994:-
BRCA	cis	rs12439619	0.846	rs62012059	ENSG00000259429.4	UBE2Q2P2	-4.03	6.01e-05	0.00402	-0.15	-0.12	Intelligence (multi-trait analysis);	chr15:82251669	chr15:82355142~82420075:+
BRCA	cis	rs7267979	1	rs2258769	ENSG00000277938.1	RP5-965G21.3	4.03	6.01e-05	0.00402	0.15	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25296044	chr20:25229150~25231933:+
BRCA	cis	rs875971	0.862	rs11773628	ENSG00000273024.4	INTS4P2	4.03	6.01e-05	0.00402	0.14	0.12	Aortic root size;	chr7:66517644	chr7:65647864~65715661:+
BRCA	cis	rs2998286	0.723	rs332191	ENSG00000237128.1	RP11-351M16.3	4.03	6.01e-05	0.00402	0.16	0.12	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28632196	chr10:28433008~28495813:-
BRCA	cis	rs10129255	0.833	rs61997797	ENSG00000211967.3	IGHV3-53	-4.03	6.01e-05	0.00402	-0.09	-0.12	Kawasaki disease;	chr14:106815190	chr14:106592676~106593347:-
BRCA	cis	rs875971	0.52	rs160645	ENSG00000273142.1	RP11-458F8.4	-4.03	6.01e-05	0.00402	-0.12	-0.12	Aortic root size;	chr7:66091320	chr7:66902857~66906297:+
BRCA	cis	rs9913711	0.689	rs8076087	ENSG00000226101.1	AC007461.2	4.03	6.01e-05	0.00402	0.12	0.12	Liver enzyme levels (gamma-glutamyl transferase);	chr17:72139914	chr17:72072333~72093481:+
BRCA	cis	rs875971	0.929	rs34406470	ENSG00000236529.1	RP13-254B10.1	4.03	6.01e-05	0.00402	0.14	0.12	Aortic root size;	chr7:66464969	chr7:65840212~65840596:+
BRCA	cis	rs4237845	0.514	rs4760339	ENSG00000270039.1	RP11-571M6.17	-4.03	6.01e-05	0.00402	-0.18	-0.12	Intelligence (multi-trait analysis);	chr12:57874366	chr12:57803838~57804415:+
BRCA	cis	rs516805	0.561	rs9320881	ENSG00000279114.1	RP3-425C14.5	4.03	6.02e-05	0.00402	0.18	0.12	Lymphocyte counts;	chr6:122613577	chr6:122471923~122484161:+
BRCA	cis	rs7267979	1	rs2258563	ENSG00000277938.1	RP5-965G21.3	4.03	6.02e-05	0.00402	0.15	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25292799	chr20:25229150~25231933:+
BRCA	cis	rs6840360	0.582	rs1372976	ENSG00000251603.1	RP11-164P12.4	-4.03	6.02e-05	0.00402	-0.11	-0.12	Intelligence (multi-trait analysis);	chr4:151530301	chr4:151667224~151670502:+
BRCA	cis	rs13401620	0.833	rs28728444	ENSG00000229326.3	AC069154.4	-4.03	6.02e-05	0.00402	-0.16	-0.12	Breast size;	chr2:119849377	chr2:119698623~119700151:+
BRCA	cis	rs9311474	0.596	rs524986	ENSG00000243224.1	RP5-1157M23.2	-4.03	6.02e-05	0.00402	-0.13	-0.12	Electroencephalogram traits;	chr3:52194480	chr3:52239258~52241097:+
BRCA	cis	rs77633900	0.772	rs284903	ENSG00000196274.5	Metazoa_SRP	4.03	6.02e-05	0.00402	0.21	0.12	Glioma;Non-glioblastoma glioma;	chr15:76452472	chr15:76230048~76230390:-
BRCA	cis	rs2832191	0.74	rs2832168	ENSG00000215533.7	LINC00189	-4.03	6.02e-05	0.00402	-0.14	-0.12	Dental caries;	chr21:29091374	chr21:29193480~29288205:+
BRCA	cis	rs4925540	0.519	rs4971314	ENSG00000215796.3	RP11-551G24.2	-4.03	6.02e-05	0.00402	-0.16	-0.12	Response to taxane treatment (docetaxel);	chr1:247044545	chr1:247042791~247044021:+
BRCA	cis	rs1009077	0.68	rs13103899	ENSG00000245958.5	RP11-33B1.1	4.03	6.02e-05	0.00402	0.16	0.12	Endometriosis;	chr4:119517147	chr4:119454791~119552025:+
BRCA	cis	rs8180040	0.62	rs7373821	ENSG00000271161.1	BOLA2P2	4.03	6.02e-05	0.00403	0.13	0.12	Colorectal cancer;	chr3:47038637	chr3:47499841~47500407:+
BRCA	cis	rs2562456	0.833	rs8106025	ENSG00000213976.4	CTD-2561J22.2	4.03	6.02e-05	0.00403	0.15	0.12	Pain;	chr19:21451922	chr19:21382865~21387177:+
BRCA	cis	rs7412746	0.611	rs7532045	ENSG00000231073.1	RP11-316M1.3	4.03	6.03e-05	0.00403	0.13	0.12	Melanoma;	chr1:150849371	chr1:150973123~150975534:+
BRCA	cis	rs875971	0.862	rs1875057	ENSG00000273024.4	INTS4P2	4.03	6.03e-05	0.00403	0.14	0.12	Aortic root size;	chr7:66266868	chr7:65647864~65715661:+
BRCA	cis	rs875971	0.862	rs6960446	ENSG00000273024.4	INTS4P2	4.03	6.03e-05	0.00403	0.14	0.12	Aortic root size;	chr7:66268272	chr7:65647864~65715661:+
BRCA	cis	rs875971	0.789	rs10260426	ENSG00000273024.4	INTS4P2	4.03	6.03e-05	0.00403	0.14	0.12	Aortic root size;	chr7:66271055	chr7:65647864~65715661:+
BRCA	cis	rs7267979	1	rs2424710	ENSG00000277938.1	RP5-965G21.3	4.03	6.03e-05	0.00403	0.15	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25303250	chr20:25229150~25231933:+
BRCA	cis	rs2274273	0.712	rs6572999	ENSG00000233924.1	AL160471.6	-4.03	6.03e-05	0.00403	-0.14	-0.12	Protein biomarker;	chr14:55060656	chr14:55004813~55005687:-
BRCA	cis	rs17270561	0.609	rs4712957	ENSG00000272462.2	U91328.19	-4.03	6.03e-05	0.00403	-0.15	-0.12	Iron status biomarkers;	chr6:25719586	chr6:25992662~26001775:+
BRCA	cis	rs17270561	0.666	rs17320090	ENSG00000272462.2	U91328.19	-4.03	6.03e-05	0.00403	-0.15	-0.12	Iron status biomarkers;	chr6:25719987	chr6:25992662~26001775:+
BRCA	cis	rs6088590	0.523	rs6059913	ENSG00000275784.1	RP5-1125A11.6	-4.03	6.03e-05	0.00403	-0.14	-0.12	Coronary artery disease;	chr20:34555484	chr20:33989480~33991818:-
BRCA	cis	rs11098499	0.754	rs878372	ENSG00000260091.1	RP11-33B1.4	-4.03	6.03e-05	0.00403	-0.11	-0.12	Corneal astigmatism;	chr4:119317625	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.863	rs6835635	ENSG00000260091.1	RP11-33B1.4	-4.03	6.03e-05	0.00403	-0.11	-0.12	Corneal astigmatism;	chr4:119537712	chr4:119409333~119410233:+
BRCA	cis	rs6496932	0.503	rs11074205	ENSG00000259630.2	CTD-2262B20.1	-4.03	6.03e-05	0.00403	-0.17	-0.12	Central corneal thickness;Corneal structure;	chr15:85401381	chr15:85415228~85415633:+
BRCA	cis	rs10129255	0.957	rs10138532	ENSG00000274576.2	IGHV2-70	4.03	6.03e-05	0.00403	0.12	0.12	Kawasaki disease;	chr14:106803901	chr14:106770577~106771020:-
BRCA	cis	rs35100037	0.803	rs10478873	ENSG00000249421.1	ADAMTS19-AS1	4.03	6.03e-05	0.00403	0.22	0.12	Ankle injury;	chr5:129294741	chr5:129459559~129460689:-
BRCA	cis	rs35520189	0.857	rs2466446	ENSG00000274877.1	RP11-65I12.1	4.03	6.03e-05	0.00403	0.17	0.12	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:112865703	chr2:113237595~113240825:+
BRCA	cis	rs1153858	1	rs1365610	ENSG00000275672.1	GATM-AS1	-4.03	6.03e-05	0.00403	-0.16	-0.12	Homoarginine levels;	chr15:45402412	chr15:45378700~45380123:+
BRCA	cis	rs9733	0.596	rs6587516	ENSG00000231073.1	RP11-316M1.3	4.03	6.03e-05	0.00403	0.13	0.12	Tonsillectomy;	chr1:150650745	chr1:150973123~150975534:+
BRCA	cis	rs9733	0.596	rs6678013	ENSG00000231073.1	RP11-316M1.3	4.03	6.03e-05	0.00403	0.13	0.12	Tonsillectomy;	chr1:150650809	chr1:150973123~150975534:+
BRCA	cis	rs9733	0.596	rs2175615	ENSG00000231073.1	RP11-316M1.3	4.03	6.03e-05	0.00403	0.13	0.12	Tonsillectomy;	chr1:150651625	chr1:150973123~150975534:+
BRCA	cis	rs9733	0.596	rs72700897	ENSG00000231073.1	RP11-316M1.3	4.03	6.03e-05	0.00403	0.13	0.12	Tonsillectomy;	chr1:150653562	chr1:150973123~150975534:+
BRCA	cis	rs9733	0.596	rs6661872	ENSG00000231073.1	RP11-316M1.3	4.03	6.03e-05	0.00403	0.13	0.12	Tonsillectomy;	chr1:150655881	chr1:150973123~150975534:+
BRCA	cis	rs9733	0.596	rs11204687	ENSG00000231073.1	RP11-316M1.3	4.03	6.03e-05	0.00403	0.13	0.12	Tonsillectomy;	chr1:150657404	chr1:150973123~150975534:+
BRCA	cis	rs9733	0.596	rs2867304	ENSG00000231073.1	RP11-316M1.3	4.03	6.03e-05	0.00403	0.13	0.12	Tonsillectomy;	chr1:150658519	chr1:150973123~150975534:+
BRCA	cis	rs9733	0.596	rs6690725	ENSG00000231073.1	RP11-316M1.3	4.03	6.03e-05	0.00403	0.13	0.12	Tonsillectomy;	chr1:150659846	chr1:150973123~150975534:+
BRCA	cis	rs9733	0.596	rs72702504	ENSG00000231073.1	RP11-316M1.3	4.03	6.03e-05	0.00403	0.13	0.12	Tonsillectomy;	chr1:150662898	chr1:150973123~150975534:+
BRCA	cis	rs9733	0.536	rs6661415	ENSG00000231073.1	RP11-316M1.3	4.03	6.03e-05	0.00403	0.13	0.12	Tonsillectomy;	chr1:150663393	chr1:150973123~150975534:+
BRCA	cis	rs9733	0.596	rs11807058	ENSG00000231073.1	RP11-316M1.3	4.03	6.03e-05	0.00403	0.13	0.12	Tonsillectomy;	chr1:150667999	chr1:150973123~150975534:+
BRCA	cis	rs9368481	0.761	rs9357028	ENSG00000224843.5	LINC00240	4.03	6.03e-05	0.00403	0.15	0.12	Autism spectrum disorder or schizophrenia;	chr6:26999445	chr6:26956992~27023924:+
BRCA	cis	rs4834770	1	rs6823963	ENSG00000250412.1	KLHL2P1	4.03	6.03e-05	0.00403	0.14	0.12	Blood protein levels;	chr4:119321009	chr4:119334329~119378233:+
BRCA	cis	rs4834770	1	rs4834771	ENSG00000250412.1	KLHL2P1	4.03	6.03e-05	0.00403	0.14	0.12	Blood protein levels;	chr4:119321617	chr4:119334329~119378233:+
BRCA	cis	rs4834770	1	rs1397613	ENSG00000250412.1	KLHL2P1	4.03	6.03e-05	0.00403	0.14	0.12	Blood protein levels;	chr4:119321774	chr4:119334329~119378233:+
BRCA	cis	rs4834770	1	rs6857641	ENSG00000250412.1	KLHL2P1	4.03	6.03e-05	0.00403	0.14	0.12	Blood protein levels;	chr4:119322356	chr4:119334329~119378233:+
BRCA	cis	rs4834770	1	rs2282688	ENSG00000250412.1	KLHL2P1	4.03	6.03e-05	0.00403	0.14	0.12	Blood protein levels;	chr4:119322567	chr4:119334329~119378233:+
BRCA	cis	rs8180040	0.627	rs6442059	ENSG00000271161.1	BOLA2P2	4.03	6.03e-05	0.00403	0.13	0.12	Colorectal cancer;	chr3:47145585	chr3:47499841~47500407:+
BRCA	cis	rs490234	0.702	rs7864945	ENSG00000232630.1	PRPS1P2	-4.03	6.03e-05	0.00403	-0.13	-0.12	Mean arterial pressure;	chr9:125611190	chr9:125150653~125151589:+
BRCA	cis	rs7267979	1	rs11100	ENSG00000277938.1	RP5-965G21.3	4.03	6.03e-05	0.00403	0.15	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25300548	chr20:25229150~25231933:+
BRCA	cis	rs7267979	1	rs1046073	ENSG00000277938.1	RP5-965G21.3	4.03	6.03e-05	0.00403	0.15	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25300697	chr20:25229150~25231933:+
BRCA	cis	rs7267979	1	rs2259926	ENSG00000277938.1	RP5-965G21.3	4.03	6.03e-05	0.00403	0.15	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25301097	chr20:25229150~25231933:+
BRCA	cis	rs7267979	1	rs2259928	ENSG00000277938.1	RP5-965G21.3	4.03	6.03e-05	0.00403	0.15	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25301198	chr20:25229150~25231933:+
BRCA	cis	rs7267979	1	rs2259956	ENSG00000277938.1	RP5-965G21.3	4.03	6.03e-05	0.00403	0.15	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25301797	chr20:25229150~25231933:+
BRCA	cis	rs875971	0.543	rs801191	ENSG00000273142.1	RP11-458F8.4	4.03	6.04e-05	0.00403	0.11	0.12	Aortic root size;	chr7:66567968	chr7:66902857~66906297:+
BRCA	cis	rs7508	0.512	rs12544390	ENSG00000253944.1	RP11-156K13.1	-4.03	6.04e-05	0.00403	-0.14	-0.12	Atrial fibrillation;	chr8:18018039	chr8:17801345~17861069:+
BRCA	cis	rs10911902	0.874	rs7515126	ENSG00000229739.2	RP11-295K2.3	-4.03	6.04e-05	0.00403	-0.18	-0.12	Schizophrenia;	chr1:186543283	chr1:186435161~186470291:+
BRCA	cis	rs6088590	0.523	rs6088536	ENSG00000275784.1	RP5-1125A11.6	-4.03	6.04e-05	0.00403	-0.14	-0.12	Coronary artery disease;	chr20:34601302	chr20:33989480~33991818:-
BRCA	cis	rs6496932	0.802	rs12439958	ENSG00000218052.5	ADAMTS7P4	4.03	6.04e-05	0.00404	0.13	0.12	Central corneal thickness;Corneal structure;	chr15:85310499	chr15:85255369~85330334:-
BRCA	cis	rs3785309	0.519	rs7197253	ENSG00000268836.1	LA16c-OS12.2	-4.03	6.04e-05	0.00404	-0.22	-0.12	Immature fraction of reticulocytes;	chr16:226550	chr16:185748~186294:-
BRCA	cis	rs17301013	0.932	rs1793297	ENSG00000234741.6	GAS5	-4.03	6.04e-05	0.00404	-0.12	-0.12	Systemic lupus erythematosus;	chr1:174784411	chr1:173863900~173868882:-
BRCA	cis	rs854765	0.647	rs854769	ENSG00000281749.1	Y_RNA	-4.03	6.04e-05	0.00404	-0.14	-0.12	Total body bone mineral density;	chr17:18115697	chr17:18001101~18001195:-
BRCA	cis	rs6121246	0.697	rs6060912	ENSG00000230613.1	HM13-AS1	4.03	6.04e-05	0.00404	0.18	0.12	Mean corpuscular hemoglobin;	chr20:31737952	chr20:31567707~31573263:-
BRCA	cis	rs6121246	0.909	rs6089058	ENSG00000230613.1	HM13-AS1	4.03	6.04e-05	0.00404	0.18	0.12	Mean corpuscular hemoglobin;	chr20:31738535	chr20:31567707~31573263:-
BRCA	cis	rs6121246	0.821	rs6119718	ENSG00000230613.1	HM13-AS1	4.03	6.04e-05	0.00404	0.18	0.12	Mean corpuscular hemoglobin;	chr20:31743271	chr20:31567707~31573263:-
BRCA	cis	rs6121246	0.821	rs6058448	ENSG00000230613.1	HM13-AS1	4.03	6.04e-05	0.00404	0.18	0.12	Mean corpuscular hemoglobin;	chr20:31744593	chr20:31567707~31573263:-
BRCA	cis	rs6121246	0.909	rs8126355	ENSG00000230613.1	HM13-AS1	4.03	6.04e-05	0.00404	0.18	0.12	Mean corpuscular hemoglobin;	chr20:31744857	chr20:31567707~31573263:-
BRCA	cis	rs6121246	0.909	rs6060923	ENSG00000230613.1	HM13-AS1	4.03	6.04e-05	0.00404	0.18	0.12	Mean corpuscular hemoglobin;	chr20:31748852	chr20:31567707~31573263:-
BRCA	cis	rs4468007	0.869	rs7037727	ENSG00000261534.1	RP11-244O19.1	-4.03	6.04e-05	0.00404	-0.14	-0.12	Educational attainment;	chr9:121842398	chr9:121815674~121819452:-
BRCA	cis	rs4302906	0.964	rs9942965	ENSG00000187984.11	ANKRD19P	-4.03	6.04e-05	0.00404	-0.11	-0.12	Lobe attachment (rater-scored or self-reported);	chr9:92975367	chr9:92809388~92888693:+
BRCA	cis	rs1998359	0.52	rs960787	ENSG00000259087.4	RP11-356O9.2	-4.03	6.04e-05	0.00404	-0.12	-0.12	Self-reported allergy;	chr14:37696579	chr14:37556158~37567095:-
BRCA	cis	rs4561483	0.767	rs33633	ENSG00000261216.1	RP11-166B2.5	-4.03	6.04e-05	0.00404	-0.15	-0.12	Testicular germ cell tumor;	chr16:11901000	chr16:11908208~11908916:+
BRCA	cis	rs875971	0.545	rs6969224	ENSG00000273142.1	RP11-458F8.4	4.03	6.04e-05	0.00404	0.13	0.12	Aortic root size;	chr7:66370011	chr7:66902857~66906297:+
BRCA	cis	rs1865760	0.623	rs12216125	ENSG00000272462.2	U91328.19	-4.03	6.04e-05	0.00404	-0.15	-0.12	Height;	chr6:25997230	chr6:25992662~26001775:+
BRCA	cis	rs1499614	0.522	rs13247442	ENSG00000229886.1	RP5-1132H15.3	4.03	6.04e-05	0.00404	0.28	0.12	Gout;	chr7:66723871	chr7:66025126~66031544:-
BRCA	cis	rs875971	1	rs778706	ENSG00000265600.1	AC006480.1	-4.03	6.05e-05	0.00404	-0.15	-0.12	Aortic root size;	chr7:66395437	chr7:67356680~67356779:+
BRCA	cis	rs2286503	0.78	rs929464	ENSG00000226329.2	AC005682.6	4.03	6.05e-05	0.00404	0.12	0.12	Fibrinogen;	chr7:22835151	chr7:22863874~22881350:-
BRCA	cis	rs9733	0.596	rs34140753	ENSG00000231073.1	RP11-316M1.3	4.03	6.05e-05	0.00404	0.13	0.12	Tonsillectomy;	chr1:150670107	chr1:150973123~150975534:+
BRCA	cis	rs9733	0.569	rs11204691	ENSG00000231073.1	RP11-316M1.3	4.03	6.05e-05	0.00404	0.13	0.12	Tonsillectomy;	chr1:150671863	chr1:150973123~150975534:+
BRCA	cis	rs801193	0.773	rs801207	ENSG00000273142.1	RP11-458F8.4	4.03	6.05e-05	0.00404	0.11	0.12	Aortic root size;	chr7:66555603	chr7:66902857~66906297:+
BRCA	cis	rs73206853	0.563	rs9300316	ENSG00000277299.1	RP11-837J7.4	-4.03	6.05e-05	0.00404	-0.21	-0.12	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr12:110758399	chr12:109948389~109949029:+
BRCA	cis	rs875971	0.66	rs28698552	ENSG00000229180.5	GS1-124K5.11	4.03	6.05e-05	0.00404	0.11	0.12	Aortic root size;	chr7:66540031	chr7:66526088~66542624:-
BRCA	cis	rs7267979	0.808	rs84816	ENSG00000277938.1	RP5-965G21.3	4.03	6.05e-05	0.00404	0.15	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25479283	chr20:25229150~25231933:+
BRCA	cis	rs11168351	0.833	rs6580652	ENSG00000226413.2	OR8T1P	-4.03	6.05e-05	0.00404	-0.16	-0.12	Bipolar disorder and schizophrenia;	chr12:48053322	chr12:48442030~48442947:-
BRCA	cis	rs2346177	0.58	rs7565770	ENSG00000279254.1	RP11-536C12.1	-4.03	6.05e-05	0.00404	-0.14	-0.12	HDL cholesterol;	chr2:46456544	chr2:46668870~46670778:+
BRCA	cis	rs860295	0.676	rs11264374	ENSG00000232093.1	RP11-307C12.11	4.03	6.05e-05	0.00404	0.14	0.12	Body mass index;	chr1:155451721	chr1:155045191~155046118:-
BRCA	cis	rs67478160	0.643	rs2887282	ENSG00000269910.1	RP11-73M18.10	4.03	6.06e-05	0.00404	0.12	0.12	Schizophrenia;	chr14:103814397	chr14:103694516~103695050:-
BRCA	cis	rs10458771	0.588	rs7917841	ENSG00000227896.2	RP11-77P6.2	4.03	6.06e-05	0.00404	0.2	0.12	Amyotrophic lateral sclerosis (sporadic);	chr10:86490495	chr10:86521945~86525101:+
BRCA	cis	rs3764563	0.799	rs2017776	ENSG00000267594.5	CYP4F24P	4.03	6.06e-05	0.00405	0.23	0.12	Inflammatory biomarkers;	chr19:15587418	chr19:15760241~15779909:-
BRCA	cis	rs3764563	0.935	rs623700	ENSG00000267594.5	CYP4F24P	4.03	6.06e-05	0.00405	0.23	0.12	Inflammatory biomarkers;	chr19:15587733	chr19:15760241~15779909:-
BRCA	cis	rs3764563	0.935	rs622886	ENSG00000267594.5	CYP4F24P	4.03	6.06e-05	0.00405	0.23	0.12	Inflammatory biomarkers;	chr19:15587885	chr19:15760241~15779909:-
BRCA	cis	rs10129255	0.556	rs8010005	ENSG00000254174.1	IGHV1-12	4.03	6.06e-05	0.00405	0.1	0.12	Kawasaki disease;	chr14:106777987	chr14:106122420~106122709:-
BRCA	cis	rs10129255	0.556	rs6576224	ENSG00000254174.1	IGHV1-12	4.03	6.06e-05	0.00405	0.1	0.12	Kawasaki disease;	chr14:106777997	chr14:106122420~106122709:-
BRCA	cis	rs10129255	0.518	rs8010020	ENSG00000254174.1	IGHV1-12	4.03	6.06e-05	0.00405	0.1	0.12	Kawasaki disease;	chr14:106778016	chr14:106122420~106122709:-
BRCA	cis	rs1670533	0.932	rs935968	ENSG00000251639.2	RP11-20I20.1	4.03	6.06e-05	0.00405	0.19	0.12	Recombination rate (females);	chr4:1069399	chr4:1100016~1101558:-
BRCA	cis	rs4819052	1	rs13052356	ENSG00000184274.3	LINC00315	-4.03	6.06e-05	0.00405	-0.18	-0.12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45243673	chr21:45300245~45305257:-
BRCA	cis	rs6452524	0.935	rs767771	ENSG00000281327.1	LINC01338	4.03	6.06e-05	0.00405	0.14	0.12	Hypertension (SNP x SNP interaction);	chr5:83108117	chr5:82850864~82859836:-
BRCA	cis	rs8130944	1	rs4920137	ENSG00000225731.1	AP001627.1	4.03	6.06e-05	0.00405	0.15	0.12	Perceived unattractiveness to mosquitoes;	chr21:42720007	chr21:42733594~42741758:-
BRCA	cis	rs7312933	0.618	rs12366848	ENSG00000257225.1	RP11-328C8.4	-4.03	6.06e-05	0.00405	-0.15	-0.12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42288413	chr12:42459366~42466128:+
BRCA	cis	rs10129255	0.5	rs8011115	ENSG00000211976.2	IGHV3-73	-4.03	6.06e-05	0.00405	-0.09	-0.12	Kawasaki disease;	chr14:106786292	chr14:106802694~106803233:-
BRCA	cis	rs1974653	0.781	rs175164	ENSG00000236540.6	AC006547.13	-4.03	6.06e-05	0.00405	-0.14	-0.12	Schizophrenia;	chr22:20128039	chr22:20058030~20070569:-
BRCA	cis	rs10266483	0.774	rs642909	ENSG00000227986.1	TRIM60P18	-4.03	6.06e-05	0.00405	-0.14	-0.12	Response to statin therapy;	chr7:64309943	chr7:64355078~64356199:+
BRCA	cis	rs875971	0.66	rs2013222	ENSG00000273142.1	RP11-458F8.4	4.03	6.06e-05	0.00405	0.11	0.12	Aortic root size;	chr7:66570949	chr7:66902857~66906297:+
BRCA	cis	rs3892630	0.824	rs12327732	ENSG00000267475.1	CTD-2538C1.2	-4.03	6.06e-05	0.00405	-0.19	-0.12	Red blood cell traits;	chr19:32730861	chr19:32687089~32691750:-
BRCA	cis	rs2274273	1	rs6573006	ENSG00000259318.1	RP11-454L9.2	4.03	6.07e-05	0.00405	0.11	0.12	Protein biomarker;	chr14:55143714	chr14:55394940~55395233:-
BRCA	cis	rs6012564	1	rs6122763	ENSG00000227431.4	CSE1L-AS1	-4.03	6.07e-05	0.00405	-0.15	-0.12	Anger;	chr20:49181116	chr20:49040463~49046044:-
BRCA	cis	rs4713675	0.604	rs791902	ENSG00000224557.6	HLA-DPB2	4.03	6.07e-05	0.00405	0.14	0.12	Plateletcrit;	chr6:33734840	chr6:33112451~33129084:+
BRCA	cis	rs8114671	0.562	rs4911447	ENSG00000126005.14	MMP24-AS1	-4.03	6.07e-05	0.00405	-0.14	-0.12	Height;	chr20:34891642	chr20:35216462~35278131:-
BRCA	cis	rs2835345	0.563	rs73204246	ENSG00000233818.1	AP000695.4	4.03	6.07e-05	0.00405	0.13	0.12	Pulmonary function;	chr21:36452402	chr21:36445731~36532408:+
BRCA	cis	rs2835345	0.563	rs73204248	ENSG00000233818.1	AP000695.4	4.03	6.07e-05	0.00405	0.13	0.12	Pulmonary function;	chr21:36452411	chr21:36445731~36532408:+
BRCA	cis	rs853679	0.517	rs1904841	ENSG00000216901.1	AL022393.7	4.03	6.07e-05	0.00406	0.18	0.12	Depression;	chr6:28140307	chr6:28176188~28176674:+
BRCA	cis	rs2998286	0.723	rs332189	ENSG00000237128.1	RP11-351M16.3	4.03	6.08e-05	0.00406	0.16	0.12	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28628292	chr10:28433008~28495813:-
BRCA	cis	rs983392	0.649	rs7936120	ENSG00000275344.1	MIR6503	-4.03	6.08e-05	0.00406	-0.13	-0.12	Alzheimer's disease (late onset);	chr11:60233101	chr11:60209071~60209156:-
BRCA	cis	rs11098499	0.865	rs11722183	ENSG00000260091.1	RP11-33B1.4	-4.03	6.08e-05	0.00406	-0.11	-0.12	Corneal astigmatism;	chr4:119359442	chr4:119409333~119410233:+
BRCA	cis	rs7487075	0.93	rs12814298	ENSG00000274723.1	RP11-618L22.1	4.03	6.08e-05	0.00406	0.15	0.12	Itch intensity from mosquito bite;	chr12:46443841	chr12:46970504~46972155:+
BRCA	cis	rs12368653	0.545	rs2277324	ENSG00000257159.1	RP11-58A17.3	-4.03	6.08e-05	0.00406	-0.15	-0.12	Multiple sclerosis;	chr12:57619392	chr12:57967058~57968399:+
BRCA	cis	rs9818758	0.607	rs9990153	ENSG00000270441.1	RP11-694I15.7	4.03	6.08e-05	0.00406	0.23	0.12	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49254450	chr3:49140086~49160851:-
BRCA	cis	rs792448	0.717	rs1389371	ENSG00000226251.4	RP11-15I11.3	-4.03	6.08e-05	0.00406	-0.16	-0.12	White blood cell count (basophil);	chr1:212236813	chr1:212225278~212238977:-
BRCA	cis	rs35740288	0.822	rs17636864	ENSG00000259407.1	RP11-158M2.3	-4.03	6.08e-05	0.00406	-0.17	-0.12	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85691358	chr15:85744109~85750281:-
BRCA	cis	rs9309473	0.607	rs2421488	ENSG00000230002.2	ALMS1-IT1	4.03	6.08e-05	0.00406	0.15	0.12	Metabolite levels;	chr2:73363497	chr2:73456764~73459484:+
BRCA	cis	rs4374383	0.884	rs4519530	ENSG00000243389.1	AC012442.5	-4.03	6.08e-05	0.00406	-0.16	-0.12	Hepatitis C induced liver fibrosis;	chr2:112001605	chr2:112589040~112614431:+
BRCA	cis	rs9308731	0.556	rs10166773	ENSG00000230499.1	AC108463.1	-4.03	6.08e-05	0.00406	-0.14	-0.12	Chronic lymphocytic leukemia;	chr2:111179358	chr2:111195963~111206494:+
BRCA	cis	rs9308731	0.548	rs7581735	ENSG00000230499.1	AC108463.1	-4.03	6.08e-05	0.00406	-0.14	-0.12	Chronic lymphocytic leukemia;	chr2:111180137	chr2:111195963~111206494:+
BRCA	cis	rs7412746	0.566	rs2864871	ENSG00000231073.1	RP11-316M1.3	4.03	6.08e-05	0.00406	0.13	0.12	Melanoma;	chr1:150794488	chr1:150973123~150975534:+
BRCA	cis	rs11098499	0.754	rs2036857	ENSG00000260091.1	RP11-33B1.4	-4.03	6.08e-05	0.00406	-0.11	-0.12	Corneal astigmatism;	chr4:119328085	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.754	rs2036856	ENSG00000260091.1	RP11-33B1.4	-4.03	6.08e-05	0.00406	-0.11	-0.12	Corneal astigmatism;	chr4:119328133	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.754	rs4443261	ENSG00000260091.1	RP11-33B1.4	-4.03	6.08e-05	0.00406	-0.11	-0.12	Corneal astigmatism;	chr4:119328146	chr4:119409333~119410233:+
BRCA	cis	rs875971	0.895	rs3857684	ENSG00000229180.5	GS1-124K5.11	4.03	6.08e-05	0.00406	0.11	0.12	Aortic root size;	chr7:66473171	chr7:66526088~66542624:-
BRCA	cis	rs10129255	1	rs9324091	ENSG00000211967.3	IGHV3-53	-4.03	6.08e-05	0.00406	-0.09	-0.12	Kawasaki disease;	chr14:106676625	chr14:106592676~106593347:-
BRCA	cis	rs6546324	0.625	rs2861695	ENSG00000236780.4	AC078941.1	4.03	6.08e-05	0.00406	0.21	0.12	Endometriosis;	chr2:67619595	chr2:67123357~67215319:-
BRCA	cis	rs6546324	0.625	rs6730286	ENSG00000236780.4	AC078941.1	4.03	6.08e-05	0.00406	0.21	0.12	Endometriosis;	chr2:67620922	chr2:67123357~67215319:-
BRCA	cis	rs990171	0.513	rs7573566	ENSG00000234389.1	AC007278.3	4.03	6.09e-05	0.00406	0.12	0.12	Lymphocyte counts;	chr2:102498746	chr2:102438713~102440475:+
BRCA	cis	rs6671200	0.607	rs6671408	ENSG00000235501.4	RP4-639F20.1	4.03	6.09e-05	0.00406	0.21	0.12	Stearic acid (18:0) levels;	chr1:95231535	chr1:94927566~94963270:+
BRCA	cis	rs1577917	0.655	rs9444352	ENSG00000220563.1	PKMP3	4.03	6.09e-05	0.00406	0.13	0.12	Response to antipsychotic treatment;	chr6:85547817	chr6:85659892~85660606:-
BRCA	cis	rs6599077	1	rs9853406	ENSG00000223797.4	ENTPD3-AS1	4.03	6.09e-05	0.00406	0.15	0.12	Sleep-related phenotypes;	chr3:40056473	chr3:40313802~40453329:-
BRCA	cis	rs6599077	1	rs113909479	ENSG00000223797.4	ENTPD3-AS1	4.03	6.09e-05	0.00406	0.15	0.12	Sleep-related phenotypes;	chr3:40056476	chr3:40313802~40453329:-
BRCA	cis	rs6599077	1	rs9870930	ENSG00000223797.4	ENTPD3-AS1	4.03	6.09e-05	0.00406	0.15	0.12	Sleep-related phenotypes;	chr3:40056480	chr3:40313802~40453329:-
BRCA	cis	rs7267979	0.966	rs2482918	ENSG00000274414.1	RP5-965G21.4	4.03	6.09e-05	0.00406	0.15	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25431499	chr20:25239007~25245229:-
BRCA	cis	rs739496	0.579	rs7973309	ENSG00000257624.1	RP1-128M12.3	4.03	6.09e-05	0.00406	0.17	0.12	Platelet count;	chr12:111944447	chr12:112000739~112000985:-
BRCA	cis	rs12435908	1	rs2300872	ENSG00000276116.2	FUT8-AS1	-4.03	6.09e-05	0.00407	-0.21	-0.12	Ischemic stroke;	chr14:65681043	chr14:65411170~65412690:-
BRCA	cis	rs11098499	0.863	rs58452170	ENSG00000260091.1	RP11-33B1.4	-4.03	6.09e-05	0.00407	-0.11	-0.12	Corneal astigmatism;	chr4:119538519	chr4:119409333~119410233:+
BRCA	cis	rs7267979	0.966	rs2261784	ENSG00000274973.1	RP13-401N8.7	-4.03	6.09e-05	0.00407	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25281760	chr20:25845497~25845862:+
BRCA	cis	rs7267979	0.966	rs2261785	ENSG00000274973.1	RP13-401N8.7	-4.03	6.09e-05	0.00407	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25281767	chr20:25845497~25845862:+
BRCA	cis	rs131805	1	rs3091397	ENSG00000205559.3	CHKB-AS1	-4.03	6.09e-05	0.00407	-0.16	-0.12	Granulocyte percentage of myeloid white cells;	chr22:50519091	chr22:50583026~50583877:+
BRCA	cis	rs60843830	1	rs17713396	ENSG00000272342.1	RP13-539J13.1	4.03	6.09e-05	0.00407	0.16	0.12	Spherical equivalent (joint analysis main effects and education interaction);	chr2:227201	chr2:739588~740164:-
BRCA	cis	rs616597	0.725	rs2925334	ENSG00000244119.1	PDCL3P4	4.03	6.09e-05	0.00407	0.1	0.12	Ulcerative colitis;	chr3:101853978	chr3:101712472~101713191:+
BRCA	cis	rs9470794	1	rs79120026	ENSG00000204110.6	RP1-153P14.8	-4.03	6.09e-05	0.00407	-0.25	-0.12	Type 2 diabetes;	chr6:37972784	chr6:37507348~37535616:+
BRCA	cis	rs2562456	0.92	rs2650784	ENSG00000268555.1	RP11-678G14.3	-4.03	6.09e-05	0.00407	-0.15	-0.12	Pain;	chr19:21483795	chr19:21570822~21587322:-
BRCA	cis	rs2274459	1	rs10456420	ENSG00000249346.5	LINC01016	4.03	6.09e-05	0.00407	0.17	0.12	Obesity (extreme);	chr6:33786524	chr6:33867506~33896914:-
BRCA	cis	rs2274459	1	rs12195409	ENSG00000249346.5	LINC01016	4.03	6.09e-05	0.00407	0.17	0.12	Obesity (extreme);	chr6:33789705	chr6:33867506~33896914:-
BRCA	cis	rs11083475	1	rs16972767	ENSG00000267892.1	CTD-2540F13.2	4.03	6.09e-05	0.00407	0.14	0.12	Heart rate;	chr19:38662404	chr19:38738284~38739863:+
BRCA	cis	rs8023401	0.816	rs28670973	ENSG00000274654.1	CTD-3247H4.2	4.03	6.09e-05	0.00407	0.18	0.12	Spherical equivalent (joint analysis main effects and education interaction);	chr15:48522457	chr15:48528980~48529728:-
BRCA	cis	rs8031584	0.679	rs34017474	ENSG00000259845.1	HERC2P10	4.03	6.1e-05	0.00407	0.14	0.12	Huntington's disease progression;	chr15:30938408	chr15:30815271~30844153:+
BRCA	cis	rs897984	0.537	rs8045637	ENSG00000275263.1	RP11-1072A3.4	-4.03	6.1e-05	0.00407	-0.15	-0.12	Dementia with Lewy bodies;	chr16:30807341	chr16:30956872~30957199:-
BRCA	cis	rs6049003	0.622	rs4432529	ENSG00000232645.4	LINC01431	4.03	6.1e-05	0.00407	0.13	0.12	Cerebrospinal fluid biomarker levels;	chr20:23726178	chr20:23356594~23358116:-
BRCA	cis	rs11098499	0.738	rs34566984	ENSG00000260404.2	RP11-384K6.6	4.03	6.1e-05	0.00407	0.12	0.12	Corneal astigmatism;	chr4:119440115	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.954	rs9685777	ENSG00000260404.2	RP11-384K6.6	4.03	6.1e-05	0.00407	0.12	0.12	Corneal astigmatism;	chr4:119444810	chr4:118591773~118633729:+
BRCA	cis	rs728616	0.558	rs7097080	ENSG00000225484.5	NUTM2B-AS1	-4.03	6.1e-05	0.00407	-0.22	-0.12	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80406944	chr10:79663088~79826594:-
BRCA	cis	rs875971	1	rs12533997	ENSG00000265600.1	AC006480.1	-4.03	6.1e-05	0.00407	-0.14	-0.12	Aortic root size;	chr7:66500390	chr7:67356680~67356779:+
BRCA	cis	rs6968419	0.641	rs17138519	ENSG00000279086.1	RP11-667F14.1	-4.03	6.1e-05	0.00407	-0.13	-0.12	Intraocular pressure;	chr7:116266124	chr7:116209234~116211511:-
BRCA	cis	rs660899	0.857	rs7516647	ENSG00000229431.1	RP1-92O14.6	4.03	6.1e-05	0.00407	0.13	0.12	Hypertension risk in short sleep duration;	chr1:43771794	chr1:43385113~43389155:+
BRCA	cis	rs910316	0.763	rs13712	ENSG00000259138.1	RP11-950C14.7	4.03	6.1e-05	0.00407	0.13	0.12	Height;	chr14:75017109	chr14:75127153~75136930:+
BRCA	cis	rs79903896	0.737	rs230345	ENSG00000257831.1	RP11-596D21.1	-4.03	6.1e-05	0.00407	-0.28	-0.12	Night sleep phenotypes;	chr14:30659139	chr14:31248628~31302739:+
BRCA	cis	rs2832191	0.716	rs7284006	ENSG00000215533.7	LINC00189	-4.03	6.1e-05	0.00407	-0.14	-0.12	Dental caries;	chr21:29102865	chr21:29193480~29288205:+
BRCA	cis	rs7412746	0.587	rs11204722	ENSG00000231073.1	RP11-316M1.3	-4.03	6.11e-05	0.00407	-0.13	-0.12	Melanoma;	chr1:150757708	chr1:150973123~150975534:+
BRCA	cis	rs2692947	0.567	rs4907276	ENSG00000237510.6	AC008268.2	-4.03	6.11e-05	0.00407	-0.17	-0.12	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95725361	chr2:95789654~95800166:+
BRCA	cis	rs6840360	0.806	rs11932383	ENSG00000251611.1	RP11-610P16.1	4.03	6.11e-05	0.00407	0.11	0.12	Intelligence (multi-trait analysis);	chr4:151794984	chr4:151407551~151408835:-
BRCA	cis	rs9879311	0.932	rs7427473	ENSG00000240288.6	GHRLOS	4.03	6.11e-05	0.00407	0.14	0.12	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr3:10371513	chr3:10285754~10293449:+
BRCA	cis	rs748404	0.666	rs60018990	ENSG00000205771.5	CATSPER2P1	-4.03	6.11e-05	0.00407	-0.18	-0.12	Lung cancer;	chr15:43504606	chr15:43726918~43747094:-
BRCA	cis	rs6546324	0.58	rs4410279	ENSG00000236780.4	AC078941.1	4.03	6.11e-05	0.00407	0.21	0.12	Endometriosis;	chr2:67623488	chr2:67123357~67215319:-
BRCA	cis	rs875971	0.66	rs7807944	ENSG00000223473.2	GS1-124K5.3	-4.03	6.11e-05	0.00408	-0.09	-0.12	Aortic root size;	chr7:66622208	chr7:66491049~66493566:-
BRCA	cis	rs2408955	0.521	rs7301003	ENSG00000257735.1	RP11-370I10.6	4.03	6.11e-05	0.00408	0.15	0.12	Glycated hemoglobin levels;	chr12:48156444	chr12:48350945~48442411:+
BRCA	cis	rs4664293	1	rs10204535	ENSG00000224152.1	AC009506.1	-4.02	6.11e-05	0.00408	-0.13	-0.12	Monocyte percentage of white cells;	chr2:159607181	chr2:159615296~159617082:+
BRCA	cis	rs848490	0.889	rs11769259	ENSG00000214293.7	APTR	4.02	6.11e-05	0.00408	0.15	0.12	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77666013	chr7:77657660~77696265:-
BRCA	cis	rs2625529	0.652	rs9302260	ENSG00000260037.4	CTD-2524L6.3	4.02	6.11e-05	0.00408	0.16	0.12	Red blood cell count;	chr15:71882270	chr15:71818396~71823384:+
BRCA	cis	rs3096299	0.685	rs12446145	ENSG00000261118.1	RP11-104N10.1	4.02	6.11e-05	0.00408	0.13	0.12	Multiple myeloma (IgH translocation);	chr16:89476287	chr16:89492017~89504460:-
BRCA	cis	rs7246967	1	rs12980225	ENSG00000198153.8	ZNF849P	-4.02	6.11e-05	0.00408	-0.17	-0.12	Bronchopulmonary dysplasia;	chr19:22843943	chr19:22685167~22686732:+
BRCA	cis	rs4835473	0.863	rs13146607	ENSG00000249741.2	RP11-673E1.3	4.02	6.11e-05	0.00408	0.14	0.12	Immature fraction of reticulocytes;	chr4:143687283	chr4:143911514~143912053:-
BRCA	cis	rs56322409	1	rs749050	ENSG00000226688.5	ENTPD1-AS1	4.02	6.11e-05	0.00408	0.14	0.12	Blood metabolite levels;	chr10:95616358	chr10:95753206~96090238:-
BRCA	cis	rs7267979	0.966	rs4813557	ENSG00000125804.12	FAM182A	4.02	6.12e-05	0.00408	0.16	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25311909	chr20:26054655~26086917:+
BRCA	cis	rs6968419	0.674	rs17138528	ENSG00000279086.1	RP11-667F14.1	-4.02	6.12e-05	0.00408	-0.13	-0.12	Intraocular pressure;	chr7:116267235	chr7:116209234~116211511:-
BRCA	cis	rs91731	1	rs155585	ENSG00000249572.1	CTD-2203K17.1	4.02	6.12e-05	0.00408	0.24	0.12	Lung function (FVC);	chr5:33362287	chr5:33424025~33440619:-
BRCA	cis	rs801193	1	rs3800812	ENSG00000229180.5	GS1-124K5.11	4.02	6.12e-05	0.00408	0.11	0.12	Aortic root size;	chr7:66758474	chr7:66526088~66542624:-
BRCA	cis	rs801193	1	rs4279493	ENSG00000229180.5	GS1-124K5.11	4.02	6.12e-05	0.00408	0.11	0.12	Aortic root size;	chr7:66761633	chr7:66526088~66542624:-
BRCA	cis	rs8054556	1	rs3935873	ENSG00000261367.1	RP11-455F5.4	4.02	6.12e-05	0.00408	0.14	0.12	Autism spectrum disorder or schizophrenia;	chr16:30007179	chr16:30107675~30110541:+
BRCA	cis	rs7727544	0.505	rs721121	ENSG00000233006.5	AC034220.3	4.02	6.12e-05	0.00408	0.09	0.12	Blood metabolite levels;	chr5:132070740	chr5:132311285~132369916:-
BRCA	cis	rs11742741	0.869	rs12187619	ENSG00000248874.4	C5orf17	-4.02	6.12e-05	0.00408	-0.16	-0.12	Educational attainment;	chr5:24092634	chr5:23951348~24178263:+
BRCA	cis	rs2229238	0.911	rs4390168	ENSG00000272030.1	RP1-178F15.4	-4.02	6.12e-05	0.00408	-0.18	-0.12	Coronary heart disease;	chr1:154536620	chr1:153631438~153634397:-
BRCA	cis	rs6593122	0.697	rs1988715	ENSG00000235454.1	HAUS6P3	-4.02	6.12e-05	0.00409	-0.17	-0.12	Vaccine-related adverse events;	chr7:54126996	chr7:53862233~53863339:+
BRCA	cis	rs6593122	0.785	rs1960339	ENSG00000235454.1	HAUS6P3	-4.02	6.12e-05	0.00409	-0.17	-0.12	Vaccine-related adverse events;	chr7:54127002	chr7:53862233~53863339:+
BRCA	cis	rs910873	0.505	rs67260051	ENSG00000202150.1	RNU6-407P	-4.02	6.13e-05	0.00409	-0.18	-0.12	Melanoma;	chr20:34860614	chr20:35030317~35030420:-
BRCA	cis	rs11892454	0.674	rs10439496	ENSG00000217643.1	PTGES3P2	-4.02	6.13e-05	0.00409	-0.14	-0.12	Heschl's gyrus morphology;	chr2:25716230	chr2:25822469~25822950:+
BRCA	cis	rs4415084	0.716	rs6451772	ENSG00000251141.4	RP11-53O19.1	4.02	6.13e-05	0.00409	0.12	0.12	Breast cancer;	chr5:44785661	chr5:44744900~44808777:-
BRCA	cis	rs4415084	0.716	rs7710952	ENSG00000251141.4	RP11-53O19.1	4.02	6.13e-05	0.00409	0.12	0.12	Breast cancer;	chr5:44785689	chr5:44744900~44808777:-
BRCA	cis	rs4415084	0.716	rs7710978	ENSG00000251141.4	RP11-53O19.1	4.02	6.13e-05	0.00409	0.12	0.12	Breast cancer;	chr5:44785762	chr5:44744900~44808777:-
BRCA	cis	rs8040855	0.579	rs28521166	ENSG00000259762.1	RP11-158M2.4	-4.02	6.13e-05	0.00409	-0.14	-0.12	Bulimia nervosa;	chr15:85184801	chr15:85750336~85752901:-
BRCA	cis	rs1008375	1	rs10019856	ENSG00000249502.1	AC006160.5	-4.02	6.13e-05	0.00409	-0.14	-0.12	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17614119	chr4:17587467~17614571:-
BRCA	cis	rs7829975	0.582	rs6983150	ENSG00000254153.1	CTA-398F10.2	-4.02	6.13e-05	0.00409	-0.15	-0.12	Mood instability;	chr8:8934916	chr8:8456909~8461337:-
BRCA	cis	rs875971	0.545	rs1909508	ENSG00000232559.3	GS1-124K5.12	4.02	6.13e-05	0.00409	0.16	0.12	Aortic root size;	chr7:66301366	chr7:66554588~66576923:-
BRCA	cis	rs10510102	0.516	rs78586895	ENSG00000226864.1	ATE1-AS1	4.02	6.14e-05	0.00409	0.25	0.12	Breast cancer;	chr10:121977081	chr10:121928312~121951965:+
BRCA	cis	rs6546324	0.625	rs2861645	ENSG00000236780.4	AC078941.1	4.02	6.14e-05	0.00409	0.21	0.12	Endometriosis;	chr2:67573206	chr2:67123357~67215319:-
BRCA	cis	rs6121246	0.909	rs7272062	ENSG00000230613.1	HM13-AS1	4.02	6.14e-05	0.00409	0.18	0.12	Mean corpuscular hemoglobin;	chr20:31671342	chr20:31567707~31573263:-
BRCA	cis	rs2708977	0.899	rs12992413	ENSG00000237510.6	AC008268.2	4.02	6.14e-05	0.00409	0.16	0.12	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96611752	chr2:95789654~95800166:+
BRCA	cis	rs7819412	0.668	rs920047	ENSG00000255046.1	RP11-297N6.4	4.02	6.14e-05	0.00409	0.15	0.12	Triglycerides;	chr8:11229966	chr8:11797928~11802568:-
BRCA	cis	rs61160187	0.582	rs56284222	ENSG00000272308.1	RP11-231G3.1	-4.02	6.14e-05	0.00409	-0.14	-0.12	Educational attainment (years of education);Educational attainment (college completion);	chr5:61065723	chr5:60866457~60866935:-
BRCA	cis	rs2904967	0.929	rs626802	ENSG00000254614.2	AP003068.23	-4.02	6.14e-05	0.00409	-0.21	-0.12	Mean corpuscular volume;	chr11:65254141	chr11:65177606~65181834:-
BRCA	cis	rs6671200	1	rs259354	ENSG00000235501.4	RP4-639F20.1	4.02	6.14e-05	0.00409	0.26	0.12	Stearic acid (18:0) levels;	chr1:95252649	chr1:94927566~94963270:+
BRCA	cis	rs9467773	0.62	rs3800303	ENSG00000224843.5	LINC00240	-4.02	6.14e-05	0.00409	-0.13	-0.12	Intelligence (multi-trait analysis);	chr6:26597960	chr6:26956992~27023924:+
BRCA	cis	rs6840360	0.533	rs13147021	ENSG00000270265.1	RP11-731D1.4	4.02	6.14e-05	0.00409	0.14	0.12	Intelligence (multi-trait analysis);	chr4:151801536	chr4:151333775~151353224:-
BRCA	cis	rs2562456	0.958	rs2562508	ENSG00000213976.4	CTD-2561J22.2	4.02	6.14e-05	0.00409	0.15	0.12	Pain;	chr19:21543479	chr19:21382865~21387177:+
BRCA	cis	rs11098499	0.754	rs938056	ENSG00000260091.1	RP11-33B1.4	-4.02	6.14e-05	0.0041	-0.11	-0.12	Corneal astigmatism;	chr4:119316298	chr4:119409333~119410233:+
BRCA	cis	rs3805389	0.504	rs10000512	ENSG00000273257.1	RP11-177J6.1	-4.02	6.14e-05	0.0041	-0.2	-0.12	Waist-to-hip ratio adjusted for body mass index;	chr4:55602855	chr4:55387949~55388271:+
BRCA	cis	rs4650943	0.586	rs2504511	ENSG00000227740.1	RP11-318C24.2	-4.02	6.14e-05	0.0041	-0.13	-0.12	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in inactive individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr1:176315614	chr1:175904762~175920513:-
BRCA	cis	rs4650943	0.586	rs2504510	ENSG00000227740.1	RP11-318C24.2	-4.02	6.14e-05	0.0041	-0.13	-0.12	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in inactive individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr1:176317043	chr1:175904762~175920513:-
BRCA	cis	rs4650943	0.597	rs2504509	ENSG00000227740.1	RP11-318C24.2	-4.02	6.14e-05	0.0041	-0.13	-0.12	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in inactive individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr1:176317334	chr1:175904762~175920513:-
BRCA	cis	rs4650943	0.564	rs2455754	ENSG00000227740.1	RP11-318C24.2	-4.02	6.14e-05	0.0041	-0.13	-0.12	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in inactive individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr1:176317882	chr1:175904762~175920513:-
BRCA	cis	rs4650943	0.586	rs2504507	ENSG00000227740.1	RP11-318C24.2	-4.02	6.14e-05	0.0041	-0.13	-0.12	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in inactive individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr1:176318148	chr1:175904762~175920513:-
BRCA	cis	rs6565189	1	rs6565189	ENSG00000273724.1	RP11-347C12.12	4.02	6.14e-05	0.0041	0.14	0.12	Tonsillectomy;	chr16:30495944	chr16:30336400~30343336:+
BRCA	cis	rs1850744	1	rs10939507	ENSG00000163612.10	FAM86KP	-4.02	6.14e-05	0.0041	-0.33	-0.12	Economic and political preferences;	chr4:9767199	chr4:9153296~9165451:+
BRCA	cis	rs9311474	0.652	rs614288	ENSG00000243224.1	RP5-1157M23.2	-4.02	6.14e-05	0.0041	-0.13	-0.12	Electroencephalogram traits;	chr3:52186187	chr3:52239258~52241097:+
BRCA	cis	rs8180040	0.966	rs12486969	ENSG00000280667.1	Y_RNA	-4.02	6.14e-05	0.0041	-0.14	-0.12	Colorectal cancer;	chr3:47387513	chr3:47501083~47501182:+
BRCA	cis	rs7412746	0.658	rs4537557	ENSG00000231073.1	RP11-316M1.3	4.02	6.14e-05	0.0041	0.13	0.12	Melanoma;	chr1:150761960	chr1:150973123~150975534:+
BRCA	cis	rs7412746	0.658	rs2864869	ENSG00000231073.1	RP11-316M1.3	4.02	6.14e-05	0.0041	0.13	0.12	Melanoma;	chr1:150762179	chr1:150973123~150975534:+
BRCA	cis	rs17228178	0.961	rs9920109	ENSG00000270055.1	CTD-3092A11.2	-4.02	6.14e-05	0.0041	-0.15	-0.12	Facial depth;Facial morphology (factor 1, breadth of lateral portion of upper face);	chr15:31177120	chr15:30487963~30490313:+
BRCA	cis	rs1722141	0.601	rs788745	ENSG00000229628.1	AC073115.7	4.02	6.15e-05	0.0041	0.17	0.12	Sitting height ratio;	chr7:46026553	chr7:45990905~46000898:+
BRCA	cis	rs11633886	0.565	rs1402164	ENSG00000273972.1	CTD-2306A12.1	4.02	6.15e-05	0.0041	0.14	0.12	Diisocyanate-induced asthma;	chr15:45779974	chr15:45702640~45703183:+
BRCA	cis	rs7592578	0.766	rs62182885	ENSG00000272979.1	RP11-647K16.1	-4.02	6.15e-05	0.0041	-0.22	-0.12	Diastolic blood pressure;	chr2:190572298	chr2:190454092~190454521:-
BRCA	cis	rs853679	0.699	rs9468318	ENSG00000204709.4	LINC01556	4.02	6.15e-05	0.0041	0.2	0.12	Depression;	chr6:28241753	chr6:28943877~28944537:+
BRCA	cis	rs2777491	0.574	rs11858812	ENSG00000247556.5	OIP5-AS1	4.02	6.15e-05	0.0041	0.14	0.12	Ulcerative colitis;	chr15:41439352	chr15:41283990~41309737:+
BRCA	cis	rs7177699	0.557	rs11072807	ENSG00000261143.1	ADAMTS7P3	-4.02	6.15e-05	0.0041	-0.15	-0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78819175	chr15:77976042~77993057:+
BRCA	cis	rs6545883	0.894	rs7572603	ENSG00000273302.1	RP11-493E12.2	-4.02	6.15e-05	0.0041	-0.11	-0.12	Tuberculosis;	chr2:61325010	chr2:61199979~61200769:+
BRCA	cis	rs11098499	0.954	rs17006190	ENSG00000260404.2	RP11-384K6.6	4.02	6.15e-05	0.0041	0.12	0.12	Corneal astigmatism;	chr4:119497683	chr4:118591773~118633729:+
BRCA	cis	rs2962370	0.842	rs2956564	ENSG00000215196.4	AC091878.1	4.02	6.15e-05	0.0041	0.15	0.12	Bipolar disorder with mood-incongruent psychosis;	chr5:17213210	chr5:17130028~17217047:-
BRCA	cis	rs12050794	0.671	rs2052713	ENSG00000260037.4	CTD-2524L6.3	4.02	6.15e-05	0.0041	0.16	0.12	Metabolite levels (HVA/MHPG ratio);	chr15:72228051	chr15:71818396~71823384:+
BRCA	cis	rs8048589	0.577	rs8055516	ENSG00000175604.2	RP11-276H1.3	-4.02	6.15e-05	0.0041	-0.18	-0.12	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);	chr16:12086341	chr16:12086746~12090302:-
BRCA	cis	rs9733	0.519	rs11204717	ENSG00000231073.1	RP11-316M1.3	4.02	6.15e-05	0.0041	0.13	0.12	Tonsillectomy;	chr1:150736653	chr1:150973123~150975534:+
BRCA	cis	rs11096990	0.634	rs4975002	ENSG00000249685.1	RP11-360F5.3	-4.02	6.16e-05	0.0041	-0.15	-0.12	Cognitive function;	chr4:39286733	chr4:39133913~39135608:+
BRCA	cis	rs7131987	0.676	rs10843407	ENSG00000257176.2	RP11-996F15.2	4.02	6.16e-05	0.0041	0.15	0.12	QT interval;	chr12:29397311	chr12:29280418~29317848:-
BRCA	cis	rs7267979	0.565	rs3752273	ENSG00000125804.12	FAM182A	4.02	6.16e-05	0.0041	0.16	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25614147	chr20:26054655~26086917:+
BRCA	cis	rs9425766	0.679	rs6670617	ENSG00000200674.1	RN7SKP160	4.02	6.16e-05	0.00411	0.16	0.12	Life satisfaction;	chr1:174277574	chr1:173791548~173791887:+
BRCA	cis	rs9733	0.526	rs6587542	ENSG00000231073.1	RP11-316M1.3	4.02	6.16e-05	0.00411	0.13	0.12	Tonsillectomy;	chr1:150935225	chr1:150973123~150975534:+
BRCA	cis	rs8192917	0.832	rs10873219	ENSG00000258744.1	RP11-80A15.1	-4.02	6.16e-05	0.00411	-0.17	-0.12	Vitiligo;	chr14:24632500	chr14:24501594~24508688:+
BRCA	cis	rs2731006	0.591	rs12227600	ENSG00000257114.2	RP11-25I15.3	4.02	6.16e-05	0.00411	0.21	0.12	Panic disorder;	chr12:42812674	chr12:42692216~42717119:+
BRCA	cis	rs7561149	0.934	rs13006510	ENSG00000270574.1	RP11-171I2.2	-4.02	6.16e-05	0.00411	-0.16	-0.12	QT interval;	chr2:178818151	chr2:178578790~178580906:+
BRCA	cis	rs6600671	1	rs7532615	ENSG00000275131.1	CH17-472G23.4	4.02	6.16e-05	0.00411	0.11	0.12	Hip geometry;	chr1:121430980	chr1:120489625~120579190:-
BRCA	cis	rs739496	0.527	rs16941703	ENSG00000234608.6	MAPKAPK5-AS1	4.02	6.16e-05	0.00411	0.15	0.12	Platelet count;	chr12:111880930	chr12:111839764~111842902:-
BRCA	cis	rs739496	0.527	rs61440627	ENSG00000234608.6	MAPKAPK5-AS1	4.02	6.16e-05	0.00411	0.15	0.12	Platelet count;	chr12:111881193	chr12:111839764~111842902:-
BRCA	cis	rs6940638	0.615	rs9393801	ENSG00000124549.13	BTN2A3P	-4.02	6.16e-05	0.00411	-0.13	-0.12	Intelligence (multi-trait analysis);	chr6:27274902	chr6:26421391~26432383:+
BRCA	cis	rs1009077	0.68	rs11724055	ENSG00000245958.5	RP11-33B1.1	4.02	6.16e-05	0.00411	0.16	0.12	Endometriosis;	chr4:119548880	chr4:119454791~119552025:+
BRCA	cis	rs6840360	0.653	rs13136369	ENSG00000278978.1	RP11-164P12.5	4.02	6.16e-05	0.00411	0.14	0.12	Intelligence (multi-trait analysis);	chr4:151810131	chr4:151669786~151670503:+
BRCA	cis	rs9879311	0.966	rs6442165	ENSG00000240288.6	GHRLOS	4.02	6.16e-05	0.00411	0.14	0.12	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr3:10373424	chr3:10285754~10293449:+
BRCA	cis	rs9307551	0.6	rs11098777	ENSG00000250334.4	LINC00989	-4.02	6.16e-05	0.00411	-0.15	-0.12	Refractive error;	chr4:79617698	chr4:79492416~79576460:+
BRCA	cis	rs8113308	0.81	rs8100541	ENSG00000269483.1	AC006272.1	4.02	6.17e-05	0.00411	0.22	0.12	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51946442	chr19:51839924~51843324:-
BRCA	cis	rs13401620	0.871	rs10177641	ENSG00000229326.3	AC069154.4	-4.02	6.17e-05	0.00411	-0.16	-0.12	Breast size;	chr2:119836455	chr2:119698623~119700151:+
BRCA	cis	rs12049351	0.774	rs11805194	ENSG00000229367.1	HMGN2P19	4.02	6.17e-05	0.00411	0.17	0.12	Circulating myeloperoxidase levels (plasma);	chr1:229495987	chr1:229570532~229570796:+
BRCA	cis	rs6430585	0.697	rs7607174	ENSG00000231890.6	DARS-AS1	-4.02	6.17e-05	0.00411	-0.2	-0.12	Corneal structure;	chr2:135756100	chr2:135985176~136022593:+
BRCA	cis	rs6430585	0.697	rs115944351	ENSG00000231890.6	DARS-AS1	-4.02	6.17e-05	0.00411	-0.2	-0.12	Corneal structure;	chr2:135757888	chr2:135985176~136022593:+
BRCA	cis	rs875971	0.545	rs2279757	ENSG00000273142.1	RP11-458F8.4	4.02	6.17e-05	0.00411	0.12	0.12	Aortic root size;	chr7:66363676	chr7:66902857~66906297:+
BRCA	cis	rs875971	0.545	rs11766183	ENSG00000273142.1	RP11-458F8.4	4.02	6.17e-05	0.00411	0.12	0.12	Aortic root size;	chr7:66374173	chr7:66902857~66906297:+
BRCA	cis	rs875971	0.545	rs1065265	ENSG00000273142.1	RP11-458F8.4	4.02	6.17e-05	0.00411	0.12	0.12	Aortic root size;	chr7:66376216	chr7:66902857~66906297:+
BRCA	cis	rs7917772	0.636	rs7079231	ENSG00000236937.2	PTGES3P4	-4.02	6.17e-05	0.00411	-0.17	-0.12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;	chr10:102767584	chr10:102845595~102845950:+
BRCA	cis	rs700651	0.675	rs1371665	ENSG00000231621.1	AC013264.2	-4.02	6.17e-05	0.00411	-0.12	-0.12	Intracranial aneurysm;	chr2:198077844	chr2:197197991~197199273:+
BRCA	cis	rs9470794	1	rs57591988	ENSG00000204110.6	RP1-153P14.8	-4.02	6.17e-05	0.00411	-0.22	-0.12	Type 2 diabetes;	chr6:37975516	chr6:37507348~37535616:+
BRCA	cis	rs957448	0.607	rs12680842	ENSG00000254315.1	RP11-267M23.3	4.02	6.17e-05	0.00411	0.15	0.12	Nonsyndromic cleft lip with cleft palate;	chr8:94570378	chr8:94533628~94534391:+
BRCA	cis	rs9788721	0.64	rs1394371	ENSG00000261762.1	RP11-650L12.2	-4.02	6.17e-05	0.00411	-0.16	-0.12	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78432127	chr15:78589123~78591276:-
BRCA	cis	rs4664293	0.647	rs10192408	ENSG00000224152.1	AC009506.1	-4.02	6.17e-05	0.00411	-0.13	-0.12	Monocyte percentage of white cells;	chr2:159568083	chr2:159615296~159617082:+
BRCA	cis	rs11686241	0.935	rs284537	ENSG00000241520.1	AC098820.4	-4.02	6.17e-05	0.00411	-0.18	-0.12	Cancer;	chr2:216508977	chr2:216483032~216487196:-
BRCA	cis	rs875971	0.66	rs10215132	ENSG00000232546.1	RP11-458F8.1	4.02	6.17e-05	0.00411	0.1	0.12	Aortic root size;	chr7:66589419	chr7:66848496~66858136:+
BRCA	cis	rs6723108	0.608	rs606076	ENSG00000224043.6	CCNT2-AS1	-4.02	6.17e-05	0.00411	-0.17	-0.12	Type 2 diabetes;	chr2:134536511	chr2:134735464~134918710:-
BRCA	cis	rs4819052	1	rs4819052	ENSG00000184274.3	LINC00315	-4.02	6.17e-05	0.00411	-0.18	-0.12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45279862	chr21:45300245~45305257:-
BRCA	cis	rs7412746	0.658	rs2275235	ENSG00000231073.1	RP11-316M1.3	4.02	6.17e-05	0.00411	0.13	0.12	Melanoma;	chr1:150757803	chr1:150973123~150975534:+
BRCA	cis	rs4713118	0.516	rs7739216	ENSG00000216901.1	AL022393.7	4.02	6.17e-05	0.00411	0.18	0.12	Parkinson's disease;	chr6:28112168	chr6:28176188~28176674:+
BRCA	cis	rs853679	0.517	rs35512245	ENSG00000216901.1	AL022393.7	4.02	6.17e-05	0.00411	0.18	0.12	Depression;	chr6:28112175	chr6:28176188~28176674:+
BRCA	cis	rs7781557	1	rs2041094	ENSG00000239969.4	RP11-163E9.2	-4.02	6.18e-05	0.00412	-0.2	-0.12	Colorectal adenoma (advanced);	chr7:102854987	chr7:102364162~102380633:+
BRCA	cis	rs72634501	0.716	rs4660165	ENSG00000182109.6	RP11-69E11.4	-4.02	6.18e-05	0.00412	-0.17	-0.12	HDL cholesterol;	chr1:39112860	chr1:39522280~39546187:-
BRCA	cis	rs11992162	0.967	rs10088415	ENSG00000227888.4	FAM66A	-4.02	6.18e-05	0.00412	-0.15	-0.12	Monocyte count;	chr8:11973316	chr8:12362019~12388296:+
BRCA	cis	rs4499344	0.73	rs417823	ENSG00000267475.1	CTD-2538C1.2	4.02	6.18e-05	0.00412	0.15	0.12	Mean platelet volume;	chr19:32613655	chr19:32687089~32691750:-
BRCA	cis	rs9527	0.59	rs2148198	ENSG00000213061.2	PFN1P11	-4.02	6.18e-05	0.00412	-0.17	-0.12	Arsenic metabolism;	chr10:103155553	chr10:102838011~102845473:-
BRCA	cis	rs7267979	0.528	rs2387976	ENSG00000277938.1	RP5-965G21.3	-4.02	6.18e-05	0.00412	-0.15	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25618924	chr20:25229150~25231933:+
BRCA	cis	rs11098499	0.909	rs73842633	ENSG00000225892.3	RP11-384K6.2	4.02	6.18e-05	0.00412	0.13	0.12	Corneal astigmatism;	chr4:119454309	chr4:118632274~118634759:+
BRCA	cis	rs8098244	0.683	rs4488534	ENSG00000265752.2	RP11-403A21.1	4.02	6.18e-05	0.00412	0.14	0.12	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23852486	chr18:23957754~23982556:-
BRCA	cis	rs28530618	0.603	rs4594522	ENSG00000198547.7	C20orf203	-4.02	6.18e-05	0.00412	-0.14	-0.12	Birth weight;	chr20:32667182	chr20:32631652~32673941:-
BRCA	cis	rs853679	0.517	rs7755442	ENSG00000261839.1	RP1-265C24.8	4.02	6.18e-05	0.00412	0.17	0.12	Depression;	chr6:28071237	chr6:28136849~28139678:+
BRCA	cis	rs853679	0.517	rs55747925	ENSG00000261839.1	RP1-265C24.8	4.02	6.18e-05	0.00412	0.17	0.12	Depression;	chr6:28076559	chr6:28136849~28139678:+
BRCA	cis	rs853679	0.517	rs34716816	ENSG00000261839.1	RP1-265C24.8	4.02	6.18e-05	0.00412	0.17	0.12	Depression;	chr6:28078391	chr6:28136849~28139678:+
BRCA	cis	rs853679	0.517	rs9380049	ENSG00000261839.1	RP1-265C24.8	4.02	6.18e-05	0.00412	0.17	0.12	Depression;	chr6:28080757	chr6:28136849~28139678:+
BRCA	cis	rs853679	0.517	rs9380050	ENSG00000261839.1	RP1-265C24.8	4.02	6.18e-05	0.00412	0.17	0.12	Depression;	chr6:28080760	chr6:28136849~28139678:+
BRCA	cis	rs8180040	0.653	rs6808742	ENSG00000276925.1	RP11-708J19.3	-4.02	6.19e-05	0.00412	-0.14	-0.12	Colorectal cancer;	chr3:47010022	chr3:47469777~47469987:+
BRCA	cis	rs9423406	0.752	rs4881421	ENSG00000224034.1	RP11-445P17.8	-4.02	6.19e-05	0.00412	-0.26	-0.12	Intelligence;	chr10:5265770	chr10:5266033~5271236:-
BRCA	cis	rs2599510	0.811	rs176413	ENSG00000276517.1	AL133243.2	4.02	6.19e-05	0.00412	0.15	0.12	Interleukin-18 levels;	chr2:32421779	chr2:32526504~32529507:+
BRCA	cis	rs2229238	0.911	rs61559765	ENSG00000272030.1	RP1-178F15.4	-4.02	6.19e-05	0.00412	-0.18	-0.12	Coronary heart disease;	chr1:154545873	chr1:153631438~153634397:-
BRCA	cis	rs17684571	0.751	rs6918949	ENSG00000231441.1	RP11-472M19.2	-4.02	6.19e-05	0.00412	-0.19	-0.12	Schizophrenia;	chr6:56845183	chr6:56844002~56864078:+
BRCA	cis	rs17270561	0.609	rs2154218	ENSG00000272462.2	U91328.19	-4.02	6.19e-05	0.00412	-0.15	-0.12	Iron status biomarkers;	chr6:25776062	chr6:25992662~26001775:+
BRCA	cis	rs2562456	0.917	rs9304987	ENSG00000213976.4	CTD-2561J22.2	4.02	6.19e-05	0.00412	0.14	0.12	Pain;	chr19:21499472	chr19:21382865~21387177:+
BRCA	cis	rs2115630	0.905	rs6496401	ENSG00000275120.1	RP11-182J1.17	-4.02	6.19e-05	0.00412	-0.14	-0.12	P wave terminal force;	chr15:84754562	chr15:84599434~84606463:-
BRCA	cis	rs62025270	0.688	rs7182210	ENSG00000259762.1	RP11-158M2.4	-4.02	6.19e-05	0.00412	-0.18	-0.12	Idiopathic pulmonary fibrosis;	chr15:85722551	chr15:85750336~85752901:-
BRCA	cis	rs7735319	0.51	rs6450946	ENSG00000249572.1	CTD-2203K17.1	4.02	6.19e-05	0.00412	0.16	0.12	Systolic blood pressure;	chr5:33119942	chr5:33424025~33440619:-
BRCA	cis	rs801193	0.935	rs2659899	ENSG00000229180.5	GS1-124K5.11	4.02	6.19e-05	0.00412	0.11	0.12	Aortic root size;	chr7:66721734	chr7:66526088~66542624:-
BRCA	cis	rs6049003	0.622	rs6138046	ENSG00000232645.4	LINC01431	-4.02	6.19e-05	0.00413	-0.13	-0.12	Cerebrospinal fluid biomarker levels;	chr20:23723751	chr20:23356594~23358116:-
BRCA	cis	rs983392	0.709	rs7928895	ENSG00000275344.1	MIR6503	-4.02	6.19e-05	0.00413	-0.13	-0.12	Alzheimer's disease (late onset);	chr11:60207692	chr11:60209071~60209156:-
BRCA	cis	rs3764563	0.932	rs617436	ENSG00000267594.5	CYP4F24P	4.02	6.2e-05	0.00413	0.23	0.12	Inflammatory biomarkers;	chr19:15582340	chr19:15760241~15779909:-
BRCA	cis	rs2732480	1	rs2732480	ENSG00000257763.1	OR5BK1P	-4.02	6.2e-05	0.00413	-0.12	-0.12	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48342520	chr12:48355792~48356614:-
BRCA	cis	rs4073582	0.595	rs801731	ENSG00000255320.1	RP11-755F10.1	-4.02	6.2e-05	0.00413	-0.15	-0.12	Gout;	chr11:66170975	chr11:66244840~66246239:-
BRCA	cis	rs10463316	0.817	rs11167545	ENSG00000260581.1	CTB-113P19.4	4.02	6.2e-05	0.00413	0.14	0.12	Metabolite levels (Pyroglutamine);	chr5:151398515	chr5:151652275~151655449:+
BRCA	cis	rs2039553	0.52	rs2802640	ENSG00000227354.5	RBM26-AS1	4.02	6.2e-05	0.00413	0.14	0.12	Pancreatic cancer;	chr13:79748735	chr13:79406309~79424328:+
BRCA	cis	rs62064224	0.589	rs9910731	ENSG00000279781.1	RP11-466A19.7	4.02	6.2e-05	0.00413	0.15	0.12	Schizophrenia;	chr17:32457016	chr17:32518322~32518934:-
BRCA	cis	rs7727544	0.625	rs4705916	ENSG00000233006.5	AC034220.3	4.02	6.2e-05	0.00413	0.1	0.12	Blood metabolite levels;	chr5:132071800	chr5:132311285~132369916:-
BRCA	cis	rs8180040	0.726	rs4234465	ENSG00000280667.1	Y_RNA	4.02	6.2e-05	0.00413	0.14	0.12	Colorectal cancer;	chr3:46985395	chr3:47501083~47501182:+
BRCA	cis	rs4478858	0.709	rs937786	ENSG00000223907.1	LINC01226	4.02	6.2e-05	0.00413	0.15	0.12	Alcohol dependence;	chr1:31385022	chr1:31518435~31524245:+
BRCA	cis	rs6964587	1	rs17164275	ENSG00000188693.7	CYP51A1-AS1	-4.02	6.2e-05	0.00413	-0.13	-0.12	Breast cancer;	chr7:91961094	chr7:92134604~92180725:+
BRCA	cis	rs2562456	0.793	rs2650819	ENSG00000213976.4	CTD-2561J22.2	4.02	6.2e-05	0.00413	0.15	0.12	Pain;	chr19:21456071	chr19:21382865~21387177:+
BRCA	cis	rs2835872	0.727	rs2835831	ENSG00000228677.1	TTC3-AS1	-4.02	6.2e-05	0.00413	-0.16	-0.12	Electroencephalographic traits in alcoholism;	chr21:37614931	chr21:37187666~37193926:-
BRCA	cis	rs11098499	0.78	rs10013652	ENSG00000260404.2	RP11-384K6.6	4.02	6.2e-05	0.00413	0.11	0.12	Corneal astigmatism;	chr4:119371101	chr4:118591773~118633729:+
BRCA	cis	rs6496044	0.568	rs6496040	ENSG00000202081.1	RNU6-1280P	4.02	6.2e-05	0.00413	0.14	0.12	Interstitial lung disease;	chr15:85520898	chr15:85651522~85651628:-
BRCA	cis	rs11711311	1	rs9879760	ENSG00000241529.3	RN7SL767P	-4.02	6.21e-05	0.00413	-0.15	-0.12	IgG glycosylation;	chr3:113739101	chr3:113632704~113632998:+
BRCA	cis	rs11711311	1	rs34475696	ENSG00000241529.3	RN7SL767P	-4.02	6.21e-05	0.00413	-0.15	-0.12	IgG glycosylation;	chr3:113739446	chr3:113632704~113632998:+
BRCA	cis	rs2243480	1	rs2465120	ENSG00000237026.1	RP11-328P23.2	4.02	6.21e-05	0.00413	0.23	0.12	Diabetic kidney disease;	chr7:66155987	chr7:65235790~65236723:-
BRCA	cis	rs2243480	0.908	rs2460431	ENSG00000237026.1	RP11-328P23.2	-4.02	6.21e-05	0.00413	-0.23	-0.12	Diabetic kidney disease;	chr7:66157859	chr7:65235790~65236723:-
BRCA	cis	rs2243480	1	rs4718309	ENSG00000237026.1	RP11-328P23.2	-4.02	6.21e-05	0.00413	-0.23	-0.12	Diabetic kidney disease;	chr7:66162777	chr7:65235790~65236723:-
BRCA	cis	rs2243480	1	rs6460274	ENSG00000237026.1	RP11-328P23.2	-4.02	6.21e-05	0.00413	-0.23	-0.12	Diabetic kidney disease;	chr7:66163497	chr7:65235790~65236723:-
BRCA	cis	rs2243480	1	rs7787230	ENSG00000237026.1	RP11-328P23.2	-4.02	6.21e-05	0.00413	-0.23	-0.12	Diabetic kidney disease;	chr7:66164112	chr7:65235790~65236723:-
BRCA	cis	rs860295	0.557	rs11264372	ENSG00000225855.5	RUSC1-AS1	4.02	6.21e-05	0.00413	0.11	0.12	Body mass index;	chr1:155443139	chr1:155316863~155324176:-
BRCA	cis	rs56322409	0.897	rs1891535	ENSG00000226688.5	ENTPD1-AS1	4.02	6.21e-05	0.00413	0.15	0.12	Blood metabolite levels;	chr10:95745521	chr10:95753206~96090238:-
BRCA	cis	rs4478858	0.735	rs6670067	ENSG00000223907.1	LINC01226	-4.02	6.21e-05	0.00413	-0.15	-0.12	Alcohol dependence;	chr1:31370100	chr1:31518435~31524245:+
BRCA	cis	rs1371614	0.655	rs7579579	ENSG00000229122.1	AGBL5-IT1	-4.02	6.21e-05	0.00413	-0.13	-0.12	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26928974	chr2:27061038~27061815:+
BRCA	cis	rs2518049	0.654	rs7070862	ENSG00000224034.1	RP11-445P17.8	-4.02	6.21e-05	0.00413	-0.24	-0.12	Metabolic traits;	chr10:5197995	chr10:5266033~5271236:-
BRCA	cis	rs9470794	0.831	rs116466698	ENSG00000204110.6	RP1-153P14.8	-4.02	6.21e-05	0.00414	-0.26	-0.12	Type 2 diabetes;	chr6:37828761	chr6:37507348~37535616:+
BRCA	cis	rs9470794	0.915	rs11759721	ENSG00000204110.6	RP1-153P14.8	-4.02	6.21e-05	0.00414	-0.26	-0.12	Type 2 diabetes;	chr6:37831458	chr6:37507348~37535616:+
BRCA	cis	rs875971	0.638	rs3898855	ENSG00000229180.5	GS1-124K5.11	-4.02	6.21e-05	0.00414	-0.11	-0.12	Aortic root size;	chr7:66571411	chr7:66526088~66542624:-
BRCA	cis	rs875971	0.638	rs10278816	ENSG00000229180.5	GS1-124K5.11	-4.02	6.21e-05	0.00414	-0.11	-0.12	Aortic root size;	chr7:66572000	chr7:66526088~66542624:-
BRCA	cis	rs875971	0.66	rs10281080	ENSG00000229180.5	GS1-124K5.11	-4.02	6.21e-05	0.00414	-0.11	-0.12	Aortic root size;	chr7:66577454	chr7:66526088~66542624:-
BRCA	cis	rs875971	0.66	rs10950044	ENSG00000229180.5	GS1-124K5.11	-4.02	6.21e-05	0.00414	-0.11	-0.12	Aortic root size;	chr7:66577989	chr7:66526088~66542624:-
BRCA	cis	rs8114671	0.527	rs6060068	ENSG00000279253.1	RP4-614O4.13	-4.02	6.21e-05	0.00414	-0.14	-0.12	Height;	chr20:34828017	chr20:35262727~35264187:-
BRCA	cis	rs9308731	0.591	rs13398360	ENSG00000230499.1	AC108463.1	-4.02	6.21e-05	0.00414	-0.14	-0.12	Chronic lymphocytic leukemia;	chr2:111180363	chr2:111195963~111206494:+
BRCA	cis	rs4415084	1	rs6890556	ENSG00000248779.1	RP11-53O19.2	4.02	6.21e-05	0.00414	0.12	0.12	Breast cancer;	chr5:44648564	chr5:44752949~44765744:+
BRCA	cis	rs8180040	0.593	rs10433549	ENSG00000271161.1	BOLA2P2	-4.02	6.22e-05	0.00414	-0.13	-0.12	Colorectal cancer;	chr3:46989943	chr3:47499841~47500407:+
BRCA	cis	rs2518049	1	rs2518049	ENSG00000224034.1	RP11-445P17.8	-4.02	6.22e-05	0.00414	-0.22	-0.12	Metabolic traits;	chr10:5095844	chr10:5266033~5271236:-
BRCA	cis	rs13434995	0.513	rs55885973	ENSG00000239040.1	Y_RNA	4.02	6.22e-05	0.00414	0.15	0.12	Adiponectin levels;	chr4:55480054	chr4:55412636~55412738:+
BRCA	cis	rs73198271	0.96	rs17154702	ENSG00000253893.2	FAM85B	4.02	6.22e-05	0.00414	0.19	0.12	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8752370	chr8:8167819~8226614:-
BRCA	cis	rs935334	1	rs2121075	ENSG00000258454.1	RP11-361H10.3	4.02	6.22e-05	0.00414	0.2	0.12	Blood pressure;	chr14:76209197	chr14:76235817~76263474:+
BRCA	cis	rs4664293	0.667	rs2042782	ENSG00000226266.5	AC009961.3	4.02	6.22e-05	0.00414	0.15	0.12	Monocyte percentage of white cells;	chr2:159789781	chr2:159670708~159712435:-
BRCA	cis	rs875971	1	rs3981131	ENSG00000236529.1	RP13-254B10.1	4.02	6.22e-05	0.00414	0.13	0.12	Aortic root size;	chr7:66486690	chr7:65840212~65840596:+
BRCA	cis	rs4478858	0.602	rs6425723	ENSG00000260386.4	LINC01225	-4.02	6.22e-05	0.00414	-0.15	-0.12	Alcohol dependence;	chr1:31242357	chr1:31500085~31540885:+
BRCA	cis	rs757081	0.658	rs214101	ENSG00000272034.1	SNORD14A	-4.02	6.22e-05	0.00414	-0.13	-0.12	Systolic blood pressure;	chr11:17267807	chr11:17074654~17074744:-
BRCA	cis	rs8040855	0.575	rs12912860	ENSG00000229212.6	RP11-561C5.4	-4.02	6.22e-05	0.00414	-0.17	-0.12	Bulimia nervosa;	chr15:85030267	chr15:85205440~85234795:-
BRCA	cis	rs6696239	0.869	rs12129704	ENSG00000215812.5	ZNF847P	4.02	6.22e-05	0.00414	0.18	0.12	Height;	chr1:227635447	chr1:227696892~227706699:-
BRCA	cis	rs73222236	0.825	rs7644471	ENSG00000239213.4	NCK1-AS1	4.02	6.22e-05	0.00414	0.14	0.12	Coronary artery disease;	chr3:136565719	chr3:136841726~136862054:-
BRCA	cis	rs1007738	0.58	rs2279439	ENSG00000200376.1	RNU5E-10P	-4.02	6.22e-05	0.00414	-0.16	-0.12	Bone mineral density (hip);	chr11:47175431	chr11:47576471~47576588:-
BRCA	cis	rs748404	0.666	rs12913977	ENSG00000205771.5	CATSPER2P1	-4.02	6.22e-05	0.00414	-0.18	-0.12	Lung cancer;	chr15:43438913	chr15:43726918~43747094:-
BRCA	cis	rs748404	0.666	rs12914122	ENSG00000205771.5	CATSPER2P1	-4.02	6.22e-05	0.00414	-0.18	-0.12	Lung cancer;	chr15:43438956	chr15:43726918~43747094:-
BRCA	cis	rs748404	0.666	rs34697113	ENSG00000205771.5	CATSPER2P1	-4.02	6.22e-05	0.00414	-0.18	-0.12	Lung cancer;	chr15:43442041	chr15:43726918~43747094:-
BRCA	cis	rs11711311	1	rs2603793	ENSG00000241529.3	RN7SL767P	-4.02	6.23e-05	0.00414	-0.14	-0.12	IgG glycosylation;	chr3:113777571	chr3:113632704~113632998:+
BRCA	cis	rs11711311	1	rs2305545	ENSG00000241529.3	RN7SL767P	-4.02	6.23e-05	0.00414	-0.14	-0.12	IgG glycosylation;	chr3:113780886	chr3:113632704~113632998:+
BRCA	cis	rs875971	0.79	rs10257911	ENSG00000273024.4	INTS4P2	4.02	6.23e-05	0.00415	0.14	0.12	Aortic root size;	chr7:66278783	chr7:65647864~65715661:+
BRCA	cis	rs1914816	0.878	rs2456078	ENSG00000196274.5	Metazoa_SRP	4.02	6.23e-05	0.00415	0.16	0.12	Response to tocilizumab in rheumatoid arthritis;	chr15:76266529	chr15:76230048~76230390:-
BRCA	cis	rs4073416	0.708	rs7146742	ENSG00000276116.2	FUT8-AS1	4.02	6.23e-05	0.00415	0.13	0.12	N-glycan levels;	chr14:65566216	chr14:65411170~65412690:-
BRCA	cis	rs7332672	0.962	rs2182885	ENSG00000228889.5	UBAC2-AS1	-4.02	6.23e-05	0.00415	-0.16	-0.12	Eosinophil counts;	chr13:99202870	chr13:99196377~99200710:-
BRCA	cis	rs10411161	0.702	rs7250138	ENSG00000269483.1	AC006272.1	4.02	6.23e-05	0.00415	0.2	0.12	Breast cancer;	chr19:51881979	chr19:51839924~51843324:-
BRCA	cis	rs11096990	0.593	rs7662880	ENSG00000249685.1	RP11-360F5.3	-4.02	6.23e-05	0.00415	-0.15	-0.12	Cognitive function;	chr4:39283604	chr4:39133913~39135608:+
BRCA	cis	rs853679	1	rs9986596	ENSG00000204709.4	LINC01556	4.02	6.23e-05	0.00415	0.22	0.12	Depression;	chr6:28251883	chr6:28943877~28944537:+
BRCA	cis	rs4835473	0.932	rs1839448	ENSG00000249741.2	RP11-673E1.3	-4.02	6.23e-05	0.00415	-0.13	-0.12	Immature fraction of reticulocytes;	chr4:143752113	chr4:143911514~143912053:-
BRCA	cis	rs4835473	0.932	rs10021860	ENSG00000249741.2	RP11-673E1.3	-4.02	6.23e-05	0.00415	-0.13	-0.12	Immature fraction of reticulocytes;	chr4:143754593	chr4:143911514~143912053:-
BRCA	cis	rs6750047	0.719	rs4670232	ENSG00000235848.3	RMDN2-AS1	-4.02	6.24e-05	0.00415	-0.16	-0.12	Cutaneous malignant melanoma;Melanoma;	chr2:38044890	chr2:37949911~38067041:-
BRCA	cis	rs3771180	0.505	rs2160203	ENSG00000234389.1	AC007278.3	4.02	6.24e-05	0.00415	0.13	0.12	Asthma;	chr2:102344364	chr2:102438713~102440475:+
BRCA	cis	rs1124769	0.57	rs1903588	ENSG00000273674.3	CTD-2378E12.1	-4.02	6.24e-05	0.00415	-0.15	-0.12	Cognitive performance;	chr15:50851849	chr15:50839875~50908599:-
BRCA	cis	rs853679	0.824	rs34712084	ENSG00000216901.1	AL022393.7	4.02	6.24e-05	0.00415	0.25	0.12	Depression;	chr6:28076050	chr6:28176188~28176674:+
BRCA	cis	rs853679	0.824	rs1321505	ENSG00000216901.1	AL022393.7	4.02	6.24e-05	0.00415	0.25	0.12	Depression;	chr6:28085045	chr6:28176188~28176674:+
BRCA	cis	rs2058059	0.636	rs2960948	ENSG00000205578.5	POM121B	-4.02	6.24e-05	0.00415	-0.2	-0.12	Subcutaneous adipose tissue;	chr7:72685439	chr7:73293497~73301161:+
BRCA	cis	rs801193	1	rs7788576	ENSG00000272831.1	RP11-792A8.4	-4.02	6.24e-05	0.00415	-0.11	-0.12	Aortic root size;	chr7:66683315	chr7:66739829~66740385:-
BRCA	cis	rs6964587	1	rs2282975	ENSG00000188693.7	CYP51A1-AS1	-4.02	6.24e-05	0.00415	-0.13	-0.12	Breast cancer;	chr7:92132324	chr7:92134604~92180725:+
BRCA	cis	rs8114671	0.562	rs3818273	ENSG00000126005.14	MMP24-AS1	-4.02	6.24e-05	0.00415	-0.14	-0.12	Height;	chr20:34921472	chr20:35216462~35278131:-
BRCA	cis	rs10895275	0.809	rs7120067	ENSG00000277459.1	RP11-732A21.3	-4.02	6.24e-05	0.00415	-0.13	-0.12	Migraine;	chr11:102194103	chr11:102109827~102110457:-
BRCA	cis	rs17695224	0.565	rs28800315	ENSG00000269483.1	AC006272.1	4.02	6.24e-05	0.00415	0.15	0.12	HDL cholesterol;HDL cholesterol levels;	chr19:51805837	chr19:51839924~51843324:-
BRCA	cis	rs2835345	0.563	rs73204244	ENSG00000233818.1	AP000695.4	4.02	6.24e-05	0.00415	0.13	0.12	Pulmonary function;	chr21:36452373	chr21:36445731~36532408:+
BRCA	cis	rs11098499	0.865	rs9994730	ENSG00000260404.2	RP11-384K6.6	4.02	6.24e-05	0.00415	0.12	0.12	Corneal astigmatism;	chr4:119460409	chr4:118591773~118633729:+
BRCA	cis	rs990171	0.538	rs12987295	ENSG00000234389.1	AC007278.3	4.02	6.24e-05	0.00416	0.12	0.12	Lymphocyte counts;	chr2:102499379	chr2:102438713~102440475:+
BRCA	cis	rs4713118	0.621	rs9295756	ENSG00000272009.1	RP1-313I6.12	-4.02	6.24e-05	0.00416	-0.18	-0.12	Parkinson's disease;	chr6:28065618	chr6:28078792~28081130:-
BRCA	cis	rs7267979	1	rs3002702	ENSG00000277938.1	RP5-965G21.3	4.02	6.25e-05	0.00416	0.15	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25288284	chr20:25229150~25231933:+
BRCA	cis	rs2436845	0.603	rs2679753	ENSG00000253669.3	KB-1732A1.1	-4.02	6.25e-05	0.00416	-0.15	-0.12	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102855232	chr8:102805517~102809971:+
BRCA	cis	rs9549260	0.755	rs2721066	ENSG00000168852.11	TPTE2P5	-4.02	6.25e-05	0.00416	-0.12	-0.12	Red blood cell count;	chr13:40582051	chr13:40822296~40921749:-
BRCA	cis	rs4415084	1	rs4419600	ENSG00000248779.1	RP11-53O19.2	4.02	6.25e-05	0.00416	0.12	0.12	Breast cancer;	chr5:44678432	chr5:44752949~44765744:+
BRCA	cis	rs12612420	0.887	rs978656	ENSG00000225953.2	SATB2-AS1	4.02	6.25e-05	0.00416	0.2	0.12	Exercise (leisure time);	chr2:200325905	chr2:199457700~199476935:+
BRCA	cis	rs3845817	0.703	rs702887	ENSG00000237979.1	AC007389.1	4.02	6.25e-05	0.00416	0.14	0.12	Bipolar disorder;	chr2:65527074	chr2:65500993~65502138:-
BRCA	cis	rs7246967	0.608	rs437859	ENSG00000198153.8	ZNF849P	4.02	6.25e-05	0.00416	0.18	0.12	Bronchopulmonary dysplasia;	chr19:22824547	chr19:22685167~22686732:+
BRCA	cis	rs2562456	0.834	rs2173727	ENSG00000213976.4	CTD-2561J22.2	4.02	6.25e-05	0.00416	0.15	0.12	Pain;	chr19:21491155	chr19:21382865~21387177:+
BRCA	cis	rs9959145	1	rs28575715	ENSG00000267108.1	RP11-861E21.1	4.02	6.25e-05	0.00416	0.22	0.12	Immune response to smallpox vaccine (IL-6);	chr18:12586349	chr18:12432897~12437635:+
BRCA	cis	rs5003154	0.905	rs4739612	ENSG00000253214.1	RP11-1149M10.2	4.02	6.25e-05	0.00416	0.13	0.12	Bladder cancer;	chr8:81081544	chr8:81154279~81164599:+
BRCA	cis	rs10505725	1	rs10505725	ENSG00000235049.1	LINC00940	4.02	6.25e-05	0.00416	0.13	0.12	Obesity-related traits;	chr12:1947197	chr12:1929202~1936574:-
BRCA	cis	rs6696239	0.531	rs10799423	ENSG00000227711.2	RP11-275O4.5	4.02	6.26e-05	0.00416	0.15	0.12	Height;	chr1:227549683	chr1:227509028~227520477:-
BRCA	cis	rs300703	0.542	rs415660	ENSG00000228643.1	AC079779.4	4.02	6.26e-05	0.00416	0.19	0.12	Blood protein levels;	chr2:189972	chr2:286419~301515:+
BRCA	cis	rs28927680	0.677	rs12280753	ENSG00000278768.1	BACE1-AS	4.02	6.26e-05	0.00416	0.18	0.12	Lipid traits;Triglycerides;	chr11:116742944	chr11:117290874~117293571:+
BRCA	cis	rs2625529	0.652	rs8040216	ENSG00000260037.4	CTD-2524L6.3	4.02	6.26e-05	0.00416	0.15	0.12	Red blood cell count;	chr15:71962908	chr15:71818396~71823384:+
BRCA	cis	rs7481584	0.624	rs693687	ENSG00000236710.1	AC108448.2	4.02	6.26e-05	0.00416	0.16	0.12	Calcium levels;	chr11:3031264	chr11:3084393~3085443:-
BRCA	cis	rs6012542	0.526	rs11907942	ENSG00000222365.1	SNORD12B	-4.02	6.26e-05	0.00416	-0.2	-0.12	Intelligence (multi-trait analysis);	chr20:48858444	chr20:49280319~49280409:+
BRCA	cis	rs938554	0.577	rs7683856	ENSG00000250413.1	RP11-448G15.1	-4.02	6.26e-05	0.00416	-0.19	-0.12	Blood metabolite levels;	chr4:9999323	chr4:10006482~10009725:+
BRCA	cis	rs7615952	0.673	rs9821905	ENSG00000248787.1	RP11-666A20.4	4.02	6.26e-05	0.00416	0.24	0.12	Blood pressure (smoking interaction);	chr3:125902007	chr3:125908005~125910272:-
BRCA	cis	rs11668609	1	rs919813	ENSG00000268058.1	BNIP3P40	-4.02	6.26e-05	0.00416	-0.15	-0.12	Response to taxane treatment (docetaxel);	chr19:24163431	chr19:24098425~24098980:-
BRCA	cis	rs2030746	0.521	rs2311598	ENSG00000237614.1	AC073257.2	4.02	6.26e-05	0.00416	0.15	0.12	LDL cholesterol;Total cholesterol levels;LDL cholesterol levels;	chr2:120573526	chr2:120542909~120544326:-
BRCA	cis	rs7937890	0.559	rs2597217	ENSG00000254418.1	RP11-21L19.1	4.02	6.26e-05	0.00417	0.15	0.12	Mitochondrial DNA levels;	chr11:14511337	chr11:14262846~14273691:-
BRCA	cis	rs875971	0.755	rs10228885	ENSG00000273024.4	INTS4P2	4.02	6.26e-05	0.00417	0.14	0.12	Aortic root size;	chr7:66315542	chr7:65647864~65715661:+
BRCA	cis	rs7105310	0.735	rs12419229	ENSG00000254905.1	RP11-712L6.7	4.02	6.26e-05	0.00417	0.25	0.12	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;	chr11:126186567	chr11:126292922~126294254:-
BRCA	cis	rs801193	0.967	rs2707841	ENSG00000229180.5	GS1-124K5.11	4.02	6.26e-05	0.00417	0.11	0.12	Aortic root size;	chr7:66692033	chr7:66526088~66542624:-
BRCA	cis	rs801193	1	rs4717310	ENSG00000229180.5	GS1-124K5.11	4.02	6.26e-05	0.00417	0.11	0.12	Aortic root size;	chr7:66696020	chr7:66526088~66542624:-
BRCA	cis	rs6545883	0.831	rs2592356	ENSG00000270820.4	RP11-355B11.2	4.02	6.26e-05	0.00417	0.14	0.12	Tuberculosis;	chr2:61583293	chr2:61471188~61484130:+
BRCA	cis	rs7586085	0.626	rs1076969	ENSG00000229195.1	AC009495.4	-4.02	6.27e-05	0.00417	-0.15	-0.12	Total body bone mineral density;	chr2:165784064	chr2:165794857~165846091:-
BRCA	cis	rs7586085	0.626	rs744158	ENSG00000229195.1	AC009495.4	-4.02	6.27e-05	0.00417	-0.15	-0.12	Total body bone mineral density;	chr2:165784065	chr2:165794857~165846091:-
BRCA	cis	rs1348850	0.914	rs6710575	ENSG00000280374.1	RP11-337N6.3	4.02	6.27e-05	0.00417	0.17	0.12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177512583	chr2:177317715~177318471:-
BRCA	cis	rs17695224	0.5	rs4801897	ENSG00000269483.1	AC006272.1	4.02	6.27e-05	0.00417	0.15	0.12	HDL cholesterol;HDL cholesterol levels;	chr19:51831942	chr19:51839924~51843324:-
BRCA	cis	rs11758351	0.866	rs2069018	ENSG00000241549.7	GUSBP2	-4.02	6.27e-05	0.00417	-0.18	-0.12	Renal underexcretion gout;Gout;	chr6:26205490	chr6:26871484~26956554:-
BRCA	cis	rs11758351	0.866	rs11757394	ENSG00000241549.7	GUSBP2	-4.02	6.27e-05	0.00417	-0.18	-0.12	Renal underexcretion gout;Gout;	chr6:26206466	chr6:26871484~26956554:-
BRCA	cis	rs977987	0.806	rs1549306	ENSG00000280152.1	RP11-331F4.5	-4.02	6.27e-05	0.00417	-0.13	-0.12	Dupuytren's disease;	chr16:75381443	chr16:75245994~75250077:-
BRCA	cis	rs13434995	0.513	rs17779627	ENSG00000239040.1	Y_RNA	4.02	6.27e-05	0.00417	0.15	0.12	Adiponectin levels;	chr4:55483775	chr4:55412636~55412738:+
BRCA	cis	rs801193	0.935	rs2659916	ENSG00000273142.1	RP11-458F8.4	-4.02	6.27e-05	0.00417	-0.11	-0.12	Aortic root size;	chr7:66686365	chr7:66902857~66906297:+
BRCA	cis	rs12285276	0.536	rs4411261	ENSG00000205106.4	DKFZp779M0652	4.02	6.27e-05	0.00417	0.16	0.12	Visceral fat;	chr11:45785530	chr11:45771432~45772358:+
BRCA	cis	rs9733	0.596	rs2867300	ENSG00000231073.1	RP11-316M1.3	4.02	6.27e-05	0.00417	0.13	0.12	Tonsillectomy;	chr1:150694514	chr1:150973123~150975534:+
BRCA	cis	rs4650943	0.586	rs4603090	ENSG00000227740.1	RP11-318C24.2	-4.02	6.27e-05	0.00417	-0.13	-0.12	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in inactive individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr1:176362354	chr1:175904762~175920513:-
BRCA	cis	rs2273156	0.587	rs8014377	ENSG00000226677.3	IGBP1P1	-4.02	6.28e-05	0.00417	-0.2	-0.12	Immunoglobulin light chain (AL) amyloidosis;	chr14:35061851	chr14:34939324~34940332:+
BRCA	cis	rs2273156	0.587	rs61125355	ENSG00000226677.3	IGBP1P1	-4.02	6.28e-05	0.00417	-0.2	-0.12	Immunoglobulin light chain (AL) amyloidosis;	chr14:35065995	chr14:34939324~34940332:+
BRCA	cis	rs8180040	0.966	rs12636851	ENSG00000280667.1	Y_RNA	4.02	6.28e-05	0.00418	0.14	0.12	Colorectal cancer;	chr3:47422077	chr3:47501083~47501182:+
BRCA	cis	rs2904967	0.778	rs689288	ENSG00000254614.2	AP003068.23	-4.02	6.28e-05	0.00418	-0.26	-0.12	Mean corpuscular volume;	chr11:65351526	chr11:65177606~65181834:-
BRCA	cis	rs9650657	0.645	rs4841409	ENSG00000154316.13	TDH	-4.02	6.28e-05	0.00418	-0.16	-0.12	Neuroticism;	chr8:10658864	chr8:11339637~11368452:+
BRCA	cis	rs13401620	0.871	rs10185037	ENSG00000229326.3	AC069154.4	-4.02	6.28e-05	0.00418	-0.16	-0.12	Breast size;	chr2:119884606	chr2:119698623~119700151:+
BRCA	cis	rs13401620	0.871	rs17049912	ENSG00000229326.3	AC069154.4	-4.02	6.28e-05	0.00418	-0.16	-0.12	Breast size;	chr2:119885441	chr2:119698623~119700151:+
BRCA	cis	rs1555322	0.932	rs1205411	ENSG00000261582.1	RP4-614O4.11	-4.02	6.28e-05	0.00418	-0.17	-0.12	Attention deficit hyperactivity disorder;	chr20:35269439	chr20:35267885~35280043:-
BRCA	cis	rs2832077	0.689	rs2832052	ENSG00000232855.5	AF131217.1	4.02	6.28e-05	0.00418	0.16	0.12	Cognitive test performance;	chr21:28757751	chr21:28439346~28674848:-
BRCA	cis	rs10463316	0.894	rs11167542	ENSG00000260581.1	CTB-113P19.4	-4.02	6.28e-05	0.00418	-0.15	-0.12	Metabolite levels (Pyroglutamine);	chr5:151380721	chr5:151652275~151655449:+
BRCA	cis	rs4916588	0.639	rs4916583	ENSG00000230732.4	AC127904.2	4.02	6.28e-05	0.00418	0.16	0.12	Night sleep phenotypes;	chr3:196911107	chr3:196912646~196914579:+
BRCA	cis	rs763121	0.776	rs4820346	ENSG00000225450.1	RP3-508I15.14	4.02	6.28e-05	0.00418	0.13	0.12	Menopause (age at onset);	chr22:38729069	chr22:38739003~38749041:+
BRCA	cis	rs6672530	0.518	rs4653850	ENSG00000227711.2	RP11-275O4.5	4.02	6.28e-05	0.00418	0.15	0.12	Hip circumference adjusted for BMI;	chr1:227550187	chr1:227509028~227520477:-
BRCA	cis	rs757081	0.667	rs644419	ENSG00000184669.7	OR7E14P	4.02	6.28e-05	0.00418	0.18	0.12	Systolic blood pressure;	chr11:17190828	chr11:17013998~17053024:+
BRCA	cis	rs7620503	1	rs35168340	ENSG00000277241.1	RP11-114M1.3	4.02	6.28e-05	0.00418	0.14	0.12	Corneal structure;	chr3:177581264	chr3:177700346~177701072:-
BRCA	cis	rs7620503	0.918	rs34316712	ENSG00000277241.1	RP11-114M1.3	4.02	6.28e-05	0.00418	0.14	0.12	Corneal structure;	chr3:177581277	chr3:177700346~177701072:-
BRCA	cis	rs9818758	0.607	rs56306491	ENSG00000270441.1	RP11-694I15.7	4.02	6.28e-05	0.00418	0.27	0.12	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49277527	chr3:49140086~49160851:-
BRCA	cis	rs7267979	0.966	rs2257233	ENSG00000274414.1	RP5-965G21.4	4.02	6.28e-05	0.00418	0.15	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25285348	chr20:25239007~25245229:-
BRCA	cis	rs721917	0.506	rs2819097	ENSG00000280355.1	RP11-119F19.5	-4.02	6.28e-05	0.00418	-0.14	-0.12	Chronic obstructive pulmonary disease;	chr10:79940225	chr10:79681973~79684094:-
BRCA	cis	rs7735319	0.565	rs1981968	ENSG00000249572.1	CTD-2203K17.1	4.02	6.29e-05	0.00418	0.15	0.12	Systolic blood pressure;	chr5:33121891	chr5:33424025~33440619:-
BRCA	cis	rs7735319	0.565	rs10058070	ENSG00000249572.1	CTD-2203K17.1	4.02	6.29e-05	0.00418	0.15	0.12	Systolic blood pressure;	chr5:33132706	chr5:33424025~33440619:-
BRCA	cis	rs7735319	0.565	rs10059641	ENSG00000249572.1	CTD-2203K17.1	4.02	6.29e-05	0.00418	0.15	0.12	Systolic blood pressure;	chr5:33132816	chr5:33424025~33440619:-
BRCA	cis	rs7735319	0.546	rs1834962	ENSG00000249572.1	CTD-2203K17.1	4.02	6.29e-05	0.00418	0.15	0.12	Systolic blood pressure;	chr5:33134513	chr5:33424025~33440619:-
BRCA	cis	rs7735319	0.565	rs4541672	ENSG00000249572.1	CTD-2203K17.1	4.02	6.29e-05	0.00418	0.15	0.12	Systolic blood pressure;	chr5:33135825	chr5:33424025~33440619:-
BRCA	cis	rs7735319	0.565	rs4478335	ENSG00000249572.1	CTD-2203K17.1	4.02	6.29e-05	0.00418	0.15	0.12	Systolic blood pressure;	chr5:33138242	chr5:33424025~33440619:-
BRCA	cis	rs1836229	0.874	rs10120501	ENSG00000225706.1	PTPRD-AS1	-4.02	6.29e-05	0.00418	-0.13	-0.12	Restless legs syndrome;	chr9:8826767	chr9:8858130~8862255:+
BRCA	cis	rs1832007	0.529	rs4880716	ENSG00000224034.1	RP11-445P17.8	4.02	6.29e-05	0.00418	0.19	0.12	Triglyceride levels;Triglycerides;	chr10:5196233	chr10:5266033~5271236:-
BRCA	cis	rs7520050	0.966	rs785481	ENSG00000281133.1	AL355480.3	4.02	6.29e-05	0.00418	0.14	0.12	Reticulocyte count;Red blood cell count;	chr1:46088846	chr1:45580892~45580996:-
BRCA	cis	rs12612435	0.83	rs6715450	ENSG00000226806.1	AC011893.3	4.02	6.29e-05	0.00418	0.14	0.12	Takotsubo syndrome;	chr2:136364161	chr2:135820191~135823087:+
BRCA	cis	rs4703129	0.527	rs2042965	ENSG00000246763.5	RGMB-AS1	4.02	6.29e-05	0.00418	0.14	0.12	Asperger disorder;	chr5:98509243	chr5:98769618~98773469:-
BRCA	cis	rs2302465	0.86	rs73239165	ENSG00000273133.1	RP11-799M12.2	-4.02	6.29e-05	0.00418	-0.24	-0.12	Blood protein levels;	chr4:15602537	chr4:15563698~15564253:-
BRCA	cis	rs4650943	0.586	rs791524	ENSG00000227740.1	RP11-318C24.2	-4.02	6.29e-05	0.00418	-0.13	-0.12	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in inactive individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr1:176296895	chr1:175904762~175920513:-
BRCA	cis	rs10129255	0.912	rs61997792	ENSG00000211958.2	IGHV3-38	4.02	6.29e-05	0.00418	0.1	0.12	Kawasaki disease;	chr14:106799304	chr14:106410493~106411021:-
BRCA	cis	rs7735319	0.546	rs10073673	ENSG00000249572.1	CTD-2203K17.1	4.02	6.29e-05	0.00418	0.15	0.12	Systolic blood pressure;	chr5:33120279	chr5:33424025~33440619:-
BRCA	cis	rs9733	0.818	rs11204695	ENSG00000203804.4	ADAMTSL4-AS1	-4.02	6.29e-05	0.00418	-0.13	-0.12	Tonsillectomy;	chr1:150684535	chr1:150560202~150574552:-
BRCA	cis	rs1009077	0.671	rs13120581	ENSG00000245958.5	RP11-33B1.1	4.02	6.29e-05	0.00418	0.18	0.12	Endometriosis;	chr4:119602481	chr4:119454791~119552025:+
BRCA	cis	rs2243480	1	rs4718269	ENSG00000226002.1	RP11-460N20.5	4.02	6.29e-05	0.00418	0.2	0.12	Diabetic kidney disease;	chr7:65735810	chr7:65084103~65100232:+
BRCA	cis	rs71520386	0.632	rs12535331	ENSG00000226329.2	AC005682.6	4.02	6.3e-05	0.00419	0.13	0.12	Fibrinogen levels;	chr7:22838485	chr7:22863874~22881350:-
BRCA	cis	rs6593122	0.755	rs2330672	ENSG00000235454.1	HAUS6P3	-4.02	6.3e-05	0.00419	-0.16	-0.12	Vaccine-related adverse events;	chr7:54122443	chr7:53862233~53863339:+
BRCA	cis	rs34773007	0.514	rs2497338	ENSG00000232709.1	MARK2P9	-4.02	6.3e-05	0.00419	-0.19	-0.12	Type 2 diabetes;	chr10:92779203	chr10:92418667~92420875:+
BRCA	cis	rs38055	0.837	rs584593	ENSG00000247796.2	CTD-2366F13.1	-4.02	6.3e-05	0.00419	-0.15	-0.12	Acne (severe);	chr5:53330398	chr5:53109842~53115126:+
BRCA	cis	rs983392	0.679	rs636341	ENSG00000275344.1	MIR6503	4.02	6.3e-05	0.00419	0.13	0.12	Alzheimer's disease (late onset);	chr11:60251688	chr11:60209071~60209156:-
BRCA	cis	rs17801127	0.688	rs4667405	ENSG00000231969.1	AC144449.1	-4.02	6.3e-05	0.00419	-0.19	-0.12	Liver enzyme levels (alanine transaminase);	chr2:149703832	chr2:149587196~149848233:+
BRCA	cis	rs4664293	0.867	rs2059698	ENSG00000224152.1	AC009506.1	4.02	6.3e-05	0.00419	0.14	0.12	Monocyte percentage of white cells;	chr2:159785905	chr2:159615296~159617082:+
BRCA	cis	rs4835473	0.808	rs2060652	ENSG00000246448.2	RP13-578N3.3	-4.02	6.3e-05	0.00419	-0.14	-0.12	Immature fraction of reticulocytes;	chr4:143739129	chr4:143700257~143865072:+
BRCA	cis	rs4218	0.648	rs58087223	ENSG00000259732.1	RP11-59H7.3	-4.02	6.3e-05	0.00419	-0.16	-0.12	Social communication problems;	chr15:59075132	chr15:59121034~59133250:+
BRCA	cis	rs6545883	0.826	rs777593	ENSG00000273302.1	RP11-493E12.2	4.02	6.3e-05	0.00419	0.12	0.12	Tuberculosis;	chr2:61191968	chr2:61199979~61200769:+
BRCA	cis	rs4415084	0.716	rs16901964	ENSG00000251141.4	RP11-53O19.1	4.02	6.3e-05	0.00419	0.12	0.12	Breast cancer;	chr5:44783153	chr5:44744900~44808777:-
BRCA	cis	rs8040855	0.599	rs1964724	ENSG00000259762.1	RP11-158M2.4	-4.02	6.3e-05	0.00419	-0.14	-0.12	Bulimia nervosa;	chr15:85183269	chr15:85750336~85752901:-
BRCA	cis	rs2842992	0.724	rs4709368	ENSG00000237927.1	RP3-393E18.2	4.02	6.3e-05	0.00419	0.16	0.12	Age-related macular degeneration (geographic atrophy);	chr6:159783095	chr6:159586955~159589169:-
BRCA	cis	rs875971	1	rs709597	ENSG00000265600.1	AC006480.1	4.02	6.3e-05	0.00419	0.15	0.12	Aortic root size;	chr7:66360996	chr7:67356680~67356779:+
BRCA	cis	rs10487112	0.833	rs7780557	ENSG00000235436.9	DPY19L2P4	-4.02	6.31e-05	0.00419	-0.13	-0.12	Perceived unattractiveness to mosquitoes;	chr7:90529783	chr7:90119400~90125600:+
BRCA	cis	rs10129255	0.872	rs8015406	ENSG00000274576.2	IGHV2-70	4.02	6.31e-05	0.00419	0.11	0.12	Kawasaki disease;	chr14:106670611	chr14:106770577~106771020:-
BRCA	cis	rs875971	0.545	rs2420456	ENSG00000232559.3	GS1-124K5.12	4.02	6.31e-05	0.00419	0.17	0.12	Aortic root size;	chr7:66280619	chr7:66554588~66576923:-
BRCA	cis	rs853679	0.517	rs2281588	ENSG00000261839.1	RP1-265C24.8	4.02	6.31e-05	0.00419	0.17	0.12	Depression;	chr6:28104824	chr6:28136849~28139678:+
BRCA	cis	rs6545883	0.929	rs1186707	ENSG00000212978.6	AC016747.3	4.02	6.31e-05	0.00419	0.17	0.12	Tuberculosis;	chr2:61446385	chr2:61141592~61144969:-
BRCA	cis	rs3812762	0.868	rs7952335	ENSG00000254860.4	TMEM9B-AS1	-4.02	6.31e-05	0.00419	-0.11	-0.12	Hypospadias;	chr11:8732484	chr11:8964675~8977527:+
BRCA	cis	rs6931421	1	rs6931421	ENSG00000272129.1	RP11-250B2.6	4.02	6.31e-05	0.0042	0.17	0.12	Sitting height ratio;	chr6:80170421	chr6:80355424~80356859:+
BRCA	cis	rs6456156	0.792	rs10946212	ENSG00000272549.1	RP11-351J23.2	-4.02	6.31e-05	0.0042	-0.13	-0.12	Primary biliary cholangitis;	chr6:167102459	chr6:167666840~167679270:-
BRCA	cis	rs2136613	0.751	rs224310	ENSG00000238280.1	RP11-436D10.3	4.02	6.31e-05	0.0042	0.16	0.12	Selective IgA deficiency;	chr10:62851821	chr10:62793562~62805887:-
BRCA	cis	rs2136613	0.751	rs224311	ENSG00000238280.1	RP11-436D10.3	4.02	6.31e-05	0.0042	0.16	0.12	Selective IgA deficiency;	chr10:62854429	chr10:62793562~62805887:-
BRCA	cis	rs812925	0.519	rs10199672	ENSG00000273302.1	RP11-493E12.2	-4.02	6.31e-05	0.0042	-0.11	-0.12	Immature fraction of reticulocytes;	chr2:61400499	chr2:61199979~61200769:+
BRCA	cis	rs6071166	0.683	rs7262449	ENSG00000224635.1	RP4-564F22.5	-4.02	6.32e-05	0.0042	-0.15	-0.12	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38680668	chr20:38406011~38416797:-
BRCA	cis	rs1850744	1	rs1519095	ENSG00000163612.10	FAM86KP	-4.02	6.32e-05	0.0042	-0.33	-0.12	Economic and political preferences;	chr4:9809307	chr4:9153296~9165451:+
BRCA	cis	rs10043228	0.702	rs62384474	ENSG00000250015.1	CTC-339F2.2	4.02	6.32e-05	0.0042	0.14	0.12	Asthma or chronic obstructive pulmonary disease;	chr5:116298321	chr5:116302354~116304134:-
BRCA	cis	rs6452524	0.901	rs10079680	ENSG00000281327.1	LINC01338	4.02	6.32e-05	0.0042	0.14	0.12	Hypertension (SNP x SNP interaction);	chr5:83082746	chr5:82850864~82859836:-
BRCA	cis	rs7308116	0.557	rs11113569	ENSG00000274395.1	RP11-554D14.8	4.02	6.32e-05	0.0042	0.13	0.12	Pelvic organ prolapse (moderate/severe);	chr12:107887158	chr12:107835541~107836555:-
BRCA	cis	rs924712	0.57	rs2134536	ENSG00000261116.1	RP3-523K23.2	4.02	6.32e-05	0.0042	0.16	0.12	Breast cancer;	chr6:54992882	chr6:54943167~54945099:+
BRCA	cis	rs9733	0.596	rs17658705	ENSG00000231073.1	RP11-316M1.3	-4.02	6.32e-05	0.0042	-0.13	-0.12	Tonsillectomy;	chr1:150705595	chr1:150973123~150975534:+
BRCA	cis	rs2030746	0.545	rs940670	ENSG00000237614.1	AC073257.2	4.02	6.32e-05	0.0042	0.15	0.12	LDL cholesterol;Total cholesterol levels;LDL cholesterol levels;	chr2:120569938	chr2:120542909~120544326:-
BRCA	cis	rs4759375	1	rs10773005	ENSG00000256092.2	RP13-942N8.1	-4.02	6.32e-05	0.0042	-0.19	-0.12	HDL cholesterol;	chr12:123305460	chr12:123363868~123366113:+
BRCA	cis	rs11742741	0.806	rs1032760	ENSG00000248874.4	C5orf17	4.02	6.32e-05	0.0042	0.16	0.12	Educational attainment;	chr5:24016911	chr5:23951348~24178263:+
BRCA	cis	rs2115630	1	rs55646601	ENSG00000275120.1	RP11-182J1.17	-4.02	6.32e-05	0.0042	-0.14	-0.12	P wave terminal force;	chr15:84780337	chr15:84599434~84606463:-
BRCA	cis	rs6500602	0.701	rs8053770	ENSG00000280063.1	RP11-295D4.3	4.02	6.32e-05	0.0042	0.09	0.12	Schizophrenia;	chr16:4489029	chr16:4346694~4348648:-
BRCA	cis	rs1143633	0.662	rs12990810	ENSG00000231747.1	AC079922.2	4.02	6.32e-05	0.0042	0.13	0.12	Allergic disease (asthma, hay fever or eczema);	chr2:112884955	chr2:112621809~112622167:-
BRCA	cis	rs9425766	0.679	rs4652234	ENSG00000200674.1	RN7SKP160	4.02	6.32e-05	0.0042	0.16	0.12	Life satisfaction;	chr1:174181712	chr1:173791548~173791887:+
BRCA	cis	rs7475343	0.501	rs17134531	ENSG00000224034.1	RP11-445P17.8	-4.02	6.32e-05	0.0042	-0.24	-0.12	Intelligence;	chr10:5204122	chr10:5266033~5271236:-
BRCA	cis	rs10504130	0.569	rs11775587	ENSG00000253844.1	RP11-546K22.1	4.02	6.32e-05	0.0042	0.18	0.12	Venous thromboembolism (SNP x SNP interaction);	chr8:51907605	chr8:51961458~52022974:+
BRCA	cis	rs656900	0.647	rs668641	ENSG00000261229.4	MTHFS	4.02	6.33e-05	0.0042	0.12	0.12	Cerebrospinal P-tau181p levels;	chr15:79826282	chr15:79843547~79897285:-
BRCA	cis	rs8058578	0.775	rs8046391	ENSG00000274678.1	RP11-2C24.7	4.02	6.33e-05	0.0042	0.15	0.12	Multiple myeloma;	chr16:30825327	chr16:30821338~30821884:+
BRCA	cis	rs7735319	0.584	rs1979419	ENSG00000249572.1	CTD-2203K17.1	4.02	6.33e-05	0.0042	0.15	0.12	Systolic blood pressure;	chr5:33121553	chr5:33424025~33440619:-
BRCA	cis	rs9959145	1	rs111268621	ENSG00000267108.1	RP11-861E21.1	4.02	6.33e-05	0.0042	0.23	0.12	Immune response to smallpox vaccine (IL-6);	chr18:12546290	chr18:12432897~12437635:+
BRCA	cis	rs6012564	0.793	rs1043361	ENSG00000227431.4	CSE1L-AS1	4.02	6.33e-05	0.0042	0.15	0.12	Anger;	chr20:49114621	chr20:49040463~49046044:-
BRCA	cis	rs516805	0.667	rs7767993	ENSG00000279114.1	RP3-425C14.5	4.02	6.33e-05	0.0042	0.15	0.12	Lymphocyte counts;	chr6:122343192	chr6:122471923~122484161:+
BRCA	cis	rs516805	0.667	rs10457432	ENSG00000279114.1	RP3-425C14.5	4.02	6.33e-05	0.0042	0.15	0.12	Lymphocyte counts;	chr6:122344699	chr6:122471923~122484161:+
BRCA	cis	rs801193	0.761	rs2659888	ENSG00000273142.1	RP11-458F8.4	-4.02	6.33e-05	0.00421	-0.11	-0.12	Aortic root size;	chr7:66765184	chr7:66902857~66906297:+
BRCA	cis	rs6490294	0.904	rs60217649	ENSG00000257624.1	RP1-128M12.3	4.02	6.33e-05	0.00421	0.17	0.12	Mean platelet volume;	chr12:111973116	chr12:112000739~112000985:-
BRCA	cis	rs2451932	0.744	rs380747	ENSG00000251050.1	RP11-168A11.4	-4.02	6.33e-05	0.00421	-0.13	-0.12	LDL peak particle diameter (total fat intake interaction);	chr5:80050744	chr5:80019609~80019920:+
BRCA	cis	rs11148252	0.624	rs6561682	ENSG00000278238.1	RP11-245D16.4	4.02	6.33e-05	0.00421	0.14	0.12	Lewy body disease;	chr13:52692162	chr13:52454775~52455331:-
BRCA	cis	rs7481584	0.517	rs80872	ENSG00000236710.1	AC108448.2	4.02	6.33e-05	0.00421	0.16	0.12	Calcium levels;	chr11:3028754	chr11:3084393~3085443:-
BRCA	cis	rs4478858	0.735	rs12563669	ENSG00000223907.1	LINC01226	-4.02	6.33e-05	0.00421	-0.15	-0.12	Alcohol dependence;	chr1:31385220	chr1:31518435~31524245:+
BRCA	cis	rs7975161	0.882	rs4406890	ENSG00000257681.1	RP11-341G23.4	-4.02	6.33e-05	0.00421	-0.17	-0.12	Toenail selenium levels;	chr12:104244995	chr12:103746315~103768858:-
BRCA	cis	rs6496932	0.802	rs10163187	ENSG00000218052.5	ADAMTS7P4	4.02	6.33e-05	0.00421	0.13	0.12	Central corneal thickness;Corneal structure;	chr15:85327287	chr15:85255369~85330334:-
BRCA	cis	rs2136613	0.751	rs224307	ENSG00000238280.1	RP11-436D10.3	4.02	6.33e-05	0.00421	0.16	0.12	Selective IgA deficiency;	chr10:62841675	chr10:62793562~62805887:-
BRCA	cis	rs1005277	0.579	rs2474580	ENSG00000272983.1	RP11-508N22.12	4.02	6.34e-05	0.00421	0.13	0.12	Extrinsic epigenetic age acceleration;	chr10:38109785	chr10:38137337~38144399:+
BRCA	cis	rs8113308	0.81	rs16983256	ENSG00000269483.1	AC006272.1	4.02	6.34e-05	0.00421	0.22	0.12	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51946228	chr19:51839924~51843324:-
BRCA	cis	rs8113308	0.81	rs8100521	ENSG00000269483.1	AC006272.1	4.02	6.34e-05	0.00421	0.22	0.12	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51946390	chr19:51839924~51843324:-
BRCA	cis	rs11668609	0.872	rs8102565	ENSG00000268442.1	CTD-2027I19.2	-4.02	6.34e-05	0.00421	-0.18	-0.12	Response to taxane treatment (docetaxel);	chr19:23884546	chr19:24162370~24163425:-
BRCA	cis	rs35520189	0.845	rs2723152	ENSG00000189223.12	PAX8-AS1	4.02	6.34e-05	0.00421	0.18	0.12	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:112888113	chr2:113211522~113276581:+
BRCA	cis	rs10463316	0.817	rs58892766	ENSG00000260581.1	CTB-113P19.4	4.02	6.34e-05	0.00421	0.14	0.12	Metabolite levels (Pyroglutamine);	chr5:151396554	chr5:151652275~151655449:+
BRCA	cis	rs739496	0.843	rs848132	ENSG00000234608.6	MAPKAPK5-AS1	4.02	6.34e-05	0.00421	0.15	0.12	Platelet count;	chr12:111552175	chr12:111839764~111842902:-
BRCA	cis	rs11009175	0.929	rs7078479	ENSG00000273038.2	RP11-479G22.8	-4.02	6.34e-05	0.00421	-0.22	-0.12	Depression (quantitative trait);	chr10:33056273	chr10:32887255~32889311:-
BRCA	cis	rs1005277	0.579	rs2474563	ENSG00000272983.1	RP11-508N22.12	4.02	6.34e-05	0.00421	0.13	0.12	Extrinsic epigenetic age acceleration;	chr10:38087010	chr10:38137337~38144399:+
BRCA	cis	rs80226907	0.634	rs45612333	ENSG00000186615.9	KTN1-AS1	-4.02	6.34e-05	0.00421	-0.26	-0.12	Mean platelet volume;	chr14:55436998	chr14:55499278~55580110:-
BRCA	cis	rs4415084	0.966	rs4492118	ENSG00000248779.1	RP11-53O19.2	4.02	6.34e-05	0.00421	0.12	0.12	Breast cancer;	chr5:44646523	chr5:44752949~44765744:+
BRCA	cis	rs11239930	0.517	rs2477569	ENSG00000237188.3	RP11-337C18.8	-4.02	6.35e-05	0.00421	-0.14	-0.12	AIDS progression;	chr1:147076261	chr1:147172771~147211568:+
BRCA	cis	rs2243480	0.522	rs73150635	ENSG00000275400.1	RP4-756H11.5	4.02	6.35e-05	0.00421	0.28	0.12	Diabetic kidney disease;	chr7:66507503	chr7:66553805~66554199:-
BRCA	cis	rs2692947	0.644	rs2969491	ENSG00000168992.4	OR7E102P	4.02	6.35e-05	0.00422	0.17	0.12	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96129243	chr2:95546531~95547545:+
BRCA	cis	rs6736093	0.966	rs3811633	ENSG00000236307.2	EEF1E1P1	-4.02	6.35e-05	0.00422	-0.15	-0.12	Coronary artery disease;	chr2:111997303	chr2:111887914~111888741:+
BRCA	cis	rs6736093	0.966	rs34527376	ENSG00000236307.2	EEF1E1P1	-4.02	6.35e-05	0.00422	-0.15	-0.12	Coronary artery disease;	chr2:111998122	chr2:111887914~111888741:+
BRCA	cis	rs35306767	0.855	rs35666723	ENSG00000229869.1	RP11-363N22.2	-4.02	6.35e-05	0.00422	-0.21	-0.12	Eosinophil percentage of granulocytes;	chr10:821406	chr10:933026~942743:+
BRCA	cis	rs875971	0.545	rs4441996	ENSG00000273142.1	RP11-458F8.4	-4.02	6.35e-05	0.00422	-0.12	-0.12	Aortic root size;	chr7:66123233	chr7:66902857~66906297:+
BRCA	cis	rs6547741	1	rs6718128	ENSG00000234072.1	AC074117.10	-4.02	6.35e-05	0.00422	-0.11	-0.12	Oral cavity cancer;	chr2:27610885	chr2:27356246~27367622:+
BRCA	cis	rs7829975	0.617	rs4841071	ENSG00000254153.1	CTA-398F10.2	4.02	6.35e-05	0.00422	0.15	0.12	Mood instability;	chr8:8933634	chr8:8456909~8461337:-
BRCA	cis	rs7267979	1	rs2297496	ENSG00000274973.1	RP13-401N8.7	4.02	6.35e-05	0.00422	0.14	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25315151	chr20:25845497~25845862:+
BRCA	cis	rs11098499	0.644	rs28787668	ENSG00000260091.1	RP11-33B1.4	-4.02	6.35e-05	0.00422	-0.11	-0.12	Corneal astigmatism;	chr4:119633532	chr4:119409333~119410233:+
BRCA	cis	rs8031584	0.678	rs3122	ENSG00000270015.1	RP11-540B6.6	4.02	6.35e-05	0.00422	0.13	0.12	Huntington's disease progression;	chr15:30878087	chr15:30926514~30928407:+
BRCA	cis	rs375066	0.935	rs425217	ENSG00000267191.1	RP11-15A1.2	-4.02	6.35e-05	0.00422	-0.16	-0.12	Breast cancer;	chr19:43889823	chr19:43902001~43926545:+
BRCA	cis	rs6738028	0.535	rs744531	ENSG00000230499.1	AC108463.1	-4.02	6.35e-05	0.00422	-0.15	-0.12	Dehydroepiandrosterone sulphate levels;	chr2:111193476	chr2:111195963~111206494:+
BRCA	cis	rs513088	0.681	rs12142855	ENSG00000225171.2	DUTP6	4.02	6.35e-05	0.00422	0.18	0.12	Schizophrenia;	chr1:166685613	chr1:166868748~166869209:+
BRCA	cis	rs3748682	0.861	rs28411034	ENSG00000252448.1	SNORA63	-4.02	6.35e-05	0.00422	-0.16	-0.12	Hypothyroidism;	chr1:37811325	chr1:37884237~37884317:+
BRCA	cis	rs77106637	0.86	rs75896506	ENSG00000245148.2	ARAP1-AS2	-4.02	6.35e-05	0.00422	-0.17	-0.12	Type 2 diabetes;	chr11:72718534	chr11:72700474~72705607:+
BRCA	cis	rs4865762	0.904	rs254199	ENSG00000247796.2	CTD-2366F13.1	4.02	6.35e-05	0.00422	0.13	0.12	Intraocular pressure;	chr5:53209434	chr5:53109842~53115126:+
BRCA	cis	rs2070615	0.545	rs2453478	ENSG00000257964.1	RP11-133N21.10	-4.02	6.36e-05	0.00422	-0.14	-0.12	Bipolar disorder;	chr12:48808960	chr12:49576840~49577505:-
BRCA	cis	rs2842992	0.724	rs9347340	ENSG00000207392.1	SNORA20	4.02	6.36e-05	0.00422	0.16	0.12	Age-related macular degeneration (geographic atrophy);	chr6:159767859	chr6:159780250~159780381:-
BRCA	cis	rs7045881	0.935	rs62544443	ENSG00000254396.1	RP11-56F10.3	4.02	6.36e-05	0.00422	0.2	0.12	Schizophrenia;	chr9:26930962	chr9:27102630~27104728:+
BRCA	cis	rs6963495	0.818	rs73192105	ENSG00000223886.3	RP11-251G23.2	4.02	6.36e-05	0.00422	0.19	0.12	Bipolar disorder (body mass index interaction);	chr7:105527498	chr7:105530209~105530671:+
BRCA	cis	rs7267979	0.789	rs4815400	ENSG00000231081.1	RP4-760C5.3	4.02	6.36e-05	0.00422	0.16	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25311924	chr20:26008791~26010531:-
BRCA	cis	rs10246939	0.543	rs9640357	ENSG00000270923.1	TAS2R6P	-4.02	6.36e-05	0.00422	-0.12	-0.12	Bitter taste perception;	chr7:141843298	chr7:141787815~141788640:+
BRCA	cis	rs2255336	0.938	rs61917750	ENSG00000245648.1	RP11-277P12.20	-4.02	6.36e-05	0.00422	-0.2	-0.12	Blood protein levels;	chr12:10480824	chr12:10363769~10398506:+
BRCA	cis	rs9525927	0.625	rs4942301	ENSG00000227258.4	SMIM2-AS1	4.02	6.36e-05	0.00422	0.18	0.12	Dupuytren's disease;	chr13:44237111	chr13:44110451~44240517:+
BRCA	cis	rs2692947	0.666	rs7566050	ENSG00000232931.4	LINC00342	4.02	6.36e-05	0.00422	0.13	0.12	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95960282	chr2:95807118~95816215:-
BRCA	cis	rs1005277	0.579	rs2504148	ENSG00000272983.1	RP11-508N22.12	4.02	6.36e-05	0.00422	0.13	0.12	Extrinsic epigenetic age acceleration;	chr10:38111860	chr10:38137337~38144399:+
BRCA	cis	rs516805	0.63	rs170422	ENSG00000279114.1	RP3-425C14.5	-4.02	6.36e-05	0.00422	-0.15	-0.12	Lymphocyte counts;	chr6:122261422	chr6:122471923~122484161:+
BRCA	cis	rs12435908	1	rs2300871	ENSG00000276116.2	FUT8-AS1	4.02	6.36e-05	0.00422	0.19	0.12	Ischemic stroke;	chr14:65680976	chr14:65411170~65412690:-
BRCA	cis	rs801193	0.66	rs974239	ENSG00000265600.1	AC006480.1	-4.02	6.36e-05	0.00423	-0.15	-0.12	Aortic root size;	chr7:66748504	chr7:67356680~67356779:+
BRCA	cis	rs8180040	0.62	rs6768722	ENSG00000271161.1	BOLA2P2	4.02	6.37e-05	0.00423	0.13	0.12	Colorectal cancer;	chr3:47037622	chr3:47499841~47500407:+
BRCA	cis	rs8180040	0.62	rs11715121	ENSG00000271161.1	BOLA2P2	-4.02	6.37e-05	0.00423	-0.13	-0.12	Colorectal cancer;	chr3:47031131	chr3:47499841~47500407:+
BRCA	cis	rs8180040	0.62	rs11709660	ENSG00000271161.1	BOLA2P2	-4.02	6.37e-05	0.00423	-0.13	-0.12	Colorectal cancer;	chr3:47033437	chr3:47499841~47500407:+
BRCA	cis	rs6480314	0.831	rs6480316	ENSG00000233590.1	RP11-153K11.3	4.02	6.37e-05	0.00423	0.19	0.12	Optic nerve measurement (disc area);	chr10:68212943	chr10:68233251~68242379:-
BRCA	cis	rs4302906	0.964	rs7848528	ENSG00000187984.11	ANKRD19P	-4.02	6.37e-05	0.00423	-0.11	-0.12	Lobe attachment (rater-scored or self-reported);	chr9:92981750	chr9:92809388~92888693:+
BRCA	cis	rs17826219	0.568	rs11658027	ENSG00000264538.5	SUZ12P1	4.02	6.37e-05	0.00423	0.17	0.12	Body mass index;	chr17:30767864	chr17:30709299~30790908:+
BRCA	cis	rs6005807	0.719	rs7289625	ENSG00000272858.1	CTA-292E10.8	-4.01	6.37e-05	0.00423	-0.22	-0.12	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28500558	chr22:28814914~28815662:+
BRCA	cis	rs6500596	0.506	rs1530088	ENSG00000280063.1	RP11-295D4.3	4.01	6.37e-05	0.00423	0.1	0.12	Schizophrenia;	chr16:4389130	chr16:4346694~4348648:-
BRCA	cis	rs948562	0.744	rs5020736	ENSG00000255299.4	RP11-655C2.3	-4.01	6.37e-05	0.00423	-0.15	-0.12	Lymphoma;	chr11:58661000	chr11:58497888~58505758:-
BRCA	cis	rs948562	0.627	rs5020737	ENSG00000255299.4	RP11-655C2.3	-4.01	6.37e-05	0.00423	-0.15	-0.12	Lymphoma;	chr11:58661003	chr11:58497888~58505758:-
BRCA	cis	rs1790761	0.52	rs1551884	ENSG00000255318.1	RP11-655M14.13	-4.01	6.37e-05	0.00423	-0.15	-0.12	Mean corpuscular volume;	chr11:67632130	chr11:67618279~67627304:-
BRCA	cis	rs7829975	0.806	rs2428	ENSG00000254153.1	CTA-398F10.2	4.01	6.37e-05	0.00423	0.14	0.12	Mood instability;	chr8:8783635	chr8:8456909~8461337:-
BRCA	cis	rs794185	0.598	rs304087	ENSG00000231249.1	ITPR1-AS1	-4.01	6.37e-05	0.00423	-0.14	-0.12	Multiple sclerosis--Brain Glutamate Levels;	chr3:4479955	chr3:4490891~4493163:-
BRCA	cis	rs11048434	0.518	rs17730331	ENSG00000256720.1	RP11-436I9.6	-4.01	6.37e-05	0.00423	-0.12	-0.12	Sjögren's syndrome;	chr12:9025836	chr12:9135084~9135591:+
BRCA	cis	rs801193	0.935	rs3800820	ENSG00000273142.1	RP11-458F8.4	4.01	6.38e-05	0.00423	0.11	0.12	Aortic root size;	chr7:66682191	chr7:66902857~66906297:+
BRCA	cis	rs1156327	0.51	rs2353658	ENSG00000188477.11	AC003003.5	-4.01	6.38e-05	0.00423	-0.33	-0.12	Periodontal disease-related phenotypes;	chr16:19317615	chr16:19285783~19310947:+
BRCA	cis	rs2832191	0.765	rs2832162	ENSG00000232855.5	AF131217.1	-4.01	6.38e-05	0.00423	-0.15	-0.12	Dental caries;	chr21:29089487	chr21:28439346~28674848:-
BRCA	cis	rs4835473	0.832	rs55935372	ENSG00000249741.2	RP11-673E1.3	4.01	6.38e-05	0.00424	0.14	0.12	Immature fraction of reticulocytes;	chr4:143700626	chr4:143911514~143912053:-
BRCA	cis	rs10411161	0.721	rs10401778	ENSG00000269483.1	AC006272.1	4.01	6.38e-05	0.00424	0.2	0.12	Breast cancer;	chr19:51881062	chr19:51839924~51843324:-
BRCA	cis	rs10411161	0.702	rs10402630	ENSG00000269483.1	AC006272.1	4.01	6.38e-05	0.00424	0.2	0.12	Breast cancer;	chr19:51881317	chr19:51839924~51843324:-
BRCA	cis	rs10411161	0.752	rs10402107	ENSG00000269483.1	AC006272.1	4.01	6.38e-05	0.00424	0.2	0.12	Breast cancer;	chr19:51881347	chr19:51839924~51843324:-
BRCA	cis	rs10411161	0.702	rs16983196	ENSG00000269483.1	AC006272.1	4.01	6.38e-05	0.00424	0.2	0.12	Breast cancer;	chr19:51881526	chr19:51839924~51843324:-
BRCA	cis	rs8180040	0.654	rs9837343	ENSG00000271161.1	BOLA2P2	4.01	6.38e-05	0.00424	0.13	0.12	Colorectal cancer;	chr3:47135898	chr3:47499841~47500407:+
BRCA	cis	rs568617	0.953	rs658938	ENSG00000254510.1	RP11-867G23.10	-4.01	6.38e-05	0.00424	-0.15	-0.12	Crohn's disease;	chr11:65884359	chr11:66409158~66417137:+
BRCA	cis	rs6545883	0.772	rs1186709	ENSG00000212978.6	AC016747.3	4.01	6.39e-05	0.00424	0.17	0.12	Tuberculosis;	chr2:61462245	chr2:61141592~61144969:-
BRCA	cis	rs8058578	1	rs67128646	ENSG00000260911.2	RP11-196G11.2	4.01	6.39e-05	0.00424	0.12	0.12	Multiple myeloma;	chr16:30660776	chr16:31043150~31049868:+
BRCA	cis	rs2408955	0.522	rs973398	ENSG00000257735.1	RP11-370I10.6	-4.01	6.39e-05	0.00424	-0.15	-0.12	Glycated hemoglobin levels;	chr12:48097265	chr12:48350945~48442411:+
BRCA	cis	rs13217239	0.646	rs10456352	ENSG00000124549.13	BTN2A3P	4.01	6.39e-05	0.00424	0.13	0.12	Schizophrenia;	chr6:27022579	chr6:26421391~26432383:+
BRCA	cis	rs13217239	0.646	rs4583981	ENSG00000124549.13	BTN2A3P	4.01	6.39e-05	0.00424	0.13	0.12	Schizophrenia;	chr6:27024244	chr6:26421391~26432383:+
BRCA	cis	rs7772486	0.817	rs9322047	ENSG00000270638.1	RP3-466P17.1	4.01	6.39e-05	0.00424	0.14	0.12	Lobe attachment (rater-scored or self-reported);	chr6:146079258	chr6:145735570~145737218:+
BRCA	cis	rs71520386	0.632	rs12532922	ENSG00000226329.2	AC005682.6	-4.01	6.39e-05	0.00424	-0.13	-0.12	Fibrinogen levels;	chr7:22820796	chr7:22863874~22881350:-
BRCA	cis	rs8064024	0.538	rs12446456	ENSG00000267077.1	RP11-127I20.5	4.01	6.39e-05	0.00424	0.12	0.12	Cancer;	chr16:4872200	chr16:4795265~4796532:-
BRCA	cis	rs4263408	0.654	rs305827	ENSG00000224097.5	RP11-472B18.1	4.01	6.39e-05	0.00424	0.16	0.12	Plasma amyloid beta peptide concentrations (ABx-40);	chr4:39758369	chr4:39480255~39481905:+
BRCA	cis	rs11686241	0.935	rs487276	ENSG00000241520.1	AC098820.4	4.01	6.39e-05	0.00424	0.18	0.12	Cancer;	chr2:216521213	chr2:216483032~216487196:-
BRCA	cis	rs11098499	0.954	rs10008392	ENSG00000225892.3	RP11-384K6.2	4.01	6.39e-05	0.00424	0.12	0.12	Corneal astigmatism;	chr4:119397684	chr4:118632274~118634759:+
BRCA	cis	rs6012564	1	rs730543	ENSG00000227431.4	CSE1L-AS1	-4.01	6.39e-05	0.00424	-0.15	-0.12	Anger;	chr20:49019178	chr20:49040463~49046044:-
BRCA	cis	rs6095360	0.934	rs6019581	ENSG00000222365.1	SNORD12B	4.01	6.39e-05	0.00424	0.13	0.12	Intelligence (multi-trait analysis);	chr20:49011035	chr20:49280319~49280409:+
BRCA	cis	rs2832191	0.716	rs7509628	ENSG00000215533.7	LINC00189	-4.01	6.39e-05	0.00424	-0.14	-0.12	Dental caries;	chr21:29081931	chr21:29193480~29288205:+
BRCA	cis	rs9868809	0.505	rs11708786	ENSG00000225399.4	RP11-3B7.1	-4.01	6.39e-05	0.00424	-0.17	-0.12	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48715221	chr3:49260085~49261316:+
BRCA	cis	rs8060686	0.516	rs7193701	ENSG00000261469.1	RP11-96D1.6	4.01	6.39e-05	0.00424	0.14	0.12	HDL cholesterol;Metabolic syndrome;	chr16:68151257	chr16:68236845~68237667:-
BRCA	cis	rs2731006	0.64	rs2730999	ENSG00000257114.2	RP11-25I15.3	-4.01	6.39e-05	0.00424	-0.2	-0.12	Panic disorder;	chr12:42787027	chr12:42692216~42717119:+
BRCA	cis	rs875971	0.66	rs801192	ENSG00000229180.5	GS1-124K5.11	-4.01	6.39e-05	0.00424	-0.11	-0.12	Aortic root size;	chr7:66566965	chr7:66526088~66542624:-
BRCA	cis	rs875971	0.66	rs801190	ENSG00000229180.5	GS1-124K5.11	-4.01	6.39e-05	0.00424	-0.11	-0.12	Aortic root size;	chr7:66568046	chr7:66526088~66542624:-
BRCA	cis	rs875971	0.66	rs3857686	ENSG00000229180.5	GS1-124K5.11	-4.01	6.39e-05	0.00424	-0.11	-0.12	Aortic root size;	chr7:66571204	chr7:66526088~66542624:-
BRCA	cis	rs2229238	0.911	rs3811448	ENSG00000272030.1	RP1-178F15.4	-4.01	6.39e-05	0.00424	-0.17	-0.12	Coronary heart disease;	chr1:154544102	chr1:153631438~153634397:-
BRCA	cis	rs2229238	0.911	rs3811449	ENSG00000272030.1	RP1-178F15.4	-4.01	6.39e-05	0.00424	-0.17	-0.12	Coronary heart disease;	chr1:154545028	chr1:153631438~153634397:-
BRCA	cis	rs7712401	1	rs7712401	ENSG00000251538.4	RP11-166A12.1	4.01	6.4e-05	0.00424	0.14	0.12	Mean platelet volume;	chr5:123038764	chr5:122628952~122730685:-
BRCA	cis	rs7703051	0.585	rs918623	ENSG00000271815.1	CTD-2235C13.3	-4.01	6.4e-05	0.00424	-0.18	-0.12	Age-related diseases, mortality and associated endophenotypes;LDL cholesterol;Age-related disease endophenotypes;	chr5:75300857	chr5:75363760~75364242:+
BRCA	cis	rs28374715	0.532	rs7168431	ENSG00000247556.5	OIP5-AS1	4.01	6.4e-05	0.00424	0.14	0.12	Ulcerative colitis;	chr15:41380186	chr15:41283990~41309737:+
BRCA	cis	rs28374715	0.532	rs11854820	ENSG00000247556.5	OIP5-AS1	4.01	6.4e-05	0.00424	0.14	0.12	Ulcerative colitis;	chr15:41384328	chr15:41283990~41309737:+
BRCA	cis	rs6088580	0.634	rs6059880	ENSG00000275784.1	RP5-1125A11.6	-4.01	6.4e-05	0.00424	-0.13	-0.12	Glomerular filtration rate (creatinine);	chr20:34500864	chr20:33989480~33991818:-
BRCA	cis	rs71636778	0.509	rs6659176	ENSG00000260063.1	RP5-968P14.2	-4.01	6.4e-05	0.00424	-0.28	-0.12	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26913429	chr1:26692132~26694131:-
BRCA	cis	rs35306767	0.903	rs765867	ENSG00000229869.1	RP11-363N22.2	-4.01	6.4e-05	0.00424	-0.19	-0.12	Eosinophil percentage of granulocytes;	chr10:823961	chr10:933026~942743:+
BRCA	cis	rs2191566	0.664	rs4482396	ENSG00000266921.1	RP11-15A1.7	-4.01	6.4e-05	0.00425	-0.15	-0.12	Acute lymphoblastic leukemia (childhood);	chr19:44057847	chr19:43996896~44002836:-
BRCA	cis	rs10448080	0.879	rs240946	ENSG00000246339.5	EXTL3-AS1	4.01	6.4e-05	0.00425	0.13	0.12	Height;	chr8:28711388	chr8:28696198~28701464:-
BRCA	cis	rs7267979	0.528	rs34485039	ENSG00000277938.1	RP5-965G21.3	-4.01	6.4e-05	0.00425	-0.15	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25603127	chr20:25229150~25231933:+
BRCA	cis	rs17270561	0.609	rs1317510	ENSG00000272462.2	U91328.19	-4.01	6.4e-05	0.00425	-0.15	-0.12	Iron status biomarkers;	chr6:25778696	chr6:25992662~26001775:+
BRCA	cis	rs7703051	0.601	rs10474433	ENSG00000271815.1	CTD-2235C13.3	-4.01	6.4e-05	0.00425	-0.16	-0.12	Age-related diseases, mortality and associated endophenotypes;LDL cholesterol;Age-related disease endophenotypes;	chr5:75321018	chr5:75363760~75364242:+
BRCA	cis	rs6012564	0.893	rs6019516	ENSG00000227431.4	CSE1L-AS1	-4.01	6.4e-05	0.00425	-0.16	-0.12	Anger;	chr20:48913613	chr20:49040463~49046044:-
BRCA	cis	rs9788721	0.836	rs55983731	ENSG00000261762.1	RP11-650L12.2	-4.01	6.4e-05	0.00425	-0.15	-0.12	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78442927	chr15:78589123~78591276:-
BRCA	cis	rs8054556	1	rs4318227	ENSG00000261367.1	RP11-455F5.4	-4.01	6.4e-05	0.00425	-0.14	-0.12	Autism spectrum disorder or schizophrenia;	chr16:29973518	chr16:30107675~30110541:+
BRCA	cis	rs8098244	0.708	rs1154244	ENSG00000265752.2	RP11-403A21.1	4.01	6.41e-05	0.00425	0.17	0.12	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23964052	chr18:23957754~23982556:-
BRCA	cis	rs853679	0.517	rs4711164	ENSG00000261839.1	RP1-265C24.8	4.01	6.41e-05	0.00425	0.17	0.12	Depression;	chr6:28147378	chr6:28136849~28139678:+
BRCA	cis	rs853679	0.517	rs4711165	ENSG00000261839.1	RP1-265C24.8	4.01	6.41e-05	0.00425	0.17	0.12	Depression;	chr6:28147406	chr6:28136849~28139678:+
BRCA	cis	rs853679	0.517	rs4713148	ENSG00000261839.1	RP1-265C24.8	4.01	6.41e-05	0.00425	0.17	0.12	Depression;	chr6:28148143	chr6:28136849~28139678:+
BRCA	cis	rs853679	0.517	rs9348794	ENSG00000261839.1	RP1-265C24.8	4.01	6.41e-05	0.00425	0.17	0.12	Depression;	chr6:28149979	chr6:28136849~28139678:+
BRCA	cis	rs853679	0.517	rs9295758	ENSG00000261839.1	RP1-265C24.8	4.01	6.41e-05	0.00425	0.17	0.12	Depression;	chr6:28152885	chr6:28136849~28139678:+
BRCA	cis	rs853679	0.517	rs17774663	ENSG00000261839.1	RP1-265C24.8	4.01	6.41e-05	0.00425	0.17	0.12	Depression;	chr6:28153120	chr6:28136849~28139678:+
BRCA	cis	rs853679	0.513	rs9468296	ENSG00000261839.1	RP1-265C24.8	4.01	6.41e-05	0.00425	0.17	0.12	Depression;	chr6:28145952	chr6:28136849~28139678:+
BRCA	cis	rs2243480	0.711	rs2420172	ENSG00000237026.1	RP11-328P23.2	-4.01	6.41e-05	0.00425	-0.23	-0.12	Diabetic kidney disease;	chr7:66170354	chr7:65235790~65236723:-
BRCA	cis	rs7937890	0.559	rs2597196	ENSG00000254418.1	RP11-21L19.1	-4.01	6.41e-05	0.00425	-0.14	-0.12	Mitochondrial DNA levels;	chr11:14470055	chr11:14262846~14273691:-
BRCA	cis	rs2625529	0.712	rs2054601	ENSG00000260037.4	CTD-2524L6.3	-4.01	6.41e-05	0.00425	-0.18	-0.12	Red blood cell count;	chr15:71892627	chr15:71818396~71823384:+
BRCA	cis	rs2908197	0.737	rs59755579	ENSG00000186704.9	DTX2P1	4.01	6.41e-05	0.00425	0.14	0.12	3-hydroxypropylmercapturic acid levels in smokers;	chr7:76363127	chr7:76978617~77004308:+
BRCA	cis	rs2731006	0.592	rs2678113	ENSG00000257114.2	RP11-25I15.3	4.01	6.41e-05	0.00425	0.2	0.12	Panic disorder;	chr12:42767047	chr12:42692216~42717119:+
BRCA	cis	rs6599077	0.95	rs4676560	ENSG00000223797.4	ENTPD3-AS1	4.01	6.41e-05	0.00425	0.15	0.12	Sleep-related phenotypes;	chr3:40056158	chr3:40313802~40453329:-
BRCA	cis	rs6599077	1	rs6809231	ENSG00000223797.4	ENTPD3-AS1	4.01	6.41e-05	0.00425	0.15	0.12	Sleep-related phenotypes;	chr3:40056298	chr3:40313802~40453329:-
BRCA	cis	rs853679	0.76	rs967005	ENSG00000204709.4	LINC01556	4.01	6.41e-05	0.00425	0.2	0.12	Depression;	chr6:28242910	chr6:28943877~28944537:+
BRCA	cis	rs12705849	0.797	rs12705847	ENSG00000214194.7	LINC00998	4.01	6.41e-05	0.00425	0.15	0.12	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Eosinophil counts;	chr7:113114047	chr7:113116718~113118613:-
BRCA	cis	rs11711311	1	rs4362695	ENSG00000241529.3	RN7SL767P	-4.01	6.41e-05	0.00425	-0.14	-0.12	IgG glycosylation;	chr3:113816009	chr3:113632704~113632998:+
BRCA	cis	rs755249	0.501	rs4660669	ENSG00000237624.1	OXCT2P1	-4.01	6.41e-05	0.00426	-0.16	-0.12	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39341786	chr1:39514956~39516490:+
BRCA	cis	rs4218	0.638	rs8042516	ENSG00000259732.1	RP11-59H7.3	-4.01	6.42e-05	0.00426	-0.15	-0.12	Social communication problems;	chr15:59067525	chr15:59121034~59133250:+
BRCA	cis	rs6963495	0.818	rs117907809	ENSG00000223886.3	RP11-251G23.2	4.01	6.42e-05	0.00426	0.19	0.12	Bipolar disorder (body mass index interaction);	chr7:105528025	chr7:105530209~105530671:+
BRCA	cis	rs801193	1	rs3800812	ENSG00000272831.1	RP11-792A8.4	4.01	6.42e-05	0.00426	0.11	0.12	Aortic root size;	chr7:66758474	chr7:66739829~66740385:-
BRCA	cis	rs801193	1	rs4279493	ENSG00000272831.1	RP11-792A8.4	4.01	6.42e-05	0.00426	0.11	0.12	Aortic root size;	chr7:66761633	chr7:66739829~66740385:-
BRCA	cis	rs853679	0.76	rs9393910	ENSG00000204709.4	LINC01556	4.01	6.42e-05	0.00426	0.2	0.12	Depression;	chr6:28240414	chr6:28943877~28944537:+
BRCA	cis	rs7011507	0.513	rs10087276	ENSG00000279881.1	RP11-513O13.1	-4.01	6.42e-05	0.00426	-0.14	-0.12	Inflammatory bowel disease;Ulcerative colitis;	chr8:48518124	chr8:48428143~48431041:-
BRCA	cis	rs875971	0.862	rs2088653	ENSG00000273024.4	INTS4P2	4.01	6.42e-05	0.00426	0.14	0.12	Aortic root size;	chr7:66343621	chr7:65647864~65715661:+
BRCA	cis	rs875971	0.862	rs6460293	ENSG00000273024.4	INTS4P2	4.01	6.42e-05	0.00426	0.14	0.12	Aortic root size;	chr7:66345205	chr7:65647864~65715661:+
BRCA	cis	rs2289328	1	rs2289328	ENSG00000259211.1	RP11-64K12.8	4.01	6.42e-05	0.00426	0.19	0.12	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr15:40413218	chr15:40464193~40466726:-
BRCA	cis	rs6142618	0.583	rs6119771	ENSG00000275576.1	RP5-836N17.4	-4.01	6.42e-05	0.00426	-0.14	-0.12	Inflammatory bowel disease;	chr20:32182572	chr20:32116171~32116629:+
BRCA	cis	rs17407555	0.518	rs16891234	ENSG00000250413.1	RP11-448G15.1	4.01	6.42e-05	0.00426	0.18	0.12	Schizophrenia (age at onset);	chr4:9944539	chr4:10006482~10009725:+
BRCA	cis	rs2302465	0.86	rs74799497	ENSG00000273133.1	RP11-799M12.2	-4.01	6.42e-05	0.00426	-0.24	-0.12	Blood protein levels;	chr4:15598740	chr4:15563698~15564253:-
BRCA	cis	rs59868192	0.925	rs1002774	ENSG00000246740.2	PLA2G4E-AS1	4.01	6.42e-05	0.00426	0.24	0.12	White blood cell count;	chr15:41969583	chr15:41972763~41999094:+
BRCA	cis	rs2243480	1	rs6958289	ENSG00000237026.1	RP11-328P23.2	-4.01	6.42e-05	0.00426	-0.23	-0.12	Diabetic kidney disease;	chr7:66192124	chr7:65235790~65236723:-
BRCA	cis	rs4374383	0.884	rs10173553	ENSG00000243389.1	AC012442.5	-4.01	6.43e-05	0.00426	-0.16	-0.12	Hepatitis C induced liver fibrosis;	chr2:111996306	chr2:112589040~112614431:+
BRCA	cis	rs2191566	0.664	rs4803669	ENSG00000266921.1	RP11-15A1.7	-4.01	6.43e-05	0.00426	-0.15	-0.12	Acute lymphoblastic leukemia (childhood);	chr19:44035809	chr19:43996896~44002836:-
BRCA	cis	rs812925	0.519	rs2694627	ENSG00000273302.1	RP11-493E12.2	-4.01	6.43e-05	0.00426	-0.11	-0.12	Immature fraction of reticulocytes;	chr2:61398371	chr2:61199979~61200769:+
BRCA	cis	rs11098499	0.909	rs28555550	ENSG00000260404.2	RP11-384K6.6	4.01	6.43e-05	0.00426	0.12	0.12	Corneal astigmatism;	chr4:119289885	chr4:118591773~118633729:+
BRCA	cis	rs11098499	1	rs28419773	ENSG00000260404.2	RP11-384K6.6	4.01	6.43e-05	0.00426	0.12	0.12	Corneal astigmatism;	chr4:119289906	chr4:118591773~118633729:+
BRCA	cis	rs4489787	0.892	rs2705161	ENSG00000240399.1	RP1-228P16.1	4.01	6.43e-05	0.00426	0.19	0.12	Prostate cancer (SNP x SNP interaction);	chr12:48506683	chr12:48054813~48055591:-
BRCA	cis	rs875971	0.895	rs12698520	ENSG00000229180.5	GS1-124K5.11	4.01	6.43e-05	0.00426	0.11	0.12	Aortic root size;	chr7:66453720	chr7:66526088~66542624:-
BRCA	cis	rs1845631	0.755	rs2729958	ENSG00000272338.2	RP11-722E23.2	4.01	6.43e-05	0.00426	0.14	0.12	Facial morphology (factor 17, height of vermillion upper lip);	chr8:34204158	chr8:33360839~33361415:-
BRCA	cis	rs1396626	0.89	rs4950067	ENSG00000235501.4	RP4-639F20.1	-4.01	6.43e-05	0.00427	-0.17	-0.12	Diabetic kidney disease;	chr1:95550623	chr1:94927566~94963270:+
BRCA	cis	rs6071166	0.683	rs1885458	ENSG00000224635.1	RP4-564F22.5	-4.01	6.43e-05	0.00427	-0.15	-0.12	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38691891	chr20:38406011~38416797:-
BRCA	cis	rs1371614	0.588	rs10181727	ENSG00000272148.1	RP11-195B17.1	-4.01	6.43e-05	0.00427	-0.14	-0.12	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26948377	chr2:27062428~27062907:-
BRCA	cis	rs1371614	0.545	rs1057115	ENSG00000272148.1	RP11-195B17.1	-4.01	6.43e-05	0.00427	-0.14	-0.12	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26949201	chr2:27062428~27062907:-
BRCA	cis	rs7131987	0.675	rs2194515	ENSG00000257176.2	RP11-996F15.2	4.01	6.44e-05	0.00427	0.15	0.12	QT interval;	chr12:29397450	chr12:29280418~29317848:-
BRCA	cis	rs875971	0.502	rs1796227	ENSG00000232559.3	GS1-124K5.12	-4.01	6.44e-05	0.00427	-0.17	-0.12	Aortic root size;	chr7:66622032	chr7:66554588~66576923:-
BRCA	cis	rs6088580	0.634	rs6087587	ENSG00000275784.1	RP5-1125A11.6	-4.01	6.44e-05	0.00427	-0.13	-0.12	Glomerular filtration rate (creatinine);	chr20:34470823	chr20:33989480~33991818:-
BRCA	cis	rs62229266	0.771	rs2835232	ENSG00000214914.3	RPL23AP3	4.01	6.44e-05	0.00427	0.15	0.12	Mitral valve prolapse;	chr21:36021129	chr21:36016079~36016546:-
BRCA	cis	rs7267979	1	rs2257982	ENSG00000274973.1	RP13-401N8.7	-4.01	6.44e-05	0.00427	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25288994	chr20:25845497~25845862:+
BRCA	cis	rs7267979	1	rs2257985	ENSG00000274973.1	RP13-401N8.7	-4.01	6.44e-05	0.00427	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25289107	chr20:25845497~25845862:+
BRCA	cis	rs7267979	1	rs2257988	ENSG00000274973.1	RP13-401N8.7	-4.01	6.44e-05	0.00427	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25289367	chr20:25845497~25845862:+
BRCA	cis	rs9392556	0.829	rs629362	ENSG00000230648.1	RP3-406P24.3	4.01	6.44e-05	0.00427	0.15	0.12	Blood metabolite levels;	chr6:4121597	chr6:4018843~4021215:-
BRCA	cis	rs4664293	0.647	rs1863686	ENSG00000226266.5	AC009961.3	-4.01	6.44e-05	0.00427	-0.15	-0.12	Monocyte percentage of white cells;	chr2:159647538	chr2:159670708~159712435:-
BRCA	cis	rs6012564	1	rs730543	ENSG00000222365.1	SNORD12B	-4.01	6.44e-05	0.00427	-0.13	-0.12	Anger;	chr20:49019178	chr20:49280319~49280409:+
BRCA	cis	rs7520050	0.966	rs7524495	ENSG00000234329.1	RP11-767N6.2	-4.01	6.44e-05	0.00427	-0.12	-0.12	Reticulocyte count;Red blood cell count;	chr1:45801260	chr1:45651039~45651826:-
BRCA	cis	rs6088590	0.735	rs6060001	ENSG00000269202.1	RP4-614O4.12	4.01	6.44e-05	0.00427	0.13	0.12	Coronary artery disease;	chr20:34706549	chr20:35201747~35203288:-
BRCA	cis	rs6545883	0.929	rs1209434	ENSG00000212978.6	AC016747.3	4.01	6.44e-05	0.00427	0.17	0.12	Tuberculosis;	chr2:61445823	chr2:61141592~61144969:-
BRCA	cis	rs72615157	0.539	rs12673441	ENSG00000235713.1	RP4-604G5.3	-4.01	6.44e-05	0.00427	-0.15	-0.12	Lung function (FEV1/FVC);	chr7:100072705	chr7:99992397~99993050:+
BRCA	cis	rs6840360	0.901	rs1443094	ENSG00000278978.1	RP11-164P12.5	-4.01	6.44e-05	0.00427	-0.14	-0.12	Intelligence (multi-trait analysis);	chr4:151535572	chr4:151669786~151670503:+
BRCA	cis	rs295490	0.748	rs17395611	ENSG00000272656.1	RP11-219D15.3	-4.01	6.44e-05	0.00427	-0.29	-0.12	PR interval in Tripanosoma cruzi seropositivity;	chr3:139425773	chr3:139349024~139349371:-
BRCA	cis	rs10852606	0.666	rs11649294	ENSG00000260381.2	RP11-429P3.5	-4.01	6.45e-05	0.00427	-0.17	-0.12	Glioma;Glioblastoma;	chr16:50057424	chr16:50100339~50121943:-
BRCA	cis	rs853679	0.542	rs9393892	ENSG00000216901.1	AL022393.7	4.01	6.45e-05	0.00427	0.18	0.12	Depression;	chr6:28113616	chr6:28176188~28176674:+
BRCA	cis	rs962856	0.964	rs12473253	ENSG00000236605.1	AC023115.4	4.01	6.45e-05	0.00427	0.14	0.12	Pancreatic cancer;	chr2:67419189	chr2:67324627~67325304:+
BRCA	cis	rs8064024	0.783	rs2341986	ENSG00000267077.1	RP11-127I20.5	4.01	6.45e-05	0.00428	0.12	0.12	Cancer;	chr16:4769495	chr16:4795265~4796532:-
BRCA	cis	rs6751744	0.855	rs10206214	ENSG00000224152.1	AC009506.1	-4.01	6.45e-05	0.00428	-0.15	-0.12	Dysphagia;	chr2:159507781	chr2:159615296~159617082:+
BRCA	cis	rs6751744	0.855	rs1425045	ENSG00000224152.1	AC009506.1	-4.01	6.45e-05	0.00428	-0.15	-0.12	Dysphagia;	chr2:159508236	chr2:159615296~159617082:+
BRCA	cis	rs6719977	0.569	rs6756258	ENSG00000226491.1	FTOP1	-4.01	6.45e-05	0.00428	-0.14	-0.12	Hyperactive-impulsive symptoms;	chr2:42741888	chr2:42797225~42798712:-
BRCA	cis	rs1371614	0.523	rs893789	ENSG00000272148.1	RP11-195B17.1	4.01	6.45e-05	0.00428	0.14	0.12	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26961102	chr2:27062428~27062907:-
BRCA	cis	rs6545883	0.794	rs778152	ENSG00000273302.1	RP11-493E12.2	-4.01	6.45e-05	0.00428	-0.11	-0.12	Tuberculosis;	chr2:61381405	chr2:61199979~61200769:+
BRCA	cis	rs4819052	0.851	rs34101026	ENSG00000215447.6	BX322557.10	-4.01	6.45e-05	0.00428	-0.13	-0.12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45242285	chr21:45288052~45291738:+
BRCA	cis	rs4819052	0.851	rs2838828	ENSG00000215447.6	BX322557.10	-4.01	6.45e-05	0.00428	-0.13	-0.12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45243508	chr21:45288052~45291738:+
BRCA	cis	rs4819052	0.851	rs13049337	ENSG00000215447.6	BX322557.10	-4.01	6.45e-05	0.00428	-0.13	-0.12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45243545	chr21:45288052~45291738:+
BRCA	cis	rs7647973	1	rs7619789	ENSG00000244380.1	RP11-24C3.2	4.01	6.45e-05	0.00428	0.16	0.12	Menarche (age at onset);	chr3:49438830	chr3:48440352~48446656:-
BRCA	cis	rs7647973	0.922	rs57273516	ENSG00000244380.1	RP11-24C3.2	4.01	6.45e-05	0.00428	0.16	0.12	Menarche (age at onset);	chr3:49445641	chr3:48440352~48446656:-
BRCA	cis	rs9470794	0.915	rs75443052	ENSG00000204110.6	RP1-153P14.8	-4.01	6.45e-05	0.00428	-0.26	-0.12	Type 2 diabetes;	chr6:37834158	chr6:37507348~37535616:+
BRCA	cis	rs7772486	0.846	rs9403767	ENSG00000270638.1	RP3-466P17.1	4.01	6.45e-05	0.00428	0.15	0.12	Lobe attachment (rater-scored or self-reported);	chr6:146081250	chr6:145735570~145737218:+
BRCA	cis	rs17027633	0.881	rs76940009	ENSG00000234020.1	CHIAP3	-4.01	6.45e-05	0.00428	-0.3	-0.12	Cerebrospinal fluid t-tau:AB1-42 ratio;	chr1:111466408	chr1:111353275~111367409:-
BRCA	cis	rs17065868	1	rs17278318	ENSG00000237361.2	TUSC8	4.01	6.46e-05	0.00428	0.28	0.12	Antineutrophil cytoplasmic antibody-associated vasculitis;	chr13:44565010	chr13:44400250~44405984:-
BRCA	cis	rs3760982	1	rs3760983	ENSG00000267191.1	RP11-15A1.2	4.01	6.46e-05	0.00428	0.15	0.12	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43782508	chr19:43902001~43926545:+
BRCA	cis	rs875971	0.929	rs6970860	ENSG00000265600.1	AC006480.1	-4.01	6.46e-05	0.00428	-0.15	-0.12	Aortic root size;	chr7:66511647	chr7:67356680~67356779:+
BRCA	cis	rs1005277	0.529	rs1780125	ENSG00000276805.1	RP11-291L22.6	4.01	6.46e-05	0.00428	0.13	0.12	Extrinsic epigenetic age acceleration;	chr10:38242448	chr10:38451030~38451785:+
BRCA	cis	rs875971	0.964	rs778721	ENSG00000265600.1	AC006480.1	-4.01	6.46e-05	0.00428	-0.15	-0.12	Aortic root size;	chr7:66380410	chr7:67356680~67356779:+
BRCA	cis	rs73222236	0.825	rs34962604	ENSG00000239213.4	NCK1-AS1	4.01	6.46e-05	0.00428	0.14	0.12	Coronary artery disease;	chr3:136511148	chr3:136841726~136862054:-
BRCA	cis	rs1910358	0.648	rs6896322	ENSG00000248874.4	C5orf17	-4.01	6.46e-05	0.00428	-0.16	-0.12	Venous thromboembolism (SNP x SNP interaction);	chr5:24007868	chr5:23951348~24178263:+
BRCA	cis	rs763121	0.853	rs9306329	ENSG00000225450.1	RP3-508I15.14	-4.01	6.46e-05	0.00428	-0.13	-0.12	Menopause (age at onset);	chr22:38676449	chr22:38739003~38749041:+
BRCA	cis	rs763121	0.853	rs5750662	ENSG00000225450.1	RP3-508I15.14	-4.01	6.46e-05	0.00428	-0.13	-0.12	Menopause (age at onset);	chr22:38676467	chr22:38739003~38749041:+
BRCA	cis	rs763121	0.853	rs5750664	ENSG00000225450.1	RP3-508I15.14	-4.01	6.46e-05	0.00428	-0.13	-0.12	Menopause (age at onset);	chr22:38676764	chr22:38739003~38749041:+
BRCA	cis	rs763121	0.626	rs5757236	ENSG00000225450.1	RP3-508I15.14	-4.01	6.46e-05	0.00428	-0.13	-0.12	Menopause (age at onset);	chr22:38677819	chr22:38739003~38749041:+
BRCA	cis	rs763121	0.853	rs6001191	ENSG00000225450.1	RP3-508I15.14	-4.01	6.46e-05	0.00428	-0.13	-0.12	Menopause (age at onset);	chr22:38678447	chr22:38739003~38749041:+
BRCA	cis	rs801193	0.935	rs2659899	ENSG00000273142.1	RP11-458F8.4	-4.01	6.46e-05	0.00428	-0.11	-0.12	Aortic root size;	chr7:66721734	chr7:66902857~66906297:+
BRCA	cis	rs801193	0.901	rs4273746	ENSG00000272831.1	RP11-792A8.4	-4.01	6.46e-05	0.00428	-0.11	-0.12	Aortic root size;	chr7:66836124	chr7:66739829~66740385:-
BRCA	cis	rs9733	0.818	rs6694531	ENSG00000203804.4	ADAMTSL4-AS1	-4.01	6.46e-05	0.00428	-0.13	-0.12	Tonsillectomy;	chr1:150711036	chr1:150560202~150574552:-
BRCA	cis	rs9733	0.818	rs10888388	ENSG00000203804.4	ADAMTSL4-AS1	-4.01	6.46e-05	0.00428	-0.13	-0.12	Tonsillectomy;	chr1:150714820	chr1:150560202~150574552:-
BRCA	cis	rs9733	0.818	rs12130363	ENSG00000203804.4	ADAMTSL4-AS1	-4.01	6.46e-05	0.00428	-0.13	-0.12	Tonsillectomy;	chr1:150716120	chr1:150560202~150574552:-
BRCA	cis	rs2255336	0.938	rs7298494	ENSG00000245648.1	RP11-277P12.20	-4.01	6.46e-05	0.00428	-0.2	-0.12	Blood protein levels;	chr12:10460666	chr12:10363769~10398506:+
BRCA	cis	rs4689592	0.546	rs10937782	ENSG00000245468.3	RP11-367J11.3	4.01	6.46e-05	0.00428	0.13	0.12	Monocyte percentage of white cells;	chr4:7055379	chr4:7094571~7103385:-
BRCA	cis	rs1048886	0.872	rs78892979	ENSG00000271967.1	RP11-134K13.4	-4.01	6.47e-05	0.00428	-0.19	-0.12	Type 2 diabetes;	chr6:70495559	chr6:70596438~70596980:+
BRCA	cis	rs1048886	0.872	rs77092253	ENSG00000271967.1	RP11-134K13.4	-4.01	6.47e-05	0.00428	-0.19	-0.12	Type 2 diabetes;	chr6:70505156	chr6:70596438~70596980:+
BRCA	cis	rs4835473	0.863	rs11735239	ENSG00000249741.2	RP11-673E1.3	4.01	6.47e-05	0.00428	0.14	0.12	Immature fraction of reticulocytes;	chr4:143689372	chr4:143911514~143912053:-
BRCA	cis	rs11035577	0.632	rs1507638	ENSG00000279675.1	RP11-454H19.2	4.01	6.47e-05	0.00429	0.19	0.12	Temperament (bipolar disorder);	chr11:39779780	chr11:40107244~40112599:-
BRCA	cis	rs875971	1	rs778726	ENSG00000265600.1	AC006480.1	-4.01	6.47e-05	0.00429	-0.15	-0.12	Aortic root size;	chr7:66363744	chr7:67356680~67356779:+
BRCA	cis	rs875971	0.767	rs1695815	ENSG00000265600.1	AC006480.1	-4.01	6.47e-05	0.00429	-0.15	-0.12	Aortic root size;	chr7:66366357	chr7:67356680~67356779:+
BRCA	cis	rs875971	1	rs778685	ENSG00000265600.1	AC006480.1	-4.01	6.47e-05	0.00429	-0.15	-0.12	Aortic root size;	chr7:66371189	chr7:67356680~67356779:+
BRCA	cis	rs875971	0.929	rs778682	ENSG00000265600.1	AC006480.1	-4.01	6.47e-05	0.00429	-0.15	-0.12	Aortic root size;	chr7:66372947	chr7:67356680~67356779:+
BRCA	cis	rs875971	0.964	rs11765965	ENSG00000265600.1	AC006480.1	-4.01	6.47e-05	0.00429	-0.15	-0.12	Aortic root size;	chr7:66377234	chr7:67356680~67356779:+
BRCA	cis	rs801193	1	rs2659912	ENSG00000273142.1	RP11-458F8.4	-4.01	6.47e-05	0.00429	-0.11	-0.12	Aortic root size;	chr7:66693012	chr7:66902857~66906297:+
BRCA	cis	rs4865762	0.904	rs39860	ENSG00000247796.2	CTD-2366F13.1	-4.01	6.47e-05	0.00429	-0.13	-0.12	Intraocular pressure;	chr5:53214703	chr5:53109842~53115126:+
BRCA	cis	rs1836229	0.874	rs6477358	ENSG00000225706.1	PTPRD-AS1	-4.01	6.47e-05	0.00429	-0.14	-0.12	Restless legs syndrome;	chr9:8832394	chr9:8858130~8862255:+
BRCA	cis	rs737008	0.96	rs34764020	ENSG00000262636.1	CTD-3088G3.4	-4.01	6.47e-05	0.00429	-0.17	-0.12	Obesity-related traits;	chr16:11284502	chr16:11380859~11381118:-
BRCA	cis	rs4374383	0.847	rs2230515	ENSG00000243389.1	AC012442.5	-4.01	6.47e-05	0.00429	-0.16	-0.12	Hepatitis C induced liver fibrosis;	chr2:111997424	chr2:112589040~112614431:+
BRCA	cis	rs2599510	0.693	rs2754514	ENSG00000276517.1	AL133243.2	-4.01	6.47e-05	0.00429	-0.15	-0.12	Interleukin-18 levels;	chr2:32563769	chr2:32526504~32529507:+
BRCA	cis	rs17684571	0.7	rs6904535	ENSG00000231441.1	RP11-472M19.2	4.01	6.47e-05	0.00429	0.18	0.12	Schizophrenia;	chr6:56767178	chr6:56844002~56864078:+
BRCA	cis	rs12122100	0.955	rs12141289	ENSG00000244371.2	PFN1P8	4.01	6.47e-05	0.00429	0.15	0.12	HIV-1 control;	chr1:147037912	chr1:146957117~146957659:-
BRCA	cis	rs875971	1	rs6958271	ENSG00000265600.1	AC006480.1	-4.01	6.47e-05	0.00429	-0.15	-0.12	Aortic root size;	chr7:66514344	chr7:67356680~67356779:+
BRCA	cis	rs875971	1	rs6958277	ENSG00000265600.1	AC006480.1	-4.01	6.47e-05	0.00429	-0.15	-0.12	Aortic root size;	chr7:66514362	chr7:67356680~67356779:+
BRCA	cis	rs9303280	0.617	rs6503525	ENSG00000266469.1	CTB-131K11.1	-4.01	6.47e-05	0.00429	-0.12	-0.12	Self-reported allergy;	chr17:39938921	chr17:39401793~39406233:+
BRCA	cis	rs55675132	0.548	rs6688350	ENSG00000226167.1	AP4B1-AS1	-4.01	6.47e-05	0.00429	-0.13	-0.12	Schizophrenia;	chr1:114813565	chr1:113856635~113901237:+
BRCA	cis	rs9381040	0.626	rs2272986	ENSG00000161912.16	ADCY10P1	4.01	6.47e-05	0.00429	0.14	0.12	Alzheimer's disease (late onset);	chr6:41070039	chr6:41101022~41140835:+
BRCA	cis	rs9381040	0.655	rs7738684	ENSG00000161912.16	ADCY10P1	4.01	6.47e-05	0.00429	0.14	0.12	Alzheimer's disease (late onset);	chr6:41070813	chr6:41101022~41140835:+
BRCA	cis	rs9381040	0.655	rs4140578	ENSG00000161912.16	ADCY10P1	4.01	6.47e-05	0.00429	0.14	0.12	Alzheimer's disease (late onset);	chr6:41074090	chr6:41101022~41140835:+
BRCA	cis	rs10457838	0.887	rs58644381	ENSG00000236591.1	RP11-162J8.3	-4.01	6.47e-05	0.00429	-0.17	-0.12	Post-traumatic stress disorder;	chr6:149073231	chr6:149027700~149032573:-
BRCA	cis	rs7914558	0.505	rs12260436	ENSG00000236937.2	PTGES3P4	4.01	6.48e-05	0.00429	0.17	0.12	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102981357	chr10:102845595~102845950:+
BRCA	cis	rs6545883	0.929	rs55806663	ENSG00000270820.4	RP11-355B11.2	4.01	6.48e-05	0.00429	0.14	0.12	Tuberculosis;	chr2:61513352	chr2:61471188~61484130:+
BRCA	cis	rs1005277	0.579	rs1780146	ENSG00000272983.1	RP11-508N22.12	4.01	6.48e-05	0.00429	0.13	0.12	Extrinsic epigenetic age acceleration;	chr10:38228946	chr10:38137337~38144399:+
BRCA	cis	rs2625529	0.526	rs8040828	ENSG00000260037.4	CTD-2524L6.3	4.01	6.48e-05	0.00429	0.16	0.12	Red blood cell count;	chr15:72200438	chr15:71818396~71823384:+
BRCA	cis	rs2704588	1	rs1246630	ENSG00000270720.1	RP11-84C13.2	-4.01	6.48e-05	0.00429	-0.19	-0.12	Longevity;	chr4:88898823	chr4:89119284~89119871:+
BRCA	cis	rs6736093	0.966	rs11681063	ENSG00000236307.2	EEF1E1P1	-4.01	6.48e-05	0.00429	-0.15	-0.12	Coronary artery disease;	chr2:111985765	chr2:111887914~111888741:+
BRCA	cis	rs853679	0.517	rs1340004	ENSG00000226314.6	ZNF192P1	-4.01	6.48e-05	0.00429	-0.19	-0.12	Depression;	chr6:28135913	chr6:28161781~28169594:+
BRCA	cis	rs9810890	1	rs73198827	ENSG00000242551.2	POU5F1P6	-4.01	6.48e-05	0.00429	-0.33	-0.12	Dental caries;	chr3:128770678	chr3:128674735~128677005:-
BRCA	cis	rs9810890	0.85	rs73198858	ENSG00000242551.2	POU5F1P6	-4.01	6.48e-05	0.00429	-0.33	-0.12	Dental caries;	chr3:128795218	chr3:128674735~128677005:-
BRCA	cis	rs9959145	1	rs9966118	ENSG00000267108.1	RP11-861E21.1	4.01	6.48e-05	0.00429	0.22	0.12	Immune response to smallpox vaccine (IL-6);	chr18:12548859	chr18:12432897~12437635:+
BRCA	cis	rs9959145	1	rs77079191	ENSG00000267108.1	RP11-861E21.1	4.01	6.48e-05	0.00429	0.22	0.12	Immune response to smallpox vaccine (IL-6);	chr18:12549379	chr18:12432897~12437635:+
BRCA	cis	rs7267979	0.668	rs2387977	ENSG00000276952.1	RP5-965G21.6	-4.01	6.48e-05	0.0043	-0.15	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25619140	chr20:25284915~25285588:-
BRCA	cis	rs6012564	1	rs3091866	ENSG00000222365.1	SNORD12B	-4.01	6.48e-05	0.0043	-0.13	-0.12	Anger;	chr20:49031816	chr20:49280319~49280409:+
BRCA	cis	rs7267979	1	rs2257432	ENSG00000274973.1	RP13-401N8.7	-4.01	6.48e-05	0.0043	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25290450	chr20:25845497~25845862:+
BRCA	cis	rs7267979	1	rs2258066	ENSG00000274973.1	RP13-401N8.7	-4.01	6.48e-05	0.0043	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25290690	chr20:25845497~25845862:+
BRCA	cis	rs7267979	1	rs2258135	ENSG00000274973.1	RP13-401N8.7	-4.01	6.48e-05	0.0043	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25291687	chr20:25845497~25845862:+
BRCA	cis	rs409045	0.9	rs423359	ENSG00000271874.1	CTD-2024P10.2	-4.01	6.48e-05	0.0043	-0.16	-0.12	Left ventricular mass;	chr5:34638058	chr5:34651457~34651888:-
BRCA	cis	rs1065852	0.526	rs9623489	ENSG00000205702.9	CYP2D7	4.01	6.48e-05	0.0043	0.11	0.12	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42001022	chr22:42140203~42144577:-
BRCA	cis	rs11892454	0.712	rs934073	ENSG00000217643.1	PTGES3P2	-4.01	6.48e-05	0.0043	-0.14	-0.12	Heschl's gyrus morphology;	chr2:25714296	chr2:25822469~25822950:+
BRCA	cis	rs6545883	0.894	rs6739427	ENSG00000212978.6	AC016747.3	-4.01	6.48e-05	0.0043	-0.17	-0.12	Tuberculosis;	chr2:61225744	chr2:61141592~61144969:-
BRCA	cis	rs300890	0.513	rs11100769	ENSG00000250326.1	RP11-284M14.1	-4.01	6.49e-05	0.0043	-0.14	-0.12	Nasopharyngeal carcinoma;	chr4:143122313	chr4:142933195~143184861:-
BRCA	cis	rs4478858	0.647	rs11581476	ENSG00000260386.4	LINC01225	-4.01	6.49e-05	0.0043	-0.15	-0.12	Alcohol dependence;	chr1:31244828	chr1:31500085~31540885:+
BRCA	cis	rs6088580	0.634	rs13041646	ENSG00000275784.1	RP5-1125A11.6	-4.01	6.49e-05	0.0043	-0.13	-0.12	Glomerular filtration rate (creatinine);	chr20:34495076	chr20:33989480~33991818:-
BRCA	cis	rs6840360	1	rs17360475	ENSG00000251611.1	RP11-610P16.1	4.01	6.49e-05	0.0043	0.11	0.12	Intelligence (multi-trait analysis);	chr4:151750488	chr4:151407551~151408835:-
BRCA	cis	rs1865760	1	rs3799371	ENSG00000272462.2	U91328.19	4.01	6.49e-05	0.0043	0.15	0.12	Height;	chr6:25912588	chr6:25992662~26001775:+
BRCA	cis	rs9840812	0.953	rs4678322	ENSG00000239213.4	NCK1-AS1	-4.01	6.49e-05	0.0043	-0.15	-0.12	Fibrinogen levels;	chr3:136093681	chr3:136841726~136862054:-
BRCA	cis	rs2562456	1	rs2562456	ENSG00000268555.1	RP11-678G14.3	4.01	6.49e-05	0.0043	0.15	0.12	Pain;	chr19:21483408	chr19:21570822~21587322:-
BRCA	cis	rs6545883	0.931	rs778765	ENSG00000270820.4	RP11-355B11.2	4.01	6.49e-05	0.0043	0.14	0.12	Tuberculosis;	chr2:61559250	chr2:61471188~61484130:+
BRCA	cis	rs8054556	1	rs4318227	ENSG00000214725.6	CDIPT-AS1	-4.01	6.49e-05	0.0043	-0.15	-0.12	Autism spectrum disorder or schizophrenia;	chr16:29973518	chr16:29863593~29868053:+
BRCA	cis	rs739496	0.843	rs616668	ENSG00000234608.6	MAPKAPK5-AS1	4.01	6.49e-05	0.0043	0.15	0.12	Platelet count;	chr12:111536476	chr12:111839764~111842902:-
BRCA	cis	rs995000	0.524	rs61775962	ENSG00000235545.1	RP11-230B22.1	-4.01	6.49e-05	0.0043	-0.14	-0.12	Triglyceride levels;	chr1:62733679	chr1:62688482~62710694:+
BRCA	cis	rs10457838	0.675	rs10782309	ENSG00000236591.1	RP11-162J8.3	4.01	6.49e-05	0.0043	0.17	0.12	Post-traumatic stress disorder;	chr6:149012041	chr6:149027700~149032573:-
BRCA	cis	rs7312933	0.584	rs6582391	ENSG00000257225.1	RP11-328C8.4	-4.01	6.49e-05	0.0043	-0.15	-0.12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42240884	chr12:42459366~42466128:+
BRCA	cis	rs11742741	0.806	rs17429271	ENSG00000248874.4	C5orf17	-4.01	6.5e-05	0.0043	-0.16	-0.12	Educational attainment;	chr5:24033730	chr5:23951348~24178263:+
BRCA	cis	rs3764021	0.527	rs11052423	ENSG00000256594.6	RP11-705C15.2	-4.01	6.5e-05	0.0043	-0.16	-0.12	Type 1 diabetes;	chr12:9687442	chr12:9633419~9658412:+
BRCA	cis	rs891378	1	rs7555030	ENSG00000274245.1	RP11-357P18.2	-4.01	6.5e-05	0.0043	-0.16	-0.12	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207335385	chr1:207372559~207373252:+
BRCA	cis	rs73198271	0.595	rs11780672	ENSG00000253893.2	FAM85B	4.01	6.5e-05	0.00431	0.21	0.12	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8726643	chr8:8167819~8226614:-
BRCA	cis	rs1994089	0.583	rs9303683	ENSG00000273687.1	RP5-837J1.6	4.01	6.5e-05	0.00431	0.14	0.12	Macrophage inflammatory protein 1b levels;	chr17:35209151	chr17:35018660~35018991:+
BRCA	cis	rs10463316	0.862	rs11740475	ENSG00000260581.1	CTB-113P19.4	4.01	6.5e-05	0.00431	0.14	0.12	Metabolite levels (Pyroglutamine);	chr5:151398436	chr5:151652275~151655449:+
BRCA	cis	rs2299587	0.519	rs3850746	ENSG00000253671.1	RP11-806O11.1	4.01	6.5e-05	0.00431	0.16	0.12	Economic and political preferences;	chr8:17930027	chr8:17808941~17820868:+
BRCA	cis	rs8016982	0.531	rs2241622	ENSG00000258999.1	RP11-114N19.3	4.01	6.5e-05	0.00431	0.18	0.12	Schizophrenia;	chr14:81270946	chr14:81107033~81170414:-
BRCA	cis	rs4218	0.597	rs62002544	ENSG00000259732.1	RP11-59H7.3	-4.01	6.5e-05	0.00431	-0.16	-0.12	Social communication problems;	chr15:59066663	chr15:59121034~59133250:+
BRCA	cis	rs11673344	0.523	rs6510584	ENSG00000276846.1	CTD-3220F14.3	4.01	6.51e-05	0.00431	0.15	0.12	Obesity-related traits;	chr19:37058699	chr19:37314868~37315620:-
BRCA	cis	rs11633886	0.528	rs3914852	ENSG00000273972.1	CTD-2306A12.1	4.01	6.51e-05	0.00431	0.14	0.12	Diisocyanate-induced asthma;	chr15:45808853	chr15:45702640~45703183:+
BRCA	cis	rs911119	1	rs3827143	ENSG00000270001.1	RP11-218C14.8	-4.01	6.51e-05	0.00431	-0.17	-0.12	Chronic kidney disease;	chr20:23638980	chr20:23631826~23632316:-
BRCA	cis	rs911119	0.909	rs3761279	ENSG00000270001.1	RP11-218C14.8	-4.01	6.51e-05	0.00431	-0.17	-0.12	Chronic kidney disease;	chr20:23639438	chr20:23631826~23632316:-
BRCA	cis	rs911119	0.779	rs3761280	ENSG00000270001.1	RP11-218C14.8	-4.01	6.51e-05	0.00431	-0.17	-0.12	Chronic kidney disease;	chr20:23639439	chr20:23631826~23632316:-
BRCA	cis	rs911119	1	rs34897231	ENSG00000270001.1	RP11-218C14.8	-4.01	6.51e-05	0.00431	-0.17	-0.12	Chronic kidney disease;	chr20:23639631	chr20:23631826~23632316:-
BRCA	cis	rs911119	1	rs35488434	ENSG00000270001.1	RP11-218C14.8	-4.01	6.51e-05	0.00431	-0.17	-0.12	Chronic kidney disease;	chr20:23639764	chr20:23631826~23632316:-
BRCA	cis	rs911119	0.955	rs59059917	ENSG00000270001.1	RP11-218C14.8	-4.01	6.51e-05	0.00431	-0.17	-0.12	Chronic kidney disease;	chr20:23615038	chr20:23631826~23632316:-
BRCA	cis	rs10864907	0.681	rs10177564	ENSG00000231747.1	AC079922.2	-4.01	6.51e-05	0.00431	-0.12	-0.12	Pulmonary function;	chr2:112970744	chr2:112621809~112622167:-
BRCA	cis	rs7481584	0.646	rs434114	ENSG00000236710.1	AC108448.2	4.01	6.51e-05	0.00431	0.16	0.12	Calcium levels;	chr11:3028980	chr11:3084393~3085443:-
BRCA	cis	rs7481584	0.624	rs511990	ENSG00000236710.1	AC108448.2	4.01	6.51e-05	0.00431	0.16	0.12	Calcium levels;	chr11:3031706	chr11:3084393~3085443:-
BRCA	cis	rs7481584	0.581	rs366422	ENSG00000236710.1	AC108448.2	4.01	6.51e-05	0.00431	0.16	0.12	Calcium levels;	chr11:3032643	chr11:3084393~3085443:-
BRCA	cis	rs11098499	0.954	rs6838814	ENSG00000260404.2	RP11-384K6.6	4.01	6.51e-05	0.00431	0.12	0.12	Corneal astigmatism;	chr4:119471288	chr4:118591773~118633729:+
BRCA	cis	rs6545883	0.524	rs4599092	ENSG00000273302.1	RP11-493E12.2	-4.01	6.51e-05	0.00431	-0.11	-0.12	Tuberculosis;	chr2:61271833	chr2:61199979~61200769:+
BRCA	cis	rs9818758	0.607	rs9837625	ENSG00000225399.4	RP11-3B7.1	-4.01	6.51e-05	0.00431	-0.2	-0.12	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49178533	chr3:49260085~49261316:+
BRCA	cis	rs8058578	0.832	rs35969813	ENSG00000274678.1	RP11-2C24.7	4.01	6.51e-05	0.00431	0.16	0.12	Multiple myeloma;	chr16:30703096	chr16:30821338~30821884:+
BRCA	cis	rs7267979	0.932	rs6138600	ENSG00000276952.1	RP5-965G21.6	4.01	6.51e-05	0.00431	0.15	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25540710	chr20:25284915~25285588:-
BRCA	cis	rs922692	0.776	rs11857532	ENSG00000261143.1	ADAMTS7P3	4.01	6.51e-05	0.00431	0.15	0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78675926	chr15:77976042~77993057:+
BRCA	cis	rs10946940	0.864	rs13201411	ENSG00000219392.1	RP1-265C24.5	4.01	6.51e-05	0.00431	0.16	0.12	Systemic lupus erythematosus;	chr6:27530438	chr6:28115628~28116551:+
BRCA	cis	rs6736093	0.966	rs2271701	ENSG00000236307.2	EEF1E1P1	-4.01	6.51e-05	0.00431	-0.15	-0.12	Coronary artery disease;	chr2:111973596	chr2:111887914~111888741:+
BRCA	cis	rs7243790	0.967	rs62091589	ENSG00000277324.1	RP11-850A17.1	-4.01	6.51e-05	0.00431	-0.14	-0.12	Diastolic blood pressure;	chr18:54425327	chr18:54268346~54270028:-
BRCA	cis	rs3760982	1	rs60184524	ENSG00000267191.1	RP11-15A1.2	-4.01	6.51e-05	0.00431	-0.15	-0.12	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43790063	chr19:43902001~43926545:+
BRCA	cis	rs7045881	0.667	rs6475948	ENSG00000254396.1	RP11-56F10.3	4.01	6.51e-05	0.00431	0.18	0.12	Schizophrenia;	chr9:26899458	chr9:27102630~27104728:+
BRCA	cis	rs9733	0.596	rs72702523	ENSG00000231073.1	RP11-316M1.3	4.01	6.51e-05	0.00431	0.13	0.12	Tonsillectomy;	chr1:150677949	chr1:150973123~150975534:+
BRCA	cis	rs2554380	0.542	rs7164141	ENSG00000176700.18	SCAND2P	4.01	6.52e-05	0.00431	0.14	0.12	Height;	chr15:83824253	chr15:84631451~84647478:+
BRCA	cis	rs62388641	0.547	rs2745610	ENSG00000218027.2	RP11-157J24.1	4.01	6.52e-05	0.00431	0.16	0.12	Daytime sleep phenotypes;	chr6:1553741	chr6:1513698~1515289:-
BRCA	cis	rs9659323	1	rs10923715	ENSG00000231365.4	RP11-418J17.1	4.01	6.52e-05	0.00431	0.14	0.12	Body mass index;	chr1:118992711	chr1:119140396~119275973:+
BRCA	cis	rs6964587	0.9	rs4279	ENSG00000188693.7	CYP51A1-AS1	-4.01	6.52e-05	0.00432	-0.13	-0.12	Breast cancer;	chr7:92134814	chr7:92134604~92180725:+
BRCA	cis	rs875971	0.628	rs6974355	ENSG00000223473.2	GS1-124K5.3	4.01	6.52e-05	0.00432	0.1	0.12	Aortic root size;	chr7:66376994	chr7:66491049~66493566:-
BRCA	cis	rs886774	0.866	rs10244319	ENSG00000273055.1	CTB-13F3.1	-4.01	6.52e-05	0.00432	-0.12	-0.12	Ulcerative colitis;	chr7:107869825	chr7:107942116~107942740:+
BRCA	cis	rs4703129	0.527	rs2042965	ENSG00000248489.1	CTD-2007H13.3	4.01	6.52e-05	0.00432	0.14	0.12	Asperger disorder;	chr5:98509243	chr5:98929171~98995013:+
BRCA	cis	rs669446	0.558	rs609171	ENSG00000236200.4	KDM4A-AS1	-4.01	6.52e-05	0.00432	-0.15	-0.12	Amyotrophic lateral sclerosis (age of onset);	chr1:43644545	chr1:43699765~43708138:-
BRCA	cis	rs304029	0.532	rs58994349	ENSG00000231249.1	ITPR1-AS1	-4.01	6.52e-05	0.00432	-0.16	-0.12	Diabetic kidney disease;	chr3:4502450	chr3:4490891~4493163:-
BRCA	cis	rs687432	0.885	rs11605988	ENSG00000265566.2	RN7SL605P	-4.01	6.52e-05	0.00432	-0.17	-0.12	Parkinson's disease;	chr11:58029628	chr11:57528085~57528365:-
BRCA	cis	rs4664293	0.647	rs1863686	ENSG00000224152.1	AC009506.1	-4.01	6.52e-05	0.00432	-0.13	-0.12	Monocyte percentage of white cells;	chr2:159647538	chr2:159615296~159617082:+
BRCA	cis	rs2832191	1	rs2832185	ENSG00000232855.5	AF131217.1	4.01	6.53e-05	0.00432	0.15	0.12	Dental caries;	chr21:29111440	chr21:28439346~28674848:-
BRCA	cis	rs739496	0.579	rs7488629	ENSG00000234608.6	MAPKAPK5-AS1	4.01	6.53e-05	0.00432	0.15	0.12	Platelet count;	chr12:111835696	chr12:111839764~111842902:-
BRCA	cis	rs6490294	0.748	rs73422316	ENSG00000234608.6	MAPKAPK5-AS1	4.01	6.53e-05	0.00432	0.15	0.12	Mean platelet volume;	chr12:111835870	chr12:111839764~111842902:-
BRCA	cis	rs7267979	0.934	rs4815423	ENSG00000276952.1	RP5-965G21.6	-4.01	6.53e-05	0.00432	-0.15	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25406885	chr20:25284915~25285588:-
BRCA	cis	rs983392	0.766	rs476722	ENSG00000275344.1	MIR6503	-4.01	6.53e-05	0.00432	-0.12	-0.12	Alzheimer's disease (late onset);	chr11:60146333	chr11:60209071~60209156:-
BRCA	cis	rs983392	0.792	rs595481	ENSG00000275344.1	MIR6503	-4.01	6.53e-05	0.00432	-0.12	-0.12	Alzheimer's disease (late onset);	chr11:60146794	chr11:60209071~60209156:-
BRCA	cis	rs7481584	0.624	rs421196	ENSG00000236710.1	AC108448.2	4.01	6.53e-05	0.00432	0.16	0.12	Calcium levels;	chr11:3027352	chr11:3084393~3085443:-
BRCA	cis	rs9470794	0.831	rs11753118	ENSG00000204110.6	RP1-153P14.8	-4.01	6.53e-05	0.00432	-0.25	-0.12	Type 2 diabetes;	chr6:37890093	chr6:37507348~37535616:+
BRCA	cis	rs867186	1	rs75287019	ENSG00000126005.14	MMP24-AS1	-4.01	6.53e-05	0.00432	-0.23	-0.12	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35133458	chr20:35216462~35278131:-
BRCA	cis	rs7954584	0.71	rs10840641	ENSG00000212694.7	LINC01089	-4.01	6.53e-05	0.00432	-0.1	-0.12	Mean corpuscular volume;	chr12:122027925	chr12:121795267~121803906:-
BRCA	cis	rs10911902	0.913	rs12131484	ENSG00000229739.2	RP11-295K2.3	-4.01	6.53e-05	0.00432	-0.18	-0.12	Schizophrenia;	chr1:186585145	chr1:186435161~186470291:+
BRCA	cis	rs7852462	0.863	rs1571567	ENSG00000203279.3	RP11-498P14.5	4.01	6.53e-05	0.00432	0.15	0.12	Barrett's esophagus  or Esophageal adenocarcinoma;Barrett's esophagus;	chr9:97543075	chr9:97200475~97238700:-
BRCA	cis	rs2625529	0.824	rs4777471	ENSG00000260037.4	CTD-2524L6.3	-4.01	6.53e-05	0.00432	-0.18	-0.12	Red blood cell count;	chr15:71915463	chr15:71818396~71823384:+
BRCA	cis	rs10504130	0.569	rs12678646	ENSG00000253844.1	RP11-546K22.1	-4.01	6.53e-05	0.00432	-0.18	-0.12	Venous thromboembolism (SNP x SNP interaction);	chr8:51755611	chr8:51961458~52022974:+
BRCA	cis	rs17027633	1	rs79891093	ENSG00000234020.1	CHIAP3	-4.01	6.53e-05	0.00432	-0.29	-0.12	Cerebrospinal fluid t-tau:AB1-42 ratio;	chr1:111423955	chr1:111353275~111367409:-
BRCA	cis	rs6088580	0.634	rs6059856	ENSG00000275784.1	RP5-1125A11.6	-4.01	6.54e-05	0.00433	-0.13	-0.12	Glomerular filtration rate (creatinine);	chr20:34470149	chr20:33989480~33991818:-
BRCA	cis	rs2625529	0.824	rs4445848	ENSG00000260037.4	CTD-2524L6.3	-4.01	6.54e-05	0.00433	-0.18	-0.12	Red blood cell count;	chr15:72062257	chr15:71818396~71823384:+
BRCA	cis	rs2625529	0.824	rs4131630	ENSG00000260037.4	CTD-2524L6.3	-4.01	6.54e-05	0.00433	-0.18	-0.12	Red blood cell count;	chr15:72063057	chr15:71818396~71823384:+
BRCA	cis	rs3750082	0.621	rs7778110	ENSG00000231952.3	DPY19L1P2	4.01	6.54e-05	0.00433	0.16	0.12	Glomerular filtration rate (creatinine);	chr7:32909389	chr7:32812757~32838570:+
BRCA	cis	rs4869313	0.869	rs10476696	ENSG00000248734.2	CTD-2260A17.1	4.01	6.54e-05	0.00433	0.13	0.12	Pediatric autoimmune diseases;	chr5:96983903	chr5:96784777~96785999:+
BRCA	cis	rs987724	1	rs987724	ENSG00000240875.4	LINC00886	4.01	6.54e-05	0.00433	0.15	0.12	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156965347	chr3:156747346~156817062:-
BRCA	cis	rs875971	0.964	rs1643388	ENSG00000265600.1	AC006480.1	-4.01	6.54e-05	0.00433	-0.15	-0.12	Aortic root size;	chr7:66379575	chr7:67356680~67356779:+
BRCA	cis	rs875971	1	rs778722	ENSG00000265600.1	AC006480.1	-4.01	6.54e-05	0.00433	-0.15	-0.12	Aortic root size;	chr7:66379841	chr7:67356680~67356779:+
BRCA	cis	rs9533282	0.826	rs12864812	ENSG00000279314.1	RP1-257C22.2	4.01	6.54e-05	0.00433	0.23	0.12	Blood pressure (smoking interaction);	chr13:32079240	chr13:31960325~31961946:-
BRCA	cis	rs35306767	1	rs35306767	ENSG00000229869.1	RP11-363N22.2	-4.01	6.54e-05	0.00433	-0.2	-0.12	Eosinophil percentage of granulocytes;	chr10:943497	chr10:933026~942743:+
BRCA	cis	rs2391285	0.609	rs757580	ENSG00000214870.7	AC004540.5	4.01	6.54e-05	0.00433	0.18	0.12	Post bronchodilator FEV1/FVC ratio;	chr7:26554129	chr7:26398593~26494256:+
BRCA	cis	rs752010	0.543	rs7545381	ENSG00000230638.4	RP11-486B10.4	-4.01	6.54e-05	0.00433	-0.15	-0.12	Lupus nephritis in systemic lupus erythematosus;	chr1:41578512	chr1:41542069~41544310:+
BRCA	cis	rs4415084	0.716	rs4395640	ENSG00000251141.4	RP11-53O19.1	-4.01	6.54e-05	0.00433	-0.12	-0.12	Breast cancer;	chr5:44868998	chr5:44744900~44808777:-
BRCA	cis	rs4415084	0.652	rs10059086	ENSG00000251141.4	RP11-53O19.1	-4.01	6.54e-05	0.00433	-0.12	-0.12	Breast cancer;	chr5:44871905	chr5:44744900~44808777:-
BRCA	cis	rs9818758	0.607	rs55873331	ENSG00000225399.4	RP11-3B7.1	-4.01	6.54e-05	0.00433	-0.24	-0.12	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49559622	chr3:49260085~49261316:+
BRCA	cis	rs4713118	0.621	rs9368548	ENSG00000272009.1	RP1-313I6.12	-4.01	6.54e-05	0.00433	-0.18	-0.12	Parkinson's disease;	chr6:28066959	chr6:28078792~28081130:-
BRCA	cis	rs4302906	0.828	rs7870077	ENSG00000187984.11	ANKRD19P	-4.01	6.54e-05	0.00433	-0.11	-0.12	Lobe attachment (rater-scored or self-reported);	chr9:92980261	chr9:92809388~92888693:+
BRCA	cis	rs2905347	0.737	rs756879	ENSG00000232949.1	AC002480.4	-4.01	6.55e-05	0.00433	-0.14	-0.12	Major depression and alcohol dependence;	chr7:22594386	chr7:22589705~22591622:+
BRCA	cis	rs9381040	0.61	rs6919961	ENSG00000161912.16	ADCY10P1	4.01	6.55e-05	0.00433	0.14	0.12	Alzheimer's disease (late onset);	chr6:41052622	chr6:41101022~41140835:+
BRCA	cis	rs875971	0.862	rs7796162	ENSG00000273024.4	INTS4P2	4.01	6.55e-05	0.00433	0.14	0.12	Aortic root size;	chr7:66280771	chr7:65647864~65715661:+
BRCA	cis	rs304029	0.512	rs2131458	ENSG00000231249.1	ITPR1-AS1	4.01	6.55e-05	0.00433	0.16	0.12	Diabetic kidney disease;	chr3:4498542	chr3:4490891~4493163:-
BRCA	cis	rs8114671	0.562	rs7266550	ENSG00000126005.14	MMP24-AS1	-4.01	6.55e-05	0.00433	-0.14	-0.12	Height;	chr20:34907707	chr20:35216462~35278131:-
BRCA	cis	rs8040855	0.627	rs4842863	ENSG00000230373.7	GOLGA6L5P	4.01	6.55e-05	0.00433	0.16	0.12	Bulimia nervosa;	chr15:85098974	chr15:84507885~84516814:-
BRCA	cis	rs11250079	0.584	rs7014285	ENSG00000246477.3	AF131216.6	-4.01	6.55e-05	0.00433	-0.12	-0.12	Lymphocyte counts;	chr8:10754372	chr8:11315859~11325429:-
BRCA	cis	rs16846053	0.786	rs1227922	ENSG00000227403.1	AC009299.3	4.01	6.55e-05	0.00433	0.29	0.12	Blood osmolality (transformed sodium);	chr2:161835130	chr2:161244739~161249050:+
BRCA	cis	rs875971	1	rs2420591	ENSG00000265600.1	AC006480.1	-4.01	6.55e-05	0.00433	-0.15	-0.12	Aortic root size;	chr7:66447394	chr7:67356680~67356779:+
BRCA	cis	rs875971	0.66	rs1860470	ENSG00000265600.1	AC006480.1	4.01	6.55e-05	0.00433	0.15	0.12	Aortic root size;	chr7:66638707	chr7:67356680~67356779:+
BRCA	cis	rs7267979	0.932	rs1541061	ENSG00000276952.1	RP5-965G21.6	4.01	6.55e-05	0.00433	0.15	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25540421	chr20:25284915~25285588:-
BRCA	cis	rs7818688	1	rs10098453	ENSG00000245080.5	RP11-320N21.1	4.01	6.55e-05	0.00433	0.21	0.12	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95017528	chr8:95066808~95073182:-
BRCA	cis	rs2832077	0.943	rs4816332	ENSG00000232855.5	AF131217.1	4.01	6.55e-05	0.00434	0.19	0.12	Cognitive test performance;	chr21:28829384	chr21:28439346~28674848:-
BRCA	cis	rs2832077	0.824	rs4816333	ENSG00000232855.5	AF131217.1	4.01	6.55e-05	0.00434	0.19	0.12	Cognitive test performance;	chr21:28829455	chr21:28439346~28674848:-
BRCA	cis	rs11098499	0.909	rs10020034	ENSG00000260091.1	RP11-33B1.4	-4.01	6.55e-05	0.00434	-0.11	-0.12	Corneal astigmatism;	chr4:119373176	chr4:119409333~119410233:+
BRCA	cis	rs11711311	1	rs9811746	ENSG00000241529.3	RN7SL767P	-4.01	6.56e-05	0.00434	-0.14	-0.12	IgG glycosylation;	chr3:113796213	chr3:113632704~113632998:+
BRCA	cis	rs2391285	0.609	rs1029555	ENSG00000280255.1	RP5-1007F24.1	4.01	6.56e-05	0.00434	0.17	0.12	Post bronchodilator FEV1/FVC ratio;	chr7:26547477	chr7:26538378~26541048:+
BRCA	cis	rs6545883	0.895	rs6545871	ENSG00000212978.6	AC016747.3	4.01	6.56e-05	0.00434	0.17	0.12	Tuberculosis;	chr2:61465068	chr2:61141592~61144969:-
BRCA	cis	rs75504410	0.579	rs337645	ENSG00000231160.8	KLF3-AS1	-4.01	6.56e-05	0.00434	-0.18	-0.12	Sum eosinophil basophil counts;Eosinophil counts;	chr4:38613462	chr4:38612701~38664883:-
BRCA	cis	rs987724	0.515	rs9876148	ENSG00000244515.1	KRT18P34	-4.01	6.56e-05	0.00434	-0.17	-0.12	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156894349	chr3:157162663~157163932:-
BRCA	cis	rs7487075	0.859	rs3782904	ENSG00000257261.4	RP11-96H19.1	4.01	6.56e-05	0.00434	0.13	0.12	Itch intensity from mosquito bite;	chr12:46364202	chr12:46383679~46876159:+
BRCA	cis	rs801193	0.967	rs2707849	ENSG00000272831.1	RP11-792A8.4	4.01	6.56e-05	0.00434	0.11	0.12	Aortic root size;	chr7:66687725	chr7:66739829~66740385:-
BRCA	cis	rs6545883	0.929	rs1186710	ENSG00000212978.6	AC016747.3	4.01	6.56e-05	0.00434	0.17	0.12	Tuberculosis;	chr2:61461592	chr2:61141592~61144969:-
BRCA	cis	rs62103177	0.564	rs1715230	ENSG00000278000.1	AC139100.4	4.01	6.56e-05	0.00434	0.18	0.12	Opioid sensitivity;	chr18:80090098	chr18:80161752~80162413:+
BRCA	cis	rs28374715	0.635	rs112547435	ENSG00000247556.5	OIP5-AS1	4.01	6.57e-05	0.00434	0.13	0.12	Ulcerative colitis;	chr15:41356539	chr15:41283990~41309737:+
BRCA	cis	rs9400467	0.506	rs12203741	ENSG00000255389.1	C6orf3	4.01	6.57e-05	0.00434	0.18	0.12	Amino acid levels;Blood metabolite levels;	chr6:111356341	chr6:111599875~111602295:+
BRCA	cis	rs6736093	0.862	rs35382200	ENSG00000236307.2	EEF1E1P1	-4.01	6.57e-05	0.00435	-0.16	-0.12	Coronary artery disease;	chr2:112023139	chr2:111887914~111888741:+
BRCA	cis	rs4689592	0.546	rs907523	ENSG00000245468.3	RP11-367J11.3	4.01	6.57e-05	0.00435	0.13	0.12	Monocyte percentage of white cells;	chr4:7051050	chr4:7094571~7103385:-
BRCA	cis	rs13401620	0.879	rs3111717	ENSG00000229326.3	AC069154.4	-4.01	6.57e-05	0.00435	-0.16	-0.12	Breast size;	chr2:119845864	chr2:119698623~119700151:+
BRCA	cis	rs7267979	1	rs1888997	ENSG00000274414.1	RP5-965G21.4	4.01	6.57e-05	0.00435	0.15	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25318352	chr20:25239007~25245229:-
BRCA	cis	rs11098499	0.754	rs878376	ENSG00000260091.1	RP11-33B1.4	-4.01	6.57e-05	0.00435	-0.11	-0.12	Corneal astigmatism;	chr4:119316547	chr4:119409333~119410233:+
BRCA	cis	rs4950322	0.547	rs6660507	ENSG00000237188.3	RP11-337C18.8	4.01	6.58e-05	0.00435	0.14	0.12	Protein quantitative trait loci;	chr1:147148574	chr1:147172771~147211568:+
BRCA	cis	rs7849270	1	rs10819471	ENSG00000223478.1	RP11-545E17.3	-4.01	6.58e-05	0.00435	-0.15	-0.12	Blood metabolite ratios;	chr9:129134046	chr9:128724445~128733194:+
BRCA	cis	rs10799445	0.531	rs6697867	ENSG00000227711.2	RP11-275O4.5	4.01	6.58e-05	0.00435	0.15	0.12	Height;	chr1:227557973	chr1:227509028~227520477:-
BRCA	cis	rs1153858	1	rs4271549	ENSG00000275672.1	GATM-AS1	-4.01	6.58e-05	0.00435	-0.16	-0.12	Homoarginine levels;	chr15:45360532	chr15:45378700~45380123:+
BRCA	cis	rs1153858	1	rs4627277	ENSG00000275672.1	GATM-AS1	-4.01	6.58e-05	0.00435	-0.16	-0.12	Homoarginine levels;	chr15:45360570	chr15:45378700~45380123:+
BRCA	cis	rs2518049	0.654	rs3812616	ENSG00000224034.1	RP11-445P17.8	-4.01	6.59e-05	0.00435	-0.24	-0.12	Metabolic traits;	chr10:5196309	chr10:5266033~5271236:-
BRCA	cis	rs2039553	0.548	rs11619959	ENSG00000227354.5	RBM26-AS1	-4.01	6.59e-05	0.00435	-0.14	-0.12	Pancreatic cancer;	chr13:79762510	chr13:79406309~79424328:+
BRCA	cis	rs7260598	1	rs7260598	ENSG00000268442.1	CTD-2027I19.2	-4.01	6.59e-05	0.00436	-0.2	-0.12	Response to taxane treatment (placlitaxel);	chr19:24039984	chr19:24162370~24163425:-
BRCA	cis	rs10129255	0.833	rs7156689	ENSG00000211967.3	IGHV3-53	-4.01	6.59e-05	0.00436	-0.09	-0.12	Kawasaki disease;	chr14:106816039	chr14:106592676~106593347:-
BRCA	cis	rs9378688	0.872	rs3800185	ENSG00000244041.6	LINC01011	-4.01	6.59e-05	0.00436	-0.19	-0.12	Caudate nucleus volume;	chr6:2211935	chr6:2987967~2991173:+
BRCA	cis	rs3753275	0.69	rs9730025	ENSG00000232912.4	RP5-1115A15.1	4.01	6.59e-05	0.00436	0.16	0.12	Educational attainment;	chr1:8559014	chr1:8424645~8434838:+
BRCA	cis	rs7481584	0.624	rs80871	ENSG00000236710.1	AC108448.2	4.01	6.59e-05	0.00436	0.16	0.12	Calcium levels;	chr11:3028613	chr11:3084393~3085443:-
BRCA	cis	rs2274459	0.908	rs34472165	ENSG00000249346.5	LINC01016	4.01	6.59e-05	0.00436	0.16	0.12	Obesity (extreme);	chr6:33782254	chr6:33867506~33896914:-
BRCA	cis	rs651907	0.535	rs11716558	ENSG00000256628.3	ZBTB11-AS1	4.01	6.59e-05	0.00436	0.16	0.12	Colorectal cancer;	chr3:101809637	chr3:101676475~101679217:+
BRCA	cis	rs950776	1	rs950776	ENSG00000279373.1	RP11-650L12.4	4.01	6.59e-05	0.00436	0.16	0.12	Sudden cardiac arrest;	chr15:78633676	chr15:78537681~78538946:+
BRCA	cis	rs1245541	0.72	rs1271933	ENSG00000226701.1	RP11-570G20.1	4.01	6.59e-05	0.00436	0.14	0.12	Insulin-like growth factors;	chr10:72143117	chr10:72189941~72190576:+
BRCA	cis	rs2281558	0.917	rs3787080	ENSG00000274414.1	RP5-965G21.4	-4.01	6.59e-05	0.00436	-0.17	-0.12	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25251968	chr20:25239007~25245229:-
BRCA	cis	rs6545883	0.718	rs2694624	ENSG00000273302.1	RP11-493E12.2	4.01	6.6e-05	0.00436	0.12	0.12	Tuberculosis;	chr2:61445178	chr2:61199979~61200769:+
BRCA	cis	rs1953600	0.87	rs12770550	ENSG00000226659.1	RP11-137H2.4	4.01	6.6e-05	0.00436	0.17	0.12	Sarcoidosis;	chr10:80193695	chr10:80529597~80535942:-
BRCA	cis	rs853679	0.517	rs1947862	ENSG00000261839.1	RP1-265C24.8	4.01	6.6e-05	0.00436	0.17	0.12	Depression;	chr6:28137418	chr6:28136849~28139678:+
BRCA	cis	rs8130944	0.964	rs4920135	ENSG00000225731.1	AP001627.1	4.01	6.6e-05	0.00436	0.14	0.12	Perceived unattractiveness to mosquitoes;	chr21:42719198	chr21:42733594~42741758:-
BRCA	cis	rs9829778	0.791	rs6583177	ENSG00000272359.1	U4	4.01	6.6e-05	0.00436	0.15	0.12	Sum eosinophil basophil counts;	chr3:196822871	chr3:196747192~196747324:-
BRCA	cis	rs2274273	1	rs1009977	ENSG00000259318.1	RP11-454L9.2	4.01	6.6e-05	0.00436	0.11	0.12	Protein biomarker;	chr14:55136284	chr14:55394940~55395233:-
BRCA	cis	rs8098244	0.537	rs11877880	ENSG00000265752.2	RP11-403A21.1	4.01	6.6e-05	0.00436	0.13	0.12	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23716401	chr18:23957754~23982556:-
BRCA	cis	rs7927592	0.956	rs12281742	ENSG00000212093.1	AP000807.1	-4.01	6.6e-05	0.00436	-0.13	-0.12	Total body bone mineral density;	chr11:68536161	chr11:68506083~68506166:-
BRCA	cis	rs642858	0.737	rs9376517	ENSG00000234147.1	RP3-460G2.2	-4.01	6.6e-05	0.00436	-0.16	-0.12	Type 2 diabetes;	chr6:140355624	chr6:140845958~140852924:-
BRCA	cis	rs801193	0.967	rs2707841	ENSG00000273142.1	RP11-458F8.4	-4.01	6.6e-05	0.00436	-0.11	-0.12	Aortic root size;	chr7:66692033	chr7:66902857~66906297:+
BRCA	cis	rs801193	1	rs4717310	ENSG00000273142.1	RP11-458F8.4	-4.01	6.6e-05	0.00436	-0.11	-0.12	Aortic root size;	chr7:66696020	chr7:66902857~66906297:+
BRCA	cis	rs7824557	0.564	rs7839307	ENSG00000255046.1	RP11-297N6.4	-4.01	6.6e-05	0.00436	-0.14	-0.12	Retinal vascular caliber;	chr8:11341283	chr8:11797928~11802568:-
BRCA	cis	rs4700393	0.517	rs17332108	ENSG00000215032.2	GNL3LP1	4.01	6.6e-05	0.00436	0.18	0.12	Intelligence (multi-trait analysis);	chr5:60836057	chr5:60891935~60893577:-
BRCA	cis	rs7520050	0.807	rs6656279	ENSG00000281133.1	AL355480.3	-4.01	6.6e-05	0.00437	-0.14	-0.12	Reticulocyte count;Red blood cell count;	chr1:45658416	chr1:45580892~45580996:-
BRCA	cis	rs7520050	0.807	rs6671802	ENSG00000281133.1	AL355480.3	-4.01	6.6e-05	0.00437	-0.14	-0.12	Reticulocyte count;Red blood cell count;	chr1:45658991	chr1:45580892~45580996:-
BRCA	cis	rs1396626	0.926	rs12402416	ENSG00000235501.4	RP4-639F20.1	-4.01	6.6e-05	0.00437	-0.17	-0.12	Diabetic kidney disease;	chr1:95549240	chr1:94927566~94963270:+
BRCA	cis	rs6121246	0.909	rs6060679	ENSG00000230613.1	HM13-AS1	-4.01	6.6e-05	0.00437	-0.18	-0.12	Mean corpuscular hemoglobin;	chr20:31682969	chr20:31567707~31573263:-
BRCA	cis	rs6430585	0.702	rs2015532	ENSG00000224043.6	CCNT2-AS1	4.01	6.61e-05	0.00437	0.2	0.12	Corneal structure;	chr2:135797955	chr2:134735464~134918710:-
BRCA	cis	rs801193	1	rs7782320	ENSG00000273142.1	RP11-458F8.4	-4.01	6.61e-05	0.00437	-0.11	-0.12	Aortic root size;	chr7:66712111	chr7:66902857~66906297:+
BRCA	cis	rs10885997	0.678	rs7072157	ENSG00000266200.5	PNLIPRP2	4.01	6.61e-05	0.00437	0.15	0.12	Phospholipid levels (plasma);	chr10:116635866	chr10:116620953~116645143:+
BRCA	cis	rs1005277	0.579	rs2474595	ENSG00000272983.1	RP11-508N22.12	-4.01	6.61e-05	0.00437	-0.13	-0.12	Extrinsic epigenetic age acceleration;	chr10:38137854	chr10:38137337~38144399:+
BRCA	cis	rs2243480	1	rs781149	ENSG00000226002.1	RP11-460N20.5	-4.01	6.61e-05	0.00437	-0.2	-0.12	Diabetic kidney disease;	chr7:66016297	chr7:65084103~65100232:+
BRCA	cis	rs2243480	0.901	rs58207111	ENSG00000226002.1	RP11-460N20.5	-4.01	6.61e-05	0.00437	-0.2	-0.12	Diabetic kidney disease;	chr7:66021736	chr7:65084103~65100232:+
BRCA	cis	rs375066	0.901	rs376069	ENSG00000267191.1	RP11-15A1.2	-4.01	6.61e-05	0.00437	-0.16	-0.12	Breast cancer;	chr19:43913143	chr19:43902001~43926545:+
BRCA	cis	rs35740288	0.731	rs11634651	ENSG00000202081.1	RNU6-1280P	4.01	6.61e-05	0.00437	0.16	0.12	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85550695	chr15:85651522~85651628:-
BRCA	cis	rs1153858	1	rs8032904	ENSG00000275672.1	GATM-AS1	-4.01	6.61e-05	0.00437	-0.16	-0.12	Homoarginine levels;	chr15:45359111	chr15:45378700~45380123:+
BRCA	cis	rs11668609	1	rs2099360	ENSG00000268058.1	BNIP3P40	-4.01	6.61e-05	0.00437	-0.15	-0.12	Response to taxane treatment (docetaxel);	chr19:24147361	chr19:24098425~24098980:-
BRCA	cis	rs11668609	1	rs2082493	ENSG00000268058.1	BNIP3P40	-4.01	6.61e-05	0.00437	-0.15	-0.12	Response to taxane treatment (docetaxel);	chr19:24147554	chr19:24098425~24098980:-
BRCA	cis	rs1223397	0.617	rs202029	ENSG00000215022.6	RP1-257A7.4	-4.01	6.61e-05	0.00437	-0.16	-0.12	Blood pressure;	chr6:13291938	chr6:13264861~13295586:-
BRCA	cis	rs6088580	0.634	rs6120644	ENSG00000275784.1	RP5-1125A11.6	-4.01	6.62e-05	0.00437	-0.13	-0.12	Glomerular filtration rate (creatinine);	chr20:34436005	chr20:33989480~33991818:-
BRCA	cis	rs2832077	0.943	rs11701777	ENSG00000232855.5	AF131217.1	4.01	6.62e-05	0.00437	0.19	0.12	Cognitive test performance;	chr21:28783506	chr21:28439346~28674848:-
BRCA	cis	rs957448	1	rs1055800	ENSG00000254315.1	RP11-267M23.3	-4.01	6.62e-05	0.00437	-0.16	-0.12	Nonsyndromic cleft lip with cleft palate;	chr8:94510810	chr8:94533628~94534391:+
BRCA	cis	rs2524005	1	rs2524005	ENSG00000235821.1	IFITM4P	-4.01	6.62e-05	0.00438	-0.19	-0.12	Bipolar disorder and schizophrenia;	chr6:29931900	chr6:29750729~29751148:-
BRCA	cis	rs6586111	0.935	rs4933463	ENSG00000226659.1	RP11-137H2.4	-4.01	6.62e-05	0.00438	-0.15	-0.12	Capecitabine sensitivity;	chr10:80613110	chr10:80529597~80535942:-
BRCA	cis	rs3748682	0.821	rs71642605	ENSG00000212541.1	RNU6-510P	-4.01	6.62e-05	0.00438	-0.19	-0.12	Hypothyroidism;	chr1:37790755	chr1:37991462~37991569:+
BRCA	cis	rs2191566	0.664	rs55958002	ENSG00000266921.1	RP11-15A1.7	-4.01	6.62e-05	0.00438	-0.15	-0.12	Acute lymphoblastic leukemia (childhood);	chr19:44039635	chr19:43996896~44002836:-
BRCA	cis	rs964611	0.882	rs8025164	ENSG00000259488.2	RP11-154J22.1	4.01	6.62e-05	0.00438	0.15	0.12	Metabolite levels (Pyroglutamine);	chr15:48346517	chr15:48312353~48331856:-
BRCA	cis	rs6545883	0.929	rs2264100	ENSG00000212978.6	AC016747.3	4.01	6.62e-05	0.00438	0.17	0.12	Tuberculosis;	chr2:61443694	chr2:61141592~61144969:-
BRCA	cis	rs6840360	0.582	rs11733820	ENSG00000251611.1	RP11-610P16.1	-4.01	6.63e-05	0.00438	-0.11	-0.12	Intelligence (multi-trait analysis);	chr4:151394987	chr4:151407551~151408835:-
BRCA	cis	rs9295536	0.651	rs6921113	ENSG00000260455.1	NBAT1	4.01	6.63e-05	0.00438	0.14	0.12	Neuroblastoma;	chr6:22136650	chr6:22134957~22147193:-
BRCA	cis	rs9467773	0.62	rs9467810	ENSG00000224843.5	LINC00240	-4.01	6.63e-05	0.00438	-0.13	-0.12	Intelligence (multi-trait analysis);	chr6:26608033	chr6:26956992~27023924:+
BRCA	cis	rs8180040	0.593	rs12715421	ENSG00000271161.1	BOLA2P2	4.01	6.63e-05	0.00438	0.13	0.12	Colorectal cancer;	chr3:47043369	chr3:47499841~47500407:+
BRCA	cis	rs2832077	0.943	rs2832084	ENSG00000232855.5	AF131217.1	4.01	6.63e-05	0.00438	0.19	0.12	Cognitive test performance;	chr21:28782476	chr21:28439346~28674848:-
BRCA	cis	rs4834770	1	rs878374	ENSG00000178636.7	RP11-455G16.1	-4.01	6.63e-05	0.00438	-0.15	-0.12	Blood protein levels;	chr4:119316409	chr4:119192773~119212644:-
BRCA	cis	rs1153858	1	rs1980288	ENSG00000275672.1	GATM-AS1	-4.01	6.63e-05	0.00438	-0.16	-0.12	Homoarginine levels;	chr15:45328414	chr15:45378700~45380123:+
BRCA	cis	rs9500256	0.966	rs1322446	ENSG00000272541.1	XXbac-BPGBPG55C20.1	-4.01	6.63e-05	0.00438	-0.13	-0.12	Eosinophilic esophagitis (pediatric);	chr6:57985672	chr6:57855891~57856468:-
BRCA	cis	rs7520050	0.966	rs1707304	ENSG00000281133.1	AL355480.3	4.01	6.63e-05	0.00438	0.14	0.12	Reticulocyte count;Red blood cell count;	chr1:46132597	chr1:45580892~45580996:-
BRCA	cis	rs73222236	0.825	rs35644083	ENSG00000239213.4	NCK1-AS1	4.01	6.63e-05	0.00438	0.14	0.12	Coronary artery disease;	chr3:136503626	chr3:136841726~136862054:-
BRCA	cis	rs2274459	1	rs12662447	ENSG00000249346.5	LINC01016	4.01	6.63e-05	0.00438	0.16	0.12	Obesity (extreme);	chr6:33746896	chr6:33867506~33896914:-
BRCA	cis	rs1005277	0.502	rs2800484	ENSG00000276805.1	RP11-291L22.6	4.01	6.63e-05	0.00438	0.13	0.12	Extrinsic epigenetic age acceleration;	chr10:38253487	chr10:38451030~38451785:+
BRCA	cis	rs11673344	0.542	rs826324	ENSG00000276846.1	CTD-3220F14.3	4.01	6.64e-05	0.00438	0.15	0.12	Obesity-related traits;	chr19:37014343	chr19:37314868~37315620:-
BRCA	cis	rs13108904	0.935	rs2293633	ENSG00000253399.1	AC078852.2	-4.01	6.64e-05	0.00438	-0.13	-0.12	Obesity-related traits;	chr4:1297852	chr4:1358479~1359461:+
BRCA	cis	rs4374383	0.884	rs3811636	ENSG00000243389.1	AC012442.5	-4.01	6.64e-05	0.00438	-0.16	-0.12	Hepatitis C induced liver fibrosis;	chr2:111997632	chr2:112589040~112614431:+
BRCA	cis	rs1005277	0.579	rs2103938	ENSG00000276805.1	RP11-291L22.6	4.01	6.64e-05	0.00438	0.13	0.12	Extrinsic epigenetic age acceleration;	chr10:38205070	chr10:38451030~38451785:+
BRCA	cis	rs853679	0.517	rs9393896	ENSG00000261839.1	RP1-265C24.8	4.01	6.64e-05	0.00439	0.17	0.12	Depression;	chr6:28159925	chr6:28136849~28139678:+
BRCA	cis	rs853679	0.517	rs9393897	ENSG00000261839.1	RP1-265C24.8	4.01	6.64e-05	0.00439	0.17	0.12	Depression;	chr6:28159932	chr6:28136849~28139678:+
BRCA	cis	rs4650943	0.658	rs2504494	ENSG00000227740.1	RP11-318C24.2	-4.01	6.64e-05	0.00439	-0.13	-0.12	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in inactive individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr1:176393065	chr1:175904762~175920513:-
BRCA	cis	rs4650943	0.658	rs2938152	ENSG00000227740.1	RP11-318C24.2	-4.01	6.64e-05	0.00439	-0.13	-0.12	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in inactive individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr1:176405575	chr1:175904762~175920513:-
BRCA	cis	rs8017423	0.647	rs12883844	ENSG00000275198.1	RP11-471B22.3	4.01	6.64e-05	0.00439	0.14	0.12	Mortality in heart failure;	chr14:90354175	chr14:90383365~90387973:+
BRCA	cis	rs875971	0.571	rs78668714	ENSG00000230295.1	RP11-458F8.2	4.01	6.64e-05	0.00439	0.12	0.12	Aortic root size;	chr7:66474464	chr7:66880708~66882981:+
BRCA	cis	rs1005277	0.579	rs1740742	ENSG00000276805.1	RP11-291L22.6	4.01	6.64e-05	0.00439	0.13	0.12	Extrinsic epigenetic age acceleration;	chr10:38229932	chr10:38451030~38451785:+
BRCA	cis	rs1005277	0.602	rs1740743	ENSG00000276805.1	RP11-291L22.6	4.01	6.64e-05	0.00439	0.13	0.12	Extrinsic epigenetic age acceleration;	chr10:38230294	chr10:38451030~38451785:+
BRCA	cis	rs1005277	0.579	rs1740745	ENSG00000276805.1	RP11-291L22.6	4.01	6.64e-05	0.00439	0.13	0.12	Extrinsic epigenetic age acceleration;	chr10:38231128	chr10:38451030~38451785:+
BRCA	cis	rs1005277	0.579	rs1740747	ENSG00000276805.1	RP11-291L22.6	4.01	6.64e-05	0.00439	0.13	0.12	Extrinsic epigenetic age acceleration;	chr10:38231537	chr10:38451030~38451785:+
BRCA	cis	rs1005277	0.579	rs1740749	ENSG00000276805.1	RP11-291L22.6	4.01	6.64e-05	0.00439	0.13	0.12	Extrinsic epigenetic age acceleration;	chr10:38232718	chr10:38451030~38451785:+
BRCA	cis	rs1005277	0.579	rs1780115	ENSG00000276805.1	RP11-291L22.6	4.01	6.64e-05	0.00439	0.13	0.12	Extrinsic epigenetic age acceleration;	chr10:38235845	chr10:38451030~38451785:+
BRCA	cis	rs17739794	0.537	rs7816826	ENSG00000253982.1	CTD-2336O2.1	-4	6.64e-05	0.00439	-0.13	-0.12	Clozapine-induced cytotoxicity;	chr8:864492	chr8:1761990~1764502:-
BRCA	cis	rs1153858	1	rs2114501	ENSG00000275672.1	GATM-AS1	-4	6.64e-05	0.00439	-0.16	-0.12	Homoarginine levels;	chr15:45378118	chr15:45378700~45380123:+
BRCA	cis	rs801193	1	rs62466793	ENSG00000272831.1	RP11-792A8.4	4	6.64e-05	0.00439	0.11	0.12	Aortic root size;	chr7:66726530	chr7:66739829~66740385:-
BRCA	cis	rs3177980	0.673	rs10919255	ENSG00000239494.2	RN7SL333P	-4	6.64e-05	0.00439	-0.12	-0.12	Amyotrophic lateral sclerosis;	chr1:169847041	chr1:169859756~169860052:+
BRCA	cis	rs6545883	0.894	rs2694634	ENSG00000273302.1	RP11-493E12.2	-4	6.64e-05	0.00439	-0.11	-0.12	Tuberculosis;	chr2:61324300	chr2:61199979~61200769:+
BRCA	cis	rs4650943	0.586	rs432510	ENSG00000227740.1	RP11-318C24.2	-4	6.65e-05	0.00439	-0.12	-0.12	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in inactive individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr1:176297849	chr1:175904762~175920513:-
BRCA	cis	rs853679	0.517	rs9468298	ENSG00000261839.1	RP1-265C24.8	4	6.65e-05	0.00439	0.17	0.12	Depression;	chr6:28154567	chr6:28136849~28139678:+
BRCA	cis	rs853679	0.517	rs9295759	ENSG00000261839.1	RP1-265C24.8	4	6.65e-05	0.00439	0.17	0.12	Depression;	chr6:28156691	chr6:28136849~28139678:+
BRCA	cis	rs853679	0.517	rs9348796	ENSG00000261839.1	RP1-265C24.8	4	6.65e-05	0.00439	0.17	0.12	Depression;	chr6:28158424	chr6:28136849~28139678:+
BRCA	cis	rs853679	0.517	rs11552219	ENSG00000261839.1	RP1-265C24.8	4	6.65e-05	0.00439	0.17	0.12	Depression;	chr6:28159056	chr6:28136849~28139678:+
BRCA	cis	rs853679	0.517	rs9357066	ENSG00000261839.1	RP1-265C24.8	4	6.65e-05	0.00439	0.17	0.12	Depression;	chr6:28162053	chr6:28136849~28139678:+
BRCA	cis	rs7267979	0.934	rs2257464	ENSG00000277938.1	RP5-965G21.3	4	6.65e-05	0.00439	0.15	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25285236	chr20:25229150~25231933:+
BRCA	cis	rs61160187	0.582	rs12653132	ENSG00000272308.1	RP11-231G3.1	-4	6.65e-05	0.00439	-0.14	-0.12	Educational attainment (years of education);Educational attainment (college completion);	chr5:61062881	chr5:60866457~60866935:-
BRCA	cis	rs2273156	0.587	rs7145474	ENSG00000226677.3	IGBP1P1	-4	6.65e-05	0.00439	-0.2	-0.12	Immunoglobulin light chain (AL) amyloidosis;	chr14:35067909	chr14:34939324~34940332:+
BRCA	cis	rs4650943	0.658	rs2504492	ENSG00000227740.1	RP11-318C24.2	-4	6.65e-05	0.00439	-0.13	-0.12	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in inactive individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr1:176393783	chr1:175904762~175920513:-
BRCA	cis	rs12826942	1	rs12826942	ENSG00000257225.1	RP11-328C8.4	-4	6.65e-05	0.00439	-0.19	-0.12	Coronary artery disease;	chr12:42402498	chr12:42459366~42466128:+
BRCA	cis	rs4478858	0.684	rs10798839	ENSG00000223907.1	LINC01226	-4	6.65e-05	0.00439	-0.15	-0.12	Alcohol dependence;	chr1:31258911	chr1:31518435~31524245:+
BRCA	cis	rs7267979	1	rs7343481	ENSG00000125804.12	FAM182A	4	6.65e-05	0.00439	0.16	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25319477	chr20:26054655~26086917:+
BRCA	cis	rs875971	0.558	rs4433015	ENSG00000223473.2	GS1-124K5.3	-4	6.65e-05	0.00439	-0.09	-0.12	Aortic root size;	chr7:66174736	chr7:66491049~66493566:-
BRCA	cis	rs7172689	0.908	rs4076201	ENSG00000271725.1	RP11-761I4.4	-4	6.65e-05	0.00439	-0.16	-0.12	Inattentive symptoms;	chr15:81279962	chr15:81303215~81309391:-
BRCA	cis	rs8180040	0.726	rs61729713	ENSG00000271161.1	BOLA2P2	-4	6.65e-05	0.00439	-0.13	-0.12	Colorectal cancer;	chr3:46985702	chr3:47499841~47500407:+
BRCA	cis	rs4950322	0.58	rs2014106	ENSG00000237188.3	RP11-337C18.8	4	6.65e-05	0.00439	0.15	0.12	Protein quantitative trait loci;	chr1:147118499	chr1:147172771~147211568:+
BRCA	cis	rs10129255	0.5	rs2027902	ENSG00000211967.3	IGHV3-53	-4	6.66e-05	0.0044	-0.08	-0.12	Kawasaki disease;	chr14:106807157	chr14:106592676~106593347:-
BRCA	cis	rs12050794	0.671	rs8192362	ENSG00000260037.4	CTD-2524L6.3	4	6.66e-05	0.0044	0.15	0.12	Metabolite levels (HVA/MHPG ratio);	chr15:72227517	chr15:71818396~71823384:+
BRCA	cis	rs1008375	1	rs62295634	ENSG00000249502.1	AC006160.5	-4	6.66e-05	0.0044	-0.14	-0.12	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17683723	chr4:17587467~17614571:-
BRCA	cis	rs4132699	0.645	rs9410490	ENSG00000225460.1	RP13-93L13.1	-4	6.66e-05	0.0044	-0.13	-0.12	Nonsyndromic cleft lip with or without cleft palate;Orofacial clefts;	chr9:89474185	chr9:89472237~89472692:+
BRCA	cis	rs4132699	0.62	rs9410323	ENSG00000225460.1	RP13-93L13.1	-4	6.66e-05	0.0044	-0.13	-0.12	Nonsyndromic cleft lip with or without cleft palate;Orofacial clefts;	chr9:89474266	chr9:89472237~89472692:+
BRCA	cis	rs4787491	0.729	rs7191849	ENSG00000183604.13	SMG1P5	-4	6.66e-05	0.0044	-0.12	-0.12	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30011836	chr16:30267553~30335374:-
BRCA	cis	rs8017423	0.522	rs12887028	ENSG00000275198.1	RP11-471B22.3	4	6.66e-05	0.0044	0.14	0.12	Mortality in heart failure;	chr14:90353261	chr14:90383365~90387973:+
BRCA	cis	rs1910358	0.69	rs7713296	ENSG00000248874.4	C5orf17	-4	6.66e-05	0.0044	-0.16	-0.12	Venous thromboembolism (SNP x SNP interaction);	chr5:23949541	chr5:23951348~24178263:+
BRCA	cis	rs4415084	0.966	rs12516900	ENSG00000248779.1	RP11-53O19.2	4	6.66e-05	0.0044	0.12	0.12	Breast cancer;	chr5:44644393	chr5:44752949~44765744:+
BRCA	cis	rs4415084	0.932	rs4321755	ENSG00000248779.1	RP11-53O19.2	4	6.66e-05	0.0044	0.12	0.12	Breast cancer;	chr5:44646093	chr5:44752949~44765744:+
BRCA	cis	rs6973609	1	rs6973609	ENSG00000271122.1	RP11-379H18.1	-4	6.67e-05	0.0044	-0.13	-0.12	Obesity-related traits;	chr7:35567623	chr7:35695214~35699413:+
BRCA	cis	rs871012	0.502	rs56259240	ENSG00000251405.2	CTB-109A12.1	-4	6.67e-05	0.0044	-0.17	-0.12	IgG glycosylation;	chr5:157464523	chr5:157362615~157460078:-
BRCA	cis	rs9818758	0.607	rs35673421	ENSG00000225399.4	RP11-3B7.1	-4	6.67e-05	0.0044	-0.22	-0.12	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49101973	chr3:49260085~49261316:+
BRCA	cis	rs875971	0.545	rs66594357	ENSG00000232559.3	GS1-124K5.12	4	6.67e-05	0.0044	0.17	0.12	Aortic root size;	chr7:66327797	chr7:66554588~66576923:-
BRCA	cis	rs6088580	0.57	rs6058057	ENSG00000275784.1	RP5-1125A11.6	-4	6.67e-05	0.0044	-0.13	-0.12	Glomerular filtration rate (creatinine);	chr20:34477478	chr20:33989480~33991818:-
BRCA	cis	rs6545883	0.894	rs778148	ENSG00000273302.1	RP11-493E12.2	-4	6.67e-05	0.0044	-0.12	-0.12	Tuberculosis;	chr2:61379731	chr2:61199979~61200769:+
BRCA	cis	rs4415084	0.716	rs6868232	ENSG00000251141.4	RP11-53O19.1	4	6.67e-05	0.0044	0.11	0.12	Breast cancer;	chr5:44827578	chr5:44744900~44808777:-
BRCA	cis	rs7829975	0.582	rs6982832	ENSG00000254153.1	CTA-398F10.2	-4	6.67e-05	0.00441	-0.15	-0.12	Mood instability;	chr8:8934707	chr8:8456909~8461337:-
BRCA	cis	rs875971	0.767	rs12668005	ENSG00000229886.1	RP5-1132H15.3	4	6.67e-05	0.00441	0.14	0.12	Aortic root size;	chr7:66444034	chr7:66025126~66031544:-
BRCA	cis	rs2486012	1	rs2906467	ENSG00000237950.1	RP11-7O11.3	4	6.67e-05	0.00441	0.22	0.12	Intelligence (multi-trait analysis);	chr1:43854804	chr1:43944370~43946551:-
BRCA	cis	rs9425766	0.962	rs1322777	ENSG00000200674.1	RN7SKP160	4	6.68e-05	0.00441	0.17	0.12	Life satisfaction;	chr1:173889962	chr1:173791548~173791887:+
BRCA	cis	rs7246967	0.8	rs2169794	ENSG00000198153.8	ZNF849P	-4	6.68e-05	0.00441	-0.17	-0.12	Bronchopulmonary dysplasia;	chr19:22842966	chr19:22685167~22686732:+
BRCA	cis	rs7246967	0.8	rs2061774	ENSG00000198153.8	ZNF849P	-4	6.68e-05	0.00441	-0.17	-0.12	Bronchopulmonary dysplasia;	chr19:22842973	chr19:22685167~22686732:+
BRCA	cis	rs7246967	0.932	rs34897621	ENSG00000198153.8	ZNF849P	-4	6.68e-05	0.00441	-0.17	-0.12	Bronchopulmonary dysplasia;	chr19:22844725	chr19:22685167~22686732:+
BRCA	cis	rs11098499	0.909	rs71614422	ENSG00000260404.2	RP11-384K6.6	4	6.68e-05	0.00441	0.12	0.12	Corneal astigmatism;	chr4:119438185	chr4:118591773~118633729:+
BRCA	cis	rs10911902	0.602	rs79668124	ENSG00000229739.2	RP11-295K2.3	-4	6.68e-05	0.00441	-0.18	-0.12	Schizophrenia;	chr1:186415103	chr1:186435161~186470291:+
BRCA	cis	rs728616	0.558	rs2343302	ENSG00000225484.5	NUTM2B-AS1	-4	6.68e-05	0.00441	-0.26	-0.12	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80403430	chr10:79663088~79826594:-
BRCA	cis	rs11773103	0.708	rs55825235	ENSG00000224046.1	AC005076.5	4	6.68e-05	0.00441	0.2	0.12	Bipolar disorder or major depressive disorder (combined);	chr7:87130385	chr7:87151423~87152420:-
BRCA	cis	rs12149695	0.966	rs4499236	ENSG00000259940.2	CTD-3203P2.1	-4	6.68e-05	0.00441	-0.15	-0.12	Gut microbiota (bacterial taxa);	chr16:27242810	chr16:27213308~27214993:-
BRCA	cis	rs7800418	0.723	rs4461797	ENSG00000214870.7	AC004540.5	4	6.68e-05	0.00441	0.15	0.12	Cognitive function;	chr7:26548425	chr7:26398593~26494256:+
BRCA	cis	rs2274273	0.682	rs7151224	ENSG00000233924.1	AL160471.6	-4	6.68e-05	0.00441	-0.14	-0.12	Protein biomarker;	chr14:55050544	chr14:55004813~55005687:-
BRCA	cis	rs7772486	0.79	rs2249386	ENSG00000270638.1	RP3-466P17.1	4	6.68e-05	0.00441	0.14	0.12	Lobe attachment (rater-scored or self-reported);	chr6:145865475	chr6:145735570~145737218:+
BRCA	cis	rs721917	0.586	rs2758550	ENSG00000280355.1	RP11-119F19.5	-4	6.68e-05	0.00441	-0.13	-0.12	Chronic obstructive pulmonary disease;	chr10:79932606	chr10:79681973~79684094:-
BRCA	cis	rs983392	0.709	rs4939320	ENSG00000275344.1	MIR6503	-4	6.68e-05	0.00441	-0.13	-0.12	Alzheimer's disease (late onset);	chr11:60214328	chr11:60209071~60209156:-
BRCA	cis	rs6012564	1	rs2426109	ENSG00000222365.1	SNORD12B	-4	6.68e-05	0.00441	-0.13	-0.12	Anger;	chr20:49046090	chr20:49280319~49280409:+
BRCA	cis	rs875971	0.66	rs3764903	ENSG00000265600.1	AC006480.1	4	6.68e-05	0.00441	0.15	0.12	Aortic root size;	chr7:66633495	chr7:67356680~67356779:+
BRCA	cis	rs72799341	1	rs7200879	ENSG00000280211.1	RP11-2C24.3	4	6.69e-05	0.00441	0.14	0.12	Diastolic blood pressure;	chr16:30936251	chr16:30773532~30776033:-
BRCA	cis	rs957448	0.561	rs71532325	ENSG00000261437.1	RP11-22C11.2	4	6.69e-05	0.00441	0.12	0.12	Nonsyndromic cleft lip with cleft palate;	chr8:94615738	chr8:94637285~94639467:-
BRCA	cis	rs12049351	0.774	rs12140727	ENSG00000229367.1	HMGN2P19	-4	6.69e-05	0.00441	-0.17	-0.12	Circulating myeloperoxidase levels (plasma);	chr1:229491144	chr1:229570532~229570796:+
BRCA	cis	rs853679	0.517	rs12174753	ENSG00000261839.1	RP1-265C24.8	4	6.69e-05	0.00441	0.17	0.12	Depression;	chr6:28074687	chr6:28136849~28139678:+
BRCA	cis	rs1178127	0.765	rs1178154	ENSG00000232821.1	AC003986.6	4	6.69e-05	0.00441	0.17	0.12	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);	chr7:18742573	chr7:19112474~19114271:+
BRCA	cis	rs875971	1	rs6961717	ENSG00000229180.5	GS1-124K5.11	-4	6.69e-05	0.00441	-0.11	-0.12	Aortic root size;	chr7:66122550	chr7:66526088~66542624:-
BRCA	cis	rs6088590	0.561	rs6059932	ENSG00000275784.1	RP5-1125A11.6	-4	6.69e-05	0.00441	-0.13	-0.12	Coronary artery disease;	chr20:34587662	chr20:33989480~33991818:-
BRCA	cis	rs7572733	0.84	rs10497807	ENSG00000231621.1	AC013264.2	4	6.69e-05	0.00442	0.11	0.12	Dermatomyositis;	chr2:197720363	chr2:197197991~197199273:+
BRCA	cis	rs8062405	0.964	rs11860513	ENSG00000261766.1	RP11-22P6.2	-4	6.69e-05	0.00442	-0.12	-0.12	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814099	chr16:28862166~28863340:-
BRCA	cis	rs1153858	0.725	rs74572151	ENSG00000275672.1	GATM-AS1	-4	6.69e-05	0.00442	-0.16	-0.12	Homoarginine levels;	chr15:45355328	chr15:45378700~45380123:+
BRCA	cis	rs80226907	0.808	rs9323280	ENSG00000258413.1	RP11-665C16.6	-4	6.69e-05	0.00442	-0.27	-0.12	Mean platelet volume;	chr14:55334969	chr14:55262767~55272075:-
BRCA	cis	rs11051970	0.879	rs2651379	ENSG00000274964.1	RP11-817I4.1	-4	6.7e-05	0.00442	-0.14	-0.12	Response to tocilizumab in rheumatoid arthritis;	chr12:32428844	chr12:32339368~32340724:+
BRCA	cis	rs11051970	0.879	rs2651378	ENSG00000274964.1	RP11-817I4.1	-4	6.7e-05	0.00442	-0.14	-0.12	Response to tocilizumab in rheumatoid arthritis;	chr12:32428860	chr12:32339368~32340724:+
BRCA	cis	rs1560104	0.709	rs8063664	ENSG00000259876.1	CTD-3037G24.4	4	6.7e-05	0.00442	0.13	0.12	Obesity-related traits;	chr16:12603354	chr16:12556353~12557694:-
BRCA	cis	rs6431644	0.64	rs2286430	ENSG00000224287.2	MSL3P1	-4	6.7e-05	0.00442	-0.15	-0.12	Left atrial antero-posterior diameter;	chr2:233852579	chr2:233865437~233868444:-
BRCA	cis	rs1348850	0.567	rs3770009	ENSG00000280374.1	RP11-337N6.3	4	6.7e-05	0.00442	0.17	0.12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177671816	chr2:177317715~177318471:-
BRCA	cis	rs73201462	1	rs2999069	ENSG00000242551.2	POU5F1P6	-4	6.7e-05	0.00442	-0.2	-0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128252766	chr3:128674735~128677005:-
BRCA	cis	rs12049351	0.719	rs34804247	ENSG00000229367.1	HMGN2P19	4	6.7e-05	0.00442	0.18	0.12	Circulating myeloperoxidase levels (plasma);	chr1:229484938	chr1:229570532~229570796:+
BRCA	cis	rs6088580	0.602	rs6059840	ENSG00000275784.1	RP5-1125A11.6	-4	6.7e-05	0.00442	-0.13	-0.12	Glomerular filtration rate (creatinine);	chr20:34442600	chr20:33989480~33991818:-
BRCA	cis	rs7487075	0.554	rs12229299	ENSG00000257261.4	RP11-96H19.1	4	6.7e-05	0.00442	0.14	0.12	Itch intensity from mosquito bite;	chr12:46691110	chr12:46383679~46876159:+
BRCA	cis	rs875971	0.862	rs12537823	ENSG00000271064.1	RP11-792A8.3	-4	6.7e-05	0.00442	-0.14	-0.12	Aortic root size;	chr7:66255897	chr7:66748838~66749077:-
BRCA	cis	rs2342371	0.539	rs35959625	ENSG00000243339.3	RN7SL738P	-4	6.7e-05	0.00442	-0.15	-0.12	Fat distribution (HIV);	chr3:196405070	chr3:196399911~196400207:+
BRCA	cis	rs1730008	1	rs827139	ENSG00000279311.1	RP11-170K4.2	4	6.71e-05	0.00442	0.14	0.12	Lobe attachment (rater-scored or self-reported);	chr3:158288574	chr3:158869898~158871821:+
BRCA	cis	rs6088580	0.524	rs1853056	ENSG00000279253.1	RP4-614O4.13	4	6.71e-05	0.00442	0.14	0.12	Glomerular filtration rate (creatinine);	chr20:34674254	chr20:35262727~35264187:-
BRCA	cis	rs849141	0.925	rs508347	ENSG00000234336.5	JAZF1-AS1	-4	6.71e-05	0.00442	-0.17	-0.12	Height;Hip circumference adjusted for BMI;	chr7:28173205	chr7:28180322~28243917:+
BRCA	cis	rs10844706	0.699	rs11052752	ENSG00000256673.1	RP11-599J14.2	-4	6.71e-05	0.00442	-0.15	-0.12	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9735222	chr12:9398355~9414851:-
BRCA	cis	rs7209700	0.821	rs4642	ENSG00000228782.6	CTD-2026D20.3	-4	6.71e-05	0.00442	-0.15	-0.12	IgG glycosylation;	chr17:47292411	chr17:47450568~47492492:-
BRCA	cis	rs7209700	0.821	rs4634	ENSG00000228782.6	CTD-2026D20.3	-4	6.71e-05	0.00442	-0.15	-0.12	IgG glycosylation;	chr17:47292423	chr17:47450568~47492492:-
BRCA	cis	rs801193	0.967	rs2707853	ENSG00000229180.5	GS1-124K5.11	4	6.71e-05	0.00442	0.11	0.12	Aortic root size;	chr7:66749023	chr7:66526088~66542624:-
BRCA	cis	rs6723226	0.699	rs805830	ENSG00000276517.1	AL133243.2	-4	6.71e-05	0.00442	-0.16	-0.12	Intelligence (multi-trait analysis);	chr2:32276406	chr2:32526504~32529507:+
BRCA	cis	rs1008375	0.966	rs7658240	ENSG00000249502.1	AC006160.5	4	6.71e-05	0.00442	0.15	0.12	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17587327	chr4:17587467~17614571:-
BRCA	cis	rs17270561	0.636	rs11794	ENSG00000272462.2	U91328.19	-4	6.71e-05	0.00443	-0.15	-0.12	Iron status biomarkers;	chr6:25701490	chr6:25992662~26001775:+
BRCA	cis	rs733592	0.56	rs2158515	ENSG00000257763.1	OR5BK1P	-4	6.71e-05	0.00443	-0.12	-0.12	Plateletcrit;	chr12:48113885	chr12:48355792~48356614:-
BRCA	cis	rs4415084	0.966	rs36068815	ENSG00000248779.1	RP11-53O19.2	4	6.71e-05	0.00443	0.12	0.12	Breast cancer;	chr5:44645896	chr5:44752949~44765744:+
BRCA	cis	rs1665650	0.957	rs1665645	ENSG00000232767.1	RP11-498B4.5	-4	6.71e-05	0.00443	-0.13	-0.12	Colorectal cancer;	chr10:116728443	chr10:116670103~116672739:+
BRCA	cis	rs66887589	0.616	rs6822808	ENSG00000250412.1	KLHL2P1	4	6.71e-05	0.00443	0.14	0.12	Diastolic blood pressure;	chr4:119296210	chr4:119334329~119378233:+
BRCA	cis	rs6671200	1	rs6678964	ENSG00000235501.4	RP4-639F20.1	-4	6.71e-05	0.00443	-0.25	-0.12	Stearic acid (18:0) levels;	chr1:95228712	chr1:94927566~94963270:+
BRCA	cis	rs801193	0.742	rs9969300	ENSG00000232546.1	RP11-458F8.1	4	6.71e-05	0.00443	0.1	0.12	Aortic root size;	chr7:66316659	chr7:66848496~66858136:+
BRCA	cis	rs2704588	1	rs2609263	ENSG00000270720.1	RP11-84C13.2	-4	6.71e-05	0.00443	-0.19	-0.12	Longevity;	chr4:88908256	chr4:89119284~89119871:+
BRCA	cis	rs11083475	1	rs9304578	ENSG00000267892.1	CTD-2540F13.2	-4	6.71e-05	0.00443	-0.14	-0.12	Heart rate;	chr19:38759697	chr19:38738284~38739863:+
BRCA	cis	rs757081	0.648	rs214907	ENSG00000184669.7	OR7E14P	-4	6.71e-05	0.00443	-0.16	-0.12	Systolic blood pressure;	chr11:17223232	chr11:17013998~17053024:+
BRCA	cis	rs6496932	0.874	rs2003294	ENSG00000259774.1	RP11-182J1.13	4	6.71e-05	0.00443	0.18	0.12	Central corneal thickness;Corneal structure;	chr15:85274141	chr15:84422618~84425882:+
BRCA	cis	rs859767	0.779	rs6430528	ENSG00000224043.6	CCNT2-AS1	4	6.72e-05	0.00443	0.17	0.12	Neuroticism;	chr2:134637778	chr2:134735464~134918710:-
BRCA	cis	rs8046148	0.694	rs877639	ENSG00000279356.1	RP11-429P3.8	-4	6.72e-05	0.00443	-0.12	-0.12	Testicular germ cell tumor;	chr16:50084334	chr16:50072862~50074986:+
BRCA	cis	rs11992162	1	rs7460395	ENSG00000205879.4	FAM90A2P	4	6.72e-05	0.00443	0.15	0.12	Monocyte count;	chr8:11977866	chr8:12172202~12178575:-
BRCA	cis	rs4650943	0.658	rs3123622	ENSG00000227740.1	RP11-318C24.2	-4	6.72e-05	0.00443	-0.13	-0.12	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in inactive individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr1:176387499	chr1:175904762~175920513:-
BRCA	cis	rs4650943	0.683	rs2221333	ENSG00000227740.1	RP11-318C24.2	-4	6.72e-05	0.00443	-0.13	-0.12	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in inactive individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr1:176389121	chr1:175904762~175920513:-
BRCA	cis	rs875971	1	rs2087647	ENSG00000229180.5	GS1-124K5.11	-4	6.72e-05	0.00443	-0.11	-0.12	Aortic root size;	chr7:66128201	chr7:66526088~66542624:-
BRCA	cis	rs739496	0.579	rs12423041	ENSG00000234608.6	MAPKAPK5-AS1	4	6.72e-05	0.00443	0.15	0.12	Platelet count;	chr12:111887042	chr12:111839764~111842902:-
BRCA	cis	rs610932	0.517	rs1530915	ENSG00000275344.1	MIR6503	4	6.72e-05	0.00443	0.12	0.12	Alzheimer's disease;	chr11:60261444	chr11:60209071~60209156:-
BRCA	cis	rs6600671	0.899	rs11249432	ENSG00000223345.3	HIST2H2BA	4	6.72e-05	0.00443	0.15	0.12	Hip geometry;	chr1:121541678	chr1:121108210~121117257:-
BRCA	cis	rs8114671	0.562	rs6087651	ENSG00000126005.14	MMP24-AS1	-4	6.72e-05	0.00443	-0.14	-0.12	Height;	chr20:34930550	chr20:35216462~35278131:-
BRCA	cis	rs8114671	0.562	rs6119545	ENSG00000126005.14	MMP24-AS1	-4	6.72e-05	0.00443	-0.14	-0.12	Height;	chr20:34935066	chr20:35216462~35278131:-
BRCA	cis	rs17772222	0.876	rs61986665	ENSG00000258789.1	RP11-507K2.3	-4	6.72e-05	0.00443	-0.15	-0.12	Coronary artery calcification;	chr14:88711354	chr14:88551597~88552493:+
BRCA	cis	rs1008375	0.932	rs10029173	ENSG00000249502.1	AC006160.5	4	6.72e-05	0.00443	0.14	0.12	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17657975	chr4:17587467~17614571:-
BRCA	cis	rs11673344	0.523	rs8108509	ENSG00000276846.1	CTD-3220F14.3	4	6.72e-05	0.00444	0.15	0.12	Obesity-related traits;	chr19:37060370	chr19:37314868~37315620:-
BRCA	cis	rs8054556	0.935	rs4788203	ENSG00000214725.6	CDIPT-AS1	-4	6.72e-05	0.00444	-0.15	-0.12	Autism spectrum disorder or schizophrenia;	chr16:29967506	chr16:29863593~29868053:+
BRCA	cis	rs2439831	0.85	rs16950562	ENSG00000206991.1	RNU6-610P	-4	6.73e-05	0.00444	-0.2	-0.12	Lung cancer in ever smokers;	chr15:43744166	chr15:43637632~43637738:-
BRCA	cis	rs2018683	1	rs4719962	ENSG00000233517.1	AC005162.5	-4	6.73e-05	0.00444	-0.15	-0.12	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28959621	chr7:28987028~28988899:+
BRCA	cis	rs1178127	0.765	rs1178155	ENSG00000232821.1	AC003986.6	4	6.73e-05	0.00444	0.17	0.12	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);	chr7:18743346	chr7:19112474~19114271:+
BRCA	cis	rs4664293	0.625	rs7595852	ENSG00000226266.5	AC009961.3	4	6.73e-05	0.00444	0.15	0.12	Monocyte percentage of white cells;	chr2:159683656	chr2:159670708~159712435:-
BRCA	cis	rs7686660	1	rs4076451	ENSG00000250326.1	RP11-284M14.1	-4	6.73e-05	0.00444	-0.15	-0.12	Asthma;	chr4:143057712	chr4:142933195~143184861:-
BRCA	cis	rs4699052	0.625	rs28397882	ENSG00000248740.4	RP11-328K4.1	4	6.73e-05	0.00444	0.14	0.12	Testicular germ cell tumor;	chr4:103361679	chr4:103256159~103453658:+
BRCA	cis	rs4699052	0.59	rs28728298	ENSG00000248740.4	RP11-328K4.1	4	6.73e-05	0.00444	0.14	0.12	Testicular germ cell tumor;	chr4:103361693	chr4:103256159~103453658:+
BRCA	cis	rs12368653	0.84	rs10877020	ENSG00000257159.1	RP11-58A17.3	-4	6.73e-05	0.00444	-0.14	-0.12	Multiple sclerosis;	chr12:57794231	chr12:57967058~57968399:+
BRCA	cis	rs113507773	1	rs113507773	ENSG00000241549.7	GUSBP2	-4	6.73e-05	0.00444	-0.2	-0.12	Iron status biomarkers (iron levels);Iron status biomarkers (transferrin saturation);	chr6:26255511	chr6:26871484~26956554:-
BRCA	cis	rs6452524	1	rs17284288	ENSG00000281327.1	LINC01338	4	6.73e-05	0.00444	0.14	0.12	Hypertension (SNP x SNP interaction);	chr5:83148997	chr5:82850864~82859836:-
BRCA	cis	rs4919694	1	rs77505796	ENSG00000236937.2	PTGES3P4	4	6.73e-05	0.00444	0.27	0.12	Arsenic metabolism;	chr10:102888017	chr10:102845595~102845950:+
BRCA	cis	rs11673344	0.504	rs4806409	ENSG00000276846.1	CTD-3220F14.3	4	6.73e-05	0.00444	0.14	0.12	Obesity-related traits;	chr19:37097923	chr19:37314868~37315620:-
BRCA	cis	rs11673344	0.562	rs7257320	ENSG00000276846.1	CTD-3220F14.3	4	6.73e-05	0.00444	0.15	0.12	Obesity-related traits;	chr19:37080933	chr19:37314868~37315620:-
BRCA	cis	rs4650943	0.658	rs2504499	ENSG00000227740.1	RP11-318C24.2	-4	6.73e-05	0.00444	-0.13	-0.12	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in inactive individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr1:176391237	chr1:175904762~175920513:-
BRCA	cis	rs9470794	0.915	rs111514722	ENSG00000204110.6	RP1-153P14.8	-4	6.73e-05	0.00444	-0.25	-0.12	Type 2 diabetes;	chr6:37880846	chr6:37507348~37535616:+
BRCA	cis	rs4869313	0.905	rs2549783	ENSG00000248734.2	CTD-2260A17.1	-4	6.73e-05	0.00444	-0.13	-0.12	Pediatric autoimmune diseases;	chr5:96895668	chr5:96784777~96785999:+
BRCA	cis	rs4415084	0.652	rs10060645	ENSG00000251141.4	RP11-53O19.1	-4	6.73e-05	0.00444	-0.11	-0.12	Breast cancer;	chr5:44908097	chr5:44744900~44808777:-
BRCA	cis	rs11098499	0.954	rs11098525	ENSG00000260404.2	RP11-384K6.6	4	6.73e-05	0.00444	0.12	0.12	Corneal astigmatism;	chr4:119468997	chr4:118591773~118633729:+
BRCA	cis	rs1371614	0.632	rs12615423	ENSG00000272148.1	RP11-195B17.1	-4	6.74e-05	0.00444	-0.14	-0.12	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26935755	chr2:27062428~27062907:-
BRCA	cis	rs739496	0.579	rs73422318	ENSG00000234608.6	MAPKAPK5-AS1	4	6.74e-05	0.00444	0.15	0.12	Platelet count;	chr12:111838169	chr12:111839764~111842902:-
BRCA	cis	rs739496	0.579	rs7314870	ENSG00000234608.6	MAPKAPK5-AS1	4	6.74e-05	0.00444	0.15	0.12	Platelet count;	chr12:111838660	chr12:111839764~111842902:-
BRCA	cis	rs6812193	0.518	rs6810903	ENSG00000271676.1	RP11-1E1.2	4	6.74e-05	0.00444	0.18	0.12	Parkinson's disease;	chr4:76277210	chr4:77112495~77113458:-
BRCA	cis	rs10191773	0.589	rs72831638	ENSG00000243389.1	AC012442.5	4	6.74e-05	0.00444	0.26	0.12	Yeast infection;	chr2:112191635	chr2:112589040~112614431:+
BRCA	cis	rs6445975	0.956	rs7631010	ENSG00000272182.1	RP11-802O23.3	4	6.74e-05	0.00444	0.14	0.12	Systemic lupus erythematosus;	chr3:58460283	chr3:58428255~58428815:+
BRCA	cis	rs983392	0.709	rs11826180	ENSG00000275344.1	MIR6503	-4	6.74e-05	0.00445	-0.13	-0.12	Alzheimer's disease (late onset);	chr11:60223860	chr11:60209071~60209156:-
BRCA	cis	rs11887277	0.771	rs4665348	ENSG00000272148.1	RP11-195B17.1	-4	6.74e-05	0.00445	-0.14	-0.12	Obesity-related traits;	chr2:26815163	chr2:27062428~27062907:-
BRCA	cis	rs11887277	0.741	rs4665351	ENSG00000272148.1	RP11-195B17.1	-4	6.74e-05	0.00445	-0.14	-0.12	Obesity-related traits;	chr2:26815338	chr2:27062428~27062907:-
BRCA	cis	rs875971	0.545	rs10950036	ENSG00000232559.3	GS1-124K5.12	4	6.74e-05	0.00445	0.17	0.12	Aortic root size;	chr7:66353241	chr7:66554588~66576923:-
BRCA	cis	rs7647973	1	rs6805609	ENSG00000244380.1	RP11-24C3.2	-4	6.74e-05	0.00445	-0.16	-0.12	Menarche (age at onset);	chr3:49434089	chr3:48440352~48446656:-
BRCA	cis	rs7656342	0.964	rs13141706	ENSG00000250342.1	SNRPCP16	4	6.74e-05	0.00445	0.14	0.12	Gut microbiota (bacterial taxa);	chr4:9816721	chr4:9051842~9052051:-
BRCA	cis	rs10829156	0.898	rs6482565	ENSG00000225527.1	RP11-383B4.4	-4	6.74e-05	0.00445	-0.17	-0.12	Sudden cardiac arrest;	chr10:18611664	chr10:18531849~18533336:-
BRCA	cis	rs10986311	0.963	rs10986318	ENSG00000227200.1	RP11-121A14.3	4	6.74e-05	0.00445	0.14	0.12	Vitiligo;	chr9:124331210	chr9:124262876~124265809:+
BRCA	cis	rs7520050	0.902	rs9429088	ENSG00000281133.1	AL355480.3	4	6.74e-05	0.00445	0.14	0.12	Reticulocyte count;Red blood cell count;	chr1:46031828	chr1:45580892~45580996:-
BRCA	cis	rs6071166	0.708	rs2902891	ENSG00000224635.1	RP4-564F22.5	-4	6.74e-05	0.00445	-0.15	-0.12	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38681144	chr20:38406011~38416797:-
BRCA	cis	rs6071166	0.683	rs1040898	ENSG00000224635.1	RP4-564F22.5	-4	6.74e-05	0.00445	-0.15	-0.12	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38681211	chr20:38406011~38416797:-
BRCA	cis	rs6071166	0.683	rs6027233	ENSG00000224635.1	RP4-564F22.5	-4	6.74e-05	0.00445	-0.15	-0.12	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38681439	chr20:38406011~38416797:-
BRCA	cis	rs6071166	0.683	rs6015618	ENSG00000224635.1	RP4-564F22.5	-4	6.74e-05	0.00445	-0.15	-0.12	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38681739	chr20:38406011~38416797:-
BRCA	cis	rs6071166	0.646	rs1033514	ENSG00000224635.1	RP4-564F22.5	-4	6.74e-05	0.00445	-0.15	-0.12	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38681871	chr20:38406011~38416797:-
BRCA	cis	rs6071166	0.646	rs1475096	ENSG00000224635.1	RP4-564F22.5	-4	6.74e-05	0.00445	-0.15	-0.12	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38682284	chr20:38406011~38416797:-
BRCA	cis	rs7267979	1	rs6083804	ENSG00000125804.12	FAM182A	4	6.75e-05	0.00445	0.16	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25336424	chr20:26054655~26086917:+
BRCA	cis	rs7267979	1	rs4815405	ENSG00000125804.12	FAM182A	4	6.75e-05	0.00445	0.16	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25336856	chr20:26054655~26086917:+
BRCA	cis	rs7267979	1	rs6050542	ENSG00000125804.12	FAM182A	4	6.75e-05	0.00445	0.16	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25338243	chr20:26054655~26086917:+
BRCA	cis	rs853679	0.517	rs9393891	ENSG00000216901.1	AL022393.7	4	6.75e-05	0.00445	0.18	0.12	Depression;	chr6:28111382	chr6:28176188~28176674:+
BRCA	cis	rs853679	0.517	rs9468286	ENSG00000216901.1	AL022393.7	4	6.75e-05	0.00445	0.18	0.12	Depression;	chr6:28111650	chr6:28176188~28176674:+
BRCA	cis	rs853679	0.517	rs9380055	ENSG00000216901.1	AL022393.7	4	6.75e-05	0.00445	0.18	0.12	Depression;	chr6:28113851	chr6:28176188~28176674:+
BRCA	cis	rs853679	0.517	rs9368553	ENSG00000216901.1	AL022393.7	4	6.75e-05	0.00445	0.18	0.12	Depression;	chr6:28114487	chr6:28176188~28176674:+
BRCA	cis	rs853679	0.517	rs9368554	ENSG00000216901.1	AL022393.7	4	6.75e-05	0.00445	0.18	0.12	Depression;	chr6:28114933	chr6:28176188~28176674:+
BRCA	cis	rs853679	0.517	rs4713137	ENSG00000216901.1	AL022393.7	4	6.75e-05	0.00445	0.18	0.12	Depression;	chr6:28115743	chr6:28176188~28176674:+
BRCA	cis	rs853679	0.517	rs9348793	ENSG00000216901.1	AL022393.7	4	6.75e-05	0.00445	0.18	0.12	Depression;	chr6:28116411	chr6:28176188~28176674:+
BRCA	cis	rs4713118	0.586	rs6905516	ENSG00000216901.1	AL022393.7	4	6.75e-05	0.00445	0.18	0.12	Parkinson's disease;	chr6:28118700	chr6:28176188~28176674:+
BRCA	cis	rs4713118	0.586	rs6905522	ENSG00000216901.1	AL022393.7	4	6.75e-05	0.00445	0.18	0.12	Parkinson's disease;	chr6:28118701	chr6:28176188~28176674:+
BRCA	cis	rs4713118	0.586	rs9468290	ENSG00000216901.1	AL022393.7	4	6.75e-05	0.00445	0.18	0.12	Parkinson's disease;	chr6:28119896	chr6:28176188~28176674:+
BRCA	cis	rs2692947	0.537	rs12471472	ENSG00000168992.4	OR7E102P	4	6.75e-05	0.00445	0.17	0.12	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95539707	chr2:95546531~95547545:+
BRCA	cis	rs7176093	1	rs112154559	ENSG00000259295.5	CSPG4P12	-4	6.75e-05	0.00445	-0.17	-0.12	Aging traits;	chr15:85824968	chr15:85191438~85213905:+
BRCA	cis	rs6547741	0.844	rs7382	ENSG00000234072.1	AC074117.10	-4	6.75e-05	0.00445	-0.12	-0.12	Oral cavity cancer;	chr2:27650548	chr2:27356246~27367622:+
BRCA	cis	rs6736093	0.799	rs13025651	ENSG00000236307.2	EEF1E1P1	-4	6.75e-05	0.00445	-0.16	-0.12	Coronary artery disease;	chr2:112020276	chr2:111887914~111888741:+
BRCA	cis	rs17684571	0.938	rs17751695	ENSG00000231441.1	RP11-472M19.2	4	6.75e-05	0.00445	0.19	0.12	Schizophrenia;	chr6:56695966	chr6:56844002~56864078:+
BRCA	cis	rs6545883	0.894	rs6545845	ENSG00000273302.1	RP11-493E12.2	-4	6.75e-05	0.00445	-0.11	-0.12	Tuberculosis;	chr2:61209909	chr2:61199979~61200769:+
BRCA	cis	rs71520386	0.632	rs10224533	ENSG00000226329.2	AC005682.6	-4	6.75e-05	0.00445	-0.13	-0.12	Fibrinogen levels;	chr7:22821522	chr7:22863874~22881350:-
BRCA	cis	rs610932	0.517	rs1786140	ENSG00000275344.1	MIR6503	-4	6.75e-05	0.00445	-0.12	-0.12	Alzheimer's disease;	chr11:60141154	chr11:60209071~60209156:-
BRCA	cis	rs11955398	0.502	rs34638	ENSG00000272308.1	RP11-231G3.1	4	6.75e-05	0.00445	0.14	0.12	Intelligence (multi-trait analysis);	chr5:61054660	chr5:60866457~60866935:-
BRCA	cis	rs1836229	0.874	rs10739173	ENSG00000225706.1	PTPRD-AS1	-4	6.75e-05	0.00445	-0.13	-0.12	Restless legs syndrome;	chr9:8827060	chr9:8858130~8862255:+
BRCA	cis	rs875971	0.545	rs7810213	ENSG00000230295.1	RP11-458F8.2	4	6.75e-05	0.00445	0.12	0.12	Aortic root size;	chr7:66481592	chr7:66880708~66882981:+
BRCA	cis	rs16826658	1	rs16826658	ENSG00000228397.1	RP1-224A6.3	-4	6.76e-05	0.00445	-0.15	-0.12	Endometriosis;	chr1:22159378	chr1:22023994~22024968:-
BRCA	cis	rs7246967	0.866	rs34294248	ENSG00000198153.8	ZNF849P	-4	6.76e-05	0.00445	-0.17	-0.12	Bronchopulmonary dysplasia;	chr19:22867667	chr19:22685167~22686732:+
BRCA	cis	rs11098499	0.954	rs10006525	ENSG00000260404.2	RP11-384K6.6	4	6.76e-05	0.00445	0.12	0.12	Corneal astigmatism;	chr4:119487776	chr4:118591773~118633729:+
BRCA	cis	rs6747488	0.513	rs160803	ENSG00000272716.1	RP11-563N4.1	4	6.76e-05	0.00445	0.13	0.12	Interleukin-18 levels;	chr2:31831228	chr2:32165046~32165757:-
BRCA	cis	rs7267979	1	rs6050626	ENSG00000277938.1	RP5-965G21.3	4	6.76e-05	0.00445	0.15	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25447625	chr20:25229150~25231933:+
BRCA	cis	rs8114671	0.836	rs1885114	ENSG00000279253.1	RP4-614O4.13	4	6.76e-05	0.00445	0.14	0.12	Height;	chr20:34989558	chr20:35262727~35264187:-
BRCA	cis	rs7789940	0.904	rs7459185	ENSG00000280388.1	RP11-229D13.3	4	6.76e-05	0.00445	0.13	0.12	Multiple sclerosis;	chr7:76305323	chr7:76043977~76045963:-
BRCA	cis	rs1998359	0.501	rs1957590	ENSG00000259087.4	RP11-356O9.2	-4	6.76e-05	0.00446	-0.12	-0.12	Self-reported allergy;	chr14:37683693	chr14:37556158~37567095:-
BRCA	cis	rs7267979	0.934	rs2261753	ENSG00000274973.1	RP13-401N8.7	-4	6.76e-05	0.00446	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25281655	chr20:25845497~25845862:+
BRCA	cis	rs7267979	1	rs2424700	ENSG00000277938.1	RP5-965G21.3	4	6.76e-05	0.00446	0.15	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25285877	chr20:25229150~25231933:+
BRCA	cis	rs375066	0.934	rs411803	ENSG00000267191.1	RP11-15A1.2	4	6.76e-05	0.00446	0.16	0.12	Breast cancer;	chr19:43928688	chr19:43902001~43926545:+
BRCA	cis	rs1479090	0.652	rs1564313	ENSG00000250027.1	RP11-563E2.2	-4	6.76e-05	0.00446	-0.16	-0.12	Lung cancer;	chr4:163154598	chr4:163108785~163119965:+
BRCA	cis	rs1371614	0.632	rs7599286	ENSG00000229122.1	AGBL5-IT1	4	6.76e-05	0.00446	0.13	0.12	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26929530	chr2:27061038~27061815:+
BRCA	cis	rs1371614	0.61	rs2384511	ENSG00000229122.1	AGBL5-IT1	4	6.76e-05	0.00446	0.13	0.12	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26929867	chr2:27061038~27061815:+
BRCA	cis	rs4415084	1	rs10805686	ENSG00000272335.1	RP11-53O19.3	4	6.76e-05	0.00446	0.12	0.12	Breast cancer;	chr5:44662026	chr5:44826076~44828592:+
BRCA	cis	rs8180040	0.62	rs9875235	ENSG00000271161.1	BOLA2P2	4	6.77e-05	0.00446	0.13	0.12	Colorectal cancer;	chr3:47042131	chr3:47499841~47500407:+
BRCA	cis	rs62025270	0.688	rs55957626	ENSG00000259762.1	RP11-158M2.4	-4	6.77e-05	0.00446	-0.18	-0.12	Idiopathic pulmonary fibrosis;	chr15:85773486	chr15:85750336~85752901:-
BRCA	cis	rs10508774	0.5	rs56278188	ENSG00000273038.2	RP11-479G22.8	4	6.77e-05	0.00446	0.27	0.12	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32962318	chr10:32887255~32889311:-
BRCA	cis	rs7267979	1	rs7018	ENSG00000277938.1	RP5-965G21.3	4	6.77e-05	0.00446	0.15	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25297625	chr20:25229150~25231933:+
BRCA	cis	rs875971	0.798	rs12698522	ENSG00000229886.1	RP5-1132H15.3	4	6.77e-05	0.00446	0.14	0.12	Aortic root size;	chr7:66502354	chr7:66025126~66031544:-
BRCA	cis	rs875971	0.83	rs28714531	ENSG00000229886.1	RP5-1132H15.3	4	6.77e-05	0.00446	0.14	0.12	Aortic root size;	chr7:66503250	chr7:66025126~66031544:-
BRCA	cis	rs875971	0.862	rs12698526	ENSG00000229886.1	RP5-1132H15.3	4	6.77e-05	0.00446	0.14	0.12	Aortic root size;	chr7:66504118	chr7:66025126~66031544:-
BRCA	cis	rs10043775	1	rs10041283	ENSG00000251330.3	CTD-2283N19.1	4	6.77e-05	0.00446	0.15	0.12	Periodontal microbiota;	chr5:148397235	chr5:148430159~148430807:-
BRCA	cis	rs6751744	0.855	rs35019796	ENSG00000230783.1	AC009961.2	-4	6.77e-05	0.00446	-0.17	-0.12	Dysphagia;	chr2:159510644	chr2:159689217~159690291:-
BRCA	cis	rs10129255	0.5	rs11627315	ENSG00000232216.1	IGHV3-43	4	6.77e-05	0.00446	0.09	0.12	Kawasaki disease;	chr14:106802182	chr14:106470264~106470800:-
BRCA	cis	rs2242116	0.592	rs2290545	ENSG00000276925.1	RP11-708J19.3	-4	6.77e-05	0.00446	-0.17	-0.12	Birth weight;	chr3:46925550	chr3:47469777~47469987:+
BRCA	cis	rs11603691	1	rs117497302	ENSG00000254662.1	RP11-872D17.4	-4	6.77e-05	0.00446	-0.31	-0.12	Low high density lipoprotein cholesterol levels;	chr11:57242333	chr11:57325603~57327958:+
BRCA	cis	rs8054556	0.692	rs12716972	ENSG00000183604.13	SMG1P5	-4	6.77e-05	0.00446	-0.12	-0.12	Autism spectrum disorder or schizophrenia;	chr16:29925333	chr16:30267553~30335374:-
BRCA	cis	rs1005277	0.541	rs1740741	ENSG00000276805.1	RP11-291L22.6	4	6.77e-05	0.00446	0.13	0.12	Extrinsic epigenetic age acceleration;	chr10:38226406	chr10:38451030~38451785:+
BRCA	cis	rs1005277	0.528	rs2057228	ENSG00000276805.1	RP11-291L22.6	4	6.77e-05	0.00446	0.13	0.12	Extrinsic epigenetic age acceleration;	chr10:38226838	chr10:38451030~38451785:+
BRCA	cis	rs11098499	0.954	rs6847248	ENSG00000225892.3	RP11-384K6.2	4	6.77e-05	0.00446	0.13	0.12	Corneal astigmatism;	chr4:119304800	chr4:118632274~118634759:+
BRCA	cis	rs1949733	0.701	rs1880024	ENSG00000251615.3	RP11-774O3.3	-4	6.77e-05	0.00446	-0.13	-0.12	Response to antineoplastic agents;	chr4:8452912	chr4:8355090~8358338:-
BRCA	cis	rs8017423	0.605	rs4904676	ENSG00000275198.1	RP11-471B22.3	4	6.77e-05	0.00446	0.14	0.12	Mortality in heart failure;	chr14:90352876	chr14:90383365~90387973:+
BRCA	cis	rs8017423	0.647	rs4904677	ENSG00000275198.1	RP11-471B22.3	4	6.77e-05	0.00446	0.14	0.12	Mortality in heart failure;	chr14:90352901	chr14:90383365~90387973:+
BRCA	cis	rs2832191	0.74	rs13048618	ENSG00000215533.7	LINC00189	-4	6.77e-05	0.00446	-0.14	-0.12	Dental caries;	chr21:29086363	chr21:29193480~29288205:+
BRCA	cis	rs860295	0.665	rs12028416	ENSG00000232093.1	RP11-307C12.11	4	6.78e-05	0.00446	0.14	0.12	Body mass index;	chr1:155431370	chr1:155045191~155046118:-
BRCA	cis	rs860295	0.629	rs12026638	ENSG00000232093.1	RP11-307C12.11	4	6.78e-05	0.00446	0.14	0.12	Body mass index;	chr1:155431469	chr1:155045191~155046118:-
BRCA	cis	rs853679	0.76	rs9468317	ENSG00000204709.4	LINC01556	4	6.78e-05	0.00446	0.19	0.12	Depression;	chr6:28230678	chr6:28943877~28944537:+
BRCA	cis	rs2255336	0.938	rs4548707	ENSG00000245648.1	RP11-277P12.20	-4	6.78e-05	0.00447	-0.19	-0.12	Blood protein levels;	chr12:10467634	chr12:10363769~10398506:+
BRCA	cis	rs2688608	0.592	rs10824032	ENSG00000213731.2	RAB5CP1	-4	6.78e-05	0.00447	-0.14	-0.12	Inflammatory bowel disease;	chr10:73768372	chr10:74423435~74424014:-
BRCA	cis	rs6968419	0.674	rs1918912	ENSG00000279086.1	RP11-667F14.1	-4	6.78e-05	0.00447	-0.13	-0.12	Intraocular pressure;	chr7:116266319	chr7:116209234~116211511:-
BRCA	cis	rs1008375	0.932	rs4698626	ENSG00000249502.1	AC006160.5	-4	6.78e-05	0.00447	-0.14	-0.12	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17604198	chr4:17587467~17614571:-
BRCA	cis	rs745109	0.882	rs60304516	ENSG00000273080.1	RP11-301O19.1	4	6.78e-05	0.00447	0.19	0.12	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86449385	chr2:86195590~86196049:+
BRCA	cis	rs11742741	0.806	rs62349719	ENSG00000248874.4	C5orf17	-4	6.78e-05	0.00447	-0.16	-0.12	Educational attainment;	chr5:24046751	chr5:23951348~24178263:+
BRCA	cis	rs6121246	0.909	rs57726761	ENSG00000230613.1	HM13-AS1	4	6.78e-05	0.00447	0.18	0.12	Mean corpuscular hemoglobin;	chr20:31726243	chr20:31567707~31573263:-
BRCA	cis	rs7927592	0.83	rs10896339	ENSG00000212093.1	AP000807.1	4	6.78e-05	0.00447	0.13	0.12	Total body bone mineral density;	chr11:68535378	chr11:68506083~68506166:-
BRCA	cis	rs7267979	1	rs6076336	ENSG00000125804.12	FAM182A	4	6.78e-05	0.00447	0.16	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25338576	chr20:26054655~26086917:+
BRCA	cis	rs2229238	0.911	rs6672087	ENSG00000272030.1	RP1-178F15.4	-4	6.78e-05	0.00447	-0.17	-0.12	Coronary heart disease;	chr1:154543646	chr1:153631438~153634397:-
BRCA	cis	rs801193	1	rs2659889	ENSG00000229180.5	GS1-124K5.11	4	6.79e-05	0.00447	0.11	0.12	Aortic root size;	chr7:66752125	chr7:66526088~66542624:-
BRCA	cis	rs957448	1	rs1055797	ENSG00000254315.1	RP11-267M23.3	4	6.79e-05	0.00447	0.16	0.12	Nonsyndromic cleft lip with cleft palate;	chr8:94511005	chr8:94533628~94534391:+
BRCA	cis	rs4916588	0.636	rs75488116	ENSG00000230732.4	AC127904.2	4	6.79e-05	0.00447	0.16	0.12	Night sleep phenotypes;	chr3:196892737	chr3:196912646~196914579:+
BRCA	cis	rs7829975	0.688	rs6995407	ENSG00000253981.4	ALG1L13P	4	6.79e-05	0.00447	0.14	0.12	Mood instability;	chr8:8527137	chr8:8236003~8244667:-
BRCA	cis	rs875971	1	rs6958484	ENSG00000229180.5	GS1-124K5.11	-4	6.79e-05	0.00447	-0.11	-0.12	Aortic root size;	chr7:66134459	chr7:66526088~66542624:-
BRCA	cis	rs948562	0.681	rs11822754	ENSG00000255299.4	RP11-655C2.3	-4	6.79e-05	0.00447	-0.15	-0.12	Lymphoma;	chr11:58665406	chr11:58497888~58505758:-
BRCA	cis	rs1722141	0.65	rs788711	ENSG00000229628.1	AC073115.7	4	6.79e-05	0.00447	0.16	0.12	Sitting height ratio;	chr7:45971115	chr7:45990905~46000898:+
BRCA	cis	rs34792	0.528	rs153803	ENSG00000207425.1	Y_RNA	4	6.79e-05	0.00447	0.14	0.12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15458303	chr16:14915457~14915556:-
BRCA	cis	rs4834770	0.792	rs7676969	ENSG00000249244.1	RP11-548H18.2	4	6.79e-05	0.00447	0.14	0.12	Blood protein levels;	chr4:119252569	chr4:119391831~119395335:-
BRCA	cis	rs4834770	0.685	rs4496567	ENSG00000249244.1	RP11-548H18.2	4	6.79e-05	0.00447	0.14	0.12	Blood protein levels;	chr4:119254470	chr4:119391831~119395335:-
BRCA	cis	rs4834770	0.792	rs6823331	ENSG00000249244.1	RP11-548H18.2	4	6.79e-05	0.00447	0.14	0.12	Blood protein levels;	chr4:119259635	chr4:119391831~119395335:-
BRCA	cis	rs35740288	0.77	rs11634177	ENSG00000202081.1	RNU6-1280P	-4	6.79e-05	0.00447	-0.16	-0.12	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85605159	chr15:85651522~85651628:-
BRCA	cis	rs7735319	0.565	rs6885506	ENSG00000249572.1	CTD-2203K17.1	4	6.79e-05	0.00447	0.16	0.12	Systolic blood pressure;	chr5:33102235	chr5:33424025~33440619:-
BRCA	cis	rs4474465	1	rs10899514	ENSG00000251323.2	RP11-452H21.4	4	6.79e-05	0.00448	0.16	0.12	Alzheimer's disease (survival time);	chr11:78461649	chr11:78423982~78429836:-
BRCA	cis	rs11642862	1	rs74483355	ENSG00000280211.1	RP11-2C24.3	-4	6.8e-05	0.00448	-0.2	-0.12	Tonsillectomy;	chr16:30825109	chr16:30773532~30776033:-
BRCA	cis	rs4869313	0.902	rs6556942	ENSG00000248734.2	CTD-2260A17.1	-4	6.8e-05	0.00448	-0.13	-0.12	Pediatric autoimmune diseases;	chr5:96890492	chr5:96784777~96785999:+
BRCA	cis	rs9527	0.59	rs7910900	ENSG00000213061.2	PFN1P11	4	6.8e-05	0.00448	0.17	0.12	Arsenic metabolism;	chr10:103070141	chr10:102838011~102845473:-
BRCA	cis	rs7267979	0.668	rs4815398	ENSG00000231081.1	RP4-760C5.3	4	6.8e-05	0.00448	0.16	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25256702	chr20:26008791~26010531:-
BRCA	cis	rs7811142	1	rs7794485	ENSG00000078319.8	PMS2P1	-4	6.8e-05	0.00448	-0.21	-0.12	Platelet count;	chr7:100471313	chr7:100320992~100341908:-
BRCA	cis	rs4835473	0.932	rs2127788	ENSG00000249741.2	RP11-673E1.3	-4	6.8e-05	0.00448	-0.13	-0.12	Immature fraction of reticulocytes;	chr4:143741996	chr4:143911514~143912053:-
BRCA	cis	rs10986311	0.814	rs10116520	ENSG00000227200.1	RP11-121A14.3	-4	6.8e-05	0.00448	-0.14	-0.12	Vitiligo;	chr9:124267351	chr9:124262876~124265809:+
BRCA	cis	rs7487075	0.859	rs956910	ENSG00000257261.4	RP11-96H19.1	4	6.8e-05	0.00448	0.13	0.12	Itch intensity from mosquito bite;	chr12:46366005	chr12:46383679~46876159:+
BRCA	cis	rs2991971	0.81	rs12119202	ENSG00000280836.1	AL355480.1	-4	6.8e-05	0.00448	-0.15	-0.12	High light scatter reticulocyte count;	chr1:45460259	chr1:45581219~45581321:-
BRCA	cis	rs73222236	0.825	rs6776841	ENSG00000239213.4	NCK1-AS1	4	6.8e-05	0.00448	0.14	0.12	Coronary artery disease;	chr3:136323322	chr3:136841726~136862054:-
BRCA	cis	rs7620503	1	rs4273409	ENSG00000277241.1	RP11-114M1.3	4	6.8e-05	0.00448	0.14	0.12	Corneal structure;	chr3:177580997	chr3:177700346~177701072:-
BRCA	cis	rs7620503	1	rs36102700	ENSG00000277241.1	RP11-114M1.3	4	6.8e-05	0.00448	0.14	0.12	Corneal structure;	chr3:177581321	chr3:177700346~177701072:-
BRCA	cis	rs4700393	0.517	rs13183561	ENSG00000215032.2	GNL3LP1	-4	6.81e-05	0.00448	-0.18	-0.12	Intelligence (multi-trait analysis);	chr5:60803976	chr5:60891935~60893577:-
BRCA	cis	rs4835473	0.932	rs6852195	ENSG00000249741.2	RP11-673E1.3	-4	6.81e-05	0.00448	-0.13	-0.12	Immature fraction of reticulocytes;	chr4:143742584	chr4:143911514~143912053:-
BRCA	cis	rs6430585	0.527	rs76622824	ENSG00000231890.6	DARS-AS1	-4	6.81e-05	0.00448	-0.19	-0.12	Corneal structure;	chr2:135654309	chr2:135985176~136022593:+
BRCA	cis	rs6546324	0.559	rs11126134	ENSG00000236780.4	AC078941.1	-4	6.81e-05	0.00448	-0.21	-0.12	Endometriosis;	chr2:67553932	chr2:67123357~67215319:-
BRCA	cis	rs4415084	0.716	rs4566804	ENSG00000251141.4	RP11-53O19.1	-4	6.81e-05	0.00448	-0.12	-0.12	Breast cancer;	chr5:44855637	chr5:44744900~44808777:-
BRCA	cis	rs738722	0.808	rs5752775	ENSG00000279978.1	chr22-38_28785274-29006793.1	-4	6.81e-05	0.00448	-0.16	-0.12	Optic cup area;Esophageal cancer and gastric cancer;	chr22:28711207	chr22:28930201~29197572:+
BRCA	cis	rs6593122	0.755	rs7800236	ENSG00000235454.1	HAUS6P3	-4	6.81e-05	0.00448	-0.17	-0.12	Vaccine-related adverse events;	chr7:54139329	chr7:53862233~53863339:+
BRCA	cis	rs10146616	0.656	rs2192594	ENSG00000259015.1	RP11-109N23.6	4	6.81e-05	0.00448	0.16	0.12	Stem cell factor levels;	chr14:72868461	chr14:72960595~72961993:+
BRCA	cis	rs6545883	0.826	rs777591	ENSG00000273302.1	RP11-493E12.2	4	6.81e-05	0.00449	0.11	0.12	Tuberculosis;	chr2:61190482	chr2:61199979~61200769:+
BRCA	cis	rs12505749	0.542	rs4864585	ENSG00000270147.1	RP11-646I6.6	-4	6.81e-05	0.00449	-0.14	-0.12	Airflow obstruction;	chr4:56494469	chr4:56396312~56396871:+
BRCA	cis	rs1075265	0.62	rs2542584	ENSG00000272156.1	RP11-477N3.1	-4	6.81e-05	0.00449	-0.13	-0.12	Chronotype;Morning vs. evening chronotype;	chr2:53782707	chr2:54082554~54085066:+
BRCA	cis	rs17756712	0.527	rs1193742	ENSG00000271911.1	RP11-532F6.5	-4	6.81e-05	0.00449	-0.16	-0.12	Vertical cup-disc ratio;	chr6:635629	chr6:761675~780648:+
BRCA	cis	rs12435908	1	rs12433827	ENSG00000276116.2	FUT8-AS1	-4	6.81e-05	0.00449	-0.2	-0.12	Ischemic stroke;	chr14:65588892	chr14:65411170~65412690:-
BRCA	cis	rs6012564	1	rs2426106	ENSG00000222365.1	SNORD12B	-4	6.82e-05	0.00449	-0.13	-0.12	Anger;	chr20:49022927	chr20:49280319~49280409:+
BRCA	cis	rs757081	0.667	rs60173525	ENSG00000184669.7	OR7E14P	-4	6.82e-05	0.00449	-0.18	-0.12	Systolic blood pressure;	chr11:17238420	chr11:17013998~17053024:+
BRCA	cis	rs757081	0.667	rs12577525	ENSG00000184669.7	OR7E14P	-4	6.82e-05	0.00449	-0.18	-0.12	Systolic blood pressure;	chr11:17238569	chr11:17013998~17053024:+
BRCA	cis	rs6671200	0.79	rs640527	ENSG00000226026.4	RP11-57H12.3	-4	6.82e-05	0.00449	-0.23	-0.12	Stearic acid (18:0) levels;	chr1:95240059	chr1:95163219~95233982:-
BRCA	cis	rs931127	0.658	rs4930305	ENSG00000245532.5	NEAT1	4	6.82e-05	0.00449	0.11	0.12	Systemic lupus erythematosus;	chr11:65696529	chr11:65422774~65445540:+
BRCA	cis	rs2731006	0.901	rs2731008	ENSG00000257114.2	RP11-25I15.3	4	6.82e-05	0.00449	0.19	0.12	Panic disorder;	chr12:42767221	chr12:42692216~42717119:+
BRCA	cis	rs7818688	1	rs10100089	ENSG00000245080.5	RP11-320N21.1	-4	6.82e-05	0.00449	-0.2	-0.12	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95012865	chr8:95066808~95073182:-
BRCA	cis	rs7818688	1	rs10111300	ENSG00000245080.5	RP11-320N21.1	-4	6.82e-05	0.00449	-0.2	-0.12	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95013403	chr8:95066808~95073182:-
BRCA	cis	rs72772090	0.522	rs111977797	ENSG00000248734.2	CTD-2260A17.1	-4	6.82e-05	0.00449	-0.29	-0.12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96680463	chr5:96784777~96785999:+
BRCA	cis	rs875971	1	rs6957199	ENSG00000265600.1	AC006480.1	-4	6.82e-05	0.00449	-0.14	-0.12	Aortic root size;	chr7:66513532	chr7:67356680~67356779:+
BRCA	cis	rs7246657	0.551	rs11084873	ENSG00000267470.4	ZNF571-AS1	4	6.82e-05	0.00449	0.19	0.12	Coronary artery calcification;	chr19:37093008	chr19:37548914~37587348:+
BRCA	cis	rs35740288	0.822	rs17574774	ENSG00000259407.1	RP11-158M2.3	4	6.83e-05	0.00449	0.17	0.12	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85690139	chr15:85744109~85750281:-
BRCA	cis	rs7267979	0.899	rs2104734	ENSG00000276952.1	RP5-965G21.6	4	6.83e-05	0.00449	0.15	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25546032	chr20:25284915~25285588:-
BRCA	cis	rs12612619	0.704	rs11680633	ENSG00000272148.1	RP11-195B17.1	4	6.83e-05	0.00449	0.14	0.12	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27001341	chr2:27062428~27062907:-
BRCA	cis	rs8094794	0.744	rs16968181	ENSG00000267707.2	RP11-95O2.5	4	6.83e-05	0.00449	0.19	0.12	Periodontal disease-related phenotypes;	chr18:36699856	chr18:37243776~37247506:+
BRCA	cis	rs4834770	1	rs4834770	ENSG00000250412.1	KLHL2P1	4	6.83e-05	0.0045	0.13	0.12	Blood protein levels;	chr4:119320694	chr4:119334329~119378233:+
BRCA	cis	rs9467773	0.62	rs2451711	ENSG00000224843.5	LINC00240	-4	6.83e-05	0.0045	-0.13	-0.12	Intelligence (multi-trait analysis);	chr6:26662882	chr6:26956992~27023924:+
BRCA	cis	rs1156327	0.655	rs4238672	ENSG00000188477.11	AC003003.5	-4	6.83e-05	0.0045	-0.32	-0.12	Periodontal disease-related phenotypes;	chr16:19314197	chr16:19285783~19310947:+
BRCA	cis	rs2243480	0.901	rs778730	ENSG00000275400.1	RP4-756H11.5	4	6.83e-05	0.0045	0.23	0.12	Diabetic kidney disease;	chr7:66358338	chr7:66553805~66554199:-
BRCA	cis	rs1790761	0.52	rs12805884	ENSG00000255318.1	RP11-655M14.13	-4	6.83e-05	0.0045	-0.15	-0.12	Mean corpuscular volume;	chr11:67620506	chr11:67618279~67627304:-
BRCA	cis	rs1408224	0.688	rs9316222	ENSG00000261097.1	LINC00563	4	6.83e-05	0.0045	0.17	0.12	QRS complex (12-leadsum);	chr13:46640555	chr13:46296445~46297844:-
BRCA	cis	rs875971	0.638	rs10249404	ENSG00000229180.5	GS1-124K5.11	-4	6.83e-05	0.0045	-0.11	-0.12	Aortic root size;	chr7:66581737	chr7:66526088~66542624:-
BRCA	cis	rs970548	0.955	rs11239551	ENSG00000230869.1	CTGLF10P	4	6.83e-05	0.0045	0.16	0.12	Total cholesterol levels;HDL cholesterol;HDL cholesterol levels;Cholesterol, total;	chr10:45530659	chr10:45678692~45700532:+
BRCA	cis	rs375066	0.935	rs423765	ENSG00000267191.1	RP11-15A1.2	-4	6.83e-05	0.0045	-0.16	-0.12	Breast cancer;	chr19:43912047	chr19:43902001~43926545:+
BRCA	cis	rs875971	0.545	rs73378304	ENSG00000230295.1	RP11-458F8.2	4	6.84e-05	0.0045	0.11	0.12	Aortic root size;	chr7:66175760	chr7:66880708~66882981:+
BRCA	cis	rs7620503	0.959	rs6443476	ENSG00000277241.1	RP11-114M1.3	4	6.84e-05	0.0045	0.14	0.12	Corneal structure;	chr3:177589907	chr3:177700346~177701072:-
BRCA	cis	rs7620503	0.959	rs6443477	ENSG00000277241.1	RP11-114M1.3	4	6.84e-05	0.0045	0.14	0.12	Corneal structure;	chr3:177590145	chr3:177700346~177701072:-
BRCA	cis	rs7620503	0.959	rs6769466	ENSG00000277241.1	RP11-114M1.3	4	6.84e-05	0.0045	0.14	0.12	Corneal structure;	chr3:177590226	chr3:177700346~177701072:-
BRCA	cis	rs1429524	0.848	rs35213298	ENSG00000243144.5	RP11-115N4.1	4	6.84e-05	0.0045	0.17	0.12	Ejection fraction in Tripanosoma cruzi seropositivity;	chr7:91303584	chr7:91311368~91515409:+
BRCA	cis	rs490049	1	rs490049	ENSG00000234535.1	RP11-37L2.1	4	6.84e-05	0.0045	0.28	0.12	Diabetic kidney disease;	chr13:32990725	chr13:33610967~33611522:+
BRCA	cis	rs875971	0.862	rs7783779	ENSG00000273024.4	INTS4P2	4	6.84e-05	0.0045	0.14	0.12	Aortic root size;	chr7:66331639	chr7:65647864~65715661:+
BRCA	cis	rs1383484	0.798	rs2086441	ENSG00000230373.7	GOLGA6L5P	-4	6.84e-05	0.0045	-0.15	-0.12	Height;	chr15:83881728	chr15:84507885~84516814:-
BRCA	cis	rs2302465	0.86	rs73241180	ENSG00000273133.1	RP11-799M12.2	-4	6.84e-05	0.0045	-0.24	-0.12	Blood protein levels;	chr4:15645092	chr4:15563698~15564253:-
BRCA	cis	rs77633900	0.772	rs284902	ENSG00000196274.5	Metazoa_SRP	4	6.84e-05	0.0045	0.21	0.12	Glioma;Non-glioblastoma glioma;	chr15:76453346	chr15:76230048~76230390:-
BRCA	cis	rs10266483	0.921	rs624257	ENSG00000227986.1	TRIM60P18	4	6.84e-05	0.0045	0.13	0.12	Response to statin therapy;	chr7:64284848	chr7:64355078~64356199:+
BRCA	cis	rs853679	1	rs10456362	ENSG00000204709.4	LINC01556	-4	6.84e-05	0.0045	-0.21	-0.12	Depression;	chr6:28254038	chr6:28943877~28944537:+
BRCA	cis	rs6496044	0.568	rs7176291	ENSG00000202081.1	RNU6-1280P	4	6.84e-05	0.0045	0.14	0.12	Interstitial lung disease;	chr15:85524167	chr15:85651522~85651628:-
BRCA	cis	rs6439699	1	rs60246781	ENSG00000239213.4	NCK1-AS1	4	6.84e-05	0.0045	0.17	0.12	Intelligence (multi-trait analysis);	chr3:137291161	chr3:136841726~136862054:-
BRCA	cis	rs7267979	0.966	rs2227890	ENSG00000274973.1	RP13-401N8.7	-4	6.84e-05	0.0045	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25280295	chr20:25845497~25845862:+
BRCA	cis	rs12612619	0.704	rs7602823	ENSG00000272148.1	RP11-195B17.1	-4	6.84e-05	0.0045	-0.14	-0.12	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27086538	chr2:27062428~27062907:-
BRCA	cis	rs7020830	0.898	rs7846747	ENSG00000260100.1	RP11-220I1.5	-4	6.85e-05	0.00451	-0.15	-0.12	Schizophrenia;	chr9:37167542	chr9:37078813~37079776:-
BRCA	cis	rs8058578	0.887	rs28421305	ENSG00000274678.1	RP11-2C24.7	4	6.85e-05	0.00451	0.15	0.12	Multiple myeloma;	chr16:30826807	chr16:30821338~30821884:+
BRCA	cis	rs453301	0.686	rs6601280	ENSG00000173295.6	FAM86B3P	4	6.85e-05	0.00451	0.13	0.12	Joint mobility (Beighton score);	chr8:9051726	chr8:8228595~8244865:+
BRCA	cis	rs2018683	0.683	rs12538606	ENSG00000233517.1	AC005162.5	-4	6.85e-05	0.00451	-0.15	-0.12	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28929791	chr7:28987028~28988899:+
BRCA	cis	rs11048470	0.638	rs2570	ENSG00000256894.1	RP11-283G6.3	4	6.85e-05	0.00451	0.13	0.12	Waist-hip ratio;	chr12:26338905	chr12:26125155~26126617:-
BRCA	cis	rs739496	0.579	rs12423041	ENSG00000257624.1	RP1-128M12.3	4	6.85e-05	0.00451	0.17	0.12	Platelet count;	chr12:111887042	chr12:112000739~112000985:-
BRCA	cis	rs524281	0.861	rs10896087	ENSG00000255557.1	RP11-770G2.2	4	6.85e-05	0.00451	0.17	0.12	Electroencephalogram traits;	chr11:66157078	chr11:65745729~65771585:+
BRCA	cis	rs524281	0.861	rs4013917	ENSG00000255557.1	RP11-770G2.2	4	6.85e-05	0.00451	0.17	0.12	Electroencephalogram traits;	chr11:66158714	chr11:65745729~65771585:+
BRCA	cis	rs860295	0.702	rs12239100	ENSG00000225855.5	RUSC1-AS1	4	6.85e-05	0.00451	0.1	0.12	Body mass index;	chr1:155458685	chr1:155316863~155324176:-
BRCA	cis	rs733175	0.857	rs7666545	ENSG00000250413.1	RP11-448G15.1	-4	6.85e-05	0.00451	-0.19	-0.12	Psychosis and Alzheimer's disease;	chr4:10010748	chr4:10006482~10009725:+
BRCA	cis	rs73242632	1	rs73242623	ENSG00000269949.1	RP11-738E22.3	4	6.85e-05	0.00451	0.29	0.12	Congenital heart disease (maternal effect);	chr4:56974377	chr4:56960927~56961373:-
BRCA	cis	rs6431644	0.694	rs648818	ENSG00000224287.2	MSL3P1	4	6.85e-05	0.00451	0.15	0.12	Left atrial antero-posterior diameter;	chr2:233846756	chr2:233865437~233868444:-
BRCA	cis	rs11098499	0.955	rs13129661	ENSG00000250412.1	KLHL2P1	4	6.85e-05	0.00451	0.15	0.12	Corneal astigmatism;	chr4:119231754	chr4:119334329~119378233:+
BRCA	cis	rs7520050	0.751	rs2991975	ENSG00000234329.1	RP11-767N6.2	-4	6.85e-05	0.00451	-0.11	-0.12	Reticulocyte count;Red blood cell count;	chr1:45558854	chr1:45651039~45651826:-
BRCA	cis	rs11098499	0.954	rs6849561	ENSG00000225892.3	RP11-384K6.2	-4	6.86e-05	0.00451	-0.13	-0.12	Corneal astigmatism;	chr4:119488539	chr4:118632274~118634759:+
BRCA	cis	rs524281	0.731	rs11227433	ENSG00000255038.1	RP11-1167A19.2	-4	6.86e-05	0.00451	-0.19	-0.12	Electroencephalogram traits;	chr11:66237222	chr11:66067277~66069619:-
BRCA	cis	rs3617	0.625	rs11719137	ENSG00000242142.1	SERBP1P3	-4	6.86e-05	0.00451	-0.14	-0.12	Red blood cell count;Autism spectrum disorder or schizophrenia;	chr3:52842373	chr3:53064283~53065091:-
BRCA	cis	rs6968419	0.788	rs10953810	ENSG00000279086.1	RP11-667F14.1	-4	6.86e-05	0.00451	-0.14	-0.12	Intraocular pressure;	chr7:116172324	chr7:116209234~116211511:-
BRCA	cis	rs11098499	0.663	rs9996501	ENSG00000225892.3	RP11-384K6.2	4	6.86e-05	0.00451	0.12	0.12	Corneal astigmatism;	chr4:119317763	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.697	rs28458294	ENSG00000225892.3	RP11-384K6.2	4	6.86e-05	0.00451	0.12	0.12	Corneal astigmatism;	chr4:119317769	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.663	rs28369503	ENSG00000225892.3	RP11-384K6.2	4	6.86e-05	0.00451	0.12	0.12	Corneal astigmatism;	chr4:119317770	chr4:118632274~118634759:+
BRCA	cis	rs6600671	1	rs4844616	ENSG00000275131.1	CH17-472G23.4	-4	6.86e-05	0.00451	-0.11	-0.12	Hip geometry;	chr1:121429348	chr1:120489625~120579190:-
BRCA	cis	rs2832270	0.562	rs8133819	ENSG00000176054.6	RPL23P2	-4	6.86e-05	0.00451	-0.18	-0.12	Response to mTOR inhibitor (everolimus);	chr21:29086433	chr21:28997613~28998033:-
BRCA	cis	rs35740288	0.539	rs4843100	ENSG00000202081.1	RNU6-1280P	4	6.86e-05	0.00451	0.18	0.12	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85795979	chr15:85651522~85651628:-
BRCA	cis	rs2115630	1	rs11073730	ENSG00000275120.1	RP11-182J1.17	-4	6.86e-05	0.00451	-0.14	-0.12	P wave terminal force;	chr15:84811365	chr15:84599434~84606463:-
BRCA	cis	rs2562456	0.793	rs73537884	ENSG00000240522.1	RPL7AP10	-4	6.86e-05	0.00451	-0.14	-0.12	Pain;	chr19:21321908	chr19:21149648~21150438:-
BRCA	cis	rs2562456	0.793	rs78467454	ENSG00000240522.1	RPL7AP10	-4	6.86e-05	0.00451	-0.14	-0.12	Pain;	chr19:21321930	chr19:21149648~21150438:-
BRCA	cis	rs7520050	0.966	rs785520	ENSG00000281133.1	AL355480.3	4	6.86e-05	0.00451	0.14	0.12	Reticulocyte count;Red blood cell count;	chr1:46103164	chr1:45580892~45580996:-
BRCA	cis	rs9527	0.59	rs11191513	ENSG00000213061.2	PFN1P11	4	6.86e-05	0.00451	0.17	0.12	Arsenic metabolism;	chr10:103013227	chr10:102838011~102845473:-
BRCA	cis	rs10986311	0.928	rs4836973	ENSG00000227200.1	RP11-121A14.3	4	6.86e-05	0.00451	0.15	0.12	Vitiligo;	chr9:124329308	chr9:124262876~124265809:+
BRCA	cis	rs9470794	0.915	rs73419447	ENSG00000204110.6	RP1-153P14.8	-4	6.86e-05	0.00451	-0.25	-0.12	Type 2 diabetes;	chr6:37889095	chr6:37507348~37535616:+
BRCA	cis	rs9921338	0.961	rs56136462	ENSG00000262636.1	CTD-3088G3.4	-4	6.86e-05	0.00452	-0.2	-0.12	Vein graft stenosis in coronary artery bypass grafting;	chr16:11321738	chr16:11380859~11381118:-
BRCA	cis	rs9423406	0.706	rs71479715	ENSG00000215267.7	AKR1C7P	-4	6.86e-05	0.00452	-0.23	-0.12	Intelligence;	chr10:5281059	chr10:5275173~5288470:-
BRCA	cis	rs4664293	0.605	rs12991516	ENSG00000224152.1	AC009506.1	-4	6.86e-05	0.00452	-0.13	-0.12	Monocyte percentage of white cells;	chr2:159585554	chr2:159615296~159617082:+
BRCA	cis	rs2070997	0.816	rs6597643	ENSG00000236986.5	RP11-544A12.4	-4	6.86e-05	0.00452	-0.18	-0.12	Response to amphetamines;	chr9:130850443	chr9:131132852~131167505:-
BRCA	cis	rs4478858	0.735	rs12563669	ENSG00000260386.4	LINC01225	-4	6.87e-05	0.00452	-0.15	-0.12	Alcohol dependence;	chr1:31385220	chr1:31500085~31540885:+
BRCA	cis	rs1549733	0.559	rs7590338	ENSG00000229754.1	CXCR2P1	-4	6.87e-05	0.00452	-0.15	-0.12	Optic disc area;	chr2:217589415	chr2:218059155~218065729:-
BRCA	cis	rs7111546	0.533	rs41486349	ENSG00000246225.5	RP11-17A1.3	4	6.87e-05	0.00452	0.2	0.12	Dialysis-related mortality;	chr11:22884149	chr11:22829380~22945393:+
BRCA	cis	rs7819412	0.806	rs6980856	ENSG00000154316.13	TDH	-4	6.87e-05	0.00452	-0.16	-0.12	Triglycerides;	chr8:11080750	chr8:11339637~11368452:+
BRCA	cis	rs6496044	0.568	rs1982742	ENSG00000202081.1	RNU6-1280P	4	6.87e-05	0.00452	0.14	0.12	Interstitial lung disease;	chr15:85525519	chr15:85651522~85651628:-
BRCA	cis	rs6496044	0.568	rs6496049	ENSG00000202081.1	RNU6-1280P	4	6.87e-05	0.00452	0.14	0.12	Interstitial lung disease;	chr15:85525974	chr15:85651522~85651628:-
BRCA	cis	rs38055	0.881	rs251525	ENSG00000247796.2	CTD-2366F13.1	-4	6.87e-05	0.00452	-0.15	-0.12	Acne (severe);	chr5:53289681	chr5:53109842~53115126:+
BRCA	cis	rs62458065	0.85	rs6462362	ENSG00000273014.1	RP11-225B17.2	-4	6.87e-05	0.00452	-0.19	-0.12	Metabolite levels (HVA/MHPG ratio);	chr7:32425121	chr7:32758882~32759353:+
BRCA	cis	rs6964587	0.9	rs7783674	ENSG00000188693.7	CYP51A1-AS1	-4	6.87e-05	0.00452	-0.13	-0.12	Breast cancer;	chr7:92154898	chr7:92134604~92180725:+
BRCA	cis	rs2274273	0.934	rs10137307	ENSG00000259318.1	RP11-454L9.2	4	6.87e-05	0.00452	0.1	0.12	Protein biomarker;	chr14:55378467	chr14:55394940~55395233:-
BRCA	cis	rs12612619	0.732	rs7585410	ENSG00000272148.1	RP11-195B17.1	4	6.87e-05	0.00452	0.14	0.12	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:26979252	chr2:27062428~27062907:-
BRCA	cis	rs11742741	0.806	rs62349715	ENSG00000248874.4	C5orf17	-4	6.87e-05	0.00452	-0.16	-0.12	Educational attainment;	chr5:24036657	chr5:23951348~24178263:+
BRCA	cis	rs6088580	0.624	rs6120645	ENSG00000275784.1	RP5-1125A11.6	-4	6.87e-05	0.00452	-0.13	-0.12	Glomerular filtration rate (creatinine);	chr20:34437366	chr20:33989480~33991818:-
BRCA	cis	rs6088590	1	rs6120750	ENSG00000276073.1	RP5-1125A11.7	-4	6.87e-05	0.00452	-0.14	-0.12	Coronary artery disease;	chr20:34877486	chr20:33985617~33988989:-
BRCA	cis	rs11673344	0.503	rs7246720	ENSG00000276846.1	CTD-3220F14.3	4	6.87e-05	0.00452	0.15	0.12	Obesity-related traits;	chr19:37073726	chr19:37314868~37315620:-
BRCA	cis	rs9402743	0.634	rs9321512	ENSG00000234084.1	RP3-388E23.2	4	6.87e-05	0.00452	0.12	0.12	Systemic lupus erythematosus;	chr6:135603299	chr6:135301568~135307158:+
BRCA	cis	rs957448	0.554	rs12682601	ENSG00000254315.1	RP11-267M23.3	4	6.88e-05	0.00452	0.15	0.12	Nonsyndromic cleft lip with cleft palate;	chr8:94582492	chr8:94533628~94534391:+
BRCA	cis	rs10937405	0.829	rs56260952	ENSG00000236182.1	RP11-297K7.1	-4	6.88e-05	0.00452	-0.15	-0.12	Lung adenocarcinoma;	chr3:189617177	chr3:188989382~188990135:-
BRCA	cis	rs1479090	0.805	rs1351222	ENSG00000250027.1	RP11-563E2.2	-4	6.88e-05	0.00452	-0.16	-0.12	Lung cancer;	chr4:163155406	chr4:163108785~163119965:+
BRCA	cis	rs6743226	0.603	rs55659209	ENSG00000266621.1	AC104841.1	4	6.88e-05	0.00452	0.15	0.12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in non-smokers;	chr2:241314902	chr2:241245202~241245299:-
BRCA	cis	rs10266483	0.739	rs12671185	ENSG00000271550.1	BNIP3P11	-4	6.88e-05	0.00453	-0.16	-0.12	Response to statin therapy;	chr7:64333329	chr7:64678954~64687393:-
BRCA	cis	rs2880765	0.527	rs35184622	ENSG00000202081.1	RNU6-1280P	4	6.88e-05	0.00453	0.16	0.12	Coronary artery disease;	chr15:85529804	chr15:85651522~85651628:-
BRCA	cis	rs2880765	0.527	rs1483578	ENSG00000202081.1	RNU6-1280P	4	6.88e-05	0.00453	0.16	0.12	Coronary artery disease;	chr15:85532186	chr15:85651522~85651628:-
BRCA	cis	rs977987	0.835	rs8046109	ENSG00000280152.1	RP11-331F4.5	-4	6.88e-05	0.00453	-0.13	-0.12	Dupuytren's disease;	chr16:75326198	chr16:75245994~75250077:-
BRCA	cis	rs7617480	0.519	rs6790914	ENSG00000270441.1	RP11-694I15.7	-4	6.88e-05	0.00453	-0.14	-0.12	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:49168885	chr3:49140086~49160851:-
BRCA	cis	rs7267979	1	rs6115146	ENSG00000274973.1	RP13-401N8.7	4	6.88e-05	0.00453	0.14	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25323871	chr20:25845497~25845862:+
BRCA	cis	rs7267979	0.934	rs6037085	ENSG00000274973.1	RP13-401N8.7	4	6.88e-05	0.00453	0.14	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25324566	chr20:25845497~25845862:+
BRCA	cis	rs2562456	0.874	rs2562417	ENSG00000213976.4	CTD-2561J22.2	4	6.88e-05	0.00453	0.15	0.12	Pain;	chr19:21528400	chr19:21382865~21387177:+
BRCA	cis	rs6547741	1	rs4666007	ENSG00000234072.1	AC074117.10	4	6.88e-05	0.00453	0.11	0.12	Oral cavity cancer;	chr2:27633628	chr2:27356246~27367622:+
BRCA	cis	rs6547741	1	rs1528402	ENSG00000234072.1	AC074117.10	4	6.88e-05	0.00453	0.11	0.12	Oral cavity cancer;	chr2:27634650	chr2:27356246~27367622:+
BRCA	cis	rs17270561	0.636	rs7453371	ENSG00000272462.2	U91328.19	-4	6.89e-05	0.00453	-0.15	-0.12	Iron status biomarkers;	chr6:25719028	chr6:25992662~26001775:+
BRCA	cis	rs2243480	1	rs1873494	ENSG00000237026.1	RP11-328P23.2	-4	6.89e-05	0.00453	-0.23	-0.12	Diabetic kidney disease;	chr7:66184912	chr7:65235790~65236723:-
BRCA	cis	rs2243480	1	rs6959002	ENSG00000237026.1	RP11-328P23.2	-4	6.89e-05	0.00453	-0.23	-0.12	Diabetic kidney disease;	chr7:66185509	chr7:65235790~65236723:-
BRCA	cis	rs1153858	1	rs8042786	ENSG00000275672.1	GATM-AS1	-4	6.89e-05	0.00453	-0.16	-0.12	Homoarginine levels;	chr15:45411341	chr15:45378700~45380123:+
BRCA	cis	rs6545883	0.929	rs12713436	ENSG00000212978.6	AC016747.3	4	6.89e-05	0.00453	0.17	0.12	Tuberculosis;	chr2:61464125	chr2:61141592~61144969:-
BRCA	cis	rs9437689	0.531	rs859046	ENSG00000235501.4	RP4-639F20.1	4	6.89e-05	0.00453	0.16	0.12	Phospholipid levels (plasma);	chr1:94913950	chr1:94927566~94963270:+
BRCA	cis	rs2898290	0.592	rs2736342	ENSG00000227888.4	FAM66A	-4	6.89e-05	0.00453	-0.15	-0.12	Systolic blood pressure;	chr8:11489780	chr8:12362019~12388296:+
BRCA	cis	rs11168618	0.74	rs12425460	ENSG00000240399.1	RP1-228P16.1	4	6.89e-05	0.00453	0.13	0.12	Adiponectin levels;	chr12:48526013	chr12:48054813~48055591:-
BRCA	cis	rs6964587	1	rs12540055	ENSG00000188693.7	CYP51A1-AS1	-4	6.89e-05	0.00453	-0.13	-0.12	Breast cancer;	chr7:92078607	chr7:92134604~92180725:+
BRCA	cis	rs62184315	0.536	rs62183659	ENSG00000253559.1	OSGEPL1-AS1	-4	6.89e-05	0.00453	-0.21	-0.12	Alcohol dependence (age at onset);	chr2:189672131	chr2:189762704~189765556:+
BRCA	cis	rs62184315	0.536	rs62185869	ENSG00000253559.1	OSGEPL1-AS1	-4	6.89e-05	0.00453	-0.21	-0.12	Alcohol dependence (age at onset);	chr2:189672330	chr2:189762704~189765556:+
BRCA	cis	rs2391285	0.609	rs2040944	ENSG00000280255.1	RP5-1007F24.1	4	6.9e-05	0.00454	0.18	0.12	Post bronchodilator FEV1/FVC ratio;	chr7:26557532	chr7:26538378~26541048:+
BRCA	cis	rs2976388	0.507	rs2572874	ENSG00000253196.1	RP11-706C16.7	4	6.9e-05	0.00454	0.12	0.12	Urinary tract infection frequency;	chr8:142755801	chr8:142763116~142766427:+
BRCA	cis	rs6840360	0.967	rs10049728	ENSG00000251611.1	RP11-610P16.1	-4	6.9e-05	0.00454	-0.11	-0.12	Intelligence (multi-trait analysis);	chr4:151750969	chr4:151407551~151408835:-
BRCA	cis	rs6840360	0.967	rs7684350	ENSG00000251611.1	RP11-610P16.1	-4	6.9e-05	0.00454	-0.11	-0.12	Intelligence (multi-trait analysis);	chr4:151751730	chr4:151407551~151408835:-
BRCA	cis	rs867186	1	rs7265317	ENSG00000126005.14	MMP24-AS1	-4	6.9e-05	0.00454	-0.24	-0.12	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35180720	chr20:35216462~35278131:-
BRCA	cis	rs867186	1	rs945961	ENSG00000126005.14	MMP24-AS1	-4	6.9e-05	0.00454	-0.24	-0.12	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35182123	chr20:35216462~35278131:-
BRCA	cis	rs3764021	0.527	rs2114870	ENSG00000256673.1	RP11-599J14.2	-4	6.9e-05	0.00454	-0.15	-0.12	Type 1 diabetes;	chr12:9670544	chr12:9398355~9414851:-
BRCA	cis	rs10989172	0.78	rs4291387	ENSG00000175611.10	LINC00476	-4	6.9e-05	0.00454	-0.15	-0.12	Common carotid intima-media thickness in HIV negative individuals;	chr9:96081356	chr9:95759231~95875977:-
BRCA	cis	rs2136613	0.751	rs10995328	ENSG00000238280.1	RP11-436D10.3	-4	6.9e-05	0.00454	-0.15	-0.12	Selective IgA deficiency;	chr10:62842848	chr10:62793562~62805887:-
BRCA	cis	rs28530618	0.603	rs750401	ENSG00000198547.7	C20orf203	-4	6.9e-05	0.00454	-0.14	-0.12	Birth weight;	chr20:32658836	chr20:32631652~32673941:-
BRCA	cis	rs28530618	0.603	rs11697988	ENSG00000198547.7	C20orf203	-4	6.9e-05	0.00454	-0.14	-0.12	Birth weight;	chr20:32660374	chr20:32631652~32673941:-
BRCA	cis	rs7772486	0.79	rs2485632	ENSG00000270638.1	RP3-466P17.1	4	6.9e-05	0.00454	0.14	0.12	Lobe attachment (rater-scored or self-reported);	chr6:145872092	chr6:145735570~145737218:+
BRCA	cis	rs7772486	0.79	rs2253307	ENSG00000270638.1	RP3-466P17.1	4	6.9e-05	0.00454	0.14	0.12	Lobe attachment (rater-scored or self-reported);	chr6:145875045	chr6:145735570~145737218:+
BRCA	cis	rs11992162	0.967	rs10108320	ENSG00000255052.4	FAM66D	4	6.91e-05	0.00454	0.15	0.12	Monocyte count;	chr8:11974754	chr8:12115782~12177550:+
BRCA	cis	rs13401620	0.917	rs10187919	ENSG00000229326.3	AC069154.4	-4	6.91e-05	0.00454	-0.16	-0.12	Breast size;	chr2:119768720	chr2:119698623~119700151:+
BRCA	cis	rs1976403	0.633	rs1780324	ENSG00000186543.7	CROCCP5	-4	6.91e-05	0.00454	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr1:21495264	chr1:21434318~21437558:+
BRCA	cis	rs3753275	0.69	rs1463055	ENSG00000232912.4	RP5-1115A15.1	4	6.91e-05	0.00454	0.16	0.12	Educational attainment;	chr1:8561527	chr1:8424645~8434838:+
BRCA	cis	rs910316	0.967	rs11624893	ENSG00000259138.1	RP11-950C14.7	-4	6.91e-05	0.00454	-0.13	-0.12	Height;	chr14:75193421	chr14:75127153~75136930:+
BRCA	cis	rs745109	0.882	rs72930336	ENSG00000273080.1	RP11-301O19.1	4	6.91e-05	0.00454	0.2	0.12	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86433304	chr2:86195590~86196049:+
BRCA	cis	rs9329221	0.537	rs6986911	ENSG00000253649.2	PRSS51	-4	6.91e-05	0.00454	-0.14	-0.12	Neuroticism;	chr8:10121013	chr8:10482878~10547585:-
BRCA	cis	rs4819052	0.851	rs914218	ENSG00000215447.6	BX322557.10	-4	6.91e-05	0.00454	-0.13	-0.12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45278530	chr21:45288052~45291738:+
BRCA	cis	rs2739330	0.796	rs1006771	ENSG00000228039.3	KB-1125A3.10	4	6.91e-05	0.00454	0.14	0.12	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23963780~23964374:+
BRCA	cis	rs17801127	1	rs16827351	ENSG00000231969.1	AC144449.1	4	6.91e-05	0.00454	0.22	0.12	Liver enzyme levels (alanine transaminase);	chr2:149698116	chr2:149587196~149848233:+
BRCA	cis	rs2692947	0.537	rs72821437	ENSG00000168992.4	OR7E102P	4	6.91e-05	0.00454	0.17	0.12	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95535051	chr2:95546531~95547545:+
BRCA	cis	rs1048886	0.938	rs74520771	ENSG00000271967.1	RP11-134K13.4	-4	6.91e-05	0.00454	-0.19	-0.12	Type 2 diabetes;	chr6:70444760	chr6:70596438~70596980:+
BRCA	cis	rs1048886	0.872	rs74716033	ENSG00000271967.1	RP11-134K13.4	-4	6.91e-05	0.00454	-0.19	-0.12	Type 2 diabetes;	chr6:70445021	chr6:70596438~70596980:+
BRCA	cis	rs1048886	0.872	rs75175495	ENSG00000271967.1	RP11-134K13.4	-4	6.91e-05	0.00454	-0.19	-0.12	Type 2 diabetes;	chr6:70451869	chr6:70596438~70596980:+
BRCA	cis	rs1048886	0.872	rs74751032	ENSG00000271967.1	RP11-134K13.4	-4	6.91e-05	0.00454	-0.19	-0.12	Type 2 diabetes;	chr6:70458728	chr6:70596438~70596980:+
BRCA	cis	rs7246967	0.673	rs407989	ENSG00000198153.8	ZNF849P	4	6.91e-05	0.00454	0.19	0.12	Bronchopulmonary dysplasia;	chr19:22808784	chr19:22685167~22686732:+
BRCA	cis	rs875971	0.66	rs801193	ENSG00000273142.1	RP11-458F8.4	4	6.91e-05	0.00454	0.11	0.12	Aortic root size;	chr7:66565625	chr7:66902857~66906297:+
BRCA	cis	rs7412746	0.611	rs9661876	ENSG00000231073.1	RP11-316M1.3	4	6.91e-05	0.00454	0.13	0.12	Melanoma;	chr1:150938435	chr1:150973123~150975534:+
BRCA	cis	rs4664293	0.585	rs34385495	ENSG00000226266.5	AC009961.3	4	6.91e-05	0.00454	0.15	0.12	Monocyte percentage of white cells;	chr2:159656372	chr2:159670708~159712435:-
BRCA	cis	rs6487679	0.526	rs7972426	ENSG00000214776.8	RP11-726G1.1	-4	6.91e-05	0.00454	-0.14	-0.12	Non-alcoholic fatty liver disease histology (AST);	chr12:9228658	chr12:9467552~9576275:+
BRCA	cis	rs801193	1	rs1553610	ENSG00000265600.1	AC006480.1	-4	6.91e-05	0.00454	-0.14	-0.12	Aortic root size;	chr7:66732246	chr7:67356680~67356779:+
BRCA	cis	rs801193	1	rs2707845	ENSG00000265600.1	AC006480.1	-4	6.91e-05	0.00454	-0.14	-0.12	Aortic root size;	chr7:66733811	chr7:67356680~67356779:+
BRCA	cis	rs801193	1	rs2707850	ENSG00000265600.1	AC006480.1	-4	6.91e-05	0.00454	-0.14	-0.12	Aortic root size;	chr7:66738883	chr7:67356680~67356779:+
BRCA	cis	rs801193	0.967	rs1110414	ENSG00000265600.1	AC006480.1	-4	6.91e-05	0.00454	-0.14	-0.12	Aortic root size;	chr7:66740595	chr7:67356680~67356779:+
BRCA	cis	rs801193	1	rs7783924	ENSG00000265600.1	AC006480.1	-4	6.91e-05	0.00454	-0.14	-0.12	Aortic root size;	chr7:66744070	chr7:67356680~67356779:+
BRCA	cis	rs801193	1	rs7789184	ENSG00000265600.1	AC006480.1	-4	6.91e-05	0.00454	-0.14	-0.12	Aortic root size;	chr7:66745208	chr7:67356680~67356779:+
BRCA	cis	rs801193	1	rs2707854	ENSG00000265600.1	AC006480.1	-4	6.91e-05	0.00454	-0.14	-0.12	Aortic root size;	chr7:66747610	chr7:67356680~67356779:+
BRCA	cis	rs801193	1	rs6975195	ENSG00000229180.5	GS1-124K5.11	-4	6.91e-05	0.00454	-0.11	-0.12	Aortic root size;	chr7:66659787	chr7:66526088~66542624:-
BRCA	cis	rs61931739	0.534	rs2220547	ENSG00000258794.3	DUX4L27	4	6.91e-05	0.00454	0.18	0.12	Morning vs. evening chronotype;	chr12:33953320	chr12:34208415~34209675:-
BRCA	cis	rs11742741	0.806	rs62349716	ENSG00000248874.4	C5orf17	-4	6.91e-05	0.00455	-0.16	-0.12	Educational attainment;	chr5:24036965	chr5:23951348~24178263:+
BRCA	cis	rs6840360	0.806	rs13149588	ENSG00000251611.1	RP11-610P16.1	4	6.92e-05	0.00455	0.11	0.12	Intelligence (multi-trait analysis);	chr4:151796605	chr4:151407551~151408835:-
BRCA	cis	rs7246967	0.736	rs423687	ENSG00000198153.8	ZNF849P	-4	6.92e-05	0.00455	-0.18	-0.12	Bronchopulmonary dysplasia;	chr19:22817943	chr19:22685167~22686732:+
BRCA	cis	rs7246967	0.736	rs386119	ENSG00000198153.8	ZNF849P	-4	6.92e-05	0.00455	-0.18	-0.12	Bronchopulmonary dysplasia;	chr19:22818016	chr19:22685167~22686732:+
BRCA	cis	rs10911902	0.643	rs10494584	ENSG00000229739.2	RP11-295K2.3	-4	6.92e-05	0.00455	-0.18	-0.12	Schizophrenia;	chr1:186321389	chr1:186435161~186470291:+
BRCA	cis	rs74665712	0.591	rs77485450	ENSG00000232400.1	RAD17P1	4	6.92e-05	0.00455	0.15	0.12	Residual cognition;	chr7:16914531	chr7:16864267~16866308:-
BRCA	cis	rs13217239	0.646	rs10946888	ENSG00000124549.13	BTN2A3P	4	6.92e-05	0.00455	0.13	0.12	Schizophrenia;	chr6:26983899	chr6:26421391~26432383:+
BRCA	cis	rs9982086	0.793	rs972389	ENSG00000260583.1	AP000223.42	4	6.92e-05	0.00455	0.28	0.12	Carboplatin disposition in epthelial ovarian cancer;	chr21:25567997	chr21:25582770~25583326:-
BRCA	cis	rs9982086	0.655	rs2211763	ENSG00000260583.1	AP000223.42	4	6.92e-05	0.00455	0.28	0.12	Carboplatin disposition in epthelial ovarian cancer;	chr21:25571293	chr21:25582770~25583326:-
BRCA	cis	rs9982086	0.793	rs1547355	ENSG00000260583.1	AP000223.42	4	6.92e-05	0.00455	0.28	0.12	Carboplatin disposition in epthelial ovarian cancer;	chr21:25575427	chr21:25582770~25583326:-
BRCA	cis	rs6545883	0.524	rs12713435	ENSG00000270820.4	RP11-355B11.2	-4	6.92e-05	0.00455	-0.13	-0.12	Tuberculosis;	chr2:61272654	chr2:61471188~61484130:+
BRCA	cis	rs1823874	0.677	rs56096943	ENSG00000182397.13	DNM1P46	-4	6.92e-05	0.00455	-0.14	-0.12	IgG glycosylation;	chr15:99820513	chr15:99790156~99806927:-
BRCA	cis	rs11711311	1	rs9854504	ENSG00000241529.3	RN7SL767P	-4	6.92e-05	0.00455	-0.14	-0.12	IgG glycosylation;	chr3:113813534	chr3:113632704~113632998:+
BRCA	cis	rs761926	0.911	rs12621192	ENSG00000272716.1	RP11-563N4.1	-4	6.92e-05	0.00455	-0.15	-0.12	Obesity-related traits;	chr2:31365798	chr2:32165046~32165757:-
BRCA	cis	rs11887277	0.708	rs4665350	ENSG00000272148.1	RP11-195B17.1	-4	6.92e-05	0.00455	-0.14	-0.12	Obesity-related traits;	chr2:26815250	chr2:27062428~27062907:-
BRCA	cis	rs4865762	0.514	rs30093	ENSG00000247796.2	CTD-2366F13.1	4	6.92e-05	0.00455	0.14	0.12	Intraocular pressure;	chr5:53127408	chr5:53109842~53115126:+
BRCA	cis	rs4950322	0.57	rs6703892	ENSG00000237188.3	RP11-337C18.8	4	6.92e-05	0.00455	0.16	0.12	Protein quantitative trait loci;	chr1:147287627	chr1:147172771~147211568:+
BRCA	cis	rs372883	0.648	rs2832296	ENSG00000176054.6	RPL23P2	-3.99	6.92e-05	0.00455	-0.14	-0.12	Pancreatic cancer;	chr21:29369133	chr21:28997613~28998033:-
BRCA	cis	rs17772222	0.917	rs61986664	ENSG00000258789.1	RP11-507K2.3	-3.99	6.92e-05	0.00455	-0.15	-0.12	Coronary artery calcification;	chr14:88711251	chr14:88551597~88552493:+
BRCA	cis	rs6545883	0.929	rs2600663	ENSG00000270820.4	RP11-355B11.2	-3.99	6.93e-05	0.00455	-0.14	-0.12	Tuberculosis;	chr2:61313552	chr2:61471188~61484130:+
BRCA	cis	rs801193	1	rs2707836	ENSG00000272831.1	RP11-792A8.4	3.99	6.93e-05	0.00455	0.11	0.12	Aortic root size;	chr7:66695448	chr7:66739829~66740385:-
BRCA	cis	rs801193	0.844	rs7779971	ENSG00000272831.1	RP11-792A8.4	3.99	6.93e-05	0.00455	0.11	0.12	Aortic root size;	chr7:66696803	chr7:66739829~66740385:-
BRCA	cis	rs4699052	0.59	rs1156669	ENSG00000248740.4	RP11-328K4.1	3.99	6.93e-05	0.00455	0.14	0.12	Testicular germ cell tumor;	chr4:103367047	chr4:103256159~103453658:+
BRCA	cis	rs1865760	0.963	rs3846838	ENSG00000272462.2	U91328.19	-3.99	6.93e-05	0.00455	-0.15	-0.12	Height;	chr6:25911547	chr6:25992662~26001775:+
BRCA	cis	rs2438150	1	rs2438150	ENSG00000251538.4	RP11-166A12.1	3.99	6.93e-05	0.00455	0.13	0.12	Plateletcrit;	chr5:122863501	chr5:122628952~122730685:-
BRCA	cis	rs2271404	0.506	rs4848426	ENSG00000227992.1	AC108463.2	3.99	6.93e-05	0.00455	0.16	0.12	Atopic dermatitis;	chr2:111244553	chr2:111203964~111206215:-
BRCA	cis	rs6496044	0.568	rs1351196	ENSG00000202081.1	RNU6-1280P	3.99	6.93e-05	0.00455	0.14	0.12	Interstitial lung disease;	chr15:85534173	chr15:85651522~85651628:-
BRCA	cis	rs6736093	0.933	rs4848238	ENSG00000236307.2	EEF1E1P1	-3.99	6.93e-05	0.00455	-0.15	-0.12	Coronary artery disease;	chr2:111997143	chr2:111887914~111888741:+
BRCA	cis	rs4374383	0.847	rs1996327	ENSG00000243389.1	AC012442.5	-3.99	6.93e-05	0.00455	-0.16	-0.12	Hepatitis C induced liver fibrosis;	chr2:111987150	chr2:112589040~112614431:+
BRCA	cis	rs2640806	0.544	rs11997526	ENSG00000253105.4	KB-1448A5.1	3.99	6.93e-05	0.00455	0.14	0.12	Obesity-related traits;	chr8:96353691	chr8:96371865~96387438:-
BRCA	cis	rs2640806	0.505	rs11990371	ENSG00000253105.4	KB-1448A5.1	3.99	6.93e-05	0.00455	0.14	0.12	Obesity-related traits;	chr8:96353700	chr8:96371865~96387438:-
BRCA	cis	rs11673344	0.523	rs2562607	ENSG00000276846.1	CTD-3220F14.3	3.99	6.93e-05	0.00456	0.15	0.12	Obesity-related traits;	chr19:37031358	chr19:37314868~37315620:-
BRCA	cis	rs10411161	0.702	rs17835311	ENSG00000269483.1	AC006272.1	3.99	6.93e-05	0.00456	0.21	0.12	Breast cancer;	chr19:51883528	chr19:51839924~51843324:-
BRCA	cis	rs757081	0.867	rs2521999	ENSG00000184669.7	OR7E14P	-3.99	6.94e-05	0.00456	-0.19	-0.12	Systolic blood pressure;	chr11:17311636	chr11:17013998~17053024:+
BRCA	cis	rs4578769	0.681	rs4517886	ENSG00000265939.1	UBE2CP2	-3.99	6.94e-05	0.00456	-0.15	-0.12	Eosinophil percentage of white cells;	chr18:22982922	chr18:22900486~22900995:-
BRCA	cis	rs1670533	1	rs2045066	ENSG00000251639.2	RP11-20I20.1	3.99	6.94e-05	0.00456	0.19	0.12	Recombination rate (females);	chr4:1058613	chr4:1100016~1101558:-
BRCA	cis	rs794185	0.561	rs304038	ENSG00000231249.1	ITPR1-AS1	-3.99	6.94e-05	0.00456	-0.14	-0.12	Multiple sclerosis--Brain Glutamate Levels;	chr3:4510491	chr3:4490891~4493163:-
BRCA	cis	rs7819412	0.54	rs2409726	ENSG00000154316.13	TDH	3.99	6.94e-05	0.00456	0.16	0.12	Triglycerides;	chr8:11185629	chr8:11339637~11368452:+
BRCA	cis	rs801193	1	rs2707836	ENSG00000273142.1	RP11-458F8.4	-3.99	6.94e-05	0.00456	-0.11	-0.12	Aortic root size;	chr7:66695448	chr7:66902857~66906297:+
BRCA	cis	rs801193	0.844	rs7779971	ENSG00000273142.1	RP11-458F8.4	-3.99	6.94e-05	0.00456	-0.11	-0.12	Aortic root size;	chr7:66696803	chr7:66902857~66906297:+
BRCA	cis	rs801193	1	rs62466794	ENSG00000229180.5	GS1-124K5.11	3.99	6.94e-05	0.00456	0.11	0.12	Aortic root size;	chr7:66726592	chr7:66526088~66542624:-
BRCA	cis	rs8054556	1	rs4283241	ENSG00000261367.1	RP11-455F5.4	3.99	6.94e-05	0.00456	0.13	0.12	Autism spectrum disorder or schizophrenia;	chr16:29977028	chr16:30107675~30110541:+
BRCA	cis	rs10937405	0.86	rs9881000	ENSG00000236182.1	RP11-297K7.1	-3.99	6.94e-05	0.00456	-0.15	-0.12	Lung adenocarcinoma;	chr3:189617817	chr3:188989382~188990135:-
BRCA	cis	rs7771547	0.519	rs12202691	ENSG00000224666.3	RP1-50J22.4	3.99	6.94e-05	0.00456	0.15	0.12	Platelet distribution width;	chr6:36410043	chr6:36386831~36393462:+
BRCA	cis	rs1005277	0.522	rs289648	ENSG00000226578.1	RP11-258F22.1	-3.99	6.94e-05	0.00456	-0.13	-0.12	Extrinsic epigenetic age acceleration;	chr10:37682909	chr10:37775371~37784131:-
BRCA	cis	rs7824557	0.606	rs2736273	ENSG00000255046.1	RP11-297N6.4	-3.99	6.94e-05	0.00456	-0.14	-0.12	Retinal vascular caliber;	chr8:11342429	chr8:11797928~11802568:-
BRCA	cis	rs13098911	0.54	rs17215981	ENSG00000223552.1	RP11-24F11.2	3.99	6.94e-05	0.00456	0.2	0.12	Celiac disease;	chr3:46082926	chr3:46364955~46407059:-
BRCA	cis	rs910316	1	rs876402	ENSG00000259138.1	RP11-950C14.7	-3.99	6.94e-05	0.00456	-0.13	-0.12	Height;	chr14:75135159	chr14:75127153~75136930:+
BRCA	cis	rs2242116	0.796	rs7623898	ENSG00000276925.1	RP11-708J19.3	3.99	6.94e-05	0.00456	0.15	0.12	Birth weight;	chr3:46932682	chr3:47469777~47469987:+
BRCA	cis	rs8058578	0.943	rs35629860	ENSG00000260911.2	RP11-196G11.2	3.99	6.94e-05	0.00456	0.12	0.12	Multiple myeloma;	chr16:30660211	chr16:31043150~31049868:+
BRCA	cis	rs8070624	0.502	rs12951376	ENSG00000281749.1	Y_RNA	3.99	6.94e-05	0.00456	0.14	0.12	Total body bone mineral density;	chr17:17849495	chr17:18001101~18001195:-
BRCA	cis	rs2274459	1	rs12193658	ENSG00000249346.5	LINC01016	3.99	6.94e-05	0.00456	0.16	0.12	Obesity (extreme);	chr6:33737751	chr6:33867506~33896914:-
BRCA	cis	rs7772486	0.754	rs9373475	ENSG00000270638.1	RP3-466P17.1	3.99	6.94e-05	0.00456	0.14	0.12	Lobe attachment (rater-scored or self-reported);	chr6:145805283	chr6:145735570~145737218:+
BRCA	cis	rs12826942	0.879	rs7312066	ENSG00000257225.1	RP11-328C8.4	-3.99	6.94e-05	0.00456	-0.18	-0.12	Coronary artery disease;	chr12:42372578	chr12:42459366~42466128:+
BRCA	cis	rs28374715	0.532	rs28477406	ENSG00000247556.5	OIP5-AS1	3.99	6.95e-05	0.00456	0.15	0.12	Ulcerative colitis;	chr15:41349838	chr15:41283990~41309737:+
BRCA	cis	rs11098499	0.954	rs11722872	ENSG00000225892.3	RP11-384K6.2	3.99	6.95e-05	0.00456	0.12	0.12	Corneal astigmatism;	chr4:119311875	chr4:118632274~118634759:+
BRCA	cis	rs1867631	0.585	rs9787219	ENSG00000248458.2	RP4-598P13.1	3.99	6.95e-05	0.00456	0.13	0.12	Menopause (age at onset);	chr1:66614476	chr1:66665864~66677027:-
BRCA	cis	rs1867631	0.585	rs11208922	ENSG00000248458.2	RP4-598P13.1	3.99	6.95e-05	0.00456	0.13	0.12	Menopause (age at onset);	chr1:66614543	chr1:66665864~66677027:-
BRCA	cis	rs9308731	0.591	rs6732491	ENSG00000230499.1	AC108463.1	-3.99	6.95e-05	0.00456	-0.14	-0.12	Chronic lymphocytic leukemia;	chr2:111181143	chr2:111195963~111206494:+
BRCA	cis	rs990171	0.513	rs6543152	ENSG00000234389.1	AC007278.3	3.99	6.95e-05	0.00456	0.12	0.12	Lymphocyte counts;	chr2:102497584	chr2:102438713~102440475:+
BRCA	cis	rs1124769	0.57	rs1903589	ENSG00000273674.3	CTD-2378E12.1	-3.99	6.95e-05	0.00457	-0.15	-0.12	Cognitive performance;	chr15:50852087	chr15:50839875~50908599:-
BRCA	cis	rs10043228	1	rs62385177	ENSG00000271918.1	CTD-2287O16.5	-3.99	6.95e-05	0.00457	-0.16	-0.12	Asthma or chronic obstructive pulmonary disease;	chr5:116144783	chr5:116083807~116085416:-
BRCA	cis	rs10043228	1	rs10051240	ENSG00000271918.1	CTD-2287O16.5	-3.99	6.95e-05	0.00457	-0.16	-0.12	Asthma or chronic obstructive pulmonary disease;	chr5:116234234	chr5:116083807~116085416:-
BRCA	cis	rs10043228	1	rs12523347	ENSG00000271918.1	CTD-2287O16.5	-3.99	6.95e-05	0.00457	-0.16	-0.12	Asthma or chronic obstructive pulmonary disease;	chr5:116236698	chr5:116083807~116085416:-
BRCA	cis	rs801193	0.935	rs11772264	ENSG00000273142.1	RP11-458F8.4	-3.99	6.95e-05	0.00457	-0.11	-0.12	Aortic root size;	chr7:66711400	chr7:66902857~66906297:+
BRCA	cis	rs6600671	0.899	rs6674392	ENSG00000223345.3	HIST2H2BA	3.99	6.95e-05	0.00457	0.15	0.12	Hip geometry;	chr1:121518864	chr1:121108210~121117257:-
BRCA	cis	rs983392	0.679	rs611418	ENSG00000275344.1	MIR6503	3.99	6.95e-05	0.00457	0.13	0.12	Alzheimer's disease (late onset);	chr11:60243540	chr11:60209071~60209156:-
BRCA	cis	rs875971	0.862	rs6978028	ENSG00000273024.4	INTS4P2	-3.99	6.96e-05	0.00457	-0.14	-0.12	Aortic root size;	chr7:66421313	chr7:65647864~65715661:+
BRCA	cis	rs6671200	1	rs259359	ENSG00000226026.4	RP11-57H12.3	-3.99	6.96e-05	0.00457	-0.23	-0.12	Stearic acid (18:0) levels;	chr1:95243483	chr1:95163219~95233982:-
BRCA	cis	rs4449834	0.773	rs4237038	ENSG00000254432.1	RP11-33I11.2	-3.99	6.96e-05	0.00457	-0.15	-0.12	Sum eosinophil basophil counts;	chr8:60818699	chr8:60808735~60809606:-
BRCA	cis	rs17065868	1	rs17277505	ENSG00000237361.2	TUSC8	3.99	6.96e-05	0.00457	0.25	0.12	Antineutrophil cytoplasmic antibody-associated vasculitis;	chr13:44531450	chr13:44400250~44405984:-
BRCA	cis	rs6142618	0.562	rs2295035	ENSG00000275576.1	RP5-836N17.4	-3.99	6.96e-05	0.00457	-0.13	-0.12	Inflammatory bowel disease;	chr20:32114341	chr20:32116171~32116629:+
BRCA	cis	rs4957048	0.577	rs56294732	ENSG00000225138.6	CTD-2228K2.7	3.99	6.96e-05	0.00457	0.17	0.12	Ulcerative colitis;	chr5:568029	chr5:473236~480884:+
BRCA	cis	rs6005807	0.719	rs16986398	ENSG00000272858.1	CTA-292E10.8	-3.99	6.96e-05	0.00457	-0.21	-0.12	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28419641	chr22:28814914~28815662:+
BRCA	cis	rs4664293	0.899	rs7588710	ENSG00000224152.1	AC009506.1	-3.99	6.96e-05	0.00457	-0.14	-0.12	Monocyte percentage of white cells;	chr2:159673011	chr2:159615296~159617082:+
BRCA	cis	rs7160336	1	rs8020019	ENSG00000259065.1	RP5-1021I20.1	3.99	6.96e-05	0.00457	0.14	0.12	Blood protein levels;	chr14:74127800	chr14:73787360~73803270:+
BRCA	cis	rs10129255	0.957	rs10136560	ENSG00000211967.3	IGHV3-53	-3.99	6.96e-05	0.00457	-0.09	-0.12	Kawasaki disease;	chr14:106787630	chr14:106592676~106593347:-
BRCA	cis	rs7674212	0.507	rs223317	ENSG00000248740.4	RP11-328K4.1	3.99	6.96e-05	0.00457	0.15	0.12	Type 2 diabetes;	chr4:102881667	chr4:103256159~103453658:+
BRCA	cis	rs6545883	0.826	rs2694617	ENSG00000212978.6	AC016747.3	-3.99	6.96e-05	0.00457	-0.16	-0.12	Tuberculosis;	chr2:61310079	chr2:61141592~61144969:-
BRCA	cis	rs1009077	0.716	rs62319658	ENSG00000245958.5	RP11-33B1.1	3.99	6.96e-05	0.00457	0.18	0.12	Endometriosis;	chr4:119623849	chr4:119454791~119552025:+
BRCA	cis	rs7647973	1	rs6446275	ENSG00000244380.1	RP11-24C3.2	-3.99	6.96e-05	0.00457	-0.16	-0.12	Menarche (age at onset);	chr3:49429438	chr3:48440352~48446656:-
BRCA	cis	rs874628	0.851	rs12461072	ENSG00000268650.3	AC068499.10	3.99	6.96e-05	0.00457	0.16	0.12	Multiple sclerosis;	chr19:18219782	chr19:18204730~18220480:+
BRCA	cis	rs9959145	1	rs78543731	ENSG00000267108.1	RP11-861E21.1	3.99	6.96e-05	0.00457	0.22	0.12	Immune response to smallpox vaccine (IL-6);	chr18:12665565	chr18:12432897~12437635:+
BRCA	cis	rs1153858	1	rs7164602	ENSG00000275672.1	GATM-AS1	-3.99	6.97e-05	0.00457	-0.16	-0.12	Homoarginine levels;	chr15:45379127	chr15:45378700~45380123:+
BRCA	cis	rs1153858	1	rs12441971	ENSG00000275672.1	GATM-AS1	-3.99	6.97e-05	0.00457	-0.16	-0.12	Homoarginine levels;	chr15:45379759	chr15:45378700~45380123:+
BRCA	cis	rs1153858	1	rs1346268	ENSG00000275672.1	GATM-AS1	-3.99	6.97e-05	0.00457	-0.16	-0.12	Homoarginine levels;	chr15:45380831	chr15:45378700~45380123:+
BRCA	cis	rs7267979	0.932	rs6115215	ENSG00000276952.1	RP5-965G21.6	3.99	6.97e-05	0.00458	0.15	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25581864	chr20:25284915~25285588:-
BRCA	cis	rs4468007	0.901	rs10760192	ENSG00000261534.1	RP11-244O19.1	3.99	6.97e-05	0.00458	0.13	0.12	Educational attainment;	chr9:121840027	chr9:121815674~121819452:-
BRCA	cis	rs4132699	0.62	rs10908928	ENSG00000225460.1	RP13-93L13.1	-3.99	6.97e-05	0.00458	-0.13	-0.12	Nonsyndromic cleft lip with or without cleft palate;Orofacial clefts;	chr9:89476942	chr9:89472237~89472692:+
BRCA	cis	rs875971	0.66	rs7807930	ENSG00000223473.2	GS1-124K5.3	-3.99	6.97e-05	0.00458	-0.09	-0.12	Aortic root size;	chr7:66622178	chr7:66491049~66493566:-
BRCA	cis	rs757081	0.648	rs1488933	ENSG00000184669.7	OR7E14P	-3.99	6.97e-05	0.00458	-0.16	-0.12	Systolic blood pressure;	chr11:17245482	chr11:17013998~17053024:+
BRCA	cis	rs4415084	0.834	rs7720787	ENSG00000248779.1	RP11-53O19.2	3.99	6.97e-05	0.00458	0.11	0.12	Breast cancer;	chr5:44817207	chr5:44752949~44765744:+
BRCA	cis	rs17711722	0.701	rs4467826	ENSG00000273142.1	RP11-458F8.4	-3.99	6.97e-05	0.00458	-0.11	-0.12	Calcium levels;	chr7:65903721	chr7:66902857~66906297:+
BRCA	cis	rs17428076	0.872	rs6761111	ENSG00000228389.1	AC068039.4	-3.99	6.97e-05	0.00458	-0.18	-0.12	Myopia;	chr2:172018664	chr2:171773482~171775844:+
BRCA	cis	rs891378	1	rs10864231	ENSG00000274245.1	RP11-357P18.2	-3.99	6.97e-05	0.00458	-0.16	-0.12	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207332984	chr1:207372559~207373252:+
BRCA	cis	rs8180040	1	rs8180040	ENSG00000276925.1	RP11-708J19.3	-3.99	6.97e-05	0.00458	-0.14	-0.12	Colorectal cancer;	chr3:47347457	chr3:47469777~47469987:+
BRCA	cis	rs8180040	1	rs11130127	ENSG00000276925.1	RP11-708J19.3	3.99	6.98e-05	0.00458	0.14	0.12	Colorectal cancer;	chr3:47357303	chr3:47469777~47469987:+
BRCA	cis	rs7658584	0.592	rs6854688	ENSG00000246375.2	RP11-10L7.1	-3.99	6.98e-05	0.00458	-0.18	-0.12	Squamous cell lung carcinoma;	chr4:88191681	chr4:88284942~88331421:+
BRCA	cis	rs11098499	0.954	rs1480931	ENSG00000260404.2	RP11-384K6.6	3.99	6.98e-05	0.00458	0.12	0.12	Corneal astigmatism;	chr4:119474654	chr4:118591773~118633729:+
BRCA	cis	rs7592578	1	rs7592578	ENSG00000272979.1	RP11-647K16.1	3.99	6.98e-05	0.00458	0.21	0.12	Diastolic blood pressure;	chr2:190574865	chr2:190454092~190454521:-
BRCA	cis	rs703842	1	rs10877013	ENSG00000270039.1	RP11-571M6.17	-3.99	6.98e-05	0.00458	-0.17	-0.12	Multiple sclerosis;	chr12:57771302	chr12:57803838~57804415:+
BRCA	cis	rs957448	0.561	rs12679785	ENSG00000261437.1	RP11-22C11.2	3.99	6.98e-05	0.00458	0.12	0.12	Nonsyndromic cleft lip with cleft palate;	chr8:94593349	chr8:94637285~94639467:-
BRCA	cis	rs17406451	0.704	rs6717153	ENSG00000234936.1	AC010883.5	3.99	6.98e-05	0.00458	0.12	0.12	Mitochondrial DNA levels;	chr2:43536390	chr2:43229573~43233394:+
BRCA	cis	rs7267979	0.78	rs2500413	ENSG00000204556.4	CTD-2514C3.1	-3.99	6.98e-05	0.00458	-0.17	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25260519	chr20:26018832~26020684:+
BRCA	cis	rs7267979	0.714	rs2474763	ENSG00000204556.4	CTD-2514C3.1	-3.99	6.98e-05	0.00458	-0.17	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25260659	chr20:26018832~26020684:+
BRCA	cis	rs728616	0.51	rs12416084	ENSG00000242600.5	MBL1P	3.99	6.98e-05	0.00458	0.21	0.12	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79989459	chr10:79904898~79950336:+
BRCA	cis	rs7481584	0.624	rs428726	ENSG00000236710.1	AC108448.2	3.99	6.98e-05	0.00458	0.16	0.12	Calcium levels;	chr11:3024971	chr11:3084393~3085443:-
BRCA	cis	rs5742933	0.51	rs10182631	ENSG00000253559.1	OSGEPL1-AS1	-3.99	6.98e-05	0.00458	-0.19	-0.12	Ferritin levels;	chr2:189635233	chr2:189762704~189765556:+
BRCA	cis	rs5758511	0.596	rs55644935	ENSG00000226450.2	CYP2D8P	3.99	6.98e-05	0.00459	0.14	0.12	Birth weight;	chr22:42270063	chr22:42149886~42155001:-
BRCA	cis	rs875971	0.545	rs7811204	ENSG00000273142.1	RP11-458F8.4	3.99	6.98e-05	0.00459	0.12	0.12	Aortic root size;	chr7:66387213	chr7:66902857~66906297:+
BRCA	cis	rs1008375	0.863	rs2058336	ENSG00000249502.1	AC006160.5	-3.99	6.98e-05	0.00459	-0.14	-0.12	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17606676	chr4:17587467~17614571:-
BRCA	cis	rs6600671	0.764	rs6600673	ENSG00000270392.2	PFN1P2	3.99	6.99e-05	0.00459	0.14	0.12	Hip geometry;	chr1:121426988	chr1:120432204~120434052:-
BRCA	cis	rs1371614	0.545	rs12105356	ENSG00000272148.1	RP11-195B17.1	3.99	6.99e-05	0.00459	0.14	0.12	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26952702	chr2:27062428~27062907:-
BRCA	cis	rs6546324	0.625	rs2861701	ENSG00000236780.4	AC078941.1	3.99	6.99e-05	0.00459	0.21	0.12	Endometriosis;	chr2:67628848	chr2:67123357~67215319:-
BRCA	cis	rs35740288	0.822	rs17637142	ENSG00000259407.1	RP11-158M2.3	-3.99	6.99e-05	0.00459	-0.17	-0.12	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85697272	chr15:85744109~85750281:-
BRCA	cis	rs7809799	0.571	rs17161687	ENSG00000244219.5	GS1-259H13.2	3.99	6.99e-05	0.00459	0.24	0.12	Ulcerative colitis;	chr7:99344286	chr7:99598066~99610813:+
BRCA	cis	rs7246967	0.932	rs11882432	ENSG00000198153.8	ZNF849P	-3.99	6.99e-05	0.00459	-0.17	-0.12	Bronchopulmonary dysplasia;	chr19:22846901	chr19:22685167~22686732:+
BRCA	cis	rs7246967	0.932	rs4932792	ENSG00000198153.8	ZNF849P	-3.99	6.99e-05	0.00459	-0.17	-0.12	Bronchopulmonary dysplasia;	chr19:22849647	chr19:22685167~22686732:+
BRCA	cis	rs7246967	0.866	rs4932695	ENSG00000198153.8	ZNF849P	-3.99	6.99e-05	0.00459	-0.17	-0.12	Bronchopulmonary dysplasia;	chr19:22853575	chr19:22685167~22686732:+
BRCA	cis	rs11887277	0.741	rs11891133	ENSG00000272148.1	RP11-195B17.1	-3.99	6.99e-05	0.00459	-0.14	-0.12	Obesity-related traits;	chr2:26813614	chr2:27062428~27062907:-
BRCA	cis	rs11887277	0.652	rs4665908	ENSG00000272148.1	RP11-195B17.1	-3.99	6.99e-05	0.00459	-0.14	-0.12	Obesity-related traits;	chr2:26814211	chr2:27062428~27062907:-
BRCA	cis	rs11887277	0.572	rs2082611	ENSG00000272148.1	RP11-195B17.1	-3.99	6.99e-05	0.00459	-0.14	-0.12	Obesity-related traits;	chr2:26814228	chr2:27062428~27062907:-
BRCA	cis	rs739496	0.895	rs2283357	ENSG00000257624.1	RP1-128M12.3	3.99	6.99e-05	0.00459	0.17	0.12	Platelet count;	chr12:111459575	chr12:112000739~112000985:-
BRCA	cis	rs4835473	0.897	rs7676614	ENSG00000249741.2	RP11-673E1.3	3.99	6.99e-05	0.00459	0.14	0.12	Immature fraction of reticulocytes;	chr4:143695213	chr4:143911514~143912053:-
BRCA	cis	rs11098499	0.863	rs12498539	ENSG00000260091.1	RP11-33B1.4	-3.99	6.99e-05	0.00459	-0.11	-0.12	Corneal astigmatism;	chr4:119547215	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.863	rs3822194	ENSG00000260091.1	RP11-33B1.4	-3.99	6.99e-05	0.00459	-0.11	-0.12	Corneal astigmatism;	chr4:119550493	chr4:119409333~119410233:+
BRCA	cis	rs4449834	0.851	rs6471903	ENSG00000254432.1	RP11-33I11.2	3.99	6.99e-05	0.00459	0.15	0.12	Sum eosinophil basophil counts;	chr8:60827718	chr8:60808735~60809606:-
BRCA	cis	rs10986311	0.889	rs3780204	ENSG00000227200.1	RP11-121A14.3	3.99	6.99e-05	0.00459	0.15	0.12	Vitiligo;	chr9:124330608	chr9:124262876~124265809:+
BRCA	cis	rs2562456	0.833	rs62110428	ENSG00000268658.4	LINC00664	3.99	7e-05	0.00459	0.21	0.12	Pain;	chr19:21430854	chr19:21483374~21503238:+
BRCA	cis	rs7577696	0.671	rs216538	ENSG00000272716.1	RP11-563N4.1	-3.99	7e-05	0.00459	-0.13	-0.12	Inflammatory biomarkers;	chr2:32065262	chr2:32165046~32165757:-
BRCA	cis	rs67981189	0.574	rs4467005	ENSG00000258571.1	PTTG4P	-3.99	7e-05	0.00459	-0.13	-0.12	Schizophrenia;	chr14:71031939	chr14:71085482~71085833:-
BRCA	cis	rs6012564	1	rs755589	ENSG00000227431.4	CSE1L-AS1	3.99	7e-05	0.00459	0.15	0.12	Anger;	chr20:49104848	chr20:49040463~49046044:-
BRCA	cis	rs62458065	0.713	rs28421905	ENSG00000273014.1	RP11-225B17.2	-3.99	7e-05	0.00459	-0.19	-0.12	Metabolite levels (HVA/MHPG ratio);	chr7:32449889	chr7:32758882~32759353:+
BRCA	cis	rs11098499	0.691	rs9996644	ENSG00000260091.1	RP11-33B1.4	-3.99	7e-05	0.00459	-0.11	-0.12	Corneal astigmatism;	chr4:119317722	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.691	rs9996494	ENSG00000260091.1	RP11-33B1.4	-3.99	7e-05	0.00459	-0.11	-0.12	Corneal astigmatism;	chr4:119317725	chr4:119409333~119410233:+
BRCA	cis	rs1476679	0.962	rs34995835	ENSG00000235713.1	RP4-604G5.3	-3.99	7e-05	0.0046	-0.15	-0.12	Alzheimer's disease (late onset);	chr7:100392741	chr7:99992397~99993050:+
BRCA	cis	rs2625529	0.652	rs8030815	ENSG00000260037.4	CTD-2524L6.3	3.99	7e-05	0.0046	0.15	0.12	Red blood cell count;	chr15:72110660	chr15:71818396~71823384:+
BRCA	cis	rs5997397	0.934	rs6005864	ENSG00000272858.1	CTA-292E10.8	3.99	7e-05	0.0046	0.15	0.12	Red cell distribution width;	chr22:28761499	chr22:28814914~28815662:+
BRCA	cis	rs2562456	0.833	rs62110429	ENSG00000268658.4	LINC00664	3.99	7e-05	0.0046	0.21	0.12	Pain;	chr19:21430984	chr19:21483374~21503238:+
BRCA	cis	rs875971	1	rs55962648	ENSG00000229180.5	GS1-124K5.11	-3.99	7e-05	0.0046	-0.11	-0.12	Aortic root size;	chr7:66160764	chr7:66526088~66542624:-
BRCA	cis	rs9952980	0.752	rs11082442	ENSG00000266968.2	RP11-116O18.1	-3.99	7e-05	0.0046	-0.15	-0.12	Breast cancer;	chr18:45309052	chr18:45646153~45647937:+
BRCA	cis	rs62229266	0.74	rs2835233	ENSG00000214914.3	RPL23AP3	3.99	7.01e-05	0.0046	0.15	0.12	Mitral valve prolapse;	chr21:36021284	chr21:36016079~36016546:-
BRCA	cis	rs4869313	0.905	rs27997	ENSG00000248734.2	CTD-2260A17.1	-3.99	7.01e-05	0.0046	-0.13	-0.12	Pediatric autoimmune diseases;	chr5:97003784	chr5:96784777~96785999:+
BRCA	cis	rs6696239	0.513	rs28407112	ENSG00000227711.2	RP11-275O4.5	3.99	7.01e-05	0.0046	0.14	0.12	Height;	chr1:227549051	chr1:227509028~227520477:-
BRCA	cis	rs2880765	0.743	rs6497194	ENSG00000230373.7	GOLGA6L5P	3.99	7.01e-05	0.0046	0.13	0.12	Coronary artery disease;	chr15:85470885	chr15:84507885~84516814:-
BRCA	cis	rs9527	0.59	rs726010	ENSG00000213061.2	PFN1P11	3.99	7.01e-05	0.0046	0.17	0.12	Arsenic metabolism;	chr10:103082220	chr10:102838011~102845473:-
BRCA	cis	rs3820068	0.603	rs35509554	ENSG00000237301.1	RP4-680D5.2	-3.99	7.01e-05	0.0046	-0.16	-0.12	Systolic blood pressure;	chr1:15667019	chr1:15586136~15603626:-
BRCA	cis	rs9513627	1	rs2390279	ENSG00000280710.1	RP11-214F16.8	-3.99	7.01e-05	0.0046	-0.21	-0.12	Obesity-related traits;	chr13:99556451	chr13:99498524~99501315:+
BRCA	cis	rs1865760	1	rs7739966	ENSG00000272462.2	U91328.19	-3.99	7.01e-05	0.0046	-0.15	-0.12	Height;	chr6:25905812	chr6:25992662~26001775:+
BRCA	cis	rs1865760	1	rs56118523	ENSG00000272462.2	U91328.19	-3.99	7.01e-05	0.0046	-0.15	-0.12	Height;	chr6:25908747	chr6:25992662~26001775:+
BRCA	cis	rs1865760	1	rs12209482	ENSG00000272462.2	U91328.19	-3.99	7.01e-05	0.0046	-0.15	-0.12	Height;	chr6:25909001	chr6:25992662~26001775:+
BRCA	cis	rs8114671	0.967	rs4911472	ENSG00000279253.1	RP4-614O4.13	-3.99	7.01e-05	0.0046	-0.14	-0.12	Height;	chr20:35187574	chr20:35262727~35264187:-
BRCA	cis	rs7520050	0.667	rs11211176	ENSG00000281133.1	AL355480.3	3.99	7.01e-05	0.0046	0.14	0.12	Reticulocyte count;Red blood cell count;	chr1:45757414	chr1:45580892~45580996:-
BRCA	cis	rs801193	0.935	rs2659916	ENSG00000272831.1	RP11-792A8.4	3.99	7.01e-05	0.0046	0.11	0.12	Aortic root size;	chr7:66686365	chr7:66739829~66740385:-
BRCA	cis	rs62025270	0.688	rs62025297	ENSG00000259762.1	RP11-158M2.4	-3.99	7.01e-05	0.0046	-0.18	-0.12	Idiopathic pulmonary fibrosis;	chr15:85773708	chr15:85750336~85752901:-
BRCA	cis	rs11764932	0.69	rs6942739	ENSG00000229108.1	MEOX2-AS1	-3.99	7.01e-05	0.0046	-0.15	-0.12	Kidney function decline traits;	chr7:15678906	chr7:15688378~15695491:+
BRCA	cis	rs35740288	0.822	rs4843092	ENSG00000259407.1	RP11-158M2.3	-3.99	7.02e-05	0.0046	-0.17	-0.12	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85689949	chr15:85744109~85750281:-
BRCA	cis	rs3858526	0.92	rs11039698	ENSG00000224295.2	AC087380.14	3.99	7.02e-05	0.0046	0.18	0.12	DNA methylation (variation);	chr11:5929677	chr11:5518441~5524955:-
BRCA	cis	rs3858526	0.959	rs11039699	ENSG00000224295.2	AC087380.14	3.99	7.02e-05	0.0046	0.18	0.12	DNA methylation (variation);	chr11:5929861	chr11:5518441~5524955:-
BRCA	cis	rs3858526	0.959	rs4758219	ENSG00000224295.2	AC087380.14	3.99	7.02e-05	0.0046	0.18	0.12	DNA methylation (variation);	chr11:5930616	chr11:5518441~5524955:-
BRCA	cis	rs75422866	0.867	rs73113143	ENSG00000276691.1	RP5-1057I20.5	3.99	7.02e-05	0.0046	0.25	0.12	Pneumonia;	chr12:47623060	chr12:47788426~47788971:+
BRCA	cis	rs654950	0.875	rs586055	ENSG00000230638.4	RP11-486B10.4	-3.99	7.02e-05	0.0046	-0.16	-0.12	Airway imaging phenotypes;	chr1:41533405	chr1:41542069~41544310:+
BRCA	cis	rs7100689	0.542	rs10887869	ENSG00000226659.1	RP11-137H2.4	-3.99	7.02e-05	0.00461	-0.16	-0.12	Post bronchodilator FEV1;	chr10:80434933	chr10:80529597~80535942:-
BRCA	cis	rs10761482	1	rs1350631	ENSG00000254271.1	RP11-131N11.4	3.99	7.02e-05	0.00461	0.17	0.12	Schizophrenia;	chr10:60322811	chr10:60734342~60741828:+
BRCA	cis	rs2991971	1	rs622798	ENSG00000280836.1	AL355480.1	3.99	7.02e-05	0.00461	0.14	0.12	High light scatter reticulocyte count;	chr1:45549599	chr1:45581219~45581321:-
BRCA	cis	rs73222236	0.963	rs10512987	ENSG00000273486.1	RP11-731C17.2	-3.99	7.02e-05	0.00461	-0.14	-0.12	Coronary artery disease;	chr3:136104235	chr3:136837338~136839021:-
BRCA	cis	rs754466	0.58	rs10762763	ENSG00000213514.2	RP11-428P16.2	3.99	7.02e-05	0.00461	0.16	0.12	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77801045	chr10:77730766~77734769:+
BRCA	cis	rs2243480	0.522	rs12698511	ENSG00000164669.11	INTS4P1	3.99	7.02e-05	0.00461	0.29	0.12	Diabetic kidney disease;	chr7:66009932	chr7:65141225~65234216:+
BRCA	cis	rs7267979	0.866	rs6138609	ENSG00000276952.1	RP5-965G21.6	3.99	7.02e-05	0.00461	0.15	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25590349	chr20:25284915~25285588:-
BRCA	cis	rs728616	0.85	rs3889823	ENSG00000242600.5	MBL1P	3.99	7.03e-05	0.00461	0.3	0.12	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80158606	chr10:79904898~79950336:+
BRCA	cis	rs9527	0.59	rs4917992	ENSG00000213061.2	PFN1P11	3.99	7.03e-05	0.00461	0.17	0.12	Arsenic metabolism;	chr10:103026556	chr10:102838011~102845473:-
BRCA	cis	rs41369048	0.66	rs10495157	ENSG00000238078.1	LINC01352	-3.99	7.03e-05	0.00461	-0.17	-0.12	Eosinophil counts;Sum eosinophil basophil counts;	chr1:220934454	chr1:220829255~220832429:+
BRCA	cis	rs2991971	1	rs606542	ENSG00000280836.1	AL355480.1	3.99	7.03e-05	0.00461	0.14	0.12	High light scatter reticulocyte count;	chr1:45548261	chr1:45581219~45581321:-
BRCA	cis	rs1941184	0.5	rs1893390	ENSG00000266521.1	RP11-650P15.1	-3.99	7.03e-05	0.00461	-0.17	-0.12	Parkinson's disease (age of onset);	chr18:31437419	chr18:31496645~31497195:-
BRCA	cis	rs2991971	0.869	rs2453404	ENSG00000280836.1	AL355480.1	3.99	7.03e-05	0.00461	0.14	0.12	High light scatter reticulocyte count;	chr1:45549063	chr1:45581219~45581321:-
BRCA	cis	rs11098499	0.954	rs7681544	ENSG00000260404.2	RP11-384K6.6	3.99	7.03e-05	0.00461	0.12	0.12	Corneal astigmatism;	chr4:119490100	chr4:118591773~118633729:+
BRCA	cis	rs6840360	0.557	rs4696261	ENSG00000251611.1	RP11-610P16.1	-3.99	7.03e-05	0.00461	-0.11	-0.12	Intelligence (multi-trait analysis);	chr4:151401507	chr4:151407551~151408835:-
BRCA	cis	rs6496932	0.802	rs4843047	ENSG00000218052.5	ADAMTS7P4	3.99	7.03e-05	0.00461	0.13	0.12	Central corneal thickness;Corneal structure;	chr15:85316545	chr15:85255369~85330334:-
BRCA	cis	rs9959145	1	rs79692970	ENSG00000267108.1	RP11-861E21.1	3.99	7.03e-05	0.00461	0.22	0.12	Immune response to smallpox vaccine (IL-6);	chr18:12580218	chr18:12432897~12437635:+
BRCA	cis	rs875971	0.66	rs6460308	ENSG00000223473.2	GS1-124K5.3	-3.99	7.03e-05	0.00461	-0.09	-0.12	Aortic root size;	chr7:66619753	chr7:66491049~66493566:-
BRCA	cis	rs794185	0.714	rs711633	ENSG00000231249.1	ITPR1-AS1	3.99	7.03e-05	0.00461	0.14	0.12	Multiple sclerosis--Brain Glutamate Levels;	chr3:4449577	chr3:4490891~4493163:-
BRCA	cis	rs12900463	0.813	rs186266	ENSG00000259295.5	CSPG4P12	3.99	7.03e-05	0.00461	0.18	0.12	Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine);	chr15:84859564	chr15:85191438~85213905:+
BRCA	cis	rs4650943	0.658	rs2455748	ENSG00000227740.1	RP11-318C24.2	-3.99	7.03e-05	0.00461	-0.13	-0.12	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in inactive individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr1:176393923	chr1:175904762~175920513:-
BRCA	cis	rs8130944	1	rs7281911	ENSG00000225731.1	AP001627.1	3.99	7.03e-05	0.00461	0.14	0.12	Perceived unattractiveness to mosquitoes;	chr21:42721800	chr21:42733594~42741758:-
BRCA	cis	rs2281558	0.837	rs56238023	ENSG00000274414.1	RP5-965G21.4	-3.99	7.04e-05	0.00461	-0.16	-0.12	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25536311	chr20:25239007~25245229:-
BRCA	cis	rs7200543	1	rs4985124	ENSG00000207425.1	Y_RNA	-3.99	7.04e-05	0.00462	-0.15	-0.12	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15031584	chr16:14915457~14915556:-
BRCA	cis	rs8030605	0.704	rs7163544	ENSG00000277245.1	RP11-48G14.3	-3.99	7.04e-05	0.00462	-0.26	-0.12	Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;	chr15:56386173	chr15:56447120~56447697:+
BRCA	cis	rs7260598	0.792	rs73021461	ENSG00000268442.1	CTD-2027I19.2	3.99	7.04e-05	0.00462	0.21	0.12	Response to taxane treatment (placlitaxel);	chr19:24140154	chr19:24162370~24163425:-
BRCA	cis	rs2251381	0.523	rs2832306	ENSG00000176054.6	RPL23P2	-3.99	7.04e-05	0.00462	-0.14	-0.12	Selective IgA deficiency;	chr21:29382148	chr21:28997613~28998033:-
BRCA	cis	rs763121	0.853	rs138716	ENSG00000273076.1	RP3-508I15.22	3.99	7.04e-05	0.00462	0.15	0.12	Menopause (age at onset);	chr22:38750522	chr22:38743495~38743910:+
BRCA	cis	rs7735319	0.584	rs7726305	ENSG00000249572.1	CTD-2203K17.1	3.99	7.04e-05	0.00462	0.16	0.12	Systolic blood pressure;	chr5:33095583	chr5:33424025~33440619:-
BRCA	cis	rs9307551	0.602	rs7697040	ENSG00000250334.4	LINC00989	3.99	7.04e-05	0.00462	0.2	0.12	Refractive error;	chr4:79644498	chr4:79492416~79576460:+
BRCA	cis	rs13126694	0.598	rs4077777	ENSG00000248429.4	RP11-597D13.9	3.99	7.04e-05	0.00462	0.11	0.12	Blood osmolality (transformed sodium);	chr4:158007502	chr4:158170752~158202877:+
BRCA	cis	rs2562456	0.833	rs2562416	ENSG00000268658.4	LINC00664	3.99	7.04e-05	0.00462	0.21	0.12	Pain;	chr19:21430609	chr19:21483374~21503238:+
BRCA	cis	rs7267979	0.966	rs6050532	ENSG00000274973.1	RP13-401N8.7	3.99	7.04e-05	0.00462	0.14	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25328157	chr20:25845497~25845862:+
BRCA	cis	rs6012564	0.928	rs8118105	ENSG00000222365.1	SNORD12B	3.99	7.04e-05	0.00462	0.13	0.12	Anger;	chr20:49182127	chr20:49280319~49280409:+
BRCA	cis	rs860818	1	rs1637223	ENSG00000230658.1	KLHL7-AS1	-3.99	7.04e-05	0.00462	-0.31	-0.12	Initial pursuit acceleration;	chr7:23189050	chr7:23101228~23105703:-
BRCA	cis	rs860818	0.744	rs1728319	ENSG00000230658.1	KLHL7-AS1	-3.99	7.04e-05	0.00462	-0.31	-0.12	Initial pursuit acceleration;	chr7:23191580	chr7:23101228~23105703:-
BRCA	cis	rs6088590	0.561	rs6087605	ENSG00000275784.1	RP5-1125A11.6	-3.99	7.04e-05	0.00462	-0.13	-0.12	Coronary artery disease;	chr20:34592820	chr20:33989480~33991818:-
BRCA	cis	rs12505749	0.542	rs6554358	ENSG00000270147.1	RP11-646I6.6	-3.99	7.05e-05	0.00462	-0.14	-0.12	Airflow obstruction;	chr4:56506410	chr4:56396312~56396871:+
BRCA	cis	rs1865760	0.928	rs9295673	ENSG00000272462.2	U91328.19	-3.99	7.05e-05	0.00462	-0.15	-0.12	Height;	chr6:25911866	chr6:25992662~26001775:+
BRCA	cis	rs7267979	0.565	rs958075	ENSG00000125804.12	FAM182A	3.99	7.05e-05	0.00462	0.16	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25614487	chr20:26054655~26086917:+
BRCA	cis	rs7071275	0.771	rs11200069	ENSG00000226864.1	ATE1-AS1	-3.99	7.05e-05	0.00462	-0.2	-0.12	Dupuytren's disease;	chr10:121669528	chr10:121928312~121951965:+
BRCA	cis	rs11168618	0.904	rs7135125	ENSG00000273765.1	RP11-370I10.11	3.99	7.05e-05	0.00462	0.14	0.12	Adiponectin levels;	chr12:48532485	chr12:48360920~48361377:+
BRCA	cis	rs11098499	0.908	rs7696649	ENSG00000225892.3	RP11-384K6.2	3.99	7.05e-05	0.00462	0.12	0.12	Corneal astigmatism;	chr4:119401022	chr4:118632274~118634759:+
BRCA	cis	rs17801127	0.688	rs1405215	ENSG00000231969.1	AC144449.1	-3.99	7.05e-05	0.00462	-0.19	-0.12	Liver enzyme levels (alanine transaminase);	chr2:149681890	chr2:149587196~149848233:+
BRCA	cis	rs8017423	0.647	rs12882575	ENSG00000275198.1	RP11-471B22.3	3.99	7.05e-05	0.00462	0.14	0.12	Mortality in heart failure;	chr14:90354110	chr14:90383365~90387973:+
BRCA	cis	rs8017423	0.647	rs12882973	ENSG00000275198.1	RP11-471B22.3	3.99	7.05e-05	0.00462	0.14	0.12	Mortality in heart failure;	chr14:90354158	chr14:90383365~90387973:+
BRCA	cis	rs8017423	0.647	rs12883000	ENSG00000275198.1	RP11-471B22.3	3.99	7.05e-05	0.00462	0.14	0.12	Mortality in heart failure;	chr14:90354213	chr14:90383365~90387973:+
BRCA	cis	rs4302906	1	rs10821048	ENSG00000187984.11	ANKRD19P	-3.99	7.05e-05	0.00462	-0.11	-0.12	Lobe attachment (rater-scored or self-reported);	chr9:92970264	chr9:92809388~92888693:+
BRCA	cis	rs875971	0.862	rs11765791	ENSG00000229886.1	RP5-1132H15.3	3.99	7.05e-05	0.00462	0.14	0.12	Aortic root size;	chr7:66471587	chr7:66025126~66031544:-
BRCA	cis	rs2274459	1	rs12211490	ENSG00000249346.5	LINC01016	3.99	7.05e-05	0.00463	0.17	0.12	Obesity (extreme);	chr6:33757751	chr6:33867506~33896914:-
BRCA	cis	rs2274459	1	rs12211565	ENSG00000249346.5	LINC01016	3.99	7.05e-05	0.00463	0.17	0.12	Obesity (extreme);	chr6:33758075	chr6:33867506~33896914:-
BRCA	cis	rs11098499	0.909	rs10026736	ENSG00000260404.2	RP11-384K6.6	3.99	7.06e-05	0.00463	0.12	0.12	Corneal astigmatism;	chr4:119463167	chr4:118591773~118633729:+
BRCA	cis	rs8180040	0.654	rs6766230	ENSG00000271161.1	BOLA2P2	3.99	7.06e-05	0.00463	0.13	0.12	Colorectal cancer;	chr3:47154719	chr3:47499841~47500407:+
BRCA	cis	rs8180040	0.627	rs9821119	ENSG00000271161.1	BOLA2P2	3.99	7.06e-05	0.00463	0.13	0.12	Colorectal cancer;	chr3:47156947	chr3:47499841~47500407:+
BRCA	cis	rs1910358	0.648	rs1910065	ENSG00000248874.4	C5orf17	-3.99	7.06e-05	0.00463	-0.16	-0.12	Venous thromboembolism (SNP x SNP interaction);	chr5:24007546	chr5:23951348~24178263:+
BRCA	cis	rs1910358	0.676	rs10074054	ENSG00000248874.4	C5orf17	-3.99	7.06e-05	0.00463	-0.16	-0.12	Venous thromboembolism (SNP x SNP interaction);	chr5:24007717	chr5:23951348~24178263:+
BRCA	cis	rs7781557	0.638	rs55781834	ENSG00000239969.4	RP11-163E9.2	-3.99	7.06e-05	0.00463	-0.2	-0.12	Colorectal adenoma (advanced);	chr7:102931986	chr7:102364162~102380633:+
BRCA	cis	rs10129255	0.518	rs7143784	ENSG00000254174.1	IGHV1-12	3.99	7.06e-05	0.00463	0.09	0.12	Kawasaki disease;	chr14:106687277	chr14:106122420~106122709:-
BRCA	cis	rs16893526	0.649	rs1931626	ENSG00000224995.1	LINC01526	-3.99	7.06e-05	0.00463	-0.2	-0.12	Coronary heart disease;	chr6:81813624	chr6:81813286~81814157:-
BRCA	cis	rs2243480	1	rs383402	ENSG00000237026.1	RP11-328P23.2	-3.99	7.06e-05	0.00463	-0.22	-0.12	Diabetic kidney disease;	chr7:66121666	chr7:65235790~65236723:-
BRCA	cis	rs10266483	0.921	rs624257	ENSG00000228653.2	HNRNPCP7	3.99	7.06e-05	0.00463	0.14	0.12	Response to statin therapy;	chr7:64284848	chr7:64500825~64501729:+
BRCA	cis	rs12900463	0.813	rs187316	ENSG00000259295.5	CSPG4P12	3.99	7.06e-05	0.00463	0.18	0.12	Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine);	chr15:84862764	chr15:85191438~85213905:+
BRCA	cis	rs875971	0.505	rs2462573	ENSG00000273142.1	RP11-458F8.4	3.99	7.06e-05	0.00463	0.11	0.12	Aortic root size;	chr7:66042405	chr7:66902857~66906297:+
BRCA	cis	rs6431644	0.731	rs503913	ENSG00000224287.2	MSL3P1	3.99	7.07e-05	0.00463	0.15	0.12	Left atrial antero-posterior diameter;	chr2:233854580	chr2:233865437~233868444:-
BRCA	cis	rs7176093	0.794	rs11852416	ENSG00000259295.5	CSPG4P12	-3.99	7.07e-05	0.00463	-0.17	-0.12	Aging traits;	chr15:85809628	chr15:85191438~85213905:+
BRCA	cis	rs10208649	1	rs6759437	ENSG00000233266.1	HMGB1P31	3.99	7.07e-05	0.00463	0.29	0.12	Body mass index;	chr2:53821907	chr2:54051334~54051760:+
BRCA	cis	rs1665650	0.957	rs1638422	ENSG00000232767.1	RP11-498B4.5	-3.99	7.07e-05	0.00463	-0.13	-0.12	Colorectal cancer;	chr10:116729073	chr10:116670103~116672739:+
BRCA	cis	rs2229238	0.911	rs12405637	ENSG00000272030.1	RP1-178F15.4	-3.99	7.07e-05	0.00463	-0.17	-0.12	Coronary heart disease;	chr1:154528809	chr1:153631438~153634397:-
BRCA	cis	rs2109514	0.765	rs768108	ENSG00000237813.3	AC002066.1	3.99	7.07e-05	0.00464	0.15	0.12	Prevalent atrial fibrillation;	chr7:116468604	chr7:116238260~116499465:-
BRCA	cis	rs6545883	1	rs6545883	ENSG00000270820.4	RP11-355B11.2	3.99	7.07e-05	0.00464	0.14	0.12	Tuberculosis;	chr2:61545122	chr2:61471188~61484130:+
BRCA	cis	rs801193	1	rs2659906	ENSG00000273142.1	RP11-458F8.4	-3.99	7.07e-05	0.00464	-0.11	-0.12	Aortic root size;	chr7:66700323	chr7:66902857~66906297:+
BRCA	cis	rs2625529	0.652	rs2957745	ENSG00000260037.4	CTD-2524L6.3	3.99	7.07e-05	0.00464	0.15	0.12	Red blood cell count;	chr15:71995736	chr15:71818396~71823384:+
BRCA	cis	rs7695732	0.743	rs2904261	ENSG00000270720.1	RP11-84C13.2	-3.99	7.07e-05	0.00464	-0.17	-0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr4:88999923	chr4:89119284~89119871:+
BRCA	cis	rs72647484	0.642	rs2744753	ENSG00000228397.1	RP1-224A6.3	-3.99	7.07e-05	0.00464	-0.32	-0.12	Colorectal cancer;	chr1:22249834	chr1:22023994~22024968:-
BRCA	cis	rs860295	0.557	rs12035524	ENSG00000225855.5	RUSC1-AS1	3.99	7.08e-05	0.00464	0.11	0.12	Body mass index;	chr1:155697311	chr1:155316863~155324176:-
BRCA	cis	rs2688608	0.592	rs10762563	ENSG00000213731.2	RAB5CP1	-3.99	7.08e-05	0.00464	-0.14	-0.12	Inflammatory bowel disease;	chr10:73765044	chr10:74423435~74424014:-
BRCA	cis	rs9307551	0.741	rs6840265	ENSG00000250334.4	LINC00989	-3.99	7.08e-05	0.00464	-0.2	-0.12	Refractive error;	chr4:79521327	chr4:79492416~79576460:+
BRCA	cis	rs886774	0.615	rs881176	ENSG00000273055.1	CTB-13F3.1	3.99	7.08e-05	0.00464	0.13	0.12	Ulcerative colitis;	chr7:107932809	chr7:107942116~107942740:+
BRCA	cis	rs11098499	1	rs6849889	ENSG00000260091.1	RP11-33B1.4	-3.99	7.08e-05	0.00464	-0.11	-0.12	Corneal astigmatism;	chr4:119265193	chr4:119409333~119410233:+
BRCA	cis	rs3743162	0.553	rs12900463	ENSG00000259295.5	CSPG4P12	3.99	7.08e-05	0.00464	0.18	0.12	Alzheimer's disease (age of onset);	chr15:84872155	chr15:85191438~85213905:+
BRCA	cis	rs7520050	0.778	rs2088102	ENSG00000234329.1	RP11-767N6.2	-3.99	7.08e-05	0.00464	-0.11	-0.12	Reticulocyte count;Red blood cell count;	chr1:45567302	chr1:45651039~45651826:-
BRCA	cis	rs4761702	0.857	rs1135400	ENSG00000257210.1	NACAP3	3.99	7.08e-05	0.00464	0.14	0.12	Immature fraction of reticulocytes;	chr12:93315763	chr12:93124063~93124543:-
BRCA	cis	rs17027633	1	rs3767604	ENSG00000260948.1	RP11-552M11.8	3.99	7.08e-05	0.00464	0.28	0.12	Cerebrospinal fluid t-tau:AB1-42 ratio;	chr1:111424855	chr1:111431046~111433068:-
BRCA	cis	rs7267979	0.866	rs437635	ENSG00000274973.1	RP13-401N8.7	-3.99	7.08e-05	0.00464	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25476252	chr20:25845497~25845862:+
BRCA	cis	rs7267979	0.932	rs417110	ENSG00000274973.1	RP13-401N8.7	-3.99	7.08e-05	0.00464	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25477661	chr20:25845497~25845862:+
BRCA	cis	rs7267979	0.932	rs449703	ENSG00000274973.1	RP13-401N8.7	-3.99	7.08e-05	0.00464	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25477923	chr20:25845497~25845862:+
BRCA	cis	rs6088813	0.702	rs6060370	ENSG00000126005.14	MMP24-AS1	-3.99	7.08e-05	0.00464	-0.15	-0.12	Height;	chr20:35321949	chr20:35216462~35278131:-
BRCA	cis	rs10844706	0.699	rs2058560	ENSG00000256673.1	RP11-599J14.2	-3.99	7.08e-05	0.00464	-0.15	-0.12	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9721093	chr12:9398355~9414851:-
BRCA	cis	rs9982086	0.655	rs915861	ENSG00000260583.1	AP000223.42	3.99	7.08e-05	0.00464	0.28	0.12	Carboplatin disposition in epthelial ovarian cancer;	chr21:25582820	chr21:25582770~25583326:-
BRCA	cis	rs11098499	0.863	rs6833334	ENSG00000260091.1	RP11-33B1.4	-3.99	7.08e-05	0.00464	-0.11	-0.12	Corneal astigmatism;	chr4:119583072	chr4:119409333~119410233:+
BRCA	cis	rs7267979	0.903	rs2474766	ENSG00000277938.1	RP5-965G21.3	3.99	7.08e-05	0.00464	0.15	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25265517	chr20:25229150~25231933:+
BRCA	cis	rs7267979	0.903	rs2474769	ENSG00000277938.1	RP5-965G21.3	3.99	7.08e-05	0.00464	0.15	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25268089	chr20:25229150~25231933:+
BRCA	cis	rs8023401	0.938	rs66993605	ENSG00000274654.1	CTD-3247H4.2	3.99	7.08e-05	0.00464	0.16	0.12	Spherical equivalent (joint analysis main effects and education interaction);	chr15:48502998	chr15:48528980~48529728:-
BRCA	cis	rs12612435	0.83	rs34608701	ENSG00000226806.1	AC011893.3	3.99	7.09e-05	0.00464	0.15	0.12	Takotsubo syndrome;	chr2:136380051	chr2:135820191~135823087:+
BRCA	cis	rs38055	1	rs38056	ENSG00000247796.2	CTD-2366F13.1	3.99	7.09e-05	0.00464	0.15	0.12	Acne (severe);	chr5:53264155	chr5:53109842~53115126:+
BRCA	cis	rs6480314	0.831	rs1900007	ENSG00000233590.1	RP11-153K11.3	-3.99	7.09e-05	0.00464	-0.2	-0.12	Optic nerve measurement (disc area);	chr10:68218018	chr10:68233251~68242379:-
BRCA	cis	rs4374383	0.847	rs1554215	ENSG00000243389.1	AC012442.5	-3.99	7.09e-05	0.00464	-0.16	-0.12	Hepatitis C induced liver fibrosis;	chr2:111986521	chr2:112589040~112614431:+
BRCA	cis	rs4374383	0.884	rs1996326	ENSG00000243389.1	AC012442.5	-3.99	7.09e-05	0.00464	-0.16	-0.12	Hepatitis C induced liver fibrosis;	chr2:111986936	chr2:112589040~112614431:+
BRCA	cis	rs4374383	0.884	rs11123073	ENSG00000243389.1	AC012442.5	-3.99	7.09e-05	0.00464	-0.16	-0.12	Hepatitis C induced liver fibrosis;	chr2:111990076	chr2:112589040~112614431:+
BRCA	cis	rs4374383	0.884	rs7564225	ENSG00000243389.1	AC012442.5	-3.99	7.09e-05	0.00464	-0.16	-0.12	Hepatitis C induced liver fibrosis;	chr2:111990555	chr2:112589040~112614431:+
BRCA	cis	rs4374383	0.884	rs10186291	ENSG00000243389.1	AC012442.5	-3.99	7.09e-05	0.00464	-0.16	-0.12	Hepatitis C induced liver fibrosis;	chr2:111990937	chr2:112589040~112614431:+
BRCA	cis	rs4374383	0.884	rs10189399	ENSG00000243389.1	AC012442.5	-3.99	7.09e-05	0.00464	-0.16	-0.12	Hepatitis C induced liver fibrosis;	chr2:111991387	chr2:112589040~112614431:+
BRCA	cis	rs4374383	0.884	rs7571009	ENSG00000243389.1	AC012442.5	-3.99	7.09e-05	0.00464	-0.16	-0.12	Hepatitis C induced liver fibrosis;	chr2:111991934	chr2:112589040~112614431:+
BRCA	cis	rs4374383	0.884	rs7571120	ENSG00000243389.1	AC012442.5	-3.99	7.09e-05	0.00464	-0.16	-0.12	Hepatitis C induced liver fibrosis;	chr2:111992017	chr2:112589040~112614431:+
BRCA	cis	rs4374383	0.884	rs7588459	ENSG00000243389.1	AC012442.5	-3.99	7.09e-05	0.00464	-0.16	-0.12	Hepatitis C induced liver fibrosis;	chr2:111992966	chr2:112589040~112614431:+
BRCA	cis	rs4374383	0.884	rs7604639	ENSG00000243389.1	AC012442.5	-3.99	7.09e-05	0.00464	-0.16	-0.12	Hepatitis C induced liver fibrosis;	chr2:111994351	chr2:112589040~112614431:+
BRCA	cis	rs4374383	0.884	rs7592909	ENSG00000243389.1	AC012442.5	-3.99	7.09e-05	0.00464	-0.16	-0.12	Hepatitis C induced liver fibrosis;	chr2:111994565	chr2:112589040~112614431:+
BRCA	cis	rs10129255	0.518	rs12590732	ENSG00000254174.1	IGHV1-12	-3.99	7.09e-05	0.00464	-0.09	-0.12	Kawasaki disease;	chr14:106779612	chr14:106122420~106122709:-
BRCA	cis	rs7267979	0.899	rs442834	ENSG00000274973.1	RP13-401N8.7	-3.99	7.09e-05	0.00464	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25477460	chr20:25845497~25845862:+
BRCA	cis	rs2136613	0.751	rs224309	ENSG00000238280.1	RP11-436D10.3	3.99	7.09e-05	0.00465	0.15	0.12	Selective IgA deficiency;	chr10:62848544	chr10:62793562~62805887:-
BRCA	cis	rs17801127	0.901	rs6727151	ENSG00000231969.1	AC144449.1	3.99	7.09e-05	0.00465	0.22	0.12	Liver enzyme levels (alanine transaminase);	chr2:149697470	chr2:149587196~149848233:+
BRCA	cis	rs8180040	0.932	rs62246474	ENSG00000276925.1	RP11-708J19.3	3.99	7.09e-05	0.00465	0.14	0.12	Colorectal cancer;	chr3:47356640	chr3:47469777~47469987:+
BRCA	cis	rs832540	0.931	rs331499	ENSG00000271828.1	CTD-2310F14.1	-3.99	7.09e-05	0.00465	-0.15	-0.12	Coronary artery disease;	chr5:56915096	chr5:56927874~56929573:+
BRCA	cis	rs4287000	0.508	rs2994370	ENSG00000227603.1	RP11-165J3.6	-3.99	7.09e-05	0.00465	-0.14	-0.12	Itch intensity from mosquito bite adjusted by bite size;	chr9:93605538	chr9:93435332~93437121:-
BRCA	cis	rs12030196	1	rs12023539	ENSG00000230812.4	LINC01358	-3.99	7.09e-05	0.00465	-0.14	-0.12	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr1:59005959	chr1:59020387~59044614:+
BRCA	cis	rs71636778	0.509	rs12741472	ENSG00000260063.1	RP5-968P14.2	-3.99	7.09e-05	0.00465	-0.28	-0.12	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26895118	chr1:26692132~26694131:-
BRCA	cis	rs71636778	0.57	rs34026565	ENSG00000260063.1	RP5-968P14.2	-3.99	7.09e-05	0.00465	-0.28	-0.12	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26903485	chr1:26692132~26694131:-
BRCA	cis	rs7703051	1	rs10038095	ENSG00000271815.1	CTD-2235C13.3	-3.99	7.09e-05	0.00465	-0.16	-0.12	Age-related diseases, mortality and associated endophenotypes;LDL cholesterol;Age-related disease endophenotypes;	chr5:75341886	chr5:75363760~75364242:+
BRCA	cis	rs739401	0.611	rs7130841	ENSG00000183562.3	CTC-343N3.1	-3.99	7.1e-05	0.00465	-0.13	-0.12	Longevity;	chr11:3022428	chr11:2989863~2991344:+
BRCA	cis	rs6479874	1	rs4558117	ENSG00000223502.1	RP11-96B5.3	-3.99	7.1e-05	0.00465	-0.23	-0.12	Migraine;	chr10:51020524	chr10:51062579~51068553:-
BRCA	cis	rs6479874	1	rs6479862	ENSG00000223502.1	RP11-96B5.3	-3.99	7.1e-05	0.00465	-0.23	-0.12	Migraine;	chr10:51021121	chr10:51062579~51068553:-
BRCA	cis	rs7226408	0.547	rs62083172	ENSG00000267707.2	RP11-95O2.5	3.99	7.1e-05	0.00465	0.21	0.12	Obesity-related traits;	chr18:36719730	chr18:37243776~37247506:+
BRCA	cis	rs9648716	0.766	rs534348	ENSG00000240889.1	NDUFB2-AS1	3.99	7.1e-05	0.00465	0.17	0.12	Type 2 diabetes;	chr7:141082435	chr7:140695336~140697077:-
BRCA	cis	rs6592362	0.54	rs7952551	ENSG00000254748.1	HNRNPCP8	-3.99	7.1e-05	0.00465	-0.17	-0.12	Inflammatory bowel disease;	chr11:87382706	chr11:87024583~87025777:+
BRCA	cis	rs656900	0.669	rs665629	ENSG00000261229.4	MTHFS	3.99	7.1e-05	0.00465	0.12	0.12	Cerebrospinal P-tau181p levels;	chr15:79826889	chr15:79843547~79897285:-
BRCA	cis	rs783540	0.5	rs7163840	ENSG00000276710.3	CSPG4P8	3.99	7.1e-05	0.00465	0.15	0.12	Schizophrenia;	chr15:82729551	chr15:82459472~82477258:+
BRCA	cis	rs10761482	0.813	rs4948411	ENSG00000254271.1	RP11-131N11.4	3.99	7.1e-05	0.00465	0.18	0.12	Schizophrenia;	chr10:60356317	chr10:60734342~60741828:+
BRCA	cis	rs1790761	0.52	rs4930461	ENSG00000231793.4	DOC2GP	3.99	7.1e-05	0.00465	0.13	0.12	Mean corpuscular volume;	chr11:67627424	chr11:67612653~67616257:-
BRCA	cis	rs4374383	0.739	rs55757240	ENSG00000243389.1	AC012442.5	3.99	7.1e-05	0.00465	0.16	0.12	Hepatitis C induced liver fibrosis;	chr2:111911983	chr2:112589040~112614431:+
BRCA	cis	rs11168618	1	rs11168621	ENSG00000273765.1	RP11-370I10.11	3.99	7.1e-05	0.00465	0.14	0.12	Adiponectin levels;	chr12:48545188	chr12:48360920~48361377:+
BRCA	cis	rs4578769	0.733	rs7226388	ENSG00000273232.1	RP11-370A5.2	3.99	7.1e-05	0.00465	0.16	0.12	Eosinophil percentage of white cells;	chr18:22865371	chr18:22882825~22883357:-
BRCA	cis	rs4499344	0.531	rs259247	ENSG00000267475.1	CTD-2538C1.2	3.99	7.11e-05	0.00465	0.16	0.12	Mean platelet volume;	chr19:32656751	chr19:32687089~32691750:-
BRCA	cis	rs7818688	1	rs7002940	ENSG00000245080.5	RP11-320N21.1	-3.99	7.11e-05	0.00465	-0.2	-0.12	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95015164	chr8:95066808~95073182:-
BRCA	cis	rs17772222	0.958	rs2274737	ENSG00000258789.1	RP11-507K2.3	-3.99	7.11e-05	0.00466	-0.15	-0.12	Coronary artery calcification;	chr14:88469307	chr14:88551597~88552493:+
BRCA	cis	rs7177699	0.557	rs3971829	ENSG00000261143.1	ADAMTS7P3	-3.99	7.11e-05	0.00466	-0.15	-0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78816710	chr15:77976042~77993057:+
BRCA	cis	rs7620503	0.959	rs6797636	ENSG00000277241.1	RP11-114M1.3	3.99	7.11e-05	0.00466	0.14	0.12	Corneal structure;	chr3:177591654	chr3:177700346~177701072:-
BRCA	cis	rs9863	0.828	rs4765127	ENSG00000270028.1	RP11-380L11.4	3.99	7.11e-05	0.00466	0.15	0.12	White blood cell count;	chr12:123975620	chr12:123925461~123926083:-
BRCA	cis	rs829883	0.966	rs249853	ENSG00000227825.4	SLC9A7P1	3.99	7.11e-05	0.00466	0.16	0.12	Colorectal adenoma (advanced);	chr12:98471130	chr12:98453835~98457145:-
BRCA	cis	rs875971	1	rs7792762	ENSG00000229180.5	GS1-124K5.11	3.99	7.11e-05	0.00466	0.11	0.12	Aortic root size;	chr7:66539151	chr7:66526088~66542624:-
BRCA	cis	rs934734	0.967	rs1866051	ENSG00000204929.10	AC074391.1	3.99	7.11e-05	0.00466	0.15	0.12	Rheumatoid arthritis;	chr2:65375015	chr2:65436711~66084639:+
BRCA	cis	rs38055	0.881	rs252042	ENSG00000247796.2	CTD-2366F13.1	-3.99	7.11e-05	0.00466	-0.14	-0.12	Acne (severe);	chr5:53308971	chr5:53109842~53115126:+
BRCA	cis	rs38055	0.881	rs252038	ENSG00000247796.2	CTD-2366F13.1	-3.99	7.11e-05	0.00466	-0.14	-0.12	Acne (severe);	chr5:53309832	chr5:53109842~53115126:+
BRCA	cis	rs2243480	0.908	rs55876148	ENSG00000226002.1	RP11-460N20.5	-3.99	7.12e-05	0.00466	-0.21	-0.12	Diabetic kidney disease;	chr7:65914813	chr7:65084103~65100232:+
BRCA	cis	rs651907	0.535	rs12633089	ENSG00000256628.3	ZBTB11-AS1	3.99	7.12e-05	0.00466	0.16	0.12	Colorectal cancer;	chr3:101809919	chr3:101676475~101679217:+
BRCA	cis	rs983392	0.709	rs11603507	ENSG00000275344.1	MIR6503	-3.99	7.12e-05	0.00466	-0.13	-0.12	Alzheimer's disease (late onset);	chr11:60214997	chr11:60209071~60209156:-
BRCA	cis	rs7615952	0.611	rs9681518	ENSG00000248787.1	RP11-666A20.4	-3.99	7.12e-05	0.00466	-0.24	-0.12	Blood pressure (smoking interaction);	chr3:125896287	chr3:125908005~125910272:-
BRCA	cis	rs1075265	0.587	rs2949812	ENSG00000272156.1	RP11-477N3.1	-3.99	7.12e-05	0.00466	-0.13	-0.12	Chronotype;Morning vs. evening chronotype;	chr2:53797190	chr2:54082554~54085066:+
BRCA	cis	rs7712401	0.791	rs6887101	ENSG00000251538.4	RP11-166A12.1	-3.99	7.12e-05	0.00466	-0.13	-0.12	Mean platelet volume;	chr5:122773512	chr5:122628952~122730685:-
BRCA	cis	rs7814319	0.966	rs10112328	ENSG00000254224.1	KB-1043D8.6	-3.99	7.12e-05	0.00466	-0.14	-0.12	Lung function (FVC);	chr8:96242144	chr8:96235427~96238034:+
BRCA	cis	rs7260598	0.642	rs10405341	ENSG00000268442.1	CTD-2027I19.2	3.99	7.12e-05	0.00466	0.19	0.12	Response to taxane treatment (placlitaxel);	chr19:23924450	chr19:24162370~24163425:-
BRCA	cis	rs1005277	0.579	rs1614236	ENSG00000272983.1	RP11-508N22.12	3.99	7.12e-05	0.00467	0.13	0.12	Extrinsic epigenetic age acceleration;	chr10:38214068	chr10:38137337~38144399:+
BRCA	cis	rs1005277	0.579	rs2749616	ENSG00000272983.1	RP11-508N22.12	3.99	7.12e-05	0.00467	0.13	0.12	Extrinsic epigenetic age acceleration;	chr10:38222065	chr10:38137337~38144399:+
BRCA	cis	rs853679	0.517	rs9393895	ENSG00000261839.1	RP1-265C24.8	3.99	7.13e-05	0.00467	0.17	0.12	Depression;	chr6:28159843	chr6:28136849~28139678:+
BRCA	cis	rs1048886	0.938	rs7752409	ENSG00000271967.1	RP11-134K13.4	-3.99	7.13e-05	0.00467	-0.16	-0.12	Type 2 diabetes;	chr6:70476578	chr6:70596438~70596980:+
BRCA	cis	rs4415084	0.716	rs4605791	ENSG00000251141.4	RP11-53O19.1	-3.99	7.13e-05	0.00467	-0.12	-0.12	Breast cancer;	chr5:44855610	chr5:44744900~44808777:-
BRCA	cis	rs4415084	0.744	rs4604199	ENSG00000251141.4	RP11-53O19.1	-3.99	7.13e-05	0.00467	-0.12	-0.12	Breast cancer;	chr5:44855614	chr5:44744900~44808777:-
BRCA	cis	rs6430585	0.527	rs62168792	ENSG00000231890.6	DARS-AS1	-3.99	7.13e-05	0.00467	-0.19	-0.12	Corneal structure;	chr2:135657647	chr2:135985176~136022593:+
BRCA	cis	rs6599077	0.853	rs9832553	ENSG00000223797.4	ENTPD3-AS1	3.99	7.13e-05	0.00467	0.15	0.12	Sleep-related phenotypes;	chr3:40055917	chr3:40313802~40453329:-
BRCA	cis	rs3748682	0.808	rs12728438	ENSG00000252448.1	SNORA63	-3.99	7.13e-05	0.00467	-0.16	-0.12	Hypothyroidism;	chr1:37883728	chr1:37884237~37884317:+
BRCA	cis	rs3858526	0.874	rs10838879	ENSG00000224295.2	AC087380.14	3.99	7.13e-05	0.00467	0.17	0.12	DNA methylation (variation);	chr11:5928939	chr11:5518441~5524955:-
BRCA	cis	rs5758659	0.819	rs134871	ENSG00000231261.1	HMGN2P10	3.99	7.13e-05	0.00467	0.13	0.12	Cognitive function;	chr22:42256710	chr22:41709225~41709489:-
BRCA	cis	rs8099594	0.565	rs8090015	ENSG00000266696.1	RP11-30L3.2	3.99	7.13e-05	0.00467	0.14	0.12	Height;	chr18:49187716	chr18:49205912~49208781:+
BRCA	cis	rs62064224	0.589	rs2285428	ENSG00000279781.1	RP11-466A19.7	-3.99	7.14e-05	0.00467	-0.15	-0.12	Schizophrenia;	chr17:32493158	chr17:32518322~32518934:-
BRCA	cis	rs6432852	0.966	rs13404648	ENSG00000232411.1	AC009495.3	-3.99	7.14e-05	0.00467	-0.14	-0.12	Diabetic kidney disease;	chr2:165891275	chr2:165833048~165839098:-
BRCA	cis	rs2136613	0.751	rs10822060	ENSG00000238280.1	RP11-436D10.3	-3.99	7.14e-05	0.00467	-0.15	-0.12	Selective IgA deficiency;	chr10:62834625	chr10:62793562~62805887:-
BRCA	cis	rs1048886	0.938	rs6900840	ENSG00000271967.1	RP11-134K13.4	-3.99	7.14e-05	0.00467	-0.16	-0.12	Type 2 diabetes;	chr6:70472101	chr6:70596438~70596980:+
BRCA	cis	rs2839186	0.771	rs2280957	ENSG00000239415.1	AP001469.9	-3.99	7.14e-05	0.00467	-0.13	-0.12	Testicular germ cell tumor;	chr21:46222358	chr21:46251549~46254133:-
BRCA	cis	rs8054556	1	rs11150577	ENSG00000261367.1	RP11-455F5.4	-3.99	7.14e-05	0.00467	-0.14	-0.12	Autism spectrum disorder or schizophrenia;	chr16:29975204	chr16:30107675~30110541:+
BRCA	cis	rs7481584	0.581	rs399565	ENSG00000236710.1	AC108448.2	3.99	7.14e-05	0.00467	0.16	0.12	Calcium levels;	chr11:3040550	chr11:3084393~3085443:-
BRCA	cis	rs17270561	0.636	rs6456694	ENSG00000272462.2	U91328.19	-3.99	7.14e-05	0.00467	-0.15	-0.12	Iron status biomarkers;	chr6:25712666	chr6:25992662~26001775:+
BRCA	cis	rs9402743	0.634	rs9494289	ENSG00000234084.1	RP3-388E23.2	-3.99	7.14e-05	0.00467	-0.12	-0.12	Systemic lupus erythematosus;	chr6:135594751	chr6:135301568~135307158:+
BRCA	cis	rs9467773	0.549	rs9467805	ENSG00000224843.5	LINC00240	-3.99	7.14e-05	0.00467	-0.13	-0.12	Intelligence (multi-trait analysis);	chr6:26583138	chr6:26956992~27023924:+
BRCA	cis	rs6831352	0.589	rs2602836	ENSG00000272777.1	RP11-571L19.8	3.99	7.14e-05	0.00467	0.12	0.12	Alcohol dependence;	chr4:99093654	chr4:99067256~99068125:-
BRCA	cis	rs34421088	0.564	rs6983129	ENSG00000270154.1	RP11-419I17.1	3.99	7.15e-05	0.00468	0.14	0.12	Neuroticism;	chr8:11733627	chr8:12476462~12477122:+
BRCA	cis	rs11096990	0.634	rs7564	ENSG00000249685.1	RP11-360F5.3	-3.99	7.15e-05	0.00468	-0.15	-0.12	Cognitive function;	chr4:39285702	chr4:39133913~39135608:+
BRCA	cis	rs7267979	0.932	rs6132848	ENSG00000276952.1	RP5-965G21.6	3.99	7.15e-05	0.00468	0.15	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25581009	chr20:25284915~25285588:-
BRCA	cis	rs11051970	0.879	rs1500874	ENSG00000274964.1	RP11-817I4.1	-3.99	7.15e-05	0.00468	-0.14	-0.12	Response to tocilizumab in rheumatoid arthritis;	chr12:32436473	chr12:32339368~32340724:+
BRCA	cis	rs739401	0.611	rs572373	ENSG00000247473.2	CARS-AS1	3.99	7.15e-05	0.00468	0.14	0.12	Longevity;	chr11:3034131	chr11:3029009~3041260:+
BRCA	cis	rs2243480	0.706	rs6460257	ENSG00000229180.5	GS1-124K5.11	3.99	7.15e-05	0.00468	0.14	0.12	Diabetic kidney disease;	chr7:65731813	chr7:66526088~66542624:-
BRCA	cis	rs4478858	0.775	rs6701667	ENSG00000260386.4	LINC01225	-3.99	7.15e-05	0.00468	-0.14	-0.12	Alcohol dependence;	chr1:31235124	chr1:31500085~31540885:+
BRCA	cis	rs11711311	1	rs9830975	ENSG00000241529.3	RN7SL767P	-3.99	7.15e-05	0.00468	-0.14	-0.12	IgG glycosylation;	chr3:113767172	chr3:113632704~113632998:+
BRCA	cis	rs8180040	0.739	rs4683320	ENSG00000276925.1	RP11-708J19.3	-3.99	7.15e-05	0.00468	-0.14	-0.12	Colorectal cancer;	chr3:47111502	chr3:47469777~47469987:+
BRCA	cis	rs1913185	0.787	rs59850864	ENSG00000240032.1	RP11-274H2.3	-3.99	7.15e-05	0.00468	-0.19	-0.12	Obesity-related traits;	chr3:146111375	chr3:146066344~146069185:-
BRCA	cis	rs7267979	0.934	rs4815423	ENSG00000274973.1	RP13-401N8.7	3.99	7.15e-05	0.00468	0.14	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25406885	chr20:25845497~25845862:+
BRCA	cis	rs6964587	0.967	rs10246036	ENSG00000188693.7	CYP51A1-AS1	3.99	7.15e-05	0.00468	0.13	0.12	Breast cancer;	chr7:91929209	chr7:92134604~92180725:+
BRCA	cis	rs6964587	0.967	rs12671991	ENSG00000188693.7	CYP51A1-AS1	3.99	7.15e-05	0.00468	0.13	0.12	Breast cancer;	chr7:91930167	chr7:92134604~92180725:+
BRCA	cis	rs2562456	0.833	rs2650801	ENSG00000213976.4	CTD-2561J22.2	-3.99	7.15e-05	0.00468	-0.15	-0.12	Pain;	chr19:21452553	chr19:21382865~21387177:+
BRCA	cis	rs10043228	1	rs62384469	ENSG00000271918.1	CTD-2287O16.5	-3.99	7.16e-05	0.00468	-0.16	-0.12	Asthma or chronic obstructive pulmonary disease;	chr5:116289267	chr5:116083807~116085416:-
BRCA	cis	rs1400745	0.756	rs761924	ENSG00000258738.1	RP11-73E17.2	-3.99	7.16e-05	0.00468	-0.17	-0.12	Monocyte count;	chr14:34864077	chr14:34874343~34876459:+
BRCA	cis	rs4819052	0.808	rs2246697	ENSG00000215447.6	BX322557.10	-3.99	7.16e-05	0.00468	-0.13	-0.12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45270084	chr21:45288052~45291738:+
BRCA	cis	rs4819052	0.819	rs7279136	ENSG00000215447.6	BX322557.10	-3.99	7.16e-05	0.00468	-0.13	-0.12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45272372	chr21:45288052~45291738:+
BRCA	cis	rs4819052	0.788	rs4819051	ENSG00000215447.6	BX322557.10	-3.99	7.16e-05	0.00468	-0.13	-0.12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45273213	chr21:45288052~45291738:+
BRCA	cis	rs4819052	0.819	rs8134084	ENSG00000215447.6	BX322557.10	-3.99	7.16e-05	0.00468	-0.13	-0.12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45273380	chr21:45288052~45291738:+
BRCA	cis	rs4819052	0.851	rs7276828	ENSG00000215447.6	BX322557.10	-3.99	7.16e-05	0.00468	-0.13	-0.12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45275124	chr21:45288052~45291738:+
BRCA	cis	rs4819052	0.851	rs7281263	ENSG00000215447.6	BX322557.10	-3.99	7.16e-05	0.00468	-0.13	-0.12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45275691	chr21:45288052~45291738:+
BRCA	cis	rs4819052	0.851	rs914214	ENSG00000215447.6	BX322557.10	-3.99	7.16e-05	0.00468	-0.13	-0.12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45277905	chr21:45288052~45291738:+
BRCA	cis	rs17027633	0.881	rs11548427	ENSG00000260948.1	RP11-552M11.8	-3.99	7.16e-05	0.00468	-0.29	-0.12	Cerebrospinal fluid t-tau:AB1-42 ratio;	chr1:111449146	chr1:111431046~111433068:-
BRCA	cis	rs7267979	0.966	rs6037097	ENSG00000274414.1	RP5-965G21.4	-3.99	7.16e-05	0.00468	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25366585	chr20:25239007~25245229:-
BRCA	cis	rs13434995	0.513	rs17722979	ENSG00000239040.1	Y_RNA	3.99	7.16e-05	0.00469	0.14	0.12	Adiponectin levels;	chr4:55480244	chr4:55412636~55412738:+
BRCA	cis	rs9818758	0.607	rs9855123	ENSG00000225399.4	RP11-3B7.1	-3.99	7.16e-05	0.00469	-0.2	-0.12	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49192024	chr3:49260085~49261316:+
BRCA	cis	rs8020289	0.56	rs4903491	ENSG00000258569.1	RP11-99E15.2	3.99	7.16e-05	0.00469	0.14	0.12	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks);	chr14:76797266	chr14:76710658~76761388:-
BRCA	cis	rs9573567	0.881	rs1570539	ENSG00000261553.4	RP11-29G8.3	3.99	7.16e-05	0.00469	0.27	0.12	Red blood cell count;Mean corpuscular volume;	chr13:75500498	chr13:75549773~75807120:+
BRCA	cis	rs9470794	1	rs9470798	ENSG00000204110.6	RP1-153P14.8	3.99	7.16e-05	0.00469	0.19	0.12	Type 2 diabetes;	chr6:38143563	chr6:37507348~37535616:+
BRCA	cis	rs1129187	1	rs1129187	ENSG00000220614.1	RP11-480N24.4	3.99	7.16e-05	0.00469	0.14	0.12	Alzheimer's disease in APOE e4+ carriers;	chr6:42964462	chr6:43328134~43328476:+
BRCA	cis	rs7267979	0.78	rs2500413	ENSG00000274414.1	RP5-965G21.4	-3.99	7.16e-05	0.00469	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25260519	chr20:25239007~25245229:-
BRCA	cis	rs7267979	0.714	rs2474763	ENSG00000274414.1	RP5-965G21.4	-3.99	7.16e-05	0.00469	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25260659	chr20:25239007~25245229:-
BRCA	cis	rs4974559	0.947	rs10018627	ENSG00000253399.1	AC078852.2	3.99	7.16e-05	0.00469	0.18	0.12	Systolic blood pressure;	chr4:1362570	chr4:1358479~1359461:+
BRCA	cis	rs970548	0.954	rs61854123	ENSG00000237840.5	FAM21FP	3.99	7.16e-05	0.00469	0.16	0.12	Total cholesterol levels;HDL cholesterol;HDL cholesterol levels;Cholesterol, total;	chr10:45570003	chr10:45706431~45727231:-
BRCA	cis	rs9733	0.596	rs12089731	ENSG00000231073.1	RP11-316M1.3	3.99	7.17e-05	0.00469	0.13	0.12	Tonsillectomy;	chr1:150675322	chr1:150973123~150975534:+
BRCA	cis	rs8114671	0.967	rs1415773	ENSG00000279253.1	RP4-614O4.13	-3.99	7.17e-05	0.00469	-0.14	-0.12	Height;	chr20:35177782	chr20:35262727~35264187:-
BRCA	cis	rs8180040	0.62	rs56217494	ENSG00000271161.1	BOLA2P2	-3.99	7.17e-05	0.00469	-0.13	-0.12	Colorectal cancer;	chr3:47006962	chr3:47499841~47500407:+
BRCA	cis	rs739496	0.947	rs7134740	ENSG00000257624.1	RP1-128M12.3	3.99	7.17e-05	0.00469	0.17	0.12	Platelet count;	chr12:111489935	chr12:112000739~112000985:-
BRCA	cis	rs10844706	0.73	rs12317499	ENSG00000256673.1	RP11-599J14.2	-3.99	7.17e-05	0.00469	-0.15	-0.12	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9732764	chr12:9398355~9414851:-
BRCA	cis	rs9733	0.596	rs7549795	ENSG00000231073.1	RP11-316M1.3	3.99	7.17e-05	0.00469	0.13	0.12	Tonsillectomy;	chr1:150684397	chr1:150973123~150975534:+
BRCA	cis	rs801193	1	rs62466794	ENSG00000273142.1	RP11-458F8.4	-3.99	7.17e-05	0.00469	-0.11	-0.12	Aortic root size;	chr7:66726592	chr7:66902857~66906297:+
BRCA	cis	rs13434995	0.513	rs73236142	ENSG00000239040.1	Y_RNA	3.99	7.17e-05	0.00469	0.15	0.12	Adiponectin levels;	chr4:55446143	chr4:55412636~55412738:+
BRCA	cis	rs11742741	0.934	rs62347916	ENSG00000248874.4	C5orf17	-3.99	7.17e-05	0.00469	-0.16	-0.12	Educational attainment;	chr5:24239889	chr5:23951348~24178263:+
BRCA	cis	rs17772222	0.958	rs2297128	ENSG00000258789.1	RP11-507K2.3	-3.99	7.17e-05	0.00469	-0.15	-0.12	Coronary artery calcification;	chr14:88469910	chr14:88551597~88552493:+
BRCA	cis	rs7267979	1	rs2258617	ENSG00000274973.1	RP13-401N8.7	-3.99	7.18e-05	0.00469	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25293682	chr20:25845497~25845862:+
BRCA	cis	rs62229266	0.74	rs4817759	ENSG00000214914.3	RPL23AP3	3.99	7.18e-05	0.0047	0.15	0.12	Mitral valve prolapse;	chr21:36017261	chr21:36016079~36016546:-
BRCA	cis	rs11148252	0.74	rs9526914	ENSG00000272281.5	TPTE2P2	-3.99	7.18e-05	0.0047	-0.12	-0.12	Lewy body disease;	chr13:52402165	chr13:52219344~52334277:-
BRCA	cis	rs2692947	0.667	rs4144055	ENSG00000232931.4	LINC00342	3.99	7.18e-05	0.0047	0.13	0.12	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95982108	chr2:95807118~95816215:-
BRCA	cis	rs7481584	0.624	rs377765	ENSG00000236710.1	AC108448.2	3.99	7.18e-05	0.0047	0.16	0.12	Calcium levels;	chr11:3025068	chr11:3084393~3085443:-
BRCA	cis	rs10844706	0.669	rs10844682	ENSG00000214776.8	RP11-726G1.1	-3.99	7.18e-05	0.0047	-0.15	-0.12	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9747028	chr12:9467552~9576275:+
BRCA	cis	rs7267979	0.844	rs4815413	ENSG00000231081.1	RP4-760C5.3	3.99	7.18e-05	0.0047	0.16	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25378593	chr20:26008791~26010531:-
BRCA	cis	rs7267979	0.844	rs6083824	ENSG00000231081.1	RP4-760C5.3	3.99	7.18e-05	0.0047	0.16	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25382421	chr20:26008791~26010531:-
BRCA	cis	rs4073416	0.684	rs883081	ENSG00000276116.2	FUT8-AS1	3.99	7.19e-05	0.0047	0.13	0.12	N-glycan levels;	chr14:65413903	chr14:65411170~65412690:-
BRCA	cis	rs10266483	0.739	rs10949900	ENSG00000271550.1	BNIP3P11	-3.99	7.19e-05	0.0047	-0.16	-0.12	Response to statin therapy;	chr7:64351751	chr7:64678954~64687393:-
BRCA	cis	rs853679	0.517	rs4713146	ENSG00000261839.1	RP1-265C24.8	3.99	7.19e-05	0.0047	0.17	0.12	Depression;	chr6:28143758	chr6:28136849~28139678:+
BRCA	cis	rs853679	0.517	rs9393894	ENSG00000261839.1	RP1-265C24.8	3.99	7.19e-05	0.0047	0.17	0.12	Depression;	chr6:28144784	chr6:28136849~28139678:+
BRCA	cis	rs6452524	0.967	rs1031901	ENSG00000281327.1	LINC01338	3.99	7.19e-05	0.0047	0.14	0.12	Hypertension (SNP x SNP interaction);	chr5:83147904	chr5:82850864~82859836:-
BRCA	cis	rs8058578	1	rs8048448	ENSG00000260911.2	RP11-196G11.2	3.99	7.19e-05	0.0047	0.12	0.12	Multiple myeloma;	chr16:30680887	chr16:31043150~31049868:+
BRCA	cis	rs516805	0.564	rs2679658	ENSG00000279114.1	RP3-425C14.5	-3.99	7.19e-05	0.0047	-0.16	-0.12	Lymphocyte counts;	chr6:122109293	chr6:122471923~122484161:+
BRCA	cis	rs11098499	0.908	rs9995234	ENSG00000250412.1	KLHL2P1	3.99	7.19e-05	0.0047	0.15	0.12	Corneal astigmatism;	chr4:119400672	chr4:119334329~119378233:+
BRCA	cis	rs6599077	1	rs9832724	ENSG00000223797.4	ENTPD3-AS1	3.99	7.19e-05	0.0047	0.15	0.12	Sleep-related phenotypes;	chr3:40056078	chr3:40313802~40453329:-
BRCA	cis	rs6599077	1	rs9832726	ENSG00000223797.4	ENTPD3-AS1	3.99	7.19e-05	0.0047	0.15	0.12	Sleep-related phenotypes;	chr3:40056085	chr3:40313802~40453329:-
BRCA	cis	rs2662776	1	rs2662775	ENSG00000232995.6	RGS5	-3.99	7.19e-05	0.0047	-0.12	-0.12	Lead levels in blood;	chr1:163192277	chr1:163244505~163321894:-
BRCA	cis	rs755249	0.509	rs710913	ENSG00000237624.1	OXCT2P1	-3.99	7.19e-05	0.0047	-0.15	-0.12	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39524254	chr1:39514956~39516490:+
BRCA	cis	rs9733	0.818	rs11204702	ENSG00000203804.4	ADAMTSL4-AS1	-3.99	7.19e-05	0.0047	-0.13	-0.12	Tonsillectomy;	chr1:150691031	chr1:150560202~150574552:-
BRCA	cis	rs911119	0.955	rs61035931	ENSG00000270001.1	RP11-218C14.8	-3.99	7.19e-05	0.0047	-0.16	-0.12	Chronic kidney disease;	chr20:23615077	chr20:23631826~23632316:-
BRCA	cis	rs911119	0.955	rs55897275	ENSG00000270001.1	RP11-218C14.8	-3.99	7.19e-05	0.0047	-0.16	-0.12	Chronic kidney disease;	chr20:23615316	chr20:23631826~23632316:-
BRCA	cis	rs28735056	0.563	rs12968139	ENSG00000261126.6	RP11-795F19.1	-3.99	7.19e-05	0.0047	-0.12	-0.12	Schizophrenia;	chr18:79925520	chr18:80046900~80095482:+
BRCA	cis	rs13393800	0.956	rs7571154	ENSG00000237126.7	AC073254.1	-3.99	7.19e-05	0.0047	-0.16	-0.12	Height;	chr2:232576214	chr2:232580948~232611971:-
BRCA	cis	rs763121	0.962	rs138703	ENSG00000225450.1	RP3-508I15.14	-3.99	7.19e-05	0.0047	-0.13	-0.12	Menopause (age at onset);	chr22:38736743	chr22:38739003~38749041:+
BRCA	cis	rs8180040	0.966	rs34634681	ENSG00000271161.1	BOLA2P2	-3.99	7.19e-05	0.0047	-0.14	-0.12	Colorectal cancer;	chr3:47537612	chr3:47499841~47500407:+
BRCA	cis	rs3858526	0.959	rs11039540	ENSG00000224295.2	AC087380.14	3.99	7.2e-05	0.00471	0.17	0.12	DNA methylation (variation);	chr11:5907104	chr11:5518441~5524955:-
BRCA	cis	rs13434995	0.513	rs11240	ENSG00000239040.1	Y_RNA	3.99	7.2e-05	0.00471	0.15	0.12	Adiponectin levels;	chr4:55453183	chr4:55412636~55412738:+
BRCA	cis	rs11098403	0.833	rs7686336	ENSG00000225892.3	RP11-384K6.2	3.99	7.2e-05	0.00471	0.12	0.12	Schizophrenia;	chr4:117794503	chr4:118632274~118634759:+
BRCA	cis	rs2243480	1	rs4718317	ENSG00000275400.1	RP4-756H11.5	-3.99	7.2e-05	0.00471	-0.21	-0.12	Diabetic kidney disease;	chr7:66183914	chr7:66553805~66554199:-
BRCA	cis	rs3858526	1	rs10838909	ENSG00000224295.2	AC087380.14	3.99	7.2e-05	0.00471	0.17	0.12	DNA methylation (variation);	chr11:5939260	chr11:5518441~5524955:-
BRCA	cis	rs11096990	0.634	rs12648793	ENSG00000249685.1	RP11-360F5.3	-3.99	7.2e-05	0.00471	-0.15	-0.12	Cognitive function;	chr4:39284473	chr4:39133913~39135608:+
BRCA	cis	rs875971	0.651	rs313829	ENSG00000232559.3	GS1-124K5.12	-3.99	7.2e-05	0.00471	-0.16	-0.12	Aortic root size;	chr7:66087510	chr7:66554588~66576923:-
BRCA	cis	rs7267979	0.714	rs3787082	ENSG00000204556.4	CTD-2514C3.1	-3.99	7.2e-05	0.00471	-0.17	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25255100	chr20:26018832~26020684:+
BRCA	cis	rs7520050	0.966	rs785488	ENSG00000281133.1	AL355480.3	3.99	7.2e-05	0.00471	0.14	0.12	Reticulocyte count;Red blood cell count;	chr1:46110423	chr1:45580892~45580996:-
BRCA	cis	rs7520050	0.966	rs785489	ENSG00000281133.1	AL355480.3	3.99	7.2e-05	0.00471	0.14	0.12	Reticulocyte count;Red blood cell count;	chr1:46110718	chr1:45580892~45580996:-
BRCA	cis	rs733175	0.855	rs10006397	ENSG00000250413.1	RP11-448G15.1	-3.99	7.2e-05	0.00471	-0.19	-0.12	Psychosis and Alzheimer's disease;	chr4:10034516	chr4:10006482~10009725:+
BRCA	cis	rs564309	0.867	rs513467	ENSG00000183929.7	DUSP5P1	3.99	7.21e-05	0.00471	0.21	0.12	Hip circumference (psychosocial stress interaction);	chr1:228399734	chr1:228650241~228651379:+
BRCA	cis	rs6592362	0.54	rs6592359	ENSG00000254748.1	HNRNPCP8	3.99	7.21e-05	0.00471	0.17	0.12	Inflammatory bowel disease;	chr11:87379683	chr11:87024583~87025777:+
BRCA	cis	rs2058059	0.512	rs3015937	ENSG00000205578.5	POM121B	-3.99	7.21e-05	0.00471	-0.2	-0.12	Subcutaneous adipose tissue;	chr7:72698883	chr7:73293497~73301161:+
BRCA	cis	rs45509595	0.749	rs401763	ENSG00000216901.1	AL022393.7	3.99	7.21e-05	0.00471	0.24	0.12	Breast cancer;	chr6:27814750	chr6:28176188~28176674:+
BRCA	cis	rs45509595	0.659	rs390764	ENSG00000216901.1	AL022393.7	3.99	7.21e-05	0.00471	0.24	0.12	Breast cancer;	chr6:27814757	chr6:28176188~28176674:+
BRCA	cis	rs45509595	0.841	rs401754	ENSG00000216901.1	AL022393.7	3.99	7.21e-05	0.00471	0.24	0.12	Breast cancer;	chr6:27814760	chr6:28176188~28176674:+
BRCA	cis	rs733592	1	rs1859440	ENSG00000273765.1	RP11-370I10.11	-3.99	7.21e-05	0.00471	-0.14	-0.12	Plateletcrit;	chr12:48033546	chr12:48360920~48361377:+
BRCA	cis	rs853679	1	rs853676	ENSG00000280107.1	AL022393.9	-3.99	7.21e-05	0.00471	-0.22	-0.12	Depression;	chr6:28331910	chr6:28170845~28172521:+
BRCA	cis	rs17711722	0.523	rs313812	ENSG00000226002.1	RP11-460N20.5	-3.99	7.21e-05	0.00471	-0.13	-0.12	Calcium levels;	chr7:66040056	chr7:65084103~65100232:+
BRCA	cis	rs6870983	0.802	rs7717613	ENSG00000247828.6	TMEM161B-AS1	-3.99	7.21e-05	0.00471	-0.15	-0.12	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index;	chr5:88444606	chr5:88268895~88436685:+
BRCA	cis	rs7412746	0.658	rs57818453	ENSG00000231073.1	RP11-316M1.3	3.99	7.21e-05	0.00471	0.13	0.12	Melanoma;	chr1:150790663	chr1:150973123~150975534:+
BRCA	cis	rs957448	0.554	rs12541408	ENSG00000254315.1	RP11-267M23.3	3.99	7.21e-05	0.00471	0.15	0.12	Nonsyndromic cleft lip with cleft palate;	chr8:94573579	chr8:94533628~94534391:+
BRCA	cis	rs7020830	0.898	rs2047010	ENSG00000260100.1	RP11-220I1.5	-3.99	7.21e-05	0.00471	-0.15	-0.12	Schizophrenia;	chr9:37077950	chr9:37078813~37079776:-
BRCA	cis	rs3753275	0.579	rs10779703	ENSG00000232912.4	RP5-1115A15.1	3.99	7.21e-05	0.00471	0.15	0.12	Educational attainment;	chr1:8536123	chr1:8424645~8434838:+
BRCA	cis	rs1974653	0.567	rs7285397	ENSG00000236540.6	AC006547.13	3.99	7.21e-05	0.00472	0.15	0.12	Schizophrenia;	chr22:20069620	chr22:20058030~20070569:-
BRCA	cis	rs983392	0.678	rs1426253	ENSG00000275344.1	MIR6503	-3.99	7.21e-05	0.00472	-0.13	-0.12	Alzheimer's disease (late onset);	chr11:60213745	chr11:60209071~60209156:-
BRCA	cis	rs17301013	0.932	rs1653627	ENSG00000234741.6	GAS5	-3.99	7.21e-05	0.00472	-0.12	-0.12	Systemic lupus erythematosus;	chr1:174771879	chr1:173863900~173868882:-
BRCA	cis	rs962856	0.964	rs13415002	ENSG00000236605.1	AC023115.4	3.99	7.21e-05	0.00472	0.15	0.12	Pancreatic cancer;	chr2:67384691	chr2:67324627~67325304:+
BRCA	cis	rs4374383	0.884	rs11683421	ENSG00000243389.1	AC012442.5	3.99	7.22e-05	0.00472	0.16	0.12	Hepatitis C induced liver fibrosis;	chr2:111995653	chr2:112589040~112614431:+
BRCA	cis	rs6674970	1	rs6674970	ENSG00000261168.1	RP11-68I18.10	-3.99	7.22e-05	0.00472	-0.16	-0.12	Childhood ear infection;	chr1:151143803	chr1:151130075~151131610:-
BRCA	cis	rs10043228	1	rs76112204	ENSG00000271918.1	CTD-2287O16.5	-3.99	7.22e-05	0.00472	-0.18	-0.12	Asthma or chronic obstructive pulmonary disease;	chr5:116283192	chr5:116083807~116085416:-
BRCA	cis	rs875971	0.545	rs35459055	ENSG00000273142.1	RP11-458F8.4	3.99	7.22e-05	0.00472	0.12	0.12	Aortic root size;	chr7:66479399	chr7:66902857~66906297:+
BRCA	cis	rs7772486	0.79	rs2253768	ENSG00000270638.1	RP3-466P17.1	3.98	7.22e-05	0.00472	0.14	0.12	Lobe attachment (rater-scored or self-reported);	chr6:145878786	chr6:145735570~145737218:+
BRCA	cis	rs3768617	0.903	rs10911251	ENSG00000224468.3	RP11-181K3.4	-3.98	7.22e-05	0.00472	-0.14	-0.12	Fuchs's corneal dystrophy;	chr1:183112059	chr1:183138402~183141282:-
BRCA	cis	rs4664293	0.867	rs13022404	ENSG00000224152.1	AC009506.1	-3.98	7.22e-05	0.00472	-0.14	-0.12	Monocyte percentage of white cells;	chr2:159732981	chr2:159615296~159617082:+
BRCA	cis	rs11992162	0.613	rs56094399	ENSG00000254866.2	DEFB109P3	3.98	7.22e-05	0.00472	0.16	0.12	Monocyte count;	chr8:11939961	chr8:12150895~12151134:-
BRCA	cis	rs1538970	0.816	rs34673142	ENSG00000281133.1	AL355480.3	-3.98	7.22e-05	0.00472	-0.17	-0.12	Platelet count;	chr1:45519889	chr1:45580892~45580996:-
BRCA	cis	rs7712401	0.791	rs154507	ENSG00000251538.4	RP11-166A12.1	-3.98	7.22e-05	0.00472	-0.14	-0.12	Mean platelet volume;	chr5:122865212	chr5:122628952~122730685:-
BRCA	cis	rs6772849	0.662	rs12494372	ENSG00000242551.2	POU5F1P6	-3.98	7.23e-05	0.00472	-0.16	-0.12	Monocyte percentage of white cells;Monocyte count;	chr3:128682850	chr3:128674735~128677005:-
BRCA	cis	rs11711311	0.668	rs11718061	ENSG00000241529.3	RN7SL767P	3.98	7.23e-05	0.00472	0.15	0.12	IgG glycosylation;	chr3:113622979	chr3:113632704~113632998:+
BRCA	cis	rs7267979	1	rs2258879	ENSG00000274973.1	RP13-401N8.7	-3.98	7.23e-05	0.00472	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25298577	chr20:25845497~25845862:+
BRCA	cis	rs7267979	1	rs2257496	ENSG00000274973.1	RP13-401N8.7	-3.98	7.23e-05	0.00472	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25298679	chr20:25845497~25845862:+
BRCA	cis	rs7267979	1	rs2258884	ENSG00000274973.1	RP13-401N8.7	-3.98	7.23e-05	0.00472	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25298903	chr20:25845497~25845862:+
BRCA	cis	rs7267979	1	rs2259837	ENSG00000274973.1	RP13-401N8.7	-3.98	7.23e-05	0.00472	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25299569	chr20:25845497~25845862:+
BRCA	cis	rs7267979	1	rs2259873	ENSG00000274973.1	RP13-401N8.7	-3.98	7.23e-05	0.00472	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25300145	chr20:25845497~25845862:+
BRCA	cis	rs72615157	0.697	rs2056726	ENSG00000242294.5	STAG3L5P	3.98	7.23e-05	0.00472	0.12	0.12	Lung function (FEV1/FVC);	chr7:100182660	chr7:100336079~100351900:+
BRCA	cis	rs7267979	1	rs6132835	ENSG00000274414.1	RP5-965G21.4	-3.98	7.23e-05	0.00473	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25454031	chr20:25239007~25245229:-
BRCA	cis	rs7267979	0.933	rs11699203	ENSG00000274414.1	RP5-965G21.4	-3.98	7.23e-05	0.00473	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25454533	chr20:25239007~25245229:-
BRCA	cis	rs7267979	0.933	rs6138571	ENSG00000274414.1	RP5-965G21.4	-3.98	7.23e-05	0.00473	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25454752	chr20:25239007~25245229:-
BRCA	cis	rs7267979	0.966	rs416745	ENSG00000274414.1	RP5-965G21.4	-3.98	7.23e-05	0.00473	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25458232	chr20:25239007~25245229:-
BRCA	cis	rs7267979	1	rs447722	ENSG00000274414.1	RP5-965G21.4	-3.98	7.23e-05	0.00473	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25462874	chr20:25239007~25245229:-
BRCA	cis	rs7267979	1	rs422424	ENSG00000274414.1	RP5-965G21.4	-3.98	7.23e-05	0.00473	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25464810	chr20:25239007~25245229:-
BRCA	cis	rs7267979	1	rs422844	ENSG00000274414.1	RP5-965G21.4	-3.98	7.23e-05	0.00473	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25464955	chr20:25239007~25245229:-
BRCA	cis	rs7267979	1	rs401166	ENSG00000274414.1	RP5-965G21.4	-3.98	7.23e-05	0.00473	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25465672	chr20:25239007~25245229:-
BRCA	cis	rs11711311	1	rs1073040	ENSG00000241529.3	RN7SL767P	-3.98	7.23e-05	0.00473	-0.14	-0.12	IgG glycosylation;	chr3:113803276	chr3:113632704~113632998:+
BRCA	cis	rs442309	0.841	rs224042	ENSG00000238280.1	RP11-436D10.3	-3.98	7.23e-05	0.00473	-0.16	-0.12	Vogt-Koyanagi-Harada syndrome;	chr10:62764530	chr10:62793562~62805887:-
BRCA	cis	rs375066	0.935	rs4803662	ENSG00000267191.1	RP11-15A1.2	-3.98	7.23e-05	0.00473	-0.16	-0.12	Breast cancer;	chr19:43855412	chr19:43902001~43926545:+
BRCA	cis	rs7267979	0.966	rs6050532	ENSG00000125804.12	FAM182A	3.98	7.23e-05	0.00473	0.16	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25328157	chr20:26054655~26086917:+
BRCA	cis	rs983392	0.792	rs583296	ENSG00000275344.1	MIR6503	-3.98	7.23e-05	0.00473	-0.12	-0.12	Alzheimer's disease (late onset);	chr11:60147253	chr11:60209071~60209156:-
BRCA	cis	rs7267979	1	rs7020	ENSG00000125804.12	FAM182A	-3.98	7.24e-05	0.00473	-0.16	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25297964	chr20:26054655~26086917:+
BRCA	cis	rs71520386	0.632	rs1474349	ENSG00000226329.2	AC005682.6	-3.98	7.24e-05	0.00473	-0.13	-0.12	Fibrinogen levels;	chr7:22814146	chr7:22863874~22881350:-
BRCA	cis	rs6049003	0.619	rs4073753	ENSG00000232645.4	LINC01431	3.98	7.24e-05	0.00473	0.13	0.12	Cerebrospinal fluid biomarker levels;	chr20:23735607	chr20:23356594~23358116:-
BRCA	cis	rs1867631	0.585	rs6694782	ENSG00000248458.2	RP4-598P13.1	-3.98	7.24e-05	0.00473	-0.13	-0.12	Menopause (age at onset);	chr1:66661079	chr1:66665864~66677027:-
BRCA	cis	rs4415084	1	rs10805686	ENSG00000248779.1	RP11-53O19.2	3.98	7.24e-05	0.00473	0.12	0.12	Breast cancer;	chr5:44662026	chr5:44752949~44765744:+
BRCA	cis	rs7475343	0.538	rs4881403	ENSG00000224034.1	RP11-445P17.8	3.98	7.24e-05	0.00473	0.23	0.12	Intelligence;	chr10:5126498	chr10:5266033~5271236:-
BRCA	cis	rs2408955	0.522	rs2051851	ENSG00000257735.1	RP11-370I10.6	-3.98	7.24e-05	0.00473	-0.15	-0.12	Glycated hemoglobin levels;	chr12:48092157	chr12:48350945~48442411:+
BRCA	cis	rs4664293	0.647	rs1966530	ENSG00000226266.5	AC009961.3	-3.98	7.24e-05	0.00473	-0.14	-0.12	Monocyte percentage of white cells;	chr2:159620897	chr2:159670708~159712435:-
BRCA	cis	rs12612435	0.779	rs34412859	ENSG00000226806.1	AC011893.3	3.98	7.24e-05	0.00473	0.15	0.12	Takotsubo syndrome;	chr2:136380896	chr2:135820191~135823087:+
BRCA	cis	rs7918232	0.556	rs788209	ENSG00000262412.1	RP11-85G18.6	3.98	7.24e-05	0.00473	0.23	0.12	Breast cancer;	chr10:27145787	chr10:27243130~27250804:+
BRCA	cis	rs38055	0.881	rs252035	ENSG00000247796.2	CTD-2366F13.1	-3.98	7.24e-05	0.00473	-0.14	-0.12	Acne (severe);	chr5:53312130	chr5:53109842~53115126:+
BRCA	cis	rs7481584	0.581	rs515481	ENSG00000236710.1	AC108448.2	3.98	7.24e-05	0.00473	0.16	0.12	Calcium levels;	chr11:3025954	chr11:3084393~3085443:-
BRCA	cis	rs801193	1	rs2659906	ENSG00000272831.1	RP11-792A8.4	3.98	7.24e-05	0.00473	0.11	0.12	Aortic root size;	chr7:66700323	chr7:66739829~66740385:-
BRCA	cis	rs7267979	1	rs11100	ENSG00000274973.1	RP13-401N8.7	-3.98	7.25e-05	0.00473	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25300548	chr20:25845497~25845862:+
BRCA	cis	rs7267979	1	rs1046073	ENSG00000274973.1	RP13-401N8.7	-3.98	7.25e-05	0.00473	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25300697	chr20:25845497~25845862:+
BRCA	cis	rs7267979	1	rs2259926	ENSG00000274973.1	RP13-401N8.7	-3.98	7.25e-05	0.00473	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25301097	chr20:25845497~25845862:+
BRCA	cis	rs7267979	1	rs2259928	ENSG00000274973.1	RP13-401N8.7	-3.98	7.25e-05	0.00473	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25301198	chr20:25845497~25845862:+
BRCA	cis	rs7267979	1	rs2259956	ENSG00000274973.1	RP13-401N8.7	-3.98	7.25e-05	0.00473	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25301797	chr20:25845497~25845862:+
BRCA	cis	rs801193	0.844	rs732465	ENSG00000273142.1	RP11-458F8.4	-3.98	7.25e-05	0.00473	-0.11	-0.12	Aortic root size;	chr7:66533463	chr7:66902857~66906297:+
BRCA	cis	rs1065852	0.526	rs1062753	ENSG00000205702.9	CYP2D7	3.98	7.25e-05	0.00473	0.11	0.12	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:41996807	chr22:42140203~42144577:-
BRCA	cis	rs7267979	1	rs2258769	ENSG00000274973.1	RP13-401N8.7	-3.98	7.25e-05	0.00474	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25296044	chr20:25845497~25845862:+
BRCA	cis	rs1865760	1	rs9393675	ENSG00000272462.2	U91328.19	-3.98	7.25e-05	0.00474	-0.15	-0.12	Height;	chr6:25929888	chr6:25992662~26001775:+
BRCA	cis	rs1218582	0.71	rs7553195	ENSG00000270361.1	RP11-307C12.13	-3.98	7.25e-05	0.00474	-0.14	-0.12	Prostate cancer;	chr1:154865320	chr1:154937370~154938059:+
BRCA	cis	rs2738459	0.5	rs2738465	ENSG00000212497.1	RNA5SP465	3.98	7.25e-05	0.00474	0.14	0.12	LDL cholesterol;	chr19:11131820	chr19:12027913~12028021:-
BRCA	cis	rs11764932	0.609	rs11975534	ENSG00000229108.1	MEOX2-AS1	-3.98	7.25e-05	0.00474	-0.14	-0.12	Kidney function decline traits;	chr7:15686504	chr7:15688378~15695491:+
BRCA	cis	rs11711311	1	rs921741	ENSG00000241529.3	RN7SL767P	-3.98	7.25e-05	0.00474	-0.14	-0.12	IgG glycosylation;	chr3:113725204	chr3:113632704~113632998:+
BRCA	cis	rs6121246	0.909	rs1994251	ENSG00000230613.1	HM13-AS1	3.98	7.25e-05	0.00474	0.18	0.12	Mean corpuscular hemoglobin;	chr20:31699525	chr20:31567707~31573263:-
BRCA	cis	rs1245541	0.681	rs1245579	ENSG00000226701.1	RP11-570G20.1	3.98	7.25e-05	0.00474	0.13	0.12	Insulin-like growth factors;	chr10:72123792	chr10:72189941~72190576:+
BRCA	cis	rs2304003	1	rs2060167	ENSG00000235192.1	AC009495.2	3.98	7.25e-05	0.00474	0.14	0.12	Social communication problems;	chr2:165832832	chr2:165794851~165810010:+
BRCA	cis	rs62244186	1	rs62244186	ENSG00000214820.3	MPRIPP1	3.98	7.25e-05	0.00474	0.14	0.12	Depressive symptoms;	chr3:44698291	chr3:44579938~44581026:-
BRCA	cis	rs1914816	1	rs2456075	ENSG00000196274.5	Metazoa_SRP	3.98	7.25e-05	0.00474	0.16	0.12	Response to tocilizumab in rheumatoid arthritis;	chr15:76263645	chr15:76230048~76230390:-
BRCA	cis	rs3755605	0.52	rs1705602	ENSG00000242578.1	RP11-469J4.3	3.98	7.25e-05	0.00474	0.15	0.12	Testicular germ cell tumor;	chr3:170215127	chr3:170410512~170418615:+
BRCA	cis	rs950776	0.684	rs61012457	ENSG00000279373.1	RP11-650L12.4	3.98	7.26e-05	0.00474	0.16	0.12	Sudden cardiac arrest;	chr15:78573352	chr15:78537681~78538946:+
BRCA	cis	rs11742741	0.818	rs1428197	ENSG00000248874.4	C5orf17	-3.98	7.26e-05	0.00474	-0.16	-0.12	Educational attainment;	chr5:24128848	chr5:23951348~24178263:+
BRCA	cis	rs7267979	1	rs2258563	ENSG00000274973.1	RP13-401N8.7	-3.98	7.26e-05	0.00474	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25292799	chr20:25845497~25845862:+
BRCA	cis	rs7267979	0.903	rs6050481	ENSG00000277938.1	RP5-965G21.3	3.98	7.26e-05	0.00474	0.15	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25243944	chr20:25229150~25231933:+
BRCA	cis	rs7267979	0.834	rs6115100	ENSG00000277938.1	RP5-965G21.3	3.98	7.26e-05	0.00474	0.15	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25245302	chr20:25229150~25231933:+
BRCA	cis	rs77633900	0.772	rs284907	ENSG00000196274.5	Metazoa_SRP	3.98	7.26e-05	0.00474	0.21	0.12	Glioma;Non-glioblastoma glioma;	chr15:76449228	chr15:76230048~76230390:-
BRCA	cis	rs11711311	0.911	rs9817327	ENSG00000241529.3	RN7SL767P	-3.98	7.26e-05	0.00474	-0.14	-0.12	IgG glycosylation;	chr3:113759653	chr3:113632704~113632998:+
BRCA	cis	rs962856	0.756	rs13016812	ENSG00000236780.4	AC078941.1	-3.98	7.26e-05	0.00474	-0.17	-0.12	Pancreatic cancer;	chr2:67397170	chr2:67123357~67215319:-
BRCA	cis	rs5758511	0.773	rs73165164	ENSG00000231261.1	HMGN2P10	-3.98	7.26e-05	0.00474	-0.16	-0.12	Birth weight;	chr22:41959545	chr22:41709225~41709489:-
BRCA	cis	rs465969	0.744	rs7758483	ENSG00000272356.1	RP5-1112D6.8	3.98	7.26e-05	0.00474	0.25	0.12	Psoriasis;	chr6:111467945	chr6:111309203~111313517:+
BRCA	cis	rs62458065	0.513	rs9655340	ENSG00000229358.3	DPY19L1P1	3.98	7.26e-05	0.00474	0.17	0.12	Metabolite levels (HVA/MHPG ratio);	chr7:32496308	chr7:32580949~32761787:-
BRCA	cis	rs10043228	1	rs17139224	ENSG00000271918.1	CTD-2287O16.5	-3.98	7.26e-05	0.00474	-0.18	-0.12	Asthma or chronic obstructive pulmonary disease;	chr5:116232496	chr5:116083807~116085416:-
BRCA	cis	rs11098499	0.738	rs34965784	ENSG00000260404.2	RP11-384K6.6	3.98	7.27e-05	0.00475	0.11	0.12	Corneal astigmatism;	chr4:119440431	chr4:118591773~118633729:+
BRCA	cis	rs6496932	0.774	rs12901648	ENSG00000259295.5	CSPG4P12	-3.98	7.27e-05	0.00475	-0.22	-0.12	Central corneal thickness;Corneal structure;	chr15:85408487	chr15:85191438~85213905:+
BRCA	cis	rs853679	0.517	rs56364346	ENSG00000261839.1	RP1-265C24.8	3.98	7.27e-05	0.00475	0.17	0.12	Depression;	chr6:28082984	chr6:28136849~28139678:+
BRCA	cis	rs853679	0.517	rs9357061	ENSG00000261839.1	RP1-265C24.8	3.98	7.27e-05	0.00475	0.17	0.12	Depression;	chr6:28083994	chr6:28136849~28139678:+
BRCA	cis	rs853679	0.517	rs9368550	ENSG00000261839.1	RP1-265C24.8	3.98	7.27e-05	0.00475	0.17	0.12	Depression;	chr6:28084025	chr6:28136849~28139678:+
BRCA	cis	rs853679	0.542	rs2295594	ENSG00000261839.1	RP1-265C24.8	3.98	7.27e-05	0.00475	0.17	0.12	Depression;	chr6:28085319	chr6:28136849~28139678:+
BRCA	cis	rs2115630	0.754	rs12595321	ENSG00000259295.5	CSPG4P12	-3.98	7.27e-05	0.00475	-0.15	-0.12	P wave terminal force;	chr15:84788038	chr15:85191438~85213905:+
BRCA	cis	rs8062405	1	rs3888190	ENSG00000261766.1	RP11-22P6.2	-3.98	7.27e-05	0.00475	-0.12	-0.12	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28878165	chr16:28862166~28863340:-
BRCA	cis	rs783540	0.9	rs4778686	ENSG00000274376.3	ADAMTS7P1	-3.98	7.27e-05	0.00475	-0.13	-0.12	Schizophrenia;	chr15:82642084	chr15:82298553~82334609:+
BRCA	cis	rs8180040	0.62	rs1811652	ENSG00000271161.1	BOLA2P2	-3.98	7.27e-05	0.00475	-0.13	-0.12	Colorectal cancer;	chr3:47167208	chr3:47499841~47500407:+
BRCA	cis	rs4374383	0.923	rs4848923	ENSG00000243389.1	AC012442.5	-3.98	7.27e-05	0.00475	-0.16	-0.12	Hepatitis C induced liver fibrosis;	chr2:111984874	chr2:112589040~112614431:+
BRCA	cis	rs4374383	0.884	rs11676037	ENSG00000243389.1	AC012442.5	-3.98	7.27e-05	0.00475	-0.16	-0.12	Hepatitis C induced liver fibrosis;	chr2:111985808	chr2:112589040~112614431:+
BRCA	cis	rs4374383	0.884	rs1516628	ENSG00000243389.1	AC012442.5	-3.98	7.27e-05	0.00475	-0.16	-0.12	Hepatitis C induced liver fibrosis;	chr2:111986223	chr2:112589040~112614431:+
BRCA	cis	rs875971	0.862	rs1968126	ENSG00000273024.4	INTS4P2	3.98	7.27e-05	0.00475	0.14	0.12	Aortic root size;	chr7:66592017	chr7:65647864~65715661:+
BRCA	cis	rs4713118	0.662	rs149900	ENSG00000216901.1	AL022393.7	3.98	7.27e-05	0.00475	0.18	0.12	Parkinson's disease;	chr6:28046819	chr6:28176188~28176674:+
BRCA	cis	rs11668609	1	rs4452076	ENSG00000268058.1	BNIP3P40	-3.98	7.27e-05	0.00475	-0.15	-0.12	Response to taxane treatment (docetaxel);	chr19:24143981	chr19:24098425~24098980:-
BRCA	cis	rs6675668	0.645	rs2298162	ENSG00000235501.4	RP4-639F20.1	-3.98	7.27e-05	0.00475	-0.15	-0.12	Stearic acid (18:0) levels;	chr1:94983477	chr1:94927566~94963270:+
BRCA	cis	rs1245541	0.562	rs3780949	ENSG00000226701.1	RP11-570G20.1	3.98	7.28e-05	0.00475	0.14	0.12	Insulin-like growth factors;	chr10:72126549	chr10:72189941~72190576:+
BRCA	cis	rs853679	0.517	rs16893666	ENSG00000216901.1	AL022393.7	-3.98	7.28e-05	0.00475	-0.17	-0.12	Depression;	chr6:28086929	chr6:28176188~28176674:+
BRCA	cis	rs7520050	0.966	rs785494	ENSG00000281133.1	AL355480.3	3.98	7.28e-05	0.00475	0.14	0.12	Reticulocyte count;Red blood cell count;	chr1:46120954	chr1:45580892~45580996:-
BRCA	cis	rs910316	0.934	rs8006587	ENSG00000259138.1	RP11-950C14.7	3.98	7.28e-05	0.00475	0.13	0.12	Height;	chr14:75198236	chr14:75127153~75136930:+
BRCA	cis	rs6012564	1	rs3091529	ENSG00000222365.1	SNORD12B	-3.98	7.28e-05	0.00476	-0.13	-0.12	Anger;	chr20:49030531	chr20:49280319~49280409:+
BRCA	cis	rs6012564	1	rs1022687	ENSG00000222365.1	SNORD12B	-3.98	7.28e-05	0.00476	-0.13	-0.12	Anger;	chr20:49032317	chr20:49280319~49280409:+
BRCA	cis	rs13098911	0.54	rs13079478	ENSG00000223552.1	RP11-24F11.2	-3.98	7.28e-05	0.00476	-0.21	-0.12	Celiac disease;	chr3:45966331	chr3:46364955~46407059:-
BRCA	cis	rs875971	0.571	rs160647	ENSG00000273142.1	RP11-458F8.4	-3.98	7.28e-05	0.00476	-0.12	-0.12	Aortic root size;	chr7:66089365	chr7:66902857~66906297:+
BRCA	cis	rs4819052	0.851	rs2838829	ENSG00000215447.6	BX322557.10	-3.98	7.28e-05	0.00476	-0.13	-0.12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244125	chr21:45288052~45291738:+
BRCA	cis	rs10911902	0.913	rs12120448	ENSG00000229739.2	RP11-295K2.3	-3.98	7.28e-05	0.00476	-0.18	-0.12	Schizophrenia;	chr1:186585134	chr1:186435161~186470291:+
BRCA	cis	rs10911902	0.874	rs12133471	ENSG00000229739.2	RP11-295K2.3	-3.98	7.28e-05	0.00476	-0.18	-0.12	Schizophrenia;	chr1:186586822	chr1:186435161~186470291:+
BRCA	cis	rs6496932	0.802	rs67928464	ENSG00000218052.5	ADAMTS7P4	3.98	7.29e-05	0.00476	0.13	0.12	Central corneal thickness;Corneal structure;	chr15:85338535	chr15:85255369~85330334:-
BRCA	cis	rs7048146	0.899	rs7032590	ENSG00000213539.4	YBX1P6	3.98	7.29e-05	0.00476	0.14	0.12	Vascular brain injury;	chr9:109575480	chr9:109532830~109534332:-
BRCA	cis	rs9470794	1	rs73421444	ENSG00000204110.6	RP1-153P14.8	-3.98	7.29e-05	0.00476	-0.24	-0.12	Type 2 diabetes;	chr6:37978498	chr6:37507348~37535616:+
BRCA	cis	rs9470794	1	rs56073681	ENSG00000204110.6	RP1-153P14.8	-3.98	7.29e-05	0.00476	-0.24	-0.12	Type 2 diabetes;	chr6:37978546	chr6:37507348~37535616:+
BRCA	cis	rs4957048	0.891	rs11960196	ENSG00000225138.6	CTD-2228K2.7	3.98	7.29e-05	0.00476	0.17	0.12	Ulcerative colitis;	chr5:568742	chr5:473236~480884:+
BRCA	cis	rs934734	0.967	rs702875	ENSG00000281920.1	RP11-418H16.1	3.98	7.29e-05	0.00476	0.14	0.12	Rheumatoid arthritis;	chr2:65387063	chr2:65623272~65628424:+
BRCA	cis	rs10129255	1	rs8012033	ENSG00000232216.1	IGHV3-43	3.98	7.3e-05	0.00476	0.1	0.12	Kawasaki disease;	chr14:106678854	chr14:106470264~106470800:-
BRCA	cis	rs4950322	0.542	rs56080828	ENSG00000237188.3	RP11-337C18.8	3.98	7.3e-05	0.00476	0.15	0.12	Protein quantitative trait loci;	chr1:147183447	chr1:147172771~147211568:+
BRCA	cis	rs13256369	1	rs10110591	ENSG00000272267.2	RP11-375N15.2	3.98	7.3e-05	0.00476	0.16	0.12	Obesity-related traits;	chr8:8719098	chr8:9555144~9556520:-
BRCA	cis	rs10129255	0.518	rs10136903	ENSG00000254174.1	IGHV1-12	3.98	7.3e-05	0.00477	0.09	0.12	Kawasaki disease;	chr14:106778866	chr14:106122420~106122709:-
BRCA	cis	rs7800418	0.817	rs882541	ENSG00000214870.7	AC004540.5	3.98	7.3e-05	0.00477	0.15	0.12	Cognitive function;	chr7:26550679	chr7:26398593~26494256:+
BRCA	cis	rs801193	0.839	rs12534943	ENSG00000273142.1	RP11-458F8.4	3.98	7.3e-05	0.00477	0.11	0.12	Aortic root size;	chr7:66605533	chr7:66902857~66906297:+
BRCA	cis	rs13434995	0.513	rs7676245	ENSG00000239040.1	Y_RNA	3.98	7.3e-05	0.00477	0.15	0.12	Adiponectin levels;	chr4:55455150	chr4:55412636~55412738:+
BRCA	cis	rs150025731	1	rs150025731	ENSG00000261801.4	LOXL1-AS1	3.98	7.31e-05	0.00477	0.15	0.12	Joint mobility (Beighton score);	chr15:73931167	chr15:73908071~73928248:-
BRCA	cis	rs7308116	1	rs11113506	ENSG00000274395.1	RP11-554D14.8	3.98	7.31e-05	0.00477	0.13	0.12	Pelvic organ prolapse (moderate/severe);	chr12:107810861	chr12:107835541~107836555:-
BRCA	cis	rs10087240	0.55	rs4733586	ENSG00000207110.1	RNU1-106P	3.98	7.31e-05	0.00477	0.14	0.12	Lymphocyte counts;White blood cell count;	chr8:128002287	chr8:127999131~127999294:+
BRCA	cis	rs6592362	0.54	rs4943982	ENSG00000254748.1	HNRNPCP8	-3.98	7.31e-05	0.00477	-0.17	-0.12	Inflammatory bowel disease;	chr11:87378615	chr11:87024583~87025777:+
BRCA	cis	rs6981523	0.553	rs11989369	ENSG00000154316.13	TDH	-3.98	7.31e-05	0.00477	-0.17	-0.12	Neuroticism;	chr8:11197876	chr8:11339637~11368452:+
BRCA	cis	rs801193	0.66	rs2659897	ENSG00000236529.1	RP13-254B10.1	-3.98	7.31e-05	0.00477	-0.13	-0.12	Aortic root size;	chr7:66722728	chr7:65840212~65840596:+
BRCA	cis	rs4374383	0.884	rs11690939	ENSG00000243389.1	AC012442.5	-3.98	7.31e-05	0.00477	-0.16	-0.12	Hepatitis C induced liver fibrosis;	chr2:111999848	chr2:112589040~112614431:+
BRCA	cis	rs2562456	0.833	rs2968076	ENSG00000213976.4	CTD-2561J22.2	3.98	7.31e-05	0.00477	0.15	0.12	Pain;	chr19:21454299	chr19:21382865~21387177:+
BRCA	cis	rs3617	0.625	rs3774364	ENSG00000242142.1	SERBP1P3	3.98	7.31e-05	0.00477	0.14	0.12	Red blood cell count;Autism spectrum disorder or schizophrenia;	chr3:52829589	chr3:53064283~53065091:-
BRCA	cis	rs6570726	0.516	rs10484700	ENSG00000235652.6	RP11-545I5.3	3.98	7.31e-05	0.00477	0.12	0.12	Lobe attachment (rater-scored or self-reported);	chr6:145407797	chr6:145799409~145886585:+
BRCA	cis	rs10844706	0.699	rs741199	ENSG00000278635.1	CTD-2318O12.1	-3.98	7.31e-05	0.00477	-0.13	-0.12	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9720769	chr12:9415641~9416718:+
BRCA	cis	rs721917	0.506	rs1923540	ENSG00000280355.1	RP11-119F19.5	-3.98	7.31e-05	0.00477	-0.13	-0.12	Chronic obstructive pulmonary disease;	chr10:79930616	chr10:79681973~79684094:-
BRCA	cis	rs11722228	1	rs6823877	ENSG00000250413.1	RP11-448G15.1	3.98	7.31e-05	0.00477	0.17	0.12	Urate levels;Serum uric acid levels;Gout;	chr4:9920307	chr4:10006482~10009725:+
BRCA	cis	rs860295	0.812	rs7556519	ENSG00000160766.13	GBAP1	-3.98	7.31e-05	0.00477	-0.13	-0.12	Body mass index;	chr1:155857755	chr1:155213821~155227422:-
BRCA	cis	rs8114671	0.562	rs725521	ENSG00000126005.14	MMP24-AS1	-3.98	7.31e-05	0.00477	-0.14	-0.12	Height;	chr20:34928268	chr20:35216462~35278131:-
BRCA	cis	rs1371614	0.632	rs3739085	ENSG00000229122.1	AGBL5-IT1	3.98	7.31e-05	0.00477	0.13	0.12	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26940176	chr2:27061038~27061815:+
BRCA	cis	rs1129187	0.967	rs6941212	ENSG00000220614.1	RP11-480N24.4	3.98	7.32e-05	0.00478	0.14	0.12	Alzheimer's disease in APOE e4+ carriers;	chr6:42948182	chr6:43328134~43328476:+
BRCA	cis	rs62247992	0.698	rs11707725	ENSG00000227245.1	RP11-136C24.2	3.98	7.32e-05	0.00478	0.18	0.12	Facial morphology (factor 15, philtrum width);	chr3:43081901	chr3:43087479~43088068:+
BRCA	cis	rs4374383	0.884	rs3811637	ENSG00000243389.1	AC012442.5	-3.98	7.32e-05	0.00478	-0.16	-0.12	Hepatitis C induced liver fibrosis;	chr2:111997669	chr2:112589040~112614431:+
BRCA	cis	rs7520050	0.966	rs785491	ENSG00000281133.1	AL355480.3	3.98	7.32e-05	0.00478	0.14	0.12	Reticulocyte count;Red blood cell count;	chr1:46117746	chr1:45580892~45580996:-
BRCA	cis	rs739401	0.572	rs404629	ENSG00000183562.3	CTC-343N3.1	-3.98	7.32e-05	0.00478	-0.13	-0.12	Longevity;	chr11:3055795	chr11:2989863~2991344:+
BRCA	cis	rs10744955	0.727	rs57187078	ENSG00000244879.4	GABPB1-AS1	-3.98	7.32e-05	0.00478	-0.13	-0.12	Lobe attachment (rater-scored or self-reported);	chr15:50157016	chr15:50354959~50372202:+
BRCA	cis	rs6545883	0.929	rs3821222	ENSG00000212978.6	AC016747.3	3.98	7.32e-05	0.00478	0.17	0.12	Tuberculosis;	chr2:61486391	chr2:61141592~61144969:-
BRCA	cis	rs1153858	0.887	rs7164139	ENSG00000275672.1	GATM-AS1	-3.98	7.32e-05	0.00478	-0.16	-0.12	Homoarginine levels;	chr15:45378653	chr15:45378700~45380123:+
BRCA	cis	rs10744955	0.727	rs12913072	ENSG00000244879.4	GABPB1-AS1	-3.98	7.32e-05	0.00478	-0.13	-0.12	Lobe attachment (rater-scored or self-reported);	chr15:50159293	chr15:50354959~50372202:+
BRCA	cis	rs11673344	0.523	rs10420330	ENSG00000276846.1	CTD-3220F14.3	3.98	7.33e-05	0.00478	0.14	0.12	Obesity-related traits;	chr19:37111269	chr19:37314868~37315620:-
BRCA	cis	rs853679	0.517	rs9380058	ENSG00000261839.1	RP1-265C24.8	3.98	7.33e-05	0.00478	0.17	0.12	Depression;	chr6:28159666	chr6:28136849~28139678:+
BRCA	cis	rs853679	0.517	rs9393898	ENSG00000261839.1	RP1-265C24.8	3.98	7.33e-05	0.00478	0.17	0.12	Depression;	chr6:28162598	chr6:28136849~28139678:+
BRCA	cis	rs8114671	0.967	rs6058202	ENSG00000279253.1	RP4-614O4.13	-3.98	7.33e-05	0.00478	-0.14	-0.12	Height;	chr20:35190180	chr20:35262727~35264187:-
BRCA	cis	rs7267979	1	rs404394	ENSG00000274414.1	RP5-965G21.4	-3.98	7.33e-05	0.00478	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25467260	chr20:25239007~25245229:-
BRCA	cis	rs71520386	0.632	rs35353454	ENSG00000226329.2	AC005682.6	-3.98	7.33e-05	0.00478	-0.13	-0.12	Fibrinogen levels;	chr7:22822120	chr7:22863874~22881350:-
BRCA	cis	rs6545883	0.931	rs778768	ENSG00000270820.4	RP11-355B11.2	3.98	7.33e-05	0.00478	0.14	0.12	Tuberculosis;	chr2:61563154	chr2:61471188~61484130:+
BRCA	cis	rs13326165	0.585	rs73088800	ENSG00000243224.1	RP5-1157M23.2	-3.98	7.33e-05	0.00478	-0.2	-0.12	HDL cholesterol levels;HDL cholesterol;	chr3:52298276	chr3:52239258~52241097:+
BRCA	cis	rs10510102	0.516	rs61071865	ENSG00000226864.1	ATE1-AS1	3.98	7.33e-05	0.00478	0.24	0.12	Breast cancer;	chr10:121986236	chr10:121928312~121951965:+
BRCA	cis	rs7267979	1	rs7020	ENSG00000276952.1	RP5-965G21.6	3.98	7.33e-05	0.00478	0.15	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25297964	chr20:25284915~25285588:-
BRCA	cis	rs2842992	0.724	rs4709368	ENSG00000251988.1	RNU4ATAC18P	-3.98	7.34e-05	0.00479	-0.15	-0.12	Age-related macular degeneration (geographic atrophy);	chr6:159783095	chr6:159720415~159720540:-
BRCA	cis	rs62344088	1	rs10037843	ENSG00000277812.1	AC021087.1	3.98	7.34e-05	0.00479	0.33	0.12	Asthma (childhood onset);	chr5:119963	chr5:262769~262881:+
BRCA	cis	rs62344088	1	rs13436694	ENSG00000277812.1	AC021087.1	3.98	7.34e-05	0.00479	0.33	0.12	Asthma (childhood onset);	chr5:122767	chr5:262769~262881:+
BRCA	cis	rs4218	0.608	rs59282449	ENSG00000259732.1	RP11-59H7.3	-3.98	7.34e-05	0.00479	-0.16	-0.12	Social communication problems;	chr15:59078881	chr15:59121034~59133250:+
BRCA	cis	rs17597773	0.674	rs903319	ENSG00000257551.1	HLX-AS1	-3.98	7.34e-05	0.00479	-0.15	-0.12	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220812469	chr1:220832763~220880140:-
BRCA	cis	rs6430585	0.702	rs73958637	ENSG00000231890.6	DARS-AS1	-3.98	7.34e-05	0.00479	-0.19	-0.12	Corneal structure;	chr2:135789357	chr2:135985176~136022593:+
BRCA	cis	rs1048886	0.872	rs6911812	ENSG00000271967.1	RP11-134K13.4	-3.98	7.34e-05	0.00479	-0.16	-0.12	Type 2 diabetes;	chr6:70473512	chr6:70596438~70596980:+
BRCA	cis	rs4237845	0.514	rs4760339	ENSG00000257159.1	RP11-58A17.3	3.98	7.34e-05	0.00479	0.15	0.12	Intelligence (multi-trait analysis);	chr12:57874366	chr12:57967058~57968399:+
BRCA	cis	rs763121	0.853	rs5750673	ENSG00000225450.1	RP3-508I15.14	-3.98	7.34e-05	0.00479	-0.13	-0.12	Menopause (age at onset);	chr22:38714119	chr22:38739003~38749041:+
BRCA	cis	rs1008375	0.932	rs4698628	ENSG00000249502.1	AC006160.5	-3.98	7.34e-05	0.00479	-0.14	-0.12	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17606997	chr4:17587467~17614571:-
BRCA	cis	rs739496	0.947	rs7134740	ENSG00000234608.6	MAPKAPK5-AS1	3.98	7.34e-05	0.00479	0.15	0.12	Platelet count;	chr12:111489935	chr12:111839764~111842902:-
BRCA	cis	rs1005277	0.541	rs2472177	ENSG00000272983.1	RP11-508N22.12	3.98	7.34e-05	0.00479	0.13	0.12	Extrinsic epigenetic age acceleration;	chr10:38095087	chr10:38137337~38144399:+
BRCA	cis	rs11773103	0.881	rs73202993	ENSG00000224046.1	AC005076.5	3.98	7.34e-05	0.00479	0.27	0.12	Bipolar disorder or major depressive disorder (combined);	chr7:87127277	chr7:87151423~87152420:-
BRCA	cis	rs4648045	0.565	rs17033014	ENSG00000251288.2	RP11-10L12.2	-3.98	7.34e-05	0.00479	-0.16	-0.12	Lymphocyte percentage of white cells;	chr4:102625029	chr4:102751401~102752641:+
BRCA	cis	rs4478858	0.684	rs4949373	ENSG00000260386.4	LINC01225	-3.98	7.35e-05	0.00479	-0.14	-0.12	Alcohol dependence;	chr1:31268730	chr1:31500085~31540885:+
BRCA	cis	rs4478858	0.684	rs7544946	ENSG00000260386.4	LINC01225	-3.98	7.35e-05	0.00479	-0.14	-0.12	Alcohol dependence;	chr1:31276889	chr1:31500085~31540885:+
BRCA	cis	rs4478858	0.684	rs7549245	ENSG00000260386.4	LINC01225	-3.98	7.35e-05	0.00479	-0.14	-0.12	Alcohol dependence;	chr1:31279340	chr1:31500085~31540885:+
BRCA	cis	rs4478858	0.684	rs4949374	ENSG00000260386.4	LINC01225	-3.98	7.35e-05	0.00479	-0.14	-0.12	Alcohol dependence;	chr1:31281664	chr1:31500085~31540885:+
BRCA	cis	rs4478858	0.684	rs3766289	ENSG00000260386.4	LINC01225	-3.98	7.35e-05	0.00479	-0.14	-0.12	Alcohol dependence;	chr1:31287281	chr1:31500085~31540885:+
BRCA	cis	rs4478858	0.684	rs7521463	ENSG00000260386.4	LINC01225	-3.98	7.35e-05	0.00479	-0.14	-0.12	Alcohol dependence;	chr1:31289089	chr1:31500085~31540885:+
BRCA	cis	rs4478858	0.611	rs7527645	ENSG00000260386.4	LINC01225	-3.98	7.35e-05	0.00479	-0.14	-0.12	Alcohol dependence;	chr1:31290940	chr1:31500085~31540885:+
BRCA	cis	rs375066	0.762	rs10424336	ENSG00000267191.1	RP11-15A1.2	-3.98	7.35e-05	0.00479	-0.16	-0.12	Breast cancer;	chr19:43887948	chr19:43902001~43926545:+
BRCA	cis	rs4854307	0.59	rs6729656	ENSG00000272342.1	RP13-539J13.1	3.98	7.35e-05	0.00479	0.23	0.12	Body mass index;	chr2:455683	chr2:739588~740164:-
BRCA	cis	rs1437396	0.657	rs2576714	ENSG00000203327.2	AC012358.7	3.98	7.35e-05	0.00479	0.13	0.12	Alcohol dependence;	chr2:55338038	chr2:55214387~55216126:-
BRCA	cis	rs7520050	0.966	rs785503	ENSG00000281133.1	AL355480.3	3.98	7.35e-05	0.00479	0.14	0.12	Reticulocyte count;Red blood cell count;	chr1:46130196	chr1:45580892~45580996:-
BRCA	cis	rs7772486	0.84	rs854144	ENSG00000235652.6	RP11-545I5.3	-3.98	7.35e-05	0.00479	-0.13	-0.12	Lobe attachment (rater-scored or self-reported);	chr6:146039744	chr6:145799409~145886585:+
BRCA	cis	rs6088580	0.543	rs4911158	ENSG00000279253.1	RP4-614O4.13	3.98	7.35e-05	0.0048	0.14	0.12	Glomerular filtration rate (creatinine);	chr20:34651708	chr20:35262727~35264187:-
BRCA	cis	rs10504130	1	rs10504130	ENSG00000272076.1	RP11-11C20.3	3.98	7.35e-05	0.0048	0.2	0.12	Venous thromboembolism (SNP x SNP interaction);	chr8:51844533	chr8:51810110~51810681:-
BRCA	cis	rs1075265	0.54	rs2542587	ENSG00000272156.1	RP11-477N3.1	-3.98	7.35e-05	0.0048	-0.13	-0.12	Chronotype;Morning vs. evening chronotype;	chr2:53788839	chr2:54082554~54085066:+
BRCA	cis	rs1075265	0.563	rs2692537	ENSG00000272156.1	RP11-477N3.1	-3.98	7.35e-05	0.0048	-0.13	-0.12	Chronotype;Morning vs. evening chronotype;	chr2:53788840	chr2:54082554~54085066:+
BRCA	cis	rs13108904	0.935	rs3755920	ENSG00000253399.1	AC078852.2	-3.98	7.36e-05	0.0048	-0.14	-0.12	Obesity-related traits;	chr4:1249829	chr4:1358479~1359461:+
BRCA	cis	rs488400	0.529	rs360936	ENSG00000270265.1	RP11-731D1.4	3.98	7.36e-05	0.0048	0.14	0.12	Trans fatty acid levels;	chr4:151925597	chr4:151333775~151353224:-
BRCA	cis	rs77956314	0.515	rs7302025	ENSG00000277840.1	RP11-103B5.4	-3.98	7.36e-05	0.0048	-0.19	-0.12	Hippocampal volume;Subcortical brain region volumes;	chr12:117005097	chr12:117002463~117003152:+
BRCA	cis	rs7221109	0.591	rs803125	ENSG00000278834.1	RP11-458J1.1	-3.98	7.36e-05	0.0048	-0.13	-0.12	Type 1 diabetes;	chr17:40581127	chr17:40648300~40649718:+
BRCA	cis	rs7572733	0.935	rs6753450	ENSG00000231621.1	AC013264.2	-3.98	7.36e-05	0.0048	-0.11	-0.12	Dermatomyositis;	chr2:197870307	chr2:197197991~197199273:+
BRCA	cis	rs801193	0.904	rs4718405	ENSG00000229180.5	GS1-124K5.11	3.98	7.37e-05	0.0048	0.1	0.12	Aortic root size;	chr7:66789659	chr7:66526088~66542624:-
BRCA	cis	rs8024893	1	rs7180114	ENSG00000270055.1	CTD-3092A11.2	3.98	7.37e-05	0.00481	0.19	0.12	Red cell distribution width;	chr15:31247976	chr15:30487963~30490313:+
BRCA	cis	rs12439619	0.774	rs2867649	ENSG00000259429.4	UBE2Q2P2	-3.98	7.37e-05	0.00481	-0.15	-0.12	Intelligence (multi-trait analysis);	chr15:82262331	chr15:82355142~82420075:+
BRCA	cis	rs4415084	0.834	rs11957920	ENSG00000248779.1	RP11-53O19.2	-3.98	7.37e-05	0.00481	-0.11	-0.12	Breast cancer;	chr5:44904984	chr5:44752949~44765744:+
BRCA	cis	rs4415084	0.804	rs10070339	ENSG00000248779.1	RP11-53O19.2	-3.98	7.37e-05	0.00481	-0.11	-0.12	Breast cancer;	chr5:44907780	chr5:44752949~44765744:+
BRCA	cis	rs8098244	0.683	rs4334381	ENSG00000265752.2	RP11-403A21.1	3.98	7.37e-05	0.00481	0.13	0.12	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23852485	chr18:23957754~23982556:-
BRCA	cis	rs970548	0.954	rs10466245	ENSG00000237840.5	FAM21FP	3.98	7.37e-05	0.00481	0.16	0.12	Total cholesterol levels;HDL cholesterol;HDL cholesterol levels;Cholesterol, total;	chr10:45536299	chr10:45706431~45727231:-
BRCA	cis	rs1153858	1	rs12439274	ENSG00000275672.1	GATM-AS1	-3.98	7.37e-05	0.00481	-0.16	-0.12	Homoarginine levels;	chr15:45344469	chr15:45378700~45380123:+
BRCA	cis	rs1065852	0.526	rs9611700	ENSG00000205702.9	CYP2D7	3.98	7.37e-05	0.00481	0.11	0.12	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42005510	chr22:42140203~42144577:-
BRCA	cis	rs1065852	0.526	rs2413663	ENSG00000205702.9	CYP2D7	3.98	7.37e-05	0.00481	0.11	0.12	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42006395	chr22:42140203~42144577:-
BRCA	cis	rs875971	0.83	rs778711	ENSG00000273024.4	INTS4P2	-3.98	7.37e-05	0.00481	-0.14	-0.12	Aortic root size;	chr7:66386670	chr7:65647864~65715661:+
BRCA	cis	rs875971	0.862	rs1083554	ENSG00000273024.4	INTS4P2	-3.98	7.37e-05	0.00481	-0.14	-0.12	Aortic root size;	chr7:66387354	chr7:65647864~65715661:+
BRCA	cis	rs875971	0.862	rs778707	ENSG00000273024.4	INTS4P2	-3.98	7.37e-05	0.00481	-0.14	-0.12	Aortic root size;	chr7:66392040	chr7:65647864~65715661:+
BRCA	cis	rs875971	0.862	rs778705	ENSG00000273024.4	INTS4P2	-3.98	7.37e-05	0.00481	-0.14	-0.12	Aortic root size;	chr7:66396128	chr7:65647864~65715661:+
BRCA	cis	rs875971	0.862	rs778697	ENSG00000273024.4	INTS4P2	-3.98	7.37e-05	0.00481	-0.14	-0.12	Aortic root size;	chr7:66405439	chr7:65647864~65715661:+
BRCA	cis	rs875971	0.798	rs7789615	ENSG00000273024.4	INTS4P2	-3.98	7.37e-05	0.00481	-0.14	-0.12	Aortic root size;	chr7:66413674	chr7:65647864~65715661:+
BRCA	cis	rs10457838	0.713	rs6929576	ENSG00000231760.4	RP11-350J20.5	3.98	7.37e-05	0.00481	0.18	0.12	Post-traumatic stress disorder;	chr6:149103868	chr6:149796151~149826294:-
BRCA	cis	rs2832077	0.943	rs4816336	ENSG00000232855.5	AF131217.1	3.98	7.38e-05	0.00481	0.19	0.12	Cognitive test performance;	chr21:28821197	chr21:28439346~28674848:-
BRCA	cis	rs7520050	0.898	rs785502	ENSG00000281133.1	AL355480.3	3.98	7.38e-05	0.00481	0.14	0.12	Reticulocyte count;Red blood cell count;	chr1:46115772	chr1:45580892~45580996:-
BRCA	cis	rs5742933	0.69	rs62183656	ENSG00000253559.1	OSGEPL1-AS1	-3.98	7.38e-05	0.00481	-0.21	-0.12	Ferritin levels;	chr2:189669387	chr2:189762704~189765556:+
BRCA	cis	rs5742933	0.69	rs62183658	ENSG00000253559.1	OSGEPL1-AS1	-3.98	7.38e-05	0.00481	-0.21	-0.12	Ferritin levels;	chr2:189669491	chr2:189762704~189765556:+
BRCA	cis	rs853679	0.76	rs9368563	ENSG00000204709.4	LINC01556	3.98	7.38e-05	0.00481	0.19	0.12	Depression;	chr6:28240780	chr6:28943877~28944537:+
BRCA	cis	rs853679	0.76	rs9295768	ENSG00000204709.4	LINC01556	3.98	7.38e-05	0.00481	0.19	0.12	Depression;	chr6:28241324	chr6:28943877~28944537:+
BRCA	cis	rs7656342	0.866	rs10013858	ENSG00000250342.1	SNRPCP16	-3.98	7.38e-05	0.00481	-0.14	-0.12	Gut microbiota (bacterial taxa);	chr4:9760837	chr4:9051842~9052051:-
BRCA	cis	rs9527	0.59	rs2274339	ENSG00000213061.2	PFN1P11	3.98	7.38e-05	0.00481	0.17	0.12	Arsenic metabolism;	chr10:103100296	chr10:102838011~102845473:-
BRCA	cis	rs2070615	0.833	rs6580695	ENSG00000239617.1	RP11-302B13.1	-3.98	7.38e-05	0.00481	-0.15	-0.12	Bipolar disorder;	chr12:48807424	chr12:48903418~48903813:-
BRCA	cis	rs8017423	0.63	rs12589687	ENSG00000275198.1	RP11-471B22.3	3.98	7.38e-05	0.00481	0.14	0.12	Mortality in heart failure;	chr14:90353226	chr14:90383365~90387973:+
BRCA	cis	rs513088	0.681	rs543408	ENSG00000225171.2	DUTP6	3.98	7.38e-05	0.00481	0.17	0.12	Schizophrenia;	chr1:166717580	chr1:166868748~166869209:+
BRCA	cis	rs2911132	0.621	rs17480169	ENSG00000272109.1	CTD-2260A17.3	-3.98	7.38e-05	0.00481	-0.17	-0.12	Urate levels (BMI interaction);	chr5:96753363	chr5:96804353~96806105:+
BRCA	cis	rs875971	0.66	rs79009421	ENSG00000223473.2	GS1-124K5.3	-3.98	7.39e-05	0.00481	-0.09	-0.12	Aortic root size;	chr7:66603522	chr7:66491049~66493566:-
BRCA	cis	rs7412746	0.611	rs16827671	ENSG00000231073.1	RP11-316M1.3	3.98	7.39e-05	0.00482	0.13	0.12	Melanoma;	chr1:150766283	chr1:150973123~150975534:+
BRCA	cis	rs2360027	0.622	rs17257972	ENSG00000231365.4	RP11-418J17.1	-3.98	7.39e-05	0.00482	-0.15	-0.12	Tonsillectomy;	chr1:118563989	chr1:119140396~119275973:+
BRCA	cis	rs10208649	0.901	rs10180492	ENSG00000233266.1	HMGB1P31	3.98	7.39e-05	0.00482	0.29	0.12	Body mass index;	chr2:53829003	chr2:54051334~54051760:+
BRCA	cis	rs513088	0.681	rs495489	ENSG00000225171.2	DUTP6	-3.98	7.39e-05	0.00482	-0.17	-0.12	Schizophrenia;	chr1:166731394	chr1:166868748~166869209:+
BRCA	cis	rs9472168	0.967	rs12205248	ENSG00000272223.1	RP1-20C7.6	3.98	7.39e-05	0.00482	0.14	0.12	Interleukin-13 levels;	chr6:43958482	chr6:43033897~43034405:-
BRCA	cis	rs9472168	1	rs7763440	ENSG00000272223.1	RP1-20C7.6	3.98	7.39e-05	0.00482	0.14	0.12	Interleukin-13 levels;	chr6:43958971	chr6:43033897~43034405:-
BRCA	cis	rs4886920	0.894	rs11637937	ENSG00000260776.4	RP11-114H24.2	-3.98	7.39e-05	0.00482	-0.14	-0.12	Neuroticism;	chr15:77827488	chr15:77914217~77926846:-
BRCA	cis	rs2408955	0.521	rs10875749	ENSG00000257735.1	RP11-370I10.6	-3.98	7.39e-05	0.00482	-0.15	-0.12	Glycated hemoglobin levels;	chr12:48138134	chr12:48350945~48442411:+
BRCA	cis	rs4819052	0.851	rs12626188	ENSG00000215447.6	BX322557.10	-3.98	7.39e-05	0.00482	-0.13	-0.12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45249343	chr21:45288052~45291738:+
BRCA	cis	rs4819052	0.851	rs13052312	ENSG00000215447.6	BX322557.10	-3.98	7.39e-05	0.00482	-0.13	-0.12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45242444	chr21:45288052~45291738:+
BRCA	cis	rs10487112	0.833	rs12704543	ENSG00000235436.9	DPY19L2P4	-3.98	7.39e-05	0.00482	-0.13	-0.12	Perceived unattractiveness to mosquitoes;	chr7:90495673	chr7:90119400~90125600:+
BRCA	cis	rs13315871	1	rs9824965	ENSG00000272182.1	RP11-802O23.3	3.98	7.39e-05	0.00482	0.24	0.12	Cholesterol, total;	chr3:58447778	chr3:58428255~58428815:+
BRCA	cis	rs13315871	1	rs13076951	ENSG00000272182.1	RP11-802O23.3	3.98	7.39e-05	0.00482	0.24	0.12	Cholesterol, total;	chr3:58450976	chr3:58428255~58428815:+
BRCA	cis	rs7520050	0.966	rs11579634	ENSG00000234329.1	RP11-767N6.2	3.98	7.39e-05	0.00482	0.11	0.12	Reticulocyte count;Red blood cell count;	chr1:46000719	chr1:45651039~45651826:-
BRCA	cis	rs12468226	1	rs7597469	ENSG00000272966.1	RP11-686O6.1	3.98	7.4e-05	0.00482	0.2	0.12	Urate levels;	chr2:202329547	chr2:202336739~202337200:+
BRCA	cis	rs2708977	0.73	rs674920	ENSG00000271569.1	IGKV1OR2-6	-3.98	7.4e-05	0.00482	-0.09	-0.12	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96404418	chr2:97355059~97355335:+
BRCA	cis	rs6049003	0.622	rs6138054	ENSG00000232645.4	LINC01431	3.98	7.4e-05	0.00482	0.13	0.12	Cerebrospinal fluid biomarker levels;	chr20:23741383	chr20:23356594~23358116:-
BRCA	cis	rs2299587	0.65	rs12548412	ENSG00000253671.1	RP11-806O11.1	-3.98	7.4e-05	0.00482	-0.16	-0.12	Economic and political preferences;	chr8:17939461	chr8:17808941~17820868:+
BRCA	cis	rs71007656	1	rs71007656	ENSG00000226578.1	RP11-258F22.1	-3.98	7.4e-05	0.00482	-0.13	-0.12	Extrinsic epigenetic age acceleration;	chr10:37681922	chr10:37775371~37784131:-
BRCA	cis	rs11098499	0.697	rs11941899	ENSG00000260404.2	RP11-384K6.6	3.98	7.4e-05	0.00482	0.12	0.12	Corneal astigmatism;	chr4:119461603	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.909	rs7681978	ENSG00000260404.2	RP11-384K6.6	3.98	7.4e-05	0.00482	0.12	0.12	Corneal astigmatism;	chr4:119462620	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.821	rs28665282	ENSG00000260404.2	RP11-384K6.6	3.98	7.4e-05	0.00482	0.12	0.12	Corneal astigmatism;	chr4:119463031	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.738	rs10026493	ENSG00000260404.2	RP11-384K6.6	3.98	7.4e-05	0.00482	0.12	0.12	Corneal astigmatism;	chr4:119463039	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.909	rs7681214	ENSG00000260404.2	RP11-384K6.6	3.98	7.4e-05	0.00482	0.12	0.12	Corneal astigmatism;	chr4:119464165	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.909	rs28632018	ENSG00000260404.2	RP11-384K6.6	3.98	7.4e-05	0.00482	0.12	0.12	Corneal astigmatism;	chr4:119465575	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.908	rs71614449	ENSG00000260404.2	RP11-384K6.6	3.98	7.4e-05	0.00482	0.12	0.12	Corneal astigmatism;	chr4:119465900	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.954	rs35063680	ENSG00000260404.2	RP11-384K6.6	3.98	7.4e-05	0.00482	0.12	0.12	Corneal astigmatism;	chr4:119465947	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.954	rs34858317	ENSG00000260404.2	RP11-384K6.6	3.98	7.4e-05	0.00482	0.12	0.12	Corneal astigmatism;	chr4:119465955	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.954	rs17046116	ENSG00000260404.2	RP11-384K6.6	3.98	7.4e-05	0.00482	0.12	0.12	Corneal astigmatism;	chr4:119466104	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.909	rs17046118	ENSG00000260404.2	RP11-384K6.6	3.98	7.4e-05	0.00482	0.12	0.12	Corneal astigmatism;	chr4:119466341	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.954	rs7654587	ENSG00000260404.2	RP11-384K6.6	3.98	7.4e-05	0.00482	0.12	0.12	Corneal astigmatism;	chr4:119467251	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.954	rs11098526	ENSG00000225892.3	RP11-384K6.2	3.98	7.4e-05	0.00482	0.12	0.12	Corneal astigmatism;	chr4:119469204	chr4:118632274~118634759:+
BRCA	cis	rs34792	0.554	rs12708796	ENSG00000260872.1	RP11-680G24.5	-3.98	7.4e-05	0.00482	-0.13	-0.12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15535980	chr16:15018106~15020488:-
BRCA	cis	rs853679	0.517	rs9468297	ENSG00000261839.1	RP1-265C24.8	3.98	7.4e-05	0.00482	0.17	0.12	Depression;	chr6:28151096	chr6:28136849~28139678:+
BRCA	cis	rs3742264	0.656	rs9534284	ENSG00000235903.6	CPB2-AS1	-3.98	7.4e-05	0.00483	-0.15	-0.12	Blood protein levels;	chr13:46016926	chr13:46052806~46113332:+
BRCA	cis	rs11083475	1	rs3786835	ENSG00000267892.1	CTD-2540F13.2	3.98	7.4e-05	0.00483	0.14	0.12	Heart rate;	chr19:38665240	chr19:38738284~38739863:+
BRCA	cis	rs1005277	0.579	rs1740737	ENSG00000272983.1	RP11-508N22.12	3.98	7.41e-05	0.00483	0.13	0.12	Extrinsic epigenetic age acceleration;	chr10:38210437	chr10:38137337~38144399:+
BRCA	cis	rs516805	0.673	rs12201010	ENSG00000279114.1	RP3-425C14.5	3.98	7.41e-05	0.00483	0.15	0.12	Lymphocyte counts;	chr6:122345675	chr6:122471923~122484161:+
BRCA	cis	rs516805	0.64	rs12208084	ENSG00000279114.1	RP3-425C14.5	3.98	7.41e-05	0.00483	0.15	0.12	Lymphocyte counts;	chr6:122345745	chr6:122471923~122484161:+
BRCA	cis	rs516805	0.706	rs17662514	ENSG00000279114.1	RP3-425C14.5	3.98	7.41e-05	0.00483	0.15	0.12	Lymphocyte counts;	chr6:122346013	chr6:122471923~122484161:+
BRCA	cis	rs516805	0.706	rs9320863	ENSG00000279114.1	RP3-425C14.5	3.98	7.41e-05	0.00483	0.15	0.12	Lymphocyte counts;	chr6:122347086	chr6:122471923~122484161:+
BRCA	cis	rs2625529	0.824	rs35167572	ENSG00000260037.4	CTD-2524L6.3	-3.98	7.41e-05	0.00483	-0.18	-0.12	Red blood cell count;	chr15:72086619	chr15:71818396~71823384:+
BRCA	cis	rs7131987	0.903	rs1035604	ENSG00000273680.1	RP11-996F15.6	3.98	7.41e-05	0.00483	0.16	0.12	QT interval;	chr12:29240169	chr12:29332733~29333383:-
BRCA	cis	rs8114671	0.562	rs6088622	ENSG00000279253.1	RP4-614O4.13	-3.98	7.41e-05	0.00483	-0.14	-0.12	Height;	chr20:34832174	chr20:35262727~35264187:-
BRCA	cis	rs409045	0.9	rs437509	ENSG00000271874.1	CTD-2024P10.2	-3.98	7.41e-05	0.00483	-0.16	-0.12	Left ventricular mass;	chr5:34638709	chr5:34651457~34651888:-
BRCA	cis	rs17756712	0.667	rs2073006	ENSG00000272463.1	RP11-532F6.3	3.98	7.41e-05	0.00483	0.21	0.12	Vertical cup-disc ratio;	chr6:637465	chr6:708592~711405:-
BRCA	cis	rs4650943	0.609	rs400589	ENSG00000227740.1	RP11-318C24.2	-3.98	7.41e-05	0.00483	-0.12	-0.12	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in inactive individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr1:176299470	chr1:175904762~175920513:-
BRCA	cis	rs4650943	0.609	rs366627	ENSG00000227740.1	RP11-318C24.2	-3.98	7.41e-05	0.00483	-0.12	-0.12	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in inactive individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr1:176300761	chr1:175904762~175920513:-
BRCA	cis	rs4650943	0.55	rs12086886	ENSG00000227740.1	RP11-318C24.2	-3.98	7.41e-05	0.00483	-0.12	-0.12	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in inactive individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr1:176301025	chr1:175904762~175920513:-
BRCA	cis	rs2243480	1	rs160634	ENSG00000222364.1	RNU6-96P	3.98	7.41e-05	0.00483	0.21	0.12	Diabetic kidney disease;	chr7:66063677	chr7:66395191~66395286:+
BRCA	cis	rs875971	0.862	rs3893216	ENSG00000273024.4	INTS4P2	3.98	7.41e-05	0.00483	0.14	0.12	Aortic root size;	chr7:66325720	chr7:65647864~65715661:+
BRCA	cis	rs875971	0.862	rs6958294	ENSG00000273024.4	INTS4P2	3.98	7.41e-05	0.00483	0.14	0.12	Aortic root size;	chr7:66329809	chr7:65647864~65715661:+
BRCA	cis	rs875971	0.862	rs2088655	ENSG00000273024.4	INTS4P2	3.98	7.41e-05	0.00483	0.14	0.12	Aortic root size;	chr7:66330724	chr7:65647864~65715661:+
BRCA	cis	rs875971	0.895	rs10447522	ENSG00000273024.4	INTS4P2	3.98	7.41e-05	0.00483	0.14	0.12	Aortic root size;	chr7:66331087	chr7:65647864~65715661:+
BRCA	cis	rs12777	1	rs11242111	ENSG00000230612.2	AC004237.1	-3.98	7.41e-05	0.00483	-0.19	-0.12	Fibrinogen levels;	chr5:132420366	chr5:132688681~132723725:+
BRCA	cis	rs4730430	0.538	rs10270301	ENSG00000226965.1	AC003088.1	3.98	7.41e-05	0.00483	0.15	0.12	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr7:110493501	chr7:110432239~110534754:-
BRCA	cis	rs651907	0.535	rs13094753	ENSG00000256628.3	ZBTB11-AS1	3.98	7.41e-05	0.00483	0.16	0.12	Colorectal cancer;	chr3:101806238	chr3:101676475~101679217:+
BRCA	cis	rs3824867	0.92	rs80241400	ENSG00000280615.1	Y_RNA	3.98	7.41e-05	0.00483	0.15	0.12	Mean corpuscular hemoglobin;	chr11:47432277	chr11:47614898~47614994:-
BRCA	cis	rs2274459	0.915	rs66617522	ENSG00000249346.5	LINC01016	3.98	7.41e-05	0.00483	0.16	0.12	Obesity (extreme);	chr6:33808532	chr6:33867506~33896914:-
BRCA	cis	rs477895	0.713	rs1059440	ENSG00000256940.1	RP11-783K16.5	-3.98	7.41e-05	0.00483	-0.17	-0.12	Mean platelet volume;	chr11:64224329	chr11:64245964~64248217:+
BRCA	cis	rs13108904	0.901	rs7673398	ENSG00000253399.1	AC078852.2	-3.98	7.41e-05	0.00483	-0.13	-0.12	Obesity-related traits;	chr4:1306289	chr4:1358479~1359461:+
BRCA	cis	rs35306767	0.903	rs12250936	ENSG00000229869.1	RP11-363N22.2	-3.98	7.42e-05	0.00483	-0.19	-0.12	Eosinophil percentage of granulocytes;	chr10:824169	chr10:933026~942743:+
BRCA	cis	rs7572644	0.537	rs13408504	ENSG00000223522.1	AC093690.1	3.98	7.42e-05	0.00483	0.13	0.12	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:28135467	chr2:28307691~28310459:-
BRCA	cis	rs1555322	0.872	rs2425048	ENSG00000269202.1	RP4-614O4.12	-3.98	7.42e-05	0.00483	-0.19	-0.12	Attention deficit hyperactivity disorder;	chr20:35284920	chr20:35201747~35203288:-
BRCA	cis	rs962856	0.822	rs1944911	ENSG00000236605.1	AC023115.4	3.98	7.42e-05	0.00483	0.15	0.12	Pancreatic cancer;	chr2:67420029	chr2:67324627~67325304:+
BRCA	cis	rs10043775	0.915	rs10077690	ENSG00000251330.3	CTD-2283N19.1	-3.98	7.42e-05	0.00483	-0.16	-0.12	Periodontal microbiota;	chr5:148409235	chr5:148430159~148430807:-
BRCA	cis	rs10043775	0.915	rs12717973	ENSG00000251330.3	CTD-2283N19.1	-3.98	7.42e-05	0.00483	-0.16	-0.12	Periodontal microbiota;	chr5:148414408	chr5:148430159~148430807:-
BRCA	cis	rs4664293	0.647	rs4665082	ENSG00000224152.1	AC009506.1	-3.98	7.42e-05	0.00483	-0.13	-0.12	Monocyte percentage of white cells;	chr2:159573455	chr2:159615296~159617082:+
BRCA	cis	rs2274459	0.841	rs34778247	ENSG00000249346.5	LINC01016	3.98	7.42e-05	0.00484	0.16	0.12	Obesity (extreme);	chr6:33690775	chr6:33867506~33896914:-
BRCA	cis	rs890448	0.796	rs7663913	ENSG00000254531.1	FLJ20021	3.98	7.42e-05	0.00484	0.14	0.12	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101411954	chr4:101347780~101348883:+
BRCA	cis	rs1008375	0.932	rs3846356	ENSG00000249502.1	AC006160.5	-3.98	7.42e-05	0.00484	-0.14	-0.12	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17612553	chr4:17587467~17614571:-
BRCA	cis	rs1008375	0.863	rs4590022	ENSG00000249502.1	AC006160.5	-3.98	7.42e-05	0.00484	-0.14	-0.12	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17612811	chr4:17587467~17614571:-
BRCA	cis	rs1008375	0.932	rs4698630	ENSG00000249502.1	AC006160.5	-3.98	7.42e-05	0.00484	-0.14	-0.12	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17613069	chr4:17587467~17614571:-
BRCA	cis	rs12368653	0.582	rs2307095	ENSG00000257159.1	RP11-58A17.3	-3.98	7.43e-05	0.00484	-0.14	-0.12	Multiple sclerosis;	chr12:57632218	chr12:57967058~57968399:+
BRCA	cis	rs970548	0.955	rs10900223	ENSG00000230869.1	CTGLF10P	3.98	7.43e-05	0.00484	0.16	0.12	Total cholesterol levels;HDL cholesterol;HDL cholesterol levels;Cholesterol, total;	chr10:45526183	chr10:45678692~45700532:+
BRCA	cis	rs2625529	0.73	rs2929527	ENSG00000260037.4	CTD-2524L6.3	3.98	7.43e-05	0.00484	0.15	0.12	Red blood cell count;	chr15:71989929	chr15:71818396~71823384:+
BRCA	cis	rs11098499	0.954	rs71629403	ENSG00000260404.2	RP11-384K6.6	3.98	7.43e-05	0.00484	0.12	0.12	Corneal astigmatism;	chr4:119451412	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.909	rs28571712	ENSG00000260404.2	RP11-384K6.6	3.98	7.43e-05	0.00484	0.12	0.12	Corneal astigmatism;	chr4:119454825	chr4:118591773~118633729:+
BRCA	cis	rs2341534	1	rs2341534	ENSG00000259318.1	RP11-454L9.2	3.98	7.43e-05	0.00484	0.12	0.12	Morning vs. evening chronotype;	chr14:55318019	chr14:55394940~55395233:-
BRCA	cis	rs1007738	0.58	rs10501319	ENSG00000200376.1	RNU5E-10P	-3.98	7.43e-05	0.00484	-0.16	-0.12	Bone mineral density (hip);	chr11:47152511	chr11:47576471~47576588:-
BRCA	cis	rs7590268	0.675	rs17030751	ENSG00000279873.2	LINC01126	3.98	7.43e-05	0.00484	0.15	0.12	Orofacial clefts;	chr2:43403320	chr2:43227210~43228855:+
BRCA	cis	rs7590268	0.675	rs17030752	ENSG00000279873.2	LINC01126	3.98	7.43e-05	0.00484	0.15	0.12	Orofacial clefts;	chr2:43403354	chr2:43227210~43228855:+
BRCA	cis	rs8054556	0.647	rs11863174	ENSG00000214725.6	CDIPT-AS1	-3.98	7.43e-05	0.00484	-0.14	-0.12	Autism spectrum disorder or schizophrenia;	chr16:30008054	chr16:29863593~29868053:+
BRCA	cis	rs6460942	0.659	rs17192500	ENSG00000226690.5	AC005281.1	3.98	7.43e-05	0.00484	0.25	0.12	Coronary artery disease;	chr7:12505753	chr7:12496429~12541910:+
BRCA	cis	rs2251301	0.891	rs6990463	ENSG00000255046.1	RP11-297N6.4	3.98	7.43e-05	0.00484	0.18	0.12	Response to antipsychotic therapy (extrapyramidal side effects);	chr8:11263751	chr8:11797928~11802568:-
BRCA	cis	rs12030196	1	rs751187	ENSG00000230812.4	LINC01358	3.98	7.43e-05	0.00484	0.13	0.12	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr1:59011719	chr1:59020387~59044614:+
BRCA	cis	rs2692947	0.537	rs72821435	ENSG00000168992.4	OR7E102P	3.98	7.43e-05	0.00484	0.17	0.12	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95522187	chr2:95546531~95547545:+
BRCA	cis	rs1396626	0.926	rs12354293	ENSG00000235501.4	RP4-639F20.1	3.98	7.43e-05	0.00484	0.16	0.12	Diabetic kidney disease;	chr1:95547517	chr1:94927566~94963270:+
BRCA	cis	rs801193	1	rs10234018	ENSG00000275400.1	RP4-756H11.5	3.98	7.43e-05	0.00484	0.14	0.12	Aortic root size;	chr7:66681297	chr7:66553805~66554199:-
BRCA	cis	rs372883	0.638	rs117213	ENSG00000176054.6	RPL23P2	-3.98	7.44e-05	0.00484	-0.14	-0.12	Pancreatic cancer;	chr21:29348215	chr21:28997613~28998033:-
BRCA	cis	rs7771547	0.519	rs28371845	ENSG00000224666.3	RP1-50J22.4	3.98	7.44e-05	0.00484	0.14	0.12	Platelet distribution width;	chr6:36409932	chr6:36386831~36393462:+
BRCA	cis	rs2243480	1	rs313820	ENSG00000237026.1	RP11-328P23.2	3.98	7.44e-05	0.00484	0.23	0.12	Diabetic kidney disease;	chr7:66109479	chr7:65235790~65236723:-
BRCA	cis	rs2749592	0.55	rs7917262	ENSG00000099251.13	HSD17B7P2	-3.98	7.44e-05	0.00484	-0.14	-0.12	Age-related hearing impairment (SNP x SNP interaction);	chr10:37585674	chr10:38356380~38378505:+
BRCA	cis	rs6005807	0.719	rs9625524	ENSG00000272858.1	CTA-292E10.8	-3.98	7.44e-05	0.00484	-0.21	-0.12	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28656963	chr22:28814914~28815662:+
BRCA	cis	rs2115630	1	rs2879828	ENSG00000275120.1	RP11-182J1.17	-3.98	7.44e-05	0.00484	-0.14	-0.12	P wave terminal force;	chr15:84818746	chr15:84599434~84606463:-
BRCA	cis	rs801193	1	rs62466793	ENSG00000265600.1	AC006480.1	-3.98	7.44e-05	0.00484	-0.14	-0.12	Aortic root size;	chr7:66726530	chr7:67356680~67356779:+
BRCA	cis	rs1665650	0.957	rs1638418	ENSG00000232767.1	RP11-498B4.5	-3.98	7.44e-05	0.00484	-0.13	-0.12	Colorectal cancer;	chr10:116734247	chr10:116670103~116672739:+
BRCA	cis	rs1665650	0.957	rs1620936	ENSG00000232767.1	RP11-498B4.5	-3.98	7.44e-05	0.00484	-0.13	-0.12	Colorectal cancer;	chr10:116734434	chr10:116670103~116672739:+
BRCA	cis	rs35306767	0.903	rs17159950	ENSG00000229869.1	RP11-363N22.2	-3.98	7.44e-05	0.00484	-0.19	-0.12	Eosinophil percentage of granulocytes;	chr10:829347	chr10:933026~942743:+
BRCA	cis	rs7267979	0.932	rs431579	ENSG00000274973.1	RP13-401N8.7	-3.98	7.44e-05	0.00484	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25489420	chr20:25845497~25845862:+
BRCA	cis	rs10847980	0.59	rs12319654	ENSG00000256092.2	RP13-942N8.1	-3.98	7.44e-05	0.00484	-0.28	-0.12	Adiponectin levels;	chr12:122842613	chr12:123363868~123366113:+
BRCA	cis	rs2274459	0.841	rs35698850	ENSG00000249346.5	LINC01016	3.98	7.44e-05	0.00485	0.16	0.12	Obesity (extreme);	chr6:33732355	chr6:33867506~33896914:-
BRCA	cis	rs853679	0.517	rs6932109	ENSG00000216901.1	AL022393.7	-3.98	7.44e-05	0.00485	-0.17	-0.12	Depression;	chr6:28110525	chr6:28176188~28176674:+
BRCA	cis	rs709400	0.93	rs10149249	ENSG00000258735.1	LINC00637	3.98	7.45e-05	0.00485	0.15	0.12	Body mass index;	chr14:103581420	chr14:103847721~103858049:+
BRCA	cis	rs1008375	1	rs10939738	ENSG00000249502.1	AC006160.5	-3.98	7.45e-05	0.00485	-0.14	-0.12	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17602672	chr4:17587467~17614571:-
BRCA	cis	rs1008375	0.932	rs4698627	ENSG00000249502.1	AC006160.5	-3.98	7.45e-05	0.00485	-0.14	-0.12	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17604336	chr4:17587467~17614571:-
BRCA	cis	rs2694917	0.631	rs2657879	ENSG00000257576.1	RP11-153M3.1	-3.98	7.45e-05	0.00485	-0.2	-0.12	Blood metabolite ratios;	chr12:56471554	chr12:56511002~56512703:+
BRCA	cis	rs17270561	0.583	rs7749149	ENSG00000272462.2	U91328.19	-3.98	7.45e-05	0.00485	-0.15	-0.12	Iron status biomarkers;	chr6:25780911	chr6:25992662~26001775:+
BRCA	cis	rs2625529	0.652	rs2957361	ENSG00000260037.4	CTD-2524L6.3	3.98	7.45e-05	0.00485	0.15	0.12	Red blood cell count;	chr15:72052877	chr15:71818396~71823384:+
BRCA	cis	rs490234	0.676	rs12202	ENSG00000232630.1	PRPS1P2	-3.98	7.45e-05	0.00485	-0.13	-0.12	Mean arterial pressure;	chr9:125438020	chr9:125150653~125151589:+
BRCA	cis	rs13098911	0.54	rs34766614	ENSG00000223552.1	RP11-24F11.2	-3.98	7.45e-05	0.00485	-0.21	-0.12	Celiac disease;	chr3:46066109	chr3:46364955~46407059:-
BRCA	cis	rs924712	0.545	rs12195438	ENSG00000224984.1	RP11-524H19.2	3.98	7.45e-05	0.00485	0.15	0.12	Breast cancer;	chr6:54845232	chr6:54840118~54840855:-
BRCA	cis	rs13217239	0.646	rs10946888	ENSG00000224843.5	LINC00240	-3.98	7.45e-05	0.00485	-0.14	-0.12	Schizophrenia;	chr6:26983899	chr6:26956992~27023924:+
BRCA	cis	rs17270561	0.636	rs9393656	ENSG00000272462.2	U91328.19	-3.98	7.45e-05	0.00485	-0.15	-0.12	Iron status biomarkers;	chr6:25721831	chr6:25992662~26001775:+
BRCA	cis	rs11642862	1	rs11642466	ENSG00000280211.1	RP11-2C24.3	-3.98	7.45e-05	0.00485	-0.2	-0.12	Tonsillectomy;	chr16:30770621	chr16:30773532~30776033:-
BRCA	cis	rs2483374	1	rs7331734	ENSG00000253771.4	TPTE2P1	3.98	7.46e-05	0.00485	0.14	0.12	Obesity-related traits;	chr13:24957117	chr13:24924677~24968487:-
BRCA	cis	rs1865760	0.865	rs1541987	ENSG00000272462.2	U91328.19	3.98	7.46e-05	0.00485	0.15	0.12	Height;	chr6:25950169	chr6:25992662~26001775:+
BRCA	cis	rs7412746	0.611	rs12410869	ENSG00000231073.1	RP11-316M1.3	3.98	7.46e-05	0.00485	0.13	0.12	Melanoma;	chr1:150883677	chr1:150973123~150975534:+
BRCA	cis	rs7412746	0.611	rs36008098	ENSG00000231073.1	RP11-316M1.3	3.98	7.46e-05	0.00485	0.13	0.12	Melanoma;	chr1:150884330	chr1:150973123~150975534:+
BRCA	cis	rs6964587	1	rs12531366	ENSG00000188693.7	CYP51A1-AS1	-3.98	7.46e-05	0.00486	-0.13	-0.12	Breast cancer;	chr7:92054535	chr7:92134604~92180725:+
BRCA	cis	rs11931598	0.509	rs13140943	ENSG00000245468.3	RP11-367J11.3	3.98	7.46e-05	0.00486	0.11	0.12	Sum basophil neutrophil counts;Neutrophil count;Granulocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;	chr4:6975382	chr4:7094571~7103385:-
BRCA	cis	rs875971	0.638	rs6960778	ENSG00000223473.2	GS1-124K5.3	-3.98	7.46e-05	0.00486	-0.09	-0.12	Aortic root size;	chr7:66606610	chr7:66491049~66493566:-
BRCA	cis	rs11098499	0.954	rs10034623	ENSG00000260404.2	RP11-384K6.6	3.98	7.46e-05	0.00486	0.11	0.12	Corneal astigmatism;	chr4:119476674	chr4:118591773~118633729:+
BRCA	cis	rs17270561	0.609	rs1317816	ENSG00000272462.2	U91328.19	-3.98	7.46e-05	0.00486	-0.15	-0.12	Iron status biomarkers;	chr6:25765162	chr6:25992662~26001775:+
BRCA	cis	rs859767	0.741	rs10803548	ENSG00000224043.6	CCNT2-AS1	3.98	7.46e-05	0.00486	0.16	0.12	Neuroticism;	chr2:134639168	chr2:134735464~134918710:-
BRCA	cis	rs35306767	0.903	rs35637113	ENSG00000229869.1	RP11-363N22.2	-3.98	7.46e-05	0.00486	-0.19	-0.12	Eosinophil percentage of granulocytes;	chr10:828209	chr10:933026~942743:+
BRCA	cis	rs300703	0.542	rs443419	ENSG00000228643.1	AC079779.4	-3.98	7.46e-05	0.00486	-0.19	-0.12	Blood protein levels;	chr2:189800	chr2:286419~301515:+
BRCA	cis	rs35343117	1	rs35343117	ENSG00000202081.1	RNU6-1280P	3.98	7.46e-05	0.00486	0.16	0.12	Psoriasis;	chr15:85535884	chr15:85651522~85651628:-
BRCA	cis	rs360929	0.935	rs168629	ENSG00000245954.5	RP11-18H21.1	-3.98	7.46e-05	0.00486	-0.13	-0.12	Volumetric brain MRI;	chr4:151974795	chr4:152100754~152104720:+
BRCA	cis	rs9437689	0.531	rs859044	ENSG00000235501.4	RP4-639F20.1	3.98	7.46e-05	0.00486	0.16	0.12	Phospholipid levels (plasma);	chr1:94915474	chr1:94927566~94963270:+
BRCA	cis	rs7119	0.651	rs12904533	ENSG00000259362.2	RP11-307C19.1	-3.98	7.46e-05	0.00486	-0.17	-0.12	Type 2 diabetes;	chr15:77553586	chr15:77525540~77534110:+
BRCA	cis	rs970548	0.862	rs10900230	ENSG00000230869.1	CTGLF10P	3.98	7.47e-05	0.00486	0.16	0.12	Total cholesterol levels;HDL cholesterol;HDL cholesterol levels;Cholesterol, total;	chr10:45634941	chr10:45678692~45700532:+
BRCA	cis	rs7746199	0.736	rs13202295	ENSG00000216901.1	AL022393.7	3.98	7.47e-05	0.00486	0.32	0.12	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27731058	chr6:28176188~28176674:+
BRCA	cis	rs7020830	0.823	rs7019699	ENSG00000260100.1	RP11-220I1.5	-3.98	7.47e-05	0.00486	-0.15	-0.12	Schizophrenia;	chr9:37125084	chr9:37078813~37079776:-
BRCA	cis	rs7020830	0.931	rs7027473	ENSG00000260100.1	RP11-220I1.5	-3.98	7.47e-05	0.00486	-0.15	-0.12	Schizophrenia;	chr9:37132465	chr9:37078813~37079776:-
BRCA	cis	rs17270561	0.609	rs760698	ENSG00000272462.2	U91328.19	-3.98	7.47e-05	0.00486	-0.15	-0.12	Iron status biomarkers;	chr6:25685661	chr6:25992662~26001775:+
BRCA	cis	rs10792665	0.649	rs4619175	ENSG00000246067.6	RAB30-AS1	-3.98	7.47e-05	0.00486	-0.13	-0.12	Obesity-related traits;	chr11:83029987	chr11:83072066~83106719:+
BRCA	cis	rs7246967	0.799	rs12983185	ENSG00000198153.8	ZNF849P	-3.98	7.47e-05	0.00486	-0.17	-0.12	Bronchopulmonary dysplasia;	chr19:22847773	chr19:22685167~22686732:+
BRCA	cis	rs17027633	1	rs80017784	ENSG00000234020.1	CHIAP3	-3.98	7.47e-05	0.00486	-0.24	-0.12	Cerebrospinal fluid t-tau:AB1-42 ratio;	chr1:111405657	chr1:111353275~111367409:-
BRCA	cis	rs17027633	1	rs74935221	ENSG00000234020.1	CHIAP3	-3.98	7.47e-05	0.00486	-0.24	-0.12	Cerebrospinal fluid t-tau:AB1-42 ratio;	chr1:111405676	chr1:111353275~111367409:-
BRCA	cis	rs17027633	1	rs74226038	ENSG00000234020.1	CHIAP3	-3.98	7.47e-05	0.00486	-0.24	-0.12	Cerebrospinal fluid t-tau:AB1-42 ratio;	chr1:111405985	chr1:111353275~111367409:-
BRCA	cis	rs4664293	1	rs10432413	ENSG00000224152.1	AC009506.1	-3.98	7.47e-05	0.00486	-0.14	-0.12	Monocyte percentage of white cells;	chr2:159639243	chr2:159615296~159617082:+
BRCA	cis	rs4218	0.551	rs12906212	ENSG00000259732.1	RP11-59H7.3	-3.98	7.47e-05	0.00486	-0.16	-0.12	Social communication problems;	chr15:59070556	chr15:59121034~59133250:+
BRCA	cis	rs651907	0.535	rs11714444	ENSG00000256628.3	ZBTB11-AS1	3.98	7.48e-05	0.00487	0.16	0.12	Colorectal cancer;	chr3:101794838	chr3:101676475~101679217:+
BRCA	cis	rs10844682	0.603	rs10844673	ENSG00000214776.8	RP11-726G1.1	3.98	7.48e-05	0.00487	0.16	0.12	Monocyte percentage of white cells;	chr12:9744969	chr12:9467552~9576275:+
BRCA	cis	rs2274273	0.745	rs8005399	ENSG00000233924.1	AL160471.6	-3.98	7.48e-05	0.00487	-0.14	-0.12	Protein biomarker;	chr14:55076127	chr14:55004813~55005687:-
BRCA	cis	rs8114671	0.57	rs3761144	ENSG00000279253.1	RP4-614O4.13	-3.98	7.48e-05	0.00487	-0.14	-0.12	Height;	chr20:34956272	chr20:35262727~35264187:-
BRCA	cis	rs2880765	0.835	rs11856869	ENSG00000202081.1	RNU6-1280P	3.98	7.48e-05	0.00487	0.14	0.12	Coronary artery disease;	chr15:85485866	chr15:85651522~85651628:-
BRCA	cis	rs7267979	0.899	rs2179459	ENSG00000274414.1	RP5-965G21.4	-3.98	7.48e-05	0.00487	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25475505	chr20:25239007~25245229:-
BRCA	cis	rs9470794	1	rs73419996	ENSG00000204110.6	RP1-153P14.8	-3.98	7.48e-05	0.00487	-0.23	-0.12	Type 2 diabetes;	chr6:38099605	chr6:37507348~37535616:+
BRCA	cis	rs2251381	0.778	rs2471947	ENSG00000232855.5	AF131217.1	-3.98	7.48e-05	0.00487	-0.16	-0.12	Selective IgA deficiency;	chr21:29161898	chr21:28439346~28674848:-
BRCA	cis	rs4415084	0.834	rs13160259	ENSG00000248779.1	RP11-53O19.2	3.98	7.48e-05	0.00487	0.11	0.12	Breast cancer;	chr5:44828862	chr5:44752949~44765744:+
BRCA	cis	rs6088580	0.634	rs6059867	ENSG00000275784.1	RP5-1125A11.6	-3.98	7.48e-05	0.00487	-0.13	-0.12	Glomerular filtration rate (creatinine);	chr20:34490298	chr20:33989480~33991818:-
BRCA	cis	rs256438	0.524	rs368936	ENSG00000251050.1	RP11-168A11.4	-3.98	7.48e-05	0.00487	-0.13	-0.12	Serum thyroid-stimulating hormone levels;	chr5:80058324	chr5:80019609~80019920:+
BRCA	cis	rs12210905	0.92	rs9393802	ENSG00000216901.1	AL022393.7	3.98	7.48e-05	0.00487	0.22	0.12	Hip circumference adjusted for BMI;	chr6:27275326	chr6:28176188~28176674:+
BRCA	cis	rs7048146	0.51	rs1109478	ENSG00000213539.4	YBX1P6	-3.98	7.48e-05	0.00487	-0.13	-0.12	Vascular brain injury;	chr9:109519583	chr9:109532830~109534332:-
BRCA	cis	rs7048146	0.51	rs10759347	ENSG00000213539.4	YBX1P6	-3.98	7.48e-05	0.00487	-0.13	-0.12	Vascular brain injury;	chr9:109521455	chr9:109532830~109534332:-
BRCA	cis	rs11668609	1	rs8100931	ENSG00000268058.1	BNIP3P40	-3.98	7.48e-05	0.00487	-0.15	-0.12	Response to taxane treatment (docetaxel);	chr19:24175770	chr19:24098425~24098980:-
BRCA	cis	rs6049003	0.622	rs6049043	ENSG00000232645.4	LINC01431	3.98	7.49e-05	0.00487	0.13	0.12	Cerebrospinal fluid biomarker levels;	chr20:23740340	chr20:23356594~23358116:-
BRCA	cis	rs6545883	0.825	rs4672426	ENSG00000212978.6	AC016747.3	-3.98	7.49e-05	0.00487	-0.16	-0.12	Tuberculosis;	chr2:61230013	chr2:61141592~61144969:-
BRCA	cis	rs6545883	0.86	rs4671399	ENSG00000212978.6	AC016747.3	-3.98	7.49e-05	0.00487	-0.16	-0.12	Tuberculosis;	chr2:61231383	chr2:61141592~61144969:-
BRCA	cis	rs9929215	1	rs9929215	ENSG00000270020.1	RP11-463O9.9	-3.98	7.49e-05	0.00487	-0.34	-0.12	Colorectal cancer;	chr16:86487884	chr16:86520383~86523897:-
BRCA	cis	rs13434995	0.513	rs62303718	ENSG00000239040.1	Y_RNA	3.98	7.49e-05	0.00487	0.14	0.12	Adiponectin levels;	chr4:55476770	chr4:55412636~55412738:+
BRCA	cis	rs13434995	0.513	rs17722870	ENSG00000239040.1	Y_RNA	3.98	7.49e-05	0.00487	0.14	0.12	Adiponectin levels;	chr4:55478519	chr4:55412636~55412738:+
BRCA	cis	rs6012564	1	rs3092720	ENSG00000222365.1	SNORD12B	-3.98	7.49e-05	0.00487	-0.13	-0.12	Anger;	chr20:49023929	chr20:49280319~49280409:+
BRCA	cis	rs4664293	0.647	rs10196064	ENSG00000224152.1	AC009506.1	-3.98	7.49e-05	0.00487	-0.13	-0.12	Monocyte percentage of white cells;	chr2:159569454	chr2:159615296~159617082:+
BRCA	cis	rs4664293	0.647	rs2162023	ENSG00000224152.1	AC009506.1	-3.98	7.49e-05	0.00487	-0.13	-0.12	Monocyte percentage of white cells;	chr2:159569719	chr2:159615296~159617082:+
BRCA	cis	rs9840812	0.906	rs61791757	ENSG00000273486.1	RP11-731C17.2	-3.98	7.49e-05	0.00487	-0.16	-0.12	Fibrinogen levels;	chr3:136186483	chr3:136837338~136839021:-
BRCA	cis	rs453301	0.658	rs9329175	ENSG00000233609.3	RP11-62H7.2	-3.98	7.49e-05	0.00487	-0.11	-0.12	Joint mobility (Beighton score);	chr8:9009151	chr8:8961200~8979025:+
BRCA	cis	rs17428076	0.83	rs62183852	ENSG00000228389.1	AC068039.4	-3.98	7.49e-05	0.00487	-0.19	-0.12	Myopia;	chr2:172061483	chr2:171773482~171775844:+
BRCA	cis	rs17428076	0.673	rs6737876	ENSG00000228389.1	AC068039.4	-3.98	7.49e-05	0.00487	-0.19	-0.12	Myopia;	chr2:172061948	chr2:171773482~171775844:+
BRCA	cis	rs1555322	1	rs2425040	ENSG00000261582.1	RP4-614O4.11	-3.98	7.49e-05	0.00487	-0.17	-0.12	Attention deficit hyperactivity disorder;	chr20:35271075	chr20:35267885~35280043:-
BRCA	cis	rs11711311	1	rs3773682	ENSG00000241529.3	RN7SL767P	-3.98	7.49e-05	0.00487	-0.14	-0.12	IgG glycosylation;	chr3:113801729	chr3:113632704~113632998:+
BRCA	cis	rs10463316	0.817	rs6895187	ENSG00000260581.1	CTB-113P19.4	3.98	7.49e-05	0.00488	0.14	0.12	Metabolite levels (Pyroglutamine);	chr5:151396348	chr5:151652275~151655449:+
BRCA	cis	rs1799955	1	rs11571725	ENSG00000215515.2	IFIT1P1	3.98	7.49e-05	0.00488	0.16	0.12	LDL cholesterol levels;	chr13:32364744	chr13:32384660~32386108:+
BRCA	cis	rs564309	1	rs532465	ENSG00000183929.7	DUSP5P1	3.98	7.49e-05	0.00488	0.22	0.12	Hip circumference (psychosocial stress interaction);	chr1:228399791	chr1:228650241~228651379:+
BRCA	cis	rs801193	1	rs2055682	ENSG00000223473.2	GS1-124K5.3	3.98	7.49e-05	0.00488	0.09	0.12	Aortic root size;	chr7:66795302	chr7:66491049~66493566:-
BRCA	cis	rs155076	1	rs155076	ENSG00000233325.3	MIPEPP3	3.98	7.49e-05	0.00488	0.19	0.12	White matter hyperintensity burden;	chr13:21295975	chr13:21298139~21306373:+
BRCA	cis	rs6088580	0.602	rs6059834	ENSG00000275784.1	RP5-1125A11.6	-3.98	7.5e-05	0.00488	-0.13	-0.12	Glomerular filtration rate (creatinine);	chr20:34431493	chr20:33989480~33991818:-
BRCA	cis	rs6088580	0.634	rs6059835	ENSG00000275784.1	RP5-1125A11.6	-3.98	7.5e-05	0.00488	-0.13	-0.12	Glomerular filtration rate (creatinine);	chr20:34432335	chr20:33989480~33991818:-
BRCA	cis	rs7312933	0.584	rs7974654	ENSG00000257225.1	RP11-328C8.4	-3.98	7.5e-05	0.00488	-0.15	-0.12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42236664	chr12:42459366~42466128:+
BRCA	cis	rs1371614	0.61	rs6547317	ENSG00000229122.1	AGBL5-IT1	3.98	7.5e-05	0.00488	0.13	0.12	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26929051	chr2:27061038~27061815:+
BRCA	cis	rs801193	1	rs3778909	ENSG00000229180.5	GS1-124K5.11	3.98	7.5e-05	0.00488	0.11	0.12	Aortic root size;	chr7:66790659	chr7:66526088~66542624:-
BRCA	cis	rs6545883	0.929	rs2593627	ENSG00000212978.6	AC016747.3	-3.98	7.5e-05	0.00488	-0.17	-0.12	Tuberculosis;	chr2:61391439	chr2:61141592~61144969:-
BRCA	cis	rs7267979	1	rs7343481	ENSG00000274973.1	RP13-401N8.7	3.98	7.5e-05	0.00488	0.14	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25319477	chr20:25845497~25845862:+
BRCA	cis	rs6088580	0.634	rs4911418	ENSG00000275784.1	RP5-1125A11.6	3.98	7.51e-05	0.00488	0.13	0.12	Glomerular filtration rate (creatinine);	chr20:34406451	chr20:33989480~33991818:-
BRCA	cis	rs6088580	0.634	rs6579165	ENSG00000275784.1	RP5-1125A11.6	3.98	7.51e-05	0.00488	0.13	0.12	Glomerular filtration rate (creatinine);	chr20:34406909	chr20:33989480~33991818:-
BRCA	cis	rs6088580	0.634	rs4911419	ENSG00000275784.1	RP5-1125A11.6	3.98	7.51e-05	0.00488	0.13	0.12	Glomerular filtration rate (creatinine);	chr20:34408067	chr20:33989480~33991818:-
BRCA	cis	rs6088580	0.634	rs4911421	ENSG00000275784.1	RP5-1125A11.6	3.98	7.51e-05	0.00488	0.13	0.12	Glomerular filtration rate (creatinine);	chr20:34411142	chr20:33989480~33991818:-
BRCA	cis	rs6088580	0.634	rs4911422	ENSG00000275784.1	RP5-1125A11.6	3.98	7.51e-05	0.00488	0.13	0.12	Glomerular filtration rate (creatinine);	chr20:34411539	chr20:33989480~33991818:-
BRCA	cis	rs6088580	0.634	rs2225837	ENSG00000275784.1	RP5-1125A11.6	3.98	7.51e-05	0.00488	0.13	0.12	Glomerular filtration rate (creatinine);	chr20:34417828	chr20:33989480~33991818:-
BRCA	cis	rs17772222	0.917	rs8018755	ENSG00000258789.1	RP11-507K2.3	-3.98	7.51e-05	0.00488	-0.15	-0.12	Coronary artery calcification;	chr14:88714249	chr14:88551597~88552493:+
BRCA	cis	rs17772222	0.917	rs8018630	ENSG00000258789.1	RP11-507K2.3	-3.98	7.51e-05	0.00488	-0.15	-0.12	Coronary artery calcification;	chr14:88714250	chr14:88551597~88552493:+
BRCA	cis	rs801193	1	rs1553610	ENSG00000272831.1	RP11-792A8.4	3.98	7.51e-05	0.00488	0.11	0.12	Aortic root size;	chr7:66732246	chr7:66739829~66740385:-
BRCA	cis	rs801193	1	rs2707845	ENSG00000272831.1	RP11-792A8.4	3.98	7.51e-05	0.00488	0.11	0.12	Aortic root size;	chr7:66733811	chr7:66739829~66740385:-
BRCA	cis	rs801193	1	rs2707850	ENSG00000272831.1	RP11-792A8.4	3.98	7.51e-05	0.00488	0.11	0.12	Aortic root size;	chr7:66738883	chr7:66739829~66740385:-
BRCA	cis	rs801193	0.967	rs1110414	ENSG00000272831.1	RP11-792A8.4	3.98	7.51e-05	0.00488	0.11	0.12	Aortic root size;	chr7:66740595	chr7:66739829~66740385:-
BRCA	cis	rs801193	1	rs7783924	ENSG00000272831.1	RP11-792A8.4	3.98	7.51e-05	0.00488	0.11	0.12	Aortic root size;	chr7:66744070	chr7:66739829~66740385:-
BRCA	cis	rs801193	1	rs7789184	ENSG00000272831.1	RP11-792A8.4	3.98	7.51e-05	0.00488	0.11	0.12	Aortic root size;	chr7:66745208	chr7:66739829~66740385:-
BRCA	cis	rs801193	1	rs2707854	ENSG00000272831.1	RP11-792A8.4	3.98	7.51e-05	0.00488	0.11	0.12	Aortic root size;	chr7:66747610	chr7:66739829~66740385:-
BRCA	cis	rs7833986	0.501	rs72653948	ENSG00000253603.1	CTA-397H3.3	-3.98	7.51e-05	0.00488	-0.17	-0.12	Height;	chr8:56043130	chr8:56074592~56075274:+
BRCA	cis	rs9399135	0.967	rs12661423	ENSG00000234084.1	RP3-388E23.2	-3.98	7.51e-05	0.00488	-0.12	-0.12	Red blood cell count;	chr6:135028432	chr6:135301568~135307158:+
BRCA	cis	rs7656342	0.729	rs10004319	ENSG00000250342.1	SNRPCP16	-3.98	7.51e-05	0.00488	-0.14	-0.12	Gut microbiota (bacterial taxa);	chr4:9760316	chr4:9051842~9052051:-
BRCA	cis	rs4664293	0.647	rs7575924	ENSG00000224152.1	AC009506.1	-3.98	7.51e-05	0.00488	-0.13	-0.12	Monocyte percentage of white cells;	chr2:159573049	chr2:159615296~159617082:+
BRCA	cis	rs338389	0.872	rs1913303	ENSG00000260657.2	RP11-315D16.4	3.98	7.51e-05	0.00488	0.14	0.12	Survival in rectal cancer;	chr15:67996718	chr15:68267792~68277994:-
BRCA	cis	rs11098499	0.644	rs3806808	ENSG00000225892.3	RP11-384K6.2	3.98	7.51e-05	0.00489	0.12	0.12	Corneal astigmatism;	chr4:119629930	chr4:118632274~118634759:+
BRCA	cis	rs875971	1	rs4717292	ENSG00000265600.1	AC006480.1	-3.98	7.51e-05	0.00489	-0.14	-0.12	Aortic root size;	chr7:66430611	chr7:67356680~67356779:+
BRCA	cis	rs875971	1	rs35149210	ENSG00000265600.1	AC006480.1	-3.98	7.51e-05	0.00489	-0.14	-0.12	Aortic root size;	chr7:66464938	chr7:67356680~67356779:+
BRCA	cis	rs875971	0.651	rs313829	ENSG00000223473.2	GS1-124K5.3	-3.98	7.51e-05	0.00489	-0.1	-0.12	Aortic root size;	chr7:66087510	chr7:66491049~66493566:-
BRCA	cis	rs2835872	0.828	rs73220495	ENSG00000228677.1	TTC3-AS1	-3.98	7.51e-05	0.00489	-0.16	-0.12	Electroencephalographic traits in alcoholism;	chr21:37617410	chr21:37187666~37193926:-
BRCA	cis	rs409045	0.84	rs404765	ENSG00000271874.1	CTD-2024P10.2	3.98	7.51e-05	0.00489	0.16	0.12	Left ventricular mass;	chr5:34640033	chr5:34651457~34651888:-
BRCA	cis	rs7246967	0.932	rs35948178	ENSG00000198153.8	ZNF849P	-3.98	7.51e-05	0.00489	-0.17	-0.12	Bronchopulmonary dysplasia;	chr19:22845717	chr19:22685167~22686732:+
BRCA	cis	rs687432	0.718	rs2441952	ENSG00000213592.4	AP000662.9	3.98	7.52e-05	0.00489	0.15	0.12	Parkinson's disease;	chr11:58024529	chr11:57718044~57718530:-
BRCA	cis	rs934734	0.967	rs1866051	ENSG00000281920.1	RP11-418H16.1	3.98	7.52e-05	0.00489	0.14	0.12	Rheumatoid arthritis;	chr2:65375015	chr2:65623272~65628424:+
BRCA	cis	rs62458065	0.85	rs62458066	ENSG00000229358.3	DPY19L1P1	-3.98	7.52e-05	0.00489	-0.17	-0.12	Metabolite levels (HVA/MHPG ratio);	chr7:32424872	chr7:32580949~32761787:-
BRCA	cis	rs6964587	1	rs11971885	ENSG00000188693.7	CYP51A1-AS1	-3.98	7.52e-05	0.00489	-0.13	-0.12	Breast cancer;	chr7:92045493	chr7:92134604~92180725:+
BRCA	cis	rs11955398	0.502	rs162251	ENSG00000272308.1	RP11-231G3.1	-3.98	7.52e-05	0.00489	-0.14	-0.12	Intelligence (multi-trait analysis);	chr5:60996457	chr5:60866457~60866935:-
BRCA	cis	rs11673344	0.636	rs7255595	ENSG00000267260.1	CTD-2162K18.4	-3.98	7.52e-05	0.00489	-0.18	-0.12	Obesity-related traits;	chr19:36896260	chr19:36773153~36777078:+
BRCA	cis	rs7772486	0.692	rs2265915	ENSG00000270638.1	RP3-466P17.1	3.98	7.52e-05	0.00489	0.14	0.12	Lobe attachment (rater-scored or self-reported);	chr6:145873196	chr6:145735570~145737218:+
BRCA	cis	rs11242704	0.632	rs2569829	ENSG00000218027.2	RP11-157J24.1	3.98	7.52e-05	0.00489	0.17	0.12	Response to hepatitis C treatment;	chr6:1539293	chr6:1513698~1515289:-
BRCA	cis	rs11051970	0.879	rs2728680	ENSG00000274964.1	RP11-817I4.1	-3.98	7.52e-05	0.00489	-0.14	-0.12	Response to tocilizumab in rheumatoid arthritis;	chr12:32430578	chr12:32339368~32340724:+
BRCA	cis	rs7772486	0.79	rs2253654	ENSG00000270638.1	RP3-466P17.1	3.98	7.52e-05	0.00489	0.14	0.12	Lobe attachment (rater-scored or self-reported);	chr6:145878309	chr6:145735570~145737218:+
BRCA	cis	rs812925	0.502	rs778150	ENSG00000270820.4	RP11-355B11.2	-3.98	7.52e-05	0.00489	-0.13	-0.12	Immature fraction of reticulocytes;	chr2:61381237	chr2:61471188~61484130:+
BRCA	cis	rs6723108	0.694	rs666614	ENSG00000224043.6	CCNT2-AS1	3.97	7.52e-05	0.00489	0.17	0.12	Type 2 diabetes;	chr2:134532882	chr2:134735464~134918710:-
BRCA	cis	rs10458771	0.915	rs7100362	ENSG00000227896.2	RP11-77P6.2	-3.97	7.52e-05	0.00489	-0.15	-0.12	Amyotrophic lateral sclerosis (sporadic);	chr10:86431550	chr10:86521945~86525101:+
BRCA	cis	rs1642645	0.872	rs642112	ENSG00000228452.1	RP5-994D16.9	-3.97	7.52e-05	0.00489	-0.16	-0.12	Left ventricular obstructive tract defect (maternal effect);	chr1:41987646	chr1:42775813~42776790:-
BRCA	cis	rs16944613	0.541	rs6496690	ENSG00000271396.1	RP11-697E2.9	-3.97	7.52e-05	0.00489	-0.2	-0.12	Colorectal cancer;	chr15:90554169	chr15:90284376~90285580:-
BRCA	cis	rs2255336	0.938	rs73070926	ENSG00000245648.1	RP11-277P12.20	-3.97	7.52e-05	0.00489	-0.2	-0.12	Blood protein levels;	chr12:10459717	chr12:10363769~10398506:+
BRCA	cis	rs7267979	1	rs2257420	ENSG00000274973.1	RP13-401N8.7	-3.97	7.52e-05	0.00489	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25295254	chr20:25845497~25845862:+
BRCA	cis	rs4664293	0.967	rs13032135	ENSG00000226266.5	AC009961.3	-3.97	7.53e-05	0.00489	-0.15	-0.12	Monocyte percentage of white cells;	chr2:159675588	chr2:159670708~159712435:-
BRCA	cis	rs2136613	0.751	rs10761667	ENSG00000238280.1	RP11-436D10.3	-3.97	7.53e-05	0.00489	-0.15	-0.12	Selective IgA deficiency;	chr10:62849038	chr10:62793562~62805887:-
BRCA	cis	rs801193	1	rs62466793	ENSG00000273142.1	RP11-458F8.4	-3.97	7.53e-05	0.00489	-0.11	-0.12	Aortic root size;	chr7:66726530	chr7:66902857~66906297:+
BRCA	cis	rs875971	0.929	rs4122249	ENSG00000236529.1	RP13-254B10.1	3.97	7.53e-05	0.00489	0.13	0.12	Aortic root size;	chr7:66455949	chr7:65840212~65840596:+
BRCA	cis	rs2109514	1	rs2270189	ENSG00000237813.3	AC002066.1	3.97	7.53e-05	0.0049	0.15	0.12	Prevalent atrial fibrillation;	chr7:116500562	chr7:116238260~116499465:-
BRCA	cis	rs8023401	0.882	rs11853045	ENSG00000274654.1	CTD-3247H4.2	-3.97	7.53e-05	0.0049	-0.17	-0.12	Spherical equivalent (joint analysis main effects and education interaction);	chr15:48507184	chr15:48528980~48529728:-
BRCA	cis	rs2243480	0.901	rs2949697	ENSG00000222364.1	RNU6-96P	-3.97	7.53e-05	0.0049	-0.22	-0.12	Diabetic kidney disease;	chr7:65999249	chr7:66395191~66395286:+
BRCA	cis	rs4237845	0.537	rs12426201	ENSG00000257159.1	RP11-58A17.3	3.97	7.53e-05	0.0049	0.15	0.12	Intelligence (multi-trait analysis);	chr12:57865969	chr12:57967058~57968399:+
BRCA	cis	rs2832191	0.967	rs2251377	ENSG00000232855.5	AF131217.1	-3.97	7.53e-05	0.0049	-0.15	-0.12	Dental caries;	chr21:29158278	chr21:28439346~28674848:-
BRCA	cis	rs2039553	0.517	rs4885658	ENSG00000227354.5	RBM26-AS1	-3.97	7.53e-05	0.0049	-0.14	-0.12	Pancreatic cancer;	chr13:79756983	chr13:79406309~79424328:+
BRCA	cis	rs7800418	0.775	rs11762404	ENSG00000214870.7	AC004540.5	-3.97	7.53e-05	0.0049	-0.15	-0.12	Cognitive function;	chr7:26564354	chr7:26398593~26494256:+
BRCA	cis	rs8114671	0.935	rs6060282	ENSG00000279253.1	RP4-614O4.13	-3.97	7.54e-05	0.0049	-0.14	-0.12	Height;	chr20:35179263	chr20:35262727~35264187:-
BRCA	cis	rs8114671	0.967	rs2065978	ENSG00000279253.1	RP4-614O4.13	-3.97	7.54e-05	0.0049	-0.14	-0.12	Height;	chr20:35179488	chr20:35262727~35264187:-
BRCA	cis	rs8114671	0.967	rs2065979	ENSG00000279253.1	RP4-614O4.13	-3.97	7.54e-05	0.0049	-0.14	-0.12	Height;	chr20:35179887	chr20:35262727~35264187:-
BRCA	cis	rs1549733	0.577	rs6414192	ENSG00000229754.1	CXCR2P1	3.97	7.54e-05	0.0049	0.12	0.12	Optic disc area;	chr2:217532877	chr2:218059155~218065729:-
BRCA	cis	rs7267979	0.868	rs6138546	ENSG00000274414.1	RP5-965G21.4	-3.97	7.54e-05	0.0049	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25235898	chr20:25239007~25245229:-
BRCA	cis	rs1009077	0.582	rs3756155	ENSG00000245958.5	RP11-33B1.1	3.97	7.54e-05	0.0049	0.18	0.12	Endometriosis;	chr4:119602915	chr4:119454791~119552025:+
BRCA	cis	rs1009077	0.716	rs78520912	ENSG00000245958.5	RP11-33B1.1	3.97	7.54e-05	0.0049	0.18	0.12	Endometriosis;	chr4:119604576	chr4:119454791~119552025:+
BRCA	cis	rs7658584	0.562	rs35677388	ENSG00000246375.2	RP11-10L7.1	3.97	7.54e-05	0.0049	0.19	0.12	Squamous cell lung carcinoma;	chr4:88185225	chr4:88284942~88331421:+
BRCA	cis	rs1124769	0.57	rs7181593	ENSG00000273674.3	CTD-2378E12.1	-3.97	7.54e-05	0.0049	-0.15	-0.12	Cognitive performance;	chr15:50853917	chr15:50839875~50908599:-
BRCA	cis	rs6860806	0.661	rs28472559	ENSG00000233006.5	AC034220.3	3.97	7.54e-05	0.0049	0.09	0.12	Breast cancer;	chr5:132245918	chr5:132311285~132369916:-
BRCA	cis	rs995000	0.64	rs4915853	ENSG00000235545.1	RP11-230B22.1	-3.97	7.54e-05	0.0049	-0.14	-0.12	Triglyceride levels;	chr1:62725906	chr1:62688482~62710694:+
BRCA	cis	rs875971	0.522	rs1701760	ENSG00000223473.2	GS1-124K5.3	3.97	7.54e-05	0.0049	0.09	0.12	Aortic root size;	chr7:66008701	chr7:66491049~66493566:-
BRCA	cis	rs853679	1	rs1778508	ENSG00000216901.1	AL022393.7	-3.97	7.54e-05	0.0049	-0.21	-0.12	Depression;	chr6:28262103	chr6:28176188~28176674:+
BRCA	cis	rs10864907	0.614	rs10199311	ENSG00000231747.1	AC079922.2	-3.97	7.54e-05	0.0049	-0.12	-0.12	Pulmonary function;	chr2:112940384	chr2:112621809~112622167:-
BRCA	cis	rs12681366	1	rs7825731	ENSG00000253175.1	RP11-267M23.6	3.97	7.54e-05	0.0049	0.14	0.12	Nonsyndromic cleft lip with cleft palate;	chr8:94362147	chr8:94565036~94565715:+
BRCA	cis	rs6496932	0.503	rs7176605	ENSG00000259630.2	CTD-2262B20.1	-3.97	7.55e-05	0.0049	-0.17	-0.12	Central corneal thickness;Corneal structure;	chr15:85443491	chr15:85415228~85415633:+
BRCA	cis	rs7726839	0.561	rs56410216	ENSG00000271781.1	CTD-2589H19.6	-3.97	7.55e-05	0.0049	-0.17	-0.12	Obesity-related traits;	chr5:583101	chr5:675826~676616:+
BRCA	cis	rs7726839	0.561	rs4957048	ENSG00000271781.1	CTD-2589H19.6	-3.97	7.55e-05	0.0049	-0.17	-0.12	Obesity-related traits;	chr5:583327	chr5:675826~676616:+
BRCA	cis	rs7726839	0.561	rs72703058	ENSG00000271781.1	CTD-2589H19.6	-3.97	7.55e-05	0.0049	-0.17	-0.12	Obesity-related traits;	chr5:584404	chr5:675826~676616:+
BRCA	cis	rs2018683	0.707	rs4722875	ENSG00000233517.1	AC005162.5	-3.97	7.55e-05	0.0049	-0.15	-0.12	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28930015	chr7:28987028~28988899:+
BRCA	cis	rs7824557	0.628	rs7820301	ENSG00000255020.1	AF131216.5	-3.97	7.55e-05	0.00491	-0.15	-0.12	Retinal vascular caliber;	chr8:11371163	chr8:11345748~11347502:-
BRCA	cis	rs6964587	1	rs411	ENSG00000188693.7	CYP51A1-AS1	3.97	7.55e-05	0.00491	0.13	0.12	Breast cancer;	chr7:91928444	chr7:92134604~92180725:+
BRCA	cis	rs9788721	0.836	rs72738718	ENSG00000261762.1	RP11-650L12.2	-3.97	7.55e-05	0.00491	-0.15	-0.12	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78443096	chr15:78589123~78591276:-
BRCA	cis	rs9381040	0.61	rs9394758	ENSG00000161912.16	ADCY10P1	3.97	7.55e-05	0.00491	0.14	0.12	Alzheimer's disease (late onset);	chr6:41050082	chr6:41101022~41140835:+
BRCA	cis	rs9381040	0.61	rs9367094	ENSG00000161912.16	ADCY10P1	3.97	7.55e-05	0.00491	0.14	0.12	Alzheimer's disease (late onset);	chr6:41050121	chr6:41101022~41140835:+
BRCA	cis	rs9381040	0.61	rs742495	ENSG00000161912.16	ADCY10P1	3.97	7.55e-05	0.00491	0.14	0.12	Alzheimer's disease (late onset);	chr6:41050494	chr6:41101022~41140835:+
BRCA	cis	rs6952407	1	rs6952407	ENSG00000223473.2	GS1-124K5.3	-3.97	7.55e-05	0.00491	-0.09	-0.12	Cotinine glucuronidation;	chr7:66580525	chr7:66491049~66493566:-
BRCA	cis	rs6860806	0.632	rs4330455	ENSG00000233006.5	AC034220.3	3.97	7.55e-05	0.00491	0.09	0.12	Breast cancer;	chr5:132250656	chr5:132311285~132369916:-
BRCA	cis	rs1664789	0.587	rs697112	ENSG00000272416.1	CTD-2081C10.7	3.97	7.55e-05	0.00491	0.12	0.12	Waist circumference adjusted for body mass index;	chr5:53964849	chr5:53880293~53881051:-
BRCA	cis	rs1577917	0.655	rs1059307	ENSG00000220563.1	PKMP3	3.97	7.55e-05	0.00491	0.12	0.12	Response to antipsychotic treatment;	chr6:85678170	chr6:85659892~85660606:-
BRCA	cis	rs7646881	0.504	rs61080878	ENSG00000240207.5	RP11-379F4.4	-3.97	7.56e-05	0.00491	-0.17	-0.12	Tetralogy of Fallot;	chr3:158745108	chr3:158732263~158784070:+
BRCA	cis	rs10504130	0.569	rs12681734	ENSG00000253844.1	RP11-546K22.1	-3.97	7.56e-05	0.00491	-0.17	-0.12	Venous thromboembolism (SNP x SNP interaction);	chr8:51893635	chr8:51961458~52022974:+
BRCA	cis	rs10463316	0.862	rs59390562	ENSG00000260581.1	CTB-113P19.4	3.97	7.56e-05	0.00491	0.14	0.12	Metabolite levels (Pyroglutamine);	chr5:151396531	chr5:151652275~151655449:+
BRCA	cis	rs10463316	0.862	rs7700650	ENSG00000260581.1	CTB-113P19.4	3.97	7.56e-05	0.00491	0.14	0.12	Metabolite levels (Pyroglutamine);	chr5:151396912	chr5:151652275~151655449:+
BRCA	cis	rs1065852	0.526	rs9623490	ENSG00000205702.9	CYP2D7	3.97	7.56e-05	0.00491	0.11	0.12	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42002262	chr22:42140203~42144577:-
BRCA	cis	rs10504130	0.932	rs79196243	ENSG00000272076.1	RP11-11C20.3	3.97	7.56e-05	0.00491	0.21	0.12	Venous thromboembolism (SNP x SNP interaction);	chr8:51834855	chr8:51810110~51810681:-
BRCA	cis	rs2115630	1	rs56074163	ENSG00000275120.1	RP11-182J1.17	-3.97	7.56e-05	0.00491	-0.14	-0.12	P wave terminal force;	chr15:84808101	chr15:84599434~84606463:-
BRCA	cis	rs1553477	0.747	rs72761327	ENSG00000272416.1	CTD-2081C10.7	3.97	7.56e-05	0.00491	0.12	0.12	Monobrow;	chr5:53844695	chr5:53880293~53881051:-
BRCA	cis	rs28530618	0.603	rs11167173	ENSG00000198547.7	C20orf203	-3.97	7.56e-05	0.00491	-0.14	-0.12	Birth weight;	chr20:32653810	chr20:32631652~32673941:-
BRCA	cis	rs1371614	0.655	rs7579579	ENSG00000272148.1	RP11-195B17.1	-3.97	7.57e-05	0.00492	-0.14	-0.12	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26928974	chr2:27062428~27062907:-
BRCA	cis	rs4242434	0.927	rs13264187	ENSG00000253483.1	CTC-756D1.1	-3.97	7.57e-05	0.00492	-0.17	-0.12	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);	chr8:22648585	chr8:23483016~23483534:-
BRCA	cis	rs1153858	1	rs60476496	ENSG00000275672.1	GATM-AS1	-3.97	7.57e-05	0.00492	-0.16	-0.12	Homoarginine levels;	chr15:45421603	chr15:45378700~45380123:+
BRCA	cis	rs17684571	0.751	rs13207768	ENSG00000231441.1	RP11-472M19.2	3.97	7.57e-05	0.00492	0.21	0.12	Schizophrenia;	chr6:56851277	chr6:56844002~56864078:+
BRCA	cis	rs2905347	0.52	rs1858936	ENSG00000179428.2	AC073072.5	3.97	7.57e-05	0.00492	0.14	0.12	Major depression and alcohol dependence;	chr7:22607934	chr7:22725395~22727620:-
BRCA	cis	rs801193	1	rs2420824	ENSG00000223473.2	GS1-124K5.3	-3.97	7.57e-05	0.00492	-0.09	-0.12	Aortic root size;	chr7:66666129	chr7:66491049~66493566:-
BRCA	cis	rs2227564	0.7	rs2688612	ENSG00000271816.1	BMS1P4	3.97	7.57e-05	0.00492	0.13	0.12	Crohn's disease;Inflammatory bowel disease;	chr10:73893447	chr10:73699151~73730487:-
BRCA	cis	rs7020830	0.931	rs7034554	ENSG00000260100.1	RP11-220I1.5	-3.97	7.58e-05	0.00492	-0.15	-0.12	Schizophrenia;	chr9:37081304	chr9:37078813~37079776:-
BRCA	cis	rs930395	0.514	rs10041518	ENSG00000251141.4	RP11-53O19.1	-3.97	7.58e-05	0.00492	-0.11	-0.12	Breast cancer;	chr5:44927304	chr5:44744900~44808777:-
BRCA	cis	rs8062405	1	rs80275162	ENSG00000261766.1	RP11-22P6.2	-3.97	7.58e-05	0.00492	-0.12	-0.12	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28852196	chr16:28862166~28863340:-
BRCA	cis	rs56322409	0.564	rs4918976	ENSG00000226688.5	ENTPD1-AS1	3.97	7.58e-05	0.00492	0.14	0.12	Blood metabolite levels;	chr10:95909787	chr10:95753206~96090238:-
BRCA	cis	rs4664293	0.647	rs10202352	ENSG00000224152.1	AC009506.1	-3.97	7.58e-05	0.00492	-0.13	-0.12	Monocyte percentage of white cells;	chr2:159571097	chr2:159615296~159617082:+
BRCA	cis	rs4664293	0.647	rs1425040	ENSG00000224152.1	AC009506.1	-3.97	7.58e-05	0.00492	-0.13	-0.12	Monocyte percentage of white cells;	chr2:159571912	chr2:159615296~159617082:+
BRCA	cis	rs4664293	0.625	rs11693108	ENSG00000224152.1	AC009506.1	-3.97	7.58e-05	0.00492	-0.13	-0.12	Monocyte percentage of white cells;	chr2:159572076	chr2:159615296~159617082:+
BRCA	cis	rs2777491	0.574	rs1757468	ENSG00000247556.5	OIP5-AS1	3.97	7.58e-05	0.00493	0.14	0.12	Ulcerative colitis;	chr15:41451376	chr15:41283990~41309737:+
BRCA	cis	rs7818688	1	rs34700722	ENSG00000245080.5	RP11-320N21.1	-3.97	7.58e-05	0.00493	-0.2	-0.12	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95009648	chr8:95066808~95073182:-
BRCA	cis	rs7818688	1	rs4323442	ENSG00000245080.5	RP11-320N21.1	-3.97	7.58e-05	0.00493	-0.2	-0.12	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95010758	chr8:95066808~95073182:-
BRCA	cis	rs2439831	0.702	rs8033995	ENSG00000206991.1	RNU6-610P	-3.97	7.58e-05	0.00493	-0.2	-0.12	Lung cancer in ever smokers;	chr15:43721311	chr15:43637632~43637738:-
BRCA	cis	rs1005277	0.579	rs1740735	ENSG00000276805.1	RP11-291L22.6	3.97	7.58e-05	0.00493	0.13	0.12	Extrinsic epigenetic age acceleration;	chr10:38208849	chr10:38451030~38451785:+
BRCA	cis	rs1005277	0.522	rs1208684	ENSG00000226578.1	RP11-258F22.1	-3.97	7.58e-05	0.00493	-0.13	-0.12	Extrinsic epigenetic age acceleration;	chr10:37805008	chr10:37775371~37784131:-
BRCA	cis	rs77633900	0.803	rs2469564	ENSG00000196274.5	Metazoa_SRP	3.97	7.58e-05	0.00493	0.18	0.12	Glioma;Non-glioblastoma glioma;	chr15:76197614	chr15:76230048~76230390:-
BRCA	cis	rs17772222	0.917	rs12588535	ENSG00000258789.1	RP11-507K2.3	-3.97	7.58e-05	0.00493	-0.15	-0.12	Coronary artery calcification;	chr14:88781900	chr14:88551597~88552493:+
BRCA	cis	rs9890032	1	rs9890032	ENSG00000276250.1	CTD-2349P21.12	3.97	7.58e-05	0.00493	0.13	0.12	Hip circumference adjusted for BMI;	chr17:30838916	chr17:30803654~30804077:+
BRCA	cis	rs1348850	0.872	rs4893825	ENSG00000280374.1	RP11-337N6.3	3.97	7.59e-05	0.00493	0.17	0.12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177433959	chr2:177317715~177318471:-
BRCA	cis	rs10986311	0.537	rs10818938	ENSG00000227200.1	RP11-121A14.3	-3.97	7.59e-05	0.00493	-0.14	-0.12	Vitiligo;	chr9:124286958	chr9:124262876~124265809:+
BRCA	cis	rs1153858	1	rs66528868	ENSG00000275672.1	GATM-AS1	-3.97	7.59e-05	0.00493	-0.16	-0.12	Homoarginine levels;	chr15:45376349	chr15:45378700~45380123:+
BRCA	cis	rs1153858	1	rs7494956	ENSG00000275672.1	GATM-AS1	-3.97	7.59e-05	0.00493	-0.16	-0.12	Homoarginine levels;	chr15:45376367	chr15:45378700~45380123:+
BRCA	cis	rs875971	0.895	rs10755833	ENSG00000265600.1	AC006480.1	-3.97	7.59e-05	0.00493	-0.14	-0.12	Aortic root size;	chr7:66448930	chr7:67356680~67356779:+
BRCA	cis	rs875971	0.895	rs1833495	ENSG00000265600.1	AC006480.1	-3.97	7.59e-05	0.00493	-0.14	-0.12	Aortic root size;	chr7:66456608	chr7:67356680~67356779:+
BRCA	cis	rs875971	0.964	rs6945032	ENSG00000265600.1	AC006480.1	-3.97	7.59e-05	0.00493	-0.14	-0.12	Aortic root size;	chr7:66457499	chr7:67356680~67356779:+
BRCA	cis	rs875971	0.929	rs12673810	ENSG00000265600.1	AC006480.1	-3.97	7.59e-05	0.00493	-0.14	-0.12	Aortic root size;	chr7:66458866	chr7:67356680~67356779:+
BRCA	cis	rs875971	1	rs6961155	ENSG00000265600.1	AC006480.1	-3.97	7.59e-05	0.00493	-0.14	-0.12	Aortic root size;	chr7:66468308	chr7:67356680~67356779:+
BRCA	cis	rs875971	1	rs7789768	ENSG00000265600.1	AC006480.1	-3.97	7.59e-05	0.00493	-0.14	-0.12	Aortic root size;	chr7:66473993	chr7:67356680~67356779:+
BRCA	cis	rs875971	1	rs1363055	ENSG00000265600.1	AC006480.1	-3.97	7.59e-05	0.00493	-0.14	-0.12	Aortic root size;	chr7:66478288	chr7:67356680~67356779:+
BRCA	cis	rs875971	0.964	rs9691480	ENSG00000265600.1	AC006480.1	-3.97	7.59e-05	0.00493	-0.14	-0.12	Aortic root size;	chr7:66479319	chr7:67356680~67356779:+
BRCA	cis	rs10463316	0.817	rs730526	ENSG00000260581.1	CTB-113P19.4	3.97	7.59e-05	0.00493	0.14	0.12	Metabolite levels (Pyroglutamine);	chr5:151409671	chr5:151652275~151655449:+
BRCA	cis	rs7811142	0.887	rs35111986	ENSG00000078319.8	PMS2P1	-3.97	7.59e-05	0.00493	-0.21	-0.12	Platelet count;	chr7:100402651	chr7:100320992~100341908:-
BRCA	cis	rs2692947	0.537	rs11677429	ENSG00000168992.4	OR7E102P	3.97	7.6e-05	0.00493	0.17	0.12	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95527313	chr2:95546531~95547545:+
BRCA	cis	rs1005277	0.522	rs289647	ENSG00000226578.1	RP11-258F22.1	-3.97	7.6e-05	0.00493	-0.13	-0.12	Extrinsic epigenetic age acceleration;	chr10:37679350	chr10:37775371~37784131:-
BRCA	cis	rs8114671	0.967	rs9574	ENSG00000279253.1	RP4-614O4.13	-3.97	7.6e-05	0.00493	-0.14	-0.12	Height;	chr20:35176829	chr20:35262727~35264187:-
BRCA	cis	rs17489649	1	rs1015975	ENSG00000271849.1	CTC-332L22.1	3.97	7.6e-05	0.00493	0.16	0.12	Intelligence (multi-trait analysis);	chr5:109699629	chr5:109687802~109688329:-
BRCA	cis	rs728616	0.867	rs61860412	ENSG00000242600.5	MBL1P	3.97	7.6e-05	0.00494	0.3	0.12	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79968730	chr10:79904898~79950336:+
BRCA	cis	rs1371614	0.635	rs10196691	ENSG00000229122.1	AGBL5-IT1	-3.97	7.6e-05	0.00494	-0.13	-0.12	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26918491	chr2:27061038~27061815:+
BRCA	cis	rs2274459	0.915	rs12198383	ENSG00000249346.5	LINC01016	3.97	7.6e-05	0.00494	0.16	0.12	Obesity (extreme);	chr6:33805527	chr6:33867506~33896914:-
BRCA	cis	rs6088580	0.634	rs6059829	ENSG00000275784.1	RP5-1125A11.6	-3.97	7.6e-05	0.00494	-0.13	-0.12	Glomerular filtration rate (creatinine);	chr20:34429268	chr20:33989480~33991818:-
BRCA	cis	rs467650	0.549	rs162676	ENSG00000248489.1	CTD-2007H13.3	-3.97	7.6e-05	0.00494	-0.13	-0.12	Venous thromboembolism (SNP x SNP interaction);	chr5:98655799	chr5:98929171~98995013:+
BRCA	cis	rs112158604	1	rs112158604	ENSG00000203804.4	ADAMTSL4-AS1	-3.97	7.6e-05	0.00494	-0.13	-0.12	Lymphocyte counts;	chr1:150724325	chr1:150560202~150574552:-
BRCA	cis	rs7647973	0.961	rs6778080	ENSG00000244380.1	RP11-24C3.2	-3.97	7.6e-05	0.00494	-0.15	-0.12	Menarche (age at onset);	chr3:49279905	chr3:48440352~48446656:-
BRCA	cis	rs28374715	0.681	rs7162231	ENSG00000247556.5	OIP5-AS1	3.97	7.6e-05	0.00494	0.14	0.12	Ulcerative colitis;	chr15:41299661	chr15:41283990~41309737:+
BRCA	cis	rs5758511	0.689	rs17478227	ENSG00000226450.2	CYP2D8P	-3.97	7.6e-05	0.00494	-0.16	-0.12	Birth weight;	chr22:42258321	chr22:42149886~42155001:-
BRCA	cis	rs11168351	0.591	rs4258439	ENSG00000257763.1	OR5BK1P	-3.97	7.61e-05	0.00494	-0.12	-0.12	Bipolar disorder and schizophrenia;	chr12:48074869	chr12:48355792~48356614:-
BRCA	cis	rs1009077	0.716	rs13136296	ENSG00000245958.5	RP11-33B1.1	3.97	7.61e-05	0.00494	0.18	0.12	Endometriosis;	chr4:119622000	chr4:119454791~119552025:+
BRCA	cis	rs73201462	1	rs2811544	ENSG00000242551.2	POU5F1P6	-3.97	7.61e-05	0.00494	-0.2	-0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128264652	chr3:128674735~128677005:-
BRCA	cis	rs73201462	1	rs2811543	ENSG00000242551.2	POU5F1P6	-3.97	7.61e-05	0.00494	-0.2	-0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128264953	chr3:128674735~128677005:-
BRCA	cis	rs73201462	1	rs2811542	ENSG00000242551.2	POU5F1P6	-3.97	7.61e-05	0.00494	-0.2	-0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128264957	chr3:128674735~128677005:-
BRCA	cis	rs73201462	1	rs2811541	ENSG00000242551.2	POU5F1P6	-3.97	7.61e-05	0.00494	-0.2	-0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128265951	chr3:128674735~128677005:-
BRCA	cis	rs73201462	1	rs2811540	ENSG00000242551.2	POU5F1P6	-3.97	7.61e-05	0.00494	-0.2	-0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128266726	chr3:128674735~128677005:-
BRCA	cis	rs73201462	1	rs2811538	ENSG00000242551.2	POU5F1P6	-3.97	7.61e-05	0.00494	-0.2	-0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128267788	chr3:128674735~128677005:-
BRCA	cis	rs8054556	1	rs11901	ENSG00000261367.1	RP11-455F5.4	-3.97	7.61e-05	0.00494	-0.14	-0.12	Autism spectrum disorder or schizophrenia;	chr16:29972749	chr16:30107675~30110541:+
BRCA	cis	rs4494364	0.502	rs4842749	ENSG00000258100.1	RP11-121E16.1	3.97	7.61e-05	0.00494	0.18	0.12	Systolic blood pressure (alcohol consumption interaction);	chr12:91036531	chr12:91362196~91368606:+
BRCA	cis	rs6049003	0.622	rs6138050	ENSG00000232645.4	LINC01431	3.97	7.61e-05	0.00494	0.13	0.12	Cerebrospinal fluid biomarker levels;	chr20:23731967	chr20:23356594~23358116:-
BRCA	cis	rs6049003	0.622	rs6114249	ENSG00000232645.4	LINC01431	3.97	7.61e-05	0.00494	0.13	0.12	Cerebrospinal fluid biomarker levels;	chr20:23732309	chr20:23356594~23358116:-
BRCA	cis	rs6049003	0.622	rs4366970	ENSG00000232645.4	LINC01431	3.97	7.61e-05	0.00494	0.13	0.12	Cerebrospinal fluid biomarker levels;	chr20:23733059	chr20:23356594~23358116:-
BRCA	cis	rs711830	1	rs6433571	ENSG00000226363.3	HAGLROS	-3.97	7.61e-05	0.00494	-0.18	-0.12	Serous invasive ovarian cancer;Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;High-grade serous ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;	chr2:176174850	chr2:176177717~176179008:+
BRCA	cis	rs1075265	0.783	rs718872	ENSG00000272156.1	RP11-477N3.1	-3.97	7.61e-05	0.00494	-0.13	-0.12	Chronotype;Morning vs. evening chronotype;	chr2:53946569	chr2:54082554~54085066:+
BRCA	cis	rs957448	1	rs12680965	ENSG00000254315.1	RP11-267M23.3	3.97	7.62e-05	0.00494	0.17	0.12	Nonsyndromic cleft lip with cleft palate;	chr8:94554069	chr8:94533628~94534391:+
BRCA	cis	rs35146811	0.735	rs858505	ENSG00000214313.7	AZGP1P1	-3.97	7.62e-05	0.00494	-0.13	-0.12	Coronary artery disease;	chr7:100221954	chr7:99980762~99987535:+
BRCA	cis	rs11098499	0.913	rs67073020	ENSG00000260091.1	RP11-33B1.4	-3.97	7.62e-05	0.00494	-0.11	-0.12	Corneal astigmatism;	chr4:119231402	chr4:119409333~119410233:+
BRCA	cis	rs651907	0.557	rs7645391	ENSG00000256628.3	ZBTB11-AS1	3.97	7.62e-05	0.00494	0.15	0.12	Colorectal cancer;	chr3:101642662	chr3:101676475~101679217:+
BRCA	cis	rs4533720	0.541	rs4560357	ENSG00000248546.3	ANP32C	3.97	7.62e-05	0.00495	0.13	0.12	Urinary uromodulin levels;	chr4:164041723	chr4:164197007~164197711:-
BRCA	cis	rs771767	1	rs771767	ENSG00000244119.1	PDCL3P4	3.97	7.62e-05	0.00495	0.11	0.12	Multiple sclerosis;	chr3:102029794	chr3:101712472~101713191:+
BRCA	cis	rs7176093	0.957	rs4130436	ENSG00000259295.5	CSPG4P12	-3.97	7.62e-05	0.00495	-0.17	-0.12	Aging traits;	chr15:85814033	chr15:85191438~85213905:+
BRCA	cis	rs2148307	0.523	rs12571856	ENSG00000228339.1	AMD1P1	-3.97	7.62e-05	0.00495	-0.16	-0.12	Photic sneeze reflex;	chr10:20807916	chr10:20350049~20351100:+
BRCA	cis	rs6496932	0.755	rs56909106	ENSG00000218052.5	ADAMTS7P4	3.97	7.62e-05	0.00495	0.13	0.12	Central corneal thickness;Corneal structure;	chr15:85320817	chr15:85255369~85330334:-
BRCA	cis	rs754466	0.606	rs3740250	ENSG00000213514.2	RP11-428P16.2	3.97	7.62e-05	0.00495	0.17	0.12	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77820343	chr10:77730766~77734769:+
BRCA	cis	rs6973609	1	rs10279722	ENSG00000271122.1	RP11-379H18.1	3.97	7.63e-05	0.00495	0.13	0.12	Obesity-related traits;	chr7:35568463	chr7:35695214~35699413:+
BRCA	cis	rs7712401	0.755	rs3756362	ENSG00000251538.4	RP11-166A12.1	3.97	7.63e-05	0.00495	0.13	0.12	Mean platelet volume;	chr5:122773195	chr5:122628952~122730685:-
BRCA	cis	rs73201462	1	rs55762931	ENSG00000242551.2	POU5F1P6	3.97	7.63e-05	0.00495	0.2	0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128128832	chr3:128674735~128677005:-
BRCA	cis	rs10761482	0.769	rs1417380	ENSG00000254271.1	RP11-131N11.4	3.97	7.63e-05	0.00495	0.18	0.12	Schizophrenia;	chr10:60351528	chr10:60734342~60741828:+
BRCA	cis	rs10487112	0.87	rs12668497	ENSG00000235436.9	DPY19L2P4	-3.97	7.63e-05	0.00495	-0.13	-0.12	Perceived unattractiveness to mosquitoes;	chr7:90486162	chr7:90119400~90125600:+
BRCA	cis	rs10487112	0.87	rs12668518	ENSG00000235436.9	DPY19L2P4	-3.97	7.63e-05	0.00495	-0.13	-0.12	Perceived unattractiveness to mosquitoes;	chr7:90486182	chr7:90119400~90125600:+
BRCA	cis	rs6088580	0.634	rs2424992	ENSG00000275784.1	RP5-1125A11.6	-3.97	7.63e-05	0.00495	-0.13	-0.12	Glomerular filtration rate (creatinine);	chr20:34424254	chr20:33989480~33991818:-
BRCA	cis	rs6088580	0.634	rs6119497	ENSG00000275784.1	RP5-1125A11.6	-3.97	7.63e-05	0.00495	-0.13	-0.12	Glomerular filtration rate (creatinine);	chr20:34424723	chr20:33989480~33991818:-
BRCA	cis	rs875971	0.638	rs35986979	ENSG00000223473.2	GS1-124K5.3	-3.97	7.63e-05	0.00496	-0.09	-0.12	Aortic root size;	chr7:66624003	chr7:66491049~66493566:-
BRCA	cis	rs651907	0.557	rs11917569	ENSG00000256628.3	ZBTB11-AS1	3.97	7.63e-05	0.00496	0.16	0.12	Colorectal cancer;	chr3:101636219	chr3:101676475~101679217:+
BRCA	cis	rs651907	0.557	rs11917682	ENSG00000256628.3	ZBTB11-AS1	3.97	7.63e-05	0.00496	0.16	0.12	Colorectal cancer;	chr3:101636583	chr3:101676475~101679217:+
BRCA	cis	rs7267979	1	rs6050631	ENSG00000274973.1	RP13-401N8.7	-3.97	7.63e-05	0.00496	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25451113	chr20:25845497~25845862:+
BRCA	cis	rs78545713	0.649	rs11753717	ENSG00000241549.7	GUSBP2	-3.97	7.64e-05	0.00496	-0.21	-0.12	Iron status biomarkers (total iron binding capacity);	chr6:26219974	chr6:26871484~26956554:-
BRCA	cis	rs12893668	0.667	rs8017628	ENSG00000269940.1	RP11-73M18.7	3.97	7.64e-05	0.00496	0.14	0.12	Reticulocyte count;	chr14:103581091	chr14:103694560~103695170:+
BRCA	cis	rs11098499	0.657	rs71614442	ENSG00000260404.2	RP11-384K6.6	3.97	7.64e-05	0.00496	0.11	0.12	Corneal astigmatism;	chr4:119458191	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.954	rs2892848	ENSG00000260404.2	RP11-384K6.6	3.97	7.64e-05	0.00496	0.11	0.12	Corneal astigmatism;	chr4:119460186	chr4:118591773~118633729:+
BRCA	cis	rs72615157	0.634	rs79986079	ENSG00000242294.5	STAG3L5P	3.97	7.64e-05	0.00496	0.12	0.12	Lung function (FEV1/FVC);	chr7:100204421	chr7:100336079~100351900:+
BRCA	cis	rs11673344	0.523	rs2562605	ENSG00000276846.1	CTD-3220F14.3	3.97	7.64e-05	0.00496	0.15	0.12	Obesity-related traits;	chr19:37029302	chr19:37314868~37315620:-
BRCA	cis	rs9392556	0.829	rs617790	ENSG00000230648.1	RP3-406P24.3	3.97	7.64e-05	0.00496	0.15	0.12	Blood metabolite levels;	chr6:4115524	chr6:4018843~4021215:-
BRCA	cis	rs2274459	0.915	rs35797388	ENSG00000249346.5	LINC01016	3.97	7.65e-05	0.00496	0.16	0.12	Obesity (extreme);	chr6:33764207	chr6:33867506~33896914:-
BRCA	cis	rs2274459	1	rs34884883	ENSG00000249346.5	LINC01016	3.97	7.65e-05	0.00496	0.16	0.12	Obesity (extreme);	chr6:33800949	chr6:33867506~33896914:-
BRCA	cis	rs4722166	0.567	rs62449490	ENSG00000179428.2	AC073072.5	-3.97	7.65e-05	0.00496	-0.13	-0.12	Lung cancer;	chr7:22708872	chr7:22725395~22727620:-
BRCA	cis	rs1722141	0.634	rs1722139	ENSG00000229628.1	AC073115.7	3.97	7.65e-05	0.00496	0.16	0.12	Sitting height ratio;	chr7:46025661	chr7:45990905~46000898:+
BRCA	cis	rs739496	0.579	rs3213628	ENSG00000234608.6	MAPKAPK5-AS1	3.97	7.65e-05	0.00496	0.15	0.12	Platelet count;	chr12:111842969	chr12:111839764~111842902:-
BRCA	cis	rs4781563	0.529	rs35320671	ENSG00000242307.1	RPS26P52	-3.97	7.65e-05	0.00496	-0.18	-0.12	Bilirubin levels;	chr16:13958524	chr16:13922332~13922679:-
BRCA	cis	rs6860806	0.661	rs2136188	ENSG00000233006.5	AC034220.3	-3.97	7.65e-05	0.00496	-0.09	-0.12	Breast cancer;	chr5:132241821	chr5:132311285~132369916:-
BRCA	cis	rs7647973	1	rs62259933	ENSG00000244380.1	RP11-24C3.2	-3.97	7.65e-05	0.00496	-0.16	-0.12	Menarche (age at onset);	chr3:49432270	chr3:48440352~48446656:-
BRCA	cis	rs8062405	1	rs62036617	ENSG00000261766.1	RP11-22P6.2	-3.97	7.65e-05	0.00496	-0.12	-0.12	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28816177	chr16:28862166~28863340:-
BRCA	cis	rs4950322	0.542	rs3766519	ENSG00000237188.3	RP11-337C18.8	3.97	7.65e-05	0.00497	0.16	0.12	Protein quantitative trait loci;	chr1:147214802	chr1:147172771~147211568:+
BRCA	cis	rs7267979	1	rs2482928	ENSG00000274414.1	RP5-965G21.4	3.97	7.65e-05	0.00497	0.15	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25350894	chr20:25239007~25245229:-
BRCA	cis	rs1910358	0.507	rs1607893	ENSG00000248874.4	C5orf17	-3.97	7.65e-05	0.00497	-0.18	-0.12	Venous thromboembolism (SNP x SNP interaction);	chr5:23750000	chr5:23951348~24178263:+
BRCA	cis	rs8091660	0.624	rs6507852	ENSG00000278983.1	RP11-426J5.3	-3.97	7.65e-05	0.00497	-0.16	-0.12	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48548678	chr18:48564795~48568342:+
BRCA	cis	rs6439699	0.941	rs16844702	ENSG00000273486.1	RP11-731C17.2	3.97	7.66e-05	0.00497	0.17	0.12	Intelligence (multi-trait analysis);	chr3:137326858	chr3:136837338~136839021:-
BRCA	cis	rs6500602	0.674	rs7191664	ENSG00000280063.1	RP11-295D4.3	3.97	7.66e-05	0.00497	0.1	0.12	Schizophrenia;	chr16:4491923	chr16:4346694~4348648:-
BRCA	cis	rs794185	0.625	rs304090	ENSG00000231249.1	ITPR1-AS1	3.97	7.66e-05	0.00497	0.14	0.12	Multiple sclerosis--Brain Glutamate Levels;	chr3:4478183	chr3:4490891~4493163:-
BRCA	cis	rs7772486	0.754	rs6937661	ENSG00000270638.1	RP3-466P17.1	-3.97	7.66e-05	0.00497	-0.14	-0.12	Lobe attachment (rater-scored or self-reported);	chr6:145792163	chr6:145735570~145737218:+
BRCA	cis	rs6012564	0.819	rs1467417	ENSG00000227431.4	CSE1L-AS1	-3.97	7.66e-05	0.00497	-0.15	-0.12	Anger;	chr20:48917118	chr20:49040463~49046044:-
BRCA	cis	rs12468226	0.938	rs12464254	ENSG00000272966.1	RP11-686O6.1	3.97	7.66e-05	0.00497	0.21	0.12	Urate levels;	chr2:202301641	chr2:202336739~202337200:+
BRCA	cis	rs7520050	0.966	rs785485	ENSG00000281133.1	AL355480.3	3.97	7.66e-05	0.00497	0.14	0.12	Reticulocyte count;Red blood cell count;	chr1:46108752	chr1:45580892~45580996:-
BRCA	cis	rs2243480	1	rs12698509	ENSG00000226002.1	RP11-460N20.5	-3.97	7.66e-05	0.00497	-0.2	-0.12	Diabetic kidney disease;	chr7:65953889	chr7:65084103~65100232:+
BRCA	cis	rs2625529	0.824	rs7183749	ENSG00000260037.4	CTD-2524L6.3	-3.97	7.67e-05	0.00497	-0.18	-0.12	Red blood cell count;	chr15:72084937	chr15:71818396~71823384:+
BRCA	cis	rs8114671	0.836	rs745849	ENSG00000279253.1	RP4-614O4.13	3.97	7.67e-05	0.00497	0.14	0.12	Height;	chr20:34984375	chr20:35262727~35264187:-
BRCA	cis	rs886774	0.866	rs2108228	ENSG00000273055.1	CTB-13F3.1	-3.97	7.67e-05	0.00497	-0.12	-0.12	Ulcerative colitis;	chr7:107860468	chr7:107942116~107942740:+
BRCA	cis	rs67981189	0.679	rs221901	ENSG00000258571.1	PTTG4P	3.97	7.67e-05	0.00497	0.13	0.12	Schizophrenia;	chr14:71135509	chr14:71085482~71085833:-
BRCA	cis	rs7412746	0.658	rs8444	ENSG00000231073.1	RP11-316M1.3	3.97	7.67e-05	0.00497	0.13	0.12	Melanoma;	chr1:150966095	chr1:150973123~150975534:+
BRCA	cis	rs17270561	0.636	rs10946793	ENSG00000272462.2	U91328.19	-3.97	7.67e-05	0.00497	-0.15	-0.12	Iron status biomarkers;	chr6:25699771	chr6:25992662~26001775:+
BRCA	cis	rs10129255	0.5	rs6576230	ENSG00000254174.1	IGHV1-12	3.97	7.67e-05	0.00498	0.09	0.12	Kawasaki disease;	chr14:106778539	chr14:106122420~106122709:-
BRCA	cis	rs6496932	0.503	rs2086756	ENSG00000259630.2	CTD-2262B20.1	-3.97	7.67e-05	0.00498	-0.17	-0.12	Central corneal thickness;Corneal structure;	chr15:85424322	chr15:85415228~85415633:+
BRCA	cis	rs10895987	0.955	rs7114094	ENSG00000255200.1	AP003068.18	3.97	7.67e-05	0.00498	0.18	0.12	Blood protein levels;	chr11:65159740	chr11:65174117~65176470:-
BRCA	cis	rs11098499	0.731	rs6846966	ENSG00000260404.2	RP11-384K6.6	3.97	7.67e-05	0.00498	0.11	0.12	Corneal astigmatism;	chr4:119372053	chr4:118591773~118633729:+
BRCA	cis	rs4388249	0.651	rs31607	ENSG00000271849.1	CTC-332L22.1	3.97	7.68e-05	0.00498	0.22	0.12	Schizophrenia;	chr5:109663965	chr5:109687802~109688329:-
BRCA	cis	rs2834288	0.618	rs9977699	ENSG00000237945.6	LINC00649	-3.97	7.68e-05	0.00498	-0.15	-0.12	Gut microbiota (bacterial taxa);	chr21:33978601	chr21:33915534~33977691:+
BRCA	cis	rs2451932	0.744	rs692979	ENSG00000251050.1	RP11-168A11.4	-3.97	7.68e-05	0.00498	-0.13	-0.12	LDL peak particle diameter (total fat intake interaction);	chr5:80057718	chr5:80019609~80019920:+
BRCA	cis	rs8062405	1	rs62036616	ENSG00000261766.1	RP11-22P6.2	-3.97	7.68e-05	0.00498	-0.13	-0.12	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814986	chr16:28862166~28863340:-
BRCA	cis	rs4819052	1	rs2838830	ENSG00000184274.3	LINC00315	-3.97	7.68e-05	0.00498	-0.18	-0.12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244312	chr21:45300245~45305257:-
BRCA	cis	rs11239930	0.517	rs678111	ENSG00000237188.3	RP11-337C18.8	3.97	7.68e-05	0.00498	0.14	0.12	AIDS progression;	chr1:147076613	chr1:147172771~147211568:+
BRCA	cis	rs1722141	0.601	rs788745	ENSG00000237471.1	AC073115.6	3.97	7.68e-05	0.00498	0.16	0.12	Sitting height ratio;	chr7:46026553	chr7:45969657~45980191:+
BRCA	cis	rs1005277	0.579	rs2472178	ENSG00000272983.1	RP11-508N22.12	3.97	7.68e-05	0.00498	0.13	0.12	Extrinsic epigenetic age acceleration;	chr10:38095822	chr10:38137337~38144399:+
BRCA	cis	rs1005277	0.579	rs2474572	ENSG00000272983.1	RP11-508N22.12	3.97	7.68e-05	0.00498	0.13	0.12	Extrinsic epigenetic age acceleration;	chr10:38096388	chr10:38137337~38144399:+
BRCA	cis	rs7246967	0.736	rs411131	ENSG00000198153.8	ZNF849P	-3.97	7.68e-05	0.00498	-0.18	-0.12	Bronchopulmonary dysplasia;	chr19:22810637	chr19:22685167~22686732:+
BRCA	cis	rs721917	0.525	rs4281433	ENSG00000225484.5	NUTM2B-AS1	-3.97	7.69e-05	0.00498	-0.16	-0.12	Chronic obstructive pulmonary disease;	chr10:79982904	chr10:79663088~79826594:-
BRCA	cis	rs9595908	0.785	rs7331393	ENSG00000212293.1	SNORA16	-3.97	7.69e-05	0.00498	-0.13	-0.12	Body mass index;	chr13:32647065	chr13:32420390~32420516:-
BRCA	cis	rs4689592	0.513	rs3857177	ENSG00000245468.3	RP11-367J11.3	3.97	7.69e-05	0.00498	0.13	0.12	Monocyte percentage of white cells;	chr4:7064605	chr4:7094571~7103385:-
BRCA	cis	rs73201462	1	rs2811396	ENSG00000242551.2	POU5F1P6	-3.97	7.69e-05	0.00498	-0.2	-0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128268513	chr3:128674735~128677005:-
BRCA	cis	rs35520189	0.857	rs2708914	ENSG00000274877.1	RP11-65I12.1	3.97	7.69e-05	0.00498	0.17	0.12	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:112869657	chr2:113237595~113240825:+
BRCA	cis	rs17507216	0.56	rs2871011	ENSG00000255769.6	GOLGA2P10	-3.97	7.69e-05	0.00499	-0.13	-0.12	Excessive daytime sleepiness;	chr15:82560792	chr15:82472993~82513950:-
BRCA	cis	rs4478858	0.684	rs12121165	ENSG00000260386.4	LINC01225	-3.97	7.69e-05	0.00499	-0.14	-0.12	Alcohol dependence;	chr1:31252695	chr1:31500085~31540885:+
BRCA	cis	rs11742741	0.777	rs1346495	ENSG00000248874.4	C5orf17	-3.97	7.69e-05	0.00499	-0.16	-0.12	Educational attainment;	chr5:24064630	chr5:23951348~24178263:+
BRCA	cis	rs62184315	0.536	rs56137655	ENSG00000253559.1	OSGEPL1-AS1	-3.97	7.69e-05	0.00499	-0.21	-0.12	Alcohol dependence (age at onset);	chr2:189675844	chr2:189762704~189765556:+
BRCA	cis	rs6463739	0.746	rs10239371	ENSG00000219545.8	UMAD1	3.97	7.7e-05	0.00499	0.12	0.12	Small cell lung carcinoma;	chr7:7859257	chr7:7640711~8004059:+
BRCA	cis	rs11098499	0.82	rs28535956	ENSG00000225892.3	RP11-384K6.2	-3.97	7.7e-05	0.00499	-0.13	-0.12	Corneal astigmatism;	chr4:119615703	chr4:118632274~118634759:+
BRCA	cis	rs6600671	0.934	rs7528274	ENSG00000231429.2	RP11-343N15.2	-3.97	7.7e-05	0.00499	-0.15	-0.12	Hip geometry;	chr1:121545103	chr1:121412719~121429274:+
BRCA	cis	rs801193	1	rs2659906	ENSG00000265600.1	AC006480.1	-3.97	7.7e-05	0.00499	-0.14	-0.12	Aortic root size;	chr7:66700323	chr7:67356680~67356779:+
BRCA	cis	rs1005277	0.579	rs932538	ENSG00000272983.1	RP11-508N22.12	3.97	7.7e-05	0.00499	0.13	0.12	Extrinsic epigenetic age acceleration;	chr10:38092386	chr10:38137337~38144399:+
BRCA	cis	rs6088580	0.634	rs4911153	ENSG00000276073.1	RP5-1125A11.7	3.97	7.7e-05	0.00499	0.13	0.12	Glomerular filtration rate (creatinine);	chr20:34373741	chr20:33985617~33988989:-
BRCA	cis	rs4266144	1	rs4266144	ENSG00000241770.1	RP11-555M1.3	-3.97	7.7e-05	0.00499	-0.16	-0.12	Coronary artery disease;	chr3:157134803	chr3:157163452~157169133:+
BRCA	cis	rs1479090	0.805	rs1479089	ENSG00000250027.1	RP11-563E2.2	-3.97	7.7e-05	0.00499	-0.16	-0.12	Lung cancer;	chr4:163146076	chr4:163108785~163119965:+
BRCA	cis	rs149866169	1	rs149866169	ENSG00000216901.1	AL022393.7	3.97	7.7e-05	0.00499	0.27	0.12	Subjective well-being (multi-trait analysis);Lung cancer;Neuroticism (multi-trait analysis);Lung cancer in ever smokers;Squamous cell lung carcinoma;	chr6:27473944	chr6:28176188~28176674:+
BRCA	cis	rs4835473	0.932	rs2060656	ENSG00000246448.2	RP13-578N3.3	-3.97	7.7e-05	0.00499	-0.14	-0.12	Immature fraction of reticulocytes;	chr4:143739330	chr4:143700257~143865072:+
BRCA	cis	rs2251381	0.75	rs2251087	ENSG00000232855.5	AF131217.1	-3.97	7.7e-05	0.00499	-0.16	-0.12	Selective IgA deficiency;	chr21:29155678	chr21:28439346~28674848:-
BRCA	cis	rs2251381	0.75	rs2776250	ENSG00000232855.5	AF131217.1	-3.97	7.7e-05	0.00499	-0.16	-0.12	Selective IgA deficiency;	chr21:29155773	chr21:28439346~28674848:-
BRCA	cis	rs6600671	1	rs6600669	ENSG00000231429.2	RP11-343N15.2	-3.97	7.7e-05	0.00499	-0.15	-0.12	Hip geometry;	chr1:121471785	chr1:121412719~121429274:+
BRCA	cis	rs11642862	1	rs11645175	ENSG00000280211.1	RP11-2C24.3	-3.97	7.7e-05	0.00499	-0.2	-0.12	Tonsillectomy;	chr16:30791978	chr16:30773532~30776033:-
BRCA	cis	rs6012564	1	rs6063360	ENSG00000222365.1	SNORD12B	3.97	7.7e-05	0.00499	0.13	0.12	Anger;	chr20:49131838	chr20:49280319~49280409:+
BRCA	cis	rs17301013	0.932	rs444678	ENSG00000234741.6	GAS5	3.97	7.7e-05	0.00499	0.12	0.12	Systemic lupus erythematosus;	chr1:174706080	chr1:173863900~173868882:-
BRCA	cis	rs11098499	0.865	rs11098513	ENSG00000250412.1	KLHL2P1	3.97	7.7e-05	0.00499	0.14	0.12	Corneal astigmatism;	chr4:119394920	chr4:119334329~119378233:+
BRCA	cis	rs6480314	0.831	rs1900009	ENSG00000233590.1	RP11-153K11.3	-3.97	7.71e-05	0.00499	-0.2	-0.12	Optic nerve measurement (disc area);	chr10:68217940	chr10:68233251~68242379:-
BRCA	cis	rs7712401	0.592	rs154515	ENSG00000251538.4	RP11-166A12.1	3.97	7.71e-05	0.00499	0.13	0.12	Mean platelet volume;	chr5:122855450	chr5:122628952~122730685:-
BRCA	cis	rs11088226	0.801	rs2833886	ENSG00000186842.4	LINC00846	-3.97	7.71e-05	0.005	-0.18	-0.12	Gastritis;	chr21:32551562	chr21:32572238~32575881:-
BRCA	cis	rs10170310	0.515	rs13004492	ENSG00000241772.2	AC092620.2	-3.97	7.71e-05	0.005	-0.2	-0.12	Response to antipsychotic treatment;	chr2:138545978	chr2:138569090~138574458:+
BRCA	cis	rs10487112	0.87	rs978103	ENSG00000235436.9	DPY19L2P4	3.97	7.71e-05	0.005	0.13	0.12	Perceived unattractiveness to mosquitoes;	chr7:90483232	chr7:90119400~90125600:+
BRCA	cis	rs6088580	0.524	rs6087616	ENSG00000279253.1	RP4-614O4.13	3.97	7.71e-05	0.005	0.14	0.12	Glomerular filtration rate (creatinine);	chr20:34675229	chr20:35262727~35264187:-
BRCA	cis	rs6430585	0.528	rs7573555	ENSG00000231890.6	DARS-AS1	3.97	7.71e-05	0.005	0.19	0.12	Corneal structure;	chr2:135937335	chr2:135985176~136022593:+
BRCA	cis	rs7615952	0.546	rs16836896	ENSG00000171084.14	FAM86JP	3.97	7.71e-05	0.005	0.21	0.12	Blood pressure (smoking interaction);	chr3:125592418	chr3:125916620~125930024:+
BRCA	cis	rs9921338	0.961	rs6498185	ENSG00000263080.1	RP11-485G7.5	3.97	7.71e-05	0.005	0.17	0.12	Vein graft stenosis in coronary artery bypass grafting;	chr16:11350869	chr16:11341809~11345211:-
BRCA	cis	rs739401	0.611	rs402276	ENSG00000247473.2	CARS-AS1	3.97	7.71e-05	0.005	0.14	0.12	Longevity;	chr11:3030174	chr11:3029009~3041260:+
BRCA	cis	rs7940866	0.834	rs1594821	ENSG00000255455.2	RP11-890B15.3	-3.97	7.71e-05	0.005	-0.12	-0.12	Schizophrenia;	chr11:130965988	chr11:130866254~130870247:-
BRCA	cis	rs4648045	0.796	rs7683854	ENSG00000246560.2	RP11-10L12.4	3.97	7.71e-05	0.005	0.14	0.12	Lymphocyte percentage of white cells;	chr4:102608899	chr4:102828055~102844075:+
BRCA	cis	rs957448	0.561	rs13258635	ENSG00000261437.1	RP11-22C11.2	3.97	7.72e-05	0.005	0.12	0.12	Nonsyndromic cleft lip with cleft palate;	chr8:94595629	chr8:94637285~94639467:-
BRCA	cis	rs2518049	1	rs2211624	ENSG00000224034.1	RP11-445P17.8	3.97	7.72e-05	0.005	0.23	0.12	Metabolic traits;	chr10:5090948	chr10:5266033~5271236:-
BRCA	cis	rs2739330	0.796	rs5760106	ENSG00000228039.3	KB-1125A3.10	-3.97	7.72e-05	0.005	-0.14	-0.12	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23963780~23964374:+
BRCA	cis	rs721917	0.525	rs10788338	ENSG00000225484.5	NUTM2B-AS1	-3.97	7.72e-05	0.005	-0.16	-0.12	Chronic obstructive pulmonary disease;	chr10:79973266	chr10:79663088~79826594:-
BRCA	cis	rs2380205	1	rs12253826	ENSG00000232807.2	RP11-536K7.3	3.97	7.72e-05	0.005	0.13	0.12	Breast cancer;	chr10:5844418	chr10:5934270~5945900:-
BRCA	cis	rs7246967	0.8	rs8111895	ENSG00000241282.1	RPL34P33	3.97	7.72e-05	0.005	0.24	0.12	Bronchopulmonary dysplasia;	chr19:22890403	chr19:22699352~22699685:+
BRCA	cis	rs875971	0.862	rs778736	ENSG00000273024.4	INTS4P2	-3.97	7.72e-05	0.005	-0.14	-0.12	Aortic root size;	chr7:66348861	chr7:65647864~65715661:+
BRCA	cis	rs6430585	0.697	rs6724569	ENSG00000231890.6	DARS-AS1	-3.97	7.73e-05	0.00501	-0.19	-0.12	Corneal structure;	chr2:135759400	chr2:135985176~136022593:+
BRCA	cis	rs891378	1	rs7512422	ENSG00000274245.1	RP11-357P18.2	-3.97	7.73e-05	0.00501	-0.16	-0.12	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207335605	chr1:207372559~207373252:+
BRCA	cis	rs6964587	0.9	rs6972027	ENSG00000188693.7	CYP51A1-AS1	-3.97	7.73e-05	0.00501	-0.13	-0.12	Breast cancer;	chr7:92152066	chr7:92134604~92180725:+
BRCA	cis	rs6964587	0.935	rs9770444	ENSG00000188693.7	CYP51A1-AS1	-3.97	7.73e-05	0.00501	-0.13	-0.12	Breast cancer;	chr7:92153848	chr7:92134604~92180725:+
BRCA	cis	rs10043228	0.826	rs4532392	ENSG00000271918.1	CTD-2287O16.5	-3.97	7.73e-05	0.00501	-0.15	-0.12	Asthma or chronic obstructive pulmonary disease;	chr5:116119808	chr5:116083807~116085416:-
BRCA	cis	rs7590268	0.789	rs35071299	ENSG00000279873.2	LINC01126	3.97	7.73e-05	0.00501	0.15	0.12	Orofacial clefts;	chr2:43415898	chr2:43227210~43228855:+
BRCA	cis	rs13401620	0.871	rs6542550	ENSG00000229326.3	AC069154.4	-3.97	7.73e-05	0.00501	-0.16	-0.12	Breast size;	chr2:119835004	chr2:119698623~119700151:+
BRCA	cis	rs9470794	0.831	rs77240185	ENSG00000204110.6	RP1-153P14.8	-3.97	7.73e-05	0.00501	-0.25	-0.12	Type 2 diabetes;	chr6:37828954	chr6:37507348~37535616:+
BRCA	cis	rs9470794	0.915	rs57269218	ENSG00000204110.6	RP1-153P14.8	-3.97	7.73e-05	0.00501	-0.25	-0.12	Type 2 diabetes;	chr6:37834296	chr6:37507348~37535616:+
BRCA	cis	rs7870657	0.535	rs7019370	ENSG00000236998.2	RP11-203L2.3	-3.97	7.73e-05	0.00501	-0.16	-0.12	Seasonality;	chr9:69128910	chr9:68788307~68789670:-
BRCA	cis	rs8141529	0.673	rs132548	ENSG00000272858.1	CTA-292E10.8	3.97	7.74e-05	0.00501	0.16	0.12	Lymphocyte counts;	chr22:28921571	chr22:28814914~28815662:+
BRCA	cis	rs752010	0.756	rs943374	ENSG00000230638.4	RP11-486B10.4	-3.97	7.74e-05	0.00501	-0.15	-0.12	Lupus nephritis in systemic lupus erythematosus;	chr1:41590523	chr1:41542069~41544310:+
BRCA	cis	rs6545883	0.86	rs6545848	ENSG00000212978.6	AC016747.3	-3.97	7.74e-05	0.00501	-0.16	-0.12	Tuberculosis;	chr2:61234048	chr2:61141592~61144969:-
BRCA	cis	rs10487112	0.87	rs10487115	ENSG00000235436.9	DPY19L2P4	-3.97	7.74e-05	0.00501	-0.13	-0.12	Perceived unattractiveness to mosquitoes;	chr7:90485962	chr7:90119400~90125600:+
BRCA	cis	rs801193	0.904	rs4718405	ENSG00000275400.1	RP4-756H11.5	-3.97	7.74e-05	0.00501	-0.13	-0.12	Aortic root size;	chr7:66789659	chr7:66553805~66554199:-
BRCA	cis	rs8180040	0.726	rs11130110	ENSG00000276925.1	RP11-708J19.3	-3.97	7.74e-05	0.00501	-0.14	-0.12	Colorectal cancer;	chr3:46959116	chr3:47469777~47469987:+
BRCA	cis	rs1062753	0.922	rs9611712	ENSG00000205702.9	CYP2D7	3.97	7.74e-05	0.00501	0.11	0.12	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42014989	chr22:42140203~42144577:-
BRCA	cis	rs9341808	0.727	rs9352809	ENSG00000279022.1	RP11-250B2.4	3.97	7.74e-05	0.00501	0.14	0.12	Sitting height ratio;	chr6:80289599	chr6:80440730~80441172:+
BRCA	cis	rs7620503	0.959	rs11708469	ENSG00000277241.1	RP11-114M1.3	3.97	7.74e-05	0.00501	0.14	0.12	Corneal structure;	chr3:177590930	chr3:177700346~177701072:-
BRCA	cis	rs16958440	1	rs62096476	ENSG00000267800.1	RP11-49K24.5	-3.97	7.74e-05	0.00501	-0.26	-0.12	Sitting height ratio;	chr18:47132250	chr18:47137018~47137290:+
BRCA	cis	rs16958440	1	rs62096478	ENSG00000267800.1	RP11-49K24.5	-3.97	7.74e-05	0.00501	-0.26	-0.12	Sitting height ratio;	chr18:47136038	chr18:47137018~47137290:+
BRCA	cis	rs2408955	0.522	rs2051851	ENSG00000226413.2	OR8T1P	-3.97	7.74e-05	0.00501	-0.16	-0.12	Glycated hemoglobin levels;	chr12:48092157	chr12:48442030~48442947:-
BRCA	cis	rs1722141	0.634	rs788746	ENSG00000229628.1	AC073115.7	3.97	7.74e-05	0.00501	0.16	0.12	Sitting height ratio;	chr7:46026353	chr7:45990905~46000898:+
BRCA	cis	rs11096990	0.634	rs11947159	ENSG00000249685.1	RP11-360F5.3	-3.97	7.74e-05	0.00502	-0.15	-0.12	Cognitive function;	chr4:39286900	chr4:39133913~39135608:+
BRCA	cis	rs4648045	0.734	rs4235406	ENSG00000246560.2	RP11-10L12.4	3.97	7.74e-05	0.00502	0.15	0.12	Lymphocyte percentage of white cells;	chr4:102605374	chr4:102828055~102844075:+
BRCA	cis	rs2243480	1	rs1964692	ENSG00000226002.1	RP11-460N20.5	-3.97	7.75e-05	0.00502	-0.2	-0.12	Diabetic kidney disease;	chr7:65989196	chr7:65084103~65100232:+
BRCA	cis	rs6995541	0.583	rs17152305	ENSG00000248896.2	CTD-2135J3.3	3.97	7.75e-05	0.00502	0.16	0.12	Triglyceride levels;	chr8:10762594	chr8:10729314~10771392:+
BRCA	cis	rs7772486	0.72	rs6931553	ENSG00000270638.1	RP3-466P17.1	-3.97	7.75e-05	0.00502	-0.14	-0.12	Lobe attachment (rater-scored or self-reported);	chr6:145791212	chr6:145735570~145737218:+
BRCA	cis	rs4374383	0.884	rs1996322	ENSG00000243389.1	AC012442.5	-3.97	7.75e-05	0.00502	-0.16	-0.12	Hepatitis C induced liver fibrosis;	chr2:111982669	chr2:112589040~112614431:+
BRCA	cis	rs4374383	0.884	rs1996323	ENSG00000243389.1	AC012442.5	-3.97	7.75e-05	0.00502	-0.16	-0.12	Hepatitis C induced liver fibrosis;	chr2:111982796	chr2:112589040~112614431:+
BRCA	cis	rs4073416	0.707	rs8003811	ENSG00000276116.2	FUT8-AS1	3.97	7.75e-05	0.00502	0.13	0.12	N-glycan levels;	chr14:65744532	chr14:65411170~65412690:-
BRCA	cis	rs8180040	0.966	rs57346147	ENSG00000280667.1	Y_RNA	-3.97	7.75e-05	0.00502	-0.14	-0.12	Colorectal cancer;	chr3:47369074	chr3:47501083~47501182:+
BRCA	cis	rs7829975	0.606	rs891570	ENSG00000254153.1	CTA-398F10.2	-3.97	7.75e-05	0.00502	-0.15	-0.12	Mood instability;	chr8:8936944	chr8:8456909~8461337:-
BRCA	cis	rs11098499	0.564	rs11098507	ENSG00000260404.2	RP11-384K6.6	3.97	7.75e-05	0.00502	0.11	0.12	Corneal astigmatism;	chr4:119367131	chr4:118591773~118633729:+
BRCA	cis	rs801193	1	rs2707836	ENSG00000265600.1	AC006480.1	-3.97	7.75e-05	0.00502	-0.14	-0.12	Aortic root size;	chr7:66695448	chr7:67356680~67356779:+
BRCA	cis	rs801193	0.844	rs7779971	ENSG00000265600.1	AC006480.1	-3.97	7.75e-05	0.00502	-0.14	-0.12	Aortic root size;	chr7:66696803	chr7:67356680~67356779:+
BRCA	cis	rs1912124	1	rs72744134	ENSG00000271983.1	RP11-28H5.2	3.97	7.75e-05	0.00502	0.25	0.12	Peripheral arterial disease (traffic-related air pollution interaction);	chr15:81218367	chr15:80693216~80693707:-
BRCA	cis	rs1912124	1	rs72744136	ENSG00000271983.1	RP11-28H5.2	3.97	7.75e-05	0.00502	0.25	0.12	Peripheral arterial disease (traffic-related air pollution interaction);	chr15:81219367	chr15:80693216~80693707:-
BRCA	cis	rs6964587	1	rs756647	ENSG00000188693.7	CYP51A1-AS1	-3.97	7.75e-05	0.00502	-0.13	-0.12	Breast cancer;	chr7:91957075	chr7:92134604~92180725:+
BRCA	cis	rs7412746	0.634	rs4451553	ENSG00000231073.1	RP11-316M1.3	3.97	7.76e-05	0.00502	0.13	0.12	Melanoma;	chr1:150964853	chr1:150973123~150975534:+
BRCA	cis	rs2692947	0.537	rs1345917	ENSG00000168992.4	OR7E102P	3.97	7.76e-05	0.00502	0.17	0.12	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95534855	chr2:95546531~95547545:+
BRCA	cis	rs4842666	0.915	rs6538195	ENSG00000270344.2	RP11-734K2.4	3.97	7.76e-05	0.00502	0.15	0.12	Blood pressure;	chr12:89668599	chr12:89525654~89548005:+
BRCA	cis	rs7800418	0.753	rs730558	ENSG00000214870.7	AC004540.5	3.97	7.76e-05	0.00502	0.15	0.12	Cognitive function;	chr7:26548534	chr7:26398593~26494256:+
BRCA	cis	rs7800418	0.723	rs1029556	ENSG00000214870.7	AC004540.5	3.97	7.76e-05	0.00502	0.15	0.12	Cognitive function;	chr7:26548567	chr7:26398593~26494256:+
BRCA	cis	rs7800418	0.723	rs1029557	ENSG00000214870.7	AC004540.5	3.97	7.76e-05	0.00502	0.15	0.12	Cognitive function;	chr7:26548639	chr7:26398593~26494256:+
BRCA	cis	rs13256369	0.802	rs11249884	ENSG00000254153.1	CTA-398F10.2	-3.97	7.76e-05	0.00503	-0.17	-0.12	Obesity-related traits;	chr8:8704042	chr8:8456909~8461337:-
BRCA	cis	rs9863	0.861	rs11057393	ENSG00000270028.1	RP11-380L11.4	3.97	7.76e-05	0.00503	0.16	0.12	White blood cell count;	chr12:123919222	chr12:123925461~123926083:-
BRCA	cis	rs1969253	0.803	rs863615	ENSG00000205955.4	HSP90AA5P	3.97	7.76e-05	0.00503	0.14	0.12	Major depressive disorder;	chr3:184147075	chr3:184115352~184117898:+
BRCA	cis	rs73222236	0.787	rs6806795	ENSG00000239213.4	NCK1-AS1	3.97	7.76e-05	0.00503	0.14	0.12	Coronary artery disease;	chr3:136587297	chr3:136841726~136862054:-
BRCA	cis	rs2243480	1	rs1723267	ENSG00000226002.1	RP11-460N20.5	-3.97	7.76e-05	0.00503	-0.2	-0.12	Diabetic kidney disease;	chr7:66008327	chr7:65084103~65100232:+
BRCA	cis	rs7586673	0.725	rs6757645	ENSG00000235724.7	AC009299.2	-3.97	7.77e-05	0.00503	-0.14	-0.12	Intelligence (multi-trait analysis);	chr2:161034871	chr2:161222785~161308303:-
BRCA	cis	rs7592578	0.581	rs59109438	ENSG00000272979.1	RP11-647K16.1	-3.97	7.77e-05	0.00503	-0.19	-0.12	Diastolic blood pressure;	chr2:190422957	chr2:190454092~190454521:-
BRCA	cis	rs7592578	0.639	rs61709084	ENSG00000272979.1	RP11-647K16.1	-3.97	7.77e-05	0.00503	-0.19	-0.12	Diastolic blood pressure;	chr2:190422959	chr2:190454092~190454521:-
BRCA	cis	rs875971	0.862	rs28470208	ENSG00000271064.1	RP11-792A8.3	3.97	7.77e-05	0.00503	0.14	0.12	Aortic root size;	chr7:66119713	chr7:66748838~66749077:-
BRCA	cis	rs4908769	0.624	rs2708633	ENSG00000270282.1	RP5-1115A15.2	-3.97	7.77e-05	0.00503	-0.15	-0.12	Allergy;	chr1:8379565	chr1:8512653~8513021:+
BRCA	cis	rs1396626	0.926	rs12353949	ENSG00000235501.4	RP4-639F20.1	-3.97	7.77e-05	0.00503	-0.16	-0.12	Diabetic kidney disease;	chr1:95547422	chr1:94927566~94963270:+
BRCA	cis	rs9532669	0.511	rs3783164	ENSG00000239827.7	SUGT1P3	3.97	7.77e-05	0.00503	0.14	0.12	Cervical cancer;	chr13:40806227	chr13:40908159~40921774:-
BRCA	cis	rs2836974	0.583	rs2735307	ENSG00000255568.3	BRWD1-AS2	3.97	7.77e-05	0.00503	0.12	0.12	Cognitive function;	chr21:39341432	chr21:39313935~39314962:+
BRCA	cis	rs256438	0.524	rs690284	ENSG00000251050.1	RP11-168A11.4	-3.97	7.77e-05	0.00503	-0.13	-0.12	Serum thyroid-stimulating hormone levels;	chr5:80057824	chr5:80019609~80019920:+
BRCA	cis	rs4906332	0.811	rs2756138	ENSG00000269940.1	RP11-73M18.7	-3.97	7.77e-05	0.00503	-0.14	-0.12	Coronary artery disease;	chr14:103530396	chr14:103694560~103695170:+
BRCA	cis	rs6671200	1	rs60929805	ENSG00000226026.4	RP11-57H12.3	3.97	7.77e-05	0.00503	0.26	0.12	Stearic acid (18:0) levels;	chr1:95180830	chr1:95163219~95233982:-
BRCA	cis	rs28829049	0.536	rs12405382	ENSG00000270728.1	RP4-657E11.10	-3.97	7.77e-05	0.00503	-0.13	-0.12	QRS duration in Tripanosoma cruzi seropositivity;	chr1:19222487	chr1:19297080~19297903:+
BRCA	cis	rs10849893	0.595	rs6489811	ENSG00000258435.1	RP11-711D18.2	3.97	7.77e-05	0.00503	0.13	0.12	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr12:121455823	chr12:121391962~121399859:+
BRCA	cis	rs875971	0.502	rs6460311	ENSG00000232559.3	GS1-124K5.12	-3.97	7.77e-05	0.00503	-0.17	-0.12	Aortic root size;	chr7:66646886	chr7:66554588~66576923:-
BRCA	cis	rs8099594	0.565	rs7238371	ENSG00000266696.1	RP11-30L3.2	3.97	7.77e-05	0.00503	0.14	0.12	Height;	chr18:49185269	chr18:49205912~49208781:+
BRCA	cis	rs12439619	0.846	rs28697264	ENSG00000259429.4	UBE2Q2P2	-3.97	7.77e-05	0.00503	-0.15	-0.12	Intelligence (multi-trait analysis);	chr15:82265559	chr15:82355142~82420075:+
BRCA	cis	rs853679	0.517	rs16893666	ENSG00000226314.6	ZNF192P1	3.97	7.77e-05	0.00503	0.18	0.12	Depression;	chr6:28086929	chr6:28161781~28169594:+
BRCA	cis	rs1560104	0.584	rs12921820	ENSG00000259876.1	CTD-3037G24.4	3.97	7.78e-05	0.00503	0.13	0.12	Obesity-related traits;	chr16:12606775	chr16:12556353~12557694:-
BRCA	cis	rs10129255	0.518	rs8009594	ENSG00000254174.1	IGHV1-12	3.97	7.78e-05	0.00503	0.09	0.12	Kawasaki disease;	chr14:106777494	chr14:106122420~106122709:-
BRCA	cis	rs6893300	0.785	rs7705530	ENSG00000250999.1	RP11-1379J22.5	3.97	7.78e-05	0.00503	0.16	0.12	Resting heart rate;	chr5:179763993	chr5:179657762~179664432:+
BRCA	cis	rs6893300	0.785	rs7704520	ENSG00000250999.1	RP11-1379J22.5	3.97	7.78e-05	0.00503	0.16	0.12	Resting heart rate;	chr5:179764053	chr5:179657762~179664432:+
BRCA	cis	rs875971	0.895	rs3857684	ENSG00000265600.1	AC006480.1	-3.97	7.78e-05	0.00503	-0.14	-0.12	Aortic root size;	chr7:66473171	chr7:67356680~67356779:+
BRCA	cis	rs9863	0.861	rs7312404	ENSG00000270028.1	RP11-380L11.4	3.97	7.78e-05	0.00503	0.15	0.12	White blood cell count;	chr12:123962181	chr12:123925461~123926083:-
BRCA	cis	rs7267979	1	rs6050547	ENSG00000125804.12	FAM182A	3.97	7.78e-05	0.00504	0.16	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25345376	chr20:26054655~26086917:+
BRCA	cis	rs8046148	0.724	rs8051216	ENSG00000260381.2	RP11-429P3.5	-3.97	7.78e-05	0.00504	-0.16	-0.12	Testicular germ cell tumor;	chr16:50079862	chr16:50100339~50121943:-
BRCA	cis	rs6049003	0.622	rs11699234	ENSG00000232645.4	LINC01431	3.97	7.78e-05	0.00504	0.13	0.12	Cerebrospinal fluid biomarker levels;	chr20:23739966	chr20:23356594~23358116:-
BRCA	cis	rs1437396	0.657	rs2576713	ENSG00000203327.2	AC012358.7	3.97	7.78e-05	0.00504	0.13	0.12	Alcohol dependence;	chr2:55338597	chr2:55214387~55216126:-
BRCA	cis	rs9733	0.791	rs11800059	ENSG00000203804.4	ADAMTSL4-AS1	-3.97	7.78e-05	0.00504	-0.13	-0.12	Tonsillectomy;	chr1:150678699	chr1:150560202~150574552:-
BRCA	cis	rs872863	1	rs872863	ENSG00000261094.2	RP11-355O1.11	3.97	7.78e-05	0.00504	0.18	0.12	Myopia (pathological);	chr9:123392075	chr9:122937623~122940333:+
BRCA	cis	rs17767294	0.708	rs72847377	ENSG00000219392.1	RP1-265C24.5	-3.97	7.78e-05	0.00504	-0.32	-0.12	Parkinson's disease;	chr6:27898411	chr6:28115628~28116551:+
BRCA	cis	rs9840812	0.861	rs684773	ENSG00000239213.4	NCK1-AS1	3.97	7.79e-05	0.00504	0.15	0.12	Fibrinogen levels;	chr3:136237463	chr3:136841726~136862054:-
BRCA	cis	rs721917	0.506	rs2758539	ENSG00000278616.1	BEND3P3	-3.97	7.79e-05	0.00504	-0.11	-0.12	Chronic obstructive pulmonary disease;	chr10:79894680	chr10:79682997~79685436:+
BRCA	cis	rs71566846	0.737	rs9475805	ENSG00000272541.1	XXbac-BPGBPG55C20.1	3.97	7.79e-05	0.00504	0.18	0.12	Coronary artery disease;	chr6:57264961	chr6:57855891~57856468:-
BRCA	cis	rs3768617	0.706	rs4129858	ENSG00000224468.3	RP11-181K3.4	-3.97	7.79e-05	0.00504	-0.14	-0.12	Fuchs's corneal dystrophy;	chr1:183035199	chr1:183138402~183141282:-
BRCA	cis	rs7800418	0.723	rs56104401	ENSG00000214870.7	AC004540.5	3.97	7.79e-05	0.00504	0.15	0.12	Cognitive function;	chr7:26550870	chr7:26398593~26494256:+
BRCA	cis	rs988913	0.515	rs11756299	ENSG00000261116.1	RP3-523K23.2	-3.97	7.79e-05	0.00504	-0.14	-0.12	Menarche (age at onset);	chr6:55086218	chr6:54943167~54945099:+
BRCA	cis	rs6973609	1	rs6973837	ENSG00000271122.1	RP11-379H18.1	3.97	7.79e-05	0.00504	0.13	0.12	Obesity-related traits;	chr7:35567864	chr7:35695214~35699413:+
BRCA	cis	rs7020830	0.928	rs11544336	ENSG00000260100.1	RP11-220I1.5	-3.97	7.79e-05	0.00504	-0.15	-0.12	Schizophrenia;	chr9:37089153	chr9:37078813~37079776:-
BRCA	cis	rs6452524	0.905	rs6884981	ENSG00000281327.1	LINC01338	3.97	7.79e-05	0.00504	0.14	0.12	Hypertension (SNP x SNP interaction);	chr5:83087339	chr5:82850864~82859836:-
BRCA	cis	rs10129255	1	rs11621409	ENSG00000211967.3	IGHV3-53	-3.97	7.79e-05	0.00505	-0.1	-0.12	Kawasaki disease;	chr14:106695603	chr14:106592676~106593347:-
BRCA	cis	rs1048886	0.938	rs76784072	ENSG00000271967.1	RP11-134K13.4	-3.97	7.8e-05	0.00505	-0.18	-0.12	Type 2 diabetes;	chr6:70417191	chr6:70596438~70596980:+
BRCA	cis	rs1048886	0.938	rs56397968	ENSG00000271967.1	RP11-134K13.4	-3.97	7.8e-05	0.00505	-0.18	-0.12	Type 2 diabetes;	chr6:70419103	chr6:70596438~70596980:+
BRCA	cis	rs7487075	0.859	rs7974529	ENSG00000257261.4	RP11-96H19.1	3.97	7.8e-05	0.00505	0.13	0.12	Itch intensity from mosquito bite;	chr12:46357605	chr12:46383679~46876159:+
BRCA	cis	rs4478858	0.684	rs7515988	ENSG00000260386.4	LINC01225	3.97	7.8e-05	0.00505	0.14	0.12	Alcohol dependence;	chr1:31258214	chr1:31500085~31540885:+
BRCA	cis	rs651907	0.535	rs12631513	ENSG00000256628.3	ZBTB11-AS1	3.97	7.8e-05	0.00505	0.16	0.12	Colorectal cancer;	chr3:101798632	chr3:101676475~101679217:+
BRCA	cis	rs651907	0.535	rs13094911	ENSG00000256628.3	ZBTB11-AS1	3.97	7.8e-05	0.00505	0.16	0.12	Colorectal cancer;	chr3:101800177	chr3:101676475~101679217:+
BRCA	cis	rs651907	0.535	rs11712309	ENSG00000256628.3	ZBTB11-AS1	3.97	7.8e-05	0.00505	0.16	0.12	Colorectal cancer;	chr3:101800253	chr3:101676475~101679217:+
BRCA	cis	rs651907	0.535	rs35799195	ENSG00000256628.3	ZBTB11-AS1	3.97	7.8e-05	0.00505	0.16	0.12	Colorectal cancer;	chr3:101803083	chr3:101676475~101679217:+
BRCA	cis	rs7119038	0.818	rs7942535	ENSG00000255422.1	AP002954.4	-3.97	7.8e-05	0.00505	-0.16	-0.12	Sjögren's syndrome;	chr11:118810755	chr11:118704607~118750263:+
BRCA	cis	rs11098499	0.954	rs28685688	ENSG00000260404.2	RP11-384K6.6	3.97	7.8e-05	0.00505	0.12	0.12	Corneal astigmatism;	chr4:119499179	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.954	rs7687843	ENSG00000260404.2	RP11-384K6.6	3.97	7.8e-05	0.00505	0.12	0.12	Corneal astigmatism;	chr4:119500056	chr4:118591773~118633729:+
BRCA	cis	rs6439699	1	rs6439699	ENSG00000273486.1	RP11-731C17.2	3.97	7.8e-05	0.00505	0.16	0.12	Intelligence (multi-trait analysis);	chr3:137296645	chr3:136837338~136839021:-
BRCA	cis	rs12036718	0.56	rs115210557	ENSG00000272491.1	RP5-1024N4.4	3.97	7.8e-05	0.00505	0.19	0.12	Yu-Zhi constitution type in type 2 diabetes;	chr1:48143910	chr1:48227888~48229561:-
BRCA	cis	rs12036718	0.511	rs12118572	ENSG00000272491.1	RP5-1024N4.4	3.97	7.8e-05	0.00505	0.19	0.12	Yu-Zhi constitution type in type 2 diabetes;	chr1:48144878	chr1:48227888~48229561:-
BRCA	cis	rs1008375	1	rs2215450	ENSG00000249502.1	AC006160.5	-3.97	7.8e-05	0.00505	-0.14	-0.12	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17673771	chr4:17587467~17614571:-
BRCA	cis	rs3760982	1	rs3760982	ENSG00000267191.1	RP11-15A1.2	-3.97	7.8e-05	0.00505	-0.15	-0.12	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43782361	chr19:43902001~43926545:+
BRCA	cis	rs61160187	0.582	rs888799	ENSG00000272308.1	RP11-231G3.1	-3.97	7.81e-05	0.00505	-0.14	-0.12	Educational attainment (years of education);Educational attainment (college completion);	chr5:61049363	chr5:60866457~60866935:-
BRCA	cis	rs4650943	0.586	rs2455760	ENSG00000227740.1	RP11-318C24.2	-3.97	7.81e-05	0.00505	-0.12	-0.12	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in inactive individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr1:176348523	chr1:175904762~175920513:-
BRCA	cis	rs7267979	1	rs2424704	ENSG00000277938.1	RP5-965G21.3	3.97	7.81e-05	0.00505	0.15	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25293293	chr20:25229150~25231933:+
BRCA	cis	rs7267979	1	rs6076339	ENSG00000276952.1	RP5-965G21.6	-3.97	7.81e-05	0.00505	-0.15	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25368076	chr20:25284915~25285588:-
BRCA	cis	rs6736093	1	rs7349221	ENSG00000236307.2	EEF1E1P1	-3.97	7.81e-05	0.00505	-0.15	-0.12	Coronary artery disease;	chr2:111910764	chr2:111887914~111888741:+
BRCA	cis	rs2281558	0.876	rs12625157	ENSG00000274414.1	RP5-965G21.4	-3.97	7.81e-05	0.00505	-0.17	-0.12	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25364913	chr20:25239007~25245229:-
BRCA	cis	rs1371614	0.611	rs4665922	ENSG00000229122.1	AGBL5-IT1	-3.97	7.81e-05	0.00505	-0.13	-0.12	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26911066	chr2:27061038~27061815:+
BRCA	cis	rs3820068	0.581	rs67806552	ENSG00000237301.1	RP4-680D5.2	-3.97	7.81e-05	0.00505	-0.16	-0.12	Systolic blood pressure;	chr1:15600643	chr1:15586136~15603626:-
BRCA	cis	rs10487112	0.833	rs2214100	ENSG00000235436.9	DPY19L2P4	-3.97	7.81e-05	0.00506	-0.13	-0.12	Perceived unattractiveness to mosquitoes;	chr7:90486930	chr7:90119400~90125600:+
BRCA	cis	rs10487112	0.833	rs11563867	ENSG00000235436.9	DPY19L2P4	-3.97	7.81e-05	0.00506	-0.13	-0.12	Perceived unattractiveness to mosquitoes;	chr7:90487255	chr7:90119400~90125600:+
BRCA	cis	rs2191566	0.639	rs7257749	ENSG00000266921.1	RP11-15A1.7	-3.97	7.81e-05	0.00506	-0.15	-0.12	Acute lymphoblastic leukemia (childhood);	chr19:44044513	chr19:43996896~44002836:-
BRCA	cis	rs2191566	0.691	rs59086054	ENSG00000266921.1	RP11-15A1.7	-3.97	7.81e-05	0.00506	-0.15	-0.12	Acute lymphoblastic leukemia (childhood);	chr19:44044943	chr19:43996896~44002836:-
BRCA	cis	rs875971	0.66	rs10263935	ENSG00000272831.1	RP11-792A8.4	3.97	7.81e-05	0.00506	0.11	0.12	Aortic root size;	chr7:66631041	chr7:66739829~66740385:-
BRCA	cis	rs7267979	0.816	rs8115257	ENSG00000274414.1	RP5-965G21.4	-3.97	7.81e-05	0.00506	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25227295	chr20:25239007~25245229:-
BRCA	cis	rs6439699	1	rs6439699	ENSG00000239213.4	NCK1-AS1	3.97	7.82e-05	0.00506	0.16	0.12	Intelligence (multi-trait analysis);	chr3:137296645	chr3:136841726~136862054:-
BRCA	cis	rs739496	0.947	rs34368158	ENSG00000234608.6	MAPKAPK5-AS1	3.97	7.82e-05	0.00506	0.15	0.12	Platelet count;	chr12:111408224	chr12:111839764~111842902:-
BRCA	cis	rs7267979	1	rs7019	ENSG00000277938.1	RP5-965G21.3	3.97	7.82e-05	0.00506	0.15	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25297642	chr20:25229150~25231933:+
BRCA	cis	rs71636778	0.509	rs11555809	ENSG00000260063.1	RP5-968P14.2	-3.97	7.82e-05	0.00506	-0.28	-0.12	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26890178	chr1:26692132~26694131:-
BRCA	cis	rs1124769	0.57	rs2614765	ENSG00000273674.3	CTD-2378E12.1	-3.97	7.82e-05	0.00506	-0.15	-0.12	Cognitive performance;	chr15:50851805	chr15:50839875~50908599:-
BRCA	cis	rs7811142	1	rs2406255	ENSG00000078319.8	PMS2P1	-3.97	7.82e-05	0.00506	-0.21	-0.12	Platelet count;	chr7:100456067	chr7:100320992~100341908:-
BRCA	cis	rs465969	1	rs459888	ENSG00000230177.1	RP5-1112D6.4	-3.97	7.82e-05	0.00506	-0.27	-0.12	Psoriasis;	chr6:111329953	chr6:111277932~111278742:+
BRCA	cis	rs10266483	0.705	rs660228	ENSG00000271550.1	BNIP3P11	3.97	7.82e-05	0.00506	0.16	0.12	Response to statin therapy;	chr7:64295867	chr7:64678954~64687393:-
BRCA	cis	rs7951911	0.915	rs12285394	ENSG00000254427.1	RP11-430H10.1	-3.97	7.82e-05	0.00506	-0.27	-0.12	IgG glycosylation;	chr11:45071817	chr11:45355371~45366121:+
BRCA	cis	rs9840812	0.769	rs4678428	ENSG00000273486.1	RP11-731C17.2	3.97	7.83e-05	0.00506	0.15	0.12	Fibrinogen levels;	chr3:136269570	chr3:136837338~136839021:-
BRCA	cis	rs1153858	0.943	rs67045941	ENSG00000275672.1	GATM-AS1	-3.97	7.83e-05	0.00506	-0.16	-0.12	Homoarginine levels;	chr15:45384813	chr15:45378700~45380123:+
BRCA	cis	rs1153858	1	rs67744121	ENSG00000275672.1	GATM-AS1	-3.97	7.83e-05	0.00506	-0.16	-0.12	Homoarginine levels;	chr15:45385039	chr15:45378700~45380123:+
BRCA	cis	rs490234	0.616	rs2841325	ENSG00000232630.1	PRPS1P2	3.97	7.83e-05	0.00506	0.12	0.12	Mean arterial pressure;	chr9:125401341	chr9:125150653~125151589:+
BRCA	cis	rs1008375	0.9	rs7658447	ENSG00000249502.1	AC006160.5	-3.97	7.83e-05	0.00506	-0.15	-0.12	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17577792	chr4:17587467~17614571:-
BRCA	cis	rs801193	1	rs2003301	ENSG00000229180.5	GS1-124K5.11	-3.97	7.83e-05	0.00506	-0.11	-0.12	Aortic root size;	chr7:66682669	chr7:66526088~66542624:-
BRCA	cis	rs11098499	0.954	rs3890049	ENSG00000260404.2	RP11-384K6.6	3.97	7.83e-05	0.00506	0.12	0.12	Corneal astigmatism;	chr4:119405128	chr4:118591773~118633729:+
BRCA	cis	rs1479090	0.802	rs28826687	ENSG00000250027.1	RP11-563E2.2	-3.97	7.83e-05	0.00506	-0.18	-0.12	Lung cancer;	chr4:163130618	chr4:163108785~163119965:+
BRCA	cis	rs6012564	0.89	rs6066976	ENSG00000222365.1	SNORD12B	3.97	7.83e-05	0.00507	0.13	0.12	Anger;	chr20:49134464	chr20:49280319~49280409:+
BRCA	cis	rs7181230	1	rs28587891	ENSG00000275636.1	RP11-521C20.5	3.97	7.83e-05	0.00507	0.15	0.12	Dehydroepiandrosterone sulphate levels;	chr15:40072905	chr15:40078892~40079347:+
BRCA	cis	rs875971	0.545	rs73148639	ENSG00000232559.3	GS1-124K5.12	3.97	7.83e-05	0.00507	0.17	0.12	Aortic root size;	chr7:66390342	chr7:66554588~66576923:-
BRCA	cis	rs812925	0.537	rs10865324	ENSG00000270820.4	RP11-355B11.2	-3.97	7.83e-05	0.00507	-0.13	-0.12	Immature fraction of reticulocytes;	chr2:61394172	chr2:61471188~61484130:+
BRCA	cis	rs7727544	0.625	rs3091338	ENSG00000233006.5	AC034220.3	3.97	7.83e-05	0.00507	0.09	0.12	Blood metabolite levels;	chr5:132067045	chr5:132311285~132369916:-
BRCA	cis	rs17270561	0.609	rs9379778	ENSG00000272462.2	U91328.19	-3.97	7.83e-05	0.00507	-0.15	-0.12	Iron status biomarkers;	chr6:25687351	chr6:25992662~26001775:+
BRCA	cis	rs17270561	0.609	rs4711093	ENSG00000272462.2	U91328.19	-3.97	7.83e-05	0.00507	-0.15	-0.12	Iron status biomarkers;	chr6:25687667	chr6:25992662~26001775:+
BRCA	cis	rs73222236	0.825	rs6804194	ENSG00000239213.4	NCK1-AS1	3.97	7.84e-05	0.00507	0.13	0.12	Coronary artery disease;	chr3:136441890	chr3:136841726~136862054:-
BRCA	cis	rs6430585	0.702	rs746857	ENSG00000224043.6	CCNT2-AS1	3.97	7.84e-05	0.00507	0.2	0.12	Corneal structure;	chr2:135797320	chr2:134735464~134918710:-
BRCA	cis	rs970548	0.955	rs61854156	ENSG00000230869.1	CTGLF10P	3.97	7.84e-05	0.00507	0.15	0.12	Total cholesterol levels;HDL cholesterol;HDL cholesterol levels;Cholesterol, total;	chr10:45643216	chr10:45678692~45700532:+
BRCA	cis	rs11742741	0.774	rs60092664	ENSG00000248874.4	C5orf17	-3.97	7.84e-05	0.00507	-0.16	-0.12	Educational attainment;	chr5:24059203	chr5:23951348~24178263:+
BRCA	cis	rs10411161	0.702	rs8113685	ENSG00000269483.1	AC006272.1	3.97	7.84e-05	0.00507	0.19	0.12	Breast cancer;	chr19:51880637	chr19:51839924~51843324:-
BRCA	cis	rs7819412	0.521	rs10100660	ENSG00000255046.1	RP11-297N6.4	3.97	7.84e-05	0.00507	0.15	0.12	Triglycerides;	chr8:11181376	chr8:11797928~11802568:-
BRCA	cis	rs4218	0.681	rs35204615	ENSG00000259732.1	RP11-59H7.3	-3.97	7.84e-05	0.00507	-0.15	-0.12	Social communication problems;	chr15:59099637	chr15:59121034~59133250:+
BRCA	cis	rs2243480	1	rs11538349	ENSG00000226002.1	RP11-460N20.5	-3.97	7.84e-05	0.00507	-0.2	-0.12	Diabetic kidney disease;	chr7:65956884	chr7:65084103~65100232:+
BRCA	cis	rs115575488	0.85	rs78270676	ENSG00000236804.1	RPS3AP12	3.97	7.84e-05	0.00507	0.22	0.12	Lobe attachment (rater-scored or self-reported);	chr1:119112207	chr1:119126539~119127291:-
BRCA	cis	rs34217772	1	rs35963043	ENSG00000258636.1	CTD-2298J14.2	3.97	7.84e-05	0.00507	0.17	0.12	Myopia;	chr14:41787813	chr14:41587861~41604856:-
BRCA	cis	rs34217772	1	rs72668845	ENSG00000258636.1	CTD-2298J14.2	3.97	7.84e-05	0.00507	0.17	0.12	Myopia;	chr14:41788844	chr14:41587861~41604856:-
BRCA	cis	rs924712	0.586	rs6908745	ENSG00000224984.1	RP11-524H19.2	3.97	7.84e-05	0.00507	0.15	0.12	Breast cancer;	chr6:54852409	chr6:54840118~54840855:-
BRCA	cis	rs924712	0.604	rs12194667	ENSG00000224984.1	RP11-524H19.2	3.97	7.84e-05	0.00507	0.15	0.12	Breast cancer;	chr6:54853795	chr6:54840118~54840855:-
BRCA	cis	rs12049351	0.719	rs3818237	ENSG00000229367.1	HMGN2P19	3.96	7.84e-05	0.00507	0.16	0.12	Circulating myeloperoxidase levels (plasma);	chr1:229495446	chr1:229570532~229570796:+
BRCA	cis	rs38055	0.813	rs27967	ENSG00000247796.2	CTD-2366F13.1	-3.96	7.84e-05	0.00507	-0.14	-0.12	Acne (severe);	chr5:53301705	chr5:53109842~53115126:+
BRCA	cis	rs7620503	1	rs6805429	ENSG00000228561.2	RP11-114M1.1	3.96	7.84e-05	0.00507	0.14	0.12	Corneal structure;	chr3:177581481	chr3:177683627~177691250:+
BRCA	cis	rs7637230	0.504	rs1707603	ENSG00000244119.1	PDCL3P4	3.96	7.84e-05	0.00507	0.1	0.12	Psoriasis vulgaris;Psoriasis;	chr3:101928244	chr3:101712472~101713191:+
BRCA	cis	rs3096299	0.563	rs4600467	ENSG00000261118.1	RP11-104N10.1	3.96	7.84e-05	0.00507	0.13	0.12	Multiple myeloma (IgH translocation);	chr16:89496108	chr16:89492017~89504460:-
BRCA	cis	rs875971	0.862	rs6952182	ENSG00000273024.4	INTS4P2	3.96	7.84e-05	0.00507	0.14	0.12	Aortic root size;	chr7:66218330	chr7:65647864~65715661:+
BRCA	cis	rs9633740	0.578	rs7084416	ENSG00000226659.1	RP11-137H2.4	3.96	7.85e-05	0.00507	0.21	0.12	Post bronchodilator FEV1;	chr10:80544541	chr10:80529597~80535942:-
BRCA	cis	rs7615952	0.673	rs35955861	ENSG00000248787.1	RP11-666A20.4	-3.96	7.85e-05	0.00507	-0.24	-0.12	Blood pressure (smoking interaction);	chr3:125907358	chr3:125908005~125910272:-
BRCA	cis	rs2835345	1	rs4817797	ENSG00000230479.1	AP000695.6	-3.96	7.85e-05	0.00507	-0.12	-0.12	Pulmonary function;	chr21:36429098	chr21:36430360~36481070:+
BRCA	cis	rs17507216	0.671	rs28582623	ENSG00000259429.4	UBE2Q2P2	-3.96	7.85e-05	0.00507	-0.15	-0.12	Excessive daytime sleepiness;	chr15:82577381	chr15:82355142~82420075:+
BRCA	cis	rs13401620	0.645	rs7592284	ENSG00000229326.3	AC069154.4	3.96	7.85e-05	0.00507	0.16	0.12	Breast size;	chr2:119928671	chr2:119698623~119700151:+
BRCA	cis	rs10986311	1	rs10986311	ENSG00000227200.1	RP11-121A14.3	-3.96	7.85e-05	0.00508	-0.15	-0.12	Vitiligo;	chr9:124309214	chr9:124262876~124265809:+
BRCA	cis	rs2911132	0.564	rs13181579	ENSG00000272109.1	CTD-2260A17.3	-3.96	7.85e-05	0.00508	-0.17	-0.12	Urate levels (BMI interaction);	chr5:96755234	chr5:96804353~96806105:+
BRCA	cis	rs7942368	1	rs10160660	ENSG00000254632.1	RP11-21L23.4	3.96	7.85e-05	0.00508	0.15	0.12	Endometriosis;	chr11:76763493	chr11:76759916~76768223:-
BRCA	cis	rs13401620	0.778	rs3111726	ENSG00000229326.3	AC069154.4	-3.96	7.85e-05	0.00508	-0.15	-0.12	Breast size;	chr2:119908079	chr2:119698623~119700151:+
BRCA	cis	rs8017423	0.647	rs4904673	ENSG00000275198.1	RP11-471B22.3	3.96	7.85e-05	0.00508	0.14	0.12	Mortality in heart failure;	chr14:90350994	chr14:90383365~90387973:+
BRCA	cis	rs8130944	0.964	rs4920138	ENSG00000225731.1	AP001627.1	3.96	7.85e-05	0.00508	0.14	0.12	Perceived unattractiveness to mosquitoes;	chr21:42720167	chr21:42733594~42741758:-
BRCA	cis	rs8130944	1	rs4920139	ENSG00000225731.1	AP001627.1	3.96	7.85e-05	0.00508	0.14	0.12	Perceived unattractiveness to mosquitoes;	chr21:42720204	chr21:42733594~42741758:-
BRCA	cis	rs6012564	0.963	rs6063359	ENSG00000222365.1	SNORD12B	3.96	7.85e-05	0.00508	0.13	0.12	Anger;	chr20:49128547	chr20:49280319~49280409:+
BRCA	cis	rs8026198	0.929	rs7183546	ENSG00000260571.1	BNIP3P5	3.96	7.85e-05	0.00508	0.2	0.12	Fibrinogen levels;	chr15:42346305	chr15:42313687~42314386:+
BRCA	cis	rs10129255	0.828	rs10140989	ENSG00000274576.2	IGHV2-70	3.96	7.85e-05	0.00508	0.11	0.12	Kawasaki disease;	chr14:106668657	chr14:106770577~106771020:-
BRCA	cis	rs875971	0.642	rs35526611	ENSG00000223473.2	GS1-124K5.3	-3.96	7.85e-05	0.00508	-0.09	-0.12	Aortic root size;	chr7:66629021	chr7:66491049~66493566:-
BRCA	cis	rs1953600	0.87	rs2788296	ENSG00000226659.1	RP11-137H2.4	3.96	7.85e-05	0.00508	0.16	0.12	Sarcoidosis;	chr10:80178133	chr10:80529597~80535942:-
BRCA	cis	rs6049003	0.584	rs4396779	ENSG00000232645.4	LINC01431	3.96	7.85e-05	0.00508	0.13	0.12	Cerebrospinal fluid biomarker levels;	chr20:23738159	chr20:23356594~23358116:-
BRCA	cis	rs7011507	0.589	rs11992271	ENSG00000233858.4	AC026904.1	-3.96	7.85e-05	0.00508	-0.15	-0.12	Inflammatory bowel disease;Ulcerative colitis;	chr8:48476560	chr8:48590401~48594621:+
BRCA	cis	rs11673344	0.504	rs4805204	ENSG00000276846.1	CTD-3220F14.3	3.96	7.86e-05	0.00508	0.14	0.12	Obesity-related traits;	chr19:37136666	chr19:37314868~37315620:-
BRCA	cis	rs11673344	0.504	rs4805205	ENSG00000276846.1	CTD-3220F14.3	3.96	7.86e-05	0.00508	0.14	0.12	Obesity-related traits;	chr19:37136693	chr19:37314868~37315620:-
BRCA	cis	rs2640806	0.656	rs6468500	ENSG00000253105.4	KB-1448A5.1	3.96	7.86e-05	0.00508	0.14	0.12	Obesity-related traits;	chr8:96327776	chr8:96371865~96387438:-
BRCA	cis	rs34792	0.688	rs170168	ENSG00000275910.1	RP11-680G24.6	-3.96	7.86e-05	0.00508	-0.15	-0.12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15507138	chr16:15015828~15016390:-
BRCA	cis	rs2274273	1	rs6573006	ENSG00000233924.1	AL160471.6	-3.96	7.86e-05	0.00508	-0.14	-0.12	Protein biomarker;	chr14:55143714	chr14:55004813~55005687:-
BRCA	cis	rs7155454	0.935	rs4899159	ENSG00000272158.1	RP11-840I19.5	-3.96	7.86e-05	0.00508	-0.15	-0.12	Mean corpuscular volume;Mean corpuscular hemoglobin;Red blood cell traits;	chr14:65013877	chr14:65003325~65003767:-
BRCA	cis	rs10771431	0.817	rs10843149	ENSG00000214776.8	RP11-726G1.1	-3.96	7.86e-05	0.00508	-0.13	-0.12	Breast size;	chr12:9209471	chr12:9467552~9576275:+
BRCA	cis	rs7246967	0.8	rs12985313	ENSG00000198153.8	ZNF849P	-3.96	7.86e-05	0.00508	-0.17	-0.12	Bronchopulmonary dysplasia;	chr19:22854978	chr19:22685167~22686732:+
BRCA	cis	rs7246967	0.932	rs7257731	ENSG00000198153.8	ZNF849P	-3.96	7.86e-05	0.00508	-0.17	-0.12	Bronchopulmonary dysplasia;	chr19:22860001	chr19:22685167~22686732:+
BRCA	cis	rs934734	0.967	rs17534670	ENSG00000281920.1	RP11-418H16.1	-3.96	7.86e-05	0.00508	-0.15	-0.12	Rheumatoid arthritis;	chr2:65388294	chr2:65623272~65628424:+
BRCA	cis	rs72634258	0.796	rs6703955	ENSG00000238290.1	RP11-431K24.1	3.96	7.86e-05	0.00508	0.17	0.12	Inflammatory bowel disease;	chr1:8105915	chr1:8026738~8122702:+
BRCA	cis	rs6121246	0.909	rs6058460	ENSG00000230613.1	HM13-AS1	3.96	7.86e-05	0.00508	0.18	0.12	Mean corpuscular hemoglobin;	chr20:31775268	chr20:31567707~31573263:-
BRCA	cis	rs957448	0.554	rs12680855	ENSG00000254315.1	RP11-267M23.3	3.96	7.86e-05	0.00508	0.15	0.12	Nonsyndromic cleft lip with cleft palate;	chr8:94570427	chr8:94533628~94534391:+
BRCA	cis	rs10506328	0.509	rs1920046	ENSG00000250432.4	RP11-834C11.5	3.96	7.86e-05	0.00508	0.14	0.12	Mean platelet volume;	chr12:54276271	chr12:54085132~54125992:-
BRCA	cis	rs1048886	0.808	rs17706748	ENSG00000271967.1	RP11-134K13.4	-3.96	7.86e-05	0.00508	-0.18	-0.12	Type 2 diabetes;	chr6:70430664	chr6:70596438~70596980:+
BRCA	cis	rs6991838	0.806	rs11777025	ENSG00000272155.1	RP11-707M3.3	3.96	7.86e-05	0.00508	0.11	0.12	Intelligence (multi-trait analysis);	chr8:65551438	chr8:65714334~65714778:-
BRCA	cis	rs11035577	0.632	rs10768535	ENSG00000279675.1	RP11-454H19.2	-3.96	7.87e-05	0.00509	-0.19	-0.12	Temperament (bipolar disorder);	chr11:39753547	chr11:40107244~40112599:-
BRCA	cis	rs748404	0.626	rs57938858	ENSG00000166763.7	STRCP1	3.96	7.87e-05	0.00509	0.18	0.12	Lung cancer;	chr15:43520259	chr15:43699488~43718184:-
BRCA	cis	rs7209700	0.708	rs2292865	ENSG00000228782.6	CTD-2026D20.3	-3.96	7.87e-05	0.00509	-0.14	-0.12	IgG glycosylation;	chr17:47287356	chr17:47450568~47492492:-
BRCA	cis	rs6964587	0.967	rs4729015	ENSG00000188693.7	CYP51A1-AS1	3.96	7.87e-05	0.00509	0.13	0.12	Breast cancer;	chr7:91932278	chr7:92134604~92180725:+
BRCA	cis	rs17684571	0.751	rs4415160	ENSG00000231441.1	RP11-472M19.2	-3.96	7.87e-05	0.00509	-0.19	-0.12	Schizophrenia;	chr6:56821424	chr6:56844002~56864078:+
BRCA	cis	rs11098499	0.954	rs4309825	ENSG00000250412.1	KLHL2P1	-3.96	7.87e-05	0.00509	-0.14	-0.12	Corneal astigmatism;	chr4:119393726	chr4:119334329~119378233:+
BRCA	cis	rs7896471	0.546	rs11190349	ENSG00000227695.4	DNMBP-AS1	-3.96	7.87e-05	0.00509	-0.28	-0.12	Blood protein levels;	chr10:99971826	chr10:99927010~99958381:+
BRCA	cis	rs721917	0.586	rs2758550	ENSG00000242600.5	MBL1P	3.96	7.87e-05	0.00509	0.15	0.12	Chronic obstructive pulmonary disease;	chr10:79932606	chr10:79904898~79950336:+
BRCA	cis	rs1009077	0.561	rs13107334	ENSG00000245958.5	RP11-33B1.1	3.96	7.87e-05	0.00509	0.15	0.12	Endometriosis;	chr4:119503425	chr4:119454791~119552025:+
BRCA	cis	rs7620503	0.959	rs13079175	ENSG00000277241.1	RP11-114M1.3	3.96	7.87e-05	0.00509	0.14	0.12	Corneal structure;	chr3:177591745	chr3:177700346~177701072:-
BRCA	cis	rs9527	0.544	rs3781280	ENSG00000213061.2	PFN1P11	3.96	7.87e-05	0.00509	0.16	0.12	Arsenic metabolism;	chr10:103104086	chr10:102838011~102845473:-
BRCA	cis	rs875971	0.638	rs35986979	ENSG00000232546.1	RP11-458F8.1	3.96	7.87e-05	0.00509	0.1	0.12	Aortic root size;	chr7:66624003	chr7:66848496~66858136:+
BRCA	cis	rs6600671	1	rs12047116	ENSG00000223345.3	HIST2H2BA	3.96	7.88e-05	0.00509	0.14	0.12	Hip geometry;	chr1:121443912	chr1:121108210~121117257:-
BRCA	cis	rs6600671	0.967	rs11249347	ENSG00000223345.3	HIST2H2BA	3.96	7.88e-05	0.00509	0.14	0.12	Hip geometry;	chr1:121446489	chr1:121108210~121117257:-
BRCA	cis	rs10463316	0.779	rs6896444	ENSG00000260581.1	CTB-113P19.4	3.96	7.88e-05	0.00509	0.14	0.12	Metabolite levels (Pyroglutamine);	chr5:151397796	chr5:151652275~151655449:+
BRCA	cis	rs6893300	0.785	rs12522263	ENSG00000250999.1	RP11-1379J22.5	3.96	7.88e-05	0.00509	0.16	0.12	Resting heart rate;	chr5:179749691	chr5:179657762~179664432:+
BRCA	cis	rs4073582	0.595	rs708472	ENSG00000255320.1	RP11-755F10.1	-3.96	7.88e-05	0.00509	-0.15	-0.12	Gout;	chr11:66163519	chr11:66244840~66246239:-
BRCA	cis	rs4073582	0.595	rs708471	ENSG00000255320.1	RP11-755F10.1	-3.96	7.88e-05	0.00509	-0.15	-0.12	Gout;	chr11:66163537	chr11:66244840~66246239:-
BRCA	cis	rs1065852	0.526	rs11090066	ENSG00000205702.9	CYP2D7	3.96	7.88e-05	0.00509	0.11	0.12	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42002191	chr22:42140203~42144577:-
BRCA	cis	rs11711311	1	rs2603792	ENSG00000241529.3	RN7SL767P	-3.96	7.88e-05	0.00509	-0.14	-0.12	IgG glycosylation;	chr3:113790340	chr3:113632704~113632998:+
BRCA	cis	rs4478858	0.647	rs11577679	ENSG00000260386.4	LINC01225	-3.96	7.88e-05	0.00509	-0.14	-0.12	Alcohol dependence;	chr1:31253338	chr1:31500085~31540885:+
BRCA	cis	rs409045	0.932	rs425051	ENSG00000271874.1	CTD-2024P10.2	-3.96	7.88e-05	0.00509	-0.16	-0.12	Left ventricular mass;	chr5:34628765	chr5:34651457~34651888:-
BRCA	cis	rs801193	1	rs6958520	ENSG00000229180.5	GS1-124K5.11	3.96	7.88e-05	0.00509	0.1	0.12	Aortic root size;	chr7:66686466	chr7:66526088~66542624:-
BRCA	cis	rs2625529	0.824	rs12917428	ENSG00000260037.4	CTD-2524L6.3	-3.96	7.88e-05	0.00509	-0.18	-0.12	Red blood cell count;	chr15:71929657	chr15:71818396~71823384:+
BRCA	cis	rs4415084	1	rs7720551	ENSG00000248779.1	RP11-53O19.2	3.96	7.88e-05	0.00509	0.12	0.12	Breast cancer;	chr5:44664375	chr5:44752949~44765744:+
BRCA	cis	rs7071275	0.891	rs725982	ENSG00000226864.1	ATE1-AS1	-3.96	7.88e-05	0.00509	-0.2	-0.12	Dupuytren's disease;	chr10:121674435	chr10:121928312~121951965:+
BRCA	cis	rs4237845	0.537	rs12312955	ENSG00000257159.1	RP11-58A17.3	3.96	7.88e-05	0.00509	0.15	0.12	Intelligence (multi-trait analysis);	chr12:57871440	chr12:57967058~57968399:+
BRCA	cis	rs12887734	0.524	rs4906363	ENSG00000269910.1	RP11-73M18.10	3.96	7.88e-05	0.0051	0.13	0.12	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103743902	chr14:103694516~103695050:-
BRCA	cis	rs8114671	0.562	rs6088642	ENSG00000126005.14	MMP24-AS1	-3.96	7.88e-05	0.0051	-0.14	-0.12	Height;	chr20:34895383	chr20:35216462~35278131:-
BRCA	cis	rs2274459	0.591	rs10947427	ENSG00000232940.4	HCG25	3.96	7.89e-05	0.0051	0.17	0.12	Obesity (extreme);	chr6:33676476	chr6:33249534~33254989:+
BRCA	cis	rs4449834	0.851	rs4391471	ENSG00000254432.1	RP11-33I11.2	-3.96	7.89e-05	0.0051	-0.16	-0.12	Sum eosinophil basophil counts;	chr8:60796941	chr8:60808735~60809606:-
BRCA	cis	rs6452524	0.935	rs11750799	ENSG00000281327.1	LINC01338	3.96	7.89e-05	0.0051	0.14	0.12	Hypertension (SNP x SNP interaction);	chr5:83082983	chr5:82850864~82859836:-
BRCA	cis	rs6860540	0.796	rs55635824	ENSG00000251405.2	CTB-109A12.1	-3.96	7.89e-05	0.0051	-0.17	-0.12	Inflammatory skin disease;	chr5:157466414	chr5:157362615~157460078:-
BRCA	cis	rs970548	1	rs970548	ENSG00000230869.1	CTGLF10P	3.96	7.89e-05	0.0051	0.15	0.12	Total cholesterol levels;HDL cholesterol;HDL cholesterol levels;Cholesterol, total;	chr10:45517829	chr10:45678692~45700532:+
BRCA	cis	rs930395	0.514	rs10073945	ENSG00000251141.4	RP11-53O19.1	-3.96	7.89e-05	0.0051	-0.12	-0.12	Breast cancer;	chr5:44932032	chr5:44744900~44808777:-
BRCA	cis	rs8062405	1	rs4788095	ENSG00000261766.1	RP11-22P6.2	-3.96	7.89e-05	0.0051	-0.12	-0.12	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28820038	chr16:28862166~28863340:-
BRCA	cis	rs8062405	0.964	rs72793809	ENSG00000261766.1	RP11-22P6.2	-3.96	7.89e-05	0.0051	-0.12	-0.12	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821061	chr16:28862166~28863340:-
BRCA	cis	rs7487075	0.93	rs7308910	ENSG00000272369.1	RP11-446N19.1	3.96	7.89e-05	0.0051	0.13	0.12	Itch intensity from mosquito bite;	chr12:46444459	chr12:46537502~46652550:+
BRCA	cis	rs568617	1	rs694994	ENSG00000254510.1	RP11-867G23.10	3.96	7.89e-05	0.0051	0.15	0.12	Crohn's disease;	chr11:65885838	chr11:66409158~66417137:+
BRCA	cis	rs9341808	0.538	rs7747327	ENSG00000233967.5	RP11-250B2.3	-3.96	7.89e-05	0.0051	-0.13	-0.12	Sitting height ratio;	chr6:80326057	chr6:80443344~80465927:+
BRCA	cis	rs4869313	1	rs4869313	ENSG00000248734.2	CTD-2260A17.1	-3.96	7.9e-05	0.0051	-0.13	-0.12	Pediatric autoimmune diseases;	chr5:96888176	chr5:96784777~96785999:+
BRCA	cis	rs6546537	0.503	rs7576953	ENSG00000231024.1	AC092431.3	-3.96	7.9e-05	0.0051	-0.17	-0.12	Serum thyroid-stimulating hormone levels;	chr2:69684784	chr2:69700192~69713847:-
BRCA	cis	rs2832191	0.935	rs11910475	ENSG00000232855.5	AF131217.1	3.96	7.9e-05	0.0051	0.15	0.12	Dental caries;	chr21:29147381	chr21:28439346~28674848:-
BRCA	cis	rs8114671	0.901	rs6119581	ENSG00000279253.1	RP4-614O4.13	-3.96	7.9e-05	0.0051	-0.14	-0.12	Height;	chr20:35185886	chr20:35262727~35264187:-
BRCA	cis	rs8114671	0.933	rs6087683	ENSG00000279253.1	RP4-614O4.13	-3.96	7.9e-05	0.0051	-0.14	-0.12	Height;	chr20:35186641	chr20:35262727~35264187:-
BRCA	cis	rs9470794	0.915	rs73417502	ENSG00000204110.6	RP1-153P14.8	-3.96	7.9e-05	0.0051	-0.25	-0.12	Type 2 diabetes;	chr6:37848857	chr6:37507348~37535616:+
BRCA	cis	rs9470794	0.915	rs75895612	ENSG00000204110.6	RP1-153P14.8	-3.96	7.9e-05	0.0051	-0.25	-0.12	Type 2 diabetes;	chr6:37852876	chr6:37507348~37535616:+
BRCA	cis	rs9470794	0.667	rs113604488	ENSG00000204110.6	RP1-153P14.8	-3.96	7.9e-05	0.0051	-0.25	-0.12	Type 2 diabetes;	chr6:37855228	chr6:37507348~37535616:+
BRCA	cis	rs9470794	0.915	rs73419414	ENSG00000204110.6	RP1-153P14.8	-3.96	7.9e-05	0.0051	-0.25	-0.12	Type 2 diabetes;	chr6:37855450	chr6:37507348~37535616:+
BRCA	cis	rs9470794	0.915	rs73419418	ENSG00000204110.6	RP1-153P14.8	-3.96	7.9e-05	0.0051	-0.25	-0.12	Type 2 diabetes;	chr6:37862878	chr6:37507348~37535616:+
BRCA	cis	rs9470794	0.915	rs73419422	ENSG00000204110.6	RP1-153P14.8	-3.96	7.9e-05	0.0051	-0.25	-0.12	Type 2 diabetes;	chr6:37865907	chr6:37507348~37535616:+
BRCA	cis	rs9470794	0.915	rs76151150	ENSG00000204110.6	RP1-153P14.8	-3.96	7.9e-05	0.0051	-0.25	-0.12	Type 2 diabetes;	chr6:37868565	chr6:37507348~37535616:+
BRCA	cis	rs13108904	0.875	rs10024013	ENSG00000253399.1	AC078852.2	3.96	7.9e-05	0.0051	0.13	0.12	Obesity-related traits;	chr4:1287004	chr4:1358479~1359461:+
BRCA	cis	rs739401	0.572	rs384490	ENSG00000183562.3	CTC-343N3.1	-3.96	7.9e-05	0.0051	-0.13	-0.12	Longevity;	chr11:3057655	chr11:2989863~2991344:+
BRCA	cis	rs875971	0.545	rs4718348	ENSG00000232546.1	RP11-458F8.1	3.96	7.9e-05	0.0051	0.12	0.12	Aortic root size;	chr7:66441589	chr7:66848496~66858136:+
BRCA	cis	rs7267979	1	rs6115140	ENSG00000277938.1	RP5-965G21.3	3.96	7.9e-05	0.0051	0.15	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25304871	chr20:25229150~25231933:+
BRCA	cis	rs11098499	0.955	rs13129661	ENSG00000260091.1	RP11-33B1.4	-3.96	7.9e-05	0.00511	-0.11	-0.12	Corneal astigmatism;	chr4:119231754	chr4:119409333~119410233:+
BRCA	cis	rs9309473	0.607	rs2421488	ENSG00000163016.8	ALMS1P	3.96	7.9e-05	0.00511	0.15	0.12	Metabolite levels;	chr2:73363497	chr2:73644919~73685576:+
BRCA	cis	rs12188164	0.62	rs56070387	ENSG00000188242.4	PP7080	3.96	7.9e-05	0.00511	0.17	0.12	Cystic fibrosis severity;	chr5:482416	chr5:466124~473098:-
BRCA	cis	rs4950322	0.58	rs17355419	ENSG00000244371.2	PFN1P8	-3.96	7.9e-05	0.00511	-0.16	-0.12	Protein quantitative trait loci;	chr1:147110094	chr1:146957117~146957659:-
BRCA	cis	rs4950322	0.58	rs72706428	ENSG00000244371.2	PFN1P8	-3.96	7.9e-05	0.00511	-0.16	-0.12	Protein quantitative trait loci;	chr1:147110219	chr1:146957117~146957659:-
BRCA	cis	rs4950322	0.563	rs61838944	ENSG00000244371.2	PFN1P8	-3.96	7.9e-05	0.00511	-0.16	-0.12	Protein quantitative trait loci;	chr1:147110275	chr1:146957117~146957659:-
BRCA	cis	rs10458771	0.667	rs2288361	ENSG00000227896.2	RP11-77P6.2	3.96	7.9e-05	0.00511	0.2	0.12	Amyotrophic lateral sclerosis (sporadic);	chr10:86471128	chr10:86521945~86525101:+
BRCA	cis	rs11673344	0.566	rs1545755	ENSG00000267422.1	CTD-2554C21.1	3.96	7.9e-05	0.00511	0.16	0.12	Obesity-related traits;	chr19:37490607	chr19:37779686~37792865:+
BRCA	cis	rs853679	0.517	rs2273564	ENSG00000261839.1	RP1-265C24.8	3.96	7.9e-05	0.00511	0.17	0.12	Depression;	chr6:28089816	chr6:28136849~28139678:+
BRCA	cis	rs853679	0.517	rs1853097	ENSG00000261839.1	RP1-265C24.8	3.96	7.9e-05	0.00511	0.17	0.12	Depression;	chr6:28090857	chr6:28136849~28139678:+
BRCA	cis	rs853679	0.517	rs9393888	ENSG00000261839.1	RP1-265C24.8	3.96	7.9e-05	0.00511	0.17	0.12	Depression;	chr6:28091439	chr6:28136849~28139678:+
BRCA	cis	rs853679	0.517	rs3734573	ENSG00000261839.1	RP1-265C24.8	3.96	7.9e-05	0.00511	0.17	0.12	Depression;	chr6:28091659	chr6:28136849~28139678:+
BRCA	cis	rs853679	0.517	rs3823180	ENSG00000261839.1	RP1-265C24.8	3.96	7.9e-05	0.00511	0.17	0.12	Depression;	chr6:28093966	chr6:28136849~28139678:+
BRCA	cis	rs853679	0.517	rs9368551	ENSG00000261839.1	RP1-265C24.8	3.96	7.9e-05	0.00511	0.17	0.12	Depression;	chr6:28094014	chr6:28136849~28139678:+
BRCA	cis	rs224278	0.789	rs224302	ENSG00000238280.1	RP11-436D10.3	3.96	7.9e-05	0.00511	0.15	0.12	Ewing sarcoma;	chr10:62833045	chr10:62793562~62805887:-
BRCA	cis	rs9470794	0.915	rs1041037	ENSG00000204110.6	RP1-153P14.8	-3.96	7.91e-05	0.00511	-0.25	-0.12	Type 2 diabetes;	chr6:37794778	chr6:37507348~37535616:+
BRCA	cis	rs7569084	1	rs7569084	ENSG00000237979.1	AC007389.1	-3.96	7.91e-05	0.00511	-0.14	-0.12	Sum eosinophil basophil counts;	chr2:65429835	chr2:65500993~65502138:-
BRCA	cis	rs3617	0.652	rs60332615	ENSG00000242142.1	SERBP1P3	-3.96	7.91e-05	0.00511	-0.14	-0.12	Red blood cell count;Autism spectrum disorder or schizophrenia;	chr3:52833579	chr3:53064283~53065091:-
BRCA	cis	rs2191566	0.664	rs3810406	ENSG00000266921.1	RP11-15A1.7	-3.96	7.91e-05	0.00511	-0.15	-0.12	Acute lymphoblastic leukemia (childhood);	chr19:44052228	chr19:43996896~44002836:-
BRCA	cis	rs3136202	0.684	rs836873	ENSG00000242307.1	RPS26P52	3.96	7.91e-05	0.00511	0.15	0.12	Conduct disorder (symptom count);	chr16:13981522	chr16:13922332~13922679:-
BRCA	cis	rs7615952	1	rs7616044	ENSG00000248787.1	RP11-666A20.4	-3.96	7.91e-05	0.00511	-0.2	-0.12	Blood pressure (smoking interaction);	chr3:125930511	chr3:125908005~125910272:-
BRCA	cis	rs11168351	1	rs11168351	ENSG00000257763.1	OR5BK1P	3.96	7.91e-05	0.00511	0.13	0.12	Bipolar disorder and schizophrenia;	chr12:48009982	chr12:48355792~48356614:-
BRCA	cis	rs2835872	0.828	rs702858	ENSG00000228677.1	TTC3-AS1	3.96	7.91e-05	0.00511	0.16	0.12	Electroencephalographic traits in alcoholism;	chr21:37622867	chr21:37187666~37193926:-
BRCA	cis	rs73222236	0.825	rs9819496	ENSG00000239213.4	NCK1-AS1	3.96	7.91e-05	0.00511	0.14	0.12	Coronary artery disease;	chr3:136421036	chr3:136841726~136862054:-
BRCA	cis	rs4869313	0.87	rs38029	ENSG00000248734.2	CTD-2260A17.1	-3.96	7.91e-05	0.00511	-0.13	-0.12	Pediatric autoimmune diseases;	chr5:97017519	chr5:96784777~96785999:+
BRCA	cis	rs4664293	0.647	rs7595044	ENSG00000224152.1	AC009506.1	-3.96	7.91e-05	0.00511	-0.13	-0.12	Monocyte percentage of white cells;	chr2:159589694	chr2:159615296~159617082:+
BRCA	cis	rs4664293	0.647	rs12623149	ENSG00000224152.1	AC009506.1	-3.96	7.91e-05	0.00511	-0.13	-0.12	Monocyte percentage of white cells;	chr2:159590835	chr2:159615296~159617082:+
BRCA	cis	rs8114671	0.527	rs2253484	ENSG00000126005.14	MMP24-AS1	3.96	7.91e-05	0.00511	0.14	0.12	Height;	chr20:34817460	chr20:35216462~35278131:-
BRCA	cis	rs13108904	0.935	rs1680072	ENSG00000253399.1	AC078852.2	3.96	7.91e-05	0.00511	0.13	0.12	Obesity-related traits;	chr4:1287907	chr4:1358479~1359461:+
BRCA	cis	rs11088226	0.846	rs13047501	ENSG00000186842.4	LINC00846	-3.96	7.92e-05	0.00511	-0.18	-0.12	Gastritis;	chr21:32552350	chr21:32572238~32575881:-
BRCA	cis	rs17489649	0.956	rs13355543	ENSG00000271849.1	CTC-332L22.1	-3.96	7.92e-05	0.00511	-0.15	-0.12	Intelligence (multi-trait analysis);	chr5:109844320	chr5:109687802~109688329:-
BRCA	cis	rs9341808	0.538	rs623048	ENSG00000233967.5	RP11-250B2.3	-3.96	7.92e-05	0.00511	-0.12	-0.12	Sitting height ratio;	chr6:80272199	chr6:80443344~80465927:+
BRCA	cis	rs7896471	0.546	rs11190350	ENSG00000227695.4	DNMBP-AS1	-3.96	7.92e-05	0.00511	-0.28	-0.12	Blood protein levels;	chr10:99975836	chr10:99927010~99958381:+
BRCA	cis	rs11668609	0.935	rs8113172	ENSG00000268058.1	BNIP3P40	-3.96	7.92e-05	0.00511	-0.15	-0.12	Response to taxane treatment (docetaxel);	chr19:24121251	chr19:24098425~24098980:-
BRCA	cis	rs2832191	0.967	rs1999321	ENSG00000232855.5	AF131217.1	-3.96	7.92e-05	0.00512	-0.15	-0.12	Dental caries;	chr21:29157912	chr21:28439346~28674848:-
BRCA	cis	rs853679	0.76	rs9357067	ENSG00000204709.4	LINC01556	3.96	7.92e-05	0.00512	0.19	0.12	Depression;	chr6:28242515	chr6:28943877~28944537:+
BRCA	cis	rs970548	0.909	rs55665473	ENSG00000237840.5	FAM21FP	3.96	7.92e-05	0.00512	0.16	0.12	Total cholesterol levels;HDL cholesterol;HDL cholesterol levels;Cholesterol, total;	chr10:45526557	chr10:45706431~45727231:-
BRCA	cis	rs4664293	0.867	rs6432553	ENSG00000226266.5	AC009961.3	-3.96	7.92e-05	0.00512	-0.15	-0.12	Monocyte percentage of white cells;	chr2:159720499	chr2:159670708~159712435:-
BRCA	cis	rs9733	0.596	rs11204697	ENSG00000231073.1	RP11-316M1.3	3.96	7.92e-05	0.00512	0.13	0.12	Tonsillectomy;	chr1:150686495	chr1:150973123~150975534:+
BRCA	cis	rs1153858	1	rs4625670	ENSG00000275672.1	GATM-AS1	-3.96	7.92e-05	0.00512	-0.16	-0.12	Homoarginine levels;	chr15:45360728	chr15:45378700~45380123:+
BRCA	cis	rs1153858	1	rs1049503	ENSG00000275672.1	GATM-AS1	-3.96	7.92e-05	0.00512	-0.16	-0.12	Homoarginine levels;	chr15:45361509	chr15:45378700~45380123:+
BRCA	cis	rs7520050	0.966	rs6675726	ENSG00000281133.1	AL355480.3	3.96	7.92e-05	0.00512	0.14	0.12	Reticulocyte count;Red blood cell count;	chr1:46094971	chr1:45580892~45580996:-
BRCA	cis	rs10508774	0.929	rs72784080	ENSG00000273038.2	RP11-479G22.8	3.96	7.92e-05	0.00512	0.27	0.12	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32934605	chr10:32887255~32889311:-
BRCA	cis	rs1665650	0.957	rs1638421	ENSG00000232767.1	RP11-498B4.5	-3.96	7.92e-05	0.00512	-0.13	-0.12	Colorectal cancer;	chr10:116729204	chr10:116670103~116672739:+
BRCA	cis	rs6071166	0.683	rs6027273	ENSG00000224635.1	RP4-564F22.5	3.96	7.93e-05	0.00512	0.15	0.12	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38688467	chr20:38406011~38416797:-
BRCA	cis	rs6088580	0.634	rs6088488	ENSG00000275784.1	RP5-1125A11.6	3.96	7.93e-05	0.00512	0.13	0.12	Glomerular filtration rate (creatinine);	chr20:34404825	chr20:33989480~33991818:-
BRCA	cis	rs7727544	0.545	rs10074490	ENSG00000233006.5	AC034220.3	3.96	7.93e-05	0.00512	0.09	0.12	Blood metabolite levels;	chr5:132004339	chr5:132311285~132369916:-
BRCA	cis	rs875971	1	rs12698523	ENSG00000265600.1	AC006480.1	-3.96	7.93e-05	0.00512	-0.14	-0.12	Aortic root size;	chr7:66503126	chr7:67356680~67356779:+
BRCA	cis	rs853679	0.517	rs868987	ENSG00000261839.1	RP1-265C24.8	-3.96	7.93e-05	0.00512	-0.17	-0.12	Depression;	chr6:28142370	chr6:28136849~28139678:+
BRCA	cis	rs561341	1	rs757009	ENSG00000277511.1	CTD-2095E4.5	3.96	7.93e-05	0.00512	0.16	0.12	Hip circumference adjusted for BMI;	chr17:31916918	chr17:32127595~32128454:+
BRCA	cis	rs2836974	0.545	rs8128901	ENSG00000255568.3	BRWD1-AS2	3.96	7.93e-05	0.00512	0.12	0.12	Cognitive function;	chr21:39338493	chr21:39313935~39314962:+
BRCA	cis	rs8062405	0.929	rs11150609	ENSG00000261766.1	RP11-22P6.2	-3.96	7.93e-05	0.00512	-0.12	-0.12	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28859275	chr16:28862166~28863340:-
BRCA	cis	rs1555322	0.929	rs2247828	ENSG00000261582.1	RP4-614O4.11	3.96	7.93e-05	0.00512	0.16	0.12	Attention deficit hyperactivity disorder;	chr20:35252136	chr20:35267885~35280043:-
BRCA	cis	rs16846053	0.71	rs62190662	ENSG00000227403.1	AC009299.3	3.96	7.93e-05	0.00512	0.3	0.12	Blood osmolality (transformed sodium);	chr2:161784499	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.792	rs62190664	ENSG00000227403.1	AC009299.3	3.96	7.93e-05	0.00512	0.3	0.12	Blood osmolality (transformed sodium);	chr2:161787284	chr2:161244739~161249050:+
BRCA	cis	rs9650657	0.596	rs2409674	ENSG00000154316.13	TDH	3.96	7.94e-05	0.00513	0.15	0.12	Neuroticism;	chr8:10738368	chr8:11339637~11368452:+
BRCA	cis	rs1434579	0.864	rs12978167	ENSG00000176761.7	ZNF285B	-3.96	7.94e-05	0.00513	-0.15	-0.12	Tuberculosis;	chr19:44438445	chr19:44467641~44473227:+
BRCA	cis	rs1153858	1	rs4395020	ENSG00000275672.1	GATM-AS1	-3.96	7.94e-05	0.00513	-0.16	-0.12	Homoarginine levels;	chr15:45360691	chr15:45378700~45380123:+
BRCA	cis	rs799165	1	rs799165	ENSG00000274080.1	CTA-315H11.2	3.96	7.94e-05	0.00513	0.2	0.12	Age-related diseases, mortality and associated endophenotypes;Age-related disease endophenotypes;	chr7:73637727	chr7:73609262~73611502:-
BRCA	cis	rs801193	1	rs2707836	ENSG00000229180.5	GS1-124K5.11	3.96	7.94e-05	0.00513	0.1	0.12	Aortic root size;	chr7:66695448	chr7:66526088~66542624:-
BRCA	cis	rs801193	0.844	rs7779971	ENSG00000229180.5	GS1-124K5.11	3.96	7.94e-05	0.00513	0.1	0.12	Aortic root size;	chr7:66696803	chr7:66526088~66542624:-
BRCA	cis	rs12681366	0.734	rs2919672	ENSG00000253175.1	RP11-267M23.6	3.96	7.94e-05	0.00513	0.14	0.12	Nonsyndromic cleft lip with cleft palate;	chr8:94424919	chr8:94565036~94565715:+
BRCA	cis	rs3816183	1	rs3816185	ENSG00000226491.1	FTOP1	-3.96	7.94e-05	0.00513	-0.15	-0.12	Hypospadias;	chr2:42788762	chr2:42797225~42798712:-
BRCA	cis	rs6601327	0.602	rs7829463	ENSG00000272267.2	RP11-375N15.2	3.96	7.94e-05	0.00513	0.15	0.12	Multiple myeloma (hyperdiploidy);	chr8:9792181	chr8:9555144~9556520:-
BRCA	cis	rs6570726	0.935	rs398060	ENSG00000270638.1	RP3-466P17.1	-3.96	7.94e-05	0.00513	-0.14	-0.12	Lobe attachment (rater-scored or self-reported);	chr6:145520379	chr6:145735570~145737218:+
BRCA	cis	rs5758511	0.689	rs17002947	ENSG00000227370.1	RP4-669P10.19	-3.96	7.94e-05	0.00513	-0.16	-0.12	Birth weight;	chr22:42292526	chr22:42132543~42132998:+
BRCA	cis	rs6723162	0.51	rs887885	ENSG00000237751.2	LINC01143	-3.96	7.94e-05	0.00513	-0.17	-0.12	Neurocognitive impairment in HIV-1 infection (dichotomous);	chr2:70921556	chr2:70887871~70889959:+
BRCA	cis	rs7620503	1	rs35921520	ENSG00000277241.1	RP11-114M1.3	3.96	7.94e-05	0.00513	0.14	0.12	Corneal structure;	chr3:177581444	chr3:177700346~177701072:-
BRCA	cis	rs7487075	0.78	rs10785624	ENSG00000274723.1	RP11-618L22.1	3.96	7.94e-05	0.00513	0.15	0.12	Itch intensity from mosquito bite;	chr12:46373004	chr12:46970504~46972155:+
BRCA	cis	rs7487075	0.78	rs2279559	ENSG00000274723.1	RP11-618L22.1	3.96	7.94e-05	0.00513	0.15	0.12	Itch intensity from mosquito bite;	chr12:46373392	chr12:46970504~46972155:+
BRCA	cis	rs7267979	0.899	rs2179459	ENSG00000276952.1	RP5-965G21.6	3.96	7.94e-05	0.00513	0.15	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25475505	chr20:25284915~25285588:-
BRCA	cis	rs67766926	1	rs10209620	ENSG00000271889.1	RP11-493E12.1	3.96	7.95e-05	0.00513	0.18	0.12	Inflammatory skin disease;	chr2:60946806	chr2:61151433~61162105:-
BRCA	cis	rs7487075	0.859	rs4768698	ENSG00000257261.4	RP11-96H19.1	-3.96	7.95e-05	0.00513	-0.13	-0.12	Itch intensity from mosquito bite;	chr12:46355305	chr12:46383679~46876159:+
BRCA	cis	rs801193	1	rs11773829	ENSG00000273142.1	RP11-458F8.4	3.96	7.95e-05	0.00513	0.11	0.12	Aortic root size;	chr7:66676087	chr7:66902857~66906297:+
BRCA	cis	rs11098499	0.754	rs1814813	ENSG00000225892.3	RP11-384K6.2	-3.96	7.95e-05	0.00513	-0.11	-0.12	Corneal astigmatism;	chr4:119337052	chr4:118632274~118634759:+
BRCA	cis	rs375066	0.934	rs2191564	ENSG00000278917.1	RP11-15A1.4	-3.96	7.95e-05	0.00513	-0.14	-0.12	Breast cancer;	chr19:43863459	chr19:43891233~43895411:+
BRCA	cis	rs73201462	1	rs7374227	ENSG00000242551.2	POU5F1P6	3.96	7.95e-05	0.00513	0.2	0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128282672	chr3:128674735~128677005:-
BRCA	cis	rs9309473	0.687	rs11126399	ENSG00000163016.8	ALMS1P	3.96	7.95e-05	0.00513	0.15	0.12	Metabolite levels;	chr2:73386213	chr2:73644919~73685576:+
BRCA	cis	rs721917	0.506	rs2758547	ENSG00000280355.1	RP11-119F19.5	-3.96	7.95e-05	0.00513	-0.13	-0.12	Chronic obstructive pulmonary disease;	chr10:79937368	chr10:79681973~79684094:-
BRCA	cis	rs17214007	0.877	rs11075281	ENSG00000260735.1	RP11-72I8.1	-3.96	7.96e-05	0.00514	-0.17	-0.12	Cognitive function;	chr16:15780585	chr16:15094411~15109197:+
BRCA	cis	rs2708977	0.637	rs654224	ENSG00000271569.1	IGKV1OR2-6	-3.96	7.96e-05	0.00514	-0.09	-0.12	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96414386	chr2:97355059~97355335:+
BRCA	cis	rs934734	0.532	rs13383320	ENSG00000281920.1	RP11-418H16.1	-3.96	7.96e-05	0.00514	-0.14	-0.12	Rheumatoid arthritis;	chr2:65418003	chr2:65623272~65628424:+
BRCA	cis	rs71636778	0.509	rs35108146	ENSG00000260063.1	RP5-968P14.2	-3.96	7.96e-05	0.00514	-0.27	-0.12	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26921949	chr1:26692132~26694131:-
BRCA	cis	rs71636778	0.509	rs12752711	ENSG00000260063.1	RP5-968P14.2	-3.96	7.96e-05	0.00514	-0.27	-0.12	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26923767	chr1:26692132~26694131:-
BRCA	cis	rs2478118	0.509	rs10752317	ENSG00000273474.1	RP11-295P9.12	-3.96	7.96e-05	0.00514	-0.13	-0.12	Lupus nephritis in systemic lupus erythematosus;	chr10:13669361	chr10:13675646~13675990:+
BRCA	cis	rs9527	0.59	rs10786738	ENSG00000213061.2	PFN1P11	3.96	7.96e-05	0.00514	0.16	0.12	Arsenic metabolism;	chr10:103109694	chr10:102838011~102845473:-
BRCA	cis	rs9527	0.59	rs1807298	ENSG00000213061.2	PFN1P11	3.96	7.96e-05	0.00514	0.16	0.12	Arsenic metabolism;	chr10:103110461	chr10:102838011~102845473:-
BRCA	cis	rs9527	0.59	rs2182348	ENSG00000213061.2	PFN1P11	3.96	7.96e-05	0.00514	0.16	0.12	Arsenic metabolism;	chr10:103112927	chr10:102838011~102845473:-
BRCA	cis	rs875971	0.862	rs1981799	ENSG00000265600.1	AC006480.1	-3.96	7.96e-05	0.00514	-0.14	-0.12	Aortic root size;	chr7:66490572	chr7:67356680~67356779:+
BRCA	cis	rs2367725	1	rs2367725	ENSG00000236200.4	KDM4A-AS1	-3.96	7.96e-05	0.00514	-0.13	-0.12	Aging (time to event);	chr1:43750157	chr1:43699765~43708138:-
BRCA	cis	rs1048886	0.938	rs114047845	ENSG00000271967.1	RP11-134K13.4	-3.96	7.97e-05	0.00514	-0.18	-0.12	Type 2 diabetes;	chr6:70421021	chr6:70596438~70596980:+
BRCA	cis	rs10129255	0.957	rs8009948	ENSG00000211958.2	IGHV3-38	3.96	7.97e-05	0.00514	0.1	0.12	Kawasaki disease;	chr14:106805607	chr14:106410493~106411021:-
BRCA	cis	rs9470794	0.831	rs11752692	ENSG00000204110.6	RP1-153P14.8	-3.96	7.97e-05	0.00514	-0.25	-0.12	Type 2 diabetes;	chr6:37822433	chr6:37507348~37535616:+
BRCA	cis	rs7131987	0.903	rs1991114	ENSG00000273680.1	RP11-996F15.6	3.96	7.97e-05	0.00514	0.15	0.12	QT interval;	chr12:29239149	chr12:29332733~29333383:-
BRCA	cis	rs5997397	0.934	rs6005863	ENSG00000272858.1	CTA-292E10.8	-3.96	7.97e-05	0.00514	-0.15	-0.12	Red cell distribution width;	chr22:28760460	chr22:28814914~28815662:+
BRCA	cis	rs6723162	0.51	rs4852238	ENSG00000237751.2	LINC01143	3.96	7.97e-05	0.00514	0.17	0.12	Neurocognitive impairment in HIV-1 infection (dichotomous);	chr2:70925370	chr2:70887871~70889959:+
BRCA	cis	rs7620503	0.959	rs7637965	ENSG00000277241.1	RP11-114M1.3	3.96	7.97e-05	0.00514	0.14	0.12	Corneal structure;	chr3:177589854	chr3:177700346~177701072:-
BRCA	cis	rs853679	0.517	rs9357065	ENSG00000261839.1	RP1-265C24.8	3.96	7.97e-05	0.00514	0.17	0.12	Depression;	chr6:28161802	chr6:28136849~28139678:+
BRCA	cis	rs6430585	0.646	rs1057031	ENSG00000224043.6	CCNT2-AS1	-3.96	7.97e-05	0.00514	-0.2	-0.12	Corneal structure;	chr2:135876392	chr2:134735464~134918710:-
BRCA	cis	rs2625529	0.652	rs8028115	ENSG00000260037.4	CTD-2524L6.3	3.96	7.97e-05	0.00514	0.15	0.12	Red blood cell count;	chr15:72047162	chr15:71818396~71823384:+
BRCA	cis	rs2191566	0.664	rs62115482	ENSG00000266921.1	RP11-15A1.7	-3.96	7.97e-05	0.00514	-0.15	-0.12	Acute lymphoblastic leukemia (childhood);	chr19:44049930	chr19:43996896~44002836:-
BRCA	cis	rs10771431	0.817	rs17202253	ENSG00000214776.8	RP11-726G1.1	-3.96	7.97e-05	0.00514	-0.13	-0.12	Breast size;	chr12:9209254	chr12:9467552~9576275:+
BRCA	cis	rs75422866	0.51	rs75424057	ENSG00000280054.1	RP1-197B17.7	3.96	7.97e-05	0.00514	0.29	0.12	Pneumonia;	chr12:47737294	chr12:47728151~47730598:-
BRCA	cis	rs9921338	0.961	rs4390613	ENSG00000262636.1	CTD-3088G3.4	3.96	7.97e-05	0.00515	0.2	0.12	Vein graft stenosis in coronary artery bypass grafting;	chr16:11328979	chr16:11380859~11381118:-
BRCA	cis	rs875971	0.545	rs73378304	ENSG00000232559.3	GS1-124K5.12	3.96	7.97e-05	0.00515	0.16	0.12	Aortic root size;	chr7:66175760	chr7:66554588~66576923:-
BRCA	cis	rs7071275	0.843	rs10886963	ENSG00000226864.1	ATE1-AS1	-3.96	7.97e-05	0.00515	-0.2	-0.12	Dupuytren's disease;	chr10:121670615	chr10:121928312~121951965:+
BRCA	cis	rs7071275	0.891	rs10886964	ENSG00000226864.1	ATE1-AS1	-3.96	7.97e-05	0.00515	-0.2	-0.12	Dupuytren's disease;	chr10:121670650	chr10:121928312~121951965:+
BRCA	cis	rs1048886	0.938	rs59275635	ENSG00000271967.1	RP11-134K13.4	-3.96	7.98e-05	0.00515	-0.17	-0.12	Type 2 diabetes;	chr6:70444020	chr6:70596438~70596980:+
BRCA	cis	rs6088580	0.602	rs6058064	ENSG00000275784.1	RP5-1125A11.6	-3.96	7.98e-05	0.00515	-0.13	-0.12	Glomerular filtration rate (creatinine);	chr20:34498817	chr20:33989480~33991818:-
BRCA	cis	rs7177699	0.534	rs7403708	ENSG00000261143.1	ADAMTS7P3	3.96	7.98e-05	0.00515	0.15	0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78831543	chr15:77976042~77993057:+
BRCA	cis	rs7177699	0.557	rs10083696	ENSG00000261143.1	ADAMTS7P3	3.96	7.98e-05	0.00515	0.15	0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78831674	chr15:77976042~77993057:+
BRCA	cis	rs7177699	0.557	rs10083697	ENSG00000261143.1	ADAMTS7P3	3.96	7.98e-05	0.00515	0.15	0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78831697	chr15:77976042~77993057:+
BRCA	cis	rs2731006	0.592	rs2678152	ENSG00000257114.2	RP11-25I15.3	3.96	7.98e-05	0.00515	0.2	0.12	Panic disorder;	chr12:42779257	chr12:42692216~42717119:+
BRCA	cis	rs6452524	0.905	rs6896548	ENSG00000281327.1	LINC01338	3.96	7.98e-05	0.00515	0.14	0.12	Hypertension (SNP x SNP interaction);	chr5:83089247	chr5:82850864~82859836:-
BRCA	cis	rs2625529	0.824	rs12595228	ENSG00000260037.4	CTD-2524L6.3	-3.96	7.98e-05	0.00515	-0.18	-0.12	Red blood cell count;	chr15:71974874	chr15:71818396~71823384:+
BRCA	cis	rs4326844	0.583	rs10506328	ENSG00000249388.1	RP11-834C11.6	-3.96	7.98e-05	0.00515	-0.16	-0.12	Platelet count;	chr12:54293448	chr12:54082118~54102693:+
BRCA	cis	rs11088226	0.681	rs4547609	ENSG00000186842.4	LINC00846	-3.96	7.98e-05	0.00515	-0.21	-0.12	Gastritis;	chr21:32581232	chr21:32572238~32575881:-
BRCA	cis	rs4489787	0.881	rs17834022	ENSG00000240399.1	RP1-228P16.1	-3.96	7.98e-05	0.00515	-0.23	-0.12	Prostate cancer (SNP x SNP interaction);	chr12:48560392	chr12:48054813~48055591:-
BRCA	cis	rs2235642	0.592	rs743963	ENSG00000260989.1	LA16c-395F10.2	-3.96	7.98e-05	0.00515	-0.13	-0.12	Coronary artery disease;	chr16:1607349	chr16:1580527~1610328:+
BRCA	cis	rs875971	1	rs9986696	ENSG00000229180.5	GS1-124K5.11	-3.96	7.98e-05	0.00515	-0.11	-0.12	Aortic root size;	chr7:66239589	chr7:66526088~66542624:-
BRCA	cis	rs7258465	1	rs8105994	ENSG00000273654.1	CTB-52I2.4	-3.96	7.98e-05	0.00515	-0.15	-0.12	Breast cancer;	chr19:18482743	chr19:18022403~18032099:+
BRCA	cis	rs4074961	0.565	rs10908362	ENSG00000233621.1	LINC01137	-3.96	7.99e-05	0.00515	-0.13	-0.12	Axial length;	chr1:37596105	chr1:37454879~37474411:-
BRCA	cis	rs2243480	1	rs313824	ENSG00000237026.1	RP11-328P23.2	3.96	7.99e-05	0.00515	0.23	0.12	Diabetic kidney disease;	chr7:66116220	chr7:65235790~65236723:-
BRCA	cis	rs2243480	1	rs186378	ENSG00000237026.1	RP11-328P23.2	3.96	7.99e-05	0.00515	0.23	0.12	Diabetic kidney disease;	chr7:66117071	chr7:65235790~65236723:-
BRCA	cis	rs2243480	1	rs160637	ENSG00000237026.1	RP11-328P23.2	3.96	7.99e-05	0.00515	0.23	0.12	Diabetic kidney disease;	chr7:66119331	chr7:65235790~65236723:-
BRCA	cis	rs7726839	0.561	rs11955068	ENSG00000271781.1	CTD-2589H19.6	-3.96	7.99e-05	0.00515	-0.17	-0.12	Obesity-related traits;	chr5:582209	chr5:675826~676616:+
BRCA	cis	rs8062405	1	rs62037365	ENSG00000261766.1	RP11-22P6.2	-3.96	7.99e-05	0.00515	-0.12	-0.12	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28857641	chr16:28862166~28863340:-
BRCA	cis	rs6430585	0.527	rs1900306	ENSG00000231890.6	DARS-AS1	-3.96	7.99e-05	0.00515	-0.2	-0.12	Corneal structure;	chr2:135658963	chr2:135985176~136022593:+
BRCA	cis	rs12681366	0.537	rs2919659	ENSG00000253175.1	RP11-267M23.6	3.96	7.99e-05	0.00516	0.15	0.12	Nonsyndromic cleft lip with cleft palate;	chr8:94459544	chr8:94565036~94565715:+
BRCA	cis	rs1202519	1	rs1202519	ENSG00000244137.1	RP11-99J16__A.2	-3.96	7.99e-05	0.00516	-0.14	-0.12	Colorectal cancer;	chr1:230811394	chr1:230710698~230795492:-
BRCA	cis	rs34792	0.554	rs12933773	ENSG00000275910.1	RP11-680G24.6	-3.96	7.99e-05	0.00516	-0.14	-0.12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15529325	chr16:15015828~15016390:-
BRCA	cis	rs11098499	0.863	rs3822190	ENSG00000250412.1	KLHL2P1	3.96	7.99e-05	0.00516	0.15	0.12	Corneal astigmatism;	chr4:119506943	chr4:119334329~119378233:+
BRCA	cis	rs11098499	0.863	rs3822191	ENSG00000250412.1	KLHL2P1	3.96	7.99e-05	0.00516	0.15	0.12	Corneal astigmatism;	chr4:119506946	chr4:119334329~119378233:+
BRCA	cis	rs1048886	0.872	rs41265349	ENSG00000271967.1	RP11-134K13.4	-3.96	7.99e-05	0.00516	-0.18	-0.12	Type 2 diabetes;	chr6:70428289	chr6:70596438~70596980:+
BRCA	cis	rs9527	0.59	rs1541213	ENSG00000213061.2	PFN1P11	3.96	8e-05	0.00516	0.16	0.12	Arsenic metabolism;	chr10:103125573	chr10:102838011~102845473:-
BRCA	cis	rs9527	0.59	rs10883836	ENSG00000213061.2	PFN1P11	3.96	8e-05	0.00516	0.16	0.12	Arsenic metabolism;	chr10:103131441	chr10:102838011~102845473:-
BRCA	cis	rs9527	0.59	rs11191572	ENSG00000213061.2	PFN1P11	3.96	8e-05	0.00516	0.16	0.12	Arsenic metabolism;	chr10:103133380	chr10:102838011~102845473:-
BRCA	cis	rs9527	0.59	rs12415199	ENSG00000213061.2	PFN1P11	3.96	8e-05	0.00516	0.16	0.12	Arsenic metabolism;	chr10:103135779	chr10:102838011~102845473:-
BRCA	cis	rs9527	0.59	rs34104646	ENSG00000213061.2	PFN1P11	3.96	8e-05	0.00516	0.16	0.12	Arsenic metabolism;	chr10:103136321	chr10:102838011~102845473:-
BRCA	cis	rs9527	0.567	rs11191573	ENSG00000213061.2	PFN1P11	3.96	8e-05	0.00516	0.16	0.12	Arsenic metabolism;	chr10:103137059	chr10:102838011~102845473:-
BRCA	cis	rs7071275	0.891	rs725983	ENSG00000226864.1	ATE1-AS1	-3.96	8e-05	0.00516	-0.2	-0.12	Dupuytren's disease;	chr10:121674436	chr10:121928312~121951965:+
BRCA	cis	rs6545883	0.965	rs3771258	ENSG00000270820.4	RP11-355B11.2	3.96	8e-05	0.00516	0.14	0.12	Tuberculosis;	chr2:61537005	chr2:61471188~61484130:+
BRCA	cis	rs754466	0.606	rs11002310	ENSG00000213514.2	RP11-428P16.2	3.96	8e-05	0.00516	0.17	0.12	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77836272	chr10:77730766~77734769:+
BRCA	cis	rs11098499	0.954	rs2389803	ENSG00000225892.3	RP11-384K6.2	-3.96	8e-05	0.00516	-0.12	-0.12	Corneal astigmatism;	chr4:119472356	chr4:118632274~118634759:+
BRCA	cis	rs7201929	1	rs8061877	ENSG00000278665.1	RP11-666O2.4	-3.96	8e-05	0.00516	-0.13	-0.12	QT interval;	chr16:28845498	chr16:28599241~28601881:-
BRCA	cis	rs972578	0.967	rs2038058	ENSG00000230319.1	AL022476.2	3.96	8e-05	0.00516	0.13	0.12	Mean platelet volume;	chr22:42938289	chr22:43038585~43052366:+
BRCA	cis	rs875971	0.895	rs12698520	ENSG00000265600.1	AC006480.1	-3.96	8e-05	0.00516	-0.14	-0.12	Aortic root size;	chr7:66453720	chr7:67356680~67356779:+
BRCA	cis	rs11642862	1	rs11642862	ENSG00000280211.1	RP11-2C24.3	3.96	8e-05	0.00516	0.18	0.12	Tonsillectomy;	chr16:30774503	chr16:30773532~30776033:-
BRCA	cis	rs11711311	1	rs1043132	ENSG00000241529.3	RN7SL767P	-3.96	8e-05	0.00516	-0.14	-0.12	IgG glycosylation;	chr3:113809842	chr3:113632704~113632998:+
BRCA	cis	rs4326844	0.583	rs10506328	ENSG00000248265.1	FLJ12825	3.96	8e-05	0.00516	0.16	0.12	Platelet count;	chr12:54293448	chr12:54058254~54122234:+
BRCA	cis	rs2842992	0.692	rs9347342	ENSG00000251988.1	RNU4ATAC18P	3.96	8e-05	0.00516	0.15	0.12	Age-related macular degeneration (geographic atrophy);	chr6:159772097	chr6:159720415~159720540:-
BRCA	cis	rs2242116	0.796	rs4683296	ENSG00000276925.1	RP11-708J19.3	3.96	8.01e-05	0.00516	0.15	0.12	Birth weight;	chr3:46932330	chr3:47469777~47469987:+
BRCA	cis	rs8114671	0.773	rs3746438	ENSG00000279253.1	RP4-614O4.13	3.96	8.01e-05	0.00516	0.14	0.12	Height;	chr20:34996486	chr20:35262727~35264187:-
BRCA	cis	rs115575488	0.778	rs17023073	ENSG00000236804.1	RPS3AP12	3.96	8.01e-05	0.00516	0.21	0.12	Lobe attachment (rater-scored or self-reported);	chr1:119027128	chr1:119126539~119127291:-
BRCA	cis	rs2243480	1	rs160643	ENSG00000222364.1	RNU6-96P	-3.96	8.01e-05	0.00517	-0.21	-0.12	Diabetic kidney disease;	chr7:66093235	chr7:66395191~66395286:+
BRCA	cis	rs8114671	0.662	rs6088664	ENSG00000279253.1	RP4-614O4.13	-3.96	8.01e-05	0.00517	-0.14	-0.12	Height;	chr20:34963297	chr20:35262727~35264187:-
BRCA	cis	rs7624327	0.831	rs6793284	ENSG00000241770.1	RP11-555M1.3	-3.96	8.01e-05	0.00517	-0.23	-0.12	Eating disorders;	chr3:157103964	chr3:157163452~157169133:+
BRCA	cis	rs4713118	0.621	rs4713132	ENSG00000272009.1	RP1-313I6.12	-3.96	8.01e-05	0.00517	-0.18	-0.12	Parkinson's disease;	chr6:28066257	chr6:28078792~28081130:-
BRCA	cis	rs4713118	0.621	rs4713133	ENSG00000272009.1	RP1-313I6.12	-3.96	8.01e-05	0.00517	-0.18	-0.12	Parkinson's disease;	chr6:28066263	chr6:28078792~28081130:-
BRCA	cis	rs4713118	0.621	rs4713134	ENSG00000272009.1	RP1-313I6.12	-3.96	8.01e-05	0.00517	-0.18	-0.12	Parkinson's disease;	chr6:28066343	chr6:28078792~28081130:-
BRCA	cis	rs17270561	0.779	rs1165200	ENSG00000272462.2	U91328.19	3.96	8.01e-05	0.00517	0.16	0.12	Iron status biomarkers;	chr6:25874984	chr6:25992662~26001775:+
BRCA	cis	rs2662776	1	rs7355070	ENSG00000232995.6	RGS5	3.96	8.01e-05	0.00517	0.12	0.12	Lead levels in blood;	chr1:163189706	chr1:163244505~163321894:-
BRCA	cis	rs1065852	0.526	rs12166549	ENSG00000205702.9	CYP2D7	3.96	8.01e-05	0.00517	0.11	0.12	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42014415	chr22:42140203~42144577:-
BRCA	cis	rs6012564	1	rs11696396	ENSG00000222365.1	SNORD12B	3.96	8.02e-05	0.00517	0.13	0.12	Anger;	chr20:49136482	chr20:49280319~49280409:+
BRCA	cis	rs6012564	1	rs6066978	ENSG00000222365.1	SNORD12B	3.96	8.02e-05	0.00517	0.13	0.12	Anger;	chr20:49139205	chr20:49280319~49280409:+
BRCA	cis	rs6012564	1	rs6063361	ENSG00000222365.1	SNORD12B	3.96	8.02e-05	0.00517	0.13	0.12	Anger;	chr20:49141426	chr20:49280319~49280409:+
BRCA	cis	rs13315871	1	rs28489489	ENSG00000272182.1	RP11-802O23.3	3.96	8.02e-05	0.00517	0.24	0.12	Cholesterol, total;	chr3:58458028	chr3:58428255~58428815:+
BRCA	cis	rs853679	0.517	rs1340004	ENSG00000261839.1	RP1-265C24.8	3.96	8.02e-05	0.00517	0.17	0.12	Depression;	chr6:28135913	chr6:28136849~28139678:+
BRCA	cis	rs80226907	0.634	rs75444477	ENSG00000186615.9	KTN1-AS1	-3.96	8.02e-05	0.00517	-0.25	-0.12	Mean platelet volume;	chr14:55428599	chr14:55499278~55580110:-
BRCA	cis	rs61160187	0.548	rs1983484	ENSG00000272308.1	RP11-231G3.1	-3.96	8.02e-05	0.00517	-0.14	-0.12	Educational attainment (years of education);Educational attainment (college completion);	chr5:61050998	chr5:60866457~60866935:-
BRCA	cis	rs4722166	0.508	rs1474347	ENSG00000225541.1	AC002480.5	3.96	8.02e-05	0.00517	0.13	0.12	Lung cancer;	chr7:22728505	chr7:22571607~22661792:-
BRCA	cis	rs300703	0.542	rs189762	ENSG00000228643.1	AC079779.4	-3.96	8.02e-05	0.00517	-0.19	-0.12	Blood protein levels;	chr2:180079	chr2:286419~301515:+
BRCA	cis	rs2411233	1	rs11070162	ENSG00000259278.1	RP11-62C7.2	3.96	8.02e-05	0.00517	0.14	0.12	Platelet count;	chr15:38978089	chr15:39019233~39024918:+
BRCA	cis	rs17684571	0.872	rs3002011	ENSG00000231441.1	RP11-472M19.2	3.96	8.02e-05	0.00517	0.18	0.12	Schizophrenia;	chr6:56760325	chr6:56844002~56864078:+
BRCA	cis	rs2835345	1	rs2835345	ENSG00000230479.1	AP000695.6	3.96	8.02e-05	0.00517	0.12	0.12	Pulmonary function;	chr21:36429136	chr21:36430360~36481070:+
BRCA	cis	rs875971	0.545	rs73150604	ENSG00000230295.1	RP11-458F8.2	3.96	8.03e-05	0.00517	0.12	0.12	Aortic root size;	chr7:66480545	chr7:66880708~66882981:+
BRCA	cis	rs4453827	0.612	rs3774583	ENSG00000271916.1	RP11-884K10.6	3.96	8.03e-05	0.00517	0.13	0.12	Blood protein levels;	chr3:53769236	chr3:53797764~53798019:-
BRCA	cis	rs2880765	0.835	rs900573	ENSG00000230373.7	GOLGA6L5P	-3.96	8.03e-05	0.00518	-0.13	-0.12	Coronary artery disease;	chr15:85494762	chr15:84507885~84516814:-
BRCA	cis	rs12030196	1	rs12030196	ENSG00000230812.4	LINC01358	3.96	8.03e-05	0.00518	0.13	0.12	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr1:59017648	chr1:59020387~59044614:+
BRCA	cis	rs8180040	0.654	rs1466740	ENSG00000271161.1	BOLA2P2	-3.96	8.03e-05	0.00518	-0.13	-0.12	Colorectal cancer;	chr3:47204393	chr3:47499841~47500407:+
BRCA	cis	rs10829156	0.732	rs7100884	ENSG00000225527.1	RP11-383B4.4	-3.96	8.03e-05	0.00518	-0.17	-0.12	Sudden cardiac arrest;	chr10:18523768	chr10:18531849~18533336:-
BRCA	cis	rs1153858	1	rs67461176	ENSG00000275672.1	GATM-AS1	-3.96	8.03e-05	0.00518	-0.16	-0.12	Homoarginine levels;	chr15:45384621	chr15:45378700~45380123:+
BRCA	cis	rs1153858	1	rs66939267	ENSG00000275672.1	GATM-AS1	-3.96	8.03e-05	0.00518	-0.16	-0.12	Homoarginine levels;	chr15:45384704	chr15:45378700~45380123:+
BRCA	cis	rs7637230	0.504	rs1616007	ENSG00000244119.1	PDCL3P4	3.96	8.03e-05	0.00518	0.1	0.12	Psoriasis vulgaris;Psoriasis;	chr3:101927235	chr3:101712472~101713191:+
BRCA	cis	rs28829049	0.508	rs4578242	ENSG00000270728.1	RP4-657E11.10	-3.96	8.03e-05	0.00518	-0.12	-0.12	QRS duration in Tripanosoma cruzi seropositivity;	chr1:19065071	chr1:19297080~19297903:+
BRCA	cis	rs7847628	0.551	rs10818476	ENSG00000238181.2	AHCYP2	-3.96	8.03e-05	0.00518	-0.16	-0.12	Birth weight;	chr9:120809760	chr9:120720673~120721972:+
BRCA	cis	rs11083475	1	rs8111746	ENSG00000267892.1	CTD-2540F13.2	3.96	8.03e-05	0.00518	0.14	0.12	Heart rate;	chr19:38722219	chr19:38738284~38739863:+
BRCA	cis	rs9905704	0.589	rs2680696	ENSG00000265148.4	BZRAP1-AS1	-3.96	8.03e-05	0.00518	-0.16	-0.12	Testicular germ cell tumor;	chr17:58395652	chr17:58325450~58415766:+
BRCA	cis	rs9307551	0.6	rs11098776	ENSG00000250334.4	LINC00989	-3.96	8.03e-05	0.00518	-0.15	-0.12	Refractive error;	chr4:79617600	chr4:79492416~79576460:+
BRCA	cis	rs4073416	0.707	rs761830	ENSG00000276116.2	FUT8-AS1	3.96	8.04e-05	0.00518	0.13	0.12	N-glycan levels;	chr14:65746268	chr14:65411170~65412690:-
BRCA	cis	rs8114671	0.562	rs1060615	ENSG00000126005.14	MMP24-AS1	3.96	8.04e-05	0.00518	0.14	0.12	Height;	chr20:34890578	chr20:35216462~35278131:-
BRCA	cis	rs9527	0.59	rs1926029	ENSG00000213061.2	PFN1P11	3.96	8.04e-05	0.00518	0.16	0.12	Arsenic metabolism;	chr10:103095913	chr10:102838011~102845473:-
BRCA	cis	rs375066	0.935	rs432454	ENSG00000267191.1	RP11-15A1.2	-3.96	8.04e-05	0.00518	-0.16	-0.12	Breast cancer;	chr19:43894679	chr19:43902001~43926545:+
BRCA	cis	rs10043775	1	rs12513547	ENSG00000251330.3	CTD-2283N19.1	-3.96	8.04e-05	0.00518	-0.14	-0.12	Periodontal microbiota;	chr5:148431902	chr5:148430159~148430807:-
BRCA	cis	rs6088580	0.609	rs945674	ENSG00000275784.1	RP5-1125A11.6	3.96	8.04e-05	0.00518	0.13	0.12	Glomerular filtration rate (creatinine);	chr20:34376441	chr20:33989480~33991818:-
BRCA	cis	rs6545883	0.894	rs2167566	ENSG00000273302.1	RP11-493E12.2	3.96	8.04e-05	0.00518	0.11	0.12	Tuberculosis;	chr2:61292273	chr2:61199979~61200769:+
BRCA	cis	rs2235682	0.862	rs9619621	ENSG00000237668.1	RPS15AP38	3.96	8.04e-05	0.00518	0.14	0.12	Airway responsiveness in chronic obstructive pulmonary disease;	chr22:36588150	chr22:36421273~36421644:-
BRCA	cis	rs9650657	0.665	rs7002117	ENSG00000248896.2	CTD-2135J3.3	3.96	8.04e-05	0.00518	0.14	0.12	Neuroticism;	chr8:10758659	chr8:10729314~10771392:+
BRCA	cis	rs9847710	0.933	rs1529544	ENSG00000242849.2	ALDOAP1	-3.96	8.04e-05	0.00519	-0.13	-0.12	Ulcerative colitis;	chr3:53005439	chr3:52193170~52194785:+
BRCA	cis	rs1065852	0.526	rs9611711	ENSG00000205702.9	CYP2D7	3.96	8.05e-05	0.00519	0.11	0.12	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42014691	chr22:42140203~42144577:-
BRCA	cis	rs7647973	0.731	rs13084037	ENSG00000272434.1	RP13-131K19.6	-3.96	8.05e-05	0.00519	-0.17	-0.12	Menarche (age at onset);	chr3:49176633	chr3:49029316~49029706:+
BRCA	cis	rs875971	1	rs7789554	ENSG00000265600.1	AC006480.1	-3.96	8.05e-05	0.00519	-0.14	-0.12	Aortic root size;	chr7:66481051	chr7:67356680~67356779:+
BRCA	cis	rs875971	1	rs4717300	ENSG00000265600.1	AC006480.1	-3.96	8.05e-05	0.00519	-0.14	-0.12	Aortic root size;	chr7:66482393	chr7:67356680~67356779:+
BRCA	cis	rs875971	0.895	rs1974769	ENSG00000265600.1	AC006480.1	-3.96	8.05e-05	0.00519	-0.14	-0.12	Aortic root size;	chr7:66485627	chr7:67356680~67356779:+
BRCA	cis	rs875971	0.895	rs6460300	ENSG00000265600.1	AC006480.1	-3.96	8.05e-05	0.00519	-0.14	-0.12	Aortic root size;	chr7:66487937	chr7:67356680~67356779:+
BRCA	cis	rs875971	0.862	rs7803416	ENSG00000265600.1	AC006480.1	-3.96	8.05e-05	0.00519	-0.14	-0.12	Aortic root size;	chr7:66489212	chr7:67356680~67356779:+
BRCA	cis	rs875971	0.964	rs2277911	ENSG00000265600.1	AC006480.1	-3.96	8.05e-05	0.00519	-0.14	-0.12	Aortic root size;	chr7:66493638	chr7:67356680~67356779:+
BRCA	cis	rs375066	0.901	rs438517	ENSG00000267191.1	RP11-15A1.2	-3.96	8.05e-05	0.00519	-0.16	-0.12	Breast cancer;	chr19:43915506	chr19:43902001~43926545:+
BRCA	cis	rs375066	0.935	rs446674	ENSG00000267191.1	RP11-15A1.2	-3.96	8.05e-05	0.00519	-0.16	-0.12	Breast cancer;	chr19:43916855	chr19:43902001~43926545:+
BRCA	cis	rs1865760	0.865	rs1436306	ENSG00000272462.2	U91328.19	-3.96	8.05e-05	0.00519	-0.15	-0.12	Height;	chr6:25948193	chr6:25992662~26001775:+
BRCA	cis	rs6496932	1	rs35796484	ENSG00000259774.1	RP11-182J1.13	3.96	8.05e-05	0.00519	0.18	0.12	Central corneal thickness;Corneal structure;	chr15:85282019	chr15:84422618~84425882:+
BRCA	cis	rs6064559	0.687	rs6064563	ENSG00000218018.2	RP4-800J21.3	-3.96	8.05e-05	0.00519	-0.11	-0.12	Hemoglobin concentration;	chr20:57550157	chr20:57384160~57393062:-
BRCA	cis	rs6600671	1	rs1986111	ENSG00000223345.3	HIST2H2BA	3.96	8.05e-05	0.00519	0.15	0.12	Hip geometry;	chr1:121462934	chr1:121108210~121117257:-
BRCA	cis	rs4950322	0.515	rs12060046	ENSG00000237188.3	RP11-337C18.8	3.96	8.05e-05	0.00519	0.15	0.12	Protein quantitative trait loci;	chr1:147249278	chr1:147172771~147211568:+
BRCA	cis	rs4664293	0.967	rs13000070	ENSG00000224152.1	AC009506.1	-3.96	8.05e-05	0.00519	-0.14	-0.12	Monocyte percentage of white cells;	chr2:159669263	chr2:159615296~159617082:+
BRCA	cis	rs7608910	0.556	rs10181042	ENSG00000237522.1	NONOP2	3.96	8.05e-05	0.00519	0.11	0.12	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;	chr2:60997124	chr2:60936819~60938049:-
BRCA	cis	rs7267979	1	rs2258563	ENSG00000125804.12	FAM182A	-3.96	8.05e-05	0.00519	-0.16	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25292799	chr20:26054655~26086917:+
BRCA	cis	rs6496932	0.503	rs4842882	ENSG00000259630.2	CTD-2262B20.1	-3.96	8.05e-05	0.00519	-0.17	-0.12	Central corneal thickness;Corneal structure;	chr15:85440952	chr15:85415228~85415633:+
BRCA	cis	rs7267979	0.714	rs6115107	ENSG00000204556.4	CTD-2514C3.1	-3.96	8.05e-05	0.00519	-0.17	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25256754	chr20:26018832~26020684:+
BRCA	cis	rs7746199	0.736	rs34965299	ENSG00000216901.1	AL022393.7	3.96	8.06e-05	0.00519	0.3	0.12	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27554077	chr6:28176188~28176674:+
BRCA	cis	rs73201462	1	rs13069054	ENSG00000242551.2	POU5F1P6	3.96	8.06e-05	0.00519	0.2	0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128137139	chr3:128674735~128677005:-
BRCA	cis	rs67981189	0.593	rs7154437	ENSG00000258571.1	PTTG4P	-3.96	8.06e-05	0.00519	-0.13	-0.12	Schizophrenia;	chr14:70974668	chr14:71085482~71085833:-
BRCA	cis	rs8114671	0.967	rs6060285	ENSG00000279253.1	RP4-614O4.13	-3.96	8.06e-05	0.00519	-0.14	-0.12	Height;	chr20:35182684	chr20:35262727~35264187:-
BRCA	cis	rs8114671	0.967	rs2378337	ENSG00000279253.1	RP4-614O4.13	-3.96	8.06e-05	0.00519	-0.14	-0.12	Height;	chr20:35183632	chr20:35262727~35264187:-
BRCA	cis	rs6546537	0.91	rs10779953	ENSG00000231024.1	AC092431.3	3.96	8.06e-05	0.00519	0.16	0.12	Serum thyroid-stimulating hormone levels;	chr2:69659625	chr2:69700192~69713847:-
BRCA	cis	rs11733008	0.87	rs56006828	ENSG00000249001.4	RP11-742B18.1	3.96	8.06e-05	0.0052	0.15	0.12	Non-small cell lung cancer (survival);	chr4:87745996	chr4:87568035~87733956:-
BRCA	cis	rs490234	0.702	rs3814129	ENSG00000232630.1	PRPS1P2	-3.96	8.06e-05	0.0052	-0.12	-0.12	Mean arterial pressure;	chr9:125603674	chr9:125150653~125151589:+
BRCA	cis	rs2562456	0.641	rs62107468	ENSG00000240522.1	RPL7AP10	-3.96	8.06e-05	0.0052	-0.14	-0.12	Pain;	chr19:21307177	chr19:21149648~21150438:-
BRCA	cis	rs2320614	0.967	rs12500406	ENSG00000250027.1	RP11-563E2.2	-3.96	8.06e-05	0.0052	-0.14	-0.12	Lung adenocarcinoma;	chr4:163113846	chr4:163108785~163119965:+
BRCA	cis	rs4356203	0.905	rs7478986	ENSG00000272034.1	SNORD14A	-3.96	8.06e-05	0.0052	-0.12	-0.12	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17109702	chr11:17074654~17074744:-
BRCA	cis	rs4415084	0.966	rs4479849	ENSG00000272335.1	RP11-53O19.3	-3.96	8.06e-05	0.0052	-0.12	-0.12	Breast cancer;	chr5:44643904	chr5:44826076~44828592:+
BRCA	cis	rs11637445	0.603	rs1478941	ENSG00000260657.2	RP11-315D16.4	-3.96	8.06e-05	0.0052	-0.15	-0.12	Posterior cortical atrophy and Alzheimer's disease;	chr15:67834803	chr15:68267792~68277994:-
BRCA	cis	rs467650	0.529	rs1508791	ENSG00000248489.1	CTD-2007H13.3	-3.96	8.07e-05	0.0052	-0.13	-0.12	Venous thromboembolism (SNP x SNP interaction);	chr5:98660173	chr5:98929171~98995013:+
BRCA	cis	rs6545883	0.524	rs2694619	ENSG00000270820.4	RP11-355B11.2	-3.96	8.07e-05	0.0052	-0.13	-0.12	Tuberculosis;	chr2:61309766	chr2:61471188~61484130:+
BRCA	cis	rs6088580	0.634	rs6058073	ENSG00000275784.1	RP5-1125A11.6	-3.96	8.07e-05	0.0052	-0.13	-0.12	Glomerular filtration rate (creatinine);	chr20:34528678	chr20:33989480~33991818:-
BRCA	cis	rs17767294	0.612	rs9461424	ENSG00000280107.1	AL022393.9	-3.96	8.07e-05	0.0052	-0.24	-0.12	Parkinson's disease;	chr6:27951623	chr6:28170845~28172521:+
BRCA	cis	rs6981523	0.5	rs4412337	ENSG00000255046.1	RP11-297N6.4	-3.96	8.07e-05	0.0052	-0.15	-0.12	Neuroticism;	chr8:11214511	chr8:11797928~11802568:-
BRCA	cis	rs2243480	1	rs34529418	ENSG00000226002.1	RP11-460N20.5	-3.96	8.07e-05	0.0052	-0.2	-0.12	Diabetic kidney disease;	chr7:65938222	chr7:65084103~65100232:+
BRCA	cis	rs10191773	0.584	rs72831633	ENSG00000243389.1	AC012442.5	3.96	8.07e-05	0.0052	0.25	0.12	Yeast infection;	chr2:112188355	chr2:112589040~112614431:+
BRCA	cis	rs3748682	0.821	rs12030690	ENSG00000212541.1	RNU6-510P	-3.96	8.07e-05	0.0052	-0.18	-0.12	Hypothyroidism;	chr1:37792335	chr1:37991462~37991569:+
BRCA	cis	rs754466	0.58	rs2289308	ENSG00000213514.2	RP11-428P16.2	3.96	8.07e-05	0.0052	0.17	0.12	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77819493	chr10:77730766~77734769:+
BRCA	cis	rs875971	0.862	rs2909688	ENSG00000273024.4	INTS4P2	-3.96	8.07e-05	0.0052	-0.14	-0.12	Aortic root size;	chr7:66376625	chr7:65647864~65715661:+
BRCA	cis	rs7481584	0.624	rs516443	ENSG00000236710.1	AC108448.2	3.96	8.08e-05	0.0052	0.16	0.12	Calcium levels;	chr11:3026064	chr11:3084393~3085443:-
BRCA	cis	rs7481584	0.624	rs412842	ENSG00000236710.1	AC108448.2	3.96	8.08e-05	0.0052	0.16	0.12	Calcium levels;	chr11:3026218	chr11:3084393~3085443:-
BRCA	cis	rs7481584	0.624	rs449466	ENSG00000236710.1	AC108448.2	3.96	8.08e-05	0.0052	0.16	0.12	Calcium levels;	chr11:3026373	chr11:3084393~3085443:-
BRCA	cis	rs7481584	0.624	rs413368	ENSG00000236710.1	AC108448.2	3.96	8.08e-05	0.0052	0.16	0.12	Calcium levels;	chr11:3026416	chr11:3084393~3085443:-
BRCA	cis	rs7267979	1	rs2500446	ENSG00000274414.1	RP5-965G21.4	3.96	8.08e-05	0.0052	0.14	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25359028	chr20:25239007~25245229:-
BRCA	cis	rs11098499	0.779	rs28495013	ENSG00000260404.2	RP11-384K6.6	3.96	8.08e-05	0.0052	0.11	0.12	Corneal astigmatism;	chr4:119454676	chr4:118591773~118633729:+
BRCA	cis	rs903552	1	rs12719737	ENSG00000259604.4	RP11-66B24.1	-3.96	8.08e-05	0.0052	-0.13	-0.12	Diabetic kidney disease;	chr15:101458921	chr15:100861843~100874369:+
BRCA	cis	rs1910358	0.769	rs7730678	ENSG00000248874.4	C5orf17	-3.96	8.08e-05	0.0052	-0.16	-0.12	Venous thromboembolism (SNP x SNP interaction);	chr5:23997930	chr5:23951348~24178263:+
BRCA	cis	rs1910358	0.769	rs1501943	ENSG00000248874.4	C5orf17	-3.96	8.08e-05	0.0052	-0.16	-0.12	Venous thromboembolism (SNP x SNP interaction);	chr5:23998687	chr5:23951348~24178263:+
BRCA	cis	rs3798305	1	rs16899788	ENSG00000233231.1	HNRNPA1P49	3.96	8.08e-05	0.0052	0.22	0.12	Smooth-surface caries;	chr6:167017838	chr6:166334568~166335471:+
BRCA	cis	rs4460629	0.742	rs11581730	ENSG00000160766.13	GBAP1	-3.96	8.08e-05	0.0052	-0.12	-0.12	Serum magnesium levels;	chr1:155109682	chr1:155213821~155227422:-
BRCA	cis	rs4460629	0.742	rs7548955	ENSG00000160766.13	GBAP1	-3.96	8.08e-05	0.0052	-0.12	-0.12	Serum magnesium levels;	chr1:155109822	chr1:155213821~155227422:-
BRCA	cis	rs4925386	0.84	rs6143024	ENSG00000275437.1	RP5-908M14.10	3.96	8.08e-05	0.0052	0.14	0.12	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62339173	chr20:62402236~62405935:-
BRCA	cis	rs11098499	0.821	rs10032151	ENSG00000260404.2	RP11-384K6.6	3.96	8.08e-05	0.0052	0.11	0.12	Corneal astigmatism;	chr4:119470473	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.865	rs10032158	ENSG00000260404.2	RP11-384K6.6	3.96	8.08e-05	0.0052	0.11	0.12	Corneal astigmatism;	chr4:119470477	chr4:118591773~118633729:+
BRCA	cis	rs4415084	0.834	rs1061310	ENSG00000248779.1	RP11-53O19.2	3.96	8.08e-05	0.00521	0.11	0.12	Breast cancer;	chr5:44820748	chr5:44752949~44765744:+
BRCA	cis	rs17684571	0.7	rs17684802	ENSG00000231441.1	RP11-472M19.2	-3.96	8.08e-05	0.00521	-0.19	-0.12	Schizophrenia;	chr6:56813854	chr6:56844002~56864078:+
BRCA	cis	rs7267979	1	rs2258769	ENSG00000125804.12	FAM182A	-3.96	8.08e-05	0.00521	-0.16	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25296044	chr20:26054655~26086917:+
BRCA	cis	rs875971	0.964	rs6945019	ENSG00000265600.1	AC006480.1	-3.96	8.08e-05	0.00521	-0.14	-0.12	Aortic root size;	chr7:66457471	chr7:67356680~67356779:+
BRCA	cis	rs11048434	0.518	rs7136274	ENSG00000256937.1	KRT17P8	3.96	8.08e-05	0.00521	0.13	0.12	Sjögren's syndrome;	chr12:9022360	chr12:9127783~9128645:+
BRCA	cis	rs4538475	0.606	rs55735476	ENSG00000273133.1	RP11-799M12.2	-3.96	8.08e-05	0.00521	-0.25	-0.12	Parkinson's disease;	chr4:15705297	chr4:15563698~15564253:-
BRCA	cis	rs4700393	0.517	rs12516248	ENSG00000215032.2	GNL3LP1	-3.96	8.08e-05	0.00521	-0.18	-0.12	Intelligence (multi-trait analysis);	chr5:60835824	chr5:60891935~60893577:-
BRCA	cis	rs7487075	0.79	rs4074773	ENSG00000257261.4	RP11-96H19.1	-3.96	8.09e-05	0.00521	-0.14	-0.12	Itch intensity from mosquito bite;	chr12:46525398	chr12:46383679~46876159:+
BRCA	cis	rs7267979	0.816	rs6115094	ENSG00000274414.1	RP5-965G21.4	-3.96	8.09e-05	0.00521	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25230191	chr20:25239007~25245229:-
BRCA	cis	rs2411233	0.967	rs2035060	ENSG00000259278.1	RP11-62C7.2	3.96	8.09e-05	0.00521	0.14	0.12	Platelet count;	chr15:38995183	chr15:39019233~39024918:+
BRCA	cis	rs7412746	0.611	rs4970931	ENSG00000231073.1	RP11-316M1.3	3.96	8.09e-05	0.00521	0.13	0.12	Melanoma;	chr1:150938251	chr1:150973123~150975534:+
BRCA	cis	rs9733	0.503	rs7556451	ENSG00000231073.1	RP11-316M1.3	3.96	8.09e-05	0.00521	0.13	0.12	Tonsillectomy;	chr1:150940666	chr1:150973123~150975534:+
BRCA	cis	rs7412746	0.611	rs2271076	ENSG00000231073.1	RP11-316M1.3	3.96	8.09e-05	0.00521	0.13	0.12	Melanoma;	chr1:150944181	chr1:150973123~150975534:+
BRCA	cis	rs874628	0.851	rs55973594	ENSG00000268650.3	AC068499.10	3.96	8.09e-05	0.00521	0.16	0.12	Multiple sclerosis;	chr19:18219858	chr19:18204730~18220480:+
BRCA	cis	rs62445005	1	rs62445005	ENSG00000281103.1	TRG-AS1	3.96	8.09e-05	0.00521	0.09	0.12	Shingles;	chr7:38346957	chr7:38341577~38378804:+
BRCA	cis	rs8114671	0.869	rs2038503	ENSG00000279253.1	RP4-614O4.13	3.96	8.09e-05	0.00521	0.14	0.12	Height;	chr20:35088097	chr20:35262727~35264187:-
BRCA	cis	rs738144	0.502	rs9611034	ENSG00000230149.2	RP3-508I15.19	-3.96	8.09e-05	0.00521	-0.13	-0.12	IgG glycosylation;	chr22:38834879	chr22:38734730~38738990:+
BRCA	cis	rs893818	1	rs893819	ENSG00000261801.4	LOXL1-AS1	3.96	8.09e-05	0.00521	0.15	0.12	Exfoliation glaucoma or exfoliation syndrome;	chr15:73937183	chr15:73908071~73928248:-
BRCA	cis	rs893818	1	rs893820	ENSG00000261801.4	LOXL1-AS1	3.96	8.09e-05	0.00521	0.15	0.12	Exfoliation glaucoma or exfoliation syndrome;	chr15:73937262	chr15:73908071~73928248:-
BRCA	cis	rs1005277	0.565	rs2474565	ENSG00000272983.1	RP11-508N22.12	3.96	8.09e-05	0.00521	0.13	0.12	Extrinsic epigenetic age acceleration;	chr10:38091900	chr10:38137337~38144399:+
BRCA	cis	rs739401	0.611	rs401707	ENSG00000247473.2	CARS-AS1	3.96	8.09e-05	0.00521	0.14	0.12	Longevity;	chr11:3029735	chr11:3029009~3041260:+
BRCA	cis	rs10043775	0.831	rs6876982	ENSG00000251330.3	CTD-2283N19.1	-3.96	8.09e-05	0.00521	-0.15	-0.12	Periodontal microbiota;	chr5:148302555	chr5:148430159~148430807:-
BRCA	cis	rs1396626	1	rs1396626	ENSG00000235501.4	RP4-639F20.1	3.96	8.09e-05	0.00521	0.16	0.12	Diabetic kidney disease;	chr1:95559990	chr1:94927566~94963270:+
BRCA	cis	rs7621331	0.963	rs6771997	ENSG00000239213.4	NCK1-AS1	-3.96	8.09e-05	0.00521	-0.14	-0.12	Waist circumference adjusted for body mass index;	chr3:136012472	chr3:136841726~136862054:-
BRCA	cis	rs2255336	0.706	rs4415856	ENSG00000245648.1	RP11-277P12.20	-3.96	8.1e-05	0.00521	-0.17	-0.12	Blood protein levels;	chr12:10448069	chr12:10363769~10398506:+
BRCA	cis	rs7412746	0.611	rs72704679	ENSG00000231073.1	RP11-316M1.3	3.96	8.1e-05	0.00522	0.13	0.12	Melanoma;	chr1:150925001	chr1:150973123~150975534:+
BRCA	cis	rs7572644	0.537	rs10204081	ENSG00000223522.1	AC093690.1	3.96	8.1e-05	0.00522	0.13	0.12	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:28135907	chr2:28307691~28310459:-
BRCA	cis	rs1048886	0.872	rs74818996	ENSG00000271967.1	RP11-134K13.4	-3.96	8.1e-05	0.00522	-0.18	-0.12	Type 2 diabetes;	chr6:70419970	chr6:70596438~70596980:+
BRCA	cis	rs7209700	0.778	rs3851807	ENSG00000228782.6	CTD-2026D20.3	-3.96	8.1e-05	0.00522	-0.14	-0.12	IgG glycosylation;	chr17:47274153	chr17:47450568~47492492:-
BRCA	cis	rs812925	0.537	rs10196146	ENSG00000270820.4	RP11-355B11.2	-3.96	8.11e-05	0.00522	-0.13	-0.12	Immature fraction of reticulocytes;	chr2:61378244	chr2:61471188~61484130:+
BRCA	cis	rs747650	0.504	rs11600292	ENSG00000200376.1	RNU5E-10P	-3.96	8.11e-05	0.00522	-0.16	-0.12	Acne (severe);	chr11:46937147	chr11:47576471~47576588:-
BRCA	cis	rs875971	0.964	rs6945019	ENSG00000229180.5	GS1-124K5.11	3.96	8.11e-05	0.00522	0.11	0.12	Aortic root size;	chr7:66457471	chr7:66526088~66542624:-
BRCA	cis	rs7608910	0.77	rs10191951	ENSG00000237522.1	NONOP2	-3.96	8.11e-05	0.00522	-0.12	-0.12	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;	chr2:60970655	chr2:60936819~60938049:-
BRCA	cis	rs7267979	1	rs2257420	ENSG00000125804.12	FAM182A	-3.96	8.11e-05	0.00522	-0.16	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25295254	chr20:26054655~26086917:+
BRCA	cis	rs6696239	0.956	rs6659349	ENSG00000215812.5	ZNF847P	3.96	8.11e-05	0.00522	0.17	0.12	Height;	chr1:227623754	chr1:227696892~227706699:-
BRCA	cis	rs7020830	0.931	rs3802422	ENSG00000260100.1	RP11-220I1.5	-3.96	8.11e-05	0.00522	-0.15	-0.12	Schizophrenia;	chr9:37097175	chr9:37078813~37079776:-
BRCA	cis	rs6708413	0.521	rs6543153	ENSG00000234389.1	AC007278.3	3.96	8.11e-05	0.00522	0.12	0.12	Crohn's disease;Inflammatory bowel disease;	chr2:102497744	chr2:102438713~102440475:+
BRCA	cis	rs1912124	0.925	rs66933405	ENSG00000271983.1	RP11-28H5.2	3.96	8.11e-05	0.00522	0.24	0.12	Peripheral arterial disease (traffic-related air pollution interaction);	chr15:81186444	chr15:80693216~80693707:-
BRCA	cis	rs2505998	0.719	rs10900296	ENSG00000273008.1	RP11-351D16.3	-3.96	8.11e-05	0.00522	-0.14	-0.12	Hirschsprung disease;	chr10:43077059	chr10:43136824~43138334:-
BRCA	cis	rs7829975	0.84	rs572366	ENSG00000254153.1	CTA-398F10.2	3.96	8.11e-05	0.00522	0.14	0.12	Mood instability;	chr8:8721284	chr8:8456909~8461337:-
BRCA	cis	rs11168618	0.74	rs4237859	ENSG00000240399.1	RP1-228P16.1	3.96	8.11e-05	0.00522	0.13	0.12	Adiponectin levels;	chr12:48530892	chr12:48054813~48055591:-
BRCA	cis	rs4478858	0.735	rs10798845	ENSG00000223907.1	LINC01226	3.96	8.11e-05	0.00522	0.15	0.12	Alcohol dependence;	chr1:31349789	chr1:31518435~31524245:+
BRCA	cis	rs11098499	0.955	rs1511019	ENSG00000260091.1	RP11-33B1.4	-3.96	8.11e-05	0.00522	-0.11	-0.12	Corneal astigmatism;	chr4:119244852	chr4:119409333~119410233:+
BRCA	cis	rs7682317	0.526	rs4693980	ENSG00000270720.1	RP11-84C13.2	3.96	8.11e-05	0.00522	0.13	0.12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr4:88964837	chr4:89119284~89119871:+
BRCA	cis	rs2836974	0.583	rs2776306	ENSG00000255568.3	BRWD1-AS2	3.96	8.11e-05	0.00522	0.12	0.12	Cognitive function;	chr21:39341828	chr21:39313935~39314962:+
BRCA	cis	rs733592	0.524	rs10875727	ENSG00000257763.1	OR5BK1P	-3.96	8.11e-05	0.00522	-0.12	-0.12	Plateletcrit;	chr12:48032360	chr12:48355792~48356614:-
BRCA	cis	rs6452524	0.935	rs10942321	ENSG00000281327.1	LINC01338	3.96	8.11e-05	0.00522	0.14	0.12	Hypertension (SNP x SNP interaction);	chr5:83083200	chr5:82850864~82859836:-
BRCA	cis	rs1949733	0.701	rs940134	ENSG00000251615.3	RP11-774O3.3	-3.96	8.11e-05	0.00522	-0.13	-0.12	Response to antineoplastic agents;	chr4:8453143	chr4:8355090~8358338:-
BRCA	cis	rs1949733	0.701	rs871768	ENSG00000251615.3	RP11-774O3.3	-3.96	8.11e-05	0.00522	-0.13	-0.12	Response to antineoplastic agents;	chr4:8453211	chr4:8355090~8358338:-
BRCA	cis	rs9472168	0.934	rs13206436	ENSG00000272223.1	RP1-20C7.6	3.96	8.11e-05	0.00523	0.13	0.12	Interleukin-13 levels;	chr6:43958041	chr6:43033897~43034405:-
BRCA	cis	rs1009077	0.716	rs13106925	ENSG00000245958.5	RP11-33B1.1	3.96	8.12e-05	0.00523	0.18	0.12	Endometriosis;	chr4:119617953	chr4:119454791~119552025:+
BRCA	cis	rs1009077	0.669	rs11730798	ENSG00000245958.5	RP11-33B1.1	3.96	8.12e-05	0.00523	0.18	0.12	Endometriosis;	chr4:119618704	chr4:119454791~119552025:+
BRCA	cis	rs11711311	1	rs9811353	ENSG00000241529.3	RN7SL767P	-3.96	8.12e-05	0.00523	-0.14	-0.12	IgG glycosylation;	chr3:113765132	chr3:113632704~113632998:+
BRCA	cis	rs11711311	1	rs28394480	ENSG00000241529.3	RN7SL767P	-3.96	8.12e-05	0.00523	-0.14	-0.12	IgG glycosylation;	chr3:113766296	chr3:113632704~113632998:+
BRCA	cis	rs1015213	1	rs1015213	ENSG00000253475.1	RP11-110G21.2	-3.96	8.12e-05	0.00523	-0.21	-0.12	Glaucoma (primary angle closure);	chr8:51974981	chr8:51895957~51896374:-
BRCA	cis	rs6901004	0.605	rs2297939	ENSG00000271789.1	RP5-1112D6.7	-3.96	8.12e-05	0.00523	-0.15	-0.12	Blood metabolite levels;	chr6:111227959	chr6:111297126~111298510:+
BRCA	cis	rs983392	1	rs1813217	ENSG00000275344.1	MIR6503	-3.96	8.12e-05	0.00523	-0.13	-0.12	Alzheimer's disease (late onset);	chr11:60105025	chr11:60209071~60209156:-
BRCA	cis	rs983392	0.6	rs1582763	ENSG00000275344.1	MIR6503	-3.96	8.12e-05	0.00523	-0.13	-0.12	Alzheimer's disease (late onset);	chr11:60254475	chr11:60209071~60209156:-
BRCA	cis	rs1048886	1	rs74552954	ENSG00000271967.1	RP11-134K13.4	-3.96	8.12e-05	0.00523	-0.18	-0.12	Type 2 diabetes;	chr6:70422914	chr6:70596438~70596980:+
BRCA	cis	rs2243480	1	rs78803505	ENSG00000226002.1	RP11-460N20.5	-3.96	8.12e-05	0.00523	-0.2	-0.12	Diabetic kidney disease;	chr7:65917585	chr7:65084103~65100232:+
BRCA	cis	rs2243480	1	rs34577383	ENSG00000226002.1	RP11-460N20.5	-3.96	8.12e-05	0.00523	-0.2	-0.12	Diabetic kidney disease;	chr7:65920739	chr7:65084103~65100232:+
BRCA	cis	rs2243480	1	rs55895244	ENSG00000226002.1	RP11-460N20.5	-3.96	8.12e-05	0.00523	-0.2	-0.12	Diabetic kidney disease;	chr7:65922691	chr7:65084103~65100232:+
BRCA	cis	rs2243480	1	rs7795242	ENSG00000226002.1	RP11-460N20.5	-3.96	8.12e-05	0.00523	-0.2	-0.12	Diabetic kidney disease;	chr7:65925107	chr7:65084103~65100232:+
BRCA	cis	rs2243480	1	rs2177703	ENSG00000226002.1	RP11-460N20.5	-3.96	8.12e-05	0.00523	-0.2	-0.12	Diabetic kidney disease;	chr7:65926730	chr7:65084103~65100232:+
BRCA	cis	rs2243480	1	rs56985706	ENSG00000226002.1	RP11-460N20.5	-3.96	8.12e-05	0.00523	-0.2	-0.12	Diabetic kidney disease;	chr7:65929575	chr7:65084103~65100232:+
BRCA	cis	rs2243480	1	rs60683927	ENSG00000226002.1	RP11-460N20.5	-3.96	8.12e-05	0.00523	-0.2	-0.12	Diabetic kidney disease;	chr7:65929781	chr7:65084103~65100232:+
BRCA	cis	rs2243480	1	rs58062456	ENSG00000226002.1	RP11-460N20.5	-3.96	8.12e-05	0.00523	-0.2	-0.12	Diabetic kidney disease;	chr7:65929865	chr7:65084103~65100232:+
BRCA	cis	rs9527	0.615	rs12248123	ENSG00000213061.2	PFN1P11	3.96	8.12e-05	0.00523	0.16	0.12	Arsenic metabolism;	chr10:102975609	chr10:102838011~102845473:-
BRCA	cis	rs1008375	1	rs10939746	ENSG00000249502.1	AC006160.5	3.96	8.12e-05	0.00523	0.14	0.12	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17683328	chr4:17587467~17614571:-
BRCA	cis	rs1577917	0.74	rs2842614	ENSG00000220563.1	PKMP3	-3.96	8.12e-05	0.00523	-0.12	-0.12	Response to antipsychotic treatment;	chr6:85596351	chr6:85659892~85660606:-
BRCA	cis	rs1479090	0.805	rs7693533	ENSG00000250027.1	RP11-563E2.2	-3.96	8.13e-05	0.00523	-0.16	-0.12	Lung cancer;	chr4:163145558	chr4:163108785~163119965:+
BRCA	cis	rs4886920	0.574	rs71407228	ENSG00000260776.4	RP11-114H24.2	3.96	8.13e-05	0.00523	0.19	0.12	Neuroticism;	chr15:77850726	chr15:77914217~77926846:-
BRCA	cis	rs1048886	0.872	rs10945230	ENSG00000271967.1	RP11-134K13.4	-3.96	8.13e-05	0.00523	-0.17	-0.12	Type 2 diabetes;	chr6:70572031	chr6:70596438~70596980:+
BRCA	cis	rs10864907	0.71	rs6758386	ENSG00000231747.1	AC079922.2	-3.96	8.13e-05	0.00523	-0.11	-0.12	Pulmonary function;	chr2:112964119	chr2:112621809~112622167:-
BRCA	cis	rs7246657	0.551	rs12978093	ENSG00000267470.4	ZNF571-AS1	3.96	8.13e-05	0.00523	0.19	0.12	Coronary artery calcification;	chr19:37093514	chr19:37548914~37587348:+
BRCA	cis	rs13434995	0.513	rs1048004	ENSG00000239040.1	Y_RNA	3.96	8.13e-05	0.00523	0.14	0.12	Adiponectin levels;	chr4:55434042	chr4:55412636~55412738:+
BRCA	cis	rs62025270	0.547	rs8035496	ENSG00000259762.1	RP11-158M2.4	-3.96	8.13e-05	0.00523	-0.16	-0.12	Idiopathic pulmonary fibrosis;	chr15:85591101	chr15:85750336~85752901:-
BRCA	cis	rs2880765	0.546	rs35316253	ENSG00000202081.1	RNU6-1280P	3.96	8.13e-05	0.00523	0.16	0.12	Coronary artery disease;	chr15:85522329	chr15:85651522~85651628:-
BRCA	cis	rs72799341	1	rs35675346	ENSG00000280211.1	RP11-2C24.3	3.96	8.13e-05	0.00523	0.13	0.12	Diastolic blood pressure;	chr16:30924760	chr16:30773532~30776033:-
BRCA	cis	rs11098499	0.58	rs12509234	ENSG00000225892.3	RP11-384K6.2	3.96	8.13e-05	0.00523	0.12	0.12	Corneal astigmatism;	chr4:119398279	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.909	rs10014719	ENSG00000225892.3	RP11-384K6.2	3.96	8.13e-05	0.00523	0.12	0.12	Corneal astigmatism;	chr4:119399560	chr4:118632274~118634759:+
BRCA	cis	rs10792665	0.649	rs10792671	ENSG00000246067.6	RAB30-AS1	-3.96	8.13e-05	0.00524	-0.13	-0.12	Obesity-related traits;	chr11:83017167	chr11:83072066~83106719:+
BRCA	cis	rs983392	1	rs17528859	ENSG00000275344.1	MIR6503	-3.96	8.13e-05	0.00524	-0.13	-0.12	Alzheimer's disease (late onset);	chr11:60099906	chr11:60209071~60209156:-
BRCA	cis	rs35851103	0.507	rs6601649	ENSG00000250794.2	ALG1L12P	3.96	8.13e-05	0.00524	0.16	0.12	Neuroticism;	chr8:11999808	chr8:12421032~12425000:+
BRCA	cis	rs7824557	0.767	rs3808513	ENSG00000154316.13	TDH	3.96	8.13e-05	0.00524	0.17	0.12	Retinal vascular caliber;	chr8:11299951	chr8:11339637~11368452:+
BRCA	cis	rs6545883	0.86	rs13023037	ENSG00000212978.6	AC016747.3	-3.96	8.13e-05	0.00524	-0.16	-0.12	Tuberculosis;	chr2:61393854	chr2:61141592~61144969:-
BRCA	cis	rs7702057	0.619	rs11956927	ENSG00000271918.1	CTD-2287O16.5	-3.96	8.14e-05	0.00524	-0.22	-0.12	Amyotrophic lateral sclerosis;	chr5:116306668	chr5:116083807~116085416:-
BRCA	cis	rs12612435	0.784	rs66516414	ENSG00000226806.1	AC011893.3	3.96	8.14e-05	0.00524	0.14	0.12	Takotsubo syndrome;	chr2:136363694	chr2:135820191~135823087:+
BRCA	cis	rs990171	0.538	rs12995030	ENSG00000234389.1	AC007278.3	3.96	8.14e-05	0.00524	0.12	0.12	Lymphocyte counts;	chr2:102500007	chr2:102438713~102440475:+
BRCA	cis	rs10504130	1	rs75061868	ENSG00000272076.1	RP11-11C20.3	3.96	8.14e-05	0.00524	0.21	0.12	Venous thromboembolism (SNP x SNP interaction);	chr8:51883380	chr8:51810110~51810681:-
BRCA	cis	rs10504130	1	rs2176120	ENSG00000272076.1	RP11-11C20.3	3.96	8.14e-05	0.00524	0.21	0.12	Venous thromboembolism (SNP x SNP interaction);	chr8:51885462	chr8:51810110~51810681:-
BRCA	cis	rs10504130	1	rs80340160	ENSG00000272076.1	RP11-11C20.3	3.96	8.14e-05	0.00524	0.21	0.12	Venous thromboembolism (SNP x SNP interaction);	chr8:51885628	chr8:51810110~51810681:-
BRCA	cis	rs10504130	1	rs9792352	ENSG00000272076.1	RP11-11C20.3	3.96	8.14e-05	0.00524	0.21	0.12	Venous thromboembolism (SNP x SNP interaction);	chr8:51886862	chr8:51810110~51810681:-
BRCA	cis	rs10504130	1	rs2037138	ENSG00000272076.1	RP11-11C20.3	3.96	8.14e-05	0.00524	0.21	0.12	Venous thromboembolism (SNP x SNP interaction);	chr8:51892153	chr8:51810110~51810681:-
BRCA	cis	rs10504130	1	rs2037139	ENSG00000272076.1	RP11-11C20.3	3.96	8.14e-05	0.00524	0.21	0.12	Venous thromboembolism (SNP x SNP interaction);	chr8:51892324	chr8:51810110~51810681:-
BRCA	cis	rs10510102	0.516	rs11200306	ENSG00000226864.1	ATE1-AS1	3.96	8.14e-05	0.00524	0.23	0.12	Breast cancer;	chr10:121980862	chr10:121928312~121951965:+
BRCA	cis	rs6504622	0.755	rs11079750	ENSG00000263142.4	LRRC37A17P	-3.96	8.14e-05	0.00524	-0.1	-0.12	Orofacial clefts;	chr17:47072149	chr17:46978481~47054569:+
BRCA	cis	rs6480314	0.831	rs7071208	ENSG00000233590.1	RP11-153K11.3	3.96	8.14e-05	0.00524	0.19	0.12	Optic nerve measurement (disc area);	chr10:68213350	chr10:68233251~68242379:-
BRCA	cis	rs9543976	0.623	rs7317250	ENSG00000261105.4	LMO7-AS1	3.96	8.14e-05	0.00524	0.18	0.12	Diabetic retinopathy;	chr13:75593005	chr13:75604700~75635994:-
BRCA	cis	rs9527	0.59	rs1926037	ENSG00000213061.2	PFN1P11	3.96	8.15e-05	0.00524	0.16	0.12	Arsenic metabolism;	chr10:103118253	chr10:102838011~102845473:-
BRCA	cis	rs9527	0.567	rs6584539	ENSG00000213061.2	PFN1P11	3.96	8.15e-05	0.00524	0.16	0.12	Arsenic metabolism;	chr10:103119645	chr10:102838011~102845473:-
BRCA	cis	rs9527	0.59	rs2148200	ENSG00000213061.2	PFN1P11	3.96	8.15e-05	0.00524	0.16	0.12	Arsenic metabolism;	chr10:103120090	chr10:102838011~102845473:-
BRCA	cis	rs9527	0.614	rs2153774	ENSG00000213061.2	PFN1P11	3.96	8.15e-05	0.00524	0.16	0.12	Arsenic metabolism;	chr10:103121278	chr10:102838011~102845473:-
BRCA	cis	rs9527	0.59	rs10883834	ENSG00000213061.2	PFN1P11	3.96	8.15e-05	0.00524	0.16	0.12	Arsenic metabolism;	chr10:103121645	chr10:102838011~102845473:-
BRCA	cis	rs9527	0.545	rs7915816	ENSG00000213061.2	PFN1P11	3.96	8.15e-05	0.00524	0.16	0.12	Arsenic metabolism;	chr10:103121993	chr10:102838011~102845473:-
BRCA	cis	rs9527	0.568	rs1926036	ENSG00000213061.2	PFN1P11	3.96	8.15e-05	0.00524	0.16	0.12	Arsenic metabolism;	chr10:103124055	chr10:102838011~102845473:-
BRCA	cis	rs6599077	0.756	rs9867657	ENSG00000223797.4	ENTPD3-AS1	3.96	8.15e-05	0.00524	0.13	0.12	Sleep-related phenotypes;	chr3:40050747	chr3:40313802~40453329:-
BRCA	cis	rs9921338	0.961	rs17605444	ENSG00000262636.1	CTD-3088G3.4	-3.96	8.15e-05	0.00524	-0.19	-0.12	Vein graft stenosis in coronary artery bypass grafting;	chr16:11319732	chr16:11380859~11381118:-
BRCA	cis	rs983392	0.679	rs1026254	ENSG00000275344.1	MIR6503	3.96	8.15e-05	0.00525	0.13	0.12	Alzheimer's disease (late onset);	chr11:60262984	chr11:60209071~60209156:-
BRCA	cis	rs2243480	0.803	rs34804747	ENSG00000226002.1	RP11-460N20.5	-3.96	8.15e-05	0.00525	-0.2	-0.12	Diabetic kidney disease;	chr7:65947955	chr7:65084103~65100232:+
BRCA	cis	rs2243480	1	rs59794892	ENSG00000226002.1	RP11-460N20.5	-3.96	8.15e-05	0.00525	-0.2	-0.12	Diabetic kidney disease;	chr7:65950886	chr7:65084103~65100232:+
BRCA	cis	rs2243480	0.803	rs36004293	ENSG00000226002.1	RP11-460N20.5	-3.96	8.15e-05	0.00525	-0.2	-0.12	Diabetic kidney disease;	chr7:65951525	chr7:65084103~65100232:+
BRCA	cis	rs2243480	0.803	rs35268390	ENSG00000226002.1	RP11-460N20.5	-3.96	8.15e-05	0.00525	-0.2	-0.12	Diabetic kidney disease;	chr7:65951549	chr7:65084103~65100232:+
BRCA	cis	rs4650943	0.586	rs2455728	ENSG00000227740.1	RP11-318C24.2	-3.96	8.15e-05	0.00525	-0.12	-0.12	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in inactive individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr1:176332664	chr1:175904762~175920513:-
BRCA	cis	rs4650943	0.586	rs2455727	ENSG00000227740.1	RP11-318C24.2	-3.96	8.15e-05	0.00525	-0.12	-0.12	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in inactive individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr1:176336275	chr1:175904762~175920513:-
BRCA	cis	rs4218	0.648	rs34407560	ENSG00000259732.1	RP11-59H7.3	-3.96	8.15e-05	0.00525	-0.15	-0.12	Social communication problems;	chr15:59073397	chr15:59121034~59133250:+
BRCA	cis	rs13401620	0.871	rs11676058	ENSG00000229326.3	AC069154.4	-3.96	8.15e-05	0.00525	-0.16	-0.12	Breast size;	chr2:119979306	chr2:119698623~119700151:+
BRCA	cis	rs8026198	0.929	rs3743006	ENSG00000260571.1	BNIP3P5	-3.96	8.16e-05	0.00525	-0.2	-0.12	Fibrinogen levels;	chr15:42353570	chr15:42313687~42314386:+
BRCA	cis	rs524281	0.861	rs3825067	ENSG00000255038.1	RP11-1167A19.2	3.96	8.16e-05	0.00525	0.18	0.12	Electroencephalogram traits;	chr11:66110948	chr11:66067277~66069619:-
BRCA	cis	rs930395	0.514	rs9292914	ENSG00000251141.4	RP11-53O19.1	-3.96	8.16e-05	0.00525	-0.12	-0.12	Breast cancer;	chr5:44871279	chr5:44744900~44808777:-
BRCA	cis	rs78487399	0.71	rs80100685	ENSG00000234936.1	AC010883.5	3.96	8.16e-05	0.00525	0.19	0.12	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43423274	chr2:43229573~43233394:+
BRCA	cis	rs8040855	0.597	rs12902942	ENSG00000259774.1	RP11-182J1.13	3.96	8.16e-05	0.00525	0.17	0.12	Bulimia nervosa;	chr15:85041573	chr15:84422618~84425882:+
BRCA	cis	rs62025270	0.688	rs62025298	ENSG00000259762.1	RP11-158M2.4	-3.96	8.16e-05	0.00525	-0.18	-0.12	Idiopathic pulmonary fibrosis;	chr15:85773921	chr15:85750336~85752901:-
BRCA	cis	rs9295536	0.62	rs6901879	ENSG00000260455.1	NBAT1	3.96	8.16e-05	0.00525	0.14	0.12	Neuroblastoma;	chr6:22137318	chr6:22134957~22147193:-
BRCA	cis	rs875971	0.66	rs801192	ENSG00000265600.1	AC006480.1	3.96	8.16e-05	0.00525	0.14	0.12	Aortic root size;	chr7:66566965	chr7:67356680~67356779:+
BRCA	cis	rs875971	0.66	rs801190	ENSG00000265600.1	AC006480.1	3.96	8.16e-05	0.00525	0.14	0.12	Aortic root size;	chr7:66568046	chr7:67356680~67356779:+
BRCA	cis	rs875971	0.66	rs3857686	ENSG00000265600.1	AC006480.1	3.96	8.16e-05	0.00525	0.14	0.12	Aortic root size;	chr7:66571204	chr7:67356680~67356779:+
BRCA	cis	rs4218	0.648	rs35769647	ENSG00000259732.1	RP11-59H7.3	-3.96	8.16e-05	0.00525	-0.16	-0.12	Social communication problems;	chr15:59081670	chr15:59121034~59133250:+
BRCA	cis	rs7267979	0.868	rs6138550	ENSG00000276952.1	RP5-965G21.6	3.96	8.16e-05	0.00525	0.15	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25242794	chr20:25284915~25285588:-
BRCA	cis	rs4073416	0.902	rs55845504	ENSG00000276116.2	FUT8-AS1	-3.96	8.16e-05	0.00525	-0.13	-0.12	N-glycan levels;	chr14:65790250	chr14:65411170~65412690:-
BRCA	cis	rs8180040	0.726	rs2305638	ENSG00000276925.1	RP11-708J19.3	-3.96	8.17e-05	0.00525	-0.14	-0.12	Colorectal cancer;	chr3:47005352	chr3:47469777~47469987:+
BRCA	cis	rs733592	0.507	rs3825403	ENSG00000257763.1	OR5BK1P	-3.96	8.17e-05	0.00526	-0.12	-0.12	Plateletcrit;	chr12:48063376	chr12:48355792~48356614:-
BRCA	cis	rs733592	0.507	rs10747529	ENSG00000257763.1	OR5BK1P	-3.96	8.17e-05	0.00526	-0.12	-0.12	Plateletcrit;	chr12:48079586	chr12:48355792~48356614:-
BRCA	cis	rs6751744	0.855	rs35019796	ENSG00000224152.1	AC009506.1	-3.95	8.17e-05	0.00526	-0.15	-0.12	Dysphagia;	chr2:159510644	chr2:159615296~159617082:+
BRCA	cis	rs1560104	0.709	rs3919630	ENSG00000259876.1	CTD-3037G24.4	3.95	8.17e-05	0.00526	0.13	0.12	Obesity-related traits;	chr16:12607086	chr16:12556353~12557694:-
BRCA	cis	rs3742264	0.656	rs4942460	ENSG00000235903.6	CPB2-AS1	-3.95	8.17e-05	0.00526	-0.14	-0.12	Blood protein levels;	chr13:45976308	chr13:46052806~46113332:+
BRCA	cis	rs721917	0.507	rs2819101	ENSG00000280355.1	RP11-119F19.5	-3.95	8.17e-05	0.00526	-0.13	-0.12	Chronic obstructive pulmonary disease;	chr10:79936986	chr10:79681973~79684094:-
BRCA	cis	rs80028505	0.908	rs58390233	ENSG00000271304.1	DPRXP2	3.95	8.17e-05	0.00526	0.24	0.12	Foot ulcer in diabetes and neuropathy;	chr6:36037323	chr6:35989515~35990436:-
BRCA	cis	rs7111546	0.514	rs1346251	ENSG00000246225.5	RP11-17A1.3	3.95	8.17e-05	0.00526	0.2	0.12	Dialysis-related mortality;	chr11:22974736	chr11:22829380~22945393:+
BRCA	cis	rs801193	0.967	rs2420827	ENSG00000223473.2	GS1-124K5.3	-3.95	8.17e-05	0.00526	-0.09	-0.12	Aortic root size;	chr7:66682114	chr7:66491049~66493566:-
BRCA	cis	rs651907	0.535	rs17412601	ENSG00000256628.3	ZBTB11-AS1	3.95	8.17e-05	0.00526	0.16	0.12	Colorectal cancer;	chr3:101780431	chr3:101676475~101679217:+
BRCA	cis	rs375066	0.935	rs399098	ENSG00000267191.1	RP11-15A1.2	-3.95	8.18e-05	0.00526	-0.16	-0.12	Breast cancer;	chr19:43914672	chr19:43902001~43926545:+
BRCA	cis	rs1577917	0.74	rs9353327	ENSG00000220563.1	PKMP3	-3.95	8.18e-05	0.00526	-0.12	-0.12	Response to antipsychotic treatment;	chr6:85684348	chr6:85659892~85660606:-
BRCA	cis	rs739496	0.947	rs2339816	ENSG00000257624.1	RP1-128M12.3	3.95	8.18e-05	0.00526	0.17	0.12	Platelet count;	chr12:111474384	chr12:112000739~112000985:-
BRCA	cis	rs2664588	0.773	rs11086234	ENSG00000276923.1	RP11-321P16.1	3.95	8.18e-05	0.00526	0.16	0.12	Cerebrospinal fluid AB1-42 levels;	chr20:47992187	chr20:48073869~48074188:+
BRCA	cis	rs1982963	1	rs4901186	ENSG00000277050.1	RP11-102G14.1	-3.95	8.18e-05	0.00526	-0.15	-0.12	Waist-to-hip ratio adjusted for body mass index;	chr14:52042766	chr14:51637348~51637947:-
BRCA	cis	rs651907	0.514	rs11706494	ENSG00000256628.3	ZBTB11-AS1	3.95	8.18e-05	0.00526	0.16	0.12	Colorectal cancer;	chr3:101790631	chr3:101676475~101679217:+
BRCA	cis	rs651907	0.535	rs34063583	ENSG00000256628.3	ZBTB11-AS1	3.95	8.18e-05	0.00526	0.16	0.12	Colorectal cancer;	chr3:101791104	chr3:101676475~101679217:+
BRCA	cis	rs7246967	0.932	rs4932800	ENSG00000198153.8	ZNF849P	-3.95	8.18e-05	0.00526	-0.17	-0.12	Bronchopulmonary dysplasia;	chr19:22868846	chr19:22685167~22686732:+
BRCA	cis	rs7246967	0.932	rs4932801	ENSG00000198153.8	ZNF849P	-3.95	8.18e-05	0.00526	-0.17	-0.12	Bronchopulmonary dysplasia;	chr19:22868851	chr19:22685167~22686732:+
BRCA	cis	rs1075265	0.749	rs6738369	ENSG00000272156.1	RP11-477N3.1	-3.95	8.18e-05	0.00526	-0.13	-0.12	Chronotype;Morning vs. evening chronotype;	chr2:53756547	chr2:54082554~54085066:+
BRCA	cis	rs17489649	1	rs17162081	ENSG00000271849.1	CTC-332L22.1	3.95	8.18e-05	0.00526	0.16	0.12	Intelligence (multi-trait analysis);	chr5:109698914	chr5:109687802~109688329:-
BRCA	cis	rs6496932	0.503	rs10520588	ENSG00000259630.2	CTD-2262B20.1	-3.95	8.19e-05	0.00527	-0.17	-0.12	Central corneal thickness;Corneal structure;	chr15:85419479	chr15:85415228~85415633:+
BRCA	cis	rs7800418	0.723	rs55716901	ENSG00000214870.7	AC004540.5	3.95	8.19e-05	0.00527	0.15	0.12	Cognitive function;	chr7:26551117	chr7:26398593~26494256:+
BRCA	cis	rs7800418	0.723	rs56156003	ENSG00000214870.7	AC004540.5	3.95	8.19e-05	0.00527	0.15	0.12	Cognitive function;	chr7:26551118	chr7:26398593~26494256:+
BRCA	cis	rs1371614	0.611	rs3845685	ENSG00000229122.1	AGBL5-IT1	-3.95	8.19e-05	0.00527	-0.13	-0.12	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26907464	chr2:27061038~27061815:+
BRCA	cis	rs9868809	0.505	rs11719291	ENSG00000225399.4	RP11-3B7.1	-3.95	8.19e-05	0.00527	-0.17	-0.12	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48698273	chr3:49260085~49261316:+
BRCA	cis	rs4374383	0.962	rs6710591	ENSG00000243389.1	AC012442.5	-3.95	8.19e-05	0.00527	-0.16	-0.12	Hepatitis C induced liver fibrosis;	chr2:112015789	chr2:112589040~112614431:+
BRCA	cis	rs7267979	1	rs2258879	ENSG00000125804.12	FAM182A	-3.95	8.19e-05	0.00527	-0.16	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25298577	chr20:26054655~26086917:+
BRCA	cis	rs7267979	1	rs2257496	ENSG00000125804.12	FAM182A	-3.95	8.19e-05	0.00527	-0.16	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25298679	chr20:26054655~26086917:+
BRCA	cis	rs7267979	1	rs2258884	ENSG00000125804.12	FAM182A	-3.95	8.19e-05	0.00527	-0.16	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25298903	chr20:26054655~26086917:+
BRCA	cis	rs7267979	1	rs2259837	ENSG00000125804.12	FAM182A	-3.95	8.19e-05	0.00527	-0.16	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25299569	chr20:26054655~26086917:+
BRCA	cis	rs7267979	1	rs2259873	ENSG00000125804.12	FAM182A	-3.95	8.19e-05	0.00527	-0.16	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25300145	chr20:26054655~26086917:+
BRCA	cis	rs6546324	0.625	rs2861698	ENSG00000236780.4	AC078941.1	3.95	8.19e-05	0.00527	0.21	0.12	Endometriosis;	chr2:67627676	chr2:67123357~67215319:-
BRCA	cis	rs73201462	0.901	rs6771646	ENSG00000242551.2	POU5F1P6	3.95	8.2e-05	0.00527	0.2	0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128315692	chr3:128674735~128677005:-
BRCA	cis	rs2665390	0.558	rs1397193	ENSG00000240875.4	LINC00886	3.95	8.2e-05	0.00527	0.21	0.12	Ovarian cancer in BRCA1 mutation carriers;Ovarian cancer;	chr3:156641491	chr3:156747346~156817062:-
BRCA	cis	rs2320614	1	rs4691894	ENSG00000250027.1	RP11-563E2.2	-3.95	8.2e-05	0.00527	-0.13	-0.12	Lung adenocarcinoma;	chr4:163126203	chr4:163108785~163119965:+
BRCA	cis	rs17772222	0.876	rs61983303	ENSG00000258789.1	RP11-507K2.3	-3.95	8.2e-05	0.00527	-0.15	-0.12	Coronary artery calcification;	chr14:88764459	chr14:88551597~88552493:+
BRCA	cis	rs1143633	0.53	rs4538207	ENSG00000231747.1	AC079922.2	-3.95	8.2e-05	0.00527	-0.12	-0.12	Allergic disease (asthma, hay fever or eczema);	chr2:112944286	chr2:112621809~112622167:-
BRCA	cis	rs10864907	0.614	rs7557537	ENSG00000231747.1	AC079922.2	-3.95	8.2e-05	0.00527	-0.12	-0.12	Pulmonary function;	chr2:112944953	chr2:112621809~112622167:-
BRCA	cis	rs8114671	0.552	rs2024635	ENSG00000261582.1	RP4-614O4.11	-3.95	8.2e-05	0.00527	-0.12	-0.12	Height;	chr20:34834811	chr20:35267885~35280043:-
BRCA	cis	rs718314	0.956	rs12814794	ENSG00000256894.1	RP11-283G6.3	-3.95	8.2e-05	0.00527	-0.14	-0.12	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Renal cell carcinoma;Waist circumference adjusted for body mass index;	chr12:26287765	chr12:26125155~26126617:-
BRCA	cis	rs7267979	1	rs11100	ENSG00000125804.12	FAM182A	-3.95	8.2e-05	0.00527	-0.16	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25300548	chr20:26054655~26086917:+
BRCA	cis	rs7267979	1	rs1046073	ENSG00000125804.12	FAM182A	-3.95	8.2e-05	0.00527	-0.16	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25300697	chr20:26054655~26086917:+
BRCA	cis	rs7267979	1	rs2259926	ENSG00000125804.12	FAM182A	-3.95	8.2e-05	0.00527	-0.16	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25301097	chr20:26054655~26086917:+
BRCA	cis	rs7267979	1	rs2259928	ENSG00000125804.12	FAM182A	-3.95	8.2e-05	0.00527	-0.16	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25301198	chr20:26054655~26086917:+
BRCA	cis	rs7267979	1	rs2259956	ENSG00000125804.12	FAM182A	-3.95	8.2e-05	0.00527	-0.16	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25301797	chr20:26054655~26086917:+
BRCA	cis	rs2692947	0.508	rs2216793	ENSG00000168992.4	OR7E102P	3.95	8.21e-05	0.00528	0.17	0.12	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95530574	chr2:95546531~95547545:+
BRCA	cis	rs11047510	0.824	rs57785077	ENSG00000164845.15	FAM86FP	3.95	8.21e-05	0.00528	0.19	0.12	Exploratory eye movement dysfunction in schizophrenia (responsive search score);	chr12:8848014	chr12:8232512~8242948:-
BRCA	cis	rs4561483	0.832	rs33645	ENSG00000261216.1	RP11-166B2.5	-3.95	8.21e-05	0.00528	-0.14	-0.12	Testicular germ cell tumor;	chr16:11891344	chr16:11908208~11908916:+
BRCA	cis	rs375066	0.935	rs11673020	ENSG00000278917.1	RP11-15A1.4	-3.95	8.21e-05	0.00528	-0.14	-0.12	Breast cancer;	chr19:43870479	chr19:43891233~43895411:+
BRCA	cis	rs6012564	1	rs6066977	ENSG00000222365.1	SNORD12B	3.95	8.21e-05	0.00528	0.13	0.12	Anger;	chr20:49138538	chr20:49280319~49280409:+
BRCA	cis	rs7246967	0.932	rs34949383	ENSG00000198153.8	ZNF849P	-3.95	8.21e-05	0.00528	-0.17	-0.12	Bronchopulmonary dysplasia;	chr19:22851056	chr19:22685167~22686732:+
BRCA	cis	rs34421088	0.548	rs2618443	ENSG00000154316.13	TDH	3.95	8.21e-05	0.00528	0.15	0.12	Neuroticism;	chr8:11527047	chr8:11339637~11368452:+
BRCA	cis	rs7267005	0.661	rs2425085	ENSG00000252549.1	RNU6-759P	-3.95	8.21e-05	0.00528	-0.3	-0.12	Response to paliperidone in schizophrenia (Multivariate);	chr20:35714480	chr20:35647328~35647430:-
BRCA	cis	rs13434995	0.513	rs1801260	ENSG00000239040.1	Y_RNA	3.95	8.21e-05	0.00528	0.14	0.12	Adiponectin levels;	chr4:55435202	chr4:55412636~55412738:+
BRCA	cis	rs13434995	0.513	rs17721215	ENSG00000239040.1	Y_RNA	3.95	8.21e-05	0.00528	0.14	0.12	Adiponectin levels;	chr4:55437620	chr4:55412636~55412738:+
BRCA	cis	rs1008375	0.9	rs6851783	ENSG00000249502.1	AC006160.5	-3.95	8.21e-05	0.00528	-0.15	-0.12	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17576846	chr4:17587467~17614571:-
BRCA	cis	rs7487075	1	rs7487075	ENSG00000272369.1	RP11-446N19.1	3.95	8.21e-05	0.00528	0.13	0.12	Itch intensity from mosquito bite;	chr12:46435135	chr12:46537502~46652550:+
BRCA	cis	rs13126694	0.778	rs6814979	ENSG00000251073.1	NUDT19P5	-3.95	8.21e-05	0.00528	-0.11	-0.12	Blood osmolality (transformed sodium);	chr4:158135798	chr4:158182825~158183393:+
BRCA	cis	rs42490	0.528	rs2840206	ENSG00000251136.7	RP11-37B2.1	3.95	8.21e-05	0.00528	0.12	0.12	Leprosy;	chr8:89670184	chr8:89609409~89757727:-
BRCA	cis	rs559406	0.54	rs2847286	ENSG00000260302.1	RP11-973H7.1	-3.95	8.21e-05	0.00528	-0.16	-0.12	Psoriasis;	chr18:12817816	chr18:12774651~12775923:-
BRCA	cis	rs2842992	0.513	rs7759086	ENSG00000251988.1	RNU4ATAC18P	3.95	8.22e-05	0.00528	0.15	0.12	Age-related macular degeneration (geographic atrophy);	chr6:159772821	chr6:159720415~159720540:-
BRCA	cis	rs1075265	0.756	rs1075264	ENSG00000272156.1	RP11-477N3.1	-3.95	8.22e-05	0.00528	-0.13	-0.12	Chronotype;Morning vs. evening chronotype;	chr2:54127916	chr2:54082554~54085066:+
BRCA	cis	rs897984	0.542	rs11864839	ENSG00000275263.1	RP11-1072A3.4	-3.95	8.22e-05	0.00528	-0.14	-0.12	Dementia with Lewy bodies;	chr16:31083930	chr16:30956872~30957199:-
BRCA	cis	rs11098499	0.863	rs10018280	ENSG00000260091.1	RP11-33B1.4	-3.95	8.22e-05	0.00528	-0.11	-0.12	Corneal astigmatism;	chr4:119556984	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.863	rs6534141	ENSG00000260091.1	RP11-33B1.4	-3.95	8.22e-05	0.00528	-0.11	-0.12	Corneal astigmatism;	chr4:119564068	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.863	rs2127823	ENSG00000260091.1	RP11-33B1.4	-3.95	8.22e-05	0.00528	-0.11	-0.12	Corneal astigmatism;	chr4:119564515	chr4:119409333~119410233:+
BRCA	cis	rs8114671	0.552	rs2024635	ENSG00000279253.1	RP4-614O4.13	-3.95	8.22e-05	0.00528	-0.14	-0.12	Height;	chr20:34834811	chr20:35262727~35264187:-
BRCA	cis	rs73201462	0.908	rs2999081	ENSG00000242551.2	POU5F1P6	3.95	8.22e-05	0.00528	0.2	0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128237429	chr3:128674735~128677005:-
BRCA	cis	rs2243480	0.901	rs778732	ENSG00000275400.1	RP4-756H11.5	3.95	8.22e-05	0.00528	0.23	0.12	Diabetic kidney disease;	chr7:66357373	chr7:66553805~66554199:-
BRCA	cis	rs7412746	0.658	rs17660092	ENSG00000224800.1	RP11-235D19.2	-3.95	8.22e-05	0.00528	-0.15	-0.12	Melanoma;	chr1:150825272	chr1:150881236~150881683:-
BRCA	cis	rs2625529	0.668	rs8192386	ENSG00000260037.4	CTD-2524L6.3	3.95	8.22e-05	0.00529	0.17	0.12	Red blood cell count;	chr15:72220807	chr15:71818396~71823384:+
BRCA	cis	rs2898290	0.592	rs2736342	ENSG00000251402.3	FAM90A25P	-3.95	8.22e-05	0.00529	-0.14	-0.12	Systolic blood pressure;	chr8:11489780	chr8:12415080~12418090:-
BRCA	cis	rs6893300	1	rs62406176	ENSG00000225051.5	HMGB3P22	3.95	8.23e-05	0.00529	0.16	0.12	Resting heart rate;	chr5:179737142	chr5:179679032~179694768:+
BRCA	cis	rs16950303	1	rs57049169	ENSG00000265496.3	MIR1539	3.95	8.23e-05	0.00529	0.25	0.12	Height;	chr18:49039427	chr18:49487339~49491878:+
BRCA	cis	rs4415084	0.966	rs4463188	ENSG00000248779.1	RP11-53O19.2	3.95	8.23e-05	0.00529	0.11	0.12	Breast cancer;	chr5:44642568	chr5:44752949~44765744:+
BRCA	cis	rs990171	0.538	rs11682754	ENSG00000234389.1	AC007278.3	3.95	8.23e-05	0.00529	0.12	0.12	Lymphocyte counts;	chr2:102500636	chr2:102438713~102440475:+
BRCA	cis	rs990171	0.538	rs4851600	ENSG00000234389.1	AC007278.3	-3.95	8.23e-05	0.00529	-0.12	-0.12	Lymphocyte counts;	chr2:102499764	chr2:102438713~102440475:+
BRCA	cis	rs1008375	0.931	rs2315558	ENSG00000249502.1	AC006160.5	-3.95	8.23e-05	0.00529	-0.14	-0.12	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17672935	chr4:17587467~17614571:-
BRCA	cis	rs6005807	0.668	rs9620808	ENSG00000272858.1	CTA-292E10.8	-3.95	8.23e-05	0.00529	-0.22	-0.12	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28597343	chr22:28814914~28815662:+
BRCA	cis	rs6005807	0.668	rs60065194	ENSG00000272858.1	CTA-292E10.8	-3.95	8.23e-05	0.00529	-0.22	-0.12	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28597768	chr22:28814914~28815662:+
BRCA	cis	rs13217239	0.646	rs11756275	ENSG00000224843.5	LINC00240	3.95	8.24e-05	0.00529	0.14	0.12	Schizophrenia;	chr6:27039334	chr6:26956992~27023924:+
BRCA	cis	rs13108904	0.935	rs1732100	ENSG00000253399.1	AC078852.2	3.95	8.24e-05	0.00529	0.13	0.12	Obesity-related traits;	chr4:1287973	chr4:1358479~1359461:+
BRCA	cis	rs9525927	0.57	rs7400099	ENSG00000227258.4	SMIM2-AS1	-3.95	8.24e-05	0.00529	-0.18	-0.12	Dupuytren's disease;	chr13:44230344	chr13:44110451~44240517:+
BRCA	cis	rs4713118	0.869	rs4713121	ENSG00000219392.1	RP1-265C24.5	-3.95	8.24e-05	0.00529	-0.17	-0.12	Parkinson's disease;	chr6:27754285	chr6:28115628~28116551:+
BRCA	cis	rs4950322	0.542	rs4950382	ENSG00000237188.3	RP11-337C18.8	3.95	8.24e-05	0.0053	0.13	0.12	Protein quantitative trait loci;	chr1:147176645	chr1:147172771~147211568:+
BRCA	cis	rs1153858	1	rs7402650	ENSG00000275672.1	GATM-AS1	-3.95	8.24e-05	0.0053	-0.16	-0.12	Homoarginine levels;	chr15:45409697	chr15:45378700~45380123:+
BRCA	cis	rs4478858	0.684	rs4949373	ENSG00000223907.1	LINC01226	-3.95	8.24e-05	0.0053	-0.15	-0.12	Alcohol dependence;	chr1:31268730	chr1:31518435~31524245:+
BRCA	cis	rs4478858	0.684	rs7544946	ENSG00000223907.1	LINC01226	-3.95	8.24e-05	0.0053	-0.15	-0.12	Alcohol dependence;	chr1:31276889	chr1:31518435~31524245:+
BRCA	cis	rs4478858	0.684	rs7549245	ENSG00000223907.1	LINC01226	-3.95	8.24e-05	0.0053	-0.15	-0.12	Alcohol dependence;	chr1:31279340	chr1:31518435~31524245:+
BRCA	cis	rs4478858	0.684	rs4949374	ENSG00000223907.1	LINC01226	-3.95	8.24e-05	0.0053	-0.15	-0.12	Alcohol dependence;	chr1:31281664	chr1:31518435~31524245:+
BRCA	cis	rs4478858	0.684	rs3766289	ENSG00000223907.1	LINC01226	-3.95	8.24e-05	0.0053	-0.15	-0.12	Alcohol dependence;	chr1:31287281	chr1:31518435~31524245:+
BRCA	cis	rs4478858	0.684	rs7521463	ENSG00000223907.1	LINC01226	-3.95	8.24e-05	0.0053	-0.15	-0.12	Alcohol dependence;	chr1:31289089	chr1:31518435~31524245:+
BRCA	cis	rs4478858	0.611	rs7527645	ENSG00000223907.1	LINC01226	-3.95	8.24e-05	0.0053	-0.15	-0.12	Alcohol dependence;	chr1:31290940	chr1:31518435~31524245:+
BRCA	cis	rs9818758	0.607	rs73084135	ENSG00000270441.1	RP11-694I15.7	3.95	8.24e-05	0.0053	0.27	0.12	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49234785	chr3:49140086~49160851:-
BRCA	cis	rs11098499	0.865	rs11098513	ENSG00000260404.2	RP11-384K6.6	3.95	8.24e-05	0.0053	0.11	0.12	Corneal astigmatism;	chr4:119394920	chr4:118591773~118633729:+
BRCA	cis	rs3742597	0.84	rs66492349	ENSG00000276116.2	FUT8-AS1	-3.95	8.25e-05	0.0053	-0.14	-0.12	N-glycan levels;	chr14:65372771	chr14:65411170~65412690:-
BRCA	cis	rs11085466	1	rs73552468	ENSG00000268081.1	RP11-678G14.2	-3.95	8.25e-05	0.0053	-0.19	-0.12	Colorectal or endometrial cancer;	chr19:21589295	chr19:21554640~21569237:-
BRCA	cis	rs11098499	0.69	rs34818745	ENSG00000250412.1	KLHL2P1	3.95	8.25e-05	0.0053	0.14	0.12	Corneal astigmatism;	chr4:119335900	chr4:119334329~119378233:+
BRCA	cis	rs524281	0.731	rs476551	ENSG00000255038.1	RP11-1167A19.2	-3.95	8.25e-05	0.0053	-0.18	-0.12	Electroencephalogram traits;	chr11:66238852	chr11:66067277~66069619:-
BRCA	cis	rs375066	0.935	rs397346	ENSG00000278917.1	RP11-15A1.4	-3.95	8.25e-05	0.0053	-0.14	-0.12	Breast cancer;	chr19:43894963	chr19:43891233~43895411:+
BRCA	cis	rs7267979	1	rs2258617	ENSG00000125804.12	FAM182A	-3.95	8.25e-05	0.0053	-0.16	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25293682	chr20:26054655~26086917:+
BRCA	cis	rs62458065	0.85	rs28677012	ENSG00000229358.3	DPY19L1P1	-3.95	8.25e-05	0.0053	-0.17	-0.12	Metabolite levels (HVA/MHPG ratio);	chr7:32430199	chr7:32580949~32761787:-
BRCA	cis	rs890448	0.694	rs2850330	ENSG00000254531.1	FLJ20021	-3.95	8.25e-05	0.0053	-0.14	-0.12	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101356898	chr4:101347780~101348883:+
BRCA	cis	rs890448	0.726	rs2850331	ENSG00000254531.1	FLJ20021	-3.95	8.25e-05	0.0053	-0.14	-0.12	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101357211	chr4:101347780~101348883:+
BRCA	cis	rs11098499	0.909	rs28714195	ENSG00000250412.1	KLHL2P1	3.95	8.25e-05	0.0053	0.14	0.12	Corneal astigmatism;	chr4:119395795	chr4:119334329~119378233:+
BRCA	cis	rs757081	0.658	rs105290	ENSG00000272034.1	SNORD14A	-3.95	8.25e-05	0.0053	-0.13	-0.12	Systolic blood pressure;	chr11:17270521	chr11:17074654~17074744:-
BRCA	cis	rs4849121	0.535	rs11892748	ENSG00000235721.1	AC013268.3	-3.95	8.26e-05	0.0053	-0.16	-0.12	IgA nephropathy;	chr2:110843417	chr2:110007675~110010783:+
BRCA	cis	rs11098499	0.73	rs78971550	ENSG00000260404.2	RP11-384K6.6	3.95	8.26e-05	0.0053	0.11	0.12	Corneal astigmatism;	chr4:119359886	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.645	rs78422072	ENSG00000260404.2	RP11-384K6.6	3.95	8.26e-05	0.0053	0.11	0.12	Corneal astigmatism;	chr4:119359887	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.954	rs10017371	ENSG00000260091.1	RP11-33B1.4	-3.95	8.26e-05	0.0053	-0.11	-0.12	Corneal astigmatism;	chr4:119372621	chr4:119409333~119410233:+
BRCA	cis	rs6452524	0.935	rs2386241	ENSG00000281327.1	LINC01338	-3.95	8.26e-05	0.0053	-0.15	-0.12	Hypertension (SNP x SNP interaction);	chr5:83149872	chr5:82850864~82859836:-
BRCA	cis	rs4834770	0.765	rs1511016	ENSG00000248280.1	RP11-33B1.2	3.95	8.26e-05	0.00531	0.12	0.12	Blood protein levels;	chr4:119249200	chr4:119440561~119450157:-
BRCA	cis	rs875971	1	rs10244498	ENSG00000273448.1	RP11-166O4.6	3.95	8.26e-05	0.00531	0.11	0.12	Aortic root size;	chr7:66651069	chr7:67333047~67334383:+
BRCA	cis	rs651907	0.535	rs34161138	ENSG00000256628.3	ZBTB11-AS1	3.95	8.26e-05	0.00531	0.16	0.12	Colorectal cancer;	chr3:101791544	chr3:101676475~101679217:+
BRCA	cis	rs11098499	0.909	rs28555550	ENSG00000225892.3	RP11-384K6.2	3.95	8.26e-05	0.00531	0.12	0.12	Corneal astigmatism;	chr4:119289885	chr4:118632274~118634759:+
BRCA	cis	rs11098499	1	rs28419773	ENSG00000225892.3	RP11-384K6.2	3.95	8.26e-05	0.00531	0.12	0.12	Corneal astigmatism;	chr4:119289906	chr4:118632274~118634759:+
BRCA	cis	rs513088	0.645	rs526834	ENSG00000225171.2	DUTP6	3.95	8.26e-05	0.00531	0.17	0.12	Schizophrenia;	chr1:166726549	chr1:166868748~166869209:+
BRCA	cis	rs875971	0.522	rs1968127	ENSG00000223473.2	GS1-124K5.3	-3.95	8.27e-05	0.00531	-0.09	-0.12	Aortic root size;	chr7:66591816	chr7:66491049~66493566:-
BRCA	cis	rs910316	0.967	rs12147532	ENSG00000259138.1	RP11-950C14.7	-3.95	8.27e-05	0.00531	-0.13	-0.12	Height;	chr14:75185155	chr14:75127153~75136930:+
BRCA	cis	rs7615952	0.673	rs35001498	ENSG00000248787.1	RP11-666A20.4	-3.95	8.27e-05	0.00531	-0.24	-0.12	Blood pressure (smoking interaction);	chr3:125909801	chr3:125908005~125910272:-
BRCA	cis	rs2301573	0.584	rs12638238	ENSG00000271270.4	TMCC1-AS1	-3.95	8.27e-05	0.00531	-0.26	-0.12	Hip circumference;	chr3:129888979	chr3:129893871~129918575:+
BRCA	cis	rs2243480	1	rs1723270	ENSG00000226002.1	RP11-460N20.5	-3.95	8.27e-05	0.00531	-0.2	-0.12	Diabetic kidney disease;	chr7:66004843	chr7:65084103~65100232:+
BRCA	cis	rs595244	1	rs11636344	ENSG00000259705.1	RP11-227D13.1	-3.95	8.27e-05	0.00531	-0.19	-0.12	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48423040	chr15:48645951~48652016:+
BRCA	cis	rs7621331	0.963	rs13317459	ENSG00000239213.4	NCK1-AS1	-3.95	8.27e-05	0.00531	-0.15	-0.12	Waist circumference adjusted for body mass index;	chr3:135951214	chr3:136841726~136862054:-
BRCA	cis	rs2439831	0.85	rs3742982	ENSG00000206991.1	RNU6-610P	-3.95	8.27e-05	0.00531	-0.2	-0.12	Lung cancer in ever smokers;	chr15:43884483	chr15:43637632~43637738:-
BRCA	cis	rs748404	0.626	rs57938858	ENSG00000201136.1	RNU6-353P	3.95	8.27e-05	0.00531	0.18	0.12	Lung cancer;	chr15:43520259	chr15:43702363~43702470:+
BRCA	cis	rs11098499	0.618	rs28491261	ENSG00000250412.1	KLHL2P1	3.95	8.27e-05	0.00531	0.14	0.12	Corneal astigmatism;	chr4:119373745	chr4:119334329~119378233:+
BRCA	cis	rs875971	0.642	rs35526611	ENSG00000229180.5	GS1-124K5.11	-3.95	8.27e-05	0.00531	-0.11	-0.12	Aortic root size;	chr7:66629021	chr7:66526088~66542624:-
BRCA	cis	rs2832191	0.716	rs1888440	ENSG00000215533.7	LINC00189	-3.95	8.27e-05	0.00531	-0.14	-0.12	Dental caries;	chr21:29082163	chr21:29193480~29288205:+
BRCA	cis	rs116175783	0.557	rs62194490	ENSG00000235724.7	AC009299.2	3.95	8.27e-05	0.00531	0.18	0.12	Intelligence (multi-trait analysis);	chr2:161344287	chr2:161222785~161308303:-
BRCA	cis	rs1910358	0.554	rs1826235	ENSG00000248874.4	C5orf17	-3.95	8.27e-05	0.00531	-0.17	-0.12	Venous thromboembolism (SNP x SNP interaction);	chr5:23805259	chr5:23951348~24178263:+
BRCA	cis	rs1665650	0.957	rs1638416	ENSG00000232767.1	RP11-498B4.5	-3.95	8.27e-05	0.00531	-0.13	-0.12	Colorectal cancer;	chr10:116734688	chr10:116670103~116672739:+
BRCA	cis	rs72615157	0.634	rs7789890	ENSG00000242294.5	STAG3L5P	3.95	8.27e-05	0.00531	0.12	0.12	Lung function (FEV1/FVC);	chr7:100202936	chr7:100336079~100351900:+
BRCA	cis	rs524281	0.773	rs7925123	ENSG00000255038.1	RP11-1167A19.2	-3.95	8.27e-05	0.00531	-0.19	-0.12	Electroencephalogram traits;	chr11:66225742	chr11:66067277~66069619:-
BRCA	cis	rs2991971	0.81	rs6657237	ENSG00000280836.1	AL355480.1	-3.95	8.27e-05	0.00531	-0.15	-0.12	High light scatter reticulocyte count;	chr1:45454436	chr1:45581219~45581321:-
BRCA	cis	rs11603691	0.901	rs11228995	ENSG00000254662.1	RP11-872D17.4	-3.95	8.27e-05	0.00531	-0.26	-0.12	Low high density lipoprotein cholesterol levels;	chr11:57316061	chr11:57325603~57327958:+
BRCA	cis	rs911119	1	rs73318135	ENSG00000270001.1	RP11-218C14.8	-3.95	8.27e-05	0.00531	-0.16	-0.12	Chronic kidney disease;	chr20:23637934	chr20:23631826~23632316:-
BRCA	cis	rs7819412	0.811	rs2409691	ENSG00000154316.13	TDH	3.95	8.27e-05	0.00531	0.16	0.12	Triglycerides;	chr8:11085766	chr8:11339637~11368452:+
BRCA	cis	rs9863	0.828	rs12303933	ENSG00000270028.1	RP11-380L11.4	3.95	8.28e-05	0.00532	0.15	0.12	White blood cell count;	chr12:123997709	chr12:123925461~123926083:-
BRCA	cis	rs874628	0.851	rs4808765	ENSG00000268650.3	AC068499.10	3.95	8.28e-05	0.00532	0.16	0.12	Multiple sclerosis;	chr19:18223633	chr19:18204730~18220480:+
BRCA	cis	rs11098499	0.954	rs6834796	ENSG00000260404.2	RP11-384K6.6	3.95	8.28e-05	0.00532	0.12	0.12	Corneal astigmatism;	chr4:119493538	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.954	rs11734241	ENSG00000260404.2	RP11-384K6.6	3.95	8.28e-05	0.00532	0.12	0.12	Corneal astigmatism;	chr4:119495717	chr4:118591773~118633729:+
BRCA	cis	rs2136613	0.751	rs10995324	ENSG00000238280.1	RP11-436D10.3	3.95	8.28e-05	0.00532	0.15	0.12	Selective IgA deficiency;	chr10:62838233	chr10:62793562~62805887:-
BRCA	cis	rs875971	0.577	rs35072105	ENSG00000223473.2	GS1-124K5.3	-3.95	8.28e-05	0.00532	-0.09	-0.12	Aortic root size;	chr7:66144830	chr7:66491049~66493566:-
BRCA	cis	rs4671400	0.571	rs62152270	ENSG00000273302.1	RP11-493E12.2	-3.95	8.28e-05	0.00532	-0.13	-0.12	3-hydroxypropylmercapturic acid levels in smokers;	chr2:61267125	chr2:61199979~61200769:+
BRCA	cis	rs804280	1	rs804280	ENSG00000255046.1	RP11-297N6.4	-3.95	8.28e-05	0.00532	-0.14	-0.12	Myopia (pathological);	chr8:11755189	chr8:11797928~11802568:-
BRCA	cis	rs6452524	0.935	rs1580311	ENSG00000281327.1	LINC01338	3.95	8.28e-05	0.00532	0.14	0.12	Hypertension (SNP x SNP interaction);	chr5:83091667	chr5:82850864~82859836:-
BRCA	cis	rs1153858	1	rs12440038	ENSG00000275672.1	GATM-AS1	-3.95	8.28e-05	0.00532	-0.16	-0.12	Homoarginine levels;	chr15:45414541	chr15:45378700~45380123:+
BRCA	cis	rs911119	1	rs71334202	ENSG00000270001.1	RP11-218C14.8	-3.95	8.29e-05	0.00532	-0.16	-0.12	Chronic kidney disease;	chr20:23638015	chr20:23631826~23632316:-
BRCA	cis	rs1555322	1	rs2425031	ENSG00000261582.1	RP4-614O4.11	-3.95	8.29e-05	0.00532	-0.16	-0.12	Attention deficit hyperactivity disorder;	chr20:35267481	chr20:35267885~35280043:-
BRCA	cis	rs875971	0.895	rs4145009	ENSG00000271064.1	RP11-792A8.3	3.95	8.29e-05	0.00532	0.14	0.12	Aortic root size;	chr7:66261628	chr7:66748838~66749077:-
BRCA	cis	rs4835473	0.864	rs7681559	ENSG00000249741.2	RP11-673E1.3	3.95	8.29e-05	0.00532	0.14	0.12	Immature fraction of reticulocytes;	chr4:143695248	chr4:143911514~143912053:-
BRCA	cis	rs875971	0.638	rs6460305	ENSG00000223473.2	GS1-124K5.3	-3.95	8.29e-05	0.00532	-0.09	-0.12	Aortic root size;	chr7:66595421	chr7:66491049~66493566:-
BRCA	cis	rs8180040	0.654	rs62246451	ENSG00000271161.1	BOLA2P2	-3.95	8.29e-05	0.00532	-0.13	-0.12	Colorectal cancer;	chr3:47170142	chr3:47499841~47500407:+
BRCA	cis	rs8180040	0.627	rs58956475	ENSG00000271161.1	BOLA2P2	-3.95	8.29e-05	0.00532	-0.13	-0.12	Colorectal cancer;	chr3:47183125	chr3:47499841~47500407:+
BRCA	cis	rs651907	0.535	rs34263427	ENSG00000256628.3	ZBTB11-AS1	3.95	8.29e-05	0.00532	0.16	0.12	Colorectal cancer;	chr3:101788961	chr3:101676475~101679217:+
BRCA	cis	rs6600671	1	rs1986111	ENSG00000231429.2	RP11-343N15.2	-3.95	8.29e-05	0.00532	-0.15	-0.12	Hip geometry;	chr1:121462934	chr1:121412719~121429274:+
BRCA	cis	rs4374383	0.884	rs13385764	ENSG00000243389.1	AC012442.5	-3.95	8.29e-05	0.00532	-0.16	-0.12	Hepatitis C induced liver fibrosis;	chr2:111989314	chr2:112589040~112614431:+
BRCA	cis	rs9470794	1	rs9462394	ENSG00000204110.6	RP1-153P14.8	-3.95	8.29e-05	0.00532	-0.19	-0.12	Type 2 diabetes;	chr6:38159426	chr6:37507348~37535616:+
BRCA	cis	rs2274459	1	rs34869648	ENSG00000249346.5	LINC01016	3.95	8.29e-05	0.00533	0.16	0.12	Obesity (extreme);	chr6:33756282	chr6:33867506~33896914:-
BRCA	cis	rs9437689	0.966	rs12563592	ENSG00000235501.4	RP4-639F20.1	3.95	8.29e-05	0.00533	0.15	0.12	Phospholipid levels (plasma);	chr1:95111204	chr1:94927566~94963270:+
BRCA	cis	rs897984	0.609	rs57576577	ENSG00000275263.1	RP11-1072A3.4	-3.95	8.3e-05	0.00533	-0.14	-0.12	Dementia with Lewy bodies;	chr16:31025046	chr16:30956872~30957199:-
BRCA	cis	rs6088590	1	rs6120747	ENSG00000276073.1	RP5-1125A11.7	-3.95	8.3e-05	0.00533	-0.14	-0.12	Coronary artery disease;	chr20:34861966	chr20:33985617~33988989:-
BRCA	cis	rs977987	0.778	rs4888413	ENSG00000280152.1	RP11-331F4.5	-3.95	8.3e-05	0.00533	-0.13	-0.12	Dupuytren's disease;	chr16:75409325	chr16:75245994~75250077:-
BRCA	cis	rs977987	0.778	rs8057849	ENSG00000280152.1	RP11-331F4.5	-3.95	8.3e-05	0.00533	-0.13	-0.12	Dupuytren's disease;	chr16:75409918	chr16:75245994~75250077:-
BRCA	cis	rs6430585	0.527	rs12467569	ENSG00000231890.6	DARS-AS1	-3.95	8.3e-05	0.00533	-0.19	-0.12	Corneal structure;	chr2:135656277	chr2:135985176~136022593:+
BRCA	cis	rs17772222	0.917	rs12431548	ENSG00000258789.1	RP11-507K2.3	-3.95	8.3e-05	0.00533	-0.15	-0.12	Coronary artery calcification;	chr14:88635826	chr14:88551597~88552493:+
BRCA	cis	rs6480314	0.522	rs10733842	ENSG00000233590.1	RP11-153K11.3	3.95	8.3e-05	0.00533	0.18	0.12	Optic nerve measurement (disc area);	chr10:68299286	chr10:68233251~68242379:-
BRCA	cis	rs853679	0.517	rs9380047	ENSG00000261839.1	RP1-265C24.8	3.95	8.3e-05	0.00533	0.17	0.12	Depression;	chr6:28070115	chr6:28136849~28139678:+
BRCA	cis	rs17406451	0.819	rs7589033	ENSG00000234936.1	AC010883.5	3.95	8.3e-05	0.00533	0.13	0.12	Mitochondrial DNA levels;	chr2:43422089	chr2:43229573~43233394:+
BRCA	cis	rs859767	0.672	rs10203582	ENSG00000224043.6	CCNT2-AS1	3.95	8.3e-05	0.00533	0.16	0.12	Neuroticism;	chr2:134605269	chr2:134735464~134918710:-
BRCA	cis	rs7267979	1	rs2500443	ENSG00000274414.1	RP5-965G21.4	3.95	8.3e-05	0.00533	0.14	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25350806	chr20:25239007~25245229:-
BRCA	cis	rs35146811	0.735	rs11767968	ENSG00000235713.1	RP4-604G5.3	3.95	8.3e-05	0.00533	0.14	0.12	Coronary artery disease;	chr7:100193348	chr7:99992397~99993050:+
BRCA	cis	rs730566	1	rs730566	ENSG00000244380.1	RP11-24C3.2	-3.95	8.31e-05	0.00533	-0.16	-0.12	Prion diseases;	chr3:48445644	chr3:48440352~48446656:-
BRCA	cis	rs56309584	0.715	rs3027234	ENSG00000269947.1	RP11-849F2.9	-3.95	8.31e-05	0.00533	-0.17	-0.12	Initial pursuit acceleration;	chr17:8232774	chr17:8277763~8278436:+
BRCA	cis	rs924712	0.604	rs10807484	ENSG00000224984.1	RP11-524H19.2	3.95	8.31e-05	0.00533	0.15	0.12	Breast cancer;	chr6:54854687	chr6:54840118~54840855:-
BRCA	cis	rs9863	0.827	rs7134121	ENSG00000270028.1	RP11-380L11.4	3.95	8.31e-05	0.00533	0.15	0.12	White blood cell count;	chr12:123962799	chr12:123925461~123926083:-
BRCA	cis	rs42490	0.528	rs7004089	ENSG00000251136.7	RP11-37B2.1	3.95	8.31e-05	0.00533	0.12	0.12	Leprosy;	chr8:89688329	chr8:89609409~89757727:-
BRCA	cis	rs6500602	0.767	rs8060219	ENSG00000280063.1	RP11-295D4.3	3.95	8.31e-05	0.00533	0.09	0.12	Schizophrenia;	chr16:4430157	chr16:4346694~4348648:-
BRCA	cis	rs10181042	0.514	rs1177289	ENSG00000270820.4	RP11-355B11.2	3.95	8.31e-05	0.00533	0.14	0.12	Crohn's disease;	chr2:61126121	chr2:61471188~61484130:+
BRCA	cis	rs12210905	1	rs9368492	ENSG00000216901.1	AL022393.7	3.95	8.31e-05	0.00534	0.22	0.12	Hip circumference adjusted for BMI;	chr6:27253739	chr6:28176188~28176674:+
BRCA	cis	rs77106637	0.86	rs11603334	ENSG00000245148.2	ARAP1-AS2	-3.95	8.31e-05	0.00534	-0.17	-0.12	Type 2 diabetes;	chr11:72721940	chr11:72700474~72705607:+
BRCA	cis	rs10266483	0.639	rs6952592	ENSG00000271550.1	BNIP3P11	3.95	8.31e-05	0.00534	0.16	0.12	Response to statin therapy;	chr7:64293667	chr7:64678954~64687393:-
BRCA	cis	rs78545713	0.649	rs79759076	ENSG00000241549.7	GUSBP2	-3.95	8.31e-05	0.00534	-0.2	-0.12	Iron status biomarkers (total iron binding capacity);	chr6:26223466	chr6:26871484~26956554:-
BRCA	cis	rs78545713	0.649	rs74928264	ENSG00000241549.7	GUSBP2	-3.95	8.31e-05	0.00534	-0.2	-0.12	Iron status biomarkers (total iron binding capacity);	chr6:26224115	chr6:26871484~26956554:-
BRCA	cis	rs78545713	0.649	rs79308455	ENSG00000241549.7	GUSBP2	-3.95	8.31e-05	0.00534	-0.2	-0.12	Iron status biomarkers (total iron binding capacity);	chr6:26224149	chr6:26871484~26956554:-
BRCA	cis	rs78545713	0.536	rs56119218	ENSG00000241549.7	GUSBP2	-3.95	8.31e-05	0.00534	-0.2	-0.12	Iron status biomarkers (total iron binding capacity);	chr6:26225653	chr6:26871484~26956554:-
BRCA	cis	rs360929	0.935	rs360926	ENSG00000245954.5	RP11-18H21.1	3.95	8.32e-05	0.00534	0.14	0.12	Volumetric brain MRI;	chr4:151984318	chr4:152100754~152104720:+
BRCA	cis	rs1865760	1	rs9348698	ENSG00000272462.2	U91328.19	-3.95	8.32e-05	0.00534	-0.15	-0.12	Height;	chr6:25929461	chr6:25992662~26001775:+
BRCA	cis	rs801193	1	rs2055682	ENSG00000229180.5	GS1-124K5.11	3.95	8.32e-05	0.00534	0.1	0.12	Aortic root size;	chr7:66795302	chr7:66526088~66542624:-
BRCA	cis	rs6751744	0.855	rs6432534	ENSG00000224152.1	AC009506.1	-3.95	8.32e-05	0.00534	-0.15	-0.12	Dysphagia;	chr2:159521561	chr2:159615296~159617082:+
BRCA	cis	rs8054556	0.692	rs4788199	ENSG00000214725.6	CDIPT-AS1	-3.95	8.32e-05	0.00534	-0.15	-0.12	Autism spectrum disorder or schizophrenia;	chr16:29959536	chr16:29863593~29868053:+
BRCA	cis	rs651907	0.535	rs11711903	ENSG00000256628.3	ZBTB11-AS1	3.95	8.32e-05	0.00534	0.15	0.12	Colorectal cancer;	chr3:101781904	chr3:101676475~101679217:+
BRCA	cis	rs2337406	1	rs17095456	ENSG00000280411.1	IGHV1-69-2	-3.95	8.32e-05	0.00534	-0.11	-0.12	Alzheimer's disease (late onset);	chr14:106676559	chr14:106762092~106762588:-
BRCA	cis	rs7267979	0.966	rs2261784	ENSG00000276952.1	RP5-965G21.6	3.95	8.32e-05	0.00534	0.15	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25281760	chr20:25284915~25285588:-
BRCA	cis	rs7267979	0.966	rs2261785	ENSG00000276952.1	RP5-965G21.6	3.95	8.32e-05	0.00534	0.15	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25281767	chr20:25284915~25285588:-
BRCA	cis	rs11887277	0.741	rs36115338	ENSG00000272148.1	RP11-195B17.1	-3.95	8.32e-05	0.00534	-0.14	-0.12	Obesity-related traits;	chr2:26815574	chr2:27062428~27062907:-
BRCA	cis	rs911119	0.955	rs2067488	ENSG00000270001.1	RP11-218C14.8	-3.95	8.32e-05	0.00534	-0.15	-0.12	Chronic kidney disease;	chr20:23613694	chr20:23631826~23632316:-
BRCA	cis	rs7267979	0.932	rs446649	ENSG00000274414.1	RP5-965G21.4	-3.95	8.32e-05	0.00534	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25486723	chr20:25239007~25245229:-
BRCA	cis	rs1434579	0.865	rs12983504	ENSG00000176761.7	ZNF285B	-3.95	8.32e-05	0.00534	-0.15	-0.12	Tuberculosis;	chr19:44438776	chr19:44467641~44473227:+
BRCA	cis	rs11098499	1	rs11098500	ENSG00000225892.3	RP11-384K6.2	3.95	8.32e-05	0.00534	0.12	0.12	Corneal astigmatism;	chr4:119298084	chr4:118632274~118634759:+
BRCA	cis	rs17783634	0.509	rs11775489	ENSG00000255046.1	RP11-297N6.4	3.95	8.33e-05	0.00534	0.15	0.12	Subjective well-being;	chr8:11179334	chr8:11797928~11802568:-
BRCA	cis	rs7267979	1	rs2482937	ENSG00000274414.1	RP5-965G21.4	3.95	8.33e-05	0.00534	0.14	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25360150	chr20:25239007~25245229:-
BRCA	cis	rs7636293	1	rs6439169	ENSG00000270773.1	RP13-685P2.7	3.95	8.33e-05	0.00534	0.14	0.12	Height;	chr3:129332792	chr3:129345411~129346164:+
BRCA	cis	rs8180040	0.654	rs4682831	ENSG00000280667.1	Y_RNA	-3.95	8.33e-05	0.00534	-0.13	-0.12	Colorectal cancer;	chr3:46985648	chr3:47501083~47501182:+
BRCA	cis	rs7618915	1	rs59565798	ENSG00000239557.1	RP11-168J18.6	3.95	8.33e-05	0.00534	0.17	0.12	Bipolar disorder;	chr3:52273153	chr3:52373652~52374882:+
BRCA	cis	rs10986311	0.816	rs912355	ENSG00000227200.1	RP11-121A14.3	3.95	8.33e-05	0.00534	0.15	0.12	Vitiligo;	chr9:124328687	chr9:124262876~124265809:+
BRCA	cis	rs3764021	0.87	rs2401391	ENSG00000256582.1	RP11-75L1.1	3.95	8.33e-05	0.00535	0.12	0.12	Type 1 diabetes;	chr12:9725987	chr12:9704077~9709350:+
BRCA	cis	rs875971	1	rs12532998	ENSG00000265600.1	AC006480.1	-3.95	8.33e-05	0.00535	-0.14	-0.12	Aortic root size;	chr7:66502472	chr7:67356680~67356779:+
BRCA	cis	rs1912124	1	rs67601221	ENSG00000271983.1	RP11-28H5.2	3.95	8.33e-05	0.00535	0.24	0.12	Peripheral arterial disease (traffic-related air pollution interaction);	chr15:81186610	chr15:80693216~80693707:-
BRCA	cis	rs794185	0.714	rs711636	ENSG00000231249.1	ITPR1-AS1	-3.95	8.33e-05	0.00535	-0.14	-0.12	Multiple sclerosis--Brain Glutamate Levels;	chr3:4448093	chr3:4490891~4493163:-
BRCA	cis	rs6964587	0.967	rs10429103	ENSG00000188693.7	CYP51A1-AS1	-3.95	8.33e-05	0.00535	-0.13	-0.12	Breast cancer;	chr7:91969129	chr7:92134604~92180725:+
BRCA	cis	rs6964587	1	rs2188155	ENSG00000188693.7	CYP51A1-AS1	-3.95	8.33e-05	0.00535	-0.13	-0.12	Breast cancer;	chr7:91970511	chr7:92134604~92180725:+
BRCA	cis	rs6964587	0.967	rs28615927	ENSG00000188693.7	CYP51A1-AS1	-3.95	8.33e-05	0.00535	-0.13	-0.12	Breast cancer;	chr7:91971334	chr7:92134604~92180725:+
BRCA	cis	rs11048434	0.518	rs2377679	ENSG00000256069.6	A2MP1	-3.95	8.33e-05	0.00535	-0.13	-0.12	Sjögren's syndrome;	chr12:9023874	chr12:9228533~9275817:-
BRCA	cis	rs11642862	1	rs11645367	ENSG00000280211.1	RP11-2C24.3	-3.95	8.34e-05	0.00535	-0.2	-0.12	Tonsillectomy;	chr16:30758753	chr16:30773532~30776033:-
BRCA	cis	rs12049351	0.774	rs34405887	ENSG00000229367.1	HMGN2P19	3.95	8.34e-05	0.00535	0.17	0.12	Circulating myeloperoxidase levels (plasma);	chr1:229482887	chr1:229570532~229570796:+
BRCA	cis	rs9420	0.528	rs11607122	ENSG00000265566.2	RN7SL605P	-3.95	8.34e-05	0.00535	-0.17	-0.12	Schizophrenia;	chr11:57622264	chr11:57528085~57528365:-
BRCA	cis	rs11096990	0.634	rs6852967	ENSG00000249685.1	RP11-360F5.3	-3.95	8.34e-05	0.00535	-0.15	-0.12	Cognitive function;	chr4:39281526	chr4:39133913~39135608:+
BRCA	cis	rs654950	0.792	rs625448	ENSG00000230638.4	RP11-486B10.4	-3.95	8.34e-05	0.00535	-0.15	-0.12	Airway imaging phenotypes;	chr1:41522870	chr1:41542069~41544310:+
BRCA	cis	rs7226408	0.842	rs62083182	ENSG00000267707.2	RP11-95O2.5	3.95	8.34e-05	0.00535	0.21	0.12	Obesity-related traits;	chr18:36759961	chr18:37243776~37247506:+
BRCA	cis	rs7267979	0.565	rs4815437	ENSG00000277938.1	RP5-965G21.3	-3.95	8.34e-05	0.00535	-0.15	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25604152	chr20:25229150~25231933:+
BRCA	cis	rs4372836	0.729	rs10174533	ENSG00000226833.4	AC097724.3	3.95	8.34e-05	0.00535	0.14	0.12	Body mass index;	chr2:28746062	chr2:28708953~28736205:-
BRCA	cis	rs6840360	0.533	rs4696295	ENSG00000270265.1	RP11-731D1.4	3.95	8.34e-05	0.00535	0.14	0.12	Intelligence (multi-trait analysis);	chr4:151796278	chr4:151333775~151353224:-
BRCA	cis	rs4218	0.608	rs16941014	ENSG00000259732.1	RP11-59H7.3	-3.95	8.34e-05	0.00535	-0.15	-0.12	Social communication problems;	chr15:59091503	chr15:59121034~59133250:+
BRCA	cis	rs965469	0.895	rs6051844	ENSG00000215063.3	RPL21P2	-3.95	8.34e-05	0.00535	-0.15	-0.12	IFN-related cytopenia;	chr20:3422027	chr20:4059633~4060113:-
BRCA	cis	rs9863	0.861	rs7132655	ENSG00000270028.1	RP11-380L11.4	3.95	8.34e-05	0.00535	0.15	0.12	White blood cell count;	chr12:123954426	chr12:123925461~123926083:-
BRCA	cis	rs6596100	0.956	rs55650161	ENSG00000248648.1	RP11-485M7.1	-3.95	8.34e-05	0.00535	-0.16	-0.12	Breast cancer;	chr5:133094833	chr5:133003119~133003365:+
BRCA	cis	rs4664293	0.647	rs7587700	ENSG00000226266.5	AC009961.3	-3.95	8.35e-05	0.00536	-0.14	-0.12	Monocyte percentage of white cells;	chr2:159587809	chr2:159670708~159712435:-
BRCA	cis	rs910316	0.934	rs8016330	ENSG00000259138.1	RP11-950C14.7	-3.95	8.35e-05	0.00536	-0.13	-0.12	Height;	chr14:75190804	chr14:75127153~75136930:+
BRCA	cis	rs9868809	0.881	rs13324142	ENSG00000225399.4	RP11-3B7.1	-3.95	8.35e-05	0.00536	-0.19	-0.12	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48632014	chr3:49260085~49261316:+
BRCA	cis	rs4478858	0.684	rs4949202	ENSG00000260386.4	LINC01225	-3.95	8.35e-05	0.00536	-0.14	-0.12	Alcohol dependence;	chr1:31263953	chr1:31500085~31540885:+
BRCA	cis	rs4478858	0.647	rs7524117	ENSG00000260386.4	LINC01225	-3.95	8.35e-05	0.00536	-0.14	-0.12	Alcohol dependence;	chr1:31265569	chr1:31500085~31540885:+
BRCA	cis	rs4974559	0.947	rs28711287	ENSG00000253399.1	AC078852.2	3.95	8.35e-05	0.00536	0.18	0.12	Systolic blood pressure;	chr4:1352894	chr4:1358479~1359461:+
BRCA	cis	rs11955398	0.502	rs162249	ENSG00000272308.1	RP11-231G3.1	-3.95	8.35e-05	0.00536	-0.14	-0.12	Intelligence (multi-trait analysis);	chr5:60999753	chr5:60866457~60866935:-
BRCA	cis	rs11711311	1	rs11719303	ENSG00000241529.3	RN7SL767P	-3.95	8.35e-05	0.00536	-0.14	-0.12	IgG glycosylation;	chr3:113775677	chr3:113632704~113632998:+
BRCA	cis	rs7267979	1	rs4815411	ENSG00000274414.1	RP5-965G21.4	3.95	8.36e-05	0.00536	0.14	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25369587	chr20:25239007~25245229:-
BRCA	cis	rs875971	0.862	rs11984115	ENSG00000273024.4	INTS4P2	3.95	8.36e-05	0.00536	0.14	0.12	Aortic root size;	chr7:66308872	chr7:65647864~65715661:+
BRCA	cis	rs12705849	0.764	rs1599834	ENSG00000214194.7	LINC00998	3.95	8.36e-05	0.00536	0.15	0.12	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Eosinophil counts;	chr7:113111711	chr7:113116718~113118613:-
BRCA	cis	rs459571	0.629	rs441233	ENSG00000235106.7	LINC00094	-3.95	8.36e-05	0.00536	-0.13	-0.12	Platelet distribution width;	chr9:134010899	chr9:134025439~134034666:+
BRCA	cis	rs875971	0.895	rs12531677	ENSG00000273024.4	INTS4P2	3.95	8.36e-05	0.00536	0.14	0.12	Aortic root size;	chr7:66304099	chr7:65647864~65715661:+
BRCA	cis	rs875971	0.862	rs7798630	ENSG00000273024.4	INTS4P2	3.95	8.36e-05	0.00536	0.14	0.12	Aortic root size;	chr7:66306492	chr7:65647864~65715661:+
BRCA	cis	rs11098499	0.954	rs6822679	ENSG00000225892.3	RP11-384K6.2	3.95	8.36e-05	0.00536	0.12	0.12	Corneal astigmatism;	chr4:119481547	chr4:118632274~118634759:+
BRCA	cis	rs9308731	0.591	rs6542350	ENSG00000230499.1	AC108463.1	-3.95	8.36e-05	0.00536	-0.14	-0.12	Chronic lymphocytic leukemia;	chr2:111187163	chr2:111195963~111206494:+
BRCA	cis	rs1865760	0.865	rs9393677	ENSG00000272462.2	U91328.19	-3.95	8.36e-05	0.00536	-0.15	-0.12	Height;	chr6:25945587	chr6:25992662~26001775:+
BRCA	cis	rs1865760	0.865	rs9393678	ENSG00000272462.2	U91328.19	-3.95	8.36e-05	0.00536	-0.15	-0.12	Height;	chr6:25945591	chr6:25992662~26001775:+
BRCA	cis	rs6671200	0.92	rs7555236	ENSG00000226026.4	RP11-57H12.3	3.95	8.36e-05	0.00537	0.26	0.12	Stearic acid (18:0) levels;	chr1:95165758	chr1:95163219~95233982:-
BRCA	cis	rs721917	0.506	rs1923538	ENSG00000280355.1	RP11-119F19.5	-3.95	8.36e-05	0.00537	-0.13	-0.12	Chronic obstructive pulmonary disease;	chr10:79935276	chr10:79681973~79684094:-
BRCA	cis	rs7177699	0.557	rs7178051	ENSG00000261143.1	ADAMTS7P3	-3.95	8.37e-05	0.00537	-0.15	-0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78825954	chr15:77976042~77993057:+
BRCA	cis	rs171748	0.649	rs159359	ENSG00000272308.1	RP11-231G3.1	-3.95	8.37e-05	0.00537	-0.15	-0.12	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:61234275	chr5:60866457~60866935:-
BRCA	cis	rs12744310	0.502	rs12027253	ENSG00000235358.1	RP11-399E6.1	3.95	8.37e-05	0.00537	0.15	0.12	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41342569	chr1:41242373~41284861:+
BRCA	cis	rs1371614	0.632	rs6707735	ENSG00000272148.1	RP11-195B17.1	3.95	8.38e-05	0.00537	0.14	0.12	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26943954	chr2:27062428~27062907:-
BRCA	cis	rs7686660	1	rs28623359	ENSG00000250326.1	RP11-284M14.1	-3.95	8.38e-05	0.00537	-0.14	-0.12	Asthma;	chr4:143056635	chr4:142933195~143184861:-
BRCA	cis	rs7686660	1	rs4077294	ENSG00000250326.1	RP11-284M14.1	-3.95	8.38e-05	0.00537	-0.14	-0.12	Asthma;	chr4:143057034	chr4:142933195~143184861:-
BRCA	cis	rs6964587	0.967	rs2188153	ENSG00000188693.7	CYP51A1-AS1	-3.95	8.38e-05	0.00537	-0.13	-0.12	Breast cancer;	chr7:91965803	chr7:92134604~92180725:+
BRCA	cis	rs4950322	0.515	rs11239958	ENSG00000237188.3	RP11-337C18.8	3.95	8.38e-05	0.00537	0.15	0.12	Protein quantitative trait loci;	chr1:147247454	chr1:147172771~147211568:+
BRCA	cis	rs6964587	0.967	rs6465340	ENSG00000188693.7	CYP51A1-AS1	-3.95	8.38e-05	0.00538	-0.13	-0.12	Breast cancer;	chr7:91959350	chr7:92134604~92180725:+
BRCA	cis	rs12049351	0.774	rs34232465	ENSG00000229367.1	HMGN2P19	3.95	8.38e-05	0.00538	0.16	0.12	Circulating myeloperoxidase levels (plasma);	chr1:229495365	chr1:229570532~229570796:+
BRCA	cis	rs13108904	0.901	rs7668661	ENSG00000253399.1	AC078852.2	-3.95	8.38e-05	0.00538	-0.13	-0.12	Obesity-related traits;	chr4:1306384	chr4:1358479~1359461:+
BRCA	cis	rs6044112	0.564	rs17673447	ENSG00000273998.1	RP4-777L9.2	-3.95	8.38e-05	0.00538	-0.21	-0.12	Response to taxane treatment (docetaxel);	chr20:16487542	chr20:16576068~16579615:+
BRCA	cis	rs8040855	0.52	rs11629963	ENSG00000230373.7	GOLGA6L5P	-3.95	8.39e-05	0.00538	-0.16	-0.12	Bulimia nervosa;	chr15:84986808	chr15:84507885~84516814:-
BRCA	cis	rs17361889	0.778	rs56279207	ENSG00000229108.1	MEOX2-AS1	3.95	8.39e-05	0.00538	0.15	0.12	Pediatric bone mineral content (hip);	chr7:16275559	chr7:15688378~15695491:+
BRCA	cis	rs17027633	1	rs17027633	ENSG00000234020.1	CHIAP3	-3.95	8.39e-05	0.00538	-0.29	-0.12	Cerebrospinal fluid t-tau:AB1-42 ratio;	chr1:111419634	chr1:111353275~111367409:-
BRCA	cis	rs17027633	1	rs2275794	ENSG00000234020.1	CHIAP3	-3.95	8.39e-05	0.00538	-0.29	-0.12	Cerebrospinal fluid t-tau:AB1-42 ratio;	chr1:111421640	chr1:111353275~111367409:-
BRCA	cis	rs17027633	1	rs17027642	ENSG00000234020.1	CHIAP3	-3.95	8.39e-05	0.00538	-0.29	-0.12	Cerebrospinal fluid t-tau:AB1-42 ratio;	chr1:111422023	chr1:111353275~111367409:-
BRCA	cis	rs35099186	0.583	rs10790800	ENSG00000254905.1	RP11-712L6.7	3.95	8.39e-05	0.00538	0.15	0.12	Coronary artery disease;	chr11:126392743	chr11:126292922~126294254:-
BRCA	cis	rs7267979	1	rs2482930	ENSG00000274414.1	RP5-965G21.4	3.95	8.39e-05	0.00538	0.14	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25353479	chr20:25239007~25245229:-
BRCA	cis	rs6456156	0.792	rs10946214	ENSG00000272549.1	RP11-351J23.2	-3.95	8.39e-05	0.00538	-0.12	-0.12	Primary biliary cholangitis;	chr6:167102634	chr6:167666840~167679270:-
BRCA	cis	rs6968419	0.674	rs12669768	ENSG00000279086.1	RP11-667F14.1	-3.95	8.39e-05	0.00538	-0.13	-0.12	Intraocular pressure;	chr7:116267086	chr7:116209234~116211511:-
BRCA	cis	rs6968419	0.674	rs11767092	ENSG00000279086.1	RP11-667F14.1	-3.95	8.39e-05	0.00538	-0.13	-0.12	Intraocular pressure;	chr7:116267811	chr7:116209234~116211511:-
BRCA	cis	rs9863	0.861	rs75321546	ENSG00000270028.1	RP11-380L11.4	3.95	8.39e-05	0.00538	0.15	0.12	White blood cell count;	chr12:123962918	chr12:123925461~123926083:-
BRCA	cis	rs9863	0.861	rs55990776	ENSG00000270028.1	RP11-380L11.4	3.95	8.39e-05	0.00538	0.15	0.12	White blood cell count;	chr12:123962919	chr12:123925461~123926083:-
BRCA	cis	rs9788721	0.806	rs4887056	ENSG00000261762.1	RP11-650L12.2	-3.95	8.39e-05	0.00538	-0.15	-0.12	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78442243	chr15:78589123~78591276:-
BRCA	cis	rs763121	0.853	rs5750659	ENSG00000225450.1	RP3-508I15.14	-3.95	8.39e-05	0.00538	-0.13	-0.12	Menopause (age at onset);	chr22:38672784	chr22:38739003~38749041:+
BRCA	cis	rs763121	0.819	rs3747173	ENSG00000225450.1	RP3-508I15.14	-3.95	8.39e-05	0.00538	-0.13	-0.12	Menopause (age at onset);	chr22:38673040	chr22:38739003~38749041:+
BRCA	cis	rs763121	0.853	rs3747174	ENSG00000225450.1	RP3-508I15.14	-3.95	8.39e-05	0.00538	-0.13	-0.12	Menopause (age at onset);	chr22:38673176	chr22:38739003~38749041:+
BRCA	cis	rs763121	0.853	rs5757226	ENSG00000225450.1	RP3-508I15.14	-3.95	8.39e-05	0.00538	-0.13	-0.12	Menopause (age at onset);	chr22:38674545	chr22:38739003~38749041:+
BRCA	cis	rs2625529	0.713	rs12903980	ENSG00000260037.4	CTD-2524L6.3	-3.95	8.39e-05	0.00538	-0.17	-0.12	Red blood cell count;	chr15:71873208	chr15:71818396~71823384:+
BRCA	cis	rs7267979	0.932	rs6107052	ENSG00000274414.1	RP5-965G21.4	-3.95	8.39e-05	0.00538	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25550202	chr20:25239007~25245229:-
BRCA	cis	rs875971	0.545	rs6460281	ENSG00000232559.3	GS1-124K5.12	3.95	8.39e-05	0.00538	0.16	0.12	Aortic root size;	chr7:66216128	chr7:66554588~66576923:-
BRCA	cis	rs11673344	0.504	rs10402907	ENSG00000276846.1	CTD-3220F14.3	3.95	8.4e-05	0.00538	0.14	0.12	Obesity-related traits;	chr19:37112874	chr19:37314868~37315620:-
BRCA	cis	rs11668609	1	rs10412517	ENSG00000268058.1	BNIP3P40	-3.95	8.4e-05	0.00538	-0.15	-0.12	Response to taxane treatment (docetaxel);	chr19:24119111	chr19:24098425~24098980:-
BRCA	cis	rs7523050	0.643	rs35924015	ENSG00000203897.3	SPATA42	-3.95	8.4e-05	0.00538	-0.21	-0.12	Fat distribution (HIV);	chr1:108862004	chr1:108857217~108858524:+
BRCA	cis	rs7166081	0.688	rs4776361	ENSG00000270964.1	RP11-502I4.3	-3.95	8.4e-05	0.00538	-0.15	-0.12	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67469718	chr15:67541072~67542604:-
BRCA	cis	rs11168618	0.715	rs35367885	ENSG00000273765.1	RP11-370I10.11	3.95	8.4e-05	0.00538	0.14	0.12	Adiponectin levels;	chr12:48525877	chr12:48360920~48361377:+
BRCA	cis	rs62025270	0.522	rs338519	ENSG00000259762.1	RP11-158M2.4	-3.95	8.4e-05	0.00539	-0.15	-0.12	Idiopathic pulmonary fibrosis;	chr15:85671648	chr15:85750336~85752901:-
BRCA	cis	rs875971	0.798	rs12698522	ENSG00000273024.4	INTS4P2	-3.95	8.4e-05	0.00539	-0.14	-0.12	Aortic root size;	chr7:66502354	chr7:65647864~65715661:+
BRCA	cis	rs875971	0.83	rs28714531	ENSG00000273024.4	INTS4P2	-3.95	8.4e-05	0.00539	-0.14	-0.12	Aortic root size;	chr7:66503250	chr7:65647864~65715661:+
BRCA	cis	rs875971	0.862	rs12698526	ENSG00000273024.4	INTS4P2	-3.95	8.4e-05	0.00539	-0.14	-0.12	Aortic root size;	chr7:66504118	chr7:65647864~65715661:+
BRCA	cis	rs7954584	0.635	rs7137218	ENSG00000272849.1	RP11-347I19.8	-3.95	8.4e-05	0.00539	-0.09	-0.12	Mean corpuscular volume;	chr12:121904971	chr12:121797511~121801972:+
BRCA	cis	rs35740288	0.77	rs17635450	ENSG00000202081.1	RNU6-1280P	-3.95	8.4e-05	0.00539	-0.16	-0.12	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85655818	chr15:85651522~85651628:-
BRCA	cis	rs34779708	0.868	rs2384352	ENSG00000269952.1	RP11-324I22.3	-3.95	8.41e-05	0.00539	-0.16	-0.12	Inflammatory bowel disease;Crohn's disease;	chr10:35203904	chr10:35210416~35210750:+
BRCA	cis	rs10129255	0.536	rs3944157	ENSG00000274576.2	IGHV2-70	-3.95	8.41e-05	0.00539	-0.1	-0.12	Kawasaki disease;	chr14:106682286	chr14:106770577~106771020:-
BRCA	cis	rs10504130	0.935	rs76813841	ENSG00000272076.1	RP11-11C20.3	3.95	8.41e-05	0.00539	0.21	0.12	Venous thromboembolism (SNP x SNP interaction);	chr8:51848253	chr8:51810110~51810681:-
BRCA	cis	rs4865762	0.904	rs254503	ENSG00000247796.2	CTD-2366F13.1	3.95	8.41e-05	0.00539	0.13	0.12	Intraocular pressure;	chr5:53196847	chr5:53109842~53115126:+
BRCA	cis	rs4713118	0.587	rs61471148	ENSG00000216901.1	AL022393.7	3.95	8.41e-05	0.00539	0.17	0.12	Parkinson's disease;	chr6:28069254	chr6:28176188~28176674:+
BRCA	cis	rs7267979	1	rs11087520	ENSG00000274973.1	RP13-401N8.7	-3.95	8.41e-05	0.00539	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25456191	chr20:25845497~25845862:+
BRCA	cis	rs6547741	0.743	rs7564625	ENSG00000234072.1	AC074117.10	-3.95	8.41e-05	0.00539	-0.12	-0.12	Oral cavity cancer;	chr2:27639530	chr2:27356246~27367622:+
BRCA	cis	rs6439699	0.83	rs7626812	ENSG00000273486.1	RP11-731C17.2	3.95	8.41e-05	0.00539	0.17	0.12	Intelligence (multi-trait analysis);	chr3:137319218	chr3:136837338~136839021:-
BRCA	cis	rs62229266	0.804	rs2835231	ENSG00000214914.3	RPL23AP3	3.95	8.41e-05	0.00539	0.15	0.12	Mitral valve prolapse;	chr21:36018300	chr21:36016079~36016546:-
BRCA	cis	rs10735946	0.904	rs10784672	ENSG00000255733.4	IFNG-AS1	-3.95	8.42e-05	0.0054	-0.11	-0.12	Anti-saccade response;	chr12:68089725	chr12:67989445~68234686:+
BRCA	cis	rs10735946	1	rs4913400	ENSG00000255733.4	IFNG-AS1	-3.95	8.42e-05	0.0054	-0.11	-0.12	Anti-saccade response;	chr12:68091912	chr12:67989445~68234686:+
BRCA	cis	rs12586478	0.519	rs4143946	ENSG00000205562.2	RP11-497E19.1	3.95	8.42e-05	0.0054	0.11	0.12	Post bronchodilator FEV1;	chr14:86323635	chr14:85524432~85529988:-
BRCA	cis	rs253959	0.545	rs712579	ENSG00000271918.1	CTD-2287O16.5	-3.95	8.42e-05	0.0054	-0.1	-0.12	Bipolar disorder and schizophrenia;	chr5:116314839	chr5:116083807~116085416:-
BRCA	cis	rs2018683	0.523	rs1499224	ENSG00000228421.2	AC005013.5	3.95	8.42e-05	0.0054	0.16	0.12	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28989852	chr7:28957667~28959345:+
BRCA	cis	rs1912124	1	rs66540250	ENSG00000271983.1	RP11-28H5.2	3.95	8.42e-05	0.0054	0.25	0.12	Peripheral arterial disease (traffic-related air pollution interaction);	chr15:81221137	chr15:80693216~80693707:-
BRCA	cis	rs2839186	0.587	rs35679325	ENSG00000223901.2	AP001469.5	-3.95	8.43e-05	0.0054	-0.12	-0.12	Testicular germ cell tumor;	chr21:46221066	chr21:46220269~46225364:+
BRCA	cis	rs8180040	0.647	rs57756484	ENSG00000271161.1	BOLA2P2	-3.95	8.43e-05	0.0054	-0.13	-0.12	Colorectal cancer;	chr3:47197843	chr3:47499841~47500407:+
BRCA	cis	rs3136202	0.643	rs1651195	ENSG00000242307.1	RPS26P52	3.95	8.43e-05	0.0054	0.15	0.12	Conduct disorder (symptom count);	chr16:13977984	chr16:13922332~13922679:-
BRCA	cis	rs4678181	1	rs12632654	ENSG00000273033.2	RP11-67L2.2	-3.95	8.43e-05	0.0054	-0.21	-0.12	Calcium levels;	chr3:122335094	chr3:122886941~122892416:+
BRCA	cis	rs6088590	1	rs2378256	ENSG00000276073.1	RP5-1125A11.7	-3.95	8.43e-05	0.0054	-0.14	-0.12	Coronary artery disease;	chr20:34704323	chr20:33985617~33988989:-
BRCA	cis	rs6860540	0.796	rs6879450	ENSG00000251405.2	CTB-109A12.1	-3.95	8.43e-05	0.0054	-0.17	-0.12	Inflammatory skin disease;	chr5:157471959	chr5:157362615~157460078:-
BRCA	cis	rs7620503	0.729	rs13082698	ENSG00000228561.2	RP11-114M1.1	3.95	8.43e-05	0.00541	0.16	0.12	Corneal structure;	chr3:177588160	chr3:177683627~177691250:+
BRCA	cis	rs1434579	0.865	rs12983645	ENSG00000176761.7	ZNF285B	-3.95	8.43e-05	0.00541	-0.15	-0.12	Tuberculosis;	chr19:44439056	chr19:44467641~44473227:+
BRCA	cis	rs55986470	0.817	rs59736380	ENSG00000186235.9	AC016757.3	3.95	8.43e-05	0.00541	0.23	0.12	Chronotype;	chr2:238496048	chr2:238224552~238231677:-
BRCA	cis	rs17772222	0.917	rs61984737	ENSG00000258789.1	RP11-507K2.3	-3.95	8.44e-05	0.00541	-0.15	-0.12	Coronary artery calcification;	chr14:88637028	chr14:88551597~88552493:+
BRCA	cis	rs6696239	0.956	rs6694427	ENSG00000215812.5	ZNF847P	3.95	8.44e-05	0.00541	0.17	0.12	Height;	chr1:227619885	chr1:227696892~227706699:-
BRCA	cis	rs10895987	1	rs9971407	ENSG00000255200.1	AP003068.18	3.95	8.44e-05	0.00541	0.18	0.12	Blood protein levels;	chr11:65130754	chr11:65174117~65176470:-
BRCA	cis	rs7120118	0.517	rs3758674	ENSG00000280615.1	Y_RNA	3.95	8.44e-05	0.00541	0.2	0.12	HDL cholesterol;	chr11:47257387	chr11:47614898~47614994:-
BRCA	cis	rs7120118	0.517	rs61896015	ENSG00000280615.1	Y_RNA	3.95	8.44e-05	0.00541	0.2	0.12	HDL cholesterol;	chr11:47258377	chr11:47614898~47614994:-
BRCA	cis	rs4835473	0.932	rs13133444	ENSG00000246448.2	RP13-578N3.3	3.95	8.44e-05	0.00541	0.14	0.12	Immature fraction of reticulocytes;	chr4:143738191	chr4:143700257~143865072:+
BRCA	cis	rs12368653	0.84	rs3816896	ENSG00000257159.1	RP11-58A17.3	-3.95	8.44e-05	0.00541	-0.14	-0.12	Multiple sclerosis;	chr12:57801990	chr12:57967058~57968399:+
BRCA	cis	rs6500602	0.627	rs11639998	ENSG00000280063.1	RP11-295D4.3	3.95	8.44e-05	0.00541	0.1	0.12	Schizophrenia;	chr16:4477108	chr16:4346694~4348648:-
BRCA	cis	rs875971	0.545	rs12671152	ENSG00000232546.1	RP11-458F8.1	3.95	8.45e-05	0.00541	0.12	0.12	Aortic root size;	chr7:66311140	chr7:66848496~66858136:+
BRCA	cis	rs2274273	0.712	rs9806049	ENSG00000259318.1	RP11-454L9.2	3.95	8.45e-05	0.00541	0.11	0.12	Protein biomarker;	chr14:55058871	chr14:55394940~55395233:-
BRCA	cis	rs10844706	0.699	rs10844633	ENSG00000256673.1	RP11-599J14.2	-3.95	8.45e-05	0.00541	-0.15	-0.12	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9734790	chr12:9398355~9414851:-
BRCA	cis	rs9381040	0.537	rs9462669	ENSG00000161912.16	ADCY10P1	3.95	8.45e-05	0.00541	0.14	0.12	Alzheimer's disease (late onset);	chr6:41045920	chr6:41101022~41140835:+
BRCA	cis	rs10844706	0.699	rs2401390	ENSG00000278635.1	CTD-2318O12.1	-3.95	8.45e-05	0.00541	-0.13	-0.12	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9719218	chr12:9415641~9416718:+
BRCA	cis	rs9527	0.59	rs2281877	ENSG00000213061.2	PFN1P11	3.95	8.45e-05	0.00541	0.16	0.12	Arsenic metabolism;	chr10:103106305	chr10:102838011~102845473:-
BRCA	cis	rs875971	0.66	rs10272357	ENSG00000223473.2	GS1-124K5.3	-3.95	8.45e-05	0.00541	-0.09	-0.12	Aortic root size;	chr7:66598087	chr7:66491049~66493566:-
BRCA	cis	rs2562456	0.917	rs2650805	ENSG00000268119.4	CTD-2561J22.5	-3.95	8.45e-05	0.00541	-0.19	-0.12	Pain;	chr19:21505137	chr19:21444241~21463908:-
BRCA	cis	rs78487399	0.808	rs13395290	ENSG00000234936.1	AC010883.5	3.95	8.45e-05	0.00542	0.17	0.12	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43479180	chr2:43229573~43233394:+
BRCA	cis	rs1941184	0.5	rs1460598	ENSG00000266521.1	RP11-650P15.1	-3.95	8.45e-05	0.00542	-0.17	-0.12	Parkinson's disease (age of onset);	chr18:31448528	chr18:31496645~31497195:-
BRCA	cis	rs7829975	0.667	rs1877119	ENSG00000233609.3	RP11-62H7.2	3.95	8.45e-05	0.00542	0.11	0.12	Mood instability;	chr8:8849687	chr8:8961200~8979025:+
BRCA	cis	rs6431644	0.731	rs609942	ENSG00000224287.2	MSL3P1	3.95	8.45e-05	0.00542	0.15	0.12	Left atrial antero-posterior diameter;	chr2:233855109	chr2:233865437~233868444:-
BRCA	cis	rs62025270	0.547	rs338540	ENSG00000259295.5	CSPG4P12	3.95	8.45e-05	0.00542	0.16	0.12	Idiopathic pulmonary fibrosis;	chr15:85652500	chr15:85191438~85213905:+
BRCA	cis	rs3768617	0.811	rs34721094	ENSG00000224468.3	RP11-181K3.4	-3.95	8.46e-05	0.00542	-0.14	-0.12	Fuchs's corneal dystrophy;	chr1:183082386	chr1:183138402~183141282:-
BRCA	cis	rs651907	0.535	rs11717638	ENSG00000256628.3	ZBTB11-AS1	3.95	8.46e-05	0.00542	0.15	0.12	Colorectal cancer;	chr3:101786624	chr3:101676475~101679217:+
BRCA	cis	rs17301013	0.896	rs332773	ENSG00000234741.6	GAS5	3.95	8.46e-05	0.00542	0.12	0.12	Systemic lupus erythematosus;	chr1:174695711	chr1:173863900~173868882:-
BRCA	cis	rs17301013	0.896	rs332791	ENSG00000234741.6	GAS5	3.95	8.46e-05	0.00542	0.12	0.12	Systemic lupus erythematosus;	chr1:174709784	chr1:173863900~173868882:-
BRCA	cis	rs7894407	0.76	rs1163085	ENSG00000213061.2	PFN1P11	3.95	8.46e-05	0.00542	0.16	0.12	White matter hyperintensity burden;	chr10:103279484	chr10:102838011~102845473:-
BRCA	cis	rs6964587	1	rs10235941	ENSG00000188693.7	CYP51A1-AS1	-3.95	8.46e-05	0.00542	-0.13	-0.12	Breast cancer;	chr7:91957736	chr7:92134604~92180725:+
BRCA	cis	rs7903456	0.648	rs1923938	ENSG00000224914.2	LINC00863	-3.95	8.46e-05	0.00542	-0.15	-0.12	Gout;Renal underexcretion gout;	chr10:87077623	chr10:87342736~87357882:+
BRCA	cis	rs1371614	0.632	rs6547318	ENSG00000229122.1	AGBL5-IT1	3.95	8.46e-05	0.00542	0.13	0.12	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26930613	chr2:27061038~27061815:+
BRCA	cis	rs2562456	0.917	rs2562466	ENSG00000268119.4	CTD-2561J22.5	-3.95	8.46e-05	0.00542	-0.18	-0.12	Pain;	chr19:21531402	chr19:21444241~21463908:-
BRCA	cis	rs4974559	0.947	rs28540746	ENSG00000253399.1	AC078852.2	3.95	8.46e-05	0.00542	0.18	0.12	Systolic blood pressure;	chr4:1359166	chr4:1358479~1359461:+
BRCA	cis	rs8058578	1	rs67128646	ENSG00000274678.1	RP11-2C24.7	3.95	8.46e-05	0.00542	0.15	0.12	Multiple myeloma;	chr16:30660776	chr16:30821338~30821884:+
BRCA	cis	rs10208649	0.611	rs1974771	ENSG00000272156.1	RP11-477N3.1	3.95	8.46e-05	0.00542	0.22	0.12	Body mass index;	chr2:54051406	chr2:54082554~54085066:+
BRCA	cis	rs17143586	0.793	rs7795490	ENSG00000265212.2	AC007009.2	3.95	8.47e-05	0.00542	0.3	0.12	Obesity-related traits;	chr7:8133881	chr7:8154916~8155027:+
BRCA	cis	rs2514805	0.803	rs2446823	ENSG00000253585.1	KB-1184D12.1	-3.95	8.47e-05	0.00542	-0.21	-0.12	Diisocyanate-induced asthma;	chr8:94115384	chr8:94097764~94104322:-
BRCA	cis	rs801193	1	rs4717319	ENSG00000229180.5	GS1-124K5.11	3.95	8.47e-05	0.00542	0.1	0.12	Aortic root size;	chr7:66777606	chr7:66526088~66542624:-
BRCA	cis	rs875971	0.862	rs6964437	ENSG00000273024.4	INTS4P2	3.95	8.47e-05	0.00542	0.14	0.12	Aortic root size;	chr7:66221457	chr7:65647864~65715661:+
BRCA	cis	rs9341808	0.6	rs590641	ENSG00000233967.5	RP11-250B2.3	3.95	8.47e-05	0.00542	0.13	0.12	Sitting height ratio;	chr6:80256766	chr6:80443344~80465927:+
BRCA	cis	rs2281558	1	rs2281558	ENSG00000274414.1	RP5-965G21.4	-3.95	8.47e-05	0.00542	-0.16	-0.12	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25259553	chr20:25239007~25245229:-
BRCA	cis	rs11098499	0.954	rs28572238	ENSG00000225892.3	RP11-384K6.2	3.95	8.47e-05	0.00542	0.12	0.12	Corneal astigmatism;	chr4:119395531	chr4:118632274~118634759:+
BRCA	cis	rs8114671	0.527	rs6060068	ENSG00000261582.1	RP4-614O4.11	-3.95	8.47e-05	0.00543	-0.12	-0.12	Height;	chr20:34828017	chr20:35267885~35280043:-
BRCA	cis	rs10938353	0.906	rs57885541	ENSG00000273369.1	RP11-700J17.1	3.95	8.47e-05	0.00543	0.15	0.12	Body mass index;	chr4:44610125	chr4:44693946~44694386:-
BRCA	cis	rs11098499	0.826	rs4472123	ENSG00000225892.3	RP11-384K6.2	3.95	8.47e-05	0.00543	0.12	0.12	Corneal astigmatism;	chr4:119315475	chr4:118632274~118634759:+
BRCA	cis	rs6736093	0.966	rs34705448	ENSG00000236307.2	EEF1E1P1	-3.95	8.47e-05	0.00543	-0.15	-0.12	Coronary artery disease;	chr2:111972512	chr2:111887914~111888741:+
BRCA	cis	rs875971	0.862	rs6460306	ENSG00000273024.4	INTS4P2	3.95	8.47e-05	0.00543	0.14	0.12	Aortic root size;	chr7:66595806	chr7:65647864~65715661:+
BRCA	cis	rs12049351	0.774	rs12030128	ENSG00000229367.1	HMGN2P19	3.95	8.47e-05	0.00543	0.17	0.12	Circulating myeloperoxidase levels (plasma);	chr1:229487116	chr1:229570532~229570796:+
BRCA	cis	rs4664293	0.647	rs357030	ENSG00000226266.5	AC009961.3	-3.95	8.47e-05	0.00543	-0.14	-0.12	Monocyte percentage of white cells;	chr2:159636515	chr2:159670708~159712435:-
BRCA	cis	rs12122100	0.545	rs1984615	ENSG00000227242.3	NBPF13P	-3.95	8.47e-05	0.00543	-0.14	-0.12	HIV-1 control;	chr1:147034652	chr1:147021320~147124525:-
BRCA	cis	rs7746199	0.736	rs13210634	ENSG00000216901.1	AL022393.7	3.95	8.48e-05	0.00543	0.31	0.12	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27678713	chr6:28176188~28176674:+
BRCA	cis	rs7746199	0.736	rs13215275	ENSG00000216901.1	AL022393.7	3.95	8.48e-05	0.00543	0.31	0.12	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27679730	chr6:28176188~28176674:+
BRCA	cis	rs7746199	0.736	rs17749927	ENSG00000216901.1	AL022393.7	3.95	8.48e-05	0.00543	0.31	0.12	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27702197	chr6:28176188~28176674:+
BRCA	cis	rs7703051	0.833	rs1423527	ENSG00000271815.1	CTD-2235C13.3	3.95	8.48e-05	0.00543	0.15	0.12	Age-related diseases, mortality and associated endophenotypes;LDL cholesterol;Age-related disease endophenotypes;	chr5:75306874	chr5:75363760~75364242:+
BRCA	cis	rs4415084	0.716	rs6451775	ENSG00000251141.4	RP11-53O19.1	-3.95	8.48e-05	0.00543	-0.11	-0.12	Breast cancer;	chr5:44836686	chr5:44744900~44808777:-
BRCA	cis	rs1008375	1	rs10805359	ENSG00000249502.1	AC006160.5	-3.95	8.48e-05	0.00543	-0.14	-0.12	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17683263	chr4:17587467~17614571:-
BRCA	cis	rs6121246	0.908	rs6089094	ENSG00000230613.1	HM13-AS1	3.95	8.48e-05	0.00543	0.18	0.12	Mean corpuscular hemoglobin;	chr20:31843968	chr20:31567707~31573263:-
BRCA	cis	rs6088580	0.634	rs2184836	ENSG00000275784.1	RP5-1125A11.6	3.95	8.48e-05	0.00543	0.13	0.12	Glomerular filtration rate (creatinine);	chr20:34375563	chr20:33989480~33991818:-
BRCA	cis	rs6088580	0.609	rs6058029	ENSG00000275784.1	RP5-1125A11.6	3.95	8.48e-05	0.00543	0.13	0.12	Glomerular filtration rate (creatinine);	chr20:34381837	chr20:33989480~33991818:-
BRCA	cis	rs6088580	0.608	rs2105109	ENSG00000275784.1	RP5-1125A11.6	3.95	8.48e-05	0.00543	0.13	0.12	Glomerular filtration rate (creatinine);	chr20:34384126	chr20:33989480~33991818:-
BRCA	cis	rs4664293	1	rs6432542	ENSG00000226266.5	AC009961.3	-3.95	8.48e-05	0.00543	-0.15	-0.12	Monocyte percentage of white cells;	chr2:159624025	chr2:159670708~159712435:-
BRCA	cis	rs34929064	0.536	rs2905307	ENSG00000232949.1	AC002480.4	3.95	8.49e-05	0.00543	0.14	0.12	Major depression and alcohol dependence;	chr7:22599344	chr7:22589705~22591622:+
BRCA	cis	rs3809912	0.693	rs12605081	ENSG00000266969.1	RP11-773H22.4	3.95	8.49e-05	0.00544	0.15	0.12	Cognitive ability;Cognitive ability (multi-trait analysis);	chr18:12999965	chr18:12984694~12991173:-
BRCA	cis	rs17772222	0.917	rs8020072	ENSG00000258789.1	RP11-507K2.3	-3.95	8.49e-05	0.00544	-0.15	-0.12	Coronary artery calcification;	chr14:88714332	chr14:88551597~88552493:+
BRCA	cis	rs17772222	0.917	rs12589982	ENSG00000258789.1	RP11-507K2.3	-3.95	8.49e-05	0.00544	-0.15	-0.12	Coronary artery calcification;	chr14:88716861	chr14:88551597~88552493:+
BRCA	cis	rs990171	0.538	rs6728288	ENSG00000234389.1	AC007278.3	3.95	8.49e-05	0.00544	0.12	0.12	Lymphocyte counts;	chr2:102500809	chr2:102438713~102440475:+
BRCA	cis	rs990171	0.538	rs6741235	ENSG00000234389.1	AC007278.3	3.95	8.49e-05	0.00544	0.12	0.12	Lymphocyte counts;	chr2:102500824	chr2:102438713~102440475:+
BRCA	cis	rs6071166	0.513	rs6123987	ENSG00000224635.1	RP4-564F22.5	3.95	8.49e-05	0.00544	0.15	0.12	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38711002	chr20:38406011~38416797:-
BRCA	cis	rs10829156	0.607	rs7908550	ENSG00000225527.1	RP11-383B4.4	-3.95	8.49e-05	0.00544	-0.18	-0.12	Sudden cardiac arrest;	chr10:18573282	chr10:18531849~18533336:-
BRCA	cis	rs11098499	0.697	rs28655325	ENSG00000260404.2	RP11-384K6.6	3.95	8.5e-05	0.00544	0.11	0.12	Corneal astigmatism;	chr4:119451844	chr4:118591773~118633729:+
BRCA	cis	rs7111546	1	rs11026798	ENSG00000246225.5	RP11-17A1.3	3.95	8.5e-05	0.00544	0.19	0.12	Dialysis-related mortality;	chr11:22801033	chr11:22829380~22945393:+
BRCA	cis	rs875971	0.642	rs35526611	ENSG00000265600.1	AC006480.1	3.95	8.5e-05	0.00544	0.14	0.12	Aortic root size;	chr7:66629021	chr7:67356680~67356779:+
BRCA	cis	rs6088580	0.66	rs6087592	ENSG00000275784.1	RP5-1125A11.6	-3.95	8.5e-05	0.00544	-0.13	-0.12	Glomerular filtration rate (creatinine);	chr20:34526698	chr20:33989480~33991818:-
BRCA	cis	rs1048886	0.872	rs17634491	ENSG00000271967.1	RP11-134K13.4	-3.95	8.5e-05	0.00544	-0.18	-0.12	Type 2 diabetes;	chr6:70456784	chr6:70596438~70596980:+
BRCA	cis	rs9840812	0.559	rs6439640	ENSG00000239213.4	NCK1-AS1	3.95	8.5e-05	0.00544	0.17	0.12	Fibrinogen levels;	chr3:136466838	chr3:136841726~136862054:-
BRCA	cis	rs2562456	1	rs2359155	ENSG00000268555.1	RP11-678G14.3	-3.95	8.5e-05	0.00544	-0.15	-0.12	Pain;	chr19:21489067	chr19:21570822~21587322:-
BRCA	cis	rs61008539	0.815	rs6960062	ENSG00000229043.2	AC091729.9	-3.95	8.5e-05	0.00544	-0.15	-0.12	Perceived unattractiveness to mosquitoes;	chr7:845028	chr7:1160374~1165267:+
BRCA	cis	rs875971	0.619	rs12533585	ENSG00000265600.1	AC006480.1	-3.95	8.5e-05	0.00544	-0.14	-0.12	Aortic root size;	chr7:66519618	chr7:67356680~67356779:+
BRCA	cis	rs9834975	0.935	rs10045	ENSG00000272758.4	RP11-299J3.8	-3.95	8.5e-05	0.00544	-0.12	-0.12	Diastolic blood pressure;	chr3:122426105	chr3:122416207~122443180:+
BRCA	cis	rs11098499	0.954	rs10017543	ENSG00000225892.3	RP11-384K6.2	3.95	8.51e-05	0.00545	0.12	0.12	Corneal astigmatism;	chr4:119400265	chr4:118632274~118634759:+
BRCA	cis	rs925550	1	rs4833840	ENSG00000224786.1	CETN4P	3.95	8.51e-05	0.00545	0.19	0.12	Primary biliary cholangitis;	chr4:122663082	chr4:122730548~122732193:-
BRCA	cis	rs642803	0.933	rs644740	ENSG00000255557.1	RP11-770G2.2	-3.95	8.51e-05	0.00545	-0.14	-0.12	Urate levels;	chr11:65793997	chr11:65745729~65771585:+
BRCA	cis	rs8023401	0.882	rs12907078	ENSG00000274654.1	CTD-3247H4.2	3.95	8.51e-05	0.00545	0.17	0.12	Spherical equivalent (joint analysis main effects and education interaction);	chr15:48536082	chr15:48528980~48529728:-
BRCA	cis	rs6736093	1	rs10496439	ENSG00000236307.2	EEF1E1P1	-3.95	8.51e-05	0.00545	-0.15	-0.12	Coronary artery disease;	chr2:111907054	chr2:111887914~111888741:+
BRCA	cis	rs962856	0.537	rs685211	ENSG00000236780.4	AC078941.1	-3.95	8.51e-05	0.00545	-0.15	-0.12	Pancreatic cancer;	chr2:67451726	chr2:67123357~67215319:-
BRCA	cis	rs7620503	1	rs4857612	ENSG00000277241.1	RP11-114M1.3	3.95	8.51e-05	0.00545	0.14	0.12	Corneal structure;	chr3:177588833	chr3:177700346~177701072:-
BRCA	cis	rs801193	0.935	rs2659916	ENSG00000229180.5	GS1-124K5.11	3.95	8.51e-05	0.00545	0.1	0.12	Aortic root size;	chr7:66686365	chr7:66526088~66542624:-
BRCA	cis	rs10483853	0.806	rs12586996	ENSG00000279026.1	RP3-414A15.12	3.94	8.51e-05	0.00545	0.16	0.12	Coronary artery calcification;	chr14:73342516	chr14:73580694~73582918:+
BRCA	cis	rs6772849	0.93	rs4857914	ENSG00000207088.1	SNORA7B	-3.94	8.52e-05	0.00545	-0.15	-0.12	Monocyte percentage of white cells;Monocyte count;	chr3:128631841	chr3:129397210~129397348:-
BRCA	cis	rs6500395	0.584	rs1420698	ENSG00000261267.1	RP11-44I10.3	-3.94	8.52e-05	0.00545	-0.16	-0.12	Response to tocilizumab in rheumatoid arthritis;	chr16:48706797	chr16:48559661~48587403:+
BRCA	cis	rs7246967	0.544	rs400275	ENSG00000198153.8	ZNF849P	-3.94	8.52e-05	0.00545	-0.17	-0.12	Bronchopulmonary dysplasia;	chr19:22833054	chr19:22685167~22686732:+
BRCA	cis	rs10744955	0.727	rs2414030	ENSG00000244879.4	GABPB1-AS1	-3.94	8.52e-05	0.00545	-0.13	-0.12	Lobe attachment (rater-scored or self-reported);	chr15:50164293	chr15:50354959~50372202:+
BRCA	cis	rs4478858	0.684	rs1532861	ENSG00000260386.4	LINC01225	-3.94	8.52e-05	0.00545	-0.14	-0.12	Alcohol dependence;	chr1:31293644	chr1:31500085~31540885:+
BRCA	cis	rs11098499	0.863	rs3775843	ENSG00000260091.1	RP11-33B1.4	-3.94	8.52e-05	0.00545	-0.11	-0.12	Corneal astigmatism;	chr4:119506689	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.863	rs3775844	ENSG00000260091.1	RP11-33B1.4	-3.94	8.52e-05	0.00545	-0.11	-0.12	Corneal astigmatism;	chr4:119506878	chr4:119409333~119410233:+
BRCA	cis	rs11242704	0.632	rs2816292	ENSG00000218027.2	RP11-157J24.1	3.94	8.52e-05	0.00545	0.16	0.12	Response to hepatitis C treatment;	chr6:1537983	chr6:1513698~1515289:-
BRCA	cis	rs7267979	0.932	rs6115214	ENSG00000276952.1	RP5-965G21.6	-3.94	8.52e-05	0.00545	-0.15	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25576790	chr20:25284915~25285588:-
BRCA	cis	rs62458065	0.713	rs3801329	ENSG00000273014.1	RP11-225B17.2	-3.94	8.52e-05	0.00545	-0.19	-0.12	Metabolite levels (HVA/MHPG ratio);	chr7:32457344	chr7:32758882~32759353:+
BRCA	cis	rs62025270	0.688	rs55738258	ENSG00000259762.1	RP11-158M2.4	-3.94	8.52e-05	0.00546	-0.18	-0.12	Idiopathic pulmonary fibrosis;	chr15:85773000	chr15:85750336~85752901:-
BRCA	cis	rs1008375	0.966	rs2286773	ENSG00000249502.1	AC006160.5	-3.94	8.52e-05	0.00546	-0.14	-0.12	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17614591	chr4:17587467~17614571:-
BRCA	cis	rs1005277	0.579	rs2474571	ENSG00000272983.1	RP11-508N22.12	3.94	8.53e-05	0.00546	0.13	0.12	Extrinsic epigenetic age acceleration;	chr10:38095711	chr10:38137337~38144399:+
BRCA	cis	rs12680842	0.842	rs34691145	ENSG00000261437.1	RP11-22C11.2	3.94	8.53e-05	0.00546	0.12	0.12	Body mass index;	chr8:94597715	chr8:94637285~94639467:-
BRCA	cis	rs2998286	0.643	rs332181	ENSG00000237128.1	RP11-351M16.3	3.94	8.53e-05	0.00546	0.16	0.12	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28621187	chr10:28433008~28495813:-
BRCA	cis	rs17684571	0.938	rs35619924	ENSG00000231441.1	RP11-472M19.2	3.94	8.53e-05	0.00546	0.19	0.12	Schizophrenia;	chr6:56695868	chr6:56844002~56864078:+
BRCA	cis	rs4908769	0.624	rs894875	ENSG00000270282.1	RP5-1115A15.2	-3.94	8.53e-05	0.00546	-0.15	-0.12	Allergy;	chr1:8372076	chr1:8512653~8513021:+
BRCA	cis	rs11242704	0.603	rs4431475	ENSG00000218027.2	RP11-157J24.1	3.94	8.53e-05	0.00546	0.16	0.12	Response to hepatitis C treatment;	chr6:1532651	chr6:1513698~1515289:-
BRCA	cis	rs757081	0.578	rs7109536	ENSG00000272034.1	SNORD14A	-3.94	8.53e-05	0.00546	-0.12	-0.12	Systolic blood pressure;	chr11:17233965	chr11:17074654~17074744:-
BRCA	cis	rs7267979	1	rs6050547	ENSG00000277938.1	RP5-965G21.3	-3.94	8.53e-05	0.00546	-0.15	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25345376	chr20:25229150~25231933:+
BRCA	cis	rs10043228	1	rs17139265	ENSG00000271918.1	CTD-2287O16.5	-3.94	8.54e-05	0.00546	-0.16	-0.12	Asthma or chronic obstructive pulmonary disease;	chr5:116243113	chr5:116083807~116085416:-
BRCA	cis	rs853679	0.517	rs9357063	ENSG00000261839.1	RP1-265C24.8	3.94	8.54e-05	0.00546	0.17	0.12	Depression;	chr6:28092227	chr6:28136849~28139678:+
BRCA	cis	rs7246967	0.736	rs398945	ENSG00000198153.8	ZNF849P	3.94	8.54e-05	0.00546	0.17	0.12	Bronchopulmonary dysplasia;	chr19:22814314	chr19:22685167~22686732:+
BRCA	cis	rs7412746	0.611	rs111842513	ENSG00000231073.1	RP11-316M1.3	3.94	8.54e-05	0.00546	0.13	0.12	Melanoma;	chr1:150740450	chr1:150973123~150975534:+
BRCA	cis	rs1075265	0.704	rs9631059	ENSG00000272156.1	RP11-477N3.1	-3.94	8.54e-05	0.00546	-0.12	-0.12	Chronotype;Morning vs. evening chronotype;	chr2:54015160	chr2:54082554~54085066:+
BRCA	cis	rs7103648	0.567	rs12287076	ENSG00000280615.1	Y_RNA	-3.94	8.54e-05	0.00546	-0.15	-0.12	Systolic blood pressure;Diastolic blood pressure;	chr11:47585313	chr11:47614898~47614994:-
BRCA	cis	rs1008375	0.931	rs3796814	ENSG00000249502.1	AC006160.5	-3.94	8.54e-05	0.00547	-0.14	-0.12	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17600410	chr4:17587467~17614571:-
BRCA	cis	rs10129255	0.912	rs8011090	ENSG00000232216.1	IGHV3-43	3.94	8.54e-05	0.00547	0.1	0.12	Kawasaki disease;	chr14:106678896	chr14:106470264~106470800:-
BRCA	cis	rs703842	0.616	rs10783851	ENSG00000270039.1	RP11-571M6.17	3.94	8.54e-05	0.00547	0.18	0.12	Multiple sclerosis;	chr12:57837372	chr12:57803838~57804415:+
BRCA	cis	rs11168618	0.904	rs7137866	ENSG00000273765.1	RP11-370I10.11	3.94	8.55e-05	0.00547	0.14	0.12	Adiponectin levels;	chr12:48529019	chr12:48360920~48361377:+
BRCA	cis	rs801193	1	rs6975195	ENSG00000273142.1	RP11-458F8.4	3.94	8.55e-05	0.00547	0.1	0.12	Aortic root size;	chr7:66659787	chr7:66902857~66906297:+
BRCA	cis	rs4578769	0.879	rs7235234	ENSG00000273232.1	RP11-370A5.2	3.94	8.55e-05	0.00547	0.16	0.12	Eosinophil percentage of white cells;	chr18:22864239	chr18:22882825~22883357:-
BRCA	cis	rs4578769	0.879	rs9950650	ENSG00000273232.1	RP11-370A5.2	3.94	8.55e-05	0.00547	0.16	0.12	Eosinophil percentage of white cells;	chr18:22864537	chr18:22882825~22883357:-
BRCA	cis	rs10043228	1	rs78362565	ENSG00000271918.1	CTD-2287O16.5	-3.94	8.55e-05	0.00547	-0.16	-0.12	Asthma or chronic obstructive pulmonary disease;	chr5:116228596	chr5:116083807~116085416:-
BRCA	cis	rs9733	0.519	rs12095002	ENSG00000231073.1	RP11-316M1.3	3.94	8.55e-05	0.00547	0.13	0.12	Tonsillectomy;	chr1:150676773	chr1:150973123~150975534:+
BRCA	cis	rs9733	0.596	rs12085275	ENSG00000231073.1	RP11-316M1.3	3.94	8.55e-05	0.00547	0.13	0.12	Tonsillectomy;	chr1:150677789	chr1:150973123~150975534:+
BRCA	cis	rs9733	0.596	rs12086630	ENSG00000231073.1	RP11-316M1.3	3.94	8.55e-05	0.00547	0.13	0.12	Tonsillectomy;	chr1:150678479	chr1:150973123~150975534:+
BRCA	cis	rs9733	0.596	rs2065900	ENSG00000231073.1	RP11-316M1.3	3.94	8.55e-05	0.00547	0.13	0.12	Tonsillectomy;	chr1:150679726	chr1:150973123~150975534:+
BRCA	cis	rs9733	0.544	rs2867302	ENSG00000231073.1	RP11-316M1.3	3.94	8.55e-05	0.00547	0.13	0.12	Tonsillectomy;	chr1:150681174	chr1:150973123~150975534:+
BRCA	cis	rs9733	0.596	rs2867301	ENSG00000231073.1	RP11-316M1.3	3.94	8.55e-05	0.00547	0.13	0.12	Tonsillectomy;	chr1:150681319	chr1:150973123~150975534:+
BRCA	cis	rs9733	0.596	rs7538493	ENSG00000231073.1	RP11-316M1.3	3.94	8.55e-05	0.00547	0.13	0.12	Tonsillectomy;	chr1:150682945	chr1:150973123~150975534:+
BRCA	cis	rs4970988	0.64	rs7524734	ENSG00000231073.1	RP11-316M1.3	3.94	8.55e-05	0.00547	0.13	0.12	Urate levels;	chr1:150683210	chr1:150973123~150975534:+
BRCA	cis	rs9733	0.596	rs6685702	ENSG00000231073.1	RP11-316M1.3	3.94	8.55e-05	0.00547	0.13	0.12	Tonsillectomy;	chr1:150683831	chr1:150973123~150975534:+
BRCA	cis	rs7412746	0.503	rs72704639	ENSG00000224800.1	RP11-235D19.2	-3.94	8.55e-05	0.00547	-0.15	-0.12	Melanoma;	chr1:150825859	chr1:150881236~150881683:-
BRCA	cis	rs11098499	0.954	rs11940028	ENSG00000260404.2	RP11-384K6.6	3.94	8.55e-05	0.00547	0.12	0.12	Corneal astigmatism;	chr4:119490752	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.954	rs11935596	ENSG00000260404.2	RP11-384K6.6	3.94	8.55e-05	0.00547	0.12	0.12	Corneal astigmatism;	chr4:119491302	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.954	rs12507964	ENSG00000260404.2	RP11-384K6.6	3.94	8.55e-05	0.00547	0.12	0.12	Corneal astigmatism;	chr4:119491906	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.909	rs11098530	ENSG00000260404.2	RP11-384K6.6	3.94	8.55e-05	0.00547	0.12	0.12	Corneal astigmatism;	chr4:119491999	chr4:118591773~118633729:+
BRCA	cis	rs669446	0.591	rs574736	ENSG00000236200.4	KDM4A-AS1	-3.94	8.55e-05	0.00547	-0.15	-0.12	Amyotrophic lateral sclerosis (age of onset);	chr1:43640595	chr1:43699765~43708138:-
BRCA	cis	rs669446	0.591	rs636547	ENSG00000236200.4	KDM4A-AS1	-3.94	8.55e-05	0.00547	-0.15	-0.12	Amyotrophic lateral sclerosis (age of onset);	chr1:43640845	chr1:43699765~43708138:-
BRCA	cis	rs17027633	1	rs3767607	ENSG00000260948.1	RP11-552M11.8	-3.94	8.55e-05	0.00547	-0.22	-0.12	Cerebrospinal fluid t-tau:AB1-42 ratio;	chr1:111415066	chr1:111431046~111433068:-
BRCA	cis	rs17818399	0.547	rs35178974	ENSG00000279254.1	RP11-536C12.1	-3.94	8.55e-05	0.00547	-0.17	-0.12	Height;	chr2:46536759	chr2:46668870~46670778:+
BRCA	cis	rs11673344	0.504	rs8109501	ENSG00000276846.1	CTD-3220F14.3	3.94	8.55e-05	0.00547	0.14	0.12	Obesity-related traits;	chr19:37102194	chr19:37314868~37315620:-
BRCA	cis	rs13401620	0.843	rs10196708	ENSG00000229326.3	AC069154.4	-3.94	8.55e-05	0.00547	-0.15	-0.12	Breast size;	chr2:119925212	chr2:119698623~119700151:+
BRCA	cis	rs1832007	0.554	rs34179396	ENSG00000215267.7	AKR1C7P	-3.94	8.56e-05	0.00547	-0.23	-0.12	Triglyceride levels;Triglycerides;	chr10:5278817	chr10:5275173~5288470:-
BRCA	cis	rs7267979	0.816	rs6076358	ENSG00000277938.1	RP5-965G21.3	-3.94	8.56e-05	0.00547	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25538767	chr20:25229150~25231933:+
BRCA	cis	rs10246939	0.543	rs35836873	ENSG00000270923.1	TAS2R6P	-3.94	8.56e-05	0.00547	-0.12	-0.12	Bitter taste perception;	chr7:141844010	chr7:141787815~141788640:+
BRCA	cis	rs10246939	0.543	rs9640358	ENSG00000270923.1	TAS2R6P	-3.94	8.56e-05	0.00547	-0.12	-0.12	Bitter taste perception;	chr7:141844082	chr7:141787815~141788640:+
BRCA	cis	rs516805	0.561	rs9482260	ENSG00000279114.1	RP3-425C14.5	3.94	8.56e-05	0.00547	0.17	0.12	Lymphocyte counts;	chr6:122606981	chr6:122471923~122484161:+
BRCA	cis	rs4950322	0.6	rs11240014	ENSG00000244371.2	PFN1P8	-3.94	8.56e-05	0.00548	-0.14	-0.12	Protein quantitative trait loci;	chr1:147380674	chr1:146957117~146957659:-
BRCA	cis	rs4950322	0.576	rs11240015	ENSG00000244371.2	PFN1P8	-3.94	8.56e-05	0.00548	-0.14	-0.12	Protein quantitative trait loci;	chr1:147380813	chr1:146957117~146957659:-
BRCA	cis	rs4950322	0.553	rs12093870	ENSG00000244371.2	PFN1P8	-3.94	8.56e-05	0.00548	-0.14	-0.12	Protein quantitative trait loci;	chr1:147380815	chr1:146957117~146957659:-
BRCA	cis	rs6442522	0.809	rs13081119	ENSG00000249786.6	EAF1-AS1	-3.94	8.56e-05	0.00548	-0.13	-0.12	Uric acid levels;	chr3:15409514	chr3:15436171~15455940:-
BRCA	cis	rs561341	0.941	rs550213	ENSG00000277511.1	CTD-2095E4.5	3.94	8.56e-05	0.00548	0.16	0.12	Hip circumference adjusted for BMI;	chr17:31990499	chr17:32127595~32128454:+
BRCA	cis	rs561341	1	rs530715	ENSG00000277511.1	CTD-2095E4.5	3.94	8.56e-05	0.00548	0.16	0.12	Hip circumference adjusted for BMI;	chr17:31993525	chr17:32127595~32128454:+
BRCA	cis	rs8054556	0.967	rs9932702	ENSG00000261367.1	RP11-455F5.4	-3.94	8.56e-05	0.00548	-0.13	-0.12	Autism spectrum disorder or schizophrenia;	chr16:29971640	chr16:30107675~30110541:+
BRCA	cis	rs8054556	1	rs9925102	ENSG00000261367.1	RP11-455F5.4	-3.94	8.56e-05	0.00548	-0.13	-0.12	Autism spectrum disorder or schizophrenia;	chr16:29971827	chr16:30107675~30110541:+
BRCA	cis	rs375066	0.967	rs8104290	ENSG00000278917.1	RP11-15A1.4	-3.94	8.56e-05	0.00548	-0.14	-0.12	Breast cancer;	chr19:43863186	chr19:43891233~43895411:+
BRCA	cis	rs3781264	0.848	rs3781265	ENSG00000268894.5	PLCE1-AS1	-3.94	8.56e-05	0.00548	-0.16	-0.12	Esophageal cancer and gastric cancer;	chr10:94303522	chr10:94279277~94287478:-
BRCA	cis	rs28735056	0.591	rs2277724	ENSG00000261126.6	RP11-795F19.1	-3.94	8.57e-05	0.00548	-0.12	-0.12	Schizophrenia;	chr18:79934294	chr18:80046900~80095482:+
BRCA	cis	rs889312	0.923	rs1862625	ENSG00000271828.1	CTD-2310F14.1	-3.94	8.57e-05	0.00548	-0.15	-0.12	Breast cancer (early onset);Breast cancer;	chr5:56736892	chr5:56927874~56929573:+
BRCA	cis	rs1949733	0.628	rs2688231	ENSG00000251615.3	RP11-774O3.3	-3.94	8.57e-05	0.00548	-0.13	-0.12	Response to antineoplastic agents;	chr4:8489254	chr4:8355090~8358338:-
BRCA	cis	rs2524005	1	rs2524005	ENSG00000204709.4	LINC01556	3.94	8.57e-05	0.00548	0.2	0.12	Bipolar disorder and schizophrenia;	chr6:29931900	chr6:28943877~28944537:+
BRCA	cis	rs911555	0.755	rs2756122	ENSG00000269940.1	RP11-73M18.7	3.94	8.57e-05	0.00548	0.13	0.12	Intelligence (multi-trait analysis);	chr14:103516696	chr14:103694560~103695170:+
BRCA	cis	rs11711311	1	rs2603789	ENSG00000241529.3	RN7SL767P	-3.94	8.57e-05	0.00548	-0.14	-0.12	IgG glycosylation;	chr3:113751632	chr3:113632704~113632998:+
BRCA	cis	rs3764021	0.527	rs10772062	ENSG00000278635.1	CTD-2318O12.1	-3.94	8.57e-05	0.00548	-0.13	-0.12	Type 1 diabetes;	chr12:9712561	chr12:9415641~9416718:+
BRCA	cis	rs11250097	0.507	rs2409779	ENSG00000255046.1	RP11-297N6.4	3.94	8.57e-05	0.00548	0.15	0.12	Neuroticism;	chr8:11453831	chr8:11797928~11802568:-
BRCA	cis	rs9863	0.861	rs12317176	ENSG00000270028.1	RP11-380L11.4	3.94	8.57e-05	0.00548	0.15	0.12	White blood cell count;	chr12:123920171	chr12:123925461~123926083:-
BRCA	cis	rs62458065	0.64	rs10274556	ENSG00000229358.3	DPY19L1P1	-3.94	8.57e-05	0.00548	-0.17	-0.12	Metabolite levels (HVA/MHPG ratio);	chr7:32474335	chr7:32580949~32761787:-
BRCA	cis	rs964611	0.882	rs11629707	ENSG00000259488.2	RP11-154J22.1	3.94	8.58e-05	0.00549	0.15	0.12	Metabolite levels (Pyroglutamine);	chr15:48348148	chr15:48312353~48331856:-
BRCA	cis	rs13126694	0.574	rs10002472	ENSG00000251429.1	RP11-597D13.7	3.94	8.58e-05	0.00549	0.12	0.12	Blood osmolality (transformed sodium);	chr4:157946821	chr4:158270378~158278676:+
BRCA	cis	rs860295	0.702	rs11264366	ENSG00000203761.5	MSTO2P	-3.94	8.58e-05	0.00549	-0.1	-0.12	Body mass index;	chr1:155365620	chr1:155745829~155750137:+
BRCA	cis	rs10463316	0.894	rs6579862	ENSG00000260581.1	CTB-113P19.4	3.94	8.58e-05	0.00549	0.14	0.12	Metabolite levels (Pyroglutamine);	chr5:151382156	chr5:151652275~151655449:+
BRCA	cis	rs875971	0.964	rs12668936	ENSG00000265600.1	AC006480.1	-3.94	8.58e-05	0.00549	-0.14	-0.12	Aortic root size;	chr7:66449417	chr7:67356680~67356779:+
BRCA	cis	rs12908161	0.515	rs12907646	ENSG00000275120.1	RP11-182J1.17	3.94	8.58e-05	0.00549	0.18	0.12	Schizophrenia;	chr15:84860265	chr15:84599434~84606463:-
BRCA	cis	rs1865760	0.593	rs2097273	ENSG00000272462.2	U91328.19	-3.94	8.58e-05	0.00549	-0.14	-0.12	Height;	chr6:25941082	chr6:25992662~26001775:+
BRCA	cis	rs62229266	0.682	rs11700546	ENSG00000214914.3	RPL23AP3	3.94	8.58e-05	0.00549	0.15	0.12	Mitral valve prolapse;	chr21:35998841	chr21:36016079~36016546:-
BRCA	cis	rs7590268	0.789	rs34992473	ENSG00000279873.2	LINC01126	3.94	8.59e-05	0.00549	0.16	0.12	Orofacial clefts;	chr2:43413064	chr2:43227210~43228855:+
BRCA	cis	rs977987	0.778	rs4888412	ENSG00000280152.1	RP11-331F4.5	-3.94	8.59e-05	0.00549	-0.13	-0.12	Dupuytren's disease;	chr16:75409298	chr16:75245994~75250077:-
BRCA	cis	rs875971	0.66	rs28698552	ENSG00000265600.1	AC006480.1	-3.94	8.59e-05	0.00549	-0.14	-0.12	Aortic root size;	chr7:66540031	chr7:67356680~67356779:+
BRCA	cis	rs6005807	0.719	rs58049055	ENSG00000272858.1	CTA-292E10.8	-3.94	8.59e-05	0.00549	-0.22	-0.12	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28611862	chr22:28814914~28815662:+
BRCA	cis	rs6088580	0.634	rs6120642	ENSG00000275784.1	RP5-1125A11.6	-3.94	8.59e-05	0.00549	-0.13	-0.12	Glomerular filtration rate (creatinine);	chr20:34424725	chr20:33989480~33991818:-
BRCA	cis	rs1048886	0.872	rs9455092	ENSG00000271967.1	RP11-134K13.4	-3.94	8.59e-05	0.00549	-0.16	-0.12	Type 2 diabetes;	chr6:70414826	chr6:70596438~70596980:+
BRCA	cis	rs1048886	0.872	rs9455093	ENSG00000271967.1	RP11-134K13.4	-3.94	8.59e-05	0.00549	-0.16	-0.12	Type 2 diabetes;	chr6:70414827	chr6:70596438~70596980:+
BRCA	cis	rs7819412	0.521	rs10110684	ENSG00000154316.13	TDH	3.94	8.59e-05	0.00549	0.16	0.12	Triglycerides;	chr8:11181650	chr8:11339637~11368452:+
BRCA	cis	rs45509595	0.841	rs9368531	ENSG00000216901.1	AL022393.7	3.94	8.59e-05	0.00549	0.23	0.12	Breast cancer;	chr6:27814094	chr6:28176188~28176674:+
BRCA	cis	rs45509595	0.841	rs2747054	ENSG00000216901.1	AL022393.7	3.94	8.59e-05	0.00549	0.23	0.12	Breast cancer;	chr6:27815581	chr6:28176188~28176674:+
BRCA	cis	rs36051895	0.559	rs7858422	ENSG00000236254.1	MTND4P14	-3.94	8.59e-05	0.00549	-0.14	-0.12	Pediatric autoimmune diseases;	chr9:5209797	chr9:5107937~5109290:+
BRCA	cis	rs6545883	0.894	rs7566035	ENSG00000273302.1	RP11-493E12.2	-3.94	8.59e-05	0.00549	-0.11	-0.12	Tuberculosis;	chr2:61293680	chr2:61199979~61200769:+
BRCA	cis	rs7818688	1	rs10100842	ENSG00000245080.5	RP11-320N21.1	-3.94	8.59e-05	0.00549	-0.2	-0.12	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95013675	chr8:95066808~95073182:-
BRCA	cis	rs7818688	1	rs10103841	ENSG00000245080.5	RP11-320N21.1	-3.94	8.59e-05	0.00549	-0.2	-0.12	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95013676	chr8:95066808~95073182:-
BRCA	cis	rs859767	0.741	rs6759065	ENSG00000224043.6	CCNT2-AS1	3.94	8.6e-05	0.0055	0.16	0.12	Neuroticism;	chr2:134631627	chr2:134735464~134918710:-
BRCA	cis	rs10504130	0.66	rs6473666	ENSG00000272024.1	RP11-546K22.3	-3.94	8.6e-05	0.0055	-0.16	-0.12	Venous thromboembolism (SNP x SNP interaction);	chr8:51925735	chr8:51950284~51950690:+
BRCA	cis	rs4865762	0.874	rs4865543	ENSG00000247796.2	CTD-2366F13.1	-3.94	8.6e-05	0.0055	-0.13	-0.12	Intraocular pressure;	chr5:53260952	chr5:53109842~53115126:+
BRCA	cis	rs4650943	0.658	rs1587712	ENSG00000227740.1	RP11-318C24.2	-3.94	8.6e-05	0.0055	-0.12	-0.12	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in inactive individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr1:176424712	chr1:175904762~175920513:-
BRCA	cis	rs409045	0.896	rs425742	ENSG00000271874.1	CTD-2024P10.2	-3.94	8.6e-05	0.0055	-0.16	-0.12	Left ventricular mass;	chr5:34626306	chr5:34651457~34651888:-
BRCA	cis	rs304029	0.512	rs17757503	ENSG00000231249.1	ITPR1-AS1	-3.94	8.6e-05	0.0055	-0.16	-0.12	Diabetic kidney disease;	chr3:4502311	chr3:4490891~4493163:-
BRCA	cis	rs1790761	0.52	rs7124513	ENSG00000231793.4	DOC2GP	-3.94	8.6e-05	0.0055	-0.13	-0.12	Mean corpuscular volume;	chr11:67628243	chr11:67612653~67616257:-
BRCA	cis	rs7620503	0.959	rs7637965	ENSG00000228561.2	RP11-114M1.1	3.94	8.6e-05	0.0055	0.14	0.12	Corneal structure;	chr3:177589854	chr3:177683627~177691250:+
BRCA	cis	rs860295	0.702	rs5005770	ENSG00000232093.1	RP11-307C12.11	-3.94	8.6e-05	0.0055	-0.14	-0.12	Body mass index;	chr1:155375252	chr1:155045191~155046118:-
BRCA	cis	rs7267979	1	rs7267979	ENSG00000276952.1	RP5-965G21.6	3.94	8.61e-05	0.0055	0.15	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25317451	chr20:25284915~25285588:-
BRCA	cis	rs11098499	0.954	rs6849171	ENSG00000260404.2	RP11-384K6.6	3.94	8.61e-05	0.0055	0.11	0.12	Corneal astigmatism;	chr4:119488394	chr4:118591773~118633729:+
BRCA	cis	rs513088	0.681	rs506349	ENSG00000225171.2	DUTP6	3.94	8.61e-05	0.0055	0.17	0.12	Schizophrenia;	chr1:166673214	chr1:166868748~166869209:+
BRCA	cis	rs755249	0.567	rs66531516	ENSG00000182109.6	RP11-69E11.4	3.94	8.61e-05	0.0055	0.17	0.12	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39163390	chr1:39522280~39546187:-
BRCA	cis	rs4415084	0.966	rs36068815	ENSG00000272335.1	RP11-53O19.3	3.94	8.61e-05	0.0055	0.12	0.12	Breast cancer;	chr5:44645896	chr5:44826076~44828592:+
BRCA	cis	rs7111546	0.514	rs116947073	ENSG00000246225.5	RP11-17A1.3	3.94	8.61e-05	0.0055	0.2	0.12	Dialysis-related mortality;	chr11:22979229	chr11:22829380~22945393:+
BRCA	cis	rs8054556	0.74	rs12716974	ENSG00000183604.13	SMG1P5	-3.94	8.61e-05	0.0055	-0.12	-0.12	Autism spectrum disorder or schizophrenia;	chr16:29933511	chr16:30267553~30335374:-
BRCA	cis	rs8180040	0.764	rs62246375	ENSG00000271161.1	BOLA2P2	-3.94	8.61e-05	0.0055	-0.13	-0.12	Colorectal cancer;	chr3:46972974	chr3:47499841~47500407:+
BRCA	cis	rs11633886	0.528	rs2248207	ENSG00000273972.1	CTD-2306A12.1	3.94	8.61e-05	0.0055	0.14	0.12	Diisocyanate-induced asthma;	chr15:45809215	chr15:45702640~45703183:+
BRCA	cis	rs8058578	0.945	rs8058961	ENSG00000280211.1	RP11-2C24.3	3.94	8.61e-05	0.0055	0.13	0.12	Multiple myeloma;	chr16:30797742	chr16:30773532~30776033:-
BRCA	cis	rs11098499	0.754	rs9991959	ENSG00000260091.1	RP11-33B1.4	3.94	8.61e-05	0.0055	0.1	0.12	Corneal astigmatism;	chr4:119332618	chr4:119409333~119410233:+
BRCA	cis	rs6496044	0.568	rs11632326	ENSG00000202081.1	RNU6-1280P	3.94	8.61e-05	0.0055	0.14	0.12	Interstitial lung disease;	chr15:85536603	chr15:85651522~85651628:-
BRCA	cis	rs12122100	1	rs12122100	ENSG00000244371.2	PFN1P8	3.94	8.61e-05	0.0055	0.15	0.12	HIV-1 control;	chr1:147037378	chr1:146957117~146957659:-
BRCA	cis	rs7119	0.604	rs939488	ENSG00000259362.2	RP11-307C19.1	3.94	8.61e-05	0.0055	0.17	0.12	Type 2 diabetes;	chr15:77575438	chr15:77525540~77534110:+
BRCA	cis	rs838721	0.74	rs838718	ENSG00000259793.1	RP11-400N9.1	3.94	8.61e-05	0.00551	0.1	0.12	Total body bone mineral density;	chr2:233388004	chr2:233351132~233353416:-
BRCA	cis	rs7260598	0.792	rs10500223	ENSG00000268442.1	CTD-2027I19.2	3.94	8.62e-05	0.00551	0.2	0.12	Response to taxane treatment (placlitaxel);	chr19:24163222	chr19:24162370~24163425:-
BRCA	cis	rs1383484	1	rs11259921	ENSG00000230373.7	GOLGA6L5P	-3.94	8.62e-05	0.00551	-0.14	-0.12	Height;	chr15:83836734	chr15:84507885~84516814:-
BRCA	cis	rs1371614	0.523	rs12991124	ENSG00000272148.1	RP11-195B17.1	-3.94	8.62e-05	0.00551	-0.14	-0.12	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26956624	chr2:27062428~27062907:-
BRCA	cis	rs890448	0.796	rs2044044	ENSG00000254531.1	FLJ20021	3.94	8.62e-05	0.00551	0.14	0.12	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101412708	chr4:101347780~101348883:+
BRCA	cis	rs875971	0.545	rs1796217	ENSG00000232559.3	GS1-124K5.12	-3.94	8.62e-05	0.00551	-0.16	-0.12	Aortic root size;	chr7:66620931	chr7:66554588~66576923:-
BRCA	cis	rs11098499	0.954	rs11729521	ENSG00000260404.2	RP11-384K6.6	3.94	8.62e-05	0.00551	0.12	0.12	Corneal astigmatism;	chr4:119495633	chr4:118591773~118633729:+
BRCA	cis	rs875971	0.545	rs4718348	ENSG00000230295.1	RP11-458F8.2	3.94	8.62e-05	0.00551	0.12	0.12	Aortic root size;	chr7:66441589	chr7:66880708~66882981:+
BRCA	cis	rs17270561	0.609	rs7450798	ENSG00000272462.2	U91328.19	-3.94	8.62e-05	0.00551	-0.15	-0.12	Iron status biomarkers;	chr6:25719052	chr6:25992662~26001775:+
BRCA	cis	rs7045881	0.935	rs59274950	ENSG00000254396.1	RP11-56F10.3	3.94	8.63e-05	0.00551	0.2	0.12	Schizophrenia;	chr9:26929387	chr9:27102630~27104728:+
BRCA	cis	rs6545883	0.894	rs2167566	ENSG00000270820.4	RP11-355B11.2	3.94	8.63e-05	0.00551	0.14	0.12	Tuberculosis;	chr2:61292273	chr2:61471188~61484130:+
BRCA	cis	rs7267979	1	rs2424700	ENSG00000274973.1	RP13-401N8.7	-3.94	8.63e-05	0.00551	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25285877	chr20:25845497~25845862:+
BRCA	cis	rs4443100	0.916	rs6003482	ENSG00000230701.2	FBXW4P1	3.94	8.63e-05	0.00551	0.15	0.12	Serum parathyroid hormone levels;	chr22:23037185	chr22:23262767~23265005:+
BRCA	cis	rs4499344	0.73	rs12460663	ENSG00000267475.1	CTD-2538C1.2	3.94	8.63e-05	0.00551	0.15	0.12	Mean platelet volume;	chr19:32607332	chr19:32687089~32691750:-
BRCA	cis	rs12468579	0.503	rs1168	ENSG00000235852.1	AC005540.3	-3.94	8.63e-05	0.00552	-0.13	-0.12	JT interval (sulfonylurea treatment interaction);	chr2:190965051	chr2:190880797~190882059:-
BRCA	cis	rs8099996	0.798	rs10409001	ENSG00000267277.1	CTD-2342J14.6	3.94	8.63e-05	0.00552	0.14	0.12	Inflammatory skin disease;	chr19:11066574	chr19:11368123~11374935:-
BRCA	cis	rs10029851	0.738	rs1436507	ENSG00000234492.4	RPL34-AS1	3.94	8.63e-05	0.00552	0.14	0.12	Amyotrophic lateral sclerosis (sporadic);	chr4:108709841	chr4:108538190~108620460:-
BRCA	cis	rs10512488	1	rs10512488	ENSG00000198496.9	NBR2	3.94	8.64e-05	0.00552	0.17	0.12	Type 2 diabetes (age of onset);	chr17:42811886	chr17:43125610~43153671:+
BRCA	cis	rs524281	0.814	rs10896093	ENSG00000255557.1	RP11-770G2.2	3.94	8.64e-05	0.00552	0.17	0.12	Electroencephalogram traits;	chr11:66190940	chr11:65745729~65771585:+
BRCA	cis	rs12612619	0.732	rs11687536	ENSG00000272148.1	RP11-195B17.1	-3.94	8.64e-05	0.00552	-0.13	-0.12	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:26976886	chr2:27062428~27062907:-
BRCA	cis	rs4478858	0.684	rs11579845	ENSG00000260386.4	LINC01225	-3.94	8.64e-05	0.00552	-0.14	-0.12	Alcohol dependence;	chr1:31263401	chr1:31500085~31540885:+
BRCA	cis	rs4561483	0.673	rs28279	ENSG00000261216.1	RP11-166B2.5	3.94	8.64e-05	0.00552	0.14	0.12	Testicular germ cell tumor;	chr16:11874698	chr16:11908208~11908916:+
BRCA	cis	rs2022309	0.962	rs12128453	ENSG00000260464.1	RP4-561L24.3	3.94	8.64e-05	0.00552	0.14	0.12	End-stage coagulation;	chr1:94584300	chr1:93847174~93848939:+
BRCA	cis	rs9818758	0.607	rs34823813	ENSG00000270441.1	RP11-694I15.7	3.94	8.65e-05	0.00552	0.27	0.12	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49712543	chr3:49140086~49160851:-
BRCA	cis	rs73201462	1	rs2811534	ENSG00000242551.2	POU5F1P6	-3.94	8.65e-05	0.00552	-0.2	-0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128272265	chr3:128674735~128677005:-
BRCA	cis	rs11633886	0.585	rs2460629	ENSG00000273972.1	CTD-2306A12.1	3.94	8.65e-05	0.00553	0.14	0.12	Diisocyanate-induced asthma;	chr15:45798785	chr15:45702640~45703183:+
BRCA	cis	rs748404	0.518	rs2899074	ENSG00000166763.7	STRCP1	3.94	8.65e-05	0.00553	0.15	0.12	Lung cancer;	chr15:43109232	chr15:43699488~43718184:-
BRCA	cis	rs11686241	0.935	rs284572	ENSG00000241520.1	AC098820.4	-3.94	8.65e-05	0.00553	-0.18	-0.12	Cancer;	chr2:216499816	chr2:216483032~216487196:-
BRCA	cis	rs11742741	0.806	rs59394630	ENSG00000248874.4	C5orf17	-3.94	8.65e-05	0.00553	-0.16	-0.12	Educational attainment;	chr5:24049355	chr5:23951348~24178263:+
BRCA	cis	rs11742741	0.774	rs55708874	ENSG00000248874.4	C5orf17	-3.94	8.65e-05	0.00553	-0.16	-0.12	Educational attainment;	chr5:24050808	chr5:23951348~24178263:+
BRCA	cis	rs36563	0.631	rs1859915	ENSG00000258571.1	PTTG4P	-3.94	8.65e-05	0.00553	-0.19	-0.12	Alcohol dependence;	chr14:71018861	chr14:71085482~71085833:-
BRCA	cis	rs801193	1	rs2659889	ENSG00000265600.1	AC006480.1	-3.94	8.66e-05	0.00553	-0.14	-0.12	Aortic root size;	chr7:66752125	chr7:67356680~67356779:+
BRCA	cis	rs11168618	0.74	rs11168617	ENSG00000240399.1	RP1-228P16.1	3.94	8.66e-05	0.00553	0.13	0.12	Adiponectin levels;	chr12:48534925	chr12:48054813~48055591:-
BRCA	cis	rs10864907	0.652	rs7580446	ENSG00000231747.1	AC079922.2	-3.94	8.66e-05	0.00553	-0.11	-0.12	Pulmonary function;	chr2:112966337	chr2:112621809~112622167:-
BRCA	cis	rs10864907	0.71	rs11691126	ENSG00000231747.1	AC079922.2	-3.94	8.66e-05	0.00553	-0.11	-0.12	Pulmonary function;	chr2:112967494	chr2:112621809~112622167:-
BRCA	cis	rs10864907	0.71	rs11884901	ENSG00000231747.1	AC079922.2	-3.94	8.66e-05	0.00553	-0.11	-0.12	Pulmonary function;	chr2:112967781	chr2:112621809~112622167:-
BRCA	cis	rs10864907	0.71	rs11902514	ENSG00000231747.1	AC079922.2	-3.94	8.66e-05	0.00553	-0.11	-0.12	Pulmonary function;	chr2:112967822	chr2:112621809~112622167:-
BRCA	cis	rs7937890	0.559	rs4369365	ENSG00000254418.1	RP11-21L19.1	3.94	8.66e-05	0.00553	0.14	0.12	Mitochondrial DNA levels;	chr11:14422969	chr11:14262846~14273691:-
BRCA	cis	rs801193	0.548	rs2659904	ENSG00000229180.5	GS1-124K5.11	3.94	8.66e-05	0.00553	0.11	0.12	Aortic root size;	chr7:66713615	chr7:66526088~66542624:-
BRCA	cis	rs2243480	1	rs73150014	ENSG00000226002.1	RP11-460N20.5	-3.94	8.66e-05	0.00553	-0.2	-0.12	Diabetic kidney disease;	chr7:65985932	chr7:65084103~65100232:+
BRCA	cis	rs73201462	0.908	rs4593050	ENSG00000242551.2	POU5F1P6	-3.94	8.66e-05	0.00553	-0.2	-0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128285688	chr3:128674735~128677005:-
BRCA	cis	rs73201462	1	rs2955101	ENSG00000242551.2	POU5F1P6	-3.94	8.66e-05	0.00553	-0.2	-0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128290769	chr3:128674735~128677005:-
BRCA	cis	rs2071426	0.622	rs34707620	ENSG00000273450.1	RP11-76P2.4	3.94	8.66e-05	0.00553	0.15	0.12	Blood metabolite levels;	chr10:95010262	chr10:94314907~94315327:-
BRCA	cis	rs12681366	0.537	rs2919656	ENSG00000253175.1	RP11-267M23.6	3.94	8.66e-05	0.00553	0.14	0.12	Nonsyndromic cleft lip with cleft palate;	chr8:94460806	chr8:94565036~94565715:+
BRCA	cis	rs459571	0.959	rs392134	ENSG00000235106.7	LINC00094	3.94	8.66e-05	0.00553	0.13	0.12	Platelet distribution width;	chr9:134043886	chr9:134025439~134034666:+
BRCA	cis	rs801193	1	rs2003301	ENSG00000273142.1	RP11-458F8.4	3.94	8.66e-05	0.00553	0.11	0.12	Aortic root size;	chr7:66682669	chr7:66902857~66906297:+
BRCA	cis	rs11070836	0.935	rs12440795	ENSG00000259378.1	DCAF13P3	3.94	8.66e-05	0.00553	0.16	0.12	Airway wall thickness;	chr15:51130732	chr15:50944663~50945996:+
BRCA	cis	rs10266483	0.921	rs687547	ENSG00000228653.2	HNRNPCP7	-3.94	8.66e-05	0.00553	-0.14	-0.12	Response to statin therapy;	chr7:64284551	chr7:64500825~64501729:+
BRCA	cis	rs7267979	1	rs448396	ENSG00000274414.1	RP5-965G21.4	-3.94	8.67e-05	0.00553	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25459633	chr20:25239007~25245229:-
BRCA	cis	rs9788721	0.934	rs55676755	ENSG00000261762.1	RP11-650L12.2	-3.94	8.67e-05	0.00553	-0.15	-0.12	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78606590	chr15:78589123~78591276:-
BRCA	cis	rs4819052	0.851	rs7275870	ENSG00000215447.6	BX322557.10	-3.94	8.67e-05	0.00553	-0.12	-0.12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251299	chr21:45288052~45291738:+
BRCA	cis	rs4819052	0.851	rs7275874	ENSG00000215447.6	BX322557.10	-3.94	8.67e-05	0.00553	-0.12	-0.12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251308	chr21:45288052~45291738:+
BRCA	cis	rs12681366	1	rs12681366	ENSG00000253175.1	RP11-267M23.6	3.94	8.67e-05	0.00554	0.14	0.12	Nonsyndromic cleft lip with cleft palate;	chr8:94389037	chr8:94565036~94565715:+
BRCA	cis	rs2832077	0.943	rs11701445	ENSG00000232855.5	AF131217.1	3.94	8.67e-05	0.00554	0.18	0.12	Cognitive test performance;	chr21:28788485	chr21:28439346~28674848:-
BRCA	cis	rs763121	1	rs763121	ENSG00000228274.3	RP3-508I15.9	3.94	8.67e-05	0.00554	0.13	0.12	Menopause (age at onset);	chr22:38483935	chr22:38667585~38681820:-
BRCA	cis	rs9879311	0.966	rs4684685	ENSG00000240288.6	GHRLOS	3.94	8.68e-05	0.00554	0.13	0.12	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr3:10369869	chr3:10285754~10293449:+
BRCA	cis	rs9376307	0.92	rs9373202	ENSG00000226004.1	RP11-10J5.1	-3.94	8.68e-05	0.00554	-0.13	-0.12	Cancer;	chr6:137964325	chr6:137943079~137945802:-
BRCA	cis	rs6071166	0.611	rs1033515	ENSG00000224635.1	RP4-564F22.5	-3.94	8.68e-05	0.00554	-0.15	-0.12	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38681866	chr20:38406011~38416797:-
BRCA	cis	rs694419	0.579	rs9965948	ENSG00000278017.1	RP11-120K19.4	3.94	8.68e-05	0.00554	0.15	0.12	Serum albumin level;	chr18:62534631	chr18:62525919~62526325:-
BRCA	cis	rs1429524	0.813	rs17163782	ENSG00000243144.5	RP11-115N4.1	-3.94	8.69e-05	0.00555	-0.17	-0.12	Ejection fraction in Tripanosoma cruzi seropositivity;	chr7:91307086	chr7:91311368~91515409:+
BRCA	cis	rs9863	0.827	rs4930706	ENSG00000270028.1	RP11-380L11.4	3.94	8.69e-05	0.00555	0.15	0.12	White blood cell count;	chr12:123932791	chr12:123925461~123926083:-
BRCA	cis	rs1008375	0.966	rs3733576	ENSG00000249502.1	AC006160.5	-3.94	8.69e-05	0.00555	-0.14	-0.12	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17585080	chr4:17587467~17614571:-
BRCA	cis	rs747650	0.504	rs10769226	ENSG00000200376.1	RNU5E-10P	3.94	8.69e-05	0.00555	0.16	0.12	Acne (severe);	chr11:46963252	chr11:47576471~47576588:-
BRCA	cis	rs3739034	0.938	rs62171393	ENSG00000224043.6	CCNT2-AS1	-3.94	8.69e-05	0.00555	-0.24	-0.12	Gut microbiome composition (winter);	chr2:134718390	chr2:134735464~134918710:-
BRCA	cis	rs3845817	0.675	rs702940	ENSG00000237979.1	AC007389.1	3.94	8.69e-05	0.00555	0.14	0.12	Bipolar disorder;	chr2:65521007	chr2:65500993~65502138:-
BRCA	cis	rs11742741	0.806	rs1346494	ENSG00000248874.4	C5orf17	-3.94	8.7e-05	0.00555	-0.16	-0.12	Educational attainment;	chr5:24064714	chr5:23951348~24178263:+
BRCA	cis	rs4664293	0.967	rs10803758	ENSG00000226266.5	AC009961.3	-3.94	8.7e-05	0.00555	-0.15	-0.12	Monocyte percentage of white cells;	chr2:159691708	chr2:159670708~159712435:-
BRCA	cis	rs10421328	0.821	rs2288867	ENSG00000267419.1	CTC-559E9.6	-3.94	8.7e-05	0.00555	-0.13	-0.12	Parental longevity (combined parental age at death);	chr19:19654759	chr19:19776602~19834927:+
BRCA	cis	rs6964587	0.773	rs13223564	ENSG00000188693.7	CYP51A1-AS1	-3.94	8.7e-05	0.00555	-0.14	-0.12	Breast cancer;	chr7:92303352	chr7:92134604~92180725:+
BRCA	cis	rs34217772	0.941	rs34543976	ENSG00000258636.1	CTD-2298J14.2	3.94	8.7e-05	0.00555	0.17	0.12	Myopia;	chr14:41782929	chr14:41587861~41604856:-
BRCA	cis	rs6063399	0.79	rs6067084	ENSG00000222365.1	SNORD12B	-3.94	8.7e-05	0.00555	-0.13	-0.12	Obesity-related traits;	chr20:49406457	chr20:49280319~49280409:+
BRCA	cis	rs6430585	0.527	rs2254780	ENSG00000224043.6	CCNT2-AS1	-3.94	8.7e-05	0.00555	-0.19	-0.12	Corneal structure;	chr2:135677956	chr2:134735464~134918710:-
BRCA	cis	rs2880765	0.743	rs12906308	ENSG00000230373.7	GOLGA6L5P	-3.94	8.7e-05	0.00556	-0.13	-0.12	Coronary artery disease;	chr15:85464828	chr15:84507885~84516814:-
BRCA	cis	rs2880765	0.743	rs8039049	ENSG00000230373.7	GOLGA6L5P	3.94	8.7e-05	0.00556	0.13	0.12	Coronary artery disease;	chr15:85464398	chr15:84507885~84516814:-
BRCA	cis	rs2880765	0.743	rs8039631	ENSG00000230373.7	GOLGA6L5P	3.94	8.7e-05	0.00556	0.13	0.12	Coronary artery disease;	chr15:85464700	chr15:84507885~84516814:-
BRCA	cis	rs1062753	0.961	rs9620007	ENSG00000205702.9	CYP2D7	3.94	8.7e-05	0.00556	0.11	0.12	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42009653	chr22:42140203~42144577:-
BRCA	cis	rs7412746	0.611	rs4319334	ENSG00000231073.1	RP11-316M1.3	3.94	8.71e-05	0.00556	0.13	0.12	Melanoma;	chr1:150794346	chr1:150973123~150975534:+
BRCA	cis	rs4478858	0.684	rs4949202	ENSG00000223907.1	LINC01226	-3.94	8.71e-05	0.00556	-0.15	-0.12	Alcohol dependence;	chr1:31263953	chr1:31518435~31524245:+
BRCA	cis	rs4478858	0.647	rs7524117	ENSG00000223907.1	LINC01226	-3.94	8.71e-05	0.00556	-0.15	-0.12	Alcohol dependence;	chr1:31265569	chr1:31518435~31524245:+
BRCA	cis	rs2274273	0.743	rs7161656	ENSG00000259318.1	RP11-454L9.2	3.94	8.71e-05	0.00556	0.1	0.12	Protein biomarker;	chr14:55057812	chr14:55394940~55395233:-
BRCA	cis	rs783540	0.5	rs1313494	ENSG00000276710.3	CSPG4P8	3.94	8.71e-05	0.00556	0.14	0.12	Schizophrenia;	chr15:82605530	chr15:82459472~82477258:+
BRCA	cis	rs4925386	0.802	rs6142735	ENSG00000275437.1	RP5-908M14.10	3.94	8.71e-05	0.00556	0.14	0.12	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62343031	chr20:62402236~62405935:-
BRCA	cis	rs6593122	0.816	rs10230619	ENSG00000235454.1	HAUS6P3	-3.94	8.71e-05	0.00556	-0.16	-0.12	Vaccine-related adverse events;	chr7:54123496	chr7:53862233~53863339:+
BRCA	cis	rs6593122	0.613	rs10234080	ENSG00000235454.1	HAUS6P3	-3.94	8.71e-05	0.00556	-0.16	-0.12	Vaccine-related adverse events;	chr7:54123803	chr7:53862233~53863339:+
BRCA	cis	rs6593122	0.755	rs10234194	ENSG00000235454.1	HAUS6P3	-3.94	8.71e-05	0.00556	-0.16	-0.12	Vaccine-related adverse events;	chr7:54123892	chr7:53862233~53863339:+
BRCA	cis	rs6593122	0.755	rs10278234	ENSG00000235454.1	HAUS6P3	-3.94	8.71e-05	0.00556	-0.16	-0.12	Vaccine-related adverse events;	chr7:54124221	chr7:53862233~53863339:+
BRCA	cis	rs35146811	0.66	rs3779046	ENSG00000235713.1	RP4-604G5.3	3.94	8.71e-05	0.00556	0.14	0.12	Coronary artery disease;	chr7:100181620	chr7:99992397~99993050:+
BRCA	cis	rs35146811	0.66	rs3779045	ENSG00000235713.1	RP4-604G5.3	3.94	8.71e-05	0.00556	0.14	0.12	Coronary artery disease;	chr7:100181636	chr7:99992397~99993050:+
BRCA	cis	rs35146811	0.7	rs4729579	ENSG00000235713.1	RP4-604G5.3	3.94	8.71e-05	0.00556	0.14	0.12	Coronary artery disease;	chr7:100182659	chr7:99992397~99993050:+
BRCA	cis	rs35146811	0.7	rs7788301	ENSG00000235713.1	RP4-604G5.3	3.94	8.71e-05	0.00556	0.14	0.12	Coronary artery disease;	chr7:100185130	chr7:99992397~99993050:+
BRCA	cis	rs35146811	0.735	rs2272344	ENSG00000235713.1	RP4-604G5.3	3.94	8.71e-05	0.00556	0.14	0.12	Coronary artery disease;	chr7:100189196	chr7:99992397~99993050:+
BRCA	cis	rs35146811	0.735	rs11764176	ENSG00000235713.1	RP4-604G5.3	3.94	8.71e-05	0.00556	0.14	0.12	Coronary artery disease;	chr7:100189341	chr7:99992397~99993050:+
BRCA	cis	rs35146811	0.735	rs6948729	ENSG00000235713.1	RP4-604G5.3	3.94	8.71e-05	0.00556	0.14	0.12	Coronary artery disease;	chr7:100189749	chr7:99992397~99993050:+
BRCA	cis	rs8105895	0.935	rs7260331	ENSG00000269345.1	VN1R85P	3.94	8.71e-05	0.00556	0.18	0.12	Body mass index (change over time);	chr19:22108969	chr19:22174766~22175191:-
BRCA	cis	rs6432852	0.966	rs6432851	ENSG00000232411.1	AC009495.3	-3.94	8.71e-05	0.00556	-0.14	-0.12	Diabetic kidney disease;	chr2:165892403	chr2:165833048~165839098:-
BRCA	cis	rs13108904	0.935	rs1620928	ENSG00000253399.1	AC078852.2	3.94	8.72e-05	0.00556	0.13	0.12	Obesity-related traits;	chr4:1285336	chr4:1358479~1359461:+
BRCA	cis	rs2274459	0.778	rs2296737	ENSG00000249346.5	LINC01016	3.94	8.72e-05	0.00556	0.15	0.12	Obesity (extreme);	chr6:33688639	chr6:33867506~33896914:-
BRCA	cis	rs2625529	0.689	rs2957742	ENSG00000260037.4	CTD-2524L6.3	3.94	8.72e-05	0.00557	0.15	0.12	Red blood cell count;	chr15:72010553	chr15:71818396~71823384:+
BRCA	cis	rs6964587	1	rs2299232	ENSG00000188693.7	CYP51A1-AS1	-3.94	8.72e-05	0.00557	-0.13	-0.12	Breast cancer;	chr7:91997385	chr7:92134604~92180725:+
BRCA	cis	rs4886920	0.894	rs7176895	ENSG00000260776.4	RP11-114H24.2	-3.94	8.72e-05	0.00557	-0.14	-0.12	Neuroticism;	chr15:77825458	chr15:77914217~77926846:-
BRCA	cis	rs57677839	1	rs57677839	ENSG00000272034.1	SNORD14A	3.94	8.72e-05	0.00557	0.13	0.12	Coronary artery disease;	chr11:17006642	chr11:17074654~17074744:-
BRCA	cis	rs9952980	0.671	rs17743054	ENSG00000266968.2	RP11-116O18.1	-3.94	8.72e-05	0.00557	-0.15	-0.12	Breast cancer;	chr18:45320927	chr18:45646153~45647937:+
BRCA	cis	rs7520050	0.931	rs11211189	ENSG00000234329.1	RP11-767N6.2	-3.94	8.73e-05	0.00557	-0.11	-0.12	Reticulocyte count;Red blood cell count;	chr1:45795912	chr1:45651039~45651826:-
BRCA	cis	rs7520050	0.966	rs12411269	ENSG00000234329.1	RP11-767N6.2	-3.94	8.73e-05	0.00557	-0.11	-0.12	Reticulocyte count;Red blood cell count;	chr1:45805380	chr1:45651039~45651826:-
BRCA	cis	rs2243480	1	rs466983	ENSG00000226002.1	RP11-460N20.5	-3.94	8.73e-05	0.00557	-0.21	-0.12	Diabetic kidney disease;	chr7:66055509	chr7:65084103~65100232:+
BRCA	cis	rs10411936	1	rs10411936	ENSG00000280332.1	CTD-2013N17.6	-3.94	8.73e-05	0.00557	-0.1	-0.12	Multiple sclerosis;White blood cell count;	chr19:16437564	chr19:16356329~16358327:-
BRCA	cis	rs12893668	0.645	rs12889403	ENSG00000269940.1	RP11-73M18.7	3.94	8.73e-05	0.00557	0.14	0.12	Reticulocyte count;	chr14:103568409	chr14:103694560~103695170:+
BRCA	cis	rs12893668	0.703	rs12894729	ENSG00000269940.1	RP11-73M18.7	3.94	8.73e-05	0.00557	0.14	0.12	Reticulocyte count;	chr14:103568955	chr14:103694560~103695170:+
BRCA	cis	rs8180040	0.587	rs1466741	ENSG00000271161.1	BOLA2P2	-3.94	8.73e-05	0.00557	-0.13	-0.12	Colorectal cancer;	chr3:47205724	chr3:47499841~47500407:+
BRCA	cis	rs442309	0.875	rs224056	ENSG00000238280.1	RP11-436D10.3	-3.94	8.73e-05	0.00557	-0.15	-0.12	Vogt-Koyanagi-Harada syndrome;	chr10:62737240	chr10:62793562~62805887:-
BRCA	cis	rs12999616	0.948	rs35958372	ENSG00000230606.9	AC159540.1	-3.94	8.73e-05	0.00557	-0.19	-0.12	Colorectal cancer;	chr2:97714395	chr2:97416165~97433527:-
BRCA	cis	rs4886920	0.894	rs4886527	ENSG00000260776.4	RP11-114H24.2	-3.94	8.73e-05	0.00557	-0.14	-0.12	Neuroticism;	chr15:77821215	chr15:77914217~77926846:-
BRCA	cis	rs1912124	1	rs17337055	ENSG00000271983.1	RP11-28H5.2	3.94	8.73e-05	0.00557	0.24	0.12	Peripheral arterial disease (traffic-related air pollution interaction);	chr15:81185331	chr15:80693216~80693707:-
BRCA	cis	rs77633900	0.772	rs166933	ENSG00000196274.5	Metazoa_SRP	3.94	8.74e-05	0.00557	0.22	0.12	Glioma;Non-glioblastoma glioma;	chr15:76443924	chr15:76230048~76230390:-
BRCA	cis	rs1075265	0.587	rs2542585	ENSG00000272156.1	RP11-477N3.1	-3.94	8.74e-05	0.00558	-0.13	-0.12	Chronotype;Morning vs. evening chronotype;	chr2:53786407	chr2:54082554~54085066:+
BRCA	cis	rs8017423	0.647	rs4904674	ENSG00000275198.1	RP11-471B22.3	3.94	8.74e-05	0.00558	0.14	0.12	Mortality in heart failure;	chr14:90351068	chr14:90383365~90387973:+
BRCA	cis	rs801193	1	rs2659912	ENSG00000229180.5	GS1-124K5.11	3.94	8.74e-05	0.00558	0.1	0.12	Aortic root size;	chr7:66693012	chr7:66526088~66542624:-
BRCA	cis	rs7985	0.901	rs5761679	ENSG00000244625.4	MIATNB	3.94	8.74e-05	0.00558	0.14	0.12	Electroencephalogram traits;	chr22:26681268	chr22:26672767~26780207:+
BRCA	cis	rs733592	0.56	rs2158515	ENSG00000273765.1	RP11-370I10.11	-3.94	8.74e-05	0.00558	-0.13	-0.12	Plateletcrit;	chr12:48113885	chr12:48360920~48361377:+
BRCA	cis	rs739496	0.579	rs2879603	ENSG00000234608.6	MAPKAPK5-AS1	3.94	8.74e-05	0.00558	0.15	0.12	Platelet count;	chr12:111840221	chr12:111839764~111842902:-
BRCA	cis	rs875971	0.964	rs6978429	ENSG00000265600.1	AC006480.1	-3.94	8.74e-05	0.00558	-0.14	-0.12	Aortic root size;	chr7:66494889	chr7:67356680~67356779:+
BRCA	cis	rs875971	1	rs4718357	ENSG00000265600.1	AC006480.1	-3.94	8.74e-05	0.00558	-0.14	-0.12	Aortic root size;	chr7:66495891	chr7:67356680~67356779:+
BRCA	cis	rs962856	1	rs4671794	ENSG00000236605.1	AC023115.4	3.94	8.74e-05	0.00558	0.14	0.12	Pancreatic cancer;	chr2:67339526	chr2:67324627~67325304:+
BRCA	cis	rs10029851	0.645	rs9996443	ENSG00000234492.4	RPL34-AS1	3.94	8.74e-05	0.00558	0.14	0.12	Amyotrophic lateral sclerosis (sporadic);	chr4:108698434	chr4:108538190~108620460:-
BRCA	cis	rs372883	0.901	rs8133749	ENSG00000215533.7	LINC00189	-3.94	8.74e-05	0.00558	-0.13	-0.12	Pancreatic cancer;	chr21:29243614	chr21:29193480~29288205:+
BRCA	cis	rs7735319	0.528	rs7707609	ENSG00000249572.1	CTD-2203K17.1	3.94	8.74e-05	0.00558	0.16	0.12	Systolic blood pressure;	chr5:33164460	chr5:33424025~33440619:-
BRCA	cis	rs930395	0.514	rs7703618	ENSG00000251141.4	RP11-53O19.1	-3.94	8.74e-05	0.00558	-0.11	-0.12	Breast cancer;	chr5:44914477	chr5:44744900~44808777:-
BRCA	cis	rs853679	1	rs7740487	ENSG00000204709.4	LINC01556	3.94	8.75e-05	0.00558	0.22	0.12	Depression;	chr6:28248708	chr6:28943877~28944537:+
BRCA	cis	rs2898290	0.5	rs11998678	ENSG00000270074.1	RP11-351I21.11	3.94	8.75e-05	0.00558	0.16	0.12	Systolic blood pressure;	chr8:11972641	chr8:12412827~12414373:+
BRCA	cis	rs6472235	0.564	rs62506650	ENSG00000272010.1	CTD-3025N20.3	-3.94	8.75e-05	0.00558	-0.15	-0.12	Plateletcrit;Myopia (pathological);	chr8:66004267	chr8:65591850~65592472:-
BRCA	cis	rs6472235	0.586	rs11984602	ENSG00000272010.1	CTD-3025N20.3	-3.94	8.75e-05	0.00558	-0.15	-0.12	Plateletcrit;Myopia (pathological);	chr8:66004338	chr8:65591850~65592472:-
BRCA	cis	rs875971	0.767	rs12668005	ENSG00000273024.4	INTS4P2	-3.94	8.75e-05	0.00558	-0.14	-0.12	Aortic root size;	chr7:66444034	chr7:65647864~65715661:+
BRCA	cis	rs10864907	0.651	rs6761372	ENSG00000231747.1	AC079922.2	-3.94	8.75e-05	0.00558	-0.11	-0.12	Pulmonary function;	chr2:112964081	chr2:112621809~112622167:-
BRCA	cis	rs10504130	1	rs763550	ENSG00000272076.1	RP11-11C20.3	-3.94	8.75e-05	0.00558	-0.21	-0.12	Venous thromboembolism (SNP x SNP interaction);	chr8:51802905	chr8:51810110~51810681:-
BRCA	cis	rs990171	0.52	rs4851605	ENSG00000234389.1	AC007278.3	3.94	8.75e-05	0.00558	0.12	0.12	Lymphocyte counts;	chr2:102504409	chr2:102438713~102440475:+
BRCA	cis	rs990171	0.538	rs4851606	ENSG00000234389.1	AC007278.3	3.94	8.75e-05	0.00558	0.12	0.12	Lymphocyte counts;	chr2:102504430	chr2:102438713~102440475:+
BRCA	cis	rs6480314	0.908	rs61854762	ENSG00000233590.1	RP11-153K11.3	-3.94	8.75e-05	0.00558	-0.19	-0.12	Optic nerve measurement (disc area);	chr10:68204891	chr10:68233251~68242379:-
BRCA	cis	rs6480314	0.908	rs61854763	ENSG00000233590.1	RP11-153K11.3	-3.94	8.75e-05	0.00558	-0.19	-0.12	Optic nerve measurement (disc area);	chr10:68205038	chr10:68233251~68242379:-
BRCA	cis	rs4950322	0.542	rs3766520	ENSG00000237188.3	RP11-337C18.8	3.94	8.75e-05	0.00558	0.16	0.12	Protein quantitative trait loci;	chr1:147214658	chr1:147172771~147211568:+
BRCA	cis	rs1075265	0.704	rs805402	ENSG00000272156.1	RP11-477N3.1	-3.94	8.75e-05	0.00558	-0.13	-0.12	Chronotype;Morning vs. evening chronotype;	chr2:53889212	chr2:54082554~54085066:+
BRCA	cis	rs7071275	0.891	rs10886965	ENSG00000226864.1	ATE1-AS1	-3.94	8.75e-05	0.00558	-0.2	-0.12	Dupuytren's disease;	chr10:121670803	chr10:121928312~121951965:+
BRCA	cis	rs11242704	0.632	rs4959568	ENSG00000218027.2	RP11-157J24.1	3.94	8.75e-05	0.00558	0.16	0.12	Response to hepatitis C treatment;	chr6:1530194	chr6:1513698~1515289:-
BRCA	cis	rs17428076	0.718	rs17499544	ENSG00000228389.1	AC068039.4	3.94	8.75e-05	0.00558	0.2	0.12	Myopia;	chr2:171784224	chr2:171773482~171775844:+
BRCA	cis	rs7267979	0.934	rs2261115	ENSG00000276952.1	RP5-965G21.6	3.94	8.76e-05	0.00559	0.15	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25279171	chr20:25284915~25285588:-
BRCA	cis	rs16846053	0.792	rs62187702	ENSG00000227403.1	AC009299.3	3.94	8.76e-05	0.00559	0.31	0.12	Blood osmolality (transformed sodium);	chr2:161826653	chr2:161244739~161249050:+
BRCA	cis	rs6928977	0.5	rs719885	ENSG00000234084.1	RP3-388E23.2	-3.94	8.76e-05	0.00559	-0.12	-0.12	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135618217	chr6:135301568~135307158:+
BRCA	cis	rs9470794	1	rs9462393	ENSG00000204110.6	RP1-153P14.8	-3.94	8.76e-05	0.00559	-0.19	-0.12	Type 2 diabetes;	chr6:38156584	chr6:37507348~37535616:+
BRCA	cis	rs7267979	1	rs7020	ENSG00000277938.1	RP5-965G21.3	3.94	8.76e-05	0.00559	0.14	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25297964	chr20:25229150~25231933:+
BRCA	cis	rs10911902	0.913	rs55660734	ENSG00000229739.2	RP11-295K2.3	-3.94	8.76e-05	0.00559	-0.18	-0.12	Schizophrenia;	chr1:186620869	chr1:186435161~186470291:+
BRCA	cis	rs875971	0.545	rs73378304	ENSG00000273142.1	RP11-458F8.4	3.94	8.76e-05	0.00559	0.12	0.12	Aortic root size;	chr7:66175760	chr7:66902857~66906297:+
BRCA	cis	rs6828577	0.626	rs17642633	ENSG00000269893.5	SNHG8	-3.94	8.76e-05	0.00559	-0.13	-0.12	Perioperative myocardial infarction in coronary artery bypass surgery;	chr4:118490945	chr4:118278709~118279823:+
BRCA	cis	rs9470794	1	rs2395692	ENSG00000204110.6	RP1-153P14.8	-3.94	8.76e-05	0.00559	-0.19	-0.12	Type 2 diabetes;	chr6:38156303	chr6:37507348~37535616:+
BRCA	cis	rs9470794	1	rs2395693	ENSG00000204110.6	RP1-153P14.8	-3.94	8.76e-05	0.00559	-0.19	-0.12	Type 2 diabetes;	chr6:38156443	chr6:37507348~37535616:+
BRCA	cis	rs9863	0.861	rs4765219	ENSG00000270028.1	RP11-380L11.4	3.94	8.76e-05	0.00559	0.15	0.12	White blood cell count;	chr12:123955563	chr12:123925461~123926083:-
BRCA	cis	rs860295	0.702	rs10796946	ENSG00000232093.1	RP11-307C12.11	3.94	8.76e-05	0.00559	0.14	0.12	Body mass index;	chr1:155459699	chr1:155045191~155046118:-
BRCA	cis	rs860295	0.676	rs10908466	ENSG00000232093.1	RP11-307C12.11	3.94	8.76e-05	0.00559	0.14	0.12	Body mass index;	chr1:155459934	chr1:155045191~155046118:-
BRCA	cis	rs28735056	0.592	rs12455965	ENSG00000261126.6	RP11-795F19.1	-3.94	8.76e-05	0.00559	-0.12	-0.12	Schizophrenia;	chr18:79928830	chr18:80046900~80095482:+
BRCA	cis	rs1048886	0.938	rs11965656	ENSG00000271967.1	RP11-134K13.4	-3.94	8.76e-05	0.00559	-0.17	-0.12	Type 2 diabetes;	chr6:70473917	chr6:70596438~70596980:+
BRCA	cis	rs2625529	0.824	rs12899485	ENSG00000260037.4	CTD-2524L6.3	3.94	8.76e-05	0.00559	0.17	0.12	Red blood cell count;	chr15:71850874	chr15:71818396~71823384:+
BRCA	cis	rs11047510	0.775	rs7300139	ENSG00000164845.15	FAM86FP	3.94	8.76e-05	0.00559	0.19	0.12	Exploratory eye movement dysfunction in schizophrenia (responsive search score);	chr12:8845245	chr12:8232512~8242948:-
BRCA	cis	rs2191566	0.664	rs62115477	ENSG00000266921.1	RP11-15A1.7	-3.94	8.77e-05	0.00559	-0.15	-0.12	Acute lymphoblastic leukemia (childhood);	chr19:44038874	chr19:43996896~44002836:-
BRCA	cis	rs8062405	1	rs3088215	ENSG00000261766.1	RP11-22P6.2	-3.94	8.77e-05	0.00559	-0.12	-0.12	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28842675	chr16:28862166~28863340:-
BRCA	cis	rs8062405	1	rs28403629	ENSG00000261766.1	RP11-22P6.2	-3.94	8.77e-05	0.00559	-0.12	-0.12	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28843448	chr16:28862166~28863340:-
BRCA	cis	rs8062405	1	rs61737565	ENSG00000261766.1	RP11-22P6.2	-3.94	8.77e-05	0.00559	-0.12	-0.12	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28844201	chr16:28862166~28863340:-
BRCA	cis	rs8062405	1	rs4788099	ENSG00000261766.1	RP11-22P6.2	-3.94	8.77e-05	0.00559	-0.12	-0.12	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28844406	chr16:28862166~28863340:-
BRCA	cis	rs78487399	0.634	rs77881454	ENSG00000234936.1	AC010883.5	3.94	8.77e-05	0.00559	0.19	0.12	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43530154	chr2:43229573~43233394:+
BRCA	cis	rs9733	0.519	rs7521898	ENSG00000231073.1	RP11-316M1.3	3.94	8.77e-05	0.00559	0.13	0.12	Tonsillectomy;	chr1:150735120	chr1:150973123~150975534:+
BRCA	cis	rs9733	0.519	rs7511673	ENSG00000231073.1	RP11-316M1.3	3.94	8.77e-05	0.00559	0.13	0.12	Tonsillectomy;	chr1:150735160	chr1:150973123~150975534:+
BRCA	cis	rs8054556	1	rs6565173	ENSG00000261367.1	RP11-455F5.4	-3.94	8.77e-05	0.00559	-0.14	-0.12	Autism spectrum disorder or schizophrenia;	chr16:29962846	chr16:30107675~30110541:+
BRCA	cis	rs360929	1	rs360929	ENSG00000245954.5	RP11-18H21.1	3.94	8.77e-05	0.00559	0.12	0.12	Volumetric brain MRI;	chr4:151986548	chr4:152100754~152104720:+
BRCA	cis	rs13108904	0.935	rs1732102	ENSG00000253399.1	AC078852.2	3.94	8.77e-05	0.00559	0.13	0.12	Obesity-related traits;	chr4:1284136	chr4:1358479~1359461:+
BRCA	cis	rs375066	0.935	rs426534	ENSG00000267191.1	RP11-15A1.2	-3.94	8.78e-05	0.0056	-0.15	-0.12	Breast cancer;	chr19:43908431	chr19:43902001~43926545:+
BRCA	cis	rs17772222	0.917	rs17188228	ENSG00000258789.1	RP11-507K2.3	-3.94	8.78e-05	0.0056	-0.15	-0.12	Coronary artery calcification;	chr14:88738921	chr14:88551597~88552493:+
BRCA	cis	rs11098499	0.865	rs4001305	ENSG00000250412.1	KLHL2P1	3.94	8.78e-05	0.0056	0.14	0.12	Corneal astigmatism;	chr4:119438081	chr4:119334329~119378233:+
BRCA	cis	rs11168351	0.517	rs10875754	ENSG00000257763.1	OR5BK1P	3.94	8.78e-05	0.0056	0.12	0.12	Bipolar disorder and schizophrenia;	chr12:48164139	chr12:48355792~48356614:-
BRCA	cis	rs2298450	0.55	rs7280997	ENSG00000231106.2	LINC01436	3.94	8.78e-05	0.0056	0.13	0.12	Schizophrenia;	chr21:36286211	chr21:36005338~36007838:+
BRCA	cis	rs9959145	1	rs11660232	ENSG00000267108.1	RP11-861E21.1	3.94	8.78e-05	0.0056	0.21	0.12	Immune response to smallpox vaccine (IL-6);	chr18:12585546	chr18:12432897~12437635:+
BRCA	cis	rs10986311	0.832	rs10123514	ENSG00000227200.1	RP11-121A14.3	-3.94	8.78e-05	0.0056	-0.14	-0.12	Vitiligo;	chr9:124380599	chr9:124262876~124265809:+
BRCA	cis	rs7727544	0.545	rs17674015	ENSG00000233006.5	AC034220.3	3.94	8.78e-05	0.0056	0.09	0.12	Blood metabolite levels;	chr5:132026085	chr5:132311285~132369916:-
BRCA	cis	rs12681366	0.683	rs1379246	ENSG00000253704.1	RP11-267M23.4	-3.94	8.78e-05	0.0056	-0.12	-0.12	Nonsyndromic cleft lip with cleft palate;	chr8:94361073	chr8:94553722~94569745:+
BRCA	cis	rs2391285	0.609	rs757580	ENSG00000280255.1	RP5-1007F24.1	3.94	8.78e-05	0.0056	0.17	0.12	Post bronchodilator FEV1/FVC ratio;	chr7:26554129	chr7:26538378~26541048:+
BRCA	cis	rs7474896	0.616	rs2474561	ENSG00000226578.1	RP11-258F22.1	-3.94	8.79e-05	0.0056	-0.17	-0.12	Obesity (extreme);	chr10:38084616	chr10:37775371~37784131:-
BRCA	cis	rs747650	0.504	rs10769225	ENSG00000200376.1	RNU5E-10P	3.94	8.79e-05	0.0056	0.16	0.12	Acne (severe);	chr11:46960930	chr11:47576471~47576588:-
BRCA	cis	rs747650	0.504	rs10769227	ENSG00000200376.1	RNU5E-10P	3.94	8.79e-05	0.0056	0.16	0.12	Acne (severe);	chr11:46981063	chr11:47576471~47576588:-
BRCA	cis	rs2243480	1	rs313803	ENSG00000237026.1	RP11-328P23.2	3.94	8.79e-05	0.0056	0.23	0.12	Diabetic kidney disease;	chr7:66049744	chr7:65235790~65236723:-
BRCA	cis	rs6490294	0.528	rs74187049	ENSG00000257624.1	RP1-128M12.3	3.94	8.79e-05	0.0056	0.22	0.12	Mean platelet volume;	chr12:112180114	chr12:112000739~112000985:-
BRCA	cis	rs6490294	0.528	rs16941909	ENSG00000257624.1	RP1-128M12.3	3.94	8.79e-05	0.0056	0.22	0.12	Mean platelet volume;	chr12:112188420	chr12:112000739~112000985:-
BRCA	cis	rs2731006	0.591	rs9788178	ENSG00000257114.2	RP11-25I15.3	3.94	8.79e-05	0.0056	0.18	0.12	Panic disorder;	chr12:42811931	chr12:42692216~42717119:+
BRCA	cis	rs801193	1	rs4717319	ENSG00000265600.1	AC006480.1	-3.94	8.79e-05	0.0056	-0.14	-0.12	Aortic root size;	chr7:66777606	chr7:67356680~67356779:+
BRCA	cis	rs801193	1	rs62466793	ENSG00000229180.5	GS1-124K5.11	3.94	8.79e-05	0.0056	0.1	0.12	Aortic root size;	chr7:66726530	chr7:66526088~66542624:-
BRCA	cis	rs6968419	0.585	rs9692117	ENSG00000279086.1	RP11-667F14.1	-3.94	8.79e-05	0.0056	-0.12	-0.12	Intraocular pressure;	chr7:116287905	chr7:116209234~116211511:-
BRCA	cis	rs934734	0.967	rs702875	ENSG00000204929.10	AC074391.1	3.94	8.79e-05	0.0056	0.15	0.12	Rheumatoid arthritis;	chr2:65387063	chr2:65436711~66084639:+
BRCA	cis	rs8094794	0.744	rs11661275	ENSG00000267707.2	RP11-95O2.5	3.94	8.79e-05	0.0056	0.19	0.12	Periodontal disease-related phenotypes;	chr18:36709401	chr18:37243776~37247506:+
BRCA	cis	rs7620503	0.917	rs6443469	ENSG00000228561.2	RP11-114M1.1	3.94	8.79e-05	0.0056	0.14	0.12	Corneal structure;	chr3:177568667	chr3:177683627~177691250:+
BRCA	cis	rs3735485	0.661	rs11761702	ENSG00000201772.1	SNORA5C	3.94	8.79e-05	0.0056	0.16	0.12	White blood cell count;Sum basophil neutrophil counts;Neutrophil count;Granulocyte percentage of myeloid white cells;Monocyte percentage of white cells;Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Lymphocyte counts;	chr7:45086584	chr7:45104906~45105042:-
BRCA	cis	rs11168618	0.703	rs11495272	ENSG00000240399.1	RP1-228P16.1	3.94	8.79e-05	0.0056	0.13	0.12	Adiponectin levels;	chr12:48535043	chr12:48054813~48055591:-
BRCA	cis	rs2243480	1	rs7804223	ENSG00000237026.1	RP11-328P23.2	-3.94	8.79e-05	0.00561	-0.23	-0.12	Diabetic kidney disease;	chr7:66199572	chr7:65235790~65236723:-
BRCA	cis	rs3764021	0.509	rs10772070	ENSG00000278635.1	CTD-2318O12.1	-3.94	8.79e-05	0.00561	-0.14	-0.12	Type 1 diabetes;	chr12:9717320	chr12:9415641~9416718:+
BRCA	cis	rs6546324	0.625	rs980227	ENSG00000236780.4	AC078941.1	3.94	8.8e-05	0.00561	0.21	0.12	Endometriosis;	chr2:67637126	chr2:67123357~67215319:-
BRCA	cis	rs6005807	0.688	rs16986077	ENSG00000235954.5	TTC28-AS1	3.94	8.8e-05	0.00561	0.24	0.12	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28152979	chr22:27919376~28008581:+
BRCA	cis	rs8114671	0.562	rs6088622	ENSG00000261582.1	RP4-614O4.11	-3.94	8.8e-05	0.00561	-0.12	-0.12	Height;	chr20:34832174	chr20:35267885~35280043:-
BRCA	cis	rs3824867	0.77	rs11820680	ENSG00000280615.1	Y_RNA	3.94	8.8e-05	0.00561	0.15	0.12	Mean corpuscular hemoglobin;	chr11:47431193	chr11:47614898~47614994:-
BRCA	cis	rs7620503	0.959	rs2863014	ENSG00000277241.1	RP11-114M1.3	3.94	8.8e-05	0.00561	0.13	0.12	Corneal structure;	chr3:177585404	chr3:177700346~177701072:-
BRCA	cis	rs9921338	0.887	rs9926136	ENSG00000262636.1	CTD-3088G3.4	-3.94	8.8e-05	0.00561	-0.2	-0.12	Vein graft stenosis in coronary artery bypass grafting;	chr16:11343418	chr16:11380859~11381118:-
BRCA	cis	rs62103177	0.525	rs4799117	ENSG00000278075.1	RP11-248M19.1	-3.94	8.8e-05	0.00561	-0.2	-0.12	Opioid sensitivity;	chr18:79996604	chr18:79900555~79900903:-
BRCA	cis	rs62103177	0.525	rs4283293	ENSG00000278075.1	RP11-248M19.1	-3.94	8.8e-05	0.00561	-0.2	-0.12	Opioid sensitivity;	chr18:79999582	chr18:79900555~79900903:-
BRCA	cis	rs6545883	0.929	rs3732170	ENSG00000270820.4	RP11-355B11.2	3.94	8.8e-05	0.00561	0.14	0.12	Tuberculosis;	chr2:61522581	chr2:61471188~61484130:+
BRCA	cis	rs1048886	0.872	rs73480280	ENSG00000271967.1	RP11-134K13.4	-3.94	8.81e-05	0.00561	-0.17	-0.12	Type 2 diabetes;	chr6:70572972	chr6:70596438~70596980:+
BRCA	cis	rs8114671	0.562	rs2425005	ENSG00000261582.1	RP4-614O4.11	3.94	8.81e-05	0.00561	0.13	0.12	Height;	chr20:34819912	chr20:35267885~35280043:-
BRCA	cis	rs13434995	0.513	rs550144	ENSG00000239040.1	Y_RNA	-3.94	8.81e-05	0.00561	-0.14	-0.12	Adiponectin levels;	chr4:55415317	chr4:55412636~55412738:+
BRCA	cis	rs11168618	0.74	rs7307588	ENSG00000240399.1	RP1-228P16.1	3.94	8.81e-05	0.00562	0.13	0.12	Adiponectin levels;	chr12:48529449	chr12:48054813~48055591:-
BRCA	cis	rs198426	0.81	rs12794220	ENSG00000243742.4	RPLP0P2	3.94	8.81e-05	0.00562	0.15	0.12	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr11:61694940	chr11:61615036~61639449:+
BRCA	cis	rs13434995	0.513	rs67963898	ENSG00000239040.1	Y_RNA	3.94	8.81e-05	0.00562	0.14	0.12	Adiponectin levels;	chr4:55475520	chr4:55412636~55412738:+
BRCA	cis	rs875971	0.929	rs12535036	ENSG00000265600.1	AC006480.1	-3.94	8.81e-05	0.00562	-0.14	-0.12	Aortic root size;	chr7:66499076	chr7:67356680~67356779:+
BRCA	cis	rs875971	1	rs6970030	ENSG00000265600.1	AC006480.1	-3.94	8.81e-05	0.00562	-0.14	-0.12	Aortic root size;	chr7:66503692	chr7:67356680~67356779:+
BRCA	cis	rs875971	0.928	rs6970357	ENSG00000265600.1	AC006480.1	-3.94	8.81e-05	0.00562	-0.14	-0.12	Aortic root size;	chr7:66503891	chr7:67356680~67356779:+
BRCA	cis	rs12586478	0.56	rs8008600	ENSG00000205562.2	RP11-497E19.1	3.94	8.82e-05	0.00562	0.11	0.12	Post bronchodilator FEV1;	chr14:86311476	chr14:85524432~85529988:-
BRCA	cis	rs4415084	0.716	rs10057341	ENSG00000251141.4	RP11-53O19.1	-3.94	8.82e-05	0.00562	-0.11	-0.12	Breast cancer;	chr5:44931738	chr5:44744900~44808777:-
BRCA	cis	rs9309473	0.607	rs6716776	ENSG00000163016.8	ALMS1P	3.94	8.82e-05	0.00562	0.15	0.12	Metabolite levels;	chr2:73360585	chr2:73644919~73685576:+
BRCA	cis	rs2280018	0.963	rs4985147	ENSG00000188599.16	NPIPP1	-3.94	8.82e-05	0.00562	-0.1	-0.12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15074903	chr16:15104312~15123498:-
BRCA	cis	rs12612619	0.695	rs11126806	ENSG00000272148.1	RP11-195B17.1	-3.94	8.82e-05	0.00562	-0.14	-0.12	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27002276	chr2:27062428~27062907:-
BRCA	cis	rs3805389	0.504	rs1873090	ENSG00000273257.1	RP11-177J6.1	-3.94	8.82e-05	0.00562	-0.2	-0.12	Waist-to-hip ratio adjusted for body mass index;	chr4:55605237	chr4:55387949~55388271:+
BRCA	cis	rs12612420	0.629	rs17446700	ENSG00000225953.2	SATB2-AS1	3.94	8.82e-05	0.00562	0.19	0.12	Exercise (leisure time);	chr2:200255505	chr2:199457700~199476935:+
BRCA	cis	rs6005451	1	rs4822881	ENSG00000225783.5	MIAT	-3.94	8.82e-05	0.00562	-0.17	-0.12	Prostate cancer (SNP x SNP interaction);	chr22:27456906	chr22:26646428~26676475:+
BRCA	cis	rs739496	0.615	rs77684561	ENSG00000226469.1	ADAM1B	3.94	8.82e-05	0.00562	0.16	0.12	Platelet count;	chr12:111623919	chr12:111927018~111929017:+
BRCA	cis	rs73201462	1	rs2811393	ENSG00000242551.2	POU5F1P6	-3.94	8.82e-05	0.00562	-0.2	-0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128305156	chr3:128674735~128677005:-
BRCA	cis	rs2153535	0.584	rs55945625	ENSG00000251164.1	HULC	3.94	8.83e-05	0.00562	0.15	0.12	Motion sickness;	chr6:8371134	chr6:8652137~8653846:+
BRCA	cis	rs13434995	0.838	rs73236165	ENSG00000273257.1	RP11-177J6.1	-3.94	8.83e-05	0.00562	-0.2	-0.12	Adiponectin levels;	chr4:55617617	chr4:55387949~55388271:+
BRCA	cis	rs8028182	0.501	rs7166281	ENSG00000260269.4	CTD-2323K18.1	3.94	8.83e-05	0.00562	0.18	0.12	Sudden cardiac arrest;	chr15:75635851	chr15:75527150~75601205:-
BRCA	cis	rs950169	0.545	rs4842841	ENSG00000275120.1	RP11-182J1.17	3.94	8.83e-05	0.00562	0.18	0.12	Schizophrenia;	chr15:83972373	chr15:84599434~84606463:-
BRCA	cis	rs6964587	1	rs13231820	ENSG00000188693.7	CYP51A1-AS1	-3.94	8.83e-05	0.00562	-0.13	-0.12	Breast cancer;	chr7:92034215	chr7:92134604~92180725:+
BRCA	cis	rs11158026	0.603	rs68065548	ENSG00000233924.1	AL160471.6	-3.94	8.83e-05	0.00562	-0.15	-0.12	Parkinson's disease;	chr14:54979835	chr14:55004813~55005687:-
BRCA	cis	rs9381040	0.655	rs2268190	ENSG00000161912.16	ADCY10P1	3.94	8.83e-05	0.00563	0.14	0.12	Alzheimer's disease (late onset);	chr6:41062487	chr6:41101022~41140835:+
BRCA	cis	rs2251666	0.514	rs17630889	ENSG00000267077.1	RP11-127I20.5	3.94	8.83e-05	0.00563	0.18	0.12	Cancer;	chr16:4831208	chr16:4795265~4796532:-
BRCA	cis	rs4819052	1	rs28628220	ENSG00000184274.3	LINC00315	-3.94	8.83e-05	0.00563	-0.18	-0.12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45243826	chr21:45300245~45305257:-
BRCA	cis	rs6901004	0.605	rs2297939	ENSG00000230177.1	RP5-1112D6.4	-3.94	8.83e-05	0.00563	-0.14	-0.12	Blood metabolite levels;	chr6:111227959	chr6:111277932~111278742:+
BRCA	cis	rs16940212	0.618	rs495348	ENSG00000259771.1	RP11-429D19.1	-3.94	8.83e-05	0.00563	-0.19	-0.12	HDL cholesterol;HDL cholesterol levels;	chr15:58395591	chr15:59266720~59271162:-
BRCA	cis	rs10508774	0.929	rs72784063	ENSG00000273038.2	RP11-479G22.8	3.94	8.83e-05	0.00563	0.26	0.12	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32906071	chr10:32887255~32889311:-
BRCA	cis	rs10508774	0.929	rs72784068	ENSG00000273038.2	RP11-479G22.8	3.94	8.83e-05	0.00563	0.26	0.12	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32912195	chr10:32887255~32889311:-
BRCA	cis	rs6012564	1	rs3092039	ENSG00000230758.1	SNAP23P	-3.94	8.84e-05	0.00563	-0.14	-0.12	Anger;	chr20:49062233	chr20:49038357~49038602:-
BRCA	cis	rs10421328	0.95	rs55831814	ENSG00000267419.1	CTC-559E9.6	-3.94	8.84e-05	0.00563	-0.15	-0.12	Parental longevity (combined parental age at death);	chr19:19666835	chr19:19776602~19834927:+
BRCA	cis	rs73201462	1	rs2955095	ENSG00000242551.2	POU5F1P6	3.94	8.84e-05	0.00563	0.2	0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128258822	chr3:128674735~128677005:-
BRCA	cis	rs1434579	0.897	rs12610672	ENSG00000176761.7	ZNF285B	3.94	8.84e-05	0.00563	0.14	0.12	Tuberculosis;	chr19:44441388	chr19:44467641~44473227:+
BRCA	cis	rs10829156	1	rs10829157	ENSG00000240291.1	RP11-499P20.2	3.94	8.85e-05	0.00563	0.15	0.12	Sudden cardiac arrest;	chr10:18662534	chr10:18513115~18545651:-
BRCA	cis	rs2075466	0.514	rs111431826	ENSG00000267077.1	RP11-127I20.5	3.94	8.85e-05	0.00563	0.18	0.12	Colonoscopy-negative controls vs population controls;	chr16:4857111	chr16:4795265~4796532:-
BRCA	cis	rs2075466	0.514	rs112861583	ENSG00000267077.1	RP11-127I20.5	3.94	8.85e-05	0.00563	0.18	0.12	Colonoscopy-negative controls vs population controls;	chr16:4857124	chr16:4795265~4796532:-
BRCA	cis	rs11098499	0.874	rs13123591	ENSG00000225892.3	RP11-384K6.2	3.94	8.85e-05	0.00563	0.13	0.12	Corneal astigmatism;	chr4:119184835	chr4:118632274~118634759:+
BRCA	cis	rs2229238	0.866	rs112231452	ENSG00000272030.1	RP1-178F15.4	-3.94	8.85e-05	0.00563	-0.17	-0.12	Coronary heart disease;	chr1:154532424	chr1:153631438~153634397:-
BRCA	cis	rs757081	0.676	rs567033	ENSG00000184669.7	OR7E14P	-3.94	8.85e-05	0.00564	-0.16	-0.12	Systolic blood pressure;	chr11:17185463	chr11:17013998~17053024:+
BRCA	cis	rs757081	0.676	rs677042	ENSG00000184669.7	OR7E14P	-3.94	8.85e-05	0.00564	-0.16	-0.12	Systolic blood pressure;	chr11:17185533	chr11:17013998~17053024:+
BRCA	cis	rs2274459	1	rs13200063	ENSG00000249346.5	LINC01016	3.94	8.85e-05	0.00564	0.16	0.12	Obesity (extreme);	chr6:33762394	chr6:33867506~33896914:-
BRCA	cis	rs9634489	0.709	rs912690	ENSG00000247400.3	DNAJC3-AS1	-3.94	8.85e-05	0.00564	-0.13	-0.12	Body mass index;	chr13:96368451	chr13:95648733~95676925:-
BRCA	cis	rs11242704	0.632	rs2816291	ENSG00000218027.2	RP11-157J24.1	3.94	8.85e-05	0.00564	0.16	0.12	Response to hepatitis C treatment;	chr6:1537887	chr6:1513698~1515289:-
BRCA	cis	rs1555322	1	rs2425034	ENSG00000279253.1	RP4-614O4.13	-3.94	8.85e-05	0.00564	-0.2	-0.12	Attention deficit hyperactivity disorder;	chr20:35268011	chr20:35262727~35264187:-
BRCA	cis	rs1555322	0.858	rs2425035	ENSG00000279253.1	RP4-614O4.13	-3.94	8.85e-05	0.00564	-0.2	-0.12	Attention deficit hyperactivity disorder;	chr20:35268016	chr20:35262727~35264187:-
BRCA	cis	rs13108904	0.935	rs4974575	ENSG00000196810.4	CTBP1-AS2	3.94	8.85e-05	0.00564	0.13	0.12	Obesity-related traits;	chr4:1258240	chr4:1249300~1288291:+
BRCA	cis	rs4478858	0.684	rs11579845	ENSG00000223907.1	LINC01226	-3.94	8.85e-05	0.00564	-0.15	-0.12	Alcohol dependence;	chr1:31263401	chr1:31518435~31524245:+
BRCA	cis	rs6893300	0.961	rs55827522	ENSG00000250999.1	RP11-1379J22.5	3.94	8.86e-05	0.00564	0.17	0.12	Resting heart rate;	chr5:179750115	chr5:179657762~179664432:+
BRCA	cis	rs865483	0.929	rs853195	ENSG00000276054.1	RP11-378E13.3	3.94	8.86e-05	0.00564	0.16	0.12	Monocyte count;	chr17:37488149	chr17:37386886~37387926:+
BRCA	cis	rs73201462	1	rs6810006	ENSG00000242551.2	POU5F1P6	3.94	8.86e-05	0.00564	0.2	0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128137215	chr3:128674735~128677005:-
BRCA	cis	rs5758659	0.652	rs133313	ENSG00000182057.4	OGFRP1	3.94	8.86e-05	0.00564	0.14	0.12	Cognitive function;	chr22:42005745	chr22:42269753~42275196:+
BRCA	cis	rs5758659	0.652	rs133314	ENSG00000182057.4	OGFRP1	3.94	8.86e-05	0.00564	0.14	0.12	Cognitive function;	chr22:42005837	chr22:42269753~42275196:+
BRCA	cis	rs911555	0.511	rs2296483	ENSG00000269910.1	RP11-73M18.10	3.94	8.86e-05	0.00564	0.12	0.12	Intelligence (multi-trait analysis);	chr14:103563455	chr14:103694516~103695050:-
BRCA	cis	rs875971	1	rs709597	ENSG00000272831.1	RP11-792A8.4	-3.94	8.86e-05	0.00564	-0.11	-0.12	Aortic root size;	chr7:66360996	chr7:66739829~66740385:-
BRCA	cis	rs8054556	1	rs4788204	ENSG00000261367.1	RP11-455F5.4	-3.94	8.86e-05	0.00564	-0.13	-0.12	Autism spectrum disorder or schizophrenia;	chr16:29983897	chr16:30107675~30110541:+
BRCA	cis	rs9733	0.596	rs11586422	ENSG00000231073.1	RP11-316M1.3	3.94	8.86e-05	0.00564	0.13	0.12	Tonsillectomy;	chr1:150706882	chr1:150973123~150975534:+
BRCA	cis	rs9733	0.596	rs72702557	ENSG00000231073.1	RP11-316M1.3	3.94	8.86e-05	0.00564	0.13	0.12	Tonsillectomy;	chr1:150707654	chr1:150973123~150975534:+
BRCA	cis	rs9733	0.596	rs17606613	ENSG00000231073.1	RP11-316M1.3	3.94	8.86e-05	0.00564	0.13	0.12	Tonsillectomy;	chr1:150710539	chr1:150973123~150975534:+
BRCA	cis	rs9733	0.543	rs72702558	ENSG00000231073.1	RP11-316M1.3	3.94	8.86e-05	0.00564	0.13	0.12	Tonsillectomy;	chr1:150710775	chr1:150973123~150975534:+
BRCA	cis	rs9733	0.628	rs11807409	ENSG00000231073.1	RP11-316M1.3	3.94	8.86e-05	0.00564	0.13	0.12	Tonsillectomy;	chr1:150710947	chr1:150973123~150975534:+
BRCA	cis	rs9733	0.565	rs11804276	ENSG00000231073.1	RP11-316M1.3	3.94	8.86e-05	0.00564	0.13	0.12	Tonsillectomy;	chr1:150713285	chr1:150973123~150975534:+
BRCA	cis	rs9733	0.596	rs12072339	ENSG00000231073.1	RP11-316M1.3	3.94	8.86e-05	0.00564	0.13	0.12	Tonsillectomy;	chr1:150713623	chr1:150973123~150975534:+
BRCA	cis	rs9733	0.596	rs34600506	ENSG00000231073.1	RP11-316M1.3	3.94	8.86e-05	0.00564	0.13	0.12	Tonsillectomy;	chr1:150715332	chr1:150973123~150975534:+
BRCA	cis	rs9733	0.596	rs72702570	ENSG00000231073.1	RP11-316M1.3	3.94	8.86e-05	0.00564	0.13	0.12	Tonsillectomy;	chr1:150715720	chr1:150973123~150975534:+
BRCA	cis	rs9733	0.596	rs11582840	ENSG00000231073.1	RP11-316M1.3	3.94	8.86e-05	0.00564	0.13	0.12	Tonsillectomy;	chr1:150716011	chr1:150973123~150975534:+
BRCA	cis	rs9733	0.569	rs11588404	ENSG00000231073.1	RP11-316M1.3	3.94	8.86e-05	0.00564	0.13	0.12	Tonsillectomy;	chr1:150716053	chr1:150973123~150975534:+
BRCA	cis	rs9733	0.596	rs72702573	ENSG00000231073.1	RP11-316M1.3	3.94	8.86e-05	0.00564	0.13	0.12	Tonsillectomy;	chr1:150716574	chr1:150973123~150975534:+
BRCA	cis	rs9733	0.596	rs72702580	ENSG00000231073.1	RP11-316M1.3	3.94	8.86e-05	0.00564	0.13	0.12	Tonsillectomy;	chr1:150718809	chr1:150973123~150975534:+
BRCA	cis	rs1009077	0.716	rs13147817	ENSG00000245958.5	RP11-33B1.1	3.94	8.86e-05	0.00564	0.18	0.12	Endometriosis;	chr4:119634500	chr4:119454791~119552025:+
BRCA	cis	rs2625529	0.73	rs2957737	ENSG00000260037.4	CTD-2524L6.3	3.94	8.87e-05	0.00565	0.16	0.12	Red blood cell count;	chr15:71973069	chr15:71818396~71823384:+
BRCA	cis	rs4713118	0.629	rs203890	ENSG00000216901.1	AL022393.7	3.94	8.87e-05	0.00565	0.17	0.12	Parkinson's disease;	chr6:28054470	chr6:28176188~28176674:+
BRCA	cis	rs801193	1	rs4717319	ENSG00000273142.1	RP11-458F8.4	-3.94	8.87e-05	0.00565	-0.1	-0.12	Aortic root size;	chr7:66777606	chr7:66902857~66906297:+
BRCA	cis	rs7523050	0.908	rs72697202	ENSG00000203897.3	SPATA42	-3.93	8.87e-05	0.00565	-0.21	-0.12	Fat distribution (HIV);	chr1:108856082	chr1:108857217~108858524:+
BRCA	cis	rs7523050	0.908	rs17621621	ENSG00000203897.3	SPATA42	-3.93	8.87e-05	0.00565	-0.21	-0.12	Fat distribution (HIV);	chr1:108856295	chr1:108857217~108858524:+
BRCA	cis	rs7523050	0.908	rs17621644	ENSG00000203897.3	SPATA42	-3.93	8.87e-05	0.00565	-0.21	-0.12	Fat distribution (HIV);	chr1:108856401	chr1:108857217~108858524:+
BRCA	cis	rs1437396	0.609	rs3099076	ENSG00000203327.2	AC012358.7	3.93	8.88e-05	0.00565	0.12	0.12	Alcohol dependence;	chr2:55368510	chr2:55214387~55216126:-
BRCA	cis	rs11168351	0.864	rs10875743	ENSG00000226413.2	OR8T1P	-3.93	8.88e-05	0.00565	-0.16	-0.12	Bipolar disorder and schizophrenia;	chr12:48104630	chr12:48442030~48442947:-
BRCA	cis	rs2320614	0.967	rs11938737	ENSG00000250027.1	RP11-563E2.2	-3.93	8.88e-05	0.00565	-0.14	-0.12	Lung adenocarcinoma;	chr4:163124239	chr4:163108785~163119965:+
BRCA	cis	rs7620503	1	rs6808260	ENSG00000277241.1	RP11-114M1.3	3.93	8.88e-05	0.00565	0.13	0.12	Corneal structure;	chr3:177582044	chr3:177700346~177701072:-
BRCA	cis	rs74233809	1	rs11191543	ENSG00000236937.2	PTGES3P4	3.93	8.88e-05	0.00565	0.25	0.12	Birth weight;	chr10:103064630	chr10:102845595~102845950:+
BRCA	cis	rs8141529	0.748	rs5762874	ENSG00000272858.1	CTA-292E10.8	-3.93	8.88e-05	0.00565	-0.16	-0.12	Lymphocyte counts;	chr22:28873670	chr22:28814914~28815662:+
BRCA	cis	rs1348850	0.958	rs1548067	ENSG00000280374.1	RP11-337N6.3	3.93	8.88e-05	0.00565	0.16	0.12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177598186	chr2:177317715~177318471:-
BRCA	cis	rs16846053	0.792	rs62187701	ENSG00000227403.1	AC009299.3	3.93	8.88e-05	0.00565	0.31	0.12	Blood osmolality (transformed sodium);	chr2:161825821	chr2:161244739~161249050:+
BRCA	cis	rs9309473	0.528	rs7573275	ENSG00000230002.2	ALMS1-IT1	3.93	8.88e-05	0.00565	0.15	0.12	Metabolite levels;	chr2:73325414	chr2:73456764~73459484:+
BRCA	cis	rs7246967	0.932	rs35687548	ENSG00000198153.8	ZNF849P	-3.93	8.88e-05	0.00565	-0.17	-0.12	Bronchopulmonary dysplasia;	chr19:22846345	chr19:22685167~22686732:+
BRCA	cis	rs7746199	0.736	rs17693963	ENSG00000216901.1	AL022393.7	3.93	8.88e-05	0.00565	0.29	0.12	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27742386	chr6:28176188~28176674:+
BRCA	cis	rs1153858	1	rs3759899	ENSG00000275672.1	GATM-AS1	-3.93	8.88e-05	0.00565	-0.16	-0.12	Homoarginine levels;	chr15:45363705	chr15:45378700~45380123:+
BRCA	cis	rs6012564	1	rs56131635	ENSG00000222365.1	SNORD12B	3.93	8.88e-05	0.00565	0.13	0.12	Anger;	chr20:49157806	chr20:49280319~49280409:+
BRCA	cis	rs4648045	0.734	rs12509517	ENSG00000246560.2	RP11-10L12.4	3.93	8.88e-05	0.00566	0.14	0.12	Lymphocyte percentage of white cells;	chr4:102604351	chr4:102828055~102844075:+
BRCA	cis	rs930421	0.544	rs4953645	ENSG00000226491.1	FTOP1	-3.93	8.89e-05	0.00566	-0.14	-0.12	Attention deficit hyperactivity disorder;	chr2:42757896	chr2:42797225~42798712:-
BRCA	cis	rs513088	0.681	rs523900	ENSG00000225171.2	DUTP6	3.93	8.89e-05	0.00566	0.17	0.12	Schizophrenia;	chr1:166680370	chr1:166868748~166869209:+
BRCA	cis	rs216345	0.699	rs6476433	ENSG00000260947.1	RP11-384P7.7	-3.93	8.89e-05	0.00566	-0.13	-0.12	Bipolar disorder;	chr9:34042373	chr9:33697459~33700986:+
BRCA	cis	rs9527	0.59	rs10786744	ENSG00000213061.2	PFN1P11	-3.93	8.89e-05	0.00566	-0.16	-0.12	Arsenic metabolism;	chr10:103185271	chr10:102838011~102845473:-
BRCA	cis	rs524281	0.861	rs12226649	ENSG00000255038.1	RP11-1167A19.2	-3.93	8.89e-05	0.00566	-0.18	-0.12	Electroencephalogram traits;	chr11:66074576	chr11:66067277~66069619:-
BRCA	cis	rs7078160	0.938	rs10787753	ENSG00000281599.1	AC023283.1	3.93	8.89e-05	0.00566	0.14	0.12	Nonsyndromic cleft lip with or without cleft palate;Orofacial clefts;	chr10:117070173	chr10:116827489~116827564:-
BRCA	cis	rs10421328	0.821	rs4808976	ENSG00000267419.1	CTC-559E9.6	-3.93	8.89e-05	0.00566	-0.13	-0.12	Parental longevity (combined parental age at death);	chr19:19648490	chr19:19776602~19834927:+
BRCA	cis	rs7246967	0.866	rs12981220	ENSG00000198153.8	ZNF849P	3.93	8.89e-05	0.00566	0.17	0.12	Bronchopulmonary dysplasia;	chr19:22838598	chr19:22685167~22686732:+
BRCA	cis	rs10504130	1	rs12675786	ENSG00000272076.1	RP11-11C20.3	3.93	8.89e-05	0.00566	0.2	0.12	Venous thromboembolism (SNP x SNP interaction);	chr8:51852132	chr8:51810110~51810681:-
BRCA	cis	rs10504130	1	rs11781330	ENSG00000272076.1	RP11-11C20.3	3.93	8.89e-05	0.00566	0.2	0.12	Venous thromboembolism (SNP x SNP interaction);	chr8:51853231	chr8:51810110~51810681:-
BRCA	cis	rs10421328	1	rs10421328	ENSG00000267419.1	CTC-559E9.6	-3.93	8.89e-05	0.00566	-0.15	-0.12	Parental longevity (combined parental age at death);	chr19:19666005	chr19:19776602~19834927:+
BRCA	cis	rs1949733	1	rs868105	ENSG00000205959.3	RP11-689P11.2	3.93	8.89e-05	0.00566	0.12	0.12	Response to antineoplastic agents;	chr4:8499303	chr4:8482270~8512610:+
BRCA	cis	rs8062405	1	rs9972693	ENSG00000261766.1	RP11-22P6.2	-3.93	8.9e-05	0.00566	-0.12	-0.12	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28848481	chr16:28862166~28863340:-
BRCA	cis	rs8062405	0.964	rs9972768	ENSG00000261766.1	RP11-22P6.2	-3.93	8.9e-05	0.00566	-0.12	-0.12	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28850413	chr16:28862166~28863340:-
BRCA	cis	rs8062405	0.965	rs62037363	ENSG00000261766.1	RP11-22P6.2	-3.93	8.9e-05	0.00566	-0.12	-0.12	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28853721	chr16:28862166~28863340:-
BRCA	cis	rs8062405	1	rs7205323	ENSG00000261766.1	RP11-22P6.2	-3.93	8.9e-05	0.00566	-0.12	-0.12	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28854571	chr16:28862166~28863340:-
BRCA	cis	rs11098499	0.874	rs13139045	ENSG00000249244.1	RP11-548H18.2	3.93	8.9e-05	0.00566	0.14	0.12	Corneal astigmatism;	chr4:119247433	chr4:119391831~119395335:-
BRCA	cis	rs35306767	0.807	rs34982663	ENSG00000229869.1	RP11-363N22.2	-3.93	8.9e-05	0.00566	-0.21	-0.12	Eosinophil percentage of granulocytes;	chr10:806581	chr10:933026~942743:+
BRCA	cis	rs11098499	0.863	rs1480940	ENSG00000260091.1	RP11-33B1.4	-3.93	8.9e-05	0.00566	-0.11	-0.12	Corneal astigmatism;	chr4:119536527	chr4:119409333~119410233:+
BRCA	cis	rs4415084	0.966	rs1898701	ENSG00000248779.1	RP11-53O19.2	3.93	8.9e-05	0.00566	0.11	0.12	Breast cancer;	chr5:44695327	chr5:44752949~44765744:+
BRCA	cis	rs66887589	0.616	rs7659403	ENSG00000250412.1	KLHL2P1	3.93	8.9e-05	0.00566	0.13	0.12	Diastolic blood pressure;	chr4:119286099	chr4:119334329~119378233:+
BRCA	cis	rs35688236	0.853	rs7611151	ENSG00000236452.1	AC123023.1	-3.93	8.9e-05	0.00566	-0.17	-0.12	Neuroticism;	chr3:34533757	chr3:34203244~34268811:+
BRCA	cis	rs2274459	0.915	rs12192035	ENSG00000249346.5	LINC01016	3.93	8.9e-05	0.00566	0.16	0.12	Obesity (extreme);	chr6:33752288	chr6:33867506~33896914:-
BRCA	cis	rs11711311	1	rs7645473	ENSG00000241529.3	RN7SL767P	-3.93	8.9e-05	0.00567	-0.14	-0.12	IgG glycosylation;	chr3:113797340	chr3:113632704~113632998:+
BRCA	cis	rs4557020	0.775	rs4671938	ENSG00000162997.14	PRORSD1P	-3.93	8.9e-05	0.00567	-0.13	-0.12	Myopia (pathological);	chr2:54466067	chr2:55282319~55284522:+
BRCA	cis	rs1707322	0.638	rs1416706	ENSG00000234329.1	RP11-767N6.2	-3.93	8.91e-05	0.00567	-0.13	-0.12	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46137172	chr1:45651039~45651826:-
BRCA	cis	rs7267979	0.789	rs6083841	ENSG00000125804.12	FAM182A	3.93	8.91e-05	0.00567	0.16	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25403928	chr20:26054655~26086917:+
BRCA	cis	rs739401	0.611	rs2071104	ENSG00000183562.3	CTC-343N3.1	-3.93	8.91e-05	0.00567	-0.13	-0.12	Longevity;	chr11:3015703	chr11:2989863~2991344:+
BRCA	cis	rs1383484	1	rs12443111	ENSG00000230373.7	GOLGA6L5P	-3.93	8.91e-05	0.00567	-0.14	-0.12	Height;	chr15:83835727	chr15:84507885~84516814:-
BRCA	cis	rs1876905	0.68	rs7767302	ENSG00000272356.1	RP5-1112D6.8	3.93	8.91e-05	0.00567	0.17	0.12	Mean corpuscular hemoglobin;	chr6:111143942	chr6:111309203~111313517:+
BRCA	cis	rs3768617	0.591	rs9787073	ENSG00000224468.3	RP11-181K3.4	-3.93	8.91e-05	0.00567	-0.13	-0.12	Fuchs's corneal dystrophy;	chr1:183005193	chr1:183138402~183141282:-
BRCA	cis	rs4689592	0.513	rs4689586	ENSG00000245468.3	RP11-367J11.3	3.93	8.91e-05	0.00567	0.13	0.12	Monocyte percentage of white cells;	chr4:7065686	chr4:7094571~7103385:-
BRCA	cis	rs10761482	0.861	rs4245587	ENSG00000254271.1	RP11-131N11.4	3.93	8.91e-05	0.00567	0.17	0.12	Schizophrenia;	chr10:60341831	chr10:60734342~60741828:+
BRCA	cis	rs10761482	0.861	rs4245588	ENSG00000254271.1	RP11-131N11.4	3.93	8.91e-05	0.00567	0.17	0.12	Schizophrenia;	chr10:60341988	chr10:60734342~60741828:+
BRCA	cis	rs17597773	0.638	rs11118609	ENSG00000238078.1	LINC01352	3.93	8.91e-05	0.00567	0.13	0.12	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220815148	chr1:220829255~220832429:+
BRCA	cis	rs72928364	1	rs13072000	ENSG00000244119.1	PDCL3P4	3.93	8.91e-05	0.00567	0.15	0.12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100906978	chr3:101712472~101713191:+
BRCA	cis	rs2905347	0.656	rs2051723	ENSG00000179428.2	AC073072.5	3.93	8.91e-05	0.00567	0.14	0.12	Major depression and alcohol dependence;	chr7:22626224	chr7:22725395~22727620:-
BRCA	cis	rs1976403	0.659	rs10799701	ENSG00000186543.7	CROCCP5	-3.93	8.92e-05	0.00567	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr1:21494497	chr1:21434318~21437558:+
BRCA	cis	rs4415084	0.716	rs9637796	ENSG00000251141.4	RP11-53O19.1	3.93	8.92e-05	0.00567	0.11	0.12	Breast cancer;	chr5:44817817	chr5:44744900~44808777:-
BRCA	cis	rs739496	0.895	rs2073950	ENSG00000234608.6	MAPKAPK5-AS1	3.93	8.92e-05	0.00567	0.15	0.12	Platelet count;	chr12:111456268	chr12:111839764~111842902:-
BRCA	cis	rs6963495	0.519	rs3892297	ENSG00000223886.3	RP11-251G23.2	3.93	8.92e-05	0.00567	0.19	0.12	Bipolar disorder (body mass index interaction);	chr7:105511726	chr7:105530209~105530671:+
BRCA	cis	rs4499344	0.623	rs11670818	ENSG00000267475.1	CTD-2538C1.2	3.93	8.92e-05	0.00567	0.17	0.12	Mean platelet volume;	chr19:32608948	chr19:32687089~32691750:-
BRCA	cis	rs28829049	0.597	rs2296107	ENSG00000270728.1	RP4-657E11.10	-3.93	8.92e-05	0.00568	-0.12	-0.12	QRS duration in Tripanosoma cruzi seropositivity;	chr1:19150155	chr1:19297080~19297903:+
BRCA	cis	rs875971	0.706	rs1643374	ENSG00000223473.2	GS1-124K5.3	3.93	8.92e-05	0.00568	0.09	0.12	Aortic root size;	chr7:66407695	chr7:66491049~66493566:-
BRCA	cis	rs1075265	0.704	rs10084374	ENSG00000272156.1	RP11-477N3.1	-3.93	8.92e-05	0.00568	-0.12	-0.12	Chronotype;Morning vs. evening chronotype;	chr2:54022175	chr2:54082554~54085066:+
BRCA	cis	rs2832191	0.967	rs2898160	ENSG00000232855.5	AF131217.1	3.93	8.92e-05	0.00568	0.14	0.12	Dental caries;	chr21:29115175	chr21:28439346~28674848:-
BRCA	cis	rs7520050	0.808	rs11211195	ENSG00000234329.1	RP11-767N6.2	-3.93	8.93e-05	0.00568	-0.11	-0.12	Reticulocyte count;Red blood cell count;	chr1:45816623	chr1:45651039~45651826:-
BRCA	cis	rs7520050	0.808	rs11211196	ENSG00000234329.1	RP11-767N6.2	-3.93	8.93e-05	0.00568	-0.11	-0.12	Reticulocyte count;Red blood cell count;	chr1:45816624	chr1:45651039~45651826:-
BRCA	cis	rs8180040	0.62	rs11707736	ENSG00000271161.1	BOLA2P2	-3.93	8.93e-05	0.00568	-0.13	-0.12	Colorectal cancer;	chr3:47028014	chr3:47499841~47500407:+
BRCA	cis	rs7771547	0.662	rs2001101	ENSG00000224666.3	RP1-50J22.4	3.93	8.93e-05	0.00568	0.16	0.12	Platelet distribution width;	chr6:36568671	chr6:36386831~36393462:+
BRCA	cis	rs1367226	0.933	rs7607070	ENSG00000272606.1	RP11-554J4.1	3.93	8.93e-05	0.00568	0.14	0.12	Height;	chr2:55851282	chr2:55617909~55618373:+
BRCA	cis	rs853679	0.882	rs9393908	ENSG00000216901.1	AL022393.7	3.93	8.93e-05	0.00568	0.25	0.12	Depression;	chr6:28223052	chr6:28176188~28176674:+
BRCA	cis	rs853679	0.882	rs9366717	ENSG00000216901.1	AL022393.7	3.93	8.93e-05	0.00568	0.25	0.12	Depression;	chr6:28223279	chr6:28176188~28176674:+
BRCA	cis	rs3764563	0.935	rs17708232	ENSG00000267594.5	CYP4F24P	-3.93	8.93e-05	0.00568	-0.22	-0.12	Inflammatory biomarkers;	chr19:15575933	chr19:15760241~15779909:-
BRCA	cis	rs1075265	0.722	rs7596349	ENSG00000272156.1	RP11-477N3.1	-3.93	8.93e-05	0.00568	-0.13	-0.12	Chronotype;Morning vs. evening chronotype;	chr2:53709123	chr2:54082554~54085066:+
BRCA	cis	rs6012564	1	rs6125540	ENSG00000227431.4	CSE1L-AS1	3.93	8.94e-05	0.00568	0.14	0.12	Anger;	chr20:49087502	chr20:49040463~49046044:-
BRCA	cis	rs4916588	0.697	rs2054200	ENSG00000230732.4	AC127904.2	3.93	8.94e-05	0.00568	0.16	0.12	Night sleep phenotypes;	chr3:196927665	chr3:196912646~196914579:+
BRCA	cis	rs4916588	0.767	rs111544824	ENSG00000230732.4	AC127904.2	3.93	8.94e-05	0.00568	0.16	0.12	Night sleep phenotypes;	chr3:196928993	chr3:196912646~196914579:+
BRCA	cis	rs2839186	0.559	rs2277826	ENSG00000223901.2	AP001469.5	-3.93	8.94e-05	0.00568	-0.12	-0.12	Testicular germ cell tumor;	chr21:46219578	chr21:46220269~46225364:+
BRCA	cis	rs10043228	1	rs10055868	ENSG00000271918.1	CTD-2287O16.5	-3.93	8.94e-05	0.00568	-0.16	-0.12	Asthma or chronic obstructive pulmonary disease;	chr5:116135915	chr5:116083807~116085416:-
BRCA	cis	rs2832191	1	rs9984793	ENSG00000232855.5	AF131217.1	3.93	8.94e-05	0.00568	0.14	0.12	Dental caries;	chr21:29114150	chr21:28439346~28674848:-
BRCA	cis	rs11088226	0.846	rs2833884	ENSG00000186842.4	LINC00846	-3.93	8.94e-05	0.00568	-0.18	-0.12	Gastritis;	chr21:32550765	chr21:32572238~32575881:-
BRCA	cis	rs9381040	0.61	rs6940356	ENSG00000161912.16	ADCY10P1	3.93	8.94e-05	0.00569	0.13	0.12	Alzheimer's disease (late onset);	chr6:41052621	chr6:41101022~41140835:+
BRCA	cis	rs9381040	0.61	rs2235678	ENSG00000161912.16	ADCY10P1	3.93	8.94e-05	0.00569	0.13	0.12	Alzheimer's disease (late onset);	chr6:41052771	chr6:41101022~41140835:+
BRCA	cis	rs6480314	0.908	rs7094934	ENSG00000233590.1	RP11-153K11.3	-3.93	8.94e-05	0.00569	-0.19	-0.12	Optic nerve measurement (disc area);	chr10:68203093	chr10:68233251~68242379:-
BRCA	cis	rs1730008	1	rs698985	ENSG00000279311.1	RP11-170K4.2	-3.93	8.94e-05	0.00569	-0.14	-0.12	Lobe attachment (rater-scored or self-reported);	chr3:158216207	chr3:158869898~158871821:+
BRCA	cis	rs34792	0.554	rs12708796	ENSG00000258354.1	MIR3180-1	-3.93	8.94e-05	0.00569	-0.16	-0.12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15535980	chr16:14909887~14911345:-
BRCA	cis	rs3617	0.625	rs7652667	ENSG00000242142.1	SERBP1P3	-3.93	8.95e-05	0.00569	-0.13	-0.12	Red blood cell count;Autism spectrum disorder or schizophrenia;	chr3:52832519	chr3:53064283~53065091:-
BRCA	cis	rs3617	0.559	rs11915546	ENSG00000242142.1	SERBP1P3	-3.93	8.95e-05	0.00569	-0.13	-0.12	Red blood cell count;Autism spectrum disorder or schizophrenia;	chr3:52832829	chr3:53064283~53065091:-
BRCA	cis	rs3617	0.591	rs11918800	ENSG00000242142.1	SERBP1P3	-3.93	8.95e-05	0.00569	-0.13	-0.12	Red blood cell count;Autism spectrum disorder or schizophrenia;	chr3:52834129	chr3:53064283~53065091:-
BRCA	cis	rs890448	0.796	rs4699212	ENSG00000254531.1	FLJ20021	-3.93	8.95e-05	0.00569	-0.14	-0.12	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101367620	chr4:101347780~101348883:+
BRCA	cis	rs7726839	0.526	rs11960158	ENSG00000225138.6	CTD-2228K2.7	3.93	8.95e-05	0.00569	0.17	0.12	Obesity-related traits;	chr5:568550	chr5:473236~480884:+
BRCA	cis	rs17772222	0.916	rs77306894	ENSG00000258789.1	RP11-507K2.3	-3.93	8.95e-05	0.00569	-0.15	-0.12	Coronary artery calcification;	chr14:88494507	chr14:88551597~88552493:+
BRCA	cis	rs7660883	0.897	rs3775214	ENSG00000251411.1	RP11-397E7.4	3.93	8.95e-05	0.00569	0.14	0.12	HDL cholesterol levels;	chr4:87102147	chr4:86913266~86914817:-
BRCA	cis	rs748404	0.626	rs57938858	ENSG00000205771.5	CATSPER2P1	-3.93	8.95e-05	0.00569	-0.18	-0.12	Lung cancer;	chr15:43520259	chr15:43726918~43747094:-
BRCA	cis	rs875971	0.862	rs778684	ENSG00000273024.4	INTS4P2	-3.93	8.95e-05	0.00569	-0.13	-0.12	Aortic root size;	chr7:66371416	chr7:65647864~65715661:+
BRCA	cis	rs7637230	0.524	rs1622608	ENSG00000244119.1	PDCL3P4	3.93	8.95e-05	0.00569	0.1	0.12	Psoriasis vulgaris;Psoriasis;	chr3:101929547	chr3:101712472~101713191:+
BRCA	cis	rs7246967	0.736	rs446058	ENSG00000198153.8	ZNF849P	-3.93	8.95e-05	0.00569	-0.18	-0.12	Bronchopulmonary dysplasia;	chr19:22817259	chr19:22685167~22686732:+
BRCA	cis	rs10829156	1	rs10829156	ENSG00000225527.1	RP11-383B4.4	-3.93	8.95e-05	0.00569	-0.17	-0.12	Sudden cardiac arrest;	chr10:18661626	chr10:18531849~18533336:-
BRCA	cis	rs11668609	0.872	rs4416149	ENSG00000268058.1	BNIP3P40	-3.93	8.95e-05	0.00569	-0.15	-0.12	Response to taxane treatment (docetaxel);	chr19:24093551	chr19:24098425~24098980:-
BRCA	cis	rs10946940	0.965	rs6910838	ENSG00000219392.1	RP1-265C24.5	3.93	8.95e-05	0.00569	0.16	0.12	Systemic lupus erythematosus;	chr6:27547740	chr6:28115628~28116551:+
BRCA	cis	rs4845570	0.831	rs11588634	ENSG00000203288.3	RP11-98D18.9	-3.93	8.95e-05	0.00569	-0.22	-0.12	Coronary artery disease;	chr1:151808210	chr1:151790804~151794402:+
BRCA	cis	rs763121	0.819	rs5757237	ENSG00000225450.1	RP3-508I15.14	-3.93	8.95e-05	0.00569	-0.13	-0.12	Menopause (age at onset);	chr22:38677830	chr22:38739003~38749041:+
BRCA	cis	rs763121	0.853	rs11704021	ENSG00000225450.1	RP3-508I15.14	-3.93	8.95e-05	0.00569	-0.13	-0.12	Menopause (age at onset);	chr22:38678711	chr22:38739003~38749041:+
BRCA	cis	rs6963495	0.592	rs114793754	ENSG00000223886.3	RP11-251G23.2	3.93	8.95e-05	0.00569	0.19	0.12	Bipolar disorder (body mass index interaction);	chr7:105511715	chr7:105530209~105530671:+
BRCA	cis	rs6963495	0.651	rs3892298	ENSG00000223886.3	RP11-251G23.2	3.93	8.95e-05	0.00569	0.19	0.12	Bipolar disorder (body mass index interaction);	chr7:105511740	chr7:105530209~105530671:+
BRCA	cis	rs1722141	0.601	rs1722144	ENSG00000237471.1	AC073115.6	3.93	8.95e-05	0.00569	0.16	0.12	Sitting height ratio;	chr7:46033701	chr7:45969657~45980191:+
BRCA	cis	rs977987	0.806	rs4146809	ENSG00000280152.1	RP11-331F4.5	3.93	8.95e-05	0.00569	0.12	0.12	Dupuytren's disease;	chr16:75381877	chr16:75245994~75250077:-
BRCA	cis	rs7176093	0.957	rs72755309	ENSG00000259295.5	CSPG4P12	-3.93	8.96e-05	0.0057	-0.17	-0.12	Aging traits;	chr15:85809412	chr15:85191438~85213905:+
BRCA	cis	rs7176093	0.957	rs8031890	ENSG00000259295.5	CSPG4P12	-3.93	8.96e-05	0.0057	-0.17	-0.12	Aging traits;	chr15:85810845	chr15:85191438~85213905:+
BRCA	cis	rs7176093	0.874	rs72755314	ENSG00000259295.5	CSPG4P12	-3.93	8.96e-05	0.0057	-0.17	-0.12	Aging traits;	chr15:85812274	chr15:85191438~85213905:+
BRCA	cis	rs5750830	0.649	rs5750811	ENSG00000280216.1	RP3-333H23.9	3.93	8.96e-05	0.0057	0.15	0.12	Intelligence (multi-trait analysis);	chr22:39397061	chr22:39379610~39380015:+
BRCA	cis	rs2562456	0.792	rs2562398	ENSG00000240522.1	RPL7AP10	3.93	8.96e-05	0.0057	0.13	0.12	Pain;	chr19:21540147	chr19:21149648~21150438:-
BRCA	cis	rs10043775	0.831	rs10072958	ENSG00000251330.3	CTD-2283N19.1	-3.93	8.96e-05	0.0057	-0.15	-0.12	Periodontal microbiota;	chr5:148310336	chr5:148430159~148430807:-
BRCA	cis	rs875971	0.619	rs10278371	ENSG00000232546.1	RP11-458F8.1	3.93	8.97e-05	0.0057	0.1	0.12	Aortic root size;	chr7:66586553	chr7:66848496~66858136:+
BRCA	cis	rs7800418	0.698	rs11761453	ENSG00000214870.7	AC004540.5	3.93	8.97e-05	0.0057	0.14	0.12	Cognitive function;	chr7:26563185	chr7:26398593~26494256:+
BRCA	cis	rs2304003	1	rs10930182	ENSG00000235192.1	AC009495.2	3.93	8.97e-05	0.0057	0.14	0.12	Social communication problems;	chr2:165831678	chr2:165794851~165810010:+
BRCA	cis	rs10411161	0.702	rs8113584	ENSG00000269483.1	AC006272.1	3.93	8.97e-05	0.0057	0.19	0.12	Breast cancer;	chr19:51880621	chr19:51839924~51843324:-
BRCA	cis	rs10411161	0.702	rs8113768	ENSG00000269483.1	AC006272.1	3.93	8.97e-05	0.0057	0.19	0.12	Breast cancer;	chr19:51880685	chr19:51839924~51843324:-
BRCA	cis	rs6500602	0.701	rs4785969	ENSG00000280063.1	RP11-295D4.3	3.93	8.97e-05	0.00571	0.09	0.12	Schizophrenia;	chr16:4486933	chr16:4346694~4348648:-
BRCA	cis	rs2562456	0.917	rs10420016	ENSG00000268555.1	RP11-678G14.3	-3.93	8.97e-05	0.00571	-0.16	-0.12	Pain;	chr19:21505800	chr19:21570822~21587322:-
BRCA	cis	rs35740288	0.787	rs2291047	ENSG00000259407.1	RP11-158M2.3	-3.93	8.97e-05	0.00571	-0.16	-0.12	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85682574	chr15:85744109~85750281:-
BRCA	cis	rs1371614	0.655	rs4665927	ENSG00000272148.1	RP11-195B17.1	-3.93	8.98e-05	0.00571	-0.13	-0.12	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26926498	chr2:27062428~27062907:-
BRCA	cis	rs672203	0.636	rs10458561	ENSG00000271992.1	RP11-42O15.3	3.93	8.98e-05	0.00571	0.16	0.12	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);	chr1:70455490	chr1:70445071~70445536:+
BRCA	cis	rs3169166	0.546	rs2280366	ENSG00000259562.2	RP11-762H8.2	-3.93	8.98e-05	0.00571	-0.09	-0.12	Reticulocyte fraction of red cells;Reticulocyte count;	chr15:78293556	chr15:78290527~78291221:-
BRCA	cis	rs854765	0.647	rs854790	ENSG00000281749.1	Y_RNA	3.93	8.98e-05	0.00571	0.14	0.12	Total body bone mineral density;	chr17:18125004	chr17:18001101~18001195:-
BRCA	cis	rs1949733	0.656	rs2688224	ENSG00000251615.3	RP11-774O3.3	-3.93	8.98e-05	0.00571	-0.12	-0.12	Response to antineoplastic agents;	chr4:8402973	chr4:8355090~8358338:-
BRCA	cis	rs6545883	0.899	rs1562309	ENSG00000270820.4	RP11-355B11.2	3.93	8.98e-05	0.00571	0.14	0.12	Tuberculosis;	chr2:61542991	chr2:61471188~61484130:+
BRCA	cis	rs9311474	0.652	rs352158	ENSG00000243224.1	RP5-1157M23.2	-3.93	8.98e-05	0.00571	-0.13	-0.12	Electroencephalogram traits;	chr3:52183688	chr3:52239258~52241097:+
BRCA	cis	rs12705849	0.764	rs1599836	ENSG00000214194.7	LINC00998	3.93	8.98e-05	0.00571	0.15	0.12	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Eosinophil counts;	chr7:113111630	chr7:113116718~113118613:-
BRCA	cis	rs7045881	0.735	rs12342005	ENSG00000254396.1	RP11-56F10.3	3.93	8.98e-05	0.00571	0.18	0.12	Schizophrenia;	chr9:26898073	chr9:27102630~27104728:+
BRCA	cis	rs6504622	0.72	rs4968304	ENSG00000263142.4	LRRC37A17P	-3.93	8.98e-05	0.00571	-0.09	-0.12	Orofacial clefts;	chr17:47063235	chr17:46978481~47054569:+
BRCA	cis	rs2832077	0.883	rs35672956	ENSG00000232855.5	AF131217.1	3.93	8.99e-05	0.00571	0.19	0.12	Cognitive test performance;	chr21:28816719	chr21:28439346~28674848:-
BRCA	cis	rs2832077	0.943	rs11700746	ENSG00000232855.5	AF131217.1	3.93	8.99e-05	0.00571	0.19	0.12	Cognitive test performance;	chr21:28816884	chr21:28439346~28674848:-
BRCA	cis	rs2832077	0.943	rs2272701	ENSG00000232855.5	AF131217.1	3.93	8.99e-05	0.00571	0.19	0.12	Cognitive test performance;	chr21:28818585	chr21:28439346~28674848:-
BRCA	cis	rs181553	0.664	rs8094480	ENSG00000266696.1	RP11-30L3.2	3.93	8.99e-05	0.00572	0.14	0.12	Hip circumference adjusted for BMI;	chr18:49161306	chr18:49205912~49208781:+
BRCA	cis	rs9394169	0.514	rs1886355	ENSG00000249346.5	LINC01016	3.93	8.99e-05	0.00572	0.16	0.12	Essential tremor;	chr6:33809100	chr6:33867506~33896914:-
BRCA	cis	rs6918586	0.658	rs198826	ENSG00000272462.2	U91328.19	3.93	8.99e-05	0.00572	0.13	0.12	Schizophrenia;	chr6:26120925	chr6:25992662~26001775:+
BRCA	cis	rs10129255	0.957	rs8009464	ENSG00000232216.1	IGHV3-43	3.93	8.99e-05	0.00572	0.1	0.12	Kawasaki disease;	chr14:106777611	chr14:106470264~106470800:-
BRCA	cis	rs494453	0.922	rs569504	ENSG00000227811.2	FAM212B-AS1	-3.93	8.99e-05	0.00572	-0.16	-0.12	Osteoporosis-related phenotypes;	chr1:111669155	chr1:111739841~111747798:+
BRCA	cis	rs4434138	0.533	rs11130324	ENSG00000243224.1	RP5-1157M23.2	-3.93	9e-05	0.00572	-0.13	-0.12	Intelligence (multi-trait analysis);	chr3:52736294	chr3:52239258~52241097:+
BRCA	cis	rs4865169	0.691	rs1056364	ENSG00000269949.1	RP11-738E22.3	-3.93	9e-05	0.00572	-0.14	-0.12	Breast cancer;	chr4:57023511	chr4:56960927~56961373:-
BRCA	cis	rs8113308	0.515	rs73066981	ENSG00000269483.1	AC006272.1	3.93	9e-05	0.00572	0.29	0.12	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51959146	chr19:51839924~51843324:-
BRCA	cis	rs2299587	0.56	rs3913556	ENSG00000253671.1	RP11-806O11.1	-3.93	9e-05	0.00572	-0.16	-0.12	Economic and political preferences;	chr8:17923892	chr8:17808941~17820868:+
BRCA	cis	rs13315871	1	rs11713214	ENSG00000272182.1	RP11-802O23.3	3.93	9e-05	0.00572	0.25	0.12	Cholesterol, total;	chr3:58460264	chr3:58428255~58428815:+
BRCA	cis	rs13315871	1	rs13066269	ENSG00000272182.1	RP11-802O23.3	3.93	9e-05	0.00572	0.25	0.12	Cholesterol, total;	chr3:58463517	chr3:58428255~58428815:+
BRCA	cis	rs1949733	1	rs2631745	ENSG00000205959.3	RP11-689P11.2	3.93	9e-05	0.00572	0.12	0.12	Response to antineoplastic agents;	chr4:8488803	chr4:8482270~8512610:+
BRCA	cis	rs6088580	0.66	rs6059893	ENSG00000275784.1	RP5-1125A11.6	-3.93	9e-05	0.00572	-0.13	-0.12	Glomerular filtration rate (creatinine);	chr20:34518092	chr20:33989480~33991818:-
BRCA	cis	rs10761482	0.813	rs2169081	ENSG00000254271.1	RP11-131N11.4	3.93	9e-05	0.00572	0.17	0.12	Schizophrenia;	chr10:60342631	chr10:60734342~60741828:+
BRCA	cis	rs35146811	0.735	rs6465766	ENSG00000235713.1	RP4-604G5.3	3.93	9e-05	0.00572	0.14	0.12	Coronary artery disease;	chr7:100188048	chr7:99992397~99993050:+
BRCA	cis	rs6545883	0.965	rs11887205	ENSG00000270820.4	RP11-355B11.2	3.93	9e-05	0.00572	0.14	0.12	Tuberculosis;	chr2:61547338	chr2:61471188~61484130:+
BRCA	cis	rs2391285	0.609	rs4275130	ENSG00000214870.7	AC004540.5	-3.93	9e-05	0.00572	-0.18	-0.12	Post bronchodilator FEV1/FVC ratio;	chr7:26553157	chr7:26398593~26494256:+
BRCA	cis	rs4272720	0.851	rs56197478	ENSG00000228754.1	RP11-534L6.3	-3.93	9e-05	0.00572	-0.17	-0.12	Platelet count;Plateletcrit;	chr10:49093847	chr10:48745545~48746128:-
BRCA	cis	rs4561483	0.801	rs8061189	ENSG00000261216.1	RP11-166B2.5	3.93	9e-05	0.00572	0.14	0.12	Testicular germ cell tumor;	chr16:11857892	chr16:11908208~11908916:+
BRCA	cis	rs73222236	0.75	rs9811261	ENSG00000239213.4	NCK1-AS1	3.93	9e-05	0.00572	0.13	0.12	Coronary artery disease;	chr3:136379717	chr3:136841726~136862054:-
BRCA	cis	rs2191566	1	rs384544	ENSG00000266921.1	RP11-15A1.7	3.93	9.01e-05	0.00572	0.16	0.12	Acute lymphoblastic leukemia (childhood);	chr19:44001103	chr19:43996896~44002836:-
BRCA	cis	rs4950322	0.518	rs55697094	ENSG00000227242.3	NBPF13P	-3.93	9.01e-05	0.00572	-0.17	-0.12	Protein quantitative trait loci;	chr1:147121205	chr1:147021320~147124525:-
BRCA	cis	rs1050288	0.525	rs10743608	ENSG00000230519.2	RP11-1060J15.5	-3.93	9.01e-05	0.00572	-0.16	-0.12	Pulse pressure;Resting heart rate;	chr12:27786422	chr12:27702338~27702906:+
BRCA	cis	rs875971	1	rs2420820	ENSG00000272831.1	RP11-792A8.4	-3.93	9.01e-05	0.00572	-0.11	-0.12	Aortic root size;	chr7:66626920	chr7:66739829~66740385:-
BRCA	cis	rs4478858	0.684	rs7519766	ENSG00000260386.4	LINC01225	-3.93	9.01e-05	0.00572	-0.14	-0.12	Alcohol dependence;	chr1:31262665	chr1:31500085~31540885:+
BRCA	cis	rs728616	0.558	rs55803802	ENSG00000242600.5	MBL1P	3.93	9.01e-05	0.00573	0.21	0.12	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79992908	chr10:79904898~79950336:+
BRCA	cis	rs6460942	0.841	rs17443848	ENSG00000226690.5	AC005281.1	3.93	9.01e-05	0.00573	0.19	0.12	Coronary artery disease;	chr7:12404062	chr7:12496429~12541910:+
BRCA	cis	rs524281	0.773	rs10791861	ENSG00000255038.1	RP11-1167A19.2	-3.93	9.01e-05	0.00573	-0.19	-0.12	Electroencephalogram traits;	chr11:66240999	chr11:66067277~66069619:-
BRCA	cis	rs7412746	0.634	rs3754212	ENSG00000231073.1	RP11-316M1.3	3.93	9.01e-05	0.00573	0.13	0.12	Melanoma;	chr1:150765724	chr1:150973123~150975534:+
BRCA	cis	rs875971	0.862	rs10263690	ENSG00000273024.4	INTS4P2	3.93	9.02e-05	0.00573	0.13	0.12	Aortic root size;	chr7:66301466	chr7:65647864~65715661:+
BRCA	cis	rs875971	0.862	rs10250544	ENSG00000273024.4	INTS4P2	3.93	9.02e-05	0.00573	0.13	0.12	Aortic root size;	chr7:66301574	chr7:65647864~65715661:+
BRCA	cis	rs801193	0.904	rs4718405	ENSG00000273142.1	RP11-458F8.4	-3.93	9.02e-05	0.00573	-0.1	-0.12	Aortic root size;	chr7:66789659	chr7:66902857~66906297:+
BRCA	cis	rs2274273	0.682	rs8008134	ENSG00000233924.1	AL160471.6	-3.93	9.02e-05	0.00573	-0.14	-0.12	Protein biomarker;	chr14:55040802	chr14:55004813~55005687:-
BRCA	cis	rs7520050	0.966	rs7556436	ENSG00000234329.1	RP11-767N6.2	3.93	9.02e-05	0.00573	0.11	0.12	Reticulocyte count;Red blood cell count;	chr1:45898208	chr1:45651039~45651826:-
BRCA	cis	rs875971	0.638	rs6460305	ENSG00000265600.1	AC006480.1	3.93	9.02e-05	0.00573	0.14	0.12	Aortic root size;	chr7:66595421	chr7:67356680~67356779:+
BRCA	cis	rs160451	0.782	rs160409	ENSG00000251136.7	RP11-37B2.1	3.93	9.02e-05	0.00573	0.12	0.12	Leprosy;	chr8:89636342	chr8:89609409~89757727:-
BRCA	cis	rs9467773	0.62	rs2451732	ENSG00000224843.5	LINC00240	3.93	9.02e-05	0.00573	0.13	0.12	Intelligence (multi-trait analysis);	chr6:26622676	chr6:26956992~27023924:+
BRCA	cis	rs9648716	0.766	rs511001	ENSG00000240889.1	NDUFB2-AS1	-3.93	9.02e-05	0.00573	-0.17	-0.12	Type 2 diabetes;	chr7:141082239	chr7:140695336~140697077:-
BRCA	cis	rs2243480	0.803	rs55700941	ENSG00000226767.1	RP11-328P23.3	-3.93	9.02e-05	0.00573	-0.21	-0.12	Diabetic kidney disease;	chr7:65924813	chr7:65508773~65508944:-
BRCA	cis	rs6088580	0.634	rs6059868	ENSG00000275784.1	RP5-1125A11.6	-3.93	9.03e-05	0.00573	-0.13	-0.12	Glomerular filtration rate (creatinine);	chr20:34491655	chr20:33989480~33991818:-
BRCA	cis	rs6005807	0.719	rs12166245	ENSG00000272858.1	CTA-292E10.8	-3.93	9.03e-05	0.00573	-0.22	-0.12	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28603902	chr22:28814914~28815662:+
BRCA	cis	rs7735319	0.565	rs55683591	ENSG00000249572.1	CTD-2203K17.1	3.93	9.03e-05	0.00573	0.15	0.12	Systolic blood pressure;	chr5:33118881	chr5:33424025~33440619:-
BRCA	cis	rs11098499	0.863	rs3775858	ENSG00000260091.1	RP11-33B1.4	-3.93	9.03e-05	0.00573	-0.11	-0.12	Corneal astigmatism;	chr4:119564873	chr4:119409333~119410233:+
BRCA	cis	rs12049351	0.774	rs6678721	ENSG00000229367.1	HMGN2P19	3.93	9.03e-05	0.00574	0.17	0.12	Circulating myeloperoxidase levels (plasma);	chr1:229487384	chr1:229570532~229570796:+
BRCA	cis	rs754466	0.606	rs11002306	ENSG00000213514.2	RP11-428P16.2	3.93	9.03e-05	0.00574	0.16	0.12	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77831761	chr10:77730766~77734769:+
BRCA	cis	rs1322639	0.574	rs9689193	ENSG00000223485.1	RP11-417E7.1	-3.93	9.03e-05	0.00574	-0.19	-0.12	Pulse pressure;	chr6:169187979	chr6:169158092~169162924:-
BRCA	cis	rs7283707	0.581	rs2823518	ENSG00000270071.1	AP001172.2	-3.93	9.03e-05	0.00574	-0.16	-0.12	QRS complex (12-leadsum);	chr21:15893696	chr21:16291791~16308133:-
BRCA	cis	rs721917	0.506	rs2819100	ENSG00000280355.1	RP11-119F19.5	-3.93	9.03e-05	0.00574	-0.13	-0.12	Chronic obstructive pulmonary disease;	chr10:79937163	chr10:79681973~79684094:-
BRCA	cis	rs721917	0.565	rs7476563	ENSG00000225484.5	NUTM2B-AS1	-3.93	9.03e-05	0.00574	-0.16	-0.12	Chronic obstructive pulmonary disease;	chr10:79975318	chr10:79663088~79826594:-
BRCA	cis	rs9470794	0.915	rs73419417	ENSG00000204110.6	RP1-153P14.8	-3.93	9.04e-05	0.00574	-0.25	-0.12	Type 2 diabetes;	chr6:37856905	chr6:37507348~37535616:+
BRCA	cis	rs848490	0.925	rs56215603	ENSG00000214293.7	APTR	3.93	9.04e-05	0.00574	0.15	0.12	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77688865	chr7:77657660~77696265:-
BRCA	cis	rs962856	0.964	rs4671183	ENSG00000236605.1	AC023115.4	3.93	9.04e-05	0.00574	0.15	0.12	Pancreatic cancer;	chr2:67416545	chr2:67324627~67325304:+
BRCA	cis	rs7572644	0.537	rs13023955	ENSG00000223522.1	AC093690.1	-3.93	9.04e-05	0.00574	-0.14	-0.12	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:28141405	chr2:28307691~28310459:-
BRCA	cis	rs448720	1	rs35768117	ENSG00000260657.2	RP11-315D16.4	-3.93	9.04e-05	0.00574	-0.14	-0.12	Cognitive performance;	chr15:67911903	chr15:68267792~68277994:-
BRCA	cis	rs2018683	0.523	rs886834	ENSG00000233517.1	AC005162.5	-3.93	9.04e-05	0.00574	-0.15	-0.12	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28981720	chr7:28987028~28988899:+
BRCA	cis	rs8141529	0.702	rs469990	ENSG00000272858.1	CTA-292E10.8	-3.93	9.04e-05	0.00574	-0.15	-0.12	Lymphocyte counts;	chr22:28908212	chr22:28814914~28815662:+
BRCA	cis	rs12049351	0.774	rs12125125	ENSG00000229367.1	HMGN2P19	3.93	9.04e-05	0.00574	0.17	0.12	Circulating myeloperoxidase levels (plasma);	chr1:229491919	chr1:229570532~229570796:+
BRCA	cis	rs12049351	0.774	rs12125978	ENSG00000229367.1	HMGN2P19	3.93	9.04e-05	0.00574	0.17	0.12	Circulating myeloperoxidase levels (plasma);	chr1:229491975	chr1:229570532~229570796:+
BRCA	cis	rs1008375	0.966	rs3775923	ENSG00000249502.1	AC006160.5	-3.93	9.04e-05	0.00574	-0.14	-0.12	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17584002	chr4:17587467~17614571:-
BRCA	cis	rs256438	0.93	rs2434284	ENSG00000251050.1	RP11-168A11.4	-3.93	9.04e-05	0.00575	-0.14	-0.12	Serum thyroid-stimulating hormone levels;	chr5:80095391	chr5:80019609~80019920:+
BRCA	cis	rs875971	0.545	rs6950988	ENSG00000232559.3	GS1-124K5.12	3.93	9.05e-05	0.00575	0.16	0.12	Aortic root size;	chr7:66511428	chr7:66554588~66576923:-
BRCA	cis	rs11098499	0.908	rs7695996	ENSG00000225892.3	RP11-384K6.2	3.93	9.05e-05	0.00575	0.12	0.12	Corneal astigmatism;	chr4:119400878	chr4:118632274~118634759:+
BRCA	cis	rs8114671	0.935	rs6142313	ENSG00000279253.1	RP4-614O4.13	3.93	9.05e-05	0.00575	0.14	0.12	Height;	chr20:35192624	chr20:35262727~35264187:-
BRCA	cis	rs7045881	0.735	rs7040516	ENSG00000254396.1	RP11-56F10.3	3.93	9.05e-05	0.00575	0.18	0.12	Schizophrenia;	chr9:26897274	chr9:27102630~27104728:+
BRCA	cis	rs987724	0.515	rs1320011	ENSG00000244515.1	KRT18P34	-3.93	9.05e-05	0.00575	-0.18	-0.12	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156899993	chr3:157162663~157163932:-
BRCA	cis	rs7267979	0.966	rs2500417	ENSG00000277938.1	RP5-965G21.3	-3.93	9.05e-05	0.00575	-0.15	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25402651	chr20:25229150~25231933:+
BRCA	cis	rs957448	0.904	rs56302978	ENSG00000254315.1	RP11-267M23.3	3.93	9.05e-05	0.00575	0.16	0.12	Nonsyndromic cleft lip with cleft palate;	chr8:94505883	chr8:94533628~94534391:+
BRCA	cis	rs1153858	0.943	rs12439575	ENSG00000275672.1	GATM-AS1	-3.93	9.05e-05	0.00575	-0.16	-0.12	Homoarginine levels;	chr15:45392618	chr15:45378700~45380123:+
BRCA	cis	rs17345786	1	rs3804778	ENSG00000256628.3	ZBTB11-AS1	3.93	9.05e-05	0.00575	0.18	0.12	Colonoscopy-negative controls vs population controls;	chr3:101575728	chr3:101676475~101679217:+
BRCA	cis	rs9733	0.818	rs4970926	ENSG00000203804.4	ADAMTSL4-AS1	-3.93	9.06e-05	0.00575	-0.13	-0.12	Tonsillectomy;	chr1:150701208	chr1:150560202~150574552:-
BRCA	cis	rs7832552	0.686	rs4735098	ENSG00000253796.1	RP11-1084E5.1	-3.93	9.06e-05	0.00575	-0.12	-0.12	Body mass (lean);	chr8:109143662	chr8:108895029~109063417:-
BRCA	cis	rs1048886	0.938	rs12526827	ENSG00000271967.1	RP11-134K13.4	-3.93	9.06e-05	0.00575	-0.17	-0.12	Type 2 diabetes;	chr6:70449931	chr6:70596438~70596980:+
BRCA	cis	rs6840360	0.533	rs13119490	ENSG00000270265.1	RP11-731D1.4	3.93	9.06e-05	0.00575	0.14	0.12	Intelligence (multi-trait analysis);	chr4:151792260	chr4:151333775~151353224:-
BRCA	cis	rs17214007	0.735	rs8045778	ENSG00000260735.1	RP11-72I8.1	3.93	9.06e-05	0.00575	0.16	0.12	Cognitive function;	chr16:15784395	chr16:15094411~15109197:+
BRCA	cis	rs13098911	0.54	rs34127208	ENSG00000223552.1	RP11-24F11.2	-3.93	9.06e-05	0.00575	-0.21	-0.12	Celiac disease;	chr3:46062188	chr3:46364955~46407059:-
BRCA	cis	rs12439619	0.81	rs62012049	ENSG00000259429.4	UBE2Q2P2	-3.93	9.06e-05	0.00576	-0.15	-0.12	Intelligence (multi-trait analysis);	chr15:82237722	chr15:82355142~82420075:+
BRCA	cis	rs703842	0.892	rs1021469	ENSG00000270039.1	RP11-571M6.17	-3.93	9.06e-05	0.00576	-0.16	-0.12	Multiple sclerosis;	chr12:57814381	chr12:57803838~57804415:+
BRCA	cis	rs2243480	1	rs73142122	ENSG00000226002.1	RP11-460N20.5	-3.93	9.07e-05	0.00576	-0.2	-0.12	Diabetic kidney disease;	chr7:65846311	chr7:65084103~65100232:+
BRCA	cis	rs2243480	0.901	rs73142137	ENSG00000226002.1	RP11-460N20.5	-3.93	9.07e-05	0.00576	-0.2	-0.12	Diabetic kidney disease;	chr7:65878455	chr7:65084103~65100232:+
BRCA	cis	rs2243480	1	rs13247184	ENSG00000226002.1	RP11-460N20.5	-3.93	9.07e-05	0.00576	-0.2	-0.12	Diabetic kidney disease;	chr7:65893941	chr7:65084103~65100232:+
BRCA	cis	rs2243480	1	rs35283677	ENSG00000226002.1	RP11-460N20.5	-3.93	9.07e-05	0.00576	-0.2	-0.12	Diabetic kidney disease;	chr7:65894246	chr7:65084103~65100232:+
BRCA	cis	rs2243480	1	rs35421653	ENSG00000226002.1	RP11-460N20.5	-3.93	9.07e-05	0.00576	-0.2	-0.12	Diabetic kidney disease;	chr7:65898442	chr7:65084103~65100232:+
BRCA	cis	rs11098499	0.69	rs34818745	ENSG00000260091.1	RP11-33B1.4	-3.93	9.07e-05	0.00576	-0.11	-0.12	Corneal astigmatism;	chr4:119335900	chr4:119409333~119410233:+
BRCA	cis	rs2692947	0.727	rs2692950	ENSG00000232931.4	LINC00342	3.93	9.07e-05	0.00576	0.13	0.12	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96007776	chr2:95807118~95816215:-
BRCA	cis	rs801193	0.967	rs2707853	ENSG00000265600.1	AC006480.1	-3.93	9.07e-05	0.00576	-0.14	-0.12	Aortic root size;	chr7:66749023	chr7:67356680~67356779:+
BRCA	cis	rs7735319	0.528	rs10037743	ENSG00000249572.1	CTD-2203K17.1	3.93	9.07e-05	0.00576	0.16	0.12	Systolic blood pressure;	chr5:33163672	chr5:33424025~33440619:-
BRCA	cis	rs1437396	0.657	rs3099075	ENSG00000203327.2	AC012358.7	3.93	9.07e-05	0.00576	0.12	0.12	Alcohol dependence;	chr2:55369555	chr2:55214387~55216126:-
BRCA	cis	rs12468226	0.938	rs3843338	ENSG00000272966.1	RP11-686O6.1	-3.93	9.07e-05	0.00576	-0.19	-0.12	Urate levels;	chr2:202246102	chr2:202336739~202337200:+
BRCA	cis	rs4415084	1	rs7735881	ENSG00000248779.1	RP11-53O19.2	3.93	9.07e-05	0.00576	0.11	0.12	Breast cancer;	chr5:44650074	chr5:44752949~44765744:+
BRCA	cis	rs7120118	0.517	rs3758671	ENSG00000280615.1	Y_RNA	3.93	9.07e-05	0.00576	0.2	0.12	HDL cholesterol;	chr11:47251538	chr11:47614898~47614994:-
BRCA	cis	rs6088580	0.634	rs6059890	ENSG00000275784.1	RP5-1125A11.6	-3.93	9.07e-05	0.00576	-0.13	-0.12	Glomerular filtration rate (creatinine);	chr20:34513848	chr20:33989480~33991818:-
BRCA	cis	rs72615157	0.539	rs72615159	ENSG00000235713.1	RP4-604G5.3	-3.93	9.07e-05	0.00576	-0.15	-0.12	Lung function (FEV1/FVC);	chr7:100076663	chr7:99992397~99993050:+
BRCA	cis	rs2243480	1	rs3885839	ENSG00000226002.1	RP11-460N20.5	-3.93	9.07e-05	0.00576	-0.2	-0.12	Diabetic kidney disease;	chr7:65825416	chr7:65084103~65100232:+
BRCA	cis	rs875971	0.545	rs1547529	ENSG00000232559.3	GS1-124K5.12	3.93	9.07e-05	0.00576	0.16	0.12	Aortic root size;	chr7:66258859	chr7:66554588~66576923:-
BRCA	cis	rs721917	0.525	rs11201011	ENSG00000242600.5	MBL1P	3.93	9.07e-05	0.00576	0.15	0.12	Chronic obstructive pulmonary disease;	chr10:79980164	chr10:79904898~79950336:+
BRCA	cis	rs34792	0.554	rs4597346	ENSG00000260872.1	RP11-680G24.5	-3.93	9.08e-05	0.00576	-0.13	-0.12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15529889	chr16:15018106~15020488:-
BRCA	cis	rs7267979	0.966	rs2263204	ENSG00000274414.1	RP5-965G21.4	3.93	9.08e-05	0.00576	0.14	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25397052	chr20:25239007~25245229:-
BRCA	cis	rs8098064	1	rs8098064	ENSG00000266053.2	NDUFV2-AS1	3.93	9.08e-05	0.00576	0.24	0.12	Dialysis-related mortality;	chr18:8209271	chr18:9121265~9136645:-
BRCA	cis	rs1949733	0.958	rs3103069	ENSG00000251615.3	RP11-774O3.3	3.93	9.08e-05	0.00576	0.13	0.12	Response to antineoplastic agents;	chr4:8507724	chr4:8355090~8358338:-
BRCA	cis	rs11667325	0.7	rs11084120	ENSG00000268316.1	AC006272.2	3.93	9.08e-05	0.00576	0.16	0.12	Neutrophil percentage of granulocytes;	chr19:51795237	chr19:51839771~51840945:-
BRCA	cis	rs11667325	0.7	rs11084121	ENSG00000268316.1	AC006272.2	3.93	9.08e-05	0.00576	0.16	0.12	Neutrophil percentage of granulocytes;	chr19:51795259	chr19:51839771~51840945:-
BRCA	cis	rs6472235	0.586	rs2357567	ENSG00000272010.1	CTD-3025N20.3	3.93	9.08e-05	0.00576	0.15	0.12	Plateletcrit;Myopia (pathological);	chr8:66003718	chr8:65591850~65592472:-
BRCA	cis	rs11098499	0.954	rs13133522	ENSG00000260404.2	RP11-384K6.6	3.93	9.08e-05	0.00576	0.11	0.12	Corneal astigmatism;	chr4:119403269	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.954	rs35091806	ENSG00000260404.2	RP11-384K6.6	3.93	9.08e-05	0.00576	0.11	0.12	Corneal astigmatism;	chr4:119404374	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.909	rs35165976	ENSG00000260404.2	RP11-384K6.6	3.93	9.08e-05	0.00576	0.11	0.12	Corneal astigmatism;	chr4:119404475	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.954	rs6846442	ENSG00000260404.2	RP11-384K6.6	3.93	9.08e-05	0.00576	0.11	0.12	Corneal astigmatism;	chr4:119405168	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.954	rs71614438	ENSG00000260404.2	RP11-384K6.6	3.93	9.08e-05	0.00576	0.11	0.12	Corneal astigmatism;	chr4:119450097	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.954	rs66506550	ENSG00000260404.2	RP11-384K6.6	3.93	9.08e-05	0.00576	0.11	0.12	Corneal astigmatism;	chr4:119450290	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.909	rs7659501	ENSG00000260404.2	RP11-384K6.6	3.93	9.08e-05	0.00576	0.11	0.12	Corneal astigmatism;	chr4:119450397	chr4:118591773~118633729:+
BRCA	cis	rs72739697	0.786	rs72739685	ENSG00000238061.2	RP4-635A23.4	3.93	9.08e-05	0.00576	0.27	0.12	Itch intensity from mosquito bite adjusted by bite size;	chr1:185032543	chr1:185280844~185281816:+
BRCA	cis	rs72739697	0.786	rs72739686	ENSG00000238061.2	RP4-635A23.4	3.93	9.08e-05	0.00576	0.27	0.12	Itch intensity from mosquito bite adjusted by bite size;	chr1:185034218	chr1:185280844~185281816:+
BRCA	cis	rs34548439	0.649	rs17354211	ENSG00000249911.1	LINC01265	-3.93	9.08e-05	0.00576	-0.16	-0.12	Colorectal adenoma (advanced);	chr5:38808544	chr5:38710367~38720273:-
BRCA	cis	rs8054556	1	rs4788201	ENSG00000261367.1	RP11-455F5.4	-3.93	9.08e-05	0.00576	-0.14	-0.12	Autism spectrum disorder or schizophrenia;	chr16:29961369	chr16:30107675~30110541:+
BRCA	cis	rs448720	1	rs8025791	ENSG00000260657.2	RP11-315D16.4	3.93	9.08e-05	0.00577	0.14	0.12	Cognitive performance;	chr15:67917807	chr15:68267792~68277994:-
BRCA	cis	rs728616	0.51	rs34817075	ENSG00000242600.5	MBL1P	3.93	9.09e-05	0.00577	0.21	0.12	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79989984	chr10:79904898~79950336:+
BRCA	cis	rs3735485	0.678	rs10233699	ENSG00000201772.1	SNORA5C	3.93	9.09e-05	0.00577	0.16	0.12	White blood cell count;Sum basophil neutrophil counts;Neutrophil count;Granulocyte percentage of myeloid white cells;Monocyte percentage of white cells;Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Lymphocyte counts;	chr7:45093111	chr7:45104906~45105042:-
BRCA	cis	rs17801127	0.818	rs13023298	ENSG00000231969.1	AC144449.1	3.93	9.09e-05	0.00577	0.21	0.12	Liver enzyme levels (alanine transaminase);	chr2:149680521	chr2:149587196~149848233:+
BRCA	cis	rs6657613	0.628	rs761423	ENSG00000215908.6	CROCCP2	3.93	9.09e-05	0.00577	0.09	0.12	Hip circumference adjusted for BMI;	chr1:16975177	chr1:16618262~16644683:-
BRCA	cis	rs7048146	0.51	rs4978821	ENSG00000213539.4	YBX1P6	-3.93	9.09e-05	0.00577	-0.13	-0.12	Vascular brain injury;	chr9:109525661	chr9:109532830~109534332:-
BRCA	cis	rs4713118	0.621	rs10484403	ENSG00000216901.1	AL022393.7	3.93	9.09e-05	0.00577	0.17	0.12	Parkinson's disease;	chr6:28065745	chr6:28176188~28176674:+
BRCA	cis	rs4237845	0.537	rs2002275	ENSG00000257159.1	RP11-58A17.3	3.93	9.09e-05	0.00577	0.15	0.12	Intelligence (multi-trait analysis);	chr12:57889602	chr12:57967058~57968399:+
BRCA	cis	rs957448	0.561	rs58663902	ENSG00000254315.1	RP11-267M23.3	3.93	9.09e-05	0.00577	0.15	0.12	Nonsyndromic cleft lip with cleft palate;	chr8:94610177	chr8:94533628~94534391:+
BRCA	cis	rs35306767	0.855	rs34318754	ENSG00000229869.1	RP11-363N22.2	-3.93	9.09e-05	0.00577	-0.21	-0.12	Eosinophil percentage of granulocytes;	chr10:844774	chr10:933026~942743:+
BRCA	cis	rs35306767	0.903	rs7914758	ENSG00000229869.1	RP11-363N22.2	-3.93	9.09e-05	0.00577	-0.21	-0.12	Eosinophil percentage of granulocytes;	chr10:845762	chr10:933026~942743:+
BRCA	cis	rs11711311	1	rs13061150	ENSG00000241529.3	RN7SL767P	-3.93	9.09e-05	0.00577	-0.14	-0.12	IgG glycosylation;	chr3:113787887	chr3:113632704~113632998:+
BRCA	cis	rs17695224	0.5	rs13346104	ENSG00000269483.1	AC006272.1	3.93	9.09e-05	0.00577	0.14	0.12	HDL cholesterol;HDL cholesterol levels;	chr19:51831173	chr19:51839924~51843324:-
BRCA	cis	rs6736093	1	rs4848861	ENSG00000236307.2	EEF1E1P1	3.93	9.1e-05	0.00577	0.15	0.12	Coronary artery disease;	chr2:111911258	chr2:111887914~111888741:+
BRCA	cis	rs6431644	0.731	rs528971	ENSG00000224287.2	MSL3P1	3.93	9.1e-05	0.00577	0.14	0.12	Left atrial antero-posterior diameter;	chr2:233857435	chr2:233865437~233868444:-
BRCA	cis	rs13323323	0.652	rs9825080	ENSG00000227123.1	RPL12P44	3.93	9.1e-05	0.00577	0.15	0.12	IgG glycosylation;	chr3:44209778	chr3:44937673~44938482:+
BRCA	cis	rs2041840	1	rs2041837	ENSG00000272054.1	RP11-423P10.2	-3.93	9.1e-05	0.00577	-0.11	-0.12	Chronic lymphocytic leukemia;	chr2:37241421	chr2:37208875~37212677:+
BRCA	cis	rs2243480	1	rs422164	ENSG00000237026.1	RP11-328P23.2	3.93	9.1e-05	0.00578	0.23	0.12	Diabetic kidney disease;	chr7:66121618	chr7:65235790~65236723:-
BRCA	cis	rs397969	0.596	rs7209653	ENSG00000261033.1	RP11-209D14.2	-3.93	9.1e-05	0.00578	-0.15	-0.12	Platelet count;	chr17:19978771	chr17:20008051~20009234:-
BRCA	cis	rs7267979	0.903	rs6050482	ENSG00000204556.4	CTD-2514C3.1	-3.93	9.1e-05	0.00578	-0.16	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25245691	chr20:26018832~26020684:+
BRCA	cis	rs1910358	0.69	rs4461602	ENSG00000248874.4	C5orf17	-3.93	9.1e-05	0.00578	-0.16	-0.12	Venous thromboembolism (SNP x SNP interaction);	chr5:23968921	chr5:23951348~24178263:+
BRCA	cis	rs8114671	0.57	rs3761144	ENSG00000126005.14	MMP24-AS1	-3.93	9.1e-05	0.00578	-0.14	-0.12	Height;	chr20:34956272	chr20:35216462~35278131:-
BRCA	cis	rs9470794	1	rs59578279	ENSG00000204110.6	RP1-153P14.8	-3.93	9.1e-05	0.00578	-0.22	-0.12	Type 2 diabetes;	chr6:38079530	chr6:37507348~37535616:+
BRCA	cis	rs9470794	1	rs56914148	ENSG00000204110.6	RP1-153P14.8	-3.93	9.1e-05	0.00578	-0.22	-0.12	Type 2 diabetes;	chr6:38080897	chr6:37507348~37535616:+
BRCA	cis	rs488400	0.529	rs2020009	ENSG00000270265.1	RP11-731D1.4	3.93	9.11e-05	0.00578	0.14	0.12	Trans fatty acid levels;	chr4:151916302	chr4:151333775~151353224:-
BRCA	cis	rs11098499	1	rs6837898	ENSG00000260091.1	RP11-33B1.4	-3.93	9.11e-05	0.00578	-0.11	-0.12	Corneal astigmatism;	chr4:119257999	chr4:119409333~119410233:+
BRCA	cis	rs2380205	0.517	rs7090411	ENSG00000232807.2	RP11-536K7.3	3.93	9.11e-05	0.00578	0.13	0.12	Breast cancer;	chr10:5920764	chr10:5934270~5945900:-
BRCA	cis	rs1048886	0.872	rs12200777	ENSG00000271967.1	RP11-134K13.4	-3.93	9.11e-05	0.00578	-0.18	-0.12	Type 2 diabetes;	chr6:70577251	chr6:70596438~70596980:+
BRCA	cis	rs13434995	0.838	rs73236165	ENSG00000249700.7	SRD5A3-AS1	-3.93	9.11e-05	0.00578	-0.19	-0.12	Adiponectin levels;	chr4:55617617	chr4:55363971~55395847:-
BRCA	cis	rs7412746	0.658	rs11589458	ENSG00000231073.1	RP11-316M1.3	3.93	9.11e-05	0.00578	0.13	0.12	Melanoma;	chr1:150820140	chr1:150973123~150975534:+
BRCA	cis	rs7800418	0.723	rs1029558	ENSG00000214870.7	AC004540.5	-3.93	9.11e-05	0.00578	-0.15	-0.12	Cognitive function;	chr7:26548772	chr7:26398593~26494256:+
BRCA	cis	rs308403	0.6	rs376131	ENSG00000224786.1	CETN4P	3.93	9.11e-05	0.00578	0.17	0.12	Blood protein levels;	chr4:122708070	chr4:122730548~122732193:-
BRCA	cis	rs763014	1	rs7205409	ENSG00000260394.2	LA16c-313D11.9	-3.93	9.11e-05	0.00578	-0.12	-0.12	Height;	chr16:592610	chr16:678504~679777:-
BRCA	cis	rs12744310	0.502	rs2363812	ENSG00000235358.1	RP11-399E6.1	3.93	9.12e-05	0.00578	0.15	0.12	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41326895	chr1:41242373~41284861:+
BRCA	cis	rs2562456	0.833	rs2154302	ENSG00000240522.1	RPL7AP10	-3.93	9.12e-05	0.00578	-0.14	-0.12	Pain;	chr19:21307609	chr19:21149648~21150438:-
BRCA	cis	rs7824557	0.767	rs7003241	ENSG00000248896.2	CTD-2135J3.3	3.93	9.12e-05	0.00579	0.16	0.12	Retinal vascular caliber;	chr8:11311566	chr8:10729314~10771392:+
BRCA	cis	rs7735319	0.546	rs6450948	ENSG00000249572.1	CTD-2203K17.1	3.93	9.12e-05	0.00579	0.15	0.12	Systolic blood pressure;	chr5:33170196	chr5:33424025~33440619:-
BRCA	cis	rs10958369	0.613	rs7812717	ENSG00000253369.1	RP11-1081M5.1	3.93	9.12e-05	0.00579	0.15	0.12	Response to antineoplastic agents;	chr8:53521362	chr8:53395211~53395946:-
BRCA	cis	rs7481584	0.581	rs105686	ENSG00000236710.1	AC108448.2	3.93	9.12e-05	0.00579	0.16	0.12	Calcium levels;	chr11:3041237	chr11:3084393~3085443:-
BRCA	cis	rs747650	0.504	rs7114683	ENSG00000200376.1	RNU5E-10P	3.93	9.12e-05	0.00579	0.16	0.12	Acne (severe);	chr11:47055695	chr11:47576471~47576588:-
BRCA	cis	rs747650	0.504	rs10838652	ENSG00000200376.1	RNU5E-10P	3.93	9.12e-05	0.00579	0.16	0.12	Acne (severe);	chr11:47056286	chr11:47576471~47576588:-
BRCA	cis	rs7746199	0.736	rs6904596	ENSG00000216901.1	AL022393.7	3.93	9.12e-05	0.00579	0.25	0.12	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27523520	chr6:28176188~28176674:+
BRCA	cis	rs4294134	0.608	rs12707239	ENSG00000223718.3	AC093107.7	3.93	9.12e-05	0.00579	0.18	0.12	Paget's disease;	chr7:135562435	chr7:135660039~135660647:+
BRCA	cis	rs4237845	0.537	rs4237844	ENSG00000257159.1	RP11-58A17.3	-3.93	9.12e-05	0.00579	-0.15	-0.12	Intelligence (multi-trait analysis);	chr12:57874204	chr12:57967058~57968399:+
BRCA	cis	rs10938353	0.906	rs73249426	ENSG00000273369.1	RP11-700J17.1	3.93	9.12e-05	0.00579	0.15	0.12	Body mass index;	chr4:44610281	chr4:44693946~44694386:-
BRCA	cis	rs2288884	0.579	rs6509603	ENSG00000275055.1	CTC-471J1.11	-3.93	9.12e-05	0.00579	-0.17	-0.12	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:51960977	chr19:52049007~52049754:+
BRCA	cis	rs801193	0.66	rs10950049	ENSG00000272831.1	RP11-792A8.4	3.93	9.12e-05	0.00579	0.11	0.12	Aortic root size;	chr7:66765873	chr7:66739829~66740385:-
BRCA	cis	rs1005277	0.54	rs1987431	ENSG00000226578.1	RP11-258F22.1	-3.93	9.13e-05	0.00579	-0.13	-0.12	Extrinsic epigenetic age acceleration;	chr10:37699959	chr10:37775371~37784131:-
BRCA	cis	rs6121246	0.909	rs6060979	ENSG00000230613.1	HM13-AS1	3.93	9.13e-05	0.00579	0.18	0.12	Mean corpuscular hemoglobin;	chr20:31829719	chr20:31567707~31573263:-
BRCA	cis	rs6952407	1	rs6952407	ENSG00000275400.1	RP4-756H11.5	3.93	9.13e-05	0.00579	0.14	0.12	Cotinine glucuronidation;	chr7:66580525	chr7:66553805~66554199:-
BRCA	cis	rs6671200	0.518	rs77369148	ENSG00000235501.4	RP4-639F20.1	-3.93	9.13e-05	0.00579	-0.26	-0.12	Stearic acid (18:0) levels;	chr1:94912122	chr1:94927566~94963270:+
BRCA	cis	rs957448	1	rs2381882	ENSG00000254315.1	RP11-267M23.3	3.93	9.13e-05	0.00579	0.16	0.12	Nonsyndromic cleft lip with cleft palate;	chr8:94535496	chr8:94533628~94534391:+
BRCA	cis	rs7976059	0.895	rs73109505	ENSG00000259887.1	RP11-923I11.5	-3.93	9.13e-05	0.00579	-0.15	-0.12	Urate levels;	chr12:51851137	chr12:51848223~51852729:+
BRCA	cis	rs875971	0.505	rs1723275	ENSG00000273142.1	RP11-458F8.4	3.93	9.13e-05	0.00579	0.11	0.12	Aortic root size;	chr7:66039646	chr7:66902857~66906297:+
BRCA	cis	rs11168351	0.864	rs12228750	ENSG00000226413.2	OR8T1P	-3.93	9.13e-05	0.00579	-0.16	-0.12	Bipolar disorder and schizophrenia;	chr12:48103214	chr12:48442030~48442947:-
BRCA	cis	rs66887589	0.616	rs11731675	ENSG00000250412.1	KLHL2P1	3.93	9.13e-05	0.00579	0.13	0.12	Diastolic blood pressure;	chr4:119291359	chr4:119334329~119378233:+
BRCA	cis	rs495337	0.76	rs2769982	ENSG00000229222.1	KRT18P4	3.93	9.13e-05	0.00579	0.15	0.12	Psoriasis;	chr20:49908290	chr20:49956745~49958032:+
BRCA	cis	rs304029	0.87	rs304032	ENSG00000231249.1	ITPR1-AS1	3.93	9.13e-05	0.00579	0.14	0.12	Diabetic kidney disease;	chr3:4505089	chr3:4490891~4493163:-
BRCA	cis	rs2274273	0.712	rs1002054	ENSG00000259318.1	RP11-454L9.2	3.93	9.13e-05	0.00579	0.1	0.12	Protein biomarker;	chr14:55062195	chr14:55394940~55395233:-
BRCA	cis	rs871012	0.542	rs58995342	ENSG00000251405.2	CTB-109A12.1	-3.93	9.14e-05	0.0058	-0.17	-0.12	IgG glycosylation;	chr5:157401332	chr5:157362615~157460078:-
BRCA	cis	rs7116495	1	rs7128317	ENSG00000248671.6	ALG1L9P	3.93	9.14e-05	0.0058	0.23	0.12	Severe influenza A (H1N1) infection;	chr11:71990321	chr11:71794363~71818238:-
BRCA	cis	rs3213758	0.588	rs12928335	ENSG00000275191.1	RP11-36I17.2	-3.93	9.14e-05	0.0058	-0.24	-0.12	Vitiligo (non-segmental);	chr16:53580834	chr16:53628256~53628816:-
BRCA	cis	rs875971	1	rs7781698	ENSG00000236529.1	RP13-254B10.1	3.93	9.14e-05	0.0058	0.13	0.12	Aortic root size;	chr7:66431325	chr7:65840212~65840596:+
BRCA	cis	rs10829156	0.732	rs10828834	ENSG00000225527.1	RP11-383B4.4	-3.93	9.14e-05	0.0058	-0.17	-0.12	Sudden cardiac arrest;	chr10:18523505	chr10:18531849~18533336:-
BRCA	cis	rs875971	0.798	rs6460304	ENSG00000229886.1	RP5-1132H15.3	3.93	9.14e-05	0.0058	0.14	0.12	Aortic root size;	chr7:66499741	chr7:66025126~66031544:-
BRCA	cis	rs875971	0.862	rs6945775	ENSG00000229886.1	RP5-1132H15.3	3.93	9.14e-05	0.0058	0.14	0.12	Aortic root size;	chr7:66503987	chr7:66025126~66031544:-
BRCA	cis	rs6545883	0.929	rs7606167	ENSG00000270820.4	RP11-355B11.2	3.93	9.14e-05	0.0058	0.14	0.12	Tuberculosis;	chr2:61515519	chr2:61471188~61484130:+
BRCA	cis	rs853679	1	rs68141011	ENSG00000204709.4	LINC01556	3.93	9.14e-05	0.0058	0.22	0.12	Depression;	chr6:28250019	chr6:28943877~28944537:+
BRCA	cis	rs853679	1	rs13200462	ENSG00000204709.4	LINC01556	3.93	9.14e-05	0.0058	0.22	0.12	Depression;	chr6:28250421	chr6:28943877~28944537:+
BRCA	cis	rs11098499	0.82	rs13128602	ENSG00000260404.2	RP11-384K6.6	-3.93	9.14e-05	0.0058	-0.12	-0.12	Corneal astigmatism;	chr4:119538211	chr4:118591773~118633729:+
BRCA	cis	rs57786342	0.569	rs8019383	ENSG00000258623.1	CTD-2325P2.3	3.93	9.14e-05	0.0058	0.15	0.12	Macrophage inflammatory protein 1a levels;	chr14:68810624	chr14:68683411~68685565:-
BRCA	cis	rs7011507	0.589	rs11985324	ENSG00000233858.4	AC026904.1	-3.93	9.14e-05	0.0058	-0.15	-0.12	Inflammatory bowel disease;Ulcerative colitis;	chr8:48476629	chr8:48590401~48594621:+
BRCA	cis	rs10864907	0.614	rs12711745	ENSG00000231747.1	AC079922.2	-3.93	9.15e-05	0.0058	-0.11	-0.12	Pulmonary function;	chr2:112942778	chr2:112621809~112622167:-
BRCA	cis	rs7120118	0.517	rs12221497	ENSG00000280615.1	Y_RNA	3.93	9.15e-05	0.0058	0.2	0.12	HDL cholesterol;	chr11:47259102	chr11:47614898~47614994:-
BRCA	cis	rs11686241	0.872	rs8179823	ENSG00000241520.1	AC098820.4	3.93	9.15e-05	0.0058	0.17	0.12	Cancer;	chr2:216483403	chr2:216483032~216487196:-
BRCA	cis	rs853679	0.599	rs188015	ENSG00000216901.1	AL022393.7	3.93	9.15e-05	0.0058	0.24	0.12	Depression;	chr6:27909668	chr6:28176188~28176674:+
BRCA	cis	rs4835473	0.932	rs5016160	ENSG00000246448.2	RP13-578N3.3	3.93	9.15e-05	0.0058	0.14	0.12	Immature fraction of reticulocytes;	chr4:143738305	chr4:143700257~143865072:+
BRCA	cis	rs11098499	0.954	rs2306455	ENSG00000260404.2	RP11-384K6.6	3.93	9.15e-05	0.0058	0.12	0.12	Corneal astigmatism;	chr4:119500814	chr4:118591773~118633729:+
BRCA	cis	rs12468226	0.873	rs79071680	ENSG00000272966.1	RP11-686O6.1	3.93	9.15e-05	0.0058	0.21	0.12	Urate levels;	chr2:202191520	chr2:202336739~202337200:+
BRCA	cis	rs12468226	0.873	rs79860867	ENSG00000272966.1	RP11-686O6.1	3.93	9.15e-05	0.0058	0.21	0.12	Urate levels;	chr2:202192397	chr2:202336739~202337200:+
BRCA	cis	rs728616	0.51	rs17617406	ENSG00000225484.5	NUTM2B-AS1	3.93	9.15e-05	0.0058	0.24	0.12	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80414800	chr10:79663088~79826594:-
BRCA	cis	rs10266483	0.741	rs10254313	ENSG00000271550.1	BNIP3P11	3.93	9.15e-05	0.0058	0.16	0.12	Response to statin therapy;	chr7:64278935	chr7:64678954~64687393:-
BRCA	cis	rs10266483	0.741	rs35244017	ENSG00000271550.1	BNIP3P11	3.93	9.15e-05	0.0058	0.16	0.12	Response to statin therapy;	chr7:64278939	chr7:64678954~64687393:-
BRCA	cis	rs8192917	0.832	rs9671454	ENSG00000258744.1	RP11-80A15.1	3.93	9.15e-05	0.00581	0.16	0.12	Vitiligo;	chr14:24632850	chr14:24501594~24508688:+
BRCA	cis	rs1949733	0.701	rs4696828	ENSG00000251615.3	RP11-774O3.3	3.93	9.16e-05	0.00581	0.13	0.12	Response to antineoplastic agents;	chr4:8453877	chr4:8355090~8358338:-
BRCA	cis	rs2562456	0.917	rs2650825	ENSG00000268119.4	CTD-2561J22.5	3.93	9.16e-05	0.00581	0.19	0.12	Pain;	chr19:21516423	chr19:21444241~21463908:-
BRCA	cis	rs6964587	1	rs2282968	ENSG00000188693.7	CYP51A1-AS1	3.93	9.16e-05	0.00581	0.13	0.12	Breast cancer;	chr7:91950973	chr7:92134604~92180725:+
BRCA	cis	rs11098499	0.775	rs10021601	ENSG00000260404.2	RP11-384K6.6	3.93	9.16e-05	0.00581	0.11	0.12	Corneal astigmatism;	chr4:119361408	chr4:118591773~118633729:+
BRCA	cis	rs9467773	0.62	rs2504571	ENSG00000224843.5	LINC00240	-3.93	9.16e-05	0.00581	-0.13	-0.12	Intelligence (multi-trait analysis);	chr6:26643207	chr6:26956992~27023924:+
BRCA	cis	rs7520050	0.807	rs28844317	ENSG00000281133.1	AL355480.3	-3.93	9.16e-05	0.00581	-0.14	-0.12	Reticulocyte count;Red blood cell count;	chr1:45743535	chr1:45580892~45580996:-
BRCA	cis	rs7520050	0.807	rs6429576	ENSG00000281133.1	AL355480.3	-3.93	9.16e-05	0.00581	-0.14	-0.12	Reticulocyte count;Red blood cell count;	chr1:45750903	chr1:45580892~45580996:-
BRCA	cis	rs7520050	0.931	rs11211198	ENSG00000234329.1	RP11-767N6.2	-3.93	9.16e-05	0.00581	-0.11	-0.12	Reticulocyte count;Red blood cell count;	chr1:45817001	chr1:45651039~45651826:-
BRCA	cis	rs7520050	0.966	rs10890352	ENSG00000234329.1	RP11-767N6.2	-3.93	9.16e-05	0.00581	-0.11	-0.12	Reticulocyte count;Red blood cell count;	chr1:45817956	chr1:45651039~45651826:-
BRCA	cis	rs7520050	0.966	rs6700597	ENSG00000234329.1	RP11-767N6.2	-3.93	9.16e-05	0.00581	-0.11	-0.12	Reticulocyte count;Red blood cell count;	chr1:45818574	chr1:45651039~45651826:-
BRCA	cis	rs256438	0.93	rs2438640	ENSG00000251050.1	RP11-168A11.4	-3.93	9.16e-05	0.00581	-0.13	-0.12	Serum thyroid-stimulating hormone levels;	chr5:80093861	chr5:80019609~80019920:+
BRCA	cis	rs256438	0.93	rs2434281	ENSG00000251050.1	RP11-168A11.4	-3.93	9.16e-05	0.00581	-0.13	-0.12	Serum thyroid-stimulating hormone levels;	chr5:80093870	chr5:80019609~80019920:+
BRCA	cis	rs4831760	1	rs11780499	ENSG00000250483.1	PPM1AP1	-3.93	9.16e-05	0.00581	-0.17	-0.12	Pulmonary function decline;	chr8:15676740	chr8:15806149~15807283:-
BRCA	cis	rs6547741	1	rs6547741	ENSG00000234072.1	AC074117.10	3.93	9.16e-05	0.00581	0.11	0.12	Oral cavity cancer;	chr2:27633057	chr2:27356246~27367622:+
BRCA	cis	rs7520050	0.966	rs7515491	ENSG00000234329.1	RP11-767N6.2	-3.93	9.16e-05	0.00581	-0.11	-0.12	Reticulocyte count;Red blood cell count;	chr1:45889407	chr1:45651039~45651826:-
BRCA	cis	rs7267979	1	rs2424716	ENSG00000274973.1	RP13-401N8.7	-3.93	9.16e-05	0.00581	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25442902	chr20:25845497~25845862:+
BRCA	cis	rs7267979	1	rs761025	ENSG00000274973.1	RP13-401N8.7	-3.93	9.16e-05	0.00581	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25446332	chr20:25845497~25845862:+
BRCA	cis	rs80226907	0.634	rs59169706	ENSG00000186615.9	KTN1-AS1	-3.93	9.17e-05	0.00581	-0.24	-0.12	Mean platelet volume;	chr14:55446364	chr14:55499278~55580110:-
BRCA	cis	rs4819052	0.84	rs914217	ENSG00000184274.3	LINC00315	-3.93	9.17e-05	0.00581	-0.18	-0.12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45278384	chr21:45300245~45305257:-
BRCA	cis	rs2839186	0.708	rs6518285	ENSG00000228137.1	AP001469.7	3.93	9.17e-05	0.00581	0.13	0.12	Testicular germ cell tumor;	chr21:46224753	chr21:46246890~46247682:+
BRCA	cis	rs6686842	0.965	rs4660184	ENSG00000235358.1	RP11-399E6.1	-3.93	9.17e-05	0.00581	-0.15	-0.12	Height;	chr1:41058866	chr1:41242373~41284861:+
BRCA	cis	rs9467773	0.62	rs2451738	ENSG00000224843.5	LINC00240	3.93	9.17e-05	0.00581	0.13	0.12	Intelligence (multi-trait analysis);	chr6:26618231	chr6:26956992~27023924:+
BRCA	cis	rs4272720	0.901	rs72785060	ENSG00000228754.1	RP11-534L6.3	-3.93	9.17e-05	0.00582	-0.18	-0.12	Platelet count;Plateletcrit;	chr10:49113422	chr10:48745545~48746128:-
BRCA	cis	rs11250098	0.574	rs4240672	ENSG00000255020.1	AF131216.5	3.93	9.17e-05	0.00582	0.14	0.12	Morning vs. evening chronotype;	chr8:10910407	chr8:11345748~11347502:-
BRCA	cis	rs739496	0.579	rs10849984	ENSG00000234608.6	MAPKAPK5-AS1	3.93	9.17e-05	0.00582	0.15	0.12	Platelet count;	chr12:111909924	chr12:111839764~111842902:-
BRCA	cis	rs739496	0.579	rs10849985	ENSG00000234608.6	MAPKAPK5-AS1	3.93	9.17e-05	0.00582	0.15	0.12	Platelet count;	chr12:111909950	chr12:111839764~111842902:-
BRCA	cis	rs2703485	0.726	rs11930260	ENSG00000249700.7	SRD5A3-AS1	3.93	9.17e-05	0.00582	0.16	0.12	Mean corpuscular volume;	chr4:54586245	chr4:55363971~55395847:-
BRCA	cis	rs4499344	0.73	rs410616	ENSG00000267475.1	CTD-2538C1.2	3.93	9.17e-05	0.00582	0.15	0.12	Mean platelet volume;	chr19:32615203	chr19:32687089~32691750:-
BRCA	cis	rs6546324	0.625	rs6546325	ENSG00000236780.4	AC078941.1	3.93	9.18e-05	0.00582	0.21	0.12	Endometriosis;	chr2:67634769	chr2:67123357~67215319:-
BRCA	cis	rs8054556	1	rs4788200	ENSG00000261367.1	RP11-455F5.4	-3.93	9.18e-05	0.00582	-0.14	-0.12	Autism spectrum disorder or schizophrenia;	chr16:29959944	chr16:30107675~30110541:+
BRCA	cis	rs66887589	0.616	rs11098497	ENSG00000250412.1	KLHL2P1	3.93	9.18e-05	0.00582	0.13	0.12	Diastolic blood pressure;	chr4:119265913	chr4:119334329~119378233:+
BRCA	cis	rs9470794	1	rs7748392	ENSG00000204110.6	RP1-153P14.8	-3.93	9.18e-05	0.00582	-0.19	-0.12	Type 2 diabetes;	chr6:38150979	chr6:37507348~37535616:+
BRCA	cis	rs9470794	1	rs60986358	ENSG00000204110.6	RP1-153P14.8	-3.93	9.18e-05	0.00582	-0.19	-0.12	Type 2 diabetes;	chr6:38158085	chr6:37507348~37535616:+
BRCA	cis	rs7819412	0.54	rs11777355	ENSG00000154316.13	TDH	3.93	9.18e-05	0.00582	0.16	0.12	Triglycerides;	chr8:11187180	chr8:11339637~11368452:+
BRCA	cis	rs17767294	0.708	rs72847383	ENSG00000219392.1	RP1-265C24.5	-3.93	9.18e-05	0.00582	-0.33	-0.12	Parkinson's disease;	chr6:27907863	chr6:28115628~28116551:+
BRCA	cis	rs1862618	0.671	rs2591961	ENSG00000271828.1	CTD-2310F14.1	-3.93	9.18e-05	0.00582	-0.15	-0.12	Initial pursuit acceleration;	chr5:56942770	chr5:56927874~56929573:+
BRCA	cis	rs747650	0.504	rs4269876	ENSG00000200376.1	RNU5E-10P	-3.93	9.18e-05	0.00582	-0.16	-0.12	Acne (severe);	chr11:47087912	chr11:47576471~47576588:-
BRCA	cis	rs747650	0.504	rs61896133	ENSG00000200376.1	RNU5E-10P	-3.93	9.18e-05	0.00582	-0.16	-0.12	Acne (severe);	chr11:47094168	chr11:47576471~47576588:-
BRCA	cis	rs747650	0.504	rs7112854	ENSG00000200376.1	RNU5E-10P	-3.93	9.18e-05	0.00582	-0.16	-0.12	Acne (severe);	chr11:47095272	chr11:47576471~47576588:-
BRCA	cis	rs1007738	0.579	rs61896136	ENSG00000200376.1	RNU5E-10P	-3.93	9.18e-05	0.00582	-0.16	-0.12	Bone mineral density (hip);	chr11:47098748	chr11:47576471~47576588:-
BRCA	cis	rs747650	0.504	rs12417519	ENSG00000200376.1	RNU5E-10P	-3.93	9.18e-05	0.00582	-0.16	-0.12	Acne (severe);	chr11:47107846	chr11:47576471~47576588:-
BRCA	cis	rs4865169	0.783	rs7668814	ENSG00000269949.1	RP11-738E22.3	3.93	9.18e-05	0.00582	0.14	0.12	Breast cancer;	chr4:56959024	chr4:56960927~56961373:-
BRCA	cis	rs6071166	0.683	rs1885460	ENSG00000224635.1	RP4-564F22.5	-3.93	9.18e-05	0.00582	-0.15	-0.12	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38685827	chr20:38406011~38416797:-
BRCA	cis	rs62103177	0.525	rs10438902	ENSG00000278075.1	RP11-248M19.1	-3.93	9.18e-05	0.00582	-0.19	-0.12	Opioid sensitivity;	chr18:79985640	chr18:79900555~79900903:-
BRCA	cis	rs1048886	0.872	rs10214805	ENSG00000271967.1	RP11-134K13.4	-3.93	9.18e-05	0.00582	-0.18	-0.12	Type 2 diabetes;	chr6:70535423	chr6:70596438~70596980:+
BRCA	cis	rs1429524	0.848	rs7802175	ENSG00000243144.5	RP11-115N4.1	3.93	9.18e-05	0.00582	0.16	0.12	Ejection fraction in Tripanosoma cruzi seropositivity;	chr7:91299608	chr7:91311368~91515409:+
BRCA	cis	rs10129255	1	rs10129407	ENSG00000211967.3	IGHV3-53	-3.93	9.18e-05	0.00582	-0.09	-0.12	Kawasaki disease;	chr14:106767956	chr14:106592676~106593347:-
BRCA	cis	rs6547741	0.844	rs55826602	ENSG00000234072.1	AC074117.10	-3.93	9.19e-05	0.00582	-0.11	-0.12	Oral cavity cancer;	chr2:27640585	chr2:27356246~27367622:+
BRCA	cis	rs4908769	0.588	rs2784737	ENSG00000270282.1	RP5-1115A15.2	-3.93	9.19e-05	0.00582	-0.15	-0.12	Allergy;	chr1:8403116	chr1:8512653~8513021:+
BRCA	cis	rs448720	1	rs7162089	ENSG00000260657.2	RP11-315D16.4	3.93	9.19e-05	0.00582	0.14	0.12	Cognitive performance;	chr15:67914114	chr15:68267792~68277994:-
BRCA	cis	rs10129255	0.957	rs10150241	ENSG00000232216.1	IGHV3-43	-3.93	9.19e-05	0.00583	-0.09	-0.12	Kawasaki disease;	chr14:106775945	chr14:106470264~106470800:-
BRCA	cis	rs2243480	1	rs313802	ENSG00000237026.1	RP11-328P23.2	3.93	9.19e-05	0.00583	0.23	0.12	Diabetic kidney disease;	chr7:66051386	chr7:65235790~65236723:-
BRCA	cis	rs2243480	0.803	rs403089	ENSG00000237026.1	RP11-328P23.2	3.93	9.19e-05	0.00583	0.23	0.12	Diabetic kidney disease;	chr7:66052736	chr7:65235790~65236723:-
BRCA	cis	rs2243480	1	rs458291	ENSG00000237026.1	RP11-328P23.2	3.93	9.19e-05	0.00583	0.23	0.12	Diabetic kidney disease;	chr7:66055492	chr7:65235790~65236723:-
BRCA	cis	rs4713118	0.662	rs149970	ENSG00000216901.1	AL022393.7	3.93	9.19e-05	0.00583	0.17	0.12	Parkinson's disease;	chr6:28012442	chr6:28176188~28176674:+
BRCA	cis	rs17270561	0.636	rs9379779	ENSG00000272462.2	U91328.19	-3.93	9.19e-05	0.00583	-0.15	-0.12	Iron status biomarkers;	chr6:25695213	chr6:25992662~26001775:+
BRCA	cis	rs6585424	1	rs11201972	ENSG00000225484.5	NUTM2B-AS1	-3.93	9.19e-05	0.00583	-0.24	-0.12	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80172924	chr10:79663088~79826594:-
BRCA	cis	rs7620503	0.959	rs6443476	ENSG00000228561.2	RP11-114M1.1	3.93	9.19e-05	0.00583	0.14	0.12	Corneal structure;	chr3:177589907	chr3:177683627~177691250:+
BRCA	cis	rs7620503	0.959	rs6443477	ENSG00000228561.2	RP11-114M1.1	3.93	9.19e-05	0.00583	0.14	0.12	Corneal structure;	chr3:177590145	chr3:177683627~177691250:+
BRCA	cis	rs7620503	0.959	rs6769466	ENSG00000228561.2	RP11-114M1.1	3.93	9.19e-05	0.00583	0.14	0.12	Corneal structure;	chr3:177590226	chr3:177683627~177691250:+
BRCA	cis	rs7267979	1	rs2297497	ENSG00000125804.12	FAM182A	3.93	9.19e-05	0.00583	0.16	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25317273	chr20:26054655~26086917:+
BRCA	cis	rs733592	0.524	rs10875744	ENSG00000273765.1	RP11-370I10.11	3.93	9.2e-05	0.00583	0.13	0.12	Plateletcrit;	chr12:48104657	chr12:48360920~48361377:+
BRCA	cis	rs6599077	1	rs2887952	ENSG00000223797.4	ENTPD3-AS1	3.93	9.2e-05	0.00583	0.15	0.12	Sleep-related phenotypes;	chr3:40056738	chr3:40313802~40453329:-
BRCA	cis	rs6599077	1	rs2371140	ENSG00000223797.4	ENTPD3-AS1	3.93	9.2e-05	0.00583	0.15	0.12	Sleep-related phenotypes;	chr3:40056890	chr3:40313802~40453329:-
BRCA	cis	rs6599077	0.95	rs2371141	ENSG00000223797.4	ENTPD3-AS1	3.93	9.2e-05	0.00583	0.15	0.12	Sleep-related phenotypes;	chr3:40057427	chr3:40313802~40453329:-
BRCA	cis	rs6599077	0.95	rs9863428	ENSG00000223797.4	ENTPD3-AS1	3.93	9.2e-05	0.00583	0.15	0.12	Sleep-related phenotypes;	chr3:40058080	chr3:40313802~40453329:-
BRCA	cis	rs6599077	0.95	rs10510706	ENSG00000223797.4	ENTPD3-AS1	3.93	9.2e-05	0.00583	0.15	0.12	Sleep-related phenotypes;	chr3:40058766	chr3:40313802~40453329:-
BRCA	cis	rs6599077	0.95	rs6782134	ENSG00000223797.4	ENTPD3-AS1	3.93	9.2e-05	0.00583	0.15	0.12	Sleep-related phenotypes;	chr3:40059201	chr3:40313802~40453329:-
BRCA	cis	rs6599077	0.95	rs6773620	ENSG00000223797.4	ENTPD3-AS1	3.93	9.2e-05	0.00583	0.15	0.12	Sleep-related phenotypes;	chr3:40059247	chr3:40313802~40453329:-
BRCA	cis	rs6599077	0.95	rs4676561	ENSG00000223797.4	ENTPD3-AS1	3.93	9.2e-05	0.00583	0.15	0.12	Sleep-related phenotypes;	chr3:40059795	chr3:40313802~40453329:-
BRCA	cis	rs1910358	0.69	rs10076817	ENSG00000248874.4	C5orf17	-3.93	9.2e-05	0.00583	-0.16	-0.12	Venous thromboembolism (SNP x SNP interaction);	chr5:23939564	chr5:23951348~24178263:+
BRCA	cis	rs7722600	0.626	rs73299210	ENSG00000253404.1	AC034243.1	-3.93	9.2e-05	0.00583	-0.21	-0.12	Heart rate;	chr5:137947117	chr5:138744434~138753309:-
BRCA	cis	rs7722600	0.752	rs73299219	ENSG00000253404.1	AC034243.1	-3.93	9.2e-05	0.00583	-0.21	-0.12	Heart rate;	chr5:137950251	chr5:138744434~138753309:-
BRCA	cis	rs7722600	0.745	rs13362264	ENSG00000253404.1	AC034243.1	-3.93	9.2e-05	0.00583	-0.21	-0.12	Heart rate;	chr5:137963749	chr5:138744434~138753309:-
BRCA	cis	rs11642862	1	rs112234000	ENSG00000280211.1	RP11-2C24.3	-3.93	9.2e-05	0.00583	-0.19	-0.12	Tonsillectomy;	chr16:30767487	chr16:30773532~30776033:-
BRCA	cis	rs11642862	1	rs75500538	ENSG00000280211.1	RP11-2C24.3	-3.93	9.2e-05	0.00583	-0.19	-0.12	Tonsillectomy;	chr16:30771128	chr16:30773532~30776033:-
BRCA	cis	rs11098499	0.955	rs1511018	ENSG00000260091.1	RP11-33B1.4	-3.93	9.2e-05	0.00583	-0.11	-0.12	Corneal astigmatism;	chr4:119240425	chr4:119409333~119410233:+
BRCA	cis	rs1865760	0.82	rs9348697	ENSG00000272462.2	U91328.19	-3.93	9.2e-05	0.00583	-0.14	-0.12	Height;	chr6:25890606	chr6:25992662~26001775:+
BRCA	cis	rs7686660	1	rs4690713	ENSG00000250326.1	RP11-284M14.1	-3.93	9.2e-05	0.00583	-0.14	-0.12	Asthma;	chr4:143055418	chr4:142933195~143184861:-
BRCA	cis	rs7267979	1	rs6050544	ENSG00000277938.1	RP5-965G21.3	-3.93	9.2e-05	0.00583	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25339592	chr20:25229150~25231933:+
BRCA	cis	rs2625529	0.775	rs35673773	ENSG00000260037.4	CTD-2524L6.3	-3.93	9.2e-05	0.00583	-0.17	-0.12	Red blood cell count;	chr15:72107545	chr15:71818396~71823384:+
BRCA	cis	rs2015599	0.549	rs7972032	ENSG00000257176.2	RP11-996F15.2	3.93	9.21e-05	0.00583	0.14	0.12	Platelet count;Mean platelet volume;	chr12:29291351	chr12:29280418~29317848:-
BRCA	cis	rs801193	1	rs6958520	ENSG00000273142.1	RP11-458F8.4	-3.93	9.21e-05	0.00583	-0.1	-0.12	Aortic root size;	chr7:66686466	chr7:66902857~66906297:+
BRCA	cis	rs7048146	0.51	rs1109477	ENSG00000213539.4	YBX1P6	-3.93	9.21e-05	0.00584	-0.13	-0.12	Vascular brain injury;	chr9:109519571	chr9:109532830~109534332:-
BRCA	cis	rs4908769	0.66	rs159962	ENSG00000270282.1	RP5-1115A15.2	3.93	9.21e-05	0.00584	0.14	0.12	Allergy;	chr1:8430923	chr1:8512653~8513021:+
BRCA	cis	rs6012564	1	rs3818262	ENSG00000222365.1	SNORD12B	3.93	9.21e-05	0.00584	0.13	0.12	Anger;	chr20:49125019	chr20:49280319~49280409:+
BRCA	cis	rs1934955	0.537	rs7097433	ENSG00000273450.1	RP11-76P2.4	3.93	9.21e-05	0.00584	0.15	0.12	Blood metabolite levels;	chr10:95017209	chr10:94314907~94315327:-
BRCA	cis	rs8049367	0.647	rs2075136	ENSG00000267077.1	RP11-127I20.5	3.93	9.21e-05	0.00584	0.12	0.12	Nonsyndromic cleft lip with or without cleft palate;	chr16:3921279	chr16:4795265~4796532:-
BRCA	cis	rs812925	0.519	rs2694638	ENSG00000270820.4	RP11-355B11.2	-3.93	9.21e-05	0.00584	-0.13	-0.12	Immature fraction of reticulocytes;	chr2:61408228	chr2:61471188~61484130:+
BRCA	cis	rs34421088	0.603	rs10086064	ENSG00000254507.2	RP11-481A20.10	-3.93	9.21e-05	0.00584	-0.15	-0.12	Neuroticism;	chr8:11726332	chr8:12003400~12004082:-
BRCA	cis	rs28374715	0.58	rs8030228	ENSG00000247556.5	OIP5-AS1	3.93	9.21e-05	0.00584	0.13	0.12	Ulcerative colitis;	chr15:41344669	chr15:41283990~41309737:+
BRCA	cis	rs875971	0.895	rs6460278	ENSG00000273024.4	INTS4P2	3.93	9.22e-05	0.00584	0.14	0.12	Aortic root size;	chr7:66197749	chr7:65647864~65715661:+
BRCA	cis	rs875971	0.862	rs6460279	ENSG00000273024.4	INTS4P2	3.93	9.22e-05	0.00584	0.14	0.12	Aortic root size;	chr7:66197774	chr7:65647864~65715661:+
BRCA	cis	rs875971	0.862	rs28491091	ENSG00000273024.4	INTS4P2	3.93	9.22e-05	0.00584	0.14	0.12	Aortic root size;	chr7:66204077	chr7:65647864~65715661:+
BRCA	cis	rs73222236	0.825	rs9834631	ENSG00000239213.4	NCK1-AS1	3.93	9.22e-05	0.00584	0.13	0.12	Coronary artery disease;	chr3:136577757	chr3:136841726~136862054:-
BRCA	cis	rs256438	0.501	rs432267	ENSG00000251050.1	RP11-168A11.4	-3.93	9.22e-05	0.00584	-0.13	-0.12	Serum thyroid-stimulating hormone levels;	chr5:80058824	chr5:80019609~80019920:+
BRCA	cis	rs6005807	0.719	rs58542867	ENSG00000272858.1	CTA-292E10.8	-3.93	9.22e-05	0.00584	-0.22	-0.12	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28592272	chr22:28814914~28815662:+
BRCA	cis	rs875971	1	rs2420820	ENSG00000265600.1	AC006480.1	3.93	9.22e-05	0.00584	0.14	0.12	Aortic root size;	chr7:66626920	chr7:67356680~67356779:+
BRCA	cis	rs1075265	0.783	rs805424	ENSG00000272156.1	RP11-477N3.1	-3.93	9.22e-05	0.00584	-0.12	-0.12	Chronotype;Morning vs. evening chronotype;	chr2:53901098	chr2:54082554~54085066:+
BRCA	cis	rs3617	0.625	rs2071042	ENSG00000242142.1	SERBP1P3	3.93	9.22e-05	0.00584	0.13	0.12	Red blood cell count;Autism spectrum disorder or schizophrenia;	chr3:52830568	chr3:53064283~53065091:-
BRCA	cis	rs721917	0.525	rs2758545	ENSG00000242600.5	MBL1P	3.93	9.22e-05	0.00584	0.15	0.12	Chronic obstructive pulmonary disease;	chr10:79940334	chr10:79904898~79950336:+
BRCA	cis	rs11098403	0.789	rs1380369	ENSG00000225892.3	RP11-384K6.2	3.93	9.22e-05	0.00584	0.12	0.12	Schizophrenia;	chr4:117751194	chr4:118632274~118634759:+
BRCA	cis	rs12908161	0.959	rs17598603	ENSG00000230373.7	GOLGA6L5P	3.93	9.23e-05	0.00585	0.15	0.12	Schizophrenia;	chr15:84656980	chr15:84507885~84516814:-
BRCA	cis	rs2880765	0.546	rs36098649	ENSG00000202081.1	RNU6-1280P	3.93	9.23e-05	0.00585	0.15	0.12	Coronary artery disease;	chr15:85513576	chr15:85651522~85651628:-
BRCA	cis	rs3858526	0.959	rs11039723	ENSG00000224295.2	AC087380.14	3.93	9.23e-05	0.00585	0.18	0.12	DNA methylation (variation);	chr11:5934772	chr11:5518441~5524955:-
BRCA	cis	rs11673344	0.665	rs74435359	ENSG00000267260.1	CTD-2162K18.4	-3.93	9.23e-05	0.00585	-0.18	-0.12	Obesity-related traits;	chr19:36955252	chr19:36773153~36777078:+
BRCA	cis	rs6546324	0.625	rs6752799	ENSG00000236780.4	AC078941.1	3.93	9.23e-05	0.00585	0.21	0.12	Endometriosis;	chr2:67631371	chr2:67123357~67215319:-
BRCA	cis	rs6546324	0.58	rs6724133	ENSG00000236780.4	AC078941.1	3.93	9.23e-05	0.00585	0.21	0.12	Endometriosis;	chr2:67631539	chr2:67123357~67215319:-
BRCA	cis	rs700651	0.789	rs882954	ENSG00000231621.1	AC013264.2	-3.93	9.23e-05	0.00585	-0.12	-0.12	Intracranial aneurysm;	chr2:198042720	chr2:197197991~197199273:+
BRCA	cis	rs2451932	0.744	rs411943	ENSG00000251050.1	RP11-168A11.4	-3.93	9.23e-05	0.00585	-0.13	-0.12	LDL peak particle diameter (total fat intake interaction);	chr5:80058879	chr5:80019609~80019920:+
BRCA	cis	rs6026584	1	rs1407040	ENSG00000270951.1	RP1-309F20.4	-3.93	9.23e-05	0.00585	-0.16	-0.12	Renal function-related traits (BUN);	chr20:58897119	chr20:58876592~58876981:-
BRCA	cis	rs752010	0.811	rs10749836	ENSG00000230638.4	RP11-486B10.4	-3.93	9.23e-05	0.00585	-0.15	-0.12	Lupus nephritis in systemic lupus erythematosus;	chr1:41621189	chr1:41542069~41544310:+
BRCA	cis	rs11637445	0.589	rs4776989	ENSG00000260657.2	RP11-315D16.4	-3.93	9.24e-05	0.00585	-0.15	-0.12	Posterior cortical atrophy and Alzheimer's disease;	chr15:67838346	chr15:68267792~68277994:-
BRCA	cis	rs2274273	1	rs8011834	ENSG00000233924.1	AL160471.6	-3.93	9.24e-05	0.00585	-0.14	-0.12	Protein biomarker;	chr14:55159259	chr14:55004813~55005687:-
BRCA	cis	rs4352251	0.841	rs4539813	ENSG00000212283.1	SNORD89	3.93	9.24e-05	0.00585	0.23	0.12	Adiponectin levels (BMI-adjusted);Adiponectin levels;	chr2:101348905	chr2:101272936~101273049:-
BRCA	cis	rs6472235	0.564	rs35753080	ENSG00000272010.1	CTD-3025N20.3	-3.93	9.24e-05	0.00585	-0.15	-0.12	Plateletcrit;Myopia (pathological);	chr8:66000762	chr8:65591850~65592472:-
BRCA	cis	rs6472235	0.586	rs7814933	ENSG00000272010.1	CTD-3025N20.3	-3.93	9.24e-05	0.00585	-0.15	-0.12	Plateletcrit;Myopia (pathological);	chr8:66000992	chr8:65591850~65592472:-
BRCA	cis	rs3824867	0.92	rs7105122	ENSG00000280615.1	Y_RNA	-3.93	9.24e-05	0.00585	-0.14	-0.12	Mean corpuscular hemoglobin;	chr11:47427993	chr11:47614898~47614994:-
BRCA	cis	rs11168618	0.904	rs10875829	ENSG00000240399.1	RP1-228P16.1	3.93	9.24e-05	0.00585	0.13	0.12	Adiponectin levels;	chr12:48533414	chr12:48054813~48055591:-
BRCA	cis	rs2625529	0.824	rs10518979	ENSG00000260037.4	CTD-2524L6.3	-3.92	9.24e-05	0.00585	-0.18	-0.12	Red blood cell count;	chr15:71976645	chr15:71818396~71823384:+
BRCA	cis	rs5758659	0.716	rs86669	ENSG00000270083.1	RP1-257I20.14	3.92	9.24e-05	0.00585	0.13	0.12	Cognitive function;	chr22:42284794	chr22:42089630~42090028:-
BRCA	cis	rs6480314	0.831	rs17538164	ENSG00000233590.1	RP11-153K11.3	3.92	9.24e-05	0.00586	0.2	0.12	Optic nerve measurement (disc area);	chr10:68215920	chr10:68233251~68242379:-
BRCA	cis	rs6005807	0.719	rs73430179	ENSG00000272858.1	CTA-292E10.8	-3.92	9.24e-05	0.00586	-0.21	-0.12	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28602833	chr22:28814914~28815662:+
BRCA	cis	rs4218	0.597	rs12438962	ENSG00000259732.1	RP11-59H7.3	-3.92	9.25e-05	0.00586	-0.15	-0.12	Social communication problems;	chr15:59065694	chr15:59121034~59133250:+
BRCA	cis	rs6545883	0.894	rs2694642	ENSG00000273302.1	RP11-493E12.2	-3.92	9.25e-05	0.00586	-0.11	-0.12	Tuberculosis;	chr2:61369045	chr2:61199979~61200769:+
BRCA	cis	rs1790761	0.52	rs4930461	ENSG00000255318.1	RP11-655M14.13	3.92	9.25e-05	0.00586	0.14	0.12	Mean corpuscular volume;	chr11:67627424	chr11:67618279~67627304:-
BRCA	cis	rs10487112	0.87	rs12666228	ENSG00000235436.9	DPY19L2P4	-3.92	9.25e-05	0.00586	-0.13	-0.12	Perceived unattractiveness to mosquitoes;	chr7:90486179	chr7:90119400~90125600:+
BRCA	cis	rs11098499	0.863	rs9997631	ENSG00000260091.1	RP11-33B1.4	-3.92	9.25e-05	0.00586	-0.11	-0.12	Corneal astigmatism;	chr4:119548840	chr4:119409333~119410233:+
BRCA	cis	rs35740288	0.822	rs2306225	ENSG00000259407.1	RP11-158M2.3	-3.92	9.25e-05	0.00586	-0.16	-0.12	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85684721	chr15:85744109~85750281:-
BRCA	cis	rs11098499	0.779	rs80242894	ENSG00000260404.2	RP11-384K6.6	3.92	9.25e-05	0.00586	0.11	0.12	Corneal astigmatism;	chr4:119454597	chr4:118591773~118633729:+
BRCA	cis	rs250585	0.667	rs380618	ENSG00000260136.4	CTD-2270L9.4	-3.92	9.25e-05	0.00586	-0.17	-0.12	Egg allergy;	chr16:23594952	chr16:23452758~23457606:+
BRCA	cis	rs3858526	0.916	rs11039551	ENSG00000224295.2	AC087380.14	3.92	9.25e-05	0.00586	0.17	0.12	DNA methylation (variation);	chr11:5909543	chr11:5518441~5524955:-
BRCA	cis	rs6671200	1	rs6678964	ENSG00000226026.4	RP11-57H12.3	3.92	9.25e-05	0.00586	0.22	0.12	Stearic acid (18:0) levels;	chr1:95228712	chr1:95163219~95233982:-
BRCA	cis	rs2271404	0.506	rs10197366	ENSG00000227992.1	AC108463.2	3.92	9.25e-05	0.00586	0.15	0.12	Atopic dermatitis;	chr2:111239208	chr2:111203964~111206215:-
BRCA	cis	rs7267979	1	rs6515651	ENSG00000274973.1	RP13-401N8.7	3.92	9.25e-05	0.00586	0.14	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25433903	chr20:25845497~25845862:+
BRCA	cis	rs3764021	0.837	rs7306557	ENSG00000256582.1	RP11-75L1.1	3.92	9.26e-05	0.00586	0.12	0.12	Type 1 diabetes;	chr12:9724760	chr12:9704077~9709350:+
BRCA	cis	rs321358	0.731	rs17459717	ENSG00000271390.1	RP11-89C3.3	3.92	9.26e-05	0.00586	0.19	0.12	Body mass index;	chr11:111139862	chr11:111089870~111090368:-
BRCA	cis	rs62458065	0.513	rs10245103	ENSG00000229358.3	DPY19L1P1	-3.92	9.26e-05	0.00586	-0.16	-0.12	Metabolite levels (HVA/MHPG ratio);	chr7:32495217	chr7:32580949~32761787:-
BRCA	cis	rs7312933	0.558	rs11181463	ENSG00000257225.1	RP11-328C8.4	-3.92	9.26e-05	0.00586	-0.15	-0.12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42369834	chr12:42459366~42466128:+
BRCA	cis	rs793571	0.822	rs10518991	ENSG00000259250.1	RP11-50C13.1	-3.92	9.26e-05	0.00586	-0.18	-0.12	Schizophrenia;	chr15:58898731	chr15:58587507~58591676:+
BRCA	cis	rs2991971	0.934	rs11211129	ENSG00000280836.1	AL355480.1	3.92	9.26e-05	0.00586	0.14	0.12	High light scatter reticulocyte count;	chr1:45517408	chr1:45581219~45581321:-
BRCA	cis	rs10043228	0.826	rs12520613	ENSG00000271918.1	CTD-2287O16.5	-3.92	9.26e-05	0.00586	-0.17	-0.12	Asthma or chronic obstructive pulmonary disease;	chr5:116286023	chr5:116083807~116085416:-
BRCA	cis	rs2139634	0.599	rs6791703	ENSG00000280173.1	RP11-447D11.3	3.92	9.26e-05	0.00586	0.1	0.12	Cerebrospinal fluid biomarker levels;	chr3:46528231	chr3:47346950~47349073:+
BRCA	cis	rs9470794	1	rs11755192	ENSG00000204110.6	RP1-153P14.8	-3.92	9.26e-05	0.00586	-0.19	-0.12	Type 2 diabetes;	chr6:38160488	chr6:37507348~37535616:+
BRCA	cis	rs9470794	0.915	rs11753067	ENSG00000204110.6	RP1-153P14.8	-3.92	9.26e-05	0.00586	-0.19	-0.12	Type 2 diabetes;	chr6:38160535	chr6:37507348~37535616:+
BRCA	cis	rs2274459	1	rs34460651	ENSG00000249346.5	LINC01016	3.92	9.26e-05	0.00587	0.16	0.12	Obesity (extreme);	chr6:33763535	chr6:33867506~33896914:-
BRCA	cis	rs2186369	0.948	rs12167679	ENSG00000211683.3	KB-1572G7.3	-3.92	9.26e-05	0.00587	-0.17	-0.12	IgG N-glycosylation phenotypes (multivariate analysis);IgG digalactosylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG glycosylation;IgG fucosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);	chr22:23799503	chr22:23630618~23638941:-
BRCA	cis	rs3764021	0.868	rs7306304	ENSG00000256582.1	RP11-75L1.1	3.92	9.26e-05	0.00587	0.12	0.12	Type 1 diabetes;	chr12:9724600	chr12:9704077~9709350:+
BRCA	cis	rs4664293	1	rs6432540	ENSG00000224152.1	AC009506.1	-3.92	9.26e-05	0.00587	-0.13	-0.12	Monocyte percentage of white cells;	chr2:159594192	chr2:159615296~159617082:+
BRCA	cis	rs6736093	1	rs11673729	ENSG00000236307.2	EEF1E1P1	-3.92	9.27e-05	0.00587	-0.15	-0.12	Coronary artery disease;	chr2:111908384	chr2:111887914~111888741:+
BRCA	cis	rs718433	0.782	rs11157216	ENSG00000256379.1	TRAV8-5	3.92	9.27e-05	0.00587	0.14	0.12	Intraocular pressure;	chr14:21773507	chr14:21903077~21903598:+
BRCA	cis	rs2109514	0.792	rs4727831	ENSG00000237813.3	AC002066.1	3.92	9.27e-05	0.00587	0.15	0.12	Prevalent atrial fibrillation;	chr7:116453929	chr7:116238260~116499465:-
BRCA	cis	rs4908769	0.66	rs172531	ENSG00000270282.1	RP5-1115A15.2	-3.92	9.27e-05	0.00587	-0.14	-0.12	Allergy;	chr1:8435530	chr1:8512653~8513021:+
BRCA	cis	rs4664293	0.647	rs7580816	ENSG00000226266.5	AC009961.3	-3.92	9.27e-05	0.00587	-0.14	-0.12	Monocyte percentage of white cells;	chr2:159619370	chr2:159670708~159712435:-
BRCA	cis	rs11098499	0.954	rs17005535	ENSG00000260404.2	RP11-384K6.6	3.92	9.27e-05	0.00587	0.11	0.12	Corneal astigmatism;	chr4:119490407	chr4:118591773~118633729:+
BRCA	cis	rs4689592	0.503	rs10516184	ENSG00000245468.3	RP11-367J11.3	3.92	9.27e-05	0.00587	0.14	0.12	Monocyte percentage of white cells;	chr4:7059232	chr4:7094571~7103385:-
BRCA	cis	rs12368653	0.693	rs2640610	ENSG00000257159.1	RP11-58A17.3	-3.92	9.27e-05	0.00587	-0.14	-0.12	Multiple sclerosis;	chr12:57643652	chr12:57967058~57968399:+
BRCA	cis	rs375066	0.901	rs1050054	ENSG00000267191.1	RP11-15A1.2	-3.92	9.27e-05	0.00587	-0.15	-0.12	Breast cancer;	chr19:43872529	chr19:43902001~43926545:+
BRCA	cis	rs875971	0.789	rs28815324	ENSG00000273142.1	RP11-458F8.4	-3.92	9.27e-05	0.00587	-0.12	-0.12	Aortic root size;	chr7:66100789	chr7:66902857~66906297:+
BRCA	cis	rs7395581	0.918	rs10501321	ENSG00000280615.1	Y_RNA	3.92	9.28e-05	0.00587	0.14	0.12	HDL cholesterol;	chr11:47273075	chr11:47614898~47614994:-
BRCA	cis	rs10129255	0.957	rs6576233	ENSG00000211967.3	IGHV3-53	-3.92	9.28e-05	0.00587	-0.09	-0.12	Kawasaki disease;	chr14:106787239	chr14:106592676~106593347:-
BRCA	cis	rs61542988	0.606	rs4722185	ENSG00000228649.7	AC005682.5	3.92	9.28e-05	0.00587	0.13	0.12	Fibrinogen levels;	chr7:22793092	chr7:22854178~22861579:+
BRCA	cis	rs2301573	0.504	rs79592825	ENSG00000271270.4	TMCC1-AS1	-3.92	9.28e-05	0.00587	-0.26	-0.12	Hip circumference;	chr3:129844012	chr3:129893871~129918575:+
BRCA	cis	rs1048886	0.872	rs77665410	ENSG00000271967.1	RP11-134K13.4	-3.92	9.28e-05	0.00587	-0.18	-0.12	Type 2 diabetes;	chr6:70569676	chr6:70596438~70596980:+
BRCA	cis	rs1048886	0.872	rs79339185	ENSG00000271967.1	RP11-134K13.4	-3.92	9.28e-05	0.00587	-0.18	-0.12	Type 2 diabetes;	chr6:70572379	chr6:70596438~70596980:+
BRCA	cis	rs4302906	0.964	rs10739940	ENSG00000187984.11	ANKRD19P	3.92	9.28e-05	0.00588	0.11	0.12	Lobe attachment (rater-scored or self-reported);	chr9:92984178	chr9:92809388~92888693:+
BRCA	cis	rs751728	0.664	rs2296744	ENSG00000224557.6	HLA-DPB2	-3.92	9.28e-05	0.00588	-0.14	-0.12	Crohn's disease;	chr6:33772605	chr6:33112451~33129084:+
BRCA	cis	rs4664293	1	rs2357382	ENSG00000226266.5	AC009961.3	-3.92	9.28e-05	0.00588	-0.15	-0.12	Monocyte percentage of white cells;	chr2:159636614	chr2:159670708~159712435:-
BRCA	cis	rs2562456	0.617	rs34203148	ENSG00000268555.1	RP11-678G14.3	3.92	9.29e-05	0.00588	0.16	0.12	Pain;	chr19:21590743	chr19:21570822~21587322:-
BRCA	cis	rs375066	0.935	rs10414702	ENSG00000278917.1	RP11-15A1.4	-3.92	9.29e-05	0.00588	-0.14	-0.12	Breast cancer;	chr19:43876384	chr19:43891233~43895411:+
BRCA	cis	rs375066	0.935	rs10421518	ENSG00000278917.1	RP11-15A1.4	-3.92	9.29e-05	0.00588	-0.14	-0.12	Breast cancer;	chr19:43877134	chr19:43891233~43895411:+
BRCA	cis	rs375066	0.87	rs7258418	ENSG00000278917.1	RP11-15A1.4	-3.92	9.29e-05	0.00588	-0.14	-0.12	Breast cancer;	chr19:43878931	chr19:43891233~43895411:+
BRCA	cis	rs2904967	0.5	rs3896078	ENSG00000254501.1	AP003068.9	3.92	9.29e-05	0.00588	0.27	0.12	Mean corpuscular volume;	chr11:65106790	chr11:65110714~65111695:-
BRCA	cis	rs56322409	0.897	rs4918966	ENSG00000226688.5	ENTPD1-AS1	3.92	9.29e-05	0.00588	0.14	0.12	Blood metabolite levels;	chr10:95753605	chr10:95753206~96090238:-
BRCA	cis	rs755249	0.567	rs61779306	ENSG00000182109.6	RP11-69E11.4	3.92	9.29e-05	0.00588	0.17	0.12	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39456754	chr1:39522280~39546187:-
BRCA	cis	rs6964587	0.732	rs12539523	ENSG00000188693.7	CYP51A1-AS1	-3.92	9.29e-05	0.00588	-0.13	-0.12	Breast cancer;	chr7:92081522	chr7:92134604~92180725:+
BRCA	cis	rs1005277	0.579	rs1740732	ENSG00000272983.1	RP11-508N22.12	3.92	9.3e-05	0.00588	0.13	0.12	Extrinsic epigenetic age acceleration;	chr10:38202457	chr10:38137337~38144399:+
BRCA	cis	rs875971	0.862	rs908915	ENSG00000271064.1	RP11-792A8.3	3.92	9.3e-05	0.00588	0.14	0.12	Aortic root size;	chr7:66149664	chr7:66748838~66749077:-
BRCA	cis	rs2274273	0.712	rs6572999	ENSG00000259318.1	RP11-454L9.2	3.92	9.3e-05	0.00588	0.1	0.12	Protein biomarker;	chr14:55060656	chr14:55394940~55395233:-
BRCA	cis	rs3764021	0.87	rs7307111	ENSG00000256582.1	RP11-75L1.1	3.92	9.3e-05	0.00589	0.12	0.12	Type 1 diabetes;	chr12:9725227	chr12:9704077~9709350:+
BRCA	cis	rs9381040	0.61	rs2235679	ENSG00000161912.16	ADCY10P1	3.92	9.3e-05	0.00589	0.13	0.12	Alzheimer's disease (late onset);	chr6:41052838	chr6:41101022~41140835:+
BRCA	cis	rs757081	0.648	rs7940253	ENSG00000272034.1	SNORD14A	-3.92	9.3e-05	0.00589	-0.13	-0.12	Systolic blood pressure;	chr11:17259049	chr11:17074654~17074744:-
BRCA	cis	rs6452524	0.935	rs1580310	ENSG00000281327.1	LINC01338	3.92	9.31e-05	0.00589	0.14	0.12	Hypertension (SNP x SNP interaction);	chr5:83091792	chr5:82850864~82859836:-
BRCA	cis	rs6952407	1	rs6952407	ENSG00000232546.1	RP11-458F8.1	3.92	9.31e-05	0.00589	0.1	0.12	Cotinine glucuronidation;	chr7:66580525	chr7:66848496~66858136:+
BRCA	cis	rs4650943	0.565	rs184764	ENSG00000227740.1	RP11-318C24.2	3.92	9.31e-05	0.00589	0.12	0.12	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in inactive individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr1:176268085	chr1:175904762~175920513:-
BRCA	cis	rs1198430	1	rs1198434	ENSG00000271420.1	RP5-1057J7.7	3.92	9.31e-05	0.00589	0.16	0.12	Total cholesterol levels;	chr1:23431641	chr1:23378380~23379029:-
BRCA	cis	rs4908769	0.624	rs301791	ENSG00000270282.1	RP5-1115A15.2	-3.92	9.31e-05	0.00589	-0.14	-0.12	Allergy;	chr1:8408312	chr1:8512653~8513021:+
BRCA	cis	rs728616	0.867	rs61860044	ENSG00000242600.5	MBL1P	3.92	9.31e-05	0.00589	0.3	0.12	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80186782	chr10:79904898~79950336:+
BRCA	cis	rs73201462	1	rs57699322	ENSG00000242551.2	POU5F1P6	3.92	9.31e-05	0.00589	0.2	0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128346470	chr3:128674735~128677005:-
BRCA	cis	rs863345	0.625	rs4609418	ENSG00000229914.1	RP11-404O13.4	-3.92	9.31e-05	0.00589	-0.13	-0.12	Pneumococcal bacteremia;	chr1:158494938	chr1:158195633~158196131:-
BRCA	cis	rs448720	1	rs379281	ENSG00000260657.2	RP11-315D16.4	-3.92	9.31e-05	0.00589	-0.14	-0.12	Cognitive performance;	chr15:67918362	chr15:68267792~68277994:-
BRCA	cis	rs11098499	0.57	rs6832740	ENSG00000260091.1	RP11-33B1.4	-3.92	9.32e-05	0.0059	-0.1	-0.12	Corneal astigmatism;	chr4:119624981	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.644	rs6855918	ENSG00000260091.1	RP11-33B1.4	-3.92	9.32e-05	0.0059	-0.1	-0.12	Corneal astigmatism;	chr4:119625144	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.866	rs6857892	ENSG00000260404.2	RP11-384K6.6	3.92	9.32e-05	0.0059	0.11	0.12	Corneal astigmatism;	chr4:119361541	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.909	rs28581362	ENSG00000260404.2	RP11-384K6.6	3.92	9.32e-05	0.0059	0.11	0.12	Corneal astigmatism;	chr4:119362393	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.82	rs12503082	ENSG00000260404.2	RP11-384K6.6	3.92	9.32e-05	0.0059	0.11	0.12	Corneal astigmatism;	chr4:119363162	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.866	rs12499602	ENSG00000260404.2	RP11-384K6.6	3.92	9.32e-05	0.0059	0.11	0.12	Corneal astigmatism;	chr4:119363232	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.774	rs11098505	ENSG00000260404.2	RP11-384K6.6	3.92	9.32e-05	0.0059	0.11	0.12	Corneal astigmatism;	chr4:119363472	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.866	rs13105020	ENSG00000260404.2	RP11-384K6.6	3.92	9.32e-05	0.0059	0.11	0.12	Corneal astigmatism;	chr4:119364533	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.866	rs6824111	ENSG00000260404.2	RP11-384K6.6	3.92	9.32e-05	0.0059	0.11	0.12	Corneal astigmatism;	chr4:119364813	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.775	rs10029303	ENSG00000260404.2	RP11-384K6.6	3.92	9.32e-05	0.0059	0.11	0.12	Corneal astigmatism;	chr4:119365600	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.866	rs9995136	ENSG00000260404.2	RP11-384K6.6	3.92	9.32e-05	0.0059	0.11	0.12	Corneal astigmatism;	chr4:119365690	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.866	rs13125526	ENSG00000260404.2	RP11-384K6.6	3.92	9.32e-05	0.0059	0.11	0.12	Corneal astigmatism;	chr4:119366864	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.866	rs12513310	ENSG00000260404.2	RP11-384K6.6	3.92	9.32e-05	0.0059	0.11	0.12	Corneal astigmatism;	chr4:119366884	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.866	rs12510451	ENSG00000260404.2	RP11-384K6.6	3.92	9.32e-05	0.0059	0.11	0.12	Corneal astigmatism;	chr4:119367988	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.774	rs73842616	ENSG00000260404.2	RP11-384K6.6	3.92	9.32e-05	0.0059	0.11	0.12	Corneal astigmatism;	chr4:119369528	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.645	rs72676059	ENSG00000260404.2	RP11-384K6.6	3.92	9.32e-05	0.0059	0.11	0.12	Corneal astigmatism;	chr4:119369673	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.569	rs55845118	ENSG00000260404.2	RP11-384K6.6	3.92	9.32e-05	0.0059	0.11	0.12	Corneal astigmatism;	chr4:119369758	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.866	rs7677068	ENSG00000260404.2	RP11-384K6.6	3.92	9.32e-05	0.0059	0.11	0.12	Corneal astigmatism;	chr4:119370549	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.866	rs9991221	ENSG00000260404.2	RP11-384K6.6	3.92	9.32e-05	0.0059	0.11	0.12	Corneal astigmatism;	chr4:119370952	chr4:118591773~118633729:+
BRCA	cis	rs73201462	1	rs11709611	ENSG00000242551.2	POU5F1P6	3.92	9.32e-05	0.0059	0.21	0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128348432	chr3:128674735~128677005:-
BRCA	cis	rs1124769	0.506	rs2614766	ENSG00000273674.3	CTD-2378E12.1	-3.92	9.32e-05	0.0059	-0.14	-0.12	Cognitive performance;	chr15:50852394	chr15:50839875~50908599:-
BRCA	cis	rs2625529	0.824	rs16956452	ENSG00000260037.4	CTD-2524L6.3	-3.92	9.32e-05	0.0059	-0.18	-0.12	Red blood cell count;	chr15:71991751	chr15:71818396~71823384:+
BRCA	cis	rs6686842	0.536	rs12121121	ENSG00000235358.1	RP11-399E6.1	-3.92	9.32e-05	0.0059	-0.16	-0.12	Height;	chr1:41218784	chr1:41242373~41284861:+
BRCA	cis	rs11175492	1	rs7307915	ENSG00000255693.1	RP11-766N7.3	3.92	9.32e-05	0.0059	0.28	0.12	Platelet count;	chr12:64687080	chr12:64883394~64977522:+
BRCA	cis	rs17772222	0.917	rs2224333	ENSG00000258789.1	RP11-507K2.3	-3.92	9.32e-05	0.0059	-0.15	-0.12	Coronary artery calcification;	chr14:88768748	chr14:88551597~88552493:+
BRCA	cis	rs17772222	0.917	rs12590826	ENSG00000258789.1	RP11-507K2.3	-3.92	9.32e-05	0.0059	-0.15	-0.12	Coronary artery calcification;	chr14:88769357	chr14:88551597~88552493:+
BRCA	cis	rs2562456	0.833	rs2562487	ENSG00000268555.1	RP11-678G14.3	3.92	9.33e-05	0.0059	0.16	0.12	Pain;	chr19:21468580	chr19:21570822~21587322:-
BRCA	cis	rs375066	0.935	rs396973	ENSG00000278917.1	RP11-15A1.4	3.92	9.33e-05	0.0059	0.14	0.12	Breast cancer;	chr19:43895154	chr19:43891233~43895411:+
BRCA	cis	rs6736093	0.966	rs870763	ENSG00000236307.2	EEF1E1P1	3.92	9.33e-05	0.0059	0.15	0.12	Coronary artery disease;	chr2:111987904	chr2:111887914~111888741:+
BRCA	cis	rs11168618	0.561	rs4075258	ENSG00000240399.1	RP1-228P16.1	3.92	9.33e-05	0.0059	0.13	0.12	Adiponectin levels;	chr12:48525876	chr12:48054813~48055591:-
BRCA	cis	rs62458065	0.64	rs6950077	ENSG00000229358.3	DPY19L1P1	3.92	9.33e-05	0.0059	0.17	0.12	Metabolite levels (HVA/MHPG ratio);	chr7:32463283	chr7:32580949~32761787:-
BRCA	cis	rs8114671	0.527	rs6088650	ENSG00000126005.14	MMP24-AS1	3.92	9.34e-05	0.00591	0.14	0.12	Height;	chr20:34926662	chr20:35216462~35278131:-
BRCA	cis	rs11098499	1	rs11726229	ENSG00000260404.2	RP11-384K6.6	3.92	9.34e-05	0.00591	0.12	0.12	Corneal astigmatism;	chr4:119290425	chr4:118591773~118633729:+
BRCA	cis	rs6012564	1	rs6122763	ENSG00000222365.1	SNORD12B	-3.92	9.34e-05	0.00591	-0.13	-0.12	Anger;	chr20:49181116	chr20:49280319~49280409:+
BRCA	cis	rs6452524	0.901	rs1600362	ENSG00000281327.1	LINC01338	3.92	9.34e-05	0.00591	0.14	0.12	Hypertension (SNP x SNP interaction);	chr5:83091354	chr5:82850864~82859836:-
BRCA	cis	rs875971	0.767	rs1643394	ENSG00000273024.4	INTS4P2	-3.92	9.34e-05	0.00591	-0.13	-0.12	Aortic root size;	chr7:66371107	chr7:65647864~65715661:+
BRCA	cis	rs11098499	0.954	rs3733519	ENSG00000260404.2	RP11-384K6.6	3.92	9.34e-05	0.00591	0.12	0.12	Corneal astigmatism;	chr4:119502293	chr4:118591773~118633729:+
BRCA	cis	rs7412746	0.586	rs2864882	ENSG00000231073.1	RP11-316M1.3	3.92	9.35e-05	0.00591	0.13	0.12	Melanoma;	chr1:150910561	chr1:150973123~150975534:+
BRCA	cis	rs875971	0.862	rs6460302	ENSG00000273024.4	INTS4P2	-3.92	9.35e-05	0.00591	-0.13	-0.12	Aortic root size;	chr7:66495270	chr7:65647864~65715661:+
BRCA	cis	rs1150668	0.796	rs9468372	ENSG00000270326.1	RP5-874C20.6	-3.92	9.35e-05	0.00591	-0.15	-0.12	Pubertal anthropometrics;	chr6:28411584	chr6:28319660~28319852:-
BRCA	cis	rs304029	0.512	rs55647430	ENSG00000231249.1	ITPR1-AS1	-3.92	9.35e-05	0.00591	-0.16	-0.12	Diabetic kidney disease;	chr3:4503580	chr3:4490891~4493163:-
BRCA	cis	rs6430585	0.64	rs6716070	ENSG00000224043.6	CCNT2-AS1	3.92	9.35e-05	0.00592	0.19	0.12	Corneal structure;	chr2:135787081	chr2:134735464~134918710:-
BRCA	cis	rs35520189	0.857	rs2466446	ENSG00000189223.12	PAX8-AS1	3.92	9.35e-05	0.00592	0.17	0.12	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:112865703	chr2:113211522~113276581:+
BRCA	cis	rs10129255	0.518	rs7143784	ENSG00000211959.2	IGHV4-39	3.92	9.35e-05	0.00592	0.08	0.12	Kawasaki disease;	chr14:106687277	chr14:106421711~106422218:-
BRCA	cis	rs647097	0.694	rs563610	ENSG00000272788.1	RP11-674N23.4	3.92	9.36e-05	0.00592	0.18	0.12	Chronic obstructive pulmonary disease;	chr18:8799296	chr18:8801656~8802305:+
BRCA	cis	rs2486012	0.737	rs641356	ENSG00000237950.1	RP11-7O11.3	3.92	9.36e-05	0.00592	0.2	0.12	Intelligence (multi-trait analysis);	chr1:43821514	chr1:43944370~43946551:-
BRCA	cis	rs10864907	0.681	rs10177563	ENSG00000231747.1	AC079922.2	-3.92	9.36e-05	0.00592	-0.11	-0.12	Pulmonary function;	chr2:112970742	chr2:112621809~112622167:-
BRCA	cis	rs10421328	0.821	rs10405234	ENSG00000267419.1	CTC-559E9.6	-3.92	9.36e-05	0.00592	-0.13	-0.12	Parental longevity (combined parental age at death);	chr19:19645853	chr19:19776602~19834927:+
BRCA	cis	rs11048470	0.569	rs4963983	ENSG00000256894.1	RP11-283G6.3	-3.92	9.36e-05	0.00592	-0.13	-0.12	Waist-hip ratio;	chr12:26334725	chr12:26125155~26126617:-
BRCA	cis	rs35306767	0.903	rs35370435	ENSG00000229869.1	RP11-363N22.2	-3.92	9.36e-05	0.00592	-0.21	-0.12	Eosinophil percentage of granulocytes;	chr10:852265	chr10:933026~942743:+
BRCA	cis	rs35306767	0.807	rs12768348	ENSG00000229869.1	RP11-363N22.2	-3.92	9.36e-05	0.00592	-0.21	-0.12	Eosinophil percentage of granulocytes;	chr10:853284	chr10:933026~942743:+
BRCA	cis	rs6964587	1	rs10228800	ENSG00000188693.7	CYP51A1-AS1	-3.92	9.36e-05	0.00592	-0.13	-0.12	Breast cancer;	chr7:91980797	chr7:92134604~92180725:+
BRCA	cis	rs6964587	1	rs6976122	ENSG00000188693.7	CYP51A1-AS1	-3.92	9.36e-05	0.00592	-0.13	-0.12	Breast cancer;	chr7:91981648	chr7:92134604~92180725:+
BRCA	cis	rs6964587	1	rs13230588	ENSG00000188693.7	CYP51A1-AS1	-3.92	9.36e-05	0.00592	-0.13	-0.12	Breast cancer;	chr7:91986113	chr7:92134604~92180725:+
BRCA	cis	rs10043228	0.826	rs77863323	ENSG00000271918.1	CTD-2287O16.5	-3.92	9.36e-05	0.00592	-0.17	-0.12	Asthma or chronic obstructive pulmonary disease;	chr5:116113415	chr5:116083807~116085416:-
BRCA	cis	rs10043228	1	rs79404901	ENSG00000271918.1	CTD-2287O16.5	-3.92	9.36e-05	0.00592	-0.17	-0.12	Asthma or chronic obstructive pulmonary disease;	chr5:116113635	chr5:116083807~116085416:-
BRCA	cis	rs4664293	0.647	rs7580539	ENSG00000224152.1	AC009506.1	-3.92	9.36e-05	0.00592	-0.13	-0.12	Monocyte percentage of white cells;	chr2:159589238	chr2:159615296~159617082:+
BRCA	cis	rs4664293	0.539	rs7580661	ENSG00000224152.1	AC009506.1	-3.92	9.36e-05	0.00592	-0.13	-0.12	Monocyte percentage of white cells;	chr2:159589326	chr2:159615296~159617082:+
BRCA	cis	rs875971	0.651	rs2420596	ENSG00000229886.1	RP5-1132H15.3	3.92	9.36e-05	0.00592	0.14	0.12	Aortic root size;	chr7:66450996	chr7:66025126~66031544:-
BRCA	cis	rs875971	0.52	rs2420597	ENSG00000229886.1	RP5-1132H15.3	3.92	9.36e-05	0.00592	0.14	0.12	Aortic root size;	chr7:66450999	chr7:66025126~66031544:-
BRCA	cis	rs77633900	0.772	rs157768	ENSG00000196274.5	Metazoa_SRP	3.92	9.36e-05	0.00592	0.2	0.12	Glioma;Non-glioblastoma glioma;	chr15:76541438	chr15:76230048~76230390:-
BRCA	cis	rs13423976	0.78	rs6720282	ENSG00000231367.4	AC016995.3	-3.92	9.36e-05	0.00592	-0.14	-0.12	Gut microbiome composition (summer);	chr2:38545045	chr2:38406719~38515740:-
BRCA	cis	rs6545883	0.86	rs777589	ENSG00000270820.4	RP11-355B11.2	3.92	9.36e-05	0.00592	0.14	0.12	Tuberculosis;	chr2:61198486	chr2:61471188~61484130:+
BRCA	cis	rs2613964	0.548	rs9870733	ENSG00000240057.4	RP11-572M11.4	3.92	9.36e-05	0.00592	0.12	0.12	Pediatric bone mineral content (spine);Pediatric bone mineral density (spine);	chr3:113130407	chr3:113019532~113183301:+
BRCA	cis	rs1479090	0.805	rs6536702	ENSG00000250027.1	RP11-563E2.2	-3.92	9.37e-05	0.00592	-0.16	-0.12	Lung cancer;	chr4:163106953	chr4:163108785~163119965:+
BRCA	cis	rs7722600	0.808	rs73300168	ENSG00000253404.1	AC034243.1	-3.92	9.37e-05	0.00592	-0.21	-0.12	Heart rate;	chr5:137934966	chr5:138744434~138753309:-
BRCA	cis	rs7246967	0.673	rs368144	ENSG00000198153.8	ZNF849P	-3.92	9.37e-05	0.00592	-0.18	-0.12	Bronchopulmonary dysplasia;	chr19:22817985	chr19:22685167~22686732:+
BRCA	cis	rs6565180	0.888	rs12447833	ENSG00000261332.1	RP11-297C4.1	3.92	9.37e-05	0.00592	0.17	0.12	Tonsillectomy;	chr16:30378993	chr16:30498766~30499554:-
BRCA	cis	rs1529711	0.5	rs17616023	ENSG00000267100.1	ILF3-AS1	-3.92	9.37e-05	0.00592	-0.2	-0.12	C-reactive protein levels or total cholesterol levels (pleiotropy);C-reactive protein levels or LDL-cholesterol levels (pleiotropy);	chr19:10792118	chr19:10651862~10653844:-
BRCA	cis	rs897984	0.568	rs8063565	ENSG00000274678.1	RP11-2C24.7	-3.92	9.37e-05	0.00593	-0.15	-0.12	Dementia with Lewy bodies;	chr16:30872644	chr16:30821338~30821884:+
BRCA	cis	rs897984	0.52	rs12928081	ENSG00000274678.1	RP11-2C24.7	-3.92	9.37e-05	0.00593	-0.15	-0.12	Dementia with Lewy bodies;	chr16:30873838	chr16:30821338~30821884:+
BRCA	cis	rs4664293	0.669	rs357021	ENSG00000226266.5	AC009961.3	-3.92	9.37e-05	0.00593	-0.14	-0.12	Monocyte percentage of white cells;	chr2:159632572	chr2:159670708~159712435:-
BRCA	cis	rs2625529	0.824	rs4777475	ENSG00000260037.4	CTD-2524L6.3	-3.92	9.37e-05	0.00593	-0.17	-0.12	Red blood cell count;	chr15:71925865	chr15:71818396~71823384:+
BRCA	cis	rs801193	1	rs7788576	ENSG00000273142.1	RP11-458F8.4	3.92	9.37e-05	0.00593	0.1	0.12	Aortic root size;	chr7:66683315	chr7:66902857~66906297:+
BRCA	cis	rs10761482	0.861	rs2393625	ENSG00000254271.1	RP11-131N11.4	-3.92	9.37e-05	0.00593	-0.17	-0.12	Schizophrenia;	chr10:60359448	chr10:60734342~60741828:+
BRCA	cis	rs2346177	0.58	rs1530628	ENSG00000279254.1	RP11-536C12.1	-3.92	9.38e-05	0.00593	-0.14	-0.12	HDL cholesterol;	chr2:46443802	chr2:46668870~46670778:+
BRCA	cis	rs801193	0.636	rs10233806	ENSG00000273448.1	RP11-166O4.6	-3.92	9.38e-05	0.00593	-0.11	-0.12	Aortic root size;	chr7:66653261	chr7:67333047~67334383:+
BRCA	cis	rs7481584	0.624	rs375579	ENSG00000236710.1	AC108448.2	3.92	9.38e-05	0.00593	0.16	0.12	Calcium levels;	chr11:3044070	chr11:3084393~3085443:-
BRCA	cis	rs28374715	0.578	rs17730888	ENSG00000247556.5	OIP5-AS1	3.92	9.38e-05	0.00593	0.14	0.12	Ulcerative colitis;	chr15:41345349	chr15:41283990~41309737:+
BRCA	cis	rs1153858	1	rs2056493	ENSG00000275672.1	GATM-AS1	-3.92	9.38e-05	0.00593	-0.16	-0.12	Homoarginine levels;	chr15:45356074	chr15:45378700~45380123:+
BRCA	cis	rs1549733	0.577	rs67436597	ENSG00000229754.1	CXCR2P1	-3.92	9.38e-05	0.00593	-0.12	-0.12	Optic disc area;	chr2:217553717	chr2:218059155~218065729:-
BRCA	cis	rs9637599	0.513	rs9995984	ENSG00000246375.2	RP11-10L7.1	3.92	9.38e-05	0.00593	0.15	0.12	Metabolite levels (small molecules and protein measures);	chr4:88303936	chr4:88284942~88331421:+
BRCA	cis	rs11098499	0.866	rs72676074	ENSG00000260404.2	RP11-384K6.6	3.92	9.38e-05	0.00593	0.11	0.12	Corneal astigmatism;	chr4:119438686	chr4:118591773~118633729:+
BRCA	cis	rs2048656	0.523	rs1976673	ENSG00000233609.3	RP11-62H7.2	3.92	9.38e-05	0.00593	0.12	0.12	Schizophrenia;	chr8:9822270	chr8:8961200~8979025:+
BRCA	cis	rs1075265	0.68	rs6715488	ENSG00000272156.1	RP11-477N3.1	-3.92	9.38e-05	0.00593	-0.12	-0.12	Chronotype;Morning vs. evening chronotype;	chr2:54004130	chr2:54082554~54085066:+
BRCA	cis	rs2115630	0.905	rs1975277	ENSG00000275120.1	RP11-182J1.17	-3.92	9.38e-05	0.00593	-0.14	-0.12	P wave terminal force;	chr15:84786327	chr15:84599434~84606463:-
BRCA	cis	rs372883	0.53	rs2832302	ENSG00000176054.6	RPL23P2	-3.92	9.39e-05	0.00593	-0.13	-0.12	Pancreatic cancer;	chr21:29377473	chr21:28997613~28998033:-
BRCA	cis	rs516805	0.561	rs9490497	ENSG00000279114.1	RP3-425C14.5	-3.92	9.39e-05	0.00593	-0.17	-0.12	Lymphocyte counts;	chr6:122615904	chr6:122471923~122484161:+
BRCA	cis	rs875971	0.66	rs801193	ENSG00000232546.1	RP11-458F8.1	3.92	9.39e-05	0.00594	0.1	0.12	Aortic root size;	chr7:66565625	chr7:66848496~66858136:+
BRCA	cis	rs9500256	1	rs9500256	ENSG00000272541.1	XXbac-BPGBPG55C20.1	-3.92	9.39e-05	0.00594	-0.13	-0.12	Eosinophilic esophagitis (pediatric);	chr6:57982677	chr6:57855891~57856468:-
BRCA	cis	rs4415084	0.8	rs994793	ENSG00000248779.1	RP11-53O19.2	3.92	9.39e-05	0.00594	0.11	0.12	Breast cancer;	chr5:44743145	chr5:44752949~44765744:+
BRCA	cis	rs1015362	0.503	rs4911371	ENSG00000275784.1	RP5-1125A11.6	-3.92	9.39e-05	0.00594	-0.17	-0.12	Freckles;Red vs. non-red hair color;Skin sensitivity to sun;Burning and freckling;	chr20:33904096	chr20:33989480~33991818:-
BRCA	cis	rs13118159	0.934	rs2878608	ENSG00000254094.1	AC078852.1	-3.92	9.39e-05	0.00594	-0.13	-0.12	Longevity;	chr4:1360498	chr4:1356581~1358075:+
BRCA	cis	rs317865	0.609	rs73234660	ENSG00000263327.5	TAPT1-AS1	-3.92	9.39e-05	0.00594	-0.21	-0.12	Kidney disease (early stage) in type 1 diabetes;	chr4:16219424	chr4:16226685~16320140:+
BRCA	cis	rs1910358	0.747	rs1354169	ENSG00000248874.4	C5orf17	-3.92	9.4e-05	0.00594	-0.17	-0.12	Venous thromboembolism (SNP x SNP interaction);	chr5:23965325	chr5:23951348~24178263:+
BRCA	cis	rs1738074	0.536	rs3117151	ENSG00000271913.4	RP1-111C20.4	-3.92	9.4e-05	0.00594	-0.14	-0.12	Multiple sclerosis;Celiac disease;	chr6:159024915	chr6:158988178~159064925:+
BRCA	cis	rs2625529	0.824	rs11072346	ENSG00000260037.4	CTD-2524L6.3	-3.92	9.4e-05	0.00594	-0.17	-0.12	Red blood cell count;	chr15:72108093	chr15:71818396~71823384:+
BRCA	cis	rs2243480	1	rs160652	ENSG00000226002.1	RP11-460N20.5	-3.92	9.4e-05	0.00594	-0.21	-0.12	Diabetic kidney disease;	chr7:66073444	chr7:65084103~65100232:+
BRCA	cis	rs9470794	1	rs73419955	ENSG00000204110.6	RP1-153P14.8	-3.92	9.4e-05	0.00594	-0.22	-0.12	Type 2 diabetes;	chr6:38077496	chr6:37507348~37535616:+
BRCA	cis	rs2018683	0.649	rs221171	ENSG00000228421.2	AC005013.5	-3.92	9.4e-05	0.00594	-0.16	-0.12	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28966523	chr7:28957667~28959345:+
BRCA	cis	rs4689592	0.513	rs3857178	ENSG00000245468.3	RP11-367J11.3	3.92	9.4e-05	0.00594	0.13	0.12	Monocyte percentage of white cells;	chr4:7064789	chr4:7094571~7103385:-
BRCA	cis	rs10844706	0.699	rs10844610	ENSG00000256673.1	RP11-599J14.2	-3.92	9.4e-05	0.00594	-0.15	-0.12	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9724016	chr12:9398355~9414851:-
BRCA	cis	rs860295	0.812	rs4278368	ENSG00000160766.13	GBAP1	-3.92	9.4e-05	0.00594	-0.13	-0.12	Body mass index;	chr1:155752766	chr1:155213821~155227422:-
BRCA	cis	rs2302465	0.86	rs56166932	ENSG00000273133.1	RP11-799M12.2	-3.92	9.4e-05	0.00594	-0.24	-0.12	Blood protein levels;	chr4:15623334	chr4:15563698~15564253:-
BRCA	cis	rs2302465	0.86	rs56093715	ENSG00000273133.1	RP11-799M12.2	-3.92	9.4e-05	0.00594	-0.24	-0.12	Blood protein levels;	chr4:15623698	chr4:15563698~15564253:-
BRCA	cis	rs35740288	0.822	rs1961601	ENSG00000259407.1	RP11-158M2.3	-3.92	9.41e-05	0.00594	-0.16	-0.12	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85686375	chr15:85744109~85750281:-
BRCA	cis	rs35740288	0.787	rs727379	ENSG00000259407.1	RP11-158M2.3	-3.92	9.41e-05	0.00594	-0.16	-0.12	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85686659	chr15:85744109~85750281:-
BRCA	cis	rs938554	0.612	rs9991278	ENSG00000250413.1	RP11-448G15.1	-3.92	9.41e-05	0.00594	-0.18	-0.12	Blood metabolite levels;	chr4:10001041	chr4:10006482~10009725:+
BRCA	cis	rs6496932	0.802	rs56306166	ENSG00000218052.5	ADAMTS7P4	3.92	9.41e-05	0.00594	0.13	0.12	Central corneal thickness;Corneal structure;	chr15:85326848	chr15:85255369~85330334:-
BRCA	cis	rs747650	0.504	rs7111270	ENSG00000200376.1	RNU5E-10P	3.92	9.41e-05	0.00594	0.16	0.12	Acne (severe);	chr11:46998226	chr11:47576471~47576588:-
BRCA	cis	rs453301	0.686	rs11785634	ENSG00000233609.3	RP11-62H7.2	-3.92	9.41e-05	0.00594	-0.11	-0.12	Joint mobility (Beighton score);	chr8:9035087	chr8:8961200~8979025:+
BRCA	cis	rs7200543	1	rs3803575	ENSG00000207425.1	Y_RNA	-3.92	9.41e-05	0.00595	-0.14	-0.12	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15044590	chr16:14915457~14915556:-
BRCA	cis	rs34792	0.554	rs12919246	ENSG00000260872.1	RP11-680G24.5	-3.92	9.41e-05	0.00595	-0.13	-0.12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15533103	chr16:15018106~15020488:-
BRCA	cis	rs875971	0.638	rs10249404	ENSG00000275400.1	RP4-756H11.5	3.92	9.41e-05	0.00595	0.14	0.12	Aortic root size;	chr7:66581737	chr7:66553805~66554199:-
BRCA	cis	rs7412746	0.611	rs1889740	ENSG00000231073.1	RP11-316M1.3	3.92	9.42e-05	0.00595	0.13	0.12	Melanoma;	chr1:150827279	chr1:150973123~150975534:+
BRCA	cis	rs9810890	1	rs73196974	ENSG00000242551.2	POU5F1P6	-3.92	9.42e-05	0.00595	-0.32	-0.12	Dental caries;	chr3:128730163	chr3:128674735~128677005:-
BRCA	cis	rs9810890	1	rs73196983	ENSG00000242551.2	POU5F1P6	-3.92	9.42e-05	0.00595	-0.32	-0.12	Dental caries;	chr3:128733657	chr3:128674735~128677005:-
BRCA	cis	rs9810890	1	rs73196988	ENSG00000242551.2	POU5F1P6	-3.92	9.42e-05	0.00595	-0.32	-0.12	Dental caries;	chr3:128734624	chr3:128674735~128677005:-
BRCA	cis	rs9810890	1	rs73196989	ENSG00000242551.2	POU5F1P6	-3.92	9.42e-05	0.00595	-0.32	-0.12	Dental caries;	chr3:128735795	chr3:128674735~128677005:-
BRCA	cis	rs9810890	1	rs77303548	ENSG00000242551.2	POU5F1P6	-3.92	9.42e-05	0.00595	-0.32	-0.12	Dental caries;	chr3:128735923	chr3:128674735~128677005:-
BRCA	cis	rs9810890	0.85	rs73196995	ENSG00000242551.2	POU5F1P6	-3.92	9.42e-05	0.00595	-0.32	-0.12	Dental caries;	chr3:128739227	chr3:128674735~128677005:-
BRCA	cis	rs9810890	1	rs73196996	ENSG00000242551.2	POU5F1P6	-3.92	9.42e-05	0.00595	-0.32	-0.12	Dental caries;	chr3:128739573	chr3:128674735~128677005:-
BRCA	cis	rs9810890	1	rs73196999	ENSG00000242551.2	POU5F1P6	-3.92	9.42e-05	0.00595	-0.32	-0.12	Dental caries;	chr3:128741738	chr3:128674735~128677005:-
BRCA	cis	rs9810890	1	rs114261227	ENSG00000242551.2	POU5F1P6	-3.92	9.42e-05	0.00595	-0.32	-0.12	Dental caries;	chr3:128750917	chr3:128674735~128677005:-
BRCA	cis	rs6586111	1	rs4933462	ENSG00000226659.1	RP11-137H2.4	-3.92	9.42e-05	0.00595	-0.15	-0.12	Capecitabine sensitivity;	chr10:80612856	chr10:80529597~80535942:-
BRCA	cis	rs7267979	0.932	rs424487	ENSG00000274414.1	RP5-965G21.4	-3.92	9.42e-05	0.00595	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25487495	chr20:25239007~25245229:-
BRCA	cis	rs7551222	0.716	rs10900601	ENSG00000240219.1	RP11-430C7.5	3.92	9.42e-05	0.00595	0.15	0.12	Schizophrenia;	chr1:204602922	chr1:204626775~204629712:+
BRCA	cis	rs6840360	0.87	rs1372978	ENSG00000278978.1	RP11-164P12.5	-3.92	9.42e-05	0.00595	-0.13	-0.12	Intelligence (multi-trait analysis);	chr4:151535028	chr4:151669786~151670503:+
BRCA	cis	rs7615952	1	rs7615952	ENSG00000250012.1	RP11-124N2.1	3.92	9.42e-05	0.00595	0.17	0.12	Blood pressure (smoking interaction);	chr3:125930560	chr3:126084220~126095349:+
BRCA	cis	rs78587638	0.843	rs72964948	ENSG00000226856.4	AC093901.1	-3.92	9.42e-05	0.00595	-0.18	-0.12	Mosquito bite size;	chr2:118409650	chr2:118132128~118186386:-
BRCA	cis	rs962856	1	rs979043	ENSG00000236605.1	AC023115.4	3.92	9.42e-05	0.00595	0.14	0.12	Pancreatic cancer;	chr2:67339149	chr2:67324627~67325304:+
BRCA	cis	rs10129255	0.957	rs10140904	ENSG00000232216.1	IGHV3-43	3.92	9.43e-05	0.00595	0.1	0.12	Kawasaki disease;	chr14:106776558	chr14:106470264~106470800:-
BRCA	cis	rs2243480	0.831	rs57294491	ENSG00000237026.1	RP11-328P23.2	-3.92	9.43e-05	0.00595	-0.23	-0.12	Diabetic kidney disease;	chr7:66219914	chr7:65235790~65236723:-
BRCA	cis	rs17489649	1	rs2269199	ENSG00000271849.1	CTC-332L22.1	3.92	9.43e-05	0.00595	0.16	0.12	Intelligence (multi-trait analysis);	chr5:109701831	chr5:109687802~109688329:-
BRCA	cis	rs2163813	1	rs2013561	ENSG00000271283.1	CTC-412M14.6	-3.92	9.43e-05	0.00595	-0.17	-0.12	Toenail selenium levels;	chr19:19715368	chr19:19699203~19699409:-
BRCA	cis	rs2163813	1	rs36006965	ENSG00000271283.1	CTC-412M14.6	-3.92	9.43e-05	0.00595	-0.17	-0.12	Toenail selenium levels;	chr19:19719242	chr19:19699203~19699409:-
BRCA	cis	rs2163813	1	rs12982273	ENSG00000271283.1	CTC-412M14.6	-3.92	9.43e-05	0.00595	-0.17	-0.12	Toenail selenium levels;	chr19:19719335	chr19:19699203~19699409:-
BRCA	cis	rs6736093	0.901	rs34875611	ENSG00000236307.2	EEF1E1P1	-3.92	9.43e-05	0.00595	-0.15	-0.12	Coronary artery disease;	chr2:112005448	chr2:111887914~111888741:+
BRCA	cis	rs17092148	0.887	rs6058104	ENSG00000202150.1	RNU6-407P	3.92	9.43e-05	0.00596	0.18	0.12	Neuroticism;	chr20:34683248	chr20:35030317~35030420:-
BRCA	cis	rs9467773	0.62	rs2494716	ENSG00000224843.5	LINC00240	-3.92	9.43e-05	0.00596	-0.13	-0.12	Intelligence (multi-trait analysis);	chr6:26662508	chr6:26956992~27023924:+
BRCA	cis	rs6490294	0.904	rs12423061	ENSG00000257624.1	RP1-128M12.3	3.92	9.43e-05	0.00596	0.16	0.12	Mean platelet volume;	chr12:111967091	chr12:112000739~112000985:-
BRCA	cis	rs6490294	0.904	rs112426410	ENSG00000257624.1	RP1-128M12.3	3.92	9.43e-05	0.00596	0.16	0.12	Mean platelet volume;	chr12:111969634	chr12:112000739~112000985:-
BRCA	cis	rs10504130	1	rs75371481	ENSG00000272076.1	RP11-11C20.3	3.92	9.43e-05	0.00596	0.2	0.12	Venous thromboembolism (SNP x SNP interaction);	chr8:51863252	chr8:51810110~51810681:-
BRCA	cis	rs10504130	1	rs77082359	ENSG00000272076.1	RP11-11C20.3	3.92	9.43e-05	0.00596	0.2	0.12	Venous thromboembolism (SNP x SNP interaction);	chr8:51866587	chr8:51810110~51810681:-
BRCA	cis	rs10504130	1	rs74769823	ENSG00000272076.1	RP11-11C20.3	3.92	9.43e-05	0.00596	0.2	0.12	Venous thromboembolism (SNP x SNP interaction);	chr8:51867608	chr8:51810110~51810681:-
BRCA	cis	rs10504130	1	rs79727212	ENSG00000272076.1	RP11-11C20.3	3.92	9.43e-05	0.00596	0.2	0.12	Venous thromboembolism (SNP x SNP interaction);	chr8:51868528	chr8:51810110~51810681:-
BRCA	cis	rs10504130	1	rs77534642	ENSG00000272076.1	RP11-11C20.3	3.92	9.43e-05	0.00596	0.2	0.12	Venous thromboembolism (SNP x SNP interaction);	chr8:51868956	chr8:51810110~51810681:-
BRCA	cis	rs10504130	1	rs16916906	ENSG00000272076.1	RP11-11C20.3	3.92	9.43e-05	0.00596	0.2	0.12	Venous thromboembolism (SNP x SNP interaction);	chr8:51869133	chr8:51810110~51810681:-
BRCA	cis	rs10504130	0.935	rs112132091	ENSG00000272076.1	RP11-11C20.3	3.92	9.43e-05	0.00596	0.2	0.12	Venous thromboembolism (SNP x SNP interaction);	chr8:51869344	chr8:51810110~51810681:-
BRCA	cis	rs10504130	1	rs77532876	ENSG00000272076.1	RP11-11C20.3	3.92	9.43e-05	0.00596	0.2	0.12	Venous thromboembolism (SNP x SNP interaction);	chr8:51873542	chr8:51810110~51810681:-
BRCA	cis	rs10504130	1	rs11777714	ENSG00000272076.1	RP11-11C20.3	3.92	9.43e-05	0.00596	0.2	0.12	Venous thromboembolism (SNP x SNP interaction);	chr8:51874273	chr8:51810110~51810681:-
BRCA	cis	rs10504130	1	rs10958300	ENSG00000272076.1	RP11-11C20.3	3.92	9.43e-05	0.00596	0.2	0.12	Venous thromboembolism (SNP x SNP interaction);	chr8:51875389	chr8:51810110~51810681:-
BRCA	cis	rs10504130	1	rs10958301	ENSG00000272076.1	RP11-11C20.3	3.92	9.43e-05	0.00596	0.2	0.12	Venous thromboembolism (SNP x SNP interaction);	chr8:51875676	chr8:51810110~51810681:-
BRCA	cis	rs10504130	0.932	rs77153951	ENSG00000272076.1	RP11-11C20.3	3.92	9.43e-05	0.00596	0.2	0.12	Venous thromboembolism (SNP x SNP interaction);	chr8:51878837	chr8:51810110~51810681:-
BRCA	cis	rs10504130	0.932	rs77140083	ENSG00000272076.1	RP11-11C20.3	3.92	9.43e-05	0.00596	0.2	0.12	Venous thromboembolism (SNP x SNP interaction);	chr8:51880352	chr8:51810110~51810681:-
BRCA	cis	rs10744955	0.727	rs11637945	ENSG00000244879.4	GABPB1-AS1	-3.92	9.43e-05	0.00596	-0.13	-0.12	Lobe attachment (rater-scored or self-reported);	chr15:50162489	chr15:50354959~50372202:+
BRCA	cis	rs16846053	0.792	rs62187700	ENSG00000227403.1	AC009299.3	3.92	9.43e-05	0.00596	0.31	0.12	Blood osmolality (transformed sodium);	chr2:161821263	chr2:161244739~161249050:+
BRCA	cis	rs4819052	0.851	rs2838848	ENSG00000215447.6	BX322557.10	-3.92	9.44e-05	0.00596	-0.12	-0.12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251102	chr21:45288052~45291738:+
BRCA	cis	rs4819052	0.851	rs2838849	ENSG00000215447.6	BX322557.10	-3.92	9.44e-05	0.00596	-0.12	-0.12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251112	chr21:45288052~45291738:+
BRCA	cis	rs11098499	0.954	rs4309825	ENSG00000260404.2	RP11-384K6.6	-3.92	9.44e-05	0.00596	-0.11	-0.12	Corneal astigmatism;	chr4:119393726	chr4:118591773~118633729:+
BRCA	cis	rs8040855	0.597	rs12902942	ENSG00000229212.6	RP11-561C5.4	-3.92	9.44e-05	0.00596	-0.17	-0.12	Bulimia nervosa;	chr15:85041573	chr15:85205440~85234795:-
BRCA	cis	rs8114671	0.527	rs2295352	ENSG00000279253.1	RP4-614O4.13	3.92	9.44e-05	0.00596	0.14	0.12	Height;	chr20:34732251	chr20:35262727~35264187:-
BRCA	cis	rs7177699	0.557	rs9806363	ENSG00000261143.1	ADAMTS7P3	3.92	9.44e-05	0.00596	0.15	0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78817960	chr15:77976042~77993057:+
BRCA	cis	rs3749237	0.964	rs13084243	ENSG00000225399.4	RP11-3B7.1	3.92	9.44e-05	0.00596	0.12	0.12	Resting heart rate;	chr3:49784445	chr3:49260085~49261316:+
BRCA	cis	rs3749237	1	rs11920900	ENSG00000225399.4	RP11-3B7.1	3.92	9.44e-05	0.00596	0.12	0.12	Resting heart rate;	chr3:49785591	chr3:49260085~49261316:+
BRCA	cis	rs921968	0.643	rs611203	ENSG00000273466.1	RP11-548H3.1	3.92	9.44e-05	0.00596	0.12	0.12	Mean corpuscular hemoglobin concentration;	chr2:218607602	chr2:218633256~218634014:-
BRCA	cis	rs8062405	1	rs4788101	ENSG00000261766.1	RP11-22P6.2	-3.92	9.44e-05	0.00596	-0.12	-0.12	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28856483	chr16:28862166~28863340:-
BRCA	cis	rs8062405	0.737	rs11861132	ENSG00000261766.1	RP11-22P6.2	-3.92	9.44e-05	0.00596	-0.12	-0.12	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28860539	chr16:28862166~28863340:-
BRCA	cis	rs8062405	1	rs11861174	ENSG00000261766.1	RP11-22P6.2	-3.92	9.44e-05	0.00596	-0.12	-0.12	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28860668	chr16:28862166~28863340:-
BRCA	cis	rs8062405	1	rs4788102	ENSG00000261766.1	RP11-22P6.2	-3.92	9.44e-05	0.00596	-0.12	-0.12	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28862077	chr16:28862166~28863340:-
BRCA	cis	rs8062405	1	rs62037367	ENSG00000261766.1	RP11-22P6.2	-3.92	9.44e-05	0.00596	-0.12	-0.12	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863226	chr16:28862166~28863340:-
BRCA	cis	rs8062405	1	rs7198606	ENSG00000261766.1	RP11-22P6.2	-3.92	9.44e-05	0.00596	-0.12	-0.12	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863801	chr16:28862166~28863340:-
BRCA	cis	rs8062405	0.929	rs11864750	ENSG00000261766.1	RP11-22P6.2	-3.92	9.44e-05	0.00596	-0.12	-0.12	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863883	chr16:28862166~28863340:-
BRCA	cis	rs8062405	0.964	rs7193733	ENSG00000261766.1	RP11-22P6.2	-3.92	9.44e-05	0.00596	-0.12	-0.12	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28864161	chr16:28862166~28863340:-
BRCA	cis	rs8062405	1	rs8055982	ENSG00000261766.1	RP11-22P6.2	-3.92	9.44e-05	0.00596	-0.12	-0.12	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28869881	chr16:28862166~28863340:-
BRCA	cis	rs8062405	1	rs7498665	ENSG00000261766.1	RP11-22P6.2	-3.92	9.44e-05	0.00596	-0.12	-0.12	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28871920	chr16:28862166~28863340:-
BRCA	cis	rs8062405	0.964	rs11864107	ENSG00000261766.1	RP11-22P6.2	-3.92	9.44e-05	0.00596	-0.12	-0.12	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28874610	chr16:28862166~28863340:-
BRCA	cis	rs539096	0.749	rs12076635	ENSG00000236200.4	KDM4A-AS1	-3.92	9.45e-05	0.00597	-0.14	-0.12	Intelligence (multi-trait analysis);	chr1:43560985	chr1:43699765~43708138:-
BRCA	cis	rs6012564	1	rs6066982	ENSG00000222365.1	SNORD12B	3.92	9.45e-05	0.00597	0.13	0.12	Anger;	chr20:49147021	chr20:49280319~49280409:+
BRCA	cis	rs6012564	1	rs7272164	ENSG00000222365.1	SNORD12B	3.92	9.45e-05	0.00597	0.13	0.12	Anger;	chr20:49149660	chr20:49280319~49280409:+
BRCA	cis	rs4494364	0.502	rs1920779	ENSG00000258100.1	RP11-121E16.1	3.92	9.45e-05	0.00597	0.17	0.12	Systolic blood pressure (alcohol consumption interaction);	chr12:91034248	chr12:91362196~91368606:+
BRCA	cis	rs3748682	0.861	rs12563037	ENSG00000252448.1	SNORA63	3.92	9.45e-05	0.00597	0.16	0.12	Hypothyroidism;	chr1:37792972	chr1:37884237~37884317:+
BRCA	cis	rs8024893	1	rs8024893	ENSG00000270055.1	CTD-3092A11.2	3.92	9.45e-05	0.00597	0.18	0.12	Red cell distribution width;	chr15:31248786	chr15:30487963~30490313:+
BRCA	cis	rs490234	0.783	rs4838278	ENSG00000232630.1	PRPS1P2	-3.92	9.45e-05	0.00597	-0.12	-0.12	Mean arterial pressure;	chr9:125641230	chr9:125150653~125151589:+
BRCA	cis	rs360929	0.935	rs360907	ENSG00000245954.5	RP11-18H21.1	3.92	9.45e-05	0.00597	0.14	0.12	Volumetric brain MRI;	chr4:151979482	chr4:152100754~152104720:+
BRCA	cis	rs38055	0.837	rs252034	ENSG00000247796.2	CTD-2366F13.1	-3.92	9.45e-05	0.00597	-0.14	-0.12	Acne (severe);	chr5:53318961	chr5:53109842~53115126:+
BRCA	cis	rs6500602	0.674	rs8051695	ENSG00000280063.1	RP11-295D4.3	3.92	9.45e-05	0.00597	0.09	0.12	Schizophrenia;	chr16:4486620	chr16:4346694~4348648:-
BRCA	cis	rs1552244	0.572	rs67439440	ENSG00000180385.7	EMC3-AS1	3.92	9.45e-05	0.00597	0.16	0.12	Alzheimer's disease;	chr3:10127819	chr3:9986893~10006990:+
BRCA	cis	rs12317459	0.591	rs11115403	ENSG00000213270.5	RPL6P25	-3.92	9.45e-05	0.00597	-0.19	-0.12	Prostate cancer (SNP x SNP interaction);	chr12:82772696	chr12:83151331~83152190:+
BRCA	cis	rs739401	0.611	rs450817	ENSG00000183562.3	CTC-343N3.1	-3.92	9.46e-05	0.00597	-0.13	-0.12	Longevity;	chr11:3035482	chr11:2989863~2991344:+
BRCA	cis	rs3858526	0.834	rs10839160	ENSG00000224295.2	AC087380.14	3.92	9.46e-05	0.00597	0.17	0.12	DNA methylation (variation);	chr11:5980883	chr11:5518441~5524955:-
BRCA	cis	rs860818	1	rs858243	ENSG00000230658.1	KLHL7-AS1	-3.92	9.46e-05	0.00597	-0.3	-0.12	Initial pursuit acceleration;	chr7:23184738	chr7:23101228~23105703:-
BRCA	cis	rs6480314	0.908	rs74817543	ENSG00000233590.1	RP11-153K11.3	-3.92	9.46e-05	0.00597	-0.19	-0.12	Optic nerve measurement (disc area);	chr10:68203791	chr10:68233251~68242379:-
BRCA	cis	rs7200543	1	rs16966953	ENSG00000207425.1	Y_RNA	-3.92	9.46e-05	0.00597	-0.15	-0.12	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15041997	chr16:14915457~14915556:-
BRCA	cis	rs7615952	0.558	rs17334039	ENSG00000248787.1	RP11-666A20.4	-3.92	9.47e-05	0.00598	-0.18	-0.12	Blood pressure (smoking interaction);	chr3:125821465	chr3:125908005~125910272:-
BRCA	cis	rs1396626	0.855	rs6684598	ENSG00000235501.4	RP4-639F20.1	-3.92	9.47e-05	0.00598	-0.16	-0.12	Diabetic kidney disease;	chr1:95512268	chr1:94927566~94963270:+
BRCA	cis	rs5742933	1	rs6719224	ENSG00000253559.1	OSGEPL1-AS1	-3.92	9.47e-05	0.00598	-0.17	-0.12	Ferritin levels;	chr2:189769545	chr2:189762704~189765556:+
BRCA	cis	rs3136202	0.68	rs857048	ENSG00000242307.1	RPS26P52	3.92	9.47e-05	0.00598	0.15	0.12	Conduct disorder (symptom count);	chr16:13981680	chr16:13922332~13922679:-
BRCA	cis	rs3136202	0.643	rs8054626	ENSG00000242307.1	RPS26P52	3.92	9.47e-05	0.00598	0.15	0.12	Conduct disorder (symptom count);	chr16:13981729	chr16:13922332~13922679:-
BRCA	cis	rs1560104	0.675	rs8063669	ENSG00000259876.1	CTD-3037G24.4	3.92	9.47e-05	0.00598	0.13	0.12	Obesity-related traits;	chr16:12603379	chr16:12556353~12557694:-
BRCA	cis	rs875971	0.545	rs316328	ENSG00000273142.1	RP11-458F8.4	-3.92	9.47e-05	0.00598	-0.11	-0.12	Aortic root size;	chr7:66143851	chr7:66902857~66906297:+
BRCA	cis	rs7819412	0.74	rs7844536	ENSG00000255046.1	RP11-297N6.4	3.92	9.47e-05	0.00598	0.14	0.12	Triglycerides;	chr8:11176519	chr8:11797928~11802568:-
BRCA	cis	rs5771242	0.518	rs7290465	ENSG00000273253.2	RP3-402G11.26	3.92	9.47e-05	0.00598	0.13	0.12	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);	chr22:50241329	chr22:50199090~50200837:-
BRCA	cis	rs6012564	1	rs6066982	ENSG00000230758.1	SNAP23P	3.92	9.47e-05	0.00598	0.14	0.12	Anger;	chr20:49147021	chr20:49038357~49038602:-
BRCA	cis	rs6012564	1	rs7272164	ENSG00000230758.1	SNAP23P	3.92	9.47e-05	0.00598	0.14	0.12	Anger;	chr20:49149660	chr20:49038357~49038602:-
BRCA	cis	rs2692947	0.794	rs2692949	ENSG00000232931.4	LINC00342	3.92	9.47e-05	0.00598	0.13	0.12	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96007777	chr2:95807118~95816215:-
BRCA	cis	rs11098499	0.644	rs7693919	ENSG00000260091.1	RP11-33B1.4	-3.92	9.47e-05	0.00598	-0.1	-0.12	Corneal astigmatism;	chr4:119619416	chr4:119409333~119410233:+
BRCA	cis	rs6840360	0.901	rs1443094	ENSG00000251611.1	RP11-610P16.1	-3.92	9.48e-05	0.00598	-0.11	-0.12	Intelligence (multi-trait analysis);	chr4:151535572	chr4:151407551~151408835:-
BRCA	cis	rs7620503	0.959	rs13079175	ENSG00000231574.4	RP11-91K9.1	3.92	9.48e-05	0.00598	0.14	0.12	Corneal structure;	chr3:177591745	chr3:177816865~177899224:+
BRCA	cis	rs1008375	0.864	rs4698196	ENSG00000249502.1	AC006160.5	-3.92	9.48e-05	0.00598	-0.15	-0.12	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17573112	chr4:17587467~17614571:-
BRCA	cis	rs11887277	0.619	rs34472003	ENSG00000272148.1	RP11-195B17.1	-3.92	9.48e-05	0.00598	-0.13	-0.12	Obesity-related traits;	chr2:26815498	chr2:27062428~27062907:-
BRCA	cis	rs11887277	0.708	rs34222834	ENSG00000272148.1	RP11-195B17.1	-3.92	9.48e-05	0.00598	-0.13	-0.12	Obesity-related traits;	chr2:26815520	chr2:27062428~27062907:-
BRCA	cis	rs930395	0.514	rs10038554	ENSG00000251141.4	RP11-53O19.1	-3.92	9.48e-05	0.00598	-0.11	-0.12	Breast cancer;	chr5:44927005	chr5:44744900~44808777:-
BRCA	cis	rs516805	0.568	rs56290570	ENSG00000279114.1	RP3-425C14.5	3.92	9.48e-05	0.00598	0.15	0.12	Lymphocyte counts;	chr6:122240177	chr6:122471923~122484161:+
BRCA	cis	rs11893307	0.566	rs10203824	ENSG00000235852.1	AC005540.3	3.92	9.48e-05	0.00598	0.16	0.12	Mean platelet volume;	chr2:190731124	chr2:190880797~190882059:-
BRCA	cis	rs990171	0.538	rs4851012	ENSG00000234389.1	AC007278.3	-3.92	9.48e-05	0.00598	-0.12	-0.12	Lymphocyte counts;	chr2:102499456	chr2:102438713~102440475:+
BRCA	cis	rs2832191	0.903	rs11700687	ENSG00000232855.5	AF131217.1	3.92	9.48e-05	0.00598	0.14	0.12	Dental caries;	chr21:29114446	chr21:28439346~28674848:-
BRCA	cis	rs2832191	1	rs2832190	ENSG00000232855.5	AF131217.1	3.92	9.48e-05	0.00598	0.14	0.12	Dental caries;	chr21:29115905	chr21:28439346~28674848:-
BRCA	cis	rs1153858	0.945	rs1974981	ENSG00000275672.1	GATM-AS1	3.92	9.48e-05	0.00598	0.16	0.12	Homoarginine levels;	chr15:45436925	chr15:45378700~45380123:+
BRCA	cis	rs875971	1	rs697970	ENSG00000271064.1	RP11-792A8.3	3.92	9.48e-05	0.00599	0.14	0.12	Aortic root size;	chr7:66095065	chr7:66748838~66749077:-
BRCA	cis	rs10129255	0.957	rs10136817	ENSG00000211958.2	IGHV3-38	3.92	9.48e-05	0.00599	0.1	0.12	Kawasaki disease;	chr14:106787730	chr14:106410493~106411021:-
BRCA	cis	rs490234	0.775	rs12341245	ENSG00000232630.1	PRPS1P2	-3.92	9.48e-05	0.00599	-0.12	-0.12	Mean arterial pressure;	chr9:125578662	chr9:125150653~125151589:+
BRCA	cis	rs2704588	1	rs1246633	ENSG00000270720.1	RP11-84C13.2	-3.92	9.48e-05	0.00599	-0.19	-0.12	Longevity;	chr4:88902169	chr4:89119284~89119871:+
BRCA	cis	rs11098499	0.738	rs28687057	ENSG00000260404.2	RP11-384K6.6	3.92	9.49e-05	0.00599	0.11	0.12	Corneal astigmatism;	chr4:119359657	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.775	rs67281037	ENSG00000260404.2	RP11-384K6.6	3.92	9.49e-05	0.00599	0.11	0.12	Corneal astigmatism;	chr4:119360002	chr4:118591773~118633729:+
BRCA	cis	rs10028773	0.506	rs12374346	ENSG00000260404.2	RP11-384K6.6	3.92	9.49e-05	0.00599	0.11	0.12	Educational attainment;	chr4:119360550	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.866	rs12374244	ENSG00000260404.2	RP11-384K6.6	3.92	9.49e-05	0.00599	0.11	0.12	Corneal astigmatism;	chr4:119360817	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.866	rs12374352	ENSG00000260404.2	RP11-384K6.6	3.92	9.49e-05	0.00599	0.11	0.12	Corneal astigmatism;	chr4:119360822	chr4:118591773~118633729:+
BRCA	cis	rs4819052	0.851	rs2255774	ENSG00000215447.6	BX322557.10	-3.92	9.49e-05	0.00599	-0.12	-0.12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45263936	chr21:45288052~45291738:+
BRCA	cis	rs131805	1	rs3091397	ENSG00000273192.1	CITF22-1A6.3	-3.92	9.49e-05	0.00599	-0.14	-0.12	Granulocyte percentage of myeloid white cells;	chr22:50519091	chr22:49902228~49904576:+
BRCA	cis	rs34014631	0.892	rs7919455	ENSG00000226009.1	KCNIP2-AS1	3.92	9.49e-05	0.00599	0.31	0.12	Coronary artery calcification;	chr10:101929419	chr10:101819078~101828779:+
BRCA	cis	rs2692947	0.673	rs4907299	ENSG00000232931.4	LINC00342	3.92	9.49e-05	0.00599	0.13	0.12	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96114374	chr2:95807118~95816215:-
BRCA	cis	rs35851103	0.507	rs6601649	ENSG00000255052.4	FAM66D	3.92	9.49e-05	0.00599	0.15	0.12	Neuroticism;	chr8:11999808	chr8:12115782~12177550:+
BRCA	cis	rs11098499	0.82	rs28535956	ENSG00000250412.1	KLHL2P1	-3.92	9.49e-05	0.00599	-0.15	-0.12	Corneal astigmatism;	chr4:119615703	chr4:119334329~119378233:+
BRCA	cis	rs804280	1	rs804280	ENSG00000270154.1	RP11-419I17.1	3.92	9.49e-05	0.00599	0.14	0.12	Myopia (pathological);	chr8:11755189	chr8:12476462~12477122:+
BRCA	cis	rs5758659	0.652	rs133323	ENSG00000182057.4	OGFRP1	3.92	9.49e-05	0.00599	0.14	0.12	Cognitive function;	chr22:42009918	chr22:42269753~42275196:+
BRCA	cis	rs5758659	0.652	rs133327	ENSG00000182057.4	OGFRP1	3.92	9.49e-05	0.00599	0.14	0.12	Cognitive function;	chr22:42011685	chr22:42269753~42275196:+
BRCA	cis	rs17489649	0.915	rs3797699	ENSG00000271849.1	CTC-332L22.1	3.92	9.49e-05	0.00599	0.15	0.12	Intelligence (multi-trait analysis);	chr5:109714733	chr5:109687802~109688329:-
BRCA	cis	rs4879656	0.593	rs13297493	ENSG00000236184.1	TCEA1P4	-3.92	9.49e-05	0.00599	-0.15	-0.12	Menopause (age at onset);	chr9:33049603	chr9:32979560~32980403:-
BRCA	cis	rs1850744	0.702	rs6836184	ENSG00000250942.1	ENPP7P11	3.92	9.49e-05	0.00599	0.23	0.12	Economic and political preferences;	chr4:9632087	chr4:9677308~9677934:+
BRCA	cis	rs740698	0.522	rs1024653	ENSG00000265702.1	RP11-156L14.1	-3.92	9.5e-05	0.00599	-0.15	-0.12	Pulse pressure;	chr17:62714457	chr17:62699244~62737922:+
BRCA	cis	rs2302465	0.86	rs115690300	ENSG00000273133.1	RP11-799M12.2	-3.92	9.5e-05	0.00599	-0.24	-0.12	Blood protein levels;	chr4:15642020	chr4:15563698~15564253:-
BRCA	cis	rs2302465	0.86	rs73241183	ENSG00000273133.1	RP11-799M12.2	-3.92	9.5e-05	0.00599	-0.24	-0.12	Blood protein levels;	chr4:15645914	chr4:15563698~15564253:-
BRCA	cis	rs2302465	0.86	rs73241195	ENSG00000273133.1	RP11-799M12.2	-3.92	9.5e-05	0.00599	-0.24	-0.12	Blood protein levels;	chr4:15654169	chr4:15563698~15564253:-
BRCA	cis	rs2302465	0.86	rs73241197	ENSG00000273133.1	RP11-799M12.2	-3.92	9.5e-05	0.00599	-0.24	-0.12	Blood protein levels;	chr4:15654172	chr4:15563698~15564253:-
BRCA	cis	rs17561351	1	rs17561351	ENSG00000214855.8	APOC1P1	-3.92	9.5e-05	0.00599	-0.29	-0.12	Mean platelet volume;	chr19:44869072	chr19:44926804~44931386:+
BRCA	cis	rs11098499	0.909	rs1809406	ENSG00000260404.2	RP11-384K6.6	3.92	9.5e-05	0.00599	0.11	0.12	Corneal astigmatism;	chr4:119455967	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.865	rs2389809	ENSG00000260404.2	RP11-384K6.6	3.92	9.5e-05	0.00599	0.11	0.12	Corneal astigmatism;	chr4:119456244	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.909	rs9994810	ENSG00000260404.2	RP11-384K6.6	3.92	9.5e-05	0.00599	0.11	0.12	Corneal astigmatism;	chr4:119460435	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.697	rs10020027	ENSG00000260404.2	RP11-384K6.6	3.92	9.5e-05	0.00599	0.11	0.12	Corneal astigmatism;	chr4:119460724	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.779	rs7356491	ENSG00000260404.2	RP11-384K6.6	3.92	9.5e-05	0.00599	0.11	0.12	Corneal astigmatism;	chr4:119460819	chr4:118591773~118633729:+
BRCA	cis	rs1538970	0.962	rs2153608	ENSG00000281133.1	AL355480.3	3.92	9.5e-05	0.00599	0.16	0.12	Platelet count;	chr1:45348269	chr1:45580892~45580996:-
BRCA	cis	rs11047510	0.793	rs4883181	ENSG00000256817.1	TPT1P12	-3.92	9.5e-05	0.006	-0.18	-0.12	Exploratory eye movement dysfunction in schizophrenia (responsive search score);	chr12:8829049	chr12:9155881~9156372:-
BRCA	cis	rs7238033	0.965	rs11082466	ENSG00000267193.4	RP11-116O18.3	3.92	9.5e-05	0.006	0.13	0.12	Bladder cancer;	chr18:45737563	chr18:45669367~45747215:-
BRCA	cis	rs11673344	0.504	rs2118208	ENSG00000276846.1	CTD-3220F14.3	3.92	9.51e-05	0.006	0.14	0.12	Obesity-related traits;	chr19:37135573	chr19:37314868~37315620:-
BRCA	cis	rs11673344	0.504	rs2118209	ENSG00000276846.1	CTD-3220F14.3	3.92	9.51e-05	0.006	0.14	0.12	Obesity-related traits;	chr19:37135618	chr19:37314868~37315620:-
BRCA	cis	rs957448	1	rs1992370	ENSG00000254315.1	RP11-267M23.3	3.92	9.51e-05	0.006	0.16	0.12	Nonsyndromic cleft lip with cleft palate;	chr8:94546466	chr8:94533628~94534391:+
BRCA	cis	rs9392556	0.829	rs634698	ENSG00000230648.1	RP3-406P24.3	3.92	9.51e-05	0.006	0.15	0.12	Blood metabolite levels;	chr6:4114013	chr6:4018843~4021215:-
BRCA	cis	rs2692947	0.832	rs2579519	ENSG00000237510.6	AC008268.2	3.92	9.51e-05	0.006	0.16	0.12	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96009418	chr2:95789654~95800166:+
BRCA	cis	rs924712	0.625	rs12191386	ENSG00000224984.1	RP11-524H19.2	-3.92	9.51e-05	0.006	-0.15	-0.12	Breast cancer;	chr6:54855645	chr6:54840118~54840855:-
BRCA	cis	rs2108622	0.711	rs113059233	ENSG00000214049.6	UCA1	3.92	9.51e-05	0.006	0.17	0.12	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15866558	chr19:15828961~15836320:+
BRCA	cis	rs977987	0.806	rs4887824	ENSG00000280152.1	RP11-331F4.5	-3.92	9.51e-05	0.006	-0.13	-0.12	Dupuytren's disease;	chr16:75407715	chr16:75245994~75250077:-
BRCA	cis	rs2411233	1	rs10851375	ENSG00000259278.1	RP11-62C7.2	3.92	9.51e-05	0.006	0.14	0.12	Platelet count;	chr15:38991778	chr15:39019233~39024918:+
BRCA	cis	rs875971	0.638	rs6960778	ENSG00000265600.1	AC006480.1	3.92	9.51e-05	0.006	0.14	0.12	Aortic root size;	chr7:66606610	chr7:67356680~67356779:+
BRCA	cis	rs524281	0.773	rs2155201	ENSG00000255038.1	RP11-1167A19.2	-3.92	9.51e-05	0.006	-0.19	-0.12	Electroencephalogram traits;	chr11:66224873	chr11:66067277~66069619:-
BRCA	cis	rs687432	0.885	rs11606464	ENSG00000265566.2	RN7SL605P	-3.92	9.51e-05	0.006	-0.17	-0.12	Parkinson's disease;	chr11:58029175	chr11:57528085~57528365:-
BRCA	cis	rs6452524	0.766	rs2252179	ENSG00000281327.1	LINC01338	-3.92	9.51e-05	0.006	-0.14	-0.12	Hypertension (SNP x SNP interaction);	chr5:83145630	chr5:82850864~82859836:-
BRCA	cis	rs61332075	0.518	rs892839	ENSG00000186235.9	AC016757.3	3.92	9.51e-05	0.006	0.23	0.12	Lung function (FEV1/FVC);	chr2:238497805	chr2:238224552~238231677:-
BRCA	cis	rs495337	0.76	rs624115	ENSG00000229222.1	KRT18P4	-3.92	9.51e-05	0.006	-0.15	-0.12	Psoriasis;	chr20:49907091	chr20:49956745~49958032:+
BRCA	cis	rs4578769	0.531	rs12969559	ENSG00000265943.1	RP11-739L10.1	3.92	9.52e-05	0.006	0.16	0.12	Eosinophil percentage of white cells;	chr18:22913702	chr18:22699481~22933764:-
BRCA	cis	rs7824557	0.606	rs1435277	ENSG00000255046.1	RP11-297N6.4	-3.92	9.52e-05	0.00601	-0.14	-0.12	Retinal vascular caliber;	chr8:11339461	chr8:11797928~11802568:-
BRCA	cis	rs10786436	0.588	rs10883133	ENSG00000224934.2	RP11-441O15.3	-3.92	9.52e-05	0.00601	-0.1	-0.12	Type 1 diabetes;	chr10:98563237	chr10:99431191~99438117:+
BRCA	cis	rs3764021	0.509	rs10772072	ENSG00000278635.1	CTD-2318O12.1	-3.92	9.52e-05	0.00601	-0.13	-0.12	Type 1 diabetes;	chr12:9717335	chr12:9415641~9416718:+
BRCA	cis	rs56322409	1	rs11188394	ENSG00000226688.5	ENTPD1-AS1	3.92	9.52e-05	0.00601	0.14	0.12	Blood metabolite levels;	chr10:95605701	chr10:95753206~96090238:-
BRCA	cis	rs3748682	0.821	rs12751325	ENSG00000252448.1	SNORA63	-3.92	9.52e-05	0.00601	-0.15	-0.12	Hypothyroidism;	chr1:37823711	chr1:37884237~37884317:+
BRCA	cis	rs2274273	0.712	rs17832311	ENSG00000259318.1	RP11-454L9.2	3.92	9.52e-05	0.00601	0.1	0.12	Protein biomarker;	chr14:55067748	chr14:55394940~55395233:-
BRCA	cis	rs147144681	1	rs147144681	ENSG00000261762.1	RP11-650L12.2	-3.92	9.52e-05	0.00601	-0.15	-0.12	Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78608566	chr15:78589123~78591276:-
BRCA	cis	rs6005807	0.843	rs9620803	ENSG00000272858.1	CTA-292E10.8	-3.92	9.53e-05	0.00601	-0.24	-0.12	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28523046	chr22:28814914~28815662:+
BRCA	cis	rs6005807	0.843	rs9620804	ENSG00000272858.1	CTA-292E10.8	-3.92	9.53e-05	0.00601	-0.24	-0.12	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28523212	chr22:28814914~28815662:+
BRCA	cis	rs2562456	0.876	rs11085465	ENSG00000268119.4	CTD-2561J22.5	-3.92	9.53e-05	0.00601	-0.18	-0.12	Pain;	chr19:21568988	chr19:21444241~21463908:-
BRCA	cis	rs524281	0.773	rs4393319	ENSG00000255038.1	RP11-1167A19.2	-3.92	9.53e-05	0.00601	-0.19	-0.12	Electroencephalogram traits;	chr11:66234407	chr11:66067277~66069619:-
BRCA	cis	rs524281	0.773	rs2236652	ENSG00000255038.1	RP11-1167A19.2	-3.92	9.53e-05	0.00601	-0.19	-0.12	Electroencephalogram traits;	chr11:66235210	chr11:66067277~66069619:-
BRCA	cis	rs11239930	0.517	rs632861	ENSG00000237188.3	RP11-337C18.8	3.92	9.53e-05	0.00601	0.14	0.12	AIDS progression;	chr1:147079826	chr1:147172771~147211568:+
BRCA	cis	rs448720	1	rs12593295	ENSG00000260657.2	RP11-315D16.4	3.92	9.53e-05	0.00601	0.14	0.12	Cognitive performance;	chr15:67916439	chr15:68267792~68277994:-
BRCA	cis	rs7188861	0.681	rs12598646	ENSG00000262636.1	CTD-3088G3.4	3.92	9.54e-05	0.00601	0.23	0.12	HDL cholesterol;	chr16:11312662	chr16:11380859~11381118:-
BRCA	cis	rs7712401	0.692	rs6881135	ENSG00000251538.4	RP11-166A12.1	-3.92	9.54e-05	0.00602	-0.13	-0.12	Mean platelet volume;	chr5:122744676	chr5:122628952~122730685:-
BRCA	cis	rs62458065	0.85	rs7785999	ENSG00000229358.3	DPY19L1P1	-3.92	9.54e-05	0.00602	-0.16	-0.12	Metabolite levels (HVA/MHPG ratio);	chr7:32421650	chr7:32580949~32761787:-
BRCA	cis	rs7412746	0.611	rs2256355	ENSG00000224800.1	RP11-235D19.2	-3.92	9.54e-05	0.00602	-0.15	-0.12	Melanoma;	chr1:150839318	chr1:150881236~150881683:-
BRCA	cis	rs4650943	0.633	rs2455722	ENSG00000227740.1	RP11-318C24.2	-3.92	9.54e-05	0.00602	-0.12	-0.12	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in inactive individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr1:176422194	chr1:175904762~175920513:-
BRCA	cis	rs4415084	0.688	rs11741772	ENSG00000251141.4	RP11-53O19.1	3.92	9.54e-05	0.00602	0.11	0.12	Breast cancer;	chr5:44814495	chr5:44744900~44808777:-
BRCA	cis	rs2749097	0.735	rs7548548	ENSG00000244256.3	RN7SL130P	-3.92	9.54e-05	0.00602	-0.17	-0.12	Alcohol consumption (transferrin glycosylation);	chr1:63685698	chr1:63655743~63656047:+
BRCA	cis	rs8099594	0.565	rs7235532	ENSG00000266696.1	RP11-30L3.2	-3.92	9.54e-05	0.00602	-0.14	-0.12	Height;	chr18:49188326	chr18:49205912~49208781:+
BRCA	cis	rs6456156	0.792	rs2039321	ENSG00000272549.1	RP11-351J23.2	-3.92	9.55e-05	0.00602	-0.12	-0.12	Primary biliary cholangitis;	chr6:167102811	chr6:167666840~167679270:-
BRCA	cis	rs875971	0.862	rs10282433	ENSG00000271064.1	RP11-792A8.3	3.92	9.55e-05	0.00602	0.14	0.12	Aortic root size;	chr7:66256452	chr7:66748838~66749077:-
BRCA	cis	rs801193	1	rs1553609	ENSG00000229180.5	GS1-124K5.11	3.92	9.55e-05	0.00602	0.1	0.12	Aortic root size;	chr7:66732152	chr7:66526088~66542624:-
BRCA	cis	rs9467773	0.62	rs2451731	ENSG00000224843.5	LINC00240	-3.92	9.55e-05	0.00602	-0.13	-0.12	Intelligence (multi-trait analysis);	chr6:26624594	chr6:26956992~27023924:+
BRCA	cis	rs2032366	0.591	rs9783921	ENSG00000267279.1	RP11-879F14.2	3.92	9.55e-05	0.00602	0.16	0.12	Obesity-related traits;	chr18:61635219	chr18:61585746~61606916:-
BRCA	cis	rs739496	0.579	rs80017658	ENSG00000257624.1	RP1-128M12.3	3.92	9.55e-05	0.00602	0.16	0.12	Platelet count;	chr12:111942568	chr12:112000739~112000985:-
BRCA	cis	rs739496	0.579	rs73426362	ENSG00000257624.1	RP1-128M12.3	3.92	9.55e-05	0.00602	0.16	0.12	Platelet count;	chr12:111942666	chr12:112000739~112000985:-
BRCA	cis	rs983392	0.679	rs72920867	ENSG00000275344.1	MIR6503	-3.92	9.55e-05	0.00602	-0.13	-0.12	Alzheimer's disease (late onset);	chr11:60237951	chr11:60209071~60209156:-
BRCA	cis	rs10043228	1	rs12516100	ENSG00000271918.1	CTD-2287O16.5	-3.92	9.55e-05	0.00602	-0.17	-0.12	Asthma or chronic obstructive pulmonary disease;	chr5:116116053	chr5:116083807~116085416:-
BRCA	cis	rs3748682	0.861	rs2291297	ENSG00000222282.1	RNU6-584P	-3.92	9.56e-05	0.00602	-0.15	-0.12	Hypothyroidism;	chr1:37806988	chr1:37885023~37885117:+
BRCA	cis	rs17027633	0.881	rs76940009	ENSG00000260948.1	RP11-552M11.8	-3.92	9.56e-05	0.00603	-0.29	-0.12	Cerebrospinal fluid t-tau:AB1-42 ratio;	chr1:111466408	chr1:111431046~111433068:-
BRCA	cis	rs13108904	0.935	rs13148614	ENSG00000196810.4	CTBP1-AS2	3.92	9.56e-05	0.00603	0.13	0.12	Obesity-related traits;	chr4:1254569	chr4:1249300~1288291:+
BRCA	cis	rs8062405	1	rs1987472	ENSG00000261766.1	RP11-22P6.2	-3.92	9.56e-05	0.00603	-0.12	-0.12	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814456	chr16:28862166~28863340:-
BRCA	cis	rs8062405	0.895	rs56186137	ENSG00000261766.1	RP11-22P6.2	-3.92	9.56e-05	0.00603	-0.12	-0.12	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814632	chr16:28862166~28863340:-
BRCA	cis	rs8114671	0.935	rs945960	ENSG00000279253.1	RP4-614O4.13	-3.92	9.56e-05	0.00603	-0.14	-0.12	Height;	chr20:35175051	chr20:35262727~35264187:-
BRCA	cis	rs8114671	0.967	rs2069952	ENSG00000279253.1	RP4-614O4.13	-3.92	9.56e-05	0.00603	-0.14	-0.12	Height;	chr20:35176148	chr20:35262727~35264187:-
BRCA	cis	rs733592	0.524	rs10875744	ENSG00000257763.1	OR5BK1P	3.92	9.56e-05	0.00603	0.12	0.12	Plateletcrit;	chr12:48104657	chr12:48355792~48356614:-
BRCA	cis	rs801193	0.904	rs4718403	ENSG00000229180.5	GS1-124K5.11	3.92	9.57e-05	0.00603	0.1	0.12	Aortic root size;	chr7:66777742	chr7:66526088~66542624:-
BRCA	cis	rs1048886	0.872	rs75179941	ENSG00000271967.1	RP11-134K13.4	-3.92	9.57e-05	0.00603	-0.18	-0.12	Type 2 diabetes;	chr6:70563130	chr6:70596438~70596980:+
BRCA	cis	rs1555133	0.92	rs4911235	ENSG00000277692.1	RP11-358N2.2	-3.92	9.57e-05	0.00603	-0.13	-0.12	Monocyte count;	chr20:32490803	chr20:32355053~32355734:+
BRCA	cis	rs1008375	0.9	rs1003413	ENSG00000249502.1	AC006160.5	3.92	9.57e-05	0.00603	0.15	0.12	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17580819	chr4:17587467~17614571:-
BRCA	cis	rs6545883	1	rs778758	ENSG00000270820.4	RP11-355B11.2	3.92	9.57e-05	0.00603	0.14	0.12	Tuberculosis;	chr2:61555026	chr2:61471188~61484130:+
BRCA	cis	rs977987	0.806	rs72787160	ENSG00000280152.1	RP11-331F4.5	-3.92	9.57e-05	0.00603	-0.12	-0.12	Dupuytren's disease;	chr16:75411264	chr16:75245994~75250077:-
BRCA	cis	rs8062405	1	rs62037371	ENSG00000261766.1	RP11-22P6.2	-3.92	9.57e-05	0.00603	-0.12	-0.12	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28878810	chr16:28862166~28863340:-
BRCA	cis	rs2278034	0.578	rs881753	ENSG00000229178.1	AC069513.4	3.92	9.57e-05	0.00603	0.14	0.12	Bronchopulmonary dysplasia;	chr3:195879899	chr3:195655565~195657927:-
BRCA	cis	rs6719977	0.935	rs2289355	ENSG00000226491.1	FTOP1	-3.92	9.57e-05	0.00603	-0.14	-0.12	Hyperactive-impulsive symptoms;	chr2:42754850	chr2:42797225~42798712:-
BRCA	cis	rs9733	0.519	rs11800855	ENSG00000231073.1	RP11-316M1.3	3.92	9.57e-05	0.00603	0.13	0.12	Tonsillectomy;	chr1:150828519	chr1:150973123~150975534:+
BRCA	cis	rs754466	0.58	rs10824576	ENSG00000213514.2	RP11-428P16.2	3.92	9.57e-05	0.00603	0.16	0.12	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77806282	chr10:77730766~77734769:+
BRCA	cis	rs11098499	0.865	rs11098513	ENSG00000225892.3	RP11-384K6.2	3.92	9.57e-05	0.00603	0.12	0.12	Corneal astigmatism;	chr4:119394920	chr4:118632274~118634759:+
BRCA	cis	rs698833	0.521	rs35627501	ENSG00000223658.6	AC011242.6	3.92	9.57e-05	0.00603	0.14	0.12	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr2:44279832	chr2:43675380~43676322:-
BRCA	cis	rs34975555	0.568	rs3739402	ENSG00000254054.2	RP11-156K13.3	-3.92	9.57e-05	0.00603	-0.17	-0.12	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:17978139	chr8:17905756~17907887:+
BRCA	cis	rs8180040	0.739	rs12488225	ENSG00000260236.1	RP11-708J19.1	3.92	9.57e-05	0.00603	0.11	0.12	Colorectal cancer;	chr3:47193617	chr3:47379089~47380999:-
BRCA	cis	rs11098499	0.908	rs28499576	ENSG00000260404.2	RP11-384K6.6	3.92	9.57e-05	0.00603	0.11	0.12	Corneal astigmatism;	chr4:119465522	chr4:118591773~118633729:+
BRCA	cis	rs8180040	0.587	rs62246398	ENSG00000271161.1	BOLA2P2	-3.92	9.58e-05	0.00604	-0.13	-0.12	Colorectal cancer;	chr3:47024713	chr3:47499841~47500407:+
BRCA	cis	rs683250	0.629	rs685398	ENSG00000254551.1	RP11-727A23.7	3.92	9.58e-05	0.00604	0.15	0.12	Subcortical brain region volumes;	chr11:83249233	chr11:83209431~83213379:-
BRCA	cis	rs11098499	0.954	rs59394118	ENSG00000250412.1	KLHL2P1	3.92	9.58e-05	0.00604	0.14	0.12	Corneal astigmatism;	chr4:119374396	chr4:119334329~119378233:+
BRCA	cis	rs11098499	0.865	rs9996417	ENSG00000250412.1	KLHL2P1	3.92	9.58e-05	0.00604	0.14	0.12	Corneal astigmatism;	chr4:119374707	chr4:119334329~119378233:+
BRCA	cis	rs6480314	0.831	rs2166221	ENSG00000233590.1	RP11-153K11.3	3.92	9.58e-05	0.00604	0.19	0.12	Optic nerve measurement (disc area);	chr10:68222541	chr10:68233251~68242379:-
BRCA	cis	rs1910358	0.69	rs951856	ENSG00000248874.4	C5orf17	-3.92	9.58e-05	0.00604	-0.16	-0.12	Venous thromboembolism (SNP x SNP interaction);	chr5:23976614	chr5:23951348~24178263:+
BRCA	cis	rs1910358	0.664	rs951855	ENSG00000248874.4	C5orf17	-3.92	9.58e-05	0.00604	-0.16	-0.12	Venous thromboembolism (SNP x SNP interaction);	chr5:23976864	chr5:23951348~24178263:+
BRCA	cis	rs2071426	0.622	rs7919295	ENSG00000273450.1	RP11-76P2.4	3.92	9.58e-05	0.00604	0.15	0.12	Blood metabolite levels;	chr10:95013051	chr10:94314907~94315327:-
BRCA	cis	rs9470794	0.915	rs55811006	ENSG00000204110.6	RP1-153P14.8	-3.92	9.58e-05	0.00604	-0.26	-0.12	Type 2 diabetes;	chr6:37795172	chr6:37507348~37535616:+
BRCA	cis	rs35740288	0.822	rs11638720	ENSG00000259407.1	RP11-158M2.3	-3.92	9.58e-05	0.00604	-0.16	-0.12	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85686042	chr15:85744109~85750281:-
BRCA	cis	rs35740288	0.822	rs2016517	ENSG00000259407.1	RP11-158M2.3	-3.92	9.58e-05	0.00604	-0.16	-0.12	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85686387	chr15:85744109~85750281:-
BRCA	cis	rs11098499	0.954	rs10518331	ENSG00000260404.2	RP11-384K6.6	3.92	9.58e-05	0.00604	0.11	0.12	Corneal astigmatism;	chr4:119402440	chr4:118591773~118633729:+
BRCA	cis	rs6121246	0.909	rs6060821	ENSG00000230613.1	HM13-AS1	3.92	9.58e-05	0.00604	0.18	0.12	Mean corpuscular hemoglobin;	chr20:31706231	chr20:31567707~31573263:-
BRCA	cis	rs728616	0.614	rs55720611	ENSG00000225484.5	NUTM2B-AS1	-3.92	9.59e-05	0.00604	-0.24	-0.12	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80030543	chr10:79663088~79826594:-
BRCA	cis	rs9346455	1	rs12055385	ENSG00000279289.1	RP3-331H24.6	3.92	9.59e-05	0.00604	0.2	0.12	Antipsychotic drug-induced weight gain;Antipsychotic drug-induced weight gain (time interaction);	chr6:71287086	chr6:71386852~71390829:-
BRCA	cis	rs6517329	0.7	rs11911678	ENSG00000231106.2	LINC01436	3.92	9.59e-05	0.00604	0.14	0.12	Schizophrenia;	chr21:36110704	chr21:36005338~36007838:+
BRCA	cis	rs4363385	0.934	rs1415964	ENSG00000272654.1	RP11-422P24.11	3.92	9.59e-05	0.00604	0.13	0.12	Inflammatory skin disease;	chr1:152982609	chr1:153977743~153979160:+
BRCA	cis	rs4950322	0.58	rs4950308	ENSG00000237188.3	RP11-337C18.8	3.92	9.59e-05	0.00604	0.14	0.12	Protein quantitative trait loci;	chr1:147120092	chr1:147172771~147211568:+
BRCA	cis	rs859767	1	rs859767	ENSG00000224043.6	CCNT2-AS1	-3.92	9.59e-05	0.00604	-0.17	-0.12	Neuroticism;	chr2:134583630	chr2:134735464~134918710:-
BRCA	cis	rs10266483	0.705	rs599522	ENSG00000271550.1	BNIP3P11	3.92	9.59e-05	0.00604	0.16	0.12	Response to statin therapy;	chr7:64298104	chr7:64678954~64687393:-
BRCA	cis	rs7833790	1	rs7833790	ENSG00000254689.1	RP11-354A14.1	3.92	9.59e-05	0.00604	0.16	0.12	Diastolic blood pressure;	chr8:81818922	chr8:81885377~81923193:+
BRCA	cis	rs2562456	0.917	rs2681392	ENSG00000268555.1	RP11-678G14.3	-3.92	9.59e-05	0.00604	-0.16	-0.12	Pain;	chr19:21513185	chr19:21570822~21587322:-
BRCA	cis	rs9733	0.596	rs72702556	ENSG00000231073.1	RP11-316M1.3	3.92	9.59e-05	0.00605	0.13	0.12	Tonsillectomy;	chr1:150707639	chr1:150973123~150975534:+
BRCA	cis	rs853679	0.546	rs35819751	ENSG00000216901.1	AL022393.7	3.92	9.59e-05	0.00605	0.31	0.12	Depression;	chr6:27842791	chr6:28176188~28176674:+
BRCA	cis	rs2835872	0.828	rs857980	ENSG00000228677.1	TTC3-AS1	3.92	9.59e-05	0.00605	0.16	0.12	Electroencephalographic traits in alcoholism;	chr21:37622840	chr21:37187666~37193926:-
BRCA	cis	rs6015450	1	rs73306860	ENSG00000228340.4	MIR646HG	3.92	9.59e-05	0.00605	0.23	0.12	Hypertension;Blood pressure;Systolic blood pressure;Diastolic blood pressure;	chr20:59150608	chr20:60087840~60527458:+
BRCA	cis	rs2274459	1	rs729376	ENSG00000249346.5	LINC01016	3.92	9.6e-05	0.00605	0.16	0.12	Obesity (extreme);	chr6:33737046	chr6:33867506~33896914:-
BRCA	cis	rs875971	0.862	rs10256544	ENSG00000229886.1	RP5-1132H15.3	3.92	9.6e-05	0.00605	0.13	0.12	Aortic root size;	chr7:66210141	chr7:66025126~66031544:-
BRCA	cis	rs5749696	1	rs5749696	ENSG00000272954.1	KB-1440D3.13	3.92	9.6e-05	0.00605	0.12	0.12	Schizophrenia;	chr22:21709048	chr22:21661934~21662363:+
BRCA	cis	rs17489649	1	rs929749	ENSG00000271849.1	CTC-332L22.1	3.92	9.6e-05	0.00605	0.16	0.12	Intelligence (multi-trait analysis);	chr5:109696816	chr5:109687802~109688329:-
BRCA	cis	rs12317459	1	rs12317459	ENSG00000213270.5	RPL6P25	-3.92	9.6e-05	0.00605	-0.17	-0.12	Prostate cancer (SNP x SNP interaction);	chr12:82770777	chr12:83151331~83152190:+
BRCA	cis	rs1910358	0.676	rs2088920	ENSG00000248874.4	C5orf17	-3.92	9.6e-05	0.00605	-0.16	-0.12	Venous thromboembolism (SNP x SNP interaction);	chr5:24008266	chr5:23951348~24178263:+
BRCA	cis	rs1910358	0.676	rs2088922	ENSG00000248874.4	C5orf17	-3.92	9.6e-05	0.00605	-0.16	-0.12	Venous thromboembolism (SNP x SNP interaction);	chr5:24008590	chr5:23951348~24178263:+
BRCA	cis	rs911119	1	rs6114208	ENSG00000270001.1	RP11-218C14.8	-3.92	9.6e-05	0.00605	-0.16	-0.12	Chronic kidney disease;	chr20:23641097	chr20:23631826~23632316:-
BRCA	cis	rs7772486	0.875	rs1331644	ENSG00000270638.1	RP3-466P17.1	3.92	9.6e-05	0.00605	0.14	0.12	Lobe attachment (rater-scored or self-reported);	chr6:146077524	chr6:145735570~145737218:+
BRCA	cis	rs962856	0.964	rs11890812	ENSG00000236605.1	AC023115.4	3.92	9.6e-05	0.00605	0.14	0.12	Pancreatic cancer;	chr2:67392883	chr2:67324627~67325304:+
BRCA	cis	rs442309	0.841	rs224030	ENSG00000238280.1	RP11-436D10.3	-3.92	9.6e-05	0.00605	-0.15	-0.12	Vogt-Koyanagi-Harada syndrome;	chr10:62760375	chr10:62793562~62805887:-
BRCA	cis	rs219780	0.948	rs219788	ENSG00000233818.1	AP000695.4	3.92	9.6e-05	0.00605	0.14	0.12	Kidney stones;	chr21:36456864	chr21:36445731~36532408:+
BRCA	cis	rs7395581	0.918	rs1052373	ENSG00000280615.1	Y_RNA	-3.92	9.6e-05	0.00605	-0.14	-0.12	HDL cholesterol;	chr11:47333236	chr11:47614898~47614994:-
BRCA	cis	rs875971	0.642	rs35526611	ENSG00000272831.1	RP11-792A8.4	-3.92	9.6e-05	0.00605	-0.11	-0.12	Aortic root size;	chr7:66629021	chr7:66739829~66740385:-
BRCA	cis	rs6429082	0.509	rs6699315	ENSG00000230026.2	RP11-382D8.5	3.92	9.61e-05	0.00605	0.13	0.12	Adiposity;	chr1:235361938	chr1:235361153~235362540:+
BRCA	cis	rs983392	0.559	rs1426249	ENSG00000275344.1	MIR6503	-3.92	9.61e-05	0.00605	-0.12	-0.12	Alzheimer's disease (late onset);	chr11:60234788	chr11:60209071~60209156:-
BRCA	cis	rs2075466	0.588	rs111618721	ENSG00000267077.1	RP11-127I20.5	3.92	9.61e-05	0.00605	0.18	0.12	Colonoscopy-negative controls vs population controls;	chr16:4827865	chr16:4795265~4796532:-
BRCA	cis	rs7037266	1	rs3818896	ENSG00000232946.1	RP11-390F4.2	-3.92	9.61e-05	0.00605	-0.14	-0.12	Menarche (age at onset);	chr9:6941889	chr9:6675284~6675614:+
BRCA	cis	rs41308713	0.681	rs8116426	ENSG00000196756.10	SNHG17	-3.92	9.61e-05	0.00605	-0.29	-0.12	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr20:38405996	chr20:38420588~38435353:-
BRCA	cis	rs41308713	0.786	rs8116471	ENSG00000196756.10	SNHG17	-3.92	9.61e-05	0.00605	-0.29	-0.12	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr20:38406047	chr20:38420588~38435353:-
BRCA	cis	rs2915864	0.718	rs2906072	ENSG00000280047.1	CTC-463A16.1	3.92	9.61e-05	0.00606	0.17	0.12	Facial morphology (factor 20);	chr5:142197921	chr5:142165767~142168387:+
BRCA	cis	rs4819052	0.851	rs2838843	ENSG00000215447.6	BX322557.10	-3.92	9.61e-05	0.00606	-0.12	-0.12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45249369	chr21:45288052~45291738:+
BRCA	cis	rs3760982	0.845	rs62116962	ENSG00000267191.1	RP11-15A1.2	3.92	9.61e-05	0.00606	0.15	0.12	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43783082	chr19:43902001~43926545:+
BRCA	cis	rs600550	0.719	rs10897020	ENSG00000275344.1	MIR6503	3.92	9.62e-05	0.00606	0.13	0.12	Lipoprotein-associated phospholipase A2 activity and mass;	chr11:60270094	chr11:60209071~60209156:-
BRCA	cis	rs10986311	0.851	rs1045774	ENSG00000227200.1	RP11-121A14.3	-3.92	9.62e-05	0.00606	-0.14	-0.12	Vitiligo;	chr9:124270328	chr9:124262876~124265809:+
BRCA	cis	rs7551222	0.752	rs4951407	ENSG00000240219.1	RP11-430C7.5	-3.92	9.62e-05	0.00606	-0.14	-0.12	Schizophrenia;	chr1:204588942	chr1:204626775~204629712:+
BRCA	cis	rs8030379	1	rs11633301	ENSG00000176700.18	SCAND2P	3.92	9.62e-05	0.00606	0.11	0.12	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83916286	chr15:84631451~84647478:+
BRCA	cis	rs6545883	0.929	rs2600663	ENSG00000212978.6	AC016747.3	-3.92	9.62e-05	0.00606	-0.16	-0.12	Tuberculosis;	chr2:61313552	chr2:61141592~61144969:-
BRCA	cis	rs2777491	0.574	rs28700583	ENSG00000247556.5	OIP5-AS1	3.92	9.62e-05	0.00606	0.14	0.12	Ulcerative colitis;	chr15:41421874	chr15:41283990~41309737:+
BRCA	cis	rs3743102	1	rs3803383	ENSG00000255769.6	GOLGA2P10	3.92	9.62e-05	0.00606	0.18	0.12	Colorectal adenoma (advanced);	chr15:82754741	chr15:82472993~82513950:-
BRCA	cis	rs4854307	0.59	rs4854263	ENSG00000272342.1	RP13-539J13.1	-3.92	9.62e-05	0.00606	-0.23	-0.12	Body mass index;	chr2:455588	chr2:739588~740164:-
BRCA	cis	rs7703051	0.601	rs13358429	ENSG00000271815.1	CTD-2235C13.3	-3.92	9.63e-05	0.00606	-0.15	-0.12	Age-related diseases, mortality and associated endophenotypes;LDL cholesterol;Age-related disease endophenotypes;	chr5:75322361	chr5:75363760~75364242:+
BRCA	cis	rs4478858	0.735	rs10914344	ENSG00000260386.4	LINC01225	-3.92	9.63e-05	0.00606	-0.14	-0.12	Alcohol dependence;	chr1:31296178	chr1:31500085~31540885:+
BRCA	cis	rs4218	0.648	rs57361749	ENSG00000259732.1	RP11-59H7.3	-3.91	9.63e-05	0.00606	-0.15	-0.12	Social communication problems;	chr15:59091352	chr15:59121034~59133250:+
BRCA	cis	rs925550	0.932	rs7685595	ENSG00000224786.1	CETN4P	-3.91	9.63e-05	0.00606	-0.2	-0.12	Primary biliary cholangitis;	chr4:122681624	chr4:122730548~122732193:-
BRCA	cis	rs801193	0.548	rs6975044	ENSG00000229886.1	RP5-1132H15.3	3.91	9.63e-05	0.00606	0.13	0.12	Aortic root size;	chr7:66762495	chr7:66025126~66031544:-
BRCA	cis	rs1881509	0.702	rs6578333	ENSG00000233930.3	KRTAP5-AS1	-3.91	9.63e-05	0.00606	-0.17	-0.12	Heroin dependence;	chr11:1415484	chr11:1571353~1599184:+
BRCA	cis	rs4415084	1	rs1371027	ENSG00000248779.1	RP11-53O19.2	3.91	9.63e-05	0.00606	0.11	0.12	Breast cancer;	chr5:44699755	chr5:44752949~44765744:+
BRCA	cis	rs4415084	0.966	rs714130	ENSG00000248779.1	RP11-53O19.2	3.91	9.63e-05	0.00606	0.11	0.12	Breast cancer;	chr5:44701316	chr5:44752949~44765744:+
BRCA	cis	rs4664293	0.605	rs2042774	ENSG00000226266.5	AC009961.3	3.91	9.63e-05	0.00606	0.14	0.12	Monocyte percentage of white cells;	chr2:159653496	chr2:159670708~159712435:-
BRCA	cis	rs4664293	0.647	rs2042775	ENSG00000226266.5	AC009961.3	3.91	9.63e-05	0.00606	0.14	0.12	Monocyte percentage of white cells;	chr2:159653581	chr2:159670708~159712435:-
BRCA	cis	rs12681366	0.537	rs3019284	ENSG00000253175.1	RP11-267M23.6	3.91	9.63e-05	0.00607	0.14	0.12	Nonsyndromic cleft lip with cleft palate;	chr8:94460848	chr8:94565036~94565715:+
BRCA	cis	rs11893307	0.599	rs11900857	ENSG00000235852.1	AC005540.3	3.91	9.63e-05	0.00607	0.16	0.12	Mean platelet volume;	chr2:190794285	chr2:190880797~190882059:-
BRCA	cis	rs818427	0.963	rs153545	ENSG00000279522.1	CTC-487M23.6	3.91	9.64e-05	0.00607	0.14	0.12	Total body bone mineral density;	chr5:112903185	chr5:112894933~112896531:+
BRCA	cis	rs9307551	0.697	rs4975052	ENSG00000250334.4	LINC00989	-3.91	9.64e-05	0.00607	-0.19	-0.12	Refractive error;	chr4:79505054	chr4:79492416~79576460:+
BRCA	cis	rs2191566	0.96	rs367209	ENSG00000266921.1	RP11-15A1.7	3.91	9.64e-05	0.00607	0.15	0.12	Acute lymphoblastic leukemia (childhood);	chr19:44002097	chr19:43996896~44002836:-
BRCA	cis	rs4237845	0.537	rs11172367	ENSG00000270039.1	RP11-571M6.17	-3.91	9.64e-05	0.00607	-0.17	-0.12	Intelligence (multi-trait analysis);	chr12:57878703	chr12:57803838~57804415:+
BRCA	cis	rs11673344	0.523	rs2385415	ENSG00000276846.1	CTD-3220F14.3	3.91	9.64e-05	0.00607	0.14	0.12	Obesity-related traits;	chr19:37035291	chr19:37314868~37315620:-
BRCA	cis	rs7576126	1	rs7576126	ENSG00000281920.1	RP11-418H16.1	-3.91	9.64e-05	0.00607	-0.14	-0.12	Severe influenza A (H1N1) infection;	chr2:65431235	chr2:65623272~65628424:+
BRCA	cis	rs4664293	0.647	rs4144512	ENSG00000226266.5	AC009961.3	3.91	9.64e-05	0.00607	0.14	0.12	Monocyte percentage of white cells;	chr2:159651008	chr2:159670708~159712435:-
BRCA	cis	rs4664293	0.625	rs13006088	ENSG00000226266.5	AC009961.3	3.91	9.64e-05	0.00607	0.14	0.12	Monocyte percentage of white cells;	chr2:159652915	chr2:159670708~159712435:-
BRCA	cis	rs10510102	0.516	rs10159759	ENSG00000226864.1	ATE1-AS1	3.91	9.65e-05	0.00607	0.24	0.12	Breast cancer;	chr10:121986533	chr10:121928312~121951965:+
BRCA	cis	rs10510102	0.516	rs10159589	ENSG00000226864.1	ATE1-AS1	3.91	9.65e-05	0.00607	0.24	0.12	Breast cancer;	chr10:121986659	chr10:121928312~121951965:+
BRCA	cis	rs2280018	1	rs2280018	ENSG00000188599.16	NPIPP1	-3.91	9.65e-05	0.00607	-0.1	-0.12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15056976	chr16:15104312~15123498:-
BRCA	cis	rs2736345	0.788	rs998683	ENSG00000255046.1	RP11-297N6.4	3.91	9.65e-05	0.00608	0.16	0.12	Systemic lupus erythematosus;Sjögren's syndrome;	chr8:11495491	chr8:11797928~11802568:-
BRCA	cis	rs7312933	0.645	rs11181404	ENSG00000257225.1	RP11-328C8.4	-3.91	9.65e-05	0.00608	-0.15	-0.12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42290038	chr12:42459366~42466128:+
BRCA	cis	rs251253	0.827	rs2560325	ENSG00000253959.1	CTB-43E15.1	-3.91	9.65e-05	0.00608	-0.11	-0.12	PR interval;	chr5:173076461	chr5:173642519~173658194:+
BRCA	cis	rs6088580	0.634	rs4911420	ENSG00000275784.1	RP5-1125A11.6	3.91	9.65e-05	0.00608	0.13	0.12	Glomerular filtration rate (creatinine);	chr20:34410848	chr20:33989480~33991818:-
BRCA	cis	rs11711311	1	rs9288984	ENSG00000241529.3	RN7SL767P	-3.91	9.65e-05	0.00608	-0.14	-0.12	IgG glycosylation;	chr3:113807109	chr3:113632704~113632998:+
BRCA	cis	rs4767841	0.868	rs2996028	ENSG00000248636.5	RP11-768F21.1	-3.91	9.66e-05	0.00608	-0.15	-0.12	Urgency urinary incontinence;	chr12:119727350	chr12:119387987~119668079:-
BRCA	cis	rs13358904	1	rs12719140	ENSG00000278921.2	EPB41L4A-AS2	3.91	9.66e-05	0.00608	0.14	0.12	Suicide ideation score in major depressive disorder;	chr5:112266906	chr5:112419583~112420978:+
BRCA	cis	rs6599077	0.95	rs60037145	ENSG00000223797.4	ENTPD3-AS1	3.91	9.66e-05	0.00608	0.15	0.12	Sleep-related phenotypes;	chr3:40061427	chr3:40313802~40453329:-
BRCA	cis	rs6599077	0.95	rs9809788	ENSG00000223797.4	ENTPD3-AS1	3.91	9.66e-05	0.00608	0.15	0.12	Sleep-related phenotypes;	chr3:40062243	chr3:40313802~40453329:-
BRCA	cis	rs6599077	0.95	rs11706046	ENSG00000223797.4	ENTPD3-AS1	3.91	9.66e-05	0.00608	0.15	0.12	Sleep-related phenotypes;	chr3:40062646	chr3:40313802~40453329:-
BRCA	cis	rs6599077	0.95	rs4676562	ENSG00000223797.4	ENTPD3-AS1	3.91	9.66e-05	0.00608	0.15	0.12	Sleep-related phenotypes;	chr3:40063548	chr3:40313802~40453329:-
BRCA	cis	rs6599077	0.95	rs4676563	ENSG00000223797.4	ENTPD3-AS1	3.91	9.66e-05	0.00608	0.15	0.12	Sleep-related phenotypes;	chr3:40063601	chr3:40313802~40453329:-
BRCA	cis	rs6599077	0.95	rs9863161	ENSG00000223797.4	ENTPD3-AS1	3.91	9.66e-05	0.00608	0.15	0.12	Sleep-related phenotypes;	chr3:40063845	chr3:40313802~40453329:-
BRCA	cis	rs17301013	0.932	rs12074753	ENSG00000234741.6	GAS5	3.91	9.66e-05	0.00608	0.12	0.12	Systemic lupus erythematosus;	chr1:174565768	chr1:173863900~173868882:-
BRCA	cis	rs17301013	0.932	rs1016466	ENSG00000234741.6	GAS5	3.91	9.66e-05	0.00608	0.12	0.12	Systemic lupus erythematosus;	chr1:174570652	chr1:173863900~173868882:-
BRCA	cis	rs17301013	0.932	rs10753086	ENSG00000234741.6	GAS5	3.91	9.66e-05	0.00608	0.12	0.12	Systemic lupus erythematosus;	chr1:174580802	chr1:173863900~173868882:-
BRCA	cis	rs8062405	1	rs2008514	ENSG00000261766.1	RP11-22P6.2	3.91	9.66e-05	0.00608	0.12	0.12	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814284	chr16:28862166~28863340:-
BRCA	cis	rs10005067	0.735	rs9998343	ENSG00000249001.4	RP11-742B18.1	-3.91	9.66e-05	0.00608	-0.14	-0.12	Total body bone mineral density (age 30-45);	chr4:87850459	chr4:87568035~87733956:-
BRCA	cis	rs1048886	0.938	rs9455094	ENSG00000271967.1	RP11-134K13.4	-3.91	9.66e-05	0.00608	-0.16	-0.12	Type 2 diabetes;	chr6:70417201	chr6:70596438~70596980:+
BRCA	cis	rs1048886	0.938	rs7766075	ENSG00000271967.1	RP11-134K13.4	-3.91	9.66e-05	0.00608	-0.16	-0.12	Type 2 diabetes;	chr6:70418235	chr6:70596438~70596980:+
BRCA	cis	rs1048886	0.938	rs3889007	ENSG00000271967.1	RP11-134K13.4	-3.91	9.66e-05	0.00608	-0.16	-0.12	Type 2 diabetes;	chr6:70419086	chr6:70596438~70596980:+
BRCA	cis	rs1048886	0.938	rs3846750	ENSG00000271967.1	RP11-134K13.4	-3.91	9.66e-05	0.00608	-0.16	-0.12	Type 2 diabetes;	chr6:70419576	chr6:70596438~70596980:+
BRCA	cis	rs957448	1	rs60655325	ENSG00000261437.1	RP11-22C11.2	3.91	9.66e-05	0.00608	0.13	0.12	Nonsyndromic cleft lip with cleft palate;	chr8:94552606	chr8:94637285~94639467:-
BRCA	cis	rs1048886	0.938	rs6901904	ENSG00000271967.1	RP11-134K13.4	-3.91	9.66e-05	0.00608	-0.17	-0.12	Type 2 diabetes;	chr6:70471972	chr6:70596438~70596980:+
BRCA	cis	rs1048886	0.938	rs73482557	ENSG00000271967.1	RP11-134K13.4	-3.91	9.66e-05	0.00608	-0.17	-0.12	Type 2 diabetes;	chr6:70473810	chr6:70596438~70596980:+
BRCA	cis	rs8180040	1	rs295442	ENSG00000276925.1	RP11-708J19.3	-3.91	9.66e-05	0.00608	-0.14	-0.12	Colorectal cancer;	chr3:47294391	chr3:47469777~47469987:+
BRCA	cis	rs4561483	0.801	rs4511557	ENSG00000261216.1	RP11-166B2.5	3.91	9.66e-05	0.00608	0.14	0.12	Testicular germ cell tumor;	chr16:11855601	chr16:11908208~11908916:+
BRCA	cis	rs3808502	0.527	rs2736374	ENSG00000248896.2	CTD-2135J3.3	-3.91	9.66e-05	0.00608	-0.15	-0.12	Neuroticism;	chr8:11256319	chr8:10729314~10771392:+
BRCA	cis	rs76092474	0.826	rs10484445	ENSG00000279114.1	RP3-425C14.5	3.91	9.67e-05	0.00608	0.18	0.12	Breast cancer;	chr6:122448707	chr6:122471923~122484161:+
BRCA	cis	rs7735319	0.565	rs9292482	ENSG00000249572.1	CTD-2203K17.1	-3.91	9.67e-05	0.00608	-0.15	-0.12	Systolic blood pressure;	chr5:33140561	chr5:33424025~33440619:-
BRCA	cis	rs875971	0.862	rs11773628	ENSG00000106610.13	STAG3L4	3.91	9.67e-05	0.00609	0.16	0.12	Aortic root size;	chr7:66517644	chr7:67302621~67321526:+
BRCA	cis	rs4415084	0.745	rs12188871	ENSG00000251141.4	RP11-53O19.1	3.91	9.67e-05	0.00609	0.11	0.12	Breast cancer;	chr5:44813902	chr5:44744900~44808777:-
BRCA	cis	rs12144309	0.577	rs11102660	ENSG00000232450.1	RP4-730K3.3	-3.91	9.67e-05	0.00609	-0.19	-0.12	Coronary artery disease;	chr1:113608095	chr1:113698884~113699631:-
BRCA	cis	rs3960554	0.569	rs1894761	ENSG00000186704.9	DTX2P1	-3.91	9.68e-05	0.00609	-0.15	-0.12	Eotaxin levels;	chr7:76247436	chr7:76978617~77004308:+
BRCA	cis	rs6973609	0.927	rs10238969	ENSG00000271122.1	RP11-379H18.1	3.91	9.68e-05	0.00609	0.13	0.12	Obesity-related traits;	chr7:35569730	chr7:35695214~35699413:+
BRCA	cis	rs962856	0.964	rs1486135	ENSG00000236605.1	AC023115.4	3.91	9.68e-05	0.00609	0.14	0.12	Pancreatic cancer;	chr2:67369133	chr2:67324627~67325304:+
BRCA	cis	rs4578769	0.879	rs12963622	ENSG00000273232.1	RP11-370A5.2	3.91	9.68e-05	0.00609	0.16	0.12	Eosinophil percentage of white cells;	chr18:22859594	chr18:22882825~22883357:-
BRCA	cis	rs4578769	0.879	rs7241050	ENSG00000273232.1	RP11-370A5.2	3.91	9.68e-05	0.00609	0.16	0.12	Eosinophil percentage of white cells;	chr18:22860300	chr18:22882825~22883357:-
BRCA	cis	rs7246657	0.508	rs10419845	ENSG00000226686.6	LINC01535	-3.91	9.69e-05	0.0061	-0.22	-0.12	Coronary artery calcification;	chr19:37000290	chr19:37251912~37265535:+
BRCA	cis	rs10129255	0.536	rs10139058	ENSG00000232216.1	IGHV3-43	3.91	9.69e-05	0.0061	0.09	0.12	Kawasaki disease;	chr14:106685899	chr14:106470264~106470800:-
BRCA	cis	rs7412746	0.611	rs6660084	ENSG00000231073.1	RP11-316M1.3	3.91	9.69e-05	0.0061	0.13	0.12	Melanoma;	chr1:150776327	chr1:150973123~150975534:+
BRCA	cis	rs8114671	0.967	rs6088753	ENSG00000279253.1	RP4-614O4.13	-3.91	9.69e-05	0.0061	-0.14	-0.12	Height;	chr20:35180449	chr20:35262727~35264187:-
BRCA	cis	rs2562456	0.876	rs62110163	ENSG00000213976.4	CTD-2561J22.2	-3.91	9.69e-05	0.0061	-0.15	-0.12	Pain;	chr19:21546020	chr19:21382865~21387177:+
BRCA	cis	rs2562456	0.761	rs35008138	ENSG00000213976.4	CTD-2561J22.2	-3.91	9.69e-05	0.0061	-0.15	-0.12	Pain;	chr19:21548822	chr19:21382865~21387177:+
BRCA	cis	rs2562456	0.833	rs2681388	ENSG00000213976.4	CTD-2561J22.2	-3.91	9.69e-05	0.0061	-0.15	-0.12	Pain;	chr19:21549451	chr19:21382865~21387177:+
BRCA	cis	rs2562456	0.876	rs2681370	ENSG00000213976.4	CTD-2561J22.2	-3.91	9.69e-05	0.0061	-0.15	-0.12	Pain;	chr19:21554036	chr19:21382865~21387177:+
BRCA	cis	rs2562456	0.876	rs11668606	ENSG00000213976.4	CTD-2561J22.2	-3.91	9.69e-05	0.0061	-0.15	-0.12	Pain;	chr19:21554618	chr19:21382865~21387177:+
BRCA	cis	rs2562456	0.876	rs2681395	ENSG00000213976.4	CTD-2561J22.2	-3.91	9.69e-05	0.0061	-0.15	-0.12	Pain;	chr19:21555338	chr19:21382865~21387177:+
BRCA	cis	rs6545883	0.524	rs12713435	ENSG00000273302.1	RP11-493E12.2	-3.91	9.69e-05	0.0061	-0.1	-0.12	Tuberculosis;	chr2:61272654	chr2:61199979~61200769:+
BRCA	cis	rs2835345	0.563	rs60511692	ENSG00000233818.1	AP000695.4	3.91	9.69e-05	0.0061	0.13	0.12	Pulmonary function;	chr21:36454091	chr21:36445731~36532408:+
BRCA	cis	rs853679	1	rs853685	ENSG00000280107.1	AL022393.9	-3.91	9.69e-05	0.0061	-0.21	-0.12	Depression;	chr6:28321008	chr6:28170845~28172521:+
BRCA	cis	rs16957304	1	rs16957304	ENSG00000263276.1	RP11-96D1.10	3.91	9.69e-05	0.0061	0.19	0.12	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);	chr16:67301066	chr16:68224713~68227734:+
BRCA	cis	rs9921338	0.561	rs11859280	ENSG00000262636.1	CTD-3088G3.4	-3.91	9.69e-05	0.0061	-0.25	-0.12	Vein graft stenosis in coronary artery bypass grafting;	chr16:11376515	chr16:11380859~11381118:-
BRCA	cis	rs10129255	0.833	rs61997797	ENSG00000211958.2	IGHV3-38	3.91	9.69e-05	0.0061	0.1	0.12	Kawasaki disease;	chr14:106815190	chr14:106410493~106411021:-
BRCA	cis	rs747650	0.504	rs2087215	ENSG00000200376.1	RNU5E-10P	-3.91	9.69e-05	0.0061	-0.17	-0.12	Acne (severe);	chr11:47122991	chr11:47576471~47576588:-
BRCA	cis	rs7615952	0.688	rs12638240	ENSG00000248787.1	RP11-666A20.4	-3.91	9.7e-05	0.0061	-0.18	-0.12	Blood pressure (smoking interaction);	chr3:125822395	chr3:125908005~125910272:-
BRCA	cis	rs4650943	0.586	rs3123620	ENSG00000227740.1	RP11-318C24.2	-3.91	9.7e-05	0.0061	-0.12	-0.12	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in inactive individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr1:176325114	chr1:175904762~175920513:-
BRCA	cis	rs6545883	0.86	rs13023037	ENSG00000270820.4	RP11-355B11.2	-3.91	9.7e-05	0.0061	-0.14	-0.12	Tuberculosis;	chr2:61393854	chr2:61471188~61484130:+
BRCA	cis	rs6747972	0.965	rs12991815	ENSG00000236259.1	AC017083.2	3.91	9.7e-05	0.0061	0.14	0.12	Restless legs syndrome;	chr2:67844858	chr2:68125265~68125747:+
BRCA	cis	rs6088590	0.561	rs6088528	ENSG00000275784.1	RP5-1125A11.6	-3.91	9.71e-05	0.00611	-0.13	-0.12	Coronary artery disease;	chr20:34568938	chr20:33989480~33991818:-
BRCA	cis	rs875971	1	rs4718307	ENSG00000229180.5	GS1-124K5.11	-3.91	9.71e-05	0.00611	-0.1	-0.12	Aortic root size;	chr7:66146001	chr7:66526088~66542624:-
BRCA	cis	rs875971	1	rs7801282	ENSG00000229180.5	GS1-124K5.11	-3.91	9.71e-05	0.00611	-0.1	-0.12	Aortic root size;	chr7:66148700	chr7:66526088~66542624:-
BRCA	cis	rs6088590	0.523	rs6058084	ENSG00000275784.1	RP5-1125A11.6	-3.91	9.71e-05	0.00611	-0.13	-0.12	Coronary artery disease;	chr20:34596000	chr20:33989480~33991818:-
BRCA	cis	rs10129255	0.957	rs11847726	ENSG00000232216.1	IGHV3-43	3.91	9.71e-05	0.00611	0.1	0.12	Kawasaki disease;	chr14:106779116	chr14:106470264~106470800:-
BRCA	cis	rs2904967	0.5	rs3896078	ENSG00000255200.1	AP003068.18	3.91	9.71e-05	0.00611	0.26	0.12	Mean corpuscular volume;	chr11:65106790	chr11:65174117~65176470:-
BRCA	cis	rs10129255	0.912	rs67410411	ENSG00000231475.3	IGHV4-31	-3.91	9.71e-05	0.00611	-0.1	-0.12	Kawasaki disease;	chr14:106680324	chr14:106349283~106349792:-
BRCA	cis	rs2880765	0.677	rs7181410	ENSG00000202081.1	RNU6-1280P	-3.91	9.71e-05	0.00611	-0.14	-0.12	Coronary artery disease;	chr15:85463104	chr15:85651522~85651628:-
BRCA	cis	rs10986311	0.747	rs10760344	ENSG00000227200.1	RP11-121A14.3	-3.91	9.71e-05	0.00611	-0.15	-0.12	Vitiligo;	chr9:124264003	chr9:124262876~124265809:+
BRCA	cis	rs4478858	0.684	rs1532861	ENSG00000223907.1	LINC01226	-3.91	9.71e-05	0.00611	-0.15	-0.12	Alcohol dependence;	chr1:31293644	chr1:31518435~31524245:+
BRCA	cis	rs9423406	0.706	rs4881427	ENSG00000215267.7	AKR1C7P	-3.91	9.71e-05	0.00611	-0.23	-0.12	Intelligence;	chr10:5280034	chr10:5275173~5288470:-
BRCA	cis	rs300890	0.901	rs6537153	ENSG00000250326.1	RP11-284M14.1	-3.91	9.72e-05	0.00611	-0.14	-0.12	Nasopharyngeal carcinoma;	chr4:143309749	chr4:142933195~143184861:-
BRCA	cis	rs853679	0.517	rs9295761	ENSG00000261839.1	RP1-265C24.8	3.91	9.72e-05	0.00611	0.17	0.12	Depression;	chr6:28180209	chr6:28136849~28139678:+
BRCA	cis	rs7620503	1	rs6806363	ENSG00000277241.1	RP11-114M1.3	3.91	9.72e-05	0.00611	0.13	0.12	Corneal structure;	chr3:177576293	chr3:177700346~177701072:-
BRCA	cis	rs7833986	0.501	rs72653951	ENSG00000253603.1	CTA-397H3.3	-3.91	9.72e-05	0.00611	-0.17	-0.12	Height;	chr8:56049278	chr8:56074592~56075274:+
BRCA	cis	rs7615952	0.688	rs12638224	ENSG00000248787.1	RP11-666A20.4	-3.91	9.72e-05	0.00611	-0.18	-0.12	Blood pressure (smoking interaction);	chr3:125822477	chr3:125908005~125910272:-
BRCA	cis	rs17027750	0.947	rs7638187	ENSG00000271870.1	RP11-97C16.1	3.91	9.72e-05	0.00611	0.15	0.12	Basophil percentage of granulocytes;Basophil percentage of white cells;	chr3:3136151	chr3:3152942~3153435:+
BRCA	cis	rs115575488	0.85	rs77277973	ENSG00000236804.1	RPS3AP12	3.91	9.72e-05	0.00611	0.22	0.12	Lobe attachment (rater-scored or self-reported);	chr1:119124655	chr1:119126539~119127291:-
BRCA	cis	rs7947761	0.715	rs61621482	ENSG00000255059.1	AP000620.1	-3.91	9.72e-05	0.00612	-0.17	-0.12	Coronary artery disease;	chr11:100699329	chr11:100666459~100666962:+
BRCA	cis	rs7947761	0.715	rs57637131	ENSG00000255059.1	AP000620.1	-3.91	9.72e-05	0.00612	-0.17	-0.12	Coronary artery disease;	chr11:100699376	chr11:100666459~100666962:+
BRCA	cis	rs62621207	0.541	rs41444045	ENSG00000236662.1	RP11-108L7.4	-3.91	9.72e-05	0.00612	-0.29	-0.12	Lung cancer;	chr10:100985749	chr10:100980507~100985614:-
BRCA	cis	rs4073582	0.576	rs556595	ENSG00000255320.1	RP11-755F10.1	-3.91	9.73e-05	0.00612	-0.15	-0.12	Gout;	chr11:66290611	chr11:66244840~66246239:-
BRCA	cis	rs1552244	0.572	rs59132826	ENSG00000180385.7	EMC3-AS1	3.91	9.73e-05	0.00612	0.17	0.12	Alzheimer's disease;	chr3:10128041	chr3:9986893~10006990:+
BRCA	cis	rs1552244	0.572	rs58223482	ENSG00000180385.7	EMC3-AS1	3.91	9.73e-05	0.00612	0.17	0.12	Alzheimer's disease;	chr3:10128062	chr3:9986893~10006990:+
BRCA	cis	rs1552244	0.572	rs113406084	ENSG00000180385.7	EMC3-AS1	3.91	9.73e-05	0.00612	0.17	0.12	Alzheimer's disease;	chr3:10128506	chr3:9986893~10006990:+
BRCA	cis	rs875971	0.862	rs6944374	ENSG00000273024.4	INTS4P2	3.91	9.73e-05	0.00612	0.14	0.12	Aortic root size;	chr7:66221942	chr7:65647864~65715661:+
BRCA	cis	rs2408955	0.568	rs12099462	ENSG00000257735.1	RP11-370I10.6	-3.91	9.73e-05	0.00612	-0.15	-0.12	Glycated hemoglobin levels;	chr12:48109321	chr12:48350945~48442411:+
BRCA	cis	rs6893300	0.961	rs56335144	ENSG00000250999.1	RP11-1379J22.5	3.91	9.73e-05	0.00612	0.17	0.12	Resting heart rate;	chr5:179749626	chr5:179657762~179664432:+
BRCA	cis	rs1322639	0.614	rs4708414	ENSG00000223485.1	RP11-417E7.1	-3.91	9.73e-05	0.00612	-0.13	-0.12	Pulse pressure;	chr6:169174049	chr6:169158092~169162924:-
BRCA	cis	rs4718428	1	rs12534637	ENSG00000222364.1	RNU6-96P	-3.91	9.73e-05	0.00612	-0.14	-0.12	Corneal structure;	chr7:66862667	chr7:66395191~66395286:+
BRCA	cis	rs4925540	1	rs4925540	ENSG00000215796.3	RP11-551G24.2	-3.91	9.74e-05	0.00612	-0.14	-0.12	Response to taxane treatment (docetaxel);	chr1:247051576	chr1:247042791~247044021:+
BRCA	cis	rs2191566	1	rs369106	ENSG00000266921.1	RP11-15A1.7	3.91	9.74e-05	0.00612	0.15	0.12	Acute lymphoblastic leukemia (childhood);	chr19:44002778	chr19:43996896~44002836:-
BRCA	cis	rs7954584	0.611	rs3887885	ENSG00000272849.1	RP11-347I19.8	-3.91	9.74e-05	0.00612	-0.09	-0.12	Mean corpuscular volume;	chr12:121898580	chr12:121797511~121801972:+
BRCA	cis	rs957448	0.948	rs11992893	ENSG00000254315.1	RP11-267M23.3	3.91	9.74e-05	0.00612	0.16	0.12	Nonsyndromic cleft lip with cleft palate;	chr8:94508473	chr8:94533628~94534391:+
BRCA	cis	rs957448	1	rs1048029	ENSG00000254315.1	RP11-267M23.3	3.91	9.74e-05	0.00612	0.16	0.12	Nonsyndromic cleft lip with cleft palate;	chr8:94510149	chr8:94533628~94534391:+
BRCA	cis	rs78487399	0.808	rs6732766	ENSG00000234936.1	AC010883.5	3.91	9.74e-05	0.00612	0.18	0.12	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43485646	chr2:43229573~43233394:+
BRCA	cis	rs35740288	0.721	rs4843093	ENSG00000259407.1	RP11-158M2.3	-3.91	9.74e-05	0.00612	-0.16	-0.12	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85694202	chr15:85744109~85750281:-
BRCA	cis	rs801193	1	rs7785213	ENSG00000273142.1	RP11-458F8.4	3.91	9.74e-05	0.00613	0.1	0.12	Aortic root size;	chr7:66673991	chr7:66902857~66906297:+
BRCA	cis	rs7520050	0.966	rs785479	ENSG00000281133.1	AL355480.3	3.91	9.75e-05	0.00613	0.14	0.12	Reticulocyte count;Red blood cell count;	chr1:46026472	chr1:45580892~45580996:-
BRCA	cis	rs4699052	0.625	rs6828829	ENSG00000248740.4	RP11-328K4.1	3.91	9.75e-05	0.00613	0.14	0.12	Testicular germ cell tumor;	chr4:103414510	chr4:103256159~103453658:+
BRCA	cis	rs2514805	0.803	rs2513787	ENSG00000253585.1	KB-1184D12.1	3.91	9.75e-05	0.00613	0.21	0.12	Diisocyanate-induced asthma;	chr8:94114852	chr8:94097764~94104322:-
BRCA	cis	rs3735485	0.738	rs4392784	ENSG00000201772.1	SNORA5C	3.91	9.75e-05	0.00613	0.16	0.12	White blood cell count;Sum basophil neutrophil counts;Neutrophil count;Granulocyte percentage of myeloid white cells;Monocyte percentage of white cells;Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Lymphocyte counts;	chr7:45090914	chr7:45104906~45105042:-
BRCA	cis	rs10266483	0.843	rs667644	ENSG00000228653.2	HNRNPCP7	-3.91	9.75e-05	0.00613	-0.14	-0.12	Response to statin therapy;	chr7:64290180	chr7:64500825~64501729:+
BRCA	cis	rs2731006	0.64	rs2730966	ENSG00000257114.2	RP11-25I15.3	3.91	9.75e-05	0.00613	0.2	0.12	Panic disorder;	chr12:42781330	chr12:42692216~42717119:+
BRCA	cis	rs2731006	0.64	rs2678148	ENSG00000257114.2	RP11-25I15.3	3.91	9.75e-05	0.00613	0.2	0.12	Panic disorder;	chr12:42783661	chr12:42692216~42717119:+
BRCA	cis	rs957448	0.554	rs72674877	ENSG00000254315.1	RP11-267M23.3	3.91	9.75e-05	0.00613	0.15	0.12	Nonsyndromic cleft lip with cleft palate;	chr8:94580479	chr8:94533628~94534391:+
BRCA	cis	rs6593122	0.755	rs10247938	ENSG00000235454.1	HAUS6P3	-3.91	9.75e-05	0.00613	-0.16	-0.12	Vaccine-related adverse events;	chr7:54122030	chr7:53862233~53863339:+
BRCA	cis	rs6547741	0.844	rs9678851	ENSG00000234072.1	AC074117.10	-3.91	9.75e-05	0.00613	-0.11	-0.12	Oral cavity cancer;	chr2:27664167	chr2:27356246~27367622:+
BRCA	cis	rs78487399	0.908	rs76450091	ENSG00000234936.1	AC010883.5	3.91	9.75e-05	0.00613	0.18	0.12	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43540050	chr2:43229573~43233394:+
BRCA	cis	rs6696239	0.956	rs6656661	ENSG00000215812.5	ZNF847P	3.91	9.75e-05	0.00613	0.17	0.12	Height;	chr1:227617485	chr1:227696892~227706699:-
BRCA	cis	rs7656342	0.791	rs13140817	ENSG00000250342.1	SNRPCP16	-3.91	9.76e-05	0.00613	-0.14	-0.12	Gut microbiota (bacterial taxa);	chr4:9761351	chr4:9051842~9052051:-
BRCA	cis	rs7481584	0.624	rs397919	ENSG00000236710.1	AC108448.2	3.91	9.76e-05	0.00613	0.16	0.12	Calcium levels;	chr11:3041864	chr11:3084393~3085443:-
BRCA	cis	rs6993270	0.779	rs73703619	ENSG00000245330.4	KB-1471A8.1	-3.91	9.76e-05	0.00613	-0.19	-0.12	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr8:119916591	chr8:119867419~119874488:-
BRCA	cis	rs7131987	0.903	rs6487796	ENSG00000257176.2	RP11-996F15.2	-3.91	9.76e-05	0.00613	-0.14	-0.12	QT interval;	chr12:29269831	chr12:29280418~29317848:-
BRCA	cis	rs513088	0.681	rs503961	ENSG00000225171.2	DUTP6	3.91	9.76e-05	0.00613	0.17	0.12	Schizophrenia;	chr1:166694494	chr1:166868748~166869209:+
BRCA	cis	rs2625529	0.701	rs2306490	ENSG00000260037.4	CTD-2524L6.3	-3.91	9.76e-05	0.00613	-0.18	-0.12	Red blood cell count;	chr15:71935496	chr15:71818396~71823384:+
BRCA	cis	rs2274459	1	rs12660955	ENSG00000249346.5	LINC01016	3.91	9.76e-05	0.00614	0.16	0.12	Obesity (extreme);	chr6:33792543	chr6:33867506~33896914:-
BRCA	cis	rs62244186	0.535	rs59726036	ENSG00000214820.3	MPRIPP1	3.91	9.76e-05	0.00614	0.14	0.12	Depressive symptoms;	chr3:44808582	chr3:44579938~44581026:-
BRCA	cis	rs990171	0.538	rs12712153	ENSG00000234389.1	AC007278.3	3.91	9.76e-05	0.00614	0.12	0.12	Lymphocyte counts;	chr2:102495302	chr2:102438713~102440475:+
BRCA	cis	rs990171	0.538	rs11687071	ENSG00000234389.1	AC007278.3	3.91	9.76e-05	0.00614	0.12	0.12	Lymphocyte counts;	chr2:102495461	chr2:102438713~102440475:+
BRCA	cis	rs1155750	1	rs1155750	ENSG00000224984.1	RP11-524H19.2	3.91	9.76e-05	0.00614	0.19	0.12	Colorectal cancer;	chr6:54865546	chr6:54840118~54840855:-
BRCA	cis	rs10463316	0.817	rs6897109	ENSG00000260581.1	CTB-113P19.4	3.91	9.76e-05	0.00614	0.14	0.12	Metabolite levels (Pyroglutamine);	chr5:151398177	chr5:151652275~151655449:+
BRCA	cis	rs970548	1	rs10900224	ENSG00000230869.1	CTGLF10P	3.91	9.76e-05	0.00614	0.15	0.12	Total cholesterol levels;HDL cholesterol;HDL cholesterol levels;Cholesterol, total;	chr10:45529086	chr10:45678692~45700532:+
BRCA	cis	rs11098499	0.909	rs2127821	ENSG00000225892.3	RP11-384K6.2	3.91	9.76e-05	0.00614	0.12	0.12	Corneal astigmatism;	chr4:119473380	chr4:118632274~118634759:+
BRCA	cis	rs8180040	0.62	rs17784127	ENSG00000271161.1	BOLA2P2	-3.91	9.77e-05	0.00614	-0.13	-0.12	Colorectal cancer;	chr3:47020210	chr3:47499841~47500407:+
BRCA	cis	rs739496	0.793	rs655107	ENSG00000257624.1	RP1-128M12.3	3.91	9.77e-05	0.00614	0.16	0.12	Platelet count;	chr12:111558753	chr12:112000739~112000985:-
BRCA	cis	rs739496	0.843	rs642536	ENSG00000257624.1	RP1-128M12.3	3.91	9.77e-05	0.00614	0.16	0.12	Platelet count;	chr12:111559219	chr12:112000739~112000985:-
BRCA	cis	rs739496	0.843	rs848129	ENSG00000257624.1	RP1-128M12.3	3.91	9.77e-05	0.00614	0.16	0.12	Platelet count;	chr12:111559698	chr12:112000739~112000985:-
BRCA	cis	rs832540	0.669	rs832538	ENSG00000271828.1	CTD-2310F14.1	3.91	9.77e-05	0.00614	0.15	0.12	Coronary artery disease;	chr5:56904189	chr5:56927874~56929573:+
BRCA	cis	rs78487399	0.808	rs17039131	ENSG00000234936.1	AC010883.5	3.91	9.77e-05	0.00614	0.18	0.12	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43425259	chr2:43229573~43233394:+
BRCA	cis	rs874628	0.851	rs28666607	ENSG00000268650.3	AC068499.10	3.91	9.77e-05	0.00614	0.16	0.12	Multiple sclerosis;	chr19:18222995	chr19:18204730~18220480:+
BRCA	cis	rs2243480	1	rs437889	ENSG00000237026.1	RP11-328P23.2	3.91	9.77e-05	0.00614	0.23	0.12	Diabetic kidney disease;	chr7:66044247	chr7:65235790~65236723:-
BRCA	cis	rs703842	1	rs4646536	ENSG00000270039.1	RP11-571M6.17	-3.91	9.77e-05	0.00614	-0.16	-0.12	Multiple sclerosis;	chr12:57764205	chr12:57803838~57804415:+
BRCA	cis	rs36051895	0.559	rs72701680	ENSG00000236254.1	MTND4P14	-3.91	9.77e-05	0.00614	-0.14	-0.12	Pediatric autoimmune diseases;	chr9:5207294	chr9:5107937~5109290:+
BRCA	cis	rs11098499	0.738	rs72918577	ENSG00000250412.1	KLHL2P1	3.91	9.77e-05	0.00614	0.14	0.12	Corneal astigmatism;	chr4:119405546	chr4:119334329~119378233:+
BRCA	cis	rs513088	0.681	rs540253	ENSG00000225171.2	DUTP6	-3.91	9.77e-05	0.00614	-0.17	-0.12	Schizophrenia;	chr1:166691952	chr1:166868748~166869209:+
BRCA	cis	rs4689592	0.619	rs2359011	ENSG00000245468.3	RP11-367J11.3	3.91	9.77e-05	0.00614	0.13	0.12	Monocyte percentage of white cells;	chr4:7064325	chr4:7094571~7103385:-
BRCA	cis	rs9925964	0.967	rs12716981	ENSG00000262766.1	RP11-196G11.4	-3.91	9.77e-05	0.00614	-0.1	-0.12	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31106703	chr16:31118078~31118747:+
BRCA	cis	rs1949733	1	rs2688233	ENSG00000205959.3	RP11-689P11.2	-3.91	9.77e-05	0.00614	-0.12	-0.12	Response to antineoplastic agents;	chr4:8490158	chr4:8482270~8512610:+
BRCA	cis	rs1048886	0.872	rs75170426	ENSG00000271967.1	RP11-134K13.4	-3.91	9.77e-05	0.00614	-0.18	-0.12	Type 2 diabetes;	chr6:70521415	chr6:70596438~70596980:+
BRCA	cis	rs73222236	0.825	rs9833162	ENSG00000239213.4	NCK1-AS1	3.91	9.77e-05	0.00614	0.13	0.12	Coronary artery disease;	chr3:136316895	chr3:136841726~136862054:-
BRCA	cis	rs10129255	0.518	rs11847766	ENSG00000254174.1	IGHV1-12	3.91	9.77e-05	0.00614	0.09	0.12	Kawasaki disease;	chr14:106779186	chr14:106122420~106122709:-
BRCA	cis	rs875971	0.66	rs7807930	ENSG00000265600.1	AC006480.1	3.91	9.77e-05	0.00614	0.14	0.12	Aortic root size;	chr7:66622178	chr7:67356680~67356779:+
BRCA	cis	rs8030605	0.704	rs72742607	ENSG00000277245.1	RP11-48G14.3	3.91	9.77e-05	0.00614	0.26	0.12	Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;	chr15:56378061	chr15:56447120~56447697:+
BRCA	cis	rs930395	0.514	rs7707315	ENSG00000251141.4	RP11-53O19.1	-3.91	9.77e-05	0.00614	-0.11	-0.12	Breast cancer;	chr5:44918703	chr5:44744900~44808777:-
BRCA	cis	rs930395	0.514	rs4298259	ENSG00000251141.4	RP11-53O19.1	-3.91	9.77e-05	0.00614	-0.11	-0.12	Breast cancer;	chr5:44920609	chr5:44744900~44808777:-
BRCA	cis	rs930395	0.514	rs7728431	ENSG00000251141.4	RP11-53O19.1	-3.91	9.77e-05	0.00614	-0.11	-0.12	Breast cancer;	chr5:44922577	chr5:44744900~44808777:-
BRCA	cis	rs6785206	0.892	rs6793907	ENSG00000242551.2	POU5F1P6	3.91	9.78e-05	0.00614	0.22	0.12	Lymphocyte percentage of white cells;	chr3:128672783	chr3:128674735~128677005:-
BRCA	cis	rs8062405	1	rs12444171	ENSG00000261766.1	RP11-22P6.2	-3.91	9.78e-05	0.00614	-0.12	-0.12	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28833930	chr16:28862166~28863340:-
BRCA	cis	rs6026584	1	rs2057291	ENSG00000270951.1	RP1-309F20.4	-3.91	9.78e-05	0.00614	-0.16	-0.12	Renal function-related traits (BUN);	chr20:58896988	chr20:58876592~58876981:-
BRCA	cis	rs12724450	0.546	rs79696733	ENSG00000228126.1	FALEC	3.91	9.78e-05	0.00614	0.21	0.12	Blood protein levels;	chr1:150462367	chr1:150515757~150518032:+
BRCA	cis	rs539096	0.607	rs11210871	ENSG00000236200.4	KDM4A-AS1	3.91	9.78e-05	0.00614	0.13	0.12	Intelligence (multi-trait analysis);	chr1:43563682	chr1:43699765~43708138:-
BRCA	cis	rs1577330	0.8	rs625630	ENSG00000254396.1	RP11-56F10.3	-3.91	9.78e-05	0.00615	-0.18	-0.12	IgG glycosylation;	chr9:27097318	chr9:27102630~27104728:+
BRCA	cis	rs9992667	0.725	rs1466414	ENSG00000231160.8	KLF3-AS1	3.91	9.78e-05	0.00615	0.13	0.12	Eosinophil percentage of granulocytes;	chr4:38662703	chr4:38612701~38664883:-
BRCA	cis	rs3808502	0.516	rs6983727	ENSG00000227888.4	FAM66A	3.91	9.78e-05	0.00615	0.15	0.12	Neuroticism;	chr8:11558303	chr8:12362019~12388296:+
BRCA	cis	rs7656342	0.93	rs13106539	ENSG00000250342.1	SNRPCP16	-3.91	9.78e-05	0.00615	-0.14	-0.12	Gut microbiota (bacterial taxa);	chr4:9796079	chr4:9051842~9052051:-
BRCA	cis	rs17428076	0.874	rs12619041	ENSG00000228389.1	AC068039.4	3.91	9.78e-05	0.00615	0.17	0.12	Myopia;	chr2:171744206	chr2:171773482~171775844:+
BRCA	cis	rs17507216	0.718	rs4779033	ENSG00000259429.4	UBE2Q2P2	3.91	9.79e-05	0.00615	0.15	0.12	Excessive daytime sleepiness;	chr15:82576634	chr15:82355142~82420075:+
BRCA	cis	rs7412746	0.552	rs4970980	ENSG00000231073.1	RP11-316M1.3	3.91	9.79e-05	0.00615	0.13	0.12	Melanoma;	chr1:150892516	chr1:150973123~150975534:+
BRCA	cis	rs5758659	0.729	rs134866	ENSG00000270083.1	RP1-257I20.14	3.91	9.79e-05	0.00615	0.13	0.12	Cognitive function;	chr22:42254657	chr22:42089630~42090028:-
BRCA	cis	rs8099996	0.798	rs11666925	ENSG00000267277.1	CTD-2342J14.6	3.91	9.79e-05	0.00615	0.14	0.12	Inflammatory skin disease;	chr19:11065175	chr19:11368123~11374935:-
BRCA	cis	rs11168618	0.904	rs7135125	ENSG00000240399.1	RP1-228P16.1	3.91	9.79e-05	0.00615	0.13	0.12	Adiponectin levels;	chr12:48532485	chr12:48054813~48055591:-
BRCA	cis	rs13188386	0.585	rs3764453	ENSG00000249779.1	RP11-447H19.3	-3.91	9.79e-05	0.00615	-0.18	-0.12	Iron status biomarkers;	chr5:42398527	chr5:43206709~43207811:+
BRCA	cis	rs1437396	0.657	rs3099079	ENSG00000203327.2	AC012358.7	3.91	9.79e-05	0.00615	0.12	0.12	Alcohol dependence;	chr2:55365816	chr2:55214387~55216126:-
BRCA	cis	rs10266483	0.881	rs665452	ENSG00000228653.2	HNRNPCP7	-3.91	9.79e-05	0.00615	-0.14	-0.12	Response to statin therapy;	chr7:64289077	chr7:64500825~64501729:+
BRCA	cis	rs699371	0.545	rs7569	ENSG00000270000.1	RP3-449M8.9	3.91	9.79e-05	0.00615	0.15	0.12	Height;	chr14:74500060	chr14:74471930~74472360:-
BRCA	cis	rs2351088	0.536	rs10483230	ENSG00000231010.1	RP6-109B7.2	3.91	9.8e-05	0.00615	0.21	0.12	Tonsillectomy;	chr22:45769221	chr22:46055740~46058160:-
BRCA	cis	rs863345	0.604	rs1342954	ENSG00000229914.1	RP11-404O13.4	-3.91	9.8e-05	0.00615	-0.13	-0.12	Pneumococcal bacteremia;	chr1:158494758	chr1:158195633~158196131:-
BRCA	cis	rs863345	0.604	rs12078065	ENSG00000229914.1	RP11-404O13.4	-3.91	9.8e-05	0.00615	-0.13	-0.12	Pneumococcal bacteremia;	chr1:158495273	chr1:158195633~158196131:-
BRCA	cis	rs863345	0.604	rs11264985	ENSG00000229914.1	RP11-404O13.4	-3.91	9.8e-05	0.00615	-0.13	-0.12	Pneumococcal bacteremia;	chr1:158495376	chr1:158195633~158196131:-
BRCA	cis	rs375066	0.935	rs396874	ENSG00000278917.1	RP11-15A1.4	-3.91	9.8e-05	0.00615	-0.14	-0.12	Breast cancer;	chr19:43893073	chr19:43891233~43895411:+
BRCA	cis	rs983392	0.967	rs2583476	ENSG00000275344.1	MIR6503	-3.91	9.8e-05	0.00615	-0.13	-0.12	Alzheimer's disease (late onset);	chr11:60090108	chr11:60209071~60209156:-
BRCA	cis	rs875971	0.545	rs11767262	ENSG00000232559.3	GS1-124K5.12	3.91	9.8e-05	0.00615	0.16	0.12	Aortic root size;	chr7:66302237	chr7:66554588~66576923:-
BRCA	cis	rs425277	0.916	rs414777	ENSG00000269227.1	RP11-345P4.6	3.91	9.8e-05	0.00616	0.13	0.12	Height;	chr1:2170248	chr1:1673275~1674397:+
BRCA	cis	rs6951245	0.554	rs79367977	ENSG00000224079.1	AC091729.7	-3.91	9.8e-05	0.00616	-0.18	-0.12	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1113021	chr7:1074450~1078036:+
BRCA	cis	rs7209700	0.821	rs2292863	ENSG00000228782.6	CTD-2026D20.3	-3.91	9.8e-05	0.00616	-0.15	-0.12	IgG glycosylation;	chr17:47291764	chr17:47450568~47492492:-
BRCA	cis	rs4664293	0.967	rs4665103	ENSG00000224152.1	AC009506.1	-3.91	9.8e-05	0.00616	-0.14	-0.12	Monocyte percentage of white cells;	chr2:159675801	chr2:159615296~159617082:+
BRCA	cis	rs467650	0.509	rs2591443	ENSG00000248489.1	CTD-2007H13.3	-3.91	9.8e-05	0.00616	-0.13	-0.12	Venous thromboembolism (SNP x SNP interaction);	chr5:98661785	chr5:98929171~98995013:+
BRCA	cis	rs4478858	0.735	rs6679365	ENSG00000260386.4	LINC01225	3.91	9.81e-05	0.00616	0.14	0.12	Alcohol dependence;	chr1:31315019	chr1:31500085~31540885:+
BRCA	cis	rs926937	0.622	rs6005500	ENSG00000244625.4	MIATNB	-3.91	9.81e-05	0.00616	-0.23	-0.12	Age-related cataracts;	chr22:27529117	chr22:26672767~26780207:+
BRCA	cis	rs73201462	1	rs6439124	ENSG00000242551.2	POU5F1P6	-3.91	9.81e-05	0.00616	-0.2	-0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128288623	chr3:128674735~128677005:-
BRCA	cis	rs73201462	1	rs7373998	ENSG00000242551.2	POU5F1P6	-3.91	9.81e-05	0.00616	-0.2	-0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128289380	chr3:128674735~128677005:-
BRCA	cis	rs718314	1	rs10842708	ENSG00000256894.1	RP11-283G6.3	3.91	9.81e-05	0.00616	0.13	0.12	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Renal cell carcinoma;Waist circumference adjusted for body mass index;	chr12:26321934	chr12:26125155~26126617:-
BRCA	cis	rs7267979	1	rs4813563	ENSG00000276952.1	RP5-965G21.6	-3.91	9.81e-05	0.00616	-0.15	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25384704	chr20:25284915~25285588:-
BRCA	cis	rs7267979	0.966	rs6037103	ENSG00000276952.1	RP5-965G21.6	-3.91	9.81e-05	0.00616	-0.15	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25388459	chr20:25284915~25285588:-
BRCA	cis	rs6751744	0.855	rs7585513	ENSG00000224152.1	AC009506.1	-3.91	9.81e-05	0.00616	-0.14	-0.12	Dysphagia;	chr2:159550379	chr2:159615296~159617082:+
BRCA	cis	rs17079773	0.764	rs12428504	ENSG00000228741.2	SPATA13	3.91	9.81e-05	0.00616	0.23	0.12	Inattentive symptoms;	chr13:24029655	chr13:23979810~24035027:+
BRCA	cis	rs6840360	0.533	rs1397683	ENSG00000270265.1	RP11-731D1.4	3.91	9.81e-05	0.00616	0.14	0.12	Intelligence (multi-trait analysis);	chr4:151794764	chr4:151333775~151353224:-
BRCA	cis	rs977987	0.778	rs1109341	ENSG00000280152.1	RP11-331F4.5	-3.91	9.81e-05	0.00616	-0.12	-0.12	Dupuytren's disease;	chr16:75411707	chr16:75245994~75250077:-
BRCA	cis	rs2243480	1	rs4548056	ENSG00000226002.1	RP11-460N20.5	-3.91	9.82e-05	0.00617	-0.2	-0.12	Diabetic kidney disease;	chr7:65833886	chr7:65084103~65100232:+
BRCA	cis	rs6893300	0.961	rs7447159	ENSG00000250999.1	RP11-1379J22.5	3.91	9.82e-05	0.00617	0.17	0.12	Resting heart rate;	chr5:179750675	chr5:179657762~179664432:+
BRCA	cis	rs6812193	0.518	rs28864163	ENSG00000271676.1	RP11-1E1.2	3.91	9.82e-05	0.00617	0.18	0.12	Parkinson's disease;	chr4:76273953	chr4:77112495~77113458:-
BRCA	cis	rs61160187	0.582	rs2049579	ENSG00000272308.1	RP11-231G3.1	-3.91	9.82e-05	0.00617	-0.14	-0.12	Educational attainment (years of education);Educational attainment (college completion);	chr5:61054838	chr5:60866457~60866935:-
BRCA	cis	rs6496932	0.865	rs4842874	ENSG00000259295.5	CSPG4P12	3.91	9.82e-05	0.00617	0.19	0.12	Central corneal thickness;Corneal structure;	chr15:85323464	chr15:85191438~85213905:+
BRCA	cis	rs737008	0.922	rs2070923	ENSG00000262636.1	CTD-3088G3.4	3.91	9.82e-05	0.00617	0.17	0.12	Obesity-related traits;	chr16:11275998	chr16:11380859~11381118:-
BRCA	cis	rs13064773	0.718	rs12629885	ENSG00000272247.1	RP11-379F4.9	3.91	9.82e-05	0.00617	0.14	0.12	Response to abacavir-containing treatment in HIV-1 infection (virologic failure);Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr3:158858710	chr3:158801257~158801935:-
BRCA	cis	rs62247992	0.698	rs11719553	ENSG00000227245.1	RP11-136C24.2	3.91	9.82e-05	0.00617	0.18	0.12	Facial morphology (factor 15, philtrum width);	chr3:43113613	chr3:43087479~43088068:+
BRCA	cis	rs9840812	0.769	rs483465	ENSG00000273486.1	RP11-731C17.2	3.91	9.83e-05	0.00617	0.15	0.12	Fibrinogen levels;	chr3:136329135	chr3:136837338~136839021:-
BRCA	cis	rs6120849	0.754	rs6087667	ENSG00000202150.1	RNU6-407P	3.91	9.83e-05	0.00617	0.17	0.12	Protein C levels;	chr20:35064084	chr20:35030317~35030420:-
BRCA	cis	rs875971	0.862	rs11765791	ENSG00000273024.4	INTS4P2	-3.91	9.83e-05	0.00617	-0.13	-0.12	Aortic root size;	chr7:66471587	chr7:65647864~65715661:+
BRCA	cis	rs6736093	0.796	rs13001162	ENSG00000236307.2	EEF1E1P1	-3.91	9.83e-05	0.00617	-0.15	-0.12	Coronary artery disease;	chr2:112048420	chr2:111887914~111888741:+
BRCA	cis	rs8017423	0.647	rs10132599	ENSG00000275198.1	RP11-471B22.3	3.91	9.83e-05	0.00617	0.14	0.12	Mortality in heart failure;	chr14:90348998	chr14:90383365~90387973:+
BRCA	cis	rs11168618	0.967	rs10875831	ENSG00000273765.1	RP11-370I10.11	3.91	9.83e-05	0.00617	0.14	0.12	Adiponectin levels;	chr12:48544597	chr12:48360920~48361377:+
BRCA	cis	rs4834770	1	rs878374	ENSG00000245958.5	RP11-33B1.1	-3.91	9.83e-05	0.00617	-0.11	-0.12	Blood protein levels;	chr4:119316409	chr4:119454791~119552025:+
BRCA	cis	rs2071426	0.622	rs34294497	ENSG00000273450.1	RP11-76P2.4	3.91	9.83e-05	0.00617	0.15	0.12	Blood metabolite levels;	chr10:95010303	chr10:94314907~94315327:-
BRCA	cis	rs11668609	1	rs66972560	ENSG00000268058.1	BNIP3P40	-3.91	9.83e-05	0.00617	-0.15	-0.12	Response to taxane treatment (docetaxel);	chr19:24178138	chr19:24098425~24098980:-
BRCA	cis	rs875971	0.862	rs10276077	ENSG00000271064.1	RP11-792A8.3	3.91	9.83e-05	0.00617	0.14	0.12	Aortic root size;	chr7:66263424	chr7:66748838~66749077:-
BRCA	cis	rs2109514	1	rs6466579	ENSG00000237813.3	AC002066.1	3.91	9.83e-05	0.00617	0.14	0.12	Prevalent atrial fibrillation;	chr7:116511101	chr7:116238260~116499465:-
BRCA	cis	rs5758511	0.633	rs5758690	ENSG00000226450.2	CYP2D8P	3.91	9.83e-05	0.00617	0.13	0.12	Birth weight;	chr22:42272289	chr22:42149886~42155001:-
BRCA	cis	rs875971	0.638	rs35986979	ENSG00000272831.1	RP11-792A8.4	-3.91	9.84e-05	0.00618	-0.11	-0.12	Aortic root size;	chr7:66624003	chr7:66739829~66740385:-
BRCA	cis	rs7048146	0.51	rs2210159	ENSG00000213539.4	YBX1P6	-3.91	9.84e-05	0.00618	-0.13	-0.12	Vascular brain injury;	chr9:109526297	chr9:109532830~109534332:-
BRCA	cis	rs2518049	0.95	rs1937847	ENSG00000224034.1	RP11-445P17.8	-3.91	9.84e-05	0.00618	-0.22	-0.12	Metabolic traits;	chr10:5092319	chr10:5266033~5271236:-
BRCA	cis	rs453301	0.606	rs6601279	ENSG00000253981.4	ALG1L13P	-3.91	9.84e-05	0.00618	-0.14	-0.12	Joint mobility (Beighton score);	chr8:9050721	chr8:8236003~8244667:-
BRCA	cis	rs453301	0.606	rs6981060	ENSG00000253981.4	ALG1L13P	-3.91	9.84e-05	0.00618	-0.14	-0.12	Joint mobility (Beighton score);	chr8:9050725	chr8:8236003~8244667:-
BRCA	cis	rs3738443	0.904	rs10924968	ENSG00000259865.1	RP11-488L18.10	3.91	9.84e-05	0.00618	0.14	0.12	Alcohol dependence;	chr1:247236957	chr1:247187281~247188526:-
BRCA	cis	rs1005277	0.579	rs2474595	ENSG00000263064.2	RP11-291L22.7	-3.91	9.85e-05	0.00618	-0.15	-0.12	Extrinsic epigenetic age acceleration;	chr10:38137854	chr10:38448689~38448949:+
BRCA	cis	rs2777491	0.574	rs316616	ENSG00000247556.5	OIP5-AS1	3.91	9.85e-05	0.00618	0.13	0.12	Ulcerative colitis;	chr15:41454078	chr15:41283990~41309737:+
BRCA	cis	rs11711311	1	rs7649590	ENSG00000241529.3	RN7SL767P	-3.91	9.85e-05	0.00618	-0.14	-0.12	IgG glycosylation;	chr3:113728420	chr3:113632704~113632998:+
BRCA	cis	rs2505998	0.912	rs2505994	ENSG00000273008.1	RP11-351D16.3	3.91	9.85e-05	0.00618	0.15	0.12	Hirschsprung disease;	chr10:43073439	chr10:43136824~43138334:-
BRCA	cis	rs3764021	0.527	rs2114870	ENSG00000256582.1	RP11-75L1.1	3.91	9.85e-05	0.00618	0.13	0.12	Type 1 diabetes;	chr12:9670544	chr12:9704077~9709350:+
BRCA	cis	rs4713118	0.629	rs203887	ENSG00000216901.1	AL022393.7	3.91	9.85e-05	0.00618	0.17	0.12	Parkinson's disease;	chr6:28053491	chr6:28176188~28176674:+
BRCA	cis	rs6822297	0.905	rs7672936	ENSG00000240005.4	RP11-293A21.1	-3.91	9.85e-05	0.00618	-0.14	-0.12	Obesity-related traits;	chr4:26882786	chr4:26859806~26860599:-
BRCA	cis	rs34975555	0.568	rs3739401	ENSG00000254054.2	RP11-156K13.3	-3.91	9.85e-05	0.00618	-0.17	-0.12	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:17978176	chr8:17905756~17907887:+
BRCA	cis	rs9467773	0.62	rs2504565	ENSG00000224843.5	LINC00240	-3.91	9.85e-05	0.00618	-0.13	-0.12	Intelligence (multi-trait analysis);	chr6:26656662	chr6:26956992~27023924:+
BRCA	cis	rs8040855	0.547	rs17611171	ENSG00000229212.6	RP11-561C5.4	-3.91	9.85e-05	0.00619	-0.17	-0.12	Bulimia nervosa;	chr15:85029468	chr15:85205440~85234795:-
BRCA	cis	rs4374383	0.884	rs6541971	ENSG00000243389.1	AC012442.5	-3.91	9.85e-05	0.00619	-0.15	-0.12	Hepatitis C induced liver fibrosis;	chr2:111964913	chr2:112589040~112614431:+
BRCA	cis	rs12050794	0.636	rs4506844	ENSG00000260037.4	CTD-2524L6.3	3.91	9.85e-05	0.00619	0.15	0.12	Metabolite levels (HVA/MHPG ratio);	chr15:72216797	chr15:71818396~71823384:+
BRCA	cis	rs7120118	0.517	rs78310113	ENSG00000280615.1	Y_RNA	3.91	9.85e-05	0.00619	0.2	0.12	HDL cholesterol;	chr11:47272002	chr11:47614898~47614994:-
BRCA	cis	rs4415084	1	rs10941677	ENSG00000248779.1	RP11-53O19.2	3.91	9.86e-05	0.00619	0.11	0.12	Breast cancer;	chr5:44662297	chr5:44752949~44765744:+
BRCA	cis	rs42490	0.51	rs218890	ENSG00000251136.7	RP11-37B2.1	-3.91	9.86e-05	0.00619	-0.12	-0.12	Leprosy;	chr8:89680848	chr8:89609409~89757727:-
BRCA	cis	rs853679	0.517	rs1904840	ENSG00000261839.1	RP1-265C24.8	3.91	9.86e-05	0.00619	0.17	0.12	Depression;	chr6:28140454	chr6:28136849~28139678:+
BRCA	cis	rs1990950	0.933	rs11747685	ENSG00000251405.2	CTB-109A12.1	-3.91	9.86e-05	0.00619	-0.15	-0.12	Lung function (FEV1/FVC);	chr5:157476582	chr5:157362615~157460078:-
BRCA	cis	rs4664293	0.632	rs7588230	ENSG00000226266.5	AC009961.3	3.91	9.86e-05	0.00619	0.14	0.12	Monocyte percentage of white cells;	chr2:159797209	chr2:159670708~159712435:-
BRCA	cis	rs7772486	0.754	rs10872580	ENSG00000270638.1	RP3-466P17.1	-3.91	9.86e-05	0.00619	-0.14	-0.12	Lobe attachment (rater-scored or self-reported);	chr6:145819145	chr6:145735570~145737218:+
BRCA	cis	rs67696533	0.6	rs910890	ENSG00000277692.1	RP11-358N2.2	-3.91	9.86e-05	0.00619	-0.14	-0.12	White blood cell count (basophil);Basophil percentage of granulocytes;Basophil percentage of white cells;	chr20:32521129	chr20:32355053~32355734:+
BRCA	cis	rs2625529	0.641	rs11852789	ENSG00000260037.4	CTD-2524L6.3	-3.91	9.86e-05	0.00619	-0.17	-0.12	Red blood cell count;	chr15:71973153	chr15:71818396~71823384:+
BRCA	cis	rs2708977	1	rs10184209	ENSG00000237510.6	AC008268.2	3.91	9.87e-05	0.00619	0.16	0.12	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96671754	chr2:95789654~95800166:+
BRCA	cis	rs8040855	0.547	rs17611171	ENSG00000259774.1	RP11-182J1.13	3.91	9.87e-05	0.00619	0.17	0.12	Bulimia nervosa;	chr15:85029468	chr15:84422618~84425882:+
BRCA	cis	rs72928364	0.86	rs16843225	ENSG00000256628.3	ZBTB11-AS1	3.91	9.87e-05	0.00619	0.22	0.12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:101082413	chr3:101676475~101679217:+
BRCA	cis	rs4302906	0.753	rs7026624	ENSG00000187984.11	ANKRD19P	3.91	9.87e-05	0.00619	0.12	0.12	Lobe attachment (rater-scored or self-reported);	chr9:92962268	chr9:92809388~92888693:+
BRCA	cis	rs16944613	0.51	rs4932353	ENSG00000245479.2	LINC01585	3.91	9.87e-05	0.0062	0.14	0.12	Colorectal cancer;	chr15:90602606	chr15:90660234~90664967:+
BRCA	cis	rs6430585	0.527	rs60966546	ENSG00000231890.6	DARS-AS1	-3.91	9.87e-05	0.0062	-0.18	-0.12	Corneal structure;	chr2:135644273	chr2:135985176~136022593:+
BRCA	cis	rs2236231	0.55	rs10151023	ENSG00000259502.1	RP11-643G16.3	3.91	9.87e-05	0.0062	0.17	0.12	Plasma kynurenine levels in major depressive disorder;	chr14:67597939	chr14:67610986~67613864:+
BRCA	cis	rs11239930	0.517	rs3011809	ENSG00000237188.3	RP11-337C18.8	3.91	9.87e-05	0.0062	0.14	0.12	AIDS progression;	chr1:147077593	chr1:147172771~147211568:+
BRCA	cis	rs12612435	0.83	rs1515064	ENSG00000226806.1	AC011893.3	3.91	9.87e-05	0.0062	0.14	0.12	Takotsubo syndrome;	chr2:136379446	chr2:135820191~135823087:+
BRCA	cis	rs12439619	0.739	rs62012046	ENSG00000259429.4	UBE2Q2P2	-3.91	9.87e-05	0.0062	-0.15	-0.12	Intelligence (multi-trait analysis);	chr15:82236824	chr15:82355142~82420075:+
BRCA	cis	rs12439619	0.774	rs62012047	ENSG00000259429.4	UBE2Q2P2	-3.91	9.87e-05	0.0062	-0.15	-0.12	Intelligence (multi-trait analysis);	chr15:82236852	chr15:82355142~82420075:+
BRCA	cis	rs12122100	0.837	rs12742539	ENSG00000244371.2	PFN1P8	3.91	9.88e-05	0.0062	0.15	0.12	HIV-1 control;	chr1:147036289	chr1:146957117~146957659:-
BRCA	cis	rs875971	0.83	rs809025	ENSG00000273024.4	INTS4P2	-3.91	9.88e-05	0.0062	-0.13	-0.12	Aortic root size;	chr7:66384832	chr7:65647864~65715661:+
BRCA	cis	rs1555322	0.872	rs2425046	ENSG00000269202.1	RP4-614O4.12	-3.91	9.88e-05	0.0062	-0.18	-0.12	Attention deficit hyperactivity disorder;	chr20:35283858	chr20:35201747~35203288:-
BRCA	cis	rs3805389	0.504	rs28756087	ENSG00000273257.1	RP11-177J6.1	-3.91	9.88e-05	0.0062	-0.2	-0.12	Waist-to-hip ratio adjusted for body mass index;	chr4:55601940	chr4:55387949~55388271:+
BRCA	cis	rs3805389	0.504	rs28713371	ENSG00000273257.1	RP11-177J6.1	-3.91	9.88e-05	0.0062	-0.2	-0.12	Waist-to-hip ratio adjusted for body mass index;	chr4:55602255	chr4:55387949~55388271:+
BRCA	cis	rs3805389	0.504	rs10011801	ENSG00000273257.1	RP11-177J6.1	-3.91	9.88e-05	0.0062	-0.2	-0.12	Waist-to-hip ratio adjusted for body mass index;	chr4:55602567	chr4:55387949~55388271:+
BRCA	cis	rs4657482	0.606	rs2241965	ENSG00000236364.3	RP11-525G13.2	-3.91	9.88e-05	0.0062	-0.11	-0.12	Testicular germ cell tumor;	chr1:165896457	chr1:165890795~165900683:-
BRCA	cis	rs2191566	0.664	rs7251083	ENSG00000266921.1	RP11-15A1.7	-3.91	9.88e-05	0.0062	-0.15	-0.12	Acute lymphoblastic leukemia (childhood);	chr19:44047713	chr19:43996896~44002836:-
BRCA	cis	rs2191566	0.664	rs7250774	ENSG00000266921.1	RP11-15A1.7	-3.91	9.88e-05	0.0062	-0.15	-0.12	Acute lymphoblastic leukemia (childhood);	chr19:44047714	chr19:43996896~44002836:-
BRCA	cis	rs6452524	0.935	rs7718472	ENSG00000281327.1	LINC01338	3.91	9.88e-05	0.0062	0.14	0.12	Hypertension (SNP x SNP interaction);	chr5:83082603	chr5:82850864~82859836:-
BRCA	cis	rs863345	0.604	rs10908660	ENSG00000229914.1	RP11-404O13.4	-3.91	9.88e-05	0.0062	-0.13	-0.12	Pneumococcal bacteremia;	chr1:158496399	chr1:158195633~158196131:-
BRCA	cis	rs6860806	0.661	rs4705927	ENSG00000233006.5	AC034220.3	3.91	9.88e-05	0.0062	0.09	0.12	Breast cancer;	chr5:132242915	chr5:132311285~132369916:-
BRCA	cis	rs1910358	0.664	rs2134240	ENSG00000248874.4	C5orf17	-3.91	9.88e-05	0.0062	-0.16	-0.12	Venous thromboembolism (SNP x SNP interaction);	chr5:23939030	chr5:23951348~24178263:+
BRCA	cis	rs10958369	0.613	rs1477957	ENSG00000253369.1	RP11-1081M5.1	3.91	9.88e-05	0.0062	0.15	0.12	Response to antineoplastic agents;	chr8:53522873	chr8:53395211~53395946:-
BRCA	cis	rs987724	0.929	rs2321455	ENSG00000240875.4	LINC00886	-3.91	9.88e-05	0.0062	-0.15	-0.12	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156975806	chr3:156747346~156817062:-
BRCA	cis	rs6545883	0.929	rs2593626	ENSG00000212978.6	AC016747.3	3.91	9.88e-05	0.0062	0.16	0.12	Tuberculosis;	chr2:61438049	chr2:61141592~61144969:-
BRCA	cis	rs6545883	0.929	rs2592352	ENSG00000212978.6	AC016747.3	3.91	9.88e-05	0.0062	0.16	0.12	Tuberculosis;	chr2:61438201	chr2:61141592~61144969:-
BRCA	cis	rs4835473	0.932	rs7356157	ENSG00000246448.2	RP13-578N3.3	3.91	9.89e-05	0.0062	0.14	0.12	Immature fraction of reticulocytes;	chr4:143739233	chr4:143700257~143865072:+
BRCA	cis	rs924712	0.625	rs12191299	ENSG00000224984.1	RP11-524H19.2	3.91	9.89e-05	0.0062	0.15	0.12	Breast cancer;	chr6:54855687	chr6:54840118~54840855:-
BRCA	cis	rs4950322	0.518	rs4950304	ENSG00000227242.3	NBPF13P	-3.91	9.89e-05	0.0062	-0.16	-0.12	Protein quantitative trait loci;	chr1:147116685	chr1:147021320~147124525:-
BRCA	cis	rs7824557	0.675	rs2736265	ENSG00000255046.1	RP11-297N6.4	-3.91	9.89e-05	0.0062	-0.14	-0.12	Retinal vascular caliber;	chr8:11329165	chr8:11797928~11802568:-
BRCA	cis	rs7131987	0.903	rs67517901	ENSG00000257176.2	RP11-996F15.2	-3.91	9.89e-05	0.00621	-0.14	-0.12	QT interval;	chr12:29268413	chr12:29280418~29317848:-
BRCA	cis	rs2163813	1	rs2013561	ENSG00000270325.1	BNIP3P9	3.91	9.89e-05	0.00621	0.16	0.12	Toenail selenium levels;	chr19:19715368	chr19:19856975~19857527:+
BRCA	cis	rs2163813	1	rs36006965	ENSG00000270325.1	BNIP3P9	3.91	9.89e-05	0.00621	0.16	0.12	Toenail selenium levels;	chr19:19719242	chr19:19856975~19857527:+
BRCA	cis	rs2163813	1	rs12982273	ENSG00000270325.1	BNIP3P9	3.91	9.89e-05	0.00621	0.16	0.12	Toenail selenium levels;	chr19:19719335	chr19:19856975~19857527:+
BRCA	cis	rs2274273	1	rs7160110	ENSG00000233924.1	AL160471.6	-3.91	9.89e-05	0.00621	-0.14	-0.12	Protein biomarker;	chr14:55127917	chr14:55004813~55005687:-
BRCA	cis	rs1005277	0.522	rs1208681	ENSG00000273019.1	RP11-508N22.13	-3.91	9.9e-05	0.00621	-0.14	-0.12	Extrinsic epigenetic age acceleration;	chr10:37804047	chr10:38149968~38150293:+
BRCA	cis	rs516805	0.561	rs7754101	ENSG00000279114.1	RP3-425C14.5	3.91	9.9e-05	0.00621	0.17	0.12	Lymphocyte counts;	chr6:122607828	chr6:122471923~122484161:+
BRCA	cis	rs16958440	0.867	rs2117373	ENSG00000267724.1	RP11-49K24.8	3.91	9.9e-05	0.00621	0.22	0.12	Sitting height ratio;	chr18:47145463	chr18:47105946~47108062:+
BRCA	cis	rs448720	1	rs372644	ENSG00000260657.2	RP11-315D16.4	-3.91	9.9e-05	0.00621	-0.14	-0.12	Cognitive performance;	chr15:67914240	chr15:68267792~68277994:-
BRCA	cis	rs7267979	1	rs6050566	ENSG00000276952.1	RP5-965G21.6	-3.91	9.9e-05	0.00621	-0.15	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25370435	chr20:25284915~25285588:-
BRCA	cis	rs11098499	1	rs11726229	ENSG00000225892.3	RP11-384K6.2	3.91	9.9e-05	0.00621	0.12	0.12	Corneal astigmatism;	chr4:119290425	chr4:118632274~118634759:+
BRCA	cis	rs77633900	0.772	rs283799	ENSG00000196274.5	Metazoa_SRP	3.91	9.9e-05	0.00621	0.21	0.12	Glioma;Non-glioblastoma glioma;	chr15:76460493	chr15:76230048~76230390:-
BRCA	cis	rs7274811	0.744	rs3213183	ENSG00000228265.4	RALY-AS1	3.91	9.91e-05	0.00621	0.13	0.12	Height;	chr20:33675156	chr20:33983052~33994357:-
BRCA	cis	rs875971	0.651	rs313829	ENSG00000230295.1	RP11-458F8.2	-3.91	9.91e-05	0.00621	-0.11	-0.12	Aortic root size;	chr7:66087510	chr7:66880708~66882981:+
BRCA	cis	rs875971	0.862	rs9791712	ENSG00000229886.1	RP5-1132H15.3	-3.91	9.91e-05	0.00622	-0.14	-0.12	Aortic root size;	chr7:66640176	chr7:66025126~66031544:-
BRCA	cis	rs875971	0.862	rs9791713	ENSG00000229886.1	RP5-1132H15.3	-3.91	9.91e-05	0.00622	-0.14	-0.12	Aortic root size;	chr7:66640211	chr7:66025126~66031544:-
BRCA	cis	rs9309473	0.607	rs7560272	ENSG00000163016.8	ALMS1P	3.91	9.91e-05	0.00622	0.14	0.12	Metabolite levels;	chr2:73334357	chr2:73644919~73685576:+
BRCA	cis	rs11992162	0.591	rs4240678	ENSG00000270154.1	RP11-419I17.1	-3.91	9.91e-05	0.00622	-0.14	-0.12	Monocyte count;	chr8:11944917	chr8:12476462~12477122:+
BRCA	cis	rs2562456	0.917	rs2681389	ENSG00000268555.1	RP11-678G14.3	-3.91	9.92e-05	0.00622	-0.16	-0.12	Pain;	chr19:21509773	chr19:21570822~21587322:-
BRCA	cis	rs4272720	0.853	rs72785087	ENSG00000228754.1	RP11-534L6.3	-3.91	9.92e-05	0.00622	-0.18	-0.12	Platelet count;Plateletcrit;	chr10:49152178	chr10:48745545~48746128:-
BRCA	cis	rs6460942	0.597	rs17448913	ENSG00000226690.5	AC005281.1	3.91	9.92e-05	0.00622	0.25	0.12	Coronary artery disease;	chr7:12494358	chr7:12496429~12541910:+
BRCA	cis	rs6460942	0.597	rs4721105	ENSG00000226690.5	AC005281.1	3.91	9.92e-05	0.00622	0.25	0.12	Coronary artery disease;	chr7:12495255	chr7:12496429~12541910:+
BRCA	cis	rs6460942	0.597	rs4721106	ENSG00000226690.5	AC005281.1	3.91	9.92e-05	0.00622	0.25	0.12	Coronary artery disease;	chr7:12495427	chr7:12496429~12541910:+
BRCA	cis	rs6460942	0.597	rs4721107	ENSG00000226690.5	AC005281.1	3.91	9.92e-05	0.00622	0.25	0.12	Coronary artery disease;	chr7:12495479	chr7:12496429~12541910:+
BRCA	cis	rs6460942	0.597	rs6977059	ENSG00000226690.5	AC005281.1	3.91	9.92e-05	0.00622	0.25	0.12	Coronary artery disease;	chr7:12495531	chr7:12496429~12541910:+
BRCA	cis	rs6460942	0.597	rs4721108	ENSG00000226690.5	AC005281.1	3.91	9.92e-05	0.00622	0.25	0.12	Coronary artery disease;	chr7:12495621	chr7:12496429~12541910:+
BRCA	cis	rs6460942	0.597	rs6961238	ENSG00000226690.5	AC005281.1	3.91	9.92e-05	0.00622	0.25	0.12	Coronary artery disease;	chr7:12495802	chr7:12496429~12541910:+
BRCA	cis	rs6460942	0.597	rs35589221	ENSG00000226690.5	AC005281.1	3.91	9.92e-05	0.00622	0.25	0.12	Coronary artery disease;	chr7:12496215	chr7:12496429~12541910:+
BRCA	cis	rs6460942	0.544	rs34644264	ENSG00000226690.5	AC005281.1	3.91	9.92e-05	0.00622	0.25	0.12	Coronary artery disease;	chr7:12496464	chr7:12496429~12541910:+
BRCA	cis	rs6460942	0.597	rs17277369	ENSG00000226690.5	AC005281.1	3.91	9.92e-05	0.00622	0.25	0.12	Coronary artery disease;	chr7:12496566	chr7:12496429~12541910:+
BRCA	cis	rs6460942	0.597	rs12699388	ENSG00000226690.5	AC005281.1	3.91	9.92e-05	0.00622	0.25	0.12	Coronary artery disease;	chr7:12496710	chr7:12496429~12541910:+
BRCA	cis	rs709400	0.93	rs2274268	ENSG00000258851.1	RP11-894P9.2	-3.91	9.92e-05	0.00622	-0.14	-0.12	Body mass index;	chr14:103563041	chr14:103553421~103561877:+
BRCA	cis	rs6964587	0.839	rs6950538	ENSG00000188693.7	CYP51A1-AS1	-3.91	9.92e-05	0.00622	-0.13	-0.12	Breast cancer;	chr7:91788501	chr7:92134604~92180725:+
BRCA	cis	rs875971	0.66	rs801193	ENSG00000229180.5	GS1-124K5.11	-3.91	9.92e-05	0.00622	-0.1	-0.12	Aortic root size;	chr7:66565625	chr7:66526088~66542624:-
BRCA	cis	rs4478858	0.735	rs6670067	ENSG00000260386.4	LINC01225	-3.91	9.92e-05	0.00622	-0.14	-0.12	Alcohol dependence;	chr1:31370100	chr1:31500085~31540885:+
BRCA	cis	rs4648045	0.734	rs11722146	ENSG00000246560.2	RP11-10L12.4	3.91	9.92e-05	0.00622	0.14	0.12	Lymphocyte percentage of white cells;	chr4:102603472	chr4:102828055~102844075:+
BRCA	cis	rs2692947	0.537	rs4907274	ENSG00000168992.4	OR7E102P	3.91	9.92e-05	0.00622	0.17	0.12	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95697934	chr2:95546531~95547545:+
BRCA	cis	rs11098403	0.833	rs12640843	ENSG00000225892.3	RP11-384K6.2	-3.91	9.92e-05	0.00622	-0.12	-0.12	Schizophrenia;	chr4:117770687	chr4:118632274~118634759:+
BRCA	cis	rs78487399	0.731	rs13408697	ENSG00000234936.1	AC010883.5	3.91	9.92e-05	0.00622	0.17	0.12	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43479105	chr2:43229573~43233394:+
BRCA	cis	rs8114671	0.586	rs6087634	ENSG00000261582.1	RP4-614O4.11	-3.91	9.93e-05	0.00622	-0.12	-0.12	Height;	chr20:34826006	chr20:35267885~35280043:-
BRCA	cis	rs2880765	0.743	rs8032488	ENSG00000230373.7	GOLGA6L5P	3.91	9.93e-05	0.00622	0.13	0.12	Coronary artery disease;	chr15:85469537	chr15:84507885~84516814:-
BRCA	cis	rs6600671	1	rs4844381	ENSG00000223345.3	HIST2H2BA	3.91	9.93e-05	0.00622	0.14	0.12	Hip geometry;	chr1:121443040	chr1:121108210~121117257:-
BRCA	cis	rs12324805	0.568	rs8039459	ENSG00000276710.3	CSPG4P8	-3.91	9.93e-05	0.00622	-0.13	-0.12	Body mass index;	chr15:82028085	chr15:82459472~82477258:+
BRCA	cis	rs916888	0.773	rs9896243	ENSG00000260075.1	NSFP1	-3.91	9.93e-05	0.00623	-0.2	-0.12	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:46372855~46487141:+
BRCA	cis	rs11070836	0.935	rs28362014	ENSG00000259378.1	DCAF13P3	3.91	9.93e-05	0.00623	0.16	0.12	Airway wall thickness;	chr15:51120823	chr15:50944663~50945996:+
BRCA	cis	rs6500602	0.527	rs13338333	ENSG00000280063.1	RP11-295D4.3	3.91	9.93e-05	0.00623	0.1	0.12	Schizophrenia;	chr16:4393249	chr16:4346694~4348648:-
BRCA	cis	rs35146811	0.735	rs1043915	ENSG00000235713.1	RP4-604G5.3	3.91	9.93e-05	0.00623	0.14	0.12	Coronary artery disease;	chr7:100202222	chr7:99992397~99993050:+
BRCA	cis	rs56281245	0.793	rs76092197	ENSG00000249363.1	CTB-78O21.1	3.91	9.93e-05	0.00623	0.26	0.12	Hepcidin levels;	chr5:145601298	chr5:145728360~145729349:-
BRCA	cis	rs56281245	0.793	rs76516313	ENSG00000249363.1	CTB-78O21.1	3.91	9.93e-05	0.00623	0.26	0.12	Hepcidin levels;	chr5:145601910	chr5:145728360~145729349:-
BRCA	cis	rs56281245	0.793	rs75320209	ENSG00000249363.1	CTB-78O21.1	3.91	9.93e-05	0.00623	0.26	0.12	Hepcidin levels;	chr5:145602336	chr5:145728360~145729349:-
BRCA	cis	rs56281245	0.793	rs77229050	ENSG00000249363.1	CTB-78O21.1	3.91	9.93e-05	0.00623	0.26	0.12	Hepcidin levels;	chr5:145603171	chr5:145728360~145729349:-
BRCA	cis	rs2227564	0.729	rs2227551	ENSG00000279689.1	RP11-574K11.32	3.91	9.93e-05	0.00623	0.13	0.12	Crohn's disease;Inflammatory bowel disease;	chr10:73909432	chr10:73769264~73772862:-
BRCA	cis	rs897984	0.542	rs6565217	ENSG00000279196.1	RP11-1072A3.3	3.91	9.93e-05	0.00623	0.12	0.12	Dementia with Lewy bodies;	chr16:31072003	chr16:30984630~30988270:-
BRCA	cis	rs8014252	0.803	rs17108201	ENSG00000259158.2	ADAM20P1	-3.91	9.93e-05	0.00623	-0.22	-0.12	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70522214	chr14:70468881~70483756:-
BRCA	cis	rs1153858	0.621	rs2413769	ENSG00000275672.1	GATM-AS1	-3.91	9.93e-05	0.00623	-0.16	-0.12	Homoarginine levels;	chr15:45269670	chr15:45378700~45380123:+
BRCA	cis	rs2303319	0.504	rs2084543	ENSG00000227403.1	AC009299.3	3.91	9.94e-05	0.00623	0.32	0.12	Cognitive function;	chr2:161839904	chr2:161244739~161249050:+
BRCA	cis	rs11696739	0.761	rs2254458	ENSG00000242324.1	RP4-576H24.2	-3.91	9.94e-05	0.00623	-0.14	-0.12	Mean platelet volume;	chr20:1570839	chr20:1516759~1557653:-
BRCA	cis	rs4664293	0.667	rs10169681	ENSG00000226266.5	AC009961.3	3.91	9.94e-05	0.00623	0.14	0.12	Monocyte percentage of white cells;	chr2:159782065	chr2:159670708~159712435:-
BRCA	cis	rs7620503	1	rs1463858	ENSG00000277241.1	RP11-114M1.3	3.91	9.94e-05	0.00623	0.13	0.12	Corneal structure;	chr3:177580339	chr3:177700346~177701072:-
BRCA	cis	rs4950322	0.947	rs58671552	ENSG00000244371.2	PFN1P8	-3.91	9.94e-05	0.00623	-0.17	-0.12	Protein quantitative trait loci;	chr1:147409534	chr1:146957117~146957659:-
BRCA	cis	rs17581137	0.591	rs4321146	ENSG00000247809.6	NR2F2-AS1	-3.91	9.95e-05	0.00624	-0.14	-0.12	Coronary artery disease;	chr15:95635587	chr15:96110040~96327361:-
BRCA	cis	rs2304003	0.95	rs1863199	ENSG00000235192.1	AC009495.2	3.91	9.95e-05	0.00624	0.14	0.12	Social communication problems;	chr2:165810140	chr2:165794851~165810010:+
BRCA	cis	rs8060686	0.516	rs7193701	ENSG00000261386.2	CTD-2012K14.6	3.91	9.95e-05	0.00624	0.15	0.12	HDL cholesterol;Metabolic syndrome;	chr16:68151257	chr16:67549214~67563958:-
BRCA	cis	rs6545883	0.894	rs6760075	ENSG00000270820.4	RP11-355B11.2	-3.91	9.95e-05	0.00624	-0.14	-0.12	Tuberculosis;	chr2:61385746	chr2:61471188~61484130:+
BRCA	cis	rs10504130	1	rs75221577	ENSG00000272076.1	RP11-11C20.3	3.91	9.95e-05	0.00624	0.2	0.12	Venous thromboembolism (SNP x SNP interaction);	chr8:51856812	chr8:51810110~51810681:-
BRCA	cis	rs10504130	1	rs74681723	ENSG00000272076.1	RP11-11C20.3	3.91	9.95e-05	0.00624	0.2	0.12	Venous thromboembolism (SNP x SNP interaction);	chr8:51857932	chr8:51810110~51810681:-
BRCA	cis	rs4849121	0.535	rs10180551	ENSG00000235721.1	AC013268.3	-3.91	9.95e-05	0.00624	-0.16	-0.12	IgA nephropathy;	chr2:110844469	chr2:110007675~110010783:+
BRCA	cis	rs930395	0.514	rs10063172	ENSG00000251141.4	RP11-53O19.1	-3.91	9.95e-05	0.00624	-0.11	-0.12	Breast cancer;	chr5:44930607	chr5:44744900~44808777:-
BRCA	cis	rs6445975	1	rs6445975	ENSG00000272182.1	RP11-802O23.3	3.91	9.95e-05	0.00624	0.14	0.12	Systemic lupus erythematosus;	chr3:58384450	chr3:58428255~58428815:+
BRCA	cis	rs73201462	1	rs11709066	ENSG00000242551.2	POU5F1P6	-3.91	9.95e-05	0.00624	-0.2	-0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128156069	chr3:128674735~128677005:-
BRCA	cis	rs6951245	0.529	rs76001997	ENSG00000224079.1	AC091729.7	-3.91	9.95e-05	0.00624	-0.18	-0.12	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1112979	chr7:1074450~1078036:+
BRCA	cis	rs73201462	1	rs2955097	ENSG00000242551.2	POU5F1P6	-3.91	9.96e-05	0.00624	-0.2	-0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128259662	chr3:128674735~128677005:-
BRCA	cis	rs7656342	0.866	rs2280206	ENSG00000250342.1	SNRPCP16	-3.91	9.96e-05	0.00624	-0.14	-0.12	Gut microbiota (bacterial taxa);	chr4:9797613	chr4:9051842~9052051:-
BRCA	cis	rs10508774	0.866	rs72784062	ENSG00000273038.2	RP11-479G22.8	3.91	9.96e-05	0.00624	0.26	0.12	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32905923	chr10:32887255~32889311:-
BRCA	cis	rs115575488	0.85	rs10494220	ENSG00000231365.4	RP11-418J17.1	3.91	9.96e-05	0.00624	0.23	0.12	Lobe attachment (rater-scored or self-reported);	chr1:119029775	chr1:119140396~119275973:+
BRCA	cis	rs6545883	0.931	rs7557230	ENSG00000270820.4	RP11-355B11.2	3.91	9.96e-05	0.00624	0.14	0.12	Tuberculosis;	chr2:61509517	chr2:61471188~61484130:+
BRCA	cis	rs13393800	0.956	rs1190445	ENSG00000237126.7	AC073254.1	3.91	9.96e-05	0.00624	0.16	0.12	Height;	chr2:232556117	chr2:232580948~232611971:-
BRCA	cis	rs2562456	0.833	rs2968078	ENSG00000213976.4	CTD-2561J22.2	3.91	9.96e-05	0.00624	0.14	0.12	Pain;	chr19:21458942	chr19:21382865~21387177:+
BRCA	cis	rs999943	0.81	rs57088429	ENSG00000224557.6	HLA-DPB2	-3.91	9.96e-05	0.00624	-0.17	-0.12	Obesity (extreme);	chr6:33676412	chr6:33112451~33129084:+
BRCA	cis	rs4415084	1	rs13155752	ENSG00000248779.1	RP11-53O19.2	3.91	9.96e-05	0.00624	0.11	0.12	Breast cancer;	chr5:44680585	chr5:44752949~44765744:+
BRCA	cis	rs4415084	0.804	rs4866922	ENSG00000248779.1	RP11-53O19.2	-3.91	9.96e-05	0.00624	-0.11	-0.12	Breast cancer;	chr5:44932403	chr5:44752949~44765744:+
BRCA	cis	rs2880765	0.743	rs8028240	ENSG00000230373.7	GOLGA6L5P	3.91	9.96e-05	0.00625	0.13	0.12	Coronary artery disease;	chr15:85470017	chr15:84507885~84516814:-
BRCA	cis	rs10958369	0.613	rs7829521	ENSG00000253369.1	RP11-1081M5.1	3.91	9.96e-05	0.00625	0.15	0.12	Response to antineoplastic agents;	chr8:53521328	chr8:53395211~53395946:-
BRCA	cis	rs7177699	0.525	rs7402376	ENSG00000261143.1	ADAMTS7P3	3.91	9.97e-05	0.00625	0.15	0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78821228	chr15:77976042~77993057:+
BRCA	cis	rs7267979	1	rs2297496	ENSG00000125804.12	FAM182A	3.91	9.97e-05	0.00625	0.16	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25315151	chr20:26054655~26086917:+
BRCA	cis	rs8040855	0.627	rs12909130	ENSG00000229212.6	RP11-561C5.4	-3.91	9.97e-05	0.00625	-0.16	-0.12	Bulimia nervosa;	chr15:85047270	chr15:85205440~85234795:-
BRCA	cis	rs6005807	0.719	rs12169071	ENSG00000272858.1	CTA-292E10.8	-3.91	9.97e-05	0.00625	-0.21	-0.12	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28637222	chr22:28814914~28815662:+
BRCA	cis	rs6005807	0.719	rs12168765	ENSG00000272858.1	CTA-292E10.8	-3.91	9.97e-05	0.00625	-0.21	-0.12	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28637320	chr22:28814914~28815662:+
BRCA	cis	rs6005807	0.719	rs12165893	ENSG00000272858.1	CTA-292E10.8	-3.91	9.97e-05	0.00625	-0.21	-0.12	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28637557	chr22:28814914~28815662:+
BRCA	cis	rs7954584	0.635	rs7309024	ENSG00000272849.1	RP11-347I19.8	-3.91	9.97e-05	0.00625	-0.09	-0.12	Mean corpuscular volume;	chr12:121900428	chr12:121797511~121801972:+
BRCA	cis	rs62458065	0.85	rs28693551	ENSG00000273014.1	RP11-225B17.2	-3.91	9.97e-05	0.00625	-0.19	-0.12	Metabolite levels (HVA/MHPG ratio);	chr7:32429775	chr7:32758882~32759353:+
BRCA	cis	rs3858526	0.959	rs61876223	ENSG00000224295.2	AC087380.14	3.91	9.97e-05	0.00625	0.17	0.12	DNA methylation (variation);	chr11:5922163	chr11:5518441~5524955:-
BRCA	cis	rs6893300	0.961	rs3797776	ENSG00000250999.1	RP11-1379J22.5	3.91	9.97e-05	0.00625	0.17	0.12	Resting heart rate;	chr5:179766597	chr5:179657762~179664432:+
BRCA	cis	rs4499344	0.73	rs7246338	ENSG00000267475.1	CTD-2538C1.2	3.91	9.97e-05	0.00625	0.15	0.12	Mean platelet volume;	chr19:32608598	chr19:32687089~32691750:-
BRCA	cis	rs8040855	0.599	rs4643289	ENSG00000259762.1	RP11-158M2.4	-3.91	9.97e-05	0.00625	-0.14	-0.12	Bulimia nervosa;	chr15:85183483	chr15:85750336~85752901:-
BRCA	cis	rs9393813	0.626	rs2235232	ENSG00000241549.7	GUSBP2	3.91	9.97e-05	0.00625	0.13	0.12	Bipolar disorder;	chr6:27359084	chr6:26871484~26956554:-
BRCA	cis	rs2915864	1	rs2961720	ENSG00000280047.1	CTC-463A16.1	-3.91	9.97e-05	0.00625	-0.2	-0.12	Facial morphology (factor 20);	chr5:142200665	chr5:142165767~142168387:+
BRCA	cis	rs7746199	0.736	rs10484399	ENSG00000216901.1	AL022393.7	3.91	9.97e-05	0.00625	0.29	0.12	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27566749	chr6:28176188~28176674:+
BRCA	cis	rs990171	0.538	rs2075188	ENSG00000234389.1	AC007278.3	3.91	9.97e-05	0.00625	0.12	0.12	Lymphocyte counts;	chr2:102503773	chr2:102438713~102440475:+
BRCA	cis	rs10735946	0.898	rs988606	ENSG00000255733.4	IFNG-AS1	3.91	9.97e-05	0.00625	0.1	0.12	Anti-saccade response;	chr12:68087631	chr12:67989445~68234686:+
BRCA	cis	rs6088590	0.965	rs910869	ENSG00000276073.1	RP5-1125A11.7	-3.91	9.97e-05	0.00625	-0.14	-0.12	Coronary artery disease;	chr20:34704973	chr20:33985617~33988989:-
BRCA	cis	rs930395	0.514	rs9791164	ENSG00000248779.1	RP11-53O19.2	3.91	9.98e-05	0.00625	0.11	0.12	Breast cancer;	chr5:44903928	chr5:44752949~44765744:+
BRCA	cis	rs6723226	0.804	rs17428810	ENSG00000276517.1	AL133243.2	3.91	9.98e-05	0.00625	0.16	0.12	Intelligence (multi-trait analysis);	chr2:32510976	chr2:32526504~32529507:+
BRCA	cis	rs7954584	0.567	rs1720037	ENSG00000212694.7	LINC01089	3.91	9.98e-05	0.00625	0.1	0.12	Mean corpuscular volume;	chr12:121944323	chr12:121795267~121803906:-
BRCA	cis	rs7267979	0.78	rs6050679	ENSG00000274414.1	RP5-965G21.4	-3.91	9.98e-05	0.00625	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25557191	chr20:25239007~25245229:-
BRCA	cis	rs1910358	0.778	rs6871150	ENSG00000248874.4	C5orf17	-3.91	9.98e-05	0.00625	-0.16	-0.12	Venous thromboembolism (SNP x SNP interaction);	chr5:23992945	chr5:23951348~24178263:+
BRCA	cis	rs3805389	0.504	rs3805388	ENSG00000249700.7	SRD5A3-AS1	-3.91	9.98e-05	0.00625	-0.19	-0.12	Waist-to-hip ratio adjusted for body mass index;	chr4:55614754	chr4:55363971~55395847:-
BRCA	cis	rs12505749	0.542	rs4340842	ENSG00000270147.1	RP11-646I6.6	-3.91	9.98e-05	0.00626	-0.14	-0.12	Airflow obstruction;	chr4:56472022	chr4:56396312~56396871:+
BRCA	cis	rs1371614	0.611	rs4665920	ENSG00000229122.1	AGBL5-IT1	-3.91	9.98e-05	0.00626	-0.13	-0.12	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26905966	chr2:27061038~27061815:+
BRCA	cis	rs9425766	0.64	rs61827925	ENSG00000200674.1	RN7SKP160	3.91	9.98e-05	0.00626	0.2	0.12	Life satisfaction;	chr1:173862619	chr1:173791548~173791887:+
BRCA	cis	rs4950322	0.58	rs7541393	ENSG00000244371.2	PFN1P8	-3.91	9.98e-05	0.00626	-0.16	-0.12	Protein quantitative trait loci;	chr1:147117186	chr1:146957117~146957659:-
BRCA	cis	rs6867032	0.834	rs10043083	ENSG00000248994.1	RP11-259O2.1	-3.91	9.99e-05	0.00626	-0.15	-0.12	Gut microbiome composition (winter);	chr5:1995573	chr5:1933863~1959176:+
BRCA	cis	rs11761441	0.669	rs13241486	ENSG00000242611.1	AC093627.8	-3.91	9.99e-05	0.00626	-0.15	-0.12	Alzheimer's disease in APOE e4- carriers;	chr7:79536	chr7:77038~80418:+
BRCA	cis	rs1914816	0.887	rs2460155	ENSG00000259422.1	RP11-593F23.1	3.91	9.99e-05	0.00626	0.18	0.12	Response to tocilizumab in rheumatoid arthritis;	chr15:76186584	chr15:76174891~76181486:-
BRCA	cis	rs739496	0.843	rs616668	ENSG00000257624.1	RP1-128M12.3	3.91	9.99e-05	0.00626	0.16	0.12	Platelet count;	chr12:111536476	chr12:112000739~112000985:-
BRCA	cis	rs7312933	0.703	rs10880264	ENSG00000257225.1	RP11-328C8.4	-3.91	9.99e-05	0.00626	-0.14	-0.12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42192733	chr12:42459366~42466128:+
BRCA	cis	rs9959145	1	rs78908311	ENSG00000267108.1	RP11-861E21.1	3.91	9.99e-05	0.00626	0.21	0.12	Immune response to smallpox vaccine (IL-6);	chr18:12688279	chr18:12432897~12437635:+
BRCA	cis	rs45509595	0.841	rs370155	ENSG00000216901.1	AL022393.7	3.91	1e-04	0.00626	0.23	0.12	Breast cancer;	chr6:27814253	chr6:28176188~28176674:+
BRCA	cis	rs9863	0.861	rs9971695	ENSG00000270028.1	RP11-380L11.4	3.91	1e-04	0.00626	0.15	0.12	White blood cell count;	chr12:123928944	chr12:123925461~123926083:-
BRCA	cis	rs10504130	0.866	rs74738864	ENSG00000272076.1	RP11-11C20.3	3.91	1e-04	0.00626	0.2	0.12	Venous thromboembolism (SNP x SNP interaction);	chr8:51878654	chr8:51810110~51810681:-
BRCA	cis	rs73201462	1	rs2955089	ENSG00000242551.2	POU5F1P6	-3.91	1e-04	0.00626	-0.2	-0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128250487	chr3:128674735~128677005:-
BRCA	cis	rs73201462	1	rs2955090	ENSG00000242551.2	POU5F1P6	-3.91	1e-04	0.00626	-0.2	-0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128250528	chr3:128674735~128677005:-
BRCA	cis	rs2243480	1	rs313813	ENSG00000275400.1	RP4-756H11.5	3.91	1e-04	0.00626	0.22	0.12	Diabetic kidney disease;	chr7:66038513	chr7:66553805~66554199:-
BRCA	cis	rs11098499	0.863	rs34868248	ENSG00000260404.2	RP11-384K6.6	3.91	1e-04	0.00626	0.12	0.12	Corneal astigmatism;	chr4:119521275	chr4:118591773~118633729:+
BRCA	cis	rs513088	0.589	rs502594	ENSG00000225171.2	DUTP6	3.91	1e-04	0.00626	0.17	0.12	Schizophrenia;	chr1:166721246	chr1:166868748~166869209:+
BRCA	cis	rs875971	0.862	rs6962717	ENSG00000273024.4	INTS4P2	-3.91	1e-04	0.00626	-0.13	-0.12	Aortic root size;	chr7:66418748	chr7:65647864~65715661:+
BRCA	cis	rs80028505	0.908	rs56413204	ENSG00000271304.1	DPRXP2	3.91	1e-04	0.00627	0.23	0.12	Foot ulcer in diabetes and neuropathy;	chr6:36037125	chr6:35989515~35990436:-
BRCA	cis	rs11096990	0.634	rs2062229	ENSG00000249685.1	RP11-360F5.3	3.91	1e-04	0.00627	0.15	0.12	Cognitive function;	chr4:39285146	chr4:39133913~39135608:+
BRCA	cis	rs7647973	1	rs13096474	ENSG00000244380.1	RP11-24C3.2	-3.91	1e-04	0.00627	-0.15	-0.12	Menarche (age at onset);	chr3:49405648	chr3:48440352~48446656:-
BRCA	cis	rs875971	0.862	rs11773628	ENSG00000229886.1	RP5-1132H15.3	-3.91	1e-04	0.00627	-0.13	-0.12	Aortic root size;	chr7:66517644	chr7:66025126~66031544:-
BRCA	cis	rs10458771	0.915	rs10400177	ENSG00000227896.2	RP11-77P6.2	-3.91	1e-04	0.00627	-0.15	-0.12	Amyotrophic lateral sclerosis (sporadic);	chr10:86434154	chr10:86521945~86525101:+
BRCA	cis	rs9863	0.828	rs952632	ENSG00000270028.1	RP11-380L11.4	3.91	1e-04	0.00627	0.15	0.12	White blood cell count;	chr12:123985191	chr12:123925461~123926083:-
BRCA	cis	rs2625529	0.938	rs4777464	ENSG00000260037.4	CTD-2524L6.3	-3.91	1e-04	0.00627	-0.16	-0.12	Red blood cell count;	chr15:71839422	chr15:71818396~71823384:+
BRCA	cis	rs4835473	0.6	rs9997101	ENSG00000246448.2	RP13-578N3.3	3.91	1e-04	0.00627	0.13	0.12	Immature fraction of reticulocytes;	chr4:143777892	chr4:143700257~143865072:+
BRCA	cis	rs62458065	0.713	rs3801329	ENSG00000229358.3	DPY19L1P1	-3.91	1e-04	0.00627	-0.17	-0.12	Metabolite levels (HVA/MHPG ratio);	chr7:32457344	chr7:32580949~32761787:-
BRCA	cis	rs35520189	0.857	rs6735739	ENSG00000189223.12	PAX8-AS1	3.91	1e-04	0.00627	0.17	0.12	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:112852309	chr2:113211522~113276581:+
BRCA	cis	rs801193	0.967	rs34356500	ENSG00000229180.5	GS1-124K5.11	3.91	1e-04	0.00627	0.1	0.12	Aortic root size;	chr7:66771620	chr7:66526088~66542624:-
BRCA	cis	rs10129255	1	rs4612959	ENSG00000211967.3	IGHV3-53	-3.91	1e-04	0.00627	-0.09	-0.12	Kawasaki disease;	chr14:106767055	chr14:106592676~106593347:-
BRCA	cis	rs9470794	0.748	rs11759475	ENSG00000204110.6	RP1-153P14.8	-3.91	1e-04	0.00627	-0.26	-0.12	Type 2 diabetes;	chr6:37819062	chr6:37507348~37535616:+
BRCA	cis	rs8062405	1	rs62036620	ENSG00000261766.1	RP11-22P6.2	-3.91	1e-04	0.00628	-0.12	-0.12	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821776	chr16:28862166~28863340:-
BRCA	cis	rs8062405	1	rs62036621	ENSG00000261766.1	RP11-22P6.2	-3.91	1e-04	0.00628	-0.12	-0.12	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821978	chr16:28862166~28863340:-
BRCA	cis	rs78545713	0.649	rs11754368	ENSG00000241549.7	GUSBP2	-3.91	1e-04	0.00628	-0.2	-0.12	Iron status biomarkers (total iron binding capacity);	chr6:26220945	chr6:26871484~26956554:-
BRCA	cis	rs6893300	0.961	rs7444006	ENSG00000250999.1	RP11-1379J22.5	3.91	1e-04	0.00628	0.17	0.12	Resting heart rate;	chr5:179750701	chr5:179657762~179664432:+
BRCA	cis	rs875971	0.545	rs801199	ENSG00000232559.3	GS1-124K5.12	-3.91	1e-04	0.00628	-0.16	-0.12	Aortic root size;	chr7:66560286	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.545	rs73152714	ENSG00000232559.3	GS1-124K5.12	3.91	1e-04	0.00628	0.16	0.12	Aortic root size;	chr7:66534641	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.545	rs4718364	ENSG00000232559.3	GS1-124K5.12	3.91	1e-04	0.00628	0.16	0.12	Aortic root size;	chr7:66536353	chr7:66554588~66576923:-
BRCA	cis	rs7818688	1	rs10113545	ENSG00000245080.5	RP11-320N21.1	-3.91	1e-04	0.00628	-0.2	-0.12	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95017479	chr8:95066808~95073182:-
BRCA	cis	rs56116382	0.604	rs9858428	ENSG00000270441.1	RP11-694I15.7	3.91	1e-04	0.00628	0.26	0.12	High light scatter reticulocyte count;Intelligence (multi-trait analysis);	chr3:49840152	chr3:49140086~49160851:-
BRCA	cis	rs6719977	0.569	rs6756140	ENSG00000226491.1	FTOP1	-3.91	1e-04	0.00628	-0.14	-0.12	Hyperactive-impulsive symptoms;	chr2:42741796	chr2:42797225~42798712:-
BRCA	cis	rs2163813	1	rs17699333	ENSG00000271283.1	CTC-412M14.6	-3.91	1e-04	0.00628	-0.16	-0.12	Toenail selenium levels;	chr19:19720735	chr19:19699203~19699409:-
BRCA	cis	rs2281603	0.762	rs61987034	ENSG00000259116.1	RP11-973N13.4	-3.91	1e-04	0.00628	-0.12	-0.12	Lymphocyte counts;	chr14:64567405	chr14:64514154~64540368:-
BRCA	cis	rs2446066	0.872	rs10876447	ENSG00000257379.1	RP11-793H13.8	3.9	1e-04	0.00628	0.18	0.12	Red blood cell count;	chr12:53377157	chr12:53441741~53467528:+
BRCA	cis	rs9470794	0.915	rs9470802	ENSG00000204110.6	RP1-153P14.8	-3.9	1e-04	0.00628	-0.19	-0.12	Type 2 diabetes;	chr6:38157768	chr6:37507348~37535616:+
BRCA	cis	rs10005067	0.967	rs4693908	ENSG00000249001.4	RP11-742B18.1	-3.9	1e-04	0.00628	-0.14	-0.12	Total body bone mineral density (age 30-45);	chr4:87901591	chr4:87568035~87733956:-
BRCA	cis	rs13126694	0.778	rs10013448	ENSG00000251073.1	NUDT19P5	3.9	1e-04	0.00628	0.11	0.12	Blood osmolality (transformed sodium);	chr4:158116101	chr4:158182825~158183393:+
BRCA	cis	rs2562456	0.874	rs9304986	ENSG00000268119.4	CTD-2561J22.5	-3.9	1e-04	0.00628	-0.18	-0.12	Pain;	chr19:21499260	chr19:21444241~21463908:-
BRCA	cis	rs7267979	1	rs6083862	ENSG00000274973.1	RP13-401N8.7	3.9	1e-04	0.00628	0.13	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25430450	chr20:25845497~25845862:+
BRCA	cis	rs757081	0.648	rs214923	ENSG00000272034.1	SNORD14A	-3.9	1e-04	0.00628	-0.12	-0.12	Systolic blood pressure;	chr11:17215533	chr11:17074654~17074744:-
BRCA	cis	rs6596100	0.956	rs7711865	ENSG00000248648.1	RP11-485M7.1	-3.9	1e-04	0.00628	-0.16	-0.12	Breast cancer;	chr5:133096838	chr5:133003119~133003365:+
BRCA	cis	rs11051970	0.879	rs2733682	ENSG00000274964.1	RP11-817I4.1	-3.9	1e-04	0.00628	-0.14	-0.12	Response to tocilizumab in rheumatoid arthritis;	chr12:32421674	chr12:32339368~32340724:+
BRCA	cis	rs11665748	0.538	rs266863	ENSG00000269388.1	AC018755.16	-3.9	1e-04	0.00628	-0.13	-0.12	Prostate-specific antigen levels (conditioned on lead SNPs);Prostate-specific antigen levels;	chr19:50852394	chr19:51594561~51606150:+
BRCA	cis	rs6005807	0.719	rs7293232	ENSG00000272858.1	CTA-292E10.8	-3.9	1e-04	0.00628	-0.21	-0.12	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28619602	chr22:28814914~28815662:+
BRCA	cis	rs6005807	0.563	rs7288792	ENSG00000272858.1	CTA-292E10.8	-3.9	1e-04	0.00628	-0.21	-0.12	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28619615	chr22:28814914~28815662:+
BRCA	cis	rs6005807	0.64	rs7289534	ENSG00000272858.1	CTA-292E10.8	-3.9	1e-04	0.00628	-0.21	-0.12	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28620069	chr22:28814914~28815662:+
BRCA	cis	rs6487679	0.526	rs34362	ENSG00000214776.8	RP11-726G1.1	3.9	1e-04	0.00628	0.14	0.12	Non-alcoholic fatty liver disease histology (AST);	chr12:9232829	chr12:9467552~9576275:+
BRCA	cis	rs2030746	0.521	rs6750309	ENSG00000237614.1	AC073257.2	3.9	1e-04	0.00629	0.15	0.12	LDL cholesterol;Total cholesterol levels;LDL cholesterol levels;	chr2:120574615	chr2:120542909~120544326:-
BRCA	cis	rs62064224	0.714	rs16967266	ENSG00000279781.1	RP11-466A19.7	3.9	1e-04	0.00629	0.15	0.12	Schizophrenia;	chr17:32305255	chr17:32518322~32518934:-
BRCA	cis	rs4073582	0.595	rs1115508	ENSG00000255320.1	RP11-755F10.1	-3.9	1e-04	0.00629	-0.15	-0.12	Gout;	chr11:66155678	chr11:66244840~66246239:-
BRCA	cis	rs7552404	0.824	rs1251077	ENSG00000181227.3	RP4-682C21.2	3.9	1e-04	0.00629	0.12	0.12	Acylcarnitine levels;Blood metabolite levels;	chr1:75724060	chr1:75743423~75744776:-
BRCA	cis	rs17092148	0.887	rs4911431	ENSG00000202150.1	RNU6-407P	3.9	1e-04	0.00629	0.18	0.12	Neuroticism;	chr20:34570514	chr20:35030317~35030420:-
BRCA	cis	rs4819052	0.851	rs13047104	ENSG00000215447.6	BX322557.10	-3.9	1e-04	0.00629	-0.12	-0.12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45253647	chr21:45288052~45291738:+
BRCA	cis	rs6840360	0.582	rs4473638	ENSG00000251611.1	RP11-610P16.1	-3.9	1e-04	0.00629	-0.11	-0.12	Intelligence (multi-trait analysis);	chr4:151400994	chr4:151407551~151408835:-
BRCA	cis	rs6840360	0.548	rs4254751	ENSG00000251611.1	RP11-610P16.1	-3.9	1e-04	0.00629	-0.11	-0.12	Intelligence (multi-trait analysis);	chr4:151401419	chr4:151407551~151408835:-
BRCA	cis	rs2304003	0.583	rs1056341	ENSG00000235192.1	AC009495.2	3.9	1e-04	0.00629	0.13	0.12	Social communication problems;	chr2:165867464	chr2:165794851~165810010:+
BRCA	cis	rs6860806	0.661	rs6871350	ENSG00000233006.5	AC034220.3	3.9	1e-04	0.00629	0.08	0.12	Breast cancer;	chr5:132244527	chr5:132311285~132369916:-
BRCA	cis	rs62458065	0.85	rs62458066	ENSG00000273014.1	RP11-225B17.2	-3.9	0.000101	0.00629	-0.19	-0.12	Metabolite levels (HVA/MHPG ratio);	chr7:32424872	chr7:32758882~32759353:+
BRCA	cis	rs747650	0.504	rs4752815	ENSG00000200376.1	RNU5E-10P	3.9	0.000101	0.00629	0.16	0.12	Acne (severe);	chr11:46957147	chr11:47576471~47576588:-
BRCA	cis	rs17801127	0.748	rs1405219	ENSG00000231969.1	AC144449.1	-3.9	0.000101	0.00629	-0.18	-0.12	Liver enzyme levels (alanine transaminase);	chr2:149687563	chr2:149587196~149848233:+
BRCA	cis	rs721917	0.525	rs4281433	ENSG00000242600.5	MBL1P	3.9	0.000101	0.00629	0.14	0.12	Chronic obstructive pulmonary disease;	chr10:79982904	chr10:79904898~79950336:+
BRCA	cis	rs6088590	0.93	rs6087618	ENSG00000276073.1	RP5-1125A11.7	-3.9	0.000101	0.0063	-0.14	-0.12	Coronary artery disease;	chr20:34700603	chr20:33985617~33988989:-
BRCA	cis	rs2274273	0.522	rs2251366	ENSG00000233924.1	AL160471.6	-3.9	0.000101	0.0063	-0.14	-0.12	Protein biomarker;	chr14:55051438	chr14:55004813~55005687:-
BRCA	cis	rs957448	1	rs16916881	ENSG00000261437.1	RP11-22C11.2	3.9	0.000101	0.0063	0.13	0.12	Nonsyndromic cleft lip with cleft palate;	chr8:94554042	chr8:94637285~94639467:-
BRCA	cis	rs8040855	0.965	rs1961276	ENSG00000230373.7	GOLGA6L5P	3.9	0.000101	0.0063	0.13	0.12	Bulimia nervosa;	chr15:85170986	chr15:84507885~84516814:-
BRCA	cis	rs7412746	0.611	rs4970984	ENSG00000231073.1	RP11-316M1.3	3.9	0.000101	0.0063	0.13	0.12	Melanoma;	chr1:150914901	chr1:150973123~150975534:+
BRCA	cis	rs4578769	0.765	rs1584428	ENSG00000265939.1	UBE2CP2	3.9	0.000101	0.0063	0.15	0.12	Eosinophil percentage of white cells;	chr18:22807886	chr18:22900486~22900995:-
BRCA	cis	rs2274273	0.84	rs10150760	ENSG00000259318.1	RP11-454L9.2	-3.9	0.000101	0.0063	-0.1	-0.12	Protein biomarker;	chr14:55354830	chr14:55394940~55395233:-
BRCA	cis	rs2303319	0.504	rs62187740	ENSG00000227403.1	AC009299.3	3.9	0.000101	0.0063	0.32	0.12	Cognitive function;	chr2:161841976	chr2:161244739~161249050:+
BRCA	cis	rs2303319	0.504	rs62187741	ENSG00000227403.1	AC009299.3	3.9	0.000101	0.0063	0.32	0.12	Cognitive function;	chr2:161842014	chr2:161244739~161249050:+
BRCA	cis	rs2303319	0.504	rs72879275	ENSG00000227403.1	AC009299.3	3.9	0.000101	0.0063	0.32	0.12	Cognitive function;	chr2:161842313	chr2:161244739~161249050:+
BRCA	cis	rs2303319	0.504	rs62187742	ENSG00000227403.1	AC009299.3	3.9	0.000101	0.0063	0.32	0.12	Cognitive function;	chr2:161843587	chr2:161244739~161249050:+
BRCA	cis	rs2303319	0.504	rs56190932	ENSG00000227403.1	AC009299.3	3.9	0.000101	0.0063	0.32	0.12	Cognitive function;	chr2:161843894	chr2:161244739~161249050:+
BRCA	cis	rs2303319	0.504	rs72879281	ENSG00000227403.1	AC009299.3	3.9	0.000101	0.0063	0.32	0.12	Cognitive function;	chr2:161844643	chr2:161244739~161249050:+
BRCA	cis	rs4742903	0.935	rs1507515	ENSG00000270332.1	SMC2-AS1	-3.9	0.000101	0.0063	-0.13	-0.12	Breast cancer;High-grade serous ovarian cancer;	chr9:104227372	chr9:104080024~104093073:-
BRCA	cis	rs2880765	0.835	rs2170735	ENSG00000230373.7	GOLGA6L5P	3.9	0.000101	0.0063	0.13	0.12	Coronary artery disease;	chr15:85500254	chr15:84507885~84516814:-
BRCA	cis	rs6452524	0.935	rs6880566	ENSG00000281327.1	LINC01338	3.9	0.000101	0.0063	0.14	0.12	Hypertension (SNP x SNP interaction);	chr5:83086909	chr5:82850864~82859836:-
BRCA	cis	rs7181230	1	rs9972424	ENSG00000275636.1	RP11-521C20.5	3.9	0.000101	0.0063	0.14	0.12	Dehydroepiandrosterone sulphate levels;	chr15:40073650	chr15:40078892~40079347:+
BRCA	cis	rs28374715	0.578	rs10518717	ENSG00000247556.5	OIP5-AS1	3.9	0.000101	0.0063	0.14	0.12	Ulcerative colitis;	chr15:41331170	chr15:41283990~41309737:+
BRCA	cis	rs4272720	0.95	rs61848377	ENSG00000228754.1	RP11-534L6.3	-3.9	0.000101	0.0063	-0.18	-0.12	Platelet count;Plateletcrit;	chr10:49075047	chr10:48745545~48746128:-
BRCA	cis	rs964611	0.882	rs7182177	ENSG00000259488.2	RP11-154J22.1	-3.9	0.000101	0.0063	-0.15	-0.12	Metabolite levels (Pyroglutamine);	chr15:48354357	chr15:48312353~48331856:-
BRCA	cis	rs1048886	0.872	rs12203298	ENSG00000271967.1	RP11-134K13.4	-3.9	0.000101	0.0063	-0.17	-0.12	Type 2 diabetes;	chr6:70568533	chr6:70596438~70596980:+
BRCA	cis	rs10129255	0.5	rs988134	ENSG00000254174.1	IGHV1-12	3.9	0.000101	0.0063	0.09	0.12	Kawasaki disease;	chr14:106776698	chr14:106122420~106122709:-
BRCA	cis	rs10129255	0.5	rs988133	ENSG00000254174.1	IGHV1-12	3.9	0.000101	0.0063	0.09	0.12	Kawasaki disease;	chr14:106776724	chr14:106122420~106122709:-
BRCA	cis	rs35146811	0.735	rs2528900	ENSG00000235713.1	RP4-604G5.3	-3.9	0.000101	0.0063	-0.14	-0.12	Coronary artery disease;	chr7:100207696	chr7:99992397~99993050:+
BRCA	cis	rs2832191	0.935	rs67287920	ENSG00000176054.6	RPL23P2	-3.9	0.000101	0.0063	-0.13	-0.12	Dental caries;	chr21:29151198	chr21:28997613~28998033:-
BRCA	cis	rs11711311	1	rs2566968	ENSG00000241529.3	RN7SL767P	-3.9	0.000101	0.0063	-0.14	-0.12	IgG glycosylation;	chr3:113755307	chr3:113632704~113632998:+
BRCA	cis	rs11098499	0.954	rs12499324	ENSG00000225892.3	RP11-384K6.2	3.9	0.000101	0.00631	0.12	0.12	Corneal astigmatism;	chr4:119472631	chr4:118632274~118634759:+
BRCA	cis	rs4372836	0.729	rs10198789	ENSG00000226833.4	AC097724.3	3.9	0.000101	0.00631	0.14	0.12	Body mass index;	chr2:28745945	chr2:28708953~28736205:-
BRCA	cis	rs1124769	0.57	rs2663552	ENSG00000273674.3	CTD-2378E12.1	3.9	0.000101	0.00631	0.15	0.12	Cognitive performance;	chr15:50839973	chr15:50839875~50908599:-
BRCA	cis	rs10504130	1	rs76649221	ENSG00000272076.1	RP11-11C20.3	3.9	0.000101	0.00631	0.21	0.12	Venous thromboembolism (SNP x SNP interaction);	chr8:51884175	chr8:51810110~51810681:-
BRCA	cis	rs448720	1	rs383144	ENSG00000260657.2	RP11-315D16.4	3.9	0.000101	0.00631	0.14	0.12	Cognitive performance;	chr15:67912243	chr15:68267792~68277994:-
BRCA	cis	rs4415084	1	rs1371027	ENSG00000272335.1	RP11-53O19.3	3.9	0.000101	0.00631	0.11	0.12	Breast cancer;	chr5:44699755	chr5:44826076~44828592:+
BRCA	cis	rs4415084	0.966	rs714130	ENSG00000272335.1	RP11-53O19.3	3.9	0.000101	0.00631	0.11	0.12	Breast cancer;	chr5:44701316	chr5:44826076~44828592:+
BRCA	cis	rs490234	0.676	rs13299008	ENSG00000232630.1	PRPS1P2	-3.9	0.000101	0.00631	-0.13	-0.12	Mean arterial pressure;	chr9:125451687	chr9:125150653~125151589:+
BRCA	cis	rs34792	0.554	rs12918517	ENSG00000258354.1	MIR3180-1	-3.9	0.000101	0.00631	-0.17	-0.12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15532974	chr16:14909887~14911345:-
BRCA	cis	rs10129255	0.957	rs12590735	ENSG00000232216.1	IGHV3-43	3.9	0.000101	0.00631	0.1	0.12	Kawasaki disease;	chr14:106779660	chr14:106470264~106470800:-
BRCA	cis	rs516805	0.667	rs7771090	ENSG00000279114.1	RP3-425C14.5	-3.9	0.000101	0.00631	-0.15	-0.12	Lymphocyte counts;	chr6:122339732	chr6:122471923~122484161:+
BRCA	cis	rs1869026	0.905	rs12623454	ENSG00000237614.1	AC073257.2	-3.9	0.000101	0.00631	-0.15	-0.12	Age-related hearing impairment (SNP x SNP interaction);	chr2:120568721	chr2:120542909~120544326:-
BRCA	cis	rs962856	0.537	rs643741	ENSG00000236780.4	AC078941.1	3.9	0.000101	0.00631	0.15	0.12	Pancreatic cancer;	chr2:67449409	chr2:67123357~67215319:-
BRCA	cis	rs10129255	0.536	rs6576223	ENSG00000254174.1	IGHV1-12	3.9	0.000101	0.00631	0.09	0.12	Kawasaki disease;	chr14:106776448	chr14:106122420~106122709:-
BRCA	cis	rs2518049	0.563	rs79618354	ENSG00000224034.1	RP11-445P17.8	-3.9	0.000101	0.00631	-0.24	-0.12	Metabolic traits;	chr10:5278987	chr10:5266033~5271236:-
BRCA	cis	rs7620503	1	rs6801659	ENSG00000277241.1	RP11-114M1.3	3.9	0.000101	0.00631	0.13	0.12	Corneal structure;	chr3:177580004	chr3:177700346~177701072:-
BRCA	cis	rs10411161	0.702	rs16983200	ENSG00000269483.1	AC006272.1	3.9	0.000101	0.00632	0.2	0.12	Breast cancer;	chr19:51883470	chr19:51839924~51843324:-
BRCA	cis	rs8105895	0.935	rs8103374	ENSG00000269345.1	VN1R85P	3.9	0.000101	0.00632	0.17	0.12	Body mass index (change over time);	chr19:22101517	chr19:22174766~22175191:-
BRCA	cis	rs8105895	0.935	rs8103279	ENSG00000269345.1	VN1R85P	3.9	0.000101	0.00632	0.17	0.12	Body mass index (change over time);	chr19:22101538	chr19:22174766~22175191:-
BRCA	cis	rs801193	1	rs13239306	ENSG00000229180.5	GS1-124K5.11	-3.9	0.000101	0.00632	-0.11	-0.12	Aortic root size;	chr7:66671030	chr7:66526088~66542624:-
BRCA	cis	rs3816183	0.958	rs4328684	ENSG00000226491.1	FTOP1	-3.9	0.000101	0.00632	-0.15	-0.12	Hypospadias;	chr2:42798601	chr2:42797225~42798712:-
BRCA	cis	rs7267979	0.966	rs4813557	ENSG00000276952.1	RP5-965G21.6	-3.9	0.000101	0.00632	-0.15	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25311909	chr20:25284915~25285588:-
BRCA	cis	rs9329221	0.868	rs7831557	ENSG00000272267.2	RP11-375N15.2	3.9	0.000101	0.00632	0.15	0.12	Neuroticism;	chr8:10422718	chr8:9555144~9556520:-
BRCA	cis	rs2832077	0.883	rs11702413	ENSG00000232855.5	AF131217.1	3.9	0.000101	0.00632	0.19	0.12	Cognitive test performance;	chr21:28816072	chr21:28439346~28674848:-
BRCA	cis	rs7948661	1	rs9332846	ENSG00000255121.2	RP11-110I1.12	-3.9	0.000101	0.00632	-0.23	-0.12	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr11:118506808	chr11:118994824~118998004:-
BRCA	cis	rs9470794	1	rs9470777	ENSG00000204110.6	RP1-153P14.8	-3.9	0.000101	0.00632	-0.19	-0.12	Type 2 diabetes;	chr6:38103679	chr6:37507348~37535616:+
BRCA	cis	rs4650943	0.529	rs11809140	ENSG00000227740.1	RP11-318C24.2	3.9	0.000101	0.00632	0.12	0.12	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in inactive individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr1:176349468	chr1:175904762~175920513:-
BRCA	cis	rs4415084	1	rs2013513	ENSG00000248779.1	RP11-53O19.2	3.9	0.000101	0.00632	0.11	0.12	Breast cancer;	chr5:44702204	chr5:44752949~44765744:+
BRCA	cis	rs3748682	0.731	rs3891572	ENSG00000252448.1	SNORA63	-3.9	0.000101	0.00632	-0.15	-0.12	Hypothyroidism;	chr1:37833204	chr1:37884237~37884317:+
BRCA	cis	rs7572644	0.537	rs2220508	ENSG00000223522.1	AC093690.1	3.9	0.000101	0.00632	0.13	0.12	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:28145642	chr2:28307691~28310459:-
BRCA	cis	rs10129255	0.556	rs6576222	ENSG00000254174.1	IGHV1-12	3.9	0.000101	0.00632	0.09	0.12	Kawasaki disease;	chr14:106776442	chr14:106122420~106122709:-
BRCA	cis	rs4272720	1	rs28505677	ENSG00000228754.1	RP11-534L6.3	-3.9	0.000101	0.00632	-0.17	-0.12	Platelet count;Plateletcrit;	chr10:49050962	chr10:48745545~48746128:-
BRCA	cis	rs2871473	1	rs1030024	ENSG00000234389.1	AC007278.3	-3.9	0.000101	0.00632	-0.13	-0.12	Blood protein levels;	chr2:102489310	chr2:102438713~102440475:+
BRCA	cis	rs6088580	0.524	rs6088570	ENSG00000279253.1	RP4-614O4.13	3.9	0.000101	0.00632	0.14	0.12	Glomerular filtration rate (creatinine);	chr20:34680491	chr20:35262727~35264187:-
BRCA	cis	rs853679	0.546	rs200995	ENSG00000216901.1	AL022393.7	-3.9	0.000101	0.00632	-0.24	-0.12	Depression;	chr6:27845916	chr6:28176188~28176674:+
BRCA	cis	rs62025270	0.632	rs6496109	ENSG00000259762.1	RP11-158M2.4	-3.9	0.000101	0.00632	-0.18	-0.12	Idiopathic pulmonary fibrosis;	chr15:85588777	chr15:85750336~85752901:-
BRCA	cis	rs2911132	0.506	rs10037212	ENSG00000272109.1	CTD-2260A17.3	3.9	0.000101	0.00632	0.17	0.12	Urate levels (BMI interaction);	chr5:96749072	chr5:96804353~96806105:+
BRCA	cis	rs8105895	0.935	rs1968446	ENSG00000269345.1	VN1R85P	3.9	0.000101	0.00632	0.17	0.12	Body mass index (change over time);	chr19:22096245	chr19:22174766~22175191:-
BRCA	cis	rs8105895	0.935	rs7256462	ENSG00000269345.1	VN1R85P	3.9	0.000101	0.00632	0.17	0.12	Body mass index (change over time);	chr19:22099191	chr19:22174766~22175191:-
BRCA	cis	rs8105895	0.935	rs10425828	ENSG00000269345.1	VN1R85P	3.9	0.000101	0.00632	0.17	0.12	Body mass index (change over time);	chr19:22100275	chr19:22174766~22175191:-
BRCA	cis	rs8105895	0.867	rs8106762	ENSG00000269345.1	VN1R85P	3.9	0.000101	0.00632	0.17	0.12	Body mass index (change over time);	chr19:22101934	chr19:22174766~22175191:-
BRCA	cis	rs6657613	0.68	rs7545518	ENSG00000186301.8	MST1P2	-3.9	0.000101	0.00633	-0.1	-0.12	Hip circumference adjusted for BMI;	chr1:17048247	chr1:16645622~16650289:+
BRCA	cis	rs4478858	0.735	rs10914344	ENSG00000223907.1	LINC01226	-3.9	0.000101	0.00633	-0.14	-0.12	Alcohol dependence;	chr1:31296178	chr1:31518435~31524245:+
BRCA	cis	rs73222236	0.825	rs9866535	ENSG00000239213.4	NCK1-AS1	3.9	0.000101	0.00633	0.13	0.12	Coronary artery disease;	chr3:136465513	chr3:136841726~136862054:-
BRCA	cis	rs6500602	0.963	rs7201012	ENSG00000280063.1	RP11-295D4.3	3.9	0.000101	0.00633	0.09	0.12	Schizophrenia;	chr16:4430681	chr16:4346694~4348648:-
BRCA	cis	rs875971	0.545	rs67397473	ENSG00000232559.3	GS1-124K5.12	3.9	0.000101	0.00633	0.16	0.12	Aortic root size;	chr7:66168318	chr7:66554588~66576923:-
BRCA	cis	rs9311474	0.652	rs411457	ENSG00000243224.1	RP5-1157M23.2	3.9	0.000101	0.00633	0.13	0.12	Electroencephalogram traits;	chr3:52194134	chr3:52239258~52241097:+
BRCA	cis	rs17507216	1	rs3850610	ENSG00000259429.4	UBE2Q2P2	3.9	0.000101	0.00633	0.13	0.12	Excessive daytime sleepiness;	chr15:82552642	chr15:82355142~82420075:+
BRCA	cis	rs748404	0.589	rs3862138	ENSG00000166763.7	STRCP1	3.9	0.000101	0.00633	0.17	0.12	Lung cancer;	chr15:43523801	chr15:43699488~43718184:-
BRCA	cis	rs957448	1	rs10956915	ENSG00000254315.1	RP11-267M23.3	3.9	0.000101	0.00633	0.16	0.12	Nonsyndromic cleft lip with cleft palate;	chr8:94502362	chr8:94533628~94534391:+
BRCA	cis	rs1008375	0.966	rs10939735	ENSG00000249502.1	AC006160.5	-3.9	0.000101	0.00633	-0.14	-0.12	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17577268	chr4:17587467~17614571:-
BRCA	cis	rs875971	0.83	rs778715	ENSG00000273024.4	INTS4P2	-3.9	0.000101	0.00633	-0.13	-0.12	Aortic root size;	chr7:66384222	chr7:65647864~65715661:+
BRCA	cis	rs1479090	0.805	rs10857351	ENSG00000250027.1	RP11-563E2.2	-3.9	0.000101	0.00633	-0.16	-0.12	Lung cancer;	chr4:163141657	chr4:163108785~163119965:+
BRCA	cis	rs4218	0.648	rs12442134	ENSG00000259732.1	RP11-59H7.3	-3.9	0.000101	0.00633	-0.15	-0.12	Social communication problems;	chr15:59074478	chr15:59121034~59133250:+
BRCA	cis	rs9467773	0.62	rs2504567	ENSG00000224843.5	LINC00240	-3.9	0.000101	0.00633	-0.13	-0.12	Intelligence (multi-trait analysis);	chr6:26662692	chr6:26956992~27023924:+
BRCA	cis	rs6893300	0.785	rs55654737	ENSG00000250999.1	RP11-1379J22.5	3.9	0.000101	0.00633	0.16	0.12	Resting heart rate;	chr5:179791841	chr5:179657762~179664432:+
BRCA	cis	rs2301573	0.584	rs62265564	ENSG00000271270.4	TMCC1-AS1	-3.9	0.000101	0.00633	-0.26	-0.12	Hip circumference;	chr3:129719537	chr3:129893871~129918575:+
BRCA	cis	rs1953600	1	rs2573346	ENSG00000226659.1	RP11-137H2.4	-3.9	0.000101	0.00633	-0.16	-0.12	Sarcoidosis;	chr10:80158285	chr10:80529597~80535942:-
BRCA	cis	rs6696239	1	rs6669236	ENSG00000215812.5	ZNF847P	3.9	0.000101	0.00633	0.17	0.12	Height;	chr1:227626208	chr1:227696892~227706699:-
BRCA	cis	rs6696239	1	rs12120182	ENSG00000215812.5	ZNF847P	3.9	0.000101	0.00633	0.17	0.12	Height;	chr1:227626631	chr1:227696892~227706699:-
BRCA	cis	rs7819412	0.668	rs2409721	ENSG00000255046.1	RP11-297N6.4	3.9	0.000101	0.00633	0.15	0.12	Triglycerides;	chr8:11180735	chr8:11797928~11802568:-
BRCA	cis	rs6964587	1	rs6952671	ENSG00000188693.7	CYP51A1-AS1	-3.9	0.000101	0.00633	-0.13	-0.12	Breast cancer;	chr7:91968620	chr7:92134604~92180725:+
BRCA	cis	rs6964587	1	rs13224513	ENSG00000188693.7	CYP51A1-AS1	-3.9	0.000101	0.00633	-0.13	-0.12	Breast cancer;	chr7:91972151	chr7:92134604~92180725:+
BRCA	cis	rs6964587	1	rs7806184	ENSG00000188693.7	CYP51A1-AS1	-3.9	0.000101	0.00633	-0.13	-0.12	Breast cancer;	chr7:91972664	chr7:92134604~92180725:+
BRCA	cis	rs2562456	0.917	rs6511256	ENSG00000268119.4	CTD-2561J22.5	-3.9	0.000101	0.00633	-0.18	-0.12	Pain;	chr19:21510513	chr19:21444241~21463908:-
BRCA	cis	rs3858526	0.883	rs7481882	ENSG00000224295.2	AC087380.14	3.9	0.000101	0.00634	0.17	0.12	DNA methylation (variation);	chr11:5922991	chr11:5518441~5524955:-
BRCA	cis	rs73201462	1	rs11706826	ENSG00000242551.2	POU5F1P6	3.9	0.000101	0.00634	0.2	0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128314148	chr3:128674735~128677005:-
BRCA	cis	rs7735319	0.525	rs6450950	ENSG00000249572.1	CTD-2203K17.1	3.9	0.000101	0.00634	0.15	0.12	Systolic blood pressure;	chr5:33170228	chr5:33424025~33440619:-
BRCA	cis	rs875971	0.522	rs6960048	ENSG00000273142.1	RP11-458F8.4	-3.9	0.000101	0.00634	-0.1	-0.12	Aortic root size;	chr7:65943052	chr7:66902857~66906297:+
BRCA	cis	rs4272720	1	rs17011715	ENSG00000228754.1	RP11-534L6.3	-3.9	0.000101	0.00634	-0.17	-0.12	Platelet count;Plateletcrit;	chr10:49053732	chr10:48745545~48746128:-
BRCA	cis	rs4272720	0.951	rs56157539	ENSG00000228754.1	RP11-534L6.3	-3.9	0.000101	0.00634	-0.17	-0.12	Platelet count;Plateletcrit;	chr10:49053835	chr10:48745545~48746128:-
BRCA	cis	rs4272720	1	rs61850689	ENSG00000228754.1	RP11-534L6.3	-3.9	0.000101	0.00634	-0.17	-0.12	Platelet count;Plateletcrit;	chr10:49054065	chr10:48745545~48746128:-
BRCA	cis	rs1009077	0.68	rs13140150	ENSG00000245958.5	RP11-33B1.1	3.9	0.000101	0.00634	0.15	0.12	Endometriosis;	chr4:119552036	chr4:119454791~119552025:+
BRCA	cis	rs10043775	0.957	rs10042369	ENSG00000251330.3	CTD-2283N19.1	-3.9	0.000101	0.00634	-0.14	-0.12	Periodontal microbiota;	chr5:148424507	chr5:148430159~148430807:-
BRCA	cis	rs4538475	0.519	rs73224650	ENSG00000273133.1	RP11-799M12.2	-3.9	0.000101	0.00634	-0.24	-0.12	Parkinson's disease;	chr4:15684116	chr4:15563698~15564253:-
BRCA	cis	rs4725617	0.822	rs73154218	ENSG00000229153.4	EPHA1-AS1	3.9	0.000101	0.00634	0.28	0.12	Blood protein levels;	chr7:143410744	chr7:143407813~143523449:+
BRCA	cis	rs736408	0.716	rs2239549	ENSG00000243224.1	RP5-1157M23.2	-3.9	0.000101	0.00634	-0.14	-0.12	Bipolar disorder;	chr3:52789110	chr3:52239258~52241097:+
BRCA	cis	rs6479874	1	rs7895755	ENSG00000223502.1	RP11-96B5.3	-3.9	0.000101	0.00634	-0.22	-0.12	Migraine;	chr10:51014288	chr10:51062579~51068553:-
BRCA	cis	rs8037818	1	rs8037102	ENSG00000261064.1	RP11-1000B6.3	-3.9	0.000101	0.00634	-0.15	-0.12	Obesity-related traits;	chr15:32640449	chr15:32536047~32587613:+
BRCA	cis	rs4763879	1	rs917911	ENSG00000278635.1	CTD-2318O12.1	3.9	0.000101	0.00634	0.13	0.12	Type 1 diabetes;	chr12:9753255	chr12:9415641~9416718:+
BRCA	cis	rs10129255	0.957	rs10132367	ENSG00000232216.1	IGHV3-43	3.9	0.000101	0.00634	0.1	0.12	Kawasaki disease;	chr14:106690981	chr14:106470264~106470800:-
BRCA	cis	rs9470794	0.915	rs56159928	ENSG00000204110.6	RP1-153P14.8	-3.9	0.000101	0.00634	-0.25	-0.12	Type 2 diabetes;	chr6:37881757	chr6:37507348~37535616:+
BRCA	cis	rs2645424	1	rs2645424	ENSG00000269899.1	RP11-589N15.2	-3.9	0.000101	0.00634	-0.14	-0.12	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);	chr8:11826954	chr8:11846154~11846391:-
BRCA	cis	rs6991838	0.584	rs10089708	ENSG00000272155.1	RP11-707M3.3	-3.9	0.000101	0.00634	-0.11	-0.12	Intelligence (multi-trait analysis);	chr8:65642927	chr8:65714334~65714778:-
BRCA	cis	rs6991838	0.584	rs6991731	ENSG00000272155.1	RP11-707M3.3	-3.9	0.000101	0.00634	-0.11	-0.12	Intelligence (multi-trait analysis);	chr8:65643232	chr8:65714334~65714778:-
BRCA	cis	rs2301573	0.584	rs75204081	ENSG00000271270.4	TMCC1-AS1	-3.9	0.000101	0.00634	-0.26	-0.12	Hip circumference;	chr3:129664103	chr3:129893871~129918575:+
BRCA	cis	rs77633900	0.772	rs157778	ENSG00000196274.5	Metazoa_SRP	3.9	0.000101	0.00634	0.21	0.12	Glioma;Non-glioblastoma glioma;	chr15:76467103	chr15:76230048~76230390:-
BRCA	cis	rs4650943	0.621	rs2504481	ENSG00000227740.1	RP11-318C24.2	-3.9	0.000101	0.00634	-0.12	-0.12	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in inactive individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr1:176420579	chr1:175904762~175920513:-
BRCA	cis	rs12682352	0.652	rs1567398	ENSG00000253981.4	ALG1L13P	-3.9	0.000101	0.00635	-0.13	-0.12	Neuroticism;	chr8:8869294	chr8:8236003~8244667:-
BRCA	cis	rs10246939	0.543	rs11765575	ENSG00000270923.1	TAS2R6P	-3.9	0.000101	0.00635	-0.12	-0.12	Bitter taste perception;	chr7:141838168	chr7:141787815~141788640:+
BRCA	cis	rs11098499	0.954	rs12506546	ENSG00000260091.1	RP11-33B1.4	-3.9	0.000101	0.00635	-0.11	-0.12	Corneal astigmatism;	chr4:119380463	chr4:119409333~119410233:+
BRCA	cis	rs6545883	0.929	rs6545877	ENSG00000270820.4	RP11-355B11.2	3.9	0.000102	0.00635	0.14	0.12	Tuberculosis;	chr2:61514812	chr2:61471188~61484130:+
BRCA	cis	rs12646107	0.512	rs17263395	ENSG00000261672.1	RP11-475B2.1	3.9	0.000102	0.00635	0.15	0.12	Response to amphetamines;	chr4:173658175	chr4:173593672~173594556:+
BRCA	cis	rs2749097	0.735	rs7548664	ENSG00000244256.3	RN7SL130P	-3.9	0.000102	0.00635	-0.17	-0.12	Alcohol consumption (transferrin glycosylation);	chr1:63685977	chr1:63655743~63656047:+
BRCA	cis	rs7204230	1	rs12598049	ENSG00000261291.1	RP11-295M3.2	-3.9	0.000102	0.00635	-0.16	-0.12	Fibrinogen;	chr16:53282942	chr16:53168522~53169450:+
BRCA	cis	rs875971	0.522	rs1917563	ENSG00000273142.1	RP11-458F8.4	3.9	0.000102	0.00635	0.1	0.12	Aortic root size;	chr7:65950660	chr7:66902857~66906297:+
BRCA	cis	rs9921338	0.961	rs72773832	ENSG00000262636.1	CTD-3088G3.4	-3.9	0.000102	0.00635	-0.2	-0.12	Vein graft stenosis in coronary artery bypass grafting;	chr16:11319266	chr16:11380859~11381118:-
BRCA	cis	rs9921338	0.961	rs72773834	ENSG00000262636.1	CTD-3088G3.4	-3.9	0.000102	0.00635	-0.2	-0.12	Vein graft stenosis in coronary artery bypass grafting;	chr16:11319436	chr16:11380859~11381118:-
BRCA	cis	rs2185341	0.788	rs12092590	ENSG00000218510.5	LINC00339	3.9	0.000102	0.00635	0.16	0.12	Amyotrophic lateral sclerosis;	chr1:22358434	chr1:22025188~22031223:+
BRCA	cis	rs17489649	0.785	rs1368357	ENSG00000271849.1	CTC-332L22.1	3.9	0.000102	0.00635	0.16	0.12	Intelligence (multi-trait analysis);	chr5:109853429	chr5:109687802~109688329:-
BRCA	cis	rs6120849	0.573	rs3746429	ENSG00000202150.1	RNU6-407P	-3.9	0.000102	0.00635	-0.19	-0.12	Protein C levels;	chr20:35115804	chr20:35030317~35030420:-
BRCA	cis	rs2625529	0.701	rs62025574	ENSG00000260037.4	CTD-2524L6.3	-3.9	0.000102	0.00635	-0.17	-0.12	Red blood cell count;	chr15:71943734	chr15:71818396~71823384:+
BRCA	cis	rs2625529	0.878	rs71395051	ENSG00000260037.4	CTD-2524L6.3	-3.9	0.000102	0.00635	-0.17	-0.12	Red blood cell count;	chr15:71947448	chr15:71818396~71823384:+
BRCA	cis	rs1552244	0.515	rs67626468	ENSG00000180385.7	EMC3-AS1	3.9	0.000102	0.00635	0.17	0.12	Alzheimer's disease;	chr3:10119834	chr3:9986893~10006990:+
BRCA	cis	rs1910358	0.959	rs6881774	ENSG00000248874.4	C5orf17	-3.9	0.000102	0.00635	-0.18	-0.12	Venous thromboembolism (SNP x SNP interaction);	chr5:23881735	chr5:23951348~24178263:+
BRCA	cis	rs7520050	0.966	rs7550746	ENSG00000234329.1	RP11-767N6.2	-3.9	0.000102	0.00635	-0.11	-0.12	Reticulocyte count;Red blood cell count;	chr1:45886047	chr1:45651039~45651826:-
BRCA	cis	rs11098499	0.955	rs56386062	ENSG00000260091.1	RP11-33B1.4	-3.9	0.000102	0.00635	-0.11	-0.12	Corneal astigmatism;	chr4:119233980	chr4:119409333~119410233:+
BRCA	cis	rs2832191	0.935	rs11910316	ENSG00000176054.6	RPL23P2	-3.9	0.000102	0.00635	-0.13	-0.12	Dental caries;	chr21:29147408	chr21:28997613~28998033:-
BRCA	cis	rs539096	0.505	rs501861	ENSG00000236200.4	KDM4A-AS1	-3.9	0.000102	0.00635	-0.15	-0.12	Intelligence (multi-trait analysis);	chr1:43635769	chr1:43699765~43708138:-
BRCA	cis	rs6120849	0.707	rs6088703	ENSG00000202150.1	RNU6-407P	3.9	0.000102	0.00635	0.17	0.12	Protein C levels;	chr20:35088246	chr20:35030317~35030420:-
BRCA	cis	rs10463316	0.817	rs10476770	ENSG00000260581.1	CTB-113P19.4	3.9	0.000102	0.00636	0.14	0.12	Metabolite levels (Pyroglutamine);	chr5:151398159	chr5:151652275~151655449:+
BRCA	cis	rs442309	0.875	rs224055	ENSG00000238280.1	RP11-436D10.3	-3.9	0.000102	0.00636	-0.15	-0.12	Vogt-Koyanagi-Harada syndrome;	chr10:62737110	chr10:62793562~62805887:-
BRCA	cis	rs34975555	0.614	rs6586675	ENSG00000254054.2	RP11-156K13.3	3.9	0.000102	0.00636	0.16	0.12	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:17983648	chr8:17905756~17907887:+
BRCA	cis	rs73201462	1	rs11706304	ENSG00000242551.2	POU5F1P6	3.9	0.000102	0.00636	0.21	0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128331771	chr3:128674735~128677005:-
BRCA	cis	rs801193	1	rs7788576	ENSG00000265600.1	AC006480.1	3.9	0.000102	0.00636	0.14	0.12	Aortic root size;	chr7:66683315	chr7:67356680~67356779:+
BRCA	cis	rs6430585	0.527	rs2278731	ENSG00000231890.6	DARS-AS1	-3.9	0.000102	0.00636	-0.18	-0.12	Corneal structure;	chr2:135638730	chr2:135985176~136022593:+
BRCA	cis	rs7267979	0.932	rs367666	ENSG00000274414.1	RP5-965G21.4	-3.9	0.000102	0.00636	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25469182	chr20:25239007~25245229:-
BRCA	cis	rs2312236	0.714	rs10918573	ENSG00000225171.2	DUTP6	3.9	0.000102	0.00636	0.18	0.12	Post-traumatic stress disorder;	chr1:166749647	chr1:166868748~166869209:+
BRCA	cis	rs6545883	0.859	rs13004855	ENSG00000273302.1	RP11-493E12.2	-3.9	0.000102	0.00636	-0.11	-0.12	Tuberculosis;	chr2:61277937	chr2:61199979~61200769:+
BRCA	cis	rs12612435	0.652	rs6739031	ENSG00000226806.1	AC011893.3	3.9	0.000102	0.00636	0.15	0.12	Takotsubo syndrome;	chr2:136382137	chr2:135820191~135823087:+
BRCA	cis	rs8040855	0.627	rs12900012	ENSG00000229212.6	RP11-561C5.4	-3.9	0.000102	0.00636	-0.16	-0.12	Bulimia nervosa;	chr15:85046955	chr15:85205440~85234795:-
BRCA	cis	rs6964587	1	rs2188154	ENSG00000188693.7	CYP51A1-AS1	-3.9	0.000102	0.00636	-0.13	-0.12	Breast cancer;	chr7:91965824	chr7:92134604~92180725:+
BRCA	cis	rs1075265	0.756	rs805367	ENSG00000272156.1	RP11-477N3.1	-3.9	0.000102	0.00637	-0.13	-0.12	Chronotype;Morning vs. evening chronotype;	chr2:53943956	chr2:54082554~54085066:+
BRCA	cis	rs8114671	0.967	rs2069948	ENSG00000279253.1	RP4-614O4.13	-3.9	0.000102	0.00637	-0.14	-0.12	Height;	chr20:35174686	chr20:35262727~35264187:-
BRCA	cis	rs6088590	0.965	rs13040449	ENSG00000276073.1	RP5-1125A11.7	-3.9	0.000102	0.00637	-0.14	-0.12	Coronary artery disease;	chr20:34771098	chr20:33985617~33988989:-
BRCA	cis	rs4237845	0.537	rs4237844	ENSG00000270039.1	RP11-571M6.17	3.9	0.000102	0.00637	0.17	0.12	Intelligence (multi-trait analysis);	chr12:57874204	chr12:57803838~57804415:+
BRCA	cis	rs74665712	0.688	rs71540776	ENSG00000232400.1	RAD17P1	3.9	0.000102	0.00637	0.14	0.12	Residual cognition;	chr7:16919859	chr7:16864267~16866308:-
BRCA	cis	rs7818688	1	rs10110635	ENSG00000245080.5	RP11-320N21.1	-3.9	0.000102	0.00637	-0.2	-0.12	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95012841	chr8:95066808~95073182:-
BRCA	cis	rs516805	0.597	rs2816157	ENSG00000279114.1	RP3-425C14.5	-3.9	0.000102	0.00637	-0.15	-0.12	Lymphocyte counts;	chr6:122124400	chr6:122471923~122484161:+
BRCA	cis	rs7481584	0.669	rs12421922	ENSG00000236710.1	AC108448.2	3.9	0.000102	0.00637	0.16	0.12	Calcium levels;	chr11:3013840	chr11:3084393~3085443:-
BRCA	cis	rs202072	1	rs202073	ENSG00000215022.6	RP1-257A7.4	3.9	0.000102	0.00637	0.16	0.12	HIV-1 viral setpoint;	chr6:13268373	chr6:13264861~13295586:-
BRCA	cis	rs9733	0.544	rs72700902	ENSG00000231073.1	RP11-316M1.3	3.9	0.000102	0.00637	0.12	0.12	Tonsillectomy;	chr1:150660871	chr1:150973123~150975534:+
BRCA	cis	rs9733	0.519	rs10788792	ENSG00000231073.1	RP11-316M1.3	3.9	0.000102	0.00637	0.12	0.12	Tonsillectomy;	chr1:150666096	chr1:150973123~150975534:+
BRCA	cis	rs13108904	0.935	rs922698	ENSG00000253399.1	AC078852.2	3.9	0.000102	0.00637	0.13	0.12	Obesity-related traits;	chr4:1288934	chr4:1358479~1359461:+
BRCA	cis	rs28374715	0.681	rs8037574	ENSG00000247556.5	OIP5-AS1	3.9	0.000102	0.00637	0.13	0.12	Ulcerative colitis;	chr15:41338572	chr15:41283990~41309737:+
BRCA	cis	rs11158026	0.576	rs56013432	ENSG00000258413.1	RP11-665C16.6	-3.9	0.000102	0.00637	-0.19	-0.12	Parkinson's disease;	chr14:54884461	chr14:55262767~55272075:-
BRCA	cis	rs2380205	1	rs867052	ENSG00000232807.2	RP11-536K7.3	3.9	0.000102	0.00637	0.12	0.12	Breast cancer;	chr10:5845220	chr10:5934270~5945900:-
BRCA	cis	rs713477	0.505	rs4901561	ENSG00000186615.9	KTN1-AS1	-3.9	0.000102	0.00637	-0.15	-0.12	Pediatric bone mineral content (femoral neck);	chr14:55421860	chr14:55499278~55580110:-
BRCA	cis	rs2562456	0.917	rs2562468	ENSG00000213976.4	CTD-2561J22.2	3.9	0.000102	0.00637	0.15	0.12	Pain;	chr19:21532048	chr19:21382865~21387177:+
BRCA	cis	rs2562456	0.917	rs2562471	ENSG00000213976.4	CTD-2561J22.2	3.9	0.000102	0.00637	0.15	0.12	Pain;	chr19:21533017	chr19:21382865~21387177:+
BRCA	cis	rs73201462	0.908	rs2811520	ENSG00000242551.2	POU5F1P6	-3.9	0.000102	0.00637	-0.2	-0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128293434	chr3:128674735~128677005:-
BRCA	cis	rs8114671	0.805	rs6060168	ENSG00000261582.1	RP4-614O4.11	-3.9	0.000102	0.00638	-0.11	-0.12	Height;	chr20:35033214	chr20:35267885~35280043:-
BRCA	cis	rs16917546	1	rs10995255	ENSG00000238280.1	RP11-436D10.3	3.9	0.000102	0.00638	0.16	0.12	Basal cell carcinoma;	chr10:62642673	chr10:62793562~62805887:-
BRCA	cis	rs16917546	0.967	rs10995256	ENSG00000238280.1	RP11-436D10.3	3.9	0.000102	0.00638	0.16	0.12	Basal cell carcinoma;	chr10:62642674	chr10:62793562~62805887:-
BRCA	cis	rs6968419	0.674	rs1918911	ENSG00000279086.1	RP11-667F14.1	-3.9	0.000102	0.00638	-0.13	-0.12	Intraocular pressure;	chr7:116266694	chr7:116209234~116211511:-
BRCA	cis	rs983392	1	rs2855017	ENSG00000275344.1	MIR6503	-3.9	0.000102	0.00638	-0.13	-0.12	Alzheimer's disease (late onset);	chr11:60098836	chr11:60209071~60209156:-
BRCA	cis	rs6064559	0.687	rs4811879	ENSG00000218018.2	RP4-800J21.3	-3.9	0.000102	0.00638	-0.11	-0.12	Hemoglobin concentration;	chr20:57549163	chr20:57384160~57393062:-
BRCA	cis	rs1008375	0.932	rs2302391	ENSG00000249502.1	AC006160.5	-3.9	0.000102	0.00638	-0.14	-0.12	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17658614	chr4:17587467~17614571:-
BRCA	cis	rs7267979	0.789	rs9927	ENSG00000274973.1	RP13-401N8.7	-3.9	0.000102	0.00638	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25296608	chr20:25845497~25845862:+
BRCA	cis	rs1009077	0.502	rs2583599	ENSG00000249244.1	RP11-548H18.2	3.9	0.000102	0.00638	0.14	0.12	Endometriosis;	chr4:119754168	chr4:119391831~119395335:-
BRCA	cis	rs1046491	0.901	rs8085549	ENSG00000264964.1	RP11-888D10.3	3.9	0.000102	0.00638	0.24	0.12	Scarlet fever;	chr18:9190595	chr18:9315194~9334441:-
BRCA	cis	rs2657888	0.93	rs7312441	ENSG00000257576.1	RP11-153M3.1	-3.9	0.000102	0.00638	-0.15	-0.12	Adiponectin levels;	chr12:56547362	chr12:56511002~56512703:+
BRCA	cis	rs2657888	1	rs73118833	ENSG00000257576.1	RP11-153M3.1	-3.9	0.000102	0.00638	-0.15	-0.12	Adiponectin levels;	chr12:56547950	chr12:56511002~56512703:+
BRCA	cis	rs62025270	0.688	rs76902341	ENSG00000259762.1	RP11-158M2.4	-3.9	0.000102	0.00638	-0.18	-0.12	Idiopathic pulmonary fibrosis;	chr15:85737059	chr15:85750336~85752901:-
BRCA	cis	rs7552404	0.765	rs1251078	ENSG00000181227.3	RP4-682C21.2	3.9	0.000102	0.00638	0.12	0.12	Acylcarnitine levels;Blood metabolite levels;	chr1:75723803	chr1:75743423~75744776:-
BRCA	cis	rs13434995	0.513	rs6554291	ENSG00000239040.1	Y_RNA	3.9	0.000102	0.00638	0.14	0.12	Adiponectin levels;	chr4:55571204	chr4:55412636~55412738:+
BRCA	cis	rs7267979	0.966	rs2261795	ENSG00000274414.1	RP5-965G21.4	-3.9	0.000102	0.00639	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25282500	chr20:25239007~25245229:-
BRCA	cis	rs13393800	0.876	rs1550096	ENSG00000237126.7	AC073254.1	3.9	0.000102	0.00639	0.16	0.12	Height;	chr2:232563675	chr2:232580948~232611971:-
BRCA	cis	rs9611565	0.625	rs9607819	ENSG00000281538.1	RP4-669P10.20	3.9	0.000102	0.00639	0.16	0.12	Vitiligo;	chr22:41562858	chr22:42138060~42139726:+
BRCA	cis	rs478607	0.831	rs61884374	ENSG00000237410.1	AP001092.4	3.9	0.000102	0.00639	0.21	0.12	Urate levels;	chr11:64621457	chr11:64646399~64659681:+
BRCA	cis	rs17489649	1	rs1370960	ENSG00000271849.1	CTC-332L22.1	3.9	0.000102	0.00639	0.15	0.12	Intelligence (multi-trait analysis);	chr5:109703598	chr5:109687802~109688329:-
BRCA	cis	rs875971	0.619	rs2302918	ENSG00000272831.1	RP11-792A8.4	3.9	0.000102	0.00639	0.11	0.12	Aortic root size;	chr7:66535945	chr7:66739829~66740385:-
BRCA	cis	rs8030605	0.704	rs72742652	ENSG00000277245.1	RP11-48G14.3	3.9	0.000102	0.00639	0.26	0.12	Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;	chr15:56430236	chr15:56447120~56447697:+
BRCA	cis	rs721917	0.506	rs2819098	ENSG00000280355.1	RP11-119F19.5	-3.9	0.000102	0.00639	-0.13	-0.12	Chronic obstructive pulmonary disease;	chr10:79938341	chr10:79681973~79684094:-
BRCA	cis	rs7267979	1	rs8125868	ENSG00000276952.1	RP5-965G21.6	-3.9	0.000102	0.00639	-0.15	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25343774	chr20:25284915~25285588:-
BRCA	cis	rs3764021	0.87	rs2401393	ENSG00000256582.1	RP11-75L1.1	3.9	0.000102	0.00639	0.12	0.12	Type 1 diabetes;	chr12:9726488	chr12:9704077~9709350:+
BRCA	cis	rs1153858	1	rs12909158	ENSG00000275672.1	GATM-AS1	-3.9	0.000102	0.0064	-0.16	-0.12	Homoarginine levels;	chr15:45328976	chr15:45378700~45380123:+
BRCA	cis	rs7267979	0.816	rs6076358	ENSG00000274414.1	RP5-965G21.4	3.9	0.000102	0.0064	0.14	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25538767	chr20:25239007~25245229:-
BRCA	cis	rs2562456	0.52	rs660063	ENSG00000268658.4	LINC00664	-3.9	0.000102	0.0064	-0.21	-0.12	Pain;	chr19:21271103	chr19:21483374~21503238:+
BRCA	cis	rs7121538	0.756	rs1003077	ENSG00000254418.1	RP11-21L19.1	3.9	0.000102	0.0064	0.18	0.12	HDL cholesterol;	chr11:14386594	chr11:14262846~14273691:-
BRCA	cis	rs7246967	0.932	rs62120766	ENSG00000198153.8	ZNF849P	-3.9	0.000102	0.0064	-0.17	-0.12	Bronchopulmonary dysplasia;	chr19:22847145	chr19:22685167~22686732:+
BRCA	cis	rs7246967	0.932	rs35039856	ENSG00000198153.8	ZNF849P	-3.9	0.000102	0.0064	-0.17	-0.12	Bronchopulmonary dysplasia;	chr19:22848537	chr19:22685167~22686732:+
BRCA	cis	rs7246967	0.932	rs66737024	ENSG00000198153.8	ZNF849P	-3.9	0.000102	0.0064	-0.17	-0.12	Bronchopulmonary dysplasia;	chr19:22848884	chr19:22685167~22686732:+
BRCA	cis	rs7246967	0.866	rs4932694	ENSG00000198153.8	ZNF849P	-3.9	0.000102	0.0064	-0.17	-0.12	Bronchopulmonary dysplasia;	chr19:22849905	chr19:22685167~22686732:+
BRCA	cis	rs7246967	0.866	rs7250801	ENSG00000198153.8	ZNF849P	-3.9	0.000102	0.0064	-0.17	-0.12	Bronchopulmonary dysplasia;	chr19:22853155	chr19:22685167~22686732:+
BRCA	cis	rs7246967	0.932	rs4932793	ENSG00000198153.8	ZNF849P	-3.9	0.000102	0.0064	-0.17	-0.12	Bronchopulmonary dysplasia;	chr19:22853647	chr19:22685167~22686732:+
BRCA	cis	rs7246967	0.8	rs4932794	ENSG00000198153.8	ZNF849P	-3.9	0.000102	0.0064	-0.17	-0.12	Bronchopulmonary dysplasia;	chr19:22853754	chr19:22685167~22686732:+
BRCA	cis	rs7267979	0.78	rs6050679	ENSG00000274973.1	RP13-401N8.7	-3.9	0.000102	0.0064	-0.13	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25557191	chr20:25845497~25845862:+
BRCA	cis	rs2380205	0.517	rs12774886	ENSG00000232807.2	RP11-536K7.3	3.9	0.000102	0.0064	0.13	0.12	Breast cancer;	chr10:5929489	chr10:5934270~5945900:-
BRCA	cis	rs28374715	0.532	rs28463309	ENSG00000247556.5	OIP5-AS1	3.9	0.000103	0.0064	0.13	0.12	Ulcerative colitis;	chr15:41374518	chr15:41283990~41309737:+
BRCA	cis	rs448720	1	rs11071969	ENSG00000260657.2	RP11-315D16.4	3.9	0.000103	0.0064	0.14	0.12	Cognitive performance;	chr15:67903240	chr15:68267792~68277994:-
BRCA	cis	rs829883	1	rs249837	ENSG00000227825.4	SLC9A7P1	3.9	0.000103	0.0064	0.15	0.12	Colorectal adenoma (advanced);	chr12:98482757	chr12:98453835~98457145:-
BRCA	cis	rs10129255	0.957	rs8014696	ENSG00000232216.1	IGHV3-43	-3.9	0.000103	0.0064	-0.1	-0.12	Kawasaki disease;	chr14:106769752	chr14:106470264~106470800:-
BRCA	cis	rs9876781	0.563	rs4858821	ENSG00000229759.1	MRPS18AP1	-3.9	0.000103	0.0064	-0.15	-0.12	Longevity;	chr3:48512515	chr3:48256350~48256938:-
BRCA	cis	rs4388249	1	rs13172735	ENSG00000271849.1	CTC-332L22.1	3.9	0.000103	0.0064	0.19	0.12	Schizophrenia;	chr5:109724132	chr5:109687802~109688329:-
BRCA	cis	rs7267979	1	rs6050544	ENSG00000276952.1	RP5-965G21.6	-3.9	0.000103	0.0064	-0.15	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25339592	chr20:25284915~25285588:-
BRCA	cis	rs35520189	0.885	rs6720230	ENSG00000189223.12	PAX8-AS1	-3.9	0.000103	0.0064	-0.19	-0.12	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:112872887	chr2:113211522~113276581:+
BRCA	cis	rs801193	1	rs6958520	ENSG00000265600.1	AC006480.1	-3.9	0.000103	0.0064	-0.14	-0.12	Aortic root size;	chr7:66686466	chr7:67356680~67356779:+
BRCA	cis	rs17772222	0.876	rs12586348	ENSG00000258789.1	RP11-507K2.3	-3.9	0.000103	0.00641	-0.15	-0.12	Coronary artery calcification;	chr14:88643523	chr14:88551597~88552493:+
BRCA	cis	rs62458065	0.85	rs7785999	ENSG00000273014.1	RP11-225B17.2	-3.9	0.000103	0.00641	-0.18	-0.12	Metabolite levels (HVA/MHPG ratio);	chr7:32421650	chr7:32758882~32759353:+
BRCA	cis	rs38055	1	rs251528	ENSG00000247796.2	CTD-2366F13.1	3.9	0.000103	0.00641	0.14	0.12	Acne (severe);	chr5:53267694	chr5:53109842~53115126:+
BRCA	cis	rs875971	0.825	rs10281499	ENSG00000273024.4	INTS4P2	3.9	0.000103	0.00641	0.13	0.12	Aortic root size;	chr7:66583979	chr7:65647864~65715661:+
BRCA	cis	rs6840360	0.593	rs6857073	ENSG00000278978.1	RP11-164P12.5	3.9	0.000103	0.00641	0.14	0.12	Intelligence (multi-trait analysis);	chr4:151768122	chr4:151669786~151670503:+
BRCA	cis	rs1730008	0.865	rs1210358	ENSG00000279311.1	RP11-170K4.2	-3.9	0.000103	0.00641	-0.13	-0.12	Lobe attachment (rater-scored or self-reported);	chr3:158310697	chr3:158869898~158871821:+
BRCA	cis	rs7620503	1	rs13077994	ENSG00000277241.1	RP11-114M1.3	3.9	0.000103	0.00641	0.13	0.12	Corneal structure;	chr3:177587917	chr3:177700346~177701072:-
BRCA	cis	rs7267979	0.966	rs2261747	ENSG00000277938.1	RP5-965G21.3	3.9	0.000103	0.00641	0.14	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25281148	chr20:25229150~25231933:+
BRCA	cis	rs6593122	0.755	rs4947868	ENSG00000235454.1	HAUS6P3	-3.9	0.000103	0.00641	-0.16	-0.12	Vaccine-related adverse events;	chr7:54121642	chr7:53862233~53863339:+
BRCA	cis	rs12612619	0.732	rs714513	ENSG00000272148.1	RP11-195B17.1	3.9	0.000103	0.00641	0.13	0.12	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:26983606	chr2:27062428~27062907:-
BRCA	cis	rs7716600	0.501	rs1438827	ENSG00000251141.4	RP11-53O19.1	3.9	0.000103	0.00641	0.11	0.12	Breast cancer;	chr5:44751854	chr5:44744900~44808777:-
BRCA	cis	rs73206853	0.563	rs881961	ENSG00000277299.1	RP11-837J7.4	-3.9	0.000103	0.00641	-0.21	-0.12	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr12:110763841	chr12:109948389~109949029:+
BRCA	cis	rs62458065	0.713	rs62463968	ENSG00000229358.3	DPY19L1P1	-3.9	0.000103	0.00642	-0.17	-0.12	Metabolite levels (HVA/MHPG ratio);	chr7:32461630	chr7:32580949~32761787:-
BRCA	cis	rs9470794	0.915	rs73417491	ENSG00000204110.6	RP1-153P14.8	-3.9	0.000103	0.00642	-0.25	-0.12	Type 2 diabetes;	chr6:37838848	chr6:37507348~37535616:+
BRCA	cis	rs9470794	0.915	rs55837436	ENSG00000204110.6	RP1-153P14.8	-3.9	0.000103	0.00642	-0.25	-0.12	Type 2 diabetes;	chr6:37841944	chr6:37507348~37535616:+
BRCA	cis	rs4664293	0.934	rs4380179	ENSG00000226266.5	AC009961.3	-3.9	0.000103	0.00642	-0.15	-0.12	Monocyte percentage of white cells;	chr2:159685064	chr2:159670708~159712435:-
BRCA	cis	rs62025270	0.547	rs386346	ENSG00000259762.1	RP11-158M2.4	-3.9	0.000103	0.00642	-0.15	-0.12	Idiopathic pulmonary fibrosis;	chr15:85651328	chr15:85750336~85752901:-
BRCA	cis	rs4787491	0.729	rs11642399	ENSG00000183604.13	SMG1P5	-3.9	0.000103	0.00642	-0.11	-0.12	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30048272	chr16:30267553~30335374:-
BRCA	cis	rs1048886	0.808	rs9455151	ENSG00000271967.1	RP11-134K13.4	-3.9	0.000103	0.00642	-0.18	-0.12	Type 2 diabetes;	chr6:70537737	chr6:70596438~70596980:+
BRCA	cis	rs1048886	0.745	rs78525529	ENSG00000271967.1	RP11-134K13.4	-3.9	0.000103	0.00642	-0.18	-0.12	Type 2 diabetes;	chr6:70538160	chr6:70596438~70596980:+
BRCA	cis	rs10266483	0.774	rs1404679	ENSG00000271550.1	BNIP3P11	-3.9	0.000103	0.00642	-0.16	-0.12	Response to statin therapy;	chr7:64358254	chr7:64678954~64687393:-
BRCA	cis	rs875971	0.825	rs28480509	ENSG00000229886.1	RP5-1132H15.3	-3.9	0.000103	0.00642	-0.14	-0.12	Aortic root size;	chr7:66634237	chr7:66025126~66031544:-
BRCA	cis	rs2908197	1	rs2908197	ENSG00000186704.9	DTX2P1	-3.9	0.000103	0.00642	-0.14	-0.12	3-hydroxypropylmercapturic acid levels in smokers;	chr7:76307732	chr7:76978617~77004308:+
BRCA	cis	rs5758659	0.652	rs133321	ENSG00000182057.4	OGFRP1	3.9	0.000103	0.00642	0.14	0.12	Cognitive function;	chr22:42009318	chr22:42269753~42275196:+
BRCA	cis	rs5758659	0.652	rs133330	ENSG00000182057.4	OGFRP1	3.9	0.000103	0.00642	0.14	0.12	Cognitive function;	chr22:42013452	chr22:42269753~42275196:+
BRCA	cis	rs4664293	0.631	rs6714899	ENSG00000224152.1	AC009506.1	-3.9	0.000103	0.00642	-0.13	-0.12	Monocyte percentage of white cells;	chr2:159592895	chr2:159615296~159617082:+
BRCA	cis	rs4664293	0.647	rs4665090	ENSG00000224152.1	AC009506.1	-3.9	0.000103	0.00642	-0.13	-0.12	Monocyte percentage of white cells;	chr2:159597396	chr2:159615296~159617082:+
BRCA	cis	rs4664293	0.647	rs4635484	ENSG00000224152.1	AC009506.1	-3.9	0.000103	0.00642	-0.13	-0.12	Monocyte percentage of white cells;	chr2:159597619	chr2:159615296~159617082:+
BRCA	cis	rs3812762	1	rs3812762	ENSG00000254860.4	TMEM9B-AS1	3.9	0.000103	0.00642	0.12	0.12	Hypospadias;	chr11:8730093	chr11:8964675~8977527:+
BRCA	cis	rs6964587	0.934	rs7798973	ENSG00000188693.7	CYP51A1-AS1	-3.9	0.000103	0.00642	-0.13	-0.12	Breast cancer;	chr7:91959046	chr7:92134604~92180725:+
BRCA	cis	rs6964587	1	rs28735847	ENSG00000188693.7	CYP51A1-AS1	-3.9	0.000103	0.00642	-0.13	-0.12	Breast cancer;	chr7:91963441	chr7:92134604~92180725:+
BRCA	cis	rs739496	0.579	rs9971746	ENSG00000257624.1	RP1-128M12.3	-3.9	0.000103	0.00642	-0.16	-0.12	Platelet count;	chr12:111899558	chr12:112000739~112000985:-
BRCA	cis	rs11098499	0.863	rs13134665	ENSG00000260091.1	RP11-33B1.4	-3.9	0.000103	0.00642	-0.11	-0.12	Corneal astigmatism;	chr4:119505275	chr4:119409333~119410233:+
BRCA	cis	rs2281558	0.837	rs67676850	ENSG00000274414.1	RP5-965G21.4	-3.9	0.000103	0.00642	-0.16	-0.12	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25388781	chr20:25239007~25245229:-
BRCA	cis	rs16960773	0.609	rs16960833	ENSG00000231409.3	RP11-83J16.1	3.9	0.000103	0.00642	0.2	0.12	Optic nerve measurement (cup-to-disc ratio);	chr15:35374528	chr15:34943080~34943394:+
BRCA	cis	rs11992162	0.636	rs11250182	ENSG00000255495.1	AC145124.2	-3.9	0.000103	0.00642	-0.13	-0.12	Monocyte count;	chr8:11950067	chr8:12194467~12196280:+
BRCA	cis	rs2704588	1	rs2609254	ENSG00000270720.1	RP11-84C13.2	-3.9	0.000103	0.00642	-0.19	-0.12	Longevity;	chr4:88889717	chr4:89119284~89119871:+
BRCA	cis	rs8114671	0.662	rs3761143	ENSG00000126005.14	MMP24-AS1	-3.9	0.000103	0.00642	-0.14	-0.12	Height;	chr20:34957942	chr20:35216462~35278131:-
BRCA	cis	rs9470794	0.748	rs11757980	ENSG00000204110.6	RP1-153P14.8	-3.9	0.000103	0.00642	-0.24	-0.12	Type 2 diabetes;	chr6:38124319	chr6:37507348~37535616:+
BRCA	cis	rs9470794	1	rs11753391	ENSG00000204110.6	RP1-153P14.8	-3.9	0.000103	0.00642	-0.24	-0.12	Type 2 diabetes;	chr6:38124690	chr6:37507348~37535616:+
BRCA	cis	rs9470794	1	rs73421855	ENSG00000204110.6	RP1-153P14.8	-3.9	0.000103	0.00642	-0.24	-0.12	Type 2 diabetes;	chr6:38126883	chr6:37507348~37535616:+
BRCA	cis	rs9470794	1	rs56178553	ENSG00000204110.6	RP1-153P14.8	-3.9	0.000103	0.00642	-0.24	-0.12	Type 2 diabetes;	chr6:38129772	chr6:37507348~37535616:+
BRCA	cis	rs9470794	1	rs11759816	ENSG00000204110.6	RP1-153P14.8	-3.9	0.000103	0.00642	-0.24	-0.12	Type 2 diabetes;	chr6:38132865	chr6:37507348~37535616:+
BRCA	cis	rs9470794	1	rs11751094	ENSG00000204110.6	RP1-153P14.8	-3.9	0.000103	0.00642	-0.24	-0.12	Type 2 diabetes;	chr6:38133221	chr6:37507348~37535616:+
BRCA	cis	rs1223397	0.651	rs202022	ENSG00000215022.6	RP1-257A7.4	3.9	0.000103	0.00642	0.14	0.12	Blood pressure;	chr6:13302699	chr6:13264861~13295586:-
BRCA	cis	rs448720	1	rs448720	ENSG00000260657.2	RP11-315D16.4	-3.9	0.000103	0.00642	-0.14	-0.12	Cognitive performance;	chr15:67906573	chr15:68267792~68277994:-
BRCA	cis	rs4415084	0.716	rs7712949	ENSG00000251141.4	RP11-53O19.1	3.9	0.000103	0.00643	0.11	0.12	Breast cancer;	chr5:44770243	chr5:44744900~44808777:-
BRCA	cis	rs10129255	0.509	rs756583	ENSG00000274576.2	IGHV2-70	-3.9	0.000103	0.00643	-0.1	-0.12	Kawasaki disease;	chr14:106680002	chr14:106770577~106771020:-
BRCA	cis	rs794185	0.564	rs304026	ENSG00000231249.1	ITPR1-AS1	-3.9	0.000103	0.00643	-0.14	-0.12	Multiple sclerosis--Brain Glutamate Levels;	chr3:4503589	chr3:4490891~4493163:-
BRCA	cis	rs4654783	0.627	rs2092322	ENSG00000271428.1	RP1-224A6.8	-3.9	0.000103	0.00643	-0.13	-0.12	Endometriosis;	chr1:22109230	chr1:22068340~22068827:-
BRCA	cis	rs375066	0.935	rs422457	ENSG00000267191.1	RP11-15A1.2	-3.9	0.000103	0.00643	-0.16	-0.12	Breast cancer;	chr19:43905259	chr19:43902001~43926545:+
BRCA	cis	rs115575488	0.85	rs114434474	ENSG00000236804.1	RPS3AP12	3.9	0.000103	0.00643	0.22	0.12	Lobe attachment (rater-scored or self-reported);	chr1:119120927	chr1:119126539~119127291:-
BRCA	cis	rs1865760	0.865	rs9467641	ENSG00000272462.2	U91328.19	-3.9	0.000103	0.00643	-0.15	-0.12	Height;	chr6:25947008	chr6:25992662~26001775:+
BRCA	cis	rs10411161	0.702	rs10424202	ENSG00000269483.1	AC006272.1	3.9	0.000103	0.00643	0.2	0.12	Breast cancer;	chr19:51884044	chr19:51839924~51843324:-
BRCA	cis	rs10411161	0.702	rs10423835	ENSG00000269483.1	AC006272.1	3.9	0.000103	0.00643	0.2	0.12	Breast cancer;	chr19:51884069	chr19:51839924~51843324:-
BRCA	cis	rs9467773	0.62	rs2504599	ENSG00000224843.5	LINC00240	-3.9	0.000103	0.00643	-0.13	-0.12	Intelligence (multi-trait analysis);	chr6:26640832	chr6:26956992~27023924:+
BRCA	cis	rs6430585	0.527	rs961360	ENSG00000231890.6	DARS-AS1	-3.9	0.000103	0.00643	-0.18	-0.12	Corneal structure;	chr2:135636088	chr2:135985176~136022593:+
BRCA	cis	rs7264396	0.79	rs761825	ENSG00000088340.14	FER1L4	-3.9	0.000103	0.00643	-0.14	-0.12	Total cholesterol levels;	chr20:35606132	chr20:35558737~35607562:-
BRCA	cis	rs5758659	0.652	rs133324	ENSG00000182057.4	OGFRP1	3.9	0.000103	0.00643	0.14	0.12	Cognitive function;	chr22:42010367	chr22:42269753~42275196:+
BRCA	cis	rs3858526	0.883	rs11039686	ENSG00000224295.2	AC087380.14	3.9	0.000103	0.00643	0.17	0.12	DNA methylation (variation);	chr11:5927495	chr11:5518441~5524955:-
BRCA	cis	rs73201462	0.908	rs2811386	ENSG00000242551.2	POU5F1P6	-3.9	0.000103	0.00643	-0.2	-0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128281172	chr3:128674735~128677005:-
BRCA	cis	rs4713118	0.621	rs4713132	ENSG00000216901.1	AL022393.7	3.9	0.000103	0.00644	0.17	0.12	Parkinson's disease;	chr6:28066257	chr6:28176188~28176674:+
BRCA	cis	rs4713118	0.621	rs4713133	ENSG00000216901.1	AL022393.7	3.9	0.000103	0.00644	0.17	0.12	Parkinson's disease;	chr6:28066263	chr6:28176188~28176674:+
BRCA	cis	rs4713118	0.621	rs4713134	ENSG00000216901.1	AL022393.7	3.9	0.000103	0.00644	0.17	0.12	Parkinson's disease;	chr6:28066343	chr6:28176188~28176674:+
BRCA	cis	rs7267979	1	rs11087521	ENSG00000274414.1	RP5-965G21.4	-3.9	0.000103	0.00644	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25460012	chr20:25239007~25245229:-
BRCA	cis	rs78487399	0.731	rs13395302	ENSG00000234936.1	AC010883.5	3.9	0.000103	0.00644	0.17	0.12	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43479211	chr2:43229573~43233394:+
BRCA	cis	rs12049351	0.774	rs4925456	ENSG00000229367.1	HMGN2P19	3.9	0.000103	0.00644	0.17	0.12	Circulating myeloperoxidase levels (plasma);	chr1:229488149	chr1:229570532~229570796:+
BRCA	cis	rs9470794	1	rs60109083	ENSG00000204110.6	RP1-153P14.8	-3.9	0.000103	0.00644	-0.24	-0.12	Type 2 diabetes;	chr6:38118538	chr6:37507348~37535616:+
BRCA	cis	rs9470794	0.915	rs73421842	ENSG00000204110.6	RP1-153P14.8	-3.9	0.000103	0.00644	-0.24	-0.12	Type 2 diabetes;	chr6:38120248	chr6:37507348~37535616:+
BRCA	cis	rs9402743	0.781	rs9494331	ENSG00000231028.7	LINC00271	3.9	0.000103	0.00644	0.14	0.12	Systemic lupus erythematosus;	chr6:135685163	chr6:135497801~135716055:+
BRCA	cis	rs5997397	1	rs5997397	ENSG00000272858.1	CTA-292E10.8	-3.9	0.000103	0.00644	-0.15	-0.12	Red cell distribution width;	chr22:28758467	chr22:28814914~28815662:+
BRCA	cis	rs875971	0.862	rs778680	ENSG00000273024.4	INTS4P2	-3.9	0.000103	0.00644	-0.13	-0.12	Aortic root size;	chr7:66375427	chr7:65647864~65715661:+
BRCA	cis	rs875971	0.862	rs11769079	ENSG00000273024.4	INTS4P2	-3.9	0.000103	0.00644	-0.13	-0.12	Aortic root size;	chr7:66377141	chr7:65647864~65715661:+
BRCA	cis	rs875971	0.862	rs1695820	ENSG00000273024.4	INTS4P2	-3.9	0.000103	0.00644	-0.13	-0.12	Aortic root size;	chr7:66379576	chr7:65647864~65715661:+
BRCA	cis	rs3617	0.572	rs2256332	ENSG00000242142.1	SERBP1P3	-3.9	0.000103	0.00644	-0.13	-0.12	Red blood cell count;Autism spectrum disorder or schizophrenia;	chr3:52821849	chr3:53064283~53065091:-
BRCA	cis	rs61160187	0.582	rs56025209	ENSG00000272308.1	RP11-231G3.1	-3.9	0.000103	0.00644	-0.14	-0.12	Educational attainment (years of education);Educational attainment (college completion);	chr5:61053793	chr5:60866457~60866935:-
BRCA	cis	rs7703051	1	rs3843480	ENSG00000271815.1	CTD-2235C13.3	-3.9	0.000103	0.00644	-0.16	-0.12	Age-related diseases, mortality and associated endophenotypes;LDL cholesterol;Age-related disease endophenotypes;	chr5:75328657	chr5:75363760~75364242:+
BRCA	cis	rs1953600	0.521	rs7067644	ENSG00000226659.1	RP11-137H2.4	-3.9	0.000103	0.00644	-0.15	-0.12	Sarcoidosis;	chr10:80164489	chr10:80529597~80535942:-
BRCA	cis	rs4272720	0.855	rs61848153	ENSG00000228754.1	RP11-534L6.3	-3.9	0.000103	0.00644	-0.18	-0.12	Platelet count;Plateletcrit;	chr10:49022082	chr10:48745545~48746128:-
BRCA	cis	rs875971	0.545	rs6460276	ENSG00000232559.3	GS1-124K5.12	3.9	0.000103	0.00645	0.16	0.12	Aortic root size;	chr7:66182290	chr7:66554588~66576923:-
BRCA	cis	rs10457838	0.751	rs12211152	ENSG00000236591.1	RP11-162J8.3	-3.9	0.000103	0.00645	-0.17	-0.12	Post-traumatic stress disorder;	chr6:149060095	chr6:149027700~149032573:-
BRCA	cis	rs9437689	0.966	rs34280926	ENSG00000235501.4	RP4-639F20.1	3.9	0.000103	0.00645	0.16	0.12	Phospholipid levels (plasma);	chr1:95062010	chr1:94927566~94963270:+
BRCA	cis	rs7712401	0.755	rs1545696	ENSG00000251538.4	RP11-166A12.1	3.9	0.000103	0.00645	0.13	0.12	Mean platelet volume;	chr5:122766747	chr5:122628952~122730685:-
BRCA	cis	rs875971	0.628	rs6974355	ENSG00000265600.1	AC006480.1	-3.9	0.000103	0.00645	-0.14	-0.12	Aortic root size;	chr7:66376994	chr7:67356680~67356779:+
BRCA	cis	rs7620503	0.959	rs11708469	ENSG00000228561.2	RP11-114M1.1	3.9	0.000103	0.00645	0.14	0.12	Corneal structure;	chr3:177590930	chr3:177683627~177691250:+
BRCA	cis	rs7637230	0.524	rs1620838	ENSG00000244119.1	PDCL3P4	3.9	0.000103	0.00645	0.1	0.12	Psoriasis vulgaris;Psoriasis;	chr3:101929766	chr3:101712472~101713191:+
BRCA	cis	rs7637230	0.504	rs1707606	ENSG00000244119.1	PDCL3P4	3.9	0.000103	0.00645	0.1	0.12	Psoriasis vulgaris;Psoriasis;	chr3:101927089	chr3:101712472~101713191:+
BRCA	cis	rs8049367	0.864	rs2283484	ENSG00000267077.1	RP11-127I20.5	3.9	0.000103	0.00645	0.12	0.12	Nonsyndromic cleft lip with or without cleft palate;	chr16:3919462	chr16:4795265~4796532:-
BRCA	cis	rs13434995	0.945	rs28473211	ENSG00000249700.7	SRD5A3-AS1	-3.9	0.000103	0.00645	-0.19	-0.12	Adiponectin levels;	chr4:55615808	chr4:55363971~55395847:-
BRCA	cis	rs6545883	0.894	rs35292974	ENSG00000273302.1	RP11-493E12.2	-3.9	0.000103	0.00645	-0.11	-0.12	Tuberculosis;	chr2:61294912	chr2:61199979~61200769:+
BRCA	cis	rs17027633	1	rs79696376	ENSG00000234020.1	CHIAP3	-3.9	0.000103	0.00645	-0.24	-0.12	Cerebrospinal fluid t-tau:AB1-42 ratio;	chr1:111405708	chr1:111353275~111367409:-
BRCA	cis	rs17027633	1	rs76747944	ENSG00000234020.1	CHIAP3	-3.9	0.000103	0.00645	-0.24	-0.12	Cerebrospinal fluid t-tau:AB1-42 ratio;	chr1:111405727	chr1:111353275~111367409:-
BRCA	cis	rs6472235	0.586	rs7812439	ENSG00000272010.1	CTD-3025N20.3	-3.9	0.000103	0.00645	-0.15	-0.12	Plateletcrit;Myopia (pathological);	chr8:66005465	chr8:65591850~65592472:-
BRCA	cis	rs6472235	0.586	rs950729	ENSG00000272010.1	CTD-3025N20.3	-3.9	0.000103	0.00645	-0.15	-0.12	Plateletcrit;Myopia (pathological);	chr8:66005518	chr8:65591850~65592472:-
BRCA	cis	rs848490	1	rs11765986	ENSG00000214293.7	APTR	3.9	0.000103	0.00645	0.16	0.12	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77727957	chr7:77657660~77696265:-
BRCA	cis	rs12612435	0.869	rs11688500	ENSG00000226806.1	AC011893.3	3.9	0.000103	0.00645	0.15	0.12	Takotsubo syndrome;	chr2:136379017	chr2:135820191~135823087:+
BRCA	cis	rs12612435	0.83	rs11694468	ENSG00000226806.1	AC011893.3	3.9	0.000103	0.00645	0.15	0.12	Takotsubo syndrome;	chr2:136379140	chr2:135820191~135823087:+
BRCA	cis	rs1005277	0.522	rs9418276	ENSG00000226578.1	RP11-258F22.1	-3.9	0.000103	0.00645	-0.13	-0.12	Extrinsic epigenetic age acceleration;	chr10:37651188	chr10:37775371~37784131:-
BRCA	cis	rs1005277	0.522	rs7072977	ENSG00000226578.1	RP11-258F22.1	-3.9	0.000103	0.00645	-0.13	-0.12	Extrinsic epigenetic age acceleration;	chr10:37651512	chr10:37775371~37784131:-
BRCA	cis	rs4415084	0.804	rs4518409	ENSG00000248779.1	RP11-53O19.2	-3.9	0.000103	0.00645	-0.11	-0.12	Breast cancer;	chr5:44870750	chr5:44752949~44765744:+
BRCA	cis	rs983392	0.679	rs600064	ENSG00000275344.1	MIR6503	3.9	0.000104	0.00646	0.12	0.12	Alzheimer's disease (late onset);	chr11:60245978	chr11:60209071~60209156:-
BRCA	cis	rs2489715	0.7	rs2245747	ENSG00000185904.10	LINC00839	3.9	0.000104	0.00646	0.14	0.12	Helix rolling;	chr10:42421167	chr10:42475543~42495336:+
BRCA	cis	rs875971	0.505	rs1167385	ENSG00000273142.1	RP11-458F8.4	3.9	0.000104	0.00646	0.1	0.12	Aortic root size;	chr7:66048321	chr7:66902857~66906297:+
BRCA	cis	rs4415084	1	rs2165010	ENSG00000248779.1	RP11-53O19.2	3.9	0.000104	0.00646	0.11	0.12	Breast cancer;	chr5:44706678	chr5:44752949~44765744:+
BRCA	cis	rs11098499	0.908	rs2017057	ENSG00000260091.1	RP11-33B1.4	-3.9	0.000104	0.00646	-0.11	-0.12	Corneal astigmatism;	chr4:119336556	chr4:119409333~119410233:+
BRCA	cis	rs6585424	1	rs6585424	ENSG00000225484.5	NUTM2B-AS1	-3.9	0.000104	0.00646	-0.24	-0.12	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80173992	chr10:79663088~79826594:-
BRCA	cis	rs6762	0.748	rs5030780	ENSG00000255108.1	AP006621.8	3.9	0.000104	0.00646	0.13	0.12	Mean platelet volume;	chr11:838110	chr11:823634~832883:-
BRCA	cis	rs10857712	0.687	rs11101742	ENSG00000214279.11	SCART1	-3.9	0.000104	0.00646	-0.11	-0.12	Systemic lupus erythematosus;	chr10:133410868	chr10:133453928~133523558:+
BRCA	cis	rs2274459	0.841	rs12661400	ENSG00000249346.5	LINC01016	3.9	0.000104	0.00646	0.15	0.12	Obesity (extreme);	chr6:33728700	chr6:33867506~33896914:-
BRCA	cis	rs651907	0.535	rs13059470	ENSG00000256628.3	ZBTB11-AS1	-3.9	0.000104	0.00646	-0.15	-0.12	Colorectal cancer;	chr3:101705956	chr3:101676475~101679217:+
BRCA	cis	rs524281	0.861	rs7931544	ENSG00000255557.1	RP11-770G2.2	3.9	0.000104	0.00646	0.17	0.12	Electroencephalogram traits;	chr11:66149563	chr11:65745729~65771585:+
BRCA	cis	rs7267979	0.966	rs2263204	ENSG00000277938.1	RP5-965G21.3	-3.9	0.000104	0.00646	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25397052	chr20:25229150~25231933:+
BRCA	cis	rs6496932	0.755	rs12905673	ENSG00000218052.5	ADAMTS7P4	-3.9	0.000104	0.00646	-0.13	-0.12	Central corneal thickness;Corneal structure;	chr15:85346540	chr15:85255369~85330334:-
BRCA	cis	rs35306767	0.951	rs61833265	ENSG00000229869.1	RP11-363N22.2	-3.9	0.000104	0.00646	-0.2	-0.12	Eosinophil percentage of granulocytes;	chr10:944203	chr10:933026~942743:+
BRCA	cis	rs7520050	0.966	rs785471	ENSG00000234329.1	RP11-767N6.2	-3.9	0.000104	0.00647	-0.11	-0.12	Reticulocyte count;Red blood cell count;	chr1:46053005	chr1:45651039~45651826:-
BRCA	cis	rs115769866	0.609	rs2859356	ENSG00000220721.1	OR1F12	3.9	0.000104	0.00647	0.16	0.12	Bipolar disorder;	chr6:28497578	chr6:28073316~28074233:+
BRCA	cis	rs1156327	0.51	rs4617845	ENSG00000188477.11	AC003003.5	-3.9	0.000104	0.00647	-0.3	-0.12	Periodontal disease-related phenotypes;	chr16:19313887	chr16:19285783~19310947:+
BRCA	cis	rs1156327	0.655	rs4441251	ENSG00000188477.11	AC003003.5	-3.9	0.000104	0.00647	-0.3	-0.12	Periodontal disease-related phenotypes;	chr16:19313917	chr16:19285783~19310947:+
BRCA	cis	rs977987	0.806	rs4888411	ENSG00000280152.1	RP11-331F4.5	-3.9	0.000104	0.00647	-0.12	-0.12	Dupuytren's disease;	chr16:75409285	chr16:75245994~75250077:-
BRCA	cis	rs13401620	0.843	rs882390	ENSG00000229326.3	AC069154.4	3.9	0.000104	0.00647	0.15	0.12	Breast size;	chr2:119942166	chr2:119698623~119700151:+
BRCA	cis	rs875971	0.545	rs12671152	ENSG00000230295.1	RP11-458F8.2	3.9	0.000104	0.00647	0.12	0.12	Aortic root size;	chr7:66311140	chr7:66880708~66882981:+
BRCA	cis	rs10761482	0.906	rs10740023	ENSG00000254271.1	RP11-131N11.4	3.9	0.000104	0.00647	0.17	0.12	Schizophrenia;	chr10:60328508	chr10:60734342~60741828:+
BRCA	cis	rs11098499	0.954	rs10518328	ENSG00000225892.3	RP11-384K6.2	3.9	0.000104	0.00647	0.12	0.12	Corneal astigmatism;	chr4:119480624	chr4:118632274~118634759:+
BRCA	cis	rs9863	0.896	rs7311233	ENSG00000270028.1	RP11-380L11.4	-3.9	0.000104	0.00647	-0.15	-0.12	White blood cell count;	chr12:123991393	chr12:123925461~123926083:-
BRCA	cis	rs11085466	1	rs73552479	ENSG00000268081.1	RP11-678G14.2	-3.9	0.000104	0.00647	-0.19	-0.12	Colorectal or endometrial cancer;	chr19:21596014	chr19:21554640~21569237:-
BRCA	cis	rs2422052	0.527	rs12466517	ENSG00000236255.1	AC009404.2	3.9	0.000104	0.00647	0.12	0.12	Mosquito bite size;	chr2:118072815	chr2:117833937~117841658:+
BRCA	cis	rs4664293	0.647	rs6432539	ENSG00000224152.1	AC009506.1	-3.9	0.000104	0.00647	-0.13	-0.12	Monocyte percentage of white cells;	chr2:159592209	chr2:159615296~159617082:+
BRCA	cis	rs7833787	1	rs7007413	ENSG00000254054.2	RP11-156K13.3	-3.9	0.000104	0.00648	-0.14	-0.12	Obesity-related traits;	chr8:18847922	chr8:17905756~17907887:+
BRCA	cis	rs6964587	1	rs55745934	ENSG00000188693.7	CYP51A1-AS1	-3.9	0.000104	0.00648	-0.13	-0.12	Breast cancer;	chr7:92041684	chr7:92134604~92180725:+
BRCA	cis	rs754466	0.606	rs11002308	ENSG00000213514.2	RP11-428P16.2	3.9	0.000104	0.00648	0.16	0.12	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77835038	chr10:77730766~77734769:+
BRCA	cis	rs7735319	0.604	rs9292485	ENSG00000249572.1	CTD-2203K17.1	3.9	0.000104	0.00648	0.15	0.12	Systolic blood pressure;	chr5:33154160	chr5:33424025~33440619:-
BRCA	cis	rs1048886	0.938	rs16869267	ENSG00000271967.1	RP11-134K13.4	-3.9	0.000104	0.00648	-0.17	-0.12	Type 2 diabetes;	chr6:70483751	chr6:70596438~70596980:+
BRCA	cis	rs17027633	0.881	rs11548427	ENSG00000234020.1	CHIAP3	-3.9	0.000104	0.00648	-0.29	-0.12	Cerebrospinal fluid t-tau:AB1-42 ratio;	chr1:111449146	chr1:111353275~111367409:-
BRCA	cis	rs425277	1	rs262651	ENSG00000269227.1	RP11-345P4.6	3.9	0.000104	0.00648	0.13	0.12	Height;	chr1:2159958	chr1:1673275~1674397:+
BRCA	cis	rs11671005	0.504	rs3794963	ENSG00000268230.4	CTD-2619J13.8	3.9	0.000104	0.00648	0.12	0.12	Mean platelet volume;	chr19:58559684	chr19:58346854~58362751:-
BRCA	cis	rs11098499	0.505	rs75122014	ENSG00000225892.3	RP11-384K6.2	3.9	0.000104	0.00648	0.12	0.12	Corneal astigmatism;	chr4:119441271	chr4:118632274~118634759:+
BRCA	cis	rs1155848	0.892	rs1023293	ENSG00000227676.3	LINC01068	-3.9	0.000104	0.00648	-0.29	-0.12	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79480285	chr13:79566727~79571436:+
BRCA	cis	rs34929064	0.629	rs17375307	ENSG00000179428.2	AC073072.5	-3.9	0.000104	0.00649	-0.17	-0.12	Major depression and alcohol dependence;	chr7:22689757	chr7:22725395~22727620:-
BRCA	cis	rs34929064	0.718	rs62447650	ENSG00000179428.2	AC073072.5	-3.9	0.000104	0.00649	-0.17	-0.12	Major depression and alcohol dependence;	chr7:22690132	chr7:22725395~22727620:-
BRCA	cis	rs2320614	1	rs6845885	ENSG00000250027.1	RP11-563E2.2	-3.9	0.000104	0.00649	-0.13	-0.12	Lung adenocarcinoma;	chr4:163114954	chr4:163108785~163119965:+
BRCA	cis	rs56322409	1	rs11188411	ENSG00000226688.5	ENTPD1-AS1	3.9	0.000104	0.00649	0.14	0.12	Blood metabolite levels;	chr10:95637587	chr10:95753206~96090238:-
BRCA	cis	rs1730008	1	rs698992	ENSG00000279311.1	RP11-170K4.2	3.9	0.000104	0.00649	0.14	0.12	Lobe attachment (rater-scored or self-reported);	chr3:158232818	chr3:158869898~158871821:+
BRCA	cis	rs56322409	0.897	rs17553401	ENSG00000226688.5	ENTPD1-AS1	3.9	0.000104	0.00649	0.14	0.12	Blood metabolite levels;	chr10:95747716	chr10:95753206~96090238:-
BRCA	cis	rs10266483	0.774	rs4718067	ENSG00000271550.1	BNIP3P11	3.9	0.000104	0.00649	0.16	0.12	Response to statin therapy;	chr7:64356018	chr7:64678954~64687393:-
BRCA	cis	rs9733	0.818	rs12403609	ENSG00000203804.4	ADAMTSL4-AS1	-3.9	0.000104	0.00649	-0.13	-0.12	Tonsillectomy;	chr1:150704009	chr1:150560202~150574552:-
BRCA	cis	rs1553477	0.719	rs62370331	ENSG00000272416.1	CTD-2081C10.7	3.9	0.000104	0.00649	0.12	0.12	Monobrow;	chr5:53844533	chr5:53880293~53881051:-
BRCA	cis	rs6951245	0.638	rs4720486	ENSG00000224079.1	AC091729.7	-3.9	0.000104	0.00649	-0.18	-0.12	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1107128	chr7:1074450~1078036:+
BRCA	cis	rs7475343	0.538	rs4880710	ENSG00000224034.1	RP11-445P17.8	3.9	0.000104	0.00649	0.22	0.12	Intelligence;	chr10:5109373	chr10:5266033~5271236:-
BRCA	cis	rs7475343	0.538	rs4622159	ENSG00000224034.1	RP11-445P17.8	3.9	0.000104	0.00649	0.22	0.12	Intelligence;	chr10:5115704	chr10:5266033~5271236:-
BRCA	cis	rs8114671	0.527	rs6060112	ENSG00000126005.14	MMP24-AS1	-3.9	0.000104	0.00649	-0.14	-0.12	Height;	chr20:34901473	chr20:35216462~35278131:-
BRCA	cis	rs2274273	0.624	rs10141396	ENSG00000259318.1	RP11-454L9.2	3.9	0.000104	0.00649	0.11	0.12	Protein biomarker;	chr14:55350207	chr14:55394940~55395233:-
BRCA	cis	rs372883	0.648	rs1153292	ENSG00000176054.6	RPL23P2	-3.9	0.000104	0.00649	-0.13	-0.12	Pancreatic cancer;	chr21:29316874	chr21:28997613~28998033:-
BRCA	cis	rs2486012	0.737	rs2906470	ENSG00000237950.1	RP11-7O11.3	3.9	0.000104	0.00649	0.22	0.12	Intelligence (multi-trait analysis);	chr1:43840887	chr1:43944370~43946551:-
BRCA	cis	rs77633900	0.772	rs157775	ENSG00000196274.5	Metazoa_SRP	3.9	0.000104	0.00649	0.21	0.12	Glioma;Non-glioblastoma glioma;	chr15:76463300	chr15:76230048~76230390:-
BRCA	cis	rs6964587	1	rs2961020	ENSG00000188693.7	CYP51A1-AS1	3.9	0.000104	0.00649	0.13	0.12	Breast cancer;	chr7:91943994	chr7:92134604~92180725:+
BRCA	cis	rs6599077	0.95	rs9867011	ENSG00000223797.4	ENTPD3-AS1	3.9	0.000104	0.00649	0.15	0.12	Sleep-related phenotypes;	chr3:40063977	chr3:40313802~40453329:-
BRCA	cis	rs12324805	0.568	rs7176867	ENSG00000276710.3	CSPG4P8	-3.9	0.000104	0.00649	-0.12	-0.12	Body mass index;	chr15:82030688	chr15:82459472~82477258:+
BRCA	cis	rs875971	0.862	rs709609	ENSG00000273024.4	INTS4P2	3.9	0.000104	0.00649	0.14	0.12	Aortic root size;	chr7:66095574	chr7:65647864~65715661:+
BRCA	cis	rs6736093	0.704	rs10207301	ENSG00000236307.2	EEF1E1P1	-3.9	0.000104	0.00649	-0.14	-0.12	Coronary artery disease;	chr2:112044768	chr2:111887914~111888741:+
BRCA	cis	rs6088580	0.634	rs6059896	ENSG00000275784.1	RP5-1125A11.6	-3.9	0.000104	0.00649	-0.13	-0.12	Glomerular filtration rate (creatinine);	chr20:34523978	chr20:33989480~33991818:-
BRCA	cis	rs2304003	1	rs2241462	ENSG00000235192.1	AC009495.2	3.9	0.000104	0.00649	0.14	0.12	Social communication problems;	chr2:165833126	chr2:165794851~165810010:+
BRCA	cis	rs2243480	1	rs35542501	ENSG00000226002.1	RP11-460N20.5	-3.9	0.000104	0.00649	-0.2	-0.12	Diabetic kidney disease;	chr7:65966228	chr7:65084103~65100232:+
BRCA	cis	rs2243480	0.708	rs781141	ENSG00000226002.1	RP11-460N20.5	-3.9	0.000104	0.00649	-0.2	-0.12	Diabetic kidney disease;	chr7:65973566	chr7:65084103~65100232:+
BRCA	cis	rs4925540	1	rs7549410	ENSG00000215796.3	RP11-551G24.2	-3.9	0.000104	0.0065	-0.14	-0.12	Response to taxane treatment (docetaxel);	chr1:247050865	chr1:247042791~247044021:+
BRCA	cis	rs7267979	0.565	rs6107059	ENSG00000277938.1	RP5-965G21.3	-3.9	0.000104	0.0065	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25611795	chr20:25229150~25231933:+
BRCA	cis	rs6095357	1	rs6095357	ENSG00000227431.4	CSE1L-AS1	-3.9	0.000104	0.0065	-0.15	-0.12	Schizophrenia;	chr20:48907328	chr20:49040463~49046044:-
BRCA	cis	rs6012564	0.859	rs1997851	ENSG00000227431.4	CSE1L-AS1	-3.9	0.000104	0.0065	-0.15	-0.12	Anger;	chr20:48909956	chr20:49040463~49046044:-
BRCA	cis	rs11239930	0.538	rs4950359	ENSG00000237188.3	RP11-337C18.8	3.9	0.000104	0.0065	0.14	0.12	AIDS progression;	chr1:147087196	chr1:147172771~147211568:+
BRCA	cis	rs859767	1	rs842361	ENSG00000224043.6	CCNT2-AS1	-3.9	0.000104	0.0065	-0.16	-0.12	Neuroticism;	chr2:134583270	chr2:134735464~134918710:-
BRCA	cis	rs6546537	0.503	rs6718872	ENSG00000231024.1	AC092431.3	3.9	0.000104	0.0065	0.16	0.12	Serum thyroid-stimulating hormone levels;	chr2:69682845	chr2:69700192~69713847:-
BRCA	cis	rs62458065	0.713	rs62463967	ENSG00000273014.1	RP11-225B17.2	-3.9	0.000104	0.0065	-0.19	-0.12	Metabolite levels (HVA/MHPG ratio);	chr7:32458717	chr7:32758882~32759353:+
BRCA	cis	rs6893300	0.745	rs6639	ENSG00000250999.1	RP11-1379J22.5	3.9	0.000104	0.0065	0.16	0.12	Resting heart rate;	chr5:179729781	chr5:179657762~179664432:+
BRCA	cis	rs3764021	0.509	rs10772071	ENSG00000278635.1	CTD-2318O12.1	-3.9	0.000104	0.0065	-0.13	-0.12	Type 1 diabetes;	chr12:9717324	chr12:9415641~9416718:+
BRCA	cis	rs11098499	0.908	rs1002152	ENSG00000260091.1	RP11-33B1.4	-3.9	0.000104	0.0065	-0.11	-0.12	Corneal astigmatism;	chr4:119352232	chr4:119409333~119410233:+
BRCA	cis	rs16959442	1	rs16959442	ENSG00000244952.2	RP11-1000B6.5	-3.9	0.000104	0.0065	-0.19	-0.12	Lobe attachment (rater-scored or self-reported);	chr15:32837121	chr15:32613733~32615111:+
BRCA	cis	rs7590368	0.926	rs12621237	ENSG00000272275.1	RP11-791G15.2	3.9	0.000104	0.0065	0.16	0.12	Educational attainment (years of education);	chr2:10817412	chr2:10767875~10770058:-
BRCA	cis	rs2015599	0.549	rs6487799	ENSG00000257176.2	RP11-996F15.2	3.9	0.000104	0.0065	0.14	0.12	Platelet count;Mean platelet volume;	chr12:29291087	chr12:29280418~29317848:-
BRCA	cis	rs67696533	0.6	rs12625036	ENSG00000277692.1	RP11-358N2.2	-3.9	0.000104	0.0065	-0.14	-0.12	White blood cell count (basophil);Basophil percentage of granulocytes;Basophil percentage of white cells;	chr20:32524886	chr20:32355053~32355734:+
BRCA	cis	rs757081	0.676	rs567033	ENSG00000272034.1	SNORD14A	-3.9	0.000104	0.0065	-0.13	-0.12	Systolic blood pressure;	chr11:17185463	chr11:17074654~17074744:-
BRCA	cis	rs757081	0.676	rs677042	ENSG00000272034.1	SNORD14A	-3.9	0.000104	0.0065	-0.13	-0.12	Systolic blood pressure;	chr11:17185533	chr11:17074654~17074744:-
BRCA	cis	rs4834770	0.792	rs7676969	ENSG00000245958.5	RP11-33B1.1	-3.9	0.000104	0.0065	-0.11	-0.12	Blood protein levels;	chr4:119252569	chr4:119454791~119552025:+
BRCA	cis	rs4834770	0.685	rs4496567	ENSG00000245958.5	RP11-33B1.1	-3.9	0.000104	0.0065	-0.11	-0.12	Blood protein levels;	chr4:119254470	chr4:119454791~119552025:+
BRCA	cis	rs4834770	0.792	rs6823331	ENSG00000245958.5	RP11-33B1.1	-3.9	0.000104	0.0065	-0.11	-0.12	Blood protein levels;	chr4:119259635	chr4:119454791~119552025:+
BRCA	cis	rs11668609	0.938	rs8110507	ENSG00000268058.1	BNIP3P40	-3.9	0.000104	0.0065	-0.15	-0.12	Response to taxane treatment (docetaxel);	chr19:24099470	chr19:24098425~24098980:-
BRCA	cis	rs7395581	0.918	rs4752825	ENSG00000280615.1	Y_RNA	3.9	0.000104	0.00651	0.14	0.12	HDL cholesterol;	chr11:47330858	chr11:47614898~47614994:-
BRCA	cis	rs10510102	0.516	rs10219133	ENSG00000226864.1	ATE1-AS1	3.89	0.000104	0.00651	0.23	0.12	Breast cancer;	chr10:121987898	chr10:121928312~121951965:+
BRCA	cis	rs477895	0.713	rs11607165	ENSG00000256940.1	RP11-783K16.5	3.89	0.000104	0.00651	0.17	0.12	Mean platelet volume;	chr11:64196475	chr11:64245964~64248217:+
BRCA	cis	rs875971	0.545	rs10950027	ENSG00000232559.3	GS1-124K5.12	3.89	0.000104	0.00651	0.16	0.12	Aortic root size;	chr7:66169164	chr7:66554588~66576923:-
BRCA	cis	rs6964587	1	rs6968870	ENSG00000188693.7	CYP51A1-AS1	-3.89	0.000104	0.00651	-0.13	-0.12	Breast cancer;	chr7:92031797	chr7:92134604~92180725:+
BRCA	cis	rs2688608	0.623	rs2633318	ENSG00000271816.1	BMS1P4	3.89	0.000104	0.00651	0.12	0.12	Inflammatory bowel disease;	chr10:73930676	chr10:73699151~73730487:-
BRCA	cis	rs2625529	0.824	rs4776586	ENSG00000260037.4	CTD-2524L6.3	-3.89	0.000104	0.00651	-0.17	-0.12	Red blood cell count;	chr15:72138162	chr15:71818396~71823384:+
BRCA	cis	rs78487399	0.808	rs6752448	ENSG00000234936.1	AC010883.5	3.89	0.000105	0.00651	0.18	0.12	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43455457	chr2:43229573~43233394:+
BRCA	cis	rs6088580	0.634	rs6059875	ENSG00000275784.1	RP5-1125A11.6	-3.89	0.000105	0.00651	-0.13	-0.12	Glomerular filtration rate (creatinine);	chr20:34498285	chr20:33989480~33991818:-
BRCA	cis	rs6088580	0.634	rs6088512	ENSG00000275784.1	RP5-1125A11.6	-3.89	0.000105	0.00651	-0.13	-0.12	Glomerular filtration rate (creatinine);	chr20:34508086	chr20:33989480~33991818:-
BRCA	cis	rs6088580	0.634	rs6058070	ENSG00000275784.1	RP5-1125A11.6	-3.89	0.000105	0.00651	-0.13	-0.12	Glomerular filtration rate (creatinine);	chr20:34515716	chr20:33989480~33991818:-
BRCA	cis	rs524281	0.861	rs9645684	ENSG00000255038.1	RP11-1167A19.2	-3.89	0.000105	0.00651	-0.17	-0.12	Electroencephalogram traits;	chr11:66140493	chr11:66067277~66069619:-
BRCA	cis	rs78487399	0.808	rs6746058	ENSG00000234936.1	AC010883.5	3.89	0.000105	0.00651	0.18	0.12	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43460403	chr2:43229573~43233394:+
BRCA	cis	rs6490294	0.904	rs60217649	ENSG00000234608.6	MAPKAPK5-AS1	3.89	0.000105	0.00651	0.15	0.12	Mean platelet volume;	chr12:111973116	chr12:111839764~111842902:-
BRCA	cis	rs757081	0.648	rs10832750	ENSG00000184669.7	OR7E14P	3.89	0.000105	0.00651	0.16	0.12	Systolic blood pressure;	chr11:17239371	chr11:17013998~17053024:+
BRCA	cis	rs11098499	0.909	rs28714195	ENSG00000225892.3	RP11-384K6.2	3.89	0.000105	0.00651	0.12	0.12	Corneal astigmatism;	chr4:119395795	chr4:118632274~118634759:+
BRCA	cis	rs875971	0.964	rs697969	ENSG00000271064.1	RP11-792A8.3	3.89	0.000105	0.00652	0.14	0.12	Aortic root size;	chr7:66093491	chr7:66748838~66749077:-
BRCA	cis	rs875971	1	rs1182882	ENSG00000271064.1	RP11-792A8.3	3.89	0.000105	0.00652	0.14	0.12	Aortic root size;	chr7:66097076	chr7:66748838~66749077:-
BRCA	cis	rs801193	0.66	rs2659914	ENSG00000265600.1	AC006480.1	-3.89	0.000105	0.00652	-0.14	-0.12	Aortic root size;	chr7:66691927	chr7:67356680~67356779:+
BRCA	cis	rs801193	0.591	rs2707839	ENSG00000265600.1	AC006480.1	-3.89	0.000105	0.00652	-0.14	-0.12	Aortic root size;	chr7:66728097	chr7:67356680~67356779:+
BRCA	cis	rs4415084	0.618	rs6872254	ENSG00000251141.4	RP11-53O19.1	3.89	0.000105	0.00652	0.11	0.12	Breast cancer;	chr5:44803682	chr5:44744900~44808777:-
BRCA	cis	rs4415084	0.716	rs13174122	ENSG00000251141.4	RP11-53O19.1	3.89	0.000105	0.00652	0.11	0.12	Breast cancer;	chr5:44810638	chr5:44744900~44808777:-
BRCA	cis	rs11051970	0.918	rs325417	ENSG00000274964.1	RP11-817I4.1	-3.89	0.000105	0.00652	-0.14	-0.12	Response to tocilizumab in rheumatoid arthritis;	chr12:32421283	chr12:32339368~32340724:+
BRCA	cis	rs1075265	0.73	rs7597188	ENSG00000272156.1	RP11-477N3.1	-3.89	0.000105	0.00652	-0.12	-0.12	Chronotype;Morning vs. evening chronotype;	chr2:54014732	chr2:54082554~54085066:+
BRCA	cis	rs1552244	0.572	rs6797536	ENSG00000180385.7	EMC3-AS1	-3.89	0.000105	0.00652	-0.17	-0.12	Alzheimer's disease;	chr3:10127118	chr3:9986893~10006990:+
BRCA	cis	rs10129255	1	rs8012033	ENSG00000211967.3	IGHV3-53	-3.89	0.000105	0.00652	-0.09	-0.12	Kawasaki disease;	chr14:106678854	chr14:106592676~106593347:-
BRCA	cis	rs17361889	0.778	rs2214626	ENSG00000229108.1	MEOX2-AS1	3.89	0.000105	0.00652	0.14	0.12	Pediatric bone mineral content (hip);	chr7:16276027	chr7:15688378~15695491:+
BRCA	cis	rs4372836	0.729	rs12714241	ENSG00000226833.4	AC097724.3	3.89	0.000105	0.00652	0.14	0.12	Body mass index;	chr2:28746547	chr2:28708953~28736205:-
BRCA	cis	rs6964587	0.773	rs62467797	ENSG00000188693.7	CYP51A1-AS1	-3.89	0.000105	0.00652	-0.14	-0.12	Breast cancer;	chr7:92260408	chr7:92134604~92180725:+
BRCA	cis	rs10129255	0.957	rs11846893	ENSG00000232216.1	IGHV3-43	3.89	0.000105	0.00652	0.09	0.12	Kawasaki disease;	chr14:106779068	chr14:106470264~106470800:-
BRCA	cis	rs7267979	1	rs4813563	ENSG00000277938.1	RP5-965G21.3	-3.89	0.000105	0.00652	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25384704	chr20:25229150~25231933:+
BRCA	cis	rs7267979	0.966	rs6037103	ENSG00000277938.1	RP5-965G21.3	-3.89	0.000105	0.00652	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25388459	chr20:25229150~25231933:+
BRCA	cis	rs1730008	1	rs827147	ENSG00000279311.1	RP11-170K4.2	-3.89	0.000105	0.00652	-0.14	-0.12	Lobe attachment (rater-scored or self-reported);	chr3:158208396	chr3:158869898~158871821:+
BRCA	cis	rs9470794	1	rs56247028	ENSG00000204110.6	RP1-153P14.8	-3.89	0.000105	0.00652	-0.18	-0.12	Type 2 diabetes;	chr6:38160274	chr6:37507348~37535616:+
BRCA	cis	rs6456156	0.792	rs4710181	ENSG00000272549.1	RP11-351J23.2	-3.89	0.000105	0.00652	-0.12	-0.12	Primary biliary cholangitis;	chr6:167100510	chr6:167666840~167679270:-
BRCA	cis	rs6456156	0.755	rs4710182	ENSG00000272549.1	RP11-351J23.2	-3.89	0.000105	0.00652	-0.12	-0.12	Primary biliary cholangitis;	chr6:167100573	chr6:167666840~167679270:-
BRCA	cis	rs754466	0.606	rs11002309	ENSG00000213514.2	RP11-428P16.2	3.89	0.000105	0.00652	0.16	0.12	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77835173	chr10:77730766~77734769:+
BRCA	cis	rs7520050	0.933	rs11211203	ENSG00000234329.1	RP11-767N6.2	-3.89	0.000105	0.00652	-0.11	-0.12	Reticulocyte count;Red blood cell count;	chr1:45849920	chr1:45651039~45651826:-
BRCA	cis	rs721917	0.565	rs2255601	ENSG00000278616.1	BEND3P3	-3.89	0.000105	0.00652	-0.11	-0.12	Chronic obstructive pulmonary disease;	chr10:79944803	chr10:79682997~79685436:+
BRCA	cis	rs2242116	0.796	rs4683297	ENSG00000276925.1	RP11-708J19.3	3.89	0.000105	0.00653	0.14	0.12	Birth weight;	chr3:46932183	chr3:47469777~47469987:+
BRCA	cis	rs739496	0.843	rs848132	ENSG00000257624.1	RP1-128M12.3	3.89	0.000105	0.00653	0.16	0.12	Platelet count;	chr12:111552175	chr12:112000739~112000985:-
BRCA	cis	rs1910358	0.676	rs1910063	ENSG00000248874.4	C5orf17	-3.89	0.000105	0.00653	-0.16	-0.12	Venous thromboembolism (SNP x SNP interaction);	chr5:24006655	chr5:23951348~24178263:+
BRCA	cis	rs9863	0.861	rs10846579	ENSG00000270028.1	RP11-380L11.4	3.89	0.000105	0.00653	0.15	0.12	White blood cell count;	chr12:123922856	chr12:123925461~123926083:-
BRCA	cis	rs9863	0.861	rs11057394	ENSG00000270028.1	RP11-380L11.4	3.89	0.000105	0.00653	0.15	0.12	White blood cell count;	chr12:123923129	chr12:123925461~123926083:-
BRCA	cis	rs9863	0.861	rs12809125	ENSG00000270028.1	RP11-380L11.4	3.89	0.000105	0.00653	0.15	0.12	White blood cell count;	chr12:123923444	chr12:123925461~123926083:-
BRCA	cis	rs8114671	0.586	rs6087634	ENSG00000279253.1	RP4-614O4.13	-3.89	0.000105	0.00653	-0.14	-0.12	Height;	chr20:34826006	chr20:35262727~35264187:-
BRCA	cis	rs12893668	0.703	rs8017993	ENSG00000269940.1	RP11-73M18.7	3.89	0.000105	0.00653	0.13	0.12	Reticulocyte count;	chr14:103581397	chr14:103694560~103695170:+
BRCA	cis	rs1437396	0.71	rs2589073	ENSG00000203327.2	AC012358.7	3.89	0.000105	0.00653	0.12	0.12	Alcohol dependence;	chr2:55340556	chr2:55214387~55216126:-
BRCA	cis	rs1437396	0.657	rs2917778	ENSG00000203327.2	AC012358.7	3.89	0.000105	0.00653	0.12	0.12	Alcohol dependence;	chr2:55340839	chr2:55214387~55216126:-
BRCA	cis	rs875971	0.825	rs1000464	ENSG00000271064.1	RP11-792A8.3	3.89	0.000105	0.00653	0.14	0.12	Aortic root size;	chr7:66312922	chr7:66748838~66749077:-
BRCA	cis	rs10508774	0.81	rs10508776	ENSG00000273038.2	RP11-479G22.8	3.89	0.000105	0.00653	0.26	0.12	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32900099	chr10:32887255~32889311:-
BRCA	cis	rs2642442	1	rs867772	ENSG00000257551.1	HLX-AS1	3.89	0.000105	0.00653	0.14	0.12	Cholesterol, total;LDL cholesterol;	chr1:220799001	chr1:220832763~220880140:-
BRCA	cis	rs1479090	0.805	rs4691896	ENSG00000250027.1	RP11-563E2.2	-3.89	0.000105	0.00653	-0.15	-0.12	Lung cancer;	chr4:163164273	chr4:163108785~163119965:+
BRCA	cis	rs11168618	1	rs10875830	ENSG00000273765.1	RP11-370I10.11	3.89	0.000105	0.00653	0.14	0.12	Adiponectin levels;	chr12:48543727	chr12:48360920~48361377:+
BRCA	cis	rs1577917	0.74	rs2758843	ENSG00000220563.1	PKMP3	-3.89	0.000105	0.00653	-0.12	-0.12	Response to antipsychotic treatment;	chr6:85618713	chr6:85659892~85660606:-
BRCA	cis	rs13434995	0.513	rs62303711	ENSG00000239040.1	Y_RNA	3.89	0.000105	0.00653	0.14	0.12	Adiponectin levels;	chr4:55458325	chr4:55412636~55412738:+
BRCA	cis	rs6500602	0.701	rs4785968	ENSG00000280063.1	RP11-295D4.3	3.89	0.000105	0.00653	0.09	0.12	Schizophrenia;	chr16:4485306	chr16:4346694~4348648:-
BRCA	cis	rs2274459	1	rs2274459	ENSG00000249346.5	LINC01016	3.89	0.000105	0.00653	0.16	0.12	Obesity (extreme);	chr6:33794465	chr6:33867506~33896914:-
BRCA	cis	rs11098403	0.833	rs17863003	ENSG00000225892.3	RP11-384K6.2	3.89	0.000105	0.00653	0.12	0.12	Schizophrenia;	chr4:117756014	chr4:118632274~118634759:+
BRCA	cis	rs1030420	0.848	rs10095182	ENSG00000200714.1	Y_RNA	-3.89	0.000105	0.00653	-0.2	-0.12	Blood metabolite levels;	chr8:66434216	chr8:65592731~65592820:+
BRCA	cis	rs3743266	0.593	rs4775276	ENSG00000245534.5	RORA-AS1	-3.89	0.000105	0.00653	-0.14	-0.12	Menarche (age at onset);	chr15:60513986	chr15:60479178~60630637:+
BRCA	cis	rs8058578	0.945	rs8058961	ENSG00000274678.1	RP11-2C24.7	3.89	0.000105	0.00653	0.15	0.12	Multiple myeloma;	chr16:30797742	chr16:30821338~30821884:+
BRCA	cis	rs7267979	1	rs6050626	ENSG00000274414.1	RP5-965G21.4	-3.89	0.000105	0.00653	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25447625	chr20:25239007~25245229:-
BRCA	cis	rs6981523	0.553	rs11783890	ENSG00000154316.13	TDH	3.89	0.000105	0.00653	0.17	0.12	Neuroticism;	chr8:11198879	chr8:11339637~11368452:+
BRCA	cis	rs9921338	0.923	rs4563054	ENSG00000263080.1	RP11-485G7.5	3.89	0.000105	0.00654	0.19	0.12	Vein graft stenosis in coronary artery bypass grafting;	chr16:11353689	chr16:11341809~11345211:-
BRCA	cis	rs4415084	1	rs2165010	ENSG00000248464.1	FGF10-AS1	3.89	0.000105	0.00654	0.13	0.12	Breast cancer;	chr5:44706678	chr5:44388732~44413989:+
BRCA	cis	rs4415084	1	rs2165010	ENSG00000272335.1	RP11-53O19.3	3.89	0.000105	0.00654	0.11	0.12	Breast cancer;	chr5:44706678	chr5:44826076~44828592:+
BRCA	cis	rs7656342	0.866	rs13124305	ENSG00000250342.1	SNRPCP16	-3.89	0.000105	0.00654	-0.14	-0.12	Gut microbiota (bacterial taxa);	chr4:9771649	chr4:9051842~9052051:-
BRCA	cis	rs10411161	0.702	rs8100716	ENSG00000269483.1	AC006272.1	3.89	0.000105	0.00654	0.19	0.12	Breast cancer;	chr19:51880808	chr19:51839924~51843324:-
BRCA	cis	rs6430585	0.591	rs12477421	ENSG00000231890.6	DARS-AS1	-3.89	0.000105	0.00654	-0.19	-0.12	Corneal structure;	chr2:135676170	chr2:135985176~136022593:+
BRCA	cis	rs73201462	1	rs6794591	ENSG00000242551.2	POU5F1P6	3.89	0.000105	0.00654	0.2	0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128312376	chr3:128674735~128677005:-
BRCA	cis	rs73201462	1	rs11706852	ENSG00000242551.2	POU5F1P6	3.89	0.000105	0.00654	0.2	0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128314044	chr3:128674735~128677005:-
BRCA	cis	rs2274459	0.908	rs13207666	ENSG00000249346.5	LINC01016	3.89	0.000105	0.00654	0.16	0.12	Obesity (extreme);	chr6:33739450	chr6:33867506~33896914:-
BRCA	cis	rs34975555	0.568	rs17635461	ENSG00000254054.2	RP11-156K13.3	-3.89	0.000105	0.00654	-0.16	-0.12	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:17976817	chr8:17905756~17907887:+
BRCA	cis	rs9863	0.828	rs7307277	ENSG00000270028.1	RP11-380L11.4	3.89	0.000105	0.00654	0.15	0.12	White blood cell count;	chr12:123990609	chr12:123925461~123926083:-
BRCA	cis	rs11098499	0.954	rs13107475	ENSG00000260404.2	RP11-384K6.6	3.89	0.000105	0.00654	0.11	0.12	Corneal astigmatism;	chr4:119471856	chr4:118591773~118633729:+
BRCA	cis	rs6430585	0.527	rs2289959	ENSG00000224043.6	CCNT2-AS1	-3.89	0.000105	0.00654	-0.19	-0.12	Corneal structure;	chr2:135666334	chr2:134735464~134918710:-
BRCA	cis	rs11168618	0.967	rs11168619	ENSG00000273765.1	RP11-370I10.11	3.89	0.000105	0.00654	0.14	0.12	Adiponectin levels;	chr12:48539822	chr12:48360920~48361377:+
BRCA	cis	rs4415084	0.716	rs930394	ENSG00000251141.4	RP11-53O19.1	3.89	0.000105	0.00654	0.11	0.12	Breast cancer;	chr5:44822515	chr5:44744900~44808777:-
BRCA	cis	rs4415084	0.716	rs12513749	ENSG00000251141.4	RP11-53O19.1	3.89	0.000105	0.00654	0.11	0.12	Breast cancer;	chr5:44828101	chr5:44744900~44808777:-
BRCA	cis	rs4415084	0.716	rs16901989	ENSG00000251141.4	RP11-53O19.1	-3.89	0.000105	0.00654	-0.11	-0.12	Breast cancer;	chr5:44837027	chr5:44744900~44808777:-
BRCA	cis	rs875971	0.862	rs778702	ENSG00000273024.4	INTS4P2	-3.89	0.000105	0.00654	-0.13	-0.12	Aortic root size;	chr7:66399848	chr7:65647864~65715661:+
BRCA	cis	rs7260598	0.792	rs11671489	ENSG00000268442.1	CTD-2027I19.2	3.89	0.000105	0.00654	0.2	0.12	Response to taxane treatment (placlitaxel);	chr19:24156070	chr19:24162370~24163425:-
BRCA	cis	rs7260598	0.792	rs60773823	ENSG00000268442.1	CTD-2027I19.2	3.89	0.000105	0.00654	0.2	0.12	Response to taxane treatment (placlitaxel);	chr19:24156730	chr19:24162370~24163425:-
BRCA	cis	rs2777491	0.574	rs72739644	ENSG00000247556.5	OIP5-AS1	3.89	0.000105	0.00654	0.14	0.12	Ulcerative colitis;	chr15:41427508	chr15:41283990~41309737:+
BRCA	cis	rs2777491	0.574	rs2730056	ENSG00000247556.5	OIP5-AS1	3.89	0.000105	0.00654	0.14	0.12	Ulcerative colitis;	chr15:41443587	chr15:41283990~41309737:+
BRCA	cis	rs889122	0.729	rs16996141	ENSG00000267289.1	CTD-2623N2.11	3.89	0.000105	0.00654	0.18	0.12	Menarche (age at onset);	chr19:9855016	chr19:9834079~9835013:-
BRCA	cis	rs2243480	1	rs160634	ENSG00000226002.1	RP11-460N20.5	3.89	0.000105	0.00655	0.19	0.12	Diabetic kidney disease;	chr7:66063677	chr7:65084103~65100232:+
BRCA	cis	rs11673344	0.504	rs4806407	ENSG00000276846.1	CTD-3220F14.3	-3.89	0.000105	0.00655	-0.14	-0.12	Obesity-related traits;	chr19:37097849	chr19:37314868~37315620:-
BRCA	cis	rs7267979	0.565	rs4815432	ENSG00000277938.1	RP5-965G21.3	-3.89	0.000105	0.00655	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25575767	chr20:25229150~25231933:+
BRCA	cis	rs4950322	0.58	rs17355419	ENSG00000237188.3	RP11-337C18.8	3.89	0.000105	0.00655	0.14	0.12	Protein quantitative trait loci;	chr1:147110094	chr1:147172771~147211568:+
BRCA	cis	rs4950322	0.58	rs72706428	ENSG00000237188.3	RP11-337C18.8	3.89	0.000105	0.00655	0.14	0.12	Protein quantitative trait loci;	chr1:147110219	chr1:147172771~147211568:+
BRCA	cis	rs4950322	0.563	rs61838944	ENSG00000237188.3	RP11-337C18.8	3.89	0.000105	0.00655	0.14	0.12	Protein quantitative trait loci;	chr1:147110275	chr1:147172771~147211568:+
BRCA	cis	rs3743162	0.553	rs12915656	ENSG00000275120.1	RP11-182J1.17	3.89	0.000105	0.00655	0.18	0.12	Alzheimer's disease (age of onset);	chr15:84872349	chr15:84599434~84606463:-
BRCA	cis	rs4218	0.648	rs17236453	ENSG00000259732.1	RP11-59H7.3	-3.89	0.000105	0.00655	-0.15	-0.12	Social communication problems;	chr15:59092156	chr15:59121034~59133250:+
BRCA	cis	rs28374715	0.681	rs7165396	ENSG00000247556.5	OIP5-AS1	3.89	0.000105	0.00655	0.14	0.12	Ulcerative colitis;	chr15:41294749	chr15:41283990~41309737:+
BRCA	cis	rs2880765	0.743	rs6416598	ENSG00000230373.7	GOLGA6L5P	3.89	0.000105	0.00655	0.13	0.12	Coronary artery disease;	chr15:85468617	chr15:84507885~84516814:-
BRCA	cis	rs8114671	0.562	rs6087653	ENSG00000126005.14	MMP24-AS1	-3.89	0.000105	0.00655	-0.14	-0.12	Height;	chr20:34934251	chr20:35216462~35278131:-
BRCA	cis	rs747650	0.504	rs7126005	ENSG00000200376.1	RNU5E-10P	3.89	0.000105	0.00655	0.16	0.12	Acne (severe);	chr11:47019514	chr11:47576471~47576588:-
BRCA	cis	rs2834188	0.538	rs2026253	ENSG00000272659.1	AP000295.10	-3.89	0.000105	0.00655	-0.16	-0.12	Narcolepsy;	chr21:33315661	chr21:33309491~33310181:+
BRCA	cis	rs875971	0.862	rs1643375	ENSG00000273024.4	INTS4P2	-3.89	0.000105	0.00655	-0.13	-0.12	Aortic root size;	chr7:66407690	chr7:65647864~65715661:+
BRCA	cis	rs2736345	0.788	rs998683	ENSG00000255354.1	RP11-148O21.2	3.89	0.000105	0.00655	0.12	0.12	Systemic lupus erythematosus;Sjögren's syndrome;	chr8:11495491	chr8:11558466~11560020:-
BRCA	cis	rs11098499	0.535	rs7671759	ENSG00000260091.1	RP11-33B1.4	-3.89	0.000105	0.00655	-0.1	-0.12	Corneal astigmatism;	chr4:119326939	chr4:119409333~119410233:+
BRCA	cis	rs4557020	0.868	rs4671939	ENSG00000203327.2	AC012358.7	3.89	0.000105	0.00656	0.12	0.12	Myopia (pathological);	chr2:54469573	chr2:55214387~55216126:-
BRCA	cis	rs8098244	0.737	rs1154232	ENSG00000265752.2	RP11-403A21.1	-3.89	0.000105	0.00656	-0.17	-0.12	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23931070	chr18:23957754~23982556:-
BRCA	cis	rs990171	0.538	rs4851016	ENSG00000234389.1	AC007278.3	3.89	0.000105	0.00656	0.12	0.12	Lymphocyte counts;	chr2:102503941	chr2:102438713~102440475:+
BRCA	cis	rs4073582	0.595	rs801737	ENSG00000255320.1	RP11-755F10.1	-3.89	0.000105	0.00656	-0.15	-0.12	Gout;	chr11:66160722	chr11:66244840~66246239:-
BRCA	cis	rs7572733	0.555	rs1837495	ENSG00000231621.1	AC013264.2	3.89	0.000105	0.00656	0.11	0.12	Dermatomyositis;	chr2:198056477	chr2:197197991~197199273:+
BRCA	cis	rs737008	0.922	rs1559394	ENSG00000262703.1	RP11-485G7.6	-3.89	0.000105	0.00656	-0.13	-0.12	Obesity-related traits;	chr16:11275348	chr16:11348143~11349321:-
BRCA	cis	rs7795541	0.71	rs1494187	ENSG00000230658.1	KLHL7-AS1	-3.89	0.000105	0.00656	-0.16	-0.12	Morning vs. evening chronotype;	chr7:24049636	chr7:23101228~23105703:-
BRCA	cis	rs11098499	0.955	rs4145951	ENSG00000260091.1	RP11-33B1.4	-3.89	0.000105	0.00656	-0.11	-0.12	Corneal astigmatism;	chr4:119234662	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.955	rs35916640	ENSG00000260091.1	RP11-33B1.4	-3.89	0.000105	0.00656	-0.11	-0.12	Corneal astigmatism;	chr4:119234697	chr4:119409333~119410233:+
BRCA	cis	rs11098403	0.764	rs4574479	ENSG00000225892.3	RP11-384K6.2	3.89	0.000105	0.00656	0.12	0.12	Schizophrenia;	chr4:117802332	chr4:118632274~118634759:+
BRCA	cis	rs6545883	0.894	rs6545845	ENSG00000270820.4	RP11-355B11.2	-3.89	0.000105	0.00656	-0.14	-0.12	Tuberculosis;	chr2:61209909	chr2:61471188~61484130:+
BRCA	cis	rs2839186	0.771	rs2839155	ENSG00000228137.1	AP001469.7	3.89	0.000105	0.00656	0.12	0.12	Testicular germ cell tumor;	chr21:46220078	chr21:46246890~46247682:+
BRCA	cis	rs4218	0.689	rs12907187	ENSG00000259732.1	RP11-59H7.3	-3.89	0.000105	0.00656	-0.15	-0.12	Social communication problems;	chr15:59100607	chr15:59121034~59133250:+
BRCA	cis	rs2274459	1	rs34339105	ENSG00000249346.5	LINC01016	3.89	0.000105	0.00656	0.16	0.12	Obesity (extreme);	chr6:33755680	chr6:33867506~33896914:-
BRCA	cis	rs8180040	0.726	rs34344887	ENSG00000276925.1	RP11-708J19.3	-3.89	0.000105	0.00656	-0.13	-0.12	Colorectal cancer;	chr3:47000671	chr3:47469777~47469987:+
BRCA	cis	rs4950322	0.58	rs7514970	ENSG00000237188.3	RP11-337C18.8	3.89	0.000105	0.00656	0.15	0.12	Protein quantitative trait loci;	chr1:147120516	chr1:147172771~147211568:+
BRCA	cis	rs4478858	0.684	rs7519766	ENSG00000223907.1	LINC01226	-3.89	0.000106	0.00657	-0.14	-0.12	Alcohol dependence;	chr1:31262665	chr1:31518435~31524245:+
BRCA	cis	rs4835473	0.932	rs5016158	ENSG00000246448.2	RP13-578N3.3	-3.89	0.000106	0.00657	-0.13	-0.12	Immature fraction of reticulocytes;	chr4:143738472	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.932	rs5016157	ENSG00000246448.2	RP13-578N3.3	-3.89	0.000106	0.00657	-0.13	-0.12	Immature fraction of reticulocytes;	chr4:143738587	chr4:143700257~143865072:+
BRCA	cis	rs11158026	0.603	rs34988865	ENSG00000233924.1	AL160471.6	-3.89	0.000106	0.00657	-0.14	-0.12	Parkinson's disease;	chr14:55008131	chr14:55004813~55005687:-
BRCA	cis	rs10266483	0.921	rs687547	ENSG00000227986.1	TRIM60P18	-3.89	0.000106	0.00657	-0.12	-0.12	Response to statin therapy;	chr7:64284551	chr7:64355078~64356199:+
BRCA	cis	rs2832191	0.791	rs2832198	ENSG00000236056.1	GAPDHP14	-3.89	0.000106	0.00657	-0.13	-0.12	Dental caries;	chr21:29125919	chr21:29222321~29223257:+
BRCA	cis	rs73201462	1	rs2955086	ENSG00000242551.2	POU5F1P6	-3.89	0.000106	0.00657	-0.2	-0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128244348	chr3:128674735~128677005:-
BRCA	cis	rs4415084	0.8	rs11949847	ENSG00000248779.1	RP11-53O19.2	3.89	0.000106	0.00657	0.11	0.12	Breast cancer;	chr5:44752067	chr5:44752949~44765744:+
BRCA	cis	rs9467773	0.62	rs9295701	ENSG00000224843.5	LINC00240	-3.89	0.000106	0.00657	-0.13	-0.12	Intelligence (multi-trait analysis);	chr6:26627280	chr6:26956992~27023924:+
BRCA	cis	rs8099996	0.798	rs10415811	ENSG00000267277.1	CTD-2342J14.6	3.89	0.000106	0.00657	0.14	0.12	Inflammatory skin disease;	chr19:11066732	chr19:11368123~11374935:-
BRCA	cis	rs2880765	0.743	rs6416598	ENSG00000202081.1	RNU6-1280P	3.89	0.000106	0.00658	0.14	0.12	Coronary artery disease;	chr15:85468617	chr15:85651522~85651628:-
BRCA	cis	rs4664293	0.605	rs890095	ENSG00000230783.1	AC009961.2	3.89	0.000106	0.00658	0.15	0.12	Monocyte percentage of white cells;	chr2:159604708	chr2:159689217~159690291:-
BRCA	cis	rs2904804	0.506	rs10751995	ENSG00000224251.5	RP11-499O7.7	3.89	0.000106	0.00658	0.13	0.12	Economic and political preferences (immigration/crime);	chr10:4925954	chr10:4995488~4997380:+
BRCA	cis	rs11098499	0.954	rs4577559	ENSG00000225892.3	RP11-384K6.2	3.89	0.000106	0.00658	0.12	0.12	Corneal astigmatism;	chr4:119482888	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.954	rs7656252	ENSG00000225892.3	RP11-384K6.2	3.89	0.000106	0.00658	0.12	0.12	Corneal astigmatism;	chr4:119483113	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.865	rs28845498	ENSG00000225892.3	RP11-384K6.2	3.89	0.000106	0.00658	0.12	0.12	Corneal astigmatism;	chr4:119484031	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.954	rs56270433	ENSG00000225892.3	RP11-384K6.2	3.89	0.000106	0.00658	0.12	0.12	Corneal astigmatism;	chr4:119484875	chr4:118632274~118634759:+
BRCA	cis	rs17772222	0.917	rs8006652	ENSG00000258789.1	RP11-507K2.3	-3.89	0.000106	0.00658	-0.14	-0.12	Coronary artery calcification;	chr14:88631290	chr14:88551597~88552493:+
BRCA	cis	rs2136613	0.751	rs1509955	ENSG00000238280.1	RP11-436D10.3	-3.89	0.000106	0.00658	-0.15	-0.12	Selective IgA deficiency;	chr10:62843559	chr10:62793562~62805887:-
BRCA	cis	rs1722141	0.57	rs788728	ENSG00000237471.1	AC073115.6	3.89	0.000106	0.00658	0.16	0.12	Sitting height ratio;	chr7:46034169	chr7:45969657~45980191:+
BRCA	cis	rs7267979	1	rs6050565	ENSG00000204556.4	CTD-2514C3.1	3.89	0.000106	0.00658	0.16	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25366927	chr20:26018832~26020684:+
BRCA	cis	rs6964587	1	rs6970277	ENSG00000188693.7	CYP51A1-AS1	-3.89	0.000106	0.00658	-0.13	-0.12	Breast cancer;	chr7:92051341	chr7:92134604~92180725:+
BRCA	cis	rs2251381	0.778	rs722013	ENSG00000232855.5	AF131217.1	-3.89	0.000106	0.00658	-0.16	-0.12	Selective IgA deficiency;	chr21:29176924	chr21:28439346~28674848:-
BRCA	cis	rs11742741	0.806	rs1032759	ENSG00000248874.4	C5orf17	3.89	0.000106	0.00658	0.16	0.12	Educational attainment;	chr5:24017421	chr5:23951348~24178263:+
BRCA	cis	rs6088590	1	rs2236270	ENSG00000276073.1	RP5-1125A11.7	-3.89	0.000106	0.00658	-0.14	-0.12	Coronary artery disease;	chr20:34935352	chr20:33985617~33988989:-
BRCA	cis	rs12073837	0.5	rs4143772	ENSG00000221571.3	RNU6ATAC35P	-3.89	0.000106	0.00658	-0.14	-0.12	F-cell distribution;	chr1:220815004	chr1:220825620~220826063:+
BRCA	cis	rs875971	0.545	rs35459055	ENSG00000232559.3	GS1-124K5.12	3.89	0.000106	0.00658	0.16	0.12	Aortic root size;	chr7:66479399	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.638	rs10249404	ENSG00000265600.1	AC006480.1	3.89	0.000106	0.00659	0.14	0.12	Aortic root size;	chr7:66581737	chr7:67356680~67356779:+
BRCA	cis	rs11158026	0.603	rs8022049	ENSG00000233924.1	AL160471.6	3.89	0.000106	0.00659	0.14	0.12	Parkinson's disease;	chr14:54996151	chr14:55004813~55005687:-
BRCA	cis	rs1577330	0.747	rs1161603	ENSG00000254396.1	RP11-56F10.3	-3.89	0.000106	0.00659	-0.18	-0.12	IgG glycosylation;	chr9:27098942	chr9:27102630~27104728:+
BRCA	cis	rs875971	0.798	rs6460304	ENSG00000271064.1	RP11-792A8.3	-3.89	0.000106	0.00659	-0.14	-0.12	Aortic root size;	chr7:66499741	chr7:66748838~66749077:-
BRCA	cis	rs875971	0.862	rs6945775	ENSG00000271064.1	RP11-792A8.3	-3.89	0.000106	0.00659	-0.14	-0.12	Aortic root size;	chr7:66503987	chr7:66748838~66749077:-
BRCA	cis	rs4538475	0.559	rs73243112	ENSG00000273133.1	RP11-799M12.2	-3.89	0.000106	0.00659	-0.24	-0.12	Parkinson's disease;	chr4:15664483	chr4:15563698~15564253:-
BRCA	cis	rs4538475	0.559	rs73243114	ENSG00000273133.1	RP11-799M12.2	-3.89	0.000106	0.00659	-0.24	-0.12	Parkinson's disease;	chr4:15665193	chr4:15563698~15564253:-
BRCA	cis	rs4538475	0.559	rs56065468	ENSG00000273133.1	RP11-799M12.2	-3.89	0.000106	0.00659	-0.24	-0.12	Parkinson's disease;	chr4:15674097	chr4:15563698~15564253:-
BRCA	cis	rs4538475	0.559	rs73243128	ENSG00000273133.1	RP11-799M12.2	-3.89	0.000106	0.00659	-0.24	-0.12	Parkinson's disease;	chr4:15674946	chr4:15563698~15564253:-
BRCA	cis	rs6847067	0.616	rs10446678	ENSG00000180769.7	WDFY3-AS2	3.89	0.000106	0.00659	0.12	0.12	Oropharynx cancer;	chr4:84613006	chr4:84965682~85011277:+
BRCA	cis	rs35306767	0.855	rs12771179	ENSG00000229869.1	RP11-363N22.2	-3.89	0.000106	0.00659	-0.21	-0.12	Eosinophil percentage of granulocytes;	chr10:826407	chr10:933026~942743:+
BRCA	cis	rs56313388	0.505	rs9923472	ENSG00000246379.5	RP11-461O7.1	-3.89	0.000106	0.00659	-0.13	-0.12	Pulse pressure;	chr16:56247842	chr16:56092987~56191094:-
BRCA	cis	rs4925386	0.84	rs8124907	ENSG00000275437.1	RP5-908M14.10	3.89	0.000106	0.00659	0.13	0.12	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62338071	chr20:62402236~62405935:-
BRCA	cis	rs7637701	0.517	rs3851992	ENSG00000240875.4	LINC00886	-3.89	0.000106	0.00659	-0.14	-0.12	Breast cancer;	chr3:156681391	chr3:156747346~156817062:-
BRCA	cis	rs7520050	0.966	rs10890354	ENSG00000234329.1	RP11-767N6.2	-3.89	0.000106	0.00659	-0.11	-0.12	Reticulocyte count;Red blood cell count;	chr1:45839675	chr1:45651039~45651826:-
BRCA	cis	rs13217239	0.646	rs9393789	ENSG00000124549.13	BTN2A3P	-3.89	0.000106	0.00659	-0.12	-0.12	Schizophrenia;	chr6:27099249	chr6:26421391~26432383:+
BRCA	cis	rs2688608	0.647	rs2633319	ENSG00000213731.2	RAB5CP1	-3.89	0.000106	0.00659	-0.13	-0.12	Inflammatory bowel disease;	chr10:73931489	chr10:74423435~74424014:-
BRCA	cis	rs2625529	0.642	rs2200056	ENSG00000260037.4	CTD-2524L6.3	-3.89	0.000106	0.00659	-0.17	-0.12	Red blood cell count;	chr15:72010326	chr15:71818396~71823384:+
BRCA	cis	rs6964587	0.9	rs62467794	ENSG00000188693.7	CYP51A1-AS1	-3.89	0.000106	0.0066	-0.14	-0.12	Breast cancer;	chr7:92221264	chr7:92134604~92180725:+
BRCA	cis	rs2304003	1	rs980231	ENSG00000235192.1	AC009495.2	3.89	0.000106	0.0066	0.14	0.12	Social communication problems;	chr2:165824612	chr2:165794851~165810010:+
BRCA	cis	rs6683071	0.54	rs1391558	ENSG00000225265.1	TAF1A-AS1	-3.89	0.000106	0.0066	-0.16	-0.12	Cognitive performance;	chr1:222674687	chr1:222589825~222593032:+
BRCA	cis	rs6914079	0.951	rs10807578	ENSG00000235488.1	JARID2-AS1	3.89	0.000106	0.0066	0.17	0.12	Cognitive test performance;	chr6:14587916	chr6:15247815~15248634:-
BRCA	cis	rs12724450	0.793	rs57323357	ENSG00000228126.1	FALEC	3.89	0.000106	0.0066	0.21	0.12	Blood protein levels;	chr1:150432534	chr1:150515757~150518032:+
BRCA	cis	rs7178375	0.607	rs7171212	ENSG00000259845.1	HERC2P10	3.89	0.000106	0.0066	0.21	0.12	Hypertriglyceridemia;	chr15:30915508	chr15:30815271~30844153:+
BRCA	cis	rs2229238	0.911	rs41269915	ENSG00000272030.1	RP1-178F15.4	-3.89	0.000106	0.0066	-0.17	-0.12	Coronary heart disease;	chr1:154549108	chr1:153631438~153634397:-
BRCA	cis	rs6964587	1	rs10264666	ENSG00000188693.7	CYP51A1-AS1	3.89	0.000106	0.0066	0.13	0.12	Breast cancer;	chr7:91949325	chr7:92134604~92180725:+
BRCA	cis	rs7572644	0.537	rs28416955	ENSG00000223522.1	AC093690.1	3.89	0.000106	0.0066	0.13	0.12	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:28155815	chr2:28307691~28310459:-
BRCA	cis	rs6545883	1	rs778763	ENSG00000270820.4	RP11-355B11.2	3.89	0.000106	0.0066	0.14	0.12	Tuberculosis;	chr2:61558504	chr2:61471188~61484130:+
BRCA	cis	rs17221829	0.681	rs75322840	ENSG00000280385.1	AP000648.5	-3.89	0.000106	0.0066	-0.14	-0.12	Anxiety in major depressive disorder;	chr11:89657226	chr11:90193614~90198120:+
BRCA	cis	rs10771431	0.81	rs10771418	ENSG00000214776.8	RP11-726G1.1	-3.89	0.000106	0.0066	-0.13	-0.12	Breast size;	chr12:9206399	chr12:9467552~9576275:+
BRCA	cis	rs2304003	1	rs12473573	ENSG00000235192.1	AC009495.2	3.89	0.000106	0.0066	0.14	0.12	Social communication problems;	chr2:165832382	chr2:165794851~165810010:+
BRCA	cis	rs801193	0.66	rs2659914	ENSG00000273448.1	RP11-166O4.6	3.89	0.000106	0.0066	0.11	0.12	Aortic root size;	chr7:66691927	chr7:67333047~67334383:+
BRCA	cis	rs801193	0.591	rs2707839	ENSG00000273448.1	RP11-166O4.6	3.89	0.000106	0.0066	0.11	0.12	Aortic root size;	chr7:66728097	chr7:67333047~67334383:+
BRCA	cis	rs4713118	0.629	rs203888	ENSG00000216901.1	AL022393.7	3.89	0.000106	0.0066	0.17	0.12	Parkinson's disease;	chr6:28053811	chr6:28176188~28176674:+
BRCA	cis	rs12122100	0.955	rs12142005	ENSG00000227242.3	NBPF13P	-3.89	0.000106	0.0066	-0.16	-0.12	HIV-1 control;	chr1:147035137	chr1:147021320~147124525:-
BRCA	cis	rs4699052	0.662	rs6828151	ENSG00000248740.4	RP11-328K4.1	3.89	0.000106	0.0066	0.13	0.12	Testicular germ cell tumor;	chr4:103363599	chr4:103256159~103453658:+
BRCA	cis	rs7120118	0.517	rs3758668	ENSG00000280615.1	Y_RNA	3.89	0.000106	0.00661	0.2	0.12	HDL cholesterol;	chr11:47249224	chr11:47614898~47614994:-
BRCA	cis	rs848490	0.962	rs55869229	ENSG00000214293.7	APTR	3.89	0.000106	0.00661	0.16	0.12	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77721148	chr7:77657660~77696265:-
BRCA	cis	rs7771547	0.519	rs6917489	ENSG00000224666.3	RP1-50J22.4	3.89	0.000106	0.00661	0.14	0.12	Platelet distribution width;	chr6:36400392	chr6:36386831~36393462:+
BRCA	cis	rs801193	0.935	rs11772264	ENSG00000265600.1	AC006480.1	-3.89	0.000106	0.00661	-0.14	-0.12	Aortic root size;	chr7:66711400	chr7:67356680~67356779:+
BRCA	cis	rs4415084	1	rs12187196	ENSG00000248779.1	RP11-53O19.2	3.89	0.000106	0.00661	0.11	0.12	Breast cancer;	chr5:44683717	chr5:44752949~44765744:+
BRCA	cis	rs8180040	0.726	rs4078466	ENSG00000276925.1	RP11-708J19.3	-3.89	0.000106	0.00661	-0.13	-0.12	Colorectal cancer;	chr3:47085053	chr3:47469777~47469987:+
BRCA	cis	rs875971	0.862	rs10256544	ENSG00000273024.4	INTS4P2	-3.89	0.000106	0.00661	-0.13	-0.12	Aortic root size;	chr7:66210141	chr7:65647864~65715661:+
BRCA	cis	rs6940638	0.513	rs4424065	ENSG00000124549.13	BTN2A3P	-3.89	0.000106	0.00661	-0.12	-0.12	Intelligence (multi-trait analysis);	chr6:27068677	chr6:26421391~26432383:+
BRCA	cis	rs6430585	0.878	rs9677760	ENSG00000231890.6	DARS-AS1	3.89	0.000106	0.00661	0.17	0.12	Corneal structure;	chr2:135781369	chr2:135985176~136022593:+
BRCA	cis	rs983392	1	rs11230147	ENSG00000275344.1	MIR6503	-3.89	0.000106	0.00661	-0.13	-0.12	Alzheimer's disease (late onset);	chr11:60109921	chr11:60209071~60209156:-
BRCA	cis	rs72827839	0.846	rs16953461	ENSG00000278765.1	RP5-890E16.5	3.89	0.000106	0.00661	0.18	0.12	Ease of getting up in the morning;	chr17:48184374	chr17:48066704~48067293:-
BRCA	cis	rs3739034	0.938	rs35220888	ENSG00000224043.6	CCNT2-AS1	-3.89	0.000106	0.00661	-0.24	-0.12	Gut microbiome composition (winter);	chr2:134722012	chr2:134735464~134918710:-
BRCA	cis	rs6988985	0.728	rs10093618	ENSG00000253741.1	CTD-2292P10.4	3.89	0.000106	0.00661	0.13	0.12	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;	chr8:142870798	chr8:142702252~142726973:-
BRCA	cis	rs9921338	0.924	rs72773831	ENSG00000262636.1	CTD-3088G3.4	-3.89	0.000106	0.00661	-0.19	-0.12	Vein graft stenosis in coronary artery bypass grafting;	chr16:11319070	chr16:11380859~11381118:-
BRCA	cis	rs6005807	0.582	rs8136767	ENSG00000272858.1	CTA-292E10.8	-3.89	0.000106	0.00661	-0.21	-0.12	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28612638	chr22:28814914~28815662:+
BRCA	cis	rs4499344	0.504	rs259248	ENSG00000267475.1	CTD-2538C1.2	3.89	0.000106	0.00661	0.16	0.12	Mean platelet volume;	chr19:32657135	chr19:32687089~32691750:-
BRCA	cis	rs73201462	1	rs2955082	ENSG00000242551.2	POU5F1P6	-3.89	0.000106	0.00661	-0.2	-0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128241491	chr3:128674735~128677005:-
BRCA	cis	rs73201462	1	rs2999073	ENSG00000242551.2	POU5F1P6	-3.89	0.000106	0.00661	-0.2	-0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128243486	chr3:128674735~128677005:-
BRCA	cis	rs73201462	1	rs2999071	ENSG00000242551.2	POU5F1P6	-3.89	0.000106	0.00661	-0.2	-0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128244772	chr3:128674735~128677005:-
BRCA	cis	rs73201462	1	rs2999070	ENSG00000242551.2	POU5F1P6	-3.89	0.000106	0.00661	-0.2	-0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128245808	chr3:128674735~128677005:-
BRCA	cis	rs6049003	0.622	rs6049048	ENSG00000232645.4	LINC01431	3.89	0.000106	0.00661	0.13	0.12	Cerebrospinal fluid biomarker levels;	chr20:23741682	chr20:23356594~23358116:-
BRCA	cis	rs8113308	0.81	rs55810059	ENSG00000269483.1	AC006272.1	3.89	0.000106	0.00661	0.21	0.12	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51947475	chr19:51839924~51843324:-
BRCA	cis	rs8113308	0.81	rs7255377	ENSG00000269483.1	AC006272.1	3.89	0.000106	0.00661	0.21	0.12	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51948085	chr19:51839924~51843324:-
BRCA	cis	rs8113308	0.81	rs7254930	ENSG00000269483.1	AC006272.1	3.89	0.000106	0.00661	0.21	0.12	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51948274	chr19:51839924~51843324:-
BRCA	cis	rs8180040	0.62	rs2305635	ENSG00000271161.1	BOLA2P2	-3.89	0.000106	0.00661	-0.13	-0.12	Colorectal cancer;	chr3:47002132	chr3:47499841~47500407:+
BRCA	cis	rs943466	1	rs12524835	ENSG00000223837.2	BRD2-IT1	3.89	0.000106	0.00661	0.15	0.12	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;	chr6:33763066	chr6:32970232~32970886:+
BRCA	cis	rs2688608	0.592	rs10762559	ENSG00000213731.2	RAB5CP1	-3.89	0.000106	0.00662	-0.13	-0.12	Inflammatory bowel disease;	chr10:73726695	chr10:74423435~74424014:-
BRCA	cis	rs12428035	0.764	rs816122	ENSG00000247400.3	DNAJC3-AS1	-3.89	0.000106	0.00662	-0.19	-0.12	Glomerular filtration rate (cystatin C);Response to statins (LDL cholesterol change);	chr13:96077340	chr13:95648733~95676925:-
BRCA	cis	rs6430585	0.527	rs1438303	ENSG00000224043.6	CCNT2-AS1	-3.89	0.000107	0.00662	-0.2	-0.12	Corneal structure;	chr2:135672287	chr2:134735464~134918710:-
BRCA	cis	rs4761702	1	rs4761701	ENSG00000257210.1	NACAP3	-3.89	0.000107	0.00662	-0.15	-0.12	Immature fraction of reticulocytes;	chr12:93315956	chr12:93124063~93124543:-
BRCA	cis	rs875971	0.638	rs35986979	ENSG00000265600.1	AC006480.1	3.89	0.000107	0.00662	0.14	0.12	Aortic root size;	chr7:66624003	chr7:67356680~67356779:+
BRCA	cis	rs4660456	0.576	rs2780948	ENSG00000238287.1	RP11-656D10.3	-3.89	0.000107	0.00662	-0.15	-0.12	Platelet count;	chr1:40776205	chr1:40493157~40508661:-
BRCA	cis	rs7620503	0.959	rs4857713	ENSG00000277241.1	RP11-114M1.3	3.89	0.000107	0.00662	0.13	0.12	Corneal structure;	chr3:177588654	chr3:177700346~177701072:-
BRCA	cis	rs11668609	0.935	rs10412575	ENSG00000268058.1	BNIP3P40	-3.89	0.000107	0.00662	-0.15	-0.12	Response to taxane treatment (docetaxel);	chr19:24186084	chr19:24098425~24098980:-
BRCA	cis	rs11742741	0.806	rs62349718	ENSG00000248874.4	C5orf17	-3.89	0.000107	0.00662	-0.15	-0.12	Educational attainment;	chr5:24046398	chr5:23951348~24178263:+
BRCA	cis	rs853679	0.517	rs9368555	ENSG00000261839.1	RP1-265C24.8	3.89	0.000107	0.00662	0.17	0.12	Depression;	chr6:28141189	chr6:28136849~28139678:+
BRCA	cis	rs853679	0.517	rs9393893	ENSG00000261839.1	RP1-265C24.8	3.89	0.000107	0.00662	0.17	0.12	Depression;	chr6:28141484	chr6:28136849~28139678:+
BRCA	cis	rs3816183	0.958	rs4952939	ENSG00000226491.1	FTOP1	-3.89	0.000107	0.00662	-0.15	-0.12	Hypospadias;	chr2:42798067	chr2:42797225~42798712:-
BRCA	cis	rs9307551	0.741	rs11936123	ENSG00000250334.4	LINC00989	-3.89	0.000107	0.00662	-0.19	-0.12	Refractive error;	chr4:79506113	chr4:79492416~79576460:+
BRCA	cis	rs4386084	1	rs12905434	ENSG00000244879.4	GABPB1-AS1	3.89	0.000107	0.00662	0.14	0.12	Basophil percentage of granulocytes;Basophil percentage of white cells;	chr15:49939630	chr15:50354959~50372202:+
BRCA	cis	rs853679	0.517	rs12332979	ENSG00000261839.1	RP1-265C24.8	3.89	0.000107	0.00662	0.17	0.12	Depression;	chr6:28173770	chr6:28136849~28139678:+
BRCA	cis	rs853679	0.517	rs67878650	ENSG00000261839.1	RP1-265C24.8	3.89	0.000107	0.00662	0.17	0.12	Depression;	chr6:28174809	chr6:28136849~28139678:+
BRCA	cis	rs853679	0.569	rs9348798	ENSG00000261839.1	RP1-265C24.8	3.89	0.000107	0.00662	0.17	0.12	Depression;	chr6:28175233	chr6:28136849~28139678:+
BRCA	cis	rs853679	0.517	rs9380065	ENSG00000261839.1	RP1-265C24.8	3.89	0.000107	0.00662	0.17	0.12	Depression;	chr6:28176973	chr6:28136849~28139678:+
BRCA	cis	rs6431644	0.694	rs637082	ENSG00000224287.2	MSL3P1	3.89	0.000107	0.00662	0.14	0.12	Left atrial antero-posterior diameter;	chr2:233847100	chr2:233865437~233868444:-
BRCA	cis	rs4561483	0.832	rs171656	ENSG00000261216.1	RP11-166B2.5	-3.89	0.000107	0.00662	-0.14	-0.12	Testicular germ cell tumor;	chr16:11859310	chr16:11908208~11908916:+
BRCA	cis	rs250518	0.708	rs258893	ENSG00000271926.1	CTD-2376I4.1	3.89	0.000107	0.00662	0.15	0.12	Mean corpuscular hemoglobin concentration;	chr5:73009376	chr5:72953635~72954274:-
BRCA	cis	rs2731006	0.592	rs908657	ENSG00000257114.2	RP11-25I15.3	-3.89	0.000107	0.00662	-0.19	-0.12	Panic disorder;	chr12:42774843	chr12:42692216~42717119:+
BRCA	cis	rs1005277	0.522	rs7090858	ENSG00000273019.1	RP11-508N22.13	3.89	0.000107	0.00662	0.14	0.12	Extrinsic epigenetic age acceleration;	chr10:37714742	chr10:38149968~38150293:+
BRCA	cis	rs10029851	0.704	rs1436506	ENSG00000234492.4	RPL34-AS1	3.89	0.000107	0.00663	0.14	0.12	Amyotrophic lateral sclerosis (sporadic);	chr4:108709795	chr4:108538190~108620460:-
BRCA	cis	rs3824867	0.92	rs7130693	ENSG00000280615.1	Y_RNA	3.89	0.000107	0.00663	0.15	0.12	Mean corpuscular hemoglobin;	chr11:47430770	chr11:47614898~47614994:-
BRCA	cis	rs3824867	0.92	rs7107853	ENSG00000280615.1	Y_RNA	3.89	0.000107	0.00663	0.15	0.12	Mean corpuscular hemoglobin;	chr11:47431967	chr11:47614898~47614994:-
BRCA	cis	rs2880765	0.546	rs11639291	ENSG00000202081.1	RNU6-1280P	3.89	0.000107	0.00663	0.15	0.12	Coronary artery disease;	chr15:85520899	chr15:85651522~85651628:-
BRCA	cis	rs875971	0.862	rs6955837	ENSG00000273024.4	INTS4P2	3.89	0.000107	0.00663	0.13	0.12	Aortic root size;	chr7:66578155	chr7:65647864~65715661:+
BRCA	cis	rs11048434	0.518	rs1805707	ENSG00000256069.6	A2MP1	-3.89	0.000107	0.00663	-0.13	-0.12	Sjögren's syndrome;	chr12:9029110	chr12:9228533~9275817:-
BRCA	cis	rs6928977	0.5	rs6570022	ENSG00000234084.1	RP3-388E23.2	-3.89	0.000107	0.00663	-0.12	-0.12	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135627683	chr6:135301568~135307158:+
BRCA	cis	rs13126694	0.65	rs6536287	ENSG00000251429.1	RP11-597D13.7	-3.89	0.000107	0.00663	-0.11	-0.12	Blood osmolality (transformed sodium);	chr4:157921400	chr4:158270378~158278676:+
BRCA	cis	rs793571	0.822	rs11637077	ENSG00000259250.1	RP11-50C13.1	-3.89	0.000107	0.00663	-0.18	-0.12	Schizophrenia;	chr15:58906197	chr15:58587507~58591676:+
BRCA	cis	rs990171	0.538	rs11690932	ENSG00000234389.1	AC007278.3	3.89	0.000107	0.00663	0.12	0.12	Lymphocyte counts;	chr2:102502570	chr2:102438713~102440475:+
BRCA	cis	rs1437396	0.657	rs2589075	ENSG00000203327.2	AC012358.7	3.89	0.000107	0.00663	0.12	0.12	Alcohol dependence;	chr2:55342008	chr2:55214387~55216126:-
BRCA	cis	rs10129255	0.957	rs10142859	ENSG00000211967.3	IGHV3-53	-3.89	0.000107	0.00663	-0.09	-0.12	Kawasaki disease;	chr14:106782238	chr14:106592676~106593347:-
BRCA	cis	rs7824557	1	rs2736371	ENSG00000255046.1	RP11-297N6.4	3.89	0.000107	0.00663	0.15	0.12	Retinal vascular caliber;	chr8:11248020	chr8:11797928~11802568:-
BRCA	cis	rs11239930	0.517	rs492243	ENSG00000237188.3	RP11-337C18.8	3.89	0.000107	0.00663	0.14	0.12	AIDS progression;	chr1:147077930	chr1:147172771~147211568:+
BRCA	cis	rs10510102	0.516	rs10437506	ENSG00000226864.1	ATE1-AS1	3.89	0.000107	0.00663	0.24	0.12	Breast cancer;	chr10:121984011	chr10:121928312~121951965:+
BRCA	cis	rs10510102	0.516	rs74461504	ENSG00000226864.1	ATE1-AS1	3.89	0.000107	0.00663	0.24	0.12	Breast cancer;	chr10:121986077	chr10:121928312~121951965:+
BRCA	cis	rs9325144	0.56	rs10785562	ENSG00000257718.1	RP11-396F22.1	-3.89	0.000107	0.00663	-0.12	-0.12	Morning vs. evening chronotype;	chr12:38243617	chr12:38906451~38909592:+
BRCA	cis	rs1722141	0.535	rs788773	ENSG00000237471.1	AC073115.6	3.89	0.000107	0.00663	0.16	0.12	Sitting height ratio;	chr7:46012657	chr7:45969657~45980191:+
BRCA	cis	rs683250	0.598	rs647200	ENSG00000254551.1	RP11-727A23.7	3.89	0.000107	0.00664	0.15	0.12	Subcortical brain region volumes;	chr11:83267482	chr11:83209431~83213379:-
BRCA	cis	rs9733	0.744	rs3754211	ENSG00000203804.4	ADAMTSL4-AS1	3.89	0.000107	0.00664	0.12	0.12	Tonsillectomy;	chr1:150979381	chr1:150560202~150574552:-
BRCA	cis	rs1478897	0.575	rs12679960	ENSG00000154316.13	TDH	-3.89	0.000107	0.00664	-0.17	-0.12	Systemic lupus erythematosus;	chr8:11573481	chr8:11339637~11368452:+
BRCA	cis	rs754466	0.58	rs11002294	ENSG00000213514.2	RP11-428P16.2	3.89	0.000107	0.00664	0.17	0.12	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77780830	chr10:77730766~77734769:+
BRCA	cis	rs12289961	0.681	rs11229315	ENSG00000265566.2	RN7SL605P	3.89	0.000107	0.00664	0.2	0.12	Lymphoma;	chr11:58252632	chr11:57528085~57528365:-
BRCA	cis	rs2486012	1	rs3011231	ENSG00000237950.1	RP11-7O11.3	3.89	0.000107	0.00664	0.22	0.12	Intelligence (multi-trait analysis);	chr1:43876563	chr1:43944370~43946551:-
BRCA	cis	rs8130944	1	rs7281934	ENSG00000225731.1	AP001627.1	3.89	0.000107	0.00664	0.14	0.12	Perceived unattractiveness to mosquitoes;	chr21:42721837	chr21:42733594~42741758:-
BRCA	cis	rs9392653	1	rs9392653	ENSG00000220685.3	RP11-530A18.1	-3.89	0.000107	0.00664	-0.17	-0.12	Venous thromboembolism (SNP x SNP interaction);	chr6:5071258	chr6:5065795~5066982:-
BRCA	cis	rs2109514	0.967	rs10271007	ENSG00000237813.3	AC002066.1	3.89	0.000107	0.00664	0.14	0.12	Prevalent atrial fibrillation;	chr7:116505795	chr7:116238260~116499465:-
BRCA	cis	rs2109514	0.967	rs4730743	ENSG00000237813.3	AC002066.1	3.89	0.000107	0.00664	0.14	0.12	Prevalent atrial fibrillation;	chr7:116505903	chr7:116238260~116499465:-
BRCA	cis	rs1124769	0.57	rs1290084	ENSG00000273674.3	CTD-2378E12.1	-3.89	0.000107	0.00664	-0.15	-0.12	Cognitive performance;	chr15:50861748	chr15:50839875~50908599:-
BRCA	cis	rs2302465	0.86	rs73239189	ENSG00000273133.1	RP11-799M12.2	-3.89	0.000107	0.00664	-0.24	-0.12	Blood protein levels;	chr4:15619187	chr4:15563698~15564253:-
BRCA	cis	rs875971	0.66	rs801193	ENSG00000272831.1	RP11-792A8.4	-3.89	0.000107	0.00665	-0.11	-0.12	Aortic root size;	chr7:66565625	chr7:66739829~66740385:-
BRCA	cis	rs875971	0.597	rs11763224	ENSG00000273448.1	RP11-166O4.6	3.89	0.000107	0.00665	0.12	0.12	Aortic root size;	chr7:66518628	chr7:67333047~67334383:+
BRCA	cis	rs375066	0.935	rs384522	ENSG00000267191.1	RP11-15A1.2	-3.89	0.000107	0.00665	-0.15	-0.12	Breast cancer;	chr19:43900892	chr19:43902001~43926545:+
BRCA	cis	rs13217239	0.572	rs9379958	ENSG00000124549.13	BTN2A3P	-3.89	0.000107	0.00665	-0.12	-0.12	Schizophrenia;	chr6:27098384	chr6:26421391~26432383:+
BRCA	cis	rs728616	0.867	rs12412257	ENSG00000242600.5	MBL1P	3.89	0.000107	0.00665	0.29	0.12	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79969847	chr10:79904898~79950336:+
BRCA	cis	rs891378	0.883	rs6671700	ENSG00000274245.1	RP11-357P18.2	-3.89	0.000107	0.00665	-0.16	-0.12	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207316614	chr1:207372559~207373252:+
BRCA	cis	rs9467773	0.62	rs2504592	ENSG00000224843.5	LINC00240	-3.89	0.000107	0.00665	-0.13	-0.12	Intelligence (multi-trait analysis);	chr6:26640723	chr6:26956992~27023924:+
BRCA	cis	rs6504622	0.755	rs11653838	ENSG00000263142.4	LRRC37A17P	-3.89	0.000107	0.00665	-0.1	-0.12	Orofacial clefts;	chr17:47006317	chr17:46978481~47054569:+
BRCA	cis	rs2625529	0.824	rs4411469	ENSG00000260037.4	CTD-2524L6.3	-3.89	0.000107	0.00665	-0.17	-0.12	Red blood cell count;	chr15:72129348	chr15:71818396~71823384:+
BRCA	cis	rs6005807	0.843	rs9306457	ENSG00000272858.1	CTA-292E10.8	-3.89	0.000107	0.00665	-0.23	-0.12	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28502139	chr22:28814914~28815662:+
BRCA	cis	rs2071426	0.622	rs7899038	ENSG00000273450.1	RP11-76P2.4	3.89	0.000107	0.00665	0.15	0.12	Blood metabolite levels;	chr10:95012655	chr10:94314907~94315327:-
BRCA	cis	rs11637445	0.603	rs7183168	ENSG00000260657.2	RP11-315D16.4	-3.89	0.000107	0.00665	-0.15	-0.12	Posterior cortical atrophy and Alzheimer's disease;	chr15:67829145	chr15:68267792~68277994:-
BRCA	cis	rs7932354	0.583	rs11039014	ENSG00000200376.1	RNU5E-10P	3.89	0.000107	0.00665	0.15	0.12	Bone mineral density (hip);Bone mineral density;	chr11:46873827	chr11:47576471~47576588:-
BRCA	cis	rs7267979	0.966	rs8123949	ENSG00000276952.1	RP5-965G21.6	-3.89	0.000107	0.00666	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25407497	chr20:25284915~25285588:-
BRCA	cis	rs7267979	1	rs2184000	ENSG00000276952.1	RP5-965G21.6	-3.89	0.000107	0.00666	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25415242	chr20:25284915~25285588:-
BRCA	cis	rs6067053	0.533	rs6067019	ENSG00000222365.1	SNORD12B	3.89	0.000107	0.00666	0.13	0.12	Intelligence (multi-trait analysis);	chr20:49211989	chr20:49280319~49280409:+
BRCA	cis	rs73195822	0.614	rs17793540	ENSG00000277299.1	RP11-837J7.4	-3.89	0.000107	0.00666	-0.2	-0.12	Itch intensity from mosquito bite;	chr12:110777770	chr12:109948389~109949029:+
BRCA	cis	rs801193	1	rs2659912	ENSG00000265600.1	AC006480.1	-3.89	0.000107	0.00666	-0.14	-0.12	Aortic root size;	chr7:66693012	chr7:67356680~67356779:+
BRCA	cis	rs372883	0.935	rs10460703	ENSG00000176054.6	RPL23P2	-3.89	0.000107	0.00666	-0.12	-0.12	Pancreatic cancer;	chr21:29250788	chr21:28997613~28998033:-
BRCA	cis	rs1048886	0.872	rs6916974	ENSG00000271967.1	RP11-134K13.4	-3.89	0.000107	0.00666	-0.17	-0.12	Type 2 diabetes;	chr6:70564254	chr6:70596438~70596980:+
BRCA	cis	rs12210905	1	rs9393796	ENSG00000216901.1	AL022393.7	3.89	0.000107	0.00666	0.22	0.12	Hip circumference adjusted for BMI;	chr6:27259186	chr6:28176188~28176674:+
BRCA	cis	rs12210905	1	rs9379965	ENSG00000216901.1	AL022393.7	3.89	0.000107	0.00666	0.22	0.12	Hip circumference adjusted for BMI;	chr6:27259282	chr6:28176188~28176674:+
BRCA	cis	rs7520050	0.966	rs6701614	ENSG00000234329.1	RP11-767N6.2	-3.89	0.000107	0.00666	-0.11	-0.12	Reticulocyte count;Red blood cell count;	chr1:45843748	chr1:45651039~45651826:-
BRCA	cis	rs10005067	0.967	rs12505719	ENSG00000249001.4	RP11-742B18.1	-3.89	0.000107	0.00666	-0.14	-0.12	Total body bone mineral density (age 30-45);	chr4:87900922	chr4:87568035~87733956:-
BRCA	cis	rs8098244	0.557	rs4347707	ENSG00000265752.2	RP11-403A21.1	3.89	0.000107	0.00666	0.13	0.12	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23710362	chr18:23957754~23982556:-
BRCA	cis	rs375066	0.935	rs398964	ENSG00000267191.1	RP11-15A1.2	-3.89	0.000107	0.00666	-0.15	-0.12	Breast cancer;	chr19:43909732	chr19:43902001~43926545:+
BRCA	cis	rs62244186	0.52	rs9311361	ENSG00000233509.2	ZNF197-AS1	3.89	0.000107	0.00666	0.15	0.12	Depressive symptoms;	chr3:44754640	chr3:44617128~44624797:-
BRCA	cis	rs7267979	0.565	rs958075	ENSG00000204556.4	CTD-2514C3.1	3.89	0.000107	0.00666	0.16	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25614487	chr20:26018832~26020684:+
BRCA	cis	rs6064559	0.687	rs4811876	ENSG00000218018.2	RP4-800J21.3	-3.89	0.000107	0.00666	-0.1	-0.12	Hemoglobin concentration;	chr20:57548744	chr20:57384160~57393062:-
BRCA	cis	rs6064559	0.664	rs4811878	ENSG00000218018.2	RP4-800J21.3	-3.89	0.000107	0.00666	-0.1	-0.12	Hemoglobin concentration;	chr20:57548807	chr20:57384160~57393062:-
BRCA	cis	rs67696533	0.6	rs6141745	ENSG00000277692.1	RP11-358N2.2	-3.89	0.000107	0.00667	-0.15	-0.12	White blood cell count (basophil);Basophil percentage of granulocytes;Basophil percentage of white cells;	chr20:32521002	chr20:32355053~32355734:+
BRCA	cis	rs2625529	0.73	rs12908882	ENSG00000260037.4	CTD-2524L6.3	-3.89	0.000107	0.00667	-0.17	-0.12	Red blood cell count;	chr15:72145231	chr15:71818396~71823384:+
BRCA	cis	rs4718428	1	rs4718428	ENSG00000222364.1	RNU6-96P	-3.89	0.000107	0.00667	-0.14	-0.12	Corneal structure;	chr7:66956459	chr7:66395191~66395286:+
BRCA	cis	rs6831352	0.589	rs1133483	ENSG00000272777.1	RP11-571L19.8	-3.89	0.000107	0.00667	-0.12	-0.12	Alcohol dependence;	chr4:99102772	chr4:99067256~99068125:-
BRCA	cis	rs10457838	0.568	rs4897080	ENSG00000231760.4	RP11-350J20.5	3.89	0.000108	0.00667	0.18	0.12	Post-traumatic stress disorder;	chr6:149102092	chr6:149796151~149826294:-
BRCA	cis	rs1910358	0.959	rs6452172	ENSG00000248874.4	C5orf17	-3.89	0.000108	0.00667	-0.18	-0.12	Venous thromboembolism (SNP x SNP interaction);	chr5:23911876	chr5:23951348~24178263:+
BRCA	cis	rs9470794	0.915	rs73419451	ENSG00000204110.6	RP1-153P14.8	-3.89	0.000108	0.00667	-0.24	-0.12	Type 2 diabetes;	chr6:37897289	chr6:37507348~37535616:+
BRCA	cis	rs7267979	1	rs7268053	ENSG00000274414.1	RP5-965G21.4	3.89	0.000108	0.00667	0.14	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25347650	chr20:25239007~25245229:-
BRCA	cis	rs7267979	1	rs6083809	ENSG00000274414.1	RP5-965G21.4	3.89	0.000108	0.00667	0.14	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25348673	chr20:25239007~25245229:-
BRCA	cis	rs9818758	0.607	rs9837237	ENSG00000225399.4	RP11-3B7.1	-3.89	0.000108	0.00667	-0.19	-0.12	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49178150	chr3:49260085~49261316:+
BRCA	cis	rs12303914	0.762	rs2617146	ENSG00000256682.2	TAS2R12	-3.89	0.000108	0.00667	-0.14	-0.12	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr12:10314370	chr12:10894943~10896952:-
BRCA	cis	rs375066	0.901	rs372491	ENSG00000267191.1	RP11-15A1.2	-3.89	0.000108	0.00667	-0.15	-0.12	Breast cancer;	chr19:43897641	chr19:43902001~43926545:+
BRCA	cis	rs375066	0.868	rs453950	ENSG00000267191.1	RP11-15A1.2	-3.89	0.000108	0.00667	-0.15	-0.12	Breast cancer;	chr19:43898903	chr19:43902001~43926545:+
BRCA	cis	rs375066	0.934	rs440784	ENSG00000267191.1	RP11-15A1.2	-3.89	0.000108	0.00667	-0.15	-0.12	Breast cancer;	chr19:43900190	chr19:43902001~43926545:+
BRCA	cis	rs375066	0.901	rs374307	ENSG00000267191.1	RP11-15A1.2	-3.89	0.000108	0.00667	-0.15	-0.12	Breast cancer;	chr19:43900246	chr19:43902001~43926545:+
BRCA	cis	rs375066	0.967	rs441344	ENSG00000267191.1	RP11-15A1.2	-3.89	0.000108	0.00667	-0.15	-0.12	Breast cancer;	chr19:43900530	chr19:43902001~43926545:+
BRCA	cis	rs375066	0.935	rs398099	ENSG00000267191.1	RP11-15A1.2	-3.89	0.000108	0.00667	-0.15	-0.12	Breast cancer;	chr19:43901129	chr19:43902001~43926545:+
BRCA	cis	rs375066	0.935	rs385321	ENSG00000267191.1	RP11-15A1.2	-3.89	0.000108	0.00667	-0.15	-0.12	Breast cancer;	chr19:43901135	chr19:43902001~43926545:+
BRCA	cis	rs375066	0.967	rs376328	ENSG00000267191.1	RP11-15A1.2	-3.89	0.000108	0.00667	-0.15	-0.12	Breast cancer;	chr19:43903335	chr19:43902001~43926545:+
BRCA	cis	rs375066	0.935	rs365556	ENSG00000267191.1	RP11-15A1.2	-3.89	0.000108	0.00667	-0.15	-0.12	Breast cancer;	chr19:43904047	chr19:43902001~43926545:+
BRCA	cis	rs375066	0.901	rs451945	ENSG00000267191.1	RP11-15A1.2	-3.89	0.000108	0.00667	-0.15	-0.12	Breast cancer;	chr19:43904601	chr19:43902001~43926545:+
BRCA	cis	rs375066	0.934	rs454813	ENSG00000267191.1	RP11-15A1.2	-3.89	0.000108	0.00667	-0.15	-0.12	Breast cancer;	chr19:43904821	chr19:43902001~43926545:+
BRCA	cis	rs375066	0.967	rs417400	ENSG00000267191.1	RP11-15A1.2	-3.89	0.000108	0.00667	-0.15	-0.12	Breast cancer;	chr19:43906694	chr19:43902001~43926545:+
BRCA	cis	rs375066	0.901	rs376457	ENSG00000267191.1	RP11-15A1.2	-3.89	0.000108	0.00667	-0.15	-0.12	Breast cancer;	chr19:43908605	chr19:43902001~43926545:+
BRCA	cis	rs375066	0.935	rs430667	ENSG00000267191.1	RP11-15A1.2	-3.89	0.000108	0.00667	-0.15	-0.12	Breast cancer;	chr19:43909101	chr19:43902001~43926545:+
BRCA	cis	rs375066	0.935	rs439665	ENSG00000267191.1	RP11-15A1.2	-3.89	0.000108	0.00667	-0.15	-0.12	Breast cancer;	chr19:43910315	chr19:43902001~43926545:+
BRCA	cis	rs1730008	1	rs699918	ENSG00000279311.1	RP11-170K4.2	-3.89	0.000108	0.00667	-0.14	-0.12	Lobe attachment (rater-scored or self-reported);	chr3:158240215	chr3:158869898~158871821:+
BRCA	cis	rs1730008	1	rs827170	ENSG00000279311.1	RP11-170K4.2	-3.89	0.000108	0.00667	-0.14	-0.12	Lobe attachment (rater-scored or self-reported);	chr3:158240282	chr3:158869898~158871821:+
BRCA	cis	rs6840360	0.806	rs11932383	ENSG00000278978.1	RP11-164P12.5	3.89	0.000108	0.00667	0.13	0.12	Intelligence (multi-trait analysis);	chr4:151794984	chr4:151669786~151670503:+
BRCA	cis	rs4713118	0.662	rs175954	ENSG00000216901.1	AL022393.7	3.89	0.000108	0.00668	0.17	0.12	Parkinson's disease;	chr6:28043807	chr6:28176188~28176674:+
BRCA	cis	rs3739034	0.823	rs17321713	ENSG00000224043.6	CCNT2-AS1	-3.89	0.000108	0.00668	-0.24	-0.12	Gut microbiome composition (winter);	chr2:134722793	chr2:134735464~134918710:-
BRCA	cis	rs7520050	0.931	rs6697557	ENSG00000234329.1	RP11-767N6.2	-3.89	0.000108	0.00668	-0.11	-0.12	Reticulocyte count;Red blood cell count;	chr1:45842137	chr1:45651039~45651826:-
BRCA	cis	rs2991971	0.967	rs12133294	ENSG00000280836.1	AL355480.1	3.89	0.000108	0.00668	0.14	0.12	High light scatter reticulocyte count;	chr1:45523092	chr1:45581219~45581321:-
BRCA	cis	rs16944613	0.588	rs6496698	ENSG00000271396.1	RP11-697E2.9	-3.89	0.000108	0.00668	-0.2	-0.12	Colorectal cancer;	chr15:90592326	chr15:90284376~90285580:-
BRCA	cis	rs853679	0.766	rs9368561	ENSG00000204709.4	LINC01556	3.89	0.000108	0.00668	0.25	0.12	Depression;	chr6:28200565	chr6:28943877~28944537:+
BRCA	cis	rs8035452	1	rs12900658	ENSG00000273674.3	CTD-2378E12.1	-3.89	0.000108	0.00668	-0.13	-0.12	Alzheimer's disease (late onset);	chr15:50724167	chr15:50839875~50908599:-
BRCA	cis	rs34792	0.525	rs12708795	ENSG00000260872.1	RP11-680G24.5	-3.89	0.000108	0.00668	-0.13	-0.12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15533861	chr16:15018106~15020488:-
BRCA	cis	rs983392	0.755	rs569046	ENSG00000275344.1	MIR6503	-3.89	0.000108	0.00669	-0.12	-0.12	Alzheimer's disease (late onset);	chr11:60143688	chr11:60209071~60209156:-
BRCA	cis	rs6585424	1	rs34162901	ENSG00000225484.5	NUTM2B-AS1	-3.89	0.000108	0.00669	-0.25	-0.12	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80187100	chr10:79663088~79826594:-
BRCA	cis	rs6585424	1	rs61860045	ENSG00000225484.5	NUTM2B-AS1	-3.89	0.000108	0.00669	-0.25	-0.12	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80187641	chr10:79663088~79826594:-
BRCA	cis	rs17270561	0.609	rs9358887	ENSG00000272462.2	U91328.19	-3.89	0.000108	0.00669	-0.15	-0.12	Iron status biomarkers;	chr6:25759178	chr6:25992662~26001775:+
BRCA	cis	rs4664293	1	rs10184034	ENSG00000226266.5	AC009961.3	-3.89	0.000108	0.00669	-0.15	-0.12	Monocyte percentage of white cells;	chr2:159648916	chr2:159670708~159712435:-
BRCA	cis	rs4664293	1	rs4664293	ENSG00000226266.5	AC009961.3	-3.89	0.000108	0.00669	-0.15	-0.12	Monocyte percentage of white cells;	chr2:159649241	chr2:159670708~159712435:-
BRCA	cis	rs4664293	1	rs10193402	ENSG00000226266.5	AC009961.3	-3.89	0.000108	0.00669	-0.15	-0.12	Monocyte percentage of white cells;	chr2:159651271	chr2:159670708~159712435:-
BRCA	cis	rs516805	0.633	rs9490414	ENSG00000279114.1	RP3-425C14.5	3.89	0.000108	0.00669	0.15	0.12	Lymphocyte counts;	chr6:122245612	chr6:122471923~122484161:+
BRCA	cis	rs17428076	0.834	rs6749895	ENSG00000228389.1	AC068039.4	-3.89	0.000108	0.00669	-0.18	-0.12	Myopia;	chr2:172010535	chr2:171773482~171775844:+
BRCA	cis	rs2836974	0.544	rs8128919	ENSG00000255568.3	BRWD1-AS2	3.89	0.000108	0.00669	0.11	0.12	Cognitive function;	chr21:39339936	chr21:39313935~39314962:+
BRCA	cis	rs6964587	1	rs2237568	ENSG00000188693.7	CYP51A1-AS1	-3.89	0.000108	0.00669	-0.13	-0.12	Breast cancer;	chr7:91993362	chr7:92134604~92180725:+
BRCA	cis	rs3796352	1	rs11707780	ENSG00000242142.1	SERBP1P3	3.89	0.000108	0.00669	0.19	0.12	Immune reponse to smallpox (secreted IL-2);	chr3:53050310	chr3:53064283~53065091:-
BRCA	cis	rs10028773	0.7	rs7671797	ENSG00000260091.1	RP11-33B1.4	-3.89	0.000108	0.00669	-0.1	-0.12	Educational attainment;	chr4:119327002	chr4:119409333~119410233:+
BRCA	cis	rs4538475	0.559	rs73243132	ENSG00000273133.1	RP11-799M12.2	-3.89	0.000108	0.00669	-0.24	-0.12	Parkinson's disease;	chr4:15679000	chr4:15563698~15564253:-
BRCA	cis	rs4538475	0.559	rs73243135	ENSG00000273133.1	RP11-799M12.2	-3.89	0.000108	0.00669	-0.24	-0.12	Parkinson's disease;	chr4:15680842	chr4:15563698~15564253:-
BRCA	cis	rs6012564	1	rs2295714	ENSG00000222365.1	SNORD12B	3.89	0.000108	0.00669	0.12	0.12	Anger;	chr20:49123277	chr20:49280319~49280409:+
BRCA	cis	rs6479874	1	rs2339683	ENSG00000223502.1	RP11-96B5.3	-3.89	0.000108	0.0067	-0.23	-0.12	Migraine;	chr10:51026658	chr10:51062579~51068553:-
BRCA	cis	rs11168618	0.74	rs11495433	ENSG00000240399.1	RP1-228P16.1	3.89	0.000108	0.0067	0.13	0.12	Adiponectin levels;	chr12:48535289	chr12:48054813~48055591:-
BRCA	cis	rs300890	0.651	rs300914	ENSG00000250326.1	RP11-284M14.1	-3.89	0.000108	0.0067	-0.14	-0.12	Nasopharyngeal carcinoma;	chr4:143353195	chr4:142933195~143184861:-
BRCA	cis	rs4578769	0.879	rs7244549	ENSG00000273232.1	RP11-370A5.2	3.89	0.000108	0.0067	0.16	0.12	Eosinophil percentage of white cells;	chr18:22866052	chr18:22882825~22883357:-
BRCA	cis	rs73222236	0.825	rs6439638	ENSG00000239213.4	NCK1-AS1	3.89	0.000108	0.0067	0.13	0.12	Coronary artery disease;	chr3:136338990	chr3:136841726~136862054:-
BRCA	cis	rs490234	0.871	rs13288032	ENSG00000232630.1	PRPS1P2	-3.89	0.000108	0.0067	-0.12	-0.12	Mean arterial pressure;	chr9:125493303	chr9:125150653~125151589:+
BRCA	cis	rs7267979	1	rs7343481	ENSG00000277938.1	RP5-965G21.3	-3.89	0.000108	0.0067	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25319477	chr20:25229150~25231933:+
BRCA	cis	rs11098499	0.913	rs68128210	ENSG00000225892.3	RP11-384K6.2	3.89	0.000108	0.0067	0.13	0.12	Corneal astigmatism;	chr4:119216664	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.913	rs13126596	ENSG00000225892.3	RP11-384K6.2	3.89	0.000108	0.0067	0.13	0.12	Corneal astigmatism;	chr4:119219574	chr4:118632274~118634759:+
BRCA	cis	rs2835345	0.563	rs12482423	ENSG00000233818.1	AP000695.4	3.89	0.000108	0.0067	0.13	0.12	Pulmonary function;	chr21:36448662	chr21:36445731~36532408:+
BRCA	cis	rs2274459	1	rs2296749	ENSG00000249346.5	LINC01016	3.89	0.000108	0.0067	0.16	0.12	Obesity (extreme);	chr6:33795350	chr6:33867506~33896914:-
BRCA	cis	rs1008375	0.863	rs7680984	ENSG00000249502.1	AC006160.5	-3.89	0.000108	0.0067	-0.14	-0.12	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17599261	chr4:17587467~17614571:-
BRCA	cis	rs2998286	0.637	rs332113	ENSG00000237128.1	RP11-351M16.3	3.89	0.000108	0.0067	0.15	0.12	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28634806	chr10:28433008~28495813:-
BRCA	cis	rs7592578	0.639	rs13417431	ENSG00000272979.1	RP11-647K16.1	-3.89	0.000108	0.0067	-0.19	-0.12	Diastolic blood pressure;	chr2:190428329	chr2:190454092~190454521:-
BRCA	cis	rs7011507	0.535	rs16937767	ENSG00000233858.4	AC026904.1	-3.89	0.000108	0.0067	-0.15	-0.12	Inflammatory bowel disease;Ulcerative colitis;	chr8:48544972	chr8:48590401~48594621:+
BRCA	cis	rs4819052	0.851	rs2838834	ENSG00000223768.1	LINC00205	-3.89	0.000108	0.0067	-0.16	-0.12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245293	chr21:45293285~45297354:+
BRCA	cis	rs6439699	0.941	rs16844702	ENSG00000239213.4	NCK1-AS1	3.89	0.000108	0.00671	0.16	0.12	Intelligence (multi-trait analysis);	chr3:137326858	chr3:136841726~136862054:-
BRCA	cis	rs1396626	0.89	rs876394	ENSG00000235501.4	RP4-639F20.1	-3.89	0.000108	0.00671	-0.16	-0.12	Diabetic kidney disease;	chr1:95516784	chr1:94927566~94963270:+
BRCA	cis	rs7267979	0.966	rs2261747	ENSG00000276952.1	RP5-965G21.6	3.89	0.000108	0.00671	0.15	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25281148	chr20:25284915~25285588:-
BRCA	cis	rs2041840	0.924	rs759461	ENSG00000272054.1	RP11-423P10.2	-3.89	0.000108	0.00671	-0.11	-0.12	Chronic lymphocytic leukemia;	chr2:37246512	chr2:37208875~37212677:+
BRCA	cis	rs2880765	0.743	rs8028240	ENSG00000202081.1	RNU6-1280P	3.89	0.000108	0.00671	0.14	0.12	Coronary artery disease;	chr15:85470017	chr15:85651522~85651628:-
BRCA	cis	rs1479090	0.762	rs6536705	ENSG00000250027.1	RP11-563E2.2	-3.89	0.000108	0.00671	-0.16	-0.12	Lung cancer;	chr4:163164619	chr4:163108785~163119965:+
BRCA	cis	rs9308731	0.568	rs28723045	ENSG00000230499.1	AC108463.1	-3.89	0.000108	0.00671	-0.14	-0.12	Chronic lymphocytic leukemia;	chr2:111178121	chr2:111195963~111206494:+
BRCA	cis	rs11009175	0.929	rs72786108	ENSG00000273038.2	RP11-479G22.8	-3.89	0.000108	0.00671	-0.22	-0.12	Depression (quantitative trait);	chr10:33059085	chr10:32887255~32889311:-
BRCA	cis	rs75422866	0.867	rs73113139	ENSG00000276691.1	RP5-1057I20.5	3.89	0.000108	0.00671	0.25	0.12	Pneumonia;	chr12:47622826	chr12:47788426~47788971:+
BRCA	cis	rs6431644	0.694	rs2302156	ENSG00000224287.2	MSL3P1	3.89	0.000108	0.00671	0.15	0.12	Left atrial antero-posterior diameter;	chr2:233845627	chr2:233865437~233868444:-
BRCA	cis	rs8062405	0.755	rs62031607	ENSG00000261766.1	RP11-22P6.2	-3.89	0.000108	0.00671	-0.12	-0.12	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620209	chr16:28862166~28863340:-
BRCA	cis	rs17428076	0.918	rs55864623	ENSG00000228389.1	AC068039.4	-3.89	0.000108	0.00671	-0.18	-0.12	Myopia;	chr2:171892180	chr2:171773482~171775844:+
BRCA	cis	rs17270561	0.609	rs9379783	ENSG00000272462.2	U91328.19	-3.89	0.000108	0.00671	-0.15	-0.12	Iron status biomarkers;	chr6:25724979	chr6:25992662~26001775:+
BRCA	cis	rs2436845	0.614	rs2436854	ENSG00000253320.4	KB-1507C5.2	-3.89	0.000108	0.00671	-0.14	-0.12	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102813809	chr8:102864300~102977876:+
BRCA	cis	rs1009077	0.716	rs35967840	ENSG00000245958.5	RP11-33B1.1	3.89	0.000108	0.00671	0.17	0.12	Endometriosis;	chr4:119612287	chr4:119454791~119552025:+
BRCA	cis	rs78487399	0.808	rs7599781	ENSG00000234936.1	AC010883.5	3.89	0.000108	0.00671	0.18	0.12	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43451587	chr2:43229573~43233394:+
BRCA	cis	rs78487399	0.808	rs17030818	ENSG00000234936.1	AC010883.5	3.89	0.000108	0.00671	0.18	0.12	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43453179	chr2:43229573~43233394:+
BRCA	cis	rs11098499	0.687	rs71610270	ENSG00000260404.2	RP11-384K6.6	3.89	0.000108	0.00671	0.11	0.12	Corneal astigmatism;	chr4:119366281	chr4:118591773~118633729:+
BRCA	cis	rs1371614	0.566	rs10203050	ENSG00000272148.1	RP11-195B17.1	-3.89	0.000108	0.00671	-0.13	-0.12	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26963693	chr2:27062428~27062907:-
BRCA	cis	rs13315871	1	rs71311873	ENSG00000272182.1	RP11-802O23.3	3.89	0.000108	0.00671	0.25	0.12	Cholesterol, total;	chr3:58461379	chr3:58428255~58428815:+
BRCA	cis	rs853679	0.517	rs1904841	ENSG00000261839.1	RP1-265C24.8	3.89	0.000108	0.00671	0.17	0.12	Depression;	chr6:28140307	chr6:28136849~28139678:+
BRCA	cis	rs6545883	0.929	rs6705235	ENSG00000212978.6	AC016747.3	3.89	0.000108	0.00671	0.16	0.12	Tuberculosis;	chr2:61486445	chr2:61141592~61144969:-
BRCA	cis	rs4415084	0.8	rs930396	ENSG00000248779.1	RP11-53O19.2	-3.89	0.000108	0.00671	-0.11	-0.12	Breast cancer;	chr5:44856349	chr5:44752949~44765744:+
BRCA	cis	rs2412819	0.545	rs17795279	ENSG00000166763.7	STRCP1	-3.89	0.000108	0.00671	-0.18	-0.12	Lung cancer;	chr15:43637180	chr15:43699488~43718184:-
BRCA	cis	rs4415084	0.932	rs2218080	ENSG00000248779.1	RP11-53O19.2	3.89	0.000108	0.00671	0.11	0.12	Breast cancer;	chr5:44714228	chr5:44752949~44765744:+
BRCA	cis	rs13326165	0.511	rs1011063	ENSG00000243224.1	RP5-1157M23.2	-3.89	0.000108	0.00671	-0.16	-0.12	HDL cholesterol levels;HDL cholesterol;	chr3:52472832	chr3:52239258~52241097:+
BRCA	cis	rs4415084	1	rs12522626	ENSG00000248779.1	RP11-53O19.2	3.89	0.000108	0.00671	0.11	0.12	Breast cancer;	chr5:44685596	chr5:44752949~44765744:+
BRCA	cis	rs7267979	1	rs2856	ENSG00000274414.1	RP5-965G21.4	-3.89	0.000108	0.00671	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25452900	chr20:25239007~25245229:-
BRCA	cis	rs4415084	0.834	rs7716571	ENSG00000248779.1	RP11-53O19.2	3.89	0.000108	0.00671	0.11	0.12	Breast cancer;	chr5:44816882	chr5:44752949~44765744:+
BRCA	cis	rs9470794	0.915	rs76277811	ENSG00000204110.6	RP1-153P14.8	-3.89	0.000108	0.00671	-0.22	-0.12	Type 2 diabetes;	chr6:37884114	chr6:37507348~37535616:+
BRCA	cis	rs13401620	0.619	rs10864989	ENSG00000229326.3	AC069154.4	-3.89	0.000108	0.00672	-0.16	-0.12	Breast size;	chr2:119896218	chr2:119698623~119700151:+
BRCA	cis	rs6840360	1	rs6840678	ENSG00000251611.1	RP11-610P16.1	3.89	0.000108	0.00672	0.11	0.12	Intelligence (multi-trait analysis);	chr4:151683179	chr4:151407551~151408835:-
BRCA	cis	rs7617480	0.61	rs4955420	ENSG00000225399.4	RP11-3B7.1	3.89	0.000108	0.00672	0.11	0.12	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:49171432	chr3:49260085~49261316:+
BRCA	cis	rs1722141	0.634	rs1723960	ENSG00000229628.1	AC073115.7	3.89	0.000108	0.00672	0.15	0.12	Sitting height ratio;	chr7:46017247	chr7:45990905~46000898:+
BRCA	cis	rs4845570	1	rs6673002	ENSG00000203288.3	RP11-98D18.9	3.89	0.000108	0.00672	0.2	0.12	Coronary artery disease;	chr1:151770799	chr1:151790804~151794402:+
BRCA	cis	rs6968419	0.755	rs6966770	ENSG00000279086.1	RP11-667F14.1	-3.89	0.000108	0.00672	-0.13	-0.12	Intraocular pressure;	chr7:116255664	chr7:116209234~116211511:-
BRCA	cis	rs11158026	0.603	rs66820631	ENSG00000233924.1	AL160471.6	-3.89	0.000108	0.00672	-0.14	-0.12	Parkinson's disease;	chr14:54998835	chr14:55004813~55005687:-
BRCA	cis	rs6430585	0.528	rs309165	ENSG00000224043.6	CCNT2-AS1	-3.89	0.000108	0.00672	-0.18	-0.12	Corneal structure;	chr2:135909731	chr2:134735464~134918710:-
BRCA	cis	rs10739695	0.51	rs10819309	ENSG00000225032.4	RP11-228B15.4	-3.89	0.000108	0.00672	-0.11	-0.12	Monocyte percentage of white cells;	chr9:127819444	chr9:127816066~127822520:+
BRCA	cis	rs7429990	0.932	rs6803741	ENSG00000199476.1	Y_RNA	3.89	0.000108	0.00672	0.16	0.12	Educational attainment (years of education);	chr3:48082050	chr3:48288587~48288694:+
BRCA	cis	rs4650994	0.593	rs6694406	ENSG00000273384.1	RP5-1098D14.1	-3.89	0.000108	0.00672	-0.16	-0.12	HDL cholesterol;HDL cholesterol levels;	chr1:178562875	chr1:178651706~178652282:+
BRCA	cis	rs794185	0.534	rs304063	ENSG00000231249.1	ITPR1-AS1	-3.89	0.000108	0.00672	-0.14	-0.12	Multiple sclerosis--Brain Glutamate Levels;	chr3:4499876	chr3:4490891~4493163:-
BRCA	cis	rs862034	0.531	rs8008540	ENSG00000270000.1	RP3-449M8.9	3.89	0.000108	0.00672	0.15	0.12	Height;	chr14:74481477	chr14:74471930~74472360:-
BRCA	cis	rs9859260	0.689	rs3817672	ENSG00000229178.1	AC069513.4	-3.89	0.000108	0.00672	-0.14	-0.12	Mean corpuscular volume;	chr3:196073940	chr3:195655565~195657927:-
BRCA	cis	rs863750	1	rs10773049	ENSG00000275389.1	RP11-214K3.24	-3.89	0.000108	0.00672	-0.15	-0.12	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-hip ratio;	chr12:124022084	chr12:124085761~124088598:+
BRCA	cis	rs763121	1	rs763121	ENSG00000225450.1	RP3-508I15.14	3.89	0.000108	0.00672	0.12	0.12	Menopause (age at onset);	chr22:38483935	chr22:38739003~38749041:+
BRCA	cis	rs4415084	1	rs1821936	ENSG00000248779.1	RP11-53O19.2	3.89	0.000108	0.00672	0.11	0.12	Breast cancer;	chr5:44699380	chr5:44752949~44765744:+
BRCA	cis	rs1048886	0.872	rs7450771	ENSG00000271967.1	RP11-134K13.4	-3.89	0.000108	0.00672	-0.18	-0.12	Type 2 diabetes;	chr6:70565926	chr6:70596438~70596980:+
BRCA	cis	rs17301013	0.861	rs332770	ENSG00000234741.6	GAS5	3.89	0.000109	0.00673	0.12	0.12	Systemic lupus erythematosus;	chr1:174681511	chr1:173863900~173868882:-
BRCA	cis	rs983392	0.792	rs525794	ENSG00000275344.1	MIR6503	-3.89	0.000109	0.00673	-0.12	-0.12	Alzheimer's disease (late onset);	chr11:60135814	chr11:60209071~60209156:-
BRCA	cis	rs4374383	0.631	rs1996330	ENSG00000243389.1	AC012442.5	-3.89	0.000109	0.00673	-0.15	-0.12	Hepatitis C induced liver fibrosis;	chr2:111921873	chr2:112589040~112614431:+
BRCA	cis	rs4374383	0.631	rs1996329	ENSG00000243389.1	AC012442.5	-3.89	0.000109	0.00673	-0.15	-0.12	Hepatitis C induced liver fibrosis;	chr2:111922175	chr2:112589040~112614431:+
BRCA	cis	rs9481169	0.85	rs13210247	ENSG00000230177.1	RP5-1112D6.4	3.89	0.000109	0.00673	0.23	0.12	Inflammatory skin disease;	chr6:111601517	chr6:111277932~111278742:+
BRCA	cis	rs4578769	0.569	rs12326874	ENSG00000265943.1	RP11-739L10.1	3.89	0.000109	0.00673	0.16	0.12	Eosinophil percentage of white cells;	chr18:22926670	chr18:22699481~22933764:-
BRCA	cis	rs2302465	0.86	rs73239167	ENSG00000273133.1	RP11-799M12.2	-3.89	0.000109	0.00673	-0.24	-0.12	Blood protein levels;	chr4:15604400	chr4:15563698~15564253:-
BRCA	cis	rs875971	0.862	rs10282433	ENSG00000273024.4	INTS4P2	3.89	0.000109	0.00673	0.13	0.12	Aortic root size;	chr7:66256452	chr7:65647864~65715661:+
BRCA	cis	rs7819412	0.502	rs11777918	ENSG00000154316.13	TDH	-3.89	0.000109	0.00673	-0.16	-0.12	Triglycerides;	chr8:11179410	chr8:11339637~11368452:+
BRCA	cis	rs853679	0.546	rs36116761	ENSG00000216901.1	AL022393.7	3.89	0.000109	0.00673	0.31	0.12	Depression;	chr6:27850704	chr6:28176188~28176674:+
BRCA	cis	rs853679	0.546	rs34194357	ENSG00000216901.1	AL022393.7	3.89	0.000109	0.00673	0.31	0.12	Depression;	chr6:27850757	chr6:28176188~28176674:+
BRCA	cis	rs1850744	0.702	rs4974812	ENSG00000250942.1	ENPP7P11	-3.89	0.000109	0.00673	-0.28	-0.12	Economic and political preferences;	chr4:9612974	chr4:9677308~9677934:+
BRCA	cis	rs11686241	0.766	rs284529	ENSG00000241520.1	AC098820.4	3.89	0.000109	0.00673	0.16	0.12	Cancer;	chr2:216469352	chr2:216483032~216487196:-
BRCA	cis	rs6964587	1	rs11982047	ENSG00000188693.7	CYP51A1-AS1	-3.89	0.000109	0.00673	-0.13	-0.12	Breast cancer;	chr7:92075960	chr7:92134604~92180725:+
BRCA	cis	rs7267979	0.966	rs454723	ENSG00000274414.1	RP5-965G21.4	-3.89	0.000109	0.00673	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25458292	chr20:25239007~25245229:-
BRCA	cis	rs67696533	0.6	rs4911237	ENSG00000277692.1	RP11-358N2.2	-3.89	0.000109	0.00674	-0.14	-0.12	White blood cell count (basophil);Basophil percentage of granulocytes;Basophil percentage of white cells;	chr20:32534541	chr20:32355053~32355734:+
BRCA	cis	rs4948102	0.655	rs4947533	ENSG00000226278.1	PSPHP1	-3.89	0.000109	0.00674	-0.14	-0.12	Plasma homocysteine levels (post-methionine load test);	chr7:56003589	chr7:55764797~55773288:+
BRCA	cis	rs35146811	0.538	rs3823642	ENSG00000235713.1	RP4-604G5.3	3.89	0.000109	0.00674	0.14	0.12	Coronary artery disease;	chr7:100198449	chr7:99992397~99993050:+
BRCA	cis	rs7267979	1	rs6050566	ENSG00000277938.1	RP5-965G21.3	-3.89	0.000109	0.00674	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25370435	chr20:25229150~25231933:+
BRCA	cis	rs6599077	0.95	rs2887954	ENSG00000223797.4	ENTPD3-AS1	3.89	0.000109	0.00674	0.15	0.12	Sleep-related phenotypes;	chr3:40060433	chr3:40313802~40453329:-
BRCA	cis	rs910316	1	rs2300601	ENSG00000259138.1	RP11-950C14.7	3.89	0.000109	0.00674	0.13	0.12	Height;	chr14:75172868	chr14:75127153~75136930:+
BRCA	cis	rs8042543	0.707	rs4779526	ENSG00000215302.7	CTD-3092A11.1	-3.89	0.000109	0.00674	-0.16	-0.12	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);	chr15:31413480	chr15:30470779~30507623:+
BRCA	cis	rs13434995	0.513	rs41324951	ENSG00000239040.1	Y_RNA	-3.88	0.000109	0.00674	-0.15	-0.12	Adiponectin levels;	chr4:55422576	chr4:55412636~55412738:+
BRCA	cis	rs11098499	0.863	rs6858592	ENSG00000260091.1	RP11-33B1.4	-3.88	0.000109	0.00674	-0.11	-0.12	Corneal astigmatism;	chr4:119537537	chr4:119409333~119410233:+
BRCA	cis	rs7209700	0.662	rs8066295	ENSG00000228782.6	CTD-2026D20.3	3.88	0.000109	0.00674	0.14	0.12	IgG glycosylation;	chr17:47270837	chr17:47450568~47492492:-
BRCA	cis	rs7308116	1	rs7134568	ENSG00000274395.1	RP11-554D14.8	-3.88	0.000109	0.00675	-0.13	-0.12	Pelvic organ prolapse (moderate/severe);	chr12:107805973	chr12:107835541~107836555:-
BRCA	cis	rs728616	0.867	rs55666905	ENSG00000242600.5	MBL1P	3.88	0.000109	0.00675	0.3	0.12	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80193883	chr10:79904898~79950336:+
BRCA	cis	rs9921338	0.961	rs66555362	ENSG00000263080.1	RP11-485G7.5	3.88	0.000109	0.00675	0.18	0.12	Vein graft stenosis in coronary artery bypass grafting;	chr16:11294976	chr16:11341809~11345211:-
BRCA	cis	rs1865760	0.515	rs2003208	ENSG00000272462.2	U91328.19	-3.88	0.000109	0.00675	-0.14	-0.12	Height;	chr6:25940491	chr6:25992662~26001775:+
BRCA	cis	rs6090583	0.646	rs1984076	ENSG00000273893.1	RP1-101A2.1	-3.88	0.000109	0.00675	-0.13	-0.12	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr20:46884796	chr20:46681676~46682375:-
BRCA	cis	rs465969	1	rs4509157	ENSG00000272356.1	RP5-1112D6.8	3.88	0.000109	0.00675	0.22	0.12	Psoriasis;	chr6:111513875	chr6:111309203~111313517:+
BRCA	cis	rs7474896	1	rs11011339	ENSG00000272983.1	RP11-508N22.12	3.88	0.000109	0.00675	0.19	0.12	Obesity (extreme);	chr10:37707418	chr10:38137337~38144399:+
BRCA	cis	rs7172689	0.908	rs11633024	ENSG00000271725.1	RP11-761I4.4	-3.88	0.000109	0.00675	-0.15	-0.12	Inattentive symptoms;	chr15:81269018	chr15:81303215~81309391:-
BRCA	cis	rs11098499	0.738	rs28408407	ENSG00000260404.2	RP11-384K6.6	3.88	0.000109	0.00675	0.11	0.12	Corneal astigmatism;	chr4:119454875	chr4:118591773~118633729:+
BRCA	cis	rs1429524	0.848	rs17163799	ENSG00000243144.5	RP11-115N4.1	-3.88	0.000109	0.00675	-0.16	-0.12	Ejection fraction in Tripanosoma cruzi seropositivity;	chr7:91316600	chr7:91311368~91515409:+
BRCA	cis	rs2243480	0.803	rs35480979	ENSG00000226002.1	RP11-460N20.5	-3.88	0.000109	0.00675	-0.2	-0.12	Diabetic kidney disease;	chr7:65892097	chr7:65084103~65100232:+
BRCA	cis	rs2243480	1	rs35391607	ENSG00000226002.1	RP11-460N20.5	-3.88	0.000109	0.00675	-0.2	-0.12	Diabetic kidney disease;	chr7:65895842	chr7:65084103~65100232:+
BRCA	cis	rs2243480	1	rs13220979	ENSG00000226002.1	RP11-460N20.5	-3.88	0.000109	0.00675	-0.2	-0.12	Diabetic kidney disease;	chr7:65898217	chr7:65084103~65100232:+
BRCA	cis	rs2243480	1	rs34974928	ENSG00000226002.1	RP11-460N20.5	-3.88	0.000109	0.00675	-0.2	-0.12	Diabetic kidney disease;	chr7:65899019	chr7:65084103~65100232:+
BRCA	cis	rs2108225	0.9	rs7805114	ENSG00000231006.1	RPL7P32	3.88	0.000109	0.00675	0.11	0.12	Ulcerative colitis;	chr7:107809588	chr7:108510233~108510976:+
BRCA	cis	rs7267979	1	rs7019	ENSG00000274414.1	RP5-965G21.4	-3.88	0.000109	0.00675	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25297642	chr20:25239007~25245229:-
BRCA	cis	rs11893307	0.599	rs12617417	ENSG00000235852.1	AC005540.3	3.88	0.000109	0.00675	0.16	0.12	Mean platelet volume;	chr2:190798845	chr2:190880797~190882059:-
BRCA	cis	rs11098499	0.865	rs9994730	ENSG00000225892.3	RP11-384K6.2	3.88	0.000109	0.00675	0.12	0.12	Corneal astigmatism;	chr4:119460409	chr4:118632274~118634759:+
BRCA	cis	rs7572644	0.537	rs12464240	ENSG00000223522.1	AC093690.1	-3.88	0.000109	0.00675	-0.14	-0.12	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:28138964	chr2:28307691~28310459:-
BRCA	cis	rs7572644	0.537	rs12467834	ENSG00000223522.1	AC093690.1	-3.88	0.000109	0.00675	-0.14	-0.12	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:28139201	chr2:28307691~28310459:-
BRCA	cis	rs6696239	0.956	rs10916189	ENSG00000215812.5	ZNF847P	3.88	0.000109	0.00675	0.17	0.12	Height;	chr1:227639425	chr1:227696892~227706699:-
BRCA	cis	rs72615157	0.634	rs2272343	ENSG00000242294.5	STAG3L5P	3.88	0.000109	0.00675	0.11	0.12	Lung function (FEV1/FVC);	chr7:100180662	chr7:100336079~100351900:+
BRCA	cis	rs10129255	0.957	rs1024349	ENSG00000232216.1	IGHV3-43	3.88	0.000109	0.00675	0.1	0.12	Kawasaki disease;	chr14:106689997	chr14:106470264~106470800:-
BRCA	cis	rs897984	0.683	rs8046001	ENSG00000275263.1	RP11-1072A3.4	-3.88	0.000109	0.00675	-0.14	-0.12	Dementia with Lewy bodies;	chr16:30822000	chr16:30956872~30957199:-
BRCA	cis	rs8060686	0.545	rs8056649	ENSG00000262691.1	CTC-277H1.7	3.88	0.000109	0.00676	0.2	0.12	HDL cholesterol;Metabolic syndrome;	chr16:68226180	chr16:67261108~67263784:+
BRCA	cis	rs875971	0.545	rs6961853	ENSG00000232559.3	GS1-124K5.12	3.88	0.000109	0.00676	0.16	0.12	Aortic root size;	chr7:66537035	chr7:66554588~66576923:-
BRCA	cis	rs8022179	0.566	rs62006258	ENSG00000244691.1	RPL10AP1	3.88	0.000109	0.00676	0.17	0.12	Monocyte count;	chr14:103372572	chr14:103412119~103412761:-
BRCA	cis	rs4925540	0.962	rs6657686	ENSG00000215796.3	RP11-551G24.2	-3.88	0.000109	0.00676	-0.14	-0.12	Response to taxane treatment (docetaxel);	chr1:247053211	chr1:247042791~247044021:+
BRCA	cis	rs875971	1	rs1167612	ENSG00000271064.1	RP11-792A8.3	3.88	0.000109	0.00676	0.14	0.12	Aortic root size;	chr7:66102989	chr7:66748838~66749077:-
BRCA	cis	rs1048886	0.872	rs56179165	ENSG00000271967.1	RP11-134K13.4	-3.88	0.000109	0.00676	-0.17	-0.12	Type 2 diabetes;	chr6:70564767	chr6:70596438~70596980:+
BRCA	cis	rs80226907	0.634	rs1959443	ENSG00000186615.9	KTN1-AS1	-3.88	0.000109	0.00676	-0.24	-0.12	Mean platelet volume;	chr14:55434603	chr14:55499278~55580110:-
BRCA	cis	rs897984	0.645	rs58726213	ENSG00000279196.1	RP11-1072A3.3	3.88	0.000109	0.00676	0.12	0.12	Dementia with Lewy bodies;	chr16:31033362	chr16:30984630~30988270:-
BRCA	cis	rs6496932	0.563	rs2344083	ENSG00000202081.1	RNU6-1280P	3.88	0.000109	0.00676	0.15	0.12	Central corneal thickness;Corneal structure;	chr15:85354201	chr15:85651522~85651628:-
BRCA	cis	rs7636293	0.964	rs10804589	ENSG00000270773.1	RP13-685P2.7	3.88	0.000109	0.00676	0.14	0.12	Height;	chr3:129331778	chr3:129345411~129346164:+
BRCA	cis	rs9959145	1	rs17595746	ENSG00000267108.1	RP11-861E21.1	3.88	0.000109	0.00676	0.21	0.12	Immune response to smallpox vaccine (IL-6);	chr18:12707859	chr18:12432897~12437635:+
BRCA	cis	rs733175	0.951	rs6826764	ENSG00000250413.1	RP11-448G15.1	3.88	0.000109	0.00676	0.18	0.12	Psychosis and Alzheimer's disease;	chr4:10029170	chr4:10006482~10009725:+
BRCA	cis	rs33995560	0.708	rs4796144	ENSG00000270977.1	AC015849.16	-3.88	0.000109	0.00676	-0.21	-0.12	Blood protein levels;	chr17:35965995	chr17:35893707~35911023:-
BRCA	cis	rs1832007	0.706	rs11253048	ENSG00000224034.1	RP11-445P17.8	-3.88	0.000109	0.00676	-0.21	-0.12	Triglyceride levels;Triglycerides;	chr10:5219196	chr10:5266033~5271236:-
BRCA	cis	rs11098499	0.738	rs72918577	ENSG00000260404.2	RP11-384K6.6	3.88	0.000109	0.00676	0.11	0.12	Corneal astigmatism;	chr4:119405546	chr4:118591773~118633729:+
BRCA	cis	rs7712401	0.655	rs6884312	ENSG00000251538.4	RP11-166A12.1	3.88	0.000109	0.00677	0.13	0.12	Mean platelet volume;	chr5:122768282	chr5:122628952~122730685:-
BRCA	cis	rs6049003	0.668	rs6114235	ENSG00000232645.4	LINC01431	3.88	0.000109	0.00677	0.14	0.12	Cerebrospinal fluid biomarker levels;	chr20:23712336	chr20:23356594~23358116:-
BRCA	cis	rs3805389	0.504	rs28416150	ENSG00000273257.1	RP11-177J6.1	-3.88	0.000109	0.00677	-0.19	-0.12	Waist-to-hip ratio adjusted for body mass index;	chr4:55608211	chr4:55387949~55388271:+
BRCA	cis	rs3742264	0.656	rs9534265	ENSG00000235903.6	CPB2-AS1	-3.88	0.000109	0.00677	-0.14	-0.12	Blood protein levels;	chr13:45972887	chr13:46052806~46113332:+
BRCA	cis	rs4073416	0.712	rs1535173	ENSG00000276116.2	FUT8-AS1	-3.88	0.000109	0.00677	-0.13	-0.12	N-glycan levels;	chr14:65732421	chr14:65411170~65412690:-
BRCA	cis	rs11017221	0.891	rs7905219	ENSG00000233122.2	CTAGE7P	-3.88	0.000109	0.00677	-0.14	-0.12	Migraine;	chr10:130364448	chr10:130106046~130108481:+
BRCA	cis	rs7712401	0.598	rs367768	ENSG00000251538.4	RP11-166A12.1	3.88	0.000109	0.00677	0.13	0.12	Mean platelet volume;	chr5:122855431	chr5:122628952~122730685:-
BRCA	cis	rs7712401	0.567	rs154516	ENSG00000251538.4	RP11-166A12.1	3.88	0.000109	0.00677	0.13	0.12	Mean platelet volume;	chr5:122855444	chr5:122628952~122730685:-
BRCA	cis	rs6005807	0.719	rs9625512	ENSG00000272858.1	CTA-292E10.8	-3.88	0.000109	0.00677	-0.21	-0.12	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28624768	chr22:28814914~28815662:+
BRCA	cis	rs6005807	0.719	rs9625513	ENSG00000272858.1	CTA-292E10.8	-3.88	0.000109	0.00677	-0.21	-0.12	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28626184	chr22:28814914~28815662:+
BRCA	cis	rs6005807	0.719	rs9625514	ENSG00000272858.1	CTA-292E10.8	-3.88	0.000109	0.00677	-0.21	-0.12	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28626200	chr22:28814914~28815662:+
BRCA	cis	rs7177699	0.557	rs4380028	ENSG00000261143.1	ADAMTS7P3	3.88	0.000109	0.00677	0.15	0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78818751	chr15:77976042~77993057:+
BRCA	cis	rs28374715	0.681	rs77187862	ENSG00000247556.5	OIP5-AS1	3.88	0.000109	0.00677	0.13	0.12	Ulcerative colitis;	chr15:41327078	chr15:41283990~41309737:+
BRCA	cis	rs2625529	0.775	rs4777477	ENSG00000260037.4	CTD-2524L6.3	-3.88	0.000109	0.00677	-0.17	-0.12	Red blood cell count;	chr15:71977271	chr15:71818396~71823384:+
BRCA	cis	rs7267979	0.966	rs6083818	ENSG00000274414.1	RP5-965G21.4	3.88	0.000109	0.00677	0.14	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25365446	chr20:25239007~25245229:-
BRCA	cis	rs7267979	1	rs4815409	ENSG00000274414.1	RP5-965G21.4	3.88	0.000109	0.00677	0.14	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25366061	chr20:25239007~25245229:-
BRCA	cis	rs875971	0.66	rs10272357	ENSG00000265600.1	AC006480.1	3.88	0.000109	0.00677	0.14	0.12	Aortic root size;	chr7:66598087	chr7:67356680~67356779:+
BRCA	cis	rs1371614	0.589	rs3739086	ENSG00000272148.1	RP11-195B17.1	-3.88	0.000109	0.00677	-0.13	-0.12	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26942334	chr2:27062428~27062907:-
BRCA	cis	rs983392	0.68	rs7929589	ENSG00000275344.1	MIR6503	-3.88	0.000109	0.00677	-0.12	-0.12	Alzheimer's disease (late onset);	chr11:60207605	chr11:60209071~60209156:-
BRCA	cis	rs78487399	0.808	rs74365854	ENSG00000234936.1	AC010883.5	3.88	0.000109	0.00677	0.18	0.12	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43434343	chr2:43229573~43233394:+
BRCA	cis	rs78487399	0.808	rs116451849	ENSG00000234936.1	AC010883.5	3.88	0.000109	0.00677	0.18	0.12	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43435772	chr2:43229573~43233394:+
BRCA	cis	rs2243480	1	rs431318	ENSG00000237026.1	RP11-328P23.2	3.88	0.000109	0.00677	0.23	0.12	Diabetic kidney disease;	chr7:66046610	chr7:65235790~65236723:-
BRCA	cis	rs6545883	0.524	rs4599092	ENSG00000270820.4	RP11-355B11.2	-3.88	0.000109	0.00678	-0.13	-0.12	Tuberculosis;	chr2:61271833	chr2:61471188~61484130:+
BRCA	cis	rs9863	0.694	rs11837287	ENSG00000270028.1	RP11-380L11.4	3.88	0.000109	0.00678	0.15	0.12	White blood cell count;	chr12:123985512	chr12:123925461~123926083:-
BRCA	cis	rs8099594	0.565	rs1893527	ENSG00000266696.1	RP11-30L3.2	-3.88	0.000109	0.00678	-0.14	-0.12	Height;	chr18:49185738	chr18:49205912~49208781:+
BRCA	cis	rs669446	0.561	rs643445	ENSG00000236200.4	KDM4A-AS1	3.88	0.00011	0.00678	0.15	0.12	Amyotrophic lateral sclerosis (age of onset);	chr1:43623961	chr1:43699765~43708138:-
BRCA	cis	rs1048886	0.938	rs80138927	ENSG00000271967.1	RP11-134K13.4	-3.88	0.00011	0.00678	-0.17	-0.12	Type 2 diabetes;	chr6:70487403	chr6:70596438~70596980:+
BRCA	cis	rs9921338	0.961	rs72773830	ENSG00000262636.1	CTD-3088G3.4	-3.88	0.00011	0.00678	-0.19	-0.12	Vein graft stenosis in coronary artery bypass grafting;	chr16:11318966	chr16:11380859~11381118:-
BRCA	cis	rs7200543	0.848	rs62039480	ENSG00000258354.1	MIR3180-1	-3.88	0.00011	0.00678	-0.15	-0.12	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15043593	chr16:14909887~14911345:-
BRCA	cis	rs67766926	0.951	rs10208137	ENSG00000237522.1	NONOP2	-3.88	0.00011	0.00678	-0.13	-0.12	Inflammatory skin disease;	chr2:60951036	chr2:60936819~60938049:-
BRCA	cis	rs9470794	1	rs76766775	ENSG00000204110.6	RP1-153P14.8	-3.88	0.00011	0.00679	-0.24	-0.12	Type 2 diabetes;	chr6:38111706	chr6:37507348~37535616:+
BRCA	cis	rs9470794	1	rs73421831	ENSG00000204110.6	RP1-153P14.8	-3.88	0.00011	0.00679	-0.24	-0.12	Type 2 diabetes;	chr6:38111870	chr6:37507348~37535616:+
BRCA	cis	rs9470794	1	rs11753563	ENSG00000204110.6	RP1-153P14.8	-3.88	0.00011	0.00679	-0.24	-0.12	Type 2 diabetes;	chr6:38112442	chr6:37507348~37535616:+
BRCA	cis	rs11239930	0.517	rs493000	ENSG00000237188.3	RP11-337C18.8	3.88	0.00011	0.00679	0.14	0.12	AIDS progression;	chr1:147077979	chr1:147172771~147211568:+
BRCA	cis	rs12949688	0.967	rs12949028	ENSG00000262623.1	RP5-1107A17.2	-3.88	0.00011	0.00679	-0.13	-0.12	Schizophrenia;	chr17:57748109	chr17:56951664~56952404:+
BRCA	cis	rs11822910	0.645	rs7122734	ENSG00000265566.2	RN7SL605P	-3.88	0.00011	0.00679	-0.16	-0.12	Platelet distribution width;	chr11:57422947	chr11:57528085~57528365:-
BRCA	cis	rs1065852	0.526	rs7290907	ENSG00000205702.9	CYP2D7	3.88	0.00011	0.00679	0.11	0.12	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:41994205	chr22:42140203~42144577:-
BRCA	cis	rs1065852	0.526	rs7290655	ENSG00000205702.9	CYP2D7	3.88	0.00011	0.00679	0.11	0.12	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:41994221	chr22:42140203~42144577:-
BRCA	cis	rs7620503	0.959	rs6797636	ENSG00000228561.2	RP11-114M1.1	3.88	0.00011	0.00679	0.14	0.12	Corneal structure;	chr3:177591654	chr3:177683627~177691250:+
BRCA	cis	rs801193	0.935	rs2659899	ENSG00000265600.1	AC006480.1	-3.88	0.00011	0.00679	-0.14	-0.12	Aortic root size;	chr7:66721734	chr7:67356680~67356779:+
BRCA	cis	rs2191566	1	rs7256908	ENSG00000266921.1	RP11-15A1.7	-3.88	0.00011	0.00679	-0.15	-0.12	Acute lymphoblastic leukemia (childhood);	chr19:44024746	chr19:43996896~44002836:-
BRCA	cis	rs11168618	0.904	rs12371700	ENSG00000273765.1	RP11-370I10.11	-3.88	0.00011	0.00679	-0.14	-0.12	Adiponectin levels;	chr12:48525430	chr12:48360920~48361377:+
BRCA	cis	rs6600671	0.934	rs12131379	ENSG00000223345.3	HIST2H2BA	3.88	0.00011	0.00679	0.14	0.12	Hip geometry;	chr1:121551639	chr1:121108210~121117257:-
BRCA	cis	rs16944613	0.636	rs6416552	ENSG00000271396.1	RP11-697E2.9	-3.88	0.00011	0.00679	-0.2	-0.12	Colorectal cancer;	chr15:90588879	chr15:90284376~90285580:-
BRCA	cis	rs4374383	0.884	rs10180345	ENSG00000243389.1	AC012442.5	-3.88	0.00011	0.00679	-0.15	-0.12	Hepatitis C induced liver fibrosis;	chr2:111983716	chr2:112589040~112614431:+
BRCA	cis	rs6840360	0.571	rs4696271	ENSG00000270265.1	RP11-731D1.4	-3.88	0.00011	0.00679	-0.14	-0.12	Intelligence (multi-trait analysis);	chr4:151587966	chr4:151333775~151353224:-
BRCA	cis	rs1910358	0.881	rs1490758	ENSG00000248874.4	C5orf17	-3.88	0.00011	0.00679	-0.18	-0.12	Venous thromboembolism (SNP x SNP interaction);	chr5:23884331	chr5:23951348~24178263:+
BRCA	cis	rs1910358	0.959	rs10942011	ENSG00000248874.4	C5orf17	-3.88	0.00011	0.00679	-0.18	-0.12	Venous thromboembolism (SNP x SNP interaction);	chr5:23885946	chr5:23951348~24178263:+
BRCA	cis	rs1910358	0.81	rs13164372	ENSG00000248874.4	C5orf17	-3.88	0.00011	0.00679	-0.18	-0.12	Venous thromboembolism (SNP x SNP interaction);	chr5:23888589	chr5:23951348~24178263:+
BRCA	cis	rs1910358	0.959	rs1602370	ENSG00000248874.4	C5orf17	-3.88	0.00011	0.00679	-0.18	-0.12	Venous thromboembolism (SNP x SNP interaction);	chr5:23891074	chr5:23951348~24178263:+
BRCA	cis	rs330048	0.545	rs11774353	ENSG00000233609.3	RP11-62H7.2	3.88	0.00011	0.00679	0.12	0.12	Systemic lupus erythematosus;	chr8:9295617	chr8:8961200~8979025:+
BRCA	cis	rs4930561	0.765	rs4930229	ENSG00000184795.9	UNC93B5	-3.88	0.00011	0.00679	-0.14	-0.12	Breast cancer in childhood cancer survivors;IgG glycosylation;	chr11:68176613	chr11:67711702~67716005:-
BRCA	cis	rs9467773	0.935	rs1056668	ENSG00000241549.7	GUSBP2	3.88	0.00011	0.00679	0.14	0.12	Intelligence (multi-trait analysis);	chr6:26510377	chr6:26871484~26956554:-
BRCA	cis	rs6430585	0.527	rs1438303	ENSG00000231890.6	DARS-AS1	-3.88	0.00011	0.00679	-0.18	-0.12	Corneal structure;	chr2:135672287	chr2:135985176~136022593:+
BRCA	cis	rs9308731	0.644	rs1439287	ENSG00000230499.1	AC108463.1	-3.88	0.00011	0.0068	-0.14	-0.12	Chronic lymphocytic leukemia;	chr2:111114320	chr2:111195963~111206494:+
BRCA	cis	rs448720	1	rs383168	ENSG00000260657.2	RP11-315D16.4	-3.88	0.00011	0.0068	-0.14	-0.12	Cognitive performance;	chr15:67912656	chr15:68267792~68277994:-
BRCA	cis	rs448720	1	rs388675	ENSG00000260657.2	RP11-315D16.4	-3.88	0.00011	0.0068	-0.14	-0.12	Cognitive performance;	chr15:67913409	chr15:68267792~68277994:-
BRCA	cis	rs448720	1	rs449761	ENSG00000260657.2	RP11-315D16.4	-3.88	0.00011	0.0068	-0.14	-0.12	Cognitive performance;	chr15:67918241	chr15:68267792~68277994:-
BRCA	cis	rs1696803	1	rs1696803	ENSG00000276742.1	RP11-500G22.4	-3.88	0.00011	0.0068	-0.18	-0.12	Breast cancer;	chr10:121677436	chr10:121956782~121957098:+
BRCA	cis	rs737008	0.922	rs28567501	ENSG00000262636.1	CTD-3088G3.4	-3.88	0.00011	0.0068	-0.17	-0.12	Obesity-related traits;	chr16:11285071	chr16:11380859~11381118:-
BRCA	cis	rs10991814	0.72	rs7028794	ENSG00000235641.4	LINC00484	3.88	0.00011	0.0068	0.18	0.12	Neutrophil percentage of granulocytes;	chr9:91269067	chr9:91159573~91165658:+
BRCA	cis	rs1555321	0.679	rs57997960	ENSG00000273038.2	RP11-479G22.8	3.88	0.00011	0.0068	0.15	0.12	Coronary artery disease;	chr10:33227498	chr10:32887255~32889311:-
BRCA	cis	rs1555321	0.65	rs56239610	ENSG00000273038.2	RP11-479G22.8	3.88	0.00011	0.0068	0.15	0.12	Coronary artery disease;	chr10:33227551	chr10:32887255~32889311:-
BRCA	cis	rs17092148	0.887	rs932542	ENSG00000202150.1	RNU6-407P	3.88	0.00011	0.0068	0.18	0.12	Neuroticism;	chr20:34583564	chr20:35030317~35030420:-
BRCA	cis	rs17092148	0.887	rs6059931	ENSG00000202150.1	RNU6-407P	3.88	0.00011	0.0068	0.18	0.12	Neuroticism;	chr20:34587534	chr20:35030317~35030420:-
BRCA	cis	rs7267979	1	rs2424710	ENSG00000274414.1	RP5-965G21.4	-3.88	0.00011	0.0068	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25303250	chr20:25239007~25245229:-
BRCA	cis	rs7048146	0.51	rs10816827	ENSG00000213539.4	YBX1P6	-3.88	0.00011	0.0068	-0.13	-0.12	Vascular brain injury;	chr9:109529829	chr9:109532830~109534332:-
BRCA	cis	rs4648045	0.861	rs230527	ENSG00000246560.2	RP11-10L12.4	-3.88	0.00011	0.00681	-0.14	-0.12	Lymphocyte percentage of white cells;	chr4:102537021	chr4:102828055~102844075:+
BRCA	cis	rs3617	0.625	rs2535633	ENSG00000279144.1	RP11-894J14.2	-3.88	0.00011	0.00681	-0.15	-0.12	Red blood cell count;Autism spectrum disorder or schizophrenia;	chr3:52825614	chr3:52848085~52848553:-
BRCA	cis	rs2243480	1	rs2462569	ENSG00000275400.1	RP4-756H11.5	-3.88	0.00011	0.00681	-0.21	-0.12	Diabetic kidney disease;	chr7:66009859	chr7:66553805~66554199:-
BRCA	cis	rs7177699	0.525	rs56076311	ENSG00000261143.1	ADAMTS7P3	3.88	0.00011	0.00681	0.15	0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78822778	chr15:77976042~77993057:+
BRCA	cis	rs1075265	0.749	rs805380	ENSG00000272156.1	RP11-477N3.1	-3.88	0.00011	0.00681	-0.12	-0.12	Chronotype;Morning vs. evening chronotype;	chr2:53867284	chr2:54082554~54085066:+
BRCA	cis	rs4415084	0.834	rs2118764	ENSG00000248779.1	RP11-53O19.2	3.88	0.00011	0.00681	0.11	0.12	Breast cancer;	chr5:44787621	chr5:44752949~44765744:+
BRCA	cis	rs78487399	0.808	rs17039133	ENSG00000234936.1	AC010883.5	3.88	0.00011	0.00681	0.18	0.12	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43467431	chr2:43229573~43233394:+
BRCA	cis	rs10208649	0.908	rs7559651	ENSG00000272156.1	RP11-477N3.1	3.88	0.00011	0.00681	0.25	0.12	Body mass index;	chr2:53981801	chr2:54082554~54085066:+
BRCA	cis	rs10463316	0.894	rs12652733	ENSG00000260581.1	CTB-113P19.4	3.88	0.00011	0.00681	0.14	0.12	Metabolite levels (Pyroglutamine);	chr5:151374438	chr5:151652275~151655449:+
BRCA	cis	rs1075265	0.716	rs7573991	ENSG00000272156.1	RP11-477N3.1	-3.88	0.00011	0.00681	-0.12	-0.12	Chronotype;Morning vs. evening chronotype;	chr2:53726830	chr2:54082554~54085066:+
BRCA	cis	rs12681366	0.614	rs2919663	ENSG00000253175.1	RP11-267M23.6	3.88	0.00011	0.00681	0.13	0.12	Nonsyndromic cleft lip with cleft palate;	chr8:94457918	chr8:94565036~94565715:+
BRCA	cis	rs9863	0.828	rs12311848	ENSG00000270028.1	RP11-380L11.4	3.88	0.00011	0.00681	0.15	0.12	White blood cell count;	chr12:124002304	chr12:123925461~123926083:-
BRCA	cis	rs2904967	0.703	rs2904982	ENSG00000255200.1	AP003068.18	-3.88	0.00011	0.00681	-0.24	-0.12	Mean corpuscular volume;	chr11:65236830	chr11:65174117~65176470:-
BRCA	cis	rs7818688	0.654	rs896848	ENSG00000253528.2	RP11-347C18.4	-3.88	0.00011	0.00681	-0.17	-0.12	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94969582	chr8:94974573~94974853:-
BRCA	cis	rs983392	0.679	rs672399	ENSG00000275344.1	MIR6503	3.88	0.00011	0.00681	0.12	0.12	Alzheimer's disease (late onset);	chr11:60252639	chr11:60209071~60209156:-
BRCA	cis	rs10864907	0.71	rs9308680	ENSG00000231747.1	AC079922.2	-3.88	0.00011	0.00681	-0.11	-0.12	Pulmonary function;	chr2:112963466	chr2:112621809~112622167:-
BRCA	cis	rs7520050	0.966	rs6695809	ENSG00000234329.1	RP11-767N6.2	-3.88	0.00011	0.00682	-0.11	-0.12	Reticulocyte count;Red blood cell count;	chr1:45819789	chr1:45651039~45651826:-
BRCA	cis	rs17767294	0.708	rs72847379	ENSG00000219392.1	RP1-265C24.5	-3.88	0.00011	0.00682	-0.32	-0.12	Parkinson's disease;	chr6:27905312	chr6:28115628~28116551:+
BRCA	cis	rs4906332	0.811	rs2021965	ENSG00000269940.1	RP11-73M18.7	-3.88	0.00011	0.00682	-0.14	-0.12	Coronary artery disease;	chr14:103530911	chr14:103694560~103695170:+
BRCA	cis	rs7620503	0.921	rs6768291	ENSG00000277241.1	RP11-114M1.3	3.88	0.00011	0.00682	0.13	0.12	Corneal structure;	chr3:177572395	chr3:177700346~177701072:-
BRCA	cis	rs7620503	0.917	rs1970861	ENSG00000277241.1	RP11-114M1.3	3.88	0.00011	0.00682	0.13	0.12	Corneal structure;	chr3:177573425	chr3:177700346~177701072:-
BRCA	cis	rs7620503	0.959	rs4241483	ENSG00000277241.1	RP11-114M1.3	3.88	0.00011	0.00682	0.13	0.12	Corneal structure;	chr3:177573530	chr3:177700346~177701072:-
BRCA	cis	rs2625529	0.824	rs12592044	ENSG00000260037.4	CTD-2524L6.3	-3.88	0.00011	0.00682	-0.17	-0.12	Red blood cell count;	chr15:72126774	chr15:71818396~71823384:+
BRCA	cis	rs728616	0.867	rs61860041	ENSG00000242600.5	MBL1P	3.88	0.00011	0.00682	0.29	0.12	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80184575	chr10:79904898~79950336:+
BRCA	cis	rs728616	0.867	rs61860042	ENSG00000242600.5	MBL1P	3.88	0.00011	0.00682	0.29	0.12	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80186482	chr10:79904898~79950336:+
BRCA	cis	rs728616	0.867	rs12415870	ENSG00000242600.5	MBL1P	3.88	0.00011	0.00682	0.29	0.12	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80189714	chr10:79904898~79950336:+
BRCA	cis	rs10504130	1	rs74953260	ENSG00000272076.1	RP11-11C20.3	3.88	0.00011	0.00682	0.2	0.12	Venous thromboembolism (SNP x SNP interaction);	chr8:51863087	chr8:51810110~51810681:-
BRCA	cis	rs10504130	1	rs75826750	ENSG00000272076.1	RP11-11C20.3	3.88	0.00011	0.00682	0.2	0.12	Venous thromboembolism (SNP x SNP interaction);	chr8:51863133	chr8:51810110~51810681:-
BRCA	cis	rs495337	0.76	rs1056200	ENSG00000229222.1	KRT18P4	-3.88	0.00011	0.00682	-0.15	-0.12	Psoriasis;	chr20:49939711	chr20:49956745~49958032:+
BRCA	cis	rs6696239	0.513	rs2088214	ENSG00000227711.2	RP11-275O4.5	-3.88	0.00011	0.00682	-0.14	-0.12	Height;	chr1:227590490	chr1:227509028~227520477:-
BRCA	cis	rs8054556	1	rs4583255	ENSG00000183604.13	SMG1P5	-3.88	0.00011	0.00682	-0.12	-0.12	Autism spectrum disorder or schizophrenia;	chr16:29977620	chr16:30267553~30335374:-
BRCA	cis	rs875971	0.862	rs4718377	ENSG00000273024.4	INTS4P2	3.88	0.00011	0.00682	0.13	0.12	Aortic root size;	chr7:66584691	chr7:65647864~65715661:+
BRCA	cis	rs875971	0.862	rs10278014	ENSG00000273024.4	INTS4P2	3.88	0.00011	0.00682	0.13	0.12	Aortic root size;	chr7:66586277	chr7:65647864~65715661:+
BRCA	cis	rs11098499	0.865	rs28634456	ENSG00000260404.2	RP11-384K6.6	3.88	0.00011	0.00682	0.11	0.12	Corneal astigmatism;	chr4:119454623	chr4:118591773~118633729:+
BRCA	cis	rs17756712	0.615	rs3823127	ENSG00000271911.1	RP11-532F6.5	3.88	0.00011	0.00682	0.18	0.12	Vertical cup-disc ratio;	chr6:593841	chr6:761675~780648:+
BRCA	cis	rs7572644	0.537	rs12618676	ENSG00000223522.1	AC093690.1	3.88	0.00011	0.00683	0.13	0.12	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:28141416	chr2:28307691~28310459:-
BRCA	cis	rs10129255	0.556	rs9324093	ENSG00000232216.1	IGHV3-43	3.88	0.00011	0.00683	0.09	0.12	Kawasaki disease;	chr14:106683893	chr14:106470264~106470800:-
BRCA	cis	rs7177699	0.534	rs4387568	ENSG00000261143.1	ADAMTS7P3	3.88	0.00011	0.00683	0.15	0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78817172	chr15:77976042~77993057:+
BRCA	cis	rs4478858	0.684	rs7528066	ENSG00000260386.4	LINC01225	-3.88	0.00011	0.00683	-0.14	-0.12	Alcohol dependence;	chr1:31276245	chr1:31500085~31540885:+
BRCA	cis	rs4478858	0.684	rs16834336	ENSG00000260386.4	LINC01225	-3.88	0.00011	0.00683	-0.14	-0.12	Alcohol dependence;	chr1:31278665	chr1:31500085~31540885:+
BRCA	cis	rs4478858	0.735	rs11583123	ENSG00000260386.4	LINC01225	-3.88	0.00011	0.00683	-0.14	-0.12	Alcohol dependence;	chr1:31278925	chr1:31500085~31540885:+
BRCA	cis	rs4478858	0.684	rs7549343	ENSG00000260386.4	LINC01225	-3.88	0.00011	0.00683	-0.14	-0.12	Alcohol dependence;	chr1:31279413	chr1:31500085~31540885:+
BRCA	cis	rs4478858	0.709	rs7514640	ENSG00000260386.4	LINC01225	-3.88	0.00011	0.00683	-0.14	-0.12	Alcohol dependence;	chr1:31279469	chr1:31500085~31540885:+
BRCA	cis	rs4478858	0.684	rs16865957	ENSG00000260386.4	LINC01225	-3.88	0.00011	0.00683	-0.14	-0.12	Alcohol dependence;	chr1:31280506	chr1:31500085~31540885:+
BRCA	cis	rs4478858	0.684	rs2062951	ENSG00000260386.4	LINC01225	-3.88	0.00011	0.00683	-0.14	-0.12	Alcohol dependence;	chr1:31290134	chr1:31500085~31540885:+
BRCA	cis	rs4478858	0.647	rs4949380	ENSG00000260386.4	LINC01225	-3.88	0.00011	0.00683	-0.14	-0.12	Alcohol dependence;	chr1:31291313	chr1:31500085~31540885:+
BRCA	cis	rs2839186	0.771	rs2839155	ENSG00000223901.2	AP001469.5	3.88	0.00011	0.00683	0.12	0.12	Testicular germ cell tumor;	chr21:46220078	chr21:46220269~46225364:+
BRCA	cis	rs58521262	0.585	rs289368	ENSG00000268105.1	RP11-369G6.2	3.88	0.00011	0.00683	0.16	0.12	Testicular germ cell tumor;	chr19:22931626	chr19:23125665~23128543:+
BRCA	cis	rs3768617	0.51	rs20563	ENSG00000224468.3	RP11-181K3.4	3.88	0.00011	0.00683	0.13	0.12	Fuchs's corneal dystrophy;	chr1:183116620	chr1:183138402~183141282:-
BRCA	cis	rs71566846	0.649	rs10949014	ENSG00000272541.1	XXbac-BPGBPG55C20.1	-3.88	0.00011	0.00683	-0.18	-0.12	Coronary artery disease;	chr6:57266415	chr6:57855891~57856468:-
BRCA	cis	rs9527	0.59	rs7089680	ENSG00000213061.2	PFN1P11	-3.88	0.00011	0.00683	-0.16	-0.12	Arsenic metabolism;	chr10:103042314	chr10:102838011~102845473:-
BRCA	cis	rs442309	0.875	rs224066	ENSG00000238280.1	RP11-436D10.3	-3.88	0.00011	0.00683	-0.15	-0.12	Vogt-Koyanagi-Harada syndrome;	chr10:62746419	chr10:62793562~62805887:-
BRCA	cis	rs8180040	0.654	rs11714373	ENSG00000271161.1	BOLA2P2	-3.88	0.000111	0.00683	-0.13	-0.12	Colorectal cancer;	chr3:47173327	chr3:47499841~47500407:+
BRCA	cis	rs964611	0.938	rs12592155	ENSG00000259488.2	RP11-154J22.1	-3.88	0.000111	0.00684	-0.15	-0.12	Metabolite levels (Pyroglutamine);	chr15:48331303	chr15:48312353~48331856:-
BRCA	cis	rs2998286	0.862	rs2807763	ENSG00000237128.1	RP11-351M16.3	-3.88	0.000111	0.00684	-0.15	-0.12	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28528702	chr10:28433008~28495813:-
BRCA	cis	rs6867032	0.527	rs4371796	ENSG00000248994.1	RP11-259O2.1	-3.88	0.000111	0.00684	-0.18	-0.12	Gut microbiome composition (winter);	chr5:1977671	chr5:1933863~1959176:+
BRCA	cis	rs7572644	0.628	rs1948922	ENSG00000223522.1	AC093690.1	-3.88	0.000111	0.00684	-0.13	-0.12	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:28119286	chr2:28307691~28310459:-
BRCA	cis	rs6870983	0.895	rs33704	ENSG00000247828.6	TMEM161B-AS1	3.88	0.000111	0.00684	0.15	0.12	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index;	chr5:88265948	chr5:88268895~88436685:+
BRCA	cis	rs4869313	0.905	rs27993	ENSG00000248734.2	CTD-2260A17.1	-3.88	0.000111	0.00684	-0.12	-0.12	Pediatric autoimmune diseases;	chr5:97019899	chr5:96784777~96785999:+
BRCA	cis	rs2278170	1	rs11032407	ENSG00000225101.4	OR52K3P	-3.88	0.000111	0.00685	-0.16	-0.12	Amyotrophic lateral sclerosis;	chr11:4476211	chr11:4474813~4475755:+
BRCA	cis	rs6951245	0.554	rs10270249	ENSG00000224079.1	AC091729.7	-3.88	0.000111	0.00685	-0.18	-0.12	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1112250	chr7:1074450~1078036:+
BRCA	cis	rs2140773	0.647	rs6741190	ENSG00000244384.3	RN7SL359P	3.88	0.000111	0.00685	0.12	0.12	Liver enzyme levels (gamma-glutamyl transferase);	chr2:232641589	chr2:232649849~232650136:+
BRCA	cis	rs6893300	0.705	rs3756614	ENSG00000250999.1	RP11-1379J22.5	3.88	0.000111	0.00685	0.17	0.12	Resting heart rate;	chr5:179796644	chr5:179657762~179664432:+
BRCA	cis	rs7520050	0.966	rs7539932	ENSG00000234329.1	RP11-767N6.2	-3.88	0.000111	0.00685	-0.11	-0.12	Reticulocyte count;Red blood cell count;	chr1:45826682	chr1:45651039~45651826:-
BRCA	cis	rs7520050	0.966	rs61783200	ENSG00000234329.1	RP11-767N6.2	-3.88	0.000111	0.00685	-0.11	-0.12	Reticulocyte count;Red blood cell count;	chr1:45831731	chr1:45651039~45651826:-
BRCA	cis	rs12468226	0.873	rs1474267	ENSG00000272966.1	RP11-686O6.1	-3.88	0.000111	0.00685	-0.2	-0.12	Urate levels;	chr2:202178596	chr2:202336739~202337200:+
BRCA	cis	rs7903456	0.648	rs9420432	ENSG00000224914.2	LINC00863	-3.88	0.000111	0.00685	-0.15	-0.12	Gout;Renal underexcretion gout;	chr10:87072473	chr10:87342736~87357882:+
BRCA	cis	rs7680126	0.644	rs4697703	ENSG00000250413.1	RP11-448G15.1	3.88	0.000111	0.00685	0.19	0.12	Urate levels in obese individuals;Urate levels in lean individuals;Urate levels in overweight individuals;	chr4:10105807	chr4:10006482~10009725:+
BRCA	cis	rs3750965	0.959	rs4930265	ENSG00000259799.1	RP11-554A11.9	3.88	0.000111	0.00685	0.14	0.12	Hair color;	chr11:69088486	chr11:69155910~69159752:+
BRCA	cis	rs9470794	1	rs77474124	ENSG00000204110.6	RP1-153P14.8	-3.88	0.000111	0.00685	-0.22	-0.12	Type 2 diabetes;	chr6:38077139	chr6:37507348~37535616:+
BRCA	cis	rs78487399	0.808	rs75126888	ENSG00000234936.1	AC010883.5	3.88	0.000111	0.00685	0.18	0.12	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43436868	chr2:43229573~43233394:+
BRCA	cis	rs1730008	0.929	rs1095636	ENSG00000279311.1	RP11-170K4.2	-3.88	0.000111	0.00685	-0.14	-0.12	Lobe attachment (rater-scored or self-reported);	chr3:158250848	chr3:158869898~158871821:+
BRCA	cis	rs1730008	1	rs1204957	ENSG00000279311.1	RP11-170K4.2	-3.88	0.000111	0.00685	-0.14	-0.12	Lobe attachment (rater-scored or self-reported);	chr3:158277314	chr3:158869898~158871821:+
BRCA	cis	rs1730008	1	rs2682402	ENSG00000279311.1	RP11-170K4.2	-3.88	0.000111	0.00685	-0.14	-0.12	Lobe attachment (rater-scored or self-reported);	chr3:158281416	chr3:158869898~158871821:+
BRCA	cis	rs1730008	1	rs2693540	ENSG00000279311.1	RP11-170K4.2	-3.88	0.000111	0.00685	-0.14	-0.12	Lobe attachment (rater-scored or self-reported);	chr3:158283766	chr3:158869898~158871821:+
BRCA	cis	rs28829049	0.597	rs72651403	ENSG00000270728.1	RP4-657E11.10	-3.88	0.000111	0.00685	-0.12	-0.12	QRS duration in Tripanosoma cruzi seropositivity;	chr1:19193393	chr1:19297080~19297903:+
BRCA	cis	rs2108622	0.683	rs111388185	ENSG00000214049.6	UCA1	3.88	0.000111	0.00685	0.17	0.12	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15866604	chr19:15828961~15836320:+
BRCA	cis	rs2108622	0.683	rs112571591	ENSG00000214049.6	UCA1	3.88	0.000111	0.00685	0.17	0.12	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15866635	chr19:15828961~15836320:+
BRCA	cis	rs2108622	0.647	rs111427692	ENSG00000214049.6	UCA1	3.88	0.000111	0.00685	0.17	0.12	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15866669	chr19:15828961~15836320:+
BRCA	cis	rs2380205	1	rs2380205	ENSG00000232807.2	RP11-536K7.3	3.88	0.000111	0.00685	0.12	0.12	Breast cancer;	chr10:5844771	chr10:5934270~5945900:-
BRCA	cis	rs10504130	0.932	rs75990306	ENSG00000272076.1	RP11-11C20.3	3.88	0.000111	0.00685	0.2	0.12	Venous thromboembolism (SNP x SNP interaction);	chr8:51837641	chr8:51810110~51810681:-
BRCA	cis	rs4713118	0.616	rs9348789	ENSG00000216901.1	AL022393.7	3.88	0.000111	0.00685	0.17	0.12	Parkinson's disease;	chr6:28057708	chr6:28176188~28176674:+
BRCA	cis	rs1865760	0.534	rs1541988	ENSG00000272462.2	U91328.19	-3.88	0.000111	0.00685	-0.14	-0.12	Height;	chr6:25950576	chr6:25992662~26001775:+
BRCA	cis	rs990171	0.538	rs7593935	ENSG00000234389.1	AC007278.3	3.88	0.000111	0.00685	0.12	0.12	Lymphocyte counts;	chr2:102501669	chr2:102438713~102440475:+
BRCA	cis	rs990171	0.538	rs2075192	ENSG00000234389.1	AC007278.3	3.88	0.000111	0.00685	0.12	0.12	Lymphocyte counts;	chr2:102501769	chr2:102438713~102440475:+
BRCA	cis	rs990171	0.538	rs2075191	ENSG00000234389.1	AC007278.3	3.88	0.000111	0.00685	0.12	0.12	Lymphocyte counts;	chr2:102501840	chr2:102438713~102440475:+
BRCA	cis	rs990171	0.511	rs2072509	ENSG00000234389.1	AC007278.3	3.88	0.000111	0.00685	0.12	0.12	Lymphocyte counts;	chr2:102501878	chr2:102438713~102440475:+
BRCA	cis	rs990171	0.538	rs2075190	ENSG00000234389.1	AC007278.3	3.88	0.000111	0.00685	0.12	0.12	Lymphocyte counts;	chr2:102502100	chr2:102438713~102440475:+
BRCA	cis	rs6708413	0.501	rs2075189	ENSG00000234389.1	AC007278.3	3.88	0.000111	0.00685	0.12	0.12	Crohn's disease;Inflammatory bowel disease;	chr2:102502230	chr2:102438713~102440475:+
BRCA	cis	rs801193	1	rs2707856	ENSG00000272831.1	RP11-792A8.4	3.88	0.000111	0.00685	0.11	0.12	Aortic root size;	chr7:66746023	chr7:66739829~66740385:-
BRCA	cis	rs11719291	0.833	rs11715835	ENSG00000225399.4	RP11-3B7.1	-3.88	0.000111	0.00686	-0.21	-0.12	Cognitive function;	chr3:48733299	chr3:49260085~49261316:+
BRCA	cis	rs1665650	0.957	rs1665644	ENSG00000232767.1	RP11-498B4.5	-3.88	0.000111	0.00686	-0.13	-0.12	Colorectal cancer;	chr10:116728527	chr10:116670103~116672739:+
BRCA	cis	rs4664293	1	rs11676412	ENSG00000226266.5	AC009961.3	-3.88	0.000111	0.00686	-0.15	-0.12	Monocyte percentage of white cells;	chr2:159651560	chr2:159670708~159712435:-
BRCA	cis	rs1722141	0.571	rs788771	ENSG00000237471.1	AC073115.6	3.88	0.000111	0.00686	0.16	0.12	Sitting height ratio;	chr7:46015281	chr7:45969657~45980191:+
BRCA	cis	rs2274273	1	rs1009977	ENSG00000233924.1	AL160471.6	-3.88	0.000111	0.00686	-0.14	-0.12	Protein biomarker;	chr14:55136284	chr14:55004813~55005687:-
BRCA	cis	rs6517329	0.674	rs1543655	ENSG00000231106.2	LINC01436	3.88	0.000111	0.00686	0.14	0.12	Schizophrenia;	chr21:36111076	chr21:36005338~36007838:+
BRCA	cis	rs10129255	0.957	rs10132367	ENSG00000211958.2	IGHV3-38	3.88	0.000111	0.00686	0.1	0.12	Kawasaki disease;	chr14:106690981	chr14:106410493~106411021:-
BRCA	cis	rs4842666	0.915	rs73437338	ENSG00000270344.2	RP11-734K2.4	3.88	0.000111	0.00686	0.15	0.12	Blood pressure;	chr12:89660842	chr12:89525654~89548005:+
BRCA	cis	rs2562456	0.874	rs9304986	ENSG00000213976.4	CTD-2561J22.2	3.88	0.000111	0.00686	0.14	0.12	Pain;	chr19:21499260	chr19:21382865~21387177:+
BRCA	cis	rs8062405	1	rs62036626	ENSG00000261766.1	RP11-22P6.2	-3.88	0.000111	0.00686	-0.12	-0.12	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28832963	chr16:28862166~28863340:-
BRCA	cis	rs8062405	1	rs62036657	ENSG00000261766.1	RP11-22P6.2	-3.88	0.000111	0.00686	-0.12	-0.12	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28833044	chr16:28862166~28863340:-
BRCA	cis	rs7267979	1	rs1077889	ENSG00000277938.1	RP5-965G21.3	3.88	0.000111	0.00686	0.14	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25287257	chr20:25229150~25231933:+
BRCA	cis	rs1008375	0.932	rs6449315	ENSG00000249502.1	AC006160.5	-3.88	0.000111	0.00686	-0.14	-0.12	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17588596	chr4:17587467~17614571:-
BRCA	cis	rs2274459	0.841	rs12205398	ENSG00000249346.5	LINC01016	3.88	0.000111	0.00686	0.15	0.12	Obesity (extreme);	chr6:33733766	chr6:33867506~33896914:-
BRCA	cis	rs2640806	0.505	rs7012725	ENSG00000253105.4	KB-1448A5.1	3.88	0.000111	0.00686	0.14	0.12	Obesity-related traits;	chr8:96349606	chr8:96371865~96387438:-
BRCA	cis	rs6867032	0.527	rs4975777	ENSG00000248994.1	RP11-259O2.1	-3.88	0.000111	0.00686	-0.17	-0.12	Gut microbiome composition (winter);	chr5:1973210	chr5:1933863~1959176:+
BRCA	cis	rs78487399	0.808	rs75934770	ENSG00000234936.1	AC010883.5	3.88	0.000111	0.00686	0.18	0.12	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43432555	chr2:43229573~43233394:+
BRCA	cis	rs73201462	1	rs11710704	ENSG00000242551.2	POU5F1P6	3.88	0.000111	0.00686	0.2	0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128328393	chr3:128674735~128677005:-
BRCA	cis	rs934734	0.563	rs11126034	ENSG00000281920.1	RP11-418H16.1	-3.88	0.000111	0.00687	-0.14	-0.12	Rheumatoid arthritis;	chr2:65353087	chr2:65623272~65628424:+
BRCA	cis	rs6493858	0.837	rs2718934	ENSG00000277245.1	RP11-48G14.3	-3.88	0.000111	0.00687	-0.14	-0.12	Relative hand skill in reading disability;	chr15:56265220	chr15:56447120~56447697:+
BRCA	cis	rs9788721	0.775	rs12914385	ENSG00000261762.1	RP11-650L12.2	-3.88	0.000111	0.00687	-0.14	-0.12	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78606381	chr15:78589123~78591276:-
BRCA	cis	rs10421328	0.784	rs8107058	ENSG00000267419.1	CTC-559E9.6	-3.88	0.000111	0.00687	-0.13	-0.12	Parental longevity (combined parental age at death);	chr19:19648842	chr19:19776602~19834927:+
BRCA	cis	rs372883	0.967	rs1153287	ENSG00000215533.7	LINC00189	-3.88	0.000111	0.00687	-0.13	-0.12	Pancreatic cancer;	chr21:29313290	chr21:29193480~29288205:+
BRCA	cis	rs61160187	0.582	rs12652830	ENSG00000272308.1	RP11-231G3.1	-3.88	0.000111	0.00687	-0.14	-0.12	Educational attainment (years of education);Educational attainment (college completion);	chr5:60956655	chr5:60866457~60866935:-
BRCA	cis	rs12887734	0.524	rs12888002	ENSG00000269910.1	RP11-73M18.10	3.88	0.000111	0.00687	0.13	0.12	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103772310	chr14:103694516~103695050:-
BRCA	cis	rs801193	1	rs2003301	ENSG00000265600.1	AC006480.1	3.88	0.000111	0.00687	0.14	0.12	Aortic root size;	chr7:66682669	chr7:67356680~67356779:+
BRCA	cis	rs17772222	0.874	rs61984746	ENSG00000258789.1	RP11-507K2.3	-3.88	0.000111	0.00687	-0.15	-0.12	Coronary artery calcification;	chr14:88668136	chr14:88551597~88552493:+
BRCA	cis	rs448720	1	rs12323989	ENSG00000260657.2	RP11-315D16.4	-3.88	0.000111	0.00687	-0.14	-0.12	Cognitive performance;	chr15:67913692	chr15:68267792~68277994:-
BRCA	cis	rs853679	0.517	rs3757187	ENSG00000261839.1	RP1-265C24.8	3.88	0.000111	0.00687	0.17	0.12	Depression;	chr6:28139876	chr6:28136849~28139678:+
BRCA	cis	rs73201462	1	rs2999086	ENSG00000242551.2	POU5F1P6	-3.88	0.000111	0.00687	-0.2	-0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128232405	chr3:128674735~128677005:-
BRCA	cis	rs73201462	1	rs2999085	ENSG00000242551.2	POU5F1P6	-3.88	0.000111	0.00687	-0.2	-0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128232716	chr3:128674735~128677005:-
BRCA	cis	rs73201462	1	rs2999084	ENSG00000242551.2	POU5F1P6	-3.88	0.000111	0.00687	-0.2	-0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128233645	chr3:128674735~128677005:-
BRCA	cis	rs73201462	0.901	rs2999082	ENSG00000242551.2	POU5F1P6	-3.88	0.000111	0.00687	-0.2	-0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128237345	chr3:128674735~128677005:-
BRCA	cis	rs1790761	0.52	rs12805884	ENSG00000231793.4	DOC2GP	-3.88	0.000111	0.00687	-0.13	-0.12	Mean corpuscular volume;	chr11:67620506	chr11:67612653~67616257:-
BRCA	cis	rs721917	0.569	rs2247820	ENSG00000242600.5	MBL1P	3.88	0.000111	0.00687	0.14	0.12	Chronic obstructive pulmonary disease;	chr10:79963123	chr10:79904898~79950336:+
BRCA	cis	rs10998036	0.591	rs10823171	ENSG00000233590.1	RP11-153K11.3	3.88	0.000111	0.00687	0.17	0.12	Optic cup area;	chr10:68292171	chr10:68233251~68242379:-
BRCA	cis	rs1665650	0.914	rs1665649	ENSG00000232767.1	RP11-498B4.5	-3.88	0.000111	0.00687	-0.13	-0.12	Colorectal cancer;	chr10:116727650	chr10:116670103~116672739:+
BRCA	cis	rs9470794	1	rs56308246	ENSG00000204110.6	RP1-153P14.8	-3.88	0.000111	0.00688	-0.25	-0.12	Type 2 diabetes;	chr6:38053961	chr6:37507348~37535616:+
BRCA	cis	rs10435719	0.902	rs4840599	ENSG00000255020.1	AF131216.5	3.88	0.000111	0.00688	0.14	0.12	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11947871	chr8:11345748~11347502:-
BRCA	cis	rs453301	0.686	rs13252797	ENSG00000233609.3	RP11-62H7.2	3.88	0.000111	0.00688	0.11	0.12	Joint mobility (Beighton score);	chr8:9003920	chr8:8961200~8979025:+
BRCA	cis	rs9788721	0.836	rs17483721	ENSG00000261762.1	RP11-650L12.2	3.88	0.000111	0.00688	0.14	0.12	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78441389	chr15:78589123~78591276:-
BRCA	cis	rs801193	0.636	rs2659895	ENSG00000273448.1	RP11-166O4.6	3.88	0.000111	0.00688	0.11	0.12	Aortic root size;	chr7:66731484	chr7:67333047~67334383:+
BRCA	cis	rs6963495	0.818	rs6944787	ENSG00000223886.3	RP11-251G23.2	3.88	0.000111	0.00688	0.18	0.12	Bipolar disorder (body mass index interaction);	chr7:105506862	chr7:105530209~105530671:+
BRCA	cis	rs6963495	0.818	rs73190133	ENSG00000223886.3	RP11-251G23.2	3.88	0.000111	0.00688	0.18	0.12	Bipolar disorder (body mass index interaction);	chr7:105507374	chr7:105530209~105530671:+
BRCA	cis	rs6963495	0.932	rs55700120	ENSG00000223886.3	RP11-251G23.2	3.88	0.000111	0.00688	0.18	0.12	Bipolar disorder (body mass index interaction);	chr7:105508013	chr7:105530209~105530671:+
BRCA	cis	rs6963495	0.818	rs6956234	ENSG00000223886.3	RP11-251G23.2	3.88	0.000111	0.00688	0.18	0.12	Bipolar disorder (body mass index interaction);	chr7:105509260	chr7:105530209~105530671:+
BRCA	cis	rs6963495	0.818	rs6956249	ENSG00000223886.3	RP11-251G23.2	3.88	0.000111	0.00688	0.18	0.12	Bipolar disorder (body mass index interaction);	chr7:105509296	chr7:105530209~105530671:+
BRCA	cis	rs9959145	0.706	rs28663159	ENSG00000267108.1	RP11-861E21.1	3.88	0.000111	0.00688	0.21	0.12	Immune response to smallpox vaccine (IL-6);	chr18:12612441	chr18:12432897~12437635:+
BRCA	cis	rs7829975	0.606	rs6422352	ENSG00000254153.1	CTA-398F10.2	-3.88	0.000111	0.00688	-0.14	-0.12	Mood instability;	chr8:8936683	chr8:8456909~8461337:-
BRCA	cis	rs4415084	0.966	rs10805685	ENSG00000248779.1	RP11-53O19.2	3.88	0.000111	0.00688	0.11	0.12	Breast cancer;	chr5:44661856	chr5:44752949~44765744:+
BRCA	cis	rs6545883	0.894	rs778143	ENSG00000273302.1	RP11-493E12.2	3.88	0.000111	0.00688	0.11	0.12	Tuberculosis;	chr2:61354755	chr2:61199979~61200769:+
BRCA	cis	rs875971	0.862	rs1612452	ENSG00000271064.1	RP11-792A8.3	3.88	0.000111	0.00688	0.14	0.12	Aortic root size;	chr7:66108909	chr7:66748838~66749077:-
BRCA	cis	rs2243480	1	rs313813	ENSG00000237026.1	RP11-328P23.2	3.88	0.000111	0.00688	0.23	0.12	Diabetic kidney disease;	chr7:66038513	chr7:65235790~65236723:-
BRCA	cis	rs7177699	0.557	rs7403728	ENSG00000261143.1	ADAMTS7P3	3.88	0.000111	0.00688	0.15	0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78819674	chr15:77976042~77993057:+
BRCA	cis	rs67981189	0.593	rs2810101	ENSG00000258571.1	PTTG4P	3.88	0.000111	0.00688	0.13	0.12	Schizophrenia;	chr14:70963110	chr14:71085482~71085833:-
BRCA	cis	rs2518049	0.654	rs61854739	ENSG00000224034.1	RP11-445P17.8	-3.88	0.000111	0.00688	-0.23	-0.12	Metabolic traits;	chr10:5200008	chr10:5266033~5271236:-
BRCA	cis	rs2243480	1	rs2462569	ENSG00000226002.1	RP11-460N20.5	3.88	0.000111	0.00688	0.19	0.12	Diabetic kidney disease;	chr7:66009859	chr7:65084103~65100232:+
BRCA	cis	rs983392	0.904	rs1125357	ENSG00000275344.1	MIR6503	-3.88	0.000111	0.00688	-0.13	-0.12	Alzheimer's disease (late onset);	chr11:60118020	chr11:60209071~60209156:-
BRCA	cis	rs9420	0.528	rs10896632	ENSG00000265566.2	RN7SL605P	-3.88	0.000111	0.00688	-0.16	-0.12	Schizophrenia;	chr11:57622829	chr11:57528085~57528365:-
BRCA	cis	rs7177699	0.55	rs4468572	ENSG00000261143.1	ADAMTS7P3	3.88	0.000112	0.00689	0.14	0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78832133	chr15:77976042~77993057:+
BRCA	cis	rs17292804	0.506	rs71417868	ENSG00000269940.1	RP11-73M18.7	3.88	0.000112	0.00689	0.13	0.12	Autism spectrum disorder or schizophrenia;	chr14:103580255	chr14:103694560~103695170:+
BRCA	cis	rs72928364	1	rs7431835	ENSG00000244119.1	PDCL3P4	3.88	0.000112	0.00689	0.14	0.12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100923879	chr3:101712472~101713191:+
BRCA	cis	rs7246967	0.932	rs62120780	ENSG00000198153.8	ZNF849P	-3.88	0.000112	0.00689	-0.17	-0.12	Bronchopulmonary dysplasia;	chr19:22860912	chr19:22685167~22686732:+
BRCA	cis	rs983392	0.591	rs3132886	ENSG00000275344.1	MIR6503	3.88	0.000112	0.00689	0.12	0.12	Alzheimer's disease (late onset);	chr11:60248914	chr11:60209071~60209156:-
BRCA	cis	rs9788721	0.835	rs17487223	ENSG00000261762.1	RP11-650L12.2	3.88	0.000112	0.00689	0.14	0.12	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78631645	chr15:78589123~78591276:-
BRCA	cis	rs2301573	0.584	rs1136553	ENSG00000271270.4	TMCC1-AS1	-3.88	0.000112	0.00689	-0.26	-0.12	Hip circumference;	chr3:129648120	chr3:129893871~129918575:+
BRCA	cis	rs4730430	0.539	rs10234862	ENSG00000226965.1	AC003088.1	3.88	0.000112	0.00689	0.14	0.12	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr7:110480134	chr7:110432239~110534754:-
BRCA	cis	rs35306767	0.855	rs12761180	ENSG00000229869.1	RP11-363N22.2	-3.88	0.000112	0.00689	-0.21	-0.12	Eosinophil percentage of granulocytes;	chr10:826146	chr10:933026~942743:+
BRCA	cis	rs1670533	0.932	rs2248083	ENSG00000251639.2	RP11-20I20.1	3.88	0.000112	0.0069	0.19	0.12	Recombination rate (females);	chr4:1058378	chr4:1100016~1101558:-
BRCA	cis	rs7267979	1	rs6115153	ENSG00000274414.1	RP5-965G21.4	3.88	0.000112	0.0069	0.14	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25344931	chr20:25239007~25245229:-
BRCA	cis	rs7917772	0.502	rs10748827	ENSG00000213061.2	PFN1P11	-3.88	0.000112	0.0069	-0.16	-0.12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;	chr10:102608579	chr10:102838011~102845473:-
BRCA	cis	rs6964587	0.967	rs34863529	ENSG00000188693.7	CYP51A1-AS1	-3.88	0.000112	0.0069	-0.13	-0.12	Breast cancer;	chr7:92015027	chr7:92134604~92180725:+
BRCA	cis	rs875971	1	rs3735148	ENSG00000265600.1	AC006480.1	-3.88	0.000112	0.0069	-0.14	-0.12	Aortic root size;	chr7:66506022	chr7:67356680~67356779:+
BRCA	cis	rs7917772	0.503	rs746552	ENSG00000213061.2	PFN1P11	-3.88	0.000112	0.0069	-0.16	-0.12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;	chr10:102582744	chr10:102838011~102845473:-
BRCA	cis	rs804280	0.662	rs11250164	ENSG00000270154.1	RP11-419I17.1	-3.88	0.000112	0.0069	-0.15	-0.12	Myopia (pathological);	chr8:11753177	chr8:12476462~12477122:+
BRCA	cis	rs1075265	0.73	rs7597189	ENSG00000272156.1	RP11-477N3.1	-3.88	0.000112	0.0069	-0.12	-0.12	Chronotype;Morning vs. evening chronotype;	chr2:54014733	chr2:54082554~54085066:+
BRCA	cis	rs651907	0.817	rs654102	ENSG00000244119.1	PDCL3P4	3.88	0.000112	0.0069	0.1	0.12	Colorectal cancer;	chr3:101889311	chr3:101712472~101713191:+
BRCA	cis	rs2880765	0.743	rs6497191	ENSG00000230373.7	GOLGA6L5P	3.88	0.000112	0.0069	0.13	0.12	Coronary artery disease;	chr15:85468270	chr15:84507885~84516814:-
BRCA	cis	rs2692947	0.864	rs2579518	ENSG00000237510.6	AC008268.2	3.88	0.000112	0.0069	0.16	0.12	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96009511	chr2:95789654~95800166:+
BRCA	cis	rs4683346	1	rs11129978	ENSG00000173811.9	CCDC13-AS1	3.88	0.000112	0.0069	0.15	0.12	Granulocyte percentage of myeloid white cells;	chr3:42842084	chr3:42732575~42746768:+
BRCA	cis	rs453301	0.686	rs1045527	ENSG00000233609.3	RP11-62H7.2	-3.88	0.000112	0.0069	-0.11	-0.12	Joint mobility (Beighton score);	chr8:9032531	chr8:8961200~8979025:+
BRCA	cis	rs4415084	1	rs6874055	ENSG00000248779.1	RP11-53O19.2	3.88	0.000112	0.0069	0.11	0.12	Breast cancer;	chr5:44666863	chr5:44752949~44765744:+
BRCA	cis	rs310501	0.921	rs587893	ENSG00000281327.1	LINC01338	-3.88	0.000112	0.0069	-0.15	-0.12	Major depressive disorder;	chr5:83591221	chr5:82850864~82859836:-
BRCA	cis	rs1371614	0.632	rs7599286	ENSG00000272148.1	RP11-195B17.1	3.88	0.000112	0.0069	0.13	0.12	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26929530	chr2:27062428~27062907:-
BRCA	cis	rs1371614	0.61	rs2384511	ENSG00000272148.1	RP11-195B17.1	3.88	0.000112	0.0069	0.13	0.12	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26929867	chr2:27062428~27062907:-
BRCA	cis	rs12724450	0.793	rs34001546	ENSG00000228126.1	FALEC	3.88	0.000112	0.0069	0.21	0.12	Blood protein levels;	chr1:150487239	chr1:150515757~150518032:+
BRCA	cis	rs7221109	0.677	rs8068721	ENSG00000229028.2	KRT223P	3.88	0.000112	0.0069	0.14	0.12	Type 1 diabetes;	chr17:40657572	chr17:40717235~40721932:-
BRCA	cis	rs6044112	0.784	rs6080293	ENSG00000273998.1	RP4-777L9.2	3.88	0.000112	0.00691	0.21	0.12	Response to taxane treatment (docetaxel);	chr20:16536269	chr20:16576068~16579615:+
BRCA	cis	rs72928364	0.86	rs17219986	ENSG00000256628.3	ZBTB11-AS1	3.88	0.000112	0.00691	0.22	0.12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:101080826	chr3:101676475~101679217:+
BRCA	cis	rs36093844	0.898	rs11234463	ENSG00000279742.1	RP11-700A24.1	-3.88	0.000112	0.00691	-0.16	-0.12	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85886042	chr11:85852557~85854943:-
BRCA	cis	rs11098403	0.833	rs1841215	ENSG00000225892.3	RP11-384K6.2	3.88	0.000112	0.00691	0.12	0.12	Schizophrenia;	chr4:117754672	chr4:118632274~118634759:+
BRCA	cis	rs2018683	0.707	rs4719961	ENSG00000228421.2	AC005013.5	3.88	0.000112	0.00691	0.15	0.12	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28929896	chr7:28957667~28959345:+
BRCA	cis	rs1434579	0.966	rs12151338	ENSG00000176761.7	ZNF285B	-3.88	0.000112	0.00691	-0.14	-0.12	Tuberculosis;	chr19:44429772	chr19:44467641~44473227:+
BRCA	cis	rs9381040	0.599	rs2057001	ENSG00000161912.16	ADCY10P1	3.88	0.000112	0.00691	0.13	0.12	Alzheimer's disease (late onset);	chr6:41055208	chr6:41101022~41140835:+
BRCA	cis	rs2333021	0.934	rs12879195	ENSG00000259015.1	RP11-109N23.6	3.88	0.000112	0.00691	0.12	0.12	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:73006248	chr14:72960595~72961993:+
BRCA	cis	rs10129255	0.957	rs10136781	ENSG00000211967.3	IGHV3-53	-3.88	0.000112	0.00691	-0.08	-0.12	Kawasaki disease;	chr14:106780451	chr14:106592676~106593347:-
BRCA	cis	rs748404	0.666	rs16957715	ENSG00000166763.7	STRCP1	3.88	0.000112	0.00691	0.17	0.12	Lung cancer;	chr15:43416539	chr15:43699488~43718184:-
BRCA	cis	rs718433	0.584	rs1569292	ENSG00000211778.2	TRAV4	-3.88	0.000112	0.00691	-0.08	-0.12	Intraocular pressure;	chr14:21748709	chr14:21736152~21736982:+
BRCA	cis	rs78487399	0.71	rs6731998	ENSG00000234936.1	AC010883.5	3.88	0.000112	0.00691	0.18	0.12	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43450134	chr2:43229573~43233394:+
BRCA	cis	rs45509595	0.822	rs200484	ENSG00000216901.1	AL022393.7	3.88	0.000112	0.00692	0.23	0.12	Breast cancer;	chr6:27807896	chr6:28176188~28176674:+
BRCA	cis	rs2270204	0.526	rs4734	ENSG00000272696.1	RP11-339B21.13	3.88	0.000112	0.00692	0.19	0.12	Body mass index;	chr9:128256360	chr9:128316337~128316909:+
BRCA	cis	rs7937682	0.602	rs11214036	ENSG00000176343.5	RPL37AP8	-3.88	0.000112	0.00692	-0.14	-0.12	Primary sclerosing cholangitis;	chr11:111902445	chr11:111889199~111889474:-
BRCA	cis	rs58521262	0.556	rs290579	ENSG00000268105.1	RP11-369G6.2	-3.88	0.000112	0.00692	-0.16	-0.12	Testicular germ cell tumor;	chr19:23038265	chr19:23125665~23128543:+
BRCA	cis	rs4648045	0.536	rs12648696	ENSG00000251288.2	RP11-10L12.2	-3.88	0.000112	0.00692	-0.15	-0.12	Lymphocyte percentage of white cells;	chr4:102625739	chr4:102751401~102752641:+
BRCA	cis	rs10107145	0.509	rs4310166	ENSG00000154316.13	TDH	3.88	0.000112	0.00692	0.16	0.12	Systolic blood pressure;	chr8:10906226	chr8:11339637~11368452:+
BRCA	cis	rs1383484	0.798	rs59355989	ENSG00000230373.7	GOLGA6L5P	-3.88	0.000112	0.00692	-0.15	-0.12	Height;	chr15:83841979	chr15:84507885~84516814:-
BRCA	cis	rs1799955	1	rs9567600	ENSG00000215515.2	IFIT1P1	-3.88	0.000112	0.00692	-0.17	-0.12	LDL cholesterol levels;	chr13:32359789	chr13:32384660~32386108:+
BRCA	cis	rs1971762	0.527	rs7976398	ENSG00000270175.1	RP11-793H13.11	-3.88	0.000112	0.00692	-0.1	-0.12	Height;	chr12:53635078	chr12:53500162~53500936:-
BRCA	cis	rs2071426	0.622	rs11188131	ENSG00000273450.1	RP11-76P2.4	3.88	0.000112	0.00692	0.15	0.12	Blood metabolite levels;	chr10:95008654	chr10:94314907~94315327:-
BRCA	cis	rs7267979	1	rs6050559	ENSG00000277938.1	RP5-965G21.3	3.88	0.000112	0.00692	0.14	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25349279	chr20:25229150~25231933:+
BRCA	cis	rs17796831	0.898	rs7147051	ENSG00000205562.2	RP11-497E19.1	-3.88	0.000112	0.00692	-0.12	-0.12	Lobe attachment (rater-scored or self-reported);	chr14:85326821	chr14:85524432~85529988:-
BRCA	cis	rs448720	1	rs4777009	ENSG00000260657.2	RP11-315D16.4	-3.88	0.000112	0.00692	-0.14	-0.12	Cognitive performance;	chr15:67908169	chr15:68267792~68277994:-
BRCA	cis	rs2243480	1	rs402418	ENSG00000237026.1	RP11-328P23.2	3.88	0.000112	0.00692	0.23	0.12	Diabetic kidney disease;	chr7:66044482	chr7:65235790~65236723:-
BRCA	cis	rs7267979	0.816	rs1044573	ENSG00000277938.1	RP5-965G21.3	3.88	0.000112	0.00693	0.14	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25226018	chr20:25229150~25231933:+
BRCA	cis	rs6012564	0.855	rs6095394	ENSG00000227431.4	CSE1L-AS1	-3.88	0.000112	0.00693	-0.15	-0.12	Anger;	chr20:49009007	chr20:49040463~49046044:-
BRCA	cis	rs7312933	0.703	rs2406567	ENSG00000257225.1	RP11-328C8.4	-3.88	0.000112	0.00693	-0.14	-0.12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42157677	chr12:42459366~42466128:+
BRCA	cis	rs7620503	1	rs4555562	ENSG00000277241.1	RP11-114M1.3	3.88	0.000112	0.00693	0.13	0.12	Corneal structure;	chr3:177580775	chr3:177700346~177701072:-
BRCA	cis	rs7620503	1	rs4257602	ENSG00000277241.1	RP11-114M1.3	3.88	0.000112	0.00693	0.13	0.12	Corneal structure;	chr3:177580907	chr3:177700346~177701072:-
BRCA	cis	rs7620503	1	rs4290846	ENSG00000277241.1	RP11-114M1.3	3.88	0.000112	0.00693	0.13	0.12	Corneal structure;	chr3:177581146	chr3:177700346~177701072:-
BRCA	cis	rs11603691	1	rs2155232	ENSG00000254662.1	RP11-872D17.4	-3.88	0.000112	0.00693	-0.25	-0.12	Low high density lipoprotein cholesterol levels;	chr11:57273904	chr11:57325603~57327958:+
BRCA	cis	rs10504130	0.569	rs34364864	ENSG00000253844.1	RP11-546K22.1	-3.88	0.000112	0.00693	-0.17	-0.12	Venous thromboembolism (SNP x SNP interaction);	chr8:51817086	chr8:51961458~52022974:+
BRCA	cis	rs970548	0.955	rs10900232	ENSG00000230869.1	CTGLF10P	3.88	0.000112	0.00693	0.15	0.12	Total cholesterol levels;HDL cholesterol;HDL cholesterol levels;Cholesterol, total;	chr10:45662444	chr10:45678692~45700532:+
BRCA	cis	rs2274273	0.623	rs1187877	ENSG00000259318.1	RP11-454L9.2	-3.88	0.000112	0.00693	-0.1	-0.12	Protein biomarker;	chr14:55028443	chr14:55394940~55395233:-
BRCA	cis	rs7267979	0.966	rs4813557	ENSG00000277938.1	RP5-965G21.3	-3.88	0.000112	0.00693	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25311909	chr20:25229150~25231933:+
BRCA	cis	rs11098499	0.874	rs6851169	ENSG00000260091.1	RP11-33B1.4	-3.88	0.000112	0.00693	-0.11	-0.12	Corneal astigmatism;	chr4:119196355	chr4:119409333~119410233:+
BRCA	cis	rs35520189	1	rs12053091	ENSG00000189223.12	PAX8-AS1	-3.88	0.000112	0.00693	-0.19	-0.12	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:112853203	chr2:113211522~113276581:+
BRCA	cis	rs12680842	0.883	rs13265241	ENSG00000254315.1	RP11-267M23.3	3.88	0.000112	0.00693	0.15	0.12	Body mass index;	chr8:94575129	chr8:94533628~94534391:+
BRCA	cis	rs988913	0.541	rs9464196	ENSG00000261116.1	RP3-523K23.2	3.88	0.000112	0.00693	0.14	0.12	Menarche (age at onset);	chr6:55132851	chr6:54943167~54945099:+
BRCA	cis	rs78487399	0.808	rs13405158	ENSG00000234936.1	AC010883.5	-3.88	0.000112	0.00693	-0.17	-0.12	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43478147	chr2:43229573~43233394:+
BRCA	cis	rs4664293	1	rs6432542	ENSG00000224152.1	AC009506.1	-3.88	0.000112	0.00693	-0.13	-0.12	Monocyte percentage of white cells;	chr2:159624025	chr2:159615296~159617082:+
BRCA	cis	rs17092148	0.636	rs7273470	ENSG00000126005.14	MMP24-AS1	-3.88	0.000112	0.00693	-0.16	-0.12	Neuroticism;	chr20:34869118	chr20:35216462~35278131:-
BRCA	cis	rs4974559	0.947	rs10000797	ENSG00000253399.1	AC078852.2	3.88	0.000112	0.00693	0.18	0.12	Systolic blood pressure;	chr4:1351859	chr4:1358479~1359461:+
BRCA	cis	rs2281603	0.762	rs10144661	ENSG00000259116.1	RP11-973N13.4	-3.88	0.000112	0.00693	-0.11	-0.12	Lymphocyte counts;	chr14:64569651	chr14:64514154~64540368:-
BRCA	cis	rs448720	1	rs410554	ENSG00000260657.2	RP11-315D16.4	-3.88	0.000112	0.00693	-0.14	-0.12	Cognitive performance;	chr15:67906161	chr15:68267792~68277994:-
BRCA	cis	rs11892454	0.599	rs6724092	ENSG00000217643.1	PTGES3P2	-3.88	0.000112	0.00693	-0.13	-0.12	Heschl's gyrus morphology;	chr2:25764137	chr2:25822469~25822950:+
BRCA	cis	rs2243480	0.803	rs423187	ENSG00000226002.1	RP11-460N20.5	-3.88	0.000112	0.00693	-0.2	-0.12	Diabetic kidney disease;	chr7:66044512	chr7:65084103~65100232:+
BRCA	cis	rs6088580	0.634	rs6087577	ENSG00000276073.1	RP5-1125A11.7	-3.88	0.000112	0.00693	-0.13	-0.12	Glomerular filtration rate (creatinine);	chr20:34367617	chr20:33985617~33988989:-
BRCA	cis	rs990171	0.538	rs6705272	ENSG00000234389.1	AC007278.3	3.88	0.000112	0.00694	0.12	0.12	Lymphocyte counts;	chr2:102490110	chr2:102438713~102440475:+
BRCA	cis	rs7833787	1	rs17468166	ENSG00000254054.2	RP11-156K13.3	3.88	0.000112	0.00694	0.14	0.12	Obesity-related traits;	chr8:18847537	chr8:17905756~17907887:+
BRCA	cis	rs1865760	0.963	rs9356991	ENSG00000272462.2	U91328.19	-3.88	0.000112	0.00694	-0.14	-0.12	Height;	chr6:25901530	chr6:25992662~26001775:+
BRCA	cis	rs12368653	0.607	rs7966795	ENSG00000257159.1	RP11-58A17.3	-3.88	0.000112	0.00694	-0.14	-0.12	Multiple sclerosis;	chr12:57637630	chr12:57967058~57968399:+
BRCA	cis	rs8114671	0.562	rs3746450	ENSG00000126005.14	MMP24-AS1	-3.88	0.000112	0.00694	-0.14	-0.12	Height;	chr20:34920785	chr20:35216462~35278131:-
BRCA	cis	rs8114671	0.562	rs6087649	ENSG00000126005.14	MMP24-AS1	-3.88	0.000112	0.00694	-0.14	-0.12	Height;	chr20:34922859	chr20:35216462~35278131:-
BRCA	cis	rs8114671	0.562	rs4911449	ENSG00000126005.14	MMP24-AS1	-3.88	0.000112	0.00694	-0.14	-0.12	Height;	chr20:34924433	chr20:35216462~35278131:-
BRCA	cis	rs1371614	0.611	rs540490	ENSG00000229122.1	AGBL5-IT1	-3.88	0.000112	0.00694	-0.13	-0.12	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26909954	chr2:27061038~27061815:+
BRCA	cis	rs4713118	0.866	rs9468217	ENSG00000219392.1	RP1-265C24.5	-3.88	0.000112	0.00694	-0.17	-0.12	Parkinson's disease;	chr6:27758688	chr6:28115628~28116551:+
BRCA	cis	rs4713118	0.911	rs9295746	ENSG00000219392.1	RP1-265C24.5	-3.88	0.000112	0.00694	-0.17	-0.12	Parkinson's disease;	chr6:27762285	chr6:28115628~28116551:+
BRCA	cis	rs801193	0.935	rs11772264	ENSG00000272831.1	RP11-792A8.4	3.88	0.000112	0.00694	0.11	0.12	Aortic root size;	chr7:66711400	chr7:66739829~66740385:-
BRCA	cis	rs1434579	0.865	rs12980701	ENSG00000176761.7	ZNF285B	-3.88	0.000113	0.00694	-0.14	-0.12	Tuberculosis;	chr19:44443830	chr19:44467641~44473227:+
BRCA	cis	rs6736093	0.897	rs4848874	ENSG00000236307.2	EEF1E1P1	-3.88	0.000113	0.00695	-0.15	-0.12	Coronary artery disease;	chr2:111923923	chr2:111887914~111888741:+
BRCA	cis	rs2380205	0.967	rs11255581	ENSG00000232807.2	RP11-536K7.3	3.88	0.000113	0.00695	0.12	0.12	Breast cancer;	chr10:5856919	chr10:5934270~5945900:-
BRCA	cis	rs4849121	0.535	rs999641	ENSG00000235721.1	AC013268.3	-3.88	0.000113	0.00695	-0.16	-0.12	IgA nephropathy;	chr2:110840830	chr2:110007675~110010783:+
BRCA	cis	rs34929064	0.718	rs1476483	ENSG00000179428.2	AC073072.5	3.88	0.000113	0.00695	0.17	0.12	Major depression and alcohol dependence;	chr7:22691580	chr7:22725395~22727620:-
BRCA	cis	rs7695732	0.743	rs2869971	ENSG00000270720.1	RP11-84C13.2	-3.88	0.000113	0.00695	-0.16	-0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr4:88999540	chr4:89119284~89119871:+
BRCA	cis	rs56281245	1	rs59004463	ENSG00000249363.1	CTB-78O21.1	3.88	0.000113	0.00695	0.25	0.12	Hepcidin levels;	chr5:145594854	chr5:145728360~145729349:-
BRCA	cis	rs6429082	0.51	rs2803849	ENSG00000230026.2	RP11-382D8.5	-3.88	0.000113	0.00695	-0.13	-0.12	Adiposity;	chr1:235339932	chr1:235361153~235362540:+
BRCA	cis	rs34929064	0.718	rs2097676	ENSG00000179428.2	AC073072.5	-3.88	0.000113	0.00695	-0.17	-0.12	Major depression and alcohol dependence;	chr7:22693186	chr7:22725395~22727620:-
BRCA	cis	rs687432	0.812	rs35401618	ENSG00000265566.2	RN7SL605P	-3.88	0.000113	0.00695	-0.17	-0.12	Parkinson's disease;	chr11:58083569	chr11:57528085~57528365:-
BRCA	cis	rs2274459	1	rs36122085	ENSG00000249346.5	LINC01016	3.88	0.000113	0.00695	0.16	0.12	Obesity (extreme);	chr6:33797478	chr6:33867506~33896914:-
BRCA	cis	rs7267979	1	rs2424712	ENSG00000204556.4	CTD-2514C3.1	-3.88	0.000113	0.00695	-0.16	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25436306	chr20:26018832~26020684:+
BRCA	cis	rs7267979	0.966	rs2424714	ENSG00000204556.4	CTD-2514C3.1	-3.88	0.000113	0.00695	-0.16	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25438045	chr20:26018832~26020684:+
BRCA	cis	rs7267979	0.966	rs2424715	ENSG00000204556.4	CTD-2514C3.1	-3.88	0.000113	0.00695	-0.16	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25439441	chr20:26018832~26020684:+
BRCA	cis	rs8062405	1	rs55830740	ENSG00000261766.1	RP11-22P6.2	-3.88	0.000113	0.00695	-0.12	-0.12	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835828	chr16:28862166~28863340:-
BRCA	cis	rs875971	0.545	rs2420612	ENSG00000232546.1	RP11-458F8.1	3.88	0.000113	0.00695	0.12	0.12	Aortic root size;	chr7:66536825	chr7:66848496~66858136:+
BRCA	cis	rs2562456	0.917	rs2681377	ENSG00000213976.4	CTD-2561J22.2	3.88	0.000113	0.00695	0.14	0.12	Pain;	chr19:21533718	chr19:21382865~21387177:+
BRCA	cis	rs12887734	0.546	rs66676135	ENSG00000269940.1	RP11-73M18.7	3.88	0.000113	0.00695	0.13	0.12	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103805167	chr14:103694560~103695170:+
BRCA	cis	rs7011507	0.617	rs10087280	ENSG00000233858.4	AC026904.1	-3.88	0.000113	0.00695	-0.15	-0.12	Inflammatory bowel disease;Ulcerative colitis;	chr8:48479276	chr8:48590401~48594621:+
BRCA	cis	rs9467773	0.62	rs2494700	ENSG00000224843.5	LINC00240	-3.88	0.000113	0.00695	-0.13	-0.12	Intelligence (multi-trait analysis);	chr6:26631078	chr6:26956992~27023924:+
BRCA	cis	rs9467773	0.584	rs1021372	ENSG00000224843.5	LINC00240	-3.88	0.000113	0.00695	-0.13	-0.12	Intelligence (multi-trait analysis);	chr6:26632216	chr6:26956992~27023924:+
BRCA	cis	rs9467773	0.583	rs1021373	ENSG00000224843.5	LINC00240	-3.88	0.000113	0.00695	-0.13	-0.12	Intelligence (multi-trait analysis);	chr6:26632229	chr6:26956992~27023924:+
BRCA	cis	rs9467773	0.62	rs2451744	ENSG00000224843.5	LINC00240	-3.88	0.000113	0.00695	-0.13	-0.12	Intelligence (multi-trait analysis);	chr6:26633235	chr6:26956992~27023924:+
BRCA	cis	rs9467773	0.62	rs2494701	ENSG00000224843.5	LINC00240	-3.88	0.000113	0.00695	-0.13	-0.12	Intelligence (multi-trait analysis);	chr6:26634204	chr6:26956992~27023924:+
BRCA	cis	rs9467773	0.62	rs1027204	ENSG00000224843.5	LINC00240	-3.88	0.000113	0.00695	-0.13	-0.12	Intelligence (multi-trait analysis);	chr6:26639385	chr6:26956992~27023924:+
BRCA	cis	rs752010	0.841	rs11210498	ENSG00000230638.4	RP11-486B10.4	-3.88	0.000113	0.00696	-0.14	-0.12	Lupus nephritis in systemic lupus erythematosus;	chr1:41612287	chr1:41542069~41544310:+
BRCA	cis	rs4538475	0.559	rs73243105	ENSG00000273133.1	RP11-799M12.2	-3.88	0.000113	0.00696	-0.24	-0.12	Parkinson's disease;	chr4:15659732	chr4:15563698~15564253:-
BRCA	cis	rs2075466	0.588	rs17832589	ENSG00000267077.1	RP11-127I20.5	-3.88	0.000113	0.00696	-0.17	-0.12	Colonoscopy-negative controls vs population controls;	chr16:4828587	chr16:4795265~4796532:-
BRCA	cis	rs860295	0.557	rs11264371	ENSG00000232093.1	RP11-307C12.11	3.88	0.000113	0.00696	0.13	0.12	Body mass index;	chr1:155442246	chr1:155045191~155046118:-
BRCA	cis	rs6071166	0.683	rs1885459	ENSG00000224635.1	RP4-564F22.5	-3.88	0.000113	0.00696	-0.14	-0.12	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38686293	chr20:38406011~38416797:-
BRCA	cis	rs2274273	0.682	rs1201378	ENSG00000233924.1	AL160471.6	3.88	0.000113	0.00696	0.13	0.12	Protein biomarker;	chr14:55026690	chr14:55004813~55005687:-
BRCA	cis	rs256438	0.524	rs405112	ENSG00000251050.1	RP11-168A11.4	-3.88	0.000113	0.00696	-0.13	-0.12	Serum thyroid-stimulating hormone levels;	chr5:80057044	chr5:80019609~80019920:+
BRCA	cis	rs7267979	1	rs6050617	ENSG00000204556.4	CTD-2514C3.1	-3.88	0.000113	0.00696	-0.16	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25441012	chr20:26018832~26020684:+
BRCA	cis	rs7267979	0.933	rs2387887	ENSG00000204556.4	CTD-2514C3.1	-3.88	0.000113	0.00696	-0.16	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25446445	chr20:26018832~26020684:+
BRCA	cis	rs7267979	1	rs6037121	ENSG00000204556.4	CTD-2514C3.1	-3.88	0.000113	0.00696	-0.16	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25447675	chr20:26018832~26020684:+
BRCA	cis	rs7267979	1	rs1047171	ENSG00000204556.4	CTD-2514C3.1	-3.88	0.000113	0.00696	-0.16	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25448150	chr20:26018832~26020684:+
BRCA	cis	rs7267979	1	rs6050629	ENSG00000204556.4	CTD-2514C3.1	-3.88	0.000113	0.00696	-0.16	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25450044	chr20:26018832~26020684:+
BRCA	cis	rs7267979	1	rs6050630	ENSG00000204556.4	CTD-2514C3.1	-3.88	0.000113	0.00696	-0.16	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25450109	chr20:26018832~26020684:+
BRCA	cis	rs957448	1	rs16916874	ENSG00000261437.1	RP11-22C11.2	3.88	0.000113	0.00696	0.13	0.12	Nonsyndromic cleft lip with cleft palate;	chr8:94537749	chr8:94637285~94639467:-
BRCA	cis	rs7712401	0.791	rs4835897	ENSG00000251538.4	RP11-166A12.1	3.88	0.000113	0.00696	0.13	0.12	Mean platelet volume;	chr5:122785809	chr5:122628952~122730685:-
BRCA	cis	rs7119	0.604	rs2682921	ENSG00000259362.2	RP11-307C19.1	3.88	0.000113	0.00696	0.17	0.12	Type 2 diabetes;	chr15:77573117	chr15:77525540~77534110:+
BRCA	cis	rs11239930	0.538	rs59064267	ENSG00000237188.3	RP11-337C18.8	3.88	0.000113	0.00696	0.14	0.12	AIDS progression;	chr1:147089146	chr1:147172771~147211568:+
BRCA	cis	rs863345	0.604	rs10908657	ENSG00000229914.1	RP11-404O13.4	-3.88	0.000113	0.00696	-0.13	-0.12	Pneumococcal bacteremia;	chr1:158495453	chr1:158195633~158196131:-
BRCA	cis	rs6593122	0.505	rs5009547	ENSG00000235454.1	HAUS6P3	-3.88	0.000113	0.00696	-0.16	-0.12	Vaccine-related adverse events;	chr7:54121792	chr7:53862233~53863339:+
BRCA	cis	rs794185	0.532	rs304072	ENSG00000231249.1	ITPR1-AS1	-3.88	0.000113	0.00696	-0.14	-0.12	Multiple sclerosis--Brain Glutamate Levels;	chr3:4496134	chr3:4490891~4493163:-
BRCA	cis	rs794185	0.504	rs304071	ENSG00000231249.1	ITPR1-AS1	3.88	0.000113	0.00696	0.14	0.12	Multiple sclerosis--Brain Glutamate Levels;	chr3:4496283	chr3:4490891~4493163:-
BRCA	cis	rs801193	0.613	rs2659900	ENSG00000273448.1	RP11-166O4.6	3.88	0.000113	0.00696	0.11	0.12	Aortic root size;	chr7:66719456	chr7:67333047~67334383:+
BRCA	cis	rs875971	0.545	rs1796219	ENSG00000232559.3	GS1-124K5.12	-3.88	0.000113	0.00696	-0.17	-0.12	Aortic root size;	chr7:66645977	chr7:66554588~66576923:-
BRCA	cis	rs8105895	0.935	rs10418804	ENSG00000269345.1	VN1R85P	3.88	0.000113	0.00697	0.17	0.12	Body mass index (change over time);	chr19:22090213	chr19:22174766~22175191:-
BRCA	cis	rs957448	0.554	rs12540967	ENSG00000254315.1	RP11-267M23.3	3.88	0.000113	0.00697	0.15	0.12	Nonsyndromic cleft lip with cleft palate;	chr8:94576862	chr8:94533628~94534391:+
BRCA	cis	rs957448	0.554	rs4735297	ENSG00000254315.1	RP11-267M23.3	3.88	0.000113	0.00697	0.15	0.12	Nonsyndromic cleft lip with cleft palate;	chr8:94577112	chr8:94533628~94534391:+
BRCA	cis	rs8180040	0.966	rs11707895	ENSG00000271161.1	BOLA2P2	-3.88	0.000113	0.00697	-0.13	-0.12	Colorectal cancer;	chr3:47533447	chr3:47499841~47500407:+
BRCA	cis	rs6785206	0.614	rs2712430	ENSG00000242551.2	POU5F1P6	-3.88	0.000113	0.00697	-0.24	-0.12	Lymphocyte percentage of white cells;	chr3:128618595	chr3:128674735~128677005:-
BRCA	cis	rs6785206	0.803	rs2712380	ENSG00000242551.2	POU5F1P6	-3.88	0.000113	0.00697	-0.24	-0.12	Lymphocyte percentage of white cells;	chr3:128619818	chr3:128674735~128677005:-
BRCA	cis	rs6840360	0.571	rs7664663	ENSG00000270265.1	RP11-731D1.4	-3.88	0.000113	0.00697	-0.14	-0.12	Intelligence (multi-trait analysis);	chr4:151586862	chr4:151333775~151353224:-
BRCA	cis	rs4415084	1	rs6861560	ENSG00000248779.1	RP11-53O19.2	3.88	0.000113	0.00697	0.11	0.12	Breast cancer;	chr5:44708276	chr5:44752949~44765744:+
BRCA	cis	rs853679	0.666	rs200956	ENSG00000216901.1	AL022393.7	3.88	0.000113	0.00697	0.19	0.12	Depression;	chr6:27871968	chr6:28176188~28176674:+
BRCA	cis	rs2562456	0.917	rs2681376	ENSG00000213976.4	CTD-2561J22.2	3.88	0.000113	0.00697	0.15	0.12	Pain;	chr19:21532723	chr19:21382865~21387177:+
BRCA	cis	rs6719977	0.51	rs1971138	ENSG00000226491.1	FTOP1	-3.88	0.000113	0.00697	-0.13	-0.12	Hyperactive-impulsive symptoms;	chr2:42742130	chr2:42797225~42798712:-
BRCA	cis	rs2554380	1	rs2730076	ENSG00000230373.7	GOLGA6L5P	-3.88	0.000113	0.00697	-0.17	-0.12	Height;	chr15:83647233	chr15:84507885~84516814:-
BRCA	cis	rs2451932	0.687	rs438042	ENSG00000251050.1	RP11-168A11.4	-3.88	0.000113	0.00697	-0.13	-0.12	LDL peak particle diameter (total fat intake interaction);	chr5:80056029	chr5:80019609~80019920:+
BRCA	cis	rs2451932	0.721	rs405482	ENSG00000251050.1	RP11-168A11.4	-3.88	0.000113	0.00697	-0.13	-0.12	LDL peak particle diameter (total fat intake interaction);	chr5:80056036	chr5:80019609~80019920:+
BRCA	cis	rs2451932	0.687	rs447875	ENSG00000251050.1	RP11-168A11.4	-3.88	0.000113	0.00697	-0.13	-0.12	LDL peak particle diameter (total fat intake interaction);	chr5:80056037	chr5:80019609~80019920:+
BRCA	cis	rs7811142	1	rs73161762	ENSG00000078319.8	PMS2P1	-3.88	0.000113	0.00697	-0.21	-0.12	Platelet count;	chr7:100417223	chr7:100320992~100341908:-
BRCA	cis	rs1193	1	rs6711700	ENSG00000266931.1	RP11-1252D15.1	-3.88	0.000113	0.00697	-0.14	-0.12	High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;High light scatter reticulocyte count;	chr2:86760864	chr2:87055658~87055800:-
BRCA	cis	rs7267979	1	rs6115140	ENSG00000274414.1	RP5-965G21.4	-3.88	0.000113	0.00697	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25304871	chr20:25239007~25245229:-
BRCA	cis	rs875971	0.66	rs7807944	ENSG00000272831.1	RP11-792A8.4	-3.88	0.000113	0.00698	-0.11	-0.12	Aortic root size;	chr7:66622208	chr7:66739829~66740385:-
BRCA	cis	rs6751744	0.855	rs6432534	ENSG00000230783.1	AC009961.2	-3.88	0.000113	0.00698	-0.16	-0.12	Dysphagia;	chr2:159521561	chr2:159689217~159690291:-
BRCA	cis	rs7020830	0.867	rs563132	ENSG00000230188.1	RP11-405L18.4	-3.88	0.000113	0.00698	-0.14	-0.12	Schizophrenia;	chr9:37245479	chr9:37490421~37490893:-
BRCA	cis	rs2304003	0.583	rs1056341	ENSG00000232411.1	AC009495.3	3.88	0.000113	0.00698	0.15	0.12	Social communication problems;	chr2:165867464	chr2:165833048~165839098:-
BRCA	cis	rs7412746	0.563	rs3768013	ENSG00000231073.1	RP11-316M1.3	3.88	0.000113	0.00698	0.13	0.12	Melanoma;	chr1:150842935	chr1:150973123~150975534:+
BRCA	cis	rs7267979	0.808	rs84816	ENSG00000274414.1	RP5-965G21.4	-3.88	0.000113	0.00698	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25479283	chr20:25239007~25245229:-
BRCA	cis	rs4865762	0.904	rs254510	ENSG00000247796.2	CTD-2366F13.1	-3.88	0.000113	0.00698	-0.13	-0.12	Intraocular pressure;	chr5:53187399	chr5:53109842~53115126:+
BRCA	cis	rs7267979	0.966	rs6083817	ENSG00000274414.1	RP5-965G21.4	3.88	0.000113	0.00698	0.14	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25363362	chr20:25239007~25245229:-
BRCA	cis	rs7267979	1	rs6050564	ENSG00000274414.1	RP5-965G21.4	3.88	0.000113	0.00698	0.14	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25363595	chr20:25239007~25245229:-
BRCA	cis	rs6496932	0.755	rs6497021	ENSG00000218052.5	ADAMTS7P4	-3.88	0.000113	0.00698	-0.13	-0.12	Central corneal thickness;Corneal structure;	chr15:85353036	chr15:85255369~85330334:-
BRCA	cis	rs7267979	1	rs6050632	ENSG00000204556.4	CTD-2514C3.1	-3.88	0.000113	0.00698	-0.16	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25451965	chr20:26018832~26020684:+
BRCA	cis	rs9650657	0.571	rs2409672	ENSG00000154316.13	TDH	3.88	0.000113	0.00698	0.15	0.12	Neuroticism;	chr8:10741270	chr8:11339637~11368452:+
BRCA	cis	rs1348850	0.914	rs6761593	ENSG00000271825.1	RP11-337N6.2	-3.88	0.000113	0.00698	-0.15	-0.12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177586872	chr2:177300600~177302006:+
BRCA	cis	rs7620503	1	rs4857612	ENSG00000228561.2	RP11-114M1.1	3.88	0.000113	0.00698	0.14	0.12	Corneal structure;	chr3:177588833	chr3:177683627~177691250:+
BRCA	cis	rs2991971	1	rs2991972	ENSG00000280836.1	AL355480.1	3.87	0.000113	0.00698	0.14	0.12	High light scatter reticulocyte count;	chr1:45547536	chr1:45581219~45581321:-
BRCA	cis	rs2991971	1	rs2993262	ENSG00000280836.1	AL355480.1	3.87	0.000113	0.00698	0.14	0.12	High light scatter reticulocyte count;	chr1:45548061	chr1:45581219~45581321:-
BRCA	cis	rs256438	0.524	rs407314	ENSG00000251050.1	RP11-168A11.4	-3.87	0.000113	0.00698	-0.13	-0.12	Serum thyroid-stimulating hormone levels;	chr5:80056787	chr5:80019609~80019920:+
BRCA	cis	rs2554380	1	rs2554380	ENSG00000230373.7	GOLGA6L5P	-3.87	0.000113	0.00698	-0.17	-0.12	Height;	chr15:83647132	chr15:84507885~84516814:-
BRCA	cis	rs4664293	0.967	rs13032135	ENSG00000224152.1	AC009506.1	-3.87	0.000113	0.00698	-0.13	-0.12	Monocyte percentage of white cells;	chr2:159675588	chr2:159615296~159617082:+
BRCA	cis	rs6964587	0.967	rs6465341	ENSG00000188693.7	CYP51A1-AS1	-3.87	0.000113	0.00698	-0.13	-0.12	Breast cancer;	chr7:91966807	chr7:92134604~92180725:+
BRCA	cis	rs1075265	0.756	rs6751105	ENSG00000272156.1	RP11-477N3.1	-3.87	0.000113	0.00699	-0.12	-0.12	Chronotype;Morning vs. evening chronotype;	chr2:54129214	chr2:54082554~54085066:+
BRCA	cis	rs7267979	1	rs7267979	ENSG00000125804.12	FAM182A	-3.87	0.000113	0.00699	-0.15	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25317451	chr20:26054655~26086917:+
BRCA	cis	rs11098499	0.874	rs6822498	ENSG00000225892.3	RP11-384K6.2	3.87	0.000113	0.00699	0.13	0.12	Corneal astigmatism;	chr4:119199028	chr4:118632274~118634759:+
BRCA	cis	rs9329221	0.502	rs11777364	ENSG00000248896.2	CTD-2135J3.3	3.87	0.000113	0.00699	0.14	0.12	Neuroticism;	chr8:10431036	chr8:10729314~10771392:+
BRCA	cis	rs733592	0.507	rs56129148	ENSG00000273765.1	RP11-370I10.11	-3.87	0.000113	0.00699	-0.13	-0.12	Plateletcrit;	chr12:48091747	chr12:48360920~48361377:+
BRCA	cis	rs11048434	0.518	rs34651717	ENSG00000256069.6	A2MP1	-3.87	0.000113	0.00699	-0.13	-0.12	Sjögren's syndrome;	chr12:9025154	chr12:9228533~9275817:-
BRCA	cis	rs11048434	0.518	rs35176717	ENSG00000256069.6	A2MP1	-3.87	0.000113	0.00699	-0.13	-0.12	Sjögren's syndrome;	chr12:9025170	chr12:9228533~9275817:-
BRCA	cis	rs11048434	0.518	rs34533518	ENSG00000256069.6	A2MP1	-3.87	0.000113	0.00699	-0.13	-0.12	Sjögren's syndrome;	chr12:9025302	chr12:9228533~9275817:-
BRCA	cis	rs78487399	0.808	rs111812200	ENSG00000234936.1	AC010883.5	3.87	0.000113	0.00699	0.18	0.12	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43447139	chr2:43229573~43233394:+
BRCA	cis	rs78487399	0.808	rs12105786	ENSG00000234936.1	AC010883.5	3.87	0.000113	0.00699	0.18	0.12	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43449294	chr2:43229573~43233394:+
BRCA	cis	rs9733	0.526	rs11204698	ENSG00000231073.1	RP11-316M1.3	3.87	0.000113	0.00699	0.12	0.12	Tonsillectomy;	chr1:150687069	chr1:150973123~150975534:+
BRCA	cis	rs61160187	0.582	rs62367903	ENSG00000272308.1	RP11-231G3.1	-3.87	0.000113	0.00699	-0.14	-0.12	Educational attainment (years of education);Educational attainment (college completion);	chr5:61023146	chr5:60866457~60866935:-
BRCA	cis	rs12105510	0.626	rs1990145	ENSG00000270696.1	RP11-342K6.1	3.87	0.000113	0.00699	0.14	0.12	Response to platinum-based chemotherapy (cisplatin);	chr2:75650524	chr2:75660462~75662208:+
BRCA	cis	rs11098499	0.863	rs10013305	ENSG00000260404.2	RP11-384K6.6	3.87	0.000113	0.00699	0.11	0.12	Corneal astigmatism;	chr4:119529269	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.863	rs3775849	ENSG00000260404.2	RP11-384K6.6	3.87	0.000113	0.00699	0.11	0.12	Corneal astigmatism;	chr4:119529753	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.818	rs7688802	ENSG00000260404.2	RP11-384K6.6	3.87	0.000113	0.00699	0.11	0.12	Corneal astigmatism;	chr4:119530513	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.863	rs7695620	ENSG00000260404.2	RP11-384K6.6	3.87	0.000113	0.00699	0.11	0.12	Corneal astigmatism;	chr4:119531621	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.863	rs12502389	ENSG00000260404.2	RP11-384K6.6	3.87	0.000113	0.00699	0.11	0.12	Corneal astigmatism;	chr4:119533036	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.821	rs3775852	ENSG00000260404.2	RP11-384K6.6	3.87	0.000113	0.00699	0.11	0.12	Corneal astigmatism;	chr4:119533401	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.82	rs6534140	ENSG00000260404.2	RP11-384K6.6	3.87	0.000113	0.00699	0.11	0.12	Corneal astigmatism;	chr4:119534156	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.863	rs7657849	ENSG00000260404.2	RP11-384K6.6	3.87	0.000113	0.00699	0.11	0.12	Corneal astigmatism;	chr4:119534339	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.863	rs10034450	ENSG00000260404.2	RP11-384K6.6	3.87	0.000113	0.00699	0.11	0.12	Corneal astigmatism;	chr4:119534494	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.863	rs1480939	ENSG00000260404.2	RP11-384K6.6	3.87	0.000113	0.00699	0.11	0.12	Corneal astigmatism;	chr4:119535772	chr4:118591773~118633729:+
BRCA	cis	rs10506328	0.509	rs4759075	ENSG00000250432.4	RP11-834C11.5	3.87	0.000113	0.00699	0.13	0.12	Mean platelet volume;	chr12:54273501	chr12:54085132~54125992:-
BRCA	cis	rs2302465	0.86	rs73241117	ENSG00000273133.1	RP11-799M12.2	-3.87	0.000114	0.00699	-0.23	-0.12	Blood protein levels;	chr4:15638200	chr4:15563698~15564253:-
BRCA	cis	rs2337406	0.538	rs10141701	ENSG00000211974.3	IGHV2-70	-3.87	0.000114	0.007	-0.14	-0.12	Alzheimer's disease (late onset);	chr14:106633467	chr14:106723574~106724093:-
BRCA	cis	rs983392	0.967	rs2847663	ENSG00000275344.1	MIR6503	-3.87	0.000114	0.007	-0.12	-0.12	Alzheimer's disease (late onset);	chr11:60090563	chr11:60209071~60209156:-
BRCA	cis	rs7267979	1	rs6083856	ENSG00000274973.1	RP13-401N8.7	3.87	0.000114	0.007	0.14	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25426949	chr20:25845497~25845862:+
BRCA	cis	rs875971	0.862	rs1167390	ENSG00000271064.1	RP11-792A8.3	3.87	0.000114	0.007	0.14	0.12	Aortic root size;	chr7:66110906	chr7:66748838~66749077:-
BRCA	cis	rs875971	0.862	rs35034167	ENSG00000271064.1	RP11-792A8.3	3.87	0.000114	0.007	0.14	0.12	Aortic root size;	chr7:66115179	chr7:66748838~66749077:-
BRCA	cis	rs6593122	0.755	rs2877182	ENSG00000235454.1	HAUS6P3	-3.87	0.000114	0.007	-0.16	-0.12	Vaccine-related adverse events;	chr7:54122522	chr7:53862233~53863339:+
BRCA	cis	rs6593122	0.755	rs1851884	ENSG00000235454.1	HAUS6P3	-3.87	0.000114	0.007	-0.16	-0.12	Vaccine-related adverse events;	chr7:54123096	chr7:53862233~53863339:+
BRCA	cis	rs6593122	0.755	rs10243670	ENSG00000235454.1	HAUS6P3	-3.87	0.000114	0.007	-0.16	-0.12	Vaccine-related adverse events;	chr7:54123212	chr7:53862233~53863339:+
BRCA	cis	rs6593122	0.755	rs1851885	ENSG00000235454.1	HAUS6P3	-3.87	0.000114	0.007	-0.16	-0.12	Vaccine-related adverse events;	chr7:54123215	chr7:53862233~53863339:+
BRCA	cis	rs2486012	0.649	rs246777	ENSG00000237950.1	RP11-7O11.3	3.87	0.000114	0.007	0.21	0.12	Intelligence (multi-trait analysis);	chr1:43808763	chr1:43944370~43946551:-
BRCA	cis	rs7267979	1	rs2500436	ENSG00000274973.1	RP13-401N8.7	3.87	0.000114	0.007	0.14	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25425730	chr20:25845497~25845862:+
BRCA	cis	rs7312933	0.618	rs7954523	ENSG00000257225.1	RP11-328C8.4	-3.87	0.000114	0.007	-0.15	-0.12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42287706	chr12:42459366~42466128:+
BRCA	cis	rs4648045	0.594	rs62327180	ENSG00000251288.2	RP11-10L12.2	-3.87	0.000114	0.007	-0.16	-0.12	Lymphocyte percentage of white cells;	chr4:102619605	chr4:102751401~102752641:+
BRCA	cis	rs875971	0.862	rs709596	ENSG00000273024.4	INTS4P2	-3.87	0.000114	0.00701	-0.13	-0.12	Aortic root size;	chr7:66360926	chr7:65647864~65715661:+
BRCA	cis	rs7914558	0.646	rs7909286	ENSG00000213277.3	MARCKSL1P1	3.87	0.000114	0.00701	0.14	0.12	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102899235	chr10:103175554~103176094:+
BRCA	cis	rs7914558	0.646	rs7909591	ENSG00000213277.3	MARCKSL1P1	3.87	0.000114	0.00701	0.14	0.12	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102899261	chr10:103175554~103176094:+
BRCA	cis	rs11158026	0.575	rs8008150	ENSG00000233924.1	AL160471.6	-3.87	0.000114	0.00701	-0.14	-0.12	Parkinson's disease;	chr14:54954718	chr14:55004813~55005687:-
BRCA	cis	rs2832191	0.729	rs2832201	ENSG00000232855.5	AF131217.1	3.87	0.000114	0.00701	0.14	0.12	Dental caries;	chr21:29127520	chr21:28439346~28674848:-
BRCA	cis	rs12122100	0.507	rs1925343	ENSG00000244371.2	PFN1P8	3.87	0.000114	0.00701	0.14	0.12	HIV-1 control;	chr1:147033981	chr1:146957117~146957659:-
BRCA	cis	rs8180040	0.726	rs61729713	ENSG00000280667.1	Y_RNA	-3.87	0.000114	0.00701	-0.13	-0.12	Colorectal cancer;	chr3:46985702	chr3:47501083~47501182:+
BRCA	cis	rs875971	0.528	rs801213	ENSG00000232559.3	GS1-124K5.12	-3.87	0.000114	0.00701	-0.16	-0.12	Aortic root size;	chr7:66549931	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.545	rs801212	ENSG00000232559.3	GS1-124K5.12	-3.87	0.000114	0.00701	-0.16	-0.12	Aortic root size;	chr7:66550643	chr7:66554588~66576923:-
BRCA	cis	rs9533799	0.966	rs7999368	ENSG00000227258.4	SMIM2-AS1	-3.87	0.000114	0.00701	-0.15	-0.12	Amyotrophic lateral sclerosis;	chr13:44233048	chr13:44110451~44240517:+
BRCA	cis	rs9533799	1	rs7999059	ENSG00000227258.4	SMIM2-AS1	-3.87	0.000114	0.00701	-0.15	-0.12	Amyotrophic lateral sclerosis;	chr13:44233058	chr13:44110451~44240517:+
BRCA	cis	rs1577917	0.74	rs7775864	ENSG00000220563.1	PKMP3	3.87	0.000114	0.00701	0.12	0.12	Response to antipsychotic treatment;	chr6:85538041	chr6:85659892~85660606:-
BRCA	cis	rs7712401	0.686	rs246305	ENSG00000251538.4	RP11-166A12.1	3.87	0.000114	0.00701	0.13	0.12	Mean platelet volume;	chr5:122863911	chr5:122628952~122730685:-
BRCA	cis	rs11098499	0.863	rs7664986	ENSG00000260091.1	RP11-33B1.4	-3.87	0.000114	0.00701	-0.11	-0.12	Corneal astigmatism;	chr4:119508797	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.818	rs10008791	ENSG00000260091.1	RP11-33B1.4	-3.87	0.000114	0.00701	-0.11	-0.12	Corneal astigmatism;	chr4:119510314	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.863	rs11736416	ENSG00000260091.1	RP11-33B1.4	-3.87	0.000114	0.00701	-0.11	-0.12	Corneal astigmatism;	chr4:119510506	chr4:119409333~119410233:+
BRCA	cis	rs12505749	0.542	rs12509542	ENSG00000270147.1	RP11-646I6.6	-3.87	0.000114	0.00701	-0.14	-0.12	Airflow obstruction;	chr4:56491078	chr4:56396312~56396871:+
BRCA	cis	rs7267979	1	rs7018	ENSG00000276952.1	RP5-965G21.6	3.87	0.000114	0.00701	0.14	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25297625	chr20:25284915~25285588:-
BRCA	cis	rs838147	0.733	rs12975781	ENSG00000232871.7	SEC1P	3.87	0.000114	0.00701	0.13	0.12	Dietary macronutrient intake;	chr19:48746441	chr19:48638071~48682245:+
BRCA	cis	rs1150668	0.796	rs728122	ENSG00000270326.1	RP5-874C20.6	-3.87	0.000114	0.00701	-0.14	-0.12	Pubertal anthropometrics;	chr6:28431347	chr6:28319660~28319852:-
BRCA	cis	rs1670533	1	rs10031302	ENSG00000251639.2	RP11-20I20.1	3.87	0.000114	0.00701	0.19	0.12	Recombination rate (females);	chr4:1065876	chr4:1100016~1101558:-
BRCA	cis	rs962856	0.537	rs686880	ENSG00000236780.4	AC078941.1	3.87	0.000114	0.00701	0.15	0.12	Pancreatic cancer;	chr2:67457960	chr2:67123357~67215319:-
BRCA	cis	rs8038465	0.615	rs11072430	ENSG00000260898.4	ADPGK-AS1	-3.87	0.000114	0.00701	-0.13	-0.12	Liver enzyme levels (gamma-glutamyl transferase);	chr15:73689360	chr15:72782835~72798199:+
BRCA	cis	rs4073416	0.872	rs2236067	ENSG00000276116.2	FUT8-AS1	3.87	0.000114	0.00701	0.12	0.12	N-glycan levels;	chr14:65781294	chr14:65411170~65412690:-
BRCA	cis	rs2357982	0.525	rs197273	ENSG00000227403.1	AC009299.3	-3.87	0.000114	0.00701	-0.16	-0.12	Presence of antiphospholipid antibodies;	chr2:161038152	chr2:161244739~161249050:+
BRCA	cis	rs8062405	1	rs56404918	ENSG00000261766.1	RP11-22P6.2	-3.87	0.000114	0.00701	-0.12	-0.12	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835519	chr16:28862166~28863340:-
BRCA	cis	rs8062405	1	rs55719896	ENSG00000261766.1	RP11-22P6.2	-3.87	0.000114	0.00701	-0.12	-0.12	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835545	chr16:28862166~28863340:-
BRCA	cis	rs801193	0.967	rs2707849	ENSG00000273142.1	RP11-458F8.4	-3.87	0.000114	0.00702	-0.1	-0.12	Aortic root size;	chr7:66687725	chr7:66902857~66906297:+
BRCA	cis	rs4835473	0.932	rs11100806	ENSG00000246448.2	RP13-578N3.3	3.87	0.000114	0.00702	0.13	0.12	Immature fraction of reticulocytes;	chr4:143761006	chr4:143700257~143865072:+
BRCA	cis	rs875971	0.505	rs1167386	ENSG00000273142.1	RP11-458F8.4	3.87	0.000114	0.00702	0.1	0.12	Aortic root size;	chr7:66048109	chr7:66902857~66906297:+
BRCA	cis	rs6049003	0.6	rs6132653	ENSG00000232645.4	LINC01431	-3.87	0.000114	0.00702	-0.13	-0.12	Cerebrospinal fluid biomarker levels;	chr20:23723651	chr20:23356594~23358116:-
BRCA	cis	rs4879656	0.593	rs7041702	ENSG00000236184.1	TCEA1P4	-3.87	0.000114	0.00702	-0.15	-0.12	Menopause (age at onset);	chr9:33053432	chr9:32979560~32980403:-
BRCA	cis	rs62458065	0.713	rs62463967	ENSG00000229358.3	DPY19L1P1	-3.87	0.000114	0.00702	-0.17	-0.12	Metabolite levels (HVA/MHPG ratio);	chr7:32458717	chr7:32580949~32761787:-
BRCA	cis	rs853679	0.607	rs13199906	ENSG00000216901.1	AL022393.7	3.87	0.000114	0.00702	0.31	0.12	Depression;	chr6:27866361	chr6:28176188~28176674:+
BRCA	cis	rs16846053	0.792	rs62190669	ENSG00000227403.1	AC009299.3	3.87	0.000114	0.00702	0.3	0.12	Blood osmolality (transformed sodium);	chr2:161795188	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.792	rs62190670	ENSG00000227403.1	AC009299.3	3.87	0.000114	0.00702	0.3	0.12	Blood osmolality (transformed sodium);	chr2:161796232	chr2:161244739~161249050:+
BRCA	cis	rs1371614	0.632	rs3769134	ENSG00000229122.1	AGBL5-IT1	3.87	0.000114	0.00702	0.13	0.12	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26928023	chr2:27061038~27061815:+
BRCA	cis	rs875971	0.66	rs1860470	ENSG00000273142.1	RP11-458F8.4	3.87	0.000114	0.00702	0.1	0.12	Aortic root size;	chr7:66638707	chr7:66902857~66906297:+
BRCA	cis	rs420259	0.727	rs249871	ENSG00000260136.4	CTD-2270L9.4	3.87	0.000114	0.00702	0.11	0.12	Bipolar disorder;	chr16:23653182	chr16:23452758~23457606:+
BRCA	cis	rs2625529	0.824	rs1074330	ENSG00000260037.4	CTD-2524L6.3	-3.87	0.000114	0.00702	-0.17	-0.12	Red blood cell count;	chr15:71958400	chr15:71818396~71823384:+
BRCA	cis	rs2625529	0.824	rs12902006	ENSG00000260037.4	CTD-2524L6.3	-3.87	0.000114	0.00702	-0.17	-0.12	Red blood cell count;	chr15:71960655	chr15:71818396~71823384:+
BRCA	cis	rs12681366	0.708	rs2930962	ENSG00000253175.1	RP11-267M23.6	3.87	0.000114	0.00703	0.13	0.12	Nonsyndromic cleft lip with cleft palate;	chr8:94433277	chr8:94565036~94565715:+
BRCA	cis	rs2692947	0.509	rs4907303	ENSG00000168992.4	OR7E102P	3.87	0.000114	0.00703	0.16	0.12	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95551486	chr2:95546531~95547545:+
BRCA	cis	rs2562456	0.917	rs2562466	ENSG00000213976.4	CTD-2561J22.2	3.87	0.000114	0.00703	0.14	0.12	Pain;	chr19:21531402	chr19:21382865~21387177:+
BRCA	cis	rs11098499	0.863	rs3733525	ENSG00000260404.2	RP11-384K6.6	3.87	0.000114	0.00703	0.11	0.12	Corneal astigmatism;	chr4:119525893	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.863	rs3775847	ENSG00000260404.2	RP11-384K6.6	3.87	0.000114	0.00703	0.11	0.12	Corneal astigmatism;	chr4:119526487	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.863	rs3775848	ENSG00000260404.2	RP11-384K6.6	3.87	0.000114	0.00703	0.11	0.12	Corneal astigmatism;	chr4:119526569	chr4:118591773~118633729:+
BRCA	cis	rs12285276	1	rs12285276	ENSG00000205106.4	DKFZp779M0652	3.87	0.000114	0.00703	0.16	0.12	Visceral fat;	chr11:45792030	chr11:45771432~45772358:+
BRCA	cis	rs9926296	0.656	rs11861084	ENSG00000261373.1	VPS9D1-AS1	3.87	0.000114	0.00703	0.13	0.12	Vitiligo;	chr16:89809302	chr16:89711856~89718165:+
BRCA	cis	rs2991971	0.81	rs2356413	ENSG00000280836.1	AL355480.1	-3.87	0.000114	0.00703	-0.14	-0.12	High light scatter reticulocyte count;	chr1:45448376	chr1:45581219~45581321:-
BRCA	cis	rs2991971	0.716	rs7532573	ENSG00000280836.1	AL355480.1	-3.87	0.000114	0.00703	-0.14	-0.12	High light scatter reticulocyte count;	chr1:45450220	chr1:45581219~45581321:-
BRCA	cis	rs375066	0.935	rs388685	ENSG00000267191.1	RP11-15A1.2	-3.87	0.000114	0.00703	-0.16	-0.12	Breast cancer;	chr19:43914528	chr19:43902001~43926545:+
BRCA	cis	rs6847067	0.8	rs11097026	ENSG00000180769.7	WDFY3-AS2	-3.87	0.000114	0.00703	-0.11	-0.12	Oropharynx cancer;	chr4:84882454	chr4:84965682~85011277:+
BRCA	cis	rs889312	0.5	rs865570	ENSG00000271828.1	CTD-2310F14.1	-3.87	0.000114	0.00703	-0.14	-0.12	Breast cancer (early onset);Breast cancer;	chr5:56866148	chr5:56927874~56929573:+
BRCA	cis	rs7474896	1	rs734512	ENSG00000272983.1	RP11-508N22.12	-3.87	0.000114	0.00703	-0.19	-0.12	Obesity (extreme);	chr10:37684144	chr10:38137337~38144399:+
BRCA	cis	rs42490	0.51	rs4961157	ENSG00000251136.7	RP11-37B2.1	-3.87	0.000114	0.00703	-0.11	-0.12	Leprosy;	chr8:89684800	chr8:89609409~89757727:-
BRCA	cis	rs11892454	0.599	rs6729339	ENSG00000217643.1	PTGES3P2	-3.87	0.000114	0.00703	-0.13	-0.12	Heschl's gyrus morphology;	chr2:25749310	chr2:25822469~25822950:+
BRCA	cis	rs821470	0.812	rs891140	ENSG00000276663.1	RP11-407G23.7	3.87	0.000114	0.00703	0.14	0.12	Bipolar disorder and schizophrenia;	chr16:57021802	chr16:57245832~57246396:-
BRCA	cis	rs11700536	0.54	rs8132259	ENSG00000236663.1	AP001631.9	3.87	0.000114	0.00703	0.13	0.12	Interleukin-18 levels;	chr21:43129548	chr21:43140523~43141092:-
BRCA	cis	rs6479874	1	rs10740093	ENSG00000223502.1	RP11-96B5.3	-3.87	0.000114	0.00703	-0.23	-0.12	Migraine;	chr10:51010802	chr10:51062579~51068553:-
BRCA	cis	rs3857043	1	rs3857043	ENSG00000270720.1	RP11-84C13.2	3.87	0.000114	0.00703	0.13	0.12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr4:88961439	chr4:89119284~89119871:+
BRCA	cis	rs1009077	0.716	rs17358524	ENSG00000245958.5	RP11-33B1.1	3.87	0.000114	0.00703	0.17	0.12	Endometriosis;	chr4:119570559	chr4:119454791~119552025:+
BRCA	cis	rs2505998	0.868	rs2505991	ENSG00000273008.1	RP11-351D16.3	-3.87	0.000114	0.00703	-0.15	-0.12	Hirschsprung disease;	chr10:43070912	chr10:43136824~43138334:-
BRCA	cis	rs6593122	0.755	rs10273743	ENSG00000235454.1	HAUS6P3	-3.87	0.000114	0.00703	-0.16	-0.12	Vaccine-related adverse events;	chr7:54122953	chr7:53862233~53863339:+
BRCA	cis	rs6593122	0.755	rs10233038	ENSG00000235454.1	HAUS6P3	-3.87	0.000114	0.00703	-0.16	-0.12	Vaccine-related adverse events;	chr7:54122956	chr7:53862233~53863339:+
BRCA	cis	rs6973609	0.671	rs889935	ENSG00000271122.1	RP11-379H18.1	3.87	0.000114	0.00703	0.12	0.12	Obesity-related traits;	chr7:35569538	chr7:35695214~35699413:+
BRCA	cis	rs4561483	0.801	rs251723	ENSG00000261216.1	RP11-166B2.5	-3.87	0.000114	0.00703	-0.14	-0.12	Testicular germ cell tumor;	chr16:11859223	chr16:11908208~11908916:+
BRCA	cis	rs2991971	0.81	rs998199	ENSG00000280836.1	AL355480.1	-3.87	0.000114	0.00703	-0.14	-0.12	High light scatter reticulocyte count;	chr1:45447226	chr1:45581219~45581321:-
BRCA	cis	rs4834272	0.58	rs9884299	ENSG00000249509.1	RP11-402J6.1	-3.87	0.000114	0.00703	-0.13	-0.12	Body mass index;	chr4:112381794	chr4:112515385~112546881:+
BRCA	cis	rs7520050	0.966	rs4376778	ENSG00000234329.1	RP11-767N6.2	-3.87	0.000114	0.00704	-0.11	-0.12	Reticulocyte count;Red blood cell count;	chr1:45823174	chr1:45651039~45651826:-
BRCA	cis	rs7520050	0.966	rs6672898	ENSG00000234329.1	RP11-767N6.2	-3.87	0.000114	0.00704	-0.11	-0.12	Reticulocyte count;Red blood cell count;	chr1:45824916	chr1:45651039~45651826:-
BRCA	cis	rs7647973	0.731	rs7617480	ENSG00000272434.1	RP13-131K19.6	3.87	0.000114	0.00704	0.16	0.12	Menarche (age at onset);	chr3:49173299	chr3:49029316~49029706:+
BRCA	cis	rs516805	0.667	rs7752093	ENSG00000279114.1	RP3-425C14.5	3.87	0.000114	0.00704	0.15	0.12	Lymphocyte counts;	chr6:122301265	chr6:122471923~122484161:+
BRCA	cis	rs4664293	0.625	rs34573069	ENSG00000226266.5	AC009961.3	3.87	0.000114	0.00704	0.14	0.12	Monocyte percentage of white cells;	chr2:159643561	chr2:159670708~159712435:-
BRCA	cis	rs4664293	0.567	rs6711125	ENSG00000226266.5	AC009961.3	3.87	0.000114	0.00704	0.14	0.12	Monocyte percentage of white cells;	chr2:159645040	chr2:159670708~159712435:-
BRCA	cis	rs66887589	0.87	rs10518336	ENSG00000249244.1	RP11-548H18.2	3.87	0.000114	0.00704	0.13	0.12	Diastolic blood pressure;	chr4:119601779	chr4:119391831~119395335:-
BRCA	cis	rs10463316	0.894	rs954339	ENSG00000260581.1	CTB-113P19.4	3.87	0.000114	0.00704	0.14	0.12	Metabolite levels (Pyroglutamine);	chr5:151372600	chr5:151652275~151655449:+
BRCA	cis	rs10463316	0.894	rs6864722	ENSG00000260581.1	CTB-113P19.4	3.87	0.000114	0.00704	0.14	0.12	Metabolite levels (Pyroglutamine);	chr5:151373381	chr5:151652275~151655449:+
BRCA	cis	rs9419788	0.557	rs2764378	ENSG00000273450.1	RP11-76P2.4	3.87	0.000114	0.00704	0.16	0.12	Personality traits in bipolar disorder;	chr10:94372349	chr10:94314907~94315327:-
BRCA	cis	rs1850744	0.702	rs10939428	ENSG00000250942.1	ENPP7P11	3.87	0.000114	0.00704	0.23	0.12	Economic and political preferences;	chr4:9628417	chr4:9677308~9677934:+
BRCA	cis	rs7954584	0.71	rs10840641	ENSG00000274292.1	RP11-347I19.7	-3.87	0.000114	0.00704	-0.1	-0.12	Mean corpuscular volume;	chr12:122027925	chr12:121800797~121803403:+
BRCA	cis	rs911119	0.955	rs17751897	ENSG00000270001.1	RP11-218C14.8	-3.87	0.000114	0.00704	-0.15	-0.12	Chronic kidney disease;	chr20:23612077	chr20:23631826~23632316:-
BRCA	cis	rs6599077	1	rs6763643	ENSG00000223797.4	ENTPD3-AS1	3.87	0.000114	0.00704	0.15	0.12	Sleep-related phenotypes;	chr3:40056500	chr3:40313802~40453329:-
BRCA	cis	rs4664293	0.647	rs7580539	ENSG00000226266.5	AC009961.3	-3.87	0.000114	0.00704	-0.14	-0.12	Monocyte percentage of white cells;	chr2:159589238	chr2:159670708~159712435:-
BRCA	cis	rs4664293	0.539	rs7580661	ENSG00000226266.5	AC009961.3	-3.87	0.000114	0.00704	-0.14	-0.12	Monocyte percentage of white cells;	chr2:159589326	chr2:159670708~159712435:-
BRCA	cis	rs1371614	0.635	rs4665923	ENSG00000229122.1	AGBL5-IT1	3.87	0.000114	0.00704	0.13	0.12	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26916043	chr2:27061038~27061815:+
BRCA	cis	rs9423406	0.615	rs117529926	ENSG00000215267.7	AKR1C7P	-3.87	0.000114	0.00704	-0.23	-0.12	Intelligence;	chr10:5273908	chr10:5275173~5288470:-
BRCA	cis	rs9423406	0.615	rs114602781	ENSG00000215267.7	AKR1C7P	-3.87	0.000114	0.00704	-0.23	-0.12	Intelligence;	chr10:5273909	chr10:5275173~5288470:-
BRCA	cis	rs56281245	1	rs116238420	ENSG00000249363.1	CTB-78O21.1	3.87	0.000114	0.00704	0.26	0.12	Hepcidin levels;	chr5:145615234	chr5:145728360~145729349:-
BRCA	cis	rs687432	0.812	rs10792125	ENSG00000213592.4	AP000662.9	3.87	0.000114	0.00704	0.17	0.12	Parkinson's disease;	chr11:58015239	chr11:57718044~57718530:-
BRCA	cis	rs964611	0.938	rs12592330	ENSG00000259488.2	RP11-154J22.1	3.87	0.000114	0.00704	0.15	0.12	Metabolite levels (Pyroglutamine);	chr15:48353083	chr15:48312353~48331856:-
BRCA	cis	rs875971	0.66	rs3764903	ENSG00000273142.1	RP11-458F8.4	3.87	0.000114	0.00704	0.1	0.12	Aortic root size;	chr7:66633495	chr7:66902857~66906297:+
BRCA	cis	rs11098499	0.874	rs6832670	ENSG00000260091.1	RP11-33B1.4	-3.87	0.000114	0.00704	-0.11	-0.12	Corneal astigmatism;	chr4:119197637	chr4:119409333~119410233:+
BRCA	cis	rs16958445	1	rs16958445	ENSG00000261801.4	LOXL1-AS1	3.87	0.000114	0.00704	0.29	0.12	Exfoliation glaucoma or exfoliation syndrome;	chr15:73884216	chr15:73908071~73928248:-
BRCA	cis	rs6071524	0.517	rs6071589	ENSG00000224635.1	RP4-564F22.5	-3.87	0.000114	0.00704	-0.14	-0.12	Autism spectrum disorder or schizophrenia;	chr20:38815578	chr20:38406011~38416797:-
BRCA	cis	rs6431644	0.694	rs169925	ENSG00000224287.2	MSL3P1	-3.87	0.000114	0.00704	-0.15	-0.12	Left atrial antero-posterior diameter;	chr2:233844362	chr2:233865437~233868444:-
BRCA	cis	rs4415084	0.966	rs1898701	ENSG00000248464.1	FGF10-AS1	3.87	0.000114	0.00704	0.13	0.12	Breast cancer;	chr5:44695327	chr5:44388732~44413989:+
BRCA	cis	rs7608910	0.832	rs10191548	ENSG00000237522.1	NONOP2	-3.87	0.000114	0.00704	-0.12	-0.12	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;	chr2:60970260	chr2:60936819~60938049:-
BRCA	cis	rs17027633	0.881	rs77558823	ENSG00000234020.1	CHIAP3	-3.87	0.000114	0.00704	-0.29	-0.12	Cerebrospinal fluid t-tau:AB1-42 ratio;	chr1:111471173	chr1:111353275~111367409:-
BRCA	cis	rs4819052	0.851	rs2255766	ENSG00000215447.6	BX322557.10	-3.87	0.000114	0.00704	-0.12	-0.12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45263862	chr21:45288052~45291738:+
BRCA	cis	rs889312	0.5	rs832577	ENSG00000271828.1	CTD-2310F14.1	-3.87	0.000115	0.00705	-0.14	-0.12	Breast cancer (early onset);Breast cancer;	chr5:56867960	chr5:56927874~56929573:+
BRCA	cis	rs853679	0.825	rs8180562	ENSG00000204709.4	LINC01556	3.87	0.000115	0.00705	0.25	0.12	Depression;	chr6:28173682	chr6:28943877~28944537:+
BRCA	cis	rs853679	0.882	rs9380064	ENSG00000204709.4	LINC01556	3.87	0.000115	0.00705	0.25	0.12	Depression;	chr6:28175340	chr6:28943877~28944537:+
BRCA	cis	rs6964587	0.967	rs10279943	ENSG00000188693.7	CYP51A1-AS1	-3.87	0.000115	0.00705	-0.13	-0.12	Breast cancer;	chr7:91958163	chr7:92134604~92180725:+
BRCA	cis	rs7722600	0.808	rs78081438	ENSG00000253404.1	AC034243.1	-3.87	0.000115	0.00705	-0.2	-0.12	Heart rate;	chr5:137963932	chr5:138744434~138753309:-
BRCA	cis	rs7847628	0.587	rs10760117	ENSG00000238181.2	AHCYP2	-3.87	0.000115	0.00705	-0.16	-0.12	Birth weight;	chr9:120824459	chr9:120720673~120721972:+
BRCA	cis	rs703842	1	rs10877014	ENSG00000270039.1	RP11-571M6.17	-3.87	0.000115	0.00705	-0.16	-0.12	Multiple sclerosis;	chr12:57773878	chr12:57803838~57804415:+
BRCA	cis	rs10129255	1	rs61997605	ENSG00000211967.3	IGHV3-53	-3.87	0.000115	0.00705	-0.09	-0.12	Kawasaki disease;	chr14:106678368	chr14:106592676~106593347:-
BRCA	cis	rs795484	0.683	rs572869	ENSG00000275409.1	RP11-131L12.4	-3.87	0.000115	0.00705	-0.14	-0.12	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;	chr12:118370362	chr12:118430147~118430699:+
BRCA	cis	rs3805389	0.504	rs3805388	ENSG00000273257.1	RP11-177J6.1	-3.87	0.000115	0.00705	-0.19	-0.12	Waist-to-hip ratio adjusted for body mass index;	chr4:55614754	chr4:55387949~55388271:+
BRCA	cis	rs8177876	0.642	rs10514513	ENSG00000245059.2	RP11-303E16.7	3.87	0.000115	0.00705	0.24	0.12	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81080578	chr16:81077319~81078861:+
BRCA	cis	rs2880765	0.714	rs6497187	ENSG00000230373.7	GOLGA6L5P	3.87	0.000115	0.00705	0.13	0.12	Coronary artery disease;	chr15:85468119	chr15:84507885~84516814:-
BRCA	cis	rs7208859	0.673	rs9889755	ENSG00000250462.7	LRRC37BP1	3.87	0.000115	0.00705	0.21	0.12	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30907487	chr17:30629680~30637466:+
BRCA	cis	rs78487399	0.808	rs6746610	ENSG00000234936.1	AC010883.5	3.87	0.000115	0.00705	0.18	0.12	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43450114	chr2:43229573~43233394:+
BRCA	cis	rs78487399	0.808	rs77527404	ENSG00000234936.1	AC010883.5	3.87	0.000115	0.00705	0.18	0.12	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43451248	chr2:43229573~43233394:+
BRCA	cis	rs490234	0.812	rs12351825	ENSG00000232630.1	PRPS1P2	-3.87	0.000115	0.00705	-0.12	-0.12	Mean arterial pressure;	chr9:125503457	chr9:125150653~125151589:+
BRCA	cis	rs6439699	0.83	rs7626812	ENSG00000239213.4	NCK1-AS1	3.87	0.000115	0.00705	0.16	0.12	Intelligence (multi-trait analysis);	chr3:137319218	chr3:136841726~136862054:-
BRCA	cis	rs11098499	0.866	rs11098506	ENSG00000225892.3	RP11-384K6.2	3.87	0.000115	0.00705	0.12	0.12	Corneal astigmatism;	chr4:119363816	chr4:118632274~118634759:+
BRCA	cis	rs890448	0.693	rs4276280	ENSG00000254531.1	FLJ20021	3.87	0.000115	0.00705	0.14	0.12	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101417442	chr4:101347780~101348883:+
BRCA	cis	rs7267979	1	rs4815406	ENSG00000274414.1	RP5-965G21.4	3.87	0.000115	0.00705	0.14	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25360680	chr20:25239007~25245229:-
BRCA	cis	rs17684571	1	rs16888128	ENSG00000231441.1	RP11-472M19.2	3.87	0.000115	0.00705	0.16	0.12	Schizophrenia;	chr6:56704306	chr6:56844002~56864078:+
BRCA	cis	rs4478858	0.735	rs10798845	ENSG00000260386.4	LINC01225	3.87	0.000115	0.00706	0.14	0.12	Alcohol dependence;	chr1:31349789	chr1:31500085~31540885:+
BRCA	cis	rs17123764	0.892	rs80071141	ENSG00000257464.1	RP11-161H23.8	-3.87	0.000115	0.00706	-0.22	-0.12	Intelligence (multi-trait analysis);	chr12:49765631	chr12:49442424~49442652:-
BRCA	cis	rs77204473	0.744	rs10892068	ENSG00000280143.1	AP000892.6	3.87	0.000115	0.00706	0.21	0.12	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117057830	chr11:117204967~117210292:+
BRCA	cis	rs35306767	0.855	rs12774985	ENSG00000229869.1	RP11-363N22.2	-3.87	0.000115	0.00706	-0.21	-0.12	Eosinophil percentage of granulocytes;	chr10:858305	chr10:933026~942743:+
BRCA	cis	rs1008375	0.966	rs2098152	ENSG00000249502.1	AC006160.5	-3.87	0.000115	0.00706	-0.14	-0.12	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17682769	chr4:17587467~17614571:-
BRCA	cis	rs801193	1	rs17566701	ENSG00000223473.2	GS1-124K5.3	3.87	0.000115	0.00706	0.09	0.12	Aortic root size;	chr7:66728196	chr7:66491049~66493566:-
BRCA	cis	rs4650943	0.586	rs2455731	ENSG00000227740.1	RP11-318C24.2	-3.87	0.000115	0.00706	-0.12	-0.12	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in inactive individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr1:176326589	chr1:175904762~175920513:-
BRCA	cis	rs9309473	0.687	rs11126399	ENSG00000230002.2	ALMS1-IT1	3.87	0.000115	0.00706	0.15	0.12	Metabolite levels;	chr2:73386213	chr2:73456764~73459484:+
BRCA	cis	rs983392	0.678	rs1562990	ENSG00000275344.1	MIR6503	3.87	0.000115	0.00706	0.13	0.12	Alzheimer's disease (late onset);	chr11:60255614	chr11:60209071~60209156:-
BRCA	cis	rs72928364	1	rs34272575	ENSG00000244119.1	PDCL3P4	3.87	0.000115	0.00706	0.15	0.12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100896563	chr3:101712472~101713191:+
BRCA	cis	rs10043775	1	rs17108251	ENSG00000251330.3	CTD-2283N19.1	-3.87	0.000115	0.00706	-0.14	-0.12	Periodontal microbiota;	chr5:148415019	chr5:148430159~148430807:-
BRCA	cis	rs4243971	0.516	rs6141285	ENSG00000275576.1	RP5-836N17.4	-3.87	0.000115	0.00706	-0.13	-0.12	Inflammatory bowel disease;Crohn's disease;	chr20:32304631	chr20:32116171~32116629:+
BRCA	cis	rs9921338	0.961	rs7195536	ENSG00000263080.1	RP11-485G7.5	3.87	0.000115	0.00706	0.18	0.12	Vein graft stenosis in coronary artery bypass grafting;	chr16:11348171	chr16:11341809~11345211:-
BRCA	cis	rs9921338	0.961	rs7191093	ENSG00000263080.1	RP11-485G7.5	3.87	0.000115	0.00706	0.18	0.12	Vein graft stenosis in coronary artery bypass grafting;	chr16:11348422	chr16:11341809~11345211:-
BRCA	cis	rs2041840	0.961	rs6742641	ENSG00000272054.1	RP11-423P10.2	-3.87	0.000115	0.00706	-0.11	-0.12	Chronic lymphocytic leukemia;	chr2:37304380	chr2:37208875~37212677:+
BRCA	cis	rs1429524	0.71	rs62468554	ENSG00000243144.5	RP11-115N4.1	3.87	0.000115	0.00706	0.17	0.12	Ejection fraction in Tripanosoma cruzi seropositivity;	chr7:91295937	chr7:91311368~91515409:+
BRCA	cis	rs7267979	0.714	rs1555329	ENSG00000204556.4	CTD-2514C3.1	-3.87	0.000115	0.00707	-0.16	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25251222	chr20:26018832~26020684:+
BRCA	cis	rs4925386	0.84	rs6143036	ENSG00000275437.1	RP5-908M14.10	3.87	0.000115	0.00707	0.13	0.12	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62346665	chr20:62402236~62405935:-
BRCA	cis	rs2562456	0.917	rs2681377	ENSG00000268119.4	CTD-2561J22.5	-3.87	0.000115	0.00707	-0.18	-0.12	Pain;	chr19:21533718	chr19:21444241~21463908:-
BRCA	cis	rs12468226	0.938	rs6435139	ENSG00000272966.1	RP11-686O6.1	-3.87	0.000115	0.00707	-0.19	-0.12	Urate levels;	chr2:202255145	chr2:202336739~202337200:+
BRCA	cis	rs1730008	1	rs1730041	ENSG00000279311.1	RP11-170K4.2	-3.87	0.000115	0.00707	-0.14	-0.12	Lobe attachment (rater-scored or self-reported);	chr3:158313803	chr3:158869898~158871821:+
BRCA	cis	rs6088580	0.609	rs6059845	ENSG00000275784.1	RP5-1125A11.6	-3.87	0.000115	0.00707	-0.13	-0.12	Glomerular filtration rate (creatinine);	chr20:34448695	chr20:33989480~33991818:-
BRCA	cis	rs11239930	0.538	rs719969	ENSG00000237188.3	RP11-337C18.8	3.87	0.000115	0.00707	0.13	0.12	AIDS progression;	chr1:147084111	chr1:147172771~147211568:+
BRCA	cis	rs2243480	1	rs316313	ENSG00000237026.1	RP11-328P23.2	3.87	0.000115	0.00707	0.22	0.12	Diabetic kidney disease;	chr7:66128561	chr7:65235790~65236723:-
BRCA	cis	rs2243480	1	rs316312	ENSG00000237026.1	RP11-328P23.2	3.87	0.000115	0.00707	0.22	0.12	Diabetic kidney disease;	chr7:66131504	chr7:65235790~65236723:-
BRCA	cis	rs2243480	1	rs419603	ENSG00000237026.1	RP11-328P23.2	3.87	0.000115	0.00707	0.22	0.12	Diabetic kidney disease;	chr7:66132354	chr7:65235790~65236723:-
BRCA	cis	rs853679	0.607	rs13199772	ENSG00000216901.1	AL022393.7	3.87	0.000115	0.00707	0.31	0.12	Depression;	chr6:27866307	chr6:28176188~28176674:+
BRCA	cis	rs2243480	1	rs34815098	ENSG00000226002.1	RP11-460N20.5	-3.87	0.000115	0.00707	-0.2	-0.12	Diabetic kidney disease;	chr7:65827267	chr7:65084103~65100232:+
BRCA	cis	rs2243480	1	rs35735127	ENSG00000226002.1	RP11-460N20.5	-3.87	0.000115	0.00707	-0.2	-0.12	Diabetic kidney disease;	chr7:65835436	chr7:65084103~65100232:+
BRCA	cis	rs2243480	0.901	rs35256305	ENSG00000226002.1	RP11-460N20.5	-3.87	0.000115	0.00707	-0.2	-0.12	Diabetic kidney disease;	chr7:65841418	chr7:65084103~65100232:+
BRCA	cis	rs2243480	0.803	rs34004500	ENSG00000226002.1	RP11-460N20.5	-3.87	0.000115	0.00707	-0.2	-0.12	Diabetic kidney disease;	chr7:65847191	chr7:65084103~65100232:+
BRCA	cis	rs2243480	1	rs35825738	ENSG00000226002.1	RP11-460N20.5	-3.87	0.000115	0.00707	-0.2	-0.12	Diabetic kidney disease;	chr7:65853040	chr7:65084103~65100232:+
BRCA	cis	rs11250098	0.567	rs4326350	ENSG00000255020.1	AF131216.5	-3.87	0.000115	0.00707	-0.14	-0.12	Morning vs. evening chronotype;	chr8:10906145	chr8:11345748~11347502:-
BRCA	cis	rs7267979	1	rs4815408	ENSG00000277938.1	RP5-965G21.3	-3.87	0.000115	0.00707	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25366042	chr20:25229150~25231933:+
BRCA	cis	rs8105895	0.935	rs2043319	ENSG00000269345.1	VN1R85P	3.87	0.000115	0.00707	0.17	0.12	Body mass index (change over time);	chr19:22091793	chr19:22174766~22175191:-
BRCA	cis	rs6951245	0.529	rs10262070	ENSG00000224079.1	AC091729.7	-3.87	0.000115	0.00707	-0.18	-0.12	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1102102	chr7:1074450~1078036:+
BRCA	cis	rs11098499	0.954	rs6848389	ENSG00000260404.2	RP11-384K6.6	3.87	0.000115	0.00707	0.11	0.12	Corneal astigmatism;	chr4:119481467	chr4:118591773~118633729:+
BRCA	cis	rs2108622	0.727	rs12609468	ENSG00000214049.6	UCA1	3.87	0.000115	0.00707	0.17	0.12	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15867004	chr19:15828961~15836320:+
BRCA	cis	rs2915864	1	rs2906070	ENSG00000280047.1	CTC-463A16.1	-3.87	0.000115	0.00708	-0.2	-0.12	Facial morphology (factor 20);	chr5:142200032	chr5:142165767~142168387:+
BRCA	cis	rs2915864	1	rs2906068	ENSG00000280047.1	CTC-463A16.1	-3.87	0.000115	0.00708	-0.2	-0.12	Facial morphology (factor 20);	chr5:142200216	chr5:142165767~142168387:+
BRCA	cis	rs2915864	0.861	rs2961719	ENSG00000280047.1	CTC-463A16.1	-3.87	0.000115	0.00708	-0.2	-0.12	Facial morphology (factor 20);	chr5:142200455	chr5:142165767~142168387:+
BRCA	cis	rs2915864	1	rs2906067	ENSG00000280047.1	CTC-463A16.1	-3.87	0.000115	0.00708	-0.2	-0.12	Facial morphology (factor 20);	chr5:142200557	chr5:142165767~142168387:+
BRCA	cis	rs2915864	1	rs2906066	ENSG00000280047.1	CTC-463A16.1	-3.87	0.000115	0.00708	-0.2	-0.12	Facial morphology (factor 20);	chr5:142200712	chr5:142165767~142168387:+
BRCA	cis	rs1048886	0.872	rs9455101	ENSG00000271967.1	RP11-134K13.4	-3.87	0.000115	0.00708	-0.16	-0.12	Type 2 diabetes;	chr6:70431863	chr6:70596438~70596980:+
BRCA	cis	rs1048886	0.938	rs9446248	ENSG00000271967.1	RP11-134K13.4	-3.87	0.000115	0.00708	-0.16	-0.12	Type 2 diabetes;	chr6:70434702	chr6:70596438~70596980:+
BRCA	cis	rs4730430	0.538	rs4455768	ENSG00000226965.1	AC003088.1	-3.87	0.000115	0.00708	-0.15	-0.12	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr7:110494533	chr7:110432239~110534754:-
BRCA	cis	rs2904804	0.506	rs4427477	ENSG00000224251.5	RP11-499O7.7	3.87	0.000115	0.00708	0.13	0.12	Economic and political preferences (immigration/crime);	chr10:4926905	chr10:4995488~4997380:+
BRCA	cis	rs875971	0.638	rs3898855	ENSG00000275400.1	RP4-756H11.5	3.87	0.000115	0.00708	0.14	0.12	Aortic root size;	chr7:66571411	chr7:66553805~66554199:-
BRCA	cis	rs875971	0.638	rs10278816	ENSG00000275400.1	RP4-756H11.5	3.87	0.000115	0.00708	0.14	0.12	Aortic root size;	chr7:66572000	chr7:66553805~66554199:-
BRCA	cis	rs875971	0.66	rs10281080	ENSG00000275400.1	RP4-756H11.5	3.87	0.000115	0.00708	0.14	0.12	Aortic root size;	chr7:66577454	chr7:66553805~66554199:-
BRCA	cis	rs875971	0.66	rs10950044	ENSG00000275400.1	RP4-756H11.5	3.87	0.000115	0.00708	0.14	0.12	Aortic root size;	chr7:66577989	chr7:66553805~66554199:-
BRCA	cis	rs10504130	1	rs75219463	ENSG00000272076.1	RP11-11C20.3	3.87	0.000115	0.00708	0.2	0.12	Venous thromboembolism (SNP x SNP interaction);	chr8:51852803	chr8:51810110~51810681:-
BRCA	cis	rs925550	0.932	rs28619895	ENSG00000224786.1	CETN4P	-3.87	0.000115	0.00708	-0.2	-0.12	Primary biliary cholangitis;	chr4:122683920	chr4:122730548~122732193:-
BRCA	cis	rs7395581	0.918	rs7120957	ENSG00000280615.1	Y_RNA	3.87	0.000115	0.00708	0.14	0.12	HDL cholesterol;	chr11:47319098	chr11:47614898~47614994:-
BRCA	cis	rs1346	0.552	rs7946115	ENSG00000245532.5	NEAT1	3.87	0.000115	0.00708	0.13	0.12	Vertical cup-disc ratio;Optic cup area;	chr11:65598721	chr11:65422774~65445540:+
BRCA	cis	rs1346	0.58	rs7932616	ENSG00000245532.5	NEAT1	3.87	0.000115	0.00708	0.13	0.12	Vertical cup-disc ratio;Optic cup area;	chr11:65598769	chr11:65422774~65445540:+
BRCA	cis	rs16846053	0.792	rs72877379	ENSG00000227403.1	AC009299.3	3.87	0.000115	0.00708	0.3	0.12	Blood osmolality (transformed sodium);	chr2:161797729	chr2:161244739~161249050:+
BRCA	cis	rs957448	1	rs72674852	ENSG00000261437.1	RP11-22C11.2	3.87	0.000115	0.00708	0.13	0.12	Nonsyndromic cleft lip with cleft palate;	chr8:94536523	chr8:94637285~94639467:-
BRCA	cis	rs73201462	1	rs2811519	ENSG00000242551.2	POU5F1P6	-3.87	0.000115	0.00708	-0.19	-0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128294033	chr3:128674735~128677005:-
BRCA	cis	rs73201462	1	rs2811518	ENSG00000242551.2	POU5F1P6	-3.87	0.000115	0.00708	-0.19	-0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128294802	chr3:128674735~128677005:-
BRCA	cis	rs911119	0.954	rs2405367	ENSG00000270001.1	RP11-218C14.8	3.87	0.000115	0.00708	0.15	0.12	Chronic kidney disease;	chr20:23642243	chr20:23631826~23632316:-
BRCA	cis	rs1816213	1	rs11898059	ENSG00000273466.1	RP11-548H3.1	-3.87	0.000115	0.00708	-0.25	-0.12	Diastolic blood pressure;	chr2:218746005	chr2:218633256~218634014:-
BRCA	cis	rs7481584	0.624	rs451060	ENSG00000236710.1	AC108448.2	3.87	0.000115	0.00708	0.16	0.12	Calcium levels;	chr11:3035159	chr11:3084393~3085443:-
BRCA	cis	rs13118159	1	rs13118159	ENSG00000254094.1	AC078852.1	-3.87	0.000115	0.00708	-0.13	-0.12	Longevity;	chr4:1371339	chr4:1356581~1358075:+
BRCA	cis	rs5758511	0.68	rs1107553	ENSG00000227370.1	RP4-669P10.19	3.87	0.000115	0.00708	0.15	0.12	Birth weight;	chr22:42271467	chr22:42132543~42132998:+
BRCA	cis	rs7824557	0.564	rs13260727	ENSG00000255310.2	AF131215.2	3.87	0.000115	0.00708	0.13	0.12	Retinal vascular caliber;	chr8:11375351	chr8:11107788~11109726:-
BRCA	cis	rs11098499	0.954	rs10006706	ENSG00000225892.3	RP11-384K6.2	3.87	0.000115	0.00708	0.12	0.12	Corneal astigmatism;	chr4:119487997	chr4:118632274~118634759:+
BRCA	cis	rs8181477	1	rs11014504	ENSG00000225527.1	RP11-383B4.4	3.87	0.000115	0.00708	0.13	0.12	Obesity-related traits;	chr10:18495059	chr10:18531849~18533336:-
BRCA	cis	rs2998286	0.678	rs332114	ENSG00000237128.1	RP11-351M16.3	-3.87	0.000115	0.00708	-0.15	-0.12	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28636772	chr10:28433008~28495813:-
BRCA	cis	rs4699052	0.59	rs1356293	ENSG00000248740.4	RP11-328K4.1	3.87	0.000115	0.00708	0.14	0.12	Testicular germ cell tumor;	chr4:103367043	chr4:103256159~103453658:+
BRCA	cis	rs794185	0.561	rs304029	ENSG00000231249.1	ITPR1-AS1	3.87	0.000115	0.00708	0.14	0.12	Multiple sclerosis--Brain Glutamate Levels;	chr3:4504140	chr3:4490891~4493163:-
BRCA	cis	rs7267979	0.966	rs910996	ENSG00000276952.1	RP5-965G21.6	3.87	0.000115	0.00709	0.15	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25283560	chr20:25284915~25285588:-
BRCA	cis	rs35740288	0.787	rs2008916	ENSG00000259407.1	RP11-158M2.3	-3.87	0.000115	0.00709	-0.16	-0.12	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85677959	chr15:85744109~85750281:-
BRCA	cis	rs2253762	0.54	rs12249581	ENSG00000226864.1	ATE1-AS1	3.87	0.000115	0.00709	0.22	0.12	Breast cancer;	chr10:122013486	chr10:121928312~121951965:+
BRCA	cis	rs763121	0.853	rs5757232	ENSG00000225450.1	RP3-508I15.14	-3.87	0.000115	0.00709	-0.13	-0.12	Menopause (age at onset);	chr22:38675672	chr22:38739003~38749041:+
BRCA	cis	rs448720	1	rs8035326	ENSG00000260657.2	RP11-315D16.4	-3.87	0.000115	0.00709	-0.14	-0.12	Cognitive performance;	chr15:67916195	chr15:68267792~68277994:-
BRCA	cis	rs8127691	0.935	rs2838519	ENSG00000237604.1	AP001056.1	3.87	0.000115	0.00709	0.13	0.12	Inflammatory bowel disease;	chr21:44195140	chr21:44175489~44176453:+
BRCA	cis	rs739496	0.843	rs610769	ENSG00000257624.1	RP1-128M12.3	3.87	0.000115	0.00709	0.16	0.12	Platelet count;	chr12:111561766	chr12:112000739~112000985:-
BRCA	cis	rs739496	0.843	rs595529	ENSG00000257624.1	RP1-128M12.3	3.87	0.000115	0.00709	0.16	0.12	Platelet count;	chr12:111562844	chr12:112000739~112000985:-
BRCA	cis	rs875971	0.545	rs10950025	ENSG00000232559.3	GS1-124K5.12	3.87	0.000115	0.00709	0.16	0.12	Aortic root size;	chr7:66158946	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.52	rs12666485	ENSG00000232559.3	GS1-124K5.12	3.87	0.000115	0.00709	0.16	0.12	Aortic root size;	chr7:66160135	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.545	rs67688847	ENSG00000232559.3	GS1-124K5.12	3.87	0.000115	0.00709	0.16	0.12	Aortic root size;	chr7:66161064	chr7:66554588~66576923:-
BRCA	cis	rs10043775	0.718	rs10056586	ENSG00000251330.3	CTD-2283N19.1	-3.87	0.000115	0.00709	-0.14	-0.12	Periodontal microbiota;	chr5:148440140	chr5:148430159~148430807:-
BRCA	cis	rs10043775	0.872	rs9325097	ENSG00000251330.3	CTD-2283N19.1	-3.87	0.000115	0.00709	-0.14	-0.12	Periodontal microbiota;	chr5:148440782	chr5:148430159~148430807:-
BRCA	cis	rs1009077	0.68	rs3775851	ENSG00000245958.5	RP11-33B1.1	3.87	0.000115	0.00709	0.14	0.12	Endometriosis;	chr4:119532261	chr4:119454791~119552025:+
BRCA	cis	rs8180040	0.764	rs12630534	ENSG00000276925.1	RP11-708J19.3	-3.87	0.000115	0.00709	-0.14	-0.12	Colorectal cancer;	chr3:46959553	chr3:47469777~47469987:+
BRCA	cis	rs12303914	0.676	rs3759273	ENSG00000256682.2	TAS2R12	3.87	0.000115	0.00709	0.14	0.12	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr12:10305422	chr12:10894943~10896952:-
BRCA	cis	rs9381040	0.655	rs879491	ENSG00000161912.16	ADCY10P1	3.87	0.000115	0.00709	0.13	0.12	Alzheimer's disease (late onset);	chr6:41059214	chr6:41101022~41140835:+
BRCA	cis	rs748404	0.666	rs66629206	ENSG00000205771.5	CATSPER2P1	-3.87	0.000115	0.00709	-0.18	-0.12	Lung cancer;	chr15:43458804	chr15:43726918~43747094:-
BRCA	cis	rs875971	0.545	rs7787063	ENSG00000232559.3	GS1-124K5.12	3.87	0.000115	0.00709	0.16	0.12	Aortic root size;	chr7:66164012	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.545	rs12673308	ENSG00000232559.3	GS1-124K5.12	3.87	0.000115	0.00709	0.16	0.12	Aortic root size;	chr7:66166374	chr7:66554588~66576923:-
BRCA	cis	rs2880765	0.743	rs6497191	ENSG00000202081.1	RNU6-1280P	3.87	0.000115	0.00709	0.14	0.12	Coronary artery disease;	chr15:85468270	chr15:85651522~85651628:-
BRCA	cis	rs2835872	0.863	rs702859	ENSG00000228677.1	TTC3-AS1	3.87	0.000115	0.00709	0.16	0.12	Electroencephalographic traits in alcoholism;	chr21:37625399	chr21:37187666~37193926:-
BRCA	cis	rs2835872	0.863	rs857979	ENSG00000228677.1	TTC3-AS1	3.87	0.000115	0.00709	0.16	0.12	Electroencephalographic traits in alcoholism;	chr21:37625791	chr21:37187666~37193926:-
BRCA	cis	rs4664293	0.625	rs6432543	ENSG00000226266.5	AC009961.3	3.87	0.000115	0.00709	0.14	0.12	Monocyte percentage of white cells;	chr2:159638820	chr2:159670708~159712435:-
BRCA	cis	rs4664293	0.647	rs4665099	ENSG00000226266.5	AC009961.3	3.87	0.000115	0.00709	0.14	0.12	Monocyte percentage of white cells;	chr2:159639027	chr2:159670708~159712435:-
BRCA	cis	rs4664293	0.647	rs6724151	ENSG00000226266.5	AC009961.3	3.87	0.000115	0.00709	0.14	0.12	Monocyte percentage of white cells;	chr2:159642788	chr2:159670708~159712435:-
BRCA	cis	rs7246967	0.932	rs62120772	ENSG00000198153.8	ZNF849P	-3.87	0.000115	0.0071	-0.17	-0.12	Bronchopulmonary dysplasia;	chr19:22854349	chr19:22685167~22686732:+
BRCA	cis	rs7246967	0.932	rs35007403	ENSG00000198153.8	ZNF849P	-3.87	0.000115	0.0071	-0.17	-0.12	Bronchopulmonary dysplasia;	chr19:22854645	chr19:22685167~22686732:+
BRCA	cis	rs7246967	0.932	rs8105614	ENSG00000198153.8	ZNF849P	-3.87	0.000115	0.0071	-0.17	-0.12	Bronchopulmonary dysplasia;	chr19:22855221	chr19:22685167~22686732:+
BRCA	cis	rs7246967	0.8	rs7256135	ENSG00000198153.8	ZNF849P	-3.87	0.000115	0.0071	-0.17	-0.12	Bronchopulmonary dysplasia;	chr19:22856319	chr19:22685167~22686732:+
BRCA	cis	rs7246967	0.932	rs58238799	ENSG00000198153.8	ZNF849P	-3.87	0.000115	0.0071	-0.17	-0.12	Bronchopulmonary dysplasia;	chr19:22857380	chr19:22685167~22686732:+
BRCA	cis	rs7246967	0.866	rs34752785	ENSG00000198153.8	ZNF849P	-3.87	0.000115	0.0071	-0.17	-0.12	Bronchopulmonary dysplasia;	chr19:22861771	chr19:22685167~22686732:+
BRCA	cis	rs7246967	0.866	rs62120784	ENSG00000198153.8	ZNF849P	-3.87	0.000115	0.0071	-0.17	-0.12	Bronchopulmonary dysplasia;	chr19:22861933	chr19:22685167~22686732:+
BRCA	cis	rs3781264	0.816	rs7084339	ENSG00000268894.5	PLCE1-AS1	3.87	0.000115	0.0071	0.16	0.12	Esophageal cancer and gastric cancer;	chr10:94283975	chr10:94279277~94287478:-
BRCA	cis	rs251253	1	rs251253	ENSG00000253959.1	CTB-43E15.1	-3.87	0.000115	0.0071	-0.11	-0.12	PR interval;	chr5:173053333	chr5:173642519~173658194:+
BRCA	cis	rs7267979	1	rs6050555	ENSG00000204556.4	CTD-2514C3.1	3.87	0.000115	0.0071	0.16	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25347907	chr20:26018832~26020684:+
BRCA	cis	rs2383024	0.645	rs4961567	ENSG00000234779.1	RP11-62F24.2	-3.87	0.000115	0.0071	-0.12	-0.12	Pulmonary function decline;	chr9:17486685	chr9:16726814~16727524:+
BRCA	cis	rs1971762	0.527	rs7300936	ENSG00000270175.1	RP11-793H13.11	-3.87	0.000115	0.0071	-0.1	-0.12	Height;	chr12:53636802	chr12:53500162~53500936:-
BRCA	cis	rs13217239	0.646	rs6456767	ENSG00000124549.13	BTN2A3P	-3.87	0.000115	0.0071	-0.12	-0.12	Schizophrenia;	chr6:27102764	chr6:26421391~26432383:+
BRCA	cis	rs6840360	0.904	rs6825241	ENSG00000251611.1	RP11-610P16.1	-3.87	0.000115	0.0071	-0.1	-0.12	Intelligence (multi-trait analysis);	chr4:151622631	chr4:151407551~151408835:-
BRCA	cis	rs7695732	0.827	rs6852373	ENSG00000270720.1	RP11-84C13.2	-3.87	0.000116	0.0071	-0.16	-0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr4:89004818	chr4:89119284~89119871:+
BRCA	cis	rs38055	0.837	rs626726	ENSG00000247796.2	CTD-2366F13.1	-3.87	0.000116	0.0071	-0.14	-0.12	Acne (severe);	chr5:53327934	chr5:53109842~53115126:+
BRCA	cis	rs7395581	0.918	rs4752824	ENSG00000280615.1	Y_RNA	3.87	0.000116	0.0071	0.14	0.12	HDL cholesterol;	chr11:47303115	chr11:47614898~47614994:-
BRCA	cis	rs7951911	0.915	rs10466475	ENSG00000254427.1	RP11-430H10.1	3.87	0.000116	0.0071	0.26	0.12	IgG glycosylation;	chr11:45076549	chr11:45355371~45366121:+
BRCA	cis	rs3820068	0.581	rs1547031	ENSG00000237301.1	RP4-680D5.2	-3.87	0.000116	0.0071	-0.15	-0.12	Systolic blood pressure;	chr1:15592465	chr1:15586136~15603626:-
BRCA	cis	rs3820068	0.581	rs1547033	ENSG00000237301.1	RP4-680D5.2	-3.87	0.000116	0.0071	-0.15	-0.12	Systolic blood pressure;	chr1:15592493	chr1:15586136~15603626:-
BRCA	cis	rs7188861	0.603	rs2113260	ENSG00000262636.1	CTD-3088G3.4	3.87	0.000116	0.0071	0.17	0.12	HDL cholesterol;	chr16:11362136	chr16:11380859~11381118:-
BRCA	cis	rs6736093	0.704	rs4848979	ENSG00000236307.2	EEF1E1P1	-3.87	0.000116	0.0071	-0.14	-0.12	Coronary artery disease;	chr2:112058659	chr2:111887914~111888741:+
BRCA	cis	rs9527	0.59	rs12414232	ENSG00000213061.2	PFN1P11	3.87	0.000116	0.0071	0.16	0.12	Arsenic metabolism;	chr10:103154734	chr10:102838011~102845473:-
BRCA	cis	rs12549025	0.536	rs9644077	ENSG00000253986.1	CTC-756D1.3	3.87	0.000116	0.0071	0.2	0.12	Reticulocyte fraction of red cells;	chr8:23502819	chr8:23493009~23494198:-
BRCA	cis	rs2880765	0.743	rs8032488	ENSG00000202081.1	RNU6-1280P	3.87	0.000116	0.0071	0.14	0.12	Coronary artery disease;	chr15:85469537	chr15:85651522~85651628:-
BRCA	cis	rs11673344	0.503	rs703531	ENSG00000276846.1	CTD-3220F14.3	3.87	0.000116	0.0071	0.14	0.12	Obesity-related traits;	chr19:37010050	chr19:37314868~37315620:-
BRCA	cis	rs7267979	0.966	rs2482918	ENSG00000274973.1	RP13-401N8.7	3.87	0.000116	0.0071	0.14	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25431499	chr20:25845497~25845862:+
BRCA	cis	rs35306767	0.807	rs34527494	ENSG00000229869.1	RP11-363N22.2	-3.87	0.000116	0.0071	-0.2	-0.12	Eosinophil percentage of granulocytes;	chr10:889252	chr10:933026~942743:+
BRCA	cis	rs2274273	0.624	rs7151581	ENSG00000259318.1	RP11-454L9.2	-3.87	0.000116	0.0071	-0.11	-0.12	Protein biomarker;	chr14:55321727	chr14:55394940~55395233:-
BRCA	cis	rs1910358	0.778	rs6452178	ENSG00000248874.4	C5orf17	-3.87	0.000116	0.00711	-0.16	-0.12	Venous thromboembolism (SNP x SNP interaction);	chr5:23986034	chr5:23951348~24178263:+
BRCA	cis	rs1910358	0.778	rs28386991	ENSG00000248874.4	C5orf17	-3.87	0.000116	0.00711	-0.16	-0.12	Venous thromboembolism (SNP x SNP interaction);	chr5:23991262	chr5:23951348~24178263:+
BRCA	cis	rs10246939	0.543	rs9640204	ENSG00000270923.1	TAS2R6P	-3.87	0.000116	0.00711	-0.12	-0.12	Bitter taste perception;	chr7:141844300	chr7:141787815~141788640:+
BRCA	cis	rs1434579	0.897	rs8102733	ENSG00000176761.7	ZNF285B	-3.87	0.000116	0.00711	-0.14	-0.12	Tuberculosis;	chr19:44440265	chr19:44467641~44473227:+
BRCA	cis	rs12549902	0.897	rs12549294	ENSG00000254165.1	RP11-503E24.2	3.87	0.000116	0.00711	0.13	0.12	Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Corrected insulin response;Type 2 diabetes;	chr8:41648861	chr8:42537529~42538304:-
BRCA	cis	rs11098499	0.908	rs11098527	ENSG00000225892.3	RP11-384K6.2	3.87	0.000116	0.00711	0.12	0.12	Corneal astigmatism;	chr4:119478751	chr4:118632274~118634759:+
BRCA	cis	rs10125054	0.685	rs10817257	ENSG00000259953.1	RP11-4O1.2	3.87	0.000116	0.00711	0.17	0.12	Obesity-related traits;	chr9:112043224	chr9:112032555~112037730:-
BRCA	cis	rs11098499	0.954	rs3890049	ENSG00000225892.3	RP11-384K6.2	3.87	0.000116	0.00711	0.12	0.12	Corneal astigmatism;	chr4:119405128	chr4:118632274~118634759:+
BRCA	cis	rs875971	0.545	rs6961853	ENSG00000273448.1	RP11-166O4.6	3.87	0.000116	0.00711	0.12	0.12	Aortic root size;	chr7:66537035	chr7:67333047~67334383:+
BRCA	cis	rs7475343	0.505	rs10752005	ENSG00000224034.1	RP11-445P17.8	3.87	0.000116	0.00711	0.22	0.12	Intelligence;	chr10:5118307	chr10:5266033~5271236:-
BRCA	cis	rs4650943	0.586	rs2455740	ENSG00000227740.1	RP11-318C24.2	-3.87	0.000116	0.00711	-0.12	-0.12	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in inactive individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr1:176320964	chr1:175904762~175920513:-
BRCA	cis	rs4650943	0.586	rs1109579	ENSG00000227740.1	RP11-318C24.2	-3.87	0.000116	0.00711	-0.12	-0.12	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in inactive individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr1:176322940	chr1:175904762~175920513:-
BRCA	cis	rs4650943	0.586	rs1009112	ENSG00000227740.1	RP11-318C24.2	-3.87	0.000116	0.00711	-0.12	-0.12	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in inactive individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr1:176323376	chr1:175904762~175920513:-
BRCA	cis	rs4650943	0.586	rs1948817	ENSG00000227740.1	RP11-318C24.2	-3.87	0.000116	0.00711	-0.12	-0.12	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in inactive individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr1:176323963	chr1:175904762~175920513:-
BRCA	cis	rs4664293	0.625	rs35241460	ENSG00000226266.5	AC009961.3	3.87	0.000116	0.00711	0.14	0.12	Monocyte percentage of white cells;	chr2:159651689	chr2:159670708~159712435:-
BRCA	cis	rs801193	0.967	rs34356500	ENSG00000275400.1	RP4-756H11.5	-3.87	0.000116	0.00711	-0.13	-0.12	Aortic root size;	chr7:66771620	chr7:66553805~66554199:-
BRCA	cis	rs1032833	0.732	rs17363393	ENSG00000271401.1	RP11-171I2.3	-3.87	0.000116	0.00711	-0.29	-0.12	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);	chr2:179141325	chr2:178644717~178645179:+
BRCA	cis	rs4478858	0.647	rs11581476	ENSG00000223907.1	LINC01226	-3.87	0.000116	0.00711	-0.14	-0.12	Alcohol dependence;	chr1:31244828	chr1:31518435~31524245:+
BRCA	cis	rs8098244	0.737	rs1258131	ENSG00000265752.2	RP11-403A21.1	-3.87	0.000116	0.00711	-0.17	-0.12	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23959755	chr18:23957754~23982556:-
BRCA	cis	rs35146811	0.844	rs13232115	ENSG00000214313.7	AZGP1P1	3.87	0.000116	0.00711	0.13	0.12	Coronary artery disease;	chr7:100073309	chr7:99980762~99987535:+
BRCA	cis	rs1371614	0.632	rs6547318	ENSG00000272148.1	RP11-195B17.1	3.87	0.000116	0.00711	0.13	0.12	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26930613	chr2:27062428~27062907:-
BRCA	cis	rs8030605	0.778	rs72742631	ENSG00000277245.1	RP11-48G14.3	3.87	0.000116	0.00712	0.25	0.12	Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;	chr15:56394101	chr15:56447120~56447697:+
BRCA	cis	rs10844706	0.669	rs10772108	ENSG00000214776.8	RP11-726G1.1	3.87	0.000116	0.00712	0.15	0.12	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9746454	chr12:9467552~9576275:+
BRCA	cis	rs2839186	0.771	rs13049175	ENSG00000228137.1	AP001469.7	-3.87	0.000116	0.00712	-0.12	-0.12	Testicular germ cell tumor;	chr21:46221412	chr21:46246890~46247682:+
BRCA	cis	rs6951245	0.554	rs4724294	ENSG00000224079.1	AC091729.7	-3.87	0.000116	0.00712	-0.18	-0.12	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1100059	chr7:1074450~1078036:+
BRCA	cis	rs11673344	0.562	rs6510580	ENSG00000276846.1	CTD-3220F14.3	3.87	0.000116	0.00712	0.14	0.12	Obesity-related traits;	chr19:37038452	chr19:37314868~37315620:-
BRCA	cis	rs11673344	0.523	rs2082009	ENSG00000276846.1	CTD-3220F14.3	3.87	0.000116	0.00712	0.14	0.12	Obesity-related traits;	chr19:37039834	chr19:37314868~37315620:-
BRCA	cis	rs1009077	0.626	rs11731568	ENSG00000245958.5	RP11-33B1.1	3.87	0.000116	0.00712	0.17	0.12	Endometriosis;	chr4:119618796	chr4:119454791~119552025:+
BRCA	cis	rs1009077	0.716	rs62319657	ENSG00000245958.5	RP11-33B1.1	3.87	0.000116	0.00712	0.17	0.12	Endometriosis;	chr4:119621367	chr4:119454791~119552025:+
BRCA	cis	rs72634258	0.945	rs12748993	ENSG00000238290.1	RP11-431K24.1	-3.87	0.000116	0.00712	-0.18	-0.12	Inflammatory bowel disease;	chr1:8069447	chr1:8026738~8122702:+
BRCA	cis	rs3750965	0.92	rs10896420	ENSG00000265539.1	MIR3164	-3.87	0.000116	0.00712	-0.14	-0.12	Hair color;	chr11:69095579	chr11:69083176~69083258:+
BRCA	cis	rs3750965	0.92	rs10896421	ENSG00000265539.1	MIR3164	-3.87	0.000116	0.00712	-0.14	-0.12	Hair color;	chr11:69095580	chr11:69083176~69083258:+
BRCA	cis	rs11098499	0.863	rs3775845	ENSG00000260091.1	RP11-33B1.4	-3.87	0.000116	0.00712	-0.11	-0.12	Corneal astigmatism;	chr4:119511292	chr4:119409333~119410233:+
BRCA	cis	rs3774749	0.565	rs2624839	ENSG00000228008.1	CTD-2330K9.3	3.87	0.000116	0.00713	0.12	0.12	Intelligence (multi-trait analysis);	chr3:50164798	chr3:49903845~49916937:+
BRCA	cis	rs9959145	0.706	rs117416781	ENSG00000267108.1	RP11-861E21.1	3.87	0.000116	0.00713	0.21	0.12	Immune response to smallpox vaccine (IL-6);	chr18:12684925	chr18:12432897~12437635:+
BRCA	cis	rs9959145	1	rs78421903	ENSG00000267108.1	RP11-861E21.1	3.87	0.000116	0.00713	0.21	0.12	Immune response to smallpox vaccine (IL-6);	chr18:12688701	chr18:12432897~12437635:+
BRCA	cis	rs2274273	0.624	rs7147247	ENSG00000259318.1	RP11-454L9.2	3.87	0.000116	0.00713	0.11	0.12	Protein biomarker;	chr14:55310995	chr14:55394940~55395233:-
BRCA	cis	rs4650943	0.586	rs877363	ENSG00000227740.1	RP11-318C24.2	-3.87	0.000116	0.00713	-0.12	-0.12	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in inactive individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr1:176323438	chr1:175904762~175920513:-
BRCA	cis	rs3136202	0.643	rs254930	ENSG00000242307.1	RPS26P52	3.87	0.000116	0.00713	0.15	0.12	Conduct disorder (symptom count);	chr16:13979938	chr16:13922332~13922679:-
BRCA	cis	rs28374715	0.681	rs7163989	ENSG00000247556.5	OIP5-AS1	3.87	0.000116	0.00713	0.12	0.12	Ulcerative colitis;	chr15:41322423	chr15:41283990~41309737:+
BRCA	cis	rs7561149	0.768	rs6709734	ENSG00000270574.1	RP11-171I2.2	-3.87	0.000116	0.00713	-0.17	-0.12	QT interval;	chr2:178864414	chr2:178578790~178580906:+
BRCA	cis	rs78487399	0.808	rs12104615	ENSG00000234936.1	AC010883.5	3.87	0.000116	0.00713	0.18	0.12	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43449799	chr2:43229573~43233394:+
BRCA	cis	rs78487399	0.808	rs12105399	ENSG00000234936.1	AC010883.5	3.87	0.000116	0.00713	0.18	0.12	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43449800	chr2:43229573~43233394:+
BRCA	cis	rs4415084	1	rs6871484	ENSG00000248779.1	RP11-53O19.2	3.87	0.000116	0.00713	0.11	0.12	Breast cancer;	chr5:44676203	chr5:44752949~44765744:+
BRCA	cis	rs10819861	0.645	rs10819835	ENSG00000175611.10	LINC00476	3.87	0.000116	0.00713	0.13	0.12	Electrocardiographic traits;	chr9:96096383	chr9:95759231~95875977:-
BRCA	cis	rs10043775	1	rs34269182	ENSG00000251330.3	CTD-2283N19.1	-3.87	0.000116	0.00713	-0.14	-0.12	Periodontal microbiota;	chr5:148444850	chr5:148430159~148430807:-
BRCA	cis	rs10043775	0.874	rs4574533	ENSG00000251330.3	CTD-2283N19.1	-3.87	0.000116	0.00713	-0.14	-0.12	Periodontal microbiota;	chr5:148445782	chr5:148430159~148430807:-
BRCA	cis	rs10043775	1	rs4274967	ENSG00000251330.3	CTD-2283N19.1	-3.87	0.000116	0.00713	-0.14	-0.12	Periodontal microbiota;	chr5:148445876	chr5:148430159~148430807:-
BRCA	cis	rs10043775	1	rs9325098	ENSG00000251330.3	CTD-2283N19.1	-3.87	0.000116	0.00713	-0.14	-0.12	Periodontal microbiota;	chr5:148447875	chr5:148430159~148430807:-
BRCA	cis	rs28829049	0.861	rs2147946	ENSG00000270728.1	RP4-657E11.10	-3.87	0.000116	0.00713	-0.12	-0.12	QRS duration in Tripanosoma cruzi seropositivity;	chr1:19042393	chr1:19297080~19297903:+
BRCA	cis	rs7590268	0.848	rs6544656	ENSG00000279873.2	LINC01126	3.87	0.000116	0.00713	0.14	0.12	Orofacial clefts;	chr2:43408004	chr2:43227210~43228855:+
BRCA	cis	rs2562456	0.755	rs1879234	ENSG00000268555.1	RP11-678G14.3	-3.87	0.000116	0.00713	-0.16	-0.12	Pain;	chr19:21521677	chr19:21570822~21587322:-
BRCA	cis	rs7233060	1	rs7231598	ENSG00000274828.1	RP11-567M16.6	-3.87	0.000116	0.00713	-0.17	-0.12	Schizophrenia;	chr18:79630317	chr18:79677287~79679358:-
BRCA	cis	rs7267979	1	rs6050561	ENSG00000274414.1	RP5-965G21.4	3.87	0.000116	0.00713	0.14	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25354219	chr20:25239007~25245229:-
BRCA	cis	rs7267979	1	rs6083813	ENSG00000274414.1	RP5-965G21.4	3.87	0.000116	0.00713	0.14	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25357035	chr20:25239007~25245229:-
BRCA	cis	rs2835345	0.596	rs2409817	ENSG00000214914.3	RPL23AP3	-3.87	0.000116	0.00713	-0.16	-0.12	Pulmonary function;	chr21:36455410	chr21:36016079~36016546:-
BRCA	cis	rs8180040	0.701	rs62248439	ENSG00000280667.1	Y_RNA	-3.87	0.000116	0.00713	-0.13	-0.12	Colorectal cancer;	chr3:46954958	chr3:47501083~47501182:+
BRCA	cis	rs28489187	0.683	rs1554597	ENSG00000223653.4	RP11-131L23.1	-3.87	0.000116	0.00713	-0.13	-0.12	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85411415	chr1:85276715~85448124:+
BRCA	cis	rs559406	0.501	rs2542167	ENSG00000260302.1	RP11-973H7.1	-3.87	0.000116	0.00714	-0.15	-0.12	Psoriasis;	chr18:12795850	chr18:12774651~12775923:-
BRCA	cis	rs7800418	0.775	rs10246255	ENSG00000214870.7	AC004540.5	3.87	0.000116	0.00714	0.14	0.12	Cognitive function;	chr7:26566979	chr7:26398593~26494256:+
BRCA	cis	rs983392	0.792	rs493692	ENSG00000275344.1	MIR6503	-3.87	0.000116	0.00714	-0.12	-0.12	Alzheimer's disease (late onset);	chr11:60142137	chr11:60209071~60209156:-
BRCA	cis	rs801193	0.967	rs2707849	ENSG00000265600.1	AC006480.1	-3.87	0.000116	0.00714	-0.14	-0.12	Aortic root size;	chr7:66687725	chr7:67356680~67356779:+
BRCA	cis	rs5758659	0.652	rs5758537	ENSG00000182057.4	OGFRP1	3.87	0.000116	0.00714	0.13	0.12	Cognitive function;	chr22:42001038	chr22:42269753~42275196:+
BRCA	cis	rs7771547	0.519	rs58153398	ENSG00000224666.3	RP1-50J22.4	3.87	0.000116	0.00714	0.14	0.12	Platelet distribution width;	chr6:36402617	chr6:36386831~36393462:+
BRCA	cis	rs7771547	0.519	rs4713972	ENSG00000224666.3	RP1-50J22.4	3.87	0.000116	0.00714	0.14	0.12	Platelet distribution width;	chr6:36403539	chr6:36386831~36393462:+
BRCA	cis	rs1865760	1	rs6938233	ENSG00000272462.2	U91328.19	-3.87	0.000116	0.00714	-0.14	-0.12	Height;	chr6:25913849	chr6:25992662~26001775:+
BRCA	cis	rs2403083	0.915	rs2278459	ENSG00000258256.1	RP11-219B4.5	3.87	0.000116	0.00714	0.15	0.12	Plasma amyloid beta peptide concentrations (ABx-40);	chr8:85202443	chr8:85222446~85245717:-
BRCA	cis	rs7917772	0.503	rs7904955	ENSG00000213061.2	PFN1P11	-3.87	0.000116	0.00714	-0.17	-0.12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;	chr10:102607335	chr10:102838011~102845473:-
BRCA	cis	rs875971	0.545	rs17138156	ENSG00000232559.3	GS1-124K5.12	3.87	0.000116	0.00714	0.16	0.12	Aortic root size;	chr7:66249708	chr7:66554588~66576923:-
BRCA	cis	rs1555322	1	rs2425032	ENSG00000261582.1	RP4-614O4.11	-3.87	0.000116	0.00714	-0.16	-0.12	Attention deficit hyperactivity disorder;	chr20:35267651	chr20:35267885~35280043:-
BRCA	cis	rs3743162	0.553	rs12900463	ENSG00000275120.1	RP11-182J1.17	3.87	0.000116	0.00715	0.17	0.12	Alzheimer's disease (age of onset);	chr15:84872155	chr15:84599434~84606463:-
BRCA	cis	rs2832191	0.967	rs2832216	ENSG00000176054.6	RPL23P2	3.87	0.000116	0.00715	0.12	0.12	Dental caries;	chr21:29149600	chr21:28997613~28998033:-
BRCA	cis	rs2688608	0.592	rs3933085	ENSG00000213731.2	RAB5CP1	-3.87	0.000116	0.00715	-0.13	-0.12	Inflammatory bowel disease;	chr10:73723573	chr10:74423435~74424014:-
BRCA	cis	rs9309473	0.607	rs7604588	ENSG00000230002.2	ALMS1-IT1	3.87	0.000116	0.00715	0.14	0.12	Metabolite levels;	chr2:73344289	chr2:73456764~73459484:+
BRCA	cis	rs8054556	1	rs9932196	ENSG00000261367.1	RP11-455F5.4	-3.87	0.000116	0.00715	-0.13	-0.12	Autism spectrum disorder or schizophrenia;	chr16:29971798	chr16:30107675~30110541:+
BRCA	cis	rs216345	0.763	rs7033336	ENSG00000260947.1	RP11-384P7.7	-3.87	0.000116	0.00715	-0.13	-0.12	Bipolar disorder;	chr9:34012524	chr9:33697459~33700986:+
BRCA	cis	rs2191566	1	rs10418363	ENSG00000266921.1	RP11-15A1.7	-3.87	0.000116	0.00715	-0.15	-0.12	Acute lymphoblastic leukemia (childhood);	chr19:44021311	chr19:43996896~44002836:-
BRCA	cis	rs9527	0.59	rs10786741	ENSG00000213061.2	PFN1P11	3.87	0.000116	0.00715	0.16	0.12	Arsenic metabolism;	chr10:103179425	chr10:102838011~102845473:-
BRCA	cis	rs2562456	0.52	rs279793	ENSG00000268658.4	LINC00664	3.87	0.000116	0.00715	0.21	0.12	Pain;	chr19:21272972	chr19:21483374~21503238:+
BRCA	cis	rs7771547	0.519	rs6928287	ENSG00000224666.3	RP1-50J22.4	3.87	0.000116	0.00715	0.14	0.12	Platelet distribution width;	chr6:36407661	chr6:36386831~36393462:+
BRCA	cis	rs13006863	0.509	rs1667605	ENSG00000257800.1	FNBP1P1	-3.87	0.000116	0.00715	-0.1	-0.12	Immune reponse to smallpox (secreted TNF-alpha);Post-traumatic stress disorder (asjusted for relatedness);	chr2:74147757	chr2:74120680~74123218:+
BRCA	cis	rs10129255	0.912	rs67410411	ENSG00000232216.1	IGHV3-43	3.87	0.000116	0.00715	0.1	0.12	Kawasaki disease;	chr14:106680324	chr14:106470264~106470800:-
BRCA	cis	rs11738223	0.678	rs17654445	ENSG00000213386.3	RP11-779O18.2	3.87	0.000116	0.00715	0.16	0.12	Menopause (age at onset);	chr5:172498860	chr5:172762521~172763258:-
BRCA	cis	rs748404	0.666	rs16957715	ENSG00000205771.5	CATSPER2P1	-3.87	0.000116	0.00715	-0.17	-0.12	Lung cancer;	chr15:43416539	chr15:43726918~43747094:-
BRCA	cis	rs9527	0.59	rs12775302	ENSG00000213061.2	PFN1P11	3.87	0.000116	0.00715	0.16	0.12	Arsenic metabolism;	chr10:103151599	chr10:102838011~102845473:-
BRCA	cis	rs9392556	0.829	rs584585	ENSG00000230648.1	RP3-406P24.3	3.87	0.000116	0.00715	0.15	0.12	Blood metabolite levels;	chr6:4118555	chr6:4018843~4021215:-
BRCA	cis	rs11098499	0.909	rs10017335	ENSG00000260404.2	RP11-384K6.6	-3.87	0.000116	0.00715	-0.11	-0.12	Corneal astigmatism;	chr4:119460368	chr4:118591773~118633729:+
BRCA	cis	rs12505749	0.542	rs17086794	ENSG00000270147.1	RP11-646I6.6	-3.87	0.000116	0.00715	-0.14	-0.12	Airflow obstruction;	chr4:56468586	chr4:56396312~56396871:+
BRCA	cis	rs1073160	0.615	rs6487460	ENSG00000256589.1	ENPP7P5	3.87	0.000116	0.00715	0.14	0.12	Small cell lung carcinoma;	chr12:8894795	chr12:8254527~8308849:-
BRCA	cis	rs7590268	0.806	rs6544652	ENSG00000279873.2	LINC01126	3.87	0.000116	0.00715	0.14	0.12	Orofacial clefts;	chr2:43399073	chr2:43227210~43228855:+
BRCA	cis	rs35520189	1	rs35520189	ENSG00000189223.12	PAX8-AS1	-3.87	0.000117	0.00715	-0.19	-0.12	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:112861653	chr2:113211522~113276581:+
BRCA	cis	rs35520189	0.961	rs12477661	ENSG00000189223.12	PAX8-AS1	-3.87	0.000117	0.00715	-0.19	-0.12	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:112863188	chr2:113211522~113276581:+
BRCA	cis	rs4919694	1	rs17727391	ENSG00000236937.2	PTGES3P4	3.87	0.000117	0.00715	0.24	0.12	Arsenic metabolism;	chr10:103076344	chr10:102845595~102845950:+
BRCA	cis	rs4073416	0.712	rs11627184	ENSG00000276116.2	FUT8-AS1	3.87	0.000117	0.00715	0.13	0.12	N-glycan levels;	chr14:65654725	chr14:65411170~65412690:-
BRCA	cis	rs9381040	0.655	rs7775972	ENSG00000161912.16	ADCY10P1	3.87	0.000117	0.00716	0.13	0.12	Alzheimer's disease (late onset);	chr6:41070377	chr6:41101022~41140835:+
BRCA	cis	rs875971	0.862	rs7809814	ENSG00000271064.1	RP11-792A8.3	3.87	0.000117	0.00716	0.14	0.12	Aortic root size;	chr7:66150410	chr7:66748838~66749077:-
BRCA	cis	rs7572644	0.537	rs1038694	ENSG00000223522.1	AC093690.1	3.87	0.000117	0.00716	0.13	0.12	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:28150685	chr2:28307691~28310459:-
BRCA	cis	rs2880765	0.566	rs17553790	ENSG00000259630.2	CTD-2262B20.1	3.87	0.000117	0.00716	0.15	0.12	Coronary artery disease;	chr15:85470434	chr15:85415228~85415633:+
BRCA	cis	rs1005277	0.579	rs2505194	ENSG00000272983.1	RP11-508N22.12	3.87	0.000117	0.00716	0.13	0.12	Extrinsic epigenetic age acceleration;	chr10:38104953	chr10:38137337~38144399:+
BRCA	cis	rs67696533	0.6	rs6119879	ENSG00000277692.1	RP11-358N2.2	-3.87	0.000117	0.00716	-0.14	-0.12	White blood cell count (basophil);Basophil percentage of granulocytes;Basophil percentage of white cells;	chr20:32517586	chr20:32355053~32355734:+
BRCA	cis	rs7074356	0.915	rs1870146	ENSG00000226659.1	RP11-137H2.4	-3.87	0.000117	0.00716	-0.26	-0.12	Borderline personality disorder;	chr10:80450623	chr10:80529597~80535942:-
BRCA	cis	rs1479090	0.804	rs11941112	ENSG00000250027.1	RP11-563E2.2	-3.87	0.000117	0.00716	-0.17	-0.12	Lung cancer;	chr4:163092728	chr4:163108785~163119965:+
BRCA	cis	rs11098499	0.954	rs11098525	ENSG00000225892.3	RP11-384K6.2	3.87	0.000117	0.00716	0.12	0.12	Corneal astigmatism;	chr4:119468997	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.954	rs9998585	ENSG00000225892.3	RP11-384K6.2	3.87	0.000117	0.00716	0.12	0.12	Corneal astigmatism;	chr4:119475647	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.909	rs6842762	ENSG00000225892.3	RP11-384K6.2	3.87	0.000117	0.00716	0.12	0.12	Corneal astigmatism;	chr4:119477081	chr4:118632274~118634759:+
BRCA	cis	rs467650	0.529	rs2549200	ENSG00000248489.1	CTD-2007H13.3	-3.87	0.000117	0.00716	-0.13	-0.12	Venous thromboembolism (SNP x SNP interaction);	chr5:98660644	chr5:98929171~98995013:+
BRCA	cis	rs7267979	0.966	rs910996	ENSG00000274973.1	RP13-401N8.7	-3.87	0.000117	0.00716	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25283560	chr20:25845497~25845862:+
BRCA	cis	rs13256369	1	rs13256369	ENSG00000254153.1	CTA-398F10.2	3.87	0.000117	0.00716	0.16	0.12	Obesity-related traits;	chr8:8719869	chr8:8456909~8461337:-
BRCA	cis	rs425277	1	rs262647	ENSG00000269227.1	RP11-345P4.6	3.87	0.000117	0.00716	0.12	0.12	Height;	chr1:2164260	chr1:1673275~1674397:+
BRCA	cis	rs7308116	0.53	rs10861828	ENSG00000274395.1	RP11-554D14.8	3.87	0.000117	0.00716	0.14	0.12	Pelvic organ prolapse (moderate/severe);	chr12:107892015	chr12:107835541~107836555:-
BRCA	cis	rs829883	0.902	rs829884	ENSG00000227825.4	SLC9A7P1	3.87	0.000117	0.00716	0.15	0.12	Colorectal adenoma (advanced);	chr12:98485722	chr12:98453835~98457145:-
BRCA	cis	rs829883	1	rs829883	ENSG00000227825.4	SLC9A7P1	3.87	0.000117	0.00716	0.15	0.12	Colorectal adenoma (advanced);	chr12:98485828	chr12:98453835~98457145:-
BRCA	cis	rs3753275	0.568	rs10864359	ENSG00000270282.1	RP5-1115A15.2	3.87	0.000117	0.00716	0.15	0.12	Educational attainment;	chr1:8638551	chr1:8512653~8513021:+
BRCA	cis	rs56046484	0.797	rs907260	ENSG00000230373.7	GOLGA6L5P	-3.87	0.000117	0.00717	-0.17	-0.12	Testicular germ cell tumor;	chr15:85133526	chr15:84507885~84516814:-
BRCA	cis	rs938554	0.612	rs28592748	ENSG00000250413.1	RP11-448G15.1	-3.87	0.000117	0.00717	-0.18	-0.12	Blood metabolite levels;	chr4:9996981	chr4:10006482~10009725:+
BRCA	cis	rs2274273	0.712	rs1002054	ENSG00000233924.1	AL160471.6	-3.87	0.000117	0.00717	-0.14	-0.12	Protein biomarker;	chr14:55062195	chr14:55004813~55005687:-
BRCA	cis	rs11098499	0.908	rs28559989	ENSG00000225892.3	RP11-384K6.2	3.87	0.000117	0.00717	0.12	0.12	Corneal astigmatism;	chr4:119465472	chr4:118632274~118634759:+
BRCA	cis	rs733592	0.507	rs7304428	ENSG00000273765.1	RP11-370I10.11	-3.87	0.000117	0.00717	-0.13	-0.12	Plateletcrit;	chr12:48100492	chr12:48360920~48361377:+
BRCA	cis	rs10871290	1	rs10871290	ENSG00000262904.1	TMPOP2	3.87	0.000117	0.00717	0.12	0.12	Breast cancer;	chr16:74438798	chr16:74667506~74668706:+
BRCA	cis	rs2991971	0.967	rs512026	ENSG00000280836.1	AL355480.1	3.87	0.000117	0.00717	0.14	0.12	High light scatter reticulocyte count;	chr1:45544274	chr1:45581219~45581321:-
BRCA	cis	rs62064224	0.553	rs9915115	ENSG00000279781.1	RP11-466A19.7	3.87	0.000117	0.00717	0.14	0.12	Schizophrenia;	chr17:32357839	chr17:32518322~32518934:-
BRCA	cis	rs1048886	0.938	rs77408282	ENSG00000271967.1	RP11-134K13.4	-3.87	0.000117	0.00717	-0.18	-0.12	Type 2 diabetes;	chr6:70433388	chr6:70596438~70596980:+
BRCA	cis	rs747650	0.504	rs10838644	ENSG00000200376.1	RNU5E-10P	3.87	0.000117	0.00717	0.16	0.12	Acne (severe);	chr11:47014210	chr11:47576471~47576588:-
BRCA	cis	rs747650	0.504	rs10838646	ENSG00000200376.1	RNU5E-10P	3.87	0.000117	0.00717	0.16	0.12	Acne (severe);	chr11:47015243	chr11:47576471~47576588:-
BRCA	cis	rs2243480	1	rs781157	ENSG00000226002.1	RP11-460N20.5	-3.87	0.000117	0.00717	-0.2	-0.12	Diabetic kidney disease;	chr7:66013324	chr7:65084103~65100232:+
BRCA	cis	rs1553477	0.747	rs7728056	ENSG00000272416.1	CTD-2081C10.7	3.87	0.000117	0.00717	0.12	0.12	Monobrow;	chr5:53847243	chr5:53880293~53881051:-
BRCA	cis	rs4415084	1	rs2013513	ENSG00000272335.1	RP11-53O19.3	3.87	0.000117	0.00717	0.11	0.12	Breast cancer;	chr5:44702204	chr5:44826076~44828592:+
BRCA	cis	rs13401620	0.843	rs3101945	ENSG00000229326.3	AC069154.4	-3.87	0.000117	0.00717	-0.15	-0.12	Breast size;	chr2:119834081	chr2:119698623~119700151:+
BRCA	cis	rs6736093	0.862	rs79798002	ENSG00000236307.2	EEF1E1P1	-3.87	0.000117	0.00717	-0.15	-0.12	Coronary artery disease;	chr2:111976401	chr2:111887914~111888741:+
BRCA	cis	rs9381040	0.61	rs6940462	ENSG00000161912.16	ADCY10P1	3.87	0.000117	0.00717	0.13	0.12	Alzheimer's disease (late onset);	chr6:41052484	chr6:41101022~41140835:+
BRCA	cis	rs6545883	0.895	rs2177961	ENSG00000273302.1	RP11-493E12.2	-3.87	0.000117	0.00718	-0.11	-0.12	Tuberculosis;	chr2:61333129	chr2:61199979~61200769:+
BRCA	cis	rs875971	0.862	rs778724	ENSG00000229886.1	RP5-1132H15.3	3.87	0.000117	0.00718	0.13	0.12	Aortic root size;	chr7:66364304	chr7:66025126~66031544:-
BRCA	cis	rs683250	0.629	rs681367	ENSG00000254551.1	RP11-727A23.7	-3.87	0.000117	0.00718	-0.15	-0.12	Subcortical brain region volumes;	chr11:83250082	chr11:83209431~83213379:-
BRCA	cis	rs2251381	0.515	rs2832299	ENSG00000176054.6	RPL23P2	3.87	0.000117	0.00718	0.13	0.12	Selective IgA deficiency;	chr21:29376917	chr21:28997613~28998033:-
BRCA	cis	rs372883	0.507	rs8132992	ENSG00000176054.6	RPL23P2	3.87	0.000117	0.00718	0.13	0.12	Pancreatic cancer;	chr21:29378241	chr21:28997613~28998033:-
BRCA	cis	rs4849121	0.535	rs4849120	ENSG00000235721.1	AC013268.3	-3.87	0.000117	0.00718	-0.16	-0.12	IgA nephropathy;	chr2:110842024	chr2:110007675~110010783:+
BRCA	cis	rs181553	0.664	rs1893529	ENSG00000266696.1	RP11-30L3.2	-3.87	0.000117	0.00718	-0.13	-0.12	Hip circumference adjusted for BMI;	chr18:49169906	chr18:49205912~49208781:+
BRCA	cis	rs1730008	1	rs827173	ENSG00000279311.1	RP11-170K4.2	3.87	0.000117	0.00718	0.14	0.12	Lobe attachment (rater-scored or self-reported);	chr3:158241741	chr3:158869898~158871821:+
BRCA	cis	rs9393813	0.626	rs9357038	ENSG00000241549.7	GUSBP2	3.87	0.000117	0.00718	0.13	0.12	Bipolar disorder;	chr6:27366794	chr6:26871484~26956554:-
BRCA	cis	rs453301	0.686	rs3989373	ENSG00000253981.4	ALG1L13P	-3.87	0.000117	0.00718	-0.13	-0.12	Joint mobility (Beighton score);	chr8:9053798	chr8:8236003~8244667:-
BRCA	cis	rs7520050	0.933	rs12045165	ENSG00000234329.1	RP11-767N6.2	-3.87	0.000117	0.00718	-0.11	-0.12	Reticulocyte count;Red blood cell count;	chr1:45790350	chr1:45651039~45651826:-
BRCA	cis	rs934734	0.532	rs10153675	ENSG00000281920.1	RP11-418H16.1	-3.87	0.000117	0.00719	-0.14	-0.12	Rheumatoid arthritis;	chr2:65422446	chr2:65623272~65628424:+
BRCA	cis	rs3753275	0.69	rs7530863	ENSG00000232912.4	RP5-1115A15.1	3.87	0.000117	0.00719	0.15	0.12	Educational attainment;	chr1:8562734	chr1:8424645~8434838:+
BRCA	cis	rs7809799	0.571	rs11978345	ENSG00000244219.5	GS1-259H13.2	-3.87	0.000117	0.00719	-0.26	-0.12	Ulcerative colitis;	chr7:99332413	chr7:99598066~99610813:+
BRCA	cis	rs739496	0.947	rs2239195	ENSG00000257624.1	RP1-128M12.3	3.87	0.000117	0.00719	0.16	0.12	Platelet count;	chr12:111443505	chr12:112000739~112000985:-
BRCA	cis	rs4664293	0.967	rs10176436	ENSG00000226266.5	AC009961.3	-3.87	0.000117	0.00719	-0.15	-0.12	Monocyte percentage of white cells;	chr2:159658883	chr2:159670708~159712435:-
BRCA	cis	rs4664293	0.967	rs7559127	ENSG00000226266.5	AC009961.3	-3.87	0.000117	0.00719	-0.15	-0.12	Monocyte percentage of white cells;	chr2:159659424	chr2:159670708~159712435:-
BRCA	cis	rs1005277	0.579	rs1740732	ENSG00000276805.1	RP11-291L22.6	3.87	0.000117	0.00719	0.13	0.12	Extrinsic epigenetic age acceleration;	chr10:38202457	chr10:38451030~38451785:+
BRCA	cis	rs2991971	0.967	rs11211130	ENSG00000280836.1	AL355480.1	3.87	0.000117	0.00719	0.14	0.12	High light scatter reticulocyte count;	chr1:45521180	chr1:45581219~45581321:-
BRCA	cis	rs7819412	0.594	rs7460507	ENSG00000154316.13	TDH	3.87	0.000117	0.00719	0.16	0.12	Triglycerides;	chr8:11111565	chr8:11339637~11368452:+
BRCA	cis	rs3755605	0.52	rs1082977	ENSG00000242578.1	RP11-469J4.3	3.87	0.000117	0.00719	0.14	0.12	Testicular germ cell tumor;	chr3:170220597	chr3:170410512~170418615:+
BRCA	cis	rs8180040	0.966	rs11705957	ENSG00000280667.1	Y_RNA	-3.87	0.000117	0.00719	-0.13	-0.12	Colorectal cancer;	chr3:47401772	chr3:47501083~47501182:+
BRCA	cis	rs860295	0.812	rs10908481	ENSG00000160766.13	GBAP1	-3.87	0.000117	0.00719	-0.13	-0.12	Body mass index;	chr1:155743859	chr1:155213821~155227422:-
BRCA	cis	rs2451932	0.744	rs2249794	ENSG00000251050.1	RP11-168A11.4	-3.87	0.000117	0.00719	-0.13	-0.12	LDL peak particle diameter (total fat intake interaction);	chr5:80057731	chr5:80019609~80019920:+
BRCA	cis	rs78472555	0.661	rs325386	ENSG00000259363.4	CTD-2054N24.2	-3.87	0.000117	0.00719	-0.16	-0.12	Post bronchodilator FEV1/FVC ratio in COPD;	chr15:99695387	chr15:99807023~99877148:+
BRCA	cis	rs2301573	0.584	rs62265590	ENSG00000271270.4	TMCC1-AS1	-3.87	0.000117	0.00719	-0.26	-0.12	Hip circumference;	chr3:129861876	chr3:129893871~129918575:+
BRCA	cis	rs1730008	0.731	rs60962704	ENSG00000279311.1	RP11-170K4.2	3.87	0.000117	0.00719	0.15	0.12	Lobe attachment (rater-scored or self-reported);	chr3:158219181	chr3:158869898~158871821:+
BRCA	cis	rs3816183	1	rs2278580	ENSG00000226491.1	FTOP1	-3.87	0.000117	0.00719	-0.15	-0.12	Hypospadias;	chr2:42793701	chr2:42797225~42798712:-
BRCA	cis	rs3816183	0.958	rs1439644	ENSG00000226491.1	FTOP1	-3.87	0.000117	0.00719	-0.15	-0.12	Hypospadias;	chr2:42794609	chr2:42797225~42798712:-
BRCA	cis	rs3816183	0.916	rs920394	ENSG00000226491.1	FTOP1	-3.87	0.000117	0.00719	-0.15	-0.12	Hypospadias;	chr2:42795356	chr2:42797225~42798712:-
BRCA	cis	rs6964587	1	rs2282972	ENSG00000188693.7	CYP51A1-AS1	-3.87	0.000117	0.00719	-0.13	-0.12	Breast cancer;	chr7:92037055	chr7:92134604~92180725:+
BRCA	cis	rs6964587	1	rs6979085	ENSG00000188693.7	CYP51A1-AS1	-3.87	0.000117	0.00719	-0.13	-0.12	Breast cancer;	chr7:92044309	chr7:92134604~92180725:+
BRCA	cis	rs11098499	0.954	rs71629403	ENSG00000225892.3	RP11-384K6.2	3.87	0.000117	0.0072	0.12	0.12	Corneal astigmatism;	chr4:119451412	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.909	rs28571712	ENSG00000225892.3	RP11-384K6.2	3.87	0.000117	0.0072	0.12	0.12	Corneal astigmatism;	chr4:119454825	chr4:118632274~118634759:+
BRCA	cis	rs6696239	0.911	rs12137233	ENSG00000215812.5	ZNF847P	3.87	0.000117	0.0072	0.18	0.12	Height;	chr1:227635445	chr1:227696892~227706699:-
BRCA	cis	rs638893	0.617	rs4938565	ENSG00000255422.1	AP002954.4	3.87	0.000117	0.0072	0.16	0.12	Vitiligo;	chr11:118850289	chr11:118704607~118750263:+
BRCA	cis	rs1143633	0.566	rs12987491	ENSG00000231747.1	AC079922.2	3.87	0.000117	0.0072	0.11	0.12	Allergic disease (asthma, hay fever or eczema);	chr2:112933922	chr2:112621809~112622167:-
BRCA	cis	rs10504130	0.932	rs11777016	ENSG00000272076.1	RP11-11C20.3	3.87	0.000117	0.0072	0.21	0.12	Venous thromboembolism (SNP x SNP interaction);	chr8:51874258	chr8:51810110~51810681:-
BRCA	cis	rs17428076	0.872	rs55863868	ENSG00000228389.1	AC068039.4	-3.87	0.000117	0.0072	-0.18	-0.12	Myopia;	chr2:172023605	chr2:171773482~171775844:+
BRCA	cis	rs11098499	0.954	rs17009122	ENSG00000225892.3	RP11-384K6.2	3.87	0.000117	0.0072	0.12	0.12	Corneal astigmatism;	chr4:119441248	chr4:118632274~118634759:+
BRCA	cis	rs4664293	0.647	rs6734085	ENSG00000224152.1	AC009506.1	-3.87	0.000117	0.0072	-0.13	-0.12	Monocyte percentage of white cells;	chr2:159595711	chr2:159615296~159617082:+
BRCA	cis	rs7267979	0.706	rs6037069	ENSG00000125804.12	FAM182A	-3.87	0.000117	0.0072	-0.16	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25253530	chr20:26054655~26086917:+
BRCA	cis	rs5997397	0.934	rs6005863	ENSG00000226471.5	CTA-292E10.6	-3.87	0.000117	0.0072	-0.13	-0.12	Red cell distribution width;	chr22:28760460	chr22:28800683~28848559:+
BRCA	cis	rs1979679	0.553	rs10459089	ENSG00000247934.4	RP11-967K21.1	-3.87	0.000117	0.0072	-0.15	-0.12	Ossification of the posterior longitudinal ligament of the spine;	chr12:28115957	chr12:28163298~28190738:-
BRCA	cis	rs6545883	0.524	rs2463101	ENSG00000273302.1	RP11-493E12.2	-3.87	0.000117	0.00721	-0.1	-0.12	Tuberculosis;	chr2:61347287	chr2:61199979~61200769:+
BRCA	cis	rs8098244	0.516	rs7236486	ENSG00000265752.2	RP11-403A21.1	3.87	0.000117	0.00721	0.13	0.12	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23685001	chr18:23957754~23982556:-
BRCA	cis	rs10043775	0.831	rs7722458	ENSG00000251330.3	CTD-2283N19.1	-3.87	0.000117	0.00721	-0.15	-0.12	Periodontal microbiota;	chr5:148355076	chr5:148430159~148430807:-
BRCA	cis	rs4819052	0.851	rs28616694	ENSG00000215447.6	BX322557.10	-3.87	0.000117	0.00721	-0.12	-0.12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45254871	chr21:45288052~45291738:+
BRCA	cis	rs4218	0.648	rs877269	ENSG00000259732.1	RP11-59H7.3	-3.87	0.000118	0.00721	-0.15	-0.12	Social communication problems;	chr15:59081595	chr15:59121034~59133250:+
BRCA	cis	rs8054556	1	rs4787486	ENSG00000261367.1	RP11-455F5.4	-3.87	0.000118	0.00721	-0.13	-0.12	Autism spectrum disorder or schizophrenia;	chr16:29966241	chr16:30107675~30110541:+
BRCA	cis	rs6964587	0.839	rs6952459	ENSG00000188693.7	CYP51A1-AS1	-3.87	0.000118	0.00721	-0.13	-0.12	Breast cancer;	chr7:91806506	chr7:92134604~92180725:+
BRCA	cis	rs7608910	0.896	rs55776317	ENSG00000237522.1	NONOP2	-3.87	0.000118	0.00721	-0.12	-0.12	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;	chr2:60964860	chr2:60936819~60938049:-
BRCA	cis	rs7005380	0.965	rs9918814	ENSG00000245330.4	KB-1471A8.1	-3.87	0.000118	0.00721	-0.17	-0.12	Interstitial lung disease;	chr8:119939362	chr8:119867419~119874488:-
BRCA	cis	rs7412746	0.611	rs4509581	ENSG00000231073.1	RP11-316M1.3	3.87	0.000118	0.00721	0.13	0.12	Melanoma;	chr1:150801989	chr1:150973123~150975534:+
BRCA	cis	rs10129255	0.957	rs12590799	ENSG00000211967.3	IGHV3-53	-3.87	0.000118	0.00721	-0.08	-0.12	Kawasaki disease;	chr14:106779713	chr14:106592676~106593347:-
BRCA	cis	rs4415084	0.8	rs2330572	ENSG00000248779.1	RP11-53O19.2	-3.87	0.000118	0.00721	-0.11	-0.12	Breast cancer;	chr5:44740887	chr5:44752949~44765744:+
BRCA	cis	rs2243480	1	rs13310597	ENSG00000237026.1	RP11-328P23.2	3.87	0.000118	0.00721	0.22	0.12	Diabetic kidney disease;	chr7:66133553	chr7:65235790~65236723:-
BRCA	cis	rs4974559	0.947	rs12639938	ENSG00000253399.1	AC078852.2	3.87	0.000118	0.00721	0.18	0.12	Systolic blood pressure;	chr4:1349347	chr4:1358479~1359461:+
BRCA	cis	rs911119	0.955	rs67997662	ENSG00000270001.1	RP11-218C14.8	-3.87	0.000118	0.00721	-0.15	-0.12	Chronic kidney disease;	chr20:23612227	chr20:23631826~23632316:-
BRCA	cis	rs4908769	0.624	rs2708630	ENSG00000270282.1	RP5-1115A15.2	-3.87	0.000118	0.00721	-0.14	-0.12	Allergy;	chr1:8387344	chr1:8512653~8513021:+
BRCA	cis	rs10266483	0.843	rs10272639	ENSG00000271550.1	BNIP3P11	3.87	0.000118	0.00721	0.15	0.12	Response to statin therapy;	chr7:64278944	chr7:64678954~64687393:-
BRCA	cis	rs6599077	1	rs6766178	ENSG00000223797.4	ENTPD3-AS1	3.87	0.000118	0.00722	0.14	0.12	Sleep-related phenotypes;	chr3:40056618	chr3:40313802~40453329:-
BRCA	cis	rs9393692	0.645	rs2179152	ENSG00000241549.7	GUSBP2	-3.87	0.000118	0.00722	-0.14	-0.12	Educational attainment;	chr6:26325660	chr6:26871484~26956554:-
BRCA	cis	rs4664293	0.609	rs10167143	ENSG00000224152.1	AC009506.1	-3.87	0.000118	0.00722	-0.13	-0.12	Monocyte percentage of white cells;	chr2:159606885	chr2:159615296~159617082:+
BRCA	cis	rs75422866	0.51	rs73105829	ENSG00000280054.1	RP1-197B17.7	3.87	0.000118	0.00722	0.29	0.12	Pneumonia;	chr12:47734162	chr12:47728151~47730598:-
BRCA	cis	rs7267979	1	rs2297496	ENSG00000277938.1	RP5-965G21.3	-3.87	0.000118	0.00722	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25315151	chr20:25229150~25231933:+
BRCA	cis	rs6088580	0.634	rs6059851	ENSG00000275784.1	RP5-1125A11.6	-3.87	0.000118	0.00722	-0.13	-0.12	Glomerular filtration rate (creatinine);	chr20:34460140	chr20:33989480~33991818:-
BRCA	cis	rs12122100	0.507	rs1925343	ENSG00000227242.3	NBPF13P	-3.87	0.000118	0.00722	-0.14	-0.12	HIV-1 control;	chr1:147033981	chr1:147021320~147124525:-
BRCA	cis	rs7246657	0.508	rs10419845	ENSG00000267470.4	ZNF571-AS1	3.87	0.000118	0.00722	0.19	0.12	Coronary artery calcification;	chr19:37000290	chr19:37548914~37587348:+
BRCA	cis	rs7267979	1	rs8125868	ENSG00000277938.1	RP5-965G21.3	-3.87	0.000118	0.00722	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25343774	chr20:25229150~25231933:+
BRCA	cis	rs798766	0.903	rs798726	ENSG00000244459.2	RP11-1398P2.1	3.87	0.000118	0.00722	0.15	0.12	Urinary bladder cancer;Bladder cancer;	chr4:1683484	chr4:1574062~1580253:-
BRCA	cis	rs1075265	0.509	rs10201938	ENSG00000233266.1	HMGB1P31	3.87	0.000118	0.00722	0.15	0.12	Chronotype;Morning vs. evening chronotype;	chr2:53728352	chr2:54051334~54051760:+
BRCA	cis	rs1153858	0.621	rs1706824	ENSG00000275672.1	GATM-AS1	-3.87	0.000118	0.00722	-0.16	-0.12	Homoarginine levels;	chr15:45287750	chr15:45378700~45380123:+
BRCA	cis	rs6120849	0.707	rs6088694	ENSG00000202150.1	RNU6-407P	3.87	0.000118	0.00722	0.17	0.12	Protein C levels;	chr20:35064568	chr20:35030317~35030420:-
BRCA	cis	rs10938353	0.906	rs9968399	ENSG00000273369.1	RP11-700J17.1	3.87	0.000118	0.00722	0.15	0.12	Body mass index;	chr4:44608471	chr4:44693946~44694386:-
BRCA	cis	rs10938353	0.817	rs11930523	ENSG00000273369.1	RP11-700J17.1	3.87	0.000118	0.00722	0.15	0.12	Body mass index;	chr4:44608628	chr4:44693946~44694386:-
BRCA	cis	rs4449834	0.851	rs4237037	ENSG00000254432.1	RP11-33I11.2	3.87	0.000118	0.00722	0.16	0.12	Sum eosinophil basophil counts;	chr8:60818514	chr8:60808735~60809606:-
BRCA	cis	rs6600671	1	rs7532615	ENSG00000231429.2	RP11-343N15.2	3.87	0.000118	0.00723	0.14	0.12	Hip geometry;	chr1:121430980	chr1:121412719~121429274:+
BRCA	cis	rs875971	0.862	rs4368860	ENSG00000271064.1	RP11-792A8.3	3.87	0.000118	0.00723	0.14	0.12	Aortic root size;	chr7:66143495	chr7:66748838~66749077:-
BRCA	cis	rs7487075	0.93	rs6582656	ENSG00000272369.1	RP11-446N19.1	3.87	0.000118	0.00723	0.13	0.12	Itch intensity from mosquito bite;	chr12:46449633	chr12:46537502~46652550:+
BRCA	cis	rs17361889	0.711	rs7782485	ENSG00000229108.1	MEOX2-AS1	3.87	0.000118	0.00723	0.14	0.12	Pediatric bone mineral content (hip);	chr7:16272940	chr7:15688378~15695491:+
BRCA	cis	rs6918586	0.658	rs198809	ENSG00000272462.2	U91328.19	-3.87	0.000118	0.00723	-0.13	-0.12	Schizophrenia;	chr6:26128538	chr6:25992662~26001775:+
BRCA	cis	rs12468226	0.872	rs1061157	ENSG00000272966.1	RP11-686O6.1	3.87	0.000118	0.00723	0.21	0.12	Urate levels;	chr2:202556476	chr2:202336739~202337200:+
BRCA	cis	rs7267979	1	rs4815424	ENSG00000277938.1	RP5-965G21.3	-3.87	0.000118	0.00723	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25409648	chr20:25229150~25231933:+
BRCA	cis	rs1552244	0.572	rs17032440	ENSG00000180385.7	EMC3-AS1	-3.87	0.000118	0.00723	-0.16	-0.12	Alzheimer's disease;	chr3:10128135	chr3:9986893~10006990:+
BRCA	cis	rs1538970	0.962	rs7532762	ENSG00000281133.1	AL355480.3	-3.86	0.000118	0.00723	-0.16	-0.12	Platelet count;	chr1:45399023	chr1:45580892~45580996:-
BRCA	cis	rs6430585	0.583	rs3769013	ENSG00000224043.6	CCNT2-AS1	-3.86	0.000118	0.00723	-0.19	-0.12	Corneal structure;	chr2:135798612	chr2:134735464~134918710:-
BRCA	cis	rs6964587	1	rs34043009	ENSG00000188693.7	CYP51A1-AS1	3.86	0.000118	0.00723	0.13	0.12	Breast cancer;	chr7:91949133	chr7:92134604~92180725:+
BRCA	cis	rs6964587	1	rs416	ENSG00000188693.7	CYP51A1-AS1	3.86	0.000118	0.00723	0.13	0.12	Breast cancer;	chr7:91951257	chr7:92134604~92180725:+
BRCA	cis	rs3739034	0.938	rs17733977	ENSG00000224043.6	CCNT2-AS1	-3.86	0.000118	0.00723	-0.24	-0.12	Gut microbiome composition (winter);	chr2:134712486	chr2:134735464~134918710:-
BRCA	cis	rs6545883	0.791	rs4672445	ENSG00000212978.6	AC016747.3	-3.86	0.000118	0.00723	-0.16	-0.12	Tuberculosis;	chr2:61427873	chr2:61141592~61144969:-
BRCA	cis	rs11892454	0.599	rs10180842	ENSG00000217643.1	PTGES3P2	-3.86	0.000118	0.00723	-0.13	-0.12	Heschl's gyrus morphology;	chr2:25747635	chr2:25822469~25822950:+
BRCA	cis	rs7267979	1	rs2387881	ENSG00000276952.1	RP5-965G21.6	-3.86	0.000118	0.00724	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25397536	chr20:25284915~25285588:-
BRCA	cis	rs2303319	0.504	rs16846073	ENSG00000227403.1	AC009299.3	3.86	0.000118	0.00724	0.26	0.12	Cognitive function;	chr2:161730038	chr2:161244739~161249050:+
BRCA	cis	rs564309	1	rs564309	ENSG00000183929.7	DUSP5P1	-3.86	0.000118	0.00724	-0.21	-0.12	Hip circumference (psychosocial stress interaction);	chr1:228397861	chr1:228650241~228651379:+
BRCA	cis	rs7615952	0.688	rs17334074	ENSG00000248787.1	RP11-666A20.4	3.86	0.000118	0.00724	0.18	0.12	Blood pressure (smoking interaction);	chr3:125821617	chr3:125908005~125910272:-
BRCA	cis	rs9863	0.828	rs12809473	ENSG00000270028.1	RP11-380L11.4	3.86	0.000118	0.00724	0.15	0.12	White blood cell count;	chr12:123992052	chr12:123925461~123926083:-
BRCA	cis	rs9863	0.828	rs12827409	ENSG00000270028.1	RP11-380L11.4	3.86	0.000118	0.00724	0.15	0.12	White blood cell count;	chr12:123992159	chr12:123925461~123926083:-
BRCA	cis	rs4374383	0.884	rs870762	ENSG00000243389.1	AC012442.5	-3.86	0.000118	0.00724	-0.15	-0.12	Hepatitis C induced liver fibrosis;	chr2:111987850	chr2:112589040~112614431:+
BRCA	cis	rs7267979	0.903	rs6050481	ENSG00000276952.1	RP5-965G21.6	3.86	0.000118	0.00724	0.14	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25243944	chr20:25284915~25285588:-
BRCA	cis	rs7267979	0.834	rs6115100	ENSG00000276952.1	RP5-965G21.6	3.86	0.000118	0.00724	0.14	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25245302	chr20:25284915~25285588:-
BRCA	cis	rs4386084	1	rs7175764	ENSG00000244879.4	GABPB1-AS1	3.86	0.000118	0.00724	0.14	0.12	Basophil percentage of granulocytes;Basophil percentage of white cells;	chr15:49928201	chr15:50354959~50372202:+
BRCA	cis	rs9309473	0.607	rs6546824	ENSG00000230002.2	ALMS1-IT1	3.86	0.000118	0.00724	0.14	0.12	Metabolite levels;	chr2:73360203	chr2:73456764~73459484:+
BRCA	cis	rs2274273	1	rs7142704	ENSG00000259318.1	RP11-454L9.2	3.86	0.000118	0.00724	0.1	0.12	Protein biomarker;	chr14:55163885	chr14:55394940~55395233:-
BRCA	cis	rs10504130	1	rs118116154	ENSG00000272076.1	RP11-11C20.3	3.86	0.000118	0.00724	0.2	0.12	Venous thromboembolism (SNP x SNP interaction);	chr8:51833124	chr8:51810110~51810681:-
BRCA	cis	rs9295536	0.651	rs6900792	ENSG00000260455.1	NBAT1	3.86	0.000118	0.00724	0.13	0.12	Neuroblastoma;	chr6:22136709	chr6:22134957~22147193:-
BRCA	cis	rs11168351	0.864	rs12228750	ENSG00000257735.1	RP11-370I10.6	-3.86	0.000118	0.00724	-0.15	-0.12	Bipolar disorder and schizophrenia;	chr12:48103214	chr12:48350945~48442411:+
BRCA	cis	rs7620503	0.959	rs7637965	ENSG00000231574.4	RP11-91K9.1	3.86	0.000118	0.00724	0.13	0.12	Corneal structure;	chr3:177589854	chr3:177816865~177899224:+
BRCA	cis	rs11098499	0.954	rs10031483	ENSG00000260404.2	RP11-384K6.6	3.86	0.000118	0.00724	0.11	0.12	Corneal astigmatism;	chr4:119501481	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.954	rs10031665	ENSG00000260404.2	RP11-384K6.6	3.86	0.000118	0.00724	0.11	0.12	Corneal astigmatism;	chr4:119501697	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.954	rs3733523	ENSG00000260404.2	RP11-384K6.6	3.86	0.000118	0.00724	0.11	0.12	Corneal astigmatism;	chr4:119502564	chr4:118591773~118633729:+
BRCA	cis	rs62103177	0.565	rs473119	ENSG00000278000.1	AC139100.4	-3.86	0.000118	0.00724	-0.18	-0.12	Opioid sensitivity;	chr18:80091557	chr18:80161752~80162413:+
BRCA	cis	rs91731	1	rs365324	ENSG00000249572.1	CTD-2203K17.1	-3.86	0.000118	0.00724	-0.23	-0.12	Lung function (FVC);	chr5:33365010	chr5:33424025~33440619:-
BRCA	cis	rs6545883	0.894	rs12622458	ENSG00000273302.1	RP11-493E12.2	-3.86	0.000118	0.00724	-0.11	-0.12	Tuberculosis;	chr2:61296419	chr2:61199979~61200769:+
BRCA	cis	rs375066	0.935	rs454559	ENSG00000267191.1	RP11-15A1.2	-3.86	0.000118	0.00724	-0.16	-0.12	Breast cancer;	chr19:43924968	chr19:43902001~43926545:+
BRCA	cis	rs1371614	0.632	rs6759548	ENSG00000229122.1	AGBL5-IT1	3.86	0.000118	0.00724	0.12	0.12	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26938192	chr2:27061038~27061815:+
BRCA	cis	rs8114671	0.562	rs6088646	ENSG00000126005.14	MMP24-AS1	-3.86	0.000118	0.00724	-0.14	-0.12	Height;	chr20:34918134	chr20:35216462~35278131:-
BRCA	cis	rs8114671	0.562	rs6120763	ENSG00000126005.14	MMP24-AS1	-3.86	0.000118	0.00724	-0.14	-0.12	Height;	chr20:34918597	chr20:35216462~35278131:-
BRCA	cis	rs2657888	1	rs17540509	ENSG00000257576.1	RP11-153M3.1	-3.86	0.000118	0.00725	-0.15	-0.12	Adiponectin levels;	chr12:56550056	chr12:56511002~56512703:+
BRCA	cis	rs6504622	0.721	rs8077021	ENSG00000263142.4	LRRC37A17P	-3.86	0.000118	0.00725	-0.09	-0.12	Orofacial clefts;	chr17:47061937	chr17:46978481~47054569:+
BRCA	cis	rs11158026	0.574	rs58055971	ENSG00000233924.1	AL160471.6	-3.86	0.000118	0.00725	-0.14	-0.12	Parkinson's disease;	chr14:54969606	chr14:55004813~55005687:-
BRCA	cis	rs2185341	0.89	rs61769165	ENSG00000218510.5	LINC00339	3.86	0.000118	0.00725	0.16	0.12	Amyotrophic lateral sclerosis;	chr1:22360101	chr1:22025188~22031223:+
BRCA	cis	rs4218	0.648	rs12442086	ENSG00000259732.1	RP11-59H7.3	-3.86	0.000118	0.00725	-0.15	-0.12	Social communication problems;	chr15:59074364	chr15:59121034~59133250:+
BRCA	cis	rs1478897	0.898	rs2248932	ENSG00000154316.13	TDH	3.86	0.000118	0.00725	0.15	0.12	Systemic lupus erythematosus;	chr8:11534141	chr8:11339637~11368452:+
BRCA	cis	rs1048886	0.872	rs12526164	ENSG00000271967.1	RP11-134K13.4	-3.86	0.000118	0.00725	-0.17	-0.12	Type 2 diabetes;	chr6:70527431	chr6:70596438~70596980:+
BRCA	cis	rs3742264	0.656	rs4460970	ENSG00000235903.6	CPB2-AS1	-3.86	0.000118	0.00725	-0.14	-0.12	Blood protein levels;	chr13:45966158	chr13:46052806~46113332:+
BRCA	cis	rs11098499	0.954	rs1480931	ENSG00000225892.3	RP11-384K6.2	3.86	0.000118	0.00726	0.12	0.12	Corneal astigmatism;	chr4:119474654	chr4:118632274~118634759:+
BRCA	cis	rs2555155	0.935	rs10769694	ENSG00000254595.1	CTD-2010I16.1	3.86	0.000118	0.00726	0.13	0.12	DNA methylation (variation);	chr11:6499273	chr11:6488186~6489377:-
BRCA	cis	rs7283707	0.681	rs61130783	ENSG00000270071.1	AP001172.2	-3.86	0.000118	0.00726	-0.16	-0.12	QRS complex (12-leadsum);	chr21:15909874	chr21:16291791~16308133:-
BRCA	cis	rs875971	0.638	rs3898855	ENSG00000265600.1	AC006480.1	3.86	0.000118	0.00726	0.14	0.12	Aortic root size;	chr7:66571411	chr7:67356680~67356779:+
BRCA	cis	rs875971	0.638	rs10278816	ENSG00000265600.1	AC006480.1	3.86	0.000118	0.00726	0.14	0.12	Aortic root size;	chr7:66572000	chr7:67356680~67356779:+
BRCA	cis	rs875971	0.66	rs10281080	ENSG00000265600.1	AC006480.1	3.86	0.000118	0.00726	0.14	0.12	Aortic root size;	chr7:66577454	chr7:67356680~67356779:+
BRCA	cis	rs875971	0.66	rs10950044	ENSG00000265600.1	AC006480.1	3.86	0.000118	0.00726	0.14	0.12	Aortic root size;	chr7:66577989	chr7:67356680~67356779:+
BRCA	cis	rs7412746	0.611	rs1889741	ENSG00000231073.1	RP11-316M1.3	3.86	0.000118	0.00726	0.12	0.12	Melanoma;	chr1:150896569	chr1:150973123~150975534:+
BRCA	cis	rs6088580	0.524	rs7274854	ENSG00000279253.1	RP4-614O4.13	-3.86	0.000118	0.00726	-0.13	-0.12	Glomerular filtration rate (creatinine);	chr20:34640868	chr20:35262727~35264187:-
BRCA	cis	rs943466	1	rs6933174	ENSG00000223837.2	BRD2-IT1	3.86	0.000118	0.00726	0.15	0.12	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;	chr6:33783226	chr6:32970232~32970886:+
BRCA	cis	rs2749097	0.735	rs12127151	ENSG00000244256.3	RN7SL130P	-3.86	0.000118	0.00726	-0.17	-0.12	Alcohol consumption (transferrin glycosylation);	chr1:63684028	chr1:63655743~63656047:+
BRCA	cis	rs26949	0.647	rs35386	ENSG00000215032.2	GNL3LP1	3.86	0.000118	0.00726	0.15	0.12	Intelligence (multi-trait analysis);	chr5:60506956	chr5:60891935~60893577:-
BRCA	cis	rs9470794	1	rs59684841	ENSG00000204110.6	RP1-153P14.8	-3.86	0.000118	0.00726	-0.18	-0.12	Type 2 diabetes;	chr6:38158987	chr6:37507348~37535616:+
BRCA	cis	rs7045881	0.877	rs111919934	ENSG00000254396.1	RP11-56F10.3	3.86	0.000118	0.00726	0.22	0.12	Schizophrenia;	chr9:26780390	chr9:27102630~27104728:+
BRCA	cis	rs728616	0.51	rs35671072	ENSG00000225484.5	NUTM2B-AS1	-3.86	0.000119	0.00726	-0.24	-0.12	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80412499	chr10:79663088~79826594:-
BRCA	cis	rs170557	0.53	rs17318612	ENSG00000203706.7	SERTAD4-AS1	-3.86	0.000119	0.00726	-0.15	-0.12	Alopecia areata;	chr1:210032834	chr1:210231456~210234047:-
BRCA	cis	rs875971	0.545	rs73152714	ENSG00000273448.1	RP11-166O4.6	3.86	0.000119	0.00726	0.12	0.12	Aortic root size;	chr7:66534641	chr7:67333047~67334383:+
BRCA	cis	rs875971	0.545	rs4718364	ENSG00000273448.1	RP11-166O4.6	3.86	0.000119	0.00726	0.12	0.12	Aortic root size;	chr7:66536353	chr7:67333047~67334383:+
BRCA	cis	rs875971	0.545	rs801199	ENSG00000273448.1	RP11-166O4.6	-3.86	0.000119	0.00726	-0.12	-0.12	Aortic root size;	chr7:66560286	chr7:67333047~67334383:+
BRCA	cis	rs801193	1	rs2707856	ENSG00000232546.1	RP11-458F8.1	-3.86	0.000119	0.00726	-0.1	-0.12	Aortic root size;	chr7:66746023	chr7:66848496~66858136:+
BRCA	cis	rs16846053	0.792	rs62187696	ENSG00000227403.1	AC009299.3	3.86	0.000119	0.00726	0.3	0.12	Blood osmolality (transformed sodium);	chr2:161819997	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.792	rs62187698	ENSG00000227403.1	AC009299.3	3.86	0.000119	0.00726	0.3	0.12	Blood osmolality (transformed sodium);	chr2:161820795	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.792	rs62187699	ENSG00000227403.1	AC009299.3	3.86	0.000119	0.00726	0.3	0.12	Blood osmolality (transformed sodium);	chr2:161820813	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.792	rs72879207	ENSG00000227403.1	AC009299.3	3.86	0.000119	0.00726	0.3	0.12	Blood osmolality (transformed sodium);	chr2:161822878	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.71	rs72879209	ENSG00000227403.1	AC009299.3	3.86	0.000119	0.00726	0.3	0.12	Blood osmolality (transformed sodium);	chr2:161822924	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.792	rs9636282	ENSG00000227403.1	AC009299.3	3.86	0.000119	0.00726	0.3	0.12	Blood osmolality (transformed sodium);	chr2:161823885	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.792	rs9636283	ENSG00000227403.1	AC009299.3	3.86	0.000119	0.00726	0.3	0.12	Blood osmolality (transformed sodium);	chr2:161823892	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.792	rs9636284	ENSG00000227403.1	AC009299.3	3.86	0.000119	0.00726	0.3	0.12	Blood osmolality (transformed sodium);	chr2:161824002	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.792	rs9636285	ENSG00000227403.1	AC009299.3	3.86	0.000119	0.00726	0.3	0.12	Blood osmolality (transformed sodium);	chr2:161824192	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.792	rs72879215	ENSG00000227403.1	AC009299.3	3.86	0.000119	0.00726	0.3	0.12	Blood osmolality (transformed sodium);	chr2:161824713	chr2:161244739~161249050:+
BRCA	cis	rs4648045	0.765	rs4699031	ENSG00000246560.2	RP11-10L12.4	3.86	0.000119	0.00726	0.13	0.12	Lymphocyte percentage of white cells;	chr4:102605271	chr4:102828055~102844075:+
BRCA	cis	rs4648045	0.796	rs3755867	ENSG00000246560.2	RP11-10L12.4	3.86	0.000119	0.00726	0.13	0.12	Lymphocyte percentage of white cells;	chr4:102605517	chr4:102828055~102844075:+
BRCA	cis	rs721917	0.565	rs7476563	ENSG00000242600.5	MBL1P	3.86	0.000119	0.00726	0.14	0.12	Chronic obstructive pulmonary disease;	chr10:79975318	chr10:79904898~79950336:+
BRCA	cis	rs6840360	0.571	rs7692700	ENSG00000278978.1	RP11-164P12.5	-3.86	0.000119	0.00726	-0.14	-0.12	Intelligence (multi-trait analysis);	chr4:151631645	chr4:151669786~151670503:+
BRCA	cis	rs860295	0.702	rs56675301	ENSG00000225855.5	RUSC1-AS1	3.86	0.000119	0.00726	0.1	0.12	Body mass index;	chr1:155394536	chr1:155316863~155324176:-
BRCA	cis	rs9470794	1	rs77446542	ENSG00000204110.6	RP1-153P14.8	-3.86	0.000119	0.00726	-0.24	-0.12	Type 2 diabetes;	chr6:38067246	chr6:37507348~37535616:+
BRCA	cis	rs9470794	1	rs77438476	ENSG00000204110.6	RP1-153P14.8	-3.86	0.000119	0.00726	-0.24	-0.12	Type 2 diabetes;	chr6:38067570	chr6:37507348~37535616:+
BRCA	cis	rs1577917	0.74	rs9344533	ENSG00000220563.1	PKMP3	3.86	0.000119	0.00727	0.12	0.12	Response to antipsychotic treatment;	chr6:85526470	chr6:85659892~85660606:-
BRCA	cis	rs7620503	1	rs6801849	ENSG00000277241.1	RP11-114M1.3	3.86	0.000119	0.00727	0.13	0.12	Corneal structure;	chr3:177580036	chr3:177700346~177701072:-
BRCA	cis	rs2243480	1	rs316327	ENSG00000237026.1	RP11-328P23.2	-3.86	0.000119	0.00727	-0.21	-0.12	Diabetic kidney disease;	chr7:66144214	chr7:65235790~65236723:-
BRCA	cis	rs4499344	0.73	rs406470	ENSG00000267475.1	CTD-2538C1.2	3.86	0.000119	0.00727	0.15	0.12	Mean platelet volume;	chr19:32613566	chr19:32687089~32691750:-
BRCA	cis	rs4664293	0.769	rs1365798	ENSG00000230783.1	AC009961.2	3.86	0.000119	0.00727	0.15	0.12	Monocyte percentage of white cells;	chr2:159795853	chr2:159689217~159690291:-
BRCA	cis	rs9733	0.566	rs72702554	ENSG00000231073.1	RP11-316M1.3	3.86	0.000119	0.00727	0.12	0.12	Tonsillectomy;	chr1:150705758	chr1:150973123~150975534:+
BRCA	cis	rs73201462	1	rs55989768	ENSG00000242551.2	POU5F1P6	3.86	0.000119	0.00727	0.2	0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128324161	chr3:128674735~128677005:-
BRCA	cis	rs73201462	1	rs55675294	ENSG00000242551.2	POU5F1P6	3.86	0.000119	0.00727	0.2	0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128324207	chr3:128674735~128677005:-
BRCA	cis	rs9733	0.65	rs4970923	ENSG00000203804.4	ADAMTSL4-AS1	-3.86	0.000119	0.00727	-0.13	-0.12	Tonsillectomy;	chr1:150635824	chr1:150560202~150574552:-
BRCA	cis	rs9420	0.528	rs7117896	ENSG00000265566.2	RN7SL605P	-3.86	0.000119	0.00727	-0.16	-0.12	Schizophrenia;	chr11:57621078	chr11:57528085~57528365:-
BRCA	cis	rs5758659	0.519	rs133307	ENSG00000182057.4	OGFRP1	3.86	0.000119	0.00727	0.13	0.12	Cognitive function;	chr22:42000564	chr22:42269753~42275196:+
BRCA	cis	rs62247992	0.546	rs9878975	ENSG00000227245.1	RP11-136C24.2	3.86	0.000119	0.00727	0.17	0.12	Facial morphology (factor 15, philtrum width);	chr3:43126730	chr3:43087479~43088068:+
BRCA	cis	rs7113211	0.729	rs12806454	ENSG00000250303.3	RP11-356J5.12	3.86	0.000119	0.00727	0.15	0.12	Expressive vocabulary in infants;	chr11:112772730	chr11:112270749~112362534:+
BRCA	cis	rs1799955	1	rs11571717	ENSG00000215515.2	IFIT1P1	-3.86	0.000119	0.00727	-0.16	-0.12	LDL cholesterol levels;	chr13:32360774	chr13:32384660~32386108:+
BRCA	cis	rs256438	0.524	rs693270	ENSG00000251050.1	RP11-168A11.4	-3.86	0.000119	0.00728	-0.13	-0.12	Serum thyroid-stimulating hormone levels;	chr5:80057805	chr5:80019609~80019920:+
BRCA	cis	rs66887589	0.616	rs11098498	ENSG00000250412.1	KLHL2P1	3.86	0.000119	0.00728	0.13	0.12	Diastolic blood pressure;	chr4:119265964	chr4:119334329~119378233:+
BRCA	cis	rs4927850	0.752	rs7624460	ENSG00000224769.1	AC069213.1	3.86	0.000119	0.00728	0.17	0.12	Pancreatic cancer;	chr3:196021659	chr3:195614947~195620233:+
BRCA	cis	rs2841277	0.708	rs10083490	ENSG00000258701.1	LINC00638	-3.86	0.000119	0.00728	-0.13	-0.12	Rheumatoid arthritis;	chr14:104936081	chr14:104821201~104823718:+
BRCA	cis	rs11242704	0.632	rs7744406	ENSG00000218027.2	RP11-157J24.1	3.86	0.000119	0.00728	0.16	0.12	Response to hepatitis C treatment;	chr6:1540572	chr6:1513698~1515289:-
BRCA	cis	rs4873772	0.8	rs4594029	ENSG00000253330.1	RP11-697N18.3	-3.86	0.000119	0.00728	-0.16	-0.12	Lobe attachment (rater-scored or self-reported);	chr8:47545661	chr8:47511034~47512141:-
BRCA	cis	rs757081	0.648	rs214907	ENSG00000272034.1	SNORD14A	-3.86	0.000119	0.00728	-0.12	-0.12	Systolic blood pressure;	chr11:17223232	chr11:17074654~17074744:-
BRCA	cis	rs7267979	0.933	rs2258728	ENSG00000277938.1	RP5-965G21.3	3.86	0.000119	0.00728	0.14	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25295707	chr20:25229150~25231933:+
BRCA	cis	rs10129255	0.912	rs8011090	ENSG00000231475.3	IGHV4-31	-3.86	0.000119	0.00728	-0.1	-0.12	Kawasaki disease;	chr14:106678896	chr14:106349283~106349792:-
BRCA	cis	rs875971	0.862	rs1860469	ENSG00000273024.4	INTS4P2	3.86	0.000119	0.00728	0.13	0.12	Aortic root size;	chr7:66641888	chr7:65647864~65715661:+
BRCA	cis	rs17772222	1	rs17772288	ENSG00000258789.1	RP11-507K2.3	-3.86	0.000119	0.00728	-0.14	-0.12	Coronary artery calcification;	chr14:88361022	chr14:88551597~88552493:+
BRCA	cis	rs875971	0.798	rs6460304	ENSG00000273024.4	INTS4P2	-3.86	0.000119	0.00728	-0.13	-0.12	Aortic root size;	chr7:66499741	chr7:65647864~65715661:+
BRCA	cis	rs875971	0.862	rs6945775	ENSG00000273024.4	INTS4P2	-3.86	0.000119	0.00728	-0.13	-0.12	Aortic root size;	chr7:66503987	chr7:65647864~65715661:+
BRCA	cis	rs875971	0.862	rs10256544	ENSG00000271064.1	RP11-792A8.3	-3.86	0.000119	0.00728	-0.14	-0.12	Aortic root size;	chr7:66210141	chr7:66748838~66749077:-
BRCA	cis	rs6964587	1	rs2157747	ENSG00000188693.7	CYP51A1-AS1	-3.86	0.000119	0.00728	-0.13	-0.12	Breast cancer;	chr7:92121264	chr7:92134604~92180725:+
BRCA	cis	rs1479090	0.762	rs7675924	ENSG00000250027.1	RP11-563E2.2	-3.86	0.000119	0.00728	-0.16	-0.12	Lung cancer;	chr4:163146703	chr4:163108785~163119965:+
BRCA	cis	rs7395581	0.918	rs3781622	ENSG00000280615.1	Y_RNA	3.86	0.000119	0.00728	0.14	0.12	HDL cholesterol;	chr11:47327151	chr11:47614898~47614994:-
BRCA	cis	rs6600671	0.764	rs6600673	ENSG00000223345.3	HIST2H2BA	3.86	0.000119	0.00728	0.14	0.12	Hip geometry;	chr1:121426988	chr1:121108210~121117257:-
BRCA	cis	rs3169166	0.5	rs12909123	ENSG00000259562.2	RP11-762H8.2	-3.86	0.000119	0.00728	-0.1	-0.12	Reticulocyte fraction of red cells;Reticulocyte count;	chr15:78267501	chr15:78290527~78291221:-
BRCA	cis	rs216345	0.902	rs216353	ENSG00000260947.1	RP11-384P7.7	3.86	0.000119	0.00729	0.13	0.12	Bipolar disorder;	chr9:33804169	chr9:33697459~33700986:+
BRCA	cis	rs4664293	0.647	rs1425039	ENSG00000226266.5	AC009961.3	-3.86	0.000119	0.00729	-0.14	-0.12	Monocyte percentage of white cells;	chr2:159571612	chr2:159670708~159712435:-
BRCA	cis	rs73201462	1	rs2037965	ENSG00000242551.2	POU5F1P6	-3.86	0.000119	0.00729	-0.2	-0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128306201	chr3:128674735~128677005:-
BRCA	cis	rs73201462	1	rs2811397	ENSG00000242551.2	POU5F1P6	-3.86	0.000119	0.00729	-0.2	-0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128308394	chr3:128674735~128677005:-
BRCA	cis	rs7520050	0.807	rs3013595	ENSG00000281133.1	AL355480.3	-3.86	0.000119	0.00729	-0.14	-0.12	Reticulocyte count;Red blood cell count;	chr1:45687531	chr1:45580892~45580996:-
BRCA	cis	rs453301	0.686	rs6987107	ENSG00000233609.3	RP11-62H7.2	-3.86	0.000119	0.00729	-0.11	-0.12	Joint mobility (Beighton score);	chr8:9036071	chr8:8961200~8979025:+
BRCA	cis	rs11098499	0.908	rs28499576	ENSG00000225892.3	RP11-384K6.2	3.86	0.000119	0.00729	0.12	0.12	Corneal astigmatism;	chr4:119465522	chr4:118632274~118634759:+
BRCA	cis	rs8040855	0.627	rs12909130	ENSG00000259774.1	RP11-182J1.13	3.86	0.000119	0.00729	0.17	0.12	Bulimia nervosa;	chr15:85047270	chr15:84422618~84425882:+
BRCA	cis	rs13256369	0.826	rs7846050	ENSG00000254153.1	CTA-398F10.2	3.86	0.000119	0.00729	0.16	0.12	Obesity-related traits;	chr8:8718159	chr8:8456909~8461337:-
BRCA	cis	rs2274459	1	rs12153877	ENSG00000249346.5	LINC01016	3.86	0.000119	0.00729	0.16	0.12	Obesity (extreme);	chr6:33797688	chr6:33867506~33896914:-
BRCA	cis	rs35520189	0.857	rs6735739	ENSG00000274877.1	RP11-65I12.1	3.86	0.000119	0.00729	0.16	0.12	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:112852309	chr2:113237595~113240825:+
BRCA	cis	rs4919687	0.55	rs11191371	ENSG00000213061.2	PFN1P11	3.86	0.000119	0.00729	0.16	0.12	Colorectal cancer;	chr10:102700140	chr10:102838011~102845473:-
BRCA	cis	rs10771431	0.817	rs17202253	ENSG00000256427.1	RP11-118B22.4	3.86	0.000119	0.0073	0.12	0.12	Breast size;	chr12:9209254	chr12:9246497~9257960:+
BRCA	cis	rs3768617	0.811	rs10911233	ENSG00000224468.3	RP11-181K3.4	-3.86	0.000119	0.0073	-0.13	-0.12	Fuchs's corneal dystrophy;	chr1:183083450	chr1:183138402~183141282:-
BRCA	cis	rs2478118	0.509	rs10796111	ENSG00000273474.1	RP11-295P9.12	-3.86	0.000119	0.0073	-0.12	-0.12	Lupus nephritis in systemic lupus erythematosus;	chr10:13669380	chr10:13675646~13675990:+
BRCA	cis	rs924712	0.625	rs10807485	ENSG00000224984.1	RP11-524H19.2	3.86	0.000119	0.0073	0.15	0.12	Breast cancer;	chr6:54854893	chr6:54840118~54840855:-
BRCA	cis	rs7819412	0.594	rs17724226	ENSG00000255046.1	RP11-297N6.4	3.86	0.000119	0.0073	0.14	0.12	Triglycerides;	chr8:11111416	chr8:11797928~11802568:-
BRCA	cis	rs9291683	0.935	rs1860910	ENSG00000250413.1	RP11-448G15.1	-3.86	0.000119	0.0073	-0.15	-0.12	Bone mineral density;	chr4:10273846	chr4:10006482~10009725:+
BRCA	cis	rs6430585	0.702	rs2015532	ENSG00000231890.6	DARS-AS1	3.86	0.000119	0.0073	0.18	0.12	Corneal structure;	chr2:135797955	chr2:135985176~136022593:+
BRCA	cis	rs8058578	1	rs8051050	ENSG00000260911.2	RP11-196G11.2	3.86	0.000119	0.0073	0.12	0.12	Multiple myeloma;	chr16:30676588	chr16:31043150~31049868:+
BRCA	cis	rs2303319	0.504	rs62188762	ENSG00000227403.1	AC009299.3	3.86	0.000119	0.0073	0.32	0.12	Cognitive function;	chr2:161863580	chr2:161244739~161249050:+
BRCA	cis	rs2380205	0.517	rs12360409	ENSG00000232807.2	RP11-536K7.3	3.86	0.000119	0.0073	0.13	0.12	Breast cancer;	chr10:5933835	chr10:5934270~5945900:-
BRCA	cis	rs2274273	0.522	rs2251366	ENSG00000259318.1	RP11-454L9.2	3.86	0.000119	0.0073	0.1	0.12	Protein biomarker;	chr14:55051438	chr14:55394940~55395233:-
BRCA	cis	rs1816752	0.905	rs7400631	ENSG00000273628.1	RP11-756A22.7	3.86	0.000119	0.0073	0.14	0.12	Obesity-related traits;	chr13:24415927	chr13:24933006~24936796:+
BRCA	cis	rs9659323	1	rs6680737	ENSG00000231365.4	RP11-418J17.1	-3.86	0.000119	0.0073	-0.14	-0.12	Body mass index;	chr1:118979008	chr1:119140396~119275973:+
BRCA	cis	rs4218	0.681	rs2121236	ENSG00000259732.1	RP11-59H7.3	-3.86	0.000119	0.00731	-0.14	-0.12	Social communication problems;	chr15:59091923	chr15:59121034~59133250:+
BRCA	cis	rs7682317	0.965	rs6837671	ENSG00000270720.1	RP11-84C13.2	3.86	0.000119	0.00731	0.13	0.12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr4:88951941	chr4:89119284~89119871:+
BRCA	cis	rs9470794	0.915	rs73421455	ENSG00000204110.6	RP1-153P14.8	-3.86	0.000119	0.00731	-0.24	-0.12	Type 2 diabetes;	chr6:37986556	chr6:37507348~37535616:+
BRCA	cis	rs7608910	0.668	rs10207958	ENSG00000237522.1	NONOP2	-3.86	0.000119	0.00731	-0.11	-0.12	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;	chr2:60998195	chr2:60936819~60938049:-
BRCA	cis	rs4664293	0.647	rs6714917	ENSG00000224152.1	AC009506.1	-3.86	0.000119	0.00731	-0.13	-0.12	Monocyte percentage of white cells;	chr2:159592942	chr2:159615296~159617082:+
BRCA	cis	rs4650943	0.586	rs352302	ENSG00000227740.1	RP11-318C24.2	-3.86	0.000119	0.00731	-0.12	-0.12	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in inactive individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr1:176286794	chr1:175904762~175920513:-
BRCA	cis	rs733592	0.524	rs10875726	ENSG00000257763.1	OR5BK1P	-3.86	0.00012	0.00731	-0.12	-0.12	Plateletcrit;	chr12:48032209	chr12:48355792~48356614:-
BRCA	cis	rs1730008	1	rs1724679	ENSG00000279311.1	RP11-170K4.2	-3.86	0.00012	0.00731	-0.14	-0.12	Lobe attachment (rater-scored or self-reported);	chr3:158235640	chr3:158869898~158871821:+
BRCA	cis	rs6088580	0.634	rs1205334	ENSG00000275784.1	RP5-1125A11.6	3.86	0.00012	0.00732	0.13	0.12	Glomerular filtration rate (creatinine);	chr20:34342563	chr20:33989480~33991818:-
BRCA	cis	rs10463316	0.894	rs7707745	ENSG00000260581.1	CTB-113P19.4	3.86	0.00012	0.00732	0.14	0.12	Metabolite levels (Pyroglutamine);	chr5:151385637	chr5:151652275~151655449:+
BRCA	cis	rs13098911	0.54	rs13071283	ENSG00000223552.1	RP11-24F11.2	-3.86	0.00012	0.00732	-0.19	-0.12	Celiac disease;	chr3:45968515	chr3:46364955~46407059:-
BRCA	cis	rs8030605	0.633	rs117893963	ENSG00000277245.1	RP11-48G14.3	3.86	0.00012	0.00732	0.25	0.12	Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;	chr15:56397793	chr15:56447120~56447697:+
BRCA	cis	rs853679	0.607	rs17763089	ENSG00000216901.1	AL022393.7	3.86	0.00012	0.00732	0.31	0.12	Depression;	chr6:27867440	chr6:28176188~28176674:+
BRCA	cis	rs853679	0.546	rs17695758	ENSG00000216901.1	AL022393.7	3.86	0.00012	0.00732	0.31	0.12	Depression;	chr6:27869405	chr6:28176188~28176674:+
BRCA	cis	rs7598759	0.584	rs4973409	ENSG00000181798.2	LINC00471	-3.86	0.00012	0.00732	-0.15	-0.12	Noise-induced hearing loss;	chr2:231447160	chr2:231508426~231514339:-
BRCA	cis	rs6439699	0.941	rs66752974	ENSG00000273486.1	RP11-731C17.2	3.86	0.00012	0.00732	0.16	0.12	Intelligence (multi-trait analysis);	chr3:137338788	chr3:136837338~136839021:-
BRCA	cis	rs2998286	0.815	rs332132	ENSG00000237128.1	RP11-351M16.3	3.86	0.00012	0.00732	0.15	0.12	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28565185	chr10:28433008~28495813:-
BRCA	cis	rs853679	0.546	rs200948	ENSG00000216901.1	AL022393.7	3.86	0.00012	0.00732	0.23	0.12	Depression;	chr6:27867494	chr6:28176188~28176674:+
BRCA	cis	rs853679	0.546	rs200950	ENSG00000216901.1	AL022393.7	3.86	0.00012	0.00732	0.23	0.12	Depression;	chr6:27867994	chr6:28176188~28176674:+
BRCA	cis	rs7474896	0.616	rs2474561	ENSG00000263064.2	RP11-291L22.7	3.86	0.00012	0.00732	0.19	0.12	Obesity (extreme);	chr10:38084616	chr10:38448689~38448949:+
BRCA	cis	rs4819052	1	rs2297285	ENSG00000223768.1	LINC00205	3.86	0.00012	0.00732	0.18	0.12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45285706	chr21:45293285~45297354:+
BRCA	cis	rs17027633	0.881	rs77558823	ENSG00000260948.1	RP11-552M11.8	-3.86	0.00012	0.00732	-0.28	-0.12	Cerebrospinal fluid t-tau:AB1-42 ratio;	chr1:111471173	chr1:111431046~111433068:-
BRCA	cis	rs9677476	0.909	rs10181602	ENSG00000224376.1	AC017104.6	3.86	0.00012	0.00732	0.13	0.12	Food antigen IgG levels;	chr2:231256929	chr2:231388976~231394991:+
BRCA	cis	rs7412746	0.611	rs66847267	ENSG00000231073.1	RP11-316M1.3	3.86	0.00012	0.00732	0.12	0.12	Melanoma;	chr1:150902697	chr1:150973123~150975534:+
BRCA	cis	rs3617	0.625	rs6445541	ENSG00000242142.1	SERBP1P3	3.86	0.00012	0.00732	0.13	0.12	Red blood cell count;Autism spectrum disorder or schizophrenia;	chr3:52846112	chr3:53064283~53065091:-
BRCA	cis	rs925550	0.866	rs4833841	ENSG00000224786.1	CETN4P	-3.86	0.00012	0.00732	-0.19	-0.12	Primary biliary cholangitis;	chr4:122663442	chr4:122730548~122732193:-
BRCA	cis	rs7894407	0.76	rs4917386	ENSG00000213061.2	PFN1P11	-3.86	0.00012	0.00732	-0.16	-0.12	White matter hyperintensity burden;	chr10:103247771	chr10:102838011~102845473:-
BRCA	cis	rs12826942	0.959	rs34507359	ENSG00000257225.1	RP11-328C8.4	-3.86	0.00012	0.00732	-0.18	-0.12	Coronary artery disease;	chr12:42343029	chr12:42459366~42466128:+
BRCA	cis	rs7011507	0.535	rs1393550	ENSG00000233858.4	AC026904.1	3.86	0.00012	0.00732	0.14	0.12	Inflammatory bowel disease;Ulcerative colitis;	chr8:48540437	chr8:48590401~48594621:+
BRCA	cis	rs3748682	0.861	rs28420383	ENSG00000252448.1	SNORA63	-3.86	0.00012	0.00733	-0.15	-0.12	Hypothyroidism;	chr1:37880733	chr1:37884237~37884317:+
BRCA	cis	rs10129255	1	rs10134517	ENSG00000211967.3	IGHV3-53	-3.86	0.00012	0.00733	-0.09	-0.12	Kawasaki disease;	chr14:106718498	chr14:106592676~106593347:-
BRCA	cis	rs875971	0.862	rs4718383	ENSG00000273024.4	INTS4P2	3.86	0.00012	0.00733	0.13	0.12	Aortic root size;	chr7:66643422	chr7:65647864~65715661:+
BRCA	cis	rs4713118	0.662	rs149961	ENSG00000216901.1	AL022393.7	3.86	0.00012	0.00733	0.17	0.12	Parkinson's disease;	chr6:28047791	chr6:28176188~28176674:+
BRCA	cis	rs3816183	1	rs6544597	ENSG00000226491.1	FTOP1	-3.86	0.00012	0.00733	-0.15	-0.12	Hypospadias;	chr2:42786453	chr2:42797225~42798712:-
BRCA	cis	rs75422866	0.717	rs73113159	ENSG00000276691.1	RP5-1057I20.5	3.86	0.00012	0.00733	0.25	0.12	Pneumonia;	chr12:47631318	chr12:47788426~47788971:+
BRCA	cis	rs75422866	0.717	rs73113161	ENSG00000276691.1	RP5-1057I20.5	3.86	0.00012	0.00733	0.25	0.12	Pneumonia;	chr12:47632361	chr12:47788426~47788971:+
BRCA	cis	rs6860806	0.661	rs3763112	ENSG00000233006.5	AC034220.3	3.86	0.00012	0.00733	0.08	0.12	Breast cancer;	chr5:132250787	chr5:132311285~132369916:-
BRCA	cis	rs6951245	0.554	rs11761322	ENSG00000224079.1	AC091729.7	-3.86	0.00012	0.00733	-0.17	-0.12	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1112021	chr7:1074450~1078036:+
BRCA	cis	rs875971	0.54	rs4717275	ENSG00000229180.5	GS1-124K5.11	-3.86	0.00012	0.00733	-0.1	-0.12	Aortic root size;	chr7:65800193	chr7:66526088~66542624:-
BRCA	cis	rs3892630	0.612	rs10413282	ENSG00000267567.1	CTD-2538C1.3	3.86	0.00012	0.00733	0.17	0.12	Red blood cell traits;	chr19:32691845	chr19:32718298~32719595:-
BRCA	cis	rs216345	0.73	rs12555291	ENSG00000260947.1	RP11-384P7.7	-3.86	0.00012	0.00733	-0.13	-0.12	Bipolar disorder;	chr9:34011393	chr9:33697459~33700986:+
BRCA	cis	rs2562456	0.876	rs10424079	ENSG00000268117.1	VN1R84P	3.86	0.00012	0.00733	0.18	0.12	Pain;	chr19:21406377	chr19:21719801~21720035:-
BRCA	cis	rs2562456	0.917	rs2562468	ENSG00000268119.4	CTD-2561J22.5	-3.86	0.00012	0.00733	-0.18	-0.12	Pain;	chr19:21532048	chr19:21444241~21463908:-
BRCA	cis	rs2562456	0.917	rs2562471	ENSG00000268119.4	CTD-2561J22.5	-3.86	0.00012	0.00733	-0.18	-0.12	Pain;	chr19:21533017	chr19:21444241~21463908:-
BRCA	cis	rs295490	0.748	rs77995988	ENSG00000272656.1	RP11-219D15.3	3.86	0.00012	0.00733	0.29	0.12	PR interval in Tripanosoma cruzi seropositivity;	chr3:139456686	chr3:139349024~139349371:-
BRCA	cis	rs7312933	0.703	rs10880259	ENSG00000257225.1	RP11-328C8.4	-3.86	0.00012	0.00733	-0.14	-0.12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42164201	chr12:42459366~42466128:+
BRCA	cis	rs11662721	0.938	rs973730	ENSG00000264188.1	RP11-13N13.5	-3.86	0.00012	0.00733	-0.16	-0.12	Phospholipid levels (plasma);	chr18:21573533	chr18:21661787~21662395:-
BRCA	cis	rs4950322	0.543	rs4950318	ENSG00000227242.3	NBPF13P	-3.86	0.00012	0.00733	-0.17	-0.12	Protein quantitative trait loci;	chr1:147316240	chr1:147021320~147124525:-
BRCA	cis	rs4950322	0.543	rs4950319	ENSG00000227242.3	NBPF13P	-3.86	0.00012	0.00733	-0.17	-0.12	Protein quantitative trait loci;	chr1:147316250	chr1:147021320~147124525:-
BRCA	cis	rs6671200	0.573	rs3738171	ENSG00000226026.4	RP11-57H12.3	-3.86	0.00012	0.00733	-0.19	-0.12	Stearic acid (18:0) levels;	chr1:95234038	chr1:95163219~95233982:-
BRCA	cis	rs801193	1	rs1553610	ENSG00000229180.5	GS1-124K5.11	3.86	0.00012	0.00733	0.1	0.12	Aortic root size;	chr7:66732246	chr7:66526088~66542624:-
BRCA	cis	rs801193	1	rs2707845	ENSG00000229180.5	GS1-124K5.11	3.86	0.00012	0.00733	0.1	0.12	Aortic root size;	chr7:66733811	chr7:66526088~66542624:-
BRCA	cis	rs801193	1	rs2707850	ENSG00000229180.5	GS1-124K5.11	3.86	0.00012	0.00733	0.1	0.12	Aortic root size;	chr7:66738883	chr7:66526088~66542624:-
BRCA	cis	rs801193	0.967	rs1110414	ENSG00000229180.5	GS1-124K5.11	3.86	0.00012	0.00733	0.1	0.12	Aortic root size;	chr7:66740595	chr7:66526088~66542624:-
BRCA	cis	rs801193	1	rs7783924	ENSG00000229180.5	GS1-124K5.11	3.86	0.00012	0.00733	0.1	0.12	Aortic root size;	chr7:66744070	chr7:66526088~66542624:-
BRCA	cis	rs801193	1	rs7789184	ENSG00000229180.5	GS1-124K5.11	3.86	0.00012	0.00733	0.1	0.12	Aortic root size;	chr7:66745208	chr7:66526088~66542624:-
BRCA	cis	rs801193	1	rs2707854	ENSG00000229180.5	GS1-124K5.11	3.86	0.00012	0.00733	0.1	0.12	Aortic root size;	chr7:66747610	chr7:66526088~66542624:-
BRCA	cis	rs9527	0.59	rs10509766	ENSG00000213061.2	PFN1P11	3.86	0.00012	0.00733	0.16	0.12	Arsenic metabolism;	chr10:103166577	chr10:102838011~102845473:-
BRCA	cis	rs737008	0.922	rs11074957	ENSG00000262636.1	CTD-3088G3.4	-3.86	0.00012	0.00733	-0.17	-0.12	Obesity-related traits;	chr16:11284294	chr16:11380859~11381118:-
BRCA	cis	rs801193	1	rs1553609	ENSG00000265600.1	AC006480.1	-3.86	0.00012	0.00733	-0.14	-0.12	Aortic root size;	chr7:66732152	chr7:67356680~67356779:+
BRCA	cis	rs10463316	0.894	rs6579863	ENSG00000260581.1	CTB-113P19.4	3.86	0.00012	0.00733	0.14	0.12	Metabolite levels (Pyroglutamine);	chr5:151382385	chr5:151652275~151655449:+
BRCA	cis	rs10463316	0.894	rs6579864	ENSG00000260581.1	CTB-113P19.4	3.86	0.00012	0.00733	0.14	0.12	Metabolite levels (Pyroglutamine);	chr5:151382620	chr5:151652275~151655449:+
BRCA	cis	rs10463316	0.894	rs7729438	ENSG00000260581.1	CTB-113P19.4	3.86	0.00012	0.00733	0.14	0.12	Metabolite levels (Pyroglutamine);	chr5:151382636	chr5:151652275~151655449:+
BRCA	cis	rs10463316	0.894	rs7729216	ENSG00000260581.1	CTB-113P19.4	3.86	0.00012	0.00733	0.14	0.12	Metabolite levels (Pyroglutamine);	chr5:151382716	chr5:151652275~151655449:+
BRCA	cis	rs10463316	0.894	rs6579865	ENSG00000260581.1	CTB-113P19.4	3.86	0.00012	0.00733	0.14	0.12	Metabolite levels (Pyroglutamine);	chr5:151382774	chr5:151652275~151655449:+
BRCA	cis	rs10463316	0.894	rs6579866	ENSG00000260581.1	CTB-113P19.4	3.86	0.00012	0.00733	0.14	0.12	Metabolite levels (Pyroglutamine);	chr5:151382963	chr5:151652275~151655449:+
BRCA	cis	rs10463316	0.894	rs6891272	ENSG00000260581.1	CTB-113P19.4	3.86	0.00012	0.00733	0.14	0.12	Metabolite levels (Pyroglutamine);	chr5:151383281	chr5:151652275~151655449:+
BRCA	cis	rs344364	0.511	rs1742472	ENSG00000219027.2	RPS3AP2	3.86	0.00012	0.00734	0.17	0.12	Glomerular filtration rate in chronic kidney disease;	chr16:1903039	chr16:1477830~1478583:+
BRCA	cis	rs1048886	0.872	rs78721430	ENSG00000271967.1	RP11-134K13.4	-3.86	0.00012	0.00734	-0.18	-0.12	Type 2 diabetes;	chr6:70520228	chr6:70596438~70596980:+
BRCA	cis	rs11098499	0.874	rs10022508	ENSG00000260091.1	RP11-33B1.4	-3.86	0.00012	0.00734	-0.11	-0.12	Corneal astigmatism;	chr4:119194073	chr4:119409333~119410233:+
BRCA	cis	rs10129255	0.957	rs8005468	ENSG00000274576.2	IGHV2-70	3.86	0.00012	0.00734	0.11	0.12	Kawasaki disease;	chr14:106686431	chr14:106770577~106771020:-
BRCA	cis	rs4218	0.648	rs60285686	ENSG00000259732.1	RP11-59H7.3	-3.86	0.00012	0.00734	-0.15	-0.12	Social communication problems;	chr15:59079829	chr15:59121034~59133250:+
BRCA	cis	rs4218	0.648	rs60741546	ENSG00000259732.1	RP11-59H7.3	-3.86	0.00012	0.00734	-0.15	-0.12	Social communication problems;	chr15:59079831	chr15:59121034~59133250:+
BRCA	cis	rs11051970	0.879	rs2728669	ENSG00000274964.1	RP11-817I4.1	-3.86	0.00012	0.00734	-0.14	-0.12	Response to tocilizumab in rheumatoid arthritis;	chr12:32437717	chr12:32339368~32340724:+
BRCA	cis	rs987724	0.515	rs6762708	ENSG00000244515.1	KRT18P34	3.86	0.00012	0.00734	0.18	0.12	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156973815	chr3:157162663~157163932:-
BRCA	cis	rs7819412	0.749	rs11991118	ENSG00000154316.13	TDH	-3.86	0.00012	0.00734	-0.15	-0.12	Triglycerides;	chr8:11081763	chr8:11339637~11368452:+
BRCA	cis	rs9308731	0.591	rs10439396	ENSG00000230499.1	AC108463.1	-3.86	0.00012	0.00734	-0.14	-0.12	Chronic lymphocytic leukemia;	chr2:111178399	chr2:111195963~111206494:+
BRCA	cis	rs35612822	0.65	rs6743973	ENSG00000232485.2	AC098820.3	-3.86	0.00012	0.00734	-0.13	-0.12	Kidney disease (early stage) in type 1 diabetes;	chr2:216405370	chr2:216479030~216498761:-
BRCA	cis	rs7520050	0.966	rs11211199	ENSG00000234329.1	RP11-767N6.2	-3.86	0.00012	0.00734	-0.11	-0.12	Reticulocyte count;Red blood cell count;	chr1:45822197	chr1:45651039~45651826:-
BRCA	cis	rs7177699	0.557	rs7403593	ENSG00000261143.1	ADAMTS7P3	3.86	0.00012	0.00734	0.15	0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78819620	chr15:77976042~77993057:+
BRCA	cis	rs6750795	0.641	rs10933375	ENSG00000223198.1	RNU2-22P	3.86	0.00012	0.00735	0.17	0.12	Height;	chr2:231502585	chr2:231501990~231502201:-
BRCA	cis	rs13401620	0.843	rs13015818	ENSG00000229326.3	AC069154.4	3.86	0.00012	0.00735	0.15	0.12	Breast size;	chr2:119766186	chr2:119698623~119700151:+
BRCA	cis	rs561341	1	rs2344312	ENSG00000277511.1	CTD-2095E4.5	3.86	0.00012	0.00735	0.15	0.12	Hip circumference adjusted for BMI;	chr17:31916564	chr17:32127595~32128454:+
BRCA	cis	rs12612435	0.91	rs6760202	ENSG00000226806.1	AC011893.3	3.86	0.00012	0.00735	0.14	0.12	Takotsubo syndrome;	chr2:136358665	chr2:135820191~135823087:+
BRCA	cis	rs34773007	0.623	rs71480840	ENSG00000232709.1	MARK2P9	3.86	0.00012	0.00735	0.2	0.12	Type 2 diabetes;	chr10:92784225	chr10:92418667~92420875:+
BRCA	cis	rs2058059	0.636	rs3015917	ENSG00000205578.5	POM121B	-3.86	0.00012	0.00735	-0.19	-0.12	Subcutaneous adipose tissue;	chr7:72679494	chr7:73293497~73301161:+
BRCA	cis	rs11098499	0.874	rs7661020	ENSG00000225892.3	RP11-384K6.2	3.86	0.00012	0.00735	0.13	0.12	Corneal astigmatism;	chr4:119185827	chr4:118632274~118634759:+
BRCA	cis	rs9472168	0.967	rs4513773	ENSG00000272223.1	RP1-20C7.6	-3.86	0.00012	0.00735	-0.13	-0.12	Interleukin-13 levels;	chr6:43957789	chr6:43033897~43034405:-
BRCA	cis	rs7620503	0.959	rs6443476	ENSG00000231574.4	RP11-91K9.1	3.86	0.00012	0.00735	0.13	0.12	Corneal structure;	chr3:177589907	chr3:177816865~177899224:+
BRCA	cis	rs7620503	0.959	rs6443477	ENSG00000231574.4	RP11-91K9.1	3.86	0.00012	0.00735	0.13	0.12	Corneal structure;	chr3:177590145	chr3:177816865~177899224:+
BRCA	cis	rs7620503	0.959	rs6769466	ENSG00000231574.4	RP11-91K9.1	3.86	0.00012	0.00735	0.13	0.12	Corneal structure;	chr3:177590226	chr3:177816865~177899224:+
BRCA	cis	rs513088	0.628	rs547863	ENSG00000225171.2	DUTP6	3.86	0.00012	0.00735	0.17	0.12	Schizophrenia;	chr1:166733136	chr1:166868748~166869209:+
BRCA	cis	rs9926296	0.744	rs164746	ENSG00000223959.7	AFG3L1P	3.86	0.00012	0.00735	0.13	0.12	Vitiligo;	chr16:89642611	chr16:89972586~90002161:+
BRCA	cis	rs6964587	1	rs4265	ENSG00000188693.7	CYP51A1-AS1	3.86	0.00012	0.00735	0.13	0.12	Breast cancer;	chr7:92090294	chr7:92134604~92180725:+
BRCA	cis	rs4388249	1	rs12656763	ENSG00000271849.1	CTC-332L22.1	-3.86	0.00012	0.00735	-0.2	-0.12	Schizophrenia;	chr5:109707482	chr5:109687802~109688329:-
BRCA	cis	rs6964587	1	rs6956596	ENSG00000188693.7	CYP51A1-AS1	-3.86	0.00012	0.00735	-0.13	-0.12	Breast cancer;	chr7:92120793	chr7:92134604~92180725:+
BRCA	cis	rs6964587	1	rs6974607	ENSG00000188693.7	CYP51A1-AS1	-3.86	0.00012	0.00735	-0.13	-0.12	Breast cancer;	chr7:92120802	chr7:92134604~92180725:+
BRCA	cis	rs4374383	0.884	rs1996325	ENSG00000243389.1	AC012442.5	3.86	0.00012	0.00736	0.15	0.12	Hepatitis C induced liver fibrosis;	chr2:111984498	chr2:112589040~112614431:+
BRCA	cis	rs251253	0.827	rs13183715	ENSG00000253959.1	CTB-43E15.1	3.86	0.00012	0.00736	0.11	0.12	PR interval;	chr5:173095980	chr5:173642519~173658194:+
BRCA	cis	rs73201462	1	rs61044849	ENSG00000242551.2	POU5F1P6	3.86	0.00012	0.00736	0.21	0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128346623	chr3:128674735~128677005:-
BRCA	cis	rs73201462	1	rs57735707	ENSG00000242551.2	POU5F1P6	3.86	0.00012	0.00736	0.21	0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128346972	chr3:128674735~128677005:-
BRCA	cis	rs6545883	0.894	rs4672423	ENSG00000270820.4	RP11-355B11.2	-3.86	0.00012	0.00736	-0.14	-0.12	Tuberculosis;	chr2:61208140	chr2:61471188~61484130:+
BRCA	cis	rs9295123	0.61	rs2197296	ENSG00000216480.2	RP3-393E18.1	-3.86	0.00012	0.00736	-0.14	-0.12	Blood protein levels;	chr6:160147965	chr6:159526062~159526527:-
BRCA	cis	rs4819052	0.851	rs9977178	ENSG00000215447.6	BX322557.10	-3.86	0.00012	0.00736	-0.12	-0.12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244616	chr21:45288052~45291738:+
BRCA	cis	rs3812762	0.917	rs905289	ENSG00000254860.4	TMEM9B-AS1	-3.86	0.00012	0.00736	-0.11	-0.12	Hypospadias;	chr11:8732005	chr11:8964675~8977527:+
BRCA	cis	rs2765539	1	rs7525637	ENSG00000231365.4	RP11-418J17.1	-3.86	0.00012	0.00736	-0.16	-0.12	Waist-hip ratio;	chr1:119000848	chr1:119140396~119275973:+
BRCA	cis	rs7246967	0.932	rs35706770	ENSG00000198153.8	ZNF849P	-3.86	0.00012	0.00736	-0.17	-0.12	Bronchopulmonary dysplasia;	chr19:22876460	chr19:22685167~22686732:+
BRCA	cis	rs7246967	1	rs11882498	ENSG00000198153.8	ZNF849P	-3.86	0.00012	0.00736	-0.17	-0.12	Bronchopulmonary dysplasia;	chr19:22877210	chr19:22685167~22686732:+
BRCA	cis	rs4148883	0.504	rs2000864	ENSG00000246090.5	RP11-696N14.1	3.86	0.00012	0.00736	0.11	0.12	Alcohol dependence;	chr4:99202619	chr4:99088857~99301356:+
BRCA	cis	rs2880765	0.714	rs6497187	ENSG00000202081.1	RNU6-1280P	3.86	0.00012	0.00736	0.14	0.12	Coronary artery disease;	chr15:85468119	chr15:85651522~85651628:-
BRCA	cis	rs801193	0.904	rs4718403	ENSG00000273142.1	RP11-458F8.4	-3.86	0.00012	0.00736	-0.1	-0.12	Aortic root size;	chr7:66777742	chr7:66902857~66906297:+
BRCA	cis	rs490234	0.702	rs13287071	ENSG00000232630.1	PRPS1P2	-3.86	0.00012	0.00736	-0.13	-0.12	Mean arterial pressure;	chr9:125505945	chr9:125150653~125151589:+
BRCA	cis	rs9423406	0.752	rs71479714	ENSG00000215267.7	AKR1C7P	-3.86	0.00012	0.00736	-0.23	-0.12	Intelligence;	chr10:5277862	chr10:5275173~5288470:-
BRCA	cis	rs6847067	0.832	rs12501525	ENSG00000180769.7	WDFY3-AS2	-3.86	0.00012	0.00736	-0.11	-0.12	Oropharynx cancer;	chr4:84865675	chr4:84965682~85011277:+
BRCA	cis	rs7131987	0.903	rs10843371	ENSG00000273680.1	RP11-996F15.6	3.86	0.00012	0.00736	0.15	0.12	QT interval;	chr12:29261299	chr12:29332733~29333383:-
BRCA	cis	rs10864907	0.71	rs11690399	ENSG00000231747.1	AC079922.2	3.86	0.00012	0.00736	0.11	0.12	Pulmonary function;	chr2:112982682	chr2:112621809~112622167:-
BRCA	cis	rs17092148	0.836	rs4911157	ENSG00000202150.1	RNU6-407P	3.86	0.00012	0.00736	0.18	0.12	Neuroticism;	chr20:34579271	chr20:35030317~35030420:-
BRCA	cis	rs9959145	0.85	rs76780647	ENSG00000267108.1	RP11-861E21.1	3.86	0.00012	0.00736	0.21	0.12	Immune response to smallpox vaccine (IL-6);	chr18:12710821	chr18:12432897~12437635:+
BRCA	cis	rs38055	0.958	rs38058	ENSG00000247796.2	CTD-2366F13.1	-3.86	0.000121	0.00736	-0.14	-0.12	Acne (severe);	chr5:53262931	chr5:53109842~53115126:+
BRCA	cis	rs2835872	0.793	rs2835833	ENSG00000228677.1	TTC3-AS1	3.86	0.000121	0.00736	0.15	0.12	Electroencephalographic traits in alcoholism;	chr21:37615595	chr21:37187666~37193926:-
BRCA	cis	rs875971	0.66	rs2013222	ENSG00000275400.1	RP4-756H11.5	3.86	0.000121	0.00737	0.13	0.12	Aortic root size;	chr7:66570949	chr7:66553805~66554199:-
BRCA	cis	rs13401620	0.879	rs10196410	ENSG00000229326.3	AC069154.4	-3.86	0.000121	0.00737	-0.15	-0.12	Breast size;	chr2:119767199	chr2:119698623~119700151:+
BRCA	cis	rs6545883	0.965	rs6734830	ENSG00000212978.6	AC016747.3	3.86	0.000121	0.00737	0.16	0.12	Tuberculosis;	chr2:61503977	chr2:61141592~61144969:-
BRCA	cis	rs1143633	0.537	rs4625908	ENSG00000231747.1	AC079922.2	3.86	0.000121	0.00737	0.12	0.12	Allergic disease (asthma, hay fever or eczema);	chr2:112870389	chr2:112621809~112622167:-
BRCA	cis	rs1009077	0.716	rs2892870	ENSG00000245958.5	RP11-33B1.1	3.86	0.000121	0.00737	0.17	0.12	Endometriosis;	chr4:119642218	chr4:119454791~119552025:+
BRCA	cis	rs448720	1	rs12900710	ENSG00000260657.2	RP11-315D16.4	-3.86	0.000121	0.00737	-0.14	-0.12	Cognitive performance;	chr15:67904997	chr15:68267792~68277994:-
BRCA	cis	rs4671400	0.516	rs2600671	ENSG00000273302.1	RP11-493E12.2	3.86	0.000121	0.00737	0.13	0.12	3-hydroxypropylmercapturic acid levels in smokers;	chr2:61167716	chr2:61199979~61200769:+
BRCA	cis	rs3816183	1	rs3772062	ENSG00000226491.1	FTOP1	-3.86	0.000121	0.00737	-0.15	-0.12	Hypospadias;	chr2:42789905	chr2:42797225~42798712:-
BRCA	cis	rs28374715	0.681	rs59000092	ENSG00000247556.5	OIP5-AS1	3.86	0.000121	0.00737	0.12	0.12	Ulcerative colitis;	chr15:41333950	chr15:41283990~41309737:+
BRCA	cis	rs6893300	0.784	rs62404347	ENSG00000250999.1	RP11-1379J22.5	3.86	0.000121	0.00737	0.16	0.12	Resting heart rate;	chr5:179718130	chr5:179657762~179664432:+
BRCA	cis	rs490234	0.676	rs1129	ENSG00000232630.1	PRPS1P2	3.86	0.000121	0.00737	0.13	0.12	Mean arterial pressure;	chr9:125437594	chr9:125150653~125151589:+
BRCA	cis	rs12439619	0.846	rs62012003	ENSG00000259429.4	UBE2Q2P2	-3.86	0.000121	0.00737	-0.15	-0.12	Intelligence (multi-trait analysis);	chr15:82183236	chr15:82355142~82420075:+
BRCA	cis	rs10129255	0.957	rs10136817	ENSG00000274576.2	IGHV2-70	3.86	0.000121	0.00738	0.11	0.12	Kawasaki disease;	chr14:106787730	chr14:106770577~106771020:-
BRCA	cis	rs2692947	0.509	rs79546441	ENSG00000168992.4	OR7E102P	3.86	0.000121	0.00738	0.17	0.12	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95553124	chr2:95546531~95547545:+
BRCA	cis	rs11098499	0.909	rs1809406	ENSG00000225892.3	RP11-384K6.2	3.86	0.000121	0.00738	0.12	0.12	Corneal astigmatism;	chr4:119455967	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.865	rs2389809	ENSG00000225892.3	RP11-384K6.2	3.86	0.000121	0.00738	0.12	0.12	Corneal astigmatism;	chr4:119456244	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.909	rs9994810	ENSG00000225892.3	RP11-384K6.2	3.86	0.000121	0.00738	0.12	0.12	Corneal astigmatism;	chr4:119460435	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.697	rs10020027	ENSG00000225892.3	RP11-384K6.2	3.86	0.000121	0.00738	0.12	0.12	Corneal astigmatism;	chr4:119460724	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.779	rs7356491	ENSG00000225892.3	RP11-384K6.2	3.86	0.000121	0.00738	0.12	0.12	Corneal astigmatism;	chr4:119460819	chr4:118632274~118634759:+
BRCA	cis	rs372883	0.564	rs766928	ENSG00000176054.6	RPL23P2	3.86	0.000121	0.00738	0.13	0.12	Pancreatic cancer;	chr21:29381286	chr21:28997613~28998033:-
BRCA	cis	rs9393777	0.92	rs34150729	ENSG00000216901.1	AL022393.7	3.86	0.000121	0.00738	0.3	0.12	Intelligence (multi-trait analysis);	chr6:27420975	chr6:28176188~28176674:+
BRCA	cis	rs9393777	0.92	rs13191227	ENSG00000216901.1	AL022393.7	3.86	0.000121	0.00738	0.3	0.12	Intelligence (multi-trait analysis);	chr6:27422336	chr6:28176188~28176674:+
BRCA	cis	rs28489187	0.683	rs1498373	ENSG00000223653.4	RP11-131L23.1	3.86	0.000121	0.00738	0.14	0.12	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85324950	chr1:85276715~85448124:+
BRCA	cis	rs28489187	0.706	rs2300634	ENSG00000223653.4	RP11-131L23.1	3.86	0.000121	0.00738	0.14	0.12	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85325574	chr1:85276715~85448124:+
BRCA	cis	rs5758659	0.652	rs133305	ENSG00000182057.4	OGFRP1	3.86	0.000121	0.00738	0.13	0.12	Cognitive function;	chr22:41999956	chr22:42269753~42275196:+
BRCA	cis	rs5758659	0.682	rs133306	ENSG00000182057.4	OGFRP1	3.86	0.000121	0.00738	0.13	0.12	Cognitive function;	chr22:42000146	chr22:42269753~42275196:+
BRCA	cis	rs683250	0.515	rs481321	ENSG00000254551.1	RP11-727A23.7	3.86	0.000121	0.00738	0.15	0.12	Subcortical brain region volumes;	chr11:83246291	chr11:83209431~83213379:-
BRCA	cis	rs3816183	0.958	rs4953663	ENSG00000226491.1	FTOP1	-3.86	0.000121	0.00738	-0.15	-0.12	Hypospadias;	chr2:42796518	chr2:42797225~42798712:-
BRCA	cis	rs1348850	0.914	rs8941	ENSG00000280374.1	RP11-337N6.3	3.86	0.000121	0.00739	0.16	0.12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177541753	chr2:177317715~177318471:-
BRCA	cis	rs17801127	0.818	rs35185541	ENSG00000231969.1	AC144449.1	3.86	0.000121	0.00739	0.21	0.12	Liver enzyme levels (alanine transaminase);	chr2:149682320	chr2:149587196~149848233:+
BRCA	cis	rs9784649	0.882	rs72753879	ENSG00000245662.2	RP11-184E9.1	3.86	0.000121	0.00739	0.19	0.12	Peripheral arterial disease (traffic-related air pollution interaction);	chr5:24947286	chr5:25190682~25306172:+
BRCA	cis	rs4664293	1	rs10184034	ENSG00000224152.1	AC009506.1	-3.86	0.000121	0.00739	-0.13	-0.12	Monocyte percentage of white cells;	chr2:159648916	chr2:159615296~159617082:+
BRCA	cis	rs4664293	1	rs4664293	ENSG00000224152.1	AC009506.1	-3.86	0.000121	0.00739	-0.13	-0.12	Monocyte percentage of white cells;	chr2:159649241	chr2:159615296~159617082:+
BRCA	cis	rs4664293	1	rs10193402	ENSG00000224152.1	AC009506.1	-3.86	0.000121	0.00739	-0.13	-0.12	Monocyte percentage of white cells;	chr2:159651271	chr2:159615296~159617082:+
BRCA	cis	rs9376307	0.647	rs9399229	ENSG00000226004.1	RP11-10J5.1	3.86	0.000121	0.00739	0.12	0.12	Cancer;	chr6:137977956	chr6:137943079~137945802:-
BRCA	cis	rs7020830	0.858	rs1492714	ENSG00000260100.1	RP11-220I1.5	-3.86	0.000121	0.00739	-0.15	-0.12	Schizophrenia;	chr9:37141262	chr9:37078813~37079776:-
BRCA	cis	rs10181042	0.565	rs1177234	ENSG00000270820.4	RP11-355B11.2	3.86	0.000121	0.00739	0.13	0.12	Crohn's disease;	chr2:61032928	chr2:61471188~61484130:+
BRCA	cis	rs4835473	0.932	rs56277406	ENSG00000246448.2	RP13-578N3.3	-3.86	0.000121	0.00739	-0.13	-0.12	Immature fraction of reticulocytes;	chr4:143740620	chr4:143700257~143865072:+
BRCA	cis	rs10861342	0.515	rs10861340	ENSG00000257999.1	RP11-61E11.2	3.86	0.000121	0.00739	0.16	0.12	IgG glycosylation;	chr12:105060319	chr12:105102472~105107179:-
BRCA	cis	rs9393777	0.92	rs67859638	ENSG00000216901.1	AL022393.7	3.86	0.000121	0.00739	0.32	0.12	Intelligence (multi-trait analysis);	chr6:27390199	chr6:28176188~28176674:+
BRCA	cis	rs6005807	0.64	rs73432205	ENSG00000272858.1	CTA-292E10.8	-3.86	0.000121	0.00739	-0.21	-0.12	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28632144	chr22:28814914~28815662:+
BRCA	cis	rs12188164	0.62	rs1043356	ENSG00000188242.4	PP7080	-3.86	0.000121	0.00739	-0.16	-0.12	Cystic fibrosis severity;	chr5:480833	chr5:466124~473098:-
BRCA	cis	rs11098499	1	rs11098500	ENSG00000260404.2	RP11-384K6.6	3.86	0.000121	0.00739	0.11	0.12	Corneal astigmatism;	chr4:119298084	chr4:118591773~118633729:+
BRCA	cis	rs4666002	0.917	rs2068834	ENSG00000234072.1	AC074117.10	3.86	0.000121	0.00739	0.12	0.12	Phospholipid levels (plasma);	chr2:27616672	chr2:27356246~27367622:+
BRCA	cis	rs7852462	0.9	rs10759765	ENSG00000203279.3	RP11-498P14.5	3.86	0.000121	0.00739	0.14	0.12	Barrett's esophagus  or Esophageal adenocarcinoma;Barrett's esophagus;	chr9:97545211	chr9:97200475~97238700:-
BRCA	cis	rs9650657	0.771	rs6601513	ENSG00000154316.13	TDH	3.86	0.000121	0.00739	0.15	0.12	Neuroticism;	chr8:10737333	chr8:11339637~11368452:+
BRCA	cis	rs80226907	0.634	rs75053482	ENSG00000186615.9	KTN1-AS1	-3.86	0.000121	0.00739	-0.24	-0.12	Mean platelet volume;	chr14:55428401	chr14:55499278~55580110:-
BRCA	cis	rs875971	0.66	rs79009421	ENSG00000265600.1	AC006480.1	3.86	0.000121	0.00739	0.14	0.12	Aortic root size;	chr7:66603522	chr7:67356680~67356779:+
BRCA	cis	rs11170468	0.722	rs55967573	ENSG00000257718.1	RP11-396F22.1	-3.86	0.000121	0.0074	-0.15	-0.12	Body mass index;	chr12:39092659	chr12:38906451~38909592:+
BRCA	cis	rs4713118	0.597	rs172166	ENSG00000216901.1	AL022393.7	3.86	0.000121	0.0074	0.17	0.12	Parkinson's disease;	chr6:28053042	chr6:28176188~28176674:+
BRCA	cis	rs5742933	1	rs12619808	ENSG00000253559.1	OSGEPL1-AS1	-3.86	0.000121	0.0074	-0.16	-0.12	Ferritin levels;	chr2:189776458	chr2:189762704~189765556:+
BRCA	cis	rs7267979	1	rs6083856	ENSG00000274414.1	RP5-965G21.4	3.86	0.000121	0.0074	0.14	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25426949	chr20:25239007~25245229:-
BRCA	cis	rs911186	0.812	rs6932590	ENSG00000216901.1	AL022393.7	3.86	0.000121	0.0074	0.17	0.12	Autism spectrum disorder or schizophrenia;	chr6:27281152	chr6:28176188~28176674:+
BRCA	cis	rs151234	0.741	rs56236750	ENSG00000259982.1	CDC37P1	-3.86	0.000121	0.0074	-0.24	-0.12	Platelet distribution width;	chr16:28583390	chr16:28700294~28701540:-
BRCA	cis	rs2070615	0.525	rs931570	ENSG00000257964.1	RP11-133N21.10	-3.86	0.000121	0.0074	-0.13	-0.12	Bipolar disorder;	chr12:48801341	chr12:49576840~49577505:-
BRCA	cis	rs7267979	1	rs6050565	ENSG00000277938.1	RP5-965G21.3	-3.86	0.000121	0.0074	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25366927	chr20:25229150~25231933:+
BRCA	cis	rs17772222	0.917	rs17260408	ENSG00000258789.1	RP11-507K2.3	-3.86	0.000121	0.0074	-0.15	-0.12	Coronary artery calcification;	chr14:88715464	chr14:88551597~88552493:+
BRCA	cis	rs17772222	0.917	rs8021690	ENSG00000258789.1	RP11-507K2.3	-3.86	0.000121	0.0074	-0.15	-0.12	Coronary artery calcification;	chr14:88717806	chr14:88551597~88552493:+
BRCA	cis	rs2408955	0.541	rs11168428	ENSG00000257735.1	RP11-370I10.6	-3.86	0.000121	0.0074	-0.15	-0.12	Glycated hemoglobin levels;	chr12:48153345	chr12:48350945~48442411:+
BRCA	cis	rs10266483	0.545	rs116760071	ENSG00000227986.1	TRIM60P18	3.86	0.000121	0.0074	0.14	0.12	Response to statin therapy;	chr7:64289082	chr7:64355078~64356199:+
BRCA	cis	rs10043228	1	rs17139457	ENSG00000271918.1	CTD-2287O16.5	3.86	0.000121	0.00741	0.15	0.12	Asthma or chronic obstructive pulmonary disease;	chr5:116304906	chr5:116083807~116085416:-
BRCA	cis	rs17092148	0.945	rs6087622	ENSG00000202150.1	RNU6-407P	3.86	0.000121	0.00741	0.17	0.12	Neuroticism;	chr20:34722667	chr20:35030317~35030420:-
BRCA	cis	rs9619254	0.92	rs16990001	ENSG00000214076.3	CPSF1P1	3.86	0.000121	0.00741	0.2	0.12	Loneliness (multivariate analysis);	chr22:32204928	chr22:32269381~32273110:+
BRCA	cis	rs4835473	0.932	rs10030428	ENSG00000249741.2	RP11-673E1.3	-3.86	0.000121	0.00741	-0.12	-0.12	Immature fraction of reticulocytes;	chr4:143762699	chr4:143911514~143912053:-
BRCA	cis	rs11096990	0.634	rs60016848	ENSG00000249685.1	RP11-360F5.3	-3.86	0.000121	0.00741	-0.15	-0.12	Cognitive function;	chr4:39281436	chr4:39133913~39135608:+
BRCA	cis	rs11096990	0.577	rs6830736	ENSG00000249685.1	RP11-360F5.3	-3.86	0.000121	0.00741	-0.15	-0.12	Cognitive function;	chr4:39281467	chr4:39133913~39135608:+
BRCA	cis	rs875971	0.66	rs6460308	ENSG00000265600.1	AC006480.1	3.86	0.000121	0.00741	0.14	0.12	Aortic root size;	chr7:66619753	chr7:67356680~67356779:+
BRCA	cis	rs10129255	0.957	rs10142918	ENSG00000211967.3	IGHV3-53	-3.86	0.000121	0.00741	-0.08	-0.12	Kawasaki disease;	chr14:106782206	chr14:106592676~106593347:-
BRCA	cis	rs7800418	0.925	rs13241848	ENSG00000214870.7	AC004540.5	3.86	0.000121	0.00741	0.15	0.12	Cognitive function;	chr7:26563849	chr7:26398593~26494256:+
BRCA	cis	rs17756712	0.725	rs55698539	ENSG00000271911.1	RP11-532F6.5	3.86	0.000121	0.00741	0.2	0.12	Vertical cup-disc ratio;	chr6:613930	chr6:761675~780648:+
BRCA	cis	rs7726839	0.561	rs72703050	ENSG00000271781.1	CTD-2589H19.6	-3.86	0.000121	0.00741	-0.17	-0.12	Obesity-related traits;	chr5:582802	chr5:675826~676616:+
BRCA	cis	rs728616	0.867	rs726289	ENSG00000242600.5	MBL1P	3.86	0.000121	0.00741	0.26	0.12	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79947195	chr10:79904898~79950336:+
BRCA	cis	rs4934494	0.727	rs1590566	ENSG00000232229.4	LINC00865	-3.86	0.000121	0.00741	-0.17	-0.12	Red blood cell count;	chr10:89778781	chr10:89829510~89840861:+
BRCA	cis	rs1910358	0.718	rs12188224	ENSG00000248874.4	C5orf17	-3.86	0.000121	0.00741	-0.16	-0.12	Venous thromboembolism (SNP x SNP interaction);	chr5:23986918	chr5:23951348~24178263:+
BRCA	cis	rs4660456	0.504	rs2253835	ENSG00000272145.1	NFYC-AS1	-3.86	0.000121	0.00741	-0.14	-0.12	Platelet count;	chr1:40635900	chr1:40690380~40692066:-
BRCA	cis	rs2109514	0.561	rs4273775	ENSG00000237813.3	AC002066.1	3.86	0.000121	0.00741	0.15	0.12	Prevalent atrial fibrillation;	chr7:116454602	chr7:116238260~116499465:-
BRCA	cis	rs6453278	0.961	rs6453277	ENSG00000250802.5	ZBED3-AS1	3.86	0.000121	0.00741	0.16	0.12	Autism;	chr5:77121056	chr5:77086740~77166909:+
BRCA	cis	rs6686842	0.536	rs12123384	ENSG00000235358.1	RP11-399E6.1	-3.86	0.000121	0.00741	-0.16	-0.12	Height;	chr1:41239346	chr1:41242373~41284861:+
BRCA	cis	rs7722600	0.683	rs10076361	ENSG00000253404.1	AC034243.1	-3.86	0.000121	0.00741	-0.2	-0.12	Heart rate;	chr5:137917251	chr5:138744434~138753309:-
BRCA	cis	rs6546324	0.625	rs2861703	ENSG00000236780.4	AC078941.1	3.86	0.000121	0.00741	0.2	0.12	Endometriosis;	chr2:67633921	chr2:67123357~67215319:-
BRCA	cis	rs7819412	0.502	rs4841499	ENSG00000255046.1	RP11-297N6.4	3.86	0.000121	0.00741	0.16	0.12	Triglycerides;	chr8:11130628	chr8:11797928~11802568:-
BRCA	cis	rs7674212	0.507	rs223322	ENSG00000248740.4	RP11-328K4.1	3.86	0.000121	0.00741	0.14	0.12	Type 2 diabetes;	chr4:102879037	chr4:103256159~103453658:+
BRCA	cis	rs7487075	0.619	rs4768718	ENSG00000257261.4	RP11-96H19.1	3.86	0.000121	0.00741	0.13	0.12	Itch intensity from mosquito bite;	chr12:46440553	chr12:46383679~46876159:+
BRCA	cis	rs80226907	0.634	rs80240665	ENSG00000186615.9	KTN1-AS1	-3.86	0.000121	0.00742	-0.26	-0.12	Mean platelet volume;	chr14:55446880	chr14:55499278~55580110:-
BRCA	cis	rs80226907	0.634	rs74535471	ENSG00000186615.9	KTN1-AS1	-3.86	0.000121	0.00742	-0.26	-0.12	Mean platelet volume;	chr14:55448382	chr14:55499278~55580110:-
BRCA	cis	rs61160187	0.582	rs34619	ENSG00000272308.1	RP11-231G3.1	-3.86	0.000121	0.00742	-0.14	-0.12	Educational attainment (years of education);Educational attainment (college completion);	chr5:61169538	chr5:60866457~60866935:-
BRCA	cis	rs11098499	0.863	rs10030660	ENSG00000260404.2	RP11-384K6.6	3.86	0.000122	0.00742	0.11	0.12	Corneal astigmatism;	chr4:119515549	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.863	rs13149407	ENSG00000260404.2	RP11-384K6.6	3.86	0.000122	0.00742	0.11	0.12	Corneal astigmatism;	chr4:119516670	chr4:118591773~118633729:+
BRCA	cis	rs8141529	0.702	rs132536	ENSG00000272858.1	CTA-292E10.8	3.86	0.000122	0.00742	0.15	0.12	Lymphocyte counts;	chr22:28906918	chr22:28814914~28815662:+
BRCA	cis	rs17092148	1	rs3787220	ENSG00000202150.1	RNU6-407P	3.86	0.000122	0.00742	0.18	0.12	Neuroticism;	chr20:34749948	chr20:35030317~35030420:-
BRCA	cis	rs6545883	0.894	rs9677047	ENSG00000273302.1	RP11-493E12.2	-3.86	0.000122	0.00742	-0.11	-0.12	Tuberculosis;	chr2:61358160	chr2:61199979~61200769:+
BRCA	cis	rs1528472	1	rs1528472	ENSG00000276533.1	RP11-139H15.5	-3.86	0.000122	0.00742	-0.14	-0.12	Urinary albumin-to-creatinine ratio;Urinary albumin-to-creatinine ratio in non-diabetics;	chr15:55028930	chr15:55288849~55289346:-
BRCA	cis	rs2451932	0.744	rs397601	ENSG00000251050.1	RP11-168A11.4	-3.86	0.000122	0.00742	-0.13	-0.12	LDL peak particle diameter (total fat intake interaction);	chr5:80057262	chr5:80019609~80019920:+
BRCA	cis	rs752010	0.841	rs58737163	ENSG00000230638.4	RP11-486B10.4	-3.86	0.000122	0.00742	-0.14	-0.12	Lupus nephritis in systemic lupus erythematosus;	chr1:41614150	chr1:41542069~41544310:+
BRCA	cis	rs7772486	0.713	rs1986729	ENSG00000270638.1	RP3-466P17.1	3.86	0.000122	0.00742	0.14	0.12	Lobe attachment (rater-scored or self-reported);	chr6:145873695	chr6:145735570~145737218:+
BRCA	cis	rs12534093	0.67	rs11773147	ENSG00000234286.1	AC006026.13	-3.86	0.000122	0.00742	-0.18	-0.12	Infant length;Height;	chr7:23549567	chr7:23680195~23680786:-
BRCA	cis	rs8098244	0.683	rs1941524	ENSG00000265752.2	RP11-403A21.1	-3.86	0.000122	0.00742	-0.13	-0.12	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23865299	chr18:23957754~23982556:-
BRCA	cis	rs10463316	0.894	rs10042030	ENSG00000260581.1	CTB-113P19.4	3.86	0.000122	0.00743	0.14	0.12	Metabolite levels (Pyroglutamine);	chr5:151388467	chr5:151652275~151655449:+
BRCA	cis	rs10463316	0.894	rs3905511	ENSG00000260581.1	CTB-113P19.4	3.86	0.000122	0.00743	0.14	0.12	Metabolite levels (Pyroglutamine);	chr5:151388643	chr5:151652275~151655449:+
BRCA	cis	rs801193	0.569	rs4717315	ENSG00000229886.1	RP5-1132H15.3	3.86	0.000122	0.00743	0.13	0.12	Aortic root size;	chr7:66713338	chr7:66025126~66031544:-
BRCA	cis	rs3760982	1	rs11665924	ENSG00000267191.1	RP11-15A1.2	-3.86	0.000122	0.00743	-0.15	-0.12	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43782830	chr19:43902001~43926545:+
BRCA	cis	rs78487399	0.808	rs7570242	ENSG00000234936.1	AC010883.5	3.86	0.000122	0.00743	0.17	0.12	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43478863	chr2:43229573~43233394:+
BRCA	cis	rs35123781	1	rs601336	ENSG00000250635.1	CTD-3224K15.2	-3.86	0.000122	0.00743	-0.13	-0.12	Schizophrenia;	chr5:139677582	chr5:139648999~139649728:-
BRCA	cis	rs938554	0.612	rs13113918	ENSG00000250413.1	RP11-448G15.1	-3.86	0.000122	0.00743	-0.18	-0.12	Blood metabolite levels;	chr4:9996869	chr4:10006482~10009725:+
BRCA	cis	rs4415084	1	rs1821936	ENSG00000248464.1	FGF10-AS1	3.86	0.000122	0.00743	0.13	0.12	Breast cancer;	chr5:44699380	chr5:44388732~44413989:+
BRCA	cis	rs7520050	0.966	rs6680380	ENSG00000234329.1	RP11-767N6.2	-3.86	0.000122	0.00743	-0.11	-0.12	Reticulocyte count;Red blood cell count;	chr1:45834517	chr1:45651039~45651826:-
BRCA	cis	rs4819052	0.851	rs28622522	ENSG00000215447.6	BX322557.10	-3.86	0.000122	0.00743	-0.12	-0.12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45256684	chr21:45288052~45291738:+
BRCA	cis	rs9914544	0.966	rs1737943	ENSG00000273018.4	CTD-2303H24.2	3.86	0.000122	0.00743	0.16	0.12	Educational attainment (years of education);	chr17:18938277	chr17:18511221~18551705:-
BRCA	cis	rs7395581	0.918	rs10838692	ENSG00000280615.1	Y_RNA	3.86	0.000122	0.00743	0.14	0.12	HDL cholesterol;	chr11:47323549	chr11:47614898~47614994:-
BRCA	cis	rs7267979	0.527	rs6083891	ENSG00000277938.1	RP5-965G21.3	-3.86	0.000122	0.00743	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25593636	chr20:25229150~25231933:+
BRCA	cis	rs7246967	0.932	rs35968517	ENSG00000198153.8	ZNF849P	-3.86	0.000122	0.00743	-0.17	-0.12	Bronchopulmonary dysplasia;	chr19:22844238	chr19:22685167~22686732:+
BRCA	cis	rs6964833	1	rs17515241	ENSG00000184616.8	AC004166.6	-3.86	0.000122	0.00743	-0.18	-0.12	Menarche (age at onset);	chr7:74717695	chr7:74906673~74913256:-
BRCA	cis	rs3136202	0.643	rs9933278	ENSG00000242307.1	RPS26P52	3.86	0.000122	0.00743	0.15	0.12	Conduct disorder (symptom count);	chr16:13982413	chr16:13922332~13922679:-
BRCA	cis	rs17221829	0.932	rs10830358	ENSG00000280385.1	AP000648.5	-3.86	0.000122	0.00743	-0.13	-0.12	Anxiety in major depressive disorder;	chr11:89719775	chr11:90193614~90198120:+
BRCA	cis	rs17489649	0.785	rs1432806	ENSG00000271849.1	CTC-332L22.1	3.86	0.000122	0.00743	0.15	0.12	Intelligence (multi-trait analysis);	chr5:109851664	chr5:109687802~109688329:-
BRCA	cis	rs7735319	0.546	rs6450951	ENSG00000249572.1	CTD-2203K17.1	3.86	0.000122	0.00743	0.15	0.12	Systolic blood pressure;	chr5:33171365	chr5:33424025~33440619:-
BRCA	cis	rs72928364	0.86	rs13085839	ENSG00000256628.3	ZBTB11-AS1	3.86	0.000122	0.00743	0.22	0.12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:101078390	chr3:101676475~101679217:+
BRCA	cis	rs1153858	1	rs11070457	ENSG00000275672.1	GATM-AS1	-3.86	0.000122	0.00743	-0.16	-0.12	Homoarginine levels;	chr15:45394745	chr15:45378700~45380123:+
BRCA	cis	rs4919694	1	rs4917382	ENSG00000236937.2	PTGES3P4	3.86	0.000122	0.00744	0.24	0.12	Arsenic metabolism;	chr10:103078753	chr10:102845595~102845950:+
BRCA	cis	rs4478858	0.806	rs6686845	ENSG00000260386.4	LINC01225	-3.86	0.000122	0.00744	-0.14	-0.12	Alcohol dependence;	chr1:31235949	chr1:31500085~31540885:+
BRCA	cis	rs7312933	0.618	rs6582390	ENSG00000257225.1	RP11-328C8.4	-3.86	0.000122	0.00744	-0.15	-0.12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42240784	chr12:42459366~42466128:+
BRCA	cis	rs739401	0.611	rs7130841	ENSG00000247473.2	CARS-AS1	3.86	0.000122	0.00744	0.14	0.12	Longevity;	chr11:3022428	chr11:3029009~3041260:+
BRCA	cis	rs17772222	0.917	rs58984912	ENSG00000258789.1	RP11-507K2.3	-3.86	0.000122	0.00744	-0.14	-0.12	Coronary artery calcification;	chr14:88698172	chr14:88551597~88552493:+
BRCA	cis	rs7172809	0.615	rs78021430	ENSG00000260139.5	CSPG4P13	-3.86	0.000122	0.00744	-0.14	-0.12	Glucose homeostasis traits;	chr15:77553740	chr15:77894684~77904674:+
BRCA	cis	rs863345	0.604	rs11264997	ENSG00000176320.2	RP11-404O13.5	-3.86	0.000122	0.00744	-0.13	-0.12	Pneumococcal bacteremia;	chr1:158515692	chr1:158197922~158203877:-
BRCA	cis	rs62458065	0.85	rs28677012	ENSG00000273014.1	RP11-225B17.2	-3.86	0.000122	0.00744	-0.18	-0.12	Metabolite levels (HVA/MHPG ratio);	chr7:32430199	chr7:32758882~32759353:+
BRCA	cis	rs801193	0.548	rs2659904	ENSG00000272831.1	RP11-792A8.4	3.86	0.000122	0.00744	0.11	0.12	Aortic root size;	chr7:66713615	chr7:66739829~66740385:-
BRCA	cis	rs4713118	0.662	rs9357060	ENSG00000216901.1	AL022393.7	3.86	0.000122	0.00744	0.17	0.12	Parkinson's disease;	chr6:28056708	chr6:28176188~28176674:+
BRCA	cis	rs4713118	0.662	rs9468271	ENSG00000216901.1	AL022393.7	3.86	0.000122	0.00744	0.17	0.12	Parkinson's disease;	chr6:28056792	chr6:28176188~28176674:+
BRCA	cis	rs6893300	0.961	rs62406223	ENSG00000250999.1	RP11-1379J22.5	3.86	0.000122	0.00744	0.17	0.12	Resting heart rate;	chr5:179791360	chr5:179657762~179664432:+
BRCA	cis	rs6893300	0.961	rs730012	ENSG00000250999.1	RP11-1379J22.5	3.86	0.000122	0.00744	0.17	0.12	Resting heart rate;	chr5:179793637	chr5:179657762~179664432:+
BRCA	cis	rs754466	0.58	rs12354903	ENSG00000213514.2	RP11-428P16.2	3.86	0.000122	0.00744	0.16	0.12	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77776707	chr10:77730766~77734769:+
BRCA	cis	rs6439699	1	rs7648738	ENSG00000239213.4	NCK1-AS1	3.86	0.000122	0.00744	0.16	0.12	Intelligence (multi-trait analysis);	chr3:137289194	chr3:136841726~136862054:-
BRCA	cis	rs2562456	0.876	rs2359144	ENSG00000268117.1	VN1R84P	3.86	0.000122	0.00745	0.18	0.12	Pain;	chr19:21407834	chr19:21719801~21720035:-
BRCA	cis	rs2562456	0.876	rs4638726	ENSG00000268117.1	VN1R84P	3.86	0.000122	0.00745	0.18	0.12	Pain;	chr19:21409710	chr19:21719801~21720035:-
BRCA	cis	rs7620503	1	rs1463859	ENSG00000277241.1	RP11-114M1.3	3.86	0.000122	0.00745	0.13	0.12	Corneal structure;	chr3:177580283	chr3:177700346~177701072:-
BRCA	cis	rs7620503	1	rs6777561	ENSG00000277241.1	RP11-114M1.3	3.86	0.000122	0.00745	0.13	0.12	Corneal structure;	chr3:177587410	chr3:177700346~177701072:-
BRCA	cis	rs10792665	0.649	rs12808296	ENSG00000246067.6	RAB30-AS1	-3.86	0.000122	0.00745	-0.12	-0.12	Obesity-related traits;	chr11:83029074	chr11:83072066~83106719:+
BRCA	cis	rs867529	0.6	rs335120	ENSG00000253497.1	IGKV1-13	3.86	0.000122	0.00745	0.11	0.12	Height;	chr2:88773214	chr2:89045995~89046466:-
BRCA	cis	rs930421	0.544	rs6719977	ENSG00000226491.1	FTOP1	-3.86	0.000122	0.00745	-0.14	-0.12	Attention deficit hyperactivity disorder;	chr2:42758663	chr2:42797225~42798712:-
BRCA	cis	rs6088580	0.634	rs6088483	ENSG00000275784.1	RP5-1125A11.6	3.86	0.000122	0.00745	0.13	0.12	Glomerular filtration rate (creatinine);	chr20:34396908	chr20:33989480~33991818:-
BRCA	cis	rs7818688	1	rs28616734	ENSG00000245080.5	RP11-320N21.1	-3.86	0.000122	0.00745	-0.2	-0.12	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95009215	chr8:95066808~95073182:-
BRCA	cis	rs728616	0.867	rs61860043	ENSG00000242600.5	MBL1P	3.86	0.000122	0.00745	0.29	0.12	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80186642	chr10:79904898~79950336:+
BRCA	cis	rs728616	0.867	rs12414521	ENSG00000242600.5	MBL1P	3.86	0.000122	0.00745	0.29	0.12	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80189778	chr10:79904898~79950336:+
BRCA	cis	rs2436153	0.564	rs11233628	ENSG00000255234.4	RP11-727A23.10	3.86	0.000122	0.00745	0.15	0.12	Facial morphology (factor 16);	chr11:83476851	chr11:83286128~83423516:+
BRCA	cis	rs34792	0.889	rs2445475	ENSG00000207425.1	Y_RNA	3.86	0.000122	0.00745	0.14	0.12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15508247	chr16:14915457~14915556:-
BRCA	cis	rs18122	0.871	rs4671802	ENSG00000236780.4	AC078941.1	3.86	0.000122	0.00745	0.17	0.12	Waist-to-hip ratio adjusted for body mass index;	chr2:67420299	chr2:67123357~67215319:-
BRCA	cis	rs9527	0.59	rs7074395	ENSG00000213061.2	PFN1P11	-3.86	0.000122	0.00745	-0.16	-0.12	Arsenic metabolism;	chr10:103085171	chr10:102838011~102845473:-
BRCA	cis	rs7429990	0.965	rs62260764	ENSG00000199476.1	Y_RNA	-3.86	0.000122	0.00745	-0.18	-0.12	Educational attainment (years of education);	chr3:47949010	chr3:48288587~48288694:+
BRCA	cis	rs73201462	1	rs58986862	ENSG00000242551.2	POU5F1P6	3.86	0.000122	0.00745	0.2	0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128342846	chr3:128674735~128677005:-
BRCA	cis	rs73201462	1	rs56850662	ENSG00000242551.2	POU5F1P6	3.86	0.000122	0.00745	0.2	0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128343079	chr3:128674735~128677005:-
BRCA	cis	rs73201462	1	rs60399786	ENSG00000242551.2	POU5F1P6	3.86	0.000122	0.00745	0.2	0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128343227	chr3:128674735~128677005:-
BRCA	cis	rs8098244	0.964	rs11662907	ENSG00000265752.2	RP11-403A21.1	3.86	0.000122	0.00746	0.15	0.12	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23875595	chr18:23957754~23982556:-
BRCA	cis	rs875971	0.505	rs2462573	ENSG00000232546.1	RP11-458F8.1	3.86	0.000122	0.00746	0.1	0.12	Aortic root size;	chr7:66042405	chr7:66848496~66858136:+
BRCA	cis	rs17027633	1	rs3754035	ENSG00000260948.1	RP11-552M11.8	-3.86	0.000122	0.00746	-0.28	-0.12	Cerebrospinal fluid t-tau:AB1-42 ratio;	chr1:111430607	chr1:111431046~111433068:-
BRCA	cis	rs11673344	0.523	rs8110158	ENSG00000276846.1	CTD-3220F14.3	3.86	0.000122	0.00746	0.14	0.12	Obesity-related traits;	chr19:37063491	chr19:37314868~37315620:-
BRCA	cis	rs9990333	0.687	rs62285383	ENSG00000231464.1	AC024937.4	3.86	0.000122	0.00746	0.15	0.12	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196087052	chr3:195996738~195998233:+
BRCA	cis	rs7953704	0.815	rs7487608	ENSG00000212694.7	LINC01089	3.86	0.000122	0.00746	0.09	0.12	Urate levels;	chr12:122129513	chr12:121795267~121803906:-
BRCA	cis	rs11098499	0.866	rs72676074	ENSG00000225892.3	RP11-384K6.2	3.86	0.000122	0.00746	0.12	0.12	Corneal astigmatism;	chr4:119438686	chr4:118632274~118634759:+
BRCA	cis	rs8062405	0.964	rs7187333	ENSG00000261766.1	RP11-22P6.2	-3.86	0.000122	0.00746	-0.12	-0.12	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28854595	chr16:28862166~28863340:-
BRCA	cis	rs4415084	0.716	rs987394	ENSG00000251141.4	RP11-53O19.1	3.86	0.000122	0.00746	0.11	0.12	Breast cancer;	chr5:44846276	chr5:44744900~44808777:-
BRCA	cis	rs6732795	0.854	rs6546486	ENSG00000179818.12	PCBP1-AS1	3.86	0.000122	0.00746	0.13	0.12	Intraocular pressure;	chr2:69186760	chr2:69962263~70103220:-
BRCA	cis	rs12220238	1	rs3812638	ENSG00000213731.2	RAB5CP1	-3.86	0.000122	0.00746	-0.2	-0.12	Soluble interleukin-2 receptor subunit alpha;	chr10:74136314	chr10:74423435~74424014:-
BRCA	cis	rs11673344	0.523	rs7260488	ENSG00000276846.1	CTD-3220F14.3	3.86	0.000122	0.00746	0.14	0.12	Obesity-related traits;	chr19:37058883	chr19:37314868~37315620:-
BRCA	cis	rs55986470	0.817	rs11883735	ENSG00000186235.9	AC016757.3	3.86	0.000122	0.00746	0.22	0.12	Chronotype;	chr2:238499003	chr2:238224552~238231677:-
BRCA	cis	rs16958440	0.708	rs62096465	ENSG00000267724.1	RP11-49K24.8	3.86	0.000122	0.00746	0.18	0.12	Sitting height ratio;	chr18:47103253	chr18:47105946~47108062:+
BRCA	cis	rs16958440	0.708	rs1434528	ENSG00000267724.1	RP11-49K24.8	3.86	0.000122	0.00746	0.18	0.12	Sitting height ratio;	chr18:47105952	chr18:47105946~47108062:+
BRCA	cis	rs718314	0.957	rs11048456	ENSG00000256894.1	RP11-283G6.3	-3.86	0.000122	0.00746	-0.13	-0.12	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Renal cell carcinoma;Waist circumference adjusted for body mass index;	chr12:26310149	chr12:26125155~26126617:-
BRCA	cis	rs718314	1	rs11048457	ENSG00000256894.1	RP11-283G6.3	-3.86	0.000122	0.00746	-0.13	-0.12	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Renal cell carcinoma;Waist circumference adjusted for body mass index;	chr12:26310241	chr12:26125155~26126617:-
BRCA	cis	rs2486012	0.579	rs4660750	ENSG00000237950.1	RP11-7O11.3	3.86	0.000122	0.00747	0.22	0.12	Intelligence (multi-trait analysis);	chr1:43784710	chr1:43944370~43946551:-
BRCA	cis	rs495337	0.72	rs6067274	ENSG00000229222.1	KRT18P4	-3.86	0.000122	0.00747	-0.15	-0.12	Psoriasis;	chr20:49927849	chr20:49956745~49958032:+
BRCA	cis	rs495337	0.72	rs6125819	ENSG00000229222.1	KRT18P4	-3.86	0.000122	0.00747	-0.15	-0.12	Psoriasis;	chr20:49929173	chr20:49956745~49958032:+
BRCA	cis	rs495337	0.786	rs6125820	ENSG00000229222.1	KRT18P4	-3.86	0.000122	0.00747	-0.15	-0.12	Psoriasis;	chr20:49929294	chr20:49956745~49958032:+
BRCA	cis	rs495337	0.76	rs6067275	ENSG00000229222.1	KRT18P4	-3.86	0.000122	0.00747	-0.15	-0.12	Psoriasis;	chr20:49929336	chr20:49956745~49958032:+
BRCA	cis	rs495337	0.76	rs6122845	ENSG00000229222.1	KRT18P4	-3.86	0.000122	0.00747	-0.15	-0.12	Psoriasis;	chr20:49929737	chr20:49956745~49958032:+
BRCA	cis	rs495337	0.721	rs11696404	ENSG00000229222.1	KRT18P4	-3.86	0.000122	0.00747	-0.15	-0.12	Psoriasis;	chr20:49931743	chr20:49956745~49958032:+
BRCA	cis	rs495337	0.76	rs11696437	ENSG00000229222.1	KRT18P4	-3.86	0.000122	0.00747	-0.15	-0.12	Psoriasis;	chr20:49931781	chr20:49956745~49958032:+
BRCA	cis	rs495337	0.721	rs6125822	ENSG00000229222.1	KRT18P4	-3.86	0.000122	0.00747	-0.15	-0.12	Psoriasis;	chr20:49932229	chr20:49956745~49958032:+
BRCA	cis	rs4699052	0.635	rs6821137	ENSG00000248740.4	RP11-328K4.1	3.86	0.000122	0.00747	0.14	0.12	Testicular germ cell tumor;	chr4:103324936	chr4:103256159~103453658:+
BRCA	cis	rs2148307	0.675	rs11012339	ENSG00000228339.1	AMD1P1	-3.86	0.000122	0.00747	-0.14	-0.12	Photic sneeze reflex;	chr10:20788706	chr10:20350049~20351100:+
BRCA	cis	rs11673344	0.544	rs6508721	ENSG00000267422.1	CTD-2554C21.1	-3.86	0.000122	0.00747	-0.15	-0.12	Obesity-related traits;	chr19:37419119	chr19:37779686~37792865:+
BRCA	cis	rs7176093	0.846	rs10163127	ENSG00000202081.1	RNU6-1280P	-3.86	0.000122	0.00747	-0.14	-0.12	Aging traits;	chr15:85802077	chr15:85651522~85651628:-
BRCA	cis	rs7656342	0.897	rs12507861	ENSG00000250342.1	SNRPCP16	-3.86	0.000122	0.00747	-0.14	-0.12	Gut microbiota (bacterial taxa);	chr4:9775966	chr4:9051842~9052051:-
BRCA	cis	rs853679	0.517	rs3757185	ENSG00000261839.1	RP1-265C24.8	3.86	0.000122	0.00747	0.16	0.12	Depression;	chr6:28139998	chr6:28136849~28139678:+
BRCA	cis	rs11098499	0.738	rs72918577	ENSG00000225892.3	RP11-384K6.2	3.86	0.000123	0.00747	0.12	0.12	Corneal astigmatism;	chr4:119405546	chr4:118632274~118634759:+
BRCA	cis	rs7818688	1	rs11786878	ENSG00000245080.5	RP11-320N21.1	-3.86	0.000123	0.00747	-0.21	-0.12	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95021064	chr8:95066808~95073182:-
BRCA	cis	rs7267979	0.789	rs6076347	ENSG00000125804.12	FAM182A	3.86	0.000123	0.00747	0.16	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25418154	chr20:26054655~26086917:+
BRCA	cis	rs10844706	0.666	rs10844609	ENSG00000278635.1	CTD-2318O12.1	-3.86	0.000123	0.00747	-0.13	-0.12	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9723909	chr12:9415641~9416718:+
BRCA	cis	rs6708331	1	rs7597199	ENSG00000231024.1	AC092431.3	-3.86	0.000123	0.00747	-0.16	-0.12	Obesity-related traits;	chr2:70114443	chr2:69700192~69713847:-
BRCA	cis	rs687432	0.688	rs17152364	ENSG00000265566.2	RN7SL605P	-3.86	0.000123	0.00747	-0.15	-0.12	Parkinson's disease;	chr11:58113253	chr11:57528085~57528365:-
BRCA	cis	rs8130944	0.964	rs12626774	ENSG00000225731.1	AP001627.1	3.86	0.000123	0.00747	0.13	0.12	Perceived unattractiveness to mosquitoes;	chr21:42718938	chr21:42733594~42741758:-
BRCA	cis	rs8049367	0.612	rs8062591	ENSG00000267077.1	RP11-127I20.5	3.86	0.000123	0.00748	0.12	0.12	Nonsyndromic cleft lip with or without cleft palate;	chr16:3920585	chr16:4795265~4796532:-
BRCA	cis	rs983392	0.792	rs502581	ENSG00000275344.1	MIR6503	-3.86	0.000123	0.00748	-0.12	-0.12	Alzheimer's disease (late onset);	chr11:60092705	chr11:60209071~60209156:-
BRCA	cis	rs10129255	0.957	rs10142859	ENSG00000232216.1	IGHV3-43	3.86	0.000123	0.00748	0.09	0.12	Kawasaki disease;	chr14:106782238	chr14:106470264~106470800:-
BRCA	cis	rs34792	0.525	rs12708795	ENSG00000258354.1	MIR3180-1	-3.86	0.000123	0.00748	-0.16	-0.12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15533861	chr16:14909887~14911345:-
BRCA	cis	rs11098499	0.874	rs12502503	ENSG00000225892.3	RP11-384K6.2	3.86	0.000123	0.00748	0.13	0.12	Corneal astigmatism;	chr4:119195100	chr4:118632274~118634759:+
BRCA	cis	rs1434579	0.865	rs35813988	ENSG00000176761.7	ZNF285B	-3.86	0.000123	0.00748	-0.14	-0.12	Tuberculosis;	chr19:44436237	chr19:44467641~44473227:+
BRCA	cis	rs6121246	0.954	rs6060978	ENSG00000230613.1	HM13-AS1	3.86	0.000123	0.00748	0.17	0.12	Mean corpuscular hemoglobin;	chr20:31829090	chr20:31567707~31573263:-
BRCA	cis	rs6460942	0.915	rs72584550	ENSG00000226690.5	AC005281.1	3.86	0.000123	0.00748	0.18	0.12	Coronary artery disease;	chr7:12265364	chr7:12496429~12541910:+
BRCA	cis	rs4415084	0.966	rs1898701	ENSG00000272335.1	RP11-53O19.3	3.86	0.000123	0.00748	0.11	0.12	Breast cancer;	chr5:44695327	chr5:44826076~44828592:+
BRCA	cis	rs524281	0.861	rs7946917	ENSG00000255557.1	RP11-770G2.2	3.86	0.000123	0.00748	0.16	0.12	Electroencephalogram traits;	chr11:66189106	chr11:65745729~65771585:+
BRCA	cis	rs524281	0.861	rs10896094	ENSG00000255557.1	RP11-770G2.2	3.86	0.000123	0.00748	0.16	0.12	Electroencephalogram traits;	chr11:66191735	chr11:65745729~65771585:+
BRCA	cis	rs1371614	0.632	rs920437	ENSG00000229122.1	AGBL5-IT1	-3.86	0.000123	0.00748	-0.13	-0.12	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26934528	chr2:27061038~27061815:+
BRCA	cis	rs6893300	0.961	rs113829727	ENSG00000250999.1	RP11-1379J22.5	3.86	0.000123	0.00748	0.17	0.12	Resting heart rate;	chr5:179764895	chr5:179657762~179664432:+
BRCA	cis	rs490234	0.615	rs2819625	ENSG00000232630.1	PRPS1P2	-3.85	0.000123	0.00749	-0.12	-0.12	Mean arterial pressure;	chr9:125394369	chr9:125150653~125151589:+
BRCA	cis	rs10463316	0.894	rs10062856	ENSG00000260581.1	CTB-113P19.4	3.85	0.000123	0.00749	0.14	0.12	Metabolite levels (Pyroglutamine);	chr5:151388635	chr5:151652275~151655449:+
BRCA	cis	rs559406	0.521	rs2847285	ENSG00000260302.1	RP11-973H7.1	-3.85	0.000123	0.00749	-0.16	-0.12	Psoriasis;	chr18:12818225	chr18:12774651~12775923:-
BRCA	cis	rs6822297	0.875	rs10939144	ENSG00000240005.4	RP11-293A21.1	-3.85	0.000123	0.00749	-0.14	-0.12	Obesity-related traits;	chr4:26965284	chr4:26859806~26860599:-
BRCA	cis	rs7772486	0.875	rs6938972	ENSG00000270638.1	RP3-466P17.1	3.85	0.000123	0.00749	0.14	0.12	Lobe attachment (rater-scored or self-reported);	chr6:146089472	chr6:145735570~145737218:+
BRCA	cis	rs6840360	0.904	rs6825241	ENSG00000278978.1	RP11-164P12.5	-3.85	0.000123	0.00749	-0.13	-0.12	Intelligence (multi-trait analysis);	chr4:151622631	chr4:151669786~151670503:+
BRCA	cis	rs875971	0.862	rs2901152	ENSG00000273024.4	INTS4P2	3.85	0.000123	0.00749	0.13	0.12	Aortic root size;	chr7:66300017	chr7:65647864~65715661:+
BRCA	cis	rs9307551	0.697	rs7691021	ENSG00000250334.4	LINC00989	-3.85	0.000123	0.00749	-0.19	-0.12	Refractive error;	chr4:79502775	chr4:79492416~79576460:+
BRCA	cis	rs477895	0.838	rs12798333	ENSG00000256940.1	RP11-783K16.5	3.85	0.000123	0.00749	0.17	0.12	Mean platelet volume;	chr11:64245312	chr11:64245964~64248217:+
BRCA	cis	rs983392	1	rs11600716	ENSG00000275344.1	MIR6503	-3.85	0.000123	0.00749	-0.13	-0.12	Alzheimer's disease (late onset);	chr11:60156949	chr11:60209071~60209156:-
BRCA	cis	rs4835473	0.864	rs67749935	ENSG00000246448.2	RP13-578N3.3	-3.85	0.000123	0.00749	-0.13	-0.12	Immature fraction of reticulocytes;	chr4:143739852	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.9	rs66934100	ENSG00000246448.2	RP13-578N3.3	-3.85	0.000123	0.00749	-0.13	-0.12	Immature fraction of reticulocytes;	chr4:143739872	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.932	rs4325971	ENSG00000246448.2	RP13-578N3.3	-3.85	0.000123	0.00749	-0.13	-0.12	Immature fraction of reticulocytes;	chr4:143740167	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.932	rs4637344	ENSG00000246448.2	RP13-578N3.3	-3.85	0.000123	0.00749	-0.13	-0.12	Immature fraction of reticulocytes;	chr4:143740434	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.932	rs13143879	ENSG00000246448.2	RP13-578N3.3	-3.85	0.000123	0.00749	-0.13	-0.12	Immature fraction of reticulocytes;	chr4:143740901	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.932	rs36086465	ENSG00000246448.2	RP13-578N3.3	-3.85	0.000123	0.00749	-0.13	-0.12	Immature fraction of reticulocytes;	chr4:143742738	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.932	rs873430	ENSG00000246448.2	RP13-578N3.3	-3.85	0.000123	0.00749	-0.13	-0.12	Immature fraction of reticulocytes;	chr4:143742953	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.932	rs873431	ENSG00000246448.2	RP13-578N3.3	-3.85	0.000123	0.00749	-0.13	-0.12	Immature fraction of reticulocytes;	chr4:143743035	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.932	rs899903	ENSG00000246448.2	RP13-578N3.3	-3.85	0.000123	0.00749	-0.13	-0.12	Immature fraction of reticulocytes;	chr4:143743551	chr4:143700257~143865072:+
BRCA	cis	rs2625529	0.775	rs4777484	ENSG00000260037.4	CTD-2524L6.3	-3.85	0.000123	0.00749	-0.17	-0.12	Red blood cell count;	chr15:72084202	chr15:71818396~71823384:+
BRCA	cis	rs875971	0.522	rs1968127	ENSG00000275400.1	RP4-756H11.5	3.85	0.000123	0.00749	0.14	0.12	Aortic root size;	chr7:66591816	chr7:66553805~66554199:-
BRCA	cis	rs11158026	0.603	rs57667631	ENSG00000233924.1	AL160471.6	-3.85	0.000123	0.00749	-0.14	-0.12	Parkinson's disease;	chr14:54976349	chr14:55004813~55005687:-
BRCA	cis	rs11158026	0.603	rs56335168	ENSG00000233924.1	AL160471.6	-3.85	0.000123	0.00749	-0.14	-0.12	Parkinson's disease;	chr14:54978414	chr14:55004813~55005687:-
BRCA	cis	rs2708977	0.73	rs596069	ENSG00000271569.1	IGKV1OR2-6	3.85	0.000123	0.00749	0.08	0.12	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96410905	chr2:97355059~97355335:+
BRCA	cis	rs3768617	0.745	rs4546885	ENSG00000224468.3	RP11-181K3.4	-3.85	0.000123	0.00749	-0.13	-0.12	Fuchs's corneal dystrophy;	chr1:183056420	chr1:183138402~183141282:-
BRCA	cis	rs6545883	0.929	rs12713436	ENSG00000270820.4	RP11-355B11.2	3.85	0.000123	0.00749	0.14	0.12	Tuberculosis;	chr2:61464125	chr2:61471188~61484130:+
BRCA	cis	rs9733	0.596	rs2275236	ENSG00000231073.1	RP11-316M1.3	-3.85	0.000123	0.00749	-0.13	-0.12	Tonsillectomy;	chr1:150697476	chr1:150973123~150975534:+
BRCA	cis	rs6964587	0.935	rs28412174	ENSG00000188693.7	CYP51A1-AS1	3.85	0.000123	0.00749	0.13	0.12	Breast cancer;	chr7:91947931	chr7:92134604~92180725:+
BRCA	cis	rs6840360	0.681	rs9968292	ENSG00000251611.1	RP11-610P16.1	-3.85	0.000123	0.00749	-0.1	-0.12	Intelligence (multi-trait analysis);	chr4:151376216	chr4:151407551~151408835:-
BRCA	cis	rs6545883	0.507	rs59981505	ENSG00000273302.1	RP11-493E12.2	-3.85	0.000123	0.00749	-0.1	-0.12	Tuberculosis;	chr2:61353394	chr2:61199979~61200769:+
BRCA	cis	rs875971	1	rs6979382	ENSG00000272831.1	RP11-792A8.4	3.85	0.000123	0.00749	0.11	0.12	Aortic root size;	chr7:66421388	chr7:66739829~66740385:-
BRCA	cis	rs875971	1	rs6961990	ENSG00000272831.1	RP11-792A8.4	3.85	0.000123	0.00749	0.11	0.12	Aortic root size;	chr7:66423583	chr7:66739829~66740385:-
BRCA	cis	rs875971	1	rs1544549	ENSG00000272831.1	RP11-792A8.4	-3.85	0.000123	0.00749	-0.11	-0.12	Aortic root size;	chr7:66625676	chr7:66739829~66740385:-
BRCA	cis	rs10129255	0.5	rs8022547	ENSG00000254174.1	IGHV1-12	3.85	0.000123	0.0075	0.09	0.12	Kawasaki disease;	chr14:106781985	chr14:106122420~106122709:-
BRCA	cis	rs875971	0.83	rs4718358	ENSG00000265600.1	AC006480.1	-3.85	0.000123	0.0075	-0.14	-0.12	Aortic root size;	chr7:66508681	chr7:67356680~67356779:+
BRCA	cis	rs2274459	0.841	rs13214874	ENSG00000249346.5	LINC01016	3.85	0.000123	0.0075	0.15	0.12	Obesity (extreme);	chr6:33718591	chr6:33867506~33896914:-
BRCA	cis	rs9392556	0.829	rs619873	ENSG00000230648.1	RP3-406P24.3	3.85	0.000123	0.0075	0.15	0.12	Blood metabolite levels;	chr6:4107221	chr6:4018843~4021215:-
BRCA	cis	rs8105895	0.877	rs8100768	ENSG00000269345.1	VN1R85P	3.85	0.000123	0.0075	0.17	0.12	Body mass index (change over time);	chr19:22087666	chr19:22174766~22175191:-
BRCA	cis	rs12887734	0.566	rs3742366	ENSG00000269958.1	RP11-73M18.8	3.85	0.000123	0.0075	0.14	0.12	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103732014	chr14:103696353~103697163:+
BRCA	cis	rs7308116	0.645	rs10861833	ENSG00000258072.1	RP11-554D14.2	3.85	0.000123	0.0075	0.14	0.12	Pelvic organ prolapse (moderate/severe);	chr12:107902358	chr12:107903270~107903948:-
BRCA	cis	rs9527	0.64	rs35195396	ENSG00000213061.2	PFN1P11	3.85	0.000123	0.0075	0.16	0.12	Arsenic metabolism;	chr10:103169013	chr10:102838011~102845473:-
BRCA	cis	rs9527	0.614	rs11191589	ENSG00000213061.2	PFN1P11	3.85	0.000123	0.0075	0.16	0.12	Arsenic metabolism;	chr10:103170625	chr10:102838011~102845473:-
BRCA	cis	rs9527	0.59	rs3740386	ENSG00000213061.2	PFN1P11	3.85	0.000123	0.0075	0.16	0.12	Arsenic metabolism;	chr10:103171294	chr10:102838011~102845473:-
BRCA	cis	rs6472235	0.524	rs11985050	ENSG00000272010.1	CTD-3025N20.3	-3.85	0.000123	0.0075	-0.14	-0.12	Plateletcrit;Myopia (pathological);	chr8:65992811	chr8:65591850~65592472:-
BRCA	cis	rs10463316	0.747	rs10077700	ENSG00000260581.1	CTB-113P19.4	3.85	0.000123	0.0075	0.14	0.12	Metabolite levels (Pyroglutamine);	chr5:151388763	chr5:151652275~151655449:+
BRCA	cis	rs10463316	0.862	rs10062928	ENSG00000260581.1	CTB-113P19.4	3.85	0.000123	0.0075	0.14	0.12	Metabolite levels (Pyroglutamine);	chr5:151388794	chr5:151652275~151655449:+
BRCA	cis	rs9818758	0.556	rs11716614	ENSG00000225399.4	RP11-3B7.1	-3.85	0.000123	0.0075	-0.24	-0.12	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:48979775	chr3:49260085~49261316:+
BRCA	cis	rs8030605	0.704	rs72742619	ENSG00000277245.1	RP11-48G14.3	3.85	0.000123	0.0075	0.25	0.12	Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;	chr15:56385765	chr15:56447120~56447697:+
BRCA	cis	rs1865760	0.613	rs9379805	ENSG00000272462.2	U91328.19	-3.85	0.000123	0.0075	-0.14	-0.12	Height;	chr6:25938536	chr6:25992662~26001775:+
BRCA	cis	rs561341	0.883	rs1034626	ENSG00000277511.1	CTD-2095E4.5	-3.85	0.000123	0.0075	-0.16	-0.12	Hip circumference adjusted for BMI;	chr17:31892481	chr17:32127595~32128454:+
BRCA	cis	rs4648045	0.734	rs4648055	ENSG00000246560.2	RP11-10L12.4	3.85	0.000123	0.0075	0.14	0.12	Lymphocyte percentage of white cells;	chr4:102594156	chr4:102828055~102844075:+
BRCA	cis	rs5758659	0.652	rs133301	ENSG00000182057.4	OGFRP1	3.85	0.000123	0.0075	0.13	0.12	Cognitive function;	chr22:41994089	chr22:42269753~42275196:+
BRCA	cis	rs7771547	0.603	rs6913530	ENSG00000224666.3	RP1-50J22.4	-3.85	0.000123	0.00751	-0.15	-0.12	Platelet distribution width;	chr6:36630432	chr6:36386831~36393462:+
BRCA	cis	rs4834770	1	rs878375	ENSG00000245958.5	RP11-33B1.1	-3.85	0.000123	0.00751	-0.11	-0.12	Blood protein levels;	chr4:119316419	chr4:119454791~119552025:+
BRCA	cis	rs9921338	0.668	rs55870745	ENSG00000262636.1	CTD-3088G3.4	-3.85	0.000123	0.00751	-0.19	-0.12	Vein graft stenosis in coronary artery bypass grafting;	chr16:11261245	chr16:11380859~11381118:-
BRCA	cis	rs9921338	0.636	rs56350515	ENSG00000262636.1	CTD-3088G3.4	-3.85	0.000123	0.00751	-0.19	-0.12	Vein graft stenosis in coronary artery bypass grafting;	chr16:11261247	chr16:11380859~11381118:-
BRCA	cis	rs2798269	0.902	rs718426	ENSG00000236953.1	ZDHHC20-IT1	-3.85	0.000123	0.00751	-0.14	-0.12	PR segment;	chr13:21511520	chr13:21376977~21377874:-
BRCA	cis	rs962856	0.506	rs6546306	ENSG00000236780.4	AC078941.1	3.85	0.000123	0.00751	0.17	0.12	Pancreatic cancer;	chr2:67413977	chr2:67123357~67215319:-
BRCA	cis	rs4533720	0.54	rs11945181	ENSG00000248546.3	ANP32C	-3.85	0.000123	0.00751	-0.13	-0.12	Urinary uromodulin levels;	chr4:164025335	chr4:164197007~164197711:-
BRCA	cis	rs62560775	0.688	rs3217986	ENSG00000279670.1	RP11-70L8.5	3.85	0.000123	0.00751	0.22	0.12	Lung cancer;Lung adenocarcinoma;	chr9:22005331	chr9:21892188~21893857:+
BRCA	cis	rs6828577	1	rs6822035	ENSG00000281731.1	RP11-384K6.8	-3.85	0.000123	0.00751	-0.14	-0.12	Perioperative myocardial infarction in coronary artery bypass surgery;	chr4:118789266	chr4:118664087~118685341:-
BRCA	cis	rs875971	0.66	rs12698534	ENSG00000265600.1	AC006480.1	-3.85	0.000123	0.00751	-0.14	-0.12	Aortic root size;	chr7:66521858	chr7:67356680~67356779:+
BRCA	cis	rs6121246	0.909	rs6060960	ENSG00000230613.1	HM13-AS1	-3.85	0.000123	0.00752	-0.17	-0.12	Mean corpuscular hemoglobin;	chr20:31806714	chr20:31567707~31573263:-
BRCA	cis	rs1552244	0.572	rs73117481	ENSG00000180385.7	EMC3-AS1	3.85	0.000123	0.00752	0.17	0.12	Alzheimer's disease;	chr3:10118448	chr3:9986893~10006990:+
BRCA	cis	rs1552244	0.572	rs59074548	ENSG00000180385.7	EMC3-AS1	3.85	0.000123	0.00752	0.17	0.12	Alzheimer's disease;	chr3:10122663	chr3:9986893~10006990:+
BRCA	cis	rs1552244	0.572	rs3774208	ENSG00000180385.7	EMC3-AS1	3.85	0.000123	0.00752	0.17	0.12	Alzheimer's disease;	chr3:10123038	chr3:9986893~10006990:+
BRCA	cis	rs1552244	0.572	rs6783705	ENSG00000180385.7	EMC3-AS1	3.85	0.000123	0.00752	0.17	0.12	Alzheimer's disease;	chr3:10123099	chr3:9986893~10006990:+
BRCA	cis	rs7703051	0.67	rs10056811	ENSG00000271815.1	CTD-2235C13.3	-3.85	0.000123	0.00752	-0.16	-0.12	Age-related diseases, mortality and associated endophenotypes;LDL cholesterol;Age-related disease endophenotypes;	chr5:75309395	chr5:75363760~75364242:+
BRCA	cis	rs853679	0.517	rs16893666	ENSG00000261839.1	RP1-265C24.8	-3.85	0.000123	0.00752	-0.16	-0.12	Depression;	chr6:28086929	chr6:28136849~28139678:+
BRCA	cis	rs7267979	1	rs2257991	ENSG00000274973.1	RP13-401N8.7	3.85	0.000123	0.00752	0.13	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25289703	chr20:25845497~25845862:+
BRCA	cis	rs7772486	0.875	rs9403770	ENSG00000270638.1	RP3-466P17.1	3.85	0.000123	0.00752	0.14	0.12	Lobe attachment (rater-scored or self-reported);	chr6:146102198	chr6:145735570~145737218:+
BRCA	cis	rs7772486	0.875	rs11155452	ENSG00000270638.1	RP3-466P17.1	3.85	0.000123	0.00752	0.14	0.12	Lobe attachment (rater-scored or self-reported);	chr6:146103495	chr6:145735570~145737218:+
BRCA	cis	rs4415084	1	rs1371027	ENSG00000248464.1	FGF10-AS1	3.85	0.000123	0.00752	0.13	0.12	Breast cancer;	chr5:44699755	chr5:44388732~44413989:+
BRCA	cis	rs4415084	0.966	rs714130	ENSG00000248464.1	FGF10-AS1	3.85	0.000123	0.00752	0.13	0.12	Breast cancer;	chr5:44701316	chr5:44388732~44413989:+
BRCA	cis	rs2041840	0.924	rs8243	ENSG00000272054.1	RP11-423P10.2	-3.85	0.000123	0.00752	-0.11	-0.12	Chronic lymphocytic leukemia;	chr2:37250651	chr2:37208875~37212677:+
BRCA	cis	rs7312933	0.703	rs1059360	ENSG00000257225.1	RP11-328C8.4	-3.85	0.000123	0.00752	-0.14	-0.12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42160703	chr12:42459366~42466128:+
BRCA	cis	rs875971	0.66	rs801211	ENSG00000265600.1	AC006480.1	3.85	0.000124	0.00752	0.14	0.12	Aortic root size;	chr7:66550702	chr7:67356680~67356779:+
BRCA	cis	rs875971	0.638	rs801205	ENSG00000265600.1	AC006480.1	3.85	0.000124	0.00752	0.14	0.12	Aortic root size;	chr7:66557157	chr7:67356680~67356779:+
BRCA	cis	rs875971	0.617	rs810400	ENSG00000265600.1	AC006480.1	3.85	0.000124	0.00752	0.14	0.12	Aortic root size;	chr7:66557902	chr7:67356680~67356779:+
BRCA	cis	rs739496	0.843	rs621899	ENSG00000257624.1	RP1-128M12.3	3.85	0.000124	0.00752	0.16	0.12	Platelet count;	chr12:111547047	chr12:112000739~112000985:-
BRCA	cis	rs739496	0.843	rs625093	ENSG00000257624.1	RP1-128M12.3	3.85	0.000124	0.00752	0.16	0.12	Platelet count;	chr12:111550628	chr12:112000739~112000985:-
BRCA	cis	rs739496	0.843	rs638791	ENSG00000257624.1	RP1-128M12.3	3.85	0.000124	0.00752	0.16	0.12	Platelet count;	chr12:111551432	chr12:112000739~112000985:-
BRCA	cis	rs9381040	0.655	rs2268194	ENSG00000161912.16	ADCY10P1	3.85	0.000124	0.00752	0.13	0.12	Alzheimer's disease (late onset);	chr6:41056708	chr6:41101022~41140835:+
BRCA	cis	rs875971	0.528	rs801213	ENSG00000273448.1	RP11-166O4.6	-3.85	0.000124	0.00752	-0.12	-0.12	Aortic root size;	chr7:66549931	chr7:67333047~67334383:+
BRCA	cis	rs875971	0.545	rs801212	ENSG00000273448.1	RP11-166O4.6	-3.85	0.000124	0.00752	-0.12	-0.12	Aortic root size;	chr7:66550643	chr7:67333047~67334383:+
BRCA	cis	rs4664293	0.647	rs7595044	ENSG00000226266.5	AC009961.3	-3.85	0.000124	0.00752	-0.14	-0.12	Monocyte percentage of white cells;	chr2:159589694	chr2:159670708~159712435:-
BRCA	cis	rs4664293	0.647	rs12623149	ENSG00000226266.5	AC009961.3	-3.85	0.000124	0.00752	-0.14	-0.12	Monocyte percentage of white cells;	chr2:159590835	chr2:159670708~159712435:-
BRCA	cis	rs6968419	0.761	rs11770268	ENSG00000279086.1	RP11-667F14.1	-3.85	0.000124	0.00752	-0.11	-0.12	Intraocular pressure;	chr7:116152844	chr7:116209234~116211511:-
BRCA	cis	rs13256369	1	rs10098234	ENSG00000254153.1	CTA-398F10.2	3.85	0.000124	0.00752	0.16	0.12	Obesity-related traits;	chr8:8719182	chr8:8456909~8461337:-
BRCA	cis	rs4538475	0.559	rs55803452	ENSG00000273133.1	RP11-799M12.2	-3.85	0.000124	0.00752	-0.23	-0.12	Parkinson's disease;	chr4:15691085	chr4:15563698~15564253:-
BRCA	cis	rs8062405	1	rs4451951	ENSG00000261766.1	RP11-22P6.2	-3.85	0.000124	0.00752	-0.12	-0.12	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28824884	chr16:28862166~28863340:-
BRCA	cis	rs1075265	0.563	rs2542588	ENSG00000272156.1	RP11-477N3.1	3.85	0.000124	0.00752	0.12	0.12	Chronotype;Morning vs. evening chronotype;	chr2:53791787	chr2:54082554~54085066:+
BRCA	cis	rs7712401	0.791	rs9327279	ENSG00000251538.4	RP11-166A12.1	3.85	0.000124	0.00752	0.13	0.12	Mean platelet volume;	chr5:122786465	chr5:122628952~122730685:-
BRCA	cis	rs6743226	0.58	rs11677414	ENSG00000266621.1	AC104841.1	3.85	0.000124	0.00753	0.14	0.12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in non-smokers;	chr2:241298382	chr2:241245202~241245299:-
BRCA	cis	rs656900	0.715	rs673018	ENSG00000261229.4	MTHFS	3.85	0.000124	0.00753	0.12	0.12	Cerebrospinal P-tau181p levels;	chr15:79823005	chr15:79843547~79897285:-
BRCA	cis	rs10771431	0.817	rs10843149	ENSG00000256427.1	RP11-118B22.4	3.85	0.000124	0.00753	0.12	0.12	Breast size;	chr12:9209471	chr12:9246497~9257960:+
BRCA	cis	rs10043775	0.75	rs2112760	ENSG00000251330.3	CTD-2283N19.1	-3.85	0.000124	0.00753	-0.14	-0.12	Periodontal microbiota;	chr5:148324579	chr5:148430159~148430807:-
BRCA	cis	rs9300255	0.722	rs12298826	ENSG00000256028.2	RP11-197N18.2	-3.85	0.000124	0.00753	-0.12	-0.12	Neutrophil percentage of white cells;	chr12:123344481	chr12:122975320~122982907:+
BRCA	cis	rs9921338	0.961	rs72773825	ENSG00000262636.1	CTD-3088G3.4	-3.85	0.000124	0.00753	-0.19	-0.12	Vein graft stenosis in coronary artery bypass grafting;	chr16:11318591	chr16:11380859~11381118:-
BRCA	cis	rs6500602	0.855	rs2304631	ENSG00000280063.1	RP11-295D4.3	3.85	0.000124	0.00753	0.09	0.12	Schizophrenia;	chr16:4425867	chr16:4346694~4348648:-
BRCA	cis	rs7208859	0.623	rs609063	ENSG00000214719.10	AC005562.1	-3.85	0.000124	0.00753	-0.22	-0.12	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30624495	chr17:30576464~30672789:+
BRCA	cis	rs17801127	0.818	rs16827347	ENSG00000231969.1	AC144449.1	3.85	0.000124	0.00753	0.21	0.12	Liver enzyme levels (alanine transaminase);	chr2:149694371	chr2:149587196~149848233:+
BRCA	cis	rs2243480	1	rs387676	ENSG00000237026.1	RP11-328P23.2	3.85	0.000124	0.00753	0.22	0.12	Diabetic kidney disease;	chr7:66133233	chr7:65235790~65236723:-
BRCA	cis	rs11098499	0.863	rs10019674	ENSG00000250412.1	KLHL2P1	-3.85	0.000124	0.00753	-0.15	-0.12	Corneal astigmatism;	chr4:119522334	chr4:119334329~119378233:+
BRCA	cis	rs875971	0.545	rs6970498	ENSG00000232559.3	GS1-124K5.12	3.85	0.000124	0.00753	0.16	0.12	Aortic root size;	chr7:66275908	chr7:66554588~66576923:-
BRCA	cis	rs2241193	0.649	rs9341191	ENSG00000232485.2	AC098820.3	3.85	0.000124	0.00753	0.23	0.12	Visceral fat;	chr2:216656925	chr2:216479030~216498761:-
BRCA	cis	rs3748682	0.731	rs9729719	ENSG00000252448.1	SNORA63	-3.85	0.000124	0.00754	-0.15	-0.12	Hypothyroidism;	chr1:37832535	chr1:37884237~37884317:+
BRCA	cis	rs6121246	0.609	rs6060948	ENSG00000230613.1	HM13-AS1	3.85	0.000124	0.00754	0.16	0.12	Mean corpuscular hemoglobin;	chr20:31788590	chr20:31567707~31573263:-
BRCA	cis	rs35520189	0.961	rs58788639	ENSG00000189223.12	PAX8-AS1	-3.85	0.000124	0.00754	-0.19	-0.12	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:112869012	chr2:113211522~113276581:+
BRCA	cis	rs6432852	0.516	rs2304002	ENSG00000229195.1	AC009495.4	3.85	0.000124	0.00754	0.14	0.12	Diabetic kidney disease;	chr2:165857585	chr2:165794857~165846091:-
BRCA	cis	rs853679	0.607	rs13194781	ENSG00000216901.1	AL022393.7	3.85	0.000124	0.00754	0.31	0.12	Depression;	chr6:27847861	chr6:28176188~28176674:+
BRCA	cis	rs10266483	0.921	rs624257	ENSG00000271550.1	BNIP3P11	-3.85	0.000124	0.00754	-0.15	-0.12	Response to statin therapy;	chr7:64284848	chr7:64678954~64687393:-
BRCA	cis	rs17507216	1	rs17158413	ENSG00000259429.4	UBE2Q2P2	-3.85	0.000124	0.00754	-0.14	-0.12	Excessive daytime sleepiness;	chr15:82566658	chr15:82355142~82420075:+
BRCA	cis	rs875971	0.638	rs10249404	ENSG00000223473.2	GS1-124K5.3	-3.85	0.000124	0.00754	-0.09	-0.12	Aortic root size;	chr7:66581737	chr7:66491049~66493566:-
BRCA	cis	rs3816183	0.959	rs3772061	ENSG00000226491.1	FTOP1	-3.85	0.000124	0.00754	-0.15	-0.12	Hypospadias;	chr2:42789801	chr2:42797225~42798712:-
BRCA	cis	rs9470794	1	rs11755600	ENSG00000204110.6	RP1-153P14.8	-3.85	0.000124	0.00754	-0.23	-0.12	Type 2 diabetes;	chr6:38140089	chr6:37507348~37535616:+
BRCA	cis	rs9470794	1	rs11753759	ENSG00000204110.6	RP1-153P14.8	-3.85	0.000124	0.00754	-0.23	-0.12	Type 2 diabetes;	chr6:38140962	chr6:37507348~37535616:+
BRCA	cis	rs9470794	1	rs75847900	ENSG00000204110.6	RP1-153P14.8	-3.85	0.000124	0.00754	-0.23	-0.12	Type 2 diabetes;	chr6:38143176	chr6:37507348~37535616:+
BRCA	cis	rs9470794	1	rs73421889	ENSG00000204110.6	RP1-153P14.8	-3.85	0.000124	0.00754	-0.23	-0.12	Type 2 diabetes;	chr6:38143380	chr6:37507348~37535616:+
BRCA	cis	rs9470794	1	rs56021282	ENSG00000204110.6	RP1-153P14.8	-3.85	0.000124	0.00754	-0.23	-0.12	Type 2 diabetes;	chr6:38147884	chr6:37507348~37535616:+
BRCA	cis	rs9470794	1	rs11755566	ENSG00000204110.6	RP1-153P14.8	-3.85	0.000124	0.00754	-0.23	-0.12	Type 2 diabetes;	chr6:38148893	chr6:37507348~37535616:+
BRCA	cis	rs9470794	1	rs11760121	ENSG00000204110.6	RP1-153P14.8	-3.85	0.000124	0.00754	-0.23	-0.12	Type 2 diabetes;	chr6:38148894	chr6:37507348~37535616:+
BRCA	cis	rs58521262	0.556	rs290578	ENSG00000268105.1	RP11-369G6.2	-3.85	0.000124	0.00754	-0.16	-0.12	Testicular germ cell tumor;	chr19:23038687	chr19:23125665~23128543:+
BRCA	cis	rs6088580	0.634	rs6088471	ENSG00000275784.1	RP5-1125A11.6	3.85	0.000124	0.00755	0.13	0.12	Glomerular filtration rate (creatinine);	chr20:34344837	chr20:33989480~33991818:-
BRCA	cis	rs7520050	0.966	rs1707336	ENSG00000281133.1	AL355480.3	3.85	0.000124	0.00755	0.14	0.12	Reticulocyte count;Red blood cell count;	chr1:46027788	chr1:45580892~45580996:-
BRCA	cis	rs9733	0.519	rs11800855	ENSG00000224800.1	RP11-235D19.2	-3.85	0.000124	0.00755	-0.15	-0.12	Tonsillectomy;	chr1:150828519	chr1:150881236~150881683:-
BRCA	cis	rs4218	0.531	rs6494065	ENSG00000259732.1	RP11-59H7.3	3.85	0.000124	0.00755	0.14	0.12	Social communication problems;	chr15:59053249	chr15:59121034~59133250:+
BRCA	cis	rs4664293	0.669	rs13389096	ENSG00000224152.1	AC009506.1	-3.85	0.000124	0.00755	-0.13	-0.12	Monocyte percentage of white cells;	chr2:159611246	chr2:159615296~159617082:+
BRCA	cis	rs4664293	0.609	rs12470879	ENSG00000224152.1	AC009506.1	-3.85	0.000124	0.00755	-0.13	-0.12	Monocyte percentage of white cells;	chr2:159612116	chr2:159615296~159617082:+
BRCA	cis	rs7412746	0.503	rs72704639	ENSG00000231073.1	RP11-316M1.3	3.85	0.000124	0.00755	0.13	0.12	Melanoma;	chr1:150825859	chr1:150973123~150975534:+
BRCA	cis	rs4780355	0.843	rs413024	ENSG00000262703.1	RP11-485G7.6	3.85	0.000124	0.00755	0.13	0.12	Crohn's disease and psoriasis;	chr16:11260234	chr16:11348143~11349321:-
BRCA	cis	rs73201462	1	rs6772407	ENSG00000242551.2	POU5F1P6	3.85	0.000124	0.00755	0.2	0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128325529	chr3:128674735~128677005:-
BRCA	cis	rs875971	0.66	rs801192	ENSG00000223473.2	GS1-124K5.3	-3.85	0.000124	0.00755	-0.09	-0.12	Aortic root size;	chr7:66566965	chr7:66491049~66493566:-
BRCA	cis	rs875971	0.66	rs801190	ENSG00000223473.2	GS1-124K5.3	-3.85	0.000124	0.00755	-0.09	-0.12	Aortic root size;	chr7:66568046	chr7:66491049~66493566:-
BRCA	cis	rs875971	0.66	rs3857686	ENSG00000223473.2	GS1-124K5.3	-3.85	0.000124	0.00755	-0.09	-0.12	Aortic root size;	chr7:66571204	chr7:66491049~66493566:-
BRCA	cis	rs3755605	0.52	rs1705579	ENSG00000242578.1	RP11-469J4.3	3.85	0.000124	0.00755	0.14	0.12	Testicular germ cell tumor;	chr3:170218756	chr3:170410512~170418615:+
BRCA	cis	rs11098499	0.909	rs1546502	ENSG00000260091.1	RP11-33B1.4	-3.85	0.000124	0.00755	-0.11	-0.12	Corneal astigmatism;	chr4:119314743	chr4:119409333~119410233:+
BRCA	cis	rs4835473	0.808	rs62339607	ENSG00000249741.2	RP11-673E1.3	3.85	0.000124	0.00756	0.12	0.12	Immature fraction of reticulocytes;	chr4:143791474	chr4:143911514~143912053:-
BRCA	cis	rs6005807	0.843	rs9625484	ENSG00000272858.1	CTA-292E10.8	-3.85	0.000124	0.00756	-0.23	-0.12	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28512613	chr22:28814914~28815662:+
BRCA	cis	rs1005277	0.522	rs9417256	ENSG00000226578.1	RP11-258F22.1	-3.85	0.000124	0.00756	-0.13	-0.12	Extrinsic epigenetic age acceleration;	chr10:37688062	chr10:37775371~37784131:-
BRCA	cis	rs11239930	0.517	rs942689	ENSG00000237188.3	RP11-337C18.8	3.85	0.000124	0.00756	0.14	0.12	AIDS progression;	chr1:147079231	chr1:147172771~147211568:+
BRCA	cis	rs2625529	0.824	rs35112434	ENSG00000260037.4	CTD-2524L6.3	-3.85	0.000124	0.00756	-0.17	-0.12	Red blood cell count;	chr15:72155985	chr15:71818396~71823384:+
BRCA	cis	rs7412746	0.611	rs111905669	ENSG00000231073.1	RP11-316M1.3	3.85	0.000124	0.00756	0.13	0.12	Melanoma;	chr1:150805089	chr1:150973123~150975534:+
BRCA	cis	rs495337	0.736	rs530461	ENSG00000229222.1	KRT18P4	3.85	0.000124	0.00756	0.15	0.12	Psoriasis;	chr20:49851179	chr20:49956745~49958032:+
BRCA	cis	rs6723162	0.51	rs11126309	ENSG00000237751.2	LINC01143	3.85	0.000124	0.00756	0.16	0.12	Neurocognitive impairment in HIV-1 infection (dichotomous);	chr2:70922163	chr2:70887871~70889959:+
BRCA	cis	rs17092148	1	rs6060025	ENSG00000202150.1	RNU6-407P	3.85	0.000124	0.00756	0.17	0.12	Neuroticism;	chr20:34739072	chr20:35030317~35030420:-
BRCA	cis	rs7119	0.637	rs2667775	ENSG00000259362.2	RP11-307C19.1	3.85	0.000124	0.00756	0.16	0.12	Type 2 diabetes;	chr15:77572460	chr15:77525540~77534110:+
BRCA	cis	rs875971	0.638	rs3898855	ENSG00000223473.2	GS1-124K5.3	-3.85	0.000124	0.00756	-0.09	-0.12	Aortic root size;	chr7:66571411	chr7:66491049~66493566:-
BRCA	cis	rs875971	0.638	rs10278816	ENSG00000223473.2	GS1-124K5.3	-3.85	0.000124	0.00756	-0.09	-0.12	Aortic root size;	chr7:66572000	chr7:66491049~66493566:-
BRCA	cis	rs875971	0.66	rs10281080	ENSG00000223473.2	GS1-124K5.3	-3.85	0.000124	0.00756	-0.09	-0.12	Aortic root size;	chr7:66577454	chr7:66491049~66493566:-
BRCA	cis	rs875971	0.66	rs10950044	ENSG00000223473.2	GS1-124K5.3	-3.85	0.000124	0.00756	-0.09	-0.12	Aortic root size;	chr7:66577989	chr7:66491049~66493566:-
BRCA	cis	rs425277	1	rs262665	ENSG00000269227.1	RP11-345P4.6	3.85	0.000124	0.00756	0.12	0.12	Height;	chr1:2151734	chr1:1673275~1674397:+
BRCA	cis	rs7395581	0.877	rs10838690	ENSG00000280615.1	Y_RNA	3.85	0.000124	0.00757	0.14	0.12	HDL cholesterol;	chr11:47313524	chr11:47614898~47614994:-
BRCA	cis	rs2243480	1	rs34560516	ENSG00000226767.1	RP11-328P23.3	-3.85	0.000124	0.00757	-0.2	-0.12	Diabetic kidney disease;	chr7:65939105	chr7:65508773~65508944:-
BRCA	cis	rs853679	0.538	rs13199081	ENSG00000220721.1	OR1F12	3.85	0.000124	0.00757	0.16	0.12	Depression;	chr6:28364057	chr6:28073316~28074233:+
BRCA	cis	rs6991838	0.584	rs2175810	ENSG00000272155.1	RP11-707M3.3	3.85	0.000124	0.00757	0.11	0.12	Intelligence (multi-trait analysis);	chr8:65643583	chr8:65714334~65714778:-
BRCA	cis	rs11098499	0.954	rs7437420	ENSG00000250412.1	KLHL2P1	3.85	0.000124	0.00757	0.14	0.12	Corneal astigmatism;	chr4:119391748	chr4:119334329~119378233:+
BRCA	cis	rs8023401	0.938	rs11852589	ENSG00000274654.1	CTD-3247H4.2	3.85	0.000124	0.00757	0.16	0.12	Spherical equivalent (joint analysis main effects and education interaction);	chr15:48490861	chr15:48528980~48529728:-
BRCA	cis	rs8023401	0.938	rs35450230	ENSG00000274654.1	CTD-3247H4.2	3.85	0.000124	0.00757	0.16	0.12	Spherical equivalent (joint analysis main effects and education interaction);	chr15:48490879	chr15:48528980~48529728:-
BRCA	cis	rs8023401	0.872	rs4283172	ENSG00000274654.1	CTD-3247H4.2	3.85	0.000124	0.00757	0.16	0.12	Spherical equivalent (joint analysis main effects and education interaction);	chr15:48491072	chr15:48528980~48529728:-
BRCA	cis	rs9921338	0.961	rs72773832	ENSG00000263080.1	RP11-485G7.5	3.85	0.000124	0.00757	0.18	0.12	Vein graft stenosis in coronary artery bypass grafting;	chr16:11319266	chr16:11341809~11345211:-
BRCA	cis	rs9921338	0.961	rs72773834	ENSG00000263080.1	RP11-485G7.5	3.85	0.000124	0.00757	0.18	0.12	Vein graft stenosis in coronary artery bypass grafting;	chr16:11319436	chr16:11341809~11345211:-
BRCA	cis	rs10129255	0.744	rs28517388	ENSG00000211967.3	IGHV3-53	-3.85	0.000124	0.00757	-0.1	-0.12	Kawasaki disease;	chr14:106704323	chr14:106592676~106593347:-
BRCA	cis	rs2625529	0.73	rs7403191	ENSG00000260037.4	CTD-2524L6.3	-3.85	0.000124	0.00757	-0.15	-0.12	Red blood cell count;	chr15:71868623	chr15:71818396~71823384:+
BRCA	cis	rs78487399	0.71	rs76857293	ENSG00000234936.1	AC010883.5	3.85	0.000124	0.00757	0.2	0.12	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43364537	chr2:43229573~43233394:+
BRCA	cis	rs11892454	0.561	rs34762852	ENSG00000217643.1	PTGES3P2	-3.85	0.000124	0.00757	-0.13	-0.12	Heschl's gyrus morphology;	chr2:25781755	chr2:25822469~25822950:+
BRCA	cis	rs1023500	0.505	rs134887	ENSG00000273366.1	CTA-989H11.1	-3.85	0.000125	0.00758	-0.14	-0.12	Schizophrenia;	chr22:42278233	chr22:42278188~42278846:+
BRCA	cis	rs10844706	0.699	rs7296241	ENSG00000256673.1	RP11-599J14.2	-3.85	0.000125	0.00758	-0.15	-0.12	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9725044	chr12:9398355~9414851:-
BRCA	cis	rs2411233	1	rs8028720	ENSG00000259278.1	RP11-62C7.2	3.85	0.000125	0.00758	0.14	0.12	Platelet count;	chr15:38978586	chr15:39019233~39024918:+
BRCA	cis	rs7267979	1	rs6138572	ENSG00000274414.1	RP5-965G21.4	-3.85	0.000125	0.00758	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25455298	chr20:25239007~25245229:-
BRCA	cis	rs7267979	1	rs6138575	ENSG00000274414.1	RP5-965G21.4	-3.85	0.000125	0.00758	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25458316	chr20:25239007~25245229:-
BRCA	cis	rs7283707	0.581	rs412155	ENSG00000270071.1	AP001172.2	-3.85	0.000125	0.00758	-0.15	-0.12	QRS complex (12-leadsum);	chr21:15927450	chr21:16291791~16308133:-
BRCA	cis	rs3740713	1	rs75740864	ENSG00000256361.1	RP11-613F22.6	3.85	0.000125	0.00758	0.18	0.12	Amyotrophic lateral sclerosis (sporadic);	chr11:18449142	chr11:18511043~18511475:-
BRCA	cis	rs4664293	0.55	rs13388082	ENSG00000226266.5	AC009961.3	-3.85	0.000125	0.00758	-0.14	-0.12	Monocyte percentage of white cells;	chr2:159616439	chr2:159670708~159712435:-
BRCA	cis	rs4664293	0.582	rs1046496	ENSG00000226266.5	AC009961.3	-3.85	0.000125	0.00758	-0.14	-0.12	Monocyte percentage of white cells;	chr2:159616888	chr2:159670708~159712435:-
BRCA	cis	rs1730008	1	rs1730039	ENSG00000279311.1	RP11-170K4.2	-3.85	0.000125	0.00758	-0.14	-0.12	Lobe attachment (rater-scored or self-reported);	chr3:158313162	chr3:158869898~158871821:+
BRCA	cis	rs10463316	0.862	rs7720582	ENSG00000260581.1	CTB-113P19.4	-3.85	0.000125	0.00758	-0.14	-0.12	Metabolite levels (Pyroglutamine);	chr5:151396941	chr5:151652275~151655449:+
BRCA	cis	rs7948661	1	rs7948661	ENSG00000278376.1	RP11-158I9.8	3.85	0.000125	0.00758	0.23	0.12	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr11:118470934	chr11:118791254~118793137:+
BRCA	cis	rs3824867	0.92	rs7108143	ENSG00000280615.1	Y_RNA	3.85	0.000125	0.00758	0.14	0.12	Mean corpuscular hemoglobin;	chr11:47432171	chr11:47614898~47614994:-
BRCA	cis	rs911119	0.954	rs2254635	ENSG00000270001.1	RP11-218C14.8	-3.85	0.000125	0.00758	-0.15	-0.12	Chronic kidney disease;	chr20:23642121	chr20:23631826~23632316:-
BRCA	cis	rs115575488	0.85	rs114544572	ENSG00000231365.4	RP11-418J17.1	3.85	0.000125	0.00758	0.22	0.12	Lobe attachment (rater-scored or self-reported);	chr1:119046840	chr1:119140396~119275973:+
BRCA	cis	rs9921338	0.961	rs7198849	ENSG00000262636.1	CTD-3088G3.4	-3.85	0.000125	0.00758	-0.18	-0.12	Vein graft stenosis in coronary artery bypass grafting;	chr16:11279444	chr16:11380859~11381118:-
BRCA	cis	rs72772090	0.634	rs10515246	ENSG00000272109.1	CTD-2260A17.3	3.85	0.000125	0.00758	0.22	0.12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96763561	chr5:96804353~96806105:+
BRCA	cis	rs4730430	0.538	rs6466339	ENSG00000226965.1	AC003088.1	3.85	0.000125	0.00759	0.13	0.12	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr7:110496940	chr7:110432239~110534754:-
BRCA	cis	rs11711311	1	rs9811200	ENSG00000241529.3	RN7SL767P	-3.85	0.000125	0.00759	-0.14	-0.12	IgG glycosylation;	chr3:113812333	chr3:113632704~113632998:+
BRCA	cis	rs9921338	0.961	rs72773833	ENSG00000262636.1	CTD-3088G3.4	-3.85	0.000125	0.00759	-0.19	-0.12	Vein graft stenosis in coronary artery bypass grafting;	chr16:11319417	chr16:11380859~11381118:-
BRCA	cis	rs35306767	0.903	rs12240651	ENSG00000229869.1	RP11-363N22.2	-3.85	0.000125	0.00759	-0.18	-0.12	Eosinophil percentage of granulocytes;	chr10:897716	chr10:933026~942743:+
BRCA	cis	rs4272720	0.855	rs11814277	ENSG00000228754.1	RP11-534L6.3	-3.85	0.000125	0.00759	-0.17	-0.12	Platelet count;Plateletcrit;	chr10:49018759	chr10:48745545~48746128:-
BRCA	cis	rs4272720	0.855	rs2377692	ENSG00000228754.1	RP11-534L6.3	-3.85	0.000125	0.00759	-0.17	-0.12	Platelet count;Plateletcrit;	chr10:49022302	chr10:48745545~48746128:-
BRCA	cis	rs4713118	0.621	rs9295756	ENSG00000216901.1	AL022393.7	3.85	0.000125	0.00759	0.17	0.12	Parkinson's disease;	chr6:28065618	chr6:28176188~28176674:+
BRCA	cis	rs875971	0.66	rs62465434	ENSG00000265600.1	AC006480.1	-3.85	0.000125	0.00759	-0.14	-0.12	Aortic root size;	chr7:66540165	chr7:67356680~67356779:+
BRCA	cis	rs4415084	1	rs13176502	ENSG00000248464.1	FGF10-AS1	3.85	0.000125	0.00759	0.13	0.12	Breast cancer;	chr5:44697806	chr5:44388732~44413989:+
BRCA	cis	rs4664293	0.867	rs6432553	ENSG00000224152.1	AC009506.1	-3.85	0.000125	0.00759	-0.13	-0.12	Monocyte percentage of white cells;	chr2:159720499	chr2:159615296~159617082:+
BRCA	cis	rs8054556	1	rs3814884	ENSG00000183604.13	SMG1P5	-3.85	0.000125	0.00759	-0.12	-0.12	Autism spectrum disorder or schizophrenia;	chr16:29983415	chr16:30267553~30335374:-
BRCA	cis	rs528808	1	rs528808	ENSG00000272017.1	RP1-199J3.7	-3.85	0.000125	0.00759	-0.18	-0.12	Age-related hearing impairment;	chr6:99656413	chr6:99568097~99569096:+
BRCA	cis	rs8062405	0.965	rs56040780	ENSG00000261766.1	RP11-22P6.2	-3.85	0.000125	0.00759	-0.12	-0.12	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28850560	chr16:28862166~28863340:-
BRCA	cis	rs9329221	0.537	rs2062331	ENSG00000272267.2	RP11-375N15.2	3.85	0.000125	0.00759	0.14	0.12	Neuroticism;	chr8:10122482	chr8:9555144~9556520:-
BRCA	cis	rs11822910	0.737	rs2584858	ENSG00000254662.1	RP11-872D17.4	3.85	0.000125	0.00759	0.16	0.12	Platelet distribution width;	chr11:57439604	chr11:57325603~57327958:+
BRCA	cis	rs78487399	0.634	rs6751035	ENSG00000234936.1	AC010883.5	3.85	0.000125	0.00759	0.19	0.12	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43525268	chr2:43229573~43233394:+
BRCA	cis	rs73201462	1	rs2811527	ENSG00000242551.2	POU5F1P6	-3.85	0.000125	0.00759	-0.2	-0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128275761	chr3:128674735~128677005:-
BRCA	cis	rs16846053	0.792	rs72877381	ENSG00000227403.1	AC009299.3	3.85	0.000125	0.00759	0.31	0.12	Blood osmolality (transformed sodium);	chr2:161799335	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.792	rs62190672	ENSG00000227403.1	AC009299.3	3.85	0.000125	0.00759	0.31	0.12	Blood osmolality (transformed sodium);	chr2:161799459	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.792	rs62190673	ENSG00000227403.1	AC009299.3	3.85	0.000125	0.00759	0.31	0.12	Blood osmolality (transformed sodium);	chr2:161800391	chr2:161244739~161249050:+
BRCA	cis	rs7917772	0.503	rs56397707	ENSG00000213061.2	PFN1P11	-3.85	0.000125	0.00759	-0.16	-0.12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;	chr10:102542936	chr10:102838011~102845473:-
BRCA	cis	rs3768617	0.811	rs6674729	ENSG00000224468.3	RP11-181K3.4	-3.85	0.000125	0.00759	-0.13	-0.12	Fuchs's corneal dystrophy;	chr1:183090008	chr1:183138402~183141282:-
BRCA	cis	rs1910358	0.959	rs10059638	ENSG00000248874.4	C5orf17	-3.85	0.000125	0.00759	-0.17	-0.12	Venous thromboembolism (SNP x SNP interaction);	chr5:23900326	chr5:23951348~24178263:+
BRCA	cis	rs1910358	0.959	rs34959020	ENSG00000248874.4	C5orf17	-3.85	0.000125	0.00759	-0.17	-0.12	Venous thromboembolism (SNP x SNP interaction);	chr5:23902454	chr5:23951348~24178263:+
BRCA	cis	rs1910358	0.959	rs10065366	ENSG00000248874.4	C5orf17	-3.85	0.000125	0.00759	-0.17	-0.12	Venous thromboembolism (SNP x SNP interaction);	chr5:23908240	chr5:23951348~24178263:+
BRCA	cis	rs524281	0.773	rs10791862	ENSG00000255038.1	RP11-1167A19.2	-3.85	0.000125	0.00759	-0.18	-0.12	Electroencephalogram traits;	chr11:66246193	chr11:66067277~66069619:-
BRCA	cis	rs524281	0.773	rs2155198	ENSG00000255038.1	RP11-1167A19.2	-3.85	0.000125	0.00759	-0.18	-0.12	Electroencephalogram traits;	chr11:66246829	chr11:66067277~66069619:-
BRCA	cis	rs17092148	1	rs6058112	ENSG00000202150.1	RNU6-407P	3.85	0.000125	0.0076	0.18	0.12	Neuroticism;	chr20:34734202	chr20:35030317~35030420:-
BRCA	cis	rs4713118	0.662	rs9380045	ENSG00000216901.1	AL022393.7	3.85	0.000125	0.0076	0.17	0.12	Parkinson's disease;	chr6:28057501	chr6:28176188~28176674:+
BRCA	cis	rs2904967	0.778	rs77130160	ENSG00000255200.1	AP003068.18	3.85	0.000125	0.0076	0.27	0.12	Mean corpuscular volume;	chr11:65355223	chr11:65174117~65176470:-
BRCA	cis	rs875971	0.545	rs12671152	ENSG00000273142.1	RP11-458F8.4	3.85	0.000125	0.0076	0.12	0.12	Aortic root size;	chr7:66311140	chr7:66902857~66906297:+
BRCA	cis	rs1005277	0.579	rs1740735	ENSG00000272983.1	RP11-508N22.12	3.85	0.000125	0.0076	0.13	0.12	Extrinsic epigenetic age acceleration;	chr10:38208849	chr10:38137337~38144399:+
BRCA	cis	rs6600671	0.692	rs11249430	ENSG00000275538.1	RNVU1-19	3.85	0.000125	0.0076	0.15	0.12	Hip geometry;	chr1:121547115	chr1:120850819~120850985:-
BRCA	cis	rs6812193	0.518	rs28698332	ENSG00000271676.1	RP11-1E1.2	3.85	0.000125	0.0076	0.17	0.12	Parkinson's disease;	chr4:76276692	chr4:77112495~77113458:-
BRCA	cis	rs6142618	0.562	rs1321415	ENSG00000275576.1	RP5-836N17.4	-3.85	0.000125	0.0076	-0.13	-0.12	Inflammatory bowel disease;	chr20:32156415	chr20:32116171~32116629:+
BRCA	cis	rs7800418	1	rs7800418	ENSG00000214870.7	AC004540.5	-3.85	0.000125	0.0076	-0.15	-0.12	Cognitive function;	chr7:26566386	chr7:26398593~26494256:+
BRCA	cis	rs1635	0.655	rs723476	ENSG00000216901.1	AL022393.7	3.85	0.000125	0.0076	0.27	0.12	Schizophrenia;	chr6:28337327	chr6:28176188~28176674:+
BRCA	cis	rs1635	0.655	rs73742539	ENSG00000216901.1	AL022393.7	3.85	0.000125	0.0076	0.27	0.12	Schizophrenia;	chr6:28337694	chr6:28176188~28176674:+
BRCA	cis	rs10938353	0.906	rs2118926	ENSG00000273369.1	RP11-700J17.1	3.85	0.000125	0.0076	0.14	0.12	Body mass index;	chr4:44604973	chr4:44693946~44694386:-
BRCA	cis	rs10938353	0.906	rs17571930	ENSG00000273369.1	RP11-700J17.1	3.85	0.000125	0.0076	0.14	0.12	Body mass index;	chr4:44605555	chr4:44693946~44694386:-
BRCA	cis	rs35123781	1	rs589153	ENSG00000250635.1	CTD-3224K15.2	-3.85	0.000125	0.0076	-0.13	-0.12	Schizophrenia;	chr5:139677963	chr5:139648999~139649728:-
BRCA	cis	rs713477	0.617	rs11627405	ENSG00000186615.9	KTN1-AS1	-3.85	0.000125	0.0076	-0.13	-0.12	Pediatric bone mineral content (femoral neck);	chr14:55444939	chr14:55499278~55580110:-
BRCA	cis	rs4664293	0.55	rs13388082	ENSG00000224152.1	AC009506.1	-3.85	0.000125	0.0076	-0.12	-0.12	Monocyte percentage of white cells;	chr2:159616439	chr2:159615296~159617082:+
BRCA	cis	rs4664293	0.582	rs1046496	ENSG00000224152.1	AC009506.1	-3.85	0.000125	0.0076	-0.12	-0.12	Monocyte percentage of white cells;	chr2:159616888	chr2:159615296~159617082:+
BRCA	cis	rs1048886	0.808	rs2207425	ENSG00000271967.1	RP11-134K13.4	-3.85	0.000125	0.00761	-0.18	-0.12	Type 2 diabetes;	chr6:70509867	chr6:70596438~70596980:+
BRCA	cis	rs1005277	0.522	rs1208681	ENSG00000226578.1	RP11-258F22.1	-3.85	0.000125	0.00761	-0.13	-0.12	Extrinsic epigenetic age acceleration;	chr10:37804047	chr10:37775371~37784131:-
BRCA	cis	rs862034	0.902	rs862052	ENSG00000270000.1	RP3-449M8.9	3.85	0.000125	0.00761	0.14	0.12	Height;	chr14:74514113	chr14:74471930~74472360:-
BRCA	cis	rs875971	0.66	rs13224319	ENSG00000265600.1	AC006480.1	-3.85	0.000125	0.00761	-0.14	-0.12	Aortic root size;	chr7:66542376	chr7:67356680~67356779:+
BRCA	cis	rs875971	0.66	rs801217	ENSG00000265600.1	AC006480.1	3.85	0.000125	0.00761	0.14	0.12	Aortic root size;	chr7:66545590	chr7:67356680~67356779:+
BRCA	cis	rs875971	0.638	rs801216	ENSG00000265600.1	AC006480.1	3.85	0.000125	0.00761	0.14	0.12	Aortic root size;	chr7:66546680	chr7:67356680~67356779:+
BRCA	cis	rs62458065	0.64	rs10274556	ENSG00000273014.1	RP11-225B17.2	-3.85	0.000125	0.00761	-0.19	-0.12	Metabolite levels (HVA/MHPG ratio);	chr7:32474335	chr7:32758882~32759353:+
BRCA	cis	rs12468226	1	rs16839077	ENSG00000272966.1	RP11-686O6.1	3.85	0.000125	0.00761	0.2	0.12	Urate levels;	chr2:202343970	chr2:202336739~202337200:+
BRCA	cis	rs11695541	0.826	rs13412862	ENSG00000270820.4	RP11-355B11.2	3.85	0.000125	0.00761	0.29	0.12	Methadone dose in opioid dependence;	chr2:60631728	chr2:61471188~61484130:+
BRCA	cis	rs28489187	0.706	rs233115	ENSG00000223653.4	RP11-131L23.1	3.85	0.000125	0.00761	0.13	0.12	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85321294	chr1:85276715~85448124:+
BRCA	cis	rs56322409	0.564	rs10786247	ENSG00000226688.5	ENTPD1-AS1	3.85	0.000125	0.00761	0.14	0.12	Blood metabolite levels;	chr10:95926394	chr10:95753206~96090238:-
BRCA	cis	rs6993270	0.779	rs7818752	ENSG00000245330.4	KB-1471A8.1	-3.85	0.000125	0.00761	-0.19	-0.12	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr8:119920791	chr8:119867419~119874488:-
BRCA	cis	rs71636778	0.584	rs17162316	ENSG00000260063.1	RP5-968P14.2	-3.85	0.000125	0.00761	-0.17	-0.12	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26851416	chr1:26692132~26694131:-
BRCA	cis	rs6964587	1	rs36120033	ENSG00000188693.7	CYP51A1-AS1	-3.85	0.000125	0.00761	-0.13	-0.12	Breast cancer;	chr7:92049984	chr7:92134604~92180725:+
BRCA	cis	rs6964587	1	rs1859113	ENSG00000188693.7	CYP51A1-AS1	-3.85	0.000125	0.00761	-0.13	-0.12	Breast cancer;	chr7:92050573	chr7:92134604~92180725:+
BRCA	cis	rs73201462	1	rs2999079	ENSG00000242551.2	POU5F1P6	-3.85	0.000125	0.00762	-0.19	-0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128238389	chr3:128674735~128677005:-
BRCA	cis	rs801193	0.967	rs34356500	ENSG00000265600.1	AC006480.1	-3.85	0.000125	0.00762	-0.14	-0.12	Aortic root size;	chr7:66771620	chr7:67356680~67356779:+
BRCA	cis	rs859767	0.709	rs1516990	ENSG00000224043.6	CCNT2-AS1	3.85	0.000125	0.00762	0.16	0.12	Neuroticism;	chr2:134612060	chr2:134735464~134918710:-
BRCA	cis	rs2625529	0.824	rs11072339	ENSG00000260037.4	CTD-2524L6.3	-3.85	0.000125	0.00762	-0.17	-0.12	Red blood cell count;	chr15:71954849	chr15:71818396~71823384:+
BRCA	cis	rs733592	0.723	rs10875766	ENSG00000257763.1	OR5BK1P	3.85	0.000125	0.00762	0.12	0.12	Plateletcrit;	chr12:48199797	chr12:48355792~48356614:-
BRCA	cis	rs3816183	1	rs6724265	ENSG00000226491.1	FTOP1	-3.85	0.000125	0.00762	-0.15	-0.12	Hypospadias;	chr2:42793096	chr2:42797225~42798712:-
BRCA	cis	rs6964587	1	rs4727266	ENSG00000188693.7	CYP51A1-AS1	3.85	0.000125	0.00762	0.13	0.12	Breast cancer;	chr7:91940815	chr7:92134604~92180725:+
BRCA	cis	rs6964587	1	rs4727267	ENSG00000188693.7	CYP51A1-AS1	3.85	0.000125	0.00762	0.13	0.12	Breast cancer;	chr7:91940976	chr7:92134604~92180725:+
BRCA	cis	rs6964587	1	rs7797369	ENSG00000188693.7	CYP51A1-AS1	3.85	0.000125	0.00762	0.13	0.12	Breast cancer;	chr7:91941301	chr7:92134604~92180725:+
BRCA	cis	rs9921338	0.961	rs72773829	ENSG00000262636.1	CTD-3088G3.4	-3.85	0.000125	0.00762	-0.19	-0.12	Vein graft stenosis in coronary artery bypass grafting;	chr16:11318766	chr16:11380859~11381118:-
BRCA	cis	rs6928977	0.86	rs2614264	ENSG00000234084.1	RP3-388E23.2	-3.85	0.000125	0.00762	-0.11	-0.12	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135389556	chr6:135301568~135307158:+
BRCA	cis	rs669446	0.591	rs607062	ENSG00000236200.4	KDM4A-AS1	-3.85	0.000125	0.00762	-0.14	-0.12	Amyotrophic lateral sclerosis (age of onset);	chr1:43667345	chr1:43699765~43708138:-
BRCA	cis	rs8030605	0.778	rs11638076	ENSG00000277245.1	RP11-48G14.3	3.85	0.000125	0.00762	0.25	0.12	Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;	chr15:56402219	chr15:56447120~56447697:+
BRCA	cis	rs4819052	1	rs9984901	ENSG00000184274.3	LINC00315	-3.85	0.000125	0.00762	-0.17	-0.12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244037	chr21:45300245~45305257:-
BRCA	cis	rs1555322	1	rs2425040	ENSG00000269202.1	RP4-614O4.12	-3.85	0.000125	0.00762	-0.17	-0.12	Attention deficit hyperactivity disorder;	chr20:35271075	chr20:35201747~35203288:-
BRCA	cis	rs7131987	0.903	rs2194519	ENSG00000273680.1	RP11-996F15.6	-3.85	0.000125	0.00762	-0.15	-0.12	QT interval;	chr12:29270650	chr12:29332733~29333383:-
BRCA	cis	rs9420	0.528	rs11229077	ENSG00000265566.2	RN7SL605P	3.85	0.000125	0.00762	0.16	0.12	Schizophrenia;	chr11:57631599	chr11:57528085~57528365:-
BRCA	cis	rs17684571	0.751	rs35080938	ENSG00000231441.1	RP11-472M19.2	3.85	0.000125	0.00762	0.2	0.12	Schizophrenia;	chr6:56847992	chr6:56844002~56864078:+
BRCA	cis	rs6963495	0.818	rs73192122	ENSG00000223886.3	RP11-251G23.2	3.85	0.000125	0.00762	0.19	0.12	Bipolar disorder (body mass index interaction);	chr7:105531024	chr7:105530209~105530671:+
BRCA	cis	rs6963495	0.818	rs73192124	ENSG00000223886.3	RP11-251G23.2	3.85	0.000125	0.00762	0.19	0.12	Bipolar disorder (body mass index interaction);	chr7:105531081	chr7:105530209~105530671:+
BRCA	cis	rs3764021	0.527	rs12227655	ENSG00000278635.1	CTD-2318O12.1	-3.85	0.000125	0.00763	-0.13	-0.12	Type 1 diabetes;	chr12:9715652	chr12:9415641~9416718:+
BRCA	cis	rs3764021	0.506	rs12228641	ENSG00000278635.1	CTD-2318O12.1	-3.85	0.000125	0.00763	-0.13	-0.12	Type 1 diabetes;	chr12:9715680	chr12:9415641~9416718:+
BRCA	cis	rs2921036	0.529	rs2979192	ENSG00000233609.3	RP11-62H7.2	3.85	0.000125	0.00763	0.12	0.12	Neuroticism;	chr8:8480637	chr8:8961200~8979025:+
BRCA	cis	rs10487112	0.87	rs11762855	ENSG00000235436.9	DPY19L2P4	-3.85	0.000126	0.00763	-0.13	-0.12	Perceived unattractiveness to mosquitoes;	chr7:90489470	chr7:90119400~90125600:+
BRCA	cis	rs2115630	1	rs2115630	ENSG00000275120.1	RP11-182J1.17	-3.85	0.000126	0.00763	-0.14	-0.12	P wave terminal force;	chr15:84821285	chr15:84599434~84606463:-
BRCA	cis	rs10043228	0.702	rs10051697	ENSG00000271918.1	CTD-2287O16.5	-3.85	0.000126	0.00763	-0.15	-0.12	Asthma or chronic obstructive pulmonary disease;	chr5:116142873	chr5:116083807~116085416:-
BRCA	cis	rs1971762	0.527	rs6580952	ENSG00000270175.1	RP11-793H13.11	-3.85	0.000126	0.00763	-0.1	-0.12	Height;	chr12:53543668	chr12:53500162~53500936:-
BRCA	cis	rs6991838	0.584	rs7835313	ENSG00000272155.1	RP11-707M3.3	-3.85	0.000126	0.00763	-0.11	-0.12	Intelligence (multi-trait analysis);	chr8:65633891	chr8:65714334~65714778:-
BRCA	cis	rs962856	0.964	rs6546303	ENSG00000236605.1	AC023115.4	3.85	0.000126	0.00763	0.14	0.12	Pancreatic cancer;	chr2:67385986	chr2:67324627~67325304:+
BRCA	cis	rs12612435	0.91	rs6714824	ENSG00000226806.1	AC011893.3	3.85	0.000126	0.00763	0.14	0.12	Takotsubo syndrome;	chr2:136361226	chr2:135820191~135823087:+
BRCA	cis	rs3096299	0.658	rs4291902	ENSG00000261118.1	RP11-104N10.1	3.85	0.000126	0.00763	0.12	0.12	Multiple myeloma (IgH translocation);	chr16:89493907	chr16:89492017~89504460:-
BRCA	cis	rs853679	0.517	rs17711344	ENSG00000226314.6	ZNF192P1	3.85	0.000126	0.00763	0.18	0.12	Depression;	chr6:28109824	chr6:28161781~28169594:+
BRCA	cis	rs2749592	0.55	rs7081464	ENSG00000099251.13	HSD17B7P2	-3.85	0.000126	0.00763	-0.13	-0.12	Age-related hearing impairment (SNP x SNP interaction);	chr10:37595009	chr10:38356380~38378505:+
BRCA	cis	rs13217239	0.646	rs7451149	ENSG00000124549.13	BTN2A3P	-3.85	0.000126	0.00763	-0.12	-0.12	Schizophrenia;	chr6:27089739	chr6:26421391~26432383:+
BRCA	cis	rs9402743	0.632	rs6570029	ENSG00000231028.7	LINC00271	-3.85	0.000126	0.00764	-0.12	-0.12	Systemic lupus erythematosus;	chr6:135757894	chr6:135497801~135716055:+
BRCA	cis	rs9402743	0.632	rs4896173	ENSG00000231028.7	LINC00271	-3.85	0.000126	0.00764	-0.12	-0.12	Systemic lupus erythematosus;	chr6:135762413	chr6:135497801~135716055:+
BRCA	cis	rs9402743	0.632	rs4896174	ENSG00000231028.7	LINC00271	-3.85	0.000126	0.00764	-0.12	-0.12	Systemic lupus erythematosus;	chr6:135762421	chr6:135497801~135716055:+
BRCA	cis	rs9402743	0.632	rs4896175	ENSG00000231028.7	LINC00271	-3.85	0.000126	0.00764	-0.12	-0.12	Systemic lupus erythematosus;	chr6:135762568	chr6:135497801~135716055:+
BRCA	cis	rs4664293	0.669	rs13389096	ENSG00000226266.5	AC009961.3	-3.85	0.000126	0.00764	-0.14	-0.12	Monocyte percentage of white cells;	chr2:159611246	chr2:159670708~159712435:-
BRCA	cis	rs4664293	0.609	rs12470879	ENSG00000226266.5	AC009961.3	-3.85	0.000126	0.00764	-0.14	-0.12	Monocyte percentage of white cells;	chr2:159612116	chr2:159670708~159712435:-
BRCA	cis	rs6545883	0.831	rs9309336	ENSG00000270820.4	RP11-355B11.2	3.85	0.000126	0.00764	0.14	0.12	Tuberculosis;	chr2:61536030	chr2:61471188~61484130:+
BRCA	cis	rs4664293	0.609	rs357033	ENSG00000224152.1	AC009506.1	-3.85	0.000126	0.00764	-0.13	-0.12	Monocyte percentage of white cells;	chr2:159637962	chr2:159615296~159617082:+
BRCA	cis	rs4478858	0.684	rs4949372	ENSG00000260386.4	LINC01225	-3.85	0.000126	0.00764	-0.14	-0.12	Alcohol dependence;	chr1:31266010	chr1:31500085~31540885:+
BRCA	cis	rs77633900	0.772	rs283796	ENSG00000196274.5	Metazoa_SRP	3.85	0.000126	0.00764	0.21	0.12	Glioma;Non-glioblastoma glioma;	chr15:76481764	chr15:76230048~76230390:-
BRCA	cis	rs78587638	0.793	rs77519193	ENSG00000226856.4	AC093901.1	-3.85	0.000126	0.00764	-0.18	-0.12	Mosquito bite size;	chr2:118409776	chr2:118132128~118186386:-
BRCA	cis	rs4700393	0.52	rs6896680	ENSG00000272308.1	RP11-231G3.1	-3.85	0.000126	0.00764	-0.15	-0.12	Intelligence (multi-trait analysis);	chr5:60695704	chr5:60866457~60866935:-
BRCA	cis	rs7568498	1	rs10164593	ENSG00000227403.1	AC009299.3	3.85	0.000126	0.00764	0.21	0.12	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);	chr2:161125461	chr2:161244739~161249050:+
BRCA	cis	rs957448	1	rs28817653	ENSG00000261437.1	RP11-22C11.2	3.85	0.000126	0.00765	0.12	0.12	Nonsyndromic cleft lip with cleft palate;	chr8:94557822	chr8:94637285~94639467:-
BRCA	cis	rs2274273	0.564	rs3783649	ENSG00000259318.1	RP11-454L9.2	3.85	0.000126	0.00765	0.11	0.12	Protein biomarker;	chr14:55367692	chr14:55394940~55395233:-
BRCA	cis	rs4950322	0.58	rs1813002	ENSG00000227242.3	NBPF13P	-3.85	0.000126	0.00765	-0.16	-0.12	Protein quantitative trait loci;	chr1:147112579	chr1:147021320~147124525:-
BRCA	cis	rs9733	0.566	rs11204675	ENSG00000203804.4	ADAMTSL4-AS1	-3.85	0.000126	0.00765	-0.12	-0.12	Tonsillectomy;	chr1:150598509	chr1:150560202~150574552:-
BRCA	cis	rs875971	0.597	rs11763224	ENSG00000232559.3	GS1-124K5.12	3.85	0.000126	0.00765	0.16	0.12	Aortic root size;	chr7:66518628	chr7:66554588~66576923:-
BRCA	cis	rs442309	0.875	rs224065	ENSG00000238280.1	RP11-436D10.3	-3.85	0.000126	0.00765	-0.15	-0.12	Vogt-Koyanagi-Harada syndrome;	chr10:62745688	chr10:62793562~62805887:-
BRCA	cis	rs889956	0.691	rs55966827	ENSG00000233251.6	AC007743.1	-3.85	0.000126	0.00765	-0.14	-0.12	Educational attainment;	chr2:57133718	chr2:56173534~56185770:-
BRCA	cis	rs7474896	0.616	rs1985260	ENSG00000263064.2	RP11-291L22.7	3.85	0.000126	0.00765	0.19	0.12	Obesity (extreme);	chr10:38145162	chr10:38448689~38448949:+
BRCA	cis	rs8114671	0.967	rs1415774	ENSG00000279253.1	RP4-614O4.13	3.85	0.000126	0.00765	0.14	0.12	Height;	chr20:35177813	chr20:35262727~35264187:-
BRCA	cis	rs11711311	0.712	rs3773683	ENSG00000241529.3	RN7SL767P	-3.85	0.000126	0.00765	-0.14	-0.12	IgG glycosylation;	chr3:113622160	chr3:113632704~113632998:+
BRCA	cis	rs17597773	1	rs17597773	ENSG00000238078.1	LINC01352	-3.85	0.000126	0.00765	-0.14	-0.12	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220881419	chr1:220829255~220832429:+
BRCA	cis	rs801193	0.569	rs11772819	ENSG00000229886.1	RP5-1132H15.3	3.85	0.000126	0.00765	0.13	0.12	Aortic root size;	chr7:66752983	chr7:66025126~66031544:-
BRCA	cis	rs801193	0.569	rs7800620	ENSG00000229886.1	RP5-1132H15.3	3.85	0.000126	0.00765	0.13	0.12	Aortic root size;	chr7:66758701	chr7:66025126~66031544:-
BRCA	cis	rs4819052	0.885	rs28576202	ENSG00000215447.6	BX322557.10	-3.85	0.000126	0.00765	-0.12	-0.12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45254769	chr21:45288052~45291738:+
BRCA	cis	rs687432	0.885	rs67305834	ENSG00000265566.2	RN7SL605P	-3.85	0.000126	0.00765	-0.17	-0.12	Parkinson's disease;	chr11:58063978	chr11:57528085~57528365:-
BRCA	cis	rs2302465	0.86	rs56094420	ENSG00000273133.1	RP11-799M12.2	-3.85	0.000126	0.00765	-0.24	-0.12	Blood protein levels;	chr4:15584124	chr4:15563698~15564253:-
BRCA	cis	rs6142618	0.562	rs6061197	ENSG00000275576.1	RP5-836N17.4	-3.85	0.000126	0.00765	-0.13	-0.12	Inflammatory bowel disease;	chr20:32162543	chr20:32116171~32116629:+
BRCA	cis	rs6142618	0.562	rs6061198	ENSG00000275576.1	RP5-836N17.4	-3.85	0.000126	0.00765	-0.13	-0.12	Inflammatory bowel disease;	chr20:32162661	chr20:32116171~32116629:+
BRCA	cis	rs12744310	0.502	rs12045676	ENSG00000235358.1	RP11-399E6.1	3.85	0.000126	0.00765	0.15	0.12	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41342591	chr1:41242373~41284861:+
BRCA	cis	rs12744310	0.502	rs12044881	ENSG00000235358.1	RP11-399E6.1	3.85	0.000126	0.00765	0.15	0.12	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41342598	chr1:41242373~41284861:+
BRCA	cis	rs9470794	0.85	rs11752799	ENSG00000204110.6	RP1-153P14.8	3.85	0.000126	0.00765	0.18	0.12	Type 2 diabetes;	chr6:38165254	chr6:37507348~37535616:+
BRCA	cis	rs1953600	0.87	rs2573353	ENSG00000226659.1	RP11-137H2.4	-3.85	0.000126	0.00765	-0.16	-0.12	Sarcoidosis;	chr10:80181161	chr10:80529597~80535942:-
BRCA	cis	rs9650657	0.737	rs4841436	ENSG00000154316.13	TDH	-3.85	0.000126	0.00766	-0.15	-0.12	Neuroticism;	chr8:10736964	chr8:11339637~11368452:+
BRCA	cis	rs9425766	0.64	rs2067079	ENSG00000200674.1	RN7SKP160	3.85	0.000126	0.00766	0.19	0.12	Life satisfaction;	chr1:173866073	chr1:173791548~173791887:+
BRCA	cis	rs62103177	0.525	rs10438902	ENSG00000267270.4	PARD6G-AS1	-3.85	0.000126	0.00766	-0.18	-0.12	Opioid sensitivity;	chr18:79985640	chr18:80147924~80178432:+
BRCA	cis	rs11098499	0.722	rs7673476	ENSG00000225892.3	RP11-384K6.2	3.85	0.000126	0.00766	0.11	0.12	Corneal astigmatism;	chr4:119327528	chr4:118632274~118634759:+
BRCA	cis	rs757081	0.738	rs1073443	ENSG00000184669.7	OR7E14P	-3.85	0.000126	0.00766	-0.18	-0.12	Systolic blood pressure;	chr11:17328847	chr11:17013998~17053024:+
BRCA	cis	rs11083475	1	rs3786851	ENSG00000267892.1	CTD-2540F13.2	3.85	0.000126	0.00766	0.13	0.12	Heart rate;	chr19:38724693	chr19:38738284~38739863:+
BRCA	cis	rs11098499	0.738	rs28408407	ENSG00000225892.3	RP11-384K6.2	3.85	0.000126	0.00766	0.12	0.12	Corneal astigmatism;	chr4:119454875	chr4:118632274~118634759:+
BRCA	cis	rs7577696	0.688	rs9677104	ENSG00000276334.1	AL133243.1	-3.85	0.000126	0.00766	-0.15	-0.12	Inflammatory biomarkers;	chr2:32110030	chr2:32521927~32523547:+
BRCA	cis	rs6095360	1	rs6095360	ENSG00000222365.1	SNORD12B	-3.85	0.000126	0.00766	-0.13	-0.12	Intelligence (multi-trait analysis);	chr20:48915999	chr20:49280319~49280409:+
BRCA	cis	rs1048886	0.938	rs59698166	ENSG00000271967.1	RP11-134K13.4	-3.85	0.000126	0.00766	-0.17	-0.12	Type 2 diabetes;	chr6:70442273	chr6:70596438~70596980:+
BRCA	cis	rs6088590	0.707	rs67159833	ENSG00000276073.1	RP5-1125A11.7	-3.85	0.000126	0.00766	-0.15	-0.12	Coronary artery disease;	chr20:34900276	chr20:33985617~33988989:-
BRCA	cis	rs2041840	1	rs2430494	ENSG00000272054.1	RP11-423P10.2	-3.85	0.000126	0.00767	-0.11	-0.12	Chronic lymphocytic leukemia;	chr2:37236477	chr2:37208875~37212677:+
BRCA	cis	rs4713118	0.662	rs9468274	ENSG00000216901.1	AL022393.7	3.85	0.000126	0.00767	0.17	0.12	Parkinson's disease;	chr6:28058299	chr6:28176188~28176674:+
BRCA	cis	rs4713118	0.662	rs9468275	ENSG00000216901.1	AL022393.7	3.85	0.000126	0.00767	0.17	0.12	Parkinson's disease;	chr6:28058358	chr6:28176188~28176674:+
BRCA	cis	rs4713118	0.662	rs9468276	ENSG00000216901.1	AL022393.7	3.85	0.000126	0.00767	0.17	0.12	Parkinson's disease;	chr6:28059910	chr6:28176188~28176674:+
BRCA	cis	rs4713118	0.662	rs9468277	ENSG00000216901.1	AL022393.7	3.85	0.000126	0.00767	0.17	0.12	Parkinson's disease;	chr6:28060612	chr6:28176188~28176674:+
BRCA	cis	rs4713118	0.662	rs9468278	ENSG00000216901.1	AL022393.7	3.85	0.000126	0.00767	0.17	0.12	Parkinson's disease;	chr6:28060704	chr6:28176188~28176674:+
BRCA	cis	rs4713118	0.662	rs13218430	ENSG00000216901.1	AL022393.7	3.85	0.000126	0.00767	0.17	0.12	Parkinson's disease;	chr6:28062059	chr6:28176188~28176674:+
BRCA	cis	rs6840360	0.837	rs13137669	ENSG00000278978.1	RP11-164P12.5	-3.85	0.000126	0.00767	-0.13	-0.12	Intelligence (multi-trait analysis);	chr4:151789791	chr4:151669786~151670503:+
BRCA	cis	rs11098499	0.874	rs9995277	ENSG00000225892.3	RP11-384K6.2	3.85	0.000126	0.00767	0.13	0.12	Corneal astigmatism;	chr4:119187448	chr4:118632274~118634759:+
BRCA	cis	rs11633886	0.585	rs2460630	ENSG00000273972.1	CTD-2306A12.1	3.85	0.000126	0.00767	0.14	0.12	Diisocyanate-induced asthma;	chr15:45799596	chr15:45702640~45703183:+
BRCA	cis	rs73222236	0.75	rs6439642	ENSG00000239213.4	NCK1-AS1	3.85	0.000126	0.00767	0.13	0.12	Coronary artery disease;	chr3:136473965	chr3:136841726~136862054:-
BRCA	cis	rs73222236	0.857	rs16843991	ENSG00000239213.4	NCK1-AS1	3.85	0.000126	0.00767	0.13	0.12	Coronary artery disease;	chr3:136477186	chr3:136841726~136862054:-
BRCA	cis	rs6439153	0.933	rs810952	ENSG00000242551.2	POU5F1P6	-3.85	0.000126	0.00767	-0.15	-0.12	Pneumococcal bacteremia;	chr3:128967062	chr3:128674735~128677005:-
BRCA	cis	rs6479874	0.736	rs2816836	ENSG00000223502.1	RP11-96B5.3	3.85	0.000126	0.00767	0.21	0.12	Migraine;	chr10:50992613	chr10:51062579~51068553:-
BRCA	cis	rs8026198	0.929	rs2289295	ENSG00000260571.1	BNIP3P5	-3.85	0.000126	0.00767	-0.2	-0.12	Fibrinogen levels;	chr15:42345577	chr15:42313687~42314386:+
BRCA	cis	rs3753275	0.64	rs6577498	ENSG00000232912.4	RP5-1115A15.1	3.85	0.000126	0.00768	0.16	0.12	Educational attainment;	chr1:8548765	chr1:8424645~8434838:+
BRCA	cis	rs4865762	0.687	rs27324	ENSG00000247796.2	CTD-2366F13.1	3.85	0.000126	0.00768	0.13	0.12	Intraocular pressure;	chr5:53254750	chr5:53109842~53115126:+
BRCA	cis	rs55780018	0.614	rs28498124	ENSG00000224137.1	AC079767.4	3.85	0.000126	0.00768	0.1	0.12	Systolic blood pressure;	chr2:207634576	chr2:207662375~207667024:+
BRCA	cis	rs6545883	0.894	rs1186703	ENSG00000212978.6	AC016747.3	3.85	0.000126	0.00768	0.16	0.12	Tuberculosis;	chr2:61445830	chr2:61141592~61144969:-
BRCA	cis	rs9300255	0.722	rs34997336	ENSG00000256028.2	RP11-197N18.2	-3.85	0.000126	0.00768	-0.12	-0.12	Neutrophil percentage of white cells;	chr12:123344569	chr12:122975320~122982907:+
BRCA	cis	rs6592362	0.517	rs4414246	ENSG00000254748.1	HNRNPCP8	-3.85	0.000126	0.00768	-0.16	-0.12	Inflammatory bowel disease;	chr11:87384275	chr11:87024583~87025777:+
BRCA	cis	rs11098499	0.954	rs6838814	ENSG00000225892.3	RP11-384K6.2	3.85	0.000126	0.00768	0.12	0.12	Corneal astigmatism;	chr4:119471288	chr4:118632274~118634759:+
BRCA	cis	rs7772486	0.817	rs2144477	ENSG00000270638.1	RP3-466P17.1	3.85	0.000126	0.00768	0.14	0.12	Lobe attachment (rater-scored or self-reported);	chr6:146085112	chr6:145735570~145737218:+
BRCA	cis	rs7772486	0.875	rs9403768	ENSG00000270638.1	RP3-466P17.1	3.85	0.000126	0.00768	0.14	0.12	Lobe attachment (rater-scored or self-reported);	chr6:146085322	chr6:145735570~145737218:+
BRCA	cis	rs7772486	0.875	rs12194437	ENSG00000270638.1	RP3-466P17.1	3.85	0.000126	0.00768	0.14	0.12	Lobe attachment (rater-scored or self-reported);	chr6:146090304	chr6:145735570~145737218:+
BRCA	cis	rs17092148	0.579	rs7265109	ENSG00000126005.14	MMP24-AS1	-3.85	0.000127	0.00768	-0.16	-0.12	Neuroticism;	chr20:34871551	chr20:35216462~35278131:-
BRCA	cis	rs13401620	0.555	rs1437421	ENSG00000223549.1	MTND5P28	-3.85	0.000127	0.00768	-0.14	-0.12	Breast size;	chr2:120218255	chr2:120215181~120217279:+
BRCA	cis	rs7267979	0.789	rs6083841	ENSG00000274414.1	RP5-965G21.4	3.85	0.000127	0.00768	0.14	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25403928	chr20:25239007~25245229:-
BRCA	cis	rs2692947	0.537	rs11164049	ENSG00000168992.4	OR7E102P	3.85	0.000127	0.00768	0.17	0.12	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95679770	chr2:95546531~95547545:+
BRCA	cis	rs2055011	1	rs1491784	ENSG00000244676.4	AL109761.5	3.85	0.000127	0.00768	0.16	0.12	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs);	chr21:18109346	chr21:17793488~17810845:+
BRCA	cis	rs4374383	0.558	rs7601798	ENSG00000243389.1	AC012442.5	-3.85	0.000127	0.00768	-0.15	-0.12	Hepatitis C induced liver fibrosis;	chr2:111947285	chr2:112589040~112614431:+
BRCA	cis	rs8130944	0.866	rs2839576	ENSG00000225731.1	AP001627.1	3.85	0.000127	0.00768	0.14	0.12	Perceived unattractiveness to mosquitoes;	chr21:42719847	chr21:42733594~42741758:-
BRCA	cis	rs8130944	1	rs7278264	ENSG00000225731.1	AP001627.1	3.85	0.000127	0.00768	0.14	0.12	Perceived unattractiveness to mosquitoes;	chr21:42719931	chr21:42733594~42741758:-
BRCA	cis	rs11098499	0.863	rs3733525	ENSG00000260091.1	RP11-33B1.4	-3.85	0.000127	0.00768	-0.11	-0.12	Corneal astigmatism;	chr4:119525893	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.863	rs3775847	ENSG00000260091.1	RP11-33B1.4	-3.85	0.000127	0.00768	-0.11	-0.12	Corneal astigmatism;	chr4:119526487	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.863	rs3775848	ENSG00000260091.1	RP11-33B1.4	-3.85	0.000127	0.00768	-0.11	-0.12	Corneal astigmatism;	chr4:119526569	chr4:119409333~119410233:+
BRCA	cis	rs13434995	0.513	rs62309729	ENSG00000239040.1	Y_RNA	3.85	0.000127	0.00768	0.14	0.12	Adiponectin levels;	chr4:55536679	chr4:55412636~55412738:+
BRCA	cis	rs61160187	0.582	rs726824	ENSG00000272308.1	RP11-231G3.1	-3.85	0.000127	0.00768	-0.14	-0.12	Educational attainment (years of education);Educational attainment (college completion);	chr5:61036989	chr5:60866457~60866935:-
BRCA	cis	rs2692947	0.537	rs12468117	ENSG00000168992.4	OR7E102P	3.85	0.000127	0.00769	0.17	0.12	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95528835	chr2:95546531~95547545:+
BRCA	cis	rs7267979	1	rs2500436	ENSG00000274414.1	RP5-965G21.4	3.85	0.000127	0.00769	0.14	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25425730	chr20:25239007~25245229:-
BRCA	cis	rs7267979	0.934	rs4815423	ENSG00000277938.1	RP5-965G21.3	-3.85	0.000127	0.00769	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25406885	chr20:25229150~25231933:+
BRCA	cis	rs6012564	1	rs6066977	ENSG00000230758.1	SNAP23P	3.85	0.000127	0.00769	0.14	0.12	Anger;	chr20:49138538	chr20:49038357~49038602:-
BRCA	cis	rs983392	0.792	rs512495	ENSG00000275344.1	MIR6503	-3.85	0.000127	0.00769	-0.12	-0.12	Alzheimer's disease (late onset);	chr11:60108563	chr11:60209071~60209156:-
BRCA	cis	rs10735946	1	rs10748095	ENSG00000255733.4	IFNG-AS1	-3.85	0.000127	0.00769	-0.1	-0.12	Anti-saccade response;	chr12:68089550	chr12:67989445~68234686:+
BRCA	cis	rs1007190	0.881	rs12941832	ENSG00000267405.1	CTC-296K1.4	3.85	0.000127	0.00769	0.21	0.12	DNA methylation (variation);	chr17:44910114	chr17:44794747~44797783:-
BRCA	cis	rs4908769	0.624	rs301790	ENSG00000232912.4	RP5-1115A15.1	3.85	0.000127	0.00769	0.13	0.12	Allergy;	chr1:8409224	chr1:8424645~8434838:+
BRCA	cis	rs11673344	0.542	rs826331	ENSG00000276846.1	CTD-3220F14.3	3.85	0.000127	0.00769	0.14	0.12	Obesity-related traits;	chr19:37007360	chr19:37314868~37315620:-
BRCA	cis	rs5742933	1	rs12622902	ENSG00000253559.1	OSGEPL1-AS1	-3.85	0.000127	0.00769	-0.16	-0.12	Ferritin levels;	chr2:189776263	chr2:189762704~189765556:+
BRCA	cis	rs4388249	0.904	rs71575306	ENSG00000271849.1	CTC-332L22.1	-3.85	0.000127	0.00769	-0.19	-0.12	Schizophrenia;	chr5:109710509	chr5:109687802~109688329:-
BRCA	cis	rs35520189	0.754	rs13013349	ENSG00000189223.12	PAX8-AS1	3.85	0.000127	0.00769	0.17	0.12	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:112842749	chr2:113211522~113276581:+
BRCA	cis	rs372883	0.901	rs8133749	ENSG00000176054.6	RPL23P2	-3.85	0.000127	0.00769	-0.12	-0.12	Pancreatic cancer;	chr21:29243614	chr21:28997613~28998033:-
BRCA	cis	rs1032833	0.732	rs112452546	ENSG00000271401.1	RP11-171I2.3	-3.85	0.000127	0.00769	-0.3	-0.12	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);	chr2:179093954	chr2:178644717~178645179:+
BRCA	cis	rs1032833	0.732	rs80238877	ENSG00000271401.1	RP11-171I2.3	-3.85	0.000127	0.00769	-0.3	-0.12	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);	chr2:179094986	chr2:178644717~178645179:+
BRCA	cis	rs1032833	0.732	rs75929971	ENSG00000271401.1	RP11-171I2.3	-3.85	0.000127	0.00769	-0.3	-0.12	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);	chr2:179095111	chr2:178644717~178645179:+
BRCA	cis	rs1032833	0.732	rs74367571	ENSG00000271401.1	RP11-171I2.3	-3.85	0.000127	0.00769	-0.3	-0.12	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);	chr2:179095163	chr2:178644717~178645179:+
BRCA	cis	rs1032833	0.732	rs4101465	ENSG00000271401.1	RP11-171I2.3	-3.85	0.000127	0.00769	-0.3	-0.12	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);	chr2:179095823	chr2:178644717~178645179:+
BRCA	cis	rs875971	0.66	rs801193	ENSG00000265600.1	AC006480.1	3.85	0.000127	0.00769	0.14	0.12	Aortic root size;	chr7:66565625	chr7:67356680~67356779:+
BRCA	cis	rs860295	0.58	rs867549	ENSG00000225082.2	DAP3P1	-3.85	0.000127	0.0077	-0.15	-0.12	Body mass index;	chr1:155910368	chr1:155586644~155602197:+
BRCA	cis	rs7246657	0.551	rs4806414	ENSG00000267470.4	ZNF571-AS1	3.85	0.000127	0.0077	0.18	0.12	Coronary artery calcification;	chr19:37147886	chr19:37548914~37587348:+
BRCA	cis	rs875971	0.862	rs6460290	ENSG00000273024.4	INTS4P2	3.85	0.000127	0.0077	0.13	0.12	Aortic root size;	chr7:66344119	chr7:65647864~65715661:+
BRCA	cis	rs4478858	0.735	rs7523438	ENSG00000260386.4	LINC01225	3.85	0.000127	0.0077	0.14	0.12	Alcohol dependence;	chr1:31315466	chr1:31500085~31540885:+
BRCA	cis	rs2262909	0.925	rs73019838	ENSG00000279377.1	AC003973.3	-3.85	0.000127	0.0077	-0.17	-0.12	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;	chr19:22064930	chr19:21965708~21968529:-
BRCA	cis	rs1949733	1	rs3103072	ENSG00000251615.3	RP11-774O3.3	3.85	0.000127	0.0077	0.13	0.12	Response to antineoplastic agents;	chr4:8506704	chr4:8355090~8358338:-
BRCA	cis	rs11992186	0.505	rs7845203	ENSG00000233609.3	RP11-62H7.2	3.85	0.000127	0.0077	0.11	0.12	Neuroticism;	chr8:8287918	chr8:8961200~8979025:+
BRCA	cis	rs2408955	0.568	rs12099462	ENSG00000226413.2	OR8T1P	-3.85	0.000127	0.0077	-0.16	-0.12	Glycated hemoglobin levels;	chr12:48109321	chr12:48442030~48442947:-
BRCA	cis	rs2486012	0.737	rs2906465	ENSG00000237950.1	RP11-7O11.3	3.85	0.000127	0.0077	0.22	0.12	Intelligence (multi-trait analysis);	chr1:43858064	chr1:43944370~43946551:-
BRCA	cis	rs2486012	1	rs3011226	ENSG00000237950.1	RP11-7O11.3	3.85	0.000127	0.0077	0.22	0.12	Intelligence (multi-trait analysis);	chr1:43858388	chr1:43944370~43946551:-
BRCA	cis	rs4243971	0.516	rs4911088	ENSG00000275576.1	RP5-836N17.4	-3.85	0.000127	0.0077	-0.13	-0.12	Inflammatory bowel disease;Crohn's disease;	chr20:32273988	chr20:32116171~32116629:+
BRCA	cis	rs9467773	0.587	rs9467722	ENSG00000124549.13	BTN2A3P	-3.85	0.000127	0.0077	-0.12	-0.12	Intelligence (multi-trait analysis);	chr6:26352338	chr6:26421391~26432383:+
BRCA	cis	rs7221109	0.677	rs8068721	ENSG00000224244.1	AC090283.3	3.85	0.000127	0.00771	0.13	0.12	Type 1 diabetes;	chr17:40657572	chr17:40687038~40689360:-
BRCA	cis	rs897984	0.52	rs4889534	ENSG00000260082.1	RP11-2C24.5	-3.85	0.000127	0.00771	-0.14	-0.12	Dementia with Lewy bodies;	chr16:30854119	chr16:30821068~30822110:-
BRCA	cis	rs2562456	0.833	rs2562507	ENSG00000213976.4	CTD-2561J22.2	3.85	0.000127	0.00771	0.14	0.12	Pain;	chr19:21543535	chr19:21382865~21387177:+
BRCA	cis	rs4699052	0.59	rs2138593	ENSG00000248740.4	RP11-328K4.1	3.85	0.000127	0.00771	0.13	0.12	Testicular germ cell tumor;	chr4:103317564	chr4:103256159~103453658:+
BRCA	cis	rs38055	0.881	rs384866	ENSG00000247796.2	CTD-2366F13.1	-3.85	0.000127	0.00771	-0.14	-0.12	Acne (severe);	chr5:53317694	chr5:53109842~53115126:+
BRCA	cis	rs7177699	0.557	rs55870734	ENSG00000261143.1	ADAMTS7P3	3.85	0.000127	0.00771	0.14	0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78825575	chr15:77976042~77993057:+
BRCA	cis	rs73222236	0.75	rs35375192	ENSG00000239213.4	NCK1-AS1	3.85	0.000127	0.00771	0.13	0.12	Coronary artery disease;	chr3:136456683	chr3:136841726~136862054:-
BRCA	cis	rs721917	0.586	rs2758550	ENSG00000225484.5	NUTM2B-AS1	-3.85	0.000127	0.00771	-0.16	-0.12	Chronic obstructive pulmonary disease;	chr10:79932606	chr10:79663088~79826594:-
BRCA	cis	rs73222236	0.787	rs34379561	ENSG00000239213.4	NCK1-AS1	3.85	0.000127	0.00771	0.13	0.12	Coronary artery disease;	chr3:136464374	chr3:136841726~136862054:-
BRCA	cis	rs42490	0.528	rs10956209	ENSG00000251136.7	RP11-37B2.1	3.85	0.000127	0.00771	0.11	0.12	Leprosy;	chr8:89670923	chr8:89609409~89757727:-
BRCA	cis	rs853679	0.546	rs200948	ENSG00000241549.7	GUSBP2	3.85	0.000127	0.00772	0.21	0.12	Depression;	chr6:27867494	chr6:26871484~26956554:-
BRCA	cis	rs853679	0.546	rs200950	ENSG00000241549.7	GUSBP2	3.85	0.000127	0.00772	0.21	0.12	Depression;	chr6:27867994	chr6:26871484~26956554:-
BRCA	cis	rs7267979	0.966	rs6037083	ENSG00000274973.1	RP13-401N8.7	3.85	0.000127	0.00772	0.13	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25309907	chr20:25845497~25845862:+
BRCA	cis	rs6049003	0.668	rs6114234	ENSG00000232645.4	LINC01431	3.85	0.000127	0.00772	0.13	0.12	Cerebrospinal fluid biomarker levels;	chr20:23712088	chr20:23356594~23358116:-
BRCA	cis	rs1008375	0.9	rs10019460	ENSG00000249502.1	AC006160.5	3.85	0.000127	0.00772	0.14	0.12	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17684714	chr4:17587467~17614571:-
BRCA	cis	rs17772222	0.958	rs60878614	ENSG00000258789.1	RP11-507K2.3	-3.85	0.000127	0.00772	-0.14	-0.12	Coronary artery calcification;	chr14:88513871	chr14:88551597~88552493:+
BRCA	cis	rs72765298	0.806	rs16927927	ENSG00000232630.1	PRPS1P2	3.85	0.000127	0.00772	0.16	0.12	Pulse pressure;	chr9:125181059	chr9:125150653~125151589:+
BRCA	cis	rs4648045	0.624	rs1609798	ENSG00000251288.2	RP11-10L12.2	-3.85	0.000127	0.00772	-0.16	-0.12	Lymphocyte percentage of white cells;	chr4:102616285	chr4:102751401~102752641:+
BRCA	cis	rs718433	0.584	rs7158042	ENSG00000211778.2	TRAV4	3.85	0.000127	0.00772	0.08	0.12	Intraocular pressure;	chr14:21752794	chr14:21736152~21736982:+
BRCA	cis	rs4474465	1	rs7933612	ENSG00000251323.2	RP11-452H21.4	-3.85	0.000127	0.00772	-0.15	-0.12	Alzheimer's disease (survival time);	chr11:78498320	chr11:78423982~78429836:-
BRCA	cis	rs6088580	0.634	rs6088475	ENSG00000275784.1	RP5-1125A11.6	3.85	0.000127	0.00773	0.13	0.12	Glomerular filtration rate (creatinine);	chr20:34377181	chr20:33989480~33991818:-
BRCA	cis	rs6545883	0.965	rs1562308	ENSG00000270820.4	RP11-355B11.2	3.85	0.000127	0.00773	0.14	0.12	Tuberculosis;	chr2:61541286	chr2:61471188~61484130:+
BRCA	cis	rs10487112	0.87	rs2188517	ENSG00000235436.9	DPY19L2P4	-3.85	0.000127	0.00773	-0.13	-0.12	Perceived unattractiveness to mosquitoes;	chr7:90478964	chr7:90119400~90125600:+
BRCA	cis	rs10958369	0.541	rs1477956	ENSG00000253369.1	RP11-1081M5.1	3.85	0.000127	0.00773	0.15	0.12	Response to antineoplastic agents;	chr8:53522667	chr8:53395211~53395946:-
BRCA	cis	rs6964587	1	rs9784993	ENSG00000188693.7	CYP51A1-AS1	-3.85	0.000127	0.00773	-0.13	-0.12	Breast cancer;	chr7:92043089	chr7:92134604~92180725:+
BRCA	cis	rs7312933	0.703	rs7957471	ENSG00000257225.1	RP11-328C8.4	-3.85	0.000127	0.00773	-0.14	-0.12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42151789	chr12:42459366~42466128:+
BRCA	cis	rs80033912	0.64	rs6785832	ENSG00000225399.4	RP11-3B7.1	3.85	0.000127	0.00773	0.12	0.12	Intelligence (multi-trait analysis);	chr3:49186883	chr3:49260085~49261316:+
BRCA	cis	rs3892630	0.588	rs7260037	ENSG00000267475.1	CTD-2538C1.2	-3.85	0.000127	0.00773	-0.17	-0.12	Red blood cell traits;	chr19:32751795	chr19:32687089~32691750:-
BRCA	cis	rs3892630	0.588	rs7245709	ENSG00000267475.1	CTD-2538C1.2	-3.85	0.000127	0.00773	-0.17	-0.12	Red blood cell traits;	chr19:32751849	chr19:32687089~32691750:-
BRCA	cis	rs2320614	1	rs66609411	ENSG00000250027.1	RP11-563E2.2	-3.85	0.000127	0.00773	-0.13	-0.12	Lung adenocarcinoma;	chr4:163130689	chr4:163108785~163119965:+
BRCA	cis	rs13126694	0.574	rs10002472	ENSG00000248429.4	RP11-597D13.9	3.85	0.000127	0.00773	0.11	0.12	Blood osmolality (transformed sodium);	chr4:157946821	chr4:158170752~158202877:+
BRCA	cis	rs801193	0.742	rs9969300	ENSG00000273142.1	RP11-458F8.4	3.85	0.000127	0.00773	0.1	0.12	Aortic root size;	chr7:66316659	chr7:66902857~66906297:+
BRCA	cis	rs1635	0.655	rs16893973	ENSG00000216901.1	AL022393.7	3.85	0.000127	0.00773	0.28	0.12	Schizophrenia;	chr6:28334336	chr6:28176188~28176674:+
BRCA	cis	rs6964587	1	rs7797834	ENSG00000188693.7	CYP51A1-AS1	3.85	0.000127	0.00773	0.13	0.12	Breast cancer;	chr7:92113836	chr7:92134604~92180725:+
BRCA	cis	rs7620503	0.959	rs937509	ENSG00000228561.2	RP11-114M1.1	3.85	0.000127	0.00773	0.14	0.12	Corneal structure;	chr3:177569913	chr3:177683627~177691250:+
BRCA	cis	rs7620503	0.959	rs2055366	ENSG00000228561.2	RP11-114M1.1	3.85	0.000127	0.00773	0.14	0.12	Corneal structure;	chr3:177572557	chr3:177683627~177691250:+
BRCA	cis	rs6547741	0.874	rs28381983	ENSG00000234072.1	AC074117.10	3.85	0.000127	0.00773	0.11	0.12	Oral cavity cancer;	chr2:27581565	chr2:27356246~27367622:+
BRCA	cis	rs875971	0.545	rs73376401	ENSG00000232559.3	GS1-124K5.12	3.85	0.000128	0.00773	0.16	0.12	Aortic root size;	chr7:66174841	chr7:66554588~66576923:-
BRCA	cis	rs524281	0.773	rs11227413	ENSG00000255557.1	RP11-770G2.2	3.85	0.000128	0.00773	0.16	0.12	Electroencephalogram traits;	chr11:66116225	chr11:65745729~65771585:+
BRCA	cis	rs9300255	0.722	rs12322888	ENSG00000256028.2	RP11-197N18.2	3.85	0.000128	0.00773	0.12	0.12	Neutrophil percentage of white cells;	chr12:123341012	chr12:122975320~122982907:+
BRCA	cis	rs2274273	0.588	rs7158791	ENSG00000259318.1	RP11-454L9.2	3.85	0.000128	0.00773	0.11	0.12	Protein biomarker;	chr14:55361889	chr14:55394940~55395233:-
BRCA	cis	rs875971	0.638	rs7793569	ENSG00000273142.1	RP11-458F8.4	3.85	0.000128	0.00774	0.1	0.12	Aortic root size;	chr7:66651646	chr7:66902857~66906297:+
BRCA	cis	rs801193	1	rs3857688	ENSG00000273142.1	RP11-458F8.4	3.85	0.000128	0.00774	0.1	0.12	Aortic root size;	chr7:66662819	chr7:66902857~66906297:+
BRCA	cis	rs801193	1	rs2286684	ENSG00000273142.1	RP11-458F8.4	3.85	0.000128	0.00774	0.1	0.12	Aortic root size;	chr7:66664843	chr7:66902857~66906297:+
BRCA	cis	rs801193	0.935	rs2286683	ENSG00000273142.1	RP11-458F8.4	3.85	0.000128	0.00774	0.1	0.12	Aortic root size;	chr7:66664856	chr7:66902857~66906297:+
BRCA	cis	rs801193	1	rs10274773	ENSG00000273142.1	RP11-458F8.4	3.85	0.000128	0.00774	0.1	0.12	Aortic root size;	chr7:66668591	chr7:66902857~66906297:+
BRCA	cis	rs4415084	0.966	rs16901937	ENSG00000248779.1	RP11-53O19.2	3.85	0.000128	0.00774	0.11	0.12	Breast cancer;	chr5:44709039	chr5:44752949~44765744:+
BRCA	cis	rs12681366	0.708	rs2470718	ENSG00000253704.1	RP11-267M23.4	-3.85	0.000128	0.00774	-0.12	-0.12	Nonsyndromic cleft lip with cleft palate;	chr8:94346849	chr8:94553722~94569745:+
BRCA	cis	rs7682431	0.513	rs2869967	ENSG00000270720.1	RP11-84C13.2	3.85	0.000128	0.00774	0.13	0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr4:88948181	chr4:89119284~89119871:+
BRCA	cis	rs2518049	0.904	rs11252922	ENSG00000224034.1	RP11-445P17.8	3.85	0.000128	0.00774	0.22	0.12	Metabolic traits;	chr10:5078522	chr10:5266033~5271236:-
BRCA	cis	rs2018683	1	rs2018683	ENSG00000233517.1	AC005162.5	-3.85	0.000128	0.00774	-0.14	-0.12	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28974579	chr7:28987028~28988899:+
BRCA	cis	rs853679	0.55	rs34477097	ENSG00000261839.1	RP1-265C24.8	3.85	0.000128	0.00774	0.16	0.12	Depression;	chr6:28229408	chr6:28136849~28139678:+
BRCA	cis	rs7781557	0.696	rs55849741	ENSG00000239969.4	RP11-163E9.2	-3.85	0.000128	0.00774	-0.19	-0.12	Colorectal adenoma (advanced);	chr7:102943622	chr7:102364162~102380633:+
BRCA	cis	rs7267979	1	rs6050573	ENSG00000274414.1	RP5-965G21.4	-3.85	0.000128	0.00774	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25385429	chr20:25239007~25245229:-
BRCA	cis	rs4819052	0.851	rs35871601	ENSG00000215447.6	BX322557.10	-3.85	0.000128	0.00774	-0.12	-0.12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45255299	chr21:45288052~45291738:+
BRCA	cis	rs9381040	0.655	rs2268193	ENSG00000161912.16	ADCY10P1	3.85	0.000128	0.00774	0.13	0.12	Alzheimer's disease (late onset);	chr6:41056886	chr6:41101022~41140835:+
BRCA	cis	rs9381040	0.655	rs2268192	ENSG00000161912.16	ADCY10P1	3.85	0.000128	0.00774	0.13	0.12	Alzheimer's disease (late onset);	chr6:41056887	chr6:41101022~41140835:+
BRCA	cis	rs7896471	0.546	rs74780217	ENSG00000227695.4	DNMBP-AS1	-3.85	0.000128	0.00774	-0.27	-0.12	Blood protein levels;	chr10:99981103	chr10:99927010~99958381:+
BRCA	cis	rs4449834	0.851	rs10957161	ENSG00000254432.1	RP11-33I11.2	-3.85	0.000128	0.00774	-0.16	-0.12	Sum eosinophil basophil counts;	chr8:60802108	chr8:60808735~60809606:-
BRCA	cis	rs4449834	0.851	rs11988338	ENSG00000254432.1	RP11-33I11.2	-3.85	0.000128	0.00774	-0.16	-0.12	Sum eosinophil basophil counts;	chr8:60804175	chr8:60808735~60809606:-
BRCA	cis	rs9952980	0.671	rs55653446	ENSG00000266968.2	RP11-116O18.1	-3.85	0.000128	0.00774	-0.15	-0.12	Breast cancer;	chr18:45328301	chr18:45646153~45647937:+
BRCA	cis	rs9733	0.596	rs12077833	ENSG00000231073.1	RP11-316M1.3	3.85	0.000128	0.00775	0.12	0.12	Tonsillectomy;	chr1:150701857	chr1:150973123~150975534:+
BRCA	cis	rs1371614	0.632	rs6707735	ENSG00000229122.1	AGBL5-IT1	3.85	0.000128	0.00775	0.13	0.12	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26943954	chr2:27061038~27061815:+
BRCA	cis	rs739496	0.843	rs10774629	ENSG00000257624.1	RP1-128M12.3	-3.85	0.000128	0.00775	-0.16	-0.12	Platelet count;	chr12:111582410	chr12:112000739~112000985:-
BRCA	cis	rs8007846	0.569	rs11848463	ENSG00000276116.2	FUT8-AS1	3.85	0.000128	0.00775	0.12	0.12	Multiple sclerosis--Brain Glutamate Levels;	chr14:65790576	chr14:65411170~65412690:-
BRCA	cis	rs11168351	0.864	rs10875743	ENSG00000257735.1	RP11-370I10.6	-3.85	0.000128	0.00775	-0.15	-0.12	Bipolar disorder and schizophrenia;	chr12:48104630	chr12:48350945~48442411:+
BRCA	cis	rs2494250	0.727	rs863011	ENSG00000260766.1	RP11-226L15.5	3.85	0.000128	0.00775	0.15	0.12	Select biomarker traits;	chr1:159224382	chr1:160024953~160026794:-
BRCA	cis	rs6012564	0.826	rs34778847	ENSG00000222365.1	SNORD12B	3.85	0.000128	0.00775	0.12	0.12	Anger;	chr20:49121421	chr20:49280319~49280409:+
BRCA	cis	rs853679	0.769	rs7752608	ENSG00000216901.1	AL022393.7	3.85	0.000128	0.00775	0.25	0.12	Depression;	chr6:28333418	chr6:28176188~28176674:+
BRCA	cis	rs6828577	1	rs6828577	ENSG00000281731.1	RP11-384K6.8	-3.85	0.000128	0.00775	-0.14	-0.12	Perioperative myocardial infarction in coronary artery bypass surgery;	chr4:118783346	chr4:118664087~118685341:-
BRCA	cis	rs9309473	0.583	rs6713196	ENSG00000230002.2	ALMS1-IT1	3.84	0.000128	0.00775	0.14	0.12	Metabolite levels;	chr2:73349277	chr2:73456764~73459484:+
BRCA	cis	rs853679	0.546	rs200952	ENSG00000241549.7	GUSBP2	3.84	0.000128	0.00775	0.21	0.12	Depression;	chr6:27869198	chr6:26871484~26956554:-
BRCA	cis	rs7089973	0.966	rs61867966	ENSG00000236799.1	RP11-383C6.2	-3.84	0.000128	0.00775	-0.15	-0.12	Bipolar disorder or attention deficit hyperactivity disorder;	chr10:114824603	chr10:114994657~114996593:+
BRCA	cis	rs11673344	0.504	rs8105065	ENSG00000276846.1	CTD-3220F14.3	3.84	0.000128	0.00775	0.14	0.12	Obesity-related traits;	chr19:37141003	chr19:37314868~37315620:-
BRCA	cis	rs11098499	0.913	rs35271032	ENSG00000260091.1	RP11-33B1.4	-3.84	0.000128	0.00775	-0.11	-0.12	Corneal astigmatism;	chr4:119235504	chr4:119409333~119410233:+
BRCA	cis	rs7615952	0.512	rs4234285	ENSG00000248787.1	RP11-666A20.4	-3.84	0.000128	0.00776	-0.17	-0.12	Blood pressure (smoking interaction);	chr3:125685633	chr3:125908005~125910272:-
BRCA	cis	rs4819052	0.851	rs8131143	ENSG00000215447.6	BX322557.10	3.84	0.000128	0.00776	0.12	0.12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251731	chr21:45288052~45291738:+
BRCA	cis	rs7569084	0.566	rs7584295	ENSG00000281920.1	RP11-418H16.1	3.84	0.000128	0.00776	0.14	0.12	Sum eosinophil basophil counts;	chr2:65353940	chr2:65623272~65628424:+
BRCA	cis	rs934734	0.563	rs11695373	ENSG00000281920.1	RP11-418H16.1	3.84	0.000128	0.00776	0.14	0.12	Rheumatoid arthritis;	chr2:65354066	chr2:65623272~65628424:+
BRCA	cis	rs2842992	0.724	rs15982	ENSG00000251988.1	RNU4ATAC18P	3.84	0.000128	0.00776	0.14	0.12	Age-related macular degeneration (geographic atrophy);	chr6:159778655	chr6:159720415~159720540:-
BRCA	cis	rs1730008	0.683	rs1714521	ENSG00000279311.1	RP11-170K4.2	-3.84	0.000128	0.00776	-0.13	-0.12	Lobe attachment (rater-scored or self-reported);	chr3:158567072	chr3:158869898~158871821:+
BRCA	cis	rs13315871	0.79	rs13066409	ENSG00000272182.1	RP11-802O23.3	3.84	0.000128	0.00776	0.24	0.12	Cholesterol, total;	chr3:58442717	chr3:58428255~58428815:+
BRCA	cis	rs490234	0.812	rs4838284	ENSG00000232630.1	PRPS1P2	-3.84	0.000128	0.00776	-0.12	-0.12	Mean arterial pressure;	chr9:125684086	chr9:125150653~125151589:+
BRCA	cis	rs3742597	0.84	rs10148907	ENSG00000276116.2	FUT8-AS1	3.84	0.000128	0.00776	0.13	0.12	N-glycan levels;	chr14:65366654	chr14:65411170~65412690:-
BRCA	cis	rs4415084	1	rs2013513	ENSG00000248464.1	FGF10-AS1	3.84	0.000128	0.00776	0.13	0.12	Breast cancer;	chr5:44702204	chr5:44388732~44413989:+
BRCA	cis	rs4713118	0.662	rs9380046	ENSG00000216901.1	AL022393.7	3.84	0.000128	0.00776	0.17	0.12	Parkinson's disease;	chr6:28062721	chr6:28176188~28176674:+
BRCA	cis	rs718314	1	rs7132434	ENSG00000256894.1	RP11-283G6.3	-3.84	0.000128	0.00776	-0.13	-0.12	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Renal cell carcinoma;Waist circumference adjusted for body mass index;	chr12:26319629	chr12:26125155~26126617:-
BRCA	cis	rs2562456	0.833	rs2562507	ENSG00000240522.1	RPL7AP10	3.84	0.000128	0.00776	0.13	0.12	Pain;	chr19:21543535	chr19:21149648~21150438:-
BRCA	cis	rs4499344	0.693	rs382416	ENSG00000267475.1	CTD-2538C1.2	-3.84	0.000128	0.00776	-0.16	-0.12	Mean platelet volume;	chr19:32617032	chr19:32687089~32691750:-
BRCA	cis	rs17684571	0.751	rs34866877	ENSG00000231441.1	RP11-472M19.2	3.84	0.000128	0.00776	0.2	0.12	Schizophrenia;	chr6:56829507	chr6:56844002~56864078:+
BRCA	cis	rs853679	0.882	rs9461432	ENSG00000216901.1	AL022393.7	3.84	0.000128	0.00776	0.23	0.12	Depression;	chr6:28119105	chr6:28176188~28176674:+
BRCA	cis	rs35520189	0.885	rs13011562	ENSG00000189223.12	PAX8-AS1	-3.84	0.000128	0.00776	-0.19	-0.12	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:112861321	chr2:113211522~113276581:+
BRCA	cis	rs4415084	1	rs58144701	ENSG00000248779.1	RP11-53O19.2	3.84	0.000128	0.00776	0.11	0.12	Breast cancer;	chr5:44676095	chr5:44752949~44765744:+
BRCA	cis	rs5758511	0.773	rs1894714	ENSG00000231261.1	HMGN2P10	3.84	0.000128	0.00776	0.16	0.12	Birth weight;	chr22:41953130	chr22:41709225~41709489:-
BRCA	cis	rs17684571	0.751	rs6910414	ENSG00000231441.1	RP11-472M19.2	3.84	0.000128	0.00776	0.17	0.12	Schizophrenia;	chr6:56861939	chr6:56844002~56864078:+
BRCA	cis	rs74233809	1	rs12219027	ENSG00000236937.2	PTGES3P4	3.84	0.000128	0.00777	0.25	0.12	Birth weight;	chr10:103051446	chr10:102845595~102845950:+
BRCA	cis	rs34421088	0.532	rs2736258	ENSG00000154316.13	TDH	-3.84	0.000128	0.00777	-0.17	-0.12	Neuroticism;	chr8:11312940	chr8:11339637~11368452:+
BRCA	cis	rs1400816	0.85	rs6433315	ENSG00000228389.1	AC068039.4	3.84	0.000128	0.00777	0.22	0.12	Amyotrophic lateral sclerosis (sporadic);	chr2:171829780	chr2:171773482~171775844:+
BRCA	cis	rs6893300	0.961	rs1469020	ENSG00000250999.1	RP11-1379J22.5	3.84	0.000128	0.00777	0.17	0.12	Resting heart rate;	chr5:179787023	chr5:179657762~179664432:+
BRCA	cis	rs6893300	0.883	rs1469021	ENSG00000250999.1	RP11-1379J22.5	3.84	0.000128	0.00777	0.17	0.12	Resting heart rate;	chr5:179787250	chr5:179657762~179664432:+
BRCA	cis	rs9437689	0.833	rs1265169	ENSG00000235501.4	RP4-639F20.1	3.84	0.000128	0.00777	0.15	0.12	Phospholipid levels (plasma);	chr1:94928979	chr1:94927566~94963270:+
BRCA	cis	rs10487112	0.833	rs12704546	ENSG00000235436.9	DPY19L2P4	-3.84	0.000128	0.00777	-0.13	-0.12	Perceived unattractiveness to mosquitoes;	chr7:90508566	chr7:90119400~90125600:+
BRCA	cis	rs804280	0.662	rs11250164	ENSG00000251402.3	FAM90A25P	-3.84	0.000128	0.00777	-0.15	-0.12	Myopia (pathological);	chr8:11753177	chr8:12415080~12418090:-
BRCA	cis	rs9921338	0.961	rs72773825	ENSG00000263080.1	RP11-485G7.5	3.84	0.000128	0.00777	0.18	0.12	Vein graft stenosis in coronary artery bypass grafting;	chr16:11318591	chr16:11341809~11345211:-
BRCA	cis	rs7020830	0.931	rs13297576	ENSG00000260100.1	RP11-220I1.5	-3.84	0.000128	0.00777	-0.15	-0.12	Schizophrenia;	chr9:37142192	chr9:37078813~37079776:-
BRCA	cis	rs11887277	0.507	rs6547274	ENSG00000272148.1	RP11-195B17.1	-3.84	0.000128	0.00777	-0.13	-0.12	Obesity-related traits;	chr2:26841481	chr2:27062428~27062907:-
BRCA	cis	rs2921036	0.545	rs4840975	ENSG00000254153.1	CTA-398F10.2	-3.84	0.000128	0.00778	-0.15	-0.12	Neuroticism;	chr8:8505748	chr8:8456909~8461337:-
BRCA	cis	rs7475343	0.505	rs12775468	ENSG00000224034.1	RP11-445P17.8	3.84	0.000128	0.00778	0.22	0.12	Intelligence;	chr10:5122084	chr10:5266033~5271236:-
BRCA	cis	rs67696533	0.6	rs1868385	ENSG00000277692.1	RP11-358N2.2	-3.84	0.000128	0.00778	-0.14	-0.12	White blood cell count (basophil);Basophil percentage of granulocytes;Basophil percentage of white cells;	chr20:32523490	chr20:32355053~32355734:+
BRCA	cis	rs4869313	0.869	rs27306	ENSG00000248734.2	CTD-2260A17.1	-3.84	0.000128	0.00778	-0.12	-0.12	Pediatric autoimmune diseases;	chr5:96998854	chr5:96784777~96785999:+
BRCA	cis	rs6545883	0.929	rs13413337	ENSG00000212978.6	AC016747.3	3.84	0.000128	0.00778	0.16	0.12	Tuberculosis;	chr2:61519988	chr2:61141592~61144969:-
BRCA	cis	rs8040855	0.575	rs12912860	ENSG00000259774.1	RP11-182J1.13	3.84	0.000128	0.00778	0.17	0.12	Bulimia nervosa;	chr15:85030267	chr15:84422618~84425882:+
BRCA	cis	rs2108622	0.785	rs3093199	ENSG00000214049.6	UCA1	3.84	0.000128	0.00778	0.17	0.12	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15879061	chr19:15828961~15836320:+
BRCA	cis	rs4478858	0.611	rs10914338	ENSG00000260386.4	LINC01225	-3.84	0.000128	0.00778	-0.14	-0.12	Alcohol dependence;	chr1:31260935	chr1:31500085~31540885:+
BRCA	cis	rs1949733	1	rs2631758	ENSG00000205959.3	RP11-689P11.2	3.84	0.000128	0.00778	0.12	0.12	Response to antineoplastic agents;	chr4:8493577	chr4:8482270~8512610:+
BRCA	cis	rs4908769	0.553	rs301792	ENSG00000232912.4	RP5-1115A15.1	3.84	0.000128	0.00778	0.13	0.12	Allergy;	chr1:8408218	chr1:8424645~8434838:+
BRCA	cis	rs937213	0.573	rs3816900	ENSG00000273855.1	RP11-133K1.12	3.84	0.000128	0.00778	0.13	0.12	Endometrial cancer;Endometrial endometrioid carcinoma;	chr15:40010042	chr15:40285468~40285909:-
BRCA	cis	rs937213	0.573	rs12592831	ENSG00000273855.1	RP11-133K1.12	3.84	0.000128	0.00778	0.13	0.12	Endometrial cancer;Endometrial endometrioid carcinoma;	chr15:40010240	chr15:40285468~40285909:-
BRCA	cis	rs17092148	0.945	rs6060009	ENSG00000202150.1	RNU6-407P	3.84	0.000128	0.00778	0.17	0.12	Neuroticism;	chr20:34716170	chr20:35030317~35030420:-
BRCA	cis	rs7771547	0.519	rs6457912	ENSG00000224666.3	RP1-50J22.4	3.84	0.000128	0.00779	0.14	0.12	Platelet distribution width;	chr6:36406017	chr6:36386831~36393462:+
BRCA	cis	rs11098499	0.644	rs34835603	ENSG00000260091.1	RP11-33B1.4	-3.84	0.000129	0.00779	-0.1	-0.12	Corneal astigmatism;	chr4:119632273	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.615	rs28850368	ENSG00000260091.1	RP11-33B1.4	-3.84	0.000129	0.00779	-0.1	-0.12	Corneal astigmatism;	chr4:119633158	chr4:119409333~119410233:+
BRCA	cis	rs244293	0.965	rs244350	ENSG00000275710.1	RP11-257O5.4	-3.84	0.000129	0.00779	-0.13	-0.12	Menarche (age at onset);	chr17:55118771	chr17:54964474~54964679:+
BRCA	cis	rs2071426	0.71	rs11188145	ENSG00000273450.1	RP11-76P2.4	3.84	0.000129	0.00779	0.15	0.12	Blood metabolite levels;	chr10:95031520	chr10:94314907~94315327:-
BRCA	cis	rs801193	1	rs62466794	ENSG00000265600.1	AC006480.1	-3.84	0.000129	0.00779	-0.14	-0.12	Aortic root size;	chr7:66726592	chr7:67356680~67356779:+
BRCA	cis	rs4831837	0.744	rs6997494	ENSG00000270074.1	RP11-351I21.11	3.84	0.000129	0.00779	0.14	0.12	Morbidity-free survival;	chr8:12833488	chr8:12412827~12414373:+
BRCA	cis	rs6991838	0.53	rs6472217	ENSG00000272155.1	RP11-707M3.3	-3.84	0.000129	0.00779	-0.11	-0.12	Intelligence (multi-trait analysis);	chr8:65635496	chr8:65714334~65714778:-
BRCA	cis	rs6991838	0.584	rs6472218	ENSG00000272155.1	RP11-707M3.3	-3.84	0.000129	0.00779	-0.11	-0.12	Intelligence (multi-trait analysis);	chr8:65635502	chr8:65714334~65714778:-
BRCA	cis	rs7520050	0.966	rs10890363	ENSG00000234329.1	RP11-767N6.2	3.84	0.000129	0.00779	0.11	0.12	Reticulocyte count;Red blood cell count;	chr1:45890476	chr1:45651039~45651826:-
BRCA	cis	rs1910358	0.734	rs7720774	ENSG00000248874.4	C5orf17	-3.84	0.000129	0.00779	-0.16	-0.12	Venous thromboembolism (SNP x SNP interaction);	chr5:23962634	chr5:23951348~24178263:+
BRCA	cis	rs9733	0.566	rs112967224	ENSG00000231073.1	RP11-316M1.3	3.84	0.000129	0.00779	0.12	0.12	Tonsillectomy;	chr1:150704787	chr1:150973123~150975534:+
BRCA	cis	rs9733	0.596	rs72702552	ENSG00000231073.1	RP11-316M1.3	3.84	0.000129	0.00779	0.12	0.12	Tonsillectomy;	chr1:150704986	chr1:150973123~150975534:+
BRCA	cis	rs7620503	0.959	rs11708469	ENSG00000231574.4	RP11-91K9.1	3.84	0.000129	0.00779	0.13	0.12	Corneal structure;	chr3:177590930	chr3:177816865~177899224:+
BRCA	cis	rs4869313	0.87	rs27711	ENSG00000248734.2	CTD-2260A17.1	-3.84	0.000129	0.00779	-0.12	-0.12	Pediatric autoimmune diseases;	chr5:97010035	chr5:96784777~96785999:+
BRCA	cis	rs12289961	0.681	rs11229323	ENSG00000265566.2	RN7SL605P	3.84	0.000129	0.0078	0.2	0.12	Lymphoma;	chr11:58265081	chr11:57528085~57528365:-
BRCA	cis	rs10487112	0.833	rs2374263	ENSG00000235436.9	DPY19L2P4	-3.84	0.000129	0.0078	-0.13	-0.12	Perceived unattractiveness to mosquitoes;	chr7:90482514	chr7:90119400~90125600:+
BRCA	cis	rs35306767	0.855	rs61830931	ENSG00000229869.1	RP11-363N22.2	-3.84	0.000129	0.0078	-0.2	-0.12	Eosinophil percentage of granulocytes;	chr10:886557	chr10:933026~942743:+
BRCA	cis	rs2451932	1	rs2451932	ENSG00000251050.1	RP11-168A11.4	3.84	0.000129	0.0078	0.13	0.12	LDL peak particle diameter (total fat intake interaction);	chr5:80007810	chr5:80019609~80019920:+
BRCA	cis	rs6545883	0.965	rs2305156	ENSG00000270820.4	RP11-355B11.2	3.84	0.000129	0.0078	0.14	0.12	Tuberculosis;	chr2:61502133	chr2:61471188~61484130:+
BRCA	cis	rs4415084	1	rs13176502	ENSG00000248779.1	RP11-53O19.2	3.84	0.000129	0.0078	0.11	0.12	Breast cancer;	chr5:44697806	chr5:44752949~44765744:+
BRCA	cis	rs718433	0.636	rs6572102	ENSG00000256379.1	TRAV8-5	3.84	0.000129	0.0078	0.14	0.12	Intraocular pressure;	chr14:21816090	chr14:21903077~21903598:+
BRCA	cis	rs11742741	0.64	rs55965054	ENSG00000248874.4	C5orf17	-3.84	0.000129	0.0078	-0.15	-0.12	Educational attainment;	chr5:24032269	chr5:23951348~24178263:+
BRCA	cis	rs73201462	1	rs6805582	ENSG00000242551.2	POU5F1P6	3.84	0.000129	0.0078	0.2	0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128310165	chr3:128674735~128677005:-
BRCA	cis	rs73201462	1	rs6805621	ENSG00000242551.2	POU5F1P6	3.84	0.000129	0.0078	0.2	0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128310361	chr3:128674735~128677005:-
BRCA	cis	rs73201462	0.831	rs2999036	ENSG00000242551.2	POU5F1P6	-3.84	0.000129	0.0078	-0.2	-0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128301858	chr3:128674735~128677005:-
BRCA	cis	rs73201462	1	rs2811390	ENSG00000242551.2	POU5F1P6	-3.84	0.000129	0.0078	-0.2	-0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128302638	chr3:128674735~128677005:-
BRCA	cis	rs73201462	1	rs2811391	ENSG00000242551.2	POU5F1P6	-3.84	0.000129	0.0078	-0.2	-0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128303525	chr3:128674735~128677005:-
BRCA	cis	rs2737273	0.769	rs2295797	ENSG00000281205.1	LINC00950	-3.84	0.000129	0.0078	-0.16	-0.12	Platelet distribution width;	chr9:35722285	chr9:35858738~35865518:+
BRCA	cis	rs7267979	0.789	rs6083820	ENSG00000274414.1	RP5-965G21.4	3.84	0.000129	0.0078	0.14	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25373542	chr20:25239007~25245229:-
BRCA	cis	rs61160187	0.582	rs4700404	ENSG00000272308.1	RP11-231G3.1	-3.84	0.000129	0.0078	-0.13	-0.12	Educational attainment (years of education);Educational attainment (college completion);	chr5:61028769	chr5:60866457~60866935:-
BRCA	cis	rs4835473	0.637	rs11932061	ENSG00000246448.2	RP13-578N3.3	3.84	0.000129	0.0078	0.13	0.12	Immature fraction of reticulocytes;	chr4:143768124	chr4:143700257~143865072:+
BRCA	cis	rs6012564	0.89	rs6066976	ENSG00000230758.1	SNAP23P	3.84	0.000129	0.0078	0.14	0.12	Anger;	chr20:49134464	chr20:49038357~49038602:-
BRCA	cis	rs17756712	0.725	rs17135679	ENSG00000271911.1	RP11-532F6.5	3.84	0.000129	0.0078	0.2	0.12	Vertical cup-disc ratio;	chr6:614787	chr6:761675~780648:+
BRCA	cis	rs7020830	0.931	rs13293916	ENSG00000260100.1	RP11-220I1.5	-3.84	0.000129	0.0078	-0.15	-0.12	Schizophrenia;	chr9:37136362	chr9:37078813~37079776:-
BRCA	cis	rs1075265	0.749	rs805375	ENSG00000272156.1	RP11-477N3.1	-3.84	0.000129	0.00781	-0.12	-0.12	Chronotype;Morning vs. evening chronotype;	chr2:53863268	chr2:54082554~54085066:+
BRCA	cis	rs5758511	0.689	rs17002947	ENSG00000233903.2	Z83851.4	-3.84	0.000129	0.00781	-0.18	-0.12	Birth weight;	chr22:42292526	chr22:42276355~42277052:+
BRCA	cis	rs6088580	0.634	rs6142164	ENSG00000275784.1	RP5-1125A11.6	3.84	0.000129	0.00781	0.13	0.12	Glomerular filtration rate (creatinine);	chr20:34418791	chr20:33989480~33991818:-
BRCA	cis	rs6088580	0.634	rs3746455	ENSG00000275784.1	RP5-1125A11.6	3.84	0.000129	0.00781	0.13	0.12	Glomerular filtration rate (creatinine);	chr20:34369410	chr20:33989480~33991818:-
BRCA	cis	rs739496	0.947	rs55851737	ENSG00000257624.1	RP1-128M12.3	3.84	0.000129	0.00781	0.16	0.12	Platelet count;	chr12:111499034	chr12:112000739~112000985:-
BRCA	cis	rs875971	0.893	rs62465470	ENSG00000271064.1	RP11-792A8.3	3.84	0.000129	0.00781	0.14	0.12	Aortic root size;	chr7:66136231	chr7:66748838~66749077:-
BRCA	cis	rs5751168	0.527	rs408785	ENSG00000211654.2	IGLV5-37	3.84	0.000129	0.00781	0.16	0.12	Prostate cancer (SNP x SNP interaction);	chr22:22485213	chr22:22427540~22428035:+
BRCA	cis	rs2274273	1	rs7142704	ENSG00000233924.1	AL160471.6	-3.84	0.000129	0.00781	-0.14	-0.12	Protein biomarker;	chr14:55163885	chr14:55004813~55005687:-
BRCA	cis	rs2281603	0.762	rs61987035	ENSG00000259116.1	RP11-973N13.4	-3.84	0.000129	0.00781	-0.11	-0.12	Lymphocyte counts;	chr14:64571149	chr14:64514154~64540368:-
BRCA	cis	rs11098499	0.863	rs10013305	ENSG00000260091.1	RP11-33B1.4	-3.84	0.000129	0.00781	-0.11	-0.12	Corneal astigmatism;	chr4:119529269	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.863	rs3775849	ENSG00000260091.1	RP11-33B1.4	-3.84	0.000129	0.00781	-0.11	-0.12	Corneal astigmatism;	chr4:119529753	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.818	rs7688802	ENSG00000260091.1	RP11-33B1.4	-3.84	0.000129	0.00781	-0.11	-0.12	Corneal astigmatism;	chr4:119530513	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.863	rs7695620	ENSG00000260091.1	RP11-33B1.4	-3.84	0.000129	0.00781	-0.11	-0.12	Corneal astigmatism;	chr4:119531621	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.863	rs12502389	ENSG00000260091.1	RP11-33B1.4	-3.84	0.000129	0.00781	-0.11	-0.12	Corneal astigmatism;	chr4:119533036	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.821	rs3775852	ENSG00000260091.1	RP11-33B1.4	-3.84	0.000129	0.00781	-0.11	-0.12	Corneal astigmatism;	chr4:119533401	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.82	rs6534140	ENSG00000260091.1	RP11-33B1.4	-3.84	0.000129	0.00781	-0.11	-0.12	Corneal astigmatism;	chr4:119534156	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.863	rs7657849	ENSG00000260091.1	RP11-33B1.4	-3.84	0.000129	0.00781	-0.11	-0.12	Corneal astigmatism;	chr4:119534339	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.863	rs10034450	ENSG00000260091.1	RP11-33B1.4	-3.84	0.000129	0.00781	-0.11	-0.12	Corneal astigmatism;	chr4:119534494	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.863	rs1480939	ENSG00000260091.1	RP11-33B1.4	-3.84	0.000129	0.00781	-0.11	-0.12	Corneal astigmatism;	chr4:119535772	chr4:119409333~119410233:+
BRCA	cis	rs10792665	0.649	rs12808296	ENSG00000254965.1	RP11-113K21.2	-3.84	0.000129	0.00781	-0.12	-0.12	Obesity-related traits;	chr11:83029074	chr11:83111060~83111442:-
BRCA	cis	rs11098499	0.779	rs10857066	ENSG00000260404.2	RP11-384K6.6	3.84	0.000129	0.00781	0.11	0.12	Corneal astigmatism;	chr4:119365441	chr4:118591773~118633729:+
BRCA	cis	rs17767294	0.612	rs12332927	ENSG00000280107.1	AL022393.9	-3.84	0.000129	0.00781	-0.22	-0.12	Parkinson's disease;	chr6:27987337	chr6:28170845~28172521:+
BRCA	cis	rs7133214	0.51	rs4931479	ENSG00000230519.2	RP11-1060J15.5	3.84	0.000129	0.00781	0.15	0.12	Gut microbiota (functional units);	chr12:27795682	chr12:27702338~27702906:+
BRCA	cis	rs7412746	0.611	rs1889740	ENSG00000224800.1	RP11-235D19.2	-3.84	0.000129	0.00781	-0.15	-0.12	Melanoma;	chr1:150827279	chr1:150881236~150881683:-
BRCA	cis	rs7712401	0.755	rs965821	ENSG00000263432.2	RN7SL689P	3.84	0.000129	0.00781	0.14	0.12	Mean platelet volume;	chr5:122802013	chr5:123022487~123022783:-
BRCA	cis	rs7680126	0.596	rs4697714	ENSG00000250413.1	RP11-448G15.1	3.84	0.000129	0.00781	0.19	0.12	Urate levels in obese individuals;Urate levels in lean individuals;Urate levels in overweight individuals;	chr4:10142162	chr4:10006482~10009725:+
BRCA	cis	rs6593122	0.755	rs2330671	ENSG00000235454.1	HAUS6P3	-3.84	0.000129	0.00781	-0.16	-0.12	Vaccine-related adverse events;	chr7:54122287	chr7:53862233~53863339:+
BRCA	cis	rs7852462	0.9	rs7045553	ENSG00000203279.3	RP11-498P14.5	3.84	0.000129	0.00781	0.15	0.12	Barrett's esophagus  or Esophageal adenocarcinoma;Barrett's esophagus;	chr9:97545507	chr9:97200475~97238700:-
BRCA	cis	rs78487399	0.808	rs7575024	ENSG00000234936.1	AC010883.5	3.84	0.000129	0.00782	0.18	0.12	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43439852	chr2:43229573~43233394:+
BRCA	cis	rs17406451	0.731	rs6544667	ENSG00000234936.1	AC010883.5	3.84	0.000129	0.00782	0.12	0.12	Mitochondrial DNA levels;	chr2:43505208	chr2:43229573~43233394:+
BRCA	cis	rs9470794	1	rs9470779	ENSG00000204110.6	RP1-153P14.8	-3.84	0.000129	0.00782	-0.21	-0.12	Type 2 diabetes;	chr6:38106046	chr6:37507348~37535616:+
BRCA	cis	rs669446	0.591	rs649504	ENSG00000236200.4	KDM4A-AS1	-3.84	0.000129	0.00782	-0.15	-0.12	Amyotrophic lateral sclerosis (age of onset);	chr1:43640277	chr1:43699765~43708138:-
BRCA	cis	rs2739330	0.734	rs2000467	ENSG00000228039.3	KB-1125A3.10	-3.84	0.000129	0.00782	-0.14	-0.12	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23963780~23964374:+
BRCA	cis	rs2835345	0.561	rs5026478	ENSG00000233818.1	AP000695.4	3.84	0.000129	0.00782	0.12	0.12	Pulmonary function;	chr21:36453531	chr21:36445731~36532408:+
BRCA	cis	rs4934494	0.822	rs3962370	ENSG00000232229.4	LINC00865	-3.84	0.000129	0.00782	-0.17	-0.12	Red blood cell count;	chr10:89777763	chr10:89829510~89840861:+
BRCA	cis	rs72482608	0.896	rs1555067	ENSG00000271811.1	RP1-79C4.4	3.84	0.000129	0.00782	0.13	0.12	Emphysema imaging phenotypes;	chr1:170805733	chr1:170667381~170669425:+
BRCA	cis	rs4578769	0.84	rs67940971	ENSG00000265939.1	UBE2CP2	-3.84	0.000129	0.00782	-0.14	-0.12	Eosinophil percentage of white cells;	chr18:22902777	chr18:22900486~22900995:-
BRCA	cis	rs7737355	0.741	rs6875363	ENSG00000224431.1	AC063976.7	-3.84	0.000129	0.00782	-0.13	-0.12	Life satisfaction;	chr5:131245502	chr5:132199456~132203487:+
BRCA	cis	rs943466	1	rs61394483	ENSG00000223837.2	BRD2-IT1	3.84	0.000129	0.00782	0.15	0.12	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;	chr6:33784168	chr6:32970232~32970886:+
BRCA	cis	rs6545883	0.965	rs7421663	ENSG00000270820.4	RP11-355B11.2	3.84	0.000129	0.00783	0.14	0.12	Tuberculosis;	chr2:61526651	chr2:61471188~61484130:+
BRCA	cis	rs2692947	0.8	rs4332959	ENSG00000232931.4	LINC00342	3.84	0.000129	0.00783	0.13	0.12	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95883373	chr2:95807118~95816215:-
BRCA	cis	rs10266483	0.921	rs683510	ENSG00000228653.2	HNRNPCP7	-3.84	0.000129	0.00783	-0.14	-0.12	Response to statin therapy;	chr7:64288983	chr7:64500825~64501729:+
BRCA	cis	rs4664293	0.625	rs6745448	ENSG00000226266.5	AC009961.3	-3.84	0.000129	0.00783	-0.14	-0.12	Monocyte percentage of white cells;	chr2:159699087	chr2:159670708~159712435:-
BRCA	cis	rs7267979	0.789	rs9927	ENSG00000276952.1	RP5-965G21.6	3.84	0.000129	0.00783	0.15	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25296608	chr20:25284915~25285588:-
BRCA	cis	rs74233809	1	rs11191548	ENSG00000236937.2	PTGES3P4	-3.84	0.000129	0.00783	-0.25	-0.12	Birth weight;	chr10:103086421	chr10:102845595~102845950:+
BRCA	cis	rs4835473	0.932	rs4443230	ENSG00000246448.2	RP13-578N3.3	-3.84	0.000129	0.00783	-0.13	-0.12	Immature fraction of reticulocytes;	chr4:143740372	chr4:143700257~143865072:+
BRCA	cis	rs17756712	0.667	rs72835984	ENSG00000272463.1	RP11-532F6.3	3.84	0.000129	0.00783	0.2	0.12	Vertical cup-disc ratio;	chr6:642017	chr6:708592~711405:-
BRCA	cis	rs7824557	0.527	rs2409756	ENSG00000255020.1	AF131216.5	3.84	0.000129	0.00783	0.14	0.12	Retinal vascular caliber;	chr8:11384516	chr8:11345748~11347502:-
BRCA	cis	rs7005380	0.965	rs9918815	ENSG00000245330.4	KB-1471A8.1	-3.84	0.000129	0.00783	-0.17	-0.12	Interstitial lung disease;	chr8:119939370	chr8:119867419~119874488:-
BRCA	cis	rs853679	0.882	rs9468300	ENSG00000204709.4	LINC01556	3.84	0.000129	0.00783	0.24	0.12	Depression;	chr6:28159062	chr6:28943877~28944537:+
BRCA	cis	rs11098499	0.874	rs9995277	ENSG00000260091.1	RP11-33B1.4	-3.84	0.000129	0.00783	-0.11	-0.12	Corneal astigmatism;	chr4:119187448	chr4:119409333~119410233:+
BRCA	cis	rs17301013	0.896	rs3118980	ENSG00000234741.6	GAS5	-3.84	0.000129	0.00783	-0.12	-0.12	Systemic lupus erythematosus;	chr1:174793701	chr1:173863900~173868882:-
BRCA	cis	rs6432852	0.516	rs12477613	ENSG00000229195.1	AC009495.4	3.84	0.000129	0.00783	0.14	0.12	Diabetic kidney disease;	chr2:165860674	chr2:165794857~165846091:-
BRCA	cis	rs2303319	0.504	rs72881015	ENSG00000227403.1	AC009299.3	3.84	0.000129	0.00783	0.32	0.12	Cognitive function;	chr2:161866033	chr2:161244739~161249050:+
BRCA	cis	rs2303319	0.504	rs62188765	ENSG00000227403.1	AC009299.3	3.84	0.000129	0.00783	0.32	0.12	Cognitive function;	chr2:161866675	chr2:161244739~161249050:+
BRCA	cis	rs2303319	0.504	rs72881021	ENSG00000227403.1	AC009299.3	3.84	0.000129	0.00783	0.32	0.12	Cognitive function;	chr2:161867540	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.685	rs55736476	ENSG00000227403.1	AC009299.3	3.84	0.000129	0.00783	0.32	0.12	Blood osmolality (transformed sodium);	chr2:161868274	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.685	rs56063742	ENSG00000227403.1	AC009299.3	3.84	0.000129	0.00783	0.32	0.12	Blood osmolality (transformed sodium);	chr2:161868447	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.685	rs62188767	ENSG00000227403.1	AC009299.3	3.84	0.000129	0.00783	0.32	0.12	Blood osmolality (transformed sodium);	chr2:161869362	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.685	rs62188768	ENSG00000227403.1	AC009299.3	3.84	0.000129	0.00783	0.32	0.12	Blood osmolality (transformed sodium);	chr2:161869414	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.685	rs72881030	ENSG00000227403.1	AC009299.3	3.84	0.000129	0.00783	0.32	0.12	Blood osmolality (transformed sodium);	chr2:161869558	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.685	rs72881034	ENSG00000227403.1	AC009299.3	3.84	0.000129	0.00783	0.32	0.12	Blood osmolality (transformed sodium);	chr2:161870456	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.685	rs72881037	ENSG00000227403.1	AC009299.3	3.84	0.000129	0.00783	0.32	0.12	Blood osmolality (transformed sodium);	chr2:161870510	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.685	rs62188769	ENSG00000227403.1	AC009299.3	3.84	0.000129	0.00783	0.32	0.12	Blood osmolality (transformed sodium);	chr2:161873159	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.685	rs72881042	ENSG00000227403.1	AC009299.3	3.84	0.000129	0.00783	0.32	0.12	Blood osmolality (transformed sodium);	chr2:161873493	chr2:161244739~161249050:+
BRCA	cis	rs881375	0.967	rs1930778	ENSG00000238181.2	AHCYP2	-3.84	0.000129	0.00783	-0.15	-0.12	Rheumatoid arthritis;	chr9:120879091	chr9:120720673~120721972:+
BRCA	cis	rs924712	0.547	rs239815	ENSG00000261116.1	RP3-523K23.2	-3.84	0.000129	0.00784	-0.15	-0.12	Breast cancer;	chr6:54951421	chr6:54943167~54945099:+
BRCA	cis	rs7312933	0.67	rs10880258	ENSG00000257225.1	RP11-328C8.4	-3.84	0.000129	0.00784	-0.14	-0.12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42153729	chr12:42459366~42466128:+
BRCA	cis	rs4263408	0.967	rs11947966	ENSG00000224097.5	RP11-472B18.1	3.84	0.000129	0.00784	0.14	0.12	Plasma amyloid beta peptide concentrations (ABx-40);	chr4:39765721	chr4:39480255~39481905:+
BRCA	cis	rs6736093	1	rs34928784	ENSG00000236307.2	EEF1E1P1	-3.84	0.000129	0.00784	-0.15	-0.12	Coronary artery disease;	chr2:111899485	chr2:111887914~111888741:+
BRCA	cis	rs7267979	0.966	rs2261747	ENSG00000274414.1	RP5-965G21.4	-3.84	0.000129	0.00784	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25281148	chr20:25239007~25245229:-
BRCA	cis	rs8094794	0.744	rs2033116	ENSG00000267707.2	RP11-95O2.5	3.84	0.00013	0.00784	0.18	0.12	Periodontal disease-related phenotypes;	chr18:36696158	chr18:37243776~37247506:+
BRCA	cis	rs6736093	0.796	rs34240639	ENSG00000236307.2	EEF1E1P1	-3.84	0.00013	0.00784	-0.15	-0.12	Coronary artery disease;	chr2:112052374	chr2:111887914~111888741:+
BRCA	cis	rs6964833	1	rs36044436	ENSG00000277072.3	STAG3L2	3.84	0.00013	0.00784	0.13	0.12	Menarche (age at onset);	chr7:74675495	chr7:74882163~74890610:-
BRCA	cis	rs938554	0.558	rs4697701	ENSG00000250413.1	RP11-448G15.1	3.84	0.00013	0.00784	0.16	0.12	Blood metabolite levels;	chr4:9944471	chr4:10006482~10009725:+
BRCA	cis	rs1910358	0.881	rs10063109	ENSG00000248874.4	C5orf17	-3.84	0.00013	0.00784	-0.17	-0.12	Venous thromboembolism (SNP x SNP interaction);	chr5:23892083	chr5:23951348~24178263:+
BRCA	cis	rs60843830	1	rs17714252	ENSG00000272342.1	RP13-539J13.1	3.84	0.00013	0.00784	0.15	0.12	Spherical equivalent (joint analysis main effects and education interaction);	chr2:285471	chr2:739588~740164:-
BRCA	cis	rs672059	1	rs483783	ENSG00000224468.3	RP11-181K3.4	-3.84	0.00013	0.00784	-0.12	-0.12	Hypertriglyceridemia;	chr1:183193017	chr1:183138402~183141282:-
BRCA	cis	rs2306786	0.558	rs3816814	ENSG00000259732.1	RP11-59H7.3	-3.84	0.00013	0.00784	-0.26	-0.12	Metabolite levels;	chr15:59208378	chr15:59121034~59133250:+
BRCA	cis	rs687432	0.851	rs12804093	ENSG00000265566.2	RN7SL605P	3.84	0.00013	0.00784	0.15	0.12	Parkinson's disease;	chr11:57966616	chr11:57528085~57528365:-
BRCA	cis	rs4916588	0.559	rs6786938	ENSG00000230732.4	AC127904.2	3.84	0.00013	0.00785	0.15	0.12	Night sleep phenotypes;	chr3:196893917	chr3:196912646~196914579:+
BRCA	cis	rs1910358	0.959	rs10044926	ENSG00000248874.4	C5orf17	-3.84	0.00013	0.00785	-0.17	-0.12	Venous thromboembolism (SNP x SNP interaction);	chr5:23909870	chr5:23951348~24178263:+
BRCA	cis	rs34975555	0.803	rs3850748	ENSG00000254054.2	RP11-156K13.3	-3.84	0.00013	0.00785	-0.18	-0.12	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:17983118	chr8:17905756~17907887:+
BRCA	cis	rs10829156	0.945	rs10741131	ENSG00000225527.1	RP11-383B4.4	-3.84	0.00013	0.00785	-0.17	-0.12	Sudden cardiac arrest;	chr10:18683130	chr10:18531849~18533336:-
BRCA	cis	rs1670533	1	rs6836350	ENSG00000251639.2	RP11-20I20.1	3.84	0.00013	0.00785	0.18	0.12	Recombination rate (females);	chr4:1076185	chr4:1100016~1101558:-
BRCA	cis	rs1670533	0.818	rs6835141	ENSG00000251639.2	RP11-20I20.1	3.84	0.00013	0.00785	0.18	0.12	Recombination rate (females);	chr4:1076352	chr4:1100016~1101558:-
BRCA	cis	rs16846053	0.792	rs72879222	ENSG00000227403.1	AC009299.3	3.84	0.00013	0.00785	0.31	0.12	Blood osmolality (transformed sodium);	chr2:161828728	chr2:161244739~161249050:+
BRCA	cis	rs7829975	0.626	rs907183	ENSG00000173295.6	FAM86B3P	-3.84	0.00013	0.00785	-0.12	-0.12	Mood instability;	chr8:8872251	chr8:8228595~8244865:+
BRCA	cis	rs16917546	1	rs12768538	ENSG00000238280.1	RP11-436D10.3	-3.84	0.00013	0.00786	-0.16	-0.12	Basal cell carcinoma;	chr10:62646598	chr10:62793562~62805887:-
BRCA	cis	rs2976388	0.556	rs4736323	ENSG00000253741.1	CTD-2292P10.4	3.84	0.00013	0.00786	0.14	0.12	Urinary tract infection frequency;	chr8:142748941	chr8:142702252~142726973:-
BRCA	cis	rs7954584	0.616	rs10743185	ENSG00000272849.1	RP11-347I19.8	-3.84	0.00013	0.00786	-0.09	-0.12	Mean corpuscular volume;	chr12:121918529	chr12:121797511~121801972:+
BRCA	cis	rs875971	0.597	rs11763224	ENSG00000273142.1	RP11-458F8.4	3.84	0.00013	0.00786	0.12	0.12	Aortic root size;	chr7:66518628	chr7:66902857~66906297:+
BRCA	cis	rs2562456	0.876	rs62110202	ENSG00000268555.1	RP11-678G14.3	3.84	0.00013	0.00786	0.15	0.12	Pain;	chr19:21571799	chr19:21570822~21587322:-
BRCA	cis	rs17756712	0.667	rs2073006	ENSG00000271911.1	RP11-532F6.5	3.84	0.00013	0.00786	0.2	0.12	Vertical cup-disc ratio;	chr6:637465	chr6:761675~780648:+
BRCA	cis	rs4908769	0.627	rs301798	ENSG00000270282.1	RP5-1115A15.2	3.84	0.00013	0.00786	0.14	0.12	Allergy;	chr1:8428505	chr1:8512653~8513021:+
BRCA	cis	rs4819052	1	rs3746980	ENSG00000184274.3	LINC00315	-3.84	0.00013	0.00786	-0.18	-0.12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45291665	chr21:45300245~45305257:-
BRCA	cis	rs4237845	0.537	rs11172369	ENSG00000257159.1	RP11-58A17.3	3.84	0.00013	0.00786	0.15	0.12	Intelligence (multi-trait analysis);	chr12:57886809	chr12:57967058~57968399:+
BRCA	cis	rs7209700	0.708	rs15908	ENSG00000228782.6	CTD-2026D20.3	-3.84	0.00013	0.00786	-0.13	-0.12	IgG glycosylation;	chr17:47290971	chr17:47450568~47492492:-
BRCA	cis	rs739496	0.843	rs10774631	ENSG00000257624.1	RP1-128M12.3	-3.84	0.00013	0.00786	-0.16	-0.12	Platelet count;	chr12:111585197	chr12:112000739~112000985:-
BRCA	cis	rs4700393	0.517	rs71592685	ENSG00000215032.2	GNL3LP1	-3.84	0.00013	0.00786	-0.17	-0.12	Intelligence (multi-trait analysis);	chr5:60825411	chr5:60891935~60893577:-
BRCA	cis	rs295490	0.748	rs78652857	ENSG00000272656.1	RP11-219D15.3	3.84	0.00013	0.00786	0.29	0.12	PR interval in Tripanosoma cruzi seropositivity;	chr3:139509107	chr3:139349024~139349371:-
BRCA	cis	rs863345	0.604	rs2157687	ENSG00000229914.1	RP11-404O13.4	-3.84	0.00013	0.00786	-0.13	-0.12	Pneumococcal bacteremia;	chr1:158523210	chr1:158195633~158196131:-
BRCA	cis	rs863345	0.548	rs1032352	ENSG00000229914.1	RP11-404O13.4	-3.84	0.00013	0.00786	-0.13	-0.12	Pneumococcal bacteremia;	chr1:158523364	chr1:158195633~158196131:-
BRCA	cis	rs62344088	1	rs7715867	ENSG00000277812.1	AC021087.1	3.84	0.00013	0.00787	0.32	0.12	Asthma (childhood onset);	chr5:128944	chr5:262769~262881:+
BRCA	cis	rs62344088	1	rs73022563	ENSG00000277812.1	AC021087.1	3.84	0.00013	0.00787	0.32	0.12	Asthma (childhood onset);	chr5:140698	chr5:262769~262881:+
BRCA	cis	rs17092148	1	rs910871	ENSG00000202150.1	RNU6-407P	3.84	0.00013	0.00787	0.17	0.12	Neuroticism;	chr20:34745404	chr20:35030317~35030420:-
BRCA	cis	rs17092148	1	rs910872	ENSG00000202150.1	RNU6-407P	3.84	0.00013	0.00787	0.17	0.12	Neuroticism;	chr20:34746736	chr20:35030317~35030420:-
BRCA	cis	rs17092148	0.945	rs17092080	ENSG00000202150.1	RNU6-407P	3.84	0.00013	0.00787	0.17	0.12	Neuroticism;	chr20:34747853	chr20:35030317~35030420:-
BRCA	cis	rs2704588	0.954	rs2704593	ENSG00000270720.1	RP11-84C13.2	-3.84	0.00013	0.00787	-0.18	-0.12	Longevity;	chr4:88907570	chr4:89119284~89119871:+
BRCA	cis	rs4699052	0.662	rs2866645	ENSG00000248740.4	RP11-328K4.1	3.84	0.00013	0.00787	0.13	0.12	Testicular germ cell tumor;	chr4:103318044	chr4:103256159~103453658:+
BRCA	cis	rs8098244	0.708	rs1131521	ENSG00000265752.2	RP11-403A21.1	-3.84	0.00013	0.00787	-0.16	-0.12	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23933804	chr18:23957754~23982556:-
BRCA	cis	rs6480314	0.522	rs10047355	ENSG00000233590.1	RP11-153K11.3	-3.84	0.00013	0.00787	-0.19	-0.12	Optic nerve measurement (disc area);	chr10:68300321	chr10:68233251~68242379:-
BRCA	cis	rs4761702	1	rs4761702	ENSG00000257210.1	NACAP3	-3.84	0.00013	0.00787	-0.15	-0.12	Immature fraction of reticulocytes;	chr12:93316116	chr12:93124063~93124543:-
BRCA	cis	rs91731	0.92	rs268728	ENSG00000249572.1	CTD-2203K17.1	-3.84	0.00013	0.00787	-0.23	-0.12	Lung function (FVC);	chr5:33362956	chr5:33424025~33440619:-
BRCA	cis	rs1953600	0.87	rs2788295	ENSG00000226659.1	RP11-137H2.4	3.84	0.00013	0.00787	0.16	0.12	Sarcoidosis;	chr10:80181251	chr10:80529597~80535942:-
BRCA	cis	rs853679	0.517	rs9380052	ENSG00000261839.1	RP1-265C24.8	3.84	0.00013	0.00787	0.16	0.12	Depression;	chr6:28096845	chr6:28136849~28139678:+
BRCA	cis	rs4664293	0.647	rs6432539	ENSG00000226266.5	AC009961.3	-3.84	0.00013	0.00787	-0.14	-0.12	Monocyte percentage of white cells;	chr2:159592209	chr2:159670708~159712435:-
BRCA	cis	rs13315871	1	rs13078787	ENSG00000272182.1	RP11-802O23.3	3.84	0.00013	0.00787	0.23	0.12	Cholesterol, total;	chr3:58444760	chr3:58428255~58428815:+
BRCA	cis	rs4950322	0.518	rs4950305	ENSG00000227242.3	NBPF13P	-3.84	0.00013	0.00787	-0.16	-0.12	Protein quantitative trait loci;	chr1:147117711	chr1:147021320~147124525:-
BRCA	cis	rs6439153	0.901	rs2630263	ENSG00000242551.2	POU5F1P6	-3.84	0.00013	0.00787	-0.15	-0.12	Pneumococcal bacteremia;	chr3:128969475	chr3:128674735~128677005:-
BRCA	cis	rs10792665	0.724	rs1320733	ENSG00000246067.6	RAB30-AS1	-3.84	0.00013	0.00787	-0.12	-0.12	Obesity-related traits;	chr11:83008768	chr11:83072066~83106719:+
BRCA	cis	rs8114671	0.562	rs1018447	ENSG00000126005.14	MMP24-AS1	3.84	0.00013	0.00787	0.13	0.12	Height;	chr20:34813904	chr20:35216462~35278131:-
BRCA	cis	rs4218	0.541	rs8030323	ENSG00000259732.1	RP11-59H7.3	-3.84	0.00013	0.00787	-0.14	-0.12	Social communication problems;	chr15:59048048	chr15:59121034~59133250:+
BRCA	cis	rs2625529	0.761	rs972028	ENSG00000260037.4	CTD-2524L6.3	-3.84	0.00013	0.00787	-0.16	-0.12	Red blood cell count;	chr15:71880751	chr15:71818396~71823384:+
BRCA	cis	rs8180040	0.966	rs11707895	ENSG00000280667.1	Y_RNA	-3.84	0.00013	0.00787	-0.14	-0.12	Colorectal cancer;	chr3:47533447	chr3:47501083~47501182:+
BRCA	cis	rs875971	0.862	rs6460290	ENSG00000229886.1	RP5-1132H15.3	-3.84	0.00013	0.00787	-0.13	-0.12	Aortic root size;	chr7:66344119	chr7:66025126~66031544:-
BRCA	cis	rs2839186	0.771	rs2280959	ENSG00000228137.1	AP001469.7	3.84	0.00013	0.00788	0.12	0.12	Testicular germ cell tumor;	chr21:46222082	chr21:46246890~46247682:+
BRCA	cis	rs2839186	0.739	rs2280958	ENSG00000228137.1	AP001469.7	3.84	0.00013	0.00788	0.12	0.12	Testicular germ cell tumor;	chr21:46222102	chr21:46246890~46247682:+
BRCA	cis	rs5003154	0.905	rs4398859	ENSG00000253214.1	RP11-1149M10.2	-3.84	0.00013	0.00788	-0.13	-0.12	Bladder cancer;	chr8:81078427	chr8:81154279~81164599:+
BRCA	cis	rs8094794	0.744	rs10502665	ENSG00000267707.2	RP11-95O2.5	-3.84	0.00013	0.00788	-0.18	-0.12	Periodontal disease-related phenotypes;	chr18:36696619	chr18:37243776~37247506:+
BRCA	cis	rs9856151	0.806	rs2137606	ENSG00000261167.1	RP11-517B11.7	-3.84	0.00013	0.00788	-0.12	-0.12	Body mass index;	chr3:131818163	chr3:131455126~131458598:-
BRCA	cis	rs7267979	1	rs4815417	ENSG00000276952.1	RP5-965G21.6	-3.84	0.00013	0.00788	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25398890	chr20:25284915~25285588:-
BRCA	cis	rs6977955	1	rs11495981	ENSG00000234336.5	JAZF1-AS1	3.84	0.00013	0.00788	0.16	0.12	Allergic disease (asthma, hay fever or eczema);	chr7:28137682	chr7:28180322~28243917:+
BRCA	cis	rs7312933	0.51	rs10880223	ENSG00000257376.1	RP11-328C8.2	-3.84	0.00013	0.00788	-0.14	-0.12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42019641	chr12:42431665~42433357:-
BRCA	cis	rs11098499	0.866	rs7665125	ENSG00000260404.2	RP11-384K6.6	3.84	0.00013	0.00788	0.11	0.12	Corneal astigmatism;	chr4:119480924	chr4:118591773~118633729:+
BRCA	cis	rs67079557	1	rs67079557	ENSG00000260206.1	CTD-2026K11.2	-3.84	0.00013	0.00788	-0.16	-0.12	Breast cancer;	chr15:75637966	chr15:75636139~75639239:+
BRCA	cis	rs983392	0.819	rs483629	ENSG00000275344.1	MIR6503	-3.84	0.00013	0.00788	-0.12	-0.12	Alzheimer's disease (late onset);	chr11:60132438	chr11:60209071~60209156:-
BRCA	cis	rs7914558	0.646	rs11191459	ENSG00000213277.3	MARCKSL1P1	3.84	0.00013	0.00788	0.14	0.12	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102902361	chr10:103175554~103176094:+
BRCA	cis	rs794185	0.561	rs304073	ENSG00000231249.1	ITPR1-AS1	-3.84	0.00013	0.00788	-0.14	-0.12	Multiple sclerosis--Brain Glutamate Levels;	chr3:4494702	chr3:4490891~4493163:-
BRCA	cis	rs867371	0.656	rs2665103	ENSG00000280753.1	AC044907.1	3.84	0.00013	0.00788	0.11	0.12	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82140374	chr15:82847870~82847998:-
BRCA	cis	rs1009077	0.716	rs35999787	ENSG00000245958.5	RP11-33B1.1	3.84	0.00013	0.00789	0.17	0.12	Endometriosis;	chr4:119597949	chr4:119454791~119552025:+
BRCA	cis	rs2380205	0.517	rs7067928	ENSG00000232807.2	RP11-536K7.3	3.84	0.00013	0.00789	0.13	0.12	Breast cancer;	chr10:5910891	chr10:5934270~5945900:-
BRCA	cis	rs17684571	0.7	rs35642890	ENSG00000231441.1	RP11-472M19.2	3.84	0.00013	0.00789	0.17	0.12	Schizophrenia;	chr6:56809919	chr6:56844002~56864078:+
BRCA	cis	rs17711722	0.701	rs781145	ENSG00000223473.2	GS1-124K5.3	3.84	0.00013	0.00789	0.09	0.12	Calcium levels;	chr7:65975383	chr7:66491049~66493566:-
BRCA	cis	rs13315871	0.929	rs9811074	ENSG00000272182.1	RP11-802O23.3	3.84	0.00013	0.00789	0.25	0.12	Cholesterol, total;	chr3:58436119	chr3:58428255~58428815:+
BRCA	cis	rs13315871	1	rs9849482	ENSG00000272182.1	RP11-802O23.3	3.84	0.00013	0.00789	0.25	0.12	Cholesterol, total;	chr3:58436360	chr3:58428255~58428815:+
BRCA	cis	rs8040855	0.576	rs62022527	ENSG00000230373.7	GOLGA6L5P	3.84	0.00013	0.00789	0.15	0.12	Bulimia nervosa;	chr15:84988022	chr15:84507885~84516814:-
BRCA	cis	rs477895	0.713	rs2282490	ENSG00000256940.1	RP11-783K16.5	3.84	0.00013	0.00789	0.17	0.12	Mean platelet volume;	chr11:64194680	chr11:64245964~64248217:+
BRCA	cis	rs477895	0.713	rs67546972	ENSG00000256940.1	RP11-783K16.5	3.84	0.00013	0.00789	0.17	0.12	Mean platelet volume;	chr11:64194690	chr11:64245964~64248217:+
BRCA	cis	rs6991838	0.584	rs3812412	ENSG00000272155.1	RP11-707M3.3	-3.84	0.00013	0.00789	-0.11	-0.12	Intelligence (multi-trait analysis);	chr8:65634857	chr8:65714334~65714778:-
BRCA	cis	rs7267979	0.789	rs6083810	ENSG00000125804.12	FAM182A	3.84	0.00013	0.00789	0.16	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25349123	chr20:26054655~26086917:+
BRCA	cis	rs4819052	0.819	rs13046807	ENSG00000215447.6	BX322557.10	-3.84	0.00013	0.00789	-0.12	-0.12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45252371	chr21:45288052~45291738:+
BRCA	cis	rs11098499	0.909	rs10026736	ENSG00000225892.3	RP11-384K6.2	3.84	0.00013	0.00789	0.12	0.12	Corneal astigmatism;	chr4:119463167	chr4:118632274~118634759:+
BRCA	cis	rs13401620	0.871	rs6732703	ENSG00000229326.3	AC069154.4	-3.84	0.00013	0.00789	-0.15	-0.12	Breast size;	chr2:119914679	chr2:119698623~119700151:+
BRCA	cis	rs11603020	0.95	rs11229067	ENSG00000265566.2	RN7SL605P	3.84	0.00013	0.00789	0.17	0.12	Blood protein levels;	chr11:57607473	chr11:57528085~57528365:-
BRCA	cis	rs1476670	1	rs1476670	ENSG00000230615.5	RP5-1198O20.4	-3.84	0.000131	0.00789	-0.2	-0.12	Eotaxin levels;	chr1:44042523	chr1:44030443~44115913:+
BRCA	cis	rs10129255	0.912	rs6576227	ENSG00000232216.1	IGHV3-43	3.84	0.000131	0.00789	0.09	0.12	Kawasaki disease;	chr14:106778202	chr14:106470264~106470800:-
BRCA	cis	rs10129255	0.957	rs6576228	ENSG00000232216.1	IGHV3-43	3.84	0.000131	0.00789	0.09	0.12	Kawasaki disease;	chr14:106778401	chr14:106470264~106470800:-
BRCA	cis	rs465969	0.546	rs77990243	ENSG00000272356.1	RP5-1112D6.8	3.84	0.000131	0.00789	0.23	0.12	Psoriasis;	chr6:111513183	chr6:111309203~111313517:+
BRCA	cis	rs2486012	0.737	rs4660749	ENSG00000237950.1	RP11-7O11.3	3.84	0.000131	0.00789	0.21	0.12	Intelligence (multi-trait analysis);	chr1:43784630	chr1:43944370~43946551:-
BRCA	cis	rs3858526	0.959	rs1840179	ENSG00000224295.2	AC087380.14	3.84	0.000131	0.00789	0.17	0.12	DNA methylation (variation);	chr11:5927918	chr11:5518441~5524955:-
BRCA	cis	rs1552244	0.572	rs58862481	ENSG00000180385.7	EMC3-AS1	3.84	0.000131	0.00789	0.17	0.12	Alzheimer's disease;	chr3:10122624	chr3:9986893~10006990:+
BRCA	cis	rs240993	0.812	rs9398272	ENSG00000230177.1	RP5-1112D6.4	3.84	0.000131	0.00789	0.15	0.12	Inflammatory skin disease;Psoriasis;	chr6:111522345	chr6:111277932~111278742:+
BRCA	cis	rs4950322	0.57	rs4950409	ENSG00000237188.3	RP11-337C18.8	3.84	0.000131	0.00789	0.15	0.12	Protein quantitative trait loci;	chr1:147335879	chr1:147172771~147211568:+
BRCA	cis	rs4950322	0.57	rs72692980	ENSG00000237188.3	RP11-337C18.8	3.84	0.000131	0.00789	0.15	0.12	Protein quantitative trait loci;	chr1:147337830	chr1:147172771~147211568:+
BRCA	cis	rs7620503	1	rs1463857	ENSG00000277241.1	RP11-114M1.3	3.84	0.000131	0.00789	0.13	0.12	Corneal structure;	chr3:177580539	chr3:177700346~177701072:-
BRCA	cis	rs875971	0.522	rs1968127	ENSG00000265600.1	AC006480.1	3.84	0.000131	0.00789	0.14	0.12	Aortic root size;	chr7:66591816	chr7:67356680~67356779:+
BRCA	cis	rs11098499	0.863	rs17050695	ENSG00000260091.1	RP11-33B1.4	-3.84	0.000131	0.00789	-0.1	-0.12	Corneal astigmatism;	chr4:119568372	chr4:119409333~119410233:+
BRCA	cis	rs8180040	0.966	rs59586735	ENSG00000280667.1	Y_RNA	-3.84	0.000131	0.00789	-0.13	-0.12	Colorectal cancer;	chr3:47476835	chr3:47501083~47501182:+
BRCA	cis	rs7914558	0.621	rs10786722	ENSG00000213277.3	MARCKSL1P1	3.84	0.000131	0.0079	0.14	0.12	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102900311	chr10:103175554~103176094:+
BRCA	cis	rs11088226	0.846	rs2154500	ENSG00000186842.4	LINC00846	-3.84	0.000131	0.0079	-0.17	-0.12	Gastritis;	chr21:32554081	chr21:32572238~32575881:-
BRCA	cis	rs2880765	0.835	rs4843063	ENSG00000230373.7	GOLGA6L5P	3.84	0.000131	0.0079	0.13	0.12	Coronary artery disease;	chr15:85505517	chr15:84507885~84516814:-
BRCA	cis	rs597539	0.652	rs667989	ENSG00000255741.1	RP11-757G1.5	-3.84	0.000131	0.0079	-0.17	-0.12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68918308	chr11:68941503~68942852:-
BRCA	cis	rs2708977	0.932	rs12329128	ENSG00000237510.6	AC008268.2	3.84	0.000131	0.0079	0.16	0.12	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96619180	chr2:95789654~95800166:+
BRCA	cis	rs7267979	1	rs6115168	ENSG00000204556.4	CTD-2514C3.1	3.84	0.000131	0.0079	0.16	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25392255	chr20:26018832~26020684:+
BRCA	cis	rs11673344	0.566	rs10419281	ENSG00000267422.1	CTD-2554C21.1	-3.84	0.000131	0.0079	-0.15	-0.12	Obesity-related traits;	chr19:37459351	chr19:37779686~37792865:+
BRCA	cis	rs1953600	0.87	rs2245168	ENSG00000226659.1	RP11-137H2.4	-3.84	0.000131	0.0079	-0.16	-0.12	Sarcoidosis;	chr10:80162162	chr10:80529597~80535942:-
BRCA	cis	rs2731006	0.64	rs2459740	ENSG00000257114.2	RP11-25I15.3	3.84	0.000131	0.0079	0.2	0.12	Panic disorder;	chr12:42799030	chr12:42692216~42717119:+
BRCA	cis	rs875971	0.862	rs12537823	ENSG00000273024.4	INTS4P2	-3.84	0.000131	0.0079	-0.13	-0.12	Aortic root size;	chr7:66255897	chr7:65647864~65715661:+
BRCA	cis	rs259282	0.583	rs12981373	ENSG00000267475.1	CTD-2538C1.2	3.84	0.000131	0.0079	0.14	0.12	Schizophrenia;	chr19:32617283	chr19:32687089~32691750:-
BRCA	cis	rs56346965	1	rs2192008	ENSG00000204253.4	HNRNPCP2	-3.84	0.000131	0.0079	-0.15	-0.12	Bone mineral density (Ward's triangle area);	chr2:190680421	chr2:189923336~189924216:+
BRCA	cis	rs7819412	0.521	rs4451268	ENSG00000255046.1	RP11-297N6.4	3.84	0.000131	0.0079	0.14	0.12	Triglycerides;	chr8:11177350	chr8:11797928~11802568:-
BRCA	cis	rs7592578	0.882	rs16832765	ENSG00000272979.1	RP11-647K16.1	-3.84	0.000131	0.0079	-0.21	-0.12	Diastolic blood pressure;	chr2:190604036	chr2:190454092~190454521:-
BRCA	cis	rs2439831	0.85	rs28590651	ENSG00000206991.1	RNU6-610P	-3.84	0.000131	0.0079	-0.19	-0.12	Lung cancer in ever smokers;	chr15:43820818	chr15:43637632~43637738:-
BRCA	cis	rs5758511	0.68	rs56111723	ENSG00000226450.2	CYP2D8P	3.84	0.000131	0.0079	0.13	0.12	Birth weight;	chr22:42268877	chr22:42149886~42155001:-
BRCA	cis	rs4718428	1	rs4718428	ENSG00000230295.1	RP11-458F8.2	-3.84	0.000131	0.00791	-0.1	-0.12	Corneal structure;	chr7:66956459	chr7:66880708~66882981:+
BRCA	cis	rs9437689	1	rs35888232	ENSG00000235501.4	RP4-639F20.1	3.84	0.000131	0.00791	0.15	0.12	Phospholipid levels (plasma);	chr1:95090868	chr1:94927566~94963270:+
BRCA	cis	rs11098499	0.874	rs17839089	ENSG00000225892.3	RP11-384K6.2	3.84	0.000131	0.00791	0.13	0.12	Corneal astigmatism;	chr4:119189914	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.874	rs6826823	ENSG00000225892.3	RP11-384K6.2	3.84	0.000131	0.00791	0.13	0.12	Corneal astigmatism;	chr4:119190943	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.874	rs12509054	ENSG00000225892.3	RP11-384K6.2	3.84	0.000131	0.00791	0.13	0.12	Corneal astigmatism;	chr4:119193920	chr4:118632274~118634759:+
BRCA	cis	rs12439619	0.768	rs28694364	ENSG00000259429.4	UBE2Q2P2	-3.84	0.000131	0.00791	-0.15	-0.12	Intelligence (multi-trait analysis);	chr15:82208119	chr15:82355142~82420075:+
BRCA	cis	rs7487075	0.567	rs4768712	ENSG00000257261.4	RP11-96H19.1	3.84	0.000131	0.00791	0.13	0.12	Itch intensity from mosquito bite;	chr12:46417738	chr12:46383679~46876159:+
BRCA	cis	rs1912124	1	rs72744137	ENSG00000271983.1	RP11-28H5.2	3.84	0.000131	0.00791	0.24	0.12	Peripheral arterial disease (traffic-related air pollution interaction);	chr15:81221240	chr15:80693216~80693707:-
BRCA	cis	rs930395	0.533	rs11948636	ENSG00000251141.4	RP11-53O19.1	-3.84	0.000131	0.00791	-0.11	-0.12	Breast cancer;	chr5:44881127	chr5:44744900~44808777:-
BRCA	cis	rs6570726	0.935	rs430561	ENSG00000270638.1	RP3-466P17.1	3.84	0.000131	0.00791	0.13	0.12	Lobe attachment (rater-scored or self-reported);	chr6:145492004	chr6:145735570~145737218:+
BRCA	cis	rs1832007	0.671	rs3750569	ENSG00000224034.1	RP11-445P17.8	-3.84	0.000131	0.00791	-0.2	-0.12	Triglyceride levels;Triglycerides;	chr10:5205567	chr10:5266033~5271236:-
BRCA	cis	rs2562456	0.755	rs1879234	ENSG00000268119.4	CTD-2561J22.5	-3.84	0.000131	0.00792	-0.18	-0.12	Pain;	chr19:21521677	chr19:21444241~21463908:-
BRCA	cis	rs4835473	0.808	rs13134564	ENSG00000246448.2	RP13-578N3.3	-3.84	0.000131	0.00792	-0.13	-0.12	Immature fraction of reticulocytes;	chr4:143738763	chr4:143700257~143865072:+
BRCA	cis	rs7682317	0.526	rs3846287	ENSG00000270720.1	RP11-84C13.2	3.84	0.000131	0.00792	0.13	0.12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr4:88961961	chr4:89119284~89119871:+
BRCA	cis	rs1914816	0.887	rs2460155	ENSG00000196274.5	Metazoa_SRP	3.84	0.000131	0.00792	0.15	0.12	Response to tocilizumab in rheumatoid arthritis;	chr15:76186584	chr15:76230048~76230390:-
BRCA	cis	rs829883	1	rs1347956	ENSG00000227825.4	SLC9A7P1	3.84	0.000131	0.00792	0.15	0.12	Colorectal adenoma (advanced);	chr12:98495786	chr12:98453835~98457145:-
BRCA	cis	rs4713118	0.621	rs9368548	ENSG00000216901.1	AL022393.7	3.84	0.000131	0.00792	0.17	0.12	Parkinson's disease;	chr6:28066959	chr6:28176188~28176674:+
BRCA	cis	rs35146811	0.696	rs1727124	ENSG00000235713.1	RP4-604G5.3	-3.84	0.000131	0.00792	-0.14	-0.12	Coronary artery disease;	chr7:100206481	chr7:99992397~99993050:+
BRCA	cis	rs11673344	0.566	rs2385181	ENSG00000233527.7	ZNF529-AS1	-3.84	0.000131	0.00792	-0.13	-0.12	Obesity-related traits;	chr19:37395428	chr19:36573070~36594708:+
BRCA	cis	rs11098499	0.874	rs6822498	ENSG00000260091.1	RP11-33B1.4	-3.84	0.000131	0.00792	-0.11	-0.12	Corneal astigmatism;	chr4:119199028	chr4:119409333~119410233:+
BRCA	cis	rs4950322	0.512	rs12409455	ENSG00000244371.2	PFN1P8	-3.84	0.000131	0.00792	-0.14	-0.12	Protein quantitative trait loci;	chr1:147378563	chr1:146957117~146957659:-
BRCA	cis	rs4819052	0.851	rs2838842	ENSG00000215447.6	BX322557.10	-3.84	0.000131	0.00792	-0.12	-0.12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45249302	chr21:45288052~45291738:+
BRCA	cis	rs7267979	1	rs2856	ENSG00000204556.4	CTD-2514C3.1	-3.84	0.000131	0.00792	-0.16	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25452900	chr20:26018832~26020684:+
BRCA	cis	rs4819052	0.851	rs35064782	ENSG00000215447.6	BX322557.10	-3.84	0.000131	0.00793	-0.12	-0.12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45254445	chr21:45288052~45291738:+
BRCA	cis	rs832187	0.64	rs3774729	ENSG00000280620.1	SCAANT1	3.84	0.000131	0.00793	0.15	0.12	Schizophrenia;	chr3:63996406	chr3:63911518~63911772:-
BRCA	cis	rs78487399	0.808	rs78191305	ENSG00000234936.1	AC010883.5	3.84	0.000131	0.00793	0.18	0.12	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43446839	chr2:43229573~43233394:+
BRCA	cis	rs801193	0.66	rs2659897	ENSG00000229180.5	GS1-124K5.11	-3.84	0.000131	0.00793	-0.1	-0.12	Aortic root size;	chr7:66722728	chr7:66526088~66542624:-
BRCA	cis	rs1479090	0.762	rs4295216	ENSG00000250027.1	RP11-563E2.2	-3.84	0.000131	0.00793	-0.16	-0.12	Lung cancer;	chr4:163173418	chr4:163108785~163119965:+
BRCA	cis	rs3805389	0.504	rs59571323	ENSG00000273257.1	RP11-177J6.1	-3.84	0.000131	0.00793	-0.19	-0.12	Waist-to-hip ratio adjusted for body mass index;	chr4:55611187	chr4:55387949~55388271:+
BRCA	cis	rs13434995	0.838	rs57178140	ENSG00000273257.1	RP11-177J6.1	-3.84	0.000131	0.00793	-0.19	-0.12	Adiponectin levels;	chr4:55611361	chr4:55387949~55388271:+
BRCA	cis	rs1156327	0.51	rs8052275	ENSG00000188477.11	AC003003.5	-3.84	0.000131	0.00793	-0.28	-0.12	Periodontal disease-related phenotypes;	chr16:19318781	chr16:19285783~19310947:+
BRCA	cis	rs6931421	0.8	rs12662365	ENSG00000272129.1	RP11-250B2.6	3.84	0.000131	0.00793	0.16	0.12	Sitting height ratio;	chr6:80195672	chr6:80355424~80356859:+
BRCA	cis	rs2562456	0.833	rs2562487	ENSG00000213976.4	CTD-2561J22.2	-3.84	0.000131	0.00793	-0.15	-0.12	Pain;	chr19:21468580	chr19:21382865~21387177:+
BRCA	cis	rs1949733	1	rs6837429	ENSG00000205959.3	RP11-689P11.2	-3.84	0.000131	0.00793	-0.12	-0.12	Response to antineoplastic agents;	chr4:8500647	chr4:8482270~8512610:+
BRCA	cis	rs1836229	0.874	rs10121203	ENSG00000225706.1	PTPRD-AS1	-3.84	0.000131	0.00793	-0.13	-0.12	Restless legs syndrome;	chr9:8833227	chr9:8858130~8862255:+
BRCA	cis	rs11158026	0.603	rs17832269	ENSG00000233924.1	AL160471.6	-3.84	0.000131	0.00793	-0.14	-0.12	Parkinson's disease;	chr14:54965373	chr14:55004813~55005687:-
BRCA	cis	rs890448	0.796	rs2433303	ENSG00000254531.1	FLJ20021	3.84	0.000131	0.00793	0.14	0.12	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101425155	chr4:101347780~101348883:+
BRCA	cis	rs9307551	0.741	rs1440860	ENSG00000250334.4	LINC00989	-3.84	0.000131	0.00793	-0.18	-0.12	Refractive error;	chr4:79509083	chr4:79492416~79576460:+
BRCA	cis	rs17756712	0.527	rs1747586	ENSG00000271911.1	RP11-532F6.5	-3.84	0.000131	0.00793	-0.16	-0.12	Vertical cup-disc ratio;	chr6:614375	chr6:761675~780648:+
BRCA	cis	rs73201462	1	rs2811526	ENSG00000242551.2	POU5F1P6	-3.84	0.000131	0.00794	-0.2	-0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128276875	chr3:128674735~128677005:-
BRCA	cis	rs73201462	0.908	rs2811373	ENSG00000242551.2	POU5F1P6	-3.84	0.000131	0.00794	-0.2	-0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128278586	chr3:128674735~128677005:-
BRCA	cis	rs4427176	0.652	rs7833036	ENSG00000233609.3	RP11-62H7.2	3.84	0.000131	0.00794	0.15	0.12	Mosquito bite size;	chr8:9615442	chr8:8961200~8979025:+
BRCA	cis	rs1075265	0.621	rs2542593	ENSG00000272156.1	RP11-477N3.1	-3.84	0.000131	0.00794	-0.12	-0.12	Chronotype;Morning vs. evening chronotype;	chr2:53804299	chr2:54082554~54085066:+
BRCA	cis	rs7243821	0.543	rs62091521	ENSG00000267112.1	RP11-839G9.1	3.84	0.000131	0.00794	0.14	0.12	Chin dimples;	chr18:54898921	chr18:54885866~54898083:-
BRCA	cis	rs739496	0.947	rs2301621	ENSG00000257624.1	RP1-128M12.3	3.84	0.000131	0.00794	0.16	0.12	Platelet count;	chr12:111457468	chr12:112000739~112000985:-
BRCA	cis	rs2400749	0.739	rs4545740	ENSG00000258521.1	RP11-638I2.9	-3.84	0.000131	0.00794	-0.12	-0.12	Alzheimer's disease (survival time);	chr14:99568912	chr14:100339832~100340554:+
BRCA	cis	rs4664293	0.631	rs6714899	ENSG00000226266.5	AC009961.3	-3.84	0.000131	0.00794	-0.14	-0.12	Monocyte percentage of white cells;	chr2:159592895	chr2:159670708~159712435:-
BRCA	cis	rs4664293	0.647	rs4665090	ENSG00000226266.5	AC009961.3	-3.84	0.000131	0.00794	-0.14	-0.12	Monocyte percentage of white cells;	chr2:159597396	chr2:159670708~159712435:-
BRCA	cis	rs4664293	0.647	rs4635484	ENSG00000226266.5	AC009961.3	-3.84	0.000131	0.00794	-0.14	-0.12	Monocyte percentage of white cells;	chr2:159597619	chr2:159670708~159712435:-
BRCA	cis	rs897984	0.542	rs6565217	ENSG00000275263.1	RP11-1072A3.4	-3.84	0.000131	0.00794	-0.13	-0.12	Dementia with Lewy bodies;	chr16:31072003	chr16:30956872~30957199:-
BRCA	cis	rs1912124	1	rs950070	ENSG00000271983.1	RP11-28H5.2	3.84	0.000131	0.00794	0.24	0.12	Peripheral arterial disease (traffic-related air pollution interaction);	chr15:81226465	chr15:80693216~80693707:-
BRCA	cis	rs1635	0.512	rs73742545	ENSG00000216901.1	AL022393.7	3.84	0.000132	0.00794	0.27	0.12	Schizophrenia;	chr6:28351246	chr6:28176188~28176674:+
BRCA	cis	rs7226408	0.842	rs8083264	ENSG00000267707.2	RP11-95O2.5	3.84	0.000132	0.00794	0.18	0.12	Obesity-related traits;	chr18:36747536	chr18:37243776~37247506:+
BRCA	cis	rs2880765	0.835	rs730372	ENSG00000230373.7	GOLGA6L5P	-3.84	0.000132	0.00795	-0.13	-0.12	Coronary artery disease;	chr15:85494962	chr15:84507885~84516814:-
BRCA	cis	rs6696239	0.956	rs6659012	ENSG00000215812.5	ZNF847P	3.84	0.000132	0.00795	0.16	0.12	Height;	chr1:227641015	chr1:227696892~227706699:-
BRCA	cis	rs17301013	0.932	rs7542389	ENSG00000234741.6	GAS5	3.84	0.000132	0.00795	0.12	0.12	Systemic lupus erythematosus;	chr1:174565104	chr1:173863900~173868882:-
BRCA	cis	rs6751744	0.514	rs12386214	ENSG00000226266.5	AC009961.3	-3.84	0.000132	0.00795	-0.14	-0.12	Dysphagia;	chr2:159675012	chr2:159670708~159712435:-
BRCA	cis	rs4664293	0.932	rs4665104	ENSG00000226266.5	AC009961.3	-3.84	0.000132	0.00795	-0.14	-0.12	Monocyte percentage of white cells;	chr2:159675847	chr2:159670708~159712435:-
BRCA	cis	rs4664293	0.967	rs7595639	ENSG00000226266.5	AC009961.3	-3.84	0.000132	0.00795	-0.14	-0.12	Monocyte percentage of white cells;	chr2:159676533	chr2:159670708~159712435:-
BRCA	cis	rs7615952	0.546	rs2976733	ENSG00000248787.1	RP11-666A20.4	-3.84	0.000132	0.00795	-0.17	-0.12	Blood pressure (smoking interaction);	chr3:125695294	chr3:125908005~125910272:-
BRCA	cis	rs1876905	0.68	rs193281	ENSG00000272356.1	RP5-1112D6.8	3.84	0.000132	0.00795	0.16	0.12	Mean corpuscular hemoglobin;	chr6:111166487	chr6:111309203~111313517:+
BRCA	cis	rs61542988	0.57	rs62448268	ENSG00000228649.7	AC005682.5	3.84	0.000132	0.00795	0.12	0.12	Fibrinogen levels;	chr7:22789845	chr7:22854178~22861579:+
BRCA	cis	rs875971	0.928	rs2036263	ENSG00000271064.1	RP11-792A8.3	3.84	0.000132	0.00795	0.14	0.12	Aortic root size;	chr7:66335210	chr7:66748838~66749077:-
BRCA	cis	rs875971	0.862	rs10240949	ENSG00000271064.1	RP11-792A8.3	3.84	0.000132	0.00795	0.14	0.12	Aortic root size;	chr7:66339430	chr7:66748838~66749077:-
BRCA	cis	rs875971	0.862	rs7782704	ENSG00000271064.1	RP11-792A8.3	3.84	0.000132	0.00795	0.14	0.12	Aortic root size;	chr7:66340379	chr7:66748838~66749077:-
BRCA	cis	rs73108077	0.92	rs6057657	ENSG00000277112.2	RP11-755J8.1	3.84	0.000132	0.00795	0.19	0.12	Red blood cell density in sickle cell anemia;	chr20:31376027	chr20:30681825~30723932:-
BRCA	cis	rs75804782	0.641	rs56000747	ENSG00000186235.9	AC016757.3	3.84	0.000132	0.00795	0.26	0.12	Chronotype;Morning vs. evening chronotype;	chr2:238409900	chr2:238224552~238231677:-
BRCA	cis	rs17756712	0.725	rs2294667	ENSG00000271911.1	RP11-532F6.5	3.84	0.000132	0.00795	0.2	0.12	Vertical cup-disc ratio;	chr6:617523	chr6:761675~780648:+
BRCA	cis	rs7935829	0.572	rs610352	ENSG00000275344.1	MIR6503	-3.84	0.000132	0.00795	-0.12	-0.12	Fibrinogen levels;	chr11:60229495	chr11:60209071~60209156:-
BRCA	cis	rs1075265	0.553	rs2692532	ENSG00000272156.1	RP11-477N3.1	-3.84	0.000132	0.00795	-0.12	-0.12	Chronotype;Morning vs. evening chronotype;	chr2:53778962	chr2:54082554~54085066:+
BRCA	cis	rs7312933	0.67	rs2406568	ENSG00000257225.1	RP11-328C8.4	-3.84	0.000132	0.00796	-0.14	-0.12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42158495	chr12:42459366~42466128:+
BRCA	cis	rs78472555	0.633	rs325412	ENSG00000259363.4	CTD-2054N24.2	-3.84	0.000132	0.00796	-0.16	-0.12	Post bronchodilator FEV1/FVC ratio in COPD;	chr15:99705654	chr15:99807023~99877148:+
BRCA	cis	rs12612435	0.793	rs35141009	ENSG00000226806.1	AC011893.3	3.84	0.000132	0.00796	0.14	0.12	Takotsubo syndrome;	chr2:136368844	chr2:135820191~135823087:+
BRCA	cis	rs45509595	0.841	rs200501	ENSG00000216901.1	AL022393.7	3.84	0.000132	0.00796	0.23	0.12	Breast cancer;	chr6:27821164	chr6:28176188~28176674:+
BRCA	cis	rs6453278	1	rs6453278	ENSG00000250802.5	ZBED3-AS1	3.84	0.000132	0.00796	0.16	0.12	Autism;	chr5:77121217	chr5:77086740~77166909:+
BRCA	cis	rs11098499	0.874	rs17839089	ENSG00000260091.1	RP11-33B1.4	-3.84	0.000132	0.00796	-0.11	-0.12	Corneal astigmatism;	chr4:119189914	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.874	rs6826823	ENSG00000260091.1	RP11-33B1.4	-3.84	0.000132	0.00796	-0.11	-0.12	Corneal astigmatism;	chr4:119190943	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.874	rs12509054	ENSG00000260091.1	RP11-33B1.4	-3.84	0.000132	0.00796	-0.11	-0.12	Corneal astigmatism;	chr4:119193920	chr4:119409333~119410233:+
BRCA	cis	rs7048146	0.51	rs7859790	ENSG00000213539.4	YBX1P6	-3.84	0.000132	0.00796	-0.13	-0.12	Vascular brain injury;	chr9:109528203	chr9:109532830~109534332:-
BRCA	cis	rs6599077	0.95	rs11713891	ENSG00000223797.4	ENTPD3-AS1	3.84	0.000132	0.00796	0.14	0.12	Sleep-related phenotypes;	chr3:40064660	chr3:40313802~40453329:-
BRCA	cis	rs6599077	0.95	rs11706060	ENSG00000223797.4	ENTPD3-AS1	3.84	0.000132	0.00796	0.14	0.12	Sleep-related phenotypes;	chr3:40064693	chr3:40313802~40453329:-
BRCA	cis	rs6599077	0.95	rs67319348	ENSG00000223797.4	ENTPD3-AS1	3.84	0.000132	0.00796	0.14	0.12	Sleep-related phenotypes;	chr3:40065439	chr3:40313802~40453329:-
BRCA	cis	rs6599077	0.95	rs9853925	ENSG00000223797.4	ENTPD3-AS1	3.84	0.000132	0.00796	0.14	0.12	Sleep-related phenotypes;	chr3:40065804	chr3:40313802~40453329:-
BRCA	cis	rs6599077	0.95	rs9816042	ENSG00000223797.4	ENTPD3-AS1	3.84	0.000132	0.00796	0.14	0.12	Sleep-related phenotypes;	chr3:40065913	chr3:40313802~40453329:-
BRCA	cis	rs6599077	0.95	rs4676565	ENSG00000223797.4	ENTPD3-AS1	3.84	0.000132	0.00796	0.14	0.12	Sleep-related phenotypes;	chr3:40066889	chr3:40313802~40453329:-
BRCA	cis	rs6599077	0.95	rs4676465	ENSG00000223797.4	ENTPD3-AS1	3.84	0.000132	0.00796	0.14	0.12	Sleep-related phenotypes;	chr3:40067704	chr3:40313802~40453329:-
BRCA	cis	rs6599077	0.95	rs9868419	ENSG00000223797.4	ENTPD3-AS1	3.84	0.000132	0.00796	0.14	0.12	Sleep-related phenotypes;	chr3:40068108	chr3:40313802~40453329:-
BRCA	cis	rs6599077	0.95	rs9868552	ENSG00000223797.4	ENTPD3-AS1	3.84	0.000132	0.00796	0.14	0.12	Sleep-related phenotypes;	chr3:40068170	chr3:40313802~40453329:-
BRCA	cis	rs8099996	0.767	rs8102273	ENSG00000267277.1	CTD-2342J14.6	3.84	0.000132	0.00797	0.14	0.12	Inflammatory skin disease;	chr19:11069371	chr19:11368123~11374935:-
BRCA	cis	rs7267979	0.604	rs242130	ENSG00000204556.4	CTD-2514C3.1	3.84	0.000132	0.00797	0.16	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25613384	chr20:26018832~26020684:+
BRCA	cis	rs58521262	0.585	rs440580	ENSG00000268105.1	RP11-369G6.2	3.84	0.000132	0.00797	0.16	0.12	Testicular germ cell tumor;	chr19:22938877	chr19:23125665~23128543:+
BRCA	cis	rs17301013	0.761	rs332805	ENSG00000234741.6	GAS5	3.84	0.000132	0.00797	0.12	0.12	Systemic lupus erythematosus;	chr1:174652487	chr1:173863900~173868882:-
BRCA	cis	rs801193	1	rs3778909	ENSG00000273142.1	RP11-458F8.4	-3.84	0.000132	0.00797	-0.1	-0.12	Aortic root size;	chr7:66790659	chr7:66902857~66906297:+
BRCA	cis	rs524281	0.773	rs2236651	ENSG00000255038.1	RP11-1167A19.2	-3.84	0.000132	0.00797	-0.18	-0.12	Electroencephalogram traits;	chr11:66233947	chr11:66067277~66069619:-
BRCA	cis	rs524281	0.773	rs10896105	ENSG00000255038.1	RP11-1167A19.2	-3.84	0.000132	0.00797	-0.18	-0.12	Electroencephalogram traits;	chr11:66234789	chr11:66067277~66069619:-
BRCA	cis	rs11098499	0.874	rs10022508	ENSG00000225892.3	RP11-384K6.2	3.84	0.000132	0.00797	0.13	0.12	Corneal astigmatism;	chr4:119194073	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.73	rs12505735	ENSG00000250412.1	KLHL2P1	3.84	0.000132	0.00797	0.14	0.12	Corneal astigmatism;	chr4:119611801	chr4:119334329~119378233:+
BRCA	cis	rs9470794	1	rs57405566	ENSG00000204110.6	RP1-153P14.8	-3.84	0.000132	0.00797	-0.18	-0.12	Type 2 diabetes;	chr6:38159093	chr6:37507348~37535616:+
BRCA	cis	rs2041840	1	rs1861444	ENSG00000272054.1	RP11-423P10.2	3.84	0.000132	0.00797	0.1	0.12	Chronic lymphocytic leukemia;	chr2:37237368	chr2:37208875~37212677:+
BRCA	cis	rs1008375	1	rs2315561	ENSG00000249502.1	AC006160.5	-3.84	0.000132	0.00797	-0.13	-0.12	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17678072	chr4:17587467~17614571:-
BRCA	cis	rs1912124	1	rs113643882	ENSG00000271983.1	RP11-28H5.2	3.84	0.000132	0.00797	0.24	0.12	Peripheral arterial disease (traffic-related air pollution interaction);	chr15:81209555	chr15:80693216~80693707:-
BRCA	cis	rs1912124	0.92	rs115480823	ENSG00000271983.1	RP11-28H5.2	3.84	0.000132	0.00797	0.24	0.12	Peripheral arterial disease (traffic-related air pollution interaction);	chr15:81209751	chr15:80693216~80693707:-
BRCA	cis	rs67696533	0.6	rs4911097	ENSG00000277692.1	RP11-358N2.2	-3.84	0.000132	0.00798	-0.14	-0.12	White blood cell count (basophil);Basophil percentage of granulocytes;Basophil percentage of white cells;	chr20:32533567	chr20:32355053~32355734:+
BRCA	cis	rs73201462	0.708	rs34862979	ENSG00000242551.2	POU5F1P6	3.84	0.000132	0.00798	0.2	0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128131521	chr3:128674735~128677005:-
BRCA	cis	rs9840812	0.769	rs606725	ENSG00000273486.1	RP11-731C17.2	-3.84	0.000132	0.00798	-0.14	-0.12	Fibrinogen levels;	chr3:136267245	chr3:136837338~136839021:-
BRCA	cis	rs11088226	0.681	rs2833906	ENSG00000186842.4	LINC00846	-3.84	0.000132	0.00798	-0.19	-0.12	Gastritis;	chr21:32573211	chr21:32572238~32575881:-
BRCA	cis	rs7267979	1	rs398036	ENSG00000274973.1	RP13-401N8.7	-3.84	0.000132	0.00798	-0.13	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25459214	chr20:25845497~25845862:+
BRCA	cis	rs7267979	1	rs397119	ENSG00000274973.1	RP13-401N8.7	-3.84	0.000132	0.00798	-0.13	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25459551	chr20:25845497~25845862:+
BRCA	cis	rs7896471	0.546	rs12248487	ENSG00000227695.4	DNMBP-AS1	-3.84	0.000132	0.00798	-0.27	-0.12	Blood protein levels;	chr10:99979542	chr10:99927010~99958381:+
BRCA	cis	rs1555322	1	rs2425032	ENSG00000279253.1	RP4-614O4.13	-3.84	0.000132	0.00798	-0.19	-0.12	Attention deficit hyperactivity disorder;	chr20:35267651	chr20:35262727~35264187:-
BRCA	cis	rs801193	1	rs11773829	ENSG00000265600.1	AC006480.1	3.84	0.000132	0.00798	0.14	0.12	Aortic root size;	chr7:66676087	chr7:67356680~67356779:+
BRCA	cis	rs739401	0.611	rs7394974	ENSG00000247473.2	CARS-AS1	3.84	0.000132	0.00798	0.14	0.12	Longevity;	chr11:3017638	chr11:3029009~3041260:+
BRCA	cis	rs8177876	0.822	rs10514514	ENSG00000261061.1	RP11-303E16.2	-3.84	0.000132	0.00798	-0.16	-0.12	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081668	chr16:81030770~81031485:+
BRCA	cis	rs6545883	0.965	rs9989775	ENSG00000270820.4	RP11-355B11.2	3.84	0.000132	0.00798	0.14	0.12	Tuberculosis;	chr2:61534639	chr2:61471188~61484130:+
BRCA	cis	rs1156327	0.51	rs28527477	ENSG00000188477.11	AC003003.5	-3.84	0.000132	0.00798	-0.28	-0.12	Periodontal disease-related phenotypes;	chr16:19317966	chr16:19285783~19310947:+
BRCA	cis	rs4886920	0.855	rs4886526	ENSG00000260776.4	RP11-114H24.2	-3.84	0.000132	0.00798	-0.14	-0.12	Neuroticism;	chr15:77821079	chr15:77914217~77926846:-
BRCA	cis	rs4415084	0.68	rs12652026	ENSG00000251141.4	RP11-53O19.1	3.84	0.000132	0.00799	0.11	0.12	Breast cancer;	chr5:44798507	chr5:44744900~44808777:-
BRCA	cis	rs6964587	1	rs34548928	ENSG00000188693.7	CYP51A1-AS1	-3.84	0.000132	0.00799	-0.13	-0.12	Breast cancer;	chr7:92039051	chr7:92134604~92180725:+
BRCA	cis	rs2243480	1	rs1618893	ENSG00000232559.3	GS1-124K5.12	3.84	0.000132	0.00799	0.21	0.12	Diabetic kidney disease;	chr7:66631132	chr7:66554588~66576923:-
BRCA	cis	rs1023500	0.505	rs134874	ENSG00000182057.4	OGFRP1	3.84	0.000132	0.00799	0.13	0.12	Schizophrenia;	chr22:42265138	chr22:42269753~42275196:+
BRCA	cis	rs2274273	0.588	rs58296156	ENSG00000259318.1	RP11-454L9.2	3.84	0.000132	0.00799	0.11	0.12	Protein biomarker;	chr14:55361609	chr14:55394940~55395233:-
BRCA	cis	rs4950322	0.576	rs4950427	ENSG00000237188.3	RP11-337C18.8	-3.84	0.000132	0.00799	-0.13	-0.12	Protein quantitative trait loci;	chr1:147391175	chr1:147172771~147211568:+
BRCA	cis	rs4713118	0.629	rs149899	ENSG00000216901.1	AL022393.7	3.84	0.000132	0.00799	0.17	0.12	Parkinson's disease;	chr6:28052201	chr6:28176188~28176674:+
BRCA	cis	rs4713118	0.629	rs172165	ENSG00000216901.1	AL022393.7	3.84	0.000132	0.00799	0.17	0.12	Parkinson's disease;	chr6:28053036	chr6:28176188~28176674:+
BRCA	cis	rs7572733	0.935	rs1607373	ENSG00000231621.1	AC013264.2	-3.84	0.000132	0.00799	-0.11	-0.12	Dermatomyositis;	chr2:197935808	chr2:197197991~197199273:+
BRCA	cis	rs2749097	0.735	rs11208271	ENSG00000244256.3	RN7SL130P	-3.84	0.000132	0.00799	-0.15	-0.12	Alcohol consumption (transferrin glycosylation);	chr1:63696394	chr1:63655743~63656047:+
BRCA	cis	rs10844706	0.699	rs2058560	ENSG00000278635.1	CTD-2318O12.1	-3.84	0.000132	0.00799	-0.13	-0.12	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9721093	chr12:9415641~9416718:+
BRCA	cis	rs934734	1	rs934734	ENSG00000204929.10	AC074391.1	-3.84	0.000132	0.00799	-0.14	-0.12	Rheumatoid arthritis;	chr2:65368452	chr2:65436711~66084639:+
BRCA	cis	rs6012564	0.964	rs6125577	ENSG00000222365.1	SNORD12B	3.84	0.000132	0.00799	0.12	0.12	Anger;	chr20:49166558	chr20:49280319~49280409:+
BRCA	cis	rs7620503	0.959	rs937509	ENSG00000277241.1	RP11-114M1.3	3.84	0.000132	0.00799	0.13	0.12	Corneal structure;	chr3:177569913	chr3:177700346~177701072:-
BRCA	cis	rs7620503	0.959	rs2055366	ENSG00000277241.1	RP11-114M1.3	3.84	0.000132	0.00799	0.13	0.12	Corneal structure;	chr3:177572557	chr3:177700346~177701072:-
BRCA	cis	rs16944613	0.588	rs12438183	ENSG00000271396.1	RP11-697E2.9	-3.84	0.000132	0.00799	-0.2	-0.12	Colorectal cancer;	chr15:90596012	chr15:90284376~90285580:-
BRCA	cis	rs6728642	0.908	rs17842456	ENSG00000270187.1	IGKV1OR2-11	-3.84	0.000133	0.008	-0.13	-0.12	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:97359380	chr2:97386082~97386368:+
BRCA	cis	rs8030605	0.778	rs72740562	ENSG00000277245.1	RP11-48G14.3	3.84	0.000133	0.008	0.25	0.12	Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;	chr15:56331172	chr15:56447120~56447697:+
BRCA	cis	rs10043775	1	rs10060623	ENSG00000251330.3	CTD-2283N19.1	-3.84	0.000133	0.008	-0.14	-0.12	Periodontal microbiota;	chr5:148411636	chr5:148430159~148430807:-
BRCA	cis	rs4930561	0.765	rs10896304	ENSG00000255306.1	RP5-901A4.1	-3.84	0.000133	0.008	-0.12	-0.12	Breast cancer in childhood cancer survivors;IgG glycosylation;	chr11:68214247	chr11:68024809~68030461:-
BRCA	cis	rs6736093	0.669	rs6704665	ENSG00000236307.2	EEF1E1P1	-3.84	0.000133	0.008	-0.14	-0.12	Coronary artery disease;	chr2:112053445	chr2:111887914~111888741:+
BRCA	cis	rs6736093	0.704	rs6722814	ENSG00000236307.2	EEF1E1P1	-3.84	0.000133	0.008	-0.14	-0.12	Coronary artery disease;	chr2:112053505	chr2:111887914~111888741:+
BRCA	cis	rs8098244	0.964	rs2082047	ENSG00000265752.2	RP11-403A21.1	3.84	0.000133	0.008	0.15	0.12	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23909922	chr18:23957754~23982556:-
BRCA	cis	rs6496932	0.503	rs7170370	ENSG00000259630.2	CTD-2262B20.1	-3.84	0.000133	0.008	-0.16	-0.12	Central corneal thickness;Corneal structure;	chr15:85414505	chr15:85415228~85415633:+
BRCA	cis	rs875971	0.66	rs801211	ENSG00000223473.2	GS1-124K5.3	-3.84	0.000133	0.008	-0.09	-0.12	Aortic root size;	chr7:66550702	chr7:66491049~66493566:-
BRCA	cis	rs875971	0.638	rs801205	ENSG00000223473.2	GS1-124K5.3	-3.84	0.000133	0.008	-0.09	-0.12	Aortic root size;	chr7:66557157	chr7:66491049~66493566:-
BRCA	cis	rs875971	0.617	rs810400	ENSG00000223473.2	GS1-124K5.3	-3.84	0.000133	0.008	-0.09	-0.12	Aortic root size;	chr7:66557902	chr7:66491049~66493566:-
BRCA	cis	rs871012	0.502	rs60416963	ENSG00000251405.2	CTB-109A12.1	-3.84	0.000133	0.008	-0.17	-0.12	IgG glycosylation;	chr5:157441157	chr5:157362615~157460078:-
BRCA	cis	rs524281	0.817	rs7115081	ENSG00000255038.1	RP11-1167A19.2	-3.84	0.000133	0.008	-0.17	-0.12	Electroencephalogram traits;	chr11:66086070	chr11:66067277~66069619:-
BRCA	cis	rs524281	0.861	rs11227403	ENSG00000255038.1	RP11-1167A19.2	-3.84	0.000133	0.008	-0.17	-0.12	Electroencephalogram traits;	chr11:66090957	chr11:66067277~66069619:-
BRCA	cis	rs524281	0.861	rs1862005	ENSG00000255038.1	RP11-1167A19.2	-3.84	0.000133	0.008	-0.17	-0.12	Electroencephalogram traits;	chr11:66095931	chr11:66067277~66069619:-
BRCA	cis	rs524281	0.861	rs7935336	ENSG00000255038.1	RP11-1167A19.2	-3.84	0.000133	0.008	-0.17	-0.12	Electroencephalogram traits;	chr11:66097854	chr11:66067277~66069619:-
BRCA	cis	rs524281	0.861	rs11227409	ENSG00000255038.1	RP11-1167A19.2	-3.84	0.000133	0.008	-0.17	-0.12	Electroencephalogram traits;	chr11:66103467	chr11:66067277~66069619:-
BRCA	cis	rs524281	0.861	rs11227410	ENSG00000255038.1	RP11-1167A19.2	-3.84	0.000133	0.008	-0.17	-0.12	Electroencephalogram traits;	chr11:66105925	chr11:66067277~66069619:-
BRCA	cis	rs613391	0.561	rs1020466	ENSG00000265194.1	RP11-70L8.4	-3.84	0.000133	0.008	-0.12	-0.12	Quantitative traits;	chr9:22720922	chr9:21858910~21861926:-
BRCA	cis	rs4415084	1	rs920329	ENSG00000248779.1	RP11-53O19.2	3.84	0.000133	0.008	0.11	0.12	Breast cancer;	chr5:44702405	chr5:44752949~44765744:+
BRCA	cis	rs8114671	0.562	rs6087642	ENSG00000279253.1	RP4-614O4.13	-3.84	0.000133	0.008	-0.13	-0.12	Height;	chr20:34880503	chr20:35262727~35264187:-
BRCA	cis	rs1009077	0.514	rs62319578	ENSG00000245958.5	RP11-33B1.1	3.84	0.000133	0.008	0.15	0.12	Endometriosis;	chr4:119487266	chr4:119454791~119552025:+
BRCA	cis	rs983392	1	rs2583471	ENSG00000275344.1	MIR6503	-3.84	0.000133	0.008	-0.12	-0.12	Alzheimer's disease (late onset);	chr11:60094341	chr11:60209071~60209156:-
BRCA	cis	rs983392	1	rs2070970	ENSG00000275344.1	MIR6503	-3.84	0.000133	0.008	-0.12	-0.12	Alzheimer's disease (late onset);	chr11:60094510	chr11:60209071~60209156:-
BRCA	cis	rs983392	1	rs2847668	ENSG00000275344.1	MIR6503	-3.84	0.000133	0.008	-0.12	-0.12	Alzheimer's disease (late onset);	chr11:60094788	chr11:60209071~60209156:-
BRCA	cis	rs2274459	0.841	rs3818526	ENSG00000249346.5	LINC01016	3.84	0.000133	0.008	0.15	0.12	Obesity (extreme);	chr6:33693196	chr6:33867506~33896914:-
BRCA	cis	rs7267979	0.565	rs6076364	ENSG00000277938.1	RP5-965G21.3	-3.84	0.000133	0.00801	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25576165	chr20:25229150~25231933:+
BRCA	cis	rs8098244	0.683	rs10853591	ENSG00000265752.2	RP11-403A21.1	3.84	0.000133	0.00801	0.13	0.12	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23845888	chr18:23957754~23982556:-
BRCA	cis	rs10788972	0.586	rs13373789	ENSG00000225183.1	RP4-758J24.4	-3.84	0.000133	0.00801	-0.14	-0.12	Parkinson disease and lewy body pathology;	chr1:54116196	chr1:54089856~54090093:+
BRCA	cis	rs9470794	1	rs11544072	ENSG00000204110.6	RP1-153P14.8	-3.84	0.000133	0.00801	-0.23	-0.12	Type 2 diabetes;	chr6:38153621	chr6:37507348~37535616:+
BRCA	cis	rs9733	0.526	rs11204696	ENSG00000231073.1	RP11-316M1.3	3.84	0.000133	0.00801	0.12	0.12	Tonsillectomy;	chr1:150686245	chr1:150973123~150975534:+
BRCA	cis	rs7712401	0.755	rs13172043	ENSG00000251538.4	RP11-166A12.1	3.84	0.000133	0.00801	0.13	0.12	Mean platelet volume;	chr5:122849064	chr5:122628952~122730685:-
BRCA	cis	rs7267979	1	rs6037095	ENSG00000277938.1	RP5-965G21.3	-3.84	0.000133	0.00801	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25355051	chr20:25229150~25231933:+
BRCA	cis	rs7267979	1	rs6050562	ENSG00000277938.1	RP5-965G21.3	-3.84	0.000133	0.00801	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25355550	chr20:25229150~25231933:+
BRCA	cis	rs2518049	0.95	rs10904411	ENSG00000224034.1	RP11-445P17.8	3.84	0.000133	0.00801	0.22	0.12	Metabolic traits;	chr10:5082563	chr10:5266033~5271236:-
BRCA	cis	rs10938353	0.906	rs17462204	ENSG00000273369.1	RP11-700J17.1	3.84	0.000133	0.00801	0.15	0.12	Body mass index;	chr4:44611465	chr4:44693946~44694386:-
BRCA	cis	rs13217239	0.646	rs12527111	ENSG00000124549.13	BTN2A3P	3.84	0.000133	0.00801	0.12	0.12	Schizophrenia;	chr6:27038696	chr6:26421391~26432383:+
BRCA	cis	rs957448	1	rs957447	ENSG00000261437.1	RP11-22C11.2	3.84	0.000133	0.00801	0.12	0.12	Nonsyndromic cleft lip with cleft palate;	chr8:94528995	chr8:94637285~94639467:-
BRCA	cis	rs3760982	0.585	rs11673534	ENSG00000267191.1	RP11-15A1.2	-3.84	0.000133	0.00801	-0.15	-0.12	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43794732	chr19:43902001~43926545:+
BRCA	cis	rs3760982	0.585	rs11673490	ENSG00000267191.1	RP11-15A1.2	-3.84	0.000133	0.00801	-0.15	-0.12	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43794733	chr19:43902001~43926545:+
BRCA	cis	rs3760982	0.585	rs11083724	ENSG00000267191.1	RP11-15A1.2	-3.84	0.000133	0.00801	-0.15	-0.12	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43794836	chr19:43902001~43926545:+
BRCA	cis	rs757081	0.658	rs214076	ENSG00000184669.7	OR7E14P	-3.84	0.000133	0.00801	-0.16	-0.12	Systolic blood pressure;	chr11:17278710	chr11:17013998~17053024:+
BRCA	cis	rs6995541	0.505	rs1055329	ENSG00000246477.3	AF131216.6	-3.84	0.000133	0.00801	-0.11	-0.12	Triglyceride levels;	chr8:10846399	chr8:11315859~11325429:-
BRCA	cis	rs7520050	0.966	rs11211208	ENSG00000234329.1	RP11-767N6.2	-3.84	0.000133	0.00801	-0.11	-0.12	Reticulocyte count;Red blood cell count;	chr1:45868584	chr1:45651039~45651826:-
BRCA	cis	rs1836229	0.874	rs7048788	ENSG00000225706.1	PTPRD-AS1	-3.84	0.000133	0.00801	-0.13	-0.12	Restless legs syndrome;	chr9:8832169	chr9:8858130~8862255:+
BRCA	cis	rs4478858	0.684	rs2271074	ENSG00000260386.4	LINC01225	-3.84	0.000133	0.00801	-0.14	-0.12	Alcohol dependence;	chr1:31261994	chr1:31500085~31540885:+
BRCA	cis	rs11098499	0.863	rs6835635	ENSG00000260404.2	RP11-384K6.6	3.84	0.000133	0.00801	0.12	0.12	Corneal astigmatism;	chr4:119537712	chr4:118591773~118633729:+
BRCA	cis	rs853679	0.546	rs200954	ENSG00000241549.7	GUSBP2	3.84	0.000133	0.00801	0.21	0.12	Depression;	chr6:27870986	chr6:26871484~26956554:-
BRCA	cis	rs7487075	0.619	rs2220727	ENSG00000257261.4	RP11-96H19.1	3.84	0.000133	0.00801	0.13	0.12	Itch intensity from mosquito bite;	chr12:46411286	chr12:46383679~46876159:+
BRCA	cis	rs13256369	0.826	rs7846050	ENSG00000233609.3	RP11-62H7.2	3.84	0.000133	0.00801	0.12	0.12	Obesity-related traits;	chr8:8718159	chr8:8961200~8979025:+
BRCA	cis	rs10463316	0.832	rs246486	ENSG00000260581.1	CTB-113P19.4	-3.84	0.000133	0.00802	-0.14	-0.12	Metabolite levels (Pyroglutamine);	chr5:151348319	chr5:151652275~151655449:+
BRCA	cis	rs757081	0.658	rs214076	ENSG00000272034.1	SNORD14A	-3.84	0.000133	0.00802	-0.13	-0.12	Systolic blood pressure;	chr11:17278710	chr11:17074654~17074744:-
BRCA	cis	rs6431644	0.694	rs638071	ENSG00000224287.2	MSL3P1	3.84	0.000133	0.00802	0.14	0.12	Left atrial antero-posterior diameter;	chr2:233846835	chr2:233865437~233868444:-
BRCA	cis	rs7267979	1	rs2482911	ENSG00000277938.1	RP5-965G21.3	-3.84	0.000133	0.00802	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25414892	chr20:25229150~25231933:+
BRCA	cis	rs2998286	0.862	rs1416816	ENSG00000237128.1	RP11-351M16.3	3.84	0.000133	0.00802	0.14	0.12	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28503491	chr10:28433008~28495813:-
BRCA	cis	rs6964587	1	rs7785095	ENSG00000188693.7	CYP51A1-AS1	3.84	0.000133	0.00802	0.13	0.12	Breast cancer;	chr7:92011459	chr7:92134604~92180725:+
BRCA	cis	rs1836229	0.874	rs7048621	ENSG00000225706.1	PTPRD-AS1	-3.84	0.000133	0.00802	-0.13	-0.12	Restless legs syndrome;	chr9:8832038	chr9:8858130~8862255:+
BRCA	cis	rs11098499	0.955	rs13114751	ENSG00000260091.1	RP11-33B1.4	-3.84	0.000133	0.00802	-0.11	-0.12	Corneal astigmatism;	chr4:119235462	chr4:119409333~119410233:+
BRCA	cis	rs7712401	0.791	rs3822367	ENSG00000251538.4	RP11-166A12.1	-3.84	0.000133	0.00802	-0.13	-0.12	Mean platelet volume;	chr5:122810577	chr5:122628952~122730685:-
BRCA	cis	rs1346	0.552	rs10791821	ENSG00000245532.5	NEAT1	-3.84	0.000133	0.00802	-0.12	-0.12	Vertical cup-disc ratio;Optic cup area;	chr11:65600852	chr11:65422774~65445540:+
BRCA	cis	rs7772486	0.875	rs10457793	ENSG00000270638.1	RP3-466P17.1	3.84	0.000133	0.00802	0.14	0.12	Lobe attachment (rater-scored or self-reported);	chr6:146094267	chr6:145735570~145737218:+
BRCA	cis	rs7772486	0.875	rs10457794	ENSG00000270638.1	RP3-466P17.1	3.84	0.000133	0.00802	0.14	0.12	Lobe attachment (rater-scored or self-reported);	chr6:146094472	chr6:145735570~145737218:+
BRCA	cis	rs28489187	0.706	rs2268667	ENSG00000223653.4	RP11-131L23.1	-3.84	0.000133	0.00802	-0.14	-0.12	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85328063	chr1:85276715~85448124:+
BRCA	cis	rs6019512	0.525	rs6125554	ENSG00000227431.4	CSE1L-AS1	3.84	0.000133	0.00802	0.14	0.12	Intelligence (multi-trait analysis);	chr20:49111570	chr20:49040463~49046044:-
BRCA	cis	rs739496	0.947	rs2285520	ENSG00000257624.1	RP1-128M12.3	3.84	0.000133	0.00802	0.16	0.12	Platelet count;	chr12:111429683	chr12:112000739~112000985:-
BRCA	cis	rs7020830	0.858	rs7856690	ENSG00000230188.1	RP11-405L18.4	-3.84	0.000133	0.00802	-0.14	-0.12	Schizophrenia;	chr9:37127548	chr9:37490421~37490893:-
BRCA	cis	rs11098499	0.954	rs28572238	ENSG00000250412.1	KLHL2P1	3.84	0.000133	0.00803	0.14	0.12	Corneal astigmatism;	chr4:119395531	chr4:119334329~119378233:+
BRCA	cis	rs7308116	0.967	rs10861788	ENSG00000274395.1	RP11-554D14.8	-3.83	0.000133	0.00803	-0.13	-0.12	Pelvic organ prolapse (moderate/severe);	chr12:107796502	chr12:107835541~107836555:-
BRCA	cis	rs733592	0.507	rs10875739	ENSG00000257763.1	OR5BK1P	3.83	0.000133	0.00803	0.12	0.12	Plateletcrit;	chr12:48087136	chr12:48355792~48356614:-
BRCA	cis	rs4666002	0.709	rs6719175	ENSG00000234072.1	AC074117.10	3.83	0.000133	0.00803	0.12	0.12	Phospholipid levels (plasma);	chr2:27636484	chr2:27356246~27367622:+
BRCA	cis	rs8049367	0.684	rs759276	ENSG00000267077.1	RP11-127I20.5	3.83	0.000133	0.00803	0.12	0.12	Nonsyndromic cleft lip with or without cleft palate;	chr16:3917543	chr16:4795265~4796532:-
BRCA	cis	rs11096990	0.634	rs6854358	ENSG00000249685.1	RP11-360F5.3	-3.83	0.000133	0.00803	-0.14	-0.12	Cognitive function;	chr4:39281492	chr4:39133913~39135608:+
BRCA	cis	rs713477	0.505	rs8019080	ENSG00000186615.9	KTN1-AS1	-3.83	0.000133	0.00803	-0.14	-0.12	Pediatric bone mineral content (femoral neck);	chr14:55424654	chr14:55499278~55580110:-
BRCA	cis	rs6993270	0.779	rs78624653	ENSG00000245330.4	KB-1471A8.1	-3.83	0.000133	0.00803	-0.18	-0.12	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr8:119916409	chr8:119867419~119874488:-
BRCA	cis	rs801193	0.548	rs6975044	ENSG00000106610.13	STAG3L4	-3.83	0.000133	0.00803	-0.16	-0.12	Aortic root size;	chr7:66762495	chr7:67302621~67321526:+
BRCA	cis	rs9470794	1	rs55825770	ENSG00000204110.6	RP1-153P14.8	-3.83	0.000133	0.00803	-0.24	-0.12	Type 2 diabetes;	chr6:38053903	chr6:37507348~37535616:+
BRCA	cis	rs9470794	1	rs55836194	ENSG00000204110.6	RP1-153P14.8	-3.83	0.000133	0.00803	-0.24	-0.12	Type 2 diabetes;	chr6:38062355	chr6:37507348~37535616:+
BRCA	cis	rs9470794	1	rs55707043	ENSG00000204110.6	RP1-153P14.8	-3.83	0.000133	0.00803	-0.24	-0.12	Type 2 diabetes;	chr6:38064215	chr6:37507348~37535616:+
BRCA	cis	rs9470794	1	rs55990078	ENSG00000204110.6	RP1-153P14.8	-3.83	0.000133	0.00803	-0.24	-0.12	Type 2 diabetes;	chr6:38064850	chr6:37507348~37535616:+
BRCA	cis	rs6088580	0.524	rs6087612	ENSG00000279253.1	RP4-614O4.13	3.83	0.000133	0.00803	0.13	0.12	Glomerular filtration rate (creatinine);	chr20:34643018	chr20:35262727~35264187:-
BRCA	cis	rs2018683	0.707	rs4722877	ENSG00000233517.1	AC005162.5	-3.83	0.000133	0.00803	-0.14	-0.12	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28933289	chr7:28987028~28988899:+
BRCA	cis	rs801193	0.636	rs2659895	ENSG00000265600.1	AC006480.1	-3.83	0.000133	0.00804	-0.14	-0.12	Aortic root size;	chr7:66731484	chr7:67356680~67356779:+
BRCA	cis	rs17767294	0.541	rs733743	ENSG00000216901.1	AL022393.7	-3.83	0.000133	0.00804	-0.24	-0.12	Parkinson's disease;	chr6:28359594	chr6:28176188~28176674:+
BRCA	cis	rs7722600	0.935	rs11957898	ENSG00000253404.1	AC034243.1	-3.83	0.000133	0.00804	-0.19	-0.12	Heart rate;	chr5:137881581	chr5:138744434~138753309:-
BRCA	cis	rs7020830	0.898	rs12554874	ENSG00000260100.1	RP11-220I1.5	-3.83	0.000133	0.00804	-0.15	-0.12	Schizophrenia;	chr9:37073905	chr9:37078813~37079776:-
BRCA	cis	rs3816183	0.958	rs2278579	ENSG00000226491.1	FTOP1	-3.83	0.000133	0.00804	-0.15	-0.12	Hypospadias;	chr2:42793695	chr2:42797225~42798712:-
BRCA	cis	rs739496	0.527	rs61612992	ENSG00000234608.6	MAPKAPK5-AS1	3.83	0.000133	0.00804	0.14	0.12	Platelet count;	chr12:111920260	chr12:111839764~111842902:-
BRCA	cis	rs739496	0.527	rs7300320	ENSG00000234608.6	MAPKAPK5-AS1	3.83	0.000133	0.00804	0.14	0.12	Platelet count;	chr12:111922364	chr12:111839764~111842902:-
BRCA	cis	rs739496	0.527	rs11066089	ENSG00000234608.6	MAPKAPK5-AS1	3.83	0.000133	0.00804	0.14	0.12	Platelet count;	chr12:111925463	chr12:111839764~111842902:-
BRCA	cis	rs7243790	0.905	rs1523871	ENSG00000277324.1	RP11-850A17.1	-3.83	0.000133	0.00804	-0.13	-0.12	Diastolic blood pressure;	chr18:54424507	chr18:54268346~54270028:-
BRCA	cis	rs2749592	0.611	rs2505199	ENSG00000273019.1	RP11-508N22.13	-3.83	0.000133	0.00804	-0.15	-0.12	Age-related hearing impairment (SNP x SNP interaction);	chr10:38103529	chr10:38149968~38150293:+
BRCA	cis	rs9921338	0.668	rs193779	ENSG00000262636.1	CTD-3088G3.4	-3.83	0.000133	0.00804	-0.19	-0.12	Vein graft stenosis in coronary artery bypass grafting;	chr16:11257108	chr16:11380859~11381118:-
BRCA	cis	rs875971	0.66	rs28698552	ENSG00000223473.2	GS1-124K5.3	3.83	0.000133	0.00804	0.09	0.12	Aortic root size;	chr7:66540031	chr7:66491049~66493566:-
BRCA	cis	rs8141529	0.748	rs5997412	ENSG00000272858.1	CTA-292E10.8	-3.83	0.000133	0.00804	-0.15	-0.12	Lymphocyte counts;	chr22:28880759	chr22:28814914~28815662:+
BRCA	cis	rs875971	0.545	rs7810213	ENSG00000273142.1	RP11-458F8.4	3.83	0.000133	0.00804	0.12	0.12	Aortic root size;	chr7:66481592	chr7:66902857~66906297:+
BRCA	cis	rs78487399	0.808	rs6717636	ENSG00000234936.1	AC010883.5	3.83	0.000133	0.00804	0.17	0.12	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43476545	chr2:43229573~43233394:+
BRCA	cis	rs62064224	0.714	rs8074594	ENSG00000279781.1	RP11-466A19.7	3.83	0.000133	0.00804	0.14	0.12	Schizophrenia;	chr17:32305979	chr17:32518322~32518934:-
BRCA	cis	rs2880765	0.835	rs4340287	ENSG00000230373.7	GOLGA6L5P	3.83	0.000133	0.00804	0.13	0.12	Coronary artery disease;	chr15:85500506	chr15:84507885~84516814:-
BRCA	cis	rs7267979	1	rs12428	ENSG00000277938.1	RP5-965G21.3	-3.83	0.000133	0.00804	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25453185	chr20:25229150~25231933:+
BRCA	cis	rs4819052	0.918	rs2330013	ENSG00000184274.3	LINC00315	-3.83	0.000133	0.00804	-0.17	-0.12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238747	chr21:45300245~45305257:-
BRCA	cis	rs875971	0.66	rs801217	ENSG00000223473.2	GS1-124K5.3	-3.83	0.000133	0.00805	-0.09	-0.12	Aortic root size;	chr7:66545590	chr7:66491049~66493566:-
BRCA	cis	rs875971	0.638	rs801216	ENSG00000223473.2	GS1-124K5.3	-3.83	0.000133	0.00805	-0.09	-0.12	Aortic root size;	chr7:66546680	chr7:66491049~66493566:-
BRCA	cis	rs875971	0.66	rs13224319	ENSG00000223473.2	GS1-124K5.3	3.83	0.000133	0.00805	0.09	0.12	Aortic root size;	chr7:66542376	chr7:66491049~66493566:-
BRCA	cis	rs7267979	1	rs6083862	ENSG00000204556.4	CTD-2514C3.1	3.83	0.000134	0.00805	0.15	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25430450	chr20:26018832~26020684:+
BRCA	cis	rs10129255	0.5	rs10143242	ENSG00000211976.2	IGHV3-73	-3.83	0.000134	0.00805	-0.09	-0.12	Kawasaki disease;	chr14:106681814	chr14:106802694~106803233:-
BRCA	cis	rs2243480	1	rs383402	ENSG00000275400.1	RP4-756H11.5	-3.83	0.000134	0.00805	-0.21	-0.12	Diabetic kidney disease;	chr7:66121666	chr7:66553805~66554199:-
BRCA	cis	rs11098499	1	rs7659194	ENSG00000260091.1	RP11-33B1.4	-3.83	0.000134	0.00805	-0.11	-0.12	Corneal astigmatism;	chr4:119285992	chr4:119409333~119410233:+
BRCA	cis	rs9650657	0.74	rs12676417	ENSG00000154316.13	TDH	-3.83	0.000134	0.00805	-0.15	-0.12	Neuroticism;	chr8:10811124	chr8:11339637~11368452:+
BRCA	cis	rs4648045	0.734	rs4648051	ENSG00000251288.2	RP11-10L12.2	-3.83	0.000134	0.00805	-0.16	-0.12	Lymphocyte percentage of white cells;	chr4:102593836	chr4:102751401~102752641:+
BRCA	cis	rs4664293	0.934	rs7604482	ENSG00000226266.5	AC009961.3	-3.83	0.000134	0.00805	-0.15	-0.12	Monocyte percentage of white cells;	chr2:159657315	chr2:159670708~159712435:-
BRCA	cis	rs7246657	0.653	rs10401525	ENSG00000267470.4	ZNF571-AS1	3.83	0.000134	0.00805	0.18	0.12	Coronary artery calcification;	chr19:37168077	chr19:37548914~37587348:+
BRCA	cis	rs6044112	0.784	rs6075067	ENSG00000273998.1	RP4-777L9.2	3.83	0.000134	0.00805	0.21	0.12	Response to taxane treatment (docetaxel);	chr20:16535179	chr20:16576068~16579615:+
BRCA	cis	rs8040855	0.627	rs17540307	ENSG00000229212.6	RP11-561C5.4	-3.83	0.000134	0.00805	-0.16	-0.12	Bulimia nervosa;	chr15:85090614	chr15:85205440~85234795:-
BRCA	cis	rs10461617	0.512	rs7715746	ENSG00000271828.1	CTD-2310F14.1	3.83	0.000134	0.00805	0.16	0.12	Type 2 diabetes;	chr5:56753010	chr5:56927874~56929573:+
BRCA	cis	rs4950322	0.57	rs4950403	ENSG00000237188.3	RP11-337C18.8	3.83	0.000134	0.00805	0.15	0.12	Protein quantitative trait loci;	chr1:147319723	chr1:147172771~147211568:+
BRCA	cis	rs4950322	0.517	rs116479391	ENSG00000237188.3	RP11-337C18.8	3.83	0.000134	0.00805	0.15	0.12	Protein quantitative trait loci;	chr1:147320940	chr1:147172771~147211568:+
BRCA	cis	rs7246967	0.608	rs370734	ENSG00000198153.8	ZNF849P	-3.83	0.000134	0.00805	-0.17	-0.12	Bronchopulmonary dysplasia;	chr19:22829784	chr19:22685167~22686732:+
BRCA	cis	rs4474465	0.85	rs10793326	ENSG00000251323.2	RP11-452H21.4	-3.83	0.000134	0.00806	-0.16	-0.12	Alzheimer's disease (survival time);	chr11:78544376	chr11:78423982~78429836:-
BRCA	cis	rs875971	0.619	rs12533585	ENSG00000223473.2	GS1-124K5.3	3.83	0.000134	0.00806	0.09	0.12	Aortic root size;	chr7:66519618	chr7:66491049~66493566:-
BRCA	cis	rs2446066	0.872	rs57676448	ENSG00000257379.1	RP11-793H13.8	3.83	0.000134	0.00806	0.18	0.12	Red blood cell count;	chr12:53401003	chr12:53441741~53467528:+
BRCA	cis	rs687432	0.627	rs1031360	ENSG00000213592.4	AP000662.9	-3.83	0.000134	0.00806	-0.14	-0.12	Parkinson's disease;	chr11:58104394	chr11:57718044~57718530:-
BRCA	cis	rs494453	0.672	rs565522	ENSG00000227811.2	FAM212B-AS1	-3.83	0.000134	0.00806	-0.15	-0.12	Osteoporosis-related phenotypes;	chr1:111718911	chr1:111739841~111747798:+
BRCA	cis	rs875971	0.54	rs35510581	ENSG00000223473.2	GS1-124K5.3	-3.83	0.000134	0.00806	-0.09	-0.12	Aortic root size;	chr7:66113790	chr7:66491049~66493566:-
BRCA	cis	rs372883	0.648	rs1003772	ENSG00000176054.6	RPL23P2	3.83	0.000134	0.00806	0.14	0.12	Pancreatic cancer;	chr21:29363824	chr21:28997613~28998033:-
BRCA	cis	rs216345	1	rs216345	ENSG00000260947.1	RP11-384P7.7	-3.83	0.000134	0.00806	-0.13	-0.12	Bipolar disorder;	chr9:33799372	chr9:33697459~33700986:+
BRCA	cis	rs875971	0.66	rs62465434	ENSG00000223473.2	GS1-124K5.3	3.83	0.000134	0.00806	0.09	0.12	Aortic root size;	chr7:66540165	chr7:66491049~66493566:-
BRCA	cis	rs863345	0.604	rs879637	ENSG00000229914.1	RP11-404O13.4	-3.83	0.000134	0.00806	-0.13	-0.12	Pneumococcal bacteremia;	chr1:158492907	chr1:158195633~158196131:-
BRCA	cis	rs863345	0.604	rs879635	ENSG00000229914.1	RP11-404O13.4	-3.83	0.000134	0.00806	-0.13	-0.12	Pneumococcal bacteremia;	chr1:158493118	chr1:158195633~158196131:-
BRCA	cis	rs11711311	0.712	rs11718013	ENSG00000241529.3	RN7SL767P	-3.83	0.000134	0.00806	-0.14	-0.12	IgG glycosylation;	chr3:113622814	chr3:113632704~113632998:+
BRCA	cis	rs7712401	0.598	rs446116	ENSG00000251538.4	RP11-166A12.1	3.83	0.000134	0.00806	0.13	0.12	Mean platelet volume;	chr5:122855435	chr5:122628952~122730685:-
BRCA	cis	rs539514	0.501	rs8000656	ENSG00000261105.4	LMO7-AS1	-3.83	0.000134	0.00806	-0.14	-0.12	Type 1 diabetes;	chr13:75826504	chr13:75604700~75635994:-
BRCA	cis	rs801193	0.967	rs2707841	ENSG00000265600.1	AC006480.1	-3.83	0.000134	0.00806	-0.14	-0.12	Aortic root size;	chr7:66692033	chr7:67356680~67356779:+
BRCA	cis	rs801193	1	rs4717310	ENSG00000265600.1	AC006480.1	-3.83	0.000134	0.00806	-0.14	-0.12	Aortic root size;	chr7:66696020	chr7:67356680~67356779:+
BRCA	cis	rs4908769	0.624	rs6678140	ENSG00000270282.1	RP5-1115A15.2	-3.83	0.000134	0.00806	-0.14	-0.12	Allergy;	chr1:8376742	chr1:8512653~8513021:+
BRCA	cis	rs7772486	0.875	rs1331640	ENSG00000270638.1	RP3-466P17.1	3.83	0.000134	0.00807	0.14	0.12	Lobe attachment (rater-scored or self-reported);	chr6:146106114	chr6:145735570~145737218:+
BRCA	cis	rs739496	0.615	rs609230	ENSG00000226469.1	ADAM1B	-3.83	0.000134	0.00807	-0.16	-0.12	Platelet count;	chr12:111709107	chr12:111927018~111929017:+
BRCA	cis	rs78487399	0.808	rs13396401	ENSG00000234936.1	AC010883.5	3.83	0.000134	0.00807	0.18	0.12	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43474074	chr2:43229573~43233394:+
BRCA	cis	rs983392	0.679	rs654415	ENSG00000275344.1	MIR6503	3.83	0.000134	0.00807	0.12	0.12	Alzheimer's disease (late onset);	chr11:60246201	chr11:60209071~60209156:-
BRCA	cis	rs1635	0.655	rs1416919	ENSG00000216901.1	AL022393.7	3.83	0.000134	0.00807	0.28	0.12	Schizophrenia;	chr6:28335107	chr6:28176188~28176674:+
BRCA	cis	rs1635	0.655	rs73742535	ENSG00000216901.1	AL022393.7	3.83	0.000134	0.00807	0.28	0.12	Schizophrenia;	chr6:28335148	chr6:28176188~28176674:+
BRCA	cis	rs1635	0.655	rs73742536	ENSG00000216901.1	AL022393.7	3.83	0.000134	0.00807	0.28	0.12	Schizophrenia;	chr6:28335466	chr6:28176188~28176674:+
BRCA	cis	rs1635	0.655	rs59598126	ENSG00000216901.1	AL022393.7	3.83	0.000134	0.00807	0.28	0.12	Schizophrenia;	chr6:28335823	chr6:28176188~28176674:+
BRCA	cis	rs1635	0.655	rs2281041	ENSG00000216901.1	AL022393.7	3.83	0.000134	0.00807	0.28	0.12	Schizophrenia;	chr6:28336068	chr6:28176188~28176674:+
BRCA	cis	rs1635	0.655	rs58019071	ENSG00000216901.1	AL022393.7	3.83	0.000134	0.00807	0.28	0.12	Schizophrenia;	chr6:28336239	chr6:28176188~28176674:+
BRCA	cis	rs6012564	1	rs6012564	ENSG00000230758.1	SNAP23P	3.83	0.000134	0.00807	0.14	0.12	Anger;	chr20:48925063	chr20:49038357~49038602:-
BRCA	cis	rs7621025	0.586	rs12330725	ENSG00000273486.1	RP11-731C17.2	-3.83	0.000134	0.00807	-0.14	-0.12	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136693738	chr3:136837338~136839021:-
BRCA	cis	rs2904967	0.703	rs2904982	ENSG00000254614.2	AP003068.23	-3.83	0.000134	0.00807	-0.26	-0.12	Mean corpuscular volume;	chr11:65236830	chr11:65177606~65181834:-
BRCA	cis	rs17772222	0.917	rs12587200	ENSG00000258789.1	RP11-507K2.3	-3.83	0.000134	0.00807	-0.14	-0.12	Coronary artery calcification;	chr14:88632060	chr14:88551597~88552493:+
BRCA	cis	rs111778408	1	rs111778408	ENSG00000258704.4	SRP54-AS1	3.83	0.000134	0.00807	0.25	0.12	Monocyte percentage of white cells;	chr14:35102957	chr14:34920858~34982532:-
BRCA	cis	rs11098499	1	rs13116504	ENSG00000260091.1	RP11-33B1.4	-3.83	0.000134	0.00807	-0.11	-0.12	Corneal astigmatism;	chr4:119288257	chr4:119409333~119410233:+
BRCA	cis	rs4449834	1	rs4449834	ENSG00000254432.1	RP11-33I11.2	-3.83	0.000134	0.00807	-0.14	-0.12	Sum eosinophil basophil counts;	chr8:60843309	chr8:60808735~60809606:-
BRCA	cis	rs2880765	0.835	rs2170736	ENSG00000230373.7	GOLGA6L5P	3.83	0.000134	0.00807	0.13	0.12	Coronary artery disease;	chr15:85500167	chr15:84507885~84516814:-
BRCA	cis	rs2514805	0.502	rs2446831	ENSG00000253585.1	KB-1184D12.1	3.83	0.000134	0.00807	0.24	0.12	Diisocyanate-induced asthma;	chr8:94103477	chr8:94097764~94104322:-
BRCA	cis	rs6012564	1	rs6063360	ENSG00000230758.1	SNAP23P	3.83	0.000134	0.00807	0.14	0.12	Anger;	chr20:49131838	chr20:49038357~49038602:-
BRCA	cis	rs754466	0.58	rs11002293	ENSG00000213514.2	RP11-428P16.2	3.83	0.000134	0.00807	0.17	0.12	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77778207	chr10:77730766~77734769:+
BRCA	cis	rs2274459	0.841	rs10456075	ENSG00000249346.5	LINC01016	3.83	0.000134	0.00807	0.15	0.12	Obesity (extreme);	chr6:33713826	chr6:33867506~33896914:-
BRCA	cis	rs9921338	0.636	rs72771866	ENSG00000262636.1	CTD-3088G3.4	-3.83	0.000134	0.00807	-0.19	-0.12	Vein graft stenosis in coronary artery bypass grafting;	chr16:11261365	chr16:11380859~11381118:-
BRCA	cis	rs6940638	0.513	rs4424065	ENSG00000224843.5	LINC00240	3.83	0.000134	0.00807	0.13	0.12	Intelligence (multi-trait analysis);	chr6:27068677	chr6:26956992~27023924:+
BRCA	cis	rs6754311	0.773	rs4988183	ENSG00000231890.6	DARS-AS1	-3.83	0.000134	0.00807	-0.15	-0.12	Mosquito bite size;	chr2:135864476	chr2:135985176~136022593:+
BRCA	cis	rs875971	0.66	rs12698534	ENSG00000223473.2	GS1-124K5.3	3.83	0.000134	0.00807	0.09	0.12	Aortic root size;	chr7:66521858	chr7:66491049~66493566:-
BRCA	cis	rs11893307	0.599	rs13423600	ENSG00000235852.1	AC005540.3	3.83	0.000134	0.00807	0.15	0.12	Mean platelet volume;	chr2:190803575	chr2:190880797~190882059:-
BRCA	cis	rs17597773	0.638	rs881995	ENSG00000257551.1	HLX-AS1	-3.83	0.000134	0.00807	-0.14	-0.12	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220811152	chr1:220832763~220880140:-
BRCA	cis	rs74233809	1	rs11191519	ENSG00000236937.2	PTGES3P4	3.83	0.000134	0.00807	0.25	0.12	Birth weight;	chr10:103025161	chr10:102845595~102845950:+
BRCA	cis	rs77741769	0.529	rs2047568	ENSG00000277423.1	RP11-173P15.9	3.83	0.000134	0.00808	0.14	0.12	Mean corpuscular volume;	chr12:120805987	chr12:120703867~120704282:+
BRCA	cis	rs4664293	0.647	rs6714917	ENSG00000226266.5	AC009961.3	-3.83	0.000134	0.00808	-0.14	-0.12	Monocyte percentage of white cells;	chr2:159592942	chr2:159670708~159712435:-
BRCA	cis	rs74233809	1	rs11191514	ENSG00000236937.2	PTGES3P4	3.83	0.000134	0.00808	0.25	0.12	Birth weight;	chr10:103013607	chr10:102845595~102845950:+
BRCA	cis	rs7020830	0.898	rs7857936	ENSG00000230188.1	RP11-405L18.4	-3.83	0.000134	0.00808	-0.14	-0.12	Schizophrenia;	chr9:37078494	chr9:37490421~37490893:-
BRCA	cis	rs4869313	0.869	rs38043	ENSG00000248734.2	CTD-2260A17.1	-3.83	0.000134	0.00808	-0.12	-0.12	Pediatric autoimmune diseases;	chr5:97001087	chr5:96784777~96785999:+
BRCA	cis	rs642803	0.551	rs1308020	ENSG00000214659.4	KRT8P26	-3.83	0.000134	0.00808	-0.15	-0.12	Urate levels;	chr11:65730087	chr11:65726939~65728214:+
BRCA	cis	rs8058578	1	rs2289442	ENSG00000280211.1	RP11-2C24.3	3.83	0.000134	0.00808	0.12	0.12	Multiple myeloma;	chr16:30728598	chr16:30773532~30776033:-
BRCA	cis	rs7809799	1	rs7809799	ENSG00000242798.1	RP11-506M12.1	3.83	0.000134	0.00808	0.21	0.12	Ulcerative colitis;	chr7:99162881	chr7:100115214~100127139:-
BRCA	cis	rs7824557	0.815	rs958648	ENSG00000154316.13	TDH	3.83	0.000134	0.00808	0.15	0.12	Retinal vascular caliber;	chr8:11246386	chr8:11339637~11368452:+
BRCA	cis	rs4266144	0.632	rs56268334	ENSG00000241770.1	RP11-555M1.3	-3.83	0.000134	0.00808	-0.18	-0.12	Coronary artery disease;	chr3:157130235	chr3:157163452~157169133:+
BRCA	cis	rs642803	0.613	rs565427	ENSG00000214659.4	KRT8P26	-3.83	0.000134	0.00809	-0.16	-0.12	Urate levels;	chr11:65765354	chr11:65726939~65728214:+
BRCA	cis	rs4699052	0.507	rs7662107	ENSG00000251288.2	RP11-10L12.2	-3.83	0.000134	0.00809	-0.15	-0.12	Testicular germ cell tumor;	chr4:103337239	chr4:102751401~102752641:+
BRCA	cis	rs72634258	0.842	rs7545745	ENSG00000238290.1	RP11-431K24.1	3.83	0.000134	0.00809	0.16	0.12	Inflammatory bowel disease;	chr1:8105607	chr1:8026738~8122702:+
BRCA	cis	rs17301013	0.861	rs34819375	ENSG00000234741.6	GAS5	3.83	0.000134	0.00809	0.12	0.12	Systemic lupus erythematosus;	chr1:174654958	chr1:173863900~173868882:-
BRCA	cis	rs6545883	0.525	rs2049747	ENSG00000273302.1	RP11-493E12.2	-3.83	0.000134	0.00809	-0.11	-0.12	Tuberculosis;	chr2:61137019	chr2:61199979~61200769:+
BRCA	cis	rs524281	0.861	rs10896081	ENSG00000255557.1	RP11-770G2.2	3.83	0.000134	0.00809	0.16	0.12	Electroencephalogram traits;	chr11:66112883	chr11:65745729~65771585:+
BRCA	cis	rs10191773	0.589	rs11691239	ENSG00000243389.1	AC012442.5	-3.83	0.000134	0.00809	-0.23	-0.12	Yeast infection;	chr2:112193023	chr2:112589040~112614431:+
BRCA	cis	rs34792	0.554	rs12929694	ENSG00000260872.1	RP11-680G24.5	-3.83	0.000134	0.00809	-0.14	-0.12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15519840	chr16:15018106~15020488:-
BRCA	cis	rs6696239	0.513	rs2999741	ENSG00000227711.2	RP11-275O4.5	-3.83	0.000134	0.00809	-0.14	-0.12	Height;	chr1:227597504	chr1:227509028~227520477:-
BRCA	cis	rs2243480	1	rs67728539	ENSG00000226002.1	RP11-460N20.5	-3.83	0.000134	0.0081	-0.19	-0.12	Diabetic kidney disease;	chr7:65913137	chr7:65084103~65100232:+
BRCA	cis	rs28829049	0.536	rs2073106	ENSG00000270728.1	RP4-657E11.10	-3.83	0.000134	0.0081	-0.13	-0.12	QRS duration in Tripanosoma cruzi seropositivity;	chr1:19222849	chr1:19297080~19297903:+
BRCA	cis	rs11098403	0.753	rs10026808	ENSG00000225892.3	RP11-384K6.2	3.83	0.000134	0.0081	0.12	0.12	Schizophrenia;	chr4:117840376	chr4:118632274~118634759:+
BRCA	cis	rs6121246	0.779	rs6060763	ENSG00000230613.1	HM13-AS1	3.83	0.000134	0.0081	0.17	0.12	Mean corpuscular hemoglobin;	chr20:31694420	chr20:31567707~31573263:-
BRCA	cis	rs11773103	1	rs73204890	ENSG00000224046.1	AC005076.5	3.83	0.000135	0.0081	0.26	0.12	Bipolar disorder or major depressive disorder (combined);	chr7:87148422	chr7:87151423~87152420:-
BRCA	cis	rs11773103	1	rs55834411	ENSG00000224046.1	AC005076.5	3.83	0.000135	0.0081	0.26	0.12	Bipolar disorder or major depressive disorder (combined);	chr7:87148864	chr7:87151423~87152420:-
BRCA	cis	rs11773103	1	rs73204892	ENSG00000224046.1	AC005076.5	3.83	0.000135	0.0081	0.26	0.12	Bipolar disorder or major depressive disorder (combined);	chr7:87149381	chr7:87151423~87152420:-
BRCA	cis	rs11773103	1	rs73204895	ENSG00000224046.1	AC005076.5	3.83	0.000135	0.0081	0.26	0.12	Bipolar disorder or major depressive disorder (combined);	chr7:87149801	chr7:87151423~87152420:-
BRCA	cis	rs11773103	0.867	rs73206912	ENSG00000224046.1	AC005076.5	3.83	0.000135	0.0081	0.26	0.12	Bipolar disorder or major depressive disorder (combined);	chr7:87159075	chr7:87151423~87152420:-
BRCA	cis	rs11773103	1	rs73210234	ENSG00000224046.1	AC005076.5	3.83	0.000135	0.0081	0.26	0.12	Bipolar disorder or major depressive disorder (combined);	chr7:87211844	chr7:87151423~87152420:-
BRCA	cis	rs10043775	0.958	rs60625004	ENSG00000251330.3	CTD-2283N19.1	-3.83	0.000135	0.0081	-0.14	-0.12	Periodontal microbiota;	chr5:148435394	chr5:148430159~148430807:-
BRCA	cis	rs11098499	0.662	rs13108589	ENSG00000225892.3	RP11-384K6.2	3.83	0.000135	0.0081	0.11	0.12	Corneal astigmatism;	chr4:119346947	chr4:118632274~118634759:+
BRCA	cis	rs8180040	0.871	rs11716661	ENSG00000280667.1	Y_RNA	-3.83	0.000135	0.0081	-0.13	-0.12	Colorectal cancer;	chr3:47476283	chr3:47501083~47501182:+
BRCA	cis	rs7833787	0.832	rs7827258	ENSG00000254054.2	RP11-156K13.3	3.83	0.000135	0.0081	0.14	0.12	Obesity-related traits;	chr8:18840785	chr8:17905756~17907887:+
BRCA	cis	rs8028182	0.501	rs7166281	ENSG00000260206.1	CTD-2026K11.2	3.83	0.000135	0.0081	0.16	0.12	Sudden cardiac arrest;	chr15:75635851	chr15:75636139~75639239:+
BRCA	cis	rs13126694	0.598	rs10005547	ENSG00000248429.4	RP11-597D13.9	3.83	0.000135	0.0081	0.11	0.12	Blood osmolality (transformed sodium);	chr4:158092407	chr4:158170752~158202877:+
BRCA	cis	rs13126694	0.633	rs9993747	ENSG00000248429.4	RP11-597D13.9	3.83	0.000135	0.0081	0.11	0.12	Blood osmolality (transformed sodium);	chr4:158092421	chr4:158170752~158202877:+
BRCA	cis	rs17756712	0.725	rs57440245	ENSG00000271911.1	RP11-532F6.5	3.83	0.000135	0.0081	0.2	0.12	Vertical cup-disc ratio;	chr6:616855	chr6:761675~780648:+
BRCA	cis	rs1912124	1	rs68020982	ENSG00000271983.1	RP11-28H5.2	3.83	0.000135	0.00811	0.25	0.12	Peripheral arterial disease (traffic-related air pollution interaction);	chr15:81222170	chr15:80693216~80693707:-
BRCA	cis	rs45509595	0.841	rs9368531	ENSG00000216676.2	RP1-15D7.1	-3.83	0.000135	0.00811	-0.2	-0.12	Breast cancer;	chr6:27814094	chr6:27652602~27652825:-
BRCA	cis	rs45509595	0.841	rs2747054	ENSG00000216676.2	RP1-15D7.1	-3.83	0.000135	0.00811	-0.2	-0.12	Breast cancer;	chr6:27815581	chr6:27652602~27652825:-
BRCA	cis	rs9847710	0.967	rs2244552	ENSG00000242849.2	ALDOAP1	3.83	0.000135	0.00811	0.13	0.12	Ulcerative colitis;	chr3:53021506	chr3:52193170~52194785:+
BRCA	cis	rs4865762	0.904	rs17242004	ENSG00000247796.2	CTD-2366F13.1	3.83	0.000135	0.00811	0.12	0.12	Intraocular pressure;	chr5:53198133	chr5:53109842~53115126:+
BRCA	cis	rs889956	0.747	rs11903925	ENSG00000233251.6	AC007743.1	-3.83	0.000135	0.00811	-0.14	-0.12	Educational attainment;	chr2:57040389	chr2:56173534~56185770:-
BRCA	cis	rs2039553	0.608	rs12428029	ENSG00000227354.5	RBM26-AS1	3.83	0.000135	0.00811	0.14	0.12	Pancreatic cancer;	chr13:79768177	chr13:79406309~79424328:+
BRCA	cis	rs6736093	0.966	rs870761	ENSG00000236307.2	EEF1E1P1	-3.83	0.000135	0.00811	-0.15	-0.12	Coronary artery disease;	chr2:111987713	chr2:111887914~111888741:+
BRCA	cis	rs12050794	0.671	rs7179427	ENSG00000260037.4	CTD-2524L6.3	3.83	0.000135	0.00811	0.15	0.12	Metabolite levels (HVA/MHPG ratio);	chr15:72224480	chr15:71818396~71823384:+
BRCA	cis	rs4415084	0.716	rs1371022	ENSG00000251141.4	RP11-53O19.1	-3.83	0.000135	0.00811	-0.11	-0.12	Breast cancer;	chr5:44847890	chr5:44744900~44808777:-
BRCA	cis	rs4415084	0.716	rs7726586	ENSG00000251141.4	RP11-53O19.1	-3.83	0.000135	0.00811	-0.11	-0.12	Breast cancer;	chr5:44848720	chr5:44744900~44808777:-
BRCA	cis	rs6585424	1	rs12779955	ENSG00000225484.5	NUTM2B-AS1	3.83	0.000135	0.00811	0.24	0.12	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80181108	chr10:79663088~79826594:-
BRCA	cis	rs9467773	0.572	rs13213953	ENSG00000224843.5	LINC00240	-3.83	0.000135	0.00811	-0.14	-0.12	Intelligence (multi-trait analysis);	chr6:26594306	chr6:26956992~27023924:+
BRCA	cis	rs1876905	0.68	rs7767302	ENSG00000255389.1	C6orf3	-3.83	0.000135	0.00811	-0.15	-0.12	Mean corpuscular hemoglobin;	chr6:111143942	chr6:111599875~111602295:+
BRCA	cis	rs10800309	0.71	rs6684960	ENSG00000225217.1	HSPA7	-3.83	0.000135	0.00811	-0.14	-0.12	Inflammatory bowel disease;Ulcerative colitis;	chr1:161494703	chr1:161606291~161608217:+
BRCA	cis	rs9650657	0.836	rs6601523	ENSG00000154316.13	TDH	3.83	0.000135	0.00811	0.15	0.12	Neuroticism;	chr8:10777631	chr8:11339637~11368452:+
BRCA	cis	rs6142618	0.543	rs2295036	ENSG00000275576.1	RP5-836N17.4	-3.83	0.000135	0.00811	-0.13	-0.12	Inflammatory bowel disease;	chr20:32115793	chr20:32116171~32116629:+
BRCA	cis	rs1437396	0.609	rs35963448	ENSG00000203327.2	AC012358.7	-3.83	0.000135	0.00812	-0.12	-0.12	Alcohol dependence;	chr2:55380316	chr2:55214387~55216126:-
BRCA	cis	rs1437396	0.657	rs4349381	ENSG00000203327.2	AC012358.7	-3.83	0.000135	0.00812	-0.12	-0.12	Alcohol dependence;	chr2:55381165	chr2:55214387~55216126:-
BRCA	cis	rs9921338	0.597	rs181582	ENSG00000262636.1	CTD-3088G3.4	-3.83	0.000135	0.00812	-0.2	-0.12	Vein graft stenosis in coronary artery bypass grafting;	chr16:11249690	chr16:11380859~11381118:-
BRCA	cis	rs6005807	0.843	rs73430186	ENSG00000272858.1	CTA-292E10.8	-3.83	0.000135	0.00812	-0.23	-0.12	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28608833	chr22:28814914~28815662:+
BRCA	cis	rs6840360	0.571	rs28608620	ENSG00000270265.1	RP11-731D1.4	-3.83	0.000135	0.00812	-0.14	-0.12	Intelligence (multi-trait analysis);	chr4:151583639	chr4:151333775~151353224:-
BRCA	cis	rs13098911	0.54	rs17214952	ENSG00000223552.1	RP11-24F11.2	-3.83	0.000135	0.00812	-0.19	-0.12	Celiac disease;	chr3:45969944	chr3:46364955~46407059:-
BRCA	cis	rs2692947	0.509	rs79546441	ENSG00000232931.4	LINC00342	3.83	0.000135	0.00812	0.13	0.12	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95553124	chr2:95807118~95816215:-
BRCA	cis	rs4073582	0.595	rs801736	ENSG00000255320.1	RP11-755F10.1	-3.83	0.000135	0.00812	-0.15	-0.12	Gout;	chr11:66160959	chr11:66244840~66246239:-
BRCA	cis	rs2694917	0.68	rs2638314	ENSG00000257576.1	RP11-153M3.1	3.83	0.000135	0.00812	0.19	0.12	Blood metabolite ratios;	chr12:56472550	chr12:56511002~56512703:+
BRCA	cis	rs13034020	0.522	rs12988616	ENSG00000271889.1	RP11-493E12.1	-3.83	0.000135	0.00812	-0.17	-0.12	Hodgkin's lymphoma;	chr2:61017528	chr2:61151433~61162105:-
BRCA	cis	rs11893307	0.536	rs6719798	ENSG00000235852.1	AC005540.3	3.83	0.000135	0.00812	0.15	0.12	Mean platelet volume;	chr2:190812938	chr2:190880797~190882059:-
BRCA	cis	rs62103177	0.525	rs8086024	ENSG00000278000.1	AC139100.4	-3.83	0.000135	0.00812	-0.16	-0.12	Opioid sensitivity;	chr18:79986623	chr18:80161752~80162413:+
BRCA	cis	rs10829156	0.66	rs7910506	ENSG00000225527.1	RP11-383B4.4	3.83	0.000135	0.00812	0.16	0.12	Sudden cardiac arrest;	chr10:18518128	chr10:18531849~18533336:-
BRCA	cis	rs11098499	0.554	rs2175381	ENSG00000260404.2	RP11-384K6.6	3.83	0.000135	0.00812	0.1	0.12	Corneal astigmatism;	chr4:119344812	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.599	rs3864142	ENSG00000260404.2	RP11-384K6.6	3.83	0.000135	0.00812	0.1	0.12	Corneal astigmatism;	chr4:119345036	chr4:118591773~118633729:+
BRCA	cis	rs17772222	0.876	rs78068036	ENSG00000258789.1	RP11-507K2.3	-3.83	0.000135	0.00812	-0.15	-0.12	Coronary artery calcification;	chr14:88754817	chr14:88551597~88552493:+
BRCA	cis	rs12446632	0.824	rs66674044	ENSG00000261195.1	CTD-2380F24.1	-3.83	0.000135	0.00812	-0.19	-0.12	Hip circumference;Body mass index (joint analysis main effects and smoking interaction);BMI in smokers;Menarche (age at onset);Obesity;Childhood body mass index;Waist circumference;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Body mass index;	chr16:19893022	chr16:19761172~19766099:-
BRCA	cis	rs875971	0.66	rs7807944	ENSG00000265600.1	AC006480.1	3.83	0.000135	0.00813	0.14	0.12	Aortic root size;	chr7:66622208	chr7:67356680~67356779:+
BRCA	cis	rs6439699	1	rs1478325	ENSG00000273486.1	RP11-731C17.2	3.83	0.000135	0.00813	0.16	0.12	Intelligence (multi-trait analysis);	chr3:137294864	chr3:136837338~136839021:-
BRCA	cis	rs7520050	0.966	rs6661910	ENSG00000234329.1	RP11-767N6.2	-3.83	0.000135	0.00813	-0.11	-0.12	Reticulocyte count;Red blood cell count;	chr1:45824960	chr1:45651039~45651826:-
BRCA	cis	rs7819412	0.521	rs11777887	ENSG00000154316.13	TDH	-3.83	0.000135	0.00813	-0.16	-0.12	Triglycerides;	chr8:11179290	chr8:11339637~11368452:+
BRCA	cis	rs8054556	1	rs7204797	ENSG00000183604.13	SMG1P5	-3.83	0.000135	0.00813	-0.11	-0.12	Autism spectrum disorder or schizophrenia;	chr16:29956694	chr16:30267553~30335374:-
BRCA	cis	rs6088580	0.634	rs6088502	ENSG00000275784.1	RP5-1125A11.6	-3.83	0.000135	0.00813	-0.13	-0.12	Glomerular filtration rate (creatinine);	chr20:34449839	chr20:33989480~33991818:-
BRCA	cis	rs9307551	0.741	rs1440863	ENSG00000250334.4	LINC00989	-3.83	0.000135	0.00813	-0.18	-0.12	Refractive error;	chr4:79503061	chr4:79492416~79576460:+
BRCA	cis	rs12468226	1	rs76021735	ENSG00000272966.1	RP11-686O6.1	3.83	0.000135	0.00813	0.2	0.12	Urate levels;	chr2:202511476	chr2:202336739~202337200:+
BRCA	cis	rs6812193	0.518	rs28597785	ENSG00000271676.1	RP11-1E1.2	3.83	0.000135	0.00813	0.17	0.12	Parkinson's disease;	chr4:76267135	chr4:77112495~77113458:-
BRCA	cis	rs6887276	0.504	rs17764688	ENSG00000245937.6	LINC01184	-3.83	0.000135	0.00813	-0.13	-0.12	Height;	chr5:128011187	chr5:127940426~128083172:-
BRCA	cis	rs4664293	0.625	rs3821300	ENSG00000224152.1	AC009506.1	3.83	0.000135	0.00813	0.12	0.12	Monocyte percentage of white cells;	chr2:159710719	chr2:159615296~159617082:+
BRCA	cis	rs9784649	1	rs3933895	ENSG00000245662.2	RP11-184E9.1	3.83	0.000135	0.00813	0.19	0.12	Peripheral arterial disease (traffic-related air pollution interaction);	chr5:25004820	chr5:25190682~25306172:+
BRCA	cis	rs11098499	0.874	rs6851169	ENSG00000225892.3	RP11-384K6.2	3.83	0.000135	0.00813	0.12	0.12	Corneal astigmatism;	chr4:119196355	chr4:118632274~118634759:+
BRCA	cis	rs6893300	0.922	rs62406187	ENSG00000250999.1	RP11-1379J22.5	3.83	0.000135	0.00813	0.17	0.12	Resting heart rate;	chr5:179758685	chr5:179657762~179664432:+
BRCA	cis	rs10129255	0.957	rs10142918	ENSG00000232216.1	IGHV3-43	3.83	0.000135	0.00813	0.09	0.12	Kawasaki disease;	chr14:106782206	chr14:106470264~106470800:-
BRCA	cis	rs10129255	0.5	rs7161740	ENSG00000254174.1	IGHV1-12	3.83	0.000135	0.00813	0.09	0.12	Kawasaki disease;	chr14:106776119	chr14:106122420~106122709:-
BRCA	cis	rs2439831	0.85	rs9944216	ENSG00000206991.1	RNU6-610P	3.83	0.000135	0.00813	0.19	0.12	Lung cancer in ever smokers;	chr15:43868575	chr15:43637632~43637738:-
BRCA	cis	rs2998286	0.723	rs332172	ENSG00000237128.1	RP11-351M16.3	3.83	0.000135	0.00813	0.15	0.12	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28610394	chr10:28433008~28495813:-
BRCA	cis	rs8049367	0.684	rs2283487	ENSG00000267077.1	RP11-127I20.5	3.83	0.000135	0.00813	0.12	0.12	Nonsyndromic cleft lip with or without cleft palate;	chr16:3919885	chr16:4795265~4796532:-
BRCA	cis	rs6546324	0.625	rs2861644	ENSG00000236780.4	AC078941.1	3.83	0.000135	0.00813	0.19	0.12	Endometriosis;	chr2:67572832	chr2:67123357~67215319:-
BRCA	cis	rs4415084	1	rs1821936	ENSG00000272335.1	RP11-53O19.3	3.83	0.000135	0.00814	0.11	0.12	Breast cancer;	chr5:44699380	chr5:44826076~44828592:+
BRCA	cis	rs2243480	1	rs34703416	ENSG00000234585.5	CCT6P3	-3.83	0.000135	0.00814	-0.18	-0.12	Diabetic kidney disease;	chr7:65835655	chr7:65038354~65074713:+
BRCA	cis	rs35306767	0.855	rs55708963	ENSG00000229869.1	RP11-363N22.2	-3.83	0.000135	0.00814	-0.2	-0.12	Eosinophil percentage of granulocytes;	chr10:879772	chr10:933026~942743:+
BRCA	cis	rs1730008	0.865	rs1095629	ENSG00000279311.1	RP11-170K4.2	-3.83	0.000135	0.00814	-0.13	-0.12	Lobe attachment (rater-scored or self-reported);	chr3:158258764	chr3:158869898~158871821:+
BRCA	cis	rs1730008	0.835	rs827091	ENSG00000279311.1	RP11-170K4.2	-3.83	0.000135	0.00814	-0.13	-0.12	Lobe attachment (rater-scored or self-reported);	chr3:158267917	chr3:158869898~158871821:+
BRCA	cis	rs10829156	0.898	rs7923072	ENSG00000225527.1	RP11-383B4.4	-3.83	0.000135	0.00814	-0.16	-0.12	Sudden cardiac arrest;	chr10:18649305	chr10:18531849~18533336:-
BRCA	cis	rs2243480	0.908	rs313822	ENSG00000237026.1	RP11-328P23.2	3.83	0.000135	0.00814	0.22	0.12	Diabetic kidney disease;	chr7:66108952	chr7:65235790~65236723:-
BRCA	cis	rs875971	0.571	rs78668714	ENSG00000273142.1	RP11-458F8.4	3.83	0.000135	0.00814	0.12	0.12	Aortic root size;	chr7:66474464	chr7:66902857~66906297:+
BRCA	cis	rs875971	0.83	rs6976714	ENSG00000273024.4	INTS4P2	-3.83	0.000135	0.00814	-0.13	-0.12	Aortic root size;	chr7:66426474	chr7:65647864~65715661:+
BRCA	cis	rs739496	0.579	rs12321677	ENSG00000234608.6	MAPKAPK5-AS1	-3.83	0.000135	0.00814	-0.14	-0.12	Platelet count;	chr12:111901211	chr12:111839764~111842902:-
BRCA	cis	rs4578769	0.836	rs3936488	ENSG00000273232.1	RP11-370A5.2	3.83	0.000135	0.00814	0.16	0.12	Eosinophil percentage of white cells;	chr18:22874459	chr18:22882825~22883357:-
BRCA	cis	rs728616	0.867	rs61860417	ENSG00000242600.5	MBL1P	3.83	0.000135	0.00815	0.27	0.12	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79974971	chr10:79904898~79950336:+
BRCA	cis	rs2411233	1	rs10851374	ENSG00000259278.1	RP11-62C7.2	3.83	0.000135	0.00815	0.14	0.12	Platelet count;	chr15:38977848	chr15:39019233~39024918:+
BRCA	cis	rs6088580	0.634	rs6058041	ENSG00000275784.1	RP5-1125A11.6	-3.83	0.000135	0.00815	-0.13	-0.12	Glomerular filtration rate (creatinine);	chr20:34430202	chr20:33989480~33991818:-
BRCA	cis	rs6600671	0.967	rs4844613	ENSG00000231429.2	RP11-343N15.2	-3.83	0.000135	0.00815	-0.14	-0.12	Hip geometry;	chr1:121431913	chr1:121412719~121429274:+
BRCA	cis	rs7339483	0.557	rs7248894	ENSG00000268442.1	CTD-2027I19.2	3.83	0.000135	0.00815	0.25	0.12	Discordance in emotional problems in monozygotic twins;	chr19:24134002	chr19:24162370~24163425:-
BRCA	cis	rs7947761	0.715	rs17712139	ENSG00000255059.1	AP000620.1	-3.83	0.000135	0.00815	-0.16	-0.12	Coronary artery disease;	chr11:100696834	chr11:100666459~100666962:+
BRCA	cis	rs35851103	0.507	rs6601649	ENSG00000154316.13	TDH	3.83	0.000136	0.00815	0.15	0.12	Neuroticism;	chr8:11999808	chr8:11339637~11368452:+
BRCA	cis	rs11673344	0.566	rs7254009	ENSG00000233527.7	ZNF529-AS1	-3.83	0.000136	0.00815	-0.13	-0.12	Obesity-related traits;	chr19:37427707	chr19:36573070~36594708:+
BRCA	cis	rs8054556	0.967	rs7193532	ENSG00000183604.13	SMG1P5	-3.83	0.000136	0.00815	-0.12	-0.12	Autism spectrum disorder or schizophrenia;	chr16:29951481	chr16:30267553~30335374:-
BRCA	cis	rs11098499	0.863	rs58452170	ENSG00000260404.2	RP11-384K6.6	3.83	0.000136	0.00815	0.11	0.12	Corneal astigmatism;	chr4:119538519	chr4:118591773~118633729:+
BRCA	cis	rs875971	0.862	rs2909688	ENSG00000229886.1	RP5-1132H15.3	3.83	0.000136	0.00815	0.13	0.12	Aortic root size;	chr7:66376625	chr7:66025126~66031544:-
BRCA	cis	rs11722228	1	rs6825187	ENSG00000250413.1	RP11-448G15.1	3.83	0.000136	0.00815	0.16	0.12	Urate levels;Serum uric acid levels;Gout;	chr4:9913701	chr4:10006482~10009725:+
BRCA	cis	rs6040449	0.847	rs1883952	ENSG00000235036.4	RP5-1099D15.1	3.83	0.000136	0.00816	0.13	0.12	Relative hand skill;	chr20:11255776	chr20:10612861~10614229:-
BRCA	cis	rs4664293	0.836	rs13421392	ENSG00000224152.1	AC009506.1	-3.83	0.000136	0.00816	-0.14	-0.12	Monocyte percentage of white cells;	chr2:159801785	chr2:159615296~159617082:+
BRCA	cis	rs12289961	0.681	rs11825676	ENSG00000265566.2	RN7SL605P	3.83	0.000136	0.00816	0.2	0.12	Lymphoma;	chr11:58260892	chr11:57528085~57528365:-
BRCA	cis	rs12289961	0.681	rs10896730	ENSG00000265566.2	RN7SL605P	3.83	0.000136	0.00816	0.2	0.12	Lymphoma;	chr11:58262603	chr11:57528085~57528365:-
BRCA	cis	rs12289961	0.681	rs61002097	ENSG00000265566.2	RN7SL605P	3.83	0.000136	0.00816	0.2	0.12	Lymphoma;	chr11:58264165	chr11:57528085~57528365:-
BRCA	cis	rs7771547	0.519	rs67313027	ENSG00000224666.3	RP1-50J22.4	3.83	0.000136	0.00816	0.14	0.12	Platelet distribution width;	chr6:36395710	chr6:36386831~36393462:+
BRCA	cis	rs1396626	0.855	rs11165438	ENSG00000235501.4	RP4-639F20.1	-3.83	0.000136	0.00816	-0.16	-0.12	Diabetic kidney disease;	chr1:95545748	chr1:94927566~94963270:+
BRCA	cis	rs1048886	1	rs12526787	ENSG00000271967.1	RP11-134K13.4	-3.83	0.000136	0.00816	-0.18	-0.12	Type 2 diabetes;	chr6:70478110	chr6:70596438~70596980:+
BRCA	cis	rs1048886	0.938	rs75668908	ENSG00000271967.1	RP11-134K13.4	-3.83	0.000136	0.00816	-0.18	-0.12	Type 2 diabetes;	chr6:70483846	chr6:70596438~70596980:+
BRCA	cis	rs375066	0.935	rs387689	ENSG00000267191.1	RP11-15A1.2	-3.83	0.000136	0.00816	-0.15	-0.12	Breast cancer;	chr19:43915959	chr19:43902001~43926545:+
BRCA	cis	rs375066	0.935	rs398193	ENSG00000267191.1	RP11-15A1.2	-3.83	0.000136	0.00816	-0.15	-0.12	Breast cancer;	chr19:43916268	chr19:43902001~43926545:+
BRCA	cis	rs375066	0.935	rs450308	ENSG00000267191.1	RP11-15A1.2	-3.83	0.000136	0.00816	-0.15	-0.12	Breast cancer;	chr19:43918206	chr19:43902001~43926545:+
BRCA	cis	rs375066	0.935	rs424729	ENSG00000267191.1	RP11-15A1.2	-3.83	0.000136	0.00816	-0.15	-0.12	Breast cancer;	chr19:43918650	chr19:43902001~43926545:+
BRCA	cis	rs375066	0.935	rs423320	ENSG00000267191.1	RP11-15A1.2	-3.83	0.000136	0.00816	-0.15	-0.12	Breast cancer;	chr19:43918830	chr19:43902001~43926545:+
BRCA	cis	rs375066	0.935	rs423752	ENSG00000267191.1	RP11-15A1.2	-3.83	0.000136	0.00816	-0.15	-0.12	Breast cancer;	chr19:43919043	chr19:43902001~43926545:+
BRCA	cis	rs11671005	0.696	rs73066211	ENSG00000265272.2	RN7SL693P	3.83	0.000136	0.00816	0.19	0.12	Mean platelet volume;	chr19:58485712	chr19:58490797~58491075:+
BRCA	cis	rs7267979	1	rs4815407	ENSG00000277938.1	RP5-965G21.3	-3.83	0.000136	0.00816	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25360842	chr20:25229150~25231933:+
BRCA	cis	rs4919687	0.55	rs10748828	ENSG00000213061.2	PFN1P11	-3.83	0.000136	0.00816	-0.16	-0.12	Colorectal cancer;	chr10:102697037	chr10:102838011~102845473:-
BRCA	cis	rs67766926	0.953	rs10193964	ENSG00000237522.1	NONOP2	-3.83	0.000136	0.00816	-0.13	-0.12	Inflammatory skin disease;	chr2:60899529	chr2:60936819~60938049:-
BRCA	cis	rs67981189	0.513	rs2526856	ENSG00000258571.1	PTTG4P	-3.83	0.000136	0.00816	-0.13	-0.12	Schizophrenia;	chr14:70946000	chr14:71085482~71085833:-
BRCA	cis	rs7246967	1	rs936526	ENSG00000198153.8	ZNF849P	-3.83	0.000136	0.00816	-0.17	-0.12	Bronchopulmonary dysplasia;	chr19:22873185	chr19:22685167~22686732:+
BRCA	cis	rs7246967	1	rs7246967	ENSG00000198153.8	ZNF849P	-3.83	0.000136	0.00816	-0.17	-0.12	Bronchopulmonary dysplasia;	chr19:22873544	chr19:22685167~22686732:+
BRCA	cis	rs1048886	0.938	rs7775962	ENSG00000271967.1	RP11-134K13.4	-3.83	0.000136	0.00816	-0.16	-0.12	Type 2 diabetes;	chr6:70422119	chr6:70596438~70596980:+
BRCA	cis	rs595982	0.517	rs10404905	ENSG00000235191.1	NUCB1-AS1	-3.83	0.000136	0.00816	-0.15	-0.12	Red cell distribution width;	chr19:48902918	chr19:48910930~48918891:-
BRCA	cis	rs6545883	0.894	rs12620105	ENSG00000273302.1	RP11-493E12.2	-3.83	0.000136	0.00816	-0.11	-0.12	Tuberculosis;	chr2:61285186	chr2:61199979~61200769:+
BRCA	cis	rs6088580	0.524	rs6088560	ENSG00000279253.1	RP4-614O4.13	3.83	0.000136	0.00816	0.13	0.12	Glomerular filtration rate (creatinine);	chr20:34640745	chr20:35262727~35264187:-
BRCA	cis	rs3015497	0.637	rs4363776	ENSG00000259113.1	RP11-406H23.2	-3.83	0.000136	0.00816	-0.13	-0.12	Mean platelet volume;	chr14:50709732	chr14:50448807~50456742:+
BRCA	cis	rs11694172	1	rs55669835	ENSG00000273456.1	RP11-686O6.2	3.83	0.000136	0.00816	0.14	0.12	Cholesterol, total;	chr2:202661245	chr2:202374932~202375604:-
BRCA	cis	rs12681366	0.663	rs2919666	ENSG00000253175.1	RP11-267M23.6	3.83	0.000136	0.00816	0.13	0.12	Nonsyndromic cleft lip with cleft palate;	chr8:94453059	chr8:94565036~94565715:+
BRCA	cis	rs11098499	0.874	rs6832670	ENSG00000225892.3	RP11-384K6.2	3.83	0.000136	0.00816	0.12	0.12	Corneal astigmatism;	chr4:119197637	chr4:118632274~118634759:+
BRCA	cis	rs8013055	0.796	rs4075105	ENSG00000275301.1	AL928761.1	-3.83	0.000136	0.00816	-0.15	-0.12	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);	chr14:105533894	chr14:105663828~105663892:+
BRCA	cis	rs1865760	0.593	rs9295678	ENSG00000272462.2	U91328.19	-3.83	0.000136	0.00817	-0.14	-0.12	Height;	chr6:25936805	chr6:25992662~26001775:+
BRCA	cis	rs17684571	0.938	rs35408048	ENSG00000231441.1	RP11-472M19.2	3.83	0.000136	0.00817	0.19	0.12	Schizophrenia;	chr6:56694746	chr6:56844002~56864078:+
BRCA	cis	rs3764021	0.506	rs10844468	ENSG00000256594.6	RP11-705C15.2	3.83	0.000136	0.00817	0.16	0.12	Type 1 diabetes;	chr12:9690799	chr12:9633419~9658412:+
BRCA	cis	rs801193	0.548	rs2109297	ENSG00000229886.1	RP5-1132H15.3	-3.83	0.000136	0.00817	-0.13	-0.12	Aortic root size;	chr7:66657397	chr7:66025126~66031544:-
BRCA	cis	rs12289961	0.681	rs11229301	ENSG00000265566.2	RN7SL605P	3.83	0.000136	0.00817	0.2	0.12	Lymphoma;	chr11:58228305	chr11:57528085~57528365:-
BRCA	cis	rs91731	0.79	rs7443939	ENSG00000249572.1	CTD-2203K17.1	-3.83	0.000136	0.00817	-0.22	-0.12	Lung function (FVC);	chr5:33229284	chr5:33424025~33440619:-
BRCA	cis	rs16846053	0.792	rs62190663	ENSG00000227403.1	AC009299.3	3.83	0.000136	0.00817	0.3	0.12	Blood osmolality (transformed sodium);	chr2:161786376	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.792	rs62190665	ENSG00000227403.1	AC009299.3	3.83	0.000136	0.00817	0.3	0.12	Blood osmolality (transformed sodium);	chr2:161787828	chr2:161244739~161249050:+
BRCA	cis	rs304029	0.512	rs56269779	ENSG00000231249.1	ITPR1-AS1	-3.83	0.000136	0.00817	-0.15	-0.12	Diabetic kidney disease;	chr3:4503408	chr3:4490891~4493163:-
BRCA	cis	rs17772222	0.876	rs56144430	ENSG00000258789.1	RP11-507K2.3	-3.83	0.000136	0.00817	-0.14	-0.12	Coronary artery calcification;	chr14:88622013	chr14:88551597~88552493:+
BRCA	cis	rs1912124	1	rs111377212	ENSG00000271983.1	RP11-28H5.2	3.83	0.000136	0.00817	0.24	0.12	Peripheral arterial disease (traffic-related air pollution interaction);	chr15:81211656	chr15:80693216~80693707:-
BRCA	cis	rs7267979	1	rs6050632	ENSG00000274414.1	RP5-965G21.4	-3.83	0.000136	0.00817	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25451965	chr20:25239007~25245229:-
BRCA	cis	rs7688540	0.723	rs7687112	ENSG00000272927.1	RP11-1191J2.5	-3.83	0.000136	0.00817	-0.15	-0.12	Facial morphology (factor 6, height of vermillion lower lip);	chr4:249767	chr4:661209~661945:-
BRCA	cis	rs9921338	0.961	rs17605444	ENSG00000263080.1	RP11-485G7.5	3.83	0.000136	0.00817	0.18	0.12	Vein graft stenosis in coronary artery bypass grafting;	chr16:11319732	chr16:11341809~11345211:-
BRCA	cis	rs2688608	0.592	rs7908825	ENSG00000213731.2	RAB5CP1	3.83	0.000136	0.00818	0.13	0.12	Inflammatory bowel disease;	chr10:73794783	chr10:74423435~74424014:-
BRCA	cis	rs10129255	0.957	rs8009948	ENSG00000211967.3	IGHV3-53	-3.83	0.000136	0.00818	-0.09	-0.12	Kawasaki disease;	chr14:106805607	chr14:106592676~106593347:-
BRCA	cis	rs11098499	0.865	rs28753180	ENSG00000225892.3	RP11-384K6.2	3.83	0.000136	0.00818	0.12	0.12	Corneal astigmatism;	chr4:119484212	chr4:118632274~118634759:+
BRCA	cis	rs6088580	0.634	rs1205336	ENSG00000276073.1	RP5-1125A11.7	3.83	0.000136	0.00818	0.13	0.12	Glomerular filtration rate (creatinine);	chr20:34338530	chr20:33985617~33988989:-
BRCA	cis	rs1949733	0.675	rs2688235	ENSG00000251615.3	RP11-774O3.3	-3.83	0.000136	0.00818	-0.12	-0.12	Response to antineoplastic agents;	chr4:8448819	chr4:8355090~8358338:-
BRCA	cis	rs4948275	0.597	rs2650713	ENSG00000237233.2	TMEM26-AS1	-3.83	0.000136	0.00818	-0.14	-0.12	Night sleep phenotypes;	chr10:61603544	chr10:61452639~61481956:+
BRCA	cis	rs4664293	0.669	rs35299907	ENSG00000224152.1	AC009506.1	3.83	0.000136	0.00818	0.13	0.12	Monocyte percentage of white cells;	chr2:159562142	chr2:159615296~159617082:+
BRCA	cis	rs8114671	0.935	rs633198	ENSG00000279253.1	RP4-614O4.13	3.83	0.000136	0.00818	0.14	0.12	Height;	chr20:35190631	chr20:35262727~35264187:-
BRCA	cis	rs6964587	1	rs10243241	ENSG00000188693.7	CYP51A1-AS1	-3.83	0.000136	0.00818	-0.13	-0.12	Breast cancer;	chr7:92076382	chr7:92134604~92180725:+
BRCA	cis	rs6430585	0.527	rs76380759	ENSG00000224043.6	CCNT2-AS1	-3.83	0.000136	0.00818	-0.19	-0.12	Corneal structure;	chr2:135680947	chr2:134735464~134918710:-
BRCA	cis	rs12210905	1	rs9368493	ENSG00000216901.1	AL022393.7	3.83	0.000136	0.00818	0.22	0.12	Hip circumference adjusted for BMI;	chr6:27260521	chr6:28176188~28176674:+
BRCA	cis	rs860295	0.557	rs11264371	ENSG00000236675.1	MTX1P1	-3.83	0.000136	0.00818	-0.15	-0.12	Body mass index;	chr1:155442246	chr1:155230975~155234325:+
BRCA	cis	rs983392	0.679	rs603648	ENSG00000275344.1	MIR6503	3.83	0.000136	0.00818	0.12	0.12	Alzheimer's disease (late onset);	chr11:60245200	chr11:60209071~60209156:-
BRCA	cis	rs4819052	0.851	rs58644915	ENSG00000215447.6	BX322557.10	-3.83	0.000136	0.00819	-0.12	-0.12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45249997	chr21:45288052~45291738:+
BRCA	cis	rs2880765	0.743	rs4551990	ENSG00000230373.7	GOLGA6L5P	3.83	0.000136	0.00819	0.13	0.12	Coronary artery disease;	chr15:85472056	chr15:84507885~84516814:-
BRCA	cis	rs6439699	1	rs35361620	ENSG00000239213.4	NCK1-AS1	3.83	0.000136	0.00819	0.16	0.12	Intelligence (multi-trait analysis);	chr3:137291095	chr3:136841726~136862054:-
BRCA	cis	rs6040449	0.847	rs6040483	ENSG00000235036.4	RP5-1099D15.1	3.83	0.000136	0.00819	0.13	0.12	Relative hand skill;	chr20:11257144	chr20:10612861~10614229:-
BRCA	cis	rs801193	0.569	rs11761542	ENSG00000229886.1	RP5-1132H15.3	3.83	0.000136	0.00819	0.13	0.12	Aortic root size;	chr7:66753209	chr7:66025126~66031544:-
BRCA	cis	rs73201462	1	rs2811416	ENSG00000242551.2	POU5F1P6	-3.83	0.000136	0.00819	-0.23	-0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128273095	chr3:128674735~128677005:-
BRCA	cis	rs6490294	0.571	rs58368428	ENSG00000234608.6	MAPKAPK5-AS1	3.83	0.000136	0.00819	0.17	0.12	Mean platelet volume;	chr12:112024471	chr12:111839764~111842902:-
BRCA	cis	rs12612435	0.869	rs16833899	ENSG00000226806.1	AC011893.3	3.83	0.000136	0.00819	0.15	0.12	Takotsubo syndrome;	chr2:136362752	chr2:135820191~135823087:+
BRCA	cis	rs7267979	0.966	rs2151144	ENSG00000274973.1	RP13-401N8.7	3.83	0.000136	0.00819	0.13	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25434288	chr20:25845497~25845862:+
BRCA	cis	rs875971	1	rs6979382	ENSG00000265600.1	AC006480.1	-3.83	0.000136	0.00819	-0.14	-0.12	Aortic root size;	chr7:66421388	chr7:67356680~67356779:+
BRCA	cis	rs875971	1	rs6961990	ENSG00000265600.1	AC006480.1	-3.83	0.000136	0.00819	-0.14	-0.12	Aortic root size;	chr7:66423583	chr7:67356680~67356779:+
BRCA	cis	rs11098499	0.644	rs7693919	ENSG00000225892.3	RP11-384K6.2	3.83	0.000136	0.00819	0.12	0.12	Corneal astigmatism;	chr4:119619416	chr4:118632274~118634759:+
BRCA	cis	rs62229266	0.773	rs878606	ENSG00000214914.3	RPL23AP3	3.83	0.000136	0.00819	0.15	0.12	Mitral valve prolapse;	chr21:36034394	chr21:36016079~36016546:-
BRCA	cis	rs2071426	0.594	rs7900980	ENSG00000273450.1	RP11-76P2.4	3.83	0.000136	0.00819	0.15	0.12	Blood metabolite levels;	chr10:95025021	chr10:94314907~94315327:-
BRCA	cis	rs7674212	0.556	rs223401	ENSG00000248740.4	RP11-328K4.1	3.83	0.000136	0.00819	0.14	0.12	Type 2 diabetes;	chr4:102817815	chr4:103256159~103453658:+
BRCA	cis	rs4664293	1	rs10432413	ENSG00000230783.1	AC009961.2	-3.83	0.000136	0.00819	-0.15	-0.12	Monocyte percentage of white cells;	chr2:159639243	chr2:159689217~159690291:-
BRCA	cis	rs10876993	0.89	rs799575	ENSG00000270039.1	RP11-571M6.17	3.83	0.000136	0.00819	0.16	0.12	Celiac disease or Rheumatoid arthritis;	chr12:57675324	chr12:57803838~57804415:+
BRCA	cis	rs5742933	1	rs2289404	ENSG00000253559.1	OSGEPL1-AS1	-3.83	0.000136	0.00819	-0.16	-0.12	Ferritin levels;	chr2:189771288	chr2:189762704~189765556:+
BRCA	cis	rs6545883	0.965	rs12713439	ENSG00000270820.4	RP11-355B11.2	3.83	0.000136	0.00819	0.14	0.12	Tuberculosis;	chr2:61525019	chr2:61471188~61484130:+
BRCA	cis	rs10043775	0.793	rs34163281	ENSG00000251330.3	CTD-2283N19.1	-3.83	0.000136	0.00819	-0.14	-0.12	Periodontal microbiota;	chr5:148309446	chr5:148430159~148430807:-
BRCA	cis	rs6044112	0.75	rs6080288	ENSG00000273998.1	RP4-777L9.2	3.83	0.000136	0.0082	0.21	0.12	Response to taxane treatment (docetaxel);	chr20:16531408	chr20:16576068~16579615:+
BRCA	cis	rs6736093	1	rs17779482	ENSG00000236307.2	EEF1E1P1	-3.83	0.000136	0.0082	-0.15	-0.12	Coronary artery disease;	chr2:111908100	chr2:111887914~111888741:+
BRCA	cis	rs11711311	1	rs9848993	ENSG00000241529.3	RN7SL767P	-3.83	0.000136	0.0082	-0.14	-0.12	IgG glycosylation;	chr3:113779067	chr3:113632704~113632998:+
BRCA	cis	rs448720	1	rs338352	ENSG00000260657.2	RP11-315D16.4	-3.83	0.000136	0.0082	-0.14	-0.12	Cognitive performance;	chr15:67900931	chr15:68267792~68277994:-
BRCA	cis	rs2136613	0.779	rs4141614	ENSG00000238280.1	RP11-436D10.3	-3.83	0.000136	0.0082	-0.15	-0.12	Selective IgA deficiency;	chr10:62854095	chr10:62793562~62805887:-
BRCA	cis	rs35306767	0.807	rs72778228	ENSG00000229869.1	RP11-363N22.2	-3.83	0.000136	0.0082	-0.2	-0.12	Eosinophil percentage of granulocytes;	chr10:892495	chr10:933026~942743:+
BRCA	cis	rs6870983	0.857	rs7444298	ENSG00000247828.6	TMEM161B-AS1	-3.83	0.000136	0.0082	-0.15	-0.12	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index;	chr5:88434210	chr5:88268895~88436685:+
BRCA	cis	rs3816183	0.958	rs2278581	ENSG00000226491.1	FTOP1	-3.83	0.000136	0.0082	-0.15	-0.12	Hypospadias;	chr2:42793774	chr2:42797225~42798712:-
BRCA	cis	rs3760982	1	rs4803658	ENSG00000267191.1	RP11-15A1.2	-3.83	0.000136	0.0082	-0.15	-0.12	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43785861	chr19:43902001~43926545:+
BRCA	cis	rs7246657	0.551	rs28462002	ENSG00000267470.4	ZNF571-AS1	3.83	0.000136	0.0082	0.18	0.12	Coronary artery calcification;	chr19:37143560	chr19:37548914~37587348:+
BRCA	cis	rs2625529	0.526	rs8031386	ENSG00000260037.4	CTD-2524L6.3	-3.83	0.000137	0.0082	-0.15	-0.12	Red blood cell count;	chr15:72216458	chr15:71818396~71823384:+
BRCA	cis	rs17684571	0.751	rs17684878	ENSG00000231441.1	RP11-472M19.2	3.83	0.000137	0.00821	0.19	0.12	Schizophrenia;	chr6:56838178	chr6:56844002~56864078:+
BRCA	cis	rs17684571	0.751	rs17684884	ENSG00000231441.1	RP11-472M19.2	3.83	0.000137	0.00821	0.19	0.12	Schizophrenia;	chr6:56838852	chr6:56844002~56864078:+
BRCA	cis	rs11696739	0.835	rs6074894	ENSG00000242324.1	RP4-576H24.2	3.83	0.000137	0.00821	0.14	0.12	Mean platelet volume;	chr20:1616404	chr20:1516759~1557653:-
BRCA	cis	rs17092148	1	rs7265992	ENSG00000202150.1	RNU6-407P	-3.83	0.000137	0.00821	-0.17	-0.12	Neuroticism;	chr20:34937604	chr20:35030317~35030420:-
BRCA	cis	rs7608910	1	rs67927699	ENSG00000237522.1	NONOP2	-3.83	0.000137	0.00821	-0.11	-0.12	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;	chr2:60960280	chr2:60936819~60938049:-
BRCA	cis	rs4415084	0.688	rs1837286	ENSG00000251141.4	RP11-53O19.1	-3.83	0.000137	0.00821	-0.11	-0.12	Breast cancer;	chr5:44858639	chr5:44744900~44808777:-
BRCA	cis	rs4415084	0.716	rs4373287	ENSG00000251141.4	RP11-53O19.1	-3.83	0.000137	0.00821	-0.11	-0.12	Breast cancer;	chr5:44862782	chr5:44744900~44808777:-
BRCA	cis	rs8098244	0.557	rs12954712	ENSG00000265752.2	RP11-403A21.1	3.83	0.000137	0.00821	0.13	0.12	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23707144	chr18:23957754~23982556:-
BRCA	cis	rs9788721	0.836	rs17483686	ENSG00000261762.1	RP11-650L12.2	-3.83	0.000137	0.00821	-0.14	-0.12	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78441048	chr15:78589123~78591276:-
BRCA	cis	rs7020830	0.931	rs6476613	ENSG00000230188.1	RP11-405L18.4	-3.83	0.000137	0.00821	-0.14	-0.12	Schizophrenia;	chr9:37084343	chr9:37490421~37490893:-
BRCA	cis	rs2731006	0.64	rs2459739	ENSG00000257114.2	RP11-25I15.3	3.83	0.000137	0.00821	0.2	0.12	Panic disorder;	chr12:42800183	chr12:42692216~42717119:+
BRCA	cis	rs2731006	0.64	rs2459738	ENSG00000257114.2	RP11-25I15.3	3.83	0.000137	0.00821	0.2	0.12	Panic disorder;	chr12:42800393	chr12:42692216~42717119:+
BRCA	cis	rs493733	0.596	rs690014	ENSG00000271964.1	RP11-415F23.2	-3.83	0.000137	0.00822	-0.12	-0.12	Urate levels (BMI interaction);	chr3:16361052	chr3:16314439~16314987:+
BRCA	cis	rs34792	0.554	rs12918517	ENSG00000260872.1	RP11-680G24.5	-3.83	0.000137	0.00822	-0.14	-0.12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15532974	chr16:15018106~15020488:-
BRCA	cis	rs4453827	0.625	rs719260	ENSG00000271916.1	RP11-884K10.6	-3.83	0.000137	0.00822	-0.13	-0.12	Blood protein levels;	chr3:53755145	chr3:53797764~53798019:-
BRCA	cis	rs1075265	0.722	rs2111623	ENSG00000272156.1	RP11-477N3.1	3.83	0.000137	0.00822	0.12	0.12	Chronotype;Morning vs. evening chronotype;	chr2:53757820	chr2:54082554~54085066:+
BRCA	cis	rs11098499	0.909	rs78332141	ENSG00000260404.2	RP11-384K6.6	3.83	0.000137	0.00822	0.11	0.12	Corneal astigmatism;	chr4:119454627	chr4:118591773~118633729:+
BRCA	cis	rs8091660	0.624	rs9952398	ENSG00000278983.1	RP11-426J5.3	3.83	0.000137	0.00822	0.16	0.12	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48550407	chr18:48564795~48568342:+
BRCA	cis	rs9437689	0.531	rs859048	ENSG00000235501.4	RP4-639F20.1	3.83	0.000137	0.00822	0.15	0.12	Phospholipid levels (plasma);	chr1:94911873	chr1:94927566~94963270:+
BRCA	cis	rs7735319	0.546	rs10472219	ENSG00000249572.1	CTD-2203K17.1	-3.83	0.000137	0.00822	-0.15	-0.12	Systolic blood pressure;	chr5:33139667	chr5:33424025~33440619:-
BRCA	cis	rs7671261	0.514	rs13138927	ENSG00000270720.1	RP11-84C13.2	3.83	0.000137	0.00822	0.14	0.12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr4:89120215	chr4:89119284~89119871:+
BRCA	cis	rs1015362	0.504	rs6059552	ENSG00000275784.1	RP5-1125A11.6	-3.83	0.000137	0.00822	-0.16	-0.12	Freckles;Red vs. non-red hair color;Skin sensitivity to sun;Burning and freckling;	chr20:33923820	chr20:33989480~33991818:-
BRCA	cis	rs6500602	0.648	rs7702	ENSG00000280063.1	RP11-295D4.3	3.83	0.000137	0.00822	0.09	0.12	Schizophrenia;	chr16:4510928	chr16:4346694~4348648:-
BRCA	cis	rs295490	0.748	rs115673919	ENSG00000272656.1	RP11-219D15.3	3.83	0.000137	0.00822	0.29	0.12	PR interval in Tripanosoma cruzi seropositivity;	chr3:139489239	chr3:139349024~139349371:-
BRCA	cis	rs6088590	1	rs6119530	ENSG00000276073.1	RP5-1125A11.7	-3.83	0.000137	0.00822	-0.14	-0.12	Coronary artery disease;	chr20:34816127	chr20:33985617~33988989:-
BRCA	cis	rs875971	1	rs1544549	ENSG00000265600.1	AC006480.1	3.83	0.000137	0.00822	0.14	0.12	Aortic root size;	chr7:66625676	chr7:67356680~67356779:+
BRCA	cis	rs9295536	0.62	rs6915330	ENSG00000260455.1	NBAT1	3.83	0.000137	0.00822	0.13	0.12	Neuroblastoma;	chr6:22135943	chr6:22134957~22147193:-
BRCA	cis	rs9844666	0.512	rs6779603	ENSG00000273486.1	RP11-731C17.2	3.83	0.000137	0.00822	0.13	0.12	Height;	chr3:135921113	chr3:136837338~136839021:-
BRCA	cis	rs495337	0.736	rs2149278	ENSG00000224397.4	LINC01272	3.83	0.000137	0.00823	0.12	0.12	Psoriasis;	chr20:49830616	chr20:50267486~50279795:+
BRCA	cis	rs12949688	0.967	rs9905938	ENSG00000262623.1	RP5-1107A17.2	-3.83	0.000137	0.00823	-0.13	-0.12	Schizophrenia;	chr17:57746990	chr17:56951664~56952404:+
BRCA	cis	rs2839186	0.771	rs2280959	ENSG00000223901.2	AP001469.5	3.83	0.000137	0.00823	0.12	0.12	Testicular germ cell tumor;	chr21:46222082	chr21:46220269~46225364:+
BRCA	cis	rs2839186	0.739	rs2280958	ENSG00000223901.2	AP001469.5	3.83	0.000137	0.00823	0.12	0.12	Testicular germ cell tumor;	chr21:46222102	chr21:46220269~46225364:+
BRCA	cis	rs7682431	0.513	rs2045517	ENSG00000270720.1	RP11-84C13.2	3.83	0.000137	0.00823	0.13	0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr4:88949813	chr4:89119284~89119871:+
BRCA	cis	rs6439153	1	rs6439153	ENSG00000242551.2	POU5F1P6	-3.83	0.000137	0.00823	-0.15	-0.12	Pneumococcal bacteremia;	chr3:128982287	chr3:128674735~128677005:-
BRCA	cis	rs3739034	1	rs16830945	ENSG00000224043.6	CCNT2-AS1	3.83	0.000137	0.00823	0.2	0.12	Gut microbiome composition (winter);	chr2:134714178	chr2:134735464~134918710:-
BRCA	cis	rs2108622	0.727	rs3093207	ENSG00000214049.6	UCA1	3.83	0.000137	0.00823	0.17	0.12	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15877848	chr19:15828961~15836320:+
BRCA	cis	rs1555322	0.932	rs1205411	ENSG00000269202.1	RP4-614O4.12	-3.83	0.000137	0.00823	-0.17	-0.12	Attention deficit hyperactivity disorder;	chr20:35269439	chr20:35201747~35203288:-
BRCA	cis	rs7267979	1	rs6050609	ENSG00000204556.4	CTD-2514C3.1	3.83	0.000137	0.00823	0.16	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25431115	chr20:26018832~26020684:+
BRCA	cis	rs4834770	0.765	rs1511016	ENSG00000249244.1	RP11-548H18.2	3.83	0.000137	0.00823	0.13	0.12	Blood protein levels;	chr4:119249200	chr4:119391831~119395335:-
BRCA	cis	rs7656342	0.636	rs4697902	ENSG00000250342.1	SNRPCP16	3.83	0.000137	0.00824	0.13	0.12	Gut microbiota (bacterial taxa);	chr4:9862312	chr4:9051842~9052051:-
BRCA	cis	rs2337406	0.925	rs2011167	ENSG00000280411.1	IGHV1-69-2	-3.83	0.000137	0.00824	-0.11	-0.12	Alzheimer's disease (late onset);	chr14:106680831	chr14:106762092~106762588:-
BRCA	cis	rs6870983	0.802	rs6452790	ENSG00000247828.6	TMEM161B-AS1	-3.83	0.000137	0.00824	-0.15	-0.12	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index;	chr5:88460891	chr5:88268895~88436685:+
BRCA	cis	rs2451932	0.625	rs60637254	ENSG00000251050.1	RP11-168A11.4	-3.83	0.000137	0.00824	-0.13	-0.12	LDL peak particle diameter (total fat intake interaction);	chr5:80027650	chr5:80019609~80019920:+
BRCA	cis	rs1333657	0.782	rs13217528	ENSG00000216368.2	RP3-486D24.1	3.83	0.000137	0.00824	0.14	0.12	Orofacial clefts;	chr6:10295663	chr6:10118452~10119253:+
BRCA	cis	rs11098499	0.863	rs1480940	ENSG00000260404.2	RP11-384K6.6	3.83	0.000137	0.00824	0.11	0.12	Corneal astigmatism;	chr4:119536527	chr4:118591773~118633729:+
BRCA	cis	rs6991838	0.584	rs34226237	ENSG00000272155.1	RP11-707M3.3	3.83	0.000137	0.00824	0.11	0.12	Intelligence (multi-trait analysis);	chr8:65600930	chr8:65714334~65714778:-
BRCA	cis	rs1865760	0.593	rs9393676	ENSG00000272462.2	U91328.19	-3.83	0.000137	0.00824	-0.14	-0.12	Height;	chr6:25936716	chr6:25992662~26001775:+
BRCA	cis	rs6893300	0.785	rs3797762	ENSG00000225051.5	HMGB3P22	3.83	0.000137	0.00825	0.15	0.12	Resting heart rate;	chr5:179775687	chr5:179679032~179694768:+
BRCA	cis	rs11773103	0.786	rs17161323	ENSG00000224046.1	AC005076.5	3.83	0.000137	0.00825	0.19	0.12	Bipolar disorder or major depressive disorder (combined);	chr7:87129922	chr7:87151423~87152420:-
BRCA	cis	rs2692947	0.631	rs2312954	ENSG00000168992.4	OR7E102P	-3.83	0.000137	0.00825	-0.17	-0.12	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96106699	chr2:95546531~95547545:+
BRCA	cis	rs61931739	0.534	rs1826144	ENSG00000258794.3	DUX4L27	3.83	0.000137	0.00825	0.17	0.12	Morning vs. evening chronotype;	chr12:33941337	chr12:34208415~34209675:-
BRCA	cis	rs8098244	0.737	rs1258147	ENSG00000265752.2	RP11-403A21.1	-3.83	0.000137	0.00825	-0.15	-0.12	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23939672	chr18:23957754~23982556:-
BRCA	cis	rs17711722	0.701	rs781143	ENSG00000223473.2	GS1-124K5.3	3.83	0.000137	0.00825	0.09	0.12	Calcium levels;	chr7:65974892	chr7:66491049~66493566:-
BRCA	cis	rs72615157	0.634	rs74742883	ENSG00000242294.5	STAG3L5P	3.83	0.000137	0.00825	0.11	0.12	Lung function (FEV1/FVC);	chr7:100188142	chr7:100336079~100351900:+
BRCA	cis	rs28489187	0.706	rs761601	ENSG00000223653.4	RP11-131L23.1	3.83	0.000137	0.00825	0.14	0.12	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85331615	chr1:85276715~85448124:+
BRCA	cis	rs9470794	1	rs76363145	ENSG00000204110.6	RP1-153P14.8	-3.83	0.000137	0.00825	-0.24	-0.12	Type 2 diabetes;	chr6:38114833	chr6:37507348~37535616:+
BRCA	cis	rs2185341	0.788	rs12089677	ENSG00000218510.5	LINC00339	3.83	0.000137	0.00825	0.16	0.12	Amyotrophic lateral sclerosis;	chr1:22356537	chr1:22025188~22031223:+
BRCA	cis	rs35491132	1	rs35491132	ENSG00000216901.1	AL022393.7	3.83	0.000137	0.00825	0.29	0.12	Urinary tract infection frequency;	chr6:27559449	chr6:28176188~28176674:+
BRCA	cis	rs12505749	0.542	rs12508008	ENSG00000270147.1	RP11-646I6.6	-3.83	0.000137	0.00825	-0.14	-0.12	Airflow obstruction;	chr4:56487601	chr4:56396312~56396871:+
BRCA	cis	rs12505749	0.542	rs12646890	ENSG00000270147.1	RP11-646I6.6	-3.83	0.000137	0.00825	-0.14	-0.12	Airflow obstruction;	chr4:56489096	chr4:56396312~56396871:+
BRCA	cis	rs1005277	0.579	rs2103938	ENSG00000272983.1	RP11-508N22.12	3.83	0.000137	0.00825	0.12	0.12	Extrinsic epigenetic age acceleration;	chr10:38205070	chr10:38137337~38144399:+
BRCA	cis	rs6546324	0.625	rs2861700	ENSG00000236780.4	AC078941.1	-3.83	0.000137	0.00825	-0.2	-0.12	Endometriosis;	chr2:67628309	chr2:67123357~67215319:-
BRCA	cis	rs6840360	0.681	rs4519779	ENSG00000251611.1	RP11-610P16.1	-3.83	0.000138	0.00826	-0.1	-0.12	Intelligence (multi-trait analysis);	chr4:151380033	chr4:151407551~151408835:-
BRCA	cis	rs4133131	0.881	rs2475177	ENSG00000279315.1	RP11-57H14.5	3.83	0.000138	0.00826	0.16	0.12	Facial morphology (factor 20);	chr10:112859170	chr10:112831169~112832454:+
BRCA	cis	rs8094794	0.744	rs72899541	ENSG00000267707.2	RP11-95O2.5	3.83	0.000138	0.00826	0.18	0.12	Periodontal disease-related phenotypes;	chr18:36712647	chr18:37243776~37247506:+
BRCA	cis	rs739401	0.611	rs7394974	ENSG00000183562.3	CTC-343N3.1	-3.83	0.000138	0.00826	-0.13	-0.12	Longevity;	chr11:3017638	chr11:2989863~2991344:+
BRCA	cis	rs8058578	1	rs56656810	ENSG00000275263.1	RP11-1072A3.4	-3.83	0.000138	0.00826	-0.15	-0.12	Multiple myeloma;	chr16:30777438	chr16:30956872~30957199:-
BRCA	cis	rs7267979	1	rs6076345	ENSG00000276952.1	RP5-965G21.6	-3.83	0.000138	0.00826	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25401259	chr20:25284915~25285588:-
BRCA	cis	rs875971	0.66	rs12698534	ENSG00000272831.1	RP11-792A8.4	3.83	0.000138	0.00826	0.11	0.12	Aortic root size;	chr7:66521858	chr7:66739829~66740385:-
BRCA	cis	rs256438	0.524	rs364988	ENSG00000251050.1	RP11-168A11.4	-3.83	0.000138	0.00826	-0.12	-0.12	Serum thyroid-stimulating hormone levels;	chr5:80054661	chr5:80019609~80019920:+
BRCA	cis	rs256438	0.524	rs10474605	ENSG00000251050.1	RP11-168A11.4	-3.83	0.000138	0.00826	-0.12	-0.12	Serum thyroid-stimulating hormone levels;	chr5:80054903	chr5:80019609~80019920:+
BRCA	cis	rs2451932	0.716	rs382746	ENSG00000251050.1	RP11-168A11.4	-3.83	0.000138	0.00826	-0.12	-0.12	LDL peak particle diameter (total fat intake interaction);	chr5:80054944	chr5:80019609~80019920:+
BRCA	cis	rs256438	0.524	rs368287	ENSG00000251050.1	RP11-168A11.4	-3.83	0.000138	0.00826	-0.12	-0.12	Serum thyroid-stimulating hormone levels;	chr5:80055317	chr5:80019609~80019920:+
BRCA	cis	rs256438	0.524	rs426623	ENSG00000251050.1	RP11-168A11.4	-3.83	0.000138	0.00826	-0.12	-0.12	Serum thyroid-stimulating hormone levels;	chr5:80055588	chr5:80019609~80019920:+
BRCA	cis	rs9818758	0.607	rs9990153	ENSG00000225399.4	RP11-3B7.1	-3.83	0.000138	0.00826	-0.18	-0.12	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49254450	chr3:49260085~49261316:+
BRCA	cis	rs34792	0.554	rs12919246	ENSG00000258354.1	MIR3180-1	-3.83	0.000138	0.00826	-0.16	-0.12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15533103	chr16:14909887~14911345:-
BRCA	cis	rs728616	0.558	rs12772945	ENSG00000225484.5	NUTM2B-AS1	-3.83	0.000138	0.00827	-0.25	-0.12	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80394740	chr10:79663088~79826594:-
BRCA	cis	rs8040855	0.576	rs62022528	ENSG00000230373.7	GOLGA6L5P	3.83	0.000138	0.00827	0.15	0.12	Bulimia nervosa;	chr15:84992030	chr15:84507885~84516814:-
BRCA	cis	rs897984	0.609	rs12445650	ENSG00000279196.1	RP11-1072A3.3	3.83	0.000138	0.00827	0.12	0.12	Dementia with Lewy bodies;	chr16:31033576	chr16:30984630~30988270:-
BRCA	cis	rs6547741	0.935	rs56001553	ENSG00000234072.1	AC074117.10	-3.83	0.000138	0.00827	-0.11	-0.12	Oral cavity cancer;	chr2:27637059	chr2:27356246~27367622:+
BRCA	cis	rs6893300	0.922	rs41458244	ENSG00000250999.1	RP11-1379J22.5	3.83	0.000138	0.00827	0.17	0.12	Resting heart rate;	chr5:179795376	chr5:179657762~179664432:+
BRCA	cis	rs2058059	0.636	rs2960968	ENSG00000205578.5	POM121B	-3.83	0.000138	0.00827	-0.2	-0.12	Subcutaneous adipose tissue;	chr7:72702378	chr7:73293497~73301161:+
BRCA	cis	rs6452524	0.561	rs4331874	ENSG00000281327.1	LINC01338	3.83	0.000138	0.00827	0.14	0.12	Hypertension (SNP x SNP interaction);	chr5:83068253	chr5:82850864~82859836:-
BRCA	cis	rs17684571	0.938	rs13196211	ENSG00000231441.1	RP11-472M19.2	3.83	0.000138	0.00827	0.19	0.12	Schizophrenia;	chr6:56697697	chr6:56844002~56864078:+
BRCA	cis	rs17684571	1	rs5024547	ENSG00000231441.1	RP11-472M19.2	3.83	0.000138	0.00827	0.19	0.12	Schizophrenia;	chr6:56698295	chr6:56844002~56864078:+
BRCA	cis	rs2625529	0.824	rs55854204	ENSG00000260037.4	CTD-2524L6.3	-3.83	0.000138	0.00827	-0.17	-0.12	Red blood cell count;	chr15:72140841	chr15:71818396~71823384:+
BRCA	cis	rs8062405	1	rs62036622	ENSG00000261766.1	RP11-22P6.2	-3.83	0.000138	0.00827	-0.12	-0.12	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28825882	chr16:28862166~28863340:-
BRCA	cis	rs78487399	0.808	rs6726917	ENSG00000234936.1	AC010883.5	3.83	0.000138	0.00827	0.18	0.12	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43526774	chr2:43229573~43233394:+
BRCA	cis	rs11098499	0.954	rs12505469	ENSG00000260091.1	RP11-33B1.4	-3.83	0.000138	0.00827	-0.11	-0.12	Corneal astigmatism;	chr4:119328430	chr4:119409333~119410233:+
BRCA	cis	rs375066	0.935	rs408549	ENSG00000267191.1	RP11-15A1.2	-3.83	0.000138	0.00827	-0.15	-0.12	Breast cancer;	chr19:43921467	chr19:43902001~43926545:+
BRCA	cis	rs375066	0.935	rs398388	ENSG00000267191.1	RP11-15A1.2	-3.83	0.000138	0.00827	-0.15	-0.12	Breast cancer;	chr19:43921530	chr19:43902001~43926545:+
BRCA	cis	rs375066	0.935	rs403137	ENSG00000267191.1	RP11-15A1.2	-3.83	0.000138	0.00827	-0.15	-0.12	Breast cancer;	chr19:43923474	chr19:43902001~43926545:+
BRCA	cis	rs375066	0.935	rs428505	ENSG00000267191.1	RP11-15A1.2	-3.83	0.000138	0.00827	-0.15	-0.12	Breast cancer;	chr19:43924759	chr19:43902001~43926545:+
BRCA	cis	rs375066	0.935	rs367741	ENSG00000267191.1	RP11-15A1.2	-3.83	0.000138	0.00827	-0.15	-0.12	Breast cancer;	chr19:43925028	chr19:43902001~43926545:+
BRCA	cis	rs1005277	0.529	rs1780125	ENSG00000272983.1	RP11-508N22.12	3.83	0.000138	0.00827	0.12	0.12	Extrinsic epigenetic age acceleration;	chr10:38242448	chr10:38137337~38144399:+
BRCA	cis	rs1387259	0.723	rs2732488	ENSG00000240399.1	RP1-228P16.1	3.83	0.000138	0.00827	0.14	0.12	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48377661	chr12:48054813~48055591:-
BRCA	cis	rs1387259	0.758	rs2634670	ENSG00000240399.1	RP1-228P16.1	3.83	0.000138	0.00827	0.14	0.12	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48378094	chr12:48054813~48055591:-
BRCA	cis	rs875971	0.545	rs4718348	ENSG00000232559.3	GS1-124K5.12	3.83	0.000138	0.00827	0.16	0.12	Aortic root size;	chr7:66441589	chr7:66554588~66576923:-
BRCA	cis	rs6964587	1	rs9690778	ENSG00000188693.7	CYP51A1-AS1	-3.83	0.000138	0.00827	-0.13	-0.12	Breast cancer;	chr7:92105985	chr7:92134604~92180725:+
BRCA	cis	rs6964587	1	rs57816416	ENSG00000188693.7	CYP51A1-AS1	-3.83	0.000138	0.00827	-0.13	-0.12	Breast cancer;	chr7:92106764	chr7:92134604~92180725:+
BRCA	cis	rs7592578	0.825	rs12477369	ENSG00000272979.1	RP11-647K16.1	3.83	0.000138	0.00827	0.2	0.12	Diastolic blood pressure;	chr2:190590898	chr2:190454092~190454521:-
BRCA	cis	rs3753275	0.69	rs10864355	ENSG00000270282.1	RP5-1115A15.2	3.83	0.000138	0.00827	0.17	0.12	Educational attainment;	chr1:8506241	chr1:8512653~8513021:+
BRCA	cis	rs3760982	0.626	rs12463370	ENSG00000267191.1	RP11-15A1.2	-3.83	0.000138	0.00827	-0.15	-0.12	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43788014	chr19:43902001~43926545:+
BRCA	cis	rs2579519	0.556	rs4907302	ENSG00000232931.4	LINC00342	3.83	0.000138	0.00827	0.13	0.12	Diastolic blood pressure;	chr2:95551449	chr2:95807118~95816215:-
BRCA	cis	rs34014631	0.786	rs79048848	ENSG00000226009.1	KCNIP2-AS1	3.83	0.000138	0.00827	0.3	0.12	Coronary artery calcification;	chr10:101995738	chr10:101819078~101828779:+
BRCA	cis	rs6964587	1	rs7781066	ENSG00000188693.7	CYP51A1-AS1	-3.83	0.000138	0.00827	-0.13	-0.12	Breast cancer;	chr7:92062632	chr7:92134604~92180725:+
BRCA	cis	rs6700559	0.565	rs12728040	ENSG00000260088.1	RP11-92G12.3	3.83	0.000138	0.00827	0.15	0.12	Coronary artery disease;	chr1:200626751	chr1:200669507~200694250:+
BRCA	cis	rs4919687	0.55	rs12784517	ENSG00000213061.2	PFN1P11	3.83	0.000138	0.00827	0.16	0.12	Colorectal cancer;	chr10:102705213	chr10:102838011~102845473:-
BRCA	cis	rs4919687	0.55	rs12761195	ENSG00000213061.2	PFN1P11	3.83	0.000138	0.00827	0.16	0.12	Colorectal cancer;	chr10:102705617	chr10:102838011~102845473:-
BRCA	cis	rs1552244	0.572	rs57268864	ENSG00000180385.7	EMC3-AS1	3.83	0.000138	0.00828	0.16	0.12	Alzheimer's disease;	chr3:10122549	chr3:9986893~10006990:+
BRCA	cis	rs2839186	0.559	rs2277826	ENSG00000228137.1	AP001469.7	-3.83	0.000138	0.00828	-0.13	-0.12	Testicular germ cell tumor;	chr21:46219578	chr21:46246890~46247682:+
BRCA	cis	rs17756712	0.725	rs55698539	ENSG00000272463.1	RP11-532F6.3	3.83	0.000138	0.00828	0.2	0.12	Vertical cup-disc ratio;	chr6:613930	chr6:708592~711405:-
BRCA	cis	rs897984	0.568	rs8050107	ENSG00000274678.1	RP11-2C24.7	-3.83	0.000138	0.00828	-0.15	-0.12	Dementia with Lewy bodies;	chr16:30882130	chr16:30821338~30821884:+
BRCA	cis	rs11673344	0.544	rs6508721	ENSG00000233527.7	ZNF529-AS1	-3.83	0.000138	0.00828	-0.13	-0.12	Obesity-related traits;	chr19:37419119	chr19:36573070~36594708:+
BRCA	cis	rs7267979	0.933	rs1130694	ENSG00000277938.1	RP5-965G21.3	3.83	0.000138	0.00828	0.14	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25295661	chr20:25229150~25231933:+
BRCA	cis	rs2274273	0.743	rs7161656	ENSG00000233924.1	AL160471.6	-3.83	0.000138	0.00828	-0.13	-0.12	Protein biomarker;	chr14:55057812	chr14:55004813~55005687:-
BRCA	cis	rs10463316	0.744	rs6579869	ENSG00000260581.1	CTB-113P19.4	3.83	0.000138	0.00828	0.14	0.12	Metabolite levels (Pyroglutamine);	chr5:151384060	chr5:151652275~151655449:+
BRCA	cis	rs10463316	0.894	rs10476769	ENSG00000260581.1	CTB-113P19.4	3.83	0.000138	0.00828	0.14	0.12	Metabolite levels (Pyroglutamine);	chr5:151384409	chr5:151652275~151655449:+
BRCA	cis	rs10463316	0.894	rs10476980	ENSG00000260581.1	CTB-113P19.4	3.83	0.000138	0.00828	0.14	0.12	Metabolite levels (Pyroglutamine);	chr5:151384596	chr5:151652275~151655449:+
BRCA	cis	rs10463316	0.894	rs7723016	ENSG00000260581.1	CTB-113P19.4	3.83	0.000138	0.00828	0.14	0.12	Metabolite levels (Pyroglutamine);	chr5:151385267	chr5:151652275~151655449:+
BRCA	cis	rs10463316	0.894	rs7703283	ENSG00000260581.1	CTB-113P19.4	3.83	0.000138	0.00828	0.14	0.12	Metabolite levels (Pyroglutamine);	chr5:151385343	chr5:151652275~151655449:+
BRCA	cis	rs10911902	0.643	rs75856021	ENSG00000229739.2	RP11-295K2.3	-3.83	0.000138	0.00828	-0.17	-0.12	Schizophrenia;	chr1:186405853	chr1:186435161~186470291:+
BRCA	cis	rs7780564	0.51	rs34174547	ENSG00000219545.8	UMAD1	-3.83	0.000138	0.00828	-0.12	-0.12	Insulin-like growth factors;	chr7:7870615	chr7:7640711~8004059:+
BRCA	cis	rs10895987	1	rs72932837	ENSG00000255200.1	AP003068.18	3.83	0.000138	0.00828	0.18	0.12	Blood protein levels;	chr11:65109268	chr11:65174117~65176470:-
BRCA	cis	rs4664293	0.902	rs13391919	ENSG00000226266.5	AC009961.3	-3.83	0.000138	0.00828	-0.14	-0.12	Monocyte percentage of white cells;	chr2:159703649	chr2:159670708~159712435:-
BRCA	cis	rs2562456	0.561	rs12610883	ENSG00000213976.4	CTD-2561J22.2	-3.83	0.000138	0.00828	-0.14	-0.12	Pain;	chr19:21567257	chr19:21382865~21387177:+
BRCA	cis	rs2562456	0.837	rs11085462	ENSG00000213976.4	CTD-2561J22.2	-3.83	0.000138	0.00828	-0.14	-0.12	Pain;	chr19:21567449	chr19:21382865~21387177:+
BRCA	cis	rs687432	0.851	rs7927022	ENSG00000265566.2	RN7SL605P	-3.83	0.000138	0.00828	-0.15	-0.12	Parkinson's disease;	chr11:57966451	chr11:57528085~57528365:-
BRCA	cis	rs6596100	0.915	rs6866500	ENSG00000248648.1	RP11-485M7.1	-3.83	0.000138	0.00828	-0.15	-0.12	Breast cancer;	chr5:133066038	chr5:133003119~133003365:+
BRCA	cis	rs6596100	0.915	rs6596098	ENSG00000248648.1	RP11-485M7.1	-3.83	0.000138	0.00828	-0.15	-0.12	Breast cancer;	chr5:133067649	chr5:133003119~133003365:+
BRCA	cis	rs6596100	0.876	rs4321746	ENSG00000248648.1	RP11-485M7.1	-3.83	0.000138	0.00828	-0.15	-0.12	Breast cancer;	chr5:133068471	chr5:133003119~133003365:+
BRCA	cis	rs4700393	0.517	rs13158594	ENSG00000215032.2	GNL3LP1	-3.83	0.000138	0.00829	-0.17	-0.12	Intelligence (multi-trait analysis);	chr5:60794183	chr5:60891935~60893577:-
BRCA	cis	rs58521262	0.615	rs289364	ENSG00000268105.1	RP11-369G6.2	3.83	0.000138	0.00829	0.16	0.12	Testicular germ cell tumor;	chr19:22934234	chr19:23125665~23128543:+
BRCA	cis	rs9308731	0.591	rs10199020	ENSG00000230499.1	AC108463.1	-3.83	0.000138	0.00829	-0.14	-0.12	Chronic lymphocytic leukemia;	chr2:111188879	chr2:111195963~111206494:+
BRCA	cis	rs78545713	1	rs114970164	ENSG00000241549.7	GUSBP2	-3.83	0.000138	0.00829	-0.18	-0.12	Iron status biomarkers (total iron binding capacity);	chr6:26241765	chr6:26871484~26956554:-
BRCA	cis	rs721917	0.506	rs1923540	ENSG00000225484.5	NUTM2B-AS1	-3.83	0.000138	0.00829	-0.16	-0.12	Chronic obstructive pulmonary disease;	chr10:79930616	chr10:79663088~79826594:-
BRCA	cis	rs7746199	0.673	rs72847313	ENSG00000216901.1	AL022393.7	3.83	0.000138	0.00829	0.3	0.12	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27762303	chr6:28176188~28176674:+
BRCA	cis	rs7746199	0.611	rs17750747	ENSG00000216901.1	AL022393.7	3.83	0.000138	0.00829	0.3	0.12	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27762555	chr6:28176188~28176674:+
BRCA	cis	rs970548	0.721	rs57491883	ENSG00000237840.5	FAM21FP	3.83	0.000138	0.00829	0.14	0.12	Total cholesterol levels;HDL cholesterol;HDL cholesterol levels;Cholesterol, total;	chr10:45604653	chr10:45706431~45727231:-
BRCA	cis	rs4415084	1	rs6884702	ENSG00000248779.1	RP11-53O19.2	3.83	0.000138	0.00829	0.11	0.12	Breast cancer;	chr5:44682487	chr5:44752949~44765744:+
BRCA	cis	rs34773007	0.623	rs34566437	ENSG00000232709.1	MARK2P9	3.83	0.000138	0.00829	0.19	0.12	Type 2 diabetes;	chr10:92790195	chr10:92418667~92420875:+
BRCA	cis	rs73201462	1	rs6798749	ENSG00000242551.2	POU5F1P6	-3.83	0.000138	0.00829	-0.19	-0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128338054	chr3:128674735~128677005:-
BRCA	cis	rs2274273	0.624	rs8015211	ENSG00000259318.1	RP11-454L9.2	3.83	0.000138	0.00829	0.11	0.12	Protein biomarker;	chr14:55374729	chr14:55394940~55395233:-
BRCA	cis	rs875971	0.83	rs778711	ENSG00000229886.1	RP5-1132H15.3	3.83	0.000138	0.00829	0.13	0.12	Aortic root size;	chr7:66386670	chr7:66025126~66031544:-
BRCA	cis	rs875971	0.862	rs1083554	ENSG00000229886.1	RP5-1132H15.3	3.83	0.000138	0.00829	0.13	0.12	Aortic root size;	chr7:66387354	chr7:66025126~66031544:-
BRCA	cis	rs875971	0.862	rs778707	ENSG00000229886.1	RP5-1132H15.3	3.83	0.000138	0.00829	0.13	0.12	Aortic root size;	chr7:66392040	chr7:66025126~66031544:-
BRCA	cis	rs875971	0.862	rs778705	ENSG00000229886.1	RP5-1132H15.3	3.83	0.000138	0.00829	0.13	0.12	Aortic root size;	chr7:66396128	chr7:66025126~66031544:-
BRCA	cis	rs875971	0.862	rs778697	ENSG00000229886.1	RP5-1132H15.3	3.83	0.000138	0.00829	0.13	0.12	Aortic root size;	chr7:66405439	chr7:66025126~66031544:-
BRCA	cis	rs875971	0.798	rs7789615	ENSG00000229886.1	RP5-1132H15.3	3.83	0.000138	0.00829	0.13	0.12	Aortic root size;	chr7:66413674	chr7:66025126~66031544:-
BRCA	cis	rs12025262	0.546	rs10754539	ENSG00000259865.1	RP11-488L18.10	3.83	0.000138	0.00829	0.1	0.12	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr1:247202128	chr1:247187281~247188526:-
BRCA	cis	rs77633900	0.772	rs182253	ENSG00000196274.5	Metazoa_SRP	3.83	0.000138	0.00829	0.2	0.12	Glioma;Non-glioblastoma glioma;	chr15:76508414	chr15:76230048~76230390:-
BRCA	cis	rs2115630	0.791	rs2008262	ENSG00000259728.4	LINC00933	-3.83	0.000138	0.00829	-0.14	-0.12	P wave terminal force;	chr15:84762039	chr15:84570649~84580175:+
BRCA	cis	rs4835473	0.808	rs4054643	ENSG00000249741.2	RP11-673E1.3	3.83	0.000138	0.00829	0.12	0.12	Immature fraction of reticulocytes;	chr4:143787329	chr4:143911514~143912053:-
BRCA	cis	rs12724450	0.793	rs11802612	ENSG00000228126.1	FALEC	3.83	0.000138	0.0083	0.21	0.12	Blood protein levels;	chr1:150454803	chr1:150515757~150518032:+
BRCA	cis	rs2638953	0.886	rs11049615	ENSG00000273989.1	RP11-425D17.2	-3.83	0.000138	0.0083	-0.18	-0.12	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28452152	chr12:28236227~28236828:+
BRCA	cis	rs8038465	0.615	rs6495076	ENSG00000260898.4	ADPGK-AS1	3.83	0.000138	0.0083	0.13	0.12	Liver enzyme levels (gamma-glutamyl transferase);	chr15:73690624	chr15:72782835~72798199:+
BRCA	cis	rs1371614	0.552	rs35538505	ENSG00000272148.1	RP11-195B17.1	-3.83	0.000138	0.0083	-0.13	-0.12	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26903159	chr2:27062428~27062907:-
BRCA	cis	rs11098499	0.913	rs10006304	ENSG00000225892.3	RP11-384K6.2	3.83	0.000138	0.0083	0.13	0.12	Corneal astigmatism;	chr4:119203150	chr4:118632274~118634759:+
BRCA	cis	rs6918586	0.658	rs198825	ENSG00000272810.1	U91328.22	-3.83	0.000138	0.0083	-0.13	-0.12	Schizophrenia;	chr6:26122274	chr6:26013241~26013757:+
BRCA	cis	rs6728642	0.519	rs6721921	ENSG00000273265.1	RP11-353K11.1	3.83	0.000138	0.0083	0.17	0.12	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:96900764	chr2:96812239~96813657:-
BRCA	cis	rs6728642	0.519	rs59131346	ENSG00000273265.1	RP11-353K11.1	3.83	0.000138	0.0083	0.17	0.12	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:96901031	chr2:96812239~96813657:-
BRCA	cis	rs73201462	1	rs2811525	ENSG00000242551.2	POU5F1P6	-3.83	0.000138	0.0083	-0.19	-0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128280587	chr3:128674735~128677005:-
BRCA	cis	rs9840812	0.598	rs1145101	ENSG00000273486.1	RP11-731C17.2	3.83	0.000138	0.0083	0.17	0.12	Fibrinogen levels;	chr3:136350444	chr3:136837338~136839021:-
BRCA	cis	rs7578361	0.959	rs6721261	ENSG00000231969.1	AC144449.1	-3.83	0.000138	0.0083	-0.18	-0.12	Acute lymphoblastic leukemia (childhood);	chr2:149598606	chr2:149587196~149848233:+
BRCA	cis	rs1387259	0.698	rs4579969	ENSG00000240399.1	RP1-228P16.1	-3.83	0.000138	0.0083	-0.13	-0.12	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48385779	chr12:48054813~48055591:-
BRCA	cis	rs962856	0.964	rs1552359	ENSG00000236605.1	AC023115.4	3.83	0.000138	0.0083	0.14	0.12	Pancreatic cancer;	chr2:67388297	chr2:67324627~67325304:+
BRCA	cis	rs17027633	1	rs77952923	ENSG00000260948.1	RP11-552M11.8	-3.83	0.000138	0.00831	-0.28	-0.12	Cerebrospinal fluid t-tau:AB1-42 ratio;	chr1:111432030	chr1:111431046~111433068:-
BRCA	cis	rs17597773	0.674	rs12117818	ENSG00000257551.1	HLX-AS1	-3.83	0.000139	0.00831	-0.14	-0.12	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220828141	chr1:220832763~220880140:-
BRCA	cis	rs875971	0.66	rs62465434	ENSG00000272831.1	RP11-792A8.4	3.83	0.000139	0.00831	0.11	0.12	Aortic root size;	chr7:66540165	chr7:66739829~66740385:-
BRCA	cis	rs7487075	0.619	rs10880968	ENSG00000257261.4	RP11-96H19.1	3.83	0.000139	0.00831	0.13	0.12	Itch intensity from mosquito bite;	chr12:46429177	chr12:46383679~46876159:+
BRCA	cis	rs4835473	0.932	rs12512652	ENSG00000246448.2	RP13-578N3.3	-3.83	0.000139	0.00831	-0.13	-0.12	Immature fraction of reticulocytes;	chr4:143736787	chr4:143700257~143865072:+
BRCA	cis	rs801193	0.548	rs2659904	ENSG00000273448.1	RP11-166O4.6	3.83	0.000139	0.00831	0.11	0.12	Aortic root size;	chr7:66713615	chr7:67333047~67334383:+
BRCA	cis	rs2243480	1	rs56016656	ENSG00000226767.1	RP11-328P23.3	-3.82	0.000139	0.00831	-0.2	-0.12	Diabetic kidney disease;	chr7:65918494	chr7:65508773~65508944:-
BRCA	cis	rs2243480	1	rs56291018	ENSG00000226767.1	RP11-328P23.3	-3.82	0.000139	0.00831	-0.2	-0.12	Diabetic kidney disease;	chr7:65925352	chr7:65508773~65508944:-
BRCA	cis	rs2243480	1	rs36033484	ENSG00000226767.1	RP11-328P23.3	-3.82	0.000139	0.00831	-0.2	-0.12	Diabetic kidney disease;	chr7:65925571	chr7:65508773~65508944:-
BRCA	cis	rs78487399	0.808	rs78108161	ENSG00000234936.1	AC010883.5	3.82	0.000139	0.00831	0.18	0.12	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43436709	chr2:43229573~43233394:+
BRCA	cis	rs962856	0.537	rs648817	ENSG00000236780.4	AC078941.1	3.82	0.000139	0.00831	0.15	0.12	Pancreatic cancer;	chr2:67453075	chr2:67123357~67215319:-
BRCA	cis	rs338389	0.711	rs7163804	ENSG00000260657.2	RP11-315D16.4	-3.82	0.000139	0.00832	-0.14	-0.12	Survival in rectal cancer;	chr15:67998608	chr15:68267792~68277994:-
BRCA	cis	rs7074356	0.915	rs17680103	ENSG00000226659.1	RP11-137H2.4	3.82	0.000139	0.00832	0.26	0.12	Borderline personality disorder;	chr10:80447862	chr10:80529597~80535942:-
BRCA	cis	rs1008375	0.931	rs6449310	ENSG00000249502.1	AC006160.5	-3.82	0.000139	0.00832	-0.14	-0.12	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17573907	chr4:17587467~17614571:-
BRCA	cis	rs2251381	0.808	rs7364112	ENSG00000232855.5	AF131217.1	-3.82	0.000139	0.00832	-0.15	-0.12	Selective IgA deficiency;	chr21:29176647	chr21:28439346~28674848:-
BRCA	cis	rs10986311	0.832	rs10119911	ENSG00000227200.1	RP11-121A14.3	3.82	0.000139	0.00832	0.13	0.12	Vitiligo;	chr9:124364893	chr9:124262876~124265809:+
BRCA	cis	rs73201462	1	rs2955079	ENSG00000242551.2	POU5F1P6	-3.82	0.000139	0.00832	-0.19	-0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128240981	chr3:128674735~128677005:-
BRCA	cis	rs73201462	1	rs2955080	ENSG00000242551.2	POU5F1P6	-3.82	0.000139	0.00832	-0.19	-0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128241022	chr3:128674735~128677005:-
BRCA	cis	rs10129255	0.957	rs28887506	ENSG00000232216.1	IGHV3-43	3.82	0.000139	0.00832	0.1	0.12	Kawasaki disease;	chr14:106785589	chr14:106470264~106470800:-
BRCA	cis	rs2562456	0.917	rs2650805	ENSG00000213976.4	CTD-2561J22.2	3.82	0.000139	0.00832	0.14	0.12	Pain;	chr19:21505137	chr19:21382865~21387177:+
BRCA	cis	rs425277	0.958	rs262660	ENSG00000269227.1	RP11-345P4.6	3.82	0.000139	0.00832	0.12	0.12	Height;	chr1:2155318	chr1:1673275~1674397:+
BRCA	cis	rs863345	0.625	rs12075903	ENSG00000229914.1	RP11-404O13.4	-3.82	0.000139	0.00832	-0.13	-0.12	Pneumococcal bacteremia;	chr1:158489142	chr1:158195633~158196131:-
BRCA	cis	rs863345	0.604	rs2023632	ENSG00000229914.1	RP11-404O13.4	-3.82	0.000139	0.00832	-0.13	-0.12	Pneumococcal bacteremia;	chr1:158489244	chr1:158195633~158196131:-
BRCA	cis	rs875971	0.66	rs13224319	ENSG00000272831.1	RP11-792A8.4	3.82	0.000139	0.00832	0.11	0.12	Aortic root size;	chr7:66542376	chr7:66739829~66740385:-
BRCA	cis	rs875971	0.66	rs801217	ENSG00000272831.1	RP11-792A8.4	-3.82	0.000139	0.00832	-0.11	-0.12	Aortic root size;	chr7:66545590	chr7:66739829~66740385:-
BRCA	cis	rs875971	0.638	rs801216	ENSG00000272831.1	RP11-792A8.4	-3.82	0.000139	0.00832	-0.11	-0.12	Aortic root size;	chr7:66546680	chr7:66739829~66740385:-
BRCA	cis	rs6840360	0.718	rs2136960	ENSG00000278978.1	RP11-164P12.5	3.82	0.000139	0.00833	0.13	0.12	Intelligence (multi-trait analysis);	chr4:151825037	chr4:151669786~151670503:+
BRCA	cis	rs12049351	0.722	rs6703347	ENSG00000229367.1	HMGN2P19	3.82	0.000139	0.00833	0.17	0.12	Circulating myeloperoxidase levels (plasma);	chr1:229490419	chr1:229570532~229570796:+
BRCA	cis	rs4415084	0.966	rs10805685	ENSG00000272335.1	RP11-53O19.3	3.82	0.000139	0.00833	0.11	0.12	Breast cancer;	chr5:44661856	chr5:44826076~44828592:+
BRCA	cis	rs683250	0.598	rs590847	ENSG00000254551.1	RP11-727A23.7	3.82	0.000139	0.00833	0.15	0.12	Subcortical brain region volumes;	chr11:83255127	chr11:83209431~83213379:-
BRCA	cis	rs7824557	0.767	rs17797443	ENSG00000154316.13	TDH	-3.82	0.000139	0.00833	-0.17	-0.12	Retinal vascular caliber;	chr8:11306503	chr8:11339637~11368452:+
BRCA	cis	rs17027633	1	rs10489792	ENSG00000260948.1	RP11-552M11.8	-3.82	0.000139	0.00833	-0.28	-0.12	Cerebrospinal fluid t-tau:AB1-42 ratio;	chr1:111419056	chr1:111431046~111433068:-
BRCA	cis	rs6964587	1	rs12704635	ENSG00000188693.7	CYP51A1-AS1	-3.82	0.000139	0.00833	-0.13	-0.12	Breast cancer;	chr7:92108010	chr7:92134604~92180725:+
BRCA	cis	rs875971	0.66	rs801211	ENSG00000272831.1	RP11-792A8.4	-3.82	0.000139	0.00833	-0.11	-0.12	Aortic root size;	chr7:66550702	chr7:66739829~66740385:-
BRCA	cis	rs875971	0.638	rs801205	ENSG00000272831.1	RP11-792A8.4	-3.82	0.000139	0.00833	-0.11	-0.12	Aortic root size;	chr7:66557157	chr7:66739829~66740385:-
BRCA	cis	rs875971	0.617	rs810400	ENSG00000272831.1	RP11-792A8.4	-3.82	0.000139	0.00833	-0.11	-0.12	Aortic root size;	chr7:66557902	chr7:66739829~66740385:-
BRCA	cis	rs8141529	0.748	rs1318025	ENSG00000272858.1	CTA-292E10.8	-3.82	0.000139	0.00834	-0.15	-0.12	Lymphocyte counts;	chr22:28887769	chr22:28814914~28815662:+
BRCA	cis	rs6743226	0.603	rs1106523	ENSG00000266621.1	AC104841.1	3.82	0.000139	0.00834	0.14	0.12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in non-smokers;	chr2:241312124	chr2:241245202~241245299:-
BRCA	cis	rs7267979	1	rs2387884	ENSG00000276952.1	RP5-965G21.6	-3.82	0.000139	0.00834	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25398433	chr20:25284915~25285588:-
BRCA	cis	rs9300255	0.722	rs11830103	ENSG00000256028.2	RP11-197N18.2	-3.82	0.000139	0.00834	-0.12	-0.12	Neutrophil percentage of white cells;	chr12:123338999	chr12:122975320~122982907:+
BRCA	cis	rs7523050	0.73	rs34254854	ENSG00000203897.3	SPATA42	-3.82	0.000139	0.00834	-0.23	-0.12	Fat distribution (HIV);	chr1:108877253	chr1:108857217~108858524:+
BRCA	cis	rs875971	0.651	rs2420596	ENSG00000273024.4	INTS4P2	-3.82	0.000139	0.00834	-0.13	-0.12	Aortic root size;	chr7:66450996	chr7:65647864~65715661:+
BRCA	cis	rs875971	0.52	rs2420597	ENSG00000273024.4	INTS4P2	-3.82	0.000139	0.00834	-0.13	-0.12	Aortic root size;	chr7:66450999	chr7:65647864~65715661:+
BRCA	cis	rs875971	0.66	rs10272357	ENSG00000275400.1	RP4-756H11.5	3.82	0.000139	0.00834	0.13	0.12	Aortic root size;	chr7:66598087	chr7:66553805~66554199:-
BRCA	cis	rs1048886	0.872	rs12530057	ENSG00000271967.1	RP11-134K13.4	-3.82	0.000139	0.00834	-0.18	-0.12	Type 2 diabetes;	chr6:70551446	chr6:70596438~70596980:+
BRCA	cis	rs6545883	0.931	rs11125885	ENSG00000270820.4	RP11-355B11.2	3.82	0.000139	0.00834	0.14	0.12	Tuberculosis;	chr2:61528593	chr2:61471188~61484130:+
BRCA	cis	rs1555322	1	rs2425036	ENSG00000269202.1	RP4-614O4.12	-3.82	0.000139	0.00834	-0.17	-0.12	Attention deficit hyperactivity disorder;	chr20:35268178	chr20:35201747~35203288:-
BRCA	cis	rs34773007	0.623	rs55880030	ENSG00000232709.1	MARK2P9	3.82	0.000139	0.00834	0.19	0.12	Type 2 diabetes;	chr10:92796240	chr10:92418667~92420875:+
BRCA	cis	rs7246967	0.608	rs2569728	ENSG00000198153.8	ZNF849P	-3.82	0.000139	0.00834	-0.17	-0.12	Bronchopulmonary dysplasia;	chr19:22831202	chr19:22685167~22686732:+
BRCA	cis	rs4908769	0.66	rs302714	ENSG00000232912.4	RP5-1115A15.1	3.82	0.000139	0.00834	0.13	0.12	Allergy;	chr1:8426071	chr1:8424645~8434838:+
BRCA	cis	rs6964587	1	rs733957	ENSG00000188693.7	CYP51A1-AS1	-3.82	0.000139	0.00834	-0.13	-0.12	Breast cancer;	chr7:92077883	chr7:92134604~92180725:+
BRCA	cis	rs962856	0.537	rs694637	ENSG00000236780.4	AC078941.1	-3.82	0.000139	0.00834	-0.15	-0.12	Pancreatic cancer;	chr2:67457580	chr2:67123357~67215319:-
BRCA	cis	rs2692947	1	rs2692947	ENSG00000232931.4	LINC00342	3.82	0.000139	0.00834	0.12	0.12	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96008368	chr2:95807118~95816215:-
BRCA	cis	rs7120118	0.517	rs12575157	ENSG00000280615.1	Y_RNA	3.82	0.000139	0.00834	0.19	0.12	HDL cholesterol;	chr11:47251195	chr11:47614898~47614994:-
BRCA	cis	rs2562456	0.917	rs6511256	ENSG00000213976.4	CTD-2561J22.2	3.82	0.000139	0.00835	0.14	0.12	Pain;	chr19:21510513	chr19:21382865~21387177:+
BRCA	cis	rs10043228	0.702	rs10051697	ENSG00000250015.1	CTC-339F2.2	3.82	0.000139	0.00835	0.15	0.12	Asthma or chronic obstructive pulmonary disease;	chr5:116142873	chr5:116302354~116304134:-
BRCA	cis	rs568617	1	rs687672	ENSG00000254614.2	AP003068.23	3.82	0.000139	0.00835	0.17	0.12	Crohn's disease;	chr11:65882513	chr11:65177606~65181834:-
BRCA	cis	rs925550	0.932	rs60318098	ENSG00000224786.1	CETN4P	-3.82	0.000139	0.00835	-0.2	-0.12	Primary biliary cholangitis;	chr4:122678743	chr4:122730548~122732193:-
BRCA	cis	rs10129255	0.957	rs10136560	ENSG00000274576.2	IGHV2-70	3.82	0.000139	0.00835	0.11	0.12	Kawasaki disease;	chr14:106787630	chr14:106770577~106771020:-
BRCA	cis	rs13434995	0.513	rs2101476	ENSG00000239040.1	Y_RNA	3.82	0.000139	0.00835	0.14	0.12	Adiponectin levels;	chr4:55578961	chr4:55412636~55412738:+
BRCA	cis	rs1009077	0.61	rs2389869	ENSG00000245958.5	RP11-33B1.1	-3.82	0.000139	0.00835	-0.13	-0.12	Endometriosis;	chr4:119596336	chr4:119454791~119552025:+
BRCA	cis	rs4842666	0.915	rs111478946	ENSG00000270344.2	RP11-734K2.4	3.82	0.000139	0.00835	0.15	0.12	Blood pressure;	chr12:89665065	chr12:89525654~89548005:+
BRCA	cis	rs687432	0.812	rs7118004	ENSG00000265566.2	RN7SL605P	-3.82	0.000139	0.00835	-0.17	-0.12	Parkinson's disease;	chr11:58094195	chr11:57528085~57528365:-
BRCA	cis	rs1048886	0.938	rs16869370	ENSG00000271967.1	RP11-134K13.4	3.82	0.000139	0.00835	0.15	0.12	Type 2 diabetes;	chr6:70557863	chr6:70596438~70596980:+
BRCA	cis	rs6012564	0.893	rs4810896	ENSG00000227431.4	CSE1L-AS1	-3.82	0.000139	0.00835	-0.15	-0.12	Anger;	chr20:48918761	chr20:49040463~49046044:-
BRCA	cis	rs2274273	0.805	rs8012156	ENSG00000233924.1	AL160471.6	-3.82	0.000139	0.00835	-0.13	-0.12	Protein biomarker;	chr14:55085782	chr14:55004813~55005687:-
BRCA	cis	rs801193	0.844	rs2244022	ENSG00000273142.1	RP11-458F8.4	-3.82	0.000139	0.00835	-0.1	-0.12	Aortic root size;	chr7:66737443	chr7:66902857~66906297:+
BRCA	cis	rs718433	0.717	rs12893255	ENSG00000211778.2	TRAV4	-3.82	0.000139	0.00835	-0.08	-0.12	Intraocular pressure;	chr14:21773162	chr14:21736152~21736982:+
BRCA	cis	rs7267979	0.932	rs6138588	ENSG00000276952.1	RP5-965G21.6	3.82	0.000139	0.00835	0.14	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25506887	chr20:25284915~25285588:-
BRCA	cis	rs74233809	1	rs77787671	ENSG00000236937.2	PTGES3P4	3.82	0.000139	0.00836	0.25	0.12	Birth weight;	chr10:103016448	chr10:102845595~102845950:+
BRCA	cis	rs7523050	0.73	rs12734623	ENSG00000203897.3	SPATA42	-3.82	0.000139	0.00836	-0.23	-0.12	Fat distribution (HIV);	chr1:108900032	chr1:108857217~108858524:+
BRCA	cis	rs11711311	0.869	rs1026364	ENSG00000241529.3	RN7SL767P	-3.82	0.000139	0.00836	-0.14	-0.12	IgG glycosylation;	chr3:113651163	chr3:113632704~113632998:+
BRCA	cis	rs891378	0.959	rs1507759	ENSG00000274245.1	RP11-357P18.2	-3.82	0.000139	0.00836	-0.15	-0.12	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207334283	chr1:207372559~207373252:+
BRCA	cis	rs4272720	0.901	rs72785084	ENSG00000228754.1	RP11-534L6.3	-3.82	0.000139	0.00836	-0.18	-0.12	Platelet count;Plateletcrit;	chr10:49151917	chr10:48745545~48746128:-
BRCA	cis	rs1953600	0.87	rs2789690	ENSG00000226659.1	RP11-137H2.4	3.82	0.000139	0.00836	0.16	0.12	Sarcoidosis;	chr10:80178448	chr10:80529597~80535942:-
BRCA	cis	rs4664293	0.669	rs357021	ENSG00000224152.1	AC009506.1	-3.82	0.000139	0.00836	-0.12	-0.12	Monocyte percentage of white cells;	chr2:159632572	chr2:159615296~159617082:+
BRCA	cis	rs4664293	0.647	rs7580816	ENSG00000224152.1	AC009506.1	-3.82	0.000139	0.00836	-0.12	-0.12	Monocyte percentage of white cells;	chr2:159619370	chr2:159615296~159617082:+
BRCA	cis	rs115344852	0.557	rs2859351	ENSG00000204709.4	LINC01556	3.82	0.000139	0.00836	0.17	0.12	Epithelial ovarian cancer;	chr6:28488418	chr6:28943877~28944537:+
BRCA	cis	rs115344852	0.575	rs2531820	ENSG00000204709.4	LINC01556	3.82	0.000139	0.00836	0.17	0.12	Epithelial ovarian cancer;	chr6:28488942	chr6:28943877~28944537:+
BRCA	cis	rs11686241	1	rs11886888	ENSG00000241520.1	AC098820.4	3.82	0.000139	0.00836	0.18	0.12	Cancer;	chr2:216424690	chr2:216483032~216487196:-
BRCA	cis	rs17169635	0.84	rs10236678	ENSG00000272941.1	RP11-134L10.1	3.82	0.00014	0.00836	0.14	0.12	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);	chr7:134865176	chr7:135168403~135169547:+
BRCA	cis	rs10129255	0.833	rs7156689	ENSG00000211958.2	IGHV3-38	3.82	0.00014	0.00836	0.09	0.12	Kawasaki disease;	chr14:106816039	chr14:106410493~106411021:-
BRCA	cis	rs875971	0.522	rs709604	ENSG00000273142.1	RP11-458F8.4	3.82	0.00014	0.00836	0.1	0.12	Aortic root size;	chr7:66032447	chr7:66902857~66906297:+
BRCA	cis	rs3760982	0.585	rs1386502	ENSG00000267191.1	RP11-15A1.2	-3.82	0.00014	0.00836	-0.15	-0.12	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43789204	chr19:43902001~43926545:+
BRCA	cis	rs7903456	0.648	rs4275529	ENSG00000200253.1	RNU6-529P	3.82	0.00014	0.00836	0.14	0.12	Gout;Renal underexcretion gout;	chr10:87069031	chr10:87041238~87041341:-
BRCA	cis	rs9392653	0.691	rs1246995	ENSG00000220685.3	RP11-530A18.1	3.82	0.00014	0.00836	0.16	0.12	Venous thromboembolism (SNP x SNP interaction);	chr6:5058939	chr6:5065795~5066982:-
BRCA	cis	rs4629607	1	rs4629607	ENSG00000251141.4	RP11-53O19.1	-3.82	0.00014	0.00836	-0.11	-0.12	Schizophrenia;	chr5:44857365	chr5:44744900~44808777:-
BRCA	cis	rs8054556	0.787	rs12444108	ENSG00000183604.13	SMG1P5	-3.82	0.00014	0.00836	-0.11	-0.12	Autism spectrum disorder or schizophrenia;	chr16:30016373	chr16:30267553~30335374:-
BRCA	cis	rs11671005	0.779	rs11670125	ENSG00000265272.2	RN7SL693P	3.82	0.00014	0.00836	0.18	0.12	Mean platelet volume;	chr19:58476023	chr19:58490797~58491075:+
BRCA	cis	rs875971	0.862	rs2088653	ENSG00000229886.1	RP5-1132H15.3	-3.82	0.00014	0.00836	-0.13	-0.12	Aortic root size;	chr7:66343621	chr7:66025126~66031544:-
BRCA	cis	rs875971	0.862	rs6460293	ENSG00000229886.1	RP5-1132H15.3	-3.82	0.00014	0.00836	-0.13	-0.12	Aortic root size;	chr7:66345205	chr7:66025126~66031544:-
BRCA	cis	rs1816752	0.905	rs1348110	ENSG00000273628.1	RP11-756A22.7	3.82	0.00014	0.00836	0.14	0.12	Obesity-related traits;	chr13:24406537	chr13:24933006~24936796:+
BRCA	cis	rs6121246	0.609	rs6088997	ENSG00000230613.1	HM13-AS1	-3.82	0.00014	0.00836	-0.16	-0.12	Mean corpuscular hemoglobin;	chr20:31702021	chr20:31567707~31573263:-
BRCA	cis	rs9309473	0.607	rs7573719	ENSG00000230002.2	ALMS1-IT1	3.82	0.00014	0.00836	0.14	0.12	Metabolite levels;	chr2:73355858	chr2:73456764~73459484:+
BRCA	cis	rs7520050	0.933	rs6661163	ENSG00000234329.1	RP11-767N6.2	-3.82	0.00014	0.00836	-0.11	-0.12	Reticulocyte count;Red blood cell count;	chr1:45789332	chr1:45651039~45651826:-
BRCA	cis	rs7824557	0.701	rs2060465	ENSG00000154316.13	TDH	-3.82	0.00014	0.00837	-0.17	-0.12	Retinal vascular caliber;	chr8:11305100	chr8:11339637~11368452:+
BRCA	cis	rs7727544	0.548	rs2069616	ENSG00000233006.5	AC034220.3	3.82	0.00014	0.00837	0.09	0.12	Blood metabolite levels;	chr5:132072384	chr5:132311285~132369916:-
BRCA	cis	rs9840812	0.725	rs3821445	ENSG00000273486.1	RP11-731C17.2	-3.82	0.00014	0.00837	-0.17	-0.12	Fibrinogen levels;	chr3:136283967	chr3:136837338~136839021:-
BRCA	cis	rs9308731	0.644	rs1837367	ENSG00000230499.1	AC108463.1	-3.82	0.00014	0.00837	-0.14	-0.12	Chronic lymphocytic leukemia;	chr2:111116974	chr2:111195963~111206494:+
BRCA	cis	rs4443100	0.67	rs3788338	ENSG00000230701.2	FBXW4P1	3.82	0.00014	0.00837	0.16	0.12	Serum parathyroid hormone levels;	chr22:23069879	chr22:23262767~23265005:+
BRCA	cis	rs930395	1	rs930395	ENSG00000251141.4	RP11-53O19.1	3.82	0.00014	0.00837	0.13	0.12	Breast cancer;	chr5:44822356	chr5:44744900~44808777:-
BRCA	cis	rs7267979	1	rs6050626	ENSG00000204556.4	CTD-2514C3.1	-3.82	0.00014	0.00837	-0.16	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25447625	chr20:26018832~26020684:+
BRCA	cis	rs56281245	1	rs114543770	ENSG00000249363.1	CTB-78O21.1	3.82	0.00014	0.00837	0.26	0.12	Hepcidin levels;	chr5:145613827	chr5:145728360~145729349:-
BRCA	cis	rs875971	0.755	rs10228885	ENSG00000229886.1	RP5-1132H15.3	-3.82	0.00014	0.00837	-0.13	-0.12	Aortic root size;	chr7:66315542	chr7:66025126~66031544:-
BRCA	cis	rs3824488	0.765	rs76597087	ENSG00000225194.2	LINC00092	3.82	0.00014	0.00837	0.19	0.12	Neuroticism;	chr9:95529571	chr9:96019732~96027965:-
BRCA	cis	rs11773103	1	rs55750589	ENSG00000224046.1	AC005076.5	3.82	0.00014	0.00837	0.25	0.12	Bipolar disorder or major depressive disorder (combined);	chr7:87168929	chr7:87151423~87152420:-
BRCA	cis	rs7267979	0.868	rs6138546	ENSG00000274973.1	RP13-401N8.7	-3.82	0.00014	0.00837	-0.13	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25235898	chr20:25845497~25845862:+
BRCA	cis	rs13434995	0.945	rs28473211	ENSG00000273257.1	RP11-177J6.1	-3.82	0.00014	0.00837	-0.19	-0.12	Adiponectin levels;	chr4:55615808	chr4:55387949~55388271:+
BRCA	cis	rs983392	0.679	rs636317	ENSG00000275344.1	MIR6503	3.82	0.00014	0.00837	0.12	0.12	Alzheimer's disease (late onset);	chr11:60251677	chr11:60209071~60209156:-
BRCA	cis	rs997295	0.592	rs2899724	ENSG00000259673.4	IQCH-AS1	3.82	0.00014	0.00837	0.13	0.12	Motion sickness;	chr15:67468470	chr15:67403619~67521844:-
BRCA	cis	rs13326165	0.543	rs10461028	ENSG00000243224.1	RP5-1157M23.2	-3.82	0.00014	0.00838	-0.19	-0.12	HDL cholesterol levels;HDL cholesterol;	chr3:52309726	chr3:52239258~52241097:+
BRCA	cis	rs7267979	1	rs2424712	ENSG00000274414.1	RP5-965G21.4	-3.82	0.00014	0.00838	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25436306	chr20:25239007~25245229:-
BRCA	cis	rs7267979	0.966	rs2424714	ENSG00000274414.1	RP5-965G21.4	-3.82	0.00014	0.00838	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25438045	chr20:25239007~25245229:-
BRCA	cis	rs7267979	0.966	rs2424715	ENSG00000274414.1	RP5-965G21.4	-3.82	0.00014	0.00838	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25439441	chr20:25239007~25245229:-
BRCA	cis	rs6596100	0.915	rs6874265	ENSG00000248648.1	RP11-485M7.1	-3.82	0.00014	0.00838	-0.15	-0.12	Breast cancer;	chr5:133055060	chr5:133003119~133003365:+
BRCA	cis	rs6596100	0.915	rs6596099	ENSG00000248648.1	RP11-485M7.1	-3.82	0.00014	0.00838	-0.15	-0.12	Breast cancer;	chr5:133067667	chr5:133003119~133003365:+
BRCA	cis	rs12530845	0.887	rs4492299	ENSG00000223718.3	AC093107.7	3.82	0.00014	0.00838	0.19	0.12	Red blood cell traits;	chr7:135630942	chr7:135660039~135660647:+
BRCA	cis	rs2274273	0.588	rs2297816	ENSG00000259318.1	RP11-454L9.2	3.82	0.00014	0.00838	0.1	0.12	Protein biomarker;	chr14:55366320	chr14:55394940~55395233:-
BRCA	cis	rs7746199	0.668	rs34864796	ENSG00000216901.1	AL022393.7	3.82	0.00014	0.00838	0.26	0.12	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27492144	chr6:28176188~28176674:+
BRCA	cis	rs375066	0.935	rs406968	ENSG00000267191.1	RP11-15A1.2	-3.82	0.00014	0.00838	-0.15	-0.12	Breast cancer;	chr19:43914191	chr19:43902001~43926545:+
BRCA	cis	rs7267979	1	rs6050617	ENSG00000274414.1	RP5-965G21.4	-3.82	0.00014	0.00838	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25441012	chr20:25239007~25245229:-
BRCA	cis	rs7267979	0.933	rs2387887	ENSG00000274414.1	RP5-965G21.4	-3.82	0.00014	0.00838	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25446445	chr20:25239007~25245229:-
BRCA	cis	rs7267979	1	rs6037121	ENSG00000274414.1	RP5-965G21.4	-3.82	0.00014	0.00838	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25447675	chr20:25239007~25245229:-
BRCA	cis	rs7267979	1	rs1047171	ENSG00000274414.1	RP5-965G21.4	-3.82	0.00014	0.00838	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25448150	chr20:25239007~25245229:-
BRCA	cis	rs7267979	1	rs6050629	ENSG00000274414.1	RP5-965G21.4	-3.82	0.00014	0.00838	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25450044	chr20:25239007~25245229:-
BRCA	cis	rs7267979	1	rs6050630	ENSG00000274414.1	RP5-965G21.4	-3.82	0.00014	0.00838	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25450109	chr20:25239007~25245229:-
BRCA	cis	rs13217239	0.646	rs4403259	ENSG00000124549.13	BTN2A3P	3.82	0.00014	0.00838	0.12	0.12	Schizophrenia;	chr6:27029838	chr6:26421391~26432383:+
BRCA	cis	rs11681884	0.681	rs11883847	ENSG00000240356.5	RP11-395L14.11	3.82	0.00014	0.00838	0.22	0.12	Stroke;	chr2:113034594	chr2:113610502~113627090:-
BRCA	cis	rs801193	0.569	rs2659908	ENSG00000229886.1	RP5-1132H15.3	3.82	0.00014	0.00838	0.13	0.12	Aortic root size;	chr7:66695835	chr7:66025126~66031544:-
BRCA	cis	rs7552404	0.824	rs1251079	ENSG00000181227.3	RP4-682C21.2	-3.82	0.00014	0.00838	-0.11	-0.12	Acylcarnitine levels;Blood metabolite levels;	chr1:75723760	chr1:75743423~75744776:-
BRCA	cis	rs6840360	0.571	rs62327269	ENSG00000270265.1	RP11-731D1.4	-3.82	0.00014	0.00838	-0.14	-0.12	Intelligence (multi-trait analysis);	chr4:151606821	chr4:151333775~151353224:-
BRCA	cis	rs6545883	0.894	rs2177962	ENSG00000273302.1	RP11-493E12.2	-3.82	0.00014	0.00838	-0.11	-0.12	Tuberculosis;	chr2:61360935	chr2:61199979~61200769:+
BRCA	cis	rs3760982	1	rs11669175	ENSG00000267191.1	RP11-15A1.2	-3.82	0.00014	0.00838	-0.15	-0.12	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43785672	chr19:43902001~43926545:+
BRCA	cis	rs62025270	0.632	rs55981798	ENSG00000259367.1	RP11-815J21.4	3.82	0.00014	0.00839	0.11	0.12	Idiopathic pulmonary fibrosis;	chr15:85600869	chr15:85619623~85670948:-
BRCA	cis	rs62025270	0.576	rs17633959	ENSG00000259367.1	RP11-815J21.4	3.82	0.00014	0.00839	0.11	0.12	Idiopathic pulmonary fibrosis;	chr15:85600950	chr15:85619623~85670948:-
BRCA	cis	rs1722141	0.634	rs788746	ENSG00000237471.1	AC073115.6	3.82	0.00014	0.00839	0.16	0.12	Sitting height ratio;	chr7:46026353	chr7:45969657~45980191:+
BRCA	cis	rs17772222	0.917	rs61982733	ENSG00000258789.1	RP11-507K2.3	-3.82	0.00014	0.00839	-0.15	-0.12	Coronary artery calcification;	chr14:88776244	chr14:88551597~88552493:+
BRCA	cis	rs17772222	0.917	rs2145120	ENSG00000258789.1	RP11-507K2.3	-3.82	0.00014	0.00839	-0.15	-0.12	Coronary artery calcification;	chr14:88777699	chr14:88551597~88552493:+
BRCA	cis	rs73201462	1	rs2999090	ENSG00000242551.2	POU5F1P6	3.82	0.00014	0.00839	0.21	0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128212497	chr3:128674735~128677005:-
BRCA	cis	rs4925540	0.963	rs12144260	ENSG00000215796.3	RP11-551G24.2	-3.82	0.00014	0.00839	-0.14	-0.12	Response to taxane treatment (docetaxel);	chr1:247036531	chr1:247042791~247044021:+
BRCA	cis	rs7917772	0.503	rs1536308	ENSG00000213061.2	PFN1P11	-3.82	0.00014	0.00839	-0.16	-0.12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;	chr10:102529020	chr10:102838011~102845473:-
BRCA	cis	rs7917772	0.503	rs11191320	ENSG00000213061.2	PFN1P11	-3.82	0.00014	0.00839	-0.16	-0.12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;	chr10:102533637	chr10:102838011~102845473:-
BRCA	cis	rs7917772	0.503	rs11191321	ENSG00000213061.2	PFN1P11	-3.82	0.00014	0.00839	-0.16	-0.12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;	chr10:102533655	chr10:102838011~102845473:-
BRCA	cis	rs7917772	0.503	rs7896841	ENSG00000213061.2	PFN1P11	-3.82	0.00014	0.00839	-0.16	-0.12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;	chr10:102534908	chr10:102838011~102845473:-
BRCA	cis	rs7917772	0.503	rs6584510	ENSG00000213061.2	PFN1P11	-3.82	0.00014	0.00839	-0.16	-0.12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;	chr10:102540111	chr10:102838011~102845473:-
BRCA	cis	rs7917772	0.503	rs56219824	ENSG00000213061.2	PFN1P11	-3.82	0.00014	0.00839	-0.16	-0.12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;	chr10:102542580	chr10:102838011~102845473:-
BRCA	cis	rs7917772	0.503	rs11191325	ENSG00000213061.2	PFN1P11	-3.82	0.00014	0.00839	-0.16	-0.12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;	chr10:102543176	chr10:102838011~102845473:-
BRCA	cis	rs860295	0.812	rs3820594	ENSG00000225855.5	RUSC1-AS1	3.82	0.00014	0.00839	0.1	0.12	Body mass index;	chr1:155859720	chr1:155316863~155324176:-
BRCA	cis	rs875971	0.522	rs1968127	ENSG00000272831.1	RP11-792A8.4	-3.82	0.00014	0.00839	-0.11	-0.12	Aortic root size;	chr7:66591816	chr7:66739829~66740385:-
BRCA	cis	rs1949733	1	rs2140337	ENSG00000205959.3	RP11-689P11.2	-3.82	0.00014	0.00839	-0.12	-0.12	Response to antineoplastic agents;	chr4:8500385	chr4:8482270~8512610:+
BRCA	cis	rs2274273	0.682	rs10145268	ENSG00000259318.1	RP11-454L9.2	3.82	0.00014	0.00839	0.1	0.12	Protein biomarker;	chr14:55037796	chr14:55394940~55395233:-
BRCA	cis	rs10246939	0.543	rs9640359	ENSG00000270923.1	TAS2R6P	-3.82	0.00014	0.00839	-0.12	-0.12	Bitter taste perception;	chr7:141844399	chr7:141787815~141788640:+
BRCA	cis	rs1048886	0.938	rs2295200	ENSG00000271967.1	RP11-134K13.4	-3.82	0.00014	0.00839	-0.17	-0.12	Type 2 diabetes;	chr6:70523848	chr6:70596438~70596980:+
BRCA	cis	rs2304003	0.95	rs6742727	ENSG00000235192.1	AC009495.2	3.82	0.00014	0.00839	0.14	0.12	Social communication problems;	chr2:165836176	chr2:165794851~165810010:+
BRCA	cis	rs875971	0.577	rs35072105	ENSG00000229180.5	GS1-124K5.11	-3.82	0.00014	0.00839	-0.1	-0.12	Aortic root size;	chr7:66144830	chr7:66526088~66542624:-
BRCA	cis	rs28374715	0.532	rs316604	ENSG00000247556.5	OIP5-AS1	3.82	0.00014	0.00839	0.13	0.12	Ulcerative colitis;	chr15:41483023	chr15:41283990~41309737:+
BRCA	cis	rs17818399	0.749	rs4142759	ENSG00000279254.1	RP11-536C12.1	-3.82	0.00014	0.0084	-0.16	-0.12	Height;	chr2:46556751	chr2:46668870~46670778:+
BRCA	cis	rs9967417	0.583	rs478682	ENSG00000266696.1	RP11-30L3.2	3.82	0.00014	0.0084	0.13	0.12	Height;	chr18:49339021	chr18:49205912~49208781:+
BRCA	cis	rs9500256	0.683	rs10458024	ENSG00000272316.1	XXbac-BPGBPG55C20.2	3.82	0.00014	0.0084	0.11	0.12	Eosinophilic esophagitis (pediatric);	chr6:57997811	chr6:57908560~57913911:-
BRCA	cis	rs4478858	0.735	rs1566963	ENSG00000260386.4	LINC01225	-3.82	0.00014	0.0084	-0.14	-0.12	Alcohol dependence;	chr1:31299359	chr1:31500085~31540885:+
BRCA	cis	rs4699052	0.662	rs6533082	ENSG00000248740.4	RP11-328K4.1	3.82	0.00014	0.0084	0.13	0.12	Testicular germ cell tumor;	chr4:103320048	chr4:103256159~103453658:+
BRCA	cis	rs9472168	0.967	rs4349808	ENSG00000272223.1	RP1-20C7.6	3.82	0.00014	0.0084	0.13	0.12	Interleukin-13 levels;	chr6:43957037	chr6:43033897~43034405:-
BRCA	cis	rs7703051	0.601	rs17671591	ENSG00000271815.1	CTD-2235C13.3	-3.82	0.00014	0.0084	-0.15	-0.12	Age-related diseases, mortality and associated endophenotypes;LDL cholesterol;Age-related disease endophenotypes;	chr5:75319196	chr5:75363760~75364242:+
BRCA	cis	rs1577917	0.74	rs7771612	ENSG00000220563.1	PKMP3	3.82	0.00014	0.00841	0.12	0.12	Response to antipsychotic treatment;	chr6:85554656	chr6:85659892~85660606:-
BRCA	cis	rs1730008	1	rs1730008	ENSG00000279311.1	RP11-170K4.2	-3.82	0.00014	0.00841	-0.14	-0.12	Lobe attachment (rater-scored or self-reported);	chr3:158318120	chr3:158869898~158871821:+
BRCA	cis	rs9470794	1	rs73419946	ENSG00000204110.6	RP1-153P14.8	-3.82	0.00014	0.00841	-0.24	-0.12	Type 2 diabetes;	chr6:38070827	chr6:37507348~37535616:+
BRCA	cis	rs698833	0.501	rs35347977	ENSG00000223658.6	AC011242.6	3.82	0.00014	0.00841	0.14	0.12	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr2:44279782	chr2:43675380~43676322:-
BRCA	cis	rs853679	0.517	rs6932109	ENSG00000261839.1	RP1-265C24.8	-3.82	0.00014	0.00841	-0.16	-0.12	Depression;	chr6:28110525	chr6:28136849~28139678:+
BRCA	cis	rs7712401	0.791	rs4836244	ENSG00000251538.4	RP11-166A12.1	3.82	0.00014	0.00841	0.13	0.12	Mean platelet volume;	chr5:122780537	chr5:122628952~122730685:-
BRCA	cis	rs4272720	0.853	rs55936311	ENSG00000228754.1	RP11-534L6.3	-3.82	0.00014	0.00841	-0.18	-0.12	Platelet count;Plateletcrit;	chr10:49140816	chr10:48745545~48746128:-
BRCA	cis	rs4272720	0.901	rs11100994	ENSG00000228754.1	RP11-534L6.3	-3.82	0.00014	0.00841	-0.18	-0.12	Platelet count;Plateletcrit;	chr10:49140891	chr10:48745545~48746128:-
BRCA	cis	rs4272720	0.901	rs11814668	ENSG00000228754.1	RP11-534L6.3	-3.82	0.00014	0.00841	-0.18	-0.12	Platelet count;Plateletcrit;	chr10:49141334	chr10:48745545~48746128:-
BRCA	cis	rs4272720	0.901	rs11815070	ENSG00000228754.1	RP11-534L6.3	-3.82	0.00014	0.00841	-0.18	-0.12	Platelet count;Plateletcrit;	chr10:49141461	chr10:48745545~48746128:-
BRCA	cis	rs11187837	0.901	rs7096883	ENSG00000273450.1	RP11-76P2.4	3.82	0.00014	0.00841	0.25	0.12	Sudden cardiac arrest;	chr10:94309392	chr10:94314907~94315327:-
BRCA	cis	rs4478858	0.735	rs6425736	ENSG00000223907.1	LINC01226	-3.82	0.00014	0.00841	-0.14	-0.12	Alcohol dependence;	chr1:31311529	chr1:31518435~31524245:+
BRCA	cis	rs11098499	0.57	rs6832740	ENSG00000225892.3	RP11-384K6.2	3.82	0.000141	0.00841	0.11	0.12	Corneal astigmatism;	chr4:119624981	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.644	rs6855918	ENSG00000225892.3	RP11-384K6.2	3.82	0.000141	0.00841	0.11	0.12	Corneal astigmatism;	chr4:119625144	chr4:118632274~118634759:+
BRCA	cis	rs8141529	0.748	rs5762874	ENSG00000226471.5	CTA-292E10.6	-3.82	0.000141	0.00841	-0.14	-0.12	Lymphocyte counts;	chr22:28873670	chr22:28800683~28848559:+
BRCA	cis	rs7896471	0.546	rs7924071	ENSG00000227695.4	DNMBP-AS1	-3.82	0.000141	0.00841	-0.25	-0.12	Blood protein levels;	chr10:99987407	chr10:99927010~99958381:+
BRCA	cis	rs516805	0.667	rs9482234	ENSG00000279114.1	RP3-425C14.5	3.82	0.000141	0.00841	0.15	0.12	Lymphocyte counts;	chr6:122313998	chr6:122471923~122484161:+
BRCA	cis	rs10761482	0.861	rs4620673	ENSG00000254271.1	RP11-131N11.4	-3.82	0.000141	0.00842	-0.17	-0.12	Schizophrenia;	chr10:60344946	chr10:60734342~60741828:+
BRCA	cis	rs1009077	0.716	rs35850447	ENSG00000245958.5	RP11-33B1.1	3.82	0.000141	0.00842	0.17	0.12	Endometriosis;	chr4:119597610	chr4:119454791~119552025:+
BRCA	cis	rs1009077	0.716	rs62319647	ENSG00000245958.5	RP11-33B1.1	3.82	0.000141	0.00842	0.17	0.12	Endometriosis;	chr4:119597862	chr4:119454791~119552025:+
BRCA	cis	rs6064559	0.687	rs6070143	ENSG00000218018.2	RP4-800J21.3	3.82	0.000141	0.00842	0.1	0.12	Hemoglobin concentration;	chr20:57548163	chr20:57384160~57393062:-
BRCA	cis	rs801193	0.569	rs2707824	ENSG00000229886.1	RP5-1132H15.3	3.82	0.000141	0.00842	0.13	0.12	Aortic root size;	chr7:66724256	chr7:66025126~66031544:-
BRCA	cis	rs739401	0.611	rs3782069	ENSG00000183562.3	CTC-343N3.1	-3.82	0.000141	0.00842	-0.13	-0.12	Longevity;	chr11:3012045	chr11:2989863~2991344:+
BRCA	cis	rs957448	1	rs72674843	ENSG00000261437.1	RP11-22C11.2	3.82	0.000141	0.00842	0.12	0.12	Nonsyndromic cleft lip with cleft palate;	chr8:94520772	chr8:94637285~94639467:-
BRCA	cis	rs7267979	0.789	rs6083810	ENSG00000274414.1	RP5-965G21.4	3.82	0.000141	0.00842	0.14	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25349123	chr20:25239007~25245229:-
BRCA	cis	rs73222236	0.787	rs35681043	ENSG00000239213.4	NCK1-AS1	3.82	0.000141	0.00842	0.13	0.12	Coronary artery disease;	chr3:136261583	chr3:136841726~136862054:-
BRCA	cis	rs11098499	0.754	rs7672372	ENSG00000260091.1	RP11-33B1.4	-3.82	0.000141	0.00842	-0.1	-0.12	Corneal astigmatism;	chr4:119327251	chr4:119409333~119410233:+
BRCA	cis	rs2625529	0.824	rs2306488	ENSG00000260037.4	CTD-2524L6.3	-3.82	0.000141	0.00842	-0.17	-0.12	Red blood cell count;	chr15:71999774	chr15:71818396~71823384:+
BRCA	cis	rs4819052	1	rs4818769	ENSG00000184274.3	LINC00315	-3.82	0.000141	0.00842	-0.17	-0.12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45247536	chr21:45300245~45305257:-
BRCA	cis	rs55780018	0.614	rs9751478	ENSG00000224137.1	AC079767.4	3.82	0.000141	0.00843	0.1	0.12	Systolic blood pressure;	chr2:207644858	chr2:207662375~207667024:+
BRCA	cis	rs7314031	1	rs7314031	ENSG00000234608.6	MAPKAPK5-AS1	3.82	0.000141	0.00843	0.17	0.12	Reticulocyte count;Reticulocyte fraction of red cells;	chr12:112392775	chr12:111839764~111842902:-
BRCA	cis	rs17772222	1	rs17698817	ENSG00000258789.1	RP11-507K2.3	-3.82	0.000141	0.00843	-0.14	-0.12	Coronary artery calcification;	chr14:88356632	chr14:88551597~88552493:+
BRCA	cis	rs6545883	0.965	rs6718887	ENSG00000212978.6	AC016747.3	3.82	0.000141	0.00843	0.16	0.12	Tuberculosis;	chr2:61500080	chr2:61141592~61144969:-
BRCA	cis	rs4664293	0.609	rs357033	ENSG00000226266.5	AC009961.3	-3.82	0.000141	0.00843	-0.14	-0.12	Monocyte percentage of white cells;	chr2:159637962	chr2:159670708~159712435:-
BRCA	cis	rs4666002	0.917	rs4666000	ENSG00000234072.1	AC074117.10	3.82	0.000141	0.00843	0.12	0.12	Phospholipid levels (plasma);	chr2:27616502	chr2:27356246~27367622:+
BRCA	cis	rs6951245	0.58	rs78894484	ENSG00000224079.1	AC091729.7	-3.82	0.000141	0.00843	-0.18	-0.12	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1099085	chr7:1074450~1078036:+
BRCA	cis	rs875971	0.862	rs778720	ENSG00000273024.4	INTS4P2	3.82	0.000141	0.00844	0.13	0.12	Aortic root size;	chr7:66381288	chr7:65647864~65715661:+
BRCA	cis	rs7818688	1	rs7832570	ENSG00000245080.5	RP11-320N21.1	-3.82	0.000141	0.00844	-0.2	-0.12	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95011567	chr8:95066808~95073182:-
BRCA	cis	rs6452524	0.836	rs1478484	ENSG00000281327.1	LINC01338	3.82	0.000141	0.00844	0.14	0.12	Hypertension (SNP x SNP interaction);	chr5:83085055	chr5:82850864~82859836:-
BRCA	cis	rs6452524	0.935	rs7714710	ENSG00000281327.1	LINC01338	3.82	0.000141	0.00844	0.14	0.12	Hypertension (SNP x SNP interaction);	chr5:83085750	chr5:82850864~82859836:-
BRCA	cis	rs9863	0.828	rs7135314	ENSG00000270028.1	RP11-380L11.4	3.82	0.000141	0.00844	0.15	0.12	White blood cell count;	chr12:123994019	chr12:123925461~123926083:-
BRCA	cis	rs2018683	0.523	rs1499227	ENSG00000228421.2	AC005013.5	3.82	0.000141	0.00844	0.15	0.12	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28985999	chr7:28957667~28959345:+
BRCA	cis	rs9733	0.65	rs11204684	ENSG00000203804.4	ADAMTSL4-AS1	-3.82	0.000141	0.00844	-0.13	-0.12	Tonsillectomy;	chr1:150636418	chr1:150560202~150574552:-
BRCA	cis	rs6142618	0.583	rs2281364	ENSG00000275576.1	RP5-836N17.4	-3.82	0.000141	0.00844	-0.13	-0.12	Inflammatory bowel disease;	chr20:32164349	chr20:32116171~32116629:+
BRCA	cis	rs6142618	0.562	rs6061203	ENSG00000275576.1	RP5-836N17.4	-3.82	0.000141	0.00844	-0.13	-0.12	Inflammatory bowel disease;	chr20:32165167	chr20:32116171~32116629:+
BRCA	cis	rs6142618	0.562	rs2377416	ENSG00000275576.1	RP5-836N17.4	-3.82	0.000141	0.00844	-0.13	-0.12	Inflammatory bowel disease;	chr20:32169571	chr20:32116171~32116629:+
BRCA	cis	rs7131987	0.874	rs10843366	ENSG00000273680.1	RP11-996F15.6	3.82	0.000141	0.00844	0.15	0.12	QT interval;	chr12:29254970	chr12:29332733~29333383:-
BRCA	cis	rs7131987	0.845	rs2042511	ENSG00000273680.1	RP11-996F15.6	3.82	0.000141	0.00844	0.15	0.12	QT interval;	chr12:29255847	chr12:29332733~29333383:-
BRCA	cis	rs6049003	0.668	rs4328700	ENSG00000232645.4	LINC01431	3.82	0.000141	0.00844	0.13	0.12	Cerebrospinal fluid biomarker levels;	chr20:23728908	chr20:23356594~23358116:-
BRCA	cis	rs12612619	0.732	rs11688708	ENSG00000272148.1	RP11-195B17.1	3.82	0.000141	0.00844	0.13	0.12	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:26976740	chr2:27062428~27062907:-
BRCA	cis	rs1912124	1	rs950071	ENSG00000271983.1	RP11-28H5.2	3.82	0.000141	0.00844	0.24	0.12	Peripheral arterial disease (traffic-related air pollution interaction);	chr15:81226479	chr15:80693216~80693707:-
BRCA	cis	rs67696533	0.6	rs3746614	ENSG00000277692.1	RP11-358N2.2	-3.82	0.000141	0.00844	-0.14	-0.12	White blood cell count (basophil);Basophil percentage of granulocytes;Basophil percentage of white cells;	chr20:32520674	chr20:32355053~32355734:+
BRCA	cis	rs6142618	0.562	rs6058541	ENSG00000224452.1	RSL24D1P6	3.82	0.000141	0.00844	0.16	0.12	Inflammatory bowel disease;	chr20:32170845	chr20:32170390~32170790:-
BRCA	cis	rs7160336	0.967	rs11624656	ENSG00000259065.1	RP5-1021I20.1	-3.82	0.000141	0.00844	-0.13	-0.12	Blood protein levels;	chr14:74182659	chr14:73787360~73803270:+
BRCA	cis	rs5758659	0.652	rs133326	ENSG00000182057.4	OGFRP1	3.82	0.000141	0.00844	0.13	0.12	Cognitive function;	chr22:42010881	chr22:42269753~42275196:+
BRCA	cis	rs875971	0.862	rs11773628	ENSG00000271064.1	RP11-792A8.3	3.82	0.000141	0.00844	0.14	0.12	Aortic root size;	chr7:66517644	chr7:66748838~66749077:-
BRCA	cis	rs3892630	0.878	rs7246451	ENSG00000267475.1	CTD-2538C1.2	-3.82	0.000141	0.00844	-0.18	-0.12	Red blood cell traits;	chr19:32718708	chr19:32687089~32691750:-
BRCA	cis	rs12705849	0.797	rs13229301	ENSG00000214194.7	LINC00998	3.82	0.000141	0.00844	0.15	0.12	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Eosinophil counts;	chr7:113105959	chr7:113116718~113118613:-
BRCA	cis	rs867186	1	rs867186	ENSG00000126005.14	MMP24-AS1	3.82	0.000141	0.00844	0.22	0.12	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35176751	chr20:35216462~35278131:-
BRCA	cis	rs2731006	0.64	rs2731002	ENSG00000257114.2	RP11-25I15.3	-3.82	0.000141	0.00844	-0.19	-0.12	Panic disorder;	chr12:42790472	chr12:42692216~42717119:+
BRCA	cis	rs7822232	1	rs7822232	ENSG00000255224.1	CTD-3065J16.9	-3.82	0.000141	0.00844	-0.14	-0.12	Blood metabolite levels;	chr8:144090784	chr8:144078002~144079265:-
BRCA	cis	rs10911902	0.58	rs16825773	ENSG00000229739.2	RP11-295K2.3	-3.82	0.000141	0.00844	-0.19	-0.12	Schizophrenia;	chr1:186699999	chr1:186435161~186470291:+
BRCA	cis	rs4713118	0.662	rs149969	ENSG00000216901.1	AL022393.7	3.82	0.000141	0.00844	0.16	0.12	Parkinson's disease;	chr6:28009959	chr6:28176188~28176674:+
BRCA	cis	rs9392556	0.829	rs643232	ENSG00000230648.1	RP3-406P24.3	3.82	0.000141	0.00845	0.15	0.12	Blood metabolite levels;	chr6:4122015	chr6:4018843~4021215:-
BRCA	cis	rs4218	0.648	rs10851642	ENSG00000259732.1	RP11-59H7.3	-3.82	0.000141	0.00845	-0.15	-0.12	Social communication problems;	chr15:59077909	chr15:59121034~59133250:+
BRCA	cis	rs2998286	0.822	rs2807737	ENSG00000237128.1	RP11-351M16.3	3.82	0.000141	0.00845	0.14	0.12	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28501052	chr10:28433008~28495813:-
BRCA	cis	rs6993270	0.779	rs7000890	ENSG00000245330.4	KB-1471A8.1	-3.82	0.000141	0.00845	-0.18	-0.12	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr8:119911053	chr8:119867419~119874488:-
BRCA	cis	rs6993270	0.725	rs76539987	ENSG00000245330.4	KB-1471A8.1	-3.82	0.000141	0.00845	-0.18	-0.12	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr8:119911058	chr8:119867419~119874488:-
BRCA	cis	rs863345	0.604	rs1157525	ENSG00000229914.1	RP11-404O13.4	-3.82	0.000141	0.00845	-0.13	-0.12	Pneumococcal bacteremia;	chr1:158487463	chr1:158195633~158196131:-
BRCA	cis	rs6012564	0.783	rs6125575	ENSG00000222365.1	SNORD12B	3.82	0.000141	0.00845	0.12	0.12	Anger;	chr20:49159159	chr20:49280319~49280409:+
BRCA	cis	rs875971	0.545	rs75840613	ENSG00000232559.3	GS1-124K5.12	3.82	0.000141	0.00845	0.16	0.12	Aortic root size;	chr7:66376399	chr7:66554588~66576923:-
BRCA	cis	rs6439699	0.825	rs66527272	ENSG00000239213.4	NCK1-AS1	3.82	0.000141	0.00845	0.17	0.12	Intelligence (multi-trait analysis);	chr3:137352185	chr3:136841726~136862054:-
BRCA	cis	rs11668609	1	rs3844579	ENSG00000268058.1	BNIP3P40	-3.82	0.000141	0.00845	-0.15	-0.12	Response to taxane treatment (docetaxel);	chr19:24120337	chr19:24098425~24098980:-
BRCA	cis	rs170557	0.573	rs6540578	ENSG00000203706.7	SERTAD4-AS1	-3.82	0.000141	0.00845	-0.15	-0.12	Alopecia areata;	chr1:210063125	chr1:210231456~210234047:-
BRCA	cis	rs7176093	0.874	rs7172952	ENSG00000259295.5	CSPG4P12	-3.82	0.000141	0.00845	-0.15	-0.12	Aging traits;	chr15:85804143	chr15:85191438~85213905:+
BRCA	cis	rs9470794	0.915	rs57630694	ENSG00000204110.6	RP1-153P14.8	-3.82	0.000141	0.00845	-0.21	-0.12	Type 2 diabetes;	chr6:38044905	chr6:37507348~37535616:+
BRCA	cis	rs73193808	0.627	rs2832233	ENSG00000236056.1	GAPDHP14	3.82	0.000141	0.00845	0.2	0.12	Coronary artery disease;	chr21:29173679	chr21:29222321~29223257:+
BRCA	cis	rs7824557	0.751	rs2099456	ENSG00000154316.13	TDH	-3.82	0.000141	0.00846	-0.15	-0.12	Retinal vascular caliber;	chr8:11269492	chr8:11339637~11368452:+
BRCA	cis	rs875971	0.862	rs6959268	ENSG00000271064.1	RP11-792A8.3	3.82	0.000141	0.00846	0.14	0.12	Aortic root size;	chr7:66347979	chr7:66748838~66749077:-
BRCA	cis	rs7020830	1	rs7020830	ENSG00000230188.1	RP11-405L18.4	-3.82	0.000141	0.00846	-0.14	-0.12	Schizophrenia;	chr9:37085187	chr9:37490421~37490893:-
BRCA	cis	rs7911264	0.967	rs2497318	ENSG00000232709.1	MARK2P9	3.82	0.000141	0.00846	0.15	0.12	Inflammatory bowel disease;	chr10:92672243	chr10:92418667~92420875:+
BRCA	cis	rs4916588	0.697	rs11550120	ENSG00000230732.4	AC127904.2	3.82	0.000141	0.00846	0.15	0.12	Night sleep phenotypes;	chr3:196936251	chr3:196912646~196914579:+
BRCA	cis	rs7577696	0.924	rs3769604	ENSG00000276334.1	AL133243.1	-3.82	0.000141	0.00846	-0.14	-0.12	Inflammatory biomarkers;	chr2:32097426	chr2:32521927~32523547:+
BRCA	cis	rs375066	0.935	rs388706	ENSG00000267191.1	RP11-15A1.2	-3.82	0.000141	0.00846	-0.15	-0.12	Breast cancer;	chr19:43914541	chr19:43902001~43926545:+
BRCA	cis	rs3768617	1	rs3820697	ENSG00000224468.3	RP11-181K3.4	-3.82	0.000141	0.00846	-0.13	-0.12	Fuchs's corneal dystrophy;	chr1:183131091	chr1:183138402~183141282:-
BRCA	cis	rs1437396	0.632	rs57410428	ENSG00000203327.2	AC012358.7	-3.82	0.000141	0.00846	-0.12	-0.12	Alcohol dependence;	chr2:55384339	chr2:55214387~55216126:-
BRCA	cis	rs6088590	0.502	rs6059861	ENSG00000275784.1	RP5-1125A11.6	-3.82	0.000141	0.00846	-0.13	-0.12	Coronary artery disease;	chr20:34480758	chr20:33989480~33991818:-
BRCA	cis	rs7267979	0.727	rs4815431	ENSG00000274414.1	RP5-965G21.4	3.82	0.000141	0.00846	0.13	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25551769	chr20:25239007~25245229:-
BRCA	cis	rs950169	0.58	rs11634320	ENSG00000230373.7	GOLGA6L5P	3.82	0.000141	0.00846	0.14	0.12	Schizophrenia;	chr15:84628952	chr15:84507885~84516814:-
BRCA	cis	rs7267979	1	rs4815418	ENSG00000276952.1	RP5-965G21.6	-3.82	0.000141	0.00846	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25401575	chr20:25284915~25285588:-
BRCA	cis	rs2991971	1	rs2991971	ENSG00000280836.1	AL355480.1	3.82	0.000141	0.00846	0.14	0.12	High light scatter reticulocyte count;	chr1:45547076	chr1:45581219~45581321:-
BRCA	cis	rs2749097	0.544	rs11208272	ENSG00000244256.3	RN7SL130P	-3.82	0.000142	0.00846	-0.15	-0.12	Alcohol consumption (transferrin glycosylation);	chr1:63696419	chr1:63655743~63656047:+
BRCA	cis	rs61931739	0.5	rs7979240	ENSG00000258794.3	DUX4L27	3.82	0.000142	0.00847	0.17	0.12	Morning vs. evening chronotype;	chr12:34356091	chr12:34208415~34209675:-
BRCA	cis	rs12474201	0.619	rs17821827	ENSG00000279254.1	RP11-536C12.1	-3.82	0.000142	0.00847	-0.16	-0.12	Height;	chr2:46691543	chr2:46668870~46670778:+
BRCA	cis	rs7395581	0.918	rs1449627	ENSG00000280615.1	Y_RNA	3.82	0.000142	0.00847	0.14	0.12	HDL cholesterol;	chr11:47269433	chr11:47614898~47614994:-
BRCA	cis	rs7395581	0.918	rs1055510	ENSG00000280615.1	Y_RNA	3.82	0.000142	0.00847	0.14	0.12	HDL cholesterol;	chr11:47270686	chr11:47614898~47614994:-
BRCA	cis	rs2073316	0.592	rs17604831	ENSG00000272716.1	RP11-563N4.1	3.82	0.000142	0.00847	0.13	0.12	Interleukin-18 levels;	chr2:31441436	chr2:32165046~32165757:-
BRCA	cis	rs875971	0.54	rs35510581	ENSG00000229180.5	GS1-124K5.11	-3.82	0.000142	0.00847	-0.1	-0.12	Aortic root size;	chr7:66113790	chr7:66526088~66542624:-
BRCA	cis	rs2160387	1	rs2160387	ENSG00000252892.1	RNU6-548P	-3.82	0.000142	0.00847	-0.15	-0.12	Metabolite levels;	chr2:64993776	chr2:64994746~64994860:+
BRCA	cis	rs17507216	0.718	rs4779034	ENSG00000259429.4	UBE2Q2P2	-3.82	0.000142	0.00847	-0.14	-0.12	Excessive daytime sleepiness;	chr15:82576799	chr15:82355142~82420075:+
BRCA	cis	rs938554	0.577	rs4591605	ENSG00000250413.1	RP11-448G15.1	-3.82	0.000142	0.00847	-0.18	-0.12	Blood metabolite levels;	chr4:10001095	chr4:10006482~10009725:+
BRCA	cis	rs478607	0.831	rs3825074	ENSG00000237410.1	AP001092.4	3.82	0.000142	0.00847	0.21	0.12	Urate levels;	chr11:64648295	chr11:64646399~64659681:+
BRCA	cis	rs478607	0.831	rs59739006	ENSG00000237410.1	AP001092.4	3.82	0.000142	0.00847	0.21	0.12	Urate levels;	chr11:64648431	chr11:64646399~64659681:+
BRCA	cis	rs1005277	0.502	rs2800484	ENSG00000272983.1	RP11-508N22.12	3.82	0.000142	0.00847	0.12	0.12	Extrinsic epigenetic age acceleration;	chr10:38253487	chr10:38137337~38144399:+
BRCA	cis	rs7246967	0.736	rs428299	ENSG00000198153.8	ZNF849P	-3.82	0.000142	0.00847	-0.18	-0.12	Bronchopulmonary dysplasia;	chr19:22813450	chr19:22685167~22686732:+
BRCA	cis	rs7246657	0.653	rs28701616	ENSG00000267470.4	ZNF571-AS1	3.82	0.000142	0.00847	0.18	0.12	Coronary artery calcification;	chr19:37190196	chr19:37548914~37587348:+
BRCA	cis	rs9470794	0.748	rs73419938	ENSG00000204110.6	RP1-153P14.8	-3.82	0.000142	0.00847	-0.24	-0.12	Type 2 diabetes;	chr6:38065757	chr6:37507348~37535616:+
BRCA	cis	rs9470794	0.915	rs73419941	ENSG00000204110.6	RP1-153P14.8	-3.82	0.000142	0.00847	-0.24	-0.12	Type 2 diabetes;	chr6:38065771	chr6:37507348~37535616:+
BRCA	cis	rs9470794	0.831	rs73419944	ENSG00000204110.6	RP1-153P14.8	-3.82	0.000142	0.00847	-0.24	-0.12	Type 2 diabetes;	chr6:38066051	chr6:37507348~37535616:+
BRCA	cis	rs9470794	1	rs73419945	ENSG00000204110.6	RP1-153P14.8	-3.82	0.000142	0.00847	-0.24	-0.12	Type 2 diabetes;	chr6:38069533	chr6:37507348~37535616:+
BRCA	cis	rs9470794	1	rs75484621	ENSG00000204110.6	RP1-153P14.8	-3.82	0.000142	0.00847	-0.24	-0.12	Type 2 diabetes;	chr6:38069593	chr6:37507348~37535616:+
BRCA	cis	rs524281	0.861	rs10750778	ENSG00000255557.1	RP11-770G2.2	3.82	0.000142	0.00847	0.16	0.12	Electroencephalogram traits;	chr11:66181177	chr11:65745729~65771585:+
BRCA	cis	rs524281	0.861	rs6591208	ENSG00000255557.1	RP11-770G2.2	3.82	0.000142	0.00847	0.16	0.12	Electroencephalogram traits;	chr11:66182218	chr11:65745729~65771585:+
BRCA	cis	rs743757	0.652	rs399484	ENSG00000230454.1	U73166.2	3.82	0.000142	0.00847	0.12	0.12	Diastolic blood pressure;	chr3:50552024	chr3:50260303~50263358:+
BRCA	cis	rs2411233	0.967	rs11632632	ENSG00000259278.1	RP11-62C7.2	3.82	0.000142	0.00847	0.14	0.12	Platelet count;	chr15:38991566	chr15:39019233~39024918:+
BRCA	cis	rs115575488	0.85	rs17023135	ENSG00000231365.4	RP11-418J17.1	3.82	0.000142	0.00847	0.21	0.12	Lobe attachment (rater-scored or self-reported);	chr1:119038528	chr1:119140396~119275973:+
BRCA	cis	rs6439699	0.941	rs7648568	ENSG00000273486.1	RP11-731C17.2	3.82	0.000142	0.00847	0.16	0.12	Intelligence (multi-trait analysis);	chr3:137341847	chr3:136837338~136839021:-
BRCA	cis	rs9844666	0.512	rs9870581	ENSG00000239213.4	NCK1-AS1	3.82	0.000142	0.00848	0.14	0.12	Height;	chr3:135922012	chr3:136841726~136862054:-
BRCA	cis	rs4415084	1	rs7720551	ENSG00000272335.1	RP11-53O19.3	3.82	0.000142	0.00848	0.11	0.12	Breast cancer;	chr5:44664375	chr5:44826076~44828592:+
BRCA	cis	rs7954584	0.616	rs10743186	ENSG00000272849.1	RP11-347I19.8	-3.82	0.000142	0.00848	-0.09	-0.12	Mean corpuscular volume;	chr12:121918530	chr12:121797511~121801972:+
BRCA	cis	rs1910358	1	rs1910358	ENSG00000248874.4	C5orf17	-3.82	0.000142	0.00848	-0.17	-0.12	Venous thromboembolism (SNP x SNP interaction);	chr5:23907464	chr5:23951348~24178263:+
BRCA	cis	rs2688608	0.592	rs7909544	ENSG00000213731.2	RAB5CP1	-3.82	0.000142	0.00848	-0.13	-0.12	Inflammatory bowel disease;	chr10:73724246	chr10:74423435~74424014:-
BRCA	cis	rs2518049	0.904	rs4881395	ENSG00000224034.1	RP11-445P17.8	3.82	0.000142	0.00848	0.22	0.12	Metabolic traits;	chr10:5077790	chr10:5266033~5271236:-
BRCA	cis	rs9959145	1	rs76195993	ENSG00000267108.1	RP11-861E21.1	3.82	0.000142	0.00848	0.21	0.12	Immune response to smallpox vaccine (IL-6);	chr18:12651888	chr18:12432897~12437635:+
BRCA	cis	rs9959145	1	rs74732619	ENSG00000267108.1	RP11-861E21.1	3.82	0.000142	0.00848	0.21	0.12	Immune response to smallpox vaccine (IL-6);	chr18:12652017	chr18:12432897~12437635:+
BRCA	cis	rs6736093	0.764	rs10176769	ENSG00000236307.2	EEF1E1P1	-3.82	0.000142	0.00848	-0.14	-0.12	Coronary artery disease;	chr2:112055586	chr2:111887914~111888741:+
BRCA	cis	rs642803	1	rs642803	ENSG00000255557.1	RP11-770G2.2	-3.82	0.000142	0.00848	-0.14	-0.12	Urate levels;	chr11:65793149	chr11:65745729~65771585:+
BRCA	cis	rs1153858	1	rs3809472	ENSG00000275672.1	GATM-AS1	-3.82	0.000142	0.00848	-0.15	-0.12	Homoarginine levels;	chr15:45402120	chr15:45378700~45380123:+
BRCA	cis	rs1153858	1	rs1820518	ENSG00000275672.1	GATM-AS1	-3.82	0.000142	0.00848	-0.15	-0.12	Homoarginine levels;	chr15:45402381	chr15:45378700~45380123:+
BRCA	cis	rs7312933	0.607	rs7965392	ENSG00000257225.1	RP11-328C8.4	-3.82	0.000142	0.00848	-0.15	-0.12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42146478	chr12:42459366~42466128:+
BRCA	cis	rs1577330	0.571	rs596427	ENSG00000254396.1	RP11-56F10.3	-3.82	0.000142	0.00848	-0.2	-0.12	IgG glycosylation;	chr9:27099246	chr9:27102630~27104728:+
BRCA	cis	rs513088	0.681	rs556498	ENSG00000225171.2	DUTP6	3.82	0.000142	0.00848	0.17	0.12	Schizophrenia;	chr1:166719963	chr1:166868748~166869209:+
BRCA	cis	rs875971	0.66	rs79009421	ENSG00000272831.1	RP11-792A8.4	-3.82	0.000142	0.00849	-0.11	-0.12	Aortic root size;	chr7:66603522	chr7:66739829~66740385:-
BRCA	cis	rs4263408	0.967	rs4974948	ENSG00000224097.5	RP11-472B18.1	3.82	0.000142	0.00849	0.14	0.12	Plasma amyloid beta peptide concentrations (ABx-40);	chr4:39751016	chr4:39480255~39481905:+
BRCA	cis	rs6840360	0.571	rs4696275	ENSG00000270265.1	RP11-731D1.4	-3.82	0.000142	0.00849	-0.14	-0.12	Intelligence (multi-trait analysis);	chr4:151609829	chr4:151333775~151353224:-
BRCA	cis	rs516805	0.667	rs9632500	ENSG00000279114.1	RP3-425C14.5	3.82	0.000142	0.00849	0.15	0.12	Lymphocyte counts;	chr6:122251472	chr6:122471923~122484161:+
BRCA	cis	rs10129255	0.957	rs1024349	ENSG00000211967.3	IGHV3-53	-3.82	0.000142	0.00849	-0.09	-0.12	Kawasaki disease;	chr14:106689997	chr14:106592676~106593347:-
BRCA	cis	rs467650	0.509	rs2545678	ENSG00000248489.1	CTD-2007H13.3	-3.82	0.000142	0.00849	-0.13	-0.12	Venous thromboembolism (SNP x SNP interaction);	chr5:98664664	chr5:98929171~98995013:+
BRCA	cis	rs9420	0.528	rs11229080	ENSG00000265566.2	RN7SL605P	-3.82	0.000142	0.00849	-0.16	-0.12	Schizophrenia;	chr11:57632038	chr11:57528085~57528365:-
BRCA	cis	rs17092148	0.945	rs6142237	ENSG00000202150.1	RNU6-407P	3.82	0.000142	0.00849	0.17	0.12	Neuroticism;	chr20:34753190	chr20:35030317~35030420:-
BRCA	cis	rs4819052	0.851	rs2838845	ENSG00000215447.6	BX322557.10	-3.82	0.000142	0.00849	-0.12	-0.12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250897	chr21:45288052~45291738:+
BRCA	cis	rs8180040	1	rs4858888	ENSG00000271161.1	BOLA2P2	-3.82	0.000142	0.00849	-0.13	-0.12	Colorectal cancer;	chr3:47363815	chr3:47499841~47500407:+
BRCA	cis	rs6496044	0.547	rs1564719	ENSG00000259630.2	CTD-2262B20.1	-3.82	0.000142	0.00849	-0.14	-0.12	Interstitial lung disease;	chr15:85511035	chr15:85415228~85415633:+
BRCA	cis	rs12680842	0.842	rs34691145	ENSG00000254315.1	RP11-267M23.3	3.82	0.000142	0.00849	0.14	0.12	Body mass index;	chr8:94597715	chr8:94533628~94534391:+
BRCA	cis	rs7267979	0.789	rs62213729	ENSG00000125804.12	FAM182A	3.82	0.000142	0.00849	0.16	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25382790	chr20:26054655~26086917:+
BRCA	cis	rs4950322	0.543	rs4453096	ENSG00000227242.3	NBPF13P	-3.82	0.000142	0.00849	-0.17	-0.12	Protein quantitative trait loci;	chr1:147316574	chr1:147021320~147124525:-
BRCA	cis	rs4660456	0.529	rs61779237	ENSG00000272145.1	NFYC-AS1	-3.82	0.000142	0.00849	-0.11	-0.12	Platelet count;	chr1:40685300	chr1:40690380~40692066:-
BRCA	cis	rs10129255	1	rs8012033	ENSG00000231475.3	IGHV4-31	-3.82	0.000142	0.00849	-0.1	-0.12	Kawasaki disease;	chr14:106678854	chr14:106349283~106349792:-
BRCA	cis	rs11098499	1	rs11098499	ENSG00000260404.2	RP11-384K6.6	3.82	0.000142	0.00849	0.11	0.12	Corneal astigmatism;	chr4:119266456	chr4:118591773~118633729:+
BRCA	cis	rs7786877	0.5	rs2272572	ENSG00000208036.1	MIR106B	3.82	0.000142	0.0085	0.17	0.12	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr7:100688265	chr7:100093993~100094074:-
BRCA	cis	rs9733	0.596	rs3087960	ENSG00000231073.1	RP11-316M1.3	3.82	0.000142	0.0085	0.12	0.12	Tonsillectomy;	chr1:150648093	chr1:150973123~150975534:+
BRCA	cis	rs8180040	0.726	rs61729713	ENSG00000276925.1	RP11-708J19.3	3.82	0.000142	0.0085	0.13	0.12	Colorectal cancer;	chr3:46985702	chr3:47469777~47469987:+
BRCA	cis	rs983392	0.792	rs574695	ENSG00000275344.1	MIR6503	-3.82	0.000142	0.0085	-0.12	-0.12	Alzheimer's disease (late onset);	chr11:60114051	chr11:60209071~60209156:-
BRCA	cis	rs4950322	0.542	rs72692942	ENSG00000237188.3	RP11-337C18.8	3.82	0.000142	0.0085	0.15	0.12	Protein quantitative trait loci;	chr1:147318467	chr1:147172771~147211568:+
BRCA	cis	rs4950322	0.57	rs4950399	ENSG00000237188.3	RP11-337C18.8	3.82	0.000142	0.0085	0.15	0.12	Protein quantitative trait loci;	chr1:147319302	chr1:147172771~147211568:+
BRCA	cis	rs236114	0.948	rs236123	ENSG00000275632.1	RP5-967N21.11	3.82	0.000142	0.0085	0.16	0.12	Menopause (age at onset);	chr20:5993147	chr20:6000418~6000941:+
BRCA	cis	rs3816183	0.805	rs2304657	ENSG00000226491.1	FTOP1	-3.82	0.000142	0.0085	-0.15	-0.12	Hypospadias;	chr2:42792787	chr2:42797225~42798712:-
BRCA	cis	rs6736093	0.862	rs11684321	ENSG00000236307.2	EEF1E1P1	-3.82	0.000142	0.0085	-0.15	-0.12	Coronary artery disease;	chr2:112018173	chr2:111887914~111888741:+
BRCA	cis	rs35740288	0.822	rs4843090	ENSG00000259407.1	RP11-158M2.3	-3.82	0.000142	0.0085	-0.16	-0.12	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85677398	chr15:85744109~85750281:-
BRCA	cis	rs375066	0.901	rs12977303	ENSG00000267191.1	RP11-15A1.2	-3.82	0.000142	0.0085	-0.15	-0.12	Breast cancer;	chr19:43873517	chr19:43902001~43926545:+
BRCA	cis	rs1555322	1	rs2425037	ENSG00000269202.1	RP4-614O4.12	3.82	0.000142	0.0085	0.17	0.12	Attention deficit hyperactivity disorder;	chr20:35268626	chr20:35201747~35203288:-
BRCA	cis	rs17685	0.884	rs8565	ENSG00000205485.12	AC004980.7	3.82	0.000142	0.0085	0.13	0.12	Coffee consumption (cups per day);Coffee consumption;	chr7:76000956	chr7:76549360~76627982:+
BRCA	cis	rs1553477	0.665	rs4865793	ENSG00000272416.1	CTD-2081C10.7	3.82	0.000142	0.00851	0.12	0.12	Monobrow;	chr5:53858609	chr5:53880293~53881051:-
BRCA	cis	rs8040855	0.627	rs72757059	ENSG00000229212.6	RP11-561C5.4	-3.82	0.000142	0.00851	-0.16	-0.12	Bulimia nervosa;	chr15:85059918	chr15:85205440~85234795:-
BRCA	cis	rs12468226	1	rs57080353	ENSG00000272966.1	RP11-686O6.1	3.82	0.000142	0.00851	0.2	0.12	Urate levels;	chr2:202511824	chr2:202336739~202337200:+
BRCA	cis	rs12468226	0.81	rs3736578	ENSG00000272966.1	RP11-686O6.1	3.82	0.000142	0.00851	0.2	0.12	Urate levels;	chr2:202519989	chr2:202336739~202337200:+
BRCA	cis	rs12468226	1	rs116439150	ENSG00000272966.1	RP11-686O6.1	3.82	0.000142	0.00851	0.2	0.12	Urate levels;	chr2:202523814	chr2:202336739~202337200:+
BRCA	cis	rs12468226	1	rs12467409	ENSG00000272966.1	RP11-686O6.1	3.82	0.000142	0.00851	0.2	0.12	Urate levels;	chr2:202529625	chr2:202336739~202337200:+
BRCA	cis	rs425277	1	rs381664	ENSG00000269227.1	RP11-345P4.6	3.82	0.000142	0.00851	0.12	0.12	Height;	chr1:2156665	chr1:1673275~1674397:+
BRCA	cis	rs2164068	0.507	rs11687698	ENSG00000231621.1	AC013264.2	-3.82	0.000142	0.00851	-0.12	-0.12	Allergy;	chr2:197703352	chr2:197197991~197199273:+
BRCA	cis	rs11098499	0.863	rs2291185	ENSG00000260404.2	RP11-384K6.6	3.82	0.000142	0.00851	0.11	0.12	Corneal astigmatism;	chr4:119513678	chr4:118591773~118633729:+
BRCA	cis	rs7111546	1	rs76008952	ENSG00000246225.5	RP11-17A1.3	3.82	0.000142	0.00851	0.2	0.12	Dialysis-related mortality;	chr11:22807890	chr11:22829380~22945393:+
BRCA	cis	rs962856	0.897	rs7579304	ENSG00000236605.1	AC023115.4	3.82	0.000142	0.00851	0.14	0.12	Pancreatic cancer;	chr2:67384118	chr2:67324627~67325304:+
BRCA	cis	rs875971	0.66	rs6460308	ENSG00000272831.1	RP11-792A8.4	-3.82	0.000143	0.00852	-0.11	-0.12	Aortic root size;	chr7:66619753	chr7:66739829~66740385:-
BRCA	cis	rs7395581	1	rs830085	ENSG00000280615.1	Y_RNA	-3.82	0.000143	0.00852	-0.14	-0.12	HDL cholesterol;	chr11:47229648	chr11:47614898~47614994:-
BRCA	cis	rs4699052	0.507	rs7662107	ENSG00000248740.4	RP11-328K4.1	3.82	0.000143	0.00852	0.15	0.12	Testicular germ cell tumor;	chr4:103337239	chr4:103256159~103453658:+
BRCA	cis	rs10043775	0.793	rs7734458	ENSG00000251330.3	CTD-2283N19.1	-3.82	0.000143	0.00852	-0.14	-0.12	Periodontal microbiota;	chr5:148306389	chr5:148430159~148430807:-
BRCA	cis	rs10043775	0.793	rs17719578	ENSG00000251330.3	CTD-2283N19.1	-3.82	0.000143	0.00852	-0.14	-0.12	Periodontal microbiota;	chr5:148307188	chr5:148430159~148430807:-
BRCA	cis	rs10043775	0.831	rs10068891	ENSG00000251330.3	CTD-2283N19.1	-3.82	0.000143	0.00852	-0.14	-0.12	Periodontal microbiota;	chr5:148308472	chr5:148430159~148430807:-
BRCA	cis	rs1008375	0.932	rs11934968	ENSG00000249502.1	AC006160.5	-3.82	0.000143	0.00852	-0.14	-0.12	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17666143	chr4:17587467~17614571:-
BRCA	cis	rs2108622	0.727	rs12610967	ENSG00000214049.6	UCA1	3.82	0.000143	0.00852	0.17	0.12	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15867119	chr19:15828961~15836320:+
BRCA	cis	rs2108622	0.711	rs12609820	ENSG00000214049.6	UCA1	3.82	0.000143	0.00852	0.17	0.12	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15867247	chr19:15828961~15836320:+
BRCA	cis	rs2108622	0.668	rs62106153	ENSG00000214049.6	UCA1	3.82	0.000143	0.00852	0.17	0.12	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15867697	chr19:15828961~15836320:+
BRCA	cis	rs2108622	0.727	rs12611242	ENSG00000214049.6	UCA1	3.82	0.000143	0.00852	0.17	0.12	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15867754	chr19:15828961~15836320:+
BRCA	cis	rs2108622	0.727	rs12611308	ENSG00000214049.6	UCA1	3.82	0.000143	0.00852	0.17	0.12	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15867776	chr19:15828961~15836320:+
BRCA	cis	rs2108622	0.727	rs12610189	ENSG00000214049.6	UCA1	3.82	0.000143	0.00852	0.17	0.12	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15867831	chr19:15828961~15836320:+
BRCA	cis	rs11673344	0.566	rs1968251	ENSG00000267422.1	CTD-2554C21.1	-3.82	0.000143	0.00852	-0.15	-0.12	Obesity-related traits;	chr19:37457005	chr19:37779686~37792865:+
BRCA	cis	rs5758511	0.689	rs55906806	ENSG00000226450.2	CYP2D8P	3.82	0.000143	0.00852	0.16	0.12	Birth weight;	chr22:42248465	chr22:42149886~42155001:-
BRCA	cis	rs62103177	0.525	rs4799117	ENSG00000267270.4	PARD6G-AS1	-3.82	0.000143	0.00852	-0.18	-0.12	Opioid sensitivity;	chr18:79996604	chr18:80147924~80178432:+
BRCA	cis	rs62103177	0.525	rs4283293	ENSG00000267270.4	PARD6G-AS1	-3.82	0.000143	0.00852	-0.18	-0.12	Opioid sensitivity;	chr18:79999582	chr18:80147924~80178432:+
BRCA	cis	rs7267979	0.932	rs2260997	ENSG00000125804.12	FAM182A	3.82	0.000143	0.00852	0.15	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25275630	chr20:26054655~26086917:+
BRCA	cis	rs2803122	0.838	rs7046816	ENSG00000272842.1	RP11-513M16.7	-3.82	0.000143	0.00852	-0.12	-0.12	Pulse pressure;	chr9:19220506	chr9:19371386~19371945:-
BRCA	cis	rs794185	0.504	rs184233	ENSG00000231249.1	ITPR1-AS1	-3.82	0.000143	0.00852	-0.14	-0.12	Multiple sclerosis--Brain Glutamate Levels;	chr3:4495754	chr3:4490891~4493163:-
BRCA	cis	rs2243480	1	rs431076	ENSG00000237026.1	RP11-328P23.2	3.82	0.000143	0.00852	0.22	0.12	Diabetic kidney disease;	chr7:66135333	chr7:65235790~65236723:-
BRCA	cis	rs2243480	1	rs2460422	ENSG00000237026.1	RP11-328P23.2	3.82	0.000143	0.00852	0.22	0.12	Diabetic kidney disease;	chr7:66136518	chr7:65235790~65236723:-
BRCA	cis	rs2243480	1	rs316334	ENSG00000237026.1	RP11-328P23.2	3.82	0.000143	0.00852	0.22	0.12	Diabetic kidney disease;	chr7:66137139	chr7:65235790~65236723:-
BRCA	cis	rs2880765	0.835	rs12324277	ENSG00000230373.7	GOLGA6L5P	3.82	0.000143	0.00852	0.13	0.12	Coronary artery disease;	chr15:85498504	chr15:84507885~84516814:-
BRCA	cis	rs78487399	0.71	rs75514072	ENSG00000234936.1	AC010883.5	3.82	0.000143	0.00852	0.18	0.12	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43523085	chr2:43229573~43233394:+
BRCA	cis	rs11098499	0.954	rs67265404	ENSG00000260404.2	RP11-384K6.6	3.82	0.000143	0.00852	0.11	0.12	Corneal astigmatism;	chr4:119438115	chr4:118591773~118633729:+
BRCA	cis	rs829883	1	rs2908843	ENSG00000227825.4	SLC9A7P1	-3.82	0.000143	0.00852	-0.15	-0.12	Colorectal adenoma (advanced);	chr12:98495554	chr12:98453835~98457145:-
BRCA	cis	rs11673344	0.504	rs4254428	ENSG00000276846.1	CTD-3220F14.3	3.82	0.000143	0.00853	0.14	0.12	Obesity-related traits;	chr19:37093748	chr19:37314868~37315620:-
BRCA	cis	rs4415084	0.834	rs7711697	ENSG00000248779.1	RP11-53O19.2	3.82	0.000143	0.00853	0.11	0.12	Breast cancer;	chr5:44780301	chr5:44752949~44765744:+
BRCA	cis	rs7395581	0.918	rs3847502	ENSG00000280615.1	Y_RNA	3.82	0.000143	0.00853	0.14	0.12	HDL cholesterol;	chr11:47312134	chr11:47614898~47614994:-
BRCA	cis	rs6460942	0.687	rs74753576	ENSG00000226690.5	AC005281.1	3.82	0.000143	0.00853	0.2	0.12	Coronary artery disease;	chr7:12424300	chr7:12496429~12541910:+
BRCA	cis	rs2391285	0.609	rs6959388	ENSG00000214870.7	AC004540.5	3.82	0.000143	0.00853	0.17	0.12	Post bronchodilator FEV1/FVC ratio;	chr7:26552629	chr7:26398593~26494256:+
BRCA	cis	rs739496	0.947	rs739497	ENSG00000257624.1	RP1-128M12.3	3.82	0.000143	0.00853	0.16	0.12	Platelet count;	chr12:111420282	chr12:112000739~112000985:-
BRCA	cis	rs2030746	0.521	rs13021979	ENSG00000237614.1	AC073257.2	3.82	0.000143	0.00853	0.15	0.12	LDL cholesterol;Total cholesterol levels;LDL cholesterol levels;	chr2:120567878	chr2:120542909~120544326:-
BRCA	cis	rs8180040	0.966	rs11710322	ENSG00000280667.1	Y_RNA	-3.82	0.000143	0.00853	-0.13	-0.12	Colorectal cancer;	chr3:47289646	chr3:47501083~47501182:+
BRCA	cis	rs13256369	1	rs10088439	ENSG00000254153.1	CTA-398F10.2	3.82	0.000143	0.00853	0.16	0.12	Obesity-related traits;	chr8:8719189	chr8:8456909~8461337:-
BRCA	cis	rs7781557	0.64	rs55681588	ENSG00000239969.4	RP11-163E9.2	-3.82	0.000143	0.00853	-0.19	-0.12	Colorectal adenoma (advanced);	chr7:102936891	chr7:102364162~102380633:+
BRCA	cis	rs67981189	0.634	rs221898	ENSG00000258571.1	PTTG4P	-3.82	0.000143	0.00854	-0.13	-0.12	Schizophrenia;	chr14:71138799	chr14:71085482~71085833:-
BRCA	cis	rs2625529	0.938	rs4776579	ENSG00000260037.4	CTD-2524L6.3	-3.82	0.000143	0.00854	-0.16	-0.12	Red blood cell count;	chr15:71840267	chr15:71818396~71823384:+
BRCA	cis	rs7674212	0.507	rs223331	ENSG00000248740.4	RP11-328K4.1	3.82	0.000143	0.00854	0.14	0.12	Type 2 diabetes;	chr4:102872408	chr4:103256159~103453658:+
BRCA	cis	rs1912124	1	rs68193205	ENSG00000271983.1	RP11-28H5.2	3.82	0.000143	0.00854	0.24	0.12	Peripheral arterial disease (traffic-related air pollution interaction);	chr15:81225114	chr15:80693216~80693707:-
BRCA	cis	rs9868809	0.505	rs73080312	ENSG00000225399.4	RP11-3B7.1	-3.82	0.000143	0.00854	-0.23	-0.12	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48700414	chr3:49260085~49261316:+
BRCA	cis	rs34014631	1	rs80080632	ENSG00000226009.1	KCNIP2-AS1	3.82	0.000143	0.00854	0.3	0.12	Coronary artery calcification;	chr10:101950244	chr10:101819078~101828779:+
BRCA	cis	rs34014631	0.901	rs80213387	ENSG00000226009.1	KCNIP2-AS1	3.82	0.000143	0.00854	0.3	0.12	Coronary artery calcification;	chr10:101957916	chr10:101819078~101828779:+
BRCA	cis	rs490234	0.841	rs13285366	ENSG00000232630.1	PRPS1P2	-3.82	0.000143	0.00854	-0.12	-0.12	Mean arterial pressure;	chr9:125612768	chr9:125150653~125151589:+
BRCA	cis	rs10986311	0.637	rs10760361	ENSG00000227200.1	RP11-121A14.3	-3.82	0.000143	0.00854	-0.14	-0.12	Vitiligo;	chr9:124415987	chr9:124262876~124265809:+
BRCA	cis	rs7520050	0.966	rs1707321	ENSG00000281133.1	AL355480.3	3.82	0.000143	0.00854	0.13	0.12	Reticulocyte count;Red blood cell count;	chr1:46039637	chr1:45580892~45580996:-
BRCA	cis	rs7917772	0.503	rs7078435	ENSG00000213061.2	PFN1P11	-3.82	0.000143	0.00854	-0.16	-0.12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;	chr10:102545009	chr10:102838011~102845473:-
BRCA	cis	rs4919669	0.668	rs17114641	ENSG00000213277.3	MARCKSL1P1	3.82	0.000143	0.00854	0.2	0.12	Mean arterial pressure (long-term average);Systolic blood pressure (long-term average);	chr10:102527602	chr10:103175554~103176094:+
BRCA	cis	rs1009077	0.68	rs28540362	ENSG00000245958.5	RP11-33B1.1	3.82	0.000143	0.00854	0.13	0.12	Endometriosis;	chr4:119570722	chr4:119454791~119552025:+
BRCA	cis	rs7722600	0.808	rs17171711	ENSG00000253404.1	AC034243.1	-3.82	0.000143	0.00854	-0.21	-0.12	Heart rate;	chr5:138029106	chr5:138744434~138753309:-
BRCA	cis	rs8054556	1	rs8054556	ENSG00000261367.1	RP11-455F5.4	-3.82	0.000143	0.00854	-0.13	-0.12	Autism spectrum disorder or schizophrenia;	chr16:29946895	chr16:30107675~30110541:+
BRCA	cis	rs875971	0.571	rs78668714	ENSG00000232546.1	RP11-458F8.1	3.82	0.000143	0.00854	0.11	0.12	Aortic root size;	chr7:66474464	chr7:66848496~66858136:+
BRCA	cis	rs9847710	0.967	rs2581778	ENSG00000242849.2	ALDOAP1	3.82	0.000143	0.00854	0.13	0.12	Ulcerative colitis;	chr3:53021295	chr3:52193170~52194785:+
BRCA	cis	rs875971	0.522	rs34973832	ENSG00000273142.1	RP11-458F8.4	-3.82	0.000143	0.00854	-0.1	-0.12	Aortic root size;	chr7:65931217	chr7:66902857~66906297:+
BRCA	cis	rs524281	0.684	rs7946447	ENSG00000255557.1	RP11-770G2.2	3.82	0.000143	0.00855	0.16	0.12	Electroencephalogram traits;	chr11:66096867	chr11:65745729~65771585:+
BRCA	cis	rs28489187	0.706	rs233113	ENSG00000223653.4	RP11-131L23.1	3.82	0.000143	0.00855	0.13	0.12	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85320616	chr1:85276715~85448124:+
BRCA	cis	rs28489187	0.667	rs233114	ENSG00000223653.4	RP11-131L23.1	3.82	0.000143	0.00855	0.13	0.12	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85321274	chr1:85276715~85448124:+
BRCA	cis	rs35740288	0.787	rs11637768	ENSG00000259407.1	RP11-158M2.3	-3.82	0.000143	0.00855	-0.16	-0.12	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85680179	chr15:85744109~85750281:-
BRCA	cis	rs12922040	1	rs12922040	ENSG00000279866.1	CTB-193M12.4	3.82	0.000143	0.00855	0.14	0.12	Serum uric acid levels in response to allopurinol in gout;	chr16:15775609	chr16:15704410~15705984:+
BRCA	cis	rs11673344	0.566	rs2385181	ENSG00000267422.1	CTD-2554C21.1	-3.82	0.000143	0.00855	-0.15	-0.12	Obesity-related traits;	chr19:37395428	chr19:37779686~37792865:+
BRCA	cis	rs4415084	1	rs10462079	ENSG00000248779.1	RP11-53O19.2	3.82	0.000143	0.00855	0.11	0.12	Breast cancer;	chr5:44700008	chr5:44752949~44765744:+
BRCA	cis	rs4415084	1	rs13179137	ENSG00000248779.1	RP11-53O19.2	3.82	0.000143	0.00855	0.11	0.12	Breast cancer;	chr5:44702590	chr5:44752949~44765744:+
BRCA	cis	rs990171	0.538	rs4851014	ENSG00000234389.1	AC007278.3	3.82	0.000143	0.00855	0.11	0.12	Lymphocyte counts;	chr2:102499817	chr2:102438713~102440475:+
BRCA	cis	rs6015450	0.702	rs6026727	ENSG00000228340.4	MIR646HG	3.82	0.000143	0.00855	0.22	0.12	Hypertension;Blood pressure;Systolic blood pressure;Diastolic blood pressure;	chr20:59147680	chr20:60087840~60527458:+
BRCA	cis	rs9470794	0.915	rs11755559	ENSG00000204110.6	RP1-153P14.8	-3.82	0.000143	0.00855	-0.25	-0.12	Type 2 diabetes;	chr6:37807272	chr6:37507348~37535616:+
BRCA	cis	rs957448	0.561	rs13258635	ENSG00000254315.1	RP11-267M23.3	3.82	0.000143	0.00855	0.14	0.12	Nonsyndromic cleft lip with cleft palate;	chr8:94595629	chr8:94533628~94534391:+
BRCA	cis	rs6012564	0.89	rs6125591	ENSG00000227431.4	CSE1L-AS1	3.82	0.000143	0.00855	0.15	0.12	Anger;	chr20:49204130	chr20:49040463~49046044:-
BRCA	cis	rs8141529	0.748	rs7287918	ENSG00000272858.1	CTA-292E10.8	-3.82	0.000143	0.00855	-0.15	-0.12	Lymphocyte counts;	chr22:28885722	chr22:28814914~28815662:+
BRCA	cis	rs2439831	0.85	rs12442297	ENSG00000206991.1	RNU6-610P	-3.82	0.000143	0.00856	-0.2	-0.12	Lung cancer in ever smokers;	chr15:43876272	chr15:43637632~43637738:-
BRCA	cis	rs17772222	0.917	rs4635267	ENSG00000258789.1	RP11-507K2.3	-3.82	0.000143	0.00856	-0.14	-0.12	Coronary artery calcification;	chr14:88621922	chr14:88551597~88552493:+
BRCA	cis	rs6893300	0.785	rs58386410	ENSG00000225051.5	HMGB3P22	3.82	0.000143	0.00856	0.15	0.12	Resting heart rate;	chr5:179778703	chr5:179679032~179694768:+
BRCA	cis	rs6893300	0.785	rs17617710	ENSG00000225051.5	HMGB3P22	3.82	0.000143	0.00856	0.15	0.12	Resting heart rate;	chr5:179779106	chr5:179679032~179694768:+
BRCA	cis	rs7746199	0.736	rs13192965	ENSG00000216901.1	AL022393.7	3.82	0.000143	0.00856	0.3	0.12	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27704046	chr6:28176188~28176674:+
BRCA	cis	rs524281	0.682	rs4483592	ENSG00000255038.1	RP11-1167A19.2	-3.82	0.000143	0.00856	-0.18	-0.12	Electroencephalogram traits;	chr11:66222968	chr11:66067277~66069619:-
BRCA	cis	rs2153535	0.584	rs62395677	ENSG00000251164.1	HULC	3.82	0.000143	0.00856	0.14	0.12	Motion sickness;	chr6:8371356	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.584	rs62395678	ENSG00000251164.1	HULC	3.82	0.000143	0.00856	0.14	0.12	Motion sickness;	chr6:8371456	chr6:8652137~8653846:+
BRCA	cis	rs6088580	0.634	rs6087579	ENSG00000275784.1	RP5-1125A11.6	3.82	0.000143	0.00856	0.13	0.12	Glomerular filtration rate (creatinine);	chr20:34397349	chr20:33989480~33991818:-
BRCA	cis	rs10129255	1	rs8010605	ENSG00000211967.3	IGHV3-53	-3.82	0.000143	0.00856	-0.09	-0.12	Kawasaki disease;	chr14:106678742	chr14:106592676~106593347:-
BRCA	cis	rs8023401	0.938	rs12904033	ENSG00000274654.1	CTD-3247H4.2	3.82	0.000143	0.00856	0.16	0.12	Spherical equivalent (joint analysis main effects and education interaction);	chr15:48504140	chr15:48528980~48529728:-
BRCA	cis	rs925550	0.932	rs7678116	ENSG00000224786.1	CETN4P	3.82	0.000143	0.00856	0.19	0.12	Primary biliary cholangitis;	chr4:122649963	chr4:122730548~122732193:-
BRCA	cis	rs875971	0.756	rs2901210	ENSG00000229886.1	RP5-1132H15.3	-3.82	0.000143	0.00856	-0.13	-0.12	Aortic root size;	chr7:66552518	chr7:66025126~66031544:-
BRCA	cis	rs1039766	0.925	rs268863	ENSG00000227791.3	AC007365.4	-3.82	0.000143	0.00856	-0.18	-0.12	Lung adenocarcinoma;Lung cancer;	chr2:65261669	chr2:64665607~64666064:+
BRCA	cis	rs739401	0.611	rs494427	ENSG00000247473.2	CARS-AS1	3.82	0.000143	0.00856	0.14	0.12	Longevity;	chr11:3026910	chr11:3029009~3041260:+
BRCA	cis	rs1346	0.552	rs11227235	ENSG00000245532.5	NEAT1	3.82	0.000143	0.00856	0.13	0.12	Vertical cup-disc ratio;Optic cup area;	chr11:65599024	chr11:65422774~65445540:+
BRCA	cis	rs875971	0.862	rs6978028	ENSG00000229886.1	RP5-1132H15.3	3.82	0.000143	0.00856	0.13	0.12	Aortic root size;	chr7:66421313	chr7:66025126~66031544:-
BRCA	cis	rs10463316	0.862	rs10071166	ENSG00000260581.1	CTB-113P19.4	3.82	0.000143	0.00856	0.14	0.12	Metabolite levels (Pyroglutamine);	chr5:151389234	chr5:151652275~151655449:+
BRCA	cis	rs2486012	1	rs2485989	ENSG00000237950.1	RP11-7O11.3	-3.82	0.000144	0.00857	-0.22	-0.12	Intelligence (multi-trait analysis);	chr1:43942782	chr1:43944370~43946551:-
BRCA	cis	rs2625529	0.824	rs7172309	ENSG00000260037.4	CTD-2524L6.3	-3.82	0.000144	0.00857	-0.17	-0.12	Red blood cell count;	chr15:72092142	chr15:71818396~71823384:+
BRCA	cis	rs891378	1	rs6662070	ENSG00000274245.1	RP11-357P18.2	-3.82	0.000144	0.00857	-0.15	-0.12	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207332364	chr1:207372559~207373252:+
BRCA	cis	rs170557	0.573	rs61820397	ENSG00000203706.7	SERTAD4-AS1	-3.82	0.000144	0.00857	-0.15	-0.12	Alopecia areata;	chr1:210015904	chr1:210231456~210234047:-
BRCA	cis	rs6599077	0.95	rs4676566	ENSG00000223797.4	ENTPD3-AS1	3.82	0.000144	0.00857	0.14	0.12	Sleep-related phenotypes;	chr3:40067145	chr3:40313802~40453329:-
BRCA	cis	rs6840360	0.571	rs875668	ENSG00000270265.1	RP11-731D1.4	-3.82	0.000144	0.00857	-0.14	-0.12	Intelligence (multi-trait analysis);	chr4:151604509	chr4:151333775~151353224:-
BRCA	cis	rs11673344	0.504	rs11084874	ENSG00000276846.1	CTD-3220F14.3	3.82	0.000144	0.00857	0.14	0.12	Obesity-related traits;	chr19:37096667	chr19:37314868~37315620:-
BRCA	cis	rs4950322	0.57	rs4950400	ENSG00000227242.3	NBPF13P	3.82	0.000144	0.00857	0.17	0.12	Protein quantitative trait loci;	chr1:147319383	chr1:147021320~147124525:-
BRCA	cis	rs6088580	0.524	rs6087612	ENSG00000261582.1	RP4-614O4.11	3.82	0.000144	0.00857	0.11	0.12	Glomerular filtration rate (creatinine);	chr20:34643018	chr20:35267885~35280043:-
BRCA	cis	rs513088	0.681	rs34900988	ENSG00000225171.2	DUTP6	-3.82	0.000144	0.00857	-0.17	-0.12	Schizophrenia;	chr1:166695161	chr1:166868748~166869209:+
BRCA	cis	rs9470794	1	rs116631087	ENSG00000204110.6	RP1-153P14.8	-3.82	0.000144	0.00858	-0.24	-0.12	Type 2 diabetes;	chr6:38048176	chr6:37507348~37535616:+
BRCA	cis	rs3805389	0.504	rs3805386	ENSG00000249700.7	SRD5A3-AS1	-3.82	0.000144	0.00858	-0.19	-0.12	Waist-to-hip ratio adjusted for body mass index;	chr4:55613838	chr4:55363971~55395847:-
BRCA	cis	rs3805389	0.504	rs3805387	ENSG00000249700.7	SRD5A3-AS1	-3.82	0.000144	0.00858	-0.19	-0.12	Waist-to-hip ratio adjusted for body mass index;	chr4:55613841	chr4:55363971~55395847:-
BRCA	cis	rs12762955	0.561	rs6560863	ENSG00000205740.2	RP11-363N22.3	-3.82	0.000144	0.00858	-0.12	-0.12	Response to angiotensin II receptor blocker therapy;	chr10:967595	chr10:971146~988341:-
BRCA	cis	rs7942368	0.818	rs10793194	ENSG00000254632.1	RP11-21L23.4	3.82	0.000144	0.00858	0.15	0.12	Endometriosis;	chr11:76764685	chr11:76759916~76768223:-
BRCA	cis	rs4073416	0.712	rs3825640	ENSG00000276116.2	FUT8-AS1	-3.82	0.000144	0.00858	-0.13	-0.12	N-glycan levels;	chr14:65494486	chr14:65411170~65412690:-
BRCA	cis	rs11098499	0.821	rs10032151	ENSG00000225892.3	RP11-384K6.2	3.82	0.000144	0.00858	0.12	0.12	Corneal astigmatism;	chr4:119470473	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.865	rs10032158	ENSG00000225892.3	RP11-384K6.2	3.82	0.000144	0.00858	0.12	0.12	Corneal astigmatism;	chr4:119470477	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.657	rs10434028	ENSG00000260404.2	RP11-384K6.6	3.82	0.000144	0.00858	0.11	0.12	Corneal astigmatism;	chr4:119373309	chr4:118591773~118633729:+
BRCA	cis	rs6005807	0.764	rs134197	ENSG00000272858.1	CTA-292E10.8	-3.82	0.000144	0.00858	-0.23	-0.12	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28267519	chr22:28814914~28815662:+
BRCA	cis	rs6012564	1	rs2295714	ENSG00000227431.4	CSE1L-AS1	3.82	0.000144	0.00858	0.14	0.12	Anger;	chr20:49123277	chr20:49040463~49046044:-
BRCA	cis	rs897984	0.568	rs4889651	ENSG00000274678.1	RP11-2C24.7	3.82	0.000144	0.00858	0.14	0.12	Dementia with Lewy bodies;	chr16:30884224	chr16:30821338~30821884:+
BRCA	cis	rs1802575	0.675	rs11694967	ENSG00000272606.1	RP11-554J4.1	3.82	0.000144	0.00858	0.21	0.12	Childhood ear infection;	chr2:55765005	chr2:55617909~55618373:+
BRCA	cis	rs1802575	0.623	rs13384182	ENSG00000272606.1	RP11-554J4.1	3.82	0.000144	0.00858	0.21	0.12	Childhood ear infection;	chr2:55766922	chr2:55617909~55618373:+
BRCA	cis	rs2841277	0.708	rs4465542	ENSG00000258701.1	LINC00638	3.82	0.000144	0.00858	0.13	0.12	Rheumatoid arthritis;	chr14:104941461	chr14:104821201~104823718:+
BRCA	cis	rs4930561	0.765	rs7931502	ENSG00000255306.1	RP5-901A4.1	3.82	0.000144	0.00859	0.12	0.12	Breast cancer in childhood cancer survivors;IgG glycosylation;	chr11:68192140	chr11:68024809~68030461:-
BRCA	cis	rs16944613	0.528	rs6416554	ENSG00000271396.1	RP11-697E2.9	-3.82	0.000144	0.00859	-0.2	-0.12	Colorectal cancer;	chr15:90595058	chr15:90284376~90285580:-
BRCA	cis	rs4660456	0.572	rs10789191	ENSG00000272145.1	NFYC-AS1	-3.82	0.000144	0.00859	-0.11	-0.12	Platelet count;	chr1:40690819	chr1:40690380~40692066:-
BRCA	cis	rs935334	1	rs11159183	ENSG00000258454.1	RP11-361H10.3	3.82	0.000144	0.00859	0.19	0.12	Blood pressure;	chr14:76196559	chr14:76235817~76263474:+
BRCA	cis	rs4835473	0.9	rs4257605	ENSG00000246448.2	RP13-578N3.3	-3.82	0.000144	0.00859	-0.13	-0.12	Immature fraction of reticulocytes;	chr4:143740081	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.932	rs4498094	ENSG00000246448.2	RP13-578N3.3	-3.82	0.000144	0.00859	-0.13	-0.12	Immature fraction of reticulocytes;	chr4:143740097	chr4:143700257~143865072:+
BRCA	cis	rs875971	0.66	rs10215132	ENSG00000272831.1	RP11-792A8.4	-3.82	0.000144	0.00859	-0.11	-0.12	Aortic root size;	chr7:66589419	chr7:66739829~66740385:-
BRCA	cis	rs375066	0.935	rs376032	ENSG00000267191.1	RP11-15A1.2	-3.82	0.000144	0.00859	-0.15	-0.12	Breast cancer;	chr19:43903412	chr19:43902001~43926545:+
BRCA	cis	rs9467773	0.595	rs13207371	ENSG00000241549.7	GUSBP2	3.82	0.000144	0.00859	0.13	0.12	Intelligence (multi-trait analysis);	chr6:26590846	chr6:26871484~26956554:-
BRCA	cis	rs1075265	0.783	rs6708095	ENSG00000272156.1	RP11-477N3.1	-3.82	0.000144	0.00859	-0.12	-0.12	Chronotype;Morning vs. evening chronotype;	chr2:53710365	chr2:54082554~54085066:+
BRCA	cis	rs2274273	0.967	rs2094102	ENSG00000233924.1	AL160471.6	-3.82	0.000144	0.00859	-0.13	-0.12	Protein biomarker;	chr14:55124380	chr14:55004813~55005687:-
BRCA	cis	rs4374383	0.631	rs67063370	ENSG00000243389.1	AC012442.5	-3.82	0.000144	0.00859	-0.15	-0.12	Hepatitis C induced liver fibrosis;	chr2:111928049	chr2:112589040~112614431:+
BRCA	cis	rs957448	0.561	rs12679785	ENSG00000254315.1	RP11-267M23.3	3.82	0.000144	0.00859	0.14	0.12	Nonsyndromic cleft lip with cleft palate;	chr8:94593349	chr8:94533628~94534391:+
BRCA	cis	rs6545883	0.868	rs2427885	ENSG00000270820.4	RP11-355B11.2	3.82	0.000144	0.00859	0.13	0.12	Tuberculosis;	chr2:61589642	chr2:61471188~61484130:+
BRCA	cis	rs957448	0.561	rs4735302	ENSG00000254315.1	RP11-267M23.3	-3.82	0.000144	0.00859	-0.14	-0.12	Nonsyndromic cleft lip with cleft palate;	chr8:94604752	chr8:94533628~94534391:+
BRCA	cis	rs317865	0.748	rs73234656	ENSG00000263327.5	TAPT1-AS1	-3.82	0.000144	0.0086	-0.21	-0.12	Kidney disease (early stage) in type 1 diabetes;	chr4:16211079	chr4:16226685~16320140:+
BRCA	cis	rs4664293	0.647	rs10196064	ENSG00000226266.5	AC009961.3	-3.82	0.000144	0.0086	-0.14	-0.12	Monocyte percentage of white cells;	chr2:159569454	chr2:159670708~159712435:-
BRCA	cis	rs4664293	0.647	rs2162023	ENSG00000226266.5	AC009961.3	-3.82	0.000144	0.0086	-0.14	-0.12	Monocyte percentage of white cells;	chr2:159569719	chr2:159670708~159712435:-
BRCA	cis	rs6496932	0.663	rs8040940	ENSG00000218052.5	ADAMTS7P4	-3.82	0.000144	0.0086	-0.12	-0.12	Central corneal thickness;Corneal structure;	chr15:85361817	chr15:85255369~85330334:-
BRCA	cis	rs73206853	0.563	rs55885633	ENSG00000277299.1	RP11-837J7.4	-3.82	0.000144	0.0086	-0.2	-0.12	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr12:110751446	chr12:109948389~109949029:+
BRCA	cis	rs17270561	0.609	rs9356984	ENSG00000272462.2	U91328.19	3.82	0.000144	0.0086	0.15	0.12	Iron status biomarkers;	chr6:25725253	chr6:25992662~26001775:+
BRCA	cis	rs1816752	0.905	rs8002215	ENSG00000273628.1	RP11-756A22.7	3.82	0.000144	0.0086	0.14	0.12	Obesity-related traits;	chr13:24416229	chr13:24933006~24936796:+
BRCA	cis	rs7184046	0.797	rs13737	ENSG00000260206.1	CTD-2026K11.2	-3.82	0.000144	0.0086	-0.16	-0.12	Height;	chr15:75639788	chr15:75636139~75639239:+
BRCA	cis	rs74233809	1	rs76752100	ENSG00000236937.2	PTGES3P4	3.82	0.000144	0.0086	0.25	0.12	Birth weight;	chr10:103034329	chr10:102845595~102845950:+
BRCA	cis	rs9527	0.59	rs7912517	ENSG00000213061.2	PFN1P11	3.82	0.000144	0.0086	0.16	0.12	Arsenic metabolism;	chr10:103145772	chr10:102838011~102845473:-
BRCA	cis	rs11098499	0.954	rs59866101	ENSG00000250412.1	KLHL2P1	3.81	0.000144	0.0086	0.14	0.12	Corneal astigmatism;	chr4:119375436	chr4:119334329~119378233:+
BRCA	cis	rs11098499	0.618	rs6858383	ENSG00000250412.1	KLHL2P1	3.81	0.000144	0.0086	0.14	0.12	Corneal astigmatism;	chr4:119375617	chr4:119334329~119378233:+
BRCA	cis	rs11098499	0.697	rs6832410	ENSG00000250412.1	KLHL2P1	3.81	0.000144	0.0086	0.14	0.12	Corneal astigmatism;	chr4:119375645	chr4:119334329~119378233:+
BRCA	cis	rs11098499	0.865	rs1112817	ENSG00000250412.1	KLHL2P1	3.81	0.000144	0.0086	0.14	0.12	Corneal astigmatism;	chr4:119376645	chr4:119334329~119378233:+
BRCA	cis	rs11098499	0.779	rs10016060	ENSG00000250412.1	KLHL2P1	3.81	0.000144	0.0086	0.14	0.12	Corneal astigmatism;	chr4:119377257	chr4:119334329~119378233:+
BRCA	cis	rs11098499	0.954	rs10005644	ENSG00000250412.1	KLHL2P1	3.81	0.000144	0.0086	0.14	0.12	Corneal astigmatism;	chr4:119377322	chr4:119334329~119378233:+
BRCA	cis	rs11098499	0.697	rs10016448	ENSG00000250412.1	KLHL2P1	3.81	0.000144	0.0086	0.14	0.12	Corneal astigmatism;	chr4:119377690	chr4:119334329~119378233:+
BRCA	cis	rs11098499	0.657	rs9996569	ENSG00000250412.1	KLHL2P1	3.81	0.000144	0.0086	0.14	0.12	Corneal astigmatism;	chr4:119377849	chr4:119334329~119378233:+
BRCA	cis	rs11098499	0.908	rs11729050	ENSG00000250412.1	KLHL2P1	3.81	0.000144	0.0086	0.14	0.12	Corneal astigmatism;	chr4:119378911	chr4:119334329~119378233:+
BRCA	cis	rs11098499	0.954	rs28429722	ENSG00000250412.1	KLHL2P1	3.81	0.000144	0.0086	0.14	0.12	Corneal astigmatism;	chr4:119378938	chr4:119334329~119378233:+
BRCA	cis	rs11098499	0.954	rs10014845	ENSG00000250412.1	KLHL2P1	3.81	0.000144	0.0086	0.14	0.12	Corneal astigmatism;	chr4:119379922	chr4:119334329~119378233:+
BRCA	cis	rs11098499	0.779	rs7674500	ENSG00000250412.1	KLHL2P1	3.81	0.000144	0.0086	0.14	0.12	Corneal astigmatism;	chr4:119382438	chr4:119334329~119378233:+
BRCA	cis	rs11098499	0.909	rs28884220	ENSG00000250412.1	KLHL2P1	3.81	0.000144	0.0086	0.14	0.12	Corneal astigmatism;	chr4:119386056	chr4:119334329~119378233:+
BRCA	cis	rs11098499	0.909	rs28793658	ENSG00000250412.1	KLHL2P1	3.81	0.000144	0.0086	0.14	0.12	Corneal astigmatism;	chr4:119386059	chr4:119334329~119378233:+
BRCA	cis	rs11098499	0.697	rs4373140	ENSG00000250412.1	KLHL2P1	3.81	0.000144	0.0086	0.14	0.12	Corneal astigmatism;	chr4:119386543	chr4:119334329~119378233:+
BRCA	cis	rs11098499	0.954	rs13113483	ENSG00000250412.1	KLHL2P1	3.81	0.000144	0.0086	0.14	0.12	Corneal astigmatism;	chr4:119387884	chr4:119334329~119378233:+
BRCA	cis	rs11098499	0.542	rs10440343	ENSG00000250412.1	KLHL2P1	3.81	0.000144	0.0086	0.14	0.12	Corneal astigmatism;	chr4:119388632	chr4:119334329~119378233:+
BRCA	cis	rs11098499	0.779	rs10011097	ENSG00000250412.1	KLHL2P1	3.81	0.000144	0.0086	0.14	0.12	Corneal astigmatism;	chr4:119389204	chr4:119334329~119378233:+
BRCA	cis	rs11098499	0.542	rs7677836	ENSG00000250412.1	KLHL2P1	3.81	0.000144	0.0086	0.14	0.12	Corneal astigmatism;	chr4:119389483	chr4:119334329~119378233:+
BRCA	cis	rs11098499	0.909	rs10002083	ENSG00000250412.1	KLHL2P1	3.81	0.000144	0.0086	0.14	0.12	Corneal astigmatism;	chr4:119389997	chr4:119334329~119378233:+
BRCA	cis	rs11098499	0.954	rs10024844	ENSG00000250412.1	KLHL2P1	3.81	0.000144	0.0086	0.14	0.12	Corneal astigmatism;	chr4:119390373	chr4:119334329~119378233:+
BRCA	cis	rs11098499	0.954	rs4345162	ENSG00000250412.1	KLHL2P1	3.81	0.000144	0.0086	0.14	0.12	Corneal astigmatism;	chr4:119391804	chr4:119334329~119378233:+
BRCA	cis	rs11098499	0.657	rs4463052	ENSG00000250412.1	KLHL2P1	3.81	0.000144	0.0086	0.14	0.12	Corneal astigmatism;	chr4:119392103	chr4:119334329~119378233:+
BRCA	cis	rs11098499	0.954	rs13151285	ENSG00000250412.1	KLHL2P1	3.81	0.000144	0.0086	0.14	0.12	Corneal astigmatism;	chr4:119393586	chr4:119334329~119378233:+
BRCA	cis	rs3816183	0.959	rs3772063	ENSG00000226491.1	FTOP1	-3.81	0.000144	0.0086	-0.15	-0.12	Hypospadias;	chr2:42789955	chr2:42797225~42798712:-
BRCA	cis	rs10829156	0.796	rs6482567	ENSG00000225527.1	RP11-383B4.4	-3.81	0.000144	0.0086	-0.17	-0.12	Sudden cardiac arrest;	chr10:18625860	chr10:18531849~18533336:-
BRCA	cis	rs962856	1	rs962856	ENSG00000236605.1	AC023115.4	3.81	0.000144	0.0086	0.14	0.12	Pancreatic cancer;	chr2:67366671	chr2:67324627~67325304:+
BRCA	cis	rs11098499	1	rs7659194	ENSG00000225892.3	RP11-384K6.2	3.81	0.000144	0.0086	0.12	0.12	Corneal astigmatism;	chr4:119285992	chr4:118632274~118634759:+
BRCA	cis	rs17801127	0.748	rs79717439	ENSG00000231969.1	AC144449.1	3.81	0.000144	0.0086	0.2	0.12	Liver enzyme levels (alanine transaminase);	chr2:149668550	chr2:149587196~149848233:+
BRCA	cis	rs875971	1	rs6946143	ENSG00000229180.5	GS1-124K5.11	3.81	0.000144	0.0086	0.1	0.12	Aortic root size;	chr7:66114735	chr7:66526088~66542624:-
BRCA	cis	rs943466	1	rs6940353	ENSG00000223837.2	BRD2-IT1	3.81	0.000144	0.0086	0.15	0.12	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;	chr6:33784773	chr6:32970232~32970886:+
BRCA	cis	rs853679	1	rs7740487	ENSG00000216901.1	AL022393.7	3.81	0.000144	0.0086	0.21	0.12	Depression;	chr6:28248708	chr6:28176188~28176674:+
BRCA	cis	rs7111546	0.791	rs77700609	ENSG00000246225.5	RP11-17A1.3	3.81	0.000144	0.0086	0.2	0.12	Dialysis-related mortality;	chr11:22856122	chr11:22829380~22945393:+
BRCA	cis	rs7111546	0.791	rs7108863	ENSG00000246225.5	RP11-17A1.3	3.81	0.000144	0.0086	0.2	0.12	Dialysis-related mortality;	chr11:22856829	chr11:22829380~22945393:+
BRCA	cis	rs34792	0.554	rs12929694	ENSG00000258354.1	MIR3180-1	-3.81	0.000144	0.0086	-0.17	-0.12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15519840	chr16:14909887~14911345:-
BRCA	cis	rs7395581	0.918	rs10742799	ENSG00000280615.1	Y_RNA	3.81	0.000144	0.00861	0.14	0.12	HDL cholesterol;	chr11:47272151	chr11:47614898~47614994:-
BRCA	cis	rs11098499	0.874	rs7661020	ENSG00000260091.1	RP11-33B1.4	-3.81	0.000144	0.00861	-0.11	-0.12	Corneal astigmatism;	chr4:119185827	chr4:119409333~119410233:+
BRCA	cis	rs7011507	0.536	rs7825135	ENSG00000233858.4	AC026904.1	-3.81	0.000144	0.00861	-0.14	-0.12	Inflammatory bowel disease;Ulcerative colitis;	chr8:48478720	chr8:48590401~48594621:+
BRCA	cis	rs6840360	0.809	rs6847303	ENSG00000278978.1	RP11-164P12.5	3.81	0.000144	0.00861	0.13	0.12	Intelligence (multi-trait analysis);	chr4:151809069	chr4:151669786~151670503:+
BRCA	cis	rs17027633	0.881	rs41301285	ENSG00000234020.1	CHIAP3	-3.81	0.000144	0.00861	-0.29	-0.12	Cerebrospinal fluid t-tau:AB1-42 ratio;	chr1:111477130	chr1:111353275~111367409:-
BRCA	cis	rs925550	0.932	rs17005992	ENSG00000224786.1	CETN4P	-3.81	0.000144	0.00861	-0.19	-0.12	Primary biliary cholangitis;	chr4:122662460	chr4:122730548~122732193:-
BRCA	cis	rs2460905	0.702	rs6993033	ENSG00000251468.2	RP11-369K16.1	-3.81	0.000144	0.00861	-0.28	-0.12	Post-traumatic stress disorder;	chr8:13011808	chr8:12958387~12962200:+
BRCA	cis	rs12439619	0.846	rs62012004	ENSG00000259429.4	UBE2Q2P2	-3.81	0.000144	0.00861	-0.15	-0.12	Intelligence (multi-trait analysis);	chr15:82183924	chr15:82355142~82420075:+
BRCA	cis	rs12738007	0.544	rs12045777	ENSG00000237934.1	RP11-467D18.2	3.81	0.000144	0.00861	0.13	0.12	Schizophrenia;	chr1:29102492	chr1:29223933~29224816:+
BRCA	cis	rs8094794	0.5	rs72883506	ENSG00000267707.2	RP11-95O2.5	3.81	0.000144	0.00861	0.21	0.12	Periodontal disease-related phenotypes;	chr18:36730286	chr18:37243776~37247506:+
BRCA	cis	rs863345	0.604	rs1157524	ENSG00000229914.1	RP11-404O13.4	-3.81	0.000144	0.00861	-0.13	-0.12	Pneumococcal bacteremia;	chr1:158487508	chr1:158195633~158196131:-
BRCA	cis	rs10788575	0.526	rs10788569	ENSG00000271880.1	AGAP11	3.81	0.000144	0.00861	0.14	0.12	Type 2 diabetes;	chr10:87844975	chr10:86970741~87010126:+
BRCA	cis	rs26949	0.647	rs35387	ENSG00000215032.2	GNL3LP1	-3.81	0.000144	0.00861	-0.15	-0.12	Intelligence (multi-trait analysis);	chr5:60506842	chr5:60891935~60893577:-
BRCA	cis	rs875971	0.83	rs778715	ENSG00000229886.1	RP5-1132H15.3	3.81	0.000144	0.00861	0.13	0.12	Aortic root size;	chr7:66384222	chr7:66025126~66031544:-
BRCA	cis	rs7177699	0.557	rs4433781	ENSG00000261143.1	ADAMTS7P3	3.81	0.000144	0.00861	0.14	0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78829493	chr15:77976042~77993057:+
BRCA	cis	rs8180040	0.932	rs62248599	ENSG00000280667.1	Y_RNA	-3.81	0.000144	0.00861	-0.13	-0.12	Colorectal cancer;	chr3:47475238	chr3:47501083~47501182:+
BRCA	cis	rs890448	0.796	rs1549513	ENSG00000254531.1	FLJ20021	3.81	0.000144	0.00861	0.14	0.12	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101419773	chr4:101347780~101348883:+
BRCA	cis	rs8180040	0.966	rs7651762	ENSG00000280667.1	Y_RNA	-3.81	0.000144	0.00861	-0.13	-0.12	Colorectal cancer;	chr3:47428994	chr3:47501083~47501182:+
BRCA	cis	rs7267979	0.932	rs6115200	ENSG00000276952.1	RP5-965G21.6	3.81	0.000145	0.00862	0.14	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25506741	chr20:25284915~25285588:-
BRCA	cis	rs1048886	0.872	rs16869371	ENSG00000271967.1	RP11-134K13.4	-3.81	0.000145	0.00862	-0.17	-0.12	Type 2 diabetes;	chr6:70559756	chr6:70596438~70596980:+
BRCA	cis	rs7412746	0.658	rs10305714	ENSG00000224800.1	RP11-235D19.2	3.81	0.000145	0.00862	0.14	0.12	Melanoma;	chr1:150828179	chr1:150881236~150881683:-
BRCA	cis	rs10129255	0.536	rs3944157	ENSG00000232216.1	IGHV3-43	3.81	0.000145	0.00862	0.09	0.12	Kawasaki disease;	chr14:106682286	chr14:106470264~106470800:-
BRCA	cis	rs4950322	0.57	rs113498894	ENSG00000237188.3	RP11-337C18.8	3.81	0.000145	0.00862	0.15	0.12	Protein quantitative trait loci;	chr1:147318880	chr1:147172771~147211568:+
BRCA	cis	rs4759375	1	rs10773003	ENSG00000256092.2	RP13-942N8.1	3.81	0.000145	0.00862	0.18	0.12	HDL cholesterol;	chr12:123290580	chr12:123363868~123366113:+
BRCA	cis	rs11098499	1	rs11098499	ENSG00000260091.1	RP11-33B1.4	-3.81	0.000145	0.00862	-0.11	-0.12	Corneal astigmatism;	chr4:119266456	chr4:119409333~119410233:+
BRCA	cis	rs875971	0.862	rs4149461	ENSG00000271064.1	RP11-792A8.3	3.81	0.000145	0.00862	0.14	0.12	Aortic root size;	chr7:66279745	chr7:66748838~66749077:-
BRCA	cis	rs375066	1	rs375066	ENSG00000267191.1	RP11-15A1.2	-3.81	0.000145	0.00862	-0.15	-0.12	Breast cancer;	chr19:43919418	chr19:43902001~43926545:+
BRCA	cis	rs11098499	0.955	rs35434465	ENSG00000260091.1	RP11-33B1.4	-3.81	0.000145	0.00862	-0.11	-0.12	Corneal astigmatism;	chr4:119248223	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.954	rs11722872	ENSG00000260091.1	RP11-33B1.4	-3.81	0.000145	0.00862	-0.11	-0.12	Corneal astigmatism;	chr4:119311875	chr4:119409333~119410233:+
BRCA	cis	rs7520050	0.966	rs785471	ENSG00000281133.1	AL355480.3	3.81	0.000145	0.00862	0.14	0.12	Reticulocyte count;Red blood cell count;	chr1:46053005	chr1:45580892~45580996:-
BRCA	cis	rs3805389	0.504	rs59571323	ENSG00000249700.7	SRD5A3-AS1	-3.81	0.000145	0.00862	-0.19	-0.12	Waist-to-hip ratio adjusted for body mass index;	chr4:55611187	chr4:55363971~55395847:-
BRCA	cis	rs13434995	0.838	rs57178140	ENSG00000249700.7	SRD5A3-AS1	-3.81	0.000145	0.00862	-0.19	-0.12	Adiponectin levels;	chr4:55611361	chr4:55363971~55395847:-
BRCA	cis	rs863345	0.604	rs1342952	ENSG00000229914.1	RP11-404O13.4	-3.81	0.000145	0.00862	-0.13	-0.12	Pneumococcal bacteremia;	chr1:158494640	chr1:158195633~158196131:-
BRCA	cis	rs1005277	0.579	rs1621040	ENSG00000272983.1	RP11-508N22.12	3.81	0.000145	0.00862	0.12	0.12	Extrinsic epigenetic age acceleration;	chr10:38208304	chr10:38137337~38144399:+
BRCA	cis	rs10129255	0.957	rs8009073	ENSG00000232216.1	IGHV3-43	3.81	0.000145	0.00863	0.1	0.12	Kawasaki disease;	chr14:106777278	chr14:106470264~106470800:-
BRCA	cis	rs875971	0.825	rs1000464	ENSG00000273024.4	INTS4P2	3.81	0.000145	0.00863	0.13	0.12	Aortic root size;	chr7:66312922	chr7:65647864~65715661:+
BRCA	cis	rs911555	0.57	rs11625397	ENSG00000258851.1	RP11-894P9.2	3.81	0.000145	0.00863	0.13	0.12	Intelligence (multi-trait analysis);	chr14:103561220	chr14:103553421~103561877:+
BRCA	cis	rs9733	0.519	rs1134067	ENSG00000231073.1	RP11-316M1.3	3.81	0.000145	0.00863	0.13	0.12	Tonsillectomy;	chr1:150748699	chr1:150973123~150975534:+
BRCA	cis	rs7771547	0.519	rs7773253	ENSG00000224666.3	RP1-50J22.4	3.81	0.000145	0.00863	0.14	0.12	Platelet distribution width;	chr6:36405674	chr6:36386831~36393462:+
BRCA	cis	rs7771547	0.723	rs1812018	ENSG00000224666.3	RP1-50J22.4	3.81	0.000145	0.00863	0.14	0.12	Platelet distribution width;	chr6:36590199	chr6:36386831~36393462:+
BRCA	cis	rs56046484	0.956	rs2174218	ENSG00000230373.7	GOLGA6L5P	-3.81	0.000145	0.00863	-0.17	-0.12	Testicular germ cell tumor;	chr15:85081425	chr15:84507885~84516814:-
BRCA	cis	rs9291683	0.669	rs887733	ENSG00000250413.1	RP11-448G15.1	3.81	0.000145	0.00863	0.16	0.12	Bone mineral density;	chr4:10181484	chr4:10006482~10009725:+
BRCA	cis	rs6812193	0.518	rs17001729	ENSG00000271676.1	RP11-1E1.2	3.81	0.000145	0.00863	0.17	0.12	Parkinson's disease;	chr4:76267265	chr4:77112495~77113458:-
BRCA	cis	rs6991838	0.584	rs4275254	ENSG00000272155.1	RP11-707M3.3	3.81	0.000145	0.00863	0.11	0.12	Intelligence (multi-trait analysis);	chr8:65589129	chr8:65714334~65714778:-
BRCA	cis	rs4978813	0.5	rs10759345	ENSG00000213539.4	YBX1P6	-3.81	0.000145	0.00863	-0.13	-0.12	Plantar warts;	chr9:109516765	chr9:109532830~109534332:-
BRCA	cis	rs6561151	0.681	rs17065161	ENSG00000274001.1	RP11-5G9.5	3.81	0.000145	0.00863	0.16	0.12	Crohn's disease;	chr13:43869587	chr13:43877715~43878163:-
BRCA	cis	rs3768617	0.966	rs10797850	ENSG00000224468.3	RP11-181K3.4	-3.81	0.000145	0.00863	-0.13	-0.12	Fuchs's corneal dystrophy;	chr1:183125667	chr1:183138402~183141282:-
BRCA	cis	rs564309	0.681	rs1188487	ENSG00000183929.7	DUSP5P1	3.81	0.000145	0.00863	0.22	0.12	Hip circumference (psychosocial stress interaction);	chr1:228432546	chr1:228650241~228651379:+
BRCA	cis	rs4699052	0.625	rs11734572	ENSG00000248740.4	RP11-328K4.1	3.81	0.000145	0.00864	0.13	0.12	Testicular germ cell tumor;	chr4:103367463	chr4:103256159~103453658:+
BRCA	cis	rs2905347	0.737	rs2010437	ENSG00000232949.1	AC002480.4	3.81	0.000145	0.00864	0.14	0.12	Major depression and alcohol dependence;	chr7:22591561	chr7:22589705~22591622:+
BRCA	cis	rs6671200	0.573	rs3738171	ENSG00000235501.4	RP4-639F20.1	3.81	0.000145	0.00864	0.2	0.12	Stearic acid (18:0) levels;	chr1:95234038	chr1:94927566~94963270:+
BRCA	cis	rs875971	0.522	rs7784623	ENSG00000273142.1	RP11-458F8.4	-3.81	0.000145	0.00864	-0.1	-0.12	Aortic root size;	chr7:65930047	chr7:66902857~66906297:+
BRCA	cis	rs45509595	0.841	rs200501	ENSG00000216676.2	RP1-15D7.1	-3.81	0.000145	0.00864	-0.2	-0.12	Breast cancer;	chr6:27821164	chr6:27652602~27652825:-
BRCA	cis	rs12468226	0.81	rs77090459	ENSG00000272966.1	RP11-686O6.1	3.81	0.000145	0.00864	0.2	0.12	Urate levels;	chr2:202542132	chr2:202336739~202337200:+
BRCA	cis	rs6545883	0.931	rs9807965	ENSG00000212978.6	AC016747.3	3.81	0.000145	0.00864	0.16	0.12	Tuberculosis;	chr2:61505024	chr2:61141592~61144969:-
BRCA	cis	rs4363385	0.667	rs454245	ENSG00000272654.1	RP11-422P24.11	-3.81	0.000145	0.00864	-0.12	-0.12	Inflammatory skin disease;	chr1:153059503	chr1:153977743~153979160:+
BRCA	cis	rs10871290	1	rs11149710	ENSG00000262904.1	TMPOP2	3.81	0.000145	0.00864	0.12	0.12	Breast cancer;	chr16:74438648	chr16:74667506~74668706:+
BRCA	cis	rs8040855	0.627	rs4842863	ENSG00000259774.1	RP11-182J1.13	3.81	0.000145	0.00864	0.16	0.12	Bulimia nervosa;	chr15:85098974	chr15:84422618~84425882:+
BRCA	cis	rs886774	0.932	rs6964972	ENSG00000273055.1	CTB-13F3.1	-3.81	0.000145	0.00864	-0.12	-0.12	Ulcerative colitis;	chr7:107859551	chr7:107942116~107942740:+
BRCA	cis	rs8114671	0.662	rs3761143	ENSG00000279253.1	RP4-614O4.13	-3.81	0.000145	0.00864	-0.14	-0.12	Height;	chr20:34957942	chr20:35262727~35264187:-
BRCA	cis	rs7771547	0.519	rs2057351	ENSG00000224666.3	RP1-50J22.4	3.81	0.000145	0.00864	0.14	0.12	Platelet distribution width;	chr6:36393905	chr6:36386831~36393462:+
BRCA	cis	rs2274273	0.588	rs11158037	ENSG00000259318.1	RP11-454L9.2	3.81	0.000145	0.00864	0.11	0.12	Protein biomarker;	chr14:55365434	chr14:55394940~55395233:-
BRCA	cis	rs4698412	0.561	rs6848779	ENSG00000273133.1	RP11-799M12.2	-3.81	0.000145	0.00864	-0.14	-0.12	Parkinson's disease;	chr4:15693874	chr4:15563698~15564253:-
BRCA	cis	rs875971	0.545	rs1638724	ENSG00000232559.3	GS1-124K5.12	-3.81	0.000145	0.00864	-0.16	-0.12	Aortic root size;	chr7:66575494	chr7:66554588~66576923:-
BRCA	cis	rs13256369	1	rs9329165	ENSG00000254153.1	CTA-398F10.2	-3.81	0.000145	0.00864	-0.16	-0.12	Obesity-related traits;	chr8:8719132	chr8:8456909~8461337:-
BRCA	cis	rs9863	0.794	rs12310367	ENSG00000270028.1	RP11-380L11.4	3.81	0.000145	0.00865	0.15	0.12	White blood cell count;	chr12:124002131	chr12:123925461~123926083:-
BRCA	cis	rs8114671	0.562	rs4911161	ENSG00000279253.1	RP4-614O4.13	-3.81	0.000145	0.00865	-0.13	-0.12	Height;	chr20:34814428	chr20:35262727~35264187:-
BRCA	cis	rs4819052	0.851	rs2838839	ENSG00000215447.6	BX322557.10	3.81	0.000145	0.00865	0.12	0.12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45247943	chr21:45288052~45291738:+
BRCA	cis	rs4415084	1	rs13156930	ENSG00000248779.1	RP11-53O19.2	3.81	0.000145	0.00865	0.11	0.12	Breast cancer;	chr5:44697933	chr5:44752949~44765744:+
BRCA	cis	rs875971	0.545	rs7810213	ENSG00000232546.1	RP11-458F8.1	3.81	0.000145	0.00865	0.11	0.12	Aortic root size;	chr7:66481592	chr7:66848496~66858136:+
BRCA	cis	rs4938303	0.788	rs12799766	ENSG00000254851.1	RP11-109L13.1	-3.81	0.000145	0.00865	-0.15	-0.12	Triglycerides;	chr11:116687711	chr11:117135528~117138582:+
BRCA	cis	rs6991838	0.612	rs7832407	ENSG00000272155.1	RP11-707M3.3	-3.81	0.000145	0.00865	-0.11	-0.12	Intelligence (multi-trait analysis);	chr8:65621071	chr8:65714334~65714778:-
BRCA	cis	rs6991838	0.551	rs7007505	ENSG00000272155.1	RP11-707M3.3	-3.81	0.000145	0.00865	-0.11	-0.12	Intelligence (multi-trait analysis);	chr8:65621719	chr8:65714334~65714778:-
BRCA	cis	rs6991838	0.584	rs7012856	ENSG00000272155.1	RP11-707M3.3	-3.81	0.000145	0.00865	-0.11	-0.12	Intelligence (multi-trait analysis);	chr8:65622740	chr8:65714334~65714778:-
BRCA	cis	rs6991838	0.55	rs7817112	ENSG00000272155.1	RP11-707M3.3	-3.81	0.000145	0.00865	-0.11	-0.12	Intelligence (multi-trait analysis);	chr8:65624885	chr8:65714334~65714778:-
BRCA	cis	rs6991838	0.584	rs2048650	ENSG00000272155.1	RP11-707M3.3	-3.81	0.000145	0.00865	-0.11	-0.12	Intelligence (multi-trait analysis);	chr8:65625664	chr8:65714334~65714778:-
BRCA	cis	rs6991838	0.584	rs4737749	ENSG00000272155.1	RP11-707M3.3	-3.81	0.000145	0.00865	-0.11	-0.12	Intelligence (multi-trait analysis);	chr8:65627672	chr8:65714334~65714778:-
BRCA	cis	rs6991838	0.584	rs10092109	ENSG00000272155.1	RP11-707M3.3	-3.81	0.000145	0.00865	-0.11	-0.12	Intelligence (multi-trait analysis);	chr8:65627683	chr8:65714334~65714778:-
BRCA	cis	rs6991838	0.584	rs6997959	ENSG00000272155.1	RP11-707M3.3	-3.81	0.000145	0.00865	-0.11	-0.12	Intelligence (multi-trait analysis);	chr8:65628247	chr8:65714334~65714778:-
BRCA	cis	rs6991838	0.584	rs7814841	ENSG00000272155.1	RP11-707M3.3	-3.81	0.000145	0.00865	-0.11	-0.12	Intelligence (multi-trait analysis);	chr8:65629328	chr8:65714334~65714778:-
BRCA	cis	rs6991838	0.584	rs11985628	ENSG00000272155.1	RP11-707M3.3	-3.81	0.000145	0.00865	-0.11	-0.12	Intelligence (multi-trait analysis);	chr8:65630504	chr8:65714334~65714778:-
BRCA	cis	rs6991838	0.557	rs13266834	ENSG00000272155.1	RP11-707M3.3	-3.81	0.000145	0.00865	-0.11	-0.12	Intelligence (multi-trait analysis);	chr8:65631303	chr8:65714334~65714778:-
BRCA	cis	rs6991838	0.584	rs13268343	ENSG00000272155.1	RP11-707M3.3	-3.81	0.000145	0.00865	-0.11	-0.12	Intelligence (multi-trait analysis);	chr8:65631742	chr8:65714334~65714778:-
BRCA	cis	rs6991838	0.584	rs1533285	ENSG00000272155.1	RP11-707M3.3	-3.81	0.000145	0.00865	-0.11	-0.12	Intelligence (multi-trait analysis);	chr8:65637129	chr8:65714334~65714778:-
BRCA	cis	rs3805389	0.504	rs3805386	ENSG00000273257.1	RP11-177J6.1	-3.81	0.000145	0.00865	-0.19	-0.12	Waist-to-hip ratio adjusted for body mass index;	chr4:55613838	chr4:55387949~55388271:+
BRCA	cis	rs3805389	0.504	rs3805387	ENSG00000273257.1	RP11-177J6.1	-3.81	0.000145	0.00865	-0.19	-0.12	Waist-to-hip ratio adjusted for body mass index;	chr4:55613841	chr4:55387949~55388271:+
BRCA	cis	rs4073416	0.842	rs968540	ENSG00000276116.2	FUT8-AS1	3.81	0.000145	0.00865	0.12	0.12	N-glycan levels;	chr14:65782346	chr14:65411170~65412690:-
BRCA	cis	rs10043775	1	rs10043775	ENSG00000251330.3	CTD-2283N19.1	-3.81	0.000145	0.00865	-0.14	-0.12	Periodontal microbiota;	chr5:148425557	chr5:148430159~148430807:-
BRCA	cis	rs7412746	0.658	rs2089082	ENSG00000224800.1	RP11-235D19.2	-3.81	0.000145	0.00865	-0.15	-0.12	Melanoma;	chr1:150827614	chr1:150881236~150881683:-
BRCA	cis	rs7487075	0.554	rs7967629	ENSG00000272369.1	RP11-446N19.1	3.81	0.000145	0.00865	0.13	0.12	Itch intensity from mosquito bite;	chr12:46234824	chr12:46537502~46652550:+
BRCA	cis	rs4700393	0.517	rs12523070	ENSG00000215032.2	GNL3LP1	-3.81	0.000145	0.00865	-0.17	-0.12	Intelligence (multi-trait analysis);	chr5:60795496	chr5:60891935~60893577:-
BRCA	cis	rs12505749	0.542	rs6824893	ENSG00000270147.1	RP11-646I6.6	-3.81	0.000145	0.00865	-0.14	-0.12	Airflow obstruction;	chr4:56506077	chr4:56396312~56396871:+
BRCA	cis	rs2835872	0.793	rs73220482	ENSG00000228677.1	TTC3-AS1	-3.81	0.000145	0.00866	-0.15	-0.12	Electroencephalographic traits in alcoholism;	chr21:37613984	chr21:37187666~37193926:-
BRCA	cis	rs9472168	0.967	rs4637627	ENSG00000272223.1	RP1-20C7.6	3.81	0.000145	0.00866	0.13	0.12	Interleukin-13 levels;	chr6:43957590	chr6:43033897~43034405:-
BRCA	cis	rs7312933	0.701	rs10880260	ENSG00000257225.1	RP11-328C8.4	-3.81	0.000145	0.00866	-0.14	-0.12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42167596	chr12:42459366~42466128:+
BRCA	cis	rs11098499	1	rs3749591	ENSG00000250412.1	KLHL2P1	3.81	0.000145	0.00866	0.15	0.12	Corneal astigmatism;	chr4:119292875	chr4:119334329~119378233:+
BRCA	cis	rs10129255	0.957	rs10136817	ENSG00000232216.1	IGHV3-43	3.81	0.000145	0.00866	0.1	0.12	Kawasaki disease;	chr14:106787730	chr14:106470264~106470800:-
BRCA	cis	rs2562456	0.754	rs55771551	ENSG00000213976.4	CTD-2561J22.2	-3.81	0.000145	0.00866	-0.14	-0.12	Pain;	chr19:21563578	chr19:21382865~21387177:+
BRCA	cis	rs7359257	0.576	rs56038097	ENSG00000270964.1	RP11-502I4.3	-3.81	0.000145	0.00866	-0.14	-0.12	Menarche (age at onset);	chr15:67612231	chr15:67541072~67542604:-
BRCA	cis	rs1048886	0.872	rs12529309	ENSG00000271967.1	RP11-134K13.4	-3.81	0.000145	0.00866	-0.18	-0.12	Type 2 diabetes;	chr6:70553931	chr6:70596438~70596980:+
BRCA	cis	rs1048886	0.872	rs56143128	ENSG00000271967.1	RP11-134K13.4	-3.81	0.000145	0.00866	-0.18	-0.12	Type 2 diabetes;	chr6:70557963	chr6:70596438~70596980:+
BRCA	cis	rs4374383	0.631	rs6711987	ENSG00000243389.1	AC012442.5	-3.81	0.000145	0.00866	-0.15	-0.12	Hepatitis C induced liver fibrosis;	chr2:111932598	chr2:112589040~112614431:+
BRCA	cis	rs2301573	0.584	rs58045532	ENSG00000271270.4	TMCC1-AS1	-3.81	0.000145	0.00866	-0.25	-0.12	Hip circumference;	chr3:129661819	chr3:129893871~129918575:+
BRCA	cis	rs2301573	0.584	rs62267600	ENSG00000271270.4	TMCC1-AS1	-3.81	0.000145	0.00866	-0.25	-0.12	Hip circumference;	chr3:129666166	chr3:129893871~129918575:+
BRCA	cis	rs1555322	0.929	rs2247828	ENSG00000269202.1	RP4-614O4.12	3.81	0.000145	0.00867	0.16	0.12	Attention deficit hyperactivity disorder;	chr20:35252136	chr20:35201747~35203288:-
BRCA	cis	rs721917	0.525	rs2819106	ENSG00000280355.1	RP11-119F19.5	-3.81	0.000145	0.00867	-0.13	-0.12	Chronic obstructive pulmonary disease;	chr10:79926324	chr10:79681973~79684094:-
BRCA	cis	rs713477	0.524	rs7149317	ENSG00000186615.9	KTN1-AS1	-3.81	0.000145	0.00867	-0.14	-0.12	Pediatric bone mineral content (femoral neck);	chr14:55435824	chr14:55499278~55580110:-
BRCA	cis	rs875971	0.862	rs3893216	ENSG00000229886.1	RP5-1132H15.3	-3.81	0.000145	0.00867	-0.13	-0.12	Aortic root size;	chr7:66325720	chr7:66025126~66031544:-
BRCA	cis	rs875971	0.862	rs6958294	ENSG00000229886.1	RP5-1132H15.3	-3.81	0.000145	0.00867	-0.13	-0.12	Aortic root size;	chr7:66329809	chr7:66025126~66031544:-
BRCA	cis	rs875971	0.862	rs2088655	ENSG00000229886.1	RP5-1132H15.3	-3.81	0.000145	0.00867	-0.13	-0.12	Aortic root size;	chr7:66330724	chr7:66025126~66031544:-
BRCA	cis	rs875971	0.895	rs10447522	ENSG00000229886.1	RP5-1132H15.3	-3.81	0.000145	0.00867	-0.13	-0.12	Aortic root size;	chr7:66331087	chr7:66025126~66031544:-
BRCA	cis	rs2058059	0.593	rs2960944	ENSG00000205578.5	POM121B	-3.81	0.000145	0.00867	-0.2	-0.12	Subcutaneous adipose tissue;	chr7:72680285	chr7:73293497~73301161:+
BRCA	cis	rs860295	0.812	rs2297775	ENSG00000225855.5	RUSC1-AS1	-3.81	0.000145	0.00867	-0.09	-0.12	Body mass index;	chr1:155765221	chr1:155316863~155324176:-
BRCA	cis	rs73201462	1	rs2811533	ENSG00000242551.2	POU5F1P6	-3.81	0.000146	0.00867	-0.19	-0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128272886	chr3:128674735~128677005:-
BRCA	cis	rs6991838	0.55	rs12335006	ENSG00000272155.1	RP11-707M3.3	-3.81	0.000146	0.00867	-0.11	-0.12	Intelligence (multi-trait analysis);	chr8:65619394	chr8:65714334~65714778:-
BRCA	cis	rs6991838	0.612	rs12335276	ENSG00000272155.1	RP11-707M3.3	-3.81	0.000146	0.00867	-0.11	-0.12	Intelligence (multi-trait analysis);	chr8:65619668	chr8:65714334~65714778:-
BRCA	cis	rs733592	0.524	rs10875726	ENSG00000273765.1	RP11-370I10.11	-3.81	0.000146	0.00867	-0.13	-0.12	Plateletcrit;	chr12:48032209	chr12:48360920~48361377:+
BRCA	cis	rs7221109	0.71	rs1048572	ENSG00000229028.2	KRT223P	-3.81	0.000146	0.00867	-0.14	-0.12	Type 1 diabetes;	chr17:40640990	chr17:40717235~40721932:-
BRCA	cis	rs1005277	0.557	rs2983338	ENSG00000272983.1	RP11-508N22.12	3.81	0.000146	0.00867	0.12	0.12	Extrinsic epigenetic age acceleration;	chr10:38261806	chr10:38137337~38144399:+
BRCA	cis	rs11673344	0.566	rs1968251	ENSG00000233527.7	ZNF529-AS1	-3.81	0.000146	0.00867	-0.13	-0.12	Obesity-related traits;	chr19:37457005	chr19:36573070~36594708:+
BRCA	cis	rs4948102	0.731	rs4689	ENSG00000226278.1	PSPHP1	-3.81	0.000146	0.00868	-0.13	-0.12	Plasma homocysteine levels (post-methionine load test);	chr7:55999323	chr7:55764797~55773288:+
BRCA	cis	rs34217772	0.524	rs41319550	ENSG00000258636.1	CTD-2298J14.2	-3.81	0.000146	0.00868	-0.15	-0.12	Myopia;	chr14:41731076	chr14:41587861~41604856:-
BRCA	cis	rs6893300	0.785	rs6895902	ENSG00000225051.5	HMGB3P22	3.81	0.000146	0.00868	0.15	0.12	Resting heart rate;	chr5:179774846	chr5:179679032~179694768:+
BRCA	cis	rs897984	0.572	rs112906665	ENSG00000279196.1	RP11-1072A3.3	3.81	0.000146	0.00868	0.12	0.12	Dementia with Lewy bodies;	chr16:31028818	chr16:30984630~30988270:-
BRCA	cis	rs73198271	0.586	rs3789850	ENSG00000233609.3	RP11-62H7.2	-3.81	0.000146	0.00868	-0.12	-0.12	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8829335	chr8:8961200~8979025:+
BRCA	cis	rs757081	0.667	rs17473243	ENSG00000184669.7	OR7E14P	-3.81	0.000146	0.00868	-0.17	-0.12	Systolic blood pressure;	chr11:17244712	chr11:17013998~17053024:+
BRCA	cis	rs7260598	1	rs11666415	ENSG00000268442.1	CTD-2027I19.2	3.81	0.000146	0.00868	0.19	0.12	Response to taxane treatment (placlitaxel);	chr19:24045710	chr19:24162370~24163425:-
BRCA	cis	rs12049351	0.774	rs6701186	ENSG00000229367.1	HMGN2P19	3.81	0.000146	0.00868	0.16	0.12	Circulating myeloperoxidase levels (plasma);	chr1:229490739	chr1:229570532~229570796:+
BRCA	cis	rs9925964	0.967	rs889548	ENSG00000260911.2	RP11-196G11.2	3.81	0.000146	0.00868	0.11	0.12	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31126391	chr16:31043150~31049868:+
BRCA	cis	rs4713118	0.516	rs6931858	ENSG00000272009.1	RP1-313I6.12	-3.81	0.000146	0.00868	-0.17	-0.12	Parkinson's disease;	chr6:28110633	chr6:28078792~28081130:-
BRCA	cis	rs17428076	0.872	rs72892835	ENSG00000228389.1	AC068039.4	-3.81	0.000146	0.00868	-0.18	-0.12	Myopia;	chr2:172029711	chr2:171773482~171775844:+
BRCA	cis	rs748404	0.666	rs8027748	ENSG00000205771.5	CATSPER2P1	-3.81	0.000146	0.00868	-0.18	-0.12	Lung cancer;	chr15:43447622	chr15:43726918~43747094:-
BRCA	cis	rs6012564	0.893	rs6012555	ENSG00000227431.4	CSE1L-AS1	-3.81	0.000146	0.00868	-0.15	-0.12	Anger;	chr20:48911205	chr20:49040463~49046044:-
BRCA	cis	rs7689350	0.634	rs9993892	ENSG00000260265.1	RP11-44F21.5	3.81	0.000146	0.00868	0.24	0.12	Classic bladder exstrophy;	chr4:75306196	chr4:75081702~75084717:-
BRCA	cis	rs10456847	0.836	rs13208456	ENSG00000229700.1	RP1-130G2.1	3.81	0.000146	0.00868	0.14	0.12	Chronic periodontitis (mean interproximal clinical attachment level);	chr6:19137726	chr6:20042455~20042940:-
BRCA	cis	rs38055	1	rs38055	ENSG00000247796.2	CTD-2366F13.1	3.81	0.000146	0.00869	0.14	0.12	Acne (severe);	chr5:53264814	chr5:53109842~53115126:+
BRCA	cis	rs10129255	0.957	rs1024349	ENSG00000211958.2	IGHV3-38	3.81	0.000146	0.00869	0.09	0.12	Kawasaki disease;	chr14:106689997	chr14:106410493~106411021:-
BRCA	cis	rs7620503	0.959	rs13079175	ENSG00000228561.2	RP11-114M1.1	3.81	0.000146	0.00869	0.14	0.12	Corneal structure;	chr3:177591745	chr3:177683627~177691250:+
BRCA	cis	rs709400	0.93	rs57447494	ENSG00000258851.1	RP11-894P9.2	-3.81	0.000146	0.00869	-0.14	-0.12	Body mass index;	chr14:103568232	chr14:103553421~103561877:+
BRCA	cis	rs733592	0.507	rs7299704	ENSG00000257763.1	OR5BK1P	3.81	0.000146	0.00869	0.11	0.12	Plateletcrit;	chr12:48050705	chr12:48355792~48356614:-
BRCA	cis	rs943466	1	rs6933568	ENSG00000223837.2	BRD2-IT1	3.81	0.000146	0.00869	0.15	0.12	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;	chr6:33783484	chr6:32970232~32970886:+
BRCA	cis	rs7985	0.901	rs6005133	ENSG00000225783.5	MIAT	-3.81	0.000146	0.00869	-0.1	-0.12	Electroencephalogram traits;	chr22:26681021	chr22:26646428~26676475:+
BRCA	cis	rs73201462	0.908	rs2955098	ENSG00000242551.2	POU5F1P6	-3.81	0.000146	0.00869	-0.2	-0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128260658	chr3:128674735~128677005:-
BRCA	cis	rs6743226	0.603	rs62186421	ENSG00000266621.1	AC104841.1	3.81	0.000146	0.00869	0.14	0.12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in non-smokers;	chr2:241309357	chr2:241245202~241245299:-
BRCA	cis	rs4713118	0.615	rs57252182	ENSG00000219392.1	RP1-265C24.5	-3.81	0.000146	0.00869	-0.16	-0.12	Parkinson's disease;	chr6:27752470	chr6:28115628~28116551:+
BRCA	cis	rs1941184	0.5	rs8096400	ENSG00000266521.1	RP11-650P15.1	3.81	0.000146	0.00869	0.15	0.12	Parkinson's disease (age of onset);	chr18:31437363	chr18:31496645~31497195:-
BRCA	cis	rs11722228	0.522	rs12503195	ENSG00000261490.1	RP11-448G15.3	3.81	0.000146	0.0087	0.11	0.12	Urate levels;Serum uric acid levels;Gout;	chr4:10081148	chr4:10068089~10073019:-
BRCA	cis	rs13126694	0.633	rs6536298	ENSG00000248429.4	RP11-597D13.9	3.81	0.000146	0.0087	0.11	0.12	Blood osmolality (transformed sodium);	chr4:158091213	chr4:158170752~158202877:+
BRCA	cis	rs13126694	0.633	rs11100149	ENSG00000248429.4	RP11-597D13.9	3.81	0.000146	0.0087	0.11	0.12	Blood osmolality (transformed sodium);	chr4:158092138	chr4:158170752~158202877:+
BRCA	cis	rs2562456	0.917	rs9304987	ENSG00000268119.4	CTD-2561J22.5	-3.81	0.000146	0.0087	-0.17	-0.12	Pain;	chr19:21499472	chr19:21444241~21463908:-
BRCA	cis	rs875971	0.545	rs73150604	ENSG00000273142.1	RP11-458F8.4	3.81	0.000146	0.0087	0.12	0.12	Aortic root size;	chr7:66480545	chr7:66902857~66906297:+
BRCA	cis	rs67478160	0.619	rs2368560	ENSG00000269910.1	RP11-73M18.10	3.81	0.000146	0.0087	0.11	0.12	Schizophrenia;	chr14:103806974	chr14:103694516~103695050:-
BRCA	cis	rs10501293	0.917	rs10838003	ENSG00000252652.1	Y_RNA	-3.81	0.000146	0.0087	-0.14	-0.12	Cognitive performance;	chr11:43050438	chr11:43331261~43331356:+
BRCA	cis	rs7572733	0.935	rs11692344	ENSG00000231621.1	AC013264.2	-3.81	0.000146	0.0087	-0.11	-0.12	Dermatomyositis;	chr2:197931139	chr2:197197991~197199273:+
BRCA	cis	rs2998286	0.723	rs332186	ENSG00000237128.1	RP11-351M16.3	3.81	0.000146	0.0087	0.15	0.12	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28624674	chr10:28433008~28495813:-
BRCA	cis	rs17406451	0.759	rs11124934	ENSG00000234936.1	AC010883.5	3.81	0.000146	0.0087	0.11	0.12	Mitochondrial DNA levels;	chr2:43425783	chr2:43229573~43233394:+
BRCA	cis	rs17772222	0.917	rs11159868	ENSG00000258789.1	RP11-507K2.3	-3.81	0.000146	0.0087	-0.15	-0.12	Coronary artery calcification;	chr14:88760528	chr14:88551597~88552493:+
BRCA	cis	rs8180040	0.934	rs62260710	ENSG00000271161.1	BOLA2P2	-3.81	0.000146	0.0087	-0.13	-0.12	Colorectal cancer;	chr3:47522972	chr3:47499841~47500407:+
BRCA	cis	rs8180040	0.966	rs62260711	ENSG00000271161.1	BOLA2P2	-3.81	0.000146	0.0087	-0.13	-0.12	Colorectal cancer;	chr3:47523001	chr3:47499841~47500407:+
BRCA	cis	rs11158026	0.574	rs7152033	ENSG00000258413.1	RP11-665C16.6	-3.81	0.000146	0.0087	-0.16	-0.12	Parkinson's disease;	chr14:54926036	chr14:55262767~55272075:-
BRCA	cis	rs6012564	1	rs11696870	ENSG00000230758.1	SNAP23P	3.81	0.000146	0.0087	0.14	0.12	Anger;	chr20:49109070	chr20:49038357~49038602:-
BRCA	cis	rs6012564	0.963	rs6063355	ENSG00000230758.1	SNAP23P	3.81	0.000146	0.0087	0.14	0.12	Anger;	chr20:49109592	chr20:49038357~49038602:-
BRCA	cis	rs2018683	0.739	rs10233884	ENSG00000233517.1	AC005162.5	-3.81	0.000146	0.0087	-0.14	-0.12	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28932690	chr7:28987028~28988899:+
BRCA	cis	rs7914558	0.646	rs1046778	ENSG00000213277.3	MARCKSL1P1	3.81	0.000146	0.0087	0.14	0.12	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102901727	chr10:103175554~103176094:+
BRCA	cis	rs4664293	0.647	rs10202352	ENSG00000226266.5	AC009961.3	-3.81	0.000146	0.0087	-0.14	-0.12	Monocyte percentage of white cells;	chr2:159571097	chr2:159670708~159712435:-
BRCA	cis	rs4664293	0.647	rs1425040	ENSG00000226266.5	AC009961.3	-3.81	0.000146	0.0087	-0.14	-0.12	Monocyte percentage of white cells;	chr2:159571912	chr2:159670708~159712435:-
BRCA	cis	rs4664293	0.625	rs11693108	ENSG00000226266.5	AC009961.3	-3.81	0.000146	0.0087	-0.14	-0.12	Monocyte percentage of white cells;	chr2:159572076	chr2:159670708~159712435:-
BRCA	cis	rs7487075	0.619	rs6582645	ENSG00000257261.4	RP11-96H19.1	3.81	0.000146	0.00871	0.13	0.12	Itch intensity from mosquito bite;	chr12:46411361	chr12:46383679~46876159:+
BRCA	cis	rs10895275	0.649	rs11225169	ENSG00000277459.1	RP11-732A21.3	3.81	0.000146	0.00871	0.11	0.12	Migraine;	chr11:102220901	chr11:102109827~102110457:-
BRCA	cis	rs911119	0.955	rs1555355	ENSG00000270001.1	RP11-218C14.8	-3.81	0.000146	0.00871	-0.15	-0.12	Chronic kidney disease;	chr20:23613943	chr20:23631826~23632316:-
BRCA	cis	rs2980439	0.525	rs2980508	ENSG00000254153.1	CTA-398F10.2	3.81	0.000146	0.00871	0.14	0.12	Neuroticism;	chr8:8314210	chr8:8456909~8461337:-
BRCA	cis	rs10129255	0.912	rs8009135	ENSG00000232216.1	IGHV3-43	3.81	0.000146	0.00871	0.09	0.12	Kawasaki disease;	chr14:106777528	chr14:106470264~106470800:-
BRCA	cis	rs4499344	0.531	rs863905	ENSG00000267475.1	CTD-2538C1.2	3.81	0.000146	0.00871	0.15	0.12	Mean platelet volume;	chr19:32655497	chr19:32687089~32691750:-
BRCA	cis	rs801193	0.904	rs4718405	ENSG00000223473.2	GS1-124K5.3	3.81	0.000146	0.00871	0.09	0.12	Aortic root size;	chr7:66789659	chr7:66491049~66493566:-
BRCA	cis	rs6090919	0.501	rs34381905	ENSG00000222365.1	SNORD12B	-3.81	0.000146	0.00871	-0.18	-0.12	Intelligence (multi-trait analysis);	chr20:48824319	chr20:49280319~49280409:+
BRCA	cis	rs2749592	0.588	rs2504144	ENSG00000273019.1	RP11-508N22.13	-3.81	0.000146	0.00871	-0.15	-0.12	Age-related hearing impairment (SNP x SNP interaction);	chr10:38094597	chr10:38149968~38150293:+
BRCA	cis	rs6708331	0.941	rs13028968	ENSG00000231024.1	AC092431.3	-3.81	0.000146	0.00871	-0.16	-0.12	Obesity-related traits;	chr2:70179991	chr2:69700192~69713847:-
BRCA	cis	rs6545883	0.965	rs6545872	ENSG00000270820.4	RP11-355B11.2	3.81	0.000146	0.00872	0.13	0.12	Tuberculosis;	chr2:61497433	chr2:61471188~61484130:+
BRCA	cis	rs7727544	0.548	rs2069614	ENSG00000233006.5	AC034220.3	3.81	0.000146	0.00872	0.09	0.12	Blood metabolite levels;	chr5:132071908	chr5:132311285~132369916:-
BRCA	cis	rs6991838	0.584	rs10957361	ENSG00000272155.1	RP11-707M3.3	-3.81	0.000146	0.00872	-0.11	-0.12	Intelligence (multi-trait analysis);	chr8:65619626	chr8:65714334~65714778:-
BRCA	cis	rs10129255	0.957	rs6576233	ENSG00000232216.1	IGHV3-43	3.81	0.000146	0.00872	0.09	0.12	Kawasaki disease;	chr14:106787239	chr14:106470264~106470800:-
BRCA	cis	rs613391	0.536	rs554191	ENSG00000265194.1	RP11-70L8.4	-3.81	0.000146	0.00872	-0.12	-0.12	Quantitative traits;	chr9:22720123	chr9:21858910~21861926:-
BRCA	cis	rs115575488	0.85	rs17185996	ENSG00000231365.4	RP11-418J17.1	3.81	0.000146	0.00872	0.22	0.12	Lobe attachment (rater-scored or self-reported);	chr1:119066109	chr1:119140396~119275973:+
BRCA	cis	rs317865	0.737	rs28516589	ENSG00000263327.5	TAPT1-AS1	-3.81	0.000146	0.00872	-0.21	-0.12	Kidney disease (early stage) in type 1 diabetes;	chr4:16232488	chr4:16226685~16320140:+
BRCA	cis	rs1007738	0.542	rs10838662	ENSG00000200376.1	RNU5E-10P	-3.81	0.000147	0.00872	-0.16	-0.12	Bone mineral density (hip);	chr11:47162566	chr11:47576471~47576588:-
BRCA	cis	rs6453278	0.559	rs4418080	ENSG00000250802.5	ZBED3-AS1	-3.81	0.000147	0.00872	-0.17	-0.12	Autism;	chr5:77099359	chr5:77086740~77166909:+
BRCA	cis	rs1552244	0.572	rs17032426	ENSG00000180385.7	EMC3-AS1	3.81	0.000147	0.00872	0.16	0.12	Alzheimer's disease;	chr3:10125428	chr3:9986893~10006990:+
BRCA	cis	rs13326165	0.585	rs56352611	ENSG00000243224.1	RP5-1157M23.2	-3.81	0.000147	0.00872	-0.19	-0.12	HDL cholesterol levels;HDL cholesterol;	chr3:52304574	chr3:52239258~52241097:+
BRCA	cis	rs1030420	0.848	rs10092151	ENSG00000200714.1	Y_RNA	-3.81	0.000147	0.00872	-0.2	-0.12	Blood metabolite levels;	chr8:66405727	chr8:65592731~65592820:+
BRCA	cis	rs4908760	0.669	rs4908506	ENSG00000232912.4	RP5-1115A15.1	3.81	0.000147	0.00872	0.11	0.12	Vitiligo;	chr1:8668919	chr1:8424645~8434838:+
BRCA	cis	rs524281	0.861	rs2177053	ENSG00000255557.1	RP11-770G2.2	3.81	0.000147	0.00872	0.16	0.12	Electroencephalogram traits;	chr11:66198674	chr11:65745729~65771585:+
BRCA	cis	rs2640806	0.505	rs13262091	ENSG00000253105.4	KB-1448A5.1	3.81	0.000147	0.00872	0.14	0.12	Obesity-related traits;	chr8:96352945	chr8:96371865~96387438:-
BRCA	cis	rs6964587	1	rs12333563	ENSG00000188693.7	CYP51A1-AS1	-3.81	0.000147	0.00872	-0.13	-0.12	Breast cancer;	chr7:92038012	chr7:92134604~92180725:+
BRCA	cis	rs2749592	0.611	rs176888	ENSG00000273019.1	RP11-508N22.13	-3.81	0.000147	0.00872	-0.15	-0.12	Age-related hearing impairment (SNP x SNP interaction);	chr10:38117233	chr10:38149968~38150293:+
BRCA	cis	rs17684571	0.751	rs7775182	ENSG00000231441.1	RP11-472M19.2	3.81	0.000147	0.00872	0.19	0.12	Schizophrenia;	chr6:56831848	chr6:56844002~56864078:+
BRCA	cis	rs1552244	0.572	rs3894321	ENSG00000180385.7	EMC3-AS1	3.81	0.000147	0.00873	0.16	0.12	Alzheimer's disease;	chr3:10127208	chr3:9986893~10006990:+
BRCA	cis	rs875971	0.825	rs4587224	ENSG00000271064.1	RP11-792A8.3	3.81	0.000147	0.00873	0.14	0.12	Aortic root size;	chr7:66271195	chr7:66748838~66749077:-
BRCA	cis	rs875971	0.792	rs6971752	ENSG00000271064.1	RP11-792A8.3	3.81	0.000147	0.00873	0.14	0.12	Aortic root size;	chr7:66272999	chr7:66748838~66749077:-
BRCA	cis	rs875971	0.862	rs10950033	ENSG00000271064.1	RP11-792A8.3	3.81	0.000147	0.00873	0.14	0.12	Aortic root size;	chr7:66274686	chr7:66748838~66749077:-
BRCA	cis	rs875971	0.862	rs11760844	ENSG00000271064.1	RP11-792A8.3	3.81	0.000147	0.00873	0.14	0.12	Aortic root size;	chr7:66274896	chr7:66748838~66749077:-
BRCA	cis	rs8180040	0.726	rs4682844	ENSG00000280667.1	Y_RNA	-3.81	0.000147	0.00873	-0.13	-0.12	Colorectal cancer;	chr3:46941247	chr3:47501083~47501182:+
BRCA	cis	rs7746199	0.736	rs13212318	ENSG00000216901.1	AL022393.7	3.81	0.000147	0.00873	0.3	0.12	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27721062	chr6:28176188~28176674:+
BRCA	cis	rs375066	0.868	rs370190	ENSG00000267191.1	RP11-15A1.2	-3.81	0.000147	0.00873	-0.15	-0.12	Breast cancer;	chr19:43920102	chr19:43902001~43926545:+
BRCA	cis	rs375066	0.935	rs413093	ENSG00000267191.1	RP11-15A1.2	-3.81	0.000147	0.00873	-0.15	-0.12	Breast cancer;	chr19:43922113	chr19:43902001~43926545:+
BRCA	cis	rs11668609	1	rs12609544	ENSG00000268058.1	BNIP3P40	-3.81	0.000147	0.00873	-0.15	-0.12	Response to taxane treatment (docetaxel);	chr19:24142763	chr19:24098425~24098980:-
BRCA	cis	rs2191566	0.576	rs397683	ENSG00000266921.1	RP11-15A1.7	3.81	0.000147	0.00873	0.15	0.12	Acute lymphoblastic leukemia (childhood);	chr19:43989902	chr19:43996896~44002836:-
BRCA	cis	rs1396626	0.926	rs17113706	ENSG00000235501.4	RP4-639F20.1	-3.81	0.000147	0.00873	-0.16	-0.12	Diabetic kidney disease;	chr1:95544715	chr1:94927566~94963270:+
BRCA	cis	rs4886920	0.862	rs11631822	ENSG00000260776.4	RP11-114H24.2	-3.81	0.000147	0.00873	-0.14	-0.12	Neuroticism;	chr15:77815324	chr15:77914217~77926846:-
BRCA	cis	rs748404	1	rs748404	ENSG00000166763.7	STRCP1	3.81	0.000147	0.00873	0.17	0.12	Lung cancer;	chr15:43267033	chr15:43699488~43718184:-
BRCA	cis	rs17767294	0.612	rs9461425	ENSG00000280107.1	AL022393.9	-3.81	0.000147	0.00873	-0.23	-0.12	Parkinson's disease;	chr6:27951910	chr6:28170845~28172521:+
BRCA	cis	rs10129255	0.917	rs8022493	ENSG00000211967.3	IGHV3-53	-3.81	0.000147	0.00873	-0.08	-0.12	Kawasaki disease;	chr14:106781820	chr14:106592676~106593347:-
BRCA	cis	rs754466	0.606	rs55854323	ENSG00000213514.2	RP11-428P16.2	3.81	0.000147	0.00873	0.17	0.12	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77830146	chr10:77730766~77734769:+
BRCA	cis	rs7020830	0.898	rs13284651	ENSG00000230188.1	RP11-405L18.4	3.81	0.000147	0.00873	0.14	0.12	Schizophrenia;	chr9:37222684	chr9:37490421~37490893:-
BRCA	cis	rs28530618	0.603	rs13043743	ENSG00000198547.7	C20orf203	-3.81	0.000147	0.00873	-0.13	-0.12	Birth weight;	chr20:32669281	chr20:32631652~32673941:-
BRCA	cis	rs2041840	0.961	rs2110964	ENSG00000272054.1	RP11-423P10.2	-3.81	0.000147	0.00874	-0.11	-0.12	Chronic lymphocytic leukemia;	chr2:37252816	chr2:37208875~37212677:+
BRCA	cis	rs2274459	1	rs12189725	ENSG00000249346.5	LINC01016	3.81	0.000147	0.00874	0.15	0.12	Obesity (extreme);	chr6:33735617	chr6:33867506~33896914:-
BRCA	cis	rs3820068	0.581	rs6692461	ENSG00000237301.1	RP4-680D5.2	-3.81	0.000147	0.00874	-0.15	-0.12	Systolic blood pressure;	chr1:15601954	chr1:15586136~15603626:-
BRCA	cis	rs3820068	0.581	rs6692489	ENSG00000237301.1	RP4-680D5.2	-3.81	0.000147	0.00874	-0.15	-0.12	Systolic blood pressure;	chr1:15602022	chr1:15586136~15603626:-
BRCA	cis	rs7267979	0.934	rs2261753	ENSG00000276952.1	RP5-965G21.6	3.81	0.000147	0.00874	0.14	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25281655	chr20:25284915~25285588:-
BRCA	cis	rs10487112	0.87	rs6966040	ENSG00000235436.9	DPY19L2P4	-3.81	0.000147	0.00874	-0.13	-0.12	Perceived unattractiveness to mosquitoes;	chr7:90491360	chr7:90119400~90125600:+
BRCA	cis	rs8180040	0.726	rs4682842	ENSG00000280667.1	Y_RNA	-3.81	0.000147	0.00874	-0.13	-0.12	Colorectal cancer;	chr3:46941283	chr3:47501083~47501182:+
BRCA	cis	rs8114671	0.562	rs2273683	ENSG00000126005.14	MMP24-AS1	-3.81	0.000147	0.00874	-0.14	-0.12	Height;	chr20:34921720	chr20:35216462~35278131:-
BRCA	cis	rs747650	0.504	rs11602250	ENSG00000200376.1	RNU5E-10P	-3.81	0.000147	0.00874	-0.16	-0.12	Acne (severe);	chr11:46944179	chr11:47576471~47576588:-
BRCA	cis	rs1075265	0.73	rs4413193	ENSG00000272156.1	RP11-477N3.1	-3.81	0.000147	0.00874	-0.12	-0.12	Chronotype;Morning vs. evening chronotype;	chr2:53710901	chr2:54082554~54085066:+
BRCA	cis	rs6893300	0.922	rs7735702	ENSG00000250999.1	RP11-1379J22.5	3.81	0.000147	0.00874	0.16	0.12	Resting heart rate;	chr5:179705611	chr5:179657762~179664432:+
BRCA	cis	rs7620503	0.765	rs2133594	ENSG00000277241.1	RP11-114M1.3	-3.81	0.000147	0.00874	-0.14	-0.12	Corneal structure;	chr3:177584329	chr3:177700346~177701072:-
BRCA	cis	rs12612435	0.83	rs10189738	ENSG00000226806.1	AC011893.3	-3.81	0.000147	0.00874	-0.14	-0.12	Takotsubo syndrome;	chr2:136377349	chr2:135820191~135823087:+
BRCA	cis	rs4648045	0.734	rs4648051	ENSG00000246560.2	RP11-10L12.4	3.81	0.000147	0.00874	0.14	0.12	Lymphocyte percentage of white cells;	chr4:102593836	chr4:102828055~102844075:+
BRCA	cis	rs6142618	0.562	rs6142616	ENSG00000275576.1	RP5-836N17.4	-3.81	0.000147	0.00874	-0.13	-0.12	Inflammatory bowel disease;	chr20:32126625	chr20:32116171~32116629:+
BRCA	cis	rs10506328	0.509	rs1920046	ENSG00000257550.1	RP11-793H13.3	3.81	0.000147	0.00874	0.14	0.12	Mean platelet volume;	chr12:54276271	chr12:53513984~53517608:+
BRCA	cis	rs17092148	1	rs17092148	ENSG00000206582.1	Y_RNA	-3.81	0.000147	0.00874	-0.17	-0.12	Neuroticism;	chr20:34847358	chr20:34526510~34526606:-
BRCA	cis	rs6964587	1	rs2097739	ENSG00000188693.7	CYP51A1-AS1	-3.81	0.000147	0.00874	-0.13	-0.12	Breast cancer;	chr7:92082152	chr7:92134604~92180725:+
BRCA	cis	rs10986311	0.747	rs2026190	ENSG00000227200.1	RP11-121A14.3	-3.81	0.000147	0.00874	-0.15	-0.12	Vitiligo;	chr9:124260984	chr9:124262876~124265809:+
BRCA	cis	rs818427	0.964	rs434090	ENSG00000279522.1	CTC-487M23.6	3.81	0.000147	0.00875	0.13	0.12	Total body bone mineral density;	chr5:112893826	chr5:112894933~112896531:+
BRCA	cis	rs2274273	0.87	rs17741542	ENSG00000259318.1	RP11-454L9.2	-3.81	0.000147	0.00875	-0.1	-0.12	Protein biomarker;	chr14:55339143	chr14:55394940~55395233:-
BRCA	cis	rs6585424	1	rs56190825	ENSG00000225484.5	NUTM2B-AS1	-3.81	0.000147	0.00875	-0.23	-0.12	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80174980	chr10:79663088~79826594:-
BRCA	cis	rs9844666	0.512	rs9829329	ENSG00000273486.1	RP11-731C17.2	3.81	0.000147	0.00875	0.13	0.12	Height;	chr3:135921818	chr3:136837338~136839021:-
BRCA	cis	rs9844666	0.512	rs9829476	ENSG00000273486.1	RP11-731C17.2	3.81	0.000147	0.00875	0.13	0.12	Height;	chr3:135921914	chr3:136837338~136839021:-
BRCA	cis	rs8114671	0.562	rs6088636	ENSG00000279253.1	RP4-614O4.13	-3.81	0.000147	0.00875	-0.13	-0.12	Height;	chr20:34881943	chr20:35262727~35264187:-
BRCA	cis	rs7267979	1	rs6050631	ENSG00000277938.1	RP5-965G21.3	3.81	0.000147	0.00875	0.14	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25451113	chr20:25229150~25231933:+
BRCA	cis	rs863345	0.604	rs1342946	ENSG00000229914.1	RP11-404O13.4	-3.81	0.000147	0.00875	-0.12	-0.12	Pneumococcal bacteremia;	chr1:158483397	chr1:158195633~158196131:-
BRCA	cis	rs4664293	0.585	rs35081473	ENSG00000230783.1	AC009961.2	3.81	0.000147	0.00875	0.14	0.12	Monocyte percentage of white cells;	chr2:159679970	chr2:159689217~159690291:-
BRCA	cis	rs4664293	0.605	rs7556888	ENSG00000230783.1	AC009961.2	3.81	0.000147	0.00875	0.14	0.12	Monocyte percentage of white cells;	chr2:159683750	chr2:159689217~159690291:-
BRCA	cis	rs12887734	0.524	rs4906364	ENSG00000269940.1	RP11-73M18.7	3.81	0.000147	0.00875	0.13	0.12	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103748005	chr14:103694560~103695170:+
BRCA	cis	rs6696239	0.513	rs2999743	ENSG00000227711.2	RP11-275O4.5	-3.81	0.000147	0.00876	-0.14	-0.12	Height;	chr1:227598205	chr1:227509028~227520477:-
BRCA	cis	rs10514758	0.744	rs72947774	ENSG00000242880.1	RP11-190P13.2	3.81	0.000147	0.00876	0.27	0.12	Urate levels in obese individuals;	chr3:115241998	chr3:115251196~115285347:+
BRCA	cis	rs2991971	0.967	rs12743512	ENSG00000280836.1	AL355480.1	-3.81	0.000147	0.00876	-0.14	-0.12	High light scatter reticulocyte count;	chr1:45488361	chr1:45581219~45581321:-
BRCA	cis	rs73201462	0.901	rs2811532	ENSG00000242551.2	POU5F1P6	-3.81	0.000147	0.00876	-0.19	-0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128273327	chr3:128674735~128677005:-
BRCA	cis	rs73201462	0.908	rs2811531	ENSG00000242551.2	POU5F1P6	-3.81	0.000147	0.00876	-0.19	-0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128273652	chr3:128674735~128677005:-
BRCA	cis	rs73201462	1	rs2955100	ENSG00000242551.2	POU5F1P6	-3.81	0.000147	0.00876	-0.19	-0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128274482	chr3:128674735~128677005:-
BRCA	cis	rs4263408	0.934	rs2381428	ENSG00000224097.5	RP11-472B18.1	3.81	0.000147	0.00876	0.14	0.12	Plasma amyloid beta peptide concentrations (ABx-40);	chr4:39761846	chr4:39480255~39481905:+
BRCA	cis	rs9990333	0.562	rs56038600	ENSG00000207650.1	MIR570	3.81	0.000147	0.00876	0.14	0.12	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196090109	chr3:195699401~195699497:+
BRCA	cis	rs943466	1	rs755495	ENSG00000223837.2	BRD2-IT1	-3.81	0.000147	0.00876	-0.15	-0.12	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;	chr6:33766351	chr6:32970232~32970886:+
BRCA	cis	rs7615952	0.515	rs7630575	ENSG00000248787.1	RP11-666A20.4	-3.81	0.000147	0.00876	-0.18	-0.12	Blood pressure (smoking interaction);	chr3:125963487	chr3:125908005~125910272:-
BRCA	cis	rs875971	0.522	rs6960048	ENSG00000232546.1	RP11-458F8.1	-3.81	0.000147	0.00876	-0.1	-0.12	Aortic root size;	chr7:65943052	chr7:66848496~66858136:+
BRCA	cis	rs8042543	0.593	rs7165900	ENSG00000215302.7	CTD-3092A11.1	-3.81	0.000147	0.00876	-0.16	-0.12	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);	chr15:31419999	chr15:30470779~30507623:+
BRCA	cis	rs8042543	0.707	rs9744263	ENSG00000215302.7	CTD-3092A11.1	-3.81	0.000147	0.00876	-0.16	-0.12	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);	chr15:31423200	chr15:30470779~30507623:+
BRCA	cis	rs74233809	1	rs74444347	ENSG00000236937.2	PTGES3P4	3.81	0.000147	0.00876	0.25	0.12	Birth weight;	chr10:103009518	chr10:102845595~102845950:+
BRCA	cis	rs74233809	1	rs12221335	ENSG00000236937.2	PTGES3P4	3.81	0.000147	0.00876	0.25	0.12	Birth weight;	chr10:103009635	chr10:102845595~102845950:+
BRCA	cis	rs1008375	0.618	rs13129002	ENSG00000249502.1	AC006160.5	-3.81	0.000147	0.00876	-0.14	-0.12	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17565890	chr4:17587467~17614571:-
BRCA	cis	rs1670533	1	rs1010342	ENSG00000251639.2	RP11-20I20.1	3.81	0.000147	0.00876	0.18	0.12	Recombination rate (females);	chr4:1075031	chr4:1100016~1101558:-
BRCA	cis	rs8024893	0.764	rs7182545	ENSG00000270055.1	CTD-3092A11.2	-3.81	0.000147	0.00877	-0.18	-0.12	Red cell distribution width;	chr15:31239638	chr15:30487963~30490313:+
BRCA	cis	rs5758511	0.773	rs62241023	ENSG00000233903.2	Z83851.4	3.81	0.000147	0.00877	0.18	0.12	Birth weight;	chr22:41989425	chr22:42276355~42277052:+
BRCA	cis	rs853679	0.517	rs9283884	ENSG00000261839.1	RP1-265C24.8	-3.81	0.000147	0.00877	-0.16	-0.12	Depression;	chr6:28167882	chr6:28136849~28139678:+
BRCA	cis	rs115769866	0.609	rs2191037	ENSG00000220721.1	OR1F12	3.81	0.000147	0.00877	0.15	0.12	Bipolar disorder;	chr6:28499211	chr6:28073316~28074233:+
BRCA	cis	rs7020830	0.898	rs7857936	ENSG00000260100.1	RP11-220I1.5	-3.81	0.000148	0.00877	-0.14	-0.12	Schizophrenia;	chr9:37078494	chr9:37078813~37079776:-
BRCA	cis	rs13434995	0.513	rs73236153	ENSG00000239040.1	Y_RNA	3.81	0.000148	0.00877	0.14	0.12	Adiponectin levels;	chr4:55585600	chr4:55412636~55412738:+
BRCA	cis	rs875971	0.54	rs736270	ENSG00000223473.2	GS1-124K5.3	3.81	0.000148	0.00877	0.09	0.12	Aortic root size;	chr7:65963835	chr7:66491049~66493566:-
BRCA	cis	rs875971	0.756	rs2901210	ENSG00000273024.4	INTS4P2	3.81	0.000148	0.00877	0.13	0.12	Aortic root size;	chr7:66552518	chr7:65647864~65715661:+
BRCA	cis	rs11098499	1	rs7659194	ENSG00000260404.2	RP11-384K6.6	3.81	0.000148	0.00877	0.11	0.12	Corneal astigmatism;	chr4:119285992	chr4:118591773~118633729:+
BRCA	cis	rs897984	0.553	rs2125293	ENSG00000260082.1	RP11-2C24.5	-3.81	0.000148	0.00878	-0.14	-0.12	Dementia with Lewy bodies;	chr16:30852554	chr16:30821068~30822110:-
BRCA	cis	rs295490	0.748	rs10513063	ENSG00000178631.7	ACTG1P1	-3.81	0.000148	0.00878	-0.23	-0.12	PR interval in Tripanosoma cruzi seropositivity;	chr3:139341586	chr3:139493809~139494937:+
BRCA	cis	rs115575488	0.85	rs17185989	ENSG00000231365.4	RP11-418J17.1	3.81	0.000148	0.00878	0.22	0.12	Lobe attachment (rater-scored or self-reported);	chr1:119035302	chr1:119140396~119275973:+
BRCA	cis	rs6964587	1	rs61244255	ENSG00000188693.7	CYP51A1-AS1	-3.81	0.000148	0.00878	-0.13	-0.12	Breast cancer;	chr7:92122348	chr7:92134604~92180725:+
BRCA	cis	rs6445975	0.915	rs11130633	ENSG00000272182.1	RP11-802O23.3	3.81	0.000148	0.00878	0.13	0.12	Systemic lupus erythematosus;	chr3:58385065	chr3:58428255~58428815:+
BRCA	cis	rs115575488	0.85	rs17023135	ENSG00000236804.1	RPS3AP12	3.81	0.000148	0.00878	0.2	0.12	Lobe attachment (rater-scored or self-reported);	chr1:119038528	chr1:119126539~119127291:-
BRCA	cis	rs4664293	0.647	rs7575924	ENSG00000226266.5	AC009961.3	-3.81	0.000148	0.00878	-0.14	-0.12	Monocyte percentage of white cells;	chr2:159573049	chr2:159670708~159712435:-
BRCA	cis	rs7829975	0.617	rs4841072	ENSG00000254153.1	CTA-398F10.2	-3.81	0.000148	0.00878	-0.14	-0.12	Mood instability;	chr8:8933743	chr8:8456909~8461337:-
BRCA	cis	rs17270561	0.609	rs4711097	ENSG00000272462.2	U91328.19	-3.81	0.000148	0.00878	-0.15	-0.12	Iron status biomarkers;	chr6:25732086	chr6:25992662~26001775:+
BRCA	cis	rs12726943	0.518	rs606189	ENSG00000229989.3	MIR181A1HG	3.81	0.000148	0.00878	0.2	0.12	Perceived unattractiveness to mosquitoes;	chr1:199433751	chr1:198807493~198937429:-
BRCA	cis	rs7429990	0.965	rs7642590	ENSG00000199476.1	Y_RNA	3.81	0.000148	0.00878	0.16	0.12	Educational attainment (years of education);	chr3:48058260	chr3:48288587~48288694:+
BRCA	cis	rs721399	0.752	rs1495743	ENSG00000253671.1	RP11-806O11.1	-3.81	0.000148	0.00878	-0.15	-0.12	Blood metabolite levels;	chr8:18415790	chr8:17808941~17820868:+
BRCA	cis	rs8073765	0.679	rs9914955	ENSG00000266744.1	RP11-131K5.1	3.81	0.000148	0.00878	0.15	0.12	Verbal memory performance (immediate recall change);	chr17:13728544	chr17:13957748~13966952:-
BRCA	cis	rs983392	0.678	rs4938931	ENSG00000275344.1	MIR6503	3.81	0.000148	0.00878	0.12	0.12	Alzheimer's disease (late onset);	chr11:60259140	chr11:60209071~60209156:-
BRCA	cis	rs7267979	0.933	rs1130694	ENSG00000125804.12	FAM182A	-3.81	0.000148	0.00878	-0.15	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25295661	chr20:26054655~26086917:+
BRCA	cis	rs1949733	1	rs1357481	ENSG00000205959.3	RP11-689P11.2	-3.81	0.000148	0.00878	-0.12	-0.12	Response to antineoplastic agents;	chr4:8494494	chr4:8482270~8512610:+
BRCA	cis	rs6121246	0.609	rs6089054	ENSG00000230613.1	HM13-AS1	3.81	0.000148	0.00878	0.16	0.12	Mean corpuscular hemoglobin;	chr20:31735338	chr20:31567707~31573263:-
BRCA	cis	rs6087771	0.851	rs6087775	ENSG00000230613.1	HM13-AS1	3.81	0.000148	0.00878	0.16	0.12	Putamen volume;Subcortical brain region volumes;	chr20:31737962	chr20:31567707~31573263:-
BRCA	cis	rs6121246	0.609	rs4453755	ENSG00000230613.1	HM13-AS1	3.81	0.000148	0.00878	0.16	0.12	Mean corpuscular hemoglobin;	chr20:31743244	chr20:31567707~31573263:-
BRCA	cis	rs4664293	0.647	rs1966530	ENSG00000224152.1	AC009506.1	-3.81	0.000148	0.00878	-0.12	-0.12	Monocyte percentage of white cells;	chr2:159620897	chr2:159615296~159617082:+
BRCA	cis	rs8060686	0.516	rs7193701	ENSG00000263276.1	RP11-96D1.10	3.81	0.000148	0.00878	0.14	0.12	HDL cholesterol;Metabolic syndrome;	chr16:68151257	chr16:68224713~68227734:+
BRCA	cis	rs3764021	0.527	rs10844380	ENSG00000256594.6	RP11-705C15.2	3.81	0.000148	0.00879	0.16	0.12	Type 1 diabetes;	chr12:9670678	chr12:9633419~9658412:+
BRCA	cis	rs1670533	1	rs2045068	ENSG00000251639.2	RP11-20I20.1	3.81	0.000148	0.00879	0.19	0.12	Recombination rate (females);	chr4:1058424	chr4:1100016~1101558:-
BRCA	cis	rs2998286	0.723	rs332177	ENSG00000237128.1	RP11-351M16.3	3.81	0.000148	0.00879	0.15	0.12	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28618221	chr10:28433008~28495813:-
BRCA	cis	rs886774	0.834	rs10215427	ENSG00000273055.1	CTB-13F3.1	3.81	0.000148	0.00879	0.12	0.12	Ulcerative colitis;	chr7:107857797	chr7:107942116~107942740:+
BRCA	cis	rs875971	0.862	rs7783779	ENSG00000229886.1	RP5-1132H15.3	-3.81	0.000148	0.00879	-0.13	-0.12	Aortic root size;	chr7:66331639	chr7:66025126~66031544:-
BRCA	cis	rs4908769	0.624	rs3765971	ENSG00000221083.1	SNORA77	-3.81	0.000148	0.00879	-0.13	-0.12	Allergy;	chr1:8385300	chr1:8511795~8511919:-
BRCA	cis	rs6452524	0.935	rs9293330	ENSG00000281327.1	LINC01338	3.81	0.000148	0.00879	0.13	0.12	Hypertension (SNP x SNP interaction);	chr5:83102299	chr5:82850864~82859836:-
BRCA	cis	rs739401	0.566	rs7931504	ENSG00000183562.3	CTC-343N3.1	-3.81	0.000148	0.00879	-0.12	-0.12	Longevity;	chr11:3005482	chr11:2989863~2991344:+
BRCA	cis	rs10849893	0.538	rs10744762	ENSG00000258435.1	RP11-711D18.2	3.81	0.000148	0.00879	0.13	0.12	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr12:121401898	chr12:121391962~121399859:+
BRCA	cis	rs11931598	0.511	rs4689576	ENSG00000245468.3	RP11-367J11.3	3.81	0.000148	0.00879	0.11	0.12	Sum basophil neutrophil counts;Neutrophil count;Granulocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;	chr4:7023796	chr4:7094571~7103385:-
BRCA	cis	rs61160187	0.582	rs2898309	ENSG00000272308.1	RP11-231G3.1	-3.81	0.000148	0.0088	-0.13	-0.12	Educational attainment (years of education);Educational attainment (college completion);	chr5:60981546	chr5:60866457~60866935:-
BRCA	cis	rs801193	1	rs2707856	ENSG00000223473.2	GS1-124K5.3	3.81	0.000148	0.0088	0.09	0.12	Aortic root size;	chr7:66746023	chr7:66491049~66493566:-
BRCA	cis	rs1396626	0.926	rs12083741	ENSG00000235501.4	RP4-639F20.1	-3.81	0.000148	0.0088	-0.16	-0.12	Diabetic kidney disease;	chr1:95540812	chr1:94927566~94963270:+
BRCA	cis	rs1396626	0.926	rs6659085	ENSG00000235501.4	RP4-639F20.1	-3.81	0.000148	0.0088	-0.16	-0.12	Diabetic kidney disease;	chr1:95541189	chr1:94927566~94963270:+
BRCA	cis	rs11668609	0.506	rs8113480	ENSG00000268442.1	CTD-2027I19.2	-3.81	0.000148	0.0088	-0.2	-0.12	Response to taxane treatment (docetaxel);	chr19:23878217	chr19:24162370~24163425:-
BRCA	cis	rs2562456	0.917	rs2562468	ENSG00000268555.1	RP11-678G14.3	-3.81	0.000148	0.0088	-0.15	-0.12	Pain;	chr19:21532048	chr19:21570822~21587322:-
BRCA	cis	rs2562456	0.917	rs2562471	ENSG00000268555.1	RP11-678G14.3	-3.81	0.000148	0.0088	-0.15	-0.12	Pain;	chr19:21533017	chr19:21570822~21587322:-
BRCA	cis	rs6012564	0.964	rs6125577	ENSG00000230758.1	SNAP23P	3.81	0.000148	0.0088	0.14	0.12	Anger;	chr20:49166558	chr20:49038357~49038602:-
BRCA	cis	rs2731006	0.901	rs2678114	ENSG00000257114.2	RP11-25I15.3	3.81	0.000148	0.0088	0.18	0.12	Panic disorder;	chr12:42766681	chr12:42692216~42717119:+
BRCA	cis	rs584438	0.873	rs584828	ENSG00000279806.1	RP11-58O9.2	3.81	0.000148	0.0088	0.16	0.12	Height;	chr17:40442978	chr17:40473554~40475289:-
BRCA	cis	rs2018683	0.707	rs4722878	ENSG00000233517.1	AC005162.5	-3.81	0.000148	0.0088	-0.14	-0.12	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28933414	chr7:28987028~28988899:+
BRCA	cis	rs7487075	0.619	rs67249026	ENSG00000257261.4	RP11-96H19.1	3.81	0.000148	0.0088	0.13	0.12	Itch intensity from mosquito bite;	chr12:46441985	chr12:46383679~46876159:+
BRCA	cis	rs1437396	0.657	rs2589077	ENSG00000203327.2	AC012358.7	3.81	0.000148	0.0088	0.12	0.12	Alcohol dependence;	chr2:55343949	chr2:55214387~55216126:-
BRCA	cis	rs5742933	1	rs5742933	ENSG00000253559.1	OSGEPL1-AS1	-3.81	0.000148	0.0088	-0.16	-0.12	Ferritin levels;	chr2:189784590	chr2:189762704~189765556:+
BRCA	cis	rs6964833	1	rs4717907	ENSG00000277072.3	STAG3L2	3.81	0.000148	0.0088	0.12	0.12	Menarche (age at onset);	chr7:74672169	chr7:74882163~74890610:-
BRCA	cis	rs983392	0.792	rs514266	ENSG00000275344.1	MIR6503	-3.81	0.000148	0.0088	-0.12	-0.12	Alzheimer's disease (late onset);	chr11:60110224	chr11:60209071~60209156:-
BRCA	cis	rs875971	0.862	rs949930	ENSG00000271064.1	RP11-792A8.3	3.81	0.000148	0.0088	0.14	0.12	Aortic root size;	chr7:66301835	chr7:66748838~66749077:-
BRCA	cis	rs11673344	0.566	rs7254009	ENSG00000267422.1	CTD-2554C21.1	-3.81	0.000148	0.0088	-0.15	-0.12	Obesity-related traits;	chr19:37427707	chr19:37779686~37792865:+
BRCA	cis	rs10463316	0.894	rs6875014	ENSG00000260581.1	CTB-113P19.4	3.81	0.000148	0.0088	0.13	0.12	Metabolite levels (Pyroglutamine);	chr5:151374784	chr5:151652275~151655449:+
BRCA	cis	rs6671200	1	rs34396223	ENSG00000226026.4	RP11-57H12.3	3.81	0.000148	0.00881	0.26	0.12	Stearic acid (18:0) levels;	chr1:95232272	chr1:95163219~95233982:-
BRCA	cis	rs6828577	0.862	rs298998	ENSG00000281731.1	RP11-384K6.8	3.81	0.000148	0.00881	0.13	0.12	Perioperative myocardial infarction in coronary artery bypass surgery;	chr4:118702312	chr4:118664087~118685341:-
BRCA	cis	rs7949566	0.557	rs2230279	ENSG00000254671.2	STT3A-AS1	-3.81	0.000148	0.00881	-0.15	-0.12	Platelet distribution width;Mean platelet volume;	chr11:126408180	chr11:125570284~125592568:-
BRCA	cis	rs10028773	0.6	rs4001390	ENSG00000260404.2	RP11-384K6.6	3.81	0.000148	0.00881	0.1	0.12	Educational attainment;	chr4:119344628	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.691	rs2136911	ENSG00000260404.2	RP11-384K6.6	3.81	0.000148	0.00881	0.1	0.12	Corneal astigmatism;	chr4:119344704	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.779	rs6815934	ENSG00000260404.2	RP11-384K6.6	3.81	0.000148	0.00881	0.1	0.12	Corneal astigmatism;	chr4:119346155	chr4:118591773~118633729:+
BRCA	cis	rs10028773	0.568	rs6838457	ENSG00000260404.2	RP11-384K6.6	3.81	0.000148	0.00881	0.1	0.12	Educational attainment;	chr4:119346212	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.535	rs10005542	ENSG00000260404.2	RP11-384K6.6	3.81	0.000148	0.00881	0.1	0.12	Corneal astigmatism;	chr4:119347147	chr4:118591773~118633729:+
BRCA	cis	rs6964587	1	rs1859114	ENSG00000188693.7	CYP51A1-AS1	-3.81	0.000148	0.00881	-0.13	-0.12	Breast cancer;	chr7:92053534	chr7:92134604~92180725:+
BRCA	cis	rs73201462	1	rs2999062	ENSG00000242551.2	POU5F1P6	-3.81	0.000148	0.00881	-0.19	-0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128274763	chr3:128674735~128677005:-
BRCA	cis	rs10266483	0.545	rs116760071	ENSG00000271550.1	BNIP3P11	-3.81	0.000148	0.00881	-0.17	-0.12	Response to statin therapy;	chr7:64289082	chr7:64678954~64687393:-
BRCA	cis	rs7917772	0.503	rs7093285	ENSG00000213061.2	PFN1P11	-3.81	0.000148	0.00881	-0.16	-0.12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;	chr10:102615058	chr10:102838011~102845473:-
BRCA	cis	rs875971	0.545	rs6969224	ENSG00000232559.3	GS1-124K5.12	3.81	0.000148	0.00881	0.16	0.12	Aortic root size;	chr7:66370011	chr7:66554588~66576923:-
BRCA	cis	rs8114671	0.562	rs6088653	ENSG00000126005.14	MMP24-AS1	-3.81	0.000148	0.00881	-0.13	-0.12	Height;	chr20:34932518	chr20:35216462~35278131:-
BRCA	cis	rs2039553	0.548	rs35661635	ENSG00000227354.5	RBM26-AS1	-3.81	0.000148	0.00881	-0.13	-0.12	Pancreatic cancer;	chr13:79752710	chr13:79406309~79424328:+
BRCA	cis	rs73201462	0.831	rs2811524	ENSG00000242551.2	POU5F1P6	-3.81	0.000148	0.00881	-0.19	-0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128281112	chr3:128674735~128677005:-
BRCA	cis	rs6751744	0.513	rs10173538	ENSG00000226266.5	AC009961.3	-3.81	0.000148	0.00882	-0.14	-0.12	Dysphagia;	chr2:159712765	chr2:159670708~159712435:-
BRCA	cis	rs1665650	0.914	rs7096380	ENSG00000232767.1	RP11-498B4.5	3.81	0.000148	0.00882	0.12	0.12	Colorectal cancer;	chr10:116728905	chr10:116670103~116672739:+
BRCA	cis	rs4073582	0.595	rs801734	ENSG00000255320.1	RP11-755F10.1	-3.81	0.000148	0.00882	-0.15	-0.12	Gout;	chr11:66163745	chr11:66244840~66246239:-
BRCA	cis	rs2289328	0.825	rs35777573	ENSG00000259211.1	RP11-64K12.8	3.81	0.000148	0.00882	0.18	0.12	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr15:40352045	chr15:40464193~40466726:-
BRCA	cis	rs6431644	0.694	rs654279	ENSG00000224287.2	MSL3P1	3.81	0.000148	0.00882	0.14	0.12	Left atrial antero-posterior diameter;	chr2:233852136	chr2:233865437~233868444:-
BRCA	cis	rs11668609	0.766	rs10414075	ENSG00000268058.1	BNIP3P40	-3.81	0.000148	0.00882	-0.14	-0.12	Response to taxane treatment (docetaxel);	chr19:24055649	chr19:24098425~24098980:-
BRCA	cis	rs4374383	0.631	rs11681295	ENSG00000243389.1	AC012442.5	-3.81	0.000148	0.00882	-0.15	-0.12	Hepatitis C induced liver fibrosis;	chr2:111927859	chr2:112589040~112614431:+
BRCA	cis	rs13217239	0.646	rs6937880	ENSG00000124549.13	BTN2A3P	3.81	0.000149	0.00882	0.12	0.12	Schizophrenia;	chr6:27032457	chr6:26421391~26432383:+
BRCA	cis	rs3742264	0.656	rs9534281	ENSG00000235903.6	CPB2-AS1	-3.81	0.000149	0.00882	-0.14	-0.12	Blood protein levels;	chr13:46012841	chr13:46052806~46113332:+
BRCA	cis	rs10510102	0.516	rs79528809	ENSG00000226864.1	ATE1-AS1	3.81	0.000149	0.00882	0.23	0.12	Breast cancer;	chr10:121980309	chr10:121928312~121951965:+
BRCA	cis	rs12289961	0.681	rs17152534	ENSG00000265566.2	RN7SL605P	3.81	0.000149	0.00883	0.2	0.12	Lymphoma;	chr11:58229282	chr11:57528085~57528365:-
BRCA	cis	rs4664293	0.647	rs6734085	ENSG00000226266.5	AC009961.3	-3.81	0.000149	0.00883	-0.14	-0.12	Monocyte percentage of white cells;	chr2:159595711	chr2:159670708~159712435:-
BRCA	cis	rs6747972	0.812	rs2116050	ENSG00000236259.1	AC017083.2	-3.81	0.000149	0.00883	-0.13	-0.12	Restless legs syndrome;	chr2:67845631	chr2:68125265~68125747:+
BRCA	cis	rs6600671	1	rs4844380	ENSG00000275131.1	CH17-472G23.4	-3.81	0.000149	0.00883	-0.11	-0.12	Hip geometry;	chr1:121451764	chr1:120489625~120579190:-
BRCA	cis	rs73201462	1	rs2811511	ENSG00000242551.2	POU5F1P6	3.81	0.000149	0.00883	0.2	0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128194145	chr3:128674735~128677005:-
BRCA	cis	rs8030605	0.778	rs795785	ENSG00000277245.1	RP11-48G14.3	-3.81	0.000149	0.00883	-0.25	-0.12	Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;	chr15:56427599	chr15:56447120~56447697:+
BRCA	cis	rs3742264	0.656	rs9534280	ENSG00000235903.6	CPB2-AS1	-3.81	0.000149	0.00883	-0.14	-0.12	Blood protein levels;	chr13:46010916	chr13:46052806~46113332:+
BRCA	cis	rs3742264	0.656	rs4941538	ENSG00000235903.6	CPB2-AS1	-3.81	0.000149	0.00883	-0.14	-0.12	Blood protein levels;	chr13:46012474	chr13:46052806~46113332:+
BRCA	cis	rs8062405	1	rs8055138	ENSG00000261766.1	RP11-22P6.2	-3.81	0.000149	0.00883	-0.12	-0.12	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28880144	chr16:28862166~28863340:-
BRCA	cis	rs13217239	0.621	rs12527231	ENSG00000124549.13	BTN2A3P	3.81	0.000149	0.00883	0.12	0.12	Schizophrenia;	chr6:27033509	chr6:26421391~26432383:+
BRCA	cis	rs13217239	0.646	rs12523820	ENSG00000124549.13	BTN2A3P	3.81	0.000149	0.00883	0.12	0.12	Schizophrenia;	chr6:27033723	chr6:26421391~26432383:+
BRCA	cis	rs2030746	0.521	rs1534099	ENSG00000237614.1	AC073257.2	3.81	0.000149	0.00883	0.14	0.12	LDL cholesterol;Total cholesterol levels;LDL cholesterol levels;	chr2:120570284	chr2:120542909~120544326:-
BRCA	cis	rs801193	0.613	rs2659900	ENSG00000265600.1	AC006480.1	-3.81	0.000149	0.00884	-0.14	-0.12	Aortic root size;	chr7:66719456	chr7:67356680~67356779:+
BRCA	cis	rs875971	0.66	rs801192	ENSG00000275400.1	RP4-756H11.5	3.81	0.000149	0.00884	0.13	0.12	Aortic root size;	chr7:66566965	chr7:66553805~66554199:-
BRCA	cis	rs875971	0.66	rs801190	ENSG00000275400.1	RP4-756H11.5	3.81	0.000149	0.00884	0.13	0.12	Aortic root size;	chr7:66568046	chr7:66553805~66554199:-
BRCA	cis	rs875971	0.66	rs3857686	ENSG00000275400.1	RP4-756H11.5	3.81	0.000149	0.00884	0.13	0.12	Aortic root size;	chr7:66571204	chr7:66553805~66554199:-
BRCA	cis	rs17027633	1	rs76261890	ENSG00000234020.1	CHIAP3	-3.81	0.000149	0.00884	-0.27	-0.12	Cerebrospinal fluid t-tau:AB1-42 ratio;	chr1:111416225	chr1:111353275~111367409:-
BRCA	cis	rs7119167	0.543	rs11235807	ENSG00000202522.1	Y_RNA	-3.81	0.000149	0.00884	-0.17	-0.12	Blood protein levels;	chr11:73561194	chr11:72766004~72766116:+
BRCA	cis	rs6600671	0.934	rs11249429	ENSG00000275131.1	CH17-472G23.4	3.81	0.000149	0.00884	0.11	0.12	Hip geometry;	chr1:121549282	chr1:120489625~120579190:-
BRCA	cis	rs7267979	1	rs6115146	ENSG00000277938.1	RP5-965G21.3	-3.81	0.000149	0.00884	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25323871	chr20:25229150~25231933:+
BRCA	cis	rs7267979	0.934	rs6037085	ENSG00000277938.1	RP5-965G21.3	-3.81	0.000149	0.00884	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25324566	chr20:25229150~25231933:+
BRCA	cis	rs7487075	0.619	rs9971879	ENSG00000257261.4	RP11-96H19.1	3.81	0.000149	0.00884	0.13	0.12	Itch intensity from mosquito bite;	chr12:46412990	chr12:46383679~46876159:+
BRCA	cis	rs7487075	0.619	rs4768710	ENSG00000257261.4	RP11-96H19.1	3.81	0.000149	0.00884	0.13	0.12	Itch intensity from mosquito bite;	chr12:46414321	chr12:46383679~46876159:+
BRCA	cis	rs7487075	0.578	rs1492895	ENSG00000257261.4	RP11-96H19.1	3.81	0.000149	0.00884	0.13	0.12	Itch intensity from mosquito bite;	chr12:46414972	chr12:46383679~46876159:+
BRCA	cis	rs7487075	0.578	rs2897951	ENSG00000257261.4	RP11-96H19.1	3.81	0.000149	0.00884	0.13	0.12	Itch intensity from mosquito bite;	chr12:46415423	chr12:46383679~46876159:+
BRCA	cis	rs7487075	0.578	rs10880967	ENSG00000257261.4	RP11-96H19.1	3.81	0.000149	0.00884	0.13	0.12	Itch intensity from mosquito bite;	chr12:46418240	chr12:46383679~46876159:+
BRCA	cis	rs56114371	0.53	rs2056923	ENSG00000204789.4	ZNF204P	3.81	0.000149	0.00884	0.2	0.12	Breast cancer;	chr6:27722160	chr6:27357825~27360221:-
BRCA	cis	rs453301	0.606	rs6601279	ENSG00000233609.3	RP11-62H7.2	-3.81	0.000149	0.00884	-0.11	-0.12	Joint mobility (Beighton score);	chr8:9050721	chr8:8961200~8979025:+
BRCA	cis	rs453301	0.606	rs6981060	ENSG00000233609.3	RP11-62H7.2	-3.81	0.000149	0.00884	-0.11	-0.12	Joint mobility (Beighton score);	chr8:9050725	chr8:8961200~8979025:+
BRCA	cis	rs62025270	0.632	rs8029034	ENSG00000259367.1	RP11-815J21.4	3.81	0.000149	0.00884	0.11	0.12	Idiopathic pulmonary fibrosis;	chr15:85582497	chr15:85619623~85670948:-
BRCA	cis	rs4542783	1	rs4072910	ENSG00000267986.1	AC130469.2	3.81	0.000149	0.00884	0.13	0.12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr19:8579147	chr19:8581160~8582715:+
BRCA	cis	rs12439619	0.846	rs62013464	ENSG00000259429.4	UBE2Q2P2	-3.81	0.000149	0.00884	-0.14	-0.12	Intelligence (multi-trait analysis);	chr15:82288250	chr15:82355142~82420075:+
BRCA	cis	rs2274273	0.682	rs10145268	ENSG00000233924.1	AL160471.6	-3.81	0.000149	0.00884	-0.13	-0.12	Protein biomarker;	chr14:55037796	chr14:55004813~55005687:-
BRCA	cis	rs801193	0.527	rs2707837	ENSG00000229886.1	RP5-1132H15.3	3.81	0.000149	0.00884	0.13	0.12	Aortic root size;	chr7:66716086	chr7:66025126~66031544:-
BRCA	cis	rs3735485	0.689	rs10235778	ENSG00000201772.1	SNORA5C	-3.81	0.000149	0.00884	-0.15	-0.12	White blood cell count;Sum basophil neutrophil counts;Neutrophil count;Granulocyte percentage of myeloid white cells;Monocyte percentage of white cells;Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Lymphocyte counts;	chr7:45010607	chr7:45104906~45105042:-
BRCA	cis	rs853679	1	rs1679709	ENSG00000216901.1	AL022393.7	-3.81	0.000149	0.00884	-0.2	-0.12	Depression;	chr6:28260564	chr6:28176188~28176674:+
BRCA	cis	rs1437396	0.657	rs7582580	ENSG00000203327.2	AC012358.7	3.81	0.000149	0.00884	0.12	0.12	Alcohol dependence;	chr2:55360802	chr2:55214387~55216126:-
BRCA	cis	rs7523050	0.908	rs17621536	ENSG00000203897.3	SPATA42	-3.81	0.000149	0.00884	-0.2	-0.12	Fat distribution (HIV);	chr1:108854286	chr1:108857217~108858524:+
BRCA	cis	rs7045881	0.735	rs10967594	ENSG00000254396.1	RP11-56F10.3	3.81	0.000149	0.00885	0.17	0.12	Schizophrenia;	chr9:26910953	chr9:27102630~27104728:+
BRCA	cis	rs516805	0.667	rs928011	ENSG00000279114.1	RP3-425C14.5	3.81	0.000149	0.00885	0.15	0.12	Lymphocyte counts;	chr6:122248991	chr6:122471923~122484161:+
BRCA	cis	rs875971	0.638	rs7793569	ENSG00000265600.1	AC006480.1	3.81	0.000149	0.00885	0.14	0.12	Aortic root size;	chr7:66651646	chr7:67356680~67356779:+
BRCA	cis	rs801193	1	rs3857688	ENSG00000265600.1	AC006480.1	3.81	0.000149	0.00885	0.14	0.12	Aortic root size;	chr7:66662819	chr7:67356680~67356779:+
BRCA	cis	rs801193	1	rs2286684	ENSG00000265600.1	AC006480.1	3.81	0.000149	0.00885	0.14	0.12	Aortic root size;	chr7:66664843	chr7:67356680~67356779:+
BRCA	cis	rs801193	0.935	rs2286683	ENSG00000265600.1	AC006480.1	3.81	0.000149	0.00885	0.14	0.12	Aortic root size;	chr7:66664856	chr7:67356680~67356779:+
BRCA	cis	rs801193	1	rs10274773	ENSG00000265600.1	AC006480.1	3.81	0.000149	0.00885	0.14	0.12	Aortic root size;	chr7:66668591	chr7:67356680~67356779:+
BRCA	cis	rs2625529	0.824	rs2279283	ENSG00000260037.4	CTD-2524L6.3	-3.81	0.000149	0.00885	-0.17	-0.12	Red blood cell count;	chr15:71951325	chr15:71818396~71823384:+
BRCA	cis	rs111669836	1	rs111669836	ENSG00000245532.5	NEAT1	3.81	0.000149	0.00885	0.12	0.12	Type 2 diabetes;	chr11:65596914	chr11:65422774~65445540:+
BRCA	cis	rs10043775	0.958	rs10055430	ENSG00000251330.3	CTD-2283N19.1	-3.81	0.000149	0.00885	-0.13	-0.12	Periodontal microbiota;	chr5:148417976	chr5:148430159~148430807:-
BRCA	cis	rs2391285	0.609	rs2107996	ENSG00000280255.1	RP5-1007F24.1	3.81	0.000149	0.00885	0.17	0.12	Post bronchodilator FEV1/FVC ratio;	chr7:26558871	chr7:26538378~26541048:+
BRCA	cis	rs8114671	0.562	rs6087641	ENSG00000279253.1	RP4-614O4.13	-3.81	0.000149	0.00885	-0.13	-0.12	Height;	chr20:34879914	chr20:35262727~35264187:-
BRCA	cis	rs4962416	0.916	rs12769019	ENSG00000199466.1	Y_RNA	-3.81	0.000149	0.00885	-0.15	-0.12	Prostate cancer (SNP x SNP interaction);Prostate cancer;	chr10:125008758	chr10:124766196~124766297:+
BRCA	cis	rs11039100	1	rs61875914	ENSG00000224295.2	AC087380.14	3.81	0.000149	0.00885	0.22	0.12	Peripheral arterial disease (traffic-related air pollution interaction);	chr11:5807069	chr11:5518441~5524955:-
BRCA	cis	rs11039100	1	rs61875915	ENSG00000224295.2	AC087380.14	3.81	0.000149	0.00885	0.22	0.12	Peripheral arterial disease (traffic-related air pollution interaction);	chr11:5807338	chr11:5518441~5524955:-
BRCA	cis	rs11039100	1	rs4319539	ENSG00000224295.2	AC087380.14	3.81	0.000149	0.00885	0.22	0.12	Peripheral arterial disease (traffic-related air pollution interaction);	chr11:5807616	chr11:5518441~5524955:-
BRCA	cis	rs11039100	1	rs4474469	ENSG00000224295.2	AC087380.14	3.81	0.000149	0.00885	0.22	0.12	Peripheral arterial disease (traffic-related air pollution interaction);	chr11:5807619	chr11:5518441~5524955:-
BRCA	cis	rs61160187	0.556	rs62367862	ENSG00000272308.1	RP11-231G3.1	-3.81	0.000149	0.00885	-0.13	-0.12	Educational attainment (years of education);Educational attainment (college completion);	chr5:60973134	chr5:60866457~60866935:-
BRCA	cis	rs1008375	1	rs11722037	ENSG00000249502.1	AC006160.5	-3.81	0.000149	0.00886	-0.13	-0.12	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17682188	chr4:17587467~17614571:-
BRCA	cis	rs1005277	0.579	rs1780133	ENSG00000272983.1	RP11-508N22.12	3.81	0.000149	0.00886	0.12	0.12	Extrinsic epigenetic age acceleration;	chr10:38210581	chr10:38137337~38144399:+
BRCA	cis	rs7267979	1	rs6050599	ENSG00000276952.1	RP5-965G21.6	-3.81	0.000149	0.00886	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25419604	chr20:25284915~25285588:-
BRCA	cis	rs4835473	0.932	rs5015757	ENSG00000246448.2	RP13-578N3.3	3.81	0.000149	0.00886	0.13	0.12	Immature fraction of reticulocytes;	chr4:143738144	chr4:143700257~143865072:+
BRCA	cis	rs7267979	1	rs2387881	ENSG00000125804.12	FAM182A	3.81	0.000149	0.00886	0.15	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25397536	chr20:26054655~26086917:+
BRCA	cis	rs524281	0.861	rs11227411	ENSG00000255038.1	RP11-1167A19.2	-3.81	0.000149	0.00886	-0.17	-0.12	Electroencephalogram traits;	chr11:66112007	chr11:66067277~66069619:-
BRCA	cis	rs2625529	0.652	rs8023788	ENSG00000260037.4	CTD-2524L6.3	3.81	0.000149	0.00886	0.15	0.12	Red blood cell count;	chr15:72167506	chr15:71818396~71823384:+
BRCA	cis	rs2625529	0.617	rs8025939	ENSG00000260037.4	CTD-2524L6.3	3.81	0.000149	0.00886	0.15	0.12	Red blood cell count;	chr15:72167998	chr15:71818396~71823384:+
BRCA	cis	rs7577696	0.853	rs212698	ENSG00000276334.1	AL133243.1	3.81	0.000149	0.00886	0.15	0.12	Inflammatory biomarkers;	chr2:32217928	chr2:32521927~32523547:+
BRCA	cis	rs1325195	0.507	rs10798652	ENSG00000227141.2	RP11-545A16.3	-3.81	0.000149	0.00886	-0.14	-0.12	IgE grass sensitization;	chr1:179092292	chr1:179586705~179589175:+
BRCA	cis	rs530081	0.531	rs580924	ENSG00000274184.1	RP11-158H5.8	3.81	0.000149	0.00886	0.14	0.12	Lobe attachment (rater-scored or self-reported);	chr18:35188820	chr18:35268218~35270238:+
BRCA	cis	rs6785206	1	rs2712370	ENSG00000242551.2	POU5F1P6	-3.81	0.000149	0.00886	-0.22	-0.12	Lymphocyte percentage of white cells;	chr3:128706361	chr3:128674735~128677005:-
BRCA	cis	rs7267979	0.934	rs2261115	ENSG00000277938.1	RP5-965G21.3	3.81	0.000149	0.00886	0.14	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25279171	chr20:25229150~25231933:+
BRCA	cis	rs301807	0.533	rs1466654	ENSG00000221083.1	SNORA77	3.81	0.000149	0.00886	0.11	0.12	Vitiligo;Sum eosinophil basophil counts;	chr1:8315853	chr1:8511795~8511919:-
BRCA	cis	rs6964587	1	rs7811564	ENSG00000188693.7	CYP51A1-AS1	-3.81	0.000149	0.00886	-0.13	-0.12	Breast cancer;	chr7:92034050	chr7:92134604~92180725:+
BRCA	cis	rs6964587	0.967	rs7781221	ENSG00000188693.7	CYP51A1-AS1	-3.81	0.000149	0.00886	-0.13	-0.12	Breast cancer;	chr7:92035331	chr7:92134604~92180725:+
BRCA	cis	rs6964587	1	rs2285333	ENSG00000188693.7	CYP51A1-AS1	-3.81	0.000149	0.00886	-0.13	-0.12	Breast cancer;	chr7:92038378	chr7:92134604~92180725:+
BRCA	cis	rs7746199	0.668	rs7749305	ENSG00000216901.1	AL022393.7	3.81	0.000149	0.00886	0.25	0.12	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27478787	chr6:28176188~28176674:+
BRCA	cis	rs801193	1	rs10252765	ENSG00000223473.2	GS1-124K5.3	3.81	0.000149	0.00886	0.09	0.12	Aortic root size;	chr7:66763745	chr7:66491049~66493566:-
BRCA	cis	rs863345	0.625	rs10908655	ENSG00000229914.1	RP11-404O13.4	-3.81	0.000149	0.00886	-0.13	-0.12	Pneumococcal bacteremia;	chr1:158491109	chr1:158195633~158196131:-
BRCA	cis	rs801193	1	rs17566701	ENSG00000232546.1	RP11-458F8.1	-3.81	0.000149	0.00887	-0.1	-0.12	Aortic root size;	chr7:66728196	chr7:66848496~66858136:+
BRCA	cis	rs9309473	0.687	rs7576824	ENSG00000163016.8	ALMS1P	-3.81	0.000149	0.00887	-0.14	-0.12	Metabolite levels;	chr2:73384153	chr2:73644919~73685576:+
BRCA	cis	rs181553	0.664	rs11874831	ENSG00000266696.1	RP11-30L3.2	3.81	0.000149	0.00887	0.13	0.12	Hip circumference adjusted for BMI;	chr18:49176221	chr18:49205912~49208781:+
BRCA	cis	rs4908769	0.624	rs301796	ENSG00000232912.4	RP5-1115A15.1	3.81	0.000149	0.00887	0.13	0.12	Allergy;	chr1:8406670	chr1:8424645~8434838:+
BRCA	cis	rs4908769	0.587	rs301795	ENSG00000232912.4	RP5-1115A15.1	3.81	0.000149	0.00887	0.13	0.12	Allergy;	chr1:8407293	chr1:8424645~8434838:+
BRCA	cis	rs4908769	0.624	rs301789	ENSG00000232912.4	RP5-1115A15.1	3.81	0.000149	0.00887	0.13	0.12	Allergy;	chr1:8409277	chr1:8424645~8434838:+
BRCA	cis	rs7847628	0.587	rs1060817	ENSG00000238181.2	AHCYP2	-3.81	0.000149	0.00887	-0.15	-0.12	Birth weight;	chr9:120820914	chr9:120720673~120721972:+
BRCA	cis	rs924712	0.545	rs12207559	ENSG00000224984.1	RP11-524H19.2	-3.81	0.000149	0.00887	-0.14	-0.12	Breast cancer;	chr6:54845070	chr6:54840118~54840855:-
BRCA	cis	rs2998286	0.723	rs332190	ENSG00000237128.1	RP11-351M16.3	3.81	0.000149	0.00887	0.17	0.12	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28630899	chr10:28433008~28495813:-
BRCA	cis	rs45509595	0.556	rs34409918	ENSG00000216901.1	AL022393.7	3.81	0.000149	0.00887	0.3	0.12	Breast cancer;	chr6:27717569	chr6:28176188~28176674:+
BRCA	cis	rs2562456	0.874	rs2562417	ENSG00000240522.1	RPL7AP10	3.81	0.00015	0.00887	0.13	0.12	Pain;	chr19:21528400	chr19:21149648~21150438:-
BRCA	cis	rs1501138	0.562	rs203444	ENSG00000263327.5	TAPT1-AS1	-3.81	0.00015	0.00887	-0.16	-0.12	Systemic juvenile idiopathic arthritis;	chr4:16247489	chr4:16226685~16320140:+
BRCA	cis	rs2712184	0.967	rs2541385	ENSG00000237930.1	AC007563.4	3.81	0.00015	0.00887	0.13	0.12	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);	chr2:216804872	chr2:216785774~216786144:-
BRCA	cis	rs2915864	1	rs2906069	ENSG00000280047.1	CTC-463A16.1	3.81	0.00015	0.00887	0.19	0.12	Facial morphology (factor 20);	chr5:142200084	chr5:142165767~142168387:+
BRCA	cis	rs11242704	0.559	rs11242706	ENSG00000218027.2	RP11-157J24.1	3.81	0.00015	0.00887	0.16	0.12	Response to hepatitis C treatment;	chr6:1539877	chr6:1513698~1515289:-
BRCA	cis	rs2243480	1	rs465359	ENSG00000237026.1	RP11-328P23.2	3.81	0.00015	0.00888	0.22	0.12	Diabetic kidney disease;	chr7:66093177	chr7:65235790~65236723:-
BRCA	cis	rs2243480	1	rs462853	ENSG00000237026.1	RP11-328P23.2	3.81	0.00015	0.00888	0.22	0.12	Diabetic kidney disease;	chr7:66093180	chr7:65235790~65236723:-
BRCA	cis	rs2243480	1	rs160644	ENSG00000237026.1	RP11-328P23.2	3.81	0.00015	0.00888	0.22	0.12	Diabetic kidney disease;	chr7:66093199	chr7:65235790~65236723:-
BRCA	cis	rs2243480	1	rs160642	ENSG00000237026.1	RP11-328P23.2	3.81	0.00015	0.00888	0.22	0.12	Diabetic kidney disease;	chr7:66093386	chr7:65235790~65236723:-
BRCA	cis	rs2243480	0.614	rs34032527	ENSG00000237026.1	RP11-328P23.2	3.81	0.00015	0.00888	0.22	0.12	Diabetic kidney disease;	chr7:66100154	chr7:65235790~65236723:-
BRCA	cis	rs477895	0.713	rs882146	ENSG00000256940.1	RP11-783K16.5	3.81	0.00015	0.00888	0.17	0.12	Mean platelet volume;	chr11:64209227	chr11:64245964~64248217:+
BRCA	cis	rs7267979	1	rs2387881	ENSG00000274973.1	RP13-401N8.7	3.81	0.00015	0.00888	0.13	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25397536	chr20:25845497~25845862:+
BRCA	cis	rs7246967	0.608	rs428613	ENSG00000198153.8	ZNF849P	-3.81	0.00015	0.00888	-0.17	-0.12	Bronchopulmonary dysplasia;	chr19:22827117	chr19:22685167~22686732:+
BRCA	cis	rs2243480	0.522	rs1638736	ENSG00000275400.1	RP4-756H11.5	3.81	0.00015	0.00888	0.25	0.12	Diabetic kidney disease;	chr7:66627321	chr7:66553805~66554199:-
BRCA	cis	rs6142618	0.562	rs2295035	ENSG00000224452.1	RSL24D1P6	3.81	0.00015	0.00888	0.16	0.12	Inflammatory bowel disease;	chr20:32114341	chr20:32170390~32170790:-
BRCA	cis	rs3742264	0.656	rs9534263	ENSG00000235903.6	CPB2-AS1	-3.81	0.00015	0.00888	-0.14	-0.12	Blood protein levels;	chr13:45967315	chr13:46052806~46113332:+
BRCA	cis	rs78547569	1	rs981071	ENSG00000233725.6	LINC00284	-3.81	0.00015	0.00888	-0.22	-0.12	Response to paliperidone in schizophrenia (negative Marder score);Response to paliperidone in schizophrenia (Multivariate);	chr13:43820758	chr13:43908669~44030461:+
BRCA	cis	rs4835473	0.932	rs13139738	ENSG00000246448.2	RP13-578N3.3	-3.81	0.00015	0.00888	-0.13	-0.12	Immature fraction of reticulocytes;	chr4:143738828	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.932	rs17018165	ENSG00000246448.2	RP13-578N3.3	-3.81	0.00015	0.00888	-0.13	-0.12	Immature fraction of reticulocytes;	chr4:143738849	chr4:143700257~143865072:+
BRCA	cis	rs6142618	0.562	rs4911545	ENSG00000275576.1	RP5-836N17.4	-3.81	0.00015	0.00888	-0.13	-0.12	Inflammatory bowel disease;	chr20:32123712	chr20:32116171~32116629:+
BRCA	cis	rs6142618	0.562	rs6142613	ENSG00000275576.1	RP5-836N17.4	-3.81	0.00015	0.00888	-0.13	-0.12	Inflammatory bowel disease;	chr20:32124203	chr20:32116171~32116629:+
BRCA	cis	rs6142618	0.562	rs6142615	ENSG00000275576.1	RP5-836N17.4	-3.81	0.00015	0.00888	-0.13	-0.12	Inflammatory bowel disease;	chr20:32124636	chr20:32116171~32116629:+
BRCA	cis	rs6142618	0.562	rs6058528	ENSG00000275576.1	RP5-836N17.4	-3.81	0.00015	0.00888	-0.13	-0.12	Inflammatory bowel disease;	chr20:32127247	chr20:32116171~32116629:+
BRCA	cis	rs6991838	0.53	rs35038843	ENSG00000272155.1	RP11-707M3.3	3.81	0.00015	0.00888	0.11	0.12	Intelligence (multi-trait analysis);	chr8:65610263	chr8:65714334~65714778:-
BRCA	cis	rs6991838	0.584	rs4737748	ENSG00000272155.1	RP11-707M3.3	-3.81	0.00015	0.00888	-0.11	-0.12	Intelligence (multi-trait analysis);	chr8:65613630	chr8:65714334~65714778:-
BRCA	cis	rs3816183	1	rs920390	ENSG00000226491.1	FTOP1	3.81	0.00015	0.00889	0.15	0.12	Hypospadias;	chr2:42792004	chr2:42797225~42798712:-
BRCA	cis	rs983392	0.755	rs516478	ENSG00000275344.1	MIR6503	-3.81	0.00015	0.00889	-0.12	-0.12	Alzheimer's disease (late onset);	chr11:60103315	chr11:60209071~60209156:-
BRCA	cis	rs12188164	0.582	rs80273890	ENSG00000221990.4	EXOC3-AS1	3.81	0.00015	0.00889	0.13	0.12	Cystic fibrosis severity;	chr5:482942	chr5:441498~443160:-
BRCA	cis	rs1635	0.655	rs723475	ENSG00000216901.1	AL022393.7	-3.81	0.00015	0.00889	-0.27	-0.12	Schizophrenia;	chr6:28337064	chr6:28176188~28176674:+
BRCA	cis	rs13217239	0.646	rs10946897	ENSG00000124549.13	BTN2A3P	3.81	0.00015	0.00889	0.12	0.12	Schizophrenia;	chr6:27027472	chr6:26421391~26432383:+
BRCA	cis	rs4713118	0.568	rs9468213	ENSG00000219392.1	RP1-265C24.5	-3.81	0.00015	0.00889	-0.15	-0.12	Parkinson's disease;	chr6:27738401	chr6:28115628~28116551:+
BRCA	cis	rs595982	0.726	rs607356	ENSG00000235191.1	NUCB1-AS1	3.81	0.00015	0.00889	0.15	0.12	Red cell distribution width;	chr19:48867984	chr19:48910930~48918891:-
BRCA	cis	rs5765524	0.584	rs5765490	ENSG00000238120.1	CTA-941F9.9	3.81	0.00015	0.00889	0.12	0.12	Red blood cell count;	chr22:45579033	chr22:45604432~45605621:-
BRCA	cis	rs6600671	1	rs4844380	ENSG00000223345.3	HIST2H2BA	3.81	0.00015	0.00889	0.14	0.12	Hip geometry;	chr1:121451764	chr1:121108210~121117257:-
BRCA	cis	rs875971	0.862	rs1968126	ENSG00000229886.1	RP5-1132H15.3	-3.81	0.00015	0.00889	-0.13	-0.12	Aortic root size;	chr7:66592017	chr7:66025126~66031544:-
BRCA	cis	rs860295	0.702	rs11264381	ENSG00000225855.5	RUSC1-AS1	-3.81	0.00015	0.00889	-0.1	-0.12	Body mass index;	chr1:155552781	chr1:155316863~155324176:-
BRCA	cis	rs6963495	0.606	rs6969426	ENSG00000223886.3	RP11-251G23.2	3.81	0.00015	0.00889	0.18	0.12	Bipolar disorder (body mass index interaction);	chr7:105506703	chr7:105530209~105530671:+
BRCA	cis	rs7260598	0.685	rs73021420	ENSG00000268442.1	CTD-2027I19.2	3.81	0.00015	0.00889	0.2	0.12	Response to taxane treatment (placlitaxel);	chr19:24082833	chr19:24162370~24163425:-
BRCA	cis	rs2998286	0.723	rs332187	ENSG00000237128.1	RP11-351M16.3	3.81	0.00015	0.0089	0.15	0.12	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28624887	chr10:28433008~28495813:-
BRCA	cis	rs295490	0.748	rs41356949	ENSG00000178631.7	ACTG1P1	-3.81	0.00015	0.0089	-0.22	-0.12	PR interval in Tripanosoma cruzi seropositivity;	chr3:139469580	chr3:139493809~139494937:+
BRCA	cis	rs4767841	0.935	rs2936831	ENSG00000248636.5	RP11-768F21.1	-3.81	0.00015	0.0089	-0.15	-0.12	Urgency urinary incontinence;	chr12:119726459	chr12:119387987~119668079:-
BRCA	cis	rs495337	0.736	rs6095681	ENSG00000229222.1	KRT18P4	3.81	0.00015	0.0089	0.15	0.12	Psoriasis;	chr20:49834592	chr20:49956745~49958032:+
BRCA	cis	rs8020289	0.56	rs7142548	ENSG00000258569.1	RP11-99E15.2	3.81	0.00015	0.0089	0.13	0.12	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks);	chr14:76784565	chr14:76710658~76761388:-
BRCA	cis	rs2832191	0.72	rs4643617	ENSG00000232855.5	AF131217.1	3.81	0.00015	0.0089	0.14	0.12	Dental caries;	chr21:29112957	chr21:28439346~28674848:-
BRCA	cis	rs2832191	0.791	rs2832187	ENSG00000232855.5	AF131217.1	3.81	0.00015	0.0089	0.14	0.12	Dental caries;	chr21:29113222	chr21:28439346~28674848:-
BRCA	cis	rs875971	0.638	rs3898855	ENSG00000272831.1	RP11-792A8.4	-3.81	0.00015	0.0089	-0.11	-0.12	Aortic root size;	chr7:66571411	chr7:66739829~66740385:-
BRCA	cis	rs875971	0.638	rs10278816	ENSG00000272831.1	RP11-792A8.4	-3.81	0.00015	0.0089	-0.11	-0.12	Aortic root size;	chr7:66572000	chr7:66739829~66740385:-
BRCA	cis	rs875971	0.66	rs10281080	ENSG00000272831.1	RP11-792A8.4	-3.81	0.00015	0.0089	-0.11	-0.12	Aortic root size;	chr7:66577454	chr7:66739829~66740385:-
BRCA	cis	rs875971	0.66	rs10950044	ENSG00000272831.1	RP11-792A8.4	-3.81	0.00015	0.0089	-0.11	-0.12	Aortic root size;	chr7:66577989	chr7:66739829~66740385:-
BRCA	cis	rs7412746	0.611	rs11803940	ENSG00000231073.1	RP11-316M1.3	3.81	0.00015	0.0089	0.12	0.12	Melanoma;	chr1:150713359	chr1:150973123~150975534:+
BRCA	cis	rs28374715	0.681	rs11629979	ENSG00000247556.5	OIP5-AS1	3.8	0.00015	0.0089	0.12	0.12	Ulcerative colitis;	chr15:41334381	chr15:41283990~41309737:+
BRCA	cis	rs1008375	0.931	rs10008337	ENSG00000249502.1	AC006160.5	-3.8	0.00015	0.0089	-0.13	-0.12	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17592226	chr4:17587467~17614571:-
BRCA	cis	rs1008375	0.898	rs61047804	ENSG00000249502.1	AC006160.5	-3.8	0.00015	0.0089	-0.13	-0.12	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17592342	chr4:17587467~17614571:-
BRCA	cis	rs1008375	0.898	rs10008445	ENSG00000249502.1	AC006160.5	-3.8	0.00015	0.0089	-0.13	-0.12	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17592355	chr4:17587467~17614571:-
BRCA	cis	rs4819052	0.819	rs34818688	ENSG00000215447.6	BX322557.10	-3.8	0.00015	0.00891	-0.12	-0.12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45252501	chr21:45288052~45291738:+
BRCA	cis	rs375066	0.869	rs379785	ENSG00000267191.1	RP11-15A1.2	-3.8	0.00015	0.00891	-0.15	-0.12	Breast cancer;	chr19:43923949	chr19:43902001~43926545:+
BRCA	cis	rs7412746	0.611	rs7532045	ENSG00000224800.1	RP11-235D19.2	-3.8	0.00015	0.00891	-0.15	-0.12	Melanoma;	chr1:150849371	chr1:150881236~150881683:-
BRCA	cis	rs6893300	0.785	rs7705530	ENSG00000225051.5	HMGB3P22	3.8	0.00015	0.00891	0.15	0.12	Resting heart rate;	chr5:179763993	chr5:179679032~179694768:+
BRCA	cis	rs6893300	0.785	rs7704520	ENSG00000225051.5	HMGB3P22	3.8	0.00015	0.00891	0.15	0.12	Resting heart rate;	chr5:179764053	chr5:179679032~179694768:+
BRCA	cis	rs35520189	0.754	rs10169916	ENSG00000189223.12	PAX8-AS1	3.8	0.00015	0.00891	0.17	0.12	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:112846151	chr2:113211522~113276581:+
BRCA	cis	rs6044112	0.784	rs17674942	ENSG00000273998.1	RP4-777L9.2	3.8	0.00015	0.00891	0.21	0.12	Response to taxane treatment (docetaxel);	chr20:16532671	chr20:16576068~16579615:+
BRCA	cis	rs8054556	0.692	rs4788199	ENSG00000183604.13	SMG1P5	-3.8	0.00015	0.00891	-0.11	-0.12	Autism spectrum disorder or schizophrenia;	chr16:29959536	chr16:30267553~30335374:-
BRCA	cis	rs2562456	0.793	rs7259708	ENSG00000213976.4	CTD-2561J22.2	-3.8	0.00015	0.00891	-0.14	-0.12	Pain;	chr19:21567846	chr19:21382865~21387177:+
BRCA	cis	rs3858526	1	rs11039787	ENSG00000224295.2	AC087380.14	3.8	0.00015	0.00892	0.17	0.12	DNA methylation (variation);	chr11:5944381	chr11:5518441~5524955:-
BRCA	cis	rs3739034	0.877	rs6761929	ENSG00000224043.6	CCNT2-AS1	-3.8	0.00015	0.00892	-0.19	-0.12	Gut microbiome composition (winter);	chr2:134704964	chr2:134735464~134918710:-
BRCA	cis	rs17092148	0.887	rs6059919	ENSG00000202150.1	RNU6-407P	3.8	0.00015	0.00892	0.18	0.12	Neuroticism;	chr20:34563741	chr20:35030317~35030420:-
BRCA	cis	rs853679	0.599	rs188015	ENSG00000241549.7	GUSBP2	3.8	0.00015	0.00892	0.21	0.12	Depression;	chr6:27909668	chr6:26871484~26956554:-
BRCA	cis	rs1075265	0.73	rs805392	ENSG00000272156.1	RP11-477N3.1	-3.8	0.00015	0.00892	-0.12	-0.12	Chronotype;Morning vs. evening chronotype;	chr2:53877594	chr2:54082554~54085066:+
BRCA	cis	rs7602460	0.74	rs12690514	ENSG00000234663.4	AC104820.2	-3.8	0.00015	0.00892	-0.09	-0.12	Atrioventricular conduction;	chr2:181388297	chr2:181101932~181399559:+
BRCA	cis	rs1371614	0.611	rs3910615	ENSG00000229122.1	AGBL5-IT1	-3.8	0.00015	0.00892	-0.12	-0.12	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26908154	chr2:27061038~27061815:+
BRCA	cis	rs10799445	0.568	rs2935147	ENSG00000227711.2	RP11-275O4.5	-3.8	0.00015	0.00892	-0.14	-0.12	Height;	chr1:227600286	chr1:227509028~227520477:-
BRCA	cis	rs12285276	0.75	rs11038658	ENSG00000205106.4	DKFZp779M0652	-3.8	0.00015	0.00892	-0.16	-0.12	Visceral fat;	chr11:45791762	chr11:45771432~45772358:+
BRCA	cis	rs4835473	0.712	rs12509607	ENSG00000246448.2	RP13-578N3.3	-3.8	0.00015	0.00892	-0.13	-0.12	Immature fraction of reticulocytes;	chr4:143736894	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.712	rs12498218	ENSG00000246448.2	RP13-578N3.3	-3.8	0.00015	0.00892	-0.13	-0.12	Immature fraction of reticulocytes;	chr4:143736900	chr4:143700257~143865072:+
BRCA	cis	rs11098499	0.866	rs72676074	ENSG00000250412.1	KLHL2P1	3.8	0.00015	0.00892	0.14	0.12	Corneal astigmatism;	chr4:119438686	chr4:119334329~119378233:+
BRCA	cis	rs4664293	0.647	rs918969	ENSG00000224152.1	AC009506.1	3.8	0.00015	0.00892	0.12	0.12	Monocyte percentage of white cells;	chr2:159610145	chr2:159615296~159617082:+
BRCA	cis	rs2562456	0.724	rs58001930	ENSG00000213976.4	CTD-2561J22.2	-3.8	0.00015	0.00892	-0.14	-0.12	Pain;	chr19:21560061	chr19:21382865~21387177:+
BRCA	cis	rs3739034	0.816	rs71417530	ENSG00000224043.6	CCNT2-AS1	-3.8	0.000151	0.00892	-0.24	-0.12	Gut microbiome composition (winter);	chr2:134691081	chr2:134735464~134918710:-
BRCA	cis	rs11185790	0.784	rs10881612	ENSG00000240996.1	RP11-80H5.7	-3.8	0.000151	0.00892	-0.15	-0.12	Metabolic traits;	chr10:89627031	chr10:89694295~89697928:-
BRCA	cis	rs7412746	0.622	rs11552229	ENSG00000224800.1	RP11-235D19.2	-3.8	0.000151	0.00893	-0.15	-0.12	Melanoma;	chr1:150811509	chr1:150881236~150881683:-
BRCA	cis	rs2579519	0.556	rs4907302	ENSG00000168992.4	OR7E102P	3.8	0.000151	0.00893	0.16	0.12	Diastolic blood pressure;	chr2:95551449	chr2:95546531~95547545:+
BRCA	cis	rs2274273	0.868	rs1572611	ENSG00000259318.1	RP11-454L9.2	3.8	0.000151	0.00893	0.1	0.12	Protein biomarker;	chr14:55367156	chr14:55394940~55395233:-
BRCA	cis	rs310291	0.585	rs182565	ENSG00000246582.2	RP11-1149O23.3	3.8	0.000151	0.00893	0.14	0.12	Breast cancer;	chr8:23835918	chr8:23224471~23230926:+
BRCA	cis	rs7020830	0.858	rs13293465	ENSG00000230188.1	RP11-405L18.4	-3.8	0.000151	0.00893	-0.14	-0.12	Schizophrenia;	chr9:37127681	chr9:37490421~37490893:-
BRCA	cis	rs41313321	0.588	rs2270203	ENSG00000228510.2	RP11-339B21.8	3.8	0.000151	0.00893	0.28	0.12	Coenzyme Q10 levels;	chr9:128325797	chr9:128444587~128446628:+
BRCA	cis	rs2108622	0.711	rs113343664	ENSG00000214049.6	UCA1	3.8	0.000151	0.00893	0.17	0.12	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15868183	chr19:15828961~15836320:+
BRCA	cis	rs6496932	0.563	rs2344083	ENSG00000202081.1	RNU6-1280P	-3.8	0.000151	0.00893	-0.13	-0.12	Central corneal thickness;Corneal structure;	chr15:85354201	chr15:85651522~85651628:-
BRCA	cis	rs7690839	1	rs4505789	ENSG00000270720.1	RP11-84C13.2	3.8	0.000151	0.00893	0.13	0.12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr4:88904464	chr4:89119284~89119871:+
BRCA	cis	rs295490	0.748	rs77342235	ENSG00000272656.1	RP11-219D15.3	3.8	0.000151	0.00893	0.28	0.12	PR interval in Tripanosoma cruzi seropositivity;	chr3:139419212	chr3:139349024~139349371:-
BRCA	cis	rs1850744	0.536	rs6843869	ENSG00000250942.1	ENPP7P11	3.8	0.000151	0.00893	0.23	0.12	Economic and political preferences;	chr4:9632827	chr4:9677308~9677934:+
BRCA	cis	rs11543198	1	rs8041357	ENSG00000259264.4	RP11-60L3.1	3.8	0.000151	0.00893	0.33	0.12	Bladder cancer;	chr15:74577097	chr15:74202705~74221557:+
BRCA	cis	rs10043228	1	rs1876673	ENSG00000271918.1	CTD-2287O16.5	-3.8	0.000151	0.00893	-0.17	-0.12	Asthma or chronic obstructive pulmonary disease;	chr5:116115076	chr5:116083807~116085416:-
BRCA	cis	rs853679	0.546	rs200952	ENSG00000216901.1	AL022393.7	3.8	0.000151	0.00893	0.23	0.12	Depression;	chr6:27869198	chr6:28176188~28176674:+
BRCA	cis	rs17772222	0.917	rs61983300	ENSG00000258789.1	RP11-507K2.3	-3.8	0.000151	0.00893	-0.14	-0.12	Coronary artery calcification;	chr14:88754047	chr14:88551597~88552493:+
BRCA	cis	rs854765	0.647	rs4426402	ENSG00000197815.4	RP1-253P7.4	3.8	0.000151	0.00893	0.08	0.12	Total body bone mineral density;	chr17:18074612	chr17:17858227~17860041:+
BRCA	cis	rs6671200	0.607	rs1927043	ENSG00000226026.4	RP11-57H12.3	-3.8	0.000151	0.00893	-0.18	-0.12	Stearic acid (18:0) levels;	chr1:95201695	chr1:95163219~95233982:-
BRCA	cis	rs35417517	1	rs35417517	ENSG00000188693.7	CYP51A1-AS1	-3.8	0.000151	0.00893	-0.13	-0.12	Breast cancer;	chr7:92143417	chr7:92134604~92180725:+
BRCA	cis	rs6964587	0.967	rs6974827	ENSG00000188693.7	CYP51A1-AS1	-3.8	0.000151	0.00893	-0.13	-0.12	Breast cancer;	chr7:92143631	chr7:92134604~92180725:+
BRCA	cis	rs6964587	0.9	rs6465352	ENSG00000188693.7	CYP51A1-AS1	-3.8	0.000151	0.00893	-0.13	-0.12	Breast cancer;	chr7:92145803	chr7:92134604~92180725:+
BRCA	cis	rs3805389	0.504	rs3805385	ENSG00000249700.7	SRD5A3-AS1	-3.8	0.000151	0.00893	-0.18	-0.12	Waist-to-hip ratio adjusted for body mass index;	chr4:55613821	chr4:55363971~55395847:-
BRCA	cis	rs6964587	1	rs9690208	ENSG00000188693.7	CYP51A1-AS1	-3.8	0.000151	0.00893	-0.13	-0.12	Breast cancer;	chr7:92106299	chr7:92134604~92180725:+
BRCA	cis	rs6964587	1	rs60147309	ENSG00000188693.7	CYP51A1-AS1	-3.8	0.000151	0.00893	-0.13	-0.12	Breast cancer;	chr7:92106784	chr7:92134604~92180725:+
BRCA	cis	rs7824557	0.836	rs765731	ENSG00000154316.13	TDH	3.8	0.000151	0.00893	0.16	0.12	Retinal vascular caliber;	chr8:11263989	chr8:11339637~11368452:+
BRCA	cis	rs75422866	0.867	rs7304743	ENSG00000276691.1	RP5-1057I20.5	-3.8	0.000151	0.00893	-0.21	-0.12	Pneumonia;	chr12:47683658	chr12:47788426~47788971:+
BRCA	cis	rs6430585	0.697	rs1050115	ENSG00000231890.6	DARS-AS1	-3.8	0.000151	0.00894	-0.19	-0.12	Corneal structure;	chr2:135754247	chr2:135985176~136022593:+
BRCA	cis	rs10464366	0.798	rs885352	ENSG00000233306.2	TRGV2	3.8	0.000151	0.00894	0.11	0.12	IgG glycosylation;	chr7:39076568	chr7:38362864~38363518:-
BRCA	cis	rs7520050	0.778	rs3014238	ENSG00000281133.1	AL355480.3	3.8	0.000151	0.00894	0.13	0.12	Reticulocyte count;Red blood cell count;	chr1:45624542	chr1:45580892~45580996:-
BRCA	cis	rs739496	0.579	rs57046217	ENSG00000234608.6	MAPKAPK5-AS1	3.8	0.000151	0.00894	0.14	0.12	Platelet count;	chr12:111847312	chr12:111839764~111842902:-
BRCA	cis	rs8030605	0.633	rs72740533	ENSG00000277245.1	RP11-48G14.3	3.8	0.000151	0.00894	0.25	0.12	Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;	chr15:56296080	chr15:56447120~56447697:+
BRCA	cis	rs12787909	1	rs12787909	ENSG00000243431.1	RPL5P30	3.8	0.000151	0.00894	0.2	0.12	Lipoprotein (a) - cholesterol levels;	chr11:117675767	chr11:118560690~118561580:+
BRCA	cis	rs478304	0.593	rs4645933	ENSG00000255557.1	RP11-770G2.2	3.8	0.000151	0.00894	0.15	0.12	Acne (severe);	chr11:65717649	chr11:65745729~65771585:+
BRCA	cis	rs4767841	0.935	rs2936830	ENSG00000248636.5	RP11-768F21.1	-3.8	0.000151	0.00894	-0.15	-0.12	Urgency urinary incontinence;	chr12:119729350	chr12:119387987~119668079:-
BRCA	cis	rs425277	1	rs262670	ENSG00000269227.1	RP11-345P4.6	3.8	0.000151	0.00894	0.12	0.12	Height;	chr1:2151019	chr1:1673275~1674397:+
BRCA	cis	rs962856	0.633	rs6755775	ENSG00000236605.1	AC023115.4	3.8	0.000151	0.00894	0.14	0.12	Pancreatic cancer;	chr2:67371451	chr2:67324627~67325304:+
BRCA	cis	rs962856	1	rs6755797	ENSG00000236605.1	AC023115.4	3.8	0.000151	0.00894	0.14	0.12	Pancreatic cancer;	chr2:67371501	chr2:67324627~67325304:+
BRCA	cis	rs4664293	1	rs11676412	ENSG00000224152.1	AC009506.1	-3.8	0.000151	0.00894	-0.13	-0.12	Monocyte percentage of white cells;	chr2:159651560	chr2:159615296~159617082:+
BRCA	cis	rs2562456	0.833	rs11666447	ENSG00000268658.4	LINC00664	3.8	0.000151	0.00894	0.2	0.12	Pain;	chr19:21416270	chr19:21483374~21503238:+
BRCA	cis	rs10514758	0.744	rs4831110	ENSG00000242880.1	RP11-190P13.2	3.8	0.000151	0.00894	0.27	0.12	Urate levels in obese individuals;	chr3:115220429	chr3:115251196~115285347:+
BRCA	cis	rs875971	0.862	rs709596	ENSG00000229886.1	RP5-1132H15.3	3.8	0.000151	0.00895	0.13	0.12	Aortic root size;	chr7:66360926	chr7:66025126~66031544:-
BRCA	cis	rs2835345	0.507	rs7280011	ENSG00000214914.3	RPL23AP3	-3.8	0.000151	0.00895	-0.16	-0.12	Pulmonary function;	chr21:36455256	chr21:36016079~36016546:-
BRCA	cis	rs74233809	1	rs77420391	ENSG00000236937.2	PTGES3P4	3.8	0.000151	0.00895	0.26	0.12	Birth weight;	chr10:103186066	chr10:102845595~102845950:+
BRCA	cis	rs853679	0.76	rs9393909	ENSG00000280107.1	AL022393.9	3.8	0.000151	0.00895	0.19	0.12	Depression;	chr6:28239422	chr6:28170845~28172521:+
BRCA	cis	rs2109514	1	rs4727833	ENSG00000237813.3	AC002066.1	3.8	0.000151	0.00895	0.14	0.12	Prevalent atrial fibrillation;	chr7:116507854	chr7:116238260~116499465:-
BRCA	cis	rs7429990	0.965	rs11707679	ENSG00000199476.1	Y_RNA	-3.8	0.000151	0.00895	-0.16	-0.12	Educational attainment (years of education);	chr3:47915016	chr3:48288587~48288694:+
BRCA	cis	rs8180040	0.966	rs17784882	ENSG00000280667.1	Y_RNA	-3.8	0.000151	0.00895	-0.13	-0.12	Colorectal cancer;	chr3:47502513	chr3:47501083~47501182:+
BRCA	cis	rs6496932	0.503	rs4564526	ENSG00000259630.2	CTD-2262B20.1	-3.8	0.000151	0.00896	-0.16	-0.12	Central corneal thickness;Corneal structure;	chr15:85455914	chr15:85415228~85415633:+
BRCA	cis	rs988913	0.723	rs6936015	ENSG00000261116.1	RP3-523K23.2	-3.8	0.000151	0.00896	-0.14	-0.12	Menarche (age at onset);	chr6:55127011	chr6:54943167~54945099:+
BRCA	cis	rs11098499	0.863	rs1383533	ENSG00000260404.2	RP11-384K6.6	3.8	0.000151	0.00896	0.11	0.12	Corneal astigmatism;	chr4:119513421	chr4:118591773~118633729:+
BRCA	cis	rs2625529	0.824	rs12901886	ENSG00000260037.4	CTD-2524L6.3	-3.8	0.000151	0.00896	-0.17	-0.12	Red blood cell count;	chr15:72115728	chr15:71818396~71823384:+
BRCA	cis	rs11673344	0.566	rs10419281	ENSG00000233527.7	ZNF529-AS1	-3.8	0.000151	0.00896	-0.13	-0.12	Obesity-related traits;	chr19:37459351	chr19:36573070~36594708:+
BRCA	cis	rs2031532	0.569	rs7326345	ENSG00000236577.1	SNRPGP14	3.8	0.000151	0.00896	0.13	0.12	Cardiac hypertrophy;	chr13:49493307	chr13:49488970~49489364:+
BRCA	cis	rs863345	0.584	rs6427438	ENSG00000229914.1	RP11-404O13.4	-3.8	0.000151	0.00896	-0.12	-0.12	Pneumococcal bacteremia;	chr1:158484940	chr1:158195633~158196131:-
BRCA	cis	rs863345	0.604	rs10908653	ENSG00000229914.1	RP11-404O13.4	-3.8	0.000151	0.00896	-0.12	-0.12	Pneumococcal bacteremia;	chr1:158485563	chr1:158195633~158196131:-
BRCA	cis	rs16846053	0.685	rs56140629	ENSG00000227403.1	AC009299.3	3.8	0.000151	0.00896	0.31	0.12	Blood osmolality (transformed sodium);	chr2:161877499	chr2:161244739~161249050:+
BRCA	cis	rs7487075	0.619	rs10785627	ENSG00000257261.4	RP11-96H19.1	3.8	0.000151	0.00896	0.13	0.12	Itch intensity from mosquito bite;	chr12:46430446	chr12:46383679~46876159:+
BRCA	cis	rs6439699	1	rs58088387	ENSG00000239213.4	NCK1-AS1	3.8	0.000151	0.00896	0.16	0.12	Intelligence (multi-trait analysis);	chr3:137291160	chr3:136841726~136862054:-
BRCA	cis	rs4218	0.608	rs34859729	ENSG00000259732.1	RP11-59H7.3	-3.8	0.000151	0.00896	-0.15	-0.12	Social communication problems;	chr15:59070117	chr15:59121034~59133250:+
BRCA	cis	rs10487112	0.87	rs17863122	ENSG00000235436.9	DPY19L2P4	-3.8	0.000151	0.00896	-0.13	-0.12	Perceived unattractiveness to mosquitoes;	chr7:90475468	chr7:90119400~90125600:+
BRCA	cis	rs10487112	0.87	rs878168	ENSG00000235436.9	DPY19L2P4	-3.8	0.000151	0.00896	-0.13	-0.12	Perceived unattractiveness to mosquitoes;	chr7:90476888	chr7:90119400~90125600:+
BRCA	cis	rs6088580	0.524	rs6088560	ENSG00000261582.1	RP4-614O4.11	3.8	0.000151	0.00896	0.11	0.12	Glomerular filtration rate (creatinine);	chr20:34640745	chr20:35267885~35280043:-
BRCA	cis	rs10129255	1	rs8010605	ENSG00000231475.3	IGHV4-31	-3.8	0.000151	0.00896	-0.09	-0.12	Kawasaki disease;	chr14:106678742	chr14:106349283~106349792:-
BRCA	cis	rs853679	0.517	rs9393884	ENSG00000226314.6	ZNF192P1	-3.8	0.000151	0.00897	-0.17	-0.12	Depression;	chr6:28079011	chr6:28161781~28169594:+
BRCA	cis	rs6445967	0.832	rs1055973	ENSG00000272182.1	RP11-802O23.3	3.8	0.000151	0.00897	0.13	0.12	Platelet count;	chr3:58323233	chr3:58428255~58428815:+
BRCA	cis	rs2514805	0.803	rs2446824	ENSG00000253585.1	KB-1184D12.1	-3.8	0.000151	0.00897	-0.21	-0.12	Diisocyanate-induced asthma;	chr8:94115346	chr8:94097764~94104322:-
BRCA	cis	rs10761482	0.861	rs7096250	ENSG00000254271.1	RP11-131N11.4	3.8	0.000151	0.00897	0.17	0.12	Schizophrenia;	chr10:60346561	chr10:60734342~60741828:+
BRCA	cis	rs12681366	0.708	rs3019154	ENSG00000253175.1	RP11-267M23.6	3.8	0.000151	0.00897	0.13	0.12	Nonsyndromic cleft lip with cleft palate;	chr8:94434280	chr8:94565036~94565715:+
BRCA	cis	rs12681366	0.708	rs3019279	ENSG00000253175.1	RP11-267M23.6	3.8	0.000151	0.00897	0.13	0.12	Nonsyndromic cleft lip with cleft palate;	chr8:94435677	chr8:94565036~94565715:+
BRCA	cis	rs28489187	0.706	rs233120	ENSG00000223653.4	RP11-131L23.1	3.8	0.000151	0.00897	0.13	0.12	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85322807	chr1:85276715~85448124:+
BRCA	cis	rs7520050	0.966	rs2486447	ENSG00000281133.1	AL355480.3	3.8	0.000151	0.00897	0.14	0.12	Reticulocyte count;Red blood cell count;	chr1:46080052	chr1:45580892~45580996:-
BRCA	cis	rs853679	0.567	rs16894091	ENSG00000220721.1	OR1F12	-3.8	0.000151	0.00897	-0.15	-0.12	Depression;	chr6:28422360	chr6:28073316~28074233:+
BRCA	cis	rs8054556	1	rs4283241	ENSG00000183604.13	SMG1P5	3.8	0.000151	0.00897	0.11	0.12	Autism spectrum disorder or schizophrenia;	chr16:29977028	chr16:30267553~30335374:-
BRCA	cis	rs7674212	0.507	rs223361	ENSG00000248740.4	RP11-328K4.1	3.8	0.000151	0.00897	0.14	0.12	Type 2 diabetes;	chr4:102848147	chr4:103256159~103453658:+
BRCA	cis	rs490049	1	rs490049	ENSG00000276672.1	RP11-142E9.1	3.8	0.000151	0.00897	0.25	0.12	Diabetic kidney disease;	chr13:32990725	chr13:33846190~33850825:+
BRCA	cis	rs1437396	0.657	rs55815858	ENSG00000203327.2	AC012358.7	-3.8	0.000151	0.00897	-0.12	-0.12	Alcohol dependence;	chr2:55376680	chr2:55214387~55216126:-
BRCA	cis	rs91731	0.92	rs268730	ENSG00000249572.1	CTD-2203K17.1	-3.8	0.000151	0.00897	-0.23	-0.12	Lung function (FVC);	chr5:33363899	chr5:33424025~33440619:-
BRCA	cis	rs7746199	0.736	rs13202291	ENSG00000216901.1	AL022393.7	3.8	0.000151	0.00897	0.3	0.12	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27731078	chr6:28176188~28176674:+
BRCA	cis	rs7746199	0.736	rs17750424	ENSG00000216901.1	AL022393.7	3.8	0.000151	0.00897	0.3	0.12	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27733343	chr6:28176188~28176674:+
BRCA	cis	rs1549733	0.515	rs6714760	ENSG00000229754.1	CXCR2P1	-3.8	0.000151	0.00897	-0.15	-0.12	Optic disc area;	chr2:217574304	chr2:218059155~218065729:-
BRCA	cis	rs17801127	0.818	rs16827311	ENSG00000231969.1	AC144449.1	3.8	0.000151	0.00897	0.2	0.12	Liver enzyme levels (alanine transaminase);	chr2:149666306	chr2:149587196~149848233:+
BRCA	cis	rs4664293	1	rs2357382	ENSG00000224152.1	AC009506.1	-3.8	0.000151	0.00897	-0.13	-0.12	Monocyte percentage of white cells;	chr2:159636614	chr2:159615296~159617082:+
BRCA	cis	rs524281	0.861	rs7943911	ENSG00000255557.1	RP11-770G2.2	3.8	0.000151	0.00897	0.16	0.12	Electroencephalogram traits;	chr11:66175583	chr11:65745729~65771585:+
BRCA	cis	rs35520189	0.806	rs11123151	ENSG00000189223.12	PAX8-AS1	-3.8	0.000151	0.00898	-0.19	-0.12	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:112910428	chr2:113211522~113276581:+
BRCA	cis	rs9628987	0.5	rs55823627	ENSG00000270282.1	RP5-1115A15.2	-3.8	0.000152	0.00898	-0.18	-0.12	Breast cancer;	chr1:8402019	chr1:8512653~8513021:+
BRCA	cis	rs4664293	0.967	rs7597482	ENSG00000226266.5	AC009961.3	-3.8	0.000152	0.00898	-0.14	-0.12	Monocyte percentage of white cells;	chr2:159690580	chr2:159670708~159712435:-
BRCA	cis	rs4664293	0.967	rs7597488	ENSG00000226266.5	AC009961.3	-3.8	0.000152	0.00898	-0.14	-0.12	Monocyte percentage of white cells;	chr2:159690585	chr2:159670708~159712435:-
BRCA	cis	rs10043228	1	rs4398671	ENSG00000250015.1	CTC-339F2.2	3.8	0.000152	0.00898	0.15	0.12	Asthma or chronic obstructive pulmonary disease;	chr5:116222145	chr5:116302354~116304134:-
BRCA	cis	rs10043228	1	rs1382340	ENSG00000250015.1	CTC-339F2.2	3.8	0.000152	0.00898	0.15	0.12	Asthma or chronic obstructive pulmonary disease;	chr5:116222464	chr5:116302354~116304134:-
BRCA	cis	rs10043228	1	rs1382339	ENSG00000250015.1	CTC-339F2.2	3.8	0.000152	0.00898	0.15	0.12	Asthma or chronic obstructive pulmonary disease;	chr5:116222466	chr5:116302354~116304134:-
BRCA	cis	rs10043228	1	rs17139192	ENSG00000250015.1	CTC-339F2.2	3.8	0.000152	0.00898	0.15	0.12	Asthma or chronic obstructive pulmonary disease;	chr5:116226013	chr5:116302354~116304134:-
BRCA	cis	rs10043228	1	rs17139193	ENSG00000250015.1	CTC-339F2.2	3.8	0.000152	0.00898	0.15	0.12	Asthma or chronic obstructive pulmonary disease;	chr5:116226376	chr5:116302354~116304134:-
BRCA	cis	rs875971	0.505	rs1167385	ENSG00000232546.1	RP11-458F8.1	3.8	0.000152	0.00898	0.1	0.12	Aortic root size;	chr7:66048321	chr7:66848496~66858136:+
BRCA	cis	rs2905347	0.52	rs2905309	ENSG00000179428.2	AC073072.5	3.8	0.000152	0.00898	0.13	0.12	Major depression and alcohol dependence;	chr7:22608923	chr7:22725395~22727620:-
BRCA	cis	rs62025270	0.547	rs338520	ENSG00000259762.1	RP11-158M2.4	3.8	0.000152	0.00898	0.14	0.12	Idiopathic pulmonary fibrosis;	chr15:85671567	chr15:85750336~85752901:-
BRCA	cis	rs4073416	0.741	rs4143898	ENSG00000276116.2	FUT8-AS1	-3.8	0.000152	0.00898	-0.12	-0.12	N-glycan levels;	chr14:65722164	chr14:65411170~65412690:-
BRCA	cis	rs425277	1	rs262667	ENSG00000269227.1	RP11-345P4.6	3.8	0.000152	0.00898	0.12	0.12	Height;	chr1:2151283	chr1:1673275~1674397:+
BRCA	cis	rs8030605	0.85	rs1553738	ENSG00000277245.1	RP11-48G14.3	3.8	0.000152	0.00898	0.25	0.12	Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;	chr15:56078753	chr15:56447120~56447697:+
BRCA	cis	rs6439699	1	rs13096023	ENSG00000273486.1	RP11-731C17.2	3.8	0.000152	0.00898	0.16	0.12	Intelligence (multi-trait analysis);	chr3:137291845	chr3:136837338~136839021:-
BRCA	cis	rs6044112	1	rs6075068	ENSG00000273998.1	RP4-777L9.2	3.8	0.000152	0.00899	0.22	0.12	Response to taxane treatment (docetaxel);	chr20:16537305	chr20:16576068~16579615:+
BRCA	cis	rs9844666	0.512	rs9834624	ENSG00000239213.4	NCK1-AS1	3.8	0.000152	0.00899	0.14	0.12	Height;	chr3:135922852	chr3:136841726~136862054:-
BRCA	cis	rs9844666	0.512	rs9854494	ENSG00000239213.4	NCK1-AS1	3.8	0.000152	0.00899	0.14	0.12	Height;	chr3:135922980	chr3:136841726~136862054:-
BRCA	cis	rs11098499	0.754	rs9991959	ENSG00000225892.3	RP11-384K6.2	-3.8	0.000152	0.00899	-0.11	-0.12	Corneal astigmatism;	chr4:119332618	chr4:118632274~118634759:+
BRCA	cis	rs4622329	0.636	rs7976056	ENSG00000257202.1	RP11-512N21.3	3.8	0.000152	0.00899	0.14	0.12	Systemic lupus erythematosus;	chr12:101919728	chr12:101923410~101924719:-
BRCA	cis	rs11098499	0.909	rs10020034	ENSG00000250412.1	KLHL2P1	3.8	0.000152	0.00899	0.14	0.12	Corneal astigmatism;	chr4:119373176	chr4:119334329~119378233:+
BRCA	cis	rs240993	0.502	rs240966	ENSG00000271789.1	RP5-1112D6.7	-3.8	0.000152	0.00899	-0.15	-0.12	Inflammatory skin disease;Psoriasis;	chr6:111323462	chr6:111297126~111298510:+
BRCA	cis	rs11098499	0.532	rs4504231	ENSG00000260091.1	RP11-33B1.4	-3.8	0.000152	0.00899	-0.1	-0.12	Corneal astigmatism;	chr4:119665736	chr4:119409333~119410233:+
BRCA	cis	rs848490	1	rs56400413	ENSG00000214293.7	APTR	3.8	0.000152	0.00899	0.15	0.12	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77711504	chr7:77657660~77696265:-
BRCA	cis	rs8054556	0.74	rs3924855	ENSG00000183604.13	SMG1P5	-3.8	0.000152	0.009	-0.11	-0.12	Autism spectrum disorder or schizophrenia;	chr16:29943634	chr16:30267553~30335374:-
BRCA	cis	rs11170468	0.722	rs11170622	ENSG00000257718.1	RP11-396F22.1	-3.8	0.000152	0.009	-0.15	-0.12	Body mass index;	chr12:39080093	chr12:38906451~38909592:+
BRCA	cis	rs7914558	0.646	rs7100709	ENSG00000213277.3	MARCKSL1P1	3.8	0.000152	0.009	0.14	0.12	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102889972	chr10:103175554~103176094:+
BRCA	cis	rs7781557	0.64	rs6955064	ENSG00000239969.4	RP11-163E9.2	-3.8	0.000152	0.009	-0.19	-0.12	Colorectal adenoma (advanced);	chr7:102939124	chr7:102364162~102380633:+
BRCA	cis	rs748404	0.626	rs17780920	ENSG00000166763.7	STRCP1	3.8	0.000152	0.009	0.17	0.12	Lung cancer;	chr15:43370164	chr15:43699488~43718184:-
BRCA	cis	rs2412819	0.545	rs3862143	ENSG00000201136.1	RNU6-353P	-3.8	0.000152	0.009	-0.16	-0.12	Lung cancer;	chr15:43779282	chr15:43702363~43702470:+
BRCA	cis	rs935334	0.935	rs1900124	ENSG00000258454.1	RP11-361H10.3	3.8	0.000152	0.009	0.19	0.12	Blood pressure;	chr14:76190323	chr14:76235817~76263474:+
BRCA	cis	rs58521262	0.585	rs2927367	ENSG00000268105.1	RP11-369G6.2	-3.8	0.000152	0.009	-0.16	-0.12	Testicular germ cell tumor;	chr19:23047317	chr19:23125665~23128543:+
BRCA	cis	rs12303914	0.713	rs7314888	ENSG00000256682.2	TAS2R12	3.8	0.000152	0.009	0.14	0.12	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr12:10304325	chr12:10894943~10896952:-
BRCA	cis	rs12317459	0.591	rs75429138	ENSG00000213270.5	RPL6P25	-3.8	0.000152	0.009	-0.18	-0.12	Prostate cancer (SNP x SNP interaction);	chr12:82773984	chr12:83151331~83152190:+
BRCA	cis	rs12317459	0.591	rs12369671	ENSG00000213270.5	RPL6P25	-3.8	0.000152	0.009	-0.18	-0.12	Prostate cancer (SNP x SNP interaction);	chr12:82774162	chr12:83151331~83152190:+
BRCA	cis	rs2835872	0.828	rs2835836	ENSG00000228677.1	TTC3-AS1	-3.8	0.000152	0.009	-0.15	-0.12	Electroencephalographic traits in alcoholism;	chr21:37616885	chr21:37187666~37193926:-
BRCA	cis	rs10411161	1	rs3848562	ENSG00000269483.1	AC006272.1	-3.8	0.000152	0.009	-0.19	-0.12	Breast cancer;	chr19:51876582	chr19:51839924~51843324:-
BRCA	cis	rs7826238	0.502	rs10503377	ENSG00000253981.4	ALG1L13P	3.8	0.000152	0.009	0.15	0.12	Systolic blood pressure;	chr8:8520912	chr8:8236003~8244667:-
BRCA	cis	rs7824557	0.701	rs4568582	ENSG00000154316.13	TDH	-3.8	0.000152	0.00901	-0.16	-0.12	Retinal vascular caliber;	chr8:11302986	chr8:11339637~11368452:+
BRCA	cis	rs8049367	0.684	rs2283485	ENSG00000267077.1	RP11-127I20.5	3.8	0.000152	0.00901	0.12	0.12	Nonsyndromic cleft lip with or without cleft palate;	chr16:3919555	chr16:4795265~4796532:-
BRCA	cis	rs11742741	0.806	rs62350768	ENSG00000248874.4	C5orf17	-3.8	0.000152	0.00901	-0.15	-0.12	Educational attainment;	chr5:24060208	chr5:23951348~24178263:+
BRCA	cis	rs62244186	1	rs62244186	ENSG00000233509.2	ZNF197-AS1	3.8	0.000152	0.00901	0.14	0.12	Depressive symptoms;	chr3:44698291	chr3:44617128~44624797:-
BRCA	cis	rs10129255	0.912	rs61997792	ENSG00000274576.2	IGHV2-70	3.8	0.000152	0.00901	0.11	0.12	Kawasaki disease;	chr14:106799304	chr14:106770577~106771020:-
BRCA	cis	rs11892454	0.565	rs13398541	ENSG00000217643.1	PTGES3P2	-3.8	0.000152	0.00901	-0.13	-0.12	Heschl's gyrus morphology;	chr2:25826254	chr2:25822469~25822950:+
BRCA	cis	rs6012564	0.749	rs8120015	ENSG00000222365.1	SNORD12B	3.8	0.000152	0.00901	0.12	0.12	Anger;	chr20:49128772	chr20:49280319~49280409:+
BRCA	cis	rs9818758	0.545	rs55921200	ENSG00000225399.4	RP11-3B7.1	-3.8	0.000152	0.00901	-0.24	-0.12	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49151883	chr3:49260085~49261316:+
BRCA	cis	rs10129255	0.789	rs61997796	ENSG00000211958.2	IGHV3-38	3.8	0.000152	0.00901	0.1	0.12	Kawasaki disease;	chr14:106813798	chr14:106410493~106411021:-
BRCA	cis	rs4363385	0.934	rs6667418	ENSG00000272654.1	RP11-422P24.11	3.8	0.000152	0.00902	0.13	0.12	Inflammatory skin disease;	chr1:152997209	chr1:153977743~153979160:+
BRCA	cis	rs2274459	1	rs12199132	ENSG00000249346.5	LINC01016	3.8	0.000152	0.00902	0.15	0.12	Obesity (extreme);	chr6:33740473	chr6:33867506~33896914:-
BRCA	cis	rs7172809	0.587	rs28375490	ENSG00000260139.5	CSPG4P13	-3.8	0.000152	0.00902	-0.14	-0.12	Glucose homeostasis traits;	chr15:77556677	chr15:77894684~77904674:+
BRCA	cis	rs17783634	0.509	rs11775489	ENSG00000154316.13	TDH	3.8	0.000152	0.00902	0.15	0.12	Subjective well-being;	chr8:11179334	chr8:11339637~11368452:+
BRCA	cis	rs12724450	0.793	rs74124663	ENSG00000228126.1	FALEC	3.8	0.000152	0.00902	0.21	0.12	Blood protein levels;	chr1:150416472	chr1:150515757~150518032:+
BRCA	cis	rs754466	0.58	rs10824573	ENSG00000213514.2	RP11-428P16.2	3.8	0.000152	0.00902	0.16	0.12	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77781211	chr10:77730766~77734769:+
BRCA	cis	rs6545883	0.931	rs12713438	ENSG00000212978.6	AC016747.3	3.8	0.000152	0.00902	0.16	0.12	Tuberculosis;	chr2:61498366	chr2:61141592~61144969:-
BRCA	cis	rs7312933	0.703	rs10459290	ENSG00000257225.1	RP11-328C8.4	-3.8	0.000152	0.00902	-0.15	-0.12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42219488	chr12:42459366~42466128:+
BRCA	cis	rs9840812	0.769	rs1279840	ENSG00000273486.1	RP11-731C17.2	3.8	0.000152	0.00902	0.14	0.12	Fibrinogen levels;	chr3:136287734	chr3:136837338~136839021:-
BRCA	cis	rs1910358	0.69	rs1501937	ENSG00000248874.4	C5orf17	-3.8	0.000152	0.00902	-0.15	-0.12	Venous thromboembolism (SNP x SNP interaction);	chr5:23941957	chr5:23951348~24178263:+
BRCA	cis	rs595982	0.517	rs4801779	ENSG00000235191.1	NUCB1-AS1	3.8	0.000152	0.00902	0.15	0.12	Red cell distribution width;	chr19:48903394	chr19:48910930~48918891:-
BRCA	cis	rs2518049	0.861	rs4881396	ENSG00000224034.1	RP11-445P17.8	3.8	0.000152	0.00902	0.22	0.12	Metabolic traits;	chr10:5077965	chr10:5266033~5271236:-
BRCA	cis	rs6088580	0.634	rs6142157	ENSG00000275784.1	RP5-1125A11.6	3.8	0.000152	0.00903	0.13	0.12	Glomerular filtration rate (creatinine);	chr20:34396366	chr20:33989480~33991818:-
BRCA	cis	rs13434995	0.513	rs58476959	ENSG00000239040.1	Y_RNA	3.8	0.000152	0.00903	0.13	0.12	Adiponectin levels;	chr4:55496234	chr4:55412636~55412738:+
BRCA	cis	rs6593122	0.755	rs6958321	ENSG00000235454.1	HAUS6P3	-3.8	0.000152	0.00903	-0.16	-0.12	Vaccine-related adverse events;	chr7:54140067	chr7:53862233~53863339:+
BRCA	cis	rs1348850	0.874	rs2166558	ENSG00000280374.1	RP11-337N6.3	3.8	0.000153	0.00903	0.16	0.12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177508924	chr2:177317715~177318471:-
BRCA	cis	rs4722166	0.508	rs4506102	ENSG00000179428.2	AC073072.5	-3.8	0.000153	0.00903	-0.12	-0.12	Lung cancer;	chr7:22707533	chr7:22725395~22727620:-
BRCA	cis	rs6479874	1	rs6479874	ENSG00000223502.1	RP11-96B5.3	3.8	0.000153	0.00903	0.21	0.12	Migraine;	chr10:51029595	chr10:51062579~51068553:-
BRCA	cis	rs6439699	0.941	rs7648568	ENSG00000239213.4	NCK1-AS1	3.8	0.000153	0.00903	0.16	0.12	Intelligence (multi-trait analysis);	chr3:137341847	chr3:136841726~136862054:-
BRCA	cis	rs4648045	0.796	rs3774963	ENSG00000246560.2	RP11-10L12.4	3.8	0.000153	0.00903	0.13	0.12	Lymphocyte percentage of white cells;	chr4:102598208	chr4:102828055~102844075:+
BRCA	cis	rs7481584	0.624	rs449164	ENSG00000236710.1	AC108448.2	3.8	0.000153	0.00903	0.15	0.12	Calcium levels;	chr11:3032224	chr11:3084393~3085443:-
BRCA	cis	rs115769866	0.569	rs2859358	ENSG00000220721.1	OR1F12	3.8	0.000153	0.00903	0.15	0.12	Bipolar disorder;	chr6:28505044	chr6:28073316~28074233:+
BRCA	cis	rs4372836	0.504	rs7601934	ENSG00000226833.4	AC097724.3	-3.8	0.000153	0.00904	-0.14	-0.12	Body mass index;	chr2:28809807	chr2:28708953~28736205:-
BRCA	cis	rs863345	0.604	rs1894038	ENSG00000229914.1	RP11-404O13.4	-3.8	0.000153	0.00904	-0.12	-0.12	Pneumococcal bacteremia;	chr1:158486157	chr1:158195633~158196131:-
BRCA	cis	rs2010672	0.5	rs9888660	ENSG00000245479.2	LINC01585	3.8	0.000153	0.00904	0.14	0.12	Eosinophil counts;Sum eosinophil basophil counts;Eosinophil percentage of white cells;	chr15:90617536	chr15:90660234~90664967:+
BRCA	cis	rs1552244	0.515	rs111560858	ENSG00000180385.7	EMC3-AS1	3.8	0.000153	0.00904	0.16	0.12	Alzheimer's disease;	chr3:10125161	chr3:9986893~10006990:+
BRCA	cis	rs2109514	0.542	rs7796627	ENSG00000237813.3	AC002066.1	3.8	0.000153	0.00904	0.14	0.12	Prevalent atrial fibrillation;	chr7:116446662	chr7:116238260~116499465:-
BRCA	cis	rs1555133	0.694	rs6141289	ENSG00000275576.1	RP5-836N17.4	-3.8	0.000153	0.00904	-0.13	-0.12	Monocyte count;	chr20:32324757	chr20:32116171~32116629:+
BRCA	cis	rs6460942	0.908	rs77799203	ENSG00000226690.5	AC005281.1	3.8	0.000153	0.00904	0.22	0.12	Coronary artery disease;	chr7:12224806	chr7:12496429~12541910:+
BRCA	cis	rs11098499	0.661	rs10015965	ENSG00000260404.2	RP11-384K6.6	3.8	0.000153	0.00904	0.1	0.12	Corneal astigmatism;	chr4:119347082	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.863	rs7678400	ENSG00000260404.2	RP11-384K6.6	3.8	0.000153	0.00904	0.11	0.12	Corneal astigmatism;	chr4:119540802	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.863	rs1480936	ENSG00000260404.2	RP11-384K6.6	3.8	0.000153	0.00904	0.11	0.12	Corneal astigmatism;	chr4:119541706	chr4:118591773~118633729:+
BRCA	cis	rs757081	0.669	rs542274	ENSG00000272034.1	SNORD14A	-3.8	0.000153	0.00904	-0.12	-0.12	Systolic blood pressure;	chr11:17185886	chr11:17074654~17074744:-
BRCA	cis	rs74233809	1	rs11191502	ENSG00000236937.2	PTGES3P4	3.8	0.000153	0.00904	0.25	0.12	Birth weight;	chr10:103005737	chr10:102845595~102845950:+
BRCA	cis	rs6785206	0.892	rs6439143	ENSG00000242551.2	POU5F1P6	-3.8	0.000153	0.00904	-0.22	-0.12	Lymphocyte percentage of white cells;	chr3:128706289	chr3:128674735~128677005:-
BRCA	cis	rs853679	0.882	rs3757188	ENSG00000219392.1	RP1-265C24.5	-3.8	0.000153	0.00904	-0.25	-0.12	Depression;	chr6:28139579	chr6:28115628~28116551:+
BRCA	cis	rs524281	0.861	rs10896080	ENSG00000255038.1	RP11-1167A19.2	-3.8	0.000153	0.00904	-0.17	-0.12	Electroencephalogram traits;	chr11:66109325	chr11:66067277~66069619:-
BRCA	cis	rs6743226	0.58	rs12619620	ENSG00000266621.1	AC104841.1	3.8	0.000153	0.00904	0.14	0.12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in non-smokers;	chr2:241310679	chr2:241245202~241245299:-
BRCA	cis	rs73201462	1	rs11721213	ENSG00000242551.2	POU5F1P6	-3.8	0.000153	0.00904	-0.19	-0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128348598	chr3:128674735~128677005:-
BRCA	cis	rs78487399	0.808	rs998768	ENSG00000234936.1	AC010883.5	3.8	0.000153	0.00905	0.16	0.12	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43484384	chr2:43229573~43233394:+
BRCA	cis	rs6964587	0.967	rs17164315	ENSG00000188693.7	CYP51A1-AS1	-3.8	0.000153	0.00905	-0.13	-0.12	Breast cancer;	chr7:92029836	chr7:92134604~92180725:+
BRCA	cis	rs9844666	0.512	rs9849088	ENSG00000273486.1	RP11-731C17.2	3.8	0.000153	0.00905	0.13	0.12	Height;	chr3:135925060	chr3:136837338~136839021:-
BRCA	cis	rs9844666	0.512	rs56807950	ENSG00000273486.1	RP11-731C17.2	3.8	0.000153	0.00905	0.13	0.12	Height;	chr3:135925531	chr3:136837338~136839021:-
BRCA	cis	rs9844666	0.512	rs59063369	ENSG00000273486.1	RP11-731C17.2	3.8	0.000153	0.00905	0.13	0.12	Height;	chr3:135925636	chr3:136837338~136839021:-
BRCA	cis	rs801193	1	rs6975195	ENSG00000265600.1	AC006480.1	3.8	0.000153	0.00905	0.14	0.12	Aortic root size;	chr7:66659787	chr7:67356680~67356779:+
BRCA	cis	rs700651	0.789	rs1147169	ENSG00000231621.1	AC013264.2	3.8	0.000153	0.00905	0.11	0.12	Intracranial aneurysm;	chr2:198036671	chr2:197197991~197199273:+
BRCA	cis	rs6736093	0.966	rs11687451	ENSG00000236307.2	EEF1E1P1	-3.8	0.000153	0.00906	-0.15	-0.12	Coronary artery disease;	chr2:111924984	chr2:111887914~111888741:+
BRCA	cis	rs6736093	0.933	rs4848229	ENSG00000236307.2	EEF1E1P1	-3.8	0.000153	0.00906	-0.15	-0.12	Coronary artery disease;	chr2:111935073	chr2:111887914~111888741:+
BRCA	cis	rs6736093	0.966	rs34087685	ENSG00000236307.2	EEF1E1P1	-3.8	0.000153	0.00906	-0.15	-0.12	Coronary artery disease;	chr2:111935433	chr2:111887914~111888741:+
BRCA	cis	rs6736093	0.966	rs6743523	ENSG00000236307.2	EEF1E1P1	-3.8	0.000153	0.00906	-0.15	-0.12	Coronary artery disease;	chr2:111936298	chr2:111887914~111888741:+
BRCA	cis	rs12681366	0.708	rs2470728	ENSG00000253704.1	RP11-267M23.4	-3.8	0.000153	0.00906	-0.12	-0.12	Nonsyndromic cleft lip with cleft palate;	chr8:94354142	chr8:94553722~94569745:+
BRCA	cis	rs16846053	0.685	rs56078948	ENSG00000227403.1	AC009299.3	3.8	0.000153	0.00906	0.31	0.12	Blood osmolality (transformed sodium);	chr2:161874482	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.685	rs72881046	ENSG00000227403.1	AC009299.3	3.8	0.000153	0.00906	0.31	0.12	Blood osmolality (transformed sodium);	chr2:161875251	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.581	rs55711310	ENSG00000227403.1	AC009299.3	3.8	0.000153	0.00906	0.31	0.12	Blood osmolality (transformed sodium);	chr2:161876140	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.685	rs72881053	ENSG00000227403.1	AC009299.3	3.8	0.000153	0.00906	0.31	0.12	Blood osmolality (transformed sodium);	chr2:161878249	chr2:161244739~161249050:+
BRCA	cis	rs637571	0.544	rs12361552	ENSG00000255320.1	RP11-755F10.1	3.8	0.000153	0.00906	0.15	0.12	Eosinophil percentage of white cells;	chr11:65933733	chr11:66244840~66246239:-
BRCA	cis	rs10504130	0.932	rs76877865	ENSG00000272076.1	RP11-11C20.3	3.8	0.000153	0.00906	0.2	0.12	Venous thromboembolism (SNP x SNP interaction);	chr8:51803967	chr8:51810110~51810681:-
BRCA	cis	rs11039100	0.599	rs34123108	ENSG00000224295.2	AC087380.14	3.8	0.000153	0.00906	0.22	0.12	Peripheral arterial disease (traffic-related air pollution interaction);	chr11:5813494	chr11:5518441~5524955:-
BRCA	cis	rs11039100	0.85	rs34286221	ENSG00000224295.2	AC087380.14	3.8	0.000153	0.00906	0.22	0.12	Peripheral arterial disease (traffic-related air pollution interaction);	chr11:5813622	chr11:5518441~5524955:-
BRCA	cis	rs7260598	0.642	rs11667315	ENSG00000268442.1	CTD-2027I19.2	3.8	0.000153	0.00906	0.19	0.12	Response to taxane treatment (placlitaxel);	chr19:23932336	chr19:24162370~24163425:-
BRCA	cis	rs2562456	0.917	rs2681377	ENSG00000268555.1	RP11-678G14.3	-3.8	0.000153	0.00906	-0.15	-0.12	Pain;	chr19:21533718	chr19:21570822~21587322:-
BRCA	cis	rs6964587	0.934	rs12531561	ENSG00000188693.7	CYP51A1-AS1	-3.8	0.000153	0.00907	-0.13	-0.12	Breast cancer;	chr7:92078466	chr7:92134604~92180725:+
BRCA	cis	rs853679	1	rs68141011	ENSG00000216901.1	AL022393.7	3.8	0.000153	0.00907	0.2	0.12	Depression;	chr6:28250019	chr6:28176188~28176674:+
BRCA	cis	rs853679	1	rs13200462	ENSG00000216901.1	AL022393.7	3.8	0.000153	0.00907	0.2	0.12	Depression;	chr6:28250421	chr6:28176188~28176674:+
BRCA	cis	rs1218582	0.774	rs12036859	ENSG00000232093.1	RP11-307C12.11	3.8	0.000153	0.00907	0.12	0.12	Prostate cancer;	chr1:154887464	chr1:155045191~155046118:-
BRCA	cis	rs2832077	0.506	rs2832081	ENSG00000232855.5	AF131217.1	-3.8	0.000153	0.00907	-0.15	-0.12	Cognitive test performance;	chr21:28780670	chr21:28439346~28674848:-
BRCA	cis	rs935334	1	rs4903386	ENSG00000258454.1	RP11-361H10.3	3.8	0.000153	0.00907	0.19	0.12	Blood pressure;	chr14:76203315	chr14:76235817~76263474:+
BRCA	cis	rs7267979	0.932	rs13040655	ENSG00000276952.1	RP5-965G21.6	3.8	0.000153	0.00907	0.14	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25601561	chr20:25284915~25285588:-
BRCA	cis	rs911119	0.955	rs8116859	ENSG00000270001.1	RP11-218C14.8	-3.8	0.000153	0.00907	-0.15	-0.12	Chronic kidney disease;	chr20:23610066	chr20:23631826~23632316:-
BRCA	cis	rs67766926	0.761	rs10179897	ENSG00000237522.1	NONOP2	-3.8	0.000153	0.00907	-0.13	-0.12	Inflammatory skin disease;	chr2:60877700	chr2:60936819~60938049:-
BRCA	cis	rs6142618	0.562	rs4911550	ENSG00000275576.1	RP5-836N17.4	-3.8	0.000153	0.00907	-0.13	-0.12	Inflammatory bowel disease;	chr20:32151639	chr20:32116171~32116629:+
BRCA	cis	rs6496932	0.663	rs7183764	ENSG00000218052.5	ADAMTS7P4	-3.8	0.000153	0.00907	-0.12	-0.12	Central corneal thickness;Corneal structure;	chr15:85359820	chr15:85255369~85330334:-
BRCA	cis	rs6496932	0.663	rs4842878	ENSG00000218052.5	ADAMTS7P4	-3.8	0.000153	0.00907	-0.12	-0.12	Central corneal thickness;Corneal structure;	chr15:85361001	chr15:85255369~85330334:-
BRCA	cis	rs7620503	0.921	rs6768291	ENSG00000228561.2	RP11-114M1.1	3.8	0.000153	0.00907	0.14	0.12	Corneal structure;	chr3:177572395	chr3:177683627~177691250:+
BRCA	cis	rs7620503	0.917	rs1970861	ENSG00000228561.2	RP11-114M1.1	3.8	0.000153	0.00907	0.14	0.12	Corneal structure;	chr3:177573425	chr3:177683627~177691250:+
BRCA	cis	rs7620503	0.959	rs4241483	ENSG00000228561.2	RP11-114M1.1	3.8	0.000153	0.00907	0.14	0.12	Corneal structure;	chr3:177573530	chr3:177683627~177691250:+
BRCA	cis	rs3858526	0.92	rs11511938	ENSG00000224295.2	AC087380.14	3.8	0.000153	0.00907	0.17	0.12	DNA methylation (variation);	chr11:5907563	chr11:5518441~5524955:-
BRCA	cis	rs8114671	0.967	rs4911476	ENSG00000279253.1	RP4-614O4.13	3.8	0.000153	0.00907	0.13	0.12	Height;	chr20:35192965	chr20:35262727~35264187:-
BRCA	cis	rs3805389	0.504	rs3805385	ENSG00000273257.1	RP11-177J6.1	-3.8	0.000153	0.00907	-0.19	-0.12	Waist-to-hip ratio adjusted for body mass index;	chr4:55613821	chr4:55387949~55388271:+
BRCA	cis	rs62458065	0.568	rs62463963	ENSG00000281332.1	LINC00997	-3.8	0.000153	0.00907	-0.18	-0.12	Metabolite levels (HVA/MHPG ratio);	chr7:32447079	chr7:32760279~32762924:+
BRCA	cis	rs6696239	0.956	rs12081818	ENSG00000215812.5	ZNF847P	3.8	0.000153	0.00907	0.16	0.12	Height;	chr1:227632673	chr1:227696892~227706699:-
BRCA	cis	rs2191566	1	rs390369	ENSG00000266921.1	RP11-15A1.7	3.8	0.000153	0.00907	0.15	0.12	Acute lymphoblastic leukemia (childhood);	chr19:44002832	chr19:43996896~44002836:-
BRCA	cis	rs13126694	0.633	rs13140039	ENSG00000248429.4	RP11-597D13.9	3.8	0.000153	0.00907	0.11	0.12	Blood osmolality (transformed sodium);	chr4:158075041	chr4:158170752~158202877:+
BRCA	cis	rs138880	0.58	rs28562884	ENSG00000229409.1	RP11-494O16.3	3.8	0.000153	0.00907	0.23	0.12	Schizophrenia;	chr22:49919221	chr22:49845929~49846090:+
BRCA	cis	rs11621710	0.557	rs799474	ENSG00000226677.3	IGBP1P1	3.8	0.000153	0.00907	0.14	0.12	Granulocyte percentage of myeloid white cells;	chr14:35046893	chr14:34939324~34940332:+
BRCA	cis	rs4415084	0.966	rs34762678	ENSG00000248779.1	RP11-53O19.2	3.8	0.000153	0.00907	0.11	0.12	Breast cancer;	chr5:44705412	chr5:44752949~44765744:+
BRCA	cis	rs801193	0.569	rs2659907	ENSG00000229886.1	RP5-1132H15.3	3.8	0.000153	0.00908	0.13	0.12	Aortic root size;	chr7:66699045	chr7:66025126~66031544:-
BRCA	cis	rs860818	1	rs1626853	ENSG00000230658.1	KLHL7-AS1	-3.8	0.000153	0.00908	-0.29	-0.12	Initial pursuit acceleration;	chr7:23195723	chr7:23101228~23105703:-
BRCA	cis	rs9663711	1	rs9663711	ENSG00000236937.2	PTGES3P4	3.8	0.000153	0.00908	0.15	0.12	Carotid plaque burden;	chr10:102787871	chr10:102845595~102845950:+
BRCA	cis	rs4664293	0.647	rs4665082	ENSG00000226266.5	AC009961.3	-3.8	0.000153	0.00908	-0.14	-0.12	Monocyte percentage of white cells;	chr2:159573455	chr2:159670708~159712435:-
BRCA	cis	rs6964587	0.967	rs2040499	ENSG00000188693.7	CYP51A1-AS1	3.8	0.000153	0.00908	0.13	0.12	Breast cancer;	chr7:92180343	chr7:92134604~92180725:+
BRCA	cis	rs11887277	0.507	rs6547275	ENSG00000272148.1	RP11-195B17.1	-3.8	0.000154	0.00908	-0.13	-0.12	Obesity-related traits;	chr2:26841709	chr2:27062428~27062907:-
BRCA	cis	rs853679	0.546	rs200954	ENSG00000216901.1	AL022393.7	3.8	0.000154	0.00908	0.23	0.12	Depression;	chr6:27870986	chr6:28176188~28176674:+
BRCA	cis	rs4388249	1	rs12656748	ENSG00000271849.1	CTC-332L22.1	-3.8	0.000154	0.00908	-0.19	-0.12	Schizophrenia;	chr5:109707528	chr5:109687802~109688329:-
BRCA	cis	rs73222236	0.737	rs9854328	ENSG00000239213.4	NCK1-AS1	3.8	0.000154	0.00908	0.12	0.12	Coronary artery disease;	chr3:136350878	chr3:136841726~136862054:-
BRCA	cis	rs7949030	0.653	rs17773169	ENSG00000254964.1	RP11-831H9.3	-3.8	0.000154	0.00908	-0.14	-0.12	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62551058	chr11:62606161~62606405:+
BRCA	cis	rs11168351	0.591	rs4258439	ENSG00000273765.1	RP11-370I10.11	-3.8	0.000154	0.00908	-0.13	-0.12	Bipolar disorder and schizophrenia;	chr12:48074869	chr12:48360920~48361377:+
BRCA	cis	rs10129255	0.957	rs8022165	ENSG00000211967.3	IGHV3-53	-3.8	0.000154	0.00908	-0.08	-0.12	Kawasaki disease;	chr14:106781682	chr14:106592676~106593347:-
BRCA	cis	rs733592	0.507	rs7299704	ENSG00000273765.1	RP11-370I10.11	3.8	0.000154	0.00908	0.13	0.12	Plateletcrit;	chr12:48050705	chr12:48360920~48361377:+
BRCA	cis	rs7267979	1	rs2482937	ENSG00000277938.1	RP5-965G21.3	-3.8	0.000154	0.00909	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25360150	chr20:25229150~25231933:+
BRCA	cis	rs7937890	0.559	rs10766184	ENSG00000254418.1	RP11-21L19.1	3.8	0.000154	0.00909	0.14	0.12	Mitochondrial DNA levels;	chr11:14521031	chr11:14262846~14273691:-
BRCA	cis	rs2411233	0.935	rs11855891	ENSG00000259278.1	RP11-62C7.2	3.8	0.000154	0.00909	0.14	0.12	Platelet count;	chr15:38977438	chr15:39019233~39024918:+
BRCA	cis	rs1023500	0.505	rs134887	ENSG00000233903.2	Z83851.4	3.8	0.000154	0.00909	0.14	0.12	Schizophrenia;	chr22:42278233	chr22:42276355~42277052:+
BRCA	cis	rs72928364	0.929	rs10511182	ENSG00000256628.3	ZBTB11-AS1	3.8	0.000154	0.00909	0.22	0.12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:101053991	chr3:101676475~101679217:+
BRCA	cis	rs7772486	0.875	rs10457795	ENSG00000270638.1	RP3-466P17.1	3.8	0.000154	0.00909	0.13	0.12	Lobe attachment (rater-scored or self-reported);	chr6:146094529	chr6:145735570~145737218:+
BRCA	cis	rs654950	0.84	rs2810551	ENSG00000230638.4	RP11-486B10.4	3.8	0.000154	0.00909	0.15	0.12	Airway imaging phenotypes;	chr1:41529731	chr1:41542069~41544310:+
BRCA	cis	rs6686842	0.932	rs3157	ENSG00000235358.1	RP11-399E6.1	3.8	0.000154	0.00909	0.15	0.12	Height;	chr1:41027439	chr1:41242373~41284861:+
BRCA	cis	rs853679	0.556	rs34706883	ENSG00000216901.1	AL022393.7	3.8	0.000154	0.00909	0.3	0.12	Depression;	chr6:27837477	chr6:28176188~28176674:+
BRCA	cis	rs11070836	0.967	rs59415822	ENSG00000259378.1	DCAF13P3	3.8	0.000154	0.00909	0.15	0.12	Airway wall thickness;	chr15:51121567	chr15:50944663~50945996:+
BRCA	cis	rs2243480	0.522	rs431168	ENSG00000164669.11	INTS4P1	3.8	0.000154	0.00909	0.28	0.12	Diabetic kidney disease;	chr7:66046617	chr7:65141225~65234216:+
BRCA	cis	rs7722600	0.808	rs77915370	ENSG00000253404.1	AC034243.1	-3.8	0.000154	0.0091	-0.2	-0.12	Heart rate;	chr5:138035301	chr5:138744434~138753309:-
BRCA	cis	rs7722600	0.683	rs13355516	ENSG00000253404.1	AC034243.1	-3.8	0.000154	0.0091	-0.2	-0.12	Heart rate;	chr5:138044914	chr5:138744434~138753309:-
BRCA	cis	rs7267979	0.932	rs433352	ENSG00000274973.1	RP13-401N8.7	3.8	0.000154	0.0091	0.13	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25487356	chr20:25845497~25845862:+
BRCA	cis	rs11039100	0.85	rs12796660	ENSG00000224295.2	AC087380.14	3.8	0.000154	0.0091	0.22	0.12	Peripheral arterial disease (traffic-related air pollution interaction);	chr11:5822451	chr11:5518441~5524955:-
BRCA	cis	rs10761482	0.861	rs1350633	ENSG00000254271.1	RP11-131N11.4	3.8	0.000154	0.0091	0.17	0.12	Schizophrenia;	chr10:60352152	chr10:60734342~60741828:+
BRCA	cis	rs10761482	0.813	rs10740026	ENSG00000254271.1	RP11-131N11.4	3.8	0.000154	0.0091	0.17	0.12	Schizophrenia;	chr10:60353084	chr10:60734342~60741828:+
BRCA	cis	rs10761482	0.861	rs4948410	ENSG00000254271.1	RP11-131N11.4	3.8	0.000154	0.0091	0.17	0.12	Schizophrenia;	chr10:60356289	chr10:60734342~60741828:+
BRCA	cis	rs6005807	0.719	rs9620810	ENSG00000272858.1	CTA-292E10.8	-3.8	0.000154	0.0091	-0.21	-0.12	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28657739	chr22:28814914~28815662:+
BRCA	cis	rs6005807	0.719	rs12169880	ENSG00000272858.1	CTA-292E10.8	-3.8	0.000154	0.0091	-0.21	-0.12	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28658887	chr22:28814914~28815662:+
BRCA	cis	rs4865169	0.623	rs6838975	ENSG00000269949.1	RP11-738E22.3	-3.8	0.000154	0.0091	-0.15	-0.12	Breast cancer;	chr4:56873650	chr4:56960927~56961373:-
BRCA	cis	rs375066	0.935	rs108775	ENSG00000278917.1	RP11-15A1.4	-3.8	0.000154	0.0091	-0.13	-0.12	Breast cancer;	chr19:43901770	chr19:43891233~43895411:+
BRCA	cis	rs7267979	1	rs6515651	ENSG00000276952.1	RP5-965G21.6	-3.8	0.000154	0.0091	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25433903	chr20:25284915~25285588:-
BRCA	cis	rs66887589	0.592	rs11731571	ENSG00000250412.1	KLHL2P1	3.8	0.000154	0.0091	0.13	0.12	Diastolic blood pressure;	chr4:119300030	chr4:119334329~119378233:+
BRCA	cis	rs4243971	0.516	rs4911229	ENSG00000275576.1	RP5-836N17.4	3.8	0.000154	0.0091	0.13	0.12	Inflammatory bowel disease;Crohn's disease;	chr20:32426173	chr20:32116171~32116629:+
BRCA	cis	rs721917	0.506	rs2819102	ENSG00000280355.1	RP11-119F19.5	-3.8	0.000154	0.0091	-0.13	-0.12	Chronic obstructive pulmonary disease;	chr10:79928914	chr10:79681973~79684094:-
BRCA	cis	rs6439699	1	rs58088387	ENSG00000273486.1	RP11-731C17.2	3.8	0.000154	0.00911	0.16	0.12	Intelligence (multi-trait analysis);	chr3:137291160	chr3:136837338~136839021:-
BRCA	cis	rs934734	0.532	rs7557569	ENSG00000281920.1	RP11-418H16.1	-3.8	0.000154	0.00911	-0.14	-0.12	Rheumatoid arthritis;	chr2:65417427	chr2:65623272~65628424:+
BRCA	cis	rs9287719	0.967	rs6712304	ENSG00000224177.5	LINC00570	3.8	0.000154	0.00911	0.14	0.12	Prostate cancer;	chr2:10614249	chr2:11393981~11403077:+
BRCA	cis	rs13272568	0.614	rs13258690	ENSG00000254352.1	RP11-578O24.2	3.8	0.000154	0.00911	0.15	0.12	Bone mineral density;	chr8:78117546	chr8:78723796~78724136:-
BRCA	cis	rs4415084	0.652	rs4591754	ENSG00000251141.4	RP11-53O19.1	-3.8	0.000154	0.00911	-0.11	-0.12	Breast cancer;	chr5:44894989	chr5:44744900~44808777:-
BRCA	cis	rs930395	0.514	rs7356604	ENSG00000251141.4	RP11-53O19.1	-3.8	0.000154	0.00911	-0.11	-0.12	Breast cancer;	chr5:44895097	chr5:44744900~44808777:-
BRCA	cis	rs7246967	1	rs34629498	ENSG00000198153.8	ZNF849P	-3.8	0.000154	0.00911	-0.17	-0.12	Bronchopulmonary dysplasia;	chr19:22877918	chr19:22685167~22686732:+
BRCA	cis	rs875971	0.862	rs10274883	ENSG00000229886.1	RP5-1132H15.3	-3.8	0.000154	0.00911	-0.13	-0.12	Aortic root size;	chr7:66651104	chr7:66025126~66031544:-
BRCA	cis	rs2307449	0.892	rs9806604	ENSG00000260123.1	RP11-326A19.4	3.8	0.000154	0.00911	0.14	0.12	Menopause (age at onset);	chr15:89283265	chr15:89041223~89082819:+
BRCA	cis	rs10461617	0.535	rs7709874	ENSG00000271828.1	CTD-2310F14.1	3.8	0.000154	0.00911	0.15	0.12	Type 2 diabetes;	chr5:56751624	chr5:56927874~56929573:+
BRCA	cis	rs1354774	0.505	rs8103659	ENSG00000197588.8	KLKP1	-3.8	0.000154	0.00911	-0.12	-0.12	Prostate-specific antigen levels;	chr19:50882146	chr19:50882096~50896398:-
BRCA	cis	rs180730	0.66	rs1114026	ENSG00000251609.2	SETP12	-3.8	0.000154	0.00911	-0.18	-0.12	Fasting plasma glucose;	chr4:120934416	chr4:120895494~120897083:-
BRCA	cis	rs7267979	1	rs6115168	ENSG00000274414.1	RP5-965G21.4	3.8	0.000154	0.00911	0.14	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25392255	chr20:25239007~25245229:-
BRCA	cis	rs10463316	0.894	rs7707964	ENSG00000260581.1	CTB-113P19.4	3.8	0.000154	0.00912	0.14	0.12	Metabolite levels (Pyroglutamine);	chr5:151385914	chr5:151652275~151655449:+
BRCA	cis	rs875971	0.862	rs10276077	ENSG00000273024.4	INTS4P2	3.8	0.000154	0.00912	0.13	0.12	Aortic root size;	chr7:66263424	chr7:65647864~65715661:+
BRCA	cis	rs10129255	0.957	rs12589190	ENSG00000211967.3	IGHV3-53	-3.8	0.000154	0.00912	-0.08	-0.12	Kawasaki disease;	chr14:106783079	chr14:106592676~106593347:-
BRCA	cis	rs10761482	0.601	rs7922622	ENSG00000254271.1	RP11-131N11.4	-3.8	0.000154	0.00912	-0.16	-0.12	Schizophrenia;	chr10:60447765	chr10:60734342~60741828:+
BRCA	cis	rs6696239	0.956	rs12133625	ENSG00000227711.2	RP11-275O4.5	-3.8	0.000154	0.00912	-0.16	-0.12	Height;	chr1:227656481	chr1:227509028~227520477:-
BRCA	cis	rs524281	0.861	rs10896091	ENSG00000255557.1	RP11-770G2.2	3.8	0.000154	0.00912	0.16	0.12	Electroencephalogram traits;	chr11:66183354	chr11:65745729~65771585:+
BRCA	cis	rs1124769	0.57	rs2414052	ENSG00000273674.3	CTD-2378E12.1	3.8	0.000154	0.00912	0.14	0.12	Cognitive performance;	chr15:50848104	chr15:50839875~50908599:-
BRCA	cis	rs9844666	0.512	rs9833699	ENSG00000239213.4	NCK1-AS1	3.8	0.000154	0.00912	0.14	0.12	Height;	chr3:135922442	chr3:136841726~136862054:-
BRCA	cis	rs9844666	0.512	rs9875948	ENSG00000239213.4	NCK1-AS1	3.8	0.000154	0.00912	0.14	0.12	Height;	chr3:135923062	chr3:136841726~136862054:-
BRCA	cis	rs8180040	0.726	rs1463393	ENSG00000280667.1	Y_RNA	-3.8	0.000154	0.00912	-0.13	-0.12	Colorectal cancer;	chr3:46953497	chr3:47501083~47501182:+
BRCA	cis	rs7267979	1	rs6083828	ENSG00000276952.1	RP5-965G21.6	-3.8	0.000154	0.00912	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25389282	chr20:25284915~25285588:-
BRCA	cis	rs4950322	0.542	rs2883434	ENSG00000237188.3	RP11-337C18.8	3.8	0.000154	0.00912	0.13	0.12	Protein quantitative trait loci;	chr1:147177505	chr1:147172771~147211568:+
BRCA	cis	rs10829156	0.755	rs10732437	ENSG00000225527.1	RP11-383B4.4	-3.8	0.000154	0.00912	-0.17	-0.12	Sudden cardiac arrest;	chr10:18626973	chr10:18531849~18533336:-
BRCA	cis	rs875971	0.862	rs778736	ENSG00000229886.1	RP5-1132H15.3	3.8	0.000154	0.00912	0.13	0.12	Aortic root size;	chr7:66348861	chr7:66025126~66031544:-
BRCA	cis	rs62458065	0.85	rs62458099	ENSG00000229358.3	DPY19L1P1	-3.8	0.000154	0.00912	-0.17	-0.12	Metabolite levels (HVA/MHPG ratio);	chr7:32432783	chr7:32580949~32761787:-
BRCA	cis	rs62458065	0.85	rs62458100	ENSG00000229358.3	DPY19L1P1	-3.8	0.000154	0.00912	-0.17	-0.12	Metabolite levels (HVA/MHPG ratio);	chr7:32433530	chr7:32580949~32761787:-
BRCA	cis	rs6762	0.748	rs1130663	ENSG00000255142.1	AP006621.6	3.8	0.000154	0.00912	0.1	0.12	Mean platelet volume;	chr11:837582	chr11:781645~782105:+
BRCA	cis	rs9470794	1	rs11756030	ENSG00000204110.6	RP1-153P14.8	-3.8	0.000154	0.00913	-0.24	-0.12	Type 2 diabetes;	chr6:37973184	chr6:37507348~37535616:+
BRCA	cis	rs2039553	0.574	rs2802641	ENSG00000227354.5	RBM26-AS1	3.8	0.000154	0.00913	0.13	0.12	Pancreatic cancer;	chr13:79749820	chr13:79406309~79424328:+
BRCA	cis	rs2729313	0.818	rs115864661	ENSG00000214073.2	RPL21P17	3.8	0.000154	0.00913	0.26	0.12	Asymmetrical dimethylarginine levels;	chr3:1963010	chr3:1905651~1906125:+
BRCA	cis	rs11098499	0.909	rs79026312	ENSG00000260091.1	RP11-33B1.4	-3.8	0.000154	0.00913	-0.11	-0.12	Corneal astigmatism;	chr4:119519522	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.909	rs35111518	ENSG00000260091.1	RP11-33B1.4	-3.8	0.000154	0.00913	-0.11	-0.12	Corneal astigmatism;	chr4:119519527	chr4:119409333~119410233:+
BRCA	cis	rs7412746	0.622	rs11552229	ENSG00000231073.1	RP11-316M1.3	3.8	0.000154	0.00913	0.13	0.12	Melanoma;	chr1:150811509	chr1:150973123~150975534:+
BRCA	cis	rs10911902	0.643	rs3820181	ENSG00000229739.2	RP11-295K2.3	-3.8	0.000155	0.00913	-0.16	-0.12	Schizophrenia;	chr1:186347067	chr1:186435161~186470291:+
BRCA	cis	rs10819861	0.679	rs7854100	ENSG00000175611.10	LINC00476	3.8	0.000155	0.00913	0.12	0.12	Electrocardiographic traits;	chr9:96102317	chr9:95759231~95875977:-
BRCA	cis	rs8099594	0.565	rs1893526	ENSG00000266696.1	RP11-30L3.2	3.8	0.000155	0.00913	0.13	0.12	Height;	chr18:49185406	chr18:49205912~49208781:+
BRCA	cis	rs2411233	1	rs11070166	ENSG00000259278.1	RP11-62C7.2	3.8	0.000155	0.00913	0.14	0.12	Platelet count;	chr15:38988596	chr15:39019233~39024918:+
BRCA	cis	rs875971	1	rs6958271	ENSG00000272831.1	RP11-792A8.4	3.8	0.000155	0.00914	0.11	0.12	Aortic root size;	chr7:66514344	chr7:66739829~66740385:-
BRCA	cis	rs875971	1	rs6958277	ENSG00000272831.1	RP11-792A8.4	3.8	0.000155	0.00914	0.11	0.12	Aortic root size;	chr7:66514362	chr7:66739829~66740385:-
BRCA	cis	rs9470794	1	rs55743233	ENSG00000204110.6	RP1-153P14.8	-3.8	0.000155	0.00914	-0.24	-0.12	Type 2 diabetes;	chr6:38062271	chr6:37507348~37535616:+
BRCA	cis	rs1019173	1	rs9655613	ENSG00000261455.1	LINC01003	3.8	0.000155	0.00914	0.13	0.12	Kidney function decline traits;	chr7:152016433	chr7:152463786~152465549:+
BRCA	cis	rs2868985	1	rs2868985	ENSG00000203327.2	AC012358.7	-3.8	0.000155	0.00914	-0.15	-0.12	Schizophrenia;	chr2:55964335	chr2:55214387~55216126:-
BRCA	cis	rs2839186	0.596	rs4819217	ENSG00000228137.1	AP001469.7	3.8	0.000155	0.00914	0.13	0.12	Testicular germ cell tumor;	chr21:46224178	chr21:46246890~46247682:+
BRCA	cis	rs6484218	0.562	rs10840399	ENSG00000250041.2	CTD-2003C8.2	3.8	0.000155	0.00914	0.19	0.12	Schizophrenia, bipolar disorder and depression (combined);	chr11:10377574	chr11:10884885~10899322:-
BRCA	cis	rs2243480	1	rs316332	ENSG00000237026.1	RP11-328P23.2	3.8	0.000155	0.00914	0.21	0.12	Diabetic kidney disease;	chr7:66139312	chr7:65235790~65236723:-
BRCA	cis	rs72799341	1	rs1458201	ENSG00000275263.1	RP11-1072A3.4	-3.8	0.000155	0.00914	-0.16	-0.12	Diastolic blood pressure;	chr16:30904808	chr16:30956872~30957199:-
BRCA	cis	rs8030379	0.519	rs11259926	ENSG00000176700.18	SCAND2P	-3.8	0.000155	0.00914	-0.11	-0.12	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83897496	chr15:84631451~84647478:+
BRCA	cis	rs2991971	0.776	rs12139364	ENSG00000280836.1	AL355480.1	3.8	0.000155	0.00914	0.14	0.12	High light scatter reticulocyte count;	chr1:45424483	chr1:45581219~45581321:-
BRCA	cis	rs1969253	0.803	rs843360	ENSG00000205955.4	HSP90AA5P	-3.8	0.000155	0.00914	-0.14	-0.12	Major depressive disorder;	chr3:184148012	chr3:184115352~184117898:+
BRCA	cis	rs116175783	0.557	rs1267058	ENSG00000235724.7	AC009299.2	-3.8	0.000155	0.00915	-0.18	-0.12	Intelligence (multi-trait analysis);	chr2:161264934	chr2:161222785~161308303:-
BRCA	cis	rs875971	0.862	rs1983372	ENSG00000273024.4	INTS4P2	3.8	0.000155	0.00915	0.13	0.12	Aortic root size;	chr7:66146364	chr7:65647864~65715661:+
BRCA	cis	rs2227564	0.597	rs2633305	ENSG00000279689.1	RP11-574K11.32	3.8	0.000155	0.00915	0.13	0.12	Crohn's disease;Inflammatory bowel disease;	chr10:73892365	chr10:73769264~73772862:-
BRCA	cis	rs17818399	0.547	rs4952831	ENSG00000279254.1	RP11-536C12.1	-3.8	0.000155	0.00915	-0.16	-0.12	Height;	chr2:46534042	chr2:46668870~46670778:+
BRCA	cis	rs13434995	0.513	rs62310862	ENSG00000239040.1	Y_RNA	3.8	0.000155	0.00915	0.14	0.12	Adiponectin levels;	chr4:55572594	chr4:55412636~55412738:+
BRCA	cis	rs3892630	0.588	rs8106748	ENSG00000267475.1	CTD-2538C1.2	-3.8	0.000155	0.00915	-0.17	-0.12	Red blood cell traits;	chr19:32791891	chr19:32687089~32691750:-
BRCA	cis	rs6963495	0.818	rs6957192	ENSG00000223886.3	RP11-251G23.2	-3.8	0.000155	0.00915	-0.18	-0.12	Bipolar disorder (body mass index interaction);	chr7:105509808	chr7:105530209~105530671:+
BRCA	cis	rs6088580	0.634	rs6088478	ENSG00000275784.1	RP5-1125A11.6	3.8	0.000155	0.00915	0.13	0.12	Glomerular filtration rate (creatinine);	chr20:34383913	chr20:33989480~33991818:-
BRCA	cis	rs2518049	0.654	rs61854738	ENSG00000224034.1	RP11-445P17.8	-3.8	0.000155	0.00916	-0.22	-0.12	Metabolic traits;	chr10:5199509	chr10:5266033~5271236:-
BRCA	cis	rs7412746	0.621	rs72704656	ENSG00000231073.1	RP11-316M1.3	3.8	0.000155	0.00916	0.13	0.12	Melanoma;	chr1:150855831	chr1:150973123~150975534:+
BRCA	cis	rs1032833	0.732	rs77225055	ENSG00000271401.1	RP11-171I2.3	-3.8	0.000155	0.00916	-0.3	-0.12	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);	chr2:179082837	chr2:178644717~178645179:+
BRCA	cis	rs7267979	0.966	rs4815425	ENSG00000276952.1	RP5-965G21.6	-3.8	0.000155	0.00916	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25418240	chr20:25284915~25285588:-
BRCA	cis	rs7777677	0.925	rs4726542	ENSG00000232869.2	TRBV29-1	-3.8	0.000155	0.00916	-0.09	-0.12	Alcoholic chronic pancreatitis;	chr7:142659516	chr7:142740206~142740894:+
BRCA	cis	rs7246967	0.544	rs403717	ENSG00000198153.8	ZNF849P	-3.8	0.000155	0.00916	-0.17	-0.12	Bronchopulmonary dysplasia;	chr19:22826001	chr19:22685167~22686732:+
BRCA	cis	rs7246967	0.544	rs391308	ENSG00000198153.8	ZNF849P	-3.8	0.000155	0.00916	-0.17	-0.12	Bronchopulmonary dysplasia;	chr19:22826758	chr19:22685167~22686732:+
BRCA	cis	rs72772090	0.522	rs17398914	ENSG00000248734.2	CTD-2260A17.1	-3.8	0.000155	0.00916	-0.25	-0.12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96669476	chr5:96784777~96785999:+
BRCA	cis	rs3808502	0.527	rs2736374	ENSG00000154316.13	TDH	3.8	0.000155	0.00916	0.15	0.12	Neuroticism;	chr8:11256319	chr8:11339637~11368452:+
BRCA	cis	rs4664293	0.647	rs10192408	ENSG00000226266.5	AC009961.3	-3.8	0.000155	0.00916	-0.14	-0.12	Monocyte percentage of white cells;	chr2:159568083	chr2:159670708~159712435:-
BRCA	cis	rs4478858	0.735	rs2889730	ENSG00000223907.1	LINC01226	-3.8	0.000155	0.00916	-0.14	-0.12	Alcohol dependence;	chr1:31354312	chr1:31518435~31524245:+
BRCA	cis	rs17772222	0.917	rs17188207	ENSG00000258789.1	RP11-507K2.3	-3.8	0.000155	0.00916	-0.14	-0.12	Coronary artery calcification;	chr14:88699579	chr14:88551597~88552493:+
BRCA	cis	rs10043775	0.793	rs13176114	ENSG00000251330.3	CTD-2283N19.1	-3.8	0.000155	0.00916	-0.14	-0.12	Periodontal microbiota;	chr5:148311357	chr5:148430159~148430807:-
BRCA	cis	rs10043775	0.793	rs6580542	ENSG00000251330.3	CTD-2283N19.1	-3.8	0.000155	0.00916	-0.14	-0.12	Periodontal microbiota;	chr5:148312943	chr5:148430159~148430807:-
BRCA	cis	rs10043775	0.793	rs3749690	ENSG00000251330.3	CTD-2283N19.1	-3.8	0.000155	0.00916	-0.14	-0.12	Periodontal microbiota;	chr5:148314263	chr5:148430159~148430807:-
BRCA	cis	rs10043775	0.831	rs7713986	ENSG00000251330.3	CTD-2283N19.1	-3.8	0.000155	0.00916	-0.14	-0.12	Periodontal microbiota;	chr5:148314552	chr5:148430159~148430807:-
BRCA	cis	rs10043775	0.709	rs6875252	ENSG00000251330.3	CTD-2283N19.1	-3.8	0.000155	0.00916	-0.14	-0.12	Periodontal microbiota;	chr5:148314776	chr5:148430159~148430807:-
BRCA	cis	rs1730008	0.701	rs11712563	ENSG00000279311.1	RP11-170K4.2	3.8	0.000155	0.00916	0.15	0.12	Lobe attachment (rater-scored or self-reported);	chr3:158319155	chr3:158869898~158871821:+
BRCA	cis	rs11662721	0.938	rs11659365	ENSG00000264188.1	RP11-13N13.5	3.8	0.000155	0.00916	0.16	0.12	Phospholipid levels (plasma);	chr18:21672540	chr18:21661787~21662395:-
BRCA	cis	rs733592	0.507	rs7304428	ENSG00000257763.1	OR5BK1P	-3.8	0.000155	0.00916	-0.11	-0.12	Plateletcrit;	chr12:48100492	chr12:48355792~48356614:-
BRCA	cis	rs1371614	0.632	rs12615423	ENSG00000229122.1	AGBL5-IT1	-3.8	0.000155	0.00917	-0.12	-0.12	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26935755	chr2:27061038~27061815:+
BRCA	cis	rs983392	1	rs10897009	ENSG00000275344.1	MIR6503	-3.8	0.000155	0.00917	-0.12	-0.12	Alzheimer's disease (late onset);	chr11:60155721	chr11:60209071~60209156:-
BRCA	cis	rs73201462	0.901	rs35347185	ENSG00000242551.2	POU5F1P6	3.8	0.000155	0.00917	0.2	0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128135684	chr3:128674735~128677005:-
BRCA	cis	rs728616	0.558	rs12414691	ENSG00000225484.5	NUTM2B-AS1	-3.8	0.000155	0.00917	-0.24	-0.12	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80397226	chr10:79663088~79826594:-
BRCA	cis	rs78487399	0.731	rs6722104	ENSG00000234936.1	AC010883.5	3.8	0.000155	0.00917	0.18	0.12	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43525207	chr2:43229573~43233394:+
BRCA	cis	rs78487399	0.808	rs6751161	ENSG00000234936.1	AC010883.5	3.8	0.000155	0.00917	0.18	0.12	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43525409	chr2:43229573~43233394:+
BRCA	cis	rs11239930	0.517	rs2477568	ENSG00000237188.3	RP11-337C18.8	-3.8	0.000155	0.00917	-0.14	-0.12	AIDS progression;	chr1:147076244	chr1:147172771~147211568:+
BRCA	cis	rs4950322	0.748	rs56392137	ENSG00000237188.3	RP11-337C18.8	3.8	0.000155	0.00917	0.16	0.12	Protein quantitative trait loci;	chr1:147352450	chr1:147172771~147211568:+
BRCA	cis	rs7703051	0.965	rs12916	ENSG00000271815.1	CTD-2235C13.3	-3.8	0.000155	0.00917	-0.15	-0.12	Age-related diseases, mortality and associated endophenotypes;LDL cholesterol;Age-related disease endophenotypes;	chr5:75360714	chr5:75363760~75364242:+
BRCA	cis	rs7818688	1	rs28496357	ENSG00000245080.5	RP11-320N21.1	-3.8	0.000155	0.00917	-0.19	-0.12	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95018283	chr8:95066808~95073182:-
BRCA	cis	rs7267979	1	rs2424716	ENSG00000276952.1	RP5-965G21.6	3.8	0.000155	0.00917	0.14	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25442902	chr20:25284915~25285588:-
BRCA	cis	rs7267979	1	rs761025	ENSG00000276952.1	RP5-965G21.6	3.8	0.000155	0.00917	0.14	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25446332	chr20:25284915~25285588:-
BRCA	cis	rs9549260	0.753	rs1986649	ENSG00000168852.11	TPTE2P5	3.8	0.000155	0.00918	0.14	0.12	Red blood cell count;	chr13:40604687	chr13:40822296~40921749:-
BRCA	cis	rs687432	0.812	rs7113760	ENSG00000265566.2	RN7SL605P	-3.8	0.000155	0.00918	-0.17	-0.12	Parkinson's disease;	chr11:58079210	chr11:57528085~57528365:-
BRCA	cis	rs4272720	1	rs36116147	ENSG00000228754.1	RP11-534L6.3	-3.8	0.000155	0.00918	-0.16	-0.12	Platelet count;Plateletcrit;	chr10:49058885	chr10:48745545~48746128:-
BRCA	cis	rs6991838	0.584	rs6993876	ENSG00000272155.1	RP11-707M3.3	-3.8	0.000155	0.00918	-0.11	-0.12	Intelligence (multi-trait analysis);	chr8:65601240	chr8:65714334~65714778:-
BRCA	cis	rs739496	0.947	rs12580300	ENSG00000257624.1	RP1-128M12.3	3.8	0.000155	0.00918	0.16	0.12	Platelet count;	chr12:111411467	chr12:112000739~112000985:-
BRCA	cis	rs739496	0.947	rs7973120	ENSG00000257624.1	RP1-128M12.3	3.8	0.000155	0.00918	0.16	0.12	Platelet count;	chr12:111418934	chr12:112000739~112000985:-
BRCA	cis	rs360929	0.935	rs191711	ENSG00000245954.5	RP11-18H21.1	3.8	0.000155	0.00918	0.13	0.12	Volumetric brain MRI;	chr4:151982386	chr4:152100754~152104720:+
BRCA	cis	rs2140773	0.935	rs13395911	ENSG00000244384.3	RN7SL359P	-3.8	0.000155	0.00918	-0.12	-0.12	Liver enzyme levels (gamma-glutamyl transferase);	chr2:232655544	chr2:232649849~232650136:+
BRCA	cis	rs4699052	0.537	rs1580278	ENSG00000251288.2	RP11-10L12.2	3.8	0.000155	0.00918	0.14	0.12	Testicular germ cell tumor;	chr4:103219691	chr4:102751401~102752641:+
BRCA	cis	rs9959145	0.925	rs75813125	ENSG00000267108.1	RP11-861E21.1	3.8	0.000155	0.00918	0.2	0.12	Immune response to smallpox vaccine (IL-6);	chr18:12612326	chr18:12432897~12437635:+
BRCA	cis	rs9959145	1	rs28565322	ENSG00000267108.1	RP11-861E21.1	3.8	0.000155	0.00918	0.2	0.12	Immune response to smallpox vaccine (IL-6);	chr18:12614184	chr18:12432897~12437635:+
BRCA	cis	rs9650657	0.623	rs7004066	ENSG00000154316.13	TDH	3.8	0.000155	0.00918	0.15	0.12	Neuroticism;	chr8:10743233	chr8:11339637~11368452:+
BRCA	cis	rs2486012	1	rs3791097	ENSG00000237950.1	RP11-7O11.3	-3.8	0.000155	0.00918	-0.21	-0.12	Intelligence (multi-trait analysis);	chr1:43883709	chr1:43944370~43946551:-
BRCA	cis	rs3781264	0.595	rs7084988	ENSG00000268894.5	PLCE1-AS1	-3.8	0.000156	0.00918	-0.16	-0.12	Esophageal cancer and gastric cancer;	chr10:94349085	chr10:94279277~94287478:-
BRCA	cis	rs75422866	0.867	rs73113117	ENSG00000276691.1	RP5-1057I20.5	3.8	0.000156	0.00918	0.24	0.12	Pneumonia;	chr12:47617299	chr12:47788426~47788971:+
BRCA	cis	rs2832077	0.506	rs2832085	ENSG00000232855.5	AF131217.1	3.8	0.000156	0.00918	0.16	0.12	Cognitive test performance;	chr21:28782936	chr21:28439346~28674848:-
BRCA	cis	rs962856	1	rs1601531	ENSG00000236605.1	AC023115.4	3.8	0.000156	0.00918	0.14	0.12	Pancreatic cancer;	chr2:67370972	chr2:67324627~67325304:+
BRCA	cis	rs4388249	1	rs13180361	ENSG00000271849.1	CTC-332L22.1	-3.8	0.000156	0.00918	-0.19	-0.12	Schizophrenia;	chr5:109707287	chr5:109687802~109688329:-
BRCA	cis	rs7833986	0.534	rs17813240	ENSG00000253603.1	CTA-397H3.3	-3.8	0.000156	0.00919	-0.17	-0.12	Height;	chr8:56013232	chr8:56074592~56075274:+
BRCA	cis	rs875971	0.862	rs11763189	ENSG00000271064.1	RP11-792A8.3	-3.8	0.000156	0.00919	-0.14	-0.12	Aortic root size;	chr7:66518542	chr7:66748838~66749077:-
BRCA	cis	rs6545883	0.831	rs1186704	ENSG00000212978.6	AC016747.3	3.8	0.000156	0.00919	0.16	0.12	Tuberculosis;	chr2:61445856	chr2:61141592~61144969:-
BRCA	cis	rs1949733	0.701	rs940136	ENSG00000251615.3	RP11-774O3.3	-3.8	0.000156	0.00919	-0.12	-0.12	Response to antineoplastic agents;	chr4:8447265	chr4:8355090~8358338:-
BRCA	cis	rs4272720	1	rs4272720	ENSG00000228754.1	RP11-534L6.3	3.8	0.000156	0.00919	0.15	0.12	Platelet count;Plateletcrit;	chr10:49055156	chr10:48745545~48746128:-
BRCA	cis	rs4218	0.648	rs12910987	ENSG00000259732.1	RP11-59H7.3	-3.8	0.000156	0.00919	-0.15	-0.12	Social communication problems;	chr15:59092782	chr15:59121034~59133250:+
BRCA	cis	rs73201462	1	rs2999076	ENSG00000242551.2	POU5F1P6	-3.8	0.000156	0.00919	-0.19	-0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128239849	chr3:128674735~128677005:-
BRCA	cis	rs875971	0.522	rs1701760	ENSG00000232559.3	GS1-124K5.12	3.8	0.000156	0.00919	0.14	0.12	Aortic root size;	chr7:66008701	chr7:66554588~66576923:-
BRCA	cis	rs1075265	0.587	rs2949811	ENSG00000272156.1	RP11-477N3.1	-3.8	0.000156	0.00919	-0.12	-0.12	Chronotype;Morning vs. evening chronotype;	chr2:53797028	chr2:54082554~54085066:+
BRCA	cis	rs7238033	0.965	rs10853535	ENSG00000267193.4	RP11-116O18.3	3.8	0.000156	0.00919	0.13	0.12	Bladder cancer;	chr18:45737582	chr18:45669367~45747215:-
BRCA	cis	rs957448	0.554	rs10956919	ENSG00000254315.1	RP11-267M23.3	3.8	0.000156	0.00919	0.14	0.12	Nonsyndromic cleft lip with cleft palate;	chr8:94572945	chr8:94533628~94534391:+
BRCA	cis	rs11233413	1	rs2127361	ENSG00000246067.6	RAB30-AS1	-3.8	0.000156	0.00919	-0.13	-0.12	Economic and political preferences (feminism/equality);	chr11:83005476	chr11:83072066~83106719:+
BRCA	cis	rs12914656	0.556	rs8027956	ENSG00000202081.1	RNU6-1280P	3.8	0.000156	0.00919	0.15	0.12	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);	chr15:86112644	chr15:85651522~85651628:-
BRCA	cis	rs6951245	0.554	rs75075857	ENSG00000224079.1	AC091729.7	-3.8	0.000156	0.0092	-0.17	-0.12	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1100662	chr7:1074450~1078036:+
BRCA	cis	rs889956	0.744	rs1345942	ENSG00000233251.6	AC007743.1	-3.8	0.000156	0.0092	-0.14	-0.12	Educational attainment;	chr2:57107909	chr2:56173534~56185770:-
BRCA	cis	rs875971	0.545	rs1796222	ENSG00000232559.3	GS1-124K5.12	-3.8	0.000156	0.0092	-0.16	-0.12	Aortic root size;	chr7:66592167	chr7:66554588~66576923:-
BRCA	cis	rs2455799	0.613	rs2166759	ENSG00000224728.1	AC090945.1	3.8	0.000156	0.0092	0.11	0.12	Mean platelet volume;	chr3:15814778	chr3:15878047~15879571:+
BRCA	cis	rs4073416	0.598	rs34357872	ENSG00000276116.2	FUT8-AS1	3.8	0.000156	0.0092	0.12	0.12	N-glycan levels;	chr14:65597197	chr14:65411170~65412690:-
BRCA	cis	rs6496932	1	rs11638110	ENSG00000259295.5	CSPG4P12	3.8	0.000156	0.0092	0.19	0.12	Central corneal thickness;Corneal structure;	chr15:85279653	chr15:85191438~85213905:+
BRCA	cis	rs17270561	0.608	rs9358875	ENSG00000272462.2	U91328.19	-3.8	0.000156	0.0092	-0.15	-0.12	Iron status biomarkers;	chr6:25737780	chr6:25992662~26001775:+
BRCA	cis	rs1355223	0.902	rs1361645	ENSG00000271369.1	RP11-350D17.3	-3.8	0.000156	0.0092	-0.13	-0.12	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34724838	chr11:34709600~34710161:+
BRCA	cis	rs875971	0.825	rs801202	ENSG00000229886.1	RP5-1132H15.3	-3.8	0.000156	0.0092	-0.13	-0.12	Aortic root size;	chr7:66558942	chr7:66025126~66031544:-
BRCA	cis	rs875971	0.767	rs61348003	ENSG00000229886.1	RP5-1132H15.3	3.8	0.000156	0.0092	0.13	0.12	Aortic root size;	chr7:66540947	chr7:66025126~66031544:-
BRCA	cis	rs73201462	1	rs2955091	ENSG00000242551.2	POU5F1P6	-3.8	0.000156	0.0092	-0.19	-0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128252518	chr3:128674735~128677005:-
BRCA	cis	rs5758511	0.773	rs8140869	ENSG00000226450.2	CYP2D8P	-3.8	0.000156	0.0092	-0.12	-0.12	Birth weight;	chr22:41948293	chr22:42149886~42155001:-
BRCA	cis	rs10514758	0.744	rs72947765	ENSG00000242880.1	RP11-190P13.2	3.8	0.000156	0.00921	0.27	0.12	Urate levels in obese individuals;	chr3:115229734	chr3:115251196~115285347:+
BRCA	cis	rs10514758	0.744	rs72947766	ENSG00000242880.1	RP11-190P13.2	3.8	0.000156	0.00921	0.27	0.12	Urate levels in obese individuals;	chr3:115230371	chr3:115251196~115285347:+
BRCA	cis	rs2303319	0.504	rs62188766	ENSG00000227403.1	AC009299.3	3.8	0.000156	0.00921	0.3	0.12	Cognitive function;	chr2:161866709	chr2:161244739~161249050:+
BRCA	cis	rs9300255	0.77	rs28683528	ENSG00000256028.2	RP11-197N18.2	-3.8	0.000156	0.00921	-0.12	-0.12	Neutrophil percentage of white cells;	chr12:123360804	chr12:122975320~122982907:+
BRCA	cis	rs75504410	0.579	rs337618	ENSG00000231160.8	KLF3-AS1	-3.8	0.000156	0.00921	-0.16	-0.12	Sum eosinophil basophil counts;Eosinophil counts;	chr4:38619623	chr4:38612701~38664883:-
BRCA	cis	rs897984	0.609	rs4889609	ENSG00000279196.1	RP11-1072A3.3	3.8	0.000156	0.00921	0.12	0.12	Dementia with Lewy bodies;	chr16:31015106	chr16:30984630~30988270:-
BRCA	cis	rs2625529	0.668	rs34189331	ENSG00000260037.4	CTD-2524L6.3	-3.8	0.000156	0.00921	-0.16	-0.12	Red blood cell count;	chr15:72112232	chr15:71818396~71823384:+
BRCA	cis	rs75504410	0.649	rs337640	ENSG00000231160.8	KLF3-AS1	-3.8	0.000156	0.00921	-0.16	-0.12	Sum eosinophil basophil counts;Eosinophil counts;	chr4:38606468	chr4:38612701~38664883:-
BRCA	cis	rs442309	0.875	rs224067	ENSG00000238280.1	RP11-436D10.3	3.8	0.000156	0.00921	0.15	0.12	Vogt-Koyanagi-Harada syndrome;	chr10:62747211	chr10:62793562~62805887:-
BRCA	cis	rs7260598	1	rs62114762	ENSG00000268442.1	CTD-2027I19.2	3.8	0.000156	0.00921	0.19	0.12	Response to taxane treatment (placlitaxel);	chr19:24051066	chr19:24162370~24163425:-
BRCA	cis	rs7267979	0.966	rs2227890	ENSG00000276952.1	RP5-965G21.6	3.8	0.000156	0.00921	0.14	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25280295	chr20:25284915~25285588:-
BRCA	cis	rs524281	0.637	rs7126075	ENSG00000255557.1	RP11-770G2.2	3.8	0.000156	0.00921	0.16	0.12	Electroencephalogram traits;	chr11:66173092	chr11:65745729~65771585:+
BRCA	cis	rs524281	0.861	rs2177054	ENSG00000255557.1	RP11-770G2.2	3.8	0.000156	0.00921	0.16	0.12	Electroencephalogram traits;	chr11:66177141	chr11:65745729~65771585:+
BRCA	cis	rs8105895	0.935	rs6511321	ENSG00000269345.1	VN1R85P	3.79	0.000156	0.00922	0.17	0.12	Body mass index (change over time);	chr19:22087266	chr19:22174766~22175191:-
BRCA	cis	rs2880765	0.743	rs16940052	ENSG00000230373.7	GOLGA6L5P	3.79	0.000156	0.00922	0.13	0.12	Coronary artery disease;	chr15:85463443	chr15:84507885~84516814:-
BRCA	cis	rs1019173	0.789	rs6971875	ENSG00000261455.1	LINC01003	-3.79	0.000156	0.00922	-0.13	-0.12	Kidney function decline traits;	chr7:152018890	chr7:152463786~152465549:+
BRCA	cis	rs756699	0.749	rs244676	ENSG00000270177.1	CTD-2410N18.3	3.79	0.000156	0.00922	0.13	0.12	Multiple sclerosis;	chr5:134095924	chr5:134226410~134227827:+
BRCA	cis	rs642803	0.613	rs489574	ENSG00000214659.4	KRT8P26	-3.79	0.000156	0.00922	-0.15	-0.12	Urate levels;	chr11:65775268	chr11:65726939~65728214:+
BRCA	cis	rs28530618	0.558	rs6058794	ENSG00000198547.7	C20orf203	-3.79	0.000156	0.00922	-0.13	-0.12	Birth weight;	chr20:32665475	chr20:32631652~32673941:-
BRCA	cis	rs3858526	0.628	rs4237762	ENSG00000224295.2	AC087380.14	3.79	0.000156	0.00922	0.15	0.12	DNA methylation (variation);	chr11:5935396	chr11:5518441~5524955:-
BRCA	cis	rs6964587	0.967	rs10953063	ENSG00000188693.7	CYP51A1-AS1	3.79	0.000156	0.00922	0.13	0.12	Breast cancer;	chr7:91947644	chr7:92134604~92180725:+
BRCA	cis	rs6964587	1	rs17164263	ENSG00000188693.7	CYP51A1-AS1	3.79	0.000156	0.00922	0.13	0.12	Breast cancer;	chr7:91952252	chr7:92134604~92180725:+
BRCA	cis	rs737008	0.96	rs949429	ENSG00000262636.1	CTD-3088G3.4	-3.79	0.000156	0.00922	-0.16	-0.12	Obesity-related traits;	chr16:11282172	chr16:11380859~11381118:-
BRCA	cis	rs853679	0.546	rs200989	ENSG00000216901.1	AL022393.7	3.79	0.000156	0.00922	0.23	0.12	Depression;	chr6:27848664	chr6:28176188~28176674:+
BRCA	cis	rs7267979	0.527	rs6076369	ENSG00000277938.1	RP5-965G21.3	-3.79	0.000156	0.00922	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25596147	chr20:25229150~25231933:+
BRCA	cis	rs66887589	0.616	rs10032299	ENSG00000250412.1	KLHL2P1	3.79	0.000156	0.00922	0.13	0.12	Diastolic blood pressure;	chr4:119285264	chr4:119334329~119378233:+
BRCA	cis	rs6964587	1	rs58965837	ENSG00000188693.7	CYP51A1-AS1	-3.79	0.000156	0.00922	-0.13	-0.12	Breast cancer;	chr7:91955944	chr7:92134604~92180725:+
BRCA	cis	rs73201462	1	rs11710627	ENSG00000242551.2	POU5F1P6	3.79	0.000156	0.00922	0.2	0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128328166	chr3:128674735~128677005:-
BRCA	cis	rs4218	0.689	rs12902628	ENSG00000259732.1	RP11-59H7.3	-3.79	0.000156	0.00923	-0.15	-0.12	Social communication problems;	chr15:59100193	chr15:59121034~59133250:+
BRCA	cis	rs2262909	0.962	rs4932952	ENSG00000279377.1	AC003973.3	-3.79	0.000156	0.00923	-0.17	-0.12	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;	chr19:22063986	chr19:21965708~21968529:-
BRCA	cis	rs2262909	0.962	rs73019842	ENSG00000279377.1	AC003973.3	-3.79	0.000156	0.00923	-0.17	-0.12	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;	chr19:22067107	chr19:21965708~21968529:-
BRCA	cis	rs2262909	0.962	rs73019844	ENSG00000279377.1	AC003973.3	-3.79	0.000156	0.00923	-0.17	-0.12	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;	chr19:22067123	chr19:21965708~21968529:-
BRCA	cis	rs2262909	0.962	rs11667209	ENSG00000279377.1	AC003973.3	-3.79	0.000156	0.00923	-0.17	-0.12	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;	chr19:22076665	chr19:21965708~21968529:-
BRCA	cis	rs970548	1	rs12257549	ENSG00000237840.5	FAM21FP	3.79	0.000156	0.00923	0.16	0.12	Total cholesterol levels;HDL cholesterol;HDL cholesterol levels;Cholesterol, total;	chr10:45534183	chr10:45706431~45727231:-
BRCA	cis	rs1355223	0.902	rs836467	ENSG00000271369.1	RP11-350D17.3	-3.79	0.000156	0.00923	-0.13	-0.12	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34715885	chr11:34709600~34710161:+
BRCA	cis	rs9921338	0.961	rs72773830	ENSG00000263080.1	RP11-485G7.5	3.79	0.000156	0.00923	0.18	0.12	Vein graft stenosis in coronary artery bypass grafting;	chr16:11318966	chr16:11341809~11345211:-
BRCA	cis	rs3749237	0.964	rs1799845	ENSG00000225399.4	RP11-3B7.1	3.79	0.000156	0.00923	0.12	0.12	Resting heart rate;	chr3:49810190	chr3:49260085~49261316:+
BRCA	cis	rs9818758	0.607	rs56004653	ENSG00000225399.4	RP11-3B7.1	-3.79	0.000156	0.00923	-0.24	-0.12	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49034795	chr3:49260085~49261316:+
BRCA	cis	rs16958440	1	rs2289132	ENSG00000267800.1	RP11-49K24.5	-3.79	0.000156	0.00923	-0.25	-0.12	Sitting height ratio;	chr18:47075921	chr18:47137018~47137290:+
BRCA	cis	rs16958440	1	rs2289131	ENSG00000267800.1	RP11-49K24.5	-3.79	0.000156	0.00923	-0.25	-0.12	Sitting height ratio;	chr18:47076493	chr18:47137018~47137290:+
BRCA	cis	rs2736345	0.516	rs7844858	ENSG00000154316.13	TDH	-3.79	0.000156	0.00923	-0.15	-0.12	Systemic lupus erythematosus;Sjögren's syndrome;	chr8:11535150	chr8:11339637~11368452:+
BRCA	cis	rs181553	0.664	rs2166670	ENSG00000266696.1	RP11-30L3.2	3.79	0.000156	0.00923	0.13	0.12	Hip circumference adjusted for BMI;	chr18:49158540	chr18:49205912~49208781:+
BRCA	cis	rs4950322	0.518	rs11811023	ENSG00000244371.2	PFN1P8	3.79	0.000156	0.00923	0.14	0.12	Protein quantitative trait loci;	chr1:147109536	chr1:146957117~146957659:-
BRCA	cis	rs2720460	0.502	rs223374	ENSG00000248740.4	RP11-328K4.1	3.79	0.000156	0.00923	0.14	0.12	Testicular germ cell tumor;	chr4:102837144	chr4:103256159~103453658:+
BRCA	cis	rs17301013	0.932	rs7555533	ENSG00000234741.6	GAS5	3.79	0.000157	0.00923	0.12	0.12	Systemic lupus erythematosus;	chr1:174589983	chr1:173863900~173868882:-
BRCA	cis	rs17301013	0.932	rs6671824	ENSG00000234741.6	GAS5	3.79	0.000157	0.00923	0.12	0.12	Systemic lupus erythematosus;	chr1:174603721	chr1:173863900~173868882:-
BRCA	cis	rs17301013	0.861	rs6672148	ENSG00000234741.6	GAS5	3.79	0.000157	0.00923	0.12	0.12	Systemic lupus erythematosus;	chr1:174604016	chr1:173863900~173868882:-
BRCA	cis	rs2518049	1	rs1937849	ENSG00000224034.1	RP11-445P17.8	3.79	0.000157	0.00923	0.21	0.12	Metabolic traits;	chr10:5091647	chr10:5266033~5271236:-
BRCA	cis	rs9287719	0.935	rs61424402	ENSG00000224177.5	LINC00570	3.79	0.000157	0.00923	0.14	0.12	Prostate cancer;	chr2:10618245	chr2:11393981~11403077:+
BRCA	cis	rs2071426	0.622	rs34946089	ENSG00000273450.1	RP11-76P2.4	3.79	0.000157	0.00924	0.15	0.12	Blood metabolite levels;	chr10:95005470	chr10:94314907~94315327:-
BRCA	cis	rs2281603	0.762	rs10150987	ENSG00000259116.1	RP11-973N13.4	-3.79	0.000157	0.00924	-0.11	-0.12	Lymphocyte counts;	chr14:64571472	chr14:64514154~64540368:-
BRCA	cis	rs2832191	0.716	rs1888439	ENSG00000215533.7	LINC00189	-3.79	0.000157	0.00924	-0.13	-0.12	Dental caries;	chr21:29082136	chr21:29193480~29288205:+
BRCA	cis	rs524281	0.861	rs3953856	ENSG00000255557.1	RP11-770G2.2	3.79	0.000157	0.00924	0.16	0.12	Electroencephalogram traits;	chr11:66198437	chr11:65745729~65771585:+
BRCA	cis	rs524281	0.861	rs2889313	ENSG00000255557.1	RP11-770G2.2	3.79	0.000157	0.00924	0.16	0.12	Electroencephalogram traits;	chr11:66198595	chr11:65745729~65771585:+
BRCA	cis	rs801193	0.591	rs721717	ENSG00000229886.1	RP5-1132H15.3	-3.79	0.000157	0.00924	-0.13	-0.12	Aortic root size;	chr7:66665305	chr7:66025126~66031544:-
BRCA	cis	rs11098499	1	rs11098499	ENSG00000225892.3	RP11-384K6.2	3.79	0.000157	0.00924	0.12	0.12	Corneal astigmatism;	chr4:119266456	chr4:118632274~118634759:+
BRCA	cis	rs1560104	0.709	rs2903042	ENSG00000259876.1	CTD-3037G24.4	3.79	0.000157	0.00924	0.13	0.12	Obesity-related traits;	chr16:12604249	chr16:12556353~12557694:-
BRCA	cis	rs9527	0.59	rs3861984	ENSG00000213061.2	PFN1P11	3.79	0.000157	0.00924	0.16	0.12	Arsenic metabolism;	chr10:103157223	chr10:102838011~102845473:-
BRCA	cis	rs4664293	0.647	rs10199805	ENSG00000224152.1	AC009506.1	-3.79	0.000157	0.00924	-0.12	-0.12	Monocyte percentage of white cells;	chr2:159570880	chr2:159615296~159617082:+
BRCA	cis	rs11098499	0.954	rs10006877	ENSG00000260091.1	RP11-33B1.4	-3.79	0.000157	0.00924	-0.1	-0.12	Corneal astigmatism;	chr4:119321638	chr4:119409333~119410233:+
BRCA	cis	rs6088580	0.634	rs6059779	ENSG00000275784.1	RP5-1125A11.6	3.79	0.000157	0.00924	0.13	0.12	Glomerular filtration rate (creatinine);	chr20:34362519	chr20:33989480~33991818:-
BRCA	cis	rs3096299	0.967	rs2965827	ENSG00000259877.2	RP11-46C24.7	3.79	0.000157	0.00925	0.11	0.12	Multiple myeloma (IgH translocation);	chr16:89390942	chr16:89215211~89217653:-
BRCA	cis	rs224278	0.624	rs2136613	ENSG00000238280.1	RP11-436D10.3	-3.79	0.000157	0.00925	-0.14	-0.12	Ewing sarcoma;	chr10:62834404	chr10:62793562~62805887:-
BRCA	cis	rs7037266	0.853	rs7043262	ENSG00000178654.11	PPIAP33	3.79	0.000157	0.00925	0.13	0.12	Menarche (age at onset);	chr9:6926738	chr9:7597823~7598377:+
BRCA	cis	rs10129255	0.957	rs7493713	ENSG00000211967.3	IGHV3-53	-3.79	0.000157	0.00925	-0.08	-0.12	Kawasaki disease;	chr14:106783685	chr14:106592676~106593347:-
BRCA	cis	rs10129255	0.912	rs35468694	ENSG00000211967.3	IGHV3-53	-3.79	0.000157	0.00925	-0.08	-0.12	Kawasaki disease;	chr14:106784199	chr14:106592676~106593347:-
BRCA	cis	rs13126694	0.778	rs10000610	ENSG00000251073.1	NUDT19P5	3.79	0.000157	0.00925	0.11	0.12	Blood osmolality (transformed sodium);	chr4:158112023	chr4:158182825~158183393:+
BRCA	cis	rs10744816	0.604	rs1247936	ENSG00000257817.1	RP4-601P9.2	3.79	0.000157	0.00925	0.14	0.12	Obesity-related traits;	chr12:114270069	chr12:114713811~114767957:+
BRCA	cis	rs10129255	0.957	rs8014696	ENSG00000231475.3	IGHV4-31	3.79	0.000157	0.00925	0.09	0.12	Kawasaki disease;	chr14:106769752	chr14:106349283~106349792:-
BRCA	cis	rs2948294	0.588	rs4840913	ENSG00000173295.6	FAM86B3P	3.79	0.000157	0.00925	0.13	0.12	Red cell distribution width;	chr8:8259384	chr8:8228595~8244865:+
BRCA	cis	rs17597773	0.674	rs2378425	ENSG00000257551.1	HLX-AS1	-3.79	0.000157	0.00925	-0.13	-0.12	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220842716	chr1:220832763~220880140:-
BRCA	cis	rs7712401	0.755	rs3213794	ENSG00000251538.4	RP11-166A12.1	3.79	0.000157	0.00925	0.13	0.12	Mean platelet volume;	chr5:122825943	chr5:122628952~122730685:-
BRCA	cis	rs9287719	0.934	rs6727884	ENSG00000224177.5	LINC00570	-3.79	0.000157	0.00925	-0.14	-0.12	Prostate cancer;	chr2:10617431	chr2:11393981~11403077:+
BRCA	cis	rs7267979	1	rs4815404	ENSG00000276952.1	RP5-965G21.6	-3.79	0.000157	0.00925	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25321209	chr20:25284915~25285588:-
BRCA	cis	rs11671005	0.693	rs11668821	ENSG00000265272.2	RN7SL693P	3.79	0.000157	0.00925	0.17	0.12	Mean platelet volume;	chr19:58444446	chr19:58490797~58491075:+
BRCA	cis	rs11671005	0.616	rs12980907	ENSG00000265272.2	RN7SL693P	3.79	0.000157	0.00925	0.17	0.12	Mean platelet volume;	chr19:58444959	chr19:58490797~58491075:+
BRCA	cis	rs17684571	0.872	rs13198597	ENSG00000231441.1	RP11-472M19.2	3.79	0.000157	0.00925	0.18	0.12	Schizophrenia;	chr6:56852929	chr6:56844002~56864078:+
BRCA	cis	rs80028505	0.908	rs73730459	ENSG00000271304.1	DPRXP2	3.79	0.000157	0.00925	0.22	0.12	Foot ulcer in diabetes and neuropathy;	chr6:36117226	chr6:35989515~35990436:-
BRCA	cis	rs7267979	1	rs2482930	ENSG00000277938.1	RP5-965G21.3	-3.79	0.000157	0.00925	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25353479	chr20:25229150~25231933:+
BRCA	cis	rs7267979	0.932	rs6115200	ENSG00000274414.1	RP5-965G21.4	-3.79	0.000157	0.00925	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25506741	chr20:25239007~25245229:-
BRCA	cis	rs1812329	1	rs1812329	ENSG00000270720.1	RP11-84C13.2	3.79	0.000157	0.00925	0.13	0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr4:88948767	chr4:89119284~89119871:+
BRCA	cis	rs875971	0.861	rs801215	ENSG00000229886.1	RP5-1132H15.3	-3.79	0.000157	0.00926	-0.13	-0.12	Aortic root size;	chr7:66546951	chr7:66025126~66031544:-
BRCA	cis	rs875971	0.545	rs6979636	ENSG00000232559.3	GS1-124K5.12	3.79	0.000157	0.00926	0.16	0.12	Aortic root size;	chr7:66276638	chr7:66554588~66576923:-
BRCA	cis	rs8040855	0.627	rs11634975	ENSG00000259774.1	RP11-182J1.13	3.79	0.000157	0.00926	0.16	0.12	Bulimia nervosa;	chr15:85063247	chr15:84422618~84425882:+
BRCA	cis	rs10844706	0.699	rs10844615	ENSG00000278635.1	CTD-2318O12.1	-3.79	0.000157	0.00926	-0.13	-0.12	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9725646	chr12:9415641~9416718:+
BRCA	cis	rs875971	0.862	rs801194	ENSG00000229886.1	RP5-1132H15.3	-3.79	0.000157	0.00926	-0.13	-0.12	Aortic root size;	chr7:66563508	chr7:66025126~66031544:-
BRCA	cis	rs8030605	0.704	rs72740592	ENSG00000277245.1	RP11-48G14.3	3.79	0.000157	0.00926	0.25	0.12	Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;	chr15:56360613	chr15:56447120~56447697:+
BRCA	cis	rs1009647	0.633	rs11626485	ENSG00000258413.1	RP11-665C16.6	-3.79	0.000157	0.00926	-0.21	-0.12	Testicular germ cell tumor;	chr14:55360046	chr14:55262767~55272075:-
BRCA	cis	rs863345	0.604	rs11264981	ENSG00000229914.1	RP11-404O13.4	-3.79	0.000157	0.00926	-0.12	-0.12	Pneumococcal bacteremia;	chr1:158486100	chr1:158195633~158196131:-
BRCA	cis	rs924712	0.545	rs12207559	ENSG00000261116.1	RP3-523K23.2	-3.79	0.000157	0.00926	-0.13	-0.12	Breast cancer;	chr6:54845070	chr6:54943167~54945099:+
BRCA	cis	rs1865760	1	rs2071301	ENSG00000272462.2	U91328.19	-3.79	0.000157	0.00926	-0.14	-0.12	Height;	chr6:25914035	chr6:25992662~26001775:+
BRCA	cis	rs7000551	0.751	rs2461481	ENSG00000254272.1	RP11-382J24.2	3.79	0.000157	0.00926	0.13	0.12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr8:22525267	chr8:22492631~22493044:+
BRCA	cis	rs304029	0.512	rs17706522	ENSG00000231249.1	ITPR1-AS1	-3.79	0.000157	0.00927	-0.15	-0.12	Diabetic kidney disease;	chr3:4497107	chr3:4490891~4493163:-
BRCA	cis	rs6599077	0.616	rs9878321	ENSG00000223797.4	ENTPD3-AS1	3.79	0.000157	0.00927	0.13	0.12	Sleep-related phenotypes;	chr3:40133367	chr3:40313802~40453329:-
BRCA	cis	rs600231	0.508	rs35292734	ENSG00000245532.5	NEAT1	3.79	0.000157	0.00927	0.13	0.12	Bone mineral density;	chr11:65460229	chr11:65422774~65445540:+
BRCA	cis	rs7267979	1	rs2482911	ENSG00000274414.1	RP5-965G21.4	3.79	0.000157	0.00927	0.14	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25414892	chr20:25239007~25245229:-
BRCA	cis	rs7812879	0.929	rs2251056	ENSG00000255354.1	RP11-148O21.2	-3.79	0.000157	0.00927	-0.14	-0.12	Systemic lupus erythematosus;	chr8:11492067	chr8:11558466~11560020:-
BRCA	cis	rs12468226	0.938	rs3731700	ENSG00000272966.1	RP11-686O6.1	3.79	0.000157	0.00927	0.2	0.12	Urate levels;	chr2:202291213	chr2:202336739~202337200:+
BRCA	cis	rs10197140	1	rs12151613	ENSG00000235721.1	AC013268.3	-3.79	0.000157	0.00927	-0.15	-0.12	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110851808	chr2:110007675~110010783:+
BRCA	cis	rs17507216	0.591	rs7163848	ENSG00000259429.4	UBE2Q2P2	-3.79	0.000157	0.00927	-0.15	-0.12	Excessive daytime sleepiness;	chr15:82729563	chr15:82355142~82420075:+
BRCA	cis	rs8114671	0.551	rs4911162	ENSG00000126005.14	MMP24-AS1	-3.79	0.000157	0.00927	-0.13	-0.12	Height;	chr20:34823622	chr20:35216462~35278131:-
BRCA	cis	rs1346	0.58	rs948577	ENSG00000245532.5	NEAT1	3.79	0.000157	0.00927	0.12	0.12	Vertical cup-disc ratio;Optic cup area;	chr11:65597847	chr11:65422774~65445540:+
BRCA	cis	rs4415084	0.804	rs57300972	ENSG00000248779.1	RP11-53O19.2	-3.79	0.000157	0.00928	-0.11	-0.12	Breast cancer;	chr5:44897734	chr5:44752949~44765744:+
BRCA	cis	rs3740713	1	rs75487138	ENSG00000256361.1	RP11-613F22.6	3.79	0.000157	0.00928	0.19	0.12	Amyotrophic lateral sclerosis (sporadic);	chr11:18440331	chr11:18511043~18511475:-
BRCA	cis	rs2839186	0.588	rs2839140	ENSG00000228137.1	AP001469.7	-3.79	0.000157	0.00928	-0.12	-0.12	Testicular germ cell tumor;	chr21:46196166	chr21:46246890~46247682:+
BRCA	cis	rs2839186	0.647	rs9976233	ENSG00000228137.1	AP001469.7	-3.79	0.000157	0.00928	-0.12	-0.12	Testicular germ cell tumor;	chr21:46196999	chr21:46246890~46247682:+
BRCA	cis	rs2562456	0.874	rs2562408	ENSG00000213976.4	CTD-2561J22.2	3.79	0.000157	0.00928	0.14	0.12	Pain;	chr19:21527079	chr19:21382865~21387177:+
BRCA	cis	rs7847628	0.587	rs3793638	ENSG00000238181.2	AHCYP2	-3.79	0.000157	0.00928	-0.15	-0.12	Birth weight;	chr9:120820419	chr9:120720673~120721972:+
BRCA	cis	rs3781913	0.874	rs12363065	ENSG00000254593.1	OR7E126P	3.79	0.000157	0.00928	0.15	0.12	Rheumatoid arthritis;	chr11:72659855	chr11:71903194~71904081:+
BRCA	cis	rs9467773	0.572	rs62394558	ENSG00000224843.5	LINC00240	-3.79	0.000157	0.00928	-0.14	-0.12	Intelligence (multi-trait analysis);	chr6:26604422	chr6:26956992~27023924:+
BRCA	cis	rs9863	0.828	rs56041971	ENSG00000270028.1	RP11-380L11.4	3.79	0.000158	0.00928	0.15	0.12	White blood cell count;	chr12:123996319	chr12:123925461~123926083:-
BRCA	cis	rs1730008	0.929	rs827174	ENSG00000279311.1	RP11-170K4.2	-3.79	0.000158	0.00928	-0.13	-0.12	Lobe attachment (rater-scored or self-reported);	chr3:158242617	chr3:158869898~158871821:+
BRCA	cis	rs6005807	0.563	rs9620811	ENSG00000272858.1	CTA-292E10.8	-3.79	0.000158	0.00928	-0.21	-0.12	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28662421	chr22:28814914~28815662:+
BRCA	cis	rs2562456	1	rs2562456	ENSG00000240522.1	RPL7AP10	-3.79	0.000158	0.00928	-0.12	-0.12	Pain;	chr19:21483408	chr19:21149648~21150438:-
BRCA	cis	rs718314	1	rs10842703	ENSG00000256894.1	RP11-283G6.3	3.79	0.000158	0.00928	0.14	0.12	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Renal cell carcinoma;Waist circumference adjusted for body mass index;	chr12:26303255	chr12:26125155~26126617:-
BRCA	cis	rs718314	1	rs1872992	ENSG00000256894.1	RP11-283G6.3	3.79	0.000158	0.00928	0.14	0.12	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Renal cell carcinoma;Waist circumference adjusted for body mass index;	chr12:26304257	chr12:26125155~26126617:-
BRCA	cis	rs875971	0.545	rs73150604	ENSG00000232546.1	RP11-458F8.1	3.79	0.000158	0.00929	0.11	0.12	Aortic root size;	chr7:66480545	chr7:66848496~66858136:+
BRCA	cis	rs7487075	0.578	rs11183486	ENSG00000257261.4	RP11-96H19.1	3.79	0.000158	0.00929	0.13	0.12	Itch intensity from mosquito bite;	chr12:46443921	chr12:46383679~46876159:+
BRCA	cis	rs9921338	0.961	rs66555362	ENSG00000262703.1	RP11-485G7.6	-3.79	0.000158	0.00929	-0.14	-0.12	Vein graft stenosis in coronary artery bypass grafting;	chr16:11294976	chr16:11348143~11349321:-
BRCA	cis	rs6736093	0.933	rs6754526	ENSG00000236307.2	EEF1E1P1	-3.79	0.000158	0.00929	-0.14	-0.12	Coronary artery disease;	chr2:111972092	chr2:111887914~111888741:+
BRCA	cis	rs75422866	0.867	rs75568526	ENSG00000276691.1	RP5-1057I20.5	3.79	0.000158	0.00929	0.24	0.12	Pneumonia;	chr12:47649718	chr12:47788426~47788971:+
BRCA	cis	rs75422866	0.867	rs116302411	ENSG00000276691.1	RP5-1057I20.5	3.79	0.000158	0.00929	0.24	0.12	Pneumonia;	chr12:47649788	chr12:47788426~47788971:+
BRCA	cis	rs8054556	1	rs3814880	ENSG00000183604.13	SMG1P5	-3.79	0.000158	0.00929	-0.12	-0.12	Autism spectrum disorder or schizophrenia;	chr16:30006574	chr16:30267553~30335374:-
BRCA	cis	rs8192917	1	rs6573910	ENSG00000258744.1	RP11-80A15.1	-3.79	0.000158	0.00929	-0.15	-0.12	Vitiligo;	chr14:24631676	chr14:24501594~24508688:+
BRCA	cis	rs2832191	0.791	rs2832178	ENSG00000232855.5	AF131217.1	3.79	0.000158	0.00929	0.14	0.12	Dental caries;	chr21:29107537	chr21:28439346~28674848:-
BRCA	cis	rs4272720	1	rs4264085	ENSG00000228754.1	RP11-534L6.3	-3.79	0.000158	0.00929	-0.16	-0.12	Platelet count;Plateletcrit;	chr10:49056918	chr10:48745545~48746128:-
BRCA	cis	rs2421332	1	rs2421332	ENSG00000273302.1	RP11-493E12.2	-3.79	0.000158	0.00929	-0.12	-0.12	Homeostasis model assessment of beta-cell function (dietary factor interaction);	chr2:61649830	chr2:61199979~61200769:+
BRCA	cis	rs1032833	0.732	rs79640162	ENSG00000271401.1	RP11-171I2.3	-3.79	0.000158	0.00929	-0.3	-0.12	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);	chr2:179140737	chr2:178644717~178645179:+
BRCA	cis	rs7520050	0.966	rs10890361	ENSG00000226957.1	RP4-533D7.4	3.79	0.000158	0.00929	0.12	0.12	Reticulocyte count;Red blood cell count;	chr1:45880562	chr1:46046818~46048368:+
BRCA	cis	rs459482	0.587	rs468207	ENSG00000227702.1	LINC00111	3.79	0.000158	0.00929	0.14	0.12	IgG glycosylation;	chr21:41436088	chr21:41679181~41697336:+
BRCA	cis	rs7267979	1	rs910997	ENSG00000276952.1	RP5-965G21.6	3.79	0.000158	0.00929	0.14	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25286665	chr20:25284915~25285588:-
BRCA	cis	rs875971	0.862	rs1167408	ENSG00000273024.4	INTS4P2	3.79	0.000158	0.00929	0.13	0.12	Aortic root size;	chr7:66091121	chr7:65647864~65715661:+
BRCA	cis	rs875971	0.83	rs1167406	ENSG00000273024.4	INTS4P2	3.79	0.000158	0.00929	0.13	0.12	Aortic root size;	chr7:66091949	chr7:65647864~65715661:+
BRCA	cis	rs875971	0.862	rs1167399	ENSG00000273024.4	INTS4P2	3.79	0.000158	0.00929	0.13	0.12	Aortic root size;	chr7:66096890	chr7:65647864~65715661:+
BRCA	cis	rs875971	0.862	rs57866200	ENSG00000273024.4	INTS4P2	3.79	0.000158	0.00929	0.13	0.12	Aortic root size;	chr7:66100405	chr7:65647864~65715661:+
BRCA	cis	rs1039766	0.925	rs268850	ENSG00000227791.3	AC007365.4	-3.79	0.000158	0.00929	-0.18	-0.12	Lung adenocarcinoma;Lung cancer;	chr2:65281152	chr2:64665607~64666064:+
BRCA	cis	rs442309	0.875	rs224063	ENSG00000238280.1	RP11-436D10.3	3.79	0.000158	0.0093	0.15	0.12	Vogt-Koyanagi-Harada syndrome;	chr10:62743589	chr10:62793562~62805887:-
BRCA	cis	rs10829156	0.57	rs7904365	ENSG00000225527.1	RP11-383B4.4	-3.79	0.000158	0.0093	-0.16	-0.12	Sudden cardiac arrest;	chr10:18542375	chr10:18531849~18533336:-
BRCA	cis	rs6860540	0.796	rs3734029	ENSG00000251405.2	CTB-109A12.1	-3.79	0.000158	0.0093	-0.16	-0.12	Inflammatory skin disease;	chr5:157473742	chr5:157362615~157460078:-
BRCA	cis	rs16917546	1	rs10995248	ENSG00000238280.1	RP11-436D10.3	-3.79	0.000158	0.0093	-0.16	-0.12	Basal cell carcinoma;	chr10:62636282	chr10:62793562~62805887:-
BRCA	cis	rs7015630	0.657	rs16900888	ENSG00000251136.7	RP11-37B2.1	3.79	0.000158	0.0093	0.14	0.12	Inflammatory bowel disease;Crohn's disease;	chr8:89825519	chr8:89609409~89757727:-
BRCA	cis	rs2880765	0.743	rs4551990	ENSG00000202081.1	RNU6-1280P	3.79	0.000158	0.0093	0.14	0.12	Coronary artery disease;	chr15:85472056	chr15:85651522~85651628:-
BRCA	cis	rs7937890	0.559	rs1116739	ENSG00000254418.1	RP11-21L19.1	3.79	0.000158	0.0093	0.14	0.12	Mitochondrial DNA levels;	chr11:14467636	chr11:14262846~14273691:-
BRCA	cis	rs4950322	0.57	rs4950401	ENSG00000227242.3	NBPF13P	-3.79	0.000158	0.0093	-0.17	-0.12	Protein quantitative trait loci;	chr1:147319571	chr1:147021320~147124525:-
BRCA	cis	rs4950322	0.57	rs4950402	ENSG00000227242.3	NBPF13P	-3.79	0.000158	0.0093	-0.17	-0.12	Protein quantitative trait loci;	chr1:147319684	chr1:147021320~147124525:-
BRCA	cis	rs4950322	0.57	rs4950404	ENSG00000227242.3	NBPF13P	-3.79	0.000158	0.0093	-0.17	-0.12	Protein quantitative trait loci;	chr1:147319834	chr1:147021320~147124525:-
BRCA	cis	rs4950322	0.57	rs72692953	ENSG00000227242.3	NBPF13P	-3.79	0.000158	0.0093	-0.17	-0.12	Protein quantitative trait loci;	chr1:147321416	chr1:147021320~147124525:-
BRCA	cis	rs80028505	1	rs2237096	ENSG00000271304.1	DPRXP2	3.79	0.000158	0.0093	0.23	0.12	Foot ulcer in diabetes and neuropathy;	chr6:36040225	chr6:35989515~35990436:-
BRCA	cis	rs56281245	0.793	rs75490337	ENSG00000249363.1	CTB-78O21.1	3.79	0.000158	0.0093	0.25	0.12	Hepcidin levels;	chr5:145588709	chr5:145728360~145729349:-
BRCA	cis	rs56281245	0.793	rs78219072	ENSG00000249363.1	CTB-78O21.1	3.79	0.000158	0.0093	0.25	0.12	Hepcidin levels;	chr5:145588719	chr5:145728360~145729349:-
BRCA	cis	rs7045881	0.696	rs10812492	ENSG00000254396.1	RP11-56F10.3	3.79	0.000158	0.0093	0.17	0.12	Schizophrenia;	chr9:26909067	chr9:27102630~27104728:+
BRCA	cis	rs2839186	0.585	rs2839154	ENSG00000228137.1	AP001469.7	-3.79	0.000158	0.0093	-0.12	-0.12	Testicular germ cell tumor;	chr21:46217846	chr21:46246890~46247682:+
BRCA	cis	rs4950322	0.512	rs2883318	ENSG00000244371.2	PFN1P8	-3.79	0.000158	0.0093	-0.14	-0.12	Protein quantitative trait loci;	chr1:147377422	chr1:146957117~146957659:-
BRCA	cis	rs17772222	0.917	rs10143767	ENSG00000258789.1	RP11-507K2.3	-3.79	0.000158	0.0093	-0.14	-0.12	Coronary artery calcification;	chr14:88514867	chr14:88551597~88552493:+
BRCA	cis	rs524281	0.861	rs7929909	ENSG00000255557.1	RP11-770G2.2	3.79	0.000158	0.0093	0.16	0.12	Electroencephalogram traits;	chr11:66184227	chr11:65745729~65771585:+
BRCA	cis	rs1982963	1	rs2749876	ENSG00000277050.1	RP11-102G14.1	-3.79	0.000158	0.0093	-0.15	-0.12	Waist-to-hip ratio adjusted for body mass index;	chr14:52037679	chr14:51637348~51637947:-
BRCA	cis	rs56104184	0.578	rs7254608	ENSG00000235191.1	NUCB1-AS1	3.79	0.000158	0.0093	0.15	0.12	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr19:48892517	chr19:48910930~48918891:-
BRCA	cis	rs13217239	0.646	rs7747454	ENSG00000124549.13	BTN2A3P	-3.79	0.000158	0.0093	-0.12	-0.12	Schizophrenia;	chr6:27066474	chr6:26421391~26432383:+
BRCA	cis	rs6142618	0.562	rs4911197	ENSG00000277692.1	RP11-358N2.2	-3.79	0.000158	0.00931	-0.13	-0.12	Inflammatory bowel disease;	chr20:32130490	chr20:32355053~32355734:+
BRCA	cis	rs6964587	1	rs2106171	ENSG00000188693.7	CYP51A1-AS1	-3.79	0.000158	0.00931	-0.13	-0.12	Breast cancer;	chr7:92121136	chr7:92134604~92180725:+
BRCA	cis	rs4302906	0.753	rs7021090	ENSG00000187984.11	ANKRD19P	-3.79	0.000158	0.00931	-0.11	-0.12	Lobe attachment (rater-scored or self-reported);	chr9:92960131	chr9:92809388~92888693:+
BRCA	cis	rs7267979	0.966	rs6050532	ENSG00000277938.1	RP5-965G21.3	-3.79	0.000158	0.00931	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25328157	chr20:25229150~25231933:+
BRCA	cis	rs2704588	0.909	rs2446302	ENSG00000270720.1	RP11-84C13.2	-3.79	0.000158	0.00931	-0.18	-0.12	Longevity;	chr4:88905198	chr4:89119284~89119871:+
BRCA	cis	rs11098499	0.954	rs10034623	ENSG00000225892.3	RP11-384K6.2	3.79	0.000158	0.00931	0.12	0.12	Corneal astigmatism;	chr4:119476674	chr4:118632274~118634759:+
BRCA	cis	rs6439153	0.967	rs61480393	ENSG00000242551.2	POU5F1P6	-3.79	0.000158	0.00931	-0.15	-0.12	Pneumococcal bacteremia;	chr3:128980916	chr3:128674735~128677005:-
BRCA	cis	rs45509595	0.749	rs401763	ENSG00000216676.2	RP1-15D7.1	-3.79	0.000158	0.00931	-0.2	-0.12	Breast cancer;	chr6:27814750	chr6:27652602~27652825:-
BRCA	cis	rs45509595	0.659	rs390764	ENSG00000216676.2	RP1-15D7.1	-3.79	0.000158	0.00931	-0.2	-0.12	Breast cancer;	chr6:27814757	chr6:27652602~27652825:-
BRCA	cis	rs45509595	0.841	rs401754	ENSG00000216676.2	RP1-15D7.1	-3.79	0.000158	0.00931	-0.2	-0.12	Breast cancer;	chr6:27814760	chr6:27652602~27652825:-
BRCA	cis	rs983392	0.792	rs1303615	ENSG00000275344.1	MIR6503	-3.79	0.000158	0.00931	-0.12	-0.12	Alzheimer's disease (late onset);	chr11:60117647	chr11:60209071~60209156:-
BRCA	cis	rs2835345	0.563	rs58602880	ENSG00000233818.1	AP000695.4	3.79	0.000158	0.00931	0.13	0.12	Pulmonary function;	chr21:36454610	chr21:36445731~36532408:+
BRCA	cis	rs2832077	0.943	rs2832099	ENSG00000232855.5	AF131217.1	3.79	0.000158	0.00931	0.18	0.12	Cognitive test performance;	chr21:28801137	chr21:28439346~28674848:-
BRCA	cis	rs801193	1	rs2055682	ENSG00000265600.1	AC006480.1	-3.79	0.000158	0.00931	-0.14	-0.12	Aortic root size;	chr7:66795302	chr7:67356680~67356779:+
BRCA	cis	rs1383484	0.958	rs5016012	ENSG00000259728.4	LINC00933	-3.79	0.000158	0.00932	-0.14	-0.12	Height;	chr15:83843253	chr15:84570649~84580175:+
BRCA	cis	rs3764563	1	rs3764563	ENSG00000267594.5	CYP4F24P	-3.79	0.000158	0.00932	-0.21	-0.12	Inflammatory biomarkers;	chr19:15613392	chr19:15760241~15779909:-
BRCA	cis	rs7520050	0.778	rs2934857	ENSG00000234329.1	RP11-767N6.2	3.79	0.000158	0.00932	0.11	0.12	Reticulocyte count;Red blood cell count;	chr1:45573940	chr1:45651039~45651826:-
BRCA	cis	rs6964833	1	rs34324835	ENSG00000184616.8	AC004166.6	3.79	0.000158	0.00932	0.18	0.12	Menarche (age at onset);	chr7:74717986	chr7:74906673~74913256:-
BRCA	cis	rs7560272	0.501	rs2006997	ENSG00000204872.3	NAT8B	3.79	0.000158	0.00932	0.16	0.12	Schizophrenia;	chr2:73720719	chr2:73700576~73701340:-
BRCA	cis	rs10129255	0.912	rs8011090	ENSG00000211967.3	IGHV3-53	-3.79	0.000158	0.00932	-0.09	-0.12	Kawasaki disease;	chr14:106678896	chr14:106592676~106593347:-
BRCA	cis	rs6071524	0.611	rs4812272	ENSG00000224635.1	RP4-564F22.5	3.79	0.000158	0.00932	0.14	0.12	Autism spectrum disorder or schizophrenia;	chr20:38794083	chr20:38406011~38416797:-
BRCA	cis	rs6785206	0.772	rs2811493	ENSG00000242551.2	POU5F1P6	-3.79	0.000158	0.00932	-0.24	-0.12	Lymphocyte percentage of white cells;	chr3:128638456	chr3:128674735~128677005:-
BRCA	cis	rs34773007	0.577	rs35626653	ENSG00000232709.1	MARK2P9	3.79	0.000158	0.00933	0.2	0.12	Type 2 diabetes;	chr10:92784269	chr10:92418667~92420875:+
BRCA	cis	rs1346	0.552	rs10896022	ENSG00000245532.5	NEAT1	3.79	0.000158	0.00933	0.13	0.12	Vertical cup-disc ratio;Optic cup area;	chr11:65599139	chr11:65422774~65445540:+
BRCA	cis	rs1346	0.552	rs10791820	ENSG00000245532.5	NEAT1	3.79	0.000158	0.00933	0.13	0.12	Vertical cup-disc ratio;Optic cup area;	chr11:65599376	chr11:65422774~65445540:+
BRCA	cis	rs1730008	0.865	rs827090	ENSG00000279311.1	RP11-170K4.2	-3.79	0.000158	0.00933	-0.13	-0.12	Lobe attachment (rater-scored or self-reported);	chr3:158268999	chr3:158869898~158871821:+
BRCA	cis	rs4519046	0.847	rs3122227	ENSG00000273008.1	RP11-351D16.3	-3.79	0.000158	0.00933	-0.15	-0.12	Hirschsprung disease;	chr10:43492825	chr10:43136824~43138334:-
BRCA	cis	rs2835872	0.663	rs73220488	ENSG00000228677.1	TTC3-AS1	-3.79	0.000158	0.00933	-0.15	-0.12	Electroencephalographic traits in alcoholism;	chr21:37614723	chr21:37187666~37193926:-
BRCA	cis	rs17684571	0.751	rs28360570	ENSG00000231441.1	RP11-472M19.2	3.79	0.000158	0.00933	0.18	0.12	Schizophrenia;	chr6:56852832	chr6:56844002~56864078:+
BRCA	cis	rs4763879	1	rs4763879	ENSG00000278635.1	CTD-2318O12.1	-3.79	0.000158	0.00933	-0.12	-0.12	Type 1 diabetes;	chr12:9757568	chr12:9415641~9416718:+
BRCA	cis	rs1065852	0.526	rs2097561	ENSG00000205702.9	CYP2D7	3.79	0.000158	0.00933	0.11	0.12	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:41993427	chr22:42140203~42144577:-
BRCA	cis	rs155346	0.901	rs265179	ENSG00000242683.1	CTB-46B19.1	-3.79	0.000158	0.00933	-0.16	-0.12	Disturbances of the gamma-frequency band of electroencephalography measures in schizophrenia;	chr5:139985867	chr5:139035148~139035987:-
BRCA	cis	rs1005277	0.522	rs289650	ENSG00000226578.1	RP11-258F22.1	-3.79	0.000158	0.00933	-0.12	-0.12	Extrinsic epigenetic age acceleration;	chr10:37686577	chr10:37775371~37784131:-
BRCA	cis	rs35306767	0.903	rs61833260	ENSG00000229869.1	RP11-363N22.2	-3.79	0.000159	0.00933	-0.19	-0.12	Eosinophil percentage of granulocytes;	chr10:929208	chr10:933026~942743:+
BRCA	cis	rs10514758	0.744	rs72947761	ENSG00000242880.1	RP11-190P13.2	3.79	0.000159	0.00933	0.27	0.12	Urate levels in obese individuals;	chr3:115227859	chr3:115251196~115285347:+
BRCA	cis	rs7339483	0.702	rs10419660	ENSG00000268442.1	CTD-2027I19.2	3.79	0.000159	0.00933	0.24	0.12	Discordance in emotional problems in monozygotic twins;	chr19:24156851	chr19:24162370~24163425:-
BRCA	cis	rs10256972	0.758	rs2280724	ENSG00000199023.2	MIR339	-3.79	0.000159	0.00933	-0.14	-0.12	Endometriosis;Longevity;	chr7:1025084	chr7:1022935~1023045:-
BRCA	cis	rs7620503	1	rs2133595	ENSG00000277241.1	RP11-114M1.3	3.79	0.000159	0.00933	0.13	0.12	Corneal structure;	chr3:177585822	chr3:177700346~177701072:-
BRCA	cis	rs17270561	0.609	rs9358873	ENSG00000272462.2	U91328.19	-3.79	0.000159	0.00934	-0.15	-0.12	Iron status biomarkers;	chr6:25731555	chr6:25992662~26001775:+
BRCA	cis	rs10958369	0.934	rs2068035	ENSG00000260484.1	RP11-1081M5.2	3.79	0.000159	0.00934	0.13	0.12	Response to antineoplastic agents;	chr8:53501695	chr8:53388701~53390872:-
BRCA	cis	rs983392	0.679	rs1026255	ENSG00000275344.1	MIR6503	-3.79	0.000159	0.00934	-0.12	-0.12	Alzheimer's disease (late onset);	chr11:60262476	chr11:60209071~60209156:-
BRCA	cis	rs17221829	0.72	rs10765237	ENSG00000280385.1	AP000648.5	-3.79	0.000159	0.00934	-0.13	-0.12	Anxiety in major depressive disorder;	chr11:89720430	chr11:90193614~90198120:+
BRCA	cis	rs35688236	0.853	rs6808710	ENSG00000236452.1	AC123023.1	3.79	0.000159	0.00934	0.16	0.12	Neuroticism;	chr3:34532963	chr3:34203244~34268811:+
BRCA	cis	rs3845817	0.843	rs4146115	ENSG00000237979.1	AC007389.1	-3.79	0.000159	0.00934	-0.13	-0.12	Bipolar disorder;	chr2:65526860	chr2:65500993~65502138:-
BRCA	cis	rs17756712	0.725	rs3757122	ENSG00000271911.1	RP11-532F6.5	3.79	0.000159	0.00934	0.19	0.12	Vertical cup-disc ratio;	chr6:611030	chr6:761675~780648:+
BRCA	cis	rs10043775	0.793	rs2400509	ENSG00000251330.3	CTD-2283N19.1	-3.79	0.000159	0.00934	-0.14	-0.12	Periodontal microbiota;	chr5:148316455	chr5:148430159~148430807:-
BRCA	cis	rs875971	0.638	rs6460305	ENSG00000275400.1	RP4-756H11.5	3.79	0.000159	0.00934	0.13	0.12	Aortic root size;	chr7:66595421	chr7:66553805~66554199:-
BRCA	cis	rs8114671	0.967	rs6088747	ENSG00000279253.1	RP4-614O4.13	-3.79	0.000159	0.00934	-0.14	-0.12	Height;	chr20:35166801	chr20:35262727~35264187:-
BRCA	cis	rs10792665	0.724	rs1904429	ENSG00000246067.6	RAB30-AS1	-3.79	0.000159	0.00934	-0.12	-0.12	Obesity-related traits;	chr11:83010543	chr11:83072066~83106719:+
BRCA	cis	rs10792665	0.724	rs948183	ENSG00000246067.6	RAB30-AS1	-3.79	0.000159	0.00934	-0.12	-0.12	Obesity-related traits;	chr11:83011258	chr11:83072066~83106719:+
BRCA	cis	rs10792665	0.698	rs948184	ENSG00000246067.6	RAB30-AS1	-3.79	0.000159	0.00934	-0.12	-0.12	Obesity-related traits;	chr11:83011617	chr11:83072066~83106719:+
BRCA	cis	rs8073060	0.963	rs11080354	ENSG00000270871.1	AC015849.19	-3.79	0.000159	0.00934	-0.11	-0.12	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35545388	chr17:35816717~35830293:-
BRCA	cis	rs891378	1	rs2184476	ENSG00000274245.1	RP11-357P18.2	-3.79	0.000159	0.00934	-0.15	-0.12	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207331324	chr1:207372559~207373252:+
BRCA	cis	rs4575098	0.681	rs11579514	ENSG00000232879.2	RP11-544M22.3	-3.79	0.000159	0.00935	-0.13	-0.12	Monocyte percentage of white cells;	chr1:161173522	chr1:161034834~161035006:+
BRCA	cis	rs17489649	1	rs13187248	ENSG00000271849.1	CTC-332L22.1	-3.79	0.000159	0.00935	-0.15	-0.12	Intelligence (multi-trait analysis);	chr5:109759726	chr5:109687802~109688329:-
BRCA	cis	rs61931739	0.534	rs1912773	ENSG00000258794.3	DUX4L27	3.79	0.000159	0.00935	0.17	0.12	Morning vs. evening chronotype;	chr12:33944466	chr12:34208415~34209675:-
BRCA	cis	rs7412746	0.597	rs868751	ENSG00000231073.1	RP11-316M1.3	3.79	0.000159	0.00935	0.12	0.12	Melanoma;	chr1:150696938	chr1:150973123~150975534:+
BRCA	cis	rs875971	0.66	rs7807930	ENSG00000272831.1	RP11-792A8.4	-3.79	0.000159	0.00935	-0.1	-0.12	Aortic root size;	chr7:66622178	chr7:66739829~66740385:-
BRCA	cis	rs6964587	1	rs10225885	ENSG00000188693.7	CYP51A1-AS1	-3.79	0.000159	0.00935	-0.13	-0.12	Breast cancer;	chr7:92041693	chr7:92134604~92180725:+
BRCA	cis	rs6430585	0.583	rs58509842	ENSG00000226806.1	AC011893.3	3.79	0.000159	0.00935	0.16	0.12	Corneal structure;	chr2:135828457	chr2:135820191~135823087:+
BRCA	cis	rs6430585	0.583	rs3769008	ENSG00000226806.1	AC011893.3	3.79	0.000159	0.00935	0.16	0.12	Corneal structure;	chr2:135828613	chr2:135820191~135823087:+
BRCA	cis	rs6430585	0.583	rs12373779	ENSG00000226806.1	AC011893.3	3.79	0.000159	0.00935	0.16	0.12	Corneal structure;	chr2:135829270	chr2:135820191~135823087:+
BRCA	cis	rs10129255	0.957	rs10138532	ENSG00000211967.3	IGHV3-53	-3.79	0.000159	0.00935	-0.09	-0.12	Kawasaki disease;	chr14:106803901	chr14:106592676~106593347:-
BRCA	cis	rs6504622	0.755	rs34038545	ENSG00000263142.4	LRRC37A17P	-3.79	0.000159	0.00935	-0.09	-0.12	Orofacial clefts;	chr17:47067541	chr17:46978481~47054569:+
BRCA	cis	rs11098499	0.954	rs1022145	ENSG00000260091.1	RP11-33B1.4	-3.79	0.000159	0.00935	-0.1	-0.12	Corneal astigmatism;	chr4:119309824	chr4:119409333~119410233:+
BRCA	cis	rs6593122	0.755	rs10247013	ENSG00000235454.1	HAUS6P3	-3.79	0.000159	0.00935	-0.16	-0.12	Vaccine-related adverse events;	chr7:54121112	chr7:53862233~53863339:+
BRCA	cis	rs2562152	0.744	rs1045001	ENSG00000233614.6	DDX11L10	3.79	0.000159	0.00935	0.18	0.12	Glioblastoma;	chr16:57275	chr16:11555~14090:+
BRCA	cis	rs442309	0.846	rs224070	ENSG00000238280.1	RP11-436D10.3	-3.79	0.000159	0.00935	-0.15	-0.12	Vogt-Koyanagi-Harada syndrome;	chr10:62748658	chr10:62793562~62805887:-
BRCA	cis	rs2555155	0.904	rs720270	ENSG00000254595.1	CTD-2010I16.1	3.79	0.000159	0.00936	0.13	0.12	DNA methylation (variation);	chr11:6508310	chr11:6488186~6489377:-
BRCA	cis	rs17711722	1	rs17711722	ENSG00000223473.2	GS1-124K5.3	-3.79	0.000159	0.00936	-0.09	-0.12	Calcium levels;	chr7:65806210	chr7:66491049~66493566:-
BRCA	cis	rs56281245	0.59	rs80338187	ENSG00000249363.1	CTB-78O21.1	3.79	0.000159	0.00936	0.25	0.12	Hepcidin levels;	chr5:145588452	chr5:145728360~145729349:-
BRCA	cis	rs11098499	0.82	rs2389885	ENSG00000225892.3	RP11-384K6.2	3.79	0.000159	0.00936	0.12	0.12	Corneal astigmatism;	chr4:119612776	chr4:118632274~118634759:+
BRCA	cis	rs13153459	0.512	rs6869262	ENSG00000279557.1	CTD-2210P15.3	-3.79	0.000159	0.00936	-0.21	-0.12	Parkinson's disease;	chr5:44579264	chr5:43586367~43587543:-
BRCA	cis	rs7608910	0.668	rs6754585	ENSG00000237522.1	NONOP2	-3.79	0.000159	0.00936	-0.11	-0.12	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;	chr2:60995008	chr2:60936819~60938049:-
BRCA	cis	rs6840360	0.571	rs62327271	ENSG00000270265.1	RP11-731D1.4	-3.79	0.000159	0.00936	-0.14	-0.12	Intelligence (multi-trait analysis);	chr4:151614764	chr4:151333775~151353224:-
BRCA	cis	rs9840812	0.769	rs1711171	ENSG00000239213.4	NCK1-AS1	3.79	0.000159	0.00937	0.15	0.12	Fibrinogen levels;	chr3:136301699	chr3:136841726~136862054:-
BRCA	cis	rs372883	0.648	rs2832297	ENSG00000176054.6	RPL23P2	3.79	0.000159	0.00937	0.13	0.12	Pancreatic cancer;	chr21:29370675	chr21:28997613~28998033:-
BRCA	cis	rs12505749	0.542	rs12505939	ENSG00000270147.1	RP11-646I6.6	-3.79	0.000159	0.00937	-0.14	-0.12	Airflow obstruction;	chr4:56498044	chr4:56396312~56396871:+
BRCA	cis	rs11098499	0.954	rs10008459	ENSG00000225892.3	RP11-384K6.2	3.79	0.000159	0.00937	0.12	0.12	Corneal astigmatism;	chr4:119473076	chr4:118632274~118634759:+
BRCA	cis	rs10208649	0.808	rs6730494	ENSG00000272156.1	RP11-477N3.1	3.79	0.000159	0.00937	0.24	0.12	Body mass index;	chr2:53992049	chr2:54082554~54085066:+
BRCA	cis	rs2742540	0.505	rs2742493	ENSG00000254860.4	TMEM9B-AS1	3.79	0.000159	0.00937	0.1	0.12	Hematocrit;	chr11:8946045	chr11:8964675~8977527:+
BRCA	cis	rs890448	0.796	rs2471681	ENSG00000254531.1	FLJ20021	3.79	0.000159	0.00937	0.14	0.12	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101426910	chr4:101347780~101348883:+
BRCA	cis	rs7809799	0.571	rs740160	ENSG00000244219.5	GS1-259H13.2	-3.79	0.000159	0.00937	-0.25	-0.12	Ulcerative colitis;	chr7:99360257	chr7:99598066~99610813:+
BRCA	cis	rs9287719	0.781	rs12472807	ENSG00000224177.5	LINC00570	3.79	0.000159	0.00938	0.14	0.12	Prostate cancer;	chr2:10641479	chr2:11393981~11403077:+
BRCA	cis	rs7267979	0.934	rs2261115	ENSG00000274414.1	RP5-965G21.4	-3.79	0.000159	0.00938	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25279171	chr20:25239007~25245229:-
BRCA	cis	rs7618915	1	rs3852063	ENSG00000239557.1	RP11-168J18.6	3.79	0.000159	0.00938	0.16	0.12	Bipolar disorder;	chr3:52315188	chr3:52373652~52374882:+
BRCA	cis	rs7429990	0.965	rs1060407	ENSG00000199476.1	Y_RNA	-3.79	0.00016	0.00938	-0.16	-0.12	Educational attainment (years of education);	chr3:47916547	chr3:48288587~48288694:+
BRCA	cis	rs754466	0.58	rs2579178	ENSG00000213514.2	RP11-428P16.2	-3.79	0.00016	0.00938	-0.16	-0.12	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77769457	chr10:77730766~77734769:+
BRCA	cis	rs8180040	0.934	rs62260710	ENSG00000280667.1	Y_RNA	-3.79	0.00016	0.00939	-0.14	-0.12	Colorectal cancer;	chr3:47522972	chr3:47501083~47501182:+
BRCA	cis	rs8180040	0.966	rs62260711	ENSG00000280667.1	Y_RNA	-3.79	0.00016	0.00939	-0.14	-0.12	Colorectal cancer;	chr3:47523001	chr3:47501083~47501182:+
BRCA	cis	rs2243480	1	rs57057549	ENSG00000226767.1	RP11-328P23.3	-3.79	0.00016	0.00939	-0.2	-0.12	Diabetic kidney disease;	chr7:65940751	chr7:65508773~65508944:-
BRCA	cis	rs4218	0.681	rs1074701	ENSG00000259732.1	RP11-59H7.3	-3.79	0.00016	0.00939	-0.14	-0.12	Social communication problems;	chr15:59073862	chr15:59121034~59133250:+
BRCA	cis	rs13401620	0.871	rs2166439	ENSG00000229326.3	AC069154.4	-3.79	0.00016	0.00939	-0.16	-0.12	Breast size;	chr2:119960068	chr2:119698623~119700151:+
BRCA	cis	rs875971	0.545	rs12670811	ENSG00000273142.1	RP11-458F8.4	3.79	0.00016	0.00939	0.12	0.12	Aortic root size;	chr7:66358032	chr7:66902857~66906297:+
BRCA	cis	rs6585424	1	rs35180576	ENSG00000225484.5	NUTM2B-AS1	-3.79	0.00016	0.00939	-0.24	-0.12	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80163215	chr10:79663088~79826594:-
BRCA	cis	rs6585424	1	rs34148644	ENSG00000225484.5	NUTM2B-AS1	-3.79	0.00016	0.00939	-0.24	-0.12	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80163700	chr10:79663088~79826594:-
BRCA	cis	rs35306767	0.903	rs35957139	ENSG00000229869.1	RP11-363N22.2	-3.79	0.00016	0.00939	-0.2	-0.12	Eosinophil percentage of granulocytes;	chr10:838949	chr10:933026~942743:+
BRCA	cis	rs35306767	0.855	rs55697724	ENSG00000229869.1	RP11-363N22.2	-3.79	0.00016	0.00939	-0.2	-0.12	Eosinophil percentage of granulocytes;	chr10:839682	chr10:933026~942743:+
BRCA	cis	rs11673344	0.566	rs2385180	ENSG00000233527.7	ZNF529-AS1	-3.79	0.00016	0.00939	-0.13	-0.12	Obesity-related traits;	chr19:37431454	chr19:36573070~36594708:+
BRCA	cis	rs6991838	0.584	rs7841652	ENSG00000272155.1	RP11-707M3.3	3.79	0.00016	0.00939	0.11	0.12	Intelligence (multi-trait analysis);	chr8:65606392	chr8:65714334~65714778:-
BRCA	cis	rs721917	0.506	rs2819097	ENSG00000225484.5	NUTM2B-AS1	-3.79	0.00016	0.00939	-0.16	-0.12	Chronic obstructive pulmonary disease;	chr10:79940225	chr10:79663088~79826594:-
BRCA	cis	rs11098499	0.738	rs34965784	ENSG00000225892.3	RP11-384K6.2	3.79	0.00016	0.00939	0.12	0.12	Corneal astigmatism;	chr4:119440431	chr4:118632274~118634759:+
BRCA	cis	rs2451932	0.688	rs2434304	ENSG00000251050.1	RP11-168A11.4	-3.79	0.00016	0.00939	-0.12	-0.12	LDL peak particle diameter (total fat intake interaction);	chr5:80059069	chr5:80019609~80019920:+
BRCA	cis	rs4767841	0.935	rs7131914	ENSG00000248636.5	RP11-768F21.1	-3.79	0.00016	0.00939	-0.14	-0.12	Urgency urinary incontinence;	chr12:119717772	chr12:119387987~119668079:-
BRCA	cis	rs11098403	0.789	rs7674473	ENSG00000225892.3	RP11-384K6.2	3.79	0.00016	0.00939	0.11	0.12	Schizophrenia;	chr4:117750315	chr4:118632274~118634759:+
BRCA	cis	rs7954584	0.52	rs1169094	ENSG00000274292.1	RP11-347I19.7	3.79	0.00016	0.0094	0.1	0.12	Mean corpuscular volume;	chr12:122027629	chr12:121800797~121803403:+
BRCA	cis	rs720475	0.732	rs62483107	ENSG00000228960.5	OR2A9P	-3.79	0.00016	0.0094	-0.18	-0.12	Breast cancer;	chr7:144442144	chr7:144294480~144300934:+
BRCA	cis	rs8141529	0.719	rs9625619	ENSG00000272858.1	CTA-292E10.8	-3.79	0.00016	0.0094	-0.15	-0.12	Lymphocyte counts;	chr22:28876340	chr22:28814914~28815662:+
BRCA	cis	rs116095464	0.558	rs9312978	ENSG00000250848.1	CTD-2083E4.5	-3.79	0.00016	0.0094	-0.18	-0.12	Breast cancer;	chr5:221815	chr5:288833~290321:-
BRCA	cis	rs116095464	0.558	rs9312979	ENSG00000250848.1	CTD-2083E4.5	-3.79	0.00016	0.0094	-0.18	-0.12	Breast cancer;	chr5:221942	chr5:288833~290321:-
BRCA	cis	rs516805	0.706	rs9490427	ENSG00000279114.1	RP3-425C14.5	3.79	0.00016	0.0094	0.14	0.12	Lymphocyte counts;	chr6:122353084	chr6:122471923~122484161:+
BRCA	cis	rs4272720	0.901	rs45563932	ENSG00000228754.1	RP11-534L6.3	-3.79	0.00016	0.0094	-0.17	-0.12	Platelet count;Plateletcrit;	chr10:49166885	chr10:48745545~48746128:-
BRCA	cis	rs8141529	0.748	rs2064261	ENSG00000272858.1	CTA-292E10.8	-3.79	0.00016	0.0094	-0.15	-0.12	Lymphocyte counts;	chr22:28891742	chr22:28814914~28815662:+
BRCA	cis	rs7267979	0.668	rs2387977	ENSG00000125804.12	FAM182A	3.79	0.00016	0.0094	0.15	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25619140	chr20:26054655~26086917:+
BRCA	cis	rs2625529	0.586	rs7175197	ENSG00000260037.4	CTD-2524L6.3	3.79	0.00016	0.0094	0.14	0.12	Red blood cell count;	chr15:72169307	chr15:71818396~71823384:+
BRCA	cis	rs7475343	0.501	rs6601924	ENSG00000224034.1	RP11-445P17.8	3.79	0.00016	0.0094	0.21	0.12	Intelligence;	chr10:5205339	chr10:5266033~5271236:-
BRCA	cis	rs317865	0.737	rs55949632	ENSG00000263327.5	TAPT1-AS1	-3.79	0.00016	0.0094	-0.2	-0.12	Kidney disease (early stage) in type 1 diabetes;	chr4:16205449	chr4:16226685~16320140:+
BRCA	cis	rs9470794	1	rs73419949	ENSG00000204110.6	RP1-153P14.8	-3.79	0.00016	0.0094	-0.24	-0.12	Type 2 diabetes;	chr6:38072898	chr6:37507348~37535616:+
BRCA	cis	rs6463739	0.736	rs10229133	ENSG00000219545.8	UMAD1	-3.79	0.00016	0.0094	-0.12	-0.12	Small cell lung carcinoma;	chr7:7852243	chr7:7640711~8004059:+
BRCA	cis	rs6964587	0.934	rs1544377	ENSG00000188693.7	CYP51A1-AS1	-3.79	0.00016	0.00941	-0.13	-0.12	Breast cancer;	chr7:92058037	chr7:92134604~92180725:+
BRCA	cis	rs3735485	0.678	rs3757574	ENSG00000201772.1	SNORA5C	3.79	0.00016	0.00941	0.15	0.12	White blood cell count;Sum basophil neutrophil counts;Neutrophil count;Granulocyte percentage of myeloid white cells;Monocyte percentage of white cells;Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Lymphocyte counts;	chr7:45108420	chr7:45104906~45105042:-
BRCA	cis	rs76878669	0.917	rs10219183	ENSG00000255320.1	RP11-755F10.1	-3.79	0.00016	0.00941	-0.18	-0.12	Educational attainment (years of education);	chr11:66322561	chr11:66244840~66246239:-
BRCA	cis	rs7621331	1	rs9843725	ENSG00000239213.4	NCK1-AS1	3.79	0.00016	0.00941	0.14	0.12	Waist circumference adjusted for body mass index;	chr3:135984023	chr3:136841726~136862054:-
BRCA	cis	rs11694172	1	rs11694172	ENSG00000273456.1	RP11-686O6.2	-3.79	0.00016	0.00941	-0.13	-0.12	Cholesterol, total;	chr2:202667581	chr2:202374932~202375604:-
BRCA	cis	rs6964587	1	rs6969536	ENSG00000188693.7	CYP51A1-AS1	-3.79	0.00016	0.00941	-0.13	-0.12	Breast cancer;	chr7:92060037	chr7:92134604~92180725:+
BRCA	cis	rs1065852	0.526	rs2097562	ENSG00000205702.9	CYP2D7	3.79	0.00016	0.00941	0.11	0.12	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:41993496	chr22:42140203~42144577:-
BRCA	cis	rs442309	0.875	rs224147	ENSG00000238280.1	RP11-436D10.3	3.79	0.00016	0.00941	0.15	0.12	Vogt-Koyanagi-Harada syndrome;	chr10:62726055	chr10:62793562~62805887:-
BRCA	cis	rs8180040	0.726	rs2385867	ENSG00000260236.1	RP11-708J19.1	3.79	0.00016	0.00941	0.1	0.12	Colorectal cancer;	chr3:47017833	chr3:47379089~47380999:-
BRCA	cis	rs2708977	1	rs13029764	ENSG00000237510.6	AC008268.2	-3.79	0.00016	0.00941	-0.15	-0.12	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96663137	chr2:95789654~95800166:+
BRCA	cis	rs2832077	0.943	rs2832091	ENSG00000215533.7	LINC00189	3.79	0.00016	0.00941	0.17	0.12	Cognitive test performance;	chr21:28790533	chr21:29193480~29288205:+
BRCA	cis	rs11158026	0.603	rs8009997	ENSG00000258413.1	RP11-665C16.6	-3.79	0.00016	0.00941	-0.16	-0.12	Parkinson's disease;	chr14:54955193	chr14:55262767~55272075:-
BRCA	cis	rs6480314	0.831	rs10740287	ENSG00000233590.1	RP11-153K11.3	3.79	0.00016	0.00941	0.18	0.12	Optic nerve measurement (disc area);	chr10:68214133	chr10:68233251~68242379:-
BRCA	cis	rs251253	0.827	rs2246091	ENSG00000253959.1	CTB-43E15.1	3.79	0.00016	0.00942	0.11	0.12	PR interval;	chr5:173076322	chr5:173642519~173658194:+
BRCA	cis	rs251253	0.827	rs2246090	ENSG00000253959.1	CTB-43E15.1	3.79	0.00016	0.00942	0.11	0.12	PR interval;	chr5:173076326	chr5:173642519~173658194:+
BRCA	cis	rs911119	0.955	rs6048930	ENSG00000270001.1	RP11-218C14.8	-3.79	0.00016	0.00942	-0.15	-0.12	Chronic kidney disease;	chr20:23611855	chr20:23631826~23632316:-
BRCA	cis	rs17772222	0.917	rs7157149	ENSG00000258789.1	RP11-507K2.3	-3.79	0.00016	0.00942	-0.15	-0.12	Coronary artery calcification;	chr14:88765501	chr14:88551597~88552493:+
BRCA	cis	rs10864907	0.71	rs7559466	ENSG00000231747.1	AC079922.2	-3.79	0.00016	0.00942	-0.11	-0.12	Pulmonary function;	chr2:112971104	chr2:112621809~112622167:-
BRCA	cis	rs4415084	1	rs13176502	ENSG00000272335.1	RP11-53O19.3	3.79	0.00016	0.00942	0.11	0.12	Breast cancer;	chr5:44697806	chr5:44826076~44828592:+
BRCA	cis	rs7267979	1	rs6050573	ENSG00000204556.4	CTD-2514C3.1	-3.79	0.00016	0.00942	-0.16	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25385429	chr20:26018832~26020684:+
BRCA	cis	rs7395581	0.959	rs326222	ENSG00000280615.1	Y_RNA	-3.79	0.00016	0.00942	-0.14	-0.12	HDL cholesterol;	chr11:47238117	chr11:47614898~47614994:-
BRCA	cis	rs2832077	0.943	rs2832100	ENSG00000215533.7	LINC00189	3.79	0.00016	0.00942	0.17	0.12	Cognitive test performance;	chr21:28803305	chr21:29193480~29288205:+
BRCA	cis	rs6071166	0.683	rs6027232	ENSG00000224635.1	RP4-564F22.5	-3.79	0.00016	0.00942	-0.14	-0.12	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38681360	chr20:38406011~38416797:-
BRCA	cis	rs77633900	0.772	rs157761	ENSG00000196274.5	Metazoa_SRP	3.79	0.00016	0.00942	0.2	0.12	Glioma;Non-glioblastoma glioma;	chr15:76503737	chr15:76230048~76230390:-
BRCA	cis	rs12477602	0.938	rs13025713	ENSG00000272966.1	RP11-686O6.1	3.79	0.00016	0.00942	0.2	0.12	Intelligence (multi-trait analysis);	chr2:202395978	chr2:202336739~202337200:+
BRCA	cis	rs1075265	0.704	rs10181999	ENSG00000272156.1	RP11-477N3.1	-3.79	0.00016	0.00942	-0.12	-0.12	Chronotype;Morning vs. evening chronotype;	chr2:54025360	chr2:54082554~54085066:+
BRCA	cis	rs7819412	0.595	rs10106914	ENSG00000154316.13	TDH	3.79	0.00016	0.00942	0.15	0.12	Triglycerides;	chr8:11130141	chr8:11339637~11368452:+
BRCA	cis	rs875971	0.862	rs2420174	ENSG00000271064.1	RP11-792A8.3	3.79	0.00016	0.00943	0.14	0.12	Aortic root size;	chr7:66180374	chr7:66748838~66749077:-
BRCA	cis	rs875971	0.862	rs2420173	ENSG00000271064.1	RP11-792A8.3	3.79	0.00016	0.00943	0.14	0.12	Aortic root size;	chr7:66180412	chr7:66748838~66749077:-
BRCA	cis	rs10129255	0.957	rs8014696	ENSG00000211967.3	IGHV3-53	3.79	0.00016	0.00943	0.08	0.12	Kawasaki disease;	chr14:106769752	chr14:106592676~106593347:-
BRCA	cis	rs10992471	0.517	rs16905839	ENSG00000187984.11	ANKRD19P	-3.79	0.00016	0.00943	-0.11	-0.12	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr9:92894771	chr9:92809388~92888693:+
BRCA	cis	rs6496932	0.913	rs4843037	ENSG00000259774.1	RP11-182J1.13	3.79	0.00016	0.00943	0.17	0.12	Central corneal thickness;Corneal structure;	chr15:85274674	chr15:84422618~84425882:+
BRCA	cis	rs7267979	1	rs6050609	ENSG00000276952.1	RP5-965G21.6	-3.79	0.00016	0.00943	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25431115	chr20:25284915~25285588:-
BRCA	cis	rs801193	1	rs2659909	ENSG00000272831.1	RP11-792A8.4	3.79	0.00016	0.00943	0.1	0.12	Aortic root size;	chr7:66695292	chr7:66739829~66740385:-
BRCA	cis	rs448720	1	rs12438699	ENSG00000260657.2	RP11-315D16.4	-3.79	0.00016	0.00943	-0.14	-0.12	Cognitive performance;	chr15:67898919	chr15:68267792~68277994:-
BRCA	cis	rs9844666	0.512	rs9833799	ENSG00000273486.1	RP11-731C17.2	3.79	0.00016	0.00943	0.13	0.12	Height;	chr3:135922325	chr3:136837338~136839021:-
BRCA	cis	rs4950322	0.57	rs17360443	ENSG00000237188.3	RP11-337C18.8	3.79	0.00016	0.00943	0.15	0.12	Protein quantitative trait loci;	chr1:147279737	chr1:147172771~147211568:+
BRCA	cis	rs6762	0.748	rs5030780	ENSG00000255142.1	AP006621.6	3.79	0.000161	0.00943	0.1	0.12	Mean platelet volume;	chr11:838110	chr11:781645~782105:+
BRCA	cis	rs1156327	0.51	rs8047832	ENSG00000188477.11	AC003003.5	-3.79	0.000161	0.00943	-0.26	-0.12	Periodontal disease-related phenotypes;	chr16:19321831	chr16:19285783~19310947:+
BRCA	cis	rs891378	0.959	rs12133548	ENSG00000274245.1	RP11-357P18.2	-3.79	0.000161	0.00943	-0.15	-0.12	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207333261	chr1:207372559~207373252:+
BRCA	cis	rs891378	1	rs11120733	ENSG00000274245.1	RP11-357P18.2	-3.79	0.000161	0.00943	-0.15	-0.12	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207333304	chr1:207372559~207373252:+
BRCA	cis	rs6596100	0.915	rs4367292	ENSG00000248648.1	RP11-485M7.1	-3.79	0.000161	0.00943	-0.14	-0.12	Breast cancer;	chr5:133099880	chr5:133003119~133003365:+
BRCA	cis	rs1348850	0.872	rs13004955	ENSG00000280374.1	RP11-337N6.3	-3.79	0.000161	0.00944	-0.16	-0.12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177534195	chr2:177317715~177318471:-
BRCA	cis	rs9807841	0.555	rs6511708	ENSG00000267100.1	ILF3-AS1	3.79	0.000161	0.00944	0.12	0.12	Inflammatory skin disease;	chr19:10678137	chr19:10651862~10653844:-
BRCA	cis	rs17801127	0.818	rs12233215	ENSG00000231969.1	AC144449.1	3.79	0.000161	0.00944	0.2	0.12	Liver enzyme levels (alanine transaminase);	chr2:149690793	chr2:149587196~149848233:+
BRCA	cis	rs2486012	0.737	rs6670344	ENSG00000237950.1	RP11-7O11.3	3.79	0.000161	0.00944	0.21	0.12	Intelligence (multi-trait analysis);	chr1:43803537	chr1:43944370~43946551:-
BRCA	cis	rs11764932	0.662	rs10046551	ENSG00000229108.1	MEOX2-AS1	3.79	0.000161	0.00944	0.14	0.12	Kidney function decline traits;	chr7:15673480	chr7:15688378~15695491:+
BRCA	cis	rs1371614	0.611	rs7557229	ENSG00000229122.1	AGBL5-IT1	-3.79	0.000161	0.00944	-0.12	-0.12	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26908023	chr2:27061038~27061815:+
BRCA	cis	rs10129255	0.789	rs61997796	ENSG00000211959.2	IGHV4-39	3.79	0.000161	0.00944	0.09	0.12	Kawasaki disease;	chr14:106813798	chr14:106421711~106422218:-
BRCA	cis	rs17270561	0.666	rs1937129	ENSG00000272462.2	U91328.19	-3.79	0.000161	0.00944	-0.14	-0.12	Iron status biomarkers;	chr6:25788904	chr6:25992662~26001775:+
BRCA	cis	rs7487075	0.558	rs3847985	ENSG00000274723.1	RP11-618L22.1	3.79	0.000161	0.00944	0.14	0.12	Itch intensity from mosquito bite;	chr12:46261504	chr12:46970504~46972155:+
BRCA	cis	rs2333021	0.934	rs4903092	ENSG00000259015.1	RP11-109N23.6	3.79	0.000161	0.00944	0.12	0.12	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:73013017	chr14:72960595~72961993:+
BRCA	cis	rs74233809	1	rs12221064	ENSG00000236937.2	PTGES3P4	3.79	0.000161	0.00944	0.25	0.12	Birth weight;	chr10:102917369	chr10:102845595~102845950:+
BRCA	cis	rs74233809	1	rs77602510	ENSG00000236937.2	PTGES3P4	3.79	0.000161	0.00944	0.25	0.12	Birth weight;	chr10:102922845	chr10:102845595~102845950:+
BRCA	cis	rs74233809	1	rs78821730	ENSG00000236937.2	PTGES3P4	3.79	0.000161	0.00944	0.25	0.12	Birth weight;	chr10:102924787	chr10:102845595~102845950:+
BRCA	cis	rs875971	0.505	rs6955582	ENSG00000273142.1	RP11-458F8.4	-3.79	0.000161	0.00944	-0.1	-0.12	Aortic root size;	chr7:65966699	chr7:66902857~66906297:+
BRCA	cis	rs4700393	0.52	rs4515250	ENSG00000272308.1	RP11-231G3.1	-3.79	0.000161	0.00944	-0.15	-0.12	Intelligence (multi-trait analysis);	chr5:60646302	chr5:60866457~60866935:-
BRCA	cis	rs1143633	0.553	rs2723197	ENSG00000231747.1	AC079922.2	3.79	0.000161	0.00944	0.11	0.12	Allergic disease (asthma, hay fever or eczema);	chr2:112932170	chr2:112621809~112622167:-
BRCA	cis	rs17581137	0.591	rs4321146	ENSG00000259275.2	RP11-522B15.3	-3.79	0.000161	0.00944	-0.13	-0.12	Coronary artery disease;	chr15:95635587	chr15:96354237~96403803:+
BRCA	cis	rs1305088	0.558	rs17561390	ENSG00000261485.1	PAN3-AS1	-3.79	0.000161	0.00944	-0.26	-0.12	Non-alcoholic fatty liver disease histology (other);	chr13:28802560	chr13:28136843~28138193:-
BRCA	cis	rs1153858	1	rs11070456	ENSG00000275672.1	GATM-AS1	-3.79	0.000161	0.00945	-0.15	-0.12	Homoarginine levels;	chr15:45394637	chr15:45378700~45380123:+
BRCA	cis	rs7020830	0.898	rs6476617	ENSG00000230188.1	RP11-405L18.4	-3.79	0.000161	0.00945	-0.14	-0.12	Schizophrenia;	chr9:37200106	chr9:37490421~37490893:-
BRCA	cis	rs983392	0.792	rs574798	ENSG00000275344.1	MIR6503	-3.79	0.000161	0.00945	-0.12	-0.12	Alzheimer's disease (late onset);	chr11:60114088	chr11:60209071~60209156:-
BRCA	cis	rs9959145	1	rs9967026	ENSG00000267108.1	RP11-861E21.1	3.79	0.000161	0.00945	0.2	0.12	Immune response to smallpox vaccine (IL-6);	chr18:12566484	chr18:12432897~12437635:+
BRCA	cis	rs4906332	1	rs3783397	ENSG00000259775.1	RP11-45P15.4	-3.79	0.000161	0.00945	-0.13	-0.12	Coronary artery disease;	chr14:103480952	chr14:103331674~103332367:-
BRCA	cis	rs490234	0.871	rs4837019	ENSG00000232630.1	PRPS1P2	-3.79	0.000161	0.00945	-0.12	-0.12	Mean arterial pressure;	chr9:125513802	chr9:125150653~125151589:+
BRCA	cis	rs524281	0.861	rs10896077	ENSG00000255038.1	RP11-1167A19.2	-3.79	0.000161	0.00945	-0.17	-0.12	Electroencephalogram traits;	chr11:66084262	chr11:66067277~66069619:-
BRCA	cis	rs11098499	0.909	rs79026312	ENSG00000260404.2	RP11-384K6.6	3.79	0.000161	0.00945	0.11	0.12	Corneal astigmatism;	chr4:119519522	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.909	rs35111518	ENSG00000260404.2	RP11-384K6.6	3.79	0.000161	0.00945	0.11	0.12	Corneal astigmatism;	chr4:119519527	chr4:118591773~118633729:+
BRCA	cis	rs6430585	0.759	rs4954623	ENSG00000224043.6	CCNT2-AS1	3.79	0.000161	0.00945	0.19	0.12	Corneal structure;	chr2:135778306	chr2:134735464~134918710:-
BRCA	cis	rs7098100	0.641	rs2807979	ENSG00000231920.1	NEBL-AS1	-3.79	0.000161	0.00945	-0.14	-0.12	Breast cancer;	chr10:21924175	chr10:21174014~21175048:+
BRCA	cis	rs860295	0.702	rs11264380	ENSG00000236675.1	MTX1P1	-3.79	0.000161	0.00945	-0.14	-0.12	Body mass index;	chr1:155550353	chr1:155230975~155234325:+
BRCA	cis	rs7620503	0.959	rs4857713	ENSG00000228561.2	RP11-114M1.1	3.79	0.000161	0.00946	0.14	0.12	Corneal structure;	chr3:177588654	chr3:177683627~177691250:+
BRCA	cis	rs12586478	0.561	rs8007032	ENSG00000205562.2	RP11-497E19.1	3.79	0.000161	0.00946	0.11	0.12	Post bronchodilator FEV1;	chr14:86311322	chr14:85524432~85529988:-
BRCA	cis	rs2795502	0.554	rs1620395	ENSG00000185904.10	LINC00839	-3.79	0.000161	0.00946	-0.14	-0.12	Blood protein levels;	chr10:42845737	chr10:42475543~42495336:+
BRCA	cis	rs13401620	0.7	rs13414116	ENSG00000229326.3	AC069154.4	-3.79	0.000161	0.00946	-0.15	-0.12	Breast size;	chr2:119901459	chr2:119698623~119700151:+
BRCA	cis	rs10923574	0.597	rs10923577	ENSG00000231365.4	RP11-418J17.1	-3.79	0.000161	0.00946	-0.14	-0.12	Breast cancer;Folding of antihelix;	chr1:118502644	chr1:119140396~119275973:+
BRCA	cis	rs10923574	0.576	rs10923578	ENSG00000231365.4	RP11-418J17.1	-3.79	0.000161	0.00946	-0.14	-0.12	Breast cancer;Folding of antihelix;	chr1:118504538	chr1:119140396~119275973:+
BRCA	cis	rs62458065	0.713	rs3801329	ENSG00000281332.1	LINC00997	-3.79	0.000161	0.00946	-0.18	-0.12	Metabolite levels (HVA/MHPG ratio);	chr7:32457344	chr7:32760279~32762924:+
BRCA	cis	rs7523050	0.73	rs77425121	ENSG00000203897.3	SPATA42	-3.79	0.000161	0.00946	-0.23	-0.12	Fat distribution (HIV);	chr1:108875055	chr1:108857217~108858524:+
BRCA	cis	rs3781264	0.56	rs3765524	ENSG00000268894.5	PLCE1-AS1	-3.79	0.000161	0.00946	-0.15	-0.12	Esophageal cancer and gastric cancer;	chr10:94298541	chr10:94279277~94287478:-
BRCA	cis	rs7620503	1	rs4857612	ENSG00000231574.4	RP11-91K9.1	3.79	0.000161	0.00946	0.13	0.12	Corneal structure;	chr3:177588833	chr3:177816865~177899224:+
BRCA	cis	rs2835872	0.793	rs976894	ENSG00000228677.1	TTC3-AS1	-3.79	0.000161	0.00947	-0.15	-0.12	Electroencephalographic traits in alcoholism;	chr21:37614181	chr21:37187666~37193926:-
BRCA	cis	rs9905704	0.718	rs4793953	ENSG00000265148.4	BZRAP1-AS1	-3.79	0.000161	0.00947	-0.15	-0.12	Testicular germ cell tumor;	chr17:58535743	chr17:58325450~58415766:+
BRCA	cis	rs73198271	0.813	rs17697237	ENSG00000253893.2	FAM85B	-3.79	0.000161	0.00947	-0.15	-0.12	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8758364	chr8:8167819~8226614:-
BRCA	cis	rs12612619	0.557	rs1368888	ENSG00000229122.1	AGBL5-IT1	-3.79	0.000161	0.00947	-0.12	-0.12	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:26845709	chr2:27061038~27061815:+
BRCA	cis	rs11887277	0.868	rs6717682	ENSG00000229122.1	AGBL5-IT1	-3.79	0.000161	0.00947	-0.12	-0.12	Obesity-related traits;	chr2:26846343	chr2:27061038~27061815:+
BRCA	cis	rs2880765	0.835	rs7163958	ENSG00000230373.7	GOLGA6L5P	3.79	0.000161	0.00947	0.12	0.12	Coronary artery disease;	chr15:85501984	chr15:84507885~84516814:-
BRCA	cis	rs7208859	0.673	rs9889755	ENSG00000276250.1	CTD-2349P21.12	3.79	0.000161	0.00947	0.17	0.12	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30907487	chr17:30803654~30804077:+
BRCA	cis	rs6964587	1	rs10274756	ENSG00000188693.7	CYP51A1-AS1	-3.79	0.000161	0.00947	-0.13	-0.12	Breast cancer;	chr7:92111482	chr7:92134604~92180725:+
BRCA	cis	rs875971	0.545	rs6950988	ENSG00000273448.1	RP11-166O4.6	3.79	0.000161	0.00947	0.12	0.12	Aortic root size;	chr7:66511428	chr7:67333047~67334383:+
BRCA	cis	rs2562456	0.917	rs2562466	ENSG00000268555.1	RP11-678G14.3	-3.79	0.000161	0.00947	-0.15	-0.12	Pain;	chr19:21531402	chr19:21570822~21587322:-
BRCA	cis	rs3740713	1	rs73440614	ENSG00000256361.1	RP11-613F22.6	3.79	0.000161	0.00947	0.19	0.12	Amyotrophic lateral sclerosis (sporadic);	chr11:18445153	chr11:18511043~18511475:-
BRCA	cis	rs7267979	0.789	rs6076347	ENSG00000274414.1	RP5-965G21.4	3.79	0.000161	0.00947	0.14	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25418154	chr20:25239007~25245229:-
BRCA	cis	rs453301	0.631	rs17700611	ENSG00000233609.3	RP11-62H7.2	-3.79	0.000161	0.00947	-0.11	-0.12	Joint mobility (Beighton score);	chr8:8936144	chr8:8961200~8979025:+
BRCA	cis	rs952623	0.717	rs12669446	ENSG00000211694.2	TRGV10	-3.79	0.000161	0.00947	-0.1	-0.12	Intelligence (multi-trait analysis);	chr7:39007308	chr7:38299811~38300322:-
BRCA	cis	rs1670533	1	rs6821725	ENSG00000251639.2	RP11-20I20.1	3.79	0.000161	0.00947	0.18	0.12	Recombination rate (females);	chr4:1066572	chr4:1100016~1101558:-
BRCA	cis	rs1670533	1	rs11247972	ENSG00000251639.2	RP11-20I20.1	3.79	0.000161	0.00947	0.18	0.12	Recombination rate (females);	chr4:1066762	chr4:1100016~1101558:-
BRCA	cis	rs91731	1	rs268731	ENSG00000249572.1	CTD-2203K17.1	-3.79	0.000161	0.00948	-0.22	-0.12	Lung function (FVC);	chr5:33364578	chr5:33424025~33440619:-
BRCA	cis	rs1005277	0.579	rs1740742	ENSG00000272983.1	RP11-508N22.12	3.79	0.000161	0.00948	0.12	0.12	Extrinsic epigenetic age acceleration;	chr10:38229932	chr10:38137337~38144399:+
BRCA	cis	rs1005277	0.602	rs1740743	ENSG00000272983.1	RP11-508N22.12	3.79	0.000161	0.00948	0.12	0.12	Extrinsic epigenetic age acceleration;	chr10:38230294	chr10:38137337~38144399:+
BRCA	cis	rs1005277	0.579	rs1740745	ENSG00000272983.1	RP11-508N22.12	3.79	0.000161	0.00948	0.12	0.12	Extrinsic epigenetic age acceleration;	chr10:38231128	chr10:38137337~38144399:+
BRCA	cis	rs1005277	0.579	rs1740747	ENSG00000272983.1	RP11-508N22.12	3.79	0.000161	0.00948	0.12	0.12	Extrinsic epigenetic age acceleration;	chr10:38231537	chr10:38137337~38144399:+
BRCA	cis	rs1005277	0.579	rs1740749	ENSG00000272983.1	RP11-508N22.12	3.79	0.000161	0.00948	0.12	0.12	Extrinsic epigenetic age acceleration;	chr10:38232718	chr10:38137337~38144399:+
BRCA	cis	rs1005277	0.579	rs1780115	ENSG00000272983.1	RP11-508N22.12	3.79	0.000161	0.00948	0.12	0.12	Extrinsic epigenetic age acceleration;	chr10:38235845	chr10:38137337~38144399:+
BRCA	cis	rs2391285	0.609	rs4552808	ENSG00000280255.1	RP5-1007F24.1	3.79	0.000161	0.00948	0.17	0.12	Post bronchodilator FEV1/FVC ratio;	chr7:26567965	chr7:26538378~26541048:+
BRCA	cis	rs10434923	0.85	rs2140630	ENSG00000233878.1	AC073133.1	-3.79	0.000161	0.00948	-0.29	-0.12	Childhood ear infection;	chr7:156472592	chr7:156437789~156445588:-
BRCA	cis	rs890448	0.796	rs10007902	ENSG00000254531.1	FLJ20021	3.79	0.000161	0.00948	0.14	0.12	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101414961	chr4:101347780~101348883:+
BRCA	cis	rs7267979	0.966	rs6050567	ENSG00000274414.1	RP5-965G21.4	3.79	0.000161	0.00948	0.14	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25373925	chr20:25239007~25245229:-
BRCA	cis	rs7590268	0.789	rs58583407	ENSG00000279873.2	LINC01126	3.79	0.000161	0.00948	0.14	0.12	Orofacial clefts;	chr2:43405198	chr2:43227210~43228855:+
BRCA	cis	rs62244186	0.545	rs725866	ENSG00000233509.2	ZNF197-AS1	3.79	0.000162	0.00948	0.14	0.12	Depressive symptoms;	chr3:44724041	chr3:44617128~44624797:-
BRCA	cis	rs875971	0.756	rs4718328	ENSG00000271064.1	RP11-792A8.3	3.79	0.000162	0.00948	0.14	0.12	Aortic root size;	chr7:66228350	chr7:66748838~66749077:-
BRCA	cis	rs8180040	0.701	rs12491473	ENSG00000280667.1	Y_RNA	-3.79	0.000162	0.00948	-0.13	-0.12	Colorectal cancer;	chr3:46948414	chr3:47501083~47501182:+
BRCA	cis	rs2732480	0.967	rs2732469	ENSG00000269514.1	RP11-370I10.12	3.79	0.000162	0.00948	0.14	0.12	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48319149	chr12:48198387~48202031:+
BRCA	cis	rs4819052	0.851	rs2838840	ENSG00000215447.6	BX322557.10	-3.79	0.000162	0.00948	-0.12	-0.12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45248579	chr21:45288052~45291738:+
BRCA	cis	rs6088580	0.634	rs6059824	ENSG00000275784.1	RP5-1125A11.6	-3.79	0.000162	0.00948	-0.12	-0.12	Glomerular filtration rate (creatinine);	chr20:34426737	chr20:33989480~33991818:-
BRCA	cis	rs7722600	0.745	rs10077062	ENSG00000253404.1	AC034243.1	-3.79	0.000162	0.00949	-0.2	-0.12	Heart rate;	chr5:138058009	chr5:138744434~138753309:-
BRCA	cis	rs11170468	0.722	rs7136587	ENSG00000257718.1	RP11-396F22.1	-3.79	0.000162	0.00949	-0.15	-0.12	Body mass index;	chr12:39093739	chr12:38906451~38909592:+
BRCA	cis	rs2301573	1	rs10934886	ENSG00000271270.4	TMCC1-AS1	-3.79	0.000162	0.00949	-0.23	-0.12	Hip circumference;	chr3:129583786	chr3:129893871~129918575:+
BRCA	cis	rs448720	1	rs440341	ENSG00000260657.2	RP11-315D16.4	-3.79	0.000162	0.00949	-0.14	-0.12	Cognitive performance;	chr15:67918621	chr15:68267792~68277994:-
BRCA	cis	rs12908161	0.959	rs17598603	ENSG00000275120.1	RP11-182J1.17	-3.79	0.000162	0.00949	-0.16	-0.12	Schizophrenia;	chr15:84656980	chr15:84599434~84606463:-
BRCA	cis	rs13434995	0.513	rs17721497	ENSG00000239040.1	Y_RNA	-3.79	0.000162	0.00949	-0.14	-0.12	Adiponectin levels;	chr4:55445081	chr4:55412636~55412738:+
BRCA	cis	rs8180040	0.726	rs10461018	ENSG00000271161.1	BOLA2P2	-3.79	0.000162	0.00949	-0.13	-0.12	Colorectal cancer;	chr3:46953752	chr3:47499841~47500407:+
BRCA	cis	rs6964587	0.967	rs1978061	ENSG00000188693.7	CYP51A1-AS1	-3.79	0.000162	0.00949	-0.13	-0.12	Breast cancer;	chr7:92149928	chr7:92134604~92180725:+
BRCA	cis	rs2262909	0.962	rs56369285	ENSG00000279377.1	AC003973.3	-3.79	0.000162	0.00949	-0.17	-0.12	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;	chr19:22084383	chr19:21965708~21968529:-
BRCA	cis	rs3764021	0.527	rs10772062	ENSG00000260423.1	RP13-735L24.1	-3.79	0.000162	0.00949	-0.14	-0.12	Type 1 diabetes;	chr12:9712561	chr12:9367464~9397617:+
BRCA	cis	rs7487075	0.578	rs4768713	ENSG00000257261.4	RP11-96H19.1	3.79	0.000162	0.00949	0.13	0.12	Itch intensity from mosquito bite;	chr12:46420264	chr12:46383679~46876159:+
BRCA	cis	rs7903456	0.648	rs6586053	ENSG00000200253.1	RNU6-529P	3.79	0.000162	0.00949	0.14	0.12	Gout;Renal underexcretion gout;	chr10:87070115	chr10:87041238~87041341:-
BRCA	cis	rs2976388	0.647	rs2164307	ENSG00000253196.1	RP11-706C16.7	3.79	0.000162	0.00949	0.11	0.12	Urinary tract infection frequency;	chr8:142707413	chr8:142763116~142766427:+
BRCA	cis	rs2976388	0.573	rs1529865	ENSG00000253196.1	RP11-706C16.7	3.79	0.000162	0.00949	0.11	0.12	Urinary tract infection frequency;	chr8:142707753	chr8:142763116~142766427:+
BRCA	cis	rs2976388	0.609	rs1560986	ENSG00000253196.1	RP11-706C16.7	3.79	0.000162	0.00949	0.11	0.12	Urinary tract infection frequency;	chr8:142708357	chr8:142763116~142766427:+
BRCA	cis	rs875971	0.66	rs12698534	ENSG00000275400.1	RP4-756H11.5	-3.79	0.000162	0.00949	-0.13	-0.12	Aortic root size;	chr7:66521858	chr7:66553805~66554199:-
BRCA	cis	rs6068583	0.789	rs66920245	ENSG00000197670.6	RP4-724E16.2	-3.79	0.000162	0.00949	-0.16	-0.12	Colorectal adenoma (advanced);	chr20:53564112	chr20:53552770~53575863:+
BRCA	cis	rs1730008	1	rs827104	ENSG00000279311.1	RP11-170K4.2	3.79	0.000162	0.0095	0.13	0.12	Lobe attachment (rater-scored or self-reported);	chr3:158213880	chr3:158869898~158871821:+
BRCA	cis	rs7714670	0.706	rs2973549	ENSG00000184084.7	CTD-2372A4.1	-3.79	0.000162	0.0095	-0.14	-0.12	Venous thromboembolism (SNP x SNP interaction);	chr5:73795301	chr5:73803296~73803599:-
BRCA	cis	rs12468226	1	rs113877751	ENSG00000272966.1	RP11-686O6.1	3.79	0.000162	0.0095	0.19	0.12	Urate levels;	chr2:202329998	chr2:202336739~202337200:+
BRCA	cis	rs12468226	0.935	rs113021930	ENSG00000272966.1	RP11-686O6.1	3.79	0.000162	0.0095	0.19	0.12	Urate levels;	chr2:202330448	chr2:202336739~202337200:+
BRCA	cis	rs12468226	1	rs113491584	ENSG00000272966.1	RP11-686O6.1	3.79	0.000162	0.0095	0.19	0.12	Urate levels;	chr2:202331724	chr2:202336739~202337200:+
BRCA	cis	rs2303319	0.504	rs62187751	ENSG00000227403.1	AC009299.3	3.79	0.000162	0.0095	0.31	0.12	Cognitive function;	chr2:161850953	chr2:161244739~161249050:+
BRCA	cis	rs11048434	0.518	rs11048496	ENSG00000256069.6	A2MP1	-3.79	0.000162	0.0095	-0.13	-0.12	Sjögren's syndrome;	chr12:9019825	chr12:9228533~9275817:-
BRCA	cis	rs1949733	0.585	rs2631768	ENSG00000205959.3	RP11-689P11.2	3.79	0.000162	0.0095	0.11	0.12	Response to antineoplastic agents;	chr4:8471323	chr4:8482270~8512610:+
BRCA	cis	rs2243480	0.706	rs34466769	ENSG00000272831.1	RP11-792A8.4	3.79	0.000162	0.0095	0.14	0.12	Diabetic kidney disease;	chr7:65988305	chr7:66739829~66740385:-
BRCA	cis	rs8180040	0.726	rs4078466	ENSG00000260236.1	RP11-708J19.1	3.79	0.000162	0.0095	0.1	0.12	Colorectal cancer;	chr3:47085053	chr3:47379089~47380999:-
BRCA	cis	rs9470794	1	rs59996041	ENSG00000204110.6	RP1-153P14.8	-3.79	0.000162	0.00951	-0.21	-0.12	Type 2 diabetes;	chr6:37984849	chr6:37507348~37535616:+
BRCA	cis	rs12681366	0.762	rs6997115	ENSG00000253175.1	RP11-267M23.6	3.79	0.000162	0.00951	0.13	0.12	Nonsyndromic cleft lip with cleft palate;	chr8:94353657	chr8:94565036~94565715:+
BRCA	cis	rs4664293	0.609	rs10209829	ENSG00000226266.5	AC009961.3	-3.79	0.000162	0.00951	-0.14	-0.12	Monocyte percentage of white cells;	chr2:159591113	chr2:159670708~159712435:-
BRCA	cis	rs9788682	0.747	rs2656072	ENSG00000261143.1	ADAMTS7P3	3.79	0.000162	0.00951	0.16	0.12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78451950	chr15:77976042~77993057:+
BRCA	cis	rs4842666	0.915	rs17249754	ENSG00000270344.2	RP11-734K2.4	-3.79	0.000162	0.00951	-0.14	-0.12	Blood pressure;	chr12:89666809	chr12:89525654~89548005:+
BRCA	cis	rs4415084	0.716	rs7703497	ENSG00000272335.1	RP11-53O19.3	3.79	0.000162	0.00951	0.11	0.12	Breast cancer;	chr5:44856926	chr5:44826076~44828592:+
BRCA	cis	rs7267979	1	rs6037099	ENSG00000274414.1	RP5-965G21.4	3.79	0.000162	0.00951	0.14	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25376240	chr20:25239007~25245229:-
BRCA	cis	rs7267979	0.966	rs4815414	ENSG00000274414.1	RP5-965G21.4	3.79	0.000162	0.00951	0.14	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25381065	chr20:25239007~25245229:-
BRCA	cis	rs7267979	1	rs6083825	ENSG00000274414.1	RP5-965G21.4	3.79	0.000162	0.00951	0.14	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25385788	chr20:25239007~25245229:-
BRCA	cis	rs7267979	1	rs34645895	ENSG00000274414.1	RP5-965G21.4	3.79	0.000162	0.00951	0.14	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25387737	chr20:25239007~25245229:-
BRCA	cis	rs7267979	1	rs6037105	ENSG00000274414.1	RP5-965G21.4	3.79	0.000162	0.00951	0.14	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25393563	chr20:25239007~25245229:-
BRCA	cis	rs875971	0.862	rs880166	ENSG00000271064.1	RP11-792A8.3	3.79	0.000162	0.00951	0.14	0.12	Aortic root size;	chr7:66205775	chr7:66748838~66749077:-
BRCA	cis	rs477895	0.713	rs3802933	ENSG00000256940.1	RP11-783K16.5	3.79	0.000162	0.00951	0.16	0.12	Mean platelet volume;	chr11:64220630	chr11:64245964~64248217:+
BRCA	cis	rs10463316	0.894	rs7719630	ENSG00000260581.1	CTB-113P19.4	3.79	0.000162	0.00952	0.14	0.12	Metabolite levels (Pyroglutamine);	chr5:151381400	chr5:151652275~151655449:+
BRCA	cis	rs7267979	0.966	rs6107031	ENSG00000274414.1	RP5-965G21.4	3.79	0.000162	0.00952	0.14	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25370041	chr20:25239007~25245229:-
BRCA	cis	rs7267979	1	rs6115159	ENSG00000274414.1	RP5-965G21.4	3.79	0.000162	0.00952	0.14	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25370308	chr20:25239007~25245229:-
BRCA	cis	rs7267979	1	rs4813562	ENSG00000274414.1	RP5-965G21.4	3.79	0.000162	0.00952	0.14	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25371952	chr20:25239007~25245229:-
BRCA	cis	rs2832077	0.527	rs9981922	ENSG00000232855.5	AF131217.1	3.79	0.000162	0.00952	0.15	0.12	Cognitive test performance;	chr21:28840396	chr21:28439346~28674848:-
BRCA	cis	rs35520189	0.857	rs2708916	ENSG00000274877.1	RP11-65I12.1	3.79	0.000162	0.00952	0.16	0.12	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:112870724	chr2:113237595~113240825:+
BRCA	cis	rs7267979	1	rs2500446	ENSG00000277938.1	RP5-965G21.3	-3.79	0.000162	0.00952	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25359028	chr20:25229150~25231933:+
BRCA	cis	rs10761482	0.861	rs7085259	ENSG00000254271.1	RP11-131N11.4	3.79	0.000162	0.00952	0.16	0.12	Schizophrenia;	chr10:60347660	chr10:60734342~60741828:+
BRCA	cis	rs10761482	0.813	rs4948402	ENSG00000254271.1	RP11-131N11.4	3.79	0.000162	0.00952	0.16	0.12	Schizophrenia;	chr10:60347694	chr10:60734342~60741828:+
BRCA	cis	rs2243480	1	rs1039664	ENSG00000226002.1	RP11-460N20.5	-3.79	0.000162	0.00952	-0.19	-0.12	Diabetic kidney disease;	chr7:65984729	chr7:65084103~65100232:+
BRCA	cis	rs595244	0.908	rs2015637	ENSG00000259705.1	RP11-227D13.1	3.79	0.000162	0.00952	0.18	0.12	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48424656	chr15:48645951~48652016:+
BRCA	cis	rs875971	0.545	rs316316	ENSG00000232559.3	GS1-124K5.12	-3.79	0.000162	0.00953	-0.16	-0.12	Aortic root size;	chr7:66149270	chr7:66554588~66576923:-
BRCA	cis	rs2274273	0.967	rs17832359	ENSG00000259318.1	RP11-454L9.2	3.79	0.000162	0.00953	0.1	0.12	Protein biomarker;	chr14:55149223	chr14:55394940~55395233:-
BRCA	cis	rs2625529	0.824	rs12592364	ENSG00000260037.4	CTD-2524L6.3	-3.79	0.000162	0.00953	-0.17	-0.12	Red blood cell count;	chr15:71992306	chr15:71818396~71823384:+
BRCA	cis	rs2880765	0.525	rs2062234	ENSG00000230373.7	GOLGA6L5P	3.79	0.000162	0.00953	0.13	0.12	Coronary artery disease;	chr15:85511259	chr15:84507885~84516814:-
BRCA	cis	rs2625529	0.824	rs12595464	ENSG00000260037.4	CTD-2524L6.3	-3.78	0.000162	0.00953	-0.17	-0.12	Red blood cell count;	chr15:72002057	chr15:71818396~71823384:+
BRCA	cis	rs2625529	0.824	rs12916694	ENSG00000260037.4	CTD-2524L6.3	-3.78	0.000162	0.00953	-0.17	-0.12	Red blood cell count;	chr15:72005799	chr15:71818396~71823384:+
BRCA	cis	rs2281603	0.57	rs3742606	ENSG00000259116.1	RP11-973N13.4	-3.78	0.000163	0.00953	-0.1	-0.12	Lymphocyte counts;	chr14:64478371	chr14:64514154~64540368:-
BRCA	cis	rs9733	0.596	rs11204704	ENSG00000231073.1	RP11-316M1.3	3.78	0.000163	0.00954	0.12	0.12	Tonsillectomy;	chr1:150699154	chr1:150973123~150975534:+
BRCA	cis	rs11696845	0.604	rs1980577	ENSG00000276223.1	RP4-781B1.5	-3.78	0.000163	0.00954	-0.12	-0.12	Obesity-related traits;	chr20:44753471	chr20:44746642~44747201:+
BRCA	cis	rs875971	0.545	rs67775320	ENSG00000232559.3	GS1-124K5.12	3.78	0.000163	0.00954	0.16	0.12	Aortic root size;	chr7:66193792	chr7:66554588~66576923:-
BRCA	cis	rs6785206	0.772	rs6439134	ENSG00000242551.2	POU5F1P6	-3.78	0.000163	0.00954	-0.24	-0.12	Lymphocyte percentage of white cells;	chr3:128604661	chr3:128674735~128677005:-
BRCA	cis	rs12317459	0.591	rs11115405	ENSG00000213270.5	RPL6P25	-3.78	0.000163	0.00954	-0.19	-0.12	Prostate cancer (SNP x SNP interaction);	chr12:82772775	chr12:83151331~83152190:+
BRCA	cis	rs2625529	0.824	rs12593134	ENSG00000260037.4	CTD-2524L6.3	-3.78	0.000163	0.00954	-0.17	-0.12	Red blood cell count;	chr15:72010666	chr15:71818396~71823384:+
BRCA	cis	rs718433	0.584	rs10133988	ENSG00000211778.2	TRAV4	-3.78	0.000163	0.00954	-0.08	-0.12	Intraocular pressure;	chr14:21746376	chr14:21736152~21736982:+
BRCA	cis	rs700651	0.789	rs892514	ENSG00000231621.1	AC013264.2	-3.78	0.000163	0.00954	-0.11	-0.12	Intracranial aneurysm;	chr2:198040546	chr2:197197991~197199273:+
BRCA	cis	rs1421334	0.679	rs2160935	ENSG00000253961.1	RP11-363L24.3	-3.78	0.000163	0.00954	-0.14	-0.12	Intelligence (multi-trait analysis);	chr8:30983135	chr8:31167078~31177167:-
BRCA	cis	rs295490	0.748	rs79361389	ENSG00000272656.1	RP11-219D15.3	3.78	0.000163	0.00954	0.29	0.12	PR interval in Tripanosoma cruzi seropositivity;	chr3:139458517	chr3:139349024~139349371:-
BRCA	cis	rs853679	0.769	rs17720293	ENSG00000204709.4	LINC01556	3.78	0.000163	0.00954	0.26	0.12	Depression;	chr6:28246920	chr6:28943877~28944537:+
BRCA	cis	rs7695732	0.7	rs28712360	ENSG00000270720.1	RP11-84C13.2	-3.78	0.000163	0.00954	-0.16	-0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr4:88998690	chr4:89119284~89119871:+
BRCA	cis	rs10844706	0.699	rs10844630	ENSG00000256673.1	RP11-599J14.2	-3.78	0.000163	0.00954	-0.14	-0.12	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9734268	chr12:9398355~9414851:-
BRCA	cis	rs16893526	0.615	rs6925561	ENSG00000224995.1	LINC01526	-3.78	0.000163	0.00954	-0.18	-0.12	Coronary heart disease;	chr6:81812022	chr6:81813286~81814157:-
BRCA	cis	rs733592	0.524	rs10875727	ENSG00000273765.1	RP11-370I10.11	-3.78	0.000163	0.00954	-0.13	-0.12	Plateletcrit;	chr12:48032360	chr12:48360920~48361377:+
BRCA	cis	rs448720	1	rs12441572	ENSG00000260657.2	RP11-315D16.4	-3.78	0.000163	0.00954	-0.14	-0.12	Cognitive performance;	chr15:67898921	chr15:68267792~68277994:-
BRCA	cis	rs7954584	0.635	rs7313252	ENSG00000272849.1	RP11-347I19.8	-3.78	0.000163	0.00954	-0.09	-0.12	Mean corpuscular volume;	chr12:121909694	chr12:121797511~121801972:+
BRCA	cis	rs11098499	0.697	rs11941899	ENSG00000225892.3	RP11-384K6.2	3.78	0.000163	0.00954	0.12	0.12	Corneal astigmatism;	chr4:119461603	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.909	rs7681978	ENSG00000225892.3	RP11-384K6.2	3.78	0.000163	0.00954	0.12	0.12	Corneal astigmatism;	chr4:119462620	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.821	rs28665282	ENSG00000225892.3	RP11-384K6.2	3.78	0.000163	0.00954	0.12	0.12	Corneal astigmatism;	chr4:119463031	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.738	rs10026493	ENSG00000225892.3	RP11-384K6.2	3.78	0.000163	0.00954	0.12	0.12	Corneal astigmatism;	chr4:119463039	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.909	rs7681214	ENSG00000225892.3	RP11-384K6.2	3.78	0.000163	0.00954	0.12	0.12	Corneal astigmatism;	chr4:119464165	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.909	rs28632018	ENSG00000225892.3	RP11-384K6.2	3.78	0.000163	0.00954	0.12	0.12	Corneal astigmatism;	chr4:119465575	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.908	rs71614449	ENSG00000225892.3	RP11-384K6.2	3.78	0.000163	0.00954	0.12	0.12	Corneal astigmatism;	chr4:119465900	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.954	rs35063680	ENSG00000225892.3	RP11-384K6.2	3.78	0.000163	0.00954	0.12	0.12	Corneal astigmatism;	chr4:119465947	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.954	rs34858317	ENSG00000225892.3	RP11-384K6.2	3.78	0.000163	0.00954	0.12	0.12	Corneal astigmatism;	chr4:119465955	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.954	rs17046116	ENSG00000225892.3	RP11-384K6.2	3.78	0.000163	0.00954	0.12	0.12	Corneal astigmatism;	chr4:119466104	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.909	rs17046118	ENSG00000225892.3	RP11-384K6.2	3.78	0.000163	0.00954	0.12	0.12	Corneal astigmatism;	chr4:119466341	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.954	rs7654587	ENSG00000225892.3	RP11-384K6.2	3.78	0.000163	0.00954	0.12	0.12	Corneal astigmatism;	chr4:119467251	chr4:118632274~118634759:+
BRCA	cis	rs1552244	0.572	rs3894322	ENSG00000180385.7	EMC3-AS1	3.78	0.000163	0.00954	0.16	0.12	Alzheimer's disease;	chr3:10127281	chr3:9986893~10006990:+
BRCA	cis	rs1552244	0.572	rs3894323	ENSG00000180385.7	EMC3-AS1	3.78	0.000163	0.00954	0.16	0.12	Alzheimer's disease;	chr3:10127283	chr3:9986893~10006990:+
BRCA	cis	rs10514758	0.744	rs72947752	ENSG00000242880.1	RP11-190P13.2	3.78	0.000163	0.00955	0.27	0.12	Urate levels in obese individuals;	chr3:115213724	chr3:115251196~115285347:+
BRCA	cis	rs875971	0.545	rs6460298	ENSG00000232559.3	GS1-124K5.12	3.78	0.000163	0.00955	0.16	0.12	Aortic root size;	chr7:66442783	chr7:66554588~66576923:-
BRCA	cis	rs4332037	0.802	rs73048106	ENSG00000273230.1	RP11-1246C19.1	3.78	0.000163	0.00955	0.18	0.12	Bipolar disorder;	chr7:1889383	chr7:1464497~1467522:-
BRCA	cis	rs812925	0.659	rs2167565	ENSG00000273302.1	RP11-493E12.2	-3.78	0.000163	0.00955	-0.11	-0.12	Immature fraction of reticulocytes;	chr2:61249323	chr2:61199979~61200769:+
BRCA	cis	rs10181042	0.514	rs1177283	ENSG00000270820.4	RP11-355B11.2	3.78	0.000163	0.00955	0.13	0.12	Crohn's disease;	chr2:61121669	chr2:61471188~61484130:+
BRCA	cis	rs8180040	0.966	rs6792488	ENSG00000280667.1	Y_RNA	-3.78	0.000163	0.00955	-0.13	-0.12	Colorectal cancer;	chr3:47461859	chr3:47501083~47501182:+
BRCA	cis	rs11742741	0.64	rs62349717	ENSG00000248874.4	C5orf17	-3.78	0.000163	0.00955	-0.15	-0.12	Educational attainment;	chr5:24045234	chr5:23951348~24178263:+
BRCA	cis	rs4489787	0.892	rs2731084	ENSG00000240399.1	RP1-228P16.1	3.78	0.000163	0.00955	0.21	0.12	Prostate cancer (SNP x SNP interaction);	chr12:48537118	chr12:48054813~48055591:-
BRCA	cis	rs10514758	0.744	rs56910101	ENSG00000242880.1	RP11-190P13.2	3.78	0.000163	0.00955	0.27	0.12	Urate levels in obese individuals;	chr3:115247800	chr3:115251196~115285347:+
BRCA	cis	rs4819052	0.851	rs4819046	ENSG00000215447.6	BX322557.10	-3.78	0.000163	0.00955	-0.12	-0.12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245040	chr21:45288052~45291738:+
BRCA	cis	rs6498068	0.677	rs2279871	ENSG00000260468.1	LINC01290	3.78	0.000163	0.00955	0.18	0.12	Metabolite levels (MHPG);	chr16:10538518	chr16:10514842~10528202:-
BRCA	cis	rs4934494	0.768	rs12771413	ENSG00000232229.4	LINC00865	3.78	0.000163	0.00955	0.18	0.12	Red blood cell count;	chr10:89633010	chr10:89829510~89840861:+
BRCA	cis	rs61931739	0.517	rs1486882	ENSG00000258794.3	DUX4L27	3.78	0.000163	0.00955	0.17	0.12	Morning vs. evening chronotype;	chr12:33872961	chr12:34208415~34209675:-
BRCA	cis	rs2262909	0.962	rs55735642	ENSG00000279377.1	AC003973.3	-3.78	0.000163	0.00955	-0.16	-0.12	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;	chr19:22058374	chr19:21965708~21968529:-
BRCA	cis	rs35146811	0.735	rs1727138	ENSG00000214313.7	AZGP1P1	-3.78	0.000163	0.00955	-0.12	-0.12	Coronary artery disease;	chr7:100217624	chr7:99980762~99987535:+
BRCA	cis	rs467650	0.5	rs13160853	ENSG00000246763.5	RGMB-AS1	-3.78	0.000163	0.00956	-0.13	-0.12	Venous thromboembolism (SNP x SNP interaction);	chr5:98585193	chr5:98769618~98773469:-
BRCA	cis	rs2803122	0.846	rs7851656	ENSG00000273226.1	RP11-513M16.8	-3.78	0.000163	0.00956	-0.12	-0.12	Pulse pressure;	chr9:19213962	chr9:19375451~19375996:+
BRCA	cis	rs4950322	0.57	rs17160051	ENSG00000237188.3	RP11-337C18.8	3.78	0.000163	0.00956	0.14	0.12	Protein quantitative trait loci;	chr1:147255733	chr1:147172771~147211568:+
BRCA	cis	rs2692947	0.702	rs7604842	ENSG00000232931.4	LINC00342	-3.78	0.000163	0.00956	-0.12	-0.12	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96111592	chr2:95807118~95816215:-
BRCA	cis	rs4557020	1	rs7605221	ENSG00000203327.2	AC012358.7	3.78	0.000163	0.00956	0.12	0.12	Myopia (pathological);	chr2:54493766	chr2:55214387~55216126:-
BRCA	cis	rs6049003	0.622	rs6049051	ENSG00000232645.4	LINC01431	3.78	0.000163	0.00956	0.13	0.12	Cerebrospinal fluid biomarker levels;	chr20:23742520	chr20:23356594~23358116:-
BRCA	cis	rs7308116	1	rs4390387	ENSG00000274395.1	RP11-554D14.8	-3.78	0.000163	0.00956	-0.13	-0.12	Pelvic organ prolapse (moderate/severe);	chr12:107812430	chr12:107835541~107836555:-
BRCA	cis	rs952623	0.649	rs6944670	ENSG00000211694.2	TRGV10	3.78	0.000163	0.00957	0.1	0.12	Intelligence (multi-trait analysis);	chr7:39017509	chr7:38299811~38300322:-
BRCA	cis	rs9549260	0.753	rs9549238	ENSG00000168852.11	TPTE2P5	3.78	0.000163	0.00957	0.14	0.12	Red blood cell count;	chr13:40605184	chr13:40822296~40921749:-
BRCA	cis	rs7487075	0.619	rs10880970	ENSG00000257261.4	RP11-96H19.1	3.78	0.000163	0.00957	0.13	0.12	Itch intensity from mosquito bite;	chr12:46436637	chr12:46383679~46876159:+
BRCA	cis	rs7487075	0.619	rs4076247	ENSG00000257261.4	RP11-96H19.1	3.78	0.000163	0.00957	0.13	0.12	Itch intensity from mosquito bite;	chr12:46439667	chr12:46383679~46876159:+
BRCA	cis	rs1005277	0.522	rs289645	ENSG00000226578.1	RP11-258F22.1	-3.78	0.000163	0.00957	-0.13	-0.12	Extrinsic epigenetic age acceleration;	chr10:37654714	chr10:37775371~37784131:-
BRCA	cis	rs801193	0.935	rs2659916	ENSG00000265600.1	AC006480.1	-3.78	0.000163	0.00957	-0.14	-0.12	Aortic root size;	chr7:66686365	chr7:67356680~67356779:+
BRCA	cis	rs6120849	0.617	rs12480442	ENSG00000202150.1	RNU6-407P	3.78	0.000163	0.00957	0.17	0.12	Protein C levels;	chr20:35060585	chr20:35030317~35030420:-
BRCA	cis	rs9840812	0.655	rs696516	ENSG00000273486.1	RP11-731C17.2	3.78	0.000163	0.00957	0.14	0.12	Fibrinogen levels;	chr3:136348936	chr3:136837338~136839021:-
BRCA	cis	rs8114671	0.562	rs2064454	ENSG00000126005.14	MMP24-AS1	-3.78	0.000163	0.00957	-0.14	-0.12	Height;	chr20:34908366	chr20:35216462~35278131:-
BRCA	cis	rs4819052	1	rs733739	ENSG00000184274.3	LINC00315	-3.78	0.000163	0.00957	-0.17	-0.12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45246295	chr21:45300245~45305257:-
BRCA	cis	rs6840360	0.571	rs4696276	ENSG00000270265.1	RP11-731D1.4	-3.78	0.000163	0.00957	-0.14	-0.12	Intelligence (multi-trait analysis);	chr4:151611530	chr4:151333775~151353224:-
BRCA	cis	rs6840360	0.571	rs62327270	ENSG00000270265.1	RP11-731D1.4	-3.78	0.000163	0.00957	-0.14	-0.12	Intelligence (multi-trait analysis);	chr4:151612466	chr4:151333775~151353224:-
BRCA	cis	rs1730008	0.731	rs1918000	ENSG00000279311.1	RP11-170K4.2	3.78	0.000163	0.00957	0.15	0.12	Lobe attachment (rater-scored or self-reported);	chr3:158299898	chr3:158869898~158871821:+
BRCA	cis	rs1730008	0.731	rs11719153	ENSG00000279311.1	RP11-170K4.2	3.78	0.000163	0.00957	0.15	0.12	Lobe attachment (rater-scored or self-reported);	chr3:158300798	chr3:158869898~158871821:+
BRCA	cis	rs62025270	0.547	rs8035496	ENSG00000259367.1	RP11-815J21.4	3.78	0.000163	0.00957	0.1	0.12	Idiopathic pulmonary fibrosis;	chr15:85591101	chr15:85619623~85670948:-
BRCA	cis	rs889312	0.5	rs11960484	ENSG00000271828.1	CTD-2310F14.1	3.78	0.000163	0.00957	0.14	0.12	Breast cancer (early onset);Breast cancer;	chr5:56813327	chr5:56927874~56929573:+
BRCA	cis	rs1730008	0.865	rs1095634	ENSG00000279311.1	RP11-170K4.2	-3.78	0.000163	0.00957	-0.13	-0.12	Lobe attachment (rater-scored or self-reported);	chr3:158247103	chr3:158869898~158871821:+
BRCA	cis	rs10829156	0.679	rs4747352	ENSG00000225527.1	RP11-383B4.4	-3.78	0.000163	0.00957	-0.16	-0.12	Sudden cardiac arrest;	chr10:18539734	chr10:18531849~18533336:-
BRCA	cis	rs733592	0.507	rs10875739	ENSG00000273765.1	RP11-370I10.11	3.78	0.000163	0.00958	0.13	0.12	Plateletcrit;	chr12:48087136	chr12:48360920~48361377:+
BRCA	cis	rs9400467	0.537	rs12211045	ENSG00000255389.1	C6orf3	3.78	0.000163	0.00958	0.18	0.12	Amino acid levels;Blood metabolite levels;	chr6:111176913	chr6:111599875~111602295:+
BRCA	cis	rs10844706	0.735	rs11052754	ENSG00000256673.1	RP11-599J14.2	-3.78	0.000163	0.00958	-0.15	-0.12	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9736046	chr12:9398355~9414851:-
BRCA	cis	rs7487075	0.606	rs4768714	ENSG00000257261.4	RP11-96H19.1	3.78	0.000163	0.00958	0.13	0.12	Itch intensity from mosquito bite;	chr12:46420462	chr12:46383679~46876159:+
BRCA	cis	rs6964587	0.967	rs6973896	ENSG00000188693.7	CYP51A1-AS1	-3.78	0.000163	0.00958	-0.13	-0.12	Breast cancer;	chr7:92149151	chr7:92134604~92180725:+
BRCA	cis	rs256438	0.502	rs2438647	ENSG00000251050.1	RP11-168A11.4	-3.78	0.000163	0.00958	-0.12	-0.12	Serum thyroid-stimulating hormone levels;	chr5:80064351	chr5:80019609~80019920:+
BRCA	cis	rs9847710	0.967	rs2581824	ENSG00000242849.2	ALDOAP1	-3.78	0.000163	0.00958	-0.13	-0.12	Ulcerative colitis;	chr3:52988392	chr3:52193170~52194785:+
BRCA	cis	rs4688759	0.719	rs73079018	ENSG00000270441.1	RP11-694I15.7	3.78	0.000163	0.00958	0.26	0.12	Blood protein levels;	chr3:49837894	chr3:49140086~49160851:-
BRCA	cis	rs962856	0.729	rs7568231	ENSG00000236780.4	AC078941.1	3.78	0.000163	0.00958	0.15	0.12	Pancreatic cancer;	chr2:67293718	chr2:67123357~67215319:-
BRCA	cis	rs875971	0.862	rs9791712	ENSG00000273024.4	INTS4P2	3.78	0.000163	0.00958	0.13	0.12	Aortic root size;	chr7:66640176	chr7:65647864~65715661:+
BRCA	cis	rs875971	0.862	rs9791713	ENSG00000273024.4	INTS4P2	3.78	0.000163	0.00958	0.13	0.12	Aortic root size;	chr7:66640211	chr7:65647864~65715661:+
BRCA	cis	rs6870983	0.802	rs62369123	ENSG00000247828.6	TMEM161B-AS1	-3.78	0.000163	0.00958	-0.15	-0.12	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index;	chr5:88459594	chr5:88268895~88436685:+
BRCA	cis	rs6893300	0.961	rs4700838	ENSG00000250999.1	RP11-1379J22.5	3.78	0.000163	0.00958	0.17	0.12	Resting heart rate;	chr5:179758120	chr5:179657762~179664432:+
BRCA	cis	rs6545883	0.868	rs6748003	ENSG00000270820.4	RP11-355B11.2	3.78	0.000164	0.00958	0.13	0.12	Tuberculosis;	chr2:61579565	chr2:61471188~61484130:+
BRCA	cis	rs6063399	0.546	rs237480	ENSG00000222365.1	SNORD12B	3.78	0.000164	0.00958	0.13	0.12	Obesity-related traits;	chr20:49377361	chr20:49280319~49280409:+
BRCA	cis	rs2041840	1	rs13409250	ENSG00000272054.1	RP11-423P10.2	-3.78	0.000164	0.00958	-0.1	-0.12	Chronic lymphocytic leukemia;	chr2:37236499	chr2:37208875~37212677:+
BRCA	cis	rs948562	0.744	rs60998298	ENSG00000280010.1	AP001350.4	3.78	0.000164	0.00958	0.23	0.12	Lymphoma;	chr11:58534382	chr11:58627435~58628528:+
BRCA	cis	rs948562	0.74	rs12361770	ENSG00000280010.1	AP001350.4	3.78	0.000164	0.00958	0.22	0.12	Lymphoma;	chr11:58666759	chr11:58627435~58628528:+
BRCA	cis	rs77741769	0.571	rs3861797	ENSG00000277423.1	RP11-173P15.9	-3.78	0.000164	0.00959	-0.13	-0.12	Mean corpuscular volume;	chr12:120817531	chr12:120703867~120704282:+
BRCA	cis	rs4664293	0.609	rs10209829	ENSG00000224152.1	AC009506.1	-3.78	0.000164	0.00959	-0.12	-0.12	Monocyte percentage of white cells;	chr2:159591113	chr2:159615296~159617082:+
BRCA	cis	rs1577917	0.682	rs1173417	ENSG00000220563.1	PKMP3	3.78	0.000164	0.00959	0.12	0.12	Response to antipsychotic treatment;	chr6:85694223	chr6:85659892~85660606:-
BRCA	cis	rs4819052	0.765	rs2838852	ENSG00000215447.6	BX322557.10	-3.78	0.000164	0.00959	-0.12	-0.12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45257122	chr21:45288052~45291738:+
BRCA	cis	rs78545713	1	rs41266821	ENSG00000241549.7	GUSBP2	-3.78	0.000164	0.00959	-0.18	-0.12	Iron status biomarkers (total iron binding capacity);	chr6:26246970	chr6:26871484~26956554:-
BRCA	cis	rs863345	0.604	rs1873509	ENSG00000229914.1	RP11-404O13.4	3.78	0.000164	0.00959	0.12	0.12	Pneumococcal bacteremia;	chr1:158491773	chr1:158195633~158196131:-
BRCA	cis	rs80226907	0.634	rs713475	ENSG00000186615.9	KTN1-AS1	-3.78	0.000164	0.00959	-0.23	-0.12	Mean platelet volume;	chr14:55437932	chr14:55499278~55580110:-
BRCA	cis	rs6088580	0.634	rs4911423	ENSG00000275784.1	RP5-1125A11.6	3.78	0.000164	0.00959	0.13	0.12	Glomerular filtration rate (creatinine);	chr20:34411580	chr20:33989480~33991818:-
BRCA	cis	rs6088580	0.634	rs6141471	ENSG00000275784.1	RP5-1125A11.6	3.78	0.000164	0.00959	0.13	0.12	Glomerular filtration rate (creatinine);	chr20:34418924	chr20:33989480~33991818:-
BRCA	cis	rs10129255	0.957	rs2013423	ENSG00000232216.1	IGHV3-43	3.78	0.000164	0.00959	0.1	0.12	Kawasaki disease;	chr14:106690675	chr14:106470264~106470800:-
BRCA	cis	rs10129255	0.957	rs56134540	ENSG00000232216.1	IGHV3-43	3.78	0.000164	0.00959	0.1	0.12	Kawasaki disease;	chr14:106691290	chr14:106470264~106470800:-
BRCA	cis	rs2486012	0.649	rs1354261	ENSG00000237950.1	RP11-7O11.3	3.78	0.000164	0.00959	0.18	0.12	Intelligence (multi-trait analysis);	chr1:43791011	chr1:43944370~43946551:-
BRCA	cis	rs801193	1	rs10252765	ENSG00000265600.1	AC006480.1	-3.78	0.000164	0.00959	-0.14	-0.12	Aortic root size;	chr7:66763745	chr7:67356680~67356779:+
BRCA	cis	rs7520050	0.966	rs4660317	ENSG00000234329.1	RP11-767N6.2	-3.78	0.000164	0.00959	-0.11	-0.12	Reticulocyte count;Red blood cell count;	chr1:45860554	chr1:45651039~45651826:-
BRCA	cis	rs7520050	0.966	rs10749860	ENSG00000234329.1	RP11-767N6.2	-3.78	0.000164	0.00959	-0.11	-0.12	Reticulocyte count;Red blood cell count;	chr1:45862538	chr1:45651039~45651826:-
BRCA	cis	rs7520050	0.931	rs6688365	ENSG00000234329.1	RP11-767N6.2	-3.78	0.000164	0.00959	-0.11	-0.12	Reticulocyte count;Red blood cell count;	chr1:45864212	chr1:45651039~45651826:-
BRCA	cis	rs7520050	0.966	rs6656992	ENSG00000234329.1	RP11-767N6.2	-3.78	0.000164	0.00959	-0.11	-0.12	Reticulocyte count;Red blood cell count;	chr1:45867396	chr1:45651039~45651826:-
BRCA	cis	rs7520050	0.966	rs61783220	ENSG00000234329.1	RP11-767N6.2	-3.78	0.000164	0.00959	-0.11	-0.12	Reticulocyte count;Red blood cell count;	chr1:45869640	chr1:45651039~45651826:-
BRCA	cis	rs7520050	0.966	rs7540325	ENSG00000234329.1	RP11-767N6.2	-3.78	0.000164	0.00959	-0.11	-0.12	Reticulocyte count;Red blood cell count;	chr1:45872545	chr1:45651039~45651826:-
BRCA	cis	rs7520050	1	rs7540699	ENSG00000234329.1	RP11-767N6.2	-3.78	0.000164	0.00959	-0.11	-0.12	Reticulocyte count;Red blood cell count;	chr1:45872913	chr1:45651039~45651826:-
BRCA	cis	rs7520050	0.966	rs4660319	ENSG00000234329.1	RP11-767N6.2	-3.78	0.000164	0.00959	-0.11	-0.12	Reticulocyte count;Red blood cell count;	chr1:45875951	chr1:45651039~45651826:-
BRCA	cis	rs7520050	0.931	rs11211213	ENSG00000234329.1	RP11-767N6.2	-3.78	0.000164	0.00959	-0.11	-0.12	Reticulocyte count;Red blood cell count;	chr1:45876845	chr1:45651039~45651826:-
BRCA	cis	rs6456156	0.792	rs4710183	ENSG00000272549.1	RP11-351J23.2	3.78	0.000164	0.00959	0.12	0.12	Primary biliary cholangitis;	chr6:167100595	chr6:167666840~167679270:-
BRCA	cis	rs7572733	1	rs6738825	ENSG00000231621.1	AC013264.2	-3.78	0.000164	0.00959	-0.11	-0.12	Dermatomyositis;	chr2:198032171	chr2:197197991~197199273:+
BRCA	cis	rs324126	0.78	rs4802926	ENSG00000277977.1	CTD-3018O17.5	-3.78	0.000164	0.0096	-0.14	-0.12	Colonoscopy-negative controls vs population controls;	chr19:52377012	chr19:52392659~52392755:+
BRCA	cis	rs3169166	0.527	rs1996625	ENSG00000259562.2	RP11-762H8.2	-3.78	0.000164	0.0096	-0.09	-0.12	Reticulocyte fraction of red cells;Reticulocyte count;	chr15:78308752	chr15:78290527~78291221:-
BRCA	cis	rs372883	0.53	rs2832305	ENSG00000176054.6	RPL23P2	3.78	0.000164	0.0096	0.13	0.12	Pancreatic cancer;	chr21:29380644	chr21:28997613~28998033:-
BRCA	cis	rs9423406	0.66	rs2895038	ENSG00000224034.1	RP11-445P17.8	-3.78	0.000164	0.0096	-0.24	-0.12	Intelligence;	chr10:5252730	chr10:5266033~5271236:-
BRCA	cis	rs4272720	0.901	rs72785076	ENSG00000228754.1	RP11-534L6.3	-3.78	0.000164	0.0096	-0.17	-0.12	Platelet count;Plateletcrit;	chr10:49139195	chr10:48745545~48746128:-
BRCA	cis	rs5750830	0.594	rs1010169	ENSG00000280216.1	RP3-333H23.9	3.78	0.000164	0.0096	0.15	0.12	Intelligence (multi-trait analysis);	chr22:39382162	chr22:39379610~39380015:+
BRCA	cis	rs801193	0.569	rs13226966	ENSG00000229886.1	RP5-1132H15.3	3.78	0.000164	0.0096	0.13	0.12	Aortic root size;	chr7:66768636	chr7:66025126~66031544:-
BRCA	cis	rs6087771	0.926	rs6058431	ENSG00000230613.1	HM13-AS1	3.78	0.000164	0.0096	0.16	0.12	Putamen volume;Subcortical brain region volumes;	chr20:31709330	chr20:31567707~31573263:-
BRCA	cis	rs801193	0.569	rs6978178	ENSG00000229886.1	RP5-1132H15.3	-3.78	0.000164	0.0096	-0.13	-0.12	Aortic root size;	chr7:66658097	chr7:66025126~66031544:-
BRCA	cis	rs6751744	0.889	rs12692553	ENSG00000230783.1	AC009961.2	-3.78	0.000164	0.00961	-0.16	-0.12	Dysphagia;	chr2:159534337	chr2:159689217~159690291:-
BRCA	cis	rs654950	0.875	rs4660544	ENSG00000230638.4	RP11-486B10.4	3.78	0.000164	0.00961	0.15	0.12	Airway imaging phenotypes;	chr1:41531200	chr1:41542069~41544310:+
BRCA	cis	rs1538970	0.961	rs4660854	ENSG00000281133.1	AL355480.3	-3.78	0.000164	0.00961	-0.15	-0.12	Platelet count;	chr1:45388415	chr1:45580892~45580996:-
BRCA	cis	rs9788682	0.747	rs2568488	ENSG00000261143.1	ADAMTS7P3	3.78	0.000164	0.00961	0.16	0.12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78444251	chr15:77976042~77993057:+
BRCA	cis	rs9788682	0.747	rs2915695	ENSG00000261143.1	ADAMTS7P3	3.78	0.000164	0.00961	0.16	0.12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78447129	chr15:77976042~77993057:+
BRCA	cis	rs2301573	0.584	rs75331563	ENSG00000271270.4	TMCC1-AS1	-3.78	0.000164	0.00961	-0.25	-0.12	Hip circumference;	chr3:129662248	chr3:129893871~129918575:+
BRCA	cis	rs6490294	0.904	rs1016078	ENSG00000234608.6	MAPKAPK5-AS1	3.78	0.000164	0.00961	0.14	0.12	Mean platelet volume;	chr12:111972273	chr12:111839764~111842902:-
BRCA	cis	rs1910358	0.69	rs1604454	ENSG00000248874.4	C5orf17	-3.78	0.000164	0.00961	-0.15	-0.12	Venous thromboembolism (SNP x SNP interaction);	chr5:23945694	chr5:23951348~24178263:+
BRCA	cis	rs17169635	0.524	rs10231387	ENSG00000272941.1	RP11-134L10.1	-3.78	0.000164	0.00961	-0.12	-0.12	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);	chr7:134860340	chr7:135168403~135169547:+
BRCA	cis	rs2085629	1	rs2085629	ENSG00000253796.1	RP11-1084E5.1	-3.78	0.000164	0.00961	-0.12	-0.12	Night sleep phenotypes;	chr8:109215815	chr8:108895029~109063417:-
BRCA	cis	rs801193	0.742	rs9969300	ENSG00000223473.2	GS1-124K5.3	-3.78	0.000164	0.00961	-0.09	-0.12	Aortic root size;	chr7:66316659	chr7:66491049~66493566:-
BRCA	cis	rs6545883	0.826	rs777591	ENSG00000270820.4	RP11-355B11.2	3.78	0.000164	0.00961	0.13	0.12	Tuberculosis;	chr2:61190482	chr2:61471188~61484130:+
BRCA	cis	rs1005277	0.579	rs2800485	ENSG00000272983.1	RP11-508N22.12	3.78	0.000164	0.00961	0.12	0.12	Extrinsic epigenetic age acceleration;	chr10:38253660	chr10:38137337~38144399:+
BRCA	cis	rs7308116	0.813	rs7959434	ENSG00000274395.1	RP11-554D14.8	3.78	0.000164	0.00962	0.13	0.12	Pelvic organ prolapse (moderate/severe);	chr12:107815797	chr12:107835541~107836555:-
BRCA	cis	rs6599077	0.789	rs2371138	ENSG00000223797.4	ENTPD3-AS1	3.78	0.000164	0.00962	0.13	0.12	Sleep-related phenotypes;	chr3:40056772	chr3:40313802~40453329:-
BRCA	cis	rs17169635	0.836	rs3800739	ENSG00000272941.1	RP11-134L10.1	3.78	0.000164	0.00962	0.12	0.12	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);	chr7:134853396	chr7:135168403~135169547:+
BRCA	cis	rs8180040	0.62	rs11720139	ENSG00000271161.1	BOLA2P2	-3.78	0.000164	0.00962	-0.13	-0.12	Colorectal cancer;	chr3:46995266	chr3:47499841~47500407:+
BRCA	cis	rs721917	0.569	rs2247820	ENSG00000278616.1	BEND3P3	-3.78	0.000164	0.00962	-0.11	-0.12	Chronic obstructive pulmonary disease;	chr10:79963123	chr10:79682997~79685436:+
BRCA	cis	rs6490294	0.571	rs6489824	ENSG00000234608.6	MAPKAPK5-AS1	3.78	0.000164	0.00962	0.17	0.12	Mean platelet volume;	chr12:112030613	chr12:111839764~111842902:-
BRCA	cis	rs6090919	0.501	rs10485608	ENSG00000222365.1	SNORD12B	-3.78	0.000164	0.00962	-0.18	-0.12	Intelligence (multi-trait analysis);	chr20:48876859	chr20:49280319~49280409:+
BRCA	cis	rs6142618	0.562	rs2235902	ENSG00000275576.1	RP5-836N17.4	-3.78	0.000164	0.00962	-0.13	-0.12	Inflammatory bowel disease;	chr20:32133547	chr20:32116171~32116629:+
BRCA	cis	rs1577917	0.771	rs7762321	ENSG00000220563.1	PKMP3	3.78	0.000164	0.00962	0.12	0.12	Response to antipsychotic treatment;	chr6:85702428	chr6:85659892~85660606:-
BRCA	cis	rs875971	0.54	rs781152	ENSG00000223473.2	GS1-124K5.3	3.78	0.000164	0.00962	0.09	0.12	Aortic root size;	chr7:66014585	chr7:66491049~66493566:-
BRCA	cis	rs17711722	0.727	rs781151	ENSG00000223473.2	GS1-124K5.3	3.78	0.000164	0.00962	0.09	0.12	Calcium levels;	chr7:66014891	chr7:66491049~66493566:-
BRCA	cis	rs4363385	0.693	rs581447	ENSG00000272654.1	RP11-422P24.11	3.78	0.000164	0.00962	0.12	0.12	Inflammatory skin disease;	chr1:153060793	chr1:153977743~153979160:+
BRCA	cis	rs4363385	0.693	rs490553	ENSG00000272654.1	RP11-422P24.11	3.78	0.000164	0.00962	0.12	0.12	Inflammatory skin disease;	chr1:153060801	chr1:153977743~153979160:+
BRCA	cis	rs2625529	0.762	rs1384007	ENSG00000260037.4	CTD-2524L6.3	-3.78	0.000164	0.00962	-0.17	-0.12	Red blood cell count;	chr15:71937193	chr15:71818396~71823384:+
BRCA	cis	rs6940638	0.662	rs7759694	ENSG00000216901.1	AL022393.7	3.78	0.000164	0.00963	0.14	0.12	Intelligence (multi-trait analysis);	chr6:27273177	chr6:28176188~28176674:+
BRCA	cis	rs6964587	1	rs10228334	ENSG00000188693.7	CYP51A1-AS1	-3.78	0.000164	0.00963	-0.13	-0.12	Breast cancer;	chr7:92084658	chr7:92134604~92180725:+
BRCA	cis	rs6964587	1	rs13239875	ENSG00000188693.7	CYP51A1-AS1	-3.78	0.000164	0.00963	-0.13	-0.12	Breast cancer;	chr7:92086790	chr7:92134604~92180725:+
BRCA	cis	rs6545883	0.929	rs6707830	ENSG00000212978.6	AC016747.3	3.78	0.000164	0.00963	0.16	0.12	Tuberculosis;	chr2:61522337	chr2:61141592~61144969:-
BRCA	cis	rs4689592	0.546	rs2359012	ENSG00000245468.3	RP11-367J11.3	3.78	0.000164	0.00963	0.13	0.12	Monocyte percentage of white cells;	chr4:7064326	chr4:7094571~7103385:-
BRCA	cis	rs256438	0.559	rs2434282	ENSG00000251050.1	RP11-168A11.4	-3.78	0.000164	0.00963	-0.12	-0.12	Serum thyroid-stimulating hormone levels;	chr5:80094734	chr5:80019609~80019920:+
BRCA	cis	rs875971	0.66	rs801217	ENSG00000275400.1	RP4-756H11.5	3.78	0.000165	0.00963	0.13	0.12	Aortic root size;	chr7:66545590	chr7:66553805~66554199:-
BRCA	cis	rs875971	0.638	rs801216	ENSG00000275400.1	RP4-756H11.5	3.78	0.000165	0.00963	0.13	0.12	Aortic root size;	chr7:66546680	chr7:66553805~66554199:-
BRCA	cis	rs875971	0.66	rs13224319	ENSG00000275400.1	RP4-756H11.5	-3.78	0.000165	0.00963	-0.13	-0.12	Aortic root size;	chr7:66542376	chr7:66553805~66554199:-
BRCA	cis	rs11185790	0.784	rs11185819	ENSG00000240996.1	RP11-80H5.7	3.78	0.000165	0.00963	0.14	0.12	Metabolic traits;	chr10:89626739	chr10:89694295~89697928:-
BRCA	cis	rs2262909	0.719	rs12461632	ENSG00000279377.1	AC003973.3	-3.78	0.000165	0.00963	-0.16	-0.12	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;	chr19:22062287	chr19:21965708~21968529:-
BRCA	cis	rs11514295	0.564	rs789569	ENSG00000257815.4	RP11-611E13.2	3.78	0.000165	0.00964	0.14	0.12	Left ventricular obstructive tract defect (inherited effect);	chr12:69981326	chr12:69904033~70243360:-
BRCA	cis	rs3755605	0.519	rs34710333	ENSG00000242578.1	RP11-469J4.3	3.78	0.000165	0.00964	0.14	0.12	Testicular germ cell tumor;	chr3:170212674	chr3:170410512~170418615:+
BRCA	cis	rs1075265	0.783	rs698858	ENSG00000272156.1	RP11-477N3.1	-3.78	0.000165	0.00964	-0.12	-0.12	Chronotype;Morning vs. evening chronotype;	chr2:53943333	chr2:54082554~54085066:+
BRCA	cis	rs9287719	1	rs9679122	ENSG00000224177.5	LINC00570	3.78	0.000165	0.00964	0.14	0.12	Prostate cancer;	chr2:10611584	chr2:11393981~11403077:+
BRCA	cis	rs7267979	0.966	rs2500417	ENSG00000274973.1	RP13-401N8.7	3.78	0.000165	0.00964	0.13	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25402651	chr20:25845497~25845862:+
BRCA	cis	rs7200786	0.667	rs9936979	ENSG00000274038.1	RP11-66H6.4	3.78	0.000165	0.00964	0.13	0.12	Systemic lupus erythematosus;Multiple sclerosis;	chr16:10986731	chr16:11056556~11057034:+
BRCA	cis	rs300703	0.542	rs376385	ENSG00000228643.1	AC079779.4	3.78	0.000165	0.00964	0.18	0.12	Blood protein levels;	chr2:190245	chr2:286419~301515:+
BRCA	cis	rs4664293	0.605	rs2042774	ENSG00000224152.1	AC009506.1	3.78	0.000165	0.00964	0.12	0.12	Monocyte percentage of white cells;	chr2:159653496	chr2:159615296~159617082:+
BRCA	cis	rs4664293	0.647	rs2042775	ENSG00000224152.1	AC009506.1	3.78	0.000165	0.00964	0.12	0.12	Monocyte percentage of white cells;	chr2:159653581	chr2:159615296~159617082:+
BRCA	cis	rs13272568	0.614	rs12675277	ENSG00000254352.1	RP11-578O24.2	-3.78	0.000165	0.00964	-0.15	-0.12	Bone mineral density;	chr8:78112427	chr8:78723796~78724136:-
BRCA	cis	rs13272568	0.614	rs11784050	ENSG00000254352.1	RP11-578O24.2	-3.78	0.000165	0.00964	-0.15	-0.12	Bone mineral density;	chr8:78114522	chr8:78723796~78724136:-
BRCA	cis	rs9840812	0.522	rs711976	ENSG00000273486.1	RP11-731C17.2	3.78	0.000165	0.00964	0.15	0.12	Fibrinogen levels;	chr3:136510180	chr3:136837338~136839021:-
BRCA	cis	rs4478858	0.735	rs6425736	ENSG00000260386.4	LINC01225	-3.78	0.000165	0.00964	-0.14	-0.12	Alcohol dependence;	chr1:31311529	chr1:31500085~31540885:+
BRCA	cis	rs1424638	0.708	rs7561865	ENSG00000233251.6	AC007743.1	-3.78	0.000165	0.00965	-0.14	-0.12	Intelligence (multi-trait analysis);	chr2:57015059	chr2:56173534~56185770:-
BRCA	cis	rs1865760	0.622	rs10946807	ENSG00000272462.2	U91328.19	-3.78	0.000165	0.00965	-0.15	-0.12	Height;	chr6:26079410	chr6:25992662~26001775:+
BRCA	cis	rs6964587	0.967	rs10248102	ENSG00000188693.7	CYP51A1-AS1	-3.78	0.000165	0.00965	-0.13	-0.12	Breast cancer;	chr7:92070465	chr7:92134604~92180725:+
BRCA	cis	rs6964587	1	rs10270598	ENSG00000188693.7	CYP51A1-AS1	-3.78	0.000165	0.00965	-0.13	-0.12	Breast cancer;	chr7:92071513	chr7:92134604~92180725:+
BRCA	cis	rs6964587	1	rs7800582	ENSG00000188693.7	CYP51A1-AS1	-3.78	0.000165	0.00965	-0.13	-0.12	Breast cancer;	chr7:92072032	chr7:92134604~92180725:+
BRCA	cis	rs875971	0.619	rs10278371	ENSG00000265600.1	AC006480.1	3.78	0.000165	0.00965	0.14	0.12	Aortic root size;	chr7:66586553	chr7:67356680~67356779:+
BRCA	cis	rs4662750	0.65	rs1083297	ENSG00000236682.1	AC068282.3	3.78	0.000165	0.00965	0.15	0.12	Renal cell carcinoma;	chr2:127599422	chr2:127389130~127400580:+
BRCA	cis	rs1061377	0.513	rs2566163	ENSG00000249685.1	RP11-360F5.3	3.78	0.000165	0.00965	0.16	0.12	Uric acid levels;	chr4:39128345	chr4:39133913~39135608:+
BRCA	cis	rs7246657	0.941	rs10418729	ENSG00000267319.1	CTD-2528L19.3	3.78	0.000165	0.00965	0.17	0.12	Coronary artery calcification;	chr19:37246163	chr19:37693280~37693564:-
BRCA	cis	rs1048886	0.938	rs9446245	ENSG00000271967.1	RP11-134K13.4	-3.78	0.000165	0.00965	-0.16	-0.12	Type 2 diabetes;	chr6:70424555	chr6:70596438~70596980:+
BRCA	cis	rs1048886	0.872	rs9455097	ENSG00000271967.1	RP11-134K13.4	-3.78	0.000165	0.00965	-0.16	-0.12	Type 2 diabetes;	chr6:70425153	chr6:70596438~70596980:+
BRCA	cis	rs10129255	0.957	rs10137980	ENSG00000232216.1	IGHV3-43	3.78	0.000165	0.00965	0.09	0.12	Kawasaki disease;	chr14:106775735	chr14:106470264~106470800:-
BRCA	cis	rs1419980	0.673	rs4883421	ENSG00000256552.2	RP11-113C12.4	-3.78	0.000165	0.00965	-0.18	-0.12	HDL cholesterol levels;	chr12:7621432	chr12:8320381~8369555:+
BRCA	cis	rs4272720	0.95	rs61848380	ENSG00000228754.1	RP11-534L6.3	-3.78	0.000165	0.00965	-0.17	-0.12	Platelet count;Plateletcrit;	chr10:49077001	chr10:48745545~48746128:-
BRCA	cis	rs73222236	0.963	rs6774226	ENSG00000273486.1	RP11-731C17.2	3.78	0.000165	0.00965	0.13	0.12	Coronary artery disease;	chr3:136083314	chr3:136837338~136839021:-
BRCA	cis	rs74233809	0.901	rs3824755	ENSG00000236937.2	PTGES3P4	3.78	0.000165	0.00965	0.22	0.12	Birth weight;	chr10:102836092	chr10:102845595~102845950:+
BRCA	cis	rs73198271	0.813	rs17697237	ENSG00000253981.4	ALG1L13P	3.78	0.000165	0.00965	0.14	0.12	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8758364	chr8:8236003~8244667:-
BRCA	cis	rs1953600	0.837	rs2573352	ENSG00000226659.1	RP11-137H2.4	3.78	0.000165	0.00966	0.15	0.12	Sarcoidosis;	chr10:80180057	chr10:80529597~80535942:-
BRCA	cis	rs2455799	0.533	rs2470550	ENSG00000224728.1	AC090945.1	-3.78	0.000165	0.00966	-0.11	-0.12	Mean platelet volume;	chr3:15702214	chr3:15878047~15879571:+
BRCA	cis	rs897984	0.568	rs4889651	ENSG00000280211.1	RP11-2C24.3	3.78	0.000165	0.00966	0.12	0.12	Dementia with Lewy bodies;	chr16:30884224	chr16:30773532~30776033:-
BRCA	cis	rs9392556	0.829	rs649725	ENSG00000230648.1	RP3-406P24.3	-3.78	0.000165	0.00966	-0.14	-0.12	Blood metabolite levels;	chr6:4109359	chr6:4018843~4021215:-
BRCA	cis	rs7172689	1	rs61219147	ENSG00000271725.1	RP11-761I4.4	3.78	0.000165	0.00966	0.17	0.12	Inattentive symptoms;	chr15:81241421	chr15:81303215~81309391:-
BRCA	cis	rs713477	0.678	rs4901566	ENSG00000186615.9	KTN1-AS1	-3.78	0.000165	0.00966	-0.13	-0.12	Pediatric bone mineral content (femoral neck);	chr14:55445945	chr14:55499278~55580110:-
BRCA	cis	rs863750	1	rs825452	ENSG00000275389.1	RP11-214K3.24	3.78	0.000165	0.00966	0.15	0.12	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-hip ratio;	chr12:124024630	chr12:124085761~124088598:+
BRCA	cis	rs4533720	0.553	rs11732646	ENSG00000248546.3	ANP32C	-3.78	0.000165	0.00966	-0.13	-0.12	Urinary uromodulin levels;	chr4:164040626	chr4:164197007~164197711:-
BRCA	cis	rs11098499	0.954	rs7681544	ENSG00000225892.3	RP11-384K6.2	3.78	0.000165	0.00966	0.12	0.12	Corneal astigmatism;	chr4:119490100	chr4:118632274~118634759:+
BRCA	cis	rs875971	0.862	rs801195	ENSG00000229886.1	RP5-1132H15.3	-3.78	0.000165	0.00966	-0.13	-0.12	Aortic root size;	chr7:66561128	chr7:66025126~66031544:-
BRCA	cis	rs6445967	1	rs6445967	ENSG00000272182.1	RP11-802O23.3	3.78	0.000165	0.00966	0.13	0.12	Platelet count;	chr3:58296849	chr3:58428255~58428815:+
BRCA	cis	rs2275848	0.866	rs13284731	ENSG00000203364.2	RP11-370F5.4	3.78	0.000165	0.00966	0.16	0.12	Obesity (early onset extreme);	chr9:93117970	chr9:93147040~93148556:+
BRCA	cis	rs739496	0.947	rs11608565	ENSG00000257624.1	RP1-128M12.3	3.78	0.000165	0.00966	0.16	0.12	Platelet count;	chr12:111484122	chr12:112000739~112000985:-
BRCA	cis	rs13217239	0.608	rs6930508	ENSG00000124549.13	BTN2A3P	-3.78	0.000165	0.00967	-0.12	-0.12	Schizophrenia;	chr6:27085363	chr6:26421391~26432383:+
BRCA	cis	rs13217239	0.646	rs2142685	ENSG00000124549.13	BTN2A3P	-3.78	0.000165	0.00967	-0.12	-0.12	Schizophrenia;	chr6:27086718	chr6:26421391~26432383:+
BRCA	cis	rs4374383	0.847	rs13394651	ENSG00000243389.1	AC012442.5	3.78	0.000165	0.00967	0.15	0.12	Hepatitis C induced liver fibrosis;	chr2:111987537	chr2:112589040~112614431:+
BRCA	cis	rs7615952	0.515	rs4441610	ENSG00000248787.1	RP11-666A20.4	-3.78	0.000165	0.00967	-0.17	-0.12	Blood pressure (smoking interaction);	chr3:125962464	chr3:125908005~125910272:-
BRCA	cis	rs35306767	0.904	rs35667562	ENSG00000229869.1	RP11-363N22.2	-3.78	0.000165	0.00967	-0.2	-0.12	Eosinophil percentage of granulocytes;	chr10:904690	chr10:933026~942743:+
BRCA	cis	rs798766	1	rs798766	ENSG00000244459.2	RP11-1398P2.1	3.78	0.000165	0.00967	0.15	0.12	Urinary bladder cancer;Bladder cancer;	chr4:1732512	chr4:1574062~1580253:-
BRCA	cis	rs11098499	0.874	rs12502503	ENSG00000260091.1	RP11-33B1.4	-3.78	0.000165	0.00967	-0.11	-0.12	Corneal astigmatism;	chr4:119195100	chr4:119409333~119410233:+
BRCA	cis	rs4218	0.587	rs1446237	ENSG00000259732.1	RP11-59H7.3	-3.78	0.000165	0.00967	-0.14	-0.12	Social communication problems;	chr15:59052603	chr15:59121034~59133250:+
BRCA	cis	rs2736345	0.755	rs2736340	ENSG00000255354.1	RP11-148O21.2	-3.78	0.000165	0.00967	-0.12	-0.12	Systemic lupus erythematosus;Sjögren's syndrome;	chr8:11486464	chr8:11558466~11560020:-
BRCA	cis	rs6472235	0.586	rs2357570	ENSG00000272010.1	CTD-3025N20.3	-3.78	0.000165	0.00967	-0.14	-0.12	Plateletcrit;Myopia (pathological);	chr8:66005760	chr8:65591850~65592472:-
BRCA	cis	rs91731	1	rs155586	ENSG00000249572.1	CTD-2203K17.1	-3.78	0.000165	0.00967	-0.24	-0.12	Lung function (FVC);	chr5:33380086	chr5:33424025~33440619:-
BRCA	cis	rs6600671	1	rs1591882	ENSG00000223345.3	HIST2H2BA	3.78	0.000165	0.00967	0.14	0.12	Hip geometry;	chr1:121441455	chr1:121108210~121117257:-
BRCA	cis	rs6121246	0.954	rs6121245	ENSG00000230613.1	HM13-AS1	3.78	0.000165	0.00967	0.17	0.12	Mean corpuscular hemoglobin;	chr20:31844257	chr20:31567707~31573263:-
BRCA	cis	rs8114671	0.562	rs4911163	ENSG00000279253.1	RP4-614O4.13	-3.78	0.000165	0.00967	-0.13	-0.12	Height;	chr20:34882891	chr20:35262727~35264187:-
BRCA	cis	rs9921338	0.961	rs12934968	ENSG00000262636.1	CTD-3088G3.4	3.78	0.000165	0.00967	0.18	0.12	Vein graft stenosis in coronary artery bypass grafting;	chr16:11320209	chr16:11380859~11381118:-
BRCA	cis	rs10043228	1	rs12520632	ENSG00000271918.1	CTD-2287O16.5	-3.78	0.000165	0.00967	-0.17	-0.12	Asthma or chronic obstructive pulmonary disease;	chr5:116256069	chr5:116083807~116085416:-
BRCA	cis	rs7267979	0.966	rs2257233	ENSG00000274973.1	RP13-401N8.7	3.78	0.000165	0.00967	0.13	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25285348	chr20:25845497~25845862:+
BRCA	cis	rs72928364	1	rs41273553	ENSG00000244119.1	PDCL3P4	3.78	0.000165	0.00968	0.14	0.12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100898688	chr3:101712472~101713191:+
BRCA	cis	rs12505749	0.542	rs55915354	ENSG00000270147.1	RP11-646I6.6	-3.78	0.000165	0.00968	-0.14	-0.12	Airflow obstruction;	chr4:56503857	chr4:56396312~56396871:+
BRCA	cis	rs7481584	0.624	rs436580	ENSG00000236710.1	AC108448.2	3.78	0.000165	0.00968	0.15	0.12	Calcium levels;	chr11:3042731	chr11:3084393~3085443:-
BRCA	cis	rs10129255	0.536	rs8004835	ENSG00000232216.1	IGHV3-43	3.78	0.000165	0.00968	0.09	0.12	Kawasaki disease;	chr14:106686361	chr14:106470264~106470800:-
BRCA	cis	rs45509595	0.822	rs200484	ENSG00000216676.2	RP1-15D7.1	-3.78	0.000165	0.00968	-0.2	-0.12	Breast cancer;	chr6:27807896	chr6:27652602~27652825:-
BRCA	cis	rs6964587	1	rs10234434	ENSG00000188693.7	CYP51A1-AS1	-3.78	0.000165	0.00968	-0.13	-0.12	Breast cancer;	chr7:92043994	chr7:92134604~92180725:+
BRCA	cis	rs62025270	0.632	rs62022915	ENSG00000259416.2	RP11-158M2.5	-3.78	0.000165	0.00968	-0.18	-0.12	Idiopathic pulmonary fibrosis;	chr15:85670365	chr15:85754941~85756237:-
BRCA	cis	rs4835473	0.838	rs10024263	ENSG00000249741.2	RP11-673E1.3	-3.78	0.000165	0.00968	-0.13	-0.12	Immature fraction of reticulocytes;	chr4:144038174	chr4:143911514~143912053:-
BRCA	cis	rs2712184	0.868	rs1548946	ENSG00000237930.1	AC007563.4	3.78	0.000165	0.00968	0.13	0.12	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);	chr2:216800645	chr2:216785774~216786144:-
BRCA	cis	rs9921338	0.561	rs78831935	ENSG00000262703.1	RP11-485G7.6	-3.78	0.000165	0.00968	-0.21	-0.12	Vein graft stenosis in coronary artery bypass grafting;	chr16:11374417	chr16:11348143~11349321:-
BRCA	cis	rs17756712	0.725	rs17135234	ENSG00000271911.1	RP11-532F6.5	3.78	0.000166	0.00968	0.2	0.12	Vertical cup-disc ratio;	chr6:593109	chr6:761675~780648:+
BRCA	cis	rs9470794	1	rs73417996	ENSG00000204110.6	RP1-153P14.8	-3.78	0.000166	0.00968	-0.24	-0.12	Type 2 diabetes;	chr6:38035521	chr6:37507348~37535616:+
BRCA	cis	rs9470794	1	rs73417997	ENSG00000204110.6	RP1-153P14.8	-3.78	0.000166	0.00968	-0.24	-0.12	Type 2 diabetes;	chr6:38035709	chr6:37507348~37535616:+
BRCA	cis	rs4478858	0.806	rs6686845	ENSG00000223907.1	LINC01226	-3.78	0.000166	0.00969	-0.14	-0.12	Alcohol dependence;	chr1:31235949	chr1:31518435~31524245:+
BRCA	cis	rs2640806	0.505	rs6981384	ENSG00000253105.4	KB-1448A5.1	3.78	0.000166	0.00969	0.13	0.12	Obesity-related traits;	chr8:96349502	chr8:96371865~96387438:-
BRCA	cis	rs970548	0.69	rs12265787	ENSG00000237840.5	FAM21FP	3.78	0.000166	0.00969	0.14	0.12	Total cholesterol levels;HDL cholesterol;HDL cholesterol levels;Cholesterol, total;	chr10:45568206	chr10:45706431~45727231:-
BRCA	cis	rs524281	0.861	rs10896085	ENSG00000255557.1	RP11-770G2.2	3.78	0.000166	0.00969	0.16	0.12	Electroencephalogram traits;	chr11:66146361	chr11:65745729~65771585:+
BRCA	cis	rs61931739	0.534	rs10844729	ENSG00000258794.3	DUX4L27	3.78	0.000166	0.00969	0.17	0.12	Morning vs. evening chronotype;	chr12:33869984	chr12:34208415~34209675:-
BRCA	cis	rs718314	0.64	rs1049380	ENSG00000256894.1	RP11-283G6.3	-3.78	0.000166	0.00969	-0.13	-0.12	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Renal cell carcinoma;Waist circumference adjusted for body mass index;	chr12:26336611	chr12:26125155~26126617:-
BRCA	cis	rs2839627	0.638	rs7276320	ENSG00000225218.1	AP001628.6	-3.78	0.000166	0.00969	-0.17	-0.12	Information processing speed;	chr21:42849478	chr21:42831040~42836477:-
BRCA	cis	rs4907240	0.806	rs4907237	ENSG00000230606.9	AC159540.1	3.78	0.000166	0.00969	0.15	0.12	Event-related brain oscillations;	chr2:96524760	chr2:97416165~97433527:-
BRCA	cis	rs875971	0.862	rs4718330	ENSG00000271064.1	RP11-792A8.3	3.78	0.000166	0.00969	0.14	0.12	Aortic root size;	chr7:66250256	chr7:66748838~66749077:-
BRCA	cis	rs34217772	0.739	rs12878452	ENSG00000258636.1	CTD-2298J14.2	-3.78	0.000166	0.00969	-0.14	-0.12	Myopia;	chr14:41842228	chr14:41587861~41604856:-
BRCA	cis	rs4650943	0.586	rs2504502	ENSG00000227740.1	RP11-318C24.2	-3.78	0.000166	0.00969	-0.12	-0.12	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in inactive individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr1:176330836	chr1:175904762~175920513:-
BRCA	cis	rs256438	0.93	rs2438639	ENSG00000251050.1	RP11-168A11.4	-3.78	0.000166	0.00969	-0.13	-0.12	Serum thyroid-stimulating hormone levels;	chr5:80094151	chr5:80019609~80019920:+
BRCA	cis	rs1429524	0.922	rs62468557	ENSG00000243144.5	RP11-115N4.1	3.78	0.000166	0.00969	0.16	0.12	Ejection fraction in Tripanosoma cruzi seropositivity;	chr7:91308880	chr7:91311368~91515409:+
BRCA	cis	rs494526	0.676	rs10886368	ENSG00000229272.1	RP11-498J9.2	3.78	0.000166	0.0097	0.15	0.12	Alcoholic chronic pancreatitis;	chr10:119022674	chr10:119003536~119003884:-
BRCA	cis	rs28489187	0.683	rs6657817	ENSG00000223653.4	RP11-131L23.1	-3.78	0.000166	0.0097	-0.13	-0.12	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85408931	chr1:85276715~85448124:+
BRCA	cis	rs9527	0.59	rs3781281	ENSG00000213061.2	PFN1P11	-3.78	0.000166	0.0097	-0.15	-0.12	Arsenic metabolism;	chr10:103092891	chr10:102838011~102845473:-
BRCA	cis	rs1910358	0.919	rs4701239	ENSG00000248874.4	C5orf17	-3.78	0.000166	0.0097	-0.17	-0.12	Venous thromboembolism (SNP x SNP interaction);	chr5:23871671	chr5:23951348~24178263:+
BRCA	cis	rs1910358	0.919	rs4701240	ENSG00000248874.4	C5orf17	-3.78	0.000166	0.0097	-0.17	-0.12	Venous thromboembolism (SNP x SNP interaction);	chr5:23871818	chr5:23951348~24178263:+
BRCA	cis	rs8058578	1	rs56656810	ENSG00000280211.1	RP11-2C24.3	3.78	0.000166	0.0097	0.12	0.12	Multiple myeloma;	chr16:30777438	chr16:30773532~30776033:-
BRCA	cis	rs6064559	0.687	rs6070142	ENSG00000218018.2	RP4-800J21.3	-3.78	0.000166	0.0097	-0.1	-0.12	Hemoglobin concentration;	chr20:57547986	chr20:57384160~57393062:-
BRCA	cis	rs11668609	1	rs11668609	ENSG00000268058.1	BNIP3P40	-3.78	0.000166	0.0097	-0.14	-0.12	Response to taxane treatment (docetaxel);	chr19:24172691	chr19:24098425~24098980:-
BRCA	cis	rs875971	0.898	rs6977501	ENSG00000230189.5	GS1-124K5.2	-3.78	0.000166	0.0097	-0.09	-0.12	Aortic root size;	chr7:66228355	chr7:66409143~66490059:-
BRCA	cis	rs12612435	0.869	rs16833906	ENSG00000226806.1	AC011893.3	3.78	0.000166	0.0097	0.14	0.12	Takotsubo syndrome;	chr2:136362807	chr2:135820191~135823087:+
BRCA	cis	rs7074356	0.915	rs17617970	ENSG00000226659.1	RP11-137H2.4	-3.78	0.000166	0.00971	-0.25	-0.12	Borderline personality disorder;	chr10:80447136	chr10:80529597~80535942:-
BRCA	cis	rs9863	0.794	rs7133378	ENSG00000270028.1	RP11-380L11.4	3.78	0.000166	0.00971	0.15	0.12	White blood cell count;	chr12:123924955	chr12:123925461~123926083:-
BRCA	cis	rs1670533	1	rs10007978	ENSG00000251639.2	RP11-20I20.1	3.78	0.000166	0.00971	0.18	0.12	Recombination rate (females);	chr4:1067196	chr4:1100016~1101558:-
BRCA	cis	rs256438	0.524	rs2241825	ENSG00000251050.1	RP11-168A11.4	-3.78	0.000166	0.00971	-0.12	-0.12	Serum thyroid-stimulating hormone levels;	chr5:80058470	chr5:80019609~80019920:+
BRCA	cis	rs6893300	1	rs6893300	ENSG00000225051.5	HMGB3P22	3.78	0.000166	0.00971	0.15	0.12	Resting heart rate;	chr5:179708814	chr5:179679032~179694768:+
BRCA	cis	rs5758511	0.731	rs5751186	ENSG00000231261.1	HMGN2P10	3.78	0.000166	0.00971	0.15	0.12	Birth weight;	chr22:41953706	chr22:41709225~41709489:-
BRCA	cis	rs2839186	0.771	rs2280957	ENSG00000228137.1	AP001469.7	-3.78	0.000166	0.00971	-0.12	-0.12	Testicular germ cell tumor;	chr21:46222358	chr21:46246890~46247682:+
BRCA	cis	rs7312933	0.703	rs11181380	ENSG00000257225.1	RP11-328C8.4	-3.78	0.000166	0.00971	-0.14	-0.12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42222238	chr12:42459366~42466128:+
BRCA	cis	rs4664293	0.647	rs4144512	ENSG00000224152.1	AC009506.1	3.78	0.000166	0.00971	0.12	0.12	Monocyte percentage of white cells;	chr2:159651008	chr2:159615296~159617082:+
BRCA	cis	rs4664293	0.625	rs13006088	ENSG00000224152.1	AC009506.1	3.78	0.000166	0.00971	0.12	0.12	Monocyte percentage of white cells;	chr2:159652915	chr2:159615296~159617082:+
BRCA	cis	rs2731006	0.64	rs2138862	ENSG00000257114.2	RP11-25I15.3	3.78	0.000166	0.00971	0.19	0.12	Panic disorder;	chr12:42789961	chr12:42692216~42717119:+
BRCA	cis	rs2411233	0.967	rs7180968	ENSG00000259278.1	RP11-62C7.2	3.78	0.000166	0.00972	0.13	0.12	Platelet count;	chr15:38996326	chr15:39019233~39024918:+
BRCA	cis	rs533581	0.866	rs475796	ENSG00000278341.1	RP5-1142A6.10	-3.78	0.000166	0.00972	-0.15	-0.12	Social autistic-like traits;	chr16:88904368	chr16:88708956~88710437:-
BRCA	cis	rs4267450	0.69	rs10422617	ENSG00000261770.1	CTC-459F4.1	3.78	0.000166	0.00972	0.24	0.12	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);	chr19:28371341	chr19:27757184~27760849:-
BRCA	cis	rs2274273	0.713	rs56725788	ENSG00000259318.1	RP11-454L9.2	3.78	0.000166	0.00972	0.1	0.12	Protein biomarker;	chr14:55073383	chr14:55394940~55395233:-
BRCA	cis	rs2274273	0.743	rs13379159	ENSG00000259318.1	RP11-454L9.2	3.78	0.000166	0.00972	0.1	0.12	Protein biomarker;	chr14:55074083	chr14:55394940~55395233:-
BRCA	cis	rs9393777	0.92	rs13207689	ENSG00000216901.1	AL022393.7	3.78	0.000166	0.00972	0.29	0.12	Intelligence (multi-trait analysis);	chr6:27401925	chr6:28176188~28176674:+
BRCA	cis	rs7267979	1	rs2297497	ENSG00000277938.1	RP5-965G21.3	-3.78	0.000166	0.00972	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25317273	chr20:25229150~25231933:+
BRCA	cis	rs4478858	0.735	rs6679365	ENSG00000223907.1	LINC01226	3.78	0.000166	0.00972	0.14	0.12	Alcohol dependence;	chr1:31315019	chr1:31518435~31524245:+
BRCA	cis	rs2785946	0.697	rs9316717	ENSG00000136149.6	RPL13AP25	-3.78	0.000166	0.00972	-0.1	-0.12	Amyotrophic lateral sclerosis;	chr13:54389017	chr13:54440704~54441315:-
BRCA	cis	rs2704588	1	rs993358	ENSG00000270720.1	RP11-84C13.2	-3.78	0.000166	0.00972	-0.18	-0.12	Longevity;	chr4:88879434	chr4:89119284~89119871:+
BRCA	cis	rs6812193	0.518	rs28498588	ENSG00000271676.1	RP11-1E1.2	3.78	0.000166	0.00972	0.16	0.12	Parkinson's disease;	chr4:76267613	chr4:77112495~77113458:-
BRCA	cis	rs73201462	1	rs2999061	ENSG00000242551.2	POU5F1P6	3.78	0.000166	0.00972	0.19	0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128274780	chr3:128674735~128677005:-
BRCA	cis	rs6671200	1	rs62625008	ENSG00000226026.4	RP11-57H12.3	3.78	0.000166	0.00972	0.26	0.12	Stearic acid (18:0) levels;	chr1:95237026	chr1:95163219~95233982:-
BRCA	cis	rs6671200	0.92	rs35403759	ENSG00000226026.4	RP11-57H12.3	3.78	0.000166	0.00972	0.26	0.12	Stearic acid (18:0) levels;	chr1:95237334	chr1:95163219~95233982:-
BRCA	cis	rs524281	0.861	rs11607393	ENSG00000255038.1	RP11-1167A19.2	-3.78	0.000166	0.00972	-0.17	-0.12	Electroencephalogram traits;	chr11:66107678	chr11:66067277~66069619:-
BRCA	cis	rs739496	0.527	rs7136469	ENSG00000234608.6	MAPKAPK5-AS1	3.78	0.000166	0.00972	0.14	0.12	Platelet count;	chr12:111910387	chr12:111839764~111842902:-
BRCA	cis	rs6490294	0.799	rs11066082	ENSG00000234608.6	MAPKAPK5-AS1	3.78	0.000166	0.00972	0.14	0.12	Mean platelet volume;	chr12:111913544	chr12:111839764~111842902:-
BRCA	cis	rs1816752	0.905	rs7317850	ENSG00000273628.1	RP11-756A22.7	3.78	0.000166	0.00972	0.14	0.12	Obesity-related traits;	chr13:24419899	chr13:24933006~24936796:+
BRCA	cis	rs9287719	0.967	rs10203785	ENSG00000224177.5	LINC00570	3.78	0.000166	0.00972	0.14	0.12	Prostate cancer;	chr2:10612382	chr2:11393981~11403077:+
BRCA	cis	rs7656342	0.836	rs13129974	ENSG00000250342.1	SNRPCP16	-3.78	0.000166	0.00972	-0.14	-0.12	Gut microbiota (bacterial taxa);	chr4:9777902	chr4:9051842~9052051:-
BRCA	cis	rs773506	0.628	rs10991816	ENSG00000235641.4	LINC00484	-3.78	0.000166	0.00972	-0.15	-0.12	Type 2 diabetes nephropathy;	chr9:91188231	chr9:91159573~91165658:+
BRCA	cis	rs9470794	1	rs112825323	ENSG00000204110.6	RP1-153P14.8	-3.78	0.000166	0.00973	-0.24	-0.12	Type 2 diabetes;	chr6:38075305	chr6:37507348~37535616:+
BRCA	cis	rs17270561	0.666	rs3923725	ENSG00000272462.2	U91328.19	-3.78	0.000166	0.00973	-0.15	-0.12	Iron status biomarkers;	chr6:25734692	chr6:25992662~26001775:+
BRCA	cis	rs3858526	0.959	rs4559671	ENSG00000224295.2	AC087380.14	3.78	0.000166	0.00973	0.16	0.12	DNA methylation (variation);	chr11:5902189	chr11:5518441~5524955:-
BRCA	cis	rs17092148	1	rs1884432	ENSG00000202150.1	RNU6-407P	3.78	0.000166	0.00973	0.17	0.12	Neuroticism;	chr20:34754636	chr20:35030317~35030420:-
BRCA	cis	rs6460942	0.915	rs6965564	ENSG00000226690.5	AC005281.1	3.78	0.000166	0.00973	0.17	0.12	Coronary artery disease;	chr7:12266387	chr7:12496429~12541910:+
BRCA	cis	rs4713118	0.629	rs203889	ENSG00000216901.1	AL022393.7	3.78	0.000166	0.00973	0.16	0.12	Parkinson's disease;	chr6:28053997	chr6:28176188~28176674:+
BRCA	cis	rs7267979	1	rs1077889	ENSG00000274973.1	RP13-401N8.7	-3.78	0.000166	0.00973	-0.13	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25287257	chr20:25845497~25845862:+
BRCA	cis	rs10938353	0.906	rs10805129	ENSG00000273369.1	RP11-700J17.1	-3.78	0.000166	0.00973	-0.14	-0.12	Body mass index;	chr4:44601051	chr4:44693946~44694386:-
BRCA	cis	rs12826942	0.959	rs12820881	ENSG00000257225.1	RP11-328C8.4	-3.78	0.000166	0.00973	-0.17	-0.12	Coronary artery disease;	chr12:42333176	chr12:42459366~42466128:+
BRCA	cis	rs875971	0.862	rs6460302	ENSG00000229886.1	RP5-1132H15.3	3.78	0.000166	0.00973	0.13	0.12	Aortic root size;	chr7:66495270	chr7:66025126~66031544:-
BRCA	cis	rs9549260	0.753	rs4943794	ENSG00000168852.11	TPTE2P5	3.78	0.000166	0.00973	0.14	0.12	Red blood cell count;	chr13:40599271	chr13:40822296~40921749:-
BRCA	cis	rs73201462	0.536	rs56397996	ENSG00000242551.2	POU5F1P6	-3.78	0.000166	0.00973	-0.19	-0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128235867	chr3:128674735~128677005:-
BRCA	cis	rs2640806	0.505	rs6999279	ENSG00000253105.4	KB-1448A5.1	3.78	0.000166	0.00973	0.13	0.12	Obesity-related traits;	chr8:96349525	chr8:96371865~96387438:-
BRCA	cis	rs1949733	1	rs3103071	ENSG00000251615.3	RP11-774O3.3	3.78	0.000166	0.00973	0.12	0.12	Response to antineoplastic agents;	chr4:8506852	chr4:8355090~8358338:-
BRCA	cis	rs7520050	0.778	rs3014238	ENSG00000234329.1	RP11-767N6.2	-3.78	0.000166	0.00973	-0.11	-0.12	Reticulocyte count;Red blood cell count;	chr1:45624542	chr1:45651039~45651826:-
BRCA	cis	rs9788721	1	rs9788721	ENSG00000261762.1	RP11-650L12.2	3.78	0.000166	0.00973	0.13	0.12	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78510527	chr15:78589123~78591276:-
BRCA	cis	rs17214007	0.877	rs2075515	ENSG00000260735.1	RP11-72I8.1	-3.78	0.000166	0.00973	-0.16	-0.12	Cognitive function;	chr16:15778462	chr16:15094411~15109197:+
BRCA	cis	rs16958440	1	rs61316646	ENSG00000267800.1	RP11-49K24.5	-3.78	0.000167	0.00973	-0.25	-0.12	Sitting height ratio;	chr18:47084299	chr18:47137018~47137290:+
BRCA	cis	rs757081	0.658	rs214075	ENSG00000184669.7	OR7E14P	-3.78	0.000167	0.00973	-0.16	-0.12	Systolic blood pressure;	chr11:17278870	chr11:17013998~17053024:+
BRCA	cis	rs7833787	1	rs34270955	ENSG00000254054.2	RP11-156K13.3	3.78	0.000167	0.00974	0.14	0.12	Obesity-related traits;	chr8:18847740	chr8:17905756~17907887:+
BRCA	cis	rs78487399	0.808	rs6726643	ENSG00000234936.1	AC010883.5	3.78	0.000167	0.00974	0.18	0.12	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43526607	chr2:43229573~43233394:+
BRCA	cis	rs78487399	0.808	rs6752964	ENSG00000234936.1	AC010883.5	3.78	0.000167	0.00974	0.18	0.12	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43527516	chr2:43229573~43233394:+
BRCA	cis	rs9818758	0.607	rs73082362	ENSG00000225399.4	RP11-3B7.1	-3.78	0.000167	0.00974	-0.24	-0.12	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49076296	chr3:49260085~49261316:+
BRCA	cis	rs7267979	1	rs7267979	ENSG00000277938.1	RP5-965G21.3	3.78	0.000167	0.00974	0.14	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25317451	chr20:25229150~25231933:+
BRCA	cis	rs4478858	0.735	rs6679393	ENSG00000223907.1	LINC01226	-3.78	0.000167	0.00974	-0.14	-0.12	Alcohol dependence;	chr1:31298097	chr1:31518435~31524245:+
BRCA	cis	rs62025270	0.632	rs10520594	ENSG00000259762.1	RP11-158M2.4	3.78	0.000167	0.00974	0.18	0.12	Idiopathic pulmonary fibrosis;	chr15:85585410	chr15:85750336~85752901:-
BRCA	cis	rs6545883	0.507	rs34668697	ENSG00000270820.4	RP11-355B11.2	-3.78	0.000167	0.00974	-0.12	-0.12	Tuberculosis;	chr2:61341214	chr2:61471188~61484130:+
BRCA	cis	rs1371614	0.632	rs7589627	ENSG00000272148.1	RP11-195B17.1	3.78	0.000167	0.00974	0.13	0.12	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26936918	chr2:27062428~27062907:-
BRCA	cis	rs6593122	0.74	rs10254056	ENSG00000235454.1	HAUS6P3	-3.78	0.000167	0.00974	-0.15	-0.12	Vaccine-related adverse events;	chr7:54120910	chr7:53862233~53863339:+
BRCA	cis	rs3617	0.625	rs11715347	ENSG00000242142.1	SERBP1P3	-3.78	0.000167	0.00974	-0.13	-0.12	Red blood cell count;Autism spectrum disorder or schizophrenia;	chr3:52849054	chr3:53064283~53065091:-
BRCA	cis	rs3916	0.794	rs3021337	ENSG00000277423.1	RP11-173P15.9	-3.78	0.000167	0.00974	-0.14	-0.12	Urinary metabolites (H-NMR features);	chr12:120725458	chr12:120703867~120704282:+
BRCA	cis	rs11098499	0.697	rs28655325	ENSG00000225892.3	RP11-384K6.2	3.78	0.000167	0.00974	0.12	0.12	Corneal astigmatism;	chr4:119451844	chr4:118632274~118634759:+
BRCA	cis	rs1577917	0.655	rs6454472	ENSG00000220563.1	PKMP3	3.78	0.000167	0.00974	0.12	0.12	Response to antipsychotic treatment;	chr6:85514335	chr6:85659892~85660606:-
BRCA	cis	rs6918586	0.636	rs198816	ENSG00000272462.2	U91328.19	-3.78	0.000167	0.00975	-0.13	-0.12	Schizophrenia;	chr6:26126956	chr6:25992662~26001775:+
BRCA	cis	rs2562456	0.917	rs11085463	ENSG00000240522.1	RPL7AP10	-3.78	0.000167	0.00975	-0.12	-0.12	Pain;	chr19:21568500	chr19:21149648~21150438:-
BRCA	cis	rs801193	1	rs2707856	ENSG00000265600.1	AC006480.1	-3.78	0.000167	0.00975	-0.14	-0.12	Aortic root size;	chr7:66746023	chr7:67356680~67356779:+
BRCA	cis	rs875971	0.798	rs57739047	ENSG00000229886.1	RP5-1132H15.3	3.78	0.000167	0.00975	0.13	0.12	Aortic root size;	chr7:66507579	chr7:66025126~66031544:-
BRCA	cis	rs853679	1	rs853694	ENSG00000280107.1	AL022393.9	-3.78	0.000167	0.00975	-0.21	-0.12	Depression;	chr6:28311323	chr6:28170845~28172521:+
BRCA	cis	rs4578769	0.959	rs6507323	ENSG00000273232.1	RP11-370A5.2	-3.78	0.000167	0.00975	-0.15	-0.12	Eosinophil percentage of white cells;	chr18:22846715	chr18:22882825~22883357:-
BRCA	cis	rs13217239	0.646	rs9379956	ENSG00000124549.13	BTN2A3P	-3.78	0.000167	0.00975	-0.12	-0.12	Schizophrenia;	chr6:27065956	chr6:26421391~26432383:+
BRCA	cis	rs8062405	0.965	rs8049439	ENSG00000261766.1	RP11-22P6.2	-3.78	0.000167	0.00975	-0.11	-0.12	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28826194	chr16:28862166~28863340:-
BRCA	cis	rs9952980	0.646	rs7232133	ENSG00000266968.2	RP11-116O18.1	-3.78	0.000167	0.00975	-0.14	-0.12	Breast cancer;	chr18:45319875	chr18:45646153~45647937:+
BRCA	cis	rs739496	0.579	rs75080921	ENSG00000234608.6	MAPKAPK5-AS1	3.78	0.000167	0.00976	0.14	0.12	Platelet count;	chr12:111861168	chr12:111839764~111842902:-
BRCA	cis	rs962856	0.575	rs18122	ENSG00000236780.4	AC078941.1	3.78	0.000167	0.00976	0.16	0.12	Pancreatic cancer;	chr2:67427302	chr2:67123357~67215319:-
BRCA	cis	rs8103278	1	rs1548029	ENSG00000268423.3	AC011551.3	3.78	0.000167	0.00976	0.14	0.12	Coronary artery disease;	chr19:45805945	chr19:46547056~46600861:-
BRCA	cis	rs1949733	0.701	rs2631754	ENSG00000251615.3	RP11-774O3.3	-3.78	0.000167	0.00976	-0.12	-0.12	Response to antineoplastic agents;	chr4:8447506	chr4:8355090~8358338:-
BRCA	cis	rs6918586	0.658	rs198814	ENSG00000272462.2	U91328.19	-3.78	0.000167	0.00976	-0.13	-0.12	Schizophrenia;	chr6:26127531	chr6:25992662~26001775:+
BRCA	cis	rs9307551	0.697	rs1561638	ENSG00000250334.4	LINC00989	-3.78	0.000167	0.00976	-0.18	-0.12	Refractive error;	chr4:79499154	chr4:79492416~79576460:+
BRCA	cis	rs7475343	0.538	rs2211630	ENSG00000224034.1	RP11-445P17.8	3.78	0.000167	0.00976	0.2	0.12	Intelligence;	chr10:5117604	chr10:5266033~5271236:-
BRCA	cis	rs2380205	0.517	rs12781700	ENSG00000232807.2	RP11-536K7.3	3.78	0.000167	0.00976	0.12	0.12	Breast cancer;	chr10:5894462	chr10:5934270~5945900:-
BRCA	cis	rs7412746	0.658	rs11582281	ENSG00000231073.1	RP11-316M1.3	3.78	0.000167	0.00977	0.13	0.12	Melanoma;	chr1:150854355	chr1:150973123~150975534:+
BRCA	cis	rs8130944	0.73	rs2250870	ENSG00000225731.1	AP001627.1	3.78	0.000167	0.00977	0.14	0.12	Perceived unattractiveness to mosquitoes;	chr21:42737077	chr21:42733594~42741758:-
BRCA	cis	rs7204230	0.538	rs11075788	ENSG00000261291.1	RP11-295M3.2	3.78	0.000167	0.00977	0.13	0.12	Fibrinogen;	chr16:53201169	chr16:53168522~53169450:+
BRCA	cis	rs74233809	1	rs79668541	ENSG00000213061.2	PFN1P11	3.78	0.000167	0.00977	0.26	0.12	Birth weight;	chr10:103034147	chr10:102838011~102845473:-
BRCA	cis	rs2688608	0.698	rs2633323	ENSG00000213731.2	RAB5CP1	-3.78	0.000167	0.00977	-0.13	-0.12	Inflammatory bowel disease;	chr10:73935068	chr10:74423435~74424014:-
BRCA	cis	rs2041840	0.96	rs4670678	ENSG00000272054.1	RP11-423P10.2	-3.78	0.000167	0.00977	-0.11	-0.12	Chronic lymphocytic leukemia;	chr2:37221783	chr2:37208875~37212677:+
BRCA	cis	rs7572733	0.905	rs6434945	ENSG00000231621.1	AC013264.2	-3.78	0.000167	0.00977	-0.11	-0.12	Dermatomyositis;	chr2:197933236	chr2:197197991~197199273:+
BRCA	cis	rs12468579	0.503	rs3088307	ENSG00000235852.1	AC005540.3	-3.78	0.000167	0.00977	-0.13	-0.12	JT interval (sulfonylurea treatment interaction);	chr2:190964686	chr2:190880797~190882059:-
BRCA	cis	rs911119	0.818	rs56077567	ENSG00000270001.1	RP11-218C14.8	-3.78	0.000167	0.00977	-0.15	-0.12	Chronic kidney disease;	chr20:23610450	chr20:23631826~23632316:-
BRCA	cis	rs1005277	0.541	rs1740741	ENSG00000272983.1	RP11-508N22.12	3.78	0.000167	0.00978	0.12	0.12	Extrinsic epigenetic age acceleration;	chr10:38226406	chr10:38137337~38144399:+
BRCA	cis	rs1005277	0.528	rs2057228	ENSG00000272983.1	RP11-508N22.12	3.78	0.000167	0.00978	0.12	0.12	Extrinsic epigenetic age acceleration;	chr10:38226838	chr10:38137337~38144399:+
BRCA	cis	rs2274273	0.682	rs8008134	ENSG00000259318.1	RP11-454L9.2	3.78	0.000167	0.00978	0.1	0.12	Protein biomarker;	chr14:55040802	chr14:55394940~55395233:-
BRCA	cis	rs7267979	0.714	rs3787082	ENSG00000274414.1	RP5-965G21.4	-3.78	0.000167	0.00978	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25255100	chr20:25239007~25245229:-
BRCA	cis	rs2742540	0.503	rs7106539	ENSG00000254860.4	TMEM9B-AS1	3.78	0.000167	0.00978	0.11	0.12	Hematocrit;	chr11:8875986	chr11:8964675~8977527:+
BRCA	cis	rs2303319	0.504	rs4455163	ENSG00000227403.1	AC009299.3	3.78	0.000167	0.00978	0.31	0.12	Cognitive function;	chr2:161846488	chr2:161244739~161249050:+
BRCA	cis	rs2303319	0.504	rs2090270	ENSG00000227403.1	AC009299.3	3.78	0.000167	0.00978	0.31	0.12	Cognitive function;	chr2:161846717	chr2:161244739~161249050:+
BRCA	cis	rs2303319	0.504	rs62187747	ENSG00000227403.1	AC009299.3	3.78	0.000167	0.00978	0.31	0.12	Cognitive function;	chr2:161849564	chr2:161244739~161249050:+
BRCA	cis	rs2303319	0.504	rs72879293	ENSG00000227403.1	AC009299.3	3.78	0.000167	0.00978	0.31	0.12	Cognitive function;	chr2:161849966	chr2:161244739~161249050:+
BRCA	cis	rs2303319	0.504	rs62187748	ENSG00000227403.1	AC009299.3	3.78	0.000167	0.00978	0.31	0.12	Cognitive function;	chr2:161850544	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.581	rs62187749	ENSG00000227403.1	AC009299.3	3.78	0.000167	0.00978	0.31	0.12	Blood osmolality (transformed sodium);	chr2:161850678	chr2:161244739~161249050:+
BRCA	cis	rs2303319	0.504	rs62187750	ENSG00000227403.1	AC009299.3	3.78	0.000167	0.00978	0.31	0.12	Cognitive function;	chr2:161850840	chr2:161244739~161249050:+
BRCA	cis	rs2303319	0.504	rs55961814	ENSG00000227403.1	AC009299.3	3.78	0.000167	0.00978	0.31	0.12	Cognitive function;	chr2:161853677	chr2:161244739~161249050:+
BRCA	cis	rs2303319	0.504	rs62187754	ENSG00000227403.1	AC009299.3	3.78	0.000167	0.00978	0.31	0.12	Cognitive function;	chr2:161854674	chr2:161244739~161249050:+
BRCA	cis	rs2303319	0.504	rs41267441	ENSG00000227403.1	AC009299.3	3.78	0.000167	0.00978	0.31	0.12	Cognitive function;	chr2:161855172	chr2:161244739~161249050:+
BRCA	cis	rs2303319	0.504	rs62187756	ENSG00000227403.1	AC009299.3	3.78	0.000167	0.00978	0.31	0.12	Cognitive function;	chr2:161855632	chr2:161244739~161249050:+
BRCA	cis	rs2303319	0.504	rs62187757	ENSG00000227403.1	AC009299.3	3.78	0.000167	0.00978	0.31	0.12	Cognitive function;	chr2:161857779	chr2:161244739~161249050:+
BRCA	cis	rs2303319	0.504	rs62187759	ENSG00000227403.1	AC009299.3	3.78	0.000167	0.00978	0.31	0.12	Cognitive function;	chr2:161859499	chr2:161244739~161249050:+
BRCA	cis	rs2303319	0.504	rs62188760	ENSG00000227403.1	AC009299.3	3.78	0.000167	0.00978	0.31	0.12	Cognitive function;	chr2:161861243	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.581	rs62188761	ENSG00000227403.1	AC009299.3	3.78	0.000167	0.00978	0.31	0.12	Blood osmolality (transformed sodium);	chr2:161862319	chr2:161244739~161249050:+
BRCA	cis	rs2998286	1	rs2807743	ENSG00000237128.1	RP11-351M16.3	-3.78	0.000167	0.00978	-0.13	-0.12	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28491364	chr10:28433008~28495813:-
BRCA	cis	rs2486012	0.649	rs39722	ENSG00000237950.1	RP11-7O11.3	3.78	0.000167	0.00978	0.21	0.12	Intelligence (multi-trait analysis);	chr1:43819991	chr1:43944370~43946551:-
BRCA	cis	rs11711311	1	rs12636577	ENSG00000241529.3	RN7SL767P	-3.78	0.000167	0.00978	-0.14	-0.12	IgG glycosylation;	chr3:113778660	chr3:113632704~113632998:+
BRCA	cis	rs997295	0.57	rs17241808	ENSG00000259673.4	IQCH-AS1	3.78	0.000167	0.00978	0.13	0.12	Motion sickness;	chr15:67600454	chr15:67403619~67521844:-
BRCA	cis	rs9952980	0.671	rs16978343	ENSG00000266968.2	RP11-116O18.1	3.78	0.000167	0.00978	0.14	0.12	Breast cancer;	chr18:45336230	chr18:45646153~45647937:+
BRCA	cis	rs1400816	0.702	rs58565148	ENSG00000228389.1	AC068039.4	-3.78	0.000167	0.00978	-0.22	-0.12	Amyotrophic lateral sclerosis (sporadic);	chr2:171678886	chr2:171773482~171775844:+
BRCA	cis	rs935334	1	rs2360977	ENSG00000258454.1	RP11-361H10.3	3.78	0.000168	0.00978	0.19	0.12	Blood pressure;	chr14:76188138	chr14:76235817~76263474:+
BRCA	cis	rs13424612	1	rs4149556	ENSG00000218416.4	PP14571	-3.78	0.000168	0.00979	-0.14	-0.12	Odorant perception (isobutyraldehyde);	chr2:239975890	chr2:240449315~240456714:-
BRCA	cis	rs875971	0.66	rs62465434	ENSG00000275400.1	RP4-756H11.5	-3.78	0.000168	0.00979	-0.13	-0.12	Aortic root size;	chr7:66540165	chr7:66553805~66554199:-
BRCA	cis	rs61160187	0.549	rs62367879	ENSG00000272308.1	RP11-231G3.1	-3.78	0.000168	0.00979	-0.13	-0.12	Educational attainment (years of education);Educational attainment (college completion);	chr5:60996384	chr5:60866457~60866935:-
BRCA	cis	rs6545883	0.929	rs9679557	ENSG00000270820.4	RP11-355B11.2	3.78	0.000168	0.00979	0.13	0.12	Tuberculosis;	chr2:61482214	chr2:61471188~61484130:+
BRCA	cis	rs7523050	0.643	rs12725689	ENSG00000203897.3	SPATA42	-3.78	0.000168	0.00979	-0.24	-0.12	Fat distribution (HIV);	chr1:108862529	chr1:108857217~108858524:+
BRCA	cis	rs2712184	0.935	rs2541387	ENSG00000237930.1	AC007563.4	3.78	0.000168	0.00979	0.13	0.12	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);	chr2:216801451	chr2:216785774~216786144:-
BRCA	cis	rs17684571	0.751	rs6905603	ENSG00000231441.1	RP11-472M19.2	3.78	0.000168	0.00979	0.18	0.12	Schizophrenia;	chr6:56848145	chr6:56844002~56864078:+
BRCA	cis	rs875971	0.83	rs6950137	ENSG00000229886.1	RP5-1132H15.3	3.78	0.000168	0.00979	0.13	0.12	Aortic root size;	chr7:66511623	chr7:66025126~66031544:-
BRCA	cis	rs74665712	0.591	rs17268110	ENSG00000232400.1	RAD17P1	-3.78	0.000168	0.00979	-0.13	-0.12	Residual cognition;	chr7:16917402	chr7:16864267~16866308:-
BRCA	cis	rs4948275	0.624	rs2606119	ENSG00000237233.2	TMEM26-AS1	-3.78	0.000168	0.00979	-0.14	-0.12	Night sleep phenotypes;	chr10:61597149	chr10:61452639~61481956:+
BRCA	cis	rs4664293	0.647	rs1425042	ENSG00000224152.1	AC009506.1	-3.78	0.000168	0.00979	-0.12	-0.12	Monocyte percentage of white cells;	chr2:159584004	chr2:159615296~159617082:+
BRCA	cis	rs4664293	0.647	rs7562850	ENSG00000224152.1	AC009506.1	-3.78	0.000168	0.00979	-0.12	-0.12	Monocyte percentage of white cells;	chr2:159585023	chr2:159615296~159617082:+
BRCA	cis	rs1371614	0.655	rs4665927	ENSG00000229122.1	AGBL5-IT1	-3.78	0.000168	0.00979	-0.12	-0.12	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26926498	chr2:27061038~27061815:+
BRCA	cis	rs6545883	0.931	rs12713437	ENSG00000270820.4	RP11-355B11.2	3.78	0.000168	0.0098	0.13	0.12	Tuberculosis;	chr2:61495769	chr2:61471188~61484130:+
BRCA	cis	rs6750047	0.771	rs1056837	ENSG00000235848.3	RMDN2-AS1	-3.78	0.000168	0.0098	-0.15	-0.12	Cutaneous malignant melanoma;Melanoma;	chr2:38071007	chr2:37949911~38067041:-
BRCA	cis	rs12681366	0.708	rs1813167	ENSG00000253704.1	RP11-267M23.4	-3.78	0.000168	0.0098	-0.12	-0.12	Nonsyndromic cleft lip with cleft palate;	chr8:94336525	chr8:94553722~94569745:+
BRCA	cis	rs1005277	0.522	rs289647	ENSG00000099251.13	HSD17B7P2	3.78	0.000168	0.0098	0.13	0.12	Extrinsic epigenetic age acceleration;	chr10:37679350	chr10:38356380~38378505:+
BRCA	cis	rs10463316	0.894	rs4099168	ENSG00000260581.1	CTB-113P19.4	3.78	0.000168	0.0098	0.14	0.12	Metabolite levels (Pyroglutamine);	chr5:151386906	chr5:151652275~151655449:+
BRCA	cis	rs10463316	0.894	rs4099170	ENSG00000260581.1	CTB-113P19.4	3.78	0.000168	0.0098	0.14	0.12	Metabolite levels (Pyroglutamine);	chr5:151387022	chr5:151652275~151655449:+
BRCA	cis	rs10463316	0.894	rs4099171	ENSG00000260581.1	CTB-113P19.4	3.78	0.000168	0.0098	0.14	0.12	Metabolite levels (Pyroglutamine);	chr5:151387062	chr5:151652275~151655449:+
BRCA	cis	rs10463316	0.894	rs7727770	ENSG00000260581.1	CTB-113P19.4	3.78	0.000168	0.0098	0.14	0.12	Metabolite levels (Pyroglutamine);	chr5:151387555	chr5:151652275~151655449:+
BRCA	cis	rs10463316	0.894	rs7727926	ENSG00000260581.1	CTB-113P19.4	3.78	0.000168	0.0098	0.14	0.12	Metabolite levels (Pyroglutamine);	chr5:151387655	chr5:151652275~151655449:+
BRCA	cis	rs10463316	0.894	rs7710277	ENSG00000260581.1	CTB-113P19.4	3.78	0.000168	0.0098	0.14	0.12	Metabolite levels (Pyroglutamine);	chr5:151387844	chr5:151652275~151655449:+
BRCA	cis	rs4916588	0.697	rs6796963	ENSG00000230732.4	AC127904.2	3.78	0.000168	0.0098	0.15	0.12	Night sleep phenotypes;	chr3:196935404	chr3:196912646~196914579:+
BRCA	cis	rs875971	0.545	rs75577046	ENSG00000232559.3	GS1-124K5.12	3.78	0.000168	0.0098	0.16	0.12	Aortic root size;	chr7:66493729	chr7:66554588~66576923:-
BRCA	cis	rs6142618	0.562	rs2235898	ENSG00000277692.1	RP11-358N2.2	-3.78	0.000168	0.0098	-0.13	-0.12	Inflammatory bowel disease;	chr20:32131259	chr20:32355053~32355734:+
BRCA	cis	rs6142618	0.562	rs2235899	ENSG00000277692.1	RP11-358N2.2	-3.78	0.000168	0.0098	-0.13	-0.12	Inflammatory bowel disease;	chr20:32131732	chr20:32355053~32355734:+
BRCA	cis	rs6142618	0.562	rs2235901	ENSG00000277692.1	RP11-358N2.2	-3.78	0.000168	0.0098	-0.13	-0.12	Inflammatory bowel disease;	chr20:32132233	chr20:32355053~32355734:+
BRCA	cis	rs7800418	0.775	rs3948698	ENSG00000214870.7	AC004540.5	3.78	0.000168	0.0098	0.14	0.12	Cognitive function;	chr7:26561044	chr7:26398593~26494256:+
BRCA	cis	rs875971	0.505	rs1723275	ENSG00000232546.1	RP11-458F8.1	3.78	0.000168	0.00981	0.1	0.12	Aortic root size;	chr7:66039646	chr7:66848496~66858136:+
BRCA	cis	rs970548	0.954	rs11239571	ENSG00000237840.5	FAM21FP	-3.78	0.000168	0.00981	-0.15	-0.12	Total cholesterol levels;HDL cholesterol;HDL cholesterol levels;Cholesterol, total;	chr10:45592444	chr10:45706431~45727231:-
BRCA	cis	rs1005277	0.579	rs1780136	ENSG00000272983.1	RP11-508N22.12	3.78	0.000168	0.00981	0.12	0.12	Extrinsic epigenetic age acceleration;	chr10:38212525	chr10:38137337~38144399:+
BRCA	cis	rs1005277	0.579	rs1780138	ENSG00000272983.1	RP11-508N22.12	3.78	0.000168	0.00981	0.12	0.12	Extrinsic epigenetic age acceleration;	chr10:38212726	chr10:38137337~38144399:+
BRCA	cis	rs1005277	0.579	rs1780139	ENSG00000272983.1	RP11-508N22.12	3.78	0.000168	0.00981	0.12	0.12	Extrinsic epigenetic age acceleration;	chr10:38214090	chr10:38137337~38144399:+
BRCA	cis	rs1005277	0.602	rs1780141	ENSG00000272983.1	RP11-508N22.12	3.78	0.000168	0.00981	0.12	0.12	Extrinsic epigenetic age acceleration;	chr10:38215371	chr10:38137337~38144399:+
BRCA	cis	rs4664293	0.903	rs10185155	ENSG00000224152.1	AC009506.1	-3.78	0.000168	0.00981	-0.13	-0.12	Monocyte percentage of white cells;	chr2:159696717	chr2:159615296~159617082:+
BRCA	cis	rs11098499	0.874	rs13123591	ENSG00000260091.1	RP11-33B1.4	-3.78	0.000168	0.00981	-0.11	-0.12	Corneal astigmatism;	chr4:119184835	chr4:119409333~119410233:+
BRCA	cis	rs11158026	0.603	rs4335711	ENSG00000233924.1	AL160471.6	-3.78	0.000168	0.00981	-0.14	-0.12	Parkinson's disease;	chr14:55004145	chr14:55004813~55005687:-
BRCA	cis	rs12644436	0.628	rs1381961	ENSG00000249001.4	RP11-742B18.1	3.78	0.000168	0.00981	0.14	0.12	HIV-1 viral setpoint;	chr4:87881306	chr4:87568035~87733956:-
BRCA	cis	rs7312933	0.51	rs61942483	ENSG00000257376.1	RP11-328C8.2	-3.78	0.000168	0.00981	-0.14	-0.12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42105736	chr12:42431665~42433357:-
BRCA	cis	rs739401	0.611	rs2071104	ENSG00000247473.2	CARS-AS1	3.78	0.000168	0.00981	0.13	0.12	Longevity;	chr11:3015703	chr11:3029009~3041260:+
BRCA	cis	rs4218	0.681	rs7178935	ENSG00000259732.1	RP11-59H7.3	-3.78	0.000168	0.00981	-0.14	-0.12	Social communication problems;	chr15:59075968	chr15:59121034~59133250:+
BRCA	cis	rs875971	1	rs7792762	ENSG00000265600.1	AC006480.1	-3.78	0.000168	0.00981	-0.14	-0.12	Aortic root size;	chr7:66539151	chr7:67356680~67356779:+
BRCA	cis	rs10844706	0.699	rs10844626	ENSG00000256673.1	RP11-599J14.2	-3.78	0.000168	0.00981	-0.14	-0.12	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9733757	chr12:9398355~9414851:-
BRCA	cis	rs853679	0.517	rs1340004	ENSG00000216901.1	AL022393.7	3.78	0.000168	0.00981	0.17	0.12	Depression;	chr6:28135913	chr6:28176188~28176674:+
BRCA	cis	rs6064559	0.664	rs4810084	ENSG00000218018.2	RP4-800J21.3	-3.78	0.000168	0.00981	-0.1	-0.12	Hemoglobin concentration;	chr20:57547582	chr20:57384160~57393062:-
BRCA	cis	rs2391285	0.609	rs6959391	ENSG00000214870.7	AC004540.5	3.78	0.000168	0.00981	0.17	0.12	Post bronchodilator FEV1/FVC ratio;	chr7:26552676	chr7:26398593~26494256:+
BRCA	cis	rs7267979	0.868	rs6138550	ENSG00000274414.1	RP5-965G21.4	-3.78	0.000168	0.00981	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25242794	chr20:25239007~25245229:-
BRCA	cis	rs62025270	0.547	rs338536	ENSG00000259762.1	RP11-158M2.4	-3.78	0.000168	0.00982	-0.14	-0.12	Idiopathic pulmonary fibrosis;	chr15:85654009	chr15:85750336~85752901:-
BRCA	cis	rs11673344	0.566	rs11666708	ENSG00000267422.1	CTD-2554C21.1	-3.78	0.000168	0.00982	-0.15	-0.12	Obesity-related traits;	chr19:37396208	chr19:37779686~37792865:+
BRCA	cis	rs7267979	0.966	rs6037083	ENSG00000125804.12	FAM182A	3.78	0.000168	0.00982	0.15	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25309907	chr20:26054655~26086917:+
BRCA	cis	rs4664293	0.647	rs357022	ENSG00000226266.5	AC009961.3	-3.78	0.000168	0.00982	-0.14	-0.12	Monocyte percentage of white cells;	chr2:159632933	chr2:159670708~159712435:-
BRCA	cis	rs8049367	0.684	rs759275	ENSG00000267077.1	RP11-127I20.5	3.78	0.000168	0.00982	0.12	0.12	Nonsyndromic cleft lip with or without cleft palate;	chr16:3917540	chr16:4795265~4796532:-
BRCA	cis	rs12760731	0.641	rs12038910	ENSG00000213057.5	C1orf220	3.78	0.000168	0.00982	0.15	0.12	Obesity-related traits;	chr1:178475772	chr1:178542752~178548889:+
BRCA	cis	rs7824557	0.872	rs2572417	ENSG00000255046.1	RP11-297N6.4	3.78	0.000168	0.00982	0.13	0.12	Retinal vascular caliber;	chr8:11253953	chr8:11797928~11802568:-
BRCA	cis	rs6964587	0.934	rs73226382	ENSG00000188693.7	CYP51A1-AS1	-3.78	0.000168	0.00982	-0.12	-0.12	Breast cancer;	chr7:92063446	chr7:92134604~92180725:+
BRCA	cis	rs13393800	0.562	rs12620925	ENSG00000237126.7	AC073254.1	-3.78	0.000168	0.00983	-0.15	-0.12	Height;	chr2:232586110	chr2:232580948~232611971:-
BRCA	cis	rs13393800	0.605	rs12617649	ENSG00000237126.7	AC073254.1	-3.78	0.000168	0.00983	-0.15	-0.12	Height;	chr2:232586114	chr2:232580948~232611971:-
BRCA	cis	rs983392	0.792	rs510518	ENSG00000275344.1	MIR6503	-3.78	0.000168	0.00983	-0.12	-0.12	Alzheimer's disease (late onset);	chr11:60139624	chr11:60209071~60209156:-
BRCA	cis	rs6064559	0.687	rs4811875	ENSG00000218018.2	RP4-800J21.3	-3.78	0.000168	0.00983	-0.1	-0.12	Hemoglobin concentration;	chr20:57546774	chr20:57384160~57393062:-
BRCA	cis	rs7954584	0.52	rs1169095	ENSG00000274292.1	RP11-347I19.7	3.78	0.000168	0.00983	0.1	0.12	Mean corpuscular volume;	chr12:122027832	chr12:121800797~121803403:+
BRCA	cis	rs6840360	0.571	rs6811676	ENSG00000278978.1	RP11-164P12.5	-3.78	0.000168	0.00983	-0.14	-0.12	Intelligence (multi-trait analysis);	chr4:151641574	chr4:151669786~151670503:+
BRCA	cis	rs13256369	0.951	rs12679360	ENSG00000248538.5	RP11-10A14.5	3.78	0.000168	0.00983	0.13	0.12	Obesity-related traits;	chr8:8708759	chr8:9189011~9202854:+
BRCA	cis	rs73195822	0.667	rs73194055	ENSG00000277299.1	RP11-837J7.4	-3.78	0.000168	0.00983	-0.21	-0.12	Itch intensity from mosquito bite;	chr12:110778487	chr12:109948389~109949029:+
BRCA	cis	rs6596100	0.915	rs6897211	ENSG00000248648.1	RP11-485M7.1	-3.78	0.000168	0.00983	-0.14	-0.12	Breast cancer;	chr5:133072939	chr5:133003119~133003365:+
BRCA	cis	rs1836229	0.839	rs10758996	ENSG00000225706.1	PTPRD-AS1	-3.78	0.000168	0.00983	-0.13	-0.12	Restless legs syndrome;	chr9:8827077	chr9:8858130~8862255:+
BRCA	cis	rs61931739	0.5	rs7306334	ENSG00000258794.3	DUX4L27	-3.78	0.000168	0.00983	-0.17	-0.12	Morning vs. evening chronotype;	chr12:34329965	chr12:34208415~34209675:-
BRCA	cis	rs8058578	1	rs2289442	ENSG00000274678.1	RP11-2C24.7	3.78	0.000168	0.00983	0.14	0.12	Multiple myeloma;	chr16:30728598	chr16:30821338~30821884:+
BRCA	cis	rs16922576	0.64	rs12343727	ENSG00000236254.1	MTND4P14	-3.78	0.000168	0.00983	-0.13	-0.12	Allergic disease (asthma, hay fever or eczema);	chr9:5215926	chr9:5107937~5109290:+
BRCA	cis	rs801193	0.569	rs881285	ENSG00000229886.1	RP5-1132H15.3	-3.78	0.000168	0.00983	-0.13	-0.12	Aortic root size;	chr7:66654433	chr7:66025126~66031544:-
BRCA	cis	rs10043228	1	rs17138917	ENSG00000271918.1	CTD-2287O16.5	-3.78	0.000168	0.00983	-0.15	-0.12	Asthma or chronic obstructive pulmonary disease;	chr5:116133619	chr5:116083807~116085416:-
BRCA	cis	rs75422866	0.541	rs12425816	ENSG00000280054.1	RP1-197B17.7	3.78	0.000169	0.00983	0.28	0.12	Pneumonia;	chr12:47731419	chr12:47728151~47730598:-
BRCA	cis	rs7487075	0.619	rs4768725	ENSG00000257261.4	RP11-96H19.1	3.78	0.000169	0.00983	0.13	0.12	Itch intensity from mosquito bite;	chr12:46454695	chr12:46383679~46876159:+
BRCA	cis	rs66887589	0.777	rs1814815	ENSG00000260404.2	RP11-384K6.6	3.78	0.000169	0.00984	0.1	0.12	Diastolic blood pressure;	chr4:119336936	chr4:118591773~118633729:+
BRCA	cis	rs1048886	0.872	rs79128960	ENSG00000271967.1	RP11-134K13.4	-3.78	0.000169	0.00984	-0.18	-0.12	Type 2 diabetes;	chr6:70425140	chr6:70596438~70596980:+
BRCA	cis	rs2835872	0.698	rs2898318	ENSG00000228677.1	TTC3-AS1	-3.78	0.000169	0.00984	-0.15	-0.12	Electroencephalographic traits in alcoholism;	chr21:37614388	chr21:37187666~37193926:-
BRCA	cis	rs7267979	0.966	rs6083817	ENSG00000204556.4	CTD-2514C3.1	3.78	0.000169	0.00984	0.16	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25363362	chr20:26018832~26020684:+
BRCA	cis	rs7267979	1	rs6050564	ENSG00000204556.4	CTD-2514C3.1	3.78	0.000169	0.00984	0.16	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25363595	chr20:26018832~26020684:+
BRCA	cis	rs244293	0.76	rs8069447	ENSG00000275710.1	RP11-257O5.4	3.78	0.000169	0.00984	0.12	0.12	Menarche (age at onset);	chr17:54931512	chr17:54964474~54964679:+
BRCA	cis	rs7267979	1	rs4815412	ENSG00000276952.1	RP5-965G21.6	3.78	0.000169	0.00984	0.14	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25369689	chr20:25284915~25285588:-
BRCA	cis	rs6964587	0.967	rs6970743	ENSG00000188693.7	CYP51A1-AS1	-3.78	0.000169	0.00984	-0.13	-0.12	Breast cancer;	chr7:92114997	chr7:92134604~92180725:+
BRCA	cis	rs875971	0.619	rs2302918	ENSG00000223473.2	GS1-124K5.3	3.78	0.000169	0.00984	0.09	0.12	Aortic root size;	chr7:66535945	chr7:66491049~66493566:-
BRCA	cis	rs7680126	0.596	rs10022911	ENSG00000250413.1	RP11-448G15.1	3.78	0.000169	0.00984	0.19	0.12	Urate levels in obese individuals;Urate levels in lean individuals;Urate levels in overweight individuals;	chr4:10138927	chr4:10006482~10009725:+
BRCA	cis	rs11673344	0.523	rs7246739	ENSG00000276846.1	CTD-3220F14.3	3.78	0.000169	0.00984	0.14	0.12	Obesity-related traits;	chr19:37040829	chr19:37314868~37315620:-
BRCA	cis	rs7506045	1	rs7506045	ENSG00000267199.1	RP11-861E21.2	3.78	0.000169	0.00984	0.18	0.12	Stroke;	chr18:11987273	chr18:12438890~12448205:+
BRCA	cis	rs2274459	1	rs66670017	ENSG00000249346.5	LINC01016	3.78	0.000169	0.00985	0.16	0.12	Obesity (extreme);	chr6:33795786	chr6:33867506~33896914:-
BRCA	cis	rs8180040	0.805	rs17410853	ENSG00000271161.1	BOLA2P2	-3.78	0.000169	0.00985	-0.13	-0.12	Colorectal cancer;	chr3:47322481	chr3:47499841~47500407:+
BRCA	cis	rs2976388	0.609	rs2376491	ENSG00000253196.1	RP11-706C16.7	3.78	0.000169	0.00985	0.11	0.12	Urinary tract infection frequency;	chr8:142709516	chr8:142763116~142766427:+
BRCA	cis	rs9925964	0.967	rs12716981	ENSG00000260911.2	RP11-196G11.2	-3.78	0.000169	0.00985	-0.11	-0.12	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31106703	chr16:31043150~31049868:+
BRCA	cis	rs863345	0.604	rs10908654	ENSG00000229914.1	RP11-404O13.4	-3.78	0.000169	0.00985	-0.12	-0.12	Pneumococcal bacteremia;	chr1:158486000	chr1:158195633~158196131:-
BRCA	cis	rs1005277	0.522	rs289649	ENSG00000226578.1	RP11-258F22.1	-3.78	0.000169	0.00985	-0.12	-0.12	Extrinsic epigenetic age acceleration;	chr10:37686456	chr10:37775371~37784131:-
BRCA	cis	rs3764563	1	rs11673070	ENSG00000267594.5	CYP4F24P	-3.78	0.000169	0.00985	-0.21	-0.12	Inflammatory biomarkers;	chr19:15635285	chr19:15760241~15779909:-
BRCA	cis	rs77633900	0.772	rs284901	ENSG00000196274.5	Metazoa_SRP	3.78	0.000169	0.00985	0.21	0.12	Glioma;Non-glioblastoma glioma;	chr15:76455420	chr15:76230048~76230390:-
BRCA	cis	rs7267979	0.966	rs3827014	ENSG00000274414.1	RP5-965G21.4	3.78	0.000169	0.00985	0.14	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25390923	chr20:25239007~25245229:-
BRCA	cis	rs74233809	1	rs12219901	ENSG00000236937.2	PTGES3P4	3.78	0.000169	0.00986	0.25	0.12	Birth weight;	chr10:103081210	chr10:102845595~102845950:+
BRCA	cis	rs74233809	1	rs10458729	ENSG00000236937.2	PTGES3P4	3.78	0.000169	0.00986	0.25	0.12	Birth weight;	chr10:103081722	chr10:102845595~102845950:+
BRCA	cis	rs669446	0.591	rs617521	ENSG00000236200.4	KDM4A-AS1	-3.78	0.000169	0.00986	-0.14	-0.12	Amyotrophic lateral sclerosis (age of onset);	chr1:43648528	chr1:43699765~43708138:-
BRCA	cis	rs62244186	0.714	rs2293600	ENSG00000227123.1	RPL12P44	-3.78	0.000169	0.00986	-0.13	-0.12	Depressive symptoms;	chr3:44557611	chr3:44937673~44938482:+
BRCA	cis	rs2411233	0.935	rs11855883	ENSG00000259278.1	RP11-62C7.2	3.78	0.000169	0.00986	0.14	0.12	Platelet count;	chr15:38977447	chr15:39019233~39024918:+
BRCA	cis	rs2411233	0.935	rs11855913	ENSG00000259278.1	RP11-62C7.2	3.78	0.000169	0.00986	0.14	0.12	Platelet count;	chr15:38977448	chr15:39019233~39024918:+
BRCA	cis	rs35306767	0.859	rs11817793	ENSG00000229869.1	RP11-363N22.2	-3.78	0.000169	0.00986	-0.17	-0.12	Eosinophil percentage of granulocytes;	chr10:832955	chr10:933026~942743:+
BRCA	cis	rs7615952	0.512	rs4679430	ENSG00000241288.6	RP11-379B18.5	-3.77	0.000169	0.00986	-0.15	-0.12	Blood pressure (smoking interaction);	chr3:125639049	chr3:125827238~125916384:-
BRCA	cis	rs7615952	0.512	rs34651730	ENSG00000241288.6	RP11-379B18.5	-3.77	0.000169	0.00986	-0.15	-0.12	Blood pressure (smoking interaction);	chr3:125639796	chr3:125827238~125916384:-
BRCA	cis	rs7615952	0.512	rs11929125	ENSG00000241288.6	RP11-379B18.5	-3.77	0.000169	0.00986	-0.15	-0.12	Blood pressure (smoking interaction);	chr3:125640599	chr3:125827238~125916384:-
BRCA	cis	rs7615952	0.512	rs2922175	ENSG00000241288.6	RP11-379B18.5	-3.77	0.000169	0.00986	-0.15	-0.12	Blood pressure (smoking interaction);	chr3:125642516	chr3:125827238~125916384:-
BRCA	cis	rs1039766	1	rs268861	ENSG00000227791.3	AC007365.4	-3.77	0.000169	0.00986	-0.18	-0.12	Lung adenocarcinoma;Lung cancer;	chr2:65261026	chr2:64665607~64666064:+
BRCA	cis	rs11711311	0.911	rs3773681	ENSG00000241529.3	RN7SL767P	-3.77	0.000169	0.00986	-0.14	-0.12	IgG glycosylation;	chr3:113805054	chr3:113632704~113632998:+
BRCA	cis	rs11711311	1	rs12637066	ENSG00000241529.3	RN7SL767P	-3.77	0.000169	0.00986	-0.14	-0.12	IgG glycosylation;	chr3:113808727	chr3:113632704~113632998:+
BRCA	cis	rs11168618	0.74	rs4523733	ENSG00000240399.1	RP1-228P16.1	-3.77	0.000169	0.00986	-0.12	-0.12	Adiponectin levels;	chr12:48533731	chr12:48054813~48055591:-
BRCA	cis	rs11098499	0.909	rs1546504	ENSG00000260091.1	RP11-33B1.4	-3.77	0.000169	0.00986	-0.1	-0.12	Corneal astigmatism;	chr4:119320024	chr4:119409333~119410233:+
BRCA	cis	rs10766496	0.673	rs61886891	ENSG00000257043.1	RP11-137N23.1	3.77	0.000169	0.00986	0.2	0.12	Diabetic kidney disease;	chr11:18716782	chr11:18665050~18665548:+
BRCA	cis	rs6964587	1	rs6951972	ENSG00000188693.7	CYP51A1-AS1	-3.77	0.000169	0.00986	-0.12	-0.12	Breast cancer;	chr7:92060132	chr7:92134604~92180725:+
BRCA	cis	rs6964587	1	rs6969981	ENSG00000188693.7	CYP51A1-AS1	-3.77	0.000169	0.00986	-0.12	-0.12	Breast cancer;	chr7:92060147	chr7:92134604~92180725:+
BRCA	cis	rs6964587	1	rs56072181	ENSG00000188693.7	CYP51A1-AS1	-3.77	0.000169	0.00986	-0.12	-0.12	Breast cancer;	chr7:92061143	chr7:92134604~92180725:+
BRCA	cis	rs6964587	1	rs10236397	ENSG00000188693.7	CYP51A1-AS1	-3.77	0.000169	0.00986	-0.12	-0.12	Breast cancer;	chr7:92062287	chr7:92134604~92180725:+
BRCA	cis	rs6964587	1	rs11981461	ENSG00000188693.7	CYP51A1-AS1	-3.77	0.000169	0.00986	-0.12	-0.12	Breast cancer;	chr7:92063348	chr7:92134604~92180725:+
BRCA	cis	rs875971	0.862	rs6460306	ENSG00000229886.1	RP5-1132H15.3	-3.77	0.000169	0.00986	-0.13	-0.12	Aortic root size;	chr7:66595806	chr7:66025126~66031544:-
BRCA	cis	rs687432	0.748	rs6591450	ENSG00000213592.4	AP000662.9	-3.77	0.000169	0.00987	-0.15	-0.12	Parkinson's disease;	chr11:58022958	chr11:57718044~57718530:-
BRCA	cis	rs875971	0.66	rs801211	ENSG00000275400.1	RP4-756H11.5	3.77	0.000169	0.00987	0.13	0.12	Aortic root size;	chr7:66550702	chr7:66553805~66554199:-
BRCA	cis	rs875971	0.638	rs801205	ENSG00000275400.1	RP4-756H11.5	3.77	0.000169	0.00987	0.13	0.12	Aortic root size;	chr7:66557157	chr7:66553805~66554199:-
BRCA	cis	rs875971	0.617	rs810400	ENSG00000275400.1	RP4-756H11.5	3.77	0.000169	0.00987	0.13	0.12	Aortic root size;	chr7:66557902	chr7:66553805~66554199:-
BRCA	cis	rs4803480	0.543	rs7257282	ENSG00000269800.1	PLEKHA3P1	-3.77	0.000169	0.00987	-0.15	-0.12	Schizophrenia;	chr19:41536585	chr19:41521043~41521989:-
BRCA	cis	rs250567	0.581	rs461494	ENSG00000260136.4	CTD-2270L9.4	3.77	0.000169	0.00987	0.16	0.12	Total cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:23597128	chr16:23452758~23457606:+
BRCA	cis	rs4819052	0.851	rs28442024	ENSG00000215447.6	BX322557.10	-3.77	0.000169	0.00987	-0.12	-0.12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45254560	chr21:45288052~45291738:+
BRCA	cis	rs11671653	1	rs76291634	ENSG00000267100.1	ILF3-AS1	3.77	0.000169	0.00987	0.18	0.12	LDL cholesterol;	chr19:10725869	chr19:10651862~10653844:-
BRCA	cis	rs7267979	1	rs4815406	ENSG00000204556.4	CTD-2514C3.1	3.77	0.000169	0.00987	0.16	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25360680	chr20:26018832~26020684:+
BRCA	cis	rs12468226	1	rs112306637	ENSG00000272966.1	RP11-686O6.1	3.77	0.000169	0.00987	0.19	0.12	Urate levels;	chr2:202334195	chr2:202336739~202337200:+
BRCA	cis	rs55780018	0.645	rs7591784	ENSG00000224137.1	AC079767.4	3.77	0.000169	0.00987	0.09	0.12	Systolic blood pressure;	chr2:207637006	chr2:207662375~207667024:+
BRCA	cis	rs4478858	0.735	rs6679393	ENSG00000260386.4	LINC01225	-3.77	0.000169	0.00987	-0.14	-0.12	Alcohol dependence;	chr1:31298097	chr1:31500085~31540885:+
BRCA	cis	rs11773103	0.867	rs11767948	ENSG00000224046.1	AC005076.5	3.77	0.000169	0.00987	0.24	0.12	Bipolar disorder or major depressive disorder (combined);	chr7:87352875	chr7:87151423~87152420:-
BRCA	cis	rs747650	0.504	rs7124648	ENSG00000200376.1	RNU5E-10P	3.77	0.000169	0.00987	0.15	0.12	Acne (severe);	chr11:47022698	chr11:47576471~47576588:-
BRCA	cis	rs997295	0.513	rs11635495	ENSG00000259673.4	IQCH-AS1	3.77	0.000169	0.00987	0.13	0.12	Motion sickness;	chr15:67512344	chr15:67403619~67521844:-
BRCA	cis	rs896655	0.631	rs1345024	ENSG00000229298.1	TUBB8P1	3.77	0.000169	0.00987	0.12	0.12	Coronary artery disease;	chr9:21785019	chr9:21811621~21812347:-
BRCA	cis	rs9925964	0.967	rs2855475	ENSG00000260911.2	RP11-196G11.2	3.77	0.000169	0.00987	0.11	0.12	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31136227	chr16:31043150~31049868:+
BRCA	cis	rs16917546	0.935	rs12766391	ENSG00000238280.1	RP11-436D10.3	3.77	0.000169	0.00987	0.16	0.12	Basal cell carcinoma;	chr10:62681444	chr10:62793562~62805887:-
BRCA	cis	rs6847067	0.86	rs11735449	ENSG00000180769.7	WDFY3-AS2	3.77	0.000169	0.00987	0.11	0.12	Oropharynx cancer;	chr4:84654230	chr4:84965682~85011277:+
BRCA	cis	rs78545713	0.536	rs2179516	ENSG00000241549.7	GUSBP2	-3.77	0.000169	0.00987	-0.2	-0.12	Iron status biomarkers (total iron binding capacity);	chr6:26229183	chr6:26871484~26956554:-
BRCA	cis	rs465969	1	rs17090837	ENSG00000271789.1	RP5-1112D6.7	3.77	0.000169	0.00987	0.28	0.12	Psoriasis;	chr6:111430650	chr6:111297126~111298510:+
BRCA	cis	rs465969	1	rs35208445	ENSG00000271789.1	RP5-1112D6.7	3.77	0.000169	0.00987	0.28	0.12	Psoriasis;	chr6:111434944	chr6:111297126~111298510:+
BRCA	cis	rs465969	1	rs35248830	ENSG00000271789.1	RP5-1112D6.7	3.77	0.000169	0.00987	0.28	0.12	Psoriasis;	chr6:111435547	chr6:111297126~111298510:+
BRCA	cis	rs465969	1	rs35151650	ENSG00000271789.1	RP5-1112D6.7	3.77	0.000169	0.00987	0.28	0.12	Psoriasis;	chr6:111436524	chr6:111297126~111298510:+
BRCA	cis	rs465969	0.744	rs34089926	ENSG00000271789.1	RP5-1112D6.7	3.77	0.000169	0.00987	0.28	0.12	Psoriasis;	chr6:111439043	chr6:111297126~111298510:+
BRCA	cis	rs465969	1	rs4580915	ENSG00000271789.1	RP5-1112D6.7	3.77	0.000169	0.00987	0.28	0.12	Psoriasis;	chr6:111439561	chr6:111297126~111298510:+
BRCA	cis	rs9437689	1	rs11591183	ENSG00000235501.4	RP4-639F20.1	3.77	0.000169	0.00987	0.15	0.12	Phospholipid levels (plasma);	chr1:95096150	chr1:94927566~94963270:+
BRCA	cis	rs7267979	1	rs6515651	ENSG00000274414.1	RP5-965G21.4	3.77	0.000169	0.00987	0.14	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25433903	chr20:25239007~25245229:-
BRCA	cis	rs78472555	0.661	rs77228427	ENSG00000259363.4	CTD-2054N24.2	-3.77	0.000169	0.00988	-0.16	-0.12	Post bronchodilator FEV1/FVC ratio in COPD;	chr15:99616153	chr15:99807023~99877148:+
BRCA	cis	rs12887734	0.566	rs8548	ENSG00000269958.1	RP11-73M18.8	3.77	0.000169	0.00988	0.14	0.12	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103733243	chr14:103696353~103697163:+
BRCA	cis	rs1552172	0.853	rs2004659	ENSG00000234222.5	RP11-315I20.1	-3.77	0.000169	0.00988	-0.14	-0.12	Breast cancer;	chr1:145846884	chr1:145926590~145959179:+
BRCA	cis	rs6964587	0.967	rs2282969	ENSG00000188693.7	CYP51A1-AS1	3.77	0.000169	0.00988	0.13	0.12	Breast cancer;	chr7:91954458	chr7:92134604~92180725:+
BRCA	cis	rs1670533	0.932	rs13108207	ENSG00000251639.2	RP11-20I20.1	3.77	0.000169	0.00988	0.18	0.12	Recombination rate (females);	chr4:1060430	chr4:1100016~1101558:-
BRCA	cis	rs7020830	0.894	rs13300951	ENSG00000260100.1	RP11-220I1.5	-3.77	0.000169	0.00988	-0.14	-0.12	Schizophrenia;	chr9:37146630	chr9:37078813~37079776:-
BRCA	cis	rs61160187	0.576	rs10805374	ENSG00000272308.1	RP11-231G3.1	-3.77	0.000169	0.00988	-0.13	-0.12	Educational attainment (years of education);Educational attainment (college completion);	chr5:61004078	chr5:60866457~60866935:-
BRCA	cis	rs13272568	0.614	rs6989005	ENSG00000254352.1	RP11-578O24.2	-3.77	0.00017	0.00988	-0.15	-0.12	Bone mineral density;	chr8:78138843	chr8:78723796~78724136:-
BRCA	cis	rs4449834	0.851	rs7017676	ENSG00000254432.1	RP11-33I11.2	-3.77	0.00017	0.00988	-0.15	-0.12	Sum eosinophil basophil counts;	chr8:60778801	chr8:60808735~60809606:-
BRCA	cis	rs7618915	1	rs34569561	ENSG00000239557.1	RP11-168J18.6	3.77	0.00017	0.00988	0.15	0.12	Bipolar disorder;	chr3:52253277	chr3:52373652~52374882:+
BRCA	cis	rs7267979	1	rs2424716	ENSG00000274414.1	RP5-965G21.4	-3.77	0.00017	0.00988	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25442902	chr20:25239007~25245229:-
BRCA	cis	rs7267979	1	rs761025	ENSG00000274414.1	RP5-965G21.4	-3.77	0.00017	0.00988	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25446332	chr20:25239007~25245229:-
BRCA	cis	rs9437689	0.531	rs859042	ENSG00000235501.4	RP4-639F20.1	3.77	0.00017	0.00989	0.15	0.12	Phospholipid levels (plasma);	chr1:94918041	chr1:94927566~94963270:+
BRCA	cis	rs5758511	0.773	rs8140869	ENSG00000231261.1	HMGN2P10	3.77	0.00017	0.00989	0.15	0.12	Birth weight;	chr22:41948293	chr22:41709225~41709489:-
BRCA	cis	rs7267979	0.966	rs2387882	ENSG00000276952.1	RP5-965G21.6	-3.77	0.00017	0.00989	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25398166	chr20:25284915~25285588:-
BRCA	cis	rs12468226	0.938	rs80315897	ENSG00000272966.1	RP11-686O6.1	3.77	0.00017	0.00989	0.2	0.12	Urate levels;	chr2:202318044	chr2:202336739~202337200:+
BRCA	cis	rs3796352	1	rs1346719	ENSG00000242142.1	SERBP1P3	-3.77	0.00017	0.00989	-0.19	-0.12	Immune reponse to smallpox (secreted IL-2);	chr3:53043356	chr3:53064283~53065091:-
BRCA	cis	rs10043228	1	rs62385980	ENSG00000271918.1	CTD-2287O16.5	-3.77	0.00017	0.00989	-0.17	-0.12	Asthma or chronic obstructive pulmonary disease;	chr5:116257211	chr5:116083807~116085416:-
BRCA	cis	rs6840360	0.571	rs1822346	ENSG00000270265.1	RP11-731D1.4	-3.77	0.00017	0.00989	-0.14	-0.12	Intelligence (multi-trait analysis);	chr4:151604151	chr4:151333775~151353224:-
BRCA	cis	rs6840360	0.571	rs1822347	ENSG00000270265.1	RP11-731D1.4	-3.77	0.00017	0.00989	-0.14	-0.12	Intelligence (multi-trait analysis);	chr4:151604167	chr4:151333775~151353224:-
BRCA	cis	rs6840360	0.571	rs4696272	ENSG00000270265.1	RP11-731D1.4	-3.77	0.00017	0.00989	-0.14	-0.12	Intelligence (multi-trait analysis);	chr4:151607077	chr4:151333775~151353224:-
BRCA	cis	rs10463316	0.894	rs7723379	ENSG00000260581.1	CTB-113P19.4	3.77	0.00017	0.00989	0.14	0.12	Metabolite levels (Pyroglutamine);	chr5:151385464	chr5:151652275~151655449:+
BRCA	cis	rs801193	0.66	rs10950049	ENSG00000273448.1	RP11-166O4.6	3.77	0.00017	0.00989	0.11	0.12	Aortic root size;	chr7:66765873	chr7:67333047~67334383:+
BRCA	cis	rs4834770	1	rs4834770	ENSG00000178636.7	RP11-455G16.1	-3.77	0.00017	0.00989	-0.14	-0.12	Blood protein levels;	chr4:119320694	chr4:119192773~119212644:-
BRCA	cis	rs11098499	0.866	rs12501602	ENSG00000260404.2	RP11-384K6.6	3.77	0.00017	0.00989	0.11	0.12	Corneal astigmatism;	chr4:119366780	chr4:118591773~118633729:+
BRCA	cis	rs6088590	0.71	rs6059992	ENSG00000276073.1	RP5-1125A11.7	-3.77	0.00017	0.00989	-0.13	-0.12	Coronary artery disease;	chr20:34694471	chr20:33985617~33988989:-
BRCA	cis	rs7735319	0.966	rs7709083	ENSG00000249572.1	CTD-2203K17.1	3.77	0.00017	0.0099	0.15	0.12	Systolic blood pressure;	chr5:33159470	chr5:33424025~33440619:-
BRCA	cis	rs9470794	1	rs11753160	ENSG00000204110.6	RP1-153P14.8	-3.77	0.00017	0.0099	-0.18	-0.12	Type 2 diabetes;	chr6:38161042	chr6:37507348~37535616:+
BRCA	cis	rs6545883	0.899	rs12473030	ENSG00000212978.6	AC016747.3	3.77	0.00017	0.0099	0.16	0.12	Tuberculosis;	chr2:61493362	chr2:61141592~61144969:-
BRCA	cis	rs6991838	0.584	rs7836349	ENSG00000272155.1	RP11-707M3.3	3.77	0.00017	0.0099	0.11	0.12	Intelligence (multi-trait analysis);	chr8:65591328	chr8:65714334~65714778:-
BRCA	cis	rs7615952	0.512	rs2979334	ENSG00000241288.6	RP11-379B18.5	-3.77	0.00017	0.0099	-0.15	-0.12	Blood pressure (smoking interaction);	chr3:125639980	chr3:125827238~125916384:-
BRCA	cis	rs7615952	0.512	rs11921452	ENSG00000241288.6	RP11-379B18.5	-3.77	0.00017	0.0099	-0.15	-0.12	Blood pressure (smoking interaction);	chr3:125640906	chr3:125827238~125916384:-
BRCA	cis	rs2065415	1	rs2065415	ENSG00000279810.1	RP3-495K2.4	3.77	0.00017	0.0099	0.18	0.12	Warfarin maintenance dose;	chr6:169037250	chr6:169033381~169034050:+
BRCA	cis	rs2562456	0.754	rs112195516	ENSG00000268117.1	VN1R84P	3.77	0.00017	0.0099	0.18	0.12	Pain;	chr19:21410849	chr19:21719801~21720035:-
BRCA	cis	rs859767	0.887	rs842362	ENSG00000224043.6	CCNT2-AS1	-3.77	0.00017	0.0099	-0.17	-0.12	Neuroticism;	chr2:134583550	chr2:134735464~134918710:-
BRCA	cis	rs304029	0.512	rs901871	ENSG00000231249.1	ITPR1-AS1	-3.77	0.00017	0.0099	-0.15	-0.12	Diabetic kidney disease;	chr3:4496837	chr3:4490891~4493163:-
BRCA	cis	rs304029	0.512	rs901872	ENSG00000231249.1	ITPR1-AS1	-3.77	0.00017	0.0099	-0.15	-0.12	Diabetic kidney disease;	chr3:4496857	chr3:4490891~4493163:-
BRCA	cis	rs4388249	0.95	rs34595717	ENSG00000271849.1	CTC-332L22.1	-3.77	0.00017	0.0099	-0.19	-0.12	Schizophrenia;	chr5:109777887	chr5:109687802~109688329:-
BRCA	cis	rs465969	1	rs7750803	ENSG00000271789.1	RP5-1112D6.7	-3.77	0.00017	0.0099	-0.28	-0.12	Psoriasis;	chr6:111478910	chr6:111297126~111298510:+
BRCA	cis	rs7267979	0.966	rs6083855	ENSG00000204556.4	CTD-2514C3.1	3.77	0.00017	0.0099	0.16	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25424482	chr20:26018832~26020684:+
BRCA	cis	rs7267979	1	rs4815426	ENSG00000204556.4	CTD-2514C3.1	3.77	0.00017	0.0099	0.16	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25424550	chr20:26018832~26020684:+
BRCA	cis	rs962856	0.537	rs673288	ENSG00000236780.4	AC078941.1	3.77	0.00017	0.0099	0.15	0.12	Pancreatic cancer;	chr2:67458647	chr2:67123357~67215319:-
BRCA	cis	rs1040	0.646	rs7450201	ENSG00000226445.1	XXyac-YX65C7_A.2	-3.77	0.00017	0.0099	-0.12	-0.12	Joint mobility (Beighton score);	chr6:169205497	chr6:169213254~169239565:+
BRCA	cis	rs7412746	0.658	rs6657388	ENSG00000231073.1	RP11-316M1.3	3.77	0.00017	0.0099	0.13	0.12	Melanoma;	chr1:150776310	chr1:150973123~150975534:+
BRCA	cis	rs748404	0.589	rs3862138	ENSG00000201136.1	RNU6-353P	3.77	0.00017	0.0099	0.17	0.12	Lung cancer;	chr15:43523801	chr15:43702363~43702470:+
BRCA	cis	rs7221109	0.633	rs7209735	ENSG00000224244.1	AC090283.3	3.77	0.00017	0.0099	0.13	0.12	Type 1 diabetes;	chr17:40662346	chr17:40687038~40689360:-
BRCA	cis	rs7267979	0.933	rs1130694	ENSG00000274973.1	RP13-401N8.7	-3.77	0.00017	0.00991	-0.13	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25295661	chr20:25845497~25845862:+
BRCA	cis	rs6460942	0.841	rs17444203	ENSG00000226690.5	AC005281.1	-3.77	0.00017	0.00991	-0.19	-0.12	Coronary artery disease;	chr7:12422238	chr7:12496429~12541910:+
BRCA	cis	rs6012564	1	rs2426112	ENSG00000230758.1	SNAP23P	-3.77	0.00017	0.00991	-0.13	-0.12	Anger;	chr20:49073602	chr20:49038357~49038602:-
BRCA	cis	rs6012564	1	rs2426113	ENSG00000230758.1	SNAP23P	-3.77	0.00017	0.00991	-0.13	-0.12	Anger;	chr20:49073652	chr20:49038357~49038602:-
BRCA	cis	rs6012564	0.929	rs2426114	ENSG00000230758.1	SNAP23P	-3.77	0.00017	0.00991	-0.13	-0.12	Anger;	chr20:49075855	chr20:49038357~49038602:-
BRCA	cis	rs6012564	1	rs2426116	ENSG00000230758.1	SNAP23P	-3.77	0.00017	0.00991	-0.13	-0.12	Anger;	chr20:49076510	chr20:49038357~49038602:-
BRCA	cis	rs875971	0.83	rs6950137	ENSG00000271064.1	RP11-792A8.3	-3.77	0.00017	0.00991	-0.14	-0.12	Aortic root size;	chr7:66511623	chr7:66748838~66749077:-
BRCA	cis	rs11088226	0.846	rs2154501	ENSG00000186842.4	LINC00846	-3.77	0.00017	0.00991	-0.17	-0.12	Gastritis;	chr21:32554141	chr21:32572238~32575881:-
BRCA	cis	rs56046484	0.956	rs17541572	ENSG00000259630.2	CTD-2262B20.1	3.77	0.00017	0.00991	0.19	0.12	Testicular germ cell tumor;	chr15:85122016	chr15:85415228~85415633:+
BRCA	cis	rs6964587	1	rs6953515	ENSG00000188693.7	CYP51A1-AS1	-3.77	0.00017	0.00991	-0.13	-0.12	Breast cancer;	chr7:92029306	chr7:92134604~92180725:+
BRCA	cis	rs4374383	0.559	rs35776963	ENSG00000243389.1	AC012442.5	-3.77	0.00017	0.00991	-0.15	-0.12	Hepatitis C induced liver fibrosis;	chr2:111947003	chr2:112589040~112614431:+
BRCA	cis	rs4878712	0.715	rs2381718	ENSG00000230188.1	RP11-405L18.4	-3.77	0.00017	0.00991	-0.14	-0.12	HIV-1 susceptibility;	chr9:37648370	chr9:37490421~37490893:-
BRCA	cis	rs1009647	0.677	rs11851870	ENSG00000258413.1	RP11-665C16.6	-3.77	0.00017	0.00991	-0.2	-0.12	Testicular germ cell tumor;	chr14:55349264	chr14:55262767~55272075:-
BRCA	cis	rs2041840	1	rs2160395	ENSG00000272054.1	RP11-423P10.2	-3.77	0.00017	0.00992	-0.11	-0.12	Chronic lymphocytic leukemia;	chr2:37252719	chr2:37208875~37212677:+
BRCA	cis	rs7267979	0.932	rs446649	ENSG00000274973.1	RP13-401N8.7	-3.77	0.00017	0.00992	-0.13	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25486723	chr20:25845497~25845862:+
BRCA	cis	rs6088590	0.965	rs6087619	ENSG00000276073.1	RP5-1125A11.7	-3.77	0.00017	0.00992	-0.13	-0.12	Coronary artery disease;	chr20:34700707	chr20:33985617~33988989:-
BRCA	cis	rs875971	0.862	rs6955837	ENSG00000229886.1	RP5-1132H15.3	-3.77	0.00017	0.00992	-0.13	-0.12	Aortic root size;	chr7:66578155	chr7:66025126~66031544:-
BRCA	cis	rs8141529	0.719	rs5762880	ENSG00000272858.1	CTA-292E10.8	-3.77	0.00017	0.00992	-0.15	-0.12	Lymphocyte counts;	chr22:28891828	chr22:28814914~28815662:+
BRCA	cis	rs1348850	0.831	rs7606235	ENSG00000280374.1	RP11-337N6.3	3.77	0.00017	0.00992	0.16	0.12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177536560	chr2:177317715~177318471:-
BRCA	cis	rs733175	0.857	rs3796835	ENSG00000250413.1	RP11-448G15.1	-3.77	0.00017	0.00992	-0.19	-0.12	Psychosis and Alzheimer's disease;	chr4:10009906	chr4:10006482~10009725:+
BRCA	cis	rs2625529	0.641	rs2035379	ENSG00000260037.4	CTD-2524L6.3	-3.77	0.00017	0.00992	-0.17	-0.12	Red blood cell count;	chr15:72000861	chr15:71818396~71823384:+
BRCA	cis	rs875971	0.638	rs10249404	ENSG00000272831.1	RP11-792A8.4	-3.77	0.00017	0.00992	-0.1	-0.12	Aortic root size;	chr7:66581737	chr7:66739829~66740385:-
BRCA	cis	rs10411161	0.721	rs1433082	ENSG00000269483.1	AC006272.1	-3.77	0.00017	0.00992	-0.18	-0.12	Breast cancer;	chr19:51887473	chr19:51839924~51843324:-
BRCA	cis	rs10129255	0.957	rs8019272	ENSG00000211967.3	IGHV3-53	-3.77	0.00017	0.00992	-0.08	-0.12	Kawasaki disease;	chr14:106784709	chr14:106592676~106593347:-
BRCA	cis	rs34787248	1	rs34787248	ENSG00000261839.1	RP1-265C24.8	3.77	0.00017	0.00992	0.17	0.12	Autism spectrum disorder or schizophrenia;	chr6:28230108	chr6:28136849~28139678:+
BRCA	cis	rs4835473	0.637	rs13110964	ENSG00000246448.2	RP13-578N3.3	3.77	0.00017	0.00992	0.13	0.12	Immature fraction of reticulocytes;	chr4:143765119	chr4:143700257~143865072:+
BRCA	cis	rs801193	0.66	rs1016265	ENSG00000272831.1	RP11-792A8.4	3.77	0.00017	0.00993	0.1	0.12	Aortic root size;	chr7:66749580	chr7:66739829~66740385:-
BRCA	cis	rs801193	0.66	rs4610622	ENSG00000272831.1	RP11-792A8.4	3.77	0.00017	0.00993	0.1	0.12	Aortic root size;	chr7:66759510	chr7:66739829~66740385:-
BRCA	cis	rs10129255	0.957	rs10141009	ENSG00000232216.1	IGHV3-43	3.77	0.00017	0.00993	0.09	0.12	Kawasaki disease;	chr14:106776695	chr14:106470264~106470800:-
BRCA	cis	rs2274273	0.682	rs7151224	ENSG00000259318.1	RP11-454L9.2	3.77	0.00017	0.00993	0.1	0.12	Protein biomarker;	chr14:55050544	chr14:55394940~55395233:-
BRCA	cis	rs74233809	1	rs3781285	ENSG00000213061.2	PFN1P11	3.77	0.00017	0.00993	0.26	0.12	Birth weight;	chr10:103065908	chr10:102838011~102845473:-
BRCA	cis	rs6545883	0.899	rs12473030	ENSG00000270820.4	RP11-355B11.2	3.77	0.00017	0.00993	0.13	0.12	Tuberculosis;	chr2:61493362	chr2:61471188~61484130:+
BRCA	cis	rs2243480	0.764	rs2460423	ENSG00000237026.1	RP11-328P23.2	3.77	0.000171	0.00993	0.22	0.12	Diabetic kidney disease;	chr7:66136229	chr7:65235790~65236723:-
BRCA	cis	rs6439153	0.933	rs34193129	ENSG00000242551.2	POU5F1P6	-3.77	0.000171	0.00994	-0.15	-0.12	Pneumococcal bacteremia;	chr3:128972564	chr3:128674735~128677005:-
BRCA	cis	rs1552244	0.572	rs68013239	ENSG00000180385.7	EMC3-AS1	3.77	0.000171	0.00994	0.16	0.12	Alzheimer's disease;	chr3:10124027	chr3:9986893~10006990:+
BRCA	cis	rs1552244	0.572	rs68121641	ENSG00000180385.7	EMC3-AS1	3.77	0.000171	0.00994	0.16	0.12	Alzheimer's disease;	chr3:10124161	chr3:9986893~10006990:+
BRCA	cis	rs1552244	0.515	rs67342818	ENSG00000180385.7	EMC3-AS1	3.77	0.000171	0.00994	0.16	0.12	Alzheimer's disease;	chr3:10124722	chr3:9986893~10006990:+
BRCA	cis	rs1552244	0.572	rs66514627	ENSG00000180385.7	EMC3-AS1	3.77	0.000171	0.00994	0.16	0.12	Alzheimer's disease;	chr3:10124948	chr3:9986893~10006990:+
BRCA	cis	rs61160187	0.556	rs10939881	ENSG00000272308.1	RP11-231G3.1	-3.77	0.000171	0.00994	-0.13	-0.12	Educational attainment (years of education);Educational attainment (college completion);	chr5:61087146	chr5:60866457~60866935:-
BRCA	cis	rs2446066	0.659	rs34109204	ENSG00000257379.1	RP11-793H13.8	3.77	0.000171	0.00994	0.19	0.12	Red blood cell count;	chr12:53478499	chr12:53441741~53467528:+
BRCA	cis	rs73198271	0.74	rs10105920	ENSG00000254153.1	CTA-398F10.2	3.77	0.000171	0.00994	0.15	0.12	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8791227	chr8:8456909~8461337:-
BRCA	cis	rs1040	0.646	rs7764005	ENSG00000226445.1	XXyac-YX65C7_A.2	-3.77	0.000171	0.00994	-0.12	-0.12	Joint mobility (Beighton score);	chr6:169207623	chr6:169213254~169239565:+
BRCA	cis	rs6472235	0.586	rs7818219	ENSG00000272010.1	CTD-3025N20.3	-3.77	0.000171	0.00994	-0.14	-0.12	Plateletcrit;Myopia (pathological);	chr8:66006888	chr8:65591850~65592472:-
BRCA	cis	rs9309473	0.607	rs12478346	ENSG00000230002.2	ALMS1-IT1	3.77	0.000171	0.00994	0.14	0.12	Metabolite levels;	chr2:73357232	chr2:73456764~73459484:+
BRCA	cis	rs62244186	0.545	rs7640654	ENSG00000233509.2	ZNF197-AS1	3.77	0.000171	0.00994	0.14	0.12	Depressive symptoms;	chr3:44721545	chr3:44617128~44624797:-
BRCA	cis	rs9549260	0.753	rs61963266	ENSG00000168852.11	TPTE2P5	3.77	0.000171	0.00994	0.14	0.12	Red blood cell count;	chr13:40596899	chr13:40822296~40921749:-
BRCA	cis	rs13272568	0.614	rs2368503	ENSG00000254352.1	RP11-578O24.2	-3.77	0.000171	0.00994	-0.15	-0.12	Bone mineral density;	chr8:78115773	chr8:78723796~78724136:-
BRCA	cis	rs8180040	0.966	rs11716763	ENSG00000280667.1	Y_RNA	-3.77	0.000171	0.00994	-0.13	-0.12	Colorectal cancer;	chr3:47476776	chr3:47501083~47501182:+
BRCA	cis	rs524281	0.861	rs10791854	ENSG00000255557.1	RP11-770G2.2	3.77	0.000171	0.00994	0.16	0.12	Electroencephalogram traits;	chr11:66196072	chr11:65745729~65771585:+
BRCA	cis	rs6801044	0.695	rs823514	ENSG00000272792.1	RP11-141C7.4	3.77	0.000171	0.00994	0.18	0.12	Creatinine levels in ischemic stroke;	chr3:195537858	chr3:195639990~195640460:+
BRCA	cis	rs7267979	0.932	rs6138588	ENSG00000274414.1	RP5-965G21.4	-3.77	0.000171	0.00994	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25506887	chr20:25239007~25245229:-
BRCA	cis	rs3176789	0.767	rs2110451	ENSG00000214776.8	RP11-726G1.1	-3.77	0.000171	0.00994	-0.14	-0.12	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9778751	chr12:9467552~9576275:+
BRCA	cis	rs1009077	0.68	rs28540362	ENSG00000249244.1	RP11-548H18.2	-3.77	0.000171	0.00995	-0.15	-0.12	Endometriosis;	chr4:119570722	chr4:119391831~119395335:-
BRCA	cis	rs4478858	0.684	rs12121165	ENSG00000223907.1	LINC01226	-3.77	0.000171	0.00995	-0.14	-0.12	Alcohol dependence;	chr1:31252695	chr1:31518435~31524245:+
BRCA	cis	rs970548	0.954	rs10900221	ENSG00000237840.5	FAM21FP	3.77	0.000171	0.00995	0.16	0.12	Total cholesterol levels;HDL cholesterol;HDL cholesterol levels;Cholesterol, total;	chr10:45493149	chr10:45706431~45727231:-
BRCA	cis	rs73206853	0.563	rs17682444	ENSG00000277299.1	RP11-837J7.4	-3.77	0.000171	0.00995	-0.21	-0.12	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr12:110716821	chr12:109948389~109949029:+
BRCA	cis	rs6142618	0.562	rs6142616	ENSG00000224452.1	RSL24D1P6	3.77	0.000171	0.00995	0.15	0.12	Inflammatory bowel disease;	chr20:32126625	chr20:32170390~32170790:-
BRCA	cis	rs9437689	0.531	rs859045	ENSG00000235501.4	RP4-639F20.1	3.77	0.000171	0.00995	0.15	0.12	Phospholipid levels (plasma);	chr1:94915378	chr1:94927566~94963270:+
BRCA	cis	rs10043775	1	rs10072051	ENSG00000251330.3	CTD-2283N19.1	-3.77	0.000171	0.00995	-0.14	-0.12	Periodontal microbiota;	chr5:148395099	chr5:148430159~148430807:-
BRCA	cis	rs1048886	0.872	rs12529284	ENSG00000271967.1	RP11-134K13.4	-3.77	0.000171	0.00995	-0.17	-0.12	Type 2 diabetes;	chr6:70553813	chr6:70596438~70596980:+
BRCA	cis	rs1048886	0.935	rs3193656	ENSG00000271967.1	RP11-134K13.4	-3.77	0.000171	0.00995	-0.17	-0.12	Type 2 diabetes;	chr6:70560840	chr6:70596438~70596980:+
BRCA	cis	rs4698412	0.561	rs10005305	ENSG00000273133.1	RP11-799M12.2	-3.77	0.000171	0.00996	-0.14	-0.12	Parkinson's disease;	chr4:15693267	chr4:15563698~15564253:-
BRCA	cis	rs4415084	0.804	rs10077814	ENSG00000248779.1	RP11-53O19.2	-3.77	0.000171	0.00996	-0.11	-0.12	Breast cancer;	chr5:44916687	chr5:44752949~44765744:+
BRCA	cis	rs2554380	0.943	rs2585049	ENSG00000230373.7	GOLGA6L5P	3.77	0.000171	0.00996	0.16	0.12	Height;	chr15:83684121	chr15:84507885~84516814:-
BRCA	cis	rs2880765	0.835	rs11856869	ENSG00000230373.7	GOLGA6L5P	3.77	0.000171	0.00996	0.12	0.12	Coronary artery disease;	chr15:85485866	chr15:84507885~84516814:-
BRCA	cis	rs1982963	0.95	rs2645738	ENSG00000277050.1	RP11-102G14.1	-3.77	0.000171	0.00996	-0.14	-0.12	Waist-to-hip ratio adjusted for body mass index;	chr14:52046484	chr14:51637348~51637947:-
BRCA	cis	rs875971	0.825	rs10281499	ENSG00000229886.1	RP5-1132H15.3	-3.77	0.000171	0.00996	-0.13	-0.12	Aortic root size;	chr7:66583979	chr7:66025126~66031544:-
BRCA	cis	rs7267979	1	rs6050631	ENSG00000276952.1	RP5-965G21.6	3.77	0.000171	0.00996	0.14	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25451113	chr20:25284915~25285588:-
BRCA	cis	rs6840360	0.809	rs6846809	ENSG00000278978.1	RP11-164P12.5	3.77	0.000171	0.00996	0.13	0.12	Intelligence (multi-trait analysis);	chr4:151809049	chr4:151669786~151670503:+
BRCA	cis	rs17301013	0.612	rs56199565	ENSG00000234741.6	GAS5	3.77	0.000171	0.00996	0.11	0.12	Systemic lupus erythematosus;	chr1:174640992	chr1:173863900~173868882:-
BRCA	cis	rs9470794	1	rs73419907	ENSG00000204110.6	RP1-153P14.8	-3.77	0.000171	0.00996	-0.24	-0.12	Type 2 diabetes;	chr6:38042865	chr6:37507348~37535616:+
BRCA	cis	rs9470794	1	rs73419916	ENSG00000204110.6	RP1-153P14.8	-3.77	0.000171	0.00996	-0.24	-0.12	Type 2 diabetes;	chr6:38046328	chr6:37507348~37535616:+
BRCA	cis	rs9470794	1	rs73419919	ENSG00000204110.6	RP1-153P14.8	-3.77	0.000171	0.00996	-0.24	-0.12	Type 2 diabetes;	chr6:38046409	chr6:37507348~37535616:+
BRCA	cis	rs9470794	1	rs75740926	ENSG00000204110.6	RP1-153P14.8	-3.77	0.000171	0.00996	-0.24	-0.12	Type 2 diabetes;	chr6:38052468	chr6:37507348~37535616:+
BRCA	cis	rs9392653	1	rs9392652	ENSG00000220685.3	RP11-530A18.1	-3.77	0.000171	0.00996	-0.16	-0.12	Venous thromboembolism (SNP x SNP interaction);	chr6:5070868	chr6:5065795~5066982:-
BRCA	cis	rs2704588	1	rs2869965	ENSG00000270720.1	RP11-84C13.2	3.77	0.000171	0.00996	0.18	0.12	Longevity;	chr4:88881692	chr4:89119284~89119871:+
BRCA	cis	rs947583	0.517	rs6935371	ENSG00000231028.7	LINC00271	-3.77	0.000171	0.00996	-0.12	-0.12	Phosphorus levels;	chr6:135779380	chr6:135497801~135716055:+
BRCA	cis	rs8062405	0.964	rs78613234	ENSG00000261766.1	RP11-22P6.2	-3.77	0.000171	0.00996	-0.11	-0.12	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828104	chr16:28862166~28863340:-
BRCA	cis	rs8062405	1	rs62036624	ENSG00000261766.1	RP11-22P6.2	-3.77	0.000171	0.00996	-0.11	-0.12	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828609	chr16:28862166~28863340:-
BRCA	cis	rs7267979	0.903	rs6050481	ENSG00000274414.1	RP5-965G21.4	-3.77	0.000171	0.00996	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25243944	chr20:25239007~25245229:-
BRCA	cis	rs7267979	0.834	rs6115100	ENSG00000274414.1	RP5-965G21.4	-3.77	0.000171	0.00996	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25245302	chr20:25239007~25245229:-
BRCA	cis	rs2136613	0.751	rs1397030	ENSG00000238280.1	RP11-436D10.3	-3.77	0.000171	0.00996	-0.14	-0.12	Selective IgA deficiency;	chr10:62838746	chr10:62793562~62805887:-
BRCA	cis	rs7819412	0.561	rs2001328	ENSG00000154316.13	TDH	3.77	0.000171	0.00997	0.15	0.12	Triglycerides;	chr8:11129689	chr8:11339637~11368452:+
BRCA	cis	rs4374383	0.551	rs6742470	ENSG00000243389.1	AC012442.5	-3.77	0.000171	0.00997	-0.15	-0.12	Hepatitis C induced liver fibrosis;	chr2:111947913	chr2:112589040~112614431:+
BRCA	cis	rs6714710	0.58	rs13032265	ENSG00000228486.8	LINC01125	-3.77	0.000171	0.00997	-0.1	-0.12	Posterior cortical atrophy and Alzheimer's disease;	chr2:97793102	chr2:97664217~97703064:+
BRCA	cis	rs6840360	0.904	rs73862064	ENSG00000278978.1	RP11-164P12.5	-3.77	0.000171	0.00997	-0.13	-0.12	Intelligence (multi-trait analysis);	chr4:151581948	chr4:151669786~151670503:+
BRCA	cis	rs9788682	0.748	rs569207	ENSG00000261143.1	ADAMTS7P3	3.77	0.000171	0.00997	0.15	0.12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78580777	chr15:77976042~77993057:+
BRCA	cis	rs12612435	0.793	rs7575620	ENSG00000226806.1	AC011893.3	3.77	0.000171	0.00997	0.13	0.12	Takotsubo syndrome;	chr2:136375000	chr2:135820191~135823087:+
BRCA	cis	rs7923837	1	rs1112718	ENSG00000236493.2	EIF2S2P3	3.77	0.000171	0.00997	0.15	0.12	Multiple sclerosis;Body mass index;	chr10:92719350	chr10:92668745~92669743:-
BRCA	cis	rs7267979	1	rs1888997	ENSG00000277938.1	RP5-965G21.3	-3.77	0.000171	0.00997	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25318352	chr20:25229150~25231933:+
BRCA	cis	rs6088580	0.634	rs6088484	ENSG00000275784.1	RP5-1125A11.6	3.77	0.000171	0.00997	0.13	0.12	Glomerular filtration rate (creatinine);	chr20:34398155	chr20:33989480~33991818:-
BRCA	cis	rs4699052	1	rs6533060	ENSG00000251288.2	RP11-10L12.2	-3.77	0.000171	0.00997	-0.13	-0.12	Testicular germ cell tumor;	chr4:103218839	chr4:102751401~102752641:+
BRCA	cis	rs9733	0.791	rs11204693	ENSG00000203804.4	ADAMTSL4-AS1	-3.77	0.000171	0.00997	-0.12	-0.12	Tonsillectomy;	chr1:150675511	chr1:150560202~150574552:-
BRCA	cis	rs7412746	0.563	rs3768013	ENSG00000224800.1	RP11-235D19.2	-3.77	0.000171	0.00997	-0.15	-0.12	Melanoma;	chr1:150842935	chr1:150881236~150881683:-
BRCA	cis	rs7487075	0.619	rs7311504	ENSG00000257261.4	RP11-96H19.1	3.77	0.000171	0.00997	0.13	0.12	Itch intensity from mosquito bite;	chr12:46436993	chr12:46383679~46876159:+
BRCA	cis	rs7208859	0.673	rs9911989	ENSG00000264538.5	SUZ12P1	3.77	0.000171	0.00997	0.18	0.12	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30910684	chr17:30709299~30790908:+
BRCA	cis	rs11098499	0.738	rs28687057	ENSG00000225892.3	RP11-384K6.2	3.77	0.000171	0.00997	0.11	0.12	Corneal astigmatism;	chr4:119359657	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.775	rs67281037	ENSG00000225892.3	RP11-384K6.2	3.77	0.000171	0.00997	0.11	0.12	Corneal astigmatism;	chr4:119360002	chr4:118632274~118634759:+
BRCA	cis	rs10028773	0.506	rs12374346	ENSG00000225892.3	RP11-384K6.2	3.77	0.000171	0.00997	0.11	0.12	Educational attainment;	chr4:119360550	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.866	rs12374244	ENSG00000225892.3	RP11-384K6.2	3.77	0.000171	0.00997	0.11	0.12	Corneal astigmatism;	chr4:119360817	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.866	rs12374352	ENSG00000225892.3	RP11-384K6.2	3.77	0.000171	0.00997	0.11	0.12	Corneal astigmatism;	chr4:119360822	chr4:118632274~118634759:+
BRCA	cis	rs7172689	1	rs61637497	ENSG00000271725.1	RP11-761I4.4	3.77	0.000171	0.00997	0.17	0.12	Inattentive symptoms;	chr15:81241104	chr15:81303215~81309391:-
BRCA	cis	rs739496	0.615	rs630616	ENSG00000226469.1	ADAM1B	3.77	0.000171	0.00997	0.15	0.12	Platelet count;	chr12:111721162	chr12:111927018~111929017:+
BRCA	cis	rs721917	0.525	rs2758545	ENSG00000225484.5	NUTM2B-AS1	-3.77	0.000171	0.00997	-0.16	-0.12	Chronic obstructive pulmonary disease;	chr10:79940334	chr10:79663088~79826594:-
BRCA	cis	rs9650657	0.623	rs10094497	ENSG00000154316.13	TDH	-3.77	0.000171	0.00997	-0.14	-0.12	Neuroticism;	chr8:10745319	chr8:11339637~11368452:+
BRCA	cis	rs7105310	1	rs7106095	ENSG00000254671.2	STT3A-AS1	3.77	0.000171	0.00997	0.21	0.12	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;	chr11:126176388	chr11:125570284~125592568:-
BRCA	cis	rs4664293	0.802	rs7563417	ENSG00000224152.1	AC009506.1	-3.77	0.000171	0.00998	-0.14	-0.12	Monocyte percentage of white cells;	chr2:159727762	chr2:159615296~159617082:+
BRCA	cis	rs11098499	0.954	rs12502423	ENSG00000260404.2	RP11-384K6.6	3.77	0.000171	0.00998	0.11	0.12	Corneal astigmatism;	chr4:119503017	chr4:118591773~118633729:+
BRCA	cis	rs728616	0.558	rs12767261	ENSG00000225484.5	NUTM2B-AS1	-3.77	0.000171	0.00998	-0.24	-0.12	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80402567	chr10:79663088~79826594:-
BRCA	cis	rs7267979	1	rs6050561	ENSG00000204556.4	CTD-2514C3.1	3.77	0.000171	0.00998	0.16	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25354219	chr20:26018832~26020684:+
BRCA	cis	rs7267979	1	rs6083813	ENSG00000204556.4	CTD-2514C3.1	3.77	0.000171	0.00998	0.16	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25357035	chr20:26018832~26020684:+
BRCA	cis	rs9287719	0.967	rs7563894	ENSG00000224177.5	LINC00570	3.77	0.000171	0.00998	0.14	0.12	Prostate cancer;	chr2:10614523	chr2:11393981~11403077:+
BRCA	cis	rs9287719	0.967	rs7566767	ENSG00000224177.5	LINC00570	3.77	0.000171	0.00998	0.14	0.12	Prostate cancer;	chr2:10614537	chr2:11393981~11403077:+
BRCA	cis	rs12726943	0.555	rs489627	ENSG00000229989.3	MIR181A1HG	3.77	0.000171	0.00998	0.2	0.12	Perceived unattractiveness to mosquitoes;	chr1:199426227	chr1:198807493~198937429:-
BRCA	cis	rs9375946	0.512	rs12191555	ENSG00000228506.1	RP11-98I9.4	3.77	0.000171	0.00998	0.16	0.12	Depressive symptoms;	chr6:99089840	chr6:99424922~99431373:+
BRCA	cis	rs7869969	0.509	rs13287066	ENSG00000227603.1	RP11-165J3.6	3.77	0.000171	0.00998	0.12	0.12	Childhood body mass index;	chr9:93416685	chr9:93435332~93437121:-
BRCA	cis	rs8114671	0.586	rs734111	ENSG00000126005.14	MMP24-AS1	-3.77	0.000171	0.00998	-0.14	-0.12	Height;	chr20:34945933	chr20:35216462~35278131:-
BRCA	cis	rs11711311	1	rs12637067	ENSG00000241529.3	RN7SL767P	-3.77	0.000171	0.00998	-0.14	-0.12	IgG glycosylation;	chr3:113808759	chr3:113632704~113632998:+
BRCA	cis	rs77633900	0.803	rs8042255	ENSG00000196274.5	Metazoa_SRP	-3.77	0.000171	0.00998	-0.17	-0.12	Glioma;Non-glioblastoma glioma;	chr15:76279269	chr15:76230048~76230390:-
BRCA	cis	rs67696533	0.636	rs6119880	ENSG00000277692.1	RP11-358N2.2	-3.77	0.000172	0.00998	-0.14	-0.12	White blood cell count (basophil);Basophil percentage of granulocytes;Basophil percentage of white cells;	chr20:32517791	chr20:32355053~32355734:+
BRCA	cis	rs721917	0.525	rs11201011	ENSG00000278616.1	BEND3P3	-3.77	0.000172	0.00998	-0.11	-0.12	Chronic obstructive pulmonary disease;	chr10:79980164	chr10:79682997~79685436:+
BRCA	cis	rs11892454	0.565	rs6748220	ENSG00000217643.1	PTGES3P2	-3.77	0.000172	0.00998	-0.13	-0.12	Heschl's gyrus morphology;	chr2:25878534	chr2:25822469~25822950:+
BRCA	cis	rs9402743	0.632	rs6900101	ENSG00000231028.7	LINC00271	-3.77	0.000172	0.00999	-0.12	-0.12	Systemic lupus erythematosus;	chr6:135773766	chr6:135497801~135716055:+
BRCA	cis	rs6964587	0.869	rs2374519	ENSG00000188693.7	CYP51A1-AS1	3.77	0.000172	0.00999	0.13	0.12	Breast cancer;	chr7:91912167	chr7:92134604~92180725:+
BRCA	cis	rs7119	0.637	rs12913005	ENSG00000259362.2	RP11-307C19.1	-3.77	0.000172	0.00999	-0.16	-0.12	Type 2 diabetes;	chr15:77564229	chr15:77525540~77534110:+
BRCA	cis	rs9341808	0.5	rs806851	ENSG00000233967.5	RP11-250B2.3	-3.77	0.000172	0.00999	-0.12	-0.12	Sitting height ratio;	chr6:80321114	chr6:80443344~80465927:+
BRCA	cis	rs2301573	0.584	rs12485251	ENSG00000271270.4	TMCC1-AS1	3.77	0.000172	0.00999	0.23	0.12	Hip circumference;	chr3:129776064	chr3:129893871~129918575:+
BRCA	cis	rs7487075	0.619	rs7134289	ENSG00000257261.4	RP11-96H19.1	3.77	0.000172	0.00999	0.13	0.12	Itch intensity from mosquito bite;	chr12:46444553	chr12:46383679~46876159:+
BRCA	cis	rs6964587	1	rs415	ENSG00000188693.7	CYP51A1-AS1	3.77	0.000172	0.00999	0.12	0.12	Breast cancer;	chr7:91951176	chr7:92134604~92180725:+
BRCA	cis	rs2625529	0.59	rs2607090	ENSG00000260037.4	CTD-2524L6.3	-3.77	0.000172	0.00999	-0.17	-0.12	Red blood cell count;	chr15:72203670	chr15:71818396~71823384:+
BRCA	cis	rs6657613	0.68	rs10887994	ENSG00000186301.8	MST1P2	-3.77	0.000172	0.00999	-0.1	-0.12	Hip circumference adjusted for BMI;	chr1:17045260	chr1:16645622~16650289:+
BRCA	cis	rs754466	0.58	rs10430530	ENSG00000213514.2	RP11-428P16.2	3.77	0.000172	0.00999	0.16	0.12	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77823054	chr10:77730766~77734769:+
BRCA	cis	rs638893	0.528	rs521910	ENSG00000255435.5	RP11-770J1.3	-3.77	0.000172	0.00999	-0.17	-0.12	Vitiligo;	chr11:118739920	chr11:118511911~118531094:-
BRCA	cis	rs6142618	0.562	rs4911545	ENSG00000224452.1	RSL24D1P6	3.77	0.000172	0.00999	0.15	0.12	Inflammatory bowel disease;	chr20:32123712	chr20:32170390~32170790:-
BRCA	cis	rs6142618	0.562	rs6142613	ENSG00000224452.1	RSL24D1P6	3.77	0.000172	0.00999	0.15	0.12	Inflammatory bowel disease;	chr20:32124203	chr20:32170390~32170790:-
BRCA	cis	rs6142618	0.562	rs6142615	ENSG00000224452.1	RSL24D1P6	3.77	0.000172	0.00999	0.15	0.12	Inflammatory bowel disease;	chr20:32124636	chr20:32170390~32170790:-
BRCA	cis	rs6142618	0.562	rs6058528	ENSG00000224452.1	RSL24D1P6	3.77	0.000172	0.00999	0.15	0.12	Inflammatory bowel disease;	chr20:32127247	chr20:32170390~32170790:-
BRCA	cis	rs6918586	0.658	rs198819	ENSG00000272462.2	U91328.19	-3.77	0.000172	0.01	-0.13	-0.12	Schizophrenia;	chr6:26124202	chr6:25992662~26001775:+
BRCA	cis	rs4714291	0.963	rs2475496	ENSG00000180211.5	RP1-278E11.3	3.77	0.000172	0.01	0.13	0.12	Strep throat;	chr6:39996111	chr6:39958414~39958833:-
BRCA	cis	rs6088580	0.634	rs6059897	ENSG00000275784.1	RP5-1125A11.6	-3.77	0.000172	0.01	-0.13	-0.12	Glomerular filtration rate (creatinine);	chr20:34525419	chr20:33989480~33991818:-
BRCA	cis	rs12612435	0.91	rs10496741	ENSG00000226806.1	AC011893.3	-3.77	0.000172	0.01	-0.14	-0.12	Takotsubo syndrome;	chr2:136359253	chr2:135820191~135823087:+
BRCA	cis	rs490234	0.783	rs13284243	ENSG00000232630.1	PRPS1P2	-3.77	0.000172	0.01	-0.12	-0.12	Mean arterial pressure;	chr9:125619506	chr9:125150653~125151589:+
BRCA	cis	rs10411161	0.702	rs7251755	ENSG00000269483.1	AC006272.1	3.77	0.000172	0.01	0.19	0.12	Breast cancer;	chr19:51885695	chr19:51839924~51843324:-
BRCA	cis	rs10411161	0.702	rs7251689	ENSG00000269483.1	AC006272.1	3.77	0.000172	0.01	0.19	0.12	Breast cancer;	chr19:51885864	chr19:51839924~51843324:-
BRCA	cis	rs10411161	0.69	rs7252336	ENSG00000269483.1	AC006272.1	3.77	0.000172	0.01	0.19	0.12	Breast cancer;	chr19:51886261	chr19:51839924~51843324:-
BRCA	cis	rs2243480	1	rs427044	ENSG00000237026.1	RP11-328P23.2	3.77	0.000172	0.01	0.22	0.12	Diabetic kidney disease;	chr7:66043558	chr7:65235790~65236723:-
BRCA	cis	rs7267979	1	rs3761117	ENSG00000276952.1	RP5-965G21.6	-3.77	0.000172	0.01	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25407434	chr20:25284915~25285588:-
BRCA	cis	rs860295	0.58	rs867548	ENSG00000225082.2	DAP3P1	-3.77	0.000172	0.01	-0.15	-0.12	Body mass index;	chr1:155910217	chr1:155586644~155602197:+
BRCA	cis	rs6893300	0.961	rs11739042	ENSG00000250999.1	RP11-1379J22.5	3.77	0.000172	0.01	0.17	0.12	Resting heart rate;	chr5:179755494	chr5:179657762~179664432:+
BRCA	cis	rs6964587	1	rs35653487	ENSG00000188693.7	CYP51A1-AS1	-3.77	0.000172	0.01	-0.12	-0.12	Breast cancer;	chr7:92116127	chr7:92134604~92180725:+
BRCA	cis	rs6964587	1	rs2301559	ENSG00000188693.7	CYP51A1-AS1	-3.77	0.000172	0.01	-0.12	-0.12	Breast cancer;	chr7:92117413	chr7:92134604~92180725:+
BRCA	cis	rs7620503	0.959	rs6797636	ENSG00000231574.4	RP11-91K9.1	3.77	0.000172	0.01	0.13	0.12	Corneal structure;	chr3:177591654	chr3:177816865~177899224:+
BRCA	cis	rs524281	0.773	rs10750781	ENSG00000255038.1	RP11-1167A19.2	-3.77	0.000172	0.01	-0.18	-0.12	Electroencephalogram traits;	chr11:66269799	chr11:66067277~66069619:-
BRCA	cis	rs524281	0.773	rs2017969	ENSG00000255038.1	RP11-1167A19.2	-3.77	0.000172	0.01	-0.18	-0.12	Electroencephalogram traits;	chr11:66271561	chr11:66067277~66069619:-
BRCA	cis	rs9650657	0.65	rs2898248	ENSG00000248896.2	CTD-2135J3.3	3.77	0.000172	0.01	0.14	0.12	Neuroticism;	chr8:10779240	chr8:10729314~10771392:+
BRCA	cis	rs1730008	0.691	rs4680425	ENSG00000279311.1	RP11-170K4.2	3.77	0.000172	0.01	0.15	0.12	Lobe attachment (rater-scored or self-reported);	chr3:158335527	chr3:158869898~158871821:+
BRCA	cis	rs7690839	1	rs1458562	ENSG00000270720.1	RP11-84C13.2	3.77	0.000172	0.01	0.13	0.12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr4:88932447	chr4:89119284~89119871:+
BRCA	cis	rs1040	0.646	rs6605528	ENSG00000226445.1	XXyac-YX65C7_A.2	-3.77	0.000172	0.01	-0.12	-0.12	Joint mobility (Beighton score);	chr6:169208712	chr6:169213254~169239565:+
BRCA	cis	rs202072	0.818	rs405078	ENSG00000272379.1	RP1-257A7.5	3.77	0.000172	0.01	0.16	0.12	HIV-1 viral setpoint;	chr6:13279635	chr6:13290018~13290490:-
BRCA	cis	rs1008375	0.966	rs6449313	ENSG00000249502.1	AC006160.5	-3.77	0.000172	0.01	-0.13	-0.12	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17586697	chr4:17587467~17614571:-
BRCA	cis	rs9308731	0.591	rs60982612	ENSG00000230499.1	AC108463.1	-3.77	0.000172	0.01	-0.13	-0.12	Chronic lymphocytic leukemia;	chr2:111183362	chr2:111195963~111206494:+
BRCA	cis	rs2991971	0.776	rs12139364	ENSG00000281133.1	AL355480.3	3.77	0.000172	0.01	0.14	0.12	High light scatter reticulocyte count;	chr1:45424483	chr1:45580892~45580996:-
BRCA	cis	rs1953600	0.837	rs2236556	ENSG00000226659.1	RP11-137H2.4	3.77	0.000172	0.01	0.15	0.12	Sarcoidosis;	chr10:80173034	chr10:80529597~80535942:-
BRCA	cis	rs9788682	0.747	rs2958719	ENSG00000261143.1	ADAMTS7P3	3.77	0.000172	0.01	0.16	0.12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78450687	chr15:77976042~77993057:+
BRCA	cis	rs4950322	0.547	rs61838945	ENSG00000227242.3	NBPF13P	-3.77	0.000172	0.01	-0.16	-0.12	Protein quantitative trait loci;	chr1:147111477	chr1:147021320~147124525:-
BRCA	cis	rs7267979	0.966	rs2500417	ENSG00000274414.1	RP5-965G21.4	3.77	0.000172	0.01	0.14	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25402651	chr20:25239007~25245229:-
BRCA	cis	rs1912124	1	rs1912124	ENSG00000271983.1	RP11-28H5.2	3.77	0.000172	0.01	0.23	0.12	Peripheral arterial disease (traffic-related air pollution interaction);	chr15:81206630	chr15:80693216~80693707:-
BRCA	cis	rs757081	0.648	rs11024231	ENSG00000272034.1	SNORD14A	-3.77	0.000172	0.01	-0.12	-0.12	Systolic blood pressure;	chr11:17265703	chr11:17074654~17074744:-
BRCA	cis	rs12438356	0.881	rs7171293	ENSG00000259222.2	RP11-809H16.5	-3.77	0.000172	0.01	-0.19	-0.12	CTACK levels;	chr15:69288082	chr15:69080879~69099987:+
BRCA	cis	rs2832270	0.562	rs2832180	ENSG00000176054.6	RPL23P2	-3.77	0.000172	0.01	-0.21	-0.12	Response to mTOR inhibitor (everolimus);	chr21:29108886	chr21:28997613~28998033:-
BRCA	cis	rs747650	0.504	rs4548577	ENSG00000200376.1	RNU5E-10P	-3.77	0.000172	0.01	-0.16	-0.12	Acne (severe);	chr11:46976961	chr11:47576471~47576588:-
BRCA	cis	rs7131987	0.903	rs11050161	ENSG00000273680.1	RP11-996F15.6	3.77	0.000172	0.01	0.15	0.12	QT interval;	chr12:29267116	chr12:29332733~29333383:-
BRCA	cis	rs7131987	0.903	rs11050162	ENSG00000273680.1	RP11-996F15.6	3.77	0.000172	0.01	0.15	0.12	QT interval;	chr12:29267121	chr12:29332733~29333383:-
BRCA	cis	rs91731	1	rs268729	ENSG00000249572.1	CTD-2203K17.1	-3.77	0.000172	0.01	-0.23	-0.12	Lung function (FVC);	chr5:33363728	chr5:33424025~33440619:-
BRCA	cis	rs495337	0.736	rs6020073	ENSG00000224397.4	LINC01272	3.77	0.000172	0.01	0.12	0.12	Psoriasis;	chr20:49831743	chr20:50267486~50279795:+
BRCA	cis	rs2274273	1	rs11621351	ENSG00000259318.1	RP11-454L9.2	3.77	0.000172	0.01	0.1	0.12	Protein biomarker;	chr14:55150022	chr14:55394940~55395233:-
BRCA	cis	rs10761482	0.668	rs1002710	ENSG00000254271.1	RP11-131N11.4	3.77	0.000172	0.01	0.15	0.12	Schizophrenia;	chr10:60362362	chr10:60734342~60741828:+
BRCA	cis	rs4148883	0.504	rs28720150	ENSG00000246090.5	RP11-696N14.1	-3.77	0.000172	0.01	-0.11	-0.12	Alcohol dependence;	chr4:99211633	chr4:99088857~99301356:+
BRCA	cis	rs8114671	0.773	rs3746438	ENSG00000126005.14	MMP24-AS1	3.77	0.000172	0.01	0.13	0.12	Height;	chr20:34996486	chr20:35216462~35278131:-
BRCA	cis	rs10923574	0.597	rs1951938	ENSG00000231365.4	RP11-418J17.1	-3.77	0.000172	0.01	-0.14	-0.12	Breast cancer;Folding of antihelix;	chr1:118507115	chr1:119140396~119275973:+
BRCA	cis	rs11098499	1	rs58601355	ENSG00000260091.1	RP11-33B1.4	-3.77	0.000172	0.01	-0.11	-0.12	Corneal astigmatism;	chr4:119265212	chr4:119409333~119410233:+
BRCA	cis	rs7395581	0.798	rs10769252	ENSG00000280615.1	Y_RNA	3.77	0.000172	0.01	0.14	0.12	HDL cholesterol;	chr11:47322404	chr11:47614898~47614994:-
BRCA	cis	rs2991971	0.81	rs6657237	ENSG00000281133.1	AL355480.3	-3.77	0.000172	0.01	-0.14	-0.12	High light scatter reticulocyte count;	chr1:45454436	chr1:45580892~45580996:-
BRCA	cis	rs4478858	0.735	rs1566961	ENSG00000260386.4	LINC01225	-3.77	0.000172	0.01	-0.14	-0.12	Alcohol dependence;	chr1:31299603	chr1:31500085~31540885:+
BRCA	cis	rs4478858	0.735	rs4622114	ENSG00000260386.4	LINC01225	-3.77	0.000172	0.01	-0.14	-0.12	Alcohol dependence;	chr1:31299724	chr1:31500085~31540885:+
BRCA	cis	rs7267979	1	rs6050602	ENSG00000204556.4	CTD-2514C3.1	3.77	0.000172	0.01	0.16	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25420567	chr20:26018832~26020684:+
BRCA	cis	rs4761470	0.511	rs7973179	ENSG00000258365.1	RP11-1105G2.3	-3.77	0.000172	0.01	-0.2	-0.12	Estradiol plasma levels (breast cancer);	chr12:94277498	chr12:94277758~94282844:-
BRCA	cis	rs115575488	0.85	rs17186024	ENSG00000236804.1	RPS3AP12	3.77	0.000172	0.01	0.22	0.12	Lobe attachment (rater-scored or self-reported);	chr1:119130026	chr1:119126539~119127291:-
BRCA	cis	rs6500602	0.563	rs917304	ENSG00000280063.1	RP11-295D4.3	3.77	0.000173	0.01	0.1	0.12	Schizophrenia;	chr16:4390425	chr16:4346694~4348648:-
BRCA	cis	rs7177699	0.567	rs67745769	ENSG00000261143.1	ADAMTS7P3	3.77	0.000173	0.01	0.14	0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78832490	chr15:77976042~77993057:+
BRCA	cis	rs6121246	0.609	rs2376998	ENSG00000230613.1	HM13-AS1	3.77	0.000173	0.01	0.16	0.12	Mean corpuscular hemoglobin;	chr20:31752860	chr20:31567707~31573263:-
BRCA	cis	rs2839186	0.558	rs2968	ENSG00000228137.1	AP001469.7	-3.77	0.000173	0.01	-0.12	-0.12	Testicular germ cell tumor;	chr21:46188666	chr21:46246890~46247682:+
BRCA	cis	rs2274273	0.774	rs9323278	ENSG00000259318.1	RP11-454L9.2	3.77	0.000173	0.01	0.1	0.12	Protein biomarker;	chr14:55074856	chr14:55394940~55395233:-
BRCA	cis	rs6593122	0.755	rs10249821	ENSG00000235454.1	HAUS6P3	-3.77	0.000173	0.01	-0.15	-0.12	Vaccine-related adverse events;	chr7:54119820	chr7:53862233~53863339:+
BRCA	cis	rs6593122	0.755	rs10239509	ENSG00000235454.1	HAUS6P3	-3.77	0.000173	0.01	-0.15	-0.12	Vaccine-related adverse events;	chr7:54119832	chr7:53862233~53863339:+
BRCA	cis	rs62184315	0.58	rs62185872	ENSG00000253559.1	OSGEPL1-AS1	-3.77	0.000173	0.01	-0.19	-0.12	Alcohol dependence (age at onset);	chr2:189690033	chr2:189762704~189765556:+
BRCA	cis	rs3820068	0.581	rs68052904	ENSG00000237301.1	RP4-680D5.2	-3.77	0.000173	0.01	-0.15	-0.12	Systolic blood pressure;	chr1:15590219	chr1:15586136~15603626:-
BRCA	cis	rs2562152	0.706	rs216598	ENSG00000231439.4	WASIR2	-3.77	0.000173	0.01	-0.18	-0.12	Glioblastoma;	chr16:58586	chr16:22910~25123:+
BRCA	cis	rs4950322	0.57	rs7554833	ENSG00000237188.3	RP11-337C18.8	-3.77	0.000173	0.01	-0.15	-0.12	Protein quantitative trait loci;	chr1:147289362	chr1:147172771~147211568:+
BRCA	cis	rs11170468	0.722	rs11170691	ENSG00000257718.1	RP11-396F22.1	-3.77	0.000173	0.01	-0.15	-0.12	Body mass index;	chr12:39096386	chr12:38906451~38909592:+
BRCA	cis	rs1354774	0.505	rs16987929	ENSG00000197588.8	KLKP1	-3.77	0.000173	0.01	-0.12	-0.12	Prostate-specific antigen levels;	chr19:50881997	chr19:50882096~50896398:-
BRCA	cis	rs251253	0.76	rs251236	ENSG00000253959.1	CTB-43E15.1	3.77	0.000173	0.01	0.1	0.12	PR interval;	chr5:173107677	chr5:173642519~173658194:+
BRCA	cis	rs3936840	0.647	rs942024	ENSG00000258512.1	LINC00239	-3.77	0.000173	0.01	-0.13	-0.12	Plateletcrit;	chr14:102513126	chr14:101730437~101732522:+
BRCA	cis	rs12289961	0.681	rs3902651	ENSG00000265566.2	RN7SL605P	3.77	0.000173	0.01	0.2	0.12	Lymphoma;	chr11:58235856	chr11:57528085~57528365:-
BRCA	cis	rs12289961	0.645	rs12362778	ENSG00000265566.2	RN7SL605P	3.77	0.000173	0.01	0.2	0.12	Lymphoma;	chr11:58236874	chr11:57528085~57528365:-
BRCA	cis	rs12289961	0.681	rs12364326	ENSG00000265566.2	RN7SL605P	3.77	0.000173	0.01	0.2	0.12	Lymphoma;	chr11:58236980	chr11:57528085~57528365:-
BRCA	cis	rs12289961	0.681	rs4587746	ENSG00000265566.2	RN7SL605P	3.77	0.000173	0.01	0.2	0.12	Lymphoma;	chr11:58237261	chr11:57528085~57528365:-
BRCA	cis	rs12289961	0.681	rs4466857	ENSG00000265566.2	RN7SL605P	3.77	0.000173	0.01	0.2	0.12	Lymphoma;	chr11:58237271	chr11:57528085~57528365:-
BRCA	cis	rs12289961	0.681	rs12361899	ENSG00000265566.2	RN7SL605P	3.77	0.000173	0.01	0.2	0.12	Lymphoma;	chr11:58239728	chr11:57528085~57528365:-
BRCA	cis	rs12289961	0.681	rs73479339	ENSG00000265566.2	RN7SL605P	3.77	0.000173	0.01	0.2	0.12	Lymphoma;	chr11:58241758	chr11:57528085~57528365:-
BRCA	cis	rs7833986	0.501	rs72651502	ENSG00000253603.1	CTA-397H3.3	-3.77	0.000173	0.0101	-0.17	-0.12	Height;	chr8:55962974	chr8:56074592~56075274:+
BRCA	cis	rs7412746	0.658	rs10305704	ENSG00000224800.1	RP11-235D19.2	-3.77	0.000173	0.0101	-0.15	-0.12	Melanoma;	chr1:150831953	chr1:150881236~150881683:-
BRCA	cis	rs2638953	0.924	rs11049606	ENSG00000247934.4	RP11-967K21.1	-3.77	0.000173	0.0101	-0.15	-0.12	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28444213	chr12:28163298~28190738:-
BRCA	cis	rs4730430	0.515	rs6943600	ENSG00000226965.1	AC003088.1	3.77	0.000173	0.0101	0.13	0.12	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr7:110492545	chr7:110432239~110534754:-
BRCA	cis	rs7120118	0.517	rs10838694	ENSG00000280615.1	Y_RNA	3.77	0.000173	0.0101	0.19	0.12	HDL cholesterol;	chr11:47330209	chr11:47614898~47614994:-
BRCA	cis	rs7111546	0.887	rs16910190	ENSG00000246225.5	RP11-17A1.3	3.77	0.000173	0.0101	0.19	0.12	Dialysis-related mortality;	chr11:22807060	chr11:22829380~22945393:+
BRCA	cis	rs10043228	0.702	rs12518094	ENSG00000250015.1	CTC-339F2.2	-3.77	0.000173	0.0101	-0.13	-0.12	Asthma or chronic obstructive pulmonary disease;	chr5:116295027	chr5:116302354~116304134:-
BRCA	cis	rs3816183	1	rs3816184	ENSG00000226491.1	FTOP1	3.77	0.000173	0.0101	0.15	0.12	Hypospadias;	chr2:42788617	chr2:42797225~42798712:-
BRCA	cis	rs875971	0.619	rs10278371	ENSG00000275400.1	RP4-756H11.5	3.77	0.000173	0.0101	0.13	0.12	Aortic root size;	chr7:66586553	chr7:66553805~66554199:-
BRCA	cis	rs4415084	0.716	rs16901990	ENSG00000251141.4	RP11-53O19.1	-3.77	0.000173	0.0101	-0.11	-0.12	Breast cancer;	chr5:44842638	chr5:44744900~44808777:-
BRCA	cis	rs4415084	0.68	rs10072025	ENSG00000251141.4	RP11-53O19.1	-3.77	0.000173	0.0101	-0.11	-0.12	Breast cancer;	chr5:44843392	chr5:44744900~44808777:-
BRCA	cis	rs3753275	0.69	rs6577500	ENSG00000270282.1	RP5-1115A15.2	3.77	0.000173	0.0101	0.16	0.12	Educational attainment;	chr1:8554512	chr1:8512653~8513021:+
BRCA	cis	rs859767	0.924	rs842349	ENSG00000224043.6	CCNT2-AS1	-3.77	0.000173	0.0101	-0.16	-0.12	Neuroticism;	chr2:134584882	chr2:134735464~134918710:-
BRCA	cis	rs361171	0.622	rs361136	ENSG00000270265.1	RP11-731D1.4	3.77	0.000173	0.0101	0.13	0.12	Trans fatty acid levels;	chr4:151897267	chr4:151333775~151353224:-
BRCA	cis	rs11711311	0.747	rs11928590	ENSG00000241529.3	RN7SL767P	-3.77	0.000173	0.0101	-0.14	-0.12	IgG glycosylation;	chr3:113624631	chr3:113632704~113632998:+
BRCA	cis	rs2839186	0.587	rs35679325	ENSG00000228137.1	AP001469.7	-3.77	0.000173	0.0101	-0.13	-0.12	Testicular germ cell tumor;	chr21:46221066	chr21:46246890~46247682:+
BRCA	cis	rs7267979	0.903	rs2500400	ENSG00000274973.1	RP13-401N8.7	3.77	0.000173	0.0101	0.13	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25374069	chr20:25845497~25845862:+
BRCA	cis	rs4648045	0.796	rs9790601	ENSG00000251288.2	RP11-10L12.2	-3.77	0.000173	0.0101	-0.15	-0.12	Lymphocyte percentage of white cells;	chr4:102608806	chr4:102751401~102752641:+
BRCA	cis	rs2692947	0.711	rs56791141	ENSG00000232931.4	LINC00342	3.77	0.000173	0.0101	0.12	0.12	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95921748	chr2:95807118~95816215:-
BRCA	cis	rs2486012	0.678	rs2906460	ENSG00000237950.1	RP11-7O11.3	3.77	0.000173	0.0101	0.19	0.12	Intelligence (multi-trait analysis);	chr1:43869651	chr1:43944370~43946551:-
BRCA	cis	rs1048886	0.872	rs75782125	ENSG00000271967.1	RP11-134K13.4	-3.77	0.000173	0.0101	-0.17	-0.12	Type 2 diabetes;	chr6:70550554	chr6:70596438~70596980:+
BRCA	cis	rs10761482	0.775	rs1459725	ENSG00000254271.1	RP11-131N11.4	3.77	0.000173	0.0101	0.17	0.12	Schizophrenia;	chr10:60378850	chr10:60734342~60741828:+
BRCA	cis	rs74233809	1	rs75970938	ENSG00000213061.2	PFN1P11	3.77	0.000173	0.0101	0.26	0.12	Birth weight;	chr10:103033891	chr10:102838011~102845473:-
BRCA	cis	rs4478858	0.647	rs11577679	ENSG00000223907.1	LINC01226	-3.77	0.000173	0.0101	-0.14	-0.12	Alcohol dependence;	chr1:31253338	chr1:31518435~31524245:+
BRCA	cis	rs911555	0.755	rs17841064	ENSG00000269910.1	RP11-73M18.10	3.77	0.000173	0.0101	0.12	0.12	Intelligence (multi-trait analysis);	chr14:103434272	chr14:103694516~103695050:-
BRCA	cis	rs180730	0.752	rs7689532	ENSG00000251609.2	SETP12	3.77	0.000173	0.0101	0.21	0.12	Fasting plasma glucose;	chr4:120928441	chr4:120895494~120897083:-
BRCA	cis	rs360929	0.608	rs360903	ENSG00000245954.5	RP11-18H21.1	3.77	0.000173	0.0101	0.14	0.12	Volumetric brain MRI;	chr4:151936959	chr4:152100754~152104720:+
BRCA	cis	rs584438	0.873	rs1009570	ENSG00000279806.1	RP11-58O9.2	-3.77	0.000173	0.0101	-0.16	-0.12	Height;	chr17:40440173	chr17:40473554~40475289:-
BRCA	cis	rs67981189	0.593	rs221917	ENSG00000258571.1	PTTG4P	3.77	0.000173	0.0101	0.13	0.12	Schizophrenia;	chr14:71123286	chr14:71085482~71085833:-
BRCA	cis	rs78472555	0.633	rs2123930	ENSG00000259363.4	CTD-2054N24.2	-3.77	0.000173	0.0101	-0.15	-0.12	Post bronchodilator FEV1/FVC ratio in COPD;	chr15:99690828	chr15:99807023~99877148:+
BRCA	cis	rs2712184	0.967	rs1014680	ENSG00000237930.1	AC007563.4	-3.77	0.000173	0.0101	-0.13	-0.12	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);	chr2:216808101	chr2:216785774~216786144:-
BRCA	cis	rs2455799	0.533	rs924754	ENSG00000224728.1	AC090945.1	-3.77	0.000173	0.0101	-0.11	-0.12	Mean platelet volume;	chr3:15714708	chr3:15878047~15879571:+
BRCA	cis	rs2835345	0.563	rs12482435	ENSG00000233818.1	AP000695.4	3.77	0.000173	0.0101	0.12	0.12	Pulmonary function;	chr21:36448658	chr21:36445731~36532408:+
BRCA	cis	rs911555	0.755	rs2756122	ENSG00000244691.1	RPL10AP1	-3.77	0.000173	0.0101	-0.15	-0.12	Intelligence (multi-trait analysis);	chr14:103516696	chr14:103412119~103412761:-
BRCA	cis	rs831571	1	rs831571	ENSG00000280620.1	SCAANT1	-3.77	0.000173	0.0101	-0.17	-0.12	Type 2 diabetes;	chr3:64062621	chr3:63911518~63911772:-
BRCA	cis	rs9844666	0.512	rs2204259	ENSG00000273486.1	RP11-731C17.2	3.77	0.000174	0.0101	0.13	0.12	Height;	chr3:135934430	chr3:136837338~136839021:-
BRCA	cis	rs11098499	0.955	rs35434465	ENSG00000260404.2	RP11-384K6.6	3.77	0.000174	0.0101	0.11	0.12	Corneal astigmatism;	chr4:119248223	chr4:118591773~118633729:+
BRCA	cis	rs2731006	0.591	rs11181692	ENSG00000257114.2	RP11-25I15.3	3.77	0.000174	0.0101	0.17	0.12	Panic disorder;	chr12:42812202	chr12:42692216~42717119:+
BRCA	cis	rs7651446	1	rs7651446	ENSG00000240875.4	LINC00886	-3.77	0.000174	0.0101	-0.26	-0.12	Ovarian cancer;Epithelial ovarian cancer;	chr3:156689208	chr3:156747346~156817062:-
BRCA	cis	rs16846053	0.792	rs62190674	ENSG00000227403.1	AC009299.3	3.77	0.000174	0.0101	0.3	0.12	Blood osmolality (transformed sodium);	chr2:161808451	chr2:161244739~161249050:+
BRCA	cis	rs78545713	0.649	rs11757549	ENSG00000241549.7	GUSBP2	-3.77	0.000174	0.0101	-0.2	-0.12	Iron status biomarkers (total iron binding capacity);	chr6:26231380	chr6:26871484~26956554:-
BRCA	cis	rs10924970	1	rs10924970	ENSG00000230026.2	RP11-382D8.5	-3.77	0.000174	0.0101	-0.12	-0.12	Asthma;	chr1:235199645	chr1:235361153~235362540:+
BRCA	cis	rs11696845	0.626	rs6073537	ENSG00000276223.1	RP4-781B1.5	3.77	0.000174	0.0101	0.12	0.12	Obesity-related traits;	chr20:44749629	chr20:44746642~44747201:+
BRCA	cis	rs18122	0.871	rs4671802	ENSG00000236605.1	AC023115.4	3.77	0.000174	0.0101	0.16	0.12	Waist-to-hip ratio adjusted for body mass index;	chr2:67420299	chr2:67324627~67325304:+
BRCA	cis	rs875971	1	rs3981131	ENSG00000271064.1	RP11-792A8.3	-3.77	0.000174	0.0101	-0.13	-0.12	Aortic root size;	chr7:66486690	chr7:66748838~66749077:-
BRCA	cis	rs935334	1	rs935334	ENSG00000258454.1	RP11-361H10.3	3.77	0.000174	0.0101	0.18	0.12	Blood pressure;	chr14:76147335	chr14:76235817~76263474:+
BRCA	cis	rs11098499	0.874	rs7661020	ENSG00000260404.2	RP11-384K6.6	3.77	0.000174	0.0101	0.12	0.12	Corneal astigmatism;	chr4:119185827	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.909	rs11723757	ENSG00000250412.1	KLHL2P1	3.77	0.000174	0.0101	0.14	0.12	Corneal astigmatism;	chr4:119378514	chr4:119334329~119378233:+
BRCA	cis	rs9921338	0.924	rs72773831	ENSG00000263080.1	RP11-485G7.5	3.77	0.000174	0.0101	0.18	0.12	Vein graft stenosis in coronary artery bypass grafting;	chr16:11319070	chr16:11341809~11345211:-
BRCA	cis	rs4916588	0.697	rs73080424	ENSG00000230732.4	AC127904.2	3.77	0.000174	0.0101	0.15	0.12	Night sleep phenotypes;	chr3:196929209	chr3:196912646~196914579:+
BRCA	cis	rs75504410	0.579	rs337626	ENSG00000231160.8	KLF3-AS1	-3.77	0.000174	0.0101	-0.16	-0.12	Sum eosinophil basophil counts;Eosinophil counts;	chr4:38629856	chr4:38612701~38664883:-
BRCA	cis	rs957448	0.561	rs7459558	ENSG00000254315.1	RP11-267M23.3	3.77	0.000174	0.0101	0.14	0.12	Nonsyndromic cleft lip with cleft palate;	chr8:94598618	chr8:94533628~94534391:+
BRCA	cis	rs7818688	1	rs7818688	ENSG00000245080.5	RP11-320N21.1	-3.77	0.000174	0.0101	-0.2	-0.12	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95011854	chr8:95066808~95073182:-
BRCA	cis	rs1865760	0.613	rs9358894	ENSG00000272462.2	U91328.19	-3.77	0.000174	0.0101	-0.14	-0.12	Height;	chr6:25923087	chr6:25992662~26001775:+
BRCA	cis	rs6121246	0.559	rs6058462	ENSG00000230613.1	HM13-AS1	3.77	0.000174	0.0101	0.16	0.12	Mean corpuscular hemoglobin;	chr20:31779871	chr20:31567707~31573263:-
BRCA	cis	rs783540	1	rs6603033	ENSG00000274376.3	ADAMTS7P1	3.77	0.000174	0.0101	0.13	0.12	Schizophrenia;	chr15:82667123	chr15:82298553~82334609:+
BRCA	cis	rs2664588	0.741	rs4810744	ENSG00000276923.1	RP11-321P16.1	-3.77	0.000174	0.0101	-0.15	-0.12	Cerebrospinal fluid AB1-42 levels;	chr20:47991053	chr20:48073869~48074188:+
BRCA	cis	rs11098499	0.618	rs35265692	ENSG00000250412.1	KLHL2P1	3.77	0.000174	0.0101	0.14	0.12	Corneal astigmatism;	chr4:119403980	chr4:119334329~119378233:+
BRCA	cis	rs7572733	0.555	rs7590828	ENSG00000231621.1	AC013264.2	3.77	0.000174	0.0101	0.11	0.12	Dermatomyositis;	chr2:198075527	chr2:197197991~197199273:+
BRCA	cis	rs4819052	0.851	rs10470258	ENSG00000215447.6	BX322557.10	-3.77	0.000174	0.0101	-0.12	-0.12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239074	chr21:45288052~45291738:+
BRCA	cis	rs4819052	0.851	rs4819038	ENSG00000215447.6	BX322557.10	-3.77	0.000174	0.0101	-0.12	-0.12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239478	chr21:45288052~45291738:+
BRCA	cis	rs4819052	0.851	rs4819039	ENSG00000215447.6	BX322557.10	-3.77	0.000174	0.0101	-0.12	-0.12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239543	chr21:45288052~45291738:+
BRCA	cis	rs4819052	0.851	rs4818768	ENSG00000215447.6	BX322557.10	-3.77	0.000174	0.0101	-0.12	-0.12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239903	chr21:45288052~45291738:+
BRCA	cis	rs4819052	0.851	rs4819042	ENSG00000215447.6	BX322557.10	-3.77	0.000174	0.0101	-0.12	-0.12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240157	chr21:45288052~45291738:+
BRCA	cis	rs4819052	0.8	rs4819045	ENSG00000215447.6	BX322557.10	-3.77	0.000174	0.0101	-0.12	-0.12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240223	chr21:45288052~45291738:+
BRCA	cis	rs4819052	0.851	rs13047598	ENSG00000215447.6	BX322557.10	-3.77	0.000174	0.0101	-0.12	-0.12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240862	chr21:45288052~45291738:+
BRCA	cis	rs4819052	0.724	rs9753962	ENSG00000215447.6	BX322557.10	-3.77	0.000174	0.0101	-0.12	-0.12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45241469	chr21:45288052~45291738:+
BRCA	cis	rs4819052	0.724	rs9753987	ENSG00000215447.6	BX322557.10	-3.77	0.000174	0.0101	-0.12	-0.12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45241474	chr21:45288052~45291738:+
BRCA	cis	rs4819052	0.851	rs9753963	ENSG00000215447.6	BX322557.10	-3.77	0.000174	0.0101	-0.12	-0.12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45241522	chr21:45288052~45291738:+
BRCA	cis	rs13126694	0.633	rs4513617	ENSG00000248429.4	RP11-597D13.9	3.77	0.000174	0.0101	0.11	0.12	Blood osmolality (transformed sodium);	chr4:158080045	chr4:158170752~158202877:+
BRCA	cis	rs7712401	0.755	rs1870560	ENSG00000251538.4	RP11-166A12.1	3.77	0.000174	0.0101	0.13	0.12	Mean platelet volume;	chr5:122775515	chr5:122628952~122730685:-
BRCA	cis	rs9470794	0.748	rs76368268	ENSG00000204110.6	RP1-153P14.8	-3.77	0.000174	0.0101	-0.25	-0.12	Type 2 diabetes;	chr6:37814967	chr6:37507348~37535616:+
BRCA	cis	rs9840812	0.773	rs61789601	ENSG00000273486.1	RP11-731C17.2	-3.77	0.000174	0.0101	-0.17	-0.12	Fibrinogen levels;	chr3:136236137	chr3:136837338~136839021:-
BRCA	cis	rs375066	0.935	rs425221	ENSG00000267191.1	RP11-15A1.2	3.77	0.000174	0.0101	0.15	0.12	Breast cancer;	chr19:43914392	chr19:43902001~43926545:+
BRCA	cis	rs7487075	0.619	rs7485580	ENSG00000257261.4	RP11-96H19.1	3.77	0.000174	0.0101	0.13	0.12	Itch intensity from mosquito bite;	chr12:46436591	chr12:46383679~46876159:+
BRCA	cis	rs7487075	0.619	rs4768717	ENSG00000257261.4	RP11-96H19.1	3.77	0.000174	0.0101	0.13	0.12	Itch intensity from mosquito bite;	chr12:46437778	chr12:46383679~46876159:+
BRCA	cis	rs219780	0.898	rs219789	ENSG00000233818.1	AP000695.4	3.77	0.000174	0.0101	0.13	0.12	Kidney stones;	chr21:36456742	chr21:36445731~36532408:+
BRCA	cis	rs6743226	0.566	rs59065053	ENSG00000266621.1	AC104841.1	3.77	0.000174	0.0101	0.14	0.12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in non-smokers;	chr2:241281151	chr2:241245202~241245299:-
BRCA	cis	rs7759001	0.681	rs7756377	ENSG00000237154.2	MCFD2P1	3.77	0.000174	0.0101	0.14	0.12	Glomerular filtration rate (creatinine);	chr6:27513882	chr6:27407697~27407996:+
BRCA	cis	rs11992162	0.591	rs35657308	ENSG00000255495.1	AC145124.2	-3.77	0.000174	0.0101	-0.13	-0.12	Monocyte count;	chr8:11946893	chr8:12194467~12196280:+
BRCA	cis	rs7712401	0.755	rs10900759	ENSG00000251538.4	RP11-166A12.1	3.77	0.000174	0.0101	0.12	0.12	Mean platelet volume;	chr5:122769385	chr5:122628952~122730685:-
BRCA	cis	rs875971	0.706	rs1643374	ENSG00000265600.1	AC006480.1	-3.77	0.000174	0.0101	-0.14	-0.12	Aortic root size;	chr7:66407695	chr7:67356680~67356779:+
BRCA	cis	rs4415084	0.804	rs4412123	ENSG00000248779.1	RP11-53O19.2	-3.77	0.000174	0.0101	-0.11	-0.12	Breast cancer;	chr5:44876186	chr5:44752949~44765744:+
BRCA	cis	rs17684571	0.938	rs13206849	ENSG00000231441.1	RP11-472M19.2	3.77	0.000174	0.0101	0.18	0.12	Schizophrenia;	chr6:56701823	chr6:56844002~56864078:+
BRCA	cis	rs7267979	1	rs6115153	ENSG00000204556.4	CTD-2514C3.1	3.77	0.000174	0.0101	0.16	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25344931	chr20:26018832~26020684:+
BRCA	cis	rs2839186	0.771	rs13046451	ENSG00000228137.1	AP001469.7	-3.77	0.000174	0.0101	-0.12	-0.12	Testicular germ cell tumor;	chr21:46221459	chr21:46246890~46247682:+
BRCA	cis	rs6600671	0.693	rs1853731	ENSG00000223345.3	HIST2H2BA	3.77	0.000174	0.0101	0.15	0.12	Hip geometry;	chr1:121510262	chr1:121108210~121117257:-
BRCA	cis	rs1730008	0.691	rs6441193	ENSG00000279311.1	RP11-170K4.2	3.77	0.000174	0.0101	0.15	0.12	Lobe attachment (rater-scored or self-reported);	chr3:158390255	chr3:158869898~158871821:+
BRCA	cis	rs1730008	0.731	rs12053865	ENSG00000279311.1	RP11-170K4.2	3.77	0.000174	0.0101	0.15	0.12	Lobe attachment (rater-scored or self-reported);	chr3:158391674	chr3:158869898~158871821:+
BRCA	cis	rs1730008	0.731	rs12053869	ENSG00000279311.1	RP11-170K4.2	3.77	0.000174	0.0101	0.15	0.12	Lobe attachment (rater-scored or self-reported);	chr3:158391935	chr3:158869898~158871821:+
BRCA	cis	rs1730008	0.691	rs7640075	ENSG00000279311.1	RP11-170K4.2	3.77	0.000174	0.0101	0.15	0.12	Lobe attachment (rater-scored or self-reported);	chr3:158392920	chr3:158869898~158871821:+
BRCA	cis	rs1730008	0.691	rs73170375	ENSG00000279311.1	RP11-170K4.2	3.77	0.000174	0.0101	0.15	0.12	Lobe attachment (rater-scored or self-reported);	chr3:158396033	chr3:158869898~158871821:+
BRCA	cis	rs9650657	0.547	rs11250099	ENSG00000255046.1	RP11-297N6.4	-3.77	0.000174	0.0101	-0.14	-0.12	Neuroticism;	chr8:10961147	chr8:11797928~11802568:-
BRCA	cis	rs12122100	0.696	rs12733095	ENSG00000278811.3	LINC00624	-3.77	0.000174	0.0101	-0.14	-0.12	HIV-1 control;	chr1:147074193	chr1:147258885~147517875:-
BRCA	cis	rs6993270	0.779	rs56331180	ENSG00000245330.4	KB-1471A8.1	-3.77	0.000174	0.0101	-0.18	-0.12	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr8:119913295	chr8:119867419~119874488:-
BRCA	cis	rs71520386	0.583	rs28799344	ENSG00000230658.1	KLHL7-AS1	3.77	0.000174	0.0101	0.17	0.12	Fibrinogen levels;	chr7:22805647	chr7:23101228~23105703:-
BRCA	cis	rs875971	0.798	rs57739047	ENSG00000271064.1	RP11-792A8.3	-3.77	0.000174	0.0101	-0.14	-0.12	Aortic root size;	chr7:66507579	chr7:66748838~66749077:-
BRCA	cis	rs9287719	0.967	rs10203664	ENSG00000224177.5	LINC00570	3.77	0.000174	0.0101	0.14	0.12	Prostate cancer;	chr2:10612251	chr2:11393981~11403077:+
BRCA	cis	rs9287719	0.934	rs10201077	ENSG00000224177.5	LINC00570	3.77	0.000174	0.0101	0.14	0.12	Prostate cancer;	chr2:10612300	chr2:11393981~11403077:+
BRCA	cis	rs9287719	0.967	rs9287720	ENSG00000224177.5	LINC00570	3.77	0.000174	0.0101	0.14	0.12	Prostate cancer;	chr2:10612538	chr2:11393981~11403077:+
BRCA	cis	rs9287719	0.87	rs10167676	ENSG00000224177.5	LINC00570	3.77	0.000174	0.0101	0.14	0.12	Prostate cancer;	chr2:10613014	chr2:11393981~11403077:+
BRCA	cis	rs9287719	0.967	rs12995159	ENSG00000224177.5	LINC00570	3.77	0.000174	0.0101	0.14	0.12	Prostate cancer;	chr2:10613197	chr2:11393981~11403077:+
BRCA	cis	rs9287719	0.967	rs12995602	ENSG00000224177.5	LINC00570	3.77	0.000174	0.0101	0.14	0.12	Prostate cancer;	chr2:10613416	chr2:11393981~11403077:+
BRCA	cis	rs9287719	0.967	rs6432119	ENSG00000224177.5	LINC00570	3.77	0.000174	0.0101	0.14	0.12	Prostate cancer;	chr2:10613561	chr2:11393981~11403077:+
BRCA	cis	rs9287719	0.967	rs6432120	ENSG00000224177.5	LINC00570	3.77	0.000174	0.0101	0.14	0.12	Prostate cancer;	chr2:10613645	chr2:11393981~11403077:+
BRCA	cis	rs9287719	0.967	rs6432122	ENSG00000224177.5	LINC00570	3.77	0.000174	0.0101	0.14	0.12	Prostate cancer;	chr2:10613718	chr2:11393981~11403077:+
BRCA	cis	rs9287719	0.967	rs6712406	ENSG00000224177.5	LINC00570	3.77	0.000174	0.0101	0.14	0.12	Prostate cancer;	chr2:10614294	chr2:11393981~11403077:+
BRCA	cis	rs9287719	0.967	rs10195802	ENSG00000224177.5	LINC00570	3.77	0.000174	0.0101	0.14	0.12	Prostate cancer;	chr2:10614406	chr2:11393981~11403077:+
BRCA	cis	rs9287719	0.967	rs7566875	ENSG00000224177.5	LINC00570	3.77	0.000174	0.0101	0.14	0.12	Prostate cancer;	chr2:10614666	chr2:11393981~11403077:+
BRCA	cis	rs9287719	0.934	rs4371336	ENSG00000224177.5	LINC00570	3.77	0.000174	0.0101	0.14	0.12	Prostate cancer;	chr2:10615597	chr2:11393981~11403077:+
BRCA	cis	rs9287719	0.967	rs4405729	ENSG00000224177.5	LINC00570	3.77	0.000174	0.0101	0.14	0.12	Prostate cancer;	chr2:10615653	chr2:11393981~11403077:+
BRCA	cis	rs17214007	0.877	rs11075281	ENSG00000279866.1	CTB-193M12.4	3.77	0.000175	0.0101	0.18	0.12	Cognitive function;	chr16:15780585	chr16:15704410~15705984:+
BRCA	cis	rs2346177	0.875	rs2166745	ENSG00000279254.1	RP11-536C12.1	-3.77	0.000175	0.0101	-0.14	-0.12	HDL cholesterol;	chr2:46419740	chr2:46668870~46670778:+
BRCA	cis	rs987724	0.778	rs35874547	ENSG00000240875.4	LINC00886	-3.77	0.000175	0.0101	-0.14	-0.12	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156972867	chr3:156747346~156817062:-
BRCA	cis	rs10129255	0.957	rs10141052	ENSG00000232216.1	IGHV3-43	3.77	0.000175	0.0101	0.09	0.12	Kawasaki disease;	chr14:106776528	chr14:106470264~106470800:-
BRCA	cis	rs17270561	0.585	rs9393663	ENSG00000272462.2	U91328.19	-3.77	0.000175	0.0101	-0.14	-0.12	Iron status biomarkers;	chr6:25740805	chr6:25992662~26001775:+
BRCA	cis	rs495337	0.965	rs6122848	ENSG00000229222.1	KRT18P4	-3.77	0.000175	0.0101	-0.14	-0.12	Psoriasis;	chr20:49930020	chr20:49956745~49958032:+
BRCA	cis	rs7682431	0.513	rs2869966	ENSG00000270720.1	RP11-84C13.2	3.77	0.000175	0.0101	0.13	0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr4:88947927	chr4:89119284~89119871:+
BRCA	cis	rs11098499	0.954	rs878373	ENSG00000260091.1	RP11-33B1.4	-3.77	0.000175	0.0101	-0.1	-0.12	Corneal astigmatism;	chr4:119316329	chr4:119409333~119410233:+
BRCA	cis	rs6964587	1	rs9691325	ENSG00000188693.7	CYP51A1-AS1	-3.77	0.000175	0.0101	-0.12	-0.12	Breast cancer;	chr7:92101733	chr7:92134604~92180725:+
BRCA	cis	rs733592	0.507	rs3825403	ENSG00000273765.1	RP11-370I10.11	-3.77	0.000175	0.0101	-0.13	-0.12	Plateletcrit;	chr12:48063376	chr12:48360920~48361377:+
BRCA	cis	rs733592	0.507	rs10747529	ENSG00000273765.1	RP11-370I10.11	-3.77	0.000175	0.0101	-0.13	-0.12	Plateletcrit;	chr12:48079586	chr12:48360920~48361377:+
BRCA	cis	rs11673344	0.566	rs11666708	ENSG00000233527.7	ZNF529-AS1	-3.77	0.000175	0.0101	-0.13	-0.12	Obesity-related traits;	chr19:37396208	chr19:36573070~36594708:+
BRCA	cis	rs295490	0.748	rs78230813	ENSG00000272656.1	RP11-219D15.3	3.77	0.000175	0.0101	0.29	0.12	PR interval in Tripanosoma cruzi seropositivity;	chr3:139441345	chr3:139349024~139349371:-
BRCA	cis	rs875971	0.862	rs4718319	ENSG00000271064.1	RP11-792A8.3	3.77	0.000175	0.0101	0.14	0.12	Aortic root size;	chr7:66187797	chr7:66748838~66749077:-
BRCA	cis	rs875971	0.723	rs28391294	ENSG00000271064.1	RP11-792A8.3	3.77	0.000175	0.0101	0.14	0.12	Aortic root size;	chr7:66189328	chr7:66748838~66749077:-
BRCA	cis	rs875971	0.83	rs6967708	ENSG00000271064.1	RP11-792A8.3	3.77	0.000175	0.0101	0.14	0.12	Aortic root size;	chr7:66192326	chr7:66748838~66749077:-
BRCA	cis	rs875971	0.895	rs7782806	ENSG00000271064.1	RP11-792A8.3	3.77	0.000175	0.0101	0.14	0.12	Aortic root size;	chr7:66192910	chr7:66748838~66749077:-
BRCA	cis	rs987724	0.593	rs2874494	ENSG00000240875.4	LINC00886	-3.77	0.000175	0.0101	-0.14	-0.12	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156964340	chr3:156747346~156817062:-
BRCA	cis	rs11603020	0.95	rs11229066	ENSG00000265566.2	RN7SL605P	-3.77	0.000175	0.0101	-0.17	-0.12	Blood protein levels;	chr11:57607398	chr11:57528085~57528365:-
BRCA	cis	rs1865760	0.534	rs2032444	ENSG00000272462.2	U91328.19	-3.77	0.000175	0.0101	-0.15	-0.12	Height;	chr6:26046516	chr6:25992662~26001775:+
BRCA	cis	rs1910358	0.718	rs6863835	ENSG00000248874.4	C5orf17	-3.77	0.000175	0.0101	-0.15	-0.12	Venous thromboembolism (SNP x SNP interaction);	chr5:23996854	chr5:23951348~24178263:+
BRCA	cis	rs1910358	0.676	rs1501942	ENSG00000248874.4	C5orf17	-3.77	0.000175	0.0101	-0.15	-0.12	Venous thromboembolism (SNP x SNP interaction);	chr5:23998508	chr5:23951348~24178263:+
BRCA	cis	rs7712401	0.755	rs965821	ENSG00000251538.4	RP11-166A12.1	3.77	0.000175	0.0102	0.13	0.12	Mean platelet volume;	chr5:122802013	chr5:122628952~122730685:-
BRCA	cis	rs8064024	0.599	rs882235	ENSG00000267077.1	RP11-127I20.5	3.77	0.000175	0.0102	0.12	0.12	Cancer;	chr16:4881650	chr16:4795265~4796532:-
BRCA	cis	rs73201462	1	rs7374952	ENSG00000242551.2	POU5F1P6	3.77	0.000175	0.0102	0.19	0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128282524	chr3:128674735~128677005:-
BRCA	cis	rs9470794	1	rs76615764	ENSG00000204110.6	RP1-153P14.8	-3.77	0.000175	0.0102	-0.24	-0.12	Type 2 diabetes;	chr6:38030400	chr6:37507348~37535616:+
BRCA	cis	rs875971	0.862	rs13226170	ENSG00000229886.1	RP5-1132H15.3	3.77	0.000175	0.0102	0.13	0.12	Aortic root size;	chr7:66534311	chr7:66025126~66031544:-
BRCA	cis	rs875971	0.862	rs2420611	ENSG00000229886.1	RP5-1132H15.3	3.77	0.000175	0.0102	0.13	0.12	Aortic root size;	chr7:66534333	chr7:66025126~66031544:-
BRCA	cis	rs42490	0.51	rs218885	ENSG00000251136.7	RP11-37B2.1	3.77	0.000175	0.0102	0.11	0.12	Leprosy;	chr8:89678313	chr8:89609409~89757727:-
BRCA	cis	rs12906542	0.516	rs4886989	ENSG00000259792.1	RP11-114H24.6	-3.77	0.000175	0.0102	-0.17	-0.12	Breast cancer;	chr15:78011406	chr15:77993405~77995289:+
BRCA	cis	rs4971059	0.654	rs4276913	ENSG00000160766.13	GBAP1	-3.77	0.000175	0.0102	-0.11	-0.12	Breast cancer;	chr1:155159197	chr1:155213821~155227422:-
BRCA	cis	rs853679	0.517	rs56310871	ENSG00000226314.6	ZNF192P1	-3.77	0.000175	0.0102	-0.17	-0.12	Depression;	chr6:28076704	chr6:28161781~28169594:+
BRCA	cis	rs2739330	0.828	rs5751770	ENSG00000228039.3	KB-1125A3.10	3.77	0.000175	0.0102	0.13	0.12	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23963780~23964374:+
BRCA	cis	rs72615157	0.539	rs2261360	ENSG00000235713.1	RP4-604G5.3	-3.77	0.000175	0.0102	-0.15	-0.12	Lung function (FEV1/FVC);	chr7:100095370	chr7:99992397~99993050:+
BRCA	cis	rs73222236	0.825	rs9868120	ENSG00000239213.4	NCK1-AS1	3.77	0.000175	0.0102	0.13	0.12	Coronary artery disease;	chr3:136446234	chr3:136841726~136862054:-
BRCA	cis	rs4845570	1	rs3811415	ENSG00000203288.3	RP11-98D18.9	-3.77	0.000175	0.0102	-0.21	-0.12	Coronary artery disease;	chr1:151791291	chr1:151790804~151794402:+
BRCA	cis	rs8062405	0.558	rs151228	ENSG00000275441.1	RP11-666O2.2	3.77	0.000175	0.0102	0.1	0.12	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28551705	chr16:28553709~28554140:-
BRCA	cis	rs2765539	1	rs2765539	ENSG00000231365.4	RP11-418J17.1	-3.77	0.000175	0.0102	-0.16	-0.12	Waist-hip ratio;	chr1:119006795	chr1:119140396~119275973:+
BRCA	cis	rs12681366	0.708	rs2515165	ENSG00000253704.1	RP11-267M23.4	-3.77	0.000175	0.0102	-0.12	-0.12	Nonsyndromic cleft lip with cleft palate;	chr8:94352616	chr8:94553722~94569745:+
BRCA	cis	rs9470794	1	rs73419947	ENSG00000204110.6	RP1-153P14.8	-3.77	0.000175	0.0102	-0.23	-0.12	Type 2 diabetes;	chr6:38070863	chr6:37507348~37535616:+
BRCA	cis	rs524281	0.861	rs10896090	ENSG00000255557.1	RP11-770G2.2	3.77	0.000175	0.0102	0.17	0.12	Electroencephalogram traits;	chr11:66177715	chr11:65745729~65771585:+
BRCA	cis	rs7985	0.901	rs736690	ENSG00000244625.4	MIATNB	3.77	0.000175	0.0102	0.13	0.12	Electroencephalogram traits;	chr22:26678805	chr22:26672767~26780207:+
BRCA	cis	rs4704187	0.506	rs3935470	ENSG00000250889.2	LINC01336	-3.77	0.000175	0.0102	-0.14	-0.12	Response to amphetamines;	chr5:75056355	chr5:75047719~75052843:-
BRCA	cis	rs801193	1	rs2420824	ENSG00000272831.1	RP11-792A8.4	-3.77	0.000175	0.0102	-0.1	-0.12	Aortic root size;	chr7:66666129	chr7:66739829~66740385:-
BRCA	cis	rs1730008	0.731	rs73168799	ENSG00000279311.1	RP11-170K4.2	3.77	0.000175	0.0102	0.15	0.12	Lobe attachment (rater-scored or self-reported);	chr3:158332149	chr3:158869898~158871821:+
BRCA	cis	rs2243480	0.522	rs431168	ENSG00000226767.1	RP11-328P23.3	-3.77	0.000175	0.0102	-0.25	-0.12	Diabetic kidney disease;	chr7:66046617	chr7:65508773~65508944:-
BRCA	cis	rs4950322	0.57	rs79810882	ENSG00000237188.3	RP11-337C18.8	3.77	0.000175	0.0102	0.15	0.12	Protein quantitative trait loci;	chr1:147235575	chr1:147172771~147211568:+
BRCA	cis	rs6545883	0.718	rs3771260	ENSG00000212978.6	AC016747.3	3.77	0.000175	0.0102	0.16	0.12	Tuberculosis;	chr2:61535249	chr2:61141592~61144969:-
BRCA	cis	rs875971	0.545	rs35459055	ENSG00000273448.1	RP11-166O4.6	3.77	0.000175	0.0102	0.12	0.12	Aortic root size;	chr7:66479399	chr7:67333047~67334383:+
BRCA	cis	rs7267979	0.934	rs2257464	ENSG00000276952.1	RP5-965G21.6	3.77	0.000175	0.0102	0.14	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25285236	chr20:25284915~25285588:-
BRCA	cis	rs853679	0.882	rs4713140	ENSG00000216901.1	AL022393.7	3.77	0.000175	0.0102	0.23	0.12	Depression;	chr6:28129415	chr6:28176188~28176674:+
BRCA	cis	rs62458065	0.568	rs62463963	ENSG00000273014.1	RP11-225B17.2	-3.77	0.000175	0.0102	-0.18	-0.12	Metabolite levels (HVA/MHPG ratio);	chr7:32447079	chr7:32758882~32759353:+
BRCA	cis	rs17123764	0.892	rs60094911	ENSG00000257464.1	RP11-161H23.8	-3.77	0.000175	0.0102	-0.21	-0.12	Intelligence (multi-trait analysis);	chr12:49726505	chr12:49442424~49442652:-
BRCA	cis	rs853679	0.567	rs13196606	ENSG00000220721.1	OR1F12	3.77	0.000175	0.0102	0.15	0.12	Depression;	chr6:28402301	chr6:28073316~28074233:+
BRCA	cis	rs4835473	0.932	rs4835279	ENSG00000249741.2	RP11-673E1.3	3.77	0.000175	0.0102	0.12	0.12	Immature fraction of reticulocytes;	chr4:143788917	chr4:143911514~143912053:-
BRCA	cis	rs2262909	0.962	rs55728714	ENSG00000279377.1	AC003973.3	-3.77	0.000175	0.0102	-0.16	-0.12	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;	chr19:22080097	chr19:21965708~21968529:-
BRCA	cis	rs2262909	0.962	rs12609368	ENSG00000279377.1	AC003973.3	-3.77	0.000175	0.0102	-0.16	-0.12	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;	chr19:22081194	chr19:21965708~21968529:-
BRCA	cis	rs2562456	0.917	rs2650805	ENSG00000268555.1	RP11-678G14.3	-3.77	0.000176	0.0102	-0.15	-0.12	Pain;	chr19:21505137	chr19:21570822~21587322:-
BRCA	cis	rs8114671	0.527	rs6088650	ENSG00000279253.1	RP4-614O4.13	3.77	0.000176	0.0102	0.13	0.12	Height;	chr20:34926662	chr20:35262727~35264187:-
BRCA	cis	rs875971	0.54	rs736270	ENSG00000273142.1	RP11-458F8.4	-3.77	0.000176	0.0102	-0.1	-0.12	Aortic root size;	chr7:65963835	chr7:66902857~66906297:+
BRCA	cis	rs1009077	0.68	rs3775856	ENSG00000245958.5	RP11-33B1.1	3.77	0.000176	0.0102	0.14	0.12	Endometriosis;	chr4:119562006	chr4:119454791~119552025:+
BRCA	cis	rs2839186	0.588	rs7280110	ENSG00000228137.1	AP001469.7	-3.77	0.000176	0.0102	-0.12	-0.12	Testicular germ cell tumor;	chr21:46199125	chr21:46246890~46247682:+
BRCA	cis	rs2839186	0.616	rs4819213	ENSG00000228137.1	AP001469.7	-3.77	0.000176	0.0102	-0.12	-0.12	Testicular germ cell tumor;	chr21:46199386	chr21:46246890~46247682:+
BRCA	cis	rs8023401	0.882	rs16961068	ENSG00000274654.1	CTD-3247H4.2	3.77	0.000176	0.0102	0.16	0.12	Spherical equivalent (joint analysis main effects and education interaction);	chr15:48514756	chr15:48528980~48529728:-
BRCA	cis	rs9470794	1	rs78106651	ENSG00000204110.6	RP1-153P14.8	-3.77	0.000176	0.0102	-0.22	-0.12	Type 2 diabetes;	chr6:38157498	chr6:37507348~37535616:+
BRCA	cis	rs11773103	0.609	rs73194676	ENSG00000224046.1	AC005076.5	3.77	0.000176	0.0102	0.24	0.12	Bipolar disorder or major depressive disorder (combined);	chr7:87353117	chr7:87151423~87152420:-
BRCA	cis	rs78487399	0.808	rs17030889	ENSG00000234936.1	AC010883.5	3.77	0.000176	0.0102	0.17	0.12	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43475690	chr2:43229573~43233394:+
BRCA	cis	rs2455799	0.573	rs2455812	ENSG00000224728.1	AC090945.1	-3.77	0.000176	0.0102	-0.11	-0.12	Mean platelet volume;	chr3:15692589	chr3:15878047~15879571:+
BRCA	cis	rs7903456	0.648	rs2296061	ENSG00000224914.2	LINC00863	-3.77	0.000176	0.0102	-0.14	-0.12	Gout;Renal underexcretion gout;	chr10:87068293	chr10:87342736~87357882:+
BRCA	cis	rs62025270	0.632	rs62023935	ENSG00000259416.2	RP11-158M2.5	-3.77	0.000176	0.0102	-0.17	-0.12	Idiopathic pulmonary fibrosis;	chr15:85605604	chr15:85754941~85756237:-
BRCA	cis	rs7267979	1	rs6115182	ENSG00000276952.1	RP5-965G21.6	-3.77	0.000176	0.0102	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25429623	chr20:25284915~25285588:-
BRCA	cis	rs1577917	0.74	rs9353320	ENSG00000220563.1	PKMP3	3.77	0.000176	0.0102	0.12	0.12	Response to antipsychotic treatment;	chr6:85535130	chr6:85659892~85660606:-
BRCA	cis	rs7824557	0.564	rs2736295	ENSG00000255020.1	AF131216.5	-3.77	0.000176	0.0102	-0.13	-0.12	Retinal vascular caliber;	chr8:11377271	chr8:11345748~11347502:-
BRCA	cis	rs7812879	0.636	rs2618455	ENSG00000254866.2	DEFB109P3	3.77	0.000176	0.0102	0.19	0.12	Systemic lupus erythematosus;	chr8:11513369	chr8:12150895~12151134:-
BRCA	cis	rs2274459	1	rs3793080	ENSG00000249346.5	LINC01016	-3.77	0.000176	0.0102	-0.15	-0.12	Obesity (extreme);	chr6:33800026	chr6:33867506~33896914:-
BRCA	cis	rs1670533	1	rs2045069	ENSG00000251639.2	RP11-20I20.1	3.77	0.000176	0.0102	0.18	0.12	Recombination rate (females);	chr4:1058418	chr4:1100016~1101558:-
BRCA	cis	rs13104971	1	rs13104971	ENSG00000212588.1	SNORA26	-3.77	0.000176	0.0102	-0.18	-0.12	Lifetime average cigarettes per day in chronic obstructive pulmonary disease;	chr4:52953988	chr4:52713249~52713370:+
BRCA	cis	rs62103177	0.525	rs4799116	ENSG00000278075.1	RP11-248M19.1	-3.76	0.000176	0.0102	-0.18	-0.12	Opioid sensitivity;	chr18:79976735	chr18:79900555~79900903:-
BRCA	cis	rs11098499	0.954	rs2389802	ENSG00000260404.2	RP11-384K6.6	3.76	0.000176	0.0102	0.11	0.12	Corneal astigmatism;	chr4:119404577	chr4:118591773~118633729:+
BRCA	cis	rs524281	0.731	rs11227439	ENSG00000255038.1	RP11-1167A19.2	-3.76	0.000176	0.0102	-0.18	-0.12	Electroencephalogram traits;	chr11:66258208	chr11:66067277~66069619:-
BRCA	cis	rs477895	0.639	rs35858916	ENSG00000256940.1	RP11-783K16.5	3.76	0.000176	0.0102	0.16	0.12	Mean platelet volume;	chr11:64183057	chr11:64245964~64248217:+
BRCA	cis	rs875971	0.862	rs35378740	ENSG00000229886.1	RP5-1132H15.3	3.76	0.000176	0.0102	0.13	0.12	Aortic root size;	chr7:66522725	chr7:66025126~66031544:-
BRCA	cis	rs10411262	0.506	rs6509290	ENSG00000245598.5	DACT3-AS1	-3.76	0.000176	0.0102	-0.16	-0.12	Tonsillectomy;	chr19:46680583	chr19:46660364~46677447:+
BRCA	cis	rs7703051	1	rs11749783	ENSG00000271815.1	CTD-2235C13.3	-3.76	0.000176	0.0102	-0.15	-0.12	Age-related diseases, mortality and associated endophenotypes;LDL cholesterol;Age-related disease endophenotypes;	chr5:75330257	chr5:75363760~75364242:+
BRCA	cis	rs1371614	0.569	rs486582	ENSG00000229122.1	AGBL5-IT1	3.76	0.000176	0.0102	0.12	0.12	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26881263	chr2:27061038~27061815:+
BRCA	cis	rs11955398	0.604	rs1445852	ENSG00000215032.2	GNL3LP1	3.76	0.000176	0.0102	0.14	0.12	Intelligence (multi-trait analysis);	chr5:60595477	chr5:60891935~60893577:-
BRCA	cis	rs7111546	0.945	rs111566585	ENSG00000246225.5	RP11-17A1.3	3.76	0.000176	0.0102	0.2	0.12	Dialysis-related mortality;	chr11:22816267	chr11:22829380~22945393:+
BRCA	cis	rs10411161	0.702	rs10403189	ENSG00000269483.1	AC006272.1	-3.76	0.000176	0.0102	-0.2	-0.12	Breast cancer;	chr19:51897420	chr19:51839924~51843324:-
BRCA	cis	rs2274273	0.682	rs1187876	ENSG00000259318.1	RP11-454L9.2	-3.76	0.000176	0.0102	-0.1	-0.12	Protein biomarker;	chr14:55028481	chr14:55394940~55395233:-
BRCA	cis	rs6431644	0.694	rs556691	ENSG00000224287.2	MSL3P1	-3.76	0.000176	0.0102	-0.14	-0.12	Left atrial antero-posterior diameter;	chr2:233846929	chr2:233865437~233868444:-
BRCA	cis	rs16958440	1	rs60422392	ENSG00000267800.1	RP11-49K24.5	-3.76	0.000176	0.0102	-0.25	-0.12	Sitting height ratio;	chr18:47095102	chr18:47137018~47137290:+
BRCA	cis	rs16958440	1	rs2289130	ENSG00000267800.1	RP11-49K24.5	-3.76	0.000176	0.0102	-0.25	-0.12	Sitting height ratio;	chr18:47100259	chr18:47137018~47137290:+
BRCA	cis	rs16958440	1	rs62096463	ENSG00000267800.1	RP11-49K24.5	-3.76	0.000176	0.0102	-0.25	-0.12	Sitting height ratio;	chr18:47102557	chr18:47137018~47137290:+
BRCA	cis	rs16958440	1	rs62096464	ENSG00000267800.1	RP11-49K24.5	-3.76	0.000176	0.0102	-0.25	-0.12	Sitting height ratio;	chr18:47102836	chr18:47137018~47137290:+
BRCA	cis	rs16958440	1	rs16958432	ENSG00000267800.1	RP11-49K24.5	-3.76	0.000176	0.0102	-0.25	-0.12	Sitting height ratio;	chr18:47105402	chr18:47137018~47137290:+
BRCA	cis	rs16958440	1	rs16958440	ENSG00000267800.1	RP11-49K24.5	-3.76	0.000176	0.0102	-0.25	-0.12	Sitting height ratio;	chr18:47106513	chr18:47137018~47137290:+
BRCA	cis	rs16958440	1	rs75800624	ENSG00000267800.1	RP11-49K24.5	-3.76	0.000176	0.0102	-0.25	-0.12	Sitting height ratio;	chr18:47107234	chr18:47137018~47137290:+
BRCA	cis	rs12612435	0.91	rs66624567	ENSG00000226806.1	AC011893.3	3.76	0.000176	0.0102	0.14	0.12	Takotsubo syndrome;	chr2:136361066	chr2:135820191~135823087:+
BRCA	cis	rs930421	0.502	rs2278582	ENSG00000226491.1	FTOP1	-3.76	0.000176	0.0102	-0.14	-0.12	Attention deficit hyperactivity disorder;	chr2:42762304	chr2:42797225~42798712:-
BRCA	cis	rs35306767	0.716	rs34487581	ENSG00000229869.1	RP11-363N22.2	-3.76	0.000176	0.0102	-0.2	-0.12	Eosinophil percentage of granulocytes;	chr10:851261	chr10:933026~942743:+
BRCA	cis	rs4835473	0.932	rs4615131	ENSG00000246448.2	RP13-578N3.3	-3.76	0.000176	0.0102	-0.13	-0.12	Immature fraction of reticulocytes;	chr4:143740295	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.932	rs4499657	ENSG00000246448.2	RP13-578N3.3	-3.76	0.000176	0.0102	-0.13	-0.12	Immature fraction of reticulocytes;	chr4:143740316	chr4:143700257~143865072:+
BRCA	cis	rs375066	0.935	rs417699	ENSG00000267191.1	RP11-15A1.2	-3.76	0.000176	0.0102	-0.15	-0.12	Breast cancer;	chr19:43913423	chr19:43902001~43926545:+
BRCA	cis	rs11711311	1	rs9828099	ENSG00000241529.3	RN7SL767P	-3.76	0.000176	0.0102	-0.14	-0.12	IgG glycosylation;	chr3:113799555	chr3:113632704~113632998:+
BRCA	cis	rs11711311	1	rs9828449	ENSG00000241529.3	RN7SL767P	-3.76	0.000176	0.0102	-0.14	-0.12	IgG glycosylation;	chr3:113799755	chr3:113632704~113632998:+
BRCA	cis	rs7020830	0.823	rs13285624	ENSG00000260100.1	RP11-220I1.5	-3.76	0.000176	0.0102	-0.14	-0.12	Schizophrenia;	chr9:37129499	chr9:37078813~37079776:-
BRCA	cis	rs970548	0.672	rs56005617	ENSG00000237840.5	FAM21FP	3.76	0.000176	0.0102	0.14	0.12	Total cholesterol levels;HDL cholesterol;HDL cholesterol levels;Cholesterol, total;	chr10:45560679	chr10:45706431~45727231:-
BRCA	cis	rs1050288	0.525	rs2113882	ENSG00000230519.2	RP11-1060J15.5	-3.76	0.000176	0.0102	-0.16	-0.12	Pulse pressure;Resting heart rate;	chr12:27787987	chr12:27702338~27702906:+
BRCA	cis	rs3790268	0.527	rs6112466	ENSG00000273148.1	RP5-1068E13.7	3.76	0.000176	0.0102	0.16	0.12	Matrix metalloproteinase levels;	chr20:19574059	chr20:18794529~18796067:+
BRCA	cis	rs12701220	0.901	rs12701713	ENSG00000224079.1	AC091729.7	3.76	0.000176	0.0102	0.17	0.12	Bronchopulmonary dysplasia;	chr7:1050869	chr7:1074450~1078036:+
BRCA	cis	rs7727544	0.508	rs10900804	ENSG00000233006.5	AC034220.3	3.76	0.000176	0.0102	0.09	0.12	Blood metabolite levels;	chr5:132066152	chr5:132311285~132369916:-
BRCA	cis	rs875971	0.862	rs778684	ENSG00000229886.1	RP5-1132H15.3	3.76	0.000176	0.0102	0.13	0.12	Aortic root size;	chr7:66371416	chr7:66025126~66031544:-
BRCA	cis	rs12188164	0.62	rs1043356	ENSG00000221990.4	EXOC3-AS1	-3.76	0.000176	0.0102	-0.13	-0.12	Cystic fibrosis severity;	chr5:480833	chr5:441498~443160:-
BRCA	cis	rs8141529	0.748	rs5997412	ENSG00000226471.5	CTA-292E10.6	-3.76	0.000176	0.0102	-0.14	-0.12	Lymphocyte counts;	chr22:28880759	chr22:28800683~28848559:+
BRCA	cis	rs17772222	0.917	rs58550317	ENSG00000258789.1	RP11-507K2.3	-3.76	0.000176	0.0102	-0.14	-0.12	Coronary artery calcification;	chr14:88775243	chr14:88551597~88552493:+
BRCA	cis	rs957448	0.561	rs71532325	ENSG00000254315.1	RP11-267M23.3	3.76	0.000176	0.0102	0.14	0.12	Nonsyndromic cleft lip with cleft palate;	chr8:94615738	chr8:94533628~94534391:+
BRCA	cis	rs925550	0.932	rs6821165	ENSG00000224786.1	CETN4P	-3.76	0.000176	0.0102	-0.2	-0.12	Primary biliary cholangitis;	chr4:122688653	chr4:122730548~122732193:-
BRCA	cis	rs8180040	0.966	rs6800271	ENSG00000271161.1	BOLA2P2	-3.76	0.000176	0.0102	-0.12	-0.12	Colorectal cancer;	chr3:47429297	chr3:47499841~47500407:+
BRCA	cis	rs8062405	1	rs12446589	ENSG00000261766.1	RP11-22P6.2	-3.76	0.000176	0.0102	-0.12	-0.12	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28859641	chr16:28862166~28863340:-
BRCA	cis	rs801193	0.569	rs7782587	ENSG00000229886.1	RP5-1132H15.3	3.76	0.000176	0.0102	0.13	0.12	Aortic root size;	chr7:66701485	chr7:66025126~66031544:-
BRCA	cis	rs61864810	1	rs61864810	ENSG00000272369.1	RP11-446N19.1	3.76	0.000176	0.0102	0.12	0.12	Itch intensity from mosquito bite;	chr12:46288226	chr12:46537502~46652550:+
BRCA	cis	rs3805389	0.504	rs1873091	ENSG00000273257.1	RP11-177J6.1	-3.76	0.000176	0.0102	-0.2	-0.12	Waist-to-hip ratio adjusted for body mass index;	chr4:55605266	chr4:55387949~55388271:+
BRCA	cis	rs3805389	0.504	rs17725110	ENSG00000273257.1	RP11-177J6.1	-3.76	0.000176	0.0102	-0.2	-0.12	Waist-to-hip ratio adjusted for body mass index;	chr4:55605855	chr4:55387949~55388271:+
BRCA	cis	rs10938353	0.906	rs10028906	ENSG00000273369.1	RP11-700J17.1	3.76	0.000176	0.0102	0.14	0.12	Body mass index;	chr4:44581434	chr4:44693946~44694386:-
BRCA	cis	rs739401	0.611	rs401707	ENSG00000183562.3	CTC-343N3.1	-3.76	0.000176	0.0102	-0.12	-0.12	Longevity;	chr11:3029735	chr11:2989863~2991344:+
BRCA	cis	rs983392	0.755	rs1441586	ENSG00000275344.1	MIR6503	-3.76	0.000177	0.0102	-0.12	-0.12	Alzheimer's disease (late onset);	chr11:60088555	chr11:60209071~60209156:-
BRCA	cis	rs6964587	1	rs6465347	ENSG00000188693.7	CYP51A1-AS1	-3.76	0.000177	0.0102	-0.12	-0.12	Breast cancer;	chr7:92064523	chr7:92134604~92180725:+
BRCA	cis	rs11098499	0.698	rs4422403	ENSG00000225892.3	RP11-384K6.2	3.76	0.000177	0.0102	0.11	0.12	Corneal astigmatism;	chr4:119337039	chr4:118632274~118634759:+
BRCA	cis	rs34792	0.821	rs153809	ENSG00000207425.1	Y_RNA	3.76	0.000177	0.0102	0.13	0.12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15464514	chr16:14915457~14915556:-
BRCA	cis	rs16917546	1	rs7905030	ENSG00000238280.1	RP11-436D10.3	3.76	0.000177	0.0102	0.16	0.12	Basal cell carcinoma;	chr10:62661840	chr10:62793562~62805887:-
BRCA	cis	rs6142618	0.562	rs4911548	ENSG00000275576.1	RP5-836N17.4	-3.76	0.000177	0.0102	-0.13	-0.12	Inflammatory bowel disease;	chr20:32147536	chr20:32116171~32116629:+
BRCA	cis	rs6142618	0.562	rs6142621	ENSG00000275576.1	RP5-836N17.4	-3.76	0.000177	0.0102	-0.13	-0.12	Inflammatory bowel disease;	chr20:32148004	chr20:32116171~32116629:+
BRCA	cis	rs17711722	0.727	rs2658585	ENSG00000223473.2	GS1-124K5.3	3.76	0.000177	0.0102	0.09	0.12	Calcium levels;	chr7:65996954	chr7:66491049~66493566:-
BRCA	cis	rs9470794	0.831	rs11759858	ENSG00000204110.6	RP1-153P14.8	-3.76	0.000177	0.0102	-0.18	-0.12	Type 2 diabetes;	chr6:38160692	chr6:37507348~37535616:+
BRCA	cis	rs9470794	0.831	rs11759859	ENSG00000204110.6	RP1-153P14.8	-3.76	0.000177	0.0102	-0.18	-0.12	Type 2 diabetes;	chr6:38160693	chr6:37507348~37535616:+
BRCA	cis	rs783540	0.934	rs1594511	ENSG00000274376.3	ADAMTS7P1	-3.76	0.000177	0.0102	-0.13	-0.12	Schizophrenia;	chr15:82638312	chr15:82298553~82334609:+
BRCA	cis	rs17767294	0.708	rs72848753	ENSG00000219392.1	RP1-265C24.5	-3.76	0.000177	0.0102	-0.3	-0.12	Parkinson's disease;	chr6:27910491	chr6:28115628~28116551:+
BRCA	cis	rs17767294	0.708	rs72848754	ENSG00000219392.1	RP1-265C24.5	-3.76	0.000177	0.0102	-0.3	-0.12	Parkinson's disease;	chr6:27910680	chr6:28115628~28116551:+
BRCA	cis	rs17767294	0.708	rs72848755	ENSG00000219392.1	RP1-265C24.5	-3.76	0.000177	0.0102	-0.3	-0.12	Parkinson's disease;	chr6:27910775	chr6:28115628~28116551:+
BRCA	cis	rs17767294	0.708	rs34957169	ENSG00000219392.1	RP1-265C24.5	-3.76	0.000177	0.0102	-0.3	-0.12	Parkinson's disease;	chr6:27911619	chr6:28115628~28116551:+
BRCA	cis	rs875971	0.862	rs4718383	ENSG00000229886.1	RP5-1132H15.3	-3.76	0.000177	0.0102	-0.13	-0.12	Aortic root size;	chr7:66643422	chr7:66025126~66031544:-
BRCA	cis	rs2731006	0.901	rs2731005	ENSG00000257114.2	RP11-25I15.3	3.76	0.000177	0.0102	0.18	0.12	Panic disorder;	chr12:42766988	chr12:42692216~42717119:+
BRCA	cis	rs10263639	0.563	rs73135794	ENSG00000225573.4	RPL35P5	-3.76	0.000177	0.0102	-0.22	-0.12	Breast cancer;	chr7:67603047	chr7:66606738~66607107:-
BRCA	cis	rs6439699	1	rs13096023	ENSG00000239213.4	NCK1-AS1	3.76	0.000177	0.0102	0.16	0.12	Intelligence (multi-trait analysis);	chr3:137291845	chr3:136841726~136862054:-
BRCA	cis	rs2625529	0.878	rs4777478	ENSG00000260037.4	CTD-2524L6.3	-3.76	0.000177	0.0102	-0.17	-0.12	Red blood cell count;	chr15:71986744	chr15:71818396~71823384:+
BRCA	cis	rs160451	0.899	rs218887	ENSG00000251136.7	RP11-37B2.1	3.76	0.000177	0.0103	0.11	0.12	Leprosy;	chr8:89679295	chr8:89609409~89757727:-
BRCA	cis	rs1417569	0.519	rs3011601	ENSG00000237135.1	DDX10P1	3.76	0.000177	0.0103	0.17	0.12	Tuberculosis;	chr10:30956400	chr10:30919012~30921235:-
BRCA	cis	rs6593122	0.71	rs10246877	ENSG00000235454.1	HAUS6P3	-3.76	0.000177	0.0103	-0.15	-0.12	Vaccine-related adverse events;	chr7:54120984	chr7:53862233~53863339:+
BRCA	cis	rs2243480	1	rs316307	ENSG00000237026.1	RP11-328P23.2	3.76	0.000177	0.0103	0.22	0.12	Diabetic kidney disease;	chr7:66105184	chr7:65235790~65236723:-
BRCA	cis	rs2241193	0.649	rs9341191	ENSG00000241520.1	AC098820.4	3.76	0.000177	0.0103	0.23	0.12	Visceral fat;	chr2:216656925	chr2:216483032~216487196:-
BRCA	cis	rs34034915	1	rs34034915	ENSG00000219392.1	RP1-265C24.5	-3.76	0.000177	0.0103	-0.15	-0.12	Hepatitis A;	chr6:27752924	chr6:28115628~28116551:+
BRCA	cis	rs4713118	0.527	rs36042294	ENSG00000219392.1	RP1-265C24.5	-3.76	0.000177	0.0103	-0.15	-0.12	Parkinson's disease;	chr6:27752933	chr6:28115628~28116551:+
BRCA	cis	rs7308116	0.645	rs10861834	ENSG00000274395.1	RP11-554D14.8	-3.76	0.000177	0.0103	-0.13	-0.12	Pelvic organ prolapse (moderate/severe);	chr12:107903134	chr12:107835541~107836555:-
BRCA	cis	rs67478160	0.643	rs2887282	ENSG00000269940.1	RP11-73M18.7	3.76	0.000177	0.0103	0.12	0.12	Schizophrenia;	chr14:103814397	chr14:103694560~103695170:+
BRCA	cis	rs6943931	0.963	rs4540317	ENSG00000230658.1	KLHL7-AS1	-3.76	0.000177	0.0103	-0.16	-0.12	Diabetic kidney disease;	chr7:22372586	chr7:23101228~23105703:-
BRCA	cis	rs6952407	1	rs6952407	ENSG00000229180.5	GS1-124K5.11	-3.76	0.000177	0.0103	-0.1	-0.12	Cotinine glucuronidation;	chr7:66580525	chr7:66526088~66542624:-
BRCA	cis	rs17301013	0.932	rs10912813	ENSG00000234741.6	GAS5	3.76	0.000177	0.0103	0.12	0.12	Systemic lupus erythematosus;	chr1:174607342	chr1:173863900~173868882:-
BRCA	cis	rs736801	0.808	rs2248116	ENSG00000233006.5	AC034220.3	-3.76	0.000177	0.0103	-0.09	-0.12	Mosquito bite size;Breast cancer;	chr5:132468655	chr5:132311285~132369916:-
BRCA	cis	rs12826942	0.876	rs17548889	ENSG00000257225.1	RP11-328C8.4	-3.76	0.000177	0.0103	-0.17	-0.12	Coronary artery disease;	chr12:42328417	chr12:42459366~42466128:+
BRCA	cis	rs9309473	0.607	rs7604588	ENSG00000163016.8	ALMS1P	3.76	0.000177	0.0103	0.14	0.12	Metabolite levels;	chr2:73344289	chr2:73644919~73685576:+
BRCA	cis	rs13034020	0.641	rs34230978	ENSG00000271889.1	RP11-493E12.1	-3.76	0.000177	0.0103	-0.21	-0.12	Hodgkin's lymphoma;	chr2:60994388	chr2:61151433~61162105:-
BRCA	cis	rs6693017	1	rs17008835	ENSG00000272823.1	RP11-295M18.6	3.76	0.000177	0.0103	0.14	0.12	Monocyte early outgrowth colony forming units;	chr1:220806087	chr1:220828676~220829211:-
BRCA	cis	rs6964587	0.869	rs34791781	ENSG00000188693.7	CYP51A1-AS1	3.76	0.000177	0.0103	0.13	0.12	Breast cancer;	chr7:91903406	chr7:92134604~92180725:+
BRCA	cis	rs863345	0.604	rs7548349	ENSG00000229914.1	RP11-404O13.4	-3.76	0.000177	0.0103	-0.12	-0.12	Pneumococcal bacteremia;	chr1:158523936	chr1:158195633~158196131:-
BRCA	cis	rs801193	0.569	rs3846973	ENSG00000229886.1	RP5-1132H15.3	-3.76	0.000177	0.0103	-0.13	-0.12	Aortic root size;	chr7:66655048	chr7:66025126~66031544:-
BRCA	cis	rs4950322	0.58	rs4950371	ENSG00000227242.3	NBPF13P	-3.76	0.000177	0.0103	-0.17	-0.12	Protein quantitative trait loci;	chr1:147114243	chr1:147021320~147124525:-
BRCA	cis	rs425277	1	rs421992	ENSG00000269227.1	RP11-345P4.6	3.76	0.000177	0.0103	0.12	0.12	Height;	chr1:2145821	chr1:1673275~1674397:+
BRCA	cis	rs10043228	1	rs12521612	ENSG00000271918.1	CTD-2287O16.5	-3.76	0.000177	0.0103	-0.17	-0.12	Asthma or chronic obstructive pulmonary disease;	chr5:116246908	chr5:116083807~116085416:-
BRCA	cis	rs6600671	0.691	rs6600662	ENSG00000223345.3	HIST2H2BA	3.76	0.000177	0.0103	0.14	0.12	Hip geometry;	chr1:121488992	chr1:121108210~121117257:-
BRCA	cis	rs2267137	0.776	rs2267145	ENSG00000279159.1	RP3-394A18.1	-3.76	0.000177	0.0103	-0.1	-0.12	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr22:29409418	chr22:29978950~30028236:-
BRCA	cis	rs6728642	0.519	rs4260285	ENSG00000273265.1	RP11-353K11.1	3.76	0.000177	0.0103	0.17	0.12	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:96904344	chr2:96812239~96813657:-
BRCA	cis	rs6964587	1	rs7806157	ENSG00000188693.7	CYP51A1-AS1	-3.76	0.000177	0.0103	-0.13	-0.12	Breast cancer;	chr7:91972616	chr7:92134604~92180725:+
BRCA	cis	rs897984	0.542	rs3751855	ENSG00000275263.1	RP11-1072A3.4	-3.76	0.000177	0.0103	-0.14	-0.12	Dementia with Lewy bodies;	chr16:31079888	chr16:30956872~30957199:-
BRCA	cis	rs62103177	0.608	rs8088089	ENSG00000278000.1	AC139100.4	-3.76	0.000177	0.0103	-0.18	-0.12	Opioid sensitivity;	chr18:80073851	chr18:80161752~80162413:+
BRCA	cis	rs11098499	0.863	rs1010740	ENSG00000260091.1	RP11-33B1.4	3.76	0.000177	0.0103	0.11	0.12	Corneal astigmatism;	chr4:119542254	chr4:119409333~119410233:+
BRCA	cis	rs875971	0.861	rs801215	ENSG00000273024.4	INTS4P2	3.76	0.000177	0.0103	0.13	0.12	Aortic root size;	chr7:66546951	chr7:65647864~65715661:+
BRCA	cis	rs9329221	1	rs9329221	ENSG00000154316.13	TDH	-3.76	0.000177	0.0103	-0.14	-0.12	Neuroticism;	chr8:10382692	chr8:11339637~11368452:+
BRCA	cis	rs516805	0.748	rs6930548	ENSG00000279114.1	RP3-425C14.5	-3.76	0.000177	0.0103	-0.14	-0.12	Lymphocyte counts;	chr6:122375807	chr6:122471923~122484161:+
BRCA	cis	rs11992162	0.967	rs10108320	ENSG00000255020.1	AF131216.5	3.76	0.000177	0.0103	0.14	0.12	Monocyte count;	chr8:11974754	chr8:11345748~11347502:-
BRCA	cis	rs7267979	0.714	rs6115107	ENSG00000274414.1	RP5-965G21.4	-3.76	0.000177	0.0103	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25256754	chr20:25239007~25245229:-
BRCA	cis	rs739496	0.895	rs2073950	ENSG00000257624.1	RP1-128M12.3	3.76	0.000177	0.0103	0.16	0.12	Platelet count;	chr12:111456268	chr12:112000739~112000985:-
BRCA	cis	rs2411233	1	rs6492851	ENSG00000259278.1	RP11-62C7.2	3.76	0.000177	0.0103	0.13	0.12	Platelet count;	chr15:38987702	chr15:39019233~39024918:+
BRCA	cis	rs7267979	1	rs7268053	ENSG00000204556.4	CTD-2514C3.1	3.76	0.000177	0.0103	0.16	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25347650	chr20:26018832~26020684:+
BRCA	cis	rs7267979	1	rs6083809	ENSG00000204556.4	CTD-2514C3.1	3.76	0.000177	0.0103	0.16	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25348673	chr20:26018832~26020684:+
BRCA	cis	rs10129255	0.957	rs2013423	ENSG00000211958.2	IGHV3-38	3.76	0.000177	0.0103	0.09	0.12	Kawasaki disease;	chr14:106690675	chr14:106410493~106411021:-
BRCA	cis	rs10129255	0.957	rs56134540	ENSG00000211958.2	IGHV3-38	3.76	0.000177	0.0103	0.09	0.12	Kawasaki disease;	chr14:106691290	chr14:106410493~106411021:-
BRCA	cis	rs7680126	0.632	rs78030862	ENSG00000250413.1	RP11-448G15.1	3.76	0.000177	0.0103	0.19	0.12	Urate levels in obese individuals;Urate levels in lean individuals;Urate levels in overweight individuals;	chr4:10148788	chr4:10006482~10009725:+
BRCA	cis	rs28489187	0.706	rs233119	ENSG00000223653.4	RP11-131L23.1	3.76	0.000177	0.0103	0.13	0.12	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85322369	chr1:85276715~85448124:+
BRCA	cis	rs2243480	1	rs34193460	ENSG00000226767.1	RP11-328P23.3	-3.76	0.000177	0.0103	-0.2	-0.12	Diabetic kidney disease;	chr7:65928123	chr7:65508773~65508944:-
BRCA	cis	rs2108622	0.683	rs6512067	ENSG00000214049.6	UCA1	3.76	0.000177	0.0103	0.16	0.12	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15872141	chr19:15828961~15836320:+
BRCA	cis	rs61542988	0.57	rs7781074	ENSG00000228649.7	AC005682.5	-3.76	0.000177	0.0103	-0.12	-0.12	Fibrinogen levels;	chr7:22786741	chr7:22854178~22861579:+
BRCA	cis	rs17123764	0.892	rs77056500	ENSG00000257464.1	RP11-161H23.8	-3.76	0.000178	0.0103	-0.21	-0.12	Intelligence (multi-trait analysis);	chr12:49755821	chr12:49442424~49442652:-
BRCA	cis	rs10129255	1	rs9324091	ENSG00000231475.3	IGHV4-31	-3.76	0.000178	0.0103	-0.09	-0.12	Kawasaki disease;	chr14:106676625	chr14:106349283~106349792:-
BRCA	cis	rs654950	0.875	rs881719	ENSG00000230638.4	RP11-486B10.4	3.76	0.000178	0.0103	0.15	0.12	Airway imaging phenotypes;	chr1:41525756	chr1:41542069~41544310:+
BRCA	cis	rs2625529	0.824	rs4238449	ENSG00000260037.4	CTD-2524L6.3	-3.76	0.000178	0.0103	-0.17	-0.12	Red blood cell count;	chr15:72129262	chr15:71818396~71823384:+
BRCA	cis	rs2712184	0.967	rs11892032	ENSG00000237930.1	AC007563.4	3.76	0.000178	0.0103	0.13	0.12	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);	chr2:216804258	chr2:216785774~216786144:-
BRCA	cis	rs6840360	0.901	rs1443094	ENSG00000251603.1	RP11-164P12.4	-3.76	0.000178	0.0103	-0.11	-0.12	Intelligence (multi-trait analysis);	chr4:151535572	chr4:151667224~151670502:+
BRCA	cis	rs7487637	0.529	rs11168244	ENSG00000257433.4	RP1-197B17.3	3.76	0.000178	0.0103	0.17	0.12	Mononucleosis;	chr12:47809158	chr12:47706085~47742294:+
BRCA	cis	rs171748	0.727	rs159540	ENSG00000215032.2	GNL3LP1	3.76	0.000178	0.0103	0.15	0.12	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:61188833	chr5:60891935~60893577:-
BRCA	cis	rs1032833	0.732	rs111644090	ENSG00000271401.1	RP11-171I2.3	-3.76	0.000178	0.0103	-0.3	-0.12	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);	chr2:179082639	chr2:178644717~178645179:+
BRCA	cis	rs7429990	0.965	rs35199727	ENSG00000199476.1	Y_RNA	-3.76	0.000178	0.0103	-0.16	-0.12	Educational attainment (years of education);	chr3:47905218	chr3:48288587~48288694:+
BRCA	cis	rs4879656	0.593	rs4879659	ENSG00000236184.1	TCEA1P4	-3.76	0.000178	0.0103	-0.15	-0.12	Menopause (age at onset);	chr9:33029470	chr9:32979560~32980403:-
BRCA	cis	rs4478858	0.66	rs10798844	ENSG00000223907.1	LINC01226	-3.76	0.000178	0.0103	-0.14	-0.12	Alcohol dependence;	chr1:31346281	chr1:31518435~31524245:+
BRCA	cis	rs295490	0.748	rs76778175	ENSG00000272656.1	RP11-219D15.3	3.76	0.000178	0.0103	0.29	0.12	PR interval in Tripanosoma cruzi seropositivity;	chr3:139440213	chr3:139349024~139349371:-
BRCA	cis	rs17684571	0.938	rs71564848	ENSG00000231441.1	RP11-472M19.2	3.76	0.000178	0.0103	0.18	0.12	Schizophrenia;	chr6:56684255	chr6:56844002~56864078:+
BRCA	cis	rs17684571	0.938	rs34576803	ENSG00000231441.1	RP11-472M19.2	3.76	0.000178	0.0103	0.18	0.12	Schizophrenia;	chr6:56684609	chr6:56844002~56864078:+
BRCA	cis	rs11121246	0.518	rs6684644	ENSG00000270282.1	RP5-1115A15.2	3.76	0.000178	0.0103	0.14	0.12	Plateletcrit;	chr1:8850519	chr1:8512653~8513021:+
BRCA	cis	rs2301573	1	rs58763722	ENSG00000271270.4	TMCC1-AS1	-3.76	0.000178	0.0103	-0.23	-0.12	Hip circumference;	chr3:129584645	chr3:129893871~129918575:+
BRCA	cis	rs1348850	0.789	rs2197611	ENSG00000280374.1	RP11-337N6.3	3.76	0.000178	0.0103	0.16	0.12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177504308	chr2:177317715~177318471:-
BRCA	cis	rs67696533	0.711	rs6119897	ENSG00000235217.6	TSPY26P	3.76	0.000178	0.0103	0.14	0.12	White blood cell count (basophil);Basophil percentage of granulocytes;Basophil percentage of white cells;	chr20:32557613	chr20:32186477~32190527:-
BRCA	cis	rs4415084	1	rs12522626	ENSG00000272335.1	RP11-53O19.3	3.76	0.000178	0.0103	0.11	0.12	Breast cancer;	chr5:44685596	chr5:44826076~44828592:+
BRCA	cis	rs11250098	0.574	rs4240672	ENSG00000255046.1	RP11-297N6.4	3.76	0.000178	0.0103	0.13	0.12	Morning vs. evening chronotype;	chr8:10910407	chr8:11797928~11802568:-
BRCA	cis	rs2391285	0.609	rs2286177	ENSG00000280255.1	RP5-1007F24.1	3.76	0.000178	0.0103	0.16	0.12	Post bronchodilator FEV1/FVC ratio;	chr7:26556504	chr7:26538378~26541048:+
BRCA	cis	rs17301013	0.861	rs61826916	ENSG00000200674.1	RN7SKP160	3.76	0.000178	0.0103	0.15	0.12	Systemic lupus erythematosus;	chr1:174616048	chr1:173791548~173791887:+
BRCA	cis	rs10761482	0.813	rs4336985	ENSG00000254271.1	RP11-131N11.4	3.76	0.000178	0.0103	0.16	0.12	Schizophrenia;	chr10:60341616	chr10:60734342~60741828:+
BRCA	cis	rs10761482	0.861	rs4600155	ENSG00000254271.1	RP11-131N11.4	3.76	0.000178	0.0103	0.16	0.12	Schizophrenia;	chr10:60341623	chr10:60734342~60741828:+
BRCA	cis	rs75920871	0.502	rs10790166	ENSG00000280143.1	AP000892.6	-3.76	0.000178	0.0103	-0.12	-0.12	Subjective well-being;	chr11:116908783	chr11:117204967~117210292:+
BRCA	cis	rs4388249	1	rs12656720	ENSG00000271849.1	CTC-332L22.1	-3.76	0.000178	0.0103	-0.19	-0.12	Schizophrenia;	chr5:109771161	chr5:109687802~109688329:-
BRCA	cis	rs4388249	1	rs4141493	ENSG00000271849.1	CTC-332L22.1	-3.76	0.000178	0.0103	-0.19	-0.12	Schizophrenia;	chr5:109771388	chr5:109687802~109688329:-
BRCA	cis	rs875971	0.54	rs4717275	ENSG00000227113.2	RP11-460N20.4	-3.76	0.000178	0.0103	-0.12	-0.12	Aortic root size;	chr7:65800193	chr7:65075023~65078780:+
BRCA	cis	rs11039100	1	rs11039101	ENSG00000224295.2	AC087380.14	-3.76	0.000178	0.0103	-0.21	-0.12	Peripheral arterial disease (traffic-related air pollution interaction);	chr11:5805850	chr11:5518441~5524955:-
BRCA	cis	rs6893300	0.785	rs6887507	ENSG00000250999.1	RP11-1379J22.5	3.76	0.000178	0.0103	0.15	0.12	Resting heart rate;	chr5:179759236	chr5:179657762~179664432:+
BRCA	cis	rs832540	0.669	rs173764	ENSG00000271828.1	CTD-2310F14.1	3.76	0.000178	0.0103	0.14	0.12	Coronary artery disease;	chr5:56903093	chr5:56927874~56929573:+
BRCA	cis	rs495337	0.736	rs967305	ENSG00000224397.4	LINC01272	3.76	0.000178	0.0103	0.12	0.12	Psoriasis;	chr20:49843409	chr20:50267486~50279795:+
BRCA	cis	rs6710503	0.632	rs13416069	ENSG00000224165.4	DNAJC27-AS1	3.76	0.000178	0.0103	0.16	0.12	Lung cancer in ever smokers;Breast cancer;	chr2:24785397	chr2:24971390~25039694:+
BRCA	cis	rs9866825	0.967	rs1386965	ENSG00000227110.5	LMCD1-AS1	3.76	0.000178	0.0103	0.14	0.12	QT interval;	chr3:8216954	chr3:7952805~8611924:-
BRCA	cis	rs2288884	0.541	rs72483948	ENSG00000275055.1	CTC-471J1.11	-3.76	0.000178	0.0103	-0.17	-0.12	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:51971668	chr19:52049007~52049754:+
BRCA	cis	rs1730008	0.631	rs76184710	ENSG00000279311.1	RP11-170K4.2	3.76	0.000178	0.0103	0.15	0.12	Lobe attachment (rater-scored or self-reported);	chr3:158376855	chr3:158869898~158871821:+
BRCA	cis	rs1437396	0.539	rs3111410	ENSG00000203327.2	AC012358.7	-3.76	0.000178	0.0103	-0.12	-0.12	Alcohol dependence;	chr2:55372150	chr2:55214387~55216126:-
BRCA	cis	rs12477438	1	rs12053372	ENSG00000231822.1	AC019097.7	-3.76	0.000178	0.0103	-0.14	-0.12	Chronic sinus infection;	chr2:99193592	chr2:99102018~99102752:+
BRCA	cis	rs4713118	0.615	rs9295747	ENSG00000219392.1	RP1-265C24.5	3.76	0.000178	0.0103	0.15	0.12	Parkinson's disease;	chr6:27769214	chr6:28115628~28116551:+
BRCA	cis	rs642803	0.591	rs620088	ENSG00000214659.4	KRT8P26	-3.76	0.000178	0.0103	-0.15	-0.12	Urate levels;	chr11:65741515	chr11:65726939~65728214:+
BRCA	cis	rs13421350	0.579	rs10207654	ENSG00000225205.4	AC093818.1	-3.76	0.000178	0.0103	-0.21	-0.12	Diabetic kidney disease;	chr2:172443028	chr2:172480840~172556596:-
BRCA	cis	rs4950322	0.547	rs6660507	ENSG00000278811.3	LINC00624	3.76	0.000178	0.0103	0.14	0.12	Protein quantitative trait loci;	chr1:147148574	chr1:147258885~147517875:-
BRCA	cis	rs6964587	0.869	rs6975243	ENSG00000188693.7	CYP51A1-AS1	3.76	0.000178	0.0103	0.13	0.12	Breast cancer;	chr7:91885358	chr7:92134604~92180725:+
BRCA	cis	rs8114671	0.562	rs6088635	ENSG00000126005.14	MMP24-AS1	-3.76	0.000179	0.0103	-0.14	-0.12	Height;	chr20:34878698	chr20:35216462~35278131:-
BRCA	cis	rs7267979	1	rs6050609	ENSG00000274414.1	RP5-965G21.4	3.76	0.000179	0.0103	0.14	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25431115	chr20:25239007~25245229:-
BRCA	cis	rs1949733	0.585	rs2631768	ENSG00000250471.2	GMPSP1	-3.76	0.000179	0.0103	-0.12	-0.12	Response to antineoplastic agents;	chr4:8471323	chr4:8174421~8174999:+
BRCA	cis	rs10771431	1	rs11611670	ENSG00000256673.1	RP11-599J14.2	3.76	0.000179	0.0103	0.13	0.12	Breast size;	chr12:9232939	chr12:9398355~9414851:-
BRCA	cis	rs259282	0.707	rs1103851	ENSG00000267475.1	CTD-2538C1.2	3.76	0.000179	0.0103	0.15	0.12	Schizophrenia;	chr19:32655508	chr19:32687089~32691750:-
BRCA	cis	rs10266483	0.921	rs687547	ENSG00000271550.1	BNIP3P11	3.76	0.000179	0.0103	0.15	0.12	Response to statin therapy;	chr7:64284551	chr7:64678954~64687393:-
BRCA	cis	rs55675132	0.548	rs10858055	ENSG00000226167.1	AP4B1-AS1	3.76	0.000179	0.0103	0.12	0.12	Schizophrenia;	chr1:114816592	chr1:113856635~113901237:+
BRCA	cis	rs11668609	0.935	rs7257096	ENSG00000268058.1	BNIP3P40	-3.76	0.000179	0.0103	-0.14	-0.12	Response to taxane treatment (docetaxel);	chr19:24098965	chr19:24098425~24098980:-
BRCA	cis	rs7712401	0.658	rs4836203	ENSG00000251538.4	RP11-166A12.1	3.76	0.000179	0.0103	0.13	0.12	Mean platelet volume;	chr5:122741382	chr5:122628952~122730685:-
BRCA	cis	rs6142618	0.562	rs4911547	ENSG00000275576.1	RP5-836N17.4	-3.76	0.000179	0.0103	-0.13	-0.12	Inflammatory bowel disease;	chr20:32145670	chr20:32116171~32116629:+
BRCA	cis	rs3748682	0.861	rs72661832	ENSG00000222282.1	RNU6-584P	-3.76	0.000179	0.0103	-0.15	-0.12	Hypothyroidism;	chr1:37795061	chr1:37885023~37885117:+
BRCA	cis	rs2832077	0.527	rs59730679	ENSG00000232855.5	AF131217.1	3.76	0.000179	0.0103	0.15	0.12	Cognitive test performance;	chr21:28853922	chr21:28439346~28674848:-
BRCA	cis	rs2243480	1	rs313814	ENSG00000237026.1	RP11-328P23.2	3.76	0.000179	0.0103	0.22	0.12	Diabetic kidney disease;	chr7:66038306	chr7:65235790~65236723:-
BRCA	cis	rs7572733	0.967	rs10166845	ENSG00000231621.1	AC013264.2	-3.76	0.000179	0.0103	-0.11	-0.12	Dermatomyositis;	chr2:198031347	chr2:197197991~197199273:+
BRCA	cis	rs2841277	0.646	rs3742935	ENSG00000258701.1	LINC00638	3.76	0.000179	0.0103	0.13	0.12	Rheumatoid arthritis;	chr14:104939262	chr14:104821201~104823718:+
BRCA	cis	rs72928364	1	rs35509049	ENSG00000244119.1	PDCL3P4	3.76	0.000179	0.0103	0.14	0.12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100941920	chr3:101712472~101713191:+
BRCA	cis	rs8030605	0.704	rs1593456	ENSG00000277245.1	RP11-48G14.3	3.76	0.000179	0.0103	0.25	0.12	Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;	chr15:56301510	chr15:56447120~56447697:+
BRCA	cis	rs910873	1	rs56020497	ENSG00000269202.1	RP4-614O4.12	-3.76	0.000179	0.0103	-0.26	-0.12	Melanoma;	chr20:34578666	chr20:35201747~35203288:-
BRCA	cis	rs8023401	0.938	rs11855770	ENSG00000274654.1	CTD-3247H4.2	3.76	0.000179	0.0104	0.17	0.12	Spherical equivalent (joint analysis main effects and education interaction);	chr15:48546822	chr15:48528980~48529728:-
BRCA	cis	rs561341	1	rs8073186	ENSG00000277511.1	CTD-2095E4.5	3.76	0.000179	0.0104	0.15	0.12	Hip circumference adjusted for BMI;	chr17:31917937	chr17:32127595~32128454:+
BRCA	cis	rs2015599	0.549	rs6487799	ENSG00000275476.1	RP11-996F15.4	3.76	0.000179	0.0104	0.13	0.12	Platelet count;Mean platelet volume;	chr12:29291087	chr12:29277397~29277882:-
BRCA	cis	rs987724	0.515	rs9870137	ENSG00000244515.1	KRT18P34	-3.76	0.000179	0.0104	-0.17	-0.12	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156898867	chr3:157162663~157163932:-
BRCA	cis	rs7637230	0.504	rs2942715	ENSG00000244119.1	PDCL3P4	3.76	0.000179	0.0104	0.1	0.12	Psoriasis vulgaris;Psoriasis;	chr3:101931016	chr3:101712472~101713191:+
BRCA	cis	rs35306767	0.903	rs12762228	ENSG00000229869.1	RP11-363N22.2	-3.76	0.000179	0.0104	-0.2	-0.12	Eosinophil percentage of granulocytes;	chr10:834914	chr10:933026~942743:+
BRCA	cis	rs875971	0.66	rs1860468	ENSG00000273142.1	RP11-458F8.4	3.76	0.000179	0.0104	0.1	0.12	Aortic root size;	chr7:66642265	chr7:66902857~66906297:+
BRCA	cis	rs4671400	0.516	rs2600671	ENSG00000271889.1	RP11-493E12.1	3.76	0.000179	0.0104	0.17	0.12	3-hydroxypropylmercapturic acid levels in smokers;	chr2:61167716	chr2:61151433~61162105:-
BRCA	cis	rs8081187	0.803	rs10491108	ENSG00000266490.1	CTD-2349P21.9	-3.76	0.000179	0.0104	-0.21	-0.12	Breast cancer;	chr17:30466299	chr17:30792372~30792833:+
BRCA	cis	rs875971	0.862	rs13232191	ENSG00000229886.1	RP5-1132H15.3	3.76	0.000179	0.0104	0.13	0.12	Aortic root size;	chr7:66521661	chr7:66025126~66031544:-
BRCA	cis	rs875971	0.862	rs10950043	ENSG00000229886.1	RP5-1132H15.3	3.76	0.000179	0.0104	0.13	0.12	Aortic root size;	chr7:66523623	chr7:66025126~66031544:-
BRCA	cis	rs875971	0.862	rs17747530	ENSG00000229886.1	RP5-1132H15.3	3.76	0.000179	0.0104	0.13	0.12	Aortic root size;	chr7:66529742	chr7:66025126~66031544:-
BRCA	cis	rs875971	0.862	rs13536	ENSG00000229886.1	RP5-1132H15.3	-3.76	0.000179	0.0104	-0.13	-0.12	Aortic root size;	chr7:66554203	chr7:66025126~66031544:-
BRCA	cis	rs875971	0.862	rs801209	ENSG00000229886.1	RP5-1132H15.3	-3.76	0.000179	0.0104	-0.13	-0.12	Aortic root size;	chr7:66554403	chr7:66025126~66031544:-
BRCA	cis	rs875971	0.862	rs801206	ENSG00000229886.1	RP5-1132H15.3	-3.76	0.000179	0.0104	-0.13	-0.12	Aortic root size;	chr7:66556979	chr7:66025126~66031544:-
BRCA	cis	rs875971	0.862	rs801204	ENSG00000229886.1	RP5-1132H15.3	-3.76	0.000179	0.0104	-0.13	-0.12	Aortic root size;	chr7:66557934	chr7:66025126~66031544:-
BRCA	cis	rs875971	0.862	rs801203	ENSG00000229886.1	RP5-1132H15.3	-3.76	0.000179	0.0104	-0.13	-0.12	Aortic root size;	chr7:66558025	chr7:66025126~66031544:-
BRCA	cis	rs12612435	0.747	rs34340901	ENSG00000226806.1	AC011893.3	3.76	0.000179	0.0104	0.14	0.12	Takotsubo syndrome;	chr2:136383238	chr2:135820191~135823087:+
BRCA	cis	rs6545883	0.507	rs4411680	ENSG00000273302.1	RP11-493E12.2	-3.76	0.000179	0.0104	-0.1	-0.12	Tuberculosis;	chr2:61356970	chr2:61199979~61200769:+
BRCA	cis	rs12264252	0.767	rs35998463	ENSG00000225484.5	NUTM2B-AS1	-3.76	0.000179	0.0104	-0.17	-0.12	Coronary artery disease;	chr10:80485754	chr10:79663088~79826594:-
BRCA	cis	rs2391285	0.609	rs1859601	ENSG00000214870.7	AC004540.5	3.76	0.000179	0.0104	0.17	0.12	Post bronchodilator FEV1/FVC ratio;	chr7:26551238	chr7:26398593~26494256:+
BRCA	cis	rs72766638	0.895	rs72766630	ENSG00000235106.7	LINC00094	3.76	0.000179	0.0104	0.15	0.12	Mosquito bite size;	chr9:134061669	chr9:134025439~134034666:+
BRCA	cis	rs1371614	0.523	rs12468721	ENSG00000272148.1	RP11-195B17.1	-3.76	0.000179	0.0104	-0.13	-0.12	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26960883	chr2:27062428~27062907:-
BRCA	cis	rs1371614	0.523	rs12468761	ENSG00000272148.1	RP11-195B17.1	-3.76	0.000179	0.0104	-0.13	-0.12	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26960925	chr2:27062428~27062907:-
BRCA	cis	rs10266483	0.881	rs636242	ENSG00000228653.2	HNRNPCP7	-3.76	0.000179	0.0104	-0.14	-0.12	Response to statin therapy;	chr7:64284377	chr7:64500825~64501729:+
BRCA	cis	rs10266483	0.921	rs653746	ENSG00000228653.2	HNRNPCP7	-3.76	0.000179	0.0104	-0.14	-0.12	Response to statin therapy;	chr7:64284399	chr7:64500825~64501729:+
BRCA	cis	rs11673344	0.704	rs571340	ENSG00000267422.1	CTD-2554C21.1	3.76	0.000179	0.0104	0.15	0.12	Obesity-related traits;	chr19:36933981	chr19:37779686~37792865:+
BRCA	cis	rs875971	0.862	rs778702	ENSG00000229886.1	RP5-1132H15.3	3.76	0.000179	0.0104	0.13	0.12	Aortic root size;	chr7:66399848	chr7:66025126~66031544:-
BRCA	cis	rs6088580	0.608	rs8114616	ENSG00000275784.1	RP5-1125A11.6	3.76	0.000179	0.0104	0.13	0.12	Glomerular filtration rate (creatinine);	chr20:34381286	chr20:33989480~33991818:-
BRCA	cis	rs11673344	0.868	rs1047333	ENSG00000267422.1	CTD-2554C21.1	3.76	0.000179	0.0104	0.16	0.12	Obesity-related traits;	chr19:37151263	chr19:37779686~37792865:+
BRCA	cis	rs739496	0.793	rs76604970	ENSG00000257624.1	RP1-128M12.3	3.76	0.000179	0.0104	0.16	0.12	Platelet count;	chr12:111529351	chr12:112000739~112000985:-
BRCA	cis	rs9788682	0.747	rs2568490	ENSG00000261143.1	ADAMTS7P3	3.76	0.000179	0.0104	0.16	0.12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78446028	chr15:77976042~77993057:+
BRCA	cis	rs80226907	0.634	rs79350514	ENSG00000186615.9	KTN1-AS1	-3.76	0.000179	0.0104	-0.24	-0.12	Mean platelet volume;	chr14:55437571	chr14:55499278~55580110:-
BRCA	cis	rs17221829	0.733	rs11018686	ENSG00000280385.1	AP000648.5	-3.76	0.000179	0.0104	-0.13	-0.12	Anxiety in major depressive disorder;	chr11:89632073	chr11:90193614~90198120:+
BRCA	cis	rs2018683	0.707	rs2057957	ENSG00000233517.1	AC005162.5	3.76	0.000179	0.0104	0.14	0.12	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28935009	chr7:28987028~28988899:+
BRCA	cis	rs2562456	0.958	rs2562508	ENSG00000240522.1	RPL7AP10	3.76	0.000179	0.0104	0.13	0.12	Pain;	chr19:21543479	chr19:21149648~21150438:-
BRCA	cis	rs853679	0.585	rs201004	ENSG00000216901.1	AL022393.7	3.76	0.000179	0.0104	0.18	0.12	Depression;	chr6:27837156	chr6:28176188~28176674:+
BRCA	cis	rs11098499	0.731	rs6846966	ENSG00000225892.3	RP11-384K6.2	3.76	0.000179	0.0104	0.11	0.12	Corneal astigmatism;	chr4:119372053	chr4:118632274~118634759:+
BRCA	cis	rs7267979	1	rs6050590	ENSG00000276952.1	RP5-965G21.6	-3.76	0.000179	0.0104	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25404358	chr20:25284915~25285588:-
BRCA	cis	rs7267979	1	rs4813566	ENSG00000276952.1	RP5-965G21.6	-3.76	0.000179	0.0104	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25405829	chr20:25284915~25285588:-
BRCA	cis	rs7267979	1	rs4815421	ENSG00000276952.1	RP5-965G21.6	-3.76	0.000179	0.0104	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25405873	chr20:25284915~25285588:-
BRCA	cis	rs4886920	0.862	rs4486846	ENSG00000260776.4	RP11-114H24.2	-3.76	0.000179	0.0104	-0.14	-0.12	Neuroticism;	chr15:77846594	chr15:77914217~77926846:-
BRCA	cis	rs2243480	1	rs34970380	ENSG00000226767.1	RP11-328P23.3	-3.76	0.00018	0.0104	-0.2	-0.12	Diabetic kidney disease;	chr7:65966506	chr7:65508773~65508944:-
BRCA	cis	rs7267979	0.966	rs2151144	ENSG00000274414.1	RP5-965G21.4	3.76	0.00018	0.0104	0.13	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25434288	chr20:25239007~25245229:-
BRCA	cis	rs12906542	0.516	rs894301	ENSG00000259792.1	RP11-114H24.6	-3.76	0.00018	0.0104	-0.17	-0.12	Breast cancer;	chr15:78005183	chr15:77993405~77995289:+
BRCA	cis	rs6088580	0.634	rs7271970	ENSG00000275784.1	RP5-1125A11.6	3.76	0.00018	0.0104	0.12	0.12	Glomerular filtration rate (creatinine);	chr20:34399860	chr20:33989480~33991818:-
BRCA	cis	rs12639258	0.714	rs7639243	ENSG00000223552.1	RP11-24F11.2	-3.76	0.00018	0.0104	-0.13	-0.12	Eotaxin levels;	chr3:46472487	chr3:46364955~46407059:-
BRCA	cis	rs2243480	1	rs7456042	ENSG00000234585.5	CCT6P3	-3.76	0.00018	0.0104	-0.17	-0.12	Diabetic kidney disease;	chr7:65834791	chr7:65038354~65074713:+
BRCA	cis	rs2243480	1	rs73142121	ENSG00000234585.5	CCT6P3	-3.76	0.00018	0.0104	-0.17	-0.12	Diabetic kidney disease;	chr7:65846219	chr7:65038354~65074713:+
BRCA	cis	rs2243480	1	rs34702770	ENSG00000234585.5	CCT6P3	-3.76	0.00018	0.0104	-0.17	-0.12	Diabetic kidney disease;	chr7:65879836	chr7:65038354~65074713:+
BRCA	cis	rs2243480	1	rs34637256	ENSG00000234585.5	CCT6P3	-3.76	0.00018	0.0104	-0.17	-0.12	Diabetic kidney disease;	chr7:65895144	chr7:65038354~65074713:+
BRCA	cis	rs3735485	0.738	rs11552377	ENSG00000201772.1	SNORA5C	3.76	0.00018	0.0104	0.15	0.12	White blood cell count;Sum basophil neutrophil counts;Neutrophil count;Granulocyte percentage of myeloid white cells;Monocyte percentage of white cells;Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Lymphocyte counts;	chr7:45064532	chr7:45104906~45105042:-
BRCA	cis	rs10129255	0.5	rs9324092	ENSG00000254174.1	IGHV1-12	-3.76	0.00018	0.0104	-0.09	-0.12	Kawasaki disease;	chr14:106683806	chr14:106122420~106122709:-
BRCA	cis	rs115575488	0.85	rs78270676	ENSG00000231365.4	RP11-418J17.1	3.76	0.00018	0.0104	0.22	0.12	Lobe attachment (rater-scored or self-reported);	chr1:119112207	chr1:119140396~119275973:+
BRCA	cis	rs871012	0.502	rs951959	ENSG00000251405.2	CTB-109A12.1	-3.76	0.00018	0.0104	-0.16	-0.12	IgG glycosylation;	chr5:157462211	chr5:157362615~157460078:-
BRCA	cis	rs7267979	0.873	rs6083853	ENSG00000274973.1	RP13-401N8.7	3.76	0.00018	0.0104	0.13	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25423905	chr20:25845497~25845862:+
BRCA	cis	rs7267979	0.934	rs2482913	ENSG00000274973.1	RP13-401N8.7	3.76	0.00018	0.0104	0.13	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25424450	chr20:25845497~25845862:+
BRCA	cis	rs2274273	0.774	rs17128440	ENSG00000259318.1	RP11-454L9.2	3.76	0.00018	0.0104	0.1	0.12	Protein biomarker;	chr14:55395194	chr14:55394940~55395233:-
BRCA	cis	rs10911902	0.913	rs6658482	ENSG00000229739.2	RP11-295K2.3	-3.76	0.00018	0.0104	-0.17	-0.12	Schizophrenia;	chr1:186629394	chr1:186435161~186470291:+
BRCA	cis	rs7412746	0.658	rs17660092	ENSG00000231073.1	RP11-316M1.3	3.76	0.00018	0.0104	0.12	0.12	Melanoma;	chr1:150825272	chr1:150973123~150975534:+
BRCA	cis	rs517811	0.564	rs7820497	ENSG00000261087.1	KB-1460A1.5	-3.76	0.00018	0.0104	-0.13	-0.12	Cognitive performance;	chr8:101963228	chr8:101166805~101169629:-
BRCA	cis	rs2562456	0.917	rs6511253	ENSG00000268119.4	CTD-2561J22.5	-3.76	0.00018	0.0104	-0.18	-0.12	Pain;	chr19:21495996	chr19:21444241~21463908:-
BRCA	cis	rs11098499	0.954	rs13107475	ENSG00000225892.3	RP11-384K6.2	3.76	0.00018	0.0104	0.11	0.12	Corneal astigmatism;	chr4:119471856	chr4:118632274~118634759:+
BRCA	cis	rs6439699	1	rs7648738	ENSG00000273486.1	RP11-731C17.2	3.76	0.00018	0.0104	0.16	0.12	Intelligence (multi-trait analysis);	chr3:137289194	chr3:136837338~136839021:-
BRCA	cis	rs6088580	0.542	rs6059882	ENSG00000275784.1	RP5-1125A11.6	-3.76	0.00018	0.0104	-0.12	-0.12	Glomerular filtration rate (creatinine);	chr20:34502362	chr20:33989480~33991818:-
BRCA	cis	rs812925	0.519	rs2463099	ENSG00000270820.4	RP11-355B11.2	-3.76	0.00018	0.0104	-0.13	-0.12	Immature fraction of reticulocytes;	chr2:61391176	chr2:61471188~61484130:+
BRCA	cis	rs2692947	0.537	rs12478605	ENSG00000168992.4	OR7E102P	3.76	0.00018	0.0104	0.16	0.12	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95711330	chr2:95546531~95547545:+
BRCA	cis	rs6964587	1	rs10234071	ENSG00000188693.7	CYP51A1-AS1	3.76	0.00018	0.0104	0.12	0.12	Breast cancer;	chr7:92015838	chr7:92134604~92180725:+
BRCA	cis	rs12530845	0.767	rs7784162	ENSG00000223718.3	AC093107.7	3.76	0.00018	0.0104	0.17	0.12	Red blood cell traits;	chr7:135621138	chr7:135660039~135660647:+
BRCA	cis	rs875971	0.66	rs10215132	ENSG00000265600.1	AC006480.1	3.76	0.00018	0.0104	0.14	0.12	Aortic root size;	chr7:66589419	chr7:67356680~67356779:+
BRCA	cis	rs7722600	1	rs7722600	ENSG00000253404.1	AC034243.1	-3.76	0.00018	0.0104	-0.18	-0.12	Heart rate;	chr5:137859073	chr5:138744434~138753309:-
BRCA	cis	rs13401620	0.555	rs2018962	ENSG00000223549.1	MTND5P28	3.76	0.00018	0.0104	0.14	0.12	Breast size;	chr2:120217026	chr2:120215181~120217279:+
BRCA	cis	rs6088580	0.634	rs4911151	ENSG00000275784.1	RP5-1125A11.6	3.76	0.00018	0.0104	0.13	0.12	Glomerular filtration rate (creatinine);	chr20:34344467	chr20:33989480~33991818:-
BRCA	cis	rs801193	0.569	rs6951302	ENSG00000229886.1	RP5-1132H15.3	-3.76	0.00018	0.0104	-0.13	-0.12	Aortic root size;	chr7:66667525	chr7:66025126~66031544:-
BRCA	cis	rs12188164	0.62	rs56070387	ENSG00000221990.4	EXOC3-AS1	3.76	0.00018	0.0104	0.13	0.12	Cystic fibrosis severity;	chr5:482416	chr5:441498~443160:-
BRCA	cis	rs11673344	0.583	rs7247090	ENSG00000267422.1	CTD-2554C21.1	3.76	0.00018	0.0104	0.15	0.12	Obesity-related traits;	chr19:37522509	chr19:37779686~37792865:+
BRCA	cis	rs7712401	0.818	rs13166350	ENSG00000251538.4	RP11-166A12.1	3.76	0.00018	0.0104	0.13	0.12	Mean platelet volume;	chr5:122817874	chr5:122628952~122730685:-
BRCA	cis	rs16950303	0.661	rs12456845	ENSG00000265496.3	MIR1539	3.76	0.00018	0.0104	0.23	0.12	Height;	chr18:49049688	chr18:49487339~49491878:+
BRCA	cis	rs10043775	0.793	rs2400510	ENSG00000251330.3	CTD-2283N19.1	-3.76	0.00018	0.0104	-0.13	-0.12	Periodontal microbiota;	chr5:148316684	chr5:148430159~148430807:-
BRCA	cis	rs10043775	0.793	rs1862430	ENSG00000251330.3	CTD-2283N19.1	-3.76	0.00018	0.0104	-0.13	-0.12	Periodontal microbiota;	chr5:148316823	chr5:148430159~148430807:-
BRCA	cis	rs4700393	0.52	rs6449484	ENSG00000272308.1	RP11-231G3.1	3.76	0.00018	0.0104	0.14	0.12	Intelligence (multi-trait analysis);	chr5:60699603	chr5:60866457~60866935:-
BRCA	cis	rs4873772	0.773	rs4873463	ENSG00000253330.1	RP11-697N18.3	-3.76	0.00018	0.0104	-0.16	-0.12	Lobe attachment (rater-scored or self-reported);	chr8:47510809	chr8:47511034~47512141:-
BRCA	cis	rs1552244	0.572	rs41464050	ENSG00000180385.7	EMC3-AS1	3.76	0.00018	0.0104	0.16	0.12	Alzheimer's disease;	chr3:10116709	chr3:9986893~10006990:+
BRCA	cis	rs7226408	0.749	rs62083174	ENSG00000267707.2	RP11-95O2.5	3.76	0.00018	0.0104	0.2	0.12	Obesity-related traits;	chr18:36734703	chr18:37243776~37247506:+
BRCA	cis	rs983392	0.792	rs574704	ENSG00000275344.1	MIR6503	-3.76	0.00018	0.0104	-0.12	-0.12	Alzheimer's disease (late onset);	chr11:60100440	chr11:60209071~60209156:-
BRCA	cis	rs61160187	0.582	rs4700402	ENSG00000272308.1	RP11-231G3.1	-3.76	0.00018	0.0104	-0.13	-0.12	Educational attainment (years of education);Educational attainment (college completion);	chr5:60966220	chr5:60866457~60866935:-
BRCA	cis	rs875971	0.862	rs2024192	ENSG00000229886.1	RP5-1132H15.3	-3.76	0.00018	0.0104	-0.13	-0.12	Aortic root size;	chr7:66576460	chr7:66025126~66031544:-
BRCA	cis	rs7246967	0.544	rs420861	ENSG00000198153.8	ZNF849P	-3.76	0.00018	0.0104	-0.17	-0.12	Bronchopulmonary dysplasia;	chr19:22823102	chr19:22685167~22686732:+
BRCA	cis	rs9467773	0.933	rs35355150	ENSG00000241549.7	GUSBP2	3.76	0.00018	0.0104	0.13	0.12	Intelligence (multi-trait analysis);	chr6:26525811	chr6:26871484~26956554:-
BRCA	cis	rs783540	0.934	rs8043401	ENSG00000274376.3	ADAMTS7P1	3.76	0.00018	0.0104	0.13	0.12	Schizophrenia;	chr15:82687507	chr15:82298553~82334609:+
BRCA	cis	rs13401620	0.719	rs2289580	ENSG00000229326.3	AC069154.4	3.76	0.00018	0.0104	0.15	0.12	Breast size;	chr2:119946590	chr2:119698623~119700151:+
BRCA	cis	rs8054556	0.967	rs11150576	ENSG00000183604.13	SMG1P5	-3.76	0.00018	0.0104	-0.11	-0.12	Autism spectrum disorder or schizophrenia;	chr16:29954175	chr16:30267553~30335374:-
BRCA	cis	rs7267979	1	rs7020	ENSG00000274973.1	RP13-401N8.7	-3.76	0.00018	0.0104	-0.13	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25297964	chr20:25845497~25845862:+
BRCA	cis	rs375066	0.935	rs384329	ENSG00000267191.1	RP11-15A1.2	-3.76	0.00018	0.0104	-0.15	-0.12	Breast cancer;	chr19:43919829	chr19:43902001~43926545:+
BRCA	cis	rs12468226	0.935	rs113188021	ENSG00000272966.1	RP11-686O6.1	3.76	0.00018	0.0104	0.19	0.12	Urate levels;	chr2:202336237	chr2:202336739~202337200:+
BRCA	cis	rs12468226	1	rs6731027	ENSG00000272966.1	RP11-686O6.1	3.76	0.00018	0.0104	0.19	0.12	Urate levels;	chr2:202337443	chr2:202336739~202337200:+
BRCA	cis	rs747650	0.504	rs7127741	ENSG00000200376.1	RNU5E-10P	3.76	0.000181	0.0104	0.15	0.12	Acne (severe);	chr11:47052928	chr11:47576471~47576588:-
BRCA	cis	rs747650	0.504	rs6485726	ENSG00000200376.1	RNU5E-10P	3.76	0.000181	0.0104	0.15	0.12	Acne (severe);	chr11:47060571	chr11:47576471~47576588:-
BRCA	cis	rs747650	0.504	rs11039080	ENSG00000200376.1	RNU5E-10P	-3.76	0.000181	0.0104	-0.15	-0.12	Acne (severe);	chr11:47071533	chr11:47576471~47576588:-
BRCA	cis	rs747650	0.504	rs11039081	ENSG00000200376.1	RNU5E-10P	-3.76	0.000181	0.0104	-0.15	-0.12	Acne (severe);	chr11:47071914	chr11:47576471~47576588:-
BRCA	cis	rs1008375	0.932	rs4698629	ENSG00000249502.1	AC006160.5	-3.76	0.000181	0.0104	-0.13	-0.12	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17607261	chr4:17587467~17614571:-
BRCA	cis	rs2281603	0.694	rs12385910	ENSG00000259116.1	RP11-973N13.4	-3.76	0.000181	0.0104	-0.11	-0.12	Lymphocyte counts;	chr14:64533252	chr14:64514154~64540368:-
BRCA	cis	rs506338	0.517	rs17146216	ENSG00000237410.1	AP001092.4	3.76	0.000181	0.0104	0.16	0.12	Body mass index;Urate levels;	chr11:64683809	chr11:64646399~64659681:+
BRCA	cis	rs703842	0.616	rs1875125	ENSG00000270039.1	RP11-571M6.17	-3.76	0.000181	0.0104	-0.18	-0.12	Multiple sclerosis;	chr12:57833458	chr12:57803838~57804415:+
BRCA	cis	rs728616	0.614	rs35193855	ENSG00000225484.5	NUTM2B-AS1	-3.76	0.000181	0.0104	-0.23	-0.12	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80028739	chr10:79663088~79826594:-
BRCA	cis	rs6840360	0.571	rs2407069	ENSG00000270265.1	RP11-731D1.4	-3.76	0.000181	0.0104	-0.14	-0.12	Intelligence (multi-trait analysis);	chr4:151612049	chr4:151333775~151353224:-
BRCA	cis	rs1124609	1	rs1365506	ENSG00000244879.4	GABPB1-AS1	3.76	0.000181	0.0104	0.18	0.12	Subjective well-being;	chr15:50184942	chr15:50354959~50372202:+
BRCA	cis	rs7267979	1	rs2257991	ENSG00000274414.1	RP5-965G21.4	3.76	0.000181	0.0104	0.14	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25289703	chr20:25239007~25245229:-
BRCA	cis	rs17221829	0.574	rs7930964	ENSG00000280385.1	AP000648.5	-3.76	0.000181	0.0104	-0.13	-0.12	Anxiety in major depressive disorder;	chr11:89644145	chr11:90193614~90198120:+
BRCA	cis	rs801193	0.967	rs2707853	ENSG00000232546.1	RP11-458F8.1	-3.76	0.000181	0.0104	-0.1	-0.12	Aortic root size;	chr7:66749023	chr7:66848496~66858136:+
BRCA	cis	rs35306767	0.951	rs12777021	ENSG00000229869.1	RP11-363N22.2	-3.76	0.000181	0.0104	-0.19	-0.12	Eosinophil percentage of granulocytes;	chr10:921330	chr10:933026~942743:+
BRCA	cis	rs6061231	0.624	rs8668	ENSG00000233017.2	RP5-908M14.5	3.76	0.000181	0.0104	0.15	0.12	Colorectal cancer;	chr20:62389008	chr20:62427827~62447621:+
BRCA	cis	rs6683071	0.688	rs2936049	ENSG00000225265.1	TAF1A-AS1	-3.76	0.000181	0.0104	-0.16	-0.12	Cognitive performance;	chr1:222684825	chr1:222589825~222593032:+
BRCA	cis	rs4919687	0.55	rs12780827	ENSG00000236937.2	PTGES3P4	3.76	0.000181	0.0104	0.16	0.12	Colorectal cancer;	chr10:102708197	chr10:102845595~102845950:+
BRCA	cis	rs6593122	0.74	rs10225470	ENSG00000235454.1	HAUS6P3	-3.76	0.000181	0.0104	-0.15	-0.12	Vaccine-related adverse events;	chr7:54120810	chr7:53862233~53863339:+
BRCA	cis	rs4713118	0.591	rs2056924	ENSG00000219392.1	RP1-265C24.5	-3.76	0.000181	0.0104	-0.15	-0.12	Parkinson's disease;	chr6:27722395	chr6:28115628~28116551:+
BRCA	cis	rs739496	0.579	rs3741998	ENSG00000234608.6	MAPKAPK5-AS1	3.76	0.000181	0.0104	0.14	0.12	Platelet count;	chr12:111902039	chr12:111839764~111842902:-
BRCA	cis	rs739496	0.527	rs12319165	ENSG00000234608.6	MAPKAPK5-AS1	3.76	0.000181	0.0104	0.14	0.12	Platelet count;	chr12:111902930	chr12:111839764~111842902:-
BRCA	cis	rs739496	0.579	rs73426310	ENSG00000234608.6	MAPKAPK5-AS1	3.76	0.000181	0.0104	0.14	0.12	Platelet count;	chr12:111904606	chr12:111839764~111842902:-
BRCA	cis	rs739496	0.527	rs12427012	ENSG00000234608.6	MAPKAPK5-AS1	3.76	0.000181	0.0104	0.14	0.12	Platelet count;	chr12:111905570	chr12:111839764~111842902:-
BRCA	cis	rs739496	0.579	rs12316525	ENSG00000234608.6	MAPKAPK5-AS1	3.76	0.000181	0.0104	0.14	0.12	Platelet count;	chr12:111906315	chr12:111839764~111842902:-
BRCA	cis	rs739496	0.579	rs73426314	ENSG00000234608.6	MAPKAPK5-AS1	3.76	0.000181	0.0104	0.14	0.12	Platelet count;	chr12:111907252	chr12:111839764~111842902:-
BRCA	cis	rs739496	0.579	rs12582302	ENSG00000234608.6	MAPKAPK5-AS1	3.76	0.000181	0.0104	0.14	0.12	Platelet count;	chr12:111907830	chr12:111839764~111842902:-
BRCA	cis	rs739496	0.579	rs11066077	ENSG00000234608.6	MAPKAPK5-AS1	3.76	0.000181	0.0104	0.14	0.12	Platelet count;	chr12:111908857	chr12:111839764~111842902:-
BRCA	cis	rs6088580	0.524	rs7274854	ENSG00000261582.1	RP4-614O4.11	-3.76	0.000181	0.0104	-0.11	-0.12	Glomerular filtration rate (creatinine);	chr20:34640868	chr20:35267885~35280043:-
BRCA	cis	rs853679	0.882	rs4713139	ENSG00000216901.1	AL022393.7	3.76	0.000181	0.0105	0.23	0.12	Depression;	chr6:28124907	chr6:28176188~28176674:+
BRCA	cis	rs875971	0.862	rs1860469	ENSG00000223473.2	GS1-124K5.3	-3.76	0.000181	0.0105	-0.09	-0.12	Aortic root size;	chr7:66641888	chr7:66491049~66493566:-
BRCA	cis	rs17301013	0.73	rs12060177	ENSG00000234741.6	GAS5	3.76	0.000181	0.0105	0.11	0.12	Systemic lupus erythematosus;	chr1:174618545	chr1:173863900~173868882:-
BRCA	cis	rs739496	0.579	rs7975437	ENSG00000234608.6	MAPKAPK5-AS1	3.76	0.000181	0.0105	0.14	0.12	Platelet count;	chr12:111939145	chr12:111839764~111842902:-
BRCA	cis	rs8114671	0.562	rs2378294	ENSG00000126005.14	MMP24-AS1	-3.76	0.000181	0.0105	-0.13	-0.12	Height;	chr20:34912575	chr20:35216462~35278131:-
BRCA	cis	rs10463316	0.817	rs10040628	ENSG00000260581.1	CTB-113P19.4	3.76	0.000181	0.0105	0.13	0.12	Metabolite levels (Pyroglutamine);	chr5:151441466	chr5:151652275~151655449:+
BRCA	cis	rs801193	0.548	rs2659891	ENSG00000229886.1	RP5-1132H15.3	3.76	0.000181	0.0105	0.13	0.12	Aortic root size;	chr7:66736127	chr7:66025126~66031544:-
BRCA	cis	rs801193	0.548	rs7805152	ENSG00000229886.1	RP5-1132H15.3	3.76	0.000181	0.0105	0.13	0.12	Aortic root size;	chr7:66744266	chr7:66025126~66031544:-
BRCA	cis	rs8058578	1	rs7204278	ENSG00000280211.1	RP11-2C24.3	3.76	0.000181	0.0105	0.12	0.12	Multiple myeloma;	chr16:30718953	chr16:30773532~30776033:-
BRCA	cis	rs16958440	1	rs62096474	ENSG00000267800.1	RP11-49K24.5	-3.76	0.000181	0.0105	-0.25	-0.12	Sitting height ratio;	chr18:47121133	chr18:47137018~47137290:+
BRCA	cis	rs10463316	0.894	rs12153347	ENSG00000260581.1	CTB-113P19.4	3.76	0.000181	0.0105	0.13	0.12	Metabolite levels (Pyroglutamine);	chr5:151385910	chr5:151652275~151655449:+
BRCA	cis	rs10761482	0.813	rs10509130	ENSG00000254271.1	RP11-131N11.4	3.76	0.000181	0.0105	0.16	0.12	Schizophrenia;	chr10:60361354	chr10:60734342~60741828:+
BRCA	cis	rs10863681	0.875	rs11118942	ENSG00000232679.1	RP11-400N13.3	3.76	0.000181	0.0105	0.12	0.12	Metabolite levels (HVA-5-HIAA Factor score);	chr1:222092211	chr1:222041705~222064763:-
BRCA	cis	rs375066	0.935	rs397913	ENSG00000267191.1	RP11-15A1.2	3.76	0.000181	0.0105	0.15	0.12	Breast cancer;	chr19:43894788	chr19:43902001~43926545:+
BRCA	cis	rs77633900	0.772	rs283802	ENSG00000196274.5	Metazoa_SRP	3.76	0.000181	0.0105	0.2	0.12	Glioma;Non-glioblastoma glioma;	chr15:76498929	chr15:76230048~76230390:-
BRCA	cis	rs4664293	0.934	rs4380179	ENSG00000224152.1	AC009506.1	-3.76	0.000181	0.0105	-0.13	-0.12	Monocyte percentage of white cells;	chr2:159685064	chr2:159615296~159617082:+
BRCA	cis	rs6840360	1	rs10007167	ENSG00000251611.1	RP11-610P16.1	-3.76	0.000181	0.0105	-0.11	-0.12	Intelligence (multi-trait analysis);	chr4:151682503	chr4:151407551~151408835:-
BRCA	cis	rs754466	0.58	rs10430529	ENSG00000213514.2	RP11-428P16.2	3.76	0.000181	0.0105	0.16	0.12	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77822865	chr10:77730766~77734769:+
BRCA	cis	rs11098499	1	rs58601355	ENSG00000260404.2	RP11-384K6.6	3.76	0.000181	0.0105	0.11	0.12	Corneal astigmatism;	chr4:119265212	chr4:118591773~118633729:+
BRCA	cis	rs2512987	0.76	rs2512988	ENSG00000254731.1	CTD-2005H7.1	-3.76	0.000181	0.0105	-0.13	-0.12	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr11:86702985	chr11:86703099~86714092:+
BRCA	cis	rs4478858	0.698	rs6669381	ENSG00000223907.1	LINC01226	-3.76	0.000181	0.0105	-0.14	-0.12	Alcohol dependence;	chr1:31360659	chr1:31518435~31524245:+
BRCA	cis	rs4533720	0.553	rs10010179	ENSG00000248546.3	ANP32C	-3.76	0.000181	0.0105	-0.13	-0.12	Urinary uromodulin levels;	chr4:164039984	chr4:164197007~164197711:-
BRCA	cis	rs6449502	0.764	rs16878397	ENSG00000251279.1	CTC-436P18.1	3.76	0.000181	0.0105	0.23	0.12	Mean platelet volume;	chr5:60769692	chr5:61162070~61232040:+
BRCA	cis	rs7520050	0.966	rs785495	ENSG00000281133.1	AL355480.3	3.76	0.000181	0.0105	0.13	0.12	Reticulocyte count;Red blood cell count;	chr1:46122215	chr1:45580892~45580996:-
BRCA	cis	rs891378	0.959	rs1507757	ENSG00000274245.1	RP11-357P18.2	-3.76	0.000181	0.0105	-0.15	-0.12	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207331403	chr1:207372559~207373252:+
BRCA	cis	rs17711722	0.727	rs1880555	ENSG00000223473.2	GS1-124K5.3	3.76	0.000181	0.0105	0.09	0.12	Calcium levels;	chr7:65967580	chr7:66491049~66493566:-
BRCA	cis	rs12122100	0.837	rs12142004	ENSG00000244371.2	PFN1P8	3.76	0.000181	0.0105	0.14	0.12	HIV-1 control;	chr1:147035122	chr1:146957117~146957659:-
BRCA	cis	rs4415084	0.804	rs10044096	ENSG00000248779.1	RP11-53O19.2	-3.76	0.000181	0.0105	-0.11	-0.12	Breast cancer;	chr5:44927263	chr5:44752949~44765744:+
BRCA	cis	rs11031096	0.655	rs1822288	ENSG00000250404.1	AC090587.2	3.76	0.000181	0.0105	0.09	0.12	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr11:4191248	chr11:3816752~3821900:+
BRCA	cis	rs3805389	0.504	rs56288855	ENSG00000273257.1	RP11-177J6.1	-3.76	0.000181	0.0105	-0.19	-0.12	Waist-to-hip ratio adjusted for body mass index;	chr4:55603178	chr4:55387949~55388271:+
BRCA	cis	rs853679	0.882	rs4713139	ENSG00000204709.4	LINC01556	3.76	0.000181	0.0105	0.24	0.12	Depression;	chr6:28124907	chr6:28943877~28944537:+
BRCA	cis	rs9393777	0.92	rs13196692	ENSG00000216901.1	AL022393.7	3.76	0.000181	0.0105	0.29	0.12	Intelligence (multi-trait analysis);	chr6:27411340	chr6:28176188~28176674:+
BRCA	cis	rs4664293	0.625	rs34573069	ENSG00000224152.1	AC009506.1	3.76	0.000181	0.0105	0.12	0.12	Monocyte percentage of white cells;	chr2:159643561	chr2:159615296~159617082:+
BRCA	cis	rs4664293	0.567	rs6711125	ENSG00000224152.1	AC009506.1	3.76	0.000181	0.0105	0.12	0.12	Monocyte percentage of white cells;	chr2:159645040	chr2:159615296~159617082:+
BRCA	cis	rs9470794	1	rs12664900	ENSG00000204110.6	RP1-153P14.8	-3.76	0.000181	0.0105	-0.21	-0.12	Type 2 diabetes;	chr6:38058227	chr6:37507348~37535616:+
BRCA	cis	rs801193	0.569	rs2013908	ENSG00000229886.1	RP5-1132H15.3	-3.76	0.000181	0.0105	-0.13	-0.12	Aortic root size;	chr7:66656082	chr7:66025126~66031544:-
BRCA	cis	rs10761482	0.769	rs4442496	ENSG00000254271.1	RP11-131N11.4	3.76	0.000181	0.0105	0.16	0.12	Schizophrenia;	chr10:60341613	chr10:60734342~60741828:+
BRCA	cis	rs2486012	0.737	rs1502907	ENSG00000237950.1	RP11-7O11.3	3.76	0.000181	0.0105	0.21	0.12	Intelligence (multi-trait analysis);	chr1:43792369	chr1:43944370~43946551:-
BRCA	cis	rs11121246	0.518	rs12135416	ENSG00000270282.1	RP5-1115A15.2	-3.76	0.000181	0.0105	-0.14	-0.12	Plateletcrit;	chr1:8850288	chr1:8512653~8513021:+
BRCA	cis	rs73222236	0.783	rs67214626	ENSG00000239213.4	NCK1-AS1	3.76	0.000181	0.0105	0.13	0.12	Coronary artery disease;	chr3:136270534	chr3:136841726~136862054:-
BRCA	cis	rs1348850	0.872	rs7559521	ENSG00000280374.1	RP11-337N6.3	-3.76	0.000181	0.0105	-0.16	-0.12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177587600	chr2:177317715~177318471:-
BRCA	cis	rs6928977	0.5	rs11154810	ENSG00000234084.1	RP3-388E23.2	3.76	0.000181	0.0105	0.11	0.12	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135629234	chr6:135301568~135307158:+
BRCA	cis	rs6490294	0.528	rs16941724	ENSG00000226469.1	ADAM1B	3.76	0.000181	0.0105	0.22	0.12	Mean platelet volume;	chr12:111889253	chr12:111927018~111929017:+
BRCA	cis	rs72928364	1	rs2245556	ENSG00000256628.3	ZBTB11-AS1	3.76	0.000181	0.0105	0.2	0.12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100896706	chr3:101676475~101679217:+
BRCA	cis	rs6719977	0.569	rs1016607	ENSG00000226491.1	FTOP1	-3.76	0.000182	0.0105	-0.13	-0.12	Hyperactive-impulsive symptoms;	chr2:42744547	chr2:42797225~42798712:-
BRCA	cis	rs2615061	0.872	rs10915872	ENSG00000229965.1	RP11-118H4.1	-3.76	0.000182	0.0105	-0.2	-0.12	Monocyte count;	chr1:225761681	chr1:226438564~226439344:+
BRCA	cis	rs4713118	0.868	rs10484401	ENSG00000280107.1	AL022393.9	3.76	0.000182	0.0105	0.17	0.12	Parkinson's disease;	chr6:27778811	chr6:28170845~28172521:+
BRCA	cis	rs2274273	0.588	rs9323285	ENSG00000259318.1	RP11-454L9.2	-3.76	0.000182	0.0105	-0.1	-0.12	Protein biomarker;	chr14:55397111	chr14:55394940~55395233:-
BRCA	cis	rs4819052	0.807	rs7283915	ENSG00000215447.6	BX322557.10	-3.76	0.000182	0.0105	-0.12	-0.12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251373	chr21:45288052~45291738:+
BRCA	cis	rs875971	0.862	rs10261398	ENSG00000271064.1	RP11-792A8.3	3.76	0.000182	0.0105	0.14	0.12	Aortic root size;	chr7:66285177	chr7:66748838~66749077:-
BRCA	cis	rs875971	0.862	rs10224872	ENSG00000271064.1	RP11-792A8.3	3.76	0.000182	0.0105	0.14	0.12	Aortic root size;	chr7:66294786	chr7:66748838~66749077:-
BRCA	cis	rs739496	0.615	rs617044	ENSG00000226469.1	ADAM1B	3.76	0.000182	0.0105	0.15	0.12	Platelet count;	chr12:111695071	chr12:111927018~111929017:+
BRCA	cis	rs739496	0.615	rs602276	ENSG00000226469.1	ADAM1B	3.76	0.000182	0.0105	0.15	0.12	Platelet count;	chr12:111696120	chr12:111927018~111929017:+
BRCA	cis	rs963265	0.658	rs10868816	ENSG00000268364.1	SMC5-AS1	3.76	0.000182	0.0105	0.14	0.12	Migraine with aura;	chr9:70386573	chr9:70193997~70258866:-
BRCA	cis	rs736408	0.716	rs2300149	ENSG00000243224.1	RP5-1157M23.2	-3.76	0.000182	0.0105	-0.13	-0.12	Bipolar disorder;	chr3:52788905	chr3:52239258~52241097:+
BRCA	cis	rs295490	0.748	rs59628512	ENSG00000178631.7	ACTG1P1	-3.76	0.000182	0.0105	-0.24	-0.12	PR interval in Tripanosoma cruzi seropositivity;	chr3:139472550	chr3:139493809~139494937:+
BRCA	cis	rs801193	0.591	rs4506088	ENSG00000229886.1	RP5-1132H15.3	-3.76	0.000182	0.0105	-0.13	-0.12	Aortic root size;	chr7:66670470	chr7:66025126~66031544:-
BRCA	cis	rs9921338	0.961	rs9936328	ENSG00000263080.1	RP11-485G7.5	3.76	0.000182	0.0105	0.18	0.12	Vein graft stenosis in coronary artery bypass grafting;	chr16:11344364	chr16:11341809~11345211:-
BRCA	cis	rs11662721	0.938	rs11662735	ENSG00000264188.1	RP11-13N13.5	3.76	0.000182	0.0105	0.16	0.12	Phospholipid levels (plasma);	chr18:21596011	chr18:21661787~21662395:-
BRCA	cis	rs875971	0.862	rs4718383	ENSG00000223473.2	GS1-124K5.3	-3.76	0.000182	0.0105	-0.09	-0.12	Aortic root size;	chr7:66643422	chr7:66491049~66493566:-
BRCA	cis	rs4950322	0.57	rs72692917	ENSG00000227242.3	NBPF13P	-3.76	0.000182	0.0105	-0.16	-0.12	Protein quantitative trait loci;	chr1:147304389	chr1:147021320~147124525:-
BRCA	cis	rs4950322	0.57	rs66580541	ENSG00000227242.3	NBPF13P	-3.76	0.000182	0.0105	-0.16	-0.12	Protein quantitative trait loci;	chr1:147308828	chr1:147021320~147124525:-
BRCA	cis	rs4950322	0.57	rs945742	ENSG00000227242.3	NBPF13P	-3.76	0.000182	0.0105	-0.16	-0.12	Protein quantitative trait loci;	chr1:147313437	chr1:147021320~147124525:-
BRCA	cis	rs6142618	0.562	rs6058541	ENSG00000275576.1	RP5-836N17.4	-3.76	0.000182	0.0105	-0.13	-0.12	Inflammatory bowel disease;	chr20:32170845	chr20:32116171~32116629:+
BRCA	cis	rs7267979	0.966	rs6083818	ENSG00000204556.4	CTD-2514C3.1	3.76	0.000182	0.0105	0.16	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25365446	chr20:26018832~26020684:+
BRCA	cis	rs7267979	1	rs4815409	ENSG00000204556.4	CTD-2514C3.1	3.76	0.000182	0.0105	0.16	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25366061	chr20:26018832~26020684:+
BRCA	cis	rs7475343	0.573	rs75857264	ENSG00000224034.1	RP11-445P17.8	-3.76	0.000182	0.0105	-0.21	-0.12	Intelligence;	chr10:5283345	chr10:5266033~5271236:-
BRCA	cis	rs897984	0.609	rs57576577	ENSG00000279196.1	RP11-1072A3.3	3.76	0.000182	0.0105	0.12	0.12	Dementia with Lewy bodies;	chr16:31025046	chr16:30984630~30988270:-
BRCA	cis	rs9982086	0.793	rs11701533	ENSG00000260583.1	AP000223.42	-3.76	0.000182	0.0105	-0.26	-0.12	Carboplatin disposition in epthelial ovarian cancer;	chr21:25551562	chr21:25582770~25583326:-
BRCA	cis	rs34217772	1	rs10483523	ENSG00000258636.1	CTD-2298J14.2	-3.76	0.000182	0.0105	-0.16	-0.12	Myopia;	chr14:41794890	chr14:41587861~41604856:-
BRCA	cis	rs718314	1	rs718314	ENSG00000256894.1	RP11-283G6.3	3.76	0.000182	0.0105	0.14	0.12	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Renal cell carcinoma;Waist circumference adjusted for body mass index;	chr12:26300350	chr12:26125155~26126617:-
BRCA	cis	rs801193	1	rs7782320	ENSG00000265600.1	AC006480.1	-3.76	0.000182	0.0105	-0.14	-0.12	Aortic root size;	chr7:66712111	chr7:67356680~67356779:+
BRCA	cis	rs6142618	0.562	rs2235898	ENSG00000275576.1	RP5-836N17.4	-3.76	0.000182	0.0105	-0.13	-0.12	Inflammatory bowel disease;	chr20:32131259	chr20:32116171~32116629:+
BRCA	cis	rs6142618	0.562	rs2235899	ENSG00000275576.1	RP5-836N17.4	-3.76	0.000182	0.0105	-0.13	-0.12	Inflammatory bowel disease;	chr20:32131732	chr20:32116171~32116629:+
BRCA	cis	rs6142618	0.562	rs2235901	ENSG00000275576.1	RP5-836N17.4	-3.76	0.000182	0.0105	-0.13	-0.12	Inflammatory bowel disease;	chr20:32132233	chr20:32116171~32116629:+
BRCA	cis	rs17695224	0.545	rs7253924	ENSG00000269483.1	AC006272.1	3.76	0.000182	0.0105	0.14	0.12	HDL cholesterol;HDL cholesterol levels;	chr19:51824960	chr19:51839924~51843324:-
BRCA	cis	rs134594	0.885	rs134636	ENSG00000272858.1	CTA-292E10.8	3.76	0.000182	0.0105	0.16	0.12	Birth weight;	chr22:29086233	chr22:28814914~28815662:+
BRCA	cis	rs1949733	1	rs6447875	ENSG00000251615.3	RP11-774O3.3	-3.76	0.000182	0.0105	-0.12	-0.12	Response to antineoplastic agents;	chr4:8501479	chr4:8355090~8358338:-
BRCA	cis	rs38055	0.752	rs372044	ENSG00000247796.2	CTD-2366F13.1	-3.76	0.000182	0.0105	-0.13	-0.12	Acne (severe);	chr5:53313889	chr5:53109842~53115126:+
BRCA	cis	rs6487679	1	rs1017302	ENSG00000214776.8	RP11-726G1.1	-3.76	0.000182	0.0105	-0.16	-0.12	Non-alcoholic fatty liver disease histology (AST);	chr12:9214806	chr12:9467552~9576275:+
BRCA	cis	rs4713118	0.581	rs200504	ENSG00000216901.1	AL022393.7	3.76	0.000182	0.0105	0.18	0.12	Parkinson's disease;	chr6:27818042	chr6:28176188~28176674:+
BRCA	cis	rs4363385	0.693	rs608509	ENSG00000272654.1	RP11-422P24.11	3.76	0.000182	0.0105	0.12	0.12	Inflammatory skin disease;	chr1:153062174	chr1:153977743~153979160:+
BRCA	cis	rs875971	0.862	rs6947339	ENSG00000229886.1	RP5-1132H15.3	3.76	0.000182	0.0105	0.13	0.12	Aortic root size;	chr7:66423483	chr7:66025126~66031544:-
BRCA	cis	rs6840360	0.598	rs11944921	ENSG00000278978.1	RP11-164P12.5	3.76	0.000182	0.0105	0.13	0.12	Intelligence (multi-trait analysis);	chr4:151809957	chr4:151669786~151670503:+
BRCA	cis	rs9611565	0.649	rs126092	ENSG00000281538.1	RP4-669P10.20	-3.76	0.000182	0.0105	-0.14	-0.12	Vitiligo;	chr22:41782437	chr22:42138060~42139726:+
BRCA	cis	rs7267979	0.966	rs2261790	ENSG00000276952.1	RP5-965G21.6	3.76	0.000182	0.0105	0.14	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25282153	chr20:25284915~25285588:-
BRCA	cis	rs7267979	0.966	rs2261794	ENSG00000276952.1	RP5-965G21.6	3.76	0.000182	0.0105	0.14	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25282426	chr20:25284915~25285588:-
BRCA	cis	rs7267979	0.966	rs2145126	ENSG00000276952.1	RP5-965G21.6	3.76	0.000182	0.0105	0.14	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25283012	chr20:25284915~25285588:-
BRCA	cis	rs7267979	0.966	rs2257705	ENSG00000276952.1	RP5-965G21.6	3.76	0.000182	0.0105	0.14	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25284028	chr20:25284915~25285588:-
BRCA	cis	rs7267979	0.966	rs2227892	ENSG00000276952.1	RP5-965G21.6	3.76	0.000182	0.0105	0.14	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25284178	chr20:25284915~25285588:-
BRCA	cis	rs7267979	0.966	rs2257712	ENSG00000276952.1	RP5-965G21.6	3.76	0.000182	0.0105	0.14	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25284274	chr20:25284915~25285588:-
BRCA	cis	rs7267979	0.966	rs2257461	ENSG00000276952.1	RP5-965G21.6	3.76	0.000182	0.0105	0.14	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25284918	chr20:25284915~25285588:-
BRCA	cis	rs2839186	0.771	rs13046451	ENSG00000223901.2	AP001469.5	-3.76	0.000182	0.0105	-0.11	-0.12	Testicular germ cell tumor;	chr21:46221459	chr21:46220269~46225364:+
BRCA	cis	rs477895	0.838	rs11607007	ENSG00000256940.1	RP11-783K16.5	3.76	0.000182	0.0105	0.17	0.12	Mean platelet volume;	chr11:64240504	chr11:64245964~64248217:+
BRCA	cis	rs17123764	0.579	rs11836837	ENSG00000257464.1	RP11-161H23.8	-3.76	0.000182	0.0105	-0.21	-0.12	Intelligence (multi-trait analysis);	chr12:49756165	chr12:49442424~49442652:-
BRCA	cis	rs11098499	0.954	rs6820115	ENSG00000260404.2	RP11-384K6.6	3.76	0.000182	0.0105	0.11	0.12	Corneal astigmatism;	chr4:119477027	chr4:118591773~118633729:+
BRCA	cis	rs7812879	0.61	rs10481455	ENSG00000255046.1	RP11-297N6.4	-3.76	0.000182	0.0105	-0.2	-0.12	Systemic lupus erythematosus;	chr8:11433832	chr8:11797928~11802568:-
BRCA	cis	rs465969	1	rs9400478	ENSG00000272356.1	RP5-1112D6.8	-3.76	0.000182	0.0105	-0.28	-0.12	Psoriasis;	chr6:111478441	chr6:111309203~111313517:+
BRCA	cis	rs1979679	0.578	rs1904387	ENSG00000278733.1	RP11-425D17.1	3.76	0.000182	0.0105	0.14	0.12	Ossification of the posterior longitudinal ligament of the spine;	chr12:28120723	chr12:28185625~28186190:-
BRCA	cis	rs28829049	0.566	rs59681755	ENSG00000270728.1	RP4-657E11.10	-3.76	0.000182	0.0105	-0.12	-0.12	QRS duration in Tripanosoma cruzi seropositivity;	chr1:19202491	chr1:19297080~19297903:+
BRCA	cis	rs7771547	0.519	rs12206445	ENSG00000224666.3	RP1-50J22.4	3.76	0.000182	0.0105	0.14	0.12	Platelet distribution width;	chr6:36411851	chr6:36386831~36393462:+
BRCA	cis	rs12439619	0.846	rs62010071	ENSG00000259429.4	UBE2Q2P2	-3.76	0.000182	0.0105	-0.14	-0.12	Intelligence (multi-trait analysis);	chr15:82289442	chr15:82355142~82420075:+
BRCA	cis	rs61160187	0.582	rs28436304	ENSG00000272308.1	RP11-231G3.1	-3.76	0.000182	0.0105	-0.13	-0.12	Educational attainment (years of education);Educational attainment (college completion);	chr5:61038584	chr5:60866457~60866935:-
BRCA	cis	rs6064559	0.611	rs6070149	ENSG00000218018.2	RP4-800J21.3	-3.76	0.000182	0.0105	-0.1	-0.12	Hemoglobin concentration;	chr20:57554682	chr20:57384160~57393062:-
BRCA	cis	rs4664293	0.625	rs6432543	ENSG00000224152.1	AC009506.1	3.76	0.000182	0.0105	0.12	0.12	Monocyte percentage of white cells;	chr2:159638820	chr2:159615296~159617082:+
BRCA	cis	rs4664293	0.647	rs4665099	ENSG00000224152.1	AC009506.1	3.76	0.000182	0.0105	0.12	0.12	Monocyte percentage of white cells;	chr2:159639027	chr2:159615296~159617082:+
BRCA	cis	rs4664293	0.647	rs6724151	ENSG00000224152.1	AC009506.1	3.76	0.000182	0.0105	0.12	0.12	Monocyte percentage of white cells;	chr2:159642788	chr2:159615296~159617082:+
BRCA	cis	rs11098499	0.909	rs28668716	ENSG00000250412.1	KLHL2P1	3.76	0.000182	0.0105	0.14	0.12	Corneal astigmatism;	chr4:119388720	chr4:119334329~119378233:+
BRCA	cis	rs2562456	0.917	rs2681376	ENSG00000268119.4	CTD-2561J22.5	-3.76	0.000182	0.0105	-0.18	-0.12	Pain;	chr19:21532723	chr19:21444241~21463908:-
BRCA	cis	rs748404	0.666	rs72709879	ENSG00000166763.7	STRCP1	3.76	0.000182	0.0105	0.17	0.12	Lung cancer;	chr15:43507777	chr15:43699488~43718184:-
BRCA	cis	rs9287719	0.901	rs55861579	ENSG00000224177.5	LINC00570	3.76	0.000182	0.0105	0.14	0.12	Prostate cancer;	chr2:10623214	chr2:11393981~11403077:+
BRCA	cis	rs17684571	0.751	rs7761729	ENSG00000231441.1	RP11-472M19.2	3.76	0.000182	0.0105	0.17	0.12	Schizophrenia;	chr6:56846478	chr6:56844002~56864078:+
BRCA	cis	rs1075265	0.749	rs805436	ENSG00000272156.1	RP11-477N3.1	-3.76	0.000182	0.0105	-0.12	-0.12	Chronotype;Morning vs. evening chronotype;	chr2:53837843	chr2:54082554~54085066:+
BRCA	cis	rs7572733	0.935	rs6434946	ENSG00000231621.1	AC013264.2	-3.76	0.000182	0.0105	-0.11	-0.12	Dermatomyositis;	chr2:197933773	chr2:197197991~197199273:+
BRCA	cis	rs62458065	0.85	rs62458098	ENSG00000229358.3	DPY19L1P1	-3.76	0.000182	0.0105	-0.16	-0.12	Metabolite levels (HVA/MHPG ratio);	chr7:32431517	chr7:32580949~32761787:-
BRCA	cis	rs375066	0.935	rs430308	ENSG00000267191.1	RP11-15A1.2	-3.76	0.000183	0.0105	-0.15	-0.12	Breast cancer;	chr19:43896223	chr19:43902001~43926545:+
BRCA	cis	rs375066	0.868	rs378112	ENSG00000267191.1	RP11-15A1.2	-3.76	0.000183	0.0105	-0.15	-0.12	Breast cancer;	chr19:43917777	chr19:43902001~43926545:+
BRCA	cis	rs375066	0.868	rs378109	ENSG00000267191.1	RP11-15A1.2	-3.76	0.000183	0.0105	-0.15	-0.12	Breast cancer;	chr19:43917785	chr19:43902001~43926545:+
BRCA	cis	rs6601327	0.898	rs1458942	ENSG00000272267.2	RP11-375N15.2	3.76	0.000183	0.0105	0.15	0.12	Multiple myeloma (hyperdiploidy);	chr8:9549092	chr8:9555144~9556520:-
BRCA	cis	rs8049367	0.647	rs6500558	ENSG00000267077.1	RP11-127I20.5	3.76	0.000183	0.0105	0.12	0.12	Nonsyndromic cleft lip with or without cleft palate;	chr16:3919125	chr16:4795265~4796532:-
BRCA	cis	rs4478858	0.735	rs1566961	ENSG00000223907.1	LINC01226	-3.76	0.000183	0.0105	-0.14	-0.12	Alcohol dependence;	chr1:31299603	chr1:31518435~31524245:+
BRCA	cis	rs4478858	0.735	rs4622114	ENSG00000223907.1	LINC01226	-3.76	0.000183	0.0105	-0.14	-0.12	Alcohol dependence;	chr1:31299724	chr1:31518435~31524245:+
BRCA	cis	rs1346	0.501	rs10750762	ENSG00000245532.5	NEAT1	3.76	0.000183	0.0105	0.12	0.12	Vertical cup-disc ratio;Optic cup area;	chr11:65600834	chr11:65422774~65445540:+
BRCA	cis	rs801193	0.844	rs2244022	ENSG00000273448.1	RP11-166O4.6	3.76	0.000183	0.0105	0.1	0.12	Aortic root size;	chr7:66737443	chr7:67333047~67334383:+
BRCA	cis	rs12478296	0.792	rs6740738	ENSG00000261186.2	RP11-341N2.1	-3.76	0.000183	0.0105	-0.18	-0.12	Obesity-related traits;	chr2:242065217	chr2:242087351~242088457:-
BRCA	cis	rs8114671	0.562	rs2424999	ENSG00000279253.1	RP4-614O4.13	-3.76	0.000183	0.0105	-0.13	-0.12	Height;	chr20:34798627	chr20:35262727~35264187:-
BRCA	cis	rs6964587	1	rs10281556	ENSG00000188693.7	CYP51A1-AS1	3.76	0.000183	0.0105	0.12	0.12	Breast cancer;	chr7:92030739	chr7:92134604~92180725:+
BRCA	cis	rs61931739	0.534	rs1586410	ENSG00000258794.3	DUX4L27	3.76	0.000183	0.0105	0.17	0.12	Morning vs. evening chronotype;	chr12:33846207	chr12:34208415~34209675:-
BRCA	cis	rs2803122	0.745	rs9802945	ENSG00000272842.1	RP11-513M16.7	3.76	0.000183	0.0105	0.12	0.12	Pulse pressure;	chr9:19385224	chr9:19371386~19371945:-
BRCA	cis	rs11239930	0.538	rs630630	ENSG00000237188.3	RP11-337C18.8	3.76	0.000183	0.0105	0.13	0.12	AIDS progression;	chr1:147080377	chr1:147172771~147211568:+
BRCA	cis	rs11239930	0.538	rs618575	ENSG00000237188.3	RP11-337C18.8	3.76	0.000183	0.0105	0.13	0.12	AIDS progression;	chr1:147080759	chr1:147172771~147211568:+
BRCA	cis	rs13434995	0.513	rs62303730	ENSG00000239040.1	Y_RNA	3.76	0.000183	0.0105	0.14	0.12	Adiponectin levels;	chr4:55498948	chr4:55412636~55412738:+
BRCA	cis	rs6142618	0.562	rs2281358	ENSG00000277692.1	RP11-358N2.2	-3.76	0.000183	0.0105	-0.13	-0.12	Inflammatory bowel disease;	chr20:32135545	chr20:32355053~32355734:+
BRCA	cis	rs9287719	0.934	rs6710033	ENSG00000224177.5	LINC00570	3.76	0.000183	0.0106	0.13	0.12	Prostate cancer;	chr2:10617551	chr2:11393981~11403077:+
BRCA	cis	rs9287719	0.967	rs4669598	ENSG00000224177.5	LINC00570	3.76	0.000183	0.0106	0.13	0.12	Prostate cancer;	chr2:10617712	chr2:11393981~11403077:+
BRCA	cis	rs9287719	0.967	rs4669599	ENSG00000224177.5	LINC00570	3.76	0.000183	0.0106	0.13	0.12	Prostate cancer;	chr2:10617903	chr2:11393981~11403077:+
BRCA	cis	rs4218	0.681	rs17302163	ENSG00000259732.1	RP11-59H7.3	-3.76	0.000183	0.0106	-0.14	-0.12	Social communication problems;	chr15:59076773	chr15:59121034~59133250:+
BRCA	cis	rs6121246	0.559	rs6060952	ENSG00000230613.1	HM13-AS1	3.76	0.000183	0.0106	0.16	0.12	Mean corpuscular hemoglobin;	chr20:31794305	chr20:31567707~31573263:-
BRCA	cis	rs860295	0.557	rs12035524	ENSG00000160766.13	GBAP1	-3.76	0.000183	0.0106	-0.13	-0.12	Body mass index;	chr1:155697311	chr1:155213821~155227422:-
BRCA	cis	rs13401620	0.871	rs9308777	ENSG00000229326.3	AC069154.4	3.76	0.000183	0.0106	0.15	0.12	Breast size;	chr2:119934525	chr2:119698623~119700151:+
BRCA	cis	rs13401620	0.833	rs11689184	ENSG00000229326.3	AC069154.4	3.76	0.000183	0.0106	0.15	0.12	Breast size;	chr2:119937888	chr2:119698623~119700151:+
BRCA	cis	rs7712401	0.72	rs12109791	ENSG00000251538.4	RP11-166A12.1	3.76	0.000183	0.0106	0.13	0.12	Mean platelet volume;	chr5:122811136	chr5:122628952~122730685:-
BRCA	cis	rs12049351	0.774	rs4925455	ENSG00000229367.1	HMGN2P19	3.76	0.000183	0.0106	0.16	0.12	Circulating myeloperoxidase levels (plasma);	chr1:229487918	chr1:229570532~229570796:+
BRCA	cis	rs9959145	1	rs28527375	ENSG00000267108.1	RP11-861E21.1	3.76	0.000183	0.0106	0.2	0.12	Immune response to smallpox vaccine (IL-6);	chr18:12593394	chr18:12432897~12437635:+
BRCA	cis	rs970548	0.954	rs12249012	ENSG00000237840.5	FAM21FP	3.76	0.000183	0.0106	0.15	0.12	Total cholesterol levels;HDL cholesterol;HDL cholesterol levels;Cholesterol, total;	chr10:45497022	chr10:45706431~45727231:-
BRCA	cis	rs1153858	1	rs7181167	ENSG00000275672.1	GATM-AS1	-3.76	0.000183	0.0106	-0.15	-0.12	Homoarginine levels;	chr15:45394038	chr15:45378700~45380123:+
BRCA	cis	rs4699052	1	rs4699055	ENSG00000251288.2	RP11-10L12.2	-3.75	0.000183	0.0106	-0.13	-0.12	Testicular germ cell tumor;	chr4:103233343	chr4:102751401~102752641:+
BRCA	cis	rs13434995	0.562	rs10529258	ENSG00000239040.1	Y_RNA	3.75	0.000183	0.0106	0.14	0.12	Adiponectin levels;	chr4:55546702	chr4:55412636~55412738:+
BRCA	cis	rs13434995	0.512	rs115635692	ENSG00000239040.1	Y_RNA	3.75	0.000183	0.0106	0.14	0.12	Adiponectin levels;	chr4:55546706	chr4:55412636~55412738:+
BRCA	cis	rs13434995	0.626	rs116135676	ENSG00000239040.1	Y_RNA	3.75	0.000183	0.0106	0.14	0.12	Adiponectin levels;	chr4:55546707	chr4:55412636~55412738:+
BRCA	cis	rs12681366	0.663	rs6980687	ENSG00000253175.1	RP11-267M23.6	3.75	0.000183	0.0106	0.13	0.12	Nonsyndromic cleft lip with cleft palate;	chr8:94469685	chr8:94565036~94565715:+
BRCA	cis	rs6596100	0.868	rs62375207	ENSG00000248648.1	RP11-485M7.1	-3.75	0.000183	0.0106	-0.14	-0.12	Breast cancer;	chr5:133060440	chr5:133003119~133003365:+
BRCA	cis	rs6596100	0.915	rs4705990	ENSG00000248648.1	RP11-485M7.1	-3.75	0.000183	0.0106	-0.14	-0.12	Breast cancer;	chr5:133067741	chr5:133003119~133003365:+
BRCA	cis	rs6496932	0.913	rs4843037	ENSG00000259295.5	CSPG4P12	3.75	0.000183	0.0106	0.18	0.12	Central corneal thickness;Corneal structure;	chr15:85274674	chr15:85191438~85213905:+
BRCA	cis	rs10043228	1	rs12519989	ENSG00000250015.1	CTC-339F2.2	3.75	0.000183	0.0106	0.15	0.12	Asthma or chronic obstructive pulmonary disease;	chr5:116226945	chr5:116302354~116304134:-
BRCA	cis	rs2243480	1	rs160639	ENSG00000237026.1	RP11-328P23.2	3.75	0.000183	0.0106	0.22	0.12	Diabetic kidney disease;	chr7:66115000	chr7:65235790~65236723:-
BRCA	cis	rs13315871	1	rs11719957	ENSG00000272182.1	RP11-802O23.3	3.75	0.000183	0.0106	0.24	0.12	Cholesterol, total;	chr3:58429304	chr3:58428255~58428815:+
BRCA	cis	rs13315871	1	rs4585221	ENSG00000272182.1	RP11-802O23.3	3.75	0.000183	0.0106	0.24	0.12	Cholesterol, total;	chr3:58429840	chr3:58428255~58428815:+
BRCA	cis	rs7954584	1	rs7954584	ENSG00000212694.7	LINC01089	-3.75	0.000183	0.0106	-0.09	-0.12	Mean corpuscular volume;	chr12:122023660	chr12:121795267~121803906:-
BRCA	cis	rs4363385	0.693	rs582345	ENSG00000272654.1	RP11-422P24.11	3.75	0.000183	0.0106	0.12	0.12	Inflammatory skin disease;	chr1:153060930	chr1:153977743~153979160:+
BRCA	cis	rs80226907	0.634	rs75001839	ENSG00000186615.9	KTN1-AS1	-3.75	0.000183	0.0106	-0.25	-0.12	Mean platelet volume;	chr14:55442857	chr14:55499278~55580110:-
BRCA	cis	rs9860340	0.69	rs7634123	ENSG00000239572.1	RP11-451B8.1	-3.75	0.000183	0.0106	-0.17	-0.12	Electroencephalographic traits in alcoholism;	chr3:87657822	chr3:87731402~87793629:-
BRCA	cis	rs3808502	0.527	rs4410870	ENSG00000248896.2	CTD-2135J3.3	-3.75	0.000183	0.0106	-0.15	-0.12	Neuroticism;	chr8:11298611	chr8:10729314~10771392:+
BRCA	cis	rs6546324	0.625	rs1430791	ENSG00000236780.4	AC078941.1	3.75	0.000183	0.0106	0.2	0.12	Endometriosis;	chr2:67637668	chr2:67123357~67215319:-
BRCA	cis	rs6991838	0.584	rs6994213	ENSG00000272155.1	RP11-707M3.3	3.75	0.000183	0.0106	0.11	0.12	Intelligence (multi-trait analysis);	chr8:65601497	chr8:65714334~65714778:-
BRCA	cis	rs372883	0.506	rs2832300	ENSG00000176054.6	RPL23P2	3.75	0.000183	0.0106	0.13	0.12	Pancreatic cancer;	chr21:29376995	chr21:28997613~28998033:-
BRCA	cis	rs372883	0.506	rs2832301	ENSG00000176054.6	RPL23P2	3.75	0.000183	0.0106	0.13	0.12	Pancreatic cancer;	chr21:29377392	chr21:28997613~28998033:-
BRCA	cis	rs13434995	0.513	rs9993599	ENSG00000249700.7	SRD5A3-AS1	3.75	0.000183	0.0106	0.17	0.12	Adiponectin levels;	chr4:55586798	chr4:55363971~55395847:-
BRCA	cis	rs6142618	0.562	rs2235902	ENSG00000277692.1	RP11-358N2.2	-3.75	0.000183	0.0106	-0.13	-0.12	Inflammatory bowel disease;	chr20:32133547	chr20:32355053~32355734:+
BRCA	cis	rs2562456	0.833	rs2650801	ENSG00000268081.1	RP11-678G14.2	3.75	0.000183	0.0106	0.17	0.12	Pain;	chr19:21452553	chr19:21554640~21569237:-
BRCA	cis	rs4352251	0.841	rs4428028	ENSG00000212283.1	SNORD89	3.75	0.000183	0.0106	0.24	0.12	Adiponectin levels (BMI-adjusted);Adiponectin levels;	chr2:101364804	chr2:101272936~101273049:-
BRCA	cis	rs6121246	0.609	rs6089075	ENSG00000230613.1	HM13-AS1	3.75	0.000183	0.0106	0.16	0.12	Mean corpuscular hemoglobin;	chr20:31805081	chr20:31567707~31573263:-
BRCA	cis	rs2765539	0.851	rs1409159	ENSG00000231365.4	RP11-418J17.1	-3.75	0.000184	0.0106	-0.16	-0.12	Waist-hip ratio;	chr1:118995810	chr1:119140396~119275973:+
BRCA	cis	rs6991838	0.557	rs7012578	ENSG00000272155.1	RP11-707M3.3	3.75	0.000184	0.0106	0.11	0.12	Intelligence (multi-trait analysis);	chr8:65592592	chr8:65714334~65714778:-
BRCA	cis	rs801193	0.569	rs35070132	ENSG00000229886.1	RP5-1132H15.3	3.75	0.000184	0.0106	0.13	0.12	Aortic root size;	chr7:66773096	chr7:66025126~66031544:-
BRCA	cis	rs6964833	0.935	rs13238996	ENSG00000277072.3	STAG3L2	3.75	0.000184	0.0106	0.13	0.12	Menarche (age at onset);	chr7:74655318	chr7:74882163~74890610:-
BRCA	cis	rs7523050	0.73	rs67312582	ENSG00000203897.3	SPATA42	-3.75	0.000184	0.0106	-0.22	-0.12	Fat distribution (HIV);	chr1:108881354	chr1:108857217~108858524:+
BRCA	cis	rs477895	0.838	rs1058735	ENSG00000256940.1	RP11-783K16.5	3.75	0.000184	0.0106	0.16	0.12	Mean platelet volume;	chr11:64232938	chr11:64245964~64248217:+
BRCA	cis	rs477895	0.838	rs35090903	ENSG00000256940.1	RP11-783K16.5	3.75	0.000184	0.0106	0.16	0.12	Mean platelet volume;	chr11:64233126	chr11:64245964~64248217:+
BRCA	cis	rs2015599	0.549	rs7972032	ENSG00000275476.1	RP11-996F15.4	3.75	0.000184	0.0106	0.13	0.12	Platelet count;Mean platelet volume;	chr12:29291351	chr12:29277397~29277882:-
BRCA	cis	rs2455799	0.573	rs2470546	ENSG00000224728.1	AC090945.1	-3.75	0.000184	0.0106	-0.11	-0.12	Mean platelet volume;	chr3:15692390	chr3:15878047~15879571:+
BRCA	cis	rs2749592	0.588	rs2505192	ENSG00000273019.1	RP11-508N22.13	-3.75	0.000184	0.0106	-0.15	-0.12	Age-related hearing impairment (SNP x SNP interaction);	chr10:38106095	chr10:38149968~38150293:+
BRCA	cis	rs9733	0.519	rs1336899	ENSG00000231073.1	RP11-316M1.3	3.75	0.000184	0.0106	0.12	0.12	Tonsillectomy;	chr1:150706434	chr1:150973123~150975534:+
BRCA	cis	rs7267979	0.727	rs4815431	ENSG00000274973.1	RP13-401N8.7	3.75	0.000184	0.0106	0.13	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25551769	chr20:25845497~25845862:+
BRCA	cis	rs11711311	1	rs9827682	ENSG00000241529.3	RN7SL767P	-3.75	0.000184	0.0106	-0.13	-0.12	IgG glycosylation;	chr3:113731404	chr3:113632704~113632998:+
BRCA	cis	rs11711311	1	rs12497716	ENSG00000241529.3	RN7SL767P	-3.75	0.000184	0.0106	-0.13	-0.12	IgG glycosylation;	chr3:113734411	chr3:113632704~113632998:+
BRCA	cis	rs7208859	0.623	rs11657662	ENSG00000276250.1	CTD-2349P21.12	3.75	0.000184	0.0106	0.19	0.12	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30749329	chr17:30803654~30804077:+
BRCA	cis	rs2835872	0.793	rs80000115	ENSG00000228677.1	TTC3-AS1	-3.75	0.000184	0.0106	-0.15	-0.12	Electroencephalographic traits in alcoholism;	chr21:37613534	chr21:37187666~37193926:-
BRCA	cis	rs4664293	0.903	rs10185155	ENSG00000230783.1	AC009961.2	-3.75	0.000184	0.0106	-0.15	-0.12	Monocyte percentage of white cells;	chr2:159696717	chr2:159689217~159690291:-
BRCA	cis	rs6743226	0.566	rs6724257	ENSG00000266621.1	AC104841.1	3.75	0.000184	0.0106	0.14	0.12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in non-smokers;	chr2:241282982	chr2:241245202~241245299:-
BRCA	cis	rs748404	0.723	rs11853991	ENSG00000166763.7	STRCP1	3.75	0.000184	0.0106	0.14	0.12	Lung cancer;	chr15:43265351	chr15:43699488~43718184:-
BRCA	cis	rs9287719	0.967	rs12467642	ENSG00000224177.5	LINC00570	3.75	0.000184	0.0106	0.14	0.12	Prostate cancer;	chr2:10621358	chr2:11393981~11403077:+
BRCA	cis	rs9287719	0.967	rs12464908	ENSG00000224177.5	LINC00570	3.75	0.000184	0.0106	0.14	0.12	Prostate cancer;	chr2:10621370	chr2:11393981~11403077:+
BRCA	cis	rs970548	1	rs970548	ENSG00000237840.5	FAM21FP	3.75	0.000184	0.0106	0.15	0.12	Total cholesterol levels;HDL cholesterol;HDL cholesterol levels;Cholesterol, total;	chr10:45517829	chr10:45706431~45727231:-
BRCA	cis	rs7312933	0.737	rs10880261	ENSG00000257225.1	RP11-328C8.4	-3.75	0.000184	0.0106	-0.14	-0.12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42180020	chr12:42459366~42466128:+
BRCA	cis	rs34792	0.554	rs2067063	ENSG00000260872.1	RP11-680G24.5	-3.75	0.000184	0.0106	-0.13	-0.12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15515106	chr16:15018106~15020488:-
BRCA	cis	rs372883	0.648	rs15092	ENSG00000176054.6	RPL23P2	-3.75	0.000184	0.0106	-0.13	-0.12	Pancreatic cancer;	chr21:29345880	chr21:28997613~28998033:-
BRCA	cis	rs13434995	0.513	rs62303728	ENSG00000239040.1	Y_RNA	3.75	0.000184	0.0106	0.14	0.12	Adiponectin levels;	chr4:55495762	chr4:55412636~55412738:+
BRCA	cis	rs7620503	1	rs1875095	ENSG00000231574.4	RP11-91K9.1	3.75	0.000184	0.0106	0.13	0.12	Corneal structure;	chr3:177585935	chr3:177816865~177899224:+
BRCA	cis	rs16944613	0.588	rs10852136	ENSG00000271396.1	RP11-697E2.9	-3.75	0.000184	0.0106	-0.2	-0.12	Colorectal cancer;	chr15:90596566	chr15:90284376~90285580:-
BRCA	cis	rs1046491	0.901	rs11663949	ENSG00000264964.1	RP11-888D10.3	3.75	0.000184	0.0106	0.24	0.12	Scarlet fever;	chr18:9189252	chr18:9315194~9334441:-
BRCA	cis	rs875971	0.862	rs778680	ENSG00000229886.1	RP5-1132H15.3	3.75	0.000184	0.0106	0.13	0.12	Aortic root size;	chr7:66375427	chr7:66025126~66031544:-
BRCA	cis	rs875971	0.862	rs11769079	ENSG00000229886.1	RP5-1132H15.3	3.75	0.000184	0.0106	0.13	0.12	Aortic root size;	chr7:66377141	chr7:66025126~66031544:-
BRCA	cis	rs875971	0.862	rs1695820	ENSG00000229886.1	RP5-1132H15.3	3.75	0.000184	0.0106	0.13	0.12	Aortic root size;	chr7:66379576	chr7:66025126~66031544:-
BRCA	cis	rs6479874	0.736	rs2816829	ENSG00000223502.1	RP11-96B5.3	-3.75	0.000184	0.0106	-0.2	-0.12	Migraine;	chr10:50993839	chr10:51062579~51068553:-
BRCA	cis	rs6479874	0.736	rs2816828	ENSG00000223502.1	RP11-96B5.3	-3.75	0.000184	0.0106	-0.2	-0.12	Migraine;	chr10:50994003	chr10:51062579~51068553:-
BRCA	cis	rs6479874	0.736	rs2816825	ENSG00000223502.1	RP11-96B5.3	-3.75	0.000184	0.0106	-0.2	-0.12	Migraine;	chr10:50994156	chr10:51062579~51068553:-
BRCA	cis	rs1850744	0.702	rs4974812	ENSG00000250342.1	SNRPCP16	3.75	0.000184	0.0106	0.28	0.12	Economic and political preferences;	chr4:9612974	chr4:9051842~9052051:-
BRCA	cis	rs9527	0.59	rs2066322	ENSG00000213061.2	PFN1P11	3.75	0.000184	0.0106	0.16	0.12	Arsenic metabolism;	chr10:103149582	chr10:102838011~102845473:-
BRCA	cis	rs1555133	0.651	rs2295762	ENSG00000275576.1	RP5-836N17.4	-3.75	0.000184	0.0106	-0.13	-0.12	Monocyte count;	chr20:32437732	chr20:32116171~32116629:+
BRCA	cis	rs67079557	1	rs67079557	ENSG00000260269.4	CTD-2323K18.1	-3.75	0.000184	0.0106	-0.17	-0.12	Breast cancer;	chr15:75637966	chr15:75527150~75601205:-
BRCA	cis	rs7267979	1	rs2387881	ENSG00000277938.1	RP5-965G21.3	-3.75	0.000184	0.0106	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25397536	chr20:25229150~25231933:+
BRCA	cis	rs17507216	0.56	rs28493687	ENSG00000255769.6	GOLGA2P10	-3.75	0.000184	0.0106	-0.13	-0.12	Excessive daytime sleepiness;	chr15:82560062	chr15:82472993~82513950:-
BRCA	cis	rs4664293	0.647	rs1549385	ENSG00000224152.1	AC009506.1	-3.75	0.000184	0.0106	-0.12	-0.12	Monocyte percentage of white cells;	chr2:159582540	chr2:159615296~159617082:+
BRCA	cis	rs17169635	0.601	rs3778853	ENSG00000272941.1	RP11-134L10.1	-3.75	0.000184	0.0106	-0.13	-0.12	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);	chr7:134860347	chr7:135168403~135169547:+
BRCA	cis	rs17301013	0.932	rs6683602	ENSG00000234741.6	GAS5	3.75	0.000184	0.0106	0.11	0.12	Systemic lupus erythematosus;	chr1:174617615	chr1:173863900~173868882:-
BRCA	cis	rs17301013	0.932	rs6696197	ENSG00000234741.6	GAS5	3.75	0.000184	0.0106	0.11	0.12	Systemic lupus erythematosus;	chr1:174617860	chr1:173863900~173868882:-
BRCA	cis	rs10411161	0.702	rs892039	ENSG00000269483.1	AC006272.1	3.75	0.000184	0.0106	0.2	0.12	Breast cancer;	chr19:51893288	chr19:51839924~51843324:-
BRCA	cis	rs10411161	0.702	rs2867319	ENSG00000269483.1	AC006272.1	3.75	0.000184	0.0106	0.2	0.12	Breast cancer;	chr19:51893907	chr19:51839924~51843324:-
BRCA	cis	rs10769025	0.511	rs7930973	ENSG00000255165.1	CTD-2609K8.3	3.75	0.000184	0.0106	0.11	0.12	Gout;	chr11:44159478	chr11:44071462~44072403:+
BRCA	cis	rs1670533	1	rs6850784	ENSG00000251639.2	RP11-20I20.1	3.75	0.000184	0.0106	0.18	0.12	Recombination rate (females);	chr4:1066021	chr4:1100016~1101558:-
BRCA	cis	rs1670533	1	rs6852558	ENSG00000251639.2	RP11-20I20.1	3.75	0.000184	0.0106	0.18	0.12	Recombination rate (females);	chr4:1066156	chr4:1100016~1101558:-
BRCA	cis	rs1348850	0.874	rs4893822	ENSG00000271825.1	RP11-337N6.2	3.75	0.000184	0.0106	0.15	0.12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177420999	chr2:177300600~177302006:+
BRCA	cis	rs1730008	0.661	rs55969621	ENSG00000279311.1	RP11-170K4.2	3.75	0.000184	0.0106	0.14	0.12	Lobe attachment (rater-scored or self-reported);	chr3:158375871	chr3:158869898~158871821:+
BRCA	cis	rs1730008	0.661	rs73170364	ENSG00000279311.1	RP11-170K4.2	3.75	0.000184	0.0106	0.14	0.12	Lobe attachment (rater-scored or self-reported);	chr3:158382647	chr3:158869898~158871821:+
BRCA	cis	rs2998286	0.784	rs998362	ENSG00000237128.1	RP11-351M16.3	3.75	0.000184	0.0106	0.14	0.12	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28528129	chr10:28433008~28495813:-
BRCA	cis	rs6840360	0.571	rs4696273	ENSG00000270265.1	RP11-731D1.4	-3.75	0.000184	0.0106	-0.14	-0.12	Intelligence (multi-trait analysis);	chr4:151607325	chr4:151333775~151353224:-
BRCA	cis	rs6840360	0.571	rs4696274	ENSG00000270265.1	RP11-731D1.4	-3.75	0.000184	0.0106	-0.14	-0.12	Intelligence (multi-trait analysis);	chr4:151607326	chr4:151333775~151353224:-
BRCA	cis	rs6840360	0.571	rs4696101	ENSG00000270265.1	RP11-731D1.4	-3.75	0.000184	0.0106	-0.14	-0.12	Intelligence (multi-trait analysis);	chr4:151607361	chr4:151333775~151353224:-
BRCA	cis	rs6064559	0.687	rs4811872	ENSG00000218018.2	RP4-800J21.3	-3.75	0.000184	0.0106	-0.1	-0.12	Hemoglobin concentration;	chr20:57546298	chr20:57384160~57393062:-
BRCA	cis	rs12761761	1	rs12764703	ENSG00000279982.1	RP11-45A17.3	-3.75	0.000184	0.0106	-0.15	-0.12	Intelligence (multi-trait analysis);Educational attainment (years of education);	chr10:131971832	chr10:131996738~131999846:+
BRCA	cis	rs10986311	0.851	rs10818940	ENSG00000227200.1	RP11-121A14.3	3.75	0.000184	0.0106	0.15	0.12	Vitiligo;	chr9:124301180	chr9:124262876~124265809:+
BRCA	cis	rs11239930	0.538	rs17160592	ENSG00000237188.3	RP11-337C18.8	3.75	0.000184	0.0106	0.13	0.12	AIDS progression;	chr1:147083644	chr1:147172771~147211568:+
BRCA	cis	rs11239930	0.538	rs56060937	ENSG00000237188.3	RP11-337C18.8	3.75	0.000184	0.0106	0.13	0.12	AIDS progression;	chr1:147083854	chr1:147172771~147211568:+
BRCA	cis	rs939563	0.894	rs2302460	ENSG00000262333.1	HNRNPA1P16	3.75	0.000184	0.0106	0.12	0.12	Mean platelet volume;	chr17:1541408	chr17:2306761~2307715:+
BRCA	cis	rs4478858	0.735	rs2271072	ENSG00000223907.1	LINC01226	-3.75	0.000184	0.0106	-0.14	-0.12	Alcohol dependence;	chr1:31367579	chr1:31518435~31524245:+
BRCA	cis	rs6968419	0.537	rs17138298	ENSG00000279086.1	RP11-667F14.1	-3.75	0.000184	0.0106	-0.12	-0.12	Intraocular pressure;	chr7:116107151	chr7:116209234~116211511:-
BRCA	cis	rs7829975	0.533	rs1039917	ENSG00000173295.6	FAM86B3P	3.75	0.000184	0.0106	0.12	0.12	Mood instability;	chr8:8861340	chr8:8228595~8244865:+
BRCA	cis	rs16846053	0.685	rs62188771	ENSG00000227403.1	AC009299.3	3.75	0.000184	0.0106	0.3	0.12	Blood osmolality (transformed sodium);	chr2:161874873	chr2:161244739~161249050:+
BRCA	cis	rs13202860	0.584	rs598958	ENSG00000272008.1	RP11-393I2.4	3.75	0.000184	0.0106	0.18	0.12	Sexual dysfunction (female);	chr6:86678312	chr6:87151159~87155285:-
BRCA	cis	rs8007846	0.536	rs4439682	ENSG00000276116.2	FUT8-AS1	-3.75	0.000185	0.0106	-0.12	-0.12	Multiple sclerosis--Brain Glutamate Levels;	chr14:65792710	chr14:65411170~65412690:-
BRCA	cis	rs12368653	0.666	rs799267	ENSG00000257159.1	RP11-58A17.3	-3.75	0.000185	0.0106	-0.13	-0.12	Multiple sclerosis;	chr12:57719375	chr12:57967058~57968399:+
BRCA	cis	rs4578769	0.765	rs1609464	ENSG00000273232.1	RP11-370A5.2	-3.75	0.000185	0.0106	-0.16	-0.12	Eosinophil percentage of white cells;	chr18:22844191	chr18:22882825~22883357:-
BRCA	cis	rs7680126	0.632	rs6834645	ENSG00000250413.1	RP11-448G15.1	3.75	0.000185	0.0106	0.19	0.12	Urate levels in obese individuals;Urate levels in lean individuals;Urate levels in overweight individuals;	chr4:10148550	chr4:10006482~10009725:+
BRCA	cis	rs17684571	0.751	rs1610157	ENSG00000231441.1	RP11-472M19.2	3.75	0.000185	0.0106	0.19	0.12	Schizophrenia;	chr6:56844035	chr6:56844002~56864078:+
BRCA	cis	rs8054556	0.967	rs11150576	ENSG00000214725.6	CDIPT-AS1	-3.75	0.000185	0.0106	-0.14	-0.12	Autism spectrum disorder or schizophrenia;	chr16:29954175	chr16:29863593~29868053:+
BRCA	cis	rs7267979	0.549	rs6138536	ENSG00000277938.1	RP5-965G21.3	3.75	0.000185	0.0106	0.14	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25202012	chr20:25229150~25231933:+
BRCA	cis	rs10043775	0.958	rs7736019	ENSG00000251330.3	CTD-2283N19.1	-3.75	0.000185	0.0106	-0.13	-0.12	Periodontal microbiota;	chr5:148419939	chr5:148430159~148430807:-
BRCA	cis	rs875971	0.862	rs1643375	ENSG00000229886.1	RP5-1132H15.3	3.75	0.000185	0.0106	0.13	0.12	Aortic root size;	chr7:66407690	chr7:66025126~66031544:-
BRCA	cis	rs1396626	0.926	rs12079798	ENSG00000235501.4	RP4-639F20.1	-3.75	0.000185	0.0106	-0.15	-0.12	Diabetic kidney disease;	chr1:95528138	chr1:94927566~94963270:+
BRCA	cis	rs6701713	0.959	rs1408077	ENSG00000274245.1	RP11-357P18.2	-3.75	0.000185	0.0106	-0.19	-0.12	Alzheimer's disease (late onset);	chr1:207630796	chr1:207372559~207373252:+
BRCA	cis	rs6496044	0.526	rs4291869	ENSG00000259630.2	CTD-2262B20.1	-3.75	0.000185	0.0106	-0.14	-0.12	Interstitial lung disease;	chr15:85511292	chr15:85415228~85415633:+
BRCA	cis	rs4478858	0.735	rs2889730	ENSG00000260386.4	LINC01225	-3.75	0.000185	0.0106	-0.14	-0.12	Alcohol dependence;	chr1:31354312	chr1:31500085~31540885:+
BRCA	cis	rs801193	1	rs10234018	ENSG00000232546.1	RP11-458F8.1	3.75	0.000185	0.0106	0.1	0.12	Aortic root size;	chr7:66681297	chr7:66848496~66858136:+
BRCA	cis	rs6921919	0.583	rs9468355	ENSG00000273712.1	RP5-874C20.7	3.75	0.000185	0.0106	0.15	0.12	Autism spectrum disorder or schizophrenia;	chr6:28374100	chr6:28315613~28315883:-
BRCA	cis	rs539096	1	rs539096	ENSG00000236200.4	KDM4A-AS1	3.75	0.000185	0.0106	0.14	0.12	Intelligence (multi-trait analysis);	chr1:43606749	chr1:43699765~43708138:-
BRCA	cis	rs224278	0.789	rs224295	ENSG00000238280.1	RP11-436D10.3	3.75	0.000185	0.0107	0.15	0.12	Ewing sarcoma;	chr10:62830498	chr10:62793562~62805887:-
BRCA	cis	rs863345	0.584	rs1342949	ENSG00000229914.1	RP11-404O13.4	-3.75	0.000185	0.0107	-0.12	-0.12	Pneumococcal bacteremia;	chr1:158493505	chr1:158195633~158196131:-
BRCA	cis	rs62458065	0.713	rs62463967	ENSG00000281332.1	LINC00997	-3.75	0.000185	0.0107	-0.17	-0.12	Metabolite levels (HVA/MHPG ratio);	chr7:32458717	chr7:32760279~32762924:+
BRCA	cis	rs10819083	0.691	rs10986983	ENSG00000232630.1	PRPS1P2	-3.75	0.000185	0.0107	-0.12	-0.12	Squamous cell lung carcinoma;	chr9:125857730	chr9:125150653~125151589:+
BRCA	cis	rs113835537	0.529	rs2305535	ENSG00000258297.1	RP11-658F2.8	3.75	0.000185	0.0107	0.16	0.12	Airway imaging phenotypes;	chr11:66504766	chr11:66666036~66668374:+
BRCA	cis	rs7267979	1	rs4815404	ENSG00000277938.1	RP5-965G21.3	-3.75	0.000185	0.0107	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25321209	chr20:25229150~25231933:+
BRCA	cis	rs1008375	0.966	rs6449329	ENSG00000249502.1	AC006160.5	-3.75	0.000185	0.0107	-0.13	-0.12	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17702054	chr4:17587467~17614571:-
BRCA	cis	rs1528472	0.868	rs1690365	ENSG00000276533.1	RP11-139H15.5	3.75	0.000185	0.0107	0.13	0.12	Urinary albumin-to-creatinine ratio;Urinary albumin-to-creatinine ratio in non-diabetics;	chr15:55019059	chr15:55288849~55289346:-
BRCA	cis	rs6088580	0.634	rs6142159	ENSG00000275784.1	RP5-1125A11.6	3.75	0.000185	0.0107	0.12	0.12	Glomerular filtration rate (creatinine);	chr20:34405229	chr20:33989480~33991818:-
BRCA	cis	rs875971	0.862	rs778686	ENSG00000273024.4	INTS4P2	-3.75	0.000185	0.0107	-0.13	-0.12	Aortic root size;	chr7:66370923	chr7:65647864~65715661:+
BRCA	cis	rs3816183	0.958	rs4953664	ENSG00000226491.1	FTOP1	3.75	0.000185	0.0107	0.14	0.12	Hypospadias;	chr2:42797536	chr2:42797225~42798712:-
BRCA	cis	rs2281603	0.762	rs10130241	ENSG00000259116.1	RP11-973N13.4	-3.75	0.000185	0.0107	-0.11	-0.12	Lymphocyte counts;	chr14:64577402	chr14:64514154~64540368:-
BRCA	cis	rs465969	1	rs34382476	ENSG00000271789.1	RP5-1112D6.7	3.75	0.000185	0.0107	0.28	0.12	Psoriasis;	chr6:111423551	chr6:111297126~111298510:+
BRCA	cis	rs1239947	0.643	rs1239945	ENSG00000231607.7	DLEU2	3.75	0.000185	0.0107	0.14	0.12	Height;	chr13:50533621	chr13:49982552~50125720:-
BRCA	cis	rs524281	0.861	rs2293121	ENSG00000255557.1	RP11-770G2.2	3.75	0.000185	0.0107	0.16	0.12	Electroencephalogram traits;	chr11:66193876	chr11:65745729~65771585:+
BRCA	cis	rs524281	0.814	rs10896098	ENSG00000255557.1	RP11-770G2.2	3.75	0.000185	0.0107	0.16	0.12	Electroencephalogram traits;	chr11:66200945	chr11:65745729~65771585:+
BRCA	cis	rs721917	0.506	rs2819100	ENSG00000225484.5	NUTM2B-AS1	-3.75	0.000185	0.0107	-0.16	-0.12	Chronic obstructive pulmonary disease;	chr10:79937163	chr10:79663088~79826594:-
BRCA	cis	rs28374715	0.681	rs28712264	ENSG00000247556.5	OIP5-AS1	3.75	0.000185	0.0107	0.14	0.12	Ulcerative colitis;	chr15:41296599	chr15:41283990~41309737:+
BRCA	cis	rs9393692	0.645	rs6939048	ENSG00000241549.7	GUSBP2	-3.75	0.000185	0.0107	-0.14	-0.12	Educational attainment;	chr6:26327725	chr6:26871484~26956554:-
BRCA	cis	rs12760731	0.565	rs7536856	ENSG00000213057.5	C1orf220	3.75	0.000185	0.0107	0.17	0.12	Obesity-related traits;	chr1:178088792	chr1:178542752~178548889:+
BRCA	cis	rs9844666	0.512	rs9864775	ENSG00000239213.4	NCK1-AS1	3.75	0.000185	0.0107	0.14	0.12	Height;	chr3:135924726	chr3:136841726~136862054:-
BRCA	cis	rs12534093	0.67	rs11764404	ENSG00000234286.1	AC006026.13	-3.75	0.000185	0.0107	-0.17	-0.12	Infant length;Height;	chr7:23547541	chr7:23680195~23680786:-
BRCA	cis	rs10129255	0.5	rs2027902	ENSG00000211976.2	IGHV3-73	-3.75	0.000186	0.0107	-0.09	-0.12	Kawasaki disease;	chr14:106807157	chr14:106802694~106803233:-
BRCA	cis	rs2136613	0.751	rs10761666	ENSG00000238280.1	RP11-436D10.3	-3.75	0.000186	0.0107	-0.14	-0.12	Selective IgA deficiency;	chr10:62848601	chr10:62793562~62805887:-
BRCA	cis	rs10266483	0.562	rs10949887	ENSG00000271550.1	BNIP3P11	3.75	0.000186	0.0107	0.17	0.12	Response to statin therapy;	chr7:64291702	chr7:64678954~64687393:-
BRCA	cis	rs9287719	0.967	rs7563816	ENSG00000224177.5	LINC00570	3.75	0.000186	0.0107	0.13	0.12	Prostate cancer;	chr2:10623274	chr2:11393981~11403077:+
BRCA	cis	rs9425766	0.679	rs7552939	ENSG00000200674.1	RN7SKP160	3.75	0.000186	0.0107	0.16	0.12	Life satisfaction;	chr1:173798305	chr1:173791548~173791887:+
BRCA	cis	rs7267979	1	rs2257808	ENSG00000276952.1	RP5-965G21.6	3.75	0.000186	0.0107	0.14	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25285814	chr20:25284915~25285588:-
BRCA	cis	rs7267979	1	rs2257809	ENSG00000276952.1	RP5-965G21.6	3.75	0.000186	0.0107	0.14	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25285840	chr20:25284915~25285588:-
BRCA	cis	rs7267979	1	rs4815424	ENSG00000274973.1	RP13-401N8.7	3.75	0.000186	0.0107	0.13	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25409648	chr20:25845497~25845862:+
BRCA	cis	rs7800418	0.694	rs6461954	ENSG00000214870.7	AC004540.5	3.75	0.000186	0.0107	0.14	0.12	Cognitive function;	chr7:26565137	chr7:26398593~26494256:+
BRCA	cis	rs910873	0.505	rs6087607	ENSG00000202150.1	RNU6-407P	3.75	0.000186	0.0107	0.17	0.12	Melanoma;	chr20:34609685	chr20:35030317~35030420:-
BRCA	cis	rs8180040	0.764	rs4683324	ENSG00000260236.1	RP11-708J19.1	3.75	0.000186	0.0107	0.1	0.12	Colorectal cancer;	chr3:47209794	chr3:47379089~47380999:-
BRCA	cis	rs6596100	0.956	rs6596097	ENSG00000248648.1	RP11-485M7.1	-3.75	0.000186	0.0107	-0.14	-0.12	Breast cancer;	chr5:133056701	chr5:133003119~133003365:+
BRCA	cis	rs964611	0.938	rs12592157	ENSG00000259488.2	RP11-154J22.1	-3.75	0.000186	0.0107	-0.15	-0.12	Metabolite levels (Pyroglutamine);	chr15:48331327	chr15:48312353~48331856:-
BRCA	cis	rs2834288	0.645	rs2032313	ENSG00000237945.6	LINC00649	3.75	0.000186	0.0107	0.14	0.12	Gut microbiota (bacterial taxa);	chr21:33981946	chr21:33915534~33977691:+
BRCA	cis	rs7267979	0.668	rs4815398	ENSG00000125804.12	FAM182A	3.75	0.000186	0.0107	0.16	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25256702	chr20:26054655~26086917:+
BRCA	cis	rs6991838	0.55	rs4737750	ENSG00000272155.1	RP11-707M3.3	-3.75	0.000186	0.0107	-0.11	-0.12	Intelligence (multi-trait analysis);	chr8:65638724	chr8:65714334~65714778:-
BRCA	cis	rs11098499	0.738	rs34566984	ENSG00000225892.3	RP11-384K6.2	3.75	0.000186	0.0107	0.12	0.12	Corneal astigmatism;	chr4:119440115	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.954	rs9685777	ENSG00000225892.3	RP11-384K6.2	3.75	0.000186	0.0107	0.12	0.12	Corneal astigmatism;	chr4:119444810	chr4:118632274~118634759:+
BRCA	cis	rs8037818	1	rs11071856	ENSG00000261064.1	RP11-1000B6.3	-3.75	0.000186	0.0107	-0.15	-0.12	Obesity-related traits;	chr15:32633591	chr15:32536047~32587613:+
BRCA	cis	rs75422866	0.867	rs117022227	ENSG00000276691.1	RP5-1057I20.5	3.75	0.000186	0.0107	0.24	0.12	Pneumonia;	chr12:47633282	chr12:47788426~47788971:+
BRCA	cis	rs997295	0.57	rs17241808	ENSG00000260657.2	RP11-315D16.4	3.75	0.000186	0.0107	0.14	0.12	Motion sickness;	chr15:67600454	chr15:68267792~68277994:-
BRCA	cis	rs687432	0.65	rs2441970	ENSG00000213592.4	AP000662.9	-3.75	0.000186	0.0107	-0.14	-0.12	Parkinson's disease;	chr11:58100668	chr11:57718044~57718530:-
BRCA	cis	rs11098499	0.564	rs11098507	ENSG00000225892.3	RP11-384K6.2	3.75	0.000186	0.0107	0.11	0.12	Corneal astigmatism;	chr4:119367131	chr4:118632274~118634759:+
BRCA	cis	rs131777	0.708	rs131749	ENSG00000273272.1	CTA-384D8.34	-3.75	0.000186	0.0107	-0.12	-0.12	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr22:50586195	chr22:50542650~50543011:+
BRCA	cis	rs9840812	0.559	rs6439640	ENSG00000273486.1	RP11-731C17.2	3.75	0.000186	0.0107	0.17	0.12	Fibrinogen levels;	chr3:136466838	chr3:136837338~136839021:-
BRCA	cis	rs1371614	0.545	rs3769138	ENSG00000272148.1	RP11-195B17.1	3.75	0.000186	0.0107	0.13	0.12	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26946672	chr2:27062428~27062907:-
BRCA	cis	rs875971	0.66	rs10215132	ENSG00000275400.1	RP4-756H11.5	3.75	0.000186	0.0107	0.13	0.12	Aortic root size;	chr7:66589419	chr7:66553805~66554199:-
BRCA	cis	rs10129255	0.912	rs8011090	ENSG00000211958.2	IGHV3-38	3.75	0.000186	0.0107	0.09	0.12	Kawasaki disease;	chr14:106678896	chr14:106410493~106411021:-
BRCA	cis	rs8062405	0.721	rs151181	ENSG00000261766.1	RP11-22P6.2	-3.75	0.000186	0.0107	-0.11	-0.12	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28479196	chr16:28862166~28863340:-
BRCA	cis	rs7412746	0.658	rs3768015	ENSG00000231073.1	RP11-316M1.3	3.75	0.000186	0.0107	0.12	0.12	Melanoma;	chr1:150840478	chr1:150973123~150975534:+
BRCA	cis	rs67072384	1	rs7124056	ENSG00000256633.1	RP11-169D4.2	-3.75	0.000186	0.0107	-0.17	-0.12	Alloimmunization response to red blood cell transfusion in sickle cell anemia;	chr11:72733702	chr11:72584572~72587979:+
BRCA	cis	rs2617170	0.845	rs1049174	ENSG00000245648.1	RP11-277P12.20	3.75	0.000186	0.0107	0.15	0.12	Behcet's disease;	chr12:10372766	chr12:10363769~10398506:+
BRCA	cis	rs801193	0.935	rs3800820	ENSG00000265600.1	AC006480.1	3.75	0.000186	0.0107	0.14	0.12	Aortic root size;	chr7:66682191	chr7:67356680~67356779:+
BRCA	cis	rs1528472	0.679	rs1728885	ENSG00000276533.1	RP11-139H15.5	3.75	0.000186	0.0107	0.13	0.12	Urinary albumin-to-creatinine ratio;Urinary albumin-to-creatinine ratio in non-diabetics;	chr15:55016395	chr15:55288849~55289346:-
BRCA	cis	rs1528472	0.679	rs1690361	ENSG00000276533.1	RP11-139H15.5	3.75	0.000186	0.0107	0.13	0.12	Urinary albumin-to-creatinine ratio;Urinary albumin-to-creatinine ratio in non-diabetics;	chr15:55016443	chr15:55288849~55289346:-
BRCA	cis	rs17685	0.884	rs3823882	ENSG00000205485.12	AC004980.7	3.75	0.000186	0.0107	0.13	0.12	Coffee consumption (cups per day);Coffee consumption;	chr7:76002595	chr7:76549360~76627982:+
BRCA	cis	rs3177980	0.632	rs1062976	ENSG00000239494.2	RN7SL333P	-3.75	0.000186	0.0107	-0.11	-0.12	Amyotrophic lateral sclerosis;	chr1:169854519	chr1:169859756~169860052:+
BRCA	cis	rs4557020	0.904	rs10496031	ENSG00000203327.2	AC012358.7	3.75	0.000186	0.0107	0.11	0.12	Myopia (pathological);	chr2:54496066	chr2:55214387~55216126:-
BRCA	cis	rs812925	0.537	rs10196146	ENSG00000273302.1	RP11-493E12.2	-3.75	0.000186	0.0107	-0.1	-0.12	Immature fraction of reticulocytes;	chr2:61378244	chr2:61199979~61200769:+
BRCA	cis	rs35146811	0.735	rs1727140	ENSG00000214313.7	AZGP1P1	-3.75	0.000186	0.0107	-0.12	-0.12	Coronary artery disease;	chr7:100217776	chr7:99980762~99987535:+
BRCA	cis	rs9309473	0.607	rs2421489	ENSG00000163016.8	ALMS1P	3.75	0.000186	0.0107	0.14	0.12	Metabolite levels;	chr2:73366320	chr2:73644919~73685576:+
BRCA	cis	rs848490	0.962	rs11768148	ENSG00000214293.7	APTR	3.75	0.000186	0.0107	0.15	0.12	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77715977	chr7:77657660~77696265:-
BRCA	cis	rs747650	0.504	rs4581406	ENSG00000200376.1	RNU5E-10P	-3.75	0.000186	0.0107	-0.16	-0.12	Acne (severe);	chr11:46940900	chr11:47576471~47576588:-
BRCA	cis	rs7520050	0.966	rs10890361	ENSG00000281133.1	AL355480.3	3.75	0.000186	0.0107	0.13	0.12	Reticulocyte count;Red blood cell count;	chr1:45880562	chr1:45580892~45580996:-
BRCA	cis	rs7267979	1	rs10966	ENSG00000274414.1	RP5-965G21.4	-3.75	0.000186	0.0107	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25302308	chr20:25239007~25245229:-
BRCA	cis	rs7620503	0.721	rs6769488	ENSG00000277241.1	RP11-114M1.3	3.75	0.000186	0.0107	0.14	0.12	Corneal structure;	chr3:177590370	chr3:177700346~177701072:-
BRCA	cis	rs6460942	0.908	rs73677570	ENSG00000226690.5	AC005281.1	3.75	0.000186	0.0107	0.21	0.12	Coronary artery disease;	chr7:12240703	chr7:12496429~12541910:+
BRCA	cis	rs3858526	0.959	rs61876224	ENSG00000224295.2	AC087380.14	3.75	0.000186	0.0107	0.16	0.12	DNA methylation (variation);	chr11:5931629	chr11:5518441~5524955:-
BRCA	cis	rs56281245	1	rs116608983	ENSG00000249363.1	CTB-78O21.1	3.75	0.000186	0.0107	0.25	0.12	Hepcidin levels;	chr5:145619632	chr5:145728360~145729349:-
BRCA	cis	rs6430585	0.527	rs62168830	ENSG00000224043.6	CCNT2-AS1	-3.75	0.000186	0.0107	-0.19	-0.12	Corneal structure;	chr2:135686330	chr2:134735464~134918710:-
BRCA	cis	rs4415084	0.834	rs1438820	ENSG00000248779.1	RP11-53O19.2	3.75	0.000186	0.0107	0.11	0.12	Breast cancer;	chr5:44797668	chr5:44752949~44765744:+
BRCA	cis	rs6984305	0.541	rs17716118	ENSG00000253130.1	CTD-3023L14.2	3.75	0.000186	0.0107	0.21	0.12	Liver enzyme levels (alkaline phosphatase);	chr8:9322624	chr8:8561391~8569688:+
BRCA	cis	rs465969	1	rs463543	ENSG00000271789.1	RP5-1112D6.7	3.75	0.000186	0.0107	0.27	0.12	Psoriasis;	chr6:111346349	chr6:111297126~111298510:+
BRCA	cis	rs10043775	0.793	rs7727886	ENSG00000251330.3	CTD-2283N19.1	-3.75	0.000186	0.0107	-0.13	-0.12	Periodontal microbiota;	chr5:148325911	chr5:148430159~148430807:-
BRCA	cis	rs925550	0.526	rs62322204	ENSG00000224786.1	CETN4P	-3.75	0.000186	0.0107	-0.17	-0.12	Primary biliary cholangitis;	chr4:122707934	chr4:122730548~122732193:-
BRCA	cis	rs4835473	0.808	rs2060653	ENSG00000246448.2	RP13-578N3.3	-3.75	0.000186	0.0107	-0.13	-0.12	Immature fraction of reticulocytes;	chr4:143739132	chr4:143700257~143865072:+
BRCA	cis	rs12935418	0.616	rs12446053	ENSG00000278985.1	RP11-303E16.9	-3.75	0.000186	0.0107	-0.16	-0.12	Mean corpuscular volume;	chr16:80930234	chr16:80982319~80984094:-
BRCA	cis	rs72928364	1	rs13079002	ENSG00000244119.1	PDCL3P4	3.75	0.000186	0.0107	0.14	0.12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100911297	chr3:101712472~101713191:+
BRCA	cis	rs2303319	0.504	rs62187745	ENSG00000227403.1	AC009299.3	3.75	0.000187	0.0107	0.31	0.12	Cognitive function;	chr2:161846296	chr2:161244739~161249050:+
BRCA	cis	rs11098499	0.78	rs10013652	ENSG00000225892.3	RP11-384K6.2	3.75	0.000187	0.0107	0.11	0.12	Corneal astigmatism;	chr4:119371101	chr4:118632274~118634759:+
BRCA	cis	rs6964587	1	rs2282971	ENSG00000188693.7	CYP51A1-AS1	-3.75	0.000187	0.0107	-0.12	-0.12	Breast cancer;	chr7:91955042	chr7:92134604~92180725:+
BRCA	cis	rs2274459	0.749	rs12190155	ENSG00000249346.5	LINC01016	3.75	0.000187	0.0107	0.15	0.12	Obesity (extreme);	chr6:33695464	chr6:33867506~33896914:-
BRCA	cis	rs8180040	1	rs807931	ENSG00000260236.1	RP11-708J19.1	3.75	0.000187	0.0107	0.1	0.12	Colorectal cancer;	chr3:47347827	chr3:47379089~47380999:-
BRCA	cis	rs838721	0.574	rs11679046	ENSG00000259793.1	RP11-400N9.1	-3.75	0.000187	0.0107	-0.1	-0.12	Total body bone mineral density;	chr2:233349455	chr2:233351132~233353416:-
BRCA	cis	rs1923539	0.713	rs2265960	ENSG00000225484.5	NUTM2B-AS1	3.75	0.000187	0.0107	0.17	0.12	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79969830	chr10:79663088~79826594:-
BRCA	cis	rs17801127	0.901	rs12233106	ENSG00000231969.1	AC144449.1	3.75	0.000187	0.0107	0.2	0.12	Liver enzyme levels (alanine transaminase);	chr2:149687521	chr2:149587196~149848233:+
BRCA	cis	rs12468226	1	rs111252524	ENSG00000272966.1	RP11-686O6.1	3.75	0.000187	0.0107	0.19	0.12	Urate levels;	chr2:202334465	chr2:202336739~202337200:+
BRCA	cis	rs12468226	1	rs112753638	ENSG00000272966.1	RP11-686O6.1	3.75	0.000187	0.0107	0.19	0.12	Urate levels;	chr2:202334496	chr2:202336739~202337200:+
BRCA	cis	rs600231	0.665	rs1621277	ENSG00000173727.10	CMB9-22P13.1	-3.75	0.000187	0.0107	-0.15	-0.12	Bone mineral density;	chr11:65454483	chr11:65455258~65466720:+
BRCA	cis	rs4415084	0.617	rs10039173	ENSG00000251141.4	RP11-53O19.1	-3.75	0.000187	0.0107	-0.11	-0.12	Breast cancer;	chr5:44903274	chr5:44744900~44808777:-
BRCA	cis	rs17756712	0.57	rs1122256	ENSG00000272463.1	RP11-532F6.3	3.75	0.000187	0.0107	0.16	0.12	Vertical cup-disc ratio;	chr6:611969	chr6:708592~711405:-
BRCA	cis	rs4650943	0.586	rs2504503	ENSG00000227740.1	RP11-318C24.2	3.75	0.000187	0.0107	0.12	0.12	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in inactive individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr1:176329041	chr1:175904762~175920513:-
BRCA	cis	rs7911264	0.905	rs7918084	ENSG00000232709.1	MARK2P9	-3.75	0.000187	0.0107	-0.14	-0.12	Inflammatory bowel disease;	chr10:92669710	chr10:92418667~92420875:+
BRCA	cis	rs897984	0.609	rs35468353	ENSG00000279196.1	RP11-1072A3.3	3.75	0.000187	0.0107	0.12	0.12	Dementia with Lewy bodies;	chr16:31045112	chr16:30984630~30988270:-
BRCA	cis	rs897984	0.609	rs11862744	ENSG00000279196.1	RP11-1072A3.3	3.75	0.000187	0.0107	0.12	0.12	Dementia with Lewy bodies;	chr16:31046479	chr16:30984630~30988270:-
BRCA	cis	rs7523050	0.73	rs35100394	ENSG00000203897.3	SPATA42	-3.75	0.000187	0.0107	-0.22	-0.12	Fat distribution (HIV);	chr1:108891367	chr1:108857217~108858524:+
BRCA	cis	rs7523050	0.73	rs72984612	ENSG00000203897.3	SPATA42	-3.75	0.000187	0.0107	-0.22	-0.12	Fat distribution (HIV);	chr1:108892204	chr1:108857217~108858524:+
BRCA	cis	rs7523050	0.73	rs72984614	ENSG00000203897.3	SPATA42	-3.75	0.000187	0.0107	-0.22	-0.12	Fat distribution (HIV);	chr1:108893226	chr1:108857217~108858524:+
BRCA	cis	rs7523050	0.73	rs12726126	ENSG00000203897.3	SPATA42	-3.75	0.000187	0.0107	-0.22	-0.12	Fat distribution (HIV);	chr1:108893506	chr1:108857217~108858524:+
BRCA	cis	rs2302465	0.86	rs73243118	ENSG00000273133.1	RP11-799M12.2	-3.75	0.000187	0.0107	-0.23	-0.12	Blood protein levels;	chr4:15668076	chr4:15563698~15564253:-
BRCA	cis	rs4538475	0.559	rs73243129	ENSG00000273133.1	RP11-799M12.2	-3.75	0.000187	0.0107	-0.23	-0.12	Parkinson's disease;	chr4:15676844	chr4:15563698~15564253:-
BRCA	cis	rs4538475	0.559	rs73243131	ENSG00000273133.1	RP11-799M12.2	-3.75	0.000187	0.0107	-0.23	-0.12	Parkinson's disease;	chr4:15677412	chr4:15563698~15564253:-
BRCA	cis	rs8049367	0.684	rs2283483	ENSG00000267077.1	RP11-127I20.5	3.75	0.000187	0.0107	0.12	0.12	Nonsyndromic cleft lip with or without cleft palate;	chr16:3919296	chr16:4795265~4796532:-
BRCA	cis	rs7695732	0.743	rs7660314	ENSG00000270720.1	RP11-84C13.2	-3.75	0.000187	0.0107	-0.16	-0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr4:88997395	chr4:89119284~89119871:+
BRCA	cis	rs1400816	0.702	rs1554165	ENSG00000228389.1	AC068039.4	-3.75	0.000187	0.0107	-0.21	-0.12	Amyotrophic lateral sclerosis (sporadic);	chr2:171695092	chr2:171773482~171775844:+
BRCA	cis	rs1400816	0.702	rs1850031	ENSG00000228389.1	AC068039.4	-3.75	0.000187	0.0107	-0.21	-0.12	Amyotrophic lateral sclerosis (sporadic);	chr2:171701229	chr2:171773482~171775844:+
BRCA	cis	rs1400816	0.702	rs1515812	ENSG00000228389.1	AC068039.4	-3.75	0.000187	0.0107	-0.21	-0.12	Amyotrophic lateral sclerosis (sporadic);	chr2:171701537	chr2:171773482~171775844:+
BRCA	cis	rs7267979	1	rs6083805	ENSG00000276952.1	RP5-965G21.6	-3.75	0.000187	0.0107	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25336720	chr20:25284915~25285588:-
BRCA	cis	rs224278	0.789	rs224299	ENSG00000238280.1	RP11-436D10.3	3.75	0.000187	0.0107	0.15	0.12	Ewing sarcoma;	chr10:62831059	chr10:62793562~62805887:-
BRCA	cis	rs224278	0.764	rs224301	ENSG00000238280.1	RP11-436D10.3	3.75	0.000187	0.0107	0.15	0.12	Ewing sarcoma;	chr10:62832252	chr10:62793562~62805887:-
BRCA	cis	rs9858542	0.537	rs9863142	ENSG00000224424.7	PRKAR2A-AS1	-3.75	0.000187	0.0107	-0.12	-0.12	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49329308	chr3:48847572~48851981:+
BRCA	cis	rs983392	1	rs920573	ENSG00000275344.1	MIR6503	-3.75	0.000187	0.0107	-0.12	-0.12	Alzheimer's disease (late onset);	chr11:60157486	chr11:60209071~60209156:-
BRCA	cis	rs1998359	0.52	rs10083306	ENSG00000259087.4	RP11-356O9.2	-3.75	0.000187	0.0107	-0.11	-0.12	Self-reported allergy;	chr14:37678182	chr14:37556158~37567095:-
BRCA	cis	rs7572733	0.967	rs11889326	ENSG00000231621.1	AC013264.2	-3.75	0.000187	0.0108	-0.11	-0.12	Dermatomyositis;	chr2:198034551	chr2:197197991~197199273:+
BRCA	cis	rs12681366	1	rs67808321	ENSG00000253175.1	RP11-267M23.6	3.75	0.000187	0.0108	0.13	0.12	Nonsyndromic cleft lip with cleft palate;	chr8:94373317	chr8:94565036~94565715:+
BRCA	cis	rs2835872	0.828	rs2835839	ENSG00000228677.1	TTC3-AS1	-3.75	0.000187	0.0108	-0.15	-0.12	Electroencephalographic traits in alcoholism;	chr21:37618732	chr21:37187666~37193926:-
BRCA	cis	rs6090583	0.646	rs4810570	ENSG00000273893.1	RP1-101A2.1	3.75	0.000187	0.0108	0.13	0.12	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr20:46891166	chr20:46681676~46682375:-
BRCA	cis	rs4388249	1	rs3753175	ENSG00000271849.1	CTC-332L22.1	-3.75	0.000187	0.0108	-0.19	-0.12	Schizophrenia;	chr5:109772237	chr5:109687802~109688329:-
BRCA	cis	rs2301573	0.584	rs12636474	ENSG00000271270.4	TMCC1-AS1	-3.75	0.000187	0.0108	-0.25	-0.12	Hip circumference;	chr3:129636397	chr3:129893871~129918575:+
BRCA	cis	rs78487399	0.808	rs7587268	ENSG00000234936.1	AC010883.5	3.75	0.000187	0.0108	0.18	0.12	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43446753	chr2:43229573~43233394:+
BRCA	cis	rs62064224	0.714	rs4794915	ENSG00000279781.1	RP11-466A19.7	-3.75	0.000187	0.0108	-0.14	-0.12	Schizophrenia;	chr17:32307344	chr17:32518322~32518934:-
BRCA	cis	rs7246657	0.598	rs28660259	ENSG00000267470.4	ZNF571-AS1	3.75	0.000187	0.0108	0.18	0.12	Coronary artery calcification;	chr19:37167779	chr19:37548914~37587348:+
BRCA	cis	rs687432	0.847	rs1376489	ENSG00000265566.2	RN7SL605P	-3.75	0.000187	0.0108	-0.16	-0.12	Parkinson's disease;	chr11:58043414	chr11:57528085~57528365:-
BRCA	cis	rs3735485	0.8	rs4724343	ENSG00000201772.1	SNORA5C	-3.75	0.000187	0.0108	-0.15	-0.12	White blood cell count;Sum basophil neutrophil counts;Neutrophil count;Granulocyte percentage of myeloid white cells;Monocyte percentage of white cells;Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Lymphocyte counts;	chr7:45012534	chr7:45104906~45105042:-
BRCA	cis	rs3735485	0.8	rs4724344	ENSG00000201772.1	SNORA5C	-3.75	0.000187	0.0108	-0.15	-0.12	White blood cell count;Sum basophil neutrophil counts;Neutrophil count;Granulocyte percentage of myeloid white cells;Monocyte percentage of white cells;Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Lymphocyte counts;	chr7:45012753	chr7:45104906~45105042:-
BRCA	cis	rs3735485	0.76	rs4724345	ENSG00000201772.1	SNORA5C	-3.75	0.000187	0.0108	-0.15	-0.12	White blood cell count;Sum basophil neutrophil counts;Neutrophil count;Granulocyte percentage of myeloid white cells;Monocyte percentage of white cells;Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Lymphocyte counts;	chr7:45013843	chr7:45104906~45105042:-
BRCA	cis	rs7131987	0.903	rs67150462	ENSG00000257599.1	OVCH1-AS1	-3.75	0.000187	0.0108	-0.14	-0.12	QT interval;	chr12:29240392	chr12:29389294~29487488:+
BRCA	cis	rs6088590	1	rs12626122	ENSG00000269202.1	RP4-614O4.12	-3.75	0.000187	0.0108	-0.13	-0.12	Coronary artery disease;	chr20:34837997	chr20:35201747~35203288:-
BRCA	cis	rs4664293	0.967	rs4665103	ENSG00000230783.1	AC009961.2	-3.75	0.000187	0.0108	-0.15	-0.12	Monocyte percentage of white cells;	chr2:159675801	chr2:159689217~159690291:-
BRCA	cis	rs4356203	0.519	rs214097	ENSG00000184669.7	OR7E14P	-3.75	0.000187	0.0108	-0.15	-0.12	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17269952	chr11:17013998~17053024:+
BRCA	cis	rs6596100	0.956	rs6892902	ENSG00000248648.1	RP11-485M7.1	-3.75	0.000187	0.0108	-0.14	-0.12	Breast cancer;	chr5:133075739	chr5:133003119~133003365:+
BRCA	cis	rs12723316	0.867	rs12746729	ENSG00000233008.4	RP11-475O6.1	-3.75	0.000187	0.0108	-0.22	-0.12	Schizophrenia;	chr1:83805565	chr1:83575776~83861023:-
BRCA	cis	rs17684571	0.938	rs17751682	ENSG00000231441.1	RP11-472M19.2	-3.75	0.000187	0.0108	-0.18	-0.12	Schizophrenia;	chr6:56695732	chr6:56844002~56864078:+
BRCA	cis	rs17027633	0.881	rs78403721	ENSG00000260948.1	RP11-552M11.8	-3.75	0.000187	0.0108	-0.27	-0.12	Cerebrospinal fluid t-tau:AB1-42 ratio;	chr1:111472244	chr1:111431046~111433068:-
BRCA	cis	rs4689592	0.619	rs3796908	ENSG00000245468.3	RP11-367J11.3	3.75	0.000187	0.0108	0.13	0.12	Monocyte percentage of white cells;	chr4:7059651	chr4:7094571~7103385:-
BRCA	cis	rs875971	0.798	rs57739047	ENSG00000273024.4	INTS4P2	-3.75	0.000187	0.0108	-0.13	-0.12	Aortic root size;	chr7:66507579	chr7:65647864~65715661:+
BRCA	cis	rs34792	0.76	rs153808	ENSG00000207425.1	Y_RNA	3.75	0.000187	0.0108	0.13	0.12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15464485	chr16:14915457~14915556:-
BRCA	cis	rs8040855	0.627	rs1532776	ENSG00000229212.6	RP11-561C5.4	-3.75	0.000187	0.0108	-0.16	-0.12	Bulimia nervosa;	chr15:85081383	chr15:85205440~85234795:-
BRCA	cis	rs10457838	0.778	rs6903827	ENSG00000231760.4	RP11-350J20.5	3.75	0.000187	0.0108	0.16	0.12	Post-traumatic stress disorder;	chr6:149082333	chr6:149796151~149826294:-
BRCA	cis	rs654950	0.875	rs687766	ENSG00000230638.4	RP11-486B10.4	-3.75	0.000187	0.0108	-0.15	-0.12	Airway imaging phenotypes;	chr1:41533178	chr1:41542069~41544310:+
BRCA	cis	rs595244	1	rs56286136	ENSG00000259705.1	RP11-227D13.1	3.75	0.000187	0.0108	0.19	0.12	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48463617	chr15:48645951~48652016:+
BRCA	cis	rs2731006	0.901	rs2056193	ENSG00000257114.2	RP11-25I15.3	3.75	0.000187	0.0108	0.18	0.12	Panic disorder;	chr12:42761973	chr12:42692216~42717119:+
BRCA	cis	rs16958440	1	rs60854219	ENSG00000267800.1	RP11-49K24.5	-3.75	0.000187	0.0108	-0.25	-0.12	Sitting height ratio;	chr18:47120293	chr18:47137018~47137290:+
BRCA	cis	rs35740288	0.822	rs34734963	ENSG00000259407.1	RP11-158M2.3	-3.75	0.000187	0.0108	-0.16	-0.12	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85674413	chr15:85744109~85750281:-
BRCA	cis	rs863345	0.604	rs11264997	ENSG00000229914.1	RP11-404O13.4	-3.75	0.000187	0.0108	-0.13	-0.12	Pneumococcal bacteremia;	chr1:158515692	chr1:158195633~158196131:-
BRCA	cis	rs4555772	0.573	rs7714420	ENSG00000272040.1	CTC-366B18.4	-3.75	0.000187	0.0108	-0.12	-0.12	Stearic acid (18:0) levels;	chr5:75044502	chr5:75608817~75609983:+
BRCA	cis	rs1178127	0.765	rs1178151	ENSG00000232821.1	AC003986.6	3.75	0.000187	0.0108	0.16	0.12	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);	chr7:18740392	chr7:19112474~19114271:+
BRCA	cis	rs848490	0.889	rs56198418	ENSG00000214293.7	APTR	3.75	0.000187	0.0108	0.14	0.12	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77659141	chr7:77657660~77696265:-
BRCA	cis	rs863345	0.604	rs1342950	ENSG00000229914.1	RP11-404O13.4	-3.75	0.000187	0.0108	-0.12	-0.12	Pneumococcal bacteremia;	chr1:158493933	chr1:158195633~158196131:-
BRCA	cis	rs863345	0.604	rs12034004	ENSG00000229914.1	RP11-404O13.4	-3.75	0.000187	0.0108	-0.12	-0.12	Pneumococcal bacteremia;	chr1:158494095	chr1:158195633~158196131:-
BRCA	cis	rs4865762	0.904	rs1392541	ENSG00000247796.2	CTD-2366F13.1	3.75	0.000187	0.0108	0.12	0.12	Intraocular pressure;	chr5:53199215	chr5:53109842~53115126:+
BRCA	cis	rs73201462	1	rs56328893	ENSG00000242551.2	POU5F1P6	3.75	0.000187	0.0108	0.2	0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128322987	chr3:128674735~128677005:-
BRCA	cis	rs10938353	0.906	rs1439376	ENSG00000273369.1	RP11-700J17.1	-3.75	0.000187	0.0108	-0.14	-0.12	Body mass index;	chr4:44591681	chr4:44693946~44694386:-
BRCA	cis	rs8192917	1	rs6573911	ENSG00000258744.1	RP11-80A15.1	-3.75	0.000187	0.0108	-0.15	-0.12	Vitiligo;	chr14:24631727	chr14:24501594~24508688:+
BRCA	cis	rs4950322	0.542	rs115179956	ENSG00000237188.3	RP11-337C18.8	3.75	0.000187	0.0108	0.13	0.12	Protein quantitative trait loci;	chr1:147172620	chr1:147172771~147211568:+
BRCA	cis	rs3816183	1	rs10193013	ENSG00000226491.1	FTOP1	-3.75	0.000187	0.0108	-0.15	-0.12	Hypospadias;	chr2:42790276	chr2:42797225~42798712:-
BRCA	cis	rs2835872	0.698	rs73220486	ENSG00000228677.1	TTC3-AS1	-3.75	0.000187	0.0108	-0.15	-0.12	Electroencephalographic traits in alcoholism;	chr21:37614386	chr21:37187666~37193926:-
BRCA	cis	rs7267979	0.565	rs13040726	ENSG00000277938.1	RP5-965G21.3	-3.75	0.000187	0.0108	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25579245	chr20:25229150~25231933:+
BRCA	cis	rs2562456	0.917	rs6511256	ENSG00000268555.1	RP11-678G14.3	-3.75	0.000188	0.0108	-0.15	-0.12	Pain;	chr19:21510513	chr19:21570822~21587322:-
BRCA	cis	rs10129255	0.957	rs12590799	ENSG00000232216.1	IGHV3-43	3.75	0.000188	0.0108	0.09	0.12	Kawasaki disease;	chr14:106779713	chr14:106470264~106470800:-
BRCA	cis	rs66887589	0.777	rs2017058	ENSG00000260404.2	RP11-384K6.6	3.75	0.000188	0.0108	0.1	0.12	Diastolic blood pressure;	chr4:119336584	chr4:118591773~118633729:+
BRCA	cis	rs10129255	0.912	rs67410411	ENSG00000211967.3	IGHV3-53	-3.75	0.000188	0.0108	-0.09	-0.12	Kawasaki disease;	chr14:106680324	chr14:106592676~106593347:-
BRCA	cis	rs10463316	0.779	rs1810084	ENSG00000260581.1	CTB-113P19.4	3.75	0.000188	0.0108	0.13	0.12	Metabolite levels (Pyroglutamine);	chr5:151397487	chr5:151652275~151655449:+
BRCA	cis	rs673253	0.581	rs2152113	ENSG00000229431.1	RP1-92O14.6	3.75	0.000188	0.0108	0.12	0.12	Intelligence (multi-trait analysis);	chr1:43517898	chr1:43385113~43389155:+
BRCA	cis	rs2514805	0.803	rs2513788	ENSG00000253585.1	KB-1184D12.1	3.75	0.000188	0.0108	0.2	0.12	Diisocyanate-induced asthma;	chr8:94115668	chr8:94097764~94104322:-
BRCA	cis	rs2514805	0.803	rs2513790	ENSG00000253585.1	KB-1184D12.1	3.75	0.000188	0.0108	0.2	0.12	Diisocyanate-induced asthma;	chr8:94115919	chr8:94097764~94104322:-
BRCA	cis	rs494453	0.677	rs548200	ENSG00000227811.2	FAM212B-AS1	3.75	0.000188	0.0108	0.16	0.12	Osteoporosis-related phenotypes;	chr1:111633409	chr1:111739841~111747798:+
BRCA	cis	rs7191439	0.858	rs11076702	ENSG00000260121.1	RP5-1142A6.9	3.75	0.000188	0.0108	0.2	0.12	Plateletcrit;	chr16:88708161	chr16:88718615~88720459:+
BRCA	cis	rs2692947	0.727	rs749459	ENSG00000232931.4	LINC00342	3.75	0.000188	0.0108	0.12	0.12	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96129975	chr2:95807118~95816215:-
BRCA	cis	rs1015362	0.503	rs1883708	ENSG00000275784.1	RP5-1125A11.6	-3.75	0.000188	0.0108	-0.16	-0.12	Freckles;Red vs. non-red hair color;Skin sensitivity to sun;Burning and freckling;	chr20:33924107	chr20:33989480~33991818:-
BRCA	cis	rs875971	0.66	rs10272357	ENSG00000272831.1	RP11-792A8.4	-3.75	0.000188	0.0108	-0.1	-0.12	Aortic root size;	chr7:66598087	chr7:66739829~66740385:-
BRCA	cis	rs12711490	0.651	rs12598434	ENSG00000270020.1	RP11-463O9.9	3.75	0.000188	0.0108	0.15	0.12	Systemic lupus erythematosus and Systemic sclerosis;Monocyte count;	chr16:85939453	chr16:86520383~86523897:-
BRCA	cis	rs4834770	1	rs4336213	ENSG00000245958.5	RP11-33B1.1	-3.75	0.000188	0.0108	-0.1	-0.12	Blood protein levels;	chr4:119315314	chr4:119454791~119552025:+
BRCA	cis	rs12723316	0.932	rs17521594	ENSG00000233008.4	RP11-475O6.1	-3.75	0.000188	0.0108	-0.22	-0.12	Schizophrenia;	chr1:83815021	chr1:83575776~83861023:-
BRCA	cis	rs2976388	0.647	rs2082801	ENSG00000253196.1	RP11-706C16.7	3.75	0.000188	0.0108	0.11	0.12	Urinary tract infection frequency;	chr8:142705043	chr8:142763116~142766427:+
BRCA	cis	rs1816752	0.905	rs9511242	ENSG00000273628.1	RP11-756A22.7	3.75	0.000188	0.0108	0.14	0.12	Obesity-related traits;	chr13:24419261	chr13:24933006~24936796:+
BRCA	cis	rs7267979	0.966	rs2151144	ENSG00000276952.1	RP5-965G21.6	-3.75	0.000188	0.0108	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25434288	chr20:25284915~25285588:-
BRCA	cis	rs13434995	0.513	rs4336288	ENSG00000249700.7	SRD5A3-AS1	3.75	0.000188	0.0108	0.17	0.12	Adiponectin levels;	chr4:55584088	chr4:55363971~55395847:-
BRCA	cis	rs8114671	0.562	rs4911161	ENSG00000261582.1	RP4-614O4.11	-3.75	0.000188	0.0108	-0.11	-0.12	Height;	chr20:34814428	chr20:35267885~35280043:-
BRCA	cis	rs6545883	0.929	rs6705235	ENSG00000270820.4	RP11-355B11.2	3.75	0.000188	0.0108	0.13	0.12	Tuberculosis;	chr2:61486445	chr2:61471188~61484130:+
BRCA	cis	rs7267979	1	rs4815411	ENSG00000204556.4	CTD-2514C3.1	3.75	0.000188	0.0108	0.16	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25369587	chr20:26018832~26020684:+
BRCA	cis	rs2731006	0.64	rs975540	ENSG00000257114.2	RP11-25I15.3	3.75	0.000188	0.0108	0.19	0.12	Panic disorder;	chr12:42784505	chr12:42692216~42717119:+
BRCA	cis	rs6964587	0.74	rs2020360	ENSG00000188693.7	CYP51A1-AS1	-3.75	0.000188	0.0108	-0.13	-0.12	Breast cancer;	chr7:91810192	chr7:92134604~92180725:+
BRCA	cis	rs11082321	1	rs11875806	ENSG00000266850.1	RP11-370A5.1	-3.75	0.000188	0.0108	-0.19	-0.12	Breast cancer;	chr18:23197450	chr18:22723491~22907721:-
BRCA	cis	rs524281	0.861	rs10896080	ENSG00000255557.1	RP11-770G2.2	3.75	0.000188	0.0108	0.16	0.12	Electroencephalogram traits;	chr11:66109325	chr11:65745729~65771585:+
BRCA	cis	rs11098499	0.866	rs6847778	ENSG00000260404.2	RP11-384K6.6	3.75	0.000188	0.0108	0.11	0.12	Corneal astigmatism;	chr4:119372427	chr4:118591773~118633729:+
BRCA	cis	rs853679	1	rs853679	ENSG00000280107.1	AL022393.9	-3.75	0.000188	0.0108	-0.2	-0.12	Depression;	chr6:28329086	chr6:28170845~28172521:+
BRCA	cis	rs853679	1	rs853678	ENSG00000280107.1	AL022393.9	-3.75	0.000188	0.0108	-0.2	-0.12	Depression;	chr6:28329536	chr6:28170845~28172521:+
BRCA	cis	rs9921338	0.961	rs7626	ENSG00000263080.1	RP11-485G7.5	3.75	0.000188	0.0108	0.18	0.12	Vein graft stenosis in coronary artery bypass grafting;	chr16:11351739	chr16:11341809~11345211:-
BRCA	cis	rs9921338	0.961	rs7193278	ENSG00000263080.1	RP11-485G7.5	3.75	0.000188	0.0108	0.18	0.12	Vein graft stenosis in coronary artery bypass grafting;	chr16:11351974	chr16:11341809~11345211:-
BRCA	cis	rs62244186	0.545	rs9284880	ENSG00000233509.2	ZNF197-AS1	3.75	0.000188	0.0108	0.14	0.12	Depressive symptoms;	chr3:44717897	chr3:44617128~44624797:-
BRCA	cis	rs7267979	0.966	rs7270835	ENSG00000274973.1	RP13-401N8.7	-3.75	0.000188	0.0108	-0.13	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25454431	chr20:25845497~25845862:+
BRCA	cis	rs7267979	1	rs6115191	ENSG00000274973.1	RP13-401N8.7	-3.75	0.000188	0.0108	-0.13	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25459842	chr20:25845497~25845862:+
BRCA	cis	rs7267979	1	rs6107045	ENSG00000274973.1	RP13-401N8.7	-3.75	0.000188	0.0108	-0.13	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25461300	chr20:25845497~25845862:+
BRCA	cis	rs7267979	1	rs6107046	ENSG00000274973.1	RP13-401N8.7	-3.75	0.000188	0.0108	-0.13	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25461413	chr20:25845497~25845862:+
BRCA	cis	rs7267979	1	rs6107047	ENSG00000274973.1	RP13-401N8.7	-3.75	0.000188	0.0108	-0.13	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25461461	chr20:25845497~25845862:+
BRCA	cis	rs33995560	0.708	rs4796144	ENSG00000271013.1	AC015849.15	-3.75	0.000188	0.0108	-0.18	-0.12	Blood protein levels;	chr17:35965995	chr17:35912635~35918010:-
BRCA	cis	rs6456156	0.792	rs10946213	ENSG00000272549.1	RP11-351J23.2	3.75	0.000188	0.0108	0.12	0.12	Primary biliary cholangitis;	chr6:167102607	chr6:167666840~167679270:-
BRCA	cis	rs6088580	0.634	rs6142153	ENSG00000275784.1	RP5-1125A11.6	3.75	0.000188	0.0108	0.12	0.12	Glomerular filtration rate (creatinine);	chr20:34380941	chr20:33989480~33991818:-
BRCA	cis	rs62458065	0.85	rs73096034	ENSG00000229358.3	DPY19L1P1	-3.75	0.000188	0.0108	-0.16	-0.12	Metabolite levels (HVA/MHPG ratio);	chr7:32432436	chr7:32580949~32761787:-
BRCA	cis	rs4664293	0.647	rs357028	ENSG00000224152.1	AC009506.1	-3.75	0.000188	0.0108	-0.12	-0.12	Monocyte percentage of white cells;	chr2:159635331	chr2:159615296~159617082:+
BRCA	cis	rs7578361	0.918	rs6751489	ENSG00000231969.1	AC144449.1	3.75	0.000188	0.0108	0.18	0.12	Acute lymphoblastic leukemia (childhood);	chr2:149521832	chr2:149587196~149848233:+
BRCA	cis	rs4713118	0.523	rs2179096	ENSG00000219392.1	RP1-265C24.5	-3.75	0.000188	0.0108	-0.15	-0.12	Parkinson's disease;	chr6:27698141	chr6:28115628~28116551:+
BRCA	cis	rs4538475	0.559	rs73243107	ENSG00000273133.1	RP11-799M12.2	-3.75	0.000188	0.0108	-0.23	-0.12	Parkinson's disease;	chr4:15661777	chr4:15563698~15564253:-
BRCA	cis	rs6088590	0.931	rs12625149	ENSG00000269202.1	RP4-614O4.12	3.75	0.000188	0.0108	0.13	0.12	Coronary artery disease;	chr20:34838009	chr20:35201747~35203288:-
BRCA	cis	rs13434995	0.588	rs114571142	ENSG00000239040.1	Y_RNA	3.75	0.000188	0.0108	0.14	0.12	Adiponectin levels;	chr4:55412991	chr4:55412636~55412738:+
BRCA	cis	rs7267979	1	rs13038834	ENSG00000274414.1	RP5-965G21.4	-3.75	0.000188	0.0108	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25460797	chr20:25239007~25245229:-
BRCA	cis	rs6696239	0.956	rs1045407	ENSG00000215812.5	ZNF847P	-3.75	0.000188	0.0108	-0.16	-0.12	Height;	chr1:227659532	chr1:227696892~227706699:-
BRCA	cis	rs11668609	0.748	rs16982728	ENSG00000268058.1	BNIP3P40	-3.75	0.000188	0.0108	-0.15	-0.12	Response to taxane treatment (docetaxel);	chr19:24186760	chr19:24098425~24098980:-
BRCA	cis	rs13068223	0.716	rs344067	ENSG00000241770.1	RP11-555M1.3	3.75	0.000188	0.0108	0.15	0.12	Age-related hearing impairment (SNP x SNP interaction);	chr3:156723825	chr3:157163452~157169133:+
BRCA	cis	rs172166	0.694	rs536704	ENSG00000219891.2	ZSCAN12P1	3.75	0.000188	0.0108	0.14	0.12	Cardiac Troponin-T levels;	chr6:28124825	chr6:28091154~28093664:+
BRCA	cis	rs10208649	0.808	rs11886366	ENSG00000272156.1	RP11-477N3.1	3.75	0.000188	0.0108	0.23	0.12	Body mass index;	chr2:53997126	chr2:54082554~54085066:+
BRCA	cis	rs495337	0.736	rs627898	ENSG00000224397.4	LINC01272	-3.75	0.000188	0.0108	-0.12	-0.12	Psoriasis;	chr20:49863717	chr20:50267486~50279795:+
BRCA	cis	rs17123764	0.892	rs56737983	ENSG00000257464.1	RP11-161H23.8	-3.75	0.000188	0.0108	-0.21	-0.12	Intelligence (multi-trait analysis);	chr12:49744682	chr12:49442424~49442652:-
BRCA	cis	rs7660883	1	rs9998251	ENSG00000251411.1	RP11-397E7.4	3.75	0.000188	0.0108	0.13	0.12	HDL cholesterol levels;	chr4:87077903	chr4:86913266~86914817:-
BRCA	cis	rs7660883	1	rs3775223	ENSG00000251411.1	RP11-397E7.4	3.75	0.000188	0.0108	0.13	0.12	HDL cholesterol levels;	chr4:87079294	chr4:86913266~86914817:-
BRCA	cis	rs6968419	0.537	rs17138327	ENSG00000279086.1	RP11-667F14.1	-3.75	0.000188	0.0108	-0.12	-0.12	Intraocular pressure;	chr7:116121869	chr7:116209234~116211511:-
BRCA	cis	rs9959145	1	rs111384103	ENSG00000267108.1	RP11-861E21.1	3.75	0.000188	0.0108	0.2	0.12	Immune response to smallpox vaccine (IL-6);	chr18:12606483	chr18:12432897~12437635:+
BRCA	cis	rs6840360	0.806	rs13149588	ENSG00000278978.1	RP11-164P12.5	3.75	0.000188	0.0108	0.13	0.12	Intelligence (multi-trait analysis);	chr4:151796605	chr4:151669786~151670503:+
BRCA	cis	rs6964587	1	rs28927678	ENSG00000188693.7	CYP51A1-AS1	-3.75	0.000188	0.0108	-0.13	-0.12	Breast cancer;	chr7:92086348	chr7:92134604~92180725:+
BRCA	cis	rs6964587	0.967	rs12535601	ENSG00000188693.7	CYP51A1-AS1	-3.75	0.000188	0.0108	-0.12	-0.12	Breast cancer;	chr7:92089032	chr7:92134604~92180725:+
BRCA	cis	rs863750	1	rs825453	ENSG00000275389.1	RP11-214K3.24	3.75	0.000188	0.0108	0.14	0.12	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-hip ratio;	chr12:124024211	chr12:124085761~124088598:+
BRCA	cis	rs6546324	0.625	rs1023693	ENSG00000236780.4	AC078941.1	3.75	0.000189	0.0108	0.2	0.12	Endometriosis;	chr2:67641600	chr2:67123357~67215319:-
BRCA	cis	rs6546324	0.625	rs1023691	ENSG00000236780.4	AC078941.1	3.75	0.000189	0.0108	0.2	0.12	Endometriosis;	chr2:67641662	chr2:67123357~67215319:-
BRCA	cis	rs561341	1	rs501957	ENSG00000265798.5	RP11-271K11.5	3.75	0.000189	0.0108	0.19	0.12	Hip circumference adjusted for BMI;	chr17:31987485	chr17:31038575~31059121:-
BRCA	cis	rs6489785	0.547	rs625228	ENSG00000277423.1	RP11-173P15.9	3.75	0.000189	0.0108	0.13	0.12	Longevity;Allergic disease (asthma, hay fever or eczema);	chr12:120840463	chr12:120703867~120704282:+
BRCA	cis	rs7954584	0.583	rs10770186	ENSG00000272849.1	RP11-347I19.8	-3.75	0.000189	0.0108	-0.09	-0.12	Mean corpuscular volume;	chr12:121923506	chr12:121797511~121801972:+
BRCA	cis	rs7583236	0.5	rs7601899	ENSG00000179818.12	PCBP1-AS1	-3.75	0.000189	0.0108	-0.21	-0.12	Obesity-related traits;	chr2:70108841	chr2:69962263~70103220:-
BRCA	cis	rs2274273	0.6	rs35112084	ENSG00000259318.1	RP11-454L9.2	3.75	0.000189	0.0108	0.1	0.12	Protein biomarker;	chr14:55314382	chr14:55394940~55395233:-
BRCA	cis	rs8003722	1	rs8003722	ENSG00000258623.1	CTD-2325P2.3	-3.75	0.000189	0.0108	-0.15	-0.12	Age-related hearing impairment (SNP x SNP interaction);	chr14:68851545	chr14:68683411~68685565:-
BRCA	cis	rs8054556	1	rs4788197	ENSG00000261367.1	RP11-455F5.4	-3.75	0.000189	0.0108	-0.13	-0.12	Autism spectrum disorder or schizophrenia;	chr16:29959513	chr16:30107675~30110541:+
BRCA	cis	rs8054556	1	rs4788198	ENSG00000261367.1	RP11-455F5.4	-3.75	0.000189	0.0108	-0.13	-0.12	Autism spectrum disorder or schizophrenia;	chr16:29959514	chr16:30107675~30110541:+
BRCA	cis	rs7172809	0.615	rs16968900	ENSG00000260139.5	CSPG4P13	-3.75	0.000189	0.0108	-0.14	-0.12	Glucose homeostasis traits;	chr15:77534569	chr15:77894684~77904674:+
BRCA	cis	rs7267979	0.816	rs3746337	ENSG00000125804.12	FAM182A	-3.75	0.000189	0.0108	-0.15	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25227636	chr20:26054655~26086917:+
BRCA	cis	rs2302465	0.86	rs73237198	ENSG00000273133.1	RP11-799M12.2	-3.75	0.000189	0.0108	-0.23	-0.12	Blood protein levels;	chr4:15592685	chr4:15563698~15564253:-
BRCA	cis	rs7267979	1	rs404394	ENSG00000204556.4	CTD-2514C3.1	-3.75	0.000189	0.0108	-0.16	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25467260	chr20:26018832~26020684:+
BRCA	cis	rs801193	0.66	rs974239	ENSG00000273448.1	RP11-166O4.6	3.75	0.000189	0.0108	0.11	0.12	Aortic root size;	chr7:66748504	chr7:67333047~67334383:+
BRCA	cis	rs16917546	1	rs7094595	ENSG00000238280.1	RP11-436D10.3	3.75	0.000189	0.0108	0.16	0.12	Basal cell carcinoma;	chr10:62655653	chr10:62793562~62805887:-
BRCA	cis	rs4767841	0.935	rs7299963	ENSG00000248636.5	RP11-768F21.1	-3.75	0.000189	0.0108	-0.14	-0.12	Urgency urinary incontinence;	chr12:119720398	chr12:119387987~119668079:-
BRCA	cis	rs73201462	0.901	rs2955133	ENSG00000242551.2	POU5F1P6	-3.75	0.000189	0.0108	-0.2	-0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128226479	chr3:128674735~128677005:-
BRCA	cis	rs17270561	0.609	rs1937131	ENSG00000272462.2	U91328.19	3.75	0.000189	0.0108	0.14	0.12	Iron status biomarkers;	chr6:25744603	chr6:25992662~26001775:+
BRCA	cis	rs524281	0.861	rs7943911	ENSG00000255038.1	RP11-1167A19.2	-3.75	0.000189	0.0108	-0.17	-0.12	Electroencephalogram traits;	chr11:66175583	chr11:66067277~66069619:-
BRCA	cis	rs524281	0.861	rs10750778	ENSG00000255038.1	RP11-1167A19.2	-3.75	0.000189	0.0108	-0.17	-0.12	Electroencephalogram traits;	chr11:66181177	chr11:66067277~66069619:-
BRCA	cis	rs524281	0.861	rs6591208	ENSG00000255038.1	RP11-1167A19.2	-3.75	0.000189	0.0108	-0.17	-0.12	Electroencephalogram traits;	chr11:66182218	chr11:66067277~66069619:-
BRCA	cis	rs4974559	0.947	rs28509315	ENSG00000253399.1	AC078852.2	3.75	0.000189	0.0108	0.17	0.12	Systolic blood pressure;	chr4:1364319	chr4:1358479~1359461:+
BRCA	cis	rs6120849	0.708	rs6087659	ENSG00000202150.1	RNU6-407P	3.75	0.000189	0.0108	0.17	0.12	Protein C levels;	chr20:35018580	chr20:35030317~35030420:-
BRCA	cis	rs2562456	0.876	rs11085467	ENSG00000213976.4	CTD-2561J22.2	-3.75	0.000189	0.0108	-0.14	-0.12	Pain;	chr19:21569041	chr19:21382865~21387177:+
BRCA	cis	rs6964587	1	rs6956431	ENSG00000188693.7	CYP51A1-AS1	-3.75	0.000189	0.0108	-0.12	-0.12	Breast cancer;	chr7:92120702	chr7:92134604~92180725:+
BRCA	cis	rs849141	0.925	rs552707	ENSG00000234336.5	JAZF1-AS1	-3.75	0.000189	0.0108	-0.16	-0.12	Height;Hip circumference adjusted for BMI;	chr7:28165684	chr7:28180322~28243917:+
BRCA	cis	rs6490294	0.571	rs7295294	ENSG00000234608.6	MAPKAPK5-AS1	3.75	0.000189	0.0108	0.17	0.12	Mean platelet volume;	chr12:112027089	chr12:111839764~111842902:-
BRCA	cis	rs1018697	0.966	rs1953930	ENSG00000236937.2	PTGES3P4	3.75	0.000189	0.0108	0.15	0.12	Colorectal adenoma (advanced);	chr10:102789704	chr10:102845595~102845950:+
BRCA	cis	rs564309	1	rs35670307	ENSG00000183929.7	DUSP5P1	3.75	0.000189	0.0108	0.27	0.12	Hip circumference (psychosocial stress interaction);	chr1:228400953	chr1:228650241~228651379:+
BRCA	cis	rs9437689	0.966	rs2766011	ENSG00000235501.4	RP4-639F20.1	-3.75	0.000189	0.0108	-0.15	-0.12	Phospholipid levels (plasma);	chr1:94979223	chr1:94927566~94963270:+
BRCA	cis	rs875971	0.862	rs7786892	ENSG00000271064.1	RP11-792A8.3	3.75	0.000189	0.0108	0.14	0.12	Aortic root size;	chr7:66163889	chr7:66748838~66749077:-
BRCA	cis	rs17801127	1	rs13014503	ENSG00000231969.1	AC144449.1	3.75	0.000189	0.0109	0.2	0.12	Liver enzyme levels (alanine transaminase);	chr2:149684562	chr2:149587196~149848233:+
BRCA	cis	rs17801127	0.901	rs71413658	ENSG00000231969.1	AC144449.1	3.75	0.000189	0.0109	0.2	0.12	Liver enzyme levels (alanine transaminase);	chr2:149685661	chr2:149587196~149848233:+
BRCA	cis	rs7620503	1	rs1875096	ENSG00000277241.1	RP11-114M1.3	3.75	0.000189	0.0109	0.13	0.12	Corneal structure;	chr3:177586076	chr3:177700346~177701072:-
BRCA	cis	rs7620503	1	rs1875097	ENSG00000277241.1	RP11-114M1.3	3.75	0.000189	0.0109	0.13	0.12	Corneal structure;	chr3:177586244	chr3:177700346~177701072:-
BRCA	cis	rs7620503	1	rs7620503	ENSG00000277241.1	RP11-114M1.3	3.75	0.000189	0.0109	0.13	0.12	Corneal structure;	chr3:177586510	chr3:177700346~177701072:-
BRCA	cis	rs516805	0.528	rs2684241	ENSG00000279114.1	RP3-425C14.5	-3.75	0.000189	0.0109	-0.14	-0.12	Lymphocyte counts;	chr6:122089903	chr6:122471923~122484161:+
BRCA	cis	rs11098499	0.954	rs7436506	ENSG00000225892.3	RP11-384K6.2	3.75	0.000189	0.0109	0.12	0.12	Corneal astigmatism;	chr4:119472614	chr4:118632274~118634759:+
BRCA	cis	rs7191700	0.509	rs415595	ENSG00000262636.1	CTD-3088G3.4	3.75	0.000189	0.0109	0.15	0.12	Multiple sclerosis;	chr16:11269835	chr16:11380859~11381118:-
BRCA	cis	rs10043775	0.958	rs7733401	ENSG00000251330.3	CTD-2283N19.1	-3.75	0.000189	0.0109	-0.13	-0.12	Periodontal microbiota;	chr5:148453718	chr5:148430159~148430807:-
BRCA	cis	rs13126694	0.778	rs7692254	ENSG00000251073.1	NUDT19P5	3.75	0.000189	0.0109	0.11	0.12	Blood osmolality (transformed sodium);	chr4:158134140	chr4:158182825~158183393:+
BRCA	cis	rs7520050	0.778	rs2991985	ENSG00000281133.1	AL355480.3	3.75	0.000189	0.0109	0.13	0.12	Reticulocyte count;Red blood cell count;	chr1:45614858	chr1:45580892~45580996:-
BRCA	cis	rs7246967	0.608	rs453175	ENSG00000198153.8	ZNF849P	-3.75	0.000189	0.0109	-0.17	-0.12	Bronchopulmonary dysplasia;	chr19:22831285	chr19:22685167~22686732:+
BRCA	cis	rs2712184	0.935	rs2712169	ENSG00000237930.1	AC007563.4	3.75	0.000189	0.0109	0.13	0.12	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);	chr2:216806626	chr2:216785774~216786144:-
BRCA	cis	rs6847067	0.631	rs17009168	ENSG00000180769.7	WDFY3-AS2	3.75	0.000189	0.0109	0.11	0.12	Oropharynx cancer;	chr4:84609643	chr4:84965682~85011277:+
BRCA	cis	rs891378	0.959	rs6681853	ENSG00000274245.1	RP11-357P18.2	-3.75	0.000189	0.0109	-0.15	-0.12	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207325299	chr1:207372559~207373252:+
BRCA	cis	rs2692947	0.832	rs2438972	ENSG00000237510.6	AC008268.2	3.75	0.000189	0.0109	0.16	0.12	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96025125	chr2:95789654~95800166:+
BRCA	cis	rs10864907	0.781	rs35978740	ENSG00000231747.1	AC079922.2	3.75	0.000189	0.0109	0.11	0.12	Pulmonary function;	chr2:112851794	chr2:112621809~112622167:-
BRCA	cis	rs5770820	1	rs5770820	ENSG00000273188.1	RP3-402G11.25	3.75	0.000189	0.0109	0.13	0.12	Intelligence (multi-trait analysis);	chr22:50712045	chr22:50191724~50192402:-
BRCA	cis	rs8023401	0.938	rs2291117	ENSG00000274654.1	CTD-3247H4.2	3.75	0.000189	0.0109	0.15	0.12	Spherical equivalent (joint analysis main effects and education interaction);	chr15:48498519	chr15:48528980~48529728:-
BRCA	cis	rs6005807	0.719	rs9625520	ENSG00000272858.1	CTA-292E10.8	-3.75	0.000189	0.0109	-0.21	-0.12	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28641876	chr22:28814914~28815662:+
BRCA	cis	rs7826238	0.502	rs10503377	ENSG00000233609.3	RP11-62H7.2	3.75	0.000189	0.0109	0.12	0.12	Systolic blood pressure;	chr8:8520912	chr8:8961200~8979025:+
BRCA	cis	rs2486012	0.649	rs9726489	ENSG00000237950.1	RP11-7O11.3	3.75	0.000189	0.0109	0.2	0.12	Intelligence (multi-trait analysis);	chr1:43801997	chr1:43944370~43946551:-
BRCA	cis	rs7620503	1	rs34332266	ENSG00000231574.4	RP11-91K9.1	3.75	0.000189	0.0109	0.13	0.12	Corneal structure;	chr3:177581273	chr3:177816865~177899224:+
BRCA	cis	rs2640806	0.505	rs34269813	ENSG00000253105.4	KB-1448A5.1	3.75	0.000189	0.0109	0.13	0.12	Obesity-related traits;	chr8:96355296	chr8:96371865~96387438:-
BRCA	cis	rs3749237	1	rs4768	ENSG00000225399.4	RP11-3B7.1	3.75	0.000189	0.0109	0.11	0.12	Resting heart rate;	chr3:49721331	chr3:49260085~49261316:+
BRCA	cis	rs763121	0.853	rs5750677	ENSG00000228274.3	RP3-508I15.9	-3.75	0.000189	0.0109	-0.13	-0.12	Menopause (age at onset);	chr22:38751710	chr22:38667585~38681820:-
BRCA	cis	rs7620503	1	rs6783033	ENSG00000277241.1	RP11-114M1.3	3.75	0.000189	0.0109	0.13	0.12	Corneal structure;	chr3:177584963	chr3:177700346~177701072:-
BRCA	cis	rs7620503	0.959	rs6770216	ENSG00000277241.1	RP11-114M1.3	3.75	0.000189	0.0109	0.13	0.12	Corneal structure;	chr3:177585139	chr3:177700346~177701072:-
BRCA	cis	rs7620503	0.959	rs2863016	ENSG00000277241.1	RP11-114M1.3	3.75	0.000189	0.0109	0.13	0.12	Corneal structure;	chr3:177585192	chr3:177700346~177701072:-
BRCA	cis	rs11098403	0.753	rs10031919	ENSG00000225892.3	RP11-384K6.2	3.75	0.00019	0.0109	0.11	0.12	Schizophrenia;	chr4:117838073	chr4:118632274~118634759:+
BRCA	cis	rs6700559	0.545	rs12744758	ENSG00000260088.1	RP11-92G12.3	3.75	0.00019	0.0109	0.14	0.12	Coronary artery disease;	chr1:200624010	chr1:200669507~200694250:+
BRCA	cis	rs934734	0.967	rs17534670	ENSG00000204929.10	AC074391.1	-3.75	0.00019	0.0109	-0.14	-0.12	Rheumatoid arthritis;	chr2:65388294	chr2:65436711~66084639:+
BRCA	cis	rs10938353	0.906	rs6852413	ENSG00000273369.1	RP11-700J17.1	-3.75	0.00019	0.0109	-0.13	-0.12	Body mass index;	chr4:44591329	chr4:44693946~44694386:-
BRCA	cis	rs13068223	0.669	rs168247	ENSG00000241770.1	RP11-555M1.3	3.75	0.00019	0.0109	0.15	0.12	Age-related hearing impairment (SNP x SNP interaction);	chr3:156722397	chr3:157163452~157169133:+
BRCA	cis	rs848490	0.889	rs6966257	ENSG00000214293.7	APTR	3.75	0.00019	0.0109	0.14	0.12	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77656151	chr7:77657660~77696265:-
BRCA	cis	rs477895	0.713	rs12787852	ENSG00000256940.1	RP11-783K16.5	3.75	0.00019	0.0109	0.16	0.12	Mean platelet volume;	chr11:64187176	chr11:64245964~64248217:+
BRCA	cis	rs1914816	1	rs2255408	ENSG00000259422.1	RP11-593F23.1	-3.75	0.00019	0.0109	-0.17	-0.12	Response to tocilizumab in rheumatoid arthritis;	chr15:76210954	chr15:76174891~76181486:-
BRCA	cis	rs2615061	0.689	rs10915874	ENSG00000229965.1	RP11-118H4.1	3.75	0.00019	0.0109	0.21	0.12	Monocyte count;	chr1:225771789	chr1:226438564~226439344:+
BRCA	cis	rs2615061	0.746	rs10915875	ENSG00000229965.1	RP11-118H4.1	3.75	0.00019	0.0109	0.21	0.12	Monocyte count;	chr1:225771817	chr1:226438564~226439344:+
BRCA	cis	rs7572733	0.935	rs10497809	ENSG00000231621.1	AC013264.2	-3.75	0.00019	0.0109	-0.11	-0.12	Dermatomyositis;	chr2:197960944	chr2:197197991~197199273:+
BRCA	cis	rs916888	0.773	rs9896243	ENSG00000264589.1	MAPT-AS1	-3.75	0.00019	0.0109	-0.14	-0.12	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:45843651~45895600:-
BRCA	cis	rs4925386	0.765	rs6142737	ENSG00000275437.1	RP5-908M14.10	3.75	0.00019	0.0109	0.13	0.12	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62344744	chr20:62402236~62405935:-
BRCA	cis	rs4664293	0.541	rs1863218	ENSG00000224152.1	AC009506.1	3.75	0.00019	0.0109	0.12	0.12	Monocyte percentage of white cells;	chr2:159512276	chr2:159615296~159617082:+
BRCA	cis	rs1910358	0.959	rs966297	ENSG00000248874.4	C5orf17	-3.75	0.00019	0.0109	-0.17	-0.12	Venous thromboembolism (SNP x SNP interaction);	chr5:23878098	chr5:23951348~24178263:+
BRCA	cis	rs4831760	0.963	rs34599046	ENSG00000250483.1	PPM1AP1	3.75	0.00019	0.0109	0.16	0.12	Pulmonary function decline;	chr8:15687363	chr8:15806149~15807283:-
BRCA	cis	rs78545713	1	rs11753610	ENSG00000241549.7	GUSBP2	3.75	0.00019	0.0109	0.18	0.12	Iron status biomarkers (total iron binding capacity);	chr6:26251373	chr6:26871484~26956554:-
BRCA	cis	rs801193	0.967	rs3800823	ENSG00000272831.1	RP11-792A8.4	-3.75	0.00019	0.0109	-0.1	-0.12	Aortic root size;	chr7:66682123	chr7:66739829~66740385:-
BRCA	cis	rs3739034	0.938	rs13018063	ENSG00000224043.6	CCNT2-AS1	-3.75	0.00019	0.0109	-0.2	-0.12	Gut microbiome composition (winter);	chr2:134718238	chr2:134735464~134918710:-
BRCA	cis	rs10029851	0.645	rs1436504	ENSG00000234492.4	RPL34-AS1	3.75	0.00019	0.0109	0.13	0.12	Amyotrophic lateral sclerosis (sporadic);	chr4:108704028	chr4:108538190~108620460:-
BRCA	cis	rs875971	0.862	rs778734	ENSG00000229886.1	RP5-1132H15.3	3.75	0.00019	0.0109	0.13	0.12	Aortic root size;	chr7:66349862	chr7:66025126~66031544:-
BRCA	cis	rs78487399	0.808	rs7559842	ENSG00000234936.1	AC010883.5	3.75	0.00019	0.0109	0.18	0.12	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43446303	chr2:43229573~43233394:+
BRCA	cis	rs8114671	0.562	rs2424999	ENSG00000126005.14	MMP24-AS1	-3.75	0.00019	0.0109	-0.13	-0.12	Height;	chr20:34798627	chr20:35216462~35278131:-
BRCA	cis	rs7621331	0.747	rs7640153	ENSG00000273486.1	RP11-731C17.2	3.75	0.00019	0.0109	0.13	0.12	Waist circumference adjusted for body mass index;	chr3:135931218	chr3:136837338~136839021:-
BRCA	cis	rs1501138	0.506	rs4317201	ENSG00000263327.5	TAPT1-AS1	-3.75	0.00019	0.0109	-0.16	-0.12	Systemic juvenile idiopathic arthritis;	chr4:16207396	chr4:16226685~16320140:+
BRCA	cis	rs73201462	1	rs56287882	ENSG00000242551.2	POU5F1P6	3.75	0.00019	0.0109	0.2	0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128311500	chr3:128674735~128677005:-
BRCA	cis	rs73201462	1	rs73197383	ENSG00000242551.2	POU5F1P6	3.75	0.00019	0.0109	0.2	0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128311631	chr3:128674735~128677005:-
BRCA	cis	rs6500602	0.701	rs4786500	ENSG00000280063.1	RP11-295D4.3	-3.75	0.00019	0.0109	-0.09	-0.12	Schizophrenia;	chr16:4475264	chr16:4346694~4348648:-
BRCA	cis	rs2625529	0.73	rs982752	ENSG00000260037.4	CTD-2524L6.3	-3.75	0.00019	0.0109	-0.15	-0.12	Red blood cell count;	chr15:71853596	chr15:71818396~71823384:+
BRCA	cis	rs801193	0.66	rs1016265	ENSG00000273448.1	RP11-166O4.6	3.75	0.00019	0.0109	0.11	0.12	Aortic root size;	chr7:66749580	chr7:67333047~67334383:+
BRCA	cis	rs801193	0.66	rs4610622	ENSG00000273448.1	RP11-166O4.6	3.75	0.00019	0.0109	0.11	0.12	Aortic root size;	chr7:66759510	chr7:67333047~67334383:+
BRCA	cis	rs957448	0.561	rs1808488	ENSG00000254315.1	RP11-267M23.3	3.75	0.00019	0.0109	0.14	0.12	Nonsyndromic cleft lip with cleft palate;	chr8:94602636	chr8:94533628~94534391:+
BRCA	cis	rs957448	0.583	rs754275	ENSG00000254315.1	RP11-267M23.3	3.75	0.00019	0.0109	0.14	0.12	Nonsyndromic cleft lip with cleft palate;	chr8:94602741	chr8:94533628~94534391:+
BRCA	cis	rs957448	0.561	rs1426172	ENSG00000254315.1	RP11-267M23.3	3.75	0.00019	0.0109	0.14	0.12	Nonsyndromic cleft lip with cleft palate;	chr8:94602988	chr8:94533628~94534391:+
BRCA	cis	rs11603020	0.95	rs28362951	ENSG00000265566.2	RN7SL605P	-3.75	0.00019	0.0109	-0.17	-0.12	Blood protein levels;	chr11:57605053	chr11:57528085~57528365:-
BRCA	cis	rs875971	0.862	rs12537823	ENSG00000229886.1	RP5-1132H15.3	3.75	0.00019	0.0109	0.13	0.12	Aortic root size;	chr7:66255897	chr7:66025126~66031544:-
BRCA	cis	rs875971	0.83	rs6950137	ENSG00000273024.4	INTS4P2	-3.75	0.00019	0.0109	-0.13	-0.12	Aortic root size;	chr7:66511623	chr7:65647864~65715661:+
BRCA	cis	rs6120849	0.707	rs3746444	ENSG00000202150.1	RNU6-407P	3.75	0.00019	0.0109	0.16	0.12	Protein C levels;	chr20:34990448	chr20:35030317~35030420:-
BRCA	cis	rs6546324	0.625	rs1430789	ENSG00000236780.4	AC078941.1	3.75	0.00019	0.0109	0.2	0.12	Endometriosis;	chr2:67639238	chr2:67123357~67215319:-
BRCA	cis	rs6546324	0.625	rs4671817	ENSG00000236780.4	AC078941.1	3.75	0.00019	0.0109	0.2	0.12	Endometriosis;	chr2:67639305	chr2:67123357~67215319:-
BRCA	cis	rs6546324	0.592	rs9309402	ENSG00000236780.4	AC078941.1	3.75	0.00019	0.0109	0.2	0.12	Endometriosis;	chr2:67642206	chr2:67123357~67215319:-
BRCA	cis	rs4883201	0.518	rs887782	ENSG00000237248.4	LINC00987	-3.75	0.00019	0.0109	-0.15	-0.12	Total cholesterol levels;Cholesterol, total;	chr12:8932082	chr12:9240003~9243052:+
BRCA	cis	rs2274273	0.624	rs8014477	ENSG00000259318.1	RP11-454L9.2	-3.75	0.00019	0.0109	-0.1	-0.12	Protein biomarker;	chr14:55374759	chr14:55394940~55395233:-
BRCA	cis	rs9470794	1	rs75761704	ENSG00000204110.6	RP1-153P14.8	-3.74	0.00019	0.0109	-0.24	-0.12	Type 2 diabetes;	chr6:38053400	chr6:37507348~37535616:+
BRCA	cis	rs56281245	0.793	rs1433030	ENSG00000249363.1	CTB-78O21.1	3.74	0.00019	0.0109	0.24	0.12	Hepcidin levels;	chr5:145580721	chr5:145728360~145729349:-
BRCA	cis	rs2880765	0.835	rs7161880	ENSG00000230373.7	GOLGA6L5P	3.74	0.00019	0.0109	0.12	0.12	Coronary artery disease;	chr15:85475515	chr15:84507885~84516814:-
BRCA	cis	rs6088765	0.606	rs2425024	ENSG00000269202.1	RP4-614O4.12	3.74	0.00019	0.0109	0.12	0.12	Ulcerative colitis;	chr20:35257135	chr20:35201747~35203288:-
BRCA	cis	rs7267979	1	rs2387880	ENSG00000274414.1	RP5-965G21.4	3.74	0.00019	0.0109	0.14	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25397151	chr20:25239007~25245229:-
BRCA	cis	rs7680126	0.5	rs4697933	ENSG00000250413.1	RP11-448G15.1	3.74	0.00019	0.0109	0.19	0.12	Urate levels in obese individuals;Urate levels in lean individuals;Urate levels in overweight individuals;	chr4:10144869	chr4:10006482~10009725:+
BRCA	cis	rs1538970	0.816	rs9727262	ENSG00000281133.1	AL355480.3	-3.74	0.00019	0.0109	-0.16	-0.12	Platelet count;	chr1:45532907	chr1:45580892~45580996:-
BRCA	cis	rs9470794	1	rs11751153	ENSG00000204110.6	RP1-153P14.8	-3.74	0.00019	0.0109	-0.24	-0.12	Type 2 diabetes;	chr6:38073337	chr6:37507348~37535616:+
BRCA	cis	rs881375	1	rs10760118	ENSG00000238181.2	AHCYP2	-3.74	0.00019	0.0109	-0.14	-0.12	Rheumatoid arthritis;	chr9:120879338	chr9:120720673~120721972:+
BRCA	cis	rs2651244	0.932	rs9424945	ENSG00000229051.1	RP5-952N6.1	3.74	0.00019	0.0109	0.12	0.12	Inflammatory bowel disease;Ulcerative colitis;	chr1:70542243	chr1:70706453~70786468:+
BRCA	cis	rs4831837	1	rs4831837	ENSG00000270074.1	RP11-351I21.11	-3.74	0.00019	0.0109	-0.14	-0.12	Morbidity-free survival;	chr8:12854354	chr8:12412827~12414373:+
BRCA	cis	rs934734	0.532	rs10166100	ENSG00000281920.1	RP11-418H16.1	-3.74	0.00019	0.0109	-0.14	-0.12	Rheumatoid arthritis;	chr2:65418616	chr2:65623272~65628424:+
BRCA	cis	rs875971	0.862	rs1860469	ENSG00000229886.1	RP5-1132H15.3	-3.74	0.00019	0.0109	-0.13	-0.12	Aortic root size;	chr7:66641888	chr7:66025126~66031544:-
BRCA	cis	rs7620503	0.765	rs2133594	ENSG00000228561.2	RP11-114M1.1	-3.74	0.00019	0.0109	-0.15	-0.12	Corneal structure;	chr3:177584329	chr3:177683627~177691250:+
BRCA	cis	rs9470794	1	rs56394600	ENSG00000204110.6	RP1-153P14.8	-3.74	0.00019	0.0109	-0.22	-0.12	Type 2 diabetes;	chr6:38160136	chr6:37507348~37535616:+
BRCA	cis	rs1949733	0.655	rs2631736	ENSG00000251615.3	RP11-774O3.3	3.74	0.000191	0.0109	0.12	0.12	Response to antineoplastic agents;	chr4:8476694	chr4:8355090~8358338:-
BRCA	cis	rs4819052	0.851	rs2838832	ENSG00000215447.6	BX322557.10	3.74	0.000191	0.0109	0.12	0.12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244989	chr21:45288052~45291738:+
BRCA	cis	rs10456847	0.806	rs9396938	ENSG00000229700.1	RP1-130G2.1	3.74	0.000191	0.0109	0.14	0.12	Chronic periodontitis (mean interproximal clinical attachment level);	chr6:19133945	chr6:20042455~20042940:-
BRCA	cis	rs251253	0.827	rs251240	ENSG00000253959.1	CTB-43E15.1	3.74	0.000191	0.0109	0.1	0.12	PR interval;	chr5:173081107	chr5:173642519~173658194:+
BRCA	cis	rs6431644	0.731	rs554699	ENSG00000224287.2	MSL3P1	-3.74	0.000191	0.0109	-0.14	-0.12	Left atrial antero-posterior diameter;	chr2:233852709	chr2:233865437~233868444:-
BRCA	cis	rs6460942	0.558	rs4330594	ENSG00000226690.5	AC005281.1	3.74	0.000191	0.0109	0.21	0.12	Coronary artery disease;	chr7:12238989	chr7:12496429~12541910:+
BRCA	cis	rs7412746	0.658	rs10305711	ENSG00000231073.1	RP11-316M1.3	3.74	0.000191	0.0109	0.12	0.12	Melanoma;	chr1:150830520	chr1:150973123~150975534:+
BRCA	cis	rs1371614	0.589	rs3739086	ENSG00000229122.1	AGBL5-IT1	-3.74	0.000191	0.0109	-0.12	-0.12	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26942334	chr2:27061038~27061815:+
BRCA	cis	rs935334	0.866	rs11850433	ENSG00000258454.1	RP11-361H10.3	-3.74	0.000191	0.0109	-0.2	-0.12	Blood pressure;	chr14:76215140	chr14:76235817~76263474:+
BRCA	cis	rs17270561	0.609	rs9358886	ENSG00000272462.2	U91328.19	-3.74	0.000191	0.0109	-0.14	-0.12	Iron status biomarkers;	chr6:25758025	chr6:25992662~26001775:+
BRCA	cis	rs172166	0.694	rs1631552	ENSG00000219891.2	ZSCAN12P1	3.74	0.000191	0.0109	0.14	0.12	Cardiac Troponin-T levels;	chr6:28121921	chr6:28091154~28093664:+
BRCA	cis	rs465969	1	rs459048	ENSG00000271789.1	RP5-1112D6.7	3.74	0.000191	0.0109	0.27	0.12	Psoriasis;	chr6:111368429	chr6:111297126~111298510:+
BRCA	cis	rs465969	1	rs479343	ENSG00000271789.1	RP5-1112D6.7	3.74	0.000191	0.0109	0.27	0.12	Psoriasis;	chr6:111369701	chr6:111297126~111298510:+
BRCA	cis	rs465969	0.744	rs458017	ENSG00000271789.1	RP5-1112D6.7	3.74	0.000191	0.0109	0.27	0.12	Psoriasis;	chr6:111374888	chr6:111297126~111298510:+
BRCA	cis	rs465969	1	rs13213522	ENSG00000271789.1	RP5-1112D6.7	3.74	0.000191	0.0109	0.27	0.12	Psoriasis;	chr6:111384138	chr6:111297126~111298510:+
BRCA	cis	rs721917	0.525	rs10788338	ENSG00000242600.5	MBL1P	3.74	0.000191	0.0109	0.14	0.12	Chronic obstructive pulmonary disease;	chr10:79973266	chr10:79904898~79950336:+
BRCA	cis	rs654950	0.875	rs2810550	ENSG00000230638.4	RP11-486B10.4	3.74	0.000191	0.0109	0.15	0.12	Airway imaging phenotypes;	chr1:41529668	chr1:41542069~41544310:+
BRCA	cis	rs875971	0.862	rs6962717	ENSG00000229886.1	RP5-1132H15.3	3.74	0.000191	0.0109	0.13	0.12	Aortic root size;	chr7:66418748	chr7:66025126~66031544:-
BRCA	cis	rs17756712	0.725	rs57440245	ENSG00000272463.1	RP11-532F6.3	3.74	0.000191	0.0109	0.2	0.12	Vertical cup-disc ratio;	chr6:616855	chr6:708592~711405:-
BRCA	cis	rs72928364	1	rs13099053	ENSG00000244119.1	PDCL3P4	3.74	0.000191	0.0109	0.14	0.12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100902060	chr3:101712472~101713191:+
BRCA	cis	rs72928364	1	rs41273557	ENSG00000244119.1	PDCL3P4	3.74	0.000191	0.0109	0.14	0.12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100902839	chr3:101712472~101713191:+
BRCA	cis	rs72928364	1	rs79265689	ENSG00000244119.1	PDCL3P4	3.74	0.000191	0.0109	0.14	0.12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100902840	chr3:101712472~101713191:+
BRCA	cis	rs13272568	0.614	rs10102046	ENSG00000254352.1	RP11-578O24.2	-3.74	0.000191	0.011	-0.15	-0.12	Bone mineral density;	chr8:78111256	chr8:78723796~78724136:-
BRCA	cis	rs1923539	0.713	rs1885553	ENSG00000225484.5	NUTM2B-AS1	3.74	0.000191	0.011	0.17	0.12	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79951955	chr10:79663088~79826594:-
BRCA	cis	rs1371614	0.632	rs4665363	ENSG00000229122.1	AGBL5-IT1	-3.74	0.000191	0.011	-0.12	-0.12	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26933548	chr2:27061038~27061815:+
BRCA	cis	rs7727544	0.545	rs3916443	ENSG00000233006.5	AC034220.3	3.74	0.000191	0.011	0.09	0.12	Blood metabolite levels;	chr5:132033386	chr5:132311285~132369916:-
BRCA	cis	rs9467773	0.587	rs10946813	ENSG00000124549.13	BTN2A3P	3.74	0.000191	0.011	0.12	0.12	Intelligence (multi-trait analysis);	chr6:26344913	chr6:26421391~26432383:+
BRCA	cis	rs7824557	0.767	rs2060463	ENSG00000154316.13	TDH	-3.74	0.000191	0.011	-0.16	-0.12	Retinal vascular caliber;	chr8:11304101	chr8:11339637~11368452:+
BRCA	cis	rs943466	0.956	rs11758463	ENSG00000223837.2	BRD2-IT1	3.74	0.000191	0.011	0.15	0.12	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;	chr6:33794848	chr6:32970232~32970886:+
BRCA	cis	rs38055	0.881	rs37809	ENSG00000247796.2	CTD-2366F13.1	3.74	0.000191	0.011	0.13	0.12	Acne (severe);	chr5:53277462	chr5:53109842~53115126:+
BRCA	cis	rs4664293	0.967	rs10803758	ENSG00000224152.1	AC009506.1	-3.74	0.000191	0.011	-0.13	-0.12	Monocyte percentage of white cells;	chr2:159691708	chr2:159615296~159617082:+
BRCA	cis	rs17270561	0.609	rs9366629	ENSG00000272462.2	U91328.19	-3.74	0.000191	0.011	-0.14	-0.12	Iron status biomarkers;	chr6:25740988	chr6:25992662~26001775:+
BRCA	cis	rs17270561	0.553	rs6456696	ENSG00000272462.2	U91328.19	-3.74	0.000191	0.011	-0.14	-0.12	Iron status biomarkers;	chr6:25741180	chr6:25992662~26001775:+
BRCA	cis	rs17270561	0.636	rs6456697	ENSG00000272462.2	U91328.19	-3.74	0.000191	0.011	-0.14	-0.12	Iron status biomarkers;	chr6:25741206	chr6:25992662~26001775:+
BRCA	cis	rs17270561	0.636	rs6456698	ENSG00000272462.2	U91328.19	-3.74	0.000191	0.011	-0.14	-0.12	Iron status biomarkers;	chr6:25741436	chr6:25992662~26001775:+
BRCA	cis	rs17270561	0.666	rs4711099	ENSG00000272462.2	U91328.19	-3.74	0.000191	0.011	-0.14	-0.12	Iron status biomarkers;	chr6:25741581	chr6:25992662~26001775:+
BRCA	cis	rs17270561	0.609	rs4711100	ENSG00000272462.2	U91328.19	-3.74	0.000191	0.011	-0.14	-0.12	Iron status biomarkers;	chr6:25741726	chr6:25992662~26001775:+
BRCA	cis	rs17270561	0.609	rs4711101	ENSG00000272462.2	U91328.19	-3.74	0.000191	0.011	-0.14	-0.12	Iron status biomarkers;	chr6:25741742	chr6:25992662~26001775:+
BRCA	cis	rs17270561	0.609	rs4712965	ENSG00000272462.2	U91328.19	-3.74	0.000191	0.011	-0.14	-0.12	Iron status biomarkers;	chr6:25741794	chr6:25992662~26001775:+
BRCA	cis	rs17270561	0.608	rs4711102	ENSG00000272462.2	U91328.19	-3.74	0.000191	0.011	-0.14	-0.12	Iron status biomarkers;	chr6:25741847	chr6:25992662~26001775:+
BRCA	cis	rs17270561	0.609	rs4711103	ENSG00000272462.2	U91328.19	-3.74	0.000191	0.011	-0.14	-0.12	Iron status biomarkers;	chr6:25741996	chr6:25992662~26001775:+
BRCA	cis	rs17270561	0.609	rs9379788	ENSG00000272462.2	U91328.19	-3.74	0.000191	0.011	-0.14	-0.12	Iron status biomarkers;	chr6:25742531	chr6:25992662~26001775:+
BRCA	cis	rs17270561	0.609	rs9358879	ENSG00000272462.2	U91328.19	-3.74	0.000191	0.011	-0.14	-0.12	Iron status biomarkers;	chr6:25742690	chr6:25992662~26001775:+
BRCA	cis	rs17270561	0.636	rs9358880	ENSG00000272462.2	U91328.19	-3.74	0.000191	0.011	-0.14	-0.12	Iron status biomarkers;	chr6:25742933	chr6:25992662~26001775:+
BRCA	cis	rs17270561	0.609	rs4145216	ENSG00000272462.2	U91328.19	-3.74	0.000191	0.011	-0.14	-0.12	Iron status biomarkers;	chr6:25743331	chr6:25992662~26001775:+
BRCA	cis	rs17270561	0.609	rs4145217	ENSG00000272462.2	U91328.19	-3.74	0.000191	0.011	-0.14	-0.12	Iron status biomarkers;	chr6:25743769	chr6:25992662~26001775:+
BRCA	cis	rs17270561	0.609	rs9393665	ENSG00000272462.2	U91328.19	-3.74	0.000191	0.011	-0.14	-0.12	Iron status biomarkers;	chr6:25744056	chr6:25992662~26001775:+
BRCA	cis	rs17270561	0.609	rs7754733	ENSG00000272462.2	U91328.19	-3.74	0.000191	0.011	-0.14	-0.12	Iron status biomarkers;	chr6:25744821	chr6:25992662~26001775:+
BRCA	cis	rs17270561	0.636	rs7754814	ENSG00000272462.2	U91328.19	-3.74	0.000191	0.011	-0.14	-0.12	Iron status biomarkers;	chr6:25745015	chr6:25992662~26001775:+
BRCA	cis	rs17270561	0.636	rs7775354	ENSG00000272462.2	U91328.19	-3.74	0.000191	0.011	-0.14	-0.12	Iron status biomarkers;	chr6:25745038	chr6:25992662~26001775:+
BRCA	cis	rs17270561	0.609	rs9379789	ENSG00000272462.2	U91328.19	-3.74	0.000191	0.011	-0.14	-0.12	Iron status biomarkers;	chr6:25745351	chr6:25992662~26001775:+
BRCA	cis	rs3805389	0.504	rs10026315	ENSG00000273257.1	RP11-177J6.1	-3.74	0.000191	0.011	-0.18	-0.12	Waist-to-hip ratio adjusted for body mass index;	chr4:55612195	chr4:55387949~55388271:+
BRCA	cis	rs937213	0.573	rs2412464	ENSG00000273855.1	RP11-133K1.12	3.74	0.000191	0.011	0.12	0.12	Endometrial cancer;Endometrial endometrioid carcinoma;	chr15:40011641	chr15:40285468~40285909:-
BRCA	cis	rs7267979	1	rs6083804	ENSG00000277938.1	RP5-965G21.3	-3.74	0.000191	0.011	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25336424	chr20:25229150~25231933:+
BRCA	cis	rs7267979	1	rs4815405	ENSG00000277938.1	RP5-965G21.3	-3.74	0.000191	0.011	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25336856	chr20:25229150~25231933:+
BRCA	cis	rs7267979	1	rs6050542	ENSG00000277938.1	RP5-965G21.3	-3.74	0.000191	0.011	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25338243	chr20:25229150~25231933:+
BRCA	cis	rs72819225	0.659	rs12263117	ENSG00000228701.1	TNKS2-AS1	3.74	0.000191	0.011	0.15	0.12	Yeast infection;	chr10:91556202	chr10:91782839~91798291:-
BRCA	cis	rs13272568	0.642	rs9643735	ENSG00000254352.1	RP11-578O24.2	-3.74	0.000191	0.011	-0.15	-0.12	Bone mineral density;	chr8:78111992	chr8:78723796~78724136:-
BRCA	cis	rs295490	0.667	rs76728176	ENSG00000178631.7	ACTG1P1	-3.74	0.000191	0.011	-0.22	-0.12	PR interval in Tripanosoma cruzi seropositivity;	chr3:139441574	chr3:139493809~139494937:+
BRCA	cis	rs13126694	0.599	rs6536297	ENSG00000248429.4	RP11-597D13.9	3.74	0.000191	0.011	0.11	0.12	Blood osmolality (transformed sodium);	chr4:158076205	chr4:158170752~158202877:+
BRCA	cis	rs12893668	0.644	rs12890820	ENSG00000269940.1	RP11-73M18.7	3.74	0.000191	0.011	0.13	0.12	Reticulocyte count;	chr14:103568512	chr14:103694560~103695170:+
BRCA	cis	rs10844706	0.699	rs10844610	ENSG00000278635.1	CTD-2318O12.1	-3.74	0.000191	0.011	-0.13	-0.12	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9724016	chr12:9415641~9416718:+
BRCA	cis	rs6005807	0.719	rs9625522	ENSG00000272858.1	CTA-292E10.8	-3.74	0.000191	0.011	-0.21	-0.12	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28649224	chr22:28814914~28815662:+
BRCA	cis	rs6005807	0.719	rs9625523	ENSG00000272858.1	CTA-292E10.8	-3.74	0.000191	0.011	-0.21	-0.12	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28649757	chr22:28814914~28815662:+
BRCA	cis	rs9346455	0.614	rs9294899	ENSG00000279289.1	RP3-331H24.6	3.74	0.000191	0.011	0.17	0.12	Antipsychotic drug-induced weight gain;Antipsychotic drug-induced weight gain (time interaction);	chr6:71306599	chr6:71386852~71390829:-
BRCA	cis	rs116175783	0.557	rs16845829	ENSG00000235724.7	AC009299.2	3.74	0.000191	0.011	0.18	0.12	Intelligence (multi-trait analysis);	chr2:161399960	chr2:161222785~161308303:-
BRCA	cis	rs116175783	0.557	rs72877940	ENSG00000235724.7	AC009299.2	3.74	0.000191	0.011	0.18	0.12	Intelligence (multi-trait analysis);	chr2:161403965	chr2:161222785~161308303:-
BRCA	cis	rs745109	0.882	rs72932316	ENSG00000273080.1	RP11-301O19.1	3.74	0.000191	0.011	0.17	0.12	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86490804	chr2:86195590~86196049:+
BRCA	cis	rs2071426	0.622	rs2211267	ENSG00000273450.1	RP11-76P2.4	3.74	0.000191	0.011	0.15	0.12	Blood metabolite levels;	chr10:95022163	chr10:94314907~94315327:-
BRCA	cis	rs2692947	0.74	rs59076415	ENSG00000168992.4	OR7E102P	3.74	0.000191	0.011	0.17	0.12	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95728196	chr2:95546531~95547545:+
BRCA	cis	rs3892630	0.588	rs28787932	ENSG00000267475.1	CTD-2538C1.2	-3.74	0.000191	0.011	-0.16	-0.12	Red blood cell traits;	chr19:32735323	chr19:32687089~32691750:-
BRCA	cis	rs442309	0.901	rs224033	ENSG00000238280.1	RP11-436D10.3	-3.74	0.000191	0.011	-0.15	-0.12	Vogt-Koyanagi-Harada syndrome;	chr10:62762354	chr10:62793562~62805887:-
BRCA	cis	rs3796352	0.571	rs11713926	ENSG00000242142.1	SERBP1P3	-3.74	0.000191	0.011	-0.22	-0.12	Immune reponse to smallpox (secreted IL-2);	chr3:53121056	chr3:53064283~53065091:-
BRCA	cis	rs9287719	0.781	rs6714795	ENSG00000224177.5	LINC00570	3.74	0.000191	0.011	0.13	0.12	Prostate cancer;	chr2:10619008	chr2:11393981~11403077:+
BRCA	cis	rs66887589	0.748	rs28439855	ENSG00000260404.2	RP11-384K6.6	3.74	0.000191	0.011	0.1	0.12	Diastolic blood pressure;	chr4:119341101	chr4:118591773~118633729:+
BRCA	cis	rs4934494	1	rs4934494	ENSG00000235100.3	RP11-80H5.9	-3.74	0.000191	0.011	-0.15	-0.12	Red blood cell count;	chr10:89687662	chr10:89667181~89699671:-
BRCA	cis	rs713477	0.618	rs6573033	ENSG00000186615.9	KTN1-AS1	-3.74	0.000191	0.011	-0.13	-0.12	Pediatric bone mineral content (femoral neck);	chr14:55452342	chr14:55499278~55580110:-
BRCA	cis	rs12136530	0.774	rs10442635	ENSG00000211454.12	AKR7L	3.74	0.000191	0.011	0.13	0.12	Lead levels in blood;	chr1:19448998	chr1:19265982~19274194:-
BRCA	cis	rs73201462	1	rs6797834	ENSG00000242551.2	POU5F1P6	3.74	0.000191	0.011	0.2	0.12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128137557	chr3:128674735~128677005:-
BRCA	cis	rs6918586	0.658	rs198826	ENSG00000272810.1	U91328.22	3.74	0.000191	0.011	0.12	0.12	Schizophrenia;	chr6:26120925	chr6:26013241~26013757:+
BRCA	cis	rs10129255	0.828	rs10140989	ENSG00000231475.3	IGHV4-31	-3.74	0.000192	0.011	-0.1	-0.12	Kawasaki disease;	chr14:106668657	chr14:106349283~106349792:-
BRCA	cis	rs13126694	0.744	rs10003459	ENSG00000251073.1	NUDT19P5	-3.74	0.000192	0.011	-0.11	-0.12	Blood osmolality (transformed sodium);	chr4:158095602	chr4:158182825~158183393:+
BRCA	cis	rs4699052	1	rs7661702	ENSG00000251288.2	RP11-10L12.2	-3.74	0.000192	0.011	-0.13	-0.12	Testicular germ cell tumor;	chr4:103218972	chr4:102751401~102752641:+
BRCA	cis	rs11764932	0.894	rs4721453	ENSG00000229108.1	MEOX2-AS1	3.74	0.000192	0.011	0.13	0.12	Kidney function decline traits;	chr7:15694049	chr7:15688378~15695491:+
BRCA	cis	rs17092148	1	rs3787223	ENSG00000202150.1	RNU6-407P	-3.74	0.000192	0.011	-0.17	-0.12	Neuroticism;	chr20:34743581	chr20:35030317~35030420:-
BRCA	cis	rs453301	0.686	rs2409120	ENSG00000233609.3	RP11-62H7.2	-3.74	0.000192	0.011	-0.11	-0.12	Joint mobility (Beighton score);	chr8:9025061	chr8:8961200~8979025:+
BRCA	cis	rs9648716	0.766	rs801158	ENSG00000240889.1	NDUFB2-AS1	-3.74	0.000192	0.011	-0.16	-0.12	Type 2 diabetes;	chr7:141081155	chr7:140695336~140697077:-
BRCA	cis	rs2297363	0.502	rs4709393	ENSG00000216480.2	RP3-393E18.1	3.74	0.000192	0.011	0.13	0.12	Total cholesterol levels;Blood protein levels;	chr6:160051000	chr6:159526062~159526527:-
BRCA	cis	rs1223397	0.651	rs2458314	ENSG00000215022.6	RP1-257A7.4	-3.74	0.000192	0.011	-0.14	-0.12	Blood pressure;	chr6:13308992	chr6:13264861~13295586:-
BRCA	cis	rs12760731	0.92	rs3813637	ENSG00000213057.5	C1orf220	3.74	0.000192	0.011	0.16	0.12	Obesity-related traits;	chr1:178522545	chr1:178542752~178548889:+
BRCA	cis	rs7829975	0.658	rs907181	ENSG00000233609.3	RP11-62H7.2	3.74	0.000192	0.011	0.1	0.12	Mood instability;	chr8:8845365	chr8:8961200~8979025:+
BRCA	cis	rs739496	0.843	rs688812	ENSG00000257624.1	RP1-128M12.3	3.74	0.000192	0.011	0.16	0.12	Platelet count;	chr12:111524777	chr12:112000739~112000985:-
BRCA	cis	rs11170468	1	rs11170468	ENSG00000257718.1	RP11-396F22.1	-3.74	0.000192	0.011	-0.14	-0.12	Body mass index;	chr12:39036246	chr12:38906451~38909592:+
BRCA	cis	rs524281	0.861	rs3825067	ENSG00000255557.1	RP11-770G2.2	-3.74	0.000192	0.011	-0.16	-0.12	Electroencephalogram traits;	chr11:66110948	chr11:65745729~65771585:+
BRCA	cis	rs4908769	0.624	rs2708632	ENSG00000232912.4	RP5-1115A15.1	-3.74	0.000192	0.011	-0.13	-0.12	Allergy;	chr1:8404449	chr1:8424645~8434838:+
BRCA	cis	rs12435908	1	rs17826724	ENSG00000276116.2	FUT8-AS1	-3.74	0.000192	0.011	-0.18	-0.12	Ischemic stroke;	chr14:65601602	chr14:65411170~65412690:-
BRCA	cis	rs12530845	0.887	rs78641973	ENSG00000223718.3	AC093107.7	3.74	0.000192	0.011	0.19	0.12	Red blood cell traits;	chr7:135639563	chr7:135660039~135660647:+
BRCA	cis	rs6012953	0.967	rs4496379	ENSG00000231715.1	COX6CP2	-3.74	0.000192	0.011	-0.12	-0.12	Vitiligo;	chr20:50543407	chr20:50479767~50479991:+
BRCA	cis	rs860295	0.557	rs11264372	ENSG00000236675.1	MTX1P1	-3.74	0.000192	0.011	-0.15	-0.12	Body mass index;	chr1:155443139	chr1:155230975~155234325:+
BRCA	cis	rs35520189	0.857	rs2708914	ENSG00000189223.12	PAX8-AS1	3.74	0.000192	0.011	0.17	0.12	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:112869657	chr2:113211522~113276581:+
BRCA	cis	rs1355223	0.902	rs865070	ENSG00000271369.1	RP11-350D17.3	-3.74	0.000192	0.011	-0.13	-0.12	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34720950	chr11:34709600~34710161:+
BRCA	cis	rs13401620	0.752	rs11693966	ENSG00000229326.3	AC069154.4	-3.74	0.000192	0.011	-0.15	-0.12	Breast size;	chr2:119985860	chr2:119698623~119700151:+
BRCA	cis	rs4664293	0.647	rs10199805	ENSG00000226266.5	AC009961.3	-3.74	0.000192	0.011	-0.14	-0.12	Monocyte percentage of white cells;	chr2:159570880	chr2:159670708~159712435:-
BRCA	cis	rs7620503	0.959	rs2863015	ENSG00000277241.1	RP11-114M1.3	3.74	0.000192	0.011	0.13	0.12	Corneal structure;	chr3:177585391	chr3:177700346~177701072:-
BRCA	cis	rs3742264	0.656	rs9526126	ENSG00000235903.6	CPB2-AS1	-3.74	0.000192	0.011	-0.14	-0.12	Blood protein levels;	chr13:45991067	chr13:46052806~46113332:+
BRCA	cis	rs3742264	0.656	rs9534272	ENSG00000235903.6	CPB2-AS1	-3.74	0.000192	0.011	-0.14	-0.12	Blood protein levels;	chr13:45992688	chr13:46052806~46113332:+
BRCA	cis	rs2075466	0.514	rs17770918	ENSG00000267077.1	RP11-127I20.5	3.74	0.000192	0.011	0.17	0.12	Colonoscopy-negative controls vs population controls;	chr16:4859622	chr16:4795265~4796532:-
BRCA	cis	rs8028182	0.537	rs4371118	ENSG00000260269.4	CTD-2323K18.1	-3.74	0.000192	0.011	-0.17	-0.12	Sudden cardiac arrest;	chr15:75606549	chr15:75527150~75601205:-
BRCA	cis	rs8114671	0.628	rs6060130	ENSG00000279253.1	RP4-614O4.13	-3.74	0.000192	0.011	-0.14	-0.12	Height;	chr20:34961516	chr20:35262727~35264187:-
BRCA	cis	rs7089973	0.641	rs17795104	ENSG00000236799.1	RP11-383C6.2	-3.74	0.000192	0.011	-0.15	-0.12	Bipolar disorder or attention deficit hyperactivity disorder;	chr10:114979772	chr10:114994657~114996593:+
BRCA	cis	rs61931739	0.5	rs11053235	ENSG00000258794.3	DUX4L27	3.74	0.000192	0.011	0.17	0.12	Morning vs. evening chronotype;	chr12:34354964	chr12:34208415~34209675:-
BRCA	cis	rs61931739	0.5	rs7979769	ENSG00000258794.3	DUX4L27	3.74	0.000192	0.011	0.17	0.12	Morning vs. evening chronotype;	chr12:34356587	chr12:34208415~34209675:-
BRCA	cis	rs875971	0.767	rs1643394	ENSG00000229886.1	RP5-1132H15.3	3.74	0.000192	0.011	0.13	0.12	Aortic root size;	chr7:66371107	chr7:66025126~66031544:-
BRCA	cis	rs4703129	1	rs1820768	ENSG00000246763.5	RGMB-AS1	-3.74	0.000192	0.011	-0.13	-0.12	Asperger disorder;	chr5:98542927	chr5:98769618~98773469:-
BRCA	cis	rs4703129	0.967	rs7711931	ENSG00000246763.5	RGMB-AS1	-3.74	0.000192	0.011	-0.13	-0.12	Asperger disorder;	chr5:98544479	chr5:98769618~98773469:-
BRCA	cis	rs4703129	1	rs2112144	ENSG00000246763.5	RGMB-AS1	-3.74	0.000192	0.011	-0.13	-0.12	Asperger disorder;	chr5:98546171	chr5:98769618~98773469:-
BRCA	cis	rs9840812	0.598	rs33999043	ENSG00000273486.1	RP11-731C17.2	3.74	0.000192	0.011	0.17	0.12	Fibrinogen levels;	chr3:136381198	chr3:136837338~136839021:-
BRCA	cis	rs7267979	1	rs6050559	ENSG00000276952.1	RP5-965G21.6	3.74	0.000192	0.011	0.14	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25349279	chr20:25284915~25285588:-
BRCA	cis	rs2148307	0.647	rs3781490	ENSG00000228339.1	AMD1P1	-3.74	0.000192	0.011	-0.14	-0.12	Photic sneeze reflex;	chr10:20792914	chr10:20350049~20351100:+
BRCA	cis	rs13126694	0.633	rs4406058	ENSG00000248429.4	RP11-597D13.9	3.74	0.000192	0.011	0.11	0.12	Blood osmolality (transformed sodium);	chr4:158083652	chr4:158170752~158202877:+
BRCA	cis	rs11048434	0.518	rs1805669	ENSG00000256069.6	A2MP1	-3.74	0.000192	0.011	-0.13	-0.12	Sjögren's syndrome;	chr12:9027655	chr12:9228533~9275817:-
BRCA	cis	rs1048886	0.938	rs55778329	ENSG00000271967.1	RP11-134K13.4	-3.74	0.000192	0.011	-0.18	-0.12	Type 2 diabetes;	chr6:70491271	chr6:70596438~70596980:+
BRCA	cis	rs1048886	0.872	rs80232745	ENSG00000271967.1	RP11-134K13.4	-3.74	0.000192	0.011	-0.18	-0.12	Type 2 diabetes;	chr6:70492385	chr6:70596438~70596980:+
BRCA	cis	rs10938353	1	rs10938353	ENSG00000273369.1	RP11-700J17.1	-3.74	0.000192	0.011	-0.13	-0.12	Body mass index;	chr4:44580470	chr4:44693946~44694386:-
BRCA	cis	rs6822297	0.841	rs6448485	ENSG00000240005.4	RP11-293A21.1	3.74	0.000192	0.011	0.13	0.12	Obesity-related traits;	chr4:26873644	chr4:26859806~26860599:-
BRCA	cis	rs73193808	0.627	rs73192202	ENSG00000236056.1	GAPDHP14	-3.74	0.000192	0.011	-0.2	-0.12	Coronary artery disease;	chr21:29148257	chr21:29222321~29223257:+
BRCA	cis	rs360929	0.816	rs171506	ENSG00000245954.5	RP11-18H21.1	3.74	0.000192	0.011	0.13	0.12	Volumetric brain MRI;	chr4:151982394	chr4:152100754~152104720:+
BRCA	cis	rs6840360	0.726	rs6816292	ENSG00000251611.1	RP11-610P16.1	3.74	0.000192	0.011	0.1	0.12	Intelligence (multi-trait analysis);	chr4:151809391	chr4:151407551~151408835:-
BRCA	cis	rs1528472	0.836	rs1728879	ENSG00000276533.1	RP11-139H15.5	3.74	0.000192	0.011	0.13	0.12	Urinary albumin-to-creatinine ratio;Urinary albumin-to-creatinine ratio in non-diabetics;	chr15:55017592	chr15:55288849~55289346:-
BRCA	cis	rs7615952	1	rs7616044	ENSG00000250012.1	RP11-124N2.1	-3.74	0.000192	0.011	-0.17	-0.12	Blood pressure (smoking interaction);	chr3:125930511	chr3:126084220~126095349:+
BRCA	cis	rs9437689	0.966	rs6698046	ENSG00000235501.4	RP4-639F20.1	3.74	0.000192	0.011	0.15	0.12	Phospholipid levels (plasma);	chr1:94983726	chr1:94927566~94963270:+
BRCA	cis	rs3735485	0.723	rs6951729	ENSG00000201772.1	SNORA5C	-3.74	0.000192	0.011	-0.15	-0.12	White blood cell count;Sum basophil neutrophil counts;Neutrophil count;Granulocyte percentage of myeloid white cells;Monocyte percentage of white cells;Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Lymphocyte counts;	chr7:45015979	chr7:45104906~45105042:-
BRCA	cis	rs3735485	0.76	rs4720491	ENSG00000201772.1	SNORA5C	-3.74	0.000192	0.011	-0.15	-0.12	White blood cell count;Sum basophil neutrophil counts;Neutrophil count;Granulocyte percentage of myeloid white cells;Monocyte percentage of white cells;Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Lymphocyte counts;	chr7:45017652	chr7:45104906~45105042:-
BRCA	cis	rs3735485	0.76	rs9639905	ENSG00000201772.1	SNORA5C	-3.74	0.000192	0.011	-0.15	-0.12	White blood cell count;Sum basophil neutrophil counts;Neutrophil count;Granulocyte percentage of myeloid white cells;Monocyte percentage of white cells;Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Lymphocyte counts;	chr7:45018144	chr7:45104906~45105042:-
BRCA	cis	rs3735485	0.76	rs4724347	ENSG00000201772.1	SNORA5C	-3.74	0.000192	0.011	-0.15	-0.12	White blood cell count;Sum basophil neutrophil counts;Neutrophil count;Granulocyte percentage of myeloid white cells;Monocyte percentage of white cells;Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Lymphocyte counts;	chr7:45019513	chr7:45104906~45105042:-
BRCA	cis	rs2991971	0.967	rs2275276	ENSG00000280836.1	AL355480.1	3.74	0.000192	0.011	0.13	0.12	High light scatter reticulocyte count;	chr1:45508256	chr1:45581219~45581321:-
BRCA	cis	rs853679	1	rs9986596	ENSG00000216901.1	AL022393.7	3.74	0.000192	0.011	0.2	0.12	Depression;	chr6:28251883	chr6:28176188~28176674:+
BRCA	cis	rs7412746	0.658	rs72704652	ENSG00000231073.1	RP11-316M1.3	3.74	0.000192	0.011	0.12	0.12	Melanoma;	chr1:150846994	chr1:150973123~150975534:+
BRCA	cis	rs7412746	0.622	rs72704654	ENSG00000231073.1	RP11-316M1.3	3.74	0.000192	0.011	0.12	0.12	Melanoma;	chr1:150853934	chr1:150973123~150975534:+
BRCA	cis	rs2274273	1	rs61508494	ENSG00000259318.1	RP11-454L9.2	3.74	0.000192	0.011	0.1	0.12	Protein biomarker;	chr14:55120579	chr14:55394940~55395233:-
BRCA	cis	rs1910358	0.919	rs4701238	ENSG00000248874.4	C5orf17	-3.74	0.000192	0.011	-0.17	-0.12	Venous thromboembolism (SNP x SNP interaction);	chr5:23870710	chr5:23951348~24178263:+
BRCA	cis	rs3018712	0.508	rs4930581	ENSG00000251637.5	RP11-119D9.1	3.74	0.000192	0.011	0.19	0.12	Total body bone mineral density;	chr11:68643625	chr11:67886477~67906350:+
BRCA	cis	rs3018712	0.547	rs4930583	ENSG00000251637.5	RP11-119D9.1	3.74	0.000192	0.011	0.19	0.12	Total body bone mineral density;	chr11:68643711	chr11:67886477~67906350:+
BRCA	cis	rs3018712	0.59	rs4930584	ENSG00000251637.5	RP11-119D9.1	3.74	0.000192	0.011	0.19	0.12	Total body bone mineral density;	chr11:68643828	chr11:67886477~67906350:+
BRCA	cis	rs11158026	0.501	rs2057368	ENSG00000258413.1	RP11-665C16.6	-3.74	0.000192	0.011	-0.18	-0.12	Parkinson's disease;	chr14:54837291	chr14:55262767~55272075:-
BRCA	cis	rs757081	0.648	rs214102	ENSG00000272034.1	SNORD14A	-3.74	0.000192	0.011	-0.12	-0.12	Systolic blood pressure;	chr11:17266751	chr11:17074654~17074744:-
BRCA	cis	rs17767294	0.614	rs72845061	ENSG00000272009.1	RP1-313I6.12	-3.74	0.000192	0.011	-0.28	-0.12	Parkinson's disease;	chr6:27685482	chr6:28078792~28081130:-
BRCA	cis	rs6142618	0.562	rs6061173	ENSG00000224452.1	RSL24D1P6	3.74	0.000192	0.011	0.15	0.12	Inflammatory bowel disease;	chr20:32129312	chr20:32170390~32170790:-
BRCA	cis	rs801193	1	rs2659889	ENSG00000232546.1	RP11-458F8.1	-3.74	0.000192	0.011	-0.1	-0.12	Aortic root size;	chr7:66752125	chr7:66848496~66858136:+
BRCA	cis	rs73242632	0.881	rs10034395	ENSG00000269949.1	RP11-738E22.3	3.74	0.000192	0.011	0.27	0.12	Congenital heart disease (maternal effect);	chr4:56996965	chr4:56960927~56961373:-
BRCA	cis	rs425277	1	rs385039	ENSG00000269227.1	RP11-345P4.6	-3.74	0.000192	0.011	-0.12	-0.12	Height;	chr1:2145970	chr1:1673275~1674397:+
BRCA	cis	rs2391285	0.566	rs4483061	ENSG00000214870.7	AC004540.5	3.74	0.000192	0.011	0.17	0.12	Post bronchodilator FEV1/FVC ratio;	chr7:26567879	chr7:26398593~26494256:+
BRCA	cis	rs11992162	1	rs7460395	ENSG00000246477.3	AF131216.6	3.74	0.000192	0.011	0.11	0.12	Monocyte count;	chr8:11977866	chr8:11315859~11325429:-
BRCA	cis	rs4415084	1	rs58144701	ENSG00000272335.1	RP11-53O19.3	3.74	0.000192	0.011	0.11	0.12	Breast cancer;	chr5:44676095	chr5:44826076~44828592:+
BRCA	cis	rs28735056	0.609	rs4799099	ENSG00000261126.6	RP11-795F19.1	3.74	0.000192	0.011	0.11	0.12	Schizophrenia;	chr18:79879585	chr18:80046900~80095482:+
BRCA	cis	rs9549260	0.755	rs9549236	ENSG00000168852.11	TPTE2P5	-3.74	0.000192	0.011	-0.11	-0.12	Red blood cell count;	chr13:40573021	chr13:40822296~40921749:-
BRCA	cis	rs2841277	0.708	rs28454709	ENSG00000258701.1	LINC00638	3.74	0.000193	0.011	0.12	0.12	Rheumatoid arthritis;	chr14:104939605	chr14:104821201~104823718:+
BRCA	cis	rs2841277	0.708	rs11623422	ENSG00000258701.1	LINC00638	3.74	0.000193	0.011	0.12	0.12	Rheumatoid arthritis;	chr14:104940694	chr14:104821201~104823718:+
BRCA	cis	rs2841277	0.708	rs11851053	ENSG00000258701.1	LINC00638	3.74	0.000193	0.011	0.12	0.12	Rheumatoid arthritis;	chr14:104940871	chr14:104821201~104823718:+
BRCA	cis	rs1008375	0.966	rs2315645	ENSG00000249502.1	AC006160.5	-3.74	0.000193	0.011	-0.13	-0.12	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17578055	chr4:17587467~17614571:-
BRCA	cis	rs11098403	0.764	rs12647615	ENSG00000225892.3	RP11-384K6.2	3.74	0.000193	0.011	0.11	0.12	Schizophrenia;	chr4:117804639	chr4:118632274~118634759:+
BRCA	cis	rs12439619	0.693	rs9944185	ENSG00000255769.6	GOLGA2P10	-3.74	0.000193	0.011	-0.15	-0.12	Intelligence (multi-trait analysis);	chr15:82157927	chr15:82472993~82513950:-
BRCA	cis	rs4919687	0.55	rs11191372	ENSG00000236937.2	PTGES3P4	3.74	0.000193	0.011	0.16	0.12	Colorectal cancer;	chr10:102702430	chr10:102845595~102845950:+
BRCA	cis	rs7914558	0.646	rs12768205	ENSG00000213277.3	MARCKSL1P1	3.74	0.000193	0.011	0.14	0.12	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102888092	chr10:103175554~103176094:+
BRCA	cis	rs7914558	0.646	rs10883795	ENSG00000213277.3	MARCKSL1P1	3.74	0.000193	0.011	0.14	0.12	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102894820	chr10:103175554~103176094:+
BRCA	cis	rs7914558	0.646	rs10883796	ENSG00000213277.3	MARCKSL1P1	3.74	0.000193	0.011	0.14	0.12	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102895558	chr10:103175554~103176094:+
BRCA	cis	rs7914558	0.646	rs4363528	ENSG00000213277.3	MARCKSL1P1	3.74	0.000193	0.011	0.14	0.12	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102895758	chr10:103175554~103176094:+
BRCA	cis	rs853679	0.517	rs7755442	ENSG00000226314.6	ZNF192P1	-3.74	0.000193	0.011	-0.17	-0.12	Depression;	chr6:28071237	chr6:28161781~28169594:+
BRCA	cis	rs853679	0.517	rs55747925	ENSG00000226314.6	ZNF192P1	-3.74	0.000193	0.011	-0.17	-0.12	Depression;	chr6:28076559	chr6:28161781~28169594:+
BRCA	cis	rs853679	0.517	rs34716816	ENSG00000226314.6	ZNF192P1	-3.74	0.000193	0.011	-0.17	-0.12	Depression;	chr6:28078391	chr6:28161781~28169594:+
BRCA	cis	rs853679	0.517	rs9380049	ENSG00000226314.6	ZNF192P1	-3.74	0.000193	0.011	-0.17	-0.12	Depression;	chr6:28080757	chr6:28161781~28169594:+
BRCA	cis	rs853679	0.517	rs9380050	ENSG00000226314.6	ZNF192P1	-3.74	0.000193	0.011	-0.17	-0.12	Depression;	chr6:28080760	chr6:28161781~28169594:+
BRCA	cis	rs8058578	1	rs8048448	ENSG00000275263.1	RP11-1072A3.4	-3.74	0.000193	0.011	-0.15	-0.12	Multiple myeloma;	chr16:30680887	chr16:30956872~30957199:-
BRCA	cis	rs77633900	0.772	rs77582696	ENSG00000196274.5	Metazoa_SRP	3.74	0.000193	0.011	0.2	0.12	Glioma;Non-glioblastoma glioma;	chr15:76376812	chr15:76230048~76230390:-
BRCA	cis	rs6545883	0.56	rs11677776	ENSG00000270820.4	RP11-355B11.2	-3.74	0.000193	0.011	-0.12	-0.12	Tuberculosis;	chr2:61275978	chr2:61471188~61484130:+
BRCA	cis	rs728616	0.51	rs7074356	ENSG00000226659.1	RP11-137H2.4	3.74	0.000193	0.011	0.19	0.12	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80431578	chr10:80529597~80535942:-
BRCA	cis	rs8130944	0.866	rs1878070	ENSG00000225731.1	AP001627.1	3.74	0.000193	0.011	0.14	0.12	Perceived unattractiveness to mosquitoes;	chr21:42703595	chr21:42733594~42741758:-
BRCA	cis	rs798766	1	rs3752749	ENSG00000244459.2	RP11-1398P2.1	-3.74	0.000193	0.011	-0.15	-0.12	Urinary bladder cancer;Bladder cancer;	chr4:1735535	chr4:1574062~1580253:-
BRCA	cis	rs11051970	0.838	rs2651369	ENSG00000274964.1	RP11-817I4.1	-3.74	0.000193	0.011	-0.13	-0.12	Response to tocilizumab in rheumatoid arthritis;	chr12:32399835	chr12:32339368~32340724:+
BRCA	cis	rs9921338	0.961	rs4315353	ENSG00000262636.1	CTD-3088G3.4	3.74	0.000193	0.011	0.18	0.12	Vein graft stenosis in coronary artery bypass grafting;	chr16:11320303	chr16:11380859~11381118:-
BRCA	cis	rs11239930	0.56	rs632334	ENSG00000237188.3	RP11-337C18.8	3.74	0.000193	0.0111	0.13	0.12	AIDS progression;	chr1:147079972	chr1:147172771~147211568:+
BRCA	cis	rs11105298	0.891	rs11105318	ENSG00000270344.2	RP11-734K2.4	3.74	0.000193	0.0111	0.14	0.12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89532881	chr12:89525654~89548005:+
BRCA	cis	rs251253	0.729	rs255298	ENSG00000253959.1	CTB-43E15.1	3.74	0.000193	0.0111	0.1	0.12	PR interval;	chr5:173158076	chr5:173642519~173658194:+
BRCA	cis	rs251253	0.664	rs255299	ENSG00000253959.1	CTB-43E15.1	3.74	0.000193	0.0111	0.1	0.12	PR interval;	chr5:173159269	chr5:173642519~173658194:+
BRCA	cis	rs61931739	0.517	rs1817760	ENSG00000258794.3	DUX4L27	3.74	0.000193	0.0111	0.17	0.12	Morning vs. evening chronotype;	chr12:33953125	chr12:34208415~34209675:-
BRCA	cis	rs2147904	0.934	rs2786487	ENSG00000228452.1	RP5-994D16.9	3.74	0.000193	0.0111	0.13	0.12	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;Sum eosinophil basophil counts;Eosinophil percentage of white cells;	chr1:41902668	chr1:42775813~42776790:-
BRCA	cis	rs7824557	0.767	rs10104728	ENSG00000248896.2	CTD-2135J3.3	3.74	0.000193	0.0111	0.15	0.12	Retinal vascular caliber;	chr8:11313791	chr8:10729314~10771392:+
BRCA	cis	rs8023401	0.882	rs5027380	ENSG00000274654.1	CTD-3247H4.2	3.74	0.000193	0.0111	0.16	0.12	Spherical equivalent (joint analysis main effects and education interaction);	chr15:48530430	chr15:48528980~48529728:-
BRCA	cis	rs745109	0.882	rs1437614	ENSG00000273080.1	RP11-301O19.1	3.74	0.000193	0.0111	0.17	0.12	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86499503	chr2:86195590~86196049:+
BRCA	cis	rs10777288	0.561	rs1920749	ENSG00000258100.1	RP11-121E16.1	3.74	0.000193	0.0111	0.15	0.12	Pulmonary function (smoking interaction);	chr12:91004470	chr12:91362196~91368606:+
BRCA	cis	rs10777288	0.561	rs6538256	ENSG00000258100.1	RP11-121E16.1	3.74	0.000193	0.0111	0.15	0.12	Pulmonary function (smoking interaction);	chr12:91006585	chr12:91362196~91368606:+
BRCA	cis	rs10777288	0.561	rs6538257	ENSG00000258100.1	RP11-121E16.1	3.74	0.000193	0.0111	0.15	0.12	Pulmonary function (smoking interaction);	chr12:91006586	chr12:91362196~91368606:+
BRCA	cis	rs10777288	0.561	rs3825275	ENSG00000258100.1	RP11-121E16.1	3.74	0.000193	0.0111	0.15	0.12	Pulmonary function (smoking interaction);	chr12:91006824	chr12:91362196~91368606:+
BRCA	cis	rs10777288	0.561	rs4842747	ENSG00000258100.1	RP11-121E16.1	3.74	0.000193	0.0111	0.15	0.12	Pulmonary function (smoking interaction);	chr12:91006943	chr12:91362196~91368606:+
BRCA	cis	rs10777288	0.561	rs4842748	ENSG00000258100.1	RP11-121E16.1	3.74	0.000193	0.0111	0.15	0.12	Pulmonary function (smoking interaction);	chr12:91007017	chr12:91362196~91368606:+
BRCA	cis	rs10777288	0.561	rs10735282	ENSG00000258100.1	RP11-121E16.1	3.74	0.000193	0.0111	0.15	0.12	Pulmonary function (smoking interaction);	chr12:91007285	chr12:91362196~91368606:+
BRCA	cis	rs7131987	0.903	rs11050161	ENSG00000257176.2	RP11-996F15.2	-3.74	0.000193	0.0111	-0.14	-0.12	QT interval;	chr12:29267116	chr12:29280418~29317848:-
BRCA	cis	rs7131987	0.903	rs11050162	ENSG00000257176.2	RP11-996F15.2	-3.74	0.000193	0.0111	-0.14	-0.12	QT interval;	chr12:29267121	chr12:29280418~29317848:-
BRCA	cis	rs7824557	0.603	rs2249804	ENSG00000255020.1	AF131216.5	-3.74	0.000193	0.0111	-0.13	-0.12	Retinal vascular caliber;	chr8:11358108	chr8:11345748~11347502:-
BRCA	cis	rs6546537	0.911	rs62133968	ENSG00000231024.1	AC092431.3	3.74	0.000193	0.0111	0.17	0.12	Serum thyroid-stimulating hormone levels;	chr2:69664778	chr2:69700192~69713847:-
BRCA	cis	rs7267979	1	rs6076336	ENSG00000277938.1	RP5-965G21.3	-3.74	0.000193	0.0111	-0.14	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25338576	chr20:25229150~25231933:+
BRCA	cis	rs875971	0.83	rs4718358	ENSG00000272831.1	RP11-792A8.4	3.74	0.000193	0.0111	0.1	0.12	Aortic root size;	chr7:66508681	chr7:66739829~66740385:-
BRCA	cis	rs2286503	0.533	rs1880239	ENSG00000230658.1	KLHL7-AS1	-3.74	0.000193	0.0111	-0.18	-0.12	Fibrinogen;	chr7:22832065	chr7:23101228~23105703:-
BRCA	cis	rs7824557	0.767	rs11250127	ENSG00000248896.2	CTD-2135J3.3	3.74	0.000193	0.0111	0.15	0.12	Retinal vascular caliber;	chr8:11312700	chr8:10729314~10771392:+
BRCA	cis	rs6840360	0.571	rs10026670	ENSG00000270265.1	RP11-731D1.4	-3.74	0.000193	0.0111	-0.14	-0.12	Intelligence (multi-trait analysis);	chr4:151618060	chr4:151333775~151353224:-
BRCA	cis	rs11696739	0.866	rs1535882	ENSG00000242324.1	RP4-576H24.2	3.74	0.000193	0.0111	0.14	0.12	Mean platelet volume;	chr20:1619878	chr20:1516759~1557653:-
BRCA	cis	rs832187	0.629	rs6798742	ENSG00000224479.4	AC136289.1	3.74	0.000193	0.0111	0.13	0.12	Schizophrenia;	chr3:63918083	chr3:63742293~63827445:-
BRCA	cis	rs17123764	0.892	rs78616783	ENSG00000257464.1	RP11-161H23.8	-3.74	0.000193	0.0111	-0.21	-0.12	Intelligence (multi-trait analysis);	chr12:49749580	chr12:49442424~49442652:-
BRCA	cis	rs7267979	0.932	rs424487	ENSG00000204556.4	CTD-2514C3.1	-3.74	0.000193	0.0111	-0.16	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25487495	chr20:26018832~26020684:+
BRCA	cis	rs13153459	0.649	rs12188390	ENSG00000279557.1	CTD-2210P15.3	-3.74	0.000193	0.0111	-0.2	-0.12	Parkinson's disease;	chr5:44567043	chr5:43586367~43587543:-
BRCA	cis	rs9952980	0.573	rs62090676	ENSG00000266968.2	RP11-116O18.1	-3.74	0.000193	0.0111	-0.15	-0.12	Breast cancer;	chr18:45320719	chr18:45646153~45647937:+
BRCA	cis	rs9329221	0.537	rs2062331	ENSG00000253649.2	PRSS51	3.74	0.000193	0.0111	0.14	0.12	Neuroticism;	chr8:10122482	chr8:10482878~10547585:-
BRCA	cis	rs6430585	0.527	rs76380759	ENSG00000231890.6	DARS-AS1	-3.74	0.000193	0.0111	-0.18	-0.12	Corneal structure;	chr2:135680947	chr2:135985176~136022593:+
BRCA	cis	rs74233809	1	rs77860422	ENSG00000236937.2	PTGES3P4	3.74	0.000193	0.0111	0.25	0.12	Birth weight;	chr10:102988252	chr10:102845595~102845950:+
BRCA	cis	rs10043228	1	rs17139314	ENSG00000271918.1	CTD-2287O16.5	-3.74	0.000193	0.0111	-0.17	-0.12	Asthma or chronic obstructive pulmonary disease;	chr5:116271430	chr5:116083807~116085416:-
BRCA	cis	rs991427	0.908	rs10859102	ENSG00000258100.1	RP11-121E16.1	-3.74	0.000193	0.0111	-0.15	-0.12	Systolic blood pressure (alcohol consumption interaction);	chr12:91062917	chr12:91362196~91368606:+
BRCA	cis	rs7267979	1	rs2258617	ENSG00000276952.1	RP5-965G21.6	3.74	0.000193	0.0111	0.14	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25293682	chr20:25284915~25285588:-
BRCA	cis	rs11673344	0.583	rs10425719	ENSG00000267682.1	CTD-3220F14.2	3.74	0.000193	0.0111	0.09	0.12	Obesity-related traits;	chr19:37459896	chr19:37337236~37337743:+
BRCA	cis	rs831571	0.519	rs13059603	ENSG00000280620.1	SCAANT1	-3.74	0.000193	0.0111	-0.16	-0.12	Type 2 diabetes;	chr3:63841705	chr3:63911518~63911772:-
BRCA	cis	rs4664293	0.899	rs7588710	ENSG00000230783.1	AC009961.2	-3.74	0.000194	0.0111	-0.15	-0.12	Monocyte percentage of white cells;	chr2:159673011	chr2:159689217~159690291:-
BRCA	cis	rs67981189	0.593	rs221917	ENSG00000269927.1	RP6-91H8.3	-3.74	0.000194	0.0111	-0.14	-0.12	Schizophrenia;	chr14:71123286	chr14:71141125~71143253:-
BRCA	cis	rs2832191	0.632	rs2246777	ENSG00000232855.5	AF131217.1	3.74	0.000194	0.0111	0.14	0.12	Dental caries;	chr21:28937264	chr21:28439346~28674848:-
BRCA	cis	rs720475	0.695	rs62483108	ENSG00000228960.5	OR2A9P	-3.74	0.000194	0.0111	-0.17	-0.12	Breast cancer;	chr7:144442326	chr7:144294480~144300934:+
BRCA	cis	rs6120849	0.754	rs6120819	ENSG00000202150.1	RNU6-407P	3.74	0.000194	0.0111	0.16	0.12	Protein C levels;	chr20:35065235	chr20:35030317~35030420:-
BRCA	cis	rs7267979	0.966	rs2261747	ENSG00000274973.1	RP13-401N8.7	-3.74	0.000194	0.0111	-0.13	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25281148	chr20:25845497~25845862:+
BRCA	cis	rs9437689	0.966	rs2797622	ENSG00000235501.4	RP4-639F20.1	-3.74	0.000194	0.0111	-0.15	-0.12	Phospholipid levels (plasma);	chr1:94978646	chr1:94927566~94963270:+
BRCA	cis	rs7620503	1	rs7630147	ENSG00000277241.1	RP11-114M1.3	3.74	0.000194	0.0111	0.13	0.12	Corneal structure;	chr3:177582603	chr3:177700346~177701072:-
BRCA	cis	rs7620503	0.959	rs4857709	ENSG00000277241.1	RP11-114M1.3	3.74	0.000194	0.0111	0.13	0.12	Corneal structure;	chr3:177583167	chr3:177700346~177701072:-
BRCA	cis	rs7620503	1	rs4857710	ENSG00000277241.1	RP11-114M1.3	3.74	0.000194	0.0111	0.13	0.12	Corneal structure;	chr3:177583177	chr3:177700346~177701072:-
BRCA	cis	rs7620503	1	rs6763782	ENSG00000277241.1	RP11-114M1.3	3.74	0.000194	0.0111	0.13	0.12	Corneal structure;	chr3:177583492	chr3:177700346~177701072:-
BRCA	cis	rs7620503	0.729	rs2863018	ENSG00000277241.1	RP11-114M1.3	3.74	0.000194	0.0111	0.13	0.12	Corneal structure;	chr3:177584123	chr3:177700346~177701072:-
BRCA	cis	rs2133593	1	rs2133593	ENSG00000277241.1	RP11-114M1.3	3.74	0.000194	0.0111	0.13	0.12	Chin dimples;	chr3:177584204	chr3:177700346~177701072:-
BRCA	cis	rs9500256	0.934	rs1343391	ENSG00000272541.1	XXbac-BPGBPG55C20.1	-3.74	0.000194	0.0111	-0.12	-0.12	Eosinophilic esophagitis (pediatric);	chr6:58017876	chr6:57855891~57856468:-
BRCA	cis	rs7680126	0.596	rs10020887	ENSG00000250413.1	RP11-448G15.1	3.74	0.000194	0.0111	0.19	0.12	Urate levels in obese individuals;Urate levels in lean individuals;Urate levels in overweight individuals;	chr4:10139127	chr4:10006482~10009725:+
BRCA	cis	rs2839186	0.77	rs2280956	ENSG00000223901.2	AP001469.5	-3.74	0.000194	0.0111	-0.11	-0.12	Testicular germ cell tumor;	chr21:46222409	chr21:46220269~46225364:+
BRCA	cis	rs10761482	0.861	rs10761488	ENSG00000254271.1	RP11-131N11.4	3.74	0.000194	0.0111	0.16	0.12	Schizophrenia;	chr10:60346234	chr10:60734342~60741828:+
BRCA	cis	rs11035577	0.778	rs2219640	ENSG00000279675.1	RP11-454H19.2	-3.74	0.000194	0.0111	-0.2	-0.12	Temperament (bipolar disorder);	chr11:39792885	chr11:40107244~40112599:-
BRCA	cis	rs524281	0.861	rs918299	ENSG00000255557.1	RP11-770G2.2	3.74	0.000194	0.0111	0.16	0.12	Electroencephalogram traits;	chr11:66160136	chr11:65745729~65771585:+
BRCA	cis	rs1005277	0.54	rs7903942	ENSG00000099251.13	HSD17B7P2	-3.74	0.000194	0.0111	-0.13	-0.12	Extrinsic epigenetic age acceleration;	chr10:37640348	chr10:38356380~38378505:+
BRCA	cis	rs58521262	0.556	rs453743	ENSG00000268105.1	RP11-369G6.2	3.74	0.000194	0.0111	0.16	0.12	Testicular germ cell tumor;	chr19:22938838	chr19:23125665~23128543:+
BRCA	cis	rs58521262	0.556	rs424913	ENSG00000268105.1	RP11-369G6.2	3.74	0.000194	0.0111	0.16	0.12	Testicular germ cell tumor;	chr19:22939624	chr19:23125665~23128543:+
BRCA	cis	rs11098499	0.954	rs9993199	ENSG00000225892.3	RP11-384K6.2	-3.74	0.000194	0.0111	-0.11	-0.12	Corneal astigmatism;	chr4:119471718	chr4:118632274~118634759:+
BRCA	cis	rs9545047	0.716	rs418150	ENSG00000227354.5	RBM26-AS1	-3.74	0.000194	0.0111	-0.13	-0.12	Schizophrenia;	chr13:79432675	chr13:79406309~79424328:+
BRCA	cis	rs4664293	0.647	rs7576644	ENSG00000224152.1	AC009506.1	-3.74	0.000194	0.0111	-0.12	-0.12	Monocyte percentage of white cells;	chr2:159584947	chr2:159615296~159617082:+
BRCA	cis	rs251253	0.795	rs1002620	ENSG00000253959.1	CTB-43E15.1	3.74	0.000194	0.0111	0.1	0.12	PR interval;	chr5:173084334	chr5:173642519~173658194:+
BRCA	cis	rs2961333	1	rs2961222	ENSG00000243635.1	RP11-281P11.1	-3.74	0.000194	0.0111	-0.19	-0.12	Pediatric bone mineral content (femoral neck);	chr3:104516117	chr3:104502700~104503266:+
BRCA	cis	rs1075265	0.749	rs805379	ENSG00000272156.1	RP11-477N3.1	-3.74	0.000194	0.0111	-0.12	-0.12	Chronotype;Morning vs. evening chronotype;	chr2:53865847	chr2:54082554~54085066:+
BRCA	cis	rs8030605	0.633	rs72740541	ENSG00000277245.1	RP11-48G14.3	3.74	0.000194	0.0111	0.25	0.12	Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;	chr15:56300222	chr15:56447120~56447697:+
BRCA	cis	rs12705849	0.732	rs12705846	ENSG00000214194.7	LINC00998	3.74	0.000194	0.0111	0.14	0.12	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Eosinophil counts;	chr7:113088952	chr7:113116718~113118613:-
BRCA	cis	rs6964587	0.773	rs13236026	ENSG00000188693.7	CYP51A1-AS1	-3.74	0.000194	0.0111	-0.13	-0.12	Breast cancer;	chr7:92256559	chr7:92134604~92180725:+
BRCA	cis	rs7020830	0.505	rs12553878	ENSG00000260100.1	RP11-220I1.5	-3.74	0.000194	0.0111	-0.13	-0.12	Schizophrenia;	chr9:37095708	chr9:37078813~37079776:-
BRCA	cis	rs1008375	0.8	rs28754811	ENSG00000249502.1	AC006160.5	-3.74	0.000194	0.0111	-0.13	-0.12	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17610689	chr4:17587467~17614571:-
BRCA	cis	rs8114671	0.562	rs6088621	ENSG00000126005.14	MMP24-AS1	-3.74	0.000194	0.0111	-0.13	-0.12	Height;	chr20:34830937	chr20:35216462~35278131:-
BRCA	cis	rs1953600	0.87	rs1049550	ENSG00000226659.1	RP11-137H2.4	-3.74	0.000194	0.0111	-0.15	-0.12	Sarcoidosis;	chr10:80166946	chr10:80529597~80535942:-
BRCA	cis	rs7020830	0.858	rs13293465	ENSG00000260100.1	RP11-220I1.5	-3.74	0.000194	0.0111	-0.14	-0.12	Schizophrenia;	chr9:37127681	chr9:37078813~37079776:-
BRCA	cis	rs6012564	0.964	rs3092302	ENSG00000230758.1	SNAP23P	-3.74	0.000194	0.0111	-0.13	-0.12	Anger;	chr20:49037721	chr20:49038357~49038602:-
BRCA	cis	rs6012564	0.964	rs73266241	ENSG00000230758.1	SNAP23P	3.74	0.000194	0.0111	0.13	0.12	Anger;	chr20:49043748	chr20:49038357~49038602:-
BRCA	cis	rs748802	0.704	rs10814296	ENSG00000231393.1	RP11-331F9.3	3.74	0.000194	0.0111	0.14	0.12	Resting heart rate;	chr9:35910804	chr9:35642514~35643517:+
BRCA	cis	rs1414896	0.646	rs12132107	ENSG00000226835.1	RP11-148B18.3	-3.74	0.000194	0.0111	-0.12	-0.12	Non-alcoholic fatty liver disease histology (AST);	chr1:95200088	chr1:94333267~94334848:+
BRCA	cis	rs78487399	0.71	rs6743071	ENSG00000234936.1	AC010883.5	3.74	0.000194	0.0111	0.19	0.12	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43359148	chr2:43229573~43233394:+
BRCA	cis	rs6724465	1	rs17608677	ENSG00000261338.2	RP11-378A13.1	3.74	0.000194	0.0111	0.16	0.12	Height;	chr2:219072149	chr2:218255319~218257366:+
BRCA	cis	rs8180040	0.966	rs34634681	ENSG00000280667.1	Y_RNA	-3.74	0.000194	0.0111	-0.13	-0.12	Colorectal cancer;	chr3:47537612	chr3:47501083~47501182:+
BRCA	cis	rs2153535	0.585	rs1814213	ENSG00000251164.1	HULC	-3.74	0.000194	0.0111	-0.14	-0.12	Motion sickness;	chr6:8619632	chr6:8652137~8653846:+
BRCA	cis	rs6142618	0.562	rs3787371	ENSG00000275576.1	RP5-836N17.4	-3.74	0.000194	0.0111	-0.13	-0.12	Inflammatory bowel disease;	chr20:32203375	chr20:32116171~32116629:+
BRCA	cis	rs952623	0.649	rs6462886	ENSG00000227191.5	TRGC2	-3.74	0.000194	0.0111	-0.1	-0.12	Intelligence (multi-trait analysis);	chr7:39026967	chr7:38239580~38368091:-
BRCA	cis	rs748404	0.589	rs62020616	ENSG00000166763.7	STRCP1	3.74	0.000194	0.0111	0.17	0.12	Lung cancer;	chr15:43558554	chr15:43699488~43718184:-
BRCA	cis	rs748404	0.626	rs60367691	ENSG00000166763.7	STRCP1	3.74	0.000194	0.0111	0.17	0.12	Lung cancer;	chr15:43559201	chr15:43699488~43718184:-
BRCA	cis	rs7572733	0.967	rs2196171	ENSG00000231621.1	AC013264.2	-3.74	0.000194	0.0111	-0.1	-0.12	Dermatomyositis;	chr2:198025083	chr2:197197991~197199273:+
BRCA	cis	rs13401620	0.833	rs2941609	ENSG00000229326.3	AC069154.4	-3.74	0.000194	0.0111	-0.15	-0.12	Breast size;	chr2:119917515	chr2:119698623~119700151:+
BRCA	cis	rs10819861	0.645	rs4078421	ENSG00000175611.10	LINC00476	3.74	0.000194	0.0111	0.12	0.12	Electrocardiographic traits;	chr9:96100887	chr9:95759231~95875977:-
BRCA	cis	rs17801127	0.901	rs1526285	ENSG00000231969.1	AC144449.1	3.74	0.000194	0.0111	0.22	0.12	Liver enzyme levels (alanine transaminase);	chr2:149652011	chr2:149587196~149848233:+
BRCA	cis	rs372883	0.613	rs1153290	ENSG00000176054.6	RPL23P2	-3.74	0.000194	0.0111	-0.12	-0.12	Pancreatic cancer;	chr21:29315083	chr21:28997613~28998033:-
BRCA	cis	rs80028505	1	rs80028505	ENSG00000271304.1	DPRXP2	3.74	0.000194	0.0111	0.23	0.12	Foot ulcer in diabetes and neuropathy;	chr6:36030611	chr6:35989515~35990436:-
BRCA	cis	rs80028505	0.908	rs6932598	ENSG00000271304.1	DPRXP2	3.74	0.000194	0.0111	0.23	0.12	Foot ulcer in diabetes and neuropathy;	chr6:36031303	chr6:35989515~35990436:-
BRCA	cis	rs9856151	1	rs6801798	ENSG00000261167.1	RP11-517B11.7	3.74	0.000194	0.0111	0.14	0.12	Body mass index;	chr3:131870241	chr3:131455126~131458598:-
BRCA	cis	rs2518049	0.904	rs7898263	ENSG00000224034.1	RP11-445P17.8	-3.74	0.000194	0.0111	-0.2	-0.12	Metabolic traits;	chr10:5079014	chr10:5266033~5271236:-
BRCA	cis	rs7781557	0.64	rs73192025	ENSG00000239969.4	RP11-163E9.2	-3.74	0.000194	0.0111	-0.18	-0.12	Colorectal adenoma (advanced);	chr7:102951042	chr7:102364162~102380633:+
BRCA	cis	rs11892454	0.599	rs7560429	ENSG00000217643.1	PTGES3P2	-3.74	0.000194	0.0111	-0.13	-0.12	Heschl's gyrus morphology;	chr2:25785136	chr2:25822469~25822950:+
BRCA	cis	rs875971	0.893	rs62465470	ENSG00000273024.4	INTS4P2	3.74	0.000195	0.0111	0.13	0.12	Aortic root size;	chr7:66136231	chr7:65647864~65715661:+
BRCA	cis	rs7620503	1	rs2173608	ENSG00000277241.1	RP11-114M1.3	3.74	0.000195	0.0111	0.13	0.12	Corneal structure;	chr3:177584550	chr3:177700346~177701072:-
BRCA	cis	rs1437396	0.657	rs3111411	ENSG00000203327.2	AC012358.7	-3.74	0.000195	0.0111	-0.12	-0.12	Alcohol dependence;	chr2:55372519	chr2:55214387~55216126:-
BRCA	cis	rs2486012	0.737	rs3791055	ENSG00000237950.1	RP11-7O11.3	3.74	0.000195	0.0111	0.21	0.12	Intelligence (multi-trait analysis);	chr1:43799984	chr1:43944370~43946551:-
BRCA	cis	rs6991838	0.584	rs3765205	ENSG00000272155.1	RP11-707M3.3	3.74	0.000195	0.0111	0.1	0.12	Intelligence (multi-trait analysis);	chr8:65605251	chr8:65714334~65714778:-
BRCA	cis	rs4879656	0.569	rs3758276	ENSG00000236184.1	TCEA1P4	-3.74	0.000195	0.0111	-0.15	-0.12	Menopause (age at onset);	chr9:33024919	chr9:32979560~32980403:-
BRCA	cis	rs7429990	0.965	rs6791834	ENSG00000228638.1	FCF1P2	3.74	0.000195	0.0111	0.11	0.12	Educational attainment (years of education);	chr3:48073598	chr3:48290793~48291375:-
BRCA	cis	rs9470794	1	rs73421825	ENSG00000204110.6	RP1-153P14.8	-3.74	0.000195	0.0111	-0.23	-0.12	Type 2 diabetes;	chr6:38109097	chr6:37507348~37535616:+
BRCA	cis	rs962856	0.506	rs6546306	ENSG00000236605.1	AC023115.4	3.74	0.000195	0.0111	0.16	0.12	Pancreatic cancer;	chr2:67413977	chr2:67324627~67325304:+
BRCA	cis	rs4664293	0.609	rs10167143	ENSG00000226266.5	AC009961.3	-3.74	0.000195	0.0111	-0.14	-0.12	Monocyte percentage of white cells;	chr2:159606885	chr2:159670708~159712435:-
BRCA	cis	rs72928364	1	rs62273925	ENSG00000244119.1	PDCL3P4	3.74	0.000195	0.0111	0.14	0.12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100922951	chr3:101712472~101713191:+
BRCA	cis	rs72928364	1	rs1036467	ENSG00000244119.1	PDCL3P4	3.74	0.000195	0.0111	0.14	0.12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100923960	chr3:101712472~101713191:+
BRCA	cis	rs72928364	0.929	rs17284842	ENSG00000244119.1	PDCL3P4	3.74	0.000195	0.0111	0.14	0.12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100926103	chr3:101712472~101713191:+
BRCA	cis	rs72928364	1	rs36156426	ENSG00000244119.1	PDCL3P4	3.74	0.000195	0.0111	0.14	0.12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100927399	chr3:101712472~101713191:+
BRCA	cis	rs72928364	1	rs13060137	ENSG00000244119.1	PDCL3P4	3.74	0.000195	0.0111	0.14	0.12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100929083	chr3:101712472~101713191:+
BRCA	cis	rs72928364	1	rs62273927	ENSG00000244119.1	PDCL3P4	3.74	0.000195	0.0111	0.14	0.12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100929596	chr3:101712472~101713191:+
BRCA	cis	rs72928364	1	rs34315591	ENSG00000244119.1	PDCL3P4	3.74	0.000195	0.0111	0.14	0.12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100930239	chr3:101712472~101713191:+
BRCA	cis	rs72928364	1	rs13100301	ENSG00000244119.1	PDCL3P4	3.74	0.000195	0.0111	0.14	0.12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100932878	chr3:101712472~101713191:+
BRCA	cis	rs911555	0.511	rs2296483	ENSG00000258851.1	RP11-894P9.2	-3.74	0.000195	0.0111	-0.13	-0.12	Intelligence (multi-trait analysis);	chr14:103563455	chr14:103553421~103561877:+
BRCA	cis	rs1476679	1	rs1476679	ENSG00000242294.5	STAG3L5P	3.74	0.000195	0.0111	0.1	0.12	Alzheimer's disease (late onset);	chr7:100406823	chr7:100336079~100351900:+
BRCA	cis	rs8030605	0.704	rs116636952	ENSG00000277245.1	RP11-48G14.3	3.74	0.000195	0.0111	0.24	0.12	Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;	chr15:56310866	chr15:56447120~56447697:+
BRCA	cis	rs7131987	0.903	rs2194520	ENSG00000273680.1	RP11-996F15.6	3.74	0.000195	0.0111	0.14	0.12	QT interval;	chr12:29270779	chr12:29332733~29333383:-
BRCA	cis	rs7267979	0.932	rs449370	ENSG00000274414.1	RP5-965G21.4	3.74	0.000195	0.0111	0.14	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25470544	chr20:25239007~25245229:-
BRCA	cis	rs3617	0.625	rs2535633	ENSG00000243224.1	RP5-1157M23.2	3.74	0.000195	0.0111	0.12	0.12	Red blood cell count;Autism spectrum disorder or schizophrenia;	chr3:52825614	chr3:52239258~52241097:+
BRCA	cis	rs1914816	0.941	rs2460151	ENSG00000259422.1	RP11-593F23.1	3.74	0.000195	0.0111	0.17	0.12	Response to tocilizumab in rheumatoid arthritis;	chr15:76195166	chr15:76174891~76181486:-
BRCA	cis	rs17214007	0.877	rs2075514	ENSG00000260735.1	RP11-72I8.1	-3.74	0.000195	0.0111	-0.16	-0.12	Cognitive function;	chr16:15778752	chr16:15094411~15109197:+
BRCA	cis	rs6743226	0.59	rs6733962	ENSG00000266621.1	AC104841.1	3.74	0.000195	0.0111	0.14	0.12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in non-smokers;	chr2:241280254	chr2:241245202~241245299:-
BRCA	cis	rs375066	0.736	rs62114649	ENSG00000267191.1	RP11-15A1.2	3.74	0.000195	0.0111	0.15	0.12	Breast cancer;	chr19:43912415	chr19:43902001~43926545:+
BRCA	cis	rs4664293	0.565	rs10165197	ENSG00000224152.1	AC009506.1	3.74	0.000195	0.0111	0.12	0.12	Monocyte percentage of white cells;	chr2:159537137	chr2:159615296~159617082:+
BRCA	cis	rs12122100	0.651	rs12728300	ENSG00000278811.3	LINC00624	-3.74	0.000195	0.0111	-0.15	-0.12	HIV-1 control;	chr1:147070640	chr1:147258885~147517875:-
BRCA	cis	rs4664293	0.967	rs10202187	ENSG00000224152.1	AC009506.1	-3.74	0.000195	0.0111	-0.13	-0.12	Monocyte percentage of white cells;	chr2:159571135	chr2:159615296~159617082:+
BRCA	cis	rs972578	1	rs2038062	ENSG00000237037.8	NDUFA6-AS1	3.74	0.000195	0.0111	0.12	0.12	Mean platelet volume;	chr22:43001960	chr22:42090931~42137742:+
BRCA	cis	rs875971	0.83	rs809025	ENSG00000229886.1	RP5-1132H15.3	3.74	0.000195	0.0111	0.13	0.12	Aortic root size;	chr7:66384832	chr7:66025126~66031544:-
BRCA	cis	rs7578361	0.918	rs16827089	ENSG00000231969.1	AC144449.1	3.74	0.000195	0.0111	0.17	0.12	Acute lymphoblastic leukemia (childhood);	chr2:149487745	chr2:149587196~149848233:+
BRCA	cis	rs9470794	1	rs73421464	ENSG00000204110.6	RP1-153P14.8	-3.74	0.000195	0.0111	-0.23	-0.12	Type 2 diabetes;	chr6:37999430	chr6:37507348~37535616:+
BRCA	cis	rs35306767	0.807	rs34885925	ENSG00000229869.1	RP11-363N22.2	-3.74	0.000195	0.0112	-0.2	-0.12	Eosinophil percentage of granulocytes;	chr10:873092	chr10:933026~942743:+
BRCA	cis	rs6743226	0.603	rs62186406	ENSG00000266621.1	AC104841.1	3.74	0.000195	0.0112	0.14	0.12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in non-smokers;	chr2:241294041	chr2:241245202~241245299:-
BRCA	cis	rs6743226	0.603	rs10933548	ENSG00000266621.1	AC104841.1	3.74	0.000195	0.0112	0.14	0.12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in non-smokers;	chr2:241295422	chr2:241245202~241245299:-
BRCA	cis	rs6743226	0.603	rs62186408	ENSG00000266621.1	AC104841.1	3.74	0.000195	0.0112	0.14	0.12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in non-smokers;	chr2:241296236	chr2:241245202~241245299:-
BRCA	cis	rs6743226	0.603	rs62186410	ENSG00000266621.1	AC104841.1	3.74	0.000195	0.0112	0.14	0.12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in non-smokers;	chr2:241296443	chr2:241245202~241245299:-
BRCA	cis	rs6743226	0.626	rs12612578	ENSG00000266621.1	AC104841.1	3.74	0.000195	0.0112	0.14	0.12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in non-smokers;	chr2:241297245	chr2:241245202~241245299:-
BRCA	cis	rs6743226	0.58	rs11884197	ENSG00000266621.1	AC104841.1	3.74	0.000195	0.0112	0.14	0.12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in non-smokers;	chr2:241303371	chr2:241245202~241245299:-
BRCA	cis	rs6743226	0.515	rs56061376	ENSG00000266621.1	AC104841.1	3.74	0.000195	0.0112	0.14	0.12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in non-smokers;	chr2:241304020	chr2:241245202~241245299:-
BRCA	cis	rs615134	0.581	rs11066027	ENSG00000234608.6	MAPKAPK5-AS1	3.74	0.000195	0.0112	0.21	0.12	Mean corpuscular volume;	chr12:111807284	chr12:111839764~111842902:-
BRCA	cis	rs10735946	1	rs2193036	ENSG00000255733.4	IFNG-AS1	-3.74	0.000195	0.0112	-0.1	-0.12	Anti-saccade response;	chr12:68081879	chr12:67989445~68234686:+
BRCA	cis	rs4950322	0.571	rs4373796	ENSG00000227242.3	NBPF13P	-3.74	0.000195	0.0112	-0.17	-0.12	Protein quantitative trait loci;	chr1:147316747	chr1:147021320~147124525:-
BRCA	cis	rs4950322	0.543	rs4568882	ENSG00000227242.3	NBPF13P	-3.74	0.000195	0.0112	-0.17	-0.12	Protein quantitative trait loci;	chr1:147316885	chr1:147021320~147124525:-
BRCA	cis	rs4950322	0.543	rs2883323	ENSG00000227242.3	NBPF13P	-3.74	0.000195	0.0112	-0.17	-0.12	Protein quantitative trait loci;	chr1:147316995	chr1:147021320~147124525:-
BRCA	cis	rs4950322	0.543	rs2883324	ENSG00000227242.3	NBPF13P	-3.74	0.000195	0.0112	-0.17	-0.12	Protein quantitative trait loci;	chr1:147317157	chr1:147021320~147124525:-
BRCA	cis	rs9309473	0.607	rs10198301	ENSG00000230002.2	ALMS1-IT1	3.74	0.000195	0.0112	0.14	0.12	Metabolite levels;	chr2:73354472	chr2:73456764~73459484:+
BRCA	cis	rs7772486	0.875	rs1412081	ENSG00000270638.1	RP3-466P17.1	3.74	0.000195	0.0112	0.13	0.12	Lobe attachment (rater-scored or self-reported);	chr6:146088597	chr6:145735570~145737218:+
BRCA	cis	rs7772486	0.875	rs10457792	ENSG00000270638.1	RP3-466P17.1	3.74	0.000195	0.0112	0.13	0.12	Lobe attachment (rater-scored or self-reported);	chr6:146091279	chr6:145735570~145737218:+
BRCA	cis	rs1150668	0.796	rs2247002	ENSG00000270326.1	RP5-874C20.6	-3.74	0.000195	0.0112	-0.14	-0.12	Pubertal anthropometrics;	chr6:28430174	chr6:28319660~28319852:-
BRCA	cis	rs875971	0.862	rs11763189	ENSG00000229886.1	RP5-1132H15.3	3.74	0.000195	0.0112	0.13	0.12	Aortic root size;	chr7:66518542	chr7:66025126~66031544:-
BRCA	cis	rs3816183	0.585	rs7574668	ENSG00000226491.1	FTOP1	-3.74	0.000195	0.0112	-0.14	-0.12	Hypospadias;	chr2:42610351	chr2:42797225~42798712:-
BRCA	cis	rs11239930	0.517	rs4950354	ENSG00000237188.3	RP11-337C18.8	3.74	0.000195	0.0112	0.13	0.12	AIDS progression;	chr1:147082674	chr1:147172771~147211568:+
BRCA	cis	rs11239930	0.538	rs4950355	ENSG00000237188.3	RP11-337C18.8	3.74	0.000195	0.0112	0.13	0.12	AIDS progression;	chr1:147082700	chr1:147172771~147211568:+
BRCA	cis	rs7246967	0.866	rs12972095	ENSG00000198153.8	ZNF849P	-3.74	0.000195	0.0112	-0.16	-0.12	Bronchopulmonary dysplasia;	chr19:22851708	chr19:22685167~22686732:+
BRCA	cis	rs3805389	0.504	rs2412666	ENSG00000273257.1	RP11-177J6.1	-3.74	0.000195	0.0112	-0.19	-0.12	Waist-to-hip ratio adjusted for body mass index;	chr4:55607192	chr4:55387949~55388271:+
BRCA	cis	rs6545883	0.542	rs2593628	ENSG00000270820.4	RP11-355B11.2	-3.74	0.000195	0.0112	-0.12	-0.12	Tuberculosis;	chr2:61346152	chr2:61471188~61484130:+
BRCA	cis	rs7267979	0.966	rs2387885	ENSG00000274973.1	RP13-401N8.7	3.74	0.000195	0.0112	0.13	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25434588	chr20:25845497~25845862:+
BRCA	cis	rs7267979	1	rs2424713	ENSG00000274973.1	RP13-401N8.7	-3.74	0.000195	0.0112	-0.13	-0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25437846	chr20:25845497~25845862:+
BRCA	cis	rs4650943	0.658	rs2504486	ENSG00000227740.1	RP11-318C24.2	-3.74	0.000195	0.0112	-0.12	-0.12	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in inactive individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr1:176427273	chr1:175904762~175920513:-
BRCA	cis	rs4950322	0.58	rs1813002	ENSG00000230832.3	RP11-325P15.2	-3.74	0.000195	0.0112	-0.17	-0.12	Protein quantitative trait loci;	chr1:147112579	chr1:147082338~147083578:-
BRCA	cis	rs1722141	0.601	rs788744	ENSG00000237471.1	AC073115.6	3.74	0.000195	0.0112	0.15	0.12	Sitting height ratio;	chr7:46028849	chr7:45969657~45980191:+
BRCA	cis	rs2657888	0.529	rs11171862	ENSG00000257576.1	RP11-153M3.1	-3.74	0.000195	0.0112	-0.15	-0.12	Adiponectin levels;	chr12:56477530	chr12:56511002~56512703:+
BRCA	cis	rs7131987	0.675	rs3847678	ENSG00000257176.2	RP11-996F15.2	3.74	0.000195	0.0112	0.13	0.12	QT interval;	chr12:29398627	chr12:29280418~29317848:-
BRCA	cis	rs7165170	0.529	rs4932357	ENSG00000245479.2	LINC01585	3.74	0.000195	0.0112	0.14	0.12	Crohn's disease;Inflammatory bowel disease;	chr15:90617652	chr15:90660234~90664967:+
BRCA	cis	rs7824557	0.547	rs2409745	ENSG00000255495.1	AC145124.2	3.74	0.000195	0.0112	0.14	0.12	Retinal vascular caliber;	chr8:11219126	chr8:12194467~12196280:+
BRCA	cis	rs11039100	1	rs1470872	ENSG00000224295.2	AC087380.14	3.74	0.000195	0.0112	0.21	0.12	Peripheral arterial disease (traffic-related air pollution interaction);	chr11:5806310	chr11:5518441~5524955:-
BRCA	cis	rs9470794	1	rs73421467	ENSG00000204110.6	RP1-153P14.8	-3.74	0.000195	0.0112	-0.23	-0.12	Type 2 diabetes;	chr6:38000200	chr6:37507348~37535616:+
BRCA	cis	rs6431644	0.622	rs2133840	ENSG00000224287.2	MSL3P1	-3.74	0.000195	0.0112	-0.14	-0.12	Left atrial antero-posterior diameter;	chr2:233883983	chr2:233865437~233868444:-
BRCA	cis	rs721917	0.506	rs2758547	ENSG00000225484.5	NUTM2B-AS1	-3.74	0.000195	0.0112	-0.15	-0.12	Chronic obstructive pulmonary disease;	chr10:79937368	chr10:79663088~79826594:-
BRCA	cis	rs7111546	0.791	rs77245818	ENSG00000246225.5	RP11-17A1.3	3.74	0.000195	0.0112	0.2	0.12	Dialysis-related mortality;	chr11:22842303	chr11:22829380~22945393:+
BRCA	cis	rs7111546	0.791	rs7117614	ENSG00000246225.5	RP11-17A1.3	3.74	0.000195	0.0112	0.2	0.12	Dialysis-related mortality;	chr11:22842445	chr11:22829380~22945393:+
BRCA	cis	rs7620503	1	rs35168340	ENSG00000231574.4	RP11-91K9.1	3.74	0.000195	0.0112	0.13	0.12	Corneal structure;	chr3:177581264	chr3:177816865~177899224:+
BRCA	cis	rs7620503	0.918	rs34316712	ENSG00000231574.4	RP11-91K9.1	3.74	0.000195	0.0112	0.13	0.12	Corneal structure;	chr3:177581277	chr3:177816865~177899224:+
BRCA	cis	rs9517313	0.551	rs2274051	ENSG00000231194.1	FARP1-AS1	3.74	0.000195	0.0112	0.16	0.12	Neuroticism;	chr13:98439380	chr13:98435405~98435840:-
BRCA	cis	rs35520189	0.754	rs16944	ENSG00000189223.12	PAX8-AS1	3.74	0.000196	0.0112	0.16	0.12	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:112837290	chr2:113211522~113276581:+
BRCA	cis	rs853679	0.505	rs200992	ENSG00000216901.1	AL022393.7	3.74	0.000196	0.0112	0.23	0.12	Depression;	chr6:27846899	chr6:28176188~28176674:+
BRCA	cis	rs875971	0.505	rs1167386	ENSG00000232546.1	RP11-458F8.1	3.74	0.000196	0.0112	0.1	0.12	Aortic root size;	chr7:66048109	chr7:66848496~66858136:+
BRCA	cis	rs10129255	0.957	rs10140904	ENSG00000211967.3	IGHV3-53	-3.74	0.000196	0.0112	-0.08	-0.12	Kawasaki disease;	chr14:106776558	chr14:106592676~106593347:-
BRCA	cis	rs957448	0.561	rs34471170	ENSG00000254315.1	RP11-267M23.3	3.74	0.000196	0.0112	0.14	0.12	Nonsyndromic cleft lip with cleft palate;	chr8:94601135	chr8:94533628~94534391:+
BRCA	cis	rs957448	0.561	rs9642927	ENSG00000254315.1	RP11-267M23.3	3.74	0.000196	0.0112	0.14	0.12	Nonsyndromic cleft lip with cleft palate;	chr8:94601414	chr8:94533628~94534391:+
BRCA	cis	rs7520050	0.831	rs61783170	ENSG00000234329.1	RP11-767N6.2	-3.74	0.000196	0.0112	-0.11	-0.12	Reticulocyte count;Red blood cell count;	chr1:45790657	chr1:45651039~45651826:-
BRCA	cis	rs13401620	0.871	rs2136835	ENSG00000229326.3	AC069154.4	-3.74	0.000196	0.0112	-0.15	-0.12	Breast size;	chr2:119856465	chr2:119698623~119700151:+
BRCA	cis	rs10129255	0.912	rs8009135	ENSG00000211967.3	IGHV3-53	-3.74	0.000196	0.0112	-0.08	-0.12	Kawasaki disease;	chr14:106777528	chr14:106592676~106593347:-
BRCA	cis	rs4869313	0.716	rs9127	ENSG00000248734.2	CTD-2260A17.1	-3.74	0.000196	0.0112	-0.11	-0.12	Pediatric autoimmune diseases;	chr5:97036461	chr5:96784777~96785999:+
BRCA	cis	rs657075	0.697	rs3792880	ENSG00000279584.1	AC005593.2	-3.74	0.000196	0.0112	-0.2	-0.12	Rheumatoid arthritis;	chr5:132309272	chr5:131797415~131797929:+
BRCA	cis	rs8099594	0.64	rs2957171	ENSG00000266696.1	RP11-30L3.2	3.74	0.000196	0.0112	0.14	0.12	Height;	chr18:49323901	chr18:49205912~49208781:+
BRCA	cis	rs6813195	0.554	rs2292743	ENSG00000245954.5	RP11-18H21.1	3.74	0.000196	0.0112	0.1	0.12	Type 2 diabetes;	chr4:152411948	chr4:152100754~152104720:+
BRCA	cis	rs721917	0.507	rs2819101	ENSG00000225484.5	NUTM2B-AS1	-3.74	0.000196	0.0112	-0.15	-0.12	Chronic obstructive pulmonary disease;	chr10:79936986	chr10:79663088~79826594:-
BRCA	cis	rs35306767	0.951	rs11253530	ENSG00000229869.1	RP11-363N22.2	-3.74	0.000196	0.0112	-0.19	-0.12	Eosinophil percentage of granulocytes;	chr10:947789	chr10:933026~942743:+
BRCA	cis	rs425277	1	rs809912	ENSG00000269227.1	RP11-345P4.6	3.74	0.000196	0.0112	0.12	0.12	Height;	chr1:2146946	chr1:1673275~1674397:+
BRCA	cis	rs425277	1	rs196128	ENSG00000269227.1	RP11-345P4.6	3.74	0.000196	0.0112	0.12	0.12	Height;	chr1:2147005	chr1:1673275~1674397:+
BRCA	cis	rs425277	1	rs262676	ENSG00000269227.1	RP11-345P4.6	3.74	0.000196	0.0112	0.12	0.12	Height;	chr1:2147043	chr1:1673275~1674397:+
BRCA	cis	rs2803122	0.807	rs10757035	ENSG00000272842.1	RP11-513M16.7	-3.74	0.000196	0.0112	-0.12	-0.12	Pulse pressure;	chr9:19230274	chr9:19371386~19371945:-
BRCA	cis	rs875971	0.862	rs6460290	ENSG00000271064.1	RP11-792A8.3	3.74	0.000196	0.0112	0.13	0.12	Aortic root size;	chr7:66344119	chr7:66748838~66749077:-
BRCA	cis	rs7651736	1	rs7651736	ENSG00000239213.4	NCK1-AS1	3.74	0.000196	0.0112	0.12	0.12	Neuroticism;	chr3:137041756	chr3:136841726~136862054:-
BRCA	cis	rs10463316	0.894	rs3846712	ENSG00000260581.1	CTB-113P19.4	3.74	0.000196	0.0112	0.13	0.12	Metabolite levels (Pyroglutamine);	chr5:151380252	chr5:151652275~151655449:+
BRCA	cis	rs970548	0.954	rs61854096	ENSG00000237840.5	FAM21FP	3.74	0.000196	0.0112	0.15	0.12	Total cholesterol levels;HDL cholesterol;HDL cholesterol levels;Cholesterol, total;	chr10:45485736	chr10:45706431~45727231:-
BRCA	cis	rs7103648	1	rs2293579	ENSG00000280615.1	Y_RNA	3.74	0.000196	0.0112	0.14	0.12	Systolic blood pressure;Diastolic blood pressure;	chr11:47419207	chr11:47614898~47614994:-
BRCA	cis	rs6599077	0.704	rs4293655	ENSG00000223797.4	ENTPD3-AS1	3.74	0.000196	0.0112	0.13	0.12	Sleep-related phenotypes;	chr3:40063850	chr3:40313802~40453329:-
BRCA	cis	rs3750965	0.959	rs3168115	ENSG00000259799.1	RP11-554A11.9	-3.74	0.000196	0.0112	-0.13	-0.12	Hair color;	chr11:69090622	chr11:69155910~69159752:+
BRCA	cis	rs6951245	0.554	rs78999139	ENSG00000224079.1	AC091729.7	-3.74	0.000196	0.0112	-0.17	-0.12	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1098889	chr7:1074450~1078036:+
BRCA	cis	rs3851179	0.503	rs11234568	ENSG00000254479.1	SLC25A1P1	-3.74	0.000196	0.0112	-0.15	-0.12	Alzheimer's disease in APOE e4- carriers;Alzheimer's disease;	chr11:86165180	chr11:85934737~85935663:+
BRCA	cis	rs7267979	1	rs6050555	ENSG00000274414.1	RP5-965G21.4	3.74	0.000196	0.0112	0.14	0.12	Liver enzyme levels (alkaline phosphatase);	chr20:25347907	chr20:25239007~25245229:-
BRCA	cis	rs1005277	0.579	rs1780130	ENSG00000276805.1	RP11-291L22.6	3.74	0.000196	0.0112	0.13	0.12	Extrinsic epigenetic age acceleration;	chr10:38196450	chr10:38451030~38451785:+
BRCA	cis	rs987724	0.964	rs1995425	ENSG00000240875.4	LINC00886	-3.74	0.000196	0.0112	-0.14	-0.12	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156944020	chr3:156747346~156817062:-
BRCA	cis	rs2486012	1	rs1859726	ENSG00000237950.1	RP11-7O11.3	3.74	0.000196	0.0112	0.2	0.12	Intelligence (multi-trait analysis);	chr1:43930543	chr1:43944370~43946551:-
BRCA	cis	rs236114	0.851	rs236116	ENSG00000275632.1	RP5-967N21.11	3.74	0.000196	0.0112	0.15	0.12	Menopause (age at onset);	chr20:5955689	chr20:6000418~6000941:+
BRCA	cis	rs875971	0.862	rs6971059	ENSG00000273024.4	INTS4P2	3.74	0.000196	0.0112	0.13	0.12	Aortic root size;	chr7:66602045	chr7:65647864~65715661:+
BRCA	cis	rs11170468	1	rs61937601	ENSG00000257718.1	RP11-396F22.1	-3.74	0.000196	0.0112	-0.14	-0.12	Body mass index;	chr12:39035877	chr12:38906451~38909592:+
BRCA	cis	rs11170468	1	rs61937603	ENSG00000257718.1	RP11-396F22.1	-3.74	0.000196	0.0112	-0.14	-0.12	Body mass index;	chr12:39035982	chr12:38906451~38909592:+
BRCA	cis	rs10043228	1	rs4398671	ENSG00000271918.1	CTD-2287O16.5	-3.74	0.000196	0.0112	-0.15	-0.12	Asthma or chronic obstructive pulmonary disease;	chr5:116222145	chr5:116083807~116085416:-
BRCA	cis	rs10043228	1	rs1382340	ENSG00000271918.1	CTD-2287O16.5	-3.74	0.000196	0.0112	-0.15	-0.12	Asthma or chronic obstructive pulmonary disease;	chr5:116222464	chr5:116083807~116085416:-
BRCA	cis	rs10043228	1	rs1382339	ENSG00000271918.1	CTD-2287O16.5	-3.74	0.000196	0.0112	-0.15	-0.12	Asthma or chronic obstructive pulmonary disease;	chr5:116222466	chr5:116083807~116085416:-
BRCA	cis	rs10043228	1	rs17139192	ENSG00000271918.1	CTD-2287O16.5	-3.74	0.000196	0.0112	-0.15	-0.12	Asthma or chronic obstructive pulmonary disease;	chr5:116226013	chr5:116083807~116085416:-
BRCA	cis	rs10043228	1	rs17139193	ENSG00000271918.1	CTD-2287O16.5	-3.74	0.000196	0.0112	-0.15	-0.12	Asthma or chronic obstructive pulmonary disease;	chr5:116226376	chr5:116083807~116085416:-
BRCA	cis	rs6012953	0.817	rs1060402	ENSG00000231715.1	COX6CP2	-3.74	0.000196	0.0112	-0.12	-0.12	Vitiligo;	chr20:50588558	chr20:50479767~50479991:+
BRCA	cis	rs6545883	0.929	rs9679557	ENSG00000212978.6	AC016747.3	3.74	0.000196	0.0112	0.16	0.12	Tuberculosis;	chr2:61482214	chr2:61141592~61144969:-
BRCA	cis	rs17711722	0.727	rs35850374	ENSG00000223473.2	GS1-124K5.3	3.74	0.000196	0.0112	0.09	0.12	Calcium levels;	chr7:65892789	chr7:66491049~66493566:-
BRCA	cis	rs6012564	0.928	rs2038509	ENSG00000227431.4	CSE1L-AS1	3.74	0.000196	0.0112	0.14	0.12	Anger;	chr20:49191533	chr20:49040463~49046044:-
BRCA	cis	rs6142618	0.562	rs2281358	ENSG00000275576.1	RP5-836N17.4	-3.74	0.000196	0.0112	-0.13	-0.12	Inflammatory bowel disease;	chr20:32135545	chr20:32116171~32116629:+
BRCA	cis	rs12915845	0.545	rs7402591	ENSG00000271997.1	RP11-97O12.6	-3.74	0.000196	0.0112	-0.09	-0.12	Menarche (age at onset);	chr15:88535203	chr15:88501944~88505787:-
BRCA	cis	rs9818758	0.556	rs9835439	ENSG00000225399.4	RP11-3B7.1	-3.74	0.000196	0.0112	-0.19	-0.12	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49182897	chr3:49260085~49261316:+
BRCA	cis	rs10129255	0.957	rs10138532	ENSG00000211958.2	IGHV3-38	3.74	0.000196	0.0112	0.1	0.12	Kawasaki disease;	chr14:106803901	chr14:106410493~106411021:-
BRCA	cis	rs11098499	0.865	rs4507344	ENSG00000250412.1	KLHL2P1	3.74	0.000196	0.0112	0.14	0.12	Corneal astigmatism;	chr4:119386330	chr4:119334329~119378233:+
BRCA	cis	rs6426833	0.687	rs10799593	ENSG00000117242.7	PINK1-AS	-3.74	0.000196	0.0112	-0.13	-0.12	Ulcerative colitis;Inflammatory bowel disease;	chr1:19890367	chr1:20642657~20652193:-
BRCA	cis	rs6600671	0.934	rs12060031	ENSG00000223345.3	HIST2H2BA	-3.74	0.000196	0.0112	-0.14	-0.12	Hip geometry;	chr1:121501652	chr1:121108210~121117257:-
BRCA	cis	rs6840360	0.571	rs11729136	ENSG00000278978.1	RP11-164P12.5	-3.74	0.000196	0.0112	-0.14	-0.12	Intelligence (multi-trait analysis);	chr4:151608075	chr4:151669786~151670503:+
BRCA	cis	rs4578769	0.879	rs11659315	ENSG00000273232.1	RP11-370A5.2	-3.74	0.000196	0.0112	-0.16	-0.11	Eosinophil percentage of white cells;	chr18:22836405	chr18:22882825~22883357:-
BRCA	cis	rs4578769	0.879	rs11659384	ENSG00000273232.1	RP11-370A5.2	-3.74	0.000196	0.0112	-0.16	-0.11	Eosinophil percentage of white cells;	chr18:22836662	chr18:22882825~22883357:-
BRCA	cis	rs13153459	0.557	rs72750289	ENSG00000279557.1	CTD-2210P15.3	-3.74	0.000196	0.0112	-0.21	-0.11	Parkinson's disease;	chr5:44570699	chr5:43586367~43587543:-
BRCA	cis	rs12188164	0.515	rs2672744	ENSG00000248925.1	CTD-2083E4.6	-3.74	0.000196	0.0112	-0.15	-0.11	Cystic fibrosis severity;	chr5:410932	chr5:269858~271516:-
BRCA	cis	rs875971	0.545	rs221986	ENSG00000232559.3	GS1-124K5.12	-3.74	0.000196	0.0112	-0.16	-0.11	Aortic root size;	chr7:66105323	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.862	rs4718377	ENSG00000229886.1	RP5-1132H15.3	-3.74	0.000196	0.0112	-0.13	-0.11	Aortic root size;	chr7:66584691	chr7:66025126~66031544:-
BRCA	cis	rs875971	0.862	rs10278014	ENSG00000229886.1	RP5-1132H15.3	-3.74	0.000196	0.0112	-0.13	-0.11	Aortic root size;	chr7:66586277	chr7:66025126~66031544:-
BRCA	cis	rs875971	0.928	rs2036263	ENSG00000229886.1	RP5-1132H15.3	-3.74	0.000196	0.0112	-0.13	-0.11	Aortic root size;	chr7:66335210	chr7:66025126~66031544:-
BRCA	cis	rs875971	0.862	rs10240949	ENSG00000229886.1	RP5-1132H15.3	-3.74	0.000196	0.0112	-0.13	-0.11	Aortic root size;	chr7:66339430	chr7:66025126~66031544:-
BRCA	cis	rs875971	0.862	rs7782704	ENSG00000229886.1	RP5-1132H15.3	-3.74	0.000196	0.0112	-0.13	-0.11	Aortic root size;	chr7:66340379	chr7:66025126~66031544:-
BRCA	cis	rs853679	1	rs1679732	ENSG00000216901.1	AL022393.7	-3.74	0.000196	0.0112	-0.19	-0.11	Depression;	chr6:28253486	chr6:28176188~28176674:+
BRCA	cis	rs9990333	0.544	rs11915082	ENSG00000207650.1	MIR570	3.74	0.000196	0.0112	0.14	0.11	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196082268	chr3:195699401~195699497:+
BRCA	cis	rs3816183	0.958	rs7582883	ENSG00000226491.1	FTOP1	-3.74	0.000197	0.0112	-0.15	-0.11	Hypospadias;	chr2:42795864	chr2:42797225~42798712:-
BRCA	cis	rs6012564	1	rs11696396	ENSG00000230758.1	SNAP23P	3.74	0.000197	0.0112	0.13	0.11	Anger;	chr20:49136482	chr20:49038357~49038602:-
BRCA	cis	rs6012564	1	rs6066978	ENSG00000230758.1	SNAP23P	3.74	0.000197	0.0112	0.13	0.11	Anger;	chr20:49139205	chr20:49038357~49038602:-
BRCA	cis	rs6012564	1	rs6063361	ENSG00000230758.1	SNAP23P	3.74	0.000197	0.0112	0.13	0.11	Anger;	chr20:49141426	chr20:49038357~49038602:-
BRCA	cis	rs875971	0.545	rs2707851	ENSG00000273448.1	RP11-166O4.6	-3.74	0.000197	0.0112	-0.12	-0.11	Aortic root size;	chr7:66624178	chr7:67333047~67334383:+
BRCA	cis	rs7712401	0.686	rs185007	ENSG00000251538.4	RP11-166A12.1	3.74	0.000197	0.0112	0.12	0.11	Mean platelet volume;	chr5:122863623	chr5:122628952~122730685:-
BRCA	cis	rs875971	0.862	rs10263690	ENSG00000229886.1	RP5-1132H15.3	-3.74	0.000197	0.0112	-0.13	-0.11	Aortic root size;	chr7:66301466	chr7:66025126~66031544:-
BRCA	cis	rs875971	0.862	rs10250544	ENSG00000229886.1	RP5-1132H15.3	-3.74	0.000197	0.0112	-0.13	-0.11	Aortic root size;	chr7:66301574	chr7:66025126~66031544:-
BRCA	cis	rs867529	0.62	rs335121	ENSG00000253497.1	IGKV1-13	3.74	0.000197	0.0112	0.11	0.11	Height;	chr2:88784810	chr2:89045995~89046466:-
BRCA	cis	rs875971	0.545	rs10950029	ENSG00000226767.1	RP11-328P23.3	3.74	0.000197	0.0112	0.14	0.11	Aortic root size;	chr7:66169334	chr7:65508773~65508944:-
BRCA	cis	rs4664293	0.605	rs890095	ENSG00000224152.1	AC009506.1	3.74	0.000197	0.0112	0.13	0.11	Monocyte percentage of white cells;	chr2:159604708	chr2:159615296~159617082:+
BRCA	cis	rs7572733	1	rs10196612	ENSG00000231621.1	AC013264.2	-3.74	0.000197	0.0112	-0.1	-0.11	Dermatomyositis;	chr2:198029415	chr2:197197991~197199273:+
BRCA	cis	rs10504130	1	rs12678680	ENSG00000272076.1	RP11-11C20.3	3.74	0.000197	0.0112	0.21	0.11	Venous thromboembolism (SNP x SNP interaction);	chr8:51755889	chr8:51810110~51810681:-
BRCA	cis	rs3892630	0.878	rs1061686	ENSG00000267475.1	CTD-2538C1.2	3.74	0.000197	0.0112	0.18	0.11	Red blood cell traits;	chr19:32713638	chr19:32687089~32691750:-
BRCA	cis	rs957448	0.529	rs9642928	ENSG00000254315.1	RP11-267M23.3	3.74	0.000197	0.0112	0.14	0.11	Nonsyndromic cleft lip with cleft palate;	chr8:94601698	chr8:94533628~94534391:+
BRCA	cis	rs3816183	1	rs12998043	ENSG00000226491.1	FTOP1	-3.74	0.000197	0.0112	-0.15	-0.11	Hypospadias;	chr2:42790914	chr2:42797225~42798712:-
BRCA	cis	rs3816183	1	rs10196492	ENSG00000226491.1	FTOP1	-3.74	0.000197	0.0112	-0.15	-0.11	Hypospadias;	chr2:42791394	chr2:42797225~42798712:-
BRCA	cis	rs3816183	0.959	rs2374444	ENSG00000226491.1	FTOP1	-3.74	0.000197	0.0112	-0.15	-0.11	Hypospadias;	chr2:42791504	chr2:42797225~42798712:-
BRCA	cis	rs10129255	1	rs11627342	ENSG00000231475.3	IGHV4-31	-3.74	0.000197	0.0112	-0.09	-0.11	Kawasaki disease;	chr14:106675823	chr14:106349283~106349792:-
BRCA	cis	rs11098499	0.863	rs13136462	ENSG00000225892.3	RP11-384K6.2	3.74	0.000197	0.0112	0.12	0.11	Corneal astigmatism;	chr4:119622018	chr4:118632274~118634759:+
BRCA	cis	rs7712401	0.692	rs9327273	ENSG00000251538.4	RP11-166A12.1	3.74	0.000197	0.0112	0.13	0.11	Mean platelet volume;	chr5:122737855	chr5:122628952~122730685:-
BRCA	cis	rs55986470	0.817	rs66895963	ENSG00000186235.9	AC016757.3	3.74	0.000197	0.0112	0.22	0.11	Chronotype;	chr2:238495261	chr2:238224552~238231677:-
BRCA	cis	rs61931739	0.534	rs1844526	ENSG00000258794.3	DUX4L27	3.74	0.000197	0.0112	0.17	0.11	Morning vs. evening chronotype;	chr12:33949845	chr12:34208415~34209675:-
BRCA	cis	rs61931739	0.517	rs1844525	ENSG00000258794.3	DUX4L27	3.74	0.000197	0.0112	0.17	0.11	Morning vs. evening chronotype;	chr12:33950248	chr12:34208415~34209675:-
BRCA	cis	rs61931739	0.534	rs11053014	ENSG00000258794.3	DUX4L27	3.74	0.000197	0.0112	0.17	0.11	Morning vs. evening chronotype;	chr12:33950584	chr12:34208415~34209675:-
BRCA	cis	rs61931739	0.534	rs11053016	ENSG00000258794.3	DUX4L27	3.74	0.000197	0.0112	0.17	0.11	Morning vs. evening chronotype;	chr12:33951437	chr12:34208415~34209675:-
BRCA	cis	rs61931739	0.534	rs1817761	ENSG00000258794.3	DUX4L27	3.74	0.000197	0.0112	0.17	0.11	Morning vs. evening chronotype;	chr12:33952784	chr12:34208415~34209675:-
BRCA	cis	rs11893307	0.566	rs13412750	ENSG00000235852.1	AC005540.3	3.74	0.000197	0.0112	0.15	0.11	Mean platelet volume;	chr2:190770232	chr2:190880797~190882059:-
BRCA	cis	rs56281245	0.793	rs10515554	ENSG00000249363.1	CTB-78O21.1	-3.74	0.000197	0.0112	-0.22	-0.11	Hepcidin levels;	chr5:145659657	chr5:145728360~145729349:-
BRCA	cis	rs9308731	0.563	rs6760053	ENSG00000230499.1	AC108463.1	-3.74	0.000197	0.0112	-0.13	-0.11	Chronic lymphocytic leukemia;	chr2:111175420	chr2:111195963~111206494:+
BRCA	cis	rs875971	0.862	rs7809814	ENSG00000273024.4	INTS4P2	3.74	0.000197	0.0112	0.13	0.11	Aortic root size;	chr7:66150410	chr7:65647864~65715661:+
BRCA	cis	rs448720	1	rs2219800	ENSG00000260657.2	RP11-315D16.4	-3.74	0.000197	0.0112	-0.14	-0.11	Cognitive performance;	chr15:67916422	chr15:68267792~68277994:-
BRCA	cis	rs8114671	0.562	rs2064454	ENSG00000279253.1	RP4-614O4.13	-3.74	0.000197	0.0112	-0.14	-0.11	Height;	chr20:34908366	chr20:35262727~35264187:-
BRCA	cis	rs4272720	1	rs61166027	ENSG00000228754.1	RP11-534L6.3	-3.74	0.000197	0.0112	-0.16	-0.11	Platelet count;Plateletcrit;	chr10:49072193	chr10:48745545~48746128:-
BRCA	cis	rs10043775	0.793	rs10476892	ENSG00000251330.3	CTD-2283N19.1	-3.74	0.000197	0.0112	-0.14	-0.11	Periodontal microbiota;	chr5:148341160	chr5:148430159~148430807:-
BRCA	cis	rs10864907	0.623	rs10200601	ENSG00000231747.1	AC079922.2	-3.74	0.000197	0.0112	-0.11	-0.11	Pulmonary function;	chr2:112966746	chr2:112621809~112622167:-
BRCA	cis	rs8040855	0.599	rs4643289	ENSG00000230373.7	GOLGA6L5P	-3.74	0.000197	0.0112	-0.12	-0.11	Bulimia nervosa;	chr15:85183483	chr15:84507885~84516814:-
BRCA	cis	rs6479874	1	rs7069183	ENSG00000223502.1	RP11-96B5.3	-3.74	0.000197	0.0112	-0.22	-0.11	Migraine;	chr10:50996579	chr10:51062579~51068553:-
BRCA	cis	rs10851478	0.802	rs12050614	ENSG00000259531.2	RP11-295H24.3	-3.74	0.000197	0.0112	-0.16	-0.11	Oral cavity cancer;	chr15:49497216	chr15:49365124~49366685:-
BRCA	cis	rs1348850	0.914	rs7604673	ENSG00000280374.1	RP11-337N6.3	3.74	0.000197	0.0112	0.16	0.11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177527618	chr2:177317715~177318471:-
BRCA	cis	rs2514805	0.892	rs2251996	ENSG00000253585.1	KB-1184D12.1	3.74	0.000197	0.0112	0.22	0.11	Diisocyanate-induced asthma;	chr8:94148060	chr8:94097764~94104322:-
BRCA	cis	rs12612435	0.866	rs6720240	ENSG00000226806.1	AC011893.3	-3.74	0.000197	0.0112	-0.14	-0.11	Takotsubo syndrome;	chr2:136359764	chr2:135820191~135823087:+
BRCA	cis	rs3096299	0.685	rs4329923	ENSG00000259877.2	RP11-46C24.7	-3.74	0.000197	0.0113	-0.11	-0.11	Multiple myeloma (IgH translocation);	chr16:89493770	chr16:89215211~89217653:-
BRCA	cis	rs2274273	0.623	rs1187877	ENSG00000233924.1	AL160471.6	3.74	0.000197	0.0113	0.13	0.11	Protein biomarker;	chr14:55028443	chr14:55004813~55005687:-
BRCA	cis	rs875971	0.545	rs316306	ENSG00000232559.3	GS1-124K5.12	-3.74	0.000197	0.0113	-0.15	-0.11	Aortic root size;	chr7:66153687	chr7:66554588~66576923:-
BRCA	cis	rs1730008	0.691	rs73170346	ENSG00000279311.1	RP11-170K4.2	3.74	0.000197	0.0113	0.14	0.11	Lobe attachment (rater-scored or self-reported);	chr3:158367724	chr3:158869898~158871821:+
BRCA	cis	rs425277	1	rs262672	ENSG00000269227.1	RP11-345P4.6	3.74	0.000197	0.0113	0.12	0.11	Height;	chr1:2149374	chr1:1673275~1674397:+
BRCA	cis	rs17197037	0.505	rs3748358	ENSG00000211800.3	TRAV20	-3.74	0.000197	0.0113	-0.09	-0.11	Bipolar disorder;	chr14:21321635	chr14:22040594~22041153:+
BRCA	cis	rs3805389	0.504	rs10017749	ENSG00000273257.1	RP11-177J6.1	-3.74	0.000197	0.0113	-0.19	-0.11	Waist-to-hip ratio adjusted for body mass index;	chr4:55613007	chr4:55387949~55388271:+
BRCA	cis	rs595244	1	rs55999498	ENSG00000259705.1	RP11-227D13.1	3.74	0.000197	0.0113	0.18	0.11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48466330	chr15:48645951~48652016:+
BRCA	cis	rs10043775	0.793	rs6580548	ENSG00000251330.3	CTD-2283N19.1	-3.74	0.000197	0.0113	-0.14	-0.11	Periodontal microbiota;	chr5:148352671	chr5:148430159~148430807:-
BRCA	cis	rs9863	0.896	rs7307053	ENSG00000270028.1	RP11-380L11.4	-3.74	0.000197	0.0113	-0.14	-0.11	White blood cell count;	chr12:124009993	chr12:123925461~123926083:-
BRCA	cis	rs2243480	1	rs2961102	ENSG00000226767.1	RP11-328P23.3	-3.74	0.000197	0.0113	-0.2	-0.11	Diabetic kidney disease;	chr7:65959671	chr7:65508773~65508944:-
BRCA	cis	rs801193	0.967	rs2420827	ENSG00000265600.1	AC006480.1	3.74	0.000197	0.0113	0.14	0.11	Aortic root size;	chr7:66682114	chr7:67356680~67356779:+
BRCA	cis	rs875971	0.862	rs2901152	ENSG00000229886.1	RP5-1132H15.3	-3.74	0.000197	0.0113	-0.13	-0.11	Aortic root size;	chr7:66300017	chr7:66025126~66031544:-
BRCA	cis	rs17270561	0.583	rs6908407	ENSG00000272462.2	U91328.19	3.74	0.000197	0.0113	0.14	0.11	Iron status biomarkers;	chr6:25703428	chr6:25992662~26001775:+
BRCA	cis	rs11673344	0.683	rs11668615	ENSG00000267682.1	CTD-3220F14.2	-3.74	0.000197	0.0113	-0.11	-0.11	Obesity-related traits;	chr19:37063632	chr19:37337236~37337743:+
BRCA	cis	rs12446632	0.511	rs13335003	ENSG00000261195.1	CTD-2380F24.1	-3.74	0.000197	0.0113	-0.16	-0.11	Hip circumference;Body mass index (joint analysis main effects and smoking interaction);BMI in smokers;Menarche (age at onset);Obesity;Childhood body mass index;Waist circumference;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Body mass index;	chr16:19893761	chr16:19761172~19766099:-
BRCA	cis	rs76798021	0.935	rs11915489	ENSG00000271976.1	RP11-884K10.7	3.74	0.000197	0.0113	0.16	0.11	Lung function (FEV1/FVC);	chr3:53672564	chr3:53858994~53861576:-
BRCA	cis	rs1005277	0.522	rs11011343	ENSG00000273019.1	RP11-508N22.13	-3.74	0.000197	0.0113	-0.13	-0.11	Extrinsic epigenetic age acceleration;	chr10:37713770	chr10:38149968~38150293:+
BRCA	cis	rs11168351	0.927	rs7971880	ENSG00000257763.1	OR5BK1P	3.74	0.000197	0.0113	0.12	0.11	Bipolar disorder and schizophrenia;	chr12:47997272	chr12:48355792~48356614:-
BRCA	cis	rs11700980	0.636	rs117634508	ENSG00000232855.5	AF131217.1	3.74	0.000197	0.0113	0.21	0.11	QRS complex (12-leadsum);	chr21:28852330	chr21:28439346~28674848:-
BRCA	cis	rs1730008	0.691	rs73170339	ENSG00000279311.1	RP11-170K4.2	3.74	0.000197	0.0113	0.15	0.11	Lobe attachment (rater-scored or self-reported);	chr3:158361037	chr3:158869898~158871821:+
BRCA	cis	rs7520050	0.966	rs12564541	ENSG00000234329.1	RP11-767N6.2	-3.74	0.000197	0.0113	-0.11	-0.11	Reticulocyte count;Red blood cell count;	chr1:45914565	chr1:45651039~45651826:-
BRCA	cis	rs930395	0.514	rs34115673	ENSG00000251141.4	RP11-53O19.1	-3.74	0.000198	0.0113	-0.11	-0.11	Breast cancer;	chr5:44892699	chr5:44744900~44808777:-
BRCA	cis	rs930395	0.514	rs10035358	ENSG00000251141.4	RP11-53O19.1	-3.74	0.000198	0.0113	-0.11	-0.11	Breast cancer;	chr5:44892800	chr5:44744900~44808777:-
BRCA	cis	rs10043228	1	rs12519989	ENSG00000271918.1	CTD-2287O16.5	-3.74	0.000198	0.0113	-0.15	-0.11	Asthma or chronic obstructive pulmonary disease;	chr5:116226945	chr5:116083807~116085416:-
BRCA	cis	rs17684571	0.751	rs35073881	ENSG00000231441.1	RP11-472M19.2	3.74	0.000198	0.0113	0.19	0.11	Schizophrenia;	chr6:56842410	chr6:56844002~56864078:+
BRCA	cis	rs875971	0.862	rs4368860	ENSG00000273024.4	INTS4P2	3.74	0.000198	0.0113	0.13	0.11	Aortic root size;	chr7:66143495	chr7:65647864~65715661:+
BRCA	cis	rs77633900	0.614	rs2629021	ENSG00000196274.5	Metazoa_SRP	3.74	0.000198	0.0113	0.17	0.11	Glioma;Non-glioblastoma glioma;	chr15:76681742	chr15:76230048~76230390:-
BRCA	cis	rs875971	1	rs1981798	ENSG00000272831.1	RP11-792A8.4	3.74	0.000198	0.0113	0.1	0.11	Aortic root size;	chr7:66489916	chr7:66739829~66740385:-
BRCA	cis	rs2143950	0.607	rs58770366	ENSG00000226677.3	IGBP1P1	-3.74	0.000198	0.0113	-0.16	-0.11	Atopic dermatitis;	chr14:35058817	chr14:34939324~34940332:+
BRCA	cis	rs7824557	0.767	rs3808509	ENSG00000154316.13	TDH	-3.74	0.000198	0.0113	-0.16	-0.11	Retinal vascular caliber;	chr8:11305747	chr8:11339637~11368452:+
BRCA	cis	rs236114	0.8	rs6053811	ENSG00000275632.1	RP5-967N21.11	3.74	0.000198	0.0113	0.15	0.11	Menopause (age at onset);	chr20:5981107	chr20:6000418~6000941:+
BRCA	cis	rs236114	0.796	rs6053812	ENSG00000275632.1	RP5-967N21.11	3.74	0.000198	0.0113	0.15	0.11	Menopause (age at onset);	chr20:5981267	chr20:6000418~6000941:+
BRCA	cis	rs6854137	0.967	rs10033898	ENSG00000214676.4	RPL9P16	3.74	0.000198	0.0113	0.13	0.11	Vein graft stenosis in coronary artery bypass grafting;	chr4:168813306	chr4:168755816~168756382:+
BRCA	cis	rs6049003	0.668	rs6132652	ENSG00000232645.4	LINC01431	3.74	0.000198	0.0113	0.13	0.11	Cerebrospinal fluid biomarker levels;	chr20:23723628	chr20:23356594~23358116:-
BRCA	cis	rs7267979	1	rs11100	ENSG00000276952.1	RP5-965G21.6	3.74	0.000198	0.0113	0.14	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25300548	chr20:25284915~25285588:-
BRCA	cis	rs7267979	1	rs1046073	ENSG00000276952.1	RP5-965G21.6	3.74	0.000198	0.0113	0.14	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25300697	chr20:25284915~25285588:-
BRCA	cis	rs7267979	1	rs2259926	ENSG00000276952.1	RP5-965G21.6	3.74	0.000198	0.0113	0.14	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25301097	chr20:25284915~25285588:-
BRCA	cis	rs7267979	1	rs2259928	ENSG00000276952.1	RP5-965G21.6	3.74	0.000198	0.0113	0.14	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25301198	chr20:25284915~25285588:-
BRCA	cis	rs7267979	1	rs2259956	ENSG00000276952.1	RP5-965G21.6	3.74	0.000198	0.0113	0.14	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25301797	chr20:25284915~25285588:-
BRCA	cis	rs4449834	0.851	rs7840098	ENSG00000254432.1	RP11-33I11.2	-3.74	0.000198	0.0113	-0.15	-0.11	Sum eosinophil basophil counts;	chr8:60807186	chr8:60808735~60809606:-
BRCA	cis	rs7412746	0.524	rs58304714	ENSG00000231073.1	RP11-316M1.3	3.74	0.000198	0.0113	0.12	0.11	Melanoma;	chr1:150859085	chr1:150973123~150975534:+
BRCA	cis	rs1538970	0.816	rs868351	ENSG00000281133.1	AL355480.3	-3.74	0.000198	0.0113	-0.16	-0.11	Platelet count;	chr1:45544146	chr1:45580892~45580996:-
BRCA	cis	rs3858526	0.796	rs9645652	ENSG00000224295.2	AC087380.14	3.74	0.000198	0.0113	0.16	0.11	DNA methylation (variation);	chr11:5923034	chr11:5518441~5524955:-
BRCA	cis	rs17684571	0.751	rs35407078	ENSG00000231441.1	RP11-472M19.2	3.74	0.000198	0.0113	0.2	0.11	Schizophrenia;	chr6:56830216	chr6:56844002~56864078:+
BRCA	cis	rs7412746	0.646	rs10399947	ENSG00000231073.1	RP11-316M1.3	3.74	0.000198	0.0113	0.12	0.11	Melanoma;	chr1:150889484	chr1:150973123~150975534:+
BRCA	cis	rs9921338	0.961	rs72773829	ENSG00000263080.1	RP11-485G7.5	3.74	0.000198	0.0113	0.18	0.11	Vein graft stenosis in coronary artery bypass grafting;	chr16:11318766	chr16:11341809~11345211:-
BRCA	cis	rs6696239	1	rs10916162	ENSG00000215812.5	ZNF847P	3.74	0.000198	0.0113	0.16	0.11	Height;	chr1:227550092	chr1:227696892~227706699:-
BRCA	cis	rs7267979	1	rs2258879	ENSG00000276952.1	RP5-965G21.6	3.74	0.000198	0.0113	0.14	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25298577	chr20:25284915~25285588:-
BRCA	cis	rs7267979	1	rs2257496	ENSG00000276952.1	RP5-965G21.6	3.74	0.000198	0.0113	0.14	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25298679	chr20:25284915~25285588:-
BRCA	cis	rs7267979	1	rs2258884	ENSG00000276952.1	RP5-965G21.6	3.74	0.000198	0.0113	0.14	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25298903	chr20:25284915~25285588:-
BRCA	cis	rs7267979	1	rs2259837	ENSG00000276952.1	RP5-965G21.6	3.74	0.000198	0.0113	0.14	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25299569	chr20:25284915~25285588:-
BRCA	cis	rs7267979	1	rs2259873	ENSG00000276952.1	RP5-965G21.6	3.74	0.000198	0.0113	0.14	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25300145	chr20:25284915~25285588:-
BRCA	cis	rs4533720	0.643	rs13119946	ENSG00000248546.3	ANP32C	-3.74	0.000198	0.0113	-0.13	-0.11	Urinary uromodulin levels;	chr4:164040250	chr4:164197007~164197711:-
BRCA	cis	rs12612435	0.793	rs16833925	ENSG00000226806.1	AC011893.3	3.74	0.000198	0.0113	0.13	0.11	Takotsubo syndrome;	chr2:136380343	chr2:135820191~135823087:+
BRCA	cis	rs116175783	0.557	rs7349280	ENSG00000235724.7	AC009299.2	3.74	0.000198	0.0113	0.19	0.11	Intelligence (multi-trait analysis);	chr2:161354120	chr2:161222785~161308303:-
BRCA	cis	rs524281	0.773	rs11227413	ENSG00000255038.1	RP11-1167A19.2	-3.74	0.000198	0.0113	-0.17	-0.11	Electroencephalogram traits;	chr11:66116225	chr11:66067277~66069619:-
BRCA	cis	rs7487075	0.619	rs12822345	ENSG00000257261.4	RP11-96H19.1	3.74	0.000198	0.0113	0.13	0.11	Itch intensity from mosquito bite;	chr12:46440894	chr12:46383679~46876159:+
BRCA	cis	rs7487075	0.619	rs12824565	ENSG00000257261.4	RP11-96H19.1	3.74	0.000198	0.0113	0.13	0.11	Itch intensity from mosquito bite;	chr12:46440910	chr12:46383679~46876159:+
BRCA	cis	rs9648716	0.766	rs801157	ENSG00000240889.1	NDUFB2-AS1	-3.73	0.000198	0.0113	-0.16	-0.11	Type 2 diabetes;	chr7:141081108	chr7:140695336~140697077:-
BRCA	cis	rs7267979	0.816	rs3746337	ENSG00000276952.1	RP5-965G21.6	3.73	0.000198	0.0113	0.14	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25227636	chr20:25284915~25285588:-
BRCA	cis	rs6071166	0.683	rs6027371	ENSG00000224635.1	RP4-564F22.5	-3.73	0.000198	0.0113	-0.14	-0.11	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38697529	chr20:38406011~38416797:-
BRCA	cis	rs17711722	0.701	rs4467826	ENSG00000232546.1	RP11-458F8.1	-3.73	0.000198	0.0113	-0.1	-0.11	Calcium levels;	chr7:65903721	chr7:66848496~66858136:+
BRCA	cis	rs7226408	0.842	rs11660592	ENSG00000267707.2	RP11-95O2.5	3.73	0.000198	0.0113	0.19	0.11	Obesity-related traits;	chr18:36753989	chr18:37243776~37247506:+
BRCA	cis	rs2692947	0.74	rs11695514	ENSG00000168992.4	OR7E102P	3.73	0.000198	0.0113	0.16	0.11	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95882320	chr2:95546531~95547545:+
BRCA	cis	rs6593122	0.606	rs10234085	ENSG00000235454.1	HAUS6P3	-3.73	0.000198	0.0113	-0.15	-0.11	Vaccine-related adverse events;	chr7:54123815	chr7:53862233~53863339:+
BRCA	cis	rs10844706	0.699	rs10772079	ENSG00000256594.6	RP11-705C15.2	3.73	0.000198	0.0113	0.15	0.11	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9721798	chr12:9633419~9658412:+
BRCA	cis	rs72928364	0.929	rs35333915	ENSG00000256628.3	ZBTB11-AS1	3.73	0.000198	0.0113	0.21	0.11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:101068217	chr3:101676475~101679217:+
BRCA	cis	rs73195822	0.667	rs73194062	ENSG00000277299.1	RP11-837J7.4	-3.73	0.000198	0.0113	-0.2	-0.11	Itch intensity from mosquito bite;	chr12:110785489	chr12:109948389~109949029:+
BRCA	cis	rs62064224	0.714	rs11653974	ENSG00000279781.1	RP11-466A19.7	3.73	0.000198	0.0113	0.14	0.11	Schizophrenia;	chr17:32307983	chr17:32518322~32518934:-
BRCA	cis	rs4819052	0.851	rs9974628	ENSG00000215447.6	BX322557.10	-3.73	0.000198	0.0113	-0.12	-0.11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45252732	chr21:45288052~45291738:+
BRCA	cis	rs10043228	1	rs77564939	ENSG00000250015.1	CTC-339F2.2	3.73	0.000198	0.0113	0.15	0.11	Asthma or chronic obstructive pulmonary disease;	chr5:116228597	chr5:116302354~116304134:-
BRCA	cis	rs524281	0.861	rs10750780	ENSG00000255557.1	RP11-770G2.2	3.73	0.000198	0.0113	0.16	0.11	Electroencephalogram traits;	chr11:66207121	chr11:65745729~65771585:+
BRCA	cis	rs16958440	1	rs62096466	ENSG00000267800.1	RP11-49K24.5	-3.73	0.000198	0.0113	-0.25	-0.11	Sitting height ratio;	chr18:47109800	chr18:47137018~47137290:+
BRCA	cis	rs16958440	1	rs76594057	ENSG00000267800.1	RP11-49K24.5	-3.73	0.000198	0.0113	-0.25	-0.11	Sitting height ratio;	chr18:47110901	chr18:47137018~47137290:+
BRCA	cis	rs16958440	1	rs62096469	ENSG00000267800.1	RP11-49K24.5	-3.73	0.000198	0.0113	-0.25	-0.11	Sitting height ratio;	chr18:47111927	chr18:47137018~47137290:+
BRCA	cis	rs16958440	1	rs60228288	ENSG00000267800.1	RP11-49K24.5	-3.73	0.000198	0.0113	-0.25	-0.11	Sitting height ratio;	chr18:47114041	chr18:47137018~47137290:+
BRCA	cis	rs16958440	1	rs62096470	ENSG00000267800.1	RP11-49K24.5	-3.73	0.000198	0.0113	-0.25	-0.11	Sitting height ratio;	chr18:47115095	chr18:47137018~47137290:+
BRCA	cis	rs16958440	1	rs62096471	ENSG00000267800.1	RP11-49K24.5	-3.73	0.000198	0.0113	-0.25	-0.11	Sitting height ratio;	chr18:47117443	chr18:47137018~47137290:+
BRCA	cis	rs16958440	1	rs4609941	ENSG00000267800.1	RP11-49K24.5	-3.73	0.000198	0.0113	-0.25	-0.11	Sitting height ratio;	chr18:47119120	chr18:47137018~47137290:+
BRCA	cis	rs16958440	1	rs57928699	ENSG00000267800.1	RP11-49K24.5	-3.73	0.000198	0.0113	-0.25	-0.11	Sitting height ratio;	chr18:47119222	chr18:47137018~47137290:+
BRCA	cis	rs6759004	1	rs6759004	ENSG00000183308.6	AC005037.3	3.73	0.000198	0.0113	0.19	0.11	Triptolide cytotoxicity;	chr2:201139953	chr2:200963263~201009102:+
BRCA	cis	rs937213	0.573	rs2412464	ENSG00000275636.1	RP11-521C20.5	-3.73	0.000198	0.0113	-0.13	-0.11	Endometrial cancer;Endometrial endometrioid carcinoma;	chr15:40011641	chr15:40078892~40079347:+
BRCA	cis	rs2645288	1	rs2645288	ENSG00000231365.4	RP11-418J17.1	-3.73	0.000198	0.0113	-0.17	-0.11	Breast size;	chr1:118957860	chr1:119140396~119275973:+
BRCA	cis	rs615134	0.581	rs10161111	ENSG00000234608.6	MAPKAPK5-AS1	3.73	0.000198	0.0113	0.21	0.11	Mean corpuscular volume;	chr12:111812396	chr12:111839764~111842902:-
BRCA	cis	rs615134	0.581	rs10160982	ENSG00000234608.6	MAPKAPK5-AS1	3.73	0.000198	0.0113	0.21	0.11	Mean corpuscular volume;	chr12:111812548	chr12:111839764~111842902:-
BRCA	cis	rs10043775	0.793	rs34001290	ENSG00000251330.3	CTD-2283N19.1	-3.73	0.000198	0.0113	-0.13	-0.11	Periodontal microbiota;	chr5:148331881	chr5:148430159~148430807:-
BRCA	cis	rs8049367	0.898	rs7193635	ENSG00000267077.1	RP11-127I20.5	3.73	0.000198	0.0113	0.12	0.11	Nonsyndromic cleft lip with or without cleft palate;	chr16:3922578	chr16:4795265~4796532:-
BRCA	cis	rs10129255	0.957	rs11846893	ENSG00000211967.3	IGHV3-53	-3.73	0.000198	0.0113	-0.08	-0.11	Kawasaki disease;	chr14:106779068	chr14:106592676~106593347:-
BRCA	cis	rs10864907	0.71	rs13029531	ENSG00000231747.1	AC079922.2	-3.73	0.000198	0.0113	-0.11	-0.11	Pulmonary function;	chr2:112973543	chr2:112621809~112622167:-
BRCA	cis	rs699371	0.548	rs2058126	ENSG00000259005.1	RP3-449M8.6	3.73	0.000198	0.0113	0.14	0.11	Height;	chr14:74432576	chr14:74474007~74474864:-
BRCA	cis	rs2243480	0.901	rs35087093	ENSG00000226767.1	RP11-328P23.3	-3.73	0.000198	0.0113	-0.19	-0.11	Diabetic kidney disease;	chr7:65940221	chr7:65508773~65508944:-
BRCA	cis	rs6736093	0.733	rs10176660	ENSG00000236307.2	EEF1E1P1	-3.73	0.000198	0.0113	-0.13	-0.11	Coronary artery disease;	chr2:112055489	chr2:111887914~111888741:+
BRCA	cis	rs7703051	1	rs7703051	ENSG00000271815.1	CTD-2235C13.3	-3.73	0.000198	0.0113	-0.15	-0.11	Age-related diseases, mortality and associated endophenotypes;LDL cholesterol;Age-related disease endophenotypes;	chr5:75329662	chr5:75363760~75364242:+
BRCA	cis	rs7308116	0.676	rs10861832	ENSG00000274395.1	RP11-554D14.8	-3.73	0.000199	0.0113	-0.13	-0.11	Pelvic organ prolapse (moderate/severe);	chr12:107901658	chr12:107835541~107836555:-
BRCA	cis	rs10139154	0.889	rs2045180	ENSG00000258640.3	RPL21P5	3.73	0.000199	0.0113	0.14	0.11	Amyotrophic lateral sclerosis;	chr14:30609296	chr14:31111569~31112239:-
BRCA	cis	rs7620503	0.613	rs11707809	ENSG00000228561.2	RP11-114M1.1	3.73	0.000199	0.0113	0.15	0.11	Corneal structure;	chr3:177567542	chr3:177683627~177691250:+
BRCA	cis	rs4664293	0.967	rs13397722	ENSG00000224152.1	AC009506.1	-3.73	0.000199	0.0113	-0.14	-0.11	Monocyte percentage of white cells;	chr2:159659140	chr2:159615296~159617082:+
BRCA	cis	rs7267979	1	rs2482928	ENSG00000277938.1	RP5-965G21.3	-3.73	0.000199	0.0113	-0.14	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25350894	chr20:25229150~25231933:+
BRCA	cis	rs7523050	0.73	rs41279678	ENSG00000203897.3	SPATA42	-3.73	0.000199	0.0113	-0.22	-0.11	Fat distribution (HIV);	chr1:108897593	chr1:108857217~108858524:+
BRCA	cis	rs683250	0.568	rs651786	ENSG00000254551.1	RP11-727A23.7	3.73	0.000199	0.0113	0.15	0.11	Subcortical brain region volumes;	chr11:83252105	chr11:83209431~83213379:-
BRCA	cis	rs9921338	0.961	rs72773833	ENSG00000263080.1	RP11-485G7.5	3.73	0.000199	0.0113	0.17	0.11	Vein graft stenosis in coronary artery bypass grafting;	chr16:11319417	chr16:11341809~11345211:-
BRCA	cis	rs13434995	0.513	rs13133077	ENSG00000249700.7	SRD5A3-AS1	3.73	0.000199	0.0113	0.17	0.11	Adiponectin levels;	chr4:55577642	chr4:55363971~55395847:-
BRCA	cis	rs13434995	0.513	rs7665286	ENSG00000249700.7	SRD5A3-AS1	3.73	0.000199	0.0113	0.17	0.11	Adiponectin levels;	chr4:55578765	chr4:55363971~55395847:-
BRCA	cis	rs13434995	0.513	rs7683997	ENSG00000249700.7	SRD5A3-AS1	3.73	0.000199	0.0113	0.17	0.11	Adiponectin levels;	chr4:55581272	chr4:55363971~55395847:-
BRCA	cis	rs7615952	1	rs7615952	ENSG00000248787.1	RP11-666A20.4	3.73	0.000199	0.0113	0.18	0.11	Blood pressure (smoking interaction);	chr3:125930560	chr3:125908005~125910272:-
BRCA	cis	rs6859974	0.73	rs7725365	ENSG00000280161.1	CTC-205M6.1	-3.73	0.000199	0.0113	-0.14	-0.11	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr5:180783118	chr5:180810401~180811384:+
BRCA	cis	rs256438	0.524	rs2249687	ENSG00000251050.1	RP11-168A11.4	3.73	0.000199	0.0113	0.12	0.11	Serum thyroid-stimulating hormone levels;	chr5:80057676	chr5:80019609~80019920:+
BRCA	cis	rs2991971	0.81	rs781058	ENSG00000281133.1	AL355480.3	-3.73	0.000199	0.0113	-0.13	-0.11	High light scatter reticulocyte count;	chr1:45469384	chr1:45580892~45580996:-
BRCA	cis	rs875971	0.545	rs11770063	ENSG00000232559.3	GS1-124K5.12	3.73	0.000199	0.0113	0.16	0.11	Aortic root size;	chr7:66318029	chr7:66554588~66576923:-
BRCA	cis	rs9437689	0.966	rs2766010	ENSG00000235501.4	RP4-639F20.1	-3.73	0.000199	0.0113	-0.14	-0.11	Phospholipid levels (plasma);	chr1:94976986	chr1:94927566~94963270:+
BRCA	cis	rs7975161	0.786	rs10861181	ENSG00000257681.1	RP11-341G23.4	-3.73	0.000199	0.0113	-0.16	-0.11	Toenail selenium levels;	chr12:104257332	chr12:103746315~103768858:-
BRCA	cis	rs9309473	0.632	rs11885217	ENSG00000230002.2	ALMS1-IT1	3.73	0.000199	0.0113	0.14	0.11	Metabolite levels;	chr2:73326080	chr2:73456764~73459484:+
BRCA	cis	rs4925540	0.962	rs12141355	ENSG00000215796.3	RP11-551G24.2	3.73	0.000199	0.0113	0.14	0.11	Response to taxane treatment (docetaxel);	chr1:247041192	chr1:247042791~247044021:+
BRCA	cis	rs17270561	0.609	rs1408271	ENSG00000272462.2	U91328.19	-3.73	0.000199	0.0113	-0.14	-0.11	Iron status biomarkers;	chr6:25859393	chr6:25992662~26001775:+
BRCA	cis	rs7474896	1	rs12360411	ENSG00000120555.12	SEPT7P9	3.73	0.000199	0.0113	0.21	0.11	Obesity (extreme);	chr10:37757706	chr10:38383069~38402916:-
BRCA	cis	rs7474896	1	rs10827824	ENSG00000120555.12	SEPT7P9	3.73	0.000199	0.0113	0.21	0.11	Obesity (extreme);	chr10:37758111	chr10:38383069~38402916:-
BRCA	cis	rs568617	0.953	rs658524	ENSG00000254614.2	AP003068.23	3.73	0.000199	0.0113	0.17	0.11	Crohn's disease;	chr11:65879789	chr11:65177606~65181834:-
BRCA	cis	rs875971	0.54	rs1723268	ENSG00000273142.1	RP11-458F8.4	-3.73	0.000199	0.0113	-0.1	-0.11	Aortic root size;	chr7:66008093	chr7:66902857~66906297:+
BRCA	cis	rs10129255	0.789	rs61997796	ENSG00000211967.3	IGHV3-53	-3.73	0.000199	0.0113	-0.09	-0.11	Kawasaki disease;	chr14:106813798	chr14:106592676~106593347:-
BRCA	cis	rs12999616	1	rs12999616	ENSG00000230606.9	AC159540.1	-3.73	0.000199	0.0113	-0.18	-0.11	Colorectal cancer;	chr2:97707918	chr2:97416165~97433527:-
BRCA	cis	rs11098499	0.954	rs6849171	ENSG00000225892.3	RP11-384K6.2	3.73	0.000199	0.0113	0.11	0.11	Corneal astigmatism;	chr4:119488394	chr4:118632274~118634759:+
BRCA	cis	rs11694172	1	rs55866932	ENSG00000273456.1	RP11-686O6.2	3.73	0.000199	0.0113	0.13	0.11	Cholesterol, total;	chr2:202658319	chr2:202374932~202375604:-
BRCA	cis	rs4478858	0.684	rs7528066	ENSG00000223907.1	LINC01226	-3.73	0.000199	0.0113	-0.14	-0.11	Alcohol dependence;	chr1:31276245	chr1:31518435~31524245:+
BRCA	cis	rs4478858	0.684	rs16834336	ENSG00000223907.1	LINC01226	-3.73	0.000199	0.0113	-0.14	-0.11	Alcohol dependence;	chr1:31278665	chr1:31518435~31524245:+
BRCA	cis	rs4478858	0.735	rs11583123	ENSG00000223907.1	LINC01226	-3.73	0.000199	0.0113	-0.14	-0.11	Alcohol dependence;	chr1:31278925	chr1:31518435~31524245:+
BRCA	cis	rs4478858	0.684	rs7549343	ENSG00000223907.1	LINC01226	-3.73	0.000199	0.0113	-0.14	-0.11	Alcohol dependence;	chr1:31279413	chr1:31518435~31524245:+
BRCA	cis	rs4478858	0.709	rs7514640	ENSG00000223907.1	LINC01226	-3.73	0.000199	0.0113	-0.14	-0.11	Alcohol dependence;	chr1:31279469	chr1:31518435~31524245:+
BRCA	cis	rs4478858	0.684	rs16865957	ENSG00000223907.1	LINC01226	-3.73	0.000199	0.0113	-0.14	-0.11	Alcohol dependence;	chr1:31280506	chr1:31518435~31524245:+
BRCA	cis	rs4478858	0.684	rs2062951	ENSG00000223907.1	LINC01226	-3.73	0.000199	0.0113	-0.14	-0.11	Alcohol dependence;	chr1:31290134	chr1:31518435~31524245:+
BRCA	cis	rs4478858	0.647	rs4949380	ENSG00000223907.1	LINC01226	-3.73	0.000199	0.0113	-0.14	-0.11	Alcohol dependence;	chr1:31291313	chr1:31518435~31524245:+
BRCA	cis	rs13393800	1	rs1307667	ENSG00000237126.7	AC073254.1	-3.73	0.000199	0.0113	-0.15	-0.11	Height;	chr2:232555262	chr2:232580948~232611971:-
BRCA	cis	rs2274273	1	rs61508494	ENSG00000233924.1	AL160471.6	-3.73	0.000199	0.0113	-0.13	-0.11	Protein biomarker;	chr14:55120579	chr14:55004813~55005687:-
BRCA	cis	rs4415084	0.834	rs11746980	ENSG00000248779.1	RP11-53O19.2	3.73	0.000199	0.0113	0.11	0.11	Breast cancer;	chr5:44777776	chr5:44752949~44765744:+
BRCA	cis	rs13256369	1	rs13266699	ENSG00000254153.1	CTA-398F10.2	-3.73	0.000199	0.0113	-0.16	-0.11	Obesity-related traits;	chr8:8712803	chr8:8456909~8461337:-
BRCA	cis	rs91731	0.92	rs7708642	ENSG00000249572.1	CTD-2203K17.1	3.73	0.000199	0.0113	0.21	0.11	Lung function (FVC);	chr5:33246962	chr5:33424025~33440619:-
BRCA	cis	rs10771511	1	rs10771511	ENSG00000257599.1	OVCH1-AS1	-3.73	0.000199	0.0113	-0.14	-0.11	Platelet distribution width;	chr12:29284284	chr12:29389294~29487488:+
BRCA	cis	rs7267979	0.714	rs1555329	ENSG00000274414.1	RP5-965G21.4	-3.73	0.000199	0.0113	-0.14	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25251222	chr20:25239007~25245229:-
BRCA	cis	rs875971	0.545	rs2460427	ENSG00000232559.3	GS1-124K5.12	-3.73	0.000199	0.0113	-0.15	-0.11	Aortic root size;	chr7:66154218	chr7:66554588~66576923:-
BRCA	cis	rs9392556	0.666	rs9503922	ENSG00000230648.1	RP3-406P24.3	3.73	0.000199	0.0113	0.19	0.11	Blood metabolite levels;	chr6:4121099	chr6:4018843~4021215:-
BRCA	cis	rs2391285	0.609	rs6959388	ENSG00000280255.1	RP5-1007F24.1	3.73	0.000199	0.0113	0.16	0.11	Post bronchodilator FEV1/FVC ratio;	chr7:26552629	chr7:26538378~26541048:+
BRCA	cis	rs1910358	0.638	rs6887361	ENSG00000248874.4	C5orf17	-3.73	0.000199	0.0113	-0.15	-0.11	Venous thromboembolism (SNP x SNP interaction);	chr5:23950889	chr5:23951348~24178263:+
BRCA	cis	rs801193	0.569	rs13242290	ENSG00000229886.1	RP5-1132H15.3	-3.73	0.000199	0.0113	-0.13	-0.11	Aortic root size;	chr7:66656898	chr7:66025126~66031544:-
BRCA	cis	rs12368653	0.666	rs1050045	ENSG00000257159.1	RP11-58A17.3	-3.73	0.000199	0.0113	-0.13	-0.11	Multiple sclerosis;	chr12:57721488	chr12:57967058~57968399:+
BRCA	cis	rs3816183	1	rs10204098	ENSG00000226491.1	FTOP1	-3.73	0.000199	0.0113	-0.15	-0.11	Hypospadias;	chr2:42790362	chr2:42797225~42798712:-
BRCA	cis	rs3816183	1	rs10204105	ENSG00000226491.1	FTOP1	-3.73	0.000199	0.0113	-0.15	-0.11	Hypospadias;	chr2:42790380	chr2:42797225~42798712:-
BRCA	cis	rs17801127	0.901	rs6709817	ENSG00000231969.1	AC144449.1	3.73	0.000199	0.0113	0.2	0.11	Liver enzyme levels (alanine transaminase);	chr2:149701004	chr2:149587196~149848233:+
BRCA	cis	rs1670533	1	rs6599279	ENSG00000251639.2	RP11-20I20.1	3.73	0.000199	0.0114	0.18	0.11	Recombination rate (females);	chr4:1065045	chr4:1100016~1101558:-
BRCA	cis	rs1437396	0.609	rs3099078	ENSG00000203327.2	AC012358.7	3.73	0.000199	0.0114	0.12	0.11	Alcohol dependence;	chr2:55367806	chr2:55214387~55216126:-
BRCA	cis	rs1437396	0.609	rs3099077	ENSG00000203327.2	AC012358.7	3.73	0.000199	0.0114	0.12	0.11	Alcohol dependence;	chr2:55367808	chr2:55214387~55216126:-
BRCA	cis	rs524281	0.773	rs10791863	ENSG00000255038.1	RP11-1167A19.2	-3.73	0.000199	0.0114	-0.18	-0.11	Electroencephalogram traits;	chr11:66259887	chr11:66067277~66069619:-
BRCA	cis	rs2288884	0.505	rs6509602	ENSG00000275055.1	CTC-471J1.11	-3.73	0.000199	0.0114	-0.17	-0.11	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:51956892	chr19:52049007~52049754:+
BRCA	cis	rs9425766	0.962	rs9425430	ENSG00000227373.4	RP11-160H22.5	3.73	0.000199	0.0114	0.16	0.11	Life satisfaction;	chr1:173888145	chr1:174115300~174160004:-
BRCA	cis	rs9733	0.519	rs72704603	ENSG00000231073.1	RP11-316M1.3	3.73	0.000199	0.0114	0.12	0.11	Tonsillectomy;	chr1:150735516	chr1:150973123~150975534:+
BRCA	cis	rs1424638	0.629	rs4462819	ENSG00000233251.6	AC007743.1	-3.73	0.000199	0.0114	-0.13	-0.11	Intelligence (multi-trait analysis);	chr2:57015489	chr2:56173534~56185770:-
BRCA	cis	rs983392	0.792	rs107903	ENSG00000275344.1	MIR6503	-3.73	0.000199	0.0114	-0.12	-0.11	Alzheimer's disease (late onset);	chr11:60158783	chr11:60209071~60209156:-
BRCA	cis	rs13118159	0.55	rs10016557	ENSG00000196810.4	CTBP1-AS2	-3.73	0.000199	0.0114	-0.14	-0.11	Longevity;	chr4:1369840	chr4:1249300~1288291:+
BRCA	cis	rs3755605	0.76	rs10936612	ENSG00000242578.1	RP11-469J4.3	3.73	0.000199	0.0114	0.13	0.11	Testicular germ cell tumor;	chr3:170127086	chr3:170410512~170418615:+
BRCA	cis	rs11668609	1	rs10414556	ENSG00000268058.1	BNIP3P40	-3.73	0.000199	0.0114	-0.15	-0.11	Response to taxane treatment (docetaxel);	chr19:24186167	chr19:24098425~24098980:-
BRCA	cis	rs848490	1	rs11770446	ENSG00000214293.7	APTR	3.73	0.000199	0.0114	0.15	0.11	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77728755	chr7:77657660~77696265:-
BRCA	cis	rs1143633	0.615	rs11687403	ENSG00000231747.1	AC079922.2	3.73	0.000199	0.0114	0.11	0.11	Allergic disease (asthma, hay fever or eczema);	chr2:112886061	chr2:112621809~112622167:-
BRCA	cis	rs7712401	0.791	rs6595409	ENSG00000251538.4	RP11-166A12.1	3.73	0.000199	0.0114	0.13	0.11	Mean platelet volume;	chr5:122778061	chr5:122628952~122730685:-
BRCA	cis	rs6743226	0.566	rs34006413	ENSG00000266621.1	AC104841.1	3.73	0.000199	0.0114	0.14	0.11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in non-smokers;	chr2:241282044	chr2:241245202~241245299:-
BRCA	cis	rs10129255	1	rs8010605	ENSG00000232216.1	IGHV3-43	3.73	0.000199	0.0114	0.1	0.11	Kawasaki disease;	chr14:106678742	chr14:106470264~106470800:-
BRCA	cis	rs277939	0.905	rs277954	ENSG00000230847.4	RP11-195E2.1	-3.73	0.000199	0.0114	-0.14	-0.11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr5:71618081	chr5:71074225~71093193:-
BRCA	cis	rs198426	0.81	rs198454	ENSG00000243742.4	RPLP0P2	-3.73	0.000199	0.0114	-0.15	-0.11	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr11:61696803	chr11:61615036~61639449:+
BRCA	cis	rs3755605	0.695	rs6444900	ENSG00000242578.1	RP11-469J4.3	3.73	0.000199	0.0114	0.13	0.11	Testicular germ cell tumor;	chr3:170119731	chr3:170410512~170418615:+
BRCA	cis	rs11673344	0.566	rs2385180	ENSG00000267422.1	CTD-2554C21.1	-3.73	0.000199	0.0114	-0.15	-0.11	Obesity-related traits;	chr19:37431454	chr19:37779686~37792865:+
BRCA	cis	rs17123764	0.892	rs74087134	ENSG00000257464.1	RP11-161H23.8	-3.73	0.000199	0.0114	-0.21	-0.11	Intelligence (multi-trait analysis);	chr12:49730474	chr12:49442424~49442652:-
BRCA	cis	rs61160187	0.549	rs61017995	ENSG00000272308.1	RP11-231G3.1	-3.73	0.000199	0.0114	-0.13	-0.11	Educational attainment (years of education);Educational attainment (college completion);	chr5:60968176	chr5:60866457~60866935:-
BRCA	cis	rs6545883	1	rs778763	ENSG00000212978.6	AC016747.3	3.73	0.000199	0.0114	0.16	0.11	Tuberculosis;	chr2:61558504	chr2:61141592~61144969:-
BRCA	cis	rs801193	1	rs7782320	ENSG00000232546.1	RP11-458F8.1	-3.73	0.000199	0.0114	-0.1	-0.11	Aortic root size;	chr7:66712111	chr7:66848496~66858136:+
BRCA	cis	rs524281	0.861	rs7120326	ENSG00000255038.1	RP11-1167A19.2	-3.73	0.000199	0.0114	-0.17	-0.11	Electroencephalogram traits;	chr11:66081785	chr11:66067277~66069619:-
BRCA	cis	rs4689592	0.503	rs56099074	ENSG00000245468.3	RP11-367J11.3	-3.73	0.000199	0.0114	-0.14	-0.11	Monocyte percentage of white cells;	chr4:7069532	chr4:7094571~7103385:-
BRCA	cis	rs6743226	0.603	rs62186405	ENSG00000266621.1	AC104841.1	3.73	0.000199	0.0114	0.14	0.11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in non-smokers;	chr2:241292738	chr2:241245202~241245299:-
BRCA	cis	rs2562456	0.516	rs56072098	ENSG00000213976.4	CTD-2561J22.2	3.73	2e-04	0.0114	0.14	0.11	Pain;	chr19:21469158	chr19:21382865~21387177:+
BRCA	cis	rs6964587	0.967	rs10280620	ENSG00000188693.7	CYP51A1-AS1	3.73	2e-04	0.0114	0.12	0.11	Breast cancer;	chr7:91952869	chr7:92134604~92180725:+
BRCA	cis	rs6964587	1	rs10280927	ENSG00000188693.7	CYP51A1-AS1	3.73	2e-04	0.0114	0.12	0.11	Breast cancer;	chr7:91952891	chr7:92134604~92180725:+
BRCA	cis	rs2274273	0.624	rs1972221	ENSG00000259318.1	RP11-454L9.2	3.73	2e-04	0.0114	0.1	0.11	Protein biomarker;	chr14:55318663	chr14:55394940~55395233:-
BRCA	cis	rs4435363	0.713	rs62136923	ENSG00000268423.3	AC011551.3	3.73	2e-04	0.0114	0.18	0.11	Immature fraction of reticulocytes;P wave terminal force;	chr19:46595260	chr19:46547056~46600861:-
BRCA	cis	rs11673344	0.542	rs1667380	ENSG00000276846.1	CTD-3220F14.3	3.73	2e-04	0.0114	0.14	0.11	Obesity-related traits;	chr19:37001848	chr19:37314868~37315620:-
BRCA	cis	rs7412746	0.634	rs7521592	ENSG00000231073.1	RP11-316M1.3	3.73	2e-04	0.0114	0.12	0.11	Melanoma;	chr1:150849215	chr1:150973123~150975534:+
BRCA	cis	rs7620503	1	rs35921520	ENSG00000231574.4	RP11-91K9.1	3.73	2e-04	0.0114	0.13	0.11	Corneal structure;	chr3:177581444	chr3:177816865~177899224:+
BRCA	cis	rs703108	0.752	rs4550131	ENSG00000279623.1	RP11-399C16.3	3.73	2e-04	0.0114	0.15	0.11	Monocyte percentage of white cells;	chr10:22058145	chr10:21865335~21865921:-
BRCA	cis	rs875971	0.928	rs2036263	ENSG00000273024.4	INTS4P2	3.73	2e-04	0.0114	0.13	0.11	Aortic root size;	chr7:66335210	chr7:65647864~65715661:+
BRCA	cis	rs875971	0.862	rs10240949	ENSG00000273024.4	INTS4P2	3.73	2e-04	0.0114	0.13	0.11	Aortic root size;	chr7:66339430	chr7:65647864~65715661:+
BRCA	cis	rs875971	0.862	rs7782704	ENSG00000273024.4	INTS4P2	3.73	2e-04	0.0114	0.13	0.11	Aortic root size;	chr7:66340379	chr7:65647864~65715661:+
BRCA	cis	rs6696239	0.876	rs4379651	ENSG00000227711.2	RP11-275O4.5	3.73	2e-04	0.0114	0.16	0.11	Height;	chr1:227579238	chr1:227509028~227520477:-
BRCA	cis	rs3764021	0.527	rs11052604	ENSG00000260423.1	RP13-735L24.1	-3.73	2e-04	0.0114	-0.13	-0.11	Type 1 diabetes;	chr12:9709952	chr12:9367464~9397617:+
BRCA	cis	rs9308731	0.583	rs6726007	ENSG00000230499.1	AC108463.1	-3.73	2e-04	0.0114	-0.14	-0.11	Chronic lymphocytic leukemia;	chr2:111174545	chr2:111195963~111206494:+
BRCA	cis	rs17767294	1	rs17767294	ENSG00000219392.1	RP1-265C24.5	-3.73	2e-04	0.0114	-0.24	-0.11	Parkinson's disease;	chr6:28086420	chr6:28115628~28116551:+
BRCA	cis	rs10129255	1	rs10129255	ENSG00000211967.3	IGHV3-53	3.73	2e-04	0.0114	0.08	0.11	Kawasaki disease;	chr14:106767970	chr14:106592676~106593347:-
BRCA	cis	rs6723162	0.51	rs7586455	ENSG00000237751.2	LINC01143	-3.73	2e-04	0.0114	-0.16	-0.11	Neurocognitive impairment in HIV-1 infection (dichotomous);	chr2:70919306	chr2:70887871~70889959:+
BRCA	cis	rs7703051	1	rs3843481	ENSG00000271815.1	CTD-2235C13.3	-3.73	2e-04	0.0114	-0.15	-0.11	Age-related diseases, mortality and associated endophenotypes;LDL cholesterol;Age-related disease endophenotypes;	chr5:75332550	chr5:75363760~75364242:+
BRCA	cis	rs6452524	1	rs10042854	ENSG00000281327.1	LINC01338	-3.73	2e-04	0.0114	-0.13	-0.11	Hypertension (SNP x SNP interaction);	chr5:83143876	chr5:82850864~82859836:-
BRCA	cis	rs859767	0.887	rs859766	ENSG00000224043.6	CCNT2-AS1	-3.73	2e-04	0.0114	-0.17	-0.11	Neuroticism;	chr2:134584684	chr2:134735464~134918710:-
BRCA	cis	rs859767	0.887	rs842348	ENSG00000224043.6	CCNT2-AS1	-3.73	2e-04	0.0114	-0.17	-0.11	Neuroticism;	chr2:134584821	chr2:134735464~134918710:-
BRCA	cis	rs10043775	0.831	rs12521065	ENSG00000251330.3	CTD-2283N19.1	3.73	2e-04	0.0114	0.14	0.11	Periodontal microbiota;	chr5:148374991	chr5:148430159~148430807:-
BRCA	cis	rs9470794	0.831	rs78117167	ENSG00000204110.6	RP1-153P14.8	-3.73	2e-04	0.0114	-0.25	-0.11	Type 2 diabetes;	chr6:37813517	chr6:37507348~37535616:+
BRCA	cis	rs4950322	0.518	rs4950304	ENSG00000230832.3	RP11-325P15.2	-3.73	2e-04	0.0114	-0.17	-0.11	Protein quantitative trait loci;	chr1:147116685	chr1:147082338~147083578:-
BRCA	cis	rs1555322	0.929	rs2247828	ENSG00000279253.1	RP4-614O4.13	3.73	2e-04	0.0114	0.18	0.11	Attention deficit hyperactivity disorder;	chr20:35252136	chr20:35262727~35264187:-
BRCA	cis	rs10844706	0.699	rs10844620	ENSG00000256673.1	RP11-599J14.2	-3.73	2e-04	0.0114	-0.14	-0.11	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9729910	chr12:9398355~9414851:-
BRCA	cis	rs6840360	0.571	rs11099823	ENSG00000270265.1	RP11-731D1.4	-3.73	2e-04	0.0114	-0.13	-0.11	Intelligence (multi-trait analysis);	chr4:151589413	chr4:151333775~151353224:-
BRCA	cis	rs12762955	0.519	rs10795306	ENSG00000205740.2	RP11-363N22.3	-3.73	2e-04	0.0114	-0.12	-0.11	Response to angiotensin II receptor blocker therapy;	chr10:973198	chr10:971146~988341:-
BRCA	cis	rs45509595	0.841	rs370155	ENSG00000216676.2	RP1-15D7.1	-3.73	2e-04	0.0114	-0.19	-0.11	Breast cancer;	chr6:27814253	chr6:27652602~27652825:-
BRCA	cis	rs295490	0.748	rs17395611	ENSG00000178631.7	ACTG1P1	3.73	2e-04	0.0114	0.23	0.11	PR interval in Tripanosoma cruzi seropositivity;	chr3:139425773	chr3:139493809~139494937:+
BRCA	cis	rs7824557	0.767	rs1897951	ENSG00000248896.2	CTD-2135J3.3	3.73	2e-04	0.0114	0.15	0.11	Retinal vascular caliber;	chr8:11312345	chr8:10729314~10771392:+
BRCA	cis	rs116175783	0.557	rs2042487	ENSG00000235724.7	AC009299.2	3.73	2e-04	0.0114	0.19	0.11	Intelligence (multi-trait analysis);	chr2:161293734	chr2:161222785~161308303:-
BRCA	cis	rs798766	0.779	rs55895920	ENSG00000244459.2	RP11-1398P2.1	-3.73	2e-04	0.0114	-0.14	-0.11	Urinary bladder cancer;Bladder cancer;	chr4:1734203	chr4:1574062~1580253:-
BRCA	cis	rs1075265	0.73	rs6711105	ENSG00000272156.1	RP11-477N3.1	-3.73	2e-04	0.0114	-0.12	-0.11	Chronotype;Morning vs. evening chronotype;	chr2:54017775	chr2:54082554~54085066:+
BRCA	cis	rs4664293	0.585	rs34385495	ENSG00000224152.1	AC009506.1	3.73	2e-04	0.0114	0.12	0.11	Monocyte percentage of white cells;	chr2:159656372	chr2:159615296~159617082:+
BRCA	cis	rs7267979	1	rs6050599	ENSG00000204556.4	CTD-2514C3.1	3.73	2e-04	0.0114	0.15	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25419604	chr20:26018832~26020684:+
BRCA	cis	rs6500602	0.627	rs4786494	ENSG00000280063.1	RP11-295D4.3	3.73	2e-04	0.0114	0.09	0.11	Schizophrenia;	chr16:4456231	chr16:4346694~4348648:-
BRCA	cis	rs6772849	0.896	rs61112519	ENSG00000207088.1	SNORA7B	-3.73	2e-04	0.0114	-0.14	-0.11	Monocyte percentage of white cells;Monocyte count;	chr3:128619333	chr3:129397210~129397348:-
BRCA	cis	rs7267979	1	rs2258563	ENSG00000276952.1	RP5-965G21.6	3.73	2e-04	0.0114	0.14	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25292799	chr20:25284915~25285588:-
BRCA	cis	rs495337	0.766	rs6122835	ENSG00000224397.4	LINC01272	3.73	2e-04	0.0114	0.12	0.11	Psoriasis;	chr20:49835961	chr20:50267486~50279795:+
BRCA	cis	rs4835473	0.932	rs17694797	ENSG00000249741.2	RP11-673E1.3	3.73	2e-04	0.0114	0.12	0.11	Immature fraction of reticulocytes;	chr4:143778812	chr4:143911514~143912053:-
BRCA	cis	rs4835473	0.932	rs35947975	ENSG00000249741.2	RP11-673E1.3	3.73	2e-04	0.0114	0.12	0.11	Immature fraction of reticulocytes;	chr4:143778969	chr4:143911514~143912053:-
BRCA	cis	rs4835473	0.932	rs1375987	ENSG00000249741.2	RP11-673E1.3	3.73	2e-04	0.0114	0.12	0.11	Immature fraction of reticulocytes;	chr4:143779622	chr4:143911514~143912053:-
BRCA	cis	rs4835473	0.932	rs7687151	ENSG00000249741.2	RP11-673E1.3	3.73	2e-04	0.0114	0.12	0.11	Immature fraction of reticulocytes;	chr4:143781681	chr4:143911514~143912053:-
BRCA	cis	rs10129255	0.957	rs10136560	ENSG00000232216.1	IGHV3-43	3.73	2e-04	0.0114	0.1	0.11	Kawasaki disease;	chr14:106787630	chr14:106470264~106470800:-
BRCA	cis	rs3858526	0.883	rs4758183	ENSG00000224295.2	AC087380.14	3.73	2e-04	0.0114	0.16	0.11	DNA methylation (variation);	chr11:5903948	chr11:5518441~5524955:-
BRCA	cis	rs4925540	0.962	rs7418825	ENSG00000215796.3	RP11-551G24.2	-3.73	2e-04	0.0114	-0.14	-0.11	Response to taxane treatment (docetaxel);	chr1:247042439	chr1:247042791~247044021:+
BRCA	cis	rs7200543	1	rs72774845	ENSG00000207425.1	Y_RNA	-3.73	2e-04	0.0114	-0.14	-0.11	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15054097	chr16:14915457~14915556:-
BRCA	cis	rs970548	1	rs10900224	ENSG00000237840.5	FAM21FP	3.73	2e-04	0.0114	0.15	0.11	Total cholesterol levels;HDL cholesterol;HDL cholesterol levels;Cholesterol, total;	chr10:45529086	chr10:45706431~45727231:-
BRCA	cis	rs7267979	0.549	rs11698185	ENSG00000277938.1	RP5-965G21.3	3.73	2e-04	0.0114	0.14	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25201362	chr20:25229150~25231933:+
BRCA	cis	rs748404	0.666	rs36078097	ENSG00000166763.7	STRCP1	3.73	2e-04	0.0114	0.16	0.11	Lung cancer;	chr15:43466209	chr15:43699488~43718184:-
BRCA	cis	rs748404	0.666	rs7181783	ENSG00000166763.7	STRCP1	3.73	2e-04	0.0114	0.16	0.11	Lung cancer;	chr15:43469723	chr15:43699488~43718184:-
BRCA	cis	rs748404	0.666	rs35903301	ENSG00000166763.7	STRCP1	3.73	2e-04	0.0114	0.16	0.11	Lung cancer;	chr15:43472332	chr15:43699488~43718184:-
BRCA	cis	rs748404	0.666	rs34002293	ENSG00000166763.7	STRCP1	3.73	2e-04	0.0114	0.16	0.11	Lung cancer;	chr15:43472401	chr15:43699488~43718184:-
BRCA	cis	rs748404	0.666	rs34181131	ENSG00000166763.7	STRCP1	3.73	2e-04	0.0114	0.16	0.11	Lung cancer;	chr15:43478527	chr15:43699488~43718184:-
BRCA	cis	rs748404	0.666	rs7173383	ENSG00000166763.7	STRCP1	3.73	2e-04	0.0114	0.16	0.11	Lung cancer;	chr15:43480838	chr15:43699488~43718184:-
BRCA	cis	rs748404	0.666	rs55801120	ENSG00000166763.7	STRCP1	3.73	2e-04	0.0114	0.16	0.11	Lung cancer;	chr15:43495042	chr15:43699488~43718184:-
BRCA	cis	rs748404	0.666	rs12911740	ENSG00000166763.7	STRCP1	3.73	2e-04	0.0114	0.16	0.11	Lung cancer;	chr15:43498254	chr15:43699488~43718184:-
BRCA	cis	rs4699052	1	rs4699052	ENSG00000251288.2	RP11-10L12.2	-3.73	2e-04	0.0114	-0.13	-0.11	Testicular germ cell tumor;	chr4:103216633	chr4:102751401~102752641:+
BRCA	cis	rs1009077	0.716	rs34676199	ENSG00000245958.5	RP11-33B1.1	3.73	2e-04	0.0114	0.17	0.11	Endometriosis;	chr4:119589154	chr4:119454791~119552025:+
BRCA	cis	rs812925	0.502	rs778150	ENSG00000273302.1	RP11-493E12.2	-3.73	2e-04	0.0114	-0.1	-0.11	Immature fraction of reticulocytes;	chr2:61381237	chr2:61199979~61200769:+
BRCA	cis	rs10992471	0.56	rs12685086	ENSG00000187984.11	ANKRD19P	3.73	2e-04	0.0114	0.11	0.11	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr9:92884838	chr9:92809388~92888693:+
BRCA	cis	rs7917772	0.503	rs7096072	ENSG00000213061.2	PFN1P11	-3.73	2e-04	0.0114	-0.16	-0.11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;	chr10:102540219	chr10:102838011~102845473:-
BRCA	cis	rs28489187	0.706	rs12124170	ENSG00000223653.4	RP11-131L23.1	3.73	2e-04	0.0114	0.13	0.11	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85345499	chr1:85276715~85448124:+
BRCA	cis	rs4845570	0.831	rs11588258	ENSG00000203288.3	RP11-98D18.9	-3.73	2e-04	0.0114	-0.21	-0.11	Coronary artery disease;	chr1:151808252	chr1:151790804~151794402:+
BRCA	cis	rs2998286	0.723	rs332162	ENSG00000237128.1	RP11-351M16.3	3.73	2e-04	0.0114	0.15	0.11	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28599960	chr10:28433008~28495813:-
BRCA	cis	rs1032833	0.732	rs76298720	ENSG00000271401.1	RP11-171I2.3	-3.73	2e-04	0.0114	-0.29	-0.11	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);	chr2:179125626	chr2:178644717~178645179:+
BRCA	cis	rs4730430	0.557	rs10953661	ENSG00000226965.1	AC003088.1	3.73	2e-04	0.0114	0.13	0.11	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr7:110495422	chr7:110432239~110534754:-
BRCA	cis	rs7615952	0.543	rs4645102	ENSG00000248787.1	RP11-666A20.4	-3.73	2e-04	0.0114	-0.17	-0.11	Blood pressure (smoking interaction);	chr3:125705597	chr3:125908005~125910272:-
BRCA	cis	rs4665809	0.941	rs3177055	ENSG00000231655.1	AC011742.3	3.73	2e-04	0.0114	0.17	0.11	Gut microbiome composition (summer);	chr2:26136446	chr2:26140263~26141264:-
BRCA	cis	rs4489787	1	rs2705141	ENSG00000240399.1	RP1-228P16.1	-3.73	2e-04	0.0114	-0.2	-0.11	Prostate cancer (SNP x SNP interaction);	chr12:48530644	chr12:48054813~48055591:-
BRCA	cis	rs2018683	0.677	rs2057956	ENSG00000233517.1	AC005162.5	-3.73	2e-04	0.0114	-0.14	-0.11	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28933843	chr7:28987028~28988899:+
BRCA	cis	rs4835473	0.9	rs4835303	ENSG00000249741.2	RP11-673E1.3	3.73	2e-04	0.0114	0.12	0.11	Immature fraction of reticulocytes;	chr4:143821533	chr4:143911514~143912053:-
BRCA	cis	rs4835473	0.932	rs4835034	ENSG00000249741.2	RP11-673E1.3	3.73	2e-04	0.0114	0.12	0.11	Immature fraction of reticulocytes;	chr4:143821538	chr4:143911514~143912053:-
BRCA	cis	rs6490294	0.571	rs11066120	ENSG00000257624.1	RP1-128M12.3	3.73	2e-04	0.0114	0.19	0.11	Mean platelet volume;	chr12:111998391	chr12:112000739~112000985:-
BRCA	cis	rs6490294	0.571	rs7312472	ENSG00000257624.1	RP1-128M12.3	3.73	2e-04	0.0114	0.19	0.11	Mean platelet volume;	chr12:112000966	chr12:112000739~112000985:-
BRCA	cis	rs6490294	0.571	rs57439171	ENSG00000257624.1	RP1-128M12.3	3.73	2e-04	0.0114	0.19	0.11	Mean platelet volume;	chr12:112001483	chr12:112000739~112000985:-
BRCA	cis	rs6490294	0.571	rs7316650	ENSG00000257624.1	RP1-128M12.3	3.73	2e-04	0.0114	0.19	0.11	Mean platelet volume;	chr12:112001860	chr12:112000739~112000985:-
BRCA	cis	rs6490294	0.571	rs7313773	ENSG00000257624.1	RP1-128M12.3	3.73	2e-04	0.0114	0.19	0.11	Mean platelet volume;	chr12:112003884	chr12:112000739~112000985:-
BRCA	cis	rs1629083	0.967	rs869638	ENSG00000255239.1	AP002954.6	-3.73	2e-04	0.0114	-0.13	-0.11	Lung cancer;	chr11:118229696	chr11:118688039~118690600:-
BRCA	cis	rs3858526	0.883	rs11039584	ENSG00000224295.2	AC087380.14	3.73	2e-04	0.0114	0.16	0.11	DNA methylation (variation);	chr11:5914021	chr11:5518441~5524955:-
BRCA	cis	rs9325144	0.56	rs11182930	ENSG00000257718.1	RP11-396F22.1	-3.73	2e-04	0.0114	-0.12	-0.11	Morning vs. evening chronotype;	chr12:38239891	chr12:38906451~38909592:+
BRCA	cis	rs7267979	0.789	rs62213729	ENSG00000274414.1	RP5-965G21.4	3.73	2e-04	0.0114	0.14	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25382790	chr20:25239007~25245229:-
BRCA	cis	rs11009175	0.929	rs7094668	ENSG00000273038.2	RP11-479G22.8	-3.73	2e-04	0.0114	-0.2	-0.11	Depression (quantitative trait);	chr10:33054429	chr10:32887255~32889311:-
BRCA	cis	rs7131987	0.903	rs918873	ENSG00000257599.1	OVCH1-AS1	-3.73	0.000201	0.0114	-0.14	-0.11	QT interval;	chr12:29237568	chr12:29389294~29487488:+
BRCA	cis	rs80028505	0.908	rs16883860	ENSG00000271304.1	DPRXP2	-3.73	0.000201	0.0114	-0.21	-0.11	Foot ulcer in diabetes and neuropathy;	chr6:36034685	chr6:35989515~35990436:-
BRCA	cis	rs11673344	0.704	rs1726724	ENSG00000267422.1	CTD-2554C21.1	3.73	0.000201	0.0114	0.15	0.11	Obesity-related traits;	chr19:36925890	chr19:37779686~37792865:+
BRCA	cis	rs4925540	1	rs56884994	ENSG00000215796.3	RP11-551G24.2	-3.73	0.000201	0.0114	-0.14	-0.11	Response to taxane treatment (docetaxel);	chr1:247047755	chr1:247042791~247044021:+
BRCA	cis	rs6120849	0.754	rs6088667	ENSG00000202150.1	RNU6-407P	3.73	0.000201	0.0114	0.16	0.11	Protein C levels;	chr20:34978919	chr20:35030317~35030420:-
BRCA	cis	rs7267979	1	rs6050547	ENSG00000276952.1	RP5-965G21.6	-3.73	0.000201	0.0114	-0.14	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25345376	chr20:25284915~25285588:-
BRCA	cis	rs6088580	0.634	rs6141465	ENSG00000275784.1	RP5-1125A11.6	3.73	0.000201	0.0114	0.12	0.11	Glomerular filtration rate (creatinine);	chr20:34379508	chr20:33989480~33991818:-
BRCA	cis	rs3808502	0.525	rs9650661	ENSG00000255020.1	AF131216.5	3.73	0.000201	0.0114	0.14	0.11	Neuroticism;	chr8:11569624	chr8:11345748~11347502:-
BRCA	cis	rs9393777	0.778	rs13219354	ENSG00000220721.1	OR1F12	3.73	0.000201	0.0114	0.21	0.11	Intelligence (multi-trait analysis);	chr6:27217885	chr6:28073316~28074233:+
BRCA	cis	rs7695732	0.7	rs4450885	ENSG00000270720.1	RP11-84C13.2	-3.73	0.000201	0.0114	-0.16	-0.11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr4:88998644	chr4:89119284~89119871:+
BRCA	cis	rs9470794	1	rs55786703	ENSG00000204110.6	RP1-153P14.8	-3.73	0.000201	0.0114	-0.21	-0.11	Type 2 diabetes;	chr6:38005259	chr6:37507348~37535616:+
BRCA	cis	rs2411233	0.935	rs2898672	ENSG00000259278.1	RP11-62C7.2	3.73	0.000201	0.0114	0.14	0.11	Platelet count;	chr15:39000233	chr15:39019233~39024918:+
BRCA	cis	rs875971	0.651	rs2420596	ENSG00000271064.1	RP11-792A8.3	-3.73	0.000201	0.0114	-0.14	-0.11	Aortic root size;	chr7:66450996	chr7:66748838~66749077:-
BRCA	cis	rs875971	0.52	rs2420597	ENSG00000271064.1	RP11-792A8.3	-3.73	0.000201	0.0114	-0.14	-0.11	Aortic root size;	chr7:66450999	chr7:66748838~66749077:-
BRCA	cis	rs78487399	0.808	rs13416978	ENSG00000234936.1	AC010883.5	-3.73	0.000201	0.0114	-0.16	-0.11	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43478126	chr2:43229573~43233394:+
BRCA	cis	rs1816752	0.905	rs4770666	ENSG00000273628.1	RP11-756A22.7	3.73	0.000201	0.0114	0.14	0.11	Obesity-related traits;	chr13:24414891	chr13:24933006~24936796:+
BRCA	cis	rs453301	0.686	rs6601280	ENSG00000233609.3	RP11-62H7.2	3.73	0.000201	0.0114	0.11	0.11	Joint mobility (Beighton score);	chr8:9051726	chr8:8961200~8979025:+
BRCA	cis	rs4073416	0.712	rs11624104	ENSG00000276116.2	FUT8-AS1	-3.73	0.000201	0.0114	-0.12	-0.11	N-glycan levels;	chr14:65729419	chr14:65411170~65412690:-
BRCA	cis	rs739496	0.843	rs598711	ENSG00000234608.6	MAPKAPK5-AS1	3.73	0.000201	0.0114	0.14	0.11	Platelet count;	chr12:111535336	chr12:111839764~111842902:-
BRCA	cis	rs739496	0.843	rs598710	ENSG00000234608.6	MAPKAPK5-AS1	3.73	0.000201	0.0114	0.14	0.11	Platelet count;	chr12:111535337	chr12:111839764~111842902:-
BRCA	cis	rs35146811	0.735	rs1727139	ENSG00000214313.7	AZGP1P1	-3.73	0.000201	0.0114	-0.12	-0.11	Coronary artery disease;	chr7:100217744	chr7:99980762~99987535:+
BRCA	cis	rs1008375	0.931	rs7672369	ENSG00000249502.1	AC006160.5	-3.73	0.000201	0.0114	-0.13	-0.11	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17603202	chr4:17587467~17614571:-
BRCA	cis	rs2708977	0.699	rs631746	ENSG00000271569.1	IGKV1OR2-6	-3.73	0.000201	0.0114	-0.08	-0.11	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96399761	chr2:97355059~97355335:+
BRCA	cis	rs75504410	0.579	rs337643	ENSG00000231160.8	KLF3-AS1	-3.73	0.000201	0.0114	-0.16	-0.11	Sum eosinophil basophil counts;Eosinophil counts;	chr4:38611522	chr4:38612701~38664883:-
BRCA	cis	rs970548	0.817	rs10900235	ENSG00000230869.1	CTGLF10P	3.73	0.000201	0.0114	0.15	0.11	Total cholesterol levels;HDL cholesterol;HDL cholesterol levels;Cholesterol, total;	chr10:45707904	chr10:45678692~45700532:+
BRCA	cis	rs72772090	0.539	rs11740375	ENSG00000272109.1	CTD-2260A17.3	3.73	0.000201	0.0114	0.22	0.11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96777193	chr5:96804353~96806105:+
BRCA	cis	rs481331	0.8	rs9422635	ENSG00000273008.1	RP11-351D16.3	-3.73	0.000201	0.0114	-0.17	-0.11	Systemic juvenile idiopathic arthritis;	chr10:42663717	chr10:43136824~43138334:-
BRCA	cis	rs6088580	0.524	rs7274854	ENSG00000126005.14	MMP24-AS1	-3.73	0.000201	0.0114	-0.13	-0.11	Glomerular filtration rate (creatinine);	chr20:34640868	chr20:35216462~35278131:-
BRCA	cis	rs7045881	0.877	rs62542156	ENSG00000254396.1	RP11-56F10.3	3.73	0.000201	0.0114	0.22	0.11	Schizophrenia;	chr9:26780640	chr9:27102630~27104728:+
BRCA	cis	rs1577917	0.518	rs2475787	ENSG00000220563.1	PKMP3	3.73	0.000201	0.0114	0.11	0.11	Response to antipsychotic treatment;	chr6:85705518	chr6:85659892~85660606:-
BRCA	cis	rs6460942	0.915	rs7803002	ENSG00000226690.5	AC005281.1	3.73	0.000201	0.0114	0.17	0.11	Coronary artery disease;	chr7:12267112	chr7:12496429~12541910:+
BRCA	cis	rs2835872	0.793	rs2835835	ENSG00000228677.1	TTC3-AS1	-3.73	0.000201	0.0114	-0.15	-0.11	Electroencephalographic traits in alcoholism;	chr21:37616770	chr21:37187666~37193926:-
BRCA	cis	rs2835872	0.828	rs73220494	ENSG00000228677.1	TTC3-AS1	-3.73	0.000201	0.0114	-0.15	-0.11	Electroencephalographic traits in alcoholism;	chr21:37616974	chr21:37187666~37193926:-
BRCA	cis	rs2411233	1	rs11855642	ENSG00000259278.1	RP11-62C7.2	3.73	0.000201	0.0114	0.13	0.11	Platelet count;	chr15:38989767	chr15:39019233~39024918:+
BRCA	cis	rs4415084	0.834	rs1048758	ENSG00000248779.1	RP11-53O19.2	3.73	0.000201	0.0114	0.11	0.11	Breast cancer;	chr5:44828492	chr5:44752949~44765744:+
BRCA	cis	rs4415084	0.834	rs7380559	ENSG00000248779.1	RP11-53O19.2	-3.73	0.000201	0.0114	-0.11	-0.11	Breast cancer;	chr5:44836908	chr5:44752949~44765744:+
BRCA	cis	rs41369048	0.858	rs1572384	ENSG00000257551.1	HLX-AS1	-3.73	0.000201	0.0114	-0.16	-0.11	Eosinophil counts;Sum eosinophil basophil counts;	chr1:220907383	chr1:220832763~220880140:-
BRCA	cis	rs2692947	0.726	rs13019188	ENSG00000232931.4	LINC00342	-3.73	0.000201	0.0114	-0.12	-0.11	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96108451	chr2:95807118~95816215:-
BRCA	cis	rs4648045	0.734	rs12509517	ENSG00000251288.2	RP11-10L12.2	-3.73	0.000201	0.0114	-0.15	-0.11	Lymphocyte percentage of white cells;	chr4:102604351	chr4:102751401~102752641:+
BRCA	cis	rs9400180	0.879	rs1064346	ENSG00000271734.1	RP1-111B22.3	-3.73	0.000201	0.0114	-0.15	-0.11	Major depressive disorder;	chr6:108043747	chr6:108030249~108030718:-
BRCA	cis	rs860295	0.812	rs2297775	ENSG00000160766.13	GBAP1	3.73	0.000201	0.0114	0.12	0.11	Body mass index;	chr1:155765221	chr1:155213821~155227422:-
BRCA	cis	rs7429990	0.965	rs62260764	ENSG00000228638.1	FCF1P2	-3.73	0.000201	0.0114	-0.14	-0.11	Educational attainment (years of education);	chr3:47949010	chr3:48290793~48291375:-
BRCA	cis	rs7520050	0.966	rs6429582	ENSG00000281133.1	AL355480.3	-3.73	0.000201	0.0114	-0.13	-0.11	Reticulocyte count;Red blood cell count;	chr1:45856171	chr1:45580892~45580996:-
BRCA	cis	rs794185	0.592	rs304041	ENSG00000231249.1	ITPR1-AS1	3.73	0.000201	0.0115	0.13	0.11	Multiple sclerosis--Brain Glutamate Levels;	chr3:4511284	chr3:4490891~4493163:-
BRCA	cis	rs13434995	0.945	rs55849318	ENSG00000249700.7	SRD5A3-AS1	-3.73	0.000201	0.0115	-0.19	-0.11	Adiponectin levels;	chr4:55615826	chr4:55363971~55395847:-
BRCA	cis	rs10771431	0.817	rs17202253	ENSG00000256069.6	A2MP1	3.73	0.000201	0.0115	0.12	0.11	Breast size;	chr12:9209254	chr12:9228533~9275817:-
BRCA	cis	rs10129255	0.957	rs8022165	ENSG00000232216.1	IGHV3-43	3.73	0.000201	0.0115	0.09	0.11	Kawasaki disease;	chr14:106781682	chr14:106470264~106470800:-
BRCA	cis	rs871012	0.502	rs57064749	ENSG00000251405.2	CTB-109A12.1	-3.73	0.000201	0.0115	-0.16	-0.11	IgG glycosylation;	chr5:157462690	chr5:157362615~157460078:-
BRCA	cis	rs6601450	0.522	rs7837979	ENSG00000154316.13	TDH	-3.73	0.000201	0.0115	-0.14	-0.11	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;	chr8:10341024	chr8:11339637~11368452:+
BRCA	cis	rs1371614	0.589	rs502751	ENSG00000229122.1	AGBL5-IT1	-3.73	0.000201	0.0115	-0.12	-0.11	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26888782	chr2:27061038~27061815:+
BRCA	cis	rs997295	0.737	rs11631474	ENSG00000270964.1	RP11-502I4.3	3.73	0.000201	0.0115	0.13	0.11	Motion sickness;	chr15:67641829	chr15:67541072~67542604:-
BRCA	cis	rs6997458	0.564	rs1995058	ENSG00000258256.1	RP11-219B4.5	-3.73	0.000201	0.0115	-0.13	-0.11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85332685	chr8:85222446~85245717:-
BRCA	cis	rs1468333	0.567	rs12514520	ENSG00000206989.1	SNORD63	3.73	0.000201	0.0115	0.13	0.11	Resting heart rate;	chr5:138442379	chr5:138561043~138561110:-
BRCA	cis	rs17486696	0.51	rs10009649	ENSG00000248771.4	LINC01207	3.73	0.000201	0.0115	0.2	0.11	Positive affect;	chr4:164761828	chr4:164754064~164803795:+
BRCA	cis	rs6049003	0.693	rs6076119	ENSG00000232645.4	LINC01431	3.73	0.000201	0.0115	0.13	0.11	Cerebrospinal fluid biomarker levels;	chr20:23714822	chr20:23356594~23358116:-
BRCA	cis	rs170557	0.573	rs34931444	ENSG00000203706.7	SERTAD4-AS1	-3.73	0.000201	0.0115	-0.14	-0.11	Alopecia areata;	chr1:209951777	chr1:210231456~210234047:-
BRCA	cis	rs8040855	0.965	rs11073990	ENSG00000259774.1	RP11-182J1.13	3.73	0.000201	0.0115	0.13	0.11	Bulimia nervosa;	chr15:85168070	chr15:84422618~84425882:+
BRCA	cis	rs35100037	0.803	rs34057383	ENSG00000249421.1	ADAMTS19-AS1	3.73	0.000201	0.0115	0.25	0.11	Ankle injury;	chr5:129264210	chr5:129459559~129460689:-
BRCA	cis	rs2478118	0.509	rs10796110	ENSG00000273474.1	RP11-295P9.12	-3.73	0.000201	0.0115	-0.12	-0.11	Lupus nephritis in systemic lupus erythematosus;	chr10:13667426	chr10:13675646~13675990:+
BRCA	cis	rs6840360	0.904	rs6825241	ENSG00000251603.1	RP11-164P12.4	-3.73	0.000201	0.0115	-0.1	-0.11	Intelligence (multi-trait analysis);	chr4:151622631	chr4:151667224~151670502:+
BRCA	cis	rs3105593	1	rs2011064	ENSG00000259298.1	RP11-562A8.4	3.73	0.000201	0.0115	0.1	0.11	QT interval;	chr15:50665428	chr15:50497195~50498744:-
BRCA	cis	rs6964587	0.869	rs6946764	ENSG00000188693.7	CYP51A1-AS1	3.73	0.000201	0.0115	0.13	0.11	Breast cancer;	chr7:91909689	chr7:92134604~92180725:+
BRCA	cis	rs4787491	0.658	rs11647753	ENSG00000275371.1	RP11-455F5.6	3.73	0.000201	0.0115	0.11	0.11	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:29916794	chr16:30110895~30111955:+
BRCA	cis	rs8114671	0.662	rs6058146	ENSG00000279253.1	RP4-614O4.13	-3.73	0.000202	0.0115	-0.13	-0.11	Height;	chr20:34952726	chr20:35262727~35264187:-
BRCA	cis	rs9341808	0.935	rs2298307	ENSG00000233967.5	RP11-250B2.3	3.73	0.000202	0.0115	0.12	0.11	Sitting height ratio;	chr6:80106579	chr6:80443344~80465927:+
BRCA	cis	rs718433	0.584	rs2204935	ENSG00000211778.2	TRAV4	-3.73	0.000202	0.0115	-0.08	-0.11	Intraocular pressure;	chr14:21744180	chr14:21736152~21736982:+
BRCA	cis	rs718433	0.584	rs4982492	ENSG00000211778.2	TRAV4	-3.73	0.000202	0.0115	-0.08	-0.11	Intraocular pressure;	chr14:21744535	chr14:21736152~21736982:+
BRCA	cis	rs863345	0.604	rs12041348	ENSG00000176320.2	RP11-404O13.5	-3.73	0.000202	0.0115	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158512252	chr1:158197922~158203877:-
BRCA	cis	rs863345	0.604	rs12041350	ENSG00000176320.2	RP11-404O13.5	-3.73	0.000202	0.0115	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158512258	chr1:158197922~158203877:-
BRCA	cis	rs962856	0.964	rs5022017	ENSG00000236605.1	AC023115.4	3.73	0.000202	0.0115	0.14	0.11	Pancreatic cancer;	chr2:67392045	chr2:67324627~67325304:+
BRCA	cis	rs801193	0.613	rs2016325	ENSG00000265600.1	AC006480.1	3.73	0.000202	0.0115	0.14	0.11	Aortic root size;	chr7:66858513	chr7:67356680~67356779:+
BRCA	cis	rs11098499	0.863	rs3775845	ENSG00000260404.2	RP11-384K6.6	3.73	0.000202	0.0115	0.11	0.11	Corneal astigmatism;	chr4:119511292	chr4:118591773~118633729:+
BRCA	cis	rs1865760	0.964	rs9379802	ENSG00000272810.1	U91328.22	-3.73	0.000202	0.0115	-0.13	-0.11	Height;	chr6:25933670	chr6:26013241~26013757:+
BRCA	cis	rs12234571	0.744	rs17159512	ENSG00000214293.7	APTR	3.73	0.000202	0.0115	0.22	0.11	Obesity-related traits;	chr7:77927697	chr7:77657660~77696265:-
BRCA	cis	rs1008375	0.8	rs10008598	ENSG00000249502.1	AC006160.5	-3.73	0.000202	0.0115	-0.13	-0.11	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17605700	chr4:17587467~17614571:-
BRCA	cis	rs524281	0.773	rs11227448	ENSG00000255038.1	RP11-1167A19.2	-3.73	0.000202	0.0115	-0.18	-0.11	Electroencephalogram traits;	chr11:66281020	chr11:66067277~66069619:-
BRCA	cis	rs11773103	1	rs73206984	ENSG00000224046.1	AC005076.5	3.73	0.000202	0.0115	0.25	0.11	Bipolar disorder or major depressive disorder (combined);	chr7:87182209	chr7:87151423~87152420:-
BRCA	cis	rs8040855	0.627	rs12909971	ENSG00000229212.6	RP11-561C5.4	-3.73	0.000202	0.0115	-0.15	-0.11	Bulimia nervosa;	chr15:85045767	chr15:85205440~85234795:-
BRCA	cis	rs10504130	0.66	rs6473666	ENSG00000253844.1	RP11-546K22.1	-3.73	0.000202	0.0115	-0.15	-0.11	Venous thromboembolism (SNP x SNP interaction);	chr8:51925735	chr8:51961458~52022974:+
BRCA	cis	rs7267979	1	rs2257420	ENSG00000276952.1	RP5-965G21.6	3.73	0.000202	0.0115	0.14	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25295254	chr20:25284915~25285588:-
BRCA	cis	rs3760982	0.585	rs68073292	ENSG00000267191.1	RP11-15A1.2	-3.73	0.000202	0.0115	-0.15	-0.11	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43787249	chr19:43902001~43926545:+
BRCA	cis	rs17684571	0.872	rs34455199	ENSG00000231441.1	RP11-472M19.2	3.73	0.000202	0.0115	0.2	0.11	Schizophrenia;	chr6:56759780	chr6:56844002~56864078:+
BRCA	cis	rs13434995	0.513	rs6802	ENSG00000239040.1	Y_RNA	3.73	0.000202	0.0115	0.14	0.11	Adiponectin levels;	chr4:55425934	chr4:55412636~55412738:+
BRCA	cis	rs465969	0.655	rs13203984	ENSG00000271789.1	RP5-1112D6.7	3.73	0.000202	0.0115	0.27	0.11	Psoriasis;	chr6:111388538	chr6:111297126~111298510:+
BRCA	cis	rs11048434	0.966	rs1805677	ENSG00000256720.1	RP11-436I9.6	3.73	0.000202	0.0115	0.12	0.11	Sjögren's syndrome;	chr12:9000963	chr12:9135084~9135591:+
BRCA	cis	rs794185	0.561	rs304040	ENSG00000231249.1	ITPR1-AS1	3.73	0.000202	0.0115	0.13	0.11	Multiple sclerosis--Brain Glutamate Levels;	chr3:4511137	chr3:4490891~4493163:-
BRCA	cis	rs950776	0.72	rs11637890	ENSG00000279373.1	RP11-650L12.4	-3.73	0.000202	0.0115	-0.15	-0.11	Sudden cardiac arrest;	chr15:78643077	chr15:78537681~78538946:+
BRCA	cis	rs10504130	1	rs41453644	ENSG00000272076.1	RP11-11C20.3	-3.73	0.000202	0.0115	-0.19	-0.11	Venous thromboembolism (SNP x SNP interaction);	chr8:51820984	chr8:51810110~51810681:-
BRCA	cis	rs11039100	1	rs11039110	ENSG00000224295.2	AC087380.14	3.73	0.000202	0.0115	0.22	0.11	Peripheral arterial disease (traffic-related air pollution interaction);	chr11:5807881	chr11:5518441~5524955:-
BRCA	cis	rs11694172	0.826	rs16839308	ENSG00000273456.1	RP11-686O6.2	-3.73	0.000202	0.0115	-0.13	-0.11	Cholesterol, total;	chr2:202757077	chr2:202374932~202375604:-
BRCA	cis	rs494526	0.871	rs10886369	ENSG00000229272.1	RP11-498J9.2	3.73	0.000202	0.0115	0.14	0.11	Alcoholic chronic pancreatitis;	chr10:119024129	chr10:119003536~119003884:-
BRCA	cis	rs6142618	0.562	rs6089193	ENSG00000275576.1	RP5-836N17.4	-3.73	0.000202	0.0115	-0.13	-0.11	Inflammatory bowel disease;	chr20:32141685	chr20:32116171~32116629:+
BRCA	cis	rs6500602	0.893	rs934888	ENSG00000280063.1	RP11-295D4.3	3.73	0.000202	0.0115	0.09	0.11	Schizophrenia;	chr16:4412831	chr16:4346694~4348648:-
BRCA	cis	rs4478858	0.735	rs7556340	ENSG00000260386.4	LINC01225	-3.73	0.000202	0.0115	-0.14	-0.11	Alcohol dependence;	chr1:31315606	chr1:31500085~31540885:+
BRCA	cis	rs7812879	0.929	rs2736344	ENSG00000255354.1	RP11-148O21.2	-3.73	0.000202	0.0115	-0.14	-0.11	Systemic lupus erythematosus;	chr8:11493169	chr8:11558466~11560020:-
BRCA	cis	rs11098499	0.657	rs71614442	ENSG00000225892.3	RP11-384K6.2	3.73	0.000202	0.0115	0.11	0.11	Corneal astigmatism;	chr4:119458191	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.954	rs2892848	ENSG00000225892.3	RP11-384K6.2	3.73	0.000202	0.0115	0.11	0.11	Corneal astigmatism;	chr4:119460186	chr4:118632274~118634759:+
BRCA	cis	rs4974559	0.69	rs28515563	ENSG00000253399.1	AC078852.2	3.73	0.000202	0.0115	0.18	0.11	Systolic blood pressure;	chr4:1321335	chr4:1358479~1359461:+
BRCA	cis	rs6991838	0.584	rs35790435	ENSG00000272155.1	RP11-707M3.3	3.73	0.000202	0.0115	0.11	0.11	Intelligence (multi-trait analysis);	chr8:65590288	chr8:65714334~65714778:-
BRCA	cis	rs13118159	0.742	rs7679860	ENSG00000254094.1	AC078852.1	-3.73	0.000202	0.0115	-0.13	-0.11	Longevity;	chr4:1340199	chr4:1356581~1358075:+
BRCA	cis	rs240993	0.812	rs9374262	ENSG00000255389.1	C6orf3	3.73	0.000202	0.0115	0.13	0.11	Inflammatory skin disease;Psoriasis;	chr6:111553772	chr6:111599875~111602295:+
BRCA	cis	rs10863681	1	rs12135862	ENSG00000200033.1	RNU6-403P	-3.73	0.000202	0.0115	-0.11	-0.11	Metabolite levels (HVA-5-HIAA Factor score);	chr1:222072045	chr1:221837334~221837437:-
BRCA	cis	rs2835872	0.759	rs4816567	ENSG00000228677.1	TTC3-AS1	-3.73	0.000202	0.0115	-0.15	-0.11	Electroencephalographic traits in alcoholism;	chr21:37615853	chr21:37187666~37193926:-
BRCA	cis	rs2446066	0.591	rs11170517	ENSG00000257379.1	RP11-793H13.8	3.73	0.000202	0.0115	0.2	0.11	Red blood cell count;	chr12:53360125	chr12:53441741~53467528:+
BRCA	cis	rs7660883	1	rs2045592	ENSG00000251411.1	RP11-397E7.4	-3.73	0.000202	0.0115	-0.13	-0.11	HDL cholesterol levels;	chr4:87093194	chr4:86913266~86914817:-
BRCA	cis	rs4415084	0.834	rs7711136	ENSG00000248779.1	RP11-53O19.2	3.73	0.000202	0.0115	0.11	0.11	Breast cancer;	chr5:44822977	chr5:44752949~44765744:+
BRCA	cis	rs4415084	0.834	rs7730841	ENSG00000248779.1	RP11-53O19.2	3.73	0.000202	0.0115	0.11	0.11	Breast cancer;	chr5:44823032	chr5:44752949~44765744:+
BRCA	cis	rs4415084	0.834	rs10512865	ENSG00000248779.1	RP11-53O19.2	3.73	0.000202	0.0115	0.11	0.11	Breast cancer;	chr5:44823265	chr5:44752949~44765744:+
BRCA	cis	rs4415084	0.834	rs6867533	ENSG00000248779.1	RP11-53O19.2	3.73	0.000202	0.0115	0.11	0.11	Breast cancer;	chr5:44827190	chr5:44752949~44765744:+
BRCA	cis	rs6430585	0.527	rs57530667	ENSG00000224043.6	CCNT2-AS1	-3.73	0.000202	0.0115	-0.19	-0.11	Corneal structure;	chr2:135686768	chr2:134735464~134918710:-
BRCA	cis	rs6430585	0.527	rs12465544	ENSG00000224043.6	CCNT2-AS1	-3.73	0.000202	0.0115	-0.19	-0.11	Corneal structure;	chr2:135694106	chr2:134735464~134918710:-
BRCA	cis	rs9844666	0.512	rs4718	ENSG00000239213.4	NCK1-AS1	3.73	0.000202	0.0115	0.14	0.11	Height;	chr3:135925965	chr3:136841726~136862054:-
BRCA	cis	rs4834770	1	rs6823963	ENSG00000178636.7	RP11-455G16.1	-3.73	0.000202	0.0115	-0.14	-0.11	Blood protein levels;	chr4:119321009	chr4:119192773~119212644:-
BRCA	cis	rs4834770	1	rs4834771	ENSG00000178636.7	RP11-455G16.1	-3.73	0.000202	0.0115	-0.14	-0.11	Blood protein levels;	chr4:119321617	chr4:119192773~119212644:-
BRCA	cis	rs4834770	1	rs1397613	ENSG00000178636.7	RP11-455G16.1	-3.73	0.000202	0.0115	-0.14	-0.11	Blood protein levels;	chr4:119321774	chr4:119192773~119212644:-
BRCA	cis	rs4834770	1	rs6857641	ENSG00000178636.7	RP11-455G16.1	-3.73	0.000202	0.0115	-0.14	-0.11	Blood protein levels;	chr4:119322356	chr4:119192773~119212644:-
BRCA	cis	rs4834770	1	rs2282688	ENSG00000178636.7	RP11-455G16.1	-3.73	0.000202	0.0115	-0.14	-0.11	Blood protein levels;	chr4:119322567	chr4:119192773~119212644:-
BRCA	cis	rs875971	0.825	rs28480509	ENSG00000223473.2	GS1-124K5.3	-3.73	0.000202	0.0115	-0.09	-0.11	Aortic root size;	chr7:66634237	chr7:66491049~66493566:-
BRCA	cis	rs8114671	0.904	rs6060197	ENSG00000126005.14	MMP24-AS1	3.73	0.000202	0.0115	0.13	0.11	Height;	chr20:35066512	chr20:35216462~35278131:-
BRCA	cis	rs8114671	0.839	rs6142290	ENSG00000126005.14	MMP24-AS1	3.73	0.000202	0.0115	0.13	0.11	Height;	chr20:35066869	chr20:35216462~35278131:-
BRCA	cis	rs8114671	0.869	rs6060199	ENSG00000126005.14	MMP24-AS1	3.73	0.000202	0.0115	0.13	0.11	Height;	chr20:35066970	chr20:35216462~35278131:-
BRCA	cis	rs8064024	0.599	rs2456779	ENSG00000267077.1	RP11-127I20.5	3.73	0.000202	0.0115	0.12	0.11	Cancer;	chr16:4875816	chr16:4795265~4796532:-
BRCA	cis	rs3740393	0.562	rs60459635	ENSG00000213277.3	MARCKSL1P1	3.73	0.000202	0.0115	0.16	0.11	Microalbuminuria;	chr10:102741231	chr10:103175554~103176094:+
BRCA	cis	rs890448	0.796	rs2433310	ENSG00000254531.1	FLJ20021	3.73	0.000202	0.0115	0.13	0.11	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101431756	chr4:101347780~101348883:+
BRCA	cis	rs7656342	0.754	rs12509511	ENSG00000250342.1	SNRPCP16	-3.73	0.000202	0.0115	-0.13	-0.11	Gut microbiota (bacterial taxa);	chr4:9767939	chr4:9051842~9052051:-
BRCA	cis	rs2991971	0.967	rs60608374	ENSG00000280836.1	AL355480.1	3.73	0.000202	0.0115	0.13	0.11	High light scatter reticulocyte count;	chr1:45543241	chr1:45581219~45581321:-
BRCA	cis	rs6121246	0.954	rs6058470	ENSG00000230613.1	HM13-AS1	3.73	0.000203	0.0115	0.17	0.11	Mean corpuscular hemoglobin;	chr20:31829024	chr20:31567707~31573263:-
BRCA	cis	rs3805389	0.504	rs10017749	ENSG00000249700.7	SRD5A3-AS1	-3.73	0.000203	0.0115	-0.18	-0.11	Waist-to-hip ratio adjusted for body mass index;	chr4:55613007	chr4:55363971~55395847:-
BRCA	cis	rs11098499	0.866	rs6857892	ENSG00000225892.3	RP11-384K6.2	3.73	0.000203	0.0115	0.11	0.11	Corneal astigmatism;	chr4:119361541	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.909	rs28581362	ENSG00000225892.3	RP11-384K6.2	3.73	0.000203	0.0115	0.11	0.11	Corneal astigmatism;	chr4:119362393	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.82	rs12503082	ENSG00000225892.3	RP11-384K6.2	3.73	0.000203	0.0115	0.11	0.11	Corneal astigmatism;	chr4:119363162	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.866	rs12499602	ENSG00000225892.3	RP11-384K6.2	3.73	0.000203	0.0115	0.11	0.11	Corneal astigmatism;	chr4:119363232	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.774	rs11098505	ENSG00000225892.3	RP11-384K6.2	3.73	0.000203	0.0115	0.11	0.11	Corneal astigmatism;	chr4:119363472	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.866	rs13105020	ENSG00000225892.3	RP11-384K6.2	3.73	0.000203	0.0115	0.11	0.11	Corneal astigmatism;	chr4:119364533	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.866	rs6824111	ENSG00000225892.3	RP11-384K6.2	3.73	0.000203	0.0115	0.11	0.11	Corneal astigmatism;	chr4:119364813	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.775	rs10029303	ENSG00000225892.3	RP11-384K6.2	3.73	0.000203	0.0115	0.11	0.11	Corneal astigmatism;	chr4:119365600	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.866	rs9995136	ENSG00000225892.3	RP11-384K6.2	3.73	0.000203	0.0115	0.11	0.11	Corneal astigmatism;	chr4:119365690	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.866	rs13125526	ENSG00000225892.3	RP11-384K6.2	3.73	0.000203	0.0115	0.11	0.11	Corneal astigmatism;	chr4:119366864	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.866	rs12513310	ENSG00000225892.3	RP11-384K6.2	3.73	0.000203	0.0115	0.11	0.11	Corneal astigmatism;	chr4:119366884	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.866	rs12510451	ENSG00000225892.3	RP11-384K6.2	3.73	0.000203	0.0115	0.11	0.11	Corneal astigmatism;	chr4:119367988	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.774	rs73842616	ENSG00000225892.3	RP11-384K6.2	3.73	0.000203	0.0115	0.11	0.11	Corneal astigmatism;	chr4:119369528	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.645	rs72676059	ENSG00000225892.3	RP11-384K6.2	3.73	0.000203	0.0115	0.11	0.11	Corneal astigmatism;	chr4:119369673	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.569	rs55845118	ENSG00000225892.3	RP11-384K6.2	3.73	0.000203	0.0115	0.11	0.11	Corneal astigmatism;	chr4:119369758	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.866	rs7677068	ENSG00000225892.3	RP11-384K6.2	3.73	0.000203	0.0115	0.11	0.11	Corneal astigmatism;	chr4:119370549	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.866	rs9991221	ENSG00000225892.3	RP11-384K6.2	3.73	0.000203	0.0115	0.11	0.11	Corneal astigmatism;	chr4:119370952	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.954	rs11729521	ENSG00000225892.3	RP11-384K6.2	3.73	0.000203	0.0115	0.12	0.11	Corneal astigmatism;	chr4:119495633	chr4:118632274~118634759:+
BRCA	cis	rs6142618	0.562	rs6061173	ENSG00000275576.1	RP5-836N17.4	-3.73	0.000203	0.0115	-0.12	-0.11	Inflammatory bowel disease;	chr20:32129312	chr20:32116171~32116629:+
BRCA	cis	rs970548	0.955	rs10900223	ENSG00000237840.5	FAM21FP	3.73	0.000203	0.0115	0.15	0.11	Total cholesterol levels;HDL cholesterol;HDL cholesterol levels;Cholesterol, total;	chr10:45526183	chr10:45706431~45727231:-
BRCA	cis	rs2880765	0.835	rs4280192	ENSG00000230373.7	GOLGA6L5P	3.73	0.000203	0.0115	0.12	0.11	Coronary artery disease;	chr15:85499789	chr15:84507885~84516814:-
BRCA	cis	rs1549733	0.552	rs34681466	ENSG00000229754.1	CXCR2P1	-3.73	0.000203	0.0115	-0.11	-0.11	Optic disc area;	chr2:217551599	chr2:218059155~218065729:-
BRCA	cis	rs4950322	0.634	rs4950415	ENSG00000237188.3	RP11-337C18.8	3.73	0.000203	0.0115	0.15	0.11	Protein quantitative trait loci;	chr1:147350951	chr1:147172771~147211568:+
BRCA	cis	rs3781264	0.595	rs6583937	ENSG00000268894.5	PLCE1-AS1	-3.73	0.000203	0.0115	-0.15	-0.11	Esophageal cancer and gastric cancer;	chr10:94323695	chr10:94279277~94287478:-
BRCA	cis	rs875971	1	rs2420820	ENSG00000273448.1	RP11-166O4.6	-3.73	0.000203	0.0115	-0.11	-0.11	Aortic root size;	chr7:66626920	chr7:67333047~67334383:+
BRCA	cis	rs7172677	0.737	rs6495154	ENSG00000260269.4	CTD-2323K18.1	-3.73	0.000203	0.0115	-0.16	-0.11	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75144921	chr15:75527150~75601205:-
BRCA	cis	rs7172677	0.737	rs12442410	ENSG00000260269.4	CTD-2323K18.1	-3.73	0.000203	0.0115	-0.16	-0.11	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75145169	chr15:75527150~75601205:-
BRCA	cis	rs17684571	0.872	rs34803237	ENSG00000231441.1	RP11-472M19.2	3.73	0.000203	0.0115	0.2	0.11	Schizophrenia;	chr6:56759620	chr6:56844002~56864078:+
BRCA	cis	rs9470794	1	rs28740822	ENSG00000204110.6	RP1-153P14.8	-3.73	0.000203	0.0115	-0.21	-0.11	Type 2 diabetes;	chr6:38040514	chr6:37507348~37535616:+
BRCA	cis	rs1730008	0.691	rs6807468	ENSG00000279311.1	RP11-170K4.2	3.73	0.000203	0.0115	0.15	0.11	Lobe attachment (rater-scored or self-reported);	chr3:158326591	chr3:158869898~158871821:+
BRCA	cis	rs251253	0.76	rs3095844	ENSG00000253959.1	CTB-43E15.1	3.73	0.000203	0.0115	0.1	0.11	PR interval;	chr5:173057038	chr5:173642519~173658194:+
BRCA	cis	rs7267979	1	rs2500443	ENSG00000277938.1	RP5-965G21.3	-3.73	0.000203	0.0115	-0.14	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25350806	chr20:25229150~25231933:+
BRCA	cis	rs10463316	0.894	rs13361298	ENSG00000260581.1	CTB-113P19.4	3.73	0.000203	0.0115	0.13	0.11	Metabolite levels (Pyroglutamine);	chr5:151385988	chr5:151652275~151655449:+
BRCA	cis	rs10463316	0.894	rs7708499	ENSG00000260581.1	CTB-113P19.4	3.73	0.000203	0.0115	0.13	0.11	Metabolite levels (Pyroglutamine);	chr5:151386345	chr5:151652275~151655449:+
BRCA	cis	rs10463316	0.894	rs7712569	ENSG00000260581.1	CTB-113P19.4	3.73	0.000203	0.0115	0.13	0.11	Metabolite levels (Pyroglutamine);	chr5:151386528	chr5:151652275~151655449:+
BRCA	cis	rs8038465	0.615	rs6495075	ENSG00000260898.4	ADPGK-AS1	3.73	0.000203	0.0115	0.12	0.11	Liver enzyme levels (gamma-glutamyl transferase);	chr15:73688664	chr15:72782835~72798199:+
BRCA	cis	rs812925	0.537	rs2463097	ENSG00000270820.4	RP11-355B11.2	-3.73	0.000203	0.0115	-0.12	-0.11	Immature fraction of reticulocytes;	chr2:61387166	chr2:61471188~61484130:+
BRCA	cis	rs17772222	1	rs3814855	ENSG00000258789.1	RP11-507K2.3	-3.73	0.000203	0.0115	-0.14	-0.11	Coronary artery calcification;	chr14:88467016	chr14:88551597~88552493:+
BRCA	cis	rs7712401	0.791	rs10063253	ENSG00000251538.4	RP11-166A12.1	3.73	0.000203	0.0115	0.13	0.11	Mean platelet volume;	chr5:122793016	chr5:122628952~122730685:-
BRCA	cis	rs7429990	0.965	rs4858881	ENSG00000228638.1	FCF1P2	3.73	0.000203	0.0115	0.11	0.11	Educational attainment (years of education);	chr3:48082306	chr3:48290793~48291375:-
BRCA	cis	rs17772222	0.917	rs57889459	ENSG00000258789.1	RP11-507K2.3	-3.73	0.000203	0.0115	-0.14	-0.11	Coronary artery calcification;	chr14:88770820	chr14:88551597~88552493:+
BRCA	cis	rs853679	0.585	rs201001	ENSG00000216901.1	AL022393.7	3.73	0.000203	0.0115	0.18	0.11	Depression;	chr6:27841121	chr6:28176188~28176674:+
BRCA	cis	rs853679	0.585	rs201000	ENSG00000216901.1	AL022393.7	3.73	0.000203	0.0115	0.18	0.11	Depression;	chr6:27841381	chr6:28176188~28176674:+
BRCA	cis	rs62458065	0.85	rs7804998	ENSG00000281332.1	LINC00997	-3.73	0.000203	0.0115	-0.17	-0.11	Metabolite levels (HVA/MHPG ratio);	chr7:32421585	chr7:32760279~32762924:+
BRCA	cis	rs11098499	0.954	rs11940028	ENSG00000225892.3	RP11-384K6.2	3.73	0.000203	0.0115	0.12	0.11	Corneal astigmatism;	chr4:119490752	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.954	rs11935596	ENSG00000225892.3	RP11-384K6.2	3.73	0.000203	0.0115	0.12	0.11	Corneal astigmatism;	chr4:119491302	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.954	rs12507964	ENSG00000225892.3	RP11-384K6.2	3.73	0.000203	0.0115	0.12	0.11	Corneal astigmatism;	chr4:119491906	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.909	rs11098530	ENSG00000225892.3	RP11-384K6.2	3.73	0.000203	0.0115	0.12	0.11	Corneal astigmatism;	chr4:119491999	chr4:118632274~118634759:+
BRCA	cis	rs17428076	0.914	rs72889094	ENSG00000228389.1	AC068039.4	-3.73	0.000203	0.0115	-0.17	-0.11	Myopia;	chr2:171938249	chr2:171773482~171775844:+
BRCA	cis	rs6142618	0.562	rs6061186	ENSG00000275576.1	RP5-836N17.4	-3.73	0.000203	0.0116	-0.12	-0.11	Inflammatory bowel disease;	chr20:32143937	chr20:32116171~32116629:+
BRCA	cis	rs2281558	0.876	rs6115135	ENSG00000274414.1	RP5-965G21.4	-3.73	0.000203	0.0116	-0.15	-0.11	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25299242	chr20:25239007~25245229:-
BRCA	cis	rs1396626	0.926	rs870984	ENSG00000235501.4	RP4-639F20.1	-3.73	0.000203	0.0116	-0.15	-0.11	Diabetic kidney disease;	chr1:95529296	chr1:94927566~94963270:+
BRCA	cis	rs251253	0.792	rs387291	ENSG00000253959.1	CTB-43E15.1	3.73	0.000203	0.0116	0.1	0.11	PR interval;	chr5:173066958	chr5:173642519~173658194:+
BRCA	cis	rs11098499	0.874	rs28452522	ENSG00000260091.1	RP11-33B1.4	-3.73	0.000203	0.0116	-0.11	-0.11	Corneal astigmatism;	chr4:119189629	chr4:119409333~119410233:+
BRCA	cis	rs7246967	0.736	rs453723	ENSG00000198153.8	ZNF849P	-3.73	0.000203	0.0116	-0.17	-0.11	Bronchopulmonary dysplasia;	chr19:22815687	chr19:22685167~22686732:+
BRCA	cis	rs4664293	0.934	rs1365800	ENSG00000224152.1	AC009506.1	-3.73	0.000203	0.0116	-0.13	-0.11	Monocyte percentage of white cells;	chr2:159699112	chr2:159615296~159617082:+
BRCA	cis	rs10883723	0.962	rs1056738	ENSG00000213061.2	PFN1P11	-3.73	0.000203	0.0116	-0.16	-0.11	Allergic disease (asthma, hay fever or eczema);	chr10:102476724	chr10:102838011~102845473:-
BRCA	cis	rs80028505	0.908	rs56156688	ENSG00000271304.1	DPRXP2	3.73	0.000203	0.0116	0.23	0.11	Foot ulcer in diabetes and neuropathy;	chr6:36027856	chr6:35989515~35990436:-
BRCA	cis	rs6012564	1	rs3092411	ENSG00000230758.1	SNAP23P	-3.73	0.000203	0.0116	-0.13	-0.11	Anger;	chr20:49074054	chr20:49038357~49038602:-
BRCA	cis	rs4557020	0.904	rs4671219	ENSG00000162997.14	PRORSD1P	-3.73	0.000203	0.0116	-0.12	-0.11	Myopia (pathological);	chr2:54496551	chr2:55282319~55284522:+
BRCA	cis	rs721917	0.525	rs2246111	ENSG00000280355.1	RP11-119F19.5	-3.73	0.000203	0.0116	-0.13	-0.11	Chronic obstructive pulmonary disease;	chr10:79929985	chr10:79681973~79684094:-
BRCA	cis	rs7267979	1	rs4815408	ENSG00000276952.1	RP5-965G21.6	-3.73	0.000204	0.0116	-0.14	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25366042	chr20:25284915~25285588:-
BRCA	cis	rs62458065	0.713	rs62463968	ENSG00000273014.1	RP11-225B17.2	-3.73	0.000204	0.0116	-0.18	-0.11	Metabolite levels (HVA/MHPG ratio);	chr7:32461630	chr7:32758882~32759353:+
BRCA	cis	rs8180040	0.701	rs7617689	ENSG00000280667.1	Y_RNA	-3.73	0.000204	0.0116	-0.13	-0.11	Colorectal cancer;	chr3:46954952	chr3:47501083~47501182:+
BRCA	cis	rs801193	0.569	rs10950050	ENSG00000265600.1	AC006480.1	-3.73	0.000204	0.0116	-0.14	-0.11	Aortic root size;	chr7:66774601	chr7:67356680~67356779:+
BRCA	cis	rs6928977	0.86	rs2614264	ENSG00000231028.7	LINC00271	-3.73	0.000204	0.0116	-0.11	-0.11	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135389556	chr6:135497801~135716055:+
BRCA	cis	rs13098911	0.54	rs13078739	ENSG00000223552.1	RP11-24F11.2	-3.73	0.000204	0.0116	-0.19	-0.11	Celiac disease;	chr3:45965996	chr3:46364955~46407059:-
BRCA	cis	rs1355223	0.902	rs34875830	ENSG00000271369.1	RP11-350D17.3	-3.73	0.000204	0.0116	-0.13	-0.11	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34700658	chr11:34709600~34710161:+
BRCA	cis	rs11043280	0.703	rs11043275	ENSG00000272849.1	RP11-347I19.8	-3.73	0.000204	0.0116	-0.09	-0.11	Mean platelet volume;	chr12:121964817	chr12:121797511~121801972:+
BRCA	cis	rs11098499	0.955	rs13113112	ENSG00000260404.2	RP11-384K6.6	3.73	0.000204	0.0116	0.11	0.11	Corneal astigmatism;	chr4:119234885	chr4:118591773~118633729:+
BRCA	cis	rs2640806	0.67	rs7822351	ENSG00000253105.4	KB-1448A5.1	3.73	0.000204	0.0116	0.14	0.11	Obesity-related traits;	chr8:96313859	chr8:96371865~96387438:-
BRCA	cis	rs6968419	0.585	rs10953816	ENSG00000279086.1	RP11-667F14.1	-3.73	0.000204	0.0116	-0.11	-0.11	Intraocular pressure;	chr7:116278473	chr7:116209234~116211511:-
BRCA	cis	rs7111546	1	rs1055321	ENSG00000246225.5	RP11-17A1.3	3.73	0.000204	0.0116	0.2	0.11	Dialysis-related mortality;	chr11:22812856	chr11:22829380~22945393:+
BRCA	cis	rs962856	0.633	rs6755775	ENSG00000236780.4	AC078941.1	-3.73	0.000204	0.0116	-0.24	-0.11	Pancreatic cancer;	chr2:67371451	chr2:67123357~67215319:-
BRCA	cis	rs13393800	1	rs13393692	ENSG00000237126.7	AC073254.1	-3.73	0.000204	0.0116	-0.15	-0.11	Height;	chr2:232577306	chr2:232580948~232611971:-
BRCA	cis	rs11648785	0.661	rs870856	ENSG00000274627.1	RP11-104N10.2	3.73	0.000204	0.0116	0.12	0.11	Tanning;	chr16:90023055	chr16:89516797~89522217:+
BRCA	cis	rs1730008	0.661	rs58925169	ENSG00000279311.1	RP11-170K4.2	3.73	0.000204	0.0116	0.14	0.11	Lobe attachment (rater-scored or self-reported);	chr3:158365166	chr3:158869898~158871821:+
BRCA	cis	rs67072384	1	rs55957377	ENSG00000256633.1	RP11-169D4.2	3.73	0.000204	0.0116	0.17	0.11	Alloimmunization response to red blood cell transfusion in sickle cell anemia;	chr11:72734431	chr11:72584572~72587979:+
BRCA	cis	rs897984	0.571	rs7184567	ENSG00000279196.1	RP11-1072A3.3	3.73	0.000204	0.0116	0.12	0.11	Dementia with Lewy bodies;	chr16:31009757	chr16:30984630~30988270:-
BRCA	cis	rs875971	0.522	rs4718286	ENSG00000223473.2	GS1-124K5.3	3.73	0.000204	0.0116	0.09	0.11	Aortic root size;	chr7:65827777	chr7:66491049~66493566:-
BRCA	cis	rs17711722	0.585	rs6942660	ENSG00000223473.2	GS1-124K5.3	3.73	0.000204	0.0116	0.09	0.11	Calcium levels;	chr7:65837419	chr7:66491049~66493566:-
BRCA	cis	rs73201462	0.901	rs2811400	ENSG00000242551.2	POU5F1P6	-3.73	0.000204	0.0116	-0.2	-0.11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128269024	chr3:128674735~128677005:-
BRCA	cis	rs73201462	1	rs2811414	ENSG00000242551.2	POU5F1P6	-3.73	0.000204	0.0116	-0.2	-0.11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128272334	chr3:128674735~128677005:-
BRCA	cis	rs897984	0.542	rs11865038	ENSG00000275263.1	RP11-1072A3.4	-3.73	0.000204	0.0116	-0.13	-0.11	Dementia with Lewy bodies;	chr16:31083850	chr16:30956872~30957199:-
BRCA	cis	rs897984	0.542	rs11864806	ENSG00000275263.1	RP11-1072A3.4	-3.73	0.000204	0.0116	-0.13	-0.11	Dementia with Lewy bodies;	chr16:31083883	chr16:30956872~30957199:-
BRCA	cis	rs897984	0.542	rs7199949	ENSG00000275263.1	RP11-1072A3.4	-3.73	0.000204	0.0116	-0.13	-0.11	Dementia with Lewy bodies;	chr16:31084843	chr16:30956872~30957199:-
BRCA	cis	rs10266483	0.661	rs608769	ENSG00000228653.2	HNRNPCP7	-3.73	0.000204	0.0116	-0.14	-0.11	Response to statin therapy;	chr7:64292783	chr7:64500825~64501729:+
BRCA	cis	rs1670533	1	rs10084890	ENSG00000251639.2	RP11-20I20.1	-3.73	0.000204	0.0116	-0.18	-0.11	Recombination rate (females);	chr4:1060146	chr4:1100016~1101558:-
BRCA	cis	rs6142618	0.562	rs4911197	ENSG00000275576.1	RP5-836N17.4	-3.73	0.000204	0.0116	-0.12	-0.11	Inflammatory bowel disease;	chr20:32130490	chr20:32116171~32116629:+
BRCA	cis	rs2380205	0.517	rs17319759	ENSG00000232807.2	RP11-536K7.3	3.73	0.000204	0.0116	0.12	0.11	Breast cancer;	chr10:5920927	chr10:5934270~5945900:-
BRCA	cis	rs8177876	0.658	rs2316730	ENSG00000245059.2	RP11-303E16.7	3.73	0.000204	0.0116	0.25	0.11	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81106035	chr16:81077319~81078861:+
BRCA	cis	rs4834770	0.746	rs2389747	ENSG00000245958.5	RP11-33B1.1	-3.73	0.000204	0.0116	-0.1	-0.11	Blood protein levels;	chr4:119314947	chr4:119454791~119552025:+
BRCA	cis	rs4834770	0.717	rs1022146	ENSG00000245958.5	RP11-33B1.1	-3.73	0.000204	0.0116	-0.1	-0.11	Blood protein levels;	chr4:119314948	chr4:119454791~119552025:+
BRCA	cis	rs58521262	0.556	rs449210	ENSG00000268105.1	RP11-369G6.2	3.73	0.000204	0.0116	0.16	0.11	Testicular germ cell tumor;	chr19:22939845	chr19:23125665~23128543:+
BRCA	cis	rs13272568	0.614	rs13274461	ENSG00000254352.1	RP11-578O24.2	-3.73	0.000204	0.0116	-0.15	-0.11	Bone mineral density;	chr8:78122992	chr8:78723796~78724136:-
BRCA	cis	rs12762955	0.561	rs1904671	ENSG00000205740.2	RP11-363N22.3	-3.73	0.000204	0.0116	-0.12	-0.11	Response to angiotensin II receptor blocker therapy;	chr10:968663	chr10:971146~988341:-
BRCA	cis	rs1510510	0.69	rs13011551	ENSG00000186235.9	AC016757.3	-3.73	0.000204	0.0116	-0.19	-0.11	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr2:238621110	chr2:238224552~238231677:-
BRCA	cis	rs13434995	0.513	rs1021307	ENSG00000249700.7	SRD5A3-AS1	3.73	0.000204	0.0116	0.17	0.11	Adiponectin levels;	chr4:55529547	chr4:55363971~55395847:-
BRCA	cis	rs13434995	0.513	rs1021306	ENSG00000249700.7	SRD5A3-AS1	3.73	0.000204	0.0116	0.17	0.11	Adiponectin levels;	chr4:55529777	chr4:55363971~55395847:-
BRCA	cis	rs718433	0.584	rs10438076	ENSG00000211778.2	TRAV4	-3.73	0.000204	0.0116	-0.08	-0.11	Intraocular pressure;	chr14:21741785	chr14:21736152~21736982:+
BRCA	cis	rs4388249	1	rs2269201	ENSG00000271849.1	CTC-332L22.1	-3.73	0.000204	0.0116	-0.19	-0.11	Schizophrenia;	chr5:109716958	chr5:109687802~109688329:-
BRCA	cis	rs4388249	0.898	rs2269203	ENSG00000271849.1	CTC-332L22.1	-3.73	0.000204	0.0116	-0.19	-0.11	Schizophrenia;	chr5:109717432	chr5:109687802~109688329:-
BRCA	cis	rs2562456	0.917	rs2681376	ENSG00000268555.1	RP11-678G14.3	-3.73	0.000204	0.0116	-0.15	-0.11	Pain;	chr19:21532723	chr19:21570822~21587322:-
BRCA	cis	rs7714670	0.736	rs2973547	ENSG00000184084.7	CTD-2372A4.1	-3.73	0.000204	0.0116	-0.14	-0.11	Venous thromboembolism (SNP x SNP interaction);	chr5:73796590	chr5:73803296~73803599:-
BRCA	cis	rs7267979	0.753	rs400357	ENSG00000277938.1	RP5-965G21.3	3.73	0.000204	0.0116	0.14	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25498422	chr20:25229150~25231933:+
BRCA	cis	rs2032314	0.527	rs13051785	ENSG00000237945.6	LINC00649	-3.73	0.000204	0.0116	-0.19	-0.11	Red blood cell traits;	chr21:33950983	chr21:33915534~33977691:+
BRCA	cis	rs10129255	0.917	rs8022493	ENSG00000232216.1	IGHV3-43	3.73	0.000204	0.0116	0.09	0.11	Kawasaki disease;	chr14:106781820	chr14:106470264~106470800:-
BRCA	cis	rs10129255	0.5	rs8004923	ENSG00000211976.2	IGHV3-73	-3.73	0.000204	0.0116	-0.09	-0.11	Kawasaki disease;	chr14:106785926	chr14:106802694~106803233:-
BRCA	cis	rs3617	0.625	rs2239548	ENSG00000279144.1	RP11-894J14.2	3.73	0.000204	0.0116	0.14	0.11	Red blood cell count;Autism spectrum disorder or schizophrenia;	chr3:52820170	chr3:52848085~52848553:-
BRCA	cis	rs8040855	0.599	rs4643289	ENSG00000259570.1	RP11-671M22.4	-3.73	0.000204	0.0116	-0.12	-0.11	Bulimia nervosa;	chr15:85183483	chr15:84394512~84395514:+
BRCA	cis	rs12594515	0.591	rs35554150	ENSG00000259200.1	RP11-718O11.1	-3.73	0.000204	0.0116	-0.14	-0.11	Weight;Waist circumference;	chr15:45698100	chr15:45705078~45931069:+
BRCA	cis	rs11773103	1	rs73206905	ENSG00000224046.1	AC005076.5	3.73	0.000204	0.0116	0.25	0.11	Bipolar disorder or major depressive disorder (combined);	chr7:87155307	chr7:87151423~87152420:-
BRCA	cis	rs11773103	1	rs73206916	ENSG00000224046.1	AC005076.5	3.73	0.000204	0.0116	0.25	0.11	Bipolar disorder or major depressive disorder (combined);	chr7:87159697	chr7:87151423~87152420:-
BRCA	cis	rs875971	0.756	rs4718328	ENSG00000273024.4	INTS4P2	3.73	0.000204	0.0116	0.13	0.11	Aortic root size;	chr7:66228350	chr7:65647864~65715661:+
BRCA	cis	rs7937682	0.632	rs11214015	ENSG00000176343.5	RPL37AP8	-3.73	0.000204	0.0116	-0.14	-0.11	Primary sclerosing cholangitis;	chr11:111848694	chr11:111889199~111889474:-
BRCA	cis	rs9844666	0.512	rs13434196	ENSG00000273486.1	RP11-731C17.2	3.73	0.000204	0.0116	0.13	0.11	Height;	chr3:135924461	chr3:136837338~136839021:-
BRCA	cis	rs7621331	0.714	rs9844478	ENSG00000273486.1	RP11-731C17.2	3.73	0.000204	0.0116	0.13	0.11	Waist circumference adjusted for body mass index;	chr3:135924473	chr3:136837338~136839021:-
BRCA	cis	rs75504410	0.579	rs168088	ENSG00000231160.8	KLF3-AS1	-3.73	0.000204	0.0116	-0.16	-0.11	Sum eosinophil basophil counts;Eosinophil counts;	chr4:38611087	chr4:38612701~38664883:-
BRCA	cis	rs4835473	0.932	rs34950821	ENSG00000246448.2	RP13-578N3.3	-3.73	0.000204	0.0116	-0.13	-0.11	Immature fraction of reticulocytes;	chr4:143738174	chr4:143700257~143865072:+
BRCA	cis	rs930395	0.514	rs10044321	ENSG00000251141.4	RP11-53O19.1	-3.73	0.000204	0.0116	-0.11	-0.11	Breast cancer;	chr5:44890658	chr5:44744900~44808777:-
BRCA	cis	rs6736093	0.796	rs13024271	ENSG00000236307.2	EEF1E1P1	-3.73	0.000204	0.0116	-0.15	-0.11	Coronary artery disease;	chr2:112056749	chr2:111887914~111888741:+
BRCA	cis	rs11098499	0.779	rs28495013	ENSG00000225892.3	RP11-384K6.2	3.73	0.000204	0.0116	0.11	0.11	Corneal astigmatism;	chr4:119454676	chr4:118632274~118634759:+
BRCA	cis	rs2991971	0.934	rs11580609	ENSG00000280836.1	AL355480.1	3.73	0.000204	0.0116	0.13	0.11	High light scatter reticulocyte count;	chr1:45510184	chr1:45581219~45581321:-
BRCA	cis	rs875971	0.789	rs7808013	ENSG00000273024.4	INTS4P2	3.73	0.000204	0.0116	0.13	0.11	Aortic root size;	chr7:66606209	chr7:65647864~65715661:+
BRCA	cis	rs34929064	0.536	rs2961278	ENSG00000179428.2	AC073072.5	3.73	0.000204	0.0116	0.14	0.11	Major depression and alcohol dependence;	chr7:22595160	chr7:22725395~22727620:-
BRCA	cis	rs78487399	0.71	rs7567685	ENSG00000234936.1	AC010883.5	3.73	0.000204	0.0116	0.18	0.11	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43441030	chr2:43229573~43233394:+
BRCA	cis	rs78487399	0.808	rs7581586	ENSG00000234936.1	AC010883.5	3.73	0.000204	0.0116	0.18	0.11	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43441037	chr2:43229573~43233394:+
BRCA	cis	rs876084	0.63	rs2037342	ENSG00000279347.1	RP11-85I17.2	3.73	0.000204	0.0116	0.11	0.11	Neurocognitive impairment in HIV-1 infection (dichotomous);	chr8:120007633	chr8:119838736~119840385:-
BRCA	cis	rs801193	1	rs3800812	ENSG00000232546.1	RP11-458F8.1	-3.73	0.000205	0.0116	-0.1	-0.11	Aortic root size;	chr7:66758474	chr7:66848496~66858136:+
BRCA	cis	rs801193	1	rs4279493	ENSG00000232546.1	RP11-458F8.1	-3.73	0.000205	0.0116	-0.1	-0.11	Aortic root size;	chr7:66761633	chr7:66848496~66858136:+
BRCA	cis	rs17123764	0.892	rs10506287	ENSG00000257464.1	RP11-161H23.8	-3.73	0.000205	0.0116	-0.21	-0.11	Intelligence (multi-trait analysis);	chr12:49762857	chr12:49442424~49442652:-
BRCA	cis	rs2274273	0.6	rs10134317	ENSG00000259318.1	RP11-454L9.2	3.73	0.000205	0.0116	0.1	0.11	Protein biomarker;	chr14:55326730	chr14:55394940~55395233:-
BRCA	cis	rs4664293	0.934	rs1365800	ENSG00000230783.1	AC009961.2	-3.73	0.000205	0.0116	-0.15	-0.11	Monocyte percentage of white cells;	chr2:159699112	chr2:159689217~159690291:-
BRCA	cis	rs6840360	0.571	rs11729136	ENSG00000270265.1	RP11-731D1.4	-3.73	0.000205	0.0116	-0.14	-0.11	Intelligence (multi-trait analysis);	chr4:151608075	chr4:151333775~151353224:-
BRCA	cis	rs763121	0.853	rs138702	ENSG00000225450.1	RP3-508I15.14	3.73	0.000205	0.0116	0.12	0.11	Menopause (age at onset);	chr22:38736596	chr22:38739003~38749041:+
BRCA	cis	rs10043228	1	rs12520076	ENSG00000271918.1	CTD-2287O16.5	-3.73	0.000205	0.0116	-0.16	-0.11	Asthma or chronic obstructive pulmonary disease;	chr5:116123133	chr5:116083807~116085416:-
BRCA	cis	rs1008375	0.932	rs11938710	ENSG00000249502.1	AC006160.5	3.73	0.000205	0.0116	0.13	0.11	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17669041	chr4:17587467~17614571:-
BRCA	cis	rs4689592	0.513	rs2358718	ENSG00000245468.3	RP11-367J11.3	-3.73	0.000205	0.0116	-0.12	-0.11	Monocyte percentage of white cells;	chr4:7067016	chr4:7094571~7103385:-
BRCA	cis	rs12468226	0.817	rs2350360	ENSG00000272966.1	RP11-686O6.1	-3.73	0.000205	0.0116	-0.19	-0.11	Urate levels;	chr2:202222980	chr2:202336739~202337200:+
BRCA	cis	rs8030605	0.778	rs4392004	ENSG00000277245.1	RP11-48G14.3	3.73	0.000205	0.0116	0.23	0.11	Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;	chr15:56256724	chr15:56447120~56447697:+
BRCA	cis	rs7608910	1	rs7608910	ENSG00000237522.1	NONOP2	3.73	0.000205	0.0116	0.11	0.11	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;	chr2:60977721	chr2:60936819~60938049:-
BRCA	cis	rs9921338	0.961	rs4356497	ENSG00000262636.1	CTD-3088G3.4	3.73	0.000205	0.0116	0.18	0.11	Vein graft stenosis in coronary artery bypass grafting;	chr16:11320339	chr16:11380859~11381118:-
BRCA	cis	rs897984	0.609	rs17839567	ENSG00000279196.1	RP11-1072A3.3	3.73	0.000205	0.0116	0.12	0.11	Dementia with Lewy bodies;	chr16:31046624	chr16:30984630~30988270:-
BRCA	cis	rs465969	0.793	rs7752225	ENSG00000271789.1	RP5-1112D6.7	-3.73	0.000205	0.0116	-0.27	-0.11	Psoriasis;	chr6:111459412	chr6:111297126~111298510:+
BRCA	cis	rs6771316	0.504	rs2174543	ENSG00000241163.6	LINC00877	-3.73	0.000205	0.0116	-0.13	-0.11	Venous thromboembolism (SNP x SNP interaction);	chr3:72090138	chr3:72035300~72279503:-
BRCA	cis	rs6771316	0.504	rs2174544	ENSG00000241163.6	LINC00877	-3.73	0.000205	0.0116	-0.13	-0.11	Venous thromboembolism (SNP x SNP interaction);	chr3:72090144	chr3:72035300~72279503:-
BRCA	cis	rs62025270	0.632	rs1807309	ENSG00000259416.2	RP11-158M2.5	-3.73	0.000205	0.0116	-0.17	-0.11	Idiopathic pulmonary fibrosis;	chr15:85668526	chr15:85754941~85756237:-
BRCA	cis	rs17489649	1	rs12518635	ENSG00000271849.1	CTC-332L22.1	3.73	0.000205	0.0116	0.15	0.11	Intelligence (multi-trait analysis);	chr5:109836647	chr5:109687802~109688329:-
BRCA	cis	rs3177980	0.564	rs10919256	ENSG00000239494.2	RN7SL333P	-3.73	0.000205	0.0116	-0.11	-0.11	Amyotrophic lateral sclerosis;	chr1:169847163	chr1:169859756~169860052:+
BRCA	cis	rs4703129	1	rs11738266	ENSG00000246763.5	RGMB-AS1	-3.73	0.000205	0.0116	-0.13	-0.11	Asperger disorder;	chr5:98553588	chr5:98769618~98773469:-
BRCA	cis	rs12317459	0.591	rs77043031	ENSG00000213270.5	RPL6P25	-3.73	0.000205	0.0116	-0.19	-0.11	Prostate cancer (SNP x SNP interaction);	chr12:82773987	chr12:83151331~83152190:+
BRCA	cis	rs2253762	0.54	rs79586669	ENSG00000226864.1	ATE1-AS1	3.73	0.000205	0.0116	0.21	0.11	Breast cancer;	chr10:122015153	chr10:121928312~121951965:+
BRCA	cis	rs12122100	0.651	rs6665411	ENSG00000278811.3	LINC00624	3.73	0.000205	0.0116	0.14	0.11	HIV-1 control;	chr1:147075547	chr1:147258885~147517875:-
BRCA	cis	rs6449502	0.541	rs767634	ENSG00000251279.1	CTC-436P18.1	3.73	0.000205	0.0116	0.26	0.11	Mean platelet volume;	chr5:61048470	chr5:61162070~61232040:+
BRCA	cis	rs61160187	0.582	rs7737276	ENSG00000272308.1	RP11-231G3.1	-3.73	0.000205	0.0116	-0.13	-0.11	Educational attainment (years of education);Educational attainment (college completion);	chr5:61102467	chr5:60866457~60866935:-
BRCA	cis	rs34217772	0.552	rs7147055	ENSG00000258636.1	CTD-2298J14.2	3.73	0.000205	0.0116	0.16	0.11	Myopia;	chr14:41947705	chr14:41587861~41604856:-
BRCA	cis	rs34792	0.525	rs66651392	ENSG00000260872.1	RP11-680G24.5	-3.73	0.000205	0.0116	-0.13	-0.11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15517735	chr16:15018106~15020488:-
BRCA	cis	rs7020830	0.571	rs3780335	ENSG00000230188.1	RP11-405L18.4	3.73	0.000205	0.0116	0.16	0.11	Schizophrenia;	chr9:37376590	chr9:37490421~37490893:-
BRCA	cis	rs7267979	1	rs2258769	ENSG00000276952.1	RP5-965G21.6	3.73	0.000205	0.0116	0.14	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25296044	chr20:25284915~25285588:-
BRCA	cis	rs5758511	0.773	rs62241023	ENSG00000226450.2	CYP2D8P	3.73	0.000205	0.0116	0.13	0.11	Birth weight;	chr22:41989425	chr22:42149886~42155001:-
BRCA	cis	rs6964587	0.773	rs10488514	ENSG00000188693.7	CYP51A1-AS1	-3.73	0.000205	0.0116	-0.13	-0.11	Breast cancer;	chr7:92322528	chr7:92134604~92180725:+
BRCA	cis	rs10883723	0.81	rs2296581	ENSG00000213061.2	PFN1P11	-3.73	0.000205	0.0116	-0.16	-0.11	Allergic disease (asthma, hay fever or eczema);	chr10:102483129	chr10:102838011~102845473:-
BRCA	cis	rs890448	0.796	rs6840099	ENSG00000254531.1	FLJ20021	3.73	0.000205	0.0116	0.14	0.11	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101423356	chr4:101347780~101348883:+
BRCA	cis	rs718433	0.532	rs6572105	ENSG00000256379.1	TRAV8-5	3.73	0.000205	0.0116	0.14	0.11	Intraocular pressure;	chr14:21819166	chr14:21903077~21903598:+
BRCA	cis	rs1910358	0.69	rs35375168	ENSG00000248874.4	C5orf17	-3.73	0.000205	0.0116	-0.15	-0.11	Venous thromboembolism (SNP x SNP interaction);	chr5:23988874	chr5:23951348~24178263:+
BRCA	cis	rs1910358	0.69	rs1304671	ENSG00000248874.4	C5orf17	-3.73	0.000205	0.0116	-0.15	-0.11	Venous thromboembolism (SNP x SNP interaction);	chr5:23990487	chr5:23951348~24178263:+
BRCA	cis	rs1910358	0.664	rs13178473	ENSG00000248874.4	C5orf17	-3.73	0.000205	0.0116	-0.15	-0.11	Venous thromboembolism (SNP x SNP interaction);	chr5:23991404	chr5:23951348~24178263:+
BRCA	cis	rs1910358	0.69	rs6887095	ENSG00000248874.4	C5orf17	-3.73	0.000205	0.0116	-0.15	-0.11	Venous thromboembolism (SNP x SNP interaction);	chr5:23991755	chr5:23951348~24178263:+
BRCA	cis	rs12682352	0.602	rs11783966	ENSG00000254153.1	CTA-398F10.2	-3.73	0.000205	0.0116	-0.14	-0.11	Neuroticism;	chr8:8807637	chr8:8456909~8461337:-
BRCA	cis	rs1577917	0.74	rs2475792	ENSG00000220563.1	PKMP3	3.73	0.000205	0.0116	0.12	0.11	Response to antipsychotic treatment;	chr6:85682384	chr6:85659892~85660606:-
BRCA	cis	rs10943724	0.959	rs11964999	ENSG00000272129.1	RP11-250B2.6	3.73	0.000205	0.0116	0.16	0.11	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr6:80548700	chr6:80355424~80356859:+
BRCA	cis	rs4560672	0.627	rs17489860	ENSG00000218226.1	TATDN2P2	-3.73	0.000205	0.0116	-0.16	-0.11	Smoking quantity;	chr6:158084889	chr6:158609706~158621636:-
BRCA	cis	rs72772090	0.539	rs11738115	ENSG00000272109.1	CTD-2260A17.3	-3.73	0.000205	0.0116	-0.23	-0.11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96777368	chr5:96804353~96806105:+
BRCA	cis	rs806795	0.605	rs809871	ENSG00000241549.7	GUSBP2	3.73	0.000205	0.0117	0.14	0.11	Mosquito bite size;	chr6:26256298	chr6:26871484~26956554:-
BRCA	cis	rs67073037	0.955	rs57693531	ENSG00000230730.1	AC074011.2	-3.73	0.000205	0.0117	-0.16	-0.11	Breast cancer;Breast cancer (estrogen-receptor negative);	chr2:28906816	chr2:28633282~28664540:-
BRCA	cis	rs67073037	0.955	rs66692018	ENSG00000230730.1	AC074011.2	-3.73	0.000205	0.0117	-0.16	-0.11	Breast cancer;Breast cancer (estrogen-receptor negative);	chr2:28909121	chr2:28633282~28664540:-
BRCA	cis	rs10992471	0.56	rs10992512	ENSG00000187984.11	ANKRD19P	-3.73	0.000205	0.0117	-0.11	-0.11	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr9:92890669	chr9:92809388~92888693:+
BRCA	cis	rs72928364	1	rs34275644	ENSG00000244119.1	PDCL3P4	3.73	0.000205	0.0117	0.14	0.11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100939221	chr3:101712472~101713191:+
BRCA	cis	rs72928364	1	rs35630894	ENSG00000244119.1	PDCL3P4	3.73	0.000205	0.0117	0.14	0.11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100942490	chr3:101712472~101713191:+
BRCA	cis	rs72928364	1	rs35617051	ENSG00000244119.1	PDCL3P4	3.73	0.000205	0.0117	0.14	0.11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100943972	chr3:101712472~101713191:+
BRCA	cis	rs10043775	0.793	rs4705250	ENSG00000251330.3	CTD-2283N19.1	-3.73	0.000205	0.0117	-0.14	-0.11	Periodontal microbiota;	chr5:148321873	chr5:148430159~148430807:-
BRCA	cis	rs8054556	1	rs7204797	ENSG00000261367.1	RP11-455F5.4	-3.73	0.000205	0.0117	-0.12	-0.11	Autism spectrum disorder or schizophrenia;	chr16:29956694	chr16:30107675~30110541:+
BRCA	cis	rs41313321	0.51	rs2286815	ENSG00000273186.1	RP11-339B21.10	3.73	0.000205	0.0117	0.28	0.11	Coenzyme Q10 levels;	chr9:128371620	chr9:128431598~128432006:+
BRCA	cis	rs875971	0.895	rs7788984	ENSG00000265600.1	AC006480.1	-3.73	0.000205	0.0117	-0.14	-0.11	Aortic root size;	chr7:66450629	chr7:67356680~67356779:+
BRCA	cis	rs699371	0.525	rs7140692	ENSG00000259005.1	RP3-449M8.6	3.73	0.000206	0.0117	0.14	0.11	Height;	chr14:74434484	chr14:74474007~74474864:-
BRCA	cis	rs9470794	1	rs80068566	ENSG00000204110.6	RP1-153P14.8	-3.73	0.000206	0.0117	-0.23	-0.11	Type 2 diabetes;	chr6:37985136	chr6:37507348~37535616:+
BRCA	cis	rs1346	0.58	rs10750763	ENSG00000245532.5	NEAT1	3.73	0.000206	0.0117	0.12	0.11	Vertical cup-disc ratio;Optic cup area;	chr11:65600963	chr11:65422774~65445540:+
BRCA	cis	rs4831760	0.715	rs13268641	ENSG00000250483.1	PPM1AP1	3.73	0.000206	0.0117	0.16	0.11	Pulmonary function decline;	chr8:15766916	chr8:15806149~15807283:-
BRCA	cis	rs4978813	0.5	rs10816830	ENSG00000213539.4	YBX1P6	-3.73	0.000206	0.0117	-0.13	-0.11	Plantar warts;	chr9:109537404	chr9:109532830~109534332:-
BRCA	cis	rs9921338	0.923	rs7186455	ENSG00000263080.1	RP11-485G7.5	3.73	0.000206	0.0117	0.17	0.11	Vein graft stenosis in coronary artery bypass grafting;	chr16:11333891	chr16:11341809~11345211:-
BRCA	cis	rs6430585	0.527	rs59413285	ENSG00000224043.6	CCNT2-AS1	-3.73	0.000206	0.0117	-0.19	-0.11	Corneal structure;	chr2:135686615	chr2:134735464~134918710:-
BRCA	cis	rs6430585	0.527	rs62168833	ENSG00000224043.6	CCNT2-AS1	-3.73	0.000206	0.0117	-0.19	-0.11	Corneal structure;	chr2:135691684	chr2:134735464~134918710:-
BRCA	cis	rs2998286	0.723	rs332131	ENSG00000237128.1	RP11-351M16.3	3.73	0.000206	0.0117	0.15	0.11	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28564933	chr10:28433008~28495813:-
BRCA	cis	rs7903456	0.648	rs4934290	ENSG00000200253.1	RNU6-529P	3.73	0.000206	0.0117	0.14	0.11	Gout;Renal underexcretion gout;	chr10:87040504	chr10:87041238~87041341:-
BRCA	cis	rs739496	0.602	rs79209359	ENSG00000257624.1	RP1-128M12.3	3.73	0.000206	0.0117	0.16	0.11	Platelet count;	chr12:111529357	chr12:112000739~112000985:-
BRCA	cis	rs8141529	0.702	rs8137262	ENSG00000272858.1	CTA-292E10.8	-3.73	0.000206	0.0117	-0.15	-0.11	Lymphocyte counts;	chr22:28896147	chr22:28814914~28815662:+
BRCA	cis	rs7267979	1	rs6050602	ENSG00000276952.1	RP5-965G21.6	-3.73	0.000206	0.0117	-0.14	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25420567	chr20:25284915~25285588:-
BRCA	cis	rs9457247	0.561	rs916331	ENSG00000272549.1	RP11-351J23.2	-3.73	0.000206	0.0117	-0.12	-0.11	Crohn's disease;	chr6:167057071	chr6:167666840~167679270:-
BRCA	cis	rs11668609	0.872	rs11668697	ENSG00000268058.1	BNIP3P40	-3.73	0.000206	0.0117	-0.14	-0.11	Response to taxane treatment (docetaxel);	chr19:24108247	chr19:24098425~24098980:-
BRCA	cis	rs10761482	0.813	rs7083624	ENSG00000254271.1	RP11-131N11.4	3.73	0.000206	0.0117	0.16	0.11	Schizophrenia;	chr10:60361481	chr10:60734342~60741828:+
BRCA	cis	rs6012564	0.963	rs6063359	ENSG00000230758.1	SNAP23P	3.73	0.000206	0.0117	0.13	0.11	Anger;	chr20:49128547	chr20:49038357~49038602:-
BRCA	cis	rs6088580	0.584	rs2378203	ENSG00000275784.1	RP5-1125A11.6	3.72	0.000206	0.0117	0.13	0.11	Glomerular filtration rate (creatinine);	chr20:34406040	chr20:33989480~33991818:-
BRCA	cis	rs6142618	0.583	rs2281364	ENSG00000224452.1	RSL24D1P6	3.72	0.000206	0.0117	0.15	0.11	Inflammatory bowel disease;	chr20:32164349	chr20:32170390~32170790:-
BRCA	cis	rs6142618	0.562	rs6061203	ENSG00000224452.1	RSL24D1P6	3.72	0.000206	0.0117	0.15	0.11	Inflammatory bowel disease;	chr20:32165167	chr20:32170390~32170790:-
BRCA	cis	rs6142618	0.562	rs2377416	ENSG00000224452.1	RSL24D1P6	3.72	0.000206	0.0117	0.15	0.11	Inflammatory bowel disease;	chr20:32169571	chr20:32170390~32170790:-
BRCA	cis	rs10266483	0.774	rs10253630	ENSG00000271550.1	BNIP3P11	-3.72	0.000206	0.0117	-0.15	-0.11	Response to statin therapy;	chr7:64366962	chr7:64678954~64687393:-
BRCA	cis	rs733175	0.951	rs7669090	ENSG00000250413.1	RP11-448G15.1	-3.72	0.000206	0.0117	-0.18	-0.11	Psychosis and Alzheimer's disease;	chr4:10026507	chr4:10006482~10009725:+
BRCA	cis	rs739496	0.843	rs598711	ENSG00000257624.1	RP1-128M12.3	3.72	0.000206	0.0117	0.16	0.11	Platelet count;	chr12:111535336	chr12:112000739~112000985:-
BRCA	cis	rs739496	0.843	rs598710	ENSG00000257624.1	RP1-128M12.3	3.72	0.000206	0.0117	0.16	0.11	Platelet count;	chr12:111535337	chr12:112000739~112000985:-
BRCA	cis	rs794185	0.561	rs304070	ENSG00000231249.1	ITPR1-AS1	3.72	0.000206	0.0117	0.13	0.11	Multiple sclerosis--Brain Glutamate Levels;	chr3:4496418	chr3:4490891~4493163:-
BRCA	cis	rs875971	0.895	rs12531677	ENSG00000229886.1	RP5-1132H15.3	-3.72	0.000206	0.0117	-0.13	-0.11	Aortic root size;	chr7:66304099	chr7:66025126~66031544:-
BRCA	cis	rs875971	0.862	rs7798630	ENSG00000229886.1	RP5-1132H15.3	-3.72	0.000206	0.0117	-0.13	-0.11	Aortic root size;	chr7:66306492	chr7:66025126~66031544:-
BRCA	cis	rs2274273	0.624	rs10146637	ENSG00000259318.1	RP11-454L9.2	3.72	0.000206	0.0117	0.1	0.11	Protein biomarker;	chr14:55278092	chr14:55394940~55395233:-
BRCA	cis	rs7824557	0.872	rs2572417	ENSG00000255020.1	AF131216.5	3.72	0.000206	0.0117	0.13	0.11	Retinal vascular caliber;	chr8:11253953	chr8:11345748~11347502:-
BRCA	cis	rs718433	0.616	rs2222916	ENSG00000211778.2	TRAV4	-3.72	0.000206	0.0117	-0.08	-0.11	Intraocular pressure;	chr14:21744319	chr14:21736152~21736982:+
BRCA	cis	rs7824557	0.767	rs2164272	ENSG00000154316.13	TDH	-3.72	0.000206	0.0117	-0.16	-0.11	Retinal vascular caliber;	chr8:11304987	chr8:11339637~11368452:+
BRCA	cis	rs6696239	0.513	rs3010194	ENSG00000227711.2	RP11-275O4.5	-3.72	0.000206	0.0117	-0.13	-0.11	Height;	chr1:227608220	chr1:227509028~227520477:-
BRCA	cis	rs1635	0.655	rs77986494	ENSG00000216901.1	AL022393.7	3.72	0.000206	0.0117	0.27	0.11	Schizophrenia;	chr6:28293720	chr6:28176188~28176674:+
BRCA	cis	rs6005807	0.506	rs28385597	ENSG00000272858.1	CTA-292E10.8	-3.72	0.000206	0.0117	-0.19	-0.11	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28048442	chr22:28814914~28815662:+
BRCA	cis	rs6005807	0.506	rs73880377	ENSG00000272858.1	CTA-292E10.8	-3.72	0.000206	0.0117	-0.19	-0.11	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28048443	chr22:28814914~28815662:+
BRCA	cis	rs1787200	0.585	rs2282546	ENSG00000265496.3	MIR1539	-3.72	0.000206	0.0117	-0.21	-0.11	Height;	chr18:49041414	chr18:49487339~49491878:+
BRCA	cis	rs3735485	0.8	rs6463260	ENSG00000201772.1	SNORA5C	-3.72	0.000206	0.0117	-0.15	-0.11	White blood cell count;Sum basophil neutrophil counts;Neutrophil count;Granulocyte percentage of myeloid white cells;Monocyte percentage of white cells;Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Lymphocyte counts;	chr7:45011291	chr7:45104906~45105042:-
BRCA	cis	rs6785206	0.892	rs2712429	ENSG00000242551.2	POU5F1P6	-3.72	0.000206	0.0117	-0.23	-0.11	Lymphocyte percentage of white cells;	chr3:128617378	chr3:128674735~128677005:-
BRCA	cis	rs9650657	0.571	rs4840512	ENSG00000154316.13	TDH	3.72	0.000206	0.0117	0.14	0.11	Neuroticism;	chr8:10739315	chr8:11339637~11368452:+
BRCA	cis	rs7487075	0.504	rs7312682	ENSG00000274723.1	RP11-618L22.1	3.72	0.000206	0.0117	0.13	0.11	Itch intensity from mosquito bite;	chr12:46254215	chr12:46970504~46972155:+
BRCA	cis	rs7487075	0.558	rs12580460	ENSG00000274723.1	RP11-618L22.1	3.72	0.000206	0.0117	0.13	0.11	Itch intensity from mosquito bite;	chr12:46255200	chr12:46970504~46972155:+
BRCA	cis	rs72928364	1	rs34999788	ENSG00000244119.1	PDCL3P4	3.72	0.000206	0.0117	0.14	0.11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100898824	chr3:101712472~101713191:+
BRCA	cis	rs1046491	0.522	rs2186914	ENSG00000264964.1	RP11-888D10.3	3.72	0.000206	0.0117	0.26	0.11	Scarlet fever;	chr18:9285724	chr18:9315194~9334441:-
BRCA	cis	rs6439699	0.941	rs66752974	ENSG00000239213.4	NCK1-AS1	3.72	0.000206	0.0117	0.16	0.11	Intelligence (multi-trait analysis);	chr3:137338788	chr3:136841726~136862054:-
BRCA	cis	rs1429524	0.778	rs28542392	ENSG00000243144.5	RP11-115N4.1	3.72	0.000206	0.0117	0.15	0.11	Ejection fraction in Tripanosoma cruzi seropositivity;	chr7:91298977	chr7:91311368~91515409:+
BRCA	cis	rs2841277	0.708	rs9671643	ENSG00000258701.1	LINC00638	3.72	0.000206	0.0117	0.12	0.11	Rheumatoid arthritis;	chr14:104941693	chr14:104821201~104823718:+
BRCA	cis	rs10883723	0.81	rs1056857	ENSG00000213061.2	PFN1P11	-3.72	0.000206	0.0117	-0.16	-0.11	Allergic disease (asthma, hay fever or eczema);	chr10:102480246	chr10:102838011~102845473:-
BRCA	cis	rs6545883	1	rs778758	ENSG00000212978.6	AC016747.3	3.72	0.000206	0.0117	0.16	0.11	Tuberculosis;	chr2:61555026	chr2:61141592~61144969:-
BRCA	cis	rs853679	1	rs2799079	ENSG00000204709.4	LINC01556	3.72	0.000206	0.0117	0.19	0.11	Depression;	chr6:28267398	chr6:28943877~28944537:+
BRCA	cis	rs10256972	0.721	rs6975972	ENSG00000199023.2	MIR339	-3.72	0.000206	0.0117	-0.14	-0.11	Endometriosis;Longevity;	chr7:1030832	chr7:1022935~1023045:-
BRCA	cis	rs324017	1	rs324017	ENSG00000201579.1	RNU6-343P	3.72	0.000206	0.0117	0.15	0.11	Schizophrenia;	chr12:57094031	chr12:56588518~56588621:+
BRCA	cis	rs3858526	0.606	rs10838883	ENSG00000229534.1	HNRNPA1P53	-3.72	0.000206	0.0117	-0.16	-0.11	DNA methylation (variation);	chr11:5930917	chr11:5571247~5572192:-
BRCA	cis	rs17489649	0.785	rs4352640	ENSG00000271849.1	CTC-332L22.1	3.72	0.000206	0.0117	0.15	0.11	Intelligence (multi-trait analysis);	chr5:109860823	chr5:109687802~109688329:-
BRCA	cis	rs17489649	0.785	rs4321784	ENSG00000271849.1	CTC-332L22.1	3.72	0.000206	0.0117	0.15	0.11	Intelligence (multi-trait analysis);	chr5:109860832	chr5:109687802~109688329:-
BRCA	cis	rs875971	0.862	rs6959268	ENSG00000273024.4	INTS4P2	3.72	0.000206	0.0117	0.13	0.11	Aortic root size;	chr7:66347979	chr7:65647864~65715661:+
BRCA	cis	rs875971	0.862	rs6959268	ENSG00000229886.1	RP5-1132H15.3	-3.72	0.000206	0.0117	-0.13	-0.11	Aortic root size;	chr7:66347979	chr7:66025126~66031544:-
BRCA	cis	rs7637701	0.713	rs9818780	ENSG00000240875.4	LINC00886	-3.72	0.000206	0.0117	-0.13	-0.11	Breast cancer;	chr3:156774969	chr3:156747346~156817062:-
BRCA	cis	rs7637701	0.713	rs9878566	ENSG00000240875.4	LINC00886	-3.72	0.000206	0.0117	-0.13	-0.11	Breast cancer;	chr3:156775424	chr3:156747346~156817062:-
BRCA	cis	rs4879656	0.593	rs10448231	ENSG00000236184.1	TCEA1P4	3.72	0.000206	0.0117	0.15	0.11	Menopause (age at onset);	chr9:33034053	chr9:32979560~32980403:-
BRCA	cis	rs1923539	0.713	rs2758544	ENSG00000225484.5	NUTM2B-AS1	3.72	0.000207	0.0117	0.16	0.11	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79970366	chr10:79663088~79826594:-
BRCA	cis	rs4934494	1	rs4934494	ENSG00000232229.4	LINC00865	-3.72	0.000207	0.0117	-0.17	-0.11	Red blood cell count;	chr10:89687662	chr10:89829510~89840861:+
BRCA	cis	rs61931739	0.5	rs11052994	ENSG00000258794.3	DUX4L27	3.72	0.000207	0.0117	0.17	0.11	Morning vs. evening chronotype;	chr12:33912908	chr12:34208415~34209675:-
BRCA	cis	rs2243480	0.808	rs12698508	ENSG00000226767.1	RP11-328P23.3	-3.72	0.000207	0.0117	-0.2	-0.11	Diabetic kidney disease;	chr7:65946971	chr7:65508773~65508944:-
BRCA	cis	rs10786436	0.588	rs2018085	ENSG00000224934.2	RP11-441O15.3	3.72	0.000207	0.0117	0.1	0.11	Type 1 diabetes;	chr10:98553285	chr10:99431191~99438117:+
BRCA	cis	rs897984	0.609	rs4889609	ENSG00000275263.1	RP11-1072A3.4	-3.72	0.000207	0.0117	-0.14	-0.11	Dementia with Lewy bodies;	chr16:31015106	chr16:30956872~30957199:-
BRCA	cis	rs10266483	0.705	rs1111649	ENSG00000271550.1	BNIP3P11	3.72	0.000207	0.0117	0.15	0.11	Response to statin therapy;	chr7:64296435	chr7:64678954~64687393:-
BRCA	cis	rs1371614	0.632	rs1992311	ENSG00000272148.1	RP11-195B17.1	3.72	0.000207	0.0117	0.13	0.11	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26936473	chr2:27062428~27062907:-
BRCA	cis	rs6012564	1	rs3818262	ENSG00000230758.1	SNAP23P	3.72	0.000207	0.0117	0.13	0.11	Anger;	chr20:49125019	chr20:49038357~49038602:-
BRCA	cis	rs8180040	0.902	rs73081205	ENSG00000280667.1	Y_RNA	-3.72	0.000207	0.0117	-0.13	-0.11	Colorectal cancer;	chr3:47476180	chr3:47501083~47501182:+
BRCA	cis	rs4272720	1	rs17011726	ENSG00000228754.1	RP11-534L6.3	-3.72	0.000207	0.0117	-0.16	-0.11	Platelet count;Plateletcrit;	chr10:49056159	chr10:48745545~48746128:-
BRCA	cis	rs11673344	0.801	rs17707446	ENSG00000267682.1	CTD-3220F14.2	3.72	0.000207	0.0117	0.11	0.11	Obesity-related traits;	chr19:37092140	chr19:37337236~37337743:+
BRCA	cis	rs875971	0.545	rs73142233	ENSG00000232559.3	GS1-124K5.12	3.72	0.000207	0.0117	0.16	0.11	Aortic root size;	chr7:66221293	chr7:66554588~66576923:-
BRCA	cis	rs7267979	1	rs2856	ENSG00000231081.1	RP4-760C5.3	-3.72	0.000207	0.0117	-0.15	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25452900	chr20:26008791~26010531:-
BRCA	cis	rs1009077	0.716	rs62319606	ENSG00000245958.5	RP11-33B1.1	3.72	0.000207	0.0117	0.17	0.11	Endometriosis;	chr4:119544091	chr4:119454791~119552025:+
BRCA	cis	rs10129255	0.518	rs2006284	ENSG00000211959.2	IGHV4-39	3.72	0.000207	0.0117	0.08	0.11	Kawasaki disease;	chr14:106676185	chr14:106421711~106422218:-
BRCA	cis	rs10043228	1	rs77564939	ENSG00000271918.1	CTD-2287O16.5	-3.72	0.000207	0.0117	-0.15	-0.11	Asthma or chronic obstructive pulmonary disease;	chr5:116228597	chr5:116083807~116085416:-
BRCA	cis	rs2991971	0.967	rs6661321	ENSG00000280836.1	AL355480.1	3.72	0.000207	0.0117	0.13	0.11	High light scatter reticulocyte count;	chr1:45488927	chr1:45581219~45581321:-
BRCA	cis	rs801193	0.935	rs2659916	ENSG00000232546.1	RP11-458F8.1	-3.72	0.000207	0.0117	-0.1	-0.11	Aortic root size;	chr7:66686365	chr7:66848496~66858136:+
BRCA	cis	rs72799341	0.706	rs11865499	ENSG00000274678.1	RP11-2C24.7	3.72	0.000207	0.0117	0.14	0.11	Diastolic blood pressure;	chr16:31120929	chr16:30821338~30821884:+
BRCA	cis	rs3753275	0.568	rs10864359	ENSG00000236266.1	RP3-467L1.4	3.72	0.000207	0.0117	0.17	0.11	Educational attainment;	chr1:8638551	chr1:7810242~7827342:-
BRCA	cis	rs853679	0.517	rs12174753	ENSG00000226314.6	ZNF192P1	-3.72	0.000207	0.0117	-0.17	-0.11	Depression;	chr6:28074687	chr6:28161781~28169594:+
BRCA	cis	rs8180040	1	rs1076394	ENSG00000280667.1	Y_RNA	-3.72	0.000207	0.0117	-0.13	-0.11	Colorectal cancer;	chr3:47281291	chr3:47501083~47501182:+
BRCA	cis	rs8180040	0.966	rs17476234	ENSG00000280667.1	Y_RNA	-3.72	0.000207	0.0117	-0.13	-0.11	Colorectal cancer;	chr3:47284808	chr3:47501083~47501182:+
BRCA	cis	rs7267979	1	rs4815420	ENSG00000204556.4	CTD-2514C3.1	3.72	0.000207	0.0117	0.15	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25403343	chr20:26018832~26020684:+
BRCA	cis	rs12474201	0.928	rs7594523	ENSG00000279254.1	RP11-536C12.1	-3.72	0.000207	0.0117	-0.14	-0.11	Height;	chr2:46708652	chr2:46668870~46670778:+
BRCA	cis	rs13401620	0.871	rs55729297	ENSG00000229326.3	AC069154.4	-3.72	0.000207	0.0117	-0.15	-0.11	Breast size;	chr2:119846824	chr2:119698623~119700151:+
BRCA	cis	rs875971	0.619	rs12533585	ENSG00000275400.1	RP4-756H11.5	-3.72	0.000207	0.0117	-0.13	-0.11	Aortic root size;	chr7:66519618	chr7:66553805~66554199:-
BRCA	cis	rs12612435	0.793	rs2360521	ENSG00000226806.1	AC011893.3	3.72	0.000207	0.0117	0.13	0.11	Takotsubo syndrome;	chr2:136376321	chr2:135820191~135823087:+
BRCA	cis	rs2803122	0.745	rs10811143	ENSG00000272842.1	RP11-513M16.7	-3.72	0.000207	0.0117	-0.12	-0.11	Pulse pressure;	chr9:19240221	chr9:19371386~19371945:-
BRCA	cis	rs8024893	1	rs8038787	ENSG00000270055.1	CTD-3092A11.2	3.72	0.000207	0.0117	0.17	0.11	Red cell distribution width;	chr15:31246171	chr15:30487963~30490313:+
BRCA	cis	rs34792	0.525	rs66651392	ENSG00000258354.1	MIR3180-1	-3.72	0.000207	0.0117	-0.16	-0.11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15517735	chr16:14909887~14911345:-
BRCA	cis	rs1468333	0.567	rs2277067	ENSG00000206989.1	SNORD63	3.72	0.000207	0.0117	0.13	0.11	Resting heart rate;	chr5:138439584	chr5:138561043~138561110:-
BRCA	cis	rs962856	1	rs6739392	ENSG00000236605.1	AC023115.4	3.72	0.000207	0.0117	0.14	0.11	Pancreatic cancer;	chr2:67374839	chr2:67324627~67325304:+
BRCA	cis	rs17214007	0.877	rs11644832	ENSG00000260735.1	RP11-72I8.1	-3.72	0.000207	0.0117	-0.16	-0.11	Cognitive function;	chr16:15778891	chr16:15094411~15109197:+
BRCA	cis	rs17214007	0.877	rs11645883	ENSG00000260735.1	RP11-72I8.1	-3.72	0.000207	0.0117	-0.16	-0.11	Cognitive function;	chr16:15778950	chr16:15094411~15109197:+
BRCA	cis	rs7031325	0.819	rs10758801	ENSG00000232946.1	RP11-390F4.2	-3.72	0.000207	0.0117	-0.13	-0.11	Systemic lupus erythematosus;	chr9:6657192	chr9:6675284~6675614:+
BRCA	cis	rs76963786	1	rs1259766	ENSG00000255760.1	RP11-428G5.5	-3.72	0.000207	0.0117	-0.17	-0.11	Interleukin-9 levels;	chr12:31918993	chr12:31877079~31887203:-
BRCA	cis	rs76963786	0.892	rs1259768	ENSG00000255760.1	RP11-428G5.5	-3.72	0.000207	0.0117	-0.17	-0.11	Interleukin-9 levels;	chr12:31921253	chr12:31877079~31887203:-
BRCA	cis	rs10771431	0.782	rs10771415	ENSG00000256069.6	A2MP1	3.72	0.000207	0.0117	0.12	0.11	Breast size;	chr12:9205627	chr12:9228533~9275817:-
BRCA	cis	rs6743226	0.521	rs12474449	ENSG00000266621.1	AC104841.1	3.72	0.000207	0.0117	0.14	0.11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in non-smokers;	chr2:241279274	chr2:241245202~241245299:-
BRCA	cis	rs6743226	0.519	rs12475374	ENSG00000266621.1	AC104841.1	3.72	0.000207	0.0117	0.14	0.11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in non-smokers;	chr2:241279347	chr2:241245202~241245299:-
BRCA	cis	rs9308731	0.583	rs10211562	ENSG00000230499.1	AC108463.1	-3.72	0.000207	0.0117	-0.14	-0.11	Chronic lymphocytic leukemia;	chr2:111173219	chr2:111195963~111206494:+
BRCA	cis	rs930395	0.514	rs13154729	ENSG00000251141.4	RP11-53O19.1	-3.72	0.000207	0.0117	-0.11	-0.11	Breast cancer;	chr5:44892827	chr5:44744900~44808777:-
BRCA	cis	rs12530845	0.887	rs73725434	ENSG00000223718.3	AC093107.7	3.72	0.000207	0.0117	0.19	0.11	Red blood cell traits;	chr7:135628909	chr7:135660039~135660647:+
BRCA	cis	rs62064224	0.714	rs62064225	ENSG00000279781.1	RP11-466A19.7	3.72	0.000207	0.0117	0.14	0.11	Schizophrenia;	chr17:32308410	chr17:32518322~32518934:-
BRCA	cis	rs62064224	0.714	rs4794917	ENSG00000279781.1	RP11-466A19.7	3.72	0.000207	0.0117	0.14	0.11	Schizophrenia;	chr17:32309127	chr17:32518322~32518934:-
BRCA	cis	rs62064224	0.675	rs12150479	ENSG00000279781.1	RP11-466A19.7	3.72	0.000207	0.0117	0.14	0.11	Schizophrenia;	chr17:32309181	chr17:32518322~32518934:-
BRCA	cis	rs4272720	1	rs61850693	ENSG00000228754.1	RP11-534L6.3	-3.72	0.000207	0.0117	-0.16	-0.11	Platelet count;Plateletcrit;	chr10:49061442	chr10:48745545~48746128:-
BRCA	cis	rs2839186	0.771	rs2280957	ENSG00000223901.2	AP001469.5	-3.72	0.000207	0.0118	-0.11	-0.11	Testicular germ cell tumor;	chr21:46222358	chr21:46220269~46225364:+
BRCA	cis	rs6012564	0.928	rs6095396	ENSG00000227431.4	CSE1L-AS1	-3.72	0.000207	0.0118	-0.14	-0.11	Anger;	chr20:49010633	chr20:49040463~49046044:-
BRCA	cis	rs2832077	0.527	rs9980449	ENSG00000232855.5	AF131217.1	3.72	0.000207	0.0118	0.14	0.11	Cognitive test performance;	chr21:28852567	chr21:28439346~28674848:-
BRCA	cis	rs9470794	1	rs35142414	ENSG00000204110.6	RP1-153P14.8	-3.72	0.000207	0.0118	-0.24	-0.11	Type 2 diabetes;	chr6:38023592	chr6:37507348~37535616:+
BRCA	cis	rs9470794	1	rs11753388	ENSG00000204110.6	RP1-153P14.8	-3.72	0.000207	0.0118	-0.24	-0.11	Type 2 diabetes;	chr6:38029574	chr6:37507348~37535616:+
BRCA	cis	rs9470794	1	rs11755894	ENSG00000204110.6	RP1-153P14.8	-3.72	0.000207	0.0118	-0.24	-0.11	Type 2 diabetes;	chr6:38029606	chr6:37507348~37535616:+
BRCA	cis	rs9470794	1	rs11759205	ENSG00000204110.6	RP1-153P14.8	-3.72	0.000207	0.0118	-0.24	-0.11	Type 2 diabetes;	chr6:38034789	chr6:37507348~37535616:+
BRCA	cis	rs9470794	1	rs56413211	ENSG00000204110.6	RP1-153P14.8	-3.72	0.000207	0.0118	-0.24	-0.11	Type 2 diabetes;	chr6:38037161	chr6:37507348~37535616:+
BRCA	cis	rs687432	0.812	rs4509781	ENSG00000265566.2	RN7SL605P	-3.72	0.000207	0.0118	-0.16	-0.11	Parkinson's disease;	chr11:58075086	chr11:57528085~57528365:-
BRCA	cis	rs718433	0.584	rs2204934	ENSG00000211778.2	TRAV4	-3.72	0.000207	0.0118	-0.08	-0.11	Intraocular pressure;	chr14:21744121	chr14:21736152~21736982:+
BRCA	cis	rs7267979	0.816	rs1044573	ENSG00000274973.1	RP13-401N8.7	-3.72	0.000207	0.0118	-0.13	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25226018	chr20:25845497~25845862:+
BRCA	cis	rs13064773	0.51	rs340277	ENSG00000272247.1	RP11-379F4.9	3.72	0.000208	0.0118	0.15	0.11	Response to abacavir-containing treatment in HIV-1 infection (virologic failure);Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr3:158869942	chr3:158801257~158801935:-
BRCA	cis	rs12122100	0.837	rs6681167	ENSG00000244371.2	PFN1P8	-3.72	0.000208	0.0118	-0.14	-0.11	HIV-1 control;	chr1:147035308	chr1:146957117~146957659:-
BRCA	cis	rs8114671	0.562	rs2273683	ENSG00000279253.1	RP4-614O4.13	-3.72	0.000208	0.0118	-0.14	-0.11	Height;	chr20:34921720	chr20:35262727~35264187:-
BRCA	cis	rs12612619	0.732	rs7560144	ENSG00000272148.1	RP11-195B17.1	3.72	0.000208	0.0118	0.13	0.11	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27057592	chr2:27062428~27062907:-
BRCA	cis	rs4699052	0.963	rs11097801	ENSG00000251288.2	RP11-10L12.2	-3.72	0.000208	0.0118	-0.13	-0.11	Testicular germ cell tumor;	chr4:103229166	chr4:102751401~102752641:+
BRCA	cis	rs4699052	0.928	rs2126473	ENSG00000251288.2	RP11-10L12.2	-3.72	0.000208	0.0118	-0.13	-0.11	Testicular germ cell tumor;	chr4:103220376	chr4:102751401~102752641:+
BRCA	cis	rs4699052	0.963	rs6816055	ENSG00000251288.2	RP11-10L12.2	-3.72	0.000208	0.0118	-0.13	-0.11	Testicular germ cell tumor;	chr4:103222003	chr4:102751401~102752641:+
BRCA	cis	rs4449834	0.816	rs4737563	ENSG00000254432.1	RP11-33I11.2	-3.72	0.000208	0.0118	-0.15	-0.11	Sum eosinophil basophil counts;	chr8:60771941	chr8:60808735~60809606:-
BRCA	cis	rs3740393	0.562	rs2297450	ENSG00000213277.3	MARCKSL1P1	3.72	0.000208	0.0118	0.16	0.11	Microalbuminuria;	chr10:102743417	chr10:103175554~103176094:+
BRCA	cis	rs6545883	0.783	rs7579651	ENSG00000212978.6	AC016747.3	3.72	0.000208	0.0118	0.16	0.11	Tuberculosis;	chr2:61573144	chr2:61141592~61144969:-
BRCA	cis	rs12317459	0.591	rs11115408	ENSG00000213270.5	RPL6P25	-3.72	0.000208	0.0118	-0.19	-0.11	Prostate cancer (SNP x SNP interaction);	chr12:82772968	chr12:83151331~83152190:+
BRCA	cis	rs801193	0.569	rs2659893	ENSG00000229886.1	RP5-1132H15.3	3.72	0.000208	0.0118	0.13	0.11	Aortic root size;	chr7:66735006	chr7:66025126~66031544:-
BRCA	cis	rs801193	0.569	rs2659892	ENSG00000229886.1	RP5-1132H15.3	3.72	0.000208	0.0118	0.13	0.11	Aortic root size;	chr7:66735318	chr7:66025126~66031544:-
BRCA	cis	rs801193	0.569	rs2707847	ENSG00000229886.1	RP5-1132H15.3	3.72	0.000208	0.0118	0.13	0.11	Aortic root size;	chr7:66737884	chr7:66025126~66031544:-
BRCA	cis	rs752010	0.871	rs10890149	ENSG00000230638.4	RP11-486B10.4	-3.72	0.000208	0.0118	-0.14	-0.11	Lupus nephritis in systemic lupus erythematosus;	chr1:41627120	chr1:41542069~41544310:+
BRCA	cis	rs6088580	0.634	rs1205345	ENSG00000275784.1	RP5-1125A11.6	3.72	0.000208	0.0118	0.12	0.11	Glomerular filtration rate (creatinine);	chr20:34326893	chr20:33989480~33991818:-
BRCA	cis	rs6840360	0.901	rs4696293	ENSG00000251611.1	RP11-610P16.1	3.72	0.000208	0.0118	0.1	0.11	Intelligence (multi-trait analysis);	chr4:151786228	chr4:151407551~151408835:-
BRCA	cis	rs4653663	0.533	rs12077115	ENSG00000226349.1	RP11-145A3.2	3.72	0.000208	0.0118	0.16	0.11	Neuroticism;	chr1:225737009	chr1:225710968~225736274:-
BRCA	cis	rs11098499	0.863	rs3775843	ENSG00000260404.2	RP11-384K6.6	3.72	0.000208	0.0118	0.11	0.11	Corneal astigmatism;	chr4:119506689	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.863	rs3775844	ENSG00000260404.2	RP11-384K6.6	3.72	0.000208	0.0118	0.11	0.11	Corneal astigmatism;	chr4:119506878	chr4:118591773~118633729:+
BRCA	cis	rs7869969	0.509	rs4481672	ENSG00000227603.1	RP11-165J3.6	3.72	0.000208	0.0118	0.12	0.11	Childhood body mass index;	chr9:93414939	chr9:93435332~93437121:-
BRCA	cis	rs495337	1	rs615926	ENSG00000229222.1	KRT18P4	-3.72	0.000208	0.0118	-0.15	-0.11	Psoriasis;	chr20:49902721	chr20:49956745~49958032:+
BRCA	cis	rs2555155	0.935	rs2555150	ENSG00000254595.1	CTD-2010I16.1	3.72	0.000208	0.0118	0.13	0.11	DNA methylation (variation);	chr11:6510993	chr11:6488186~6489377:-
BRCA	cis	rs8042849	1	rs8042849	ENSG00000261762.1	RP11-650L12.2	3.72	0.000208	0.0118	0.13	0.11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1/FVC ratio in COPD;Parental lifespan;	chr15:78525587	chr15:78589123~78591276:-
BRCA	cis	rs28374715	0.532	rs11854632	ENSG00000247556.5	OIP5-AS1	-3.72	0.000208	0.0118	-0.13	-0.11	Ulcerative colitis;	chr15:41389896	chr15:41283990~41309737:+
BRCA	cis	rs7903456	0.648	rs9421576	ENSG00000224914.2	LINC00863	-3.72	0.000208	0.0118	-0.14	-0.11	Gout;Renal underexcretion gout;	chr10:87069444	chr10:87342736~87357882:+
BRCA	cis	rs7267979	1	rs6083805	ENSG00000274973.1	RP13-401N8.7	3.72	0.000208	0.0118	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25336720	chr20:25845497~25845862:+
BRCA	cis	rs506338	0.517	rs12269736	ENSG00000237410.1	AP001092.4	3.72	0.000208	0.0118	0.16	0.11	Body mass index;Urate levels;	chr11:64704514	chr11:64646399~64659681:+
BRCA	cis	rs11121246	0.518	rs6673587	ENSG00000270282.1	RP5-1115A15.2	-3.72	0.000208	0.0118	-0.13	-0.11	Plateletcrit;	chr1:8850646	chr1:8512653~8513021:+
BRCA	cis	rs7267979	0.966	rs6037083	ENSG00000276952.1	RP5-965G21.6	-3.72	0.000208	0.0118	-0.14	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25309907	chr20:25284915~25285588:-
BRCA	cis	rs7632954	0.596	rs7611030	ENSG00000227110.5	LMCD1-AS1	-3.72	0.000208	0.0118	-0.14	-0.11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr3:8470235	chr3:7952805~8611924:-
BRCA	cis	rs2281558	0.754	rs73597824	ENSG00000274414.1	RP5-965G21.4	-3.72	0.000208	0.0118	-0.15	-0.11	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25610841	chr20:25239007~25245229:-
BRCA	cis	rs12949688	0.967	rs8064970	ENSG00000262623.1	RP5-1107A17.2	-3.72	0.000208	0.0118	-0.12	-0.11	Schizophrenia;	chr17:57747326	chr17:56951664~56952404:+
BRCA	cis	rs17301013	0.932	rs67967476	ENSG00000234741.6	GAS5	3.72	0.000208	0.0118	0.11	0.11	Systemic lupus erythematosus;	chr1:174616119	chr1:173863900~173868882:-
BRCA	cis	rs2274273	0.745	rs56262555	ENSG00000233924.1	AL160471.6	-3.72	0.000208	0.0118	-0.13	-0.11	Protein biomarker;	chr14:55095244	chr14:55004813~55005687:-
BRCA	cis	rs1730008	0.691	rs73170352	ENSG00000279311.1	RP11-170K4.2	3.72	0.000208	0.0118	0.14	0.11	Lobe attachment (rater-scored or self-reported);	chr3:158374434	chr3:158869898~158871821:+
BRCA	cis	rs7703051	0.52	rs13354746	ENSG00000271815.1	CTD-2235C13.3	-3.72	0.000208	0.0118	-0.18	-0.11	Age-related diseases, mortality and associated endophenotypes;LDL cholesterol;Age-related disease endophenotypes;	chr5:75323307	chr5:75363760~75364242:+
BRCA	cis	rs10043775	0.793	rs10041765	ENSG00000251330.3	CTD-2283N19.1	-3.72	0.000208	0.0118	-0.13	-0.11	Periodontal microbiota;	chr5:148323068	chr5:148430159~148430807:-
BRCA	cis	rs58521262	0.53	rs289367	ENSG00000268105.1	RP11-369G6.2	3.72	0.000208	0.0118	0.16	0.11	Testicular germ cell tumor;	chr19:22931728	chr19:23125665~23128543:+
BRCA	cis	rs73201462	0.901	rs2811486	ENSG00000242551.2	POU5F1P6	3.72	0.000208	0.0118	0.19	0.11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128201232	chr3:128674735~128677005:-
BRCA	cis	rs643177	0.963	rs612217	ENSG00000226004.1	RP11-10J5.1	-3.72	0.000208	0.0118	-0.11	-0.11	Psoriasis;Inflammatory skin disease;	chr6:137891824	chr6:137943079~137945802:-
BRCA	cis	rs524281	0.684	rs7946447	ENSG00000255038.1	RP11-1167A19.2	-3.72	0.000208	0.0118	-0.16	-0.11	Electroencephalogram traits;	chr11:66096867	chr11:66067277~66069619:-
BRCA	cis	rs11893307	0.537	rs61345672	ENSG00000235852.1	AC005540.3	3.72	0.000208	0.0118	0.15	0.11	Mean platelet volume;	chr2:190642288	chr2:190880797~190882059:-
BRCA	cis	rs4919669	0.719	rs17114803	ENSG00000213277.3	MARCKSL1P1	3.72	0.000208	0.0118	0.18	0.11	Mean arterial pressure (long-term average);Systolic blood pressure (long-term average);	chr10:102627177	chr10:103175554~103176094:+
BRCA	cis	rs7617773	0.963	rs12494304	ENSG00000199476.1	Y_RNA	3.72	0.000208	0.0118	0.15	0.11	Coronary artery disease;	chr3:48136539	chr3:48288587~48288694:+
BRCA	cis	rs4699052	0.963	rs56144793	ENSG00000251288.2	RP11-10L12.2	-3.72	0.000208	0.0118	-0.13	-0.11	Testicular germ cell tumor;	chr4:103229496	chr4:102751401~102752641:+
BRCA	cis	rs5758511	0.773	rs62240999	ENSG00000233903.2	Z83851.4	3.72	0.000208	0.0118	0.17	0.11	Birth weight;	chr22:41959559	chr22:42276355~42277052:+
BRCA	cis	rs2712184	0.873	rs1548945	ENSG00000237930.1	AC007563.4	3.72	0.000208	0.0118	0.12	0.11	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);	chr2:216801065	chr2:216785774~216786144:-
BRCA	cis	rs67073037	0.955	rs4666133	ENSG00000230730.1	AC074011.2	-3.72	0.000208	0.0118	-0.16	-0.11	Breast cancer;Breast cancer (estrogen-receptor negative);	chr2:28913757	chr2:28633282~28664540:-
BRCA	cis	rs591584	1	rs6483348	ENSG00000255893.1	RP11-685N10.1	-3.72	0.000208	0.0118	-0.12	-0.11	Macrophage Migration Inhibitory Factor levels;	chr11:94594211	chr11:94472908~94473570:-
BRCA	cis	rs6545883	0.868	rs7594191	ENSG00000212978.6	AC016747.3	-3.72	0.000208	0.0118	-0.15	-0.11	Tuberculosis;	chr2:61612883	chr2:61141592~61144969:-
BRCA	cis	rs7709909	0.755	rs2081853	ENSG00000249655.1	CTC-325J23.2	3.72	0.000208	0.0118	0.12	0.11	HDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;	chr5:80668530	chr5:80630313~80631590:-
BRCA	cis	rs7395581	1	rs7395581	ENSG00000280615.1	Y_RNA	-3.72	0.000208	0.0118	-0.14	-0.11	HDL cholesterol;	chr11:47224846	chr11:47614898~47614994:-
BRCA	cis	rs9329221	0.537	rs6986911	ENSG00000253641.4	RP11-981G7.2	-3.72	0.000208	0.0118	-0.13	-0.11	Neuroticism;	chr8:10121013	chr8:10474565~10481974:+
BRCA	cis	rs7590368	0.926	rs12623588	ENSG00000272275.1	RP11-791G15.2	-3.72	0.000209	0.0118	-0.15	-0.11	Educational attainment (years of education);	chr2:10817486	chr2:10767875~10770058:-
BRCA	cis	rs1032833	0.732	rs17363246	ENSG00000271401.1	RP11-171I2.3	-3.72	0.000209	0.0118	-0.29	-0.11	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);	chr2:179118768	chr2:178644717~178645179:+
BRCA	cis	rs1032833	0.732	rs17454108	ENSG00000271401.1	RP11-171I2.3	-3.72	0.000209	0.0118	-0.29	-0.11	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);	chr2:179122316	chr2:178644717~178645179:+
BRCA	cis	rs4512344	0.509	rs2409784	ENSG00000254948.1	OR7E158P	3.72	0.000209	0.0118	0.13	0.11	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:11539347	chr8:11919900~11920809:-
BRCA	cis	rs10829156	0.732	rs1917823	ENSG00000240291.1	RP11-499P20.2	3.72	0.000209	0.0118	0.14	0.11	Sudden cardiac arrest;	chr10:18528184	chr10:18513115~18545651:-
BRCA	cis	rs72928364	1	rs67991823	ENSG00000244119.1	PDCL3P4	3.72	0.000209	0.0118	0.14	0.11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100912833	chr3:101712472~101713191:+
BRCA	cis	rs7682431	0.551	rs4416442	ENSG00000270720.1	RP11-84C13.2	3.72	0.000209	0.0118	0.13	0.11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr4:88945562	chr4:89119284~89119871:+
BRCA	cis	rs9733	0.596	rs12063547	ENSG00000231073.1	RP11-316M1.3	-3.72	0.000209	0.0118	-0.12	-0.11	Tonsillectomy;	chr1:150701577	chr1:150973123~150975534:+
BRCA	cis	rs6693017	0.818	rs61830270	ENSG00000272823.1	RP11-295M18.6	-3.72	0.000209	0.0118	-0.15	-0.11	Monocyte early outgrowth colony forming units;	chr1:220806392	chr1:220828676~220829211:-
BRCA	cis	rs2154490	0.853	rs2832394	ENSG00000176054.6	RPL23P2	-3.72	0.000209	0.0118	-0.13	-0.11	Glucocorticoid-induced osteonecrosis;	chr21:29546454	chr21:28997613~28998033:-
BRCA	cis	rs6696239	0.956	rs6678802	ENSG00000227711.2	RP11-275O4.5	-3.72	0.000209	0.0118	-0.16	-0.11	Height;	chr1:227652030	chr1:227509028~227520477:-
BRCA	cis	rs6696239	0.911	rs10799437	ENSG00000227711.2	RP11-275O4.5	-3.72	0.000209	0.0118	-0.16	-0.11	Height;	chr1:227652145	chr1:227509028~227520477:-
BRCA	cis	rs465969	1	rs35856111	ENSG00000271789.1	RP5-1112D6.7	3.72	0.000209	0.0118	0.27	0.11	Psoriasis;	chr6:111452265	chr6:111297126~111298510:+
BRCA	cis	rs4470077	1	rs4470077	ENSG00000258413.1	RP11-665C16.6	-3.72	0.000209	0.0118	-0.17	-0.11	Platelet count;	chr14:55430820	chr14:55262767~55272075:-
BRCA	cis	rs7201929	0.801	rs9933198	ENSG00000278665.1	RP11-666O2.4	-3.72	0.000209	0.0118	-0.13	-0.11	QT interval;	chr16:28877088	chr16:28599241~28601881:-
BRCA	cis	rs7267979	0.966	rs3827014	ENSG00000204556.4	CTD-2514C3.1	3.72	0.000209	0.0118	0.15	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25390923	chr20:26018832~26020684:+
BRCA	cis	rs875971	0.862	rs778734	ENSG00000273024.4	INTS4P2	-3.72	0.000209	0.0118	-0.13	-0.11	Aortic root size;	chr7:66349862	chr7:65647864~65715661:+
BRCA	cis	rs3742264	0.656	rs9526128	ENSG00000235903.6	CPB2-AS1	-3.72	0.000209	0.0118	-0.14	-0.11	Blood protein levels;	chr13:46004219	chr13:46052806~46113332:+
BRCA	cis	rs875971	0.558	rs4433015	ENSG00000272831.1	RP11-792A8.4	-3.72	0.000209	0.0118	-0.1	-0.11	Aortic root size;	chr7:66174736	chr7:66739829~66740385:-
BRCA	cis	rs77633900	0.614	rs280005	ENSG00000196274.5	Metazoa_SRP	3.72	0.000209	0.0118	0.17	0.11	Glioma;Non-glioblastoma glioma;	chr15:76716844	chr15:76230048~76230390:-
BRCA	cis	rs6674176	0.551	rs12045544	ENSG00000237950.1	RP11-7O11.3	-3.72	0.000209	0.0118	-0.23	-0.11	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43959042	chr1:43944370~43946551:-
BRCA	cis	rs3816183	1	rs13026205	ENSG00000226491.1	FTOP1	-3.72	0.000209	0.0118	-0.15	-0.11	Hypospadias;	chr2:42790947	chr2:42797225~42798712:-
BRCA	cis	rs77633900	0.614	rs2930681	ENSG00000196274.5	Metazoa_SRP	3.72	0.000209	0.0118	0.17	0.11	Glioma;Non-glioblastoma glioma;	chr15:76702809	chr15:76230048~76230390:-
BRCA	cis	rs2386661	1	rs4749853	ENSG00000242147.1	RP13-463N16.6	-3.72	0.000209	0.0118	-0.15	-0.11	Breast cancer;	chr10:5632795	chr10:5594991~5596118:-
BRCA	cis	rs2832077	0.527	rs11088095	ENSG00000232855.5	AF131217.1	3.72	0.000209	0.0118	0.14	0.11	Cognitive test performance;	chr21:28850866	chr21:28439346~28674848:-
BRCA	cis	rs2832077	0.527	rs2142375	ENSG00000232855.5	AF131217.1	3.72	0.000209	0.0118	0.14	0.11	Cognitive test performance;	chr21:28851420	chr21:28439346~28674848:-
BRCA	cis	rs9287719	0.967	rs6432121	ENSG00000224177.5	LINC00570	3.72	0.000209	0.0118	0.13	0.11	Prostate cancer;	chr2:10613678	chr2:11393981~11403077:+
BRCA	cis	rs7914558	0.621	rs7896290	ENSG00000213277.3	MARCKSL1P1	3.72	0.000209	0.0118	0.14	0.11	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102896258	chr10:103175554~103176094:+
BRCA	cis	rs17406451	0.759	rs12989996	ENSG00000234936.1	AC010883.5	3.72	0.000209	0.0118	0.11	0.11	Mitochondrial DNA levels;	chr2:43425030	chr2:43229573~43233394:+
BRCA	cis	rs7395581	0.918	rs11039166	ENSG00000280615.1	Y_RNA	3.72	0.000209	0.0118	0.14	0.11	HDL cholesterol;	chr11:47295140	chr11:47614898~47614994:-
BRCA	cis	rs2518049	0.904	rs4881397	ENSG00000224034.1	RP11-445P17.8	3.72	0.000209	0.0118	0.22	0.11	Metabolic traits;	chr10:5079680	chr10:5266033~5271236:-
BRCA	cis	rs7267979	1	rs2297496	ENSG00000276952.1	RP5-965G21.6	-3.72	0.000209	0.0118	-0.14	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25315151	chr20:25284915~25285588:-
BRCA	cis	rs11148252	0.74	rs3803264	ENSG00000272281.5	TPTE2P2	3.72	0.000209	0.0118	0.11	0.11	Lewy body disease;	chr13:52397758	chr13:52219344~52334277:-
BRCA	cis	rs1949733	0.958	rs3103069	ENSG00000205959.3	RP11-689P11.2	3.72	0.000209	0.0118	0.12	0.11	Response to antineoplastic agents;	chr4:8507724	chr4:8482270~8512610:+
BRCA	cis	rs10510102	0.516	rs11200301	ENSG00000226864.1	ATE1-AS1	3.72	0.000209	0.0118	0.22	0.11	Breast cancer;	chr10:121977976	chr10:121928312~121951965:+
BRCA	cis	rs2286503	0.533	rs1880239	ENSG00000226329.2	AC005682.6	3.72	0.000209	0.0118	0.12	0.11	Fibrinogen;	chr7:22832065	chr7:22863874~22881350:-
BRCA	cis	rs7412746	0.566	rs11204743	ENSG00000224800.1	RP11-235D19.2	-3.72	0.000209	0.0118	-0.15	-0.11	Melanoma;	chr1:150917930	chr1:150881236~150881683:-
BRCA	cis	rs4237845	0.537	rs1599931	ENSG00000257159.1	RP11-58A17.3	3.72	0.000209	0.0118	0.15	0.11	Intelligence (multi-trait analysis);	chr12:57865067	chr12:57967058~57968399:+
BRCA	cis	rs6870983	0.802	rs10214175	ENSG00000247828.6	TMEM161B-AS1	-3.72	0.000209	0.0118	-0.14	-0.11	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index;	chr5:88468530	chr5:88268895~88436685:+
BRCA	cis	rs2562456	0.682	rs11085464	ENSG00000213976.4	CTD-2561J22.2	-3.72	0.000209	0.0118	-0.14	-0.11	Pain;	chr19:21568976	chr19:21382865~21387177:+
BRCA	cis	rs7246967	0.866	rs6511385	ENSG00000198153.8	ZNF849P	-3.72	0.000209	0.0118	-0.16	-0.11	Bronchopulmonary dysplasia;	chr19:22854134	chr19:22685167~22686732:+
BRCA	cis	rs7246967	0.932	rs35735434	ENSG00000198153.8	ZNF849P	-3.72	0.000209	0.0118	-0.16	-0.11	Bronchopulmonary dysplasia;	chr19:22856675	chr19:22685167~22686732:+
BRCA	cis	rs7246967	0.932	rs34373479	ENSG00000198153.8	ZNF849P	-3.72	0.000209	0.0118	-0.16	-0.11	Bronchopulmonary dysplasia;	chr19:22861060	chr19:22685167~22686732:+
BRCA	cis	rs16893526	0.649	rs9344224	ENSG00000224995.1	LINC01526	-3.72	0.000209	0.0118	-0.18	-0.11	Coronary heart disease;	chr6:81808355	chr6:81813286~81814157:-
BRCA	cis	rs1411478	1	rs3789362	ENSG00000243155.1	RP11-46A10.5	3.72	0.000209	0.0118	0.12	0.11	Menopause (age at onset);Progressive supranuclear palsy;	chr1:180982556	chr1:180944042~180976482:-
BRCA	cis	rs10777288	0.561	rs7358706	ENSG00000258100.1	RP11-121E16.1	3.72	0.000209	0.0118	0.15	0.11	Pulmonary function (smoking interaction);	chr12:90997701	chr12:91362196~91368606:+
BRCA	cis	rs10777288	0.561	rs7358707	ENSG00000258100.1	RP11-121E16.1	3.72	0.000209	0.0118	0.15	0.11	Pulmonary function (smoking interaction);	chr12:90997793	chr12:91362196~91368606:+
BRCA	cis	rs1119582	0.632	rs454949	ENSG00000279118.1	RP11-517I3.2	3.72	0.000209	0.0118	0.12	0.11	Select biomarker traits;	chr5:126000699	chr5:126496279~126498604:+
BRCA	cis	rs73222236	0.787	rs7621970	ENSG00000239213.4	NCK1-AS1	3.72	0.000209	0.0118	0.13	0.11	Coronary artery disease;	chr3:136645500	chr3:136841726~136862054:-
BRCA	cis	rs1008375	0.931	rs10019482	ENSG00000249502.1	AC006160.5	-3.72	0.000209	0.0119	-0.13	-0.11	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17576456	chr4:17587467~17614571:-
BRCA	cis	rs9650657	0.623	rs7004253	ENSG00000154316.13	TDH	3.72	0.000209	0.0119	0.14	0.11	Neuroticism;	chr8:10743347	chr8:11339637~11368452:+
BRCA	cis	rs28680850	0.541	rs1024549	ENSG00000253982.1	CTD-2336O2.1	3.72	0.000209	0.0119	0.16	0.11	Triglycerides;	chr8:1429025	chr8:1761990~1764502:-
BRCA	cis	rs11098499	0.954	rs6834796	ENSG00000225892.3	RP11-384K6.2	3.72	0.000209	0.0119	0.12	0.11	Corneal astigmatism;	chr4:119493538	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.954	rs11734241	ENSG00000225892.3	RP11-384K6.2	3.72	0.000209	0.0119	0.12	0.11	Corneal astigmatism;	chr4:119495717	chr4:118632274~118634759:+
BRCA	cis	rs1046491	0.901	rs7226632	ENSG00000264964.1	RP11-888D10.3	3.72	0.000209	0.0119	0.24	0.11	Scarlet fever;	chr18:9179151	chr18:9315194~9334441:-
BRCA	cis	rs1046491	1	rs11877843	ENSG00000264964.1	RP11-888D10.3	3.72	0.000209	0.0119	0.24	0.11	Scarlet fever;	chr18:9180217	chr18:9315194~9334441:-
BRCA	cis	rs11239930	0.538	rs3011810	ENSG00000237188.3	RP11-337C18.8	3.72	0.000209	0.0119	0.13	0.11	AIDS progression;	chr1:147082079	chr1:147172771~147211568:+
BRCA	cis	rs875971	0.862	rs4236208	ENSG00000271064.1	RP11-792A8.3	3.72	0.00021	0.0119	0.13	0.11	Aortic root size;	chr7:66284091	chr7:66748838~66749077:-
BRCA	cis	rs5758511	0.773	rs62240997	ENSG00000231261.1	HMGN2P10	-3.72	0.00021	0.0119	-0.15	-0.11	Birth weight;	chr22:41958563	chr22:41709225~41709489:-
BRCA	cis	rs9300255	0.722	rs12304248	ENSG00000256028.2	RP11-197N18.2	-3.72	0.00021	0.0119	-0.12	-0.11	Neutrophil percentage of white cells;	chr12:123325878	chr12:122975320~122982907:+
BRCA	cis	rs4930561	0.765	rs4930564	ENSG00000255306.1	RP5-901A4.1	3.72	0.00021	0.0119	0.12	0.11	Breast cancer in childhood cancer survivors;IgG glycosylation;	chr11:68215814	chr11:68024809~68030461:-
BRCA	cis	rs875971	0.825	rs4587224	ENSG00000273024.4	INTS4P2	3.72	0.00021	0.0119	0.13	0.11	Aortic root size;	chr7:66271195	chr7:65647864~65715661:+
BRCA	cis	rs875971	0.792	rs6971752	ENSG00000273024.4	INTS4P2	3.72	0.00021	0.0119	0.13	0.11	Aortic root size;	chr7:66272999	chr7:65647864~65715661:+
BRCA	cis	rs875971	0.862	rs10950033	ENSG00000273024.4	INTS4P2	3.72	0.00021	0.0119	0.13	0.11	Aortic root size;	chr7:66274686	chr7:65647864~65715661:+
BRCA	cis	rs875971	0.862	rs11760844	ENSG00000273024.4	INTS4P2	3.72	0.00021	0.0119	0.13	0.11	Aortic root size;	chr7:66274896	chr7:65647864~65715661:+
BRCA	cis	rs6801044	1	rs6801044	ENSG00000272792.1	RP11-141C7.4	-3.72	0.00021	0.0119	-0.18	-0.11	Creatinine levels in ischemic stroke;	chr3:195562517	chr3:195639990~195640460:+
BRCA	cis	rs1479090	0.805	rs4691895	ENSG00000250027.1	RP11-563E2.2	-3.72	0.00021	0.0119	-0.15	-0.11	Lung cancer;	chr4:163127047	chr4:163108785~163119965:+
BRCA	cis	rs987724	0.515	rs11914959	ENSG00000244515.1	KRT18P34	-3.72	0.00021	0.0119	-0.18	-0.11	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156898616	chr3:157162663~157163932:-
BRCA	cis	rs987724	0.501	rs4680313	ENSG00000244515.1	KRT18P34	-3.72	0.00021	0.0119	-0.18	-0.11	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156901348	chr3:157162663~157163932:-
BRCA	cis	rs442309	0.807	rs224073	ENSG00000238280.1	RP11-436D10.3	-3.72	0.00021	0.0119	-0.15	-0.11	Vogt-Koyanagi-Harada syndrome;	chr10:62750344	chr10:62793562~62805887:-
BRCA	cis	rs442309	0.841	rs224074	ENSG00000238280.1	RP11-436D10.3	-3.72	0.00021	0.0119	-0.15	-0.11	Vogt-Koyanagi-Harada syndrome;	chr10:62750627	chr10:62793562~62805887:-
BRCA	cis	rs442309	0.841	rs224076	ENSG00000238280.1	RP11-436D10.3	-3.72	0.00021	0.0119	-0.15	-0.11	Vogt-Koyanagi-Harada syndrome;	chr10:62751881	chr10:62793562~62805887:-
BRCA	cis	rs442309	0.841	rs224078	ENSG00000238280.1	RP11-436D10.3	-3.72	0.00021	0.0119	-0.15	-0.11	Vogt-Koyanagi-Harada syndrome;	chr10:62752000	chr10:62793562~62805887:-
BRCA	cis	rs442309	0.775	rs7893375	ENSG00000238280.1	RP11-436D10.3	-3.72	0.00021	0.0119	-0.15	-0.11	Vogt-Koyanagi-Harada syndrome;	chr10:62757846	chr10:62793562~62805887:-
BRCA	cis	rs9470794	0.915	rs73421477	ENSG00000204110.6	RP1-153P14.8	-3.72	0.00021	0.0119	-0.23	-0.11	Type 2 diabetes;	chr6:38009039	chr6:37507348~37535616:+
BRCA	cis	rs9470794	0.748	rs73421479	ENSG00000204110.6	RP1-153P14.8	-3.72	0.00021	0.0119	-0.23	-0.11	Type 2 diabetes;	chr6:38009299	chr6:37507348~37535616:+
BRCA	cis	rs7267979	1	rs6132835	ENSG00000204556.4	CTD-2514C3.1	-3.72	0.00021	0.0119	-0.16	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25454031	chr20:26018832~26020684:+
BRCA	cis	rs7267979	0.933	rs11699203	ENSG00000204556.4	CTD-2514C3.1	-3.72	0.00021	0.0119	-0.16	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25454533	chr20:26018832~26020684:+
BRCA	cis	rs7267979	0.933	rs6138571	ENSG00000204556.4	CTD-2514C3.1	-3.72	0.00021	0.0119	-0.16	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25454752	chr20:26018832~26020684:+
BRCA	cis	rs7267979	0.966	rs416745	ENSG00000204556.4	CTD-2514C3.1	-3.72	0.00021	0.0119	-0.16	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25458232	chr20:26018832~26020684:+
BRCA	cis	rs7267979	1	rs447722	ENSG00000204556.4	CTD-2514C3.1	-3.72	0.00021	0.0119	-0.16	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25462874	chr20:26018832~26020684:+
BRCA	cis	rs7267979	1	rs422424	ENSG00000204556.4	CTD-2514C3.1	-3.72	0.00021	0.0119	-0.16	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25464810	chr20:26018832~26020684:+
BRCA	cis	rs7267979	1	rs422844	ENSG00000204556.4	CTD-2514C3.1	-3.72	0.00021	0.0119	-0.16	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25464955	chr20:26018832~26020684:+
BRCA	cis	rs7267979	1	rs401166	ENSG00000204556.4	CTD-2514C3.1	-3.72	0.00021	0.0119	-0.16	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25465672	chr20:26018832~26020684:+
BRCA	cis	rs9287719	0.81	rs1990612	ENSG00000224177.5	LINC00570	3.72	0.00021	0.0119	0.13	0.11	Prostate cancer;	chr2:10641818	chr2:11393981~11403077:+
BRCA	cis	rs1005277	0.522	rs289643	ENSG00000226578.1	RP11-258F22.1	-3.72	0.00021	0.0119	-0.12	-0.11	Extrinsic epigenetic age acceleration;	chr10:37652566	chr10:37775371~37784131:-
BRCA	cis	rs91731	0.92	rs10073359	ENSG00000249572.1	CTD-2203K17.1	3.72	0.00021	0.0119	0.21	0.11	Lung function (FVC);	chr5:33235953	chr5:33424025~33440619:-
BRCA	cis	rs962856	1	rs1032157	ENSG00000236605.1	AC023115.4	3.72	0.00021	0.0119	0.14	0.11	Pancreatic cancer;	chr2:67374684	chr2:67324627~67325304:+
BRCA	cis	rs17169635	0.879	rs7801596	ENSG00000272941.1	RP11-134L10.1	-3.72	0.00021	0.0119	-0.13	-0.11	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);	chr7:134859303	chr7:135168403~135169547:+
BRCA	cis	rs2411233	0.967	rs1347270	ENSG00000259278.1	RP11-62C7.2	3.72	0.00021	0.0119	0.14	0.11	Platelet count;	chr15:38994342	chr15:39019233~39024918:+
BRCA	cis	rs9549260	0.564	rs6563844	ENSG00000168852.11	TPTE2P5	3.72	0.00021	0.0119	0.11	0.11	Red blood cell count;	chr13:40724054	chr13:40822296~40921749:-
BRCA	cis	rs74233809	1	rs11191593	ENSG00000236937.2	PTGES3P4	3.72	0.00021	0.0119	0.25	0.11	Birth weight;	chr10:103179458	chr10:102845595~102845950:+
BRCA	cis	rs10043775	0.831	rs7731526	ENSG00000251330.3	CTD-2283N19.1	-3.72	0.00021	0.0119	-0.14	-0.11	Periodontal microbiota;	chr5:148341330	chr5:148430159~148430807:-
BRCA	cis	rs2839186	0.771	rs13049175	ENSG00000223901.2	AP001469.5	-3.72	0.00021	0.0119	-0.11	-0.11	Testicular germ cell tumor;	chr21:46221412	chr21:46220269~46225364:+
BRCA	cis	rs10844706	0.699	rs10772087	ENSG00000256673.1	RP11-599J14.2	-3.72	0.00021	0.0119	-0.14	-0.11	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9730515	chr12:9398355~9414851:-
BRCA	cis	rs10043228	1	rs62385993	ENSG00000271918.1	CTD-2287O16.5	-3.72	0.00021	0.0119	-0.17	-0.11	Asthma or chronic obstructive pulmonary disease;	chr5:116266557	chr5:116083807~116085416:-
BRCA	cis	rs897984	0.571	rs7184567	ENSG00000275263.1	RP11-1072A3.4	-3.72	0.00021	0.0119	-0.14	-0.11	Dementia with Lewy bodies;	chr16:31009757	chr16:30956872~30957199:-
BRCA	cis	rs17801127	0.748	rs6708998	ENSG00000231969.1	AC144449.1	3.72	0.00021	0.0119	0.2	0.11	Liver enzyme levels (alanine transaminase);	chr2:149656004	chr2:149587196~149848233:+
BRCA	cis	rs8098244	0.52	rs12955607	ENSG00000265752.2	RP11-403A21.1	-3.72	0.00021	0.0119	-0.13	-0.11	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23677671	chr18:23957754~23982556:-
BRCA	cis	rs11098499	0.874	rs13123591	ENSG00000260404.2	RP11-384K6.6	3.72	0.00021	0.0119	0.11	0.11	Corneal astigmatism;	chr4:119184835	chr4:118591773~118633729:+
BRCA	cis	rs2274273	0.554	rs3742564	ENSG00000259318.1	RP11-454L9.2	-3.72	0.00021	0.0119	-0.1	-0.11	Protein biomarker;	chr14:55063402	chr14:55394940~55395233:-
BRCA	cis	rs7617773	0.963	rs12493256	ENSG00000199476.1	Y_RNA	3.72	0.00021	0.0119	0.15	0.11	Coronary artery disease;	chr3:48135257	chr3:48288587~48288694:+
BRCA	cis	rs6545883	0.929	rs2421203	ENSG00000270820.4	RP11-355B11.2	3.72	0.00021	0.0119	0.13	0.11	Tuberculosis;	chr2:61442113	chr2:61471188~61484130:+
BRCA	cis	rs6840360	0.571	rs2406976	ENSG00000270265.1	RP11-731D1.4	-3.72	0.00021	0.0119	-0.13	-0.11	Intelligence (multi-trait analysis);	chr4:151619904	chr4:151333775~151353224:-
BRCA	cis	rs91731	0.79	rs4498262	ENSG00000249572.1	CTD-2203K17.1	3.72	0.00021	0.0119	0.21	0.11	Lung function (FVC);	chr5:33229068	chr5:33424025~33440619:-
BRCA	cis	rs4243971	0.516	rs2208131	ENSG00000275576.1	RP5-836N17.4	-3.72	0.00021	0.0119	-0.13	-0.11	Inflammatory bowel disease;Crohn's disease;	chr20:32360478	chr20:32116171~32116629:+
BRCA	cis	rs253959	0.545	rs712596	ENSG00000248445.4	SEMA6A-AS1	-3.72	0.00021	0.0119	-0.11	-0.11	Bipolar disorder and schizophrenia;	chr5:116322214	chr5:116447547~116508276:+
BRCA	cis	rs12122100	0.545	rs1984615	ENSG00000244371.2	PFN1P8	3.72	0.00021	0.0119	0.13	0.11	HIV-1 control;	chr1:147034652	chr1:146957117~146957659:-
BRCA	cis	rs16917546	1	rs10995251	ENSG00000238280.1	RP11-436D10.3	3.72	0.00021	0.0119	0.15	0.11	Basal cell carcinoma;	chr10:62638706	chr10:62793562~62805887:-
BRCA	cis	rs10457838	0.755	rs11755147	ENSG00000231760.4	RP11-350J20.5	-3.72	0.00021	0.0119	-0.16	-0.11	Post-traumatic stress disorder;	chr6:149090029	chr6:149796151~149826294:-
BRCA	cis	rs9470794	1	rs876818	ENSG00000204110.6	RP1-153P14.8	-3.72	0.00021	0.0119	-0.2	-0.11	Type 2 diabetes;	chr6:38152884	chr6:37507348~37535616:+
BRCA	cis	rs56281245	0.793	rs75707738	ENSG00000249363.1	CTB-78O21.1	3.72	0.00021	0.0119	0.25	0.11	Hepcidin levels;	chr5:145593459	chr5:145728360~145729349:-
BRCA	cis	rs12030196	1	rs11207369	ENSG00000230812.4	LINC01358	3.72	0.00021	0.0119	0.12	0.11	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr1:59019419	chr1:59020387~59044614:+
BRCA	cis	rs4478858	0.684	rs4949372	ENSG00000223907.1	LINC01226	-3.72	0.00021	0.0119	-0.14	-0.11	Alcohol dependence;	chr1:31266010	chr1:31518435~31524245:+
BRCA	cis	rs301807	0.533	rs1466654	ENSG00000232912.4	RP5-1115A15.1	3.72	0.00021	0.0119	0.11	0.11	Vitiligo;Sum eosinophil basophil counts;	chr1:8315853	chr1:8424645~8434838:+
BRCA	cis	rs7246967	0.608	rs396440	ENSG00000198153.8	ZNF849P	-3.72	0.00021	0.0119	-0.17	-0.11	Bronchopulmonary dysplasia;	chr19:22820164	chr19:22685167~22686732:+
BRCA	cis	rs7246967	0.608	rs433579	ENSG00000198153.8	ZNF849P	-3.72	0.00021	0.0119	-0.17	-0.11	Bronchopulmonary dysplasia;	chr19:22820325	chr19:22685167~22686732:+
BRCA	cis	rs6088590	1	rs2076668	ENSG00000276073.1	RP5-1125A11.7	-3.72	0.00021	0.0119	-0.13	-0.11	Coronary artery disease;	chr20:34849818	chr20:33985617~33988989:-
BRCA	cis	rs1075265	0.84	rs10084355	ENSG00000272156.1	RP11-477N3.1	-3.72	0.00021	0.0119	-0.12	-0.11	Chronotype;Morning vs. evening chronotype;	chr2:54021711	chr2:54082554~54085066:+
BRCA	cis	rs524281	0.861	rs10896091	ENSG00000255038.1	RP11-1167A19.2	-3.72	0.00021	0.0119	-0.17	-0.11	Electroencephalogram traits;	chr11:66183354	chr11:66067277~66069619:-
BRCA	cis	rs1348850	0.872	rs4893825	ENSG00000271825.1	RP11-337N6.2	3.72	0.00021	0.0119	0.15	0.11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177433959	chr2:177300600~177302006:+
BRCA	cis	rs12468226	1	rs16824599	ENSG00000272966.1	RP11-686O6.1	3.72	0.00021	0.0119	0.2	0.11	Urate levels;	chr2:202358243	chr2:202336739~202337200:+
BRCA	cis	rs256438	0.896	rs34655435	ENSG00000251050.1	RP11-168A11.4	-3.72	0.00021	0.0119	-0.13	-0.11	Serum thyroid-stimulating hormone levels;	chr5:80095187	chr5:80019609~80019920:+
BRCA	cis	rs2998286	0.723	rs332152	ENSG00000237128.1	RP11-351M16.3	3.72	0.00021	0.0119	0.15	0.11	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28585602	chr10:28433008~28495813:-
BRCA	cis	rs17756712	0.528	rs2073008	ENSG00000271727.1	RP11-532F6.4	3.72	0.00021	0.0119	0.17	0.11	Vertical cup-disc ratio;	chr6:638345	chr6:711533~750729:+
BRCA	cis	rs3758086	0.542	rs1731273	ENSG00000246582.2	RP11-1149O23.3	-3.72	0.00021	0.0119	-0.14	-0.11	Glomerular filtration rate (creatinine);	chr8:23901742	chr8:23224471~23230926:+
BRCA	cis	rs10129255	0.912	rs61997792	ENSG00000232216.1	IGHV3-43	3.72	0.00021	0.0119	0.1	0.11	Kawasaki disease;	chr14:106799304	chr14:106470264~106470800:-
BRCA	cis	rs16917546	1	rs10995258	ENSG00000238280.1	RP11-436D10.3	3.72	0.00021	0.0119	0.15	0.11	Basal cell carcinoma;	chr10:62649027	chr10:62793562~62805887:-
BRCA	cis	rs67073037	0.868	rs11127193	ENSG00000230730.1	AC074011.2	-3.72	0.000211	0.0119	-0.16	-0.11	Breast cancer;Breast cancer (estrogen-receptor negative);	chr2:28910255	chr2:28633282~28664540:-
BRCA	cis	rs6439699	1	rs35361620	ENSG00000273486.1	RP11-731C17.2	3.72	0.000211	0.0119	0.16	0.11	Intelligence (multi-trait analysis);	chr3:137291095	chr3:136837338~136839021:-
BRCA	cis	rs58521262	0.556	rs289362	ENSG00000268105.1	RP11-369G6.2	3.72	0.000211	0.0119	0.16	0.11	Testicular germ cell tumor;	chr19:22935597	chr19:23125665~23128543:+
BRCA	cis	rs7561149	0.768	rs6709708	ENSG00000270574.1	RP11-171I2.2	-3.72	0.000211	0.0119	-0.16	-0.11	QT interval;	chr2:178864354	chr2:178578790~178580906:+
BRCA	cis	rs8054556	1	rs11150577	ENSG00000214725.6	CDIPT-AS1	-3.72	0.000211	0.0119	-0.14	-0.11	Autism spectrum disorder or schizophrenia;	chr16:29975204	chr16:29863593~29868053:+
BRCA	cis	rs9470794	0.915	rs57160603	ENSG00000204110.6	RP1-153P14.8	-3.72	0.000211	0.0119	-0.21	-0.11	Type 2 diabetes;	chr6:38038623	chr6:37507348~37535616:+
BRCA	cis	rs448720	1	rs11853797	ENSG00000260657.2	RP11-315D16.4	3.72	0.000211	0.0119	0.14	0.11	Cognitive performance;	chr15:67908240	chr15:68267792~68277994:-
BRCA	cis	rs17169635	0.601	rs993034	ENSG00000272941.1	RP11-134L10.1	-3.72	0.000211	0.0119	-0.12	-0.11	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);	chr7:134862058	chr7:135168403~135169547:+
BRCA	cis	rs721917	0.526	rs2256574	ENSG00000280355.1	RP11-119F19.5	-3.72	0.000211	0.0119	-0.12	-0.11	Chronic obstructive pulmonary disease;	chr10:79925283	chr10:79681973~79684094:-
BRCA	cis	rs10129255	1	rs10141557	ENSG00000253132.1	IGHV3-62	-3.72	0.000211	0.0119	-0.09	-0.11	Kawasaki disease;	chr14:106767990	chr14:106643142~106643585:-
BRCA	cis	rs9818758	0.607	rs11716445	ENSG00000270441.1	RP11-694I15.7	3.72	0.000211	0.0119	0.26	0.11	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49368662	chr3:49140086~49160851:-
BRCA	cis	rs962856	0.693	rs2902005	ENSG00000236605.1	AC023115.4	3.72	0.000211	0.0119	0.15	0.11	Pancreatic cancer;	chr2:67395949	chr2:67324627~67325304:+
BRCA	cis	rs889956	0.747	rs1429316	ENSG00000233251.6	AC007743.1	-3.72	0.000211	0.0119	-0.14	-0.11	Educational attainment;	chr2:57032480	chr2:56173534~56185770:-
BRCA	cis	rs6545883	0.965	rs7421663	ENSG00000212978.6	AC016747.3	3.72	0.000211	0.0119	0.16	0.11	Tuberculosis;	chr2:61526651	chr2:61141592~61144969:-
BRCA	cis	rs801193	0.935	rs11772264	ENSG00000232546.1	RP11-458F8.1	-3.72	0.000211	0.0119	-0.09	-0.11	Aortic root size;	chr7:66711400	chr7:66848496~66858136:+
BRCA	cis	rs7267979	1	rs4815404	ENSG00000274414.1	RP5-965G21.4	3.72	0.000211	0.0119	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25321209	chr20:25239007~25245229:-
BRCA	cis	rs6545883	0.965	rs3771261	ENSG00000212978.6	AC016747.3	3.72	0.000211	0.0119	0.15	0.11	Tuberculosis;	chr2:61535026	chr2:61141592~61144969:-
BRCA	cis	rs79280654	0.867	rs17368999	ENSG00000237301.1	RP4-680D5.2	3.72	0.000211	0.0119	0.23	0.11	Alcoholic chronic pancreatitis;	chr1:15375938	chr1:15586136~15603626:-
BRCA	cis	rs9341808	0.727	rs4706834	ENSG00000233967.5	RP11-250B2.3	3.72	0.000211	0.0119	0.11	0.11	Sitting height ratio;	chr6:80302888	chr6:80443344~80465927:+
BRCA	cis	rs9287719	0.934	rs6721510	ENSG00000224177.5	LINC00570	3.72	0.000211	0.0119	0.13	0.11	Prostate cancer;	chr2:10610920	chr2:11393981~11403077:+
BRCA	cis	rs9287719	0.967	rs6721514	ENSG00000224177.5	LINC00570	3.72	0.000211	0.0119	0.13	0.11	Prostate cancer;	chr2:10610936	chr2:11393981~11403077:+
BRCA	cis	rs9287719	0.934	rs6706763	ENSG00000224177.5	LINC00570	3.72	0.000211	0.0119	0.13	0.11	Prostate cancer;	chr2:10611281	chr2:11393981~11403077:+
BRCA	cis	rs7620503	1	rs7645281	ENSG00000277241.1	RP11-114M1.3	3.72	0.000211	0.0119	0.13	0.11	Corneal structure;	chr3:177587048	chr3:177700346~177701072:-
BRCA	cis	rs669446	0.527	rs72883034	ENSG00000236200.4	KDM4A-AS1	-3.72	0.000211	0.0119	-0.14	-0.11	Amyotrophic lateral sclerosis (age of onset);	chr1:43646708	chr1:43699765~43708138:-
BRCA	cis	rs2298450	0.55	rs9974155	ENSG00000231106.2	LINC01436	3.72	0.000211	0.0119	0.12	0.11	Schizophrenia;	chr21:36282092	chr21:36005338~36007838:+
BRCA	cis	rs2298450	0.55	rs9977284	ENSG00000231106.2	LINC01436	3.72	0.000211	0.0119	0.12	0.11	Schizophrenia;	chr21:36282329	chr21:36005338~36007838:+
BRCA	cis	rs853679	0.545	rs35949109	ENSG00000216901.1	AL022393.7	3.72	0.000211	0.0119	0.22	0.11	Depression;	chr6:28058148	chr6:28176188~28176674:+
BRCA	cis	rs1710990	1	rs11158784	ENSG00000259165.1	DDX18P1	-3.72	0.000211	0.0119	-0.14	-0.11	Intelligence (multi-trait analysis);	chr14:69086688	chr14:69083398~69085389:+
BRCA	cis	rs9921338	0.961	rs9937269	ENSG00000262636.1	CTD-3088G3.4	3.72	0.000211	0.0119	0.18	0.11	Vein graft stenosis in coronary artery bypass grafting;	chr16:11322822	chr16:11380859~11381118:-
BRCA	cis	rs2991971	0.967	rs2356551	ENSG00000280836.1	AL355480.1	3.72	0.000211	0.0119	0.13	0.11	High light scatter reticulocyte count;	chr1:45543646	chr1:45581219~45581321:-
BRCA	cis	rs6585424	1	rs12763392	ENSG00000225484.5	NUTM2B-AS1	3.72	0.000211	0.0119	0.22	0.11	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80175239	chr10:79663088~79826594:-
BRCA	cis	rs6840360	1	rs3749561	ENSG00000251611.1	RP11-610P16.1	3.72	0.000211	0.0119	0.1	0.11	Intelligence (multi-trait analysis);	chr4:151688965	chr4:151407551~151408835:-
BRCA	cis	rs372883	0.648	rs1153288	ENSG00000176054.6	RPL23P2	3.72	0.000211	0.0119	0.13	0.11	Pancreatic cancer;	chr21:29313770	chr21:28997613~28998033:-
BRCA	cis	rs4538475	0.559	rs73243126	ENSG00000273133.1	RP11-799M12.2	-3.72	0.000211	0.0119	-0.24	-0.11	Parkinson's disease;	chr4:15674059	chr4:15563698~15564253:-
BRCA	cis	rs10761482	0.769	rs10761483	ENSG00000254271.1	RP11-131N11.4	3.72	0.000211	0.0119	0.17	0.11	Schizophrenia;	chr10:60338640	chr10:60734342~60741828:+
BRCA	cis	rs478607	0.831	rs11602411	ENSG00000237410.1	AP001092.4	-3.72	0.000211	0.0119	-0.19	-0.11	Urate levels;	chr11:64681751	chr11:64646399~64659681:+
BRCA	cis	rs7839435	1	rs11780592	ENSG00000279302.1	RP11-16P20.4	-3.72	0.000211	0.0119	-0.16	-0.11	Lung adenocarcinoma;	chr8:27561230	chr8:27701194~27703789:+
BRCA	cis	rs9341808	0.754	rs6907729	ENSG00000233967.5	RP11-250B2.3	-3.72	0.000211	0.0119	-0.11	-0.11	Sitting height ratio;	chr6:80295205	chr6:80443344~80465927:+
BRCA	cis	rs9309473	0.687	rs6748040	ENSG00000230002.2	ALMS1-IT1	-3.72	0.000211	0.0119	-0.14	-0.11	Metabolite levels;	chr2:73382800	chr2:73456764~73459484:+
BRCA	cis	rs10043228	0.826	rs12514785	ENSG00000250015.1	CTC-339F2.2	3.72	0.000211	0.0119	0.17	0.11	Asthma or chronic obstructive pulmonary disease;	chr5:116139040	chr5:116302354~116304134:-
BRCA	cis	rs2243480	1	rs35058610	ENSG00000226767.1	RP11-328P23.3	-3.72	0.000211	0.0119	-0.19	-0.11	Diabetic kidney disease;	chr7:65925938	chr7:65508773~65508944:-
BRCA	cis	rs1015362	0.54	rs2050209	ENSG00000276073.1	RP5-1125A11.7	3.72	0.000211	0.0119	0.15	0.11	Freckles;Red vs. non-red hair color;Skin sensitivity to sun;Burning and freckling;	chr20:33897730	chr20:33985617~33988989:-
BRCA	cis	rs17092148	0.666	rs62212084	ENSG00000126005.14	MMP24-AS1	-3.72	0.000211	0.0119	-0.15	-0.11	Neuroticism;	chr20:34871048	chr20:35216462~35278131:-
BRCA	cis	rs8114671	0.562	rs959829	ENSG00000279253.1	RP4-614O4.13	3.72	0.000212	0.012	0.14	0.11	Height;	chr20:34758244	chr20:35262727~35264187:-
BRCA	cis	rs1484642	0.881	rs7005350	ENSG00000272267.2	RP11-375N15.2	-3.72	0.000212	0.012	-0.21	-0.11	Bipolar disorder and schizophrenia;	chr8:10132588	chr8:9555144~9556520:-
BRCA	cis	rs4908769	0.66	rs159962	ENSG00000232912.4	RP5-1115A15.1	3.72	0.000212	0.012	0.12	0.11	Allergy;	chr1:8430923	chr1:8424645~8434838:+
BRCA	cis	rs11098499	0.73	rs12505735	ENSG00000260091.1	RP11-33B1.4	-3.72	0.000212	0.012	-0.1	-0.11	Corneal astigmatism;	chr4:119611801	chr4:119409333~119410233:+
BRCA	cis	rs7572733	1	rs11683222	ENSG00000231621.1	AC013264.2	-3.72	0.000212	0.012	-0.1	-0.11	Dermatomyositis;	chr2:198019304	chr2:197197991~197199273:+
BRCA	cis	rs7572733	1	rs2139049	ENSG00000231621.1	AC013264.2	-3.72	0.000212	0.012	-0.1	-0.11	Dermatomyositis;	chr2:198022936	chr2:197197991~197199273:+
BRCA	cis	rs7572733	1	rs2196172	ENSG00000231621.1	AC013264.2	-3.72	0.000212	0.012	-0.1	-0.11	Dermatomyositis;	chr2:198025169	chr2:197197991~197199273:+
BRCA	cis	rs7572733	1	rs1595823	ENSG00000231621.1	AC013264.2	-3.72	0.000212	0.012	-0.1	-0.11	Dermatomyositis;	chr2:198027075	chr2:197197991~197199273:+
BRCA	cis	rs8098244	0.964	rs79685315	ENSG00000265752.2	RP11-403A21.1	-3.72	0.000212	0.012	-0.15	-0.11	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23913774	chr18:23957754~23982556:-
BRCA	cis	rs752010	0.756	rs6600380	ENSG00000230638.4	RP11-486B10.4	3.72	0.000212	0.012	0.14	0.11	Lupus nephritis in systemic lupus erythematosus;	chr1:41589143	chr1:41542069~41544310:+
BRCA	cis	rs9840812	0.861	rs684773	ENSG00000273486.1	RP11-731C17.2	3.72	0.000212	0.012	0.15	0.11	Fibrinogen levels;	chr3:136237463	chr3:136837338~136839021:-
BRCA	cis	rs7824557	0.564	rs7839307	ENSG00000255020.1	AF131216.5	-3.72	0.000212	0.012	-0.13	-0.11	Retinal vascular caliber;	chr8:11341283	chr8:11345748~11347502:-
BRCA	cis	rs295490	0.748	rs78251555	ENSG00000272656.1	RP11-219D15.3	3.72	0.000212	0.012	0.28	0.11	PR interval in Tripanosoma cruzi seropositivity;	chr3:139460159	chr3:139349024~139349371:-
BRCA	cis	rs1722141	0.634	rs1722139	ENSG00000237471.1	AC073115.6	3.72	0.000212	0.012	0.15	0.11	Sitting height ratio;	chr7:46025661	chr7:45969657~45980191:+
BRCA	cis	rs3136441	1	rs7941964	ENSG00000200376.1	RNU5E-10P	3.72	0.000212	0.012	0.18	0.11	HDL cholesterol;	chr11:46784025	chr11:47576471~47576588:-
BRCA	cis	rs6142618	0.562	rs6142616	ENSG00000277692.1	RP11-358N2.2	-3.72	0.000212	0.012	-0.12	-0.11	Inflammatory bowel disease;	chr20:32126625	chr20:32355053~32355734:+
BRCA	cis	rs897984	0.513	rs17839568	ENSG00000275263.1	RP11-1072A3.4	-3.72	0.000212	0.012	-0.13	-0.11	Dementia with Lewy bodies;	chr16:31088462	chr16:30956872~30957199:-
BRCA	cis	rs3753275	0.69	rs11121197	ENSG00000232912.4	RP5-1115A15.1	3.72	0.000212	0.012	0.15	0.11	Educational attainment;	chr1:8526274	chr1:8424645~8434838:+
BRCA	cis	rs115575488	0.85	rs17186003	ENSG00000231365.4	RP11-418J17.1	3.72	0.000212	0.012	0.22	0.11	Lobe attachment (rater-scored or self-reported);	chr1:119074504	chr1:119140396~119275973:+
BRCA	cis	rs9788721	0.836	rs17405217	ENSG00000261762.1	RP11-650L12.2	-3.72	0.000212	0.012	-0.15	-0.11	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78438807	chr15:78589123~78591276:-
BRCA	cis	rs1670533	1	rs6822863	ENSG00000251639.2	RP11-20I20.1	3.72	0.000212	0.012	0.18	0.11	Recombination rate (females);	chr4:1061818	chr4:1100016~1101558:-
BRCA	cis	rs6964587	0.869	rs2013334	ENSG00000188693.7	CYP51A1-AS1	3.72	0.000212	0.012	0.12	0.11	Breast cancer;	chr7:91920343	chr7:92134604~92180725:+
BRCA	cis	rs4243971	0.516	rs62208761	ENSG00000275576.1	RP5-836N17.4	-3.72	0.000212	0.012	-0.13	-0.11	Inflammatory bowel disease;Crohn's disease;	chr20:32275071	chr20:32116171~32116629:+
BRCA	cis	rs595982	0.501	rs112370206	ENSG00000235191.1	NUCB1-AS1	3.72	0.000212	0.012	0.15	0.11	Red cell distribution width;	chr19:48893366	chr19:48910930~48918891:-
BRCA	cis	rs595982	0.546	rs9941490	ENSG00000235191.1	NUCB1-AS1	3.72	0.000212	0.012	0.15	0.11	Red cell distribution width;	chr19:48893480	chr19:48910930~48918891:-
BRCA	cis	rs10412972	1	rs10412972	ENSG00000273837.1	LLNLR-470E3.1	-3.72	0.000212	0.012	-0.16	-0.11	Plasma plasminogen levels;	chr19:51651652	chr19:51639478~51639931:-
BRCA	cis	rs7903456	0.648	rs9421580	ENSG00000200253.1	RNU6-529P	3.72	0.000212	0.012	0.14	0.11	Gout;Renal underexcretion gout;	chr10:87075497	chr10:87041238~87041341:-
BRCA	cis	rs62025270	0.576	rs55639123	ENSG00000259416.2	RP11-158M2.5	-3.72	0.000212	0.012	-0.18	-0.11	Idiopathic pulmonary fibrosis;	chr15:85617037	chr15:85754941~85756237:-
BRCA	cis	rs7722600	1	rs73298155	ENSG00000253404.1	AC034243.1	-3.72	0.000212	0.012	-0.19	-0.11	Heart rate;	chr5:137755134	chr5:138744434~138753309:-
BRCA	cis	rs11168618	1	rs11168618	ENSG00000273765.1	RP11-370I10.11	3.72	0.000212	0.012	0.13	0.11	Adiponectin levels;	chr12:48539450	chr12:48360920~48361377:+
BRCA	cis	rs9400180	0.959	rs9400191	ENSG00000271734.1	RP1-111B22.3	-3.72	0.000212	0.012	-0.15	-0.11	Major depressive disorder;	chr6:108066924	chr6:108030249~108030718:-
BRCA	cis	rs9400180	0.959	rs9374018	ENSG00000271734.1	RP1-111B22.3	-3.72	0.000212	0.012	-0.15	-0.11	Major depressive disorder;	chr6:108067073	chr6:108030249~108030718:-
BRCA	cis	rs7620503	0.959	rs7627379	ENSG00000277241.1	RP11-114M1.3	3.72	0.000212	0.012	0.13	0.11	Corneal structure;	chr3:177569158	chr3:177700346~177701072:-
BRCA	cis	rs13401620	0.784	rs7604224	ENSG00000229326.3	AC069154.4	-3.72	0.000212	0.012	-0.15	-0.11	Breast size;	chr2:119838307	chr2:119698623~119700151:+
BRCA	cis	rs4950322	0.563	rs6686480	ENSG00000227242.3	NBPF13P	-3.72	0.000212	0.012	-0.15	-0.11	Protein quantitative trait loci;	chr1:147111986	chr1:147021320~147124525:-
BRCA	cis	rs1153858	1	rs4775911	ENSG00000275672.1	GATM-AS1	3.72	0.000212	0.012	0.15	0.11	Homoarginine levels;	chr15:45357589	chr15:45378700~45380123:+
BRCA	cis	rs77956314	0.818	rs12296869	ENSG00000277840.1	RP11-103B5.4	3.72	0.000212	0.012	0.21	0.11	Hippocampal volume;Subcortical brain region volumes;	chr12:116993398	chr12:117002463~117003152:+
BRCA	cis	rs6812193	0.518	rs17236661	ENSG00000271676.1	RP11-1E1.2	3.72	0.000212	0.012	0.17	0.11	Parkinson's disease;	chr4:76275323	chr4:77112495~77113458:-
BRCA	cis	rs6918586	0.658	rs198813	ENSG00000272462.2	U91328.19	-3.72	0.000212	0.012	-0.13	-0.11	Schizophrenia;	chr6:26127998	chr6:25992662~26001775:+
BRCA	cis	rs12479254	0.701	rs6718026	ENSG00000228989.1	AC133528.2	3.72	0.000212	0.012	0.12	0.11	Brain structure;	chr2:241555977	chr2:241690414~241694289:+
BRCA	cis	rs983392	0.803	rs56189574	ENSG00000275344.1	MIR6503	-3.72	0.000212	0.012	-0.12	-0.11	Alzheimer's disease (late onset);	chr11:60166019	chr11:60209071~60209156:-
BRCA	cis	rs2562456	0.876	rs2650844	ENSG00000268117.1	VN1R84P	3.72	0.000212	0.012	0.17	0.11	Pain;	chr19:21419288	chr19:21719801~21720035:-
BRCA	cis	rs28489187	0.706	rs233066	ENSG00000223653.4	RP11-131L23.1	3.72	0.000212	0.012	0.13	0.11	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85339247	chr1:85276715~85448124:+
BRCA	cis	rs4272720	1	rs4453139	ENSG00000228754.1	RP11-534L6.3	-3.72	0.000212	0.012	-0.16	-0.11	Platelet count;Plateletcrit;	chr10:49056985	chr10:48745545~48746128:-
BRCA	cis	rs3748682	0.861	rs72661832	ENSG00000212541.1	RNU6-510P	-3.72	0.000212	0.012	-0.17	-0.11	Hypothyroidism;	chr1:37795061	chr1:37991462~37991569:+
BRCA	cis	rs34792	0.524	rs34629185	ENSG00000260872.1	RP11-680G24.5	-3.72	0.000212	0.012	-0.13	-0.11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15517597	chr16:15018106~15020488:-
BRCA	cis	rs832540	0.931	rs33319	ENSG00000271828.1	CTD-2310F14.1	-3.72	0.000212	0.012	-0.14	-0.11	Coronary artery disease;	chr5:56910848	chr5:56927874~56929573:+
BRCA	cis	rs36051895	0.559	rs72701682	ENSG00000236254.1	MTND4P14	-3.72	0.000212	0.012	-0.14	-0.11	Pediatric autoimmune diseases;	chr9:5208025	chr9:5107937~5109290:+
BRCA	cis	rs3858526	0.834	rs10839169	ENSG00000224295.2	AC087380.14	3.72	0.000212	0.012	0.16	0.11	DNA methylation (variation);	chr11:5981960	chr11:5518441~5524955:-
BRCA	cis	rs3760982	0.585	rs67648499	ENSG00000267191.1	RP11-15A1.2	-3.72	0.000212	0.012	-0.15	-0.11	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43789903	chr19:43902001~43926545:+
BRCA	cis	rs8058578	0.832	rs7500719	ENSG00000260082.1	RP11-2C24.5	3.72	0.000212	0.012	0.13	0.11	Multiple myeloma;	chr16:30829556	chr16:30821068~30822110:-
BRCA	cis	rs1865760	0.622	rs9968910	ENSG00000272462.2	U91328.19	-3.72	0.000212	0.012	-0.14	-0.11	Height;	chr6:26071867	chr6:25992662~26001775:+
BRCA	cis	rs7746199	0.736	rs13193542	ENSG00000216901.1	AL022393.7	3.72	0.000212	0.012	0.3	0.11	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27734646	chr6:28176188~28176674:+
BRCA	cis	rs7746199	0.736	rs13193480	ENSG00000216901.1	AL022393.7	3.72	0.000212	0.012	0.3	0.11	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27734782	chr6:28176188~28176674:+
BRCA	cis	rs964611	1	rs7168752	ENSG00000259488.2	RP11-154J22.1	-3.72	0.000212	0.012	-0.16	-0.11	Metabolite levels (Pyroglutamine);	chr15:48308583	chr15:48312353~48331856:-
BRCA	cis	rs964611	1	rs79040993	ENSG00000259488.2	RP11-154J22.1	-3.72	0.000212	0.012	-0.16	-0.11	Metabolite levels (Pyroglutamine);	chr15:48309949	chr15:48312353~48331856:-
BRCA	cis	rs964611	0.935	rs76749119	ENSG00000259488.2	RP11-154J22.1	-3.72	0.000212	0.012	-0.16	-0.11	Metabolite levels (Pyroglutamine);	chr15:48312868	chr15:48312353~48331856:-
BRCA	cis	rs964611	1	rs74012001	ENSG00000259488.2	RP11-154J22.1	-3.72	0.000212	0.012	-0.16	-0.11	Metabolite levels (Pyroglutamine);	chr15:48313011	chr15:48312353~48331856:-
BRCA	cis	rs6500596	0.506	rs1530088	ENSG00000267077.1	RP11-127I20.5	3.72	0.000212	0.012	0.13	0.11	Schizophrenia;	chr16:4389130	chr16:4795265~4796532:-
BRCA	cis	rs9333290	0.93	rs34483988	ENSG00000259915.2	RP11-410E4.1	3.72	0.000212	0.012	0.15	0.11	Urinary albumin-to-creatinine ratio in non-diabetics;Urinary albumin-to-creatinine ratio;	chr2:186695046	chr2:186354570~186356773:-
BRCA	cis	rs9307551	0.741	rs11098735	ENSG00000250334.4	LINC00989	-3.72	0.000212	0.012	-0.18	-0.11	Refractive error;	chr4:79537259	chr4:79492416~79576460:+
BRCA	cis	rs7179228	0.613	rs7178537	ENSG00000260657.2	RP11-315D16.4	3.72	0.000212	0.012	0.2	0.11	Systolic blood pressure;	chr15:68338627	chr15:68267792~68277994:-
BRCA	cis	rs6993270	0.779	rs7017821	ENSG00000245330.4	KB-1471A8.1	-3.72	0.000212	0.012	-0.18	-0.11	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr8:119908658	chr8:119867419~119874488:-
BRCA	cis	rs6993270	0.779	rs7017583	ENSG00000245330.4	KB-1471A8.1	-3.72	0.000212	0.012	-0.18	-0.11	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr8:119908740	chr8:119867419~119874488:-
BRCA	cis	rs6993270	0.779	rs4128183	ENSG00000245330.4	KB-1471A8.1	-3.72	0.000212	0.012	-0.18	-0.11	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr8:119909248	chr8:119867419~119874488:-
BRCA	cis	rs7005380	0.606	rs6469869	ENSG00000245330.4	KB-1471A8.1	-3.72	0.000212	0.012	-0.18	-0.11	Interstitial lung disease;	chr8:119909696	chr8:119867419~119874488:-
BRCA	cis	rs6993270	0.817	rs4053280	ENSG00000245330.4	KB-1471A8.1	-3.72	0.000212	0.012	-0.18	-0.11	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr8:119911667	chr8:119867419~119874488:-
BRCA	cis	rs6993270	0.779	rs16893285	ENSG00000245330.4	KB-1471A8.1	-3.72	0.000212	0.012	-0.18	-0.11	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr8:119912499	chr8:119867419~119874488:-
BRCA	cis	rs6993270	0.779	rs7011167	ENSG00000245330.4	KB-1471A8.1	-3.72	0.000212	0.012	-0.18	-0.11	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr8:119912823	chr8:119867419~119874488:-
BRCA	cis	rs6993270	0.779	rs7010899	ENSG00000245330.4	KB-1471A8.1	-3.72	0.000212	0.012	-0.18	-0.11	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr8:119912870	chr8:119867419~119874488:-
BRCA	cis	rs6993270	0.725	rs6993186	ENSG00000245330.4	KB-1471A8.1	-3.72	0.000212	0.012	-0.18	-0.11	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr8:119912897	chr8:119867419~119874488:-
BRCA	cis	rs7267979	1	rs4815408	ENSG00000274973.1	RP13-401N8.7	3.72	0.000212	0.012	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25366042	chr20:25845497~25845862:+
BRCA	cis	rs7312933	0.703	rs10492388	ENSG00000257225.1	RP11-328C8.4	-3.72	0.000212	0.012	-0.14	-0.11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42214199	chr12:42459366~42466128:+
BRCA	cis	rs11773103	1	rs73208507	ENSG00000224046.1	AC005076.5	3.72	0.000212	0.012	0.25	0.11	Bipolar disorder or major depressive disorder (combined);	chr7:87192492	chr7:87151423~87152420:-
BRCA	cis	rs11773103	1	rs11773103	ENSG00000224046.1	AC005076.5	3.72	0.000212	0.012	0.25	0.11	Bipolar disorder or major depressive disorder (combined);	chr7:87192664	chr7:87151423~87152420:-
BRCA	cis	rs11773103	0.867	rs73208517	ENSG00000224046.1	AC005076.5	3.72	0.000212	0.012	0.25	0.11	Bipolar disorder or major depressive disorder (combined);	chr7:87198251	chr7:87151423~87152420:-
BRCA	cis	rs11773103	1	rs73208522	ENSG00000224046.1	AC005076.5	3.72	0.000212	0.012	0.25	0.11	Bipolar disorder or major depressive disorder (combined);	chr7:87198863	chr7:87151423~87152420:-
BRCA	cis	rs672059	0.967	rs514183	ENSG00000224468.3	RP11-181K3.4	-3.72	0.000212	0.012	-0.12	-0.11	Hypertriglyceridemia;	chr1:183194039	chr1:183138402~183141282:-
BRCA	cis	rs875971	0.83	rs778715	ENSG00000271064.1	RP11-792A8.3	-3.72	0.000212	0.012	-0.14	-0.11	Aortic root size;	chr7:66384222	chr7:66748838~66749077:-
BRCA	cis	rs9785234	1	rs35890695	ENSG00000175611.10	LINC00476	3.72	0.000212	0.012	0.15	0.11	Glomerular filtration rate in chronic kidney disease;	chr9:96169373	chr9:95759231~95875977:-
BRCA	cis	rs4761470	0.511	rs1880936	ENSG00000258365.1	RP11-1105G2.3	-3.72	0.000212	0.012	-0.2	-0.11	Estradiol plasma levels (breast cancer);	chr12:94277816	chr12:94277758~94282844:-
BRCA	cis	rs875971	0.862	rs778720	ENSG00000271064.1	RP11-792A8.3	3.72	0.000212	0.012	0.14	0.11	Aortic root size;	chr7:66381288	chr7:66748838~66749077:-
BRCA	cis	rs8054556	1	rs11150579	ENSG00000183604.13	SMG1P5	-3.72	0.000213	0.012	-0.11	-0.11	Autism spectrum disorder or schizophrenia;	chr16:29989009	chr16:30267553~30335374:-
BRCA	cis	rs6142618	0.562	rs4911545	ENSG00000277692.1	RP11-358N2.2	-3.72	0.000213	0.012	-0.12	-0.11	Inflammatory bowel disease;	chr20:32123712	chr20:32355053~32355734:+
BRCA	cis	rs6142618	0.562	rs6142613	ENSG00000277692.1	RP11-358N2.2	-3.72	0.000213	0.012	-0.12	-0.11	Inflammatory bowel disease;	chr20:32124203	chr20:32355053~32355734:+
BRCA	cis	rs6142618	0.562	rs6142615	ENSG00000277692.1	RP11-358N2.2	-3.72	0.000213	0.012	-0.12	-0.11	Inflammatory bowel disease;	chr20:32124636	chr20:32355053~32355734:+
BRCA	cis	rs6142618	0.562	rs6058528	ENSG00000277692.1	RP11-358N2.2	-3.72	0.000213	0.012	-0.12	-0.11	Inflammatory bowel disease;	chr20:32127247	chr20:32355053~32355734:+
BRCA	cis	rs3735485	0.738	rs28636402	ENSG00000201772.1	SNORA5C	3.72	0.000213	0.012	0.15	0.11	White blood cell count;Sum basophil neutrophil counts;Neutrophil count;Granulocyte percentage of myeloid white cells;Monocyte percentage of white cells;Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Lymphocyte counts;	chr7:45067278	chr7:45104906~45105042:-
BRCA	cis	rs2191566	0.959	rs7256345	ENSG00000266921.1	RP11-15A1.7	-3.72	0.000213	0.012	-0.14	-0.11	Acute lymphoblastic leukemia (childhood);	chr19:44006753	chr19:43996896~44002836:-
BRCA	cis	rs2191566	0.959	rs7255623	ENSG00000266921.1	RP11-15A1.7	-3.72	0.000213	0.012	-0.14	-0.11	Acute lymphoblastic leukemia (childhood);	chr19:44006754	chr19:43996896~44002836:-
BRCA	cis	rs11168618	0.703	rs4760721	ENSG00000240399.1	RP1-228P16.1	3.72	0.000213	0.012	0.12	0.11	Adiponectin levels;	chr12:48531941	chr12:48054813~48055591:-
BRCA	cis	rs17711722	0.675	rs6947132	ENSG00000223473.2	GS1-124K5.3	-3.72	0.000213	0.012	-0.09	-0.11	Calcium levels;	chr7:65808508	chr7:66491049~66493566:-
BRCA	cis	rs7722600	0.745	rs73299268	ENSG00000253404.1	AC034243.1	-3.72	0.000213	0.012	-0.19	-0.11	Heart rate;	chr5:137992634	chr5:138744434~138753309:-
BRCA	cis	rs4835473	0.932	rs6852195	ENSG00000246448.2	RP13-578N3.3	3.72	0.000213	0.012	0.13	0.11	Immature fraction of reticulocytes;	chr4:143742584	chr4:143700257~143865072:+
BRCA	cis	rs6500602	0.563	rs917305	ENSG00000280063.1	RP11-295D4.3	3.72	0.000213	0.012	0.1	0.11	Schizophrenia;	chr16:4390592	chr16:4346694~4348648:-
BRCA	cis	rs1670533	1	rs12645644	ENSG00000251639.2	RP11-20I20.1	3.72	0.000213	0.012	0.18	0.11	Recombination rate (females);	chr4:1060371	chr4:1100016~1101558:-
BRCA	cis	rs35176054	0.73	rs7906955	ENSG00000280693.1	SH3PXD2A-AS1	-3.72	0.000213	0.012	-0.21	-0.11	Atrial fibrillation;	chr10:103758786	chr10:103745966~103755423:+
BRCA	cis	rs3824867	0.92	rs7948705	ENSG00000280615.1	Y_RNA	3.72	0.000213	0.012	0.14	0.11	Mean corpuscular hemoglobin;	chr11:47426404	chr11:47614898~47614994:-
BRCA	cis	rs2274273	0.624	rs7155954	ENSG00000259318.1	RP11-454L9.2	3.72	0.000213	0.012	0.1	0.11	Protein biomarker;	chr14:55284225	chr14:55394940~55395233:-
BRCA	cis	rs372883	0.967	rs1153280	ENSG00000215533.7	LINC00189	3.72	0.000213	0.012	0.13	0.11	Pancreatic cancer;	chr21:29305751	chr21:29193480~29288205:+
BRCA	cis	rs2795502	0.872	rs2744062	ENSG00000185904.10	LINC00839	-3.72	0.000213	0.012	-0.19	-0.11	Blood protein levels;	chr10:42759341	chr10:42475543~42495336:+
BRCA	cis	rs8005172	0.801	rs2008686	ENSG00000258867.4	LINC01146	3.72	0.000213	0.012	0.12	0.11	Parkinson's disease;	chr14:88019433	chr14:88024550~88097619:+
BRCA	cis	rs7172809	0.643	rs61483316	ENSG00000260139.5	CSPG4P13	-3.72	0.000213	0.012	-0.14	-0.11	Glucose homeostasis traits;	chr15:77541805	chr15:77894684~77904674:+
BRCA	cis	rs9921338	0.668	rs193778	ENSG00000262636.1	CTD-3088G3.4	-3.72	0.000213	0.012	-0.19	-0.11	Vein graft stenosis in coronary artery bypass grafting;	chr16:11257354	chr16:11380859~11381118:-
BRCA	cis	rs11098499	0.863	rs3775841	ENSG00000260091.1	RP11-33B1.4	-3.72	0.000213	0.012	-0.1	-0.11	Corneal astigmatism;	chr4:119504622	chr4:119409333~119410233:+
BRCA	cis	rs4538475	0.559	rs2302469	ENSG00000273133.1	RP11-799M12.2	-3.72	0.000213	0.012	-0.23	-0.11	Parkinson's disease;	chr4:15686981	chr4:15563698~15564253:-
BRCA	cis	rs10463316	0.894	rs4099169	ENSG00000260581.1	CTB-113P19.4	3.72	0.000213	0.012	0.13	0.11	Metabolite levels (Pyroglutamine);	chr5:151386965	chr5:151652275~151655449:+
BRCA	cis	rs3740713	1	rs60376560	ENSG00000256361.1	RP11-613F22.6	3.72	0.000213	0.012	0.18	0.11	Amyotrophic lateral sclerosis (sporadic);	chr11:18432195	chr11:18511043~18511475:-
BRCA	cis	rs73198271	0.74	rs964771	ENSG00000233609.3	RP11-62H7.2	3.72	0.000213	0.012	0.11	0.11	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8793429	chr8:8961200~8979025:+
BRCA	cis	rs6964587	1	rs1063243	ENSG00000188693.7	CYP51A1-AS1	-3.72	0.000213	0.012	-0.12	-0.11	Breast cancer;	chr7:92097613	chr7:92134604~92180725:+
BRCA	cis	rs6943931	0.895	rs12540864	ENSG00000230658.1	KLHL7-AS1	-3.72	0.000213	0.012	-0.15	-0.11	Diabetic kidney disease;	chr7:22374792	chr7:23101228~23105703:-
BRCA	cis	rs7703051	0.763	rs6871667	ENSG00000271815.1	CTD-2235C13.3	-3.72	0.000213	0.012	-0.15	-0.11	Age-related diseases, mortality and associated endophenotypes;LDL cholesterol;Age-related disease endophenotypes;	chr5:75308917	chr5:75363760~75364242:+
BRCA	cis	rs13401620	0.81	rs7558053	ENSG00000229326.3	AC069154.4	-3.72	0.000213	0.012	-0.15	-0.11	Breast size;	chr2:119772244	chr2:119698623~119700151:+
BRCA	cis	rs7474896	0.616	rs1985260	ENSG00000226578.1	RP11-258F22.1	-3.72	0.000213	0.012	-0.16	-0.11	Obesity (extreme);	chr10:38145162	chr10:37775371~37784131:-
BRCA	cis	rs911119	0.913	rs12710327	ENSG00000270001.1	RP11-218C14.8	-3.72	0.000213	0.012	-0.15	-0.11	Chronic kidney disease;	chr20:23589052	chr20:23631826~23632316:-
BRCA	cis	rs6964587	0.773	rs2097810	ENSG00000188693.7	CYP51A1-AS1	-3.72	0.000213	0.012	-0.13	-0.11	Breast cancer;	chr7:92347912	chr7:92134604~92180725:+
BRCA	cis	rs251253	0.827	rs3097320	ENSG00000253959.1	CTB-43E15.1	3.72	0.000213	0.012	0.1	0.11	PR interval;	chr5:173074970	chr5:173642519~173658194:+
BRCA	cis	rs251253	0.827	rs3095842	ENSG00000253959.1	CTB-43E15.1	3.72	0.000213	0.012	0.1	0.11	PR interval;	chr5:173074983	chr5:173642519~173658194:+
BRCA	cis	rs3015497	0.637	rs7153431	ENSG00000259113.1	RP11-406H23.2	-3.72	0.000213	0.012	-0.13	-0.11	Mean platelet volume;	chr14:50706760	chr14:50448807~50456742:+
BRCA	cis	rs8054556	1	rs9924686	ENSG00000183604.13	SMG1P5	-3.72	0.000213	0.012	-0.11	-0.11	Autism spectrum disorder or schizophrenia;	chr16:29991755	chr16:30267553~30335374:-
BRCA	cis	rs11098499	0.863	rs13134665	ENSG00000260404.2	RP11-384K6.6	3.72	0.000213	0.012	0.11	0.11	Corneal astigmatism;	chr4:119505275	chr4:118591773~118633729:+
BRCA	cis	rs12530845	0.887	rs79100776	ENSG00000223718.3	AC093107.7	3.72	0.000213	0.012	0.19	0.11	Red blood cell traits;	chr7:135631069	chr7:135660039~135660647:+
BRCA	cis	rs524281	0.861	rs11227415	ENSG00000255557.1	RP11-770G2.2	-3.72	0.000213	0.012	-0.16	-0.11	Electroencephalogram traits;	chr11:66117988	chr11:65745729~65771585:+
BRCA	cis	rs2965260	0.621	rs17305059	ENSG00000269051.4	CTD-2245F17.3	3.72	0.000213	0.012	0.2	0.11	IgG glycosylation;	chr19:53257505	chr19:53197111~53211015:+
BRCA	cis	rs1479090	0.723	rs7675998	ENSG00000250027.1	RP11-563E2.2	-3.72	0.000213	0.012	-0.15	-0.11	Lung cancer;	chr4:163086668	chr4:163108785~163119965:+
BRCA	cis	rs875971	1	rs6945843	ENSG00000229180.5	GS1-124K5.11	-3.72	0.000213	0.012	-0.1	-0.11	Aortic root size;	chr7:66269796	chr7:66526088~66542624:-
BRCA	cis	rs11233413	0.874	rs3793986	ENSG00000246067.6	RAB30-AS1	3.72	0.000213	0.012	0.13	0.11	Economic and political preferences (feminism/equality);	chr11:82993925	chr11:83072066~83106719:+
BRCA	cis	rs6547741	0.844	rs7586655	ENSG00000234072.1	AC074117.10	-3.72	0.000213	0.012	-0.11	-0.11	Oral cavity cancer;	chr2:27692792	chr2:27356246~27367622:+
BRCA	cis	rs3015469	0.671	rs2883951	ENSG00000269906.1	RP11-248J18.2	3.72	0.000213	0.012	0.17	0.11	Plasma amyloid beta peptide concentrations (ABx-40);	chr14:50687775	chr14:50662511~50663178:-
BRCA	cis	rs1971762	0.509	rs10783592	ENSG00000270175.1	RP11-793H13.11	-3.72	0.000213	0.012	-0.1	-0.11	Height;	chr12:53643646	chr12:53500162~53500936:-
BRCA	cis	rs2562456	0.792	rs2562398	ENSG00000268119.4	CTD-2561J22.5	-3.72	0.000213	0.012	-0.17	-0.11	Pain;	chr19:21540147	chr19:21444241~21463908:-
BRCA	cis	rs8098244	0.756	rs1154229	ENSG00000265752.2	RP11-403A21.1	-3.72	0.000213	0.012	-0.13	-0.11	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23902252	chr18:23957754~23982556:-
BRCA	cis	rs2281603	0.762	rs12588437	ENSG00000259116.1	RP11-973N13.4	-3.72	0.000213	0.012	-0.11	-0.11	Lymphocyte counts;	chr14:64580366	chr14:64514154~64540368:-
BRCA	cis	rs12887734	0.546	rs66676135	ENSG00000269910.1	RP11-73M18.10	3.72	0.000213	0.012	0.12	0.11	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103805167	chr14:103694516~103695050:-
BRCA	cis	rs11039100	0.527	rs10769249	ENSG00000224295.2	AC087380.14	-3.72	0.000213	0.012	-0.18	-0.11	Peripheral arterial disease (traffic-related air pollution interaction);	chr11:5818096	chr11:5518441~5524955:-
BRCA	cis	rs6918586	0.658	rs198825	ENSG00000272462.2	U91328.19	-3.72	0.000213	0.012	-0.13	-0.11	Schizophrenia;	chr6:26122274	chr6:25992662~26001775:+
BRCA	cis	rs591584	1	rs11020851	ENSG00000255893.1	RP11-685N10.1	-3.72	0.000213	0.012	-0.12	-0.11	Macrophage Migration Inhibitory Factor levels;	chr11:94593461	chr11:94472908~94473570:-
BRCA	cis	rs495337	0.736	rs595027	ENSG00000224397.4	LINC01272	-3.72	0.000213	0.012	-0.12	-0.11	Psoriasis;	chr20:49849185	chr20:50267486~50279795:+
BRCA	cis	rs7712401	0.755	rs1545697	ENSG00000251538.4	RP11-166A12.1	3.72	0.000213	0.012	0.12	0.11	Mean platelet volume;	chr5:122766582	chr5:122628952~122730685:-
BRCA	cis	rs875971	0.862	rs801194	ENSG00000273024.4	INTS4P2	3.72	0.000213	0.012	0.13	0.11	Aortic root size;	chr7:66563508	chr7:65647864~65715661:+
BRCA	cis	rs7176093	1	rs17641145	ENSG00000259295.5	CSPG4P12	-3.72	0.000213	0.012	-0.16	-0.11	Aging traits;	chr15:85823316	chr15:85191438~85213905:+
BRCA	cis	rs875971	0.825	rs66981195	ENSG00000273024.4	INTS4P2	3.72	0.000213	0.012	0.13	0.11	Aortic root size;	chr7:66614048	chr7:65647864~65715661:+
BRCA	cis	rs875971	0.862	rs3926380	ENSG00000273024.4	INTS4P2	3.72	0.000213	0.012	0.13	0.11	Aortic root size;	chr7:66615658	chr7:65647864~65715661:+
BRCA	cis	rs875971	0.825	rs1860472	ENSG00000273024.4	INTS4P2	3.72	0.000213	0.012	0.13	0.11	Aortic root size;	chr7:66617736	chr7:65647864~65715661:+
BRCA	cis	rs2795502	1	rs2795508	ENSG00000185904.10	LINC00839	3.72	0.000213	0.012	0.16	0.11	Blood protein levels;	chr10:42858107	chr10:42475543~42495336:+
BRCA	cis	rs5742933	0.842	rs1225101	ENSG00000253559.1	OSGEPL1-AS1	-3.72	0.000213	0.012	-0.16	-0.11	Ferritin levels;	chr2:189740695	chr2:189762704~189765556:+
BRCA	cis	rs875971	0.54	rs35510581	ENSG00000232546.1	RP11-458F8.1	3.72	0.000213	0.012	0.1	0.11	Aortic root size;	chr7:66113790	chr7:66848496~66858136:+
BRCA	cis	rs10844706	0.699	rs10844636	ENSG00000278635.1	CTD-2318O12.1	3.72	0.000213	0.012	0.12	0.11	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9735420	chr12:9415641~9416718:+
BRCA	cis	rs72720396	0.789	rs12022460	ENSG00000272931.1	RP5-943J3.2	3.72	0.000213	0.012	0.15	0.11	Chronotype;Morning vs. evening chronotype;	chr1:90736700	chr1:89820174~89820868:-
BRCA	cis	rs4272720	0.851	rs72789086	ENSG00000228754.1	RP11-534L6.3	-3.72	0.000213	0.012	-0.17	-0.11	Platelet count;Plateletcrit;	chr10:49171952	chr10:48745545~48746128:-
BRCA	cis	rs875971	0.862	rs13226170	ENSG00000273024.4	INTS4P2	-3.72	0.000213	0.012	-0.13	-0.11	Aortic root size;	chr7:66534311	chr7:65647864~65715661:+
BRCA	cis	rs875971	0.862	rs2420611	ENSG00000273024.4	INTS4P2	-3.72	0.000213	0.012	-0.13	-0.11	Aortic root size;	chr7:66534333	chr7:65647864~65715661:+
BRCA	cis	rs4819052	0.851	rs2877018	ENSG00000215447.6	BX322557.10	-3.72	0.000214	0.012	-0.12	-0.11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238391	chr21:45288052~45291738:+
BRCA	cis	rs4819052	0.851	rs2330012	ENSG00000215447.6	BX322557.10	-3.72	0.000214	0.012	-0.12	-0.11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238677	chr21:45288052~45291738:+
BRCA	cis	rs4819052	0.851	rs2877019	ENSG00000215447.6	BX322557.10	-3.72	0.000214	0.012	-0.12	-0.11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238732	chr21:45288052~45291738:+
BRCA	cis	rs4819052	0.851	rs2877020	ENSG00000215447.6	BX322557.10	-3.72	0.000214	0.012	-0.12	-0.11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238827	chr21:45288052~45291738:+
BRCA	cis	rs4819052	0.851	rs10470245	ENSG00000215447.6	BX322557.10	-3.72	0.000214	0.012	-0.12	-0.11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238997	chr21:45288052~45291738:+
BRCA	cis	rs1075265	0.756	rs809280	ENSG00000272156.1	RP11-477N3.1	-3.72	0.000214	0.012	-0.12	-0.11	Chronotype;Morning vs. evening chronotype;	chr2:53921270	chr2:54082554~54085066:+
BRCA	cis	rs6496044	0.547	rs7173125	ENSG00000230373.7	GOLGA6L5P	-3.72	0.000214	0.012	-0.12	-0.11	Interstitial lung disease;	chr15:85512214	chr15:84507885~84516814:-
BRCA	cis	rs9527	0.59	rs1935323	ENSG00000213061.2	PFN1P11	3.72	0.000214	0.012	0.16	0.11	Arsenic metabolism;	chr10:103117278	chr10:102838011~102845473:-
BRCA	cis	rs4449834	0.816	rs11985638	ENSG00000254432.1	RP11-33I11.2	-3.72	0.000214	0.0121	-0.15	-0.11	Sum eosinophil basophil counts;	chr8:60758961	chr8:60808735~60809606:-
BRCA	cis	rs34421088	0.532	rs3808515	ENSG00000154316.13	TDH	-3.72	0.000214	0.0121	-0.15	-0.11	Neuroticism;	chr8:11298532	chr8:11339637~11368452:+
BRCA	cis	rs7412746	0.634	rs72704658	ENSG00000231073.1	RP11-316M1.3	3.72	0.000214	0.0121	0.12	0.11	Melanoma;	chr1:150860534	chr1:150973123~150975534:+
BRCA	cis	rs10129255	0.83	rs61997609	ENSG00000211958.2	IGHV3-38	3.72	0.000214	0.0121	0.09	0.11	Kawasaki disease;	chr14:106692376	chr14:106410493~106411021:-
BRCA	cis	rs6545883	0.965	rs12713439	ENSG00000212978.6	AC016747.3	3.72	0.000214	0.0121	0.16	0.11	Tuberculosis;	chr2:61525019	chr2:61141592~61144969:-
BRCA	cis	rs6893300	0.785	rs6895902	ENSG00000250999.1	RP11-1379J22.5	3.72	0.000214	0.0121	0.15	0.11	Resting heart rate;	chr5:179774846	chr5:179657762~179664432:+
BRCA	cis	rs13401620	0.871	rs55658716	ENSG00000229326.3	AC069154.4	-3.72	0.000214	0.0121	-0.15	-0.11	Breast size;	chr2:119912650	chr2:119698623~119700151:+
BRCA	cis	rs251253	0.795	rs251234	ENSG00000253959.1	CTB-43E15.1	3.72	0.000214	0.0121	0.1	0.11	PR interval;	chr5:173104860	chr5:173642519~173658194:+
BRCA	cis	rs251253	0.795	rs173692	ENSG00000253959.1	CTB-43E15.1	3.72	0.000214	0.0121	0.1	0.11	PR interval;	chr5:173105562	chr5:173642519~173658194:+
BRCA	cis	rs9470794	1	rs35248010	ENSG00000204110.6	RP1-153P14.8	-3.72	0.000214	0.0121	-0.23	-0.11	Type 2 diabetes;	chr6:38026808	chr6:37507348~37535616:+
BRCA	cis	rs6750047	0.549	rs151096	ENSG00000235848.3	RMDN2-AS1	3.72	0.000214	0.0121	0.15	0.11	Cutaneous malignant melanoma;Melanoma;	chr2:38089429	chr2:37949911~38067041:-
BRCA	cis	rs9470794	1	rs34370874	ENSG00000204110.6	RP1-153P14.8	-3.72	0.000214	0.0121	-0.21	-0.11	Type 2 diabetes;	chr6:38026810	chr6:37507348~37535616:+
BRCA	cis	rs9470794	1	rs11757323	ENSG00000204110.6	RP1-153P14.8	-3.72	0.000214	0.0121	-0.21	-0.11	Type 2 diabetes;	chr6:38028313	chr6:37507348~37535616:+
BRCA	cis	rs3798305	1	rs16899788	ENSG00000272980.3	RP11-517H2.6	3.72	0.000214	0.0121	0.23	0.11	Smooth-surface caries;	chr6:167017838	chr6:166999405~167139141:+
BRCA	cis	rs7267979	1	rs3761117	ENSG00000274414.1	RP5-965G21.4	3.72	0.000214	0.0121	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25407434	chr20:25239007~25245229:-
BRCA	cis	rs11673344	0.67	rs73039188	ENSG00000267260.1	CTD-2162K18.4	-3.72	0.000214	0.0121	-0.17	-0.11	Obesity-related traits;	chr19:36922449	chr19:36773153~36777078:+
BRCA	cis	rs2657888	1	rs28697089	ENSG00000257576.1	RP11-153M3.1	-3.72	0.000214	0.0121	-0.14	-0.11	Adiponectin levels;	chr12:56544919	chr12:56511002~56512703:+
BRCA	cis	rs13217239	0.646	rs62401067	ENSG00000124549.13	BTN2A3P	3.72	0.000214	0.0121	0.12	0.11	Schizophrenia;	chr6:27050322	chr6:26421391~26432383:+
BRCA	cis	rs875971	0.545	rs3735147	ENSG00000232559.3	GS1-124K5.12	3.72	0.000214	0.0121	0.15	0.11	Aortic root size;	chr7:66505541	chr7:66554588~66576923:-
BRCA	cis	rs2555155	1	rs2555155	ENSG00000254595.1	CTD-2010I16.1	3.72	0.000214	0.0121	0.13	0.11	DNA methylation (variation);	chr11:6501574	chr11:6488186~6489377:-
BRCA	cis	rs7602460	0.74	rs13339780	ENSG00000234663.4	AC104820.2	-3.72	0.000214	0.0121	-0.09	-0.11	Atrioventricular conduction;	chr2:181389982	chr2:181101932~181399559:+
BRCA	cis	rs11082321	1	rs11875806	ENSG00000265943.1	RP11-739L10.1	-3.72	0.000214	0.0121	-0.2	-0.11	Breast cancer;	chr18:23197450	chr18:22699481~22933764:-
BRCA	cis	rs7621331	0.684	rs66626713	ENSG00000273486.1	RP11-731C17.2	3.72	0.000214	0.0121	0.13	0.11	Waist circumference adjusted for body mass index;	chr3:135940152	chr3:136837338~136839021:-
BRCA	cis	rs2835872	0.793	rs73220480	ENSG00000228677.1	TTC3-AS1	-3.72	0.000214	0.0121	-0.15	-0.11	Electroencephalographic traits in alcoholism;	chr21:37613426	chr21:37187666~37193926:-
BRCA	cis	rs73201462	1	rs2955126	ENSG00000242551.2	POU5F1P6	-3.71	0.000214	0.0121	-0.19	-0.11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128207411	chr3:128674735~128677005:-
BRCA	cis	rs78487399	0.808	rs74600494	ENSG00000234936.1	AC010883.5	3.71	0.000214	0.0121	0.18	0.11	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43516352	chr2:43229573~43233394:+
BRCA	cis	rs11098499	0.954	rs12510138	ENSG00000260404.2	RP11-384K6.6	3.71	0.000214	0.0121	0.11	0.11	Corneal astigmatism;	chr4:119502780	chr4:118591773~118633729:+
BRCA	cis	rs17106184	0.591	rs76910682	ENSG00000236434.2	RP11-296A18.6	3.71	0.000214	0.0121	0.17	0.11	Type 2 diabetes;	chr1:50408548	chr1:51264916~51266074:-
BRCA	cis	rs801193	1	rs7785213	ENSG00000265600.1	AC006480.1	3.71	0.000214	0.0121	0.14	0.11	Aortic root size;	chr7:66673991	chr7:67356680~67356779:+
BRCA	cis	rs2243480	0.711	rs1626926	ENSG00000226767.1	RP11-328P23.3	-3.71	0.000214	0.0121	-0.19	-0.11	Diabetic kidney disease;	chr7:65970805	chr7:65508773~65508944:-
BRCA	cis	rs2573652	1	rs2581363	ENSG00000254744.3	CTD-3076O17.1	-3.71	0.000214	0.0121	-0.14	-0.11	Height;	chr15:99973159	chr15:99970215~99974010:+
BRCA	cis	rs1437396	0.657	rs3791653	ENSG00000203327.2	AC012358.7	-3.71	0.000214	0.0121	-0.12	-0.11	Alcohol dependence;	chr2:55373197	chr2:55214387~55216126:-
BRCA	cis	rs17092148	0.895	rs4417778	ENSG00000202150.1	RNU6-407P	3.71	0.000214	0.0121	0.17	0.11	Neuroticism;	chr20:34763184	chr20:35030317~35030420:-
BRCA	cis	rs62458065	0.85	rs7808992	ENSG00000229358.3	DPY19L1P1	-3.71	0.000214	0.0121	-0.16	-0.11	Metabolite levels (HVA/MHPG ratio);	chr7:32431065	chr7:32580949~32761787:-
BRCA	cis	rs8007846	0.524	rs6573625	ENSG00000276116.2	FUT8-AS1	3.71	0.000214	0.0121	0.12	0.11	Multiple sclerosis--Brain Glutamate Levels;	chr14:65773916	chr14:65411170~65412690:-
BRCA	cis	rs4073416	0.777	rs7158556	ENSG00000276116.2	FUT8-AS1	3.71	0.000214	0.0121	0.12	0.11	N-glycan levels;	chr14:65774011	chr14:65411170~65412690:-
BRCA	cis	rs3816183	1	rs2304656	ENSG00000226491.1	FTOP1	-3.71	0.000214	0.0121	-0.15	-0.11	Hypospadias;	chr2:42792590	chr2:42797225~42798712:-
BRCA	cis	rs4948102	0.731	rs4543497	ENSG00000226278.1	PSPHP1	-3.71	0.000214	0.0121	-0.13	-0.11	Plasma homocysteine levels (post-methionine load test);	chr7:55979522	chr7:55764797~55773288:+
BRCA	cis	rs4948102	0.767	rs4948096	ENSG00000226278.1	PSPHP1	-3.71	0.000214	0.0121	-0.13	-0.11	Plasma homocysteine levels (post-methionine load test);	chr7:55985425	chr7:55764797~55773288:+
BRCA	cis	rs2562456	0.876	rs62110202	ENSG00000240522.1	RPL7AP10	-3.71	0.000214	0.0121	-0.12	-0.11	Pain;	chr19:21571799	chr19:21149648~21150438:-
BRCA	cis	rs1949733	1	rs6447875	ENSG00000205959.3	RP11-689P11.2	-3.71	0.000214	0.0121	-0.11	-0.11	Response to antineoplastic agents;	chr4:8501479	chr4:8482270~8512610:+
BRCA	cis	rs372883	0.935	rs10460703	ENSG00000215533.7	LINC00189	-3.71	0.000214	0.0121	-0.12	-0.11	Pancreatic cancer;	chr21:29250788	chr21:29193480~29288205:+
BRCA	cis	rs62458065	0.64	rs6950077	ENSG00000281332.1	LINC00997	3.71	0.000214	0.0121	0.17	0.11	Metabolite levels (HVA/MHPG ratio);	chr7:32463283	chr7:32760279~32762924:+
BRCA	cis	rs2976388	0.565	rs2572905	ENSG00000253196.1	RP11-706C16.7	3.71	0.000214	0.0121	0.11	0.11	Urinary tract infection frequency;	chr8:142715686	chr8:142763116~142766427:+
BRCA	cis	rs8113308	0.81	rs8105110	ENSG00000269483.1	AC006272.1	3.71	0.000214	0.0121	0.2	0.11	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51948863	chr19:51839924~51843324:-
BRCA	cis	rs721917	0.506	rs2758555	ENSG00000280355.1	RP11-119F19.5	-3.71	0.000214	0.0121	-0.12	-0.11	Chronic obstructive pulmonary disease;	chr10:79931278	chr10:79681973~79684094:-
BRCA	cis	rs4921164	1	rs41406347	ENSG00000245812.2	RP11-175K6.1	-3.71	0.000214	0.0121	-0.15	-0.11	Gut microbiome composition (winter);	chr5:159117493	chr5:159100483~159117478:+
BRCA	cis	rs7809799	0.571	rs66478766	ENSG00000244219.5	GS1-259H13.2	-3.71	0.000214	0.0121	-0.24	-0.11	Ulcerative colitis;	chr7:99317778	chr7:99598066~99610813:+
BRCA	cis	rs2562456	0.874	rs2562408	ENSG00000240522.1	RPL7AP10	3.71	0.000214	0.0121	0.13	0.11	Pain;	chr19:21527079	chr19:21149648~21150438:-
BRCA	cis	rs7312933	0.645	rs12049942	ENSG00000257225.1	RP11-328C8.4	-3.71	0.000214	0.0121	-0.14	-0.11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42193250	chr12:42459366~42466128:+
BRCA	cis	rs8098244	0.928	rs1893289	ENSG00000265752.2	RP11-403A21.1	3.71	0.000214	0.0121	0.14	0.11	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23908983	chr18:23957754~23982556:-
BRCA	cis	rs9467773	0.595	rs13207371	ENSG00000224843.5	LINC00240	-3.71	0.000214	0.0121	-0.13	-0.11	Intelligence (multi-trait analysis);	chr6:26590846	chr6:26956992~27023924:+
BRCA	cis	rs2274273	0.624	rs10143136	ENSG00000259318.1	RP11-454L9.2	3.71	0.000214	0.0121	0.1	0.11	Protein biomarker;	chr14:55276810	chr14:55394940~55395233:-
BRCA	cis	rs853679	0.882	rs9461432	ENSG00000204709.4	LINC01556	3.71	0.000214	0.0121	0.23	0.11	Depression;	chr6:28119105	chr6:28943877~28944537:+
BRCA	cis	rs2411233	1	rs13379846	ENSG00000259278.1	RP11-62C7.2	3.71	0.000214	0.0121	0.13	0.11	Platelet count;	chr15:38980212	chr15:39019233~39024918:+
BRCA	cis	rs8054556	0.935	rs4788203	ENSG00000261367.1	RP11-455F5.4	-3.71	0.000214	0.0121	-0.13	-0.11	Autism spectrum disorder or schizophrenia;	chr16:29967506	chr16:30107675~30110541:+
BRCA	cis	rs948562	0.681	rs10750901	ENSG00000255299.4	RP11-655C2.3	-3.71	0.000214	0.0121	-0.14	-0.11	Lymphoma;	chr11:58660110	chr11:58497888~58505758:-
BRCA	cis	rs3816183	1	rs893731	ENSG00000226491.1	FTOP1	-3.71	0.000214	0.0121	-0.15	-0.11	Hypospadias;	chr2:42788292	chr2:42797225~42798712:-
BRCA	cis	rs7896471	0.546	rs113183335	ENSG00000227695.4	DNMBP-AS1	-3.71	0.000214	0.0121	-0.25	-0.11	Blood protein levels;	chr10:99981204	chr10:99927010~99958381:+
BRCA	cis	rs875971	0.83	rs6976714	ENSG00000229886.1	RP5-1132H15.3	3.71	0.000214	0.0121	0.13	0.11	Aortic root size;	chr7:66426474	chr7:66025126~66031544:-
BRCA	cis	rs7572733	1	rs10184227	ENSG00000231621.1	AC013264.2	-3.71	0.000214	0.0121	-0.1	-0.11	Dermatomyositis;	chr2:198029581	chr2:197197991~197199273:+
BRCA	cis	rs4835473	0.932	rs2323190	ENSG00000246448.2	RP13-578N3.3	-3.71	0.000214	0.0121	-0.13	-0.11	Immature fraction of reticulocytes;	chr4:143744282	chr4:143700257~143865072:+
BRCA	cis	rs6049003	0.668	rs6049062	ENSG00000232645.4	LINC01431	3.71	0.000214	0.0121	0.12	0.11	Cerebrospinal fluid biomarker levels;	chr20:23746320	chr20:23356594~23358116:-
BRCA	cis	rs934734	0.699	rs268138	ENSG00000204929.10	AC074391.1	-3.71	0.000214	0.0121	-0.14	-0.11	Rheumatoid arthritis;	chr2:65380160	chr2:65436711~66084639:+
BRCA	cis	rs7267979	1	rs4813563	ENSG00000274414.1	RP5-965G21.4	3.71	0.000214	0.0121	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25384704	chr20:25239007~25245229:-
BRCA	cis	rs7267979	0.966	rs6037103	ENSG00000274414.1	RP5-965G21.4	3.71	0.000214	0.0121	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25388459	chr20:25239007~25245229:-
BRCA	cis	rs564309	1	rs35670307	ENSG00000212237.1	RNA5SP18	3.71	0.000214	0.0121	0.25	0.11	Hip circumference (psychosocial stress interaction);	chr1:228400953	chr1:228647912~228648032:-
BRCA	cis	rs747650	0.504	rs923324	ENSG00000200376.1	RNU5E-10P	3.71	0.000214	0.0121	0.15	0.11	Acne (severe);	chr11:47142657	chr11:47576471~47576588:-
BRCA	cis	rs4415084	0.834	rs6896417	ENSG00000248779.1	RP11-53O19.2	3.71	0.000214	0.0121	0.1	0.11	Breast cancer;	chr5:44802536	chr5:44752949~44765744:+
BRCA	cis	rs4415084	0.834	rs13159598	ENSG00000248779.1	RP11-53O19.2	3.71	0.000214	0.0121	0.1	0.11	Breast cancer;	chr5:44805824	chr5:44752949~44765744:+
BRCA	cis	rs35123781	1	rs599946	ENSG00000250635.1	CTD-3224K15.2	-3.71	0.000214	0.0121	-0.13	-0.11	Schizophrenia;	chr5:139677876	chr5:139648999~139649728:-
BRCA	cis	rs1049564	0.569	rs1713421	ENSG00000258515.1	RP11-203M5.7	-3.71	0.000214	0.0121	-0.12	-0.11	Interferon alpha levels in systemic lupus erythematosus;	chr14:20474292	chr14:20451305~20451918:+
BRCA	cis	rs875971	0.862	rs709596	ENSG00000265600.1	AC006480.1	-3.71	0.000215	0.0121	-0.14	-0.11	Aortic root size;	chr7:66360926	chr7:67356680~67356779:+
BRCA	cis	rs4374383	0.631	rs34648366	ENSG00000243389.1	AC012442.5	-3.71	0.000215	0.0121	-0.14	-0.11	Hepatitis C induced liver fibrosis;	chr2:111948860	chr2:112589040~112614431:+
BRCA	cis	rs55966801	0.898	rs11602248	ENSG00000255328.1	RP11-326C3.12	3.71	0.000215	0.0121	0.18	0.11	Plateletcrit;	chr11:231305	chr11:327171~330122:+
BRCA	cis	rs4950322	1	rs4950429	ENSG00000244371.2	PFN1P8	-3.71	0.000215	0.0121	-0.16	-0.11	Protein quantitative trait loci;	chr1:147400227	chr1:146957117~146957659:-
BRCA	cis	rs4950322	1	rs59498179	ENSG00000244371.2	PFN1P8	-3.71	0.000215	0.0121	-0.16	-0.11	Protein quantitative trait loci;	chr1:147400417	chr1:146957117~146957659:-
BRCA	cis	rs6840360	0.571	rs11932059	ENSG00000270265.1	RP11-731D1.4	-3.71	0.000215	0.0121	-0.14	-0.11	Intelligence (multi-trait analysis);	chr4:151603344	chr4:151333775~151353224:-
BRCA	cis	rs979233	0.935	rs6897318	ENSG00000188850.9	RP11-159F24.2	3.71	0.000215	0.0121	0.13	0.11	Systemic lupus erythematosus;	chr5:42524791	chr5:43336164~43348716:+
BRCA	cis	rs10899021	0.512	rs2186955	ENSG00000279353.1	RP11-864N7.4	-3.71	0.000215	0.0121	-0.17	-0.11	Response to metformin (IC50);	chr11:74664430	chr11:74698231~74699658:-
BRCA	cis	rs72928364	1	rs36165056	ENSG00000244119.1	PDCL3P4	3.71	0.000215	0.0121	0.14	0.11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100896971	chr3:101712472~101713191:+
BRCA	cis	rs10800309	0.71	rs6684851	ENSG00000225217.1	HSPA7	-3.71	0.000215	0.0121	-0.13	-0.11	Inflammatory bowel disease;Ulcerative colitis;	chr1:161494622	chr1:161606291~161608217:+
BRCA	cis	rs13272568	0.614	rs6991500	ENSG00000254352.1	RP11-578O24.2	-3.71	0.000215	0.0121	-0.14	-0.11	Bone mineral density;	chr8:78118024	chr8:78723796~78724136:-
BRCA	cis	rs7267979	1	rs6050566	ENSG00000274414.1	RP5-965G21.4	3.71	0.000215	0.0121	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25370435	chr20:25239007~25245229:-
BRCA	cis	rs8023401	0.938	rs12591552	ENSG00000274654.1	CTD-3247H4.2	3.71	0.000215	0.0121	0.16	0.11	Spherical equivalent (joint analysis main effects and education interaction);	chr15:48478687	chr15:48528980~48529728:-
BRCA	cis	rs9400180	0.959	rs2027877	ENSG00000271734.1	RP1-111B22.3	-3.71	0.000215	0.0121	-0.15	-0.11	Major depressive disorder;	chr6:108065829	chr6:108030249~108030718:-
BRCA	cis	rs9400180	0.959	rs2027876	ENSG00000271734.1	RP1-111B22.3	-3.71	0.000215	0.0121	-0.15	-0.11	Major depressive disorder;	chr6:108066028	chr6:108030249~108030718:-
BRCA	cis	rs9400180	0.918	rs2027875	ENSG00000271734.1	RP1-111B22.3	-3.71	0.000215	0.0121	-0.15	-0.11	Major depressive disorder;	chr6:108066125	chr6:108030249~108030718:-
BRCA	cis	rs9400180	0.959	rs9374017	ENSG00000271734.1	RP1-111B22.3	-3.71	0.000215	0.0121	-0.15	-0.11	Major depressive disorder;	chr6:108066362	chr6:108030249~108030718:-
BRCA	cis	rs2216824	1	rs79831870	ENSG00000278908.1	RP11-523J2.1	3.71	0.000215	0.0121	0.2	0.11	Oropharynx cancer;	chr2:30882479	chr2:30677762~30679895:+
BRCA	cis	rs875971	0.767	rs61348003	ENSG00000273024.4	INTS4P2	-3.71	0.000215	0.0121	-0.13	-0.11	Aortic root size;	chr7:66540947	chr7:65647864~65715661:+
BRCA	cis	rs875971	0.825	rs801202	ENSG00000273024.4	INTS4P2	3.71	0.000215	0.0121	0.13	0.11	Aortic root size;	chr7:66558942	chr7:65647864~65715661:+
BRCA	cis	rs6657613	0.503	rs9435739	ENSG00000186301.8	MST1P2	-3.71	0.000215	0.0121	-0.1	-0.11	Hip circumference adjusted for BMI;	chr1:17016429	chr1:16645622~16650289:+
BRCA	cis	rs7819412	0.875	rs11250121	ENSG00000154316.13	TDH	3.71	0.000215	0.0121	0.15	0.11	Triglycerides;	chr8:11202802	chr8:11339637~11368452:+
BRCA	cis	rs12545912	0.821	rs1055328	ENSG00000272267.2	RP11-375N15.2	3.71	0.000215	0.0121	0.15	0.11	Multiple myeloma (hyperdiploidy);	chr8:9781806	chr8:9555144~9556520:-
BRCA	cis	rs721917	0.506	rs1923538	ENSG00000225484.5	NUTM2B-AS1	-3.71	0.000215	0.0121	-0.15	-0.11	Chronic obstructive pulmonary disease;	chr10:79935276	chr10:79663088~79826594:-
BRCA	cis	rs875971	0.66	rs28698552	ENSG00000275400.1	RP4-756H11.5	-3.71	0.000215	0.0121	-0.13	-0.11	Aortic root size;	chr7:66540031	chr7:66553805~66554199:-
BRCA	cis	rs13434995	0.513	rs62303722	ENSG00000239040.1	Y_RNA	3.71	0.000215	0.0121	0.14	0.11	Adiponectin levels;	chr4:55482076	chr4:55412636~55412738:+
BRCA	cis	rs12468226	0.873	rs12472035	ENSG00000272966.1	RP11-686O6.1	3.71	0.000215	0.0121	0.2	0.11	Urate levels;	chr2:202221970	chr2:202336739~202337200:+
BRCA	cis	rs495337	0.736	rs537672	ENSG00000224397.4	LINC01272	-3.71	0.000215	0.0121	-0.12	-0.11	Psoriasis;	chr20:49857009	chr20:50267486~50279795:+
BRCA	cis	rs495337	0.736	rs595777	ENSG00000224397.4	LINC01272	-3.71	0.000215	0.0121	-0.12	-0.11	Psoriasis;	chr20:49858282	chr20:50267486~50279795:+
BRCA	cis	rs495337	0.736	rs686996	ENSG00000224397.4	LINC01272	-3.71	0.000215	0.0121	-0.12	-0.11	Psoriasis;	chr20:49859729	chr20:50267486~50279795:+
BRCA	cis	rs495337	0.736	rs527892	ENSG00000224397.4	LINC01272	-3.71	0.000215	0.0121	-0.12	-0.11	Psoriasis;	chr20:49860917	chr20:50267486~50279795:+
BRCA	cis	rs495337	0.706	rs671130	ENSG00000224397.4	LINC01272	-3.71	0.000215	0.0121	-0.12	-0.11	Psoriasis;	chr20:49860921	chr20:50267486~50279795:+
BRCA	cis	rs9329221	0.967	rs7005363	ENSG00000154316.13	TDH	3.71	0.000215	0.0121	0.14	0.11	Neuroticism;	chr8:10426238	chr8:11339637~11368452:+
BRCA	cis	rs983392	0.679	rs1026253	ENSG00000275344.1	MIR6503	3.71	0.000215	0.0121	0.12	0.11	Alzheimer's disease (late onset);	chr11:60263083	chr11:60209071~60209156:-
BRCA	cis	rs983392	0.679	rs1026252	ENSG00000275344.1	MIR6503	3.71	0.000215	0.0121	0.12	0.11	Alzheimer's disease (late onset);	chr11:60263086	chr11:60209071~60209156:-
BRCA	cis	rs10129255	0.872	rs8015406	ENSG00000231475.3	IGHV4-31	-3.71	0.000215	0.0121	-0.09	-0.11	Kawasaki disease;	chr14:106670611	chr14:106349283~106349792:-
BRCA	cis	rs34217772	0.739	rs12432485	ENSG00000258636.1	CTD-2298J14.2	3.71	0.000215	0.0121	0.16	0.11	Myopia;	chr14:41838612	chr14:41587861~41604856:-
BRCA	cis	rs6120849	0.707	rs6120826	ENSG00000202150.1	RNU6-407P	3.71	0.000215	0.0121	0.16	0.11	Protein C levels;	chr20:35084028	chr20:35030317~35030420:-
BRCA	cis	rs78487399	0.808	rs7567535	ENSG00000234936.1	AC010883.5	3.71	0.000215	0.0121	0.17	0.11	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43441122	chr2:43229573~43233394:+
BRCA	cis	rs6801044	0.789	rs823525	ENSG00000272792.1	RP11-141C7.4	3.71	0.000215	0.0121	0.18	0.11	Creatinine levels in ischemic stroke;	chr3:195552301	chr3:195639990~195640460:+
BRCA	cis	rs595244	0.908	rs2118181	ENSG00000259705.1	RP11-227D13.1	-3.71	0.000215	0.0121	-0.16	-0.11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48623687	chr15:48645951~48652016:+
BRCA	cis	rs6545883	0.965	rs1992765	ENSG00000212978.6	AC016747.3	3.71	0.000215	0.0121	0.15	0.11	Tuberculosis;	chr2:61524198	chr2:61141592~61144969:-
BRCA	cis	rs13420028	0.565	rs7592134	ENSG00000230992.3	FAM201B	3.71	0.000215	0.0121	0.13	0.11	Hypertension (SNP x SNP interaction);	chr2:132415492	chr2:132352722~132353318:+
BRCA	cis	rs11673344	0.704	rs484001	ENSG00000267422.1	CTD-2554C21.1	3.71	0.000215	0.0121	0.15	0.11	Obesity-related traits;	chr19:36931320	chr19:37779686~37792865:+
BRCA	cis	rs13401620	0.871	rs13390087	ENSG00000229326.3	AC069154.4	-3.71	0.000215	0.0121	-0.15	-0.11	Breast size;	chr2:119877069	chr2:119698623~119700151:+
BRCA	cis	rs13434995	0.513	rs6554285	ENSG00000249700.7	SRD5A3-AS1	3.71	0.000215	0.0121	0.17	0.11	Adiponectin levels;	chr4:55533953	chr4:55363971~55395847:-
BRCA	cis	rs13434995	0.513	rs7660668	ENSG00000249700.7	SRD5A3-AS1	3.71	0.000215	0.0121	0.17	0.11	Adiponectin levels;	chr4:55535530	chr4:55363971~55395847:-
BRCA	cis	rs7829975	0.577	rs940030	ENSG00000254153.1	CTA-398F10.2	-3.71	0.000215	0.0121	-0.14	-0.11	Mood instability;	chr8:8689418	chr8:8456909~8461337:-
BRCA	cis	rs11098499	0.874	rs12502503	ENSG00000260404.2	RP11-384K6.6	3.71	0.000215	0.0121	0.11	0.11	Corneal astigmatism;	chr4:119195100	chr4:118591773~118633729:+
BRCA	cis	rs7847628	0.587	rs4837796	ENSG00000238181.2	AHCYP2	3.71	0.000215	0.0121	0.15	0.11	Birth weight;	chr9:120848010	chr9:120720673~120721972:+
BRCA	cis	rs17345786	0.906	rs11708616	ENSG00000244119.1	PDCL3P4	3.71	0.000215	0.0121	0.1	0.11	Colonoscopy-negative controls vs population controls;	chr3:101512887	chr3:101712472~101713191:+
BRCA	cis	rs80226907	0.539	rs17743595	ENSG00000186615.9	KTN1-AS1	-3.71	0.000215	0.0121	-0.25	-0.11	Mean platelet volume;	chr14:55435208	chr14:55499278~55580110:-
BRCA	cis	rs80226907	0.634	rs10483641	ENSG00000186615.9	KTN1-AS1	-3.71	0.000215	0.0121	-0.25	-0.11	Mean platelet volume;	chr14:55435251	chr14:55499278~55580110:-
BRCA	cis	rs80226907	0.634	rs112331246	ENSG00000186615.9	KTN1-AS1	-3.71	0.000215	0.0121	-0.25	-0.11	Mean platelet volume;	chr14:55435576	chr14:55499278~55580110:-
BRCA	cis	rs1799955	1	rs1799955	ENSG00000215515.2	IFIT1P1	-3.71	0.000215	0.0121	-0.16	-0.11	LDL cholesterol levels;	chr13:32355095	chr13:32384660~32386108:+
BRCA	cis	rs1670533	1	rs4690213	ENSG00000251639.2	RP11-20I20.1	3.71	0.000215	0.0121	0.18	0.11	Recombination rate (females);	chr4:1061080	chr4:1100016~1101558:-
BRCA	cis	rs1670533	0.872	rs6854793	ENSG00000251639.2	RP11-20I20.1	3.71	0.000215	0.0121	0.18	0.11	Recombination rate (females);	chr4:1061980	chr4:1100016~1101558:-
BRCA	cis	rs1670533	0.932	rs10902753	ENSG00000251639.2	RP11-20I20.1	3.71	0.000215	0.0121	0.18	0.11	Recombination rate (females);	chr4:1062435	chr4:1100016~1101558:-
BRCA	cis	rs1722141	0.601	rs2690723	ENSG00000237471.1	AC073115.6	3.71	0.000215	0.0121	0.15	0.11	Sitting height ratio;	chr7:46031071	chr7:45969657~45980191:+
BRCA	cis	rs9733	0.519	rs2184833	ENSG00000231073.1	RP11-316M1.3	3.71	0.000215	0.0121	0.12	0.11	Tonsillectomy;	chr1:150703007	chr1:150973123~150975534:+
BRCA	cis	rs6747972	1	rs1820988	ENSG00000236259.1	AC017083.2	3.71	0.000215	0.0121	0.14	0.11	Restless legs syndrome;	chr2:67842757	chr2:68125265~68125747:+
BRCA	cis	rs6747972	1	rs1820989	ENSG00000236259.1	AC017083.2	3.71	0.000215	0.0121	0.14	0.11	Restless legs syndrome;	chr2:67842758	chr2:68125265~68125747:+
BRCA	cis	rs34773007	0.577	rs67412949	ENSG00000232709.1	MARK2P9	3.71	0.000215	0.0121	0.18	0.11	Type 2 diabetes;	chr10:92790889	chr10:92418667~92420875:+
BRCA	cis	rs6871536	1	rs2706347	ENSG00000233006.5	AC034220.3	-3.71	0.000215	0.0121	-0.09	-0.11	Asthma (childhood onset);	chr5:132569425	chr5:132311285~132369916:-
BRCA	cis	rs8054556	1	rs4788200	ENSG00000183604.13	SMG1P5	-3.71	0.000215	0.0121	-0.11	-0.11	Autism spectrum disorder or schizophrenia;	chr16:29959944	chr16:30267553~30335374:-
BRCA	cis	rs4478858	0.735	rs7556340	ENSG00000223907.1	LINC01226	-3.71	0.000215	0.0121	-0.14	-0.11	Alcohol dependence;	chr1:31315606	chr1:31518435~31524245:+
BRCA	cis	rs251253	0.827	rs427684	ENSG00000253959.1	CTB-43E15.1	3.71	0.000215	0.0121	0.1	0.11	PR interval;	chr5:173065446	chr5:173642519~173658194:+
BRCA	cis	rs7800418	0.544	rs11767539	ENSG00000280255.1	RP5-1007F24.1	3.71	0.000215	0.0121	0.13	0.11	Cognitive function;	chr7:26586792	chr7:26538378~26541048:+
BRCA	cis	rs1005277	0.522	rs1208684	ENSG00000273019.1	RP11-508N22.13	-3.71	0.000215	0.0121	-0.13	-0.11	Extrinsic epigenetic age acceleration;	chr10:37805008	chr10:38149968~38150293:+
BRCA	cis	rs2976388	0.647	rs2585154	ENSG00000253196.1	RP11-706C16.7	3.71	0.000215	0.0121	0.11	0.11	Urinary tract infection frequency;	chr8:142702067	chr8:142763116~142766427:+
BRCA	cis	rs4784227	0.627	rs12922061	ENSG00000249231.6	CASC16	-3.71	0.000215	0.0121	-0.15	-0.11	Breast cancer (estrogen-receptor negative);Breast cancer;Parkinson's disease;	chr16:52601088	chr16:52552090~52652105:-
BRCA	cis	rs9847710	1	rs9847710	ENSG00000242849.2	ALDOAP1	3.71	0.000215	0.0121	0.13	0.11	Ulcerative colitis;	chr3:53028645	chr3:52193170~52194785:+
BRCA	cis	rs12760731	0.641	rs11590951	ENSG00000213057.5	C1orf220	3.71	0.000216	0.0121	0.16	0.11	Obesity-related traits;	chr1:178353622	chr1:178542752~178548889:+
BRCA	cis	rs3760982	0.585	rs67773424	ENSG00000267191.1	RP11-15A1.2	-3.71	0.000216	0.0121	-0.15	-0.11	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43789842	chr19:43902001~43926545:+
BRCA	cis	rs9437689	0.934	rs9437665	ENSG00000235501.4	RP4-639F20.1	3.71	0.000216	0.0121	0.15	0.11	Phospholipid levels (plasma);	chr1:95060715	chr1:94927566~94963270:+
BRCA	cis	rs7015630	0.657	rs34525502	ENSG00000251136.7	RP11-37B2.1	-3.71	0.000216	0.0121	-0.15	-0.11	Inflammatory bowel disease;Crohn's disease;	chr8:89840352	chr8:89609409~89757727:-
BRCA	cis	rs73201462	1	rs2955129	ENSG00000242551.2	POU5F1P6	-3.71	0.000216	0.0121	-0.2	-0.11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128210364	chr3:128674735~128677005:-
BRCA	cis	rs17123764	0.892	rs11837639	ENSG00000257464.1	RP11-161H23.8	-3.71	0.000216	0.0121	-0.21	-0.11	Intelligence (multi-trait analysis);	chr12:49757569	chr12:49442424~49442652:-
BRCA	cis	rs17123764	0.786	rs57291131	ENSG00000257464.1	RP11-161H23.8	-3.71	0.000216	0.0121	-0.21	-0.11	Intelligence (multi-trait analysis);	chr12:49761330	chr12:49442424~49442652:-
BRCA	cis	rs7020830	0.823	rs13285624	ENSG00000230188.1	RP11-405L18.4	-3.71	0.000216	0.0121	-0.14	-0.11	Schizophrenia;	chr9:37129499	chr9:37490421~37490893:-
BRCA	cis	rs10431058	1	rs10431058	ENSG00000261098.1	RP11-819C21.1	-3.71	0.000216	0.0121	-0.11	-0.11	Common traits (Other);	chr11:107610792	chr11:107312132~107316271:-
BRCA	cis	rs7949566	0.557	rs2230279	ENSG00000254905.1	RP11-712L6.7	3.71	0.000216	0.0121	0.14	0.11	Platelet distribution width;Mean platelet volume;	chr11:126408180	chr11:126292922~126294254:-
BRCA	cis	rs10005067	0.874	rs10031822	ENSG00000249001.4	RP11-742B18.1	-3.71	0.000216	0.0121	-0.14	-0.11	Total body bone mineral density (age 30-45);	chr4:87899461	chr4:87568035~87733956:-
BRCA	cis	rs2243480	0.908	rs4718273	ENSG00000226767.1	RP11-328P23.3	3.71	0.000216	0.0122	0.2	0.11	Diabetic kidney disease;	chr7:65751112	chr7:65508773~65508944:-
BRCA	cis	rs6964587	0.626	rs35849169	ENSG00000188693.7	CYP51A1-AS1	-3.71	0.000216	0.0122	-0.12	-0.11	Breast cancer;	chr7:91877999	chr7:92134604~92180725:+
BRCA	cis	rs2765539	0.851	rs1409158	ENSG00000231365.4	RP11-418J17.1	3.71	0.000216	0.0122	0.15	0.11	Waist-hip ratio;	chr1:118996267	chr1:119140396~119275973:+
BRCA	cis	rs4835473	0.932	rs2127788	ENSG00000246448.2	RP13-578N3.3	3.71	0.000216	0.0122	0.13	0.11	Immature fraction of reticulocytes;	chr4:143741996	chr4:143700257~143865072:+
BRCA	cis	rs938554	0.501	rs7671266	ENSG00000250413.1	RP11-448G15.1	3.71	0.000216	0.0122	0.18	0.11	Blood metabolite levels;	chr4:10054752	chr4:10006482~10009725:+
BRCA	cis	rs6918586	0.636	rs198817	ENSG00000272462.2	U91328.19	-3.71	0.000216	0.0122	-0.13	-0.11	Schizophrenia;	chr6:26126296	chr6:25992662~26001775:+
BRCA	cis	rs13256369	0.951	rs13260947	ENSG00000254153.1	CTA-398F10.2	3.71	0.000216	0.0122	0.16	0.11	Obesity-related traits;	chr8:8708373	chr8:8456909~8461337:-
BRCA	cis	rs1039766	1	rs268871	ENSG00000227791.3	AC007365.4	-3.71	0.000216	0.0122	-0.17	-0.11	Lung adenocarcinoma;Lung cancer;	chr2:65253874	chr2:64665607~64666064:+
BRCA	cis	rs9470794	1	rs74958299	ENSG00000204110.6	RP1-153P14.8	-3.71	0.000216	0.0122	-0.22	-0.11	Type 2 diabetes;	chr6:38138736	chr6:37507348~37535616:+
BRCA	cis	rs459482	0.576	rs461448	ENSG00000227702.1	LINC00111	-3.71	0.000216	0.0122	-0.13	-0.11	IgG glycosylation;	chr21:41428996	chr21:41679181~41697336:+
BRCA	cis	rs7267979	1	rs2387880	ENSG00000276952.1	RP5-965G21.6	-3.71	0.000216	0.0122	-0.14	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25397151	chr20:25284915~25285588:-
BRCA	cis	rs1437396	0.657	rs7586529	ENSG00000203327.2	AC012358.7	-3.71	0.000216	0.0122	-0.12	-0.11	Alcohol dependence;	chr2:55382857	chr2:55214387~55216126:-
BRCA	cis	rs9549260	0.709	rs4943795	ENSG00000168852.11	TPTE2P5	-3.71	0.000216	0.0122	-0.11	-0.11	Red blood cell count;	chr13:40599296	chr13:40822296~40921749:-
BRCA	cis	rs13421350	0.579	rs13410475	ENSG00000225205.4	AC093818.1	-3.71	0.000216	0.0122	-0.21	-0.11	Diabetic kidney disease;	chr2:172444890	chr2:172480840~172556596:-
BRCA	cis	rs11668609	1	rs10413344	ENSG00000268058.1	BNIP3P40	-3.71	0.000216	0.0122	-0.15	-0.11	Response to taxane treatment (docetaxel);	chr19:24186158	chr19:24098425~24098980:-
BRCA	cis	rs11098499	0.863	rs10019674	ENSG00000225892.3	RP11-384K6.2	-3.71	0.000216	0.0122	-0.12	-0.11	Corneal astigmatism;	chr4:119522334	chr4:118632274~118634759:+
BRCA	cis	rs17684571	0.751	rs17752106	ENSG00000231441.1	RP11-472M19.2	3.71	0.000216	0.0122	0.18	0.11	Schizophrenia;	chr6:56837455	chr6:56844002~56864078:+
BRCA	cis	rs17684571	0.751	rs7761501	ENSG00000231441.1	RP11-472M19.2	3.71	0.000216	0.0122	0.18	0.11	Schizophrenia;	chr6:56839187	chr6:56844002~56864078:+
BRCA	cis	rs116175783	0.557	rs62188136	ENSG00000235724.7	AC009299.2	3.71	0.000216	0.0122	0.17	0.11	Intelligence (multi-trait analysis);	chr2:161399439	chr2:161222785~161308303:-
BRCA	cis	rs13126694	0.744	rs4077776	ENSG00000251073.1	NUDT19P5	3.71	0.000216	0.0122	0.11	0.11	Blood osmolality (transformed sodium);	chr4:158008446	chr4:158182825~158183393:+
BRCA	cis	rs3820068	0.559	rs6675334	ENSG00000237301.1	RP4-680D5.2	-3.71	0.000216	0.0122	-0.15	-0.11	Systolic blood pressure;	chr1:15597085	chr1:15586136~15603626:-
BRCA	cis	rs875971	0.862	rs6460302	ENSG00000271064.1	RP11-792A8.3	-3.71	0.000216	0.0122	-0.13	-0.11	Aortic root size;	chr7:66495270	chr7:66748838~66749077:-
BRCA	cis	rs4950322	0.57	rs72692946	ENSG00000227242.3	NBPF13P	-3.71	0.000216	0.0122	-0.16	-0.11	Protein quantitative trait loci;	chr1:147319966	chr1:147021320~147124525:-
BRCA	cis	rs4950322	0.57	rs72692948	ENSG00000227242.3	NBPF13P	-3.71	0.000216	0.0122	-0.16	-0.11	Protein quantitative trait loci;	chr1:147320298	chr1:147021320~147124525:-
BRCA	cis	rs4950322	0.57	rs72692951	ENSG00000227242.3	NBPF13P	-3.71	0.000216	0.0122	-0.16	-0.11	Protein quantitative trait loci;	chr1:147320551	chr1:147021320~147124525:-
BRCA	cis	rs4950322	0.57	rs77118461	ENSG00000227242.3	NBPF13P	-3.71	0.000216	0.0122	-0.16	-0.11	Protein quantitative trait loci;	chr1:147320718	chr1:147021320~147124525:-
BRCA	cis	rs4950322	0.57	rs78681047	ENSG00000227242.3	NBPF13P	-3.71	0.000216	0.0122	-0.16	-0.11	Protein quantitative trait loci;	chr1:147321013	chr1:147021320~147124525:-
BRCA	cis	rs875971	1	rs697970	ENSG00000230189.5	GS1-124K5.2	-3.71	0.000216	0.0122	-0.09	-0.11	Aortic root size;	chr7:66095065	chr7:66409143~66490059:-
BRCA	cis	rs3796352	1	rs71617204	ENSG00000280417.1	RP11-5O17.1	-3.71	0.000216	0.0122	-0.22	-0.11	Immune reponse to smallpox (secreted IL-2);	chr3:53008935	chr3:53046166~53048122:+
BRCA	cis	rs68170813	0.652	rs76924513	ENSG00000241764.3	AC002467.7	3.71	0.000216	0.0122	0.2	0.11	Coronary artery disease;	chr7:107565442	chr7:107742817~107744581:-
BRCA	cis	rs68170813	0.652	rs4730250	ENSG00000241764.3	AC002467.7	3.71	0.000216	0.0122	0.2	0.11	Coronary artery disease;	chr7:107567250	chr7:107742817~107744581:-
BRCA	cis	rs6088580	0.543	rs13042351	ENSG00000261582.1	RP4-614O4.11	3.71	0.000216	0.0122	0.11	0.11	Glomerular filtration rate (creatinine);	chr20:34650769	chr20:35267885~35280043:-
BRCA	cis	rs7243821	0.543	rs8092980	ENSG00000267112.1	RP11-839G9.1	3.71	0.000216	0.0122	0.14	0.11	Chin dimples;	chr18:54896710	chr18:54885866~54898083:-
BRCA	cis	rs2380205	0.517	rs11255971	ENSG00000232807.2	RP11-536K7.3	3.71	0.000216	0.0122	0.12	0.11	Breast cancer;	chr10:5925213	chr10:5934270~5945900:-
BRCA	cis	rs11633886	0.585	rs2244179	ENSG00000273972.1	CTD-2306A12.1	3.71	0.000216	0.0122	0.13	0.11	Diisocyanate-induced asthma;	chr15:45797924	chr15:45702640~45703183:+
BRCA	cis	rs7267979	1	rs6076339	ENSG00000204556.4	CTD-2514C3.1	3.71	0.000216	0.0122	0.16	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25368076	chr20:26018832~26020684:+
BRCA	cis	rs6500602	0.682	rs3761679	ENSG00000280063.1	RP11-295D4.3	3.71	0.000216	0.0122	0.09	0.11	Schizophrenia;	chr16:4407906	chr16:4346694~4348648:-
BRCA	cis	rs7712401	0.791	rs1870559	ENSG00000251538.4	RP11-166A12.1	3.71	0.000216	0.0122	0.13	0.11	Mean platelet volume;	chr5:122781011	chr5:122628952~122730685:-
BRCA	cis	rs7712401	0.791	rs10059964	ENSG00000251538.4	RP11-166A12.1	3.71	0.000216	0.0122	0.13	0.11	Mean platelet volume;	chr5:122782598	chr5:122628952~122730685:-
BRCA	cis	rs962856	1	rs6546294	ENSG00000236605.1	AC023115.4	3.71	0.000216	0.0122	0.13	0.11	Pancreatic cancer;	chr2:67335098	chr2:67324627~67325304:+
BRCA	cis	rs8105895	0.799	rs6511327	ENSG00000269345.1	VN1R85P	3.71	0.000216	0.0122	0.17	0.11	Body mass index (change over time);	chr19:22104097	chr19:22174766~22175191:-
BRCA	cis	rs1635	0.826	rs3800324	ENSG00000216901.1	AL022393.7	3.71	0.000216	0.0122	0.27	0.11	Schizophrenia;	chr6:28296904	chr6:28176188~28176674:+
BRCA	cis	rs4648045	0.861	rs230534	ENSG00000246560.2	RP11-10L12.4	-3.71	0.000216	0.0122	-0.13	-0.11	Lymphocyte percentage of white cells;	chr4:102527884	chr4:102828055~102844075:+
BRCA	cis	rs2823962	0.857	rs13052682	ENSG00000270093.1	AP000473.8	-3.71	0.000217	0.0122	-0.11	-0.11	Amyotrophic lateral sclerosis;	chr21:16655378	chr21:16643529~16645065:+
BRCA	cis	rs7800418	0.578	rs10244951	ENSG00000280255.1	RP5-1007F24.1	-3.71	0.000217	0.0122	-0.13	-0.11	Cognitive function;	chr7:26586399	chr7:26538378~26541048:+
BRCA	cis	rs10043775	0.831	rs10072817	ENSG00000251330.3	CTD-2283N19.1	-3.71	0.000217	0.0122	-0.14	-0.11	Periodontal microbiota;	chr5:148310124	chr5:148430159~148430807:-
BRCA	cis	rs7917772	0.503	rs7068535	ENSG00000213061.2	PFN1P11	-3.71	0.000217	0.0122	-0.16	-0.11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;	chr10:102589370	chr10:102838011~102845473:-
BRCA	cis	rs6593122	0.755	rs4574800	ENSG00000235454.1	HAUS6P3	-3.71	0.000217	0.0122	-0.15	-0.11	Vaccine-related adverse events;	chr7:54125390	chr7:53862233~53863339:+
BRCA	cis	rs6601530	0.544	rs733396	ENSG00000248896.2	CTD-2135J3.3	-3.71	0.000217	0.0122	-0.14	-0.11	Carotid intima media thickness;	chr8:10764471	chr8:10729314~10771392:+
BRCA	cis	rs7824557	0.734	rs2293856	ENSG00000154316.13	TDH	-3.71	0.000217	0.0122	-0.16	-0.11	Retinal vascular caliber;	chr8:11319938	chr8:11339637~11368452:+
BRCA	cis	rs4713118	0.587	rs61471148	ENSG00000261839.1	RP1-265C24.8	3.71	0.000217	0.0122	0.16	0.11	Parkinson's disease;	chr6:28069254	chr6:28136849~28139678:+
BRCA	cis	rs504458	0.618	rs10923054	ENSG00000241975.1	TCEB1P19	-3.71	0.000217	0.0122	-0.13	-0.11	Childhood ear infection;	chr1:88284858	chr1:88829102~88829419:+
BRCA	cis	rs6088580	0.634	rs945673	ENSG00000275784.1	RP5-1125A11.6	3.71	0.000217	0.0122	0.12	0.11	Glomerular filtration rate (creatinine);	chr20:34376459	chr20:33989480~33991818:-
BRCA	cis	rs16940212	0.58	rs74019425	ENSG00000259771.1	RP11-429D19.1	-3.71	0.000217	0.0122	-0.19	-0.11	HDL cholesterol;HDL cholesterol levels;	chr15:58395266	chr15:59266720~59271162:-
BRCA	cis	rs7172677	0.711	rs8035588	ENSG00000260269.4	CTD-2323K18.1	-3.71	0.000217	0.0122	-0.16	-0.11	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75144502	chr15:75527150~75601205:-
BRCA	cis	rs7267979	0.966	rs2387882	ENSG00000274414.1	RP5-965G21.4	3.71	0.000217	0.0122	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25398166	chr20:25239007~25245229:-
BRCA	cis	rs524281	0.861	rs10750779	ENSG00000255557.1	RP11-770G2.2	3.71	0.000217	0.0122	0.16	0.11	Electroencephalogram traits;	chr11:66207120	chr11:65745729~65771585:+
BRCA	cis	rs2555155	0.87	rs2555145	ENSG00000254595.1	CTD-2010I16.1	3.71	0.000217	0.0122	0.13	0.11	DNA methylation (variation);	chr11:6512962	chr11:6488186~6489377:-
BRCA	cis	rs4718428	0.705	rs3800817	ENSG00000229886.1	RP5-1132H15.3	3.71	0.000217	0.0122	0.14	0.11	Corneal structure;	chr7:66798563	chr7:66025126~66031544:-
BRCA	cis	rs8058578	1	rs56656810	ENSG00000274678.1	RP11-2C24.7	3.71	0.000217	0.0122	0.14	0.11	Multiple myeloma;	chr16:30777438	chr16:30821338~30821884:+
BRCA	cis	rs6545883	0.929	rs10173974	ENSG00000212978.6	AC016747.3	3.71	0.000217	0.0122	0.15	0.11	Tuberculosis;	chr2:61521765	chr2:61141592~61144969:-
BRCA	cis	rs17221829	0.703	rs11018680	ENSG00000280385.1	AP000648.5	-3.71	0.000217	0.0122	-0.13	-0.11	Anxiety in major depressive disorder;	chr11:89630843	chr11:90193614~90198120:+
BRCA	cis	rs2239547	0.563	rs4687699	ENSG00000279144.1	RP11-894J14.2	3.71	0.000217	0.0122	0.15	0.11	Schizophrenia;	chr3:53067208	chr3:52848085~52848553:-
BRCA	cis	rs2274459	0.841	rs2281918	ENSG00000249346.5	LINC01016	3.71	0.000217	0.0122	0.15	0.11	Obesity (extreme);	chr6:33695278	chr6:33867506~33896914:-
BRCA	cis	rs6840360	0.87	rs1372978	ENSG00000251603.1	RP11-164P12.4	-3.71	0.000217	0.0122	-0.1	-0.11	Intelligence (multi-trait analysis);	chr4:151535028	chr4:151667224~151670502:+
BRCA	cis	rs17221829	0.764	rs7930024	ENSG00000280385.1	AP000648.5	-3.71	0.000217	0.0122	-0.13	-0.11	Anxiety in major depressive disorder;	chr11:89652870	chr11:90193614~90198120:+
BRCA	cis	rs17221829	0.692	rs55823055	ENSG00000280385.1	AP000648.5	-3.71	0.000217	0.0122	-0.13	-0.11	Anxiety in major depressive disorder;	chr11:89655576	chr11:90193614~90198120:+
BRCA	cis	rs17221829	0.645	rs12288897	ENSG00000280385.1	AP000648.5	-3.71	0.000217	0.0122	-0.13	-0.11	Anxiety in major depressive disorder;	chr11:89655648	chr11:90193614~90198120:+
BRCA	cis	rs11098499	0.954	rs13133522	ENSG00000225892.3	RP11-384K6.2	3.71	0.000217	0.0122	0.11	0.11	Corneal astigmatism;	chr4:119403269	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.954	rs35091806	ENSG00000225892.3	RP11-384K6.2	3.71	0.000217	0.0122	0.11	0.11	Corneal astigmatism;	chr4:119404374	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.909	rs35165976	ENSG00000225892.3	RP11-384K6.2	3.71	0.000217	0.0122	0.11	0.11	Corneal astigmatism;	chr4:119404475	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.954	rs6846442	ENSG00000225892.3	RP11-384K6.2	3.71	0.000217	0.0122	0.11	0.11	Corneal astigmatism;	chr4:119405168	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.954	rs71614438	ENSG00000225892.3	RP11-384K6.2	3.71	0.000217	0.0122	0.11	0.11	Corneal astigmatism;	chr4:119450097	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.954	rs66506550	ENSG00000225892.3	RP11-384K6.2	3.71	0.000217	0.0122	0.11	0.11	Corneal astigmatism;	chr4:119450290	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.909	rs7659501	ENSG00000225892.3	RP11-384K6.2	3.71	0.000217	0.0122	0.11	0.11	Corneal astigmatism;	chr4:119450397	chr4:118632274~118634759:+
BRCA	cis	rs6088580	0.619	rs1205335	ENSG00000275784.1	RP5-1125A11.6	3.71	0.000217	0.0122	0.12	0.11	Glomerular filtration rate (creatinine);	chr20:34339701	chr20:33989480~33991818:-
BRCA	cis	rs11098499	0.569	rs10023641	ENSG00000225892.3	RP11-384K6.2	3.71	0.000217	0.0122	0.11	0.11	Corneal astigmatism;	chr4:119337255	chr4:118632274~118634759:+
BRCA	cis	rs35176054	0.73	rs34880818	ENSG00000280693.1	SH3PXD2A-AS1	-3.71	0.000217	0.0122	-0.21	-0.11	Atrial fibrillation;	chr10:103762002	chr10:103745966~103755423:+
BRCA	cis	rs873549	0.883	rs6604700	ENSG00000227925.1	RP11-191N8.2	3.71	0.000217	0.0122	0.13	0.11	Keloid;	chr1:222093982	chr1:221827666~221840666:-
BRCA	cis	rs867186	0.614	rs74358111	ENSG00000126005.14	MMP24-AS1	-3.71	0.000217	0.0122	-0.27	-0.11	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:34811274	chr20:35216462~35278131:-
BRCA	cis	rs11877825	0.865	rs34956381	ENSG00000265728.1	RP11-883A18.3	-3.71	0.000217	0.0122	-0.16	-0.11	Gut microbiota (bacterial taxa);	chr18:10571024	chr18:10594590~10604798:+
BRCA	cis	rs875971	1	rs1981798	ENSG00000265600.1	AC006480.1	-3.71	0.000217	0.0122	-0.14	-0.11	Aortic root size;	chr7:66489916	chr7:67356680~67356779:+
BRCA	cis	rs4243971	0.516	rs966979	ENSG00000275576.1	RP5-836N17.4	-3.71	0.000217	0.0122	-0.13	-0.11	Inflammatory bowel disease;Crohn's disease;	chr20:32343222	chr20:32116171~32116629:+
BRCA	cis	rs10761482	1	rs10821722	ENSG00000254271.1	RP11-131N11.4	3.71	0.000217	0.0122	0.16	0.11	Schizophrenia;	chr10:60321327	chr10:60734342~60741828:+
BRCA	cis	rs853679	0.546	rs200989	ENSG00000241549.7	GUSBP2	3.71	0.000217	0.0122	0.2	0.11	Depression;	chr6:27848664	chr6:26871484~26956554:-
BRCA	cis	rs11088226	0.681	rs2833911	ENSG00000186842.4	LINC00846	3.71	0.000217	0.0122	0.18	0.11	Gastritis;	chr21:32577319	chr21:32572238~32575881:-
BRCA	cis	rs7226408	0.79	rs58099133	ENSG00000267707.2	RP11-95O2.5	3.71	0.000217	0.0122	0.18	0.11	Obesity-related traits;	chr18:36752370	chr18:37243776~37247506:+
BRCA	cis	rs875971	0.545	rs3735147	ENSG00000273448.1	RP11-166O4.6	3.71	0.000218	0.0122	0.12	0.11	Aortic root size;	chr7:66505541	chr7:67333047~67334383:+
BRCA	cis	rs2148307	0.55	rs10828133	ENSG00000228339.1	AMD1P1	-3.71	0.000218	0.0122	-0.15	-0.11	Photic sneeze reflex;	chr10:20800105	chr10:20350049~20351100:+
BRCA	cis	rs8114671	0.562	rs2424999	ENSG00000261582.1	RP4-614O4.11	-3.71	0.000218	0.0122	-0.11	-0.11	Height;	chr20:34798627	chr20:35267885~35280043:-
BRCA	cis	rs251253	0.827	rs251242	ENSG00000253959.1	CTB-43E15.1	3.71	0.000218	0.0122	0.1	0.11	PR interval;	chr5:173072584	chr5:173642519~173658194:+
BRCA	cis	rs251253	0.827	rs251243	ENSG00000253959.1	CTB-43E15.1	3.71	0.000218	0.0122	0.1	0.11	PR interval;	chr5:173073572	chr5:173642519~173658194:+
BRCA	cis	rs251253	0.792	rs251244	ENSG00000253959.1	CTB-43E15.1	3.71	0.000218	0.0122	0.1	0.11	PR interval;	chr5:173074038	chr5:173642519~173658194:+
BRCA	cis	rs8098244	0.603	rs1788787	ENSG00000265752.2	RP11-403A21.1	3.71	0.000218	0.0122	0.12	0.11	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23694775	chr18:23957754~23982556:-
BRCA	cis	rs2145598	0.802	rs2147610	ENSG00000257621.6	PSMA3-AS1	-3.71	0.000218	0.0122	-0.1	-0.11	Coronary artery disease;	chr14:58380269	chr14:58265365~58298134:-
BRCA	cis	rs35612822	0.556	rs62178599	ENSG00000232485.2	AC098820.3	-3.71	0.000218	0.0122	-0.15	-0.11	Kidney disease (early stage) in type 1 diabetes;	chr2:216388376	chr2:216479030~216498761:-
BRCA	cis	rs12760731	0.641	rs12691479	ENSG00000213057.5	C1orf220	3.71	0.000218	0.0122	0.16	0.11	Obesity-related traits;	chr1:178359619	chr1:178542752~178548889:+
BRCA	cis	rs67696533	0.636	rs910889	ENSG00000277692.1	RP11-358N2.2	-3.71	0.000218	0.0122	-0.14	-0.11	White blood cell count (basophil);Basophil percentage of granulocytes;Basophil percentage of white cells;	chr20:32517147	chr20:32355053~32355734:+
BRCA	cis	rs6490294	0.747	rs659964	ENSG00000226469.1	ADAM1B	3.71	0.000218	0.0122	0.16	0.11	Mean platelet volume;	chr12:111692395	chr12:111927018~111929017:+
BRCA	cis	rs35740288	0.688	rs12904047	ENSG00000259295.5	CSPG4P12	3.71	0.000218	0.0122	0.16	0.11	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85669635	chr15:85191438~85213905:+
BRCA	cis	rs4478858	0.735	rs12134484	ENSG00000223907.1	LINC01226	-3.71	0.000218	0.0122	-0.14	-0.11	Alcohol dependence;	chr1:31350894	chr1:31518435~31524245:+
BRCA	cis	rs4873772	0.535	rs12547497	ENSG00000253330.1	RP11-697N18.3	-3.71	0.000218	0.0122	-0.17	-0.11	Lobe attachment (rater-scored or self-reported);	chr8:47466818	chr8:47511034~47512141:-
BRCA	cis	rs6088580	0.634	rs1205344	ENSG00000276073.1	RP5-1125A11.7	3.71	0.000218	0.0122	0.12	0.11	Glomerular filtration rate (creatinine);	chr20:34330492	chr20:33985617~33988989:-
BRCA	cis	rs745109	0.882	rs72932319	ENSG00000273080.1	RP11-301O19.1	3.71	0.000218	0.0122	0.17	0.11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86493480	chr2:86195590~86196049:+
BRCA	cis	rs745109	0.882	rs59336972	ENSG00000273080.1	RP11-301O19.1	3.71	0.000218	0.0122	0.17	0.11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86494059	chr2:86195590~86196049:+
BRCA	cis	rs7412746	0.634	rs4451553	ENSG00000224800.1	RP11-235D19.2	-3.71	0.000218	0.0122	-0.15	-0.11	Melanoma;	chr1:150964853	chr1:150881236~150881683:-
BRCA	cis	rs7221109	0.625	rs2008469	ENSG00000224244.1	AC090283.3	3.71	0.000218	0.0122	0.13	0.11	Type 1 diabetes;	chr17:40660343	chr17:40687038~40689360:-
BRCA	cis	rs7221109	0.677	rs12943859	ENSG00000224244.1	AC090283.3	3.71	0.000218	0.0122	0.13	0.11	Type 1 diabetes;	chr17:40661128	chr17:40687038~40689360:-
BRCA	cis	rs11098499	0.863	rs1155576	ENSG00000260091.1	RP11-33B1.4	-3.71	0.000218	0.0123	-0.1	-0.11	Corneal astigmatism;	chr4:119529004	chr4:119409333~119410233:+
BRCA	cis	rs1161098	0.671	rs1161177	ENSG00000203585.3	RP11-542B15.1	-3.71	0.000218	0.0123	-0.18	-0.11	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr12:67428826	chr12:67519829~67567126:+
BRCA	cis	rs9287719	0.967	rs6432116	ENSG00000224177.5	LINC00570	3.71	0.000218	0.0123	0.13	0.11	Prostate cancer;	chr2:10608489	chr2:11393981~11403077:+
BRCA	cis	rs9287719	0.967	rs2110776	ENSG00000224177.5	LINC00570	3.71	0.000218	0.0123	0.13	0.11	Prostate cancer;	chr2:10608684	chr2:11393981~11403077:+
BRCA	cis	rs9287719	0.967	rs2110778	ENSG00000224177.5	LINC00570	3.71	0.000218	0.0123	0.13	0.11	Prostate cancer;	chr2:10608844	chr2:11393981~11403077:+
BRCA	cis	rs9287719	0.967	rs6432117	ENSG00000224177.5	LINC00570	3.71	0.000218	0.0123	0.13	0.11	Prostate cancer;	chr2:10609233	chr2:11393981~11403077:+
BRCA	cis	rs9287719	0.967	rs6432118	ENSG00000224177.5	LINC00570	3.71	0.000218	0.0123	0.13	0.11	Prostate cancer;	chr2:10609315	chr2:11393981~11403077:+
BRCA	cis	rs9287719	0.935	rs728283	ENSG00000224177.5	LINC00570	3.71	0.000218	0.0123	0.13	0.11	Prostate cancer;	chr2:10609964	chr2:11393981~11403077:+
BRCA	cis	rs9287719	0.967	rs728282	ENSG00000224177.5	LINC00570	3.71	0.000218	0.0123	0.13	0.11	Prostate cancer;	chr2:10610177	chr2:11393981~11403077:+
BRCA	cis	rs9287719	0.967	rs728281	ENSG00000224177.5	LINC00570	3.71	0.000218	0.0123	0.13	0.11	Prostate cancer;	chr2:10610229	chr2:11393981~11403077:+
BRCA	cis	rs1008375	0.898	rs7670500	ENSG00000249502.1	AC006160.5	-3.71	0.000218	0.0123	-0.13	-0.11	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17585334	chr4:17587467~17614571:-
BRCA	cis	rs1008375	0.966	rs7675735	ENSG00000249502.1	AC006160.5	-3.71	0.000218	0.0123	-0.13	-0.11	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17585514	chr4:17587467~17614571:-
BRCA	cis	rs1008375	0.898	rs4698620	ENSG00000249502.1	AC006160.5	-3.71	0.000218	0.0123	-0.13	-0.11	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17585738	chr4:17587467~17614571:-
BRCA	cis	rs4948102	0.653	rs6593294	ENSG00000226278.1	PSPHP1	-3.71	0.000218	0.0123	-0.13	-0.11	Plasma homocysteine levels (post-methionine load test);	chr7:55995508	chr7:55764797~55773288:+
BRCA	cis	rs4919694	1	rs17787717	ENSG00000236937.2	PTGES3P4	3.71	0.000218	0.0123	0.25	0.11	Arsenic metabolism;	chr10:102935942	chr10:102845595~102845950:+
BRCA	cis	rs2991971	0.934	rs7903	ENSG00000280836.1	AL355480.1	3.71	0.000218	0.0123	0.13	0.11	High light scatter reticulocyte count;	chr1:45510800	chr1:45581219~45581321:-
BRCA	cis	rs9513627	0.915	rs7327204	ENSG00000224418.1	STK24-AS1	-3.71	0.000218	0.0123	-0.17	-0.11	Obesity-related traits;	chr13:99474698	chr13:98577244~98578830:+
BRCA	cis	rs10844706	0.699	rs10844632	ENSG00000256673.1	RP11-599J14.2	-3.71	0.000218	0.0123	-0.14	-0.11	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9734309	chr12:9398355~9414851:-
BRCA	cis	rs1009077	0.716	rs2389868	ENSG00000245958.5	RP11-33B1.1	3.71	0.000218	0.0123	0.16	0.11	Endometriosis;	chr4:119594344	chr4:119454791~119552025:+
BRCA	cis	rs1075265	0.704	rs6711217	ENSG00000272156.1	RP11-477N3.1	-3.71	0.000218	0.0123	-0.12	-0.11	Chronotype;Morning vs. evening chronotype;	chr2:54017892	chr2:54082554~54085066:+
BRCA	cis	rs2976388	0.647	rs2572906	ENSG00000253196.1	RP11-706C16.7	3.71	0.000218	0.0123	0.11	0.11	Urinary tract infection frequency;	chr8:142716851	chr8:142763116~142766427:+
BRCA	cis	rs2075466	0.514	rs3747614	ENSG00000267077.1	RP11-127I20.5	-3.71	0.000218	0.0123	-0.17	-0.11	Colonoscopy-negative controls vs population controls;	chr16:4858666	chr16:4795265~4796532:-
BRCA	cis	rs11098499	0.954	rs6849561	ENSG00000260091.1	RP11-33B1.4	3.71	0.000218	0.0123	0.1	0.11	Corneal astigmatism;	chr4:119488539	chr4:119409333~119410233:+
BRCA	cis	rs9628987	0.5	rs11121179	ENSG00000270282.1	RP5-1115A15.2	-3.71	0.000218	0.0123	-0.17	-0.11	Breast cancer;	chr1:8395652	chr1:8512653~8513021:+
BRCA	cis	rs6496932	0.503	rs10220820	ENSG00000259630.2	CTD-2262B20.1	-3.71	0.000218	0.0123	-0.16	-0.11	Central corneal thickness;Corneal structure;	chr15:85441932	chr15:85415228~85415633:+
BRCA	cis	rs4332037	0.754	rs62436669	ENSG00000273230.1	RP11-1246C19.1	3.71	0.000218	0.0123	0.18	0.11	Bipolar disorder;	chr7:1887000	chr7:1464497~1467522:-
BRCA	cis	rs853679	0.517	rs868987	ENSG00000226314.6	ZNF192P1	3.71	0.000218	0.0123	0.17	0.11	Depression;	chr6:28142370	chr6:28161781~28169594:+
BRCA	cis	rs2839186	0.872	rs13052233	ENSG00000215424.8	MCM3AP-AS1	3.71	0.000218	0.0123	0.1	0.11	Testicular germ cell tumor;	chr21:46287370	chr21:46229217~46259390:+
BRCA	cis	rs16940212	0.618	rs16940181	ENSG00000259771.1	RP11-429D19.1	-3.71	0.000218	0.0123	-0.19	-0.11	HDL cholesterol;HDL cholesterol levels;	chr15:58395325	chr15:59266720~59271162:-
BRCA	cis	rs61931739	0.534	rs10844728	ENSG00000258794.3	DUX4L27	3.71	0.000218	0.0123	0.17	0.11	Morning vs. evening chronotype;	chr12:33867174	chr12:34208415~34209675:-
BRCA	cis	rs6840360	1	rs2278304	ENSG00000251611.1	RP11-610P16.1	3.71	0.000218	0.0123	0.1	0.11	Intelligence (multi-trait analysis);	chr4:151672257	chr4:151407551~151408835:-
BRCA	cis	rs2579519	0.547	rs11683523	ENSG00000168992.4	OR7E102P	3.71	0.000218	0.0123	0.17	0.11	Diastolic blood pressure;	chr2:95879107	chr2:95546531~95547545:+
BRCA	cis	rs875971	0.862	rs1983372	ENSG00000271064.1	RP11-792A8.3	3.71	0.000218	0.0123	0.13	0.11	Aortic root size;	chr7:66146364	chr7:66748838~66749077:-
BRCA	cis	rs4494364	0.502	rs1073763	ENSG00000258100.1	RP11-121E16.1	3.71	0.000218	0.0123	0.16	0.11	Systolic blood pressure (alcohol consumption interaction);	chr12:91018760	chr12:91362196~91368606:+
BRCA	cis	rs4494364	0.502	rs7973685	ENSG00000258100.1	RP11-121E16.1	3.71	0.000218	0.0123	0.16	0.11	Systolic blood pressure (alcohol consumption interaction);	chr12:91023030	chr12:91362196~91368606:+
BRCA	cis	rs10777288	0.632	rs7963970	ENSG00000258100.1	RP11-121E16.1	3.71	0.000218	0.0123	0.16	0.11	Pulmonary function (smoking interaction);	chr12:91023796	chr12:91362196~91368606:+
BRCA	cis	rs9307239	0.501	rs9997653	ENSG00000246090.5	RP11-696N14.1	3.71	0.000218	0.0123	0.11	0.11	Alcohol dependence;	chr4:99378296	chr4:99088857~99301356:+
BRCA	cis	rs8062405	1	rs55991577	ENSG00000261766.1	RP11-22P6.2	-3.71	0.000218	0.0123	-0.11	-0.11	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28831704	chr16:28862166~28863340:-
BRCA	cis	rs8062405	1	rs56358680	ENSG00000261766.1	RP11-22P6.2	-3.71	0.000218	0.0123	-0.11	-0.11	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28831797	chr16:28862166~28863340:-
BRCA	cis	rs3820068	0.581	rs16851819	ENSG00000237301.1	RP4-680D5.2	3.71	0.000218	0.0123	0.15	0.11	Systolic blood pressure;	chr1:15592244	chr1:15586136~15603626:-
BRCA	cis	rs7829975	0.84	rs572366	ENSG00000233609.3	RP11-62H7.2	3.71	0.000218	0.0123	0.11	0.11	Mood instability;	chr8:8721284	chr8:8961200~8979025:+
BRCA	cis	rs1008375	0.966	rs4698621	ENSG00000249502.1	AC006160.5	-3.71	0.000218	0.0123	-0.13	-0.11	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17585942	chr4:17587467~17614571:-
BRCA	cis	rs8030605	0.704	rs72740560	ENSG00000277245.1	RP11-48G14.3	3.71	0.000218	0.0123	0.24	0.11	Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;	chr15:56321705	chr15:56447120~56447697:+
BRCA	cis	rs35934224	0.628	rs2073750	ENSG00000232926.1	AC000078.5	3.71	0.000219	0.0123	0.12	0.11	Glaucoma (primary open-angle);	chr22:19885834	chr22:19887289~19887970:+
BRCA	cis	rs12317459	0.591	rs12369186	ENSG00000213270.5	RPL6P25	-3.71	0.000219	0.0123	-0.19	-0.11	Prostate cancer (SNP x SNP interaction);	chr12:82772705	chr12:83151331~83152190:+
BRCA	cis	rs6599077	0.95	rs9311231	ENSG00000223797.4	ENTPD3-AS1	3.71	0.000219	0.0123	0.14	0.11	Sleep-related phenotypes;	chr3:40064192	chr3:40313802~40453329:-
BRCA	cis	rs17027633	1	rs17027601	ENSG00000234020.1	CHIAP3	-3.71	0.000219	0.0123	-0.27	-0.11	Cerebrospinal fluid t-tau:AB1-42 ratio;	chr1:111413650	chr1:111353275~111367409:-
BRCA	cis	rs4950322	0.576	rs2353979	ENSG00000237188.3	RP11-337C18.8	-3.71	0.000219	0.0123	-0.12	-0.11	Protein quantitative trait loci;	chr1:147368185	chr1:147172771~147211568:+
BRCA	cis	rs4950322	0.576	rs2353980	ENSG00000237188.3	RP11-337C18.8	-3.71	0.000219	0.0123	-0.12	-0.11	Protein quantitative trait loci;	chr1:147368274	chr1:147172771~147211568:+
BRCA	cis	rs8113308	0.752	rs8113758	ENSG00000270248.1	CTC-471J1.10	3.71	0.000219	0.0123	0.19	0.11	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51990054	chr19:52110318~52110726:-
BRCA	cis	rs375066	0.967	rs436249	ENSG00000267191.1	RP11-15A1.2	-3.71	0.000219	0.0123	-0.15	-0.11	Breast cancer;	chr19:43895413	chr19:43902001~43926545:+
BRCA	cis	rs6452524	0.935	rs7718284	ENSG00000281327.1	LINC01338	-3.71	0.000219	0.0123	-0.13	-0.11	Hypertension (SNP x SNP interaction);	chr5:83082488	chr5:82850864~82859836:-
BRCA	cis	rs7759001	0.681	rs6918131	ENSG00000237154.2	MCFD2P1	3.71	0.000219	0.0123	0.14	0.11	Glomerular filtration rate (creatinine);	chr6:27513138	chr6:27407697~27407996:+
BRCA	cis	rs10411161	0.702	rs11878580	ENSG00000269483.1	AC006272.1	3.71	0.000219	0.0123	0.18	0.11	Breast cancer;	chr19:51885232	chr19:51839924~51843324:-
BRCA	cis	rs10411161	0.702	rs11878586	ENSG00000269483.1	AC006272.1	3.71	0.000219	0.0123	0.18	0.11	Breast cancer;	chr19:51885323	chr19:51839924~51843324:-
BRCA	cis	rs7312933	0.669	rs7974476	ENSG00000257225.1	RP11-328C8.4	-3.71	0.000219	0.0123	-0.14	-0.11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42148682	chr12:42459366~42466128:+
BRCA	cis	rs903107	1	rs903107	ENSG00000266501.1	RP11-766H1.1	-3.71	0.000219	0.0123	-0.14	-0.11	Liver enzyme levels (alanine transaminase);	chr17:73065795	chr17:73067870~73068288:-
BRCA	cis	rs61931739	0.534	rs11053000	ENSG00000258794.3	DUX4L27	3.71	0.000219	0.0123	0.17	0.11	Morning vs. evening chronotype;	chr12:33926087	chr12:34208415~34209675:-
BRCA	cis	rs4578769	0.959	rs3851816	ENSG00000273232.1	RP11-370A5.2	3.71	0.000219	0.0123	0.15	0.11	Eosinophil percentage of white cells;	chr18:22866880	chr18:22882825~22883357:-
BRCA	cis	rs4267450	0.842	rs11666278	ENSG00000261770.1	CTC-459F4.1	3.71	0.000219	0.0123	0.23	0.11	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);	chr19:28363434	chr19:27757184~27760849:-
BRCA	cis	rs12289961	0.681	rs11822750	ENSG00000265566.2	RN7SL605P	3.71	0.000219	0.0123	0.19	0.11	Lymphoma;	chr11:58232290	chr11:57528085~57528365:-
BRCA	cis	rs12289961	0.681	rs112853019	ENSG00000265566.2	RN7SL605P	3.71	0.000219	0.0123	0.19	0.11	Lymphoma;	chr11:58232964	chr11:57528085~57528365:-
BRCA	cis	rs859767	0.704	rs7570717	ENSG00000224043.6	CCNT2-AS1	3.71	0.000219	0.0123	0.16	0.11	Neuroticism;	chr2:134603465	chr2:134735464~134918710:-
BRCA	cis	rs6504622	0.755	rs12942936	ENSG00000263142.4	LRRC37A17P	-3.71	0.000219	0.0123	-0.09	-0.11	Orofacial clefts;	chr17:47075062	chr17:46978481~47054569:+
BRCA	cis	rs17221829	0.965	rs10830366	ENSG00000280385.1	AP000648.5	-3.71	0.000219	0.0123	-0.13	-0.11	Anxiety in major depressive disorder;	chr11:89726086	chr11:90193614~90198120:+
BRCA	cis	rs875971	0.862	rs801195	ENSG00000273024.4	INTS4P2	3.71	0.000219	0.0123	0.13	0.11	Aortic root size;	chr7:66561128	chr7:65647864~65715661:+
BRCA	cis	rs11098499	0.618	rs35265692	ENSG00000225892.3	RP11-384K6.2	3.71	0.000219	0.0123	0.11	0.11	Corneal astigmatism;	chr4:119403980	chr4:118632274~118634759:+
BRCA	cis	rs2391285	0.609	rs4275130	ENSG00000280255.1	RP5-1007F24.1	-3.71	0.000219	0.0123	-0.16	-0.11	Post bronchodilator FEV1/FVC ratio;	chr7:26553157	chr7:26538378~26541048:+
BRCA	cis	rs4654783	0.627	rs66766977	ENSG00000230068.2	CDC42-IT1	3.71	0.000219	0.0123	0.13	0.11	Endometriosis;	chr1:22104599	chr1:22059197~22064199:+
BRCA	cis	rs1008375	0.931	rs1860592	ENSG00000249502.1	AC006160.5	-3.71	0.000219	0.0123	-0.13	-0.11	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17575405	chr4:17587467~17614571:-
BRCA	cis	rs1867631	0.585	rs12094526	ENSG00000248458.2	RP4-598P13.1	3.71	0.000219	0.0123	0.12	0.11	Menopause (age at onset);	chr1:66660431	chr1:66665864~66677027:-
BRCA	cis	rs55675132	0.548	rs3911879	ENSG00000226167.1	AP4B1-AS1	3.71	0.000219	0.0123	0.12	0.11	Schizophrenia;	chr1:114835411	chr1:113856635~113901237:+
BRCA	cis	rs2841277	0.77	rs10149193	ENSG00000258701.1	LINC00638	3.71	0.000219	0.0123	0.12	0.11	Rheumatoid arthritis;	chr14:104937137	chr14:104821201~104823718:+
BRCA	cis	rs10043775	0.831	rs9325094	ENSG00000251330.3	CTD-2283N19.1	-3.71	0.000219	0.0123	-0.14	-0.11	Periodontal microbiota;	chr5:148350228	chr5:148430159~148430807:-
BRCA	cis	rs2615061	0.746	rs1849685	ENSG00000229965.1	RP11-118H4.1	3.71	0.000219	0.0123	0.2	0.11	Monocyte count;	chr1:225774823	chr1:226438564~226439344:+
BRCA	cis	rs1245541	0.595	rs7072673	ENSG00000226701.1	RP11-570G20.1	3.71	0.000219	0.0123	0.12	0.11	Insulin-like growth factors;	chr10:72105984	chr10:72189941~72190576:+
BRCA	cis	rs4648045	0.734	rs4235406	ENSG00000251288.2	RP11-10L12.2	-3.71	0.000219	0.0123	-0.15	-0.11	Lymphocyte percentage of white cells;	chr4:102605374	chr4:102751401~102752641:+
BRCA	cis	rs442309	0.875	rs224068	ENSG00000238280.1	RP11-436D10.3	-3.71	0.000219	0.0123	-0.14	-0.11	Vogt-Koyanagi-Harada syndrome;	chr10:62748340	chr10:62793562~62805887:-
BRCA	cis	rs5758511	0.68	rs1107553	ENSG00000231261.1	HMGN2P10	-3.71	0.000219	0.0123	-0.16	-0.11	Birth weight;	chr22:42271467	chr22:41709225~41709489:-
BRCA	cis	rs7246657	0.943	rs8109038	ENSG00000267470.4	ZNF571-AS1	-3.71	0.000219	0.0123	-0.15	-0.11	Coronary artery calcification;	chr19:37524807	chr19:37548914~37587348:+
BRCA	cis	rs10777288	0.561	rs7358749	ENSG00000258100.1	RP11-121E16.1	3.71	0.000219	0.0123	0.15	0.11	Pulmonary function (smoking interaction);	chr12:90998062	chr12:91362196~91368606:+
BRCA	cis	rs2302465	0.86	rs17385951	ENSG00000273133.1	RP11-799M12.2	-3.71	0.000219	0.0123	-0.23	-0.11	Blood protein levels;	chr4:15559469	chr4:15563698~15564253:-
BRCA	cis	rs4950322	0.58	rs7514970	ENSG00000227242.3	NBPF13P	-3.71	0.000219	0.0123	-0.16	-0.11	Protein quantitative trait loci;	chr1:147120516	chr1:147021320~147124525:-
BRCA	cis	rs7647973	0.516	rs4536858	ENSG00000272434.1	RP13-131K19.6	-3.71	0.000219	0.0123	-0.13	-0.11	Menarche (age at onset);	chr3:49155648	chr3:49029316~49029706:+
BRCA	cis	rs12971120	0.891	rs2303463	ENSG00000276934.1	RP11-231E4.5	3.71	0.000219	0.0123	0.17	0.11	Refractive error;	chr18:74501373	chr18:74504766~74505248:+
BRCA	cis	rs7312933	0.528	rs10880238	ENSG00000257376.1	RP11-328C8.2	-3.71	0.000219	0.0123	-0.13	-0.11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42095811	chr12:42431665~42433357:-
BRCA	cis	rs13118159	0.934	rs4974553	ENSG00000254094.1	AC078852.1	-3.71	0.000219	0.0123	-0.12	-0.11	Longevity;	chr4:1363123	chr4:1356581~1358075:+
BRCA	cis	rs9921338	0.961	rs7200667	ENSG00000263080.1	RP11-485G7.5	3.71	0.00022	0.0123	0.18	0.11	Vein graft stenosis in coronary artery bypass grafting;	chr16:11346547	chr16:11341809~11345211:-
BRCA	cis	rs2562456	0.876	rs62110163	ENSG00000240522.1	RPL7AP10	-3.71	0.00022	0.0123	-0.13	-0.11	Pain;	chr19:21546020	chr19:21149648~21150438:-
BRCA	cis	rs2562456	0.761	rs35008138	ENSG00000240522.1	RPL7AP10	-3.71	0.00022	0.0123	-0.13	-0.11	Pain;	chr19:21548822	chr19:21149648~21150438:-
BRCA	cis	rs2562456	0.833	rs2681388	ENSG00000240522.1	RPL7AP10	-3.71	0.00022	0.0123	-0.13	-0.11	Pain;	chr19:21549451	chr19:21149648~21150438:-
BRCA	cis	rs2562456	0.876	rs2681370	ENSG00000240522.1	RPL7AP10	-3.71	0.00022	0.0123	-0.13	-0.11	Pain;	chr19:21554036	chr19:21149648~21150438:-
BRCA	cis	rs2562456	0.876	rs11668606	ENSG00000240522.1	RPL7AP10	-3.71	0.00022	0.0123	-0.13	-0.11	Pain;	chr19:21554618	chr19:21149648~21150438:-
BRCA	cis	rs2562456	0.876	rs2681395	ENSG00000240522.1	RPL7AP10	-3.71	0.00022	0.0123	-0.13	-0.11	Pain;	chr19:21555338	chr19:21149648~21150438:-
BRCA	cis	rs1528472	0.619	rs7173577	ENSG00000276533.1	RP11-139H15.5	-3.71	0.00022	0.0123	-0.13	-0.11	Urinary albumin-to-creatinine ratio;Urinary albumin-to-creatinine ratio in non-diabetics;	chr15:55012805	chr15:55288849~55289346:-
BRCA	cis	rs6545883	0.507	rs12617371	ENSG00000270820.4	RP11-355B11.2	-3.71	0.00022	0.0123	-0.12	-0.11	Tuberculosis;	chr2:61341999	chr2:61471188~61484130:+
BRCA	cis	rs7267979	1	rs6050566	ENSG00000274973.1	RP13-401N8.7	3.71	0.00022	0.0123	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25370435	chr20:25845497~25845862:+
BRCA	cis	rs4879656	0.593	rs4879660	ENSG00000236184.1	TCEA1P4	-3.71	0.00022	0.0123	-0.15	-0.11	Menopause (age at onset);	chr9:33032835	chr9:32979560~32980403:-
BRCA	cis	rs7395581	0.918	rs61896050	ENSG00000280615.1	Y_RNA	3.71	0.00022	0.0123	0.14	0.11	HDL cholesterol;	chr11:47287512	chr11:47614898~47614994:-
BRCA	cis	rs4948102	0.727	rs4948097	ENSG00000226278.1	PSPHP1	-3.71	0.00022	0.0123	-0.13	-0.11	Plasma homocysteine levels (post-methionine load test);	chr7:55988878	chr7:55764797~55773288:+
BRCA	cis	rs7267979	0.933	rs2258728	ENSG00000125804.12	FAM182A	-3.71	0.00022	0.0123	-0.15	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25295707	chr20:26054655~26086917:+
BRCA	cis	rs13256369	1	rs12550762	ENSG00000254153.1	CTA-398F10.2	3.71	0.00022	0.0123	0.15	0.11	Obesity-related traits;	chr8:8719025	chr8:8456909~8461337:-
BRCA	cis	rs7395581	0.877	rs7127907	ENSG00000280615.1	Y_RNA	3.71	0.00022	0.0123	0.14	0.11	HDL cholesterol;	chr11:47302921	chr11:47614898~47614994:-
BRCA	cis	rs613391	0.522	rs555828	ENSG00000265194.1	RP11-70L8.4	3.71	0.00022	0.0123	0.12	0.11	Quantitative traits;	chr9:22733239	chr9:21858910~21861926:-
BRCA	cis	rs6545883	0.868	rs2518933	ENSG00000212978.6	AC016747.3	3.71	0.00022	0.0123	0.16	0.11	Tuberculosis;	chr2:61569895	chr2:61141592~61144969:-
BRCA	cis	rs875971	1	rs10244498	ENSG00000265600.1	AC006480.1	-3.71	0.00022	0.0123	-0.14	-0.11	Aortic root size;	chr7:66651069	chr7:67356680~67356779:+
BRCA	cis	rs6456156	0.805	rs6909252	ENSG00000272549.1	RP11-351J23.2	3.71	0.00022	0.0123	0.11	0.11	Primary biliary cholangitis;	chr6:167113609	chr6:167666840~167679270:-
BRCA	cis	rs6071166	1	rs6071166	ENSG00000224635.1	RP4-564F22.5	-3.71	0.00022	0.0123	-0.14	-0.11	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38704369	chr20:38406011~38416797:-
BRCA	cis	rs11098499	0.954	rs1546505	ENSG00000260091.1	RP11-33B1.4	-3.71	0.00022	0.0123	-0.1	-0.11	Corneal astigmatism;	chr4:119320069	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.644	rs10012252	ENSG00000260091.1	RP11-33B1.4	-3.71	0.00022	0.0123	-0.1	-0.11	Corneal astigmatism;	chr4:119637984	chr4:119409333~119410233:+
BRCA	cis	rs17507216	0.628	rs4627310	ENSG00000259429.4	UBE2Q2P2	-3.71	0.00022	0.0123	-0.15	-0.11	Excessive daytime sleepiness;	chr15:82708330	chr15:82355142~82420075:+
BRCA	cis	rs80226907	0.634	rs80272214	ENSG00000186615.9	KTN1-AS1	-3.71	0.00022	0.0123	-0.25	-0.11	Mean platelet volume;	chr14:55436290	chr14:55499278~55580110:-
BRCA	cis	rs6142618	0.562	rs4589835	ENSG00000224452.1	RSL24D1P6	3.71	0.00022	0.0123	0.15	0.11	Inflammatory bowel disease;	chr20:32168811	chr20:32170390~32170790:-
BRCA	cis	rs9958734	0.579	rs4939591	ENSG00000263916.1	RP11-110H1.4	-3.71	0.00022	0.0123	-0.23	-0.11	Total cholesterol levels;	chr18:49633547	chr18:49484536~49486149:-
BRCA	cis	rs11098499	0.605	rs6833140	ENSG00000260404.2	RP11-384K6.6	3.71	0.00022	0.0123	0.1	0.11	Corneal astigmatism;	chr4:119345667	chr4:118591773~118633729:+
BRCA	cis	rs4819052	0.851	rs13048789	ENSG00000215447.6	BX322557.10	-3.71	0.00022	0.0123	-0.12	-0.11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240799	chr21:45288052~45291738:+
BRCA	cis	rs7246967	0.551	rs7351072	ENSG00000198153.8	ZNF849P	-3.71	0.00022	0.0124	-0.16	-0.11	Bronchopulmonary dysplasia;	chr19:22861727	chr19:22685167~22686732:+
BRCA	cis	rs9300255	0.722	rs10773008	ENSG00000256028.2	RP11-197N18.2	3.71	0.00022	0.0124	0.11	0.11	Neutrophil percentage of white cells;	chr12:123316273	chr12:122975320~122982907:+
BRCA	cis	rs11773103	1	rs73208546	ENSG00000224046.1	AC005076.5	3.71	0.00022	0.0124	0.25	0.11	Bipolar disorder or major depressive disorder (combined);	chr7:87203799	chr7:87151423~87152420:-
BRCA	cis	rs11773103	1	rs117742735	ENSG00000224046.1	AC005076.5	3.71	0.00022	0.0124	0.25	0.11	Bipolar disorder or major depressive disorder (combined);	chr7:87205452	chr7:87151423~87152420:-
BRCA	cis	rs11098499	0.687	rs71610270	ENSG00000225892.3	RP11-384K6.2	3.71	0.00022	0.0124	0.11	0.11	Corneal astigmatism;	chr4:119366281	chr4:118632274~118634759:+
BRCA	cis	rs1008375	0.966	rs2010053	ENSG00000249502.1	AC006160.5	-3.71	0.00022	0.0124	-0.13	-0.11	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17582183	chr4:17587467~17614571:-
BRCA	cis	rs1008375	0.966	rs1476836	ENSG00000249502.1	AC006160.5	-3.71	0.00022	0.0124	-0.13	-0.11	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17583391	chr4:17587467~17614571:-
BRCA	cis	rs853679	0.882	rs3757188	ENSG00000216901.1	AL022393.7	3.71	0.00022	0.0124	0.23	0.11	Depression;	chr6:28139579	chr6:28176188~28176674:+
BRCA	cis	rs73201462	1	rs2811536	ENSG00000242551.2	POU5F1P6	-3.71	0.00022	0.0124	-0.2	-0.11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128270076	chr3:128674735~128677005:-
BRCA	cis	rs524281	0.861	rs7929909	ENSG00000255038.1	RP11-1167A19.2	-3.71	0.00022	0.0124	-0.17	-0.11	Electroencephalogram traits;	chr11:66184227	chr11:66067277~66069619:-
BRCA	cis	rs4660456	0.504	rs491619	ENSG00000272145.1	NFYC-AS1	-3.71	0.00022	0.0124	-0.13	-0.11	Platelet count;	chr1:40641688	chr1:40690380~40692066:-
BRCA	cis	rs7917772	0.503	rs7899576	ENSG00000213061.2	PFN1P11	-3.71	0.00022	0.0124	-0.16	-0.11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;	chr10:102547747	chr10:102838011~102845473:-
BRCA	cis	rs295490	0.831	rs57707457	ENSG00000178631.7	ACTG1P1	-3.71	0.00022	0.0124	-0.21	-0.11	PR interval in Tripanosoma cruzi seropositivity;	chr3:139520256	chr3:139493809~139494937:+
BRCA	cis	rs2281603	0.762	rs12588509	ENSG00000259116.1	RP11-973N13.4	3.71	0.00022	0.0124	0.11	0.11	Lymphocyte counts;	chr14:64580554	chr14:64514154~64540368:-
BRCA	cis	rs7975161	1	rs4964728	ENSG00000257681.1	RP11-341G23.4	-3.71	0.00022	0.0124	-0.16	-0.11	Toenail selenium levels;	chr12:104255955	chr12:103746315~103768858:-
BRCA	cis	rs7201929	1	rs7499878	ENSG00000278665.1	RP11-666O2.4	-3.71	0.00022	0.0124	-0.13	-0.11	QT interval;	chr16:28857143	chr16:28599241~28601881:-
BRCA	cis	rs11098499	0.913	rs68128210	ENSG00000260091.1	RP11-33B1.4	-3.71	0.00022	0.0124	-0.11	-0.11	Corneal astigmatism;	chr4:119216664	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.913	rs13126596	ENSG00000260091.1	RP11-33B1.4	-3.71	0.00022	0.0124	-0.11	-0.11	Corneal astigmatism;	chr4:119219574	chr4:119409333~119410233:+
BRCA	cis	rs35612822	0.556	rs12694387	ENSG00000232485.2	AC098820.3	-3.71	0.00022	0.0124	-0.15	-0.11	Kidney disease (early stage) in type 1 diabetes;	chr2:216391308	chr2:216479030~216498761:-
BRCA	cis	rs7709909	0.686	rs6151617	ENSG00000249655.1	CTC-325J23.2	3.71	0.00022	0.0124	0.12	0.11	HDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;	chr5:80665824	chr5:80630313~80631590:-
BRCA	cis	rs938554	0.744	rs7675964	ENSG00000250413.1	RP11-448G15.1	3.71	0.00022	0.0124	0.15	0.11	Blood metabolite levels;	chr4:9939810	chr4:10006482~10009725:+
BRCA	cis	rs3764563	0.877	rs4646526	ENSG00000267594.5	CYP4F24P	-3.71	0.00022	0.0124	-0.21	-0.11	Inflammatory biomarkers;	chr19:15618962	chr19:15760241~15779909:-
BRCA	cis	rs875971	0.862	rs7786892	ENSG00000273024.4	INTS4P2	3.71	0.00022	0.0124	0.13	0.11	Aortic root size;	chr7:66163889	chr7:65647864~65715661:+
BRCA	cis	rs7903456	0.648	rs9420429	ENSG00000224914.2	LINC00863	-3.71	0.00022	0.0124	-0.14	-0.11	Gout;Renal underexcretion gout;	chr10:87049058	chr10:87342736~87357882:+
BRCA	cis	rs853679	0.517	rs56364346	ENSG00000226314.6	ZNF192P1	-3.71	0.00022	0.0124	-0.17	-0.11	Depression;	chr6:28082984	chr6:28161781~28169594:+
BRCA	cis	rs853679	0.517	rs9357061	ENSG00000226314.6	ZNF192P1	-3.71	0.00022	0.0124	-0.17	-0.11	Depression;	chr6:28083994	chr6:28161781~28169594:+
BRCA	cis	rs853679	0.517	rs9368550	ENSG00000226314.6	ZNF192P1	-3.71	0.00022	0.0124	-0.17	-0.11	Depression;	chr6:28084025	chr6:28161781~28169594:+
BRCA	cis	rs853679	0.542	rs2295594	ENSG00000226314.6	ZNF192P1	-3.71	0.00022	0.0124	-0.17	-0.11	Depression;	chr6:28085319	chr6:28161781~28169594:+
BRCA	cis	rs7781266	0.842	rs62469986	ENSG00000226205.1	AC007790.4	3.71	0.00022	0.0124	0.16	0.11	Educational attainment (college completion);	chr7:133547842	chr7:133732493~133733595:-
BRCA	cis	rs970548	0.865	rs12246131	ENSG00000237840.5	FAM21FP	3.71	0.00022	0.0124	0.15	0.11	Total cholesterol levels;HDL cholesterol;HDL cholesterol levels;Cholesterol, total;	chr10:45498334	chr10:45706431~45727231:-
BRCA	cis	rs970548	0.908	rs11239538	ENSG00000237840.5	FAM21FP	3.71	0.00022	0.0124	0.15	0.11	Total cholesterol levels;HDL cholesterol;HDL cholesterol levels;Cholesterol, total;	chr10:45499148	chr10:45706431~45727231:-
BRCA	cis	rs970548	0.954	rs7076198	ENSG00000237840.5	FAM21FP	3.71	0.00022	0.0124	0.15	0.11	Total cholesterol levels;HDL cholesterol;HDL cholesterol levels;Cholesterol, total;	chr10:45500861	chr10:45706431~45727231:-
BRCA	cis	rs7260598	0.579	rs9676579	ENSG00000268442.1	CTD-2027I19.2	3.71	0.00022	0.0124	0.19	0.11	Response to taxane treatment (placlitaxel);	chr19:24029180	chr19:24162370~24163425:-
BRCA	cis	rs4478858	0.735	rs1566963	ENSG00000223907.1	LINC01226	-3.71	0.00022	0.0124	-0.14	-0.11	Alcohol dependence;	chr1:31299359	chr1:31518435~31524245:+
BRCA	cis	rs60012524	1	rs60012524	ENSG00000231822.1	AC019097.7	-3.71	0.00022	0.0124	-0.15	-0.11	Chronic sinus infection;	chr2:98942654	chr2:99102018~99102752:+
BRCA	cis	rs2115536	0.606	rs8024713	ENSG00000278600.1	RP11-81A1.6	-3.71	0.00022	0.0124	-0.1	-0.11	Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Eosinophil counts;Neutrophil percentage of granulocytes;	chr15:79914616	chr15:79920195~79922455:-
BRCA	cis	rs7221109	0.592	rs917595	ENSG00000224244.1	AC090283.3	3.71	0.00022	0.0124	0.13	0.11	Type 1 diabetes;	chr17:40663246	chr17:40687038~40689360:-
BRCA	cis	rs62246343	0.605	rs17050395	ENSG00000214041.4	PGAM1P4	3.71	0.00022	0.0124	0.14	0.11	Fibrinogen levels;	chr3:9492290	chr3:9348443~9349192:+
BRCA	cis	rs3743162	1	rs12917429	ENSG00000275120.1	RP11-182J1.17	-3.71	0.00022	0.0124	-0.17	-0.11	Alzheimer's disease (age of onset);	chr15:84881866	chr15:84599434~84606463:-
BRCA	cis	rs739496	0.579	rs3752631	ENSG00000234608.6	MAPKAPK5-AS1	3.71	0.00022	0.0124	0.14	0.11	Platelet count;	chr12:111938353	chr12:111839764~111842902:-
BRCA	cis	rs739496	0.579	rs7959619	ENSG00000234608.6	MAPKAPK5-AS1	3.71	0.00022	0.0124	0.14	0.11	Platelet count;	chr12:111938793	chr12:111839764~111842902:-
BRCA	cis	rs1008375	0.966	rs3775924	ENSG00000249502.1	AC006160.5	-3.71	0.000221	0.0124	-0.13	-0.11	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17584361	chr4:17587467~17614571:-
BRCA	cis	rs4415084	1	rs2218081	ENSG00000248779.1	RP11-53O19.2	3.71	0.000221	0.0124	0.11	0.11	Breast cancer;	chr5:44705038	chr5:44752949~44765744:+
BRCA	cis	rs6993270	0.779	rs111486708	ENSG00000245330.4	KB-1471A8.1	-3.71	0.000221	0.0124	-0.18	-0.11	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr8:119917454	chr8:119867419~119874488:-
BRCA	cis	rs11048434	0.518	rs17730331	ENSG00000111788.10	RP11-22B23.1	3.71	0.000221	0.0124	0.11	0.11	Sjögren's syndrome;	chr12:9025836	chr12:9277235~9313241:+
BRCA	cis	rs6121246	0.909	rs6119729	ENSG00000230613.1	HM13-AS1	-3.71	0.000221	0.0124	-0.17	-0.11	Mean corpuscular hemoglobin;	chr20:31825360	chr20:31567707~31573263:-
BRCA	cis	rs80028505	0.908	rs7766032	ENSG00000271304.1	DPRXP2	3.71	0.000221	0.0124	0.22	0.11	Foot ulcer in diabetes and neuropathy;	chr6:36101212	chr6:35989515~35990436:-
BRCA	cis	rs1912124	1	rs67895155	ENSG00000271983.1	RP11-28H5.2	3.71	0.000221	0.0124	0.23	0.11	Peripheral arterial disease (traffic-related air pollution interaction);	chr15:81215978	chr15:80693216~80693707:-
BRCA	cis	rs1912124	1	rs66484136	ENSG00000271983.1	RP11-28H5.2	3.71	0.000221	0.0124	0.23	0.11	Peripheral arterial disease (traffic-related air pollution interaction);	chr15:81216042	chr15:80693216~80693707:-
BRCA	cis	rs8180040	0.783	rs11710121	ENSG00000271161.1	BOLA2P2	-3.71	0.000221	0.0124	-0.13	-0.11	Colorectal cancer;	chr3:47310011	chr3:47499841~47500407:+
BRCA	cis	rs10421328	0.821	rs10423311	ENSG00000267419.1	CTC-559E9.6	-3.71	0.000221	0.0124	-0.13	-0.11	Parental longevity (combined parental age at death);	chr19:19646453	chr19:19776602~19834927:+
BRCA	cis	rs6736093	0.796	rs4848980	ENSG00000236307.2	EEF1E1P1	-3.71	0.000221	0.0124	-0.14	-0.11	Coronary artery disease;	chr2:112058771	chr2:111887914~111888741:+
BRCA	cis	rs11168618	0.74	rs4760723	ENSG00000240399.1	RP1-228P16.1	3.71	0.000221	0.0124	0.12	0.11	Adiponectin levels;	chr12:48532079	chr12:48054813~48055591:-
BRCA	cis	rs6734238	0.702	rs6731551	ENSG00000231747.1	AC079922.2	-3.71	0.000221	0.0124	-0.11	-0.11	Fibrinogen levels;C-reactive protein levels or total cholesterol levels (pleiotropy);Fibrinogen;C-reactive protein;White blood cell count;C-reactive protein levels;	chr2:113086976	chr2:112621809~112622167:-
BRCA	cis	rs12462428	1	rs12462428	ENSG00000279748.1	CTD-3222D19.9	-3.71	0.000221	0.0124	-0.15	-0.11	Educational attainment (years of education);	chr19:16583799	chr19:16586905~16589409:+
BRCA	cis	rs2191566	0.664	rs7255512	ENSG00000266921.1	RP11-15A1.7	-3.71	0.000221	0.0124	-0.14	-0.11	Acute lymphoblastic leukemia (childhood);	chr19:44070547	chr19:43996896~44002836:-
BRCA	cis	rs8114671	0.562	rs6060064	ENSG00000279253.1	RP4-614O4.13	3.71	0.000221	0.0124	0.13	0.11	Height;	chr20:34818536	chr20:35262727~35264187:-
BRCA	cis	rs6545883	0.525	rs2049747	ENSG00000270820.4	RP11-355B11.2	-3.71	0.000221	0.0124	-0.13	-0.11	Tuberculosis;	chr2:61137019	chr2:61471188~61484130:+
BRCA	cis	rs6831352	0.589	rs2924584	ENSG00000272777.1	RP11-571L19.8	-3.71	0.000221	0.0124	-0.11	-0.11	Alcohol dependence;	chr4:99067057	chr4:99067256~99068125:-
BRCA	cis	rs9287719	0.967	rs6709466	ENSG00000224177.5	LINC00570	3.71	0.000221	0.0124	0.13	0.11	Prostate cancer;	chr2:10608131	chr2:11393981~11403077:+
BRCA	cis	rs9287719	0.967	rs6719701	ENSG00000224177.5	LINC00570	3.71	0.000221	0.0124	0.13	0.11	Prostate cancer;	chr2:10608157	chr2:11393981~11403077:+
BRCA	cis	rs9287719	0.934	rs6432115	ENSG00000224177.5	LINC00570	3.71	0.000221	0.0124	0.13	0.11	Prostate cancer;	chr2:10608217	chr2:11393981~11403077:+
BRCA	cis	rs737008	0.922	rs28567501	ENSG00000262703.1	RP11-485G7.6	-3.71	0.000221	0.0124	-0.12	-0.11	Obesity-related traits;	chr16:11285071	chr16:11348143~11349321:-
BRCA	cis	rs73201462	1	rs73201462	ENSG00000242551.2	POU5F1P6	3.71	0.000221	0.0124	0.2	0.11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128340450	chr3:128674735~128677005:-
BRCA	cis	rs2411233	1	rs11070161	ENSG00000259278.1	RP11-62C7.2	3.71	0.000221	0.0124	0.13	0.11	Platelet count;	chr15:38977992	chr15:39019233~39024918:+
BRCA	cis	rs4664293	0.605	rs12474082	ENSG00000224152.1	AC009506.1	3.71	0.000221	0.0124	0.12	0.11	Monocyte percentage of white cells;	chr2:159657403	chr2:159615296~159617082:+
BRCA	cis	rs4664293	0.585	rs1991372	ENSG00000224152.1	AC009506.1	3.71	0.000221	0.0124	0.12	0.11	Monocyte percentage of white cells;	chr2:159659556	chr2:159615296~159617082:+
BRCA	cis	rs4664293	0.546	rs1991373	ENSG00000224152.1	AC009506.1	3.71	0.000221	0.0124	0.12	0.11	Monocyte percentage of white cells;	chr2:159659714	chr2:159615296~159617082:+
BRCA	cis	rs4664293	0.625	rs6707985	ENSG00000224152.1	AC009506.1	3.71	0.000221	0.0124	0.12	0.11	Monocyte percentage of white cells;	chr2:159659877	chr2:159615296~159617082:+
BRCA	cis	rs4664293	0.625	rs62171641	ENSG00000224152.1	AC009506.1	3.71	0.000221	0.0124	0.12	0.11	Monocyte percentage of white cells;	chr2:159659994	chr2:159615296~159617082:+
BRCA	cis	rs4664293	0.585	rs35293435	ENSG00000224152.1	AC009506.1	3.71	0.000221	0.0124	0.12	0.11	Monocyte percentage of white cells;	chr2:159662396	chr2:159615296~159617082:+
BRCA	cis	rs4664293	0.625	rs62171646	ENSG00000224152.1	AC009506.1	3.71	0.000221	0.0124	0.12	0.11	Monocyte percentage of white cells;	chr2:159662563	chr2:159615296~159617082:+
BRCA	cis	rs4664293	0.625	rs4664295	ENSG00000224152.1	AC009506.1	3.71	0.000221	0.0124	0.12	0.11	Monocyte percentage of white cells;	chr2:159663807	chr2:159615296~159617082:+
BRCA	cis	rs2243480	1	rs34933526	ENSG00000226767.1	RP11-328P23.3	-3.71	0.000221	0.0124	-0.19	-0.11	Diabetic kidney disease;	chr7:65918212	chr7:65508773~65508944:-
BRCA	cis	rs2243480	1	rs6949812	ENSG00000226767.1	RP11-328P23.3	-3.71	0.000221	0.0124	-0.19	-0.11	Diabetic kidney disease;	chr7:65922114	chr7:65508773~65508944:-
BRCA	cis	rs2243480	1	rs6970243	ENSG00000226767.1	RP11-328P23.3	-3.71	0.000221	0.0124	-0.19	-0.11	Diabetic kidney disease;	chr7:65923503	chr7:65508773~65508944:-
BRCA	cis	rs2243480	0.708	rs35310401	ENSG00000226767.1	RP11-328P23.3	-3.71	0.000221	0.0124	-0.19	-0.11	Diabetic kidney disease;	chr7:65925372	chr7:65508773~65508944:-
BRCA	cis	rs2243480	0.831	rs7806717	ENSG00000226767.1	RP11-328P23.3	3.71	0.000221	0.0124	0.19	0.11	Diabetic kidney disease;	chr7:65928187	chr7:65508773~65508944:-
BRCA	cis	rs863345	0.548	rs857687	ENSG00000176320.2	RP11-404O13.5	-3.71	0.000221	0.0124	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158608208	chr1:158197922~158203877:-
BRCA	cis	rs6142618	0.562	rs2295035	ENSG00000277692.1	RP11-358N2.2	-3.71	0.000221	0.0124	-0.12	-0.11	Inflammatory bowel disease;	chr20:32114341	chr20:32355053~32355734:+
BRCA	cis	rs910873	1	rs17305573	ENSG00000269202.1	RP4-614O4.12	-3.71	0.000221	0.0124	-0.26	-0.11	Melanoma;	chr20:34592348	chr20:35201747~35203288:-
BRCA	cis	rs8141529	0.748	rs5752826	ENSG00000272858.1	CTA-292E10.8	-3.71	0.000221	0.0124	-0.15	-0.11	Lymphocyte counts;	chr22:28873820	chr22:28814914~28815662:+
BRCA	cis	rs6453278	0.768	rs13358038	ENSG00000250802.5	ZBED3-AS1	3.71	0.000221	0.0124	0.17	0.11	Autism;	chr5:77108226	chr5:77086740~77166909:+
BRCA	cis	rs8040855	0.579	rs28521166	ENSG00000259416.2	RP11-158M2.5	-3.71	0.000221	0.0124	-0.13	-0.11	Bulimia nervosa;	chr15:85184801	chr15:85754941~85756237:-
BRCA	cis	rs9959145	1	rs9959145	ENSG00000267108.1	RP11-861E21.1	3.71	0.000221	0.0124	0.2	0.11	Immune response to smallpox vaccine (IL-6);	chr18:12606464	chr18:12432897~12437635:+
BRCA	cis	rs875971	0.545	rs4718348	ENSG00000273142.1	RP11-458F8.4	3.71	0.000221	0.0124	0.11	0.11	Aortic root size;	chr7:66441589	chr7:66902857~66906297:+
BRCA	cis	rs10504130	1	rs12675907	ENSG00000272076.1	RP11-11C20.3	3.71	0.000221	0.0124	0.2	0.11	Venous thromboembolism (SNP x SNP interaction);	chr8:51773102	chr8:51810110~51810681:-
BRCA	cis	rs738722	0.836	rs5752773	ENSG00000279978.1	chr22-38_28785274-29006793.1	-3.71	0.000221	0.0124	-0.15	-0.11	Optic cup area;Esophageal cancer and gastric cancer;	chr22:28709427	chr22:28930201~29197572:+
BRCA	cis	rs6088590	0.735	rs6060003	ENSG00000269202.1	RP4-614O4.12	-3.71	0.000221	0.0124	-0.12	-0.11	Coronary artery disease;	chr20:34707141	chr20:35201747~35203288:-
BRCA	cis	rs17169635	0.601	rs2347900	ENSG00000272941.1	RP11-134L10.1	-3.71	0.000221	0.0124	-0.12	-0.11	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);	chr7:134861654	chr7:135168403~135169547:+
BRCA	cis	rs2880765	0.835	rs7162502	ENSG00000230373.7	GOLGA6L5P	3.71	0.000221	0.0124	0.12	0.11	Coronary artery disease;	chr15:85501242	chr15:84507885~84516814:-
BRCA	cis	rs2880765	0.835	rs12910373	ENSG00000230373.7	GOLGA6L5P	3.71	0.000221	0.0124	0.12	0.11	Coronary artery disease;	chr15:85503571	chr15:84507885~84516814:-
BRCA	cis	rs11098499	0.865	rs4001305	ENSG00000260404.2	RP11-384K6.6	3.71	0.000221	0.0124	0.11	0.11	Corneal astigmatism;	chr4:119438081	chr4:118591773~118633729:+
BRCA	cis	rs4449834	0.851	rs6471902	ENSG00000254432.1	RP11-33I11.2	-3.71	0.000221	0.0124	-0.15	-0.11	Sum eosinophil basophil counts;	chr8:60819962	chr8:60808735~60809606:-
BRCA	cis	rs2823962	0.892	rs2823941	ENSG00000270093.1	AP000473.8	-3.71	0.000221	0.0124	-0.11	-0.11	Amyotrophic lateral sclerosis;	chr21:16654384	chr21:16643529~16645065:+
BRCA	cis	rs5167	0.781	rs2075619	ENSG00000214855.8	APOC1P1	3.71	0.000221	0.0124	0.14	0.11	Blood protein levels;	chr19:44992424	chr19:44926804~44931386:+
BRCA	cis	rs17270561	0.609	rs9379785	ENSG00000272462.2	U91328.19	-3.71	0.000221	0.0124	-0.14	-0.11	Iron status biomarkers;	chr6:25725985	chr6:25992662~26001775:+
BRCA	cis	rs17270561	0.609	rs9358871	ENSG00000272462.2	U91328.19	-3.71	0.000221	0.0124	-0.14	-0.11	Iron status biomarkers;	chr6:25726447	chr6:25992662~26001775:+
BRCA	cis	rs17270561	0.609	rs4711095	ENSG00000272462.2	U91328.19	-3.71	0.000221	0.0124	-0.14	-0.11	Iron status biomarkers;	chr6:25726546	chr6:25992662~26001775:+
BRCA	cis	rs17270561	0.609	rs4712959	ENSG00000272462.2	U91328.19	-3.71	0.000221	0.0124	-0.14	-0.11	Iron status biomarkers;	chr6:25726829	chr6:25992662~26001775:+
BRCA	cis	rs17270561	0.609	rs4712960	ENSG00000272462.2	U91328.19	-3.71	0.000221	0.0124	-0.14	-0.11	Iron status biomarkers;	chr6:25727037	chr6:25992662~26001775:+
BRCA	cis	rs17270561	0.609	rs4712961	ENSG00000272462.2	U91328.19	-3.71	0.000221	0.0124	-0.14	-0.11	Iron status biomarkers;	chr6:25727106	chr6:25992662~26001775:+
BRCA	cis	rs17270561	0.609	rs9358872	ENSG00000272462.2	U91328.19	-3.71	0.000221	0.0124	-0.14	-0.11	Iron status biomarkers;	chr6:25727289	chr6:25992662~26001775:+
BRCA	cis	rs17270561	0.609	rs9356985	ENSG00000272462.2	U91328.19	-3.71	0.000221	0.0124	-0.14	-0.11	Iron status biomarkers;	chr6:25727870	chr6:25992662~26001775:+
BRCA	cis	rs11098499	0.913	rs10006304	ENSG00000260404.2	RP11-384K6.6	3.71	0.000221	0.0124	0.11	0.11	Corneal astigmatism;	chr4:119203150	chr4:118591773~118633729:+
BRCA	cis	rs6545883	0.929	rs2600663	ENSG00000273302.1	RP11-493E12.2	-3.71	0.000221	0.0124	-0.11	-0.11	Tuberculosis;	chr2:61313552	chr2:61199979~61200769:+
BRCA	cis	rs11047510	0.73	rs55906630	ENSG00000164845.15	FAM86FP	3.71	0.000221	0.0124	0.18	0.11	Exploratory eye movement dysfunction in schizophrenia (responsive search score);	chr12:8846296	chr12:8232512~8242948:-
BRCA	cis	rs7620503	1	rs6443474	ENSG00000277241.1	RP11-114M1.3	3.71	0.000221	0.0124	0.13	0.11	Corneal structure;	chr3:177587336	chr3:177700346~177701072:-
BRCA	cis	rs12530845	0.887	rs61360007	ENSG00000223718.3	AC093107.7	3.71	0.000221	0.0124	0.19	0.11	Red blood cell traits;	chr7:135632131	chr7:135660039~135660647:+
BRCA	cis	rs4578769	0.842	rs8093152	ENSG00000273232.1	RP11-370A5.2	3.71	0.000221	0.0124	0.15	0.11	Eosinophil percentage of white cells;	chr18:22867925	chr18:22882825~22883357:-
BRCA	cis	rs875971	0.83	rs809025	ENSG00000271064.1	RP11-792A8.3	-3.71	0.000221	0.0124	-0.14	-0.11	Aortic root size;	chr7:66384832	chr7:66748838~66749077:-
BRCA	cis	rs7520050	0.966	rs4660321	ENSG00000234329.1	RP11-767N6.2	-3.71	0.000221	0.0124	-0.11	-0.11	Reticulocyte count;Red blood cell count;	chr1:45901088	chr1:45651039~45651826:-
BRCA	cis	rs7520050	0.931	rs6698247	ENSG00000234329.1	RP11-767N6.2	-3.71	0.000221	0.0124	-0.11	-0.11	Reticulocyte count;Red blood cell count;	chr1:45905814	chr1:45651039~45651826:-
BRCA	cis	rs7520050	0.966	rs6675946	ENSG00000234329.1	RP11-767N6.2	-3.71	0.000221	0.0124	-0.11	-0.11	Reticulocyte count;Red blood cell count;	chr1:45906102	chr1:45651039~45651826:-
BRCA	cis	rs7520050	0.931	rs7526678	ENSG00000234329.1	RP11-767N6.2	-3.71	0.000221	0.0124	-0.11	-0.11	Reticulocyte count;Red blood cell count;	chr1:45908487	chr1:45651039~45651826:-
BRCA	cis	rs2391285	0.609	rs4552808	ENSG00000214870.7	AC004540.5	3.71	0.000222	0.0124	0.17	0.11	Post bronchodilator FEV1/FVC ratio;	chr7:26567965	chr7:26398593~26494256:+
BRCA	cis	rs6964587	0.773	rs17757926	ENSG00000188693.7	CYP51A1-AS1	-3.71	0.000222	0.0124	-0.13	-0.11	Breast cancer;	chr7:92358388	chr7:92134604~92180725:+
BRCA	cis	rs860295	0.756	rs7546258	ENSG00000203761.5	MSTO2P	-3.71	0.000222	0.0124	-0.1	-0.11	Body mass index;	chr1:155728854	chr1:155745829~155750137:+
BRCA	cis	rs10807026	1	rs10807026	ENSG00000216901.1	AL022393.7	-3.71	0.000222	0.0124	-0.15	-0.11	Lung adenocarcinoma;	chr6:27587740	chr6:28176188~28176674:+
BRCA	cis	rs875971	0.862	rs778686	ENSG00000229886.1	RP5-1132H15.3	3.71	0.000222	0.0124	0.13	0.11	Aortic root size;	chr7:66370923	chr7:66025126~66031544:-
BRCA	cis	rs78487399	0.808	rs28700209	ENSG00000234936.1	AC010883.5	3.71	0.000222	0.0124	0.17	0.11	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43440326	chr2:43229573~43233394:+
BRCA	cis	rs962856	0.719	rs12713597	ENSG00000236605.1	AC023115.4	3.71	0.000222	0.0124	0.14	0.11	Pancreatic cancer;	chr2:67393935	chr2:67324627~67325304:+
BRCA	cis	rs29784	0.526	rs255292	ENSG00000253959.1	CTB-43E15.1	3.71	0.000222	0.0124	0.1	0.11	Infantile hypertrophic pyloric stenosis;	chr5:173153863	chr5:173642519~173658194:+
BRCA	cis	rs875971	0.502	rs11769702	ENSG00000232559.3	GS1-124K5.12	3.71	0.000222	0.0124	0.16	0.11	Aortic root size;	chr7:66255529	chr7:66554588~66576923:-
BRCA	cis	rs9470794	1	rs11754980	ENSG00000204110.6	RP1-153P14.8	-3.71	0.000222	0.0124	-0.23	-0.11	Type 2 diabetes;	chr6:37989776	chr6:37507348~37535616:+
BRCA	cis	rs7267979	1	rs4813563	ENSG00000274973.1	RP13-401N8.7	3.71	0.000222	0.0124	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25384704	chr20:25845497~25845862:+
BRCA	cis	rs7267979	0.966	rs6037103	ENSG00000274973.1	RP13-401N8.7	3.71	0.000222	0.0124	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25388459	chr20:25845497~25845862:+
BRCA	cis	rs180730	0.752	rs2667195	ENSG00000251609.2	SETP12	3.71	0.000222	0.0124	0.2	0.11	Fasting plasma glucose;	chr4:120886535	chr4:120895494~120897083:-
BRCA	cis	rs6991838	0.584	rs4388482	ENSG00000272155.1	RP11-707M3.3	3.71	0.000222	0.0124	0.1	0.11	Intelligence (multi-trait analysis);	chr8:65583968	chr8:65714334~65714778:-
BRCA	cis	rs6991838	0.584	rs4637885	ENSG00000272155.1	RP11-707M3.3	3.71	0.000222	0.0124	0.1	0.11	Intelligence (multi-trait analysis);	chr8:65584849	chr8:65714334~65714778:-
BRCA	cis	rs9788682	0.706	rs2568493	ENSG00000261143.1	ADAMTS7P3	3.71	0.000222	0.0124	0.16	0.11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78447891	chr15:77976042~77993057:+
BRCA	cis	rs189798	0.592	rs10111263	ENSG00000253981.4	ALG1L13P	-3.71	0.000222	0.0124	-0.14	-0.11	Myopia (pathological);	chr8:9111923	chr8:8236003~8244667:-
BRCA	cis	rs7520050	0.898	rs4660885	ENSG00000226957.1	RP4-533D7.4	3.71	0.000222	0.0124	0.12	0.11	Reticulocyte count;Red blood cell count;	chr1:45778084	chr1:46046818~46048368:+
BRCA	cis	rs983392	0.679	rs7121656	ENSG00000275344.1	MIR6503	3.71	0.000222	0.0124	0.12	0.11	Alzheimer's disease (late onset);	chr11:60256535	chr11:60209071~60209156:-
BRCA	cis	rs2555155	0.935	rs2555158	ENSG00000254595.1	CTD-2010I16.1	3.71	0.000222	0.0124	0.13	0.11	DNA methylation (variation);	chr11:6498934	chr11:6488186~6489377:-
BRCA	cis	rs7914558	1	rs10883826	ENSG00000213277.3	MARCKSL1P1	3.71	0.000222	0.0124	0.13	0.11	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103071062	chr10:103175554~103176094:+
BRCA	cis	rs7903456	0.648	rs1923939	ENSG00000200253.1	RNU6-529P	3.71	0.000222	0.0124	0.14	0.11	Gout;Renal underexcretion gout;	chr10:87068411	chr10:87041238~87041341:-
BRCA	cis	rs344364	0.511	rs1742473	ENSG00000219027.2	RPS3AP2	3.71	0.000222	0.0124	0.17	0.11	Glomerular filtration rate in chronic kidney disease;	chr16:1903094	chr16:1477830~1478583:+
BRCA	cis	rs10786436	0.588	rs10883134	ENSG00000224934.2	RP11-441O15.3	-3.71	0.000222	0.0124	-0.1	-0.11	Type 1 diabetes;	chr10:98566249	chr10:99431191~99438117:+
BRCA	cis	rs875971	0.825	rs28480509	ENSG00000273024.4	INTS4P2	3.71	0.000222	0.0125	0.13	0.11	Aortic root size;	chr7:66634237	chr7:65647864~65715661:+
BRCA	cis	rs4699052	0.662	rs6533083	ENSG00000248740.4	RP11-328K4.1	3.71	0.000222	0.0125	0.13	0.11	Testicular germ cell tumor;	chr4:103320110	chr4:103256159~103453658:+
BRCA	cis	rs8023401	0.938	rs4374113	ENSG00000274654.1	CTD-3247H4.2	-3.71	0.000222	0.0125	-0.16	-0.11	Spherical equivalent (joint analysis main effects and education interaction);	chr15:48528704	chr15:48528980~48529728:-
BRCA	cis	rs9788721	0.836	rs17483548	ENSG00000261762.1	RP11-650L12.2	-3.71	0.000222	0.0125	-0.15	-0.11	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78437971	chr15:78589123~78591276:-
BRCA	cis	rs740363	0.56	rs1681720	ENSG00000281599.1	AC023283.1	3.71	0.000222	0.0125	0.11	0.11	Heart failure;	chr10:116834881	chr10:116827489~116827564:-
BRCA	cis	rs16893526	0.649	rs9353031	ENSG00000224995.1	LINC01526	-3.71	0.000222	0.0125	-0.18	-0.11	Coronary heart disease;	chr6:81812924	chr6:81813286~81814157:-
BRCA	cis	rs28489187	0.706	rs2300637	ENSG00000223653.4	RP11-131L23.1	3.71	0.000222	0.0125	0.13	0.11	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85357089	chr1:85276715~85448124:+
BRCA	cis	rs950169	0.58	rs2271431	ENSG00000230373.7	GOLGA6L5P	-3.71	0.000222	0.0125	-0.14	-0.11	Schizophrenia;	chr15:84646233	chr15:84507885~84516814:-
BRCA	cis	rs250518	0.926	rs6873718	ENSG00000271926.1	CTD-2376I4.1	3.71	0.000222	0.0125	0.15	0.11	Mean corpuscular hemoglobin concentration;	chr5:72747581	chr5:72953635~72954274:-
BRCA	cis	rs7176093	1	rs17580705	ENSG00000259295.5	CSPG4P12	-3.71	0.000222	0.0125	-0.16	-0.11	Aging traits;	chr15:85830776	chr15:85191438~85213905:+
BRCA	cis	rs11992162	0.967	rs10108320	ENSG00000154316.13	TDH	3.71	0.000222	0.0125	0.15	0.11	Monocyte count;	chr8:11974754	chr8:11339637~11368452:+
BRCA	cis	rs1355223	0.902	rs1578622	ENSG00000271369.1	RP11-350D17.3	-3.71	0.000222	0.0125	-0.13	-0.11	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34704368	chr11:34709600~34710161:+
BRCA	cis	rs1949733	1	rs868105	ENSG00000251615.3	RP11-774O3.3	3.71	0.000222	0.0125	0.12	0.11	Response to antineoplastic agents;	chr4:8499303	chr4:8355090~8358338:-
BRCA	cis	rs1850744	0.702	rs10939428	ENSG00000250342.1	SNRPCP16	-3.71	0.000222	0.0125	-0.23	-0.11	Economic and political preferences;	chr4:9628417	chr4:9051842~9052051:-
BRCA	cis	rs2288327	0.673	rs35504893	ENSG00000271011.1	RP11-171I2.5	3.71	0.000222	0.0125	0.18	0.11	Atrial fibrillation;	chr2:178556567	chr2:178577103~178577622:+
BRCA	cis	rs17123764	0.892	rs11169143	ENSG00000257464.1	RP11-161H23.8	-3.71	0.000222	0.0125	-0.19	-0.11	Intelligence (multi-trait analysis);	chr12:49753767	chr12:49442424~49442652:-
BRCA	cis	rs568617	0.953	rs658938	ENSG00000254614.2	AP003068.23	3.71	0.000222	0.0125	0.17	0.11	Crohn's disease;	chr11:65884359	chr11:65177606~65181834:-
BRCA	cis	rs12681963	0.686	rs11557703	ENSG00000248159.1	HSPA8P11	3.71	0.000222	0.0125	0.23	0.11	Migraine;	chr8:30104435	chr8:30237382~30240997:+
BRCA	cis	rs4906332	1	rs7155822	ENSG00000259775.1	RP11-45P15.4	-3.71	0.000222	0.0125	-0.13	-0.11	Coronary artery disease;	chr14:103456053	chr14:103331674~103332367:-
BRCA	cis	rs7267979	0.932	rs367666	ENSG00000204556.4	CTD-2514C3.1	-3.71	0.000222	0.0125	-0.16	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25469182	chr20:26018832~26020684:+
BRCA	cis	rs7824557	0.767	rs1897950	ENSG00000248896.2	CTD-2135J3.3	3.71	0.000222	0.0125	0.15	0.11	Retinal vascular caliber;	chr8:11312042	chr8:10729314~10771392:+
BRCA	cis	rs832540	0.931	rs1445996	ENSG00000271828.1	CTD-2310F14.1	3.71	0.000222	0.0125	0.14	0.11	Coronary artery disease;	chr5:56939721	chr5:56927874~56929573:+
BRCA	cis	rs12681366	0.663	rs2919665	ENSG00000253175.1	RP11-267M23.6	3.71	0.000222	0.0125	0.13	0.11	Nonsyndromic cleft lip with cleft palate;	chr8:94453147	chr8:94565036~94565715:+
BRCA	cis	rs7572733	0.935	rs1518360	ENSG00000231621.1	AC013264.2	3.71	0.000222	0.0125	0.11	0.11	Dermatomyositis;	chr2:197950579	chr2:197197991~197199273:+
BRCA	cis	rs17796831	0.965	rs8018535	ENSG00000205562.2	RP11-497E19.1	-3.71	0.000222	0.0125	-0.12	-0.11	Lobe attachment (rater-scored or self-reported);	chr14:85333912	chr14:85524432~85529988:-
BRCA	cis	rs848490	0.889	rs11489585	ENSG00000214293.7	APTR	3.7	0.000223	0.0125	0.14	0.11	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77685535	chr7:77657660~77696265:-
BRCA	cis	rs375066	0.901	rs1978723	ENSG00000278917.1	RP11-15A1.4	3.7	0.000223	0.0125	0.13	0.11	Breast cancer;	chr19:43879648	chr19:43891233~43895411:+
BRCA	cis	rs875971	0.895	rs7788984	ENSG00000272831.1	RP11-792A8.4	3.7	0.000223	0.0125	0.1	0.11	Aortic root size;	chr7:66450629	chr7:66739829~66740385:-
BRCA	cis	rs875971	0.825	rs7384021	ENSG00000273024.4	INTS4P2	3.7	0.000223	0.0125	0.13	0.11	Aortic root size;	chr7:66612917	chr7:65647864~65715661:+
BRCA	cis	rs490234	0.783	rs28729336	ENSG00000232630.1	PRPS1P2	-3.7	0.000223	0.0125	-0.12	-0.11	Mean arterial pressure;	chr9:125643209	chr9:125150653~125151589:+
BRCA	cis	rs17662327	0.945	rs7872943	ENSG00000220937.3	HNRNPA1P41	3.7	0.000223	0.0125	0.16	0.11	Positive affect;	chr9:4969787	chr9:4944670~4945902:-
BRCA	cis	rs7520050	0.966	rs12144263	ENSG00000234329.1	RP11-767N6.2	-3.7	0.000223	0.0125	-0.11	-0.11	Reticulocyte count;Red blood cell count;	chr1:45886774	chr1:45651039~45651826:-
BRCA	cis	rs2227564	0.729	rs2675674	ENSG00000279689.1	RP11-574K11.32	3.7	0.000223	0.0125	0.13	0.11	Crohn's disease;Inflammatory bowel disease;	chr10:73892924	chr10:73769264~73772862:-
BRCA	cis	rs524281	0.861	rs11607393	ENSG00000255557.1	RP11-770G2.2	3.7	0.000223	0.0125	0.16	0.11	Electroencephalogram traits;	chr11:66107678	chr11:65745729~65771585:+
BRCA	cis	rs6772849	0.83	rs7633674	ENSG00000207088.1	SNORA7B	-3.7	0.000223	0.0125	-0.14	-0.11	Monocyte percentage of white cells;Monocyte count;	chr3:128636183	chr3:129397210~129397348:-
BRCA	cis	rs10876993	0.928	rs2640631	ENSG00000270039.1	RP11-571M6.17	3.7	0.000223	0.0125	0.15	0.11	Celiac disease or Rheumatoid arthritis;	chr12:57673749	chr12:57803838~57804415:+
BRCA	cis	rs448720	1	rs430610	ENSG00000260657.2	RP11-315D16.4	3.7	0.000223	0.0125	0.14	0.11	Cognitive performance;	chr15:67906284	chr15:68267792~68277994:-
BRCA	cis	rs11098499	0.913	rs10006304	ENSG00000260091.1	RP11-33B1.4	-3.7	0.000223	0.0125	-0.11	-0.11	Corneal astigmatism;	chr4:119203150	chr4:119409333~119410233:+
BRCA	cis	rs7520050	0.966	rs12139630	ENSG00000234329.1	RP11-767N6.2	-3.7	0.000223	0.0125	-0.11	-0.11	Reticulocyte count;Red blood cell count;	chr1:45885263	chr1:45651039~45651826:-
BRCA	cis	rs62064224	0.714	rs11657299	ENSG00000279781.1	RP11-466A19.7	3.7	0.000223	0.0125	0.14	0.11	Schizophrenia;	chr17:32307932	chr17:32518322~32518934:-
BRCA	cis	rs6672530	0.518	rs6671825	ENSG00000227711.2	RP11-275O4.5	-3.7	0.000223	0.0125	-0.13	-0.11	Hip circumference adjusted for BMI;	chr1:227677737	chr1:227509028~227520477:-
BRCA	cis	rs75920871	0.66	rs12271161	ENSG00000280143.1	AP000892.6	-3.7	0.000223	0.0125	-0.12	-0.11	Subjective well-being;	chr11:117109195	chr11:117204967~117210292:+
BRCA	cis	rs72928364	1	rs62273928	ENSG00000244119.1	PDCL3P4	3.7	0.000223	0.0125	0.14	0.11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100933356	chr3:101712472~101713191:+
BRCA	cis	rs72928364	1	rs34565718	ENSG00000244119.1	PDCL3P4	3.7	0.000223	0.0125	0.14	0.11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100934046	chr3:101712472~101713191:+
BRCA	cis	rs1912124	1	rs66709425	ENSG00000271983.1	RP11-28H5.2	3.7	0.000223	0.0125	0.22	0.11	Peripheral arterial disease (traffic-related air pollution interaction);	chr15:81199120	chr15:80693216~80693707:-
BRCA	cis	rs11098499	0.644	rs3806808	ENSG00000260091.1	RP11-33B1.4	-3.7	0.000223	0.0125	-0.1	-0.11	Corneal astigmatism;	chr4:119629930	chr4:119409333~119410233:+
BRCA	cis	rs964611	0.748	rs61248772	ENSG00000259488.2	RP11-154J22.1	-3.7	0.000223	0.0125	-0.16	-0.11	Metabolite levels (Pyroglutamine);	chr15:48306529	chr15:48312353~48331856:-
BRCA	cis	rs10844706	0.699	rs10844627	ENSG00000256673.1	RP11-599J14.2	-3.7	0.000223	0.0125	-0.14	-0.11	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9733781	chr12:9398355~9414851:-
BRCA	cis	rs7267979	0.966	rs3002698	ENSG00000277938.1	RP5-965G21.3	-3.7	0.000223	0.0125	-0.14	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25322743	chr20:25229150~25231933:+
BRCA	cis	rs7620503	1	rs6808260	ENSG00000231574.4	RP11-91K9.1	3.7	0.000223	0.0125	0.13	0.11	Corneal structure;	chr3:177582044	chr3:177816865~177899224:+
BRCA	cis	rs875971	0.571	rs160647	ENSG00000232559.3	GS1-124K5.12	-3.7	0.000223	0.0125	-0.16	-0.11	Aortic root size;	chr7:66089365	chr7:66554588~66576923:-
BRCA	cis	rs36051895	0.664	rs7847141	ENSG00000237711.1	RP11-39K24.13	-3.7	0.000223	0.0125	-0.13	-0.11	Pediatric autoimmune diseases;	chr9:5097171	chr9:5100236~5101009:+
BRCA	cis	rs12681366	1	rs10956911	ENSG00000253175.1	RP11-267M23.6	3.7	0.000223	0.0125	0.13	0.11	Nonsyndromic cleft lip with cleft palate;	chr8:94371647	chr8:94565036~94565715:+
BRCA	cis	rs4664293	0.625	rs6722715	ENSG00000224152.1	AC009506.1	3.7	0.000223	0.0125	0.12	0.11	Monocyte percentage of white cells;	chr2:159668515	chr2:159615296~159617082:+
BRCA	cis	rs375066	0.806	rs415168	ENSG00000267191.1	RP11-15A1.2	-3.7	0.000223	0.0125	-0.15	-0.11	Breast cancer;	chr19:43898422	chr19:43902001~43926545:+
BRCA	cis	rs683250	0.629	rs504105	ENSG00000254551.1	RP11-727A23.7	-3.7	0.000223	0.0125	-0.17	-0.11	Subcortical brain region volumes;	chr11:83252917	chr11:83209431~83213379:-
BRCA	cis	rs7246967	0.866	rs62120785	ENSG00000198153.8	ZNF849P	-3.7	0.000223	0.0125	-0.19	-0.11	Bronchopulmonary dysplasia;	chr19:22861997	chr19:22685167~22686732:+
BRCA	cis	rs6088580	0.524	rs7269596	ENSG00000261582.1	RP4-614O4.11	3.7	0.000223	0.0125	0.11	0.11	Glomerular filtration rate (creatinine);	chr20:34641259	chr20:35267885~35280043:-
BRCA	cis	rs9470794	1	rs2281265	ENSG00000204110.6	RP1-153P14.8	-3.7	0.000223	0.0125	-0.18	-0.11	Type 2 diabetes;	chr6:38162579	chr6:37507348~37535616:+
BRCA	cis	rs651477	0.92	rs10181336	ENSG00000279227.1	AC009303.2	3.7	0.000223	0.0125	0.12	0.11	Multiple sclerosis;	chr2:118688509	chr2:118014174~118015673:+
BRCA	cis	rs4148883	0.545	rs17595102	ENSG00000272777.1	RP11-571L19.8	-3.7	0.000223	0.0125	-0.12	-0.11	Alcohol dependence;	chr4:99065165	chr4:99067256~99068125:-
BRCA	cis	rs2281603	0.598	rs10151656	ENSG00000259116.1	RP11-973N13.4	-3.7	0.000223	0.0125	-0.11	-0.11	Lymphocyte counts;	chr14:64594970	chr14:64514154~64540368:-
BRCA	cis	rs295490	0.748	rs114423015	ENSG00000178631.7	ACTG1P1	-3.7	0.000223	0.0125	-0.21	-0.11	PR interval in Tripanosoma cruzi seropositivity;	chr3:139488980	chr3:139493809~139494937:+
BRCA	cis	rs6452790	0.543	rs4579285	ENSG00000247828.6	TMEM161B-AS1	-3.7	0.000223	0.0125	-0.17	-0.11	Cognitive function;	chr5:88082882	chr5:88268895~88436685:+
BRCA	cis	rs6005807	0.843	rs55738739	ENSG00000272858.1	CTA-292E10.8	-3.7	0.000223	0.0125	-0.22	-0.11	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28402667	chr22:28814914~28815662:+
BRCA	cis	rs6088590	0.931	rs6088624	ENSG00000276073.1	RP5-1125A11.7	-3.7	0.000223	0.0125	-0.13	-0.11	Coronary artery disease;	chr20:34849049	chr20:33985617~33988989:-
BRCA	cis	rs875971	0.545	rs2420612	ENSG00000232559.3	GS1-124K5.12	3.7	0.000223	0.0125	0.16	0.11	Aortic root size;	chr7:66536825	chr7:66554588~66576923:-
BRCA	cis	rs6142618	0.562	rs6061173	ENSG00000277692.1	RP11-358N2.2	-3.7	0.000223	0.0125	-0.12	-0.11	Inflammatory bowel disease;	chr20:32129312	chr20:32355053~32355734:+
BRCA	cis	rs495337	1	rs4810997	ENSG00000229222.1	KRT18P4	-3.7	0.000224	0.0125	-0.14	-0.11	Psoriasis;	chr20:49962811	chr20:49956745~49958032:+
BRCA	cis	rs853679	0.517	rs4713135	ENSG00000226314.6	ZNF192P1	-3.7	0.000224	0.0125	-0.17	-0.11	Depression;	chr6:28071808	chr6:28161781~28169594:+
BRCA	cis	rs875971	0.862	rs778684	ENSG00000271064.1	RP11-792A8.3	-3.7	0.000224	0.0125	-0.13	-0.11	Aortic root size;	chr7:66371416	chr7:66748838~66749077:-
BRCA	cis	rs7267979	1	rs6083805	ENSG00000277938.1	RP5-965G21.3	-3.7	0.000224	0.0125	-0.14	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25336720	chr20:25229150~25231933:+
BRCA	cis	rs13401620	0.871	rs3111718	ENSG00000229326.3	AC069154.4	-3.7	0.000224	0.0125	-0.15	-0.11	Breast size;	chr2:119855812	chr2:119698623~119700151:+
BRCA	cis	rs2281558	0.876	rs6107025	ENSG00000274414.1	RP5-965G21.4	-3.7	0.000224	0.0125	-0.15	-0.11	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25299244	chr20:25239007~25245229:-
BRCA	cis	rs2243480	0.522	rs12698511	ENSG00000226002.1	RP11-460N20.5	-3.7	0.000224	0.0125	-0.23	-0.11	Diabetic kidney disease;	chr7:66009932	chr7:65084103~65100232:+
BRCA	cis	rs4665809	0.941	rs2289021	ENSG00000231655.1	AC011742.3	-3.7	0.000224	0.0125	-0.16	-0.11	Gut microbiome composition (summer);	chr2:26139646	chr2:26140263~26141264:-
BRCA	cis	rs11711311	1	rs2712348	ENSG00000241529.3	RN7SL767P	-3.7	0.000224	0.0125	-0.13	-0.11	IgG glycosylation;	chr3:113741767	chr3:113632704~113632998:+
BRCA	cis	rs17756712	0.725	rs17135357	ENSG00000271911.1	RP11-532F6.5	3.7	0.000224	0.0125	0.2	0.11	Vertical cup-disc ratio;	chr6:602983	chr6:761675~780648:+
BRCA	cis	rs7705042	0.581	rs11745706	ENSG00000280047.1	CTC-463A16.1	-3.7	0.000224	0.0125	-0.13	-0.11	Asthma;	chr5:142173180	chr5:142165767~142168387:+
BRCA	cis	rs2032314	0.527	rs13051329	ENSG00000237945.6	LINC00649	-3.7	0.000224	0.0125	-0.19	-0.11	Red blood cell traits;	chr21:33950586	chr21:33915534~33977691:+
BRCA	cis	rs875971	0.862	rs6962717	ENSG00000271064.1	RP11-792A8.3	-3.7	0.000224	0.0125	-0.14	-0.11	Aortic root size;	chr7:66418748	chr7:66748838~66749077:-
BRCA	cis	rs11711311	0.784	rs13081931	ENSG00000241529.3	RN7SL767P	-3.7	0.000224	0.0125	-0.13	-0.11	IgG glycosylation;	chr3:113631081	chr3:113632704~113632998:+
BRCA	cis	rs853679	0.546	rs200977	ENSG00000216901.1	AL022393.7	3.7	0.000224	0.0125	0.23	0.11	Depression;	chr6:27886523	chr6:28176188~28176674:+
BRCA	cis	rs7954584	0.583	rs6486782	ENSG00000272849.1	RP11-347I19.8	-3.7	0.000224	0.0125	-0.09	-0.11	Mean corpuscular volume;	chr12:121921266	chr12:121797511~121801972:+
BRCA	cis	rs17221829	0.733	rs10830329	ENSG00000280385.1	AP000648.5	-3.7	0.000224	0.0125	-0.13	-0.11	Anxiety in major depressive disorder;	chr11:89657444	chr11:90193614~90198120:+
BRCA	cis	rs17221829	0.627	rs12421880	ENSG00000280385.1	AP000648.5	-3.7	0.000224	0.0125	-0.13	-0.11	Anxiety in major depressive disorder;	chr11:89658545	chr11:90193614~90198120:+
BRCA	cis	rs17221829	0.703	rs12418019	ENSG00000280385.1	AP000648.5	-3.7	0.000224	0.0125	-0.13	-0.11	Anxiety in major depressive disorder;	chr11:89658589	chr11:90193614~90198120:+
BRCA	cis	rs17221829	0.71	rs12421890	ENSG00000280385.1	AP000648.5	-3.7	0.000224	0.0125	-0.13	-0.11	Anxiety in major depressive disorder;	chr11:89658631	chr11:90193614~90198120:+
BRCA	cis	rs17221829	0.703	rs10765229	ENSG00000280385.1	AP000648.5	-3.7	0.000224	0.0125	-0.13	-0.11	Anxiety in major depressive disorder;	chr11:89659407	chr11:90193614~90198120:+
BRCA	cis	rs17221829	0.733	rs11018715	ENSG00000280385.1	AP000648.5	-3.7	0.000224	0.0125	-0.13	-0.11	Anxiety in major depressive disorder;	chr11:89661294	chr11:90193614~90198120:+
BRCA	cis	rs6671200	0.541	rs7555339	ENSG00000235501.4	RP4-639F20.1	3.7	0.000224	0.0125	0.19	0.11	Stearic acid (18:0) levels;	chr1:95226023	chr1:94927566~94963270:+
BRCA	cis	rs11098499	0.82	rs28394116	ENSG00000225892.3	RP11-384K6.2	3.7	0.000224	0.0125	0.12	0.11	Corneal astigmatism;	chr4:119603128	chr4:118632274~118634759:+
BRCA	cis	rs55780018	0.645	rs12998817	ENSG00000224137.1	AC079767.4	-3.7	0.000224	0.0125	-0.09	-0.11	Systolic blood pressure;	chr2:207636221	chr2:207662375~207667024:+
BRCA	cis	rs9437689	0.839	rs12748237	ENSG00000235501.4	RP4-639F20.1	3.7	0.000224	0.0125	0.15	0.11	Phospholipid levels (plasma);	chr1:95106457	chr1:94927566~94963270:+
BRCA	cis	rs62244186	0.714	rs2293600	ENSG00000214820.3	MPRIPP1	-3.7	0.000224	0.0125	-0.13	-0.11	Depressive symptoms;	chr3:44557611	chr3:44579938~44581026:-
BRCA	cis	rs12277962	0.501	rs11024330	ENSG00000256464.1	YWHABP2	-3.7	0.000224	0.0125	-0.19	-0.11	Night sleep phenotypes;	chr11:17588506	chr11:18490243~18490955:-
BRCA	cis	rs4499344	0.604	rs259245	ENSG00000267475.1	CTD-2538C1.2	3.7	0.000224	0.0125	0.15	0.11	Mean platelet volume;	chr19:32654200	chr19:32687089~32691750:-
BRCA	cis	rs2281558	0.876	rs2281562	ENSG00000274414.1	RP5-965G21.4	-3.7	0.000224	0.0125	-0.15	-0.11	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25292726	chr20:25239007~25245229:-
BRCA	cis	rs6490294	0.528	rs57866673	ENSG00000257624.1	RP1-128M12.3	3.7	0.000224	0.0125	0.21	0.11	Mean platelet volume;	chr12:112195500	chr12:112000739~112000985:-
BRCA	cis	rs1348850	0.914	rs4893823	ENSG00000280374.1	RP11-337N6.3	-3.7	0.000224	0.0126	-0.15	-0.11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177421083	chr2:177317715~177318471:-
BRCA	cis	rs5742933	1	rs12052909	ENSG00000253559.1	OSGEPL1-AS1	-3.7	0.000224	0.0126	-0.16	-0.11	Ferritin levels;	chr2:189742484	chr2:189762704~189765556:+
BRCA	cis	rs5742933	1	rs16831955	ENSG00000253559.1	OSGEPL1-AS1	-3.7	0.000224	0.0126	-0.16	-0.11	Ferritin levels;	chr2:189745811	chr2:189762704~189765556:+
BRCA	cis	rs3808502	0.525	rs9650661	ENSG00000227888.4	FAM66A	-3.7	0.000224	0.0126	-0.15	-0.11	Neuroticism;	chr8:11569624	chr8:12362019~12388296:+
BRCA	cis	rs34779708	0.966	rs11010135	ENSG00000269952.1	RP11-324I22.3	-3.7	0.000224	0.0126	-0.16	-0.11	Inflammatory bowel disease;Crohn's disease;	chr10:35229135	chr10:35210416~35210750:+
BRCA	cis	rs875971	0.825	rs7384021	ENSG00000229886.1	RP5-1132H15.3	-3.7	0.000224	0.0126	-0.13	-0.11	Aortic root size;	chr7:66612917	chr7:66025126~66031544:-
BRCA	cis	rs739401	0.967	rs451041	ENSG00000183562.3	CTC-343N3.1	-3.7	0.000224	0.0126	-0.12	-0.11	Longevity;	chr11:3039495	chr11:2989863~2991344:+
BRCA	cis	rs863345	0.564	rs12145401	ENSG00000229914.1	RP11-404O13.4	-3.7	0.000224	0.0126	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158524903	chr1:158195633~158196131:-
BRCA	cis	rs1411478	1	rs6425658	ENSG00000243155.1	RP11-46A10.5	3.7	0.000224	0.0126	0.12	0.11	Menopause (age at onset);Progressive supranuclear palsy;	chr1:180987849	chr1:180944042~180976482:-
BRCA	cis	rs10844706	0.699	rs1008610	ENSG00000256673.1	RP11-599J14.2	-3.7	0.000224	0.0126	-0.14	-0.11	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9731264	chr12:9398355~9414851:-
BRCA	cis	rs2832270	0.562	rs2832188	ENSG00000176054.6	RPL23P2	-3.7	0.000224	0.0126	-0.21	-0.11	Response to mTOR inhibitor (everolimus);	chr21:29114942	chr21:28997613~28998033:-
BRCA	cis	rs9316337	0.611	rs9285163	ENSG00000236953.1	ZDHHC20-IT1	-3.7	0.000224	0.0126	-0.13	-0.11	Schizophrenia;	chr13:21352761	chr13:21376977~21377874:-
BRCA	cis	rs1029738	0.535	rs10262258	ENSG00000228649.7	AC005682.5	3.7	0.000224	0.0126	0.1	0.11	Fibrinogen levels;	chr7:22802700	chr7:22854178~22861579:+
BRCA	cis	rs930395	0.514	rs4866920	ENSG00000251141.4	RP11-53O19.1	-3.7	0.000224	0.0126	-0.11	-0.11	Breast cancer;	chr5:44879044	chr5:44744900~44808777:-
BRCA	cis	rs930395	0.514	rs10040488	ENSG00000251141.4	RP11-53O19.1	-3.7	0.000224	0.0126	-0.11	-0.11	Breast cancer;	chr5:44880186	chr5:44744900~44808777:-
BRCA	cis	rs3735485	0.8	rs6951022	ENSG00000201772.1	SNORA5C	-3.7	0.000224	0.0126	-0.15	-0.11	White blood cell count;Sum basophil neutrophil counts;Neutrophil count;Granulocyte percentage of myeloid white cells;Monocyte percentage of white cells;Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Lymphocyte counts;	chr7:45015516	chr7:45104906~45105042:-
BRCA	cis	rs3735485	0.8	rs4724348	ENSG00000201772.1	SNORA5C	-3.7	0.000224	0.0126	-0.15	-0.11	White blood cell count;Sum basophil neutrophil counts;Neutrophil count;Granulocyte percentage of myeloid white cells;Monocyte percentage of white cells;Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Lymphocyte counts;	chr7:45019640	chr7:45104906~45105042:-
BRCA	cis	rs3735485	0.8	rs4724349	ENSG00000201772.1	SNORA5C	-3.7	0.000224	0.0126	-0.15	-0.11	White blood cell count;Sum basophil neutrophil counts;Neutrophil count;Granulocyte percentage of myeloid white cells;Monocyte percentage of white cells;Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Lymphocyte counts;	chr7:45019648	chr7:45104906~45105042:-
BRCA	cis	rs3735485	0.8	rs4724350	ENSG00000201772.1	SNORA5C	-3.7	0.000224	0.0126	-0.15	-0.11	White blood cell count;Sum basophil neutrophil counts;Neutrophil count;Granulocyte percentage of myeloid white cells;Monocyte percentage of white cells;Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Lymphocyte counts;	chr7:45019740	chr7:45104906~45105042:-
BRCA	cis	rs1912124	1	rs68188101	ENSG00000271983.1	RP11-28H5.2	3.7	0.000224	0.0126	0.23	0.11	Peripheral arterial disease (traffic-related air pollution interaction);	chr15:81215591	chr15:80693216~80693707:-
BRCA	cis	rs957448	1	rs12678305	ENSG00000254315.1	RP11-267M23.3	3.7	0.000224	0.0126	0.15	0.11	Nonsyndromic cleft lip with cleft palate;	chr8:94508911	chr8:94533628~94534391:+
BRCA	cis	rs7089973	0.872	rs36036948	ENSG00000236799.1	RP11-383C6.2	-3.7	0.000224	0.0126	-0.14	-0.11	Bipolar disorder or attention deficit hyperactivity disorder;	chr10:114871890	chr10:114994657~114996593:+
BRCA	cis	rs2839186	0.564	rs4819215	ENSG00000228137.1	AP001469.7	3.7	0.000224	0.0126	0.12	0.11	Testicular germ cell tumor;	chr21:46203659	chr21:46246890~46247682:+
BRCA	cis	rs9470794	1	rs11757072	ENSG00000204110.6	RP1-153P14.8	-3.7	0.000224	0.0126	-0.21	-0.11	Type 2 diabetes;	chr6:38050852	chr6:37507348~37535616:+
BRCA	cis	rs9470794	1	rs73419927	ENSG00000204110.6	RP1-153P14.8	-3.7	0.000224	0.0126	-0.21	-0.11	Type 2 diabetes;	chr6:38052720	chr6:37507348~37535616:+
BRCA	cis	rs11154801	0.589	rs6924066	ENSG00000234084.1	RP3-388E23.2	-3.7	0.000224	0.0126	-0.11	-0.11	Multiple sclerosis;	chr6:135598006	chr6:135301568~135307158:+
BRCA	cis	rs7771547	0.519	rs12663882	ENSG00000224666.3	RP1-50J22.4	-3.7	0.000224	0.0126	-0.13	-0.11	Platelet distribution width;	chr6:36394664	chr6:36386831~36393462:+
BRCA	cis	rs6968419	0.504	rs2402032	ENSG00000279086.1	RP11-667F14.1	-3.7	0.000224	0.0126	-0.12	-0.11	Intraocular pressure;	chr7:116119830	chr7:116209234~116211511:-
BRCA	cis	rs860295	1	rs822490	ENSG00000225855.5	RUSC1-AS1	3.7	0.000224	0.0126	0.09	0.11	Body mass index;	chr1:155853180	chr1:155316863~155324176:-
BRCA	cis	rs372883	0.6	rs2832298	ENSG00000176054.6	RPL23P2	3.7	0.000224	0.0126	0.13	0.11	Pancreatic cancer;	chr21:29371542	chr21:28997613~28998033:-
BRCA	cis	rs62458065	0.64	rs10274556	ENSG00000281332.1	LINC00997	-3.7	0.000225	0.0126	-0.17	-0.11	Metabolite levels (HVA/MHPG ratio);	chr7:32474335	chr7:32760279~32762924:+
BRCA	cis	rs295490	0.748	rs17494356	ENSG00000272656.1	RP11-219D15.3	3.7	0.000225	0.0126	0.28	0.11	PR interval in Tripanosoma cruzi seropositivity;	chr3:139465126	chr3:139349024~139349371:-
BRCA	cis	rs9287719	0.967	rs6432126	ENSG00000224177.5	LINC00570	3.7	0.000225	0.0126	0.13	0.11	Prostate cancer;	chr2:10616975	chr2:11393981~11403077:+
BRCA	cis	rs9287719	0.904	rs55738250	ENSG00000224177.5	LINC00570	3.7	0.000225	0.0126	0.13	0.11	Prostate cancer;	chr2:10617006	chr2:11393981~11403077:+
BRCA	cis	rs1912124	0.841	rs114721012	ENSG00000271983.1	RP11-28H5.2	3.7	0.000225	0.0126	0.23	0.11	Peripheral arterial disease (traffic-related air pollution interaction);	chr15:81209717	chr15:80693216~80693707:-
BRCA	cis	rs9341808	0.527	rs2505946	ENSG00000272129.1	RP11-250B2.6	3.7	0.000225	0.0126	0.14	0.11	Sitting height ratio;	chr6:80100966	chr6:80355424~80356859:+
BRCA	cis	rs931127	0.547	rs3886859	ENSG00000245532.5	NEAT1	-3.7	0.000225	0.0126	-0.1	-0.11	Systemic lupus erythematosus;	chr11:65690839	chr11:65422774~65445540:+
BRCA	cis	rs9425766	0.64	rs2281486	ENSG00000227373.4	RP11-160H22.5	3.7	0.000225	0.0126	0.18	0.11	Life satisfaction;	chr1:173853083	chr1:174115300~174160004:-
BRCA	cis	rs9425766	0.64	rs16846439	ENSG00000227373.4	RP11-160H22.5	3.7	0.000225	0.0126	0.18	0.11	Life satisfaction;	chr1:173854900	chr1:174115300~174160004:-
BRCA	cis	rs875971	0.862	rs11984115	ENSG00000229886.1	RP5-1132H15.3	-3.7	0.000225	0.0126	-0.13	-0.11	Aortic root size;	chr7:66308872	chr7:66025126~66031544:-
BRCA	cis	rs2281558	0.583	rs7260957	ENSG00000274973.1	RP13-401N8.7	3.7	0.000225	0.0126	0.17	0.11	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25741826	chr20:25845497~25845862:+
BRCA	cis	rs11673344	0.504	rs7258360	ENSG00000276846.1	CTD-3220F14.3	3.7	0.000225	0.0126	0.13	0.11	Obesity-related traits;	chr19:37115015	chr19:37314868~37315620:-
BRCA	cis	rs7712401	0.755	rs6595407	ENSG00000251538.4	RP11-166A12.1	3.7	0.000225	0.0126	0.12	0.11	Mean platelet volume;	chr5:122764703	chr5:122628952~122730685:-
BRCA	cis	rs7712401	0.755	rs4283786	ENSG00000251538.4	RP11-166A12.1	3.7	0.000225	0.0126	0.12	0.11	Mean platelet volume;	chr5:122765355	chr5:122628952~122730685:-
BRCA	cis	rs7520050	0.966	rs12405451	ENSG00000234329.1	RP11-767N6.2	-3.7	0.000225	0.0126	-0.11	-0.11	Reticulocyte count;Red blood cell count;	chr1:45918654	chr1:45651039~45651826:-
BRCA	cis	rs10506328	0.509	rs4759075	ENSG00000257550.1	RP11-793H13.3	3.7	0.000225	0.0126	0.13	0.11	Mean platelet volume;	chr12:54273501	chr12:53513984~53517608:+
BRCA	cis	rs17027633	1	rs1343350	ENSG00000234020.1	CHIAP3	-3.7	0.000225	0.0126	-0.27	-0.11	Cerebrospinal fluid t-tau:AB1-42 ratio;	chr1:111406901	chr1:111353275~111367409:-
BRCA	cis	rs17027633	1	rs76876038	ENSG00000234020.1	CHIAP3	-3.7	0.000225	0.0126	-0.27	-0.11	Cerebrospinal fluid t-tau:AB1-42 ratio;	chr1:111407235	chr1:111353275~111367409:-
BRCA	cis	rs8105895	0.825	rs62112369	ENSG00000269345.1	VN1R85P	3.7	0.000225	0.0126	0.17	0.11	Body mass index (change over time);	chr19:22131099	chr19:22174766~22175191:-
BRCA	cis	rs8114671	0.562	rs2378294	ENSG00000279253.1	RP4-614O4.13	-3.7	0.000225	0.0126	-0.13	-0.11	Height;	chr20:34912575	chr20:35262727~35264187:-
BRCA	cis	rs11098499	0.863	rs7664986	ENSG00000260404.2	RP11-384K6.6	3.7	0.000225	0.0126	0.11	0.11	Corneal astigmatism;	chr4:119508797	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.818	rs10008791	ENSG00000260404.2	RP11-384K6.6	3.7	0.000225	0.0126	0.11	0.11	Corneal astigmatism;	chr4:119510314	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.863	rs11736416	ENSG00000260404.2	RP11-384K6.6	3.7	0.000225	0.0126	0.11	0.11	Corneal astigmatism;	chr4:119510506	chr4:118591773~118633729:+
BRCA	cis	rs2031532	0.544	rs9526563	ENSG00000236577.1	SNRPGP14	3.7	0.000225	0.0126	0.13	0.11	Cardiac hypertrophy;	chr13:49471613	chr13:49488970~49489364:+
BRCA	cis	rs1156327	0.51	rs2027818	ENSG00000188477.11	AC003003.5	3.7	0.000225	0.0126	0.26	0.11	Periodontal disease-related phenotypes;	chr16:19320372	chr16:19285783~19310947:+
BRCA	cis	rs13256369	0.951	rs13259955	ENSG00000254153.1	CTA-398F10.2	3.7	0.000225	0.0126	0.15	0.11	Obesity-related traits;	chr8:8708375	chr8:8456909~8461337:-
BRCA	cis	rs7572733	0.576	rs1368989	ENSG00000231621.1	AC013264.2	-3.7	0.000225	0.0126	-0.11	-0.11	Dermatomyositis;	chr2:198072358	chr2:197197991~197199273:+
BRCA	cis	rs8054556	1	rs4787489	ENSG00000183604.13	SMG1P5	-3.7	0.000225	0.0126	-0.11	-0.11	Autism spectrum disorder or schizophrenia;	chr16:29984559	chr16:30267553~30335374:-
BRCA	cis	rs11039100	1	rs1470873	ENSG00000224295.2	AC087380.14	3.7	0.000225	0.0126	0.21	0.11	Peripheral arterial disease (traffic-related air pollution interaction);	chr11:5806165	chr11:5518441~5524955:-
BRCA	cis	rs2562456	0.833	rs11666525	ENSG00000268117.1	VN1R84P	3.7	0.000225	0.0126	0.18	0.11	Pain;	chr19:21416503	chr19:21719801~21720035:-
BRCA	cis	rs481331	0.799	rs210270	ENSG00000273008.1	RP11-351D16.3	3.7	0.000225	0.0126	0.17	0.11	Systemic juvenile idiopathic arthritis;	chr10:42505362	chr10:43136824~43138334:-
BRCA	cis	rs2985684	0.948	rs12897941	ENSG00000258568.1	RHOQP1	3.7	0.000225	0.0126	0.14	0.11	Carotid intima media thickness;	chr14:49549983	chr14:49599994~49600572:+
BRCA	cis	rs77204473	1	rs17120157	ENSG00000280143.1	AP000892.6	3.7	0.000225	0.0126	0.2	0.11	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116941912	chr11:117204967~117210292:+
BRCA	cis	rs9470794	1	rs59450336	ENSG00000204110.6	RP1-153P14.8	-3.7	0.000225	0.0126	-0.23	-0.11	Type 2 diabetes;	chr6:37998642	chr6:37507348~37535616:+
BRCA	cis	rs91731	0.92	rs77927210	ENSG00000249572.1	CTD-2203K17.1	3.7	0.000225	0.0126	0.23	0.11	Lung function (FVC);	chr5:33244591	chr5:33424025~33440619:-
BRCA	cis	rs983392	0.792	rs652354	ENSG00000275344.1	MIR6503	-3.7	0.000225	0.0126	-0.12	-0.11	Alzheimer's disease (late onset);	chr11:60156518	chr11:60209071~60209156:-
BRCA	cis	rs2262909	0.962	rs411020	ENSG00000279377.1	AC003973.3	3.7	0.000225	0.0126	0.16	0.11	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;	chr19:22048300	chr19:21965708~21968529:-
BRCA	cis	rs2262909	0.962	rs408687	ENSG00000279377.1	AC003973.3	3.7	0.000225	0.0126	0.16	0.11	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;	chr19:22048321	chr19:21965708~21968529:-
BRCA	cis	rs2262909	0.962	rs436662	ENSG00000279377.1	AC003973.3	3.7	0.000225	0.0126	0.16	0.11	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;	chr19:22049305	chr19:21965708~21968529:-
BRCA	cis	rs1156327	0.51	rs8051165	ENSG00000188477.11	AC003003.5	-3.7	0.000225	0.0126	-0.26	-0.11	Periodontal disease-related phenotypes;	chr16:19318951	chr16:19285783~19310947:+
BRCA	cis	rs12303914	0.502	rs2270238	ENSG00000256682.2	TAS2R12	3.7	0.000225	0.0126	0.15	0.11	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr12:10309917	chr12:10894943~10896952:-
BRCA	cis	rs7308116	0.967	rs7133509	ENSG00000274395.1	RP11-554D14.8	-3.7	0.000225	0.0126	-0.13	-0.11	Pelvic organ prolapse (moderate/severe);	chr12:107812344	chr12:107835541~107836555:-
BRCA	cis	rs748404	0.55	rs12912505	ENSG00000166763.7	STRCP1	3.7	0.000225	0.0126	0.17	0.11	Lung cancer;	chr15:43525206	chr15:43699488~43718184:-
BRCA	cis	rs4819052	0.885	rs9980676	ENSG00000215447.6	BX322557.10	-3.7	0.000225	0.0126	-0.12	-0.11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245515	chr21:45288052~45291738:+
BRCA	cis	rs524281	0.773	rs2282568	ENSG00000255038.1	RP11-1167A19.2	-3.7	0.000225	0.0126	-0.18	-0.11	Electroencephalogram traits;	chr11:66285361	chr11:66067277~66069619:-
BRCA	cis	rs10895275	0.924	rs12786272	ENSG00000277459.1	RP11-732A21.3	-3.7	0.000225	0.0126	-0.12	-0.11	Migraine;	chr11:102215632	chr11:102109827~102110457:-
BRCA	cis	rs6585424	1	rs35025775	ENSG00000225484.5	NUTM2B-AS1	-3.7	0.000225	0.0126	-0.23	-0.11	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80164529	chr10:79663088~79826594:-
BRCA	cis	rs17221829	0.899	rs10830367	ENSG00000280385.1	AP000648.5	-3.7	0.000225	0.0126	-0.13	-0.11	Anxiety in major depressive disorder;	chr11:89726232	chr11:90193614~90198120:+
BRCA	cis	rs67696533	0.588	rs6141743	ENSG00000277692.1	RP11-358N2.2	-3.7	0.000225	0.0126	-0.14	-0.11	White blood cell count (basophil);Basophil percentage of granulocytes;Basophil percentage of white cells;	chr20:32519596	chr20:32355053~32355734:+
BRCA	cis	rs9470794	1	rs74987919	ENSG00000204110.6	RP1-153P14.8	-3.7	0.000225	0.0126	-0.24	-0.11	Type 2 diabetes;	chr6:38017654	chr6:37507348~37535616:+
BRCA	cis	rs4703129	1	rs4703129	ENSG00000246763.5	RGMB-AS1	-3.7	0.000225	0.0126	-0.13	-0.11	Asperger disorder;	chr5:98553032	chr5:98769618~98773469:-
BRCA	cis	rs7714670	0.736	rs2973548	ENSG00000184084.7	CTD-2372A4.1	-3.7	0.000226	0.0126	-0.14	-0.11	Venous thromboembolism (SNP x SNP interaction);	chr5:73795403	chr5:73803296~73803599:-
BRCA	cis	rs7475343	0.573	rs2226260	ENSG00000224034.1	RP11-445P17.8	3.7	0.000226	0.0126	0.2	0.11	Intelligence;	chr10:5117405	chr10:5266033~5271236:-
BRCA	cis	rs875971	0.545	rs73150604	ENSG00000232559.3	GS1-124K5.12	3.7	0.000226	0.0126	0.16	0.11	Aortic root size;	chr7:66480545	chr7:66554588~66576923:-
BRCA	cis	rs2704588	1	rs2704572	ENSG00000270720.1	RP11-84C13.2	-3.7	0.000226	0.0126	-0.17	-0.11	Longevity;	chr4:88891143	chr4:89119284~89119871:+
BRCA	cis	rs7577894	0.967	rs6761334	ENSG00000272606.1	RP11-554J4.1	3.7	0.000226	0.0126	0.12	0.11	Amyotrophic lateral sclerosis;	chr2:55779463	chr2:55617909~55618373:+
BRCA	cis	rs1032833	0.732	rs17363323	ENSG00000271401.1	RP11-171I2.3	-3.7	0.000226	0.0126	-0.29	-0.11	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);	chr2:179132250	chr2:178644717~178645179:+
BRCA	cis	rs853679	0.76	rs11967137	ENSG00000261839.1	RP1-265C24.8	3.7	0.000226	0.0126	0.17	0.11	Depression;	chr6:28231986	chr6:28136849~28139678:+
BRCA	cis	rs6599077	0.901	rs9311232	ENSG00000223797.4	ENTPD3-AS1	3.7	0.000226	0.0126	0.14	0.11	Sleep-related phenotypes;	chr3:40064359	chr3:40313802~40453329:-
BRCA	cis	rs12530845	0.945	rs73725433	ENSG00000223718.3	AC093107.7	3.7	0.000226	0.0126	0.17	0.11	Red blood cell traits;	chr7:135628503	chr7:135660039~135660647:+
BRCA	cis	rs67073037	0.955	rs11688605	ENSG00000230730.1	AC074011.2	3.7	0.000226	0.0126	0.16	0.11	Breast cancer;Breast cancer (estrogen-receptor negative);	chr2:28906552	chr2:28633282~28664540:-
BRCA	cis	rs4272720	1	rs61850690	ENSG00000228754.1	RP11-534L6.3	-3.7	0.000226	0.0126	-0.16	-0.11	Platelet count;Plateletcrit;	chr10:49055831	chr10:48745545~48746128:-
BRCA	cis	rs4835473	0.832	rs35398499	ENSG00000246448.2	RP13-578N3.3	-3.7	0.000226	0.0126	-0.13	-0.11	Immature fraction of reticulocytes;	chr4:143737715	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.832	rs35763177	ENSG00000246448.2	RP13-578N3.3	-3.7	0.000226	0.0126	-0.13	-0.11	Immature fraction of reticulocytes;	chr4:143737717	chr4:143700257~143865072:+
BRCA	cis	rs61160187	0.582	rs13359074	ENSG00000272308.1	RP11-231G3.1	-3.7	0.000226	0.0126	-0.13	-0.11	Educational attainment (years of education);Educational attainment (college completion);	chr5:60906758	chr5:60866457~60866935:-
BRCA	cis	rs2342371	0.756	rs3973	ENSG00000243339.3	RN7SL738P	3.7	0.000226	0.0126	0.16	0.11	Fat distribution (HIV);	chr3:196397407	chr3:196399911~196400207:+
BRCA	cis	rs56114371	0.777	rs200482	ENSG00000216901.1	AL022393.7	3.7	0.000226	0.0126	0.22	0.11	Breast cancer;	chr6:27806126	chr6:28176188~28176674:+
BRCA	cis	rs2562456	0.917	rs2681376	ENSG00000240522.1	RPL7AP10	3.7	0.000226	0.0126	0.13	0.11	Pain;	chr19:21532723	chr19:21149648~21150438:-
BRCA	cis	rs4427176	0.714	rs7827278	ENSG00000233609.3	RP11-62H7.2	3.7	0.000226	0.0126	0.14	0.11	Mosquito bite size;	chr8:9613792	chr8:8961200~8979025:+
BRCA	cis	rs35306767	0.903	rs11253460	ENSG00000229869.1	RP11-363N22.2	-3.7	0.000226	0.0126	-0.17	-0.11	Eosinophil percentage of granulocytes;	chr10:841442	chr10:933026~942743:+
BRCA	cis	rs17801127	0.748	rs12990272	ENSG00000231969.1	AC144449.1	3.7	0.000226	0.0126	0.19	0.11	Liver enzyme levels (alanine transaminase);	chr2:149670563	chr2:149587196~149848233:+
BRCA	cis	rs7523050	0.643	rs12752417	ENSG00000203897.3	SPATA42	3.7	0.000226	0.0126	0.23	0.11	Fat distribution (HIV);	chr1:108858017	chr1:108857217~108858524:+
BRCA	cis	rs7412746	0.658	rs7521719	ENSG00000231073.1	RP11-316M1.3	3.7	0.000226	0.0126	0.12	0.11	Melanoma;	chr1:150940658	chr1:150973123~150975534:+
BRCA	cis	rs56281245	1	rs74319125	ENSG00000249363.1	CTB-78O21.1	3.7	0.000226	0.0126	0.23	0.11	Hepcidin levels;	chr5:145657150	chr5:145728360~145729349:-
BRCA	cis	rs1552244	0.572	rs3894321	ENSG00000269894.1	RP11-1020A11.1	-3.7	0.000226	0.0126	-0.14	-0.11	Alzheimer's disease;	chr3:10127208	chr3:9935706~9936258:+
BRCA	cis	rs3755605	0.728	rs6808369	ENSG00000242578.1	RP11-469J4.3	3.7	0.000226	0.0126	0.13	0.11	Testicular germ cell tumor;	chr3:170089028	chr3:170410512~170418615:+
BRCA	cis	rs6840360	0.615	rs4696097	ENSG00000270265.1	RP11-731D1.4	3.7	0.000226	0.0126	0.13	0.11	Intelligence (multi-trait analysis);	chr4:151558613	chr4:151333775~151353224:-
BRCA	cis	rs7221109	0.71	rs4890093	ENSG00000224244.1	AC090283.3	3.7	0.000226	0.0126	0.13	0.11	Type 1 diabetes;	chr17:40639691	chr17:40687038~40689360:-
BRCA	cis	rs2243480	1	rs781142	ENSG00000226767.1	RP11-328P23.3	-3.7	0.000226	0.0126	-0.19	-0.11	Diabetic kidney disease;	chr7:65973791	chr7:65508773~65508944:-
BRCA	cis	rs6840360	0.55	rs11723438	ENSG00000270265.1	RP11-731D1.4	3.7	0.000226	0.0126	0.14	0.11	Intelligence (multi-trait analysis);	chr4:151610649	chr4:151333775~151353224:-
BRCA	cis	rs853679	0.517	rs9393884	ENSG00000272009.1	RP1-313I6.12	-3.7	0.000226	0.0127	-0.16	-0.11	Depression;	chr6:28079011	chr6:28078792~28081130:-
BRCA	cis	rs4908769	0.624	rs2708633	ENSG00000232912.4	RP5-1115A15.1	-3.7	0.000226	0.0127	-0.12	-0.11	Allergy;	chr1:8379565	chr1:8424645~8434838:+
BRCA	cis	rs9287719	0.639	rs2357649	ENSG00000243819.4	RN7SL832P	-3.7	0.000226	0.0127	-0.11	-0.11	Prostate cancer;	chr2:10556662	chr2:10690344~10692099:+
BRCA	cis	rs3764021	0.509	rs10844569	ENSG00000260423.1	RP13-735L24.1	-3.7	0.000226	0.0127	-0.13	-0.11	Type 1 diabetes;	chr12:9717756	chr12:9367464~9397617:+
BRCA	cis	rs4538475	0.539	rs73237182	ENSG00000273133.1	RP11-799M12.2	-3.7	0.000226	0.0127	-0.23	-0.11	Parkinson's disease;	chr4:15571987	chr4:15563698~15564253:-
BRCA	cis	rs2302465	0.789	rs4279202	ENSG00000273133.1	RP11-799M12.2	-3.7	0.000226	0.0127	-0.23	-0.11	Blood protein levels;	chr4:15573801	chr4:15563698~15564253:-
BRCA	cis	rs3749237	1	rs11130216	ENSG00000225399.4	RP11-3B7.1	3.7	0.000226	0.0127	0.11	0.11	Resting heart rate;	chr3:49698739	chr3:49260085~49261316:+
BRCA	cis	rs3735485	0.8	rs4724351	ENSG00000201772.1	SNORA5C	-3.7	0.000226	0.0127	-0.15	-0.11	White blood cell count;Sum basophil neutrophil counts;Neutrophil count;Granulocyte percentage of myeloid white cells;Monocyte percentage of white cells;Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Lymphocyte counts;	chr7:45019946	chr7:45104906~45105042:-
BRCA	cis	rs2905347	0.895	rs2961280	ENSG00000232949.1	AC002480.4	-3.7	0.000226	0.0127	-0.13	-0.11	Major depression and alcohol dependence;	chr7:22600098	chr7:22589705~22591622:+
BRCA	cis	rs9533799	1	rs2282064	ENSG00000227258.4	SMIM2-AS1	-3.7	0.000226	0.0127	-0.15	-0.11	Amyotrophic lateral sclerosis;	chr13:44231734	chr13:44110451~44240517:+
BRCA	cis	rs3213961	0.786	rs1947179	ENSG00000187999.4	HNRNPA1P61	-3.7	0.000226	0.0127	-0.15	-0.11	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:33596450	chr2:33636502~33637425:+
BRCA	cis	rs7267979	0.934	rs2261115	ENSG00000274973.1	RP13-401N8.7	-3.7	0.000226	0.0127	-0.13	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25279171	chr20:25845497~25845862:+
BRCA	cis	rs11089937	0.616	rs713644	ENSG00000211638.2	IGLV8-61	-3.7	0.000226	0.0127	-0.11	-0.11	Periodontitis (PAL4Q3);	chr22:22180747	chr22:22098700~22099212:+
BRCA	cis	rs11089937	0.616	rs713624	ENSG00000211638.2	IGLV8-61	-3.7	0.000226	0.0127	-0.11	-0.11	Periodontitis (PAL4Q3);	chr22:22180754	chr22:22098700~22099212:+
BRCA	cis	rs548181	0.736	rs1941558	ENSG00000254671.2	STT3A-AS1	-3.7	0.000226	0.0127	-0.22	-0.11	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr11:125555710	chr11:125570284~125592568:-
BRCA	cis	rs962856	1	rs6722203	ENSG00000236605.1	AC023115.4	3.7	0.000226	0.0127	0.14	0.11	Pancreatic cancer;	chr2:67342061	chr2:67324627~67325304:+
BRCA	cis	rs7771547	0.519	rs6923337	ENSG00000224666.3	RP1-50J22.4	3.7	0.000226	0.0127	0.13	0.11	Platelet distribution width;	chr6:36401483	chr6:36386831~36393462:+
BRCA	cis	rs875971	0.619	rs2302918	ENSG00000232546.1	RP11-458F8.1	-3.7	0.000226	0.0127	-0.1	-0.11	Aortic root size;	chr7:66535945	chr7:66848496~66858136:+
BRCA	cis	rs10411161	0.702	rs7251929	ENSG00000269483.1	AC006272.1	3.7	0.000226	0.0127	0.19	0.11	Breast cancer;	chr19:51886005	chr19:51839924~51843324:-
BRCA	cis	rs10411161	0.64	rs7252303	ENSG00000269483.1	AC006272.1	3.7	0.000226	0.0127	0.19	0.11	Breast cancer;	chr19:51886104	chr19:51839924~51843324:-
BRCA	cis	rs930395	0.514	rs13157608	ENSG00000251141.4	RP11-53O19.1	-3.7	0.000226	0.0127	-0.11	-0.11	Breast cancer;	chr5:44881402	chr5:44744900~44808777:-
BRCA	cis	rs930395	0.514	rs4642377	ENSG00000251141.4	RP11-53O19.1	-3.7	0.000226	0.0127	-0.11	-0.11	Breast cancer;	chr5:44885138	chr5:44744900~44808777:-
BRCA	cis	rs4713118	0.662	rs156744	ENSG00000216901.1	AL022393.7	3.7	0.000226	0.0127	0.16	0.11	Parkinson's disease;	chr6:27999496	chr6:28176188~28176674:+
BRCA	cis	rs4713118	0.662	rs149947	ENSG00000216901.1	AL022393.7	3.7	0.000226	0.0127	0.16	0.11	Parkinson's disease;	chr6:28004655	chr6:28176188~28176674:+
BRCA	cis	rs758129	0.501	rs2239286	ENSG00000260123.1	RP11-326A19.4	3.7	0.000226	0.0127	0.13	0.11	Schizophrenia;	chr15:89332812	chr15:89041223~89082819:+
BRCA	cis	rs758129	0.501	rs2283430	ENSG00000260123.1	RP11-326A19.4	3.7	0.000226	0.0127	0.13	0.11	Schizophrenia;	chr15:89333005	chr15:89041223~89082819:+
BRCA	cis	rs7267979	1	rs2257432	ENSG00000276952.1	RP5-965G21.6	3.7	0.000227	0.0127	0.14	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25290450	chr20:25284915~25285588:-
BRCA	cis	rs7267979	1	rs2258066	ENSG00000276952.1	RP5-965G21.6	3.7	0.000227	0.0127	0.14	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25290690	chr20:25284915~25285588:-
BRCA	cis	rs7267979	1	rs2258135	ENSG00000276952.1	RP5-965G21.6	3.7	0.000227	0.0127	0.14	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25291687	chr20:25284915~25285588:-
BRCA	cis	rs7267979	0.565	rs6107060	ENSG00000274973.1	RP13-401N8.7	-3.7	0.000227	0.0127	-0.13	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25611840	chr20:25845497~25845862:+
BRCA	cis	rs875971	0.862	rs4149461	ENSG00000273024.4	INTS4P2	3.7	0.000227	0.0127	0.13	0.11	Aortic root size;	chr7:66279745	chr7:65647864~65715661:+
BRCA	cis	rs490049	1	rs490049	ENSG00000229800.1	ATP8A2P2	3.7	0.000227	0.0127	0.26	0.11	Diabetic kidney disease;	chr13:32990725	chr13:32477274~32478841:+
BRCA	cis	rs875971	0.545	rs4718348	ENSG00000273448.1	RP11-166O4.6	3.7	0.000227	0.0127	0.12	0.11	Aortic root size;	chr7:66441589	chr7:67333047~67334383:+
BRCA	cis	rs10771431	0.817	rs10843149	ENSG00000256069.6	A2MP1	3.7	0.000227	0.0127	0.12	0.11	Breast size;	chr12:9209471	chr12:9228533~9275817:-
BRCA	cis	rs4237845	0.537	rs12426201	ENSG00000270039.1	RP11-571M6.17	-3.7	0.000227	0.0127	-0.16	-0.11	Intelligence (multi-trait analysis);	chr12:57865969	chr12:57803838~57804415:+
BRCA	cis	rs8040855	0.627	rs11634975	ENSG00000229212.6	RP11-561C5.4	-3.7	0.000227	0.0127	-0.15	-0.11	Bulimia nervosa;	chr15:85063247	chr15:85205440~85234795:-
BRCA	cis	rs12303914	0.676	rs3927994	ENSG00000256682.2	TAS2R12	-3.7	0.000227	0.0127	-0.14	-0.11	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr12:10306191	chr12:10894943~10896952:-
BRCA	cis	rs12303914	0.713	rs2302489	ENSG00000256682.2	TAS2R12	-3.7	0.000227	0.0127	-0.14	-0.11	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr12:10307944	chr12:10894943~10896952:-
BRCA	cis	rs2274273	0.967	rs67756714	ENSG00000259318.1	RP11-454L9.2	3.7	0.000227	0.0127	0.1	0.11	Protein biomarker;	chr14:55123105	chr14:55394940~55395233:-
BRCA	cis	rs60843830	1	rs3791224	ENSG00000223751.1	AC116609.2	3.7	0.000227	0.0127	0.15	0.11	Spherical equivalent (joint analysis main effects and education interaction);	chr2:221981	chr2:742488~747767:+
BRCA	cis	rs2692947	0.8	rs61409777	ENSG00000232931.4	LINC00342	3.7	0.000227	0.0127	0.12	0.11	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95915625	chr2:95807118~95816215:-
BRCA	cis	rs1046491	1	rs11660889	ENSG00000264964.1	RP11-888D10.3	3.7	0.000227	0.0127	0.23	0.11	Scarlet fever;	chr18:9177299	chr18:9315194~9334441:-
BRCA	cis	rs4388249	1	rs17638392	ENSG00000271849.1	CTC-332L22.1	-3.7	0.000227	0.0127	-0.19	-0.11	Schizophrenia;	chr5:109716385	chr5:109687802~109688329:-
BRCA	cis	rs2337406	1	rs11845269	ENSG00000280411.1	IGHV1-69-2	-3.7	0.000227	0.0127	-0.1	-0.11	Alzheimer's disease (late onset);	chr14:106683851	chr14:106762092~106762588:-
BRCA	cis	rs11048434	0.518	rs7311267	ENSG00000256069.6	A2MP1	3.7	0.000227	0.0127	0.12	0.11	Sjögren's syndrome;	chr12:9026082	chr12:9228533~9275817:-
BRCA	cis	rs7200543	1	rs72774845	ENSG00000270580.4	PKD1P6	3.7	0.000227	0.0127	0.13	0.11	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15054097	chr16:15104723~15131601:-
BRCA	cis	rs1371614	0.632	rs7589627	ENSG00000229122.1	AGBL5-IT1	3.7	0.000227	0.0127	0.12	0.11	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26936918	chr2:27061038~27061815:+
BRCA	cis	rs77633900	0.614	rs280012	ENSG00000196274.5	Metazoa_SRP	3.7	0.000227	0.0127	0.17	0.11	Glioma;Non-glioblastoma glioma;	chr15:76682513	chr15:76230048~76230390:-
BRCA	cis	rs6071166	0.683	rs722079	ENSG00000224635.1	RP4-564F22.5	-3.7	0.000227	0.0127	-0.14	-0.11	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38694192	chr20:38406011~38416797:-
BRCA	cis	rs7023329	0.811	rs3928894	ENSG00000229298.1	TUBB8P1	3.7	0.000227	0.0127	0.13	0.11	Melanoma;	chr9:21818311	chr9:21811621~21812347:-
BRCA	cis	rs9368481	0.645	rs10456350	ENSG00000224843.5	LINC00240	-3.7	0.000227	0.0127	-0.13	-0.11	Autism spectrum disorder or schizophrenia;	chr6:27007802	chr6:26956992~27023924:+
BRCA	cis	rs2955081	1	rs2955081	ENSG00000242551.2	POU5F1P6	-3.7	0.000227	0.0127	-0.19	-0.11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128241456	chr3:128674735~128677005:-
BRCA	cis	rs73201462	1	rs2955085	ENSG00000242551.2	POU5F1P6	-3.7	0.000227	0.0127	-0.19	-0.11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128243914	chr3:128674735~128677005:-
BRCA	cis	rs73201462	1	rs2999072	ENSG00000242551.2	POU5F1P6	-3.7	0.000227	0.0127	-0.19	-0.11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128244033	chr3:128674735~128677005:-
BRCA	cis	rs73201462	1	rs2955088	ENSG00000242551.2	POU5F1P6	-3.7	0.000227	0.0127	-0.19	-0.11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128244867	chr3:128674735~128677005:-
BRCA	cis	rs801193	0.935	rs3800820	ENSG00000232546.1	RP11-458F8.1	3.7	0.000227	0.0127	0.1	0.11	Aortic root size;	chr7:66682191	chr7:66848496~66858136:+
BRCA	cis	rs4664293	0.625	rs6713600	ENSG00000224152.1	AC009506.1	3.7	0.000227	0.0127	0.12	0.11	Monocyte percentage of white cells;	chr2:159706559	chr2:159615296~159617082:+
BRCA	cis	rs4664293	0.625	rs7607394	ENSG00000224152.1	AC009506.1	3.7	0.000227	0.0127	0.12	0.11	Monocyte percentage of white cells;	chr2:159707286	chr2:159615296~159617082:+
BRCA	cis	rs2562456	0.755	rs1879234	ENSG00000213976.4	CTD-2561J22.2	3.7	0.000227	0.0127	0.14	0.11	Pain;	chr19:21521677	chr19:21382865~21387177:+
BRCA	cis	rs7520050	0.966	rs12409773	ENSG00000234329.1	RP11-767N6.2	-3.7	0.000227	0.0127	-0.11	-0.11	Reticulocyte count;Red blood cell count;	chr1:45893159	chr1:45651039~45651826:-
BRCA	cis	rs7520050	1	rs12410070	ENSG00000234329.1	RP11-767N6.2	-3.7	0.000227	0.0127	-0.11	-0.11	Reticulocyte count;Red blood cell count;	chr1:45893210	chr1:45651039~45651826:-
BRCA	cis	rs7520050	0.966	rs12410071	ENSG00000234329.1	RP11-767N6.2	-3.7	0.000227	0.0127	-0.11	-0.11	Reticulocyte count;Red blood cell count;	chr1:45893214	chr1:45651039~45651826:-
BRCA	cis	rs8023401	0.938	rs11854914	ENSG00000274654.1	CTD-3247H4.2	3.7	0.000227	0.0127	0.16	0.11	Spherical equivalent (joint analysis main effects and education interaction);	chr15:48511017	chr15:48528980~48529728:-
BRCA	cis	rs17711722	0.565	rs4717276	ENSG00000226002.1	RP11-460N20.5	3.7	0.000227	0.0127	0.12	0.11	Calcium levels;	chr7:65829754	chr7:65084103~65100232:+
BRCA	cis	rs801193	0.636	rs10233806	ENSG00000265600.1	AC006480.1	3.7	0.000227	0.0127	0.14	0.11	Aortic root size;	chr7:66653261	chr7:67356680~67356779:+
BRCA	cis	rs874460	0.932	rs313841	ENSG00000211513.4	MIR320E	3.7	0.000227	0.0127	0.19	0.11	Chronic lymphocytic leukemia;	chr19:46720692	chr19:46709271~46709382:-
BRCA	cis	rs6723162	0.51	rs7564382	ENSG00000237751.2	LINC01143	-3.7	0.000227	0.0127	-0.16	-0.11	Neurocognitive impairment in HIV-1 infection (dichotomous);	chr2:70920915	chr2:70887871~70889959:+
BRCA	cis	rs8180040	0.726	rs4682842	ENSG00000271161.1	BOLA2P2	-3.7	0.000227	0.0127	-0.12	-0.11	Colorectal cancer;	chr3:46941283	chr3:47499841~47500407:+
BRCA	cis	rs875971	0.66	rs3764903	ENSG00000232546.1	RP11-458F8.1	3.7	0.000227	0.0127	0.1	0.11	Aortic root size;	chr7:66633495	chr7:66848496~66858136:+
BRCA	cis	rs875971	0.619	rs2302918	ENSG00000265600.1	AC006480.1	-3.7	0.000227	0.0127	-0.14	-0.11	Aortic root size;	chr7:66535945	chr7:67356680~67356779:+
BRCA	cis	rs9308731	0.583	rs7567184	ENSG00000230499.1	AC108463.1	-3.7	0.000227	0.0127	-0.13	-0.11	Chronic lymphocytic leukemia;	chr2:111173495	chr2:111195963~111206494:+
BRCA	cis	rs72928364	0.929	rs35999953	ENSG00000244119.1	PDCL3P4	3.7	0.000227	0.0127	0.14	0.11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100901336	chr3:101712472~101713191:+
BRCA	cis	rs72928364	1	rs13092605	ENSG00000244119.1	PDCL3P4	3.7	0.000227	0.0127	0.14	0.11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100901559	chr3:101712472~101713191:+
BRCA	cis	rs9308731	0.583	rs2165107	ENSG00000230499.1	AC108463.1	-3.7	0.000227	0.0127	-0.13	-0.11	Chronic lymphocytic leukemia;	chr2:111173773	chr2:111195963~111206494:+
BRCA	cis	rs591584	0.874	rs7105524	ENSG00000255893.1	RP11-685N10.1	-3.7	0.000227	0.0127	-0.13	-0.11	Macrophage Migration Inhibitory Factor levels;	chr11:94593276	chr11:94472908~94473570:-
BRCA	cis	rs12893668	0.608	rs12889721	ENSG00000269940.1	RP11-73M18.7	3.7	0.000227	0.0127	0.13	0.11	Reticulocyte count;	chr14:103568526	chr14:103694560~103695170:+
BRCA	cis	rs10938353	0.906	rs993372	ENSG00000273369.1	RP11-700J17.1	-3.7	0.000227	0.0127	-0.13	-0.11	Body mass index;	chr4:44582619	chr4:44693946~44694386:-
BRCA	cis	rs35740288	0.571	rs11633790	ENSG00000202081.1	RNU6-1280P	3.7	0.000227	0.0127	0.16	0.11	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85783139	chr15:85651522~85651628:-
BRCA	cis	rs7267979	0.966	rs4813557	ENSG00000274973.1	RP13-401N8.7	3.7	0.000227	0.0127	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25311909	chr20:25845497~25845862:+
BRCA	cis	rs2304003	0.583	rs962501	ENSG00000232411.1	AC009495.3	3.7	0.000227	0.0127	0.14	0.11	Social communication problems;	chr2:165864741	chr2:165833048~165839098:-
BRCA	cis	rs875971	0.505	rs1723275	ENSG00000223473.2	GS1-124K5.3	-3.7	0.000227	0.0127	-0.09	-0.11	Aortic root size;	chr7:66039646	chr7:66491049~66493566:-
BRCA	cis	rs6750047	0.756	rs4670233	ENSG00000235848.3	RMDN2-AS1	-3.7	0.000227	0.0127	-0.15	-0.11	Cutaneous malignant melanoma;Melanoma;	chr2:38045199	chr2:37949911~38067041:-
BRCA	cis	rs7620503	0.921	rs7620560	ENSG00000277241.1	RP11-114M1.3	3.7	0.000227	0.0127	0.13	0.11	Corneal structure;	chr3:177586388	chr3:177700346~177701072:-
BRCA	cis	rs12149862	1	rs12149862	ENSG00000196696.11	PDXDC2P	3.7	0.000227	0.0127	0.12	0.11	Blood pressure (smoking interaction);	chr16:69463300	chr16:69976297~70065948:-
BRCA	cis	rs4415084	1	rs2165009	ENSG00000248779.1	RP11-53O19.2	3.7	0.000227	0.0127	0.11	0.11	Breast cancer;	chr5:44697814	chr5:44752949~44765744:+
BRCA	cis	rs17428076	0.872	rs17500114	ENSG00000228389.1	AC068039.4	-3.7	0.000227	0.0127	-0.17	-0.11	Myopia;	chr2:172031684	chr2:171773482~171775844:+
BRCA	cis	rs889956	0.652	rs35557355	ENSG00000233251.6	AC007743.1	-3.7	0.000227	0.0127	-0.13	-0.11	Educational attainment;	chr2:57019659	chr2:56173534~56185770:-
BRCA	cis	rs12681366	0.553	rs2930967	ENSG00000253175.1	RP11-267M23.6	-3.7	0.000228	0.0127	-0.13	-0.11	Nonsyndromic cleft lip with cleft palate;	chr8:94450371	chr8:94565036~94565715:+
BRCA	cis	rs10056811	0.538	rs2035191	ENSG00000271815.1	CTD-2235C13.3	-3.7	0.000228	0.0127	-0.18	-0.11	Coronary artery disease;	chr5:75117888	chr5:75363760~75364242:+
BRCA	cis	rs9921338	0.924	rs7202024	ENSG00000263080.1	RP11-485G7.5	3.7	0.000228	0.0127	0.18	0.11	Vein graft stenosis in coronary artery bypass grafting;	chr16:11346901	chr16:11341809~11345211:-
BRCA	cis	rs9921338	0.961	rs7206017	ENSG00000263080.1	RP11-485G7.5	3.7	0.000228	0.0127	0.18	0.11	Vein graft stenosis in coronary artery bypass grafting;	chr16:11347004	chr16:11341809~11345211:-
BRCA	cis	rs72819225	0.616	rs7895083	ENSG00000228701.1	TNKS2-AS1	3.7	0.000228	0.0127	0.15	0.11	Yeast infection;	chr10:91568274	chr10:91782839~91798291:-
BRCA	cis	rs6433921	0.964	rs56136548	ENSG00000260742.1	RP11-366L5.1	3.7	0.000228	0.0127	0.14	0.11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;	chr2:181522022	chr2:181887851~181891663:-
BRCA	cis	rs2625529	1	rs2625529	ENSG00000261187.1	RP11-1007O24.2	3.7	0.000228	0.0127	0.13	0.11	Red blood cell count;	chr15:71826436	chr15:72465128~72466262:-
BRCA	cis	rs7267979	1	rs2257991	ENSG00000277938.1	RP5-965G21.3	-3.7	0.000228	0.0127	-0.14	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25289703	chr20:25229150~25231933:+
BRCA	cis	rs11098499	0.675	rs11098534	ENSG00000260091.1	RP11-33B1.4	-3.7	0.000228	0.0127	-0.1	-0.11	Corneal astigmatism;	chr4:119635617	chr4:119409333~119410233:+
BRCA	cis	rs11048434	0.535	rs2377680	ENSG00000111788.10	RP11-22B23.1	3.7	0.000228	0.0127	0.12	0.11	Sjögren's syndrome;	chr12:9038809	chr12:9277235~9313241:+
BRCA	cis	rs9470794	1	rs2073021	ENSG00000204110.6	RP1-153P14.8	-3.7	0.000228	0.0127	-0.18	-0.11	Type 2 diabetes;	chr6:38163666	chr6:37507348~37535616:+
BRCA	cis	rs7267979	1	rs2387884	ENSG00000204556.4	CTD-2514C3.1	3.7	0.000228	0.0127	0.15	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25398433	chr20:26018832~26020684:+
BRCA	cis	rs9295536	0.58	rs9366428	ENSG00000260455.1	NBAT1	3.7	0.000228	0.0127	0.13	0.11	Neuroblastoma;	chr6:22130375	chr6:22134957~22147193:-
BRCA	cis	rs313426	0.501	rs1946019	ENSG00000260966.1	RP11-690D19.3	3.7	0.000228	0.0127	0.13	0.11	Toenail selenium levels;	chr11:103472526	chr11:103050687~103055799:-
BRCA	cis	rs530081	0.726	rs497999	ENSG00000274184.1	RP11-158H5.8	-3.7	0.000228	0.0127	-0.15	-0.11	Lobe attachment (rater-scored or self-reported);	chr18:35092872	chr18:35268218~35270238:+
BRCA	cis	rs875971	0.66	rs1860470	ENSG00000232546.1	RP11-458F8.1	3.7	0.000228	0.0127	0.1	0.11	Aortic root size;	chr7:66638707	chr7:66848496~66858136:+
BRCA	cis	rs7027203	0.759	rs10761282	ENSG00000232063.1	RP11-307E17.8	-3.7	0.000228	0.0127	-0.12	-0.11	DNA methylation (variation);	chr9:93823893	chr9:94332476~94360948:+
BRCA	cis	rs170557	0.573	rs6657016	ENSG00000203706.7	SERTAD4-AS1	-3.7	0.000228	0.0127	-0.14	-0.11	Alopecia areata;	chr1:209941503	chr1:210231456~210234047:-
BRCA	cis	rs6696239	0.911	rs56950588	ENSG00000215812.5	ZNF847P	3.7	0.000228	0.0127	0.16	0.11	Height;	chr1:227680773	chr1:227696892~227706699:-
BRCA	cis	rs2274273	0.837	rs10141552	ENSG00000259318.1	RP11-454L9.2	-3.7	0.000228	0.0127	-0.09	-0.11	Protein biomarker;	chr14:55279373	chr14:55394940~55395233:-
BRCA	cis	rs3735485	0.738	rs2289370	ENSG00000201772.1	SNORA5C	3.7	0.000228	0.0127	0.15	0.11	White blood cell count;Sum basophil neutrophil counts;Neutrophil count;Granulocyte percentage of myeloid white cells;Monocyte percentage of white cells;Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Lymphocyte counts;	chr7:45074490	chr7:45104906~45105042:-
BRCA	cis	rs3735485	0.738	rs2289372	ENSG00000201772.1	SNORA5C	3.7	0.000228	0.0127	0.15	0.11	White blood cell count;Sum basophil neutrophil counts;Neutrophil count;Granulocyte percentage of myeloid white cells;Monocyte percentage of white cells;Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Lymphocyte counts;	chr7:45074627	chr7:45104906~45105042:-
BRCA	cis	rs11098499	0.954	rs17005535	ENSG00000225892.3	RP11-384K6.2	3.7	0.000228	0.0127	0.11	0.11	Corneal astigmatism;	chr4:119490407	chr4:118632274~118634759:+
BRCA	cis	rs10043775	0.793	rs9784645	ENSG00000251330.3	CTD-2283N19.1	-3.7	0.000228	0.0127	-0.13	-0.11	Periodontal microbiota;	chr5:148337418	chr5:148430159~148430807:-
BRCA	cis	rs2908197	0.806	rs2961047	ENSG00000186704.9	DTX2P1	3.7	0.000228	0.0127	0.13	0.11	3-hydroxypropylmercapturic acid levels in smokers;	chr7:76305739	chr7:76978617~77004308:+
BRCA	cis	rs3755605	0.728	rs7638448	ENSG00000242578.1	RP11-469J4.3	3.7	0.000228	0.0127	0.13	0.11	Testicular germ cell tumor;	chr3:170083749	chr3:170410512~170418615:+
BRCA	cis	rs10895275	0.961	rs11225165	ENSG00000277459.1	RP11-732A21.3	-3.7	0.000228	0.0127	-0.12	-0.11	Migraine;	chr11:102213843	chr11:102109827~102110457:-
BRCA	cis	rs7267979	1	rs2257982	ENSG00000276952.1	RP5-965G21.6	3.7	0.000228	0.0127	0.14	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25288994	chr20:25284915~25285588:-
BRCA	cis	rs7267979	1	rs2257985	ENSG00000276952.1	RP5-965G21.6	3.7	0.000228	0.0127	0.14	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25289107	chr20:25284915~25285588:-
BRCA	cis	rs7267979	1	rs2257988	ENSG00000276952.1	RP5-965G21.6	3.7	0.000228	0.0127	0.14	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25289367	chr20:25284915~25285588:-
BRCA	cis	rs7615952	0.512	rs4234285	ENSG00000241288.6	RP11-379B18.5	-3.7	0.000228	0.0127	-0.14	-0.11	Blood pressure (smoking interaction);	chr3:125685633	chr3:125827238~125916384:-
BRCA	cis	rs4664293	0.647	rs918969	ENSG00000226266.5	AC009961.3	3.7	0.000228	0.0127	0.13	0.11	Monocyte percentage of white cells;	chr2:159610145	chr2:159670708~159712435:-
BRCA	cis	rs875971	0.862	rs35378740	ENSG00000273024.4	INTS4P2	-3.7	0.000228	0.0127	-0.13	-0.11	Aortic root size;	chr7:66522725	chr7:65647864~65715661:+
BRCA	cis	rs7267979	1	rs6083805	ENSG00000274414.1	RP5-965G21.4	3.7	0.000228	0.0127	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25336720	chr20:25239007~25245229:-
BRCA	cis	rs875971	0.862	rs2024192	ENSG00000273024.4	INTS4P2	3.7	0.000228	0.0127	0.13	0.11	Aortic root size;	chr7:66576460	chr7:65647864~65715661:+
BRCA	cis	rs2380205	0.935	rs2380201	ENSG00000232807.2	RP11-536K7.3	3.7	0.000228	0.0127	0.12	0.11	Breast cancer;	chr10:5852687	chr10:5934270~5945900:-
BRCA	cis	rs1008375	0.966	rs4698619	ENSG00000249502.1	AC006160.5	-3.7	0.000228	0.0127	-0.13	-0.11	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17579332	chr4:17587467~17614571:-
BRCA	cis	rs1008375	0.966	rs10939736	ENSG00000249502.1	AC006160.5	-3.7	0.000228	0.0127	-0.13	-0.11	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17579994	chr4:17587467~17614571:-
BRCA	cis	rs2288327	0.818	rs3731749	ENSG00000271011.1	RP11-171I2.5	3.7	0.000228	0.0127	0.21	0.11	Atrial fibrillation;	chr2:178541464	chr2:178577103~178577622:+
BRCA	cis	rs9959145	0.925	rs78425322	ENSG00000267199.1	RP11-861E21.2	3.7	0.000228	0.0127	0.2	0.11	Immune response to smallpox vaccine (IL-6);	chr18:12725105	chr18:12438890~12448205:+
BRCA	cis	rs4761702	0.551	rs11106987	ENSG00000257322.4	RP11-511B23.2	-3.7	0.000228	0.0127	-0.14	-0.11	Immature fraction of reticulocytes;	chr12:93339760	chr12:93003415~93215679:-
BRCA	cis	rs9949617	0.712	rs4800467	ENSG00000266495.1	RP11-17J14.2	3.7	0.000228	0.0127	0.19	0.11	Hypertriglyceridemia;	chr18:23324442	chr18:23257164~23260354:-
BRCA	cis	rs12906542	0.516	rs56357772	ENSG00000259792.1	RP11-114H24.6	-3.7	0.000228	0.0127	-0.17	-0.11	Breast cancer;	chr15:78020699	chr15:77993405~77995289:+
BRCA	cis	rs12906542	0.516	rs16969422	ENSG00000259792.1	RP11-114H24.6	-3.7	0.000228	0.0127	-0.17	-0.11	Breast cancer;	chr15:78033857	chr15:77993405~77995289:+
BRCA	cis	rs13272568	0.614	rs13281068	ENSG00000254352.1	RP11-578O24.2	-3.7	0.000228	0.0127	-0.14	-0.11	Bone mineral density;	chr8:78119653	chr8:78723796~78724136:-
BRCA	cis	rs875971	0.545	rs6460298	ENSG00000273448.1	RP11-166O4.6	3.7	0.000228	0.0127	0.12	0.11	Aortic root size;	chr7:66442783	chr7:67333047~67334383:+
BRCA	cis	rs6881634	0.501	rs6453392	ENSG00000253558.1	CTD-2179L22.1	-3.7	0.000228	0.0127	-0.14	-0.11	Hippocampal atrophy;	chr5:78461721	chr5:78041879~78044138:-
BRCA	cis	rs2657888	1	rs7309685	ENSG00000257576.1	RP11-153M3.1	-3.7	0.000228	0.0127	-0.14	-0.11	Adiponectin levels;	chr12:56541629	chr12:56511002~56512703:+
BRCA	cis	rs8023401	0.745	rs16961033	ENSG00000274654.1	CTD-3247H4.2	3.7	0.000228	0.0127	0.15	0.11	Spherical equivalent (joint analysis main effects and education interaction);	chr15:48503680	chr15:48528980~48529728:-
BRCA	cis	rs7267979	0.966	rs8123949	ENSG00000204556.4	CTD-2514C3.1	3.7	0.000228	0.0127	0.15	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25407497	chr20:26018832~26020684:+
BRCA	cis	rs7267979	1	rs2184000	ENSG00000204556.4	CTD-2514C3.1	3.7	0.000228	0.0127	0.15	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25415242	chr20:26018832~26020684:+
BRCA	cis	rs4363385	0.867	rs310103	ENSG00000272654.1	RP11-422P24.11	3.7	0.000228	0.0128	0.12	0.11	Inflammatory skin disease;	chr1:153070078	chr1:153977743~153979160:+
BRCA	cis	rs6088590	0.965	rs6120730	ENSG00000276073.1	RP5-1125A11.7	-3.7	0.000228	0.0128	-0.13	-0.11	Coronary artery disease;	chr20:34797299	chr20:33985617~33988989:-
BRCA	cis	rs7267979	1	rs6037099	ENSG00000204556.4	CTD-2514C3.1	3.7	0.000228	0.0128	0.15	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25376240	chr20:26018832~26020684:+
BRCA	cis	rs7267979	0.966	rs4815414	ENSG00000204556.4	CTD-2514C3.1	3.7	0.000228	0.0128	0.15	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25381065	chr20:26018832~26020684:+
BRCA	cis	rs7267979	1	rs6083825	ENSG00000204556.4	CTD-2514C3.1	3.7	0.000228	0.0128	0.15	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25385788	chr20:26018832~26020684:+
BRCA	cis	rs7267979	1	rs34645895	ENSG00000204556.4	CTD-2514C3.1	3.7	0.000228	0.0128	0.15	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25387737	chr20:26018832~26020684:+
BRCA	cis	rs7267979	1	rs6037105	ENSG00000204556.4	CTD-2514C3.1	3.7	0.000228	0.0128	0.15	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25393563	chr20:26018832~26020684:+
BRCA	cis	rs4415084	0.804	rs13177711	ENSG00000248779.1	RP11-53O19.2	3.7	0.000228	0.0128	0.1	0.11	Breast cancer;	chr5:44796860	chr5:44752949~44765744:+
BRCA	cis	rs3764563	1	rs4239617	ENSG00000267594.5	CYP4F24P	-3.7	0.000228	0.0128	-0.21	-0.11	Inflammatory biomarkers;	chr19:15630727	chr19:15760241~15779909:-
BRCA	cis	rs3764563	1	rs1022413	ENSG00000267594.5	CYP4F24P	-3.7	0.000228	0.0128	-0.21	-0.11	Inflammatory biomarkers;	chr19:15631174	chr19:15760241~15779909:-
BRCA	cis	rs7267979	1	rs6050547	ENSG00000274414.1	RP5-965G21.4	3.7	0.000228	0.0128	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25345376	chr20:25239007~25245229:-
BRCA	cis	rs848490	0.889	rs11764525	ENSG00000214293.7	APTR	3.7	0.000228	0.0128	0.14	0.11	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77648608	chr7:77657660~77696265:-
BRCA	cis	rs9470794	0.915	rs11759574	ENSG00000204110.6	RP1-153P14.8	-3.7	0.000228	0.0128	-0.23	-0.11	Type 2 diabetes;	chr6:37841393	chr6:37507348~37535616:+
BRCA	cis	rs10043775	0.831	rs13358385	ENSG00000251330.3	CTD-2283N19.1	-3.7	0.000228	0.0128	-0.14	-0.11	Periodontal microbiota;	chr5:148344294	chr5:148430159~148430807:-
BRCA	cis	rs7824557	0.583	rs2736306	ENSG00000255046.1	RP11-297N6.4	-3.7	0.000229	0.0128	-0.14	-0.11	Retinal vascular caliber;	chr8:11382253	chr8:11797928~11802568:-
BRCA	cis	rs10895275	0.961	rs10895273	ENSG00000277459.1	RP11-732A21.3	-3.7	0.000229	0.0128	-0.12	-0.11	Migraine;	chr11:102211945	chr11:102109827~102110457:-
BRCA	cis	rs504458	0.515	rs664544	ENSG00000207234.1	RNU6-125P	-3.7	0.000229	0.0128	-0.13	-0.11	Childhood ear infection;	chr1:88250394	chr1:88816779~88816885:+
BRCA	cis	rs7267979	0.966	rs6107031	ENSG00000204556.4	CTD-2514C3.1	3.7	0.000229	0.0128	0.15	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25370041	chr20:26018832~26020684:+
BRCA	cis	rs7267979	1	rs6115159	ENSG00000204556.4	CTD-2514C3.1	3.7	0.000229	0.0128	0.15	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25370308	chr20:26018832~26020684:+
BRCA	cis	rs7267979	1	rs4813562	ENSG00000204556.4	CTD-2514C3.1	3.7	0.000229	0.0128	0.15	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25371952	chr20:26018832~26020684:+
BRCA	cis	rs2554380	0.943	rs2585038	ENSG00000230373.7	GOLGA6L5P	-3.7	0.000229	0.0128	-0.16	-0.11	Height;	chr15:83668506	chr15:84507885~84516814:-
BRCA	cis	rs983392	1	rs17529983	ENSG00000275344.1	MIR6503	-3.7	0.000229	0.0128	-0.12	-0.11	Alzheimer's disease (late onset);	chr11:60159566	chr11:60209071~60209156:-
BRCA	cis	rs2555155	0.935	rs10839567	ENSG00000254595.1	CTD-2010I16.1	3.7	0.000229	0.0128	0.13	0.11	DNA methylation (variation);	chr11:6499434	chr11:6488186~6489377:-
BRCA	cis	rs7267979	0.78	rs6050679	ENSG00000204556.4	CTD-2514C3.1	-3.7	0.000229	0.0128	-0.15	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25557191	chr20:26018832~26020684:+
BRCA	cis	rs17027633	1	rs1343349	ENSG00000234020.1	CHIAP3	-3.7	0.000229	0.0128	-0.27	-0.11	Cerebrospinal fluid t-tau:AB1-42 ratio;	chr1:111406665	chr1:111353275~111367409:-
BRCA	cis	rs35860234	0.571	rs61960926	ENSG00000271216.1	LINC01050	-3.7	0.000229	0.0128	-0.14	-0.11	Vitiligo;	chr13:42395889	chr13:42810366~42812562:-
BRCA	cis	rs7412746	0.634	rs12096831	ENSG00000231073.1	RP11-316M1.3	3.7	0.000229	0.0128	0.12	0.11	Melanoma;	chr1:150891637	chr1:150973123~150975534:+
BRCA	cis	rs6715284	1	rs13408294	ENSG00000232719.1	RP11-13J8.1	3.7	0.000229	0.0128	0.18	0.11	Rheumatoid arthritis;	chr2:201306850	chr2:201101382~201103136:+
BRCA	cis	rs2380205	0.517	rs2387092	ENSG00000232807.2	RP11-536K7.3	3.7	0.000229	0.0128	0.12	0.11	Breast cancer;	chr10:5918246	chr10:5934270~5945900:-
BRCA	cis	rs10181042	0.565	rs62150982	ENSG00000273302.1	RP11-493E12.2	-3.7	0.000229	0.0128	-0.1	-0.11	Crohn's disease;	chr2:61053540	chr2:61199979~61200769:+
BRCA	cis	rs35306767	0.903	rs61830933	ENSG00000229869.1	RP11-363N22.2	-3.7	0.000229	0.0128	-0.2	-0.11	Eosinophil percentage of granulocytes;	chr10:888255	chr10:933026~942743:+
BRCA	cis	rs7405404	0.913	rs1076883	ENSG00000276564.1	CTA-276F8.1	3.7	0.000229	0.0128	0.14	0.11	Bipolar disorder lithium response (categorical) or schizophrenia;Schizophrenia;	chr16:13653807	chr16:14150833~14153235:+
BRCA	cis	rs4263408	0.935	rs62310123	ENSG00000224097.5	RP11-472B18.1	3.7	0.000229	0.0128	0.13	0.11	Plasma amyloid beta peptide concentrations (ABx-40);	chr4:39744462	chr4:39480255~39481905:+
BRCA	cis	rs740160	0.681	rs11974885	ENSG00000244219.5	GS1-259H13.2	-3.7	0.000229	0.0128	-0.2	-0.11	Dehydroepiandrosterone sulphate levels;	chr7:99293532	chr7:99598066~99610813:+
BRCA	cis	rs853679	0.517	rs9380047	ENSG00000272009.1	RP1-313I6.12	-3.7	0.000229	0.0128	-0.17	-0.11	Depression;	chr6:28070115	chr6:28078792~28081130:-
BRCA	cis	rs11098499	0.863	rs3775841	ENSG00000260404.2	RP11-384K6.6	3.7	0.000229	0.0128	0.11	0.11	Corneal astigmatism;	chr4:119504622	chr4:118591773~118633729:+
BRCA	cis	rs6120849	0.663	rs6088662	ENSG00000202150.1	RNU6-407P	3.7	0.000229	0.0128	0.16	0.11	Protein C levels;	chr20:34959830	chr20:35030317~35030420:-
BRCA	cis	rs987724	0.515	rs1574980	ENSG00000244515.1	KRT18P34	-3.7	0.000229	0.0128	-0.17	-0.11	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156917639	chr3:157162663~157163932:-
BRCA	cis	rs11098499	0.954	rs3733520	ENSG00000260404.2	RP11-384K6.6	3.7	0.000229	0.0128	0.11	0.11	Corneal astigmatism;	chr4:119502325	chr4:118591773~118633729:+
BRCA	cis	rs6964587	1	rs10234290	ENSG00000188693.7	CYP51A1-AS1	-3.7	0.000229	0.0128	-0.12	-0.11	Breast cancer;	chr7:92087637	chr7:92134604~92180725:+
BRCA	cis	rs4699052	0.625	rs1400365	ENSG00000248740.4	RP11-328K4.1	3.7	0.000229	0.0128	0.13	0.11	Testicular germ cell tumor;	chr4:103368239	chr4:103256159~103453658:+
BRCA	cis	rs11098499	0.874	rs6822498	ENSG00000260404.2	RP11-384K6.6	3.7	0.000229	0.0128	0.11	0.11	Corneal astigmatism;	chr4:119199028	chr4:118591773~118633729:+
BRCA	cis	rs739401	0.611	rs2239899	ENSG00000183562.3	CTC-343N3.1	3.7	0.000229	0.0128	0.12	0.11	Longevity;	chr11:3003394	chr11:2989863~2991344:+
BRCA	cis	rs12701220	0.894	rs10257744	ENSG00000224079.1	AC091729.7	3.7	0.000229	0.0128	0.18	0.11	Bronchopulmonary dysplasia;	chr7:1005976	chr7:1074450~1078036:+
BRCA	cis	rs2451932	0.669	rs2913545	ENSG00000251050.1	RP11-168A11.4	-3.7	0.000229	0.0128	-0.12	-0.11	LDL peak particle diameter (total fat intake interaction);	chr5:80027661	chr5:80019609~80019920:+
BRCA	cis	rs10129255	1	rs8012033	ENSG00000211958.2	IGHV3-38	3.7	0.000229	0.0128	0.09	0.11	Kawasaki disease;	chr14:106678854	chr14:106410493~106411021:-
BRCA	cis	rs2243480	0.901	rs73148097	ENSG00000226767.1	RP11-328P23.3	-3.7	0.000229	0.0128	-0.2	-0.11	Diabetic kidney disease;	chr7:65966800	chr7:65508773~65508944:-
BRCA	cis	rs2243480	1	rs906134	ENSG00000226767.1	RP11-328P23.3	-3.7	0.000229	0.0128	-0.2	-0.11	Diabetic kidney disease;	chr7:65979301	chr7:65508773~65508944:-
BRCA	cis	rs10129255	1	rs61997605	ENSG00000231475.3	IGHV4-31	-3.7	0.000229	0.0128	-0.09	-0.11	Kawasaki disease;	chr14:106678368	chr14:106349283~106349792:-
BRCA	cis	rs875971	0.545	rs73136346	ENSG00000232559.3	GS1-124K5.12	-3.7	0.000229	0.0128	-0.16	-0.11	Aortic root size;	chr7:66101095	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.862	rs908915	ENSG00000273024.4	INTS4P2	3.7	0.000229	0.0128	0.13	0.11	Aortic root size;	chr7:66149664	chr7:65647864~65715661:+
BRCA	cis	rs891378	1	rs1507760	ENSG00000274245.1	RP11-357P18.2	3.7	0.000229	0.0128	0.15	0.11	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207336020	chr1:207372559~207373252:+
BRCA	cis	rs754466	0.58	rs2289309	ENSG00000213514.2	RP11-428P16.2	3.7	0.000229	0.0128	0.15	0.11	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77811350	chr10:77730766~77734769:+
BRCA	cis	rs6681460	0.966	rs10789215	ENSG00000248458.2	RP4-598P13.1	-3.7	0.000229	0.0128	-0.12	-0.11	Presence of antiphospholipid antibodies;	chr1:66685502	chr1:66665864~66677027:-
BRCA	cis	rs2841277	0.708	rs28600075	ENSG00000258701.1	LINC00638	3.7	0.000229	0.0128	0.12	0.11	Rheumatoid arthritis;	chr14:104941978	chr14:104821201~104823718:+
BRCA	cis	rs7015630	0.779	rs13260987	ENSG00000251136.7	RP11-37B2.1	-3.7	0.000229	0.0128	-0.13	-0.11	Inflammatory bowel disease;Crohn's disease;	chr8:89854126	chr8:89609409~89757727:-
BRCA	cis	rs10864907	0.71	rs13029703	ENSG00000231747.1	AC079922.2	-3.7	0.000229	0.0128	-0.11	-0.11	Pulmonary function;	chr2:112973583	chr2:112621809~112622167:-
BRCA	cis	rs875971	0.862	rs13232191	ENSG00000273024.4	INTS4P2	-3.7	0.000229	0.0128	-0.13	-0.11	Aortic root size;	chr7:66521661	chr7:65647864~65715661:+
BRCA	cis	rs875971	0.862	rs10950043	ENSG00000273024.4	INTS4P2	-3.7	0.000229	0.0128	-0.13	-0.11	Aortic root size;	chr7:66523623	chr7:65647864~65715661:+
BRCA	cis	rs875971	0.862	rs17747530	ENSG00000273024.4	INTS4P2	-3.7	0.000229	0.0128	-0.13	-0.11	Aortic root size;	chr7:66529742	chr7:65647864~65715661:+
BRCA	cis	rs875971	0.862	rs13536	ENSG00000273024.4	INTS4P2	3.7	0.000229	0.0128	0.13	0.11	Aortic root size;	chr7:66554203	chr7:65647864~65715661:+
BRCA	cis	rs875971	0.862	rs801209	ENSG00000273024.4	INTS4P2	3.7	0.000229	0.0128	0.13	0.11	Aortic root size;	chr7:66554403	chr7:65647864~65715661:+
BRCA	cis	rs875971	0.862	rs801206	ENSG00000273024.4	INTS4P2	3.7	0.000229	0.0128	0.13	0.11	Aortic root size;	chr7:66556979	chr7:65647864~65715661:+
BRCA	cis	rs875971	0.862	rs801204	ENSG00000273024.4	INTS4P2	3.7	0.000229	0.0128	0.13	0.11	Aortic root size;	chr7:66557934	chr7:65647864~65715661:+
BRCA	cis	rs875971	0.862	rs801203	ENSG00000273024.4	INTS4P2	3.7	0.000229	0.0128	0.13	0.11	Aortic root size;	chr7:66558025	chr7:65647864~65715661:+
BRCA	cis	rs897984	0.52	rs4889622	ENSG00000260082.1	RP11-2C24.5	-3.7	0.00023	0.0128	-0.14	-0.11	Dementia with Lewy bodies;	chr16:30859636	chr16:30821068~30822110:-
BRCA	cis	rs172166	0.694	rs9295760	ENSG00000219891.2	ZSCAN12P1	3.7	0.00023	0.0128	0.14	0.11	Cardiac Troponin-T levels;	chr6:28179607	chr6:28091154~28093664:+
BRCA	cis	rs930395	0.514	rs10060878	ENSG00000251141.4	RP11-53O19.1	-3.7	0.00023	0.0128	-0.11	-0.11	Breast cancer;	chr5:44899322	chr5:44744900~44808777:-
BRCA	cis	rs7267979	0.933	rs2261109	ENSG00000276952.1	RP5-965G21.6	3.7	0.00023	0.0128	0.14	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25278564	chr20:25284915~25285588:-
BRCA	cis	rs7267979	0.966	rs2261720	ENSG00000276952.1	RP5-965G21.6	3.7	0.00023	0.0128	0.14	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25280005	chr20:25284915~25285588:-
BRCA	cis	rs4713118	0.669	rs200997	ENSG00000219392.1	RP1-265C24.5	-3.7	0.00023	0.0128	-0.16	-0.11	Parkinson's disease;	chr6:27844037	chr6:28115628~28116551:+
BRCA	cis	rs757081	0.648	rs1488933	ENSG00000272034.1	SNORD14A	-3.7	0.00023	0.0128	-0.12	-0.11	Systolic blood pressure;	chr11:17245482	chr11:17074654~17074744:-
BRCA	cis	rs516805	0.706	rs11752939	ENSG00000279114.1	RP3-425C14.5	3.7	0.00023	0.0128	0.14	0.11	Lymphocyte counts;	chr6:122350062	chr6:122471923~122484161:+
BRCA	cis	rs4835473	0.932	rs13135034	ENSG00000246448.2	RP13-578N3.3	3.7	0.00023	0.0128	0.13	0.11	Immature fraction of reticulocytes;	chr4:143738247	chr4:143700257~143865072:+
BRCA	cis	rs12468226	0.873	rs12470401	ENSG00000272966.1	RP11-686O6.1	3.7	0.00023	0.0128	0.2	0.11	Urate levels;	chr2:202236436	chr2:202336739~202337200:+
BRCA	cis	rs4950322	1	rs72694750	ENSG00000244371.2	PFN1P8	-3.7	0.00023	0.0128	-0.16	-0.11	Protein quantitative trait loci;	chr1:147396856	chr1:146957117~146957659:-
BRCA	cis	rs4950322	1	rs1986987	ENSG00000244371.2	PFN1P8	-3.7	0.00023	0.0128	-0.16	-0.11	Protein quantitative trait loci;	chr1:147397553	chr1:146957117~146957659:-
BRCA	cis	rs4950322	1	rs61230354	ENSG00000244371.2	PFN1P8	-3.7	0.00023	0.0128	-0.16	-0.11	Protein quantitative trait loci;	chr1:147398161	chr1:146957117~146957659:-
BRCA	cis	rs952623	1	rs952623	ENSG00000211694.2	TRGV10	3.7	0.00023	0.0128	0.1	0.11	Intelligence (multi-trait analysis);	chr7:38998316	chr7:38299811~38300322:-
BRCA	cis	rs782590	0.607	rs2061032	ENSG00000272606.1	RP11-554J4.1	-3.7	0.00023	0.0128	-0.13	-0.11	Metabolic syndrome;	chr2:55452354	chr2:55617909~55618373:+
BRCA	cis	rs6545883	0.965	rs10186325	ENSG00000212978.6	AC016747.3	3.7	0.00023	0.0128	0.15	0.11	Tuberculosis;	chr2:61530586	chr2:61141592~61144969:-
BRCA	cis	rs72634258	0.796	rs4369247	ENSG00000238290.1	RP11-431K24.1	3.7	0.00023	0.0128	0.16	0.11	Inflammatory bowel disease;	chr1:8108933	chr1:8026738~8122702:+
BRCA	cis	rs7561149	0.902	rs3769858	ENSG00000270574.1	RP11-171I2.2	-3.7	0.00023	0.0128	-0.15	-0.11	QT interval;	chr2:178803079	chr2:178578790~178580906:+
BRCA	cis	rs295490	0.748	rs76522909	ENSG00000178631.7	ACTG1P1	-3.7	0.00023	0.0128	-0.22	-0.11	PR interval in Tripanosoma cruzi seropositivity;	chr3:139444006	chr3:139493809~139494937:+
BRCA	cis	rs875971	0.789	rs7808013	ENSG00000229886.1	RP5-1132H15.3	-3.7	0.00023	0.0128	-0.13	-0.11	Aortic root size;	chr7:66606209	chr7:66025126~66031544:-
BRCA	cis	rs6487679	1	rs10734765	ENSG00000214776.8	RP11-726G1.1	-3.7	0.00023	0.0128	-0.15	-0.11	Non-alcoholic fatty liver disease histology (AST);	chr12:9216789	chr12:9467552~9576275:+
BRCA	cis	rs4664293	0.605	rs6745815	ENSG00000224152.1	AC009506.1	3.7	0.00023	0.0128	0.12	0.11	Monocyte percentage of white cells;	chr2:159693558	chr2:159615296~159617082:+
BRCA	cis	rs4664293	0.551	rs11898293	ENSG00000224152.1	AC009506.1	3.7	0.00023	0.0128	0.12	0.11	Monocyte percentage of white cells;	chr2:159696082	chr2:159615296~159617082:+
BRCA	cis	rs801193	0.569	rs13226966	ENSG00000265600.1	AC006480.1	-3.7	0.00023	0.0128	-0.14	-0.11	Aortic root size;	chr7:66768636	chr7:67356680~67356779:+
BRCA	cis	rs987724	0.574	rs2321292	ENSG00000240875.4	LINC00886	-3.7	0.00023	0.0128	-0.13	-0.11	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156925970	chr3:156747346~156817062:-
BRCA	cis	rs962856	0.575	rs612624	ENSG00000236780.4	AC078941.1	3.7	0.00023	0.0128	0.16	0.11	Pancreatic cancer;	chr2:67430179	chr2:67123357~67215319:-
BRCA	cis	rs7238033	0.9	rs10775480	ENSG00000267193.4	RP11-116O18.3	3.7	0.00023	0.0128	0.13	0.11	Bladder cancer;	chr18:45737317	chr18:45669367~45747215:-
BRCA	cis	rs16950303	0.661	rs10502896	ENSG00000265496.3	MIR1539	3.7	0.00023	0.0128	0.22	0.11	Height;	chr18:49052056	chr18:49487339~49491878:+
BRCA	cis	rs1865760	0.929	rs1436307	ENSG00000272810.1	U91328.22	-3.7	0.00023	0.0128	-0.13	-0.11	Height;	chr6:25939495	chr6:26013241~26013757:+
BRCA	cis	rs9400180	0.84	rs9400189	ENSG00000271734.1	RP1-111B22.3	-3.7	0.00023	0.0128	-0.15	-0.11	Major depressive disorder;	chr6:108063303	chr6:108030249~108030718:-
BRCA	cis	rs8180040	0.62	rs9845728	ENSG00000260236.1	RP11-708J19.1	3.7	0.00023	0.0128	0.1	0.11	Colorectal cancer;	chr3:47061886	chr3:47379089~47380999:-
BRCA	cis	rs8180040	0.62	rs9844122	ENSG00000260236.1	RP11-708J19.1	3.7	0.00023	0.0128	0.1	0.11	Colorectal cancer;	chr3:47066840	chr3:47379089~47380999:-
BRCA	cis	rs35306767	0.903	rs12769002	ENSG00000229869.1	RP11-363N22.2	3.7	0.00023	0.0128	0.19	0.11	Eosinophil percentage of granulocytes;	chr10:881726	chr10:933026~942743:+
BRCA	cis	rs3858526	0.834	rs7128847	ENSG00000224295.2	AC087380.14	3.7	0.00023	0.0128	0.16	0.11	DNA methylation (variation);	chr11:5981881	chr11:5518441~5524955:-
BRCA	cis	rs172166	0.611	rs203882	ENSG00000219891.2	ZSCAN12P1	3.7	0.00023	0.0128	0.14	0.11	Cardiac Troponin-T levels;	chr6:28110724	chr6:28091154~28093664:+
BRCA	cis	rs7812879	0.929	rs2736343	ENSG00000255354.1	RP11-148O21.2	-3.7	0.00023	0.0128	-0.14	-0.11	Systemic lupus erythematosus;	chr8:11491741	chr8:11558466~11560020:-
BRCA	cis	rs11098499	0.863	rs11098531	ENSG00000260404.2	RP11-384K6.6	3.7	0.00023	0.0128	0.11	0.11	Corneal astigmatism;	chr4:119543846	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.863	rs28718422	ENSG00000260404.2	RP11-384K6.6	3.7	0.00023	0.0128	0.11	0.11	Corneal astigmatism;	chr4:119545149	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.818	rs12498599	ENSG00000260404.2	RP11-384K6.6	3.7	0.00023	0.0128	0.11	0.11	Corneal astigmatism;	chr4:119547348	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.863	rs10009626	ENSG00000260404.2	RP11-384K6.6	3.7	0.00023	0.0128	0.11	0.11	Corneal astigmatism;	chr4:119548850	chr4:118591773~118633729:+
BRCA	cis	rs7267979	1	rs6076345	ENSG00000204556.4	CTD-2514C3.1	3.7	0.00023	0.0128	0.15	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25401259	chr20:26018832~26020684:+
BRCA	cis	rs6545883	0.868	rs2518933	ENSG00000270820.4	RP11-355B11.2	3.7	0.00023	0.0128	0.13	0.11	Tuberculosis;	chr2:61569895	chr2:61471188~61484130:+
BRCA	cis	rs3735485	0.738	rs11765226	ENSG00000201772.1	SNORA5C	3.7	0.00023	0.0128	0.15	0.11	White blood cell count;Sum basophil neutrophil counts;Neutrophil count;Granulocyte percentage of myeloid white cells;Monocyte percentage of white cells;Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Lymphocyte counts;	chr7:45092254	chr7:45104906~45105042:-
BRCA	cis	rs12612619	0.579	rs11887277	ENSG00000229122.1	AGBL5-IT1	-3.7	0.00023	0.0128	-0.12	-0.11	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:26860401	chr2:27061038~27061815:+
BRCA	cis	rs10463316	0.817	rs7709507	ENSG00000260581.1	CTB-113P19.4	3.7	0.00023	0.0128	0.13	0.11	Metabolite levels (Pyroglutamine);	chr5:151403788	chr5:151652275~151655449:+
BRCA	cis	rs6600671	1	rs1832558	ENSG00000275131.1	CH17-472G23.4	-3.7	0.00023	0.0128	-0.1	-0.11	Hip geometry;	chr1:121435521	chr1:120489625~120579190:-
BRCA	cis	rs6600671	0.967	rs11249349	ENSG00000275131.1	CH17-472G23.4	-3.7	0.00023	0.0128	-0.1	-0.11	Hip geometry;	chr1:121437310	chr1:120489625~120579190:-
BRCA	cis	rs13126694	0.62	rs6844184	ENSG00000251073.1	NUDT19P5	3.7	0.00023	0.0128	0.11	0.11	Blood osmolality (transformed sodium);	chr4:158094156	chr4:158182825~158183393:+
BRCA	cis	rs9367716	0.917	rs1013146	ENSG00000276576.1	MRPL30P1	3.7	0.00023	0.0128	0.14	0.11	Coronary artery disease;	chr6:57260245	chr6:57029521~57029988:+
BRCA	cis	rs4388249	1	rs11241032	ENSG00000271849.1	CTC-332L22.1	-3.7	0.00023	0.0128	-0.19	-0.11	Schizophrenia;	chr5:109723507	chr5:109687802~109688329:-
BRCA	cis	rs2739330	0.76	rs5751761	ENSG00000228039.3	KB-1125A3.10	-3.7	0.00023	0.0128	-0.13	-0.11	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23963780~23964374:+
BRCA	cis	rs875971	0.862	rs1643375	ENSG00000271064.1	RP11-792A8.3	-3.7	0.00023	0.0128	-0.13	-0.11	Aortic root size;	chr7:66407690	chr7:66748838~66749077:-
BRCA	cis	rs9470794	1	rs11752623	ENSG00000204110.6	RP1-153P14.8	-3.7	0.00023	0.0128	-0.24	-0.11	Type 2 diabetes;	chr6:38011084	chr6:37507348~37535616:+
BRCA	cis	rs34975555	0.568	rs2285308	ENSG00000254054.2	RP11-156K13.3	-3.7	0.00023	0.0128	-0.16	-0.11	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:17969806	chr8:17905756~17907887:+
BRCA	cis	rs7190551	0.51	rs4438302	ENSG00000260979.1	RP11-77H9.8	3.7	0.00023	0.0128	0.15	0.11	Platelet distribution width;	chr16:8996758	chr16:8962706~8966990:+
BRCA	cis	rs1912124	1	rs59415196	ENSG00000271983.1	RP11-28H5.2	3.7	0.00023	0.0128	0.23	0.11	Peripheral arterial disease (traffic-related air pollution interaction);	chr15:81214642	chr15:80693216~80693707:-
BRCA	cis	rs10463316	0.855	rs13359064	ENSG00000260581.1	CTB-113P19.4	3.7	0.00023	0.0128	0.13	0.11	Metabolite levels (Pyroglutamine);	chr5:151386014	chr5:151652275~151655449:+
BRCA	cis	rs10463316	0.894	rs13361316	ENSG00000260581.1	CTB-113P19.4	3.7	0.00023	0.0128	0.13	0.11	Metabolite levels (Pyroglutamine);	chr5:151386032	chr5:151652275~151655449:+
BRCA	cis	rs2562456	0.52	rs250001	ENSG00000268081.1	RP11-678G14.2	3.7	0.00023	0.0128	0.19	0.11	Pain;	chr19:21225387	chr19:21554640~21569237:-
BRCA	cis	rs7656342	0.808	rs6835741	ENSG00000250342.1	SNRPCP16	-3.7	0.00023	0.0128	-0.13	-0.11	Gut microbiota (bacterial taxa);	chr4:9777287	chr4:9051842~9052051:-
BRCA	cis	rs739496	0.615	rs12427276	ENSG00000226469.1	ADAM1B	3.7	0.00023	0.0128	0.15	0.11	Platelet count;	chr12:111675704	chr12:111927018~111929017:+
BRCA	cis	rs9527	0.59	rs12785223	ENSG00000213061.2	PFN1P11	-3.7	0.00023	0.0129	-0.15	-0.11	Arsenic metabolism;	chr10:103084254	chr10:102838011~102845473:-
BRCA	cis	rs9287719	0.967	rs6727768	ENSG00000224177.5	LINC00570	3.7	0.00023	0.0129	0.13	0.11	Prostate cancer;	chr2:10617353	chr2:11393981~11403077:+
BRCA	cis	rs9287719	0.967	rs10167129	ENSG00000224177.5	LINC00570	3.7	0.00023	0.0129	0.13	0.11	Prostate cancer;	chr2:10618449	chr2:11393981~11403077:+
BRCA	cis	rs6700559	0.565	rs11807125	ENSG00000260088.1	RP11-92G12.3	3.7	0.00023	0.0129	0.14	0.11	Coronary artery disease;	chr1:200623167	chr1:200669507~200694250:+
BRCA	cis	rs9783347	0.621	rs11024606	ENSG00000256361.1	RP11-613F22.6	-3.7	0.00023	0.0129	-0.14	-0.11	Pancreatic cancer;	chr11:18296317	chr11:18511043~18511475:-
BRCA	cis	rs6991838	0.584	rs7842085	ENSG00000272155.1	RP11-707M3.3	-3.7	0.000231	0.0129	-0.11	-0.11	Intelligence (multi-trait analysis);	chr8:65636787	chr8:65714334~65714778:-
BRCA	cis	rs7111546	0.791	rs2191690	ENSG00000246225.5	RP11-17A1.3	3.7	0.000231	0.0129	0.2	0.11	Dialysis-related mortality;	chr11:22852659	chr11:22829380~22945393:+
BRCA	cis	rs72772090	0.539	rs11750671	ENSG00000272109.1	CTD-2260A17.3	3.7	0.000231	0.0129	0.23	0.11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96852779	chr5:96804353~96806105:+
BRCA	cis	rs13256369	0.802	rs11249885	ENSG00000248538.5	RP11-10A14.5	-3.7	0.000231	0.0129	-0.12	-0.11	Obesity-related traits;	chr8:8704498	chr8:9189011~9202854:+
BRCA	cis	rs737008	0.959	rs11865598	ENSG00000262636.1	CTD-3088G3.4	3.7	0.000231	0.0129	0.16	0.11	Obesity-related traits;	chr16:11309575	chr16:11380859~11381118:-
BRCA	cis	rs703842	0.616	rs4760332	ENSG00000270039.1	RP11-571M6.17	3.7	0.000231	0.0129	0.17	0.11	Multiple sclerosis;	chr12:57828889	chr12:57803838~57804415:+
BRCA	cis	rs6545883	1	rs6742276	ENSG00000212978.6	AC016747.3	3.7	0.000231	0.0129	0.15	0.11	Tuberculosis;	chr2:61541610	chr2:61141592~61144969:-
BRCA	cis	rs3858526	0.92	rs10742832	ENSG00000224295.2	AC087380.14	3.7	0.000231	0.0129	0.16	0.11	DNA methylation (variation);	chr11:5904790	chr11:5518441~5524955:-
BRCA	cis	rs3858526	0.833	rs4758184	ENSG00000224295.2	AC087380.14	3.7	0.000231	0.0129	0.16	0.11	DNA methylation (variation);	chr11:5905489	chr11:5518441~5524955:-
BRCA	cis	rs11098499	0.775	rs10021601	ENSG00000225892.3	RP11-384K6.2	3.7	0.000231	0.0129	0.11	0.11	Corneal astigmatism;	chr4:119361408	chr4:118632274~118634759:+
BRCA	cis	rs62244186	1	rs62244186	ENSG00000227123.1	RPL12P44	3.7	0.000231	0.0129	0.13	0.11	Depressive symptoms;	chr3:44698291	chr3:44937673~44938482:+
BRCA	cis	rs794185	0.561	rs304036	ENSG00000231249.1	ITPR1-AS1	3.7	0.000231	0.0129	0.13	0.11	Multiple sclerosis--Brain Glutamate Levels;	chr3:4509513	chr3:4490891~4493163:-
BRCA	cis	rs943466	1	rs55775340	ENSG00000223837.2	BRD2-IT1	3.7	0.000231	0.0129	0.14	0.11	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;	chr6:33784007	chr6:32970232~32970886:+
BRCA	cis	rs11170468	1	rs10876418	ENSG00000257718.1	RP11-396F22.1	-3.7	0.000231	0.0129	-0.14	-0.11	Body mass index;	chr12:39035000	chr12:38906451~38909592:+
BRCA	cis	rs12612435	0.83	rs13009321	ENSG00000226806.1	AC011893.3	3.7	0.000231	0.0129	0.14	0.11	Takotsubo syndrome;	chr2:136379672	chr2:135820191~135823087:+
BRCA	cis	rs17711722	0.701	rs55773927	ENSG00000223473.2	GS1-124K5.3	3.7	0.000231	0.0129	0.09	0.11	Calcium levels;	chr7:65872915	chr7:66491049~66493566:-
BRCA	cis	rs7267979	0.966	rs6050567	ENSG00000204556.4	CTD-2514C3.1	3.7	0.000231	0.0129	0.15	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25373925	chr20:26018832~26020684:+
BRCA	cis	rs1865760	0.786	rs1436308	ENSG00000272810.1	U91328.22	-3.7	0.000231	0.0129	-0.13	-0.11	Height;	chr6:25939339	chr6:26013241~26013757:+
BRCA	cis	rs1008375	0.898	rs2079892	ENSG00000249502.1	AC006160.5	-3.7	0.000231	0.0129	-0.13	-0.11	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17575540	chr4:17587467~17614571:-
BRCA	cis	rs1178127	0.659	rs1178149	ENSG00000232821.1	AC003986.6	3.7	0.000231	0.0129	0.16	0.11	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);	chr7:18740049	chr7:19112474~19114271:+
BRCA	cis	rs893818	1	rs2028387	ENSG00000261801.4	LOXL1-AS1	3.7	0.000231	0.0129	0.14	0.11	Exfoliation glaucoma or exfoliation syndrome;	chr15:73934696	chr15:73908071~73928248:-
BRCA	cis	rs6801044	0.741	rs823510	ENSG00000272792.1	RP11-141C7.4	3.7	0.000231	0.0129	0.17	0.11	Creatinine levels in ischemic stroke;	chr3:195535719	chr3:195639990~195640460:+
BRCA	cis	rs2777491	0.507	rs34040639	ENSG00000247556.5	OIP5-AS1	3.7	0.000231	0.0129	0.13	0.11	Ulcerative colitis;	chr15:41468609	chr15:41283990~41309737:+
BRCA	cis	rs7312933	0.702	rs10785333	ENSG00000257225.1	RP11-328C8.4	3.7	0.000231	0.0129	0.14	0.11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42192668	chr12:42459366~42466128:+
BRCA	cis	rs722782	1	rs722782	ENSG00000223508.5	RPL23AP53	3.7	0.000231	0.0129	0.19	0.11	Age-related macular degeneration (geographic atrophy);	chr8:566479	chr8:213186~232231:-
BRCA	cis	rs13434995	0.513	rs7698022	ENSG00000249700.7	SRD5A3-AS1	3.7	0.000231	0.0129	0.16	0.11	Adiponectin levels;	chr4:55541180	chr4:55363971~55395847:-
BRCA	cis	rs4879656	0.797	rs10971389	ENSG00000225693.1	LAGE3P1	-3.7	0.000231	0.0129	-0.13	-0.11	Menopause (age at onset);	chr9:33081125	chr9:33019682~33020165:-
BRCA	cis	rs524281	0.648	rs10896089	ENSG00000255557.1	RP11-770G2.2	3.7	0.000231	0.0129	0.16	0.11	Electroencephalogram traits;	chr11:66168821	chr11:65745729~65771585:+
BRCA	cis	rs863345	0.564	rs4614256	ENSG00000229914.1	RP11-404O13.4	-3.7	0.000231	0.0129	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158494821	chr1:158195633~158196131:-
BRCA	cis	rs863345	0.604	rs4373761	ENSG00000229914.1	RP11-404O13.4	-3.7	0.000231	0.0129	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158494844	chr1:158195633~158196131:-
BRCA	cis	rs863345	0.604	rs11264984	ENSG00000229914.1	RP11-404O13.4	-3.7	0.000231	0.0129	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158495200	chr1:158195633~158196131:-
BRCA	cis	rs863345	0.604	rs10908658	ENSG00000229914.1	RP11-404O13.4	-3.7	0.000231	0.0129	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158495466	chr1:158195633~158196131:-
BRCA	cis	rs863345	0.604	rs10797011	ENSG00000229914.1	RP11-404O13.4	-3.7	0.000231	0.0129	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158495581	chr1:158195633~158196131:-
BRCA	cis	rs672059	1	rs674343	ENSG00000224468.3	RP11-181K3.4	-3.7	0.000231	0.0129	-0.12	-0.11	Hypertriglyceridemia;	chr1:183192917	chr1:183138402~183141282:-
BRCA	cis	rs4388249	0.948	rs13163089	ENSG00000271849.1	CTC-332L22.1	-3.7	0.000231	0.0129	-0.19	-0.11	Schizophrenia;	chr5:109774537	chr5:109687802~109688329:-
BRCA	cis	rs6460942	0.511	rs13245890	ENSG00000226690.5	AC005281.1	3.7	0.000231	0.0129	0.24	0.11	Coronary artery disease;	chr7:12503508	chr7:12496429~12541910:+
BRCA	cis	rs91731	0.79	rs7445720	ENSG00000249572.1	CTD-2203K17.1	3.7	0.000231	0.0129	0.21	0.11	Lung function (FVC);	chr5:33230791	chr5:33424025~33440619:-
BRCA	cis	rs91731	0.79	rs7445791	ENSG00000249572.1	CTD-2203K17.1	3.7	0.000231	0.0129	0.21	0.11	Lung function (FVC);	chr5:33230917	chr5:33424025~33440619:-
BRCA	cis	rs703842	0.616	rs10877023	ENSG00000270039.1	RP11-571M6.17	-3.7	0.000231	0.0129	-0.16	-0.11	Multiple sclerosis;	chr12:57830416	chr12:57803838~57804415:+
BRCA	cis	rs1538970	0.851	rs2055145	ENSG00000281133.1	AL355480.3	-3.7	0.000231	0.0129	-0.16	-0.11	Platelet count;	chr1:45460823	chr1:45580892~45580996:-
BRCA	cis	rs4950322	0.542	rs72692942	ENSG00000227242.3	NBPF13P	-3.7	0.000231	0.0129	-0.16	-0.11	Protein quantitative trait loci;	chr1:147318467	chr1:147021320~147124525:-
BRCA	cis	rs4950322	0.57	rs4950399	ENSG00000227242.3	NBPF13P	-3.7	0.000231	0.0129	-0.16	-0.11	Protein quantitative trait loci;	chr1:147319302	chr1:147021320~147124525:-
BRCA	cis	rs7267979	0.789	rs6083820	ENSG00000125804.12	FAM182A	3.7	0.000231	0.0129	0.15	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25373542	chr20:26054655~26086917:+
BRCA	cis	rs10958369	0.934	rs11781325	ENSG00000260484.1	RP11-1081M5.2	3.7	0.000231	0.0129	0.13	0.11	Response to antineoplastic agents;	chr8:53500119	chr8:53388701~53390872:-
BRCA	cis	rs1642645	0.872	rs639559	ENSG00000228452.1	RP5-994D16.9	-3.69	0.000231	0.0129	-0.15	-0.11	Left ventricular obstructive tract defect (maternal effect);	chr1:41959825	chr1:42775813~42776790:-
BRCA	cis	rs4415084	0.834	rs1438820	ENSG00000251141.4	RP11-53O19.1	3.69	0.000231	0.0129	0.1	0.11	Breast cancer;	chr5:44797668	chr5:44744900~44808777:-
BRCA	cis	rs9923856	0.653	rs9937309	ENSG00000263033.2	RP11-396B14.2	-3.69	0.000231	0.0129	-0.14	-0.11	Atopic dermatitis;Adult asthma;	chr16:11018255	chr16:11196177~11224969:+
BRCA	cis	rs2615061	0.746	rs716966	ENSG00000229965.1	RP11-118H4.1	3.69	0.000231	0.0129	0.2	0.11	Monocyte count;	chr1:225775215	chr1:226438564~226439344:+
BRCA	cis	rs3816183	1	rs1821981	ENSG00000226491.1	FTOP1	-3.69	0.000231	0.0129	-0.14	-0.11	Hypospadias;	chr2:42791776	chr2:42797225~42798712:-
BRCA	cis	rs9470794	1	rs55878533	ENSG00000204110.6	RP1-153P14.8	-3.69	0.000231	0.0129	-0.23	-0.11	Type 2 diabetes;	chr6:38095324	chr6:37507348~37535616:+
BRCA	cis	rs897984	0.572	rs4889526	ENSG00000275263.1	RP11-1072A3.4	-3.69	0.000231	0.0129	-0.13	-0.11	Dementia with Lewy bodies;	chr16:31019023	chr16:30956872~30957199:-
BRCA	cis	rs9470794	1	rs56229452	ENSG00000204110.6	RP1-153P14.8	-3.69	0.000231	0.0129	-0.23	-0.11	Type 2 diabetes;	chr6:38076517	chr6:37507348~37535616:+
BRCA	cis	rs9470794	1	rs73419960	ENSG00000204110.6	RP1-153P14.8	-3.69	0.000231	0.0129	-0.23	-0.11	Type 2 diabetes;	chr6:38079593	chr6:37507348~37535616:+
BRCA	cis	rs4950322	0.57	rs4950409	ENSG00000227242.3	NBPF13P	-3.69	0.000232	0.0129	-0.16	-0.11	Protein quantitative trait loci;	chr1:147335879	chr1:147021320~147124525:-
BRCA	cis	rs4950322	0.57	rs72692980	ENSG00000227242.3	NBPF13P	-3.69	0.000232	0.0129	-0.16	-0.11	Protein quantitative trait loci;	chr1:147337830	chr1:147021320~147124525:-
BRCA	cis	rs2274459	0.841	rs2281919	ENSG00000249346.5	LINC01016	3.69	0.000232	0.0129	0.14	0.11	Obesity (extreme);	chr6:33695394	chr6:33867506~33896914:-
BRCA	cis	rs6490294	0.904	rs9971871	ENSG00000234608.6	MAPKAPK5-AS1	3.69	0.000232	0.0129	0.14	0.11	Mean platelet volume;	chr12:111970572	chr12:111839764~111842902:-
BRCA	cis	rs7771547	0.521	rs2180929	ENSG00000224666.3	RP1-50J22.4	3.69	0.000232	0.0129	0.14	0.11	Platelet distribution width;	chr6:36426310	chr6:36386831~36393462:+
BRCA	cis	rs478304	0.593	rs4645933	ENSG00000255320.1	RP11-755F10.1	3.69	0.000232	0.0129	0.15	0.11	Acne (severe);	chr11:65717649	chr11:66244840~66246239:-
BRCA	cis	rs7572733	0.555	rs6434954	ENSG00000231621.1	AC013264.2	-3.69	0.000232	0.0129	-0.11	-0.11	Dermatomyositis;	chr2:198064992	chr2:197197991~197199273:+
BRCA	cis	rs171748	0.649	rs34628	ENSG00000272308.1	RP11-231G3.1	3.69	0.000232	0.0129	0.14	0.11	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:61231693	chr5:60866457~60866935:-
BRCA	cis	rs2839186	0.619	rs55689527	ENSG00000228137.1	AP001469.7	3.69	0.000232	0.0129	0.12	0.11	Testicular germ cell tumor;	chr21:46202813	chr21:46246890~46247682:+
BRCA	cis	rs2882667	0.69	rs423469	ENSG00000242683.1	CTB-46B19.1	3.69	0.000232	0.0129	0.13	0.11	Age-related hearing impairment (SNP x SNP interaction);	chr5:138898427	chr5:139035148~139035987:-
BRCA	cis	rs1008375	0.966	rs6825133	ENSG00000249502.1	AC006160.5	-3.69	0.000232	0.0129	-0.13	-0.11	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17576153	chr4:17587467~17614571:-
BRCA	cis	rs7267979	1	rs6083862	ENSG00000277938.1	RP5-965G21.3	-3.69	0.000232	0.0129	-0.13	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25430450	chr20:25229150~25231933:+
BRCA	cis	rs7791133	0.667	rs2348775	ENSG00000223718.3	AC093107.7	3.69	0.000232	0.0129	0.14	0.11	Educational attainment (college completion);Educational attainment (years of education);	chr7:135514763	chr7:135660039~135660647:+
BRCA	cis	rs7246657	0.551	rs10407224	ENSG00000267470.4	ZNF571-AS1	3.69	0.000232	0.0129	0.17	0.11	Coronary artery calcification;	chr19:37160568	chr19:37548914~37587348:+
BRCA	cis	rs1032833	0.732	rs17454150	ENSG00000271401.1	RP11-171I2.3	-3.69	0.000232	0.0129	-0.28	-0.11	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);	chr2:179129634	chr2:178644717~178645179:+
BRCA	cis	rs3755605	0.728	rs1386333	ENSG00000242578.1	RP11-469J4.3	3.69	0.000232	0.0129	0.13	0.11	Testicular germ cell tumor;	chr3:170176892	chr3:170410512~170418615:+
BRCA	cis	rs2018683	0.707	rs1021689	ENSG00000233517.1	AC005162.5	-3.69	0.000232	0.0129	-0.14	-0.11	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28934606	chr7:28987028~28988899:+
BRCA	cis	rs11098499	0.82	rs28394116	ENSG00000260091.1	RP11-33B1.4	-3.69	0.000232	0.0129	-0.1	-0.11	Corneal astigmatism;	chr4:119603128	chr4:119409333~119410233:+
BRCA	cis	rs13401620	0.843	rs3106246	ENSG00000229326.3	AC069154.4	3.69	0.000232	0.0129	0.14	0.11	Breast size;	chr2:119820630	chr2:119698623~119700151:+
BRCA	cis	rs9400467	0.922	rs1216019	ENSG00000271789.1	RP5-1112D6.7	-3.69	0.000232	0.0129	-0.14	-0.11	Amino acid levels;Blood metabolite levels;	chr6:111181991	chr6:111297126~111298510:+
BRCA	cis	rs4834770	0.668	rs6833072	ENSG00000248280.1	RP11-33B1.2	-3.69	0.000232	0.0129	-0.11	-0.11	Blood protein levels;	chr4:119212737	chr4:119440561~119450157:-
BRCA	cis	rs2880765	0.835	rs4526974	ENSG00000230373.7	GOLGA6L5P	3.69	0.000232	0.0129	0.12	0.11	Coronary artery disease;	chr15:85481053	chr15:84507885~84516814:-
BRCA	cis	rs4243971	0.516	rs966979	ENSG00000277692.1	RP11-358N2.2	-3.69	0.000232	0.0129	-0.13	-0.11	Inflammatory bowel disease;Crohn's disease;	chr20:32343222	chr20:32355053~32355734:+
BRCA	cis	rs11673344	0.832	rs56080874	ENSG00000267682.1	CTD-3220F14.2	-3.69	0.000232	0.0129	-0.11	-0.11	Obesity-related traits;	chr19:37085487	chr19:37337236~37337743:+
BRCA	cis	rs495337	0.797	rs2025958	ENSG00000224397.4	LINC01272	3.69	0.000232	0.0129	0.12	0.11	Psoriasis;	chr20:49839701	chr20:50267486~50279795:+
BRCA	cis	rs6600233	1	rs6600233	ENSG00000233614.6	DDX11L10	-3.69	0.000232	0.0129	-0.15	-0.11	High light scatter reticulocyte percentage of red cells;	chr16:93505	chr16:11555~14090:+
BRCA	cis	rs6088590	0.561	rs764597	ENSG00000275784.1	RP5-1125A11.6	-3.69	0.000232	0.0129	-0.12	-0.11	Coronary artery disease;	chr20:34573421	chr20:33989480~33991818:-
BRCA	cis	rs2298450	0.55	rs2156416	ENSG00000231106.2	LINC01436	3.69	0.000232	0.0129	0.12	0.11	Schizophrenia;	chr21:36289615	chr21:36005338~36007838:+
BRCA	cis	rs35306767	0.903	rs12244355	ENSG00000229869.1	RP11-363N22.2	-3.69	0.000232	0.0129	-0.17	-0.11	Eosinophil percentage of granulocytes;	chr10:898525	chr10:933026~942743:+
BRCA	cis	rs2439831	0.85	rs8042868	ENSG00000206991.1	RNU6-610P	-3.69	0.000232	0.0129	-0.19	-0.11	Lung cancer in ever smokers;	chr15:43647444	chr15:43637632~43637738:-
BRCA	cis	rs2411233	1	rs8034449	ENSG00000259278.1	RP11-62C7.2	3.69	0.000232	0.0129	0.13	0.11	Platelet count;	chr15:38986739	chr15:39019233~39024918:+
BRCA	cis	rs7045881	0.696	rs10812500	ENSG00000254396.1	RP11-56F10.3	3.69	0.000232	0.0129	0.16	0.11	Schizophrenia;	chr9:26946578	chr9:27102630~27104728:+
BRCA	cis	rs2731006	0.901	rs2731007	ENSG00000257114.2	RP11-25I15.3	-3.69	0.000232	0.0129	-0.18	-0.11	Panic disorder;	chr12:42767101	chr12:42692216~42717119:+
BRCA	cis	rs12701220	0.894	rs8591	ENSG00000224079.1	AC091729.7	3.69	0.000232	0.0129	0.18	0.11	Bronchopulmonary dysplasia;	chr7:997163	chr7:1074450~1078036:+
BRCA	cis	rs804280	0.56	rs10503426	ENSG00000254948.1	OR7E158P	-3.69	0.000232	0.0129	-0.14	-0.11	Myopia (pathological);	chr8:11731874	chr8:11919900~11920809:-
BRCA	cis	rs16893526	0.649	rs9341901	ENSG00000224995.1	LINC01526	-3.69	0.000232	0.0129	-0.18	-0.11	Coronary heart disease;	chr6:81813053	chr6:81813286~81814157:-
BRCA	cis	rs7947761	0.953	rs17095426	ENSG00000254506.1	RP11-748H22.1	3.69	0.000232	0.0129	0.13	0.11	Coronary artery disease;	chr11:100767872	chr11:101584295~101595156:+
BRCA	cis	rs7267979	1	rs404394	ENSG00000277938.1	RP5-965G21.3	3.69	0.000232	0.0129	0.14	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25467260	chr20:25229150~25231933:+
BRCA	cis	rs11168618	0.765	rs7301368	ENSG00000240399.1	RP1-228P16.1	3.69	0.000232	0.0129	0.12	0.11	Adiponectin levels;	chr12:48533009	chr12:48054813~48055591:-
BRCA	cis	rs2562456	0.72	rs6511250	ENSG00000213976.4	CTD-2561J22.2	3.69	0.000232	0.0129	0.14	0.11	Pain;	chr19:21473244	chr19:21382865~21387177:+
BRCA	cis	rs660899	0.857	rs3791047	ENSG00000229431.1	RP1-92O14.6	-3.69	0.000232	0.0129	-0.12	-0.11	Hypertension risk in short sleep duration;	chr1:43770443	chr1:43385113~43389155:+
BRCA	cis	rs9472719	0.891	rs6918355	ENSG00000231769.2	RP1-8B1.4	3.69	0.000232	0.0129	0.16	0.11	Total cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;	chr6:46187917	chr6:46097093~46129706:-
BRCA	cis	rs11673344	0.504	rs2595555	ENSG00000276846.1	CTD-3220F14.3	3.69	0.000232	0.0129	0.13	0.11	Obesity-related traits;	chr19:37000219	chr19:37314868~37315620:-
BRCA	cis	rs11673344	0.504	rs1667377	ENSG00000276846.1	CTD-3220F14.3	3.69	0.000232	0.0129	0.13	0.11	Obesity-related traits;	chr19:37000966	chr19:37314868~37315620:-
BRCA	cis	rs11673344	0.523	rs1667379	ENSG00000276846.1	CTD-3220F14.3	3.69	0.000232	0.0129	0.13	0.11	Obesity-related traits;	chr19:37001192	chr19:37314868~37315620:-
BRCA	cis	rs7267979	1	rs6037095	ENSG00000274973.1	RP13-401N8.7	3.69	0.000232	0.0129	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25355051	chr20:25845497~25845862:+
BRCA	cis	rs7267979	1	rs6050562	ENSG00000274973.1	RP13-401N8.7	3.69	0.000232	0.0129	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25355550	chr20:25845497~25845862:+
BRCA	cis	rs7120173	1	rs7120173	ENSG00000280143.1	AP000892.6	-3.69	0.000232	0.0129	-0.14	-0.11	Visceral adipose tissue adjusted for BMI;	chr11:116958937	chr11:117204967~117210292:+
BRCA	cis	rs1949733	1	rs3103072	ENSG00000205959.3	RP11-689P11.2	3.69	0.000232	0.0129	0.11	0.11	Response to antineoplastic agents;	chr4:8506704	chr4:8482270~8512610:+
BRCA	cis	rs6071524	0.517	rs1006945	ENSG00000224635.1	RP4-564F22.5	-3.69	0.000232	0.0129	-0.13	-0.11	Autism spectrum disorder or schizophrenia;	chr20:38829366	chr20:38406011~38416797:-
BRCA	cis	rs216345	0.966	rs1971430	ENSG00000260947.1	RP11-384P7.7	-3.69	0.000232	0.0129	-0.12	-0.11	Bipolar disorder;	chr9:33782377	chr9:33697459~33700986:+
BRCA	cis	rs7412746	0.658	rs10305704	ENSG00000231073.1	RP11-316M1.3	3.69	0.000232	0.0129	0.12	0.11	Melanoma;	chr1:150831953	chr1:150973123~150975534:+
BRCA	cis	rs35306767	0.903	rs12249634	ENSG00000229869.1	RP11-363N22.2	-3.69	0.000232	0.0129	-0.18	-0.11	Eosinophil percentage of granulocytes;	chr10:826804	chr10:933026~942743:+
BRCA	cis	rs58521262	0.556	rs380541	ENSG00000268105.1	RP11-369G6.2	3.69	0.000232	0.0129	0.16	0.11	Testicular germ cell tumor;	chr19:22936129	chr19:23125665~23128543:+
BRCA	cis	rs80028505	0.908	rs61763101	ENSG00000271304.1	DPRXP2	3.69	0.000232	0.0129	0.22	0.11	Foot ulcer in diabetes and neuropathy;	chr6:36028636	chr6:35989515~35990436:-
BRCA	cis	rs7520050	0.966	rs1707321	ENSG00000234329.1	RP11-767N6.2	-3.69	0.000232	0.0129	-0.11	-0.11	Reticulocyte count;Red blood cell count;	chr1:46039637	chr1:45651039~45651826:-
BRCA	cis	rs78487399	0.52	rs7609256	ENSG00000234936.1	AC010883.5	3.69	0.000232	0.0129	0.17	0.11	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43445360	chr2:43229573~43233394:+
BRCA	cis	rs11098499	0.909	rs9759478	ENSG00000260404.2	RP11-384K6.6	3.69	0.000232	0.0129	0.11	0.11	Corneal astigmatism;	chr4:119446843	chr4:118591773~118633729:+
BRCA	cis	rs2991971	0.933	rs12568144	ENSG00000280836.1	AL355480.1	3.69	0.000232	0.0129	0.13	0.11	High light scatter reticulocyte count;	chr1:45499635	chr1:45581219~45581321:-
BRCA	cis	rs4664293	0.647	rs1425042	ENSG00000226266.5	AC009961.3	-3.69	0.000232	0.0129	-0.13	-0.11	Monocyte percentage of white cells;	chr2:159584004	chr2:159670708~159712435:-
BRCA	cis	rs4664293	0.647	rs7562850	ENSG00000226266.5	AC009961.3	-3.69	0.000232	0.0129	-0.13	-0.11	Monocyte percentage of white cells;	chr2:159585023	chr2:159670708~159712435:-
BRCA	cis	rs7267979	1	rs4815407	ENSG00000274973.1	RP13-401N8.7	3.69	0.000232	0.0129	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25360842	chr20:25845497~25845862:+
BRCA	cis	rs13401620	0.871	rs6542552	ENSG00000229326.3	AC069154.4	3.69	0.000232	0.0129	0.15	0.11	Breast size;	chr2:119933166	chr2:119698623~119700151:+
BRCA	cis	rs10005067	0.967	rs4693902	ENSG00000249001.4	RP11-742B18.1	-3.69	0.000233	0.013	-0.13	-0.11	Total body bone mineral density (age 30-45);	chr4:87898000	chr4:87568035~87733956:-
BRCA	cis	rs10005067	0.967	rs12511140	ENSG00000249001.4	RP11-742B18.1	-3.69	0.000233	0.013	-0.13	-0.11	Total body bone mineral density (age 30-45);	chr4:87898272	chr4:87568035~87733956:-
BRCA	cis	rs10005067	0.967	rs12503426	ENSG00000249001.4	RP11-742B18.1	-3.69	0.000233	0.013	-0.13	-0.11	Total body bone mineral density (age 30-45);	chr4:87898385	chr4:87568035~87733956:-
BRCA	cis	rs721917	0.569	rs2247820	ENSG00000225484.5	NUTM2B-AS1	-3.69	0.000233	0.013	-0.15	-0.11	Chronic obstructive pulmonary disease;	chr10:79963123	chr10:79663088~79826594:-
BRCA	cis	rs7520050	0.966	rs1085244	ENSG00000281133.1	AL355480.3	3.69	0.000233	0.013	0.13	0.11	Reticulocyte count;Red blood cell count;	chr1:46098008	chr1:45580892~45580996:-
BRCA	cis	rs7520050	0.966	rs6662641	ENSG00000281133.1	AL355480.3	3.69	0.000233	0.013	0.13	0.11	Reticulocyte count;Red blood cell count;	chr1:46105837	chr1:45580892~45580996:-
BRCA	cis	rs7520050	0.966	rs1707335	ENSG00000281133.1	AL355480.3	3.69	0.000233	0.013	0.13	0.11	Reticulocyte count;Red blood cell count;	chr1:46106249	chr1:45580892~45580996:-
BRCA	cis	rs2991971	0.782	rs10789463	ENSG00000280836.1	AL355480.1	-3.69	0.000233	0.013	-0.13	-0.11	High light scatter reticulocyte count;	chr1:45462176	chr1:45581219~45581321:-
BRCA	cis	rs6545883	0.794	rs12053388	ENSG00000273302.1	RP11-493E12.2	-3.69	0.000233	0.013	-0.11	-0.11	Tuberculosis;	chr2:61305185	chr2:61199979~61200769:+
BRCA	cis	rs62344088	1	rs6872393	ENSG00000277812.1	AC021087.1	-3.69	0.000233	0.013	-0.29	-0.11	Asthma (childhood onset);	chr5:155739	chr5:262769~262881:+
BRCA	cis	rs34792	0.524	rs34629185	ENSG00000258354.1	MIR3180-1	-3.69	0.000233	0.013	-0.16	-0.11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15517597	chr16:14909887~14911345:-
BRCA	cis	rs4660456	0.572	rs1008204	ENSG00000272145.1	NFYC-AS1	-3.69	0.000233	0.013	-0.11	-0.11	Platelet count;	chr1:40700189	chr1:40690380~40692066:-
BRCA	cis	rs6125597	0.516	rs6019537	ENSG00000230758.1	SNAP23P	-3.69	0.000233	0.013	-0.13	-0.11	Intelligence (multi-trait analysis);	chr20:48927067	chr20:49038357~49038602:-
BRCA	cis	rs1528472	0.836	rs8042768	ENSG00000276533.1	RP11-139H15.5	3.69	0.000233	0.013	0.13	0.11	Urinary albumin-to-creatinine ratio;Urinary albumin-to-creatinine ratio in non-diabetics;	chr15:55017885	chr15:55288849~55289346:-
BRCA	cis	rs7267979	0.966	rs2261795	ENSG00000276952.1	RP5-965G21.6	3.69	0.000233	0.013	0.14	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25282500	chr20:25284915~25285588:-
BRCA	cis	rs12324805	0.568	rs8039459	ENSG00000255769.6	GOLGA2P10	-3.69	0.000233	0.013	-0.13	-0.11	Body mass index;	chr15:82028085	chr15:82472993~82513950:-
BRCA	cis	rs7165170	0.529	rs3743406	ENSG00000245479.2	LINC01585	3.69	0.000233	0.013	0.14	0.11	Crohn's disease;Inflammatory bowel disease;	chr15:90618316	chr15:90660234~90664967:+
BRCA	cis	rs3781264	0.595	rs7085378	ENSG00000268894.5	PLCE1-AS1	-3.69	0.000233	0.013	-0.15	-0.11	Esophageal cancer and gastric cancer;	chr10:94349568	chr10:94279277~94287478:-
BRCA	cis	rs2298450	0.575	rs2268299	ENSG00000231106.2	LINC01436	3.69	0.000233	0.013	0.12	0.11	Schizophrenia;	chr21:36287863	chr21:36005338~36007838:+
BRCA	cis	rs7959452	0.649	rs4761239	ENSG00000274979.1	RP11-1143G9.5	-3.69	0.000233	0.013	-0.12	-0.11	Blood protein levels;	chr12:69383106	chr12:69326574~69331882:-
BRCA	cis	rs11098499	0.863	rs1383533	ENSG00000260091.1	RP11-33B1.4	-3.69	0.000233	0.013	-0.1	-0.11	Corneal astigmatism;	chr4:119513421	chr4:119409333~119410233:+
BRCA	cis	rs860295	0.58	rs867550	ENSG00000225082.2	DAP3P1	-3.69	0.000233	0.013	-0.15	-0.11	Body mass index;	chr1:155910600	chr1:155586644~155602197:+
BRCA	cis	rs7267979	1	rs6107033	ENSG00000204556.4	CTD-2514C3.1	3.69	0.000233	0.013	0.15	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25382955	chr20:26018832~26020684:+
BRCA	cis	rs10129255	0.957	rs10150241	ENSG00000211967.3	IGHV3-53	3.69	0.000233	0.013	0.08	0.11	Kawasaki disease;	chr14:106775945	chr14:106592676~106593347:-
BRCA	cis	rs17169635	0.765	rs1014832	ENSG00000272941.1	RP11-134L10.1	3.69	0.000233	0.013	0.13	0.11	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);	chr7:134887921	chr7:135168403~135169547:+
BRCA	cis	rs6044112	0.718	rs73101048	ENSG00000273998.1	RP4-777L9.2	3.69	0.000233	0.013	0.2	0.11	Response to taxane treatment (docetaxel);	chr20:16530595	chr20:16576068~16579615:+
BRCA	cis	rs801193	0.761	rs2659888	ENSG00000232546.1	RP11-458F8.1	-3.69	0.000233	0.013	-0.09	-0.11	Aortic root size;	chr7:66765184	chr7:66848496~66858136:+
BRCA	cis	rs34792	0.554	rs12918517	ENSG00000275910.1	RP11-680G24.6	-3.69	0.000233	0.013	-0.14	-0.11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15532974	chr16:15015828~15016390:-
BRCA	cis	rs853679	0.517	rs9393887	ENSG00000226314.6	ZNF192P1	-3.69	0.000233	0.013	-0.17	-0.11	Depression;	chr6:28091242	chr6:28161781~28169594:+
BRCA	cis	rs12303914	0.502	rs61917598	ENSG00000256682.2	TAS2R12	3.69	0.000233	0.013	0.15	0.11	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr12:10301724	chr12:10894943~10896952:-
BRCA	cis	rs11158026	0.567	rs61224609	ENSG00000233924.1	AL160471.6	-3.69	0.000233	0.013	-0.14	-0.11	Parkinson's disease;	chr14:54936490	chr14:55004813~55005687:-
BRCA	cis	rs721917	0.506	rs2758556	ENSG00000280355.1	RP11-119F19.5	3.69	0.000233	0.013	0.12	0.11	Chronic obstructive pulmonary disease;	chr10:79931229	chr10:79681973~79684094:-
BRCA	cis	rs8141529	0.748	rs5762882	ENSG00000272858.1	CTA-292E10.8	-3.69	0.000233	0.013	-0.15	-0.11	Lymphocyte counts;	chr22:28894692	chr22:28814914~28815662:+
BRCA	cis	rs7312933	0.576	rs11181364	ENSG00000257225.1	RP11-328C8.4	-3.69	0.000233	0.013	-0.14	-0.11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42173998	chr12:42459366~42466128:+
BRCA	cis	rs13126694	0.743	rs12512643	ENSG00000251073.1	NUDT19P5	3.69	0.000233	0.013	0.11	0.11	Blood osmolality (transformed sodium);	chr4:158115588	chr4:158182825~158183393:+
BRCA	cis	rs853679	1	rs1778511	ENSG00000216901.1	AL022393.7	-3.69	0.000233	0.013	-0.19	-0.11	Depression;	chr6:28261633	chr6:28176188~28176674:+
BRCA	cis	rs6490294	0.571	rs12300496	ENSG00000257624.1	RP1-128M12.3	3.69	0.000233	0.013	0.19	0.11	Mean platelet volume;	chr12:112012629	chr12:112000739~112000985:-
BRCA	cis	rs7914558	0.752	rs7896519	ENSG00000213277.3	MARCKSL1P1	3.69	0.000233	0.013	0.13	0.11	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103107106	chr10:103175554~103176094:+
BRCA	cis	rs6993270	0.725	rs7016479	ENSG00000245330.4	KB-1471A8.1	-3.69	0.000233	0.013	-0.18	-0.11	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr8:119913927	chr8:119867419~119874488:-
BRCA	cis	rs6993270	0.725	rs7016372	ENSG00000245330.4	KB-1471A8.1	-3.69	0.000233	0.013	-0.18	-0.11	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr8:119913977	chr8:119867419~119874488:-
BRCA	cis	rs6993270	0.725	rs6983678	ENSG00000245330.4	KB-1471A8.1	-3.69	0.000233	0.013	-0.18	-0.11	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr8:119914835	chr8:119867419~119874488:-
BRCA	cis	rs6993270	0.779	rs6988573	ENSG00000245330.4	KB-1471A8.1	-3.69	0.000233	0.013	-0.18	-0.11	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr8:119915619	chr8:119867419~119874488:-
BRCA	cis	rs1722141	0.633	rs2471552	ENSG00000237471.1	AC073115.6	3.69	0.000233	0.013	0.15	0.11	Sitting height ratio;	chr7:45937574	chr7:45969657~45980191:+
BRCA	cis	rs801193	1	rs4717319	ENSG00000275400.1	RP4-756H11.5	-3.69	0.000233	0.013	-0.13	-0.11	Aortic root size;	chr7:66777606	chr7:66553805~66554199:-
BRCA	cis	rs4950322	0.57	rs72692907	ENSG00000227242.3	NBPF13P	-3.69	0.000233	0.013	-0.16	-0.11	Protein quantitative trait loci;	chr1:147301921	chr1:147021320~147124525:-
BRCA	cis	rs4950322	0.57	rs72692914	ENSG00000227242.3	NBPF13P	-3.69	0.000233	0.013	-0.16	-0.11	Protein quantitative trait loci;	chr1:147302946	chr1:147021320~147124525:-
BRCA	cis	rs10938353	0.906	rs6829080	ENSG00000273369.1	RP11-700J17.1	-3.69	0.000233	0.013	-0.13	-0.11	Body mass index;	chr4:44585378	chr4:44693946~44694386:-
BRCA	cis	rs10129255	1	rs4612959	ENSG00000232216.1	IGHV3-43	3.69	0.000233	0.013	0.09	0.11	Kawasaki disease;	chr14:106767055	chr14:106470264~106470800:-
BRCA	cis	rs694419	0.679	rs637828	ENSG00000278017.1	RP11-120K19.4	-3.69	0.000233	0.013	-0.14	-0.11	Serum albumin level;	chr18:62486056	chr18:62525919~62526325:-
BRCA	cis	rs11892454	0.565	rs6758088	ENSG00000217643.1	PTGES3P2	3.69	0.000233	0.013	0.12	0.11	Heschl's gyrus morphology;	chr2:25813167	chr2:25822469~25822950:+
BRCA	cis	rs1106529	0.528	rs1779445	ENSG00000231365.4	RP11-418J17.1	-3.69	0.000233	0.013	-0.17	-0.11	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);	chr1:118965789	chr1:119140396~119275973:+
BRCA	cis	rs4415084	0.744	rs1371023	ENSG00000248779.1	RP11-53O19.2	-3.69	0.000233	0.013	-0.1	-0.11	Breast cancer;	chr5:44846473	chr5:44752949~44765744:+
BRCA	cis	rs12915845	0.545	rs4407042	ENSG00000271997.1	RP11-97O12.6	-3.69	0.000233	0.013	-0.09	-0.11	Menarche (age at onset);	chr15:88534654	chr15:88501944~88505787:-
BRCA	cis	rs7647973	0.626	rs62262672	ENSG00000228008.1	CTD-2330K9.3	3.69	0.000233	0.013	0.16	0.11	Menarche (age at onset);	chr3:49618494	chr3:49903845~49916937:+
BRCA	cis	rs75804782	0.641	rs72983853	ENSG00000186235.9	AC016757.3	3.69	0.000233	0.013	0.25	0.11	Chronotype;Morning vs. evening chronotype;	chr2:238415569	chr2:238224552~238231677:-
BRCA	cis	rs7818688	1	rs28406132	ENSG00000245080.5	RP11-320N21.1	-3.69	0.000233	0.013	-0.19	-0.11	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95018149	chr8:95066808~95073182:-
BRCA	cis	rs2243480	1	rs6460260	ENSG00000226767.1	RP11-328P23.3	3.69	0.000233	0.013	0.2	0.11	Diabetic kidney disease;	chr7:65750468	chr7:65508773~65508944:-
BRCA	cis	rs2243480	1	rs6460261	ENSG00000226767.1	RP11-328P23.3	3.69	0.000233	0.013	0.2	0.11	Diabetic kidney disease;	chr7:65750593	chr7:65508773~65508944:-
BRCA	cis	rs10129255	0.912	rs6576227	ENSG00000211967.3	IGHV3-53	-3.69	0.000233	0.013	-0.08	-0.11	Kawasaki disease;	chr14:106778202	chr14:106592676~106593347:-
BRCA	cis	rs10129255	0.957	rs6576228	ENSG00000211967.3	IGHV3-53	-3.69	0.000233	0.013	-0.08	-0.11	Kawasaki disease;	chr14:106778401	chr14:106592676~106593347:-
BRCA	cis	rs12724450	0.793	rs74922169	ENSG00000228126.1	FALEC	3.69	0.000233	0.013	0.2	0.11	Blood protein levels;	chr1:150392482	chr1:150515757~150518032:+
BRCA	cis	rs12724450	0.793	rs7546610	ENSG00000228126.1	FALEC	3.69	0.000233	0.013	0.2	0.11	Blood protein levels;	chr1:150395093	chr1:150515757~150518032:+
BRCA	cis	rs10844706	0.699	rs11052717	ENSG00000278635.1	CTD-2318O12.1	-3.69	0.000233	0.013	-0.13	-0.11	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9726217	chr12:9415641~9416718:+
BRCA	cis	rs7620503	1	rs6806363	ENSG00000228561.2	RP11-114M1.1	3.69	0.000233	0.013	0.13	0.11	Corneal structure;	chr3:177576293	chr3:177683627~177691250:+
BRCA	cis	rs7176093	1	rs72757353	ENSG00000259295.5	CSPG4P12	-3.69	0.000233	0.013	-0.16	-0.11	Aging traits;	chr15:85832411	chr15:85191438~85213905:+
BRCA	cis	rs1371614	0.61	rs3820822	ENSG00000229122.1	AGBL5-IT1	-3.69	0.000234	0.013	-0.12	-0.11	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26932994	chr2:27061038~27061815:+
BRCA	cis	rs10028773	0.546	rs13117947	ENSG00000260404.2	RP11-384K6.6	3.69	0.000234	0.013	0.1	0.11	Educational attainment;	chr4:119335905	chr4:118591773~118633729:+
BRCA	cis	rs804280	0.525	rs1004712	ENSG00000270154.1	RP11-419I17.1	3.69	0.000234	0.013	0.13	0.11	Myopia (pathological);	chr8:11764784	chr8:12476462~12477122:+
BRCA	cis	rs863345	0.604	rs7514968	ENSG00000229914.1	RP11-404O13.4	-3.69	0.000234	0.013	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158524062	chr1:158195633~158196131:-
BRCA	cis	rs863345	0.604	rs7525362	ENSG00000229914.1	RP11-404O13.4	-3.69	0.000234	0.013	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158524100	chr1:158195633~158196131:-
BRCA	cis	rs6600671	1	rs12145080	ENSG00000275131.1	CH17-472G23.4	3.69	0.000234	0.013	0.1	0.11	Hip geometry;	chr1:121443673	chr1:120489625~120579190:-
BRCA	cis	rs757081	0.648	rs10832752	ENSG00000272034.1	SNORD14A	-3.69	0.000234	0.013	-0.12	-0.11	Systolic blood pressure;	chr11:17263940	chr11:17074654~17074744:-
BRCA	cis	rs10435719	0.902	rs4840599	ENSG00000254866.2	DEFB109P3	3.69	0.000234	0.013	0.15	0.11	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11947871	chr8:12150895~12151134:-
BRCA	cis	rs7267979	1	rs6037095	ENSG00000276952.1	RP5-965G21.6	-3.69	0.000234	0.013	-0.14	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25355051	chr20:25284915~25285588:-
BRCA	cis	rs7267979	1	rs6050562	ENSG00000276952.1	RP5-965G21.6	-3.69	0.000234	0.013	-0.14	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25355550	chr20:25284915~25285588:-
BRCA	cis	rs10129255	0.5	rs11627315	ENSG00000211976.2	IGHV3-73	-3.69	0.000234	0.013	-0.09	-0.11	Kawasaki disease;	chr14:106802182	chr14:106802694~106803233:-
BRCA	cis	rs10819861	0.645	rs4743527	ENSG00000175611.10	LINC00476	3.69	0.000234	0.013	0.12	0.11	Electrocardiographic traits;	chr9:96088793	chr9:95759231~95875977:-
BRCA	cis	rs2839186	0.749	rs62226488	ENSG00000215424.8	MCM3AP-AS1	3.69	0.000234	0.013	0.1	0.11	Testicular germ cell tumor;	chr21:46290603	chr21:46229217~46259390:+
BRCA	cis	rs2839186	0.749	rs62226489	ENSG00000215424.8	MCM3AP-AS1	3.69	0.000234	0.013	0.1	0.11	Testicular germ cell tumor;	chr21:46290605	chr21:46229217~46259390:+
BRCA	cis	rs9868809	0.772	rs13070798	ENSG00000223343.1	RP13-131K19.2	3.69	0.000234	0.013	0.15	0.11	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48668501	chr3:48985049~48989988:-
BRCA	cis	rs11673344	0.504	rs1667378	ENSG00000276846.1	CTD-3220F14.3	3.69	0.000234	0.013	0.14	0.11	Obesity-related traits;	chr19:37001171	chr19:37314868~37315620:-
BRCA	cis	rs854765	0.647	rs854769	ENSG00000197815.4	RP1-253P7.4	3.69	0.000234	0.013	0.08	0.11	Total body bone mineral density;	chr17:18115697	chr17:17858227~17860041:+
BRCA	cis	rs7302981	0.746	rs2272391	ENSG00000272368.2	RP4-605O3.4	-3.69	0.000234	0.013	-0.12	-0.11	Systolic blood pressure;	chr12:50077847	chr12:50112197~50165618:+
BRCA	cis	rs672059	1	rs479994	ENSG00000224468.3	RP11-181K3.4	-3.69	0.000234	0.013	-0.12	-0.11	Hypertriglyceridemia;	chr1:183192594	chr1:183138402~183141282:-
BRCA	cis	rs672059	1	rs480132	ENSG00000224468.3	RP11-181K3.4	-3.69	0.000234	0.013	-0.12	-0.11	Hypertriglyceridemia;	chr1:183192644	chr1:183138402~183141282:-
BRCA	cis	rs801193	1	rs11773829	ENSG00000232546.1	RP11-458F8.1	3.69	0.000234	0.013	0.09	0.11	Aortic root size;	chr7:66676087	chr7:66848496~66858136:+
BRCA	cis	rs7267979	0.789	rs2260197	ENSG00000125804.12	FAM182A	-3.69	0.000234	0.013	-0.15	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25303707	chr20:26054655~26086917:+
BRCA	cis	rs7620503	0.959	rs2863014	ENSG00000231574.4	RP11-91K9.1	3.69	0.000234	0.013	0.13	0.11	Corneal structure;	chr3:177585404	chr3:177816865~177899224:+
BRCA	cis	rs7461897	0.511	rs1383916	ENSG00000228451.3	SDAD1P1	3.69	0.000234	0.013	0.19	0.11	Epilepsy and lamotrigine-induced maculopapular eruptions;	chr8:26967728	chr8:26379259~26382953:-
BRCA	cis	rs962856	0.515	rs588454	ENSG00000236780.4	AC078941.1	3.69	0.000234	0.013	0.14	0.11	Pancreatic cancer;	chr2:67451550	chr2:67123357~67215319:-
BRCA	cis	rs1865760	0.892	rs9379806	ENSG00000272810.1	U91328.22	-3.69	0.000234	0.013	-0.13	-0.11	Height;	chr6:25940730	chr6:26013241~26013757:+
BRCA	cis	rs7572733	0.935	rs10207433	ENSG00000231621.1	AC013264.2	-3.69	0.000234	0.013	-0.11	-0.11	Dermatomyositis;	chr2:197941206	chr2:197197991~197199273:+
BRCA	cis	rs7829975	0.688	rs7817376	ENSG00000173295.6	FAM86B3P	-3.69	0.000234	0.013	-0.12	-0.11	Mood instability;	chr8:8523020	chr8:8228595~8244865:+
BRCA	cis	rs3743102	1	rs3803383	ENSG00000259429.4	UBE2Q2P2	3.69	0.000234	0.013	0.15	0.11	Colorectal adenoma (advanced);	chr15:82754741	chr15:82355142~82420075:+
BRCA	cis	rs8099996	0.651	rs876794	ENSG00000267277.1	CTD-2342J14.6	3.69	0.000234	0.013	0.14	0.11	Inflammatory skin disease;	chr19:11066083	chr19:11368123~11374935:-
BRCA	cis	rs7705042	0.581	rs17649451	ENSG00000280047.1	CTC-463A16.1	-3.69	0.000234	0.013	-0.13	-0.11	Asthma;	chr5:142169971	chr5:142165767~142168387:+
BRCA	cis	rs6671200	0.607	rs6671408	ENSG00000226026.4	RP11-57H12.3	-3.69	0.000234	0.013	-0.17	-0.11	Stearic acid (18:0) levels;	chr1:95231535	chr1:95163219~95233982:-
BRCA	cis	rs4243971	0.557	rs1984792	ENSG00000275576.1	RP5-836N17.4	-3.69	0.000234	0.013	-0.13	-0.11	Inflammatory bowel disease;Crohn's disease;	chr20:32279465	chr20:32116171~32116629:+
BRCA	cis	rs2243480	1	rs160646	ENSG00000237026.1	RP11-328P23.2	3.69	0.000234	0.013	0.21	0.11	Diabetic kidney disease;	chr7:66091293	chr7:65235790~65236723:-
BRCA	cis	rs295490	0.748	rs77036655	ENSG00000178631.7	ACTG1P1	-3.69	0.000234	0.013	-0.22	-0.11	PR interval in Tripanosoma cruzi seropositivity;	chr3:139436231	chr3:139493809~139494937:+
BRCA	cis	rs1008375	0.932	rs12500947	ENSG00000249502.1	AC006160.5	-3.69	0.000234	0.013	-0.13	-0.11	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17601801	chr4:17587467~17614571:-
BRCA	cis	rs804280	0.56	rs10503426	ENSG00000270154.1	RP11-419I17.1	3.69	0.000234	0.013	0.14	0.11	Myopia (pathological);	chr8:11731874	chr8:12476462~12477122:+
BRCA	cis	rs1156327	0.51	rs8051268	ENSG00000188477.11	AC003003.5	-3.69	0.000234	0.013	-0.24	-0.11	Periodontal disease-related phenotypes;	chr16:19318866	chr16:19285783~19310947:+
BRCA	cis	rs4648045	0.765	rs3774967	ENSG00000246560.2	RP11-10L12.4	3.69	0.000234	0.013	0.13	0.11	Lymphocyte percentage of white cells;	chr4:102604774	chr4:102828055~102844075:+
BRCA	cis	rs9467773	0.506	rs9393709	ENSG00000124549.13	BTN2A3P	-3.69	0.000234	0.013	-0.12	-0.11	Intelligence (multi-trait analysis);	chr6:26364919	chr6:26421391~26432383:+
BRCA	cis	rs9467773	0.526	rs12199613	ENSG00000124549.13	BTN2A3P	-3.69	0.000234	0.013	-0.12	-0.11	Intelligence (multi-trait analysis);	chr6:26366990	chr6:26421391~26432383:+
BRCA	cis	rs9467773	0.526	rs9688946	ENSG00000124549.13	BTN2A3P	-3.69	0.000234	0.013	-0.12	-0.11	Intelligence (multi-trait analysis);	chr6:26367217	chr6:26421391~26432383:+
BRCA	cis	rs516805	0.528	rs2679708	ENSG00000279114.1	RP3-425C14.5	3.69	0.000234	0.013	0.13	0.11	Lymphocyte counts;	chr6:122079365	chr6:122471923~122484161:+
BRCA	cis	rs7608910	0.896	rs1962449	ENSG00000237522.1	NONOP2	-3.69	0.000234	0.013	-0.11	-0.11	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;	chr2:60975414	chr2:60936819~60938049:-
BRCA	cis	rs17270561	0.609	rs9467572	ENSG00000272462.2	U91328.19	3.69	0.000234	0.013	0.14	0.11	Iron status biomarkers;	chr6:25703898	chr6:25992662~26001775:+
BRCA	cis	rs7903456	0.648	rs9421565	ENSG00000224914.2	LINC00863	-3.69	0.000234	0.013	-0.14	-0.11	Gout;Renal underexcretion gout;	chr10:87045655	chr10:87342736~87357882:+
BRCA	cis	rs613391	0.561	rs496615	ENSG00000265194.1	RP11-70L8.4	-3.69	0.000234	0.013	-0.11	-0.11	Quantitative traits;	chr9:22718466	chr9:21858910~21861926:-
BRCA	cis	rs10777288	0.561	rs1920752	ENSG00000258100.1	RP11-121E16.1	3.69	0.000234	0.013	0.15	0.11	Pulmonary function (smoking interaction);	chr12:91000205	chr12:91362196~91368606:+
BRCA	cis	rs10777288	0.561	rs1920751	ENSG00000258100.1	RP11-121E16.1	3.69	0.000234	0.013	0.15	0.11	Pulmonary function (smoking interaction);	chr12:91000519	chr12:91362196~91368606:+
BRCA	cis	rs11098499	0.82	rs13122709	ENSG00000260091.1	RP11-33B1.4	-3.69	0.000234	0.013	-0.1	-0.11	Corneal astigmatism;	chr4:119634201	chr4:119409333~119410233:+
BRCA	cis	rs2505998	0.871	rs2505987	ENSG00000273008.1	RP11-351D16.3	-3.69	0.000234	0.013	-0.14	-0.11	Hirschsprung disease;	chr10:43064631	chr10:43136824~43138334:-
BRCA	cis	rs672059	1	rs563026	ENSG00000224468.3	RP11-181K3.4	3.69	0.000234	0.013	0.12	0.11	Hypertriglyceridemia;	chr1:183191902	chr1:183138402~183141282:-
BRCA	cis	rs13434995	0.513	rs62303711	ENSG00000273257.1	RP11-177J6.1	-3.69	0.000234	0.013	-0.17	-0.11	Adiponectin levels;	chr4:55458325	chr4:55387949~55388271:+
BRCA	cis	rs6599077	0.574	rs73067612	ENSG00000223797.4	ENTPD3-AS1	3.69	0.000234	0.013	0.15	0.11	Sleep-related phenotypes;	chr3:40144666	chr3:40313802~40453329:-
BRCA	cis	rs11686241	0.935	rs284530	ENSG00000232485.2	AC098820.3	3.69	0.000234	0.013	0.16	0.11	Cancer;	chr2:216468816	chr2:216479030~216498761:-
BRCA	cis	rs13434995	0.513	rs2412658	ENSG00000249700.7	SRD5A3-AS1	3.69	0.000234	0.013	0.16	0.11	Adiponectin levels;	chr4:55577050	chr4:55363971~55395847:-
BRCA	cis	rs7546	0.501	rs12102426	ENSG00000267077.1	RP11-127I20.5	3.69	0.000234	0.013	0.11	0.11	Cancer;	chr16:4872449	chr16:4795265~4796532:-
BRCA	cis	rs6785206	0.667	rs6439139	ENSG00000242551.2	POU5F1P6	-3.69	0.000234	0.013	-0.22	-0.11	Lymphocyte percentage of white cells;	chr3:128691442	chr3:128674735~128677005:-
BRCA	cis	rs11088226	0.709	rs55860967	ENSG00000186842.4	LINC00846	-3.69	0.000235	0.013	-0.18	-0.11	Gastritis;	chr21:32507708	chr21:32572238~32575881:-
BRCA	cis	rs875971	0.545	rs7811204	ENSG00000232559.3	GS1-124K5.12	3.69	0.000235	0.013	0.16	0.11	Aortic root size;	chr7:66387213	chr7:66554588~66576923:-
BRCA	cis	rs3816183	1	rs920391	ENSG00000226491.1	FTOP1	-3.69	0.000235	0.0131	-0.15	-0.11	Hypospadias;	chr2:42792207	chr2:42797225~42798712:-
BRCA	cis	rs875971	0.825	rs1129531	ENSG00000271064.1	RP11-792A8.3	3.69	0.000235	0.0131	0.13	0.11	Aortic root size;	chr7:66154117	chr7:66748838~66749077:-
BRCA	cis	rs1005277	0.54	rs2145487	ENSG00000273019.1	RP11-508N22.13	-3.69	0.000235	0.0131	-0.13	-0.11	Extrinsic epigenetic age acceleration;	chr10:37721149	chr10:38149968~38150293:+
BRCA	cis	rs134594	0.885	rs134653	ENSG00000272858.1	CTA-292E10.8	3.69	0.000235	0.0131	0.15	0.11	Birth weight;	chr22:29090791	chr22:28814914~28815662:+
BRCA	cis	rs3796352	0.527	rs11715498	ENSG00000275956.1	RP5-966M1.7	-3.69	0.000235	0.0131	-0.2	-0.11	Immune reponse to smallpox (secreted IL-2);	chr3:52909535	chr3:52732547~52733867:+
BRCA	cis	rs2708377	0.789	rs3911150	ENSG00000212125.2	TAS2R15P	-3.69	0.000235	0.0131	-0.19	-0.11	Bitter taste perception;	chr12:11049649	chr12:10964425~10965352:-
BRCA	cis	rs11047510	0.73	rs6487407	ENSG00000164845.15	FAM86FP	3.69	0.000235	0.0131	0.18	0.11	Exploratory eye movement dysfunction in schizophrenia (responsive search score);	chr12:8850336	chr12:8232512~8242948:-
BRCA	cis	rs848490	0.851	rs62473663	ENSG00000214293.7	APTR	3.69	0.000235	0.0131	0.14	0.11	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77587098	chr7:77657660~77696265:-
BRCA	cis	rs2839186	0.934	rs17182538	ENSG00000215424.8	MCM3AP-AS1	3.69	0.000235	0.0131	0.1	0.11	Testicular germ cell tumor;	chr21:46285759	chr21:46229217~46259390:+
BRCA	cis	rs7221109	0.56	rs758630	ENSG00000278834.1	RP11-458J1.1	-3.69	0.000235	0.0131	-0.12	-0.11	Type 1 diabetes;	chr17:40713053	chr17:40648300~40649718:+
BRCA	cis	rs7267979	0.903	rs2474766	ENSG00000274973.1	RP13-401N8.7	-3.69	0.000235	0.0131	-0.13	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25265517	chr20:25845497~25845862:+
BRCA	cis	rs7267979	0.903	rs2474769	ENSG00000274973.1	RP13-401N8.7	-3.69	0.000235	0.0131	-0.13	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25268089	chr20:25845497~25845862:+
BRCA	cis	rs2911132	0.506	rs7705827	ENSG00000272109.1	CTD-2260A17.3	-3.69	0.000235	0.0131	-0.16	-0.11	Urate levels (BMI interaction);	chr5:96746729	chr5:96804353~96806105:+
BRCA	cis	rs875971	0.66	rs1860468	ENSG00000232546.1	RP11-458F8.1	3.69	0.000235	0.0131	0.09	0.11	Aortic root size;	chr7:66642265	chr7:66848496~66858136:+
BRCA	cis	rs8062405	0.679	rs72793818	ENSG00000261766.1	RP11-22P6.2	-3.69	0.000235	0.0131	-0.11	-0.11	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28881816	chr16:28862166~28863340:-
BRCA	cis	rs4388249	0.95	rs2042164	ENSG00000271849.1	CTC-332L22.1	-3.69	0.000235	0.0131	-0.18	-0.11	Schizophrenia;	chr5:109776323	chr5:109687802~109688329:-
BRCA	cis	rs6142618	0.562	rs4589835	ENSG00000275576.1	RP5-836N17.4	-3.69	0.000235	0.0131	-0.12	-0.11	Inflammatory bowel disease;	chr20:32168811	chr20:32116171~32116629:+
BRCA	cis	rs6088590	1	rs55753039	ENSG00000276073.1	RP5-1125A11.7	-3.69	0.000235	0.0131	-0.13	-0.11	Coronary artery disease;	chr20:34807137	chr20:33985617~33988989:-
BRCA	cis	rs10819861	0.611	rs10124975	ENSG00000175611.10	LINC00476	3.69	0.000235	0.0131	0.12	0.11	Electrocardiographic traits;	chr9:96084748	chr9:95759231~95875977:-
BRCA	cis	rs11673344	0.542	rs826325	ENSG00000276846.1	CTD-3220F14.3	3.69	0.000235	0.0131	0.13	0.11	Obesity-related traits;	chr19:37003580	chr19:37314868~37315620:-
BRCA	cis	rs4449834	0.775	rs7846065	ENSG00000254432.1	RP11-33I11.2	-3.69	0.000235	0.0131	-0.15	-0.11	Sum eosinophil basophil counts;	chr8:60748881	chr8:60808735~60809606:-
BRCA	cis	rs3743162	0.553	rs4842994	ENSG00000259295.5	CSPG4P12	-3.69	0.000235	0.0131	-0.17	-0.11	Alzheimer's disease (age of onset);	chr15:84872568	chr15:85191438~85213905:+
BRCA	cis	rs1949733	1	rs1916326	ENSG00000205959.3	RP11-689P11.2	3.69	0.000235	0.0131	0.11	0.11	Response to antineoplastic agents;	chr4:8498296	chr4:8482270~8512610:+
BRCA	cis	rs67696533	0.636	rs6141741	ENSG00000277692.1	RP11-358N2.2	-3.69	0.000235	0.0131	-0.14	-0.11	White blood cell count (basophil);Basophil percentage of granulocytes;Basophil percentage of white cells;	chr20:32518764	chr20:32355053~32355734:+
BRCA	cis	rs875971	0.767	rs1643394	ENSG00000271064.1	RP11-792A8.3	-3.69	0.000235	0.0131	-0.13	-0.11	Aortic root size;	chr7:66371107	chr7:66748838~66749077:-
BRCA	cis	rs7179228	0.613	rs898585	ENSG00000260657.2	RP11-315D16.4	3.69	0.000235	0.0131	0.2	0.11	Systolic blood pressure;	chr15:68336661	chr15:68267792~68277994:-
BRCA	cis	rs1075265	0.836	rs1421622	ENSG00000272156.1	RP11-477N3.1	3.69	0.000235	0.0131	0.12	0.11	Chronotype;Morning vs. evening chronotype;	chr2:54062644	chr2:54082554~54085066:+
BRCA	cis	rs11098403	0.753	rs4452508	ENSG00000225892.3	RP11-384K6.2	3.69	0.000235	0.0131	0.11	0.11	Schizophrenia;	chr4:117835694	chr4:118632274~118634759:+
BRCA	cis	rs1153858	0.621	rs1719237	ENSG00000275672.1	GATM-AS1	-3.69	0.000235	0.0131	-0.15	-0.11	Homoarginine levels;	chr15:45287624	chr15:45378700~45380123:+
BRCA	cis	rs2243480	1	rs937108	ENSG00000226767.1	RP11-328P23.3	-3.69	0.000235	0.0131	-0.19	-0.11	Diabetic kidney disease;	chr7:65963465	chr7:65508773~65508944:-
BRCA	cis	rs7267979	1	rs6115182	ENSG00000204556.4	CTD-2514C3.1	3.69	0.000235	0.0131	0.15	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25429623	chr20:26018832~26020684:+
BRCA	cis	rs930395	0.514	rs13168400	ENSG00000251141.4	RP11-53O19.1	-3.69	0.000235	0.0131	-0.11	-0.11	Breast cancer;	chr5:44883434	chr5:44744900~44808777:-
BRCA	cis	rs61931739	0.534	rs7313137	ENSG00000258794.3	DUX4L27	3.69	0.000235	0.0131	0.17	0.11	Morning vs. evening chronotype;	chr12:33857296	chr12:34208415~34209675:-
BRCA	cis	rs61931739	0.534	rs1608911	ENSG00000258794.3	DUX4L27	3.69	0.000235	0.0131	0.17	0.11	Morning vs. evening chronotype;	chr12:33857314	chr12:34208415~34209675:-
BRCA	cis	rs61931739	0.5	rs1843736	ENSG00000258794.3	DUX4L27	3.69	0.000235	0.0131	0.17	0.11	Morning vs. evening chronotype;	chr12:33859145	chr12:34208415~34209675:-
BRCA	cis	rs2386661	0.523	rs61832677	ENSG00000231483.1	RP11-336A10.5	3.69	0.000235	0.0131	0.14	0.11	Breast cancer;	chr10:5610514	chr10:5608475~5610793:-
BRCA	cis	rs477895	0.838	rs11605738	ENSG00000256940.1	RP11-783K16.5	3.69	0.000235	0.0131	0.16	0.11	Mean platelet volume;	chr11:64245934	chr11:64245964~64248217:+
BRCA	cis	rs10129255	0.5	rs9324092	ENSG00000211976.2	IGHV3-73	3.69	0.000235	0.0131	0.09	0.11	Kawasaki disease;	chr14:106683806	chr14:106802694~106803233:-
BRCA	cis	rs12999542	0.706	rs17651485	ENSG00000234389.1	AC007278.3	3.69	0.000235	0.0131	0.18	0.11	Serum protein levels (sST2);	chr2:102385190	chr2:102438713~102440475:+
BRCA	cis	rs300890	1	rs300904	ENSG00000250326.1	RP11-284M14.1	3.69	0.000235	0.0131	0.13	0.11	Nasopharyngeal carcinoma;	chr4:143318672	chr4:142933195~143184861:-
BRCA	cis	rs6445975	0.666	rs4681844	ENSG00000272360.1	RP11-359I18.5	-3.69	0.000235	0.0131	-0.14	-0.11	Systemic lupus erythematosus;	chr3:58346719	chr3:58490830~58491291:-
BRCA	cis	rs890448	0.796	rs6532934	ENSG00000254531.1	FLJ20021	3.69	0.000235	0.0131	0.13	0.11	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101386461	chr4:101347780~101348883:+
BRCA	cis	rs890448	0.796	rs6847376	ENSG00000254531.1	FLJ20021	3.69	0.000235	0.0131	0.13	0.11	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101387340	chr4:101347780~101348883:+
BRCA	cis	rs890448	0.796	rs6825658	ENSG00000254531.1	FLJ20021	3.69	0.000235	0.0131	0.13	0.11	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101387944	chr4:101347780~101348883:+
BRCA	cis	rs890448	0.76	rs833948	ENSG00000254531.1	FLJ20021	3.69	0.000235	0.0131	0.13	0.11	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101391529	chr4:101347780~101348883:+
BRCA	cis	rs890448	0.796	rs293213	ENSG00000254531.1	FLJ20021	3.69	0.000235	0.0131	0.13	0.11	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101393716	chr4:101347780~101348883:+
BRCA	cis	rs890448	0.76	rs833946	ENSG00000254531.1	FLJ20021	3.69	0.000235	0.0131	0.13	0.11	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101395742	chr4:101347780~101348883:+
BRCA	cis	rs890448	0.796	rs210811	ENSG00000254531.1	FLJ20021	3.69	0.000235	0.0131	0.13	0.11	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101395833	chr4:101347780~101348883:+
BRCA	cis	rs2108622	0.727	rs62106157	ENSG00000214049.6	UCA1	3.69	0.000235	0.0131	0.16	0.11	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15869638	chr19:15828961~15836320:+
BRCA	cis	rs2108622	0.727	rs62106158	ENSG00000214049.6	UCA1	3.69	0.000235	0.0131	0.16	0.11	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15869682	chr19:15828961~15836320:+
BRCA	cis	rs2692947	0.727	rs2692950	ENSG00000168992.4	OR7E102P	3.69	0.000235	0.0131	0.16	0.11	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96007776	chr2:95546531~95547545:+
BRCA	cis	rs17214007	0.877	rs4482303	ENSG00000260735.1	RP11-72I8.1	-3.69	0.000235	0.0131	-0.16	-0.11	Cognitive function;	chr16:15777020	chr16:15094411~15109197:+
BRCA	cis	rs748404	1	rs12909095	ENSG00000205771.5	CATSPER2P1	-3.69	0.000236	0.0131	-0.16	-0.11	Lung cancer;	chr15:43265944	chr15:43726918~43747094:-
BRCA	cis	rs4415084	0.966	rs16901937	ENSG00000272335.1	RP11-53O19.3	3.69	0.000236	0.0131	0.11	0.11	Breast cancer;	chr5:44709039	chr5:44826076~44828592:+
BRCA	cis	rs11098499	0.954	rs6848389	ENSG00000225892.3	RP11-384K6.2	3.69	0.000236	0.0131	0.11	0.11	Corneal astigmatism;	chr4:119481467	chr4:118632274~118634759:+
BRCA	cis	rs2694917	0.68	rs73114872	ENSG00000257576.1	RP11-153M3.1	3.69	0.000236	0.0131	0.19	0.11	Blood metabolite ratios;	chr12:56467250	chr12:56511002~56512703:+
BRCA	cis	rs17711722	0.522	rs6957759	ENSG00000226002.1	RP11-460N20.5	3.69	0.000236	0.0131	0.12	0.11	Calcium levels;	chr7:65806798	chr7:65084103~65100232:+
BRCA	cis	rs67073037	0.955	rs4666127	ENSG00000230730.1	AC074011.2	-3.69	0.000236	0.0131	-0.16	-0.11	Breast cancer;Breast cancer (estrogen-receptor negative);	chr2:28904879	chr2:28633282~28664540:-
BRCA	cis	rs8099594	0.64	rs528691	ENSG00000266696.1	RP11-30L3.2	3.69	0.000236	0.0131	0.14	0.11	Height;	chr18:49343863	chr18:49205912~49208781:+
BRCA	cis	rs10883723	0.773	rs1326193	ENSG00000213061.2	PFN1P11	-3.69	0.000236	0.0131	-0.16	-0.11	Allergic disease (asthma, hay fever or eczema);	chr10:102511917	chr10:102838011~102845473:-
BRCA	cis	rs10883723	0.81	rs10883729	ENSG00000213061.2	PFN1P11	-3.69	0.000236	0.0131	-0.16	-0.11	Allergic disease (asthma, hay fever or eczema);	chr10:102514186	chr10:102838011~102845473:-
BRCA	cis	rs4243971	0.516	rs2151437	ENSG00000275576.1	RP5-836N17.4	-3.69	0.000236	0.0131	-0.12	-0.11	Inflammatory bowel disease;Crohn's disease;	chr20:32333144	chr20:32116171~32116629:+
BRCA	cis	rs595982	0.702	rs626974	ENSG00000235191.1	NUCB1-AS1	3.69	0.000236	0.0131	0.14	0.11	Red cell distribution width;	chr19:48872643	chr19:48910930~48918891:-
BRCA	cis	rs6964587	0.967	rs6980247	ENSG00000188693.7	CYP51A1-AS1	-3.69	0.000236	0.0131	-0.12	-0.11	Breast cancer;	chr7:91964914	chr7:92134604~92180725:+
BRCA	cis	rs12505749	0.542	rs4618376	ENSG00000270147.1	RP11-646I6.6	-3.69	0.000236	0.0131	-0.13	-0.11	Airflow obstruction;	chr4:56479493	chr4:56396312~56396871:+
BRCA	cis	rs773506	0.655	rs9792456	ENSG00000273381.1	RP11-305L7.7	3.69	0.000236	0.0131	0.14	0.11	Type 2 diabetes nephropathy;	chr9:91206063	chr9:91206175~91210299:-
BRCA	cis	rs321358	0.731	rs7939631	ENSG00000271390.1	RP11-89C3.3	3.69	0.000236	0.0131	0.17	0.11	Body mass index;	chr11:111153506	chr11:111089870~111090368:-
BRCA	cis	rs8130944	1	rs2269152	ENSG00000225731.1	AP001627.1	3.69	0.000236	0.0131	0.13	0.11	Perceived unattractiveness to mosquitoes;	chr21:42724534	chr21:42733594~42741758:-
BRCA	cis	rs11187837	0.803	rs74825688	ENSG00000273450.1	RP11-76P2.4	3.69	0.000236	0.0131	0.25	0.11	Sudden cardiac arrest;	chr10:94359930	chr10:94314907~94315327:-
BRCA	cis	rs3796352	0.527	rs11716506	ENSG00000275956.1	RP5-966M1.7	-3.69	0.000236	0.0131	-0.2	-0.11	Immune reponse to smallpox (secreted IL-2);	chr3:52910312	chr3:52732547~52733867:+
BRCA	cis	rs11098499	0.954	rs28685688	ENSG00000225892.3	RP11-384K6.2	3.69	0.000236	0.0131	0.11	0.11	Corneal astigmatism;	chr4:119499179	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.954	rs7687843	ENSG00000225892.3	RP11-384K6.2	3.69	0.000236	0.0131	0.11	0.11	Corneal astigmatism;	chr4:119500056	chr4:118632274~118634759:+
BRCA	cis	rs6071166	0.838	rs6027384	ENSG00000224635.1	RP4-564F22.5	-3.69	0.000236	0.0131	-0.13	-0.11	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38698783	chr20:38406011~38416797:-
BRCA	cis	rs1008375	0.898	rs7678654	ENSG00000249502.1	AC006160.5	-3.69	0.000236	0.0131	-0.13	-0.11	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17573753	chr4:17587467~17614571:-
BRCA	cis	rs61931739	0.534	rs11053005	ENSG00000258794.3	DUX4L27	3.69	0.000236	0.0131	0.17	0.11	Morning vs. evening chronotype;	chr12:33938691	chr12:34208415~34209675:-
BRCA	cis	rs61931739	0.534	rs11053010	ENSG00000258794.3	DUX4L27	3.69	0.000236	0.0131	0.17	0.11	Morning vs. evening chronotype;	chr12:33940293	chr12:34208415~34209675:-
BRCA	cis	rs3770752	0.897	rs1158219	ENSG00000272054.1	RP11-423P10.2	-3.69	0.000236	0.0131	-0.1	-0.11	Schizophrenia;	chr2:37319677	chr2:37208875~37212677:+
BRCA	cis	rs9400180	0.765	rs9374012	ENSG00000271734.1	RP1-111B22.3	-3.69	0.000236	0.0131	-0.15	-0.11	Major depressive disorder;	chr6:108060085	chr6:108030249~108030718:-
BRCA	cis	rs8017423	0.647	rs12883357	ENSG00000275198.1	RP11-471B22.3	3.69	0.000236	0.0131	0.13	0.11	Mortality in heart failure;	chr14:90348688	chr14:90383365~90387973:+
BRCA	cis	rs4699052	0.625	rs6822783	ENSG00000248740.4	RP11-328K4.1	3.69	0.000236	0.0131	0.13	0.11	Testicular germ cell tumor;	chr4:103363767	chr4:103256159~103453658:+
BRCA	cis	rs5750830	0.594	rs1010170	ENSG00000273096.1	RP3-508I15.20	3.69	0.000236	0.0131	0.12	0.11	Intelligence (multi-trait analysis);	chr22:39382322	chr22:38736610~38736792:-
BRCA	cis	rs2562456	0.876	rs11085468	ENSG00000268555.1	RP11-678G14.3	3.69	0.000236	0.0131	0.15	0.11	Pain;	chr19:21569087	chr19:21570822~21587322:-
BRCA	cis	rs8040855	0.627	rs72757059	ENSG00000259774.1	RP11-182J1.13	3.69	0.000236	0.0131	0.16	0.11	Bulimia nervosa;	chr15:85059918	chr15:84422618~84425882:+
BRCA	cis	rs6545883	0.524	rs7561697	ENSG00000270820.4	RP11-355B11.2	-3.69	0.000236	0.0131	-0.12	-0.11	Tuberculosis;	chr2:61292030	chr2:61471188~61484130:+
BRCA	cis	rs8058578	0.832	rs7500719	ENSG00000274678.1	RP11-2C24.7	3.69	0.000236	0.0131	0.14	0.11	Multiple myeloma;	chr16:30829556	chr16:30821338~30821884:+
BRCA	cis	rs6490294	0.571	rs11066127	ENSG00000257624.1	RP1-128M12.3	3.69	0.000236	0.0131	0.19	0.11	Mean platelet volume;	chr12:112008551	chr12:112000739~112000985:-
BRCA	cis	rs2108622	0.727	rs8102532	ENSG00000214049.6	UCA1	3.69	0.000236	0.0131	0.16	0.11	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15869250	chr19:15828961~15836320:+
BRCA	cis	rs11603020	0.95	rs78624400	ENSG00000265566.2	RN7SL605P	-3.69	0.000236	0.0131	-0.16	-0.11	Blood protein levels;	chr11:57607990	chr11:57528085~57528365:-
BRCA	cis	rs7602460	1	rs7602460	ENSG00000234663.4	AC104820.2	3.69	0.000236	0.0131	0.09	0.11	Atrioventricular conduction;	chr2:181397142	chr2:181101932~181399559:+
BRCA	cis	rs17092148	1	rs2425004	ENSG00000202150.1	RNU6-407P	-3.69	0.000236	0.0131	-0.17	-0.11	Neuroticism;	chr20:34818153	chr20:35030317~35030420:-
BRCA	cis	rs1823874	0.677	rs8042705	ENSG00000259363.4	CTD-2054N24.2	3.69	0.000236	0.0131	0.13	0.11	IgG glycosylation;	chr15:99824501	chr15:99807023~99877148:+
BRCA	cis	rs2243480	1	rs4718270	ENSG00000226767.1	RP11-328P23.3	-3.69	0.000236	0.0131	-0.19	-0.11	Diabetic kidney disease;	chr7:65737415	chr7:65508773~65508944:-
BRCA	cis	rs801193	1	rs10234018	ENSG00000265600.1	AC006480.1	3.69	0.000236	0.0131	0.13	0.11	Aortic root size;	chr7:66681297	chr7:67356680~67356779:+
BRCA	cis	rs17092148	1	rs6058117	ENSG00000202150.1	RNU6-407P	3.69	0.000236	0.0131	0.17	0.11	Neuroticism;	chr20:34779102	chr20:35030317~35030420:-
BRCA	cis	rs17092148	1	rs6088603	ENSG00000202150.1	RNU6-407P	3.69	0.000236	0.0131	0.17	0.11	Neuroticism;	chr20:34783142	chr20:35030317~35030420:-
BRCA	cis	rs17092148	1	rs2378260	ENSG00000202150.1	RNU6-407P	3.69	0.000236	0.0131	0.17	0.11	Neuroticism;	chr20:34787094	chr20:35030317~35030420:-
BRCA	cis	rs4761470	0.577	rs57925369	ENSG00000258172.1	RP11-1105G2.4	-3.69	0.000236	0.0131	-0.15	-0.11	Estradiol plasma levels (breast cancer);	chr12:94295732	chr12:94272150~94277195:-
BRCA	cis	rs2281558	0.793	rs6115227	ENSG00000274414.1	RP5-965G21.4	-3.69	0.000236	0.0131	-0.15	-0.11	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25610741	chr20:25239007~25245229:-
BRCA	cis	rs61160187	0.582	rs7713481	ENSG00000272308.1	RP11-231G3.1	-3.69	0.000236	0.0131	-0.13	-0.11	Educational attainment (years of education);Educational attainment (college completion);	chr5:61093038	chr5:60866457~60866935:-
BRCA	cis	rs4819052	0.851	rs2838850	ENSG00000215447.6	BX322557.10	-3.69	0.000236	0.0131	-0.12	-0.11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251530	chr21:45288052~45291738:+
BRCA	cis	rs6585424	1	rs35483545	ENSG00000225484.5	NUTM2B-AS1	-3.69	0.000236	0.0131	-0.24	-0.11	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80179417	chr10:79663088~79826594:-
BRCA	cis	rs6585424	1	rs34386571	ENSG00000225484.5	NUTM2B-AS1	-3.69	0.000236	0.0131	-0.24	-0.11	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80179676	chr10:79663088~79826594:-
BRCA	cis	rs9470794	0.831	rs11759725	ENSG00000204110.6	RP1-153P14.8	-3.69	0.000236	0.0131	-0.21	-0.11	Type 2 diabetes;	chr6:38014311	chr6:37507348~37535616:+
BRCA	cis	rs715987	0.906	rs575430	ENSG00000215267.7	AKR1C7P	-3.69	0.000236	0.0131	-0.17	-0.11	Major depressive disorder;	chr10:4561508	chr10:5275173~5288470:-
BRCA	cis	rs9733	0.65	rs1971378	ENSG00000203804.4	ADAMTSL4-AS1	-3.69	0.000236	0.0131	-0.12	-0.11	Tonsillectomy;	chr1:150624785	chr1:150560202~150574552:-
BRCA	cis	rs8049367	0.684	rs2238420	ENSG00000267077.1	RP11-127I20.5	3.69	0.000236	0.0131	0.12	0.11	Nonsyndromic cleft lip with or without cleft palate;	chr16:3915814	chr16:4795265~4796532:-
BRCA	cis	rs910316	1	rs3742778	ENSG00000259138.1	RP11-950C14.7	-3.69	0.000236	0.0131	-0.12	-0.11	Height;	chr14:75071514	chr14:75127153~75136930:+
BRCA	cis	rs875971	0.862	rs4718330	ENSG00000273024.4	INTS4P2	3.69	0.000236	0.0131	0.13	0.11	Aortic root size;	chr7:66250256	chr7:65647864~65715661:+
BRCA	cis	rs7131987	0.641	rs2015599	ENSG00000257599.1	OVCH1-AS1	-3.69	0.000236	0.0131	-0.14	-0.11	QT interval;	chr12:29282547	chr12:29389294~29487488:+
BRCA	cis	rs7131987	0.63	rs1006409	ENSG00000257599.1	OVCH1-AS1	-3.69	0.000236	0.0131	-0.14	-0.11	QT interval;	chr12:29282742	chr12:29389294~29487488:+
BRCA	cis	rs10448080	0.879	rs240946	ENSG00000253567.1	RP11-181B11.2	3.69	0.000236	0.0131	0.13	0.11	Height;	chr8:28711388	chr8:28447264~28455902:+
BRCA	cis	rs11108495	0.789	rs10745762	ENSG00000258177.1	RP11-394J1.2	3.69	0.000236	0.0131	0.14	0.11	Weight;	chr12:96417600	chr12:96222797~96223973:-
BRCA	cis	rs763121	0.853	rs2072798	ENSG00000228274.3	RP3-508I15.9	-3.69	0.000237	0.0131	-0.13	-0.11	Menopause (age at onset);	chr22:38752478	chr22:38667585~38681820:-
BRCA	cis	rs6456156	1	rs7761159	ENSG00000272549.1	RP11-351J23.2	-3.69	0.000237	0.0131	-0.11	-0.11	Primary biliary cholangitis;	chr6:167106419	chr6:167666840~167679270:-
BRCA	cis	rs2274459	1	rs877187	ENSG00000249346.5	LINC01016	-3.69	0.000237	0.0131	-0.15	-0.11	Obesity (extreme);	chr6:33738434	chr6:33867506~33896914:-
BRCA	cis	rs11098499	1	rs13116504	ENSG00000260404.2	RP11-384K6.6	3.69	0.000237	0.0131	0.11	0.11	Corneal astigmatism;	chr4:119288257	chr4:118591773~118633729:+
BRCA	cis	rs4703129	1	rs929738	ENSG00000246763.5	RGMB-AS1	-3.69	0.000237	0.0131	-0.13	-0.11	Asperger disorder;	chr5:98539135	chr5:98769618~98773469:-
BRCA	cis	rs4948102	0.731	rs4535700	ENSG00000226278.1	PSPHP1	-3.69	0.000237	0.0131	-0.13	-0.11	Plasma homocysteine levels (post-methionine load test);	chr7:55977755	chr7:55764797~55773288:+
BRCA	cis	rs4948102	0.691	rs10435504	ENSG00000226278.1	PSPHP1	-3.69	0.000237	0.0131	-0.13	-0.11	Plasma homocysteine levels (post-methionine load test);	chr7:55991898	chr7:55764797~55773288:+
BRCA	cis	rs9470794	1	rs73421817	ENSG00000204110.6	RP1-153P14.8	-3.69	0.000237	0.0131	-0.23	-0.11	Type 2 diabetes;	chr6:38106090	chr6:37507348~37535616:+
BRCA	cis	rs9470794	1	rs73421819	ENSG00000204110.6	RP1-153P14.8	-3.69	0.000237	0.0131	-0.23	-0.11	Type 2 diabetes;	chr6:38106100	chr6:37507348~37535616:+
BRCA	cis	rs9470794	1	rs73421822	ENSG00000204110.6	RP1-153P14.8	-3.69	0.000237	0.0131	-0.23	-0.11	Type 2 diabetes;	chr6:38106705	chr6:37507348~37535616:+
BRCA	cis	rs875971	0.545	rs316305	ENSG00000232559.3	GS1-124K5.12	-3.69	0.000237	0.0131	-0.15	-0.11	Aortic root size;	chr7:66152984	chr7:66554588~66576923:-
BRCA	cis	rs73201462	1	rs2811392	ENSG00000242551.2	POU5F1P6	-3.69	0.000237	0.0131	-0.2	-0.11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128305133	chr3:128674735~128677005:-
BRCA	cis	rs2280018	0.963	rs11075255	ENSG00000188599.16	NPIPP1	-3.69	0.000237	0.0131	-0.09	-0.11	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15072375	chr16:15104312~15123498:-
BRCA	cis	rs875971	0.964	rs778735	ENSG00000272831.1	RP11-792A8.4	3.69	0.000237	0.0131	0.1	0.11	Aortic root size;	chr7:66349822	chr7:66739829~66740385:-
BRCA	cis	rs763121	0.524	rs760645	ENSG00000225450.1	RP3-508I15.14	-3.69	0.000237	0.0131	-0.12	-0.11	Menopause (age at onset);	chr22:38636265	chr22:38739003~38749041:+
BRCA	cis	rs61931739	0.517	rs11513277	ENSG00000258794.3	DUX4L27	3.69	0.000237	0.0131	0.17	0.11	Morning vs. evening chronotype;	chr12:33921864	chr12:34208415~34209675:-
BRCA	cis	rs61931739	0.517	rs11513519	ENSG00000258794.3	DUX4L27	3.69	0.000237	0.0131	0.17	0.11	Morning vs. evening chronotype;	chr12:33922142	chr12:34208415~34209675:-
BRCA	cis	rs739401	0.527	rs418832	ENSG00000183562.3	CTC-343N3.1	-3.69	0.000237	0.0131	-0.12	-0.11	Longevity;	chr11:3051006	chr11:2989863~2991344:+
BRCA	cis	rs4664293	0.647	rs7576644	ENSG00000226266.5	AC009961.3	-3.69	0.000237	0.0131	-0.13	-0.11	Monocyte percentage of white cells;	chr2:159584947	chr2:159670708~159712435:-
BRCA	cis	rs12477602	0.882	rs71425935	ENSG00000272966.1	RP11-686O6.1	3.69	0.000237	0.0131	0.19	0.11	Intelligence (multi-trait analysis);	chr2:202373784	chr2:202336739~202337200:+
BRCA	cis	rs891378	1	rs6700079	ENSG00000274245.1	RP11-357P18.2	-3.69	0.000237	0.0131	-0.15	-0.11	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207328527	chr1:207372559~207373252:+
BRCA	cis	rs1865760	0.929	rs9358896	ENSG00000272810.1	U91328.22	-3.69	0.000237	0.0131	-0.13	-0.11	Height;	chr6:25942969	chr6:26013241~26013757:+
BRCA	cis	rs4835473	0.932	rs4835278	ENSG00000249741.2	RP11-673E1.3	3.69	0.000237	0.0132	0.12	0.11	Immature fraction of reticulocytes;	chr4:143788433	chr4:143911514~143912053:-
BRCA	cis	rs875971	0.545	rs75577046	ENSG00000273448.1	RP11-166O4.6	3.69	0.000237	0.0132	0.12	0.11	Aortic root size;	chr7:66493729	chr7:67333047~67334383:+
BRCA	cis	rs7520050	0.897	rs4440807	ENSG00000226957.1	RP4-533D7.4	3.69	0.000237	0.0132	0.12	0.11	Reticulocyte count;Red blood cell count;	chr1:46005206	chr1:46046818~46048368:+
BRCA	cis	rs953492	0.731	rs10803133	ENSG00000214837.7	LINC01347	-3.69	0.000237	0.0132	-0.12	-0.11	Diastolic blood pressure;	chr1:243290712	chr1:243056307~243101744:-
BRCA	cis	rs524281	0.861	rs7941431	ENSG00000255557.1	RP11-770G2.2	3.69	0.000237	0.0132	0.16	0.11	Electroencephalogram traits;	chr11:66192686	chr11:65745729~65771585:+
BRCA	cis	rs372883	0.532	rs388707	ENSG00000176054.6	RPL23P2	-3.69	0.000237	0.0132	-0.12	-0.11	Pancreatic cancer;	chr21:29342455	chr21:28997613~28998033:-
BRCA	cis	rs1979679	0.682	rs4359252	ENSG00000244712.1	RP11-874G11.1	3.69	0.000237	0.0132	0.18	0.11	Ossification of the posterior longitudinal ligament of the spine;	chr12:28434298	chr12:28564678~28565141:-
BRCA	cis	rs34792	0.626	rs153788	ENSG00000275910.1	RP11-680G24.6	-3.69	0.000237	0.0132	-0.14	-0.11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15500346	chr16:15015828~15016390:-
BRCA	cis	rs7172689	0.908	rs67396561	ENSG00000271725.1	RP11-761I4.4	3.69	0.000237	0.0132	0.15	0.11	Inattentive symptoms;	chr15:81268783	chr15:81303215~81309391:-
BRCA	cis	rs7412746	0.658	rs11589458	ENSG00000224800.1	RP11-235D19.2	-3.69	0.000237	0.0132	-0.14	-0.11	Melanoma;	chr1:150820140	chr1:150881236~150881683:-
BRCA	cis	rs911119	0.913	rs34792920	ENSG00000270001.1	RP11-218C14.8	-3.69	0.000237	0.0132	-0.16	-0.11	Chronic kidney disease;	chr20:23601239	chr20:23631826~23632316:-
BRCA	cis	rs75804782	0.641	rs2340870	ENSG00000186235.9	AC016757.3	3.69	0.000237	0.0132	0.24	0.11	Chronotype;Morning vs. evening chronotype;	chr2:238447385	chr2:238224552~238231677:-
BRCA	cis	rs61931739	0.5	rs34107854	ENSG00000258794.3	DUX4L27	3.69	0.000237	0.0132	0.16	0.11	Morning vs. evening chronotype;	chr12:34329398	chr12:34208415~34209675:-
BRCA	cis	rs11098499	0.863	rs10030660	ENSG00000260091.1	RP11-33B1.4	-3.69	0.000237	0.0132	-0.1	-0.11	Corneal astigmatism;	chr4:119515549	chr4:119409333~119410233:+
BRCA	cis	rs11098499	0.863	rs13149407	ENSG00000260091.1	RP11-33B1.4	-3.69	0.000237	0.0132	-0.1	-0.11	Corneal astigmatism;	chr4:119516670	chr4:119409333~119410233:+
BRCA	cis	rs3864261	0.515	rs55769858	ENSG00000251613.3	CTC-347C20.1	-3.69	0.000237	0.0132	-0.14	-0.11	Discordance in emotional problems in monozygotic twins;	chr5:72984937	chr5:72687112~72762727:-
BRCA	cis	rs6460942	0.908	rs59410610	ENSG00000226690.5	AC005281.1	3.69	0.000237	0.0132	0.21	0.11	Coronary artery disease;	chr7:12243221	chr7:12496429~12541910:+
BRCA	cis	rs10829156	0.947	rs7081435	ENSG00000225527.1	RP11-383B4.4	-3.69	0.000237	0.0132	-0.15	-0.11	Sudden cardiac arrest;	chr10:18667411	chr10:18531849~18533336:-
BRCA	cis	rs1552244	0.572	rs7645667	ENSG00000180385.7	EMC3-AS1	3.69	0.000237	0.0132	0.16	0.11	Alzheimer's disease;	chr3:10115653	chr3:9986893~10006990:+
BRCA	cis	rs7695732	0.743	rs9991237	ENSG00000270720.1	RP11-84C13.2	-3.69	0.000237	0.0132	-0.15	-0.11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr4:88997536	chr4:89119284~89119871:+
BRCA	cis	rs7695732	0.743	rs11097208	ENSG00000270720.1	RP11-84C13.2	-3.69	0.000237	0.0132	-0.15	-0.11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr4:88998048	chr4:89119284~89119871:+
BRCA	cis	rs7695732	0.743	rs2869972	ENSG00000270720.1	RP11-84C13.2	-3.69	0.000237	0.0132	-0.15	-0.11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr4:88998262	chr4:89119284~89119871:+
BRCA	cis	rs12467847	0.965	rs12467810	ENSG00000231747.1	AC079922.2	-3.69	0.000237	0.0132	-0.11	-0.11	Response to amphetamines;	chr2:112933483	chr2:112621809~112622167:-
BRCA	cis	rs6064559	0.622	rs4811871	ENSG00000218018.2	RP4-800J21.3	-3.69	0.000237	0.0132	-0.1	-0.11	Hemoglobin concentration;	chr20:57546170	chr20:57384160~57393062:-
BRCA	cis	rs6088580	0.634	rs6088498	ENSG00000275784.1	RP5-1125A11.6	-3.69	0.000237	0.0132	-0.12	-0.11	Glomerular filtration rate (creatinine);	chr20:34432640	chr20:33989480~33991818:-
BRCA	cis	rs6732795	0.858	rs10189815	ENSG00000179818.12	PCBP1-AS1	-3.69	0.000237	0.0132	-0.12	-0.11	Intraocular pressure;	chr2:69187364	chr2:69962263~70103220:-
BRCA	cis	rs957448	1	rs72674861	ENSG00000261437.1	RP11-22C11.2	3.69	0.000237	0.0132	0.12	0.11	Nonsyndromic cleft lip with cleft palate;	chr8:94550051	chr8:94637285~94639467:-
BRCA	cis	rs683250	0.598	rs657824	ENSG00000254551.1	RP11-727A23.7	3.69	0.000237	0.0132	0.14	0.11	Subcortical brain region volumes;	chr11:83257376	chr11:83209431~83213379:-
BRCA	cis	rs7520050	0.966	rs6668284	ENSG00000234329.1	RP11-767N6.2	-3.69	0.000237	0.0132	-0.11	-0.11	Reticulocyte count;Red blood cell count;	chr1:45888838	chr1:45651039~45651826:-
BRCA	cis	rs6599077	0.724	rs13326962	ENSG00000223797.4	ENTPD3-AS1	3.69	0.000237	0.0132	0.13	0.11	Sleep-related phenotypes;	chr3:40045690	chr3:40313802~40453329:-
BRCA	cis	rs524281	0.861	rs6591207	ENSG00000255038.1	RP11-1167A19.2	-3.69	0.000237	0.0132	-0.17	-0.11	Electroencephalogram traits;	chr11:66182203	chr11:66067277~66069619:-
BRCA	cis	rs11887277	0.507	rs1821410	ENSG00000272148.1	RP11-195B17.1	-3.69	0.000237	0.0132	-0.13	-0.11	Obesity-related traits;	chr2:26835639	chr2:27062428~27062907:-
BRCA	cis	rs7712401	0.686	rs154509	ENSG00000251538.4	RP11-166A12.1	3.69	0.000238	0.0132	0.12	0.11	Mean platelet volume;	chr5:122862645	chr5:122628952~122730685:-
BRCA	cis	rs1032833	0.732	rs17454164	ENSG00000271401.1	RP11-171I2.3	-3.69	0.000238	0.0132	-0.29	-0.11	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);	chr2:179131112	chr2:178644717~178645179:+
BRCA	cis	rs7726839	0.526	rs11960159	ENSG00000225138.6	CTD-2228K2.7	3.69	0.000238	0.0132	0.15	0.11	Obesity-related traits;	chr5:568570	chr5:473236~480884:+
BRCA	cis	rs875971	0.862	rs778680	ENSG00000271064.1	RP11-792A8.3	-3.69	0.000238	0.0132	-0.13	-0.11	Aortic root size;	chr7:66375427	chr7:66748838~66749077:-
BRCA	cis	rs875971	0.862	rs11769079	ENSG00000271064.1	RP11-792A8.3	-3.69	0.000238	0.0132	-0.13	-0.11	Aortic root size;	chr7:66377141	chr7:66748838~66749077:-
BRCA	cis	rs875971	0.862	rs1695820	ENSG00000271064.1	RP11-792A8.3	-3.69	0.000238	0.0132	-0.13	-0.11	Aortic root size;	chr7:66379576	chr7:66748838~66749077:-
BRCA	cis	rs11098499	0.588	rs2389874	ENSG00000249244.1	RP11-548H18.2	-3.69	0.000238	0.0132	-0.13	-0.11	Corneal astigmatism;	chr4:119633836	chr4:119391831~119395335:-
BRCA	cis	rs12303914	0.802	rs1600126	ENSG00000256682.2	TAS2R12	3.69	0.000238	0.0132	0.13	0.11	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr12:10317430	chr12:10894943~10896952:-
BRCA	cis	rs7809799	1	rs62473047	ENSG00000242798.1	RP11-506M12.1	3.69	0.000238	0.0132	0.21	0.11	Ulcerative colitis;	chr7:99171484	chr7:100115214~100127139:-
BRCA	cis	rs897984	0.52	rs4889536	ENSG00000260082.1	RP11-2C24.5	-3.69	0.000238	0.0132	-0.14	-0.11	Dementia with Lewy bodies;	chr16:30860434	chr16:30821068~30822110:-
BRCA	cis	rs7045881	0.877	rs17840677	ENSG00000254396.1	RP11-56F10.3	3.69	0.000238	0.0132	0.2	0.11	Schizophrenia;	chr9:26777706	chr9:27102630~27104728:+
BRCA	cis	rs2108622	0.727	rs7256877	ENSG00000214049.6	UCA1	3.69	0.000238	0.0132	0.16	0.11	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15869873	chr19:15828961~15836320:+
BRCA	cis	rs12497850	0.931	rs6442130	ENSG00000225399.4	RP11-3B7.1	3.69	0.000238	0.0132	0.11	0.11	Parkinson's disease;	chr3:48740594	chr3:49260085~49261316:+
BRCA	cis	rs7246657	0.525	rs1667351	ENSG00000267422.1	CTD-2554C21.1	-3.69	0.000238	0.0132	-0.17	-0.11	Coronary artery calcification;	chr19:36987125	chr19:37779686~37792865:+
BRCA	cis	rs4326844	0.583	rs10506328	ENSG00000257534.1	RP11-834C11.10	3.69	0.000238	0.0132	0.14	0.11	Platelet count;	chr12:54293448	chr12:54162065~54164452:-
BRCA	cis	rs17684571	0.751	rs35828379	ENSG00000231441.1	RP11-472M19.2	3.69	0.000238	0.0132	0.19	0.11	Schizophrenia;	chr6:56839003	chr6:56844002~56864078:+
BRCA	cis	rs17684571	0.751	rs71564863	ENSG00000231441.1	RP11-472M19.2	3.69	0.000238	0.0132	0.19	0.11	Schizophrenia;	chr6:56840372	chr6:56844002~56864078:+
BRCA	cis	rs4478858	0.698	rs6669381	ENSG00000260386.4	LINC01225	-3.69	0.000238	0.0132	-0.14	-0.11	Alcohol dependence;	chr1:31360659	chr1:31500085~31540885:+
BRCA	cis	rs7267979	1	rs2482911	ENSG00000274973.1	RP13-401N8.7	3.69	0.000238	0.0132	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25414892	chr20:25845497~25845862:+
BRCA	cis	rs829883	0.934	rs249814	ENSG00000227825.4	SLC9A7P1	3.69	0.000238	0.0132	0.14	0.11	Colorectal adenoma (advanced);	chr12:98499186	chr12:98453835~98457145:-
BRCA	cis	rs6736093	0.932	rs17174697	ENSG00000236307.2	EEF1E1P1	-3.69	0.000238	0.0132	-0.14	-0.11	Coronary artery disease;	chr2:111905337	chr2:111887914~111888741:+
BRCA	cis	rs1552244	0.572	rs7645759	ENSG00000180385.7	EMC3-AS1	3.69	0.000238	0.0132	0.16	0.11	Alzheimer's disease;	chr3:10115684	chr3:9986893~10006990:+
BRCA	cis	rs61931739	0.517	rs12816252	ENSG00000258794.3	DUX4L27	3.69	0.000238	0.0132	0.17	0.11	Morning vs. evening chronotype;	chr12:33914758	chr12:34208415~34209675:-
BRCA	cis	rs61931739	0.517	rs12816423	ENSG00000258794.3	DUX4L27	3.69	0.000238	0.0132	0.17	0.11	Morning vs. evening chronotype;	chr12:33914801	chr12:34208415~34209675:-
BRCA	cis	rs11098499	0.954	rs10518331	ENSG00000225892.3	RP11-384K6.2	3.69	0.000238	0.0132	0.11	0.11	Corneal astigmatism;	chr4:119402440	chr4:118632274~118634759:+
BRCA	cis	rs7267979	1	rs3761117	ENSG00000204556.4	CTD-2514C3.1	3.69	0.000238	0.0132	0.15	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25407434	chr20:26018832~26020684:+
BRCA	cis	rs7937682	0.632	rs14133	ENSG00000176343.5	RPL37AP8	3.69	0.000238	0.0132	0.14	0.11	Primary sclerosing cholangitis;	chr11:111911973	chr11:111889199~111889474:-
BRCA	cis	rs1577330	0.747	rs2991949	ENSG00000254396.1	RP11-56F10.3	3.69	0.000238	0.0132	0.16	0.11	IgG glycosylation;	chr9:27100893	chr9:27102630~27104728:+
BRCA	cis	rs17406451	0.788	rs72790935	ENSG00000234936.1	AC010883.5	3.69	0.000238	0.0132	0.11	0.11	Mitochondrial DNA levels;	chr2:43463896	chr2:43229573~43233394:+
BRCA	cis	rs9470794	1	rs73419963	ENSG00000204110.6	RP1-153P14.8	-3.69	0.000238	0.0132	-0.23	-0.11	Type 2 diabetes;	chr6:38081305	chr6:37507348~37535616:+
BRCA	cis	rs13434995	0.513	rs2171617	ENSG00000239040.1	Y_RNA	-3.69	0.000238	0.0132	-0.14	-0.11	Adiponectin levels;	chr4:55591023	chr4:55412636~55412738:+
BRCA	cis	rs2692947	0.795	rs2252697	ENSG00000232931.4	LINC00342	-3.69	0.000238	0.0132	-0.12	-0.11	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96112442	chr2:95807118~95816215:-
BRCA	cis	rs3760982	0.585	rs67704568	ENSG00000267191.1	RP11-15A1.2	-3.69	0.000238	0.0132	-0.15	-0.11	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43789867	chr19:43902001~43926545:+
BRCA	cis	rs13401620	0.871	rs3768915	ENSG00000229326.3	AC069154.4	-3.69	0.000238	0.0132	-0.15	-0.11	Breast size;	chr2:119863215	chr2:119698623~119700151:+
BRCA	cis	rs10844682	0.603	rs10844673	ENSG00000278635.1	CTD-2318O12.1	-3.69	0.000238	0.0132	-0.13	-0.11	Monocyte percentage of white cells;	chr12:9744969	chr12:9415641~9416718:+
BRCA	cis	rs6840360	0.571	rs718800	ENSG00000270265.1	RP11-731D1.4	3.69	0.000238	0.0132	0.14	0.11	Intelligence (multi-trait analysis);	chr4:151628155	chr4:151333775~151353224:-
BRCA	cis	rs4073582	0.595	rs801741	ENSG00000255320.1	RP11-755F10.1	-3.69	0.000238	0.0132	-0.14	-0.11	Gout;	chr11:66149613	chr11:66244840~66246239:-
BRCA	cis	rs4950322	0.57	rs17360443	ENSG00000227242.3	NBPF13P	-3.69	0.000238	0.0132	-0.16	-0.11	Protein quantitative trait loci;	chr1:147279737	chr1:147021320~147124525:-
BRCA	cis	rs11673344	0.542	rs826327	ENSG00000276846.1	CTD-3220F14.3	3.69	0.000238	0.0132	0.13	0.11	Obesity-related traits;	chr19:37004397	chr19:37314868~37315620:-
BRCA	cis	rs6840360	0.571	rs1473305	ENSG00000270265.1	RP11-731D1.4	-3.69	0.000238	0.0132	-0.14	-0.11	Intelligence (multi-trait analysis);	chr4:151590569	chr4:151333775~151353224:-
BRCA	cis	rs6840360	0.571	rs62329101	ENSG00000270265.1	RP11-731D1.4	-3.69	0.000238	0.0132	-0.14	-0.11	Intelligence (multi-trait analysis);	chr4:151591087	chr4:151333775~151353224:-
BRCA	cis	rs6840360	0.571	rs4696100	ENSG00000270265.1	RP11-731D1.4	-3.69	0.000238	0.0132	-0.14	-0.11	Intelligence (multi-trait analysis);	chr4:151593090	chr4:151333775~151353224:-
BRCA	cis	rs295490	0.667	rs79661321	ENSG00000178631.7	ACTG1P1	-3.69	0.000238	0.0132	-0.22	-0.11	PR interval in Tripanosoma cruzi seropositivity;	chr3:139434762	chr3:139493809~139494937:+
BRCA	cis	rs8099996	0.798	rs11879026	ENSG00000267277.1	CTD-2342J14.6	3.69	0.000238	0.0132	0.13	0.11	Inflammatory skin disease;	chr19:11067083	chr19:11368123~11374935:-
BRCA	cis	rs17345786	1	rs17345786	ENSG00000256628.3	ZBTB11-AS1	-3.69	0.000238	0.0132	-0.16	-0.11	Colonoscopy-negative controls vs population controls;	chr3:101599474	chr3:101676475~101679217:+
BRCA	cis	rs983392	0.792	rs581133	ENSG00000275344.1	MIR6503	-3.69	0.000238	0.0132	-0.11	-0.11	Alzheimer's disease (late onset);	chr11:60114833	chr11:60209071~60209156:-
BRCA	cis	rs863345	0.564	rs34701257	ENSG00000176320.2	RP11-404O13.5	-3.69	0.000238	0.0132	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158511165	chr1:158197922~158203877:-
BRCA	cis	rs2411233	1	rs9919993	ENSG00000259278.1	RP11-62C7.2	3.69	0.000238	0.0132	0.13	0.11	Platelet count;	chr15:38980932	chr15:39019233~39024918:+
BRCA	cis	rs2400362	0.752	rs4739772	ENSG00000254162.1	RP11-48B3.3	-3.69	0.000238	0.0132	-0.12	-0.11	Glucocorticoid-induced osteonecrosis (age 10 years and older);	chr8:80930234	chr8:80535006~80539135:-
BRCA	cis	rs9470794	1	rs77756496	ENSG00000204110.6	RP1-153P14.8	-3.69	0.000238	0.0132	-0.23	-0.11	Type 2 diabetes;	chr6:37991004	chr6:37507348~37535616:+
BRCA	cis	rs2847297	1	rs2847297	ENSG00000260302.1	RP11-973H7.1	3.69	0.000238	0.0132	0.14	0.11	Rheumatoid arthritis;	chr18:12797695	chr18:12774651~12775923:-
BRCA	cis	rs9470794	1	rs11756626	ENSG00000204110.6	RP1-153P14.8	-3.69	0.000238	0.0132	-0.23	-0.11	Type 2 diabetes;	chr6:38098069	chr6:37507348~37535616:+
BRCA	cis	rs9470794	1	rs55786741	ENSG00000204110.6	RP1-153P14.8	-3.69	0.000238	0.0132	-0.23	-0.11	Type 2 diabetes;	chr6:38102147	chr6:37507348~37535616:+
BRCA	cis	rs9470794	0.915	rs57564251	ENSG00000204110.6	RP1-153P14.8	-3.69	0.000238	0.0132	-0.23	-0.11	Type 2 diabetes;	chr6:38102780	chr6:37507348~37535616:+
BRCA	cis	rs9470794	0.748	rs55972258	ENSG00000204110.6	RP1-153P14.8	-3.69	0.000238	0.0132	-0.23	-0.11	Type 2 diabetes;	chr6:38103429	chr6:37507348~37535616:+
BRCA	cis	rs9470794	1	rs73421810	ENSG00000204110.6	RP1-153P14.8	-3.69	0.000238	0.0132	-0.23	-0.11	Type 2 diabetes;	chr6:38103895	chr6:37507348~37535616:+
BRCA	cis	rs1005277	0.54	rs4934907	ENSG00000273019.1	RP11-508N22.13	-3.69	0.000238	0.0132	-0.13	-0.11	Extrinsic epigenetic age acceleration;	chr10:37726302	chr10:38149968~38150293:+
BRCA	cis	rs1005277	0.54	rs11011351	ENSG00000273019.1	RP11-508N22.13	-3.69	0.000238	0.0132	-0.13	-0.11	Extrinsic epigenetic age acceleration;	chr10:37741597	chr10:38149968~38150293:+
BRCA	cis	rs1005277	0.522	rs1208767	ENSG00000273019.1	RP11-508N22.13	-3.69	0.000238	0.0132	-0.13	-0.11	Extrinsic epigenetic age acceleration;	chr10:37753367	chr10:38149968~38150293:+
BRCA	cis	rs687432	0.812	rs61902761	ENSG00000265566.2	RN7SL605P	-3.69	0.000238	0.0132	-0.16	-0.11	Parkinson's disease;	chr11:58107722	chr11:57528085~57528365:-
BRCA	cis	rs12644436	0.628	rs1540587	ENSG00000249001.4	RP11-742B18.1	3.69	0.000238	0.0132	0.14	0.11	HIV-1 viral setpoint;	chr4:87884658	chr4:87568035~87733956:-
BRCA	cis	rs7208859	0.673	rs3816780	ENSG00000214719.10	AC005562.1	-3.69	0.000238	0.0132	-0.2	-0.11	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30834340	chr17:30576464~30672789:+
BRCA	cis	rs6500602	0.592	rs4785966	ENSG00000280063.1	RP11-295D4.3	-3.69	0.000238	0.0132	-0.08	-0.11	Schizophrenia;	chr16:4468753	chr16:4346694~4348648:-
BRCA	cis	rs853679	0.882	rs4713140	ENSG00000204709.4	LINC01556	3.69	0.000238	0.0132	0.23	0.11	Depression;	chr6:28129415	chr6:28943877~28944537:+
BRCA	cis	rs6142618	0.543	rs2295036	ENSG00000224452.1	RSL24D1P6	3.69	0.000238	0.0132	0.15	0.11	Inflammatory bowel disease;	chr20:32115793	chr20:32170390~32170790:-
BRCA	cis	rs10863681	1	rs10863681	ENSG00000200033.1	RNU6-403P	3.69	0.000238	0.0132	0.11	0.11	Metabolite levels (HVA-5-HIAA Factor score);	chr1:222071916	chr1:221837334~221837437:-
BRCA	cis	rs8054556	0.787	rs12444108	ENSG00000214725.6	CDIPT-AS1	-3.69	0.000238	0.0132	-0.14	-0.11	Autism spectrum disorder or schizophrenia;	chr16:30016373	chr16:29863593~29868053:+
BRCA	cis	rs6696239	0.956	rs6426471	ENSG00000227711.2	RP11-275O4.5	-3.69	0.000238	0.0132	-0.16	-0.11	Height;	chr1:227666115	chr1:227509028~227520477:-
BRCA	cis	rs7267979	0.528	rs6076366	ENSG00000277938.1	RP5-965G21.3	-3.69	0.000238	0.0132	-0.14	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25583990	chr20:25229150~25231933:+
BRCA	cis	rs7918232	0.882	rs6415983	ENSG00000262412.1	RP11-85G18.6	3.69	0.000238	0.0132	0.18	0.11	Breast cancer;	chr10:27068282	chr10:27243130~27250804:+
BRCA	cis	rs7572733	0.935	rs1518364	ENSG00000231621.1	AC013264.2	-3.69	0.000238	0.0132	-0.1	-0.11	Dermatomyositis;	chr2:197945251	chr2:197197991~197199273:+
BRCA	cis	rs11098499	0.779	rs80242894	ENSG00000225892.3	RP11-384K6.2	3.69	0.000238	0.0132	0.11	0.11	Corneal astigmatism;	chr4:119454597	chr4:118632274~118634759:+
BRCA	cis	rs13437751	0.649	rs9654806	ENSG00000226342.1	NMD3P1	3.69	0.000238	0.0132	0.24	0.11	QT interval (drug interaction);	chr7:63879429	chr7:63908966~63910453:-
BRCA	cis	rs524281	0.861	rs10896085	ENSG00000255038.1	RP11-1167A19.2	-3.69	0.000238	0.0132	-0.16	-0.11	Electroencephalogram traits;	chr11:66146361	chr11:66067277~66069619:-
BRCA	cis	rs6545883	0.868	rs2441381	ENSG00000212978.6	AC016747.3	3.69	0.000239	0.0132	0.15	0.11	Tuberculosis;	chr2:61571694	chr2:61141592~61144969:-
BRCA	cis	rs934734	0.752	rs2661795	ENSG00000204929.10	AC074391.1	-3.69	0.000239	0.0132	-0.14	-0.11	Rheumatoid arthritis;	chr2:65399672	chr2:65436711~66084639:+
BRCA	cis	rs7267979	1	rs4815407	ENSG00000276952.1	RP5-965G21.6	-3.69	0.000239	0.0132	-0.14	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25360842	chr20:25284915~25285588:-
BRCA	cis	rs890448	0.796	rs11097747	ENSG00000254531.1	FLJ20021	3.69	0.000239	0.0132	0.13	0.11	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101376639	chr4:101347780~101348883:+
BRCA	cis	rs863345	0.584	rs6672789	ENSG00000229914.1	RP11-404O13.4	-3.69	0.000239	0.0132	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158527349	chr1:158195633~158196131:-
BRCA	cis	rs17027633	1	rs75755924	ENSG00000234020.1	CHIAP3	-3.69	0.000239	0.0132	-0.27	-0.11	Cerebrospinal fluid t-tau:AB1-42 ratio;	chr1:111406197	chr1:111353275~111367409:-
BRCA	cis	rs6546324	0.625	rs1430792	ENSG00000236780.4	AC078941.1	3.69	0.000239	0.0132	0.19	0.11	Endometriosis;	chr2:67637612	chr2:67123357~67215319:-
BRCA	cis	rs495337	0.76	rs2769978	ENSG00000229222.1	KRT18P4	-3.69	0.000239	0.0132	-0.14	-0.11	Psoriasis;	chr20:49910886	chr20:49956745~49958032:+
BRCA	cis	rs7759001	0.681	rs7776338	ENSG00000237154.2	MCFD2P1	3.69	0.000239	0.0132	0.14	0.11	Glomerular filtration rate (creatinine);	chr6:27513892	chr6:27407697~27407996:+
BRCA	cis	rs871012	0.692	rs10037531	ENSG00000248544.2	CTB-47B11.3	3.69	0.000239	0.0132	0.13	0.11	IgG glycosylation;	chr5:157378896	chr5:157375741~157384950:-
BRCA	cis	rs2262909	0.925	rs56073035	ENSG00000279377.1	AC003973.3	-3.69	0.000239	0.0132	-0.16	-0.11	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;	chr19:22093496	chr19:21965708~21968529:-
BRCA	cis	rs11098499	0.863	rs34868248	ENSG00000260091.1	RP11-33B1.4	-3.69	0.000239	0.0132	-0.1	-0.11	Corneal astigmatism;	chr4:119521275	chr4:119409333~119410233:+
BRCA	cis	rs4819052	0.808	rs11909411	ENSG00000215447.6	BX322557.10	-3.69	0.000239	0.0132	-0.12	-0.11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45256641	chr21:45288052~45291738:+
BRCA	cis	rs4819052	0.851	rs28676615	ENSG00000215447.6	BX322557.10	-3.69	0.000239	0.0132	-0.12	-0.11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45256661	chr21:45288052~45291738:+
BRCA	cis	rs875971	0.545	rs313828	ENSG00000232559.3	GS1-124K5.12	-3.69	0.000239	0.0132	-0.16	-0.11	Aortic root size;	chr7:66087627	chr7:66554588~66576923:-
BRCA	cis	rs7520050	0.931	rs11211224	ENSG00000234329.1	RP11-767N6.2	-3.69	0.000239	0.0132	-0.11	-0.11	Reticulocyte count;Red blood cell count;	chr1:45918716	chr1:45651039~45651826:-
BRCA	cis	rs875971	0.862	rs778702	ENSG00000271064.1	RP11-792A8.3	-3.69	0.000239	0.0132	-0.13	-0.11	Aortic root size;	chr7:66399848	chr7:66748838~66749077:-
BRCA	cis	rs7671261	1	rs7671261	ENSG00000270720.1	RP11-84C13.2	3.69	0.000239	0.0132	0.12	0.11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr4:88962667	chr4:89119284~89119871:+
BRCA	cis	rs1008375	1	rs10440301	ENSG00000249502.1	AC006160.5	-3.69	0.000239	0.0132	-0.13	-0.11	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17661576	chr4:17587467~17614571:-
BRCA	cis	rs4243971	0.516	rs6141685	ENSG00000275576.1	RP5-836N17.4	-3.69	0.000239	0.0132	-0.13	-0.11	Inflammatory bowel disease;Crohn's disease;	chr20:32349772	chr20:32116171~32116629:+
BRCA	cis	rs5752326	0.51	rs877593	ENSG00000261188.1	CTA-445C9.14	3.69	0.000239	0.0132	0.16	0.11	Ischemic stroke;	chr22:26471689	chr22:26512537~26514568:+
BRCA	cis	rs10943724	0.713	rs10943720	ENSG00000233967.5	RP11-250B2.3	3.69	0.000239	0.0132	0.12	0.11	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr6:80564619	chr6:80443344~80465927:+
BRCA	cis	rs12477438	0.52	rs13010904	ENSG00000231822.1	AC019097.7	3.69	0.000239	0.0132	0.12	0.11	Chronic sinus infection;	chr2:99137826	chr2:99102018~99102752:+
BRCA	cis	rs12477438	0.52	rs13012481	ENSG00000231822.1	AC019097.7	3.69	0.000239	0.0132	0.12	0.11	Chronic sinus infection;	chr2:99137827	chr2:99102018~99102752:+
BRCA	cis	rs3755605	0.728	rs7638591	ENSG00000242578.1	RP11-469J4.3	3.69	0.000239	0.0132	0.13	0.11	Testicular germ cell tumor;	chr3:170120212	chr3:170410512~170418615:+
BRCA	cis	rs13434995	0.536	rs62303712	ENSG00000239040.1	Y_RNA	3.69	0.000239	0.0132	0.14	0.11	Adiponectin levels;	chr4:55460484	chr4:55412636~55412738:+
BRCA	cis	rs10463316	0.894	rs6880137	ENSG00000260581.1	CTB-113P19.4	3.69	0.000239	0.0133	0.13	0.11	Metabolite levels (Pyroglutamine);	chr5:151375671	chr5:151652275~151655449:+
BRCA	cis	rs7221109	0.625	rs2008469	ENSG00000229028.2	KRT223P	3.69	0.000239	0.0133	0.13	0.11	Type 1 diabetes;	chr17:40660343	chr17:40717235~40721932:-
BRCA	cis	rs7221109	0.677	rs12943859	ENSG00000229028.2	KRT223P	3.69	0.000239	0.0133	0.13	0.11	Type 1 diabetes;	chr17:40661128	chr17:40717235~40721932:-
BRCA	cis	rs9287719	0.967	rs963831	ENSG00000224177.5	LINC00570	3.69	0.000239	0.0133	0.13	0.11	Prostate cancer;	chr2:10605058	chr2:11393981~11403077:+
BRCA	cis	rs9287719	0.967	rs728134	ENSG00000224177.5	LINC00570	3.69	0.000239	0.0133	0.13	0.11	Prostate cancer;	chr2:10605061	chr2:11393981~11403077:+
BRCA	cis	rs7590720	1	rs7590720	ENSG00000230838.1	AC093850.2	3.69	0.000239	0.0133	0.1	0.11	Alcohol dependence;	chr2:216033935	chr2:215718043~215719424:+
BRCA	cis	rs2439831	0.85	rs28564774	ENSG00000206991.1	RNU6-610P	-3.69	0.000239	0.0133	-0.19	-0.11	Lung cancer in ever smokers;	chr15:43833277	chr15:43637632~43637738:-
BRCA	cis	rs2749592	0.531	rs10764134	ENSG00000099251.13	HSD17B7P2	-3.69	0.000239	0.0133	-0.13	-0.11	Age-related hearing impairment (SNP x SNP interaction);	chr10:37567732	chr10:38356380~38378505:+
BRCA	cis	rs2303319	0.504	rs62187680	ENSG00000227403.1	AC009299.3	3.69	0.000239	0.0133	0.3	0.11	Cognitive function;	chr2:161809217	chr2:161244739~161249050:+
BRCA	cis	rs687432	0.812	rs10792125	ENSG00000265566.2	RN7SL605P	3.69	0.000239	0.0133	0.16	0.11	Parkinson's disease;	chr11:58015239	chr11:57528085~57528365:-
BRCA	cis	rs9287719	0.781	rs6714413	ENSG00000224177.5	LINC00570	3.69	0.000239	0.0133	0.13	0.11	Prostate cancer;	chr2:10618733	chr2:11393981~11403077:+
BRCA	cis	rs9287719	0.753	rs2018512	ENSG00000224177.5	LINC00570	3.69	0.000239	0.0133	0.13	0.11	Prostate cancer;	chr2:10619153	chr2:11393981~11403077:+
BRCA	cis	rs928391	1	rs2768767	ENSG00000223356.1	RP11-66D17.5	-3.69	0.000239	0.0133	-0.15	-0.11	Platelet count;	chr1:156797933	chr1:156712212~156713174:-
BRCA	cis	rs2905347	1	rs2905347	ENSG00000232949.1	AC002480.4	3.69	0.000239	0.0133	0.13	0.11	Major depression and alcohol dependence;	chr7:22580700	chr7:22589705~22591622:+
BRCA	cis	rs6771316	0.504	rs2135317	ENSG00000241163.6	LINC00877	-3.69	0.000239	0.0133	-0.13	-0.11	Venous thromboembolism (SNP x SNP interaction);	chr3:72090226	chr3:72035300~72279503:-
BRCA	cis	rs875971	0.798	rs12698522	ENSG00000271064.1	RP11-792A8.3	-3.69	0.000239	0.0133	-0.13	-0.11	Aortic root size;	chr7:66502354	chr7:66748838~66749077:-
BRCA	cis	rs875971	0.83	rs28714531	ENSG00000271064.1	RP11-792A8.3	-3.69	0.000239	0.0133	-0.13	-0.11	Aortic root size;	chr7:66503250	chr7:66748838~66749077:-
BRCA	cis	rs875971	0.862	rs12698526	ENSG00000271064.1	RP11-792A8.3	-3.69	0.000239	0.0133	-0.13	-0.11	Aortic root size;	chr7:66504118	chr7:66748838~66749077:-
BRCA	cis	rs2998286	0.862	rs2790460	ENSG00000237128.1	RP11-351M16.3	3.69	0.000239	0.0133	0.14	0.11	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28502093	chr10:28433008~28495813:-
BRCA	cis	rs4453827	0.611	rs35447065	ENSG00000271916.1	RP11-884K10.6	3.69	0.000239	0.0133	0.13	0.11	Blood protein levels;	chr3:53755327	chr3:53797764~53798019:-
BRCA	cis	rs10129255	0.912	rs67410411	ENSG00000211958.2	IGHV3-38	3.69	0.000239	0.0133	0.09	0.11	Kawasaki disease;	chr14:106680324	chr14:106410493~106411021:-
BRCA	cis	rs11168618	1	rs10875833	ENSG00000273765.1	RP11-370I10.11	3.69	0.000239	0.0133	0.13	0.11	Adiponectin levels;	chr12:48559585	chr12:48360920~48361377:+
BRCA	cis	rs2337406	1	rs10459466	ENSG00000211970.3	IGHV4-61	3.69	0.000239	0.0133	0.11	0.11	Alzheimer's disease (late onset);	chr14:106689255	chr14:106639119~106639657:-
BRCA	cis	rs7089973	0.641	rs7079234	ENSG00000236799.1	RP11-383C6.2	-3.69	0.000239	0.0133	-0.14	-0.11	Bipolar disorder or attention deficit hyperactivity disorder;	chr10:114982051	chr10:114994657~114996593:+
BRCA	cis	rs10028773	0.515	rs9994651	ENSG00000249244.1	RP11-548H18.2	3.69	0.000239	0.0133	0.13	0.11	Educational attainment;	chr4:119666648	chr4:119391831~119395335:-
BRCA	cis	rs7620503	0.921	rs7620560	ENSG00000231574.4	RP11-91K9.1	3.69	0.000239	0.0133	0.13	0.11	Corneal structure;	chr3:177586388	chr3:177816865~177899224:+
BRCA	cis	rs12819124	0.502	rs10875718	ENSG00000257763.1	OR5BK1P	3.69	0.000239	0.0133	0.12	0.11	Glycated hemoglobin levels;	chr12:48017319	chr12:48355792~48356614:-
BRCA	cis	rs9307239	0.533	rs1826906	ENSG00000246090.5	RP11-696N14.1	3.69	0.000239	0.0133	0.11	0.11	Alcohol dependence;	chr4:99379891	chr4:99088857~99301356:+
BRCA	cis	rs10804591	0.848	rs6782700	ENSG00000206417.7	H1FX-AS1	3.69	0.000239	0.0133	0.11	0.11	Waist-hip ratio;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Hip circumference adjusted for BMI;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;	chr3:129590304	chr3:129315392~129326225:+
BRCA	cis	rs2455799	0.613	rs6802048	ENSG00000224728.1	AC090945.1	-3.69	0.000239	0.0133	-0.11	-0.11	Mean platelet volume;	chr3:15842426	chr3:15878047~15879571:+
BRCA	cis	rs13401620	0.917	rs4263120	ENSG00000229326.3	AC069154.4	3.69	0.000239	0.0133	0.15	0.11	Breast size;	chr2:119811577	chr2:119698623~119700151:+
BRCA	cis	rs5758511	0.773	rs62240999	ENSG00000231261.1	HMGN2P10	-3.69	0.000239	0.0133	-0.15	-0.11	Birth weight;	chr22:41959559	chr22:41709225~41709489:-
BRCA	cis	rs801193	1	rs2707856	ENSG00000229180.5	GS1-124K5.11	3.69	0.000239	0.0133	0.1	0.11	Aortic root size;	chr7:66746023	chr7:66526088~66542624:-
BRCA	cis	rs700651	0.789	rs10190226	ENSG00000231621.1	AC013264.2	3.69	0.000239	0.0133	0.11	0.11	Intracranial aneurysm;	chr2:198036840	chr2:197197991~197199273:+
BRCA	cis	rs4819052	0.851	rs2236444	ENSG00000215447.6	BX322557.10	-3.69	0.000239	0.0133	-0.12	-0.11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258311	chr21:45288052~45291738:+
BRCA	cis	rs35520189	0.591	rs11690185	ENSG00000189223.12	PAX8-AS1	-3.69	0.000239	0.0133	-0.18	-0.11	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:112940559	chr2:113211522~113276581:+
BRCA	cis	rs361171	0.622	rs535047	ENSG00000270265.1	RP11-731D1.4	3.69	0.000239	0.0133	0.13	0.11	Trans fatty acid levels;	chr4:151902981	chr4:151333775~151353224:-
BRCA	cis	rs11098499	0.779	rs10857066	ENSG00000225892.3	RP11-384K6.2	3.69	0.000239	0.0133	0.11	0.11	Corneal astigmatism;	chr4:119365441	chr4:118632274~118634759:+
BRCA	cis	rs853679	0.517	rs1904841	ENSG00000226314.6	ZNF192P1	-3.69	0.000239	0.0133	-0.17	-0.11	Depression;	chr6:28140307	chr6:28161781~28169594:+
BRCA	cis	rs7259811	0.812	rs730846	ENSG00000268266.1	AC003005.2	3.69	0.000239	0.0133	0.15	0.11	Western dietary pattern;	chr19:56713054	chr19:57477649~57482996:+
BRCA	cis	rs7259811	0.851	rs730847	ENSG00000268266.1	AC003005.2	3.69	0.000239	0.0133	0.15	0.11	Western dietary pattern;	chr19:56713210	chr19:57477649~57482996:+
BRCA	cis	rs2108622	0.727	rs2158511	ENSG00000214049.6	UCA1	3.69	0.00024	0.0133	0.16	0.11	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15875837	chr19:15828961~15836320:+
BRCA	cis	rs7267979	0.966	rs7270835	ENSG00000276952.1	RP5-965G21.6	3.69	0.00024	0.0133	0.14	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25454431	chr20:25284915~25285588:-
BRCA	cis	rs7267979	1	rs6115191	ENSG00000276952.1	RP5-965G21.6	3.69	0.00024	0.0133	0.14	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25459842	chr20:25284915~25285588:-
BRCA	cis	rs7267979	1	rs6107045	ENSG00000276952.1	RP5-965G21.6	3.69	0.00024	0.0133	0.14	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25461300	chr20:25284915~25285588:-
BRCA	cis	rs7267979	1	rs6107046	ENSG00000276952.1	RP5-965G21.6	3.69	0.00024	0.0133	0.14	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25461413	chr20:25284915~25285588:-
BRCA	cis	rs7267979	1	rs6107047	ENSG00000276952.1	RP5-965G21.6	3.69	0.00024	0.0133	0.14	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25461461	chr20:25284915~25285588:-
BRCA	cis	rs1371614	0.523	rs7585127	ENSG00000272148.1	RP11-195B17.1	3.69	0.00024	0.0133	0.13	0.11	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26956503	chr2:27062428~27062907:-
BRCA	cis	rs4664293	0.647	rs10198053	ENSG00000224152.1	AC009506.1	-3.69	0.00024	0.0133	-0.12	-0.11	Monocyte percentage of white cells;	chr2:159605169	chr2:159615296~159617082:+
BRCA	cis	rs4664293	0.669	rs10174515	ENSG00000224152.1	AC009506.1	-3.69	0.00024	0.0133	-0.12	-0.11	Monocyte percentage of white cells;	chr2:159605524	chr2:159615296~159617082:+
BRCA	cis	rs875971	0.862	rs949930	ENSG00000273024.4	INTS4P2	3.69	0.00024	0.0133	0.12	0.11	Aortic root size;	chr7:66301835	chr7:65647864~65715661:+
BRCA	cis	rs4713118	0.868	rs9468220	ENSG00000219392.1	RP1-265C24.5	3.69	0.00024	0.0133	0.17	0.11	Parkinson's disease;	chr6:27765197	chr6:28115628~28116551:+
BRCA	cis	rs6545883	0.894	rs1186703	ENSG00000270820.4	RP11-355B11.2	3.69	0.00024	0.0133	0.13	0.11	Tuberculosis;	chr2:61445830	chr2:61471188~61484130:+
BRCA	cis	rs2562456	0.874	rs2562408	ENSG00000268119.4	CTD-2561J22.5	-3.69	0.00024	0.0133	-0.17	-0.11	Pain;	chr19:21527079	chr19:21444241~21463908:-
BRCA	cis	rs220519	0.811	rs220515	ENSG00000235408.4	SNORA71B	3.69	0.00024	0.0133	0.11	0.11	Schizophrenia;	chr20:38654863	chr20:38425083~38425354:-
BRCA	cis	rs8072100	0.871	rs7206971	ENSG00000263293.2	RP11-290H9.4	-3.69	0.00024	0.0133	-0.13	-0.11	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47347749	chr17:47303460~47323613:-
BRCA	cis	rs1987511	0.963	rs11253093	ENSG00000224034.1	RP11-445P17.8	-3.69	0.00024	0.0133	-0.15	-0.11	Intelligence;	chr10:5307134	chr10:5266033~5271236:-
BRCA	cis	rs2739330	0.828	rs2877178	ENSG00000228039.3	KB-1125A3.10	3.69	0.00024	0.0133	0.13	0.11	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23963780~23964374:+
BRCA	cis	rs999943	0.846	rs1570760	ENSG00000224557.6	HLA-DPB2	-3.69	0.00024	0.0133	-0.16	-0.11	Obesity (extreme);	chr6:33655156	chr6:33112451~33129084:+
BRCA	cis	rs4478858	0.735	rs2271072	ENSG00000260386.4	LINC01225	-3.69	0.00024	0.0133	-0.13	-0.11	Alcohol dependence;	chr1:31367579	chr1:31500085~31540885:+
BRCA	cis	rs17270561	0.583	rs6908713	ENSG00000272462.2	U91328.19	3.69	0.00024	0.0133	0.14	0.11	Iron status biomarkers;	chr6:25703383	chr6:25992662~26001775:+
BRCA	cis	rs2640806	0.505	rs7837495	ENSG00000253105.4	KB-1448A5.1	3.69	0.00024	0.0133	0.13	0.11	Obesity-related traits;	chr8:96347280	chr8:96371865~96387438:-
BRCA	cis	rs1008375	1	rs1008375	ENSG00000249502.1	AC006160.5	-3.69	0.00024	0.0133	-0.13	-0.11	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17681211	chr4:17587467~17614571:-
BRCA	cis	rs7339483	0.618	rs4932944	ENSG00000268442.1	CTD-2027I19.2	3.69	0.00024	0.0133	0.22	0.11	Discordance in emotional problems in monozygotic twins;	chr19:24101653	chr19:24162370~24163425:-
BRCA	cis	rs4703129	0.967	rs12188210	ENSG00000246763.5	RGMB-AS1	-3.69	0.00024	0.0133	-0.13	-0.11	Asperger disorder;	chr5:98559278	chr5:98769618~98773469:-
BRCA	cis	rs72819225	0.616	rs72819252	ENSG00000228701.1	TNKS2-AS1	3.69	0.00024	0.0133	0.15	0.11	Yeast infection;	chr10:91569366	chr10:91782839~91798291:-
BRCA	cis	rs4664293	0.605	rs12991516	ENSG00000230783.1	AC009961.2	-3.69	0.00024	0.0133	-0.14	-0.11	Monocyte percentage of white cells;	chr2:159585554	chr2:159689217~159690291:-
BRCA	cis	rs7735319	0.565	rs10079558	ENSG00000249572.1	CTD-2203K17.1	3.69	0.00024	0.0133	0.14	0.11	Systolic blood pressure;	chr5:33163419	chr5:33424025~33440619:-
BRCA	cis	rs11696845	0.649	rs6031782	ENSG00000276223.1	RP4-781B1.5	3.69	0.00024	0.0133	0.11	0.11	Obesity-related traits;	chr20:44755191	chr20:44746642~44747201:+
BRCA	cis	rs7243821	0.543	rs28808398	ENSG00000267112.1	RP11-839G9.1	3.69	0.00024	0.0133	0.14	0.11	Chin dimples;	chr18:54899169	chr18:54885866~54898083:-
BRCA	cis	rs9633740	0.578	rs11185982	ENSG00000226659.1	RP11-137H2.4	-3.69	0.00024	0.0133	-0.2	-0.11	Post bronchodilator FEV1;	chr10:80545871	chr10:80529597~80535942:-
BRCA	cis	rs983392	0.679	rs1019671	ENSG00000275344.1	MIR6503	-3.69	0.00024	0.0133	-0.12	-0.11	Alzheimer's disease (late onset);	chr11:60240678	chr11:60209071~60209156:-
BRCA	cis	rs897984	0.645	rs58726213	ENSG00000275263.1	RP11-1072A3.4	-3.69	0.00024	0.0133	-0.13	-0.11	Dementia with Lewy bodies;	chr16:31033362	chr16:30956872~30957199:-
BRCA	cis	rs9527	0.59	rs7073323	ENSG00000213061.2	PFN1P11	3.69	0.00024	0.0133	0.15	0.11	Arsenic metabolism;	chr10:103037666	chr10:102838011~102845473:-
BRCA	cis	rs17801127	0.818	rs16825494	ENSG00000231969.1	AC144449.1	3.69	0.00024	0.0133	0.19	0.11	Liver enzyme levels (alanine transaminase);	chr2:149675536	chr2:149587196~149848233:+
BRCA	cis	rs6142618	0.562	rs2281360	ENSG00000275576.1	RP5-836N17.4	-3.69	0.00024	0.0133	-0.12	-0.11	Inflammatory bowel disease;	chr20:32139026	chr20:32116171~32116629:+
BRCA	cis	rs9990333	0.544	rs73208092	ENSG00000207650.1	MIR570	3.69	0.00024	0.0133	0.14	0.11	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196091703	chr3:195699401~195699497:+
BRCA	cis	rs61931739	0.5	rs11053236	ENSG00000258794.3	DUX4L27	3.69	0.00024	0.0133	0.16	0.11	Morning vs. evening chronotype;	chr12:34355027	chr12:34208415~34209675:-
BRCA	cis	rs1730008	0.865	rs699917	ENSG00000279311.1	RP11-170K4.2	-3.69	0.00024	0.0133	-0.12	-0.11	Lobe attachment (rater-scored or self-reported);	chr3:158240630	chr3:158869898~158871821:+
BRCA	cis	rs1730008	0.865	rs699916	ENSG00000279311.1	RP11-170K4.2	-3.69	0.00024	0.0133	-0.12	-0.11	Lobe attachment (rater-scored or self-reported);	chr3:158240727	chr3:158869898~158871821:+
BRCA	cis	rs1730008	0.835	rs827172	ENSG00000279311.1	RP11-170K4.2	-3.69	0.00024	0.0133	-0.12	-0.11	Lobe attachment (rater-scored or self-reported);	chr3:158240928	chr3:158869898~158871821:+
BRCA	cis	rs2880765	0.743	rs11630410	ENSG00000230373.7	GOLGA6L5P	3.69	0.00024	0.0133	0.12	0.11	Coronary artery disease;	chr15:85461510	chr15:84507885~84516814:-
BRCA	cis	rs2880765	0.71	rs11630457	ENSG00000230373.7	GOLGA6L5P	3.69	0.00024	0.0133	0.12	0.11	Coronary artery disease;	chr15:85461570	chr15:84507885~84516814:-
BRCA	cis	rs4446794	1	rs4446794	ENSG00000261534.1	RP11-244O19.1	-3.69	0.00024	0.0133	-0.12	-0.11	Intelligence (multi-trait analysis);	chr9:121846986	chr9:121815674~121819452:-
BRCA	cis	rs7735319	0.565	rs7707319	ENSG00000249572.1	CTD-2203K17.1	3.69	0.00024	0.0133	0.14	0.11	Systolic blood pressure;	chr5:33164388	chr5:33424025~33440619:-
BRCA	cis	rs3816183	1	rs920392	ENSG00000226491.1	FTOP1	-3.69	0.00024	0.0133	-0.14	-0.11	Hypospadias;	chr2:42792224	chr2:42797225~42798712:-
BRCA	cis	rs2562456	0.839	rs2562411	ENSG00000268117.1	VN1R84P	3.69	0.00024	0.0133	0.17	0.11	Pain;	chr19:21419181	chr19:21719801~21720035:-
BRCA	cis	rs2562456	0.876	rs2562413	ENSG00000268117.1	VN1R84P	3.69	0.00024	0.0133	0.17	0.11	Pain;	chr19:21420084	chr19:21719801~21720035:-
BRCA	cis	rs2562456	0.916	rs1967182	ENSG00000268117.1	VN1R84P	3.69	0.00024	0.0133	0.17	0.11	Pain;	chr19:21420337	chr19:21719801~21720035:-
BRCA	cis	rs8114671	0.562	rs6088655	ENSG00000279253.1	RP4-614O4.13	-3.69	0.00024	0.0133	-0.13	-0.11	Height;	chr20:34940035	chr20:35262727~35264187:-
BRCA	cis	rs10129255	0.556	rs8010005	ENSG00000211976.2	IGHV3-73	-3.69	0.00024	0.0133	-0.09	-0.11	Kawasaki disease;	chr14:106777987	chr14:106802694~106803233:-
BRCA	cis	rs10129255	0.556	rs6576224	ENSG00000211976.2	IGHV3-73	-3.69	0.00024	0.0133	-0.09	-0.11	Kawasaki disease;	chr14:106777997	chr14:106802694~106803233:-
BRCA	cis	rs10129255	0.518	rs8010020	ENSG00000211976.2	IGHV3-73	-3.69	0.00024	0.0133	-0.09	-0.11	Kawasaki disease;	chr14:106778016	chr14:106802694~106803233:-
BRCA	cis	rs2765539	0.701	rs10754391	ENSG00000231365.4	RP11-418J17.1	-3.69	0.00024	0.0133	-0.15	-0.11	Waist-hip ratio;	chr1:119087081	chr1:119140396~119275973:+
BRCA	cis	rs8030379	0.667	rs4842921	ENSG00000176700.18	SCAND2P	-3.69	0.00024	0.0133	-0.1	-0.11	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83887871	chr15:84631451~84647478:+
BRCA	cis	rs2108622	0.559	rs7252638	ENSG00000214049.6	UCA1	3.69	0.00024	0.0133	0.16	0.11	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15870215	chr19:15828961~15836320:+
BRCA	cis	rs2108622	0.727	rs7253684	ENSG00000214049.6	UCA1	3.69	0.00024	0.0133	0.16	0.11	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15870316	chr19:15828961~15836320:+
BRCA	cis	rs7267979	1	rs2297497	ENSG00000276952.1	RP5-965G21.6	-3.69	0.00024	0.0133	-0.14	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25317273	chr20:25284915~25285588:-
BRCA	cis	rs6984305	0.541	rs17716118	ENSG00000279949.1	RP11-10A14.9	3.69	0.00024	0.0133	0.2	0.11	Liver enzyme levels (alkaline phosphatase);	chr8:9322624	chr8:9158063~9158621:+
BRCA	cis	rs4449834	0.781	rs7011972	ENSG00000254432.1	RP11-33I11.2	3.69	0.00024	0.0133	0.14	0.11	Sum eosinophil basophil counts;	chr8:60713973	chr8:60808735~60809606:-
BRCA	cis	rs6121246	0.954	rs6060989	ENSG00000230613.1	HM13-AS1	3.69	0.00024	0.0133	0.17	0.11	Mean corpuscular hemoglobin;	chr20:31841960	chr20:31567707~31573263:-
BRCA	cis	rs957448	0.948	rs1470153	ENSG00000254315.1	RP11-267M23.3	3.69	0.00024	0.0133	0.15	0.11	Nonsyndromic cleft lip with cleft palate;	chr8:94514587	chr8:94533628~94534391:+
BRCA	cis	rs2274273	0.624	rs66551709	ENSG00000259318.1	RP11-454L9.2	3.68	0.00024	0.0133	0.1	0.11	Protein biomarker;	chr14:55324304	chr14:55394940~55395233:-
BRCA	cis	rs7267979	1	rs4815412	ENSG00000204556.4	CTD-2514C3.1	-3.68	0.000241	0.0133	-0.15	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25369689	chr20:26018832~26020684:+
BRCA	cis	rs2625529	0.824	rs4777480	ENSG00000260037.4	CTD-2524L6.3	-3.68	0.000241	0.0133	-0.16	-0.11	Red blood cell count;	chr15:72036656	chr15:71818396~71823384:+
BRCA	cis	rs67073037	0.955	rs11689719	ENSG00000230730.1	AC074011.2	-3.68	0.000241	0.0133	-0.15	-0.11	Breast cancer;Breast cancer (estrogen-receptor negative);	chr2:28899135	chr2:28633282~28664540:-
BRCA	cis	rs4577244	0.505	rs12616009	ENSG00000230730.1	AC074011.2	-3.68	0.000241	0.0133	-0.15	-0.11	Breast cancer (estrogen-receptor negative);	chr2:28900325	chr2:28633282~28664540:-
BRCA	cis	rs7267979	1	rs2258719	ENSG00000274414.1	RP5-965G21.4	-3.68	0.000241	0.0133	-0.14	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25295207	chr20:25239007~25245229:-
BRCA	cis	rs11048434	0.518	rs2377678	ENSG00000111788.10	RP11-22B23.1	3.68	0.000241	0.0133	0.11	0.11	Sjögren's syndrome;	chr12:9021562	chr12:9277235~9313241:+
BRCA	cis	rs7089973	0.872	rs41284358	ENSG00000236799.1	RP11-383C6.2	-3.68	0.000241	0.0133	-0.14	-0.11	Bipolar disorder or attention deficit hyperactivity disorder;	chr10:114862580	chr10:114994657~114996593:+
BRCA	cis	rs7818688	1	rs10093594	ENSG00000245080.5	RP11-320N21.1	3.68	0.000241	0.0133	0.19	0.11	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95021008	chr8:95066808~95073182:-
BRCA	cis	rs1876206	0.554	rs645509	ENSG00000274654.1	CTD-3247H4.2	3.68	0.000241	0.0133	0.14	0.11	Breast cancer;	chr15:48609192	chr15:48528980~48529728:-
BRCA	cis	rs7267979	1	rs2424704	ENSG00000276952.1	RP5-965G21.6	3.68	0.000241	0.0133	0.14	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25293293	chr20:25284915~25285588:-
BRCA	cis	rs6005807	0.719	rs134506	ENSG00000272858.1	CTA-292E10.8	-3.68	0.000241	0.0133	-0.2	-0.11	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28356517	chr22:28814914~28815662:+
BRCA	cis	rs970548	0.954	rs72796498	ENSG00000237840.5	FAM21FP	3.68	0.000241	0.0133	0.15	0.11	Total cholesterol levels;HDL cholesterol;HDL cholesterol levels;Cholesterol, total;	chr10:45486771	chr10:45706431~45727231:-
BRCA	cis	rs8005172	0.966	rs1561758	ENSG00000258867.4	LINC01146	3.68	0.000241	0.0133	0.12	0.11	Parkinson's disease;	chr14:88021226	chr14:88024550~88097619:+
BRCA	cis	rs7074356	0.831	rs12764048	ENSG00000225484.5	NUTM2B-AS1	-3.68	0.000241	0.0133	-0.23	-0.11	Borderline personality disorder;	chr10:80389207	chr10:79663088~79826594:-
BRCA	cis	rs6736093	1	rs7604403	ENSG00000236307.2	EEF1E1P1	-3.68	0.000241	0.0133	-0.14	-0.11	Coronary artery disease;	chr2:111899075	chr2:111887914~111888741:+
BRCA	cis	rs12935418	0.616	rs12446053	ENSG00000260213.4	RP11-303E16.3	3.68	0.000241	0.0133	0.19	0.11	Mean corpuscular volume;	chr16:80930234	chr16:81016792~81035759:-
BRCA	cis	rs11088226	0.681	rs1015048	ENSG00000186842.4	LINC00846	-3.68	0.000241	0.0133	-0.18	-0.11	Gastritis;	chr21:32576996	chr21:32572238~32575881:-
BRCA	cis	rs2304003	0.583	rs1023706	ENSG00000232411.1	AC009495.3	3.68	0.000241	0.0133	0.14	0.11	Social communication problems;	chr2:165863636	chr2:165833048~165839098:-
BRCA	cis	rs448720	1	rs1606524	ENSG00000260657.2	RP11-315D16.4	3.68	0.000241	0.0133	0.13	0.11	Cognitive performance;	chr15:67902830	chr15:68267792~68277994:-
BRCA	cis	rs957448	1	rs957448	ENSG00000261437.1	RP11-22C11.2	3.68	0.000241	0.0133	0.11	0.11	Nonsyndromic cleft lip with cleft palate;	chr8:94529074	chr8:94637285~94639467:-
BRCA	cis	rs9470794	1	rs11753054	ENSG00000204110.6	RP1-153P14.8	-3.68	0.000241	0.0133	-0.21	-0.11	Type 2 diabetes;	chr6:38024024	chr6:37507348~37535616:+
BRCA	cis	rs9470794	0.831	rs76379664	ENSG00000204110.6	RP1-153P14.8	-3.68	0.000241	0.0133	-0.21	-0.11	Type 2 diabetes;	chr6:38024498	chr6:37507348~37535616:+
BRCA	cis	rs9470794	1	rs59769374	ENSG00000204110.6	RP1-153P14.8	-3.68	0.000241	0.0133	-0.21	-0.11	Type 2 diabetes;	chr6:38030480	chr6:37507348~37535616:+
BRCA	cis	rs9470794	1	rs10947710	ENSG00000204110.6	RP1-153P14.8	-3.68	0.000241	0.0133	-0.21	-0.11	Type 2 diabetes;	chr6:38034972	chr6:37507348~37535616:+
BRCA	cis	rs9470794	1	rs56348433	ENSG00000204110.6	RP1-153P14.8	-3.68	0.000241	0.0133	-0.21	-0.11	Type 2 diabetes;	chr6:38037216	chr6:37507348~37535616:+
BRCA	cis	rs6600671	1	rs11249351	ENSG00000270231.3	NBPF8P	3.68	0.000241	0.0133	0.12	0.11	Hip geometry;	chr1:121430082	chr1:120436353~120467739:+
BRCA	cis	rs6964587	0.839	rs6949881	ENSG00000188693.7	CYP51A1-AS1	-3.68	0.000241	0.0133	-0.12	-0.11	Breast cancer;	chr7:91804513	chr7:92134604~92180725:+
BRCA	cis	rs1008375	0.606	rs6828925	ENSG00000249502.1	AC006160.5	-3.68	0.000241	0.0133	-0.13	-0.11	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17559516	chr4:17587467~17614571:-
BRCA	cis	rs6881634	0.501	rs7356762	ENSG00000253558.1	CTD-2179L22.1	-3.68	0.000241	0.0134	-0.14	-0.11	Hippocampal atrophy;	chr5:78463697	chr5:78041879~78044138:-
BRCA	cis	rs35146811	0.735	rs1636975	ENSG00000214313.7	AZGP1P1	-3.68	0.000241	0.0134	-0.12	-0.11	Coronary artery disease;	chr7:100214466	chr7:99980762~99987535:+
BRCA	cis	rs4835473	0.932	rs6851999	ENSG00000246448.2	RP13-578N3.3	3.68	0.000241	0.0134	0.13	0.11	Immature fraction of reticulocytes;	chr4:143742567	chr4:143700257~143865072:+
BRCA	cis	rs12220238	0.915	rs10824164	ENSG00000213731.2	RAB5CP1	-3.68	0.000241	0.0134	-0.18	-0.11	Soluble interleukin-2 receptor subunit alpha;	chr10:74377274	chr10:74423435~74424014:-
BRCA	cis	rs853679	0.527	rs9461443	ENSG00000261839.1	RP1-265C24.8	3.68	0.000241	0.0134	0.15	0.11	Depression;	chr6:28226851	chr6:28136849~28139678:+
BRCA	cis	rs365302	0.556	rs653521	ENSG00000235086.1	FNDC1-IT1	-3.68	0.000241	0.0134	-0.17	-0.11	Coronary heart disease;	chr6:159233881	chr6:159240786~159243329:+
BRCA	cis	rs13401620	0.833	rs3106240	ENSG00000229326.3	AC069154.4	-3.68	0.000241	0.0134	-0.15	-0.11	Breast size;	chr2:119900311	chr2:119698623~119700151:+
BRCA	cis	rs2749592	0.55	rs9733309	ENSG00000099251.13	HSD17B7P2	-3.68	0.000241	0.0134	-0.13	-0.11	Age-related hearing impairment (SNP x SNP interaction);	chr10:37593477	chr10:38356380~38378505:+
BRCA	cis	rs853679	0.546	rs34295134	ENSG00000216901.1	AL022393.7	3.68	0.000241	0.0134	0.22	0.11	Depression;	chr6:27860373	chr6:28176188~28176674:+
BRCA	cis	rs4664293	0.647	rs357030	ENSG00000224152.1	AC009506.1	-3.68	0.000241	0.0134	-0.12	-0.11	Monocyte percentage of white cells;	chr2:159636515	chr2:159615296~159617082:+
BRCA	cis	rs2108622	0.527	rs67617968	ENSG00000214049.6	UCA1	3.68	0.000241	0.0134	0.15	0.11	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15866755	chr19:15828961~15836320:+
BRCA	cis	rs17221829	0.669	rs7128681	ENSG00000280385.1	AP000648.5	-3.68	0.000241	0.0134	-0.13	-0.11	Anxiety in major depressive disorder;	chr11:89650476	chr11:90193614~90198120:+
BRCA	cis	rs3755605	0.728	rs1352204	ENSG00000242578.1	RP11-469J4.3	3.68	0.000241	0.0134	0.13	0.11	Testicular germ cell tumor;	chr3:170098722	chr3:170410512~170418615:+
BRCA	cis	rs7121538	0.756	rs61884006	ENSG00000254418.1	RP11-21L19.1	3.68	0.000241	0.0134	0.18	0.11	HDL cholesterol;	chr11:14385566	chr11:14262846~14273691:-
BRCA	cis	rs1437396	0.526	rs2917776	ENSG00000203327.2	AC012358.7	-3.68	0.000241	0.0134	-0.11	-0.11	Alcohol dependence;	chr2:55315496	chr2:55214387~55216126:-
BRCA	cis	rs17684571	0.872	rs35206656	ENSG00000231441.1	RP11-472M19.2	3.68	0.000241	0.0134	0.16	0.11	Schizophrenia;	chr6:56706662	chr6:56844002~56864078:+
BRCA	cis	rs8130944	0.964	rs1029332	ENSG00000225731.1	AP001627.1	3.68	0.000241	0.0134	0.13	0.11	Perceived unattractiveness to mosquitoes;	chr21:42722869	chr21:42733594~42741758:-
BRCA	cis	rs17092148	0.943	rs4911160	ENSG00000202150.1	RNU6-407P	3.68	0.000241	0.0134	0.17	0.11	Neuroticism;	chr20:34762137	chr20:35030317~35030420:-
BRCA	cis	rs17092148	0.945	rs6060034	ENSG00000202150.1	RNU6-407P	3.68	0.000241	0.0134	0.17	0.11	Neuroticism;	chr20:34764061	chr20:35030317~35030420:-
BRCA	cis	rs17092148	0.945	rs6058115	ENSG00000202150.1	RNU6-407P	3.68	0.000241	0.0134	0.17	0.11	Neuroticism;	chr20:34770594	chr20:35030317~35030420:-
BRCA	cis	rs17092148	1	rs6060043	ENSG00000202150.1	RNU6-407P	3.68	0.000241	0.0134	0.17	0.11	Neuroticism;	chr20:34776781	chr20:35030317~35030420:-
BRCA	cis	rs9287719	0.839	rs11683335	ENSG00000224177.5	LINC00570	3.68	0.000241	0.0134	0.13	0.11	Prostate cancer;	chr2:10616539	chr2:11393981~11403077:+
BRCA	cis	rs7267979	1	rs6050626	ENSG00000276952.1	RP5-965G21.6	3.68	0.000241	0.0134	0.14	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25447625	chr20:25284915~25285588:-
BRCA	cis	rs9470794	1	rs113094729	ENSG00000204110.6	RP1-153P14.8	-3.68	0.000242	0.0134	-0.23	-0.11	Type 2 diabetes;	chr6:37985484	chr6:37507348~37535616:+
BRCA	cis	rs11673344	0.566	rs256733	ENSG00000267422.1	CTD-2554C21.1	3.68	0.000242	0.0134	0.14	0.11	Obesity-related traits;	chr19:37384729	chr19:37779686~37792865:+
BRCA	cis	rs8180040	0.966	rs3736177	ENSG00000280667.1	Y_RNA	-3.68	0.000242	0.0134	-0.13	-0.11	Colorectal cancer;	chr3:47409921	chr3:47501083~47501182:+
BRCA	cis	rs863345	0.647	rs923663	ENSG00000229914.1	RP11-404O13.4	3.68	0.000242	0.0134	0.12	0.11	Pneumococcal bacteremia;	chr1:158537942	chr1:158195633~158196131:-
BRCA	cis	rs9287719	0.746	rs6742448	ENSG00000224177.5	LINC00570	3.68	0.000242	0.0134	0.13	0.11	Prostate cancer;	chr2:10619000	chr2:11393981~11403077:+
BRCA	cis	rs9287719	0.781	rs6732671	ENSG00000224177.5	LINC00570	3.68	0.000242	0.0134	0.13	0.11	Prostate cancer;	chr2:10619023	chr2:11393981~11403077:+
BRCA	cis	rs7200543	1	rs16966952	ENSG00000207425.1	Y_RNA	-3.68	0.000242	0.0134	-0.14	-0.11	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15042086	chr16:14915457~14915556:-
BRCA	cis	rs672059	0.812	rs61418038	ENSG00000224468.3	RP11-181K3.4	-3.68	0.000242	0.0134	-0.12	-0.11	Hypertriglyceridemia;	chr1:183186582	chr1:183138402~183141282:-
BRCA	cis	rs4478858	0.735	rs6425737	ENSG00000260386.4	LINC01225	-3.68	0.000242	0.0134	-0.13	-0.11	Alcohol dependence;	chr1:31317441	chr1:31500085~31540885:+
BRCA	cis	rs4478858	0.735	rs3806255	ENSG00000260386.4	LINC01225	-3.68	0.000242	0.0134	-0.13	-0.11	Alcohol dependence;	chr1:31318731	chr1:31500085~31540885:+
BRCA	cis	rs7412746	0.658	rs2089082	ENSG00000231073.1	RP11-316M1.3	3.68	0.000242	0.0134	0.12	0.11	Melanoma;	chr1:150827614	chr1:150973123~150975534:+
BRCA	cis	rs10991814	0.513	rs7852888	ENSG00000235641.4	LINC00484	3.68	0.000242	0.0134	0.17	0.11	Neutrophil percentage of granulocytes;	chr9:91292564	chr9:91159573~91165658:+
BRCA	cis	rs4468007	0.831	rs10985420	ENSG00000261534.1	RP11-244O19.1	-3.68	0.000242	0.0134	-0.13	-0.11	Educational attainment;	chr9:121849237	chr9:121815674~121819452:-
BRCA	cis	rs17092148	1	rs6060040	ENSG00000202150.1	RNU6-407P	3.68	0.000242	0.0134	0.17	0.11	Neuroticism;	chr20:34771251	chr20:35030317~35030420:-
BRCA	cis	rs853679	0.546	rs200949	ENSG00000216901.1	AL022393.7	3.68	0.000242	0.0134	0.21	0.11	Depression;	chr6:27867657	chr6:28176188~28176674:+
BRCA	cis	rs465969	1	rs17510761	ENSG00000271789.1	RP5-1112D6.7	3.68	0.000242	0.0134	0.27	0.11	Psoriasis;	chr6:111387380	chr6:111297126~111298510:+
BRCA	cis	rs465969	1	rs78945802	ENSG00000271789.1	RP5-1112D6.7	3.68	0.000242	0.0134	0.27	0.11	Psoriasis;	chr6:111407143	chr6:111297126~111298510:+
BRCA	cis	rs465969	1	rs17072683	ENSG00000271789.1	RP5-1112D6.7	3.68	0.000242	0.0134	0.27	0.11	Psoriasis;	chr6:111410007	chr6:111297126~111298510:+
BRCA	cis	rs7131987	0.675	rs1436322	ENSG00000257176.2	RP11-996F15.2	3.68	0.000242	0.0134	0.13	0.11	QT interval;	chr12:29401872	chr12:29280418~29317848:-
BRCA	cis	rs863345	0.604	rs60104403	ENSG00000229914.1	RP11-404O13.4	-3.68	0.000242	0.0134	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158531057	chr1:158195633~158196131:-
BRCA	cis	rs6723162	0.51	rs7556718	ENSG00000237751.2	LINC01143	-3.68	0.000242	0.0134	-0.16	-0.11	Neurocognitive impairment in HIV-1 infection (dichotomous);	chr2:70918611	chr2:70887871~70889959:+
BRCA	cis	rs35304300	1	rs35304300	ENSG00000225177.4	RP11-390P2.4	3.68	0.000242	0.0134	0.13	0.11	Mean platelet volume;	chr6:139536204	chr6:138692548~138697288:+
BRCA	cis	rs891378	1	rs925130	ENSG00000274245.1	RP11-357P18.2	-3.68	0.000242	0.0134	-0.15	-0.11	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207330087	chr1:207372559~207373252:+
BRCA	cis	rs7914558	0.621	rs12219346	ENSG00000213277.3	MARCKSL1P1	3.68	0.000242	0.0134	0.14	0.11	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102897543	chr10:103175554~103176094:+
BRCA	cis	rs75804782	0.52	rs34058921	ENSG00000186235.9	AC016757.3	3.68	0.000242	0.0134	0.25	0.11	Chronotype;Morning vs. evening chronotype;	chr2:238410024	chr2:238224552~238231677:-
BRCA	cis	rs75804782	0.641	rs56134361	ENSG00000186235.9	AC016757.3	3.68	0.000242	0.0134	0.25	0.11	Chronotype;Morning vs. evening chronotype;	chr2:238410264	chr2:238224552~238231677:-
BRCA	cis	rs75804782	0.691	rs55886641	ENSG00000186235.9	AC016757.3	3.68	0.000242	0.0134	0.25	0.11	Chronotype;Morning vs. evening chronotype;	chr2:238410544	chr2:238224552~238231677:-
BRCA	cis	rs75804782	0.641	rs72983834	ENSG00000186235.9	AC016757.3	3.68	0.000242	0.0134	0.25	0.11	Chronotype;Morning vs. evening chronotype;	chr2:238411254	chr2:238224552~238231677:-
BRCA	cis	rs75804782	0.581	rs13415491	ENSG00000186235.9	AC016757.3	3.68	0.000242	0.0134	0.25	0.11	Chronotype;Morning vs. evening chronotype;	chr2:238411260	chr2:238224552~238231677:-
BRCA	cis	rs75804782	0.641	rs55844289	ENSG00000186235.9	AC016757.3	3.68	0.000242	0.0134	0.25	0.11	Chronotype;Morning vs. evening chronotype;	chr2:238414566	chr2:238224552~238231677:-
BRCA	cis	rs7208859	0.623	rs9898084	ENSG00000276250.1	CTD-2349P21.12	-3.68	0.000242	0.0134	-0.18	-0.11	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30755316	chr17:30803654~30804077:+
BRCA	cis	rs889312	0.961	rs6450401	ENSG00000271828.1	CTD-2310F14.1	-3.68	0.000242	0.0134	-0.14	-0.11	Breast cancer (early onset);Breast cancer;	chr5:56737407	chr5:56927874~56929573:+
BRCA	cis	rs6452790	0.529	rs11948159	ENSG00000247828.6	TMEM161B-AS1	3.68	0.000242	0.0134	0.15	0.11	Cognitive function;	chr5:87973188	chr5:88268895~88436685:+
BRCA	cis	rs7246657	0.943	rs4802766	ENSG00000267470.4	ZNF571-AS1	3.68	0.000242	0.0134	0.15	0.11	Coronary artery calcification;	chr19:37491031	chr19:37548914~37587348:+
BRCA	cis	rs6736093	0.796	rs13006228	ENSG00000236307.2	EEF1E1P1	-3.68	0.000242	0.0134	-0.14	-0.11	Coronary artery disease;	chr2:112049161	chr2:111887914~111888741:+
BRCA	cis	rs6964587	0.934	rs7793861	ENSG00000188693.7	CYP51A1-AS1	-3.68	0.000242	0.0134	-0.12	-0.11	Breast cancer;	chr7:92113414	chr7:92134604~92180725:+
BRCA	cis	rs739496	0.579	rs11066095	ENSG00000234608.6	MAPKAPK5-AS1	3.68	0.000242	0.0134	0.14	0.11	Platelet count;	chr12:111939733	chr12:111839764~111842902:-
BRCA	cis	rs739496	0.579	rs7133881	ENSG00000234608.6	MAPKAPK5-AS1	3.68	0.000242	0.0134	0.14	0.11	Platelet count;	chr12:111940964	chr12:111839764~111842902:-
BRCA	cis	rs6490294	0.748	rs7295665	ENSG00000234608.6	MAPKAPK5-AS1	3.68	0.000242	0.0134	0.14	0.11	Mean platelet volume;	chr12:111941467	chr12:111839764~111842902:-
BRCA	cis	rs739496	0.614	rs7137889	ENSG00000234608.6	MAPKAPK5-AS1	3.68	0.000242	0.0134	0.14	0.11	Platelet count;	chr12:111941783	chr12:111839764~111842902:-
BRCA	cis	rs6490294	0.904	rs12579298	ENSG00000234608.6	MAPKAPK5-AS1	3.68	0.000242	0.0134	0.14	0.11	Mean platelet volume;	chr12:111956218	chr12:111839764~111842902:-
BRCA	cis	rs6490294	0.904	rs12306814	ENSG00000234608.6	MAPKAPK5-AS1	3.68	0.000242	0.0134	0.14	0.11	Mean platelet volume;	chr12:111966009	chr12:111839764~111842902:-
BRCA	cis	rs61931739	0.5	rs11053246	ENSG00000258794.3	DUX4L27	3.68	0.000242	0.0134	0.16	0.11	Morning vs. evening chronotype;	chr12:34363685	chr12:34208415~34209675:-
BRCA	cis	rs7020830	0.931	rs6476613	ENSG00000260100.1	RP11-220I1.5	-3.68	0.000242	0.0134	-0.14	-0.11	Schizophrenia;	chr9:37084343	chr9:37078813~37079776:-
BRCA	cis	rs983392	0.755	rs556917	ENSG00000275344.1	MIR6503	-3.68	0.000242	0.0134	-0.11	-0.11	Alzheimer's disease (late onset);	chr11:60091239	chr11:60209071~60209156:-
BRCA	cis	rs253959	0.545	rs712599	ENSG00000271918.1	CTD-2287O16.5	-3.68	0.000242	0.0134	-0.09	-0.11	Bipolar disorder and schizophrenia;	chr5:116323068	chr5:116083807~116085416:-
BRCA	cis	rs12549902	0.932	rs6981607	ENSG00000254165.1	RP11-503E24.2	3.68	0.000242	0.0134	0.12	0.11	Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Corrected insulin response;Type 2 diabetes;	chr8:41650649	chr8:42537529~42538304:-
BRCA	cis	rs62244186	0.659	rs12108134	ENSG00000233509.2	ZNF197-AS1	-3.68	0.000242	0.0134	-0.14	-0.11	Depressive symptoms;	chr3:44501538	chr3:44617128~44624797:-
BRCA	cis	rs6120849	0.754	rs1885116	ENSG00000202150.1	RNU6-407P	3.68	0.000242	0.0134	0.16	0.11	Protein C levels;	chr20:35012757	chr20:35030317~35030420:-
BRCA	cis	rs6120849	0.754	rs1885117	ENSG00000202150.1	RNU6-407P	3.68	0.000242	0.0134	0.16	0.11	Protein C levels;	chr20:35012937	chr20:35030317~35030420:-
BRCA	cis	rs9650657	0.589	rs6985109	ENSG00000255046.1	RP11-297N6.4	-3.68	0.000242	0.0134	-0.13	-0.11	Neuroticism;	chr8:10904075	chr8:11797928~11802568:-
BRCA	cis	rs3764563	1	rs2283603	ENSG00000267594.5	CYP4F24P	-3.68	0.000242	0.0134	-0.21	-0.11	Inflammatory biomarkers;	chr19:15620318	chr19:15760241~15779909:-
BRCA	cis	rs3816183	0.916	rs920393	ENSG00000226491.1	FTOP1	-3.68	0.000242	0.0134	-0.14	-0.11	Hypospadias;	chr2:42795268	chr2:42797225~42798712:-
BRCA	cis	rs875971	0.545	rs73142245	ENSG00000232559.3	GS1-124K5.12	3.68	0.000242	0.0134	0.16	0.11	Aortic root size;	chr7:66226662	chr7:66554588~66576923:-
BRCA	cis	rs2882667	0.964	rs12055237	ENSG00000242683.1	CTB-46B19.1	3.68	0.000242	0.0134	0.13	0.11	Age-related hearing impairment (SNP x SNP interaction);	chr5:138971617	chr5:139035148~139035987:-
BRCA	cis	rs67981189	0.572	rs2810077	ENSG00000258571.1	PTTG4P	3.68	0.000242	0.0134	0.12	0.11	Schizophrenia;	chr14:70897097	chr14:71085482~71085833:-
BRCA	cis	rs875971	1	rs937495	ENSG00000272831.1	RP11-792A8.4	-3.68	0.000242	0.0134	-0.1	-0.11	Aortic root size;	chr7:66314811	chr7:66739829~66740385:-
BRCA	cis	rs875971	1	rs2036264	ENSG00000272831.1	RP11-792A8.4	-3.68	0.000242	0.0134	-0.1	-0.11	Aortic root size;	chr7:66334917	chr7:66739829~66740385:-
BRCA	cis	rs875971	1	rs7783613	ENSG00000272831.1	RP11-792A8.4	-3.68	0.000242	0.0134	-0.1	-0.11	Aortic root size;	chr7:66340274	chr7:66739829~66740385:-
BRCA	cis	rs1008375	0.931	rs6449328	ENSG00000249502.1	AC006160.5	-3.68	0.000242	0.0134	-0.13	-0.11	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17698851	chr4:17587467~17614571:-
BRCA	cis	rs7824557	0.767	rs7003241	ENSG00000154316.13	TDH	-3.68	0.000242	0.0134	-0.16	-0.11	Retinal vascular caliber;	chr8:11311566	chr8:11339637~11368452:+
BRCA	cis	rs6585424	1	rs34749786	ENSG00000225484.5	NUTM2B-AS1	-3.68	0.000242	0.0134	-0.23	-0.11	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80164634	chr10:79663088~79826594:-
BRCA	cis	rs6585424	1	rs61860024	ENSG00000225484.5	NUTM2B-AS1	-3.68	0.000242	0.0134	-0.23	-0.11	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80165607	chr10:79663088~79826594:-
BRCA	cis	rs10464366	0.879	rs10464368	ENSG00000233306.2	TRGV2	3.68	0.000242	0.0134	0.11	0.11	IgG glycosylation;	chr7:39081981	chr7:38362864~38363518:-
BRCA	cis	rs2108622	0.727	rs62106155	ENSG00000214049.6	UCA1	3.68	0.000243	0.0134	0.16	0.11	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15869550	chr19:15828961~15836320:+
BRCA	cis	rs10043228	1	rs62384678	ENSG00000271918.1	CTD-2287O16.5	-3.68	0.000243	0.0134	-0.15	-0.11	Asthma or chronic obstructive pulmonary disease;	chr5:116086991	chr5:116083807~116085416:-
BRCA	cis	rs5742933	1	rs1317751	ENSG00000253559.1	OSGEPL1-AS1	-3.68	0.000243	0.0134	-0.16	-0.11	Ferritin levels;	chr2:189807898	chr2:189762704~189765556:+
BRCA	cis	rs6924995	0.956	rs6921316	ENSG00000218073.1	RP1-13D10.2	3.68	0.000243	0.0134	0.15	0.11	Response to statins (LDL cholesterol change);	chr6:16157030	chr6:16160926~16161411:+
BRCA	cis	rs4950322	0.57	rs72692979	ENSG00000227242.3	NBPF13P	-3.68	0.000243	0.0134	-0.16	-0.11	Protein quantitative trait loci;	chr1:147336094	chr1:147021320~147124525:-
BRCA	cis	rs1371614	0.632	rs10196501	ENSG00000229122.1	AGBL5-IT1	3.68	0.000243	0.0134	0.12	0.11	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26924404	chr2:27061038~27061815:+
BRCA	cis	rs6964587	0.967	rs2299235	ENSG00000188693.7	CYP51A1-AS1	-3.68	0.000243	0.0134	-0.12	-0.11	Breast cancer;	chr7:91998186	chr7:92134604~92180725:+
BRCA	cis	rs4449834	0.816	rs11992809	ENSG00000254432.1	RP11-33I11.2	-3.68	0.000243	0.0134	-0.15	-0.11	Sum eosinophil basophil counts;	chr8:60759071	chr8:60808735~60809606:-
BRCA	cis	rs1998359	0.953	rs17768503	ENSG00000259087.4	RP11-356O9.2	3.68	0.000243	0.0134	0.13	0.11	Self-reported allergy;	chr14:37706836	chr14:37556158~37567095:-
BRCA	cis	rs897984	0.572	rs4889526	ENSG00000279196.1	RP11-1072A3.3	3.68	0.000243	0.0134	0.12	0.11	Dementia with Lewy bodies;	chr16:31019023	chr16:30984630~30988270:-
BRCA	cis	rs56281245	0.793	rs1594675	ENSG00000249363.1	CTB-78O21.1	3.68	0.000243	0.0134	0.23	0.11	Hepcidin levels;	chr5:145593467	chr5:145728360~145729349:-
BRCA	cis	rs56281245	0.793	rs17103502	ENSG00000249363.1	CTB-78O21.1	3.68	0.000243	0.0134	0.23	0.11	Hepcidin levels;	chr5:145596439	chr5:145728360~145729349:-
BRCA	cis	rs56281245	0.793	rs953408	ENSG00000249363.1	CTB-78O21.1	3.68	0.000243	0.0134	0.23	0.11	Hepcidin levels;	chr5:145597245	chr5:145728360~145729349:-
BRCA	cis	rs721917	0.525	rs4281433	ENSG00000278616.1	BEND3P3	-3.68	0.000243	0.0134	-0.1	-0.11	Chronic obstructive pulmonary disease;	chr10:79982904	chr10:79682997~79685436:+
BRCA	cis	rs7267979	1	rs448396	ENSG00000277938.1	RP5-965G21.3	3.68	0.000243	0.0134	0.14	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25459633	chr20:25229150~25231933:+
BRCA	cis	rs13401620	0.871	rs4533476	ENSG00000229326.3	AC069154.4	3.68	0.000243	0.0134	0.15	0.11	Breast size;	chr2:119933881	chr2:119698623~119700151:+
BRCA	cis	rs13126694	0.744	rs7657303	ENSG00000251073.1	NUDT19P5	-3.68	0.000243	0.0134	-0.11	-0.11	Blood osmolality (transformed sodium);	chr4:157992992	chr4:158182825~158183393:+
BRCA	cis	rs600626	0.636	rs10793125	ENSG00000255507.4	RP11-535A19.2	3.68	0.000243	0.0134	0.19	0.11	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr11:75741319	chr11:75803431~75815406:-
BRCA	cis	rs2274273	0.87	rs11851169	ENSG00000259318.1	RP11-454L9.2	3.68	0.000243	0.0134	0.1	0.11	Protein biomarker;	chr14:55349214	chr14:55394940~55395233:-
BRCA	cis	rs1510510	0.742	rs1027927	ENSG00000186235.9	AC016757.3	3.68	0.000243	0.0134	0.19	0.11	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr2:238615957	chr2:238224552~238231677:-
BRCA	cis	rs41369048	0.66	rs10495157	ENSG00000272823.1	RP11-295M18.6	-3.68	0.000243	0.0134	-0.16	-0.11	Eosinophil counts;Sum eosinophil basophil counts;	chr1:220934454	chr1:220828676~220829211:-
BRCA	cis	rs8035452	1	rs8035635	ENSG00000273674.3	CTD-2378E12.1	-3.68	0.000243	0.0134	-0.13	-0.11	Alzheimer's disease (late onset);	chr15:50718632	chr15:50839875~50908599:-
BRCA	cis	rs6736093	0.7	rs4848958	ENSG00000243389.1	AC012442.5	-3.68	0.000243	0.0134	-0.16	-0.11	Coronary artery disease;	chr2:112028198	chr2:112589040~112614431:+
BRCA	cis	rs11242704	0.632	rs3000065	ENSG00000218027.2	RP11-157J24.1	3.68	0.000243	0.0134	0.15	0.11	Response to hepatitis C treatment;	chr6:1536463	chr6:1513698~1515289:-
BRCA	cis	rs6431644	0.694	rs580045	ENSG00000224287.2	MSL3P1	-3.68	0.000243	0.0134	-0.14	-0.11	Left atrial antero-posterior diameter;	chr2:233853169	chr2:233865437~233868444:-
BRCA	cis	rs13325613	0.834	rs13075270	ENSG00000223552.1	RP11-24F11.2	-3.68	0.000243	0.0134	-0.18	-0.11	Monocyte count;	chr3:46212298	chr3:46364955~46407059:-
BRCA	cis	rs4714291	1	rs4714291	ENSG00000180211.5	RP1-278E11.3	3.68	0.000243	0.0134	0.12	0.11	Strep throat;	chr6:40035893	chr6:39958414~39958833:-
BRCA	cis	rs11098499	1	rs11098500	ENSG00000260091.1	RP11-33B1.4	-3.68	0.000243	0.0134	-0.1	-0.11	Corneal astigmatism;	chr4:119298084	chr4:119409333~119410233:+
BRCA	cis	rs61931739	0.534	rs10844725	ENSG00000258794.3	DUX4L27	3.68	0.000243	0.0134	0.16	0.11	Morning vs. evening chronotype;	chr12:33856569	chr12:34208415~34209675:-
BRCA	cis	rs595982	0.702	rs638050	ENSG00000235191.1	NUCB1-AS1	3.68	0.000243	0.0134	0.14	0.11	Red cell distribution width;	chr19:48872419	chr19:48910930~48918891:-
BRCA	cis	rs1348850	0.768	rs57681892	ENSG00000271825.1	RP11-337N6.2	3.68	0.000243	0.0134	0.15	0.11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177492917	chr2:177300600~177302006:+
BRCA	cis	rs801193	1	rs2055682	ENSG00000232546.1	RP11-458F8.1	-3.68	0.000243	0.0134	-0.09	-0.11	Aortic root size;	chr7:66795302	chr7:66848496~66858136:+
BRCA	cis	rs7267979	0.903	rs2474766	ENSG00000274414.1	RP5-965G21.4	-3.68	0.000243	0.0134	-0.13	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25265517	chr20:25239007~25245229:-
BRCA	cis	rs7267979	0.903	rs2474769	ENSG00000274414.1	RP5-965G21.4	-3.68	0.000243	0.0134	-0.13	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25268089	chr20:25239007~25245229:-
BRCA	cis	rs72928364	1	rs62273935	ENSG00000244119.1	PDCL3P4	3.68	0.000243	0.0134	0.14	0.11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100950732	chr3:101712472~101713191:+
BRCA	cis	rs863345	0.604	rs6699473	ENSG00000229914.1	RP11-404O13.4	-3.68	0.000243	0.0135	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158525419	chr1:158195633~158196131:-
BRCA	cis	rs1910358	0.554	rs10057796	ENSG00000248874.4	C5orf17	3.68	0.000243	0.0135	0.17	0.11	Venous thromboembolism (SNP x SNP interaction);	chr5:23759637	chr5:23951348~24178263:+
BRCA	cis	rs736408	0.812	rs2071508	ENSG00000242142.1	SERBP1P3	-3.68	0.000243	0.0135	-0.13	-0.11	Bipolar disorder;	chr3:52792830	chr3:53064283~53065091:-
BRCA	cis	rs6964587	1	rs28584017	ENSG00000188693.7	CYP51A1-AS1	-3.68	0.000243	0.0135	-0.12	-0.11	Breast cancer;	chr7:92089854	chr7:92134604~92180725:+
BRCA	cis	rs144943143	1	rs144943143	ENSG00000279311.1	RP11-170K4.2	-3.68	0.000243	0.0135	-0.12	-0.11	Subjective well-being (multi-trait analysis);	chr3:158229062	chr3:158869898~158871821:+
BRCA	cis	rs4415084	0.966	rs34762678	ENSG00000248464.1	FGF10-AS1	3.68	0.000243	0.0135	0.13	0.11	Breast cancer;	chr5:44705412	chr5:44388732~44413989:+
BRCA	cis	rs4819052	0.851	rs8130285	ENSG00000215447.6	BX322557.10	-3.68	0.000243	0.0135	-0.12	-0.11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251786	chr21:45288052~45291738:+
BRCA	cis	rs4664293	0.669	rs2042778	ENSG00000224152.1	AC009506.1	3.68	0.000243	0.0135	0.12	0.11	Monocyte percentage of white cells;	chr2:159672119	chr2:159615296~159617082:+
BRCA	cis	rs4664293	0.625	rs62171654	ENSG00000224152.1	AC009506.1	3.68	0.000243	0.0135	0.12	0.11	Monocyte percentage of white cells;	chr2:159675107	chr2:159615296~159617082:+
BRCA	cis	rs4664293	0.625	rs11903816	ENSG00000224152.1	AC009506.1	3.68	0.000243	0.0135	0.12	0.11	Monocyte percentage of white cells;	chr2:159675347	chr2:159615296~159617082:+
BRCA	cis	rs4664293	0.625	rs6738523	ENSG00000224152.1	AC009506.1	3.68	0.000243	0.0135	0.12	0.11	Monocyte percentage of white cells;	chr2:159681203	chr2:159615296~159617082:+
BRCA	cis	rs4664293	0.585	rs11893106	ENSG00000224152.1	AC009506.1	3.68	0.000243	0.0135	0.12	0.11	Monocyte percentage of white cells;	chr2:159684294	chr2:159615296~159617082:+
BRCA	cis	rs17428076	0.872	rs17428174	ENSG00000228389.1	AC068039.4	-3.68	0.000243	0.0135	-0.17	-0.11	Myopia;	chr2:172021244	chr2:171773482~171775844:+
BRCA	cis	rs10129255	0.957	rs10141009	ENSG00000211967.3	IGHV3-53	-3.68	0.000243	0.0135	-0.08	-0.11	Kawasaki disease;	chr14:106776695	chr14:106592676~106593347:-
BRCA	cis	rs17214007	0.877	rs1569300	ENSG00000260735.1	RP11-72I8.1	-3.68	0.000243	0.0135	-0.16	-0.11	Cognitive function;	chr16:15776891	chr16:15094411~15109197:+
BRCA	cis	rs2836974	0.545	rs8128901	ENSG00000238141.2	BRWD1-AS1	3.68	0.000243	0.0135	0.13	0.11	Cognitive function;	chr21:39338493	chr21:39315707~39323218:+
BRCA	cis	rs4449834	0.851	rs4738824	ENSG00000254432.1	RP11-33I11.2	-3.68	0.000243	0.0135	-0.15	-0.11	Sum eosinophil basophil counts;	chr8:60777762	chr8:60808735~60809606:-
BRCA	cis	rs10487112	0.696	rs12154773	ENSG00000235436.9	DPY19L2P4	-3.68	0.000244	0.0135	-0.12	-0.11	Perceived unattractiveness to mosquitoes;	chr7:90532014	chr7:90119400~90125600:+
BRCA	cis	rs35146811	0.695	rs1618851	ENSG00000214313.7	AZGP1P1	-3.68	0.000244	0.0135	-0.12	-0.11	Coronary artery disease;	chr7:100213020	chr7:99980762~99987535:+
BRCA	cis	rs35146811	0.735	rs1727130	ENSG00000214313.7	AZGP1P1	-3.68	0.000244	0.0135	-0.12	-0.11	Coronary artery disease;	chr7:100213841	chr7:99980762~99987535:+
BRCA	cis	rs35146811	0.695	rs1727132	ENSG00000214313.7	AZGP1P1	-3.68	0.000244	0.0135	-0.12	-0.11	Coronary artery disease;	chr7:100214674	chr7:99980762~99987535:+
BRCA	cis	rs35146811	0.735	rs1727133	ENSG00000214313.7	AZGP1P1	-3.68	0.000244	0.0135	-0.12	-0.11	Coronary artery disease;	chr7:100215247	chr7:99980762~99987535:+
BRCA	cis	rs6964587	0.934	rs7811328	ENSG00000188693.7	CYP51A1-AS1	-3.68	0.000244	0.0135	-0.12	-0.11	Breast cancer;	chr7:92091617	chr7:92134604~92180725:+
BRCA	cis	rs568617	1	rs656980	ENSG00000254614.2	AP003068.23	-3.68	0.000244	0.0135	-0.17	-0.11	Crohn's disease;	chr11:65888811	chr11:65177606~65181834:-
BRCA	cis	rs7395581	0.918	rs12575456	ENSG00000280615.1	Y_RNA	3.68	0.000244	0.0135	0.14	0.11	HDL cholesterol;	chr11:47304522	chr11:47614898~47614994:-
BRCA	cis	rs7395581	0.918	rs1375688	ENSG00000280615.1	Y_RNA	3.68	0.000244	0.0135	0.14	0.11	HDL cholesterol;	chr11:47305666	chr11:47614898~47614994:-
BRCA	cis	rs1949733	1	rs6837429	ENSG00000251615.3	RP11-774O3.3	-3.68	0.000244	0.0135	-0.12	-0.11	Response to antineoplastic agents;	chr4:8500647	chr4:8355090~8358338:-
BRCA	cis	rs2274273	1	rs7160110	ENSG00000259318.1	RP11-454L9.2	3.68	0.000244	0.0135	0.1	0.11	Protein biomarker;	chr14:55127917	chr14:55394940~55395233:-
BRCA	cis	rs72819225	0.616	rs4933665	ENSG00000228701.1	TNKS2-AS1	3.68	0.000244	0.0135	0.14	0.11	Yeast infection;	chr10:91567549	chr10:91782839~91798291:-
BRCA	cis	rs7267979	0.966	rs6083855	ENSG00000276952.1	RP5-965G21.6	-3.68	0.000244	0.0135	-0.14	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25424482	chr20:25284915~25285588:-
BRCA	cis	rs7267979	1	rs4815426	ENSG00000276952.1	RP5-965G21.6	-3.68	0.000244	0.0135	-0.14	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25424550	chr20:25284915~25285588:-
BRCA	cis	rs7246657	0.943	rs2291004	ENSG00000267470.4	ZNF571-AS1	3.68	0.000244	0.0135	0.15	0.11	Coronary artery calcification;	chr19:37507050	chr19:37548914~37587348:+
BRCA	cis	rs3850699	0.666	rs7905481	ENSG00000236937.2	PTGES3P4	3.68	0.000244	0.0135	0.16	0.11	Prostate cancer;	chr10:102716535	chr10:102845595~102845950:+
BRCA	cis	rs7426380	0.525	rs6545527	ENSG00000272606.1	RP11-554J4.1	3.68	0.000244	0.0135	0.13	0.11	Intraocular pressure;	chr2:55846674	chr2:55617909~55618373:+
BRCA	cis	rs4950322	0.58	rs7541393	ENSG00000230832.3	RP11-325P15.2	-3.68	0.000244	0.0135	-0.17	-0.11	Protein quantitative trait loci;	chr1:147117186	chr1:147082338~147083578:-
BRCA	cis	rs11154801	0.732	rs13202115	ENSG00000234084.1	RP3-388E23.2	-3.68	0.000244	0.0135	-0.11	-0.11	Multiple sclerosis;	chr6:135604386	chr6:135301568~135307158:+
BRCA	cis	rs17374749	0.598	rs17309935	ENSG00000273486.1	RP11-731C17.2	3.68	0.000244	0.0135	0.15	0.11	Anxiety in major depressive disorder;	chr3:137124201	chr3:136837338~136839021:-
BRCA	cis	rs9500256	0.711	rs6588685	ENSG00000272316.1	XXbac-BPGBPG55C20.2	3.68	0.000244	0.0135	0.1	0.11	Eosinophilic esophagitis (pediatric);	chr6:57993375	chr6:57908560~57913911:-
BRCA	cis	rs4849845	0.653	rs3925970	ENSG00000223549.1	MTND5P28	3.68	0.000244	0.0135	0.13	0.11	Mean platelet volume;	chr2:120260577	chr2:120215181~120217279:+
BRCA	cis	rs2274273	0.624	rs7157308	ENSG00000259318.1	RP11-454L9.2	3.68	0.000244	0.0135	0.1	0.11	Protein biomarker;	chr14:55315325	chr14:55394940~55395233:-
BRCA	cis	rs73198271	0.96	rs10503392	ENSG00000253893.2	FAM85B	3.68	0.000244	0.0135	0.18	0.11	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8752045	chr8:8167819~8226614:-
BRCA	cis	rs4664293	0.967	rs2357526	ENSG00000224152.1	AC009506.1	3.68	0.000244	0.0135	0.12	0.11	Monocyte percentage of white cells;	chr2:159668085	chr2:159615296~159617082:+
BRCA	cis	rs6504622	0.755	rs7219544	ENSG00000263142.4	LRRC37A17P	-3.68	0.000244	0.0135	-0.09	-0.11	Orofacial clefts;	chr17:47089562	chr17:46978481~47054569:+
BRCA	cis	rs75804782	0.641	rs60841092	ENSG00000186235.9	AC016757.3	3.68	0.000244	0.0135	0.25	0.11	Chronotype;Morning vs. evening chronotype;	chr2:238440999	chr2:238224552~238231677:-
BRCA	cis	rs28489187	0.683	rs11161607	ENSG00000223653.4	RP11-131L23.1	3.68	0.000244	0.0135	0.13	0.11	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85390172	chr1:85276715~85448124:+
BRCA	cis	rs11668609	0.515	rs58278214	ENSG00000268442.1	CTD-2027I19.2	3.68	0.000244	0.0135	0.2	0.11	Response to taxane treatment (docetaxel);	chr19:23888887	chr19:24162370~24163425:-
BRCA	cis	rs11668609	0.515	rs2195971	ENSG00000268442.1	CTD-2027I19.2	3.68	0.000244	0.0135	0.2	0.11	Response to taxane treatment (docetaxel);	chr19:23897191	chr19:24162370~24163425:-
BRCA	cis	rs991427	1	rs991427	ENSG00000258100.1	RP11-121E16.1	-3.68	0.000244	0.0135	-0.15	-0.11	Systolic blood pressure (alcohol consumption interaction);	chr12:91080645	chr12:91362196~91368606:+
BRCA	cis	rs3742264	0.656	rs1041166	ENSG00000235903.6	CPB2-AS1	-3.68	0.000244	0.0135	-0.14	-0.11	Blood protein levels;	chr13:45981085	chr13:46052806~46113332:+
BRCA	cis	rs10043775	1	rs10044061	ENSG00000251330.3	CTD-2283N19.1	-3.68	0.000244	0.0135	-0.13	-0.11	Periodontal microbiota;	chr5:148396934	chr5:148430159~148430807:-
BRCA	cis	rs11893307	0.566	rs10170782	ENSG00000235852.1	AC005540.3	3.68	0.000244	0.0135	0.15	0.11	Mean platelet volume;	chr2:190758510	chr2:190880797~190882059:-
BRCA	cis	rs6545883	0.929	rs12612982	ENSG00000212978.6	AC016747.3	3.68	0.000244	0.0135	0.15	0.11	Tuberculosis;	chr2:61520220	chr2:61141592~61144969:-
BRCA	cis	rs4886920	0.672	rs4886939	ENSG00000259792.1	RP11-114H24.6	3.68	0.000244	0.0135	0.12	0.11	Neuroticism;	chr15:77847251	chr15:77993405~77995289:+
BRCA	cis	rs116175783	0.557	rs16845844	ENSG00000235724.7	AC009299.2	-3.68	0.000244	0.0135	-0.17	-0.11	Intelligence (multi-trait analysis);	chr2:161408759	chr2:161222785~161308303:-
BRCA	cis	rs875971	0.825	rs66981195	ENSG00000229886.1	RP5-1132H15.3	-3.68	0.000244	0.0135	-0.13	-0.11	Aortic root size;	chr7:66614048	chr7:66025126~66031544:-
BRCA	cis	rs875971	0.862	rs3926380	ENSG00000229886.1	RP5-1132H15.3	-3.68	0.000244	0.0135	-0.13	-0.11	Aortic root size;	chr7:66615658	chr7:66025126~66031544:-
BRCA	cis	rs875971	0.825	rs1860472	ENSG00000229886.1	RP5-1132H15.3	-3.68	0.000244	0.0135	-0.13	-0.11	Aortic root size;	chr7:66617736	chr7:66025126~66031544:-
BRCA	cis	rs889956	0.714	rs11886848	ENSG00000233251.6	AC007743.1	-3.68	0.000244	0.0135	-0.13	-0.11	Educational attainment;	chr2:57039636	chr2:56173534~56185770:-
BRCA	cis	rs3753275	0.519	rs7533442	ENSG00000270282.1	RP5-1115A15.2	3.68	0.000244	0.0135	0.16	0.11	Educational attainment;	chr1:8690532	chr1:8512653~8513021:+
BRCA	cis	rs2227564	0.62	rs10740418	ENSG00000242288.9	RP11-464F9.1	3.68	0.000244	0.0135	0.15	0.11	Crohn's disease;Inflammatory bowel disease;	chr10:73759564	chr10:73674295~73730466:-
BRCA	cis	rs860295	0.812	rs12081192	ENSG00000160766.13	GBAP1	-3.68	0.000244	0.0135	-0.12	-0.11	Body mass index;	chr1:155768253	chr1:155213821~155227422:-
BRCA	cis	rs9863	0.896	rs76283024	ENSG00000270028.1	RP11-380L11.4	3.68	0.000244	0.0135	0.14	0.11	White blood cell count;	chr12:123982232	chr12:123925461~123926083:-
BRCA	cis	rs7045881	0.696	rs7871286	ENSG00000254396.1	RP11-56F10.3	3.68	0.000244	0.0135	0.17	0.11	Schizophrenia;	chr9:26917720	chr9:27102630~27104728:+
BRCA	cis	rs4478858	0.735	rs6676354	ENSG00000260386.4	LINC01225	-3.68	0.000244	0.0135	-0.13	-0.11	Alcohol dependence;	chr1:31327899	chr1:31500085~31540885:+
BRCA	cis	rs3735485	0.698	rs10248390	ENSG00000201772.1	SNORA5C	3.68	0.000244	0.0135	0.15	0.11	White blood cell count;Sum basophil neutrophil counts;Neutrophil count;Granulocyte percentage of myeloid white cells;Monocyte percentage of white cells;Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Lymphocyte counts;	chr7:45071352	chr7:45104906~45105042:-
BRCA	cis	rs2562456	0.833	rs2650776	ENSG00000268117.1	VN1R84P	3.68	0.000245	0.0135	0.17	0.11	Pain;	chr19:21430595	chr19:21719801~21720035:-
BRCA	cis	rs13256369	0.76	rs7816171	ENSG00000233609.3	RP11-62H7.2	3.68	0.000245	0.0135	0.12	0.11	Obesity-related traits;	chr8:8718325	chr8:8961200~8979025:+
BRCA	cis	rs13256369	0.76	rs7839473	ENSG00000233609.3	RP11-62H7.2	3.68	0.000245	0.0135	0.12	0.11	Obesity-related traits;	chr8:8718326	chr8:8961200~8979025:+
BRCA	cis	rs7937682	0.961	rs17113227	ENSG00000230911.1	PPIHP1	-3.68	0.000245	0.0135	-0.16	-0.11	Primary sclerosing cholangitis;	chr11:111749767	chr11:112029858~112030367:-
BRCA	cis	rs7722600	1	rs112579530	ENSG00000253404.1	AC034243.1	-3.68	0.000245	0.0135	-0.18	-0.11	Heart rate;	chr5:137763121	chr5:138744434~138753309:-
BRCA	cis	rs7722600	0.808	rs11955012	ENSG00000253404.1	AC034243.1	-3.68	0.000245	0.0135	-0.19	-0.11	Heart rate;	chr5:138012328	chr5:138744434~138753309:-
BRCA	cis	rs301801	0.803	rs2661863	ENSG00000232912.4	RP5-1115A15.1	-3.68	0.000245	0.0135	-0.12	-0.11	Optic cup area;Vertical cup-disc ratio;	chr1:8392665	chr1:8424645~8434838:+
BRCA	cis	rs6736093	0.966	rs11676040	ENSG00000236307.2	EEF1E1P1	-3.68	0.000245	0.0135	-0.14	-0.11	Coronary artery disease;	chr2:111955538	chr2:111887914~111888741:+
BRCA	cis	rs6736093	0.966	rs11674891	ENSG00000236307.2	EEF1E1P1	-3.68	0.000245	0.0135	-0.14	-0.11	Coronary artery disease;	chr2:111955539	chr2:111887914~111888741:+
BRCA	cis	rs6736093	0.931	rs7578435	ENSG00000236307.2	EEF1E1P1	-3.68	0.000245	0.0135	-0.14	-0.11	Coronary artery disease;	chr2:111957174	chr2:111887914~111888741:+
BRCA	cis	rs1046491	0.901	rs8085669	ENSG00000264964.1	RP11-888D10.3	3.68	0.000245	0.0135	0.23	0.11	Scarlet fever;	chr18:9190644	chr18:9315194~9334441:-
BRCA	cis	rs9287719	0.967	rs9679581	ENSG00000224177.5	LINC00570	3.68	0.000245	0.0135	0.13	0.11	Prostate cancer;	chr2:10611610	chr2:11393981~11403077:+
BRCA	cis	rs6840360	0.532	rs4235221	ENSG00000270265.1	RP11-731D1.4	-3.68	0.000245	0.0135	-0.14	-0.11	Intelligence (multi-trait analysis);	chr4:151590041	chr4:151333775~151353224:-
BRCA	cis	rs6840360	0.571	rs62327268	ENSG00000270265.1	RP11-731D1.4	-3.68	0.000245	0.0135	-0.14	-0.11	Intelligence (multi-trait analysis);	chr4:151601174	chr4:151333775~151353224:-
BRCA	cis	rs4374383	0.631	rs11673958	ENSG00000243389.1	AC012442.5	-3.68	0.000245	0.0135	-0.14	-0.11	Hepatitis C induced liver fibrosis;	chr2:111952687	chr2:112589040~112614431:+
BRCA	cis	rs4374383	0.631	rs4848901	ENSG00000243389.1	AC012442.5	-3.68	0.000245	0.0135	-0.14	-0.11	Hepatitis C induced liver fibrosis;	chr2:111953251	chr2:112589040~112614431:+
BRCA	cis	rs4374383	0.558	rs17042095	ENSG00000243389.1	AC012442.5	-3.68	0.000245	0.0135	-0.14	-0.11	Hepatitis C induced liver fibrosis;	chr2:111955081	chr2:112589040~112614431:+
BRCA	cis	rs448720	1	rs338354	ENSG00000260657.2	RP11-315D16.4	-3.68	0.000245	0.0135	-0.13	-0.11	Cognitive performance;	chr15:67901279	chr15:68267792~68277994:-
BRCA	cis	rs911119	0.913	rs1158167	ENSG00000270001.1	RP11-218C14.8	3.68	0.000245	0.0135	0.14	0.11	Chronic kidney disease;	chr20:23597552	chr20:23631826~23632316:-
BRCA	cis	rs7475343	0.573	rs61854735	ENSG00000224034.1	RP11-445P17.8	-3.68	0.000245	0.0135	-0.21	-0.11	Intelligence;	chr10:5193799	chr10:5266033~5271236:-
BRCA	cis	rs7475343	0.573	rs61854736	ENSG00000224034.1	RP11-445P17.8	-3.68	0.000245	0.0135	-0.21	-0.11	Intelligence;	chr10:5193861	chr10:5266033~5271236:-
BRCA	cis	rs1538970	0.924	rs4660851	ENSG00000281133.1	AL355480.3	-3.68	0.000245	0.0135	-0.15	-0.11	Platelet count;	chr1:45378138	chr1:45580892~45580996:-
BRCA	cis	rs1555133	0.694	rs2295764	ENSG00000275576.1	RP5-836N17.4	-3.68	0.000245	0.0135	-0.13	-0.11	Monocyte count;	chr20:32437360	chr20:32116171~32116629:+
BRCA	cis	rs1555133	0.694	rs2295763	ENSG00000275576.1	RP5-836N17.4	-3.68	0.000245	0.0135	-0.13	-0.11	Monocyte count;	chr20:32437428	chr20:32116171~32116629:+
BRCA	cis	rs6142618	0.543	rs2295036	ENSG00000277692.1	RP11-358N2.2	-3.68	0.000245	0.0135	-0.12	-0.11	Inflammatory bowel disease;	chr20:32115793	chr20:32355053~32355734:+
BRCA	cis	rs6498068	0.594	rs1875928	ENSG00000279662.1	RP11-609N14.4	-3.68	0.000245	0.0135	-0.13	-0.11	Metabolite levels (MHPG);	chr16:10528028	chr16:10445309~10449747:-
BRCA	cis	rs10744955	0.727	rs11070759	ENSG00000244879.4	GABPB1-AS1	3.68	0.000245	0.0135	0.12	0.11	Lobe attachment (rater-scored or self-reported);	chr15:50165661	chr15:50354959~50372202:+
BRCA	cis	rs12317459	0.591	rs7295371	ENSG00000213270.5	RPL6P25	-3.68	0.000245	0.0135	-0.19	-0.11	Prostate cancer (SNP x SNP interaction);	chr12:82768303	chr12:83151331~83152190:+
BRCA	cis	rs8180040	0.62	rs749511	ENSG00000271161.1	BOLA2P2	-3.68	0.000245	0.0135	-0.12	-0.11	Colorectal cancer;	chr3:46994245	chr3:47499841~47500407:+
BRCA	cis	rs78545713	1	rs77281308	ENSG00000241549.7	GUSBP2	-3.68	0.000245	0.0135	-0.18	-0.11	Iron status biomarkers (total iron binding capacity);	chr6:26249801	chr6:26871484~26956554:-
BRCA	cis	rs78545713	1	rs78661760	ENSG00000241549.7	GUSBP2	-3.68	0.000245	0.0135	-0.18	-0.11	Iron status biomarkers (total iron binding capacity);	chr6:26249805	chr6:26871484~26956554:-
BRCA	cis	rs8127691	0.935	rs2838519	ENSG00000232124.1	AP001057.1	-3.68	0.000245	0.0135	-0.14	-0.11	Inflammatory bowel disease;	chr21:44195140	chr21:44201290~44202696:+
BRCA	cis	rs6736093	0.966	rs1122970	ENSG00000236307.2	EEF1E1P1	-3.68	0.000245	0.0135	-0.14	-0.11	Coronary artery disease;	chr2:111959120	chr2:111887914~111888741:+
BRCA	cis	rs863345	0.604	rs10797012	ENSG00000229914.1	RP11-404O13.4	-3.68	0.000245	0.0135	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158495695	chr1:158195633~158196131:-
BRCA	cis	rs863345	0.604	rs10797013	ENSG00000229914.1	RP11-404O13.4	-3.68	0.000245	0.0135	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158495716	chr1:158195633~158196131:-
BRCA	cis	rs2274273	0.624	rs4580079	ENSG00000259318.1	RP11-454L9.2	3.68	0.000245	0.0135	0.1	0.11	Protein biomarker;	chr14:55313648	chr14:55394940~55395233:-
BRCA	cis	rs7267979	1	rs4815420	ENSG00000274414.1	RP5-965G21.4	3.68	0.000245	0.0135	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25403343	chr20:25239007~25245229:-
BRCA	cis	rs7172677	0.737	rs12910348	ENSG00000260269.4	CTD-2323K18.1	-3.68	0.000245	0.0135	-0.16	-0.11	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75145301	chr15:75527150~75601205:-
BRCA	cis	rs8114671	0.836	rs3746432	ENSG00000261582.1	RP4-614O4.11	3.68	0.000245	0.0135	0.11	0.11	Height;	chr20:35004960	chr20:35267885~35280043:-
BRCA	cis	rs7690839	1	rs4693978	ENSG00000270720.1	RP11-84C13.2	3.68	0.000245	0.0135	0.13	0.11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr4:88933016	chr4:89119284~89119871:+
BRCA	cis	rs6490294	0.571	rs7959011	ENSG00000234608.6	MAPKAPK5-AS1	3.68	0.000245	0.0135	0.17	0.11	Mean platelet volume;	chr12:112063433	chr12:111839764~111842902:-
BRCA	cis	rs6490294	0.747	rs632650	ENSG00000226469.1	ADAM1B	3.68	0.000245	0.0135	0.16	0.11	Mean platelet volume;	chr12:111693894	chr12:111927018~111929017:+
BRCA	cis	rs9341808	0.739	rs4706831	ENSG00000279022.1	RP11-250B2.4	3.68	0.000245	0.0135	0.13	0.11	Sitting height ratio;	chr6:80297982	chr6:80440730~80441172:+
BRCA	cis	rs739496	0.947	rs2283358	ENSG00000257624.1	RP1-128M12.3	3.68	0.000245	0.0135	0.15	0.11	Platelet count;	chr12:111427761	chr12:112000739~112000985:-
BRCA	cis	rs45509595	0.841	rs17751184	ENSG00000216901.1	AL022393.7	3.68	0.000245	0.0135	0.29	0.11	Breast cancer;	chr6:27807250	chr6:28176188~28176674:+
BRCA	cis	rs9844666	0.512	rs9820057	ENSG00000273486.1	RP11-731C17.2	3.68	0.000245	0.0135	0.13	0.11	Height;	chr3:135937896	chr3:136837338~136839021:-
BRCA	cis	rs9844666	0.512	rs7623721	ENSG00000273486.1	RP11-731C17.2	3.68	0.000245	0.0135	0.13	0.11	Height;	chr3:135938572	chr3:136837338~136839021:-
BRCA	cis	rs9844666	0.512	rs35896773	ENSG00000273486.1	RP11-731C17.2	3.68	0.000245	0.0135	0.13	0.11	Height;	chr3:135940724	chr3:136837338~136839021:-
BRCA	cis	rs3096299	0.685	rs3803681	ENSG00000261118.1	RP11-104N10.1	3.68	0.000245	0.0135	0.12	0.11	Multiple myeloma (IgH translocation);	chr16:89478348	chr16:89492017~89504460:-
BRCA	cis	rs8094794	0.744	rs11664154	ENSG00000267707.2	RP11-95O2.5	3.68	0.000245	0.0136	0.17	0.11	Periodontal disease-related phenotypes;	chr18:36705459	chr18:37243776~37247506:+
BRCA	cis	rs4835473	0.932	rs13134327	ENSG00000246448.2	RP13-578N3.3	3.68	0.000245	0.0136	0.13	0.11	Immature fraction of reticulocytes;	chr4:143738642	chr4:143700257~143865072:+
BRCA	cis	rs875971	0.545	rs12670811	ENSG00000232559.3	GS1-124K5.12	3.68	0.000245	0.0136	0.15	0.11	Aortic root size;	chr7:66358032	chr7:66554588~66576923:-
BRCA	cis	rs3735485	0.689	rs4599721	ENSG00000201772.1	SNORA5C	-3.68	0.000245	0.0136	-0.15	-0.11	White blood cell count;Sum basophil neutrophil counts;Neutrophil count;Granulocyte percentage of myeloid white cells;Monocyte percentage of white cells;Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Lymphocyte counts;	chr7:45020112	chr7:45104906~45105042:-
BRCA	cis	rs3760982	0.585	rs10422108	ENSG00000267191.1	RP11-15A1.2	-3.68	0.000245	0.0136	-0.15	-0.11	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43790716	chr19:43902001~43926545:+
BRCA	cis	rs873549	1	rs753962	ENSG00000238042.4	RP11-815M8.1	3.68	0.000245	0.0136	0.13	0.11	Keloid;	chr1:222099722	chr1:221880981~221978523:-
BRCA	cis	rs7712401	0.791	rs1531340	ENSG00000251538.4	RP11-166A12.1	3.68	0.000245	0.0136	0.12	0.11	Mean platelet volume;	chr5:122772322	chr5:122628952~122730685:-
BRCA	cis	rs875971	0.52	rs160645	ENSG00000232559.3	GS1-124K5.12	-3.68	0.000245	0.0136	-0.16	-0.11	Aortic root size;	chr7:66091320	chr7:66554588~66576923:-
BRCA	cis	rs16846053	0.792	rs3849342	ENSG00000227403.1	AC009299.3	3.68	0.000246	0.0136	0.3	0.11	Blood osmolality (transformed sodium);	chr2:161811831	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.792	rs3849344	ENSG00000227403.1	AC009299.3	3.68	0.000246	0.0136	0.3	0.11	Blood osmolality (transformed sodium);	chr2:161812034	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.792	rs62187684	ENSG00000227403.1	AC009299.3	3.68	0.000246	0.0136	0.3	0.11	Blood osmolality (transformed sodium);	chr2:161812361	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.792	rs4603779	ENSG00000227403.1	AC009299.3	3.68	0.000246	0.0136	0.3	0.11	Blood osmolality (transformed sodium);	chr2:161812774	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.792	rs3849345	ENSG00000227403.1	AC009299.3	3.68	0.000246	0.0136	0.3	0.11	Blood osmolality (transformed sodium);	chr2:161813045	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.792	rs59829975	ENSG00000227403.1	AC009299.3	3.68	0.000246	0.0136	0.3	0.11	Blood osmolality (transformed sodium);	chr2:161815323	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.792	rs60050769	ENSG00000227403.1	AC009299.3	3.68	0.000246	0.0136	0.3	0.11	Blood osmolality (transformed sodium);	chr2:161815379	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.792	rs56154342	ENSG00000227403.1	AC009299.3	3.68	0.000246	0.0136	0.3	0.11	Blood osmolality (transformed sodium);	chr2:161816300	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.792	rs60064564	ENSG00000227403.1	AC009299.3	3.68	0.000246	0.0136	0.3	0.11	Blood osmolality (transformed sodium);	chr2:161816489	chr2:161244739~161249050:+
BRCA	cis	rs11587682	0.76	rs7542068	ENSG00000228126.1	FALEC	-3.68	0.000246	0.0136	-0.15	-0.11	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr1:150491296	chr1:150515757~150518032:+
BRCA	cis	rs4703129	0.967	rs13173749	ENSG00000246763.5	RGMB-AS1	-3.68	0.000246	0.0136	-0.13	-0.11	Asperger disorder;	chr5:98559857	chr5:98769618~98773469:-
BRCA	cis	rs863345	0.604	rs12133794	ENSG00000229914.1	RP11-404O13.4	-3.68	0.000246	0.0136	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158536907	chr1:158195633~158196131:-
BRCA	cis	rs61931739	0.5	rs11053248	ENSG00000258794.3	DUX4L27	3.68	0.000246	0.0136	0.16	0.11	Morning vs. evening chronotype;	chr12:34365076	chr12:34208415~34209675:-
BRCA	cis	rs61931739	0.5	rs34061369	ENSG00000258794.3	DUX4L27	3.68	0.000246	0.0136	0.16	0.11	Morning vs. evening chronotype;	chr12:34366348	chr12:34208415~34209675:-
BRCA	cis	rs61931739	0.5	rs7965421	ENSG00000258794.3	DUX4L27	3.68	0.000246	0.0136	0.16	0.11	Morning vs. evening chronotype;	chr12:34370689	chr12:34208415~34209675:-
BRCA	cis	rs61931739	0.5	rs6488222	ENSG00000258794.3	DUX4L27	3.68	0.000246	0.0136	0.16	0.11	Morning vs. evening chronotype;	chr12:34373354	chr12:34208415~34209675:-
BRCA	cis	rs61931739	0.5	rs34167298	ENSG00000258794.3	DUX4L27	3.68	0.000246	0.0136	0.16	0.11	Morning vs. evening chronotype;	chr12:34381403	chr12:34208415~34209675:-
BRCA	cis	rs61931739	0.5	rs7489130	ENSG00000258794.3	DUX4L27	3.68	0.000246	0.0136	0.16	0.11	Morning vs. evening chronotype;	chr12:34386739	chr12:34208415~34209675:-
BRCA	cis	rs61931739	0.5	rs7489132	ENSG00000258794.3	DUX4L27	3.68	0.000246	0.0136	0.16	0.11	Morning vs. evening chronotype;	chr12:34386777	chr12:34208415~34209675:-
BRCA	cis	rs61869271	0.688	rs7904605	ENSG00000236799.1	RP11-383C6.2	-3.68	0.000246	0.0136	-0.13	-0.11	Tonsillectomy;	chr10:114952570	chr10:114994657~114996593:+
BRCA	cis	rs72799341	1	rs72799341	ENSG00000275263.1	RP11-1072A3.4	-3.68	0.000246	0.0136	-0.16	-0.11	Diastolic blood pressure;	chr16:30925422	chr16:30956872~30957199:-
BRCA	cis	rs12324805	1	rs12324805	ENSG00000255769.6	GOLGA2P10	3.68	0.000246	0.0136	0.13	0.11	Body mass index;	chr15:82059859	chr15:82472993~82513950:-
BRCA	cis	rs6759004	1	rs6759004	ENSG00000201499.1	RNU6-312P	-3.68	0.000246	0.0136	-0.16	-0.11	Triptolide cytotoxicity;	chr2:201139953	chr2:200881715~200881821:-
BRCA	cis	rs2562456	0.72	rs6511250	ENSG00000268555.1	RP11-678G14.3	-3.68	0.000246	0.0136	-0.15	-0.11	Pain;	chr19:21473244	chr19:21570822~21587322:-
BRCA	cis	rs12530845	0.83	rs73721678	ENSG00000223718.3	AC093107.7	3.68	0.000246	0.0136	0.19	0.11	Red blood cell traits;	chr7:135670962	chr7:135660039~135660647:+
BRCA	cis	rs10129255	0.957	rs10136560	ENSG00000211958.2	IGHV3-38	3.68	0.000246	0.0136	0.09	0.11	Kawasaki disease;	chr14:106787630	chr14:106410493~106411021:-
BRCA	cis	rs853679	0.567	rs1005126	ENSG00000220721.1	OR1F12	3.68	0.000246	0.0136	0.15	0.11	Depression;	chr6:28399846	chr6:28073316~28074233:+
BRCA	cis	rs7267979	1	rs453329	ENSG00000204556.4	CTD-2514C3.1	-3.68	0.000246	0.0136	-0.15	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25459957	chr20:26018832~26020684:+
BRCA	cis	rs889312	0.5	rs702691	ENSG00000271828.1	CTD-2310F14.1	-3.68	0.000246	0.0136	-0.14	-0.11	Breast cancer (early onset);Breast cancer;	chr5:56818699	chr5:56927874~56929573:+
BRCA	cis	rs17695224	0.545	rs10853846	ENSG00000269483.1	AC006272.1	3.68	0.000246	0.0136	0.14	0.11	HDL cholesterol;HDL cholesterol levels;	chr19:51826595	chr19:51839924~51843324:-
BRCA	cis	rs6743226	0.603	rs11896191	ENSG00000266621.1	AC104841.1	3.68	0.000246	0.0136	0.13	0.11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in non-smokers;	chr2:241287336	chr2:241245202~241245299:-
BRCA	cis	rs8049367	0.684	rs11076791	ENSG00000267077.1	RP11-127I20.5	-3.68	0.000246	0.0136	-0.12	-0.11	Nonsyndromic cleft lip with or without cleft palate;	chr16:3914750	chr16:4795265~4796532:-
BRCA	cis	rs9381040	0.655	rs2294695	ENSG00000161912.16	ADCY10P1	3.68	0.000246	0.0136	0.13	0.11	Alzheimer's disease (late onset);	chr6:41069031	chr6:41101022~41140835:+
BRCA	cis	rs9472155	0.95	rs62401233	ENSG00000220614.1	RP11-480N24.4	3.68	0.000246	0.0136	0.15	0.11	Vascular endothelial growth factor levels;	chr6:43931579	chr6:43328134~43328476:+
BRCA	cis	rs7620503	0.613	rs11707809	ENSG00000231574.4	RP11-91K9.1	3.68	0.000246	0.0136	0.14	0.11	Corneal structure;	chr3:177567542	chr3:177816865~177899224:+
BRCA	cis	rs5742933	1	rs5742998	ENSG00000253559.1	OSGEPL1-AS1	-3.68	0.000246	0.0136	-0.16	-0.11	Ferritin levels;	chr2:189799626	chr2:189762704~189765556:+
BRCA	cis	rs7221109	0.585	rs6503547	ENSG00000229028.2	KRT223P	3.68	0.000246	0.0136	0.13	0.11	Type 1 diabetes;	chr17:40662956	chr17:40717235~40721932:-
BRCA	cis	rs718433	0.585	rs11844749	ENSG00000256379.1	TRAV8-5	3.68	0.000246	0.0136	0.15	0.11	Intraocular pressure;	chr14:21808964	chr14:21903077~21903598:+
BRCA	cis	rs172166	0.694	rs1770131	ENSG00000219891.2	ZSCAN12P1	3.68	0.000246	0.0136	0.14	0.11	Cardiac Troponin-T levels;	chr6:28118635	chr6:28091154~28093664:+
BRCA	cis	rs2018683	0.707	rs917218	ENSG00000233517.1	AC005162.5	-3.68	0.000246	0.0136	-0.14	-0.11	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28935505	chr7:28987028~28988899:+
BRCA	cis	rs495337	0.736	rs6095681	ENSG00000224397.4	LINC01272	3.68	0.000246	0.0136	0.11	0.11	Psoriasis;	chr20:49834592	chr20:50267486~50279795:+
BRCA	cis	rs1972460	0.506	rs62012050	ENSG00000274376.3	ADAMTS7P1	3.68	0.000246	0.0136	0.14	0.11	Intelligence (multi-trait analysis);	chr15:82239933	chr15:82298553~82334609:+
BRCA	cis	rs1124769	0.57	rs2414052	ENSG00000259298.1	RP11-562A8.4	3.68	0.000246	0.0136	0.11	0.11	Cognitive performance;	chr15:50848104	chr15:50497195~50498744:-
BRCA	cis	rs6840360	0.571	rs1978955	ENSG00000270265.1	RP11-731D1.4	-3.68	0.000246	0.0136	-0.14	-0.11	Intelligence (multi-trait analysis);	chr4:151588357	chr4:151333775~151353224:-
BRCA	cis	rs911555	0.755	rs17841064	ENSG00000269940.1	RP11-73M18.7	3.68	0.000246	0.0136	0.12	0.11	Intelligence (multi-trait analysis);	chr14:103434272	chr14:103694560~103695170:+
BRCA	cis	rs875971	0.965	rs6971509	ENSG00000230189.5	GS1-124K5.2	-3.68	0.000246	0.0136	-0.09	-0.11	Aortic root size;	chr7:66249983	chr7:66409143~66490059:-
BRCA	cis	rs2312236	0.759	rs12758334	ENSG00000225171.2	DUTP6	-3.68	0.000246	0.0136	-0.17	-0.11	Post-traumatic stress disorder;	chr1:166758441	chr1:166868748~166869209:+
BRCA	cis	rs2615061	0.746	rs12562612	ENSG00000229965.1	RP11-118H4.1	3.68	0.000246	0.0136	0.2	0.11	Monocyte count;	chr1:225770397	chr1:226438564~226439344:+
BRCA	cis	rs7267979	0.966	rs6037083	ENSG00000277938.1	RP5-965G21.3	-3.68	0.000246	0.0136	-0.13	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25309907	chr20:25229150~25231933:+
BRCA	cis	rs61931739	0.553	rs68124042	ENSG00000258794.3	DUX4L27	3.68	0.000246	0.0136	0.17	0.11	Morning vs. evening chronotype;	chr12:33911496	chr12:34208415~34209675:-
BRCA	cis	rs9392556	0.829	rs693953	ENSG00000230648.1	RP3-406P24.3	3.68	0.000246	0.0136	0.14	0.11	Blood metabolite levels;	chr6:4120331	chr6:4018843~4021215:-
BRCA	cis	rs9392556	0.829	rs613260	ENSG00000230648.1	RP3-406P24.3	3.68	0.000246	0.0136	0.14	0.11	Blood metabolite levels;	chr6:4120333	chr6:4018843~4021215:-
BRCA	cis	rs3750082	0.611	rs2392151	ENSG00000231952.3	DPY19L1P2	-3.68	0.000246	0.0136	-0.14	-0.11	Glomerular filtration rate (creatinine);	chr7:32851070	chr7:32812757~32838570:+
BRCA	cis	rs4819052	0.851	rs8133045	ENSG00000215447.6	BX322557.10	-3.68	0.000246	0.0136	-0.12	-0.11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238222	chr21:45288052~45291738:+
BRCA	cis	rs2395128	0.667	rs10824252	ENSG00000213731.2	RAB5CP1	3.68	0.000247	0.0136	0.21	0.11	Ulcerative colitis;Inflammatory bowel disease;	chr10:74964971	chr10:74423435~74424014:-
BRCA	cis	rs17684571	0.751	rs13192540	ENSG00000231441.1	RP11-472M19.2	3.68	0.000247	0.0136	0.19	0.11	Schizophrenia;	chr6:56842637	chr6:56844002~56864078:+
BRCA	cis	rs17684571	0.751	rs13192931	ENSG00000231441.1	RP11-472M19.2	3.68	0.000247	0.0136	0.19	0.11	Schizophrenia;	chr6:56842921	chr6:56844002~56864078:+
BRCA	cis	rs7520050	0.966	rs2275426	ENSG00000281133.1	AL355480.3	3.68	0.000247	0.0136	0.13	0.11	Reticulocyte count;Red blood cell count;	chr1:46021880	chr1:45580892~45580996:-
BRCA	cis	rs72772090	0.539	rs72775817	ENSG00000272109.1	CTD-2260A17.3	3.68	0.000247	0.0136	0.23	0.11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96855006	chr5:96804353~96806105:+
BRCA	cis	rs72772090	0.539	rs72775818	ENSG00000272109.1	CTD-2260A17.3	3.68	0.000247	0.0136	0.23	0.11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96857512	chr5:96804353~96806105:+
BRCA	cis	rs7495132	0.688	rs56961537	ENSG00000245479.2	LINC01585	-3.68	0.000247	0.0136	-0.16	-0.11	Ulcerative colitis;Inflammatory bowel disease;	chr15:90624175	chr15:90660234~90664967:+
BRCA	cis	rs8180040	0.726	rs7625070	ENSG00000260236.1	RP11-708J19.1	3.68	0.000247	0.0136	0.1	0.11	Colorectal cancer;	chr3:47054028	chr3:47379089~47380999:-
BRCA	cis	rs4761702	0.527	rs11106988	ENSG00000257322.4	RP11-511B23.2	-3.68	0.000247	0.0136	-0.14	-0.11	Immature fraction of reticulocytes;	chr12:93340674	chr12:93003415~93215679:-
BRCA	cis	rs11662721	0.935	rs2850559	ENSG00000264188.1	RP11-13N13.5	3.68	0.000247	0.0136	0.16	0.11	Phospholipid levels (plasma);	chr18:21617237	chr18:21661787~21662395:-
BRCA	cis	rs9400180	0.84	rs59994360	ENSG00000271734.1	RP1-111B22.3	-3.68	0.000247	0.0136	-0.15	-0.11	Major depressive disorder;	chr6:108054993	chr6:108030249~108030718:-
BRCA	cis	rs7829975	0.533	rs1039917	ENSG00000254153.1	CTA-398F10.2	3.68	0.000247	0.0136	0.14	0.11	Mood instability;	chr8:8861340	chr8:8456909~8461337:-
BRCA	cis	rs3858526	0.959	rs10838901	ENSG00000224295.2	AC087380.14	3.68	0.000247	0.0136	0.16	0.11	DNA methylation (variation);	chr11:5937898	chr11:5518441~5524955:-
BRCA	cis	rs7682431	0.513	rs7682317	ENSG00000270720.1	RP11-84C13.2	3.68	0.000247	0.0136	0.13	0.11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr4:88939679	chr4:89119284~89119871:+
BRCA	cis	rs6943931	1	rs73685429	ENSG00000230658.1	KLHL7-AS1	-3.68	0.000247	0.0136	-0.15	-0.11	Diabetic kidney disease;	chr7:22376765	chr7:23101228~23105703:-
BRCA	cis	rs7833787	0.896	rs2029610	ENSG00000254054.2	RP11-156K13.3	3.68	0.000247	0.0136	0.14	0.11	Obesity-related traits;	chr8:18849471	chr8:17905756~17907887:+
BRCA	cis	rs7412746	0.634	rs12409208	ENSG00000231073.1	RP11-316M1.3	3.68	0.000247	0.0136	0.12	0.11	Melanoma;	chr1:150887579	chr1:150973123~150975534:+
BRCA	cis	rs7412746	0.658	rs12410394	ENSG00000231073.1	RP11-316M1.3	3.68	0.000247	0.0136	0.12	0.11	Melanoma;	chr1:150887710	chr1:150973123~150975534:+
BRCA	cis	rs11168351	0.517	rs10875754	ENSG00000273765.1	RP11-370I10.11	3.68	0.000247	0.0136	0.12	0.11	Bipolar disorder and schizophrenia;	chr12:48164139	chr12:48360920~48361377:+
BRCA	cis	rs10090774	0.965	rs4961234	ENSG00000280303.2	ERICD	3.68	0.000247	0.0136	0.13	0.11	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140830782	chr8:140636281~140638283:+
BRCA	cis	rs11039100	1	rs35466594	ENSG00000224295.2	AC087380.14	3.68	0.000247	0.0136	0.21	0.11	Peripheral arterial disease (traffic-related air pollution interaction);	chr11:5805454	chr11:5518441~5524955:-
BRCA	cis	rs11039100	1	rs12798822	ENSG00000224295.2	AC087380.14	3.68	0.000247	0.0136	0.21	0.11	Peripheral arterial disease (traffic-related air pollution interaction);	chr11:5805481	chr11:5518441~5524955:-
BRCA	cis	rs11039100	1	rs12798823	ENSG00000224295.2	AC087380.14	3.68	0.000247	0.0136	0.21	0.11	Peripheral arterial disease (traffic-related air pollution interaction);	chr11:5805486	chr11:5518441~5524955:-
BRCA	cis	rs2071426	0.755	rs11572177	ENSG00000273450.1	RP11-76P2.4	3.68	0.000247	0.0136	0.15	0.11	Blood metabolite levels;	chr10:95037513	chr10:94314907~94315327:-
BRCA	cis	rs591584	0.802	rs7927312	ENSG00000255893.1	RP11-685N10.1	-3.68	0.000247	0.0136	-0.12	-0.11	Macrophage Migration Inhibitory Factor levels;	chr11:94554323	chr11:94472908~94473570:-
BRCA	cis	rs9549260	0.753	rs61963264	ENSG00000168852.11	TPTE2P5	3.68	0.000247	0.0136	0.13	0.11	Red blood cell count;	chr13:40580655	chr13:40822296~40921749:-
BRCA	cis	rs7475343	0.573	rs61854737	ENSG00000224034.1	RP11-445P17.8	-3.68	0.000247	0.0136	-0.21	-0.11	Intelligence;	chr10:5194167	chr10:5266033~5271236:-
BRCA	cis	rs7620503	1	rs13077994	ENSG00000231574.4	RP11-91K9.1	3.68	0.000247	0.0136	0.13	0.11	Corneal structure;	chr3:177587917	chr3:177816865~177899224:+
BRCA	cis	rs4073582	0.595	rs10896104	ENSG00000255320.1	RP11-755F10.1	-3.68	0.000247	0.0136	-0.15	-0.11	Gout;	chr11:66234398	chr11:66244840~66246239:-
BRCA	cis	rs9847710	0.967	rs4687694	ENSG00000242849.2	ALDOAP1	3.68	0.000247	0.0136	0.12	0.11	Ulcerative colitis;	chr3:53015031	chr3:52193170~52194785:+
BRCA	cis	rs4835473	0.897	rs13145976	ENSG00000246448.2	RP13-578N3.3	-3.68	0.000247	0.0136	-0.13	-0.11	Immature fraction of reticulocytes;	chr4:143735710	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.897	rs13114071	ENSG00000246448.2	RP13-578N3.3	-3.68	0.000247	0.0136	-0.13	-0.11	Immature fraction of reticulocytes;	chr4:143735728	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.897	rs13140654	ENSG00000246448.2	RP13-578N3.3	-3.68	0.000247	0.0136	-0.13	-0.11	Immature fraction of reticulocytes;	chr4:143735733	chr4:143700257~143865072:+
BRCA	cis	rs4415084	0.716	rs9637783	ENSG00000251141.4	RP11-53O19.1	3.68	0.000247	0.0136	0.1	0.11	Breast cancer;	chr5:44819544	chr5:44744900~44808777:-
BRCA	cis	rs6964587	1	rs6952389	ENSG00000188693.7	CYP51A1-AS1	-3.68	0.000247	0.0136	-0.12	-0.11	Breast cancer;	chr7:92028680	chr7:92134604~92180725:+
BRCA	cis	rs1969253	0.771	rs843359	ENSG00000205955.4	HSP90AA5P	-3.68	0.000247	0.0136	-0.14	-0.11	Major depressive disorder;	chr3:184143276	chr3:184115352~184117898:+
BRCA	cis	rs3770752	0.836	rs10176949	ENSG00000272054.1	RP11-423P10.2	-3.68	0.000247	0.0136	-0.1	-0.11	Schizophrenia;	chr2:37260580	chr2:37208875~37212677:+
BRCA	cis	rs9840812	0.68	rs17252498	ENSG00000273486.1	RP11-731C17.2	-3.68	0.000247	0.0136	-0.16	-0.11	Fibrinogen levels;	chr3:136295356	chr3:136837338~136839021:-
BRCA	cis	rs10744955	0.727	rs59983467	ENSG00000244879.4	GABPB1-AS1	-3.68	0.000247	0.0136	-0.12	-0.11	Lobe attachment (rater-scored or self-reported);	chr15:50156817	chr15:50354959~50372202:+
BRCA	cis	rs9309473	0.607	rs7560272	ENSG00000230002.2	ALMS1-IT1	3.68	0.000247	0.0136	0.14	0.11	Metabolite levels;	chr2:73334357	chr2:73456764~73459484:+
BRCA	cis	rs17428076	0.872	rs56218609	ENSG00000228389.1	AC068039.4	-3.68	0.000247	0.0136	-0.17	-0.11	Myopia;	chr2:171997407	chr2:171773482~171775844:+
BRCA	cis	rs7172677	0.737	rs7178625	ENSG00000260269.4	CTD-2323K18.1	-3.68	0.000247	0.0136	-0.16	-0.11	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75148676	chr15:75527150~75601205:-
BRCA	cis	rs2749097	0.66	rs11208270	ENSG00000244256.3	RN7SL130P	-3.68	0.000247	0.0136	-0.14	-0.11	Alcohol consumption (transferrin glycosylation);	chr1:63696251	chr1:63655743~63656047:+
BRCA	cis	rs7172809	0.643	rs16968930	ENSG00000260139.5	CSPG4P13	-3.68	0.000247	0.0136	-0.14	-0.11	Glucose homeostasis traits;	chr15:77551092	chr15:77894684~77904674:+
BRCA	cis	rs2478118	0.509	rs7093256	ENSG00000273474.1	RP11-295P9.12	-3.68	0.000247	0.0136	-0.11	-0.11	Lupus nephritis in systemic lupus erythematosus;	chr10:13668836	chr10:13675646~13675990:+
BRCA	cis	rs1730008	0.661	rs73170310	ENSG00000279311.1	RP11-170K4.2	3.68	0.000247	0.0136	0.14	0.11	Lobe attachment (rater-scored or self-reported);	chr3:158336424	chr3:158869898~158871821:+
BRCA	cis	rs1730008	0.691	rs4680428	ENSG00000279311.1	RP11-170K4.2	3.68	0.000247	0.0136	0.14	0.11	Lobe attachment (rater-scored or self-reported);	chr3:158342165	chr3:158869898~158871821:+
BRCA	cis	rs1730008	0.691	rs73170326	ENSG00000279311.1	RP11-170K4.2	3.68	0.000247	0.0136	0.14	0.11	Lobe attachment (rater-scored or self-reported);	chr3:158353728	chr3:158869898~158871821:+
BRCA	cis	rs2243480	0.901	rs57126451	ENSG00000226767.1	RP11-328P23.3	-3.68	0.000247	0.0136	-0.19	-0.11	Diabetic kidney disease;	chr7:65951319	chr7:65508773~65508944:-
BRCA	cis	rs2998286	0.541	rs332180	ENSG00000237128.1	RP11-351M16.3	3.68	0.000247	0.0136	0.17	0.11	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28621166	chr10:28433008~28495813:-
BRCA	cis	rs875971	0.825	rs1129531	ENSG00000273024.4	INTS4P2	3.68	0.000247	0.0136	0.13	0.11	Aortic root size;	chr7:66154117	chr7:65647864~65715661:+
BRCA	cis	rs7267979	0.604	rs242130	ENSG00000231081.1	RP4-760C5.3	3.68	0.000247	0.0137	0.14	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25613384	chr20:26008791~26010531:-
BRCA	cis	rs7107174	0.792	rs10899488	ENSG00000251323.2	RP11-452H21.4	3.68	0.000247	0.0137	0.16	0.11	Testicular germ cell tumor;	chr11:78377708	chr11:78423982~78429836:-
BRCA	cis	rs6545883	0.524	rs811871	ENSG00000270820.4	RP11-355B11.2	-3.68	0.000248	0.0137	-0.12	-0.11	Tuberculosis;	chr2:61350814	chr2:61471188~61484130:+
BRCA	cis	rs804280	0.662	rs11250164	ENSG00000238460.1	AC068587.2	-3.68	0.000248	0.0137	-0.12	-0.11	Myopia (pathological);	chr8:11753177	chr8:12578005~12578152:+
BRCA	cis	rs7188697	0.922	rs37060	ENSG00000276259.1	RP11-481J2.4	-3.68	0.000248	0.0137	-0.12	-0.11	QT interval;	chr16:58532400	chr16:58522970~58523842:+
BRCA	cis	rs703842	0.616	rs10877024	ENSG00000270039.1	RP11-571M6.17	-3.68	0.000248	0.0137	-0.17	-0.11	Multiple sclerosis;	chr12:57832926	chr12:57803838~57804415:+
BRCA	cis	rs8114671	0.562	rs6060064	ENSG00000261582.1	RP4-614O4.11	3.68	0.000248	0.0137	0.11	0.11	Height;	chr20:34818536	chr20:35267885~35280043:-
BRCA	cis	rs6743226	0.811	rs10933537	ENSG00000266621.1	AC104841.1	-3.68	0.000248	0.0137	-0.13	-0.11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in non-smokers;	chr2:241215515	chr2:241245202~241245299:-
BRCA	cis	rs6545883	0.507	rs4411680	ENSG00000270820.4	RP11-355B11.2	-3.68	0.000248	0.0137	-0.12	-0.11	Tuberculosis;	chr2:61356970	chr2:61471188~61484130:+
BRCA	cis	rs28735056	0.935	rs11662267	ENSG00000261126.6	RP11-795F19.1	-3.68	0.000248	0.0137	-0.11	-0.11	Schizophrenia;	chr18:79881902	chr18:80046900~80095482:+
BRCA	cis	rs829883	0.966	rs249815	ENSG00000227825.4	SLC9A7P1	3.68	0.000248	0.0137	0.14	0.11	Colorectal adenoma (advanced);	chr12:98499931	chr12:98453835~98457145:-
BRCA	cis	rs10129255	0.957	rs28887506	ENSG00000211967.3	IGHV3-53	-3.68	0.000248	0.0137	-0.08	-0.11	Kawasaki disease;	chr14:106785589	chr14:106592676~106593347:-
BRCA	cis	rs962856	0.673	rs11696003	ENSG00000236780.4	AC078941.1	3.68	0.000248	0.0137	0.14	0.11	Pancreatic cancer;	chr2:67294260	chr2:67123357~67215319:-
BRCA	cis	rs7267979	0.966	rs6037097	ENSG00000204556.4	CTD-2514C3.1	-3.68	0.000248	0.0137	-0.15	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25366585	chr20:26018832~26020684:+
BRCA	cis	rs13401620	0.871	rs55744502	ENSG00000229326.3	AC069154.4	-3.68	0.000248	0.0137	-0.15	-0.11	Breast size;	chr2:119919947	chr2:119698623~119700151:+
BRCA	cis	rs794185	0.561	rs304067	ENSG00000231249.1	ITPR1-AS1	-3.68	0.000248	0.0137	-0.13	-0.11	Multiple sclerosis--Brain Glutamate Levels;	chr3:4499254	chr3:4490891~4493163:-
BRCA	cis	rs75504410	0.579	rs170908	ENSG00000231160.8	KLF3-AS1	-3.68	0.000248	0.0137	-0.16	-0.11	Sum eosinophil basophil counts;Eosinophil counts;	chr4:38618114	chr4:38612701~38664883:-
BRCA	cis	rs10791097	0.72	rs4936121	ENSG00000254842.5	RP11-890B15.2	3.68	0.000248	0.0137	0.13	0.11	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:130863983	chr11:130844191~130865561:-
BRCA	cis	rs321358	0.731	rs73021576	ENSG00000271390.1	RP11-89C3.3	3.68	0.000248	0.0137	0.17	0.11	Body mass index;	chr11:111155690	chr11:111089870~111090368:-
BRCA	cis	rs6585424	1	rs61860035	ENSG00000225484.5	NUTM2B-AS1	-3.68	0.000248	0.0137	-0.23	-0.11	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80172697	chr10:79663088~79826594:-
BRCA	cis	rs6585424	0.85	rs75804987	ENSG00000225484.5	NUTM2B-AS1	-3.68	0.000248	0.0137	-0.23	-0.11	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80172753	chr10:79663088~79826594:-
BRCA	cis	rs4374383	0.631	rs4632346	ENSG00000243389.1	AC012442.5	-3.68	0.000248	0.0137	-0.14	-0.11	Hepatitis C induced liver fibrosis;	chr2:111951152	chr2:112589040~112614431:+
BRCA	cis	rs4950322	0.58	rs2014106	ENSG00000227242.3	NBPF13P	-3.68	0.000248	0.0137	-0.16	-0.11	Protein quantitative trait loci;	chr1:147118499	chr1:147021320~147124525:-
BRCA	cis	rs797680	0.856	rs6541404	ENSG00000229635.1	RP4-713B5.2	-3.68	0.000248	0.0137	-0.15	-0.11	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93277877	chr1:93384487~93384998:-
BRCA	cis	rs1529711	0.5	rs80091992	ENSG00000267100.1	ILF3-AS1	3.68	0.000248	0.0137	0.19	0.11	C-reactive protein levels or total cholesterol levels (pleiotropy);C-reactive protein levels or LDL-cholesterol levels (pleiotropy);	chr19:10794226	chr19:10651862~10653844:-
BRCA	cis	rs1730008	0.865	rs57361244	ENSG00000279311.1	RP11-170K4.2	-3.68	0.000248	0.0137	-0.12	-0.11	Lobe attachment (rater-scored or self-reported);	chr3:158229327	chr3:158869898~158871821:+
BRCA	cis	rs1730008	0.865	rs698990	ENSG00000279311.1	RP11-170K4.2	-3.68	0.000248	0.0137	-0.12	-0.11	Lobe attachment (rater-scored or self-reported);	chr3:158229919	chr3:158869898~158871821:+
BRCA	cis	rs1730008	0.835	rs698991	ENSG00000279311.1	RP11-170K4.2	-3.68	0.000248	0.0137	-0.12	-0.11	Lobe attachment (rater-scored or self-reported);	chr3:158230680	chr3:158869898~158871821:+
BRCA	cis	rs1730008	0.835	rs827122	ENSG00000279311.1	RP11-170K4.2	-3.68	0.000248	0.0137	-0.12	-0.11	Lobe attachment (rater-scored or self-reported);	chr3:158230994	chr3:158869898~158871821:+
BRCA	cis	rs1730008	0.865	rs827123	ENSG00000279311.1	RP11-170K4.2	-3.68	0.000248	0.0137	-0.12	-0.11	Lobe attachment (rater-scored or self-reported);	chr3:158233092	chr3:158869898~158871821:+
BRCA	cis	rs1730008	0.865	rs1724676	ENSG00000279311.1	RP11-170K4.2	-3.68	0.000248	0.0137	-0.12	-0.11	Lobe attachment (rater-scored or self-reported);	chr3:158233715	chr3:158869898~158871821:+
BRCA	cis	rs1730008	0.865	rs1724677	ENSG00000279311.1	RP11-170K4.2	-3.68	0.000248	0.0137	-0.12	-0.11	Lobe attachment (rater-scored or self-reported);	chr3:158234421	chr3:158869898~158871821:+
BRCA	cis	rs1730008	0.865	rs827125	ENSG00000279311.1	RP11-170K4.2	-3.68	0.000248	0.0137	-0.12	-0.11	Lobe attachment (rater-scored or self-reported);	chr3:158235384	chr3:158869898~158871821:+
BRCA	cis	rs4478858	0.735	rs11576621	ENSG00000260386.4	LINC01225	-3.68	0.000248	0.0137	-0.13	-0.11	Alcohol dependence;	chr1:31322613	chr1:31500085~31540885:+
BRCA	cis	rs12612619	0.627	rs13391244	ENSG00000229122.1	AGBL5-IT1	-3.68	0.000248	0.0137	-0.12	-0.11	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27064741	chr2:27061038~27061815:+
BRCA	cis	rs4950322	0.57	rs4950403	ENSG00000227242.3	NBPF13P	-3.68	0.000248	0.0137	-0.16	-0.11	Protein quantitative trait loci;	chr1:147319723	chr1:147021320~147124525:-
BRCA	cis	rs4950322	0.517	rs116479391	ENSG00000227242.3	NBPF13P	-3.68	0.000248	0.0137	-0.16	-0.11	Protein quantitative trait loci;	chr1:147320940	chr1:147021320~147124525:-
BRCA	cis	rs3753275	0.69	rs7530863	ENSG00000270282.1	RP5-1115A15.2	3.68	0.000248	0.0137	0.16	0.11	Educational attainment;	chr1:8562734	chr1:8512653~8513021:+
BRCA	cis	rs7267979	1	rs448396	ENSG00000204556.4	CTD-2514C3.1	-3.68	0.000248	0.0137	-0.15	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25459633	chr20:26018832~26020684:+
BRCA	cis	rs17801127	0.818	rs16827337	ENSG00000231969.1	AC144449.1	3.68	0.000248	0.0137	0.2	0.11	Liver enzyme levels (alanine transaminase);	chr2:149690094	chr2:149587196~149848233:+
BRCA	cis	rs952623	0.501	rs1000869	ENSG00000227191.5	TRGC2	3.68	0.000248	0.0137	0.11	0.11	Intelligence (multi-trait analysis);	chr7:39042627	chr7:38239580~38368091:-
BRCA	cis	rs7577599	0.773	rs1369704	ENSG00000224220.1	AC104699.1	3.68	0.000248	0.0137	0.1	0.11	Multiple myeloma (IgH translocation);Multiple myeloma;	chr2:25400721	chr2:25421117~25427643:+
BRCA	cis	rs7017914	0.644	rs13258800	ENSG00000246366.5	RP11-382J12.1	3.68	0.000248	0.0137	0.12	0.11	Bone mineral density;	chr8:70819867	chr8:70608577~70663279:+
BRCA	cis	rs4834770	1	rs878375	ENSG00000178636.7	RP11-455G16.1	-3.68	0.000248	0.0137	-0.14	-0.11	Blood protein levels;	chr4:119316419	chr4:119192773~119212644:-
BRCA	cis	rs13108904	0.901	rs13119532	ENSG00000196810.4	CTBP1-AS2	3.68	0.000248	0.0137	0.13	0.11	Obesity-related traits;	chr4:1310717	chr4:1249300~1288291:+
BRCA	cis	rs35520189	0.754	rs13013349	ENSG00000274877.1	RP11-65I12.1	3.68	0.000248	0.0137	0.15	0.11	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:112842749	chr2:113237595~113240825:+
BRCA	cis	rs9303280	0.617	rs6503525	ENSG00000273576.1	RP11-390P24.1	-3.68	0.000248	0.0137	-0.12	-0.11	Self-reported allergy;	chr17:39938921	chr17:39566915~39567559:+
BRCA	cis	rs6432852	0.516	rs12477613	ENSG00000235192.1	AC009495.2	3.68	0.000248	0.0137	0.12	0.11	Diabetic kidney disease;	chr2:165860674	chr2:165794851~165810010:+
BRCA	cis	rs7660883	0.964	rs17012368	ENSG00000251411.1	RP11-397E7.4	3.68	0.000248	0.0137	0.13	0.11	HDL cholesterol levels;	chr4:87074967	chr4:86913266~86914817:-
BRCA	cis	rs4700393	0.517	rs71592686	ENSG00000215032.2	GNL3LP1	-3.68	0.000248	0.0137	-0.16	-0.11	Intelligence (multi-trait analysis);	chr5:60825444	chr5:60891935~60893577:-
BRCA	cis	rs4622329	0.615	rs7975309	ENSG00000257202.1	RP11-512N21.3	-3.68	0.000248	0.0137	-0.13	-0.11	Systemic lupus erythematosus;	chr12:101894703	chr12:101923410~101924719:-
BRCA	cis	rs2562456	0.917	rs2681377	ENSG00000240522.1	RPL7AP10	3.68	0.000248	0.0137	0.13	0.11	Pain;	chr19:21533718	chr19:21149648~21150438:-
BRCA	cis	rs77633900	0.772	rs157760	ENSG00000196274.5	Metazoa_SRP	3.68	0.000248	0.0137	0.19	0.11	Glioma;Non-glioblastoma glioma;	chr15:76507919	chr15:76230048~76230390:-
BRCA	cis	rs860818	1	rs1637216	ENSG00000230658.1	KLHL7-AS1	-3.68	0.000248	0.0137	-0.28	-0.11	Initial pursuit acceleration;	chr7:23196510	chr7:23101228~23105703:-
BRCA	cis	rs2274273	0.87	rs10139083	ENSG00000259318.1	RP11-454L9.2	3.68	0.000248	0.0137	0.1	0.11	Protein biomarker;	chr14:55316017	chr14:55394940~55395233:-
BRCA	cis	rs11158026	0.574	rs7152033	ENSG00000233924.1	AL160471.6	-3.68	0.000248	0.0137	-0.14	-0.11	Parkinson's disease;	chr14:54926036	chr14:55004813~55005687:-
BRCA	cis	rs739496	0.579	rs57046217	ENSG00000257624.1	RP1-128M12.3	3.68	0.000248	0.0137	0.15	0.11	Platelet count;	chr12:111847312	chr12:112000739~112000985:-
BRCA	cis	rs6015450	1	rs78628461	ENSG00000228340.4	MIR646HG	3.68	0.000248	0.0137	0.24	0.11	Hypertension;Blood pressure;Systolic blood pressure;Diastolic blood pressure;	chr20:59151307	chr20:60087840~60527458:+
BRCA	cis	rs4950322	0.57	rs4301678	ENSG00000237188.3	RP11-337C18.8	3.68	0.000248	0.0137	0.15	0.11	Protein quantitative trait loci;	chr1:147261907	chr1:147172771~147211568:+
BRCA	cis	rs2832077	0.506	rs2832093	ENSG00000236056.1	GAPDHP14	3.68	0.000248	0.0137	0.14	0.11	Cognitive test performance;	chr21:28792533	chr21:29222321~29223257:+
BRCA	cis	rs1046491	1	rs71362073	ENSG00000264964.1	RP11-888D10.3	3.68	0.000248	0.0137	0.23	0.11	Scarlet fever;	chr18:9208548	chr18:9315194~9334441:-
BRCA	cis	rs1046491	1	rs62085924	ENSG00000264964.1	RP11-888D10.3	3.68	0.000248	0.0137	0.23	0.11	Scarlet fever;	chr18:9209456	chr18:9315194~9334441:-
BRCA	cis	rs4388249	1	rs3753176	ENSG00000271849.1	CTC-332L22.1	-3.68	0.000248	0.0137	-0.18	-0.11	Schizophrenia;	chr5:109772581	chr5:109687802~109688329:-
BRCA	cis	rs55780018	0.645	rs7588951	ENSG00000224137.1	AC079767.4	3.68	0.000248	0.0137	0.09	0.11	Systolic blood pressure;	chr2:207636785	chr2:207662375~207667024:+
BRCA	cis	rs2411233	1	rs11070163	ENSG00000259278.1	RP11-62C7.2	-3.68	0.000248	0.0137	-0.13	-0.11	Platelet count;	chr15:38984950	chr15:39019233~39024918:+
BRCA	cis	rs10129255	0.5	rs6576232	ENSG00000211976.2	IGHV3-73	-3.68	0.000249	0.0137	-0.09	-0.11	Kawasaki disease;	chr14:106787090	chr14:106802694~106803233:-
BRCA	cis	rs7267979	0.966	rs6050567	ENSG00000276952.1	RP5-965G21.6	-3.68	0.000249	0.0137	-0.14	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25373925	chr20:25284915~25285588:-
BRCA	cis	rs703842	0.616	rs10783850	ENSG00000270039.1	RP11-571M6.17	-3.68	0.000249	0.0137	-0.17	-0.11	Multiple sclerosis;	chr12:57835594	chr12:57803838~57804415:+
BRCA	cis	rs710865	0.723	rs710870	ENSG00000270728.1	RP4-657E11.10	-3.68	0.000249	0.0137	-0.1	-0.11	Brain structure;	chr1:19223265	chr1:19297080~19297903:+
BRCA	cis	rs875971	0.545	rs7810213	ENSG00000232559.3	GS1-124K5.12	3.68	0.000249	0.0137	0.16	0.11	Aortic root size;	chr7:66481592	chr7:66554588~66576923:-
BRCA	cis	rs6600671	0.967	rs12069545	ENSG00000275131.1	CH17-472G23.4	-3.68	0.000249	0.0137	-0.1	-0.11	Hip geometry;	chr1:121430343	chr1:120489625~120579190:-
BRCA	cis	rs6918586	1	rs198811	ENSG00000272462.2	U91328.19	3.68	0.000249	0.0137	0.13	0.11	Schizophrenia;	chr6:26128218	chr6:25992662~26001775:+
BRCA	cis	rs344364	0.636	rs344363	ENSG00000219027.2	RPS3AP2	3.68	0.000249	0.0137	0.19	0.11	Glomerular filtration rate in chronic kidney disease;	chr16:1922547	chr16:1477830~1478583:+
BRCA	cis	rs4449834	0.775	rs7842498	ENSG00000254432.1	RP11-33I11.2	-3.68	0.000249	0.0137	-0.15	-0.11	Sum eosinophil basophil counts;	chr8:60772566	chr8:60808735~60809606:-
BRCA	cis	rs10829156	0.898	rs10741120	ENSG00000240291.1	RP11-499P20.2	3.68	0.000249	0.0137	0.14	0.11	Sudden cardiac arrest;	chr10:18641063	chr10:18513115~18545651:-
BRCA	cis	rs890448	0.796	rs2119592	ENSG00000254531.1	FLJ20021	3.68	0.000249	0.0137	0.13	0.11	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101387981	chr4:101347780~101348883:+
BRCA	cis	rs7520050	0.966	rs785492	ENSG00000281133.1	AL355480.3	3.68	0.000249	0.0137	0.13	0.11	Reticulocyte count;Red blood cell count;	chr1:46117935	chr1:45580892~45580996:-
BRCA	cis	rs1635	0.655	rs16893917	ENSG00000216901.1	AL022393.7	3.68	0.000249	0.0137	0.26	0.11	Schizophrenia;	chr6:28301630	chr6:28176188~28176674:+
BRCA	cis	rs1635	0.655	rs16893929	ENSG00000216901.1	AL022393.7	3.68	0.000249	0.0137	0.26	0.11	Schizophrenia;	chr6:28303040	chr6:28176188~28176674:+
BRCA	cis	rs4950322	0.57	rs72692979	ENSG00000237188.3	RP11-337C18.8	3.68	0.000249	0.0137	0.15	0.11	Protein quantitative trait loci;	chr1:147336094	chr1:147172771~147211568:+
BRCA	cis	rs12122100	0.526	rs12122534	ENSG00000244371.2	PFN1P8	-3.68	0.000249	0.0137	-0.13	-0.11	HIV-1 control;	chr1:147032846	chr1:146957117~146957659:-
BRCA	cis	rs875971	0.522	rs1701760	ENSG00000272831.1	RP11-792A8.4	3.68	0.000249	0.0137	0.1	0.11	Aortic root size;	chr7:66008701	chr7:66739829~66740385:-
BRCA	cis	rs12324805	0.532	rs1587706	ENSG00000255769.6	GOLGA2P10	3.68	0.000249	0.0137	0.14	0.11	Body mass index;	chr15:82025904	chr15:82472993~82513950:-
BRCA	cis	rs13160562	0.666	rs28096	ENSG00000248734.2	CTD-2260A17.1	3.68	0.000249	0.0137	0.13	0.11	Alcohol dependence;	chr5:96773540	chr5:96784777~96785999:+
BRCA	cis	rs11098499	0.909	rs71614422	ENSG00000225892.3	RP11-384K6.2	3.68	0.000249	0.0137	0.11	0.11	Corneal astigmatism;	chr4:119438185	chr4:118632274~118634759:+
BRCA	cis	rs6545883	1	rs778762	ENSG00000212978.6	AC016747.3	3.68	0.000249	0.0137	0.15	0.11	Tuberculosis;	chr2:61555786	chr2:61141592~61144969:-
BRCA	cis	rs67478160	0.643	rs4900594	ENSG00000269910.1	RP11-73M18.10	3.68	0.000249	0.0137	0.11	0.11	Schizophrenia;	chr14:103784669	chr14:103694516~103695050:-
BRCA	cis	rs67478160	0.643	rs3742369	ENSG00000269910.1	RP11-73M18.10	3.68	0.000249	0.0137	0.11	0.11	Schizophrenia;	chr14:103784939	chr14:103694516~103695050:-
BRCA	cis	rs495337	0.662	rs6020072	ENSG00000229222.1	KRT18P4	3.68	0.000249	0.0137	0.14	0.11	Psoriasis;	chr20:49828917	chr20:49956745~49958032:+
BRCA	cis	rs847649	0.842	rs869332	ENSG00000239969.4	RP11-163E9.2	-3.68	0.000249	0.0137	-0.14	-0.11	Morning vs. evening chronotype;	chr7:102991800	chr7:102364162~102380633:+
BRCA	cis	rs67072384	1	rs7120605	ENSG00000256633.1	RP11-169D4.2	3.68	0.000249	0.0137	0.17	0.11	Alloimmunization response to red blood cell transfusion in sickle cell anemia;	chr11:72733570	chr11:72584572~72587979:+
BRCA	cis	rs67072384	1	rs56693670	ENSG00000256633.1	RP11-169D4.2	3.68	0.000249	0.0137	0.17	0.11	Alloimmunization response to red blood cell transfusion in sickle cell anemia;	chr11:72734098	chr11:72584572~72587979:+
BRCA	cis	rs17214007	0.877	rs11075280	ENSG00000279866.1	CTB-193M12.4	3.68	0.000249	0.0137	0.17	0.11	Cognitive function;	chr16:15776630	chr16:15704410~15705984:+
BRCA	cis	rs62229266	0.804	rs11088331	ENSG00000214914.3	RPL23AP3	3.68	0.000249	0.0137	0.14	0.11	Mitral valve prolapse;	chr21:36049574	chr21:36016079~36016546:-
BRCA	cis	rs875971	0.571	rs78668714	ENSG00000232559.3	GS1-124K5.12	3.68	0.000249	0.0137	0.16	0.11	Aortic root size;	chr7:66474464	chr7:66554588~66576923:-
BRCA	cis	rs9470794	1	rs78309997	ENSG00000204110.6	RP1-153P14.8	-3.68	0.000249	0.0137	-0.23	-0.11	Type 2 diabetes;	chr6:38003510	chr6:37507348~37535616:+
BRCA	cis	rs9470794	1	rs73421473	ENSG00000204110.6	RP1-153P14.8	-3.68	0.000249	0.0137	-0.23	-0.11	Type 2 diabetes;	chr6:38004103	chr6:37507348~37535616:+
BRCA	cis	rs2108622	0.527	rs67617968	ENSG00000267594.5	CYP4F24P	-3.68	0.000249	0.0137	-0.13	-0.11	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15866755	chr19:15760241~15779909:-
BRCA	cis	rs9287719	0.87	rs728135	ENSG00000224177.5	LINC00570	3.68	0.000249	0.0137	0.13	0.11	Prostate cancer;	chr2:10605006	chr2:11393981~11403077:+
BRCA	cis	rs9287719	0.967	rs2884233	ENSG00000224177.5	LINC00570	3.68	0.000249	0.0137	0.13	0.11	Prostate cancer;	chr2:10605177	chr2:11393981~11403077:+
BRCA	cis	rs9287719	0.839	rs12692415	ENSG00000224177.5	LINC00570	3.68	0.000249	0.0137	0.13	0.11	Prostate cancer;	chr2:10605348	chr2:11393981~11403077:+
BRCA	cis	rs9287719	0.934	rs12692416	ENSG00000224177.5	LINC00570	3.68	0.000249	0.0137	0.13	0.11	Prostate cancer;	chr2:10605501	chr2:11393981~11403077:+
BRCA	cis	rs9287719	0.967	rs12692417	ENSG00000224177.5	LINC00570	3.68	0.000249	0.0137	0.13	0.11	Prostate cancer;	chr2:10605592	chr2:11393981~11403077:+
BRCA	cis	rs9287719	0.934	rs12692418	ENSG00000224177.5	LINC00570	3.68	0.000249	0.0137	0.13	0.11	Prostate cancer;	chr2:10605744	chr2:11393981~11403077:+
BRCA	cis	rs9287719	0.967	rs6755548	ENSG00000224177.5	LINC00570	3.68	0.000249	0.0137	0.13	0.11	Prostate cancer;	chr2:10606000	chr2:11393981~11403077:+
BRCA	cis	rs9287719	0.967	rs6761678	ENSG00000224177.5	LINC00570	3.68	0.000249	0.0137	0.13	0.11	Prostate cancer;	chr2:10606215	chr2:11393981~11403077:+
BRCA	cis	rs9287719	0.967	rs6759100	ENSG00000224177.5	LINC00570	3.68	0.000249	0.0137	0.13	0.11	Prostate cancer;	chr2:10606584	chr2:11393981~11403077:+
BRCA	cis	rs7267979	1	rs4815417	ENSG00000204556.4	CTD-2514C3.1	3.68	0.000249	0.0137	0.15	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25398890	chr20:26018832~26020684:+
BRCA	cis	rs8099594	0.72	rs7506911	ENSG00000266696.1	RP11-30L3.2	3.68	0.000249	0.0137	0.13	0.11	Height;	chr18:49350091	chr18:49205912~49208781:+
BRCA	cis	rs7947761	0.715	rs17712139	ENSG00000254506.1	RP11-748H22.1	-3.68	0.000249	0.0137	-0.14	-0.11	Coronary artery disease;	chr11:100696834	chr11:101584295~101595156:+
BRCA	cis	rs10883723	0.81	rs1409311	ENSG00000213061.2	PFN1P11	-3.68	0.000249	0.0137	-0.16	-0.11	Allergic disease (asthma, hay fever or eczema);	chr10:102522403	chr10:102838011~102845473:-
BRCA	cis	rs853679	0.517	rs6932109	ENSG00000272009.1	RP1-313I6.12	3.68	0.000249	0.0137	0.16	0.11	Depression;	chr6:28110525	chr6:28078792~28081130:-
BRCA	cis	rs7829975	0.508	rs4841006	ENSG00000254153.1	CTA-398F10.2	-3.68	0.000249	0.0137	-0.14	-0.11	Mood instability;	chr8:8643964	chr8:8456909~8461337:-
BRCA	cis	rs728616	0.558	rs61859215	ENSG00000225484.5	NUTM2B-AS1	-3.68	0.000249	0.0137	-0.23	-0.11	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80391392	chr10:79663088~79826594:-
BRCA	cis	rs2991971	0.81	rs12738318	ENSG00000280836.1	AL355480.1	-3.68	0.000249	0.0137	-0.14	-0.11	High light scatter reticulocyte count;	chr1:45463917	chr1:45581219~45581321:-
BRCA	cis	rs812925	0.502	rs2053750	ENSG00000273302.1	RP11-493E12.2	-3.68	0.000249	0.0137	-0.1	-0.11	Immature fraction of reticulocytes;	chr2:61429138	chr2:61199979~61200769:+
BRCA	cis	rs7520050	0.807	rs28647556	ENSG00000281133.1	AL355480.3	-3.68	0.000249	0.0137	-0.13	-0.11	Reticulocyte count;Red blood cell count;	chr1:45740727	chr1:45580892~45580996:-
BRCA	cis	rs7520050	0.807	rs4274104	ENSG00000281133.1	AL355480.3	-3.68	0.000249	0.0137	-0.13	-0.11	Reticulocyte count;Red blood cell count;	chr1:45752269	chr1:45580892~45580996:-
BRCA	cis	rs6012564	1	rs6066968	ENSG00000230758.1	SNAP23P	3.68	0.000249	0.0137	0.13	0.11	Anger;	chr20:49110804	chr20:49038357~49038602:-
BRCA	cis	rs11170468	1	rs11170455	ENSG00000257718.1	RP11-396F22.1	-3.68	0.00025	0.0137	-0.15	-0.11	Body mass index;	chr12:39034640	chr12:38906451~38909592:+
BRCA	cis	rs2048656	0.605	rs7837008	ENSG00000233609.3	RP11-62H7.2	3.68	0.00025	0.0137	0.11	0.11	Schizophrenia;	chr8:9788996	chr8:8961200~8979025:+
BRCA	cis	rs875971	0.862	rs778734	ENSG00000271064.1	RP11-792A8.3	-3.68	0.00025	0.0137	-0.13	-0.11	Aortic root size;	chr7:66349862	chr7:66748838~66749077:-
BRCA	cis	rs889312	0.961	rs1862626	ENSG00000271828.1	CTD-2310F14.1	-3.68	0.00025	0.0138	-0.14	-0.11	Breast cancer (early onset);Breast cancer;	chr5:56737113	chr5:56927874~56929573:+
BRCA	cis	rs36051895	0.589	rs7848312	ENSG00000237711.1	RP11-39K24.13	-3.68	0.00025	0.0138	-0.14	-0.11	Pediatric autoimmune diseases;	chr9:5237442	chr9:5100236~5101009:+
BRCA	cis	rs36051895	0.623	rs7859361	ENSG00000237711.1	RP11-39K24.13	-3.68	0.00025	0.0138	-0.14	-0.11	Pediatric autoimmune diseases;	chr9:5237479	chr9:5100236~5101009:+
BRCA	cis	rs10883723	0.81	rs913025	ENSG00000213061.2	PFN1P11	-3.68	0.00025	0.0138	-0.16	-0.11	Allergic disease (asthma, hay fever or eczema);	chr10:102516286	chr10:102838011~102845473:-
BRCA	cis	rs2337406	0.925	rs2011167	ENSG00000211970.3	IGHV4-61	3.68	0.00025	0.0138	0.1	0.11	Alzheimer's disease (late onset);	chr14:106680831	chr14:106639119~106639657:-
BRCA	cis	rs6490294	0.571	rs58368428	ENSG00000257624.1	RP1-128M12.3	3.68	0.00025	0.0138	0.18	0.11	Mean platelet volume;	chr12:112024471	chr12:112000739~112000985:-
BRCA	cis	rs4664293	0.541	rs1425047	ENSG00000224152.1	AC009506.1	3.68	0.00025	0.0138	0.12	0.11	Monocyte percentage of white cells;	chr2:159517946	chr2:159615296~159617082:+
BRCA	cis	rs1050288	0.525	rs2113882	ENSG00000256377.4	RP11-1060J15.4	-3.68	0.00025	0.0138	-0.16	-0.11	Pulse pressure;Resting heart rate;	chr12:27787987	chr12:27696388~27710770:-
BRCA	cis	rs1032833	0.732	rs77593278	ENSG00000271401.1	RP11-171I2.3	-3.68	0.00025	0.0138	-0.29	-0.11	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);	chr2:179165128	chr2:178644717~178645179:+
BRCA	cis	rs1032833	0.732	rs60072979	ENSG00000271401.1	RP11-171I2.3	-3.68	0.00025	0.0138	-0.29	-0.11	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);	chr2:179165759	chr2:178644717~178645179:+
BRCA	cis	rs1032833	0.732	rs79496068	ENSG00000271401.1	RP11-171I2.3	-3.68	0.00025	0.0138	-0.29	-0.11	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);	chr2:179167696	chr2:178644717~178645179:+
BRCA	cis	rs1032833	0.732	rs61179885	ENSG00000271401.1	RP11-171I2.3	-3.68	0.00025	0.0138	-0.29	-0.11	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);	chr2:179168863	chr2:178644717~178645179:+
BRCA	cis	rs1032833	0.732	rs79717491	ENSG00000271401.1	RP11-171I2.3	-3.68	0.00025	0.0138	-0.29	-0.11	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);	chr2:179169117	chr2:178644717~178645179:+
BRCA	cis	rs10484434	0.792	rs9689245	ENSG00000216331.1	HIST1H1PS1	3.68	0.00025	0.0138	0.2	0.11	HIV-1 viral setpoint;	chr6:26050617	chr6:26195566~26195771:+
BRCA	cis	rs6142618	0.583	rs2235904	ENSG00000275576.1	RP5-836N17.4	-3.68	0.00025	0.0138	-0.12	-0.11	Inflammatory bowel disease;	chr20:32133909	chr20:32116171~32116629:+
BRCA	cis	rs7267979	1	rs6083844	ENSG00000204556.4	CTD-2514C3.1	3.68	0.00025	0.0138	0.15	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25406196	chr20:26018832~26020684:+
BRCA	cis	rs7267979	1	rs6037099	ENSG00000276952.1	RP5-965G21.6	-3.68	0.00025	0.0138	-0.14	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25376240	chr20:25284915~25285588:-
BRCA	cis	rs7267979	0.966	rs4815414	ENSG00000276952.1	RP5-965G21.6	-3.68	0.00025	0.0138	-0.14	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25381065	chr20:25284915~25285588:-
BRCA	cis	rs7267979	1	rs6083825	ENSG00000276952.1	RP5-965G21.6	-3.68	0.00025	0.0138	-0.14	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25385788	chr20:25284915~25285588:-
BRCA	cis	rs7267979	1	rs34645895	ENSG00000276952.1	RP5-965G21.6	-3.68	0.00025	0.0138	-0.14	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25387737	chr20:25284915~25285588:-
BRCA	cis	rs7267979	1	rs6037105	ENSG00000276952.1	RP5-965G21.6	-3.68	0.00025	0.0138	-0.14	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25393563	chr20:25284915~25285588:-
BRCA	cis	rs9527	0.535	rs4917999	ENSG00000236937.2	PTGES3P4	-3.68	0.00025	0.0138	-0.15	-0.11	Arsenic metabolism;	chr10:103203294	chr10:102845595~102845950:+
BRCA	cis	rs16917546	1	rs10995260	ENSG00000238280.1	RP11-436D10.3	3.68	0.00025	0.0138	0.15	0.11	Basal cell carcinoma;	chr10:62650820	chr10:62793562~62805887:-
BRCA	cis	rs7829975	0.509	rs7838674	ENSG00000253981.4	ALG1L13P	-3.68	0.00025	0.0138	-0.13	-0.11	Mood instability;	chr8:8939563	chr8:8236003~8244667:-
BRCA	cis	rs17214007	0.877	rs10852376	ENSG00000260735.1	RP11-72I8.1	3.68	0.00025	0.0138	0.16	0.11	Cognitive function;	chr16:15778216	chr16:15094411~15109197:+
BRCA	cis	rs9467773	0.526	rs3734536	ENSG00000124549.13	BTN2A3P	-3.67	0.00025	0.0138	-0.12	-0.11	Intelligence (multi-trait analysis);	chr6:26365118	chr6:26421391~26432383:+
BRCA	cis	rs8115445	0.515	rs34655128	ENSG00000214535.3	RPS15AP1	3.67	0.00025	0.0138	0.17	0.11	Pediatric bone mineral content (radius);	chr20:21449876	chr20:21166206~21166596:-
BRCA	cis	rs11018874	0.709	rs10830428	ENSG00000280385.1	AP000648.5	-3.67	0.00025	0.0138	-0.16	-0.11	White blood cell types;	chr11:90161126	chr11:90193614~90198120:+
BRCA	cis	rs1453414	1	rs1453414	ENSG00000224295.2	AC087380.14	3.67	0.00025	0.0138	0.21	0.11	Oral cavity and pharyngeal cancer;Oropharynx cancer;	chr11:5807854	chr11:5518441~5524955:-
BRCA	cis	rs2904967	0.631	rs650056	ENSG00000254501.1	AP003068.9	-3.67	0.00025	0.0138	-0.24	-0.11	Mean corpuscular volume;	chr11:65257635	chr11:65110714~65111695:-
BRCA	cis	rs1144333	0.737	rs1144331	ENSG00000181227.3	RP4-682C21.2	3.67	0.00025	0.0138	0.16	0.11	Attention function in attention deficit hyperactive disorder;	chr1:75806672	chr1:75743423~75744776:-
BRCA	cis	rs1144333	0.85	rs1146651	ENSG00000181227.3	RP4-682C21.2	3.67	0.00025	0.0138	0.16	0.11	Attention function in attention deficit hyperactive disorder;	chr1:75807909	chr1:75743423~75744776:-
BRCA	cis	rs10487112	0.87	rs11771199	ENSG00000235436.9	DPY19L2P4	-3.67	0.00025	0.0138	-0.12	-0.11	Perceived unattractiveness to mosquitoes;	chr7:90458023	chr7:90119400~90125600:+
BRCA	cis	rs4689592	0.554	rs66925245	ENSG00000245468.3	RP11-367J11.3	-3.67	0.00025	0.0138	-0.14	-0.11	Monocyte percentage of white cells;	chr4:7070272	chr4:7094571~7103385:-
BRCA	cis	rs10129255	0.785	rs10150044	ENSG00000232216.1	IGHV3-43	3.67	0.00025	0.0138	0.09	0.11	Kawasaki disease;	chr14:106775695	chr14:106470264~106470800:-
BRCA	cis	rs7520050	0.778	rs3014216	ENSG00000234329.1	RP11-767N6.2	3.67	0.00025	0.0138	0.11	0.11	Reticulocyte count;Red blood cell count;	chr1:45570088	chr1:45651039~45651826:-
BRCA	cis	rs4950322	0.857	rs72693002	ENSG00000237188.3	RP11-337C18.8	3.67	0.00025	0.0138	0.14	0.11	Protein quantitative trait loci;	chr1:147357593	chr1:147172771~147211568:+
BRCA	cis	rs4950322	0.857	rs72694703	ENSG00000237188.3	RP11-337C18.8	3.67	0.00025	0.0138	0.14	0.11	Protein quantitative trait loci;	chr1:147358427	chr1:147172771~147211568:+
BRCA	cis	rs3748682	0.861	rs72661832	ENSG00000252448.1	SNORA63	-3.67	0.00025	0.0138	-0.15	-0.11	Hypothyroidism;	chr1:37795061	chr1:37884237~37884317:+
BRCA	cis	rs67478160	0.583	rs12879612	ENSG00000269910.1	RP11-73M18.10	3.67	0.00025	0.0138	0.11	0.11	Schizophrenia;	chr14:103767281	chr14:103694516~103695050:-
BRCA	cis	rs10181042	0.565	rs3108630	ENSG00000273302.1	RP11-493E12.2	-3.67	0.00025	0.0138	-0.1	-0.11	Crohn's disease;	chr2:61041025	chr2:61199979~61200769:+
BRCA	cis	rs11187837	0.901	rs11187852	ENSG00000273450.1	RP11-76P2.4	3.67	0.00025	0.0138	0.25	0.11	Sudden cardiac arrest;	chr10:94310375	chr10:94314907~94315327:-
BRCA	cis	rs17711722	0.64	rs13237956	ENSG00000223473.2	GS1-124K5.3	3.67	0.00025	0.0138	0.09	0.11	Calcium levels;	chr7:65853042	chr7:66491049~66493566:-
BRCA	cis	rs56281245	0.793	rs6880648	ENSG00000249363.1	CTB-78O21.1	3.67	0.00025	0.0138	0.25	0.11	Hepcidin levels;	chr5:145589370	chr5:145728360~145729349:-
BRCA	cis	rs1549733	0.577	rs16857849	ENSG00000229754.1	CXCR2P1	-3.67	0.00025	0.0138	-0.11	-0.11	Optic disc area;	chr2:217553410	chr2:218059155~218065729:-
BRCA	cis	rs875971	0.862	rs6971059	ENSG00000229886.1	RP5-1132H15.3	-3.67	0.00025	0.0138	-0.13	-0.11	Aortic root size;	chr7:66602045	chr7:66025126~66031544:-
BRCA	cis	rs829883	0.966	rs249818	ENSG00000227825.4	SLC9A7P1	3.67	0.00025	0.0138	0.14	0.11	Colorectal adenoma (advanced);	chr12:98503216	chr12:98453835~98457145:-
BRCA	cis	rs17756712	0.725	rs57111852	ENSG00000271911.1	RP11-532F6.5	3.67	0.00025	0.0138	0.19	0.11	Vertical cup-disc ratio;	chr6:606263	chr6:761675~780648:+
BRCA	cis	rs7520050	0.966	rs6669522	ENSG00000234329.1	RP11-767N6.2	-3.67	0.00025	0.0138	-0.11	-0.11	Reticulocyte count;Red blood cell count;	chr1:45932269	chr1:45651039~45651826:-
BRCA	cis	rs6504622	0.755	rs7216950	ENSG00000263142.4	LRRC37A17P	-3.67	0.00025	0.0138	-0.09	-0.11	Orofacial clefts;	chr17:47011089	chr17:46978481~47054569:+
BRCA	cis	rs3755605	0.694	rs12487269	ENSG00000242578.1	RP11-469J4.3	3.67	0.00025	0.0138	0.13	0.11	Testicular germ cell tumor;	chr3:170081757	chr3:170410512~170418615:+
BRCA	cis	rs561341	1	rs508192	ENSG00000277511.1	CTD-2095E4.5	-3.67	0.00025	0.0138	-0.16	-0.11	Hip circumference adjusted for BMI;	chr17:31988128	chr17:32127595~32128454:+
BRCA	cis	rs11148252	0.819	rs7336679	ENSG00000198384.8	TPTE2P3	3.67	0.00025	0.0138	0.13	0.11	Lewy body disease;	chr13:52469198	chr13:52522632~52586906:+
BRCA	cis	rs2281603	0.762	rs11850291	ENSG00000259116.1	RP11-973N13.4	-3.67	0.00025	0.0138	-0.11	-0.11	Lymphocyte counts;	chr14:64582676	chr14:64514154~64540368:-
BRCA	cis	rs801193	1	rs1553609	ENSG00000232546.1	RP11-458F8.1	-3.67	0.000251	0.0138	-0.09	-0.11	Aortic root size;	chr7:66732152	chr7:66848496~66858136:+
BRCA	cis	rs10844706	1	rs10844706	ENSG00000214776.8	RP11-726G1.1	3.67	0.000251	0.0138	0.13	0.11	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9757536	chr12:9467552~9576275:+
BRCA	cis	rs2554380	0.943	rs2401128	ENSG00000230373.7	GOLGA6L5P	-3.67	0.000251	0.0138	-0.16	-0.11	Height;	chr15:83678426	chr15:84507885~84516814:-
BRCA	cis	rs739496	0.546	rs11066055	ENSG00000234608.6	MAPKAPK5-AS1	3.67	0.000251	0.0138	0.14	0.11	Platelet count;	chr12:111875412	chr12:111839764~111842902:-
BRCA	cis	rs2439831	0.85	rs28513374	ENSG00000206991.1	RNU6-610P	-3.67	0.000251	0.0138	-0.19	-0.11	Lung cancer in ever smokers;	chr15:43833297	chr15:43637632~43637738:-
BRCA	cis	rs2839186	0.967	rs2839191	ENSG00000215424.8	MCM3AP-AS1	3.67	0.000251	0.0138	0.1	0.11	Testicular germ cell tumor;	chr21:46275481	chr21:46229217~46259390:+
BRCA	cis	rs219780	1	rs219780	ENSG00000233818.1	AP000695.4	3.67	0.000251	0.0138	0.13	0.11	Kidney stones;	chr21:36461009	chr21:36445731~36532408:+
BRCA	cis	rs2268983	0.714	rs10141794	ENSG00000259165.1	DDX18P1	3.67	0.000251	0.0138	0.13	0.11	Smoking behavior;	chr14:68940108	chr14:69083398~69085389:+
BRCA	cis	rs1998359	0.626	rs177865	ENSG00000259087.4	RP11-356O9.2	3.67	0.000251	0.0138	0.11	0.11	Self-reported allergy;	chr14:37653301	chr14:37556158~37567095:-
BRCA	cis	rs1998359	0.651	rs177867	ENSG00000259087.4	RP11-356O9.2	3.67	0.000251	0.0138	0.11	0.11	Self-reported allergy;	chr14:37653923	chr14:37556158~37567095:-
BRCA	cis	rs9470794	1	rs73421874	ENSG00000204110.6	RP1-153P14.8	-3.67	0.000251	0.0138	-0.22	-0.11	Type 2 diabetes;	chr6:38138991	chr6:37507348~37535616:+
BRCA	cis	rs9470794	1	rs11757654	ENSG00000204110.6	RP1-153P14.8	-3.67	0.000251	0.0138	-0.22	-0.11	Type 2 diabetes;	chr6:38139444	chr6:37507348~37535616:+
BRCA	cis	rs9470794	1	rs58003999	ENSG00000204110.6	RP1-153P14.8	-3.67	0.000251	0.0138	-0.22	-0.11	Type 2 diabetes;	chr6:38139535	chr6:37507348~37535616:+
BRCA	cis	rs7647973	0.516	rs4955418	ENSG00000272434.1	RP13-131K19.6	-3.67	0.000251	0.0138	-0.13	-0.11	Menarche (age at onset);	chr3:49163194	chr3:49029316~49029706:+
BRCA	cis	rs4478858	0.698	rs4949385	ENSG00000260386.4	LINC01225	-3.67	0.000251	0.0138	-0.13	-0.11	Alcohol dependence;	chr1:31320409	chr1:31500085~31540885:+
BRCA	cis	rs17767294	0.708	rs72848760	ENSG00000219392.1	RP1-265C24.5	-3.67	0.000251	0.0138	-0.31	-0.11	Parkinson's disease;	chr6:27919099	chr6:28115628~28116551:+
BRCA	cis	rs17767294	0.708	rs72848763	ENSG00000219392.1	RP1-265C24.5	-3.67	0.000251	0.0138	-0.31	-0.11	Parkinson's disease;	chr6:27934710	chr6:28115628~28116551:+
BRCA	cis	rs17767294	0.708	rs72848766	ENSG00000219392.1	RP1-265C24.5	-3.67	0.000251	0.0138	-0.31	-0.11	Parkinson's disease;	chr6:27940978	chr6:28115628~28116551:+
BRCA	cis	rs17767294	0.708	rs72848767	ENSG00000219392.1	RP1-265C24.5	-3.67	0.000251	0.0138	-0.31	-0.11	Parkinson's disease;	chr6:27941509	chr6:28115628~28116551:+
BRCA	cis	rs17767294	0.708	rs72848769	ENSG00000219392.1	RP1-265C24.5	-3.67	0.000251	0.0138	-0.31	-0.11	Parkinson's disease;	chr6:27950601	chr6:28115628~28116551:+
BRCA	cis	rs17767294	0.708	rs72848770	ENSG00000219392.1	RP1-265C24.5	-3.67	0.000251	0.0138	-0.31	-0.11	Parkinson's disease;	chr6:27951371	chr6:28115628~28116551:+
BRCA	cis	rs17767294	0.708	rs72848772	ENSG00000219392.1	RP1-265C24.5	-3.67	0.000251	0.0138	-0.31	-0.11	Parkinson's disease;	chr6:27953170	chr6:28115628~28116551:+
BRCA	cis	rs757081	0.514	rs214087	ENSG00000272034.1	SNORD14A	-3.67	0.000251	0.0138	-0.12	-0.11	Systolic blood pressure;	chr11:17276818	chr11:17074654~17074744:-
BRCA	cis	rs8141529	0.748	rs5762881	ENSG00000272858.1	CTA-292E10.8	-3.67	0.000251	0.0138	-0.15	-0.11	Lymphocyte counts;	chr22:28893358	chr22:28814914~28815662:+
BRCA	cis	rs10463316	0.817	rs6879238	ENSG00000260581.1	CTB-113P19.4	3.67	0.000251	0.0138	0.13	0.11	Metabolite levels (Pyroglutamine);	chr5:151441013	chr5:151652275~151655449:+
BRCA	cis	rs17684571	0.872	rs13203000	ENSG00000231441.1	RP11-472M19.2	3.67	0.000251	0.0138	0.2	0.11	Schizophrenia;	chr6:56758921	chr6:56844002~56864078:+
BRCA	cis	rs17684571	0.872	rs13217390	ENSG00000231441.1	RP11-472M19.2	3.67	0.000251	0.0138	0.2	0.11	Schizophrenia;	chr6:56758953	chr6:56844002~56864078:+
BRCA	cis	rs8049367	0.684	rs759273	ENSG00000267077.1	RP11-127I20.5	3.67	0.000251	0.0138	0.12	0.11	Nonsyndromic cleft lip with or without cleft palate;	chr16:3917239	chr16:4795265~4796532:-
BRCA	cis	rs11668609	0.505	rs60605343	ENSG00000268442.1	CTD-2027I19.2	3.67	0.000251	0.0138	0.18	0.11	Response to taxane treatment (docetaxel);	chr19:23968486	chr19:24162370~24163425:-
BRCA	cis	rs928391	1	rs2777929	ENSG00000223356.1	RP11-66D17.5	-3.67	0.000251	0.0138	-0.15	-0.11	Platelet count;	chr1:156797879	chr1:156712212~156713174:-
BRCA	cis	rs13315871	0.929	rs11715290	ENSG00000272182.1	RP11-802O23.3	3.67	0.000251	0.0138	0.23	0.11	Cholesterol, total;	chr3:58312686	chr3:58428255~58428815:+
BRCA	cis	rs11098499	0.865	rs28634456	ENSG00000225892.3	RP11-384K6.2	3.67	0.000251	0.0138	0.11	0.11	Corneal astigmatism;	chr4:119454623	chr4:118632274~118634759:+
BRCA	cis	rs6600671	0.934	rs11249348	ENSG00000275131.1	CH17-472G23.4	-3.67	0.000251	0.0138	-0.1	-0.11	Hip geometry;	chr1:121446444	chr1:120489625~120579190:-
BRCA	cis	rs17214007	0.877	rs2075515	ENSG00000279866.1	CTB-193M12.4	3.67	0.000251	0.0138	0.17	0.11	Cognitive function;	chr16:15778462	chr16:15704410~15705984:+
BRCA	cis	rs561341	1	rs4795670	ENSG00000277511.1	CTD-2095E4.5	3.67	0.000251	0.0138	0.15	0.11	Hip circumference adjusted for BMI;	chr17:31917820	chr17:32127595~32128454:+
BRCA	cis	rs9307239	0.533	rs1442487	ENSG00000246090.5	RP11-696N14.1	3.67	0.000251	0.0138	0.11	0.11	Alcohol dependence;	chr4:99393381	chr4:99088857~99301356:+
BRCA	cis	rs6723162	0.51	rs3771394	ENSG00000237751.2	LINC01143	-3.67	0.000251	0.0138	-0.16	-0.11	Neurocognitive impairment in HIV-1 infection (dichotomous);	chr2:70918081	chr2:70887871~70889959:+
BRCA	cis	rs13256369	1	rs13267501	ENSG00000254153.1	CTA-398F10.2	3.67	0.000251	0.0138	0.15	0.11	Obesity-related traits;	chr8:8716548	chr8:8456909~8461337:-
BRCA	cis	rs13256369	0.95	rs13270006	ENSG00000254153.1	CTA-398F10.2	3.67	0.000251	0.0138	0.15	0.11	Obesity-related traits;	chr8:8716687	chr8:8456909~8461337:-
BRCA	cis	rs6964587	1	rs3753109	ENSG00000188693.7	CYP51A1-AS1	-3.67	0.000251	0.0138	-0.12	-0.11	Breast cancer;	chr7:92000687	chr7:92134604~92180725:+
BRCA	cis	rs73222236	0.794	rs60614489	ENSG00000239213.4	NCK1-AS1	3.67	0.000251	0.0138	0.13	0.11	Coronary artery disease;	chr3:136268136	chr3:136841726~136862054:-
BRCA	cis	rs11887277	0.586	rs34995758	ENSG00000272148.1	RP11-195B17.1	-3.67	0.000251	0.0138	-0.13	-0.11	Obesity-related traits;	chr2:26765143	chr2:27062428~27062907:-
BRCA	cis	rs1730008	0.661	rs6784968	ENSG00000279311.1	RP11-170K4.2	3.67	0.000251	0.0138	0.14	0.11	Lobe attachment (rater-scored or self-reported);	chr3:158338985	chr3:158869898~158871821:+
BRCA	cis	rs1730008	0.691	rs59478536	ENSG00000279311.1	RP11-170K4.2	3.67	0.000251	0.0138	0.14	0.11	Lobe attachment (rater-scored or self-reported);	chr3:158348593	chr3:158869898~158871821:+
BRCA	cis	rs1730008	0.691	rs10936131	ENSG00000279311.1	RP11-170K4.2	3.67	0.000251	0.0138	0.14	0.11	Lobe attachment (rater-scored or self-reported);	chr3:158353069	chr3:158869898~158871821:+
BRCA	cis	rs1730008	0.691	rs6800853	ENSG00000279311.1	RP11-170K4.2	3.67	0.000251	0.0138	0.14	0.11	Lobe attachment (rater-scored or self-reported);	chr3:158357699	chr3:158869898~158871821:+
BRCA	cis	rs1730008	0.691	rs58195752	ENSG00000279311.1	RP11-170K4.2	3.67	0.000251	0.0138	0.14	0.11	Lobe attachment (rater-scored or self-reported);	chr3:158360168	chr3:158869898~158871821:+
BRCA	cis	rs1730008	0.691	rs73170337	ENSG00000279311.1	RP11-170K4.2	3.67	0.000251	0.0138	0.14	0.11	Lobe attachment (rater-scored or self-reported);	chr3:158360857	chr3:158869898~158871821:+
BRCA	cis	rs1730008	0.691	rs10936132	ENSG00000279311.1	RP11-170K4.2	3.67	0.000251	0.0138	0.14	0.11	Lobe attachment (rater-scored or self-reported);	chr3:158362863	chr3:158869898~158871821:+
BRCA	cis	rs1730008	0.691	rs12634807	ENSG00000279311.1	RP11-170K4.2	3.67	0.000251	0.0138	0.14	0.11	Lobe attachment (rater-scored or self-reported);	chr3:158363114	chr3:158869898~158871821:+
BRCA	cis	rs2880765	0.805	rs34598679	ENSG00000230373.7	GOLGA6L5P	3.67	0.000251	0.0138	0.12	0.11	Coronary artery disease;	chr15:85498974	chr15:84507885~84516814:-
BRCA	cis	rs2880765	0.835	rs4344688	ENSG00000230373.7	GOLGA6L5P	3.67	0.000251	0.0138	0.12	0.11	Coronary artery disease;	chr15:85499776	chr15:84507885~84516814:-
BRCA	cis	rs8114671	0.562	rs6088621	ENSG00000279253.1	RP4-614O4.13	-3.67	0.000251	0.0138	-0.13	-0.11	Height;	chr20:34830937	chr20:35262727~35264187:-
BRCA	cis	rs9300255	0.664	rs12316131	ENSG00000256028.2	RP11-197N18.2	-3.67	0.000251	0.0138	-0.11	-0.11	Neutrophil percentage of white cells;	chr12:123333249	chr12:122975320~122982907:+
BRCA	cis	rs10043228	1	rs62384714	ENSG00000271918.1	CTD-2287O16.5	-3.67	0.000251	0.0138	-0.16	-0.11	Asthma or chronic obstructive pulmonary disease;	chr5:116116900	chr5:116083807~116085416:-
BRCA	cis	rs6012564	1	rs755587	ENSG00000230758.1	SNAP23P	3.67	0.000251	0.0138	0.13	0.11	Anger;	chr20:49104420	chr20:49038357~49038602:-
BRCA	cis	rs964611	1	rs74011998	ENSG00000259488.2	RP11-154J22.1	-3.67	0.000251	0.0138	-0.15	-0.11	Metabolite levels (Pyroglutamine);	chr15:48304516	chr15:48312353~48331856:-
BRCA	cis	rs13326165	0.76	rs6763882	ENSG00000243224.1	RP5-1157M23.2	3.67	0.000251	0.0138	0.16	0.11	HDL cholesterol levels;HDL cholesterol;	chr3:52320756	chr3:52239258~52241097:+
BRCA	cis	rs708547	0.541	rs6554392	ENSG00000269949.1	RP11-738E22.3	-3.67	0.000251	0.0138	-0.14	-0.11	Response to bleomycin (chromatid breaks);	chr4:56873782	chr4:56960927~56961373:-
BRCA	cis	rs863345	0.604	rs2873595	ENSG00000229914.1	RP11-404O13.4	-3.67	0.000251	0.0138	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158538592	chr1:158195633~158196131:-
BRCA	cis	rs7267979	0.966	rs6107031	ENSG00000276952.1	RP5-965G21.6	-3.67	0.000251	0.0138	-0.14	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25370041	chr20:25284915~25285588:-
BRCA	cis	rs7267979	1	rs6115159	ENSG00000276952.1	RP5-965G21.6	-3.67	0.000251	0.0138	-0.14	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25370308	chr20:25284915~25285588:-
BRCA	cis	rs7267979	1	rs4813562	ENSG00000276952.1	RP5-965G21.6	-3.67	0.000251	0.0138	-0.14	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25371952	chr20:25284915~25285588:-
BRCA	cis	rs35306767	0.903	rs7067865	ENSG00000229869.1	RP11-363N22.2	-3.67	0.000251	0.0138	-0.17	-0.11	Eosinophil percentage of granulocytes;	chr10:862447	chr10:933026~942743:+
BRCA	cis	rs2692947	0.683	rs2315416	ENSG00000232931.4	LINC00342	3.67	0.000251	0.0138	0.12	0.11	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95892729	chr2:95807118~95816215:-
BRCA	cis	rs11035577	0.632	rs4756517	ENSG00000279675.1	RP11-454H19.2	-3.67	0.000251	0.0138	-0.18	-0.11	Temperament (bipolar disorder);	chr11:39748270	chr11:40107244~40112599:-
BRCA	cis	rs11035577	0.632	rs4756518	ENSG00000279675.1	RP11-454H19.2	-3.67	0.000251	0.0138	-0.18	-0.11	Temperament (bipolar disorder);	chr11:39748283	chr11:40107244~40112599:-
BRCA	cis	rs4478858	0.735	rs10798843	ENSG00000260386.4	LINC01225	-3.67	0.000251	0.0138	-0.13	-0.11	Alcohol dependence;	chr1:31324247	chr1:31500085~31540885:+
BRCA	cis	rs4478858	0.735	rs7526095	ENSG00000260386.4	LINC01225	-3.67	0.000251	0.0138	-0.13	-0.11	Alcohol dependence;	chr1:31324734	chr1:31500085~31540885:+
BRCA	cis	rs4478858	0.735	rs6681286	ENSG00000260386.4	LINC01225	-3.67	0.000251	0.0138	-0.13	-0.11	Alcohol dependence;	chr1:31326537	chr1:31500085~31540885:+
BRCA	cis	rs4478858	0.698	rs4949204	ENSG00000260386.4	LINC01225	-3.67	0.000251	0.0138	-0.13	-0.11	Alcohol dependence;	chr1:31327568	chr1:31500085~31540885:+
BRCA	cis	rs4478858	0.735	rs4949205	ENSG00000260386.4	LINC01225	-3.67	0.000251	0.0138	-0.13	-0.11	Alcohol dependence;	chr1:31327732	chr1:31500085~31540885:+
BRCA	cis	rs4478858	0.735	rs6687819	ENSG00000260386.4	LINC01225	-3.67	0.000251	0.0138	-0.13	-0.11	Alcohol dependence;	chr1:31328265	chr1:31500085~31540885:+
BRCA	cis	rs4478858	0.698	rs7543348	ENSG00000260386.4	LINC01225	-3.67	0.000251	0.0138	-0.13	-0.11	Alcohol dependence;	chr1:31331958	chr1:31500085~31540885:+
BRCA	cis	rs4478858	0.698	rs11802155	ENSG00000260386.4	LINC01225	-3.67	0.000251	0.0138	-0.13	-0.11	Alcohol dependence;	chr1:31332165	chr1:31500085~31540885:+
BRCA	cis	rs4478858	0.735	rs12126725	ENSG00000260386.4	LINC01225	-3.67	0.000251	0.0138	-0.13	-0.11	Alcohol dependence;	chr1:31333006	chr1:31500085~31540885:+
BRCA	cis	rs4478858	0.735	rs68008576	ENSG00000260386.4	LINC01225	-3.67	0.000251	0.0138	-0.13	-0.11	Alcohol dependence;	chr1:31333058	chr1:31500085~31540885:+
BRCA	cis	rs4478858	0.735	rs11582342	ENSG00000260386.4	LINC01225	-3.67	0.000251	0.0138	-0.13	-0.11	Alcohol dependence;	chr1:31337834	chr1:31500085~31540885:+
BRCA	cis	rs4478858	0.735	rs34960310	ENSG00000260386.4	LINC01225	-3.67	0.000251	0.0138	-0.13	-0.11	Alcohol dependence;	chr1:31343350	chr1:31500085~31540885:+
BRCA	cis	rs4478858	0.735	rs10914361	ENSG00000260386.4	LINC01225	-3.67	0.000251	0.0138	-0.13	-0.11	Alcohol dependence;	chr1:31344695	chr1:31500085~31540885:+
BRCA	cis	rs4478858	0.735	rs4531329	ENSG00000260386.4	LINC01225	-3.67	0.000251	0.0138	-0.13	-0.11	Alcohol dependence;	chr1:31344963	chr1:31500085~31540885:+
BRCA	cis	rs4478858	0.709	rs3766296	ENSG00000260386.4	LINC01225	-3.67	0.000251	0.0138	-0.13	-0.11	Alcohol dependence;	chr1:31347376	chr1:31500085~31540885:+
BRCA	cis	rs10043228	1	rs1422500	ENSG00000271918.1	CTD-2287O16.5	-3.67	0.000251	0.0138	-0.16	-0.11	Asthma or chronic obstructive pulmonary disease;	chr5:116233615	chr5:116083807~116085416:-
BRCA	cis	rs1371614	0.632	rs1992311	ENSG00000229122.1	AGBL5-IT1	3.67	0.000251	0.0138	0.12	0.11	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26936473	chr2:27061038~27061815:+
BRCA	cis	rs9921338	0.632	rs149310	ENSG00000262636.1	CTD-3088G3.4	3.67	0.000251	0.0138	0.18	0.11	Vein graft stenosis in coronary artery bypass grafting;	chr16:11251842	chr16:11380859~11381118:-
BRCA	cis	rs6964587	1	rs6964587	ENSG00000188693.7	CYP51A1-AS1	-3.67	0.000251	0.0138	-0.12	-0.11	Breast cancer;	chr7:92001306	chr7:92134604~92180725:+
BRCA	cis	rs2562456	0.874	rs2562408	ENSG00000268555.1	RP11-678G14.3	-3.67	0.000251	0.0138	-0.15	-0.11	Pain;	chr19:21527079	chr19:21570822~21587322:-
BRCA	cis	rs4415084	0.804	rs9790879	ENSG00000248779.1	RP11-53O19.2	-3.67	0.000251	0.0138	-0.1	-0.11	Breast cancer;	chr5:44899783	chr5:44752949~44765744:+
BRCA	cis	rs7520050	0.931	rs6686134	ENSG00000234329.1	RP11-767N6.2	-3.67	0.000251	0.0138	-0.11	-0.11	Reticulocyte count;Red blood cell count;	chr1:45912596	chr1:45651039~45651826:-
BRCA	cis	rs201673768	1	rs201673768	ENSG00000257763.1	OR5BK1P	3.67	0.000251	0.0138	0.12	0.11	Platelet count;	chr12:48305834	chr12:48355792~48356614:-
BRCA	cis	rs10895275	0.961	rs10895274	ENSG00000277459.1	RP11-732A21.3	-3.67	0.000251	0.0138	-0.12	-0.11	Migraine;	chr11:102212338	chr11:102109827~102110457:-
BRCA	cis	rs863345	0.625	rs10908663	ENSG00000176320.2	RP11-404O13.5	-3.67	0.000251	0.0138	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158522331	chr1:158197922~158203877:-
BRCA	cis	rs2262909	0.962	rs390730	ENSG00000279377.1	AC003973.3	3.67	0.000251	0.0138	0.16	0.11	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;	chr19:22050707	chr19:21965708~21968529:-
BRCA	cis	rs6071166	0.683	rs1885456	ENSG00000224635.1	RP4-564F22.5	-3.67	0.000252	0.0138	-0.14	-0.11	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38695853	chr20:38406011~38416797:-
BRCA	cis	rs6071166	0.683	rs6015665	ENSG00000224635.1	RP4-564F22.5	-3.67	0.000252	0.0138	-0.14	-0.11	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38695969	chr20:38406011~38416797:-
BRCA	cis	rs6071166	0.683	rs6015666	ENSG00000224635.1	RP4-564F22.5	-3.67	0.000252	0.0138	-0.14	-0.11	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38695984	chr20:38406011~38416797:-
BRCA	cis	rs6071166	0.683	rs6027369	ENSG00000224635.1	RP4-564F22.5	-3.67	0.000252	0.0138	-0.14	-0.11	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38697441	chr20:38406011~38416797:-
BRCA	cis	rs6071166	0.683	rs6071139	ENSG00000224635.1	RP4-564F22.5	-3.67	0.000252	0.0138	-0.14	-0.11	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38697906	chr20:38406011~38416797:-
BRCA	cis	rs11098499	0.863	rs13136462	ENSG00000260091.1	RP11-33B1.4	-3.67	0.000252	0.0138	-0.1	-0.11	Corneal astigmatism;	chr4:119622018	chr4:119409333~119410233:+
BRCA	cis	rs4767841	0.935	rs4766946	ENSG00000248636.5	RP11-768F21.1	-3.67	0.000252	0.0138	-0.14	-0.11	Urgency urinary incontinence;	chr12:119723516	chr12:119387987~119668079:-
BRCA	cis	rs7299940	1	rs7299940	ENSG00000256299.1	RP11-989F5.3	-3.67	0.000252	0.0138	-0.12	-0.11	Panic disorder;	chr12:130906209	chr12:130810821~130812622:-
BRCA	cis	rs35306767	0.903	rs12769873	ENSG00000229869.1	RP11-363N22.2	-3.67	0.000252	0.0138	-0.17	-0.11	Eosinophil percentage of granulocytes;	chr10:890586	chr10:933026~942743:+
BRCA	cis	rs73191547	0.965	rs12548428	ENSG00000272267.2	RP11-375N15.2	3.67	0.000252	0.0138	0.14	0.11	Schizophrenia;	chr8:10173188	chr8:9555144~9556520:-
BRCA	cis	rs13272568	0.614	rs972845	ENSG00000254352.1	RP11-578O24.2	-3.67	0.000252	0.0138	-0.14	-0.11	Bone mineral density;	chr8:78130401	chr8:78723796~78724136:-
BRCA	cis	rs1555133	0.92	rs12480462	ENSG00000277692.1	RP11-358N2.2	-3.67	0.000252	0.0138	-0.13	-0.11	Monocyte count;	chr20:32477375	chr20:32355053~32355734:+
BRCA	cis	rs4478858	0.735	rs7547897	ENSG00000260386.4	LINC01225	-3.67	0.000252	0.0138	-0.13	-0.11	Alcohol dependence;	chr1:31324746	chr1:31500085~31540885:+
BRCA	cis	rs73201462	1	rs2811387	ENSG00000242551.2	POU5F1P6	-3.67	0.000252	0.0138	-0.19	-0.11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128296335	chr3:128674735~128677005:-
BRCA	cis	rs4925540	1	rs7512150	ENSG00000215796.3	RP11-551G24.2	-3.67	0.000252	0.0138	-0.13	-0.11	Response to taxane treatment (docetaxel);	chr1:247049024	chr1:247042791~247044021:+
BRCA	cis	rs9400180	0.802	rs9398160	ENSG00000271734.1	RP1-111B22.3	-3.67	0.000252	0.0138	-0.14	-0.11	Major depressive disorder;	chr6:108068296	chr6:108030249~108030718:-
BRCA	cis	rs7020830	1	rs7020830	ENSG00000260100.1	RP11-220I1.5	-3.67	0.000252	0.0139	-0.14	-0.11	Schizophrenia;	chr9:37085187	chr9:37078813~37079776:-
BRCA	cis	rs4950322	0.57	rs4950401	ENSG00000237188.3	RP11-337C18.8	3.67	0.000252	0.0139	0.14	0.11	Protein quantitative trait loci;	chr1:147319571	chr1:147172771~147211568:+
BRCA	cis	rs4950322	0.57	rs4950402	ENSG00000237188.3	RP11-337C18.8	3.67	0.000252	0.0139	0.14	0.11	Protein quantitative trait loci;	chr1:147319684	chr1:147172771~147211568:+
BRCA	cis	rs4950322	0.57	rs4950404	ENSG00000237188.3	RP11-337C18.8	3.67	0.000252	0.0139	0.14	0.11	Protein quantitative trait loci;	chr1:147319834	chr1:147172771~147211568:+
BRCA	cis	rs4950322	0.57	rs72692953	ENSG00000237188.3	RP11-337C18.8	3.67	0.000252	0.0139	0.14	0.11	Protein quantitative trait loci;	chr1:147321416	chr1:147172771~147211568:+
BRCA	cis	rs7620503	0.959	rs4857713	ENSG00000231574.4	RP11-91K9.1	3.67	0.000252	0.0139	0.13	0.11	Corneal structure;	chr3:177588654	chr3:177816865~177899224:+
BRCA	cis	rs7267979	0.966	rs454723	ENSG00000204556.4	CTD-2514C3.1	-3.67	0.000252	0.0139	-0.15	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25458292	chr20:26018832~26020684:+
BRCA	cis	rs4886920	0.748	rs8036045	ENSG00000260776.4	RP11-114H24.2	-3.67	0.000252	0.0139	-0.14	-0.11	Neuroticism;	chr15:77855299	chr15:77914217~77926846:-
BRCA	cis	rs7624327	0.831	rs6805954	ENSG00000241770.1	RP11-555M1.3	-3.67	0.000252	0.0139	-0.21	-0.11	Eating disorders;	chr3:157104029	chr3:157163452~157169133:+
BRCA	cis	rs61931739	0.534	rs4001713	ENSG00000258794.3	DUX4L27	-3.67	0.000252	0.0139	-0.16	-0.11	Morning vs. evening chronotype;	chr12:34001260	chr12:34208415~34209675:-
BRCA	cis	rs6545883	0.501	rs935860	ENSG00000270820.4	RP11-355B11.2	3.67	0.000252	0.0139	0.12	0.11	Tuberculosis;	chr2:61179426	chr2:61471188~61484130:+
BRCA	cis	rs2732480	1	rs2732480	ENSG00000269514.1	RP11-370I10.12	-3.67	0.000252	0.0139	-0.13	-0.11	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48342520	chr12:48198387~48202031:+
BRCA	cis	rs4835473	0.838	rs13134571	ENSG00000246448.2	RP13-578N3.3	-3.67	0.000252	0.0139	-0.13	-0.11	Immature fraction of reticulocytes;	chr4:143738771	chr4:143700257~143865072:+
BRCA	cis	rs78487399	0.808	rs17030800	ENSG00000234936.1	AC010883.5	3.67	0.000252	0.0139	0.17	0.11	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43443864	chr2:43229573~43233394:+
BRCA	cis	rs4948102	0.731	rs6593292	ENSG00000226278.1	PSPHP1	-3.67	0.000252	0.0139	-0.13	-0.11	Plasma homocysteine levels (post-methionine load test);	chr7:55975344	chr7:55764797~55773288:+
BRCA	cis	rs4654783	0.521	rs59709264	ENSG00000230068.2	CDC42-IT1	3.67	0.000252	0.0139	0.13	0.11	Endometriosis;	chr1:22122832	chr1:22059197~22064199:+
BRCA	cis	rs739496	0.579	rs80017658	ENSG00000234608.6	MAPKAPK5-AS1	3.67	0.000252	0.0139	0.14	0.11	Platelet count;	chr12:111942568	chr12:111839764~111842902:-
BRCA	cis	rs739496	0.579	rs73426362	ENSG00000234608.6	MAPKAPK5-AS1	3.67	0.000252	0.0139	0.14	0.11	Platelet count;	chr12:111942666	chr12:111839764~111842902:-
BRCA	cis	rs477895	0.838	rs12794145	ENSG00000256940.1	RP11-783K16.5	3.67	0.000252	0.0139	0.16	0.11	Mean platelet volume;	chr11:64239012	chr11:64245964~64248217:+
BRCA	cis	rs7712401	0.755	rs10071705	ENSG00000251538.4	RP11-166A12.1	3.67	0.000252	0.0139	0.12	0.11	Mean platelet volume;	chr5:122797030	chr5:122628952~122730685:-
BRCA	cis	rs91731	0.79	rs7703512	ENSG00000249572.1	CTD-2203K17.1	-3.67	0.000252	0.0139	-0.21	-0.11	Lung function (FVC);	chr5:33253313	chr5:33424025~33440619:-
BRCA	cis	rs7763441	0.545	rs9378700	ENSG00000272465.1	RP1-136B1.1	3.67	0.000252	0.0139	0.15	0.11	Monobrow;	chr6:2452320	chr6:2437549~2438249:+
BRCA	cis	rs4950322	0.57	rs72692963	ENSG00000227242.3	NBPF13P	-3.67	0.000252	0.0139	-0.16	-0.11	Protein quantitative trait loci;	chr1:147331090	chr1:147021320~147124525:-
BRCA	cis	rs4950322	0.518	rs72692965	ENSG00000227242.3	NBPF13P	-3.67	0.000252	0.0139	-0.16	-0.11	Protein quantitative trait loci;	chr1:147332085	chr1:147021320~147124525:-
BRCA	cis	rs4950322	0.518	rs72692968	ENSG00000227242.3	NBPF13P	-3.67	0.000252	0.0139	-0.16	-0.11	Protein quantitative trait loci;	chr1:147332884	chr1:147021320~147124525:-
BRCA	cis	rs4950322	0.518	rs72692970	ENSG00000227242.3	NBPF13P	-3.67	0.000252	0.0139	-0.16	-0.11	Protein quantitative trait loci;	chr1:147332887	chr1:147021320~147124525:-
BRCA	cis	rs4950322	0.57	rs72692971	ENSG00000227242.3	NBPF13P	-3.67	0.000252	0.0139	-0.16	-0.11	Protein quantitative trait loci;	chr1:147333088	chr1:147021320~147124525:-
BRCA	cis	rs4950322	0.57	rs72692973	ENSG00000227242.3	NBPF13P	-3.67	0.000252	0.0139	-0.16	-0.11	Protein quantitative trait loci;	chr1:147333281	chr1:147021320~147124525:-
BRCA	cis	rs4950322	0.57	rs72692975	ENSG00000227242.3	NBPF13P	-3.67	0.000252	0.0139	-0.16	-0.11	Protein quantitative trait loci;	chr1:147333506	chr1:147021320~147124525:-
BRCA	cis	rs9925964	0.933	rs56314408	ENSG00000260911.2	RP11-196G11.2	3.67	0.000252	0.0139	0.11	0.11	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31106068	chr16:31043150~31049868:+
BRCA	cis	rs8054556	1	rs4788209	ENSG00000183604.13	SMG1P5	-3.67	0.000252	0.0139	-0.11	-0.11	Autism spectrum disorder or schizophrenia;	chr16:30001945	chr16:30267553~30335374:-
BRCA	cis	rs8054556	1	rs4788210	ENSG00000183604.13	SMG1P5	-3.67	0.000252	0.0139	-0.11	-0.11	Autism spectrum disorder or schizophrenia;	chr16:30002353	chr16:30267553~30335374:-
BRCA	cis	rs721917	0.525	rs2758545	ENSG00000280355.1	RP11-119F19.5	-3.67	0.000252	0.0139	-0.12	-0.11	Chronic obstructive pulmonary disease;	chr10:79940334	chr10:79681973~79684094:-
BRCA	cis	rs7709909	0.72	rs6151603	ENSG00000249655.1	CTC-325J23.2	3.67	0.000252	0.0139	0.12	0.11	HDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;	chr5:80664309	chr5:80630313~80631590:-
BRCA	cis	rs7226408	0.842	rs56239982	ENSG00000267707.2	RP11-95O2.5	3.67	0.000252	0.0139	0.18	0.11	Obesity-related traits;	chr18:36751791	chr18:37243776~37247506:+
BRCA	cis	rs7226408	0.842	rs56178761	ENSG00000267707.2	RP11-95O2.5	3.67	0.000252	0.0139	0.18	0.11	Obesity-related traits;	chr18:36751792	chr18:37243776~37247506:+
BRCA	cis	rs17221829	0.764	rs7945447	ENSG00000280385.1	AP000648.5	-3.67	0.000252	0.0139	-0.13	-0.11	Anxiety in major depressive disorder;	chr11:89652902	chr11:90193614~90198120:+
BRCA	cis	rs17221829	0.764	rs7931085	ENSG00000280385.1	AP000648.5	-3.67	0.000252	0.0139	-0.13	-0.11	Anxiety in major depressive disorder;	chr11:89653029	chr11:90193614~90198120:+
BRCA	cis	rs17221829	0.764	rs6483020	ENSG00000280385.1	AP000648.5	-3.67	0.000252	0.0139	-0.13	-0.11	Anxiety in major depressive disorder;	chr11:89653216	chr11:90193614~90198120:+
BRCA	cis	rs17221829	0.627	rs7130892	ENSG00000280385.1	AP000648.5	-3.67	0.000252	0.0139	-0.13	-0.11	Anxiety in major depressive disorder;	chr11:89653438	chr11:90193614~90198120:+
BRCA	cis	rs17221829	0.673	rs10830324	ENSG00000280385.1	AP000648.5	-3.67	0.000252	0.0139	-0.13	-0.11	Anxiety in major depressive disorder;	chr11:89655677	chr11:90193614~90198120:+
BRCA	cis	rs17221829	0.645	rs10830325	ENSG00000280385.1	AP000648.5	-3.67	0.000252	0.0139	-0.13	-0.11	Anxiety in major depressive disorder;	chr11:89655900	chr11:90193614~90198120:+
BRCA	cis	rs17221829	0.733	rs10830326	ENSG00000280385.1	AP000648.5	-3.67	0.000252	0.0139	-0.13	-0.11	Anxiety in major depressive disorder;	chr11:89655942	chr11:90193614~90198120:+
BRCA	cis	rs17221829	0.733	rs10830327	ENSG00000280385.1	AP000648.5	-3.67	0.000252	0.0139	-0.13	-0.11	Anxiety in major depressive disorder;	chr11:89655954	chr11:90193614~90198120:+
BRCA	cis	rs17221829	0.549	rs1844196	ENSG00000280385.1	AP000648.5	-3.67	0.000252	0.0139	-0.13	-0.11	Anxiety in major depressive disorder;	chr11:89656088	chr11:90193614~90198120:+
BRCA	cis	rs17221829	0.617	rs1844194	ENSG00000280385.1	AP000648.5	-3.67	0.000252	0.0139	-0.13	-0.11	Anxiety in major depressive disorder;	chr11:89656199	chr11:90193614~90198120:+
BRCA	cis	rs17221829	0.733	rs12277139	ENSG00000280385.1	AP000648.5	-3.67	0.000252	0.0139	-0.13	-0.11	Anxiety in major depressive disorder;	chr11:89656438	chr11:90193614~90198120:+
BRCA	cis	rs375066	0.762	rs239939	ENSG00000267191.1	RP11-15A1.2	-3.67	0.000252	0.0139	-0.15	-0.11	Breast cancer;	chr19:43883815	chr19:43902001~43926545:+
BRCA	cis	rs375066	0.762	rs239938	ENSG00000267191.1	RP11-15A1.2	-3.67	0.000252	0.0139	-0.15	-0.11	Breast cancer;	chr19:43886153	chr19:43902001~43926545:+
BRCA	cis	rs12234571	1	rs73372301	ENSG00000214293.7	APTR	3.67	0.000252	0.0139	0.23	0.11	Obesity-related traits;	chr7:77723502	chr7:77657660~77696265:-
BRCA	cis	rs17801127	0.818	rs34462373	ENSG00000231969.1	AC144449.1	3.67	0.000252	0.0139	0.19	0.11	Liver enzyme levels (alanine transaminase);	chr2:149674998	chr2:149587196~149848233:+
BRCA	cis	rs829883	0.867	rs1641640	ENSG00000227825.4	SLC9A7P1	3.67	0.000252	0.0139	0.14	0.11	Colorectal adenoma (advanced);	chr12:98502239	chr12:98453835~98457145:-
BRCA	cis	rs829883	0.872	rs1641641	ENSG00000227825.4	SLC9A7P1	3.67	0.000252	0.0139	0.14	0.11	Colorectal adenoma (advanced);	chr12:98502240	chr12:98453835~98457145:-
BRCA	cis	rs10043775	0.793	rs6893378	ENSG00000251330.3	CTD-2283N19.1	-3.67	0.000252	0.0139	-0.13	-0.11	Periodontal microbiota;	chr5:148332311	chr5:148430159~148430807:-
BRCA	cis	rs2109514	0.74	rs10464649	ENSG00000237813.3	AC002066.1	3.67	0.000252	0.0139	0.14	0.11	Prevalent atrial fibrillation;	chr7:116433513	chr7:116238260~116499465:-
BRCA	cis	rs7487075	0.893	rs1471223	ENSG00000257261.4	RP11-96H19.1	-3.67	0.000252	0.0139	-0.12	-0.11	Itch intensity from mosquito bite;	chr12:46333987	chr12:46383679~46876159:+
BRCA	cis	rs4648045	0.796	rs12509403	ENSG00000246560.2	RP11-10L12.4	3.67	0.000252	0.0139	0.13	0.11	Lymphocyte percentage of white cells;	chr4:102604193	chr4:102828055~102844075:+
BRCA	cis	rs1642645	0.872	rs10890170	ENSG00000228452.1	RP5-994D16.9	-3.67	0.000253	0.0139	-0.15	-0.11	Left ventricular obstructive tract defect (maternal effect);	chr1:41943851	chr1:42775813~42776790:-
BRCA	cis	rs13256369	0.76	rs7816171	ENSG00000254153.1	CTA-398F10.2	3.67	0.000253	0.0139	0.15	0.11	Obesity-related traits;	chr8:8718325	chr8:8456909~8461337:-
BRCA	cis	rs13256369	0.76	rs7839473	ENSG00000254153.1	CTA-398F10.2	3.67	0.000253	0.0139	0.15	0.11	Obesity-related traits;	chr8:8718326	chr8:8456909~8461337:-
BRCA	cis	rs4938330	0.629	rs12269901	ENSG00000280143.1	AP000892.6	-3.67	0.000253	0.0139	-0.11	-0.11	Blood protein levels;	chr11:117103213	chr11:117204967~117210292:+
BRCA	cis	rs910873	1	rs62212343	ENSG00000269202.1	RP4-614O4.12	-3.67	0.000253	0.0139	-0.25	-0.11	Melanoma;	chr20:34609133	chr20:35201747~35203288:-
BRCA	cis	rs8114671	0.527	rs6060112	ENSG00000279253.1	RP4-614O4.13	-3.67	0.000253	0.0139	-0.13	-0.11	Height;	chr20:34901473	chr20:35262727~35264187:-
BRCA	cis	rs13358904	1	rs13358904	ENSG00000278921.2	EPB41L4A-AS2	3.67	0.000253	0.0139	0.13	0.11	Suicide ideation score in major depressive disorder;	chr5:112267016	chr5:112419583~112420978:+
BRCA	cis	rs736801	0.808	rs2706396	ENSG00000233006.5	AC034220.3	-3.67	0.000253	0.0139	-0.09	-0.11	Mosquito bite size;Breast cancer;	chr5:132461117	chr5:132311285~132369916:-
BRCA	cis	rs2380205	0.517	rs11255974	ENSG00000232807.2	RP11-536K7.3	3.67	0.000253	0.0139	0.12	0.11	Breast cancer;	chr10:5926931	chr10:5934270~5945900:-
BRCA	cis	rs12612619	0.732	rs11126857	ENSG00000272148.1	RP11-195B17.1	-3.67	0.000253	0.0139	-0.12	-0.11	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27074889	chr2:27062428~27062907:-
BRCA	cis	rs9402743	0.632	rs7766804	ENSG00000231028.7	LINC00271	-3.67	0.000253	0.0139	-0.12	-0.11	Systemic lupus erythematosus;	chr6:135772118	chr6:135497801~135716055:+
BRCA	cis	rs2274273	0.673	rs2209808	ENSG00000259318.1	RP11-454L9.2	3.67	0.000253	0.0139	0.1	0.11	Protein biomarker;	chr14:55340977	chr14:55394940~55395233:-
BRCA	cis	rs10129255	0.957	rs8009948	ENSG00000211959.2	IGHV4-39	3.67	0.000253	0.0139	0.09	0.11	Kawasaki disease;	chr14:106805607	chr14:106421711~106422218:-
BRCA	cis	rs7130284	1	rs10830276	ENSG00000134612.10	FOLH1B	3.67	0.000253	0.0139	0.25	0.11	Homocysteine levels;	chr11:89472757	chr11:89639227~89698718:+
BRCA	cis	rs3735485	0.657	rs10951786	ENSG00000201772.1	SNORA5C	-3.67	0.000253	0.0139	-0.15	-0.11	White blood cell count;Sum basophil neutrophil counts;Neutrophil count;Granulocyte percentage of myeloid white cells;Monocyte percentage of white cells;Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Lymphocyte counts;	chr7:45008291	chr7:45104906~45105042:-
BRCA	cis	rs3735485	0.738	rs10951788	ENSG00000201772.1	SNORA5C	-3.67	0.000253	0.0139	-0.15	-0.11	White blood cell count;Sum basophil neutrophil counts;Neutrophil count;Granulocyte percentage of myeloid white cells;Monocyte percentage of white cells;Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Lymphocyte counts;	chr7:45008320	chr7:45104906~45105042:-
BRCA	cis	rs4073416	0.771	rs4902412	ENSG00000276116.2	FUT8-AS1	3.67	0.000253	0.0139	0.12	0.11	N-glycan levels;	chr14:65720349	chr14:65411170~65412690:-
BRCA	cis	rs4819052	0.851	rs8126930	ENSG00000215447.6	BX322557.10	-3.67	0.000253	0.0139	-0.11	-0.11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251800	chr21:45288052~45291738:+
BRCA	cis	rs6556937	0.736	rs1421911	ENSG00000272109.1	CTD-2260A17.3	3.67	0.000253	0.0139	0.19	0.11	Blood protein levels;	chr5:96665243	chr5:96804353~96806105:+
BRCA	cis	rs6840360	0.571	rs11723395	ENSG00000270265.1	RP11-731D1.4	-3.67	0.000253	0.0139	-0.14	-0.11	Intelligence (multi-trait analysis);	chr4:151603039	chr4:151333775~151353224:-
BRCA	cis	rs9287719	0.967	rs7355649	ENSG00000224177.5	LINC00570	3.67	0.000253	0.0139	0.13	0.11	Prostate cancer;	chr2:10607968	chr2:11393981~11403077:+
BRCA	cis	rs3105593	1	rs2011064	ENSG00000259618.1	RP11-562A8.5	3.67	0.000253	0.0139	0.12	0.11	QT interval;	chr15:50665428	chr15:50494018~50497080:-
BRCA	cis	rs13326165	0.76	rs34762015	ENSG00000243224.1	RP5-1157M23.2	-3.67	0.000253	0.0139	-0.16	-0.11	HDL cholesterol levels;HDL cholesterol;	chr3:52332028	chr3:52239258~52241097:+
BRCA	cis	rs13326165	0.76	rs2335640	ENSG00000243224.1	RP5-1157M23.2	-3.67	0.000253	0.0139	-0.16	-0.11	HDL cholesterol levels;HDL cholesterol;	chr3:52334371	chr3:52239258~52241097:+
BRCA	cis	rs13326165	0.76	rs56357549	ENSG00000243224.1	RP5-1157M23.2	-3.67	0.000253	0.0139	-0.16	-0.11	HDL cholesterol levels;HDL cholesterol;	chr3:52340500	chr3:52239258~52241097:+
BRCA	cis	rs7632954	0.567	rs6793940	ENSG00000227110.5	LMCD1-AS1	3.67	0.000253	0.0139	0.14	0.11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr3:8493320	chr3:7952805~8611924:-
BRCA	cis	rs11667325	0.727	rs10424234	ENSG00000268316.1	AC006272.2	-3.67	0.000253	0.0139	-0.14	-0.11	Neutrophil percentage of granulocytes;	chr19:51796174	chr19:51839771~51840945:-
BRCA	cis	rs987724	0.574	rs7638625	ENSG00000240875.4	LINC00886	-3.67	0.000253	0.0139	-0.13	-0.11	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156840267	chr3:156747346~156817062:-
BRCA	cis	rs6445967	1	rs14927	ENSG00000272182.1	RP11-802O23.3	-3.67	0.000253	0.0139	-0.13	-0.11	Platelet count;	chr3:58319306	chr3:58428255~58428815:+
BRCA	cis	rs748404	0.626	rs17780920	ENSG00000205771.5	CATSPER2P1	-3.67	0.000253	0.0139	-0.17	-0.11	Lung cancer;	chr15:43370164	chr15:43726918~43747094:-
BRCA	cis	rs2041840	1	rs2041840	ENSG00000272054.1	RP11-423P10.2	-3.67	0.000253	0.0139	-0.1	-0.11	Chronic lymphocytic leukemia;	chr2:37240121	chr2:37208875~37212677:+
BRCA	cis	rs6012564	1	rs3091529	ENSG00000230758.1	SNAP23P	-3.67	0.000253	0.0139	-0.13	-0.11	Anger;	chr20:49030531	chr20:49038357~49038602:-
BRCA	cis	rs6012564	1	rs1022687	ENSG00000230758.1	SNAP23P	-3.67	0.000253	0.0139	-0.13	-0.11	Anger;	chr20:49032317	chr20:49038357~49038602:-
BRCA	cis	rs4908769	0.624	rs894875	ENSG00000232912.4	RP5-1115A15.1	-3.67	0.000253	0.0139	-0.12	-0.11	Allergy;	chr1:8372076	chr1:8424645~8434838:+
BRCA	cis	rs7695732	0.743	rs9307061	ENSG00000270720.1	RP11-84C13.2	-3.67	0.000253	0.0139	-0.15	-0.11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr4:88997478	chr4:89119284~89119871:+
BRCA	cis	rs2253762	0.54	rs10887051	ENSG00000226864.1	ATE1-AS1	3.67	0.000253	0.0139	0.2	0.11	Breast cancer;	chr10:122026030	chr10:121928312~121951965:+
BRCA	cis	rs4449834	0.816	rs9650201	ENSG00000254432.1	RP11-33I11.2	-3.67	0.000253	0.0139	-0.14	-0.11	Sum eosinophil basophil counts;	chr8:60755758	chr8:60808735~60809606:-
BRCA	cis	rs524281	0.861	rs10896087	ENSG00000255038.1	RP11-1167A19.2	-3.67	0.000253	0.0139	-0.16	-0.11	Electroencephalogram traits;	chr11:66157078	chr11:66067277~66069619:-
BRCA	cis	rs524281	0.861	rs4013917	ENSG00000255038.1	RP11-1167A19.2	-3.67	0.000253	0.0139	-0.16	-0.11	Electroencephalogram traits;	chr11:66158714	chr11:66067277~66069619:-
BRCA	cis	rs4835473	0.778	rs75562808	ENSG00000249741.2	RP11-673E1.3	3.67	0.000253	0.0139	0.12	0.11	Immature fraction of reticulocytes;	chr4:143779065	chr4:143911514~143912053:-
BRCA	cis	rs7620503	1	rs2173608	ENSG00000231574.4	RP11-91K9.1	3.67	0.000253	0.0139	0.13	0.11	Corneal structure;	chr3:177584550	chr3:177816865~177899224:+
BRCA	cis	rs5742933	1	rs3762545	ENSG00000253559.1	OSGEPL1-AS1	-3.67	0.000253	0.0139	-0.16	-0.11	Ferritin levels;	chr2:189790835	chr2:189762704~189765556:+
BRCA	cis	rs7727544	0.545	rs7716474	ENSG00000233006.5	AC034220.3	3.67	0.000253	0.0139	0.09	0.11	Blood metabolite levels;	chr5:132048290	chr5:132311285~132369916:-
BRCA	cis	rs295490	0.748	rs77131232	ENSG00000178631.7	ACTG1P1	-3.67	0.000253	0.0139	-0.22	-0.11	PR interval in Tripanosoma cruzi seropositivity;	chr3:139415468	chr3:139493809~139494937:+
BRCA	cis	rs295490	0.588	rs75694829	ENSG00000178631.7	ACTG1P1	-3.67	0.000253	0.0139	-0.22	-0.11	PR interval in Tripanosoma cruzi seropositivity;	chr3:139416582	chr3:139493809~139494937:+
BRCA	cis	rs295490	0.748	rs76520271	ENSG00000178631.7	ACTG1P1	-3.67	0.000253	0.0139	-0.22	-0.11	PR interval in Tripanosoma cruzi seropositivity;	chr3:139422441	chr3:139493809~139494937:+
BRCA	cis	rs295490	0.748	rs77343695	ENSG00000178631.7	ACTG1P1	-3.67	0.000253	0.0139	-0.22	-0.11	PR interval in Tripanosoma cruzi seropositivity;	chr3:139430617	chr3:139493809~139494937:+
BRCA	cis	rs7246967	1	rs35332070	ENSG00000198153.8	ZNF849P	-3.67	0.000253	0.0139	-0.16	-0.11	Bronchopulmonary dysplasia;	chr19:22851464	chr19:22685167~22686732:+
BRCA	cis	rs801193	0.967	rs2420827	ENSG00000232546.1	RP11-458F8.1	3.67	0.000253	0.0139	0.1	0.11	Aortic root size;	chr7:66682114	chr7:66848496~66858136:+
BRCA	cis	rs7246657	0.765	rs10402455	ENSG00000267470.4	ZNF571-AS1	3.67	0.000253	0.0139	0.17	0.11	Coronary artery calcification;	chr19:37237805	chr19:37548914~37587348:+
BRCA	cis	rs11667325	0.656	rs10423494	ENSG00000268316.1	AC006272.2	-3.67	0.000253	0.0139	-0.15	-0.11	Neutrophil percentage of granulocytes;	chr19:51796100	chr19:51839771~51840945:-
BRCA	cis	rs863345	0.584	rs11265018	ENSG00000229914.1	RP11-404O13.4	-3.67	0.000253	0.0139	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158536619	chr1:158195633~158196131:-
BRCA	cis	rs863345	0.604	rs12133791	ENSG00000229914.1	RP11-404O13.4	-3.67	0.000253	0.0139	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158536892	chr1:158195633~158196131:-
BRCA	cis	rs863345	0.604	rs12122663	ENSG00000229914.1	RP11-404O13.4	-3.67	0.000253	0.0139	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158536934	chr1:158195633~158196131:-
BRCA	cis	rs2835872	0.76	rs73220491	ENSG00000228677.1	TTC3-AS1	-3.67	0.000253	0.0139	-0.14	-0.11	Electroencephalographic traits in alcoholism;	chr21:37616021	chr21:37187666~37193926:-
BRCA	cis	rs2835872	0.793	rs4817877	ENSG00000228677.1	TTC3-AS1	-3.67	0.000253	0.0139	-0.14	-0.11	Electroencephalographic traits in alcoholism;	chr21:37616091	chr21:37187666~37193926:-
BRCA	cis	rs863345	0.604	rs2317969	ENSG00000176320.2	RP11-404O13.5	-3.67	0.000253	0.0139	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158521963	chr1:158197922~158203877:-
BRCA	cis	rs2391285	0.609	rs6959391	ENSG00000280255.1	RP5-1007F24.1	3.67	0.000253	0.0139	0.16	0.11	Post bronchodilator FEV1/FVC ratio;	chr7:26552676	chr7:26538378~26541048:+
BRCA	cis	rs6678639	0.522	rs112615305	ENSG00000225154.2	RP11-184J23.2	-3.67	0.000253	0.0139	-0.18	-0.11	Blood metabolite ratios;	chr1:47036370	chr1:47074778~47075979:-
BRCA	cis	rs7089973	0.836	rs7895551	ENSG00000236799.1	RP11-383C6.2	-3.67	0.000254	0.0139	-0.14	-0.11	Bipolar disorder or attention deficit hyperactivity disorder;	chr10:114865722	chr10:114994657~114996593:+
BRCA	cis	rs7089973	0.872	rs60820172	ENSG00000236799.1	RP11-383C6.2	-3.67	0.000254	0.0139	-0.14	-0.11	Bipolar disorder or attention deficit hyperactivity disorder;	chr10:114866132	chr10:114994657~114996593:+
BRCA	cis	rs7089973	0.872	rs7075888	ENSG00000236799.1	RP11-383C6.2	-3.67	0.000254	0.0139	-0.14	-0.11	Bipolar disorder or attention deficit hyperactivity disorder;	chr10:114867358	chr10:114994657~114996593:+
BRCA	cis	rs7089973	0.872	rs7094072	ENSG00000236799.1	RP11-383C6.2	-3.67	0.000254	0.0139	-0.14	-0.11	Bipolar disorder or attention deficit hyperactivity disorder;	chr10:114867401	chr10:114994657~114996593:+
BRCA	cis	rs7089973	0.872	rs7909657	ENSG00000236799.1	RP11-383C6.2	-3.67	0.000254	0.0139	-0.14	-0.11	Bipolar disorder or attention deficit hyperactivity disorder;	chr10:114869337	chr10:114994657~114996593:+
BRCA	cis	rs7089973	0.872	rs7909566	ENSG00000236799.1	RP11-383C6.2	-3.67	0.000254	0.0139	-0.14	-0.11	Bipolar disorder or attention deficit hyperactivity disorder;	chr10:114869377	chr10:114994657~114996593:+
BRCA	cis	rs7089973	0.872	rs17092542	ENSG00000236799.1	RP11-383C6.2	-3.67	0.000254	0.0139	-0.14	-0.11	Bipolar disorder or attention deficit hyperactivity disorder;	chr10:114870530	chr10:114994657~114996593:+
BRCA	cis	rs1979679	0.578	rs1904387	ENSG00000247934.4	RP11-967K21.1	-3.67	0.000254	0.0139	-0.14	-0.11	Ossification of the posterior longitudinal ligament of the spine;	chr12:28120723	chr12:28163298~28190738:-
BRCA	cis	rs8040855	0.597	rs994989	ENSG00000259774.1	RP11-182J1.13	3.67	0.000254	0.0139	0.16	0.11	Bulimia nervosa;	chr15:85117485	chr15:84422618~84425882:+
BRCA	cis	rs34286592	1	rs4788187	ENSG00000238045.8	AC009133.12	-3.67	0.000254	0.0139	-0.15	-0.11	Multiple sclerosis;	chr16:29834364	chr16:29808636~29821252:-
BRCA	cis	rs853679	0.546	rs493161	ENSG00000216901.1	AL022393.7	3.67	0.000254	0.0139	0.23	0.11	Depression;	chr6:27882936	chr6:28176188~28176674:+
BRCA	cis	rs7637701	0.713	rs9867857	ENSG00000240875.4	LINC00886	-3.67	0.000254	0.0139	-0.13	-0.11	Breast cancer;	chr3:156773371	chr3:156747346~156817062:-
BRCA	cis	rs7487075	0.893	rs2408508	ENSG00000257261.4	RP11-96H19.1	3.67	0.000254	0.0139	0.12	0.11	Itch intensity from mosquito bite;	chr12:46336817	chr12:46383679~46876159:+
BRCA	cis	rs2243480	1	rs35046236	ENSG00000226767.1	RP11-328P23.3	-3.67	0.000254	0.0139	-0.19	-0.11	Diabetic kidney disease;	chr7:65943626	chr7:65508773~65508944:-
BRCA	cis	rs2243480	1	rs36068983	ENSG00000226767.1	RP11-328P23.3	-3.67	0.000254	0.0139	-0.19	-0.11	Diabetic kidney disease;	chr7:65944004	chr7:65508773~65508944:-
BRCA	cis	rs2243480	1	rs68189316	ENSG00000226767.1	RP11-328P23.3	-3.67	0.000254	0.0139	-0.19	-0.11	Diabetic kidney disease;	chr7:65944182	chr7:65508773~65508944:-
BRCA	cis	rs67539049	1	rs2001462	ENSG00000255020.1	AF131216.5	-3.67	0.000254	0.0139	-0.17	-0.11	Itch intensity from mosquito bite;	chr8:11437301	chr8:11345748~11347502:-
BRCA	cis	rs748404	0.666	rs7177146	ENSG00000166763.7	STRCP1	3.67	0.000254	0.0139	0.16	0.11	Lung cancer;	chr15:43506110	chr15:43699488~43718184:-
BRCA	cis	rs8040855	0.627	rs11630697	ENSG00000229212.6	RP11-561C5.4	-3.67	0.000254	0.0139	-0.15	-0.11	Bulimia nervosa;	chr15:85063214	chr15:85205440~85234795:-
BRCA	cis	rs6867032	0.695	rs3902820	ENSG00000248994.1	RP11-259O2.1	-3.67	0.000254	0.0139	-0.15	-0.11	Gut microbiome composition (winter);	chr5:2000216	chr5:1933863~1959176:+
BRCA	cis	rs11711311	0.747	rs2895415	ENSG00000241529.3	RN7SL767P	-3.67	0.000254	0.0139	-0.14	-0.11	IgG glycosylation;	chr3:113626718	chr3:113632704~113632998:+
BRCA	cis	rs6951245	0.554	rs35126802	ENSG00000224079.1	AC091729.7	-3.67	0.000254	0.0139	-0.17	-0.11	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1095206	chr7:1074450~1078036:+
BRCA	cis	rs4660456	0.504	rs587064	ENSG00000272145.1	NFYC-AS1	-3.67	0.000254	0.0139	-0.13	-0.11	Platelet count;	chr1:40640238	chr1:40690380~40692066:-
BRCA	cis	rs4919687	0.55	rs12784517	ENSG00000236937.2	PTGES3P4	3.67	0.000254	0.0139	0.15	0.11	Colorectal cancer;	chr10:102705213	chr10:102845595~102845950:+
BRCA	cis	rs4919687	0.55	rs12761195	ENSG00000236937.2	PTGES3P4	3.67	0.000254	0.0139	0.15	0.11	Colorectal cancer;	chr10:102705617	chr10:102845595~102845950:+
BRCA	cis	rs8180040	0.726	rs1463393	ENSG00000271161.1	BOLA2P2	-3.67	0.000254	0.0139	-0.12	-0.11	Colorectal cancer;	chr3:46953497	chr3:47499841~47500407:+
BRCA	cis	rs911555	0.57	rs11625397	ENSG00000269958.1	RP11-73M18.8	-3.67	0.000254	0.0139	-0.12	-0.11	Intelligence (multi-trait analysis);	chr14:103561220	chr14:103696353~103697163:+
BRCA	cis	rs875971	0.505	rs2462573	ENSG00000223473.2	GS1-124K5.3	-3.67	0.000254	0.0139	-0.09	-0.11	Aortic root size;	chr7:66042405	chr7:66491049~66493566:-
BRCA	cis	rs801193	1	rs4717319	ENSG00000232546.1	RP11-458F8.1	-3.67	0.000254	0.0139	-0.09	-0.11	Aortic root size;	chr7:66777606	chr7:66848496~66858136:+
BRCA	cis	rs2835872	0.828	rs2835838	ENSG00000228677.1	TTC3-AS1	-3.67	0.000254	0.0139	-0.14	-0.11	Electroencephalographic traits in alcoholism;	chr21:37618692	chr21:37187666~37193926:-
BRCA	cis	rs911119	0.913	rs67483168	ENSG00000270001.1	RP11-218C14.8	-3.67	0.000254	0.0139	-0.16	-0.11	Chronic kidney disease;	chr20:23600675	chr20:23631826~23632316:-
BRCA	cis	rs138880	0.542	rs9616393	ENSG00000229409.1	RP11-494O16.3	-3.67	0.000254	0.0139	-0.22	-0.11	Schizophrenia;	chr22:49921161	chr22:49845929~49846090:+
BRCA	cis	rs7620503	1	rs6783033	ENSG00000231574.4	RP11-91K9.1	3.67	0.000254	0.0139	0.13	0.11	Corneal structure;	chr3:177584963	chr3:177816865~177899224:+
BRCA	cis	rs7620503	0.959	rs6770216	ENSG00000231574.4	RP11-91K9.1	3.67	0.000254	0.0139	0.13	0.11	Corneal structure;	chr3:177585139	chr3:177816865~177899224:+
BRCA	cis	rs7620503	0.959	rs2863016	ENSG00000231574.4	RP11-91K9.1	3.67	0.000254	0.0139	0.13	0.11	Corneal structure;	chr3:177585192	chr3:177816865~177899224:+
BRCA	cis	rs8105895	0.935	rs10417916	ENSG00000269345.1	VN1R85P	3.67	0.000254	0.0139	0.16	0.11	Body mass index (change over time);	chr19:22089813	chr19:22174766~22175191:-
BRCA	cis	rs9650657	0.623	rs6601517	ENSG00000154316.13	TDH	3.67	0.000254	0.0139	0.14	0.11	Neuroticism;	chr8:10746283	chr8:11339637~11368452:+
BRCA	cis	rs710913	0.618	rs6587	ENSG00000243970.1	PPIEL	3.67	0.000254	0.0139	0.14	0.11	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39624273	chr1:39531838~39558707:-
BRCA	cis	rs10844706	0.669	rs10772102	ENSG00000214776.8	RP11-726G1.1	3.67	0.000254	0.0139	0.14	0.11	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9744357	chr12:9467552~9576275:+
BRCA	cis	rs10129255	0.744	rs28517388	ENSG00000211958.2	IGHV3-38	3.67	0.000254	0.0139	0.1	0.11	Kawasaki disease;	chr14:106704323	chr14:106410493~106411021:-
BRCA	cis	rs4664293	0.647	rs10198053	ENSG00000226266.5	AC009961.3	-3.67	0.000254	0.0139	-0.13	-0.11	Monocyte percentage of white cells;	chr2:159605169	chr2:159670708~159712435:-
BRCA	cis	rs4664293	0.669	rs10174515	ENSG00000226266.5	AC009961.3	-3.67	0.000254	0.0139	-0.13	-0.11	Monocyte percentage of white cells;	chr2:159605524	chr2:159670708~159712435:-
BRCA	cis	rs12723316	0.932	rs77784317	ENSG00000233008.4	RP11-475O6.1	-3.67	0.000254	0.0139	-0.22	-0.11	Schizophrenia;	chr1:83814658	chr1:83575776~83861023:-
BRCA	cis	rs17684571	0.938	rs56101897	ENSG00000231441.1	RP11-472M19.2	3.67	0.000254	0.014	0.18	0.11	Schizophrenia;	chr6:56687628	chr6:56844002~56864078:+
BRCA	cis	rs6005807	0.843	rs9625515	ENSG00000272858.1	CTA-292E10.8	-3.67	0.000254	0.014	-0.22	-0.11	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28628315	chr22:28814914~28815662:+
BRCA	cis	rs7829975	0.533	rs13274028	ENSG00000253981.4	ALG1L13P	3.67	0.000254	0.014	0.13	0.11	Mood instability;	chr8:8871683	chr8:8236003~8244667:-
BRCA	cis	rs4767841	0.935	rs4767840	ENSG00000248636.5	RP11-768F21.1	-3.67	0.000254	0.014	-0.14	-0.11	Urgency urinary incontinence;	chr12:119724393	chr12:119387987~119668079:-
BRCA	cis	rs67073037	0.911	rs11688844	ENSG00000230730.1	AC074011.2	-3.67	0.000254	0.014	-0.15	-0.11	Breast cancer;Breast cancer (estrogen-receptor negative);	chr2:28907057	chr2:28633282~28664540:-
BRCA	cis	rs67073037	0.955	rs11684312	ENSG00000230730.1	AC074011.2	-3.67	0.000254	0.014	-0.15	-0.11	Breast cancer;Breast cancer (estrogen-receptor negative);	chr2:28907358	chr2:28633282~28664540:-
BRCA	cis	rs2486012	0.737	rs37468	ENSG00000237950.1	RP11-7O11.3	-3.67	0.000254	0.014	-0.2	-0.11	Intelligence (multi-trait analysis);	chr1:43814709	chr1:43944370~43946551:-
BRCA	cis	rs891378	1	rs4844591	ENSG00000274245.1	RP11-357P18.2	-3.67	0.000254	0.014	-0.15	-0.11	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207326948	chr1:207372559~207373252:+
BRCA	cis	rs721917	0.565	rs7476563	ENSG00000278616.1	BEND3P3	-3.67	0.000254	0.014	-0.1	-0.11	Chronic obstructive pulmonary disease;	chr10:79975318	chr10:79682997~79685436:+
BRCA	cis	rs2486012	1	rs2906459	ENSG00000237950.1	RP11-7O11.3	3.67	0.000254	0.014	0.18	0.11	Intelligence (multi-trait analysis);	chr1:43869985	chr1:43944370~43946551:-
BRCA	cis	rs7523050	0.643	rs35520362	ENSG00000203897.3	SPATA42	-3.67	0.000254	0.014	-0.22	-0.11	Fat distribution (HIV);	chr1:108877219	chr1:108857217~108858524:+
BRCA	cis	rs6479874	0.736	rs2816834	ENSG00000223502.1	RP11-96B5.3	-3.67	0.000254	0.014	-0.2	-0.11	Migraine;	chr10:50992971	chr10:51062579~51068553:-
BRCA	cis	rs6785206	1	rs6785206	ENSG00000242551.2	POU5F1P6	-3.67	0.000254	0.014	-0.22	-0.11	Lymphocyte percentage of white cells;	chr3:128693181	chr3:128674735~128677005:-
BRCA	cis	rs7703051	0.901	rs984976	ENSG00000271815.1	CTD-2235C13.3	-3.67	0.000254	0.014	-0.16	-0.11	Age-related diseases, mortality and associated endophenotypes;LDL cholesterol;Age-related disease endophenotypes;	chr5:75615045	chr5:75363760~75364242:+
BRCA	cis	rs656900	0.74	rs1675181	ENSG00000261229.4	MTHFS	3.67	0.000254	0.014	0.11	0.11	Cerebrospinal P-tau181p levels;	chr15:79819296	chr15:79843547~79897285:-
BRCA	cis	rs7267979	0.745	rs6132845	ENSG00000274414.1	RP5-965G21.4	-3.67	0.000254	0.014	-0.13	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25567131	chr20:25239007~25245229:-
BRCA	cis	rs2400362	0.618	rs7007683	ENSG00000260317.1	RP11-48B3.4	-3.67	0.000254	0.014	-0.14	-0.11	Glucocorticoid-induced osteonecrosis (age 10 years and older);	chr8:80928640	chr8:80541300~80543104:+
BRCA	cis	rs4950322	0.57	rs72691102	ENSG00000227242.3	NBPF13P	-3.67	0.000254	0.014	-0.16	-0.11	Protein quantitative trait loci;	chr1:147301189	chr1:147021320~147124525:-
BRCA	cis	rs4950322	0.57	rs72692904	ENSG00000227242.3	NBPF13P	-3.67	0.000254	0.014	-0.16	-0.11	Protein quantitative trait loci;	chr1:147301437	chr1:147021320~147124525:-
BRCA	cis	rs4950322	0.57	rs72692905	ENSG00000227242.3	NBPF13P	-3.67	0.000254	0.014	-0.16	-0.11	Protein quantitative trait loci;	chr1:147301560	chr1:147021320~147124525:-
BRCA	cis	rs321358	0.707	rs73021578	ENSG00000271390.1	RP11-89C3.3	3.67	0.000254	0.014	0.17	0.11	Body mass index;	chr11:111156211	chr11:111089870~111090368:-
BRCA	cis	rs9467773	0.549	rs9461273	ENSG00000224843.5	LINC00240	3.67	0.000254	0.014	0.12	0.11	Intelligence (multi-trait analysis);	chr6:26584298	chr6:26956992~27023924:+
BRCA	cis	rs3760982	1	rs12460161	ENSG00000267191.1	RP11-15A1.2	-3.67	0.000254	0.014	-0.14	-0.11	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43789834	chr19:43902001~43926545:+
BRCA	cis	rs763121	0.853	rs6001214	ENSG00000228274.3	RP3-508I15.9	-3.67	0.000254	0.014	-0.13	-0.11	Menopause (age at onset);	chr22:38753150	chr22:38667585~38681820:-
BRCA	cis	rs13401620	0.843	rs11682213	ENSG00000229326.3	AC069154.4	3.67	0.000254	0.014	0.14	0.11	Breast size;	chr2:119779771	chr2:119698623~119700151:+
BRCA	cis	rs6496932	0.802	rs12441698	ENSG00000218052.5	ADAMTS7P4	3.67	0.000254	0.014	0.12	0.11	Central corneal thickness;Corneal structure;	chr15:85310470	chr15:85255369~85330334:-
BRCA	cis	rs6433921	0.964	rs3770112	ENSG00000260742.1	RP11-366L5.1	3.67	0.000255	0.014	0.14	0.11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;	chr2:181512814	chr2:181887851~181891663:-
BRCA	cis	rs7474896	0.806	rs1779150	ENSG00000120555.12	SEPT7P9	3.67	0.000255	0.014	0.25	0.11	Obesity (extreme);	chr10:37749759	chr10:38383069~38402916:-
BRCA	cis	rs9300255	0.722	rs10846515	ENSG00000256028.2	RP11-197N18.2	3.67	0.000255	0.014	0.11	0.11	Neutrophil percentage of white cells;	chr12:123317125	chr12:122975320~122982907:+
BRCA	cis	rs3739034	0.938	rs6747587	ENSG00000224043.6	CCNT2-AS1	-3.67	0.000255	0.014	-0.19	-0.11	Gut microbiome composition (winter);	chr2:134711944	chr2:134735464~134918710:-
BRCA	cis	rs180730	0.752	rs343168	ENSG00000251609.2	SETP12	-3.67	0.000255	0.014	-0.18	-0.11	Fasting plasma glucose;	chr4:120895346	chr4:120895494~120897083:-
BRCA	cis	rs7560272	0.501	rs10191988	ENSG00000204872.3	NAT8B	3.67	0.000255	0.014	0.15	0.11	Schizophrenia;	chr2:73720660	chr2:73700576~73701340:-
BRCA	cis	rs10761482	0.906	rs991405	ENSG00000254271.1	RP11-131N11.4	-3.67	0.000255	0.014	-0.16	-0.11	Schizophrenia;	chr10:60334444	chr10:60734342~60741828:+
BRCA	cis	rs4478858	0.735	rs12134484	ENSG00000260386.4	LINC01225	-3.67	0.000255	0.014	-0.13	-0.11	Alcohol dependence;	chr1:31350894	chr1:31500085~31540885:+
BRCA	cis	rs6067053	0.633	rs7266044	ENSG00000227431.4	CSE1L-AS1	-3.67	0.000255	0.014	-0.14	-0.11	Intelligence (multi-trait analysis);	chr20:49274119	chr20:49040463~49046044:-
BRCA	cis	rs67478160	0.679	rs7156834	ENSG00000269910.1	RP11-73M18.10	3.67	0.000255	0.014	0.11	0.11	Schizophrenia;	chr14:103744843	chr14:103694516~103695050:-
BRCA	cis	rs1559040	0.615	rs11891079	ENSG00000272156.1	RP11-477N3.1	-3.67	0.000255	0.014	-0.15	-0.11	Sudden cardiac arrest;	chr2:54139157	chr2:54082554~54085066:+
BRCA	cis	rs17167170	0.572	rs6956293	ENSG00000226205.1	AC007790.4	-3.67	0.000255	0.014	-0.15	-0.11	Educational attainment (years of education);	chr7:133445424	chr7:133732493~133733595:-
BRCA	cis	rs9309473	0.607	rs11686504	ENSG00000230002.2	ALMS1-IT1	3.67	0.000255	0.014	0.14	0.11	Metabolite levels;	chr2:73352684	chr2:73456764~73459484:+
BRCA	cis	rs2274459	0.915	rs12192087	ENSG00000249346.5	LINC01016	3.67	0.000255	0.014	0.15	0.11	Obesity (extreme);	chr6:33812515	chr6:33867506~33896914:-
BRCA	cis	rs8105895	0.935	rs62111038	ENSG00000269345.1	VN1R85P	3.67	0.000255	0.014	0.18	0.11	Body mass index (change over time);	chr19:22103812	chr19:22174766~22175191:-
BRCA	cis	rs1075265	0.744	rs2909460	ENSG00000272156.1	RP11-477N3.1	-3.67	0.000255	0.014	-0.12	-0.11	Chronotype;Morning vs. evening chronotype;	chr2:53967611	chr2:54082554~54085066:+
BRCA	cis	rs4664293	0.631	rs13024749	ENSG00000226266.5	AC009961.3	3.67	0.000255	0.014	0.13	0.11	Monocyte percentage of white cells;	chr2:159799606	chr2:159670708~159712435:-
BRCA	cis	rs6490294	0.528	rs60998439	ENSG00000257624.1	RP1-128M12.3	3.67	0.000255	0.014	0.21	0.11	Mean platelet volume;	chr12:112008165	chr12:112000739~112000985:-
BRCA	cis	rs36132109	0.858	rs2288370	ENSG00000273328.4	RP11-141M3.6	3.67	0.000255	0.014	0.15	0.11	Monocyte chemoattractant protein-1 levels;	chr3:42935944	chr3:42809414~42908105:+
BRCA	cis	rs875971	0.825	rs4587224	ENSG00000229886.1	RP5-1132H15.3	-3.67	0.000255	0.014	-0.13	-0.11	Aortic root size;	chr7:66271195	chr7:66025126~66031544:-
BRCA	cis	rs875971	0.792	rs6971752	ENSG00000229886.1	RP5-1132H15.3	-3.67	0.000255	0.014	-0.13	-0.11	Aortic root size;	chr7:66272999	chr7:66025126~66031544:-
BRCA	cis	rs875971	0.862	rs10950033	ENSG00000229886.1	RP5-1132H15.3	-3.67	0.000255	0.014	-0.13	-0.11	Aortic root size;	chr7:66274686	chr7:66025126~66031544:-
BRCA	cis	rs875971	0.862	rs11760844	ENSG00000229886.1	RP5-1132H15.3	-3.67	0.000255	0.014	-0.13	-0.11	Aortic root size;	chr7:66274896	chr7:66025126~66031544:-
BRCA	cis	rs1437396	0.657	rs3111413	ENSG00000203327.2	AC012358.7	3.67	0.000255	0.014	0.12	0.11	Alcohol dependence;	chr2:55365111	chr2:55214387~55216126:-
BRCA	cis	rs1437396	0.657	rs3111404	ENSG00000203327.2	AC012358.7	3.67	0.000255	0.014	0.12	0.11	Alcohol dependence;	chr2:55365874	chr2:55214387~55216126:-
BRCA	cis	rs372883	0.648	rs1153291	ENSG00000176054.6	RPL23P2	-3.67	0.000255	0.014	-0.12	-0.11	Pancreatic cancer;	chr21:29316749	chr21:28997613~28998033:-
BRCA	cis	rs10129255	0.872	rs1858683	ENSG00000231475.3	IGHV4-31	-3.67	0.000255	0.014	-0.09	-0.11	Kawasaki disease;	chr14:106670217	chr14:106349283~106349792:-
BRCA	cis	rs860295	0.58	rs2282301	ENSG00000160766.13	GBAP1	3.67	0.000255	0.014	0.12	0.11	Body mass index;	chr1:155898834	chr1:155213821~155227422:-
BRCA	cis	rs1670533	0.932	rs3796620	ENSG00000251639.2	RP11-20I20.1	-3.67	0.000255	0.014	-0.18	-0.11	Recombination rate (females);	chr4:1101291	chr4:1100016~1101558:-
BRCA	cis	rs4819052	0.851	rs13052344	ENSG00000215447.6	BX322557.10	-3.67	0.000255	0.014	-0.12	-0.11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45256186	chr21:45288052~45291738:+
BRCA	cis	rs4819052	0.851	rs28501512	ENSG00000215447.6	BX322557.10	-3.67	0.000255	0.014	-0.12	-0.11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45256787	chr21:45288052~45291738:+
BRCA	cis	rs983392	0.792	rs617916	ENSG00000275344.1	MIR6503	-3.67	0.000255	0.014	-0.12	-0.11	Alzheimer's disease (late onset);	chr11:60149276	chr11:60209071~60209156:-
BRCA	cis	rs13098911	0.54	rs13072267	ENSG00000223552.1	RP11-24F11.2	-3.67	0.000255	0.014	-0.19	-0.11	Celiac disease;	chr3:46074518	chr3:46364955~46407059:-
BRCA	cis	rs13098911	0.598	rs36057789	ENSG00000223552.1	RP11-24F11.2	-3.67	0.000255	0.014	-0.19	-0.11	Celiac disease;	chr3:46075604	chr3:46364955~46407059:-
BRCA	cis	rs13063635	0.92	rs76647202	ENSG00000223552.1	RP11-24F11.2	-3.67	0.000255	0.014	-0.19	-0.11	Eosinophil percentage of granulocytes;	chr3:46076468	chr3:46364955~46407059:-
BRCA	cis	rs35520189	0.857	rs2708916	ENSG00000231747.1	AC079922.2	3.67	0.000255	0.014	0.11	0.11	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:112870724	chr2:112621809~112622167:-
BRCA	cis	rs2041840	0.92	rs2160391	ENSG00000272054.1	RP11-423P10.2	-3.67	0.000255	0.014	-0.11	-0.11	Chronic lymphocytic leukemia;	chr2:37208163	chr2:37208875~37212677:+
BRCA	cis	rs1143633	0.566	rs2708932	ENSG00000231747.1	AC079922.2	3.67	0.000255	0.014	0.11	0.11	Allergic disease (asthma, hay fever or eczema);	chr2:112933098	chr2:112621809~112622167:-
BRCA	cis	rs34779708	0.931	rs2148482	ENSG00000269952.1	RP11-324I22.3	-3.67	0.000255	0.014	-0.15	-0.11	Inflammatory bowel disease;Crohn's disease;	chr10:35059982	chr10:35210416~35210750:+
BRCA	cis	rs6490294	0.851	rs56814171	ENSG00000234608.6	MAPKAPK5-AS1	3.67	0.000255	0.014	0.14	0.11	Mean platelet volume;	chr12:111965146	chr12:111839764~111842902:-
BRCA	cis	rs10992471	0.56	rs12003227	ENSG00000187984.11	ANKRD19P	-3.67	0.000255	0.014	-0.1	-0.11	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr9:92890026	chr9:92809388~92888693:+
BRCA	cis	rs2191566	0.691	rs62115513	ENSG00000266921.1	RP11-15A1.7	-3.67	0.000255	0.014	-0.14	-0.11	Acute lymphoblastic leukemia (childhood);	chr19:44083039	chr19:43996896~44002836:-
BRCA	cis	rs7260598	0.539	rs11672512	ENSG00000268442.1	CTD-2027I19.2	3.67	0.000255	0.014	0.2	0.11	Response to taxane treatment (placlitaxel);	chr19:23885948	chr19:24162370~24163425:-
BRCA	cis	rs17345786	1	rs3762729	ENSG00000256628.3	ZBTB11-AS1	3.67	0.000255	0.014	0.16	0.11	Colonoscopy-negative controls vs population controls;	chr3:101590030	chr3:101676475~101679217:+
BRCA	cis	rs13393800	1	rs1729245	ENSG00000237126.7	AC073254.1	3.67	0.000255	0.014	0.15	0.11	Height;	chr2:232560181	chr2:232580948~232611971:-
BRCA	cis	rs9650657	0.74	rs7002282	ENSG00000270076.1	AF131215.8	3.67	0.000255	0.014	0.13	0.11	Neuroticism;	chr8:10809483	chr8:11202965~11203671:+
BRCA	cis	rs7520050	0.966	rs946529	ENSG00000281133.1	AL355480.3	3.67	0.000255	0.014	0.13	0.11	Reticulocyte count;Red blood cell count;	chr1:46019876	chr1:45580892~45580996:-
BRCA	cis	rs983392	0.679	rs1530914	ENSG00000275344.1	MIR6503	3.67	0.000255	0.014	0.12	0.11	Alzheimer's disease (late onset);	chr11:60261467	chr11:60209071~60209156:-
BRCA	cis	rs7221109	0.592	rs917595	ENSG00000229028.2	KRT223P	3.67	0.000256	0.014	0.13	0.11	Type 1 diabetes;	chr17:40663246	chr17:40717235~40721932:-
BRCA	cis	rs896854	0.738	rs527234	ENSG00000245080.5	RP11-320N21.1	-3.67	0.000256	0.014	-0.14	-0.11	Type 2 diabetes;	chr8:94951570	chr8:95066808~95073182:-
BRCA	cis	rs4478858	0.735	rs6676682	ENSG00000260386.4	LINC01225	-3.67	0.000256	0.014	-0.13	-0.11	Alcohol dependence;	chr1:31336969	chr1:31500085~31540885:+
BRCA	cis	rs1124769	0.57	rs2614765	ENSG00000259298.1	RP11-562A8.4	-3.67	0.000256	0.014	-0.11	-0.11	Cognitive performance;	chr15:50851805	chr15:50497195~50498744:-
BRCA	cis	rs7520050	0.966	rs4134386	ENSG00000234329.1	RP11-767N6.2	-3.67	0.000256	0.014	-0.11	-0.11	Reticulocyte count;Red blood cell count;	chr1:45929417	chr1:45651039~45651826:-
BRCA	cis	rs7520050	0.966	rs12561806	ENSG00000234329.1	RP11-767N6.2	-3.67	0.000256	0.014	-0.11	-0.11	Reticulocyte count;Red blood cell count;	chr1:45931104	chr1:45651039~45651826:-
BRCA	cis	rs6964587	1	rs13231238	ENSG00000188693.7	CYP51A1-AS1	-3.67	0.000256	0.014	-0.12	-0.11	Breast cancer;	chr7:92024537	chr7:92134604~92180725:+
BRCA	cis	rs6964587	1	rs2299238	ENSG00000188693.7	CYP51A1-AS1	-3.67	0.000256	0.014	-0.12	-0.11	Breast cancer;	chr7:92025203	chr7:92134604~92180725:+
BRCA	cis	rs6964587	1	rs2299239	ENSG00000188693.7	CYP51A1-AS1	-3.67	0.000256	0.014	-0.12	-0.11	Breast cancer;	chr7:92025303	chr7:92134604~92180725:+
BRCA	cis	rs863345	0.584	rs1117125	ENSG00000229914.1	RP11-404O13.4	-3.67	0.000256	0.014	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158539606	chr1:158195633~158196131:-
BRCA	cis	rs4950322	0.563	rs6700783	ENSG00000227242.3	NBPF13P	-3.67	0.000256	0.014	-0.15	-0.11	Protein quantitative trait loci;	chr1:147111987	chr1:147021320~147124525:-
BRCA	cis	rs2274273	0.682	rs1201378	ENSG00000259318.1	RP11-454L9.2	-3.67	0.000256	0.014	-0.1	-0.11	Protein biomarker;	chr14:55026690	chr14:55394940~55395233:-
BRCA	cis	rs6545883	0.868	rs6748003	ENSG00000212978.6	AC016747.3	3.67	0.000256	0.014	0.15	0.11	Tuberculosis;	chr2:61579565	chr2:61141592~61144969:-
BRCA	cis	rs6914598	0.876	rs9460602	ENSG00000240869.3	RN7SL128P	-3.67	0.000256	0.014	-0.17	-0.11	Cutaneous malignant melanoma;Melanoma;	chr6:21153901	chr6:20421583~20421887:-
BRCA	cis	rs8114671	0.586	rs734111	ENSG00000279253.1	RP4-614O4.13	-3.67	0.000256	0.014	-0.14	-0.11	Height;	chr20:34945933	chr20:35262727~35264187:-
BRCA	cis	rs1008375	0.966	rs6449330	ENSG00000249502.1	AC006160.5	3.67	0.000256	0.014	0.13	0.11	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17702326	chr4:17587467~17614571:-
BRCA	cis	rs2243480	1	rs34529418	ENSG00000226767.1	RP11-328P23.3	-3.67	0.000256	0.014	-0.19	-0.11	Diabetic kidney disease;	chr7:65938222	chr7:65508773~65508944:-
BRCA	cis	rs1015213	1	rs57182175	ENSG00000253475.1	RP11-110G21.2	3.67	0.000256	0.014	0.21	0.11	Glaucoma (primary angle closure);	chr8:51977171	chr8:51895957~51896374:-
BRCA	cis	rs11887277	0.708	rs12474330	ENSG00000229122.1	AGBL5-IT1	-3.67	0.000256	0.014	-0.12	-0.11	Obesity-related traits;	chr2:26840392	chr2:27061038~27061815:+
BRCA	cis	rs875971	0.862	rs778686	ENSG00000271064.1	RP11-792A8.3	-3.67	0.000256	0.014	-0.13	-0.11	Aortic root size;	chr7:66370923	chr7:66748838~66749077:-
BRCA	cis	rs10829156	0.947	rs7081435	ENSG00000240291.1	RP11-499P20.2	3.67	0.000256	0.014	0.13	0.11	Sudden cardiac arrest;	chr10:18667411	chr10:18513115~18545651:-
BRCA	cis	rs970548	0.908	rs10900229	ENSG00000237840.5	FAM21FP	3.67	0.000256	0.014	0.15	0.11	Total cholesterol levels;HDL cholesterol;HDL cholesterol levels;Cholesterol, total;	chr10:45625598	chr10:45706431~45727231:-
BRCA	cis	rs2411233	1	rs12910426	ENSG00000259278.1	RP11-62C7.2	3.67	0.000256	0.014	0.13	0.11	Platelet count;	chr15:38986537	chr15:39019233~39024918:+
BRCA	cis	rs67981189	0.634	rs221900	ENSG00000258571.1	PTTG4P	-3.67	0.000256	0.014	-0.13	-0.11	Schizophrenia;	chr14:71137637	chr14:71085482~71085833:-
BRCA	cis	rs1404100	0.531	rs1038271	ENSG00000249274.1	PDLIM1P4	3.67	0.000256	0.014	0.13	0.11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:99067399	chr3:98782188~98783193:+
BRCA	cis	rs442309	0.841	rs224079	ENSG00000238280.1	RP11-436D10.3	-3.67	0.000256	0.014	-0.14	-0.11	Vogt-Koyanagi-Harada syndrome;	chr10:62753470	chr10:62793562~62805887:-
BRCA	cis	rs74233809	1	rs12221193	ENSG00000236937.2	PTGES3P4	3.67	0.000256	0.014	0.25	0.11	Birth weight;	chr10:102905510	chr10:102845595~102845950:+
BRCA	cis	rs74233809	1	rs77180047	ENSG00000236937.2	PTGES3P4	3.67	0.000256	0.014	0.25	0.11	Birth weight;	chr10:102907000	chr10:102845595~102845950:+
BRCA	cis	rs8054556	1	rs3814881	ENSG00000214725.6	CDIPT-AS1	-3.67	0.000256	0.0141	-0.14	-0.11	Autism spectrum disorder or schizophrenia;	chr16:29989580	chr16:29863593~29868053:+
BRCA	cis	rs7267979	0.933	rs1130694	ENSG00000276952.1	RP5-965G21.6	3.67	0.000256	0.0141	0.14	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25295661	chr20:25284915~25285588:-
BRCA	cis	rs8040855	0.627	rs12913859	ENSG00000229212.6	RP11-561C5.4	-3.67	0.000256	0.0141	-0.15	-0.11	Bulimia nervosa;	chr15:85095187	chr15:85205440~85234795:-
BRCA	cis	rs9951698	0.655	rs6505774	ENSG00000267533.1	RP11-815J4.7	-3.67	0.000256	0.0141	-0.14	-0.11	Intelligence (multi-trait analysis);	chr18:12976468	chr18:12067173~12068417:-
BRCA	cis	rs528301	0.707	rs338070	ENSG00000259439.2	RP11-89K21.1	3.67	0.000256	0.0141	0.15	0.11	Alcohol and nicotine co-dependence;	chr2:44948150	chr2:44921077~44939199:-
BRCA	cis	rs11098499	0.82	rs13128602	ENSG00000260091.1	RP11-33B1.4	3.67	0.000256	0.0141	0.1	0.11	Corneal astigmatism;	chr4:119538211	chr4:119409333~119410233:+
BRCA	cis	rs4478858	0.684	rs2271074	ENSG00000223907.1	LINC01226	-3.67	0.000256	0.0141	-0.14	-0.11	Alcohol dependence;	chr1:31261994	chr1:31518435~31524245:+
BRCA	cis	rs6600671	1	rs2319969	ENSG00000223345.3	HIST2H2BA	3.67	0.000256	0.0141	0.14	0.11	Hip geometry;	chr1:121465481	chr1:121108210~121117257:-
BRCA	cis	rs13401620	0.843	rs2928634	ENSG00000229326.3	AC069154.4	-3.67	0.000256	0.0141	-0.14	-0.11	Breast size;	chr2:119831219	chr2:119698623~119700151:+
BRCA	cis	rs910316	0.763	rs175047	ENSG00000259138.1	RP11-950C14.7	-3.67	0.000256	0.0141	-0.12	-0.11	Height;	chr14:75012336	chr14:75127153~75136930:+
BRCA	cis	rs12505328	0.669	rs2028537	ENSG00000213370.3	RANP6	3.67	0.000256	0.0141	0.15	0.11	Chin dimples;	chr4:173435635	chr4:173633728~173634371:-
BRCA	cis	rs8130944	0.964	rs9653815	ENSG00000225731.1	AP001627.1	3.67	0.000256	0.0141	0.13	0.11	Perceived unattractiveness to mosquitoes;	chr21:42723133	chr21:42733594~42741758:-
BRCA	cis	rs10043228	1	rs12332658	ENSG00000250015.1	CTC-339F2.2	3.67	0.000256	0.0141	0.15	0.11	Asthma or chronic obstructive pulmonary disease;	chr5:116209909	chr5:116302354~116304134:-
BRCA	cis	rs9470794	0.831	rs111937094	ENSG00000204110.6	RP1-153P14.8	-3.67	0.000256	0.0141	-0.23	-0.11	Type 2 diabetes;	chr6:38135755	chr6:37507348~37535616:+
BRCA	cis	rs9470794	1	rs73421866	ENSG00000204110.6	RP1-153P14.8	-3.67	0.000256	0.0141	-0.23	-0.11	Type 2 diabetes;	chr6:38136077	chr6:37507348~37535616:+
BRCA	cis	rs4478858	0.735	rs6685728	ENSG00000260386.4	LINC01225	-3.67	0.000256	0.0141	-0.13	-0.11	Alcohol dependence;	chr1:31329703	chr1:31500085~31540885:+
BRCA	cis	rs891378	1	rs6702997	ENSG00000274245.1	RP11-357P18.2	-3.67	0.000256	0.0141	-0.15	-0.11	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207329002	chr1:207372559~207373252:+
BRCA	cis	rs891378	1	rs6703002	ENSG00000274245.1	RP11-357P18.2	-3.67	0.000256	0.0141	-0.15	-0.11	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207329027	chr1:207372559~207373252:+
BRCA	cis	rs80226907	0.634	rs75716622	ENSG00000186615.9	KTN1-AS1	-3.67	0.000256	0.0141	-0.23	-0.11	Mean platelet volume;	chr14:55446872	chr14:55499278~55580110:-
BRCA	cis	rs1823874	0.71	rs58572174	ENSG00000259363.4	CTD-2054N24.2	3.67	0.000256	0.0141	0.13	0.11	IgG glycosylation;	chr15:99822635	chr15:99807023~99877148:+
BRCA	cis	rs1823874	0.71	rs1993297	ENSG00000259363.4	CTD-2054N24.2	3.67	0.000256	0.0141	0.13	0.11	IgG glycosylation;	chr15:99823423	chr15:99807023~99877148:+
BRCA	cis	rs1823874	0.613	rs4608318	ENSG00000259363.4	CTD-2054N24.2	3.67	0.000256	0.0141	0.13	0.11	IgG glycosylation;	chr15:99823621	chr15:99807023~99877148:+
BRCA	cis	rs7914558	0.646	rs10883799	ENSG00000213277.3	MARCKSL1P1	3.67	0.000256	0.0141	0.14	0.11	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102903553	chr10:103175554~103176094:+
BRCA	cis	rs77741769	0.571	rs11065284	ENSG00000277423.1	RP11-173P15.9	-3.67	0.000257	0.0141	-0.13	-0.11	Mean corpuscular volume;	chr12:120828818	chr12:120703867~120704282:+
BRCA	cis	rs28374715	0.532	rs316606	ENSG00000247556.5	OIP5-AS1	3.67	0.000257	0.0141	0.13	0.11	Ulcerative colitis;	chr15:41480004	chr15:41283990~41309737:+
BRCA	cis	rs875971	0.862	rs4149461	ENSG00000229886.1	RP5-1132H15.3	-3.67	0.000257	0.0141	-0.13	-0.11	Aortic root size;	chr7:66279745	chr7:66025126~66031544:-
BRCA	cis	rs875971	0.862	rs778720	ENSG00000229886.1	RP5-1132H15.3	-3.67	0.000257	0.0141	-0.13	-0.11	Aortic root size;	chr7:66381288	chr7:66025126~66031544:-
BRCA	cis	rs2243480	0.803	rs36127118	ENSG00000237026.1	RP11-328P23.2	3.67	0.000257	0.0141	0.21	0.11	Diabetic kidney disease;	chr7:66100518	chr7:65235790~65236723:-
BRCA	cis	rs34792	0.554	rs2067063	ENSG00000258354.1	MIR3180-1	-3.67	0.000257	0.0141	-0.16	-0.11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15515106	chr16:14909887~14911345:-
BRCA	cis	rs8114671	0.562	rs6087653	ENSG00000279253.1	RP4-614O4.13	-3.67	0.000257	0.0141	-0.13	-0.11	Height;	chr20:34934251	chr20:35262727~35264187:-
BRCA	cis	rs7246967	0.932	rs4932798	ENSG00000198153.8	ZNF849P	-3.67	0.000257	0.0141	-0.16	-0.11	Bronchopulmonary dysplasia;	chr19:22868705	chr19:22685167~22686732:+
BRCA	cis	rs7712401	0.658	rs4836203	ENSG00000263432.2	RN7SL689P	3.67	0.000257	0.0141	0.13	0.11	Mean platelet volume;	chr5:122741382	chr5:123022487~123022783:-
BRCA	cis	rs7572733	0.536	rs6732517	ENSG00000231621.1	AC013264.2	-3.67	0.000257	0.0141	-0.1	-0.11	Dermatomyositis;	chr2:198048178	chr2:197197991~197199273:+
BRCA	cis	rs801193	0.569	rs11772819	ENSG00000265600.1	AC006480.1	-3.67	0.000257	0.0141	-0.13	-0.11	Aortic root size;	chr7:66752983	chr7:67356680~67356779:+
BRCA	cis	rs801193	0.569	rs7800620	ENSG00000265600.1	AC006480.1	-3.67	0.000257	0.0141	-0.13	-0.11	Aortic root size;	chr7:66758701	chr7:67356680~67356779:+
BRCA	cis	rs13256369	1	rs10095733	ENSG00000254153.1	CTA-398F10.2	3.67	0.000257	0.0141	0.15	0.11	Obesity-related traits;	chr8:8717136	chr8:8456909~8461337:-
BRCA	cis	rs2243480	1	rs34136756	ENSG00000226767.1	RP11-328P23.3	-3.67	0.000257	0.0141	-0.19	-0.11	Diabetic kidney disease;	chr7:65916269	chr7:65508773~65508944:-
BRCA	cis	rs7819412	0.74	rs11250119	ENSG00000255046.1	RP11-297N6.4	3.67	0.000257	0.0141	0.14	0.11	Triglycerides;	chr8:11179525	chr8:11797928~11802568:-
BRCA	cis	rs6012564	0.793	rs6125552	ENSG00000230758.1	SNAP23P	3.67	0.000257	0.0141	0.13	0.11	Anger;	chr20:49107788	chr20:49038357~49038602:-
BRCA	cis	rs7703051	0.965	rs3846663	ENSG00000271815.1	CTD-2235C13.3	-3.67	0.000257	0.0141	-0.15	-0.11	Age-related diseases, mortality and associated endophenotypes;LDL cholesterol;Age-related disease endophenotypes;	chr5:75359901	chr5:75363760~75364242:+
BRCA	cis	rs6429422	0.769	rs6668649	ENSG00000224727.1	FCF1P7	-3.67	0.000257	0.0141	-0.14	-0.11	Cognitive ability (multi-trait analysis);	chr1:243253490	chr1:243267257~243268119:-
BRCA	cis	rs80226907	0.539	rs74976892	ENSG00000186615.9	KTN1-AS1	-3.67	0.000257	0.0141	-0.24	-0.11	Mean platelet volume;	chr14:55432641	chr14:55499278~55580110:-
BRCA	cis	rs962856	0.575	rs1486134	ENSG00000236780.4	AC078941.1	3.67	0.000257	0.0141	0.16	0.11	Pancreatic cancer;	chr2:67412637	chr2:67123357~67215319:-
BRCA	cis	rs6120849	0.754	rs6120812	ENSG00000202150.1	RNU6-407P	3.67	0.000257	0.0141	0.16	0.11	Protein C levels;	chr20:35041624	chr20:35030317~35030420:-
BRCA	cis	rs6120849	0.754	rs6120813	ENSG00000202150.1	RNU6-407P	3.67	0.000257	0.0141	0.16	0.11	Protein C levels;	chr20:35054309	chr20:35030317~35030420:-
BRCA	cis	rs6772849	0.901	rs9289330	ENSG00000242551.2	POU5F1P6	-3.67	0.000257	0.0141	-0.14	-0.11	Monocyte percentage of white cells;Monocyte count;	chr3:128592224	chr3:128674735~128677005:-
BRCA	cis	rs1552244	0.572	rs3843008	ENSG00000269894.1	RP11-1020A11.1	-3.67	0.000257	0.0141	-0.16	-0.11	Alzheimer's disease;	chr3:10132058	chr3:9935706~9936258:+
BRCA	cis	rs5167	0.781	rs909134	ENSG00000214855.8	APOC1P1	3.67	0.000257	0.0141	0.14	0.11	Blood protein levels;	chr19:44989803	chr19:44926804~44931386:+
BRCA	cis	rs6071524	0.5	rs2247054	ENSG00000224635.1	RP4-564F22.5	3.67	0.000257	0.0141	0.13	0.11	Autism spectrum disorder or schizophrenia;	chr20:38736338	chr20:38406011~38416797:-
BRCA	cis	rs9516	0.966	rs2887135	ENSG00000254631.4	RP11-702H23.4	3.67	0.000257	0.0141	0.14	0.11	Facial morphology (factor 15, philtrum width);	chr11:74452810	chr11:74397549~74485742:+
BRCA	cis	rs2243480	1	rs35542501	ENSG00000226767.1	RP11-328P23.3	-3.67	0.000257	0.0141	-0.19	-0.11	Diabetic kidney disease;	chr7:65966228	chr7:65508773~65508944:-
BRCA	cis	rs2243480	0.708	rs781141	ENSG00000226767.1	RP11-328P23.3	-3.67	0.000257	0.0141	-0.19	-0.11	Diabetic kidney disease;	chr7:65973566	chr7:65508773~65508944:-
BRCA	cis	rs6044112	0.769	rs12479533	ENSG00000273998.1	RP4-777L9.2	3.67	0.000257	0.0141	0.18	0.11	Response to taxane treatment (docetaxel);	chr20:16556970	chr20:16576068~16579615:+
BRCA	cis	rs6754311	0.861	rs12475139	ENSG00000226806.1	AC011893.3	3.67	0.000257	0.0141	0.13	0.11	Mosquito bite size;	chr2:136029081	chr2:135820191~135823087:+
BRCA	cis	rs9914544	0.545	rs8067882	ENSG00000235672.1	AC090286.2	-3.67	0.000257	0.0141	-0.13	-0.11	Educational attainment (years of education);	chr17:18903818	chr17:18908279~18908865:+
BRCA	cis	rs6490294	0.904	rs12423061	ENSG00000234608.6	MAPKAPK5-AS1	3.67	0.000257	0.0141	0.14	0.11	Mean platelet volume;	chr12:111967091	chr12:111839764~111842902:-
BRCA	cis	rs6490294	0.904	rs112426410	ENSG00000234608.6	MAPKAPK5-AS1	3.67	0.000257	0.0141	0.14	0.11	Mean platelet volume;	chr12:111969634	chr12:111839764~111842902:-
BRCA	cis	rs3760982	0.585	rs62116964	ENSG00000267191.1	RP11-15A1.2	-3.67	0.000257	0.0141	-0.15	-0.11	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43787834	chr19:43902001~43926545:+
BRCA	cis	rs17756712	0.725	rs998777	ENSG00000271911.1	RP11-532F6.5	3.67	0.000257	0.0141	0.2	0.11	Vertical cup-disc ratio;	chr6:610431	chr6:761675~780648:+
BRCA	cis	rs10266483	0.661	rs608769	ENSG00000271550.1	BNIP3P11	3.67	0.000257	0.0141	0.15	0.11	Response to statin therapy;	chr7:64292783	chr7:64678954~64687393:-
BRCA	cis	rs5997397	0.967	rs5762777	ENSG00000272858.1	CTA-292E10.8	-3.67	0.000257	0.0141	-0.14	-0.11	Red cell distribution width;	chr22:28754056	chr22:28814914~28815662:+
BRCA	cis	rs2803122	0.871	rs3802333	ENSG00000272842.1	RP11-513M16.7	-3.67	0.000257	0.0141	-0.12	-0.11	Pulse pressure;	chr9:19232137	chr9:19371386~19371945:-
BRCA	cis	rs7267979	1	rs2258201	ENSG00000276952.1	RP5-965G21.6	3.67	0.000257	0.0141	0.14	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25291854	chr20:25284915~25285588:-
BRCA	cis	rs6708331	1	rs7578027	ENSG00000231024.1	AC092431.3	-3.67	0.000257	0.0141	-0.16	-0.11	Obesity-related traits;	chr2:70173976	chr2:69700192~69713847:-
BRCA	cis	rs8054556	1	rs4788195	ENSG00000261367.1	RP11-455F5.4	-3.67	0.000257	0.0141	-0.13	-0.11	Autism spectrum disorder or schizophrenia;	chr16:29949272	chr16:30107675~30110541:+
BRCA	cis	rs4478858	0.611	rs10914338	ENSG00000223907.1	LINC01226	-3.67	0.000257	0.0141	-0.14	-0.11	Alcohol dependence;	chr1:31260935	chr1:31518435~31524245:+
BRCA	cis	rs442309	1	rs224058	ENSG00000238280.1	RP11-436D10.3	3.67	0.000257	0.0141	0.15	0.11	Vogt-Koyanagi-Harada syndrome;	chr10:62739105	chr10:62793562~62805887:-
BRCA	cis	rs6005807	0.719	rs9625521	ENSG00000272858.1	CTA-292E10.8	-3.67	0.000257	0.0141	-0.2	-0.11	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28643965	chr22:28814914~28815662:+
BRCA	cis	rs6005807	0.719	rs12167434	ENSG00000272858.1	CTA-292E10.8	-3.67	0.000257	0.0141	-0.2	-0.11	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28644833	chr22:28814914~28815662:+
BRCA	cis	rs6005807	0.719	rs28818228	ENSG00000272858.1	CTA-292E10.8	-3.67	0.000257	0.0141	-0.2	-0.11	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28646037	chr22:28814914~28815662:+
BRCA	cis	rs6005807	0.719	rs12169460	ENSG00000272858.1	CTA-292E10.8	-3.67	0.000257	0.0141	-0.2	-0.11	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28646091	chr22:28814914~28815662:+
BRCA	cis	rs6005807	0.719	rs60693420	ENSG00000272858.1	CTA-292E10.8	-3.67	0.000257	0.0141	-0.2	-0.11	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28649942	chr22:28814914~28815662:+
BRCA	cis	rs17221829	0.61	rs1844195	ENSG00000280385.1	AP000648.5	-3.67	0.000257	0.0141	-0.13	-0.11	Anxiety in major depressive disorder;	chr11:89656164	chr11:90193614~90198120:+
BRCA	cis	rs7474896	0.616	rs2505239	ENSG00000226578.1	RP11-258F22.1	-3.67	0.000257	0.0141	-0.16	-0.11	Obesity (extreme);	chr10:38151837	chr10:37775371~37784131:-
BRCA	cis	rs67766926	1	rs17538840	ENSG00000237522.1	NONOP2	3.67	0.000257	0.0141	0.13	0.11	Inflammatory skin disease;	chr2:60850682	chr2:60936819~60938049:-
BRCA	cis	rs2657888	0.56	rs6581096	ENSG00000257576.1	RP11-153M3.1	-3.67	0.000258	0.0141	-0.15	-0.11	Adiponectin levels;	chr12:56484336	chr12:56511002~56512703:+
BRCA	cis	rs5762752	0.555	rs695629	ENSG00000235954.5	TTC28-AS1	-3.67	0.000258	0.0141	-0.12	-0.11	Optic disc area;	chr22:28438781	chr22:27919376~28008581:+
BRCA	cis	rs7572733	0.935	rs1105078	ENSG00000231621.1	AC013264.2	-3.67	0.000258	0.0141	-0.1	-0.11	Dermatomyositis;	chr2:197943161	chr2:197197991~197199273:+
BRCA	cis	rs67073037	0.955	rs4577244	ENSG00000230730.1	AC074011.2	-3.67	0.000258	0.0141	-0.15	-0.11	Breast cancer;Breast cancer (estrogen-receptor negative);	chr2:28897867	chr2:28633282~28664540:-
BRCA	cis	rs6090583	0.618	rs2903948	ENSG00000273893.1	RP1-101A2.1	3.67	0.000258	0.0141	0.13	0.11	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr20:46876267	chr20:46681676~46682375:-
BRCA	cis	rs9500256	0.655	rs12208465	ENSG00000272316.1	XXbac-BPGBPG55C20.2	3.67	0.000258	0.0141	0.1	0.11	Eosinophilic esophagitis (pediatric);	chr6:58004603	chr6:57908560~57913911:-
BRCA	cis	rs9921338	1	rs9921338	ENSG00000262636.1	CTD-3088G3.4	3.67	0.000258	0.0141	0.18	0.11	Vein graft stenosis in coronary artery bypass grafting;	chr16:11322982	chr16:11380859~11381118:-
BRCA	cis	rs7020830	0.898	rs7038219	ENSG00000230188.1	RP11-405L18.4	-3.67	0.000258	0.0141	-0.13	-0.11	Schizophrenia;	chr9:37182895	chr9:37490421~37490893:-
BRCA	cis	rs6012564	1	rs911411	ENSG00000230758.1	SNAP23P	3.67	0.000258	0.0141	0.13	0.11	Anger;	chr20:49101894	chr20:49038357~49038602:-
BRCA	cis	rs6012564	1	rs6063352	ENSG00000230758.1	SNAP23P	3.67	0.000258	0.0141	0.13	0.11	Anger;	chr20:49102057	chr20:49038357~49038602:-
BRCA	cis	rs6012564	1	rs6063353	ENSG00000230758.1	SNAP23P	3.67	0.000258	0.0141	0.13	0.11	Anger;	chr20:49103273	chr20:49038357~49038602:-
BRCA	cis	rs6012564	1	rs6063354	ENSG00000230758.1	SNAP23P	3.67	0.000258	0.0141	0.13	0.11	Anger;	chr20:49103412	chr20:49038357~49038602:-
BRCA	cis	rs240993	0.812	rs9374262	ENSG00000230177.1	RP5-1112D6.4	3.67	0.000258	0.0141	0.15	0.11	Inflammatory skin disease;Psoriasis;	chr6:111553772	chr6:111277932~111278742:+
BRCA	cis	rs6964587	1	rs6961928	ENSG00000188693.7	CYP51A1-AS1	-3.67	0.000258	0.0141	-0.12	-0.11	Breast cancer;	chr7:92040494	chr7:92134604~92180725:+
BRCA	cis	rs6545883	0.868	rs2427885	ENSG00000212978.6	AC016747.3	3.67	0.000258	0.0141	0.15	0.11	Tuberculosis;	chr2:61589642	chr2:61141592~61144969:-
BRCA	cis	rs1143633	0.577	rs6745746	ENSG00000231747.1	AC079922.2	3.67	0.000258	0.0141	0.11	0.11	Allergic disease (asthma, hay fever or eczema);	chr2:112852467	chr2:112621809~112622167:-
BRCA	cis	rs7429990	0.932	rs6442101	ENSG00000199476.1	Y_RNA	3.67	0.000258	0.0141	0.16	0.11	Educational attainment (years of education);	chr3:48089403	chr3:48288587~48288694:+
BRCA	cis	rs6750047	0.628	rs2855655	ENSG00000235848.3	RMDN2-AS1	-3.67	0.000258	0.0141	-0.14	-0.11	Cutaneous malignant melanoma;Melanoma;	chr2:38077346	chr2:37949911~38067041:-
BRCA	cis	rs277939	0.967	rs277986	ENSG00000230847.4	RP11-195E2.1	-3.67	0.000258	0.0141	-0.14	-0.11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr5:71622068	chr5:71074225~71093193:-
BRCA	cis	rs12317459	0.591	rs11115407	ENSG00000213270.5	RPL6P25	-3.67	0.000258	0.0141	-0.18	-0.11	Prostate cancer (SNP x SNP interaction);	chr12:82772881	chr12:83151331~83152190:+
BRCA	cis	rs17428076	0.872	rs62183808	ENSG00000228389.1	AC068039.4	-3.67	0.000258	0.0141	-0.17	-0.11	Myopia;	chr2:172015170	chr2:171773482~171775844:+
BRCA	cis	rs6058526	0.568	rs13040716	ENSG00000275576.1	RP5-836N17.4	3.67	0.000258	0.0141	0.19	0.11	Chronic obstructive pulmonary disease;	chr20:32182402	chr20:32116171~32116629:+
BRCA	cis	rs9659323	1	rs6700415	ENSG00000231365.4	RP11-418J17.1	-3.67	0.000258	0.0141	-0.14	-0.11	Body mass index;	chr1:118973551	chr1:119140396~119275973:+
BRCA	cis	rs4664293	0.647	rs357028	ENSG00000226266.5	AC009961.3	-3.67	0.000258	0.0141	-0.13	-0.11	Monocyte percentage of white cells;	chr2:159635331	chr2:159670708~159712435:-
BRCA	cis	rs4578769	1	rs4578769	ENSG00000273232.1	RP11-370A5.2	3.67	0.000258	0.0141	0.15	0.11	Eosinophil percentage of white cells;	chr18:22815141	chr18:22882825~22883357:-
BRCA	cis	rs4374383	0.631	rs3761700	ENSG00000243389.1	AC012442.5	-3.67	0.000258	0.0141	-0.14	-0.11	Hepatitis C induced liver fibrosis;	chr2:111947608	chr2:112589040~112614431:+
BRCA	cis	rs9470794	1	rs11756902	ENSG00000204110.6	RP1-153P14.8	-3.67	0.000258	0.0141	-0.2	-0.11	Type 2 diabetes;	chr6:38150862	chr6:37507348~37535616:+
BRCA	cis	rs9470794	1	rs3800364	ENSG00000204110.6	RP1-153P14.8	-3.67	0.000258	0.0141	-0.2	-0.11	Type 2 diabetes;	chr6:38153435	chr6:37507348~37535616:+
BRCA	cis	rs10129255	0.957	rs10138532	ENSG00000232216.1	IGHV3-43	3.67	0.000258	0.0141	0.1	0.11	Kawasaki disease;	chr14:106803901	chr14:106470264~106470800:-
BRCA	cis	rs1949733	0.675	rs2688219	ENSG00000251615.3	RP11-774O3.3	-3.67	0.000258	0.0141	-0.12	-0.11	Response to antineoplastic agents;	chr4:8442904	chr4:8355090~8358338:-
BRCA	cis	rs2991971	0.901	rs11211122	ENSG00000280836.1	AL355480.1	3.67	0.000258	0.0141	0.13	0.11	High light scatter reticulocyte count;	chr1:45488978	chr1:45581219~45581321:-
BRCA	cis	rs16893526	0.649	rs9344225	ENSG00000224995.1	LINC01526	3.67	0.000258	0.0141	0.18	0.11	Coronary heart disease;	chr6:81814826	chr6:81813286~81814157:-
BRCA	cis	rs2386661	0.523	rs7896088	ENSG00000231483.1	RP11-336A10.5	3.67	0.000258	0.0141	0.14	0.11	Breast cancer;	chr10:5610323	chr10:5608475~5610793:-
BRCA	cis	rs669446	0.591	rs483679	ENSG00000236200.4	KDM4A-AS1	-3.67	0.000258	0.0141	-0.14	-0.11	Amyotrophic lateral sclerosis (age of onset);	chr1:43642448	chr1:43699765~43708138:-
BRCA	cis	rs669446	0.558	rs594293	ENSG00000236200.4	KDM4A-AS1	-3.67	0.000258	0.0141	-0.14	-0.11	Amyotrophic lateral sclerosis (age of onset);	chr1:43643528	chr1:43699765~43708138:-
BRCA	cis	rs669446	0.558	rs620851	ENSG00000236200.4	KDM4A-AS1	-3.67	0.000258	0.0141	-0.14	-0.11	Amyotrophic lateral sclerosis (age of onset);	chr1:43644818	chr1:43699765~43708138:-
BRCA	cis	rs669446	0.622	rs623965	ENSG00000236200.4	KDM4A-AS1	-3.67	0.000258	0.0141	-0.14	-0.11	Amyotrophic lateral sclerosis (age of onset);	chr1:43645516	chr1:43699765~43708138:-
BRCA	cis	rs4578769	0.959	rs3898593	ENSG00000273232.1	RP11-370A5.2	3.67	0.000258	0.0141	0.15	0.11	Eosinophil percentage of white cells;	chr18:22909074	chr18:22882825~22883357:-
BRCA	cis	rs7647973	0.961	rs6778080	ENSG00000281433.1	Metazoa_SRP	-3.67	0.000258	0.0141	-0.12	-0.11	Menarche (age at onset);	chr3:49279905	chr3:49320296~49320564:+
BRCA	cis	rs67073037	0.955	rs12620330	ENSG00000230730.1	AC074011.2	-3.67	0.000258	0.0141	-0.15	-0.11	Breast cancer;Breast cancer (estrogen-receptor negative);	chr2:28910822	chr2:28633282~28664540:-
BRCA	cis	rs67073037	0.955	rs12053141	ENSG00000230730.1	AC074011.2	-3.67	0.000258	0.0141	-0.15	-0.11	Breast cancer;Breast cancer (estrogen-receptor negative);	chr2:28911877	chr2:28633282~28664540:-
BRCA	cis	rs67073037	0.955	rs4666131	ENSG00000230730.1	AC074011.2	-3.67	0.000258	0.0141	-0.15	-0.11	Breast cancer;Breast cancer (estrogen-receptor negative);	chr2:28913406	chr2:28633282~28664540:-
BRCA	cis	rs67073037	0.955	rs4666132	ENSG00000230730.1	AC074011.2	-3.67	0.000258	0.0141	-0.15	-0.11	Breast cancer;Breast cancer (estrogen-receptor negative);	chr2:28913623	chr2:28633282~28664540:-
BRCA	cis	rs67073037	0.955	rs12472068	ENSG00000230730.1	AC074011.2	-3.67	0.000258	0.0141	-0.15	-0.11	Breast cancer;Breast cancer (estrogen-receptor negative);	chr2:28913819	chr2:28633282~28664540:-
BRCA	cis	rs67073037	0.955	rs56289239	ENSG00000230730.1	AC074011.2	-3.67	0.000258	0.0141	-0.15	-0.11	Breast cancer;Breast cancer (estrogen-receptor negative);	chr2:28914443	chr2:28633282~28664540:-
BRCA	cis	rs67073037	0.826	rs6728138	ENSG00000230730.1	AC074011.2	-3.67	0.000258	0.0141	-0.15	-0.11	Breast cancer;Breast cancer (estrogen-receptor negative);	chr2:28916112	chr2:28633282~28664540:-
BRCA	cis	rs67073037	0.955	rs4389288	ENSG00000230730.1	AC074011.2	-3.67	0.000258	0.0141	-0.15	-0.11	Breast cancer;Breast cancer (estrogen-receptor negative);	chr2:28917845	chr2:28633282~28664540:-
BRCA	cis	rs6991838	0.556	rs7846527	ENSG00000272155.1	RP11-707M3.3	3.67	0.000258	0.0141	0.1	0.11	Intelligence (multi-trait analysis);	chr8:65586522	chr8:65714334~65714778:-
BRCA	cis	rs6991838	0.584	rs4320587	ENSG00000272155.1	RP11-707M3.3	3.67	0.000258	0.0141	0.1	0.11	Intelligence (multi-trait analysis);	chr8:65586991	chr8:65714334~65714778:-
BRCA	cis	rs6991838	0.584	rs35941313	ENSG00000272155.1	RP11-707M3.3	3.67	0.000258	0.0141	0.1	0.11	Intelligence (multi-trait analysis);	chr8:65587498	chr8:65714334~65714778:-
BRCA	cis	rs8180040	0.726	rs10461018	ENSG00000280667.1	Y_RNA	-3.67	0.000258	0.0141	-0.13	-0.11	Colorectal cancer;	chr3:46953752	chr3:47501083~47501182:+
BRCA	cis	rs7914558	0.966	rs10786745	ENSG00000213277.3	MARCKSL1P1	3.67	0.000258	0.0141	0.13	0.11	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103197070	chr10:103175554~103176094:+
BRCA	cis	rs970548	1	rs11239545	ENSG00000230869.1	CTGLF10P	-3.67	0.000258	0.0142	-0.14	-0.11	Total cholesterol levels;HDL cholesterol;HDL cholesterol levels;Cholesterol, total;	chr10:45516797	chr10:45678692~45700532:+
BRCA	cis	rs7412746	0.588	rs10305664	ENSG00000231073.1	RP11-316M1.3	3.67	0.000258	0.0142	0.12	0.11	Melanoma;	chr1:150867210	chr1:150973123~150975534:+
BRCA	cis	rs6490294	0.571	rs7965087	ENSG00000234608.6	MAPKAPK5-AS1	3.67	0.000258	0.0142	0.17	0.11	Mean platelet volume;	chr12:112110758	chr12:111839764~111842902:-
BRCA	cis	rs863345	0.604	rs11264999	ENSG00000229914.1	RP11-404O13.4	-3.67	0.000258	0.0142	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158519070	chr1:158195633~158196131:-
BRCA	cis	rs17826057	1	rs17826057	ENSG00000239335.4	LLPH-AS1	3.67	0.000258	0.0142	0.27	0.11	Smooth-surface caries;	chr12:66239384	chr12:66130751~66134449:+
BRCA	cis	rs2216824	1	rs77499150	ENSG00000278908.1	RP11-523J2.1	3.67	0.000258	0.0142	0.2	0.11	Oropharynx cancer;	chr2:30882942	chr2:30677762~30679895:+
BRCA	cis	rs2216824	1	rs75610176	ENSG00000278908.1	RP11-523J2.1	3.67	0.000258	0.0142	0.2	0.11	Oropharynx cancer;	chr2:30882957	chr2:30677762~30679895:+
BRCA	cis	rs2839186	0.9	rs56840278	ENSG00000215424.8	MCM3AP-AS1	3.67	0.000258	0.0142	0.1	0.11	Testicular germ cell tumor;	chr21:46289019	chr21:46229217~46259390:+
BRCA	cis	rs2839186	0.933	rs56955294	ENSG00000215424.8	MCM3AP-AS1	3.67	0.000258	0.0142	0.1	0.11	Testicular germ cell tumor;	chr21:46289039	chr21:46229217~46259390:+
BRCA	cis	rs2562456	0.55	rs4809143	ENSG00000268535.1	RP11-420K14.3	3.67	0.000258	0.0142	0.17	0.11	Pain;	chr19:21589926	chr19:21709522~21710191:+
BRCA	cis	rs2562456	0.583	rs4809144	ENSG00000268535.1	RP11-420K14.3	3.67	0.000258	0.0142	0.17	0.11	Pain;	chr19:21589928	chr19:21709522~21710191:+
BRCA	cis	rs1998359	0.953	rs17179330	ENSG00000259087.4	RP11-356O9.2	3.67	0.000259	0.0142	0.13	0.11	Self-reported allergy;	chr14:37701954	chr14:37556158~37567095:-
BRCA	cis	rs7267979	1	rs2424700	ENSG00000274414.1	RP5-965G21.4	-3.67	0.000259	0.0142	-0.13	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25285877	chr20:25239007~25245229:-
BRCA	cis	rs6005807	0.843	rs9625525	ENSG00000272858.1	CTA-292E10.8	-3.67	0.000259	0.0142	-0.22	-0.11	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28657021	chr22:28814914~28815662:+
BRCA	cis	rs2562456	0.917	rs6511253	ENSG00000268555.1	RP11-678G14.3	-3.67	0.000259	0.0142	-0.15	-0.11	Pain;	chr19:21495996	chr19:21570822~21587322:-
BRCA	cis	rs11887277	0.507	rs6547254	ENSG00000272148.1	RP11-195B17.1	-3.67	0.000259	0.0142	-0.13	-0.11	Obesity-related traits;	chr2:26832750	chr2:27062428~27062907:-
BRCA	cis	rs11887277	0.507	rs6743539	ENSG00000272148.1	RP11-195B17.1	-3.67	0.000259	0.0142	-0.13	-0.11	Obesity-related traits;	chr2:26833371	chr2:27062428~27062907:-
BRCA	cis	rs11070836	0.935	rs35079663	ENSG00000259378.1	DCAF13P3	3.67	0.000259	0.0142	0.14	0.11	Airway wall thickness;	chr15:51130169	chr15:50944663~50945996:+
BRCA	cis	rs6599077	0.756	rs67870180	ENSG00000223797.4	ENTPD3-AS1	3.67	0.000259	0.0142	0.12	0.11	Sleep-related phenotypes;	chr3:40050291	chr3:40313802~40453329:-
BRCA	cis	rs875971	0.522	rs2949690	ENSG00000223473.2	GS1-124K5.3	-3.67	0.000259	0.0142	-0.09	-0.11	Aortic root size;	chr7:66018255	chr7:66491049~66493566:-
BRCA	cis	rs375066	0.762	rs239943	ENSG00000267191.1	RP11-15A1.2	-3.67	0.000259	0.0142	-0.15	-0.11	Breast cancer;	chr19:43870564	chr19:43902001~43926545:+
BRCA	cis	rs7260598	0.539	rs11672509	ENSG00000268442.1	CTD-2027I19.2	3.67	0.000259	0.0142	0.2	0.11	Response to taxane treatment (placlitaxel);	chr19:23885967	chr19:24162370~24163425:-
BRCA	cis	rs7260598	0.539	rs13345286	ENSG00000268442.1	CTD-2027I19.2	3.67	0.000259	0.0142	0.2	0.11	Response to taxane treatment (placlitaxel);	chr19:23886611	chr19:24162370~24163425:-
BRCA	cis	rs7260598	0.539	rs73525884	ENSG00000268442.1	CTD-2027I19.2	3.67	0.000259	0.0142	0.2	0.11	Response to taxane treatment (placlitaxel);	chr19:23886899	chr19:24162370~24163425:-
BRCA	cis	rs7260598	0.539	rs73525888	ENSG00000268442.1	CTD-2027I19.2	3.67	0.000259	0.0142	0.2	0.11	Response to taxane treatment (placlitaxel);	chr19:23887039	chr19:24162370~24163425:-
BRCA	cis	rs7260598	0.539	rs73525890	ENSG00000268442.1	CTD-2027I19.2	3.67	0.000259	0.0142	0.2	0.11	Response to taxane treatment (placlitaxel);	chr19:23887109	chr19:24162370~24163425:-
BRCA	cis	rs7260598	0.539	rs73525891	ENSG00000268442.1	CTD-2027I19.2	3.67	0.000259	0.0142	0.2	0.11	Response to taxane treatment (placlitaxel);	chr19:23887131	chr19:24162370~24163425:-
BRCA	cis	rs7260598	0.539	rs76305873	ENSG00000268442.1	CTD-2027I19.2	3.67	0.000259	0.0142	0.2	0.11	Response to taxane treatment (placlitaxel);	chr19:23887151	chr19:24162370~24163425:-
BRCA	cis	rs11668609	0.515	rs73525894	ENSG00000268442.1	CTD-2027I19.2	3.67	0.000259	0.0142	0.2	0.11	Response to taxane treatment (docetaxel);	chr19:23887976	chr19:24162370~24163425:-
BRCA	cis	rs11668609	0.515	rs13346480	ENSG00000268442.1	CTD-2027I19.2	3.67	0.000259	0.0142	0.2	0.11	Response to taxane treatment (docetaxel);	chr19:23889271	chr19:24162370~24163425:-
BRCA	cis	rs7260598	0.539	rs1347177	ENSG00000268442.1	CTD-2027I19.2	3.67	0.000259	0.0142	0.2	0.11	Response to taxane treatment (placlitaxel);	chr19:23896658	chr19:24162370~24163425:-
BRCA	cis	rs7260598	0.539	rs10412189	ENSG00000268442.1	CTD-2027I19.2	3.67	0.000259	0.0142	0.2	0.11	Response to taxane treatment (placlitaxel);	chr19:23897536	chr19:24162370~24163425:-
BRCA	cis	rs7260598	0.539	rs7254143	ENSG00000268442.1	CTD-2027I19.2	3.67	0.000259	0.0142	0.2	0.11	Response to taxane treatment (placlitaxel);	chr19:23897735	chr19:24162370~24163425:-
BRCA	cis	rs7260598	0.539	rs10418417	ENSG00000268442.1	CTD-2027I19.2	3.67	0.000259	0.0142	0.2	0.11	Response to taxane treatment (placlitaxel);	chr19:23898005	chr19:24162370~24163425:-
BRCA	cis	rs7260598	0.539	rs10425498	ENSG00000268442.1	CTD-2027I19.2	3.67	0.000259	0.0142	0.2	0.11	Response to taxane treatment (placlitaxel);	chr19:23898869	chr19:24162370~24163425:-
BRCA	cis	rs10129255	0.833	rs7156689	ENSG00000211959.2	IGHV4-39	3.67	0.000259	0.0142	0.09	0.11	Kawasaki disease;	chr14:106816039	chr14:106421711~106422218:-
BRCA	cis	rs12531458	1	rs12531458	ENSG00000249978.1	TRGV7	-3.67	0.000259	0.0142	-0.09	-0.11	Educational attainment (years of education);	chr7:39051098	chr7:38335041~38335514:-
BRCA	cis	rs61931739	0.5	rs73103774	ENSG00000258794.3	DUX4L27	3.67	0.000259	0.0142	0.16	0.11	Morning vs. evening chronotype;	chr12:34329344	chr12:34208415~34209675:-
BRCA	cis	rs1387259	0.69	rs1601985	ENSG00000240399.1	RP1-228P16.1	3.67	0.000259	0.0142	0.13	0.11	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48368131	chr12:48054813~48055591:-
BRCA	cis	rs8141529	0.748	rs1318026	ENSG00000272858.1	CTA-292E10.8	-3.67	0.000259	0.0142	-0.15	-0.11	Lymphocyte counts;	chr22:28887530	chr22:28814914~28815662:+
BRCA	cis	rs745109	0.882	rs60717666	ENSG00000273080.1	RP11-301O19.1	3.67	0.000259	0.0142	0.17	0.11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86479711	chr2:86195590~86196049:+
BRCA	cis	rs4664293	0.51	rs1968343	ENSG00000224152.1	AC009506.1	3.67	0.000259	0.0142	0.12	0.11	Monocyte percentage of white cells;	chr2:159712247	chr2:159615296~159617082:+
BRCA	cis	rs3169166	0.5	rs3813575	ENSG00000259562.2	RP11-762H8.2	3.67	0.000259	0.0142	0.09	0.11	Reticulocyte fraction of red cells;Reticulocyte count;	chr15:78268400	chr15:78290527~78291221:-
BRCA	cis	rs11098499	0.874	rs10022508	ENSG00000260404.2	RP11-384K6.6	3.67	0.000259	0.0142	0.11	0.11	Corneal astigmatism;	chr4:119194073	chr4:118591773~118633729:+
BRCA	cis	rs10129255	0.957	rs1024349	ENSG00000231475.3	IGHV4-31	-3.67	0.000259	0.0142	-0.09	-0.11	Kawasaki disease;	chr14:106689997	chr14:106349283~106349792:-
BRCA	cis	rs13416342	0.681	rs11126164	ENSG00000236259.1	AC017083.2	-3.67	0.000259	0.0142	-0.13	-0.11	Breast cancer;	chr2:67861067	chr2:68125265~68125747:+
BRCA	cis	rs10129255	0.957	rs10136781	ENSG00000232216.1	IGHV3-43	3.67	0.000259	0.0142	0.09	0.11	Kawasaki disease;	chr14:106780451	chr14:106470264~106470800:-
BRCA	cis	rs4664293	0.647	rs1549385	ENSG00000226266.5	AC009961.3	-3.67	0.000259	0.0142	-0.13	-0.11	Monocyte percentage of white cells;	chr2:159582540	chr2:159670708~159712435:-
BRCA	cis	rs61931739	0.5	rs11053272	ENSG00000258794.3	DUX4L27	3.67	0.000259	0.0142	0.16	0.11	Morning vs. evening chronotype;	chr12:34394085	chr12:34208415~34209675:-
BRCA	cis	rs9549260	0.753	rs10507486	ENSG00000168852.11	TPTE2P5	-3.67	0.000259	0.0142	-0.13	-0.11	Red blood cell count;	chr13:40612364	chr13:40822296~40921749:-
BRCA	cis	rs2841277	0.616	rs1048257	ENSG00000258701.1	LINC00638	3.67	0.000259	0.0142	0.12	0.11	Rheumatoid arthritis;	chr14:104938047	chr14:104821201~104823718:+
BRCA	cis	rs11673344	0.566	rs256735	ENSG00000267422.1	CTD-2554C21.1	-3.67	0.000259	0.0142	-0.14	-0.11	Obesity-related traits;	chr19:37375141	chr19:37779686~37792865:+
BRCA	cis	rs5758511	0.773	rs11913631	ENSG00000231261.1	HMGN2P10	-3.67	0.000259	0.0142	-0.15	-0.11	Birth weight;	chr22:41951367	chr22:41709225~41709489:-
BRCA	cis	rs875971	0.522	rs6960048	ENSG00000223473.2	GS1-124K5.3	3.67	0.000259	0.0142	0.09	0.11	Aortic root size;	chr7:65943052	chr7:66491049~66493566:-
BRCA	cis	rs321358	0.731	rs73003515	ENSG00000271390.1	RP11-89C3.3	3.67	0.000259	0.0142	0.17	0.11	Body mass index;	chr11:111160734	chr11:111089870~111090368:-
BRCA	cis	rs672059	0.934	rs6703054	ENSG00000224468.3	RP11-181K3.4	-3.67	0.000259	0.0142	-0.12	-0.11	Hypertriglyceridemia;	chr1:183186643	chr1:183138402~183141282:-
BRCA	cis	rs6063399	0.79	rs7353256	ENSG00000222365.1	SNORD12B	-3.67	0.000259	0.0142	-0.12	-0.11	Obesity-related traits;	chr20:49406382	chr20:49280319~49280409:+
BRCA	cis	rs7620503	1	rs7630147	ENSG00000231574.4	RP11-91K9.1	3.67	0.000259	0.0142	0.13	0.11	Corneal structure;	chr3:177582603	chr3:177816865~177899224:+
BRCA	cis	rs7620503	0.959	rs4857709	ENSG00000231574.4	RP11-91K9.1	3.67	0.000259	0.0142	0.13	0.11	Corneal structure;	chr3:177583167	chr3:177816865~177899224:+
BRCA	cis	rs7620503	1	rs4857710	ENSG00000231574.4	RP11-91K9.1	3.67	0.000259	0.0142	0.13	0.11	Corneal structure;	chr3:177583177	chr3:177816865~177899224:+
BRCA	cis	rs7620503	1	rs6763782	ENSG00000231574.4	RP11-91K9.1	3.67	0.000259	0.0142	0.13	0.11	Corneal structure;	chr3:177583492	chr3:177816865~177899224:+
BRCA	cis	rs7620503	0.729	rs2863018	ENSG00000231574.4	RP11-91K9.1	3.67	0.000259	0.0142	0.13	0.11	Corneal structure;	chr3:177584123	chr3:177816865~177899224:+
BRCA	cis	rs2133593	1	rs2133593	ENSG00000231574.4	RP11-91K9.1	3.67	0.000259	0.0142	0.13	0.11	Chin dimples;	chr3:177584204	chr3:177816865~177899224:+
BRCA	cis	rs890448	0.796	rs2119591	ENSG00000254531.1	FLJ20021	3.67	0.000259	0.0142	0.13	0.11	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101398487	chr4:101347780~101348883:+
BRCA	cis	rs45509595	0.841	rs200485	ENSG00000216676.2	RP1-15D7.1	-3.67	0.000259	0.0142	-0.19	-0.11	Breast cancer;	chr6:27807919	chr6:27652602~27652825:-
BRCA	cis	rs11098499	0.913	rs68128210	ENSG00000260404.2	RP11-384K6.6	3.67	0.000259	0.0142	0.11	0.11	Corneal astigmatism;	chr4:119216664	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.913	rs13126596	ENSG00000260404.2	RP11-384K6.6	3.67	0.000259	0.0142	0.11	0.11	Corneal astigmatism;	chr4:119219574	chr4:118591773~118633729:+
BRCA	cis	rs7267979	1	rs2424700	ENSG00000276952.1	RP5-965G21.6	3.67	0.000259	0.0142	0.14	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25285877	chr20:25284915~25285588:-
BRCA	cis	rs6487679	1	rs6487679	ENSG00000214776.8	RP11-726G1.1	-3.67	0.000259	0.0142	-0.15	-0.11	Non-alcoholic fatty liver disease histology (AST);	chr12:9218736	chr12:9467552~9576275:+
BRCA	cis	rs16950303	0.661	rs12606199	ENSG00000265496.3	MIR1539	3.67	0.000259	0.0142	0.23	0.11	Height;	chr18:49045546	chr18:49487339~49491878:+
BRCA	cis	rs4243971	0.516	rs2281542	ENSG00000275576.1	RP5-836N17.4	-3.67	0.000259	0.0142	-0.13	-0.11	Inflammatory bowel disease;Crohn's disease;	chr20:32427840	chr20:32116171~32116629:+
BRCA	cis	rs9987353	0.518	rs4841110	ENSG00000233609.3	RP11-62H7.2	3.67	0.000259	0.0142	0.11	0.11	Recombination measurement;	chr8:9228513	chr8:8961200~8979025:+
BRCA	cis	rs6736093	0.871	rs35471545	ENSG00000236307.2	EEF1E1P1	-3.67	0.000259	0.0142	-0.13	-0.11	Coronary artery disease;	chr2:111999134	chr2:111887914~111888741:+
BRCA	cis	rs9346455	0.614	rs9294899	ENSG00000199094.2	MIR30C2	3.67	0.000259	0.0142	0.16	0.11	Antipsychotic drug-induced weight gain;Antipsychotic drug-induced weight gain (time interaction);	chr6:71306599	chr6:71376933~71377045:-
BRCA	cis	rs4835473	0.932	rs62339580	ENSG00000249741.2	RP11-673E1.3	3.67	0.000259	0.0142	0.12	0.11	Immature fraction of reticulocytes;	chr4:143785090	chr4:143911514~143912053:-
BRCA	cis	rs4835473	0.932	rs62339581	ENSG00000249741.2	RP11-673E1.3	3.67	0.000259	0.0142	0.12	0.11	Immature fraction of reticulocytes;	chr4:143785172	chr4:143911514~143912053:-
BRCA	cis	rs4835473	0.932	rs7666368	ENSG00000249741.2	RP11-673E1.3	3.67	0.000259	0.0142	0.12	0.11	Immature fraction of reticulocytes;	chr4:143785372	chr4:143911514~143912053:-
BRCA	cis	rs4835473	0.932	rs7690428	ENSG00000249741.2	RP11-673E1.3	3.67	0.000259	0.0142	0.12	0.11	Immature fraction of reticulocytes;	chr4:143785400	chr4:143911514~143912053:-
BRCA	cis	rs4835473	0.932	rs34781605	ENSG00000249741.2	RP11-673E1.3	3.67	0.000259	0.0142	0.12	0.11	Immature fraction of reticulocytes;	chr4:143785486	chr4:143911514~143912053:-
BRCA	cis	rs4835473	0.9	rs11100810	ENSG00000249741.2	RP11-673E1.3	3.67	0.000259	0.0142	0.12	0.11	Immature fraction of reticulocytes;	chr4:143787518	chr4:143911514~143912053:-
BRCA	cis	rs4713118	0.662	rs149946	ENSG00000226314.6	ZNF192P1	3.67	0.000259	0.0142	0.17	0.11	Parkinson's disease;	chr6:28002253	chr6:28161781~28169594:+
BRCA	cis	rs4648045	0.734	rs11722146	ENSG00000251288.2	RP11-10L12.2	-3.67	0.000259	0.0142	-0.15	-0.11	Lymphocyte percentage of white cells;	chr4:102603472	chr4:102751401~102752641:+
BRCA	cis	rs62025270	0.688	rs76902341	ENSG00000259367.1	RP11-815J21.4	3.67	0.000259	0.0142	0.11	0.11	Idiopathic pulmonary fibrosis;	chr15:85737059	chr15:85619623~85670948:-
BRCA	cis	rs17684571	0.7	rs1610156	ENSG00000231441.1	RP11-472M19.2	3.67	0.000259	0.0142	0.18	0.11	Schizophrenia;	chr6:56844274	chr6:56844002~56864078:+
BRCA	cis	rs2880765	0.835	rs11638498	ENSG00000230373.7	GOLGA6L5P	3.67	0.000259	0.0142	0.12	0.11	Coronary artery disease;	chr15:85479787	chr15:84507885~84516814:-
BRCA	cis	rs9868809	0.772	rs13070798	ENSG00000228350.1	CELSR3-AS1	3.67	0.000259	0.0142	0.19	0.11	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48668501	chr3:48663776~48669174:+
BRCA	cis	rs75422866	0.867	rs73102168	ENSG00000276691.1	RP5-1057I20.5	3.67	0.000259	0.0142	0.24	0.11	Pneumonia;	chr12:47654010	chr12:47788426~47788971:+
BRCA	cis	rs2288327	0.545	rs2562834	ENSG00000270574.1	RP11-171I2.2	3.67	0.00026	0.0142	0.19	0.11	Atrial fibrillation;	chr2:178715856	chr2:178578790~178580906:+
BRCA	cis	rs12738007	0.544	rs12408688	ENSG00000237934.1	RP11-467D18.2	-3.67	0.00026	0.0142	-0.13	-0.11	Schizophrenia;	chr1:29104560	chr1:29223933~29224816:+
BRCA	cis	rs12738007	0.544	rs4654390	ENSG00000237934.1	RP11-467D18.2	-3.67	0.00026	0.0142	-0.13	-0.11	Schizophrenia;	chr1:29112504	chr1:29223933~29224816:+
BRCA	cis	rs6121246	0.738	rs6121242	ENSG00000230613.1	HM13-AS1	3.67	0.00026	0.0142	0.17	0.11	Mean corpuscular hemoglobin;	chr20:31823074	chr20:31567707~31573263:-
BRCA	cis	rs3764021	0.509	rs10772073	ENSG00000260423.1	RP13-735L24.1	-3.67	0.00026	0.0142	-0.13	-0.11	Type 1 diabetes;	chr12:9717428	chr12:9367464~9397617:+
BRCA	cis	rs3764021	0.509	rs10772074	ENSG00000260423.1	RP13-735L24.1	-3.67	0.00026	0.0142	-0.13	-0.11	Type 1 diabetes;	chr12:9717686	chr12:9367464~9397617:+
BRCA	cis	rs2274273	0.87	rs10145203	ENSG00000259318.1	RP11-454L9.2	3.67	0.00026	0.0142	0.1	0.11	Protein biomarker;	chr14:55317740	chr14:55394940~55395233:-
BRCA	cis	rs1696803	1	rs1696803	ENSG00000226864.1	ATE1-AS1	-3.67	0.00026	0.0142	-0.18	-0.11	Breast cancer;	chr10:121677436	chr10:121928312~121951965:+
BRCA	cis	rs6600671	0.967	rs12069545	ENSG00000270231.3	NBPF8P	3.66	0.00026	0.0142	0.12	0.11	Hip geometry;	chr1:121430343	chr1:120436353~120467739:+
BRCA	cis	rs12586478	0.56	rs12888523	ENSG00000205562.2	RP11-497E19.1	3.66	0.00026	0.0142	0.11	0.11	Post bronchodilator FEV1;	chr14:86318811	chr14:85524432~85529988:-
BRCA	cis	rs11098499	0.874	rs17839089	ENSG00000260404.2	RP11-384K6.6	3.66	0.00026	0.0142	0.11	0.11	Corneal astigmatism;	chr4:119189914	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.874	rs6826823	ENSG00000260404.2	RP11-384K6.6	3.66	0.00026	0.0142	0.11	0.11	Corneal astigmatism;	chr4:119190943	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.874	rs12509054	ENSG00000260404.2	RP11-384K6.6	3.66	0.00026	0.0142	0.11	0.11	Corneal astigmatism;	chr4:119193920	chr4:118591773~118633729:+
BRCA	cis	rs2991971	0.967	rs10789465	ENSG00000280836.1	AL355480.1	3.66	0.00026	0.0142	0.13	0.11	High light scatter reticulocyte count;	chr1:45506087	chr1:45581219~45581321:-
BRCA	cis	rs12922040	0.651	rs35288467	ENSG00000260872.1	RP11-680G24.5	3.66	0.00026	0.0142	0.11	0.11	Serum uric acid levels in response to allopurinol in gout;	chr16:15773097	chr16:15018106~15020488:-
BRCA	cis	rs4272720	0.951	rs61848370	ENSG00000228754.1	RP11-534L6.3	-3.66	0.00026	0.0142	-0.16	-0.11	Platelet count;Plateletcrit;	chr10:49069530	chr10:48745545~48746128:-
BRCA	cis	rs4272720	0.951	rs61848371	ENSG00000228754.1	RP11-534L6.3	-3.66	0.00026	0.0142	-0.16	-0.11	Platelet count;Plateletcrit;	chr10:49069540	chr10:48745545~48746128:-
BRCA	cis	rs6801044	0.954	rs28564334	ENSG00000272792.1	RP11-141C7.4	-3.66	0.00026	0.0142	-0.17	-0.11	Creatinine levels in ischemic stroke;	chr3:195560481	chr3:195639990~195640460:+
BRCA	cis	rs478304	0.593	rs9666878	ENSG00000255320.1	RP11-755F10.1	-3.66	0.00026	0.0142	-0.14	-0.11	Acne (severe);	chr11:65708345	chr11:66244840~66246239:-
BRCA	cis	rs516805	0.561	rs7772659	ENSG00000279114.1	RP3-425C14.5	3.66	0.00026	0.0142	0.16	0.11	Lymphocyte counts;	chr6:122608055	chr6:122471923~122484161:+
BRCA	cis	rs13098911	0.54	rs76597151	ENSG00000223552.1	RP11-24F11.2	-3.66	0.00026	0.0142	-0.18	-0.11	Celiac disease;	chr3:45959735	chr3:46364955~46407059:-
BRCA	cis	rs1998359	0.52	rs1951646	ENSG00000259087.4	RP11-356O9.2	-3.66	0.00026	0.0142	-0.11	-0.11	Self-reported allergy;	chr14:37677543	chr14:37556158~37567095:-
BRCA	cis	rs71520386	0.583	rs35322907	ENSG00000230658.1	KLHL7-AS1	3.66	0.00026	0.0142	0.16	0.11	Fibrinogen levels;	chr7:22806592	chr7:23101228~23105703:-
BRCA	cis	rs7577894	0.934	rs1465625	ENSG00000272606.1	RP11-554J4.1	3.66	0.00026	0.0142	0.12	0.11	Amyotrophic lateral sclerosis;	chr2:55763498	chr2:55617909~55618373:+
BRCA	cis	rs2692947	0.832	rs2438978	ENSG00000168992.4	OR7E102P	3.66	0.00026	0.0142	0.16	0.11	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96013992	chr2:95546531~95547545:+
BRCA	cis	rs9287719	0.967	rs1541573	ENSG00000224177.5	LINC00570	3.66	0.00026	0.0142	0.13	0.11	Prostate cancer;	chr2:10633259	chr2:11393981~11403077:+
BRCA	cis	rs9287719	0.967	rs1541574	ENSG00000224177.5	LINC00570	3.66	0.00026	0.0142	0.13	0.11	Prostate cancer;	chr2:10633382	chr2:11393981~11403077:+
BRCA	cis	rs875971	0.545	rs1796226	ENSG00000273448.1	RP11-166O4.6	3.66	0.00026	0.0142	0.11	0.11	Aortic root size;	chr7:66622723	chr7:67333047~67334383:+
BRCA	cis	rs643177	1	rs582757	ENSG00000226004.1	RP11-10J5.1	-3.66	0.00026	0.0142	-0.1	-0.11	Psoriasis;Inflammatory skin disease;	chr6:137876687	chr6:137943079~137945802:-
BRCA	cis	rs7772486	0.754	rs1415746	ENSG00000270638.1	RP3-466P17.1	-3.66	0.00026	0.0142	-0.13	-0.11	Lobe attachment (rater-scored or self-reported);	chr6:145755971	chr6:145735570~145737218:+
BRCA	cis	rs34779708	0.966	rs2045917	ENSG00000269952.1	RP11-324I22.3	-3.66	0.00026	0.0142	-0.15	-0.11	Inflammatory bowel disease;Crohn's disease;	chr10:35129598	chr10:35210416~35210750:+
BRCA	cis	rs7267979	0.966	rs6083855	ENSG00000274414.1	RP5-965G21.4	3.66	0.00026	0.0142	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25424482	chr20:25239007~25245229:-
BRCA	cis	rs7267979	1	rs4815426	ENSG00000274414.1	RP5-965G21.4	3.66	0.00026	0.0142	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25424550	chr20:25239007~25245229:-
BRCA	cis	rs7177699	0.526	rs7165733	ENSG00000261143.1	ADAMTS7P3	-3.66	0.00026	0.0142	-0.13	-0.11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78831163	chr15:77976042~77993057:+
BRCA	cis	rs7177699	0.526	rs7182529	ENSG00000261143.1	ADAMTS7P3	-3.66	0.00026	0.0142	-0.13	-0.11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78831289	chr15:77976042~77993057:+
BRCA	cis	rs745109	0.882	rs56085540	ENSG00000273080.1	RP11-301O19.1	3.66	0.00026	0.0142	0.17	0.11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86487308	chr2:86195590~86196049:+
BRCA	cis	rs28530618	0.84	rs11697969	ENSG00000198547.7	C20orf203	3.66	0.00026	0.0142	0.12	0.11	Birth weight;	chr20:32651496	chr20:32631652~32673941:-
BRCA	cis	rs2243480	1	rs35432774	ENSG00000226767.1	RP11-328P23.3	-3.66	0.00026	0.0142	-0.19	-0.11	Diabetic kidney disease;	chr7:65928032	chr7:65508773~65508944:-
BRCA	cis	rs7487075	0.619	rs7959731	ENSG00000257261.4	RP11-96H19.1	-3.66	0.00026	0.0142	-0.12	-0.11	Itch intensity from mosquito bite;	chr12:46445874	chr12:46383679~46876159:+
BRCA	cis	rs875971	0.862	rs1875057	ENSG00000229886.1	RP5-1132H15.3	-3.66	0.00026	0.0142	-0.13	-0.11	Aortic root size;	chr7:66266868	chr7:66025126~66031544:-
BRCA	cis	rs875971	0.862	rs6960446	ENSG00000229886.1	RP5-1132H15.3	-3.66	0.00026	0.0142	-0.13	-0.11	Aortic root size;	chr7:66268272	chr7:66025126~66031544:-
BRCA	cis	rs875971	0.789	rs10260426	ENSG00000229886.1	RP5-1132H15.3	-3.66	0.00026	0.0142	-0.13	-0.11	Aortic root size;	chr7:66271055	chr7:66025126~66031544:-
BRCA	cis	rs13256369	1	rs7004438	ENSG00000254153.1	CTA-398F10.2	3.66	0.00026	0.0143	0.15	0.11	Obesity-related traits;	chr8:8716869	chr8:8456909~8461337:-
BRCA	cis	rs6813195	0.751	rs10014554	ENSG00000245954.5	RP11-18H21.1	3.66	0.00026	0.0143	0.1	0.11	Type 2 diabetes;	chr4:152596644	chr4:152100754~152104720:+
BRCA	cis	rs4664293	0.625	rs6760931	ENSG00000224152.1	AC009506.1	3.66	0.000261	0.0143	0.12	0.11	Monocyte percentage of white cells;	chr2:159702600	chr2:159615296~159617082:+
BRCA	cis	rs11673344	0.566	rs185369	ENSG00000267422.1	CTD-2554C21.1	-3.66	0.000261	0.0143	-0.14	-0.11	Obesity-related traits;	chr19:37376137	chr19:37779686~37792865:+
BRCA	cis	rs8023401	0.938	rs12902728	ENSG00000274654.1	CTD-3247H4.2	3.66	0.000261	0.0143	0.15	0.11	Spherical equivalent (joint analysis main effects and education interaction);	chr15:48479222	chr15:48528980~48529728:-
BRCA	cis	rs12532214	1	rs12532214	ENSG00000217455.7	AC091801.1	3.66	0.000261	0.0143	0.17	0.11	Itch intensity from mosquito bite;	chr7:3130256	chr7:3140234~3174654:-
BRCA	cis	rs7119	0.604	rs2667781	ENSG00000259362.2	RP11-307C19.1	3.66	0.000261	0.0143	0.16	0.11	Type 2 diabetes;	chr15:77566277	chr15:77525540~77534110:+
BRCA	cis	rs1476679	0.962	rs34995835	ENSG00000242294.5	STAG3L5P	3.66	0.000261	0.0143	0.1	0.11	Alzheimer's disease (late onset);	chr7:100392741	chr7:100336079~100351900:+
BRCA	cis	rs568617	0.953	rs583887	ENSG00000254614.2	AP003068.23	3.66	0.000261	0.0143	0.16	0.11	Crohn's disease;	chr11:65876556	chr11:65177606~65181834:-
BRCA	cis	rs4578769	0.531	rs12969559	ENSG00000266850.1	RP11-370A5.1	3.66	0.000261	0.0143	0.14	0.11	Eosinophil percentage of white cells;	chr18:22913702	chr18:22723491~22907721:-
BRCA	cis	rs3781264	0.848	rs7897678	ENSG00000268894.5	PLCE1-AS1	-3.66	0.000261	0.0143	-0.15	-0.11	Esophageal cancer and gastric cancer;	chr10:94300853	chr10:94279277~94287478:-
BRCA	cis	rs3781264	0.804	rs7914672	ENSG00000268894.5	PLCE1-AS1	-3.66	0.000261	0.0143	-0.15	-0.11	Esophageal cancer and gastric cancer;	chr10:94301090	chr10:94279277~94287478:-
BRCA	cis	rs11668609	0.938	rs28720079	ENSG00000268058.1	BNIP3P40	-3.66	0.000261	0.0143	-0.14	-0.11	Response to taxane treatment (docetaxel);	chr19:24184823	chr19:24098425~24098980:-
BRCA	cis	rs12760731	0.72	rs12035174	ENSG00000213057.5	C1orf220	3.66	0.000261	0.0143	0.16	0.11	Obesity-related traits;	chr1:178345176	chr1:178542752~178548889:+
BRCA	cis	rs6429082	0.51	rs2803849	ENSG00000227962.1	RP11-382D8.3	-3.66	0.000261	0.0143	-0.11	-0.11	Adiposity;	chr1:235339932	chr1:235336806~235337087:+
BRCA	cis	rs17801127	1	rs848226	ENSG00000231969.1	AC144449.1	-3.66	0.000261	0.0143	-0.18	-0.11	Liver enzyme levels (alanine transaminase);	chr2:149700260	chr2:149587196~149848233:+
BRCA	cis	rs761926	1	rs2295475	ENSG00000272716.1	RP11-563N4.1	3.66	0.000261	0.0143	0.14	0.11	Obesity-related traits;	chr2:31366981	chr2:32165046~32165757:-
BRCA	cis	rs9973361	1	rs9973361	ENSG00000232411.1	AC009495.3	-3.66	0.000261	0.0143	-0.15	-0.11	Total body bone mineral density;	chr2:165859989	chr2:165833048~165839098:-
BRCA	cis	rs7520050	0.966	rs61102033	ENSG00000234329.1	RP11-767N6.2	-3.66	0.000261	0.0143	-0.11	-0.11	Reticulocyte count;Red blood cell count;	chr1:45916769	chr1:45651039~45651826:-
BRCA	cis	rs4388249	1	rs12189512	ENSG00000271849.1	CTC-332L22.1	-3.66	0.000261	0.0143	-0.19	-0.11	Schizophrenia;	chr5:109714412	chr5:109687802~109688329:-
BRCA	cis	rs875971	0.545	rs13311962	ENSG00000273448.1	RP11-166O4.6	-3.66	0.000261	0.0143	-0.12	-0.11	Aortic root size;	chr7:66603142	chr7:67333047~67334383:+
BRCA	cis	rs564309	0.681	rs1188488	ENSG00000183929.7	DUSP5P1	3.66	0.000261	0.0143	0.21	0.11	Hip circumference (psychosocial stress interaction);	chr1:228433925	chr1:228650241~228651379:+
BRCA	cis	rs957448	1	rs72674855	ENSG00000261437.1	RP11-22C11.2	3.66	0.000261	0.0143	0.11	0.11	Nonsyndromic cleft lip with cleft palate;	chr8:94536706	chr8:94637285~94639467:-
BRCA	cis	rs35520189	0.845	rs34899562	ENSG00000189223.12	PAX8-AS1	-3.66	0.000261	0.0143	-0.18	-0.11	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:112883895	chr2:113211522~113276581:+
BRCA	cis	rs35520189	0.845	rs13021862	ENSG00000189223.12	PAX8-AS1	-3.66	0.000261	0.0143	-0.18	-0.11	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:112884367	chr2:113211522~113276581:+
BRCA	cis	rs73198271	0.653	rs10099808	ENSG00000233609.3	RP11-62H7.2	3.66	0.000261	0.0143	0.11	0.11	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8802363	chr8:8961200~8979025:+
BRCA	cis	rs7572733	0.555	rs7420608	ENSG00000231621.1	AC013264.2	-3.66	0.000261	0.0143	-0.1	-0.11	Dermatomyositis;	chr2:198051206	chr2:197197991~197199273:+
BRCA	cis	rs6545883	0.507	rs4672427	ENSG00000270820.4	RP11-355B11.2	-3.66	0.000261	0.0143	-0.12	-0.11	Tuberculosis;	chr2:61242115	chr2:61471188~61484130:+
BRCA	cis	rs1787200	0.588	rs45588531	ENSG00000265496.3	MIR1539	3.66	0.000261	0.0143	0.2	0.11	Height;	chr18:49044334	chr18:49487339~49491878:+
BRCA	cis	rs4074961	0.527	rs6704190	ENSG00000233621.1	LINC01137	-3.66	0.000261	0.0143	-0.12	-0.11	Axial length;	chr1:37545150	chr1:37454879~37474411:-
BRCA	cis	rs6005807	0.719	rs73430189	ENSG00000272858.1	CTA-292E10.8	-3.66	0.000261	0.0143	-0.2	-0.11	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28608893	chr22:28814914~28815662:+
BRCA	cis	rs6005807	0.545	rs12169120	ENSG00000272858.1	CTA-292E10.8	-3.66	0.000261	0.0143	-0.2	-0.11	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28609314	chr22:28814914~28815662:+
BRCA	cis	rs6005807	0.719	rs12165715	ENSG00000272858.1	CTA-292E10.8	-3.66	0.000261	0.0143	-0.2	-0.11	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28609607	chr22:28814914~28815662:+
BRCA	cis	rs6736093	0.769	rs56361454	ENSG00000243389.1	AC012442.5	-3.66	0.000261	0.0143	-0.16	-0.11	Coronary artery disease;	chr2:112016528	chr2:112589040~112614431:+
BRCA	cis	rs897984	0.553	rs2125293	ENSG00000280211.1	RP11-2C24.3	-3.66	0.000261	0.0143	-0.12	-0.11	Dementia with Lewy bodies;	chr16:30852554	chr16:30773532~30776033:-
BRCA	cis	rs6743226	0.603	rs67625947	ENSG00000266621.1	AC104841.1	3.66	0.000261	0.0143	0.13	0.11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in non-smokers;	chr2:241287985	chr2:241245202~241245299:-
BRCA	cis	rs6743226	0.603	rs58226367	ENSG00000266621.1	AC104841.1	3.66	0.000261	0.0143	0.13	0.11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in non-smokers;	chr2:241288132	chr2:241245202~241245299:-
BRCA	cis	rs116175783	0.557	rs1733180	ENSG00000235724.7	AC009299.2	-3.66	0.000261	0.0143	-0.17	-0.11	Intelligence (multi-trait analysis);	chr2:161277119	chr2:161222785~161308303:-
BRCA	cis	rs2991971	0.967	rs937291	ENSG00000280836.1	AL355480.1	3.66	0.000261	0.0143	0.13	0.11	High light scatter reticulocyte count;	chr1:45491367	chr1:45581219~45581321:-
BRCA	cis	rs4950322	0.542	rs3766519	ENSG00000227242.3	NBPF13P	-3.66	0.000261	0.0143	-0.16	-0.11	Protein quantitative trait loci;	chr1:147214802	chr1:147021320~147124525:-
BRCA	cis	rs10761482	0.861	rs10821737	ENSG00000254271.1	RP11-131N11.4	3.66	0.000261	0.0143	0.16	0.11	Schizophrenia;	chr10:60348044	chr10:60734342~60741828:+
BRCA	cis	rs17772222	1	rs17772222	ENSG00000258789.1	RP11-507K2.3	3.66	0.000261	0.0143	0.14	0.11	Coronary artery calcification;	chr14:88360138	chr14:88551597~88552493:+
BRCA	cis	rs654950	0.875	rs600109	ENSG00000230638.4	RP11-486B10.4	3.66	0.000261	0.0143	0.15	0.11	Airway imaging phenotypes;	chr1:41532575	chr1:41542069~41544310:+
BRCA	cis	rs4578769	0.918	rs4800138	ENSG00000273232.1	RP11-370A5.2	-3.66	0.000261	0.0143	-0.15	-0.11	Eosinophil percentage of white cells;	chr18:22934334	chr18:22882825~22883357:-
BRCA	cis	rs875971	0.522	rs2008188	ENSG00000223473.2	GS1-124K5.3	3.66	0.000261	0.0143	0.09	0.11	Aortic root size;	chr7:65964026	chr7:66491049~66493566:-
BRCA	cis	rs12681366	0.659	rs2470735	ENSG00000253175.1	RP11-267M23.6	-3.66	0.000261	0.0143	-0.12	-0.11	Nonsyndromic cleft lip with cleft palate;	chr8:94403670	chr8:94565036~94565715:+
BRCA	cis	rs12681366	0.636	rs2246066	ENSG00000253175.1	RP11-267M23.6	-3.66	0.000261	0.0143	-0.12	-0.11	Nonsyndromic cleft lip with cleft palate;	chr8:94406927	chr8:94565036~94565715:+
BRCA	cis	rs2832077	0.527	rs2738953	ENSG00000232855.5	AF131217.1	-3.66	0.000261	0.0143	-0.14	-0.11	Cognitive test performance;	chr21:28866041	chr21:28439346~28674848:-
BRCA	cis	rs3749237	1	rs6804655	ENSG00000225399.4	RP11-3B7.1	3.66	0.000261	0.0143	0.11	0.11	Resting heart rate;	chr3:49701512	chr3:49260085~49261316:+
BRCA	cis	rs11887277	0.708	rs12470698	ENSG00000229122.1	AGBL5-IT1	-3.66	0.000261	0.0143	-0.12	-0.11	Obesity-related traits;	chr2:26840393	chr2:27061038~27061815:+
BRCA	cis	rs6060987	1	rs6060987	ENSG00000230613.1	HM13-AS1	3.66	0.000261	0.0143	0.17	0.11	Mean corpuscular volume;	chr20:31839274	chr20:31567707~31573263:-
BRCA	cis	rs7267979	0.932	rs928121	ENSG00000276952.1	RP5-965G21.6	3.66	0.000261	0.0143	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25554182	chr20:25284915~25285588:-
BRCA	cis	rs7267979	0.966	rs4815425	ENSG00000204556.4	CTD-2514C3.1	3.66	0.000261	0.0143	0.15	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25418240	chr20:26018832~26020684:+
BRCA	cis	rs875971	0.522	rs1880556	ENSG00000223473.2	GS1-124K5.3	3.66	0.000262	0.0143	0.09	0.11	Aortic root size;	chr7:65967557	chr7:66491049~66493566:-
BRCA	cis	rs12612435	0.91	rs1515069	ENSG00000226806.1	AC011893.3	3.66	0.000262	0.0143	0.14	0.11	Takotsubo syndrome;	chr2:136354992	chr2:135820191~135823087:+
BRCA	cis	rs12612435	0.91	rs1515068	ENSG00000226806.1	AC011893.3	3.66	0.000262	0.0143	0.14	0.11	Takotsubo syndrome;	chr2:136355048	chr2:135820191~135823087:+
BRCA	cis	rs13434995	0.513	rs6554285	ENSG00000273257.1	RP11-177J6.1	3.66	0.000262	0.0143	0.17	0.11	Adiponectin levels;	chr4:55533953	chr4:55387949~55388271:+
BRCA	cis	rs13434995	0.513	rs7660668	ENSG00000273257.1	RP11-177J6.1	3.66	0.000262	0.0143	0.17	0.11	Adiponectin levels;	chr4:55535530	chr4:55387949~55388271:+
BRCA	cis	rs7267979	0.966	rs2261698	ENSG00000276952.1	RP5-965G21.6	3.66	0.000262	0.0143	0.14	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25279274	chr20:25284915~25285588:-
BRCA	cis	rs957448	0.561	rs4734282	ENSG00000254315.1	RP11-267M23.3	3.66	0.000262	0.0143	0.14	0.11	Nonsyndromic cleft lip with cleft palate;	chr8:94603827	chr8:94533628~94534391:+
BRCA	cis	rs801193	1	rs7788576	ENSG00000232546.1	RP11-458F8.1	3.66	0.000262	0.0143	0.09	0.11	Aortic root size;	chr7:66683315	chr7:66848496~66858136:+
BRCA	cis	rs2832191	0.633	rs2832166	ENSG00000215533.7	LINC00189	-3.66	0.000262	0.0143	-0.13	-0.11	Dental caries;	chr21:29090074	chr21:29193480~29288205:+
BRCA	cis	rs251253	0.792	rs13172948	ENSG00000253959.1	CTB-43E15.1	3.66	0.000262	0.0143	0.1	0.11	PR interval;	chr5:173063711	chr5:173642519~173658194:+
BRCA	cis	rs3749237	0.964	rs11714957	ENSG00000225399.4	RP11-3B7.1	3.66	0.000262	0.0143	0.11	0.11	Resting heart rate;	chr3:49738745	chr3:49260085~49261316:+
BRCA	cis	rs4243971	0.516	rs1412997	ENSG00000275576.1	RP5-836N17.4	-3.66	0.000262	0.0143	-0.12	-0.11	Inflammatory bowel disease;Crohn's disease;	chr20:32354795	chr20:32116171~32116629:+
BRCA	cis	rs739401	0.572	rs410820	ENSG00000183562.3	CTC-343N3.1	-3.66	0.000262	0.0143	-0.12	-0.11	Longevity;	chr11:3058872	chr11:2989863~2991344:+
BRCA	cis	rs7246657	0.943	rs713256	ENSG00000267470.4	ZNF571-AS1	3.66	0.000262	0.0143	0.15	0.11	Coronary artery calcification;	chr19:37374463	chr19:37548914~37587348:+
BRCA	cis	rs295490	0.748	rs3772876	ENSG00000178631.7	ACTG1P1	-3.66	0.000262	0.0143	-0.22	-0.11	PR interval in Tripanosoma cruzi seropositivity;	chr3:139469035	chr3:139493809~139494937:+
BRCA	cis	rs6480314	0.831	rs6480317	ENSG00000233590.1	RP11-153K11.3	3.66	0.000262	0.0143	0.17	0.11	Optic nerve measurement (disc area);	chr10:68216837	chr10:68233251~68242379:-
BRCA	cis	rs6600671	1	rs11249351	ENSG00000275131.1	CH17-472G23.4	-3.66	0.000262	0.0143	-0.1	-0.11	Hip geometry;	chr1:121430082	chr1:120489625~120579190:-
BRCA	cis	rs16953946	0.504	rs9924703	ENSG00000260643.1	RP11-303E16.8	-3.66	0.000262	0.0143	-0.18	-0.11	Inflammatory bowel disease;	chr16:80745284	chr16:81053665~81087651:-
BRCA	cis	rs11662721	0.872	rs10502435	ENSG00000264188.1	RP11-13N13.5	3.66	0.000262	0.0143	0.16	0.11	Phospholipid levels (plasma);	chr18:21527130	chr18:21661787~21662395:-
BRCA	cis	rs35306767	0.903	rs12764024	ENSG00000229869.1	RP11-363N22.2	-3.66	0.000262	0.0143	-0.16	-0.11	Eosinophil percentage of granulocytes;	chr10:876921	chr10:933026~942743:+
BRCA	cis	rs875971	0.862	rs7796162	ENSG00000229886.1	RP5-1132H15.3	-3.66	0.000262	0.0143	-0.13	-0.11	Aortic root size;	chr7:66280771	chr7:66025126~66031544:-
BRCA	cis	rs7947761	0.715	rs73001993	ENSG00000254506.1	RP11-748H22.1	-3.66	0.000262	0.0143	-0.14	-0.11	Coronary artery disease;	chr11:100698687	chr11:101584295~101595156:+
BRCA	cis	rs6088590	1	rs2295353	ENSG00000276073.1	RP5-1125A11.7	-3.66	0.000262	0.0143	-0.13	-0.11	Coronary artery disease;	chr20:34768708	chr20:33985617~33988989:-
BRCA	cis	rs6088590	1	rs2295354	ENSG00000276073.1	RP5-1125A11.7	-3.66	0.000262	0.0143	-0.13	-0.11	Coronary artery disease;	chr20:34768738	chr20:33985617~33988989:-
BRCA	cis	rs875971	0.66	rs2013222	ENSG00000223473.2	GS1-124K5.3	-3.66	0.000262	0.0143	-0.08	-0.11	Aortic root size;	chr7:66570949	chr7:66491049~66493566:-
BRCA	cis	rs2273156	0.517	rs7159324	ENSG00000226677.3	IGBP1P1	3.66	0.000262	0.0143	0.17	0.11	Immunoglobulin light chain (AL) amyloidosis;	chr14:35157791	chr14:34939324~34940332:+
BRCA	cis	rs17801127	0.748	rs1526282	ENSG00000231969.1	AC144449.1	3.66	0.000262	0.0143	0.2	0.11	Liver enzyme levels (alanine transaminase);	chr2:149658765	chr2:149587196~149848233:+
BRCA	cis	rs6948772	1	rs6948772	ENSG00000216895.7	AC009403.2	3.66	0.000262	0.0143	0.14	0.11	Colorectal cancer;	chr7:155608201	chr7:155611231~155645205:-
BRCA	cis	rs7089973	0.934	rs68085797	ENSG00000236799.1	RP11-383C6.2	-3.66	0.000262	0.0143	-0.14	-0.11	Bipolar disorder or attention deficit hyperactivity disorder;	chr10:114872371	chr10:114994657~114996593:+
BRCA	cis	rs1528472	0.804	rs2641591	ENSG00000276533.1	RP11-139H15.5	3.66	0.000262	0.0143	0.13	0.11	Urinary albumin-to-creatinine ratio;Urinary albumin-to-creatinine ratio in non-diabetics;	chr15:55018374	chr15:55288849~55289346:-
BRCA	cis	rs6964587	1	rs6946356	ENSG00000188693.7	CYP51A1-AS1	-3.66	0.000262	0.0143	-0.12	-0.11	Breast cancer;	chr7:92098071	chr7:92134604~92180725:+
BRCA	cis	rs977987	0.835	rs8046109	ENSG00000261476.1	RP11-77K12.3	-3.66	0.000262	0.0143	-0.12	-0.11	Dupuytren's disease;	chr16:75326198	chr16:75458252~75460017:-
BRCA	cis	rs4266144	0.592	rs1545854	ENSG00000241770.1	RP11-555M1.3	3.66	0.000262	0.0143	0.17	0.11	Coronary artery disease;	chr3:157122349	chr3:157163452~157169133:+
BRCA	cis	rs10043228	1	rs12514600	ENSG00000250015.1	CTC-339F2.2	3.66	0.000262	0.0143	0.17	0.11	Asthma or chronic obstructive pulmonary disease;	chr5:116134958	chr5:116302354~116304134:-
BRCA	cis	rs7089973	0.872	rs7923295	ENSG00000236799.1	RP11-383C6.2	3.66	0.000262	0.0143	0.14	0.11	Bipolar disorder or attention deficit hyperactivity disorder;	chr10:114865400	chr10:114994657~114996593:+
BRCA	cis	rs6968419	0.761	rs9691405	ENSG00000279086.1	RP11-667F14.1	-3.66	0.000262	0.0143	-0.11	-0.11	Intraocular pressure;	chr7:116102603	chr7:116209234~116211511:-
BRCA	cis	rs3739034	0.652	rs35865359	ENSG00000224043.6	CCNT2-AS1	-3.66	0.000262	0.0143	-0.2	-0.11	Gut microbiome composition (winter);	chr2:134617025	chr2:134735464~134918710:-
BRCA	cis	rs13434995	0.513	rs2130040	ENSG00000249700.7	SRD5A3-AS1	3.66	0.000262	0.0143	0.16	0.11	Adiponectin levels;	chr4:55564036	chr4:55363971~55395847:-
BRCA	cis	rs11711311	0.747	rs7638378	ENSG00000241529.3	RN7SL767P	-3.66	0.000262	0.0143	-0.14	-0.11	IgG glycosylation;	chr3:113624783	chr3:113632704~113632998:+
BRCA	cis	rs6964587	1	rs2888851	ENSG00000188693.7	CYP51A1-AS1	-3.66	0.000262	0.0143	-0.12	-0.11	Breast cancer;	chr7:92019027	chr7:92134604~92180725:+
BRCA	cis	rs67340775	0.748	rs13212651	ENSG00000216901.1	AL022393.7	3.66	0.000262	0.0143	0.29	0.11	Lung cancer in ever smokers;	chr6:27839207	chr6:28176188~28176674:+
BRCA	cis	rs7267979	0.966	rs2261790	ENSG00000274414.1	RP5-965G21.4	-3.66	0.000262	0.0143	-0.13	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25282153	chr20:25239007~25245229:-
BRCA	cis	rs7267979	0.966	rs2261794	ENSG00000274414.1	RP5-965G21.4	-3.66	0.000262	0.0143	-0.13	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25282426	chr20:25239007~25245229:-
BRCA	cis	rs7267979	0.966	rs2145126	ENSG00000274414.1	RP5-965G21.4	-3.66	0.000262	0.0143	-0.13	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25283012	chr20:25239007~25245229:-
BRCA	cis	rs7267979	0.966	rs2257705	ENSG00000274414.1	RP5-965G21.4	-3.66	0.000262	0.0143	-0.13	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25284028	chr20:25239007~25245229:-
BRCA	cis	rs7267979	0.966	rs2227892	ENSG00000274414.1	RP5-965G21.4	-3.66	0.000262	0.0143	-0.13	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25284178	chr20:25239007~25245229:-
BRCA	cis	rs7267979	0.966	rs2257712	ENSG00000274414.1	RP5-965G21.4	-3.66	0.000262	0.0143	-0.13	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25284274	chr20:25239007~25245229:-
BRCA	cis	rs7267979	0.966	rs2257461	ENSG00000274414.1	RP5-965G21.4	-3.66	0.000262	0.0143	-0.13	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25284918	chr20:25239007~25245229:-
BRCA	cis	rs34773007	0.569	rs12415602	ENSG00000232709.1	MARK2P9	-3.66	0.000262	0.0143	-0.15	-0.11	Type 2 diabetes;	chr10:92939866	chr10:92418667~92420875:+
BRCA	cis	rs7172677	0.737	rs6495153	ENSG00000260269.4	CTD-2323K18.1	-3.66	0.000262	0.0143	-0.15	-0.11	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75144669	chr15:75527150~75601205:-
BRCA	cis	rs7943953	0.865	rs11604452	ENSG00000254717.2	GLYATL1P2	-3.66	0.000262	0.0143	-0.15	-0.11	Odorant perception (&beta-ionone);	chr11:59453532	chr11:58878302~58893460:+
BRCA	cis	rs6714710	0.603	rs2305143	ENSG00000228486.8	LINC01125	-3.66	0.000262	0.0143	-0.1	-0.11	Posterior cortical atrophy and Alzheimer's disease;	chr2:97797318	chr2:97664217~97703064:+
BRCA	cis	rs6714710	0.603	rs11691494	ENSG00000228486.8	LINC01125	-3.66	0.000262	0.0143	-0.1	-0.11	Posterior cortical atrophy and Alzheimer's disease;	chr2:97803263	chr2:97664217~97703064:+
BRCA	cis	rs6714710	0.58	rs17489915	ENSG00000228486.8	LINC01125	-3.66	0.000262	0.0143	-0.1	-0.11	Posterior cortical atrophy and Alzheimer's disease;	chr2:97803968	chr2:97664217~97703064:+
BRCA	cis	rs6751744	0.514	rs12386214	ENSG00000224152.1	AC009506.1	-3.66	0.000262	0.0143	-0.12	-0.11	Dysphagia;	chr2:159675012	chr2:159615296~159617082:+
BRCA	cis	rs4664293	0.932	rs4665104	ENSG00000224152.1	AC009506.1	-3.66	0.000262	0.0143	-0.12	-0.11	Monocyte percentage of white cells;	chr2:159675847	chr2:159615296~159617082:+
BRCA	cis	rs4664293	0.967	rs7595639	ENSG00000224152.1	AC009506.1	-3.66	0.000262	0.0143	-0.12	-0.11	Monocyte percentage of white cells;	chr2:159676533	chr2:159615296~159617082:+
BRCA	cis	rs2271404	1	rs72837860	ENSG00000227992.1	AC108463.2	3.66	0.000262	0.0143	0.18	0.11	Atopic dermatitis;	chr2:111249995	chr2:111203964~111206215:-
BRCA	cis	rs17684571	0.751	rs13195601	ENSG00000231441.1	RP11-472M19.2	3.66	0.000262	0.0143	0.19	0.11	Schizophrenia;	chr6:56836186	chr6:56844002~56864078:+
BRCA	cis	rs8054556	1	rs12921996	ENSG00000183604.13	SMG1P5	-3.66	0.000263	0.0143	-0.11	-0.11	Autism spectrum disorder or schizophrenia;	chr16:30000297	chr16:30267553~30335374:-
BRCA	cis	rs7620503	0.571	rs6443468	ENSG00000228221.4	LINC00578	3.66	0.000263	0.0143	0.14	0.11	Corneal structure;	chr3:177565231	chr3:177441921~177752305:+
BRCA	cis	rs860295	0.812	rs3820594	ENSG00000160766.13	GBAP1	-3.66	0.000263	0.0143	-0.12	-0.11	Body mass index;	chr1:155859720	chr1:155213821~155227422:-
BRCA	cis	rs7709377	0.595	rs27125	ENSG00000271918.1	CTD-2287O16.5	3.66	0.000263	0.0143	0.09	0.11	Metabolite levels  (X-11787);	chr5:116302058	chr5:116083807~116085416:-
BRCA	cis	rs1510510	0.676	rs13003403	ENSG00000186235.9	AC016757.3	-3.66	0.000263	0.0143	-0.19	-0.11	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr2:238619078	chr2:238224552~238231677:-
BRCA	cis	rs2216824	1	rs77827192	ENSG00000278908.1	RP11-523J2.1	3.66	0.000263	0.0143	0.2	0.11	Oropharynx cancer;	chr2:30882711	chr2:30677762~30679895:+
BRCA	cis	rs1520724	0.552	rs4761611	ENSG00000258172.1	RP11-1105G2.4	-3.66	0.000263	0.0143	-0.14	-0.11	Obesity-related traits;	chr12:94375982	chr12:94272150~94277195:-
BRCA	cis	rs891378	1	rs7548463	ENSG00000274245.1	RP11-357P18.2	-3.66	0.000263	0.0143	-0.15	-0.11	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207329546	chr1:207372559~207373252:+
BRCA	cis	rs7134599	0.561	rs4913395	ENSG00000203585.3	RP11-542B15.1	-3.66	0.000263	0.0143	-0.12	-0.11	Inflammatory bowel disease;Ulcerative colitis;	chr12:68076705	chr12:67519829~67567126:+
BRCA	cis	rs2562456	0.617	rs34203148	ENSG00000268535.1	RP11-420K14.3	3.66	0.000263	0.0143	0.16	0.11	Pain;	chr19:21590743	chr19:21709522~21710191:+
BRCA	cis	rs524281	0.731	rs2276036	ENSG00000255038.1	RP11-1167A19.2	-3.66	0.000263	0.0144	-0.18	-0.11	Electroencephalogram traits;	chr11:66265959	chr11:66067277~66069619:-
BRCA	cis	rs12478296	1	rs12478296	ENSG00000235351.1	AC114730.11	3.66	0.000263	0.0144	0.12	0.11	Obesity-related traits;	chr2:242106609	chr2:241724615~241725693:-
BRCA	cis	rs2554380	0.943	rs2585040	ENSG00000230373.7	GOLGA6L5P	-3.66	0.000263	0.0144	-0.16	-0.11	Height;	chr15:83671716	chr15:84507885~84516814:-
BRCA	cis	rs1061377	0.513	rs2712000	ENSG00000249685.1	RP11-360F5.3	3.66	0.000263	0.0144	0.15	0.11	Uric acid levels;	chr4:39135462	chr4:39133913~39135608:+
BRCA	cis	rs2638953	0.853	rs10506037	ENSG00000273989.1	RP11-425D17.2	-3.66	0.000263	0.0144	-0.17	-0.11	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28498213	chr12:28236227~28236828:+
BRCA	cis	rs7819412	0.505	rs17726209	ENSG00000154316.13	TDH	-3.66	0.000263	0.0144	-0.15	-0.11	Triglycerides;	chr8:11164675	chr8:11339637~11368452:+
BRCA	cis	rs9844666	0.532	rs9857579	ENSG00000273486.1	RP11-731C17.2	3.66	0.000263	0.0144	0.13	0.11	Height;	chr3:135937654	chr3:136837338~136839021:-
BRCA	cis	rs9844666	0.512	rs9819707	ENSG00000273486.1	RP11-731C17.2	3.66	0.000263	0.0144	0.13	0.11	Height;	chr3:135937664	chr3:136837338~136839021:-
BRCA	cis	rs9844666	0.532	rs12330820	ENSG00000273486.1	RP11-731C17.2	3.66	0.000263	0.0144	0.13	0.11	Height;	chr3:135940543	chr3:136837338~136839021:-
BRCA	cis	rs10504130	1	rs75527521	ENSG00000272076.1	RP11-11C20.3	3.66	0.000263	0.0144	0.2	0.11	Venous thromboembolism (SNP x SNP interaction);	chr8:51769788	chr8:51810110~51810681:-
BRCA	cis	rs8180040	0.966	rs2062278	ENSG00000260236.1	RP11-708J19.1	3.66	0.000263	0.0144	0.1	0.11	Colorectal cancer;	chr3:47375271	chr3:47379089~47380999:-
BRCA	cis	rs9308731	0.583	rs7596789	ENSG00000230499.1	AC108463.1	-3.66	0.000263	0.0144	-0.13	-0.11	Chronic lymphocytic leukemia;	chr2:111175039	chr2:111195963~111206494:+
BRCA	cis	rs9308731	0.563	rs11899831	ENSG00000230499.1	AC108463.1	-3.66	0.000263	0.0144	-0.13	-0.11	Chronic lymphocytic leukemia;	chr2:111175117	chr2:111195963~111206494:+
BRCA	cis	rs16944613	0.51	rs8026218	ENSG00000245479.2	LINC01585	3.66	0.000263	0.0144	0.13	0.11	Colorectal cancer;	chr15:90602033	chr15:90660234~90664967:+
BRCA	cis	rs9549260	0.569	rs73174811	ENSG00000168852.11	TPTE2P5	3.66	0.000263	0.0144	0.14	0.11	Red blood cell count;	chr13:40741862	chr13:40822296~40921749:-
BRCA	cis	rs6991838	0.584	rs4449837	ENSG00000272155.1	RP11-707M3.3	3.66	0.000263	0.0144	0.1	0.11	Intelligence (multi-trait analysis);	chr8:65575917	chr8:65714334~65714778:-
BRCA	cis	rs6991838	0.584	rs57042777	ENSG00000272155.1	RP11-707M3.3	3.66	0.000263	0.0144	0.1	0.11	Intelligence (multi-trait analysis);	chr8:65576855	chr8:65714334~65714778:-
BRCA	cis	rs4243971	0.516	rs1412998	ENSG00000275576.1	RP5-836N17.4	-3.66	0.000263	0.0144	-0.13	-0.11	Inflammatory bowel disease;Crohn's disease;	chr20:32355017	chr20:32116171~32116629:+
BRCA	cis	rs801193	1	rs2659889	ENSG00000275400.1	RP4-756H11.5	-3.66	0.000263	0.0144	-0.13	-0.11	Aortic root size;	chr7:66752125	chr7:66553805~66554199:-
BRCA	cis	rs35612822	0.556	rs10199099	ENSG00000232485.2	AC098820.3	-3.66	0.000263	0.0144	-0.15	-0.11	Kidney disease (early stage) in type 1 diabetes;	chr2:216388554	chr2:216479030~216498761:-
BRCA	cis	rs295490	0.748	rs80175427	ENSG00000178631.7	ACTG1P1	-3.66	0.000263	0.0144	-0.21	-0.11	PR interval in Tripanosoma cruzi seropositivity;	chr3:139498904	chr3:139493809~139494937:+
BRCA	cis	rs295490	0.748	rs17494482	ENSG00000178631.7	ACTG1P1	-3.66	0.000263	0.0144	-0.21	-0.11	PR interval in Tripanosoma cruzi seropositivity;	chr3:139499028	chr3:139493809~139494937:+
BRCA	cis	rs295490	0.748	rs2882080	ENSG00000178631.7	ACTG1P1	-3.66	0.000263	0.0144	-0.21	-0.11	PR interval in Tripanosoma cruzi seropositivity;	chr3:139499109	chr3:139493809~139494937:+
BRCA	cis	rs295490	0.748	rs2882081	ENSG00000178631.7	ACTG1P1	-3.66	0.000263	0.0144	-0.21	-0.11	PR interval in Tripanosoma cruzi seropositivity;	chr3:139499427	chr3:139493809~139494937:+
BRCA	cis	rs295490	0.748	rs7428398	ENSG00000178631.7	ACTG1P1	-3.66	0.000263	0.0144	-0.21	-0.11	PR interval in Tripanosoma cruzi seropositivity;	chr3:139499687	chr3:139493809~139494937:+
BRCA	cis	rs295490	0.748	rs77398474	ENSG00000178631.7	ACTG1P1	-3.66	0.000263	0.0144	-0.21	-0.11	PR interval in Tripanosoma cruzi seropositivity;	chr3:139502307	chr3:139493809~139494937:+
BRCA	cis	rs4908769	0.66	rs301797	ENSG00000270282.1	RP5-1115A15.2	3.66	0.000263	0.0144	0.13	0.11	Allergy;	chr1:8427263	chr1:8512653~8513021:+
BRCA	cis	rs747650	0.532	rs7128650	ENSG00000200376.1	RNU5E-10P	3.66	0.000263	0.0144	0.15	0.11	Acne (severe);	chr11:47025508	chr11:47576471~47576588:-
BRCA	cis	rs2562152	0.706	rs216598	ENSG00000260803.1	Z84812.4	-3.66	0.000263	0.0144	-0.17	-0.11	Glioblastoma;	chr16:58586	chr16:17514~35195:-
BRCA	cis	rs11892454	0.533	rs10469884	ENSG00000217643.1	PTGES3P2	-3.66	0.000263	0.0144	-0.12	-0.11	Heschl's gyrus morphology;	chr2:25878763	chr2:25822469~25822950:+
BRCA	cis	rs73201462	0.908	rs2999083	ENSG00000242551.2	POU5F1P6	-3.66	0.000263	0.0144	-0.19	-0.11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128235591	chr3:128674735~128677005:-
BRCA	cis	rs7660883	0.836	rs442177	ENSG00000251411.1	RP11-397E7.4	-3.66	0.000263	0.0144	-0.12	-0.11	HDL cholesterol levels;	chr4:87109109	chr4:86913266~86914817:-
BRCA	cis	rs440932	1	rs365309	ENSG00000253981.4	ALG1L13P	-3.66	0.000264	0.0144	-0.14	-0.11	High light scatter reticulocyte percentage of red cells;	chr8:9169430	chr8:8236003~8244667:-
BRCA	cis	rs495337	1	rs644013	ENSG00000229222.1	KRT18P4	-3.66	0.000264	0.0144	-0.14	-0.11	Psoriasis;	chr20:49899301	chr20:49956745~49958032:+
BRCA	cis	rs687432	0.924	rs714942	ENSG00000265566.2	RN7SL605P	-3.66	0.000264	0.0144	-0.16	-0.11	Parkinson's disease;	chr11:57929222	chr11:57528085~57528365:-
BRCA	cis	rs2692947	0.526	rs58719199	ENSG00000168992.4	OR7E102P	3.66	0.000264	0.0144	0.16	0.11	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95912499	chr2:95546531~95547545:+
BRCA	cis	rs6456156	0.586	rs9459862	ENSG00000227598.1	RP1-167A14.2	3.66	0.000264	0.0144	0.11	0.11	Primary biliary cholangitis;	chr6:167073523	chr6:166969626~166999065:-
BRCA	cis	rs2307449	0.929	rs16942893	ENSG00000260123.1	RP11-326A19.4	-3.66	0.000264	0.0144	-0.13	-0.11	Menopause (age at onset);	chr15:89243190	chr15:89041223~89082819:+
BRCA	cis	rs73201462	0.901	rs56175090	ENSG00000242551.2	POU5F1P6	3.66	0.000264	0.0144	0.19	0.11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128141237	chr3:128674735~128677005:-
BRCA	cis	rs73201462	0.808	rs34372443	ENSG00000242551.2	POU5F1P6	3.66	0.000264	0.0144	0.19	0.11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128141651	chr3:128674735~128677005:-
BRCA	cis	rs8105895	0.935	rs6511314	ENSG00000269345.1	VN1R85P	-3.66	0.000264	0.0144	-0.16	-0.11	Body mass index (change over time);	chr19:22053593	chr19:22174766~22175191:-
BRCA	cis	rs12477438	0.501	rs7349217	ENSG00000231822.1	AC019097.7	3.66	0.000264	0.0144	0.12	0.11	Chronic sinus infection;	chr2:99198683	chr2:99102018~99102752:+
BRCA	cis	rs3011225	0.738	rs2788371	ENSG00000237950.1	RP11-7O11.3	-3.66	0.000264	0.0144	-0.17	-0.11	Amyotrophic lateral sclerosis (age of onset);	chr1:43878290	chr1:43944370~43946551:-
BRCA	cis	rs4761470	0.577	rs7302972	ENSG00000258172.1	RP11-1105G2.4	-3.66	0.000264	0.0144	-0.16	-0.11	Estradiol plasma levels (breast cancer);	chr12:94288831	chr12:94272150~94277195:-
BRCA	cis	rs957448	1	rs1055800	ENSG00000261437.1	RP11-22C11.2	-3.66	0.000264	0.0144	-0.11	-0.11	Nonsyndromic cleft lip with cleft palate;	chr8:94510810	chr8:94637285~94639467:-
BRCA	cis	rs12324805	0.568	rs8039459	ENSG00000259429.4	UBE2Q2P2	-3.66	0.000264	0.0144	-0.11	-0.11	Body mass index;	chr15:82028085	chr15:82355142~82420075:+
BRCA	cis	rs8054556	1	rs4788195	ENSG00000214725.6	CDIPT-AS1	-3.66	0.000264	0.0144	-0.14	-0.11	Autism spectrum disorder or schizophrenia;	chr16:29949272	chr16:29863593~29868053:+
BRCA	cis	rs875971	1	rs1544549	ENSG00000273448.1	RP11-166O4.6	-3.66	0.000264	0.0144	-0.1	-0.11	Aortic root size;	chr7:66625676	chr7:67333047~67334383:+
BRCA	cis	rs7189233	0.955	rs16952242	ENSG00000249231.6	CASC16	3.66	0.000264	0.0144	0.13	0.11	Intelligence (multi-trait analysis);	chr16:53440338	chr16:52552090~52652105:-
BRCA	cis	rs4761470	0.577	rs4761602	ENSG00000258172.1	RP11-1105G2.4	-3.66	0.000264	0.0144	-0.16	-0.11	Estradiol plasma levels (breast cancer);	chr12:94291262	chr12:94272150~94277195:-
BRCA	cis	rs495337	0.699	rs6020074	ENSG00000229222.1	KRT18P4	3.66	0.000264	0.0144	0.14	0.11	Psoriasis;	chr20:49832122	chr20:49956745~49958032:+
BRCA	cis	rs2749592	0.531	rs994804	ENSG00000099251.13	HSD17B7P2	-3.66	0.000264	0.0144	-0.13	-0.11	Age-related hearing impairment (SNP x SNP interaction);	chr10:37611212	chr10:38356380~38378505:+
BRCA	cis	rs997295	0.592	rs12594849	ENSG00000259673.4	IQCH-AS1	3.66	0.000264	0.0144	0.13	0.11	Motion sickness;	chr15:67424234	chr15:67403619~67521844:-
BRCA	cis	rs875971	0.79	rs10257911	ENSG00000229886.1	RP5-1132H15.3	-3.66	0.000264	0.0144	-0.13	-0.11	Aortic root size;	chr7:66278783	chr7:66025126~66031544:-
BRCA	cis	rs1075265	0.575	rs2692531	ENSG00000272156.1	RP11-477N3.1	-3.66	0.000264	0.0144	-0.12	-0.11	Chronotype;Morning vs. evening chronotype;	chr2:53776640	chr2:54082554~54085066:+
BRCA	cis	rs6792584	0.743	rs4479607	ENSG00000241316.5	SUCLG2-AS1	3.66	0.000264	0.0144	0.12	0.11	Corneal astigmatism;	chr3:67461527	chr3:67654697~67947713:+
BRCA	cis	rs9367716	0.917	rs1013147	ENSG00000276576.1	MRPL30P1	-3.66	0.000264	0.0144	-0.14	-0.11	Coronary artery disease;	chr6:57260083	chr6:57029521~57029988:+
BRCA	cis	rs9500256	0.655	rs12210275	ENSG00000272316.1	XXbac-BPGBPG55C20.2	3.66	0.000264	0.0144	0.1	0.11	Eosinophilic esophagitis (pediatric);	chr6:58005481	chr6:57908560~57913911:-
BRCA	cis	rs9400180	0.84	rs4270829	ENSG00000271734.1	RP1-111B22.3	-3.66	0.000264	0.0144	-0.15	-0.11	Major depressive disorder;	chr6:108046896	chr6:108030249~108030718:-
BRCA	cis	rs970548	0.506	rs11239548	ENSG00000237840.5	FAM21FP	3.66	0.000264	0.0144	0.13	0.11	Total cholesterol levels;HDL cholesterol;HDL cholesterol levels;Cholesterol, total;	chr10:45522720	chr10:45706431~45727231:-
BRCA	cis	rs7221109	0.677	rs917593	ENSG00000229028.2	KRT223P	3.66	0.000264	0.0144	0.13	0.11	Type 1 diabetes;	chr17:40660274	chr17:40717235~40721932:-
BRCA	cis	rs524281	0.861	rs7937281	ENSG00000255038.1	RP11-1167A19.2	-3.66	0.000264	0.0144	-0.16	-0.11	Electroencephalogram traits;	chr11:66182603	chr11:66067277~66069619:-
BRCA	cis	rs495337	0.736	rs530461	ENSG00000224397.4	LINC01272	3.66	0.000264	0.0144	0.11	0.11	Psoriasis;	chr20:49851179	chr20:50267486~50279795:+
BRCA	cis	rs61931739	0.5	rs12809868	ENSG00000258794.3	DUX4L27	3.66	0.000264	0.0144	0.16	0.11	Morning vs. evening chronotype;	chr12:34311970	chr12:34208415~34209675:-
BRCA	cis	rs36051895	0.664	rs7847141	ENSG00000236254.1	MTND4P14	-3.66	0.000264	0.0144	-0.13	-0.11	Pediatric autoimmune diseases;	chr9:5097171	chr9:5107937~5109290:+
BRCA	cis	rs1046491	1	rs8089577	ENSG00000264964.1	RP11-888D10.3	3.66	0.000264	0.0144	0.23	0.11	Scarlet fever;	chr18:9217484	chr18:9315194~9334441:-
BRCA	cis	rs17027633	1	rs77952923	ENSG00000234020.1	CHIAP3	-3.66	0.000264	0.0144	-0.28	-0.11	Cerebrospinal fluid t-tau:AB1-42 ratio;	chr1:111432030	chr1:111353275~111367409:-
BRCA	cis	rs9393777	0.778	rs67457459	ENSG00000220721.1	OR1F12	3.66	0.000264	0.0144	0.21	0.11	Intelligence (multi-trait analysis);	chr6:27230564	chr6:28073316~28074233:+
BRCA	cis	rs1998359	0.906	rs75083875	ENSG00000259087.4	RP11-356O9.2	3.66	0.000264	0.0144	0.13	0.11	Self-reported allergy;	chr14:37698503	chr14:37556158~37567095:-
BRCA	cis	rs516805	0.665	rs225077	ENSG00000279114.1	RP3-425C14.5	-3.66	0.000264	0.0144	-0.14	-0.11	Lymphocyte counts;	chr6:122269794	chr6:122471923~122484161:+
BRCA	cis	rs13126694	0.633	rs4326059	ENSG00000248429.4	RP11-597D13.9	-3.66	0.000264	0.0144	-0.11	-0.11	Blood osmolality (transformed sodium);	chr4:158075315	chr4:158170752~158202877:+
BRCA	cis	rs718433	0.636	rs2157015	ENSG00000256379.1	TRAV8-5	3.66	0.000264	0.0144	0.14	0.11	Intraocular pressure;	chr14:21810566	chr14:21903077~21903598:+
BRCA	cis	rs251253	0.765	rs251237	ENSG00000253959.1	CTB-43E15.1	3.66	0.000264	0.0144	0.1	0.11	PR interval;	chr5:173116814	chr5:173642519~173658194:+
BRCA	cis	rs251253	0.795	rs166122	ENSG00000253959.1	CTB-43E15.1	3.66	0.000264	0.0144	0.1	0.11	PR interval;	chr5:173121706	chr5:173642519~173658194:+
BRCA	cis	rs1049564	0.597	rs1713420	ENSG00000258515.1	RP11-203M5.7	3.66	0.000264	0.0144	0.12	0.11	Interferon alpha levels in systemic lupus erythematosus;	chr14:20474585	chr14:20451305~20451918:+
BRCA	cis	rs801193	1	rs1553610	ENSG00000232546.1	RP11-458F8.1	-3.66	0.000265	0.0144	-0.09	-0.11	Aortic root size;	chr7:66732246	chr7:66848496~66858136:+
BRCA	cis	rs801193	1	rs2707845	ENSG00000232546.1	RP11-458F8.1	-3.66	0.000265	0.0144	-0.09	-0.11	Aortic root size;	chr7:66733811	chr7:66848496~66858136:+
BRCA	cis	rs801193	1	rs2707850	ENSG00000232546.1	RP11-458F8.1	-3.66	0.000265	0.0144	-0.09	-0.11	Aortic root size;	chr7:66738883	chr7:66848496~66858136:+
BRCA	cis	rs801193	0.967	rs1110414	ENSG00000232546.1	RP11-458F8.1	-3.66	0.000265	0.0144	-0.09	-0.11	Aortic root size;	chr7:66740595	chr7:66848496~66858136:+
BRCA	cis	rs801193	1	rs7783924	ENSG00000232546.1	RP11-458F8.1	-3.66	0.000265	0.0144	-0.09	-0.11	Aortic root size;	chr7:66744070	chr7:66848496~66858136:+
BRCA	cis	rs801193	1	rs7789184	ENSG00000232546.1	RP11-458F8.1	-3.66	0.000265	0.0144	-0.09	-0.11	Aortic root size;	chr7:66745208	chr7:66848496~66858136:+
BRCA	cis	rs801193	1	rs2707854	ENSG00000232546.1	RP11-458F8.1	-3.66	0.000265	0.0144	-0.09	-0.11	Aortic root size;	chr7:66747610	chr7:66848496~66858136:+
BRCA	cis	rs6545883	0.525	rs1621048	ENSG00000270820.4	RP11-355B11.2	-3.66	0.000265	0.0144	-0.13	-0.11	Tuberculosis;	chr2:61137081	chr2:61471188~61484130:+
BRCA	cis	rs10463316	0.894	rs13357969	ENSG00000260581.1	CTB-113P19.4	3.66	0.000265	0.0144	0.13	0.11	Metabolite levels (Pyroglutamine);	chr5:151371996	chr5:151652275~151655449:+
BRCA	cis	rs875971	0.619	rs12533585	ENSG00000272831.1	RP11-792A8.4	3.66	0.000265	0.0144	0.1	0.11	Aortic root size;	chr7:66519618	chr7:66739829~66740385:-
BRCA	cis	rs962856	0.756	rs4671799	ENSG00000236605.1	AC023115.4	3.66	0.000265	0.0144	0.14	0.11	Pancreatic cancer;	chr2:67395111	chr2:67324627~67325304:+
BRCA	cis	rs962856	0.756	rs4671800	ENSG00000236605.1	AC023115.4	3.66	0.000265	0.0144	0.14	0.11	Pancreatic cancer;	chr2:67395216	chr2:67324627~67325304:+
BRCA	cis	rs7267979	0.903	rs2500400	ENSG00000274414.1	RP5-965G21.4	3.66	0.000265	0.0144	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25374069	chr20:25239007~25245229:-
BRCA	cis	rs2274273	0.624	rs11158034	ENSG00000259318.1	RP11-454L9.2	3.66	0.000265	0.0144	0.1	0.11	Protein biomarker;	chr14:55286842	chr14:55394940~55395233:-
BRCA	cis	rs8180040	0.726	rs4682844	ENSG00000271161.1	BOLA2P2	-3.66	0.000265	0.0144	-0.12	-0.11	Colorectal cancer;	chr3:46941247	chr3:47499841~47500407:+
BRCA	cis	rs6545883	0.965	rs766447	ENSG00000212978.6	AC016747.3	3.66	0.000265	0.0144	0.15	0.11	Tuberculosis;	chr2:61508434	chr2:61141592~61144969:-
BRCA	cis	rs12549902	0.871	rs4736819	ENSG00000254165.1	RP11-503E24.2	3.66	0.000265	0.0144	0.12	0.11	Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Corrected insulin response;Type 2 diabetes;	chr8:41652396	chr8:42537529~42538304:-
BRCA	cis	rs6585424	1	rs61860025	ENSG00000225484.5	NUTM2B-AS1	-3.66	0.000265	0.0145	-0.23	-0.11	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80165798	chr10:79663088~79826594:-
BRCA	cis	rs6585424	1	rs12411386	ENSG00000225484.5	NUTM2B-AS1	-3.66	0.000265	0.0145	-0.23	-0.11	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80166475	chr10:79663088~79826594:-
BRCA	cis	rs6585424	1	rs2228427	ENSG00000225484.5	NUTM2B-AS1	-3.66	0.000265	0.0145	-0.23	-0.11	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80166962	chr10:79663088~79826594:-
BRCA	cis	rs6585424	1	rs34332933	ENSG00000225484.5	NUTM2B-AS1	-3.66	0.000265	0.0145	-0.23	-0.11	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80166994	chr10:79663088~79826594:-
BRCA	cis	rs16846053	0.792	rs55647762	ENSG00000227403.1	AC009299.3	3.66	0.000265	0.0145	0.29	0.11	Blood osmolality (transformed sodium);	chr2:161810807	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.792	rs56018438	ENSG00000227403.1	AC009299.3	3.66	0.000265	0.0145	0.29	0.11	Blood osmolality (transformed sodium);	chr2:161810867	chr2:161244739~161249050:+
BRCA	cis	rs9549260	0.564	rs9646110	ENSG00000168852.11	TPTE2P5	-3.66	0.000265	0.0145	-0.11	-0.11	Red blood cell count;	chr13:40734165	chr13:40822296~40921749:-
BRCA	cis	rs875971	0.545	rs2279757	ENSG00000232559.3	GS1-124K5.12	3.66	0.000265	0.0145	0.16	0.11	Aortic root size;	chr7:66363676	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.545	rs11766183	ENSG00000232559.3	GS1-124K5.12	3.66	0.000265	0.0145	0.16	0.11	Aortic root size;	chr7:66374173	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.545	rs1065265	ENSG00000232559.3	GS1-124K5.12	3.66	0.000265	0.0145	0.16	0.11	Aortic root size;	chr7:66376216	chr7:66554588~66576923:-
BRCA	cis	rs853679	0.882	rs4713140	ENSG00000219392.1	RP1-265C24.5	-3.66	0.000265	0.0145	-0.23	-0.11	Depression;	chr6:28129415	chr6:28115628~28116551:+
BRCA	cis	rs2243480	1	rs78803505	ENSG00000226767.1	RP11-328P23.3	-3.66	0.000265	0.0145	-0.19	-0.11	Diabetic kidney disease;	chr7:65917585	chr7:65508773~65508944:-
BRCA	cis	rs2243480	1	rs34577383	ENSG00000226767.1	RP11-328P23.3	-3.66	0.000265	0.0145	-0.19	-0.11	Diabetic kidney disease;	chr7:65920739	chr7:65508773~65508944:-
BRCA	cis	rs2243480	1	rs55895244	ENSG00000226767.1	RP11-328P23.3	-3.66	0.000265	0.0145	-0.19	-0.11	Diabetic kidney disease;	chr7:65922691	chr7:65508773~65508944:-
BRCA	cis	rs2243480	1	rs7795242	ENSG00000226767.1	RP11-328P23.3	-3.66	0.000265	0.0145	-0.19	-0.11	Diabetic kidney disease;	chr7:65925107	chr7:65508773~65508944:-
BRCA	cis	rs2243480	1	rs2177703	ENSG00000226767.1	RP11-328P23.3	-3.66	0.000265	0.0145	-0.19	-0.11	Diabetic kidney disease;	chr7:65926730	chr7:65508773~65508944:-
BRCA	cis	rs2243480	1	rs56985706	ENSG00000226767.1	RP11-328P23.3	-3.66	0.000265	0.0145	-0.19	-0.11	Diabetic kidney disease;	chr7:65929575	chr7:65508773~65508944:-
BRCA	cis	rs2243480	1	rs60683927	ENSG00000226767.1	RP11-328P23.3	-3.66	0.000265	0.0145	-0.19	-0.11	Diabetic kidney disease;	chr7:65929781	chr7:65508773~65508944:-
BRCA	cis	rs2243480	1	rs58062456	ENSG00000226767.1	RP11-328P23.3	-3.66	0.000265	0.0145	-0.19	-0.11	Diabetic kidney disease;	chr7:65929865	chr7:65508773~65508944:-
BRCA	cis	rs1730008	0.691	rs73170303	ENSG00000279311.1	RP11-170K4.2	3.66	0.000265	0.0145	0.14	0.11	Lobe attachment (rater-scored or self-reported);	chr3:158333925	chr3:158869898~158871821:+
BRCA	cis	rs1730008	0.691	rs73170306	ENSG00000279311.1	RP11-170K4.2	3.66	0.000265	0.0145	0.14	0.11	Lobe attachment (rater-scored or self-reported);	chr3:158334464	chr3:158869898~158871821:+
BRCA	cis	rs28530618	0.603	rs6119924	ENSG00000198547.7	C20orf203	-3.66	0.000265	0.0145	-0.13	-0.11	Birth weight;	chr20:32662663	chr20:32631652~32673941:-
BRCA	cis	rs61931739	0.517	rs11611190	ENSG00000258794.3	DUX4L27	3.66	0.000265	0.0145	0.16	0.11	Morning vs. evening chronotype;	chr12:33862762	chr12:34208415~34209675:-
BRCA	cis	rs10992471	0.56	rs2281715	ENSG00000187984.11	ANKRD19P	-3.66	0.000265	0.0145	-0.1	-0.11	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr9:92885692	chr9:92809388~92888693:+
BRCA	cis	rs4462272	0.557	rs17882802	ENSG00000230224.1	PHBP9	3.66	0.000265	0.0145	0.1	0.11	Age-related hearing impairment (SNP x SNP interaction);	chr10:100223656	chr10:100248271~100249095:+
BRCA	cis	rs4462272	0.557	rs34027394	ENSG00000230224.1	PHBP9	3.66	0.000265	0.0145	0.1	0.11	Age-related hearing impairment (SNP x SNP interaction);	chr10:100224059	chr10:100248271~100249095:+
BRCA	cis	rs4927850	0.723	rs7630825	ENSG00000271662.1	RP11-141C7.3	-3.66	0.000265	0.0145	-0.14	-0.11	Pancreatic cancer;	chr3:196026869	chr3:195650146~195651472:-
BRCA	cis	rs17345786	1	rs73863360	ENSG00000256628.3	ZBTB11-AS1	3.66	0.000265	0.0145	0.16	0.11	Colonoscopy-negative controls vs population controls;	chr3:101597993	chr3:101676475~101679217:+
BRCA	cis	rs1008375	0.932	rs11941874	ENSG00000249502.1	AC006160.5	3.66	0.000265	0.0145	0.13	0.11	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17664793	chr4:17587467~17614571:-
BRCA	cis	rs17270561	0.636	rs12194699	ENSG00000272462.2	U91328.19	-3.66	0.000265	0.0145	-0.14	-0.11	Iron status biomarkers;	chr6:25729001	chr6:25992662~26001775:+
BRCA	cis	rs17270561	0.609	rs9379786	ENSG00000272462.2	U91328.19	-3.66	0.000265	0.0145	-0.14	-0.11	Iron status biomarkers;	chr6:25730027	chr6:25992662~26001775:+
BRCA	cis	rs17270561	0.609	rs9393658	ENSG00000272462.2	U91328.19	-3.66	0.000265	0.0145	-0.14	-0.11	Iron status biomarkers;	chr6:25730210	chr6:25992662~26001775:+
BRCA	cis	rs17270561	0.609	rs12529272	ENSG00000272462.2	U91328.19	-3.66	0.000265	0.0145	-0.14	-0.11	Iron status biomarkers;	chr6:25731114	chr6:25992662~26001775:+
BRCA	cis	rs17270561	0.609	rs9393659	ENSG00000272462.2	U91328.19	-3.66	0.000265	0.0145	-0.14	-0.11	Iron status biomarkers;	chr6:25731130	chr6:25992662~26001775:+
BRCA	cis	rs17270561	0.609	rs12203927	ENSG00000272462.2	U91328.19	-3.66	0.000265	0.0145	-0.14	-0.11	Iron status biomarkers;	chr6:25732462	chr6:25992662~26001775:+
BRCA	cis	rs17270561	0.609	rs12192077	ENSG00000272462.2	U91328.19	-3.66	0.000265	0.0145	-0.14	-0.11	Iron status biomarkers;	chr6:25732566	chr6:25992662~26001775:+
BRCA	cis	rs67696533	0.711	rs6119897	ENSG00000277692.1	RP11-358N2.2	3.66	0.000265	0.0145	0.13	0.11	White blood cell count (basophil);Basophil percentage of granulocytes;Basophil percentage of white cells;	chr20:32557613	chr20:32355053~32355734:+
BRCA	cis	rs6728515	0.901	rs10208318	ENSG00000232642.1	AC008073.7	-3.66	0.000265	0.0145	-0.2	-0.11	Conotruncal heart defects (maternal effects);	chr2:23487330	chr2:24165884~24175005:-
BRCA	cis	rs6728515	1	rs10169305	ENSG00000232642.1	AC008073.7	-3.66	0.000265	0.0145	-0.2	-0.11	Conotruncal heart defects (maternal effects);	chr2:23487353	chr2:24165884~24175005:-
BRCA	cis	rs787274	1	rs813101	ENSG00000271631.1	RP11-408O19.5	3.66	0.000265	0.0145	0.19	0.11	Age-related hearing impairment (SNP x SNP interaction);	chr9:112770627	chr9:112885158~112885767:+
BRCA	cis	rs10043228	1	rs12520076	ENSG00000250015.1	CTC-339F2.2	3.66	0.000265	0.0145	0.16	0.11	Asthma or chronic obstructive pulmonary disease;	chr5:116123133	chr5:116302354~116304134:-
BRCA	cis	rs1953600	0.754	rs2573348	ENSG00000226659.1	RP11-137H2.4	-3.66	0.000265	0.0145	-0.15	-0.11	Sarcoidosis;	chr10:80166029	chr10:80529597~80535942:-
BRCA	cis	rs6973609	0.554	rs28731457	ENSG00000271122.1	RP11-379H18.1	-3.66	0.000265	0.0145	-0.14	-0.11	Obesity-related traits;	chr7:35567426	chr7:35695214~35699413:+
BRCA	cis	rs6439153	0.933	rs7648877	ENSG00000242551.2	POU5F1P6	-3.66	0.000265	0.0145	-0.14	-0.11	Pneumococcal bacteremia;	chr3:128991137	chr3:128674735~128677005:-
BRCA	cis	rs73242632	1	rs3775083	ENSG00000269949.1	RP11-738E22.3	3.66	0.000265	0.0145	0.26	0.11	Congenital heart disease (maternal effect);	chr4:57002020	chr4:56960927~56961373:-
BRCA	cis	rs73242632	1	rs56798906	ENSG00000269949.1	RP11-738E22.3	3.66	0.000265	0.0145	0.26	0.11	Congenital heart disease (maternal effect);	chr4:57009559	chr4:56960927~56961373:-
BRCA	cis	rs73242632	1	rs28719609	ENSG00000269949.1	RP11-738E22.3	3.66	0.000265	0.0145	0.26	0.11	Congenital heart disease (maternal effect);	chr4:57015696	chr4:56960927~56961373:-
BRCA	cis	rs35304300	0.909	rs11753362	ENSG00000225177.4	RP11-390P2.4	3.66	0.000265	0.0145	0.13	0.11	Mean platelet volume;	chr6:139536233	chr6:138692548~138697288:+
BRCA	cis	rs6480314	0.809	rs10509300	ENSG00000233590.1	RP11-153K11.3	-3.66	0.000265	0.0145	-0.18	-0.11	Optic nerve measurement (disc area);	chr10:68201078	chr10:68233251~68242379:-
BRCA	cis	rs6599077	0.616	rs11706943	ENSG00000223797.4	ENTPD3-AS1	3.66	0.000265	0.0145	0.14	0.11	Sleep-related phenotypes;	chr3:40132418	chr3:40313802~40453329:-
BRCA	cis	rs73198271	0.813	rs17697237	ENSG00000233609.3	RP11-62H7.2	3.66	0.000265	0.0145	0.11	0.11	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8758364	chr8:8961200~8979025:+
BRCA	cis	rs7111546	0.734	rs56073540	ENSG00000246225.5	RP11-17A1.3	3.66	0.000265	0.0145	0.19	0.11	Dialysis-related mortality;	chr11:22854894	chr11:22829380~22945393:+
BRCA	cis	rs10419113	0.668	rs10403851	ENSG00000268379.1	CTC-360J11.4	-3.66	0.000265	0.0145	-0.13	-0.11	Pediatric bone mineral density (spine);	chr19:57667866	chr19:57175233~57177921:+
BRCA	cis	rs61931739	0.517	rs56308002	ENSG00000258794.3	DUX4L27	3.66	0.000265	0.0145	0.16	0.11	Morning vs. evening chronotype;	chr12:33863086	chr12:34208415~34209675:-
BRCA	cis	rs6772849	0.93	rs55987729	ENSG00000207088.1	SNORA7B	-3.66	0.000265	0.0145	-0.14	-0.11	Monocyte percentage of white cells;Monocyte count;	chr3:128621267	chr3:129397210~129397348:-
BRCA	cis	rs67340775	0.541	rs200964	ENSG00000219392.1	RP1-265C24.5	-3.66	0.000265	0.0145	-0.19	-0.11	Lung cancer in ever smokers;	chr6:27899165	chr6:28115628~28116551:+
BRCA	cis	rs7412746	0.658	rs10305714	ENSG00000231073.1	RP11-316M1.3	-3.66	0.000265	0.0145	-0.12	-0.11	Melanoma;	chr1:150828179	chr1:150973123~150975534:+
BRCA	cis	rs7267979	1	rs4815404	ENSG00000274973.1	RP13-401N8.7	3.66	0.000265	0.0145	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25321209	chr20:25845497~25845862:+
BRCA	cis	rs1914816	1	rs2255408	ENSG00000196274.5	Metazoa_SRP	-3.66	0.000265	0.0145	-0.15	-0.11	Response to tocilizumab in rheumatoid arthritis;	chr15:76210954	chr15:76230048~76230390:-
BRCA	cis	rs875971	1	rs3735148	ENSG00000272831.1	RP11-792A8.4	3.66	0.000265	0.0145	0.1	0.11	Aortic root size;	chr7:66506022	chr7:66739829~66740385:-
BRCA	cis	rs1143633	0.579	rs3811042	ENSG00000231747.1	AC079922.2	3.66	0.000265	0.0145	0.11	0.11	Allergic disease (asthma, hay fever or eczema);	chr2:112913257	chr2:112621809~112622167:-
BRCA	cis	rs13326165	0.76	rs11707931	ENSG00000243224.1	RP5-1157M23.2	-3.66	0.000266	0.0145	-0.16	-0.11	HDL cholesterol levels;HDL cholesterol;	chr3:52324401	chr3:52239258~52241097:+
BRCA	cis	rs13326165	0.76	rs35133416	ENSG00000243224.1	RP5-1157M23.2	-3.66	0.000266	0.0145	-0.16	-0.11	HDL cholesterol levels;HDL cholesterol;	chr3:52325024	chr3:52239258~52241097:+
BRCA	cis	rs10771431	0.597	rs7976807	ENSG00000256427.1	RP11-118B22.4	3.66	0.000266	0.0145	0.12	0.11	Breast size;	chr12:9199863	chr12:9246497~9257960:+
BRCA	cis	rs17818399	0.547	rs4952833	ENSG00000279254.1	RP11-536C12.1	-3.66	0.000266	0.0145	-0.15	-0.11	Height;	chr2:46534895	chr2:46668870~46670778:+
BRCA	cis	rs17221829	0.673	rs1962257	ENSG00000280385.1	AP000648.5	-3.66	0.000266	0.0145	-0.13	-0.11	Anxiety in major depressive disorder;	chr11:89647569	chr11:90193614~90198120:+
BRCA	cis	rs6479874	0.736	rs2660218	ENSG00000223502.1	RP11-96B5.3	-3.66	0.000266	0.0145	-0.2	-0.11	Migraine;	chr10:50992711	chr10:51062579~51068553:-
BRCA	cis	rs703842	0.616	rs10877023	ENSG00000257159.1	RP11-58A17.3	3.66	0.000266	0.0145	0.14	0.11	Multiple sclerosis;	chr12:57830416	chr12:57967058~57968399:+
BRCA	cis	rs801193	0.967	rs3800823	ENSG00000265600.1	AC006480.1	3.66	0.000266	0.0145	0.13	0.11	Aortic root size;	chr7:66682123	chr7:67356680~67356779:+
BRCA	cis	rs821931	1	rs821940	ENSG00000213260.3	YWHAZP5	3.66	0.000266	0.0145	0.16	0.11	Asparaginase hypersensitivity in acute lymphoblastic leukemia;	chr10:106685211	chr10:105686322~105687051:+
BRCA	cis	rs7209700	0.638	rs4629025	ENSG00000228782.6	CTD-2026D20.3	-3.66	0.000266	0.0145	-0.13	-0.11	IgG glycosylation;	chr17:47260069	chr17:47450568~47492492:-
BRCA	cis	rs6431644	0.694	rs525359	ENSG00000224287.2	MSL3P1	3.66	0.000266	0.0145	0.14	0.11	Left atrial antero-posterior diameter;	chr2:233851828	chr2:233865437~233868444:-
BRCA	cis	rs6600671	0.966	rs6600664	ENSG00000223345.3	HIST2H2BA	3.66	0.000266	0.0145	0.14	0.11	Hip geometry;	chr1:121480638	chr1:121108210~121117257:-
BRCA	cis	rs6600671	0.932	rs6600663	ENSG00000223345.3	HIST2H2BA	3.66	0.000266	0.0145	0.14	0.11	Hip geometry;	chr1:121480639	chr1:121108210~121117257:-
BRCA	cis	rs4819052	0.851	rs2838836	ENSG00000215447.6	BX322557.10	-3.66	0.000266	0.0145	-0.12	-0.11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245960	chr21:45288052~45291738:+
BRCA	cis	rs854765	0.52	rs7219324	ENSG00000197815.4	RP1-253P7.4	3.66	0.000266	0.0145	0.08	0.11	Total body bone mineral density;	chr17:18006461	chr17:17858227~17860041:+
BRCA	cis	rs73201462	1	rs2999077	ENSG00000242551.2	POU5F1P6	-3.66	0.000266	0.0145	-0.19	-0.11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128239571	chr3:128674735~128677005:-
BRCA	cis	rs4237845	0.537	rs7312623	ENSG00000270039.1	RP11-571M6.17	-3.66	0.000266	0.0145	-0.16	-0.11	Intelligence (multi-trait analysis);	chr12:57868740	chr12:57803838~57804415:+
BRCA	cis	rs9470794	1	rs73417971	ENSG00000204110.6	RP1-153P14.8	-3.66	0.000266	0.0145	-0.23	-0.11	Type 2 diabetes;	chr6:38018623	chr6:37507348~37535616:+
BRCA	cis	rs9470794	0.915	rs73417972	ENSG00000204110.6	RP1-153P14.8	-3.66	0.000266	0.0145	-0.23	-0.11	Type 2 diabetes;	chr6:38018654	chr6:37507348~37535616:+
BRCA	cis	rs863345	0.565	rs2051665	ENSG00000229914.1	RP11-404O13.4	-3.66	0.000266	0.0145	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158537367	chr1:158195633~158196131:-
BRCA	cis	rs863345	0.526	rs2051666	ENSG00000229914.1	RP11-404O13.4	-3.66	0.000266	0.0145	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158537370	chr1:158195633~158196131:-
BRCA	cis	rs12549902	0.8	rs7825494	ENSG00000254165.1	RP11-503E24.2	3.66	0.000266	0.0145	0.12	0.11	Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Corrected insulin response;Type 2 diabetes;	chr8:41649831	chr8:42537529~42538304:-
BRCA	cis	rs7487075	0.619	rs4768724	ENSG00000257261.4	RP11-96H19.1	3.66	0.000266	0.0145	0.13	0.11	Itch intensity from mosquito bite;	chr12:46454633	chr12:46383679~46876159:+
BRCA	cis	rs7267979	0.789	rs9927	ENSG00000277938.1	RP5-965G21.3	3.66	0.000266	0.0145	0.14	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25296608	chr20:25229150~25231933:+
BRCA	cis	rs11098499	0.863	rs2291185	ENSG00000260091.1	RP11-33B1.4	-3.66	0.000266	0.0145	-0.1	-0.11	Corneal astigmatism;	chr4:119513678	chr4:119409333~119410233:+
BRCA	cis	rs60678552	0.642	rs73548947	ENSG00000237021.2	RP3-486I3.7	3.66	0.000266	0.0145	0.2	0.11	Heschl's gyrus morphology;	chr6:116318148	chr6:116254207~116256743:+
BRCA	cis	rs801193	0.548	rs2659904	ENSG00000265600.1	AC006480.1	-3.66	0.000266	0.0145	-0.14	-0.11	Aortic root size;	chr7:66713615	chr7:67356680~67356779:+
BRCA	cis	rs801193	0.967	rs2707853	ENSG00000275400.1	RP4-756H11.5	-3.66	0.000266	0.0145	-0.13	-0.11	Aortic root size;	chr7:66749023	chr7:66553805~66554199:-
BRCA	cis	rs3755605	0.694	rs34124911	ENSG00000242578.1	RP11-469J4.3	3.66	0.000266	0.0145	0.13	0.11	Testicular germ cell tumor;	chr3:170136883	chr3:170410512~170418615:+
BRCA	cis	rs2274273	0.84	rs7144737	ENSG00000259318.1	RP11-454L9.2	3.66	0.000266	0.0145	0.1	0.11	Protein biomarker;	chr14:55356228	chr14:55394940~55395233:-
BRCA	cis	rs67478160	0.643	rs7156697	ENSG00000269910.1	RP11-73M18.10	3.66	0.000266	0.0145	0.11	0.11	Schizophrenia;	chr14:103744799	chr14:103694516~103695050:-
BRCA	cis	rs17270561	0.609	rs4464787	ENSG00000272462.2	U91328.19	-3.66	0.000266	0.0145	-0.14	-0.11	Iron status biomarkers;	chr6:25733330	chr6:25992662~26001775:+
BRCA	cis	rs897984	0.553	rs2335013	ENSG00000260082.1	RP11-2C24.5	-3.66	0.000266	0.0145	-0.14	-0.11	Dementia with Lewy bodies;	chr16:30866025	chr16:30821068~30822110:-
BRCA	cis	rs7246657	0.598	rs10417545	ENSG00000267470.4	ZNF571-AS1	3.66	0.000266	0.0145	0.17	0.11	Coronary artery calcification;	chr19:37163361	chr19:37548914~37587348:+
BRCA	cis	rs10883723	0.962	rs1056740	ENSG00000213061.2	PFN1P11	-3.66	0.000266	0.0145	-0.16	-0.11	Allergic disease (asthma, hay fever or eczema);	chr10:102476795	chr10:102838011~102845473:-
BRCA	cis	rs7267979	1	rs453329	ENSG00000277938.1	RP5-965G21.3	3.66	0.000266	0.0145	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25459957	chr20:25229150~25231933:+
BRCA	cis	rs7267979	1	rs4815408	ENSG00000274414.1	RP5-965G21.4	3.66	0.000266	0.0145	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25366042	chr20:25239007~25245229:-
BRCA	cis	rs7246967	1	rs62120832	ENSG00000198153.8	ZNF849P	-3.66	0.000266	0.0145	-0.16	-0.11	Bronchopulmonary dysplasia;	chr19:22881462	chr19:22685167~22686732:+
BRCA	cis	rs4272720	1	rs59889308	ENSG00000228754.1	RP11-534L6.3	-3.66	0.000266	0.0145	-0.16	-0.11	Platelet count;Plateletcrit;	chr10:49072747	chr10:48745545~48746128:-
BRCA	cis	rs4272720	1	rs74939581	ENSG00000228754.1	RP11-534L6.3	-3.66	0.000266	0.0145	-0.16	-0.11	Platelet count;Plateletcrit;	chr10:49074184	chr10:48745545~48746128:-
BRCA	cis	rs12289961	0.681	rs11229308	ENSG00000265566.2	RN7SL605P	-3.66	0.000266	0.0145	-0.18	-0.11	Lymphoma;	chr11:58234369	chr11:57528085~57528365:-
BRCA	cis	rs6500602	0.701	rs4786508	ENSG00000280063.1	RP11-295D4.3	3.66	0.000266	0.0145	0.09	0.11	Schizophrenia;	chr16:4518042	chr16:4346694~4348648:-
BRCA	cis	rs7165170	0.554	rs12904055	ENSG00000245479.2	LINC01585	-3.66	0.000266	0.0145	-0.14	-0.11	Crohn's disease;Inflammatory bowel disease;	chr15:90605042	chr15:90660234~90664967:+
BRCA	cis	rs7165170	0.554	rs34759713	ENSG00000245479.2	LINC01585	-3.66	0.000266	0.0145	-0.14	-0.11	Crohn's disease;Inflammatory bowel disease;	chr15:90605394	chr15:90660234~90664967:+
BRCA	cis	rs911119	0.913	rs3004139	ENSG00000270001.1	RP11-218C14.8	3.66	0.000266	0.0145	0.14	0.11	Chronic kidney disease;	chr20:23598037	chr20:23631826~23632316:-
BRCA	cis	rs75422866	1	rs73102120	ENSG00000276691.1	RP5-1057I20.5	3.66	0.000266	0.0145	0.24	0.11	Pneumonia;	chr12:47637280	chr12:47788426~47788971:+
BRCA	cis	rs75422866	0.867	rs12422974	ENSG00000276691.1	RP5-1057I20.5	3.66	0.000266	0.0145	0.24	0.11	Pneumonia;	chr12:47644559	chr12:47788426~47788971:+
BRCA	cis	rs75422866	0.867	rs73102127	ENSG00000276691.1	RP5-1057I20.5	3.66	0.000266	0.0145	0.24	0.11	Pneumonia;	chr12:47645341	chr12:47788426~47788971:+
BRCA	cis	rs75422866	0.867	rs73102166	ENSG00000276691.1	RP5-1057I20.5	3.66	0.000266	0.0145	0.24	0.11	Pneumonia;	chr12:47653769	chr12:47788426~47788971:+
BRCA	cis	rs75422866	0.867	rs73102171	ENSG00000276691.1	RP5-1057I20.5	3.66	0.000266	0.0145	0.24	0.11	Pneumonia;	chr12:47656077	chr12:47788426~47788971:+
BRCA	cis	rs75422866	0.867	rs76100981	ENSG00000276691.1	RP5-1057I20.5	3.66	0.000266	0.0145	0.24	0.11	Pneumonia;	chr12:47660092	chr12:47788426~47788971:+
BRCA	cis	rs4243971	0.516	rs3818190	ENSG00000275576.1	RP5-836N17.4	-3.66	0.000266	0.0145	-0.13	-0.11	Inflammatory bowel disease;Crohn's disease;	chr20:32428511	chr20:32116171~32116629:+
BRCA	cis	rs17684571	0.872	rs6901176	ENSG00000231441.1	RP11-472M19.2	3.66	0.000267	0.0145	0.15	0.11	Schizophrenia;	chr6:56696759	chr6:56844002~56864078:+
BRCA	cis	rs1971762	0.545	rs10783585	ENSG00000270175.1	RP11-793H13.11	-3.66	0.000267	0.0145	-0.1	-0.11	Height;	chr12:53583533	chr12:53500162~53500936:-
BRCA	cis	rs1075265	0.756	rs805423	ENSG00000272156.1	RP11-477N3.1	-3.66	0.000267	0.0145	-0.12	-0.11	Chronotype;Morning vs. evening chronotype;	chr2:53899904	chr2:54082554~54085066:+
BRCA	cis	rs13434995	0.513	rs62305264	ENSG00000249700.7	SRD5A3-AS1	-3.66	0.000267	0.0145	-0.16	-0.11	Adiponectin levels;	chr4:55502968	chr4:55363971~55395847:-
BRCA	cis	rs3177980	0.564	rs2272918	ENSG00000239494.2	RN7SL333P	-3.66	0.000267	0.0145	-0.1	-0.11	Amyotrophic lateral sclerosis;	chr1:169849739	chr1:169859756~169860052:+
BRCA	cis	rs11874712	1	rs1800640	ENSG00000251939.1	RNU6-1278P	-3.66	0.000267	0.0145	-0.12	-0.11	Migraine - clinic-based;	chr18:46091434	chr18:46121615~46121721:-
BRCA	cis	rs7520050	0.966	rs785479	ENSG00000226957.1	RP4-533D7.4	3.66	0.000267	0.0145	0.12	0.11	Reticulocyte count;Red blood cell count;	chr1:46026472	chr1:46046818~46048368:+
BRCA	cis	rs6964587	0.9	rs11984136	ENSG00000188693.7	CYP51A1-AS1	-3.66	0.000267	0.0145	-0.12	-0.11	Breast cancer;	chr7:92137639	chr7:92134604~92180725:+
BRCA	cis	rs7487075	0.578	rs12319162	ENSG00000257261.4	RP11-96H19.1	3.66	0.000267	0.0145	0.12	0.11	Itch intensity from mosquito bite;	chr12:46444131	chr12:46383679~46876159:+
BRCA	cis	rs8098244	0.603	rs4800507	ENSG00000265752.2	RP11-403A21.1	3.66	0.000267	0.0145	0.12	0.11	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23726168	chr18:23957754~23982556:-
BRCA	cis	rs3745567	1	rs3745565	ENSG00000276980.1	CTD-3128G10.7	3.66	0.000267	0.0145	0.18	0.11	Complement C3 and C4 levels;	chr19:6690971	chr19:6716386~6717742:-
BRCA	cis	rs7173064	0.935	rs4777698	ENSG00000272888.4	LINC01578	3.66	0.000267	0.0145	0.12	0.11	White matter hyperintensity burden;	chr15:93756844	chr15:92882707~92899701:+
BRCA	cis	rs2486012	1	rs3011221	ENSG00000237950.1	RP11-7O11.3	3.66	0.000267	0.0145	0.18	0.11	Intelligence (multi-trait analysis);	chr1:43846437	chr1:43944370~43946551:-
BRCA	cis	rs2243480	0.901	rs2949697	ENSG00000226002.1	RP11-460N20.5	-3.66	0.000267	0.0145	-0.19	-0.11	Diabetic kidney disease;	chr7:65999249	chr7:65084103~65100232:+
BRCA	cis	rs7824557	1	rs7824557	ENSG00000255046.1	RP11-297N6.4	3.66	0.000267	0.0145	0.14	0.11	Retinal vascular caliber;	chr8:11246602	chr8:11797928~11802568:-
BRCA	cis	rs6751744	1	rs6751744	ENSG00000230783.1	AC009961.2	-3.66	0.000267	0.0145	-0.15	-0.11	Dysphagia;	chr2:159550974	chr2:159689217~159690291:-
BRCA	cis	rs1039766	1	rs268862	ENSG00000227791.3	AC007365.4	-3.66	0.000267	0.0145	-0.17	-0.11	Lung adenocarcinoma;Lung cancer;	chr2:65261404	chr2:64665607~64666064:+
BRCA	cis	rs7221109	0.633	rs7209735	ENSG00000229028.2	KRT223P	3.66	0.000267	0.0145	0.13	0.11	Type 1 diabetes;	chr17:40662346	chr17:40717235~40721932:-
BRCA	cis	rs4302906	0.787	rs6479441	ENSG00000187984.11	ANKRD19P	-3.66	0.000267	0.0146	-0.11	-0.11	Lobe attachment (rater-scored or self-reported);	chr9:92951080	chr9:92809388~92888693:+
BRCA	cis	rs1008375	0.966	rs3796813	ENSG00000249502.1	AC006160.5	-3.66	0.000267	0.0146	-0.13	-0.11	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17590025	chr4:17587467~17614571:-
BRCA	cis	rs13434995	0.513	rs6554282	ENSG00000249700.7	SRD5A3-AS1	3.66	0.000267	0.0146	0.16	0.11	Adiponectin levels;	chr4:55519812	chr4:55363971~55395847:-
BRCA	cis	rs13434995	0.513	rs6554283	ENSG00000249700.7	SRD5A3-AS1	3.66	0.000267	0.0146	0.16	0.11	Adiponectin levels;	chr4:55521053	chr4:55363971~55395847:-
BRCA	cis	rs13434995	0.513	rs1546004	ENSG00000249700.7	SRD5A3-AS1	3.66	0.000267	0.0146	0.16	0.11	Adiponectin levels;	chr4:55521612	chr4:55363971~55395847:-
BRCA	cis	rs13434995	0.513	rs4865006	ENSG00000249700.7	SRD5A3-AS1	3.66	0.000267	0.0146	0.16	0.11	Adiponectin levels;	chr4:55526112	chr4:55363971~55395847:-
BRCA	cis	rs13434995	0.513	rs62303691	ENSG00000239040.1	Y_RNA	3.66	0.000267	0.0146	0.14	0.11	Adiponectin levels;	chr4:55442085	chr4:55412636~55412738:+
BRCA	cis	rs11098499	0.863	rs3822192	ENSG00000250412.1	KLHL2P1	3.66	0.000267	0.0146	0.14	0.11	Corneal astigmatism;	chr4:119524565	chr4:119334329~119378233:+
BRCA	cis	rs9287719	0.967	rs6759714	ENSG00000224177.5	LINC00570	3.66	0.000267	0.0146	0.13	0.11	Prostate cancer;	chr2:10607081	chr2:11393981~11403077:+
BRCA	cis	rs9287719	0.967	rs6744854	ENSG00000224177.5	LINC00570	3.66	0.000267	0.0146	0.13	0.11	Prostate cancer;	chr2:10607120	chr2:11393981~11403077:+
BRCA	cis	rs9287719	0.967	rs6759740	ENSG00000224177.5	LINC00570	3.66	0.000267	0.0146	0.13	0.11	Prostate cancer;	chr2:10607145	chr2:11393981~11403077:+
BRCA	cis	rs7520050	0.966	rs12049588	ENSG00000226957.1	RP4-533D7.4	3.66	0.000267	0.0146	0.12	0.11	Reticulocyte count;Red blood cell count;	chr1:46006750	chr1:46046818~46048368:+
BRCA	cis	rs7520050	0.966	rs12021587	ENSG00000226957.1	RP4-533D7.4	3.66	0.000267	0.0146	0.12	0.11	Reticulocyte count;Red blood cell count;	chr1:46007087	chr1:46046818~46048368:+
BRCA	cis	rs12908161	0.96	rs17599989	ENSG00000229212.6	RP11-561C5.4	-3.66	0.000267	0.0146	-0.14	-0.11	Schizophrenia;	chr15:84742305	chr15:85205440~85234795:-
BRCA	cis	rs11686241	0.935	rs55671904	ENSG00000241520.1	AC098820.4	3.66	0.000267	0.0146	0.17	0.11	Cancer;	chr2:216448732	chr2:216483032~216487196:-
BRCA	cis	rs848490	0.889	rs17156247	ENSG00000214293.7	APTR	-3.66	0.000267	0.0146	-0.14	-0.11	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77668224	chr7:77657660~77696265:-
BRCA	cis	rs3743162	1	rs12909280	ENSG00000259295.5	CSPG4P12	3.66	0.000267	0.0146	0.17	0.11	Alzheimer's disease (age of onset);	chr15:84886125	chr15:85191438~85213905:+
BRCA	cis	rs11098499	0.863	rs7699064	ENSG00000225892.3	RP11-384K6.2	-3.66	0.000267	0.0146	-0.12	-0.11	Corneal astigmatism;	chr4:119507154	chr4:118632274~118634759:+
BRCA	cis	rs4742903	0.935	rs17237053	ENSG00000270332.1	SMC2-AS1	-3.66	0.000267	0.0146	-0.13	-0.11	Breast cancer;High-grade serous ovarian cancer;	chr9:104184078	chr9:104080024~104093073:-
BRCA	cis	rs17507216	0.628	rs28371837	ENSG00000259429.4	UBE2Q2P2	-3.66	0.000267	0.0146	-0.14	-0.11	Excessive daytime sleepiness;	chr15:82714435	chr15:82355142~82420075:+
BRCA	cis	rs17092148	1	rs62211612	ENSG00000202150.1	RNU6-407P	-3.66	0.000267	0.0146	-0.16	-0.11	Neuroticism;	chr20:34798353	chr20:35030317~35030420:-
BRCA	cis	rs8180040	1	rs1024037	ENSG00000280667.1	Y_RNA	-3.66	0.000267	0.0146	-0.13	-0.11	Colorectal cancer;	chr3:47276959	chr3:47501083~47501182:+
BRCA	cis	rs4819052	0.851	rs2838837	ENSG00000215447.6	BX322557.10	-3.66	0.000267	0.0146	-0.12	-0.11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45246073	chr21:45288052~45291738:+
BRCA	cis	rs13126694	0.617	rs10008900	ENSG00000251073.1	NUDT19P5	3.66	0.000267	0.0146	0.11	0.11	Blood osmolality (transformed sodium);	chr4:157948827	chr4:158182825~158183393:+
BRCA	cis	rs7615952	0.546	rs2976733	ENSG00000241288.6	RP11-379B18.5	-3.66	0.000267	0.0146	-0.14	-0.11	Blood pressure (smoking interaction);	chr3:125695294	chr3:125827238~125916384:-
BRCA	cis	rs7475343	0.573	rs61854733	ENSG00000224034.1	RP11-445P17.8	-3.66	0.000267	0.0146	-0.21	-0.11	Intelligence;	chr10:5193570	chr10:5266033~5271236:-
BRCA	cis	rs7475343	0.573	rs61854734	ENSG00000224034.1	RP11-445P17.8	-3.66	0.000267	0.0146	-0.21	-0.11	Intelligence;	chr10:5193631	chr10:5266033~5271236:-
BRCA	cis	rs875971	0.789	rs28815324	ENSG00000232559.3	GS1-124K5.12	-3.66	0.000267	0.0146	-0.15	-0.11	Aortic root size;	chr7:66100789	chr7:66554588~66576923:-
BRCA	cis	rs73201462	0.901	rs2999080	ENSG00000242551.2	POU5F1P6	-3.66	0.000267	0.0146	-0.19	-0.11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128237865	chr3:128674735~128677005:-
BRCA	cis	rs11168618	1	rs11168637	ENSG00000273765.1	RP11-370I10.11	3.66	0.000267	0.0146	0.13	0.11	Adiponectin levels;	chr12:48559721	chr12:48360920~48361377:+
BRCA	cis	rs863345	0.526	rs2051067	ENSG00000229914.1	RP11-404O13.4	-3.66	0.000268	0.0146	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158537608	chr1:158195633~158196131:-
BRCA	cis	rs55675132	0.548	rs12142149	ENSG00000226167.1	AP4B1-AS1	3.66	0.000268	0.0146	0.12	0.11	Schizophrenia;	chr1:114822024	chr1:113856635~113901237:+
BRCA	cis	rs55675132	0.548	rs12136501	ENSG00000226167.1	AP4B1-AS1	3.66	0.000268	0.0146	0.12	0.11	Schizophrenia;	chr1:114823862	chr1:113856635~113901237:+
BRCA	cis	rs2018683	0.677	rs55718000	ENSG00000233517.1	AC005162.5	-3.66	0.000268	0.0146	-0.14	-0.11	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28936008	chr7:28987028~28988899:+
BRCA	cis	rs6964587	1	rs13231578	ENSG00000188693.7	CYP51A1-AS1	-3.66	0.000268	0.0146	-0.12	-0.11	Breast cancer;	chr7:92033952	chr7:92134604~92180725:+
BRCA	cis	rs17796831	0.931	rs1449428	ENSG00000205562.2	RP11-497E19.1	-3.66	0.000268	0.0146	-0.12	-0.11	Lobe attachment (rater-scored or self-reported);	chr14:85323748	chr14:85524432~85529988:-
BRCA	cis	rs8098244	0.603	rs2960580	ENSG00000265752.2	RP11-403A21.1	3.66	0.000268	0.0146	0.12	0.11	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23712058	chr18:23957754~23982556:-
BRCA	cis	rs372883	0.901	rs733610	ENSG00000215533.7	LINC00189	-3.66	0.000268	0.0146	-0.13	-0.11	Pancreatic cancer;	chr21:29283878	chr21:29193480~29288205:+
BRCA	cis	rs10943724	1	rs10943726	ENSG00000272129.1	RP11-250B2.6	3.66	0.000268	0.0146	0.15	0.11	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr6:80594193	chr6:80355424~80356859:+
BRCA	cis	rs13256369	0.951	rs10503394	ENSG00000254153.1	CTA-398F10.2	3.66	0.000268	0.0146	0.15	0.11	Obesity-related traits;	chr8:8708265	chr8:8456909~8461337:-
BRCA	cis	rs8105895	0.932	rs28600030	ENSG00000269345.1	VN1R85P	3.66	0.000268	0.0146	0.16	0.11	Body mass index (change over time);	chr19:22085641	chr19:22174766~22175191:-
BRCA	cis	rs80226907	0.634	rs80040481	ENSG00000186615.9	KTN1-AS1	-3.66	0.000268	0.0146	-0.24	-0.11	Mean platelet volume;	chr14:55432698	chr14:55499278~55580110:-
BRCA	cis	rs1528472	0.836	rs1728878	ENSG00000276533.1	RP11-139H15.5	3.66	0.000268	0.0146	0.13	0.11	Urinary albumin-to-creatinine ratio;Urinary albumin-to-creatinine ratio in non-diabetics;	chr15:55017654	chr15:55288849~55289346:-
BRCA	cis	rs7713065	0.531	rs2522051	ENSG00000233006.5	AC034220.3	3.66	0.000268	0.0146	0.08	0.11	Lung function (FEV1/FVC);	chr5:132461886	chr5:132311285~132369916:-
BRCA	cis	rs2274273	0.967	rs2094102	ENSG00000259318.1	RP11-454L9.2	3.66	0.000268	0.0146	0.1	0.11	Protein biomarker;	chr14:55124380	chr14:55394940~55395233:-
BRCA	cis	rs950893	0.769	rs11135761	ENSG00000253483.1	CTC-756D1.1	3.66	0.000268	0.0146	0.14	0.11	Mean corpuscular hemoglobin;	chr8:23621225	chr8:23483016~23483534:-
BRCA	cis	rs35079454	1	rs35079454	ENSG00000223653.4	RP11-131L23.1	3.66	0.000268	0.0146	0.13	0.11	Lobe attachment (rater-scored or self-reported);	chr1:85315181	chr1:85276715~85448124:+
BRCA	cis	rs6918586	0.658	rs198828	ENSG00000272462.2	U91328.19	-3.66	0.000268	0.0146	-0.13	-0.11	Schizophrenia;	chr6:26119231	chr6:25992662~26001775:+
BRCA	cis	rs7647973	0.588	rs62262675	ENSG00000228008.1	CTD-2330K9.3	3.66	0.000268	0.0146	0.16	0.11	Menarche (age at onset);	chr3:49636229	chr3:49903845~49916937:+
BRCA	cis	rs6460942	0.915	rs7803051	ENSG00000226690.5	AC005281.1	3.66	0.000268	0.0146	0.17	0.11	Coronary artery disease;	chr7:12267278	chr7:12496429~12541910:+
BRCA	cis	rs6460942	0.915	rs7803056	ENSG00000226690.5	AC005281.1	3.66	0.000268	0.0146	0.17	0.11	Coronary artery disease;	chr7:12267287	chr7:12496429~12541910:+
BRCA	cis	rs2216824	1	rs78918390	ENSG00000278908.1	RP11-523J2.1	3.66	0.000268	0.0146	0.2	0.11	Oropharynx cancer;	chr2:30882902	chr2:30677762~30679895:+
BRCA	cis	rs1910358	0.554	rs2139793	ENSG00000248874.4	C5orf17	3.66	0.000268	0.0146	0.16	0.11	Venous thromboembolism (SNP x SNP interaction);	chr5:23748760	chr5:23951348~24178263:+
BRCA	cis	rs34421088	0.532	rs1369368	ENSG00000154316.13	TDH	-3.66	0.000268	0.0146	-0.15	-0.11	Neuroticism;	chr8:11292704	chr8:11339637~11368452:+
BRCA	cis	rs9739070	1	rs9739070	ENSG00000256028.2	RP11-197N18.2	3.66	0.000268	0.0146	0.12	0.11	Allergy;	chr12:123286485	chr12:122975320~122982907:+
BRCA	cis	rs3808502	0.525	rs9650661	ENSG00000255046.1	RP11-297N6.4	3.66	0.000268	0.0146	0.14	0.11	Neuroticism;	chr8:11569624	chr8:11797928~11802568:-
BRCA	cis	rs11098499	0.866	rs12501602	ENSG00000225892.3	RP11-384K6.2	3.66	0.000268	0.0146	0.11	0.11	Corneal astigmatism;	chr4:119366780	chr4:118632274~118634759:+
BRCA	cis	rs875971	0.66	rs28698552	ENSG00000272831.1	RP11-792A8.4	3.66	0.000268	0.0146	0.1	0.11	Aortic root size;	chr7:66540031	chr7:66739829~66740385:-
BRCA	cis	rs2640806	0.656	rs17781044	ENSG00000253105.4	KB-1448A5.1	-3.66	0.000268	0.0146	-0.13	-0.11	Obesity-related traits;	chr8:96326703	chr8:96371865~96387438:-
BRCA	cis	rs7620503	1	rs7645281	ENSG00000231574.4	RP11-91K9.1	3.66	0.000268	0.0146	0.13	0.11	Corneal structure;	chr3:177587048	chr3:177816865~177899224:+
BRCA	cis	rs6044112	0.718	rs73101044	ENSG00000273998.1	RP4-777L9.2	3.66	0.000268	0.0146	0.2	0.11	Response to taxane treatment (docetaxel);	chr20:16530131	chr20:16576068~16579615:+
BRCA	cis	rs4356203	0.519	rs214084	ENSG00000184669.7	OR7E14P	-3.66	0.000268	0.0146	-0.15	-0.11	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17277267	chr11:17013998~17053024:+
BRCA	cis	rs4356203	0.519	rs214083	ENSG00000184669.7	OR7E14P	-3.66	0.000268	0.0146	-0.15	-0.11	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17277312	chr11:17013998~17053024:+
BRCA	cis	rs4356203	0.519	rs214082	ENSG00000184669.7	OR7E14P	-3.66	0.000268	0.0146	-0.15	-0.11	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17277843	chr11:17013998~17053024:+
BRCA	cis	rs1876905	0.68	rs193281	ENSG00000230177.1	RP5-1112D6.4	3.66	0.000268	0.0146	0.16	0.11	Mean corpuscular hemoglobin;	chr6:111166487	chr6:111277932~111278742:+
BRCA	cis	rs3735485	0.738	rs3735489	ENSG00000201772.1	SNORA5C	3.66	0.000268	0.0146	0.15	0.11	White blood cell count;Sum basophil neutrophil counts;Neutrophil count;Granulocyte percentage of myeloid white cells;Monocyte percentage of white cells;Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Lymphocyte counts;	chr7:45065860	chr7:45104906~45105042:-
BRCA	cis	rs7412746	0.658	rs72704652	ENSG00000224800.1	RP11-235D19.2	-3.66	0.000268	0.0146	-0.14	-0.11	Melanoma;	chr1:150846994	chr1:150881236~150881683:-
BRCA	cis	rs7412746	0.622	rs72704654	ENSG00000224800.1	RP11-235D19.2	-3.66	0.000268	0.0146	-0.14	-0.11	Melanoma;	chr1:150853934	chr1:150881236~150881683:-
BRCA	cis	rs7089973	0.872	rs34064819	ENSG00000236799.1	RP11-383C6.2	-3.66	0.000268	0.0146	-0.14	-0.11	Bipolar disorder or attention deficit hyperactivity disorder;	chr10:114861395	chr10:114994657~114996593:+
BRCA	cis	rs890448	0.796	rs2912483	ENSG00000254531.1	FLJ20021	3.66	0.000268	0.0146	0.13	0.11	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101428540	chr4:101347780~101348883:+
BRCA	cis	rs890448	0.796	rs2960588	ENSG00000254531.1	FLJ20021	3.66	0.000268	0.0146	0.13	0.11	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101429307	chr4:101347780~101348883:+
BRCA	cis	rs300890	1	rs300895	ENSG00000250326.1	RP11-284M14.1	-3.66	0.000268	0.0146	-0.13	-0.11	Nasopharyngeal carcinoma;	chr4:143334685	chr4:142933195~143184861:-
BRCA	cis	rs7184046	0.797	rs13737	ENSG00000260269.4	CTD-2323K18.1	-3.66	0.000269	0.0146	-0.17	-0.11	Height;	chr15:75639788	chr15:75527150~75601205:-
BRCA	cis	rs2018683	0.523	rs1499227	ENSG00000233517.1	AC005162.5	-3.66	0.000269	0.0146	-0.14	-0.11	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28985999	chr7:28987028~28988899:+
BRCA	cis	rs5758511	0.68	rs5758698	ENSG00000231261.1	HMGN2P10	-3.66	0.000269	0.0146	-0.16	-0.11	Birth weight;	chr22:42288812	chr22:41709225~41709489:-
BRCA	cis	rs17428076	0.958	rs62183762	ENSG00000228389.1	AC068039.4	-3.66	0.000269	0.0146	-0.17	-0.11	Myopia;	chr2:171972289	chr2:171773482~171775844:+
BRCA	cis	rs4711336	0.633	rs9469583	ENSG00000224557.6	HLA-DPB2	-3.66	0.000269	0.0146	-0.13	-0.11	Height;	chr6:33749993	chr6:33112451~33129084:+
BRCA	cis	rs987724	0.927	rs6803064	ENSG00000240875.4	LINC00886	-3.66	0.000269	0.0146	-0.14	-0.11	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156960821	chr3:156747346~156817062:-
BRCA	cis	rs1823874	0.71	rs2902472	ENSG00000259363.4	CTD-2054N24.2	3.66	0.000269	0.0146	0.13	0.11	IgG glycosylation;	chr15:99824257	chr15:99807023~99877148:+
BRCA	cis	rs73242632	1	rs114513553	ENSG00000269949.1	RP11-738E22.3	3.66	0.000269	0.0146	0.26	0.11	Congenital heart disease (maternal effect);	chr4:56992292	chr4:56960927~56961373:-
BRCA	cis	rs9951698	0.66	rs12955780	ENSG00000266969.1	RP11-773H22.4	3.66	0.000269	0.0146	0.15	0.11	Intelligence (multi-trait analysis);	chr18:12982761	chr18:12984694~12991173:-
BRCA	cis	rs67981189	0.613	rs4366661	ENSG00000258571.1	PTTG4P	3.66	0.000269	0.0146	0.12	0.11	Schizophrenia;	chr14:70985599	chr14:71085482~71085833:-
BRCA	cis	rs2486012	0.85	rs2906462	ENSG00000237950.1	RP11-7O11.3	3.66	0.000269	0.0146	0.18	0.11	Intelligence (multi-trait analysis);	chr1:43866412	chr1:43944370~43946551:-
BRCA	cis	rs853679	0.517	rs3757187	ENSG00000226314.6	ZNF192P1	-3.66	0.000269	0.0146	-0.17	-0.11	Depression;	chr6:28139876	chr6:28161781~28169594:+
BRCA	cis	rs10129255	0.833	rs61997797	ENSG00000211959.2	IGHV4-39	3.66	0.000269	0.0146	0.09	0.11	Kawasaki disease;	chr14:106815190	chr14:106421711~106422218:-
BRCA	cis	rs2692947	0.666	rs10183151	ENSG00000232931.4	LINC00342	-3.66	0.000269	0.0146	-0.12	-0.11	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96109038	chr2:95807118~95816215:-
BRCA	cis	rs6973609	0.554	rs17616342	ENSG00000271122.1	RP11-379H18.1	3.66	0.000269	0.0146	0.14	0.11	Obesity-related traits;	chr7:35567112	chr7:35695214~35699413:+
BRCA	cis	rs7267979	1	rs1077889	ENSG00000276952.1	RP5-965G21.6	3.66	0.000269	0.0146	0.14	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25287257	chr20:25284915~25285588:-
BRCA	cis	rs2274273	0.624	rs11848575	ENSG00000259318.1	RP11-454L9.2	3.66	0.000269	0.0146	0.1	0.11	Protein biomarker;	chr14:55289070	chr14:55394940~55395233:-
BRCA	cis	rs7824557	0.736	rs35392635	ENSG00000154316.13	TDH	-3.66	0.000269	0.0146	-0.16	-0.11	Retinal vascular caliber;	chr8:11306840	chr8:11339637~11368452:+
BRCA	cis	rs6102185	0.572	rs6129698	ENSG00000229771.2	RP4-644L1.2	-3.66	0.000269	0.0146	-0.14	-0.11	IgG glycosylation;	chr20:40889786	chr20:40696499~40698616:-
BRCA	cis	rs2439831	0.618	rs8023508	ENSG00000206991.1	RNU6-610P	3.66	0.000269	0.0146	0.16	0.11	Lung cancer in ever smokers;	chr15:43883905	chr15:43637632~43637738:-
BRCA	cis	rs6918586	0.658	rs198829	ENSG00000272462.2	U91328.19	-3.66	0.000269	0.0147	-0.13	-0.11	Schizophrenia;	chr6:26118665	chr6:25992662~26001775:+
BRCA	cis	rs1670533	1	rs62294756	ENSG00000251639.2	RP11-20I20.1	-3.66	0.000269	0.0147	-0.18	-0.11	Recombination rate (females);	chr4:1103888	chr4:1100016~1101558:-
BRCA	cis	rs56281245	0.793	rs6879415	ENSG00000249363.1	CTB-78O21.1	3.66	0.000269	0.0147	0.23	0.11	Hepcidin levels;	chr5:145589306	chr5:145728360~145729349:-
BRCA	cis	rs11098499	0.863	rs1552092	ENSG00000260404.2	RP11-384K6.6	3.66	0.000269	0.0147	0.11	0.11	Corneal astigmatism;	chr4:119567341	chr4:118591773~118633729:+
BRCA	cis	rs12949688	0.967	rs12950062	ENSG00000262623.1	RP5-1107A17.2	-3.66	0.000269	0.0147	-0.12	-0.11	Schizophrenia;	chr17:57748173	chr17:56951664~56952404:+
BRCA	cis	rs4664293	0.967	rs10176436	ENSG00000224152.1	AC009506.1	-3.66	0.000269	0.0147	-0.12	-0.11	Monocyte percentage of white cells;	chr2:159658883	chr2:159615296~159617082:+
BRCA	cis	rs4664293	0.967	rs7559127	ENSG00000224152.1	AC009506.1	-3.66	0.000269	0.0147	-0.12	-0.11	Monocyte percentage of white cells;	chr2:159659424	chr2:159615296~159617082:+
BRCA	cis	rs1552244	0.572	rs17032440	ENSG00000269894.1	RP11-1020A11.1	3.66	0.000269	0.0147	0.15	0.11	Alzheimer's disease;	chr3:10128135	chr3:9935706~9936258:+
BRCA	cis	rs3755605	0.728	rs6444902	ENSG00000242578.1	RP11-469J4.3	3.66	0.000269	0.0147	0.13	0.11	Testicular germ cell tumor;	chr3:170177230	chr3:170410512~170418615:+
BRCA	cis	rs2346177	0.846	rs62138876	ENSG00000279254.1	RP11-536C12.1	-3.66	0.000269	0.0147	-0.13	-0.11	HDL cholesterol;	chr2:46423533	chr2:46668870~46670778:+
BRCA	cis	rs4845570	1	rs11585294	ENSG00000203288.3	RP11-98D18.9	-3.66	0.000269	0.0147	-0.21	-0.11	Coronary artery disease;	chr1:151797411	chr1:151790804~151794402:+
BRCA	cis	rs875971	0.522	rs781144	ENSG00000223473.2	GS1-124K5.3	3.66	0.000269	0.0147	0.09	0.11	Aortic root size;	chr7:65975357	chr7:66491049~66493566:-
BRCA	cis	rs6028335	0.61	rs72623594	ENSG00000274825.1	RP4-616B8.5	-3.66	0.000269	0.0147	-0.14	-0.11	Alcohol and nicotine co-dependence;	chr20:38947612	chr20:38955910~38956547:+
BRCA	cis	rs6545883	0.783	rs7579651	ENSG00000270820.4	RP11-355B11.2	3.66	0.000269	0.0147	0.13	0.11	Tuberculosis;	chr2:61573144	chr2:61471188~61484130:+
BRCA	cis	rs56281245	0.793	rs116021505	ENSG00000249363.1	CTB-78O21.1	3.66	0.000269	0.0147	0.24	0.11	Hepcidin levels;	chr5:145584858	chr5:145728360~145729349:-
BRCA	cis	rs4759375	1	rs10773005	ENSG00000235423.7	RP11-282O18.3	3.66	0.000269	0.0147	0.19	0.11	HDL cholesterol;	chr12:123305460	chr12:123252030~123261483:-
BRCA	cis	rs10849893	0.595	rs6489811	ENSG00000212694.7	LINC01089	-3.66	0.000269	0.0147	-0.09	-0.11	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr12:121455823	chr12:121795267~121803906:-
BRCA	cis	rs13082711	0.595	rs4973762	ENSG00000230807.1	AC099535.4	-3.66	0.000269	0.0147	-0.19	-0.11	Blood pressure;Systolic blood pressure;Diastolic blood pressure;	chr3:27323298	chr3:27486247~27486617:+
BRCA	cis	rs7429990	0.932	rs7620736	ENSG00000228638.1	FCF1P2	3.66	0.00027	0.0147	0.11	0.11	Educational attainment (years of education);	chr3:48068479	chr3:48290793~48291375:-
BRCA	cis	rs12681366	0.708	rs2515165	ENSG00000253175.1	RP11-267M23.6	-3.66	0.00027	0.0147	-0.12	-0.11	Nonsyndromic cleft lip with cleft palate;	chr8:94352616	chr8:94565036~94565715:+
BRCA	cis	rs2348114	0.609	rs7584595	ENSG00000243478.6	AOX2P	-3.66	0.00027	0.0147	-0.16	-0.11	Intelligence;	chr2:200727928	chr2:200695917~200794239:+
BRCA	cis	rs757978	0.777	rs11693232	ENSG00000223374.1	AC005104.3	3.66	0.00027	0.0147	0.15	0.11	Chronic lymphocytic leukemia;	chr2:241422825	chr2:241351340~241353104:-
BRCA	cis	rs748404	0.666	rs60018990	ENSG00000166763.7	STRCP1	3.66	0.00027	0.0147	0.16	0.11	Lung cancer;	chr15:43504606	chr15:43699488~43718184:-
BRCA	cis	rs2562456	0.917	rs2562466	ENSG00000240522.1	RPL7AP10	3.66	0.00027	0.0147	0.12	0.11	Pain;	chr19:21531402	chr19:21149648~21150438:-
BRCA	cis	rs2425143	0.908	rs6120998	ENSG00000088340.14	FER1L4	-3.66	0.00027	0.0147	-0.15	-0.11	Blood protein levels;	chr20:35599391	chr20:35558737~35607562:-
BRCA	cis	rs62025270	0.632	rs17571078	ENSG00000259367.1	RP11-815J21.4	3.66	0.00027	0.0147	0.11	0.11	Idiopathic pulmonary fibrosis;	chr15:85597248	chr15:85619623~85670948:-
BRCA	cis	rs3892630	0.588	rs12610342	ENSG00000267475.1	CTD-2538C1.2	-3.66	0.00027	0.0147	-0.16	-0.11	Red blood cell traits;	chr19:32759784	chr19:32687089~32691750:-
BRCA	cis	rs2281603	0.951	rs1453004	ENSG00000259116.1	RP11-973N13.4	-3.66	0.00027	0.0147	-0.11	-0.11	Lymphocyte counts;	chr14:64530237	chr14:64514154~64540368:-
BRCA	cis	rs10456847	0.806	rs9383467	ENSG00000229700.1	RP1-130G2.1	3.66	0.00027	0.0147	0.13	0.11	Chronic periodontitis (mean interproximal clinical attachment level);	chr6:19133944	chr6:20042455~20042940:-
BRCA	cis	rs17228178	0.961	rs7172386	ENSG00000270055.1	CTD-3092A11.2	-3.66	0.00027	0.0147	-0.14	-0.11	Facial depth;Facial morphology (factor 1, breadth of lateral portion of upper face);	chr15:31175149	chr15:30487963~30490313:+
BRCA	cis	rs4713118	0.619	rs200486	ENSG00000216901.1	AL022393.7	3.66	0.00027	0.0147	0.18	0.11	Parkinson's disease;	chr6:27811728	chr6:28176188~28176674:+
BRCA	cis	rs80226907	0.634	rs41437744	ENSG00000186615.9	KTN1-AS1	3.66	0.00027	0.0147	0.24	0.11	Mean platelet volume;	chr14:55441587	chr14:55499278~55580110:-
BRCA	cis	rs6545883	0.759	rs777585	ENSG00000273302.1	RP11-493E12.2	-3.66	0.00027	0.0147	-0.1	-0.11	Tuberculosis;	chr2:61185424	chr2:61199979~61200769:+
BRCA	cis	rs7680126	0.5	rs4697935	ENSG00000250413.1	RP11-448G15.1	3.66	0.00027	0.0147	0.19	0.11	Urate levels in obese individuals;Urate levels in lean individuals;Urate levels in overweight individuals;	chr4:10147969	chr4:10006482~10009725:+
BRCA	cis	rs7680126	0.5	rs4697717	ENSG00000250413.1	RP11-448G15.1	3.66	0.00027	0.0147	0.19	0.11	Urate levels in obese individuals;Urate levels in lean individuals;Urate levels in overweight individuals;	chr4:10148160	chr4:10006482~10009725:+
BRCA	cis	rs11039100	0.681	rs11039170	ENSG00000224295.2	AC087380.14	3.66	0.00027	0.0147	0.22	0.11	Peripheral arterial disease (traffic-related air pollution interaction);	chr11:5823957	chr11:5518441~5524955:-
BRCA	cis	rs2919009	0.537	rs11199606	ENSG00000271670.1	RP11-95I16.4	3.66	0.00027	0.0147	0.13	0.11	Obesity-related traits;	chr10:120866005	chr10:120879256~120880667:-
BRCA	cis	rs875971	0.545	rs1267814	ENSG00000273448.1	RP11-166O4.6	-3.65	0.00027	0.0147	-0.12	-0.11	Aortic root size;	chr7:66579422	chr7:67333047~67334383:+
BRCA	cis	rs7267979	0.932	rs433352	ENSG00000277938.1	RP5-965G21.3	-3.65	0.00027	0.0147	-0.13	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25487356	chr20:25229150~25231933:+
BRCA	cis	rs4879656	0.593	rs10971307	ENSG00000236184.1	TCEA1P4	-3.65	0.00027	0.0147	-0.15	-0.11	Menopause (age at onset);	chr9:33009726	chr9:32979560~32980403:-
BRCA	cis	rs4879656	0.569	rs10971308	ENSG00000236184.1	TCEA1P4	-3.65	0.00027	0.0147	-0.15	-0.11	Menopause (age at onset);	chr9:33009727	chr9:32979560~32980403:-
BRCA	cis	rs952623	0.501	rs12671046	ENSG00000227191.5	TRGC2	-3.65	0.00027	0.0147	-0.11	-0.11	Intelligence (multi-trait analysis);	chr7:39042266	chr7:38239580~38368091:-
BRCA	cis	rs6964587	0.869	rs11769294	ENSG00000188693.7	CYP51A1-AS1	-3.65	0.00027	0.0147	-0.12	-0.11	Breast cancer;	chr7:91920623	chr7:92134604~92180725:+
BRCA	cis	rs13434995	0.513	rs67963898	ENSG00000249700.7	SRD5A3-AS1	-3.65	0.00027	0.0147	-0.16	-0.11	Adiponectin levels;	chr4:55475520	chr4:55363971~55395847:-
BRCA	cis	rs9863	0.861	rs9971695	ENSG00000256596.1	RP11-522N14.2	3.65	0.00027	0.0147	0.15	0.11	White blood cell count;	chr12:123928944	chr12:124206228~124209018:+
BRCA	cis	rs10043228	1	rs7727882	ENSG00000250015.1	CTC-339F2.2	3.65	0.00027	0.0147	0.14	0.11	Asthma or chronic obstructive pulmonary disease;	chr5:116278810	chr5:116302354~116304134:-
BRCA	cis	rs4834770	0.668	rs10007409	ENSG00000248280.1	RP11-33B1.2	-3.65	0.00027	0.0147	-0.11	-0.11	Blood protein levels;	chr4:119221151	chr4:119440561~119450157:-
BRCA	cis	rs7267979	0.966	rs2227890	ENSG00000274414.1	RP5-965G21.4	-3.65	0.00027	0.0147	-0.13	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25280295	chr20:25239007~25245229:-
BRCA	cis	rs36051895	0.623	rs7847811	ENSG00000237711.1	RP11-39K24.13	-3.65	0.00027	0.0147	-0.14	-0.11	Pediatric autoimmune diseases;	chr9:5237081	chr9:5100236~5101009:+
BRCA	cis	rs12411860	1	rs12569936	ENSG00000226200.5	SGMS1-AS1	-3.65	0.00027	0.0147	-0.11	-0.11	Blood protein levels;	chr10:50274612	chr10:50624951~50641451:+
BRCA	cis	rs5167	0.75	rs3786505	ENSG00000214855.8	APOC1P1	3.65	0.00027	0.0147	0.14	0.11	Blood protein levels;	chr19:44987312	chr19:44926804~44931386:+
BRCA	cis	rs13401620	0.797	rs3738973	ENSG00000229326.3	AC069154.4	3.65	0.00027	0.0147	0.15	0.11	Breast size;	chr2:119981660	chr2:119698623~119700151:+
BRCA	cis	rs1007738	0.507	rs4752969	ENSG00000200376.1	RNU5E-10P	-3.65	0.00027	0.0147	-0.15	-0.11	Bone mineral density (hip);	chr11:47163959	chr11:47576471~47576588:-
BRCA	cis	rs875971	0.638	rs6460305	ENSG00000272831.1	RP11-792A8.4	-3.65	0.00027	0.0147	-0.1	-0.11	Aortic root size;	chr7:66595421	chr7:66739829~66740385:-
BRCA	cis	rs60843830	0.517	rs58416198	ENSG00000272342.1	RP13-539J13.1	3.65	0.00027	0.0147	0.16	0.11	Spherical equivalent (joint analysis main effects and education interaction);	chr2:175580	chr2:739588~740164:-
BRCA	cis	rs2346177	0.875	rs4413204	ENSG00000279254.1	RP11-536C12.1	-3.65	0.00027	0.0147	-0.13	-0.11	HDL cholesterol;	chr2:46419953	chr2:46668870~46670778:+
BRCA	cis	rs17756712	0.725	rs17135679	ENSG00000272463.1	RP11-532F6.3	3.65	0.00027	0.0147	0.19	0.11	Vertical cup-disc ratio;	chr6:614787	chr6:708592~711405:-
BRCA	cis	rs1949733	1	rs2688233	ENSG00000251615.3	RP11-774O3.3	-3.65	0.00027	0.0147	-0.12	-0.11	Response to antineoplastic agents;	chr4:8490158	chr4:8355090~8358338:-
BRCA	cis	rs7020830	0.928	rs11544336	ENSG00000230188.1	RP11-405L18.4	-3.65	0.00027	0.0147	-0.14	-0.11	Schizophrenia;	chr9:37089153	chr9:37490421~37490893:-
BRCA	cis	rs17684571	0.751	rs16888184	ENSG00000231441.1	RP11-472M19.2	3.65	0.00027	0.0147	0.17	0.11	Schizophrenia;	chr6:56861347	chr6:56844002~56864078:+
BRCA	cis	rs7267979	1	rs6050590	ENSG00000204556.4	CTD-2514C3.1	3.65	0.00027	0.0147	0.15	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25404358	chr20:26018832~26020684:+
BRCA	cis	rs7267979	1	rs4813566	ENSG00000204556.4	CTD-2514C3.1	3.65	0.00027	0.0147	0.15	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25405829	chr20:26018832~26020684:+
BRCA	cis	rs7267979	1	rs4815421	ENSG00000204556.4	CTD-2514C3.1	3.65	0.00027	0.0147	0.15	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25405873	chr20:26018832~26020684:+
BRCA	cis	rs9921338	0.961	rs56136462	ENSG00000263080.1	RP11-485G7.5	3.65	0.00027	0.0147	0.17	0.11	Vein graft stenosis in coronary artery bypass grafting;	chr16:11321738	chr16:11341809~11345211:-
BRCA	cis	rs17684571	0.808	rs6938003	ENSG00000231441.1	RP11-472M19.2	3.65	0.00027	0.0147	0.17	0.11	Schizophrenia;	chr6:56753365	chr6:56844002~56864078:+
BRCA	cis	rs801193	0.591	rs9986881	ENSG00000230295.1	RP11-458F8.2	3.65	0.00027	0.0147	0.1	0.11	Aortic root size;	chr7:66708053	chr7:66880708~66882981:+
BRCA	cis	rs75422866	0.867	rs7303895	ENSG00000276691.1	RP5-1057I20.5	3.65	0.00027	0.0147	0.21	0.11	Pneumonia;	chr12:47683290	chr12:47788426~47788971:+
BRCA	cis	rs34792	0.528	rs153800	ENSG00000207425.1	Y_RNA	3.65	0.000271	0.0147	0.12	0.11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15455900	chr16:14915457~14915556:-
BRCA	cis	rs700651	0.789	rs2196176	ENSG00000231621.1	AC013264.2	-3.65	0.000271	0.0147	-0.11	-0.11	Intracranial aneurysm;	chr2:198040190	chr2:197197991~197199273:+
BRCA	cis	rs4819052	0.851	rs2838844	ENSG00000215447.6	BX322557.10	-3.65	0.000271	0.0147	-0.12	-0.11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250818	chr21:45288052~45291738:+
BRCA	cis	rs251253	0.795	rs251232	ENSG00000253959.1	CTB-43E15.1	3.65	0.000271	0.0147	0.1	0.11	PR interval;	chr5:173125399	chr5:173642519~173658194:+
BRCA	cis	rs61931739	0.5	rs7309421	ENSG00000258794.3	DUX4L27	3.65	0.000271	0.0147	0.16	0.11	Morning vs. evening chronotype;	chr12:34400860	chr12:34208415~34209675:-
BRCA	cis	rs6088580	0.524	rs6142210	ENSG00000279253.1	RP4-614O4.13	3.65	0.000271	0.0147	0.13	0.11	Glomerular filtration rate (creatinine);	chr20:34635208	chr20:35262727~35264187:-
BRCA	cis	rs4950322	0.57	rs11800580	ENSG00000227242.3	NBPF13P	3.65	0.000271	0.0147	0.15	0.11	Protein quantitative trait loci;	chr1:147261053	chr1:147021320~147124525:-
BRCA	cis	rs2562456	0.874	rs9304986	ENSG00000268555.1	RP11-678G14.3	-3.65	0.000271	0.0147	-0.15	-0.11	Pain;	chr19:21499260	chr19:21570822~21587322:-
BRCA	cis	rs4908769	0.66	rs159961	ENSG00000270282.1	RP5-1115A15.2	3.65	0.000271	0.0147	0.13	0.11	Allergy;	chr1:8424168	chr1:8512653~8513021:+
BRCA	cis	rs6919210	0.95	rs6940876	ENSG00000271967.1	RP11-134K13.4	-3.65	0.000271	0.0147	-0.16	-0.11	Subjective well-being;	chr6:69888162	chr6:70596438~70596980:+
BRCA	cis	rs80226907	0.57	rs76278827	ENSG00000186615.9	KTN1-AS1	-3.65	0.000271	0.0147	-0.22	-0.11	Mean platelet volume;	chr14:55441289	chr14:55499278~55580110:-
BRCA	cis	rs4415084	1	rs12522626	ENSG00000248464.1	FGF10-AS1	3.65	0.000271	0.0147	0.13	0.11	Breast cancer;	chr5:44685596	chr5:44388732~44413989:+
BRCA	cis	rs4950322	0.57	rs113498894	ENSG00000227242.3	NBPF13P	-3.65	0.000271	0.0147	-0.16	-0.11	Protein quantitative trait loci;	chr1:147318880	chr1:147021320~147124525:-
BRCA	cis	rs72819225	0.616	rs7908831	ENSG00000228701.1	TNKS2-AS1	3.65	0.000271	0.0147	0.14	0.11	Yeast infection;	chr10:91571370	chr10:91782839~91798291:-
BRCA	cis	rs739496	0.579	rs75080921	ENSG00000257624.1	RP1-128M12.3	3.65	0.000271	0.0147	0.15	0.11	Platelet count;	chr12:111861168	chr12:112000739~112000985:-
BRCA	cis	rs4713118	0.868	rs35069907	ENSG00000280107.1	AL022393.9	-3.65	0.000271	0.0147	-0.17	-0.11	Parkinson's disease;	chr6:27778913	chr6:28170845~28172521:+
BRCA	cis	rs12530845	0.887	rs6948382	ENSG00000223718.3	AC093107.7	3.65	0.000271	0.0147	0.19	0.11	Red blood cell traits;	chr7:135638828	chr7:135660039~135660647:+
BRCA	cis	rs7620503	0.959	rs2863015	ENSG00000231574.4	RP11-91K9.1	3.65	0.000271	0.0147	0.12	0.11	Corneal structure;	chr3:177585391	chr3:177816865~177899224:+
BRCA	cis	rs6743068	0.709	rs9288316	ENSG00000232719.1	RP11-13J8.1	3.65	0.000271	0.0147	0.12	0.11	Lymphocyte percentage of white cells;	chr2:201298760	chr2:201101382~201103136:+
BRCA	cis	rs6812193	0.518	rs7664593	ENSG00000271676.1	RP11-1E1.2	3.65	0.000271	0.0147	0.16	0.11	Parkinson's disease;	chr4:76266763	chr4:77112495~77113458:-
BRCA	cis	rs11098499	0.863	rs2306456	ENSG00000260404.2	RP11-384K6.6	3.65	0.000271	0.0147	0.11	0.11	Corneal astigmatism;	chr4:119551267	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.863	rs11947234	ENSG00000260404.2	RP11-384K6.6	3.65	0.000271	0.0147	0.11	0.11	Corneal astigmatism;	chr4:119553704	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.863	rs11933966	ENSG00000260404.2	RP11-384K6.6	3.65	0.000271	0.0147	0.11	0.11	Corneal astigmatism;	chr4:119555560	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.863	rs36040693	ENSG00000260404.2	RP11-384K6.6	3.65	0.000271	0.0147	0.11	0.11	Corneal astigmatism;	chr4:119556461	chr4:118591773~118633729:+
BRCA	cis	rs3755397	1	rs3755397	ENSG00000223374.1	AC005104.3	3.65	0.000271	0.0147	0.18	0.11	Sum eosinophil basophil counts;Eosinophil percentage of white cells;Chronic lymphocytic leukemia;Eosinophil percentage of granulocytes;Eosinophil counts;Neutrophil percentage of granulocytes;	chr2:241355498	chr2:241351340~241353104:-
BRCA	cis	rs6490294	0.571	rs73421065	ENSG00000257624.1	RP1-128M12.3	3.65	0.000271	0.0147	0.18	0.11	Mean platelet volume;	chr12:112121575	chr12:112000739~112000985:-
BRCA	cis	rs6490294	0.528	rs58047810	ENSG00000257624.1	RP1-128M12.3	3.65	0.000271	0.0147	0.18	0.11	Mean platelet volume;	chr12:112124682	chr12:112000739~112000985:-
BRCA	cis	rs1730008	0.835	rs1095630	ENSG00000279311.1	RP11-170K4.2	-3.65	0.000271	0.0147	-0.12	-0.11	Lobe attachment (rater-scored or self-reported);	chr3:158243163	chr3:158869898~158871821:+
BRCA	cis	rs7267979	0.934	rs2261753	ENSG00000274414.1	RP5-965G21.4	-3.65	0.000271	0.0147	-0.13	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25281655	chr20:25239007~25245229:-
BRCA	cis	rs7523050	0.73	rs72984628	ENSG00000203897.3	SPATA42	-3.65	0.000271	0.0148	-0.21	-0.11	Fat distribution (HIV);	chr1:108918186	chr1:108857217~108858524:+
BRCA	cis	rs6762	0.719	rs28655651	ENSG00000255142.1	AP006621.6	3.65	0.000271	0.0148	0.1	0.11	Mean platelet volume;	chr11:837121	chr11:781645~782105:+
BRCA	cis	rs7620503	0.506	rs2242401	ENSG00000231574.4	RP11-91K9.1	3.65	0.000271	0.0148	0.14	0.11	Corneal structure;	chr3:177620492	chr3:177816865~177899224:+
BRCA	cis	rs7267979	1	rs10966	ENSG00000276952.1	RP5-965G21.6	3.65	0.000271	0.0148	0.14	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25302308	chr20:25284915~25285588:-
BRCA	cis	rs1722141	0.601	rs809299	ENSG00000237471.1	AC073115.6	3.65	0.000271	0.0148	0.15	0.11	Sitting height ratio;	chr7:46015660	chr7:45969657~45980191:+
BRCA	cis	rs2274273	0.87	rs59629906	ENSG00000259318.1	RP11-454L9.2	3.65	0.000271	0.0148	0.1	0.11	Protein biomarker;	chr14:55314471	chr14:55394940~55395233:-
BRCA	cis	rs875971	0.862	rs9791712	ENSG00000223473.2	GS1-124K5.3	-3.65	0.000271	0.0148	-0.09	-0.11	Aortic root size;	chr7:66640176	chr7:66491049~66493566:-
BRCA	cis	rs875971	0.862	rs9791713	ENSG00000223473.2	GS1-124K5.3	-3.65	0.000271	0.0148	-0.09	-0.11	Aortic root size;	chr7:66640211	chr7:66491049~66493566:-
BRCA	cis	rs703842	0.585	rs10877022	ENSG00000257159.1	RP11-58A17.3	3.65	0.000272	0.0148	0.14	0.11	Multiple sclerosis;	chr12:57830154	chr12:57967058~57968399:+
BRCA	cis	rs9470794	1	rs11753122	ENSG00000204110.6	RP1-153P14.8	-3.65	0.000272	0.0148	-0.23	-0.11	Type 2 diabetes;	chr6:38011284	chr6:37507348~37535616:+
BRCA	cis	rs9470794	1	rs73421483	ENSG00000204110.6	RP1-153P14.8	-3.65	0.000272	0.0148	-0.23	-0.11	Type 2 diabetes;	chr6:38012140	chr6:37507348~37535616:+
BRCA	cis	rs9470794	1	rs73417963	ENSG00000204110.6	RP1-153P14.8	-3.65	0.000272	0.0148	-0.23	-0.11	Type 2 diabetes;	chr6:38013403	chr6:37507348~37535616:+
BRCA	cis	rs6840360	0.55	rs62327267	ENSG00000270265.1	RP11-731D1.4	-3.65	0.000272	0.0148	-0.13	-0.11	Intelligence (multi-trait analysis);	chr4:151597601	chr4:151333775~151353224:-
BRCA	cis	rs6840360	0.571	rs28454076	ENSG00000270265.1	RP11-731D1.4	-3.65	0.000272	0.0148	-0.13	-0.11	Intelligence (multi-trait analysis);	chr4:151598931	chr4:151333775~151353224:-
BRCA	cis	rs10056811	0.538	rs4703645	ENSG00000271815.1	CTD-2235C13.3	-3.65	0.000272	0.0148	-0.2	-0.11	Coronary artery disease;	chr5:75065315	chr5:75363760~75364242:+
BRCA	cis	rs6696239	0.868	rs74579475	ENSG00000215812.5	ZNF847P	3.65	0.000272	0.0148	0.16	0.11	Height;	chr1:227551606	chr1:227696892~227706699:-
BRCA	cis	rs12324805	0.568	rs7176867	ENSG00000255769.6	GOLGA2P10	-3.65	0.000272	0.0148	-0.13	-0.11	Body mass index;	chr15:82030688	chr15:82472993~82513950:-
BRCA	cis	rs13118159	0.55	rs2878607	ENSG00000273179.1	RP11-20I20.4	3.65	0.000272	0.0148	0.12	0.11	Longevity;	chr4:1359522	chr4:1167778~1168174:+
BRCA	cis	rs6490294	0.571	rs11066118	ENSG00000257624.1	RP1-128M12.3	3.65	0.000272	0.0148	0.18	0.11	Mean platelet volume;	chr12:111996348	chr12:112000739~112000985:-
BRCA	cis	rs7795541	0.683	rs104986	ENSG00000230658.1	KLHL7-AS1	3.65	0.000272	0.0148	0.15	0.11	Morning vs. evening chronotype;	chr7:24057354	chr7:23101228~23105703:-
BRCA	cis	rs875971	0.83	rs4718358	ENSG00000273448.1	RP11-166O4.6	3.65	0.000272	0.0148	0.1	0.11	Aortic root size;	chr7:66508681	chr7:67333047~67334383:+
BRCA	cis	rs957448	1	rs56716157	ENSG00000261437.1	RP11-22C11.2	3.65	0.000272	0.0148	0.13	0.11	Nonsyndromic cleft lip with cleft palate;	chr8:94530644	chr8:94637285~94639467:-
BRCA	cis	rs10761482	0.861	rs4520549	ENSG00000254271.1	RP11-131N11.4	3.65	0.000272	0.0148	0.16	0.11	Schizophrenia;	chr10:60344758	chr10:60734342~60741828:+
BRCA	cis	rs10895275	0.961	rs7122907	ENSG00000277459.1	RP11-732A21.3	3.65	0.000272	0.0148	0.12	0.11	Migraine;	chr11:102215051	chr11:102109827~102110457:-
BRCA	cis	rs4449834	0.816	rs7843033	ENSG00000254432.1	RP11-33I11.2	-3.65	0.000272	0.0148	-0.14	-0.11	Sum eosinophil basophil counts;	chr8:60759956	chr8:60808735~60809606:-
BRCA	cis	rs8040855	0.579	rs28521166	ENSG00000230373.7	GOLGA6L5P	-3.65	0.000272	0.0148	-0.12	-0.11	Bulimia nervosa;	chr15:85184801	chr15:84507885~84516814:-
BRCA	cis	rs524281	0.773	rs2298468	ENSG00000255038.1	RP11-1167A19.2	-3.65	0.000272	0.0148	-0.18	-0.11	Electroencephalogram traits;	chr11:66275491	chr11:66067277~66069619:-
BRCA	cis	rs12786942	0.8	rs11224805	ENSG00000254506.1	RP11-748H22.1	3.65	0.000272	0.0148	0.19	0.11	Facial depth;	chr11:101502783	chr11:101584295~101595156:+
BRCA	cis	rs516805	0.528	rs2684241	ENSG00000279453.1	RP3-425C14.4	-3.65	0.000272	0.0148	-0.16	-0.11	Lymphocyte counts;	chr6:122089903	chr6:122436789~122439223:-
BRCA	cis	rs11098499	0.874	rs6832670	ENSG00000260404.2	RP11-384K6.6	3.65	0.000272	0.0148	0.11	0.11	Corneal astigmatism;	chr4:119197637	chr4:118591773~118633729:+
BRCA	cis	rs9863	0.827	rs4930706	ENSG00000256596.1	RP11-522N14.2	3.65	0.000272	0.0148	0.15	0.11	White blood cell count;	chr12:123932791	chr12:124206228~124209018:+
BRCA	cis	rs875971	0.862	rs7783779	ENSG00000271064.1	RP11-792A8.3	3.65	0.000272	0.0148	0.13	0.11	Aortic root size;	chr7:66331639	chr7:66748838~66749077:-
BRCA	cis	rs7176093	0.874	rs7172359	ENSG00000259295.5	CSPG4P12	-3.65	0.000272	0.0148	-0.14	-0.11	Aging traits;	chr15:85803916	chr15:85191438~85213905:+
BRCA	cis	rs3796352	0.571	rs71301816	ENSG00000242142.1	SERBP1P3	-3.65	0.000272	0.0148	-0.21	-0.11	Immune reponse to smallpox (secreted IL-2);	chr3:53108055	chr3:53064283~53065091:-
BRCA	cis	rs28530618	0.58	rs11167174	ENSG00000198547.7	C20orf203	-3.65	0.000272	0.0148	-0.13	-0.11	Birth weight;	chr20:32661077	chr20:32631652~32673941:-
BRCA	cis	rs10829156	1	rs10829157	ENSG00000225527.1	RP11-383B4.4	-3.65	0.000272	0.0148	-0.16	-0.11	Sudden cardiac arrest;	chr10:18662534	chr10:18531849~18533336:-
BRCA	cis	rs4372836	0.754	rs6709674	ENSG00000226833.4	AC097724.3	3.65	0.000272	0.0148	0.13	0.11	Body mass index;	chr2:28766801	chr2:28708953~28736205:-
BRCA	cis	rs9402743	0.632	rs9399166	ENSG00000231028.7	LINC00271	-3.65	0.000272	0.0148	-0.12	-0.11	Systemic lupus erythematosus;	chr6:135776762	chr6:135497801~135716055:+
BRCA	cis	rs9564692	0.577	rs3736861	ENSG00000229427.1	ANKRD26P4	3.65	0.000272	0.0148	0.13	0.11	Advanced age-related macular degeneration;	chr13:31151237	chr13:31311289~31312921:+
BRCA	cis	rs12999542	1	rs13014644	ENSG00000234389.1	AC007278.3	3.65	0.000272	0.0148	0.16	0.11	Serum protein levels (sST2);	chr2:102354903	chr2:102438713~102440475:+
BRCA	cis	rs4835473	0.808	rs1984810	ENSG00000246448.2	RP13-578N3.3	3.65	0.000272	0.0148	0.13	0.11	Immature fraction of reticulocytes;	chr4:143824970	chr4:143700257~143865072:+
BRCA	cis	rs1730008	0.691	rs11717923	ENSG00000279311.1	RP11-170K4.2	3.65	0.000272	0.0148	0.14	0.11	Lobe attachment (rater-scored or self-reported);	chr3:158359738	chr3:158869898~158871821:+
BRCA	cis	rs801193	0.548	rs6975044	ENSG00000265600.1	AC006480.1	-3.65	0.000272	0.0148	-0.13	-0.11	Aortic root size;	chr7:66762495	chr7:67356680~67356779:+
BRCA	cis	rs172166	0.694	rs2791332	ENSG00000219891.2	ZSCAN12P1	3.65	0.000272	0.0148	0.14	0.11	Cardiac Troponin-T levels;	chr6:28141010	chr6:28091154~28093664:+
BRCA	cis	rs728616	0.867	rs34870056	ENSG00000242600.5	MBL1P	3.65	0.000272	0.0148	0.27	0.11	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80188299	chr10:79904898~79950336:+
BRCA	cis	rs7781557	1	rs12113073	ENSG00000239969.4	RP11-163E9.2	-3.65	0.000272	0.0148	-0.18	-0.11	Colorectal adenoma (advanced);	chr7:102842080	chr7:102364162~102380633:+
BRCA	cis	rs4699052	0.927	rs1870888	ENSG00000251288.2	RP11-10L12.2	-3.65	0.000272	0.0148	-0.13	-0.11	Testicular germ cell tumor;	chr4:103248169	chr4:102751401~102752641:+
BRCA	cis	rs12368653	0.666	rs799265	ENSG00000257159.1	RP11-58A17.3	-3.65	0.000272	0.0148	-0.13	-0.11	Multiple sclerosis;	chr12:57718406	chr12:57967058~57968399:+
BRCA	cis	rs7781266	0.79	rs4728284	ENSG00000226205.1	AC007790.4	3.65	0.000272	0.0148	0.17	0.11	Educational attainment (college completion);	chr7:133417541	chr7:133732493~133733595:-
BRCA	cis	rs73242632	1	rs73242625	ENSG00000269949.1	RP11-738E22.3	3.65	0.000272	0.0148	0.26	0.11	Congenital heart disease (maternal effect);	chr4:56990173	chr4:56960927~56961373:-
BRCA	cis	rs561341	1	rs550264	ENSG00000265798.5	RP11-271K11.5	3.65	0.000272	0.0148	0.19	0.11	Hip circumference adjusted for BMI;	chr17:31990521	chr17:31038575~31059121:-
BRCA	cis	rs561341	1	rs111454793	ENSG00000265798.5	RP11-271K11.5	3.65	0.000272	0.0148	0.19	0.11	Hip circumference adjusted for BMI;	chr17:31992248	chr17:31038575~31059121:-
BRCA	cis	rs561341	1	rs527256	ENSG00000265798.5	RP11-271K11.5	3.65	0.000272	0.0148	0.19	0.11	Hip circumference adjusted for BMI;	chr17:31994274	chr17:31038575~31059121:-
BRCA	cis	rs561341	1	rs473356	ENSG00000265798.5	RP11-271K11.5	3.65	0.000272	0.0148	0.19	0.11	Hip circumference adjusted for BMI;	chr17:31994743	chr17:31038575~31059121:-
BRCA	cis	rs3213961	0.744	rs6746691	ENSG00000187999.4	HNRNPA1P61	-3.65	0.000272	0.0148	-0.15	-0.11	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:33589264	chr2:33636502~33637425:+
BRCA	cis	rs11662586	1	rs12605316	ENSG00000267270.4	PARD6G-AS1	-3.65	0.000272	0.0148	-0.15	-0.11	Exploratory eye movement dysfunction in schizophrenia (responsive search score);	chr18:79933600	chr18:80147924~80178432:+
BRCA	cis	rs801193	1	rs62466794	ENSG00000232546.1	RP11-458F8.1	-3.65	0.000273	0.0148	-0.09	-0.11	Aortic root size;	chr7:66726592	chr7:66848496~66858136:+
BRCA	cis	rs739496	0.579	rs3752630	ENSG00000234608.6	MAPKAPK5-AS1	3.65	0.000273	0.0148	0.14	0.11	Platelet count;	chr12:111938186	chr12:111839764~111842902:-
BRCA	cis	rs4835473	0.932	rs5015760	ENSG00000246448.2	RP13-578N3.3	-3.65	0.000273	0.0148	-0.13	-0.11	Immature fraction of reticulocytes;	chr4:143737955	chr4:143700257~143865072:+
BRCA	cis	rs3796352	0.568	rs11713376	ENSG00000243224.1	RP5-1157M23.2	-3.65	0.000273	0.0148	-0.2	-0.11	Immune reponse to smallpox (secreted IL-2);	chr3:52924911	chr3:52239258~52241097:+
BRCA	cis	rs8098244	0.929	rs34963231	ENSG00000265752.2	RP11-403A21.1	-3.65	0.000273	0.0148	-0.14	-0.11	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23916890	chr18:23957754~23982556:-
BRCA	cis	rs180730	0.752	rs4639096	ENSG00000251609.2	SETP12	3.65	0.000273	0.0148	0.2	0.11	Fasting plasma glucose;	chr4:120902221	chr4:120895494~120897083:-
BRCA	cis	rs80028505	0.908	rs7752459	ENSG00000271304.1	DPRXP2	3.65	0.000273	0.0148	0.22	0.11	Foot ulcer in diabetes and neuropathy;	chr6:36116895	chr6:35989515~35990436:-
BRCA	cis	rs7520050	0.966	rs11589562	ENSG00000281133.1	AL355480.3	-3.65	0.000273	0.0148	-0.13	-0.11	Reticulocyte count;Red blood cell count;	chr1:46001049	chr1:45580892~45580996:-
BRCA	cis	rs7914558	0.966	rs10748839	ENSG00000213277.3	MARCKSL1P1	3.65	0.000273	0.0148	0.13	0.11	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103193790	chr10:103175554~103176094:+
BRCA	cis	rs427943	0.639	rs2838820	ENSG00000184274.3	LINC00315	-3.65	0.000273	0.0148	-0.14	-0.11	Body mass index;	chr21:45226090	chr21:45300245~45305257:-
BRCA	cis	rs10838634	1	rs61897302	ENSG00000280615.1	Y_RNA	-3.65	0.000273	0.0148	-0.23	-0.11	Schizophrenia;	chr11:46776680	chr11:47614898~47614994:-
BRCA	cis	rs948562	0.793	rs11229552	ENSG00000280010.1	AP001350.4	3.65	0.000273	0.0148	0.22	0.11	Lymphoma;	chr11:58633441	chr11:58627435~58628528:+
BRCA	cis	rs61931739	0.534	rs11052959	ENSG00000258794.3	DUX4L27	3.65	0.000273	0.0148	0.16	0.11	Morning vs. evening chronotype;	chr12:33844160	chr12:34208415~34209675:-
BRCA	cis	rs61931739	0.534	rs11052960	ENSG00000258794.3	DUX4L27	3.65	0.000273	0.0148	0.16	0.11	Morning vs. evening chronotype;	chr12:33844819	chr12:34208415~34209675:-
BRCA	cis	rs61931739	0.5	rs12367292	ENSG00000258794.3	DUX4L27	3.65	0.000273	0.0148	0.16	0.11	Morning vs. evening chronotype;	chr12:33845140	chr12:34208415~34209675:-
BRCA	cis	rs11603020	1	rs11603020	ENSG00000265566.2	RN7SL605P	3.65	0.000273	0.0148	0.16	0.11	Blood protein levels;	chr11:57606859	chr11:57528085~57528365:-
BRCA	cis	rs7618501	1	rs7634902	ENSG00000228008.1	CTD-2330K9.3	-3.65	0.000273	0.0148	-0.11	-0.11	Intelligence (multi-trait analysis);	chr3:49725229	chr3:49903845~49916937:+
BRCA	cis	rs7618501	1	rs1049256	ENSG00000228008.1	CTD-2330K9.3	-3.65	0.000273	0.0148	-0.11	-0.11	Intelligence (multi-trait analysis);	chr3:49725905	chr3:49903845~49916937:+
BRCA	cis	rs72615157	0.634	rs11762932	ENSG00000242294.5	STAG3L5P	-3.65	0.000273	0.0148	-0.11	-0.11	Lung function (FEV1/FVC);	chr7:100195043	chr7:100336079~100351900:+
BRCA	cis	rs6490294	0.571	rs77176084	ENSG00000257624.1	RP1-128M12.3	3.65	0.000273	0.0148	0.2	0.11	Mean platelet volume;	chr12:112077508	chr12:112000739~112000985:-
BRCA	cis	rs6490294	0.528	rs74636821	ENSG00000257624.1	RP1-128M12.3	3.65	0.000273	0.0148	0.2	0.11	Mean platelet volume;	chr12:112078108	chr12:112000739~112000985:-
BRCA	cis	rs8114671	0.562	rs7263157	ENSG00000261582.1	RP4-614O4.11	-3.65	0.000273	0.0148	-0.11	-0.11	Height;	chr20:34871324	chr20:35267885~35280043:-
BRCA	cis	rs3749237	0.964	rs10865959	ENSG00000225399.4	RP11-3B7.1	3.65	0.000273	0.0148	0.11	0.11	Resting heart rate;	chr3:49853569	chr3:49260085~49261316:+
BRCA	cis	rs11098499	0.866	rs3756156	ENSG00000225892.3	RP11-384K6.2	3.65	0.000273	0.0148	0.12	0.11	Corneal astigmatism;	chr4:119603686	chr4:118632274~118634759:+
BRCA	cis	rs6456156	1	rs9457274	ENSG00000272549.1	RP11-351J23.2	-3.65	0.000273	0.0148	-0.11	-0.11	Primary biliary cholangitis;	chr6:167107377	chr6:167666840~167679270:-
BRCA	cis	rs11098499	0.954	rs17006190	ENSG00000225892.3	RP11-384K6.2	3.65	0.000273	0.0148	0.11	0.11	Corneal astigmatism;	chr4:119497683	chr4:118632274~118634759:+
BRCA	cis	rs2847281	0.587	rs2542157	ENSG00000260302.1	RP11-973H7.1	-3.65	0.000273	0.0148	-0.14	-0.11	C-reactive protein levels;Esophageal cancer (squamous cell);	chr18:12787248	chr18:12774651~12775923:-
BRCA	cis	rs6456156	1	rs6456156	ENSG00000272549.1	RP11-351J23.2	-3.65	0.000273	0.0148	-0.11	-0.11	Primary biliary cholangitis;	chr6:167108812	chr6:167666840~167679270:-
BRCA	cis	rs12317459	0.591	rs11115406	ENSG00000213270.5	RPL6P25	-3.65	0.000273	0.0148	-0.18	-0.11	Prostate cancer (SNP x SNP interaction);	chr12:82772810	chr12:83151331~83152190:+
BRCA	cis	rs11098499	0.913	rs56122576	ENSG00000225892.3	RP11-384K6.2	3.65	0.000273	0.0148	0.12	0.11	Corneal astigmatism;	chr4:119208181	chr4:118632274~118634759:+
BRCA	cis	rs875971	0.522	rs7784623	ENSG00000223473.2	GS1-124K5.3	3.65	0.000273	0.0148	0.09	0.11	Aortic root size;	chr7:65930047	chr7:66491049~66493566:-
BRCA	cis	rs62458065	0.64	rs10271491	ENSG00000229358.3	DPY19L1P1	-3.65	0.000273	0.0148	-0.16	-0.11	Metabolite levels (HVA/MHPG ratio);	chr7:32491053	chr7:32580949~32761787:-
BRCA	cis	rs4835473	0.932	rs1450236	ENSG00000249741.2	RP11-673E1.3	3.65	0.000273	0.0148	0.12	0.11	Immature fraction of reticulocytes;	chr4:143783069	chr4:143911514~143912053:-
BRCA	cis	rs61542988	0.535	rs10807813	ENSG00000228649.7	AC005682.5	3.65	0.000273	0.0148	0.12	0.11	Fibrinogen levels;	chr7:22790342	chr7:22854178~22861579:+
BRCA	cis	rs8040855	0.52	rs11629962	ENSG00000230373.7	GOLGA6L5P	3.65	0.000273	0.0148	0.15	0.11	Bulimia nervosa;	chr15:84986797	chr15:84507885~84516814:-
BRCA	cis	rs6964587	0.869	rs10278155	ENSG00000188693.7	CYP51A1-AS1	3.65	0.000273	0.0148	0.12	0.11	Breast cancer;	chr7:91903142	chr7:92134604~92180725:+
BRCA	cis	rs863345	0.564	rs10908662	ENSG00000229914.1	RP11-404O13.4	-3.65	0.000273	0.0148	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158519410	chr1:158195633~158196131:-
BRCA	cis	rs61931739	0.517	rs4104182	ENSG00000258794.3	DUX4L27	3.65	0.000273	0.0148	0.16	0.11	Morning vs. evening chronotype;	chr12:33928408	chr12:34208415~34209675:-
BRCA	cis	rs251253	0.795	rs3131913	ENSG00000253959.1	CTB-43E15.1	3.65	0.000273	0.0148	0.1	0.11	PR interval;	chr5:173131193	chr5:173642519~173658194:+
BRCA	cis	rs6991838	0.557	rs4737222	ENSG00000272155.1	RP11-707M3.3	3.65	0.000273	0.0148	0.1	0.11	Intelligence (multi-trait analysis);	chr8:65587878	chr8:65714334~65714778:-
BRCA	cis	rs6964587	1	rs12536529	ENSG00000188693.7	CYP51A1-AS1	3.65	0.000273	0.0148	0.12	0.11	Breast cancer;	chr7:92054772	chr7:92134604~92180725:+
BRCA	cis	rs1865760	0.964	rs9295677	ENSG00000272810.1	U91328.22	-3.65	0.000273	0.0148	-0.13	-0.11	Height;	chr6:25933484	chr6:26013241~26013757:+
BRCA	cis	rs17123764	0.892	rs74952881	ENSG00000257464.1	RP11-161H23.8	-3.65	0.000273	0.0148	-0.21	-0.11	Intelligence (multi-trait analysis);	chr12:49715160	chr12:49442424~49442652:-
BRCA	cis	rs17123764	0.892	rs74903123	ENSG00000257464.1	RP11-161H23.8	-3.65	0.000273	0.0148	-0.21	-0.11	Intelligence (multi-trait analysis);	chr12:49719346	chr12:49442424~49442652:-
BRCA	cis	rs17123764	0.892	rs60126713	ENSG00000257464.1	RP11-161H23.8	-3.65	0.000273	0.0148	-0.21	-0.11	Intelligence (multi-trait analysis);	chr12:49721893	chr12:49442424~49442652:-
BRCA	cis	rs2301573	0.584	rs16863175	ENSG00000271270.4	TMCC1-AS1	-3.65	0.000273	0.0148	-0.24	-0.11	Hip circumference;	chr3:129798686	chr3:129893871~129918575:+
BRCA	cis	rs2301573	0.584	rs62265582	ENSG00000271270.4	TMCC1-AS1	-3.65	0.000273	0.0148	-0.24	-0.11	Hip circumference;	chr3:129804071	chr3:129893871~129918575:+
BRCA	cis	rs2301573	0.584	rs10934894	ENSG00000271270.4	TMCC1-AS1	-3.65	0.000273	0.0148	-0.24	-0.11	Hip circumference;	chr3:129807714	chr3:129893871~129918575:+
BRCA	cis	rs7590268	0.789	rs35234516	ENSG00000279873.2	LINC01126	3.65	0.000273	0.0148	0.13	0.11	Orofacial clefts;	chr2:43415866	chr2:43227210~43228855:+
BRCA	cis	rs2562456	0.652	rs62110214	ENSG00000268535.1	RP11-420K14.3	3.65	0.000273	0.0148	0.17	0.11	Pain;	chr19:21592406	chr19:21709522~21710191:+
BRCA	cis	rs5742933	1	rs3791770	ENSG00000253559.1	OSGEPL1-AS1	-3.65	0.000273	0.0148	-0.16	-0.11	Ferritin levels;	chr2:189809109	chr2:189762704~189765556:+
BRCA	cis	rs6893300	1	rs62406177	ENSG00000225051.5	HMGB3P22	3.65	0.000273	0.0148	0.15	0.11	Resting heart rate;	chr5:179737208	chr5:179679032~179694768:+
BRCA	cis	rs2692947	0.637	rs72492201	ENSG00000168992.4	OR7E102P	3.65	0.000273	0.0148	0.16	0.11	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95964453	chr2:95546531~95547545:+
BRCA	cis	rs6918586	0.658	rs198803	ENSG00000272462.2	U91328.19	-3.65	0.000273	0.0148	-0.13	-0.11	Schizophrenia;	chr6:26134824	chr6:25992662~26001775:+
BRCA	cis	rs2302465	0.86	rs17476879	ENSG00000273133.1	RP11-799M12.2	-3.65	0.000273	0.0148	-0.23	-0.11	Blood protein levels;	chr4:15560390	chr4:15563698~15564253:-
BRCA	cis	rs7620503	1	rs4273409	ENSG00000231574.4	RP11-91K9.1	3.65	0.000273	0.0148	0.13	0.11	Corneal structure;	chr3:177580997	chr3:177816865~177899224:+
BRCA	cis	rs7620503	1	rs36102700	ENSG00000231574.4	RP11-91K9.1	3.65	0.000273	0.0148	0.13	0.11	Corneal structure;	chr3:177581321	chr3:177816865~177899224:+
BRCA	cis	rs9527	0.59	rs7917650	ENSG00000213061.2	PFN1P11	3.65	0.000273	0.0148	0.15	0.11	Arsenic metabolism;	chr10:103177343	chr10:102838011~102845473:-
BRCA	cis	rs2251301	1	rs2251301	ENSG00000154316.13	TDH	-3.65	0.000273	0.0148	-0.19	-0.11	Response to antipsychotic therapy (extrapyramidal side effects);	chr8:11261528	chr8:11339637~11368452:+
BRCA	cis	rs62025270	0.547	rs416916	ENSG00000259762.1	RP11-158M2.4	-3.65	0.000273	0.0148	-0.14	-0.11	Idiopathic pulmonary fibrosis;	chr15:85649185	chr15:85750336~85752901:-
BRCA	cis	rs8049367	0.656	rs60482171	ENSG00000267077.1	RP11-127I20.5	-3.65	0.000273	0.0149	-0.12	-0.11	Nonsyndromic cleft lip with or without cleft palate;	chr16:3913932	chr16:4795265~4796532:-
BRCA	cis	rs8040855	0.627	rs12905036	ENSG00000229212.6	RP11-561C5.4	-3.65	0.000273	0.0149	-0.15	-0.11	Bulimia nervosa;	chr15:85094557	chr15:85205440~85234795:-
BRCA	cis	rs713477	0.654	rs6573030	ENSG00000186615.9	KTN1-AS1	-3.65	0.000274	0.0149	-0.13	-0.11	Pediatric bone mineral content (femoral neck);	chr14:55447002	chr14:55499278~55580110:-
BRCA	cis	rs4703129	1	rs11954892	ENSG00000246763.5	RGMB-AS1	-3.65	0.000274	0.0149	-0.13	-0.11	Asperger disorder;	chr5:98545297	chr5:98769618~98773469:-
BRCA	cis	rs863345	0.564	rs10908662	ENSG00000176320.2	RP11-404O13.5	-3.65	0.000274	0.0149	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158519410	chr1:158197922~158203877:-
BRCA	cis	rs9400180	0.959	rs9400193	ENSG00000271734.1	RP1-111B22.3	-3.65	0.000274	0.0149	-0.14	-0.11	Major depressive disorder;	chr6:108067808	chr6:108030249~108030718:-
BRCA	cis	rs250518	0.926	rs34749191	ENSG00000271926.1	CTD-2376I4.1	3.65	0.000274	0.0149	0.15	0.11	Mean corpuscular hemoglobin concentration;	chr5:72749431	chr5:72953635~72954274:-
BRCA	cis	rs859767	0.741	rs11682346	ENSG00000224043.6	CCNT2-AS1	3.65	0.000274	0.0149	0.15	0.11	Neuroticism;	chr2:134630691	chr2:134735464~134918710:-
BRCA	cis	rs2109514	0.542	rs4540346	ENSG00000237813.3	AC002066.1	3.65	0.000274	0.0149	0.14	0.11	Prevalent atrial fibrillation;	chr7:116427829	chr7:116238260~116499465:-
BRCA	cis	rs1371614	0.632	rs920437	ENSG00000272148.1	RP11-195B17.1	-3.65	0.000274	0.0149	-0.13	-0.11	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26934528	chr2:27062428~27062907:-
BRCA	cis	rs943466	1	rs73412140	ENSG00000223837.2	BRD2-IT1	3.65	0.000274	0.0149	0.15	0.11	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;	chr6:33789237	chr6:32970232~32970886:+
BRCA	cis	rs11098499	0.874	rs9995277	ENSG00000260404.2	RP11-384K6.6	3.65	0.000274	0.0149	0.11	0.11	Corneal astigmatism;	chr4:119187448	chr4:118591773~118633729:+
BRCA	cis	rs7111546	0.945	rs1019216	ENSG00000246225.5	RP11-17A1.3	3.65	0.000274	0.0149	0.19	0.11	Dialysis-related mortality;	chr11:22821674	chr11:22829380~22945393:+
BRCA	cis	rs911555	0.755	rs17841064	ENSG00000269958.1	RP11-73M18.8	3.65	0.000274	0.0149	0.12	0.11	Intelligence (multi-trait analysis);	chr14:103434272	chr14:103696353~103697163:+
BRCA	cis	rs6840360	0.558	rs2709821	ENSG00000278978.1	RP11-164P12.5	-3.65	0.000274	0.0149	-0.13	-0.11	Intelligence (multi-trait analysis);	chr4:151421038	chr4:151669786~151670503:+
BRCA	cis	rs875971	0.862	rs10261398	ENSG00000229886.1	RP5-1132H15.3	-3.65	0.000274	0.0149	-0.13	-0.11	Aortic root size;	chr7:66285177	chr7:66025126~66031544:-
BRCA	cis	rs875971	0.862	rs10224872	ENSG00000229886.1	RP5-1132H15.3	-3.65	0.000274	0.0149	-0.13	-0.11	Aortic root size;	chr7:66294786	chr7:66025126~66031544:-
BRCA	cis	rs1865760	1	rs9393675	ENSG00000272810.1	U91328.22	-3.65	0.000274	0.0149	-0.13	-0.11	Height;	chr6:25929888	chr6:26013241~26013757:+
BRCA	cis	rs8040855	0.52	rs67613323	ENSG00000230373.7	GOLGA6L5P	3.65	0.000274	0.0149	0.15	0.11	Bulimia nervosa;	chr15:84986541	chr15:84507885~84516814:-
BRCA	cis	rs2554380	0.628	rs7177929	ENSG00000259570.1	RP11-671M22.4	3.65	0.000274	0.0149	0.14	0.11	Height;	chr15:83809927	chr15:84394512~84395514:+
BRCA	cis	rs17772222	1	rs17772064	ENSG00000258789.1	RP11-507K2.3	-3.65	0.000274	0.0149	-0.13	-0.11	Coronary artery calcification;	chr14:88356527	chr14:88551597~88552493:+
BRCA	cis	rs9287719	0.967	rs4284804	ENSG00000224177.5	LINC00570	3.65	0.000274	0.0149	0.13	0.11	Prostate cancer;	chr2:10581998	chr2:11393981~11403077:+
BRCA	cis	rs9287719	0.935	rs10803723	ENSG00000224177.5	LINC00570	3.65	0.000274	0.0149	0.13	0.11	Prostate cancer;	chr2:10582751	chr2:11393981~11403077:+
BRCA	cis	rs9287719	0.935	rs6751075	ENSG00000224177.5	LINC00570	3.65	0.000274	0.0149	0.13	0.11	Prostate cancer;	chr2:10583420	chr2:11393981~11403077:+
BRCA	cis	rs6964587	0.869	rs2023784	ENSG00000188693.7	CYP51A1-AS1	3.65	0.000274	0.0149	0.12	0.11	Breast cancer;	chr7:91895363	chr7:92134604~92180725:+
BRCA	cis	rs6964587	0.869	rs401	ENSG00000188693.7	CYP51A1-AS1	3.65	0.000274	0.0149	0.12	0.11	Breast cancer;	chr7:91898631	chr7:92134604~92180725:+
BRCA	cis	rs7208859	0.623	rs122898	ENSG00000250462.7	LRRC37BP1	3.65	0.000274	0.0149	0.21	0.11	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30578236	chr17:30629680~30637466:+
BRCA	cis	rs7572733	0.935	rs1878732	ENSG00000231621.1	AC013264.2	-3.65	0.000274	0.0149	-0.1	-0.11	Dermatomyositis;	chr2:197944821	chr2:197197991~197199273:+
BRCA	cis	rs143000161	1	rs143000161	ENSG00000223318.1	RNA5SP111	3.65	0.000274	0.0149	0.19	0.11	Heschl's gyrus morphology;	chr2:164854030	chr2:164895677~164895777:-
BRCA	cis	rs17767294	0.708	rs72849204	ENSG00000219392.1	RP1-265C24.5	-3.65	0.000274	0.0149	-0.3	-0.11	Parkinson's disease;	chr6:28203165	chr6:28115628~28116551:+
BRCA	cis	rs17767294	0.708	rs72849205	ENSG00000219392.1	RP1-265C24.5	-3.65	0.000274	0.0149	-0.3	-0.11	Parkinson's disease;	chr6:28203751	chr6:28115628~28116551:+
BRCA	cis	rs17767294	0.708	rs72849206	ENSG00000219392.1	RP1-265C24.5	-3.65	0.000274	0.0149	-0.3	-0.11	Parkinson's disease;	chr6:28204926	chr6:28115628~28116551:+
BRCA	cis	rs4267450	0.793	rs73021318	ENSG00000261770.1	CTC-459F4.1	3.65	0.000274	0.0149	0.24	0.11	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);	chr19:28357972	chr19:27757184~27760849:-
BRCA	cis	rs6049003	0.584	rs4349407	ENSG00000232645.4	LINC01431	3.65	0.000274	0.0149	0.12	0.11	Cerebrospinal fluid biomarker levels;	chr20:23719994	chr20:23356594~23358116:-
BRCA	cis	rs11613048	0.524	rs7138891	ENSG00000273680.1	RP11-996F15.6	3.65	0.000274	0.0149	0.14	0.11	Major depressive disorder;	chr12:30191382	chr12:29332733~29333383:-
BRCA	cis	rs2692947	0.568	rs57579941	ENSG00000168992.4	OR7E102P	3.65	0.000274	0.0149	0.15	0.11	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95670505	chr2:95546531~95547545:+
BRCA	cis	rs2574985	0.689	rs1203375	ENSG00000231345.3	BEND3P1	-3.65	0.000274	0.0149	-0.18	-0.11	Subjective well-being;	chr10:50427544	chr10:50655967~50660472:+
BRCA	cis	rs3760982	0.565	rs8104300	ENSG00000267191.1	RP11-15A1.2	-3.65	0.000274	0.0149	-0.15	-0.11	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43788992	chr19:43902001~43926545:+
BRCA	cis	rs847845	0.535	rs67385931	ENSG00000272374.1	RP3-329A5.8	3.65	0.000274	0.0149	0.19	0.11	Non-small cell lung cancer;	chr6:35018729	chr6:35220370~35224630:-
BRCA	cis	rs55675132	0.587	rs3905243	ENSG00000226167.1	AP4B1-AS1	3.65	0.000274	0.0149	0.1	0.11	Schizophrenia;	chr1:114813353	chr1:113856635~113901237:+
BRCA	cis	rs11668609	0.505	rs60888272	ENSG00000268442.1	CTD-2027I19.2	3.65	0.000274	0.0149	0.18	0.11	Response to taxane treatment (docetaxel);	chr19:23968491	chr19:24162370~24163425:-
BRCA	cis	rs10895987	1	rs10895987	ENSG00000255200.1	AP003068.18	-3.65	0.000274	0.0149	-0.16	-0.11	Blood protein levels;	chr11:65137437	chr11:65174117~65176470:-
BRCA	cis	rs4372836	0.681	rs6419696	ENSG00000226833.4	AC097724.3	3.65	0.000274	0.0149	0.13	0.11	Body mass index;	chr2:28787473	chr2:28708953~28736205:-
BRCA	cis	rs1371614	0.632	rs3820823	ENSG00000229122.1	AGBL5-IT1	3.65	0.000275	0.0149	0.12	0.11	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26941938	chr2:27061038~27061815:+
BRCA	cis	rs11892454	0.565	rs10182811	ENSG00000217643.1	PTGES3P2	-3.65	0.000275	0.0149	-0.12	-0.11	Heschl's gyrus morphology;	chr2:25833004	chr2:25822469~25822950:+
BRCA	cis	rs853679	0.607	rs67101035	ENSG00000216901.1	AL022393.7	3.65	0.000275	0.0149	0.29	0.11	Depression;	chr6:27831109	chr6:28176188~28176674:+
BRCA	cis	rs8114671	0.562	rs6088621	ENSG00000261582.1	RP4-614O4.11	-3.65	0.000275	0.0149	-0.11	-0.11	Height;	chr20:34830937	chr20:35267885~35280043:-
BRCA	cis	rs28374715	0.532	rs316607	ENSG00000247556.5	OIP5-AS1	3.65	0.000275	0.0149	0.13	0.11	Ulcerative colitis;	chr15:41480495	chr15:41283990~41309737:+
BRCA	cis	rs73222236	0.825	rs9860801	ENSG00000239213.4	NCK1-AS1	3.65	0.000275	0.0149	0.12	0.11	Coronary artery disease;	chr3:136369196	chr3:136841726~136862054:-
BRCA	cis	rs853679	0.546	rs493161	ENSG00000241549.7	GUSBP2	3.65	0.000275	0.0149	0.21	0.11	Depression;	chr6:27882936	chr6:26871484~26956554:-
BRCA	cis	rs875971	0.522	rs781144	ENSG00000229180.5	GS1-124K5.11	3.65	0.000275	0.0149	0.1	0.11	Aortic root size;	chr7:65975357	chr7:66526088~66542624:-
BRCA	cis	rs9346455	0.614	rs2273888	ENSG00000279312.1	RP3-331H24.7	-3.65	0.000275	0.0149	-0.17	-0.11	Antipsychotic drug-induced weight gain;Antipsychotic drug-induced weight gain (time interaction);	chr6:71296809	chr6:71373253~71375387:-
BRCA	cis	rs2602836	0.83	rs2602874	ENSG00000246090.5	RP11-696N14.1	3.65	0.000275	0.0149	0.11	0.11	HDL cholesterol;HDL cholesterol levels;	chr4:99118245	chr4:99088857~99301356:+
BRCA	cis	rs669446	0.591	rs607062	ENSG00000237950.1	RP11-7O11.3	3.65	0.000275	0.0149	0.14	0.11	Amyotrophic lateral sclerosis (age of onset);	chr1:43667345	chr1:43944370~43946551:-
BRCA	cis	rs7267979	0.966	rs454723	ENSG00000231081.1	RP4-760C5.3	-3.65	0.000275	0.0149	-0.14	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25458292	chr20:26008791~26010531:-
BRCA	cis	rs9308731	0.583	rs4848406	ENSG00000230499.1	AC108463.1	-3.65	0.000275	0.0149	-0.13	-0.11	Chronic lymphocytic leukemia;	chr2:111176181	chr2:111195963~111206494:+
BRCA	cis	rs4950322	0.57	rs72692946	ENSG00000237188.3	RP11-337C18.8	3.65	0.000275	0.0149	0.14	0.11	Protein quantitative trait loci;	chr1:147319966	chr1:147172771~147211568:+
BRCA	cis	rs4950322	0.57	rs72692948	ENSG00000237188.3	RP11-337C18.8	3.65	0.000275	0.0149	0.14	0.11	Protein quantitative trait loci;	chr1:147320298	chr1:147172771~147211568:+
BRCA	cis	rs4950322	0.57	rs72692951	ENSG00000237188.3	RP11-337C18.8	3.65	0.000275	0.0149	0.14	0.11	Protein quantitative trait loci;	chr1:147320551	chr1:147172771~147211568:+
BRCA	cis	rs4950322	0.57	rs77118461	ENSG00000237188.3	RP11-337C18.8	3.65	0.000275	0.0149	0.14	0.11	Protein quantitative trait loci;	chr1:147320718	chr1:147172771~147211568:+
BRCA	cis	rs4950322	0.57	rs78681047	ENSG00000237188.3	RP11-337C18.8	3.65	0.000275	0.0149	0.14	0.11	Protein quantitative trait loci;	chr1:147321013	chr1:147172771~147211568:+
BRCA	cis	rs4664293	0.836	rs13421392	ENSG00000226266.5	AC009961.3	-3.65	0.000275	0.0149	-0.14	-0.11	Monocyte percentage of white cells;	chr2:159801785	chr2:159670708~159712435:-
BRCA	cis	rs875971	0.825	rs6951503	ENSG00000271064.1	RP11-792A8.3	3.65	0.000275	0.0149	0.13	0.11	Aortic root size;	chr7:66253949	chr7:66748838~66749077:-
BRCA	cis	rs10266483	0.96	rs13221291	ENSG00000271550.1	BNIP3P11	3.65	0.000275	0.0149	0.14	0.11	Response to statin therapy;	chr7:64279114	chr7:64678954~64687393:-
BRCA	cis	rs7267979	0.966	rs6050532	ENSG00000276952.1	RP5-965G21.6	-3.65	0.000275	0.0149	-0.14	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25328157	chr20:25284915~25285588:-
BRCA	cis	rs7917772	0.503	rs11191342	ENSG00000213061.2	PFN1P11	-3.65	0.000275	0.0149	-0.15	-0.11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;	chr10:102584693	chr10:102838011~102845473:-
BRCA	cis	rs4950322	0.58	rs17355474	ENSG00000227242.3	NBPF13P	-3.65	0.000275	0.0149	-0.16	-0.11	Protein quantitative trait loci;	chr1:147120541	chr1:147021320~147124525:-
BRCA	cis	rs4919687	0.55	rs7907503	ENSG00000236937.2	PTGES3P4	3.65	0.000275	0.0149	0.15	0.11	Colorectal cancer;	chr10:102680293	chr10:102845595~102845950:+
BRCA	cis	rs854765	0.547	rs4584886	ENSG00000154874.13	CCDC144B	-3.65	0.000275	0.0149	-0.13	-0.11	Total body bone mineral density;	chr17:17992891	chr17:18537800~18625617:-
BRCA	cis	rs1008375	0.932	rs12500912	ENSG00000249502.1	AC006160.5	-3.65	0.000275	0.0149	-0.13	-0.11	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17601695	chr4:17587467~17614571:-
BRCA	cis	rs6439699	1	rs1478325	ENSG00000239213.4	NCK1-AS1	3.65	0.000275	0.0149	0.15	0.11	Intelligence (multi-trait analysis);	chr3:137294864	chr3:136841726~136862054:-
BRCA	cis	rs875971	0.545	rs1796226	ENSG00000232559.3	GS1-124K5.12	3.65	0.000275	0.0149	0.15	0.11	Aortic root size;	chr7:66622723	chr7:66554588~66576923:-
BRCA	cis	rs6696239	0.513	rs2088211	ENSG00000227711.2	RP11-275O4.5	3.65	0.000275	0.0149	0.13	0.11	Height;	chr1:227575956	chr1:227509028~227520477:-
BRCA	cis	rs867371	0.717	rs3858954	ENSG00000278603.1	RP13-608F4.5	3.65	0.000275	0.0149	0.16	0.11	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82265693	chr15:82472203~82472426:+
BRCA	cis	rs337100	0.546	rs375185	ENSG00000263432.2	RN7SL689P	-3.65	0.000275	0.0149	-0.14	-0.11	Pulse pressure;	chr5:123136165	chr5:123022487~123022783:-
BRCA	cis	rs295490	0.748	rs78103472	ENSG00000272656.1	RP11-219D15.3	3.65	0.000275	0.0149	0.28	0.11	PR interval in Tripanosoma cruzi seropositivity;	chr3:139433304	chr3:139349024~139349371:-
BRCA	cis	rs9747201	1	rs9747201	ENSG00000266654.1	RP11-1376P16.1	-3.65	0.000275	0.0149	-0.15	-0.11	Peripheral arterial disease (traffic-related air pollution interaction);	chr17:82219976	chr17:82160056~82160452:+
BRCA	cis	rs10771431	0.597	rs10843144	ENSG00000256673.1	RP11-599J14.2	3.65	0.000275	0.0149	0.12	0.11	Breast size;	chr12:9204981	chr12:9398355~9414851:-
BRCA	cis	rs875971	0.571	rs160641	ENSG00000232559.3	GS1-124K5.12	-3.65	0.000275	0.0149	-0.15	-0.11	Aortic root size;	chr7:66112359	chr7:66554588~66576923:-
BRCA	cis	rs4835473	0.932	rs10857413	ENSG00000246448.2	RP13-578N3.3	3.65	0.000275	0.0149	0.13	0.11	Immature fraction of reticulocytes;	chr4:143827752	chr4:143700257~143865072:+
BRCA	cis	rs10129255	0.5	rs11628999	ENSG00000211976.2	IGHV3-73	-3.65	0.000275	0.0149	-0.08	-0.11	Kawasaki disease;	chr14:106800208	chr14:106802694~106803233:-
BRCA	cis	rs1962073	0.623	rs7459532	ENSG00000154316.13	TDH	3.65	0.000275	0.0149	0.14	0.11	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);	chr8:10403558	chr8:11339637~11368452:+
BRCA	cis	rs11158026	0.603	rs8009997	ENSG00000233924.1	AL160471.6	-3.65	0.000275	0.0149	-0.13	-0.11	Parkinson's disease;	chr14:54955193	chr14:55004813~55005687:-
BRCA	cis	rs9921338	0.961	rs8043692	ENSG00000263080.1	RP11-485G7.5	3.65	0.000275	0.0149	0.17	0.11	Vein graft stenosis in coronary artery bypass grafting;	chr16:11333100	chr16:11341809~11345211:-
BRCA	cis	rs9921338	0.923	rs6498181	ENSG00000263080.1	RP11-485G7.5	3.65	0.000275	0.0149	0.17	0.11	Vein graft stenosis in coronary artery bypass grafting;	chr16:11333336	chr16:11341809~11345211:-
BRCA	cis	rs6840360	0.593	rs1877185	ENSG00000270265.1	RP11-731D1.4	-3.65	0.000275	0.0149	-0.13	-0.11	Intelligence (multi-trait analysis);	chr4:151769196	chr4:151333775~151353224:-
BRCA	cis	rs3767633	0.858	rs6698065	ENSG00000229808.1	RP11-456P18.2	-3.65	0.000275	0.0149	-0.2	-0.11	IgG glycosylation;	chr1:161921738	chr1:161890833~161892196:+
BRCA	cis	rs524281	0.861	rs11227411	ENSG00000255557.1	RP11-770G2.2	3.65	0.000275	0.0149	0.16	0.11	Electroencephalogram traits;	chr11:66112007	chr11:65745729~65771585:+
BRCA	cis	rs6120849	0.754	rs3746446	ENSG00000202150.1	RNU6-407P	3.65	0.000276	0.0149	0.16	0.11	Protein C levels;	chr20:34986962	chr20:35030317~35030420:-
BRCA	cis	rs6071166	0.683	rs1358900	ENSG00000224635.1	RP4-564F22.5	-3.65	0.000276	0.0149	-0.14	-0.11	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38695327	chr20:38406011~38416797:-
BRCA	cis	rs4819052	1	rs2297285	ENSG00000215447.6	BX322557.10	3.65	0.000276	0.0149	0.13	0.11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45285706	chr21:45288052~45291738:+
BRCA	cis	rs6743226	0.542	rs62186397	ENSG00000266621.1	AC104841.1	3.65	0.000276	0.015	0.13	0.11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in non-smokers;	chr2:241284497	chr2:241245202~241245299:-
BRCA	cis	rs12612619	0.689	rs11681145	ENSG00000272148.1	RP11-195B17.1	3.65	0.000276	0.015	0.13	0.11	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27067657	chr2:27062428~27062907:-
BRCA	cis	rs10504130	0.569	rs6473653	ENSG00000272024.1	RP11-546K22.3	3.65	0.000276	0.015	0.16	0.11	Venous thromboembolism (SNP x SNP interaction);	chr8:51757562	chr8:51950284~51950690:+
BRCA	cis	rs10761482	0.861	rs7084803	ENSG00000254271.1	RP11-131N11.4	3.65	0.000276	0.015	0.16	0.11	Schizophrenia;	chr10:60347343	chr10:60734342~60741828:+
BRCA	cis	rs10761482	0.813	rs7100985	ENSG00000254271.1	RP11-131N11.4	3.65	0.000276	0.015	0.16	0.11	Schizophrenia;	chr10:60347408	chr10:60734342~60741828:+
BRCA	cis	rs10761482	0.769	rs4948403	ENSG00000254271.1	RP11-131N11.4	3.65	0.000276	0.015	0.16	0.11	Schizophrenia;	chr10:60347904	chr10:60734342~60741828:+
BRCA	cis	rs10761482	0.861	rs1380458	ENSG00000254271.1	RP11-131N11.4	3.65	0.000276	0.015	0.16	0.11	Schizophrenia;	chr10:60347932	chr10:60734342~60741828:+
BRCA	cis	rs7914558	0.646	rs7897654	ENSG00000213277.3	MARCKSL1P1	3.65	0.000276	0.015	0.13	0.11	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102902701	chr10:103175554~103176094:+
BRCA	cis	rs17767294	0.708	rs72846802	ENSG00000219392.1	RP1-265C24.5	-3.65	0.000276	0.015	-0.3	-0.11	Parkinson's disease;	chr6:28197064	chr6:28115628~28116551:+
BRCA	cis	rs11098499	0.913	rs56122576	ENSG00000260404.2	RP11-384K6.6	3.65	0.000276	0.015	0.11	0.11	Corneal astigmatism;	chr4:119208181	chr4:118591773~118633729:+
BRCA	cis	rs4578769	0.959	rs11082169	ENSG00000273232.1	RP11-370A5.2	3.65	0.000276	0.015	0.15	0.11	Eosinophil percentage of white cells;	chr18:22850034	chr18:22882825~22883357:-
BRCA	cis	rs4578769	0.959	rs2100191	ENSG00000273232.1	RP11-370A5.2	3.65	0.000276	0.015	0.15	0.11	Eosinophil percentage of white cells;	chr18:22851428	chr18:22882825~22883357:-
BRCA	cis	rs4578769	0.959	rs2100190	ENSG00000273232.1	RP11-370A5.2	3.65	0.000276	0.015	0.15	0.11	Eosinophil percentage of white cells;	chr18:22851857	chr18:22882825~22883357:-
BRCA	cis	rs1009077	0.514	rs13126170	ENSG00000245958.5	RP11-33B1.1	3.65	0.000276	0.015	0.14	0.11	Endometriosis;	chr4:119402033	chr4:119454791~119552025:+
BRCA	cis	rs240764	0.578	rs9322216	ENSG00000260000.2	RP3-467N11.1	3.65	0.000276	0.015	0.13	0.11	Neuroticism;	chr6:100803844	chr6:100881471~100882987:+
BRCA	cis	rs6431644	0.694	rs619929	ENSG00000224287.2	MSL3P1	3.65	0.000276	0.015	0.14	0.11	Left atrial antero-posterior diameter;	chr2:233848626	chr2:233865437~233868444:-
BRCA	cis	rs4950322	0.57	rs80070044	ENSG00000227242.3	NBPF13P	-3.65	0.000276	0.015	-0.16	-0.11	Protein quantitative trait loci;	chr1:147330238	chr1:147021320~147124525:-
BRCA	cis	rs2573652	1	rs2581346	ENSG00000254744.3	CTD-3076O17.1	-3.65	0.000276	0.015	-0.13	-0.11	Height;	chr15:99973973	chr15:99970215~99974010:+
BRCA	cis	rs12554020	0.786	rs16909150	ENSG00000227603.1	RP11-165J3.6	-3.65	0.000276	0.015	-0.19	-0.11	Schizophrenia;	chr9:93454464	chr9:93435332~93437121:-
BRCA	cis	rs7267979	1	rs6115146	ENSG00000274414.1	RP5-965G21.4	3.65	0.000276	0.015	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25323871	chr20:25239007~25245229:-
BRCA	cis	rs7267979	0.934	rs6037085	ENSG00000274414.1	RP5-965G21.4	3.65	0.000276	0.015	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25324566	chr20:25239007~25245229:-
BRCA	cis	rs2422052	0.792	rs4849637	ENSG00000236255.1	AC009404.2	-3.65	0.000276	0.015	-0.11	-0.11	Mosquito bite size;	chr2:117887999	chr2:117833937~117841658:+
BRCA	cis	rs4835473	0.831	rs1984809	ENSG00000246448.2	RP13-578N3.3	3.65	0.000276	0.015	0.13	0.11	Immature fraction of reticulocytes;	chr4:143825018	chr4:143700257~143865072:+
BRCA	cis	rs9392556	0.829	rs660560	ENSG00000230648.1	RP3-406P24.3	3.65	0.000276	0.015	0.14	0.11	Blood metabolite levels;	chr6:4125707	chr6:4018843~4021215:-
BRCA	cis	rs7826238	0.72	rs12546760	ENSG00000233609.3	RP11-62H7.2	-3.65	0.000276	0.015	-0.1	-0.11	Systolic blood pressure;	chr8:8517326	chr8:8961200~8979025:+
BRCA	cis	rs8098244	0.597	rs1154246	ENSG00000265752.2	RP11-403A21.1	3.65	0.000276	0.015	0.16	0.11	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23984242	chr18:23957754~23982556:-
BRCA	cis	rs6044112	0.619	rs10485556	ENSG00000273998.1	RP4-777L9.2	3.65	0.000276	0.015	0.19	0.11	Response to taxane treatment (docetaxel);	chr20:16525737	chr20:16576068~16579615:+
BRCA	cis	rs6088580	0.634	rs1890000	ENSG00000275784.1	RP5-1125A11.6	3.65	0.000276	0.015	0.12	0.11	Glomerular filtration rate (creatinine);	chr20:34380506	chr20:33989480~33991818:-
BRCA	cis	rs4759375	1	rs10773006	ENSG00000256092.2	RP13-942N8.1	-3.65	0.000276	0.015	-0.17	-0.11	HDL cholesterol;	chr12:123305504	chr12:123363868~123366113:+
BRCA	cis	rs818427	0.926	rs434157	ENSG00000279522.1	CTC-487M23.6	3.65	0.000276	0.015	0.14	0.11	Total body bone mineral density;	chr5:112855945	chr5:112894933~112896531:+
BRCA	cis	rs4372836	0.576	rs6547880	ENSG00000226833.4	AC097724.3	3.65	0.000276	0.015	0.13	0.11	Body mass index;	chr2:28796023	chr2:28708953~28736205:-
BRCA	cis	rs11098499	0.874	rs6851169	ENSG00000260404.2	RP11-384K6.6	3.65	0.000276	0.015	0.11	0.11	Corneal astigmatism;	chr4:119196355	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.909	rs9759478	ENSG00000225892.3	RP11-384K6.2	3.65	0.000276	0.015	0.11	0.11	Corneal astigmatism;	chr4:119446843	chr4:118632274~118634759:+
BRCA	cis	rs928391	0.681	rs12145743	ENSG00000223356.1	RP11-66D17.5	-3.65	0.000276	0.015	-0.14	-0.11	Platelet count;	chr1:156730859	chr1:156712212~156713174:-
BRCA	cis	rs17801127	0.892	rs13005911	ENSG00000231969.1	AC144449.1	-3.65	0.000276	0.015	-0.19	-0.11	Liver enzyme levels (alanine transaminase);	chr2:149698695	chr2:149587196~149848233:+
BRCA	cis	rs10129255	0.957	rs10132367	ENSG00000211967.3	IGHV3-53	-3.65	0.000276	0.015	-0.08	-0.11	Kawasaki disease;	chr14:106690981	chr14:106592676~106593347:-
BRCA	cis	rs1075265	0.811	rs805308	ENSG00000272156.1	RP11-477N3.1	-3.65	0.000276	0.015	-0.12	-0.11	Chronotype;Morning vs. evening chronotype;	chr2:53967797	chr2:54082554~54085066:+
BRCA	cis	rs1383484	0.64	rs12101685	ENSG00000259728.4	LINC00933	-3.65	0.000276	0.015	-0.14	-0.11	Height;	chr15:83974905	chr15:84570649~84580175:+
BRCA	cis	rs935334	1	rs4899586	ENSG00000258454.1	RP11-361H10.3	3.65	0.000276	0.015	0.18	0.11	Blood pressure;	chr14:76194513	chr14:76235817~76263474:+
BRCA	cis	rs34779708	0.966	rs12765038	ENSG00000269952.1	RP11-324I22.3	-3.65	0.000276	0.015	-0.15	-0.11	Inflammatory bowel disease;Crohn's disease;	chr10:35127585	chr10:35210416~35210750:+
BRCA	cis	rs17301013	0.932	rs10912813	ENSG00000200674.1	RN7SKP160	3.65	0.000276	0.015	0.15	0.11	Systemic lupus erythematosus;	chr1:174607342	chr1:173791548~173791887:+
BRCA	cis	rs7267979	1	rs6115168	ENSG00000276952.1	RP5-965G21.6	-3.65	0.000276	0.015	-0.14	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25392255	chr20:25284915~25285588:-
BRCA	cis	rs10761482	0.861	rs7097138	ENSG00000254271.1	RP11-131N11.4	3.65	0.000276	0.015	0.16	0.11	Schizophrenia;	chr10:60346997	chr10:60734342~60741828:+
BRCA	cis	rs7120118	0.517	rs17726390	ENSG00000280615.1	Y_RNA	3.65	0.000276	0.015	0.18	0.11	HDL cholesterol;	chr11:47298155	chr11:47614898~47614994:-
BRCA	cis	rs1710990	1	rs11158785	ENSG00000259165.1	DDX18P1	3.65	0.000276	0.015	0.14	0.11	Intelligence (multi-trait analysis);	chr14:69086703	chr14:69083398~69085389:+
BRCA	cis	rs12723316	0.799	rs17580638	ENSG00000233008.4	RP11-475O6.1	-3.65	0.000276	0.015	-0.21	-0.11	Schizophrenia;	chr1:83810648	chr1:83575776~83861023:-
BRCA	cis	rs34779708	0.966	rs4934735	ENSG00000269952.1	RP11-324I22.3	3.65	0.000276	0.015	0.15	0.11	Inflammatory bowel disease;Crohn's disease;	chr10:35207802	chr10:35210416~35210750:+
BRCA	cis	rs875971	1	rs7792762	ENSG00000273448.1	RP11-166O4.6	3.65	0.000276	0.015	0.1	0.11	Aortic root size;	chr7:66539151	chr7:67333047~67334383:+
BRCA	cis	rs8030605	0.704	rs1715919	ENSG00000277245.1	RP11-48G14.3	3.65	0.000276	0.015	0.22	0.11	Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;	chr15:56464087	chr15:56447120~56447697:+
BRCA	cis	rs10266483	0.96	rs679883	ENSG00000228653.2	HNRNPCP7	3.65	0.000276	0.015	0.13	0.11	Response to statin therapy;	chr7:64289990	chr7:64500825~64501729:+
BRCA	cis	rs7267979	1	rs7018	ENSG00000274973.1	RP13-401N8.7	-3.65	0.000276	0.015	-0.13	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25297625	chr20:25845497~25845862:+
BRCA	cis	rs7824557	0.591	rs2572452	ENSG00000255020.1	AF131216.5	3.65	0.000277	0.015	0.13	0.11	Retinal vascular caliber;	chr8:11370745	chr8:11345748~11347502:-
BRCA	cis	rs13434995	0.513	rs1979604	ENSG00000249700.7	SRD5A3-AS1	3.65	0.000277	0.015	0.16	0.11	Adiponectin levels;	chr4:55552588	chr4:55363971~55395847:-
BRCA	cis	rs13434995	0.537	rs4865012	ENSG00000249700.7	SRD5A3-AS1	3.65	0.000277	0.015	0.16	0.11	Adiponectin levels;	chr4:55554619	chr4:55363971~55395847:-
BRCA	cis	rs801193	1	rs6975195	ENSG00000232546.1	RP11-458F8.1	3.65	0.000277	0.015	0.09	0.11	Aortic root size;	chr7:66659787	chr7:66848496~66858136:+
BRCA	cis	rs8094794	0.744	rs61735993	ENSG00000267707.2	RP11-95O2.5	3.65	0.000277	0.015	0.17	0.11	Periodontal disease-related phenotypes;	chr18:36693316	chr18:37243776~37247506:+
BRCA	cis	rs9863	0.828	rs11057408	ENSG00000270028.1	RP11-380L11.4	3.65	0.000277	0.015	0.14	0.11	White blood cell count;	chr12:123980289	chr12:123925461~123926083:-
BRCA	cis	rs72928364	0.929	rs62275826	ENSG00000244119.1	PDCL3P4	3.65	0.000277	0.015	0.14	0.11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:101043800	chr3:101712472~101713191:+
BRCA	cis	rs4478858	0.735	rs1566964	ENSG00000260386.4	LINC01225	-3.65	0.000277	0.015	-0.13	-0.11	Alcohol dependence;	chr1:31319947	chr1:31500085~31540885:+
BRCA	cis	rs3755021	1	rs17224524	ENSG00000260742.1	RP11-366L5.1	3.65	0.000277	0.015	0.16	0.11	Monocyte-lymphocyte ratio;	chr2:181481419	chr2:181887851~181891663:-
BRCA	cis	rs17169635	0.601	rs4732062	ENSG00000272941.1	RP11-134L10.1	-3.65	0.000277	0.015	-0.12	-0.11	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);	chr7:134863204	chr7:135168403~135169547:+
BRCA	cis	rs8054556	1	rs11901	ENSG00000183604.13	SMG1P5	-3.65	0.000277	0.015	-0.11	-0.11	Autism spectrum disorder or schizophrenia;	chr16:29972749	chr16:30267553~30335374:-
BRCA	cis	rs6964587	0.967	rs7786031	ENSG00000188693.7	CYP51A1-AS1	-3.65	0.000277	0.015	-0.12	-0.11	Breast cancer;	chr7:92019687	chr7:92134604~92180725:+
BRCA	cis	rs7071275	0.6	rs11200051	ENSG00000226864.1	ATE1-AS1	3.65	0.000277	0.015	0.2	0.11	Dupuytren's disease;	chr10:121642661	chr10:121928312~121951965:+
BRCA	cis	rs7569084	1	rs7583469	ENSG00000281920.1	RP11-418H16.1	3.65	0.000277	0.015	0.14	0.11	Sum eosinophil basophil counts;	chr2:65424222	chr2:65623272~65628424:+
BRCA	cis	rs7120118	0.517	rs56168519	ENSG00000280615.1	Y_RNA	3.65	0.000277	0.015	0.18	0.11	HDL cholesterol;	chr11:47296436	chr11:47614898~47614994:-
BRCA	cis	rs10266483	0.705	rs660228	ENSG00000227986.1	TRIM60P18	-3.65	0.000277	0.015	-0.12	-0.11	Response to statin therapy;	chr7:64295867	chr7:64355078~64356199:+
BRCA	cis	rs4819052	0.808	rs2838825	ENSG00000215447.6	BX322557.10	-3.65	0.000277	0.015	-0.11	-0.11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45235736	chr21:45288052~45291738:+
BRCA	cis	rs72819225	0.616	rs4933667	ENSG00000228701.1	TNKS2-AS1	3.65	0.000277	0.015	0.14	0.11	Yeast infection;	chr10:91569338	chr10:91782839~91798291:-
BRCA	cis	rs4589258	1	rs7937113	ENSG00000280367.1	RP11-121L10.2	3.65	0.000277	0.015	0.13	0.11	Intelligence (multi-trait analysis);	chr11:90733217	chr11:90223153~90226538:+
BRCA	cis	rs4665809	0.818	rs35413760	ENSG00000231655.1	AC011742.3	-3.65	0.000277	0.015	-0.19	-0.11	Gut microbiome composition (summer);	chr2:26044268	chr2:26140263~26141264:-
BRCA	cis	rs9329221	0.772	rs7824675	ENSG00000154316.13	TDH	3.65	0.000277	0.015	0.14	0.11	Neuroticism;	chr8:10385908	chr8:11339637~11368452:+
BRCA	cis	rs875971	0.522	rs4718285	ENSG00000223473.2	GS1-124K5.3	3.65	0.000277	0.015	0.09	0.11	Aortic root size;	chr7:65827018	chr7:66491049~66493566:-
BRCA	cis	rs783540	1	rs11637433	ENSG00000274376.3	ADAMTS7P1	3.65	0.000277	0.015	0.12	0.11	Schizophrenia;	chr15:82652585	chr15:82298553~82334609:+
BRCA	cis	rs7617773	0.925	rs7374376	ENSG00000199476.1	Y_RNA	3.65	0.000277	0.015	0.15	0.11	Coronary artery disease;	chr3:48131197	chr3:48288587~48288694:+
BRCA	cis	rs4664293	0.967	rs13397722	ENSG00000230783.1	AC009961.2	-3.65	0.000277	0.015	-0.15	-0.11	Monocyte percentage of white cells;	chr2:159659140	chr2:159689217~159690291:-
BRCA	cis	rs7572733	0.935	rs10177758	ENSG00000231621.1	AC013264.2	-3.65	0.000277	0.015	-0.1	-0.11	Dermatomyositis;	chr2:197994193	chr2:197197991~197199273:+
BRCA	cis	rs875971	0.862	rs2088653	ENSG00000271064.1	RP11-792A8.3	3.65	0.000277	0.015	0.13	0.11	Aortic root size;	chr7:66343621	chr7:66748838~66749077:-
BRCA	cis	rs875971	0.862	rs6460293	ENSG00000271064.1	RP11-792A8.3	3.65	0.000277	0.015	0.13	0.11	Aortic root size;	chr7:66345205	chr7:66748838~66749077:-
BRCA	cis	rs91731	0.85	rs2916181	ENSG00000249572.1	CTD-2203K17.1	-3.65	0.000277	0.015	-0.21	-0.11	Lung function (FVC);	chr5:33262022	chr5:33424025~33440619:-
BRCA	cis	rs91731	0.92	rs6450975	ENSG00000249572.1	CTD-2203K17.1	-3.65	0.000277	0.015	-0.21	-0.11	Lung function (FVC);	chr5:33262283	chr5:33424025~33440619:-
BRCA	cis	rs74233809	1	rs12413409	ENSG00000236937.2	PTGES3P4	3.65	0.000277	0.015	0.24	0.11	Birth weight;	chr10:102959339	chr10:102845595~102845950:+
BRCA	cis	rs2274459	0.778	rs2281917	ENSG00000249346.5	LINC01016	3.65	0.000277	0.015	0.13	0.11	Obesity (extreme);	chr6:33687951	chr6:33867506~33896914:-
BRCA	cis	rs2562456	0.917	rs10420016	ENSG00000213976.4	CTD-2561J22.2	3.65	0.000277	0.015	0.14	0.11	Pain;	chr19:21505800	chr19:21382865~21387177:+
BRCA	cis	rs7487075	0.82	rs2408505	ENSG00000257261.4	RP11-96H19.1	3.65	0.000277	0.015	0.12	0.11	Itch intensity from mosquito bite;	chr12:46324041	chr12:46383679~46876159:+
BRCA	cis	rs930395	0.514	rs10057521	ENSG00000251141.4	RP11-53O19.1	-3.65	0.000277	0.015	-0.1	-0.11	Breast cancer;	chr5:44865884	chr5:44744900~44808777:-
BRCA	cis	rs930395	0.514	rs11958451	ENSG00000251141.4	RP11-53O19.1	-3.65	0.000277	0.015	-0.1	-0.11	Breast cancer;	chr5:44866800	chr5:44744900~44808777:-
BRCA	cis	rs10043228	1	rs62385177	ENSG00000250015.1	CTC-339F2.2	3.65	0.000277	0.015	0.14	0.11	Asthma or chronic obstructive pulmonary disease;	chr5:116144783	chr5:116302354~116304134:-
BRCA	cis	rs875971	1	rs778710	ENSG00000271064.1	RP11-792A8.3	-3.65	0.000277	0.015	-0.13	-0.11	Aortic root size;	chr7:66389847	chr7:66748838~66749077:-
BRCA	cis	rs853679	0.517	rs9357063	ENSG00000226314.6	ZNF192P1	-3.65	0.000277	0.015	-0.17	-0.11	Depression;	chr6:28092227	chr6:28161781~28169594:+
BRCA	cis	rs564309	0.867	rs513467	ENSG00000212237.1	RNA5SP18	3.65	0.000277	0.015	0.18	0.11	Hip circumference (psychosocial stress interaction);	chr1:228399734	chr1:228647912~228648032:-
BRCA	cis	rs7267979	0.727	rs4815431	ENSG00000204556.4	CTD-2514C3.1	3.65	0.000277	0.015	0.15	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25551769	chr20:26018832~26020684:+
BRCA	cis	rs7177699	0.526	rs7165042	ENSG00000261143.1	ADAMTS7P3	-3.65	0.000277	0.015	-0.13	-0.11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78830996	chr15:77976042~77993057:+
BRCA	cis	rs7177699	0.581	rs7165081	ENSG00000261143.1	ADAMTS7P3	-3.65	0.000277	0.015	-0.13	-0.11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78831054	chr15:77976042~77993057:+
BRCA	cis	rs17209837	1	rs45590633	ENSG00000224046.1	AC005076.5	3.65	0.000277	0.015	0.17	0.11	Gallbladder cancer;	chr7:87461164	chr7:87151423~87152420:-
BRCA	cis	rs7620503	0.613	rs11707809	ENSG00000277241.1	RP11-114M1.3	3.65	0.000277	0.015	0.14	0.11	Corneal structure;	chr3:177567542	chr3:177700346~177701072:-
BRCA	cis	rs7097397	0.591	rs17836440	ENSG00000265018.5	CTGLF12P	3.65	0.000277	0.015	0.15	0.11	Systemic lupus erythematosus;	chr10:48768184	chr10:48009873~48031640:-
BRCA	cis	rs11668609	0.81	rs10407383	ENSG00000268058.1	BNIP3P40	-3.65	0.000277	0.015	-0.15	-0.11	Response to taxane treatment (docetaxel);	chr19:24134099	chr19:24098425~24098980:-
BRCA	cis	rs12586478	0.585	rs12879709	ENSG00000205562.2	RP11-497E19.1	3.65	0.000278	0.015	0.1	0.11	Post bronchodilator FEV1;	chr14:86320796	chr14:85524432~85529988:-
BRCA	cis	rs890448	0.796	rs13135111	ENSG00000254531.1	FLJ20021	3.65	0.000278	0.015	0.13	0.11	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101380662	chr4:101347780~101348883:+
BRCA	cis	rs890448	0.694	rs2119593	ENSG00000254531.1	FLJ20021	3.65	0.000278	0.015	0.13	0.11	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101381407	chr4:101347780~101348883:+
BRCA	cis	rs4302906	0.964	rs10992564	ENSG00000187984.11	ANKRD19P	3.65	0.000278	0.015	0.1	0.11	Lobe attachment (rater-scored or self-reported);	chr9:92984654	chr9:92809388~92888693:+
BRCA	cis	rs6088580	0.634	rs4142007	ENSG00000275784.1	RP5-1125A11.6	3.65	0.000278	0.015	0.12	0.11	Glomerular filtration rate (creatinine);	chr20:34402244	chr20:33989480~33991818:-
BRCA	cis	rs910316	0.726	rs61979167	ENSG00000259138.1	RP11-950C14.7	-3.65	0.000278	0.015	-0.12	-0.11	Height;	chr14:75196907	chr14:75127153~75136930:+
BRCA	cis	rs6929812	0.588	rs6456788	ENSG00000220721.1	OR1F12	-3.65	0.000278	0.015	-0.13	-0.11	Neuroticism (multi-trait analysis);	chr6:27454287	chr6:28073316~28074233:+
BRCA	cis	rs56114371	0.777	rs200483	ENSG00000216901.1	AL022393.7	3.65	0.000278	0.015	0.21	0.11	Breast cancer;	chr6:27807046	chr6:28176188~28176674:+
BRCA	cis	rs11686241	0.935	rs284524	ENSG00000232485.2	AC098820.3	3.65	0.000278	0.015	0.16	0.11	Cancer;	chr2:216478050	chr2:216479030~216498761:-
BRCA	cis	rs2243480	0.522	rs73150635	ENSG00000226767.1	RP11-328P23.3	-3.65	0.000278	0.015	-0.24	-0.11	Diabetic kidney disease;	chr7:66507503	chr7:65508773~65508944:-
BRCA	cis	rs34779708	0.931	rs11010132	ENSG00000269952.1	RP11-324I22.3	-3.65	0.000278	0.0151	-0.15	-0.11	Inflammatory bowel disease;Crohn's disease;	chr10:35228337	chr10:35210416~35210750:+
BRCA	cis	rs7267979	1	rs4815418	ENSG00000204556.4	CTD-2514C3.1	3.65	0.000278	0.0151	0.15	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25401575	chr20:26018832~26020684:+
BRCA	cis	rs924712	0.596	rs2816810	ENSG00000261116.1	RP3-523K23.2	-3.65	0.000278	0.0151	-0.14	-0.11	Breast cancer;	chr6:54906339	chr6:54943167~54945099:+
BRCA	cis	rs6121246	0.954	rs6060992	ENSG00000230613.1	HM13-AS1	3.65	0.000278	0.0151	0.16	0.11	Mean corpuscular hemoglobin;	chr20:31843452	chr20:31567707~31573263:-
BRCA	cis	rs7089973	0.836	rs1046492	ENSG00000236799.1	RP11-383C6.2	-3.65	0.000278	0.0151	-0.14	-0.11	Bipolar disorder or attention deficit hyperactivity disorder;	chr10:114864308	chr10:114994657~114996593:+
BRCA	cis	rs10043228	0.826	rs11241356	ENSG00000271918.1	CTD-2287O16.5	-3.65	0.000278	0.0151	-0.15	-0.11	Asthma or chronic obstructive pulmonary disease;	chr5:116110826	chr5:116083807~116085416:-
BRCA	cis	rs713477	0.654	rs11158040	ENSG00000186615.9	KTN1-AS1	-3.65	0.000278	0.0151	-0.13	-0.11	Pediatric bone mineral content (femoral neck);	chr14:55447889	chr14:55499278~55580110:-
BRCA	cis	rs12705849	0.702	rs1610281	ENSG00000214194.7	LINC00998	3.65	0.000278	0.0151	0.15	0.11	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Eosinophil counts;	chr7:113101182	chr7:113116718~113118613:-
BRCA	cis	rs8180040	0.654	rs4682831	ENSG00000276925.1	RP11-708J19.3	3.65	0.000278	0.0151	0.13	0.11	Colorectal cancer;	chr3:46985648	chr3:47469777~47469987:+
BRCA	cis	rs4478858	0.595	rs4949387	ENSG00000260386.4	LINC01225	-3.65	0.000278	0.0151	-0.13	-0.11	Alcohol dependence;	chr1:31330593	chr1:31500085~31540885:+
BRCA	cis	rs875971	1	rs2220626	ENSG00000230189.5	GS1-124K5.2	-3.65	0.000278	0.0151	-0.09	-0.11	Aortic root size;	chr7:66081075	chr7:66409143~66490059:-
BRCA	cis	rs2136613	0.751	rs10995334	ENSG00000238280.1	RP11-436D10.3	-3.65	0.000278	0.0151	-0.14	-0.11	Selective IgA deficiency;	chr10:62858052	chr10:62793562~62805887:-
BRCA	cis	rs2108622	0.727	rs7253873	ENSG00000214049.6	UCA1	3.65	0.000278	0.0151	0.16	0.11	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15870090	chr19:15828961~15836320:+
BRCA	cis	rs17221829	0.549	rs72969202	ENSG00000280385.1	AP000648.5	-3.65	0.000278	0.0151	-0.13	-0.11	Anxiety in major depressive disorder;	chr11:89625187	chr11:90193614~90198120:+
BRCA	cis	rs6812193	0.518	rs62300803	ENSG00000271676.1	RP11-1E1.2	3.65	0.000278	0.0151	0.16	0.11	Parkinson's disease;	chr4:76268265	chr4:77112495~77113458:-
BRCA	cis	rs875971	0.83	rs587360	ENSG00000271064.1	RP11-792A8.3	-3.65	0.000278	0.0151	-0.13	-0.11	Aortic root size;	chr7:66057711	chr7:66748838~66749077:-
BRCA	cis	rs13272568	0.614	rs17483138	ENSG00000254352.1	RP11-578O24.2	-3.65	0.000278	0.0151	-0.14	-0.11	Bone mineral density;	chr8:78122698	chr8:78723796~78724136:-
BRCA	cis	rs17270561	0.514	rs10946805	ENSG00000272810.1	U91328.22	-3.65	0.000278	0.0151	-0.16	-0.11	Iron status biomarkers;	chr6:26077663	chr6:26013241~26013757:+
BRCA	cis	rs17270561	0.636	rs4360128	ENSG00000272462.2	U91328.19	-3.65	0.000278	0.0151	-0.14	-0.11	Iron status biomarkers;	chr6:25734330	chr6:25992662~26001775:+
BRCA	cis	rs11700980	0.748	rs17734876	ENSG00000232855.5	AF131217.1	3.65	0.000278	0.0151	0.22	0.11	QRS complex (12-leadsum);	chr21:28887822	chr21:28439346~28674848:-
BRCA	cis	rs4246129	0.838	rs12676904	ENSG00000259891.1	CTA-204B4.2	-3.65	0.000278	0.0151	-0.14	-0.11	Cleft palate;	chr8:140488654	chr8:140505813~140508043:-
BRCA	cis	rs4660456	0.542	rs850009	ENSG00000272145.1	NFYC-AS1	-3.65	0.000278	0.0151	-0.13	-0.11	Platelet count;	chr1:40643593	chr1:40690380~40692066:-
BRCA	cis	rs76917914	1	rs4743150	ENSG00000236896.1	RP11-535C21.3	3.65	0.000278	0.0151	0.14	0.11	Immature fraction of reticulocytes;	chr9:97977842	chr9:97986551~97987656:-
BRCA	cis	rs10043775	1	rs1971431	ENSG00000251330.3	CTD-2283N19.1	-3.65	0.000278	0.0151	-0.13	-0.11	Periodontal microbiota;	chr5:148452493	chr5:148430159~148430807:-
BRCA	cis	rs12612435	0.91	rs7589760	ENSG00000226806.1	AC011893.3	3.65	0.000278	0.0151	0.14	0.11	Takotsubo syndrome;	chr2:136354152	chr2:135820191~135823087:+
BRCA	cis	rs853679	0.55	rs9295762	ENSG00000261839.1	RP1-265C24.8	-3.65	0.000279	0.0151	-0.15	-0.11	Depression;	chr6:28187640	chr6:28136849~28139678:+
BRCA	cis	rs253959	0.545	rs712599	ENSG00000272265.1	CTD-2287O16.4	-3.65	0.000279	0.0151	-0.13	-0.11	Bipolar disorder and schizophrenia;	chr5:116323068	chr5:116078110~116078570:-
BRCA	cis	rs17214007	0.877	rs2075514	ENSG00000279866.1	CTB-193M12.4	3.65	0.000279	0.0151	0.17	0.11	Cognitive function;	chr16:15778752	chr16:15704410~15705984:+
BRCA	cis	rs72819225	0.696	rs12268133	ENSG00000228701.1	TNKS2-AS1	3.65	0.000279	0.0151	0.14	0.11	Yeast infection;	chr10:91555514	chr10:91782839~91798291:-
BRCA	cis	rs7512898	0.9	rs6427851	ENSG00000260088.1	RP11-92G12.3	-3.65	0.000279	0.0151	-0.14	-0.11	Electrocardiographic conduction measures;	chr1:200704177	chr1:200669507~200694250:+
BRCA	cis	rs4388249	1	rs4388249	ENSG00000249068.1	CTC-287O8.1	-3.65	0.000279	0.0151	-0.16	-0.11	Schizophrenia;	chr5:109700365	chr5:109840128~109840692:-
BRCA	cis	rs1528472	0.836	rs67460780	ENSG00000276533.1	RP11-139H15.5	3.65	0.000279	0.0151	0.13	0.11	Urinary albumin-to-creatinine ratio;Urinary albumin-to-creatinine ratio in non-diabetics;	chr15:55018293	chr15:55288849~55289346:-
BRCA	cis	rs7520050	0.931	rs35743647	ENSG00000234329.1	RP11-767N6.2	-3.65	0.000279	0.0151	-0.11	-0.11	Reticulocyte count;Red blood cell count;	chr1:45941580	chr1:45651039~45651826:-
BRCA	cis	rs10129255	0.5	rs10131875	ENSG00000211976.2	IGHV3-73	-3.65	0.000279	0.0151	-0.08	-0.11	Kawasaki disease;	chr14:106792798	chr14:106802694~106803233:-
BRCA	cis	rs321358	0.731	rs576877	ENSG00000271390.1	RP11-89C3.3	3.65	0.000279	0.0151	0.17	0.11	Body mass index;	chr11:111147472	chr11:111089870~111090368:-
BRCA	cis	rs2562456	0.917	rs2681392	ENSG00000213976.4	CTD-2561J22.2	3.65	0.000279	0.0151	0.14	0.11	Pain;	chr19:21513185	chr19:21382865~21387177:+
BRCA	cis	rs11047510	0.593	rs7136690	ENSG00000164845.15	FAM86FP	3.65	0.000279	0.0151	0.18	0.11	Exploratory eye movement dysfunction in schizophrenia (responsive search score);	chr12:8850431	chr12:8232512~8242948:-
BRCA	cis	rs11048434	0.518	rs7311509	ENSG00000111788.10	RP11-22B23.1	3.65	0.000279	0.0151	0.1	0.11	Sjögren's syndrome;	chr12:9026438	chr12:9277235~9313241:+
BRCA	cis	rs2839186	0.814	rs13052376	ENSG00000215424.8	MCM3AP-AS1	3.65	0.000279	0.0151	0.1	0.11	Testicular germ cell tumor;	chr21:46287489	chr21:46229217~46259390:+
BRCA	cis	rs2839186	0.934	rs13046494	ENSG00000215424.8	MCM3AP-AS1	3.65	0.000279	0.0151	0.1	0.11	Testicular germ cell tumor;	chr21:46287516	chr21:46229217~46259390:+
BRCA	cis	rs2839186	0.872	rs13052495	ENSG00000215424.8	MCM3AP-AS1	3.65	0.000279	0.0151	0.1	0.11	Testicular germ cell tumor;	chr21:46287560	chr21:46229217~46259390:+
BRCA	cis	rs4835473	0.9	rs5015759	ENSG00000246448.2	RP13-578N3.3	-3.65	0.000279	0.0151	-0.13	-0.11	Immature fraction of reticulocytes;	chr4:143738050	chr4:143700257~143865072:+
BRCA	cis	rs4415084	0.834	rs1438821	ENSG00000248779.1	RP11-53O19.2	-3.65	0.000279	0.0151	-0.1	-0.11	Breast cancer;	chr5:44858349	chr5:44752949~44765744:+
BRCA	cis	rs4427176	0.507	rs7010270	ENSG00000272267.2	RP11-375N15.2	3.65	0.000279	0.0151	0.13	0.11	Mosquito bite size;	chr8:9699337	chr8:9555144~9556520:-
BRCA	cis	rs7412746	0.658	rs6660845	ENSG00000231073.1	RP11-316M1.3	3.65	0.000279	0.0151	0.12	0.11	Melanoma;	chr1:150868590	chr1:150973123~150975534:+
BRCA	cis	rs73201462	1	rs2811530	ENSG00000242551.2	POU5F1P6	-3.65	0.000279	0.0151	-0.19	-0.11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128274323	chr3:128674735~128677005:-
BRCA	cis	rs6460942	0.908	rs73677573	ENSG00000226690.5	AC005281.1	3.65	0.000279	0.0151	0.21	0.11	Coronary artery disease;	chr7:12243972	chr7:12496429~12541910:+
BRCA	cis	rs739401	0.611	rs2239899	ENSG00000247473.2	CARS-AS1	-3.65	0.000279	0.0151	-0.13	-0.11	Longevity;	chr11:3003394	chr11:3029009~3041260:+
BRCA	cis	rs2835872	0.828	rs111576572	ENSG00000228677.1	TTC3-AS1	-3.65	0.000279	0.0151	-0.14	-0.11	Electroencephalographic traits in alcoholism;	chr21:37617262	chr21:37187666~37193926:-
BRCA	cis	rs8114671	0.562	rs4911447	ENSG00000279253.1	RP4-614O4.13	-3.65	0.000279	0.0151	-0.13	-0.11	Height;	chr20:34891642	chr20:35262727~35264187:-
BRCA	cis	rs889312	0.5	rs252920	ENSG00000271828.1	CTD-2310F14.1	-3.65	0.000279	0.0151	-0.14	-0.11	Breast cancer (early onset);Breast cancer;	chr5:56852914	chr5:56927874~56929573:+
BRCA	cis	rs13434995	0.513	rs2130040	ENSG00000273257.1	RP11-177J6.1	3.65	0.000279	0.0151	0.17	0.11	Adiponectin levels;	chr4:55564036	chr4:55387949~55388271:+
BRCA	cis	rs7824557	0.872	rs2572431	ENSG00000154316.13	TDH	3.65	0.000279	0.0151	0.14	0.11	Retinal vascular caliber;	chr8:11247568	chr8:11339637~11368452:+
BRCA	cis	rs911119	0.955	rs7270413	ENSG00000270001.1	RP11-218C14.8	-3.65	0.000279	0.0151	-0.15	-0.11	Chronic kidney disease;	chr20:23613184	chr20:23631826~23632316:-
BRCA	cis	rs9788682	0.747	rs2656074	ENSG00000261143.1	ADAMTS7P3	3.65	0.000279	0.0151	0.15	0.11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78449042	chr15:77976042~77993057:+
BRCA	cis	rs11098499	0.954	rs9993199	ENSG00000260404.2	RP11-384K6.6	-3.65	0.000279	0.0151	-0.1	-0.11	Corneal astigmatism;	chr4:119471718	chr4:118591773~118633729:+
BRCA	cis	rs17684571	0.687	rs35461301	ENSG00000231441.1	RP11-472M19.2	3.65	0.000279	0.0151	0.18	0.11	Schizophrenia;	chr6:56832577	chr6:56844002~56864078:+
BRCA	cis	rs17684571	0.687	rs35851452	ENSG00000231441.1	RP11-472M19.2	3.65	0.000279	0.0151	0.18	0.11	Schizophrenia;	chr6:56832602	chr6:56844002~56864078:+
BRCA	cis	rs13272568	0.614	rs7819667	ENSG00000254352.1	RP11-578O24.2	-3.65	0.000279	0.0151	-0.14	-0.11	Bone mineral density;	chr8:78129333	chr8:78723796~78724136:-
BRCA	cis	rs7520050	0.966	rs12049588	ENSG00000281133.1	AL355480.3	3.65	0.000279	0.0151	0.13	0.11	Reticulocyte count;Red blood cell count;	chr1:46006750	chr1:45580892~45580996:-
BRCA	cis	rs7520050	0.966	rs12021587	ENSG00000281133.1	AL355480.3	3.65	0.000279	0.0151	0.13	0.11	Reticulocyte count;Red blood cell count;	chr1:46007087	chr1:45580892~45580996:-
BRCA	cis	rs2609255	1	rs2125409	ENSG00000270720.1	RP11-84C13.2	3.65	0.000279	0.0151	0.13	0.11	Interstitial lung disease;	chr4:88929391	chr4:89119284~89119871:+
BRCA	cis	rs17270561	0.609	rs9358876	ENSG00000272462.2	U91328.19	-3.65	0.000279	0.0151	-0.14	-0.11	Iron status biomarkers;	chr6:25738728	chr6:25992662~26001775:+
BRCA	cis	rs17270561	0.583	rs9393661	ENSG00000272462.2	U91328.19	-3.65	0.000279	0.0151	-0.14	-0.11	Iron status biomarkers;	chr6:25738852	chr6:25992662~26001775:+
BRCA	cis	rs17270561	0.609	rs9356986	ENSG00000272462.2	U91328.19	-3.65	0.000279	0.0151	-0.14	-0.11	Iron status biomarkers;	chr6:25738891	chr6:25992662~26001775:+
BRCA	cis	rs17270561	0.609	rs9358877	ENSG00000272462.2	U91328.19	-3.65	0.000279	0.0151	-0.14	-0.11	Iron status biomarkers;	chr6:25739000	chr6:25992662~26001775:+
BRCA	cis	rs17270561	0.609	rs12663099	ENSG00000272462.2	U91328.19	-3.65	0.000279	0.0151	-0.14	-0.11	Iron status biomarkers;	chr6:25739290	chr6:25992662~26001775:+
BRCA	cis	rs17270561	0.609	rs9393662	ENSG00000272462.2	U91328.19	-3.65	0.000279	0.0151	-0.14	-0.11	Iron status biomarkers;	chr6:25739442	chr6:25992662~26001775:+
BRCA	cis	rs4908769	0.627	rs301798	ENSG00000232912.4	RP5-1115A15.1	3.65	0.000279	0.0151	0.12	0.11	Allergy;	chr1:8428505	chr1:8424645~8434838:+
BRCA	cis	rs854765	0.547	rs9896837	ENSG00000154874.13	CCDC144B	-3.65	0.000279	0.0151	-0.13	-0.11	Total body bone mineral density;	chr17:18021554	chr17:18537800~18625617:-
BRCA	cis	rs4713675	0.709	rs626156	ENSG00000249346.5	LINC01016	3.65	0.000279	0.0151	0.11	0.11	Plateletcrit;	chr6:33702705	chr6:33867506~33896914:-
BRCA	cis	rs1949733	1	rs1916326	ENSG00000251615.3	RP11-774O3.3	3.65	0.000279	0.0151	0.12	0.11	Response to antineoplastic agents;	chr4:8498296	chr4:8355090~8358338:-
BRCA	cis	rs853679	0.546	rs200490	ENSG00000216901.1	AL022393.7	3.65	0.000279	0.0151	0.22	0.11	Depression;	chr6:27829157	chr6:28176188~28176674:+
BRCA	cis	rs2274273	0.967	rs11622740	ENSG00000259318.1	RP11-454L9.2	3.65	0.000279	0.0151	0.1	0.11	Protein biomarker;	chr14:55151126	chr14:55394940~55395233:-
BRCA	cis	rs16950303	0.661	rs12456273	ENSG00000265496.3	MIR1539	3.65	0.000279	0.0151	0.22	0.11	Height;	chr18:49058381	chr18:49487339~49491878:+
BRCA	cis	rs2998286	0.822	rs2095901	ENSG00000237128.1	RP11-351M16.3	3.65	0.000279	0.0151	0.14	0.11	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28514790	chr10:28433008~28495813:-
BRCA	cis	rs2998286	0.862	rs2993990	ENSG00000237128.1	RP11-351M16.3	3.65	0.000279	0.0151	0.14	0.11	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28518041	chr10:28433008~28495813:-
BRCA	cis	rs375066	0.935	rs429027	ENSG00000278917.1	RP11-15A1.4	-3.65	0.000279	0.0151	-0.13	-0.11	Breast cancer;	chr19:43891337	chr19:43891233~43895411:+
BRCA	cis	rs871012	0.502	rs4704865	ENSG00000251405.2	CTB-109A12.1	-3.65	0.000279	0.0151	-0.15	-0.11	IgG glycosylation;	chr5:157465802	chr5:157362615~157460078:-
BRCA	cis	rs7412746	0.611	rs2864873	ENSG00000231073.1	RP11-316M1.3	3.65	0.000279	0.0151	0.12	0.11	Melanoma;	chr1:150841698	chr1:150973123~150975534:+
BRCA	cis	rs6696239	0.956	rs6426470	ENSG00000227711.2	RP11-275O4.5	-3.65	0.00028	0.0151	-0.15	-0.11	Height;	chr1:227665920	chr1:227509028~227520477:-
BRCA	cis	rs2436153	0.645	rs1367987	ENSG00000254551.1	RP11-727A23.7	3.65	0.00028	0.0151	0.13	0.11	Facial morphology (factor 16);	chr11:83530818	chr11:83209431~83213379:-
BRCA	cis	rs7267979	1	rs4815407	ENSG00000274414.1	RP5-965G21.4	3.65	0.00028	0.0151	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25360842	chr20:25239007~25245229:-
BRCA	cis	rs2360027	0.644	rs60865692	ENSG00000231365.4	RP11-418J17.1	-3.65	0.00028	0.0151	-0.14	-0.11	Tonsillectomy;	chr1:118564312	chr1:119140396~119275973:+
BRCA	cis	rs1008375	1	rs2058337	ENSG00000249502.1	AC006160.5	-3.65	0.00028	0.0151	-0.12	-0.11	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17677026	chr4:17587467~17614571:-
BRCA	cis	rs957448	0.948	rs11992893	ENSG00000261437.1	RP11-22C11.2	3.65	0.00028	0.0151	0.12	0.11	Nonsyndromic cleft lip with cleft palate;	chr8:94508473	chr8:94637285~94639467:-
BRCA	cis	rs957448	1	rs1048029	ENSG00000261437.1	RP11-22C11.2	3.65	0.00028	0.0151	0.12	0.11	Nonsyndromic cleft lip with cleft palate;	chr8:94510149	chr8:94637285~94639467:-
BRCA	cis	rs757081	0.514	rs214087	ENSG00000184669.7	OR7E14P	-3.65	0.00028	0.0151	-0.15	-0.11	Systolic blood pressure;	chr11:17276818	chr11:17013998~17053024:+
BRCA	cis	rs1044573	0.514	rs2268879	ENSG00000277938.1	RP5-965G21.3	-3.65	0.00028	0.0151	-0.13	-0.11	Allergic rhinitis;	chr20:25197169	chr20:25229150~25231933:+
BRCA	cis	rs875971	0.545	rs73146609	ENSG00000232559.3	GS1-124K5.12	3.65	0.00028	0.0151	0.16	0.11	Aortic root size;	chr7:66302477	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.545	rs2173571	ENSG00000232559.3	GS1-124K5.12	3.65	0.00028	0.0151	0.16	0.11	Aortic root size;	chr7:66305392	chr7:66554588~66576923:-
BRCA	cis	rs1876905	0.764	rs4947106	ENSG00000272356.1	RP5-1112D6.8	3.65	0.00028	0.0151	0.15	0.11	Mean corpuscular hemoglobin;	chr6:111100163	chr6:111309203~111313517:+
BRCA	cis	rs983392	0.679	rs10736700	ENSG00000275344.1	MIR6503	3.65	0.00028	0.0151	0.12	0.11	Alzheimer's disease (late onset);	chr11:60263926	chr11:60209071~60209156:-
BRCA	cis	rs6071166	0.683	rs6071127	ENSG00000224635.1	RP4-564F22.5	-3.65	0.00028	0.0151	-0.14	-0.11	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38693614	chr20:38406011~38416797:-
BRCA	cis	rs8023401	0.938	rs12906911	ENSG00000274654.1	CTD-3247H4.2	3.65	0.00028	0.0151	0.17	0.11	Spherical equivalent (joint analysis main effects and education interaction);	chr15:48535964	chr15:48528980~48529728:-
BRCA	cis	rs2243480	0.901	rs2900904	ENSG00000226767.1	RP11-328P23.3	-3.65	0.00028	0.0151	-0.19	-0.11	Diabetic kidney disease;	chr7:65739282	chr7:65508773~65508944:-
BRCA	cis	rs10129255	0.957	rs2013423	ENSG00000211967.3	IGHV3-53	-3.65	0.00028	0.0151	-0.08	-0.11	Kawasaki disease;	chr14:106690675	chr14:106592676~106593347:-
BRCA	cis	rs10129255	0.957	rs56134540	ENSG00000211967.3	IGHV3-53	-3.65	0.00028	0.0151	-0.08	-0.11	Kawasaki disease;	chr14:106691290	chr14:106592676~106593347:-
BRCA	cis	rs739496	0.947	rs7299849	ENSG00000257624.1	RP1-128M12.3	3.65	0.00028	0.0151	0.15	0.11	Platelet count;	chr12:111417657	chr12:112000739~112000985:-
BRCA	cis	rs530081	0.729	rs476348	ENSG00000274184.1	RP11-158H5.8	-3.65	0.00028	0.0151	-0.15	-0.11	Lobe attachment (rater-scored or self-reported);	chr18:35090057	chr18:35268218~35270238:+
BRCA	cis	rs1065852	0.526	rs56234624	ENSG00000205702.9	CYP2D7	3.65	0.00028	0.0151	0.1	0.11	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:41992822	chr22:42140203~42144577:-
BRCA	cis	rs3749237	1	rs3749237	ENSG00000225399.4	RP11-3B7.1	3.65	0.00028	0.0151	0.11	0.11	Resting heart rate;	chr3:49732599	chr3:49260085~49261316:+
BRCA	cis	rs3755605	0.728	rs2901549	ENSG00000242578.1	RP11-469J4.3	3.65	0.00028	0.0151	0.13	0.11	Testicular germ cell tumor;	chr3:170176555	chr3:170410512~170418615:+
BRCA	cis	rs7111546	0.791	rs80318330	ENSG00000246225.5	RP11-17A1.3	3.65	0.00028	0.0151	0.19	0.11	Dialysis-related mortality;	chr11:22851095	chr11:22829380~22945393:+
BRCA	cis	rs35306767	0.903	rs11815185	ENSG00000229869.1	RP11-363N22.2	-3.65	0.00028	0.0151	-0.17	-0.11	Eosinophil percentage of granulocytes;	chr10:877677	chr10:933026~942743:+
BRCA	cis	rs35306767	0.903	rs12260800	ENSG00000229869.1	RP11-363N22.2	-3.65	0.00028	0.0151	-0.17	-0.11	Eosinophil percentage of granulocytes;	chr10:881993	chr10:933026~942743:+
BRCA	cis	rs324126	0.78	rs55748277	ENSG00000277977.1	CTD-3018O17.5	3.65	0.00028	0.0151	0.13	0.11	Colonoscopy-negative controls vs population controls;	chr19:52384992	chr19:52392659~52392755:+
BRCA	cis	rs2998286	0.723	rs332161	ENSG00000237128.1	RP11-351M16.3	-3.65	0.00028	0.0151	-0.15	-0.11	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28599911	chr10:28433008~28495813:-
BRCA	cis	rs12681366	0.571	rs2930959	ENSG00000253175.1	RP11-267M23.6	3.65	0.00028	0.0151	0.13	0.11	Nonsyndromic cleft lip with cleft palate;	chr8:94461930	chr8:94565036~94565715:+
BRCA	cis	rs6918586	0.565	rs198855	ENSG00000272810.1	U91328.22	-3.65	0.00028	0.0151	-0.14	-0.11	Schizophrenia;	chr6:26103170	chr6:26013241~26013757:+
BRCA	cis	rs4302906	0.753	rs3936098	ENSG00000187984.11	ANKRD19P	-3.65	0.00028	0.0151	-0.11	-0.11	Lobe attachment (rater-scored or self-reported);	chr9:92949080	chr9:92809388~92888693:+
BRCA	cis	rs524281	0.773	rs11227447	ENSG00000255038.1	RP11-1167A19.2	-3.65	0.00028	0.0151	-0.18	-0.11	Electroencephalogram traits;	chr11:66280809	chr11:66067277~66069619:-
BRCA	cis	rs11098403	0.764	rs17866935	ENSG00000225892.3	RP11-384K6.2	3.65	0.00028	0.0151	0.11	0.11	Schizophrenia;	chr4:117810509	chr4:118632274~118634759:+
BRCA	cis	rs17684571	0.938	rs4074102	ENSG00000231441.1	RP11-472M19.2	3.65	0.00028	0.0152	0.18	0.11	Schizophrenia;	chr6:56697497	chr6:56844002~56864078:+
BRCA	cis	rs17684571	0.938	rs4074101	ENSG00000231441.1	RP11-472M19.2	3.65	0.00028	0.0152	0.18	0.11	Schizophrenia;	chr6:56697654	chr6:56844002~56864078:+
BRCA	cis	rs2243480	1	rs12698509	ENSG00000226767.1	RP11-328P23.3	-3.65	0.00028	0.0152	-0.19	-0.11	Diabetic kidney disease;	chr7:65953889	chr7:65508773~65508944:-
BRCA	cis	rs2274273	1	rs2075603	ENSG00000259318.1	RP11-454L9.2	3.65	0.00028	0.0152	0.1	0.11	Protein biomarker;	chr14:55143237	chr14:55394940~55395233:-
BRCA	cis	rs4835473	0.801	rs35839125	ENSG00000249741.2	RP11-673E1.3	3.65	0.00028	0.0152	0.11	0.11	Immature fraction of reticulocytes;	chr4:143792351	chr4:143911514~143912053:-
BRCA	cis	rs4835473	0.9	rs7698963	ENSG00000246448.2	RP13-578N3.3	3.65	0.00028	0.0152	0.13	0.11	Immature fraction of reticulocytes;	chr4:143733190	chr4:143700257~143865072:+
BRCA	cis	rs67073037	1	rs7580240	ENSG00000230730.1	AC074011.2	-3.65	0.00028	0.0152	-0.15	-0.11	Breast cancer;Breast cancer (estrogen-receptor negative);	chr2:28891506	chr2:28633282~28664540:-
BRCA	cis	rs690037	0.966	rs574083	ENSG00000272498.1	RP11-415F23.3	3.65	0.00028	0.0152	0.11	0.11	Optic nerve measurement (cup-to-disc ratio);Optic nerve measurement (cup area);	chr3:16354006	chr3:16339308~16339871:+
BRCA	cis	rs2562456	1	rs2359155	ENSG00000213976.4	CTD-2561J22.2	3.65	0.00028	0.0152	0.13	0.11	Pain;	chr19:21489067	chr19:21382865~21387177:+
BRCA	cis	rs6439699	0.941	rs13067731	ENSG00000239213.4	NCK1-AS1	3.65	0.00028	0.0152	0.15	0.11	Intelligence (multi-trait analysis);	chr3:137271149	chr3:136841726~136862054:-
BRCA	cis	rs2692947	0.832	rs62153679	ENSG00000232931.4	LINC00342	3.65	0.00028	0.0152	0.12	0.11	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95892652	chr2:95807118~95816215:-
BRCA	cis	rs10829156	0.738	rs4748502	ENSG00000225527.1	RP11-383B4.4	-3.65	0.00028	0.0152	-0.15	-0.11	Sudden cardiac arrest;	chr10:18647032	chr10:18531849~18533336:-
BRCA	cis	rs4664293	0.934	rs7604482	ENSG00000224152.1	AC009506.1	-3.65	0.00028	0.0152	-0.12	-0.11	Monocyte percentage of white cells;	chr2:159657315	chr2:159615296~159617082:+
BRCA	cis	rs7226408	0.749	rs11665002	ENSG00000267707.2	RP11-95O2.5	3.65	0.00028	0.0152	0.17	0.11	Obesity-related traits;	chr18:36734060	chr18:37243776~37247506:+
BRCA	cis	rs12760731	0.641	rs11588490	ENSG00000213057.5	C1orf220	3.65	0.00028	0.0152	0.16	0.11	Obesity-related traits;	chr1:178359004	chr1:178542752~178548889:+
BRCA	cis	rs12760731	0.72	rs34194793	ENSG00000213057.5	C1orf220	3.65	0.00028	0.0152	0.16	0.11	Obesity-related traits;	chr1:178359930	chr1:178542752~178548889:+
BRCA	cis	rs2412819	0.597	rs7181912	ENSG00000201136.1	RNU6-353P	-3.65	0.00028	0.0152	-0.16	-0.11	Lung cancer;	chr15:43770676	chr15:43702363~43702470:+
BRCA	cis	rs7698598	1	rs10103	ENSG00000178636.7	RP11-455G16.1	-3.65	0.00028	0.0152	-0.19	-0.11	Amyotrophic lateral sclerosis (sporadic);	chr4:119035530	chr4:119192773~119212644:-
BRCA	cis	rs9549260	0.604	rs9549273	ENSG00000168852.11	TPTE2P5	-3.65	0.00028	0.0152	-0.14	-0.11	Red blood cell count;	chr13:40728011	chr13:40822296~40921749:-
BRCA	cis	rs2109514	0.602	rs1858810	ENSG00000237813.3	AC002066.1	-3.65	0.00028	0.0152	-0.14	-0.11	Prevalent atrial fibrillation;	chr7:116418805	chr7:116238260~116499465:-
BRCA	cis	rs2554380	0.943	rs2585061	ENSG00000230373.7	GOLGA6L5P	-3.65	0.00028	0.0152	-0.16	-0.11	Height;	chr15:83678999	chr15:84507885~84516814:-
BRCA	cis	rs988913	0.697	rs9475159	ENSG00000261116.1	RP3-523K23.2	3.65	0.00028	0.0152	0.13	0.11	Menarche (age at onset);	chr6:55130719	chr6:54943167~54945099:+
BRCA	cis	rs7828089	0.744	rs10108011	ENSG00000253125.1	RP11-459E5.1	3.65	0.00028	0.0152	0.11	0.11	Verbal declarative memory;	chr8:22463293	chr8:22690150~22798616:+
BRCA	cis	rs9467773	0.935	rs1884947	ENSG00000224843.5	LINC00240	-3.65	0.00028	0.0152	-0.13	-0.11	Intelligence (multi-trait analysis);	chr6:26553045	chr6:26956992~27023924:+
BRCA	cis	rs6964587	0.967	rs28399886	ENSG00000188693.7	CYP51A1-AS1	-3.65	0.00028	0.0152	-0.12	-0.11	Breast cancer;	chr7:92009137	chr7:92134604~92180725:+
BRCA	cis	rs603446	1	rs1145208	ENSG00000280143.1	AP000892.6	3.65	0.00028	0.0152	0.11	0.11	Triglycerides;	chr11:116767269	chr11:117204967~117210292:+
BRCA	cis	rs2274273	0.934	rs10139337	ENSG00000259318.1	RP11-454L9.2	3.65	0.00028	0.0152	0.1	0.11	Protein biomarker;	chr14:55275395	chr14:55394940~55395233:-
BRCA	cis	rs2115630	0.967	rs28595395	ENSG00000275120.1	RP11-182J1.17	-3.65	0.000281	0.0152	-0.13	-0.11	P wave terminal force;	chr15:84791721	chr15:84599434~84606463:-
BRCA	cis	rs2276314	0.857	rs7237599	ENSG00000267627.4	RP11-905K4.1	-3.65	0.000281	0.0152	-0.15	-0.11	Endometriosis;Drug-induced torsades de pointes;	chr18:36059433	chr18:35951803~35966118:-
BRCA	cis	rs1552244	0.572	rs6785976	ENSG00000180385.7	EMC3-AS1	3.65	0.000281	0.0152	0.15	0.11	Alzheimer's disease;	chr3:10126963	chr3:9986893~10006990:+
BRCA	cis	rs36051895	0.632	rs7850484	ENSG00000236254.1	MTND4P14	-3.64	0.000281	0.0152	-0.13	-0.11	Pediatric autoimmune diseases;	chr9:5147817	chr9:5107937~5109290:+
BRCA	cis	rs6088580	0.634	rs62212172	ENSG00000275784.1	RP5-1125A11.6	3.64	0.000281	0.0152	0.12	0.11	Glomerular filtration rate (creatinine);	chr20:34399899	chr20:33989480~33991818:-
BRCA	cis	rs6964833	0.935	rs34630792	ENSG00000277072.3	STAG3L2	3.64	0.000281	0.0152	0.12	0.11	Menarche (age at onset);	chr7:74646869	chr7:74882163~74890610:-
BRCA	cis	rs9844666	0.532	rs7625040	ENSG00000273486.1	RP11-731C17.2	3.64	0.000281	0.0152	0.13	0.11	Height;	chr3:135943623	chr3:136837338~136839021:-
BRCA	cis	rs1208	0.777	rs2410563	ENSG00000253671.1	RP11-806O11.1	3.64	0.000281	0.0152	0.13	0.11	Insulin resistance/response;	chr8:18413741	chr8:17808941~17820868:+
BRCA	cis	rs4476553	0.868	rs2280041	ENSG00000247708.6	STX18-AS1	3.64	0.000281	0.0152	0.11	0.11	Response to amphetamines;	chr4:4707930	chr4:4542131~4710938:+
BRCA	cis	rs251253	0.795	rs251246	ENSG00000253959.1	CTB-43E15.1	3.64	0.000281	0.0152	0.1	0.11	PR interval;	chr5:173060892	chr5:173642519~173658194:+
BRCA	cis	rs251253	0.827	rs251245	ENSG00000253959.1	CTB-43E15.1	3.64	0.000281	0.0152	0.1	0.11	PR interval;	chr5:173061333	chr5:173642519~173658194:+
BRCA	cis	rs7521902	0.617	rs7412010	ENSG00000228397.1	RP1-224A6.3	-3.64	0.000281	0.0152	-0.2	-0.11	Endometriosis;Ovarian cancer;Bone mineral density;Hip circumference adjusted for BMI;	chr1:22109953	chr1:22023994~22024968:-
BRCA	cis	rs7267979	1	rs6050590	ENSG00000274414.1	RP5-965G21.4	3.64	0.000281	0.0152	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25404358	chr20:25239007~25245229:-
BRCA	cis	rs7267979	1	rs4813566	ENSG00000274414.1	RP5-965G21.4	3.64	0.000281	0.0152	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25405829	chr20:25239007~25245229:-
BRCA	cis	rs7267979	1	rs4815421	ENSG00000274414.1	RP5-965G21.4	3.64	0.000281	0.0152	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25405873	chr20:25239007~25245229:-
BRCA	cis	rs1876206	0.554	rs612617	ENSG00000274654.1	CTD-3247H4.2	-3.64	0.000281	0.0152	-0.14	-0.11	Breast cancer;	chr15:48614380	chr15:48528980~48529728:-
BRCA	cis	rs7089973	0.872	rs12773943	ENSG00000236799.1	RP11-383C6.2	-3.64	0.000281	0.0152	-0.14	-0.11	Bipolar disorder or attention deficit hyperactivity disorder;	chr10:114871425	chr10:114994657~114996593:+
BRCA	cis	rs9470794	1	rs11750950	ENSG00000204110.6	RP1-153P14.8	-3.64	0.000281	0.0152	-0.21	-0.11	Type 2 diabetes;	chr6:38011404	chr6:37507348~37535616:+
BRCA	cis	rs2731006	0.901	rs2678118	ENSG00000257114.2	RP11-25I15.3	3.64	0.000281	0.0152	0.17	0.11	Panic disorder;	chr12:42764365	chr12:42692216~42717119:+
BRCA	cis	rs2731006	0.901	rs2678116	ENSG00000257114.2	RP11-25I15.3	3.64	0.000281	0.0152	0.17	0.11	Panic disorder;	chr12:42764824	chr12:42692216~42717119:+
BRCA	cis	rs13098911	0.54	rs35827997	ENSG00000223552.1	RP11-24F11.2	-3.64	0.000281	0.0152	-0.18	-0.11	Celiac disease;	chr3:45960228	chr3:46364955~46407059:-
BRCA	cis	rs853679	0.517	rs3757185	ENSG00000226314.6	ZNF192P1	-3.64	0.000281	0.0152	-0.17	-0.11	Depression;	chr6:28139998	chr6:28161781~28169594:+
BRCA	cis	rs8180040	0.62	rs1811652	ENSG00000280667.1	Y_RNA	-3.64	0.000281	0.0152	-0.13	-0.11	Colorectal cancer;	chr3:47167208	chr3:47501083~47501182:+
BRCA	cis	rs12530845	0.945	rs59664351	ENSG00000223718.3	AC093107.7	3.64	0.000281	0.0152	0.17	0.11	Red blood cell traits;	chr7:135629969	chr7:135660039~135660647:+
BRCA	cis	rs3768617	0.811	rs10911232	ENSG00000224468.3	RP11-181K3.4	-3.64	0.000281	0.0152	-0.12	-0.11	Fuchs's corneal dystrophy;	chr1:183083398	chr1:183138402~183141282:-
BRCA	cis	rs9346455	0.614	rs2273888	ENSG00000199094.2	MIR30C2	-3.64	0.000281	0.0152	-0.16	-0.11	Antipsychotic drug-induced weight gain;Antipsychotic drug-induced weight gain (time interaction);	chr6:71296809	chr6:71376933~71377045:-
BRCA	cis	rs801193	0.66	rs1962050	ENSG00000067601.7	PMS2P4	3.64	0.000281	0.0152	0.13	0.11	Aortic root size;	chr7:66775021	chr7:67295608~67302907:-
BRCA	cis	rs2262909	0.962	rs409835	ENSG00000279377.1	AC003973.3	3.64	0.000281	0.0152	0.16	0.11	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;	chr19:22047869	chr19:21965708~21968529:-
BRCA	cis	rs17684571	0.688	rs35440408	ENSG00000231441.1	RP11-472M19.2	3.64	0.000281	0.0152	0.17	0.11	Schizophrenia;	chr6:56866055	chr6:56844002~56864078:+
BRCA	cis	rs875971	0.545	rs4718325	ENSG00000232559.3	GS1-124K5.12	3.64	0.000281	0.0152	0.15	0.11	Aortic root size;	chr7:66215323	chr7:66554588~66576923:-
BRCA	cis	rs10181042	0.528	rs2564118	ENSG00000273302.1	RP11-493E12.2	3.64	0.000281	0.0152	0.1	0.11	Crohn's disease;	chr2:61006154	chr2:61199979~61200769:+
BRCA	cis	rs2411233	1	rs11638272	ENSG00000259278.1	RP11-62C7.2	3.64	0.000281	0.0152	0.13	0.11	Platelet count;	chr15:38974592	chr15:39019233~39024918:+
BRCA	cis	rs6600671	0.934	rs7528274	ENSG00000223345.3	HIST2H2BA	3.64	0.000281	0.0152	0.13	0.11	Hip geometry;	chr1:121545103	chr1:121108210~121117257:-
BRCA	cis	rs2692947	0.55	rs4613327	ENSG00000168992.4	OR7E102P	3.64	0.000281	0.0152	0.16	0.11	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95918075	chr2:95546531~95547545:+
BRCA	cis	rs4819052	0.851	rs2838865	ENSG00000215447.6	BX322557.10	-3.64	0.000281	0.0152	-0.12	-0.11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45292384	chr21:45288052~45291738:+
BRCA	cis	rs6088580	0.668	rs1205337	ENSG00000275784.1	RP5-1125A11.6	3.64	0.000281	0.0152	0.12	0.11	Glomerular filtration rate (creatinine);	chr20:34338235	chr20:33989480~33991818:-
BRCA	cis	rs7487075	0.828	rs7132228	ENSG00000257261.4	RP11-96H19.1	3.64	0.000281	0.0152	0.12	0.11	Itch intensity from mosquito bite;	chr12:46338178	chr12:46383679~46876159:+
BRCA	cis	rs7487075	0.893	rs4768116	ENSG00000257261.4	RP11-96H19.1	3.64	0.000281	0.0152	0.12	0.11	Itch intensity from mosquito bite;	chr12:46339247	chr12:46383679~46876159:+
BRCA	cis	rs4835473	0.9	rs58106929	ENSG00000246448.2	RP13-578N3.3	3.64	0.000281	0.0152	0.13	0.11	Immature fraction of reticulocytes;	chr4:143733166	chr4:143700257~143865072:+
BRCA	cis	rs2153535	0.606	rs11243253	ENSG00000251164.1	HULC	3.64	0.000282	0.0152	0.14	0.11	Motion sickness;	chr6:8379960	chr6:8652137~8653846:+
BRCA	cis	rs250518	0.926	rs34426717	ENSG00000271926.1	CTD-2376I4.1	3.64	0.000282	0.0152	0.15	0.11	Mean corpuscular hemoglobin concentration;	chr5:72752640	chr5:72953635~72954274:-
BRCA	cis	rs7172677	0.737	rs8033754	ENSG00000260269.4	CTD-2323K18.1	3.64	0.000282	0.0152	0.15	0.11	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75147439	chr15:75527150~75601205:-
BRCA	cis	rs739496	0.615	rs847895	ENSG00000226469.1	ADAM1B	3.64	0.000282	0.0152	0.15	0.11	Platelet count;	chr12:111680772	chr12:111927018~111929017:+
BRCA	cis	rs7690839	0.967	rs13149750	ENSG00000270720.1	RP11-84C13.2	3.64	0.000282	0.0152	0.13	0.11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr4:88933843	chr4:89119284~89119871:+
BRCA	cis	rs34929064	0.718	rs60783174	ENSG00000179428.2	AC073072.5	-3.64	0.000282	0.0152	-0.16	-0.11	Major depression and alcohol dependence;	chr7:22686270	chr7:22725395~22727620:-
BRCA	cis	rs80028505	0.908	rs16884628	ENSG00000271304.1	DPRXP2	3.64	0.000282	0.0152	0.2	0.11	Foot ulcer in diabetes and neuropathy;	chr6:36090191	chr6:35989515~35990436:-
BRCA	cis	rs9866825	0.967	rs6767349	ENSG00000227110.5	LMCD1-AS1	-3.64	0.000282	0.0152	-0.13	-0.11	QT interval;	chr3:8203642	chr3:7952805~8611924:-
BRCA	cis	rs721917	0.506	rs2819098	ENSG00000225484.5	NUTM2B-AS1	-3.64	0.000282	0.0152	-0.15	-0.11	Chronic obstructive pulmonary disease;	chr10:79938341	chr10:79663088~79826594:-
BRCA	cis	rs9308731	0.605	rs6754738	ENSG00000230499.1	AC108463.1	-3.64	0.000282	0.0152	-0.13	-0.11	Chronic lymphocytic leukemia;	chr2:111190966	chr2:111195963~111206494:+
BRCA	cis	rs863345	0.604	rs1578761	ENSG00000229914.1	RP11-404O13.4	-3.64	0.000282	0.0152	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158527782	chr1:158195633~158196131:-
BRCA	cis	rs7577696	0.889	rs6725184	ENSG00000276334.1	AL133243.1	-3.64	0.000282	0.0152	-0.14	-0.11	Inflammatory biomarkers;	chr2:32105816	chr2:32521927~32523547:+
BRCA	cis	rs6480314	0.711	rs11815154	ENSG00000233590.1	RP11-153K11.3	-3.64	0.000282	0.0152	-0.18	-0.11	Optic nerve measurement (disc area);	chr10:68194544	chr10:68233251~68242379:-
BRCA	cis	rs8058578	1	rs3747481	ENSG00000280211.1	RP11-2C24.3	3.64	0.000282	0.0152	0.12	0.11	Multiple myeloma;	chr16:30655046	chr16:30773532~30776033:-
BRCA	cis	rs2839186	0.934	rs13049797	ENSG00000215424.8	MCM3AP-AS1	3.64	0.000282	0.0152	0.1	0.11	Testicular germ cell tumor;	chr21:46287668	chr21:46229217~46259390:+
BRCA	cis	rs2839186	0.732	rs55904887	ENSG00000215424.8	MCM3AP-AS1	3.64	0.000282	0.0152	0.1	0.11	Testicular germ cell tumor;	chr21:46287897	chr21:46229217~46259390:+
BRCA	cis	rs2839186	0.934	rs2839197	ENSG00000215424.8	MCM3AP-AS1	3.64	0.000282	0.0152	0.1	0.11	Testicular germ cell tumor;	chr21:46288219	chr21:46229217~46259390:+
BRCA	cis	rs2839186	0.868	rs2839199	ENSG00000215424.8	MCM3AP-AS1	3.64	0.000282	0.0152	0.1	0.11	Testicular germ cell tumor;	chr21:46288355	chr21:46229217~46259390:+
BRCA	cis	rs2839186	0.933	rs4818832	ENSG00000215424.8	MCM3AP-AS1	3.64	0.000282	0.0152	0.1	0.11	Testicular germ cell tumor;	chr21:46288720	chr21:46229217~46259390:+
BRCA	cis	rs2839186	0.9	rs59828751	ENSG00000215424.8	MCM3AP-AS1	3.64	0.000282	0.0152	0.1	0.11	Testicular germ cell tumor;	chr21:46289004	chr21:46229217~46259390:+
BRCA	cis	rs8192917	0.887	rs2236337	ENSG00000258744.1	RP11-80A15.1	3.64	0.000282	0.0152	0.15	0.11	Vitiligo;	chr14:24631041	chr14:24501594~24508688:+
BRCA	cis	rs7246967	0.932	rs34622638	ENSG00000198153.8	ZNF849P	-3.64	0.000282	0.0152	-0.16	-0.11	Bronchopulmonary dysplasia;	chr19:22880850	chr19:22685167~22686732:+
BRCA	cis	rs9788682	0.747	rs2938671	ENSG00000261143.1	ADAMTS7P3	3.64	0.000282	0.0152	0.16	0.11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78440412	chr15:77976042~77993057:+
BRCA	cis	rs2625529	0.668	rs12591313	ENSG00000260037.4	CTD-2524L6.3	-3.64	0.000282	0.0152	-0.16	-0.11	Red blood cell count;	chr15:72264405	chr15:71818396~71823384:+
BRCA	cis	rs2625529	0.668	rs12591338	ENSG00000260037.4	CTD-2524L6.3	-3.64	0.000282	0.0152	-0.16	-0.11	Red blood cell count;	chr15:72264506	chr15:71818396~71823384:+
BRCA	cis	rs7572733	0.935	rs1914690	ENSG00000231621.1	AC013264.2	-3.64	0.000282	0.0152	-0.1	-0.11	Dermatomyositis;	chr2:197944644	chr2:197197991~197199273:+
BRCA	cis	rs890448	0.796	rs4698957	ENSG00000254531.1	FLJ20021	3.64	0.000282	0.0152	0.13	0.11	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101367762	chr4:101347780~101348883:+
BRCA	cis	rs890448	0.796	rs4699213	ENSG00000254531.1	FLJ20021	3.64	0.000282	0.0152	0.13	0.11	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101367950	chr4:101347780~101348883:+
BRCA	cis	rs890448	0.792	rs6824603	ENSG00000254531.1	FLJ20021	3.64	0.000282	0.0152	0.13	0.11	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101368745	chr4:101347780~101348883:+
BRCA	cis	rs890448	0.76	rs6856370	ENSG00000254531.1	FLJ20021	3.64	0.000282	0.0152	0.13	0.11	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101369529	chr4:101347780~101348883:+
BRCA	cis	rs890448	0.796	rs1946946	ENSG00000254531.1	FLJ20021	3.64	0.000282	0.0152	0.13	0.11	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101370420	chr4:101347780~101348883:+
BRCA	cis	rs890448	0.796	rs4699214	ENSG00000254531.1	FLJ20021	3.64	0.000282	0.0152	0.13	0.11	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101371077	chr4:101347780~101348883:+
BRCA	cis	rs890448	0.726	rs13135441	ENSG00000254531.1	FLJ20021	3.64	0.000282	0.0152	0.13	0.11	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101371727	chr4:101347780~101348883:+
BRCA	cis	rs890448	0.796	rs1822169	ENSG00000254531.1	FLJ20021	3.64	0.000282	0.0152	0.13	0.11	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101372107	chr4:101347780~101348883:+
BRCA	cis	rs890448	0.76	rs1822168	ENSG00000254531.1	FLJ20021	3.64	0.000282	0.0152	0.13	0.11	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101372387	chr4:101347780~101348883:+
BRCA	cis	rs890448	0.726	rs6532928	ENSG00000254531.1	FLJ20021	3.64	0.000282	0.0152	0.13	0.11	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101373080	chr4:101347780~101348883:+
BRCA	cis	rs890448	0.661	rs1583911	ENSG00000254531.1	FLJ20021	3.64	0.000282	0.0152	0.13	0.11	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101374542	chr4:101347780~101348883:+
BRCA	cis	rs890448	0.796	rs6532929	ENSG00000254531.1	FLJ20021	3.64	0.000282	0.0152	0.13	0.11	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101377307	chr4:101347780~101348883:+
BRCA	cis	rs890448	0.796	rs7670594	ENSG00000254531.1	FLJ20021	3.64	0.000282	0.0152	0.13	0.11	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101378105	chr4:101347780~101348883:+
BRCA	cis	rs890448	0.796	rs12499349	ENSG00000254531.1	FLJ20021	3.64	0.000282	0.0152	0.13	0.11	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101380198	chr4:101347780~101348883:+
BRCA	cis	rs890448	0.796	rs13135270	ENSG00000254531.1	FLJ20021	3.64	0.000282	0.0152	0.13	0.11	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101380602	chr4:101347780~101348883:+
BRCA	cis	rs442309	1	rs442309	ENSG00000238280.1	RP11-436D10.3	-3.64	0.000282	0.0152	-0.14	-0.11	Vogt-Koyanagi-Harada syndrome;	chr10:62730735	chr10:62793562~62805887:-
BRCA	cis	rs442309	1	rs224048	ENSG00000238280.1	RP11-436D10.3	-3.64	0.000282	0.0152	-0.14	-0.11	Vogt-Koyanagi-Harada syndrome;	chr10:62731789	chr10:62793562~62805887:-
BRCA	cis	rs73198271	0.96	rs11778970	ENSG00000253893.2	FAM85B	3.64	0.000282	0.0152	0.18	0.11	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8751824	chr8:8167819~8226614:-
BRCA	cis	rs875971	0.54	rs781152	ENSG00000232559.3	GS1-124K5.12	3.64	0.000282	0.0153	0.14	0.11	Aortic root size;	chr7:66014585	chr7:66554588~66576923:-
BRCA	cis	rs17711722	0.727	rs781151	ENSG00000232559.3	GS1-124K5.12	3.64	0.000282	0.0153	0.14	0.11	Calcium levels;	chr7:66014891	chr7:66554588~66576923:-
BRCA	cis	rs12612619	0.579	rs6722906	ENSG00000229122.1	AGBL5-IT1	-3.64	0.000282	0.0153	-0.12	-0.11	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:26857167	chr2:27061038~27061815:+
BRCA	cis	rs6460942	0.597	rs7798779	ENSG00000226690.5	AC005281.1	3.64	0.000282	0.0153	0.23	0.11	Coronary artery disease;	chr7:12503864	chr7:12496429~12541910:+
BRCA	cis	rs13434995	0.513	rs1021307	ENSG00000273257.1	RP11-177J6.1	3.64	0.000282	0.0153	0.17	0.11	Adiponectin levels;	chr4:55529547	chr4:55387949~55388271:+
BRCA	cis	rs13434995	0.513	rs1021306	ENSG00000273257.1	RP11-177J6.1	3.64	0.000282	0.0153	0.17	0.11	Adiponectin levels;	chr4:55529777	chr4:55387949~55388271:+
BRCA	cis	rs4664293	0.647	rs1425039	ENSG00000224152.1	AC009506.1	-3.64	0.000282	0.0153	-0.12	-0.11	Monocyte percentage of white cells;	chr2:159571612	chr2:159615296~159617082:+
BRCA	cis	rs7267979	0.932	rs4280527	ENSG00000276952.1	RP5-965G21.6	3.64	0.000282	0.0153	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25563378	chr20:25284915~25285588:-
BRCA	cis	rs7267979	1	rs6132835	ENSG00000277938.1	RP5-965G21.3	3.64	0.000282	0.0153	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25454031	chr20:25229150~25231933:+
BRCA	cis	rs7267979	0.933	rs11699203	ENSG00000277938.1	RP5-965G21.3	3.64	0.000282	0.0153	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25454533	chr20:25229150~25231933:+
BRCA	cis	rs7267979	0.933	rs6138571	ENSG00000277938.1	RP5-965G21.3	3.64	0.000282	0.0153	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25454752	chr20:25229150~25231933:+
BRCA	cis	rs7267979	0.966	rs416745	ENSG00000277938.1	RP5-965G21.3	3.64	0.000282	0.0153	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25458232	chr20:25229150~25231933:+
BRCA	cis	rs7267979	1	rs447722	ENSG00000277938.1	RP5-965G21.3	3.64	0.000282	0.0153	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25462874	chr20:25229150~25231933:+
BRCA	cis	rs7267979	1	rs422424	ENSG00000277938.1	RP5-965G21.3	3.64	0.000282	0.0153	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25464810	chr20:25229150~25231933:+
BRCA	cis	rs7267979	1	rs422844	ENSG00000277938.1	RP5-965G21.3	3.64	0.000282	0.0153	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25464955	chr20:25229150~25231933:+
BRCA	cis	rs7267979	1	rs401166	ENSG00000277938.1	RP5-965G21.3	3.64	0.000282	0.0153	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25465672	chr20:25229150~25231933:+
BRCA	cis	rs6088590	0.603	rs6579186	ENSG00000276073.1	RP5-1125A11.7	-3.64	0.000282	0.0153	-0.12	-0.11	Coronary artery disease;	chr20:34694394	chr20:33985617~33988989:-
BRCA	cis	rs1348850	0.914	rs8941	ENSG00000271825.1	RP11-337N6.2	3.64	0.000282	0.0153	0.15	0.11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177541753	chr2:177300600~177302006:+
BRCA	cis	rs27434	0.66	rs27043	ENSG00000248734.2	CTD-2260A17.1	-3.64	0.000282	0.0153	-0.15	-0.11	Ankylosing spondylitis;	chr5:96781596	chr5:96784777~96785999:+
BRCA	cis	rs863345	0.604	rs1578763	ENSG00000229914.1	RP11-404O13.4	-3.64	0.000282	0.0153	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158527624	chr1:158195633~158196131:-
BRCA	cis	rs863345	0.604	rs1578762	ENSG00000229914.1	RP11-404O13.4	-3.64	0.000282	0.0153	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158527650	chr1:158195633~158196131:-
BRCA	cis	rs9467773	0.596	rs62396201	ENSG00000241549.7	GUSBP2	3.64	0.000282	0.0153	0.12	0.11	Intelligence (multi-trait analysis);	chr6:26667988	chr6:26871484~26956554:-
BRCA	cis	rs4272720	0.756	rs35905744	ENSG00000228754.1	RP11-534L6.3	-3.64	0.000282	0.0153	-0.14	-0.11	Platelet count;Plateletcrit;	chr10:49075109	chr10:48745545~48746128:-
BRCA	cis	rs425277	1	rs262641	ENSG00000269227.1	RP11-345P4.6	-3.64	0.000282	0.0153	-0.11	-0.11	Height;	chr1:2173542	chr1:1673275~1674397:+
BRCA	cis	rs860295	0.756	rs7546258	ENSG00000160766.13	GBAP1	-3.64	0.000283	0.0153	-0.12	-0.11	Body mass index;	chr1:155728854	chr1:155213821~155227422:-
BRCA	cis	rs1008375	1	rs4235388	ENSG00000249502.1	AC006160.5	-3.64	0.000283	0.0153	-0.13	-0.11	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17680407	chr4:17587467~17614571:-
BRCA	cis	rs17270561	0.609	rs4711098	ENSG00000272462.2	U91328.19	-3.64	0.000283	0.0153	-0.14	-0.11	Iron status biomarkers;	chr6:25734111	chr6:25992662~26001775:+
BRCA	cis	rs17270561	0.609	rs3922699	ENSG00000272462.2	U91328.19	-3.64	0.000283	0.0153	-0.14	-0.11	Iron status biomarkers;	chr6:25734741	chr6:25992662~26001775:+
BRCA	cis	rs17270561	0.609	rs6924782	ENSG00000272462.2	U91328.19	-3.64	0.000283	0.0153	-0.14	-0.11	Iron status biomarkers;	chr6:25735588	chr6:25992662~26001775:+
BRCA	cis	rs17270561	0.609	rs6924794	ENSG00000272462.2	U91328.19	-3.64	0.000283	0.0153	-0.14	-0.11	Iron status biomarkers;	chr6:25735646	chr6:25992662~26001775:+
BRCA	cis	rs17270561	0.609	rs3922842	ENSG00000272462.2	U91328.19	-3.64	0.000283	0.0153	-0.14	-0.11	Iron status biomarkers;	chr6:25736336	chr6:25992662~26001775:+
BRCA	cis	rs4919694	1	rs12245779	ENSG00000236937.2	PTGES3P4	3.64	0.000283	0.0153	0.23	0.11	Arsenic metabolism;	chr10:102886187	chr10:102845595~102845950:+
BRCA	cis	rs4919694	1	rs11191445	ENSG00000236937.2	PTGES3P4	3.64	0.000283	0.0153	0.23	0.11	Arsenic metabolism;	chr10:102891298	chr10:102845595~102845950:+
BRCA	cis	rs4689592	0.503	rs59640165	ENSG00000245468.3	RP11-367J11.3	-3.64	0.000283	0.0153	-0.14	-0.11	Monocyte percentage of white cells;	chr4:7049934	chr4:7094571~7103385:-
BRCA	cis	rs11098499	0.954	rs10006525	ENSG00000225892.3	RP11-384K6.2	3.64	0.000283	0.0153	0.11	0.11	Corneal astigmatism;	chr4:119487776	chr4:118632274~118634759:+
BRCA	cis	rs1008375	0.966	rs3775925	ENSG00000249502.1	AC006160.5	-3.64	0.000283	0.0153	-0.13	-0.11	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17586814	chr4:17587467~17614571:-
BRCA	cis	rs1479090	0.509	rs6823527	ENSG00000250027.1	RP11-563E2.2	-3.64	0.000283	0.0153	-0.15	-0.11	Lung cancer;	chr4:163097415	chr4:163108785~163119965:+
BRCA	cis	rs747650	0.532	rs4587689	ENSG00000200376.1	RNU5E-10P	-3.64	0.000283	0.0153	-0.15	-0.11	Acne (severe);	chr11:47108303	chr11:47576471~47576588:-
BRCA	cis	rs564309	1	rs474600	ENSG00000212237.1	RNA5SP18	3.64	0.000283	0.0153	0.19	0.11	Hip circumference (psychosocial stress interaction);	chr1:228398136	chr1:228647912~228648032:-
BRCA	cis	rs4713118	0.587	rs61471148	ENSG00000272009.1	RP1-313I6.12	-3.64	0.000283	0.0153	-0.16	-0.11	Parkinson's disease;	chr6:28069254	chr6:28078792~28081130:-
BRCA	cis	rs17801127	0.748	rs12989809	ENSG00000231969.1	AC144449.1	3.64	0.000283	0.0153	0.19	0.11	Liver enzyme levels (alanine transaminase);	chr2:149670312	chr2:149587196~149848233:+
BRCA	cis	rs7107174	1	rs2244508	ENSG00000251323.2	RP11-452H21.4	3.64	0.000283	0.0153	0.16	0.11	Testicular germ cell tumor;	chr11:78237469	chr11:78423982~78429836:-
BRCA	cis	rs10838634	1	rs4500447	ENSG00000280615.1	Y_RNA	-3.64	0.000283	0.0153	-0.19	-0.11	Schizophrenia;	chr11:46754543	chr11:47614898~47614994:-
BRCA	cis	rs10838634	1	rs10466477	ENSG00000280615.1	Y_RNA	-3.64	0.000283	0.0153	-0.19	-0.11	Schizophrenia;	chr11:46760922	chr11:47614898~47614994:-
BRCA	cis	rs10838634	1	rs7928445	ENSG00000280615.1	Y_RNA	-3.64	0.000283	0.0153	-0.19	-0.11	Schizophrenia;	chr11:46763147	chr11:47614898~47614994:-
BRCA	cis	rs10838634	0.901	rs57485117	ENSG00000280615.1	Y_RNA	-3.64	0.000283	0.0153	-0.19	-0.11	Schizophrenia;	chr11:46782150	chr11:47614898~47614994:-
BRCA	cis	rs5167	0.781	rs11672748	ENSG00000214855.8	APOC1P1	3.64	0.000283	0.0153	0.14	0.11	Blood protein levels;	chr19:44986934	chr19:44926804~44931386:+
BRCA	cis	rs1949733	1	rs2631745	ENSG00000251615.3	RP11-774O3.3	3.64	0.000283	0.0153	0.12	0.11	Response to antineoplastic agents;	chr4:8488803	chr4:8355090~8358338:-
BRCA	cis	rs17122021	0.74	rs2853009	ENSG00000255239.1	AP002954.6	3.64	0.000283	0.0153	0.13	0.11	Pain;	chr11:118277431	chr11:118688039~118690600:-
BRCA	cis	rs10819861	0.645	rs4743537	ENSG00000175611.10	LINC00476	3.64	0.000283	0.0153	0.12	0.11	Electrocardiographic traits;	chr9:96100579	chr9:95759231~95875977:-
BRCA	cis	rs2411233	0.967	rs10851376	ENSG00000259278.1	RP11-62C7.2	-3.64	0.000283	0.0153	-0.13	-0.11	Platelet count;	chr15:38994427	chr15:39019233~39024918:+
BRCA	cis	rs11098499	0.954	rs4309825	ENSG00000225892.3	RP11-384K6.2	-3.64	0.000283	0.0153	-0.11	-0.11	Corneal astigmatism;	chr4:119393726	chr4:118632274~118634759:+
BRCA	cis	rs748404	0.666	rs7177146	ENSG00000201136.1	RNU6-353P	3.64	0.000283	0.0153	0.16	0.11	Lung cancer;	chr15:43506110	chr15:43702363~43702470:+
BRCA	cis	rs1279750	0.651	rs2546421	ENSG00000248103.1	CTC-338M12.9	-3.64	0.000283	0.0153	-0.19	-0.11	Platelet count;	chr5:181159879	chr5:181281375~181283652:+
BRCA	cis	rs1279750	0.651	rs2770969	ENSG00000248103.1	CTC-338M12.9	-3.64	0.000283	0.0153	-0.19	-0.11	Platelet count;	chr5:181159883	chr5:181281375~181283652:+
BRCA	cis	rs7620503	1	rs4555562	ENSG00000231574.4	RP11-91K9.1	3.64	0.000283	0.0153	0.13	0.11	Corneal structure;	chr3:177580775	chr3:177816865~177899224:+
BRCA	cis	rs7620503	1	rs4257602	ENSG00000231574.4	RP11-91K9.1	3.64	0.000283	0.0153	0.13	0.11	Corneal structure;	chr3:177580907	chr3:177816865~177899224:+
BRCA	cis	rs7620503	1	rs4290846	ENSG00000231574.4	RP11-91K9.1	3.64	0.000283	0.0153	0.13	0.11	Corneal structure;	chr3:177581146	chr3:177816865~177899224:+
BRCA	cis	rs709400	0.93	rs57447494	ENSG00000258735.1	LINC00637	3.64	0.000283	0.0153	0.14	0.11	Body mass index;	chr14:103568232	chr14:103847721~103858049:+
BRCA	cis	rs4478858	0.735	rs6425737	ENSG00000223907.1	LINC01226	-3.64	0.000283	0.0153	-0.14	-0.11	Alcohol dependence;	chr1:31317441	chr1:31518435~31524245:+
BRCA	cis	rs4478858	0.735	rs3806255	ENSG00000223907.1	LINC01226	-3.64	0.000283	0.0153	-0.14	-0.11	Alcohol dependence;	chr1:31318731	chr1:31518435~31524245:+
BRCA	cis	rs4415084	1	rs10462079	ENSG00000248464.1	FGF10-AS1	3.64	0.000283	0.0153	0.13	0.11	Breast cancer;	chr5:44700008	chr5:44388732~44413989:+
BRCA	cis	rs4415084	1	rs13179137	ENSG00000248464.1	FGF10-AS1	3.64	0.000283	0.0153	0.13	0.11	Breast cancer;	chr5:44702590	chr5:44388732~44413989:+
BRCA	cis	rs7591351	0.517	rs2005270	ENSG00000239332.4	LINC01119	3.64	0.000283	0.0153	0.12	0.11	Pathological gambling;	chr2:45837817	chr2:46816697~46859007:+
BRCA	cis	rs12935418	0.83	rs12928638	ENSG00000261838.4	RP11-303E16.6	3.64	0.000283	0.0153	0.18	0.11	Mean corpuscular volume;	chr16:81016195	chr16:81069854~81076598:+
BRCA	cis	rs11877825	0.826	rs6505573	ENSG00000265728.1	RP11-883A18.3	-3.64	0.000283	0.0153	-0.16	-0.11	Gut microbiota (bacterial taxa);	chr18:10579545	chr18:10594590~10604798:+
BRCA	cis	rs875971	0.638	rs6960778	ENSG00000272831.1	RP11-792A8.4	-3.64	0.000283	0.0153	-0.1	-0.11	Aortic root size;	chr7:66606610	chr7:66739829~66740385:-
BRCA	cis	rs8114671	0.562	rs6088646	ENSG00000279253.1	RP4-614O4.13	-3.64	0.000283	0.0153	-0.13	-0.11	Height;	chr20:34918134	chr20:35262727~35264187:-
BRCA	cis	rs8114671	0.562	rs6120763	ENSG00000279253.1	RP4-614O4.13	-3.64	0.000283	0.0153	-0.13	-0.11	Height;	chr20:34918597	chr20:35262727~35264187:-
BRCA	cis	rs71566846	0.649	rs10949013	ENSG00000272541.1	XXbac-BPGBPG55C20.1	-3.64	0.000283	0.0153	-0.18	-0.11	Coronary artery disease;	chr6:57264889	chr6:57855891~57856468:-
BRCA	cis	rs7572733	0.935	rs1518366	ENSG00000231621.1	AC013264.2	-3.64	0.000283	0.0153	-0.1	-0.11	Dermatomyositis;	chr2:197944472	chr2:197197991~197199273:+
BRCA	cis	rs875971	0.862	rs778724	ENSG00000265600.1	AC006480.1	-3.64	0.000283	0.0153	-0.13	-0.11	Aortic root size;	chr7:66364304	chr7:67356680~67356779:+
BRCA	cis	rs2640806	0.645	rs11786602	ENSG00000253105.4	KB-1448A5.1	3.64	0.000283	0.0153	0.13	0.11	Obesity-related traits;	chr8:96315001	chr8:96371865~96387438:-
BRCA	cis	rs2717559	0.683	rs2717611	ENSG00000253741.1	CTD-2292P10.4	3.64	0.000283	0.0153	0.12	0.11	Urinary tract infection frequency;	chr8:142798511	chr8:142702252~142726973:-
BRCA	cis	rs17027633	0.881	rs78403721	ENSG00000234020.1	CHIAP3	-3.64	0.000283	0.0153	-0.28	-0.11	Cerebrospinal fluid t-tau:AB1-42 ratio;	chr1:111472244	chr1:111353275~111367409:-
BRCA	cis	rs41369048	0.858	rs2807866	ENSG00000257551.1	HLX-AS1	-3.64	0.000283	0.0153	-0.15	-0.11	Eosinophil counts;Sum eosinophil basophil counts;	chr1:220907587	chr1:220832763~220880140:-
BRCA	cis	rs4665809	0.877	rs34536218	ENSG00000231655.1	AC011742.3	-3.64	0.000283	0.0153	-0.19	-0.11	Gut microbiome composition (summer);	chr2:26064507	chr2:26140263~26141264:-
BRCA	cis	rs13287066	0.935	rs10821124	ENSG00000227603.1	RP11-165J3.6	3.64	0.000283	0.0153	0.12	0.11	Intelligence (multi-trait analysis);	chr9:93415833	chr9:93435332~93437121:-
BRCA	cis	rs7523050	0.73	rs12079547	ENSG00000203897.3	SPATA42	-3.64	0.000283	0.0153	-0.21	-0.11	Fat distribution (HIV);	chr1:108926692	chr1:108857217~108858524:+
BRCA	cis	rs875971	0.619	rs10278371	ENSG00000272831.1	RP11-792A8.4	-3.64	0.000283	0.0153	-0.1	-0.11	Aortic root size;	chr7:66586553	chr7:66739829~66740385:-
BRCA	cis	rs7837791	0.647	rs12682313	ENSG00000242970.2	AC068522.4	-3.64	0.000284	0.0153	-0.14	-0.11	Refractive error;	chr8:59259698	chr8:58588420~58588764:-
BRCA	cis	rs34792	0.853	rs170194	ENSG00000207425.1	Y_RNA	-3.64	0.000284	0.0153	-0.13	-0.11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15464415	chr16:14915457~14915556:-
BRCA	cis	rs3755605	0.694	rs6765667	ENSG00000242578.1	RP11-469J4.3	3.64	0.000284	0.0153	0.13	0.11	Testicular germ cell tumor;	chr3:170175610	chr3:170410512~170418615:+
BRCA	cis	rs67696533	0.711	rs4911241	ENSG00000277692.1	RP11-358N2.2	-3.64	0.000284	0.0153	-0.13	-0.11	White blood cell count (basophil);Basophil percentage of granulocytes;Basophil percentage of white cells;	chr20:32552363	chr20:32355053~32355734:+
BRCA	cis	rs7260598	0.539	rs10424758	ENSG00000268442.1	CTD-2027I19.2	3.64	0.000284	0.0153	0.19	0.11	Response to taxane treatment (placlitaxel);	chr19:23907698	chr19:24162370~24163425:-
BRCA	cis	rs295490	0.667	rs2289350	ENSG00000178631.7	ACTG1P1	-3.64	0.000284	0.0153	-0.22	-0.11	PR interval in Tripanosoma cruzi seropositivity;	chr3:139462436	chr3:139493809~139494937:+
BRCA	cis	rs295490	0.748	rs80323892	ENSG00000178631.7	ACTG1P1	-3.64	0.000284	0.0153	-0.22	-0.11	PR interval in Tripanosoma cruzi seropositivity;	chr3:139464658	chr3:139493809~139494937:+
BRCA	cis	rs6088590	0.965	rs6058108	ENSG00000276073.1	RP5-1125A11.7	-3.64	0.000284	0.0153	-0.13	-0.11	Coronary artery disease;	chr20:34700851	chr20:33985617~33988989:-
BRCA	cis	rs311904	1	rs8031540	ENSG00000212766.8	EWSAT1	3.64	0.000284	0.0153	0.22	0.11	Obesity-related traits;	chr15:69036266	chr15:69072926~69095820:+
BRCA	cis	rs4478858	0.735	rs11436	ENSG00000223907.1	LINC01226	-3.64	0.000284	0.0153	-0.14	-0.11	Alcohol dependence;	chr1:31364473	chr1:31518435~31524245:+
BRCA	cis	rs1045529	0.524	rs34251783	ENSG00000233609.3	RP11-62H7.2	-3.64	0.000284	0.0153	-0.11	-0.11	Myopia (pathological);Myopia;	chr8:9033866	chr8:8961200~8979025:+
BRCA	cis	rs8180040	0.701	rs12491473	ENSG00000271161.1	BOLA2P2	-3.64	0.000284	0.0153	-0.12	-0.11	Colorectal cancer;	chr3:46948414	chr3:47499841~47500407:+
BRCA	cis	rs11239930	0.538	rs9663073	ENSG00000237188.3	RP11-337C18.8	3.64	0.000284	0.0153	0.13	0.11	AIDS progression;	chr1:147083022	chr1:147172771~147211568:+
BRCA	cis	rs12701220	0.725	rs13242971	ENSG00000224079.1	AC091729.7	3.64	0.000284	0.0153	0.17	0.11	Bronchopulmonary dysplasia;	chr7:1015879	chr7:1074450~1078036:+
BRCA	cis	rs6754311	0.608	rs3739020	ENSG00000231890.6	DARS-AS1	-3.64	0.000284	0.0153	-0.15	-0.11	Mosquito bite size;	chr2:135844921	chr2:135985176~136022593:+
BRCA	cis	rs2998286	0.723	rs2772435	ENSG00000237128.1	RP11-351M16.3	3.64	0.000284	0.0153	0.14	0.11	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28546534	chr10:28433008~28495813:-
BRCA	cis	rs2998286	0.723	rs2807759	ENSG00000237128.1	RP11-351M16.3	3.64	0.000284	0.0153	0.14	0.11	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28548682	chr10:28433008~28495813:-
BRCA	cis	rs875971	0.83	rs427575	ENSG00000271064.1	RP11-792A8.3	-3.64	0.000284	0.0153	-0.13	-0.11	Aortic root size;	chr7:66054232	chr7:66748838~66749077:-
BRCA	cis	rs6088580	0.634	rs4258875	ENSG00000275784.1	RP5-1125A11.6	3.64	0.000284	0.0153	0.12	0.11	Glomerular filtration rate (creatinine);	chr20:34337089	chr20:33989480~33991818:-
BRCA	cis	rs10829156	0.945	rs10829199	ENSG00000225527.1	RP11-383B4.4	-3.64	0.000284	0.0153	-0.16	-0.11	Sudden cardiac arrest;	chr10:18679012	chr10:18531849~18533336:-
BRCA	cis	rs863345	0.625	rs4575081	ENSG00000229914.1	RP11-404O13.4	-3.64	0.000284	0.0153	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158535047	chr1:158195633~158196131:-
BRCA	cis	rs6893300	0.922	rs7735702	ENSG00000225051.5	HMGB3P22	3.64	0.000284	0.0153	0.14	0.11	Resting heart rate;	chr5:179705611	chr5:179679032~179694768:+
BRCA	cis	rs11039100	0.765	rs72896130	ENSG00000224295.2	AC087380.14	3.64	0.000284	0.0153	0.21	0.11	Peripheral arterial disease (traffic-related air pollution interaction);	chr11:5813175	chr11:5518441~5524955:-
BRCA	cis	rs11039100	0.85	rs34818213	ENSG00000224295.2	AC087380.14	3.64	0.000284	0.0153	0.21	0.11	Peripheral arterial disease (traffic-related air pollution interaction);	chr11:5813361	chr11:5518441~5524955:-
BRCA	cis	rs11039100	0.765	rs35863959	ENSG00000224295.2	AC087380.14	3.64	0.000284	0.0153	0.21	0.11	Peripheral arterial disease (traffic-related air pollution interaction);	chr11:5813392	chr11:5518441~5524955:-
BRCA	cis	rs11039100	0.85	rs34037040	ENSG00000224295.2	AC087380.14	3.64	0.000284	0.0153	0.21	0.11	Peripheral arterial disease (traffic-related air pollution interaction);	chr11:5813443	chr11:5518441~5524955:-
BRCA	cis	rs1555322	1	rs2425041	ENSG00000269202.1	RP4-614O4.12	-3.64	0.000284	0.0153	-0.17	-0.11	Attention deficit hyperactivity disorder;	chr20:35271210	chr20:35201747~35203288:-
BRCA	cis	rs8040855	0.627	rs12900012	ENSG00000259774.1	RP11-182J1.13	3.64	0.000284	0.0153	0.15	0.11	Bulimia nervosa;	chr15:85046955	chr15:84422618~84425882:+
BRCA	cis	rs2281603	0.674	rs74883409	ENSG00000259116.1	RP11-973N13.4	-3.64	0.000284	0.0153	-0.11	-0.11	Lymphocyte counts;	chr14:64594361	chr14:64514154~64540368:-
BRCA	cis	rs5742933	0.948	rs62184286	ENSG00000253559.1	OSGEPL1-AS1	-3.64	0.000284	0.0153	-0.16	-0.11	Ferritin levels;	chr2:189812147	chr2:189762704~189765556:+
BRCA	cis	rs4243971	0.516	rs35290636	ENSG00000275576.1	RP5-836N17.4	-3.64	0.000284	0.0153	-0.13	-0.11	Inflammatory bowel disease;Crohn's disease;	chr20:32285000	chr20:32116171~32116629:+
BRCA	cis	rs4415084	0.966	rs4492118	ENSG00000272335.1	RP11-53O19.3	3.64	0.000284	0.0153	0.1	0.11	Breast cancer;	chr5:44646523	chr5:44826076~44828592:+
BRCA	cis	rs477895	0.838	rs2070765	ENSG00000256940.1	RP11-783K16.5	3.64	0.000284	0.0153	0.16	0.11	Mean platelet volume;	chr11:64242613	chr11:64245964~64248217:+
BRCA	cis	rs7267979	1	rs6050631	ENSG00000274414.1	RP5-965G21.4	-3.64	0.000284	0.0153	-0.13	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25451113	chr20:25239007~25245229:-
BRCA	cis	rs3015497	0.711	rs4343181	ENSG00000259113.1	RP11-406H23.2	-3.64	0.000284	0.0153	-0.13	-0.11	Mean platelet volume;	chr14:50696130	chr14:50448807~50456742:+
BRCA	cis	rs6012564	0.826	rs34778847	ENSG00000230758.1	SNAP23P	3.64	0.000284	0.0153	0.13	0.11	Anger;	chr20:49121421	chr20:49038357~49038602:-
BRCA	cis	rs7267979	0.932	rs367666	ENSG00000231081.1	RP4-760C5.3	-3.64	0.000284	0.0153	-0.15	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25469182	chr20:26008791~26010531:-
BRCA	cis	rs875971	0.862	rs11763189	ENSG00000273024.4	INTS4P2	-3.64	0.000284	0.0153	-0.12	-0.11	Aortic root size;	chr7:66518542	chr7:65647864~65715661:+
BRCA	cis	rs2555155	0.935	rs10769693	ENSG00000254595.1	CTD-2010I16.1	3.64	0.000284	0.0153	0.12	0.11	DNA methylation (variation);	chr11:6499116	chr11:6488186~6489377:-
BRCA	cis	rs875971	0.522	rs1880556	ENSG00000229180.5	GS1-124K5.11	3.64	0.000284	0.0153	0.1	0.11	Aortic root size;	chr7:65967557	chr7:66526088~66542624:-
BRCA	cis	rs2288327	0.591	rs2562845	ENSG00000270574.1	RP11-171I2.2	3.64	0.000284	0.0153	0.18	0.11	Atrial fibrillation;	chr2:178649706	chr2:178578790~178580906:+
BRCA	cis	rs2998286	0.723	rs332139	ENSG00000237128.1	RP11-351M16.3	3.64	0.000284	0.0153	0.14	0.11	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28570150	chr10:28433008~28495813:-
BRCA	cis	rs4702718	0.651	rs2930047	ENSG00000272324.4	CTD-2154B17.4	-3.64	0.000284	0.0153	-0.13	-0.11	Obesity-related traits;	chr5:10695414	chr5:10761065~10770294:+
BRCA	cis	rs4332037	0.851	rs73050128	ENSG00000273230.1	RP11-1246C19.1	3.64	0.000284	0.0153	0.18	0.11	Bipolar disorder;	chr7:1922246	chr7:1464497~1467522:-
BRCA	cis	rs11603691	0.892	rs668408	ENSG00000254662.1	RP11-872D17.4	3.64	0.000284	0.0153	0.22	0.11	Low high density lipoprotein cholesterol levels;	chr11:57249260	chr11:57325603~57327958:+
BRCA	cis	rs62229266	0.804	rs880221	ENSG00000214914.3	RPL23AP3	3.64	0.000284	0.0153	0.14	0.11	Mitral valve prolapse;	chr21:36048487	chr21:36016079~36016546:-
BRCA	cis	rs6964587	0.967	rs10279210	ENSG00000188693.7	CYP51A1-AS1	-3.64	0.000284	0.0153	-0.12	-0.11	Breast cancer;	chr7:91987577	chr7:92134604~92180725:+
BRCA	cis	rs10129255	0.957	rs8005468	ENSG00000232216.1	IGHV3-43	3.64	0.000284	0.0153	0.09	0.11	Kawasaki disease;	chr14:106686431	chr14:106470264~106470800:-
BRCA	cis	rs1005277	0.54	rs289638	ENSG00000226578.1	RP11-258F22.1	-3.64	0.000284	0.0153	-0.12	-0.11	Extrinsic epigenetic age acceleration;	chr10:37634803	chr10:37775371~37784131:-
BRCA	cis	rs970548	1	rs58865519	ENSG00000237840.5	FAM21FP	3.64	0.000284	0.0153	0.15	0.11	Total cholesterol levels;HDL cholesterol;HDL cholesterol levels;Cholesterol, total;	chr10:45515443	chr10:45706431~45727231:-
BRCA	cis	rs1670533	1	rs7669399	ENSG00000251639.2	RP11-20I20.1	3.64	0.000284	0.0154	0.18	0.11	Recombination rate (females);	chr4:1064690	chr4:1100016~1101558:-
BRCA	cis	rs2243480	1	rs7794661	ENSG00000226767.1	RP11-328P23.3	-3.64	0.000284	0.0154	-0.19	-0.11	Diabetic kidney disease;	chr7:65924743	chr7:65508773~65508944:-
BRCA	cis	rs6840360	0.593	rs2089811	ENSG00000270265.1	RP11-731D1.4	3.64	0.000284	0.0154	0.13	0.11	Intelligence (multi-trait analysis);	chr4:151764019	chr4:151333775~151353224:-
BRCA	cis	rs4650994	0.593	rs10753180	ENSG00000273384.1	RP5-1098D14.1	-3.64	0.000284	0.0154	-0.15	-0.11	HDL cholesterol;HDL cholesterol levels;	chr1:178551518	chr1:178651706~178652282:+
BRCA	cis	rs67766926	0.909	rs13420509	ENSG00000237522.1	NONOP2	-3.64	0.000284	0.0154	-0.12	-0.11	Inflammatory skin disease;	chr2:60874753	chr2:60936819~60938049:-
BRCA	cis	rs875971	0.505	rs6955582	ENSG00000223473.2	GS1-124K5.3	3.64	0.000284	0.0154	0.09	0.11	Aortic root size;	chr7:65966699	chr7:66491049~66493566:-
BRCA	cis	rs9921338	1	rs8049173	ENSG00000263080.1	RP11-485G7.5	3.64	0.000284	0.0154	0.17	0.11	Vein graft stenosis in coronary artery bypass grafting;	chr16:11343025	chr16:11341809~11345211:-
BRCA	cis	rs9921338	1	rs8055427	ENSG00000263080.1	RP11-485G7.5	3.64	0.000284	0.0154	0.17	0.11	Vein graft stenosis in coronary artery bypass grafting;	chr16:11343026	chr16:11341809~11345211:-
BRCA	cis	rs9921338	0.961	rs9936093	ENSG00000263080.1	RP11-485G7.5	3.64	0.000284	0.0154	0.17	0.11	Vein graft stenosis in coronary artery bypass grafting;	chr16:11343459	chr16:11341809~11345211:-
BRCA	cis	rs7818688	1	rs77257477	ENSG00000245080.5	RP11-320N21.1	-3.64	0.000285	0.0154	-0.2	-0.11	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95033171	chr8:95066808~95073182:-
BRCA	cis	rs7818688	0.79	rs74395342	ENSG00000245080.5	RP11-320N21.1	-3.64	0.000285	0.0154	-0.2	-0.11	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95034723	chr8:95066808~95073182:-
BRCA	cis	rs7818688	1	rs6651271	ENSG00000245080.5	RP11-320N21.1	-3.64	0.000285	0.0154	-0.2	-0.11	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95035393	chr8:95066808~95073182:-
BRCA	cis	rs3735485	0.8	rs6943774	ENSG00000201772.1	SNORA5C	-3.64	0.000285	0.0154	-0.15	-0.11	White blood cell count;Sum basophil neutrophil counts;Neutrophil count;Granulocyte percentage of myeloid white cells;Monocyte percentage of white cells;Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Lymphocyte counts;	chr7:45005769	chr7:45104906~45105042:-
BRCA	cis	rs7177699	0.55	rs7182716	ENSG00000261143.1	ADAMTS7P3	-3.64	0.000285	0.0154	-0.13	-0.11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78831411	chr15:77976042~77993057:+
BRCA	cis	rs7177699	0.581	rs7181432	ENSG00000261143.1	ADAMTS7P3	-3.64	0.000285	0.0154	-0.13	-0.11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78831437	chr15:77976042~77993057:+
BRCA	cis	rs7177699	0.55	rs7182103	ENSG00000261143.1	ADAMTS7P3	-3.64	0.000285	0.0154	-0.13	-0.11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78831604	chr15:77976042~77993057:+
BRCA	cis	rs4243971	0.516	rs6141687	ENSG00000275576.1	RP5-836N17.4	-3.64	0.000285	0.0154	-0.13	-0.11	Inflammatory bowel disease;Crohn's disease;	chr20:32351737	chr20:32116171~32116629:+
BRCA	cis	rs672059	1	rs660602	ENSG00000224468.3	RP11-181K3.4	-3.64	0.000285	0.0154	-0.12	-0.11	Hypertriglyceridemia;	chr1:183193639	chr1:183138402~183141282:-
BRCA	cis	rs672059	1	rs510642	ENSG00000224468.3	RP11-181K3.4	-3.64	0.000285	0.0154	-0.12	-0.11	Hypertriglyceridemia;	chr1:183193641	chr1:183138402~183141282:-
BRCA	cis	rs672059	1	rs672119	ENSG00000224468.3	RP11-181K3.4	-3.64	0.000285	0.0154	-0.12	-0.11	Hypertriglyceridemia;	chr1:183193371	chr1:183138402~183141282:-
BRCA	cis	rs672059	1	rs672059	ENSG00000224468.3	RP11-181K3.4	-3.64	0.000285	0.0154	-0.12	-0.11	Hypertriglyceridemia;	chr1:183193404	chr1:183138402~183141282:-
BRCA	cis	rs6088590	1	rs6120748	ENSG00000276073.1	RP5-1125A11.7	-3.64	0.000285	0.0154	-0.13	-0.11	Coronary artery disease;	chr20:34870481	chr20:33985617~33988989:-
BRCA	cis	rs61931739	0.5	rs56404399	ENSG00000258794.3	DUX4L27	3.64	0.000285	0.0154	0.16	0.11	Morning vs. evening chronotype;	chr12:34390166	chr12:34208415~34209675:-
BRCA	cis	rs61931739	0.5	rs11053271	ENSG00000258794.3	DUX4L27	3.64	0.000285	0.0154	0.16	0.11	Morning vs. evening chronotype;	chr12:34392472	chr12:34208415~34209675:-
BRCA	cis	rs61931739	0.5	rs11053273	ENSG00000258794.3	DUX4L27	3.64	0.000285	0.0154	0.16	0.11	Morning vs. evening chronotype;	chr12:34394320	chr12:34208415~34209675:-
BRCA	cis	rs61931739	0.5	rs35030191	ENSG00000258794.3	DUX4L27	3.64	0.000285	0.0154	0.16	0.11	Morning vs. evening chronotype;	chr12:34395930	chr12:34208415~34209675:-
BRCA	cis	rs61931739	0.5	rs34997501	ENSG00000258794.3	DUX4L27	3.64	0.000285	0.0154	0.16	0.11	Morning vs. evening chronotype;	chr12:34396893	chr12:34208415~34209675:-
BRCA	cis	rs61931739	0.5	rs11053280	ENSG00000258794.3	DUX4L27	3.64	0.000285	0.0154	0.16	0.11	Morning vs. evening chronotype;	chr12:34406362	chr12:34208415~34209675:-
BRCA	cis	rs739496	0.895	rs7977752	ENSG00000257624.1	RP1-128M12.3	3.64	0.000285	0.0154	0.15	0.11	Platelet count;	chr12:111412426	chr12:112000739~112000985:-
BRCA	cis	rs4713118	0.512	rs2622319	ENSG00000219891.2	ZSCAN12P1	3.64	0.000285	0.0154	0.14	0.11	Parkinson's disease;	chr6:28152623	chr6:28091154~28093664:+
BRCA	cis	rs172166	0.694	rs1150666	ENSG00000219891.2	ZSCAN12P1	3.64	0.000285	0.0154	0.14	0.11	Cardiac Troponin-T levels;	chr6:28156150	chr6:28091154~28093664:+
BRCA	cis	rs875971	1	rs2420820	ENSG00000230189.5	GS1-124K5.2	-3.64	0.000285	0.0154	-0.09	-0.11	Aortic root size;	chr7:66626920	chr7:66409143~66490059:-
BRCA	cis	rs2795502	1	rs1852959	ENSG00000185904.10	LINC00839	3.64	0.000285	0.0154	0.16	0.11	Blood protein levels;	chr10:42864188	chr10:42475543~42495336:+
BRCA	cis	rs13434995	0.513	rs1979605	ENSG00000273257.1	RP11-177J6.1	3.64	0.000285	0.0154	0.17	0.11	Adiponectin levels;	chr4:55552706	chr4:55387949~55388271:+
BRCA	cis	rs9346455	0.554	rs9346457	ENSG00000279289.1	RP3-331H24.6	3.64	0.000285	0.0154	0.17	0.11	Antipsychotic drug-induced weight gain;Antipsychotic drug-induced weight gain (time interaction);	chr6:71299599	chr6:71386852~71390829:-
BRCA	cis	rs801193	0.904	rs4718403	ENSG00000232546.1	RP11-458F8.1	-3.64	0.000285	0.0154	-0.09	-0.11	Aortic root size;	chr7:66777742	chr7:66848496~66858136:+
BRCA	cis	rs7620503	0.917	rs6443469	ENSG00000277241.1	RP11-114M1.3	3.64	0.000285	0.0154	0.12	0.11	Corneal structure;	chr3:177568667	chr3:177700346~177701072:-
BRCA	cis	rs13217239	0.511	rs4546474	ENSG00000216901.1	AL022393.7	-3.64	0.000285	0.0154	-0.13	-0.11	Schizophrenia;	chr6:27256854	chr6:28176188~28176674:+
BRCA	cis	rs10916772	0.618	rs12566008	ENSG00000236963.4	LINC01141	3.64	0.000285	0.0154	0.2	0.11	Psychosis proneness (perceptual aberration scale);	chr1:20362057	chr1:20360579~20431234:-
BRCA	cis	rs8030605	0.633	rs72740534	ENSG00000277245.1	RP11-48G14.3	3.64	0.000285	0.0154	0.24	0.11	Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;	chr15:56296206	chr15:56447120~56447697:+
BRCA	cis	rs9659323	1	rs11584380	ENSG00000231365.4	RP11-418J17.1	-3.64	0.000285	0.0154	-0.14	-0.11	Body mass index;	chr1:118974797	chr1:119140396~119275973:+
BRCA	cis	rs8180040	0.62	rs11917361	ENSG00000260236.1	RP11-708J19.1	-3.64	0.000285	0.0154	-0.1	-0.11	Colorectal cancer;	chr3:47029007	chr3:47379089~47380999:-
BRCA	cis	rs8007846	0.521	rs1003401	ENSG00000276116.2	FUT8-AS1	3.64	0.000285	0.0154	0.11	0.11	Multiple sclerosis--Brain Glutamate Levels;	chr14:65771002	chr14:65411170~65412690:-
BRCA	cis	rs7620503	1	rs6443474	ENSG00000231574.4	RP11-91K9.1	3.64	0.000285	0.0154	0.12	0.11	Corneal structure;	chr3:177587336	chr3:177816865~177899224:+
BRCA	cis	rs7620503	0.516	rs1566409	ENSG00000231574.4	RP11-91K9.1	3.64	0.000285	0.0154	0.14	0.11	Corneal structure;	chr3:177616400	chr3:177816865~177899224:+
BRCA	cis	rs983392	0.679	rs4938932	ENSG00000275344.1	MIR6503	3.64	0.000285	0.0154	0.12	0.11	Alzheimer's disease (late onset);	chr11:60265975	chr11:60209071~60209156:-
BRCA	cis	rs6964587	1	rs7805077	ENSG00000188693.7	CYP51A1-AS1	-3.64	0.000285	0.0154	-0.12	-0.11	Breast cancer;	chr7:92015239	chr7:92134604~92180725:+
BRCA	cis	rs7647973	0.516	rs4499638	ENSG00000272434.1	RP13-131K19.6	-3.64	0.000285	0.0154	-0.13	-0.11	Menarche (age at onset);	chr3:49165349	chr3:49029316~49029706:+
BRCA	cis	rs295490	0.748	rs77876369	ENSG00000178631.7	ACTG1P1	-3.64	0.000285	0.0154	-0.22	-0.11	PR interval in Tripanosoma cruzi seropositivity;	chr3:139412070	chr3:139493809~139494937:+
BRCA	cis	rs3755605	0.52	rs28857583	ENSG00000242578.1	RP11-469J4.3	3.64	0.000285	0.0154	0.14	0.11	Testicular germ cell tumor;	chr3:170217576	chr3:170410512~170418615:+
BRCA	cis	rs375066	0.762	rs62114648	ENSG00000267191.1	RP11-15A1.2	3.64	0.000285	0.0154	0.15	0.11	Breast cancer;	chr19:43910664	chr19:43902001~43926545:+
BRCA	cis	rs58904263	1	rs58904263	ENSG00000230613.1	HM13-AS1	3.64	0.000285	0.0154	0.17	0.11	Monocyte count;	chr20:31813603	chr20:31567707~31573263:-
BRCA	cis	rs6964587	1	rs35317449	ENSG00000188693.7	CYP51A1-AS1	-3.64	0.000285	0.0154	-0.12	-0.11	Breast cancer;	chr7:92007696	chr7:92134604~92180725:+
BRCA	cis	rs875971	0.522	rs2949690	ENSG00000273142.1	RP11-458F8.4	3.64	0.000285	0.0154	0.1	0.11	Aortic root size;	chr7:66018255	chr7:66902857~66906297:+
BRCA	cis	rs7818688	1	rs10112230	ENSG00000245080.5	RP11-320N21.1	-3.64	0.000285	0.0154	-0.18	-0.11	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95025844	chr8:95066808~95073182:-
BRCA	cis	rs7818688	1	rs10106491	ENSG00000245080.5	RP11-320N21.1	-3.64	0.000285	0.0154	-0.18	-0.11	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95026731	chr8:95066808~95073182:-
BRCA	cis	rs7818688	1	rs73276444	ENSG00000245080.5	RP11-320N21.1	-3.64	0.000285	0.0154	-0.18	-0.11	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95027019	chr8:95066808~95073182:-
BRCA	cis	rs2839186	0.867	rs13050387	ENSG00000215424.8	MCM3AP-AS1	3.64	0.000285	0.0154	0.1	0.11	Testicular germ cell tumor;	chr21:46281509	chr21:46229217~46259390:+
BRCA	cis	rs2839186	0.872	rs13046834	ENSG00000215424.8	MCM3AP-AS1	3.64	0.000285	0.0154	0.1	0.11	Testicular germ cell tumor;	chr21:46281571	chr21:46229217~46259390:+
BRCA	cis	rs2839186	0.721	rs13051200	ENSG00000215424.8	MCM3AP-AS1	3.64	0.000285	0.0154	0.1	0.11	Testicular germ cell tumor;	chr21:46281779	chr21:46229217~46259390:+
BRCA	cis	rs17270561	0.609	rs9358878	ENSG00000272462.2	U91328.19	-3.64	0.000285	0.0154	-0.14	-0.11	Iron status biomarkers;	chr6:25740045	chr6:25992662~26001775:+
BRCA	cis	rs17270561	0.609	rs4131670	ENSG00000272462.2	U91328.19	-3.64	0.000285	0.0154	-0.14	-0.11	Iron status biomarkers;	chr6:25738391	chr6:25992662~26001775:+
BRCA	cis	rs2274273	1	rs4644	ENSG00000259318.1	RP11-454L9.2	3.64	0.000285	0.0154	0.1	0.11	Protein biomarker;	chr14:55138217	chr14:55394940~55395233:-
BRCA	cis	rs13287066	0.967	rs7022679	ENSG00000227603.1	RP11-165J3.6	3.64	0.000286	0.0154	0.12	0.11	Intelligence (multi-trait analysis);	chr9:93410508	chr9:93435332~93437121:-
BRCA	cis	rs7869969	0.527	rs10992726	ENSG00000227603.1	RP11-165J3.6	3.64	0.000286	0.0154	0.12	0.11	Childhood body mass index;	chr9:93410762	chr9:93435332~93437121:-
BRCA	cis	rs7598759	1	rs7598759	ENSG00000281035.1	AC017104.3	-3.64	0.000286	0.0154	-0.12	-0.11	Noise-induced hearing loss;	chr2:231457245	chr2:231456417~231456557:-
BRCA	cis	rs4218	0.541	rs1374155	ENSG00000259732.1	RP11-59H7.3	-3.64	0.000286	0.0154	-0.13	-0.11	Social communication problems;	chr15:59030630	chr15:59121034~59133250:+
BRCA	cis	rs1730008	0.865	rs1618377	ENSG00000279311.1	RP11-170K4.2	-3.64	0.000286	0.0154	-0.12	-0.11	Lobe attachment (rater-scored or self-reported);	chr3:158204935	chr3:158869898~158871821:+
BRCA	cis	rs2998286	0.723	rs332142	ENSG00000237128.1	RP11-351M16.3	3.64	0.000286	0.0154	0.14	0.11	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28575026	chr10:28433008~28495813:-
BRCA	cis	rs2998286	0.723	rs332143	ENSG00000237128.1	RP11-351M16.3	3.64	0.000286	0.0154	0.14	0.11	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28575777	chr10:28433008~28495813:-
BRCA	cis	rs6088580	0.524	rs7269596	ENSG00000279253.1	RP4-614O4.13	3.64	0.000286	0.0154	0.13	0.11	Glomerular filtration rate (creatinine);	chr20:34641259	chr20:35262727~35264187:-
BRCA	cis	rs2191566	0.576	rs393195	ENSG00000266921.1	RP11-15A1.7	3.64	0.000286	0.0154	0.14	0.11	Acute lymphoblastic leukemia (childhood);	chr19:43988990	chr19:43996896~44002836:-
BRCA	cis	rs7572733	1	rs1025549	ENSG00000231621.1	AC013264.2	-3.64	0.000286	0.0154	-0.1	-0.11	Dermatomyositis;	chr2:198016459	chr2:197197991~197199273:+
BRCA	cis	rs863345	0.604	rs6666805	ENSG00000229914.1	RP11-404O13.4	-3.64	0.000286	0.0154	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158528515	chr1:158195633~158196131:-
BRCA	cis	rs863345	0.604	rs12120526	ENSG00000229914.1	RP11-404O13.4	-3.64	0.000286	0.0154	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158528614	chr1:158195633~158196131:-
BRCA	cis	rs875971	1	rs778706	ENSG00000272831.1	RP11-792A8.4	3.64	0.000286	0.0154	0.1	0.11	Aortic root size;	chr7:66395437	chr7:66739829~66740385:-
BRCA	cis	rs6964587	1	rs7802668	ENSG00000188693.7	CYP51A1-AS1	-3.64	0.000286	0.0154	-0.12	-0.11	Breast cancer;	chr7:92019625	chr7:92134604~92180725:+
BRCA	cis	rs804280	0.525	rs17153755	ENSG00000270154.1	RP11-419I17.1	3.64	0.000286	0.0154	0.13	0.11	Myopia (pathological);	chr8:11753991	chr8:12476462~12477122:+
BRCA	cis	rs983392	0.792	rs606588	ENSG00000275344.1	MIR6503	-3.64	0.000286	0.0154	-0.12	-0.11	Alzheimer's disease (late onset);	chr11:60149432	chr11:60209071~60209156:-
BRCA	cis	rs4664293	0.967	rs13000070	ENSG00000230783.1	AC009961.2	-3.64	0.000286	0.0154	-0.14	-0.11	Monocyte percentage of white cells;	chr2:159669263	chr2:159689217~159690291:-
BRCA	cis	rs4388249	1	rs4388249	ENSG00000271849.1	CTC-332L22.1	3.64	0.000286	0.0154	0.18	0.11	Schizophrenia;	chr5:109700365	chr5:109687802~109688329:-
BRCA	cis	rs9494145	0.648	rs7758845	ENSG00000236703.1	MYB-AS1	-3.64	0.000286	0.0154	-0.11	-0.11	Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count;	chr6:135107399	chr6:135195083~135195995:-
BRCA	cis	rs7267979	1	rs6037095	ENSG00000274414.1	RP5-965G21.4	3.64	0.000286	0.0154	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25355051	chr20:25239007~25245229:-
BRCA	cis	rs7267979	1	rs6050562	ENSG00000274414.1	RP5-965G21.4	3.64	0.000286	0.0154	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25355550	chr20:25239007~25245229:-
BRCA	cis	rs4449834	0.851	rs6982898	ENSG00000254432.1	RP11-33I11.2	-3.64	0.000286	0.0154	-0.14	-0.11	Sum eosinophil basophil counts;	chr8:60791524	chr8:60808735~60809606:-
BRCA	cis	rs7098100	0.641	rs2666782	ENSG00000231920.1	NEBL-AS1	3.64	0.000286	0.0154	0.13	0.11	Breast cancer;	chr10:21923627	chr10:21174014~21175048:+
BRCA	cis	rs4073416	0.842	rs4080329	ENSG00000276116.2	FUT8-AS1	-3.64	0.000286	0.0154	-0.12	-0.11	N-glycan levels;	chr14:65766772	chr14:65411170~65412690:-
BRCA	cis	rs1555133	0.924	rs4911234	ENSG00000277692.1	RP11-358N2.2	-3.64	0.000286	0.0154	-0.12	-0.11	Monocyte count;	chr20:32470559	chr20:32355053~32355734:+
BRCA	cis	rs11892454	0.599	rs11888512	ENSG00000217643.1	PTGES3P2	-3.64	0.000286	0.0154	-0.12	-0.11	Heschl's gyrus morphology;	chr2:25761341	chr2:25822469~25822950:+
BRCA	cis	rs11892454	0.566	rs11888724	ENSG00000217643.1	PTGES3P2	-3.64	0.000286	0.0154	-0.12	-0.11	Heschl's gyrus morphology;	chr2:25761772	chr2:25822469~25822950:+
BRCA	cis	rs11892454	0.566	rs11893562	ENSG00000217643.1	PTGES3P2	-3.64	0.000286	0.0154	-0.12	-0.11	Heschl's gyrus morphology;	chr2:25761826	chr2:25822469~25822950:+
BRCA	cis	rs9423406	0.706	rs9423584	ENSG00000224034.1	RP11-445P17.8	3.64	0.000286	0.0154	0.18	0.11	Intelligence;	chr10:5261779	chr10:5266033~5271236:-
BRCA	cis	rs7260598	0.605	rs78358879	ENSG00000268442.1	CTD-2027I19.2	3.64	0.000286	0.0154	0.19	0.11	Response to taxane treatment (placlitaxel);	chr19:23904434	chr19:24162370~24163425:-
BRCA	cis	rs13315871	0.929	rs9818581	ENSG00000272182.1	RP11-802O23.3	3.64	0.000286	0.0154	0.23	0.11	Cholesterol, total;	chr3:58307374	chr3:58428255~58428815:+
BRCA	cis	rs13315871	0.929	rs13075746	ENSG00000272182.1	RP11-802O23.3	3.64	0.000286	0.0154	0.23	0.11	Cholesterol, total;	chr3:58308140	chr3:58428255~58428815:+
BRCA	cis	rs8180040	0.966	rs11710322	ENSG00000260236.1	RP11-708J19.1	-3.64	0.000286	0.0154	-0.1	-0.11	Colorectal cancer;	chr3:47289646	chr3:47379089~47380999:-
BRCA	cis	rs10844706	0.604	rs7964018	ENSG00000278635.1	CTD-2318O12.1	3.64	0.000286	0.0154	0.11	0.11	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9713803	chr12:9415641~9416718:+
BRCA	cis	rs4974559	0.739	rs28429103	ENSG00000253399.1	AC078852.2	3.64	0.000286	0.0154	0.17	0.11	Systolic blood pressure;	chr4:1326235	chr4:1358479~1359461:+
BRCA	cis	rs10487112	0.833	rs11563847	ENSG00000235436.9	DPY19L2P4	-3.64	0.000286	0.0154	-0.12	-0.11	Perceived unattractiveness to mosquitoes;	chr7:90519643	chr7:90119400~90125600:+
BRCA	cis	rs8026198	0.929	rs4924674	ENSG00000260571.1	BNIP3P5	-3.64	0.000286	0.0154	-0.19	-0.11	Fibrinogen levels;	chr15:42376300	chr15:42313687~42314386:+
BRCA	cis	rs3805389	0.504	rs10018932	ENSG00000273257.1	RP11-177J6.1	-3.64	0.000286	0.0154	-0.18	-0.11	Waist-to-hip ratio adjusted for body mass index;	chr4:55601699	chr4:55387949~55388271:+
BRCA	cis	rs7523050	0.73	rs11102650	ENSG00000203897.3	SPATA42	-3.64	0.000286	0.0154	-0.21	-0.11	Fat distribution (HIV);	chr1:108921606	chr1:108857217~108858524:+
BRCA	cis	rs219780	0.796	rs219793	ENSG00000233818.1	AP000695.4	-3.64	0.000286	0.0154	-0.14	-0.11	Kidney stones;	chr21:36454012	chr21:36445731~36532408:+
BRCA	cis	rs4415084	0.8	rs1821934	ENSG00000248779.1	RP11-53O19.2	3.64	0.000286	0.0154	0.1	0.11	Breast cancer;	chr5:44789070	chr5:44752949~44765744:+
BRCA	cis	rs10043775	0.831	rs1422969	ENSG00000251330.3	CTD-2283N19.1	-3.64	0.000286	0.0154	-0.13	-0.11	Periodontal microbiota;	chr5:148323853	chr5:148430159~148430807:-
BRCA	cis	rs748404	0.666	rs10518812	ENSG00000205771.5	CATSPER2P1	3.64	0.000286	0.0154	0.17	0.11	Lung cancer;	chr15:43360739	chr15:43726918~43747094:-
BRCA	cis	rs722864	0.704	rs734993	ENSG00000238133.5	MLK7-AS1	-3.64	0.000286	0.0154	-0.17	-0.11	Lung cancer;	chr2:173161271	chr2:173166446~173282036:-
BRCA	cis	rs2880765	0.835	rs7180213	ENSG00000230373.7	GOLGA6L5P	3.64	0.000286	0.0154	0.12	0.11	Coronary artery disease;	chr15:85477956	chr15:84507885~84516814:-
BRCA	cis	rs962856	1	rs11888062	ENSG00000236605.1	AC023115.4	3.64	0.000286	0.0154	0.13	0.11	Pancreatic cancer;	chr2:67378226	chr2:67324627~67325304:+
BRCA	cis	rs1437396	0.657	rs1545555	ENSG00000203327.2	AC012358.7	-3.64	0.000286	0.0154	-0.11	-0.11	Alcohol dependence;	chr2:55390468	chr2:55214387~55216126:-
BRCA	cis	rs12549902	0.966	rs4737000	ENSG00000254165.1	RP11-503E24.2	3.64	0.000286	0.0154	0.12	0.11	Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Corrected insulin response;Type 2 diabetes;	chr8:41652208	chr8:42537529~42538304:-
BRCA	cis	rs2625529	0.668	rs34487006	ENSG00000260037.4	CTD-2524L6.3	-3.64	0.000286	0.0154	-0.16	-0.11	Red blood cell count;	chr15:72170009	chr15:71818396~71823384:+
BRCA	cis	rs7777677	0.925	rs4726540	ENSG00000211752.3	TRBV27	-3.64	0.000286	0.0154	-0.09	-0.11	Alcoholic chronic pancreatitis;	chr7:142658771	chr7:142715346~142715861:+
BRCA	cis	rs495337	1	rs4810998	ENSG00000229222.1	KRT18P4	-3.64	0.000286	0.0154	-0.14	-0.11	Psoriasis;	chr20:49963473	chr20:49956745~49958032:+
BRCA	cis	rs2640806	0.645	rs13255914	ENSG00000253105.4	KB-1448A5.1	3.64	0.000286	0.0154	0.13	0.11	Obesity-related traits;	chr8:96317138	chr8:96371865~96387438:-
BRCA	cis	rs747650	0.504	rs7108822	ENSG00000200376.1	RNU5E-10P	3.64	0.000286	0.0154	0.15	0.11	Acne (severe);	chr11:47022804	chr11:47576471~47576588:-
BRCA	cis	rs6495122	0.501	rs6495144	ENSG00000260269.4	CTD-2323K18.1	3.64	0.000286	0.0154	0.14	0.11	Diastolic blood pressure;Coffee consumption;Caffeine consumption;	chr15:75051097	chr15:75527150~75601205:-
BRCA	cis	rs9470794	1	rs73419959	ENSG00000204110.6	RP1-153P14.8	-3.64	0.000286	0.0154	-0.23	-0.11	Type 2 diabetes;	chr6:38078581	chr6:37507348~37535616:+
BRCA	cis	rs1876206	0.554	rs1678979	ENSG00000274654.1	CTD-3247H4.2	-3.64	0.000286	0.0154	-0.13	-0.11	Breast cancer;	chr15:48604633	chr15:48528980~48529728:-
BRCA	cis	rs453301	0.658	rs12114954	ENSG00000253981.4	ALG1L13P	-3.64	0.000286	0.0154	-0.13	-0.11	Joint mobility (Beighton score);	chr8:9047352	chr8:8236003~8244667:-
BRCA	cis	rs867371	0.722	rs8033050	ENSG00000278603.1	RP13-608F4.5	3.64	0.000286	0.0154	0.16	0.11	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82269648	chr15:82472203~82472426:+
BRCA	cis	rs10129255	1	rs10129319	ENSG00000211967.3	IGHV3-53	-3.64	0.000286	0.0154	-0.08	-0.11	Kawasaki disease;	chr14:106767996	chr14:106592676~106593347:-
BRCA	cis	rs6490294	0.571	rs11066119	ENSG00000257624.1	RP1-128M12.3	3.64	0.000286	0.0154	0.18	0.11	Mean platelet volume;	chr12:111996700	chr12:112000739~112000985:-
BRCA	cis	rs8141529	0.748	rs6005936	ENSG00000226471.5	CTA-292E10.6	-3.64	0.000286	0.0154	-0.13	-0.11	Lymphocyte counts;	chr22:28893262	chr22:28800683~28848559:+
BRCA	cis	rs1424638	0.655	rs2217360	ENSG00000233251.6	AC007743.1	-3.64	0.000286	0.0154	-0.13	-0.11	Intelligence (multi-trait analysis);	chr2:57015694	chr2:56173534~56185770:-
BRCA	cis	rs875971	0.862	rs949930	ENSG00000229886.1	RP5-1132H15.3	-3.64	0.000286	0.0154	-0.12	-0.11	Aortic root size;	chr7:66301835	chr7:66025126~66031544:-
BRCA	cis	rs16958440	0.737	rs16958699	ENSG00000267800.1	RP11-49K24.5	-3.64	0.000286	0.0154	-0.24	-0.11	Sitting height ratio;	chr18:47128475	chr18:47137018~47137290:+
BRCA	cis	rs16958440	1	rs16958701	ENSG00000267800.1	RP11-49K24.5	-3.64	0.000286	0.0154	-0.24	-0.11	Sitting height ratio;	chr18:47128870	chr18:47137018~47137290:+
BRCA	cis	rs6743226	0.603	rs10933546	ENSG00000266621.1	AC104841.1	3.64	0.000286	0.0154	0.13	0.11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in non-smokers;	chr2:241286583	chr2:241245202~241245299:-
BRCA	cis	rs13401620	0.917	rs6711896	ENSG00000229326.3	AC069154.4	-3.64	0.000286	0.0154	-0.15	-0.11	Breast size;	chr2:119770941	chr2:119698623~119700151:+
BRCA	cis	rs875971	0.545	rs3936065	ENSG00000232559.3	GS1-124K5.12	3.64	0.000286	0.0154	0.15	0.11	Aortic root size;	chr7:66325577	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.545	rs4718335	ENSG00000232559.3	GS1-124K5.12	3.64	0.000286	0.0154	0.15	0.11	Aortic root size;	chr7:66339619	chr7:66554588~66576923:-
BRCA	cis	rs1869026	1	rs1880542	ENSG00000237614.1	AC073257.2	-3.64	0.000286	0.0154	-0.14	-0.11	Age-related hearing impairment (SNP x SNP interaction);	chr2:120581008	chr2:120542909~120544326:-
BRCA	cis	rs1528472	0.679	rs17818939	ENSG00000276533.1	RP11-139H15.5	3.64	0.000286	0.0154	0.13	0.11	Urinary albumin-to-creatinine ratio;Urinary albumin-to-creatinine ratio in non-diabetics;	chr15:55016650	chr15:55288849~55289346:-
BRCA	cis	rs5167	0.743	rs8111069	ENSG00000214855.8	APOC1P1	3.64	0.000286	0.0154	0.14	0.11	Blood protein levels;	chr19:44980181	chr19:44926804~44931386:+
BRCA	cis	rs17270561	0.609	rs1937132	ENSG00000272462.2	U91328.19	-3.64	0.000287	0.0154	-0.14	-0.11	Iron status biomarkers;	chr6:25756789	chr6:25992662~26001775:+
BRCA	cis	rs9325144	0.56	rs11182952	ENSG00000257718.1	RP11-396F22.1	-3.64	0.000287	0.0154	-0.11	-0.11	Morning vs. evening chronotype;	chr12:38242476	chr12:38906451~38909592:+
BRCA	cis	rs9990333	0.521	rs3862281	ENSG00000207650.1	MIR570	3.64	0.000287	0.0155	0.14	0.11	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196092985	chr3:195699401~195699497:+
BRCA	cis	rs754466	0.58	rs12357670	ENSG00000213514.2	RP11-428P16.2	3.64	0.000287	0.0155	0.16	0.11	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77798422	chr10:77730766~77734769:+
BRCA	cis	rs12303914	0.713	rs3809214	ENSG00000256682.2	TAS2R12	-3.64	0.000287	0.0155	-0.13	-0.11	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr12:10306970	chr12:10894943~10896952:-
BRCA	cis	rs198426	0.81	rs198456	ENSG00000243742.4	RPLP0P2	-3.64	0.000287	0.0155	-0.14	-0.11	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr11:61695916	chr11:61615036~61639449:+
BRCA	cis	rs948562	0.793	rs1944051	ENSG00000280010.1	AP001350.4	3.64	0.000287	0.0155	0.22	0.11	Lymphoma;	chr11:58607820	chr11:58627435~58628528:+
BRCA	cis	rs948562	0.793	rs1800169	ENSG00000280010.1	AP001350.4	3.64	0.000287	0.0155	0.22	0.11	Lymphoma;	chr11:58624028	chr11:58627435~58628528:+
BRCA	cis	rs948562	0.696	rs17568220	ENSG00000280010.1	AP001350.4	3.64	0.000287	0.0155	0.22	0.11	Lymphoma;	chr11:58627550	chr11:58627435~58628528:+
BRCA	cis	rs867186	0.92	rs17092456	ENSG00000279253.1	RP4-614O4.13	-3.64	0.000287	0.0155	-0.19	-0.11	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35208389	chr20:35262727~35264187:-
BRCA	cis	rs7267979	0.903	rs2500400	ENSG00000277938.1	RP5-965G21.3	-3.64	0.000287	0.0155	-0.13	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25374069	chr20:25229150~25231933:+
BRCA	cis	rs10792665	0.724	rs1904427	ENSG00000246067.6	RAB30-AS1	-3.64	0.000287	0.0155	-0.12	-0.11	Obesity-related traits;	chr11:83003206	chr11:83072066~83106719:+
BRCA	cis	rs4243971	0.516	rs6141294	ENSG00000275576.1	RP5-836N17.4	-3.64	0.000287	0.0155	-0.13	-0.11	Inflammatory bowel disease;Crohn's disease;	chr20:32365359	chr20:32116171~32116629:+
BRCA	cis	rs4243971	0.516	rs2295454	ENSG00000275576.1	RP5-836N17.4	-3.64	0.000287	0.0155	-0.13	-0.11	Inflammatory bowel disease;Crohn's disease;	chr20:32366492	chr20:32116171~32116629:+
BRCA	cis	rs2274273	0.624	rs78205412	ENSG00000259318.1	RP11-454L9.2	3.64	0.000287	0.0155	0.1	0.11	Protein biomarker;	chr14:55314532	chr14:55394940~55395233:-
BRCA	cis	rs7777677	0.925	rs4726542	ENSG00000211752.3	TRBV27	-3.64	0.000287	0.0155	-0.09	-0.11	Alcoholic chronic pancreatitis;	chr7:142659516	chr7:142715346~142715861:+
BRCA	cis	rs9868809	0.881	rs13063312	ENSG00000225399.4	RP11-3B7.1	-3.64	0.000287	0.0155	-0.18	-0.11	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48624552	chr3:49260085~49261316:+
BRCA	cis	rs6545883	0.868	rs7608483	ENSG00000212978.6	AC016747.3	3.64	0.000287	0.0155	0.15	0.11	Tuberculosis;	chr2:61609100	chr2:61141592~61144969:-
BRCA	cis	rs801193	1	rs62466793	ENSG00000232546.1	RP11-458F8.1	-3.64	0.000287	0.0155	-0.09	-0.11	Aortic root size;	chr7:66726530	chr7:66848496~66858136:+
BRCA	cis	rs4713118	0.869	rs9283883	ENSG00000219392.1	RP1-265C24.5	-3.64	0.000287	0.0155	-0.16	-0.11	Parkinson's disease;	chr6:27747691	chr6:28115628~28116551:+
BRCA	cis	rs9309473	0.554	rs4330127	ENSG00000230002.2	ALMS1-IT1	3.64	0.000287	0.0155	0.13	0.11	Metabolite levels;	chr2:73354192	chr2:73456764~73459484:+
BRCA	cis	rs6918586	0.532	rs198800	ENSG00000272810.1	U91328.22	-3.64	0.000287	0.0155	-0.12	-0.11	Schizophrenia;	chr6:26139705	chr6:26013241~26013757:+
BRCA	cis	rs4648045	0.565	rs11733749	ENSG00000251288.2	RP11-10L12.2	-3.64	0.000287	0.0155	-0.14	-0.11	Lymphocyte percentage of white cells;	chr4:102625985	chr4:102751401~102752641:+
BRCA	cis	rs78487399	0.808	rs6761129	ENSG00000234936.1	AC010883.5	3.64	0.000287	0.0155	0.16	0.11	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43508574	chr2:43229573~43233394:+
BRCA	cis	rs36051895	0.664	rs3780372	ENSG00000236254.1	MTND4P14	-3.64	0.000287	0.0155	-0.13	-0.11	Pediatric autoimmune diseases;	chr9:5097544	chr9:5107937~5109290:+
BRCA	cis	rs9329221	0.537	rs2062331	ENSG00000253641.4	RP11-981G7.2	3.64	0.000287	0.0155	0.13	0.11	Neuroticism;	chr8:10122482	chr8:10474565~10481974:+
BRCA	cis	rs4819052	0.851	rs2838833	ENSG00000215447.6	BX322557.10	-3.64	0.000287	0.0155	-0.12	-0.11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245245	chr21:45288052~45291738:+
BRCA	cis	rs2562456	0.917	rs2562468	ENSG00000240522.1	RPL7AP10	3.64	0.000287	0.0155	0.12	0.11	Pain;	chr19:21532048	chr19:21149648~21150438:-
BRCA	cis	rs2562456	0.917	rs2562471	ENSG00000240522.1	RPL7AP10	3.64	0.000287	0.0155	0.12	0.11	Pain;	chr19:21533017	chr19:21149648~21150438:-
BRCA	cis	rs359466	0.938	rs35447628	ENSG00000254164.1	CTB-33O18.2	-3.64	0.000287	0.0155	-0.18	-0.11	QRS complex (Sokolow-Lyon);	chr5:173958905	chr5:173574938~173576275:+
BRCA	cis	rs7695732	0.743	rs7656238	ENSG00000270720.1	RP11-84C13.2	-3.64	0.000287	0.0155	-0.15	-0.11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr4:89000830	chr4:89119284~89119871:+
BRCA	cis	rs2904524	1	rs17107924	ENSG00000257613.1	LINC01481	3.64	0.000287	0.0155	0.19	0.11	Amyotrophic lateral sclerosis (age of onset);	chr12:70280875	chr12:70219132~70221862:-
BRCA	cis	rs4449834	0.816	rs2326598	ENSG00000254432.1	RP11-33I11.2	-3.64	0.000287	0.0155	-0.15	-0.11	Sum eosinophil basophil counts;	chr8:60762419	chr8:60808735~60809606:-
BRCA	cis	rs4919694	1	rs80327774	ENSG00000236937.2	PTGES3P4	3.64	0.000287	0.0155	0.23	0.11	Arsenic metabolism;	chr10:102896914	chr10:102845595~102845950:+
BRCA	cis	rs9659323	1	rs10923714	ENSG00000231365.4	RP11-418J17.1	-3.64	0.000287	0.0155	-0.13	-0.11	Body mass index;	chr1:118970290	chr1:119140396~119275973:+
BRCA	cis	rs91731	0.92	rs7711070	ENSG00000249572.1	CTD-2203K17.1	3.64	0.000287	0.0155	0.21	0.11	Lung function (FVC);	chr5:33242561	chr5:33424025~33440619:-
BRCA	cis	rs4243971	0.516	rs6141695	ENSG00000275576.1	RP5-836N17.4	-3.64	0.000287	0.0155	-0.12	-0.11	Inflammatory bowel disease;Crohn's disease;	chr20:32381247	chr20:32116171~32116629:+
BRCA	cis	rs10463316	0.832	rs246483	ENSG00000260581.1	CTB-113P19.4	3.64	0.000288	0.0155	0.13	0.11	Metabolite levels (Pyroglutamine);	chr5:151351501	chr5:151652275~151655449:+
BRCA	cis	rs4650943	0.703	rs352300	ENSG00000227740.1	RP11-318C24.2	-3.64	0.000288	0.0155	-0.11	-0.11	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in inactive individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr1:176280916	chr1:175904762~175920513:-
BRCA	cis	rs7943953	1	rs1453541	ENSG00000254717.2	GLYATL1P2	3.64	0.000288	0.0155	0.14	0.11	Odorant perception (&beta-ionone);	chr11:59457748	chr11:58878302~58893460:+
BRCA	cis	rs9473147	0.551	rs6900120	ENSG00000270761.1	RP11-385F7.1	3.64	0.000288	0.0155	0.12	0.11	Platelet distribution width;Mean platelet volume;	chr6:47684774	chr6:47477243~47477572:-
BRCA	cis	rs12118297	1	rs1537058	ENSG00000261737.1	RP4-612B15.3	-3.64	0.000288	0.0155	-0.16	-0.11	Breast cancer;	chr1:87304690	chr1:86703502~86704462:-
BRCA	cis	rs11673344	0.566	rs185368	ENSG00000267422.1	CTD-2554C21.1	-3.64	0.000288	0.0155	-0.14	-0.11	Obesity-related traits;	chr19:37381827	chr19:37779686~37792865:+
BRCA	cis	rs28489187	0.617	rs7547571	ENSG00000223653.4	RP11-131L23.1	-3.64	0.000288	0.0155	-0.12	-0.11	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85418408	chr1:85276715~85448124:+
BRCA	cis	rs754466	0.58	rs10824577	ENSG00000213514.2	RP11-428P16.2	3.64	0.000288	0.0155	0.15	0.11	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77817650	chr10:77730766~77734769:+
BRCA	cis	rs875971	0.66	rs801192	ENSG00000272831.1	RP11-792A8.4	-3.64	0.000288	0.0155	-0.1	-0.11	Aortic root size;	chr7:66566965	chr7:66739829~66740385:-
BRCA	cis	rs875971	0.66	rs801190	ENSG00000272831.1	RP11-792A8.4	-3.64	0.000288	0.0155	-0.1	-0.11	Aortic root size;	chr7:66568046	chr7:66739829~66740385:-
BRCA	cis	rs875971	0.66	rs3857686	ENSG00000272831.1	RP11-792A8.4	-3.64	0.000288	0.0155	-0.1	-0.11	Aortic root size;	chr7:66571204	chr7:66739829~66740385:-
BRCA	cis	rs72799341	1	rs1458201	ENSG00000280211.1	RP11-2C24.3	3.64	0.000288	0.0155	0.13	0.11	Diastolic blood pressure;	chr16:30904808	chr16:30773532~30776033:-
BRCA	cis	rs7722600	0.808	rs11959181	ENSG00000253404.1	AC034243.1	-3.64	0.000288	0.0155	-0.19	-0.11	Heart rate;	chr5:138005126	chr5:138744434~138753309:-
BRCA	cis	rs10254160	1	rs2396535	ENSG00000214194.7	LINC00998	3.64	0.000288	0.0155	0.27	0.11	Parental extreme longevity (95 years and older);	chr7:112415266	chr7:113116718~113118613:-
BRCA	cis	rs1555133	0.625	rs6141297	ENSG00000275576.1	RP5-836N17.4	-3.64	0.000288	0.0155	-0.12	-0.11	Monocyte count;	chr20:32375694	chr20:32116171~32116629:+
BRCA	cis	rs1538970	0.851	rs61788285	ENSG00000281133.1	AL355480.3	-3.64	0.000288	0.0155	-0.15	-0.11	Platelet count;	chr1:45453562	chr1:45580892~45580996:-
BRCA	cis	rs6991838	0.557	rs67685675	ENSG00000272155.1	RP11-707M3.3	3.64	0.000288	0.0155	0.1	0.11	Intelligence (multi-trait analysis);	chr8:65574371	chr8:65714334~65714778:-
BRCA	cis	rs6991838	0.584	rs66486920	ENSG00000272155.1	RP11-707M3.3	3.64	0.000288	0.0155	0.1	0.11	Intelligence (multi-trait analysis);	chr8:65574458	chr8:65714334~65714778:-
BRCA	cis	rs6991838	0.584	rs60023200	ENSG00000272155.1	RP11-707M3.3	3.64	0.000288	0.0155	0.1	0.11	Intelligence (multi-trait analysis);	chr8:65574547	chr8:65714334~65714778:-
BRCA	cis	rs6991838	0.584	rs61083799	ENSG00000272155.1	RP11-707M3.3	3.64	0.000288	0.0155	0.1	0.11	Intelligence (multi-trait analysis);	chr8:65574868	chr8:65714334~65714778:-
BRCA	cis	rs1208	0.741	rs13276600	ENSG00000253671.1	RP11-806O11.1	-3.64	0.000288	0.0155	-0.13	-0.11	Insulin resistance/response;	chr8:18413680	chr8:17808941~17820868:+
BRCA	cis	rs1208	0.777	rs7813156	ENSG00000253671.1	RP11-806O11.1	-3.64	0.000288	0.0155	-0.13	-0.11	Insulin resistance/response;	chr8:18413789	chr8:17808941~17820868:+
BRCA	cis	rs10129255	1	rs10129255	ENSG00000253132.1	IGHV3-62	3.64	0.000288	0.0155	0.09	0.11	Kawasaki disease;	chr14:106767970	chr14:106643142~106643585:-
BRCA	cis	rs11098499	0.739	rs10031033	ENSG00000249244.1	RP11-548H18.2	3.64	0.000288	0.0155	0.13	0.11	Corneal astigmatism;	chr4:119230297	chr4:119391831~119395335:-
BRCA	cis	rs13256369	1	rs1109619	ENSG00000254153.1	CTA-398F10.2	3.64	0.000288	0.0155	0.15	0.11	Obesity-related traits;	chr8:8714106	chr8:8456909~8461337:-
BRCA	cis	rs8054556	0.669	rs9972866	ENSG00000183604.13	SMG1P5	-3.64	0.000288	0.0155	-0.11	-0.11	Autism spectrum disorder or schizophrenia;	chr16:30007661	chr16:30267553~30335374:-
BRCA	cis	rs10090774	0.71	rs4413752	ENSG00000279766.1	RP11-642A1.2	-3.64	0.000288	0.0155	-0.13	-0.11	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140678873	chr8:140572142~140572812:-
BRCA	cis	rs6479874	0.688	rs2660217	ENSG00000223502.1	RP11-96B5.3	-3.64	0.000288	0.0155	-0.2	-0.11	Migraine;	chr10:50992200	chr10:51062579~51068553:-
BRCA	cis	rs875971	0.522	rs7784623	ENSG00000232546.1	RP11-458F8.1	-3.64	0.000288	0.0155	-0.09	-0.11	Aortic root size;	chr7:65930047	chr7:66848496~66858136:+
BRCA	cis	rs7520050	0.966	rs11810993	ENSG00000226957.1	RP4-533D7.4	3.64	0.000288	0.0155	0.12	0.11	Reticulocyte count;Red blood cell count;	chr1:46013121	chr1:46046818~46048368:+
BRCA	cis	rs6429082	0.51	rs2789367	ENSG00000230026.2	RP11-382D8.5	-3.64	0.000288	0.0155	-0.12	-0.11	Adiposity;	chr1:235343603	chr1:235361153~235362540:+
BRCA	cis	rs7221109	0.585	rs6503547	ENSG00000224244.1	AC090283.3	3.64	0.000288	0.0155	0.13	0.11	Type 1 diabetes;	chr17:40662956	chr17:40687038~40689360:-
BRCA	cis	rs6012564	1	rs3091866	ENSG00000230758.1	SNAP23P	-3.64	0.000288	0.0155	-0.13	-0.11	Anger;	chr20:49031816	chr20:49038357~49038602:-
BRCA	cis	rs6964587	1	rs11982213	ENSG00000188693.7	CYP51A1-AS1	-3.64	0.000288	0.0155	-0.12	-0.11	Breast cancer;	chr7:92093652	chr7:92134604~92180725:+
BRCA	cis	rs739496	0.793	rs73199895	ENSG00000257624.1	RP1-128M12.3	3.64	0.000288	0.0155	0.15	0.11	Platelet count;	chr12:111428283	chr12:112000739~112000985:-
BRCA	cis	rs6840360	0.571	rs4696278	ENSG00000278978.1	RP11-164P12.5	-3.64	0.000288	0.0155	-0.13	-0.11	Intelligence (multi-trait analysis);	chr4:151637826	chr4:151669786~151670503:+
BRCA	cis	rs6840360	0.571	rs4696279	ENSG00000278978.1	RP11-164P12.5	-3.64	0.000288	0.0155	-0.13	-0.11	Intelligence (multi-trait analysis);	chr4:151639297	chr4:151669786~151670503:+
BRCA	cis	rs17092148	0.731	rs35507767	ENSG00000202150.1	RNU6-407P	3.64	0.000288	0.0155	0.16	0.11	Neuroticism;	chr20:34773561	chr20:35030317~35030420:-
BRCA	cis	rs2514805	0.803	rs2340023	ENSG00000253585.1	KB-1184D12.1	3.64	0.000288	0.0155	0.19	0.11	Diisocyanate-induced asthma;	chr8:94145248	chr8:94097764~94104322:-
BRCA	cis	rs6600671	0.966	rs6600664	ENSG00000275131.1	CH17-472G23.4	-3.64	0.000288	0.0155	-0.11	-0.11	Hip geometry;	chr1:121480638	chr1:120489625~120579190:-
BRCA	cis	rs6600671	0.932	rs6600663	ENSG00000275131.1	CH17-472G23.4	-3.64	0.000288	0.0155	-0.11	-0.11	Hip geometry;	chr1:121480639	chr1:120489625~120579190:-
BRCA	cis	rs7429990	0.965	rs1060407	ENSG00000228638.1	FCF1P2	-3.64	0.000288	0.0155	-0.12	-0.11	Educational attainment (years of education);	chr3:47916547	chr3:48290793~48291375:-
BRCA	cis	rs13256369	0.901	rs4841015	ENSG00000254153.1	CTA-398F10.2	3.64	0.000288	0.0155	0.15	0.11	Obesity-related traits;	chr8:8709630	chr8:8456909~8461337:-
BRCA	cis	rs7267979	0.966	rs2257233	ENSG00000277938.1	RP5-965G21.3	-3.64	0.000288	0.0155	-0.13	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25285348	chr20:25229150~25231933:+
BRCA	cis	rs6964587	1	rs4644173	ENSG00000188693.7	CYP51A1-AS1	-3.64	0.000288	0.0155	-0.12	-0.11	Breast cancer;	chr7:92130283	chr7:92134604~92180725:+
BRCA	cis	rs6785206	0.803	rs6774512	ENSG00000242551.2	POU5F1P6	-3.64	0.000289	0.0155	-0.22	-0.11	Lymphocyte percentage of white cells;	chr3:128697025	chr3:128674735~128677005:-
BRCA	cis	rs5742933	1	rs16831939	ENSG00000253559.1	OSGEPL1-AS1	-3.64	0.000289	0.0155	-0.16	-0.11	Ferritin levels;	chr2:189739282	chr2:189762704~189765556:+
BRCA	cis	rs2834288	0.613	rs2834297	ENSG00000237945.6	LINC00649	-3.64	0.000289	0.0155	-0.13	-0.11	Gut microbiota (bacterial taxa);	chr21:33910534	chr21:33915534~33977691:+
BRCA	cis	rs74233809	1	rs11191543	ENSG00000213061.2	PFN1P11	3.64	0.000289	0.0155	0.24	0.11	Birth weight;	chr10:103064630	chr10:102838011~102845473:-
BRCA	cis	rs7577696	0.924	rs7605242	ENSG00000276334.1	AL133243.1	-3.64	0.000289	0.0155	-0.14	-0.11	Inflammatory biomarkers;	chr2:32099066	chr2:32521927~32523547:+
BRCA	cis	rs11098499	0.955	rs1511018	ENSG00000260404.2	RP11-384K6.6	3.64	0.000289	0.0155	0.11	0.11	Corneal astigmatism;	chr4:119240425	chr4:118591773~118633729:+
BRCA	cis	rs13434995	0.513	rs17721497	ENSG00000273257.1	RP11-177J6.1	3.64	0.000289	0.0155	0.17	0.11	Adiponectin levels;	chr4:55445081	chr4:55387949~55388271:+
BRCA	cis	rs6439153	0.933	rs9822511	ENSG00000242551.2	POU5F1P6	-3.64	0.000289	0.0155	-0.14	-0.11	Pneumococcal bacteremia;	chr3:128986724	chr3:128674735~128677005:-
BRCA	cis	rs9346455	0.614	rs1322759	ENSG00000279289.1	RP3-331H24.6	3.64	0.000289	0.0155	0.16	0.11	Antipsychotic drug-induced weight gain;Antipsychotic drug-induced weight gain (time interaction);	chr6:71303320	chr6:71386852~71390829:-
BRCA	cis	rs9634489	0.677	rs7996639	ENSG00000247400.3	DNAJC3-AS1	-3.64	0.000289	0.0155	-0.12	-0.11	Body mass index;	chr13:96366836	chr13:95648733~95676925:-
BRCA	cis	rs62229266	0.804	rs62230821	ENSG00000214914.3	RPL23AP3	3.64	0.000289	0.0155	0.14	0.11	Mitral valve prolapse;	chr21:36052818	chr21:36016079~36016546:-
BRCA	cis	rs72928364	1	rs13077353	ENSG00000244119.1	PDCL3P4	3.64	0.000289	0.0155	0.13	0.11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100931463	chr3:101712472~101713191:+
BRCA	cis	rs728616	0.51	rs12411989	ENSG00000225484.5	NUTM2B-AS1	-3.64	0.000289	0.0155	-0.23	-0.11	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80178094	chr10:79663088~79826594:-
BRCA	cis	rs890448	0.796	rs13148645	ENSG00000254531.1	FLJ20021	3.64	0.000289	0.0155	0.13	0.11	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101385675	chr4:101347780~101348883:+
BRCA	cis	rs2243480	1	rs11538349	ENSG00000226767.1	RP11-328P23.3	-3.64	0.000289	0.0156	-0.19	-0.11	Diabetic kidney disease;	chr7:65956884	chr7:65508773~65508944:-
BRCA	cis	rs4849845	0.678	rs3896632	ENSG00000223549.1	MTND5P28	3.64	0.000289	0.0156	0.13	0.11	Mean platelet volume;	chr2:120265920	chr2:120215181~120217279:+
BRCA	cis	rs7037266	0.783	rs10975923	ENSG00000232946.1	RP11-390F4.2	-3.64	0.000289	0.0156	-0.14	-0.11	Menarche (age at onset);	chr9:6941302	chr9:6675284~6675614:+
BRCA	cis	rs13434995	0.513	rs13133077	ENSG00000273257.1	RP11-177J6.1	3.64	0.000289	0.0156	0.17	0.11	Adiponectin levels;	chr4:55577642	chr4:55387949~55388271:+
BRCA	cis	rs13434995	0.513	rs7665286	ENSG00000273257.1	RP11-177J6.1	3.64	0.000289	0.0156	0.17	0.11	Adiponectin levels;	chr4:55578765	chr4:55387949~55388271:+
BRCA	cis	rs13434995	0.513	rs7683997	ENSG00000273257.1	RP11-177J6.1	3.64	0.000289	0.0156	0.17	0.11	Adiponectin levels;	chr4:55581272	chr4:55387949~55388271:+
BRCA	cis	rs2562456	0.917	rs2681389	ENSG00000213976.4	CTD-2561J22.2	3.64	0.000289	0.0156	0.14	0.11	Pain;	chr19:21509773	chr19:21382865~21387177:+
BRCA	cis	rs337100	0.581	rs397955	ENSG00000263432.2	RN7SL689P	-3.64	0.000289	0.0156	-0.14	-0.11	Pulse pressure;	chr5:123134332	chr5:123022487~123022783:-
BRCA	cis	rs10043775	1	rs13174567	ENSG00000251330.3	CTD-2283N19.1	-3.64	0.000289	0.0156	-0.13	-0.11	Periodontal microbiota;	chr5:148432003	chr5:148430159~148430807:-
BRCA	cis	rs6071166	0.873	rs6071120	ENSG00000224635.1	RP4-564F22.5	-3.64	0.000289	0.0156	-0.13	-0.11	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38693424	chr20:38406011~38416797:-
BRCA	cis	rs7172677	0.737	rs6495155	ENSG00000260269.4	CTD-2323K18.1	-3.64	0.000289	0.0156	-0.15	-0.11	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75144970	chr15:75527150~75601205:-
BRCA	cis	rs7172677	0.737	rs7178005	ENSG00000260269.4	CTD-2323K18.1	-3.64	0.000289	0.0156	-0.15	-0.11	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75145079	chr15:75527150~75601205:-
BRCA	cis	rs7172677	0.737	rs12442392	ENSG00000260269.4	CTD-2323K18.1	-3.64	0.000289	0.0156	-0.15	-0.11	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75145137	chr15:75527150~75601205:-
BRCA	cis	rs863345	0.604	rs1342947	ENSG00000229914.1	RP11-404O13.4	-3.64	0.000289	0.0156	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158489924	chr1:158195633~158196131:-
BRCA	cis	rs863345	0.625	rs950487	ENSG00000229914.1	RP11-404O13.4	-3.64	0.000289	0.0156	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158490340	chr1:158195633~158196131:-
BRCA	cis	rs863345	0.625	rs6427439	ENSG00000229914.1	RP11-404O13.4	-3.64	0.000289	0.0156	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158490567	chr1:158195633~158196131:-
BRCA	cis	rs1005277	0.522	rs7090858	ENSG00000099251.13	HSD17B7P2	-3.64	0.000289	0.0156	-0.12	-0.11	Extrinsic epigenetic age acceleration;	chr10:37714742	chr10:38356380~38378505:+
BRCA	cis	rs7520050	0.898	rs34175029	ENSG00000281133.1	AL355480.3	3.64	0.000289	0.0156	0.13	0.11	Reticulocyte count;Red blood cell count;	chr1:46018199	chr1:45580892~45580996:-
BRCA	cis	rs7267979	0.932	rs449370	ENSG00000277938.1	RP5-965G21.3	-3.64	0.000289	0.0156	-0.13	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25470544	chr20:25229150~25231933:+
BRCA	cis	rs13126694	0.649	rs4615226	ENSG00000251073.1	NUDT19P5	3.64	0.000289	0.0156	0.11	0.11	Blood osmolality (transformed sodium);	chr4:157979297	chr4:158182825~158183393:+
BRCA	cis	rs4700393	0.52	rs5012862	ENSG00000272308.1	RP11-231G3.1	-3.64	0.000289	0.0156	-0.14	-0.11	Intelligence (multi-trait analysis);	chr5:60588926	chr5:60866457~60866935:-
BRCA	cis	rs6088590	1	rs12626122	ENSG00000275784.1	RP5-1125A11.6	-3.64	0.000289	0.0156	-0.14	-0.11	Coronary artery disease;	chr20:34837997	chr20:33989480~33991818:-
BRCA	cis	rs7267979	1	rs3002702	ENSG00000204556.4	CTD-2514C3.1	-3.64	0.000289	0.0156	-0.15	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25288284	chr20:26018832~26020684:+
BRCA	cis	rs7656342	0.866	rs13145733	ENSG00000250342.1	SNRPCP16	-3.64	0.000289	0.0156	-0.13	-0.11	Gut microbiota (bacterial taxa);	chr4:9759021	chr4:9051842~9052051:-
BRCA	cis	rs7487075	0.567	rs7486580	ENSG00000257261.4	RP11-96H19.1	3.64	0.000289	0.0156	0.12	0.11	Itch intensity from mosquito bite;	chr12:46434565	chr12:46383679~46876159:+
BRCA	cis	rs6012564	0.893	rs6066909	ENSG00000227431.4	CSE1L-AS1	3.64	0.000289	0.0156	0.14	0.11	Anger;	chr20:48913376	chr20:49040463~49046044:-
BRCA	cis	rs7695732	0.743	rs7680864	ENSG00000270720.1	RP11-84C13.2	-3.64	0.000289	0.0156	-0.15	-0.11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr4:89000748	chr4:89119284~89119871:+
BRCA	cis	rs4921164	0.943	rs4921162	ENSG00000245812.2	RP11-175K6.1	-3.64	0.000289	0.0156	-0.14	-0.11	Gut microbiome composition (winter);	chr5:159118322	chr5:159100483~159117478:+
BRCA	cis	rs6498068	0.594	rs3087620	ENSG00000279662.1	RP11-609N14.4	-3.64	0.000289	0.0156	-0.13	-0.11	Metabolite levels (MHPG);	chr16:10529475	chr16:10445309~10449747:-
BRCA	cis	rs4835473	0.932	rs2323191	ENSG00000246448.2	RP13-578N3.3	-3.64	0.000289	0.0156	-0.13	-0.11	Immature fraction of reticulocytes;	chr4:143744472	chr4:143700257~143865072:+
BRCA	cis	rs11696845	0.626	rs1111032	ENSG00000276223.1	RP4-781B1.5	-3.64	0.00029	0.0156	-0.11	-0.11	Obesity-related traits;	chr20:44750129	chr20:44746642~44747201:+
BRCA	cis	rs2976388	0.609	rs2717550	ENSG00000253196.1	RP11-706C16.7	3.64	0.00029	0.0156	0.11	0.11	Urinary tract infection frequency;	chr8:142706390	chr8:142763116~142766427:+
BRCA	cis	rs4700393	0.52	rs206789	ENSG00000272308.1	RP11-231G3.1	-3.64	0.00029	0.0156	-0.14	-0.11	Intelligence (multi-trait analysis);	chr5:60608144	chr5:60866457~60866935:-
BRCA	cis	rs938554	0.612	rs7669607	ENSG00000250413.1	RP11-448G15.1	3.64	0.00029	0.0156	0.17	0.11	Blood metabolite levels;	chr4:9996177	chr4:10006482~10009725:+
BRCA	cis	rs7312933	0.703	rs12370778	ENSG00000257225.1	RP11-328C8.4	-3.64	0.00029	0.0156	-0.14	-0.11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42205894	chr12:42459366~42466128:+
BRCA	cis	rs7312933	0.703	rs11181378	ENSG00000257225.1	RP11-328C8.4	-3.64	0.00029	0.0156	-0.14	-0.11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42206856	chr12:42459366~42466128:+
BRCA	cis	rs7312933	0.67	rs10880269	ENSG00000257225.1	RP11-328C8.4	-3.64	0.00029	0.0156	-0.14	-0.11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42212333	chr12:42459366~42466128:+
BRCA	cis	rs17092148	0.945	rs6060042	ENSG00000202150.1	RNU6-407P	3.64	0.00029	0.0156	0.17	0.11	Neuroticism;	chr20:34773918	chr20:35030317~35030420:-
BRCA	cis	rs2278331	1	rs2278331	ENSG00000278902.1	RP11-25L3.1	-3.64	0.00029	0.0156	-0.13	-0.11	Sleep duration;	chr18:73914271	chr18:73921939~73922631:-
BRCA	cis	rs251253	0.827	rs251248	ENSG00000253959.1	CTB-43E15.1	3.64	0.00029	0.0156	0.1	0.11	PR interval;	chr5:173060115	chr5:173642519~173658194:+
BRCA	cis	rs4950322	0.57	rs72692920	ENSG00000227242.3	NBPF13P	-3.64	0.00029	0.0156	-0.16	-0.11	Protein quantitative trait loci;	chr1:147308501	chr1:147021320~147124525:-
BRCA	cis	rs8192917	0.667	rs34037718	ENSG00000258744.1	RP11-80A15.1	3.64	0.00029	0.0156	0.16	0.11	Vitiligo;	chr14:24597522	chr14:24501594~24508688:+
BRCA	cis	rs5758511	0.731	rs58302269	ENSG00000233903.2	Z83851.4	3.64	0.00029	0.0156	0.17	0.11	Birth weight;	chr22:41955305	chr22:42276355~42277052:+
BRCA	cis	rs8114671	0.562	rs3746450	ENSG00000279253.1	RP4-614O4.13	-3.64	0.00029	0.0156	-0.13	-0.11	Height;	chr20:34920785	chr20:35262727~35264187:-
BRCA	cis	rs8114671	0.562	rs6087649	ENSG00000279253.1	RP4-614O4.13	-3.64	0.00029	0.0156	-0.13	-0.11	Height;	chr20:34922859	chr20:35262727~35264187:-
BRCA	cis	rs8114671	0.562	rs4911449	ENSG00000279253.1	RP4-614O4.13	-3.64	0.00029	0.0156	-0.13	-0.11	Height;	chr20:34924433	chr20:35262727~35264187:-
BRCA	cis	rs2965260	0.621	rs12609049	ENSG00000269051.4	CTD-2245F17.3	-3.64	0.00029	0.0156	-0.19	-0.11	IgG glycosylation;	chr19:53259284	chr19:53197111~53211015:+
BRCA	cis	rs9470794	1	rs56195121	ENSG00000204110.6	RP1-153P14.8	-3.64	0.00029	0.0156	-0.18	-0.11	Type 2 diabetes;	chr6:38161266	chr6:37507348~37535616:+
BRCA	cis	rs250518	0.926	rs6896898	ENSG00000271926.1	CTD-2376I4.1	3.64	0.00029	0.0156	0.15	0.11	Mean corpuscular hemoglobin concentration;	chr5:72795174	chr5:72953635~72954274:-
BRCA	cis	rs4415084	0.966	rs12516900	ENSG00000272335.1	RP11-53O19.3	3.64	0.00029	0.0156	0.1	0.11	Breast cancer;	chr5:44644393	chr5:44826076~44828592:+
BRCA	cis	rs4415084	0.932	rs4321755	ENSG00000272335.1	RP11-53O19.3	3.64	0.00029	0.0156	0.1	0.11	Breast cancer;	chr5:44646093	chr5:44826076~44828592:+
BRCA	cis	rs67073037	0.955	rs4438440	ENSG00000230730.1	AC074011.2	-3.64	0.00029	0.0156	-0.15	-0.11	Breast cancer;Breast cancer (estrogen-receptor negative);	chr2:28898745	chr2:28633282~28664540:-
BRCA	cis	rs7412746	0.658	rs3768015	ENSG00000224800.1	RP11-235D19.2	-3.64	0.00029	0.0156	-0.14	-0.11	Melanoma;	chr1:150840478	chr1:150881236~150881683:-
BRCA	cis	rs73201462	1	rs2811549	ENSG00000242551.2	POU5F1P6	-3.64	0.00029	0.0156	-0.19	-0.11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128219865	chr3:128674735~128677005:-
BRCA	cis	rs9918079	0.56	rs4698406	ENSG00000214846.4	RP11-115L11.1	3.64	0.00029	0.0156	0.14	0.11	Obesity-related traits;	chr4:15638994	chr4:15730962~15731627:-
BRCA	cis	rs3805389	0.504	rs17781708	ENSG00000249700.7	SRD5A3-AS1	3.64	0.00029	0.0156	0.18	0.11	Waist-to-hip ratio adjusted for body mass index;	chr4:55614902	chr4:55363971~55395847:-
BRCA	cis	rs6964587	1	rs10263309	ENSG00000188693.7	CYP51A1-AS1	-3.64	0.00029	0.0156	-0.12	-0.11	Breast cancer;	chr7:92015951	chr7:92134604~92180725:+
BRCA	cis	rs925550	0.8	rs6837455	ENSG00000224786.1	CETN4P	-3.64	0.00029	0.0156	-0.19	-0.11	Primary biliary cholangitis;	chr4:122667787	chr4:122730548~122732193:-
BRCA	cis	rs6812193	0.518	rs28649105	ENSG00000271676.1	RP11-1E1.2	3.64	0.00029	0.0156	0.16	0.11	Parkinson's disease;	chr4:76264726	chr4:77112495~77113458:-
BRCA	cis	rs886774	1	rs886774	ENSG00000273055.1	CTB-13F3.1	3.64	0.00029	0.0156	0.12	0.11	Ulcerative colitis;	chr7:107854989	chr7:107942116~107942740:+
BRCA	cis	rs62025270	0.576	rs62022947	ENSG00000259367.1	RP11-815J21.4	3.64	0.00029	0.0156	0.11	0.11	Idiopathic pulmonary fibrosis;	chr15:85728091	chr15:85619623~85670948:-
BRCA	cis	rs13063635	0.915	rs35855315	ENSG00000223552.1	RP11-24F11.2	-3.64	0.00029	0.0156	-0.18	-0.11	Eosinophil percentage of granulocytes;	chr3:45964747	chr3:46364955~46407059:-
BRCA	cis	rs13063635	0.915	rs35525815	ENSG00000223552.1	RP11-24F11.2	-3.64	0.00029	0.0156	-0.18	-0.11	Eosinophil percentage of granulocytes;	chr3:45964777	chr3:46364955~46407059:-
BRCA	cis	rs13063635	0.748	rs17280623	ENSG00000223552.1	RP11-24F11.2	-3.64	0.00029	0.0156	-0.18	-0.11	Eosinophil percentage of granulocytes;	chr3:45964849	chr3:46364955~46407059:-
BRCA	cis	rs672059	1	rs559476	ENSG00000224468.3	RP11-181K3.4	-3.64	0.00029	0.0156	-0.12	-0.11	Hypertriglyceridemia;	chr1:183191569	chr1:183138402~183141282:-
BRCA	cis	rs672059	0.966	rs689375	ENSG00000224468.3	RP11-181K3.4	-3.64	0.00029	0.0156	-0.12	-0.11	Hypertriglyceridemia;	chr1:183191838	chr1:183138402~183141282:-
BRCA	cis	rs9659323	1	rs9658899	ENSG00000231365.4	RP11-418J17.1	-3.64	0.00029	0.0156	-0.13	-0.11	Body mass index;	chr1:118961920	chr1:119140396~119275973:+
BRCA	cis	rs9866825	0.935	rs7611811	ENSG00000227110.5	LMCD1-AS1	3.64	0.00029	0.0156	0.13	0.11	QT interval;	chr3:8203142	chr3:7952805~8611924:-
BRCA	cis	rs9866825	0.967	rs6443172	ENSG00000227110.5	LMCD1-AS1	3.64	0.00029	0.0156	0.13	0.11	QT interval;	chr3:8203360	chr3:7952805~8611924:-
BRCA	cis	rs2998286	0.768	rs332140	ENSG00000237128.1	RP11-351M16.3	3.64	0.00029	0.0156	0.14	0.11	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28570431	chr10:28433008~28495813:-
BRCA	cis	rs6696239	0.956	rs1045407	ENSG00000227711.2	RP11-275O4.5	3.64	0.00029	0.0156	0.15	0.11	Height;	chr1:227659532	chr1:227509028~227520477:-
BRCA	cis	rs890448	0.796	rs13143896	ENSG00000254531.1	FLJ20021	3.64	0.00029	0.0156	0.13	0.11	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101440045	chr4:101347780~101348883:+
BRCA	cis	rs35520189	0.754	rs10169916	ENSG00000274877.1	RP11-65I12.1	3.64	0.00029	0.0156	0.15	0.11	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:112846151	chr2:113237595~113240825:+
BRCA	cis	rs13098911	0.54	rs36039366	ENSG00000223552.1	RP11-24F11.2	-3.64	0.00029	0.0156	-0.18	-0.11	Celiac disease;	chr3:45962045	chr3:46364955~46407059:-
BRCA	cis	rs2031532	0.587	rs2038638	ENSG00000236577.1	SNRPGP14	3.64	0.00029	0.0156	0.13	0.11	Cardiac hypertrophy;	chr13:49474839	chr13:49488970~49489364:+
BRCA	cis	rs10463316	0.928	rs10060441	ENSG00000260581.1	CTB-113P19.4	3.64	0.00029	0.0156	0.13	0.11	Metabolite levels (Pyroglutamine);	chr5:151370445	chr5:151652275~151655449:+
BRCA	cis	rs848490	0.889	rs6960913	ENSG00000214293.7	APTR	3.64	0.000291	0.0156	0.14	0.11	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77647943	chr7:77657660~77696265:-
BRCA	cis	rs848490	0.889	rs35392227	ENSG00000214293.7	APTR	3.64	0.000291	0.0156	0.14	0.11	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77648452	chr7:77657660~77696265:-
BRCA	cis	rs10991814	0.72	rs7028794	ENSG00000273381.1	RP11-305L7.7	3.64	0.000291	0.0156	0.16	0.11	Neutrophil percentage of granulocytes;	chr9:91269067	chr9:91206175~91210299:-
BRCA	cis	rs755249	0.567	rs1537817	ENSG00000182109.6	RP11-69E11.4	-3.64	0.000291	0.0156	-0.15	-0.11	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39173981	chr1:39522280~39546187:-
BRCA	cis	rs10761482	0.861	rs7084499	ENSG00000254271.1	RP11-131N11.4	3.64	0.000291	0.0156	0.16	0.11	Schizophrenia;	chr10:60347124	chr10:60734342~60741828:+
BRCA	cis	rs35520189	0.857	rs2708916	ENSG00000189223.12	PAX8-AS1	3.64	0.000291	0.0156	0.16	0.11	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:112870724	chr2:113211522~113276581:+
BRCA	cis	rs7312933	0.703	rs10880268	ENSG00000257225.1	RP11-328C8.4	-3.64	0.000291	0.0156	-0.14	-0.11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42205320	chr12:42459366~42466128:+
BRCA	cis	rs2278331	0.501	rs41377344	ENSG00000278902.1	RP11-25L3.1	-3.64	0.000291	0.0156	-0.13	-0.11	Sleep duration;	chr18:73912202	chr18:73921939~73922631:-
BRCA	cis	rs654950	0.841	rs676383	ENSG00000230638.4	RP11-486B10.4	3.64	0.000291	0.0156	0.14	0.11	Airway imaging phenotypes;	chr1:41528082	chr1:41542069~41544310:+
BRCA	cis	rs2803122	0.871	rs10733360	ENSG00000272842.1	RP11-513M16.7	-3.64	0.000291	0.0156	-0.12	-0.11	Pulse pressure;	chr9:19221580	chr9:19371386~19371945:-
BRCA	cis	rs8099594	0.64	rs527265	ENSG00000266696.1	RP11-30L3.2	3.64	0.000291	0.0156	0.13	0.11	Height;	chr18:49332354	chr18:49205912~49208781:+
BRCA	cis	rs853679	0.517	rs16893666	ENSG00000272009.1	RP1-313I6.12	3.64	0.000291	0.0156	0.16	0.11	Depression;	chr6:28086929	chr6:28078792~28081130:-
BRCA	cis	rs72772090	0.539	rs72775809	ENSG00000272109.1	CTD-2260A17.3	3.64	0.000291	0.0156	0.22	0.11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96847853	chr5:96804353~96806105:+
BRCA	cis	rs2274273	0.837	rs56949365	ENSG00000259318.1	RP11-454L9.2	3.64	0.000291	0.0156	0.09	0.11	Protein biomarker;	chr14:55323360	chr14:55394940~55395233:-
BRCA	cis	rs2274273	0.87	rs4496026	ENSG00000259318.1	RP11-454L9.2	3.64	0.000291	0.0156	0.09	0.11	Protein biomarker;	chr14:55323794	chr14:55394940~55395233:-
BRCA	cis	rs2274273	0.87	rs4366639	ENSG00000259318.1	RP11-454L9.2	3.64	0.000291	0.0156	0.09	0.11	Protein biomarker;	chr14:55323798	chr14:55394940~55395233:-
BRCA	cis	rs987724	0.964	rs9814813	ENSG00000240875.4	LINC00886	-3.64	0.000291	0.0156	-0.13	-0.11	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156962229	chr3:156747346~156817062:-
BRCA	cis	rs7177699	0.526	rs7166764	ENSG00000261143.1	ADAMTS7P3	-3.64	0.000291	0.0156	-0.13	-0.11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78831167	chr15:77976042~77993057:+
BRCA	cis	rs116095464	0.558	rs9687621	ENSG00000250848.1	CTD-2083E4.5	-3.64	0.000291	0.0156	-0.17	-0.11	Breast cancer;	chr5:229079	chr5:288833~290321:-
BRCA	cis	rs10771431	0.597	rs3759275	ENSG00000256673.1	RP11-599J14.2	3.64	0.000291	0.0157	0.13	0.11	Breast size;	chr12:9201232	chr12:9398355~9414851:-
BRCA	cis	rs10771431	0.597	rs3759274	ENSG00000256673.1	RP11-599J14.2	3.64	0.000291	0.0157	0.13	0.11	Breast size;	chr12:9201279	chr12:9398355~9414851:-
BRCA	cis	rs10771431	0.597	rs10771412	ENSG00000256673.1	RP11-599J14.2	3.64	0.000291	0.0157	0.13	0.11	Breast size;	chr12:9201757	chr12:9398355~9414851:-
BRCA	cis	rs10771431	0.597	rs10771413	ENSG00000256673.1	RP11-599J14.2	3.64	0.000291	0.0157	0.13	0.11	Breast size;	chr12:9201817	chr12:9398355~9414851:-
BRCA	cis	rs7520050	0.966	rs11589562	ENSG00000226957.1	RP4-533D7.4	-3.64	0.000291	0.0157	-0.12	-0.11	Reticulocyte count;Red blood cell count;	chr1:46001049	chr1:46046818~46048368:+
BRCA	cis	rs1005277	0.54	rs289638	ENSG00000099251.13	HSD17B7P2	3.64	0.000291	0.0157	0.13	0.11	Extrinsic epigenetic age acceleration;	chr10:37634803	chr10:38356380~38378505:+
BRCA	cis	rs9659323	1	rs56897173	ENSG00000231365.4	RP11-418J17.1	-3.64	0.000291	0.0157	-0.13	-0.11	Body mass index;	chr1:118973109	chr1:119140396~119275973:+
BRCA	cis	rs250518	0.926	rs6875887	ENSG00000271926.1	CTD-2376I4.1	3.64	0.000291	0.0157	0.15	0.11	Mean corpuscular hemoglobin concentration;	chr5:72795067	chr5:72953635~72954274:-
BRCA	cis	rs250518	0.926	rs6876549	ENSG00000271926.1	CTD-2376I4.1	3.64	0.000291	0.0157	0.15	0.11	Mean corpuscular hemoglobin concentration;	chr5:72795463	chr5:72953635~72954274:-
BRCA	cis	rs250518	0.926	rs6897422	ENSG00000271926.1	CTD-2376I4.1	3.64	0.000291	0.0157	0.15	0.11	Mean corpuscular hemoglobin concentration;	chr5:72795532	chr5:72953635~72954274:-
BRCA	cis	rs250518	0.926	rs6452687	ENSG00000271926.1	CTD-2376I4.1	3.64	0.000291	0.0157	0.15	0.11	Mean corpuscular hemoglobin concentration;	chr5:72795688	chr5:72953635~72954274:-
BRCA	cis	rs250518	0.926	rs6452690	ENSG00000271926.1	CTD-2376I4.1	3.64	0.000291	0.0157	0.15	0.11	Mean corpuscular hemoglobin concentration;	chr5:72795785	chr5:72953635~72954274:-
BRCA	cis	rs13434995	0.513	rs62303718	ENSG00000249700.7	SRD5A3-AS1	-3.64	0.000291	0.0157	-0.16	-0.11	Adiponectin levels;	chr4:55476770	chr4:55363971~55395847:-
BRCA	cis	rs13434995	0.513	rs17722870	ENSG00000249700.7	SRD5A3-AS1	-3.64	0.000291	0.0157	-0.16	-0.11	Adiponectin levels;	chr4:55478519	chr4:55363971~55395847:-
BRCA	cis	rs7781266	0.739	rs17576069	ENSG00000226205.1	AC007790.4	3.64	0.000291	0.0157	0.17	0.11	Educational attainment (college completion);	chr7:133381760	chr7:133732493~133733595:-
BRCA	cis	rs3820068	0.581	rs34453754	ENSG00000237301.1	RP4-680D5.2	-3.64	0.000291	0.0157	-0.14	-0.11	Systolic blood pressure;	chr1:15666713	chr1:15586136~15603626:-
BRCA	cis	rs2625529	0.627	rs1037680	ENSG00000260037.4	CTD-2524L6.3	-3.64	0.000291	0.0157	-0.16	-0.11	Red blood cell count;	chr15:72221978	chr15:71818396~71823384:+
BRCA	cis	rs4243971	0.516	rs6141664	ENSG00000275576.1	RP5-836N17.4	-3.64	0.000291	0.0157	-0.13	-0.11	Inflammatory bowel disease;Crohn's disease;	chr20:32300565	chr20:32116171~32116629:+
BRCA	cis	rs1443512	0.812	rs1975470	ENSG00000228630.4	HOTAIR	-3.64	0.000291	0.0157	-0.14	-0.11	Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-hip ratio;Waist-to-hip ratio adjusted for body mass index;	chr12:53943057	chr12:53962308~53974956:-
BRCA	cis	rs62458065	0.713	rs921406	ENSG00000281332.1	LINC00997	-3.64	0.000291	0.0157	-0.17	-0.11	Metabolite levels (HVA/MHPG ratio);	chr7:32446593	chr7:32760279~32762924:+
BRCA	cis	rs2976388	0.609	rs2263092	ENSG00000253196.1	RP11-706C16.7	3.64	0.000291	0.0157	0.11	0.11	Urinary tract infection frequency;	chr8:142708548	chr8:142763116~142766427:+
BRCA	cis	rs73201462	1	rs2811528	ENSG00000242551.2	POU5F1P6	-3.64	0.000291	0.0157	-0.19	-0.11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128275593	chr3:128674735~128677005:-
BRCA	cis	rs73201462	1	rs2811381	ENSG00000242551.2	POU5F1P6	-3.64	0.000291	0.0157	-0.19	-0.11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128279069	chr3:128674735~128677005:-
BRCA	cis	rs9392556	0.829	rs633290	ENSG00000230648.1	RP3-406P24.3	-3.64	0.000291	0.0157	-0.14	-0.11	Blood metabolite levels;	chr6:4114554	chr6:4018843~4021215:-
BRCA	cis	rs2380205	0.517	rs56369297	ENSG00000232807.2	RP11-536K7.3	3.64	0.000291	0.0157	0.12	0.11	Breast cancer;	chr10:5904680	chr10:5934270~5945900:-
BRCA	cis	rs13256369	1	rs883648	ENSG00000254153.1	CTA-398F10.2	3.64	0.000292	0.0157	0.15	0.11	Obesity-related traits;	chr8:8712011	chr8:8456909~8461337:-
BRCA	cis	rs8114671	0.562	rs725521	ENSG00000279253.1	RP4-614O4.13	-3.64	0.000292	0.0157	-0.13	-0.11	Height;	chr20:34928268	chr20:35262727~35264187:-
BRCA	cis	rs8114671	0.562	rs7266550	ENSG00000279253.1	RP4-614O4.13	-3.64	0.000292	0.0157	-0.13	-0.11	Height;	chr20:34907707	chr20:35262727~35264187:-
BRCA	cis	rs7031417	1	rs7031417	ENSG00000226327.3	RP11-350G13.1	-3.64	0.000292	0.0157	-0.24	-0.11	Longitudinal alcohol consumption;	chr9:88211338	chr9:88324454~88325339:+
BRCA	cis	rs6893300	1	rs62406178	ENSG00000225051.5	HMGB3P22	3.64	0.000292	0.0157	0.15	0.11	Resting heart rate;	chr5:179737217	chr5:179679032~179694768:+
BRCA	cis	rs6088580	0.634	rs11700221	ENSG00000275784.1	RP5-1125A11.6	3.64	0.000292	0.0157	0.12	0.11	Glomerular filtration rate (creatinine);	chr20:34352514	chr20:33989480~33991818:-
BRCA	cis	rs465969	1	rs17510733	ENSG00000271789.1	RP5-1112D6.7	3.63	0.000292	0.0157	0.27	0.11	Psoriasis;	chr6:111389715	chr6:111297126~111298510:+
BRCA	cis	rs7637701	1	rs7637701	ENSG00000240875.4	LINC00886	-3.63	0.000292	0.0157	-0.13	-0.11	Breast cancer;	chr3:156927968	chr3:156747346~156817062:-
BRCA	cis	rs7637701	0.967	rs9865905	ENSG00000240875.4	LINC00886	-3.63	0.000292	0.0157	-0.13	-0.11	Breast cancer;	chr3:156931805	chr3:156747346~156817062:-
BRCA	cis	rs7474896	0.561	rs2474603	ENSG00000226578.1	RP11-258F22.1	-3.63	0.000292	0.0157	-0.16	-0.11	Obesity (extreme);	chr10:38156754	chr10:37775371~37784131:-
BRCA	cis	rs962856	0.575	rs2035565	ENSG00000236605.1	AC023115.4	3.63	0.000292	0.0157	0.15	0.11	Pancreatic cancer;	chr2:67392524	chr2:67324627~67325304:+
BRCA	cis	rs2880765	0.835	rs7174323	ENSG00000230373.7	GOLGA6L5P	3.63	0.000292	0.0157	0.12	0.11	Coronary artery disease;	chr15:85506488	chr15:84507885~84516814:-
BRCA	cis	rs12462428	0.876	rs5002162	ENSG00000279748.1	CTD-3222D19.9	3.63	0.000292	0.0157	0.14	0.11	Educational attainment (years of education);	chr19:16627558	chr19:16586905~16589409:+
BRCA	cis	rs11098499	0.954	rs67265404	ENSG00000225892.3	RP11-384K6.2	3.63	0.000292	0.0157	0.11	0.11	Corneal astigmatism;	chr4:119438115	chr4:118632274~118634759:+
BRCA	cis	rs8114671	0.662	rs6058146	ENSG00000126005.14	MMP24-AS1	-3.63	0.000292	0.0157	-0.13	-0.11	Height;	chr20:34952726	chr20:35216462~35278131:-
BRCA	cis	rs12468226	0.938	rs56684065	ENSG00000272966.1	RP11-686O6.1	3.63	0.000292	0.0157	0.19	0.11	Urate levels;	chr2:202289528	chr2:202336739~202337200:+
BRCA	cis	rs12468226	0.938	rs1474001	ENSG00000272966.1	RP11-686O6.1	3.63	0.000292	0.0157	0.19	0.11	Urate levels;	chr2:202290230	chr2:202336739~202337200:+
BRCA	cis	rs12468226	0.938	rs76664732	ENSG00000272966.1	RP11-686O6.1	3.63	0.000292	0.0157	0.19	0.11	Urate levels;	chr2:202296298	chr2:202336739~202337200:+
BRCA	cis	rs1376877	0.902	rs11676242	ENSG00000273456.1	RP11-686O6.2	3.63	0.000292	0.0157	0.11	0.11	Subclinical atherosclerosis traits (other);	chr2:203323598	chr2:202374932~202375604:-
BRCA	cis	rs801193	0.569	rs13226966	ENSG00000271064.1	RP11-792A8.3	-3.63	0.000292	0.0157	-0.13	-0.11	Aortic root size;	chr7:66768636	chr7:66748838~66749077:-
BRCA	cis	rs4660456	0.504	rs587963	ENSG00000272145.1	NFYC-AS1	-3.63	0.000292	0.0157	-0.13	-0.11	Platelet count;	chr1:40640045	chr1:40690380~40692066:-
BRCA	cis	rs4374383	0.884	rs3761701	ENSG00000243389.1	AC012442.5	-3.63	0.000292	0.0157	-0.14	-0.11	Hepatitis C induced liver fibrosis;	chr2:111947580	chr2:112589040~112614431:+
BRCA	cis	rs3768617	0.677	rs12739316	ENSG00000224468.3	RP11-181K3.4	-3.63	0.000292	0.0157	-0.12	-0.11	Fuchs's corneal dystrophy;	chr1:183082945	chr1:183138402~183141282:-
BRCA	cis	rs4836891	0.667	rs7860446	ENSG00000261534.1	RP11-244O19.1	-3.63	0.000292	0.0157	-0.17	-0.11	Colorectal cancer;	chr9:122570651	chr9:121815674~121819452:-
BRCA	cis	rs2243480	0.803	rs160649	ENSG00000275400.1	RP4-756H11.5	3.63	0.000292	0.0157	0.21	0.11	Diabetic kidney disease;	chr7:66078212	chr7:66553805~66554199:-
BRCA	cis	rs2243480	1	rs160648	ENSG00000275400.1	RP4-756H11.5	3.63	0.000292	0.0157	0.21	0.11	Diabetic kidney disease;	chr7:66078397	chr7:66553805~66554199:-
BRCA	cis	rs875971	0.545	rs10950036	ENSG00000273448.1	RP11-166O4.6	3.63	0.000292	0.0157	0.12	0.11	Aortic root size;	chr7:66353241	chr7:67333047~67334383:+
BRCA	cis	rs6496932	0.635	rs11074191	ENSG00000218052.5	ADAMTS7P4	-3.63	0.000292	0.0157	-0.12	-0.11	Central corneal thickness;Corneal structure;	chr15:85388794	chr15:85255369~85330334:-
BRCA	cis	rs9307551	0.741	rs9307532	ENSG00000250334.4	LINC00989	-3.63	0.000292	0.0157	-0.17	-0.11	Refractive error;	chr4:79510067	chr4:79492416~79576460:+
BRCA	cis	rs7267979	1	rs6076345	ENSG00000274414.1	RP5-965G21.4	3.63	0.000292	0.0157	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25401259	chr20:25239007~25245229:-
BRCA	cis	rs11673344	0.668	rs7248693	ENSG00000267682.1	CTD-3220F14.2	-3.63	0.000292	0.0157	-0.11	-0.11	Obesity-related traits;	chr19:36991864	chr19:37337236~37337743:+
BRCA	cis	rs863345	0.604	rs6674656	ENSG00000229914.1	RP11-404O13.4	-3.63	0.000292	0.0157	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158525641	chr1:158195633~158196131:-
BRCA	cis	rs863345	0.584	rs10797023	ENSG00000229914.1	RP11-404O13.4	-3.63	0.000292	0.0157	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158527289	chr1:158195633~158196131:-
BRCA	cis	rs863345	0.584	rs10797024	ENSG00000229914.1	RP11-404O13.4	-3.63	0.000292	0.0157	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158527373	chr1:158195633~158196131:-
BRCA	cis	rs863345	0.584	rs6657638	ENSG00000229914.1	RP11-404O13.4	-3.63	0.000292	0.0157	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158527394	chr1:158195633~158196131:-
BRCA	cis	rs863345	0.604	rs6670343	ENSG00000229914.1	RP11-404O13.4	-3.63	0.000292	0.0157	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158527468	chr1:158195633~158196131:-
BRCA	cis	rs4363385	1	rs4363385	ENSG00000272654.1	RP11-422P24.11	3.63	0.000292	0.0157	0.12	0.11	Inflammatory skin disease;	chr1:153016845	chr1:153977743~153979160:+
BRCA	cis	rs13401620	0.871	rs56303543	ENSG00000229326.3	AC069154.4	-3.63	0.000292	0.0157	-0.15	-0.11	Breast size;	chr2:119799069	chr2:119698623~119700151:+
BRCA	cis	rs6943931	1	rs6943931	ENSG00000230658.1	KLHL7-AS1	-3.63	0.000292	0.0157	-0.15	-0.11	Diabetic kidney disease;	chr7:22375027	chr7:23101228~23105703:-
BRCA	cis	rs7656342	0.897	rs1967551	ENSG00000250342.1	SNRPCP16	-3.63	0.000292	0.0157	-0.13	-0.11	Gut microbiota (bacterial taxa);	chr4:9783510	chr4:9051842~9052051:-
BRCA	cis	rs853679	0.546	rs200977	ENSG00000241549.7	GUSBP2	3.63	0.000292	0.0157	0.21	0.11	Depression;	chr6:27886523	chr6:26871484~26956554:-
BRCA	cis	rs7705042	0.581	rs10074925	ENSG00000280047.1	CTC-463A16.1	-3.63	0.000292	0.0157	-0.13	-0.11	Asthma;	chr5:142168825	chr5:142165767~142168387:+
BRCA	cis	rs2022309	0.926	rs2022030	ENSG00000260464.1	RP4-561L24.3	3.63	0.000292	0.0157	0.13	0.11	End-stage coagulation;	chr1:94586476	chr1:93847174~93848939:+
BRCA	cis	rs539096	0.83	rs10789435	ENSG00000236200.4	KDM4A-AS1	-3.63	0.000292	0.0157	-0.13	-0.11	Intelligence (multi-trait analysis);	chr1:43560382	chr1:43699765~43708138:-
BRCA	cis	rs539096	0.789	rs68191270	ENSG00000236200.4	KDM4A-AS1	-3.63	0.000292	0.0157	-0.13	-0.11	Intelligence (multi-trait analysis);	chr1:43560509	chr1:43699765~43708138:-
BRCA	cis	rs801193	1	rs2707856	ENSG00000275400.1	RP4-756H11.5	-3.63	0.000292	0.0157	-0.13	-0.11	Aortic root size;	chr7:66746023	chr7:66553805~66554199:-
BRCA	cis	rs6500602	0.609	rs7202910	ENSG00000280063.1	RP11-295D4.3	3.63	0.000292	0.0157	0.09	0.11	Schizophrenia;	chr16:4468947	chr16:4346694~4348648:-
BRCA	cis	rs4835473	0.932	rs6828935	ENSG00000246448.2	RP13-578N3.3	3.63	0.000293	0.0157	0.13	0.11	Immature fraction of reticulocytes;	chr4:143829113	chr4:143700257~143865072:+
BRCA	cis	rs890448	0.796	rs13148622	ENSG00000254531.1	FLJ20021	3.63	0.000293	0.0157	0.13	0.11	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101382421	chr4:101347780~101348883:+
BRCA	cis	rs2692947	0.673	rs3111873	ENSG00000168992.4	OR7E102P	-3.63	0.000293	0.0157	-0.16	-0.11	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96116247	chr2:95546531~95547545:+
BRCA	cis	rs12762955	0.561	rs4880744	ENSG00000205740.2	RP11-363N22.3	-3.63	0.000293	0.0157	-0.12	-0.11	Response to angiotensin II receptor blocker therapy;	chr10:966086	chr10:971146~988341:-
BRCA	cis	rs62244186	0.632	rs1402751	ENSG00000227123.1	RPL12P44	3.63	0.000293	0.0157	0.12	0.11	Depressive symptoms;	chr3:44552538	chr3:44937673~44938482:+
BRCA	cis	rs1032833	0.732	rs10497533	ENSG00000271401.1	RP11-171I2.3	-3.63	0.000293	0.0157	-0.29	-0.11	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);	chr2:179134488	chr2:178644717~178645179:+
BRCA	cis	rs4925386	0.84	rs6142738	ENSG00000275437.1	RP5-908M14.10	-3.63	0.000293	0.0157	-0.12	-0.11	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62344904	chr20:62402236~62405935:-
BRCA	cis	rs12446632	0.511	rs13335015	ENSG00000261195.1	CTD-2380F24.1	-3.63	0.000293	0.0157	-0.16	-0.11	Hip circumference;Body mass index (joint analysis main effects and smoking interaction);BMI in smokers;Menarche (age at onset);Obesity;Childhood body mass index;Waist circumference;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Body mass index;	chr16:19893842	chr16:19761172~19766099:-
BRCA	cis	rs2274459	0.591	rs16868575	ENSG00000232940.4	HCG25	-3.63	0.000293	0.0157	-0.15	-0.11	Obesity (extreme);	chr6:33661269	chr6:33249534~33254989:+
BRCA	cis	rs10744816	0.515	rs11067036	ENSG00000257817.1	RP4-601P9.2	3.63	0.000293	0.0157	0.15	0.11	Obesity-related traits;	chr12:114309102	chr12:114713811~114767957:+
BRCA	cis	rs1998359	0.953	rs17768466	ENSG00000259087.4	RP11-356O9.2	3.63	0.000293	0.0157	0.13	0.11	Self-reported allergy;	chr14:37680726	chr14:37556158~37567095:-
BRCA	cis	rs251253	0.737	rs384717	ENSG00000253959.1	CTB-43E15.1	3.63	0.000293	0.0157	0.1	0.11	PR interval;	chr5:173102788	chr5:173642519~173658194:+
BRCA	cis	rs29784	0.503	rs807428	ENSG00000253959.1	CTB-43E15.1	3.63	0.000293	0.0157	0.1	0.11	Infantile hypertrophic pyloric stenosis;	chr5:173103474	chr5:173642519~173658194:+
BRCA	cis	rs251253	0.827	rs793356	ENSG00000253959.1	CTB-43E15.1	3.63	0.000293	0.0157	0.1	0.11	PR interval;	chr5:173103558	chr5:173642519~173658194:+
BRCA	cis	rs7267979	1	rs2387884	ENSG00000274414.1	RP5-965G21.4	3.63	0.000293	0.0157	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25398433	chr20:25239007~25245229:-
BRCA	cis	rs17756712	0.725	rs2294667	ENSG00000272463.1	RP11-532F6.3	3.63	0.000293	0.0157	0.19	0.11	Vertical cup-disc ratio;	chr6:617523	chr6:708592~711405:-
BRCA	cis	rs2692947	0.832	rs2692954	ENSG00000168992.4	OR7E102P	3.63	0.000293	0.0157	0.16	0.11	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96017630	chr2:95546531~95547545:+
BRCA	cis	rs3748682	0.861	rs12563037	ENSG00000212541.1	RNU6-510P	3.63	0.000293	0.0157	0.16	0.11	Hypothyroidism;	chr1:37792972	chr1:37991462~37991569:+
BRCA	cis	rs4934494	0.834	rs1359624	ENSG00000235100.3	RP11-80H5.9	-3.63	0.000293	0.0157	-0.14	-0.11	Red blood cell count;	chr10:89635671	chr10:89667181~89699671:-
BRCA	cis	rs7561149	0.902	rs6733291	ENSG00000270574.1	RP11-171I2.2	-3.63	0.000293	0.0157	-0.15	-0.11	QT interval;	chr2:178785144	chr2:178578790~178580906:+
BRCA	cis	rs1942	0.837	rs12440045	ENSG00000223313.1	RNU6-516P	3.63	0.000293	0.0158	0.14	0.11	Eosinophil percentage of granulocytes;	chr15:41490486	chr15:40529570~40529673:+
BRCA	cis	rs7208859	0.673	rs11657270	ENSG00000264538.5	SUZ12P1	-3.63	0.000293	0.0158	-0.17	-0.11	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887369	chr17:30709299~30790908:+
BRCA	cis	rs7395581	0.918	rs3816725	ENSG00000280615.1	Y_RNA	3.63	0.000293	0.0158	0.13	0.11	HDL cholesterol;	chr11:47284118	chr11:47614898~47614994:-
BRCA	cis	rs17756712	0.528	rs2073007	ENSG00000271727.1	RP11-532F6.4	3.63	0.000293	0.0158	0.17	0.11	Vertical cup-disc ratio;	chr6:638267	chr6:711533~750729:+
BRCA	cis	rs9287719	0.901	rs10210859	ENSG00000224177.5	LINC00570	3.63	0.000293	0.0158	0.13	0.11	Prostate cancer;	chr2:10593803	chr2:11393981~11403077:+
BRCA	cis	rs7809799	1	rs6969313	ENSG00000242798.1	RP11-506M12.1	3.63	0.000293	0.0158	0.21	0.11	Ulcerative colitis;	chr7:99156384	chr7:100115214~100127139:-
BRCA	cis	rs950027	0.62	rs1346267	ENSG00000259479.5	SORD2P	3.63	0.000293	0.0158	0.14	0.11	Response to fenofibrate (adiponectin levels);	chr15:45398791	chr15:44826371~44884694:-
BRCA	cis	rs16852403	0.619	rs10798597	ENSG00000224687.1	RASAL2-AS1	3.63	0.000293	0.0158	0.14	0.11	Childhood ear infection;	chr1:178139113	chr1:178091508~178093984:-
BRCA	cis	rs4950322	0.57	rs80070044	ENSG00000237188.3	RP11-337C18.8	3.63	0.000293	0.0158	0.14	0.11	Protein quantitative trait loci;	chr1:147330238	chr1:147172771~147211568:+
BRCA	cis	rs9287719	0.967	rs10929688	ENSG00000224177.5	LINC00570	3.63	0.000293	0.0158	0.13	0.11	Prostate cancer;	chr2:10616524	chr2:11393981~11403077:+
BRCA	cis	rs66624999	0.508	rs12443838	ENSG00000261390.4	RP11-345M22.2	3.63	0.000293	0.0158	0.26	0.11	Prostate-specific antigen levels (conditioned on lead SNPs);	chr16:79775758	chr16:79715232~79770563:-
BRCA	cis	rs7166081	0.672	rs3865018	ENSG00000270964.1	RP11-502I4.3	3.63	0.000293	0.0158	0.13	0.11	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67600428	chr15:67541072~67542604:-
BRCA	cis	rs4243971	0.516	rs2208131	ENSG00000277692.1	RP11-358N2.2	-3.63	0.000293	0.0158	-0.13	-0.11	Inflammatory bowel disease;Crohn's disease;	chr20:32360478	chr20:32355053~32355734:+
BRCA	cis	rs4388249	1	rs1866373	ENSG00000271849.1	CTC-332L22.1	-3.63	0.000293	0.0158	-0.18	-0.11	Schizophrenia;	chr5:109704541	chr5:109687802~109688329:-
BRCA	cis	rs687432	0.774	rs7120102	ENSG00000265566.2	RN7SL605P	-3.63	0.000293	0.0158	-0.16	-0.11	Parkinson's disease;	chr11:58100658	chr11:57528085~57528365:-
BRCA	cis	rs8054556	1	rs11150580	ENSG00000183604.13	SMG1P5	-3.63	0.000293	0.0158	-0.11	-0.11	Autism spectrum disorder or schizophrenia;	chr16:30003243	chr16:30267553~30335374:-
BRCA	cis	rs4415084	0.966	rs4463188	ENSG00000272335.1	RP11-53O19.3	3.63	0.000294	0.0158	0.1	0.11	Breast cancer;	chr5:44642568	chr5:44826076~44828592:+
BRCA	cis	rs8114671	0.562	rs1018447	ENSG00000279253.1	RP4-614O4.13	3.63	0.000294	0.0158	0.13	0.11	Height;	chr20:34813904	chr20:35262727~35264187:-
BRCA	cis	rs2976388	0.609	rs1594999	ENSG00000253196.1	RP11-706C16.7	3.63	0.000294	0.0158	0.11	0.11	Urinary tract infection frequency;	chr8:142709156	chr8:142763116~142766427:+
BRCA	cis	rs34656763	0.666	rs616030	ENSG00000236317.1	RP11-348H3.5	-3.63	0.000294	0.0158	-0.15	-0.11	Loneliness;Loneliness (multivariate analysis);Loneliness (linear analysis);	chr1:212522883	chr1:212855175~212855366:-
BRCA	cis	rs12971120	0.891	rs12605820	ENSG00000276934.1	RP11-231E4.5	3.63	0.000294	0.0158	0.16	0.11	Refractive error;	chr18:74500567	chr18:74504766~74505248:+
BRCA	cis	rs7267979	1	rs910997	ENSG00000274414.1	RP5-965G21.4	-3.63	0.000294	0.0158	-0.13	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25286665	chr20:25239007~25245229:-
BRCA	cis	rs2749592	0.55	rs10764135	ENSG00000263064.2	RP11-291L22.7	-3.63	0.000294	0.0158	-0.14	-0.11	Age-related hearing impairment (SNP x SNP interaction);	chr10:37577917	chr10:38448689~38448949:+
BRCA	cis	rs2803122	0.775	rs10118150	ENSG00000272842.1	RP11-513M16.7	-3.63	0.000294	0.0158	-0.11	-0.11	Pulse pressure;	chr9:19235482	chr9:19371386~19371945:-
BRCA	cis	rs2411233	0.967	rs11070167	ENSG00000259278.1	RP11-62C7.2	3.63	0.000294	0.0158	0.14	0.11	Platelet count;	chr15:38996400	chr15:39019233~39024918:+
BRCA	cis	rs890448	0.796	rs6532930	ENSG00000254531.1	FLJ20021	3.63	0.000294	0.0158	0.13	0.11	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101383758	chr4:101347780~101348883:+
BRCA	cis	rs10129255	0.518	rs2006284	ENSG00000211964.3	IGHV3-48	-3.63	0.000294	0.0158	-0.08	-0.11	Kawasaki disease;	chr14:106676185	chr14:106537810~106538344:-
BRCA	cis	rs4476553	1	rs4476553	ENSG00000247708.6	STX18-AS1	3.63	0.000294	0.0158	0.11	0.11	Response to amphetamines;	chr4:4702287	chr4:4542131~4710938:+
BRCA	cis	rs6736093	0.966	rs4848899	ENSG00000236307.2	EEF1E1P1	-3.63	0.000294	0.0158	-0.14	-0.11	Coronary artery disease;	chr2:111952534	chr2:111887914~111888741:+
BRCA	cis	rs2562456	0.754	rs55771551	ENSG00000240522.1	RPL7AP10	-3.63	0.000294	0.0158	-0.12	-0.11	Pain;	chr19:21563578	chr19:21149648~21150438:-
BRCA	cis	rs2692947	0.77	rs62153678	ENSG00000168992.4	OR7E102P	3.63	0.000294	0.0158	0.16	0.11	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95892598	chr2:95546531~95547545:+
BRCA	cis	rs2032314	0.527	rs2834311	ENSG00000237945.6	LINC00649	3.63	0.000294	0.0158	0.2	0.11	Red blood cell traits;	chr21:33973107	chr21:33915534~33977691:+
BRCA	cis	rs7572733	0.935	rs4410288	ENSG00000231621.1	AC013264.2	-3.63	0.000294	0.0158	-0.1	-0.11	Dermatomyositis;	chr2:197955100	chr2:197197991~197199273:+
BRCA	cis	rs6490294	0.528	rs7980579	ENSG00000257624.1	RP1-128M12.3	3.63	0.000294	0.0158	0.19	0.11	Mean platelet volume;	chr12:112009556	chr12:112000739~112000985:-
BRCA	cis	rs6490294	0.571	rs7952986	ENSG00000257624.1	RP1-128M12.3	3.63	0.000294	0.0158	0.19	0.11	Mean platelet volume;	chr12:112010358	chr12:112000739~112000985:-
BRCA	cis	rs6490294	0.571	rs7132863	ENSG00000257624.1	RP1-128M12.3	3.63	0.000294	0.0158	0.19	0.11	Mean platelet volume;	chr12:112011079	chr12:112000739~112000985:-
BRCA	cis	rs6490294	0.571	rs11066128	ENSG00000257624.1	RP1-128M12.3	3.63	0.000294	0.0158	0.19	0.11	Mean platelet volume;	chr12:112012950	chr12:112000739~112000985:-
BRCA	cis	rs28489187	0.577	rs6697083	ENSG00000223653.4	RP11-131L23.1	-3.63	0.000294	0.0158	-0.12	-0.11	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85422092	chr1:85276715~85448124:+
BRCA	cis	rs6121246	0.908	rs17093657	ENSG00000230613.1	HM13-AS1	3.63	0.000294	0.0158	0.16	0.11	Mean corpuscular hemoglobin;	chr20:31841091	chr20:31567707~31573263:-
BRCA	cis	rs448720	0.967	rs338358	ENSG00000260657.2	RP11-315D16.4	-3.63	0.000294	0.0158	-0.13	-0.11	Cognitive performance;	chr15:67902716	chr15:68267792~68277994:-
BRCA	cis	rs448720	1	rs338359	ENSG00000260657.2	RP11-315D16.4	-3.63	0.000294	0.0158	-0.13	-0.11	Cognitive performance;	chr15:67902731	chr15:68267792~68277994:-
BRCA	cis	rs853679	0.517	rs4713135	ENSG00000272009.1	RP1-313I6.12	-3.63	0.000294	0.0158	-0.16	-0.11	Depression;	chr6:28071808	chr6:28078792~28081130:-
BRCA	cis	rs875971	0.862	rs3893216	ENSG00000271064.1	RP11-792A8.3	3.63	0.000294	0.0158	0.13	0.11	Aortic root size;	chr7:66325720	chr7:66748838~66749077:-
BRCA	cis	rs875971	0.862	rs6958294	ENSG00000271064.1	RP11-792A8.3	3.63	0.000294	0.0158	0.13	0.11	Aortic root size;	chr7:66329809	chr7:66748838~66749077:-
BRCA	cis	rs875971	0.862	rs2088655	ENSG00000271064.1	RP11-792A8.3	3.63	0.000294	0.0158	0.13	0.11	Aortic root size;	chr7:66330724	chr7:66748838~66749077:-
BRCA	cis	rs875971	0.895	rs10447522	ENSG00000271064.1	RP11-792A8.3	3.63	0.000294	0.0158	0.13	0.11	Aortic root size;	chr7:66331087	chr7:66748838~66749077:-
BRCA	cis	rs34421088	0.586	rs2272594	ENSG00000154316.13	TDH	-3.63	0.000294	0.0158	-0.15	-0.11	Neuroticism;	chr8:11285116	chr8:11339637~11368452:+
BRCA	cis	rs962856	0.729	rs7559393	ENSG00000236780.4	AC078941.1	3.63	0.000294	0.0158	0.14	0.11	Pancreatic cancer;	chr2:67294608	chr2:67123357~67215319:-
BRCA	cis	rs5758659	0.714	rs5758589	ENSG00000205702.9	CYP2D7	-3.63	0.000294	0.0158	-0.09	-0.11	Cognitive function;	chr22:42122378	chr22:42140203~42144577:-
BRCA	cis	rs13434995	0.513	rs6846764	ENSG00000249700.7	SRD5A3-AS1	3.63	0.000294	0.0158	0.16	0.11	Adiponectin levels;	chr4:55557322	chr4:55363971~55395847:-
BRCA	cis	rs13434995	0.513	rs6853506	ENSG00000249700.7	SRD5A3-AS1	3.63	0.000294	0.0158	0.16	0.11	Adiponectin levels;	chr4:55558207	chr4:55363971~55395847:-
BRCA	cis	rs13434995	0.513	rs880358	ENSG00000239040.1	Y_RNA	3.63	0.000294	0.0158	0.13	0.11	Adiponectin levels;	chr4:55410311	chr4:55412636~55412738:+
BRCA	cis	rs7412746	0.524	rs58304714	ENSG00000224800.1	RP11-235D19.2	-3.63	0.000294	0.0158	-0.14	-0.11	Melanoma;	chr1:150859085	chr1:150881236~150881683:-
BRCA	cis	rs7914558	1	rs3740387	ENSG00000213277.3	MARCKSL1P1	3.63	0.000294	0.0158	0.13	0.11	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103089711	chr10:103175554~103176094:+
BRCA	cis	rs687432	0.924	rs2089747	ENSG00000265566.2	RN7SL605P	-3.63	0.000294	0.0158	-0.16	-0.11	Parkinson's disease;	chr11:57977570	chr11:57528085~57528365:-
BRCA	cis	rs59827721	0.769	rs17219646	ENSG00000272871.1	RP11-408A13.4	3.63	0.000294	0.0158	0.14	0.11	Inflammatory skin disease;	chr9:13841499	chr9:14588797~14590065:-
BRCA	cis	rs3735485	0.579	rs10269518	ENSG00000201772.1	SNORA5C	3.63	0.000294	0.0158	0.15	0.11	White blood cell count;Sum basophil neutrophil counts;Neutrophil count;Granulocyte percentage of myeloid white cells;Monocyte percentage of white cells;Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Lymphocyte counts;	chr7:45076670	chr7:45104906~45105042:-
BRCA	cis	rs17345786	0.628	rs11718446	ENSG00000256628.3	ZBTB11-AS1	3.63	0.000294	0.0158	0.15	0.11	Colonoscopy-negative controls vs population controls;	chr3:101833709	chr3:101676475~101679217:+
BRCA	cis	rs863345	0.604	rs6689657	ENSG00000229914.1	RP11-404O13.4	-3.63	0.000295	0.0158	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158492719	chr1:158195633~158196131:-
BRCA	cis	rs871012	0.502	rs2112691	ENSG00000251405.2	CTB-109A12.1	-3.63	0.000295	0.0158	-0.15	-0.11	IgG glycosylation;	chr5:157456328	chr5:157362615~157460078:-
BRCA	cis	rs7020830	0.898	rs308521	ENSG00000230188.1	RP11-405L18.4	-3.63	0.000295	0.0158	-0.13	-0.11	Schizophrenia;	chr9:37367097	chr9:37490421~37490893:-
BRCA	cis	rs2839186	0.967	rs4819222	ENSG00000215424.8	MCM3AP-AS1	3.63	0.000295	0.0158	0.1	0.11	Testicular germ cell tumor;	chr21:46287864	chr21:46229217~46259390:+
BRCA	cis	rs4415084	0.87	rs66996829	ENSG00000272335.1	RP11-53O19.3	3.63	0.000295	0.0158	0.11	0.11	Breast cancer;	chr5:44649295	chr5:44826076~44828592:+
BRCA	cis	rs7267979	0.966	rs8123949	ENSG00000274414.1	RP5-965G21.4	3.63	0.000295	0.0158	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25407497	chr20:25239007~25245229:-
BRCA	cis	rs7267979	1	rs2184000	ENSG00000274414.1	RP5-965G21.4	3.63	0.000295	0.0158	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25415242	chr20:25239007~25245229:-
BRCA	cis	rs9584850	0.834	rs745638	ENSG00000231194.1	FARP1-AS1	-3.63	0.000295	0.0158	-0.15	-0.11	Neuroticism;	chr13:98467053	chr13:98435405~98435840:-
BRCA	cis	rs17027633	1	rs10489792	ENSG00000234020.1	CHIAP3	-3.63	0.000295	0.0158	-0.27	-0.11	Cerebrospinal fluid t-tau:AB1-42 ratio;	chr1:111419056	chr1:111353275~111367409:-
BRCA	cis	rs8098244	0.894	rs9304392	ENSG00000265752.2	RP11-403A21.1	3.63	0.000295	0.0158	0.13	0.11	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23831440	chr18:23957754~23982556:-
BRCA	cis	rs11187837	0.901	rs79746649	ENSG00000273450.1	RP11-76P2.4	3.63	0.000295	0.0158	0.25	0.11	Sudden cardiac arrest;	chr10:94360461	chr10:94314907~94315327:-
BRCA	cis	rs3770752	0.836	rs1137437	ENSG00000272054.1	RP11-423P10.2	3.63	0.000295	0.0158	0.1	0.11	Schizophrenia;	chr2:37211850	chr2:37208875~37212677:+
BRCA	cis	rs875971	0.545	rs12670811	ENSG00000273448.1	RP11-166O4.6	3.63	0.000295	0.0158	0.12	0.11	Aortic root size;	chr7:66358032	chr7:67333047~67334383:+
BRCA	cis	rs1434579	0.526	rs204547	ENSG00000176761.7	ZNF285B	3.63	0.000295	0.0158	0.13	0.11	Tuberculosis;	chr19:44443000	chr19:44467641~44473227:+
BRCA	cis	rs787274	0.85	rs7862183	ENSG00000271631.1	RP11-408O19.5	3.63	0.000295	0.0158	0.19	0.11	Age-related hearing impairment (SNP x SNP interaction);	chr9:112767416	chr9:112885158~112885767:+
BRCA	cis	rs10005067	0.967	rs13140622	ENSG00000249001.4	RP11-742B18.1	-3.63	0.000295	0.0158	-0.13	-0.11	Total body bone mineral density (age 30-45);	chr4:87907623	chr4:87568035~87733956:-
BRCA	cis	rs10005067	0.967	rs34586520	ENSG00000249001.4	RP11-742B18.1	-3.63	0.000295	0.0158	-0.13	-0.11	Total body bone mineral density (age 30-45);	chr4:87908231	chr4:87568035~87733956:-
BRCA	cis	rs10895275	0.961	rs10895277	ENSG00000277459.1	RP11-732A21.3	-3.63	0.000295	0.0158	-0.12	-0.11	Migraine;	chr11:102214209	chr11:102109827~102110457:-
BRCA	cis	rs6997458	0.564	rs3808539	ENSG00000258256.1	RP11-219B4.5	-3.63	0.000295	0.0158	-0.13	-0.11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85327956	chr8:85222446~85245717:-
BRCA	cis	rs7308116	1	rs7134063	ENSG00000274395.1	RP11-554D14.8	-3.63	0.000295	0.0158	-0.12	-0.11	Pelvic organ prolapse (moderate/severe);	chr12:107805554	chr12:107835541~107836555:-
BRCA	cis	rs71520386	0.561	rs10274260	ENSG00000230658.1	KLHL7-AS1	3.63	0.000295	0.0158	0.16	0.11	Fibrinogen levels;	chr7:22805227	chr7:23101228~23105703:-
BRCA	cis	rs863345	0.604	rs12025831	ENSG00000229914.1	RP11-404O13.4	-3.63	0.000295	0.0159	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158526492	chr1:158195633~158196131:-
BRCA	cis	rs80226907	1	rs79554957	ENSG00000258413.1	RP11-665C16.6	-3.63	0.000295	0.0159	-0.29	-0.11	Mean platelet volume;	chr14:55384972	chr14:55262767~55272075:-
BRCA	cis	rs80226907	0.901	rs113716510	ENSG00000258413.1	RP11-665C16.6	-3.63	0.000295	0.0159	-0.29	-0.11	Mean platelet volume;	chr14:55387081	chr14:55262767~55272075:-
BRCA	cis	rs80226907	0.901	rs79816457	ENSG00000258413.1	RP11-665C16.6	-3.63	0.000295	0.0159	-0.29	-0.11	Mean platelet volume;	chr14:55387092	chr14:55262767~55272075:-
BRCA	cis	rs983392	1	rs11230161	ENSG00000275344.1	MIR6503	3.63	0.000295	0.0159	0.12	0.11	Alzheimer's disease (late onset);	chr11:60152758	chr11:60209071~60209156:-
BRCA	cis	rs10943724	0.959	rs13203786	ENSG00000272129.1	RP11-250B2.6	3.63	0.000295	0.0159	0.15	0.11	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr6:80515832	chr6:80355424~80356859:+
BRCA	cis	rs6011368	0.84	rs2427638	ENSG00000149656.7	LINC00266-1	3.63	0.000295	0.0159	0.12	0.11	Clozapine-induced cytotoxicity;	chr20:64269364	chr20:64290385~64313132:+
BRCA	cis	rs13434995	0.513	rs4336288	ENSG00000273257.1	RP11-177J6.1	3.63	0.000295	0.0159	0.17	0.11	Adiponectin levels;	chr4:55584088	chr4:55387949~55388271:+
BRCA	cis	rs4950322	0.518	rs56151278	ENSG00000237188.3	RP11-337C18.8	3.63	0.000295	0.0159	0.14	0.11	Protein quantitative trait loci;	chr1:147117421	chr1:147172771~147211568:+
BRCA	cis	rs7474896	1	rs72639538	ENSG00000120555.12	SEPT7P9	3.63	0.000295	0.0159	0.2	0.11	Obesity (extreme);	chr10:38071588	chr10:38383069~38402916:-
BRCA	cis	rs7474896	1	rs61858886	ENSG00000120555.12	SEPT7P9	3.63	0.000295	0.0159	0.2	0.11	Obesity (extreme);	chr10:38071773	chr10:38383069~38402916:-
BRCA	cis	rs17270561	0.609	rs4712964	ENSG00000272462.2	U91328.19	-3.63	0.000295	0.0159	-0.14	-0.11	Iron status biomarkers;	chr6:25740594	chr6:25992662~26001775:+
BRCA	cis	rs747650	0.504	rs7950753	ENSG00000200376.1	RNU5E-10P	3.63	0.000295	0.0159	0.15	0.11	Acne (severe);	chr11:47050346	chr11:47576471~47576588:-
BRCA	cis	rs8103278	0.864	rs2070737	ENSG00000268423.3	AC011551.3	3.63	0.000296	0.0159	0.14	0.11	Coronary artery disease;	chr19:45779632	chr19:46547056~46600861:-
BRCA	cis	rs442309	1	rs224057	ENSG00000238280.1	RP11-436D10.3	-3.63	0.000296	0.0159	-0.14	-0.11	Vogt-Koyanagi-Harada syndrome;	chr10:62738008	chr10:62793562~62805887:-
BRCA	cis	rs1730008	0.556	rs1656368	ENSG00000279311.1	RP11-170K4.2	3.63	0.000296	0.0159	0.13	0.11	Lobe attachment (rater-scored or self-reported);	chr3:158563232	chr3:158869898~158871821:+
BRCA	cis	rs72739697	0.892	rs72739673	ENSG00000238061.2	RP4-635A23.4	3.63	0.000296	0.0159	0.25	0.11	Itch intensity from mosquito bite adjusted by bite size;	chr1:185014041	chr1:185280844~185281816:+
BRCA	cis	rs72739697	0.892	rs55939185	ENSG00000238061.2	RP4-635A23.4	3.63	0.000296	0.0159	0.25	0.11	Itch intensity from mosquito bite adjusted by bite size;	chr1:185022981	chr1:185280844~185281816:+
BRCA	cis	rs13434995	0.562	rs73236140	ENSG00000239040.1	Y_RNA	3.63	0.000296	0.0159	0.14	0.11	Adiponectin levels;	chr4:55440049	chr4:55412636~55412738:+
BRCA	cis	rs875971	0.862	rs880166	ENSG00000273024.4	INTS4P2	3.63	0.000296	0.0159	0.12	0.11	Aortic root size;	chr7:66205775	chr7:65647864~65715661:+
BRCA	cis	rs2704588	1	rs2704602	ENSG00000270720.1	RP11-84C13.2	-3.63	0.000296	0.0159	-0.17	-0.11	Longevity;	chr4:88933880	chr4:89119284~89119871:+
BRCA	cis	rs7412746	0.611	rs7556661	ENSG00000231073.1	RP11-316M1.3	3.63	0.000296	0.0159	0.12	0.11	Melanoma;	chr1:150919533	chr1:150973123~150975534:+
BRCA	cis	rs3742264	0.656	rs9316177	ENSG00000235903.6	CPB2-AS1	-3.63	0.000296	0.0159	-0.13	-0.11	Blood protein levels;	chr13:45987676	chr13:46052806~46113332:+
BRCA	cis	rs9402743	0.597	rs9483879	ENSG00000231028.7	LINC00271	-3.63	0.000296	0.0159	-0.12	-0.11	Systemic lupus erythematosus;	chr6:135778024	chr6:135497801~135716055:+
BRCA	cis	rs9402743	0.632	rs9494383	ENSG00000231028.7	LINC00271	-3.63	0.000296	0.0159	-0.12	-0.11	Systemic lupus erythematosus;	chr6:135778026	chr6:135497801~135716055:+
BRCA	cis	rs8098244	0.58	rs1711452	ENSG00000265752.2	RP11-403A21.1	3.63	0.000296	0.0159	0.12	0.11	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23692607	chr18:23957754~23982556:-
BRCA	cis	rs425277	0.917	rs262656	ENSG00000269227.1	RP11-345P4.6	3.63	0.000296	0.0159	0.12	0.11	Height;	chr1:2157315	chr1:1673275~1674397:+
BRCA	cis	rs7071275	0.525	rs1696813	ENSG00000226864.1	ATE1-AS1	-3.63	0.000296	0.0159	-0.17	-0.11	Dupuytren's disease;	chr10:121617683	chr10:121928312~121951965:+
BRCA	cis	rs853679	0.517	rs2273564	ENSG00000226314.6	ZNF192P1	-3.63	0.000296	0.0159	-0.17	-0.11	Depression;	chr6:28089816	chr6:28161781~28169594:+
BRCA	cis	rs853679	0.517	rs1853097	ENSG00000226314.6	ZNF192P1	-3.63	0.000296	0.0159	-0.17	-0.11	Depression;	chr6:28090857	chr6:28161781~28169594:+
BRCA	cis	rs853679	0.517	rs9393888	ENSG00000226314.6	ZNF192P1	-3.63	0.000296	0.0159	-0.17	-0.11	Depression;	chr6:28091439	chr6:28161781~28169594:+
BRCA	cis	rs853679	0.517	rs3734573	ENSG00000226314.6	ZNF192P1	-3.63	0.000296	0.0159	-0.17	-0.11	Depression;	chr6:28091659	chr6:28161781~28169594:+
BRCA	cis	rs853679	0.517	rs3823180	ENSG00000226314.6	ZNF192P1	-3.63	0.000296	0.0159	-0.17	-0.11	Depression;	chr6:28093966	chr6:28161781~28169594:+
BRCA	cis	rs853679	0.517	rs9368551	ENSG00000226314.6	ZNF192P1	-3.63	0.000296	0.0159	-0.17	-0.11	Depression;	chr6:28094014	chr6:28161781~28169594:+
BRCA	cis	rs2839186	0.732	rs8131458	ENSG00000215424.8	MCM3AP-AS1	3.63	0.000296	0.0159	0.1	0.11	Testicular germ cell tumor;	chr21:46274798	chr21:46229217~46259390:+
BRCA	cis	rs4820539	1	rs4822357	ENSG00000211650.2	IGLV5-45	-3.63	0.000296	0.0159	-0.09	-0.11	Bone mineral density;	chr22:23131044	chr22:22375986~22376505:+
BRCA	cis	rs962856	0.514	rs694130	ENSG00000236780.4	AC078941.1	3.63	0.000296	0.0159	0.14	0.11	Pancreatic cancer;	chr2:67457469	chr2:67123357~67215319:-
BRCA	cis	rs957448	1	rs1055797	ENSG00000261437.1	RP11-22C11.2	3.63	0.000296	0.0159	0.12	0.11	Nonsyndromic cleft lip with cleft palate;	chr8:94511005	chr8:94637285~94639467:-
BRCA	cis	rs11673344	0.598	rs826326	ENSG00000276846.1	CTD-3220F14.3	3.63	0.000296	0.0159	0.13	0.11	Obesity-related traits;	chr19:37003863	chr19:37314868~37315620:-
BRCA	cis	rs2769264	0.602	rs11204777	ENSG00000261168.1	RP11-68I18.10	-3.63	0.000296	0.0159	-0.17	-0.11	Blood trace element (Cu levels);	chr1:151099573	chr1:151130075~151131610:-
BRCA	cis	rs9921338	0.886	rs3931015	ENSG00000263080.1	RP11-485G7.5	-3.63	0.000296	0.0159	-0.16	-0.11	Vein graft stenosis in coronary artery bypass grafting;	chr16:11321782	chr16:11341809~11345211:-
BRCA	cis	rs17684571	0.872	rs3002008	ENSG00000231441.1	RP11-472M19.2	3.63	0.000296	0.0159	0.17	0.11	Schizophrenia;	chr6:56757527	chr6:56844002~56864078:+
BRCA	cis	rs7267979	1	rs2856	ENSG00000276952.1	RP5-965G21.6	3.63	0.000296	0.0159	0.14	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25452900	chr20:25284915~25285588:-
BRCA	cis	rs17106184	0.591	rs72896969	ENSG00000236434.2	RP11-296A18.6	3.63	0.000296	0.0159	0.16	0.11	Type 2 diabetes;	chr1:50398349	chr1:51264916~51266074:-
BRCA	cis	rs5167	0.645	rs1130742	ENSG00000214855.8	APOC1P1	3.63	0.000296	0.0159	0.15	0.11	Blood protein levels;	chr19:44949555	chr19:44926804~44931386:+
BRCA	cis	rs35306767	0.855	rs12770190	ENSG00000229869.1	RP11-363N22.2	-3.63	0.000296	0.0159	-0.18	-0.11	Eosinophil percentage of granulocytes;	chr10:905322	chr10:933026~942743:+
BRCA	cis	rs67073037	1	rs67073037	ENSG00000230730.1	AC074011.2	-3.63	0.000296	0.0159	-0.15	-0.11	Breast cancer;Breast cancer (estrogen-receptor negative);	chr2:28896719	chr2:28633282~28664540:-
BRCA	cis	rs7176093	1	rs16944851	ENSG00000259295.5	CSPG4P12	-3.63	0.000296	0.0159	-0.15	-0.11	Aging traits;	chr15:85820210	chr15:85191438~85213905:+
BRCA	cis	rs72739697	0.892	rs6684708	ENSG00000238061.2	RP4-635A23.4	3.63	0.000296	0.0159	0.24	0.11	Itch intensity from mosquito bite adjusted by bite size;	chr1:185017332	chr1:185280844~185281816:+
BRCA	cis	rs1914816	0.702	rs157779	ENSG00000196274.5	Metazoa_SRP	3.63	0.000296	0.0159	0.16	0.11	Response to tocilizumab in rheumatoid arthritis;	chr15:76468965	chr15:76230048~76230390:-
BRCA	cis	rs74233809	0.892	rs11191447	ENSG00000236937.2	PTGES3P4	3.63	0.000296	0.0159	0.24	0.11	Birth weight;	chr10:102892566	chr10:102845595~102845950:+
BRCA	cis	rs74233809	1	rs74233296	ENSG00000236937.2	PTGES3P4	3.63	0.000296	0.0159	0.24	0.11	Birth weight;	chr10:102895593	chr10:102845595~102845950:+
BRCA	cis	rs7551222	0.749	rs4951409	ENSG00000240219.1	RP11-430C7.5	3.63	0.000296	0.0159	0.13	0.11	Schizophrenia;	chr1:204591862	chr1:204626775~204629712:+
BRCA	cis	rs10056811	0.538	rs3923323	ENSG00000271815.1	CTD-2235C13.3	3.63	0.000296	0.0159	0.19	0.11	Coronary artery disease;	chr5:75076316	chr5:75363760~75364242:+
BRCA	cis	rs2562456	0.876	rs11085467	ENSG00000268555.1	RP11-678G14.3	3.63	0.000296	0.0159	0.15	0.11	Pain;	chr19:21569041	chr19:21570822~21587322:-
BRCA	cis	rs9346455	1	rs9354986	ENSG00000279289.1	RP3-331H24.6	3.63	0.000296	0.0159	0.18	0.11	Antipsychotic drug-induced weight gain;Antipsychotic drug-induced weight gain (time interaction);	chr6:71286502	chr6:71386852~71390829:-
BRCA	cis	rs4415084	1	rs10462079	ENSG00000272335.1	RP11-53O19.3	3.63	0.000296	0.0159	0.11	0.11	Breast cancer;	chr5:44700008	chr5:44826076~44828592:+
BRCA	cis	rs4415084	1	rs13179137	ENSG00000272335.1	RP11-53O19.3	3.63	0.000296	0.0159	0.11	0.11	Breast cancer;	chr5:44702590	chr5:44826076~44828592:+
BRCA	cis	rs804280	0.662	rs11250164	ENSG00000205879.4	FAM90A2P	-3.63	0.000296	0.0159	-0.14	-0.11	Myopia (pathological);	chr8:11753177	chr8:12172202~12178575:-
BRCA	cis	rs115769866	0.618	rs7759252	ENSG00000220721.1	OR1F12	3.63	0.000296	0.0159	0.15	0.11	Bipolar disorder;	chr6:28501645	chr6:28073316~28074233:+
BRCA	cis	rs442309	1	rs224052	ENSG00000238280.1	RP11-436D10.3	-3.63	0.000296	0.0159	-0.14	-0.11	Vogt-Koyanagi-Harada syndrome;	chr10:62734414	chr10:62793562~62805887:-
BRCA	cis	rs2692947	0.77	rs4527246	ENSG00000232931.4	LINC00342	3.63	0.000296	0.0159	0.12	0.11	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95894555	chr2:95807118~95816215:-
BRCA	cis	rs7267979	1	rs3002702	ENSG00000274414.1	RP5-965G21.4	-3.63	0.000296	0.0159	-0.13	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25288284	chr20:25239007~25245229:-
BRCA	cis	rs10844706	0.699	rs7296241	ENSG00000278635.1	CTD-2318O12.1	-3.63	0.000296	0.0159	-0.12	-0.11	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9725044	chr12:9415641~9416718:+
BRCA	cis	rs683250	0.629	rs612008	ENSG00000254551.1	RP11-727A23.7	3.63	0.000296	0.0159	0.14	0.11	Subcortical brain region volumes;	chr11:83232441	chr11:83209431~83213379:-
BRCA	cis	rs683250	0.629	rs613790	ENSG00000254551.1	RP11-727A23.7	3.63	0.000296	0.0159	0.14	0.11	Subcortical brain region volumes;	chr11:83232853	chr11:83209431~83213379:-
BRCA	cis	rs2274273	0.712	rs7144652	ENSG00000259318.1	RP11-454L9.2	3.63	0.000296	0.0159	0.1	0.11	Protein biomarker;	chr14:55071000	chr14:55394940~55395233:-
BRCA	cis	rs7267005	0.661	rs2425099	ENSG00000252549.1	RNU6-759P	-3.63	0.000296	0.0159	-0.29	-0.11	Response to paliperidone in schizophrenia (Multivariate);	chr20:35721721	chr20:35647328~35647430:-
BRCA	cis	rs7824557	0.815	rs2736372	ENSG00000154316.13	TDH	3.63	0.000296	0.0159	0.14	0.11	Retinal vascular caliber;	chr8:11248532	chr8:11339637~11368452:+
BRCA	cis	rs7520050	0.966	rs1707336	ENSG00000234329.1	RP11-767N6.2	-3.63	0.000296	0.0159	-0.11	-0.11	Reticulocyte count;Red blood cell count;	chr1:46027788	chr1:45651039~45651826:-
BRCA	cis	rs34421088	0.548	rs2618443	ENSG00000255020.1	AF131216.5	3.63	0.000296	0.0159	0.13	0.11	Neuroticism;	chr8:11527047	chr8:11345748~11347502:-
BRCA	cis	rs9309473	0.687	rs12465867	ENSG00000230002.2	ALMS1-IT1	3.63	0.000296	0.0159	0.13	0.11	Metabolite levels;	chr2:73384974	chr2:73456764~73459484:+
BRCA	cis	rs9309473	0.583	rs35885918	ENSG00000230002.2	ALMS1-IT1	3.63	0.000296	0.0159	0.13	0.11	Metabolite levels;	chr2:73385106	chr2:73456764~73459484:+
BRCA	cis	rs9635324	0.964	rs12902310	ENSG00000223313.1	RNU6-516P	3.63	0.000297	0.0159	0.14	0.11	Blood metabolite ratios;Blood metabolite levels;	chr15:40423228	chr15:40529570~40529673:+
BRCA	cis	rs12530845	0.887	rs59400686	ENSG00000223718.3	AC093107.7	3.63	0.000297	0.0159	0.19	0.11	Red blood cell traits;	chr7:135675281	chr7:135660039~135660647:+
BRCA	cis	rs853679	0.546	rs200981	ENSG00000216901.1	AL022393.7	3.63	0.000297	0.0159	0.22	0.11	Depression;	chr6:27865396	chr6:28176188~28176674:+
BRCA	cis	rs4767841	0.552	rs4767833	ENSG00000248636.5	RP11-768F21.1	-3.63	0.000297	0.0159	-0.14	-0.11	Urgency urinary incontinence;	chr12:119613165	chr12:119387987~119668079:-
BRCA	cis	rs16940212	0.618	rs8032310	ENSG00000259771.1	RP11-429D19.1	-3.63	0.000297	0.0159	-0.18	-0.11	HDL cholesterol;HDL cholesterol levels;	chr15:58395663	chr15:59266720~59271162:-
BRCA	cis	rs687432	0.812	rs7935428	ENSG00000265566.2	RN7SL605P	-3.63	0.000297	0.0159	-0.16	-0.11	Parkinson's disease;	chr11:58108964	chr11:57528085~57528365:-
BRCA	cis	rs12468226	0.873	rs59293950	ENSG00000272966.1	RP11-686O6.1	3.63	0.000297	0.0159	0.2	0.11	Urate levels;	chr2:202214069	chr2:202336739~202337200:+
BRCA	cis	rs9545047	0.716	rs9565500	ENSG00000227354.5	RBM26-AS1	-3.63	0.000297	0.0159	-0.13	-0.11	Schizophrenia;	chr13:79433416	chr13:79406309~79424328:+
BRCA	cis	rs4415084	0.834	rs13362132	ENSG00000248779.1	RP11-53O19.2	3.63	0.000297	0.0159	0.1	0.11	Breast cancer;	chr5:44858158	chr5:44752949~44765744:+
BRCA	cis	rs2298450	0.541	rs2835332	ENSG00000231106.2	LINC01436	3.63	0.000297	0.0159	0.12	0.11	Schizophrenia;	chr21:36284642	chr21:36005338~36007838:+
BRCA	cis	rs11098499	0.955	rs13113112	ENSG00000225892.3	RP11-384K6.2	3.63	0.000297	0.0159	0.12	0.11	Corneal astigmatism;	chr4:119234885	chr4:118632274~118634759:+
BRCA	cis	rs2018683	1	rs160837	ENSG00000233517.1	AC005162.5	-3.63	0.000297	0.0159	-0.14	-0.11	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28973116	chr7:28987028~28988899:+
BRCA	cis	rs6490294	0.571	rs12423960	ENSG00000257624.1	RP1-128M12.3	3.63	0.000297	0.0159	0.18	0.11	Mean platelet volume;	chr12:112004612	chr12:112000739~112000985:-
BRCA	cis	rs6490294	0.571	rs10849992	ENSG00000257624.1	RP1-128M12.3	3.63	0.000297	0.0159	0.18	0.11	Mean platelet volume;	chr12:112005213	chr12:112000739~112000985:-
BRCA	cis	rs6490294	0.571	rs7310545	ENSG00000257624.1	RP1-128M12.3	3.63	0.000297	0.0159	0.18	0.11	Mean platelet volume;	chr12:112006156	chr12:112000739~112000985:-
BRCA	cis	rs6490294	0.571	rs7296841	ENSG00000257624.1	RP1-128M12.3	3.63	0.000297	0.0159	0.18	0.11	Mean platelet volume;	chr12:112006305	chr12:112000739~112000985:-
BRCA	cis	rs11098499	0.908	rs9995234	ENSG00000225892.3	RP11-384K6.2	3.63	0.000297	0.0159	0.12	0.11	Corneal astigmatism;	chr4:119400672	chr4:118632274~118634759:+
BRCA	cis	rs73201462	1	rs2955077	ENSG00000242551.2	POU5F1P6	-3.63	0.000297	0.0159	-0.19	-0.11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128240026	chr3:128674735~128677005:-
BRCA	cis	rs73201462	1	rs2955078	ENSG00000242551.2	POU5F1P6	-3.63	0.000297	0.0159	-0.19	-0.11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128240343	chr3:128674735~128677005:-
BRCA	cis	rs7620503	1	rs2133595	ENSG00000231574.4	RP11-91K9.1	3.63	0.000297	0.0159	0.12	0.11	Corneal structure;	chr3:177585822	chr3:177816865~177899224:+
BRCA	cis	rs29784	0.503	rs416043	ENSG00000253959.1	CTB-43E15.1	3.63	0.000297	0.0159	0.1	0.11	Infantile hypertrophic pyloric stenosis;	chr5:173101696	chr5:173642519~173658194:+
BRCA	cis	rs13401620	0.81	rs12477760	ENSG00000223549.1	MTND5P28	-3.63	0.000297	0.0159	-0.14	-0.11	Breast size;	chr2:119800891	chr2:120215181~120217279:+
BRCA	cis	rs7267979	0.932	rs367666	ENSG00000277938.1	RP5-965G21.3	3.63	0.000297	0.0159	0.14	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25469182	chr20:25229150~25231933:+
BRCA	cis	rs13256369	1	rs13271966	ENSG00000254153.1	CTA-398F10.2	3.63	0.000297	0.0159	0.15	0.11	Obesity-related traits;	chr8:8717962	chr8:8456909~8461337:-
BRCA	cis	rs251253	0.796	rs412682	ENSG00000253959.1	CTB-43E15.1	3.63	0.000297	0.0159	0.1	0.11	PR interval;	chr5:173101548	chr5:173642519~173658194:+
BRCA	cis	rs4415084	1	rs7735881	ENSG00000272335.1	RP11-53O19.3	3.63	0.000297	0.0159	0.1	0.11	Breast cancer;	chr5:44650074	chr5:44826076~44828592:+
BRCA	cis	rs8040855	0.627	rs3816105	ENSG00000229212.6	RP11-561C5.4	-3.63	0.000297	0.0159	-0.15	-0.11	Bulimia nervosa;	chr15:85097680	chr15:85205440~85234795:-
BRCA	cis	rs8040855	0.627	rs2304418	ENSG00000229212.6	RP11-561C5.4	-3.63	0.000297	0.0159	-0.15	-0.11	Bulimia nervosa;	chr15:85097752	chr15:85205440~85234795:-
BRCA	cis	rs739401	0.572	rs7111857	ENSG00000183562.3	CTC-343N3.1	3.63	0.000297	0.0159	0.12	0.11	Longevity;	chr11:3046876	chr11:2989863~2991344:+
BRCA	cis	rs9650657	0.771	rs12542888	ENSG00000255046.1	RP11-297N6.4	3.63	0.000297	0.0159	0.13	0.11	Neuroticism;	chr8:10805045	chr8:11797928~11802568:-
BRCA	cis	rs9287719	0.967	rs6432114	ENSG00000224177.5	LINC00570	3.63	0.000297	0.0159	0.13	0.11	Prostate cancer;	chr2:10604804	chr2:11393981~11403077:+
BRCA	cis	rs2243480	1	rs73142162	ENSG00000226767.1	RP11-328P23.3	-3.63	0.000297	0.0159	-0.19	-0.11	Diabetic kidney disease;	chr7:65909309	chr7:65508773~65508944:-
BRCA	cis	rs27432	0.608	rs2927619	ENSG00000272109.1	CTD-2260A17.3	-3.63	0.000297	0.0159	-0.15	-0.11	Psoriasis vulgaris;	chr5:96847014	chr5:96804353~96806105:+
BRCA	cis	rs2749592	0.531	rs1208559	ENSG00000226578.1	RP11-258F22.1	3.63	0.000297	0.0159	0.13	0.11	Age-related hearing impairment (SNP x SNP interaction);	chr10:37932442	chr10:37775371~37784131:-
BRCA	cis	rs6964587	1	rs13245393	ENSG00000188693.7	CYP51A1-AS1	-3.63	0.000297	0.0159	-0.12	-0.11	Breast cancer;	chr7:92012614	chr7:92134604~92180725:+
BRCA	cis	rs6964587	1	rs6944591	ENSG00000188693.7	CYP51A1-AS1	-3.63	0.000297	0.0159	-0.12	-0.11	Breast cancer;	chr7:92013400	chr7:92134604~92180725:+
BRCA	cis	rs4648045	0.796	rs3817685	ENSG00000251288.2	RP11-10L12.2	-3.63	0.000297	0.0159	-0.14	-0.11	Lymphocyte percentage of white cells;	chr4:102613403	chr4:102751401~102752641:+
BRCA	cis	rs17301013	0.869	rs3133270	ENSG00000234741.6	GAS5	-3.63	0.000297	0.0159	-0.11	-0.11	Systemic lupus erythematosus;	chr1:174819547	chr1:173863900~173868882:-
BRCA	cis	rs16852403	0.619	rs10913513	ENSG00000224687.1	RASAL2-AS1	3.63	0.000297	0.0159	0.14	0.11	Childhood ear infection;	chr1:178166806	chr1:178091508~178093984:-
BRCA	cis	rs9287719	0.967	rs12622765	ENSG00000224177.5	LINC00570	3.63	0.000297	0.0159	0.13	0.11	Prostate cancer;	chr2:10588205	chr2:11393981~11403077:+
BRCA	cis	rs9287719	0.967	rs759402	ENSG00000224177.5	LINC00570	3.63	0.000297	0.0159	0.13	0.11	Prostate cancer;	chr2:10589428	chr2:11393981~11403077:+
BRCA	cis	rs9287719	0.967	rs759403	ENSG00000224177.5	LINC00570	3.63	0.000297	0.0159	0.13	0.11	Prostate cancer;	chr2:10589771	chr2:11393981~11403077:+
BRCA	cis	rs9287719	0.967	rs11674433	ENSG00000224177.5	LINC00570	3.63	0.000297	0.0159	0.13	0.11	Prostate cancer;	chr2:10590713	chr2:11393981~11403077:+
BRCA	cis	rs9287719	0.967	rs2024431	ENSG00000224177.5	LINC00570	3.63	0.000297	0.0159	0.13	0.11	Prostate cancer;	chr2:10591201	chr2:11393981~11403077:+
BRCA	cis	rs9866825	0.967	rs7631774	ENSG00000227110.5	LMCD1-AS1	3.63	0.000297	0.0159	0.13	0.11	QT interval;	chr3:8205200	chr3:7952805~8611924:-
BRCA	cis	rs9866825	0.905	rs7618198	ENSG00000227110.5	LMCD1-AS1	3.63	0.000297	0.0159	0.13	0.11	QT interval;	chr3:8205335	chr3:7952805~8611924:-
BRCA	cis	rs3760982	0.585	rs8109812	ENSG00000267191.1	RP11-15A1.2	-3.63	0.000297	0.0159	-0.15	-0.11	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43794342	chr19:43902001~43926545:+
BRCA	cis	rs4449834	1	rs4307377	ENSG00000254432.1	RP11-33I11.2	-3.63	0.000297	0.0159	-0.14	-0.11	Sum eosinophil basophil counts;	chr8:60843407	chr8:60808735~60809606:-
BRCA	cis	rs7894407	0.76	rs1163072	ENSG00000213061.2	PFN1P11	-3.63	0.000297	0.0159	-0.15	-0.11	White matter hyperintensity burden;	chr10:103264621	chr10:102838011~102845473:-
BRCA	cis	rs863345	0.625	rs10908663	ENSG00000229914.1	RP11-404O13.4	-3.63	0.000297	0.0159	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158522331	chr1:158195633~158196131:-
BRCA	cis	rs6088590	0.735	rs2273684	ENSG00000206582.1	Y_RNA	3.63	0.000297	0.0159	0.12	0.11	Coronary artery disease;	chr20:34941963	chr20:34526510~34526606:-
BRCA	cis	rs10986311	0.775	rs11791153	ENSG00000227200.1	RP11-121A14.3	-3.63	0.000297	0.0159	-0.14	-0.11	Vitiligo;	chr9:124404178	chr9:124262876~124265809:+
BRCA	cis	rs6600671	1	rs1832558	ENSG00000270231.3	NBPF8P	3.63	0.000297	0.0159	0.12	0.11	Hip geometry;	chr1:121435521	chr1:120436353~120467739:+
BRCA	cis	rs10035650	0.562	rs7725095	ENSG00000243806.1	RPL7P18	-3.63	0.000297	0.0159	-0.14	-0.11	Cancer;	chr5:94735699	chr5:94825961~94826694:-
BRCA	cis	rs4869266	0.503	rs4869282	ENSG00000250551.1	RP11-254I22.1	-3.63	0.000297	0.0159	-0.13	-0.11	IgG glycosylation;	chr5:96334461	chr5:96050115~96215519:+
BRCA	cis	rs34421088	0.506	rs2572428	ENSG00000154316.13	TDH	-3.63	0.000297	0.0159	-0.15	-0.11	Neuroticism;	chr8:11289163	chr8:11339637~11368452:+
BRCA	cis	rs853679	1	rs2799079	ENSG00000226314.6	ZNF192P1	-3.63	0.000297	0.0159	-0.19	-0.11	Depression;	chr6:28267398	chr6:28161781~28169594:+
BRCA	cis	rs4835473	0.9	rs1375982	ENSG00000246448.2	RP13-578N3.3	-3.63	0.000297	0.0159	-0.13	-0.11	Immature fraction of reticulocytes;	chr4:143745764	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.9	rs4835237	ENSG00000246448.2	RP13-578N3.3	-3.63	0.000297	0.0159	-0.13	-0.11	Immature fraction of reticulocytes;	chr4:143746349	chr4:143700257~143865072:+
BRCA	cis	rs10843647	0.51	rs10843606	ENSG00000245614.3	DDX11-AS1	3.63	0.000297	0.0159	0.12	0.11	Glucose homeostasis traits;	chr12:30106517	chr12:31020763~31073847:-
BRCA	cis	rs754466	0.58	rs1058198	ENSG00000213514.2	RP11-428P16.2	3.63	0.000297	0.0159	0.15	0.11	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77806874	chr10:77730766~77734769:+
BRCA	cis	rs4243971	0.516	rs6141282	ENSG00000275576.1	RP5-836N17.4	-3.63	0.000297	0.0159	-0.13	-0.11	Inflammatory bowel disease;Crohn's disease;	chr20:32289514	chr20:32116171~32116629:+
BRCA	cis	rs4919687	0.55	rs11191371	ENSG00000236937.2	PTGES3P4	3.63	0.000297	0.0159	0.15	0.11	Colorectal cancer;	chr10:102700140	chr10:102845595~102845950:+
BRCA	cis	rs488400	0.676	rs165581	ENSG00000278978.1	RP11-164P12.5	-3.63	0.000298	0.016	-0.14	-0.11	Trans fatty acid levels;	chr4:151868634	chr4:151669786~151670503:+
BRCA	cis	rs12744310	0.502	rs2154317	ENSG00000235358.1	RP11-399E6.1	3.63	0.000298	0.016	0.14	0.11	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41320120	chr1:41242373~41284861:+
BRCA	cis	rs8114671	0.562	rs6088653	ENSG00000279253.1	RP4-614O4.13	-3.63	0.000298	0.016	-0.13	-0.11	Height;	chr20:34932518	chr20:35262727~35264187:-
BRCA	cis	rs11088226	0.645	rs2833904	ENSG00000186842.4	LINC00846	-3.63	0.000298	0.016	-0.18	-0.11	Gastritis;	chr21:32568779	chr21:32572238~32575881:-
BRCA	cis	rs3760047	0.609	rs2541639	ENSG00000268836.1	LA16c-OS12.2	3.63	0.000298	0.016	0.13	0.11	Mean corpuscular hemoglobin concentration;	chr16:155036	chr16:185748~186294:-
BRCA	cis	rs890448	0.76	rs7677595	ENSG00000254531.1	FLJ20021	3.63	0.000298	0.016	0.13	0.11	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101382570	chr4:101347780~101348883:+
BRCA	cis	rs7824557	0.592	rs2572371	ENSG00000255020.1	AF131216.5	-3.63	0.000298	0.016	-0.13	-0.11	Retinal vascular caliber;	chr8:11366284	chr8:11345748~11347502:-
BRCA	cis	rs9863	0.896	rs34854841	ENSG00000270028.1	RP11-380L11.4	3.63	0.000298	0.016	0.14	0.11	White blood cell count;	chr12:123966957	chr12:123925461~123926083:-
BRCA	cis	rs812925	0.537	rs2593620	ENSG00000273302.1	RP11-493E12.2	-3.63	0.000298	0.016	-0.1	-0.11	Immature fraction of reticulocytes;	chr2:61386126	chr2:61199979~61200769:+
BRCA	cis	rs12999542	1	rs11465567	ENSG00000234389.1	AC007278.3	3.63	0.000298	0.016	0.16	0.11	Serum protein levels (sST2);	chr2:102361940	chr2:102438713~102440475:+
BRCA	cis	rs12999542	1	rs11465572	ENSG00000234389.1	AC007278.3	3.63	0.000298	0.016	0.16	0.11	Serum protein levels (sST2);	chr2:102363763	chr2:102438713~102440475:+
BRCA	cis	rs4853525	0.62	rs1914408	ENSG00000235852.1	AC005540.3	-3.63	0.000298	0.016	-0.14	-0.11	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190975250	chr2:190880797~190882059:-
BRCA	cis	rs4272720	0.951	rs17011692	ENSG00000228754.1	RP11-534L6.3	-3.63	0.000298	0.016	-0.15	-0.11	Platelet count;Plateletcrit;	chr10:49047523	chr10:48745545~48746128:-
BRCA	cis	rs1032833	0.732	rs17454192	ENSG00000271401.1	RP11-171I2.3	-3.63	0.000298	0.016	-0.29	-0.11	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);	chr2:179136089	chr2:178644717~178645179:+
BRCA	cis	rs1032833	0.732	rs4499457	ENSG00000271401.1	RP11-171I2.3	-3.63	0.000298	0.016	-0.29	-0.11	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);	chr2:179138349	chr2:178644717~178645179:+
BRCA	cis	rs1032833	0.732	rs879539	ENSG00000271401.1	RP11-171I2.3	-3.63	0.000298	0.016	-0.29	-0.11	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);	chr2:179138604	chr2:178644717~178645179:+
BRCA	cis	rs6593122	0.628	rs10231339	ENSG00000235454.1	HAUS6P3	-3.63	0.000298	0.016	-0.15	-0.11	Vaccine-related adverse events;	chr7:54118124	chr7:53862233~53863339:+
BRCA	cis	rs11673344	0.832	rs76470527	ENSG00000267682.1	CTD-3220F14.2	-3.63	0.000298	0.016	-0.11	-0.11	Obesity-related traits;	chr19:37035981	chr19:37337236~37337743:+
BRCA	cis	rs8114671	0.562	rs3818273	ENSG00000279253.1	RP4-614O4.13	-3.63	0.000298	0.016	-0.13	-0.11	Height;	chr20:34921472	chr20:35262727~35264187:-
BRCA	cis	rs74233809	1	rs11191607	ENSG00000236937.2	PTGES3P4	3.63	0.000298	0.016	0.24	0.11	Birth weight;	chr10:103199431	chr10:102845595~102845950:+
BRCA	cis	rs3735485	0.8	rs2079321	ENSG00000201772.1	SNORA5C	-3.63	0.000298	0.016	-0.15	-0.11	White blood cell count;Sum basophil neutrophil counts;Neutrophil count;Granulocyte percentage of myeloid white cells;Monocyte percentage of white cells;Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Lymphocyte counts;	chr7:45004714	chr7:45104906~45105042:-
BRCA	cis	rs875971	0.862	rs1860469	ENSG00000271064.1	RP11-792A8.3	3.63	0.000298	0.016	0.13	0.11	Aortic root size;	chr7:66641888	chr7:66748838~66749077:-
BRCA	cis	rs9650657	0.547	rs11250099	ENSG00000248896.2	CTD-2135J3.3	3.63	0.000298	0.016	0.14	0.11	Neuroticism;	chr8:10961147	chr8:10729314~10771392:+
BRCA	cis	rs13315871	0.929	rs13322000	ENSG00000272182.1	RP11-802O23.3	3.63	0.000298	0.016	0.23	0.11	Cholesterol, total;	chr3:58301202	chr3:58428255~58428815:+
BRCA	cis	rs13315871	0.929	rs13322156	ENSG00000272182.1	RP11-802O23.3	3.63	0.000298	0.016	0.23	0.11	Cholesterol, total;	chr3:58301893	chr3:58428255~58428815:+
BRCA	cis	rs7615952	0.512	rs2979336	ENSG00000241288.6	RP11-379B18.5	-3.63	0.000298	0.016	-0.14	-0.11	Blood pressure (smoking interaction);	chr3:125638626	chr3:125827238~125916384:-
BRCA	cis	rs61931739	0.5	rs11513287	ENSG00000258794.3	DUX4L27	3.63	0.000298	0.016	0.16	0.11	Morning vs. evening chronotype;	chr12:34431416	chr12:34208415~34209675:-
BRCA	cis	rs962856	0.729	rs11695960	ENSG00000236780.4	AC078941.1	3.63	0.000298	0.016	0.14	0.11	Pancreatic cancer;	chr2:67294235	chr2:67123357~67215319:-
BRCA	cis	rs2243480	1	rs4548056	ENSG00000234585.5	CCT6P3	-3.63	0.000298	0.016	-0.17	-0.11	Diabetic kidney disease;	chr7:65833886	chr7:65038354~65074713:+
BRCA	cis	rs9470794	1	rs57995712	ENSG00000204110.6	RP1-153P14.8	-3.63	0.000298	0.016	-0.21	-0.11	Type 2 diabetes;	chr6:38020856	chr6:37507348~37535616:+
BRCA	cis	rs7412746	0.658	rs4970986	ENSG00000231073.1	RP11-316M1.3	3.63	0.000298	0.016	0.12	0.11	Melanoma;	chr1:150935479	chr1:150973123~150975534:+
BRCA	cis	rs7412746	0.658	rs59024312	ENSG00000231073.1	RP11-316M1.3	3.63	0.000298	0.016	0.12	0.11	Melanoma;	chr1:150936529	chr1:150973123~150975534:+
BRCA	cis	rs7412746	0.658	rs7528773	ENSG00000231073.1	RP11-316M1.3	3.63	0.000298	0.016	0.12	0.11	Melanoma;	chr1:150943399	chr1:150973123~150975534:+
BRCA	cis	rs6490294	0.571	rs12312538	ENSG00000234608.6	MAPKAPK5-AS1	3.63	0.000298	0.016	0.17	0.11	Mean platelet volume;	chr12:112051717	chr12:111839764~111842902:-
BRCA	cis	rs8098244	0.964	rs17203003	ENSG00000265752.2	RP11-403A21.1	-3.63	0.000298	0.016	-0.14	-0.11	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23913926	chr18:23957754~23982556:-
BRCA	cis	rs8180040	0.966	rs7649234	ENSG00000271161.1	BOLA2P2	3.63	0.000298	0.016	0.12	0.11	Colorectal cancer;	chr3:47452890	chr3:47499841~47500407:+
BRCA	cis	rs3755021	1	rs2305588	ENSG00000260742.1	RP11-366L5.1	3.63	0.000298	0.016	0.16	0.11	Monocyte-lymphocyte ratio;	chr2:181482345	chr2:181887851~181891663:-
BRCA	cis	rs794185	0.501	rs304043	ENSG00000231249.1	ITPR1-AS1	3.63	0.000298	0.016	0.13	0.11	Multiple sclerosis--Brain Glutamate Levels;	chr3:4512097	chr3:4490891~4493163:-
BRCA	cis	rs10504130	0.518	rs6473654	ENSG00000253844.1	RP11-546K22.1	3.63	0.000298	0.016	0.15	0.11	Venous thromboembolism (SNP x SNP interaction);	chr8:51758954	chr8:51961458~52022974:+
BRCA	cis	rs561341	1	rs15654	ENSG00000265798.5	RP11-271K11.5	3.63	0.000298	0.016	0.19	0.11	Hip circumference adjusted for BMI;	chr17:31999341	chr17:31038575~31059121:-
BRCA	cis	rs561341	1	rs550923	ENSG00000265798.5	RP11-271K11.5	3.63	0.000298	0.016	0.19	0.11	Hip circumference adjusted for BMI;	chr17:31999994	chr17:31038575~31059121:-
BRCA	cis	rs17756712	0.528	rs2073008	ENSG00000272463.1	RP11-532F6.3	3.63	0.000298	0.016	0.16	0.11	Vertical cup-disc ratio;	chr6:638345	chr6:708592~711405:-
BRCA	cis	rs7089973	0.836	rs1966384	ENSG00000236799.1	RP11-383C6.2	-3.63	0.000298	0.016	-0.14	-0.11	Bipolar disorder or attention deficit hyperactivity disorder;	chr10:114868151	chr10:114994657~114996593:+
BRCA	cis	rs931127	0.719	rs11227259	ENSG00000245532.5	NEAT1	-3.63	0.000298	0.016	-0.1	-0.11	Systemic lupus erythematosus;	chr11:65691933	chr11:65422774~65445540:+
BRCA	cis	rs6743226	0.603	rs12619677	ENSG00000266621.1	AC104841.1	3.63	0.000298	0.016	0.13	0.11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in non-smokers;	chr2:241273780	chr2:241245202~241245299:-
BRCA	cis	rs11673344	0.864	rs79407399	ENSG00000267260.1	CTD-2162K18.4	-3.63	0.000298	0.016	-0.17	-0.11	Obesity-related traits;	chr19:37000004	chr19:36773153~36777078:+
BRCA	cis	rs2041840	1	rs2714470	ENSG00000272054.1	RP11-423P10.2	-3.63	0.000298	0.016	-0.1	-0.11	Chronic lymphocytic leukemia;	chr2:37259384	chr2:37208875~37212677:+
BRCA	cis	rs7312933	0.51	rs1907705	ENSG00000257376.1	RP11-328C8.2	-3.63	0.000299	0.016	-0.13	-0.11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42057320	chr12:42431665~42433357:-
BRCA	cis	rs1008375	1	rs2058338	ENSG00000249502.1	AC006160.5	3.63	0.000299	0.016	0.13	0.11	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17676977	chr4:17587467~17614571:-
BRCA	cis	rs698833	0.828	rs1067341	ENSG00000259439.2	RP11-89K21.1	3.63	0.000299	0.016	0.14	0.11	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr2:44396548	chr2:44921077~44939199:-
BRCA	cis	rs4243971	0.516	rs3818190	ENSG00000277692.1	RP11-358N2.2	-3.63	0.000299	0.016	-0.13	-0.11	Inflammatory bowel disease;Crohn's disease;	chr20:32428511	chr20:32355053~32355734:+
BRCA	cis	rs3764021	0.509	rs10772070	ENSG00000260423.1	RP13-735L24.1	-3.63	0.000299	0.016	-0.13	-0.11	Type 1 diabetes;	chr12:9717320	chr12:9367464~9397617:+
BRCA	cis	rs2562456	0.724	rs58001930	ENSG00000240522.1	RPL7AP10	-3.63	0.000299	0.016	-0.12	-0.11	Pain;	chr19:21560061	chr19:21149648~21150438:-
BRCA	cis	rs6772849	0.93	rs4857912	ENSG00000207088.1	SNORA7B	-3.63	0.000299	0.016	-0.14	-0.11	Monocyte percentage of white cells;Monocyte count;	chr3:128610381	chr3:129397210~129397348:-
BRCA	cis	rs1008375	0.931	rs6449309	ENSG00000249502.1	AC006160.5	-3.63	0.000299	0.016	-0.13	-0.11	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17571585	chr4:17587467~17614571:-
BRCA	cis	rs875971	0.929	rs34406470	ENSG00000273024.4	INTS4P2	-3.63	0.000299	0.016	-0.12	-0.11	Aortic root size;	chr7:66464969	chr7:65647864~65715661:+
BRCA	cis	rs672059	0.967	rs657901	ENSG00000224468.3	RP11-181K3.4	-3.63	0.000299	0.016	-0.12	-0.11	Hypertriglyceridemia;	chr1:183194276	chr1:183138402~183141282:-
BRCA	cis	rs7089973	0.872	rs17092497	ENSG00000236799.1	RP11-383C6.2	-3.63	0.000299	0.016	-0.14	-0.11	Bipolar disorder or attention deficit hyperactivity disorder;	chr10:114852869	chr10:114994657~114996593:+
BRCA	cis	rs2022309	0.962	rs12029080	ENSG00000260464.1	RP4-561L24.3	3.63	0.000299	0.016	0.13	0.11	End-stage coagulation;	chr1:94587797	chr1:93847174~93848939:+
BRCA	cis	rs757081	0.648	rs7108315	ENSG00000272034.1	SNORD14A	-3.63	0.000299	0.016	-0.12	-0.11	Systolic blood pressure;	chr11:17245617	chr11:17074654~17074744:-
BRCA	cis	rs7176093	0.874	rs9635398	ENSG00000202081.1	RNU6-1280P	-3.63	0.000299	0.016	-0.13	-0.11	Aging traits;	chr15:85802824	chr15:85651522~85651628:-
BRCA	cis	rs11892454	0.599	rs10171348	ENSG00000217643.1	PTGES3P2	-3.63	0.000299	0.016	-0.12	-0.11	Heschl's gyrus morphology;	chr2:25753906	chr2:25822469~25822950:+
BRCA	cis	rs11892454	0.599	rs10194371	ENSG00000217643.1	PTGES3P2	-3.63	0.000299	0.016	-0.12	-0.11	Heschl's gyrus morphology;	chr2:25754096	chr2:25822469~25822950:+
BRCA	cis	rs11098499	0.863	rs7699064	ENSG00000260091.1	RP11-33B1.4	3.63	0.000299	0.016	0.1	0.11	Corneal astigmatism;	chr4:119507154	chr4:119409333~119410233:+
BRCA	cis	rs739496	0.579	rs7973309	ENSG00000234608.6	MAPKAPK5-AS1	3.63	0.000299	0.016	0.13	0.11	Platelet count;	chr12:111944447	chr12:111839764~111842902:-
BRCA	cis	rs7947761	0.715	rs73001993	ENSG00000255059.1	AP000620.1	-3.63	0.000299	0.016	-0.16	-0.11	Coronary artery disease;	chr11:100698687	chr11:100666459~100666962:+
BRCA	cis	rs13118159	0.55	rs13123016	ENSG00000273179.1	RP11-20I20.4	3.63	0.000299	0.016	0.13	0.11	Longevity;	chr4:1347101	chr4:1167778~1168174:+
BRCA	cis	rs6696239	1	rs12123996	ENSG00000215812.5	ZNF847P	3.63	0.000299	0.016	0.15	0.11	Height;	chr1:227557389	chr1:227696892~227706699:-
BRCA	cis	rs7412746	0.658	rs12090215	ENSG00000231073.1	RP11-316M1.3	3.63	0.000299	0.016	0.12	0.11	Melanoma;	chr1:150921184	chr1:150973123~150975534:+
BRCA	cis	rs7412746	0.658	rs72704682	ENSG00000231073.1	RP11-316M1.3	3.63	0.000299	0.016	0.12	0.11	Melanoma;	chr1:150925201	chr1:150973123~150975534:+
BRCA	cis	rs7412746	0.658	rs72704685	ENSG00000231073.1	RP11-316M1.3	3.63	0.000299	0.016	0.12	0.11	Melanoma;	chr1:150925211	chr1:150973123~150975534:+
BRCA	cis	rs9837347	0.602	rs6792126	ENSG00000228956.7	SATB1-AS1	3.63	0.000299	0.016	0.13	0.11	Itch intensity from mosquito bite adjusted by bite size;	chr3:18727401	chr3:18445024~18920401:+
BRCA	cis	rs17756712	0.667	rs72835984	ENSG00000271911.1	RP11-532F6.5	3.63	0.000299	0.016	0.19	0.11	Vertical cup-disc ratio;	chr6:642017	chr6:761675~780648:+
BRCA	cis	rs9420	0.528	rs11229075	ENSG00000265566.2	RN7SL605P	-3.63	0.000299	0.016	-0.16	-0.11	Schizophrenia;	chr11:57623550	chr11:57528085~57528365:-
BRCA	cis	rs10484434	0.792	rs7757646	ENSG00000272810.1	U91328.22	3.63	0.000299	0.016	0.17	0.11	HIV-1 viral setpoint;	chr6:26064151	chr6:26013241~26013757:+
BRCA	cis	rs2795502	1	rs2796575	ENSG00000185904.10	LINC00839	3.63	0.000299	0.016	0.16	0.11	Blood protein levels;	chr10:42879463	chr10:42475543~42495336:+
BRCA	cis	rs9381040	0.61	rs2268196	ENSG00000161912.16	ADCY10P1	-3.63	0.000299	0.016	-0.12	-0.11	Alzheimer's disease (late onset);	chr6:41054211	chr6:41101022~41140835:+
BRCA	cis	rs673253	0.65	rs2819335	ENSG00000229431.1	RP1-92O14.6	3.63	0.000299	0.016	0.12	0.11	Intelligence (multi-trait analysis);	chr1:43549154	chr1:43385113~43389155:+
BRCA	cis	rs4908769	0.66	rs159961	ENSG00000232912.4	RP5-1115A15.1	3.63	0.000299	0.016	0.12	0.11	Allergy;	chr1:8424168	chr1:8424645~8434838:+
BRCA	cis	rs3743162	1	rs12917429	ENSG00000259295.5	CSPG4P12	-3.63	0.000299	0.016	-0.17	-0.11	Alzheimer's disease (age of onset);	chr15:84881866	chr15:85191438~85213905:+
BRCA	cis	rs360932	0.674	rs361148	ENSG00000270265.1	RP11-731D1.4	3.63	0.000299	0.016	0.13	0.11	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr4:151970137	chr4:151333775~151353224:-
BRCA	cis	rs10129255	0.828	rs10140989	ENSG00000253132.1	IGHV3-62	-3.63	0.000299	0.016	-0.09	-0.11	Kawasaki disease;	chr14:106668657	chr14:106643142~106643585:-
BRCA	cis	rs12893668	0.703	rs729438	ENSG00000269958.1	RP11-73M18.8	-3.63	0.000299	0.016	-0.13	-0.11	Reticulocyte count;	chr14:103626452	chr14:103696353~103697163:+
BRCA	cis	rs9472719	0.891	rs6927617	ENSG00000231769.2	RP1-8B1.4	3.63	0.000299	0.016	0.16	0.11	Total cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;	chr6:46185202	chr6:46097093~46129706:-
BRCA	cis	rs7412746	0.658	rs11582281	ENSG00000224800.1	RP11-235D19.2	-3.63	0.000299	0.016	-0.14	-0.11	Melanoma;	chr1:150854355	chr1:150881236~150881683:-
BRCA	cis	rs4654783	0.627	rs1046310	ENSG00000230068.2	CDC42-IT1	3.63	0.000299	0.016	0.13	0.11	Endometriosis;	chr1:22117394	chr1:22059197~22064199:+
BRCA	cis	rs853679	0.517	rs1904840	ENSG00000226314.6	ZNF192P1	-3.63	0.000299	0.016	-0.17	-0.11	Depression;	chr6:28140454	chr6:28161781~28169594:+
BRCA	cis	rs2109514	0.74	rs1476451	ENSG00000237813.3	AC002066.1	3.63	0.000299	0.016	0.14	0.11	Prevalent atrial fibrillation;	chr7:116429257	chr7:116238260~116499465:-
BRCA	cis	rs2109514	0.74	rs7781492	ENSG00000237813.3	AC002066.1	3.63	0.000299	0.016	0.14	0.11	Prevalent atrial fibrillation;	chr7:116429921	chr7:116238260~116499465:-
BRCA	cis	rs4589258	0.966	rs4381333	ENSG00000280367.1	RP11-121L10.2	3.63	0.000299	0.016	0.13	0.11	Intelligence (multi-trait analysis);	chr11:90769311	chr11:90223153~90226538:+
BRCA	cis	rs867529	1	rs1606803	ENSG00000253497.1	IGKV1-13	-3.63	0.000299	0.016	-0.11	-0.11	Height;	chr2:88633798	chr2:89045995~89046466:-
BRCA	cis	rs10484434	0.818	rs62394555	ENSG00000272810.1	U91328.22	3.63	0.000299	0.016	0.17	0.11	HIV-1 viral setpoint;	chr6:26071861	chr6:26013241~26013757:+
BRCA	cis	rs4415084	1	rs6890556	ENSG00000272335.1	RP11-53O19.3	3.63	3e-04	0.016	0.1	0.11	Breast cancer;	chr5:44648564	chr5:44826076~44828592:+
BRCA	cis	rs11711311	0.712	rs3773684	ENSG00000241529.3	RN7SL767P	3.63	3e-04	0.016	0.13	0.11	IgG glycosylation;	chr3:113615641	chr3:113632704~113632998:+
BRCA	cis	rs6964587	1	rs7455444	ENSG00000188693.7	CYP51A1-AS1	-3.63	3e-04	0.016	-0.12	-0.11	Breast cancer;	chr7:92009999	chr7:92134604~92180725:+
BRCA	cis	rs1730008	0.731	rs4680435	ENSG00000279311.1	RP11-170K4.2	-3.63	3e-04	0.016	-0.14	-0.11	Lobe attachment (rater-scored or self-reported);	chr3:158440576	chr3:158869898~158871821:+
BRCA	cis	rs748404	0.518	rs2899074	ENSG00000249839.1	AC011330.5	-3.63	3e-04	0.016	-0.14	-0.11	Lung cancer;	chr15:43109232	chr15:43663654~43684339:-
BRCA	cis	rs1075232	1	rs16956707	ENSG00000260128.5	ULK4P2	3.63	3e-04	0.016	0.27	0.11	Survival in colorectal cancer (non-distant metastatic);	chr15:31349430	chr15:30572738~30600647:+
BRCA	cis	rs1106529	0.51	rs7526102	ENSG00000231365.4	RP11-418J17.1	-3.63	3e-04	0.016	-0.16	-0.11	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);	chr1:118984604	chr1:119140396~119275973:+
BRCA	cis	rs4664293	0.801	rs7590595	ENSG00000224152.1	AC009506.1	-3.63	3e-04	0.016	-0.13	-0.11	Monocyte percentage of white cells;	chr2:159715198	chr2:159615296~159617082:+
BRCA	cis	rs1376877	0.934	rs1048013	ENSG00000273456.1	RP11-686O6.2	-3.63	3e-04	0.016	-0.11	-0.11	Subclinical atherosclerosis traits (other);	chr2:203289829	chr2:202374932~202375604:-
BRCA	cis	rs6545883	0.859	rs2600661	ENSG00000273302.1	RP11-493E12.2	-3.63	3e-04	0.016	-0.1	-0.11	Tuberculosis;	chr2:61315946	chr2:61199979~61200769:+
BRCA	cis	rs7267979	0.932	rs417130	ENSG00000274973.1	RP13-401N8.7	-3.63	3e-04	0.016	-0.12	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25477684	chr20:25845497~25845862:+
BRCA	cis	rs7267979	0.932	rs372678	ENSG00000274973.1	RP13-401N8.7	-3.63	3e-04	0.016	-0.12	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25484612	chr20:25845497~25845862:+
BRCA	cis	rs2274273	0.624	rs11848456	ENSG00000259318.1	RP11-454L9.2	3.63	3e-04	0.016	0.1	0.11	Protein biomarker;	chr14:55288674	chr14:55394940~55395233:-
BRCA	cis	rs6088580	0.524	rs6142210	ENSG00000261582.1	RP4-614O4.11	3.63	3e-04	0.016	0.11	0.11	Glomerular filtration rate (creatinine);	chr20:34635208	chr20:35267885~35280043:-
BRCA	cis	rs568617	0.859	rs1204650	ENSG00000254614.2	AP003068.23	3.63	3e-04	0.016	0.16	0.11	Crohn's disease;	chr11:65878109	chr11:65177606~65181834:-
BRCA	cis	rs568617	0.953	rs1151519	ENSG00000254614.2	AP003068.23	3.63	3e-04	0.016	0.16	0.11	Crohn's disease;	chr11:65878360	chr11:65177606~65181834:-
BRCA	cis	rs568617	0.903	rs601863	ENSG00000254614.2	AP003068.23	3.63	3e-04	0.016	0.16	0.11	Crohn's disease;	chr11:65879086	chr11:65177606~65181834:-
BRCA	cis	rs9287719	0.639	rs2357650	ENSG00000243819.4	RN7SL832P	3.63	3e-04	0.0161	0.11	0.11	Prostate cancer;	chr2:10556751	chr2:10690344~10692099:+
BRCA	cis	rs6430585	0.941	rs7589832	ENSG00000231890.6	DARS-AS1	-3.63	3e-04	0.0161	-0.16	-0.11	Corneal structure;	chr2:135746531	chr2:135985176~136022593:+
BRCA	cis	rs7487075	0.619	rs7486495	ENSG00000257261.4	RP11-96H19.1	3.63	3e-04	0.0161	0.12	0.11	Itch intensity from mosquito bite;	chr12:46432553	chr12:46383679~46876159:+
BRCA	cis	rs13434995	0.513	rs7665846	ENSG00000249700.7	SRD5A3-AS1	3.63	3e-04	0.0161	0.16	0.11	Adiponectin levels;	chr4:55573078	chr4:55363971~55395847:-
BRCA	cis	rs250518	0.926	rs1509131	ENSG00000271926.1	CTD-2376I4.1	3.63	3e-04	0.0161	0.15	0.11	Mean corpuscular hemoglobin concentration;	chr5:72797651	chr5:72953635~72954274:-
BRCA	cis	rs943466	1	rs11755593	ENSG00000223837.2	BRD2-IT1	3.63	3e-04	0.0161	0.14	0.11	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;	chr6:33772548	chr6:32970232~32970886:+
BRCA	cis	rs61931739	0.5	rs7306435	ENSG00000258794.3	DUX4L27	-3.63	3e-04	0.0161	-0.16	-0.11	Morning vs. evening chronotype;	chr12:34329998	chr12:34208415~34209675:-
BRCA	cis	rs561341	1	rs576985	ENSG00000265798.5	RP11-271K11.5	3.63	3e-04	0.0161	0.19	0.11	Hip circumference adjusted for BMI;	chr17:31996304	chr17:31038575~31059121:-
BRCA	cis	rs2617170	0.961	rs2617171	ENSG00000245648.1	RP11-277P12.20	3.63	3e-04	0.0161	0.14	0.11	Behcet's disease;	chr12:10408680	chr12:10363769~10398506:+
BRCA	cis	rs2555155	0.935	rs2555157	ENSG00000254595.1	CTD-2010I16.1	3.63	3e-04	0.0161	0.13	0.11	DNA methylation (variation);	chr11:6500124	chr11:6488186~6489377:-
BRCA	cis	rs2018683	0.707	rs1021690	ENSG00000233517.1	AC005162.5	-3.63	3e-04	0.0161	-0.14	-0.11	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28934871	chr7:28987028~28988899:+
BRCA	cis	rs2018683	0.707	rs1021691	ENSG00000233517.1	AC005162.5	-3.63	3e-04	0.0161	-0.14	-0.11	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28934879	chr7:28987028~28988899:+
BRCA	cis	rs8103278	1	rs8109951	ENSG00000268423.3	AC011551.3	3.63	3e-04	0.0161	0.14	0.11	Coronary artery disease;	chr19:45786245	chr19:46547056~46600861:-
BRCA	cis	rs10043775	0.793	rs17776554	ENSG00000251330.3	CTD-2283N19.1	-3.63	3e-04	0.0161	-0.14	-0.11	Periodontal microbiota;	chr5:148340924	chr5:148430159~148430807:-
BRCA	cis	rs10829156	0.732	rs1917823	ENSG00000225527.1	RP11-383B4.4	-3.63	3e-04	0.0161	-0.17	-0.11	Sudden cardiac arrest;	chr10:18528184	chr10:18531849~18533336:-
BRCA	cis	rs1322639	0.668	rs9766666	ENSG00000261039.2	RP11-417E7.2	-3.63	3e-04	0.0161	-0.11	-0.11	Pulse pressure;	chr6:169213446	chr6:169175304~169182740:-
BRCA	cis	rs6088580	0.634	rs4911153	ENSG00000275784.1	RP5-1125A11.6	3.63	3e-04	0.0161	0.12	0.11	Glomerular filtration rate (creatinine);	chr20:34373741	chr20:33989480~33991818:-
BRCA	cis	rs6088580	0.567	rs6088520	ENSG00000206582.1	Y_RNA	3.63	3e-04	0.0161	0.13	0.11	Glomerular filtration rate (creatinine);	chr20:34544560	chr20:34526510~34526606:-
BRCA	cis	rs7020830	0.898	rs12555207	ENSG00000230188.1	RP11-405L18.4	-3.63	3e-04	0.0161	-0.14	-0.11	Schizophrenia;	chr9:37315479	chr9:37490421~37490893:-
BRCA	cis	rs801193	1	rs2659906	ENSG00000232546.1	RP11-458F8.1	-3.63	3e-04	0.0161	-0.09	-0.11	Aortic root size;	chr7:66700323	chr7:66848496~66858136:+
BRCA	cis	rs6840360	1	rs7439465	ENSG00000278978.1	RP11-164P12.5	3.63	3e-04	0.0161	0.13	0.11	Intelligence (multi-trait analysis);	chr4:151673662	chr4:151669786~151670503:+
BRCA	cis	rs7267979	0.744	rs6050464	ENSG00000125804.12	FAM182A	-3.63	3e-04	0.0161	-0.14	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25228663	chr20:26054655~26086917:+
BRCA	cis	rs7267979	1	rs2387880	ENSG00000204556.4	CTD-2514C3.1	3.63	3e-04	0.0161	0.15	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25397151	chr20:26018832~26020684:+
BRCA	cis	rs2243480	0.706	rs6460257	ENSG00000232559.3	GS1-124K5.12	3.63	3e-04	0.0161	0.18	0.11	Diabetic kidney disease;	chr7:65731813	chr7:66554588~66576923:-
BRCA	cis	rs12468226	0.873	rs6435138	ENSG00000272966.1	RP11-686O6.1	-3.63	3e-04	0.0161	-0.18	-0.11	Urate levels;	chr2:202234310	chr2:202336739~202337200:+
BRCA	cis	rs12413361	0.967	rs2994655	ENSG00000272914.1	RP11-330O11.3	3.63	3e-04	0.0161	0.14	0.11	Height;	chr10:30836579	chr10:30831828~30833387:-
BRCA	cis	rs1670533	0.585	rs6827206	ENSG00000251639.2	RP11-20I20.1	3.63	3e-04	0.0161	0.18	0.11	Recombination rate (females);	chr4:1071283	chr4:1100016~1101558:-
BRCA	cis	rs1371614	0.632	rs4665363	ENSG00000272148.1	RP11-195B17.1	-3.63	3e-04	0.0161	-0.13	-0.11	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26933548	chr2:27062428~27062907:-
BRCA	cis	rs4363385	0.51	rs11803710	ENSG00000231416.1	RP11-422P24.9	3.63	3e-04	0.0161	0.12	0.11	Inflammatory skin disease;	chr1:153080620	chr1:153995632~153995960:+
BRCA	cis	rs4814894	0.679	rs1884770	ENSG00000236992.2	RPL12L3	3.63	0.000301	0.0161	0.12	0.11	Breast cancer;	chr20:19772430	chr20:19823443~19823943:-
BRCA	cis	rs5758511	0.773	rs9623482	ENSG00000231261.1	HMGN2P10	-3.63	0.000301	0.0161	-0.15	-0.11	Birth weight;	chr22:41964570	chr22:41709225~41709489:-
BRCA	cis	rs17684571	0.751	rs35242294	ENSG00000231441.1	RP11-472M19.2	3.63	0.000301	0.0161	0.19	0.11	Schizophrenia;	chr6:56846131	chr6:56844002~56864078:+
BRCA	cis	rs28735056	0.592	rs2277725	ENSG00000261126.6	RP11-795F19.1	-3.63	0.000301	0.0161	-0.11	-0.11	Schizophrenia;	chr18:79934168	chr18:80046900~80095482:+
BRCA	cis	rs17221829	0.733	rs35757457	ENSG00000280385.1	AP000648.5	-3.63	0.000301	0.0161	-0.13	-0.11	Anxiety in major depressive disorder;	chr11:89625082	chr11:90193614~90198120:+
BRCA	cis	rs477895	0.653	rs11602181	ENSG00000256940.1	RP11-783K16.5	3.63	0.000301	0.0161	0.15	0.11	Mean platelet volume;	chr11:64129119	chr11:64245964~64248217:+
BRCA	cis	rs6812193	0.518	rs77937770	ENSG00000271676.1	RP11-1E1.2	3.63	0.000301	0.0161	0.17	0.11	Parkinson's disease;	chr4:76272055	chr4:77112495~77113458:-
BRCA	cis	rs72799341	1	rs7200879	ENSG00000275263.1	RP11-1072A3.4	-3.63	0.000301	0.0161	-0.16	-0.11	Diastolic blood pressure;	chr16:30936251	chr16:30956872~30957199:-
BRCA	cis	rs1075232	1	rs72722829	ENSG00000260128.5	ULK4P2	3.63	0.000301	0.0161	0.27	0.11	Survival in colorectal cancer (non-distant metastatic);	chr15:31346911	chr15:30572738~30600647:+
BRCA	cis	rs10464366	0.879	rs10464368	ENSG00000227191.5	TRGC2	3.63	0.000301	0.0161	0.11	0.11	IgG glycosylation;	chr7:39081981	chr7:38239580~38368091:-
BRCA	cis	rs11795343	0.503	rs10813831	ENSG00000235453.6	TOPORS-AS1	3.63	0.000301	0.0161	0.14	0.11	Psoriasis;Psoriasis vulgaris;Inflammatory skin disease;	chr9:32526148	chr9:32551144~32567005:+
BRCA	cis	rs4648045	0.734	rs4648055	ENSG00000251288.2	RP11-10L12.2	-3.63	0.000301	0.0161	-0.15	-0.11	Lymphocyte percentage of white cells;	chr4:102594156	chr4:102751401~102752641:+
BRCA	cis	rs4294134	0.545	rs11534080	ENSG00000223718.3	AC093107.7	3.63	0.000301	0.0161	0.16	0.11	Paget's disease;	chr7:135562780	chr7:135660039~135660647:+
BRCA	cis	rs9329221	0.736	rs11249999	ENSG00000154316.13	TDH	3.63	0.000301	0.0161	0.15	0.11	Neuroticism;	chr8:10393755	chr8:11339637~11368452:+
BRCA	cis	rs6088590	0.542	rs6059956	ENSG00000275784.1	RP5-1125A11.6	-3.63	0.000301	0.0161	-0.12	-0.11	Coronary artery disease;	chr20:34632266	chr20:33989480~33991818:-
BRCA	cis	rs863345	0.565	rs6679056	ENSG00000229914.1	RP11-404O13.4	-3.63	0.000301	0.0161	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158480524	chr1:158195633~158196131:-
BRCA	cis	rs733175	0.951	rs6846692	ENSG00000250413.1	RP11-448G15.1	-3.63	0.000301	0.0161	-0.17	-0.11	Psychosis and Alzheimer's disease;	chr4:10029509	chr4:10006482~10009725:+
BRCA	cis	rs35520189	0.845	rs12479173	ENSG00000189223.12	PAX8-AS1	-3.63	0.000301	0.0161	-0.18	-0.11	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:112891633	chr2:113211522~113276581:+
BRCA	cis	rs8098244	0.603	rs1711460	ENSG00000265752.2	RP11-403A21.1	3.63	0.000301	0.0161	0.12	0.11	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23711441	chr18:23957754~23982556:-
BRCA	cis	rs2411233	0.875	rs1991886	ENSG00000259278.1	RP11-62C7.2	3.63	0.000301	0.0161	0.13	0.11	Platelet count;	chr15:38999795	chr15:39019233~39024918:+
BRCA	cis	rs9788682	0.706	rs924840	ENSG00000261143.1	ADAMTS7P3	-3.63	0.000301	0.0161	-0.16	-0.11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78439466	chr15:77976042~77993057:+
BRCA	cis	rs6688363	0.943	rs1016732	ENSG00000228917.1	RP11-544M22.8	-3.63	0.000301	0.0161	-0.17	-0.11	Response to antipsychotic treatment;	chr1:160117178	chr1:161084465~161087571:+
BRCA	cis	rs6439153	0.933	rs11711812	ENSG00000242551.2	POU5F1P6	-3.63	0.000301	0.0161	-0.14	-0.11	Pneumococcal bacteremia;	chr3:128989711	chr3:128674735~128677005:-
BRCA	cis	rs12906542	0.507	rs4395040	ENSG00000260776.4	RP11-114H24.2	3.63	0.000301	0.0161	0.15	0.11	Breast cancer;	chr15:77990191	chr15:77914217~77926846:-
BRCA	cis	rs10129255	0.518	rs12590732	ENSG00000211976.2	IGHV3-73	3.63	0.000301	0.0161	0.08	0.11	Kawasaki disease;	chr14:106779612	chr14:106802694~106803233:-
BRCA	cis	rs13401620	0.833	rs3106242	ENSG00000229326.3	AC069154.4	-3.63	0.000301	0.0161	-0.15	-0.11	Breast size;	chr2:119903425	chr2:119698623~119700151:+
BRCA	cis	rs9470794	1	rs9462396	ENSG00000204110.6	RP1-153P14.8	-3.63	0.000301	0.0161	-0.18	-0.11	Type 2 diabetes;	chr6:38164560	chr6:37507348~37535616:+
BRCA	cis	rs4578769	0.959	rs11082184	ENSG00000273232.1	RP11-370A5.2	3.63	0.000301	0.0161	0.15	0.11	Eosinophil percentage of white cells;	chr18:22872288	chr18:22882825~22883357:-
BRCA	cis	rs875971	0.522	rs10807697	ENSG00000273142.1	RP11-458F8.4	-3.63	0.000301	0.0161	-0.1	-0.11	Aortic root size;	chr7:65951183	chr7:66902857~66906297:+
BRCA	cis	rs10043775	1	rs3734120	ENSG00000251330.3	CTD-2283N19.1	-3.63	0.000301	0.0161	-0.13	-0.11	Periodontal microbiota;	chr5:148441906	chr5:148430159~148430807:-
BRCA	cis	rs6708331	0.941	rs12989257	ENSG00000231024.1	AC092431.3	-3.63	0.000301	0.0161	-0.15	-0.11	Obesity-related traits;	chr2:70141466	chr2:69700192~69713847:-
BRCA	cis	rs7267979	1	rs2500448	ENSG00000274973.1	RP13-401N8.7	3.63	0.000301	0.0161	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25423391	chr20:25845497~25845862:+
BRCA	cis	rs11098499	0.863	rs6835635	ENSG00000225892.3	RP11-384K6.2	3.63	0.000301	0.0161	0.12	0.11	Corneal astigmatism;	chr4:119537712	chr4:118632274~118634759:+
BRCA	cis	rs7735319	0.565	rs6883710	ENSG00000249572.1	CTD-2203K17.1	3.63	0.000301	0.0161	0.14	0.11	Systolic blood pressure;	chr5:33167192	chr5:33424025~33440619:-
BRCA	cis	rs7267979	1	rs11087520	ENSG00000277938.1	RP5-965G21.3	3.63	0.000301	0.0161	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25456191	chr20:25229150~25231933:+
BRCA	cis	rs7620503	0.729	rs13082698	ENSG00000277241.1	RP11-114M1.3	3.63	0.000301	0.0161	0.14	0.11	Corneal structure;	chr3:177588160	chr3:177700346~177701072:-
BRCA	cis	rs6840360	0.55	rs7689266	ENSG00000278978.1	RP11-164P12.5	-3.63	0.000301	0.0161	-0.13	-0.11	Intelligence (multi-trait analysis);	chr4:151639896	chr4:151669786~151670503:+
BRCA	cis	rs10838634	0.803	rs3136433	ENSG00000280615.1	Y_RNA	-3.63	0.000301	0.0161	-0.23	-0.11	Schizophrenia;	chr11:46720358	chr11:47614898~47614994:-
BRCA	cis	rs10838634	1	rs3136434	ENSG00000280615.1	Y_RNA	-3.63	0.000301	0.0161	-0.23	-0.11	Schizophrenia;	chr11:46720699	chr11:47614898~47614994:-
BRCA	cis	rs10838634	1	rs3136436	ENSG00000280615.1	Y_RNA	-3.63	0.000301	0.0161	-0.23	-0.11	Schizophrenia;	chr11:46720939	chr11:47614898~47614994:-
BRCA	cis	rs10838634	0.901	rs3136443	ENSG00000280615.1	Y_RNA	-3.63	0.000301	0.0161	-0.23	-0.11	Schizophrenia;	chr11:46721784	chr11:47614898~47614994:-
BRCA	cis	rs10838634	0.901	rs3136446	ENSG00000280615.1	Y_RNA	-3.63	0.000301	0.0161	-0.23	-0.11	Schizophrenia;	chr11:46722807	chr11:47614898~47614994:-
BRCA	cis	rs17214007	0.877	rs4482303	ENSG00000279866.1	CTB-193M12.4	3.63	0.000302	0.0161	0.17	0.11	Cognitive function;	chr16:15777020	chr16:15704410~15705984:+
BRCA	cis	rs875971	0.54	rs1723268	ENSG00000223473.2	GS1-124K5.3	3.63	0.000302	0.0161	0.09	0.11	Aortic root size;	chr7:66008093	chr7:66491049~66493566:-
BRCA	cis	rs4835473	0.75	rs12498381	ENSG00000249741.2	RP11-673E1.3	3.63	0.000302	0.0161	0.11	0.11	Immature fraction of reticulocytes;	chr4:143793928	chr4:143911514~143912053:-
BRCA	cis	rs12701220	0.847	rs10272002	ENSG00000224079.1	AC091729.7	3.63	0.000302	0.0161	0.17	0.11	Bronchopulmonary dysplasia;	chr7:1007979	chr7:1074450~1078036:+
BRCA	cis	rs6547741	0.844	rs9941696	ENSG00000234072.1	AC074117.10	-3.63	0.000302	0.0161	-0.11	-0.11	Oral cavity cancer;	chr2:27697197	chr2:27356246~27367622:+
BRCA	cis	rs8030605	0.704	rs11638872	ENSG00000277245.1	RP11-48G14.3	3.63	0.000302	0.0161	0.24	0.11	Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;	chr15:56384620	chr15:56447120~56447697:+
BRCA	cis	rs465969	1	rs459888	ENSG00000272356.1	RP5-1112D6.8	-3.63	0.000302	0.0161	-0.23	-0.11	Psoriasis;	chr6:111329953	chr6:111309203~111313517:+
BRCA	cis	rs787274	1	rs787297	ENSG00000271631.1	RP11-408O19.5	3.63	0.000302	0.0161	0.19	0.11	Age-related hearing impairment (SNP x SNP interaction);	chr9:112779853	chr9:112885158~112885767:+
BRCA	cis	rs10129255	1	rs10129319	ENSG00000253132.1	IGHV3-62	-3.63	0.000302	0.0161	-0.09	-0.11	Kawasaki disease;	chr14:106767996	chr14:106643142~106643585:-
BRCA	cis	rs6714710	0.603	rs11684749	ENSG00000228486.8	LINC01125	-3.63	0.000302	0.0161	-0.1	-0.11	Posterior cortical atrophy and Alzheimer's disease;	chr2:97803679	chr2:97664217~97703064:+
BRCA	cis	rs7809799	1	rs6975245	ENSG00000242798.1	RP11-506M12.1	3.63	0.000302	0.0161	0.21	0.11	Ulcerative colitis;	chr7:99157649	chr7:100115214~100127139:-
BRCA	cis	rs11702148	0.552	rs2834235	ENSG00000231355.1	AP000302.58	-3.63	0.000302	0.0161	-0.13	-0.11	Mean corpuscular hemoglobin;	chr21:33529117	chr21:33482499~33484258:-
BRCA	cis	rs6088580	0.524	rs6142210	ENSG00000126005.14	MMP24-AS1	3.63	0.000302	0.0161	0.13	0.11	Glomerular filtration rate (creatinine);	chr20:34635208	chr20:35216462~35278131:-
BRCA	cis	rs62458065	0.64	rs10241303	ENSG00000229358.3	DPY19L1P1	-3.63	0.000302	0.0161	-0.16	-0.11	Metabolite levels (HVA/MHPG ratio);	chr7:32494591	chr7:32580949~32761787:-
BRCA	cis	rs9788682	0.747	rs2656069	ENSG00000261143.1	ADAMTS7P3	3.63	0.000302	0.0161	0.15	0.11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78453365	chr15:77976042~77993057:+
BRCA	cis	rs930395	0.514	rs4866784	ENSG00000251141.4	RP11-53O19.1	3.63	0.000302	0.0161	0.1	0.11	Breast cancer;	chr5:44901029	chr5:44744900~44808777:-
BRCA	cis	rs853679	0.76	rs2299029	ENSG00000261839.1	RP1-265C24.8	3.63	0.000302	0.0161	0.16	0.11	Depression;	chr6:28231053	chr6:28136849~28139678:+
BRCA	cis	rs7777677	0.925	rs4726547	ENSG00000211752.3	TRBV27	-3.63	0.000302	0.0161	-0.09	-0.11	Alcoholic chronic pancreatitis;	chr7:142662750	chr7:142715346~142715861:+
BRCA	cis	rs6490294	0.528	rs12423268	ENSG00000257624.1	RP1-128M12.3	3.63	0.000302	0.0161	0.21	0.11	Mean platelet volume;	chr12:112203903	chr12:112000739~112000985:-
BRCA	cis	rs1133146	1	rs12971799	ENSG00000269051.4	CTD-2245F17.3	-3.63	0.000302	0.0161	-0.12	-0.11	Yu-Zhi constitution type in type 2 diabetes;	chr19:53163873	chr19:53197111~53211015:+
BRCA	cis	rs17092148	1	rs57131731	ENSG00000202150.1	RNU6-407P	-3.63	0.000302	0.0161	-0.16	-0.11	Neuroticism;	chr20:34804936	chr20:35030317~35030420:-
BRCA	cis	rs17092148	1	rs7271289	ENSG00000202150.1	RNU6-407P	-3.63	0.000302	0.0161	-0.16	-0.11	Neuroticism;	chr20:34809500	chr20:35030317~35030420:-
BRCA	cis	rs11098499	0.954	rs2306455	ENSG00000225892.3	RP11-384K6.2	3.63	0.000302	0.0161	0.11	0.11	Corneal astigmatism;	chr4:119500814	chr4:118632274~118634759:+
BRCA	cis	rs7824557	0.767	rs1897950	ENSG00000154316.13	TDH	-3.63	0.000302	0.0162	-0.16	-0.11	Retinal vascular caliber;	chr8:11312042	chr8:11339637~11368452:+
BRCA	cis	rs7474896	1	rs11011366	ENSG00000120555.12	SEPT7P9	3.63	0.000302	0.0162	0.2	0.11	Obesity (extreme);	chr10:37785230	chr10:38383069~38402916:-
BRCA	cis	rs7474896	1	rs11595684	ENSG00000120555.12	SEPT7P9	3.63	0.000302	0.0162	0.2	0.11	Obesity (extreme);	chr10:37794876	chr10:38383069~38402916:-
BRCA	cis	rs7474896	1	rs12763390	ENSG00000120555.12	SEPT7P9	3.63	0.000302	0.0162	0.2	0.11	Obesity (extreme);	chr10:37795504	chr10:38383069~38402916:-
BRCA	cis	rs6142618	0.583	rs6119771	ENSG00000224452.1	RSL24D1P6	3.63	0.000302	0.0162	0.15	0.11	Inflammatory bowel disease;	chr20:32182572	chr20:32170390~32170790:-
BRCA	cis	rs9650657	0.538	rs11250093	ENSG00000255020.1	AF131216.5	-3.63	0.000302	0.0162	-0.13	-0.11	Neuroticism;	chr8:10941318	chr8:11345748~11347502:-
BRCA	cis	rs801193	1	rs1553609	ENSG00000275400.1	RP4-756H11.5	-3.63	0.000302	0.0162	-0.13	-0.11	Aortic root size;	chr7:66732152	chr7:66553805~66554199:-
BRCA	cis	rs7577696	0.924	rs6749336	ENSG00000276334.1	AL133243.1	-3.63	0.000302	0.0162	-0.14	-0.11	Inflammatory biomarkers;	chr2:32046641	chr2:32521927~32523547:+
BRCA	cis	rs9295536	0.59	rs6939950	ENSG00000260455.1	NBAT1	3.63	0.000302	0.0162	0.13	0.11	Neuroblastoma;	chr6:22132801	chr6:22134957~22147193:-
BRCA	cis	rs3750965	0.959	rs2253658	ENSG00000259799.1	RP11-554A11.9	3.63	0.000302	0.0162	0.13	0.11	Hair color;	chr11:69089336	chr11:69155910~69159752:+
BRCA	cis	rs7620503	1	rs1875096	ENSG00000231574.4	RP11-91K9.1	3.63	0.000302	0.0162	0.12	0.11	Corneal structure;	chr3:177586076	chr3:177816865~177899224:+
BRCA	cis	rs7620503	1	rs1875097	ENSG00000231574.4	RP11-91K9.1	3.63	0.000302	0.0162	0.12	0.11	Corneal structure;	chr3:177586244	chr3:177816865~177899224:+
BRCA	cis	rs7620503	1	rs7620503	ENSG00000231574.4	RP11-91K9.1	3.63	0.000302	0.0162	0.12	0.11	Corneal structure;	chr3:177586510	chr3:177816865~177899224:+
BRCA	cis	rs7267979	1	rs2424712	ENSG00000276952.1	RP5-965G21.6	3.63	0.000302	0.0162	0.14	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25436306	chr20:25284915~25285588:-
BRCA	cis	rs7267979	0.966	rs2424714	ENSG00000276952.1	RP5-965G21.6	3.63	0.000302	0.0162	0.14	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25438045	chr20:25284915~25285588:-
BRCA	cis	rs7267979	0.966	rs2424715	ENSG00000276952.1	RP5-965G21.6	3.63	0.000302	0.0162	0.14	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25439441	chr20:25284915~25285588:-
BRCA	cis	rs11673344	0.864	rs1533736	ENSG00000267682.1	CTD-3220F14.2	-3.63	0.000302	0.0162	-0.11	-0.11	Obesity-related traits;	chr19:37164074	chr19:37337236~37337743:+
BRCA	cis	rs867186	0.698	rs11699306	ENSG00000261582.1	RP4-614O4.11	-3.63	0.000302	0.0162	-0.17	-0.11	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35213480	chr20:35267885~35280043:-
BRCA	cis	rs6964587	0.773	rs59242586	ENSG00000188693.7	CYP51A1-AS1	-3.63	0.000302	0.0162	-0.13	-0.11	Breast cancer;	chr7:92288831	chr7:92134604~92180725:+
BRCA	cis	rs6071166	0.683	rs6071119	ENSG00000224635.1	RP4-564F22.5	-3.63	0.000302	0.0162	-0.14	-0.11	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38693380	chr20:38406011~38416797:-
BRCA	cis	rs6071166	0.683	rs6071126	ENSG00000224635.1	RP4-564F22.5	-3.63	0.000302	0.0162	-0.14	-0.11	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38693582	chr20:38406011~38416797:-
BRCA	cis	rs6071166	0.683	rs722077	ENSG00000224635.1	RP4-564F22.5	-3.63	0.000302	0.0162	-0.14	-0.11	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38694105	chr20:38406011~38416797:-
BRCA	cis	rs8098244	0.706	rs1154227	ENSG00000265752.2	RP11-403A21.1	-3.63	0.000302	0.0162	-0.12	-0.11	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23901376	chr18:23957754~23982556:-
BRCA	cis	rs62458065	0.85	rs73096034	ENSG00000273014.1	RP11-225B17.2	-3.63	0.000302	0.0162	-0.18	-0.11	Metabolite levels (HVA/MHPG ratio);	chr7:32432436	chr7:32758882~32759353:+
BRCA	cis	rs9733	0.527	rs11204694	ENSG00000231073.1	RP11-316M1.3	3.63	0.000302	0.0162	0.12	0.11	Tonsillectomy;	chr1:150680915	chr1:150973123~150975534:+
BRCA	cis	rs12744310	0.526	rs11209858	ENSG00000235358.1	RP11-399E6.1	-3.63	0.000302	0.0162	-0.14	-0.11	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41316522	chr1:41242373~41284861:+
BRCA	cis	rs6696239	0.869	rs61824940	ENSG00000227711.2	RP11-275O4.5	-3.63	0.000302	0.0162	-0.16	-0.11	Height;	chr1:227642791	chr1:227509028~227520477:-
BRCA	cis	rs10181042	0.565	rs2564117	ENSG00000273302.1	RP11-493E12.2	3.63	0.000302	0.0162	0.1	0.11	Crohn's disease;	chr2:61005887	chr2:61199979~61200769:+
BRCA	cis	rs35306767	0.903	rs11253492	ENSG00000229869.1	RP11-363N22.2	-3.63	0.000302	0.0162	-0.17	-0.11	Eosinophil percentage of granulocytes;	chr10:890933	chr10:933026~942743:+
BRCA	cis	rs35306767	0.903	rs11253493	ENSG00000229869.1	RP11-363N22.2	-3.63	0.000302	0.0162	-0.17	-0.11	Eosinophil percentage of granulocytes;	chr10:890991	chr10:933026~942743:+
BRCA	cis	rs2346177	0.875	rs2346178	ENSG00000279254.1	RP11-536C12.1	-3.63	0.000302	0.0162	-0.13	-0.11	HDL cholesterol;	chr2:46419922	chr2:46668870~46670778:+
BRCA	cis	rs17801127	0.818	rs16827349	ENSG00000231969.1	AC144449.1	3.63	0.000302	0.0162	0.19	0.11	Liver enzyme levels (alanine transaminase);	chr2:149695891	chr2:149587196~149848233:+
BRCA	cis	rs2412819	0.571	rs2729494	ENSG00000201136.1	RNU6-353P	-3.63	0.000302	0.0162	-0.15	-0.11	Lung cancer;	chr15:43837395	chr15:43702363~43702470:+
BRCA	cis	rs516805	0.667	rs225074	ENSG00000279114.1	RP3-425C14.5	-3.63	0.000302	0.0162	-0.14	-0.11	Lymphocyte counts;	chr6:122265102	chr6:122471923~122484161:+
BRCA	cis	rs4909189	1	rs4909189	ENSG00000225365.1	AC078942.1	3.63	0.000302	0.0162	0.15	0.11	Response to amphetamines;	chr7:158344294	chr7:158537495~158539879:+
BRCA	cis	rs10911902	0.602	rs10494583	ENSG00000229739.2	RP11-295K2.3	-3.63	0.000303	0.0162	-0.15	-0.11	Schizophrenia;	chr1:186321363	chr1:186435161~186470291:+
BRCA	cis	rs4664293	0.647	rs6711049	ENSG00000226266.5	AC009961.3	-3.63	0.000303	0.0162	-0.13	-0.11	Monocyte percentage of white cells;	chr2:159584634	chr2:159670708~159712435:-
BRCA	cis	rs11098499	0.754	rs1980025	ENSG00000225892.3	RP11-384K6.2	-3.63	0.000303	0.0162	-0.11	-0.11	Corneal astigmatism;	chr4:119331651	chr4:118632274~118634759:+
BRCA	cis	rs12893668	0.703	rs2403197	ENSG00000258914.1	CTD-2134A5.3	3.63	0.000303	0.0162	0.16	0.11	Reticulocyte count;	chr14:103587427	chr14:103875055~103877478:+
BRCA	cis	rs372883	0.597	rs2018956	ENSG00000176054.6	RPL23P2	3.63	0.000303	0.0162	0.12	0.11	Pancreatic cancer;	chr21:29364301	chr21:28997613~28998033:-
BRCA	cis	rs1075265	0.749	rs2357693	ENSG00000272156.1	RP11-477N3.1	-3.63	0.000303	0.0162	-0.12	-0.11	Chronotype;Morning vs. evening chronotype;	chr2:53735699	chr2:54082554~54085066:+
BRCA	cis	rs7487075	0.578	rs4768118	ENSG00000257261.4	RP11-96H19.1	3.63	0.000303	0.0162	0.12	0.11	Itch intensity from mosquito bite;	chr12:46390961	chr12:46383679~46876159:+
BRCA	cis	rs6088580	0.524	rs6088552	ENSG00000126005.14	MMP24-AS1	3.63	0.000303	0.0162	0.13	0.11	Glomerular filtration rate (creatinine);	chr20:34638687	chr20:35216462~35278131:-
BRCA	cis	rs5758659	0.652	rs6519301	ENSG00000231261.1	HMGN2P10	3.63	0.000303	0.0162	0.12	0.11	Cognitive function;	chr22:41989963	chr22:41709225~41709489:-
BRCA	cis	rs2243480	0.803	rs34804747	ENSG00000226767.1	RP11-328P23.3	-3.63	0.000303	0.0162	-0.19	-0.11	Diabetic kidney disease;	chr7:65947955	chr7:65508773~65508944:-
BRCA	cis	rs2243480	1	rs59794892	ENSG00000226767.1	RP11-328P23.3	-3.63	0.000303	0.0162	-0.19	-0.11	Diabetic kidney disease;	chr7:65950886	chr7:65508773~65508944:-
BRCA	cis	rs2243480	0.803	rs36004293	ENSG00000226767.1	RP11-328P23.3	-3.63	0.000303	0.0162	-0.19	-0.11	Diabetic kidney disease;	chr7:65951525	chr7:65508773~65508944:-
BRCA	cis	rs2243480	0.803	rs35268390	ENSG00000226767.1	RP11-328P23.3	-3.63	0.000303	0.0162	-0.19	-0.11	Diabetic kidney disease;	chr7:65951549	chr7:65508773~65508944:-
BRCA	cis	rs6671200	0.607	rs1927043	ENSG00000235501.4	RP4-639F20.1	3.63	0.000303	0.0162	0.19	0.11	Stearic acid (18:0) levels;	chr1:95201695	chr1:94927566~94963270:+
BRCA	cis	rs6951245	0.572	rs112072378	ENSG00000229043.2	AC091729.9	-3.63	0.000303	0.0162	-0.26	-0.11	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:999764	chr7:1160374~1165267:+
BRCA	cis	rs728616	0.867	rs723193	ENSG00000242600.5	MBL1P	3.63	0.000303	0.0162	0.26	0.11	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79948399	chr10:79904898~79950336:+
BRCA	cis	rs7829975	0.688	rs13270194	ENSG00000173295.6	FAM86B3P	3.63	0.000303	0.0162	0.12	0.11	Mood instability;	chr8:8520592	chr8:8228595~8244865:+
BRCA	cis	rs1380551	0.872	rs1563819	ENSG00000274471.1	HERC2P2	-3.63	0.000303	0.0162	-0.14	-0.11	Major depressive disorder;	chr15:23862293	chr15:23309607~23313276:+
BRCA	cis	rs7577696	0.85	rs11676938	ENSG00000276334.1	AL133243.1	-3.63	0.000303	0.0162	-0.14	-0.11	Inflammatory biomarkers;	chr2:32090954	chr2:32521927~32523547:+
BRCA	cis	rs10129255	0.509	rs756583	ENSG00000232216.1	IGHV3-43	3.63	0.000303	0.0162	0.08	0.11	Kawasaki disease;	chr14:106680002	chr14:106470264~106470800:-
BRCA	cis	rs737008	0.922	rs1559394	ENSG00000262636.1	CTD-3088G3.4	-3.62	0.000303	0.0162	-0.16	-0.11	Obesity-related traits;	chr16:11275348	chr16:11380859~11381118:-
BRCA	cis	rs4842666	0.831	rs11105378	ENSG00000270344.2	RP11-734K2.4	3.62	0.000303	0.0162	0.14	0.11	Blood pressure;	chr12:89696964	chr12:89525654~89548005:+
BRCA	cis	rs875971	0.522	rs709604	ENSG00000223473.2	GS1-124K5.3	-3.62	0.000303	0.0162	-0.09	-0.11	Aortic root size;	chr7:66032447	chr7:66491049~66493566:-
BRCA	cis	rs4449834	0.816	rs13264014	ENSG00000254432.1	RP11-33I11.2	-3.62	0.000303	0.0162	-0.14	-0.11	Sum eosinophil basophil counts;	chr8:60747137	chr8:60808735~60809606:-
BRCA	cis	rs4664293	0.967	rs10202187	ENSG00000230783.1	AC009961.2	-3.62	0.000303	0.0162	-0.14	-0.11	Monocyte percentage of white cells;	chr2:159571135	chr2:159689217~159690291:-
BRCA	cis	rs11686241	0.748	rs13411746	ENSG00000232485.2	AC098820.3	3.62	0.000303	0.0162	0.2	0.11	Cancer;	chr2:216441893	chr2:216479030~216498761:-
BRCA	cis	rs1430193	0.527	rs3791660	ENSG00000272606.1	RP11-554J4.1	3.62	0.000303	0.0162	0.12	0.11	Lung function (forced vital capacity);	chr2:55902745	chr2:55617909~55618373:+
BRCA	cis	rs6064559	0.687	rs4811870	ENSG00000218018.2	RP4-800J21.3	-3.62	0.000303	0.0162	-0.1	-0.11	Hemoglobin concentration;	chr20:57545873	chr20:57384160~57393062:-
BRCA	cis	rs4763555	1	rs4763555	ENSG00000256039.1	RP11-291B21.2	-3.62	0.000303	0.0162	-0.1	-0.11	Cognitive function;	chr12:10568857	chr12:10553363~10558049:+
BRCA	cis	rs7089973	0.872	rs34683721	ENSG00000236799.1	RP11-383C6.2	-3.62	0.000303	0.0162	-0.14	-0.11	Bipolar disorder or attention deficit hyperactivity disorder;	chr10:114860090	chr10:114994657~114996593:+
BRCA	cis	rs138880	0.505	rs56248708	ENSG00000229409.1	RP11-494O16.3	3.62	0.000303	0.0162	0.22	0.11	Schizophrenia;	chr22:49913321	chr22:49845929~49846090:+
BRCA	cis	rs7267979	1	rs2424704	ENSG00000274414.1	RP5-965G21.4	-3.62	0.000303	0.0162	-0.13	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25293293	chr20:25239007~25245229:-
BRCA	cis	rs3750965	0.959	rs3376	ENSG00000259799.1	RP11-554A11.9	3.62	0.000303	0.0162	0.13	0.11	Hair color;	chr11:69089212	chr11:69155910~69159752:+
BRCA	cis	rs925550	0.592	rs1026157	ENSG00000224786.1	CETN4P	3.62	0.000303	0.0162	0.16	0.11	Primary biliary cholangitis;	chr4:122702738	chr4:122730548~122732193:-
BRCA	cis	rs7267979	1	rs6050617	ENSG00000276952.1	RP5-965G21.6	3.62	0.000303	0.0162	0.14	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25441012	chr20:25284915~25285588:-
BRCA	cis	rs7267979	0.933	rs2387887	ENSG00000276952.1	RP5-965G21.6	3.62	0.000303	0.0162	0.14	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25446445	chr20:25284915~25285588:-
BRCA	cis	rs7267979	1	rs6037121	ENSG00000276952.1	RP5-965G21.6	3.62	0.000303	0.0162	0.14	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25447675	chr20:25284915~25285588:-
BRCA	cis	rs7267979	1	rs1047171	ENSG00000276952.1	RP5-965G21.6	3.62	0.000303	0.0162	0.14	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25448150	chr20:25284915~25285588:-
BRCA	cis	rs7267979	1	rs6050629	ENSG00000276952.1	RP5-965G21.6	3.62	0.000303	0.0162	0.14	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25450044	chr20:25284915~25285588:-
BRCA	cis	rs7267979	1	rs6050630	ENSG00000276952.1	RP5-965G21.6	3.62	0.000303	0.0162	0.14	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25450109	chr20:25284915~25285588:-
BRCA	cis	rs3136202	0.684	rs3974346	ENSG00000242307.1	RPS26P52	3.62	0.000303	0.0162	0.14	0.11	Conduct disorder (symptom count);	chr16:13970254	chr16:13922332~13922679:-
BRCA	cis	rs67180937	0.553	rs3008629	ENSG00000225265.1	TAF1A-AS1	-3.62	0.000304	0.0162	-0.15	-0.11	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222662588	chr1:222589825~222593032:+
BRCA	cis	rs7429990	0.965	rs35689209	ENSG00000228638.1	FCF1P2	3.62	0.000304	0.0162	0.11	0.11	Educational attainment (years of education);	chr3:48078273	chr3:48290793~48291375:-
BRCA	cis	rs6997458	0.742	rs955007	ENSG00000258256.1	RP11-219B4.5	-3.62	0.000304	0.0162	-0.13	-0.11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85458166	chr8:85222446~85245717:-
BRCA	cis	rs60822569	1	rs60822569	ENSG00000248265.1	FLJ12825	3.62	0.000304	0.0162	0.15	0.11	Mean platelet volume;	chr12:54323724	chr12:54058254~54122234:+
BRCA	cis	rs61931739	0.517	rs11053224	ENSG00000258794.3	DUX4L27	3.62	0.000304	0.0162	0.16	0.11	Morning vs. evening chronotype;	chr12:34331984	chr12:34208415~34209675:-
BRCA	cis	rs8056446	0.837	rs4888748	ENSG00000276007.1	RP11-358L22.3	-3.62	0.000304	0.0162	-0.13	-0.11	Pulmonary function (smoking interaction);	chr16:78139257	chr16:78123243~78124332:+
BRCA	cis	rs6740462	0.959	rs268124	ENSG00000237979.1	AC007389.1	3.62	0.000304	0.0162	0.14	0.11	Inflammatory bowel disease;Crohn's disease;	chr2:65427230	chr2:65500993~65502138:-
BRCA	cis	rs4925540	1	rs7546342	ENSG00000215796.3	RP11-551G24.2	-3.62	0.000304	0.0162	-0.13	-0.11	Response to taxane treatment (docetaxel);	chr1:247049990	chr1:247042791~247044021:+
BRCA	cis	rs4650943	0.503	rs34511428	ENSG00000227740.1	RP11-318C24.2	3.62	0.000304	0.0162	0.12	0.11	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in inactive individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr1:176195481	chr1:175904762~175920513:-
BRCA	cis	rs62229266	0.804	rs62230822	ENSG00000214914.3	RPL23AP3	3.62	0.000304	0.0162	0.14	0.11	Mitral valve prolapse;	chr21:36057647	chr21:36016079~36016546:-
BRCA	cis	rs4243971	0.516	rs1885292	ENSG00000275576.1	RP5-836N17.4	-3.62	0.000304	0.0162	-0.13	-0.11	Inflammatory bowel disease;Crohn's disease;	chr20:32432426	chr20:32116171~32116629:+
BRCA	cis	rs4919694	0.808	rs80020194	ENSG00000213061.2	PFN1P11	3.62	0.000304	0.0162	0.25	0.11	Arsenic metabolism;	chr10:103276197	chr10:102838011~102845473:-
BRCA	cis	rs477895	0.652	rs72920332	ENSG00000256940.1	RP11-783K16.5	3.62	0.000304	0.0162	0.16	0.11	Mean platelet volume;	chr11:64179599	chr11:64245964~64248217:+
BRCA	cis	rs12701220	0.894	rs13224488	ENSG00000224079.1	AC091729.7	3.62	0.000304	0.0162	0.17	0.11	Bronchopulmonary dysplasia;	chr7:1012717	chr7:1074450~1078036:+
BRCA	cis	rs9381040	0.655	rs6903444	ENSG00000161912.16	ADCY10P1	-3.62	0.000304	0.0162	-0.12	-0.11	Alzheimer's disease (late onset);	chr6:41046481	chr6:41101022~41140835:+
BRCA	cis	rs2688608	0.647	rs2227575	ENSG00000213731.2	RAB5CP1	-3.62	0.000304	0.0162	-0.13	-0.11	Inflammatory bowel disease;	chr10:73918082	chr10:74423435~74424014:-
BRCA	cis	rs17772222	0.561	rs8020376	ENSG00000258789.1	RP11-507K2.3	-3.62	0.000304	0.0162	-0.13	-0.11	Coronary artery calcification;	chr14:88349823	chr14:88551597~88552493:+
BRCA	cis	rs7020830	0.898	rs495863	ENSG00000230188.1	RP11-405L18.4	-3.62	0.000304	0.0162	-0.13	-0.11	Schizophrenia;	chr9:37346958	chr9:37490421~37490893:-
BRCA	cis	rs875971	1	rs6956179	ENSG00000230189.5	GS1-124K5.2	-3.62	0.000304	0.0162	-0.09	-0.11	Aortic root size;	chr7:66341672	chr7:66409143~66490059:-
BRCA	cis	rs6108958	0.838	rs6078204	ENSG00000235036.4	RP5-1099D15.1	-3.62	0.000304	0.0162	-0.12	-0.11	Gut microbiome composition (summer);	chr20:11472543	chr20:10612861~10614229:-
BRCA	cis	rs2298450	0.55	rs36037816	ENSG00000231106.2	LINC01436	3.62	0.000304	0.0162	0.12	0.11	Schizophrenia;	chr21:36283817	chr21:36005338~36007838:+
BRCA	cis	rs7665090	0.714	rs5026475	ENSG00000251288.2	RP11-10L12.2	-3.62	0.000304	0.0162	-0.13	-0.11	Primary biliary cholangitis;	chr4:102633664	chr4:102751401~102752641:+
BRCA	cis	rs10992471	0.528	rs10761180	ENSG00000187984.11	ANKRD19P	-3.62	0.000304	0.0162	-0.1	-0.11	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr9:92890624	chr9:92809388~92888693:+
BRCA	cis	rs7474896	0.806	rs1779150	ENSG00000120555.12	SEPT7P9	3.62	0.000304	0.0162	0.2	0.11	Obesity (extreme);	chr10:37749759	chr10:38383069~38402916:-
BRCA	cis	rs6120849	0.754	rs7268266	ENSG00000202150.1	RNU6-407P	3.62	0.000304	0.0162	0.16	0.11	Protein C levels;	chr20:34994086	chr20:35030317~35030420:-
BRCA	cis	rs4865762	0.687	rs27316	ENSG00000247796.2	CTD-2366F13.1	3.62	0.000304	0.0162	0.12	0.11	Intraocular pressure;	chr5:53240936	chr5:53109842~53115126:+
BRCA	cis	rs638893	0.578	rs500254	ENSG00000255422.1	AP002954.4	3.62	0.000304	0.0162	0.19	0.11	Vitiligo;	chr11:118808071	chr11:118704607~118750263:+
BRCA	cis	rs798766	1	rs798767	ENSG00000244459.2	RP11-1398P2.1	-3.62	0.000304	0.0163	-0.14	-0.11	Urinary bladder cancer;Bladder cancer;	chr4:1732554	chr4:1574062~1580253:-
BRCA	cis	rs931127	0.658	rs7926512	ENSG00000245532.5	NEAT1	-3.62	0.000304	0.0163	-0.1	-0.11	Systemic lupus erythematosus;	chr11:65697016	chr11:65422774~65445540:+
BRCA	cis	rs1046491	1	rs12455304	ENSG00000264964.1	RP11-888D10.3	3.62	0.000304	0.0163	0.23	0.11	Scarlet fever;	chr18:9200840	chr18:9315194~9334441:-
BRCA	cis	rs2625529	0.59	rs713048	ENSG00000260037.4	CTD-2524L6.3	-3.62	0.000304	0.0163	-0.15	-0.11	Red blood cell count;	chr15:72250743	chr15:71818396~71823384:+
BRCA	cis	rs74233809	1	rs76752100	ENSG00000213061.2	PFN1P11	3.62	0.000304	0.0163	0.24	0.11	Birth weight;	chr10:103034329	chr10:102838011~102845473:-
BRCA	cis	rs3096299	0.685	rs4238830	ENSG00000261118.1	RP11-104N10.1	3.62	0.000304	0.0163	0.12	0.11	Multiple myeloma (IgH translocation);	chr16:89473833	chr16:89492017~89504460:-
BRCA	cis	rs2657888	1	rs7310284	ENSG00000257576.1	RP11-153M3.1	3.62	0.000304	0.0163	0.14	0.11	Adiponectin levels;	chr12:56541868	chr12:56511002~56512703:+
BRCA	cis	rs875971	0.545	rs73148639	ENSG00000273448.1	RP11-166O4.6	3.62	0.000304	0.0163	0.12	0.11	Aortic root size;	chr7:66390342	chr7:67333047~67334383:+
BRCA	cis	rs12612619	0.579	rs41448746	ENSG00000229122.1	AGBL5-IT1	-3.62	0.000304	0.0163	-0.12	-0.11	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:26857838	chr2:27061038~27061815:+
BRCA	cis	rs10129255	0.957	rs8019272	ENSG00000232216.1	IGHV3-43	3.62	0.000304	0.0163	0.09	0.11	Kawasaki disease;	chr14:106784709	chr14:106470264~106470800:-
BRCA	cis	rs6088580	0.608	rs1205342	ENSG00000275784.1	RP5-1125A11.6	3.62	0.000304	0.0163	0.12	0.11	Glomerular filtration rate (creatinine);	chr20:34334036	chr20:33989480~33991818:-
BRCA	cis	rs1389993	0.752	rs719500	ENSG00000280594.1	AP000432.1	3.62	0.000304	0.0163	0.11	0.11	Intelligence (multi-trait analysis);	chr21:17663826	chr21:17611744~17633199:+
BRCA	cis	rs9650657	0.803	rs13276026	ENSG00000255020.1	AF131216.5	3.62	0.000304	0.0163	0.13	0.11	Neuroticism;	chr8:10752445	chr8:11345748~11347502:-
BRCA	cis	rs11048434	0.518	rs17730331	ENSG00000256069.6	A2MP1	-3.62	0.000304	0.0163	-0.12	-0.11	Sjögren's syndrome;	chr12:9025836	chr12:9228533~9275817:-
BRCA	cis	rs7176093	0.874	rs9635397	ENSG00000202081.1	RNU6-1280P	-3.62	0.000304	0.0163	-0.13	-0.11	Aging traits;	chr15:85802759	chr15:85651522~85651628:-
BRCA	cis	rs4388249	1	rs12656080	ENSG00000271849.1	CTC-332L22.1	-3.62	0.000304	0.0163	-0.18	-0.11	Schizophrenia;	chr5:109776981	chr5:109687802~109688329:-
BRCA	cis	rs877819	0.549	rs7900483	ENSG00000278561.1	PTPN20CP	3.62	0.000304	0.0163	0.13	0.11	Systemic lupus erythematosus;	chr10:48890430	chr10:48064308~48119455:-
BRCA	cis	rs983392	0.792	rs684961	ENSG00000275344.1	MIR6503	-3.62	0.000304	0.0163	-0.11	-0.11	Alzheimer's disease (late onset);	chr11:60151364	chr11:60209071~60209156:-
BRCA	cis	rs13256369	1	rs13271966	ENSG00000233609.3	RP11-62H7.2	3.62	0.000304	0.0163	0.12	0.11	Obesity-related traits;	chr8:8717962	chr8:8961200~8979025:+
BRCA	cis	rs35791980	0.584	rs1181897	ENSG00000242435.1	UPK3BP1	3.62	0.000304	0.0163	0.13	0.11	Pursuit maintenance gain;	chr7:77366149	chr7:77004662~77005774:+
BRCA	cis	rs2625529	0.713	rs16956634	ENSG00000260037.4	CTD-2524L6.3	3.62	0.000304	0.0163	0.15	0.11	Red blood cell count;	chr15:72259902	chr15:71818396~71823384:+
BRCA	cis	rs11098499	0.644	rs3986377	ENSG00000225892.3	RP11-384K6.2	3.62	0.000304	0.0163	0.11	0.11	Corneal astigmatism;	chr4:119339115	chr4:118632274~118634759:+
BRCA	cis	rs10028773	0.556	rs4473640	ENSG00000225892.3	RP11-384K6.2	3.62	0.000304	0.0163	0.11	0.11	Educational attainment;	chr4:119339282	chr4:118632274~118634759:+
BRCA	cis	rs4908768	0.657	rs4908510	ENSG00000270282.1	RP5-1115A15.2	3.62	0.000304	0.0163	0.14	0.11	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8746286	chr1:8512653~8513021:+
BRCA	cis	rs9333290	0.897	rs1839124	ENSG00000259915.2	RP11-410E4.1	-3.62	0.000305	0.0163	-0.16	-0.11	Urinary albumin-to-creatinine ratio in non-diabetics;Urinary albumin-to-creatinine ratio;	chr2:186661887	chr2:186354570~186356773:-
BRCA	cis	rs11773103	1	rs73208537	ENSG00000224046.1	AC005076.5	3.62	0.000305	0.0163	0.24	0.11	Bipolar disorder or major depressive disorder (combined);	chr7:87200814	chr7:87151423~87152420:-
BRCA	cis	rs1371614	0.611	rs3843322	ENSG00000229122.1	AGBL5-IT1	3.62	0.000305	0.0163	0.12	0.11	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26908981	chr2:27061038~27061815:+
BRCA	cis	rs818427	1	rs712664	ENSG00000279522.1	CTC-487M23.6	3.62	0.000305	0.0163	0.13	0.11	Total body bone mineral density;	chr5:112887904	chr5:112894933~112896531:+
BRCA	cis	rs4759375	1	rs10773006	ENSG00000235423.7	RP11-282O18.3	3.62	0.000305	0.0163	0.19	0.11	HDL cholesterol;	chr12:123305504	chr12:123252030~123261483:-
BRCA	cis	rs7572733	0.806	rs10169453	ENSG00000231621.1	AC013264.2	-3.62	0.000305	0.0163	-0.1	-0.11	Dermatomyositis;	chr2:197970488	chr2:197197991~197199273:+
BRCA	cis	rs7572733	0.935	rs10204166	ENSG00000231621.1	AC013264.2	-3.62	0.000305	0.0163	-0.1	-0.11	Dermatomyositis;	chr2:197970540	chr2:197197991~197199273:+
BRCA	cis	rs11239930	0.538	rs4950362	ENSG00000237188.3	RP11-337C18.8	3.62	0.000305	0.0163	0.13	0.11	AIDS progression;	chr1:147088336	chr1:147172771~147211568:+
BRCA	cis	rs4703129	1	rs72771735	ENSG00000246763.5	RGMB-AS1	-3.62	0.000305	0.0163	-0.13	-0.11	Asperger disorder;	chr5:98546570	chr5:98769618~98773469:-
BRCA	cis	rs4703129	1	rs72771737	ENSG00000246763.5	RGMB-AS1	-3.62	0.000305	0.0163	-0.13	-0.11	Asperger disorder;	chr5:98546571	chr5:98769618~98773469:-
BRCA	cis	rs1552244	0.572	rs6442154	ENSG00000180385.7	EMC3-AS1	3.62	0.000305	0.0163	0.15	0.11	Alzheimer's disease;	chr3:10127101	chr3:9986893~10006990:+
BRCA	cis	rs10043228	0.702	rs6873950	ENSG00000250015.1	CTC-339F2.2	3.62	0.000305	0.0163	0.13	0.11	Asthma or chronic obstructive pulmonary disease;	chr5:116293998	chr5:116302354~116304134:-
BRCA	cis	rs2041840	0.53	rs3845784	ENSG00000272054.1	RP11-423P10.2	-3.62	0.000305	0.0163	-0.1	-0.11	Chronic lymphocytic leukemia;	chr2:37175730	chr2:37208875~37212677:+
BRCA	cis	rs539096	0.83	rs2819339	ENSG00000236200.4	KDM4A-AS1	3.62	0.000305	0.0163	0.14	0.11	Intelligence (multi-trait analysis);	chr1:43552933	chr1:43699765~43708138:-
BRCA	cis	rs6088580	0.66	rs6087592	ENSG00000269202.1	RP4-614O4.12	-3.62	0.000305	0.0163	-0.11	-0.11	Glomerular filtration rate (creatinine);	chr20:34526698	chr20:35201747~35203288:-
BRCA	cis	rs9309473	0.607	rs4641966	ENSG00000230002.2	ALMS1-IT1	3.62	0.000305	0.0163	0.13	0.11	Metabolite levels;	chr2:73363678	chr2:73456764~73459484:+
BRCA	cis	rs863345	0.564	rs1418844	ENSG00000229914.1	RP11-404O13.4	-3.62	0.000305	0.0163	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158487779	chr1:158195633~158196131:-
BRCA	cis	rs3768617	0.966	rs10911253	ENSG00000224468.3	RP11-181K3.4	-3.62	0.000305	0.0163	-0.12	-0.11	Fuchs's corneal dystrophy;	chr1:183117055	chr1:183138402~183141282:-
BRCA	cis	rs12534093	1	rs35319316	ENSG00000234286.1	AC006026.13	-3.62	0.000305	0.0163	-0.17	-0.11	Infant length;Height;	chr7:23462137	chr7:23680195~23680786:-
BRCA	cis	rs9876781	0.507	rs1824362	ENSG00000244380.1	RP11-24C3.2	-3.62	0.000305	0.0163	-0.13	-0.11	Longevity;	chr3:48360459	chr3:48440352~48446656:-
BRCA	cis	rs3781264	0.6	rs10882416	ENSG00000268894.5	PLCE1-AS1	3.62	0.000305	0.0163	0.15	0.11	Esophageal cancer and gastric cancer;	chr10:94285297	chr10:94279277~94287478:-
BRCA	cis	rs283610	0.77	rs438452	ENSG00000249149.2	RP11-79P5.3	3.62	0.000305	0.0163	0.14	0.11	Obesity-related traits;	chr5:73963954	chr5:73382384~73410509:+
BRCA	cis	rs2562456	0.958	rs2562508	ENSG00000268119.4	CTD-2561J22.5	-3.62	0.000305	0.0163	-0.17	-0.11	Pain;	chr19:21543479	chr19:21444241~21463908:-
BRCA	cis	rs752010	0.875	rs11210501	ENSG00000230638.4	RP11-486B10.4	-3.62	0.000305	0.0163	-0.14	-0.11	Lupus nephritis in systemic lupus erythematosus;	chr1:41625963	chr1:41542069~41544310:+
BRCA	cis	rs6964587	1	rs6465343	ENSG00000188693.7	CYP51A1-AS1	-3.62	0.000305	0.0163	-0.12	-0.11	Breast cancer;	chr7:91988894	chr7:92134604~92180725:+
BRCA	cis	rs10843647	0.51	rs10771633	ENSG00000245614.3	DDX11-AS1	3.62	0.000305	0.0163	0.12	0.11	Glucose homeostasis traits;	chr12:30107878	chr12:31020763~31073847:-
BRCA	cis	rs962856	0.575	rs644032	ENSG00000236780.4	AC078941.1	3.62	0.000305	0.0163	0.15	0.11	Pancreatic cancer;	chr2:67432524	chr2:67123357~67215319:-
BRCA	cis	rs17270561	0.609	rs9358883	ENSG00000272462.2	U91328.19	-3.62	0.000305	0.0163	-0.14	-0.11	Iron status biomarkers;	chr6:25755287	chr6:25992662~26001775:+
BRCA	cis	rs875971	1	rs778696	ENSG00000271064.1	RP11-792A8.3	-3.62	0.000305	0.0163	-0.13	-0.11	Aortic root size;	chr7:66405826	chr7:66748838~66749077:-
BRCA	cis	rs875971	1	rs778694	ENSG00000271064.1	RP11-792A8.3	-3.62	0.000305	0.0163	-0.13	-0.11	Aortic root size;	chr7:66406571	chr7:66748838~66749077:-
BRCA	cis	rs875971	1	rs4718344	ENSG00000271064.1	RP11-792A8.3	-3.62	0.000305	0.0163	-0.13	-0.11	Aortic root size;	chr7:66409394	chr7:66748838~66749077:-
BRCA	cis	rs875971	0.737	rs7803424	ENSG00000271064.1	RP11-792A8.3	-3.62	0.000305	0.0163	-0.13	-0.11	Aortic root size;	chr7:66415618	chr7:66748838~66749077:-
BRCA	cis	rs875971	0.83	rs7799834	ENSG00000271064.1	RP11-792A8.3	-3.62	0.000305	0.0163	-0.13	-0.11	Aortic root size;	chr7:66415707	chr7:66748838~66749077:-
BRCA	cis	rs2835345	0.596	rs62229441	ENSG00000233818.1	AP000695.4	3.62	0.000305	0.0163	0.12	0.11	Pulmonary function;	chr21:36447559	chr21:36445731~36532408:+
BRCA	cis	rs12468226	0.938	rs79117531	ENSG00000272966.1	RP11-686O6.1	3.62	0.000305	0.0163	0.18	0.11	Urate levels;	chr2:202307690	chr2:202336739~202337200:+
BRCA	cis	rs7412746	0.658	rs6669855	ENSG00000231073.1	RP11-316M1.3	3.62	0.000305	0.0163	0.12	0.11	Melanoma;	chr1:150888753	chr1:150973123~150975534:+
BRCA	cis	rs654950	0.807	rs941970	ENSG00000230638.4	RP11-486B10.4	3.62	0.000305	0.0163	0.14	0.11	Airway imaging phenotypes;	chr1:41525196	chr1:41542069~41544310:+
BRCA	cis	rs739496	0.894	rs11065898	ENSG00000257624.1	RP1-128M12.3	3.62	0.000305	0.0163	0.15	0.11	Platelet count;	chr12:111424771	chr12:112000739~112000985:-
BRCA	cis	rs7954584	1	rs7954584	ENSG00000274292.1	RP11-347I19.7	-3.62	0.000305	0.0163	-0.09	-0.11	Mean corpuscular volume;	chr12:122023660	chr12:121800797~121803403:+
BRCA	cis	rs4664293	0.51	rs1968343	ENSG00000230783.1	AC009961.2	3.62	0.000305	0.0163	0.14	0.11	Monocyte percentage of white cells;	chr2:159712247	chr2:159689217~159690291:-
BRCA	cis	rs10129255	0.957	rs7493713	ENSG00000232216.1	IGHV3-43	3.62	0.000305	0.0163	0.09	0.11	Kawasaki disease;	chr14:106783685	chr14:106470264~106470800:-
BRCA	cis	rs10129255	0.912	rs35468694	ENSG00000232216.1	IGHV3-43	3.62	0.000305	0.0163	0.09	0.11	Kawasaki disease;	chr14:106784199	chr14:106470264~106470800:-
BRCA	cis	rs2688608	0.623	rs2633318	ENSG00000213731.2	RAB5CP1	-3.62	0.000305	0.0163	-0.13	-0.11	Inflammatory bowel disease;	chr10:73930676	chr10:74423435~74424014:-
BRCA	cis	rs7520050	0.966	rs1085244	ENSG00000234329.1	RP11-767N6.2	-3.62	0.000305	0.0163	-0.11	-0.11	Reticulocyte count;Red blood cell count;	chr1:46098008	chr1:45651039~45651826:-
BRCA	cis	rs7520050	0.966	rs6662641	ENSG00000234329.1	RP11-767N6.2	-3.62	0.000305	0.0163	-0.11	-0.11	Reticulocyte count;Red blood cell count;	chr1:46105837	chr1:45651039~45651826:-
BRCA	cis	rs7520050	0.966	rs1707335	ENSG00000234329.1	RP11-767N6.2	-3.62	0.000305	0.0163	-0.11	-0.11	Reticulocyte count;Red blood cell count;	chr1:46106249	chr1:45651039~45651826:-
BRCA	cis	rs2905347	0.895	rs2961282	ENSG00000232949.1	AC002480.4	-3.62	0.000305	0.0163	-0.13	-0.11	Major depression and alcohol dependence;	chr7:22600770	chr7:22589705~22591622:+
BRCA	cis	rs2904967	0.703	rs2957111	ENSG00000254501.1	AP003068.9	-3.62	0.000305	0.0163	-0.23	-0.11	Mean corpuscular volume;	chr11:65235976	chr11:65110714~65111695:-
BRCA	cis	rs9918079	0.542	rs7688984	ENSG00000214846.4	RP11-115L11.1	3.62	0.000305	0.0163	0.14	0.11	Obesity-related traits;	chr4:15655630	chr4:15730962~15731627:-
BRCA	cis	rs1670533	0.932	rs13140571	ENSG00000251639.2	RP11-20I20.1	3.62	0.000306	0.0163	0.18	0.11	Recombination rate (females);	chr4:1060570	chr4:1100016~1101558:-
BRCA	cis	rs6736093	0.733	rs34974772	ENSG00000236307.2	EEF1E1P1	-3.62	0.000306	0.0163	-0.14	-0.11	Coronary artery disease;	chr2:112052434	chr2:111887914~111888741:+
BRCA	cis	rs6736093	0.796	rs34128716	ENSG00000236307.2	EEF1E1P1	-3.62	0.000306	0.0163	-0.14	-0.11	Coronary artery disease;	chr2:112055279	chr2:111887914~111888741:+
BRCA	cis	rs2243480	1	rs160643	ENSG00000237026.1	RP11-328P23.2	3.62	0.000306	0.0163	0.19	0.11	Diabetic kidney disease;	chr7:66093235	chr7:65235790~65236723:-
BRCA	cis	rs826838	0.616	rs10880751	ENSG00000257718.1	RP11-396F22.1	3.62	0.000306	0.0163	0.11	0.11	Heart rate;	chr12:38233683	chr12:38906451~38909592:+
BRCA	cis	rs16950303	0.661	rs16950298	ENSG00000265496.3	MIR1539	3.62	0.000306	0.0163	0.2	0.11	Height;	chr18:49055954	chr18:49487339~49491878:+
BRCA	cis	rs295490	0.748	rs2289348	ENSG00000178631.7	ACTG1P1	-3.62	0.000306	0.0163	-0.22	-0.11	PR interval in Tripanosoma cruzi seropositivity;	chr3:139445424	chr3:139493809~139494937:+
BRCA	cis	rs10883723	0.962	rs10883726	ENSG00000213061.2	PFN1P11	-3.62	0.000306	0.0163	-0.15	-0.11	Allergic disease (asthma, hay fever or eczema);	chr10:102476519	chr10:102838011~102845473:-
BRCA	cis	rs10883723	0.962	rs1056739	ENSG00000213061.2	PFN1P11	-3.62	0.000306	0.0163	-0.15	-0.11	Allergic disease (asthma, hay fever or eczema);	chr10:102476785	chr10:102838011~102845473:-
BRCA	cis	rs2554380	0.6	rs6602986	ENSG00000259570.1	RP11-671M22.4	3.62	0.000306	0.0163	0.14	0.11	Height;	chr15:83778347	chr15:84394512~84395514:+
BRCA	cis	rs7037266	1	rs7037266	ENSG00000232946.1	RP11-390F4.2	-3.62	0.000306	0.0163	-0.13	-0.11	Menarche (age at onset);	chr9:6942940	chr9:6675284~6675614:+
BRCA	cis	rs13272568	0.614	rs4308718	ENSG00000254352.1	RP11-578O24.2	-3.62	0.000306	0.0163	-0.14	-0.11	Bone mineral density;	chr8:78113797	chr8:78723796~78724136:-
BRCA	cis	rs7618501	1	rs3749241	ENSG00000228008.1	CTD-2330K9.3	-3.62	0.000306	0.0163	-0.11	-0.11	Intelligence (multi-trait analysis);	chr3:49706959	chr3:49903845~49916937:+
BRCA	cis	rs12960472	0.524	rs12456854	ENSG00000277324.1	RP11-850A17.1	3.62	0.000306	0.0163	0.15	0.11	Positive affect;	chr18:54435946	chr18:54268346~54270028:-
BRCA	cis	rs66887589	0.87	rs10518336	ENSG00000260091.1	RP11-33B1.4	-3.62	0.000306	0.0163	-0.09	-0.11	Diastolic blood pressure;	chr4:119601779	chr4:119409333~119410233:+
BRCA	cis	rs7267979	1	rs4815420	ENSG00000276952.1	RP5-965G21.6	-3.62	0.000306	0.0163	-0.14	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25403343	chr20:25284915~25285588:-
BRCA	cis	rs2288327	0.818	rs3829747	ENSG00000271011.1	RP11-171I2.5	3.62	0.000306	0.0163	0.21	0.11	Atrial fibrillation;	chr2:178532834	chr2:178577103~178577622:+
BRCA	cis	rs7267979	0.966	rs3827014	ENSG00000276952.1	RP5-965G21.6	-3.62	0.000306	0.0163	-0.14	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25390923	chr20:25284915~25285588:-
BRCA	cis	rs2288884	0.579	rs6509609	ENSG00000275055.1	CTC-471J1.11	-3.62	0.000306	0.0163	-0.16	-0.11	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:51970353	chr19:52049007~52049754:+
BRCA	cis	rs13256369	1	rs13267501	ENSG00000233609.3	RP11-62H7.2	3.62	0.000306	0.0163	0.12	0.11	Obesity-related traits;	chr8:8716548	chr8:8961200~8979025:+
BRCA	cis	rs13256369	0.95	rs13270006	ENSG00000233609.3	RP11-62H7.2	3.62	0.000306	0.0163	0.12	0.11	Obesity-related traits;	chr8:8716687	chr8:8961200~8979025:+
BRCA	cis	rs6696239	0.956	rs1390401	ENSG00000227711.2	RP11-275O4.5	-3.62	0.000306	0.0163	-0.15	-0.11	Height;	chr1:227610249	chr1:227509028~227520477:-
BRCA	cis	rs875971	1	rs6946143	ENSG00000271064.1	RP11-792A8.3	-3.62	0.000306	0.0163	-0.13	-0.11	Aortic root size;	chr7:66114735	chr7:66748838~66749077:-
BRCA	cis	rs7818688	1	rs10096455	ENSG00000245080.5	RP11-320N21.1	-3.62	0.000306	0.0163	-0.18	-0.11	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95029022	chr8:95066808~95073182:-
BRCA	cis	rs7818688	1	rs9297951	ENSG00000245080.5	RP11-320N21.1	-3.62	0.000306	0.0163	-0.18	-0.11	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95029209	chr8:95066808~95073182:-
BRCA	cis	rs7818688	1	rs11781040	ENSG00000245080.5	RP11-320N21.1	-3.62	0.000306	0.0163	-0.18	-0.11	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95029518	chr8:95066808~95073182:-
BRCA	cis	rs28714278	0.857	rs12164905	ENSG00000248508.5	SRP14-AS1	3.62	0.000306	0.0163	0.17	0.11	Mean corpuscular hemoglobin;	chr15:40008490	chr15:40039311~40067290:+
BRCA	cis	rs321358	0.731	rs547367	ENSG00000271390.1	RP11-89C3.3	-3.62	0.000306	0.0163	-0.16	-0.11	Body mass index;	chr11:111165382	chr11:111089870~111090368:-
BRCA	cis	rs6696239	1	rs6698409	ENSG00000227711.2	RP11-275O4.5	-3.62	0.000306	0.0163	-0.15	-0.11	Height;	chr1:227580657	chr1:227509028~227520477:-
BRCA	cis	rs4908769	0.66	rs301803	ENSG00000232912.4	RP5-1115A15.1	3.62	0.000306	0.0163	0.12	0.11	Allergy;	chr1:8438620	chr1:8424645~8434838:+
BRCA	cis	rs8114671	0.551	rs4911162	ENSG00000279253.1	RP4-614O4.13	-3.62	0.000306	0.0163	-0.13	-0.11	Height;	chr20:34823622	chr20:35262727~35264187:-
BRCA	cis	rs91731	0.607	rs2033186	ENSG00000249572.1	CTD-2203K17.1	-3.62	0.000306	0.0163	-0.21	-0.11	Lung function (FVC);	chr5:33256271	chr5:33424025~33440619:-
BRCA	cis	rs91731	0.92	rs2967090	ENSG00000249572.1	CTD-2203K17.1	-3.62	0.000306	0.0163	-0.21	-0.11	Lung function (FVC);	chr5:33257021	chr5:33424025~33440619:-
BRCA	cis	rs91731	0.736	rs2967085	ENSG00000249572.1	CTD-2203K17.1	-3.62	0.000306	0.0163	-0.21	-0.11	Lung function (FVC);	chr5:33260860	chr5:33424025~33440619:-
BRCA	cis	rs6840360	0.571	rs7695866	ENSG00000270265.1	RP11-731D1.4	-3.62	0.000306	0.0163	-0.13	-0.11	Intelligence (multi-trait analysis);	chr4:151566958	chr4:151333775~151353224:-
BRCA	cis	rs6708331	0.938	rs13389246	ENSG00000231024.1	AC092431.3	-3.62	0.000306	0.0164	-0.16	-0.11	Obesity-related traits;	chr2:70127099	chr2:69700192~69713847:-
BRCA	cis	rs3096299	0.606	rs8052103	ENSG00000261118.1	RP11-104N10.1	-3.62	0.000306	0.0164	-0.13	-0.11	Multiple myeloma (IgH translocation);	chr16:89474835	chr16:89492017~89504460:-
BRCA	cis	rs6088590	1	rs6119535	ENSG00000269202.1	RP4-614O4.12	-3.62	0.000306	0.0164	-0.12	-0.11	Coronary artery disease;	chr20:34854335	chr20:35201747~35203288:-
BRCA	cis	rs12220238	0.915	rs11001021	ENSG00000213731.2	RAB5CP1	-3.62	0.000306	0.0164	-0.17	-0.11	Soluble interleukin-2 receptor subunit alpha;	chr10:74379899	chr10:74423435~74424014:-
BRCA	cis	rs6893300	0.961	rs7447159	ENSG00000225051.5	HMGB3P22	3.62	0.000306	0.0164	0.15	0.11	Resting heart rate;	chr5:179750675	chr5:179679032~179694768:+
BRCA	cis	rs10029851	0.645	rs17039240	ENSG00000234492.4	RPL34-AS1	-3.62	0.000307	0.0164	-0.13	-0.11	Amyotrophic lateral sclerosis (sporadic);	chr4:108703926	chr4:108538190~108620460:-
BRCA	cis	rs7267979	0.932	rs928121	ENSG00000274414.1	RP5-965G21.4	-3.62	0.000307	0.0164	-0.13	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25554182	chr20:25239007~25245229:-
BRCA	cis	rs6017317	0.614	rs12479863	ENSG00000223891.4	OSER1-AS1	-3.62	0.000307	0.0164	-0.18	-0.11	Type 2 diabetes;	chr20:44279502	chr20:44210960~44226027:+
BRCA	cis	rs597539	0.652	rs569777	ENSG00000255741.1	RP11-757G1.5	-3.62	0.000307	0.0164	-0.16	-0.11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68939380	chr11:68941503~68942852:-
BRCA	cis	rs6142618	0.583	rs2235904	ENSG00000277692.1	RP11-358N2.2	-3.62	0.000307	0.0164	-0.12	-0.11	Inflammatory bowel disease;	chr20:32133909	chr20:32355053~32355734:+
BRCA	cis	rs2380205	0.538	rs11255774	ENSG00000232807.2	RP11-536K7.3	3.62	0.000307	0.0164	0.12	0.11	Breast cancer;	chr10:5897096	chr10:5934270~5945900:-
BRCA	cis	rs61931739	0.534	rs12371021	ENSG00000258794.3	DUX4L27	3.62	0.000307	0.0164	0.16	0.11	Morning vs. evening chronotype;	chr12:33909317	chr12:34208415~34209675:-
BRCA	cis	rs9467773	0.873	rs9295698	ENSG00000224843.5	LINC00240	-3.62	0.000307	0.0164	-0.12	-0.11	Intelligence (multi-trait analysis);	chr6:26565871	chr6:26956992~27023924:+
BRCA	cis	rs11085466	0.615	rs76695906	ENSG00000268081.1	RP11-678G14.2	-3.62	0.000307	0.0164	-0.18	-0.11	Colorectal or endometrial cancer;	chr19:21583908	chr19:21554640~21569237:-
BRCA	cis	rs8054556	1	rs6565173	ENSG00000183604.13	SMG1P5	-3.62	0.000307	0.0164	-0.11	-0.11	Autism spectrum disorder or schizophrenia;	chr16:29962846	chr16:30267553~30335374:-
BRCA	cis	rs10129255	0.518	rs8009612	ENSG00000211976.2	IGHV3-73	-3.62	0.000307	0.0164	-0.08	-0.11	Kawasaki disease;	chr14:106777510	chr14:106802694~106803233:-
BRCA	cis	rs465969	0.744	rs13220692	ENSG00000271789.1	RP5-1112D6.7	3.62	0.000307	0.0164	0.27	0.11	Psoriasis;	chr6:111455836	chr6:111297126~111298510:+
BRCA	cis	rs9467773	0.935	rs11752946	ENSG00000224843.5	LINC00240	-3.62	0.000307	0.0164	-0.13	-0.11	Intelligence (multi-trait analysis);	chr6:26560136	chr6:26956992~27023924:+
BRCA	cis	rs8098244	0.58	rs1620152	ENSG00000265752.2	RP11-403A21.1	3.62	0.000307	0.0164	0.12	0.11	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23678335	chr18:23957754~23982556:-
BRCA	cis	rs983392	0.792	rs558375	ENSG00000275344.1	MIR6503	-3.62	0.000307	0.0164	-0.11	-0.11	Alzheimer's disease (late onset);	chr11:60147656	chr11:60209071~60209156:-
BRCA	cis	rs4374383	0.631	rs1113418	ENSG00000243389.1	AC012442.5	-3.62	0.000307	0.0164	-0.14	-0.11	Hepatitis C induced liver fibrosis;	chr2:111949701	chr2:112589040~112614431:+
BRCA	cis	rs61352607	0.881	rs1106766	ENSG00000259125.1	RP11-545N8.3	-3.62	0.000307	0.0164	-0.16	-0.11	Triglycerides;	chr12:57415673	chr12:57144620~57147619:-
BRCA	cis	rs7107174	0.901	rs7941639	ENSG00000251323.2	RP11-452H21.4	-3.62	0.000307	0.0164	-0.16	-0.11	Testicular germ cell tumor;	chr11:78405913	chr11:78423982~78429836:-
BRCA	cis	rs67073037	0.955	rs67873458	ENSG00000230730.1	AC074011.2	-3.62	0.000307	0.0164	-0.15	-0.11	Breast cancer;Breast cancer (estrogen-receptor negative);	chr2:28896907	chr2:28633282~28664540:-
BRCA	cis	rs67073037	0.955	rs6721781	ENSG00000230730.1	AC074011.2	-3.62	0.000307	0.0164	-0.15	-0.11	Breast cancer;Breast cancer (estrogen-receptor negative);	chr2:28897164	chr2:28633282~28664540:-
BRCA	cis	rs7172809	0.643	rs907370	ENSG00000260139.5	CSPG4P13	-3.62	0.000307	0.0164	-0.13	-0.11	Glucose homeostasis traits;	chr15:77551930	chr15:77894684~77904674:+
BRCA	cis	rs7204230	1	rs12596712	ENSG00000261291.1	RP11-295M3.2	-3.62	0.000307	0.0164	-0.14	-0.11	Fibrinogen;	chr16:53192186	chr16:53168522~53169450:+
BRCA	cis	rs12546962	0.731	rs9329185	ENSG00000272267.2	RP11-375N15.2	-3.62	0.000307	0.0164	-0.14	-0.11	Body mass index;	chr8:9346915	chr8:9555144~9556520:-
BRCA	cis	rs11098499	1	rs58601355	ENSG00000225892.3	RP11-384K6.2	3.62	0.000307	0.0164	0.11	0.11	Corneal astigmatism;	chr4:119265212	chr4:118632274~118634759:+
BRCA	cis	rs58521262	0.516	rs1842018	ENSG00000268105.1	RP11-369G6.2	3.62	0.000307	0.0164	0.15	0.11	Testicular germ cell tumor;	chr19:22912431	chr19:23125665~23128543:+
BRCA	cis	rs709400	0.93	rs2274268	ENSG00000258735.1	LINC00637	3.62	0.000307	0.0164	0.14	0.11	Body mass index;	chr14:103563041	chr14:103847721~103858049:+
BRCA	cis	rs10129255	0.719	rs7156660	ENSG00000231475.3	IGHV4-31	-3.62	0.000307	0.0164	-0.09	-0.11	Kawasaki disease;	chr14:106673171	chr14:106349283~106349792:-
BRCA	cis	rs62025270	0.632	rs13379832	ENSG00000259367.1	RP11-815J21.4	3.62	0.000307	0.0164	0.11	0.11	Idiopathic pulmonary fibrosis;	chr15:85572669	chr15:85619623~85670948:-
BRCA	cis	rs943466	1	rs6933607	ENSG00000223837.2	BRD2-IT1	3.62	0.000307	0.0164	0.14	0.11	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;	chr6:33776220	chr6:32970232~32970886:+
BRCA	cis	rs943466	1	rs11754690	ENSG00000223837.2	BRD2-IT1	3.62	0.000307	0.0164	0.14	0.11	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;	chr6:33776380	chr6:32970232~32970886:+
BRCA	cis	rs943466	1	rs61662306	ENSG00000223837.2	BRD2-IT1	3.62	0.000307	0.0164	0.14	0.11	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;	chr6:33778920	chr6:32970232~32970886:+
BRCA	cis	rs8038465	0.638	rs12591473	ENSG00000260898.4	ADPGK-AS1	3.62	0.000307	0.0164	0.12	0.11	Liver enzyme levels (gamma-glutamyl transferase);	chr15:73675144	chr15:72782835~72798199:+
BRCA	cis	rs860295	0.58	rs66466805	ENSG00000225082.2	DAP3P1	-3.62	0.000307	0.0164	-0.15	-0.11	Body mass index;	chr1:155918875	chr1:155586644~155602197:+
BRCA	cis	rs4415084	0.966	rs34762678	ENSG00000272335.1	RP11-53O19.3	3.62	0.000307	0.0164	0.11	0.11	Breast cancer;	chr5:44705412	chr5:44826076~44828592:+
BRCA	cis	rs4700393	0.542	rs4370226	ENSG00000272308.1	RP11-231G3.1	-3.62	0.000307	0.0164	-0.14	-0.11	Intelligence (multi-trait analysis);	chr5:60705295	chr5:60866457~60866935:-
BRCA	cis	rs7674212	0.507	rs223471	ENSG00000248740.4	RP11-328K4.1	3.62	0.000307	0.0164	0.13	0.11	Type 2 diabetes;	chr4:102777629	chr4:103256159~103453658:+
BRCA	cis	rs8180040	0.966	rs2101247	ENSG00000280667.1	Y_RNA	-3.62	0.000307	0.0164	-0.13	-0.11	Colorectal cancer;	chr3:47452813	chr3:47501083~47501182:+
BRCA	cis	rs7735319	0.506	rs6877481	ENSG00000249572.1	CTD-2203K17.1	3.62	0.000307	0.0164	0.14	0.11	Systolic blood pressure;	chr5:33173212	chr5:33424025~33440619:-
BRCA	cis	rs947583	0.955	rs7760254	ENSG00000231028.7	LINC00271	3.62	0.000307	0.0164	0.12	0.11	Phosphorus levels;	chr6:135811157	chr6:135497801~135716055:+
BRCA	cis	rs10129255	0.5	rs7157975	ENSG00000211976.2	IGHV3-73	-3.62	0.000307	0.0164	-0.08	-0.11	Kawasaki disease;	chr14:106804049	chr14:106802694~106803233:-
BRCA	cis	rs6736093	1	rs79688911	ENSG00000236307.2	EEF1E1P1	-3.62	0.000307	0.0164	-0.14	-0.11	Coronary artery disease;	chr2:111900330	chr2:111887914~111888741:+
BRCA	cis	rs5762752	0.555	rs134527	ENSG00000235954.5	TTC28-AS1	3.62	0.000307	0.0164	0.12	0.11	Optic disc area;	chr22:28380003	chr22:27919376~28008581:+
BRCA	cis	rs4835473	0.868	rs4629390	ENSG00000246448.2	RP13-578N3.3	-3.62	0.000307	0.0164	-0.13	-0.11	Immature fraction of reticulocytes;	chr4:143735302	chr4:143700257~143865072:+
BRCA	cis	rs77437330	0.73	rs2269618	ENSG00000231889.6	TRAF3IP2-AS1	-3.62	0.000308	0.0164	-0.24	-0.11	Skin pigmentation;	chr6:111719463	chr6:111483511~111598302:+
BRCA	cis	rs8180040	0.681	rs9818382	ENSG00000280667.1	Y_RNA	3.62	0.000308	0.0164	0.12	0.11	Colorectal cancer;	chr3:47151544	chr3:47501083~47501182:+
BRCA	cis	rs6088590	0.965	rs6087639	ENSG00000276073.1	RP5-1125A11.7	-3.62	0.000308	0.0164	-0.13	-0.11	Coronary artery disease;	chr20:34856063	chr20:33985617~33988989:-
BRCA	cis	rs848087	0.564	rs848097	ENSG00000200385.1	SNORA42	3.62	0.000308	0.0164	0.09	0.11	Breast cancer;	chr14:36792277	chr14:37720425~37720561:+
BRCA	cis	rs875971	0.929	rs778712	ENSG00000271064.1	RP11-792A8.3	-3.62	0.000308	0.0164	-0.13	-0.11	Aortic root size;	chr7:66384991	chr7:66748838~66749077:-
BRCA	cis	rs10411161	1	rs10411161	ENSG00000269483.1	AC006272.1	3.62	0.000308	0.0164	0.19	0.11	Breast cancer;	chr19:51869723	chr19:51839924~51843324:-
BRCA	cis	rs7487075	0.78	rs10785620	ENSG00000274723.1	RP11-618L22.1	3.62	0.000308	0.0164	0.14	0.11	Itch intensity from mosquito bite;	chr12:46343469	chr12:46970504~46972155:+
BRCA	cis	rs9402743	0.632	rs6570038	ENSG00000231028.7	LINC00271	-3.62	0.000308	0.0164	-0.12	-0.11	Systemic lupus erythematosus;	chr6:135775465	chr6:135497801~135716055:+
BRCA	cis	rs10791097	0.694	rs1050071	ENSG00000254842.5	RP11-890B15.2	3.62	0.000308	0.0164	0.14	0.11	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:130877336	chr11:130844191~130865561:-
BRCA	cis	rs6071166	0.708	rs9679799	ENSG00000224635.1	RP4-564F22.5	3.62	0.000308	0.0164	0.13	0.11	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38702935	chr20:38406011~38416797:-
BRCA	cis	rs2562456	0.793	rs3853837	ENSG00000268117.1	VN1R84P	3.62	0.000308	0.0164	0.17	0.11	Pain;	chr19:21419172	chr19:21719801~21720035:-
BRCA	cis	rs2562456	0.793	rs3853838	ENSG00000268117.1	VN1R84P	3.62	0.000308	0.0164	0.17	0.11	Pain;	chr19:21419192	chr19:21719801~21720035:-
BRCA	cis	rs2562456	0.833	rs62110426	ENSG00000268117.1	VN1R84P	3.62	0.000308	0.0164	0.17	0.11	Pain;	chr19:21420124	chr19:21719801~21720035:-
BRCA	cis	rs8099594	0.64	rs7505791	ENSG00000266696.1	RP11-30L3.2	3.62	0.000308	0.0164	0.13	0.11	Height;	chr18:49348631	chr18:49205912~49208781:+
BRCA	cis	rs7914558	1	rs10883824	ENSG00000213277.3	MARCKSL1P1	3.62	0.000308	0.0164	0.12	0.11	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103053140	chr10:103175554~103176094:+
BRCA	cis	rs67478160	0.571	rs1155751	ENSG00000269910.1	RP11-73M18.10	3.62	0.000308	0.0164	0.11	0.11	Schizophrenia;	chr14:103820210	chr14:103694516~103695050:-
BRCA	cis	rs7475343	0.538	rs7917079	ENSG00000224034.1	RP11-445P17.8	3.62	0.000308	0.0164	0.19	0.11	Intelligence;	chr10:5116283	chr10:5266033~5271236:-
BRCA	cis	rs7475343	0.538	rs2398195	ENSG00000224034.1	RP11-445P17.8	3.62	0.000308	0.0164	0.19	0.11	Intelligence;	chr10:5116417	chr10:5266033~5271236:-
BRCA	cis	rs7475343	0.505	rs1892404	ENSG00000224034.1	RP11-445P17.8	3.62	0.000308	0.0164	0.19	0.11	Intelligence;	chr10:5116851	chr10:5266033~5271236:-
BRCA	cis	rs853679	1	rs6901575	ENSG00000216901.1	AL022393.7	3.62	0.000308	0.0164	0.19	0.11	Depression;	chr6:28283207	chr6:28176188~28176674:+
BRCA	cis	rs7131987	0.903	rs7974221	ENSG00000257599.1	OVCH1-AS1	-3.62	0.000308	0.0164	-0.14	-0.11	QT interval;	chr12:29246515	chr12:29389294~29487488:+
BRCA	cis	rs9860340	0.609	rs4630962	ENSG00000239572.1	RP11-451B8.1	-3.62	0.000308	0.0164	-0.14	-0.11	Electroencephalographic traits in alcoholism;	chr3:87789838	chr3:87731402~87793629:-
BRCA	cis	rs4722585	0.533	rs2237335	ENSG00000273237.1	CTB-119C2.1	-3.62	0.000308	0.0164	-0.14	-0.11	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);	chr7:26160593	chr7:26173533~26174945:-
BRCA	cis	rs2625529	0.617	rs8557	ENSG00000261187.1	RP11-1007O24.2	-3.62	0.000308	0.0164	-0.12	-0.11	Red blood cell count;	chr15:71823392	chr15:72465128~72466262:-
BRCA	cis	rs6696239	0.78	rs10799424	ENSG00000227711.2	RP11-275O4.5	-3.62	0.000308	0.0164	-0.15	-0.11	Height;	chr1:227567774	chr1:227509028~227520477:-
BRCA	cis	rs890448	0.796	rs1596061	ENSG00000254531.1	FLJ20021	3.62	0.000308	0.0164	0.13	0.11	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101379218	chr4:101347780~101348883:+
BRCA	cis	rs11089937	0.585	rs6001229	ENSG00000279278.1	CH17-264L24.1	-3.62	0.000308	0.0164	-0.1	-0.11	Periodontitis (PAL4Q3);	chr22:22187693	chr22:22264601~22273020:+
BRCA	cis	rs1998359	0.501	rs8010816	ENSG00000259087.4	RP11-356O9.2	-3.62	0.000308	0.0164	-0.11	-0.11	Self-reported allergy;	chr14:37709735	chr14:37556158~37567095:-
BRCA	cis	rs987724	0.57	rs4680318	ENSG00000244515.1	KRT18P34	-3.62	0.000308	0.0164	-0.18	-0.11	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156953850	chr3:157162663~157163932:-
BRCA	cis	rs987724	0.515	rs4234315	ENSG00000244515.1	KRT18P34	-3.62	0.000308	0.0164	-0.18	-0.11	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156955749	chr3:157162663~157163932:-
BRCA	cis	rs7089973	0.872	rs7072364	ENSG00000236799.1	RP11-383C6.2	-3.62	0.000308	0.0164	-0.14	-0.11	Bipolar disorder or attention deficit hyperactivity disorder;	chr10:114861081	chr10:114994657~114996593:+
BRCA	cis	rs7226408	0.842	rs2033117	ENSG00000267707.2	RP11-95O2.5	3.62	0.000308	0.0164	0.16	0.11	Obesity-related traits;	chr18:36769999	chr18:37243776~37247506:+
BRCA	cis	rs1910358	0.919	rs1960853	ENSG00000248874.4	C5orf17	-3.62	0.000308	0.0164	-0.17	-0.11	Venous thromboembolism (SNP x SNP interaction);	chr5:23872606	chr5:23951348~24178263:+
BRCA	cis	rs1910358	0.919	rs1960854	ENSG00000248874.4	C5orf17	-3.62	0.000308	0.0164	-0.17	-0.11	Venous thromboembolism (SNP x SNP interaction);	chr5:23872617	chr5:23951348~24178263:+
BRCA	cis	rs1009077	0.563	rs10518335	ENSG00000245958.5	RP11-33B1.1	3.62	0.000308	0.0164	0.12	0.11	Endometriosis;	chr4:119601017	chr4:119454791~119552025:+
BRCA	cis	rs2048656	0.605	rs7814507	ENSG00000233609.3	RP11-62H7.2	3.62	0.000308	0.0164	0.11	0.11	Schizophrenia;	chr8:9789050	chr8:8961200~8979025:+
BRCA	cis	rs7267979	1	rs2500418	ENSG00000274973.1	RP13-401N8.7	3.62	0.000308	0.0164	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25401632	chr20:25845497~25845862:+
BRCA	cis	rs6012564	0.783	rs6125575	ENSG00000230758.1	SNAP23P	3.62	0.000308	0.0164	0.13	0.11	Anger;	chr20:49159159	chr20:49038357~49038602:-
BRCA	cis	rs6840360	0.809	rs6847303	ENSG00000251611.1	RP11-610P16.1	3.62	0.000308	0.0164	0.1	0.11	Intelligence (multi-trait analysis);	chr4:151809069	chr4:151407551~151408835:-
BRCA	cis	rs7520050	0.966	rs7550746	ENSG00000281133.1	AL355480.3	3.62	0.000308	0.0164	0.13	0.11	Reticulocyte count;Red blood cell count;	chr1:45886047	chr1:45580892~45580996:-
BRCA	cis	rs7617480	0.519	rs6790914	ENSG00000272434.1	RP13-131K19.6	-3.62	0.000308	0.0164	-0.14	-0.11	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:49168885	chr3:49029316~49029706:+
BRCA	cis	rs9400180	0.84	rs10484902	ENSG00000271734.1	RP1-111B22.3	-3.62	0.000309	0.0164	-0.15	-0.11	Major depressive disorder;	chr6:108054377	chr6:108030249~108030718:-
BRCA	cis	rs962856	0.866	rs13387185	ENSG00000236605.1	AC023115.4	3.62	0.000309	0.0165	0.13	0.11	Pancreatic cancer;	chr2:67401517	chr2:67324627~67325304:+
BRCA	cis	rs2880765	0.835	rs7169632	ENSG00000230373.7	GOLGA6L5P	3.62	0.000309	0.0165	0.12	0.11	Coronary artery disease;	chr15:85501436	chr15:84507885~84516814:-
BRCA	cis	rs6723162	0.51	rs4852730	ENSG00000237751.2	LINC01143	-3.62	0.000309	0.0165	-0.16	-0.11	Neurocognitive impairment in HIV-1 infection (dichotomous);	chr2:70917475	chr2:70887871~70889959:+
BRCA	cis	rs6723162	0.51	rs3771393	ENSG00000237751.2	LINC01143	-3.62	0.000309	0.0165	-0.16	-0.11	Neurocognitive impairment in HIV-1 infection (dichotomous);	chr2:70918116	chr2:70887871~70889959:+
BRCA	cis	rs6893300	0.961	rs7444006	ENSG00000225051.5	HMGB3P22	3.62	0.000309	0.0165	0.15	0.11	Resting heart rate;	chr5:179750701	chr5:179679032~179694768:+
BRCA	cis	rs453301	0.653	rs7016139	ENSG00000253981.4	ALG1L13P	-3.62	0.000309	0.0165	-0.13	-0.11	Joint mobility (Beighton score);	chr8:9037960	chr8:8236003~8244667:-
BRCA	cis	rs8180040	0.627	rs6442059	ENSG00000280667.1	Y_RNA	3.62	0.000309	0.0165	0.12	0.11	Colorectal cancer;	chr3:47145585	chr3:47501083~47501182:+
BRCA	cis	rs921968	0.643	rs2278529	ENSG00000273466.1	RP11-548H3.1	3.62	0.000309	0.0165	0.11	0.11	Mean corpuscular hemoglobin concentration;	chr2:218637409	chr2:218633256~218634014:-
BRCA	cis	rs12264252	0.767	rs7902355	ENSG00000225484.5	NUTM2B-AS1	-3.62	0.000309	0.0165	-0.18	-0.11	Coronary artery disease;	chr10:80489352	chr10:79663088~79826594:-
BRCA	cis	rs7267979	1	rs6050632	ENSG00000276952.1	RP5-965G21.6	3.62	0.000309	0.0165	0.14	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25451965	chr20:25284915~25285588:-
BRCA	cis	rs4950322	0.58	rs7515160	ENSG00000230832.3	RP11-325P15.2	-3.62	0.000309	0.0165	-0.17	-0.11	Protein quantitative trait loci;	chr1:147120714	chr1:147082338~147083578:-
BRCA	cis	rs12534093	0.96	rs11769151	ENSG00000234286.1	AC006026.13	-3.62	0.000309	0.0165	-0.17	-0.11	Infant length;Height;	chr7:23464689	chr7:23680195~23680786:-
BRCA	cis	rs875971	0.522	rs34973832	ENSG00000232546.1	RP11-458F8.1	-3.62	0.000309	0.0165	-0.09	-0.11	Aortic root size;	chr7:65931217	chr7:66848496~66858136:+
BRCA	cis	rs4243971	0.516	rs6141720	ENSG00000275576.1	RP5-836N17.4	-3.62	0.000309	0.0165	-0.12	-0.11	Inflammatory bowel disease;Crohn's disease;	chr20:32431922	chr20:32116171~32116629:+
BRCA	cis	rs36093844	0.752	rs56396016	ENSG00000279742.1	RP11-700A24.1	-3.62	0.000309	0.0165	-0.18	-0.11	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85885347	chr11:85852557~85854943:-
BRCA	cis	rs9951698	0.678	rs11080620	ENSG00000266969.1	RP11-773H22.4	-3.62	0.000309	0.0165	-0.15	-0.11	Intelligence (multi-trait analysis);	chr18:13029069	chr18:12984694~12991173:-
BRCA	cis	rs4664293	0.605	rs6741498	ENSG00000224152.1	AC009506.1	3.62	0.000309	0.0165	0.12	0.11	Monocyte percentage of white cells;	chr2:159698111	chr2:159615296~159617082:+
BRCA	cis	rs61931739	0.5	rs12371415	ENSG00000258794.3	DUX4L27	3.62	0.000309	0.0165	0.16	0.11	Morning vs. evening chronotype;	chr12:34368427	chr12:34208415~34209675:-
BRCA	cis	rs877819	0.697	rs6537582	ENSG00000228403.1	RP11-563N6.6	-3.62	0.000309	0.0165	-0.12	-0.11	Systemic lupus erythematosus;	chr10:48838600	chr10:48878022~48878649:+
BRCA	cis	rs4965598	0.518	rs7172834	ENSG00000270127.2	RP11-526I2.5	-3.62	0.000309	0.0165	-0.14	-0.11	Height;	chr15:100253967	chr15:100547765~100550153:-
BRCA	cis	rs1861050	0.546	rs16892054	ENSG00000214846.4	RP11-115L11.1	3.62	0.000309	0.0165	0.25	0.11	Conduct disorder;	chr4:15494646	chr4:15730962~15731627:-
BRCA	cis	rs295490	0.748	rs58234450	ENSG00000178631.7	ACTG1P1	-3.62	0.000309	0.0165	-0.21	-0.11	PR interval in Tripanosoma cruzi seropositivity;	chr3:139481465	chr3:139493809~139494937:+
BRCA	cis	rs6671200	0.573	rs3738171	ENSG00000228852.5	RP11-57H12.5	-3.62	0.000309	0.0165	-0.14	-0.11	Stearic acid (18:0) levels;	chr1:95234038	chr1:95243167~95278940:-
BRCA	cis	rs10911902	0.643	rs7556543	ENSG00000229739.2	RP11-295K2.3	-3.62	0.000309	0.0165	-0.16	-0.11	Schizophrenia;	chr1:186301287	chr1:186435161~186470291:+
BRCA	cis	rs7781266	0.79	rs17654334	ENSG00000226205.1	AC007790.4	3.62	0.000309	0.0165	0.17	0.11	Educational attainment (college completion);	chr7:133398480	chr7:133732493~133733595:-
BRCA	cis	rs62025270	0.688	rs62022940	ENSG00000259367.1	RP11-815J21.4	3.62	0.000309	0.0165	0.1	0.11	Idiopathic pulmonary fibrosis;	chr15:85709289	chr15:85619623~85670948:-
BRCA	cis	rs11700980	0.636	rs73190119	ENSG00000232855.5	AF131217.1	3.62	0.000309	0.0165	0.18	0.11	QRS complex (12-leadsum);	chr21:28931363	chr21:28439346~28674848:-
BRCA	cis	rs863345	0.564	rs7515245	ENSG00000229914.1	RP11-404O13.4	-3.62	0.000309	0.0165	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158524320	chr1:158195633~158196131:-
BRCA	cis	rs863345	0.604	rs10797022	ENSG00000229914.1	RP11-404O13.4	-3.62	0.000309	0.0165	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158524403	chr1:158195633~158196131:-
BRCA	cis	rs13434995	0.513	rs972446	ENSG00000273257.1	RP11-177J6.1	3.62	0.000309	0.0165	0.17	0.11	Adiponectin levels;	chr4:55569581	chr4:55387949~55388271:+
BRCA	cis	rs13434995	0.513	rs11732481	ENSG00000273257.1	RP11-177J6.1	3.62	0.000309	0.0165	0.17	0.11	Adiponectin levels;	chr4:55570212	chr4:55387949~55388271:+
BRCA	cis	rs71520386	0.807	rs10263435	ENSG00000179428.2	AC073072.5	3.62	0.000309	0.0165	0.15	0.11	Fibrinogen levels;	chr7:22790243	chr7:22725395~22727620:-
BRCA	cis	rs10266483	0.515	rs17689514	ENSG00000227986.1	TRIM60P18	3.62	0.000309	0.0165	0.14	0.11	Response to statin therapy;	chr7:64279269	chr7:64355078~64356199:+
BRCA	cis	rs713477	0.692	rs10146713	ENSG00000186615.9	KTN1-AS1	-3.62	0.000309	0.0165	-0.13	-0.11	Pediatric bone mineral content (femoral neck);	chr14:55444879	chr14:55499278~55580110:-
BRCA	cis	rs17270561	0.609	rs4711096	ENSG00000272462.2	U91328.19	-3.62	0.000309	0.0165	-0.14	-0.11	Iron status biomarkers;	chr6:25726826	chr6:25992662~26001775:+
BRCA	cis	rs875971	0.66	rs7807944	ENSG00000275400.1	RP4-756H11.5	3.62	0.000309	0.0165	0.13	0.11	Aortic root size;	chr7:66622208	chr7:66553805~66554199:-
BRCA	cis	rs4650943	0.586	rs10798450	ENSG00000227740.1	RP11-318C24.2	-3.62	0.000309	0.0165	-0.11	-0.11	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in inactive individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr1:176298908	chr1:175904762~175920513:-
BRCA	cis	rs35306767	0.903	rs13377166	ENSG00000229869.1	RP11-363N22.2	-3.62	0.000309	0.0165	-0.17	-0.11	Eosinophil percentage of granulocytes;	chr10:840319	chr10:933026~942743:+
BRCA	cis	rs1730008	0.691	rs34434866	ENSG00000279311.1	RP11-170K4.2	3.62	0.000309	0.0165	0.14	0.11	Lobe attachment (rater-scored or self-reported);	chr3:158380528	chr3:158869898~158871821:+
BRCA	cis	rs1555133	0.694	rs3787373	ENSG00000275576.1	RP5-836N17.4	-3.62	0.000309	0.0165	-0.13	-0.11	Monocyte count;	chr20:32285519	chr20:32116171~32116629:+
BRCA	cis	rs763121	0.962	rs138711	ENSG00000279738.1	RP5-1014D13.2	3.62	0.00031	0.0165	0.14	0.11	Menopause (age at onset);	chr22:38743908	chr22:37876148~37895563:+
BRCA	cis	rs2338971	0.571	rs263914	ENSG00000260940.1	RP4-575N6.5	3.62	0.00031	0.0165	0.15	0.11	Parkinson's disease;	chr1:101510997	chr1:101243158~101243749:+
BRCA	cis	rs3770752	0.897	rs1158218	ENSG00000272054.1	RP11-423P10.2	-3.62	0.00031	0.0165	-0.1	-0.11	Schizophrenia;	chr2:37319702	chr2:37208875~37212677:+
BRCA	cis	rs9921338	0.886	rs3931015	ENSG00000262636.1	CTD-3088G3.4	3.62	0.00031	0.0165	0.17	0.11	Vein graft stenosis in coronary artery bypass grafting;	chr16:11321782	chr16:11380859~11381118:-
BRCA	cis	rs1348850	0.914	rs4893957	ENSG00000280374.1	RP11-337N6.3	3.62	0.00031	0.0165	0.15	0.11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177515681	chr2:177317715~177318471:-
BRCA	cis	rs17801127	0.901	rs16827293	ENSG00000231969.1	AC144449.1	-3.62	0.00031	0.0165	-0.19	-0.11	Liver enzyme levels (alanine transaminase);	chr2:149652818	chr2:149587196~149848233:+
BRCA	cis	rs875971	0.862	rs778720	ENSG00000106610.13	STAG3L4	3.62	0.00031	0.0165	0.15	0.11	Aortic root size;	chr7:66381288	chr7:67302621~67321526:+
BRCA	cis	rs7615952	0.688	rs9754526	ENSG00000248787.1	RP11-666A20.4	-3.62	0.00031	0.0165	-0.17	-0.11	Blood pressure (smoking interaction);	chr3:125824023	chr3:125908005~125910272:-
BRCA	cis	rs4950322	0.58	rs17359629	ENSG00000227242.3	NBPF13P	-3.62	0.00031	0.0165	-0.14	-0.11	Protein quantitative trait loci;	chr1:147121537	chr1:147021320~147124525:-
BRCA	cis	rs2562456	0.754	rs11666213	ENSG00000268117.1	VN1R84P	3.62	0.00031	0.0165	0.17	0.11	Pain;	chr19:21422843	chr19:21719801~21720035:-
BRCA	cis	rs6672530	0.518	rs11484723	ENSG00000227711.2	RP11-275O4.5	-3.62	0.00031	0.0165	-0.13	-0.11	Hip circumference adjusted for BMI;	chr1:227715357	chr1:227509028~227520477:-
BRCA	cis	rs62025270	0.547	rs1026722	ENSG00000259367.1	RP11-815J21.4	-3.62	0.00031	0.0165	-0.09	-0.11	Idiopathic pulmonary fibrosis;	chr15:85576168	chr15:85619623~85670948:-
BRCA	cis	rs1910358	0.919	rs34315763	ENSG00000248874.4	C5orf17	-3.62	0.00031	0.0165	-0.17	-0.11	Venous thromboembolism (SNP x SNP interaction);	chr5:23868813	chr5:23951348~24178263:+
BRCA	cis	rs683250	0.629	rs669290	ENSG00000254551.1	RP11-727A23.7	3.62	0.00031	0.0165	0.14	0.11	Subcortical brain region volumes;	chr11:83238015	chr11:83209431~83213379:-
BRCA	cis	rs683250	0.629	rs573053	ENSG00000254551.1	RP11-727A23.7	3.62	0.00031	0.0165	0.14	0.11	Subcortical brain region volumes;	chr11:83239931	chr11:83209431~83213379:-
BRCA	cis	rs11123694	1	rs11123694	ENSG00000228763.1	AC010095.5	-3.62	0.00031	0.0165	-0.12	-0.11	Mean platelet volume;	chr2:108448107	chr2:108676795~108678601:-
BRCA	cis	rs4703129	1	rs1550808	ENSG00000246763.5	RGMB-AS1	-3.62	0.00031	0.0165	-0.13	-0.11	Asperger disorder;	chr5:98556562	chr5:98769618~98773469:-
BRCA	cis	rs12439619	0.846	rs62011975	ENSG00000259429.4	UBE2Q2P2	-3.62	0.00031	0.0165	-0.14	-0.11	Intelligence (multi-trait analysis);	chr15:82159213	chr15:82355142~82420075:+
BRCA	cis	rs736408	0.924	rs2535629	ENSG00000242142.1	SERBP1P3	3.62	0.00031	0.0165	0.13	0.11	Bipolar disorder;	chr3:52799203	chr3:53064283~53065091:-
BRCA	cis	rs62458065	0.85	rs62458098	ENSG00000273014.1	RP11-225B17.2	-3.62	0.00031	0.0165	-0.18	-0.11	Metabolite levels (HVA/MHPG ratio);	chr7:32431517	chr7:32758882~32759353:+
BRCA	cis	rs8114671	0.805	rs4616	ENSG00000261582.1	RP4-614O4.11	3.62	0.00031	0.0165	0.11	0.11	Height;	chr20:35002555	chr20:35267885~35280043:-
BRCA	cis	rs875971	0.8	rs427557	ENSG00000271064.1	RP11-792A8.3	-3.62	0.00031	0.0165	-0.13	-0.11	Aortic root size;	chr7:66054263	chr7:66748838~66749077:-
BRCA	cis	rs875971	1	rs6979382	ENSG00000271064.1	RP11-792A8.3	-3.62	0.00031	0.0165	-0.13	-0.11	Aortic root size;	chr7:66421388	chr7:66748838~66749077:-
BRCA	cis	rs875971	1	rs6961990	ENSG00000271064.1	RP11-792A8.3	-3.62	0.00031	0.0165	-0.13	-0.11	Aortic root size;	chr7:66423583	chr7:66748838~66749077:-
BRCA	cis	rs80226907	0.634	rs74968826	ENSG00000186615.9	KTN1-AS1	-3.62	0.00031	0.0165	-0.24	-0.11	Mean platelet volume;	chr14:55449257	chr14:55499278~55580110:-
BRCA	cis	rs3015497	0.673	rs4391968	ENSG00000259113.1	RP11-406H23.2	-3.62	0.00031	0.0165	-0.12	-0.11	Mean platelet volume;	chr14:50707714	chr14:50448807~50456742:+
BRCA	cis	rs587080	0.559	rs12364730	ENSG00000245532.5	NEAT1	3.62	0.00031	0.0165	0.13	0.11	Plateletcrit;	chr11:65460807	chr11:65422774~65445540:+
BRCA	cis	rs240993	0.516	rs414763	ENSG00000271789.1	RP5-1112D6.7	-3.62	0.00031	0.0165	-0.17	-0.11	Inflammatory skin disease;Psoriasis;	chr6:111324561	chr6:111297126~111298510:+
BRCA	cis	rs10504130	0.569	rs34213209	ENSG00000272076.1	RP11-11C20.3	3.62	0.00031	0.0165	0.16	0.11	Venous thromboembolism (SNP x SNP interaction);	chr8:51773341	chr8:51810110~51810681:-
BRCA	cis	rs12612435	0.784	rs6738835	ENSG00000226806.1	AC011893.3	3.62	0.00031	0.0165	0.13	0.11	Takotsubo syndrome;	chr2:136381978	chr2:135820191~135823087:+
BRCA	cis	rs35123781	1	rs601324	ENSG00000250635.1	CTD-3224K15.2	-3.62	0.00031	0.0165	-0.12	-0.11	Schizophrenia;	chr5:139677594	chr5:139648999~139649728:-
BRCA	cis	rs35123781	1	rs600848	ENSG00000250635.1	CTD-3224K15.2	-3.62	0.00031	0.0165	-0.12	-0.11	Schizophrenia;	chr5:139677685	chr5:139648999~139649728:-
BRCA	cis	rs6088590	0.648	rs6058105	ENSG00000275784.1	RP5-1125A11.6	-3.62	0.00031	0.0165	-0.12	-0.11	Coronary artery disease;	chr20:34683915	chr20:33989480~33991818:-
BRCA	cis	rs6479874	1	rs2879550	ENSG00000223502.1	RP11-96B5.3	-3.62	0.00031	0.0165	-0.2	-0.11	Migraine;	chr10:50995464	chr10:51062579~51068553:-
BRCA	cis	rs890448	0.693	rs2433309	ENSG00000254531.1	FLJ20021	3.62	0.00031	0.0165	0.13	0.11	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101436381	chr4:101347780~101348883:+
BRCA	cis	rs9638182	1	rs1178977	ENSG00000274080.1	CTA-315H11.2	3.62	0.00031	0.0165	0.21	0.11	Triglycerides;	chr7:73442719	chr7:73609262~73611502:-
BRCA	cis	rs875971	0.66	rs79009421	ENSG00000275400.1	RP4-756H11.5	3.62	0.00031	0.0165	0.13	0.11	Aortic root size;	chr7:66603522	chr7:66553805~66554199:-
BRCA	cis	rs67073037	0.955	rs12620306	ENSG00000230730.1	AC074011.2	-3.62	0.00031	0.0165	-0.15	-0.11	Breast cancer;Breast cancer (estrogen-receptor negative);	chr2:28910734	chr2:28633282~28664540:-
BRCA	cis	rs67073037	0.91	rs4666134	ENSG00000230730.1	AC074011.2	-3.62	0.00031	0.0165	-0.15	-0.11	Breast cancer;Breast cancer (estrogen-receptor negative);	chr2:28913787	chr2:28633282~28664540:-
BRCA	cis	rs67073037	0.955	rs4273183	ENSG00000230730.1	AC074011.2	-3.62	0.00031	0.0165	-0.15	-0.11	Breast cancer;Breast cancer (estrogen-receptor negative);	chr2:28915570	chr2:28633282~28664540:-
BRCA	cis	rs9494145	0.526	rs9494154	ENSG00000232876.1	CTA-212D2.2	3.62	0.00031	0.0165	0.17	0.11	Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count;	chr6:135146867	chr6:135055033~135060550:+
BRCA	cis	rs2243480	0.706	rs34466769	ENSG00000273024.4	INTS4P2	3.62	0.00031	0.0165	0.17	0.11	Diabetic kidney disease;	chr7:65988305	chr7:65647864~65715661:+
BRCA	cis	rs4835473	0.932	rs17018500	ENSG00000246448.2	RP13-578N3.3	-3.62	0.00031	0.0165	-0.12	-0.11	Immature fraction of reticulocytes;	chr4:143824849	chr4:143700257~143865072:+
BRCA	cis	rs801193	1	rs2659915	ENSG00000265600.1	AC006480.1	-3.62	0.000311	0.0165	-0.13	-0.11	Aortic root size;	chr7:66688114	chr7:67356680~67356779:+
BRCA	cis	rs8105895	0.799	rs10426159	ENSG00000269345.1	VN1R85P	3.62	0.000311	0.0165	0.16	0.11	Body mass index (change over time);	chr19:22084522	chr19:22174766~22175191:-
BRCA	cis	rs2965260	0.621	rs117943561	ENSG00000269051.4	CTD-2245F17.3	3.62	0.000311	0.0165	0.19	0.11	IgG glycosylation;	chr19:53261469	chr19:53197111~53211015:+
BRCA	cis	rs2243480	1	rs1039664	ENSG00000226767.1	RP11-328P23.3	-3.62	0.000311	0.0165	-0.19	-0.11	Diabetic kidney disease;	chr7:65984729	chr7:65508773~65508944:-
BRCA	cis	rs957448	1	rs1992370	ENSG00000261437.1	RP11-22C11.2	3.62	0.000311	0.0165	0.12	0.11	Nonsyndromic cleft lip with cleft palate;	chr8:94546466	chr8:94637285~94639467:-
BRCA	cis	rs2642442	0.962	rs2642439	ENSG00000257551.1	HLX-AS1	-3.62	0.000311	0.0165	-0.13	-0.11	Cholesterol, total;LDL cholesterol;	chr1:220797157	chr1:220832763~220880140:-
BRCA	cis	rs801193	0.569	rs10950050	ENSG00000229886.1	RP5-1132H15.3	3.62	0.000311	0.0165	0.12	0.11	Aortic root size;	chr7:66774601	chr7:66025126~66031544:-
BRCA	cis	rs17214007	0.877	rs4541094	ENSG00000279866.1	CTB-193M12.4	3.62	0.000311	0.0165	0.17	0.11	Cognitive function;	chr16:15776878	chr16:15704410~15705984:+
BRCA	cis	rs6120849	0.707	rs752075	ENSG00000202150.1	RNU6-407P	3.62	0.000311	0.0165	0.16	0.11	Protein C levels;	chr20:35003788	chr20:35030317~35030420:-
BRCA	cis	rs6120849	0.754	rs752448	ENSG00000202150.1	RNU6-407P	3.62	0.000311	0.0165	0.16	0.11	Protein C levels;	chr20:35004445	chr20:35030317~35030420:-
BRCA	cis	rs7405404	0.672	rs6498448	ENSG00000276564.1	CTA-276F8.1	3.62	0.000311	0.0166	0.12	0.11	Bipolar disorder lithium response (categorical) or schizophrenia;Schizophrenia;	chr16:13645962	chr16:14150833~14153235:+
BRCA	cis	rs860295	0.812	rs12081192	ENSG00000246203.2	RP11-29H23.5	-3.62	0.000311	0.0166	-0.13	-0.11	Body mass index;	chr1:155768253	chr1:155614726~155660245:-
BRCA	cis	rs2395128	0.667	rs10824253	ENSG00000213731.2	RAB5CP1	3.62	0.000311	0.0166	0.2	0.11	Ulcerative colitis;Inflammatory bowel disease;	chr10:74965105	chr10:74423435~74424014:-
BRCA	cis	rs4950322	0.518	rs4950306	ENSG00000237188.3	RP11-337C18.8	3.62	0.000311	0.0166	0.14	0.11	Protein quantitative trait loci;	chr1:147117838	chr1:147172771~147211568:+
BRCA	cis	rs6714710	0.603	rs4311104	ENSG00000228486.8	LINC01125	-3.62	0.000311	0.0166	-0.1	-0.11	Posterior cortical atrophy and Alzheimer's disease;	chr2:97808339	chr2:97664217~97703064:+
BRCA	cis	rs10895987	0.83	rs12292693	ENSG00000255200.1	AP003068.18	-3.62	0.000311	0.0166	-0.15	-0.11	Blood protein levels;	chr11:65169248	chr11:65174117~65176470:-
BRCA	cis	rs2243480	1	rs160655	ENSG00000275400.1	RP4-756H11.5	3.62	0.000311	0.0166	0.21	0.11	Diabetic kidney disease;	chr7:66068227	chr7:66553805~66554199:-
BRCA	cis	rs4650943	0.503	rs10798442	ENSG00000227740.1	RP11-318C24.2	3.62	0.000311	0.0166	0.12	0.11	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in inactive individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr1:176035413	chr1:175904762~175920513:-
BRCA	cis	rs442309	1	rs224150	ENSG00000238280.1	RP11-436D10.3	-3.62	0.000311	0.0166	-0.14	-0.11	Vogt-Koyanagi-Harada syndrome;	chr10:62728327	chr10:62793562~62805887:-
BRCA	cis	rs442309	1	rs190113	ENSG00000238280.1	RP11-436D10.3	-3.62	0.000311	0.0166	-0.14	-0.11	Vogt-Koyanagi-Harada syndrome;	chr10:62728463	chr10:62793562~62805887:-
BRCA	cis	rs8141529	0.748	rs132533	ENSG00000272858.1	CTA-292E10.8	3.62	0.000311	0.0166	0.15	0.11	Lymphocyte counts;	chr22:28903583	chr22:28814914~28815662:+
BRCA	cis	rs7618501	1	rs7649348	ENSG00000228008.1	CTD-2330K9.3	-3.62	0.000311	0.0166	-0.11	-0.11	Intelligence (multi-trait analysis);	chr3:49734942	chr3:49903845~49916937:+
BRCA	cis	rs6840360	1	rs3749561	ENSG00000278978.1	RP11-164P12.5	3.62	0.000311	0.0166	0.12	0.11	Intelligence (multi-trait analysis);	chr4:151688965	chr4:151669786~151670503:+
BRCA	cis	rs11048434	0.518	rs7311509	ENSG00000256720.1	RP11-436I9.6	-3.62	0.000311	0.0166	-0.11	-0.11	Sjögren's syndrome;	chr12:9026438	chr12:9135084~9135591:+
BRCA	cis	rs10043775	0.831	rs13158948	ENSG00000251330.3	CTD-2283N19.1	-3.62	0.000311	0.0166	-0.14	-0.11	Periodontal microbiota;	chr5:148320137	chr5:148430159~148430807:-
BRCA	cis	rs7267979	1	rs7343481	ENSG00000276952.1	RP5-965G21.6	-3.62	0.000311	0.0166	-0.14	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25319477	chr20:25284915~25285588:-
BRCA	cis	rs16940212	0.618	rs920917	ENSG00000259771.1	RP11-429D19.1	-3.62	0.000311	0.0166	-0.19	-0.11	HDL cholesterol;HDL cholesterol levels;	chr15:58396279	chr15:59266720~59271162:-
BRCA	cis	rs7902871	0.66	rs2636770	ENSG00000225850.3	RP11-452K12.4	-3.62	0.000311	0.0166	-0.19	-0.11	Diastolic blood pressure (alcohol consumption interaction);	chr10:97045855	chr10:97334564~97343203:+
BRCA	cis	rs4356203	0.543	rs214088	ENSG00000184669.7	OR7E14P	-3.62	0.000311	0.0166	-0.15	-0.11	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17276578	chr11:17013998~17053024:+
BRCA	cis	rs2657888	0.529	rs11171863	ENSG00000257576.1	RP11-153M3.1	-3.62	0.000311	0.0166	-0.14	-0.11	Adiponectin levels;	chr12:56485764	chr12:56511002~56512703:+
BRCA	cis	rs7487075	0.897	rs7979418	ENSG00000274723.1	RP11-618L22.1	3.62	0.000311	0.0166	0.14	0.11	Itch intensity from mosquito bite;	chr12:46380988	chr12:46970504~46972155:+
BRCA	cis	rs7260598	0.71	rs10423819	ENSG00000268058.1	BNIP3P40	-3.62	0.000311	0.0166	-0.14	-0.11	Response to taxane treatment (placlitaxel);	chr19:24153857	chr19:24098425~24098980:-
BRCA	cis	rs6840360	0.573	rs4696080	ENSG00000278978.1	RP11-164P12.5	-3.62	0.000311	0.0166	-0.12	-0.11	Intelligence (multi-trait analysis);	chr4:151355313	chr4:151669786~151670503:+
BRCA	cis	rs6942407	0.546	rs10257953	ENSG00000224046.1	AC005076.5	-3.62	0.000311	0.0166	-0.16	-0.11	Food allergy;	chr7:87170410	chr7:87151423~87152420:-
BRCA	cis	rs9400180	0.765	rs62427448	ENSG00000271734.1	RP1-111B22.3	-3.62	0.000311	0.0166	-0.15	-0.11	Major depressive disorder;	chr6:108056507	chr6:108030249~108030718:-
BRCA	cis	rs2991971	0.81	rs12119202	ENSG00000281133.1	AL355480.3	-3.62	0.000311	0.0166	-0.13	-0.11	High light scatter reticulocyte count;	chr1:45460259	chr1:45580892~45580996:-
BRCA	cis	rs2109514	0.703	rs13225166	ENSG00000237813.3	AC002066.1	3.62	0.000311	0.0166	0.14	0.11	Prevalent atrial fibrillation;	chr7:116435397	chr7:116238260~116499465:-
BRCA	cis	rs6496932	0.866	rs4842870	ENSG00000259774.1	RP11-182J1.13	3.62	0.000311	0.0166	0.17	0.11	Central corneal thickness;Corneal structure;	chr15:85277568	chr15:84422618~84425882:+
BRCA	cis	rs7819412	0.595	rs4841500	ENSG00000254507.2	RP11-481A20.10	3.62	0.000312	0.0166	0.14	0.11	Triglycerides;	chr8:11130765	chr8:12003400~12004082:-
BRCA	cis	rs875971	0.862	rs6460302	ENSG00000106610.13	STAG3L4	-3.62	0.000312	0.0166	-0.15	-0.11	Aortic root size;	chr7:66495270	chr7:67302621~67321526:+
BRCA	cis	rs721917	0.565	rs2255601	ENSG00000225484.5	NUTM2B-AS1	-3.62	0.000312	0.0166	-0.15	-0.11	Chronic obstructive pulmonary disease;	chr10:79944803	chr10:79663088~79826594:-
BRCA	cis	rs2274273	0.934	rs10140869	ENSG00000259318.1	RP11-454L9.2	3.62	0.000312	0.0166	0.09	0.11	Protein biomarker;	chr14:55328565	chr14:55394940~55395233:-
BRCA	cis	rs2625529	0.761	rs11853268	ENSG00000260037.4	CTD-2524L6.3	-3.62	0.000312	0.0166	-0.16	-0.11	Red blood cell count;	chr15:71946632	chr15:71818396~71823384:+
BRCA	cis	rs7954584	0.567	rs1720033	ENSG00000212694.7	LINC01089	3.62	0.000312	0.0166	0.09	0.11	Mean corpuscular volume;	chr12:121946438	chr12:121795267~121803906:-
BRCA	cis	rs6071166	0.683	rs6064886	ENSG00000224635.1	RP4-564F22.5	-3.62	0.000312	0.0166	-0.14	-0.11	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38692725	chr20:38406011~38416797:-
BRCA	cis	rs910316	1	rs175436	ENSG00000259138.1	RP11-950C14.7	-3.62	0.000312	0.0166	-0.11	-0.11	Height;	chr14:75141980	chr14:75127153~75136930:+
BRCA	cis	rs10829156	0.51	rs1490197	ENSG00000240291.1	RP11-499P20.2	3.62	0.000312	0.0166	0.13	0.11	Sudden cardiac arrest;	chr10:18696785	chr10:18513115~18545651:-
BRCA	cis	rs11098499	1	rs13116504	ENSG00000225892.3	RP11-384K6.2	3.62	0.000312	0.0166	0.11	0.11	Corneal astigmatism;	chr4:119288257	chr4:118632274~118634759:+
BRCA	cis	rs11892454	0.599	rs10202756	ENSG00000217643.1	PTGES3P2	-3.62	0.000312	0.0166	-0.12	-0.11	Heschl's gyrus morphology;	chr2:25769963	chr2:25822469~25822950:+
BRCA	cis	rs11098499	0.863	rs3822190	ENSG00000260404.2	RP11-384K6.6	3.62	0.000312	0.0166	0.11	0.11	Corneal astigmatism;	chr4:119506943	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.863	rs3822191	ENSG00000260404.2	RP11-384K6.6	3.62	0.000312	0.0166	0.11	0.11	Corneal astigmatism;	chr4:119506946	chr4:118591773~118633729:+
BRCA	cis	rs6545883	0.868	rs7574631	ENSG00000212978.6	AC016747.3	3.62	0.000312	0.0166	0.15	0.11	Tuberculosis;	chr2:61598007	chr2:61141592~61144969:-
BRCA	cis	rs792448	0.717	rs7544225	ENSG00000226251.4	RP11-15I11.3	3.62	0.000312	0.0166	0.15	0.11	White blood cell count (basophil);	chr1:212235666	chr1:212225278~212238977:-
BRCA	cis	rs10043228	0.59	rs10519448	ENSG00000271918.1	CTD-2287O16.5	-3.62	0.000312	0.0166	-0.16	-0.11	Asthma or chronic obstructive pulmonary disease;	chr5:116238364	chr5:116083807~116085416:-
BRCA	cis	rs6565180	1	rs12930787	ENSG00000261332.1	RP11-297C4.1	-3.62	0.000312	0.0166	-0.15	-0.11	Tonsillectomy;	chr16:30369982	chr16:30498766~30499554:-
BRCA	cis	rs6142618	0.562	rs2235898	ENSG00000224452.1	RSL24D1P6	3.62	0.000312	0.0166	0.15	0.11	Inflammatory bowel disease;	chr20:32131259	chr20:32170390~32170790:-
BRCA	cis	rs6142618	0.562	rs2235899	ENSG00000224452.1	RSL24D1P6	3.62	0.000312	0.0166	0.15	0.11	Inflammatory bowel disease;	chr20:32131732	chr20:32170390~32170790:-
BRCA	cis	rs6142618	0.562	rs2235901	ENSG00000224452.1	RSL24D1P6	3.62	0.000312	0.0166	0.15	0.11	Inflammatory bowel disease;	chr20:32132233	chr20:32170390~32170790:-
BRCA	cis	rs35306767	0.903	rs7074642	ENSG00000229869.1	RP11-363N22.2	-3.62	0.000312	0.0166	-0.17	-0.11	Eosinophil percentage of granulocytes;	chr10:832419	chr10:933026~942743:+
BRCA	cis	rs1479090	0.774	rs6841345	ENSG00000250027.1	RP11-563E2.2	3.62	0.000312	0.0166	0.14	0.11	Lung cancer;	chr4:163109121	chr4:163108785~163119965:+
BRCA	cis	rs9470794	1	rs55902626	ENSG00000204110.6	RP1-153P14.8	-3.62	0.000312	0.0166	-0.21	-0.11	Type 2 diabetes;	chr6:38161153	chr6:37507348~37535616:+
BRCA	cis	rs10129255	0.83	rs61997609	ENSG00000232216.1	IGHV3-43	3.62	0.000312	0.0166	0.09	0.11	Kawasaki disease;	chr14:106692376	chr14:106470264~106470800:-
BRCA	cis	rs7824557	0.767	rs2164273	ENSG00000248896.2	CTD-2135J3.3	3.62	0.000312	0.0166	0.15	0.11	Retinal vascular caliber;	chr8:11310990	chr8:10729314~10771392:+
BRCA	cis	rs6840360	0.615	rs4696094	ENSG00000278978.1	RP11-164P12.5	-3.62	0.000312	0.0166	-0.14	-0.11	Intelligence (multi-trait analysis);	chr4:151544349	chr4:151669786~151670503:+
BRCA	cis	rs1865760	0.964	rs3799373	ENSG00000272810.1	U91328.22	-3.62	0.000312	0.0166	-0.13	-0.11	Height;	chr6:25928945	chr6:26013241~26013757:+
BRCA	cis	rs6736093	0.769	rs56361454	ENSG00000236307.2	EEF1E1P1	-3.62	0.000312	0.0166	-0.14	-0.11	Coronary artery disease;	chr2:112016528	chr2:111887914~111888741:+
BRCA	cis	rs6142618	0.562	rs2281360	ENSG00000277692.1	RP11-358N2.2	-3.62	0.000312	0.0166	-0.12	-0.11	Inflammatory bowel disease;	chr20:32139026	chr20:32355053~32355734:+
BRCA	cis	rs1030420	0.796	rs17320665	ENSG00000200714.1	Y_RNA	-3.62	0.000312	0.0166	-0.18	-0.11	Blood metabolite levels;	chr8:66408896	chr8:65592731~65592820:+
BRCA	cis	rs983392	0.792	rs563803	ENSG00000275344.1	MIR6503	-3.62	0.000312	0.0166	-0.11	-0.11	Alzheimer's disease (late onset);	chr11:60110528	chr11:60209071~60209156:-
BRCA	cis	rs10504130	1	rs77712895	ENSG00000272076.1	RP11-11C20.3	3.62	0.000312	0.0166	0.19	0.11	Venous thromboembolism (SNP x SNP interaction);	chr8:51821121	chr8:51810110~51810681:-
BRCA	cis	rs1008375	0.897	rs67455495	ENSG00000249502.1	AC006160.5	3.62	0.000312	0.0166	0.13	0.11	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17663615	chr4:17587467~17614571:-
BRCA	cis	rs1008375	0.932	rs6845288	ENSG00000249502.1	AC006160.5	3.62	0.000312	0.0166	0.13	0.11	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17663875	chr4:17587467~17614571:-
BRCA	cis	rs7903456	0.648	rs9421561	ENSG00000200253.1	RNU6-529P	-3.62	0.000312	0.0166	-0.14	-0.11	Gout;Renal underexcretion gout;	chr10:87039315	chr10:87041238~87041341:-
BRCA	cis	rs711244	0.935	rs6752845	ENSG00000279519.1	RP11-288C18.1	3.62	0.000312	0.0166	0.1	0.11	Mean platelet volume;	chr2:36867996	chr2:36839922~36842539:-
BRCA	cis	rs9287719	0.967	rs6432112	ENSG00000224177.5	LINC00570	-3.62	0.000312	0.0166	-0.13	-0.11	Prostate cancer;	chr2:10604748	chr2:11393981~11403077:+
BRCA	cis	rs875971	0.862	rs10276077	ENSG00000229886.1	RP5-1132H15.3	-3.62	0.000312	0.0166	-0.12	-0.11	Aortic root size;	chr7:66263424	chr7:66025126~66031544:-
BRCA	cis	rs6723162	0.51	rs3771392	ENSG00000237751.2	LINC01143	-3.62	0.000312	0.0166	-0.16	-0.11	Neurocognitive impairment in HIV-1 infection (dichotomous);	chr2:70918157	chr2:70887871~70889959:+
BRCA	cis	rs13315871	1	rs71311864	ENSG00000272182.1	RP11-802O23.3	3.62	0.000312	0.0166	0.22	0.11	Cholesterol, total;	chr3:58386597	chr3:58428255~58428815:+
BRCA	cis	rs13315871	1	rs71311865	ENSG00000272182.1	RP11-802O23.3	3.62	0.000312	0.0166	0.22	0.11	Cholesterol, total;	chr3:58386696	chr3:58428255~58428815:+
BRCA	cis	rs13315871	1	rs28417694	ENSG00000272182.1	RP11-802O23.3	3.62	0.000312	0.0166	0.22	0.11	Cholesterol, total;	chr3:58388212	chr3:58428255~58428815:+
BRCA	cis	rs957448	0.904	rs56302978	ENSG00000261437.1	RP11-22C11.2	3.62	0.000312	0.0166	0.12	0.11	Nonsyndromic cleft lip with cleft palate;	chr8:94505883	chr8:94637285~94639467:-
BRCA	cis	rs13217239	0.646	rs11756275	ENSG00000124549.13	BTN2A3P	-3.62	0.000312	0.0166	-0.12	-0.11	Schizophrenia;	chr6:27039334	chr6:26421391~26432383:+
BRCA	cis	rs2274273	0.563	rs79163357	ENSG00000259318.1	RP11-454L9.2	3.62	0.000312	0.0166	0.1	0.11	Protein biomarker;	chr14:55271731	chr14:55394940~55395233:-
BRCA	cis	rs6071524	0.534	rs12625702	ENSG00000224635.1	RP4-564F22.5	-3.62	0.000312	0.0166	-0.13	-0.11	Autism spectrum disorder or schizophrenia;	chr20:38813292	chr20:38406011~38416797:-
BRCA	cis	rs1348850	0.914	rs3813259	ENSG00000280374.1	RP11-337N6.3	3.62	0.000312	0.0166	0.15	0.11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177392486	chr2:177317715~177318471:-
BRCA	cis	rs1005277	0.54	rs1814077	ENSG00000273019.1	RP11-508N22.13	-3.62	0.000312	0.0166	-0.13	-0.11	Extrinsic epigenetic age acceleration;	chr10:37703090	chr10:38149968~38150293:+
BRCA	cis	rs2991971	0.81	rs2036021	ENSG00000281133.1	AL355480.3	3.62	0.000312	0.0166	0.13	0.11	High light scatter reticulocyte count;	chr1:45435698	chr1:45580892~45580996:-
BRCA	cis	rs12681366	0.663	rs3099398	ENSG00000253175.1	RP11-267M23.6	3.62	0.000312	0.0166	0.12	0.11	Nonsyndromic cleft lip with cleft palate;	chr8:94467651	chr8:94565036~94565715:+
BRCA	cis	rs4950322	0.57	rs17356492	ENSG00000227242.3	NBPF13P	-3.62	0.000312	0.0166	-0.16	-0.11	Protein quantitative trait loci;	chr1:147296089	chr1:147021320~147124525:-
BRCA	cis	rs9470794	1	rs57180729	ENSG00000204110.6	RP1-153P14.8	-3.62	0.000312	0.0166	-0.23	-0.11	Type 2 diabetes;	chr6:38016088	chr6:37507348~37535616:+
BRCA	cis	rs757110	0.526	rs757081	ENSG00000184669.7	OR7E14P	-3.62	0.000312	0.0166	-0.16	-0.11	Type 2 diabetes;	chr11:17330136	chr11:17013998~17053024:+
BRCA	cis	rs853679	1	rs2799077	ENSG00000216901.1	AL022393.7	3.62	0.000312	0.0166	0.19	0.11	Depression;	chr6:28266819	chr6:28176188~28176674:+
BRCA	cis	rs13136331	0.684	rs7677103	ENSG00000249001.4	RP11-742B18.1	-3.62	0.000312	0.0166	-0.15	-0.11	Sitting height ratio;	chr4:87800127	chr4:87568035~87733956:-
BRCA	cis	rs2898290	0.592	rs2736342	ENSG00000255046.1	RP11-297N6.4	3.62	0.000312	0.0166	0.13	0.11	Systolic blood pressure;	chr8:11489780	chr8:11797928~11802568:-
BRCA	cis	rs11098499	0.955	rs1511019	ENSG00000260404.2	RP11-384K6.6	3.62	0.000312	0.0166	0.11	0.11	Corneal astigmatism;	chr4:119244852	chr4:118591773~118633729:+
BRCA	cis	rs2625529	0.824	rs12439900	ENSG00000260037.4	CTD-2524L6.3	-3.62	0.000313	0.0166	-0.16	-0.11	Red blood cell count;	chr15:72081299	chr15:71818396~71823384:+
BRCA	cis	rs13118159	0.836	rs2293630	ENSG00000254094.1	AC078852.1	-3.62	0.000313	0.0166	-0.12	-0.11	Longevity;	chr4:1348733	chr4:1356581~1358075:+
BRCA	cis	rs1009077	0.514	rs71614451	ENSG00000245958.5	RP11-33B1.1	3.62	0.000313	0.0166	0.14	0.11	Endometriosis;	chr4:119483305	chr4:119454791~119552025:+
BRCA	cis	rs801193	0.935	rs2659899	ENSG00000232546.1	RP11-458F8.1	-3.62	0.000313	0.0166	-0.09	-0.11	Aortic root size;	chr7:66721734	chr7:66848496~66858136:+
BRCA	cis	rs2301573	0.584	rs12497351	ENSG00000271270.4	TMCC1-AS1	-3.62	0.000313	0.0166	-0.24	-0.11	Hip circumference;	chr3:129634716	chr3:129893871~129918575:+
BRCA	cis	rs7267979	0.932	rs431579	ENSG00000204556.4	CTD-2514C3.1	-3.62	0.000313	0.0166	-0.15	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25489420	chr20:26018832~26020684:+
BRCA	cis	rs321358	0.731	rs1517581	ENSG00000271390.1	RP11-89C3.3	3.62	0.000313	0.0166	0.17	0.11	Body mass index;	chr11:111164533	chr11:111089870~111090368:-
BRCA	cis	rs11031096	0.702	rs11030980	ENSG00000224513.2	AC109309.4	-3.62	0.000313	0.0166	-0.14	-0.11	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr11:4109313	chr11:3226061~3232838:+
BRCA	cis	rs10129255	0.957	rs10141052	ENSG00000211967.3	IGHV3-53	-3.62	0.000313	0.0166	-0.08	-0.11	Kawasaki disease;	chr14:106776528	chr14:106592676~106593347:-
BRCA	cis	rs6088580	0.524	rs6088552	ENSG00000261582.1	RP4-614O4.11	3.62	0.000313	0.0166	0.11	0.11	Glomerular filtration rate (creatinine);	chr20:34638687	chr20:35267885~35280043:-
BRCA	cis	rs17027633	0.881	rs41301285	ENSG00000260948.1	RP11-552M11.8	-3.62	0.000313	0.0166	-0.26	-0.11	Cerebrospinal fluid t-tau:AB1-42 ratio;	chr1:111477130	chr1:111431046~111433068:-
BRCA	cis	rs6991838	0.584	rs73236948	ENSG00000272155.1	RP11-707M3.3	3.62	0.000313	0.0166	0.1	0.11	Intelligence (multi-trait analysis);	chr8:65609176	chr8:65714334~65714778:-
BRCA	cis	rs13315871	1	rs9862969	ENSG00000272182.1	RP11-802O23.3	3.62	0.000313	0.0166	0.22	0.11	Cholesterol, total;	chr3:58356190	chr3:58428255~58428815:+
BRCA	cis	rs1730008	0.731	rs1851062	ENSG00000279311.1	RP11-170K4.2	3.62	0.000313	0.0166	0.14	0.11	Lobe attachment (rater-scored or self-reported);	chr3:158274574	chr3:158869898~158871821:+
BRCA	cis	rs67696533	0.6	rs6141745	ENSG00000275576.1	RP5-836N17.4	-3.62	0.000313	0.0166	-0.14	-0.11	White blood cell count (basophil);Basophil percentage of granulocytes;Basophil percentage of white cells;	chr20:32521002	chr20:32116171~32116629:+
BRCA	cis	rs17428076	0.958	rs72890842	ENSG00000228389.1	AC068039.4	-3.62	0.000313	0.0166	-0.17	-0.11	Myopia;	chr2:171978369	chr2:171773482~171775844:+
BRCA	cis	rs4819052	0.765	rs2838854	ENSG00000215447.6	BX322557.10	-3.62	0.000313	0.0166	-0.11	-0.11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260449	chr21:45288052~45291738:+
BRCA	cis	rs10501293	1	rs1425850	ENSG00000252652.1	Y_RNA	3.62	0.000313	0.0166	0.13	0.11	Cognitive performance;	chr11:43088283	chr11:43331261~43331356:+
BRCA	cis	rs6601327	0.641	rs12155819	ENSG00000233609.3	RP11-62H7.2	-3.62	0.000313	0.0166	-0.11	-0.11	Multiple myeloma (hyperdiploidy);	chr8:9715169	chr8:8961200~8979025:+
BRCA	cis	rs6601327	0.7	rs12114661	ENSG00000233609.3	RP11-62H7.2	-3.62	0.000313	0.0166	-0.11	-0.11	Multiple myeloma (hyperdiploidy);	chr8:9715644	chr8:8961200~8979025:+
BRCA	cis	rs6545883	0.931	rs11125885	ENSG00000212978.6	AC016747.3	3.62	0.000313	0.0166	0.15	0.11	Tuberculosis;	chr2:61528593	chr2:61141592~61144969:-
BRCA	cis	rs2243480	1	rs35820085	ENSG00000226767.1	RP11-328P23.3	-3.62	0.000313	0.0166	-0.19	-0.11	Diabetic kidney disease;	chr7:65977771	chr7:65508773~65508944:-
BRCA	cis	rs2243480	1	rs4718269	ENSG00000226767.1	RP11-328P23.3	3.62	0.000313	0.0166	0.19	0.11	Diabetic kidney disease;	chr7:65735810	chr7:65508773~65508944:-
BRCA	cis	rs7520050	0.966	rs10789481	ENSG00000234329.1	RP11-767N6.2	-3.62	0.000313	0.0166	-0.11	-0.11	Reticulocyte count;Red blood cell count;	chr1:45917911	chr1:45651039~45651826:-
BRCA	cis	rs10266483	0.576	rs2863327	ENSG00000227986.1	TRIM60P18	3.62	0.000313	0.0166	0.14	0.11	Response to statin therapy;	chr7:64268698	chr7:64355078~64356199:+
BRCA	cis	rs9400467	0.537	rs449308	ENSG00000231889.6	TRAF3IP2-AS1	3.62	0.000313	0.0166	0.16	0.11	Amino acid levels;Blood metabolite levels;	chr6:111159192	chr6:111483511~111598302:+
BRCA	cis	rs6840360	0.809	rs6846809	ENSG00000251611.1	RP11-610P16.1	3.62	0.000313	0.0166	0.1	0.11	Intelligence (multi-trait analysis);	chr4:151809049	chr4:151407551~151408835:-
BRCA	cis	rs10043228	1	rs12517508	ENSG00000271918.1	CTD-2287O16.5	-3.62	0.000313	0.0167	-0.14	-0.11	Asthma or chronic obstructive pulmonary disease;	chr5:116087877	chr5:116083807~116085416:-
BRCA	cis	rs962856	0.537	rs619884	ENSG00000236780.4	AC078941.1	3.62	0.000313	0.0167	0.14	0.11	Pancreatic cancer;	chr2:67451180	chr2:67123357~67215319:-
BRCA	cis	rs983392	0.792	rs580817	ENSG00000275344.1	MIR6503	-3.62	0.000313	0.0167	-0.11	-0.11	Alzheimer's disease (late onset);	chr11:60101617	chr11:60209071~60209156:-
BRCA	cis	rs9650657	0.655	rs10093774	ENSG00000154316.13	TDH	-3.62	0.000313	0.0167	-0.14	-0.11	Neuroticism;	chr8:10845783	chr8:11339637~11368452:+
BRCA	cis	rs792448	0.717	rs1389371	ENSG00000229983.1	RP11-15I11.2	3.62	0.000313	0.0167	0.13	0.11	White blood cell count (basophil);	chr1:212236813	chr1:212168207~212190259:+
BRCA	cis	rs1555322	1	rs6058219	ENSG00000261582.1	RP4-614O4.11	-3.62	0.000313	0.0167	-0.15	-0.11	Attention deficit hyperactivity disorder;	chr20:35271441	chr20:35267885~35280043:-
BRCA	cis	rs6545883	0.929	rs2463100	ENSG00000270820.4	RP11-355B11.2	3.62	0.000313	0.0167	0.14	0.11	Tuberculosis;	chr2:61432064	chr2:61471188~61484130:+
BRCA	cis	rs7618501	1	rs6785549	ENSG00000228008.1	CTD-2330K9.3	-3.62	0.000313	0.0167	-0.11	-0.11	Intelligence (multi-trait analysis);	chr3:49699132	chr3:49903845~49916937:+
BRCA	cis	rs10504130	1	rs16916820	ENSG00000272076.1	RP11-11C20.3	3.62	0.000313	0.0167	0.2	0.11	Venous thromboembolism (SNP x SNP interaction);	chr8:51800156	chr8:51810110~51810681:-
BRCA	cis	rs7572733	1	rs35062652	ENSG00000231621.1	AC013264.2	-3.62	0.000313	0.0167	-0.1	-0.11	Dermatomyositis;	chr2:198063203	chr2:197197991~197199273:+
BRCA	cis	rs11242704	0.962	rs12200039	ENSG00000218027.2	RP11-157J24.1	3.62	0.000313	0.0167	0.15	0.11	Response to hepatitis C treatment;	chr6:1536150	chr6:1513698~1515289:-
BRCA	cis	rs8180040	0.966	rs6800271	ENSG00000260236.1	RP11-708J19.1	-3.62	0.000313	0.0167	-0.1	-0.11	Colorectal cancer;	chr3:47429297	chr3:47379089~47380999:-
BRCA	cis	rs1150668	0.83	rs2859365	ENSG00000270326.1	RP5-874C20.6	3.62	0.000313	0.0167	0.14	0.11	Pubertal anthropometrics;	chr6:28423688	chr6:28319660~28319852:-
BRCA	cis	rs863345	0.565	rs2220633	ENSG00000229914.1	RP11-404O13.4	-3.62	0.000313	0.0167	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158475482	chr1:158195633~158196131:-
BRCA	cis	rs2514805	0.803	rs2513791	ENSG00000253585.1	KB-1184D12.1	3.62	0.000313	0.0167	0.2	0.11	Diisocyanate-induced asthma;	chr8:94116301	chr8:94097764~94104322:-
BRCA	cis	rs6813195	0.918	rs10011838	ENSG00000245954.5	RP11-18H21.1	-3.62	0.000313	0.0167	-0.1	-0.11	Type 2 diabetes;	chr4:152599127	chr4:152100754~152104720:+
BRCA	cis	rs62064224	0.554	rs9901737	ENSG00000279781.1	RP11-466A19.7	3.62	0.000313	0.0167	0.13	0.11	Schizophrenia;	chr17:32354335	chr17:32518322~32518934:-
BRCA	cis	rs9952980	0.671	rs35752582	ENSG00000266968.2	RP11-116O18.1	-3.62	0.000313	0.0167	-0.14	-0.11	Breast cancer;	chr18:45320617	chr18:45646153~45647937:+
BRCA	cis	rs7176093	1	rs12148863	ENSG00000259295.5	CSPG4P12	-3.62	0.000314	0.0167	-0.15	-0.11	Aging traits;	chr15:85831964	chr15:85191438~85213905:+
BRCA	cis	rs7176093	1	rs72757351	ENSG00000259295.5	CSPG4P12	-3.62	0.000314	0.0167	-0.15	-0.11	Aging traits;	chr15:85832282	chr15:85191438~85213905:+
BRCA	cis	rs2904967	0.778	rs689288	ENSG00000255200.1	AP003068.18	-3.62	0.000314	0.0167	-0.22	-0.11	Mean corpuscular volume;	chr11:65351526	chr11:65174117~65176470:-
BRCA	cis	rs3735485	0.698	rs62458154	ENSG00000201772.1	SNORA5C	3.62	0.000314	0.0167	0.14	0.11	White blood cell count;Sum basophil neutrophil counts;Neutrophil count;Granulocyte percentage of myeloid white cells;Monocyte percentage of white cells;Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Lymphocyte counts;	chr7:45078349	chr7:45104906~45105042:-
BRCA	cis	rs3735485	0.738	rs62458155	ENSG00000201772.1	SNORA5C	3.62	0.000314	0.0167	0.14	0.11	White blood cell count;Sum basophil neutrophil counts;Neutrophil count;Granulocyte percentage of myeloid white cells;Monocyte percentage of white cells;Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Lymphocyte counts;	chr7:45078599	chr7:45104906~45105042:-
BRCA	cis	rs7572733	0.555	rs11889006	ENSG00000231621.1	AC013264.2	-3.62	0.000314	0.0167	-0.1	-0.11	Dermatomyositis;	chr2:198063923	chr2:197197991~197199273:+
BRCA	cis	rs17301013	0.932	rs7555533	ENSG00000200674.1	RN7SKP160	3.62	0.000314	0.0167	0.15	0.11	Systemic lupus erythematosus;	chr1:174589983	chr1:173791548~173791887:+
BRCA	cis	rs17301013	0.932	rs6671824	ENSG00000200674.1	RN7SKP160	3.62	0.000314	0.0167	0.15	0.11	Systemic lupus erythematosus;	chr1:174603721	chr1:173791548~173791887:+
BRCA	cis	rs17301013	0.861	rs6672148	ENSG00000200674.1	RN7SKP160	3.62	0.000314	0.0167	0.15	0.11	Systemic lupus erythematosus;	chr1:174604016	chr1:173791548~173791887:+
BRCA	cis	rs250518	0.926	rs1912005	ENSG00000271926.1	CTD-2376I4.1	-3.62	0.000314	0.0167	-0.15	-0.11	Mean corpuscular hemoglobin concentration;	chr5:72772227	chr5:72953635~72954274:-
BRCA	cis	rs62229266	0.804	rs2255858	ENSG00000214914.3	RPL23AP3	3.62	0.000314	0.0167	0.13	0.11	Mitral valve prolapse;	chr21:36040454	chr21:36016079~36016546:-
BRCA	cis	rs4148883	0.645	rs1154404	ENSG00000272777.1	RP11-571L19.8	-3.62	0.000314	0.0167	-0.12	-0.11	Alcohol dependence;	chr4:99087853	chr4:99067256~99068125:-
BRCA	cis	rs7781266	0.79	rs73148998	ENSG00000226205.1	AC007790.4	3.62	0.000314	0.0167	0.16	0.11	Educational attainment (college completion);	chr7:133497058	chr7:133732493~133733595:-
BRCA	cis	rs2692947	0.77	rs11689832	ENSG00000168992.4	OR7E102P	3.62	0.000314	0.0167	0.16	0.11	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95889103	chr2:95546531~95547545:+
BRCA	cis	rs2274273	1	rs67098772	ENSG00000259318.1	RP11-454L9.2	3.62	0.000314	0.0167	0.1	0.11	Protein biomarker;	chr14:55128524	chr14:55394940~55395233:-
BRCA	cis	rs2274273	1	rs2147972	ENSG00000259318.1	RP11-454L9.2	3.62	0.000314	0.0167	0.1	0.11	Protein biomarker;	chr14:55131312	chr14:55394940~55395233:-
BRCA	cis	rs7103648	0.695	rs6485758	ENSG00000280615.1	Y_RNA	3.62	0.000314	0.0167	0.14	0.11	Systolic blood pressure;Diastolic blood pressure;	chr11:47508472	chr11:47614898~47614994:-
BRCA	cis	rs801193	1	rs17566701	ENSG00000265600.1	AC006480.1	-3.62	0.000314	0.0167	-0.13	-0.11	Aortic root size;	chr7:66728196	chr7:67356680~67356779:+
BRCA	cis	rs9650657	0.504	rs7813802	ENSG00000154316.13	TDH	-3.62	0.000314	0.0167	-0.14	-0.11	Neuroticism;	chr8:11176467	chr8:11339637~11368452:+
BRCA	cis	rs3858526	0.959	rs10838797	ENSG00000224295.2	AC087380.14	3.62	0.000314	0.0167	0.16	0.11	DNA methylation (variation);	chr11:5899747	chr11:5518441~5524955:-
BRCA	cis	rs2342371	0.539	rs35959625	ENSG00000273013.1	CTD-2002J20.1	-3.62	0.000314	0.0167	-0.14	-0.11	Fat distribution (HIV);	chr3:196405070	chr3:196474801~196475394:+
BRCA	cis	rs55675132	0.585	rs12135727	ENSG00000226167.1	AP4B1-AS1	3.62	0.000314	0.0167	0.12	0.11	Schizophrenia;	chr1:114800111	chr1:113856635~113901237:+
BRCA	cis	rs2018683	0.707	rs10279610	ENSG00000233517.1	AC005162.5	3.62	0.000314	0.0167	0.14	0.11	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28936079	chr7:28987028~28988899:+
BRCA	cis	rs1008375	0.966	rs10006317	ENSG00000249502.1	AC006160.5	-3.62	0.000314	0.0167	-0.13	-0.11	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17700902	chr4:17587467~17614571:-
BRCA	cis	rs300890	1	rs300905	ENSG00000250326.1	RP11-284M14.1	3.62	0.000314	0.0167	0.12	0.11	Nasopharyngeal carcinoma;	chr4:143319320	chr4:142933195~143184861:-
BRCA	cis	rs321358	0.731	rs12421339	ENSG00000271390.1	RP11-89C3.3	3.62	0.000314	0.0167	0.16	0.11	Body mass index;	chr11:111168744	chr11:111089870~111090368:-
BRCA	cis	rs6545883	0.965	rs9989775	ENSG00000212978.6	AC016747.3	3.62	0.000314	0.0167	0.15	0.11	Tuberculosis;	chr2:61534639	chr2:61141592~61144969:-
BRCA	cis	rs17796831	0.93	rs34128774	ENSG00000205562.2	RP11-497E19.1	3.62	0.000314	0.0167	0.11	0.11	Lobe attachment (rater-scored or self-reported);	chr14:85326057	chr14:85524432~85529988:-
BRCA	cis	rs1346	0.552	rs4326800	ENSG00000245532.5	NEAT1	3.62	0.000314	0.0167	0.12	0.11	Vertical cup-disc ratio;Optic cup area;	chr11:65599782	chr11:65422774~65445540:+
BRCA	cis	rs875971	0.755	rs10228885	ENSG00000271064.1	RP11-792A8.3	3.62	0.000314	0.0167	0.13	0.11	Aortic root size;	chr7:66315542	chr7:66748838~66749077:-
BRCA	cis	rs55675132	0.548	rs12144576	ENSG00000226167.1	AP4B1-AS1	3.62	0.000314	0.0167	0.12	0.11	Schizophrenia;	chr1:114819112	chr1:113856635~113901237:+
BRCA	cis	rs13326165	0.76	rs34523877	ENSG00000243224.1	RP5-1157M23.2	-3.62	0.000314	0.0167	-0.15	-0.11	HDL cholesterol levels;HDL cholesterol;	chr3:52341695	chr3:52239258~52241097:+
BRCA	cis	rs1949733	1	rs1880023	ENSG00000251615.3	RP11-774O3.3	3.62	0.000314	0.0167	0.12	0.11	Response to antineoplastic agents;	chr4:8479104	chr4:8355090~8358338:-
BRCA	cis	rs3096299	0.685	rs8050512	ENSG00000259877.2	RP11-46C24.7	-3.62	0.000314	0.0167	-0.1	-0.11	Multiple myeloma (IgH translocation);	chr16:89485912	chr16:89215211~89217653:-
BRCA	cis	rs4925386	0.84	rs6143034	ENSG00000275437.1	RP5-908M14.10	3.62	0.000314	0.0167	0.12	0.11	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62345489	chr20:62402236~62405935:-
BRCA	cis	rs9925964	0.967	rs2855475	ENSG00000279196.1	RP11-1072A3.3	3.62	0.000314	0.0167	0.12	0.11	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31136227	chr16:30984630~30988270:-
BRCA	cis	rs453301	0.686	rs6748	ENSG00000233609.3	RP11-62H7.2	-3.62	0.000314	0.0167	-0.11	-0.11	Joint mobility (Beighton score);	chr8:9033292	chr8:8961200~8979025:+
BRCA	cis	rs997295	0.57	rs72747462	ENSG00000259673.4	IQCH-AS1	3.62	0.000314	0.0167	0.13	0.11	Motion sickness;	chr15:67526200	chr15:67403619~67521844:-
BRCA	cis	rs2243480	1	rs2257790	ENSG00000237026.1	RP11-328P23.2	3.62	0.000314	0.0167	0.21	0.11	Diabetic kidney disease;	chr7:66135463	chr7:65235790~65236723:-
BRCA	cis	rs943466	1	rs4711346	ENSG00000223837.2	BRD2-IT1	3.62	0.000314	0.0167	0.14	0.11	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;	chr6:33763219	chr6:32970232~32970886:+
BRCA	cis	rs4972806	0.739	rs10834	ENSG00000272729.1	RP11-387A1.5	-3.62	0.000314	0.0167	-0.14	-0.11	IgG glycosylation;	chr2:176177359	chr2:176164164~176165716:-
BRCA	cis	rs739496	0.546	rs11066055	ENSG00000257624.1	RP1-128M12.3	3.62	0.000314	0.0167	0.15	0.11	Platelet count;	chr12:111875412	chr12:112000739~112000985:-
BRCA	cis	rs10760158	0.865	rs10739594	ENSG00000235865.2	GSN-AS1	3.62	0.000314	0.0167	0.09	0.11	Pulse pressure;	chr9:121273102	chr9:121280768~121285530:-
BRCA	cis	rs17192198	0.904	rs17192114	ENSG00000270344.2	RP11-734K2.4	-3.62	0.000314	0.0167	-0.16	-0.11	Diastolic blood pressure;	chr12:89777661	chr12:89525654~89548005:+
BRCA	cis	rs2574985	0.813	rs1203382	ENSG00000226200.5	SGMS1-AS1	-3.62	0.000314	0.0167	-0.11	-0.11	Subjective well-being;	chr10:50452549	chr10:50624951~50641451:+
BRCA	cis	rs7985	0.901	rs5761679	ENSG00000225783.5	MIAT	-3.62	0.000314	0.0167	-0.09	-0.11	Electroencephalogram traits;	chr22:26681268	chr22:26646428~26676475:+
BRCA	cis	rs2287838	1	rs11667192	ENSG00000267289.1	CTD-2623N2.11	-3.62	0.000314	0.0167	-0.13	-0.11	Sleep duration;	chr19:9865294	chr19:9834079~9835013:-
BRCA	cis	rs4148883	0.713	rs3828541	ENSG00000272777.1	RP11-571L19.8	-3.62	0.000314	0.0167	-0.11	-0.11	Alcohol dependence;	chr4:99121111	chr4:99067256~99068125:-
BRCA	cis	rs1048886	0.882	rs2346889	ENSG00000271967.1	RP11-134K13.4	-3.62	0.000314	0.0167	-0.15	-0.11	Type 2 diabetes;	chr6:70406469	chr6:70596438~70596980:+
BRCA	cis	rs6840360	0.571	rs11931934	ENSG00000278978.1	RP11-164P12.5	-3.62	0.000314	0.0167	-0.13	-0.11	Intelligence (multi-trait analysis);	chr4:151630930	chr4:151669786~151670503:+
BRCA	cis	rs2625529	0.526	rs11637611	ENSG00000260037.4	CTD-2524L6.3	3.62	0.000314	0.0167	0.14	0.11	Red blood cell count;	chr15:72259371	chr15:71818396~71823384:+
BRCA	cis	rs4356203	0.519	rs214092	ENSG00000184669.7	OR7E14P	-3.62	0.000314	0.0167	-0.15	-0.11	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17273499	chr11:17013998~17053024:+
BRCA	cis	rs1914816	0.941	rs2469544	ENSG00000259422.1	RP11-593F23.1	3.62	0.000314	0.0167	0.17	0.11	Response to tocilizumab in rheumatoid arthritis;	chr15:76192606	chr15:76174891~76181486:-
BRCA	cis	rs2422052	0.654	rs1433530	ENSG00000236255.1	AC009404.2	-3.62	0.000314	0.0167	-0.11	-0.11	Mosquito bite size;	chr2:117891507	chr2:117833937~117841658:+
BRCA	cis	rs875971	0.862	rs4236208	ENSG00000229886.1	RP5-1132H15.3	-3.62	0.000314	0.0167	-0.12	-0.11	Aortic root size;	chr7:66284091	chr7:66025126~66031544:-
BRCA	cis	rs6840360	0.837	rs13137669	ENSG00000251611.1	RP11-610P16.1	-3.62	0.000315	0.0167	-0.1	-0.11	Intelligence (multi-trait analysis);	chr4:151789791	chr4:151407551~151408835:-
BRCA	cis	rs12760731	0.72	rs10913540	ENSG00000213057.5	C1orf220	3.62	0.000315	0.0167	0.16	0.11	Obesity-related traits;	chr1:178370925	chr1:178542752~178548889:+
BRCA	cis	rs1971762	0.527	rs7952858	ENSG00000270175.1	RP11-793H13.11	-3.62	0.000315	0.0167	-0.1	-0.11	Height;	chr12:53645908	chr12:53500162~53500936:-
BRCA	cis	rs2976388	0.609	rs2585148	ENSG00000253196.1	RP11-706C16.7	3.62	0.000315	0.0167	0.11	0.11	Urinary tract infection frequency;	chr8:142714775	chr8:142763116~142766427:+
BRCA	cis	rs654950	0.934	rs665223	ENSG00000230638.4	RP11-486B10.4	3.62	0.000315	0.0167	0.14	0.11	Airway imaging phenotypes;	chr1:41534983	chr1:41542069~41544310:+
BRCA	cis	rs28530618	0.754	rs8120730	ENSG00000175730.8	BAK1P1	3.62	0.000315	0.0167	0.14	0.11	Birth weight;	chr20:32652127	chr20:32690180~32690815:-
BRCA	cis	rs10484434	0.901	rs56073264	ENSG00000272810.1	U91328.22	3.62	0.000315	0.0167	0.17	0.11	HIV-1 viral setpoint;	chr6:26079188	chr6:26013241~26013757:+
BRCA	cis	rs7177699	0.557	rs7164479	ENSG00000261143.1	ADAMTS7P3	-3.62	0.000315	0.0167	-0.13	-0.11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78830712	chr15:77976042~77993057:+
BRCA	cis	rs2255336	0.671	rs7301582	ENSG00000245648.1	RP11-277P12.20	-3.61	0.000315	0.0167	-0.16	-0.11	Blood protein levels;	chr12:10449091	chr12:10363769~10398506:+
BRCA	cis	rs736408	0.716	rs2239550	ENSG00000243224.1	RP5-1157M23.2	-3.61	0.000315	0.0167	-0.12	-0.11	Bipolar disorder;	chr3:52788493	chr3:52239258~52241097:+
BRCA	cis	rs4908769	0.624	rs6678140	ENSG00000232912.4	RP5-1115A15.1	-3.61	0.000315	0.0167	-0.12	-0.11	Allergy;	chr1:8376742	chr1:8424645~8434838:+
BRCA	cis	rs5758659	0.714	rs2284087	ENSG00000205702.9	CYP2D7	-3.61	0.000315	0.0167	-0.09	-0.11	Cognitive function;	chr22:42089667	chr22:42140203~42144577:-
BRCA	cis	rs875971	0.516	rs6945322	ENSG00000223473.2	GS1-124K5.3	3.61	0.000315	0.0167	0.09	0.11	Aortic root size;	chr7:65871069	chr7:66491049~66493566:-
BRCA	cis	rs733175	0.857	rs751092	ENSG00000250413.1	RP11-448G15.1	-3.61	0.000315	0.0167	-0.17	-0.11	Psychosis and Alzheimer's disease;	chr4:10004273	chr4:10006482~10009725:+
BRCA	cis	rs9866825	0.967	rs6798623	ENSG00000227110.5	LMCD1-AS1	3.61	0.000315	0.0167	0.13	0.11	QT interval;	chr3:8206270	chr3:7952805~8611924:-
BRCA	cis	rs957448	0.539	rs9643346	ENSG00000254315.1	RP11-267M23.3	3.61	0.000315	0.0167	0.14	0.11	Nonsyndromic cleft lip with cleft palate;	chr8:94601587	chr8:94533628~94534391:+
BRCA	cis	rs7267979	0.966	rs2263204	ENSG00000274973.1	RP13-401N8.7	3.61	0.000315	0.0167	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25397052	chr20:25845497~25845862:+
BRCA	cis	rs875971	0.522	rs9530	ENSG00000223473.2	GS1-124K5.3	3.61	0.000315	0.0167	0.09	0.11	Aortic root size;	chr7:65960907	chr7:66491049~66493566:-
BRCA	cis	rs10005067	0.967	rs4693907	ENSG00000249001.4	RP11-742B18.1	-3.61	0.000315	0.0167	-0.13	-0.11	Total body bone mineral density (age 30-45);	chr4:87901493	chr4:87568035~87733956:-
BRCA	cis	rs7520050	0.966	rs2486447	ENSG00000234329.1	RP11-767N6.2	-3.61	0.000315	0.0167	-0.1	-0.11	Reticulocyte count;Red blood cell count;	chr1:46080052	chr1:45651039~45651826:-
BRCA	cis	rs9656709	1	rs9656709	ENSG00000226278.1	PSPHP1	-3.61	0.000315	0.0167	-0.11	-0.11	Behavioural disinhibition (generation interaction);	chr7:55656752	chr7:55764797~55773288:+
BRCA	cis	rs7804356	0.626	rs11772673	ENSG00000199085.2	MIR148A	3.61	0.000315	0.0167	0.13	0.11	Type 1 diabetes;	chr7:26735350	chr7:25949903~25950013:-
BRCA	cis	rs7572644	0.537	rs7608642	ENSG00000223522.1	AC093690.1	-3.61	0.000315	0.0167	-0.12	-0.11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:28144382	chr2:28307691~28310459:-
BRCA	cis	rs12468226	0.938	rs16841867	ENSG00000272966.1	RP11-686O6.1	3.61	0.000315	0.0167	0.18	0.11	Urate levels;	chr2:202303512	chr2:202336739~202337200:+
BRCA	cis	rs12468226	0.938	rs16839065	ENSG00000272966.1	RP11-686O6.1	3.61	0.000315	0.0167	0.18	0.11	Urate levels;	chr2:202308774	chr2:202336739~202337200:+
BRCA	cis	rs6671200	0.92	rs259350	ENSG00000235501.4	RP4-639F20.1	3.61	0.000315	0.0168	0.24	0.11	Stearic acid (18:0) levels;	chr1:95259275	chr1:94927566~94963270:+
BRCA	cis	rs875971	0.929	rs778692	ENSG00000271064.1	RP11-792A8.3	-3.61	0.000315	0.0168	-0.13	-0.11	Aortic root size;	chr7:66407462	chr7:66748838~66749077:-
BRCA	cis	rs875971	1	rs4718343	ENSG00000271064.1	RP11-792A8.3	-3.61	0.000315	0.0168	-0.13	-0.11	Aortic root size;	chr7:66409301	chr7:66748838~66749077:-
BRCA	cis	rs875971	1	rs1968225	ENSG00000271064.1	RP11-792A8.3	-3.61	0.000315	0.0168	-0.13	-0.11	Aortic root size;	chr7:66409786	chr7:66748838~66749077:-
BRCA	cis	rs875971	1	rs6460295	ENSG00000271064.1	RP11-792A8.3	-3.61	0.000315	0.0168	-0.13	-0.11	Aortic root size;	chr7:66417741	chr7:66748838~66749077:-
BRCA	cis	rs875971	0.964	rs6978721	ENSG00000271064.1	RP11-792A8.3	-3.61	0.000315	0.0168	-0.13	-0.11	Aortic root size;	chr7:66418217	chr7:66748838~66749077:-
BRCA	cis	rs9308731	0.568	rs6754736	ENSG00000230499.1	AC108463.1	-3.61	0.000315	0.0168	-0.13	-0.11	Chronic lymphocytic leukemia;	chr2:111190964	chr2:111195963~111206494:+
BRCA	cis	rs4865762	0.514	rs251330	ENSG00000247796.2	CTD-2366F13.1	3.61	0.000315	0.0168	0.12	0.11	Intraocular pressure;	chr5:53140374	chr5:53109842~53115126:+
BRCA	cis	rs2562456	0.917	rs2650825	ENSG00000268555.1	RP11-678G14.3	3.61	0.000315	0.0168	0.15	0.11	Pain;	chr19:21516423	chr19:21570822~21587322:-
BRCA	cis	rs9733	0.565	rs7524620	ENSG00000231073.1	RP11-316M1.3	-3.61	0.000315	0.0168	-0.11	-0.11	Tonsillectomy;	chr1:150644223	chr1:150973123~150975534:+
BRCA	cis	rs6812193	0.518	rs6822055	ENSG00000271676.1	RP11-1E1.2	-3.61	0.000315	0.0168	-0.16	-0.11	Parkinson's disease;	chr4:76275035	chr4:77112495~77113458:-
BRCA	cis	rs7824557	0.737	rs2293855	ENSG00000154316.13	TDH	-3.61	0.000315	0.0168	-0.15	-0.11	Retinal vascular caliber;	chr8:11319901	chr8:11339637~11368452:+
BRCA	cis	rs1371614	0.501	rs6745807	ENSG00000272148.1	RP11-195B17.1	3.61	0.000315	0.0168	0.13	0.11	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26962449	chr2:27062428~27062907:-
BRCA	cis	rs568617	0.953	rs645900	ENSG00000254614.2	AP003068.23	3.61	0.000315	0.0168	0.16	0.11	Crohn's disease;	chr11:65880664	chr11:65177606~65181834:-
BRCA	cis	rs62458065	0.64	rs79619897	ENSG00000229358.3	DPY19L1P1	-3.61	0.000316	0.0168	-0.16	-0.11	Metabolite levels (HVA/MHPG ratio);	chr7:32475207	chr7:32580949~32761787:-
BRCA	cis	rs3781264	0.816	rs2274223	ENSG00000268894.5	PLCE1-AS1	-3.61	0.000316	0.0168	-0.15	-0.11	Esophageal cancer and gastric cancer;	chr10:94306584	chr10:94279277~94287478:-
BRCA	cis	rs9500256	0.515	rs12207710	ENSG00000272316.1	XXbac-BPGBPG55C20.2	3.61	0.000316	0.0168	0.1	0.11	Eosinophilic esophagitis (pediatric);	chr6:57943175	chr6:57908560~57913911:-
BRCA	cis	rs68170813	0.652	rs17403088	ENSG00000241764.3	AC002467.7	3.61	0.000316	0.0168	0.2	0.11	Coronary artery disease;	chr7:107470928	chr7:107742817~107744581:-
BRCA	cis	rs875971	0.522	rs4502988	ENSG00000223473.2	GS1-124K5.3	3.61	0.000316	0.0168	0.09	0.11	Aortic root size;	chr7:65832759	chr7:66491049~66493566:-
BRCA	cis	rs9437689	1	rs12569038	ENSG00000235501.4	RP4-639F20.1	3.61	0.000316	0.0168	0.14	0.11	Phospholipid levels (plasma);	chr1:95094826	chr1:94927566~94963270:+
BRCA	cis	rs3617	0.572	rs2256332	ENSG00000243224.1	RP5-1157M23.2	3.61	0.000316	0.0168	0.12	0.11	Red blood cell count;Autism spectrum disorder or schizophrenia;	chr3:52821849	chr3:52239258~52241097:+
BRCA	cis	rs4664293	0.801	rs7607143	ENSG00000224152.1	AC009506.1	-3.61	0.000316	0.0168	-0.13	-0.11	Monocyte percentage of white cells;	chr2:159728250	chr2:159615296~159617082:+
BRCA	cis	rs4664293	0.833	rs10170336	ENSG00000224152.1	AC009506.1	-3.61	0.000316	0.0168	-0.13	-0.11	Monocyte percentage of white cells;	chr2:159732832	chr2:159615296~159617082:+
BRCA	cis	rs10876993	0.89	rs1689584	ENSG00000270039.1	RP11-571M6.17	3.61	0.000316	0.0168	0.15	0.11	Celiac disease or Rheumatoid arthritis;	chr12:57687695	chr12:57803838~57804415:+
BRCA	cis	rs256438	0.524	rs412379	ENSG00000251050.1	RP11-168A11.4	-3.61	0.000316	0.0168	-0.12	-0.11	Serum thyroid-stimulating hormone levels;	chr5:80055721	chr5:80019609~80019920:+
BRCA	cis	rs2400749	0.798	rs2400746	ENSG00000258521.1	RP11-638I2.9	-3.61	0.000316	0.0168	-0.11	-0.11	Alzheimer's disease (survival time);	chr14:99568390	chr14:100339832~100340554:+
BRCA	cis	rs35306767	0.855	rs61830932	ENSG00000229869.1	RP11-363N22.2	-3.61	0.000316	0.0168	-0.17	-0.11	Eosinophil percentage of granulocytes;	chr10:888243	chr10:933026~942743:+
BRCA	cis	rs7618915	0.851	rs34228726	ENSG00000239557.1	RP11-168J18.6	3.61	0.000316	0.0168	0.15	0.11	Bipolar disorder;	chr3:52288781	chr3:52373652~52374882:+
BRCA	cis	rs3018712	0.532	rs61889616	ENSG00000251637.5	RP11-119D9.1	3.61	0.000316	0.0168	0.2	0.11	Total body bone mineral density;	chr11:68644538	chr11:67886477~67906350:+
BRCA	cis	rs11048434	0.518	rs1805669	ENSG00000111788.10	RP11-22B23.1	3.61	0.000316	0.0168	0.11	0.11	Sjögren's syndrome;	chr12:9027655	chr12:9277235~9313241:+
BRCA	cis	rs5758511	0.773	rs9623482	ENSG00000233903.2	Z83851.4	3.61	0.000316	0.0168	0.17	0.11	Birth weight;	chr22:41964570	chr22:42276355~42277052:+
BRCA	cis	rs13434995	0.513	rs7698022	ENSG00000273257.1	RP11-177J6.1	3.61	0.000316	0.0168	0.17	0.11	Adiponectin levels;	chr4:55541180	chr4:55387949~55388271:+
BRCA	cis	rs17767294	0.708	rs78094982	ENSG00000219392.1	RP1-265C24.5	-3.61	0.000316	0.0168	-0.3	-0.11	Parkinson's disease;	chr6:28000572	chr6:28115628~28116551:+
BRCA	cis	rs17767294	0.708	rs72848785	ENSG00000219392.1	RP1-265C24.5	-3.61	0.000316	0.0168	-0.3	-0.11	Parkinson's disease;	chr6:28009825	chr6:28115628~28116551:+
BRCA	cis	rs6696239	1	rs12092054	ENSG00000215812.5	ZNF847P	3.61	0.000316	0.0168	0.15	0.11	Height;	chr1:227556548	chr1:227696892~227706699:-
BRCA	cis	rs17711722	0.74	rs7809991	ENSG00000273142.1	RP11-458F8.4	-3.61	0.000316	0.0168	-0.1	-0.11	Calcium levels;	chr7:65941231	chr7:66902857~66906297:+
BRCA	cis	rs10197140	0.925	rs9308691	ENSG00000235721.1	AC013268.3	-3.61	0.000316	0.0168	-0.14	-0.11	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110883561	chr2:110007675~110010783:+
BRCA	cis	rs2274273	0.588	rs7154831	ENSG00000259318.1	RP11-454L9.2	3.61	0.000316	0.0168	0.1	0.11	Protein biomarker;	chr14:55357247	chr14:55394940~55395233:-
BRCA	cis	rs1008375	0.646	rs13145480	ENSG00000249502.1	AC006160.5	3.61	0.000316	0.0168	0.13	0.11	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17563520	chr4:17587467~17614571:-
BRCA	cis	rs4950322	0.57	rs72691097	ENSG00000227242.3	NBPF13P	-3.61	0.000316	0.0168	-0.16	-0.11	Protein quantitative trait loci;	chr1:147299711	chr1:147021320~147124525:-
BRCA	cis	rs4950322	0.57	rs72691098	ENSG00000227242.3	NBPF13P	-3.61	0.000316	0.0168	-0.16	-0.11	Protein quantitative trait loci;	chr1:147300142	chr1:147021320~147124525:-
BRCA	cis	rs172166	0.611	rs203883	ENSG00000219891.2	ZSCAN12P1	3.61	0.000316	0.0168	0.14	0.11	Cardiac Troponin-T levels;	chr6:28110578	chr6:28091154~28093664:+
BRCA	cis	rs62458065	0.85	rs10239812	ENSG00000281332.1	LINC00997	-3.61	0.000316	0.0168	-0.17	-0.11	Metabolite levels (HVA/MHPG ratio);	chr7:32420736	chr7:32760279~32762924:+
BRCA	cis	rs9868809	1	rs2310997	ENSG00000225399.4	RP11-3B7.1	-3.61	0.000317	0.0168	-0.18	-0.11	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48640578	chr3:49260085~49261316:+
BRCA	cis	rs1670533	1	rs6837145	ENSG00000251639.2	RP11-20I20.1	3.61	0.000317	0.0168	0.17	0.11	Recombination rate (females);	chr4:1077279	chr4:1100016~1101558:-
BRCA	cis	rs2262909	0.962	rs409439	ENSG00000279377.1	AC003973.3	3.61	0.000317	0.0168	0.16	0.11	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;	chr19:22044630	chr19:21965708~21968529:-
BRCA	cis	rs2262909	0.962	rs425781	ENSG00000279377.1	AC003973.3	3.61	0.000317	0.0168	0.16	0.11	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;	chr19:22046504	chr19:21965708~21968529:-
BRCA	cis	rs5742933	1	rs5743032	ENSG00000253559.1	OSGEPL1-AS1	-3.61	0.000317	0.0168	-0.16	-0.11	Ferritin levels;	chr2:189814077	chr2:189762704~189765556:+
BRCA	cis	rs7577696	0.962	rs212679	ENSG00000276334.1	AL133243.1	3.61	0.000317	0.0168	0.14	0.11	Inflammatory biomarkers;	chr2:32206038	chr2:32521927~32523547:+
BRCA	cis	rs6120849	0.518	rs11696652	ENSG00000202150.1	RNU6-407P	3.61	0.000317	0.0168	0.16	0.11	Protein C levels;	chr20:35049257	chr20:35030317~35030420:-
BRCA	cis	rs2562456	0.833	rs56179986	ENSG00000268117.1	VN1R84P	3.61	0.000317	0.0168	0.17	0.11	Pain;	chr19:21337882	chr19:21719801~21720035:-
BRCA	cis	rs4538475	0.559	rs79686577	ENSG00000273133.1	RP11-799M12.2	-3.61	0.000317	0.0168	-0.22	-0.11	Parkinson's disease;	chr4:15683762	chr4:15563698~15564253:-
BRCA	cis	rs7560272	0.501	rs12624267	ENSG00000204872.3	NAT8B	3.61	0.000317	0.0168	0.15	0.11	Schizophrenia;	chr2:73759804	chr2:73700576~73701340:-
BRCA	cis	rs6120849	0.754	rs36003887	ENSG00000202150.1	RNU6-407P	3.61	0.000317	0.0168	0.16	0.11	Protein C levels;	chr20:35001304	chr20:35030317~35030420:-
BRCA	cis	rs7712401	0.72	rs10075963	ENSG00000251538.4	RP11-166A12.1	3.61	0.000317	0.0168	0.12	0.11	Mean platelet volume;	chr5:122849726	chr5:122628952~122730685:-
BRCA	cis	rs6432852	1	rs6432852	ENSG00000232411.1	AC009495.3	-3.61	0.000317	0.0168	-0.13	-0.11	Diabetic kidney disease;	chr2:165898043	chr2:165833048~165839098:-
BRCA	cis	rs4589258	1	rs9651551	ENSG00000280367.1	RP11-121L10.2	3.61	0.000317	0.0168	0.13	0.11	Intelligence (multi-trait analysis);	chr11:90769728	chr11:90223153~90226538:+
BRCA	cis	rs453301	0.719	rs34004903	ENSG00000233609.3	RP11-62H7.2	-3.61	0.000317	0.0168	-0.11	-0.11	Joint mobility (Beighton score);	chr8:9035094	chr8:8961200~8979025:+
BRCA	cis	rs4499344	0.73	rs380320	ENSG00000267475.1	CTD-2538C1.2	3.61	0.000317	0.0168	0.14	0.11	Mean platelet volume;	chr19:32614998	chr19:32687089~32691750:-
BRCA	cis	rs27434	0.607	rs34753	ENSG00000248734.2	CTD-2260A17.1	3.61	0.000317	0.0168	0.13	0.11	Ankylosing spondylitis;	chr5:96815208	chr5:96784777~96785999:+
BRCA	cis	rs9341808	0.754	rs3793000	ENSG00000279022.1	RP11-250B2.4	3.61	0.000317	0.0168	0.12	0.11	Sitting height ratio;	chr6:80285420	chr6:80440730~80441172:+
BRCA	cis	rs6452790	0.543	rs737021	ENSG00000247828.6	TMEM161B-AS1	-3.61	0.000317	0.0168	-0.16	-0.11	Cognitive function;	chr5:88061469	chr5:88268895~88436685:+
BRCA	cis	rs9866825	0.967	rs1906546	ENSG00000227110.5	LMCD1-AS1	3.61	0.000317	0.0168	0.13	0.11	QT interval;	chr3:8205658	chr3:7952805~8611924:-
BRCA	cis	rs1876905	0.597	rs354538	ENSG00000255389.1	C6orf3	3.61	0.000317	0.0168	0.14	0.11	Mean corpuscular hemoglobin;	chr6:111196863	chr6:111599875~111602295:+
BRCA	cis	rs8040855	0.599	rs1964724	ENSG00000259416.2	RP11-158M2.5	-3.61	0.000317	0.0168	-0.13	-0.11	Bulimia nervosa;	chr15:85183269	chr15:85754941~85756237:-
BRCA	cis	rs7705042	0.581	rs3764	ENSG00000280047.1	CTC-463A16.1	-3.61	0.000317	0.0168	-0.13	-0.11	Asthma;	chr5:142171563	chr5:142165767~142168387:+
BRCA	cis	rs10426930	0.69	rs710956	ENSG00000280239.1	CTB-50L17.8	-3.61	0.000317	0.0168	-0.09	-0.11	Monocyte percentage of white cells;	chr19:5054499	chr19:4448810~4450836:+
BRCA	cis	rs7429990	0.965	rs1550914	ENSG00000228638.1	FCF1P2	-3.61	0.000317	0.0168	-0.11	-0.11	Educational attainment (years of education);	chr3:47953678	chr3:48290793~48291375:-
BRCA	cis	rs6696239	0.911	rs10753436	ENSG00000227711.2	RP11-275O4.5	-3.61	0.000317	0.0168	-0.15	-0.11	Height;	chr1:227609163	chr1:227509028~227520477:-
BRCA	cis	rs7620503	1	rs34332266	ENSG00000228561.2	RP11-114M1.1	3.61	0.000317	0.0168	0.13	0.11	Corneal structure;	chr3:177581273	chr3:177683627~177691250:+
BRCA	cis	rs73201462	1	rs11712798	ENSG00000242551.2	POU5F1P6	3.61	0.000317	0.0168	0.19	0.11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128175451	chr3:128674735~128677005:-
BRCA	cis	rs12446632	0.599	rs2354584	ENSG00000261195.1	CTD-2380F24.1	-3.61	0.000317	0.0168	-0.19	-0.11	Hip circumference;Body mass index (joint analysis main effects and smoking interaction);BMI in smokers;Menarche (age at onset);Obesity;Childhood body mass index;Waist circumference;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Body mass index;	chr16:19767253	chr16:19761172~19766099:-
BRCA	cis	rs6762	0.748	rs1130663	ENSG00000255108.1	AP006621.8	3.61	0.000317	0.0168	0.12	0.11	Mean platelet volume;	chr11:837582	chr11:823634~832883:-
BRCA	cis	rs6430585	0.591	rs309170	ENSG00000224043.6	CCNT2-AS1	-3.61	0.000317	0.0168	-0.17	-0.11	Corneal structure;	chr2:135915205	chr2:134735464~134918710:-
BRCA	cis	rs10838634	0.901	rs3136448	ENSG00000280615.1	Y_RNA	-3.61	0.000317	0.0168	-0.23	-0.11	Schizophrenia;	chr11:46722819	chr11:47614898~47614994:-
BRCA	cis	rs9467773	0.967	rs1056347	ENSG00000261353.1	CTA-14H9.5	-3.61	0.000317	0.0168	-0.11	-0.11	Intelligence (multi-trait analysis);	chr6:26527296	chr6:26527063~26527404:+
BRCA	cis	rs12761761	0.744	rs12769669	ENSG00000279982.1	RP11-45A17.3	-3.61	0.000317	0.0168	-0.14	-0.11	Intelligence (multi-trait analysis);Educational attainment (years of education);	chr10:131992356	chr10:131996738~131999846:+
BRCA	cis	rs853679	0.546	rs200990	ENSG00000216901.1	AL022393.7	3.61	0.000317	0.0168	0.22	0.11	Depression;	chr6:27848045	chr6:28176188~28176674:+
BRCA	cis	rs8114671	0.562	rs6058120	ENSG00000279253.1	RP4-614O4.13	-3.61	0.000317	0.0168	-0.12	-0.11	Height;	chr20:34815026	chr20:35262727~35264187:-
BRCA	cis	rs72739697	0.892	rs6668714	ENSG00000238061.2	RP4-635A23.4	3.61	0.000317	0.0168	0.25	0.11	Itch intensity from mosquito bite adjusted by bite size;	chr1:185030299	chr1:185280844~185281816:+
BRCA	cis	rs7412746	0.658	rs10305711	ENSG00000224800.1	RP11-235D19.2	-3.61	0.000317	0.0168	-0.14	-0.11	Melanoma;	chr1:150830520	chr1:150881236~150881683:-
BRCA	cis	rs4937076	0.51	rs13424	ENSG00000254967.5	RP11-680F20.6	3.61	0.000317	0.0168	0.12	0.11	Primary tooth development (time to first tooth eruption);	chr11:125957058	chr11:125950116~125956319:+
BRCA	cis	rs7618501	1	rs7374277	ENSG00000228008.1	CTD-2330K9.3	-3.61	0.000318	0.0169	-0.11	-0.11	Intelligence (multi-trait analysis);	chr3:49747344	chr3:49903845~49916937:+
BRCA	cis	rs801193	1	rs2420824	ENSG00000275400.1	RP4-756H11.5	3.61	0.000318	0.0169	0.12	0.11	Aortic root size;	chr7:66666129	chr7:66553805~66554199:-
BRCA	cis	rs17711722	0.522	rs4642526	ENSG00000226002.1	RP11-460N20.5	3.61	0.000318	0.0169	0.12	0.11	Calcium levels;	chr7:65751755	chr7:65084103~65100232:+
BRCA	cis	rs13434995	0.513	rs11240	ENSG00000273257.1	RP11-177J6.1	-3.61	0.000318	0.0169	-0.17	-0.11	Adiponectin levels;	chr4:55453183	chr4:55387949~55388271:+
BRCA	cis	rs34792	0.554	rs12929694	ENSG00000275910.1	RP11-680G24.6	-3.61	0.000318	0.0169	-0.14	-0.11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15519840	chr16:15015828~15016390:-
BRCA	cis	rs61869271	0.736	rs11197010	ENSG00000236799.1	RP11-383C6.2	-3.61	0.000318	0.0169	-0.13	-0.11	Tonsillectomy;	chr10:114955200	chr10:114994657~114996593:+
BRCA	cis	rs875971	0.862	rs778736	ENSG00000271064.1	RP11-792A8.3	-3.61	0.000318	0.0169	-0.13	-0.11	Aortic root size;	chr7:66348861	chr7:66748838~66749077:-
BRCA	cis	rs78487399	0.808	rs6746632	ENSG00000234936.1	AC010883.5	3.61	0.000318	0.0169	0.17	0.11	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43485024	chr2:43229573~43233394:+
BRCA	cis	rs1421334	0.781	rs11778607	ENSG00000271869.1	RP11-51J9.5	3.61	0.000318	0.0169	0.11	0.11	Intelligence (multi-trait analysis);	chr8:30982052	chr8:30155830~30156232:-
BRCA	cis	rs10829156	0.898	rs10741120	ENSG00000225527.1	RP11-383B4.4	-3.61	0.000318	0.0169	-0.16	-0.11	Sudden cardiac arrest;	chr10:18641063	chr10:18531849~18533336:-
BRCA	cis	rs2274273	0.901	rs17674563	ENSG00000259318.1	RP11-454L9.2	3.61	0.000318	0.0169	0.1	0.11	Protein biomarker;	chr14:55364407	chr14:55394940~55395233:-
BRCA	cis	rs35146811	0.657	rs36019559	ENSG00000214313.7	AZGP1P1	-3.61	0.000318	0.0169	-0.12	-0.11	Coronary artery disease;	chr7:100216963	chr7:99980762~99987535:+
BRCA	cis	rs62244186	0.659	rs12108134	ENSG00000227123.1	RPL12P44	-3.61	0.000318	0.0169	-0.12	-0.11	Depressive symptoms;	chr3:44501538	chr3:44937673~44938482:+
BRCA	cis	rs17581137	0.591	rs2397804	ENSG00000259275.2	RP11-522B15.3	-3.61	0.000318	0.0169	-0.13	-0.11	Coronary artery disease;	chr15:95635794	chr15:96354237~96403803:+
BRCA	cis	rs4699052	0.739	rs11936824	ENSG00000248740.4	RP11-328K4.1	3.61	0.000318	0.0169	0.12	0.11	Testicular germ cell tumor;	chr4:103316846	chr4:103256159~103453658:+
BRCA	cis	rs1528472	0.836	rs1690363	ENSG00000276533.1	RP11-139H15.5	3.61	0.000318	0.0169	0.12	0.11	Urinary albumin-to-creatinine ratio;Urinary albumin-to-creatinine ratio in non-diabetics;	chr15:55018629	chr15:55288849~55289346:-
BRCA	cis	rs55780018	0.645	rs7591789	ENSG00000224137.1	AC079767.4	3.61	0.000318	0.0169	0.09	0.11	Systolic blood pressure;	chr2:207637014	chr2:207662375~207667024:+
BRCA	cis	rs10411161	0.702	rs7247017	ENSG00000269483.1	AC006272.1	3.61	0.000318	0.0169	0.19	0.11	Breast cancer;	chr19:51888516	chr19:51839924~51843324:-
BRCA	cis	rs10411161	0.702	rs7256926	ENSG00000269483.1	AC006272.1	3.61	0.000318	0.0169	0.19	0.11	Breast cancer;	chr19:51888735	chr19:51839924~51843324:-
BRCA	cis	rs4073416	0.967	rs4131095	ENSG00000276116.2	FUT8-AS1	-3.61	0.000318	0.0169	-0.12	-0.11	N-glycan levels;	chr14:65792719	chr14:65411170~65412690:-
BRCA	cis	rs10911902	0.643	rs76748438	ENSG00000229739.2	RP11-295K2.3	-3.61	0.000318	0.0169	-0.15	-0.11	Schizophrenia;	chr1:186367379	chr1:186435161~186470291:+
BRCA	cis	rs9309473	0.632	rs6706179	ENSG00000230002.2	ALMS1-IT1	3.61	0.000318	0.0169	0.13	0.11	Metabolite levels;	chr2:73351449	chr2:73456764~73459484:+
BRCA	cis	rs656900	0.692	rs7171819	ENSG00000261229.4	MTHFS	-3.61	0.000318	0.0169	-0.11	-0.11	Cerebrospinal P-tau181p levels;	chr15:79815677	chr15:79843547~79897285:-
BRCA	cis	rs7246967	0.932	rs7256599	ENSG00000198153.8	ZNF849P	-3.61	0.000318	0.0169	-0.16	-0.11	Bronchopulmonary dysplasia;	chr19:22863119	chr19:22685167~22686732:+
BRCA	cis	rs17684571	0.751	rs74777312	ENSG00000231441.1	RP11-472M19.2	3.61	0.000318	0.0169	0.18	0.11	Schizophrenia;	chr6:56845568	chr6:56844002~56864078:+
BRCA	cis	rs4919687	0.55	rs10437480	ENSG00000236937.2	PTGES3P4	3.61	0.000318	0.0169	0.15	0.11	Colorectal cancer;	chr10:102693267	chr10:102845595~102845950:+
BRCA	cis	rs4919687	0.55	rs4264100	ENSG00000236937.2	PTGES3P4	3.61	0.000318	0.0169	0.15	0.11	Colorectal cancer;	chr10:102694356	chr10:102845595~102845950:+
BRCA	cis	rs7487075	0.502	rs12299843	ENSG00000274723.1	RP11-618L22.1	3.61	0.000318	0.0169	0.13	0.11	Itch intensity from mosquito bite;	chr12:46242227	chr12:46970504~46972155:+
BRCA	cis	rs17270561	0.666	rs9356987	ENSG00000272462.2	U91328.19	-3.61	0.000318	0.0169	-0.14	-0.11	Iron status biomarkers;	chr6:25738959	chr6:25992662~26001775:+
BRCA	cis	rs7176093	0.874	rs9635398	ENSG00000259295.5	CSPG4P12	-3.61	0.000318	0.0169	-0.14	-0.11	Aging traits;	chr15:85802824	chr15:85191438~85213905:+
BRCA	cis	rs13126694	0.679	rs4072170	ENSG00000251073.1	NUDT19P5	3.61	0.000318	0.0169	0.11	0.11	Blood osmolality (transformed sodium);	chr4:157980683	chr4:158182825~158183393:+
BRCA	cis	rs1949733	1	rs2140337	ENSG00000251615.3	RP11-774O3.3	-3.61	0.000318	0.0169	-0.12	-0.11	Response to antineoplastic agents;	chr4:8500385	chr4:8355090~8358338:-
BRCA	cis	rs467650	0.509	rs29768	ENSG00000248489.1	CTD-2007H13.3	3.61	0.000318	0.0169	0.12	0.11	Venous thromboembolism (SNP x SNP interaction);	chr5:98645743	chr5:98929171~98995013:+
BRCA	cis	rs1642645	0.872	rs604145	ENSG00000228452.1	RP5-994D16.9	-3.61	0.000318	0.0169	-0.14	-0.11	Left ventricular obstructive tract defect (maternal effect);	chr1:41979442	chr1:42775813~42776790:-
BRCA	cis	rs6108958	0.838	rs8123803	ENSG00000235036.4	RP5-1099D15.1	-3.61	0.000318	0.0169	-0.12	-0.11	Gut microbiome composition (summer);	chr20:11468195	chr20:10612861~10614229:-
BRCA	cis	rs4873772	0.558	rs6472452	ENSG00000253330.1	RP11-697N18.3	-3.61	0.000318	0.0169	-0.16	-0.11	Lobe attachment (rater-scored or self-reported);	chr8:47464657	chr8:47511034~47512141:-
BRCA	cis	rs7487075	0.558	rs56988021	ENSG00000274723.1	RP11-618L22.1	3.61	0.000318	0.0169	0.13	0.11	Itch intensity from mosquito bite;	chr12:46243568	chr12:46970504~46972155:+
BRCA	cis	rs860295	0.702	rs12239100	ENSG00000232093.1	RP11-307C12.11	3.61	0.000318	0.0169	0.13	0.11	Body mass index;	chr1:155458685	chr1:155045191~155046118:-
BRCA	cis	rs448720	0.935	rs431214	ENSG00000260657.2	RP11-315D16.4	-3.61	0.000318	0.0169	-0.13	-0.11	Cognitive performance;	chr15:67918255	chr15:68267792~68277994:-
BRCA	cis	rs2185341	0.788	rs11578020	ENSG00000218510.5	LINC00339	-3.61	0.000318	0.0169	-0.15	-0.11	Amyotrophic lateral sclerosis;	chr1:22355640	chr1:22025188~22031223:+
BRCA	cis	rs2451932	0.745	rs2434302	ENSG00000251050.1	RP11-168A11.4	-3.61	0.000319	0.0169	-0.12	-0.11	LDL peak particle diameter (total fat intake interaction);	chr5:80059369	chr5:80019609~80019920:+
BRCA	cis	rs755249	0.509	rs11206378	ENSG00000237624.1	OXCT2P1	-3.61	0.000319	0.0169	-0.13	-0.11	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39583512	chr1:39514956~39516490:+
BRCA	cis	rs7412746	0.658	rs3843843	ENSG00000231073.1	RP11-316M1.3	3.61	0.000319	0.0169	0.12	0.11	Melanoma;	chr1:150945608	chr1:150973123~150975534:+
BRCA	cis	rs7903456	0.648	rs9421565	ENSG00000200253.1	RNU6-529P	3.61	0.000319	0.0169	0.14	0.11	Gout;Renal underexcretion gout;	chr10:87045655	chr10:87041238~87041341:-
BRCA	cis	rs875971	0.964	rs778721	ENSG00000272831.1	RP11-792A8.4	3.61	0.000319	0.0169	0.1	0.11	Aortic root size;	chr7:66380410	chr7:66739829~66740385:-
BRCA	cis	rs6964587	1	rs10225892	ENSG00000188693.7	CYP51A1-AS1	-3.61	0.000319	0.0169	-0.12	-0.11	Breast cancer;	chr7:92041706	chr7:92134604~92180725:+
BRCA	cis	rs11887277	0.507	rs7602471	ENSG00000272148.1	RP11-195B17.1	-3.61	0.000319	0.0169	-0.13	-0.11	Obesity-related traits;	chr2:26827859	chr2:27062428~27062907:-
BRCA	cis	rs1424638	0.581	rs2865292	ENSG00000233251.6	AC007743.1	-3.61	0.000319	0.0169	-0.13	-0.11	Intelligence (multi-trait analysis);	chr2:57021493	chr2:56173534~56185770:-
BRCA	cis	rs4374383	0.884	rs4353657	ENSG00000243389.1	AC012442.5	3.61	0.000319	0.0169	0.14	0.11	Hepatitis C induced liver fibrosis;	chr2:112003367	chr2:112589040~112614431:+
BRCA	cis	rs7267979	1	rs4815411	ENSG00000277938.1	RP5-965G21.3	-3.61	0.000319	0.0169	-0.13	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25369587	chr20:25229150~25231933:+
BRCA	cis	rs10911902	0.643	rs3766704	ENSG00000229739.2	RP11-295K2.3	-3.61	0.000319	0.0169	-0.15	-0.11	Schizophrenia;	chr1:186342710	chr1:186435161~186470291:+
BRCA	cis	rs1193	0.955	rs1049458	ENSG00000266931.1	RP11-1252D15.1	3.61	0.000319	0.0169	0.13	0.11	High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;High light scatter reticulocyte count;	chr2:86776074	chr2:87055658~87055800:-
BRCA	cis	rs5167	0.536	rs1882752	ENSG00000214855.8	APOC1P1	3.61	0.000319	0.0169	0.15	0.11	Blood protein levels;	chr19:44958085	chr19:44926804~44931386:+
BRCA	cis	rs7264396	0.563	rs2425138	ENSG00000088340.14	FER1L4	-3.61	0.000319	0.0169	-0.16	-0.11	Total cholesterol levels;	chr20:35757788	chr20:35558737~35607562:-
BRCA	cis	rs1455244	0.813	rs2282533	ENSG00000267533.1	RP11-815J4.7	-3.61	0.000319	0.0169	-0.14	-0.11	Schizophrenia;	chr18:11466279	chr18:12067173~12068417:-
BRCA	cis	rs935334	1	rs2121077	ENSG00000258454.1	RP11-361H10.3	-3.61	0.000319	0.0169	-0.19	-0.11	Blood pressure;	chr14:76210012	chr14:76235817~76263474:+
BRCA	cis	rs875971	0.66	rs6460308	ENSG00000275400.1	RP4-756H11.5	3.61	0.000319	0.0169	0.13	0.11	Aortic root size;	chr7:66619753	chr7:66553805~66554199:-
BRCA	cis	rs9368481	0.761	rs6918835	ENSG00000224843.5	LINC00240	3.61	0.000319	0.0169	0.13	0.11	Autism spectrum disorder or schizophrenia;	chr6:27050048	chr6:26956992~27023924:+
BRCA	cis	rs61931739	0.5	rs11053197	ENSG00000258794.3	DUX4L27	3.61	0.000319	0.0169	0.16	0.11	Morning vs. evening chronotype;	chr12:34289014	chr12:34208415~34209675:-
BRCA	cis	rs4664293	0.625	rs7595852	ENSG00000224152.1	AC009506.1	3.61	0.000319	0.0169	0.12	0.11	Monocyte percentage of white cells;	chr2:159683656	chr2:159615296~159617082:+
BRCA	cis	rs950169	0.519	rs7237	ENSG00000230373.7	GOLGA6L5P	-3.61	0.000319	0.0169	-0.14	-0.11	Schizophrenia;	chr15:84643346	chr15:84507885~84516814:-
BRCA	cis	rs7131987	0.903	rs6487796	ENSG00000273680.1	RP11-996F15.6	3.61	0.000319	0.0169	0.14	0.11	QT interval;	chr12:29269831	chr12:29332733~29333383:-
BRCA	cis	rs17406451	0.759	rs35340152	ENSG00000234936.1	AC010883.5	3.61	0.000319	0.0169	0.11	0.11	Mitochondrial DNA levels;	chr2:43430371	chr2:43229573~43233394:+
BRCA	cis	rs1368882	0.814	rs1702020	ENSG00000225183.1	RP4-758J24.4	3.61	0.000319	0.0169	0.14	0.11	Non-substance related behavioral disinhibition;	chr1:54640055	chr1:54089856~54090093:+
BRCA	cis	rs10005067	0.935	rs13133865	ENSG00000249001.4	RP11-742B18.1	-3.61	0.000319	0.0169	-0.13	-0.11	Total body bone mineral density (age 30-45);	chr4:87906745	chr4:87568035~87733956:-
BRCA	cis	rs10005067	0.967	rs10018378	ENSG00000249001.4	RP11-742B18.1	-3.61	0.000319	0.0169	-0.13	-0.11	Total body bone mineral density (age 30-45);	chr4:87907966	chr4:87568035~87733956:-
BRCA	cis	rs10005067	0.935	rs9995995	ENSG00000249001.4	RP11-742B18.1	-3.61	0.000319	0.0169	-0.13	-0.11	Total body bone mineral density (age 30-45);	chr4:87907973	chr4:87568035~87733956:-
BRCA	cis	rs10005067	0.967	rs10007881	ENSG00000249001.4	RP11-742B18.1	-3.61	0.000319	0.0169	-0.13	-0.11	Total body bone mineral density (age 30-45);	chr4:87907987	chr4:87568035~87733956:-
BRCA	cis	rs10005067	0.935	rs10018473	ENSG00000249001.4	RP11-742B18.1	-3.61	0.000319	0.0169	-0.13	-0.11	Total body bone mineral density (age 30-45);	chr4:87908103	chr4:87568035~87733956:-
BRCA	cis	rs10005067	0.967	rs13121427	ENSG00000249001.4	RP11-742B18.1	-3.61	0.000319	0.0169	-0.13	-0.11	Total body bone mineral density (age 30-45);	chr4:87909054	chr4:87568035~87733956:-
BRCA	cis	rs2154490	0.853	rs1011794	ENSG00000176054.6	RPL23P2	3.61	0.000319	0.0169	0.12	0.11	Glucocorticoid-induced osteonecrosis;	chr21:29544809	chr21:28997613~28998033:-
BRCA	cis	rs7165170	0.72	rs724925	ENSG00000259685.2	CTD-2315E11.1	-3.61	0.000319	0.0169	-0.17	-0.11	Crohn's disease;Inflammatory bowel disease;	chr15:90678076	chr15:90102649~90133445:+
BRCA	cis	rs4650943	0.503	rs2861672	ENSG00000227740.1	RP11-318C24.2	3.61	0.000319	0.0169	0.12	0.11	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in inactive individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr1:176153781	chr1:175904762~175920513:-
BRCA	cis	rs13272568	0.614	rs10109008	ENSG00000254352.1	RP11-578O24.2	3.61	0.000319	0.0169	0.14	0.11	Bone mineral density;	chr8:78127693	chr8:78723796~78724136:-
BRCA	cis	rs2835872	0.965	rs1515050	ENSG00000228677.1	TTC3-AS1	3.61	0.000319	0.0169	0.15	0.11	Electroencephalographic traits in alcoholism;	chr21:37630840	chr21:37187666~37193926:-
BRCA	cis	rs4919087	0.527	rs6584123	ENSG00000225850.3	RP11-452K12.4	3.61	0.000319	0.0169	0.14	0.11	Monocyte count;	chr10:97372326	chr10:97334564~97343203:+
BRCA	cis	rs6088580	0.634	rs4911152	ENSG00000275784.1	RP5-1125A11.6	3.61	0.000319	0.0169	0.12	0.11	Glomerular filtration rate (creatinine);	chr20:34367218	chr20:33989480~33991818:-
BRCA	cis	rs1124769	0.506	rs2614766	ENSG00000259298.1	RP11-562A8.4	-3.61	0.000319	0.0169	-0.11	-0.11	Cognitive performance;	chr15:50852394	chr15:50497195~50498744:-
BRCA	cis	rs72634258	0.945	rs12745223	ENSG00000238290.1	RP11-431K24.1	-3.61	0.000319	0.0169	-0.18	-0.11	Inflammatory bowel disease;	chr1:8034918	chr1:8026738~8122702:+
BRCA	cis	rs7182621	0.774	rs12101368	ENSG00000182397.13	DNM1P46	3.61	0.000319	0.0169	0.12	0.11	Colonoscopy-negative controls vs population controls;	chr15:99872475	chr15:99790156~99806927:-
BRCA	cis	rs34779708	0.931	rs11010101	ENSG00000269952.1	RP11-324I22.3	-3.61	0.000319	0.0169	-0.15	-0.11	Inflammatory bowel disease;Crohn's disease;	chr10:35122117	chr10:35210416~35210750:+
BRCA	cis	rs34779708	0.966	rs11010102	ENSG00000269952.1	RP11-324I22.3	-3.61	0.000319	0.0169	-0.15	-0.11	Inflammatory bowel disease;Crohn's disease;	chr10:35122138	chr10:35210416~35210750:+
BRCA	cis	rs7771547	0.519	rs12190911	ENSG00000224666.3	RP1-50J22.4	-3.61	0.000319	0.0169	-0.14	-0.11	Platelet distribution width;	chr6:36410710	chr6:36386831~36393462:+
BRCA	cis	rs6452524	0.901	rs1580309	ENSG00000281327.1	LINC01338	3.61	0.000319	0.0169	0.13	0.11	Hypertension (SNP x SNP interaction);	chr5:83091948	chr5:82850864~82859836:-
BRCA	cis	rs934734	1	rs934734	ENSG00000281920.1	RP11-418H16.1	-3.61	0.000319	0.0169	-0.13	-0.11	Rheumatoid arthritis;	chr2:65368452	chr2:65623272~65628424:+
BRCA	cis	rs8105895	0.935	rs8111854	ENSG00000269345.1	VN1R85P	3.61	0.000319	0.0169	0.16	0.11	Body mass index (change over time);	chr19:22057411	chr19:22174766~22175191:-
BRCA	cis	rs7802263	0.806	rs717240	ENSG00000279419.1	RP5-907C10.3	-3.61	0.00032	0.0169	-0.16	-0.11	Reading and spelling;	chr7:124738751	chr7:124742312~124745017:-
BRCA	cis	rs987360	0.585	rs13118853	ENSG00000248869.4	RP11-138I17.1	3.61	0.00032	0.0169	0.12	0.11	Temperament;	chr4:137261294	chr4:136796722~137212799:-
BRCA	cis	rs172166	0.652	rs476167	ENSG00000219891.2	ZSCAN12P1	3.61	0.00032	0.0169	0.14	0.11	Cardiac Troponin-T levels;	chr6:28098110	chr6:28091154~28093664:+
BRCA	cis	rs17221829	0.699	rs7129641	ENSG00000280385.1	AP000648.5	-3.61	0.00032	0.0169	-0.13	-0.11	Anxiety in major depressive disorder;	chr11:89650538	chr11:90193614~90198120:+
BRCA	cis	rs6120849	0.754	rs8501	ENSG00000202150.1	RNU6-407P	3.61	0.00032	0.0169	0.16	0.11	Protein C levels;	chr20:35002781	chr20:35030317~35030420:-
BRCA	cis	rs6736093	0.966	rs11683694	ENSG00000236307.2	EEF1E1P1	-3.61	0.00032	0.0169	-0.14	-0.11	Coronary artery disease;	chr2:111945070	chr2:111887914~111888741:+
BRCA	cis	rs6479874	1	rs6479840	ENSG00000223502.1	RP11-96B5.3	-3.61	0.00032	0.0169	-0.21	-0.11	Migraine;	chr10:50997141	chr10:51062579~51068553:-
BRCA	cis	rs6479874	1	rs7919300	ENSG00000223502.1	RP11-96B5.3	-3.61	0.00032	0.0169	-0.21	-0.11	Migraine;	chr10:50997481	chr10:51062579~51068553:-
BRCA	cis	rs6479874	1	rs7916094	ENSG00000223502.1	RP11-96B5.3	-3.61	0.00032	0.0169	-0.21	-0.11	Migraine;	chr10:50997509	chr10:51062579~51068553:-
BRCA	cis	rs6479874	1	rs2339688	ENSG00000223502.1	RP11-96B5.3	-3.61	0.00032	0.0169	-0.21	-0.11	Migraine;	chr10:50998248	chr10:51062579~51068553:-
BRCA	cis	rs6479874	1	rs10761662	ENSG00000223502.1	RP11-96B5.3	-3.61	0.00032	0.0169	-0.21	-0.11	Migraine;	chr10:50998461	chr10:51062579~51068553:-
BRCA	cis	rs13401620	0.81	rs13030004	ENSG00000229326.3	AC069154.4	3.61	0.00032	0.0169	0.14	0.11	Breast size;	chr2:119798531	chr2:119698623~119700151:+
BRCA	cis	rs7111546	0.791	rs112122189	ENSG00000246225.5	RP11-17A1.3	3.61	0.00032	0.017	0.19	0.11	Dialysis-related mortality;	chr11:22848172	chr11:22829380~22945393:+
BRCA	cis	rs7111546	0.791	rs78131192	ENSG00000246225.5	RP11-17A1.3	3.61	0.00032	0.017	0.19	0.11	Dialysis-related mortality;	chr11:22849056	chr11:22829380~22945393:+
BRCA	cis	rs10771431	0.81	rs10771418	ENSG00000256069.6	A2MP1	3.61	0.00032	0.017	0.11	0.11	Breast size;	chr12:9206399	chr12:9228533~9275817:-
BRCA	cis	rs11242704	0.662	rs12201506	ENSG00000218027.2	RP11-157J24.1	3.61	0.00032	0.017	0.15	0.11	Response to hepatitis C treatment;	chr6:1536205	chr6:1513698~1515289:-
BRCA	cis	rs8054556	1	rs4788201	ENSG00000183604.13	SMG1P5	-3.61	0.00032	0.017	-0.11	-0.11	Autism spectrum disorder or schizophrenia;	chr16:29961369	chr16:30267553~30335374:-
BRCA	cis	rs6696239	0.823	rs12124388	ENSG00000215812.5	ZNF847P	3.61	0.00032	0.017	0.15	0.11	Height;	chr1:227683125	chr1:227696892~227706699:-
BRCA	cis	rs6600671	0.934	rs12131379	ENSG00000275131.1	CH17-472G23.4	-3.61	0.00032	0.017	-0.1	-0.11	Hip geometry;	chr1:121551639	chr1:120489625~120579190:-
BRCA	cis	rs2276314	0.857	rs28396546	ENSG00000267627.4	RP11-905K4.1	-3.61	0.00032	0.017	-0.15	-0.11	Endometriosis;Drug-induced torsades de pointes;	chr18:36059061	chr18:35951803~35966118:-
BRCA	cis	rs5742933	1	rs3791773	ENSG00000253559.1	OSGEPL1-AS1	-3.61	0.00032	0.017	-0.16	-0.11	Ferritin levels;	chr2:189817906	chr2:189762704~189765556:+
BRCA	cis	rs3755605	0.728	rs6444903	ENSG00000242578.1	RP11-469J4.3	3.61	0.00032	0.017	0.13	0.11	Testicular germ cell tumor;	chr3:170177236	chr3:170410512~170418615:+
BRCA	cis	rs28489187	0.617	rs2840319	ENSG00000223653.4	RP11-131L23.1	-3.61	0.00032	0.017	-0.12	-0.11	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85420541	chr1:85276715~85448124:+
BRCA	cis	rs925550	0.932	rs6534358	ENSG00000224786.1	CETN4P	-3.61	0.00032	0.017	-0.19	-0.11	Primary biliary cholangitis;	chr4:122674036	chr4:122730548~122732193:-
BRCA	cis	rs3785982	0.71	rs11078792	ENSG00000178977.3	LINC00324	-3.61	0.00032	0.017	-0.15	-0.11	Breast cancer (prognosis);	chr17:9188987	chr17:8220642~8224043:-
BRCA	cis	rs10129255	0.957	rs17113284	ENSG00000231475.3	IGHV4-31	3.61	0.00032	0.017	0.09	0.11	Kawasaki disease;	chr14:106684476	chr14:106349283~106349792:-
BRCA	cis	rs7201408	0.528	rs12926725	ENSG00000276571.1	AC002550.6	3.61	0.00032	0.017	0.16	0.11	Attention deficit hyperactivity disorder (inattention symptoms);	chr16:20048355	chr16:19694035~19694428:-
BRCA	cis	rs62025270	0.649	rs12148610	ENSG00000259416.2	RP11-158M2.5	-3.61	0.00032	0.017	-0.17	-0.11	Idiopathic pulmonary fibrosis;	chr15:85702697	chr15:85754941~85756237:-
BRCA	cis	rs73195822	0.614	rs1123852	ENSG00000277299.1	RP11-837J7.4	-3.61	0.00032	0.017	-0.18	-0.11	Itch intensity from mosquito bite;	chr12:110783603	chr12:109948389~109949029:+
BRCA	cis	rs1009077	0.578	rs6834347	ENSG00000245958.5	RP11-33B1.1	-3.61	0.00032	0.017	-0.12	-0.11	Endometriosis;	chr4:119583524	chr4:119454791~119552025:+
BRCA	cis	rs10895275	0.924	rs11225167	ENSG00000277459.1	RP11-732A21.3	-3.61	0.00032	0.017	-0.12	-0.11	Migraine;	chr11:102220170	chr11:102109827~102110457:-
BRCA	cis	rs11892454	0.565	rs7572629	ENSG00000217643.1	PTGES3P2	-3.61	0.00032	0.017	-0.12	-0.11	Heschl's gyrus morphology;	chr2:25731333	chr2:25822469~25822950:+
BRCA	cis	rs11892454	0.599	rs3731639	ENSG00000217643.1	PTGES3P2	-3.61	0.00032	0.017	-0.12	-0.11	Heschl's gyrus morphology;	chr2:25734667	chr2:25822469~25822950:+
BRCA	cis	rs134594	0.885	rs134666	ENSG00000272858.1	CTA-292E10.8	3.61	0.00032	0.017	0.16	0.11	Birth weight;	chr22:29099266	chr22:28814914~28815662:+
BRCA	cis	rs56281245	1	rs1529709	ENSG00000249363.1	CTB-78O21.1	3.61	0.00032	0.017	0.23	0.11	Hepcidin levels;	chr5:145578864	chr5:145728360~145729349:-
BRCA	cis	rs751728	0.687	rs943471	ENSG00000224557.6	HLA-DPB2	-3.61	0.00032	0.017	-0.13	-0.11	Crohn's disease;	chr6:33770537	chr6:33112451~33129084:+
BRCA	cis	rs7487075	0.558	rs4768692	ENSG00000274723.1	RP11-618L22.1	3.61	0.00032	0.017	0.13	0.11	Itch intensity from mosquito bite;	chr12:46245852	chr12:46970504~46972155:+
BRCA	cis	rs2018683	0.707	rs4719961	ENSG00000233517.1	AC005162.5	-3.61	0.00032	0.017	-0.14	-0.11	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28929896	chr7:28987028~28988899:+
BRCA	cis	rs253959	0.545	rs712597	ENSG00000272265.1	CTD-2287O16.4	-3.61	0.00032	0.017	-0.13	-0.11	Bipolar disorder and schizophrenia;	chr5:116322485	chr5:116078110~116078570:-
BRCA	cis	rs6600671	1	rs6600669	ENSG00000275131.1	CH17-472G23.4	-3.61	0.00032	0.017	-0.1	-0.11	Hip geometry;	chr1:121471785	chr1:120489625~120579190:-
BRCA	cis	rs1039766	1	rs268882	ENSG00000227791.3	AC007365.4	3.61	0.00032	0.017	0.16	0.11	Lung adenocarcinoma;Lung cancer;	chr2:65275668	chr2:64665607~64666064:+
BRCA	cis	rs495337	0.699	rs6020075	ENSG00000224397.4	LINC01272	3.61	0.000321	0.017	0.11	0.11	Psoriasis;	chr20:49832158	chr20:50267486~50279795:+
BRCA	cis	rs860295	0.557	rs11264371	ENSG00000203761.5	MSTO2P	-3.61	0.000321	0.017	-0.1	-0.11	Body mass index;	chr1:155442246	chr1:155745829~155750137:+
BRCA	cis	rs9470794	0.92	rs11758747	ENSG00000204110.6	RP1-153P14.8	-3.61	0.000321	0.017	-0.2	-0.11	Type 2 diabetes;	chr6:38088495	chr6:37507348~37535616:+
BRCA	cis	rs897984	0.609	rs17839567	ENSG00000275263.1	RP11-1072A3.4	-3.61	0.000321	0.017	-0.13	-0.11	Dementia with Lewy bodies;	chr16:31046624	chr16:30956872~30957199:-
BRCA	cis	rs11098499	0.909	rs78332141	ENSG00000225892.3	RP11-384K6.2	3.61	0.000321	0.017	0.11	0.11	Corneal astigmatism;	chr4:119454627	chr4:118632274~118634759:+
BRCA	cis	rs2880765	0.835	rs4360874	ENSG00000230373.7	GOLGA6L5P	3.61	0.000321	0.017	0.12	0.11	Coronary artery disease;	chr15:85497589	chr15:84507885~84516814:-
BRCA	cis	rs10943724	1	rs1454446	ENSG00000272129.1	RP11-250B2.6	3.61	0.000321	0.017	0.15	0.11	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr6:80588971	chr6:80355424~80356859:+
BRCA	cis	rs4272720	0.805	rs61848124	ENSG00000228754.1	RP11-534L6.3	-3.61	0.000321	0.017	-0.17	-0.11	Platelet count;Plateletcrit;	chr10:49002665	chr10:48745545~48746128:-
BRCA	cis	rs673253	0.686	rs2842188	ENSG00000229431.1	RP1-92O14.6	3.61	0.000321	0.017	0.12	0.11	Intelligence (multi-trait analysis);	chr1:43548609	chr1:43385113~43389155:+
BRCA	cis	rs801193	0.569	rs35070132	ENSG00000265600.1	AC006480.1	-3.61	0.000321	0.017	-0.13	-0.11	Aortic root size;	chr7:66773096	chr7:67356680~67356779:+
BRCA	cis	rs6500602	0.819	rs3747580	ENSG00000280063.1	RP11-295D4.3	3.61	0.000321	0.017	0.09	0.11	Schizophrenia;	chr16:4405674	chr16:4346694~4348648:-
BRCA	cis	rs4919694	1	rs12257941	ENSG00000236937.2	PTGES3P4	3.61	0.000321	0.017	0.23	0.11	Arsenic metabolism;	chr10:103073404	chr10:102845595~102845950:+
BRCA	cis	rs7412746	0.658	rs12097963	ENSG00000231073.1	RP11-316M1.3	3.61	0.000321	0.017	0.12	0.11	Melanoma;	chr1:150897974	chr1:150973123~150975534:+
BRCA	cis	rs863345	0.604	rs7549581	ENSG00000176320.2	RP11-404O13.5	-3.61	0.000321	0.017	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158519914	chr1:158197922~158203877:-
BRCA	cis	rs863345	0.604	rs7512592	ENSG00000176320.2	RP11-404O13.5	-3.61	0.000321	0.017	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158520155	chr1:158197922~158203877:-
BRCA	cis	rs863345	0.604	rs10797018	ENSG00000176320.2	RP11-404O13.5	-3.61	0.000321	0.017	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158520322	chr1:158197922~158203877:-
BRCA	cis	rs863345	0.527	rs10797019	ENSG00000176320.2	RP11-404O13.5	-3.61	0.000321	0.017	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158520431	chr1:158197922~158203877:-
BRCA	cis	rs863345	0.604	rs10797020	ENSG00000176320.2	RP11-404O13.5	-3.61	0.000321	0.017	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158520534	chr1:158197922~158203877:-
BRCA	cis	rs863345	0.625	rs10489833	ENSG00000176320.2	RP11-404O13.5	-3.61	0.000321	0.017	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158520661	chr1:158197922~158203877:-
BRCA	cis	rs863345	0.604	rs11265003	ENSG00000176320.2	RP11-404O13.5	-3.61	0.000321	0.017	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158520841	chr1:158197922~158203877:-
BRCA	cis	rs863345	0.604	rs950260	ENSG00000176320.2	RP11-404O13.5	-3.61	0.000321	0.017	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158521730	chr1:158197922~158203877:-
BRCA	cis	rs863345	0.604	rs7518808	ENSG00000176320.2	RP11-404O13.5	-3.61	0.000321	0.017	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158522030	chr1:158197922~158203877:-
BRCA	cis	rs9303029	1	rs9898723	ENSG00000265458.1	RP13-20L14.6	3.61	0.000321	0.017	0.18	0.11	Protein quantitative trait loci;	chr17:82482031	chr17:82454273~82458521:-
BRCA	cis	rs10838634	0.803	rs7105217	ENSG00000280615.1	Y_RNA	-3.61	0.000321	0.017	-0.19	-0.11	Schizophrenia;	chr11:46817287	chr11:47614898~47614994:-
BRCA	cis	rs17711722	0.727	rs1880555	ENSG00000272831.1	RP11-792A8.4	3.61	0.000321	0.017	0.1	0.11	Calcium levels;	chr7:65967580	chr7:66739829~66740385:-
BRCA	cis	rs72799341	0.706	rs59735493	ENSG00000274678.1	RP11-2C24.7	3.61	0.000321	0.017	0.13	0.11	Diastolic blood pressure;	chr16:31121779	chr16:30821338~30821884:+
BRCA	cis	rs6490294	0.528	rs12579336	ENSG00000257624.1	RP1-128M12.3	3.61	0.000321	0.017	0.2	0.11	Mean platelet volume;	chr12:112177734	chr12:112000739~112000985:-
BRCA	cis	rs4578769	0.959	rs12964817	ENSG00000273232.1	RP11-370A5.2	3.61	0.000321	0.017	0.15	0.11	Eosinophil percentage of white cells;	chr18:22876657	chr18:22882825~22883357:-
BRCA	cis	rs6504622	0.577	rs197925	ENSG00000263142.4	LRRC37A17P	3.61	0.000321	0.017	0.09	0.11	Orofacial clefts;	chr17:46933355	chr17:46978481~47054569:+
BRCA	cis	rs6504622	0.702	rs11079747	ENSG00000263142.4	LRRC37A17P	-3.61	0.000321	0.017	-0.09	-0.11	Orofacial clefts;	chr17:47001484	chr17:46978481~47054569:+
BRCA	cis	rs7818688	1	rs10098197	ENSG00000245080.5	RP11-320N21.1	-3.61	0.000321	0.017	-0.18	-0.11	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95030662	chr8:95066808~95073182:-
BRCA	cis	rs7818688	1	rs56901035	ENSG00000245080.5	RP11-320N21.1	-3.61	0.000321	0.017	-0.18	-0.11	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95030960	chr8:95066808~95073182:-
BRCA	cis	rs745109	0.882	rs17027265	ENSG00000273080.1	RP11-301O19.1	3.61	0.000321	0.017	0.17	0.11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86488771	chr2:86195590~86196049:+
BRCA	cis	rs745109	0.882	rs61028062	ENSG00000273080.1	RP11-301O19.1	3.61	0.000321	0.017	0.17	0.11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86488958	chr2:86195590~86196049:+
BRCA	cis	rs9295536	0.651	rs9466269	ENSG00000260455.1	NBAT1	-3.61	0.000321	0.017	-0.12	-0.11	Neuroblastoma;	chr6:22136180	chr6:22134957~22147193:-
BRCA	cis	rs13118159	0.509	rs1882098	ENSG00000273179.1	RP11-20I20.4	3.61	0.000321	0.017	0.12	0.11	Longevity;	chr4:1358643	chr4:1167778~1168174:+
BRCA	cis	rs10181042	0.565	rs2564117	ENSG00000270820.4	RP11-355B11.2	3.61	0.000321	0.017	0.12	0.11	Crohn's disease;	chr2:61005887	chr2:61471188~61484130:+
BRCA	cis	rs6991838	0.584	rs7463649	ENSG00000272155.1	RP11-707M3.3	3.61	0.000321	0.017	0.1	0.11	Intelligence (multi-trait analysis);	chr8:65573760	chr8:65714334~65714778:-
BRCA	cis	rs6991838	0.584	rs7463740	ENSG00000272155.1	RP11-707M3.3	3.61	0.000321	0.017	0.1	0.11	Intelligence (multi-trait analysis);	chr8:65573950	chr8:65714334~65714778:-
BRCA	cis	rs6991838	0.584	rs66467166	ENSG00000272155.1	RP11-707M3.3	3.61	0.000321	0.017	0.1	0.11	Intelligence (multi-trait analysis);	chr8:65574165	chr8:65714334~65714778:-
BRCA	cis	rs6600671	0.692	rs11249430	ENSG00000223345.3	HIST2H2BA	3.61	0.000321	0.017	0.14	0.11	Hip geometry;	chr1:121547115	chr1:121108210~121117257:-
BRCA	cis	rs4919687	0.55	rs17784294	ENSG00000236937.2	PTGES3P4	3.61	0.000322	0.017	0.15	0.11	Colorectal cancer;	chr10:102719628	chr10:102845595~102845950:+
BRCA	cis	rs875971	0.862	rs4718383	ENSG00000271064.1	RP11-792A8.3	3.61	0.000322	0.017	0.13	0.11	Aortic root size;	chr7:66643422	chr7:66748838~66749077:-
BRCA	cis	rs7267979	1	rs2257808	ENSG00000274414.1	RP5-965G21.4	-3.61	0.000322	0.017	-0.13	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25285814	chr20:25239007~25245229:-
BRCA	cis	rs7267979	1	rs2257809	ENSG00000274414.1	RP5-965G21.4	-3.61	0.000322	0.017	-0.13	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25285840	chr20:25239007~25245229:-
BRCA	cis	rs10266483	0.639	rs6952592	ENSG00000227986.1	TRIM60P18	-3.61	0.000322	0.017	-0.12	-0.11	Response to statin therapy;	chr7:64293667	chr7:64355078~64356199:+
BRCA	cis	rs17711722	0.522	rs62469933	ENSG00000226002.1	RP11-460N20.5	3.61	0.000322	0.017	0.12	0.11	Calcium levels;	chr7:65800652	chr7:65084103~65100232:+
BRCA	cis	rs6991838	0.584	rs16932250	ENSG00000272155.1	RP11-707M3.3	3.61	0.000322	0.017	0.1	0.11	Intelligence (multi-trait analysis);	chr8:65598779	chr8:65714334~65714778:-
BRCA	cis	rs4978813	0.5	rs58522556	ENSG00000213539.4	YBX1P6	-3.61	0.000322	0.017	-0.12	-0.11	Plantar warts;	chr9:109536728	chr9:109532830~109534332:-
BRCA	cis	rs9788682	0.633	rs2656070	ENSG00000261143.1	ADAMTS7P3	3.61	0.000322	0.017	0.16	0.11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78437910	chr15:77976042~77993057:+
BRCA	cis	rs1075265	0.744	rs10203576	ENSG00000272156.1	RP11-477N3.1	-3.61	0.000322	0.017	-0.11	-0.11	Chronotype;Morning vs. evening chronotype;	chr2:54060939	chr2:54082554~54085066:+
BRCA	cis	rs3015497	0.611	rs6572691	ENSG00000259113.1	RP11-406H23.2	-3.61	0.000322	0.017	-0.12	-0.11	Mean platelet volume;	chr14:50708046	chr14:50448807~50456742:+
BRCA	cis	rs1979679	0.842	rs12049916	ENSG00000256056.1	RP11-709A23.2	3.61	0.000322	0.017	0.16	0.11	Ossification of the posterior longitudinal ligament of the spine;	chr12:28207052	chr12:27592461~27594039:-
BRCA	cis	rs875971	0.862	rs9791712	ENSG00000271064.1	RP11-792A8.3	3.61	0.000322	0.017	0.13	0.11	Aortic root size;	chr7:66640176	chr7:66748838~66749077:-
BRCA	cis	rs875971	0.862	rs9791713	ENSG00000271064.1	RP11-792A8.3	3.61	0.000322	0.017	0.13	0.11	Aortic root size;	chr7:66640211	chr7:66748838~66749077:-
BRCA	cis	rs8064024	0.599	rs3185547	ENSG00000267077.1	RP11-127I20.5	3.61	0.000322	0.017	0.12	0.11	Cancer;	chr16:4881099	chr16:4795265~4796532:-
BRCA	cis	rs867529	0.924	rs6739095	ENSG00000234028.3	AC062029.1	-3.61	0.000322	0.017	-0.12	-0.11	Height;	chr2:88580546	chr2:88627539~88631821:+
BRCA	cis	rs751728	0.664	rs4711349	ENSG00000224557.6	HLA-DPB2	-3.61	0.000322	0.0171	-0.13	-0.11	Crohn's disease;	chr6:33772815	chr6:33112451~33129084:+
BRCA	cis	rs3749237	0.964	rs35210174	ENSG00000225399.4	RP11-3B7.1	3.61	0.000322	0.0171	0.11	0.11	Resting heart rate;	chr3:49775173	chr3:49260085~49261316:+
BRCA	cis	rs983392	0.755	rs688030	ENSG00000275344.1	MIR6503	-3.61	0.000322	0.0171	-0.11	-0.11	Alzheimer's disease (late onset);	chr11:60150689	chr11:60209071~60209156:-
BRCA	cis	rs10777288	0.561	rs10777281	ENSG00000258100.1	RP11-121E16.1	3.61	0.000322	0.0171	0.14	0.11	Pulmonary function (smoking interaction);	chr12:91009642	chr12:91362196~91368606:+
BRCA	cis	rs2274273	0.87	rs11625423	ENSG00000259318.1	RP11-454L9.2	3.61	0.000322	0.0171	0.09	0.11	Protein biomarker;	chr14:55329195	chr14:55394940~55395233:-
BRCA	cis	rs10863681	0.664	rs10863680	ENSG00000238042.4	RP11-815M8.1	-3.61	0.000322	0.0171	-0.12	-0.11	Metabolite levels (HVA-5-HIAA Factor score);	chr1:222071538	chr1:221880981~221978523:-
BRCA	cis	rs11603020	0.851	rs10896631	ENSG00000265566.2	RN7SL605P	-3.61	0.000322	0.0171	-0.16	-0.11	Blood protein levels;	chr11:57613790	chr11:57528085~57528365:-
BRCA	cis	rs11603020	0.904	rs4926	ENSG00000265566.2	RN7SL605P	-3.61	0.000322	0.0171	-0.16	-0.11	Blood protein levels;	chr11:57614516	chr11:57528085~57528365:-
BRCA	cis	rs11603020	0.904	rs11606677	ENSG00000265566.2	RN7SL605P	-3.61	0.000322	0.0171	-0.16	-0.11	Blood protein levels;	chr11:57615904	chr11:57528085~57528365:-
BRCA	cis	rs3743266	0.613	rs8027901	ENSG00000245534.5	RORA-AS1	3.61	0.000322	0.0171	0.13	0.11	Menarche (age at onset);	chr15:60441265	chr15:60479178~60630637:+
BRCA	cis	rs1404100	0.51	rs6768480	ENSG00000249274.1	PDLIM1P4	3.61	0.000322	0.0171	0.12	0.11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:99070070	chr3:98782188~98783193:+
BRCA	cis	rs875971	0.628	rs6974355	ENSG00000272831.1	RP11-792A8.4	3.61	0.000322	0.0171	0.1	0.11	Aortic root size;	chr7:66376994	chr7:66739829~66740385:-
BRCA	cis	rs2033711	0.654	rs734380	ENSG00000268307.1	CTD-2619J13.13	3.61	0.000322	0.0171	0.13	0.11	Uric acid clearance;	chr19:58387596	chr19:58400221~58400679:+
BRCA	cis	rs4478858	0.775	rs6701861	ENSG00000229447.2	RP11-490K7.4	-3.61	0.000322	0.0171	-0.1	-0.11	Alcohol dependence;	chr1:31235278	chr1:31263245~31263681:-
BRCA	cis	rs17684571	0.938	rs16888124	ENSG00000231441.1	RP11-472M19.2	3.61	0.000322	0.0171	0.15	0.11	Schizophrenia;	chr6:56700826	chr6:56844002~56864078:+
BRCA	cis	rs2839627	0.683	rs73233342	ENSG00000225218.1	AP001628.6	3.61	0.000322	0.0171	0.21	0.11	Information processing speed;	chr21:42923265	chr21:42831040~42836477:-
BRCA	cis	rs6088580	0.634	rs2378134	ENSG00000275784.1	RP5-1125A11.6	3.61	0.000322	0.0171	0.12	0.11	Glomerular filtration rate (creatinine);	chr20:34350279	chr20:33989480~33991818:-
BRCA	cis	rs13272568	0.614	rs62510275	ENSG00000254352.1	RP11-578O24.2	-3.61	0.000322	0.0171	-0.14	-0.11	Bone mineral density;	chr8:78119259	chr8:78723796~78724136:-
BRCA	cis	rs7267979	1	rs7343481	ENSG00000274414.1	RP5-965G21.4	3.61	0.000323	0.0171	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25319477	chr20:25239007~25245229:-
BRCA	cis	rs739496	0.615	rs4648328	ENSG00000257624.1	RP1-128M12.3	3.61	0.000323	0.0171	0.16	0.11	Platelet count;	chr12:111784984	chr12:112000739~112000985:-
BRCA	cis	rs10844706	0.735	rs11052754	ENSG00000214776.8	RP11-726G1.1	3.61	0.000323	0.0171	0.14	0.11	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9736046	chr12:9467552~9576275:+
BRCA	cis	rs17270561	0.609	rs6941933	ENSG00000272462.2	U91328.19	-3.61	0.000323	0.0171	-0.14	-0.11	Iron status biomarkers;	chr6:25745474	chr6:25992662~26001775:+
BRCA	cis	rs10005067	0.967	rs17783002	ENSG00000249001.4	RP11-742B18.1	-3.61	0.000323	0.0171	-0.13	-0.11	Total body bone mineral density (age 30-45);	chr4:87903064	chr4:87568035~87733956:-
BRCA	cis	rs4950322	0.58	rs7541393	ENSG00000227242.3	NBPF13P	-3.61	0.000323	0.0171	-0.15	-0.11	Protein quantitative trait loci;	chr1:147117186	chr1:147021320~147124525:-
BRCA	cis	rs683250	0.629	rs588016	ENSG00000254551.1	RP11-727A23.7	3.61	0.000323	0.0171	0.14	0.11	Subcortical brain region volumes;	chr11:83236701	chr11:83209431~83213379:-
BRCA	cis	rs6964587	0.692	rs4727268	ENSG00000188693.7	CYP51A1-AS1	-3.61	0.000323	0.0171	-0.12	-0.11	Breast cancer;	chr7:92211410	chr7:92134604~92180725:+
BRCA	cis	rs6964587	0.692	rs6970629	ENSG00000188693.7	CYP51A1-AS1	-3.61	0.000323	0.0171	-0.12	-0.11	Breast cancer;	chr7:92217285	chr7:92134604~92180725:+
BRCA	cis	rs6121246	0.954	rs6089093	ENSG00000230613.1	HM13-AS1	3.61	0.000323	0.0171	0.16	0.11	Mean corpuscular hemoglobin;	chr20:31833656	chr20:31567707~31573263:-
BRCA	cis	rs561341	1	rs530209	ENSG00000265798.5	RP11-271K11.5	3.61	0.000323	0.0171	0.19	0.11	Hip circumference adjusted for BMI;	chr17:31988268	chr17:31038575~31059121:-
BRCA	cis	rs561341	1	rs561341	ENSG00000265798.5	RP11-271K11.5	3.61	0.000323	0.0171	0.19	0.11	Hip circumference adjusted for BMI;	chr17:31989366	chr17:31038575~31059121:-
BRCA	cis	rs8037137	0.915	rs2290202	ENSG00000258725.1	PRC1-AS1	-3.61	0.000323	0.0171	-0.18	-0.11	Platelet count;Invasive epithelial ovarian cancer;Serous invasive ovarian cancer;High-grade serous ovarian cancer;	chr15:90969037	chr15:90966345~90988624:+
BRCA	cis	rs4835473	0.932	rs34653324	ENSG00000246448.2	RP13-578N3.3	-3.61	0.000323	0.0171	-0.13	-0.11	Immature fraction of reticulocytes;	chr4:143735058	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.932	rs35947648	ENSG00000246448.2	RP13-578N3.3	-3.61	0.000323	0.0171	-0.13	-0.11	Immature fraction of reticulocytes;	chr4:143735092	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.838	rs35800634	ENSG00000246448.2	RP13-578N3.3	-3.61	0.000323	0.0171	-0.13	-0.11	Immature fraction of reticulocytes;	chr4:143735199	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.838	rs34505330	ENSG00000246448.2	RP13-578N3.3	-3.61	0.000323	0.0171	-0.13	-0.11	Immature fraction of reticulocytes;	chr4:143735206	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.932	rs4597770	ENSG00000246448.2	RP13-578N3.3	-3.61	0.000323	0.0171	-0.13	-0.11	Immature fraction of reticulocytes;	chr4:143735239	chr4:143700257~143865072:+
BRCA	cis	rs6489785	0.521	rs668622	ENSG00000277423.1	RP11-173P15.9	-3.61	0.000323	0.0171	-0.13	-0.11	Longevity;Allergic disease (asthma, hay fever or eczema);	chr12:120760496	chr12:120703867~120704282:+
BRCA	cis	rs250518	0.926	rs34919293	ENSG00000271926.1	CTD-2376I4.1	3.61	0.000323	0.0171	0.15	0.11	Mean corpuscular hemoglobin concentration;	chr5:72756687	chr5:72953635~72954274:-
BRCA	cis	rs739401	0.611	rs417957	ENSG00000247473.2	CARS-AS1	3.61	0.000323	0.0171	0.13	0.11	Longevity;	chr11:3025001	chr11:3029009~3041260:+
BRCA	cis	rs6964587	1	rs28410528	ENSG00000188693.7	CYP51A1-AS1	-3.61	0.000323	0.0171	-0.12	-0.11	Breast cancer;	chr7:92018076	chr7:92134604~92180725:+
BRCA	cis	rs849141	0.89	rs849143	ENSG00000234336.5	JAZF1-AS1	-3.61	0.000323	0.0171	-0.16	-0.11	Height;Hip circumference adjusted for BMI;	chr7:28146854	chr7:28180322~28243917:+
BRCA	cis	rs17214007	0.877	rs1569300	ENSG00000279866.1	CTB-193M12.4	3.61	0.000323	0.0171	0.17	0.11	Cognitive function;	chr16:15776891	chr16:15704410~15705984:+
BRCA	cis	rs2615061	0.746	rs2078389	ENSG00000229965.1	RP11-118H4.1	-3.61	0.000323	0.0171	-0.19	-0.11	Monocyte count;	chr1:225769181	chr1:226438564~226439344:+
BRCA	cis	rs11170631	0.504	rs12817180	ENSG00000270175.1	RP11-793H13.11	-3.61	0.000323	0.0171	-0.1	-0.11	Height;	chr12:53641664	chr12:53500162~53500936:-
BRCA	cis	rs13434995	0.513	rs7676245	ENSG00000273257.1	RP11-177J6.1	-3.61	0.000323	0.0171	-0.17	-0.11	Adiponectin levels;	chr4:55455150	chr4:55387949~55388271:+
BRCA	cis	rs2638953	0.924	rs11049610	ENSG00000273989.1	RP11-425D17.2	-3.61	0.000323	0.0171	-0.17	-0.11	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28446674	chr12:28236227~28236828:+
BRCA	cis	rs875971	0.545	rs316324	ENSG00000232559.3	GS1-124K5.12	-3.61	0.000323	0.0171	-0.15	-0.11	Aortic root size;	chr7:66145627	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.545	rs316323	ENSG00000232559.3	GS1-124K5.12	-3.61	0.000323	0.0171	-0.15	-0.11	Aortic root size;	chr7:66146002	chr7:66554588~66576923:-
BRCA	cis	rs6545883	0.929	rs3732170	ENSG00000212978.6	AC016747.3	3.61	0.000323	0.0171	0.15	0.11	Tuberculosis;	chr2:61522581	chr2:61141592~61144969:-
BRCA	cis	rs4865762	0.687	rs153120	ENSG00000247796.2	CTD-2366F13.1	3.61	0.000323	0.0171	0.12	0.11	Intraocular pressure;	chr5:53231957	chr5:53109842~53115126:+
BRCA	cis	rs10943724	1	rs10943725	ENSG00000272129.1	RP11-250B2.6	3.61	0.000323	0.0171	0.15	0.11	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr6:80593266	chr6:80355424~80356859:+
BRCA	cis	rs1642645	0.831	rs348128	ENSG00000228452.1	RP5-994D16.9	-3.61	0.000323	0.0171	-0.15	-0.11	Left ventricular obstructive tract defect (maternal effect);	chr1:42022690	chr1:42775813~42776790:-
BRCA	cis	rs66887589	0.627	rs3872807	ENSG00000260404.2	RP11-384K6.6	3.61	0.000323	0.0171	0.1	0.11	Diastolic blood pressure;	chr4:119439096	chr4:118591773~118633729:+
BRCA	cis	rs6981523	0.553	rs2409730	ENSG00000255046.1	RP11-297N6.4	3.61	0.000323	0.0171	0.14	0.11	Neuroticism;	chr8:11203129	chr8:11797928~11802568:-
BRCA	cis	rs2243480	1	rs160652	ENSG00000237026.1	RP11-328P23.2	3.61	0.000323	0.0171	0.22	0.11	Diabetic kidney disease;	chr7:66073444	chr7:65235790~65236723:-
BRCA	cis	rs7131987	0.903	rs10843371	ENSG00000257176.2	RP11-996F15.2	-3.61	0.000323	0.0171	-0.13	-0.11	QT interval;	chr12:29261299	chr12:29280418~29317848:-
BRCA	cis	rs1867631	0.585	rs6670827	ENSG00000248458.2	RP4-598P13.1	3.61	0.000323	0.0171	0.11	0.11	Menopause (age at onset);	chr1:66661323	chr1:66665864~66677027:-
BRCA	cis	rs6943931	1	rs6964510	ENSG00000230658.1	KLHL7-AS1	-3.61	0.000324	0.0171	-0.15	-0.11	Diabetic kidney disease;	chr7:22375155	chr7:23101228~23105703:-
BRCA	cis	rs6439699	0.941	rs13068466	ENSG00000239213.4	NCK1-AS1	3.61	0.000324	0.0171	0.15	0.11	Intelligence (multi-trait analysis);	chr3:137271599	chr3:136841726~136862054:-
BRCA	cis	rs11892454	0.599	rs919205	ENSG00000217643.1	PTGES3P2	-3.61	0.000324	0.0171	-0.12	-0.11	Heschl's gyrus morphology;	chr2:25733576	chr2:25822469~25822950:+
BRCA	cis	rs11892454	0.561	rs7591277	ENSG00000217643.1	PTGES3P2	-3.61	0.000324	0.0171	-0.12	-0.11	Heschl's gyrus morphology;	chr2:25736054	chr2:25822469~25822950:+
BRCA	cis	rs11892454	0.599	rs10153560	ENSG00000217643.1	PTGES3P2	-3.61	0.000324	0.0171	-0.12	-0.11	Heschl's gyrus morphology;	chr2:25738714	chr2:25822469~25822950:+
BRCA	cis	rs10838687	0.8	rs3729802	ENSG00000243802.2	RP11-390K5.1	3.61	0.000324	0.0171	0.16	0.11	Proinsulin levels;	chr11:47332517	chr11:47191181~47191542:-
BRCA	cis	rs2148307	0.964	rs1926207	ENSG00000228339.1	AMD1P1	-3.61	0.000324	0.0171	-0.13	-0.11	Photic sneeze reflex;	chr10:20789611	chr10:20350049~20351100:+
BRCA	cis	rs848490	0.889	rs12113982	ENSG00000214293.7	APTR	3.61	0.000324	0.0171	0.14	0.11	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77547073	chr7:77657660~77696265:-
BRCA	cis	rs846271	0.843	rs846274	ENSG00000224116.5	INHBA-AS1	3.61	0.000324	0.0171	0.14	0.11	IgG glycosylation;	chr7:42022387	chr7:41693916~41779388:+
BRCA	cis	rs6596100	0.915	rs28548389	ENSG00000248648.1	RP11-485M7.1	-3.61	0.000324	0.0171	-0.14	-0.11	Breast cancer;	chr5:133100700	chr5:133003119~133003365:+
BRCA	cis	rs12723316	0.932	rs17521573	ENSG00000233008.4	RP11-475O6.1	-3.61	0.000324	0.0171	-0.21	-0.11	Schizophrenia;	chr1:83814830	chr1:83575776~83861023:-
BRCA	cis	rs17818399	0.547	rs12997164	ENSG00000279254.1	RP11-536C12.1	-3.61	0.000324	0.0171	-0.14	-0.11	Height;	chr2:46531607	chr2:46668870~46670778:+
BRCA	cis	rs4478858	0.735	rs1566964	ENSG00000223907.1	LINC01226	-3.61	0.000324	0.0171	-0.13	-0.11	Alcohol dependence;	chr1:31319947	chr1:31518435~31524245:+
BRCA	cis	rs739496	0.615	rs59905228	ENSG00000226469.1	ADAM1B	3.61	0.000324	0.0171	0.15	0.11	Platelet count;	chr12:111743422	chr12:111927018~111929017:+
BRCA	cis	rs875971	0.545	rs12670811	ENSG00000226767.1	RP11-328P23.3	3.61	0.000324	0.0171	0.14	0.11	Aortic root size;	chr7:66358032	chr7:65508773~65508944:-
BRCA	cis	rs3136202	0.684	rs12448995	ENSG00000242307.1	RPS26P52	3.61	0.000324	0.0171	0.14	0.11	Conduct disorder (symptom count);	chr16:13982365	chr16:13922332~13922679:-
BRCA	cis	rs1348850	0.526	rs6433672	ENSG00000271825.1	RP11-337N6.2	3.61	0.000324	0.0171	0.19	0.11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177513447	chr2:177300600~177302006:+
BRCA	cis	rs600550	0.588	rs12225299	ENSG00000275344.1	MIR6503	3.61	0.000324	0.0171	0.12	0.11	Lipoprotein-associated phospholipase A2 activity and mass;	chr11:60316992	chr11:60209071~60209156:-
BRCA	cis	rs8054556	0.647	rs4077410	ENSG00000214725.6	CDIPT-AS1	-3.61	0.000324	0.0171	-0.13	-0.11	Autism spectrum disorder or schizophrenia;	chr16:29986879	chr16:29863593~29868053:+
BRCA	cis	rs7089973	0.934	rs12771956	ENSG00000236799.1	RP11-383C6.2	-3.61	0.000324	0.0171	-0.15	-0.11	Bipolar disorder or attention deficit hyperactivity disorder;	chr10:114816469	chr10:114994657~114996593:+
BRCA	cis	rs3847687	1	rs3847688	ENSG00000250208.5	FZD10-AS1	3.61	0.000324	0.0171	0.13	0.11	Longevity;	chr12:131040765	chr12:130144315~130162256:-
BRCA	cis	rs875971	0.505	rs1167386	ENSG00000223473.2	GS1-124K5.3	-3.61	0.000324	0.0171	-0.09	-0.11	Aortic root size;	chr7:66048109	chr7:66491049~66493566:-
BRCA	cis	rs4908769	0.66	rs301797	ENSG00000232912.4	RP5-1115A15.1	3.61	0.000324	0.0171	0.12	0.11	Allergy;	chr1:8427263	chr1:8424645~8434838:+
BRCA	cis	rs4908768	0.657	rs6693466	ENSG00000270282.1	RP5-1115A15.2	-3.61	0.000324	0.0171	-0.14	-0.11	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8757879	chr1:8512653~8513021:+
BRCA	cis	rs829883	0.872	rs1641637	ENSG00000227825.4	SLC9A7P1	3.61	0.000324	0.0171	0.14	0.11	Colorectal adenoma (advanced);	chr12:98496786	chr12:98453835~98457145:-
BRCA	cis	rs829883	0.902	rs1620317	ENSG00000227825.4	SLC9A7P1	3.61	0.000324	0.0171	0.14	0.11	Colorectal adenoma (advanced);	chr12:98496788	chr12:98453835~98457145:-
BRCA	cis	rs9402743	0.775	rs9494322	ENSG00000231028.7	LINC00271	3.61	0.000324	0.0171	0.11	0.11	Systemic lupus erythematosus;	chr6:135660922	chr6:135497801~135716055:+
BRCA	cis	rs11892454	0.599	rs35701447	ENSG00000217643.1	PTGES3P2	-3.61	0.000324	0.0172	-0.12	-0.11	Heschl's gyrus morphology;	chr2:25789022	chr2:25822469~25822950:+
BRCA	cis	rs7914558	1	rs943036	ENSG00000213277.3	MARCKSL1P1	3.61	0.000324	0.0172	0.12	0.11	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103076290	chr10:103175554~103176094:+
BRCA	cis	rs10744816	0.846	rs7963168	ENSG00000257817.1	RP4-601P9.2	-3.61	0.000324	0.0172	-0.14	-0.11	Obesity-related traits;	chr12:114273261	chr12:114713811~114767957:+
BRCA	cis	rs6545883	0.931	rs778765	ENSG00000212978.6	AC016747.3	3.61	0.000324	0.0172	0.15	0.11	Tuberculosis;	chr2:61559250	chr2:61141592~61144969:-
BRCA	cis	rs7618501	1	rs11130221	ENSG00000228008.1	CTD-2330K9.3	3.61	0.000324	0.0172	0.11	0.11	Intelligence (multi-trait analysis);	chr3:49781669	chr3:49903845~49916937:+
BRCA	cis	rs7819412	0.561	rs2001328	ENSG00000254507.2	RP11-481A20.10	3.61	0.000324	0.0172	0.14	0.11	Triglycerides;	chr8:11129689	chr8:12003400~12004082:-
BRCA	cis	rs863345	0.604	rs6663277	ENSG00000229914.1	RP11-404O13.4	-3.61	0.000324	0.0172	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158525211	chr1:158195633~158196131:-
BRCA	cis	rs365302	0.556	rs558804	ENSG00000235086.1	FNDC1-IT1	3.61	0.000324	0.0172	0.16	0.11	Coronary heart disease;	chr6:159226422	chr6:159240786~159243329:+
BRCA	cis	rs6088580	0.634	rs6059866	ENSG00000275784.1	RP5-1125A11.6	-3.61	0.000324	0.0172	-0.12	-0.11	Glomerular filtration rate (creatinine);	chr20:34488005	chr20:33989480~33991818:-
BRCA	cis	rs2251381	0.565	rs2832279	ENSG00000232855.5	AF131217.1	-3.61	0.000324	0.0172	-0.14	-0.11	Selective IgA deficiency;	chr21:29241145	chr21:28439346~28674848:-
BRCA	cis	rs2832270	0.562	rs2832250	ENSG00000176054.6	RPL23P2	3.61	0.000325	0.0172	0.2	0.11	Response to mTOR inhibitor (everolimus);	chr21:29185397	chr21:28997613~28998033:-
BRCA	cis	rs9733	0.519	rs3768005	ENSG00000231073.1	RP11-316M1.3	3.61	0.000325	0.0172	0.12	0.11	Tonsillectomy;	chr1:150708512	chr1:150973123~150975534:+
BRCA	cis	rs2562456	0.917	rs2681389	ENSG00000268705.1	BNIP3P26	-3.61	0.000325	0.0172	-0.12	-0.11	Pain;	chr19:21509773	chr19:21521343~21521896:-
BRCA	cis	rs875971	1	rs6957199	ENSG00000272831.1	RP11-792A8.4	3.61	0.000325	0.0172	0.1	0.11	Aortic root size;	chr7:66513532	chr7:66739829~66740385:-
BRCA	cis	rs10876993	0.893	rs4760168	ENSG00000270039.1	RP11-571M6.17	3.61	0.000325	0.0172	0.15	0.11	Celiac disease or Rheumatoid arthritis;	chr12:57693954	chr12:57803838~57804415:+
BRCA	cis	rs13315871	1	rs75828026	ENSG00000272182.1	RP11-802O23.3	3.61	0.000325	0.0172	0.22	0.11	Cholesterol, total;	chr3:58361009	chr3:58428255~58428815:+
BRCA	cis	rs875971	0.545	rs1638735	ENSG00000273448.1	RP11-166O4.6	3.61	0.000325	0.0172	0.11	0.11	Aortic root size;	chr7:66630751	chr7:67333047~67334383:+
BRCA	cis	rs2274273	1	rs7140872	ENSG00000259318.1	RP11-454L9.2	3.61	0.000325	0.0172	0.09	0.11	Protein biomarker;	chr14:55146026	chr14:55394940~55395233:-
BRCA	cis	rs7590268	0.666	rs12104876	ENSG00000279873.2	LINC01126	3.61	0.000325	0.0172	0.13	0.11	Orofacial clefts;	chr2:43400239	chr2:43227210~43228855:+
BRCA	cis	rs11158026	0.757	rs8013521	ENSG00000233924.1	AL160471.6	-3.61	0.000325	0.0172	-0.13	-0.11	Parkinson's disease;	chr14:54947007	chr14:55004813~55005687:-
BRCA	cis	rs10005067	0.967	rs12498766	ENSG00000249001.4	RP11-742B18.1	-3.61	0.000325	0.0172	-0.13	-0.11	Total body bone mineral density (age 30-45);	chr4:87906314	chr4:87568035~87733956:-
BRCA	cis	rs10005067	0.967	rs6826633	ENSG00000249001.4	RP11-742B18.1	-3.61	0.000325	0.0172	-0.13	-0.11	Total body bone mineral density (age 30-45);	chr4:87907446	chr4:87568035~87733956:-
BRCA	cis	rs539096	0.83	rs2842176	ENSG00000236200.4	KDM4A-AS1	3.61	0.000325	0.0172	0.14	0.11	Intelligence (multi-trait analysis);	chr1:43556863	chr1:43699765~43708138:-
BRCA	cis	rs7267979	1	rs6076336	ENSG00000276952.1	RP5-965G21.6	-3.61	0.000325	0.0172	-0.14	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25338576	chr20:25284915~25285588:-
BRCA	cis	rs17221829	0.733	rs11018699	ENSG00000280385.1	AP000648.5	-3.61	0.000325	0.0172	-0.13	-0.11	Anxiety in major depressive disorder;	chr11:89646794	chr11:90193614~90198120:+
BRCA	cis	rs4648045	0.796	rs4648050	ENSG00000246560.2	RP11-10L12.4	3.61	0.000325	0.0172	0.13	0.11	Lymphocyte percentage of white cells;	chr4:102593584	chr4:102828055~102844075:+
BRCA	cis	rs863345	0.625	rs11265006	ENSG00000229914.1	RP11-404O13.4	-3.61	0.000325	0.0172	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158528695	chr1:158195633~158196131:-
BRCA	cis	rs7618501	1	rs3749240	ENSG00000228008.1	CTD-2330K9.3	-3.61	0.000325	0.0172	-0.11	-0.11	Intelligence (multi-trait analysis);	chr3:49712755	chr3:49903845~49916937:+
BRCA	cis	rs13217239	0.646	rs10946898	ENSG00000124549.13	BTN2A3P	3.61	0.000325	0.0172	0.11	0.11	Schizophrenia;	chr6:27036105	chr6:26421391~26432383:+
BRCA	cis	rs9650657	0.655	rs1991651	ENSG00000154316.13	TDH	-3.61	0.000325	0.0172	-0.14	-0.11	Neuroticism;	chr8:10848901	chr8:11339637~11368452:+
BRCA	cis	rs295490	0.748	rs59628512	ENSG00000272656.1	RP11-219D15.3	3.61	0.000325	0.0172	0.27	0.11	PR interval in Tripanosoma cruzi seropositivity;	chr3:139472550	chr3:139349024~139349371:-
BRCA	cis	rs1443512	0.796	rs1822437	ENSG00000274817.1	HOTAIR_4	3.61	0.000325	0.0172	0.13	0.11	Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-hip ratio;Waist-to-hip ratio adjusted for body mass index;	chr12:53946293	chr12:53968002~53968178:+
BRCA	cis	rs6545883	0.524	rs12992614	ENSG00000270820.4	RP11-355B11.2	-3.61	0.000325	0.0172	-0.12	-0.11	Tuberculosis;	chr2:61365941	chr2:61471188~61484130:+
BRCA	cis	rs55780018	0.614	rs4675690	ENSG00000224137.1	AC079767.4	3.61	0.000325	0.0172	0.09	0.11	Systolic blood pressure;	chr2:207643083	chr2:207662375~207667024:+
BRCA	cis	rs853679	0.517	rs17711344	ENSG00000216901.1	AL022393.7	-3.61	0.000325	0.0172	-0.16	-0.11	Depression;	chr6:28109824	chr6:28176188~28176674:+
BRCA	cis	rs9467773	0.587	rs10946812	ENSG00000124549.13	BTN2A3P	-3.61	0.000325	0.0172	-0.11	-0.11	Intelligence (multi-trait analysis);	chr6:26344747	chr6:26421391~26432383:+
BRCA	cis	rs10838634	1	rs61884304	ENSG00000280615.1	Y_RNA	-3.61	0.000325	0.0172	-0.23	-0.11	Schizophrenia;	chr11:46711341	chr11:47614898~47614994:-
BRCA	cis	rs10838634	1	rs61884305	ENSG00000280615.1	Y_RNA	-3.61	0.000325	0.0172	-0.23	-0.11	Schizophrenia;	chr11:46714406	chr11:47614898~47614994:-
BRCA	cis	rs35520189	1	rs35520189	ENSG00000274877.1	RP11-65I12.1	-3.61	0.000325	0.0172	-0.17	-0.11	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:112861653	chr2:113237595~113240825:+
BRCA	cis	rs35520189	0.961	rs12477661	ENSG00000274877.1	RP11-65I12.1	-3.61	0.000325	0.0172	-0.17	-0.11	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:112863188	chr2:113237595~113240825:+
BRCA	cis	rs812925	0.537	rs778146	ENSG00000270820.4	RP11-355B11.2	-3.61	0.000325	0.0172	-0.12	-0.11	Immature fraction of reticulocytes;	chr2:61379340	chr2:61471188~61484130:+
BRCA	cis	rs6696239	0.911	rs28446171	ENSG00000227711.2	RP11-275O4.5	-3.61	0.000325	0.0172	-0.15	-0.11	Height;	chr1:227643475	chr1:227509028~227520477:-
BRCA	cis	rs1434579	0.897	rs12977016	ENSG00000176761.7	ZNF285B	-3.61	0.000325	0.0172	-0.14	-0.11	Tuberculosis;	chr19:44438573	chr19:44467641~44473227:+
BRCA	cis	rs12200782	0.505	rs7765920	ENSG00000261353.1	CTA-14H9.5	-3.61	0.000325	0.0172	-0.13	-0.11	Small cell lung carcinoma;	chr6:26514543	chr6:26527063~26527404:+
BRCA	cis	rs3735485	0.76	rs4720488	ENSG00000201772.1	SNORA5C	-3.61	0.000325	0.0172	-0.15	-0.11	White blood cell count;Sum basophil neutrophil counts;Neutrophil count;Granulocyte percentage of myeloid white cells;Monocyte percentage of white cells;Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Lymphocyte counts;	chr7:45001512	chr7:45104906~45105042:-
BRCA	cis	rs3735485	0.8	rs4720489	ENSG00000201772.1	SNORA5C	-3.61	0.000325	0.0172	-0.15	-0.11	White blood cell count;Sum basophil neutrophil counts;Neutrophil count;Granulocyte percentage of myeloid white cells;Monocyte percentage of white cells;Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Lymphocyte counts;	chr7:45002214	chr7:45104906~45105042:-
BRCA	cis	rs17756712	0.528	rs2073007	ENSG00000272463.1	RP11-532F6.3	3.61	0.000325	0.0172	0.16	0.11	Vertical cup-disc ratio;	chr6:638267	chr6:708592~711405:-
BRCA	cis	rs7647973	0.925	rs7429661	ENSG00000272434.1	RP13-131K19.6	-3.61	0.000325	0.0172	-0.15	-0.11	Menarche (age at onset);	chr3:49191367	chr3:49029316~49029706:+
BRCA	cis	rs7680126	0.5	rs11735668	ENSG00000250413.1	RP11-448G15.1	3.61	0.000325	0.0172	0.19	0.11	Urate levels in obese individuals;Urate levels in lean individuals;Urate levels in overweight individuals;	chr4:10147031	chr4:10006482~10009725:+
BRCA	cis	rs6012953	0.967	rs6020585	ENSG00000231715.1	COX6CP2	3.61	0.000325	0.0172	0.11	0.11	Vitiligo;	chr20:50530955	chr20:50479767~50479991:+
BRCA	cis	rs6496932	0.802	rs6497006	ENSG00000218052.5	ADAMTS7P4	3.61	0.000325	0.0172	0.12	0.11	Central corneal thickness;Corneal structure;	chr15:85330306	chr15:85255369~85330334:-
BRCA	cis	rs11170468	0.621	rs11170782	ENSG00000257718.1	RP11-396F22.1	3.61	0.000325	0.0172	0.14	0.11	Body mass index;	chr12:39116581	chr12:38906451~38909592:+
BRCA	cis	rs61931739	0.5	rs11053282	ENSG00000258794.3	DUX4L27	3.61	0.000325	0.0172	0.16	0.11	Morning vs. evening chronotype;	chr12:34408216	chr12:34208415~34209675:-
BRCA	cis	rs7267979	1	rs6083804	ENSG00000276952.1	RP5-965G21.6	-3.61	0.000325	0.0172	-0.14	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25336424	chr20:25284915~25285588:-
BRCA	cis	rs7267979	1	rs4815405	ENSG00000276952.1	RP5-965G21.6	-3.61	0.000325	0.0172	-0.14	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25336856	chr20:25284915~25285588:-
BRCA	cis	rs7267979	1	rs6050542	ENSG00000276952.1	RP5-965G21.6	-3.61	0.000325	0.0172	-0.14	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25338243	chr20:25284915~25285588:-
BRCA	cis	rs4921164	1	rs13154096	ENSG00000245812.2	RP11-175K6.1	-3.61	0.000325	0.0172	-0.14	-0.11	Gut microbiome composition (winter);	chr5:159118303	chr5:159100483~159117478:+
BRCA	cis	rs7712401	0.755	rs27740	ENSG00000249996.1	RP11-359P5.1	-3.61	0.000325	0.0172	-0.13	-0.11	Mean platelet volume;	chr5:122869077	chr5:123036271~123054667:+
BRCA	cis	rs7131987	0.903	rs7302129	ENSG00000273680.1	RP11-996F15.6	3.61	0.000325	0.0172	0.14	0.11	QT interval;	chr12:29262347	chr12:29332733~29333383:-
BRCA	cis	rs9467773	1	rs6456733	ENSG00000224843.5	LINC00240	-3.61	0.000325	0.0172	-0.12	-0.11	Intelligence (multi-trait analysis);	chr6:26566576	chr6:26956992~27023924:+
BRCA	cis	rs7267979	1	rs7267979	ENSG00000274973.1	RP13-401N8.7	-3.61	0.000326	0.0172	-0.13	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25317451	chr20:25845497~25845862:+
BRCA	cis	rs7837791	0.647	rs4636195	ENSG00000242970.2	AC068522.4	3.61	0.000326	0.0172	0.14	0.11	Refractive error;	chr8:59258667	chr8:58588420~58588764:-
BRCA	cis	rs7618501	1	rs34451146	ENSG00000228008.1	CTD-2330K9.3	3.61	0.000326	0.0172	0.11	0.11	Intelligence (multi-trait analysis);	chr3:49775580	chr3:49903845~49916937:+
BRCA	cis	rs66887589	0.72	rs2036858	ENSG00000225892.3	RP11-384K6.2	3.61	0.000326	0.0172	0.1	0.11	Diastolic blood pressure;	chr4:119328082	chr4:118632274~118634759:+
BRCA	cis	rs7267979	1	rs8125868	ENSG00000274414.1	RP5-965G21.4	3.61	0.000326	0.0172	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25343774	chr20:25239007~25245229:-
BRCA	cis	rs4835473	0.643	rs34680080	ENSG00000249741.2	RP11-673E1.3	3.61	0.000326	0.0172	0.12	0.11	Immature fraction of reticulocytes;	chr4:143797290	chr4:143911514~143912053:-
BRCA	cis	rs7432375	0.61	rs56695781	ENSG00000273486.1	RP11-731C17.2	3.61	0.000326	0.0172	0.12	0.11	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136791759	chr3:136837338~136839021:-
BRCA	cis	rs12701220	0.901	rs12701710	ENSG00000224079.1	AC091729.7	-3.61	0.000326	0.0172	-0.16	-0.11	Bronchopulmonary dysplasia;	chr7:1050760	chr7:1074450~1078036:+
BRCA	cis	rs4665809	0.878	rs892448	ENSG00000231655.1	AC011742.3	3.61	0.000326	0.0172	0.16	0.11	Gut microbiome composition (summer);	chr2:26143336	chr2:26140263~26141264:-
BRCA	cis	rs6964587	0.626	rs6979235	ENSG00000188693.7	CYP51A1-AS1	3.61	0.000326	0.0172	0.12	0.11	Breast cancer;	chr7:91882462	chr7:92134604~92180725:+
BRCA	cis	rs7267979	0.816	rs1044573	ENSG00000274414.1	RP5-965G21.4	-3.61	0.000326	0.0172	-0.13	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25226018	chr20:25239007~25245229:-
BRCA	cis	rs7621025	0.755	rs1017881	ENSG00000273486.1	RP11-731C17.2	3.61	0.000326	0.0172	0.13	0.11	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136638851	chr3:136837338~136839021:-
BRCA	cis	rs6460942	0.597	rs7778131	ENSG00000226690.5	AC005281.1	3.61	0.000326	0.0172	0.23	0.11	Coronary artery disease;	chr7:12503607	chr7:12496429~12541910:+
BRCA	cis	rs2274273	0.87	rs8021583	ENSG00000259318.1	RP11-454L9.2	3.61	0.000326	0.0172	0.09	0.11	Protein biomarker;	chr14:55282889	chr14:55394940~55395233:-
BRCA	cis	rs7267979	0.565	rs6107060	ENSG00000277938.1	RP5-965G21.3	3.61	0.000326	0.0172	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25611840	chr20:25229150~25231933:+
BRCA	cis	rs9467773	1	rs4871	ENSG00000261353.1	CTA-14H9.5	-3.61	0.000326	0.0172	-0.11	-0.11	Intelligence (multi-trait analysis);	chr6:26545404	chr6:26527063~26527404:+
BRCA	cis	rs5167	0.777	rs56784978	ENSG00000214855.8	APOC1P1	3.61	0.000326	0.0172	0.14	0.11	Blood protein levels;	chr19:44996130	chr19:44926804~44931386:+
BRCA	cis	rs7713065	0.959	rs2548992	ENSG00000202533.1	Y_RNA	-3.61	0.000326	0.0172	-0.11	-0.11	Lung function (FEV1/FVC);	chr5:132472976	chr5:132468147~132468257:+
BRCA	cis	rs359466	0.938	rs359415	ENSG00000254164.1	CTB-33O18.2	-3.61	0.000326	0.0172	-0.18	-0.11	QRS complex (Sokolow-Lyon);	chr5:173918484	chr5:173574938~173576275:+
BRCA	cis	rs6951245	0.554	rs76243429	ENSG00000224079.1	AC091729.7	-3.61	0.000326	0.0172	-0.17	-0.11	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1112907	chr7:1074450~1078036:+
BRCA	cis	rs690037	0.773	rs689779	ENSG00000272498.1	RP11-415F23.3	3.61	0.000326	0.0172	0.11	0.11	Optic nerve measurement (cup-to-disc ratio);Optic nerve measurement (cup area);	chr3:16351804	chr3:16339308~16339871:+
BRCA	cis	rs34792	0.853	rs170194	ENSG00000258354.1	MIR3180-1	-3.61	0.000326	0.0172	-0.14	-0.11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15464415	chr16:14909887~14911345:-
BRCA	cis	rs7412746	0.658	rs1027699	ENSG00000224800.1	RP11-235D19.2	-3.61	0.000326	0.0172	-0.14	-0.11	Melanoma;	chr1:150839236	chr1:150881236~150881683:-
BRCA	cis	rs10916248	1	rs10916248	ENSG00000272645.2	RP11-504P24.8	-3.61	0.000326	0.0172	-0.1	-0.11	QT interval (drug interaction);	chr1:224068646	chr1:223951388~223953439:-
BRCA	cis	rs7238033	1	rs7238033	ENSG00000267193.4	RP11-116O18.3	3.61	0.000326	0.0172	0.12	0.11	Bladder cancer;	chr18:45737001	chr18:45669367~45747215:-
BRCA	cis	rs991427	0.841	rs10777287	ENSG00000258100.1	RP11-121E16.1	3.61	0.000326	0.0172	0.14	0.11	Systolic blood pressure (alcohol consumption interaction);	chr12:91075973	chr12:91362196~91368606:+
BRCA	cis	rs6714710	0.603	rs13008968	ENSG00000228486.8	LINC01125	-3.61	0.000326	0.0172	-0.1	-0.11	Posterior cortical atrophy and Alzheimer's disease;	chr2:97819519	chr2:97664217~97703064:+
BRCA	cis	rs4148883	0.651	rs2851301	ENSG00000272777.1	RP11-571L19.8	-3.61	0.000326	0.0172	-0.12	-0.11	Alcohol dependence;	chr4:99088976	chr4:99067256~99068125:-
BRCA	cis	rs4148883	0.629	rs2602899	ENSG00000272777.1	RP11-571L19.8	-3.61	0.000326	0.0172	-0.12	-0.11	Alcohol dependence;	chr4:99088977	chr4:99067256~99068125:-
BRCA	cis	rs3760982	0.585	rs8109478	ENSG00000267191.1	RP11-15A1.2	-3.61	0.000326	0.0172	-0.14	-0.11	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43794104	chr19:43902001~43926545:+
BRCA	cis	rs6142618	0.562	rs2281358	ENSG00000224452.1	RSL24D1P6	3.61	0.000326	0.0172	0.15	0.11	Inflammatory bowel disease;	chr20:32135545	chr20:32170390~32170790:-
BRCA	cis	rs4468007	0.901	rs9886840	ENSG00000261534.1	RP11-244O19.1	-3.61	0.000326	0.0172	-0.12	-0.11	Educational attainment;	chr9:121840449	chr9:121815674~121819452:-
BRCA	cis	rs1971762	0.527	rs11170590	ENSG00000270175.1	RP11-793H13.11	-3.61	0.000326	0.0172	-0.09	-0.11	Height;	chr12:53545129	chr12:53500162~53500936:-
BRCA	cis	rs10005067	0.967	rs4693903	ENSG00000249001.4	RP11-742B18.1	-3.61	0.000326	0.0172	-0.13	-0.11	Total body bone mineral density (age 30-45);	chr4:87898028	chr4:87568035~87733956:-
BRCA	cis	rs875971	0.964	rs1643388	ENSG00000272831.1	RP11-792A8.4	3.61	0.000326	0.0172	0.1	0.11	Aortic root size;	chr7:66379575	chr7:66739829~66740385:-
BRCA	cis	rs875971	1	rs778722	ENSG00000272831.1	RP11-792A8.4	3.61	0.000326	0.0172	0.1	0.11	Aortic root size;	chr7:66379841	chr7:66739829~66740385:-
BRCA	cis	rs35306767	0.903	rs11253458	ENSG00000229869.1	RP11-363N22.2	-3.61	0.000326	0.0172	-0.17	-0.11	Eosinophil percentage of granulocytes;	chr10:836903	chr10:933026~942743:+
BRCA	cis	rs10761482	0.701	rs7087958	ENSG00000254271.1	RP11-131N11.4	3.61	0.000326	0.0173	0.15	0.11	Schizophrenia;	chr10:60362133	chr10:60734342~60741828:+
BRCA	cis	rs7590268	0.731	rs17030749	ENSG00000279873.2	LINC01126	3.61	0.000327	0.0173	0.14	0.11	Orofacial clefts;	chr2:43403083	chr2:43227210~43228855:+
BRCA	cis	rs874460	0.932	rs160544	ENSG00000211513.4	MIR320E	3.61	0.000327	0.0173	0.19	0.11	Chronic lymphocytic leukemia;	chr19:46731628	chr19:46709271~46709382:-
BRCA	cis	rs2692947	0.794	rs2692949	ENSG00000168992.4	OR7E102P	3.61	0.000327	0.0173	0.16	0.11	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96007777	chr2:95546531~95547545:+
BRCA	cis	rs6449502	0.614	rs13159372	ENSG00000251279.1	CTC-436P18.1	3.61	0.000327	0.0173	0.24	0.11	Mean platelet volume;	chr5:60820706	chr5:61162070~61232040:+
BRCA	cis	rs12049351	0.524	rs4925495	ENSG00000229367.1	HMGN2P19	3.61	0.000327	0.0173	0.15	0.11	Circulating myeloperoxidase levels (plasma);	chr1:229488677	chr1:229570532~229570796:+
BRCA	cis	rs11122895	0.509	rs10174353	ENSG00000236307.2	EEF1E1P1	3.61	0.000327	0.0173	0.12	0.11	Allergic sensitization;	chr2:111690311	chr2:111887914~111888741:+
BRCA	cis	rs1008375	0.931	rs10939733	ENSG00000249502.1	AC006160.5	-3.61	0.000327	0.0173	-0.13	-0.11	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17569035	chr4:17587467~17614571:-
BRCA	cis	rs7937682	0.881	rs4936678	ENSG00000230911.1	PPIHP1	3.6	0.000327	0.0173	0.17	0.11	Primary sclerosing cholangitis;	chr11:111754361	chr11:112029858~112030367:-
BRCA	cis	rs10411262	0.506	rs11083845	ENSG00000245598.5	DACT3-AS1	-3.6	0.000327	0.0173	-0.15	-0.11	Tonsillectomy;	chr19:46683398	chr19:46660364~46677447:+
BRCA	cis	rs7590268	0.789	rs34023310	ENSG00000279873.2	LINC01126	3.6	0.000327	0.0173	0.13	0.11	Orofacial clefts;	chr2:43405096	chr2:43227210~43228855:+
BRCA	cis	rs11673344	0.542	rs826328	ENSG00000276846.1	CTD-3220F14.3	3.6	0.000327	0.0173	0.13	0.11	Obesity-related traits;	chr19:37004479	chr19:37314868~37315620:-
BRCA	cis	rs11887277	0.528	rs13016101	ENSG00000272148.1	RP11-195B17.1	-3.6	0.000327	0.0173	-0.13	-0.11	Obesity-related traits;	chr2:26822229	chr2:27062428~27062907:-
BRCA	cis	rs11887277	0.513	rs13016313	ENSG00000272148.1	RP11-195B17.1	-3.6	0.000327	0.0173	-0.13	-0.11	Obesity-related traits;	chr2:26822339	chr2:27062428~27062907:-
BRCA	cis	rs10043775	0.793	rs2161430	ENSG00000251330.3	CTD-2283N19.1	3.6	0.000327	0.0173	0.13	0.11	Periodontal microbiota;	chr5:148324318	chr5:148430159~148430807:-
BRCA	cis	rs853679	0.546	rs200977	ENSG00000216676.2	RP1-15D7.1	-3.6	0.000327	0.0173	-0.2	-0.11	Depression;	chr6:27886523	chr6:27652602~27652825:-
BRCA	cis	rs9990333	0.562	rs55970879	ENSG00000207650.1	MIR570	3.6	0.000327	0.0173	0.14	0.11	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196095095	chr3:195699401~195699497:+
BRCA	cis	rs7620503	1	rs6777561	ENSG00000231574.4	RP11-91K9.1	3.6	0.000327	0.0173	0.12	0.11	Corneal structure;	chr3:177587410	chr3:177816865~177899224:+
BRCA	cis	rs1555133	0.625	rs62206927	ENSG00000275576.1	RP5-836N17.4	-3.6	0.000327	0.0173	-0.13	-0.11	Monocyte count;	chr20:32411796	chr20:32116171~32116629:+
BRCA	cis	rs6088580	0.634	rs9789792	ENSG00000275784.1	RP5-1125A11.6	3.6	0.000327	0.0173	0.12	0.11	Glomerular filtration rate (creatinine);	chr20:34369903	chr20:33989480~33991818:-
BRCA	cis	rs11696845	0.776	rs6073538	ENSG00000276223.1	RP4-781B1.5	-3.6	0.000327	0.0173	-0.11	-0.11	Obesity-related traits;	chr20:44750623	chr20:44746642~44747201:+
BRCA	cis	rs9818758	0.607	rs34823813	ENSG00000225399.4	RP11-3B7.1	-3.6	0.000327	0.0173	-0.21	-0.11	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49712543	chr3:49260085~49261316:+
BRCA	cis	rs7246657	0.55	rs10411176	ENSG00000267470.4	ZNF571-AS1	3.6	0.000327	0.0173	0.17	0.11	Coronary artery calcification;	chr19:37196051	chr19:37548914~37587348:+
BRCA	cis	rs2274273	1	rs57970196	ENSG00000259318.1	RP11-454L9.2	3.6	0.000327	0.0173	0.1	0.11	Protein biomarker;	chr14:55133687	chr14:55394940~55395233:-
BRCA	cis	rs7520050	0.966	rs11810993	ENSG00000281133.1	AL355480.3	3.6	0.000327	0.0173	0.13	0.11	Reticulocyte count;Red blood cell count;	chr1:46013121	chr1:45580892~45580996:-
BRCA	cis	rs3760982	0.935	rs10422990	ENSG00000267191.1	RP11-15A1.2	-3.6	0.000327	0.0173	-0.14	-0.11	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43791121	chr19:43902001~43926545:+
BRCA	cis	rs2625529	0.526	rs8032222	ENSG00000260037.4	CTD-2524L6.3	3.6	0.000327	0.0173	0.14	0.11	Red blood cell count;	chr15:72186837	chr15:71818396~71823384:+
BRCA	cis	rs6600671	1	rs10903161	ENSG00000275131.1	CH17-472G23.4	-3.6	0.000327	0.0173	-0.1	-0.11	Hip geometry;	chr1:121436882	chr1:120489625~120579190:-
BRCA	cis	rs259282	0.524	rs731674	ENSG00000267475.1	CTD-2538C1.2	3.6	0.000327	0.0173	0.13	0.11	Schizophrenia;	chr19:32641489	chr19:32687089~32691750:-
BRCA	cis	rs2439831	0.85	rs28524541	ENSG00000206991.1	RNU6-610P	-3.6	0.000327	0.0173	-0.18	-0.11	Lung cancer in ever smokers;	chr15:43832633	chr15:43637632~43637738:-
BRCA	cis	rs9420	0.528	rs73480556	ENSG00000265566.2	RN7SL605P	-3.6	0.000328	0.0173	-0.15	-0.11	Schizophrenia;	chr11:57632989	chr11:57528085~57528365:-
BRCA	cis	rs859767	0.741	rs1516991	ENSG00000224043.6	CCNT2-AS1	3.6	0.000328	0.0173	0.15	0.11	Neuroticism;	chr2:134612482	chr2:134735464~134918710:-
BRCA	cis	rs683250	0.629	rs682713	ENSG00000254551.1	RP11-727A23.7	-3.6	0.000328	0.0173	-0.14	-0.11	Subcortical brain region volumes;	chr11:83223343	chr11:83209431~83213379:-
BRCA	cis	rs11662721	0.938	rs1318652	ENSG00000264188.1	RP11-13N13.5	-3.6	0.000328	0.0173	-0.15	-0.11	Phospholipid levels (plasma);	chr18:21597324	chr18:21661787~21662395:-
BRCA	cis	rs11662721	0.938	rs2850567	ENSG00000264188.1	RP11-13N13.5	-3.6	0.000328	0.0173	-0.15	-0.11	Phospholipid levels (plasma);	chr18:21598765	chr18:21661787~21662395:-
BRCA	cis	rs10129255	0.536	rs6576201	ENSG00000274576.2	IGHV2-70	3.6	0.000328	0.0173	0.09	0.11	Kawasaki disease;	chr14:106683696	chr14:106770577~106771020:-
BRCA	cis	rs7824557	0.564	rs13260727	ENSG00000269918.1	AF131215.9	3.6	0.000328	0.0173	0.13	0.11	Retinal vascular caliber;	chr8:11375351	chr8:11104691~11106704:-
BRCA	cis	rs17270561	0.636	rs6923367	ENSG00000272462.2	U91328.19	-3.6	0.000328	0.0173	-0.14	-0.11	Iron status biomarkers;	chr6:25745624	chr6:25992662~26001775:+
BRCA	cis	rs17270561	0.636	rs6923839	ENSG00000272462.2	U91328.19	-3.6	0.000328	0.0173	-0.14	-0.11	Iron status biomarkers;	chr6:25745625	chr6:25992662~26001775:+
BRCA	cis	rs17270561	0.636	rs4145218	ENSG00000272462.2	U91328.19	-3.6	0.000328	0.0173	-0.14	-0.11	Iron status biomarkers;	chr6:25745855	chr6:25992662~26001775:+
BRCA	cis	rs5752326	0.51	rs877593	ENSG00000235271.4	RP1-90L6.3	3.6	0.000328	0.0173	0.19	0.11	Ischemic stroke;	chr22:26471689	chr22:26903292~26920611:+
BRCA	cis	rs2411233	1	rs8026431	ENSG00000259278.1	RP11-62C7.2	3.6	0.000328	0.0173	0.13	0.11	Platelet count;	chr15:38982060	chr15:39019233~39024918:+
BRCA	cis	rs4835473	0.9	rs34569841	ENSG00000246448.2	RP13-578N3.3	-3.6	0.000328	0.0173	-0.13	-0.11	Immature fraction of reticulocytes;	chr4:143738060	chr4:143700257~143865072:+
BRCA	cis	rs669446	0.591	rs586339	ENSG00000236200.4	KDM4A-AS1	-3.6	0.000328	0.0173	-0.14	-0.11	Amyotrophic lateral sclerosis (age of onset);	chr1:43671586	chr1:43699765~43708138:-
BRCA	cis	rs863345	0.604	rs923664	ENSG00000229914.1	RP11-404O13.4	-3.6	0.000328	0.0173	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158537901	chr1:158195633~158196131:-
BRCA	cis	rs12049351	0.665	rs1838464	ENSG00000229367.1	HMGN2P19	3.6	0.000328	0.0173	0.15	0.11	Circulating myeloperoxidase levels (plasma);	chr1:229480946	chr1:229570532~229570796:+
BRCA	cis	rs12477438	0.822	rs6727170	ENSG00000231822.1	AC019097.7	-3.6	0.000328	0.0173	-0.14	-0.11	Chronic sinus infection;	chr2:98971579	chr2:99102018~99102752:+
BRCA	cis	rs7620503	1	rs1463857	ENSG00000231574.4	RP11-91K9.1	3.6	0.000328	0.0173	0.12	0.11	Corneal structure;	chr3:177580539	chr3:177816865~177899224:+
BRCA	cis	rs3892630	0.588	rs7260037	ENSG00000267567.1	CTD-2538C1.3	3.6	0.000328	0.0173	0.16	0.11	Red blood cell traits;	chr19:32751795	chr19:32718298~32719595:-
BRCA	cis	rs3892630	0.588	rs7245709	ENSG00000267567.1	CTD-2538C1.3	3.6	0.000328	0.0173	0.16	0.11	Red blood cell traits;	chr19:32751849	chr19:32718298~32719595:-
BRCA	cis	rs10043228	1	rs10055868	ENSG00000250015.1	CTC-339F2.2	3.6	0.000328	0.0173	0.14	0.11	Asthma or chronic obstructive pulmonary disease;	chr5:116135915	chr5:116302354~116304134:-
BRCA	cis	rs9325144	0.56	rs13377717	ENSG00000257718.1	RP11-396F22.1	-3.6	0.000328	0.0173	-0.11	-0.11	Morning vs. evening chronotype;	chr12:38245672	chr12:38906451~38909592:+
BRCA	cis	rs67766926	1	rs13008738	ENSG00000237522.1	NONOP2	-3.6	0.000328	0.0173	-0.12	-0.11	Inflammatory skin disease;	chr2:60851786	chr2:60936819~60938049:-
BRCA	cis	rs7412746	0.658	rs11581757	ENSG00000231073.1	RP11-316M1.3	3.6	0.000328	0.0173	0.12	0.11	Melanoma;	chr1:150919768	chr1:150973123~150975534:+
BRCA	cis	rs686320	0.748	rs673753	ENSG00000173727.10	CMB9-22P13.1	-3.6	0.000328	0.0173	-0.21	-0.11	Hip circumference adjusted for BMI;	chr11:65438546	chr11:65455258~65466720:+
BRCA	cis	rs337100	0.522	rs413186	ENSG00000263432.2	RN7SL689P	-3.6	0.000328	0.0173	-0.13	-0.11	Pulse pressure;	chr5:123134604	chr5:123022487~123022783:-
BRCA	cis	rs4927850	0.752	rs7624460	ENSG00000271662.1	RP11-141C7.3	-3.6	0.000328	0.0173	-0.14	-0.11	Pancreatic cancer;	chr3:196021659	chr3:195650146~195651472:-
BRCA	cis	rs28530618	0.603	rs7268180	ENSG00000198547.7	C20orf203	-3.6	0.000328	0.0173	-0.12	-0.11	Birth weight;	chr20:32664640	chr20:32631652~32673941:-
BRCA	cis	rs860295	0.702	rs2025669	ENSG00000232093.1	RP11-307C12.11	3.6	0.000328	0.0173	0.13	0.11	Body mass index;	chr1:155387818	chr1:155045191~155046118:-
BRCA	cis	rs4832312	1	rs4832312	ENSG00000266931.1	RP11-1252D15.1	-3.6	0.000328	0.0173	-0.13	-0.11	Mean corpuscular volume;Mean corpuscular hemoglobin;Reticulocyte fraction of red cells;	chr2:86762839	chr2:87055658~87055800:-
BRCA	cis	rs4281086	0.833	rs6601483	ENSG00000253641.4	RP11-981G7.2	-3.6	0.000328	0.0173	-0.14	-0.11	Obesity-related traits;	chr8:10538544	chr8:10474565~10481974:+
BRCA	cis	rs875971	0.522	rs1701760	ENSG00000229180.5	GS1-124K5.11	3.6	0.000328	0.0173	0.1	0.11	Aortic root size;	chr7:66008701	chr7:66526088~66542624:-
BRCA	cis	rs10129255	0.518	rs8009594	ENSG00000211976.2	IGHV3-73	-3.6	0.000328	0.0173	-0.08	-0.11	Kawasaki disease;	chr14:106777494	chr14:106802694~106803233:-
BRCA	cis	rs7520050	0.898	rs34175029	ENSG00000234329.1	RP11-767N6.2	-3.6	0.000328	0.0173	-0.1	-0.11	Reticulocyte count;Red blood cell count;	chr1:46018199	chr1:45651039~45651826:-
BRCA	cis	rs6088590	0.687	rs6088582	ENSG00000269202.1	RP4-614O4.12	-3.6	0.000328	0.0173	-0.11	-0.11	Coronary artery disease;	chr20:34698994	chr20:35201747~35203288:-
BRCA	cis	rs7802263	0.876	rs2107931	ENSG00000279419.1	RP5-907C10.3	-3.6	0.000328	0.0173	-0.16	-0.11	Reading and spelling;	chr7:124740680	chr7:124742312~124745017:-
BRCA	cis	rs7136259	0.545	rs6538192	ENSG00000258302.2	RP11-981P6.1	-3.6	0.000328	0.0173	-0.12	-0.11	Coronary heart disease;	chr12:89570585	chr12:89561129~89594878:+
BRCA	cis	rs4950322	0.748	rs17356680	ENSG00000237188.3	RP11-337C18.8	3.6	0.000329	0.0173	0.15	0.11	Protein quantitative trait loci;	chr1:147354934	chr1:147172771~147211568:+
BRCA	cis	rs7267979	0.966	rs2261784	ENSG00000274414.1	RP5-965G21.4	-3.6	0.000329	0.0173	-0.13	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25281760	chr20:25239007~25245229:-
BRCA	cis	rs7267979	0.966	rs2261785	ENSG00000274414.1	RP5-965G21.4	-3.6	0.000329	0.0173	-0.13	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25281767	chr20:25239007~25245229:-
BRCA	cis	rs875971	0.862	rs10263690	ENSG00000271064.1	RP11-792A8.3	3.6	0.000329	0.0173	0.13	0.11	Aortic root size;	chr7:66301466	chr7:66748838~66749077:-
BRCA	cis	rs875971	0.862	rs10250544	ENSG00000271064.1	RP11-792A8.3	3.6	0.000329	0.0173	0.13	0.11	Aortic root size;	chr7:66301574	chr7:66748838~66749077:-
BRCA	cis	rs17270561	0.583	rs7765833	ENSG00000272462.2	U91328.19	-3.6	0.000329	0.0173	-0.13	-0.11	Iron status biomarkers;	chr6:25712205	chr6:25992662~26001775:+
BRCA	cis	rs748404	0.666	rs72709850	ENSG00000166763.7	STRCP1	3.6	0.000329	0.0174	0.16	0.11	Lung cancer;	chr15:43462486	chr15:43699488~43718184:-
BRCA	cis	rs2048656	0.57	rs7814635	ENSG00000233609.3	RP11-62H7.2	3.6	0.000329	0.0174	0.11	0.11	Schizophrenia;	chr8:9789110	chr8:8961200~8979025:+
BRCA	cis	rs564309	0.681	rs6426501	ENSG00000183929.7	DUSP5P1	-3.6	0.000329	0.0174	-0.21	-0.11	Hip circumference (psychosocial stress interaction);	chr1:228435542	chr1:228650241~228651379:+
BRCA	cis	rs7520050	0.966	rs946529	ENSG00000234329.1	RP11-767N6.2	-3.6	0.000329	0.0174	-0.1	-0.11	Reticulocyte count;Red blood cell count;	chr1:46019876	chr1:45651039~45651826:-
BRCA	cis	rs875971	0.964	rs778708	ENSG00000271064.1	RP11-792A8.3	-3.6	0.000329	0.0174	-0.13	-0.11	Aortic root size;	chr7:66391332	chr7:66748838~66749077:-
BRCA	cis	rs1153858	1	rs1554521	ENSG00000275672.1	GATM-AS1	3.6	0.000329	0.0174	0.14	0.11	Homoarginine levels;	chr15:45371991	chr15:45378700~45380123:+
BRCA	cis	rs7074356	0.522	rs1591958	ENSG00000225484.5	NUTM2B-AS1	-3.6	0.000329	0.0174	-0.17	-0.11	Borderline personality disorder;	chr10:80302905	chr10:79663088~79826594:-
BRCA	cis	rs6840360	0.571	rs55808836	ENSG00000278978.1	RP11-164P12.5	-3.6	0.000329	0.0174	-0.13	-0.11	Intelligence (multi-trait analysis);	chr4:151633839	chr4:151669786~151670503:+
BRCA	cis	rs6840360	0.571	rs11726892	ENSG00000278978.1	RP11-164P12.5	-3.6	0.000329	0.0174	-0.13	-0.11	Intelligence (multi-trait analysis);	chr4:151633954	chr4:151669786~151670503:+
BRCA	cis	rs983392	0.792	rs487997	ENSG00000275344.1	MIR6503	-3.6	0.000329	0.0174	-0.11	-0.11	Alzheimer's disease (late onset);	chr11:60104131	chr11:60209071~60209156:-
BRCA	cis	rs7947761	0.715	rs61621482	ENSG00000254506.1	RP11-748H22.1	-3.6	0.000329	0.0174	-0.14	-0.11	Coronary artery disease;	chr11:100699329	chr11:101584295~101595156:+
BRCA	cis	rs7947761	0.715	rs57637131	ENSG00000254506.1	RP11-748H22.1	-3.6	0.000329	0.0174	-0.14	-0.11	Coronary artery disease;	chr11:100699376	chr11:101584295~101595156:+
BRCA	cis	rs13434995	0.513	rs62303726	ENSG00000249700.7	SRD5A3-AS1	-3.6	0.000329	0.0174	-0.16	-0.11	Adiponectin levels;	chr4:55490415	chr4:55363971~55395847:-
BRCA	cis	rs13434995	0.513	rs55729020	ENSG00000249700.7	SRD5A3-AS1	-3.6	0.000329	0.0174	-0.16	-0.11	Adiponectin levels;	chr4:55491681	chr4:55363971~55395847:-
BRCA	cis	rs13434995	0.513	rs3805156	ENSG00000249700.7	SRD5A3-AS1	-3.6	0.000329	0.0174	-0.16	-0.11	Adiponectin levels;	chr4:55497925	chr4:55363971~55395847:-
BRCA	cis	rs13434995	0.513	rs62303731	ENSG00000249700.7	SRD5A3-AS1	-3.6	0.000329	0.0174	-0.16	-0.11	Adiponectin levels;	chr4:55499667	chr4:55363971~55395847:-
BRCA	cis	rs13434995	0.513	rs62303732	ENSG00000249700.7	SRD5A3-AS1	-3.6	0.000329	0.0174	-0.16	-0.11	Adiponectin levels;	chr4:55499868	chr4:55363971~55395847:-
BRCA	cis	rs13434995	0.513	rs56196624	ENSG00000249700.7	SRD5A3-AS1	-3.6	0.000329	0.0174	-0.16	-0.11	Adiponectin levels;	chr4:55500340	chr4:55363971~55395847:-
BRCA	cis	rs13434995	0.513	rs62305265	ENSG00000249700.7	SRD5A3-AS1	-3.6	0.000329	0.0174	-0.16	-0.11	Adiponectin levels;	chr4:55503474	chr4:55363971~55395847:-
BRCA	cis	rs11214606	0.546	rs17602285	ENSG00000270179.1	RP11-159N11.4	-3.6	0.000329	0.0174	-0.22	-0.11	Response to antipsychotic treatment in schizophrenia (working memory);	chr11:113502555	chr11:113368478~113369117:+
BRCA	cis	rs2625529	0.586	rs7170456	ENSG00000260037.4	CTD-2524L6.3	3.6	0.000329	0.0174	0.14	0.11	Red blood cell count;	chr15:72177605	chr15:71818396~71823384:+
BRCA	cis	rs12234571	1	rs12673402	ENSG00000214293.7	APTR	3.6	0.000329	0.0174	0.21	0.11	Obesity-related traits;	chr7:77729666	chr7:77657660~77696265:-
BRCA	cis	rs6012953	0.845	rs718053	ENSG00000231715.1	COX6CP2	-3.6	0.000329	0.0174	-0.12	-0.11	Vitiligo;	chr20:50580065	chr20:50479767~50479991:+
BRCA	cis	rs687432	0.924	rs11601082	ENSG00000265566.2	RN7SL605P	-3.6	0.000329	0.0174	-0.15	-0.11	Parkinson's disease;	chr11:57959612	chr11:57528085~57528365:-
BRCA	cis	rs3755605	0.727	rs6799087	ENSG00000242578.1	RP11-469J4.3	3.6	0.000329	0.0174	0.13	0.11	Testicular germ cell tumor;	chr3:170155618	chr3:170410512~170418615:+
BRCA	cis	rs6015450	1	rs7267618	ENSG00000228340.4	MIR646HG	3.6	0.000329	0.0174	0.22	0.11	Hypertension;Blood pressure;Systolic blood pressure;Diastolic blood pressure;	chr20:59131469	chr20:60087840~60527458:+
BRCA	cis	rs180730	0.66	rs10857075	ENSG00000251609.2	SETP12	-3.6	0.000329	0.0174	-0.18	-0.11	Fasting plasma glucose;	chr4:120930300	chr4:120895494~120897083:-
BRCA	cis	rs180730	0.66	rs10857076	ENSG00000251609.2	SETP12	-3.6	0.000329	0.0174	-0.18	-0.11	Fasting plasma glucose;	chr4:120930379	chr4:120895494~120897083:-
BRCA	cis	rs10411161	0.702	rs79180893	ENSG00000269483.1	AC006272.1	3.6	0.000329	0.0174	0.19	0.11	Breast cancer;	chr19:51892362	chr19:51839924~51843324:-
BRCA	cis	rs10411161	0.702	rs11879436	ENSG00000269483.1	AC006272.1	3.6	0.000329	0.0174	0.19	0.11	Breast cancer;	chr19:51894562	chr19:51839924~51843324:-
BRCA	cis	rs10411161	0.702	rs10420224	ENSG00000269483.1	AC006272.1	3.6	0.000329	0.0174	0.19	0.11	Breast cancer;	chr19:51895702	chr19:51839924~51843324:-
BRCA	cis	rs10411161	0.702	rs75647161	ENSG00000269483.1	AC006272.1	3.6	0.000329	0.0174	0.19	0.11	Breast cancer;	chr19:51895731	chr19:51839924~51843324:-
BRCA	cis	rs10411161	0.702	rs17778790	ENSG00000269483.1	AC006272.1	3.6	0.000329	0.0174	0.19	0.11	Breast cancer;	chr19:51896306	chr19:51839924~51843324:-
BRCA	cis	rs62229266	0.804	rs2835259	ENSG00000214914.3	RPL23AP3	3.6	0.000329	0.0174	0.13	0.11	Mitral valve prolapse;	chr21:36053004	chr21:36016079~36016546:-
BRCA	cis	rs4664293	0.647	rs357022	ENSG00000224152.1	AC009506.1	-3.6	0.000329	0.0174	-0.12	-0.11	Monocyte percentage of white cells;	chr2:159632933	chr2:159615296~159617082:+
BRCA	cis	rs6088590	0.735	rs6060001	ENSG00000206582.1	Y_RNA	3.6	0.000329	0.0174	0.12	0.11	Coronary artery disease;	chr20:34706549	chr20:34526510~34526606:-
BRCA	cis	rs13434995	0.513	rs2171617	ENSG00000249700.7	SRD5A3-AS1	3.6	0.000329	0.0174	0.16	0.11	Adiponectin levels;	chr4:55591023	chr4:55363971~55395847:-
BRCA	cis	rs7618501	0.966	rs13063621	ENSG00000228008.1	CTD-2330K9.3	3.6	0.000329	0.0174	0.11	0.11	Intelligence (multi-trait analysis);	chr3:49784192	chr3:49903845~49916937:+
BRCA	cis	rs711830	0.587	rs10188827	ENSG00000272729.1	RP11-387A1.5	-3.6	0.000329	0.0174	-0.15	-0.11	Serous invasive ovarian cancer;Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;High-grade serous ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;	chr2:176142936	chr2:176164164~176165716:-
BRCA	cis	rs6964587	1	rs12539231	ENSG00000188693.7	CYP51A1-AS1	-3.6	0.000329	0.0174	-0.12	-0.11	Breast cancer;	chr7:92005649	chr7:92134604~92180725:+
BRCA	cis	rs8054556	1	rs4318227	ENSG00000183604.13	SMG1P5	-3.6	0.000329	0.0174	-0.11	-0.11	Autism spectrum disorder or schizophrenia;	chr16:29973518	chr16:30267553~30335374:-
BRCA	cis	rs7178375	0.607	rs7171212	ENSG00000270015.1	RP11-540B6.6	3.6	0.000329	0.0174	0.17	0.11	Hypertriglyceridemia;	chr15:30915508	chr15:30926514~30928407:+
BRCA	cis	rs9470794	1	rs78077223	ENSG00000204110.6	RP1-153P14.8	-3.6	0.000329	0.0174	-0.23	-0.11	Type 2 diabetes;	chr6:38079481	chr6:37507348~37535616:+
BRCA	cis	rs2692947	0.702	rs6717101	ENSG00000237510.6	AC008268.2	3.6	0.00033	0.0174	0.15	0.11	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95839804	chr2:95789654~95800166:+
BRCA	cis	rs6120849	0.754	rs6120793	ENSG00000202150.1	RNU6-407P	3.6	0.00033	0.0174	0.16	0.11	Protein C levels;	chr20:35016604	chr20:35030317~35030420:-
BRCA	cis	rs2277027	0.552	rs5023028	ENSG00000251405.2	CTB-109A12.1	3.6	0.00033	0.0174	0.14	0.11	Pulmonary function;Pulmonary function (smoking interaction);	chr5:157530428	chr5:157362615~157460078:-
BRCA	cis	rs2832077	0.527	rs2705690	ENSG00000232855.5	AF131217.1	-3.6	0.00033	0.0174	-0.14	-0.11	Cognitive test performance;	chr21:28866923	chr21:28439346~28674848:-
BRCA	cis	rs8180040	0.729	rs11720439	ENSG00000271161.1	BOLA2P2	-3.6	0.00033	0.0174	-0.12	-0.11	Colorectal cancer;	chr3:47305513	chr3:47499841~47500407:+
BRCA	cis	rs4703129	1	rs13177443	ENSG00000246763.5	RGMB-AS1	-3.6	0.00033	0.0174	-0.13	-0.11	Asperger disorder;	chr5:98540387	chr5:98769618~98773469:-
BRCA	cis	rs2692947	0.727	rs1657502	ENSG00000232931.4	LINC00342	3.6	0.00033	0.0174	0.11	0.11	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96129869	chr2:95807118~95816215:-
BRCA	cis	rs4263408	0.935	rs62310129	ENSG00000224097.5	RP11-472B18.1	3.6	0.00033	0.0174	0.13	0.11	Plasma amyloid beta peptide concentrations (ABx-40);	chr4:39772802	chr4:39480255~39481905:+
BRCA	cis	rs875971	0.642	rs35526611	ENSG00000275400.1	RP4-756H11.5	3.6	0.00033	0.0174	0.13	0.11	Aortic root size;	chr7:66629021	chr7:66553805~66554199:-
BRCA	cis	rs697003	0.52	rs7553718	ENSG00000231057.3	RP11-122M14.1	3.6	0.00033	0.0174	0.12	0.11	Red cell distribution width;	chr1:211651455	chr1:211675762~211690103:+
BRCA	cis	rs3805389	0.504	rs13434995	ENSG00000273257.1	RP11-177J6.1	-3.6	0.00033	0.0174	-0.18	-0.11	Waist-to-hip ratio adjusted for body mass index;	chr4:55601047	chr4:55387949~55388271:+
BRCA	cis	rs2305707	0.544	rs2470157	ENSG00000273674.3	CTD-2378E12.1	3.6	0.00033	0.0174	0.21	0.11	Height;	chr15:51297703	chr15:50839875~50908599:-
BRCA	cis	rs2305707	0.544	rs2470156	ENSG00000273674.3	CTD-2378E12.1	3.6	0.00033	0.0174	0.21	0.11	Height;	chr15:51298216	chr15:50839875~50908599:-
BRCA	cis	rs7131987	0.868	rs7958210	ENSG00000257599.1	OVCH1-AS1	-3.6	0.00033	0.0174	-0.14	-0.11	QT interval;	chr12:29242248	chr12:29389294~29487488:+
BRCA	cis	rs35520189	0.885	rs6720230	ENSG00000274877.1	RP11-65I12.1	-3.6	0.00033	0.0174	-0.17	-0.11	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:112872887	chr2:113237595~113240825:+
BRCA	cis	rs13113518	0.51	rs6828454	ENSG00000273257.1	RP11-177J6.1	3.6	0.00033	0.0174	0.15	0.11	Height;	chr4:55424329	chr4:55387949~55388271:+
BRCA	cis	rs853679	0.517	rs6932109	ENSG00000226314.6	ZNF192P1	3.6	0.00033	0.0174	0.16	0.11	Depression;	chr6:28110525	chr6:28161781~28169594:+
BRCA	cis	rs12477438	1	rs11897712	ENSG00000231822.1	AC019097.7	-3.6	0.00033	0.0174	-0.15	-0.11	Chronic sinus infection;	chr2:99119234	chr2:99102018~99102752:+
BRCA	cis	rs17406451	0.659	rs13396727	ENSG00000234936.1	AC010883.5	3.6	0.00033	0.0174	0.11	0.11	Mitochondrial DNA levels;	chr2:43497505	chr2:43229573~43233394:+
BRCA	cis	rs2573652	1	rs2581362	ENSG00000254744.3	CTD-3076O17.1	-3.6	0.00033	0.0174	-0.13	-0.11	Height;	chr15:99973319	chr15:99970215~99974010:+
BRCA	cis	rs2573652	1	rs2727196	ENSG00000254744.3	CTD-3076O17.1	-3.6	0.00033	0.0174	-0.13	-0.11	Height;	chr15:99973324	chr15:99970215~99974010:+
BRCA	cis	rs1046491	0.901	rs11663175	ENSG00000264964.1	RP11-888D10.3	3.6	0.00033	0.0174	0.23	0.11	Scarlet fever;	chr18:9175448	chr18:9315194~9334441:-
BRCA	cis	rs17345786	0.906	rs55710435	ENSG00000244119.1	PDCL3P4	3.6	0.00033	0.0174	0.1	0.11	Colonoscopy-negative controls vs population controls;	chr3:101461486	chr3:101712472~101713191:+
BRCA	cis	rs9309473	0.632	rs6546825	ENSG00000230002.2	ALMS1-IT1	3.6	0.00033	0.0174	0.13	0.11	Metabolite levels;	chr2:73365125	chr2:73456764~73459484:+
BRCA	cis	rs1730008	0.778	rs827121	ENSG00000279311.1	RP11-170K4.2	-3.6	0.00033	0.0174	-0.12	-0.11	Lobe attachment (rater-scored or self-reported);	chr3:158229257	chr3:158869898~158871821:+
BRCA	cis	rs9990333	0.562	rs75681503	ENSG00000207650.1	MIR570	3.6	0.000331	0.0174	0.14	0.11	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196095414	chr3:195699401~195699497:+
BRCA	cis	rs2574985	0.777	rs74998492	ENSG00000226200.5	SGMS1-AS1	-3.6	0.000331	0.0174	-0.11	-0.11	Subjective well-being;	chr10:50476347	chr10:50624951~50641451:+
BRCA	cis	rs12303914	0.762	rs3912117	ENSG00000256682.2	TAS2R12	-3.6	0.000331	0.0174	-0.13	-0.11	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr12:10301957	chr12:10894943~10896952:-
BRCA	cis	rs6964587	0.872	rs57969083	ENSG00000188693.7	CYP51A1-AS1	-3.6	0.000331	0.0174	-0.12	-0.11	Breast cancer;	chr7:92036313	chr7:92134604~92180725:+
BRCA	cis	rs801193	1	rs10252765	ENSG00000273142.1	RP11-458F8.4	-3.6	0.000331	0.0174	-0.1	-0.11	Aortic root size;	chr7:66763745	chr7:66902857~66906297:+
BRCA	cis	rs2305707	0.544	rs2470158	ENSG00000273674.3	CTD-2378E12.1	-3.6	0.000331	0.0174	-0.21	-0.11	Height;	chr15:51296198	chr15:50839875~50908599:-
BRCA	cis	rs6426833	0.715	rs6670226	ENSG00000117242.7	PINK1-AS	-3.6	0.000331	0.0174	-0.13	-0.11	Ulcerative colitis;Inflammatory bowel disease;	chr1:19868209	chr1:20642657~20652193:-
BRCA	cis	rs6500395	0.962	rs9937623	ENSG00000260052.1	CTC-527H23.3	-3.6	0.000331	0.0174	-0.13	-0.11	Response to tocilizumab in rheumatoid arthritis;	chr16:48537679	chr16:48637143~48638719:+
BRCA	cis	rs7835340	0.647	rs4308714	ENSG00000272010.1	CTD-3025N20.3	3.6	0.000331	0.0174	0.12	0.11	Recurrent major depressive disorder;	chr8:66082912	chr8:65591850~65592472:-
BRCA	cis	rs4722166	0.704	rs4321884	ENSG00000225541.1	AC002480.5	-3.6	0.000331	0.0174	-0.11	-0.11	Lung cancer;	chr7:22701840	chr7:22571607~22661792:-
BRCA	cis	rs6545883	0.868	rs6545887	ENSG00000212978.6	AC016747.3	3.6	0.000331	0.0175	0.15	0.11	Tuberculosis;	chr2:61601683	chr2:61141592~61144969:-
BRCA	cis	rs13434995	0.513	rs2412658	ENSG00000273257.1	RP11-177J6.1	3.6	0.000331	0.0175	0.16	0.11	Adiponectin levels;	chr4:55577050	chr4:55387949~55388271:+
BRCA	cis	rs8099594	0.64	rs1539965	ENSG00000266696.1	RP11-30L3.2	3.6	0.000331	0.0175	0.13	0.11	Height;	chr18:49327971	chr18:49205912~49208781:+
BRCA	cis	rs7954584	0.635	rs7137218	ENSG00000212694.7	LINC01089	-3.6	0.000331	0.0175	-0.09	-0.11	Mean corpuscular volume;	chr12:121904971	chr12:121795267~121803906:-
BRCA	cis	rs8014204	0.816	rs4903262	ENSG00000279594.1	RP11-950C14.10	3.6	0.000331	0.0175	0.12	0.11	Caffeine consumption;	chr14:74874115	chr14:75011269~75012851:-
BRCA	cis	rs11662721	0.938	rs11662724	ENSG00000264188.1	RP11-13N13.5	3.6	0.000331	0.0175	0.16	0.11	Phospholipid levels (plasma);	chr18:21600917	chr18:21661787~21662395:-
BRCA	cis	rs11662721	0.872	rs34373167	ENSG00000264188.1	RP11-13N13.5	3.6	0.000331	0.0175	0.16	0.11	Phospholipid levels (plasma);	chr18:21603013	chr18:21661787~21662395:-
BRCA	cis	rs11662721	0.938	rs76355272	ENSG00000264188.1	RP11-13N13.5	3.6	0.000331	0.0175	0.16	0.11	Phospholipid levels (plasma);	chr18:21605431	chr18:21661787~21662395:-
BRCA	cis	rs7649443	0.917	rs13099700	ENSG00000243339.3	RN7SL738P	-3.6	0.000331	0.0175	-0.15	-0.11	Nonsyndromic cleft lip with cleft palate;	chr3:197091982	chr3:196399911~196400207:+
BRCA	cis	rs1998359	0.953	rs61977074	ENSG00000259087.4	RP11-356O9.2	3.6	0.000331	0.0175	0.13	0.11	Self-reported allergy;	chr14:37694685	chr14:37556158~37567095:-
BRCA	cis	rs2274273	0.588	rs2880103	ENSG00000259318.1	RP11-454L9.2	3.6	0.000331	0.0175	0.1	0.11	Protein biomarker;	chr14:55271114	chr14:55394940~55395233:-
BRCA	cis	rs13434995	0.513	rs1979605	ENSG00000249700.7	SRD5A3-AS1	3.6	0.000331	0.0175	0.16	0.11	Adiponectin levels;	chr4:55552706	chr4:55363971~55395847:-
BRCA	cis	rs17027633	1	rs3754035	ENSG00000234020.1	CHIAP3	-3.6	0.000331	0.0175	-0.27	-0.11	Cerebrospinal fluid t-tau:AB1-42 ratio;	chr1:111430607	chr1:111353275~111367409:-
BRCA	cis	rs1670533	1	rs651017	ENSG00000251639.2	RP11-20I20.1	3.6	0.000331	0.0175	0.17	0.11	Recombination rate (females);	chr4:1097274	chr4:1100016~1101558:-
BRCA	cis	rs3099143	1	rs4541044	ENSG00000196274.5	Metazoa_SRP	-3.6	0.000331	0.0175	-0.16	-0.11	Recalcitrant atopic dermatitis;	chr15:76880852	chr15:76230048~76230390:-
BRCA	cis	rs7660883	0.866	rs342456	ENSG00000251411.1	RP11-397E7.4	-3.6	0.000331	0.0175	-0.12	-0.11	HDL cholesterol levels;	chr4:87102718	chr4:86913266~86914817:-
BRCA	cis	rs11098499	0.863	rs1552095	ENSG00000225892.3	RP11-384K6.2	3.6	0.000331	0.0175	0.12	0.11	Corneal astigmatism;	chr4:119539151	chr4:118632274~118634759:+
BRCA	cis	rs72387598	1	rs72387598	ENSG00000281133.1	AL355480.3	-3.6	0.000331	0.0175	-0.15	-0.11	Platelet distribution width;	chr1:45457307	chr1:45580892~45580996:-
BRCA	cis	rs189798	0.807	rs9949	ENSG00000233609.3	RP11-62H7.2	3.6	0.000331	0.0175	0.12	0.11	Myopia (pathological);	chr8:9137002	chr8:8961200~8979025:+
BRCA	cis	rs875971	0.862	rs778724	ENSG00000271064.1	RP11-792A8.3	-3.6	0.000331	0.0175	-0.13	-0.11	Aortic root size;	chr7:66364304	chr7:66748838~66749077:-
BRCA	cis	rs7260598	0.539	rs10425192	ENSG00000268442.1	CTD-2027I19.2	3.6	0.000331	0.0175	0.19	0.11	Response to taxane treatment (placlitaxel);	chr19:23907909	chr19:24162370~24163425:-
BRCA	cis	rs6142618	0.562	rs1321415	ENSG00000224452.1	RSL24D1P6	3.6	0.000331	0.0175	0.15	0.11	Inflammatory bowel disease;	chr20:32156415	chr20:32170390~32170790:-
BRCA	cis	rs13401620	0.555	rs1437421	ENSG00000236878.1	AC012363.7	-3.6	0.000331	0.0175	-0.13	-0.11	Breast size;	chr2:120218255	chr2:120211054~120211715:+
BRCA	cis	rs6120849	0.754	rs6120828	ENSG00000202150.1	RNU6-407P	3.6	0.000332	0.0175	0.16	0.11	Protein C levels;	chr20:35086657	chr20:35030317~35030420:-
BRCA	cis	rs2274273	1	rs66871576	ENSG00000259318.1	RP11-454L9.2	3.6	0.000332	0.0175	0.1	0.11	Protein biomarker;	chr14:55162332	chr14:55394940~55395233:-
BRCA	cis	rs7267979	1	rs12428	ENSG00000204556.4	CTD-2514C3.1	3.6	0.000332	0.0175	0.15	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25453185	chr20:26018832~26020684:+
BRCA	cis	rs10986311	0.722	rs10760347	ENSG00000227200.1	RP11-121A14.3	-3.6	0.000332	0.0175	-0.12	-0.11	Vitiligo;	chr9:124290307	chr9:124262876~124265809:+
BRCA	cis	rs10771431	0.597	rs10843142	ENSG00000256427.1	RP11-118B22.4	3.6	0.000332	0.0175	0.12	0.11	Breast size;	chr12:9204906	chr12:9246497~9257960:+
BRCA	cis	rs801193	1	rs3778909	ENSG00000232546.1	RP11-458F8.1	-3.6	0.000332	0.0175	-0.09	-0.11	Aortic root size;	chr7:66790659	chr7:66848496~66858136:+
BRCA	cis	rs58521262	0.556	rs396653	ENSG00000268105.1	RP11-369G6.2	3.6	0.000332	0.0175	0.15	0.11	Testicular germ cell tumor;	chr19:22938482	chr19:23125665~23128543:+
BRCA	cis	rs35520189	0.796	rs1143627	ENSG00000189223.12	PAX8-AS1	3.6	0.000332	0.0175	0.16	0.11	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:112836810	chr2:113211522~113276581:+
BRCA	cis	rs2803122	0.756	rs1129101	ENSG00000272842.1	RP11-513M16.7	3.6	0.000332	0.0175	0.11	0.11	Pulse pressure;	chr9:19372992	chr9:19371386~19371945:-
BRCA	cis	rs250585	0.516	rs426745	ENSG00000260136.4	CTD-2270L9.4	3.6	0.000332	0.0175	0.15	0.11	Egg allergy;	chr16:23590214	chr16:23452758~23457606:+
BRCA	cis	rs77633900	0.614	rs280024	ENSG00000196274.5	Metazoa_SRP	3.6	0.000332	0.0175	0.16	0.11	Glioma;Non-glioblastoma glioma;	chr15:76742177	chr15:76230048~76230390:-
BRCA	cis	rs60871478	0.636	rs56393680	ENSG00000237181.1	AC147651.4	3.6	0.000332	0.0175	0.13	0.11	Cerebrospinal P-tau181p levels;	chr7:846059	chr7:603185~608482:+
BRCA	cis	rs875971	0.862	rs6460282	ENSG00000229886.1	RP5-1132H15.3	-3.6	0.000332	0.0175	-0.13	-0.11	Aortic root size;	chr7:66226259	chr7:66025126~66031544:-
BRCA	cis	rs875971	0.545	rs73142265	ENSG00000232559.3	GS1-124K5.12	3.6	0.000332	0.0175	0.15	0.11	Aortic root size;	chr7:66234510	chr7:66554588~66576923:-
BRCA	cis	rs28489187	0.577	rs3920521	ENSG00000223653.4	RP11-131L23.1	3.6	0.000332	0.0175	0.12	0.11	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85383183	chr1:85276715~85448124:+
BRCA	cis	rs9470794	1	rs75362474	ENSG00000204110.6	RP1-153P14.8	-3.6	0.000332	0.0175	-0.23	-0.11	Type 2 diabetes;	chr6:38108301	chr6:37507348~37535616:+
BRCA	cis	rs9866825	0.934	rs6443170	ENSG00000227110.5	LMCD1-AS1	3.6	0.000332	0.0175	0.13	0.11	QT interval;	chr3:8203127	chr3:7952805~8611924:-
BRCA	cis	rs9866825	0.967	rs6443171	ENSG00000227110.5	LMCD1-AS1	3.6	0.000332	0.0175	0.13	0.11	QT interval;	chr3:8203223	chr3:7952805~8611924:-
BRCA	cis	rs35520189	0.885	rs13011562	ENSG00000274877.1	RP11-65I12.1	-3.6	0.000332	0.0175	-0.17	-0.11	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:112861321	chr2:113237595~113240825:+
BRCA	cis	rs11098499	0.866	rs10518329	ENSG00000260404.2	RP11-384K6.6	3.6	0.000332	0.0175	0.1	0.11	Corneal astigmatism;	chr4:119480680	chr4:118591773~118633729:+
BRCA	cis	rs11877825	0.826	rs8088257	ENSG00000265728.1	RP11-883A18.3	-3.6	0.000332	0.0175	-0.15	-0.11	Gut microbiota (bacterial taxa);	chr18:10579956	chr18:10594590~10604798:+
BRCA	cis	rs35306767	0.903	rs10508208	ENSG00000229869.1	RP11-363N22.2	-3.6	0.000332	0.0175	-0.17	-0.11	Eosinophil percentage of granulocytes;	chr10:865043	chr10:933026~942743:+
BRCA	cis	rs12468226	0.873	rs78798541	ENSG00000272966.1	RP11-686O6.1	3.6	0.000332	0.0175	0.19	0.11	Urate levels;	chr2:202194708	chr2:202336739~202337200:+
BRCA	cis	rs7656342	0.636	rs1914874	ENSG00000250342.1	SNRPCP16	3.6	0.000332	0.0175	0.12	0.11	Gut microbiota (bacterial taxa);	chr4:9837866	chr4:9051842~9052051:-
BRCA	cis	rs2562456	0.793	rs7259708	ENSG00000240522.1	RPL7AP10	-3.6	0.000332	0.0175	-0.12	-0.11	Pain;	chr19:21567846	chr19:21149648~21150438:-
BRCA	cis	rs61931739	0.534	rs6488189	ENSG00000258794.3	DUX4L27	3.6	0.000332	0.0175	0.16	0.11	Morning vs. evening chronotype;	chr12:33842930	chr12:34208415~34209675:-
BRCA	cis	rs6929812	0.613	rs9468140	ENSG00000271755.1	RP1-153G14.4	3.6	0.000332	0.0175	0.13	0.11	Neuroticism (multi-trait analysis);	chr6:27503736	chr6:27404010~27406964:-
BRCA	cis	rs7777677	0.925	rs6956269	ENSG00000211752.3	TRBV27	-3.6	0.000332	0.0175	-0.09	-0.11	Alcoholic chronic pancreatitis;	chr7:142661303	chr7:142715346~142715861:+
BRCA	cis	rs11662721	0.622	rs77637769	ENSG00000264188.1	RP11-13N13.5	3.6	0.000332	0.0175	0.16	0.11	Phospholipid levels (plasma);	chr18:21611346	chr18:21661787~21662395:-
BRCA	cis	rs568617	1	rs568617	ENSG00000254614.2	AP003068.23	-3.6	0.000332	0.0175	-0.16	-0.11	Crohn's disease;	chr11:65885771	chr11:65177606~65181834:-
BRCA	cis	rs568617	1	rs693824	ENSG00000254614.2	AP003068.23	-3.6	0.000332	0.0175	-0.16	-0.11	Crohn's disease;	chr11:65887312	chr11:65177606~65181834:-
BRCA	cis	rs4578769	0.569	rs12326874	ENSG00000266850.1	RP11-370A5.1	3.6	0.000332	0.0175	0.14	0.11	Eosinophil percentage of white cells;	chr18:22926670	chr18:22723491~22907721:-
BRCA	cis	rs11048434	0.518	rs2377679	ENSG00000111788.10	RP11-22B23.1	3.6	0.000332	0.0175	0.1	0.11	Sjögren's syndrome;	chr12:9023874	chr12:9277235~9313241:+
BRCA	cis	rs265981	0.666	rs1496133	ENSG00000213376.4	GAPDHP71	3.6	0.000332	0.0175	0.13	0.11	Night sleep phenotypes;	chr5:175466277	chr5:174513305~174514307:+
BRCA	cis	rs2518049	1	rs12387	ENSG00000224034.1	RP11-445P17.8	-3.6	0.000333	0.0175	-0.19	-0.11	Metabolic traits;	chr10:5097493	chr10:5266033~5271236:-
BRCA	cis	rs7246657	0.678	rs2927740	ENSG00000267470.4	ZNF571-AS1	-3.6	0.000333	0.0175	-0.14	-0.11	Coronary artery calcification;	chr19:37650065	chr19:37548914~37587348:+
BRCA	cis	rs11683197	1	rs11683197	ENSG00000237979.1	AC007389.1	3.6	0.000333	0.0175	0.15	0.11	Visceral fat;	chr2:64800490	chr2:65500993~65502138:-
BRCA	cis	rs7412746	0.566	rs2864871	ENSG00000224800.1	RP11-235D19.2	-3.6	0.000333	0.0175	-0.14	-0.11	Melanoma;	chr1:150794488	chr1:150881236~150881683:-
BRCA	cis	rs2395128	0.667	rs4307657	ENSG00000213731.2	RAB5CP1	3.6	0.000333	0.0175	0.21	0.11	Ulcerative colitis;Inflammatory bowel disease;	chr10:74905350	chr10:74423435~74424014:-
BRCA	cis	rs997295	0.57	rs7172298	ENSG00000260657.2	RP11-315D16.4	3.6	0.000333	0.0175	0.13	0.11	Motion sickness;	chr15:67580645	chr15:68267792~68277994:-
BRCA	cis	rs12549902	1	rs12549902	ENSG00000254165.1	RP11-503E24.2	3.6	0.000333	0.0175	0.12	0.11	Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Corrected insulin response;Type 2 diabetes;	chr8:41651740	chr8:42537529~42538304:-
BRCA	cis	rs9634489	0.709	rs7491529	ENSG00000247400.3	DNAJC3-AS1	-3.6	0.000333	0.0175	-0.12	-0.11	Body mass index;	chr13:96368380	chr13:95648733~95676925:-
BRCA	cis	rs881375	1	rs1953126	ENSG00000238181.2	AHCYP2	-3.6	0.000333	0.0175	-0.14	-0.11	Rheumatoid arthritis;	chr9:120878222	chr9:120720673~120721972:+
BRCA	cis	rs7267979	0.966	rs2482918	ENSG00000277938.1	RP5-965G21.3	-3.6	0.000333	0.0175	-0.13	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25431499	chr20:25229150~25231933:+
BRCA	cis	rs1949733	1	rs1949733	ENSG00000205959.3	RP11-689P11.2	3.6	0.000333	0.0175	0.11	0.11	Response to antineoplastic agents;	chr4:8501632	chr4:8482270~8512610:+
BRCA	cis	rs201673768	1	rs201673768	ENSG00000273765.1	RP11-370I10.11	3.6	0.000333	0.0175	0.13	0.11	Platelet count;	chr12:48305834	chr12:48360920~48361377:+
BRCA	cis	rs4664293	0.625	rs35241460	ENSG00000224152.1	AC009506.1	3.6	0.000333	0.0175	0.12	0.11	Monocyte percentage of white cells;	chr2:159651689	chr2:159615296~159617082:+
BRCA	cis	rs853679	0.517	rs9393885	ENSG00000226314.6	ZNF192P1	-3.6	0.000333	0.0175	-0.17	-0.11	Depression;	chr6:28082231	chr6:28161781~28169594:+
BRCA	cis	rs853679	0.517	rs9393886	ENSG00000226314.6	ZNF192P1	-3.6	0.000333	0.0175	-0.17	-0.11	Depression;	chr6:28082261	chr6:28161781~28169594:+
BRCA	cis	rs4713118	0.515	rs9368549	ENSG00000226314.6	ZNF192P1	-3.6	0.000333	0.0175	-0.17	-0.11	Parkinson's disease;	chr6:28082269	chr6:28161781~28169594:+
BRCA	cis	rs863345	0.604	rs12118446	ENSG00000229914.1	RP11-404O13.4	-3.6	0.000333	0.0175	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158526445	chr1:158195633~158196131:-
BRCA	cis	rs9650657	0.623	rs10091636	ENSG00000154316.13	TDH	3.6	0.000333	0.0175	0.14	0.11	Neuroticism;	chr8:10745456	chr8:11339637~11368452:+
BRCA	cis	rs9650657	0.54	rs10094732	ENSG00000154316.13	TDH	3.6	0.000333	0.0175	0.14	0.11	Neuroticism;	chr8:10745505	chr8:11339637~11368452:+
BRCA	cis	rs13434995	0.513	rs67963898	ENSG00000273257.1	RP11-177J6.1	-3.6	0.000333	0.0175	-0.16	-0.11	Adiponectin levels;	chr4:55475520	chr4:55387949~55388271:+
BRCA	cis	rs4664293	0.902	rs13391919	ENSG00000224152.1	AC009506.1	-3.6	0.000333	0.0175	-0.12	-0.11	Monocyte percentage of white cells;	chr2:159703649	chr2:159615296~159617082:+
BRCA	cis	rs925550	0.56	rs17006053	ENSG00000224786.1	CETN4P	-3.6	0.000333	0.0175	-0.16	-0.11	Primary biliary cholangitis;	chr4:122708506	chr4:122730548~122732193:-
BRCA	cis	rs7959452	0.59	rs11177644	ENSG00000274979.1	RP11-1143G9.5	-3.6	0.000333	0.0175	-0.12	-0.11	Blood protein levels;	chr12:69391968	chr12:69326574~69331882:-
BRCA	cis	rs4819052	0.851	rs8134392	ENSG00000223768.1	LINC00205	3.6	0.000333	0.0175	0.15	0.11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45243875	chr21:45293285~45297354:+
BRCA	cis	rs6011368	0.84	rs6062361	ENSG00000149656.7	LINC00266-1	-3.6	0.000333	0.0175	-0.12	-0.11	Clozapine-induced cytotoxicity;	chr20:64273189	chr20:64290385~64313132:+
BRCA	cis	rs1816752	0.935	rs4770676	ENSG00000273628.1	RP11-756A22.7	3.6	0.000333	0.0175	0.14	0.11	Obesity-related traits;	chr13:24429745	chr13:24933006~24936796:+
BRCA	cis	rs875971	0.83	rs6976714	ENSG00000271064.1	RP11-792A8.3	-3.6	0.000333	0.0175	-0.13	-0.11	Aortic root size;	chr7:66426474	chr7:66748838~66749077:-
BRCA	cis	rs62229266	0.804	rs12483151	ENSG00000214914.3	RPL23AP3	3.6	0.000333	0.0175	0.13	0.11	Mitral valve prolapse;	chr21:36047280	chr21:36016079~36016546:-
BRCA	cis	rs13272568	0.614	rs11775216	ENSG00000254352.1	RP11-578O24.2	-3.6	0.000333	0.0175	-0.15	-0.11	Bone mineral density;	chr8:78105343	chr8:78723796~78724136:-
BRCA	cis	rs17221829	0.733	rs12421173	ENSG00000280385.1	AP000648.5	-3.6	0.000333	0.0175	-0.13	-0.11	Anxiety in major depressive disorder;	chr11:89651320	chr11:90193614~90198120:+
BRCA	cis	rs7131987	0.903	rs11050152	ENSG00000273680.1	RP11-996F15.6	3.6	0.000333	0.0175	0.14	0.11	QT interval;	chr12:29251491	chr12:29332733~29333383:-
BRCA	cis	rs4243971	0.516	rs6141295	ENSG00000275576.1	RP5-836N17.4	-3.6	0.000333	0.0175	-0.12	-0.11	Inflammatory bowel disease;Crohn's disease;	chr20:32368199	chr20:32116171~32116629:+
BRCA	cis	rs7647973	0.621	rs3774800	ENSG00000244380.1	RP11-24C3.2	-3.6	0.000333	0.0175	-0.13	-0.11	Menarche (age at onset);	chr3:49297335	chr3:48440352~48446656:-
BRCA	cis	rs9549328	0.756	rs2993291	ENSG00000269356.1	RP11-120K24.4	-3.6	0.000333	0.0176	-0.15	-0.11	Systolic blood pressure;	chr13:112999532	chr13:113008778~113009424:+
BRCA	cis	rs4849845	0.653	rs34874174	ENSG00000223549.1	MTND5P28	3.6	0.000333	0.0176	0.13	0.11	Mean platelet volume;	chr2:120254404	chr2:120215181~120217279:+
BRCA	cis	rs4449834	0.816	rs1483206	ENSG00000254432.1	RP11-33I11.2	-3.6	0.000333	0.0176	-0.14	-0.11	Sum eosinophil basophil counts;	chr8:60754487	chr8:60808735~60809606:-
BRCA	cis	rs4449834	0.816	rs6994180	ENSG00000254432.1	RP11-33I11.2	-3.6	0.000333	0.0176	-0.14	-0.11	Sum eosinophil basophil counts;	chr8:60754848	chr8:60808735~60809606:-
BRCA	cis	rs4449834	0.702	rs1905305	ENSG00000254432.1	RP11-33I11.2	-3.6	0.000333	0.0176	-0.14	-0.11	Sum eosinophil basophil counts;	chr8:60755362	chr8:60808735~60809606:-
BRCA	cis	rs597539	0.652	rs622082	ENSG00000255741.1	RP11-757G1.5	-3.6	0.000333	0.0176	-0.16	-0.11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68936491	chr11:68941503~68942852:-
BRCA	cis	rs597539	0.652	rs546382	ENSG00000255741.1	RP11-757G1.5	-3.6	0.000333	0.0176	-0.16	-0.11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68936796	chr11:68941503~68942852:-
BRCA	cis	rs3169166	0.546	rs4887029	ENSG00000259562.2	RP11-762H8.2	3.6	0.000333	0.0176	0.09	0.11	Reticulocyte fraction of red cells;Reticulocyte count;	chr15:78299168	chr15:78290527~78291221:-
BRCA	cis	rs9628987	0.5	rs1443929	ENSG00000270282.1	RP5-1115A15.2	3.6	0.000333	0.0176	0.16	0.11	Breast cancer;	chr1:8397563	chr1:8512653~8513021:+
BRCA	cis	rs9921338	0.961	rs12934968	ENSG00000263080.1	RP11-485G7.5	-3.6	0.000333	0.0176	-0.16	-0.11	Vein graft stenosis in coronary artery bypass grafting;	chr16:11320209	chr16:11341809~11345211:-
BRCA	cis	rs983392	0.792	rs564912	ENSG00000275344.1	MIR6503	-3.6	0.000333	0.0176	-0.11	-0.11	Alzheimer's disease (late onset);	chr11:60118415	chr11:60209071~60209156:-
BRCA	cis	rs11673344	0.931	rs73622783	ENSG00000267005.1	AC002984.2	3.6	0.000333	0.0176	0.13	0.11	Obesity-related traits;	chr19:37165155	chr19:36173406~36173853:-
BRCA	cis	rs9308731	0.614	rs6755484	ENSG00000230499.1	AC108463.1	-3.6	0.000333	0.0176	-0.13	-0.11	Chronic lymphocytic leukemia;	chr2:111191519	chr2:111195963~111206494:+
BRCA	cis	rs35146811	0.735	rs1061230	ENSG00000214313.7	AZGP1P1	-3.6	0.000334	0.0176	-0.12	-0.11	Coronary artery disease;	chr7:100209642	chr7:99980762~99987535:+
BRCA	cis	rs10991814	0.513	rs7852888	ENSG00000273381.1	RP11-305L7.7	3.6	0.000334	0.0176	0.16	0.11	Neutrophil percentage of granulocytes;	chr9:91292564	chr9:91206175~91210299:-
BRCA	cis	rs6088580	0.668	rs1205340	ENSG00000276073.1	RP5-1125A11.7	3.6	0.000334	0.0176	0.12	0.11	Glomerular filtration rate (creatinine);	chr20:34336065	chr20:33985617~33988989:-
BRCA	cis	rs999943	0.846	rs9348923	ENSG00000224557.6	HLA-DPB2	-3.6	0.000334	0.0176	-0.15	-0.11	Obesity (extreme);	chr6:33650147	chr6:33112451~33129084:+
BRCA	cis	rs6142618	0.562	rs6061197	ENSG00000224452.1	RSL24D1P6	3.6	0.000334	0.0176	0.15	0.11	Inflammatory bowel disease;	chr20:32162543	chr20:32170390~32170790:-
BRCA	cis	rs6142618	0.562	rs6061198	ENSG00000224452.1	RSL24D1P6	3.6	0.000334	0.0176	0.15	0.11	Inflammatory bowel disease;	chr20:32162661	chr20:32170390~32170790:-
BRCA	cis	rs7772486	0.875	rs10457796	ENSG00000270638.1	RP3-466P17.1	3.6	0.000334	0.0176	0.13	0.11	Lobe attachment (rater-scored or self-reported);	chr6:146094951	chr6:145735570~145737218:+
BRCA	cis	rs1670533	1	rs604597	ENSG00000251639.2	RP11-20I20.1	-3.6	0.000334	0.0176	-0.18	-0.11	Recombination rate (females);	chr4:1100363	chr4:1100016~1101558:-
BRCA	cis	rs7119	0.634	rs2667782	ENSG00000259362.2	RP11-307C19.1	3.6	0.000334	0.0176	0.15	0.11	Type 2 diabetes;	chr15:77569954	chr15:77525540~77534110:+
BRCA	cis	rs7119	0.604	rs2667783	ENSG00000259362.2	RP11-307C19.1	3.6	0.000334	0.0176	0.15	0.11	Type 2 diabetes;	chr15:77570187	chr15:77525540~77534110:+
BRCA	cis	rs7119	0.604	rs2458035	ENSG00000259362.2	RP11-307C19.1	3.6	0.000334	0.0176	0.15	0.11	Type 2 diabetes;	chr15:77570464	chr15:77525540~77534110:+
BRCA	cis	rs300703	0.542	rs300696	ENSG00000228643.1	AC079779.4	-3.6	0.000334	0.0176	-0.18	-0.11	Blood protein levels;	chr2:183330	chr2:286419~301515:+
BRCA	cis	rs8098244	1	rs938602	ENSG00000265752.2	RP11-403A21.1	-3.6	0.000334	0.0176	-0.14	-0.11	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23812714	chr18:23957754~23982556:-
BRCA	cis	rs801193	0.904	rs4718403	ENSG00000275400.1	RP4-756H11.5	-3.6	0.000334	0.0176	-0.13	-0.11	Aortic root size;	chr7:66777742	chr7:66553805~66554199:-
BRCA	cis	rs910316	1	rs910316	ENSG00000259138.1	RP11-950C14.7	3.6	0.000334	0.0176	0.12	0.11	Height;	chr14:75159339	chr14:75127153~75136930:+
BRCA	cis	rs1122401	0.921	rs10069245	ENSG00000280159.1	CTD-2591A1.1	-3.6	0.000334	0.0176	-0.14	-0.11	Smoking initiation;	chr5:54578455	chr5:54643557~54645987:+
BRCA	cis	rs3764021	0.527	rs11052604	ENSG00000278635.1	CTD-2318O12.1	-3.6	0.000334	0.0176	-0.12	-0.11	Type 1 diabetes;	chr12:9709952	chr12:9415641~9416718:+
BRCA	cis	rs9650657	0.623	rs11250066	ENSG00000154316.13	TDH	3.6	0.000334	0.0176	0.14	0.11	Neuroticism;	chr8:10742957	chr8:11339637~11368452:+
BRCA	cis	rs7795541	0.739	rs10280205	ENSG00000230658.1	KLHL7-AS1	3.6	0.000334	0.0176	0.15	0.11	Morning vs. evening chronotype;	chr7:24042444	chr7:23101228~23105703:-
BRCA	cis	rs10501293	0.956	rs10837999	ENSG00000252652.1	Y_RNA	-3.6	0.000334	0.0176	-0.13	-0.11	Cognitive performance;	chr11:43047310	chr11:43331261~43331356:+
BRCA	cis	rs1124769	0.57	rs7181593	ENSG00000259298.1	RP11-562A8.4	-3.6	0.000334	0.0176	-0.11	-0.11	Cognitive performance;	chr15:50853917	chr15:50497195~50498744:-
BRCA	cis	rs1949733	0.816	rs2631746	ENSG00000205959.3	RP11-689P11.2	3.6	0.000334	0.0176	0.11	0.11	Response to antineoplastic agents;	chr4:8489207	chr4:8482270~8512610:+
BRCA	cis	rs2436153	0.676	rs1367988	ENSG00000254551.1	RP11-727A23.7	3.6	0.000334	0.0176	0.13	0.11	Facial morphology (factor 16);	chr11:83527341	chr11:83209431~83213379:-
BRCA	cis	rs28489187	0.617	rs11161606	ENSG00000223653.4	RP11-131L23.1	3.6	0.000334	0.0176	0.12	0.11	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85388219	chr1:85276715~85448124:+
BRCA	cis	rs539514	0.51	rs7335067	ENSG00000261105.4	LMO7-AS1	3.6	0.000334	0.0176	0.13	0.11	Type 1 diabetes;	chr13:75769797	chr13:75604700~75635994:-
BRCA	cis	rs7267979	1	rs6083844	ENSG00000276952.1	RP5-965G21.6	-3.6	0.000334	0.0176	-0.13	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25406196	chr20:25284915~25285588:-
BRCA	cis	rs875971	0.929	rs4122249	ENSG00000230189.5	GS1-124K5.2	3.6	0.000334	0.0176	0.09	0.11	Aortic root size;	chr7:66455949	chr7:66409143~66490059:-
BRCA	cis	rs3739034	0.938	rs6749329	ENSG00000224043.6	CCNT2-AS1	-3.6	0.000334	0.0176	-0.19	-0.11	Gut microbiome composition (winter);	chr2:134716795	chr2:134735464~134918710:-
BRCA	cis	rs3739034	0.938	rs4954169	ENSG00000224043.6	CCNT2-AS1	-3.6	0.000334	0.0176	-0.19	-0.11	Gut microbiome composition (winter);	chr2:134717626	chr2:134735464~134918710:-
BRCA	cis	rs3739034	0.759	rs62171394	ENSG00000224043.6	CCNT2-AS1	-3.6	0.000334	0.0176	-0.19	-0.11	Gut microbiome composition (winter);	chr2:134719225	chr2:134735464~134918710:-
BRCA	cis	rs3739034	0.816	rs62171396	ENSG00000224043.6	CCNT2-AS1	-3.6	0.000334	0.0176	-0.19	-0.11	Gut microbiome composition (winter);	chr2:134719289	chr2:134735464~134918710:-
BRCA	cis	rs12413361	0.967	rs2994653	ENSG00000237135.1	DDX10P1	-3.6	0.000334	0.0176	-0.13	-0.11	Height;	chr10:30835310	chr10:30919012~30921235:-
BRCA	cis	rs172166	0.694	rs203884	ENSG00000219891.2	ZSCAN12P1	3.6	0.000334	0.0176	0.14	0.11	Cardiac Troponin-T levels;	chr6:28109596	chr6:28091154~28093664:+
BRCA	cis	rs4272720	0.805	rs17700388	ENSG00000228754.1	RP11-534L6.3	-3.6	0.000334	0.0176	-0.16	-0.11	Platelet count;Plateletcrit;	chr10:49010047	chr10:48745545~48746128:-
BRCA	cis	rs6991838	0.584	rs4737747	ENSG00000272155.1	RP11-707M3.3	3.6	0.000334	0.0176	0.1	0.11	Intelligence (multi-trait analysis);	chr8:65607024	chr8:65714334~65714778:-
BRCA	cis	rs524281	0.861	rs10791855	ENSG00000255557.1	RP11-770G2.2	3.6	0.000334	0.0176	0.15	0.11	Electroencephalogram traits;	chr11:66196266	chr11:65745729~65771585:+
BRCA	cis	rs793571	0.694	rs12910580	ENSG00000259250.1	RP11-50C13.1	-3.6	0.000334	0.0176	-0.16	-0.11	Schizophrenia;	chr15:58979854	chr15:58587507~58591676:+
BRCA	cis	rs911119	0.913	rs6048929	ENSG00000270001.1	RP11-218C14.8	-3.6	0.000334	0.0176	-0.14	-0.11	Chronic kidney disease;	chr20:23608218	chr20:23631826~23632316:-
BRCA	cis	rs60843830	1	rs9213	ENSG00000223751.1	AC116609.2	3.6	0.000335	0.0176	0.15	0.11	Spherical equivalent (joint analysis main effects and education interaction);	chr2:218386	chr2:742488~747767:+
BRCA	cis	rs1949733	1	rs2631758	ENSG00000251615.3	RP11-774O3.3	3.6	0.000335	0.0176	0.12	0.11	Response to antineoplastic agents;	chr4:8493577	chr4:8355090~8358338:-
BRCA	cis	rs4835473	0.838	rs56033497	ENSG00000246448.2	RP13-578N3.3	-3.6	0.000335	0.0176	-0.12	-0.11	Immature fraction of reticulocytes;	chr4:143792341	chr4:143700257~143865072:+
BRCA	cis	rs4302906	0.542	rs12685670	ENSG00000187984.11	ANKRD19P	-3.6	0.000335	0.0176	-0.11	-0.11	Lobe attachment (rater-scored or self-reported);	chr9:93005636	chr9:92809388~92888693:+
BRCA	cis	rs13315871	0.929	rs13101057	ENSG00000272182.1	RP11-802O23.3	3.6	0.000335	0.0176	0.22	0.11	Cholesterol, total;	chr3:58305740	chr3:58428255~58428815:+
BRCA	cis	rs13315871	0.929	rs9871725	ENSG00000272182.1	RP11-802O23.3	3.6	0.000335	0.0176	0.22	0.11	Cholesterol, total;	chr3:58306798	chr3:58428255~58428815:+
BRCA	cis	rs34792	0.554	rs12933773	ENSG00000258354.1	MIR3180-1	-3.6	0.000335	0.0176	-0.15	-0.11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15529325	chr16:14909887~14911345:-
BRCA	cis	rs977987	0.585	rs62059845	ENSG00000280152.1	RP11-331F4.5	-3.6	0.000335	0.0176	-0.11	-0.11	Dupuytren's disease;	chr16:75396815	chr16:75245994~75250077:-
BRCA	cis	rs977987	0.778	rs62059846	ENSG00000280152.1	RP11-331F4.5	-3.6	0.000335	0.0176	-0.11	-0.11	Dupuytren's disease;	chr16:75396911	chr16:75245994~75250077:-
BRCA	cis	rs9470794	1	rs73423525	ENSG00000204110.6	RP1-153P14.8	-3.6	0.000335	0.0176	-0.21	-0.11	Type 2 diabetes;	chr6:38161073	chr6:37507348~37535616:+
BRCA	cis	rs2274273	0.624	rs67795323	ENSG00000259318.1	RP11-454L9.2	3.6	0.000335	0.0176	0.1	0.11	Protein biomarker;	chr14:55331115	chr14:55394940~55395233:-
BRCA	cis	rs2274273	0.624	rs8005450	ENSG00000259318.1	RP11-454L9.2	3.6	0.000335	0.0176	0.1	0.11	Protein biomarker;	chr14:55332447	chr14:55394940~55395233:-
BRCA	cis	rs11892454	0.565	rs13021454	ENSG00000217643.1	PTGES3P2	-3.6	0.000335	0.0176	-0.12	-0.11	Heschl's gyrus morphology;	chr2:25844570	chr2:25822469~25822950:+
BRCA	cis	rs7715806	0.517	rs34340	ENSG00000271815.1	CTD-2235C13.3	-3.6	0.000335	0.0176	-0.15	-0.11	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr5:75636274	chr5:75363760~75364242:+
BRCA	cis	rs597539	0.652	rs674654	ENSG00000255741.1	RP11-757G1.5	-3.6	0.000335	0.0176	-0.16	-0.11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68931294	chr11:68941503~68942852:-
BRCA	cis	rs597539	0.616	rs513476	ENSG00000255741.1	RP11-757G1.5	-3.6	0.000335	0.0176	-0.16	-0.11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68931528	chr11:68941503~68942852:-
BRCA	cis	rs295490	0.748	rs76778175	ENSG00000178631.7	ACTG1P1	-3.6	0.000335	0.0176	-0.23	-0.11	PR interval in Tripanosoma cruzi seropositivity;	chr3:139440213	chr3:139493809~139494937:+
BRCA	cis	rs2148307	0.55	rs3858197	ENSG00000228339.1	AMD1P1	-3.6	0.000335	0.0176	-0.15	-0.11	Photic sneeze reflex;	chr10:20806854	chr10:20350049~20351100:+
BRCA	cis	rs17123764	0.71	rs74089182	ENSG00000257464.1	RP11-161H23.8	-3.6	0.000335	0.0176	-0.19	-0.11	Intelligence (multi-trait analysis);	chr12:49669985	chr12:49442424~49442652:-
BRCA	cis	rs4763879	0.502	rs11052552	ENSG00000256594.6	RP11-705C15.2	3.6	0.000335	0.0176	0.13	0.11	Type 1 diabetes;	chr12:9703362	chr12:9633419~9658412:+
BRCA	cis	rs6088590	0.687	rs73106933	ENSG00000269202.1	RP4-614O4.12	-3.6	0.000335	0.0176	-0.11	-0.11	Coronary artery disease;	chr20:34699621	chr20:35201747~35203288:-
BRCA	cis	rs7560272	0.538	rs1806683	ENSG00000204872.3	NAT8B	-3.6	0.000335	0.0176	-0.15	-0.11	Schizophrenia;	chr2:73712685	chr2:73700576~73701340:-
BRCA	cis	rs6751744	0.513	rs10173538	ENSG00000224152.1	AC009506.1	-3.6	0.000335	0.0176	-0.12	-0.11	Dysphagia;	chr2:159712765	chr2:159615296~159617082:+
BRCA	cis	rs8040855	0.627	rs11632899	ENSG00000229212.6	RP11-561C5.4	-3.6	0.000335	0.0176	-0.14	-0.11	Bulimia nervosa;	chr15:85057609	chr15:85205440~85234795:-
BRCA	cis	rs569805	0.706	rs2685812	ENSG00000227617.7	CERS6-AS1	3.6	0.000335	0.0176	0.12	0.11	Metabolic syndrome (bivariate traits);	chr2:168941661	chr2:168771953~168786961:-
BRCA	cis	rs2708977	0.637	rs618454	ENSG00000271569.1	IGKV1OR2-6	-3.6	0.000335	0.0176	-0.08	-0.11	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96414356	chr2:97355059~97355335:+
BRCA	cis	rs4589258	1	rs10741363	ENSG00000280367.1	RP11-121L10.2	3.6	0.000335	0.0176	0.13	0.11	Intelligence (multi-trait analysis);	chr11:90751632	chr11:90223153~90226538:+
BRCA	cis	rs4950322	0.543	rs4950318	ENSG00000237188.3	RP11-337C18.8	3.6	0.000335	0.0176	0.14	0.11	Protein quantitative trait loci;	chr1:147316240	chr1:147172771~147211568:+
BRCA	cis	rs4950322	0.543	rs4950319	ENSG00000237188.3	RP11-337C18.8	3.6	0.000335	0.0176	0.14	0.11	Protein quantitative trait loci;	chr1:147316250	chr1:147172771~147211568:+
BRCA	cis	rs35520189	0.754	rs16944	ENSG00000274877.1	RP11-65I12.1	3.6	0.000335	0.0176	0.15	0.11	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:112837290	chr2:113237595~113240825:+
BRCA	cis	rs863345	0.604	rs2051451	ENSG00000229914.1	RP11-404O13.4	-3.6	0.000335	0.0176	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158494475	chr1:158195633~158196131:-
BRCA	cis	rs375066	0.762	rs1073654	ENSG00000267191.1	RP11-15A1.2	3.6	0.000335	0.0176	0.15	0.11	Breast cancer;	chr19:43907268	chr19:43902001~43926545:+
BRCA	cis	rs375066	0.762	rs1073653	ENSG00000267191.1	RP11-15A1.2	3.6	0.000335	0.0176	0.15	0.11	Breast cancer;	chr19:43907391	chr19:43902001~43926545:+
BRCA	cis	rs867186	1	rs6060244	ENSG00000126005.14	MMP24-AS1	3.6	0.000335	0.0176	0.2	0.11	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35111632	chr20:35216462~35278131:-
BRCA	cis	rs2904804	0.729	rs4339935	ENSG00000238840.1	U8	3.6	0.000335	0.0176	0.11	0.11	Economic and political preferences (immigration/crime);	chr10:4943852	chr10:4962436~4962568:-
BRCA	cis	rs4869313	0.668	rs2549787	ENSG00000248734.2	CTD-2260A17.1	-3.6	0.000335	0.0177	-0.11	-0.11	Pediatric autoimmune diseases;	chr5:96904133	chr5:96784777~96785999:+
BRCA	cis	rs2411233	1	rs11630969	ENSG00000259278.1	RP11-62C7.2	3.6	0.000335	0.0177	0.13	0.11	Platelet count;	chr15:38999334	chr15:39019233~39024918:+
BRCA	cis	rs8192917	1	rs10909625	ENSG00000258744.1	RP11-80A15.1	3.6	0.000335	0.0177	0.14	0.11	Vitiligo;	chr14:24632423	chr14:24501594~24508688:+
BRCA	cis	rs9309473	0.718	rs6546829	ENSG00000230002.2	ALMS1-IT1	3.6	0.000335	0.0177	0.13	0.11	Metabolite levels;	chr2:73386661	chr2:73456764~73459484:+
BRCA	cis	rs886774	1	rs2395932	ENSG00000273055.1	CTB-13F3.1	-3.6	0.000336	0.0177	-0.11	-0.11	Ulcerative colitis;	chr7:107854700	chr7:107942116~107942740:+
BRCA	cis	rs4835473	0.932	rs13121861	ENSG00000249741.2	RP11-673E1.3	3.6	0.000336	0.0177	0.11	0.11	Immature fraction of reticulocytes;	chr4:143814007	chr4:143911514~143912053:-
BRCA	cis	rs13434995	0.513	rs55885973	ENSG00000249700.7	SRD5A3-AS1	-3.6	0.000336	0.0177	-0.16	-0.11	Adiponectin levels;	chr4:55480054	chr4:55363971~55395847:-
BRCA	cis	rs6678639	0.522	rs11211420	ENSG00000225154.2	RP11-184J23.2	-3.6	0.000336	0.0177	-0.15	-0.11	Blood metabolite ratios;	chr1:47031365	chr1:47074778~47075979:-
BRCA	cis	rs4664293	0.585	rs35081473	ENSG00000224152.1	AC009506.1	3.6	0.000336	0.0177	0.12	0.11	Monocyte percentage of white cells;	chr2:159679970	chr2:159615296~159617082:+
BRCA	cis	rs4664293	0.605	rs7556888	ENSG00000224152.1	AC009506.1	3.6	0.000336	0.0177	0.12	0.11	Monocyte percentage of white cells;	chr2:159683750	chr2:159615296~159617082:+
BRCA	cis	rs172166	0.694	rs203893	ENSG00000219891.2	ZSCAN12P1	3.6	0.000336	0.0177	0.14	0.11	Cardiac Troponin-T levels;	chr6:28094288	chr6:28091154~28093664:+
BRCA	cis	rs7632954	0.567	rs6768518	ENSG00000227110.5	LMCD1-AS1	3.6	0.000336	0.0177	0.13	0.11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr3:8493142	chr3:7952805~8611924:-
BRCA	cis	rs910316	0.874	rs61980828	ENSG00000259138.1	RP11-950C14.7	-3.6	0.000336	0.0177	-0.12	-0.11	Height;	chr14:75163675	chr14:75127153~75136930:+
BRCA	cis	rs3743266	0.613	rs1869484	ENSG00000245534.5	RORA-AS1	3.6	0.000336	0.0177	0.13	0.11	Menarche (age at onset);	chr15:60449864	chr15:60479178~60630637:+
BRCA	cis	rs860295	0.702	rs12081067	ENSG00000232093.1	RP11-307C12.11	3.6	0.000336	0.0177	0.13	0.11	Body mass index;	chr1:155389191	chr1:155045191~155046118:-
BRCA	cis	rs6479874	1	rs4515917	ENSG00000223502.1	RP11-96B5.3	-3.6	0.000336	0.0177	-0.21	-0.11	Migraine;	chr10:50999188	chr10:51062579~51068553:-
BRCA	cis	rs6479874	0.85	rs7076470	ENSG00000223502.1	RP11-96B5.3	-3.6	0.000336	0.0177	-0.21	-0.11	Migraine;	chr10:50999427	chr10:51062579~51068553:-
BRCA	cis	rs6479874	1	rs7076631	ENSG00000223502.1	RP11-96B5.3	-3.6	0.000336	0.0177	-0.21	-0.11	Migraine;	chr10:50999563	chr10:51062579~51068553:-
BRCA	cis	rs10132760	0.616	rs9323020	ENSG00000255569.1	TRAV1-1	-3.6	0.000336	0.0177	-0.11	-0.11	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;	chr14:21690420	chr14:21621838~21622567:+
BRCA	cis	rs34929064	0.536	rs2905306	ENSG00000232949.1	AC002480.4	3.6	0.000336	0.0177	0.13	0.11	Major depression and alcohol dependence;	chr7:22599199	chr7:22589705~22591622:+
BRCA	cis	rs9866825	0.967	rs9813172	ENSG00000227110.5	LMCD1-AS1	3.6	0.000336	0.0177	0.13	0.11	QT interval;	chr3:8209541	chr3:7952805~8611924:-
BRCA	cis	rs1039766	1	rs10116	ENSG00000227791.3	AC007365.4	-3.6	0.000336	0.0177	-0.17	-0.11	Lung adenocarcinoma;Lung cancer;	chr2:65269595	chr2:64665607~64666064:+
BRCA	cis	rs1039766	0.929	rs268881	ENSG00000227791.3	AC007365.4	-3.6	0.000336	0.0177	-0.17	-0.11	Lung adenocarcinoma;Lung cancer;	chr2:65274249	chr2:64665607~64666064:+
BRCA	cis	rs9990333	0.562	rs58079878	ENSG00000207650.1	MIR570	3.6	0.000336	0.0177	0.14	0.11	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196100620	chr3:195699401~195699497:+
BRCA	cis	rs758324	0.947	rs7708140	ENSG00000237714.1	P4HA2-AS1	3.6	0.000336	0.0177	0.15	0.11	Alzheimer's disease in APOE e4- carriers;	chr5:131916703	chr5:132184876~132192808:+
BRCA	cis	rs8114671	0.562	rs6088642	ENSG00000279253.1	RP4-614O4.13	-3.6	0.000336	0.0177	-0.13	-0.11	Height;	chr20:34895383	chr20:35262727~35264187:-
BRCA	cis	rs6142102	0.923	rs4911379	ENSG00000206582.1	Y_RNA	-3.6	0.000336	0.0177	-0.14	-0.11	Skin pigmentation;	chr20:33947499	chr20:34526510~34526606:-
BRCA	cis	rs875971	0.862	rs10282433	ENSG00000229886.1	RP5-1132H15.3	-3.6	0.000336	0.0177	-0.12	-0.11	Aortic root size;	chr7:66256452	chr7:66025126~66031544:-
BRCA	cis	rs4974559	0.641	rs28647383	ENSG00000253399.1	AC078852.2	3.6	0.000336	0.0177	0.17	0.11	Systolic blood pressure;	chr4:1319120	chr4:1358479~1359461:+
BRCA	cis	rs586313	1	rs586313	ENSG00000204241.6	RP11-713P17.3	3.6	0.000336	0.0177	0.14	0.11	Granulocyte-colony stimulating factor levels;	chr11:134004817	chr11:134032272~134046849:+
BRCA	cis	rs2839186	0.9	rs2839200	ENSG00000215424.8	MCM3AP-AS1	3.6	0.000336	0.0177	0.1	0.11	Testicular germ cell tumor;	chr21:46289181	chr21:46229217~46259390:+
BRCA	cis	rs2599510	0.811	rs176410	ENSG00000276517.1	AL133243.2	3.6	0.000336	0.0177	0.13	0.11	Interleukin-18 levels;	chr2:32418369	chr2:32526504~32529507:+
BRCA	cis	rs17221829	0.702	rs72969198	ENSG00000280385.1	AP000648.5	-3.6	0.000336	0.0177	-0.13	-0.11	Anxiety in major depressive disorder;	chr11:89624439	chr11:90193614~90198120:+
BRCA	cis	rs11098499	0.865	rs4001305	ENSG00000225892.3	RP11-384K6.2	3.6	0.000336	0.0177	0.11	0.11	Corneal astigmatism;	chr4:119438081	chr4:118632274~118634759:+
BRCA	cis	rs10883723	0.81	rs2296585	ENSG00000213061.2	PFN1P11	-3.6	0.000336	0.0177	-0.15	-0.11	Allergic disease (asthma, hay fever or eczema);	chr10:102485792	chr10:102838011~102845473:-
BRCA	cis	rs4664293	0.647	rs6711049	ENSG00000224152.1	AC009506.1	-3.6	0.000336	0.0177	-0.12	-0.11	Monocyte percentage of white cells;	chr2:159584634	chr2:159615296~159617082:+
BRCA	cis	rs1850744	0.702	rs6836184	ENSG00000250342.1	SNRPCP16	-3.6	0.000336	0.0177	-0.23	-0.11	Economic and political preferences;	chr4:9632087	chr4:9051842~9052051:-
BRCA	cis	rs7020830	0.83	rs12554976	ENSG00000230188.1	RP11-405L18.4	-3.6	0.000336	0.0177	-0.13	-0.11	Schizophrenia;	chr9:37244508	chr9:37490421~37490893:-
BRCA	cis	rs2333021	0.866	rs10133784	ENSG00000258408.1	NT5CP2	3.6	0.000336	0.0177	0.12	0.11	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:73003328	chr14:73539221~73539781:-
BRCA	cis	rs962856	0.537	rs594289	ENSG00000236780.4	AC078941.1	3.6	0.000336	0.0177	0.14	0.11	Pancreatic cancer;	chr2:67456811	chr2:67123357~67215319:-
BRCA	cis	rs875971	0.862	rs6944374	ENSG00000229886.1	RP5-1132H15.3	-3.6	0.000336	0.0177	-0.13	-0.11	Aortic root size;	chr7:66221942	chr7:66025126~66031544:-
BRCA	cis	rs6840360	0.55	rs7683134	ENSG00000270265.1	RP11-731D1.4	-3.6	0.000336	0.0177	-0.13	-0.11	Intelligence (multi-trait analysis);	chr4:151582210	chr4:151333775~151353224:-
BRCA	cis	rs7683574	0.56	rs9684176	ENSG00000251313.1	RP11-747H12.5	3.6	0.000336	0.0177	0.12	0.11	Lung cancer;	chr4:9714762	chr4:9030286~9031066:+
BRCA	cis	rs12744310	0.525	rs12406967	ENSG00000235358.1	RP11-399E6.1	3.6	0.000336	0.0177	0.14	0.11	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41319742	chr1:41242373~41284861:+
BRCA	cis	rs10486158	0.521	rs11526212	ENSG00000265212.2	AC007009.2	3.6	0.000336	0.0177	0.13	0.11	Bipolar disorder and schizophrenia;	chr7:7387904	chr7:8154916~8155027:+
BRCA	cis	rs6710503	0.723	rs2076885	ENSG00000224165.4	DNAJC27-AS1	3.6	0.000336	0.0177	0.14	0.11	Lung cancer in ever smokers;Breast cancer;	chr2:24778032	chr2:24971390~25039694:+
BRCA	cis	rs34929064	0.536	rs2961279	ENSG00000232949.1	AC002480.4	-3.6	0.000336	0.0177	-0.13	-0.11	Major depression and alcohol dependence;	chr7:22598535	chr7:22589705~22591622:+
BRCA	cis	rs733592	0.507	rs7138917	ENSG00000257763.1	OR5BK1P	-3.6	0.000336	0.0177	-0.11	-0.11	Plateletcrit;	chr12:48061472	chr12:48355792~48356614:-
BRCA	cis	rs17801127	1	rs848222	ENSG00000231969.1	AC144449.1	-3.6	0.000336	0.0177	-0.18	-0.11	Liver enzyme levels (alanine transaminase);	chr2:149693982	chr2:149587196~149848233:+
BRCA	cis	rs1348850	0.958	rs4893941	ENSG00000280374.1	RP11-337N6.3	3.6	0.000336	0.0177	0.15	0.11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177404803	chr2:177317715~177318471:-
BRCA	cis	rs8040855	0.579	rs6496797	ENSG00000259570.1	RP11-671M22.4	-3.6	0.000336	0.0177	-0.12	-0.11	Bulimia nervosa;	chr15:85183624	chr15:84394512~84395514:+
BRCA	cis	rs7474896	1	rs12781703	ENSG00000120555.12	SEPT7P9	3.6	0.000336	0.0177	0.2	0.11	Obesity (extreme);	chr10:37755699	chr10:38383069~38402916:-
BRCA	cis	rs7474896	0.943	rs11011355	ENSG00000120555.12	SEPT7P9	3.6	0.000336	0.0177	0.2	0.11	Obesity (extreme);	chr10:37759257	chr10:38383069~38402916:-
BRCA	cis	rs7267979	0.966	rs4815425	ENSG00000274414.1	RP5-965G21.4	3.6	0.000336	0.0177	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25418240	chr20:25239007~25245229:-
BRCA	cis	rs16917546	1	rs10995249	ENSG00000238280.1	RP11-436D10.3	3.6	0.000336	0.0177	0.15	0.11	Basal cell carcinoma;	chr10:62637156	chr10:62793562~62805887:-
BRCA	cis	rs16917546	1	rs10995250	ENSG00000238280.1	RP11-436D10.3	3.6	0.000336	0.0177	0.15	0.11	Basal cell carcinoma;	chr10:62637161	chr10:62793562~62805887:-
BRCA	cis	rs7120118	0.517	rs56825896	ENSG00000280615.1	Y_RNA	3.6	0.000336	0.0177	0.18	0.11	HDL cholesterol;	chr11:47304633	chr11:47614898~47614994:-
BRCA	cis	rs7120118	0.517	rs56177220	ENSG00000280615.1	Y_RNA	3.6	0.000336	0.0177	0.18	0.11	HDL cholesterol;	chr11:47306826	chr11:47614898~47614994:-
BRCA	cis	rs12701220	0.894	rs34712249	ENSG00000224079.1	AC091729.7	3.6	0.000336	0.0177	0.17	0.11	Bronchopulmonary dysplasia;	chr7:996998	chr7:1074450~1078036:+
BRCA	cis	rs2712184	1	rs2712184	ENSG00000237930.1	AC007563.4	3.6	0.000337	0.0177	0.12	0.11	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);	chr2:216818056	chr2:216785774~216786144:-
BRCA	cis	rs9393813	0.509	rs10946915	ENSG00000241549.7	GUSBP2	-3.6	0.000337	0.0177	-0.12	-0.11	Bipolar disorder;	chr6:27410051	chr6:26871484~26956554:-
BRCA	cis	rs16958440	0.541	rs62095459	ENSG00000267724.1	RP11-49K24.8	3.6	0.000337	0.0177	0.16	0.11	Sitting height ratio;	chr18:47095011	chr18:47105946~47108062:+
BRCA	cis	rs2562456	0.876	rs7252585	ENSG00000240522.1	RPL7AP10	3.6	0.000337	0.0177	0.11	0.11	Pain;	chr19:21475141	chr19:21149648~21150438:-
BRCA	cis	rs2833693	0.521	rs12483200	ENSG00000261610.1	AP000265.1	3.6	0.000337	0.0177	0.14	0.11	Temperament;	chr21:32171166	chr21:32259804~32261585:-
BRCA	cis	rs1562975	0.855	rs76813126	ENSG00000234492.4	RPL34-AS1	3.6	0.000337	0.0177	0.15	0.11	Height;	chr4:108486647	chr4:108538190~108620460:-
BRCA	cis	rs2163813	0.959	rs247770	ENSG00000271283.1	CTC-412M14.6	3.6	0.000337	0.0177	0.15	0.11	Toenail selenium levels;	chr19:19737995	chr19:19699203~19699409:-
BRCA	cis	rs7020830	0.505	rs12553878	ENSG00000281649.1	EBLN3	-3.6	0.000337	0.0177	-0.1	-0.11	Schizophrenia;	chr9:37095708	chr9:37079857~37090507:+
BRCA	cis	rs8180040	0.966	rs11130128	ENSG00000280667.1	Y_RNA	-3.6	0.000337	0.0177	-0.13	-0.11	Colorectal cancer;	chr3:47445142	chr3:47501083~47501182:+
BRCA	cis	rs4713118	0.869	rs10214440	ENSG00000219392.1	RP1-265C24.5	-3.6	0.000337	0.0177	-0.16	-0.11	Parkinson's disease;	chr6:27734661	chr6:28115628~28116551:+
BRCA	cis	rs62229266	0.804	rs56279140	ENSG00000214914.3	RPL23AP3	3.6	0.000337	0.0177	0.13	0.11	Mitral valve prolapse;	chr21:36052063	chr21:36016079~36016546:-
BRCA	cis	rs10864907	0.805	rs2466452	ENSG00000231747.1	AC079922.2	3.6	0.000337	0.0177	0.11	0.11	Pulmonary function;	chr2:112865248	chr2:112621809~112622167:-
BRCA	cis	rs7520050	0.966	rs12139630	ENSG00000281133.1	AL355480.3	3.6	0.000337	0.0177	0.13	0.11	Reticulocyte count;Red blood cell count;	chr1:45885263	chr1:45580892~45580996:-
BRCA	cis	rs6964587	1	rs12540565	ENSG00000188693.7	CYP51A1-AS1	-3.6	0.000337	0.0177	-0.12	-0.11	Breast cancer;	chr7:92003899	chr7:92134604~92180725:+
BRCA	cis	rs3781264	0.6	rs12263737	ENSG00000268894.5	PLCE1-AS1	-3.6	0.000337	0.0177	-0.15	-0.11	Esophageal cancer and gastric cancer;	chr10:94285156	chr10:94279277~94287478:-
BRCA	cis	rs6600671	0.902	rs2222371	ENSG00000223345.3	HIST2H2BA	-3.6	0.000337	0.0177	-0.14	-0.11	Hip geometry;	chr1:121547320	chr1:121108210~121117257:-
BRCA	cis	rs2562456	0.876	rs11085468	ENSG00000240522.1	RPL7AP10	-3.6	0.000337	0.0177	-0.12	-0.11	Pain;	chr19:21569087	chr19:21149648~21150438:-
BRCA	cis	rs2998286	0.774	rs2790442	ENSG00000237128.1	RP11-351M16.3	3.6	0.000337	0.0177	0.16	0.11	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28539597	chr10:28433008~28495813:-
BRCA	cis	rs2554380	0.628	rs6602990	ENSG00000259570.1	RP11-671M22.4	3.6	0.000337	0.0177	0.14	0.11	Height;	chr15:83783470	chr15:84394512~84395514:+
BRCA	cis	rs875971	0.83	rs4718358	ENSG00000229886.1	RP5-1132H15.3	3.6	0.000337	0.0177	0.12	0.11	Aortic root size;	chr7:66508681	chr7:66025126~66031544:-
BRCA	cis	rs863345	0.565	rs10908668	ENSG00000229914.1	RP11-404O13.4	-3.6	0.000337	0.0177	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158532143	chr1:158195633~158196131:-
BRCA	cis	rs863345	0.526	rs10908669	ENSG00000229914.1	RP11-404O13.4	-3.6	0.000337	0.0177	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158532148	chr1:158195633~158196131:-
BRCA	cis	rs4689592	0.503	rs11937667	ENSG00000245468.3	RP11-367J11.3	-3.6	0.000337	0.0177	-0.14	-0.11	Monocyte percentage of white cells;	chr4:7055310	chr4:7094571~7103385:-
BRCA	cis	rs2731006	0.901	rs2678115	ENSG00000257114.2	RP11-25I15.3	3.6	0.000337	0.0177	0.17	0.11	Panic disorder;	chr12:42766492	chr12:42692216~42717119:+
BRCA	cis	rs6545883	0.931	rs778768	ENSG00000212978.6	AC016747.3	3.6	0.000337	0.0177	0.15	0.11	Tuberculosis;	chr2:61563154	chr2:61141592~61144969:-
BRCA	cis	rs295490	0.748	rs17494356	ENSG00000178631.7	ACTG1P1	-3.6	0.000337	0.0177	-0.23	-0.11	PR interval in Tripanosoma cruzi seropositivity;	chr3:139465126	chr3:139493809~139494937:+
BRCA	cis	rs61931739	0.5	rs9705909	ENSG00000258794.3	DUX4L27	3.6	0.000337	0.0177	0.16	0.11	Morning vs. evening chronotype;	chr12:34423484	chr12:34208415~34209675:-
BRCA	cis	rs7267979	1	rs6050602	ENSG00000274414.1	RP5-965G21.4	3.6	0.000337	0.0177	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25420567	chr20:25239007~25245229:-
BRCA	cis	rs10129255	0.957	rs12589190	ENSG00000232216.1	IGHV3-43	3.6	0.000337	0.0177	0.09	0.11	Kawasaki disease;	chr14:106783079	chr14:106470264~106470800:-
BRCA	cis	rs12664873	0.566	rs17201852	ENSG00000279453.1	RP3-425C14.4	-3.6	0.000337	0.0177	-0.15	-0.11	Atrial fibrillation;	chr6:122470945	chr6:122436789~122439223:-
BRCA	cis	rs11098499	0.913	rs56122576	ENSG00000260091.1	RP11-33B1.4	-3.6	0.000337	0.0177	-0.1	-0.11	Corneal astigmatism;	chr4:119208181	chr4:119409333~119410233:+
BRCA	cis	rs4478858	0.698	rs4949385	ENSG00000223907.1	LINC01226	-3.6	0.000337	0.0177	-0.13	-0.11	Alcohol dependence;	chr1:31320409	chr1:31518435~31524245:+
BRCA	cis	rs12220238	0.841	rs11000952	ENSG00000213731.2	RAB5CP1	-3.6	0.000337	0.0177	-0.17	-0.11	Soluble interleukin-2 receptor subunit alpha;	chr10:74277578	chr10:74423435~74424014:-
BRCA	cis	rs2573652	0.928	rs2581348	ENSG00000254744.3	CTD-3076O17.1	-3.6	0.000338	0.0177	-0.13	-0.11	Height;	chr15:99973858	chr15:99970215~99974010:+
BRCA	cis	rs6964587	0.869	rs7812219	ENSG00000188693.7	CYP51A1-AS1	3.6	0.000338	0.0177	0.12	0.11	Breast cancer;	chr7:91916413	chr7:92134604~92180725:+
BRCA	cis	rs7089973	0.966	rs36089581	ENSG00000236799.1	RP11-383C6.2	-3.6	0.000338	0.0177	-0.14	-0.11	Bipolar disorder or attention deficit hyperactivity disorder;	chr10:114863300	chr10:114994657~114996593:+
BRCA	cis	rs999943	0.846	rs9357162	ENSG00000224557.6	HLA-DPB2	-3.6	0.000338	0.0177	-0.15	-0.11	Obesity (extreme);	chr6:33645567	chr6:33112451~33129084:+
BRCA	cis	rs897984	0.52	rs4889614	ENSG00000260082.1	RP11-2C24.5	-3.6	0.000338	0.0177	-0.14	-0.11	Dementia with Lewy bodies;	chr16:30850814	chr16:30821068~30822110:-
BRCA	cis	rs801193	0.548	rs2659891	ENSG00000271064.1	RP11-792A8.3	-3.6	0.000338	0.0178	-0.13	-0.11	Aortic root size;	chr7:66736127	chr7:66748838~66749077:-
BRCA	cis	rs801193	0.548	rs7805152	ENSG00000271064.1	RP11-792A8.3	-3.6	0.000338	0.0178	-0.13	-0.11	Aortic root size;	chr7:66744266	chr7:66748838~66749077:-
BRCA	cis	rs1075265	0.518	rs13414393	ENSG00000235937.1	AC008280.1	3.6	0.000338	0.0178	0.12	0.11	Chronotype;Morning vs. evening chronotype;	chr2:54048025	chr2:54029552~54030682:-
BRCA	cis	rs962856	0.575	rs2035565	ENSG00000236780.4	AC078941.1	3.6	0.000338	0.0178	0.15	0.11	Pancreatic cancer;	chr2:67392524	chr2:67123357~67215319:-
BRCA	cis	rs745109	0.816	rs72932307	ENSG00000273080.1	RP11-301O19.1	3.6	0.000338	0.0178	0.17	0.11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86481440	chr2:86195590~86196049:+
BRCA	cis	rs889312	0.5	rs33328	ENSG00000271828.1	CTD-2310F14.1	-3.6	0.000338	0.0178	-0.13	-0.11	Breast cancer (early onset);Breast cancer;	chr5:56847592	chr5:56927874~56929573:+
BRCA	cis	rs7246657	0.943	rs35540940	ENSG00000267470.4	ZNF571-AS1	3.6	0.000338	0.0178	0.15	0.11	Coronary artery calcification;	chr19:37517333	chr19:37548914~37587348:+
BRCA	cis	rs3213961	0.744	rs4627543	ENSG00000187999.4	HNRNPA1P61	-3.6	0.000338	0.0178	-0.15	-0.11	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:33590881	chr2:33636502~33637425:+
BRCA	cis	rs2880765	0.835	rs12708553	ENSG00000230373.7	GOLGA6L5P	-3.6	0.000338	0.0178	-0.12	-0.11	Coronary artery disease;	chr15:85503602	chr15:84507885~84516814:-
BRCA	cis	rs2638953	0.853	rs11049679	ENSG00000273989.1	RP11-425D17.2	-3.6	0.000338	0.0178	-0.17	-0.11	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28508161	chr12:28236227~28236828:+
BRCA	cis	rs7824557	0.583	rs2736306	ENSG00000255495.1	AC145124.2	3.6	0.000338	0.0178	0.14	0.11	Retinal vascular caliber;	chr8:11382253	chr8:12194467~12196280:+
BRCA	cis	rs13082711	0.516	rs13084067	ENSG00000230807.1	AC099535.4	-3.6	0.000338	0.0178	-0.17	-0.11	Blood pressure;Systolic blood pressure;Diastolic blood pressure;	chr3:27317444	chr3:27486247~27486617:+
BRCA	cis	rs8192917	0.614	rs8021523	ENSG00000258744.1	RP11-80A15.1	3.6	0.000338	0.0178	0.16	0.11	Vitiligo;	chr14:24596738	chr14:24501594~24508688:+
BRCA	cis	rs748404	0.629	rs34657657	ENSG00000205771.5	CATSPER2P1	-3.6	0.000338	0.0178	-0.17	-0.11	Lung cancer;	chr15:43315763	chr15:43726918~43747094:-
BRCA	cis	rs748404	0.626	rs62019432	ENSG00000205771.5	CATSPER2P1	-3.6	0.000338	0.0178	-0.17	-0.11	Lung cancer;	chr15:43316482	chr15:43726918~43747094:-
BRCA	cis	rs1424638	0.655	rs12619309	ENSG00000233251.6	AC007743.1	-3.6	0.000338	0.0178	-0.13	-0.11	Intelligence (multi-trait analysis);	chr2:57021041	chr2:56173534~56185770:-
BRCA	cis	rs9393813	0.626	rs12664996	ENSG00000241549.7	GUSBP2	-3.6	0.000338	0.0178	-0.12	-0.11	Bipolar disorder;	chr6:27395865	chr6:26871484~26956554:-
BRCA	cis	rs7308116	0.645	rs10861833	ENSG00000274395.1	RP11-554D14.8	-3.6	0.000338	0.0178	-0.13	-0.11	Pelvic organ prolapse (moderate/severe);	chr12:107902358	chr12:107835541~107836555:-
BRCA	cis	rs12468226	0.938	rs76501067	ENSG00000272966.1	RP11-686O6.1	3.6	0.000338	0.0178	0.18	0.11	Urate levels;	chr2:202318042	chr2:202336739~202337200:+
BRCA	cis	rs2736345	0.788	rs998683	ENSG00000270154.1	RP11-419I17.1	-3.6	0.000338	0.0178	-0.14	-0.11	Systemic lupus erythematosus;Sjögren's syndrome;	chr8:11495491	chr8:12476462~12477122:+
BRCA	cis	rs10851411	0.647	rs17708630	ENSG00000260490.2	RP11-265N6.3	-3.6	0.000338	0.0178	-0.21	-0.11	Glucose homeostasis traits;	chr15:42417979	chr15:42571927~42572433:+
BRCA	cis	rs9470794	1	rs79616439	ENSG00000204110.6	RP1-153P14.8	-3.6	0.000338	0.0178	-0.23	-0.11	Type 2 diabetes;	chr6:38094977	chr6:37507348~37535616:+
BRCA	cis	rs9470794	1	rs74441639	ENSG00000204110.6	RP1-153P14.8	-3.6	0.000338	0.0178	-0.23	-0.11	Type 2 diabetes;	chr6:38096905	chr6:37507348~37535616:+
BRCA	cis	rs17684571	0.872	rs3002004	ENSG00000231441.1	RP11-472M19.2	3.6	0.000338	0.0178	0.16	0.11	Schizophrenia;	chr6:56743331	chr6:56844002~56864078:+
BRCA	cis	rs4557020	0.935	rs6545410	ENSG00000162997.14	PRORSD1P	-3.6	0.000338	0.0178	-0.12	-0.11	Myopia (pathological);	chr2:54484406	chr2:55282319~55284522:+
BRCA	cis	rs8141529	0.748	rs9620841	ENSG00000272858.1	CTA-292E10.8	-3.6	0.000338	0.0178	-0.14	-0.11	Lymphocyte counts;	chr22:28894993	chr22:28814914~28815662:+
BRCA	cis	rs4849845	0.598	rs3933620	ENSG00000223549.1	MTND5P28	3.6	0.000338	0.0178	0.13	0.11	Mean platelet volume;	chr2:120277360	chr2:120215181~120217279:+
BRCA	cis	rs80028505	0.614	rs3761980	ENSG00000271304.1	DPRXP2	-3.6	0.000338	0.0178	-0.21	-0.11	Foot ulcer in diabetes and neuropathy;	chr6:36026129	chr6:35989515~35990436:-
BRCA	cis	rs9381040	0.701	rs6933231	ENSG00000261068.2	RP11-7K24.3	-3.6	0.000338	0.0178	-0.15	-0.11	Alzheimer's disease (late onset);	chr6:41195962	chr6:42092233~42094259:-
BRCA	cis	rs2965260	0.621	rs17305073	ENSG00000269051.4	CTD-2245F17.3	3.6	0.000338	0.0178	0.19	0.11	IgG glycosylation;	chr19:53264900	chr19:53197111~53211015:+
BRCA	cis	rs4356203	0.543	rs214093	ENSG00000184669.7	OR7E14P	-3.6	0.000338	0.0178	-0.15	-0.11	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17273241	chr11:17013998~17053024:+
BRCA	cis	rs56322409	0.896	rs11188393	ENSG00000226688.5	ENTPD1-AS1	3.6	0.000338	0.0178	0.13	0.11	Blood metabolite levels;	chr10:95604266	chr10:95753206~96090238:-
BRCA	cis	rs4263408	1	rs7661070	ENSG00000224097.5	RP11-472B18.1	3.6	0.000338	0.0178	0.13	0.11	Plasma amyloid beta peptide concentrations (ABx-40);	chr4:39722745	chr4:39480255~39481905:+
BRCA	cis	rs372883	0.648	rs11088117	ENSG00000176054.6	RPL23P2	3.6	0.000338	0.0178	0.12	0.11	Pancreatic cancer;	chr21:29365495	chr21:28997613~28998033:-
BRCA	cis	rs4660456	0.913	rs6667368	ENSG00000272145.1	NFYC-AS1	-3.6	0.000338	0.0178	-0.12	-0.11	Platelet count;	chr1:40694887	chr1:40690380~40692066:-
BRCA	cis	rs11134654	1	rs1422160	ENSG00000253966.1	CTC-455F18.3	-3.6	0.000338	0.0178	-0.18	-0.11	Smooth-surface caries;	chr5:170816429	chr5:170896929~170904461:+
BRCA	cis	rs7267979	1	rs6083856	ENSG00000277938.1	RP5-965G21.3	-3.6	0.000338	0.0178	-0.13	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25426949	chr20:25229150~25231933:+
BRCA	cis	rs6893300	1	rs55975622	ENSG00000225051.5	HMGB3P22	3.6	0.000339	0.0178	0.15	0.11	Resting heart rate;	chr5:179740704	chr5:179679032~179694768:+
BRCA	cis	rs6893300	1	rs17617068	ENSG00000225051.5	HMGB3P22	3.6	0.000339	0.0178	0.15	0.11	Resting heart rate;	chr5:179741096	chr5:179679032~179694768:+
BRCA	cis	rs6108958	0.803	rs6108990	ENSG00000235036.4	RP5-1099D15.1	-3.6	0.000339	0.0178	-0.12	-0.11	Gut microbiome composition (summer);	chr20:11463488	chr20:10612861~10614229:-
BRCA	cis	rs2191566	0.691	rs55812285	ENSG00000266921.1	RP11-15A1.7	-3.6	0.000339	0.0178	-0.14	-0.11	Acute lymphoblastic leukemia (childhood);	chr19:44083777	chr19:43996896~44002836:-
BRCA	cis	rs801193	0.761	rs2659888	ENSG00000275400.1	RP4-756H11.5	-3.6	0.000339	0.0178	-0.13	-0.11	Aortic root size;	chr7:66765184	chr7:66553805~66554199:-
BRCA	cis	rs654950	0.875	rs34227270	ENSG00000230638.4	RP11-486B10.4	-3.6	0.000339	0.0178	-0.14	-0.11	Airway imaging phenotypes;	chr1:41533296	chr1:41542069~41544310:+
BRCA	cis	rs13068223	0.74	rs344003	ENSG00000241770.1	RP11-555M1.3	3.6	0.000339	0.0178	0.14	0.11	Age-related hearing impairment (SNP x SNP interaction);	chr3:156739931	chr3:157163452~157169133:+
BRCA	cis	rs11098499	0.954	rs6847248	ENSG00000250412.1	KLHL2P1	3.6	0.000339	0.0178	0.14	0.11	Corneal astigmatism;	chr4:119304800	chr4:119334329~119378233:+
BRCA	cis	rs9926296	0.581	rs6500457	ENSG00000261373.1	VPS9D1-AS1	3.6	0.000339	0.0178	0.12	0.11	Vitiligo;	chr16:89832356	chr16:89711856~89718165:+
BRCA	cis	rs1411478	1	rs2331903	ENSG00000243155.1	RP11-46A10.5	3.6	0.000339	0.0178	0.12	0.11	Menopause (age at onset);Progressive supranuclear palsy;	chr1:180981733	chr1:180944042~180976482:-
BRCA	cis	rs6460942	0.908	rs3887296	ENSG00000226690.5	AC005281.1	3.6	0.000339	0.0178	0.2	0.11	Coronary artery disease;	chr7:12218340	chr7:12496429~12541910:+
BRCA	cis	rs2262909	0.925	rs73019900	ENSG00000279377.1	AC003973.3	-3.6	0.000339	0.0178	-0.16	-0.11	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;	chr19:22103878	chr19:21965708~21968529:-
BRCA	cis	rs863345	0.625	rs11264978	ENSG00000176320.2	RP11-404O13.5	-3.6	0.000339	0.0178	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158478131	chr1:158197922~158203877:-
BRCA	cis	rs10043775	1	rs36028618	ENSG00000251330.3	CTD-2283N19.1	-3.6	0.000339	0.0178	-0.13	-0.11	Periodontal microbiota;	chr5:148411578	chr5:148430159~148430807:-
BRCA	cis	rs10043775	1	rs4639212	ENSG00000251330.3	CTD-2283N19.1	-3.6	0.000339	0.0178	-0.13	-0.11	Periodontal microbiota;	chr5:148413387	chr5:148430159~148430807:-
BRCA	cis	rs10043775	1	rs13354454	ENSG00000251330.3	CTD-2283N19.1	-3.6	0.000339	0.0178	-0.13	-0.11	Periodontal microbiota;	chr5:148414845	chr5:148430159~148430807:-
BRCA	cis	rs3781264	0.848	rs6583935	ENSG00000268894.5	PLCE1-AS1	-3.6	0.000339	0.0178	-0.15	-0.11	Esophageal cancer and gastric cancer;	chr10:94313568	chr10:94279277~94287478:-
BRCA	cis	rs1555133	0.584	rs4911093	ENSG00000277692.1	RP11-358N2.2	-3.6	0.000339	0.0178	-0.12	-0.11	Monocyte count;	chr20:32430560	chr20:32355053~32355734:+
BRCA	cis	rs4449834	0.816	rs7838426	ENSG00000254432.1	RP11-33I11.2	-3.6	0.000339	0.0178	-0.15	-0.11	Sum eosinophil basophil counts;	chr8:60755879	chr8:60808735~60809606:-
BRCA	cis	rs754466	0.58	rs2289311	ENSG00000213514.2	RP11-428P16.2	3.6	0.000339	0.0178	0.15	0.11	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77805897	chr10:77730766~77734769:+
BRCA	cis	rs4648045	0.687	rs4699030	ENSG00000246560.2	RP11-10L12.4	-3.6	0.000339	0.0178	-0.12	-0.11	Lymphocyte percentage of white cells;	chr4:102582667	chr4:102828055~102844075:+
BRCA	cis	rs10514758	0.744	rs1949122	ENSG00000242880.1	RP11-190P13.2	3.6	0.000339	0.0178	0.26	0.11	Urate levels in obese individuals;	chr3:115204222	chr3:115251196~115285347:+
BRCA	cis	rs10514758	0.744	rs34711605	ENSG00000242880.1	RP11-190P13.2	3.6	0.000339	0.0178	0.26	0.11	Urate levels in obese individuals;	chr3:115205275	chr3:115251196~115285347:+
BRCA	cis	rs10514758	0.744	rs72947749	ENSG00000242880.1	RP11-190P13.2	3.6	0.000339	0.0178	0.26	0.11	Urate levels in obese individuals;	chr3:115208221	chr3:115251196~115285347:+
BRCA	cis	rs934734	0.752	rs1876518	ENSG00000204929.10	AC074391.1	-3.6	0.000339	0.0178	-0.13	-0.11	Rheumatoid arthritis;	chr2:65381775	chr2:65436711~66084639:+
BRCA	cis	rs10986311	0.713	rs944337	ENSG00000227200.1	RP11-121A14.3	-3.6	0.000339	0.0178	-0.14	-0.11	Vitiligo;	chr9:124259987	chr9:124262876~124265809:+
BRCA	cis	rs10986311	0.747	rs944338	ENSG00000227200.1	RP11-121A14.3	-3.6	0.000339	0.0178	-0.14	-0.11	Vitiligo;	chr9:124259988	chr9:124262876~124265809:+
BRCA	cis	rs4934494	0.911	rs7098233	ENSG00000235100.3	RP11-80H5.9	3.6	0.000339	0.0178	0.15	0.11	Red blood cell count;	chr10:89663111	chr10:89667181~89699671:-
BRCA	cis	rs13113518	0.51	rs6828454	ENSG00000249700.7	SRD5A3-AS1	3.6	0.000339	0.0178	0.14	0.11	Height;	chr4:55424329	chr4:55363971~55395847:-
BRCA	cis	rs647097	0.694	rs564629	ENSG00000265962.1	GACAT2	3.6	0.000339	0.0178	0.15	0.11	Chronic obstructive pulmonary disease;	chr18:8799450	chr18:8695856~8707621:-
BRCA	cis	rs2486012	0.826	rs3011229	ENSG00000237950.1	RP11-7O11.3	3.6	0.000339	0.0178	0.18	0.11	Intelligence (multi-trait analysis);	chr1:43862345	chr1:43944370~43946551:-
BRCA	cis	rs2486012	1	rs2906463	ENSG00000237950.1	RP11-7O11.3	3.6	0.000339	0.0178	0.18	0.11	Intelligence (multi-trait analysis);	chr1:43864376	chr1:43944370~43946551:-
BRCA	cis	rs716804	0.566	rs7927874	ENSG00000254554.1	RP11-351I24.1	3.6	0.000339	0.0178	0.14	0.11	Neuroticism;	chr11:10302644	chr11:10302657~10303704:-
BRCA	cis	rs7338174	0.655	rs4942995	ENSG00000224892.5	RPS4XP16	3.6	0.000339	0.0178	0.28	0.11	Mitochondrial DNA levels;	chr13:51355168	chr13:51454164~51461315:+
BRCA	cis	rs875971	1	rs778726	ENSG00000272831.1	RP11-792A8.4	3.6	0.000339	0.0178	0.1	0.11	Aortic root size;	chr7:66363744	chr7:66739829~66740385:-
BRCA	cis	rs875971	0.767	rs1695815	ENSG00000272831.1	RP11-792A8.4	3.6	0.000339	0.0178	0.1	0.11	Aortic root size;	chr7:66366357	chr7:66739829~66740385:-
BRCA	cis	rs875971	1	rs778685	ENSG00000272831.1	RP11-792A8.4	3.6	0.000339	0.0178	0.1	0.11	Aortic root size;	chr7:66371189	chr7:66739829~66740385:-
BRCA	cis	rs875971	0.929	rs778682	ENSG00000272831.1	RP11-792A8.4	3.6	0.000339	0.0178	0.1	0.11	Aortic root size;	chr7:66372947	chr7:66739829~66740385:-
BRCA	cis	rs875971	0.964	rs11765965	ENSG00000272831.1	RP11-792A8.4	3.6	0.000339	0.0178	0.1	0.11	Aortic root size;	chr7:66377234	chr7:66739829~66740385:-
BRCA	cis	rs1009077	0.68	rs61747388	ENSG00000245958.5	RP11-33B1.1	3.6	0.000339	0.0178	0.14	0.11	Endometriosis;	chr4:119512860	chr4:119454791~119552025:+
BRCA	cis	rs7412746	0.658	rs3843843	ENSG00000224800.1	RP11-235D19.2	-3.6	0.000339	0.0178	-0.14	-0.11	Melanoma;	chr1:150945608	chr1:150881236~150881683:-
BRCA	cis	rs7267979	1	rs398036	ENSG00000277938.1	RP5-965G21.3	3.6	0.000339	0.0178	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25459214	chr20:25229150~25231933:+
BRCA	cis	rs7267979	1	rs397119	ENSG00000277938.1	RP5-965G21.3	3.6	0.000339	0.0178	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25459551	chr20:25229150~25231933:+
BRCA	cis	rs1555133	0.625	rs6141696	ENSG00000275576.1	RP5-836N17.4	-3.6	0.000339	0.0178	-0.12	-0.11	Monocyte count;	chr20:32381800	chr20:32116171~32116629:+
BRCA	cis	rs4243971	0.537	rs6141697	ENSG00000275576.1	RP5-836N17.4	-3.6	0.000339	0.0178	-0.12	-0.11	Inflammatory bowel disease;Crohn's disease;	chr20:32381803	chr20:32116171~32116629:+
BRCA	cis	rs4243971	0.516	rs6141299	ENSG00000275576.1	RP5-836N17.4	-3.6	0.000339	0.0178	-0.12	-0.11	Inflammatory bowel disease;Crohn's disease;	chr20:32382267	chr20:32116171~32116629:+
BRCA	cis	rs6840360	0.547	rs9991859	ENSG00000278978.1	RP11-164P12.5	-3.6	0.000339	0.0178	-0.12	-0.11	Intelligence (multi-trait analysis);	chr4:151344420	chr4:151669786~151670503:+
BRCA	cis	rs875971	0.619	rs2302918	ENSG00000229180.5	GS1-124K5.11	3.6	0.000339	0.0178	0.1	0.11	Aortic root size;	chr7:66535945	chr7:66526088~66542624:-
BRCA	cis	rs9876781	0.559	rs1841178	ENSG00000199476.1	Y_RNA	-3.6	0.000339	0.0178	-0.15	-0.11	Longevity;	chr3:48355556	chr3:48288587~48288694:+
BRCA	cis	rs10411161	0.721	rs1433082	ENSG00000268095.1	ZNF649-AS1	-3.6	0.000339	0.0178	-0.18	-0.11	Breast cancer;	chr19:51887473	chr19:51888025~51900463:+
BRCA	cis	rs886774	0.74	rs13646	ENSG00000273055.1	CTB-13F3.1	3.6	0.000339	0.0178	0.11	0.11	Ulcerative colitis;	chr7:107924693	chr7:107942116~107942740:+
BRCA	cis	rs4835473	0.932	rs7683686	ENSG00000249741.2	RP11-673E1.3	3.6	0.000339	0.0178	0.11	0.11	Immature fraction of reticulocytes;	chr4:143784352	chr4:143911514~143912053:-
BRCA	cis	rs17079773	0.867	rs10507336	ENSG00000228741.2	SPATA13	-3.6	0.000339	0.0178	-0.21	-0.11	Inattentive symptoms;	chr13:24031661	chr13:23979810~24035027:+
BRCA	cis	rs6733011	0.542	rs6542860	ENSG00000226791.5	AC109826.1	3.6	0.000339	0.0178	0.13	0.11	Bipolar disorder;	chr2:99062913	chr2:98761938~98772920:-
BRCA	cis	rs465969	0.546	rs7772141	ENSG00000271789.1	RP5-1112D6.7	-3.6	0.000339	0.0178	-0.26	-0.11	Psoriasis;	chr6:111472358	chr6:111297126~111298510:+
BRCA	cis	rs465969	0.793	rs7776047	ENSG00000271789.1	RP5-1112D6.7	-3.6	0.000339	0.0178	-0.26	-0.11	Psoriasis;	chr6:111472391	chr6:111297126~111298510:+
BRCA	cis	rs2243480	0.901	rs2456483	ENSG00000226002.1	RP11-460N20.5	-3.6	0.000339	0.0178	-0.18	-0.11	Diabetic kidney disease;	chr7:65996588	chr7:65084103~65100232:+
BRCA	cis	rs2243480	1	rs1701750	ENSG00000226002.1	RP11-460N20.5	-3.6	0.000339	0.0178	-0.18	-0.11	Diabetic kidney disease;	chr7:66002158	chr7:65084103~65100232:+
BRCA	cis	rs868153	1	rs17084154	ENSG00000279453.1	RP3-425C14.4	3.6	0.000339	0.0178	0.13	0.11	Vertical cup-disc ratio;	chr6:122072298	chr6:122436789~122439223:-
BRCA	cis	rs6840360	0.55	rs6535806	ENSG00000270265.1	RP11-731D1.4	-3.59	0.00034	0.0178	-0.13	-0.11	Intelligence (multi-trait analysis);	chr4:151562754	chr4:151333775~151353224:-
BRCA	cis	rs6840360	0.53	rs6839802	ENSG00000270265.1	RP11-731D1.4	-3.59	0.00034	0.0178	-0.13	-0.11	Intelligence (multi-trait analysis);	chr4:151564682	chr4:151333775~151353224:-
BRCA	cis	rs6840360	0.571	rs7674244	ENSG00000270265.1	RP11-731D1.4	-3.59	0.00034	0.0178	-0.13	-0.11	Intelligence (multi-trait analysis);	chr4:151567150	chr4:151333775~151353224:-
BRCA	cis	rs6840360	1	rs6535819	ENSG00000251611.1	RP11-610P16.1	-3.59	0.00034	0.0178	-0.1	-0.11	Intelligence (multi-trait analysis);	chr4:151730351	chr4:151407551~151408835:-
BRCA	cis	rs4664293	0.801	rs6432552	ENSG00000224152.1	AC009506.1	-3.59	0.00034	0.0178	-0.13	-0.11	Monocyte percentage of white cells;	chr2:159717613	chr2:159615296~159617082:+
BRCA	cis	rs7917772	0.502	rs4919670	ENSG00000236937.2	PTGES3P4	3.59	0.00034	0.0178	0.15	0.11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;	chr10:102756042	chr10:102845595~102845950:+
BRCA	cis	rs983392	0.678	rs4938933	ENSG00000275344.1	MIR6503	3.59	0.00034	0.0178	0.11	0.11	Alzheimer's disease (late onset);	chr11:60266956	chr11:60209071~60209156:-
BRCA	cis	rs16858210	0.52	rs10460892	ENSG00000233885.6	YEATS2-AS1	-3.59	0.00034	0.0178	-0.16	-0.11	Menopause (age at onset);	chr3:183828336	chr3:183806457~183810783:-
BRCA	cis	rs4714291	0.963	rs1923466	ENSG00000180211.5	RP1-278E11.3	3.59	0.00034	0.0178	0.12	0.11	Strep throat;	chr6:39998207	chr6:39958414~39958833:-
BRCA	cis	rs4703129	1	rs1820767	ENSG00000246763.5	RGMB-AS1	-3.59	0.00034	0.0178	-0.13	-0.11	Asperger disorder;	chr5:98542933	chr5:98769618~98773469:-
BRCA	cis	rs6490294	0.571	rs11066117	ENSG00000257624.1	RP1-128M12.3	3.59	0.00034	0.0178	0.18	0.11	Mean platelet volume;	chr12:111994905	chr12:112000739~112000985:-
BRCA	cis	rs6456156	0.774	rs6931530	ENSG00000272549.1	RP11-351J23.2	3.59	0.00034	0.0178	0.11	0.11	Primary biliary cholangitis;	chr6:167113712	chr6:167666840~167679270:-
BRCA	cis	rs7267979	0.866	rs2424698	ENSG00000274973.1	RP13-401N8.7	-3.59	0.00034	0.0178	-0.13	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25275470	chr20:25845497~25845862:+
BRCA	cis	rs8049367	0.684	rs2238419	ENSG00000267077.1	RP11-127I20.5	3.59	0.00034	0.0178	0.11	0.11	Nonsyndromic cleft lip with or without cleft palate;	chr16:3915365	chr16:4795265~4796532:-
BRCA	cis	rs965513	0.901	rs7045465	ENSG00000236896.1	RP11-535C21.3	-3.59	0.00034	0.0178	-0.13	-0.11	Thyroid cancer (Papillary, radiation-related);Thyroid cancer;	chr9:97772541	chr9:97986551~97987656:-
BRCA	cis	rs4243971	0.516	rs6141689	ENSG00000275576.1	RP5-836N17.4	-3.59	0.00034	0.0178	-0.12	-0.11	Inflammatory bowel disease;Crohn's disease;	chr20:32363324	chr20:32116171~32116629:+
BRCA	cis	rs687432	0.885	rs35713433	ENSG00000265566.2	RN7SL605P	-3.59	0.00034	0.0179	-0.16	-0.11	Parkinson's disease;	chr11:57940928	chr11:57528085~57528365:-
BRCA	cis	rs172166	0.694	rs203892	ENSG00000219891.2	ZSCAN12P1	3.59	0.00034	0.0179	0.14	0.11	Cardiac Troponin-T levels;	chr6:28099418	chr6:28091154~28093664:+
BRCA	cis	rs172166	0.694	rs188105	ENSG00000219891.2	ZSCAN12P1	3.59	0.00034	0.0179	0.14	0.11	Cardiac Troponin-T levels;	chr6:28103615	chr6:28091154~28093664:+
BRCA	cis	rs8062405	1	rs8062405	ENSG00000261766.1	RP11-22P6.2	3.59	0.00034	0.0179	0.11	0.11	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28826585	chr16:28862166~28863340:-
BRCA	cis	rs801193	1	rs1553610	ENSG00000275400.1	RP4-756H11.5	-3.59	0.00034	0.0179	-0.13	-0.11	Aortic root size;	chr7:66732246	chr7:66553805~66554199:-
BRCA	cis	rs801193	1	rs2707845	ENSG00000275400.1	RP4-756H11.5	-3.59	0.00034	0.0179	-0.13	-0.11	Aortic root size;	chr7:66733811	chr7:66553805~66554199:-
BRCA	cis	rs801193	1	rs2707850	ENSG00000275400.1	RP4-756H11.5	-3.59	0.00034	0.0179	-0.13	-0.11	Aortic root size;	chr7:66738883	chr7:66553805~66554199:-
BRCA	cis	rs801193	0.967	rs1110414	ENSG00000275400.1	RP4-756H11.5	-3.59	0.00034	0.0179	-0.13	-0.11	Aortic root size;	chr7:66740595	chr7:66553805~66554199:-
BRCA	cis	rs801193	1	rs7783924	ENSG00000275400.1	RP4-756H11.5	-3.59	0.00034	0.0179	-0.13	-0.11	Aortic root size;	chr7:66744070	chr7:66553805~66554199:-
BRCA	cis	rs801193	1	rs7789184	ENSG00000275400.1	RP4-756H11.5	-3.59	0.00034	0.0179	-0.13	-0.11	Aortic root size;	chr7:66745208	chr7:66553805~66554199:-
BRCA	cis	rs801193	1	rs2707854	ENSG00000275400.1	RP4-756H11.5	-3.59	0.00034	0.0179	-0.13	-0.11	Aortic root size;	chr7:66747610	chr7:66553805~66554199:-
BRCA	cis	rs6479874	0.736	rs2816837	ENSG00000223502.1	RP11-96B5.3	-3.59	0.00034	0.0179	-0.19	-0.11	Migraine;	chr10:50992404	chr10:51062579~51068553:-
BRCA	cis	rs2562456	0.52	rs660063	ENSG00000268081.1	RP11-678G14.2	-3.59	0.00034	0.0179	-0.19	-0.11	Pain;	chr19:21271103	chr19:21554640~21569237:-
BRCA	cis	rs6964587	0.626	rs1011372	ENSG00000188693.7	CYP51A1-AS1	3.59	0.00034	0.0179	0.12	0.11	Breast cancer;	chr7:91880553	chr7:92134604~92180725:+
BRCA	cis	rs849141	0.89	rs481806	ENSG00000234336.5	JAZF1-AS1	-3.59	0.00034	0.0179	-0.16	-0.11	Height;Hip circumference adjusted for BMI;	chr7:28167681	chr7:28180322~28243917:+
BRCA	cis	rs13315871	0.929	rs77487951	ENSG00000272182.1	RP11-802O23.3	3.59	0.00034	0.0179	0.22	0.11	Cholesterol, total;	chr3:58305165	chr3:58428255~58428815:+
BRCA	cis	rs7637701	0.967	rs6784421	ENSG00000240875.4	LINC00886	-3.59	0.00034	0.0179	-0.13	-0.11	Breast cancer;	chr3:156937705	chr3:156747346~156817062:-
BRCA	cis	rs4835473	0.9	rs5015758	ENSG00000246448.2	RP13-578N3.3	-3.59	0.00034	0.0179	-0.13	-0.11	Immature fraction of reticulocytes;	chr4:143738052	chr4:143700257~143865072:+
BRCA	cis	rs4819052	0.851	rs10470246	ENSG00000215447.6	BX322557.10	-3.59	0.00034	0.0179	-0.11	-0.11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239102	chr21:45288052~45291738:+
BRCA	cis	rs4819052	0.851	rs10470247	ENSG00000215447.6	BX322557.10	-3.59	0.00034	0.0179	-0.11	-0.11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239103	chr21:45288052~45291738:+
BRCA	cis	rs4819052	0.851	rs4819043	ENSG00000215447.6	BX322557.10	-3.59	0.00034	0.0179	-0.11	-0.11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240163	chr21:45288052~45291738:+
BRCA	cis	rs4819052	0.851	rs4819044	ENSG00000215447.6	BX322557.10	-3.59	0.00034	0.0179	-0.11	-0.11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240203	chr21:45288052~45291738:+
BRCA	cis	rs3735485	0.8	rs6969223	ENSG00000201772.1	SNORA5C	-3.59	0.00034	0.0179	-0.14	-0.11	White blood cell count;Sum basophil neutrophil counts;Neutrophil count;Granulocyte percentage of myeloid white cells;Monocyte percentage of white cells;Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Lymphocyte counts;	chr7:45015615	chr7:45104906~45105042:-
BRCA	cis	rs8030605	0.778	rs72742636	ENSG00000277245.1	RP11-48G14.3	3.59	0.00034	0.0179	0.23	0.11	Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;	chr15:56410015	chr15:56447120~56447697:+
BRCA	cis	rs7824557	0.836	rs2736378	ENSG00000255046.1	RP11-297N6.4	3.59	0.00034	0.0179	0.14	0.11	Retinal vascular caliber;	chr8:11262251	chr8:11797928~11802568:-
BRCA	cis	rs8105895	1	rs2359811	ENSG00000269345.1	VN1R85P	3.59	0.00034	0.0179	0.18	0.11	Body mass index (change over time);	chr19:21970074	chr19:22174766~22175191:-
BRCA	cis	rs453301	0.686	rs10217044	ENSG00000233609.3	RP11-62H7.2	-3.59	0.00034	0.0179	-0.1	-0.11	Joint mobility (Beighton score);	chr8:9037242	chr8:8961200~8979025:+
BRCA	cis	rs1411478	1	rs3789364	ENSG00000243155.1	RP11-46A10.5	3.59	0.00034	0.0179	0.12	0.11	Menopause (age at onset);Progressive supranuclear palsy;	chr1:180981907	chr1:180944042~180976482:-
BRCA	cis	rs8040855	0.627	rs11631548	ENSG00000229212.6	RP11-561C5.4	-3.59	0.00034	0.0179	-0.15	-0.11	Bulimia nervosa;	chr15:85076017	chr15:85205440~85234795:-
BRCA	cis	rs71520386	0.579	rs4394299	ENSG00000179428.2	AC073072.5	3.59	0.00034	0.0179	0.13	0.11	Fibrinogen levels;	chr7:22825763	chr7:22725395~22727620:-
BRCA	cis	rs3739034	1	rs2276161	ENSG00000224043.6	CCNT2-AS1	-3.59	0.000341	0.0179	-0.19	-0.11	Gut microbiome composition (winter);	chr2:134713165	chr2:134735464~134918710:-
BRCA	cis	rs999943	0.846	rs999942	ENSG00000224557.6	HLA-DPB2	-3.59	0.000341	0.0179	-0.15	-0.11	Obesity (extreme);	chr6:33657125	chr6:33112451~33129084:+
BRCA	cis	rs13401620	0.917	rs11681963	ENSG00000229326.3	AC069154.4	-3.59	0.000341	0.0179	-0.15	-0.11	Breast size;	chr2:119785239	chr2:119698623~119700151:+
BRCA	cis	rs62458065	0.713	rs921406	ENSG00000273014.1	RP11-225B17.2	-3.59	0.000341	0.0179	-0.17	-0.11	Metabolite levels (HVA/MHPG ratio);	chr7:32446593	chr7:32758882~32759353:+
BRCA	cis	rs60843830	1	rs3791223	ENSG00000223751.1	AC116609.2	3.59	0.000341	0.0179	0.15	0.11	Spherical equivalent (joint analysis main effects and education interaction);	chr2:222336	chr2:742488~747767:+
BRCA	cis	rs4415084	1	rs12187196	ENSG00000272335.1	RP11-53O19.3	3.59	0.000341	0.0179	0.11	0.11	Breast cancer;	chr5:44683717	chr5:44826076~44828592:+
BRCA	cis	rs6881634	0.501	rs11958920	ENSG00000253558.1	CTD-2179L22.1	-3.59	0.000341	0.0179	-0.13	-0.11	Hippocampal atrophy;	chr5:78468068	chr5:78041879~78044138:-
BRCA	cis	rs4978813	0.538	rs59486669	ENSG00000213539.4	YBX1P6	-3.59	0.000341	0.0179	-0.12	-0.11	Plantar warts;	chr9:109494004	chr9:109532830~109534332:-
BRCA	cis	rs863345	0.604	rs59427353	ENSG00000229914.1	RP11-404O13.4	-3.59	0.000341	0.0179	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158530831	chr1:158195633~158196131:-
BRCA	cis	rs863345	0.565	rs59188837	ENSG00000229914.1	RP11-404O13.4	-3.59	0.000341	0.0179	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158530846	chr1:158195633~158196131:-
BRCA	cis	rs17711722	0.74	rs7809991	ENSG00000223473.2	GS1-124K5.3	3.59	0.000341	0.0179	0.08	0.11	Calcium levels;	chr7:65941231	chr7:66491049~66493566:-
BRCA	cis	rs7694379	0.704	rs6834488	ENSG00000251411.1	RP11-397E7.4	-3.59	0.000341	0.0179	-0.12	-0.11	Platelet count;	chr4:87257767	chr4:86913266~86914817:-
BRCA	cis	rs2153535	0.585	rs980083	ENSG00000251164.1	HULC	3.59	0.000341	0.0179	0.13	0.11	Motion sickness;	chr6:8589683	chr6:8652137~8653846:+
BRCA	cis	rs853679	0.517	rs1947862	ENSG00000226314.6	ZNF192P1	-3.59	0.000341	0.0179	-0.17	-0.11	Depression;	chr6:28137418	chr6:28161781~28169594:+
BRCA	cis	rs2274273	1	rs7493394	ENSG00000259318.1	RP11-454L9.2	3.59	0.000341	0.0179	0.09	0.11	Protein biomarker;	chr14:55151037	chr14:55394940~55395233:-
BRCA	cis	rs34792	0.525	rs66651392	ENSG00000275910.1	RP11-680G24.6	-3.59	0.000341	0.0179	-0.14	-0.11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15517735	chr16:15015828~15016390:-
BRCA	cis	rs687432	0.718	rs10896687	ENSG00000213592.4	AP000662.9	-3.59	0.000341	0.0179	-0.14	-0.11	Parkinson's disease;	chr11:58019373	chr11:57718044~57718530:-
BRCA	cis	rs6736093	0.932	rs77096506	ENSG00000236307.2	EEF1E1P1	-3.59	0.000341	0.0179	-0.14	-0.11	Coronary artery disease;	chr2:111899977	chr2:111887914~111888741:+
BRCA	cis	rs6736093	1	rs6755101	ENSG00000236307.2	EEF1E1P1	-3.59	0.000341	0.0179	-0.14	-0.11	Coronary artery disease;	chr2:111901387	chr2:111887914~111888741:+
BRCA	cis	rs6736093	1	rs1967530	ENSG00000236307.2	EEF1E1P1	-3.59	0.000341	0.0179	-0.14	-0.11	Coronary artery disease;	chr2:111901935	chr2:111887914~111888741:+
BRCA	cis	rs6736093	1	rs13006203	ENSG00000236307.2	EEF1E1P1	-3.59	0.000341	0.0179	-0.14	-0.11	Coronary artery disease;	chr2:111903573	chr2:111887914~111888741:+
BRCA	cis	rs6736093	0.932	rs7595212	ENSG00000236307.2	EEF1E1P1	-3.59	0.000341	0.0179	-0.14	-0.11	Coronary artery disease;	chr2:111905190	chr2:111887914~111888741:+
BRCA	cis	rs875971	0.522	rs2008188	ENSG00000273142.1	RP11-458F8.4	-3.59	0.000341	0.0179	-0.1	-0.11	Aortic root size;	chr7:65964026	chr7:66902857~66906297:+
BRCA	cis	rs875971	0.862	rs4236208	ENSG00000273024.4	INTS4P2	3.59	0.000341	0.0179	0.12	0.11	Aortic root size;	chr7:66284091	chr7:65647864~65715661:+
BRCA	cis	rs35520189	0.754	rs1143629	ENSG00000189223.12	PAX8-AS1	3.59	0.000341	0.0179	0.16	0.11	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:112835941	chr2:113211522~113276581:+
BRCA	cis	rs1670533	1	rs6812586	ENSG00000251639.2	RP11-20I20.1	3.59	0.000341	0.0179	0.18	0.11	Recombination rate (females);	chr4:1076063	chr4:1100016~1101558:-
BRCA	cis	rs1670533	1	rs6812596	ENSG00000251639.2	RP11-20I20.1	3.59	0.000341	0.0179	0.18	0.11	Recombination rate (females);	chr4:1076078	chr4:1100016~1101558:-
BRCA	cis	rs68170813	0.652	rs12533694	ENSG00000241764.3	AC002467.7	3.59	0.000341	0.0179	0.2	0.11	Coronary artery disease;	chr7:107462372	chr7:107742817~107744581:-
BRCA	cis	rs7267979	1	rs6050547	ENSG00000204556.4	CTD-2514C3.1	3.59	0.000341	0.0179	0.15	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25345376	chr20:26018832~26020684:+
BRCA	cis	rs9467773	0.534	rs34453863	ENSG00000224843.5	LINC00240	-3.59	0.000341	0.0179	-0.13	-0.11	Intelligence (multi-trait analysis);	chr6:26627777	chr6:26956992~27023924:+
BRCA	cis	rs16846053	0.605	rs62188819	ENSG00000227403.1	AC009299.3	3.59	0.000341	0.0179	0.27	0.11	Blood osmolality (transformed sodium);	chr2:161902799	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.605	rs61744553	ENSG00000227403.1	AC009299.3	3.59	0.000341	0.0179	0.27	0.11	Blood osmolality (transformed sodium);	chr2:161902992	chr2:161244739~161249050:+
BRCA	cis	rs13256369	1	rs4841016	ENSG00000254153.1	CTA-398F10.2	3.59	0.000341	0.0179	0.15	0.11	Obesity-related traits;	chr8:8715051	chr8:8456909~8461337:-
BRCA	cis	rs801193	0.66	rs2659897	ENSG00000229886.1	RP5-1132H15.3	-3.59	0.000341	0.0179	-0.12	-0.11	Aortic root size;	chr7:66722728	chr7:66025126~66031544:-
BRCA	cis	rs11673344	0.566	rs185368	ENSG00000233527.7	ZNF529-AS1	-3.59	0.000341	0.0179	-0.12	-0.11	Obesity-related traits;	chr19:37381827	chr19:36573070~36594708:+
BRCA	cis	rs4218	0.541	rs8030246	ENSG00000259732.1	RP11-59H7.3	-3.59	0.000341	0.0179	-0.13	-0.11	Social communication problems;	chr15:59049447	chr15:59121034~59133250:+
BRCA	cis	rs13434995	0.513	rs17776975	ENSG00000239040.1	Y_RNA	3.59	0.000341	0.0179	0.13	0.11	Adiponectin levels;	chr4:55410728	chr4:55412636~55412738:+
BRCA	cis	rs754466	0.606	rs10824581	ENSG00000213514.2	RP11-428P16.2	3.59	0.000341	0.0179	0.16	0.11	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77839743	chr10:77730766~77734769:+
BRCA	cis	rs7267979	1	rs6050599	ENSG00000274414.1	RP5-965G21.4	3.59	0.000341	0.0179	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25419604	chr20:25239007~25245229:-
BRCA	cis	rs4869313	0.668	rs2548521	ENSG00000248734.2	CTD-2260A17.1	-3.59	0.000341	0.0179	-0.11	-0.11	Pediatric autoimmune diseases;	chr5:96915224	chr5:96784777~96785999:+
BRCA	cis	rs2455799	0.573	rs2455793	ENSG00000224728.1	AC090945.1	-3.59	0.000341	0.0179	-0.1	-0.11	Mean platelet volume;	chr3:15702337	chr3:15878047~15879571:+
BRCA	cis	rs9467773	0.596	rs62396201	ENSG00000261353.1	CTA-14H9.5	-3.59	0.000341	0.0179	-0.11	-0.11	Intelligence (multi-trait analysis);	chr6:26667988	chr6:26527063~26527404:+
BRCA	cis	rs2288327	0.818	rs16866365	ENSG00000271011.1	RP11-171I2.5	3.59	0.000341	0.0179	0.21	0.11	Atrial fibrillation;	chr2:178521125	chr2:178577103~178577622:+
BRCA	cis	rs2288327	0.818	rs13034990	ENSG00000271011.1	RP11-171I2.5	3.59	0.000341	0.0179	0.21	0.11	Atrial fibrillation;	chr2:178521513	chr2:178577103~178577622:+
BRCA	cis	rs1046491	0.901	rs7229685	ENSG00000264964.1	RP11-888D10.3	3.59	0.000341	0.0179	0.23	0.11	Scarlet fever;	chr18:9194172	chr18:9315194~9334441:-
BRCA	cis	rs13118159	0.55	rs10016557	ENSG00000272588.1	RP11-440L14.4	-3.59	0.000341	0.0179	-0.13	-0.11	Longevity;	chr4:1369840	chr4:757022~757740:-
BRCA	cis	rs8141529	0.702	rs5762870	ENSG00000272858.1	CTA-292E10.8	-3.59	0.000341	0.0179	-0.14	-0.11	Lymphocyte counts;	chr22:28865171	chr22:28814914~28815662:+
BRCA	cis	rs13434995	0.513	rs9993599	ENSG00000273257.1	RP11-177J6.1	3.59	0.000341	0.0179	0.16	0.11	Adiponectin levels;	chr4:55586798	chr4:55387949~55388271:+
BRCA	cis	rs7618501	0.932	rs4855850	ENSG00000228008.1	CTD-2330K9.3	-3.59	0.000341	0.0179	-0.11	-0.11	Intelligence (multi-trait analysis);	chr3:49724138	chr3:49903845~49916937:+
BRCA	cis	rs7618501	1	rs3811696	ENSG00000228008.1	CTD-2330K9.3	-3.59	0.000341	0.0179	-0.11	-0.11	Intelligence (multi-trait analysis);	chr3:49724172	chr3:49903845~49916937:+
BRCA	cis	rs863345	0.604	rs2317970	ENSG00000229914.1	RP11-404O13.4	-3.59	0.000341	0.0179	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158534980	chr1:158195633~158196131:-
BRCA	cis	rs863345	0.604	rs2873594	ENSG00000229914.1	RP11-404O13.4	-3.59	0.000341	0.0179	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158535000	chr1:158195633~158196131:-
BRCA	cis	rs7914558	1	rs10786733	ENSG00000213277.3	MARCKSL1P1	3.59	0.000341	0.0179	0.12	0.11	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103035190	chr10:103175554~103176094:+
BRCA	cis	rs16846053	0.605	rs72865293	ENSG00000227403.1	AC009299.3	3.59	0.000341	0.0179	0.26	0.11	Blood osmolality (transformed sodium);	chr2:161921589	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.605	rs62188857	ENSG00000227403.1	AC009299.3	3.59	0.000341	0.0179	0.26	0.11	Blood osmolality (transformed sodium);	chr2:161927352	chr2:161244739~161249050:+
BRCA	cis	rs1371614	0.523	rs2891534	ENSG00000272148.1	RP11-195B17.1	3.59	0.000341	0.0179	0.12	0.11	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26961578	chr2:27062428~27062907:-
BRCA	cis	rs801193	0.569	rs11772819	ENSG00000271064.1	RP11-792A8.3	-3.59	0.000341	0.0179	-0.13	-0.11	Aortic root size;	chr7:66752983	chr7:66748838~66749077:-
BRCA	cis	rs801193	0.569	rs7800620	ENSG00000271064.1	RP11-792A8.3	-3.59	0.000341	0.0179	-0.13	-0.11	Aortic root size;	chr7:66758701	chr7:66748838~66749077:-
BRCA	cis	rs2835872	0.694	rs4816568	ENSG00000228677.1	TTC3-AS1	-3.59	0.000341	0.0179	-0.14	-0.11	Electroencephalographic traits in alcoholism;	chr21:37616044	chr21:37187666~37193926:-
BRCA	cis	rs8105895	0.935	rs1560716	ENSG00000269345.1	VN1R85P	3.59	0.000341	0.0179	0.18	0.11	Body mass index (change over time);	chr19:22123099	chr19:22174766~22175191:-
BRCA	cis	rs7299940	0.967	rs9738957	ENSG00000256299.1	RP11-989F5.3	3.59	0.000341	0.0179	0.12	0.11	Panic disorder;	chr12:130904256	chr12:130810821~130812622:-
BRCA	cis	rs7520050	0.966	rs12144263	ENSG00000281133.1	AL355480.3	3.59	0.000341	0.0179	0.13	0.11	Reticulocyte count;Red blood cell count;	chr1:45886774	chr1:45580892~45580996:-
BRCA	cis	rs1730008	0.731	rs12636733	ENSG00000279311.1	RP11-170K4.2	3.59	0.000341	0.0179	0.14	0.11	Lobe attachment (rater-scored or self-reported);	chr3:158323282	chr3:158869898~158871821:+
BRCA	cis	rs2625529	0.627	rs11858015	ENSG00000260037.4	CTD-2524L6.3	-3.59	0.000341	0.0179	-0.16	-0.11	Red blood cell count;	chr15:72260151	chr15:71818396~71823384:+
BRCA	cis	rs11098403	0.753	rs10005440	ENSG00000225892.3	RP11-384K6.2	3.59	0.000342	0.0179	0.11	0.11	Schizophrenia;	chr4:117858327	chr4:118632274~118634759:+
BRCA	cis	rs2287838	1	rs12609594	ENSG00000267370.1	CTD-2623N2.3	-3.59	0.000342	0.0179	-0.1	-0.11	Sleep duration;	chr19:9861741	chr19:9756152~9756863:-
BRCA	cis	rs867186	0.541	rs77173268	ENSG00000126005.14	MMP24-AS1	-3.59	0.000342	0.0179	-0.26	-0.11	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:34700198	chr20:35216462~35278131:-
BRCA	cis	rs78545713	1	rs78545713	ENSG00000241549.7	GUSBP2	-3.59	0.000342	0.0179	-0.18	-0.11	Iron status biomarkers (total iron binding capacity);	chr6:26248612	chr6:26871484~26956554:-
BRCA	cis	rs2274273	0.837	rs7146748	ENSG00000259318.1	RP11-454L9.2	3.59	0.000342	0.0179	0.09	0.11	Protein biomarker;	chr14:55280368	chr14:55394940~55395233:-
BRCA	cis	rs6952407	1	rs6952407	ENSG00000272831.1	RP11-792A8.4	-3.59	0.000342	0.0179	-0.1	-0.11	Cotinine glucuronidation;	chr7:66580525	chr7:66739829~66740385:-
BRCA	cis	rs17092148	1	rs1884431	ENSG00000202150.1	RNU6-407P	3.59	0.000342	0.0179	0.16	0.11	Neuroticism;	chr20:34750782	chr20:35030317~35030420:-
BRCA	cis	rs6991838	0.584	rs16932245	ENSG00000272155.1	RP11-707M3.3	3.59	0.000342	0.0179	0.1	0.11	Intelligence (multi-trait analysis);	chr8:65597810	chr8:65714334~65714778:-
BRCA	cis	rs6991838	0.557	rs57419568	ENSG00000272155.1	RP11-707M3.3	3.59	0.000342	0.0179	0.1	0.11	Intelligence (multi-trait analysis);	chr8:65598633	chr8:65714334~65714778:-
BRCA	cis	rs3755605	0.728	rs60284850	ENSG00000242578.1	RP11-469J4.3	3.59	0.000342	0.0179	0.13	0.11	Testicular germ cell tumor;	chr3:170082613	chr3:170410512~170418615:+
BRCA	cis	rs11696845	0.666	rs13042905	ENSG00000276223.1	RP4-781B1.5	-3.59	0.000342	0.0179	-0.11	-0.11	Obesity-related traits;	chr20:44750813	chr20:44746642~44747201:+
BRCA	cis	rs6600671	1	rs1986111	ENSG00000275131.1	CH17-472G23.4	-3.59	0.000342	0.0179	-0.1	-0.11	Hip geometry;	chr1:121462934	chr1:120489625~120579190:-
BRCA	cis	rs7481584	0.624	rs438384	ENSG00000236710.1	AC108448.2	3.59	0.000342	0.0179	0.15	0.11	Calcium levels;	chr11:3024421	chr11:3084393~3085443:-
BRCA	cis	rs9472719	0.891	rs9296480	ENSG00000231769.2	RP1-8B1.4	3.59	0.000342	0.0179	0.16	0.11	Total cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;	chr6:46187671	chr6:46097093~46129706:-
BRCA	cis	rs72482608	0.596	rs4483469	ENSG00000271811.1	RP1-79C4.4	3.59	0.000342	0.0179	0.12	0.11	Emphysema imaging phenotypes;	chr1:170917202	chr1:170667381~170669425:+
BRCA	cis	rs3764021	0.509	rs10772071	ENSG00000260423.1	RP13-735L24.1	-3.59	0.000342	0.0179	-0.13	-0.11	Type 1 diabetes;	chr12:9717324	chr12:9367464~9397617:+
BRCA	cis	rs1032833	0.66	rs10497534	ENSG00000271401.1	RP11-171I2.3	3.59	0.000342	0.0179	0.27	0.11	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);	chr2:179172048	chr2:178644717~178645179:+
BRCA	cis	rs7429990	0.93	rs71323371	ENSG00000199476.1	Y_RNA	-3.59	0.000342	0.0179	-0.15	-0.11	Educational attainment (years of education);	chr3:47904327	chr3:48288587~48288694:+
BRCA	cis	rs11700980	0.636	rs77555990	ENSG00000232855.5	AF131217.1	3.59	0.000342	0.0179	0.21	0.11	QRS complex (12-leadsum);	chr21:28857454	chr21:28439346~28674848:-
BRCA	cis	rs7943953	0.765	rs12787182	ENSG00000254717.2	GLYATL1P2	-3.59	0.000342	0.0179	-0.15	-0.11	Odorant perception (&beta-ionone);	chr11:59423338	chr11:58878302~58893460:+
BRCA	cis	rs7172677	0.737	rs12914536	ENSG00000260269.4	CTD-2323K18.1	-3.59	0.000342	0.0179	-0.15	-0.11	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75145374	chr15:75527150~75601205:-
BRCA	cis	rs9470794	1	rs752110	ENSG00000204110.6	RP1-153P14.8	3.59	0.000342	0.0179	0.2	0.11	Type 2 diabetes;	chr6:37986212	chr6:37507348~37535616:+
BRCA	cis	rs7620503	1	rs13077994	ENSG00000228561.2	RP11-114M1.1	3.59	0.000342	0.018	0.13	0.11	Corneal structure;	chr3:177587917	chr3:177683627~177691250:+
BRCA	cis	rs11082321	1	rs9946944	ENSG00000266850.1	RP11-370A5.1	3.59	0.000342	0.018	0.21	0.11	Breast cancer;	chr18:23198534	chr18:22723491~22907721:-
BRCA	cis	rs77320796	1	rs7542907	ENSG00000259943.1	RP1-39G22.7	-3.59	0.000342	0.018	-0.12	-0.11	Platelet count;	chr1:39926080	chr1:40256427~40257967:-
BRCA	cis	rs863345	0.604	rs1112915	ENSG00000176320.2	RP11-404O13.5	-3.59	0.000342	0.018	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158474657	chr1:158197922~158203877:-
BRCA	cis	rs752010	0.905	rs4525030	ENSG00000230638.4	RP11-486B10.4	-3.59	0.000342	0.018	-0.13	-0.11	Lupus nephritis in systemic lupus erythematosus;	chr1:41625636	chr1:41542069~41544310:+
BRCA	cis	rs3739034	0.938	rs4954168	ENSG00000224043.6	CCNT2-AS1	-3.59	0.000342	0.018	-0.19	-0.11	Gut microbiome composition (winter);	chr2:134707503	chr2:134735464~134918710:-
BRCA	cis	rs6545883	0.524	rs778159	ENSG00000270820.4	RP11-355B11.2	-3.59	0.000343	0.018	-0.12	-0.11	Tuberculosis;	chr2:61329609	chr2:61471188~61484130:+
BRCA	cis	rs295490	0.748	rs115177972	ENSG00000178631.7	ACTG1P1	-3.59	0.000343	0.018	-0.21	-0.11	PR interval in Tripanosoma cruzi seropositivity;	chr3:139410696	chr3:139493809~139494937:+
BRCA	cis	rs752010	0.841	rs17363834	ENSG00000230638.4	RP11-486B10.4	-3.59	0.000343	0.018	-0.13	-0.11	Lupus nephritis in systemic lupus erythematosus;	chr1:41610936	chr1:41542069~41544310:+
BRCA	cis	rs4950322	0.543	rs4453096	ENSG00000237188.3	RP11-337C18.8	3.59	0.000343	0.018	0.14	0.11	Protein quantitative trait loci;	chr1:147316574	chr1:147172771~147211568:+
BRCA	cis	rs10876993	0.928	rs813854	ENSG00000270039.1	RP11-571M6.17	3.59	0.000343	0.018	0.15	0.11	Celiac disease or Rheumatoid arthritis;	chr12:57677564	chr12:57803838~57804415:+
BRCA	cis	rs10484434	0.901	rs62396160	ENSG00000272810.1	U91328.22	3.59	0.000343	0.018	0.16	0.11	HIV-1 viral setpoint;	chr6:26075165	chr6:26013241~26013757:+
BRCA	cis	rs2439831	0.85	rs3736180	ENSG00000206991.1	RNU6-610P	-3.59	0.000343	0.018	-0.18	-0.11	Lung cancer in ever smokers;	chr15:43814426	chr15:43637632~43637738:-
BRCA	cis	rs4478858	0.647	rs6425720	ENSG00000229447.2	RP11-490K7.4	-3.59	0.000343	0.018	-0.1	-0.11	Alcohol dependence;	chr1:31236708	chr1:31263245~31263681:-
BRCA	cis	rs3099143	0.908	rs6495222	ENSG00000196274.5	Metazoa_SRP	-3.59	0.000343	0.018	-0.16	-0.11	Recalcitrant atopic dermatitis;	chr15:76887674	chr15:76230048~76230390:-
BRCA	cis	rs6545883	0.831	rs2592356	ENSG00000212978.6	AC016747.3	3.59	0.000343	0.018	0.15	0.11	Tuberculosis;	chr2:61583293	chr2:61141592~61144969:-
BRCA	cis	rs9420	0.961	rs527528	ENSG00000265566.2	RN7SL605P	-3.59	0.000343	0.018	-0.15	-0.11	Schizophrenia;	chr11:57665855	chr11:57528085~57528365:-
BRCA	cis	rs490234	0.691	rs3104551	ENSG00000232630.1	PRPS1P2	-3.59	0.000343	0.018	-0.11	-0.11	Mean arterial pressure;	chr9:125402000	chr9:125150653~125151589:+
BRCA	cis	rs7819412	0.521	rs10100660	ENSG00000154316.13	TDH	3.59	0.000343	0.018	0.15	0.11	Triglycerides;	chr8:11181376	chr8:11339637~11368452:+
BRCA	cis	rs721917	0.525	rs7903576	ENSG00000242600.5	MBL1P	3.59	0.000343	0.018	0.14	0.11	Chronic obstructive pulmonary disease;	chr10:79981386	chr10:79904898~79950336:+
BRCA	cis	rs4578769	0.959	rs9961893	ENSG00000273232.1	RP11-370A5.2	3.59	0.000343	0.018	0.15	0.11	Eosinophil percentage of white cells;	chr18:22849805	chr18:22882825~22883357:-
BRCA	cis	rs875971	0.66	rs7807930	ENSG00000275400.1	RP4-756H11.5	3.59	0.000343	0.018	0.13	0.11	Aortic root size;	chr7:66622178	chr7:66553805~66554199:-
BRCA	cis	rs6012564	1	rs2426106	ENSG00000230758.1	SNAP23P	-3.59	0.000343	0.018	-0.13	-0.11	Anger;	chr20:49022927	chr20:49038357~49038602:-
BRCA	cis	rs10992471	0.566	rs4076629	ENSG00000187984.11	ANKRD19P	-3.59	0.000343	0.018	-0.1	-0.11	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr9:92919375	chr9:92809388~92888693:+
BRCA	cis	rs801193	0.742	rs9969300	ENSG00000229180.5	GS1-124K5.11	-3.59	0.000343	0.018	-0.09	-0.11	Aortic root size;	chr7:66316659	chr7:66526088~66542624:-
BRCA	cis	rs654950	0.934	rs654220	ENSG00000230638.4	RP11-486B10.4	3.59	0.000343	0.018	0.14	0.11	Airway imaging phenotypes;	chr1:41536885	chr1:41542069~41544310:+
BRCA	cis	rs6696239	0.956	rs6426471	ENSG00000215812.5	ZNF847P	3.59	0.000343	0.018	0.15	0.11	Height;	chr1:227666115	chr1:227696892~227706699:-
BRCA	cis	rs867371	0.826	rs2047678	ENSG00000276710.3	CSPG4P8	-3.59	0.000343	0.018	-0.12	-0.11	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82205857	chr15:82459472~82477258:+
BRCA	cis	rs13434995	0.513	rs62303718	ENSG00000273257.1	RP11-177J6.1	-3.59	0.000343	0.018	-0.16	-0.11	Adiponectin levels;	chr4:55476770	chr4:55387949~55388271:+
BRCA	cis	rs13434995	0.513	rs17722870	ENSG00000273257.1	RP11-177J6.1	-3.59	0.000343	0.018	-0.16	-0.11	Adiponectin levels;	chr4:55478519	chr4:55387949~55388271:+
BRCA	cis	rs1555133	0.625	rs6141691	ENSG00000275576.1	RP5-836N17.4	-3.59	0.000343	0.018	-0.12	-0.11	Monocyte count;	chr20:32375123	chr20:32116171~32116629:+
BRCA	cis	rs12744310	0.502	rs4660187	ENSG00000235358.1	RP11-399E6.1	3.59	0.000343	0.018	0.14	0.11	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41333488	chr1:41242373~41284861:+
BRCA	cis	rs28489187	0.706	rs173026	ENSG00000223653.4	RP11-131L23.1	3.59	0.000343	0.018	0.13	0.11	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85338566	chr1:85276715~85448124:+
BRCA	cis	rs28489187	0.706	rs233069	ENSG00000223653.4	RP11-131L23.1	3.59	0.000343	0.018	0.13	0.11	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85339783	chr1:85276715~85448124:+
BRCA	cis	rs7824557	0.527	rs2409756	ENSG00000255046.1	RP11-297N6.4	3.59	0.000344	0.018	0.13	0.11	Retinal vascular caliber;	chr8:11384516	chr8:11797928~11802568:-
BRCA	cis	rs875971	1	rs1981798	ENSG00000273448.1	RP11-166O4.6	3.59	0.000344	0.018	0.1	0.11	Aortic root size;	chr7:66489916	chr7:67333047~67334383:+
BRCA	cis	rs983392	0.792	rs555635	ENSG00000275344.1	MIR6503	-3.59	0.000344	0.018	-0.11	-0.11	Alzheimer's disease (late onset);	chr11:60109670	chr11:60209071~60209156:-
BRCA	cis	rs11892454	0.599	rs13410396	ENSG00000217643.1	PTGES3P2	-3.59	0.000344	0.018	-0.12	-0.11	Heschl's gyrus morphology;	chr2:25787550	chr2:25822469~25822950:+
BRCA	cis	rs7200543	0.583	rs4985149	ENSG00000270580.4	PKD1P6	3.59	0.000344	0.018	0.12	0.11	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15053481	chr16:15104723~15131601:-
BRCA	cis	rs6490294	0.571	rs7316563	ENSG00000257624.1	RP1-128M12.3	3.59	0.000344	0.018	0.18	0.11	Mean platelet volume;	chr12:112015831	chr12:112000739~112000985:-
BRCA	cis	rs4478858	0.735	rs11436	ENSG00000260386.4	LINC01225	-3.59	0.000344	0.018	-0.13	-0.11	Alcohol dependence;	chr1:31364473	chr1:31500085~31540885:+
BRCA	cis	rs5758659	0.714	rs5758574	ENSG00000205702.9	CYP2D7	-3.59	0.000344	0.018	-0.09	-0.11	Cognitive function;	chr22:42085396	chr22:42140203~42144577:-
BRCA	cis	rs17798800	0.689	rs1337948	ENSG00000271850.1	RP11-16D22.2	3.59	0.000344	0.018	0.12	0.11	Response to cholinesterase inhibitors in Alzheimer's disease;	chr13:34336157	chr13:34348043~34614170:+
BRCA	cis	rs4388249	0.95	rs12656712	ENSG00000249068.1	CTC-287O8.1	3.59	0.000344	0.018	0.15	0.11	Schizophrenia;	chr5:109849713	chr5:109840128~109840692:-
BRCA	cis	rs2991971	0.81	rs998199	ENSG00000281133.1	AL355480.3	-3.59	0.000344	0.018	-0.13	-0.11	High light scatter reticulocyte count;	chr1:45447226	chr1:45580892~45580996:-
BRCA	cis	rs7267979	0.966	rs2387882	ENSG00000204556.4	CTD-2514C3.1	3.59	0.000344	0.018	0.15	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25398166	chr20:26018832~26020684:+
BRCA	cis	rs875971	0.862	rs6460307	ENSG00000229886.1	RP5-1132H15.3	3.59	0.000344	0.018	0.13	0.11	Aortic root size;	chr7:66595884	chr7:66025126~66031544:-
BRCA	cis	rs1404100	0.51	rs1038273	ENSG00000249274.1	PDLIM1P4	3.59	0.000344	0.018	0.12	0.11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:99067757	chr3:98782188~98783193:+
BRCA	cis	rs17301013	0.932	rs11804941	ENSG00000234741.6	GAS5	-3.59	0.000344	0.018	-0.11	-0.11	Systemic lupus erythematosus;	chr1:174624074	chr1:173863900~173868882:-
BRCA	cis	rs2439831	0.85	rs12440573	ENSG00000206991.1	RNU6-610P	-3.59	0.000344	0.018	-0.19	-0.11	Lung cancer in ever smokers;	chr15:43816799	chr15:43637632~43637738:-
BRCA	cis	rs8098244	0.964	rs729814	ENSG00000265752.2	RP11-403A21.1	-3.59	0.000344	0.018	-0.14	-0.11	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23903242	chr18:23957754~23982556:-
BRCA	cis	rs568617	1	rs694994	ENSG00000254614.2	AP003068.23	-3.59	0.000344	0.018	-0.16	-0.11	Crohn's disease;	chr11:65885838	chr11:65177606~65181834:-
BRCA	cis	rs2554380	0.628	rs963690	ENSG00000259570.1	RP11-671M22.4	3.59	0.000344	0.018	0.14	0.11	Height;	chr15:83771068	chr15:84394512~84395514:+
BRCA	cis	rs2562456	0.561	rs12610883	ENSG00000240522.1	RPL7AP10	-3.59	0.000344	0.018	-0.12	-0.11	Pain;	chr19:21567257	chr19:21149648~21150438:-
BRCA	cis	rs2562456	0.837	rs11085462	ENSG00000240522.1	RPL7AP10	-3.59	0.000344	0.018	-0.12	-0.11	Pain;	chr19:21567449	chr19:21149648~21150438:-
BRCA	cis	rs478607	0.748	rs61884413	ENSG00000237410.1	AP001092.4	3.59	0.000344	0.018	0.2	0.11	Urate levels;	chr11:64691934	chr11:64646399~64659681:+
BRCA	cis	rs2455799	0.634	rs13085226	ENSG00000224728.1	AC090945.1	-3.59	0.000344	0.018	-0.11	-0.11	Mean platelet volume;	chr3:15882243	chr3:15878047~15879571:+
BRCA	cis	rs7824557	0.767	rs11775635	ENSG00000154316.13	TDH	-3.59	0.000344	0.018	-0.16	-0.11	Retinal vascular caliber;	chr8:11307356	chr8:11339637~11368452:+
BRCA	cis	rs2692947	0.526	rs4907225	ENSG00000168992.4	OR7E102P	3.59	0.000344	0.018	0.16	0.11	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95910922	chr2:95546531~95547545:+
BRCA	cis	rs7111546	0.791	rs113593294	ENSG00000246225.5	RP11-17A1.3	3.59	0.000344	0.018	0.19	0.11	Dialysis-related mortality;	chr11:22843378	chr11:22829380~22945393:+
BRCA	cis	rs34174370	1	rs34174370	ENSG00000242551.2	POU5F1P6	3.59	0.000344	0.018	0.19	0.11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128130901	chr3:128674735~128677005:-
BRCA	cis	rs6600671	0.934	rs67718113	ENSG00000275131.1	CH17-472G23.4	3.59	0.000344	0.018	0.11	0.11	Hip geometry;	chr1:121497112	chr1:120489625~120579190:-
BRCA	cis	rs6671200	0.607	rs3753872	ENSG00000226026.4	RP11-57H12.3	-3.59	0.000344	0.018	-0.17	-0.11	Stearic acid (18:0) levels;	chr1:95233628	chr1:95163219~95233982:-
BRCA	cis	rs4478858	0.735	rs11576621	ENSG00000223907.1	LINC01226	-3.59	0.000344	0.018	-0.13	-0.11	Alcohol dependence;	chr1:31322613	chr1:31518435~31524245:+
BRCA	cis	rs170557	0.573	rs56131913	ENSG00000203706.7	SERTAD4-AS1	-3.59	0.000344	0.018	-0.13	-0.11	Alopecia areata;	chr1:209972702	chr1:210231456~210234047:-
BRCA	cis	rs6870983	0.857	rs6452788	ENSG00000247828.6	TMEM161B-AS1	-3.59	0.000344	0.018	-0.13	-0.11	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index;	chr5:88417096	chr5:88268895~88436685:+
BRCA	cis	rs5742933	1	rs3791767	ENSG00000253559.1	OSGEPL1-AS1	3.59	0.000344	0.018	0.15	0.11	Ferritin levels;	chr2:189775189	chr2:189762704~189765556:+
BRCA	cis	rs9346455	0.614	rs9364151	ENSG00000279289.1	RP3-331H24.6	3.59	0.000344	0.018	0.16	0.11	Antipsychotic drug-induced weight gain;Antipsychotic drug-induced weight gain (time interaction);	chr6:71287368	chr6:71386852~71390829:-
BRCA	cis	rs9346455	0.614	rs2208845	ENSG00000279289.1	RP3-331H24.6	3.59	0.000344	0.018	0.16	0.11	Antipsychotic drug-induced weight gain;Antipsychotic drug-induced weight gain (time interaction);	chr6:71287575	chr6:71386852~71390829:-
BRCA	cis	rs9307551	0.741	rs1440866	ENSG00000250334.4	LINC00989	-3.59	0.000344	0.018	-0.17	-0.11	Refractive error;	chr4:79545005	chr4:79492416~79576460:+
BRCA	cis	rs61931739	0.5	rs34418276	ENSG00000258794.3	DUX4L27	3.59	0.000344	0.018	0.16	0.11	Morning vs. evening chronotype;	chr12:34383041	chr12:34208415~34209675:-
BRCA	cis	rs897984	0.542	rs750952	ENSG00000232748.3	RP11-196G11.6	-3.59	0.000344	0.018	-0.13	-0.11	Dementia with Lewy bodies;	chr16:31082633	chr16:31056460~31062803:+
BRCA	cis	rs7703051	0.513	rs59014134	ENSG00000271815.1	CTD-2235C13.3	-3.59	0.000344	0.018	-0.18	-0.11	Age-related diseases, mortality and associated endophenotypes;LDL cholesterol;Age-related disease endophenotypes;	chr5:75293560	chr5:75363760~75364242:+
BRCA	cis	rs6714710	0.603	rs35505530	ENSG00000228486.8	LINC01125	-3.59	0.000344	0.018	-0.1	-0.11	Posterior cortical atrophy and Alzheimer's disease;	chr2:97890447	chr2:97664217~97703064:+
BRCA	cis	rs495337	1	rs486206	ENSG00000229222.1	KRT18P4	-3.59	0.000345	0.0181	-0.14	-0.11	Psoriasis;	chr20:49900196	chr20:49956745~49958032:+
BRCA	cis	rs2518049	0.95	rs10904419	ENSG00000224034.1	RP11-445P17.8	3.59	0.000345	0.0181	0.21	0.11	Metabolic traits;	chr10:5102407	chr10:5266033~5271236:-
BRCA	cis	rs2562456	0.917	rs2681392	ENSG00000268705.1	BNIP3P26	-3.59	0.000345	0.0181	-0.12	-0.11	Pain;	chr19:21513185	chr19:21521343~21521896:-
BRCA	cis	rs2625529	0.73	rs6494975	ENSG00000260037.4	CTD-2524L6.3	3.59	0.000345	0.0181	0.14	0.11	Red blood cell count;	chr15:71885484	chr15:71818396~71823384:+
BRCA	cis	rs13230714	0.858	rs2888075	ENSG00000170356.8	OR2A20P	-3.59	0.000345	0.0181	-0.15	-0.11	Breast cancer;	chr7:144456786	chr7:144250045~144252957:-
BRCA	cis	rs925550	0.932	rs6811007	ENSG00000224786.1	CETN4P	3.59	0.000345	0.0181	0.18	0.11	Primary biliary cholangitis;	chr4:122664207	chr4:122730548~122732193:-
BRCA	cis	rs198813	0.611	rs198823	ENSG00000272462.2	U91328.19	-3.59	0.000345	0.0181	-0.13	-0.11	Intelligence (multi-trait analysis);	chr6:26122705	chr6:25992662~26001775:+
BRCA	cis	rs514024	0.668	rs1573178	ENSG00000225032.4	RP11-228B15.4	3.59	0.000345	0.0181	0.1	0.11	Eating disorders (purging via substances);	chr9:127610208	chr9:127816066~127822520:+
BRCA	cis	rs2991971	0.81	rs2356413	ENSG00000281133.1	AL355480.3	-3.59	0.000345	0.0181	-0.13	-0.11	High light scatter reticulocyte count;	chr1:45448376	chr1:45580892~45580996:-
BRCA	cis	rs2991971	0.716	rs7532573	ENSG00000281133.1	AL355480.3	-3.59	0.000345	0.0181	-0.13	-0.11	High light scatter reticulocyte count;	chr1:45450220	chr1:45580892~45580996:-
BRCA	cis	rs6452790	0.543	rs10056702	ENSG00000247828.6	TMEM161B-AS1	-3.59	0.000345	0.0181	-0.16	-0.11	Cognitive function;	chr5:88037364	chr5:88268895~88436685:+
BRCA	cis	rs6452790	0.543	rs7700770	ENSG00000247828.6	TMEM161B-AS1	-3.59	0.000345	0.0181	-0.16	-0.11	Cognitive function;	chr5:88043567	chr5:88268895~88436685:+
BRCA	cis	rs6452790	0.502	rs28484589	ENSG00000247828.6	TMEM161B-AS1	-3.59	0.000345	0.0181	-0.16	-0.11	Cognitive function;	chr5:88047740	chr5:88268895~88436685:+
BRCA	cis	rs4835473	0.868	rs62337291	ENSG00000249741.2	RP11-673E1.3	3.59	0.000345	0.0181	0.11	0.11	Immature fraction of reticulocytes;	chr4:143807903	chr4:143911514~143912053:-
BRCA	cis	rs17270561	0.609	rs9366627	ENSG00000272462.2	U91328.19	-3.59	0.000345	0.0181	-0.14	-0.11	Iron status biomarkers;	chr6:25686177	chr6:25992662~26001775:+
BRCA	cis	rs7520050	0.933	rs6656022	ENSG00000234329.1	RP11-767N6.2	-3.59	0.000345	0.0181	-0.1	-0.11	Reticulocyte count;Red blood cell count;	chr1:45928643	chr1:45651039~45651826:-
BRCA	cis	rs7267979	1	rs2500436	ENSG00000277938.1	RP5-965G21.3	-3.59	0.000345	0.0181	-0.13	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25425730	chr20:25229150~25231933:+
BRCA	cis	rs1009077	0.68	rs35289699	ENSG00000245958.5	RP11-33B1.1	3.59	0.000345	0.0181	0.13	0.11	Endometriosis;	chr4:119529235	chr4:119454791~119552025:+
BRCA	cis	rs962856	0.521	rs668175	ENSG00000236605.1	AC023115.4	3.59	0.000345	0.0181	0.15	0.11	Pancreatic cancer;	chr2:67437055	chr2:67324627~67325304:+
BRCA	cis	rs6964587	0.626	rs2106745	ENSG00000188693.7	CYP51A1-AS1	3.59	0.000345	0.0181	0.12	0.11	Breast cancer;	chr7:91877321	chr7:92134604~92180725:+
BRCA	cis	rs8023401	0.938	rs16961084	ENSG00000274654.1	CTD-3247H4.2	-3.59	0.000345	0.0181	-0.16	-0.11	Spherical equivalent (joint analysis main effects and education interaction);	chr15:48521638	chr15:48528980~48529728:-
BRCA	cis	rs6088580	0.634	rs1205336	ENSG00000275784.1	RP5-1125A11.6	3.59	0.000345	0.0181	0.12	0.11	Glomerular filtration rate (creatinine);	chr20:34338530	chr20:33989480~33991818:-
BRCA	cis	rs792448	0.717	rs7544225	ENSG00000229983.1	RP11-15I11.2	-3.59	0.000345	0.0181	-0.14	-0.11	White blood cell count (basophil);	chr1:212235666	chr1:212168207~212190259:+
BRCA	cis	rs253959	0.545	rs712592	ENSG00000272265.1	CTD-2287O16.4	-3.59	0.000345	0.0181	-0.13	-0.11	Bipolar disorder and schizophrenia;	chr5:116321684	chr5:116078110~116078570:-
BRCA	cis	rs253959	0.545	rs712593	ENSG00000272265.1	CTD-2287O16.4	-3.59	0.000345	0.0181	-0.13	-0.11	Bipolar disorder and schizophrenia;	chr5:116321700	chr5:116078110~116078570:-
BRCA	cis	rs253959	0.545	rs712594	ENSG00000272265.1	CTD-2287O16.4	-3.59	0.000345	0.0181	-0.13	-0.11	Bipolar disorder and schizophrenia;	chr5:116321762	chr5:116078110~116078570:-
BRCA	cis	rs253959	0.545	rs712595	ENSG00000272265.1	CTD-2287O16.4	-3.59	0.000345	0.0181	-0.13	-0.11	Bipolar disorder and schizophrenia;	chr5:116321801	chr5:116078110~116078570:-
BRCA	cis	rs9527	0.64	rs6584541	ENSG00000213061.2	PFN1P11	3.59	0.000345	0.0181	0.15	0.11	Arsenic metabolism;	chr10:103169367	chr10:102838011~102845473:-
BRCA	cis	rs5167	0.566	rs2075620	ENSG00000214855.8	APOC1P1	-3.59	0.000345	0.0181	-0.15	-0.11	Blood protein levels;	chr19:44976780	chr19:44926804~44931386:+
BRCA	cis	rs4835473	0.932	rs4835305	ENSG00000249741.2	RP11-673E1.3	3.59	0.000345	0.0181	0.11	0.11	Immature fraction of reticulocytes;	chr4:143823646	chr4:143911514~143912053:-
BRCA	cis	rs4835473	0.932	rs11721700	ENSG00000249741.2	RP11-673E1.3	3.59	0.000345	0.0181	0.11	0.11	Immature fraction of reticulocytes;	chr4:143824264	chr4:143911514~143912053:-
BRCA	cis	rs6545883	0.931	rs778756	ENSG00000212978.6	AC016747.3	3.59	0.000345	0.0181	0.15	0.11	Tuberculosis;	chr2:61554859	chr2:61141592~61144969:-
BRCA	cis	rs7647973	0.593	rs1799844	ENSG00000228008.1	CTD-2330K9.3	3.59	0.000345	0.0181	0.15	0.11	Menarche (age at onset);	chr3:49810209	chr3:49903845~49916937:+
BRCA	cis	rs8103278	1	rs17571725	ENSG00000268423.3	AC011551.3	3.59	0.000345	0.0181	0.14	0.11	Coronary artery disease;	chr19:45787564	chr19:46547056~46600861:-
BRCA	cis	rs34779708	0.931	rs12776390	ENSG00000269952.1	RP11-324I22.3	-3.59	0.000345	0.0181	-0.15	-0.11	Inflammatory bowel disease;Crohn's disease;	chr10:35102607	chr10:35210416~35210750:+
BRCA	cis	rs4835473	0.932	rs1842484	ENSG00000246448.2	RP13-578N3.3	3.59	0.000345	0.0181	0.12	0.11	Immature fraction of reticulocytes;	chr4:143793829	chr4:143700257~143865072:+
BRCA	cis	rs4927850	1	rs7630875	ENSG00000278820.1	AC024937.1	3.59	0.000345	0.0181	0.13	0.11	Pancreatic cancer;	chr3:196026895	chr3:195960500~195960612:-
BRCA	cis	rs11098499	0.954	rs3733524	ENSG00000250412.1	KLHL2P1	3.59	0.000345	0.0181	0.14	0.11	Corneal astigmatism;	chr4:119502574	chr4:119334329~119378233:+
BRCA	cis	rs9467773	1	rs9986382	ENSG00000224843.5	LINC00240	-3.59	0.000345	0.0181	-0.12	-0.11	Intelligence (multi-trait analysis);	chr6:26550391	chr6:26956992~27023924:+
BRCA	cis	rs9287719	0.967	rs4669596	ENSG00000224177.5	LINC00570	3.59	0.000345	0.0181	0.13	0.11	Prostate cancer;	chr2:10580446	chr2:11393981~11403077:+
BRCA	cis	rs7937682	0.575	rs7107213	ENSG00000176343.5	RPL37AP8	3.59	0.000345	0.0181	0.13	0.11	Primary sclerosing cholangitis;	chr11:111879706	chr11:111889199~111889474:-
BRCA	cis	rs11098499	0.78	rs12504773	ENSG00000260091.1	RP11-33B1.4	-3.59	0.000345	0.0181	-0.1	-0.11	Corneal astigmatism;	chr4:119640994	chr4:119409333~119410233:+
BRCA	cis	rs9307551	0.656	rs6818695	ENSG00000250334.4	LINC00989	-3.59	0.000346	0.0181	-0.17	-0.11	Refractive error;	chr4:79540680	chr4:79492416~79576460:+
BRCA	cis	rs1008375	0.931	rs2098151	ENSG00000249502.1	AC006160.5	-3.59	0.000346	0.0181	-0.13	-0.11	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17575867	chr4:17587467~17614571:-
BRCA	cis	rs9341808	0.519	rs59232999	ENSG00000233967.5	RP11-250B2.3	-3.59	0.000346	0.0181	-0.12	-0.11	Sitting height ratio;	chr6:80309066	chr6:80443344~80465927:+
BRCA	cis	rs17818399	0.645	rs35870739	ENSG00000279254.1	RP11-536C12.1	-3.59	0.000346	0.0181	-0.15	-0.11	Height;	chr2:46557092	chr2:46668870~46670778:+
BRCA	cis	rs6012953	0.845	rs968701	ENSG00000231715.1	COX6CP2	-3.59	0.000346	0.0181	-0.12	-0.11	Vitiligo;	chr20:50578711	chr20:50479767~50479991:+
BRCA	cis	rs2998286	0.723	rs231202	ENSG00000237128.1	RP11-351M16.3	3.59	0.000346	0.0181	0.14	0.11	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28560111	chr10:28433008~28495813:-
BRCA	cis	rs9470794	1	rs73419930	ENSG00000204110.6	RP1-153P14.8	-3.59	0.000346	0.0181	-0.2	-0.11	Type 2 diabetes;	chr6:38060214	chr6:37507348~37535616:+
BRCA	cis	rs9470794	1	rs57142729	ENSG00000204110.6	RP1-153P14.8	-3.59	0.000346	0.0181	-0.2	-0.11	Type 2 diabetes;	chr6:38061123	chr6:37507348~37535616:+
BRCA	cis	rs9470794	1	rs58332635	ENSG00000204110.6	RP1-153P14.8	-3.59	0.000346	0.0181	-0.2	-0.11	Type 2 diabetes;	chr6:38061280	chr6:37507348~37535616:+
BRCA	cis	rs61931739	0.5	rs35391785	ENSG00000258794.3	DUX4L27	3.59	0.000346	0.0181	0.16	0.11	Morning vs. evening chronotype;	chr12:34291543	chr12:34208415~34209675:-
BRCA	cis	rs9923856	0.695	rs13337334	ENSG00000263033.2	RP11-396B14.2	-3.59	0.000346	0.0181	-0.14	-0.11	Atopic dermatitis;Adult asthma;	chr16:11000561	chr16:11196177~11224969:+
BRCA	cis	rs853679	0.607	rs13208096	ENSG00000216901.1	AL022393.7	3.59	0.000346	0.0181	0.29	0.11	Depression;	chr6:28257533	chr6:28176188~28176674:+
BRCA	cis	rs2562456	0.834	rs2173727	ENSG00000268119.4	CTD-2561J22.5	-3.59	0.000346	0.0181	-0.16	-0.11	Pain;	chr19:21491155	chr19:21444241~21463908:-
BRCA	cis	rs11671005	0.735	rs11671591	ENSG00000265272.2	RN7SL693P	-3.59	0.000346	0.0181	-0.16	-0.11	Mean platelet volume;	chr19:58406970	chr19:58490797~58491075:+
BRCA	cis	rs6496932	0.874	rs2003294	ENSG00000259295.5	CSPG4P12	3.59	0.000346	0.0181	0.17	0.11	Central corneal thickness;Corneal structure;	chr15:85274141	chr15:85191438~85213905:+
BRCA	cis	rs11187837	0.901	rs10509672	ENSG00000273450.1	RP11-76P2.4	3.59	0.000346	0.0181	0.25	0.11	Sudden cardiac arrest;	chr10:94356200	chr10:94314907~94315327:-
BRCA	cis	rs2262909	0.962	rs73019889	ENSG00000279377.1	AC003973.3	-3.59	0.000346	0.0181	-0.16	-0.11	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;	chr19:22095024	chr19:21965708~21968529:-
BRCA	cis	rs12612435	1	rs12612435	ENSG00000226806.1	AC011893.3	-3.59	0.000346	0.0181	-0.14	-0.11	Takotsubo syndrome;	chr2:136347972	chr2:135820191~135823087:+
BRCA	cis	rs5742933	1	rs5743052	ENSG00000253559.1	OSGEPL1-AS1	-3.59	0.000346	0.0181	-0.15	-0.11	Ferritin levels;	chr2:189824558	chr2:189762704~189765556:+
BRCA	cis	rs4873772	0.773	rs7833589	ENSG00000253330.1	RP11-697N18.3	-3.59	0.000346	0.0181	-0.15	-0.11	Lobe attachment (rater-scored or self-reported);	chr8:47479733	chr8:47511034~47512141:-
BRCA	cis	rs2998286	0.768	rs332137	ENSG00000237128.1	RP11-351M16.3	3.59	0.000346	0.0181	0.14	0.11	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28570050	chr10:28433008~28495813:-
BRCA	cis	rs875971	0.895	rs778700	ENSG00000272831.1	RP11-792A8.4	3.59	0.000346	0.0181	0.1	0.11	Aortic root size;	chr7:66401463	chr7:66739829~66740385:-
BRCA	cis	rs875971	1	rs778699	ENSG00000272831.1	RP11-792A8.4	3.59	0.000346	0.0181	0.1	0.11	Aortic root size;	chr7:66403303	chr7:66739829~66740385:-
BRCA	cis	rs13401620	0.655	rs1446306	ENSG00000229326.3	AC069154.4	3.59	0.000346	0.0181	0.14	0.11	Breast size;	chr2:120041296	chr2:119698623~119700151:+
BRCA	cis	rs2836974	0.644	rs7281853	ENSG00000255568.3	BRWD1-AS2	-3.59	0.000346	0.0181	-0.11	-0.11	Cognitive function;	chr21:39321564	chr21:39313935~39314962:+
BRCA	cis	rs17507216	0.667	rs72753916	ENSG00000255769.6	GOLGA2P10	-3.59	0.000346	0.0181	-0.15	-0.11	Excessive daytime sleepiness;	chr15:82684001	chr15:82472993~82513950:-
BRCA	cis	rs4478858	0.647	rs10798836	ENSG00000229447.2	RP11-490K7.4	-3.59	0.000346	0.0181	-0.1	-0.11	Alcohol dependence;	chr1:31236367	chr1:31263245~31263681:-
BRCA	cis	rs7615952	0.512	rs2979351	ENSG00000241288.6	RP11-379B18.5	-3.59	0.000346	0.0181	-0.14	-0.11	Blood pressure (smoking interaction);	chr3:125644755	chr3:125827238~125916384:-
BRCA	cis	rs2191566	0.691	rs56320525	ENSG00000266921.1	RP11-15A1.7	-3.59	0.000346	0.0181	-0.14	-0.11	Acute lymphoblastic leukemia (childhood);	chr19:44083726	chr19:43996896~44002836:-
BRCA	cis	rs375066	0.762	rs12610287	ENSG00000267191.1	RP11-15A1.2	3.59	0.000346	0.0181	0.14	0.11	Breast cancer;	chr19:43896511	chr19:43902001~43926545:+
BRCA	cis	rs987724	0.501	rs2321293	ENSG00000244515.1	KRT18P34	-3.59	0.000346	0.0181	-0.16	-0.11	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156931311	chr3:157162663~157163932:-
BRCA	cis	rs10829156	0.607	rs4293025	ENSG00000240291.1	RP11-499P20.2	-3.59	0.000347	0.0181	-0.12	-0.11	Sudden cardiac arrest;	chr10:18693315	chr10:18513115~18545651:-
BRCA	cis	rs365302	0.556	rs638551	ENSG00000235086.1	FNDC1-IT1	-3.59	0.000347	0.0181	-0.16	-0.11	Coronary heart disease;	chr6:159233797	chr6:159240786~159243329:+
BRCA	cis	rs4819052	0.851	rs8126930	ENSG00000223768.1	LINC00205	-3.59	0.000347	0.0181	-0.14	-0.11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251800	chr21:45293285~45297354:+
BRCA	cis	rs3099143	1	rs2629034	ENSG00000196274.5	Metazoa_SRP	3.59	0.000347	0.0181	0.16	0.11	Recalcitrant atopic dermatitis;	chr15:76749899	chr15:76230048~76230390:-
BRCA	cis	rs10090774	0.965	rs306957	ENSG00000280303.2	ERICD	3.59	0.000347	0.0181	0.13	0.11	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140999493	chr8:140636281~140638283:+
BRCA	cis	rs1143633	0.515	rs2723167	ENSG00000231747.1	AC079922.2	3.59	0.000347	0.0181	0.11	0.11	Allergic disease (asthma, hay fever or eczema);	chr2:112863633	chr2:112621809~112622167:-
BRCA	cis	rs433406	0.935	rs415055	ENSG00000255455.2	RP11-890B15.3	3.59	0.000347	0.0181	0.11	0.11	Male fertility;	chr11:131502316	chr11:130866254~130870247:-
BRCA	cis	rs997295	0.57	rs7170299	ENSG00000260657.2	RP11-315D16.4	3.59	0.000347	0.0182	0.13	0.11	Motion sickness;	chr15:67580380	chr15:68267792~68277994:-
BRCA	cis	rs13287066	0.508	rs2927567	ENSG00000203364.2	RP11-370F5.4	-3.59	0.000347	0.0182	-0.12	-0.11	Intelligence (multi-trait analysis);	chr9:93333961	chr9:93147040~93148556:+
BRCA	cis	rs35304300	1	rs10484820	ENSG00000225177.4	RP11-390P2.4	-3.59	0.000347	0.0182	-0.13	-0.11	Mean platelet volume;	chr6:139537156	chr6:138692548~138697288:+
BRCA	cis	rs6964587	0.967	rs9656003	ENSG00000188693.7	CYP51A1-AS1	-3.59	0.000347	0.0182	-0.12	-0.11	Breast cancer;	chr7:92137008	chr7:92134604~92180725:+
BRCA	cis	rs6964587	0.933	rs28671255	ENSG00000188693.7	CYP51A1-AS1	-3.59	0.000347	0.0182	-0.12	-0.11	Breast cancer;	chr7:92141391	chr7:92134604~92180725:+
BRCA	cis	rs7833790	0.676	rs7834555	ENSG00000254689.1	RP11-354A14.1	3.59	0.000347	0.0182	0.14	0.11	Diastolic blood pressure;	chr8:81785390	chr8:81885377~81923193:+
BRCA	cis	rs9650657	0.596	rs2409675	ENSG00000154316.13	TDH	3.59	0.000347	0.0182	0.14	0.11	Neuroticism;	chr8:10737749	chr8:11339637~11368452:+
BRCA	cis	rs6893300	0.961	rs56335144	ENSG00000225051.5	HMGB3P22	3.59	0.000347	0.0182	0.15	0.11	Resting heart rate;	chr5:179749626	chr5:179679032~179694768:+
BRCA	cis	rs10129255	0.957	rs10138532	ENSG00000211959.2	IGHV4-39	3.59	0.000347	0.0182	0.09	0.11	Kawasaki disease;	chr14:106803901	chr14:106421711~106422218:-
BRCA	cis	rs17428076	0.749	rs62182439	ENSG00000228389.1	AC068039.4	-3.59	0.000347	0.0182	-0.17	-0.11	Myopia;	chr2:171943275	chr2:171773482~171775844:+
BRCA	cis	rs9646944	0.501	rs3771161	ENSG00000234389.1	AC007278.3	3.59	0.000347	0.0182	0.13	0.11	Blood protein levels;	chr2:102387501	chr2:102438713~102440475:+
BRCA	cis	rs2337406	1	rs17095456	ENSG00000211970.3	IGHV4-61	3.59	0.000347	0.0182	0.1	0.11	Alzheimer's disease (late onset);	chr14:106676559	chr14:106639119~106639657:-
BRCA	cis	rs2692947	0.673	rs4907279	ENSG00000168992.4	OR7E102P	3.59	0.000347	0.0182	0.16	0.11	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95734220	chr2:95546531~95547545:+
BRCA	cis	rs1119582	0.636	rs389333	ENSG00000279118.1	RP11-517I3.2	-3.59	0.000347	0.0182	-0.16	-0.11	Select biomarker traits;	chr5:125867587	chr5:126496279~126498604:+
BRCA	cis	rs9863	0.828	rs11057413	ENSG00000270028.1	RP11-380L11.4	3.59	0.000347	0.0182	0.14	0.11	White blood cell count;	chr12:124004615	chr12:123925461~123926083:-
BRCA	cis	rs7568498	1	rs13004784	ENSG00000235724.7	AC009299.2	-3.59	0.000347	0.0182	-0.17	-0.11	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);	chr2:161022320	chr2:161222785~161308303:-
BRCA	cis	rs875971	0.8	rs427557	ENSG00000230189.5	GS1-124K5.2	3.59	0.000347	0.0182	0.09	0.11	Aortic root size;	chr7:66054263	chr7:66409143~66490059:-
BRCA	cis	rs7267979	1	rs8125868	ENSG00000274973.1	RP13-401N8.7	3.59	0.000347	0.0182	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25343774	chr20:25845497~25845862:+
BRCA	cis	rs9341808	0.754	rs3793000	ENSG00000233967.5	RP11-250B2.3	3.59	0.000347	0.0182	0.11	0.11	Sitting height ratio;	chr6:80285420	chr6:80443344~80465927:+
BRCA	cis	rs12681366	0.571	rs2919654	ENSG00000253175.1	RP11-267M23.6	3.59	0.000347	0.0182	0.12	0.11	Nonsyndromic cleft lip with cleft palate;	chr8:94464045	chr8:94565036~94565715:+
BRCA	cis	rs10819861	0.645	rs3802440	ENSG00000175611.10	LINC00476	3.59	0.000347	0.0182	0.12	0.11	Electrocardiographic traits;	chr9:96097656	chr9:95759231~95875977:-
BRCA	cis	rs365302	0.556	rs537693	ENSG00000235086.1	FNDC1-IT1	-3.59	0.000347	0.0182	-0.15	-0.11	Coronary heart disease;	chr6:159241104	chr6:159240786~159243329:+
BRCA	cis	rs2904967	0.81	rs507005	ENSG00000254614.2	AP003068.23	3.59	0.000347	0.0182	0.19	0.11	Mean corpuscular volume;	chr11:65278144	chr11:65177606~65181834:-
BRCA	cis	rs2904967	0.852	rs668735	ENSG00000254614.2	AP003068.23	3.59	0.000347	0.0182	0.19	0.11	Mean corpuscular volume;	chr11:65278254	chr11:65177606~65181834:-
BRCA	cis	rs889956	0.776	rs17189361	ENSG00000233251.6	AC007743.1	3.59	0.000347	0.0182	0.13	0.11	Educational attainment;	chr2:57139485	chr2:56173534~56185770:-
BRCA	cis	rs17767294	0.708	rs72848784	ENSG00000219392.1	RP1-265C24.5	-3.59	0.000347	0.0182	-0.31	-0.11	Parkinson's disease;	chr6:28003005	chr6:28115628~28116551:+
BRCA	cis	rs12612619	0.689	rs1124649	ENSG00000229122.1	AGBL5-IT1	-3.59	0.000348	0.0182	-0.12	-0.11	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27037601	chr2:27061038~27061815:+
BRCA	cis	rs7020830	0.83	rs13296413	ENSG00000230188.1	RP11-405L18.4	-3.59	0.000348	0.0182	-0.14	-0.11	Schizophrenia;	chr9:37258108	chr9:37490421~37490893:-
BRCA	cis	rs875971	1	rs6460296	ENSG00000229886.1	RP5-1132H15.3	3.59	0.000348	0.0182	0.12	0.11	Aortic root size;	chr7:66430152	chr7:66025126~66031544:-
BRCA	cis	rs863345	0.604	rs2317969	ENSG00000229914.1	RP11-404O13.4	-3.59	0.000348	0.0182	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158521963	chr1:158195633~158196131:-
BRCA	cis	rs7520050	0.966	rs7556615	ENSG00000234329.1	RP11-767N6.2	-3.59	0.000348	0.0182	-0.1	-0.11	Reticulocyte count;Red blood cell count;	chr1:45995697	chr1:45651039~45651826:-
BRCA	cis	rs12612619	0.579	rs13029206	ENSG00000229122.1	AGBL5-IT1	-3.59	0.000348	0.0182	-0.12	-0.11	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:26854742	chr2:27061038~27061815:+
BRCA	cis	rs7020830	0.522	rs10814509	ENSG00000281649.1	EBLN3	-3.59	0.000348	0.0182	-0.1	-0.11	Schizophrenia;	chr9:37111060	chr9:37079857~37090507:+
BRCA	cis	rs10844706	0.699	rs741199	ENSG00000256594.6	RP11-705C15.2	3.59	0.000348	0.0182	0.15	0.11	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9720769	chr12:9633419~9658412:+
BRCA	cis	rs13126694	0.778	rs12503001	ENSG00000251073.1	NUDT19P5	3.59	0.000348	0.0182	0.11	0.11	Blood osmolality (transformed sodium);	chr4:158100822	chr4:158182825~158183393:+
BRCA	cis	rs7932354	0.583	rs2070851	ENSG00000200376.1	RNU5E-10P	-3.59	0.000348	0.0182	-0.15	-0.11	Bone mineral density (hip);Bone mineral density;	chr11:46722978	chr11:47576471~47576588:-
BRCA	cis	rs754466	0.58	rs11002301	ENSG00000213514.2	RP11-428P16.2	3.59	0.000348	0.0182	0.15	0.11	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77814320	chr10:77730766~77734769:+
BRCA	cis	rs35306767	0.903	rs12244253	ENSG00000229869.1	RP11-363N22.2	-3.59	0.000348	0.0182	-0.17	-0.11	Eosinophil percentage of granulocytes;	chr10:843380	chr10:933026~942743:+
BRCA	cis	rs9650657	0.74	rs10481451	ENSG00000154316.13	TDH	3.59	0.000348	0.0182	0.14	0.11	Neuroticism;	chr8:10791818	chr8:11339637~11368452:+
BRCA	cis	rs1429264	0.791	rs7188531	ENSG00000261286.1	RP11-517C16.2	3.59	0.000348	0.0182	0.14	0.11	Epilepsy and lamotrigine-induced maculopapular eruptions;	chr16:84586390	chr16:84459259~84467361:-
BRCA	cis	rs10876993	0.749	rs703832	ENSG00000270039.1	RP11-571M6.17	3.59	0.000348	0.0182	0.15	0.11	Celiac disease or Rheumatoid arthritis;	chr12:57630843	chr12:57803838~57804415:+
BRCA	cis	rs13179617	0.887	rs12188685	ENSG00000272308.1	RP11-231G3.1	-3.59	0.000348	0.0182	-0.14	-0.11	Intelligence (multi-trait analysis);	chr5:61548097	chr5:60866457~60866935:-
BRCA	cis	rs6840360	0.571	rs4696099	ENSG00000278978.1	RP11-164P12.5	-3.59	0.000348	0.0182	-0.13	-0.11	Intelligence (multi-trait analysis);	chr4:151580799	chr4:151669786~151670503:+
BRCA	cis	rs703108	0.545	rs7100772	ENSG00000279623.1	RP11-399C16.3	-3.59	0.000348	0.0182	-0.16	-0.11	Monocyte percentage of white cells;	chr10:22015309	chr10:21865335~21865921:-
BRCA	cis	rs7267979	1	rs2482928	ENSG00000274973.1	RP13-401N8.7	3.59	0.000348	0.0182	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25350894	chr20:25845497~25845862:+
BRCA	cis	rs4908769	0.66	rs301803	ENSG00000270282.1	RP5-1115A15.2	3.59	0.000348	0.0182	0.13	0.11	Allergy;	chr1:8438620	chr1:8512653~8513021:+
BRCA	cis	rs7209700	0.692	rs11652097	ENSG00000263293.2	RP11-290H9.4	-3.59	0.000348	0.0182	-0.13	-0.11	IgG glycosylation;	chr17:47239351	chr17:47303460~47323613:-
BRCA	cis	rs8115445	0.515	rs12625687	ENSG00000214535.3	RPS15AP1	3.59	0.000348	0.0182	0.16	0.11	Pediatric bone mineral content (radius);	chr20:21430599	chr20:21166206~21166596:-
BRCA	cis	rs8115445	0.515	rs4813427	ENSG00000214535.3	RPS15AP1	3.59	0.000348	0.0182	0.16	0.11	Pediatric bone mineral content (radius);	chr20:21434361	chr20:21166206~21166596:-
BRCA	cis	rs8115445	0.515	rs12626076	ENSG00000214535.3	RPS15AP1	3.59	0.000348	0.0182	0.16	0.11	Pediatric bone mineral content (radius);	chr20:21450118	chr20:21166206~21166596:-
BRCA	cis	rs8115445	0.515	rs34648998	ENSG00000214535.3	RPS15AP1	3.59	0.000348	0.0182	0.16	0.11	Pediatric bone mineral content (radius);	chr20:21452289	chr20:21166206~21166596:-
BRCA	cis	rs250518	0.852	rs3846640	ENSG00000271926.1	CTD-2376I4.1	3.59	0.000348	0.0182	0.15	0.11	Mean corpuscular hemoglobin concentration;	chr5:72724139	chr5:72953635~72954274:-
BRCA	cis	rs8114671	0.967	rs2069945	ENSG00000126005.14	MMP24-AS1	-3.59	0.000348	0.0182	-0.21	-0.11	Height;	chr20:35174034	chr20:35216462~35278131:-
BRCA	cis	rs13434995	0.513	rs17779627	ENSG00000249700.7	SRD5A3-AS1	-3.59	0.000348	0.0182	-0.16	-0.11	Adiponectin levels;	chr4:55483775	chr4:55363971~55395847:-
BRCA	cis	rs897984	0.542	rs7197717	ENSG00000279196.1	RP11-1072A3.3	3.59	0.000348	0.0182	0.11	0.11	Dementia with Lewy bodies;	chr16:31071754	chr16:30984630~30988270:-
BRCA	cis	rs7637701	0.773	rs4098	ENSG00000240875.4	LINC00886	-3.59	0.000348	0.0182	-0.13	-0.11	Breast cancer;	chr3:156783274	chr3:156747346~156817062:-
BRCA	cis	rs6671200	1	rs933107	ENSG00000226026.4	RP11-57H12.3	-3.59	0.000348	0.0182	-0.2	-0.11	Stearic acid (18:0) levels;	chr1:95206673	chr1:95163219~95233982:-
BRCA	cis	rs7520050	0.778	rs2934857	ENSG00000281133.1	AL355480.3	-3.59	0.000348	0.0182	-0.13	-0.11	Reticulocyte count;Red blood cell count;	chr1:45573940	chr1:45580892~45580996:-
BRCA	cis	rs9400180	0.879	rs9374013	ENSG00000271734.1	RP1-111B22.3	-3.59	0.000348	0.0182	-0.15	-0.11	Major depressive disorder;	chr6:108060143	chr6:108030249~108030718:-
BRCA	cis	rs9400180	0.879	rs6906264	ENSG00000271734.1	RP1-111B22.3	-3.59	0.000348	0.0182	-0.15	-0.11	Major depressive disorder;	chr6:108060516	chr6:108030249~108030718:-
BRCA	cis	rs9400180	0.879	rs9386706	ENSG00000271734.1	RP1-111B22.3	-3.59	0.000348	0.0182	-0.15	-0.11	Major depressive disorder;	chr6:108064908	chr6:108030249~108030718:-
BRCA	cis	rs875971	0.66	rs2013222	ENSG00000232546.1	RP11-458F8.1	3.59	0.000348	0.0182	0.09	0.11	Aortic root size;	chr7:66570949	chr7:66848496~66858136:+
BRCA	cis	rs67696533	0.711	rs1108445	ENSG00000277692.1	RP11-358N2.2	-3.59	0.000348	0.0182	-0.13	-0.11	White blood cell count (basophil);Basophil percentage of granulocytes;Basophil percentage of white cells;	chr20:32539844	chr20:32355053~32355734:+
BRCA	cis	rs3617	0.625	rs2535633	ENSG00000242142.1	SERBP1P3	-3.59	0.000348	0.0182	-0.12	-0.11	Red blood cell count;Autism spectrum disorder or schizophrenia;	chr3:52825614	chr3:53064283~53065091:-
BRCA	cis	rs8114671	0.562	rs6088640	ENSG00000279253.1	RP4-614O4.13	-3.59	0.000348	0.0182	-0.12	-0.11	Height;	chr20:34884706	chr20:35262727~35264187:-
BRCA	cis	rs330048	0.545	rs11249913	ENSG00000254153.1	CTA-398F10.2	-3.59	0.000348	0.0182	-0.14	-0.11	Systemic lupus erythematosus;	chr8:9286011	chr8:8456909~8461337:-
BRCA	cis	rs172166	0.694	rs1225716	ENSG00000219891.2	ZSCAN12P1	3.59	0.000348	0.0182	0.14	0.11	Cardiac Troponin-T levels;	chr6:28145968	chr6:28091154~28093664:+
BRCA	cis	rs2286492	1	rs2286492	ENSG00000228649.7	AC005682.5	3.59	0.000348	0.0182	0.15	0.11	Bipolar disorder;	chr7:22945391	chr7:22854178~22861579:+
BRCA	cis	rs6460942	0.908	rs73677559	ENSG00000226690.5	AC005281.1	3.59	0.000348	0.0182	0.2	0.11	Coronary artery disease;	chr7:12231193	chr7:12496429~12541910:+
BRCA	cis	rs4648045	0.535	rs4698861	ENSG00000246560.2	RP11-10L12.4	-3.59	0.000348	0.0182	-0.13	-0.11	Lymphocyte percentage of white cells;	chr4:102624330	chr4:102828055~102844075:+
BRCA	cis	rs875971	0.862	rs7796162	ENSG00000271064.1	RP11-792A8.3	3.59	0.000348	0.0182	0.13	0.11	Aortic root size;	chr7:66280771	chr7:66748838~66749077:-
BRCA	cis	rs11892454	0.534	rs13030095	ENSG00000217643.1	PTGES3P2	-3.59	0.000349	0.0182	-0.12	-0.11	Heschl's gyrus morphology;	chr2:25803729	chr2:25822469~25822950:+
BRCA	cis	rs4845570	1	rs11586946	ENSG00000203288.3	RP11-98D18.9	-3.59	0.000349	0.0182	-0.2	-0.11	Coronary artery disease;	chr1:151797330	chr1:151790804~151794402:+
BRCA	cis	rs1075265	0.597	rs10490471	ENSG00000272156.1	RP11-477N3.1	-3.59	0.000349	0.0182	-0.12	-0.11	Chronotype;Morning vs. evening chronotype;	chr2:53769446	chr2:54082554~54085066:+
BRCA	cis	rs3858526	0.834	rs10839166	ENSG00000224295.2	AC087380.14	3.59	0.000349	0.0182	0.15	0.11	DNA methylation (variation);	chr11:5981234	chr11:5518441~5524955:-
BRCA	cis	rs10129255	0.912	rs61997792	ENSG00000211959.2	IGHV4-39	3.59	0.000349	0.0182	0.09	0.11	Kawasaki disease;	chr14:106799304	chr14:106421711~106422218:-
BRCA	cis	rs6696239	0.956	rs1995019	ENSG00000227711.2	RP11-275O4.5	-3.59	0.000349	0.0182	-0.15	-0.11	Height;	chr1:227580096	chr1:227509028~227520477:-
BRCA	cis	rs372883	0.648	rs368322	ENSG00000176054.6	RPL23P2	-3.59	0.000349	0.0182	-0.12	-0.11	Pancreatic cancer;	chr21:29344830	chr21:28997613~28998033:-
BRCA	cis	rs9650657	0.623	rs6601517	ENSG00000248896.2	CTD-2135J3.3	-3.59	0.000349	0.0182	-0.13	-0.11	Neuroticism;	chr8:10746283	chr8:10729314~10771392:+
BRCA	cis	rs7179228	0.613	rs72743232	ENSG00000260657.2	RP11-315D16.4	-3.59	0.000349	0.0182	-0.2	-0.11	Systolic blood pressure;	chr15:68336784	chr15:68267792~68277994:-
BRCA	cis	rs1560104	0.709	rs7194367	ENSG00000259876.1	CTD-3037G24.4	3.59	0.000349	0.0182	0.12	0.11	Obesity-related traits;	chr16:12604376	chr16:12556353~12557694:-
BRCA	cis	rs6433921	1	rs2124442	ENSG00000260742.1	RP11-366L5.1	-3.59	0.000349	0.0182	-0.14	-0.11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;	chr2:181566850	chr2:181887851~181891663:-
BRCA	cis	rs10771431	0.597	rs10843142	ENSG00000256673.1	RP11-599J14.2	3.59	0.000349	0.0182	0.12	0.11	Breast size;	chr12:9204906	chr12:9398355~9414851:-
BRCA	cis	rs801193	1	rs7785213	ENSG00000232546.1	RP11-458F8.1	3.59	0.000349	0.0182	0.09	0.11	Aortic root size;	chr7:66673991	chr7:66848496~66858136:+
BRCA	cis	rs6430585	0.528	rs3098102	ENSG00000224043.6	CCNT2-AS1	-3.59	0.000349	0.0182	-0.17	-0.11	Corneal structure;	chr2:135897263	chr2:134735464~134918710:-
BRCA	cis	rs9633740	1	rs10749609	ENSG00000226659.1	RP11-137H2.4	-3.59	0.000349	0.0182	-0.18	-0.11	Post bronchodilator FEV1;	chr10:80489996	chr10:80529597~80535942:-
BRCA	cis	rs16940212	0.618	rs16940170	ENSG00000259771.1	RP11-429D19.1	3.59	0.000349	0.0182	0.18	0.11	HDL cholesterol;HDL cholesterol levels;	chr15:58392083	chr15:59266720~59271162:-
BRCA	cis	rs17092148	1	rs2425003	ENSG00000202150.1	RNU6-407P	-3.59	0.000349	0.0182	-0.16	-0.11	Neuroticism;	chr20:34815781	chr20:35030317~35030420:-
BRCA	cis	rs11892454	0.565	rs11897276	ENSG00000217643.1	PTGES3P2	-3.59	0.000349	0.0182	-0.12	-0.11	Heschl's gyrus morphology;	chr2:25867544	chr2:25822469~25822950:+
BRCA	cis	rs495337	0.699	rs2982414	ENSG00000224397.4	LINC01272	-3.59	0.000349	0.0182	-0.11	-0.11	Psoriasis;	chr20:49846521	chr20:50267486~50279795:+
BRCA	cis	rs2998286	0.678	rs332184	ENSG00000237128.1	RP11-351M16.3	3.59	0.000349	0.0183	0.16	0.11	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28624042	chr10:28433008~28495813:-
BRCA	cis	rs10986311	0.862	rs10818950	ENSG00000227200.1	RP11-121A14.3	-3.59	0.000349	0.0183	-0.13	-0.11	Vitiligo;	chr9:124367858	chr9:124262876~124265809:+
BRCA	cis	rs739401	0.967	rs451041	ENSG00000247473.2	CARS-AS1	3.59	0.000349	0.0183	0.12	0.11	Longevity;	chr11:3039495	chr11:3029009~3041260:+
BRCA	cis	rs11733008	1	rs4693177	ENSG00000249001.4	RP11-742B18.1	3.59	0.000349	0.0183	0.13	0.11	Non-small cell lung cancer (survival);	chr4:87752803	chr4:87568035~87733956:-
BRCA	cis	rs2562456	0.837	rs62110205	ENSG00000240522.1	RPL7AP10	-3.59	0.000349	0.0183	-0.12	-0.11	Pain;	chr19:21577269	chr19:21149648~21150438:-
BRCA	cis	rs1479090	0.712	rs10006476	ENSG00000250027.1	RP11-563E2.2	-3.59	0.000349	0.0183	-0.14	-0.11	Lung cancer;	chr4:163099727	chr4:163108785~163119965:+
BRCA	cis	rs8073060	0.586	rs2626625	ENSG00000267554.1	RP11-686D22.10	-3.59	0.000349	0.0183	-0.12	-0.11	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35700588	chr17:35470069~35470628:-
BRCA	cis	rs867186	0.698	rs11699306	ENSG00000279253.1	RP4-614O4.13	-3.59	0.000349	0.0183	-0.19	-0.11	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35213480	chr20:35262727~35264187:-
BRCA	cis	rs40067	1	rs288131	ENSG00000272523.1	LINC01023	3.59	0.000349	0.0183	0.12	0.11	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr5:108047156	chr5:108727825~108728260:-
BRCA	cis	rs1005277	0.563	rs2505215	ENSG00000276805.1	RP11-291L22.6	3.59	0.000349	0.0183	0.12	0.11	Extrinsic epigenetic age acceleration;	chr10:38192345	chr10:38451030~38451785:+
BRCA	cis	rs17684571	0.938	rs35668437	ENSG00000231441.1	RP11-472M19.2	3.59	0.000349	0.0183	0.17	0.11	Schizophrenia;	chr6:56701058	chr6:56844002~56864078:+
BRCA	cis	rs17684571	0.938	rs17684511	ENSG00000231441.1	RP11-472M19.2	3.59	0.000349	0.0183	0.17	0.11	Schizophrenia;	chr6:56701217	chr6:56844002~56864078:+
BRCA	cis	rs6714710	0.603	rs1470483	ENSG00000228486.8	LINC01125	-3.59	0.000349	0.0183	-0.1	-0.11	Posterior cortical atrophy and Alzheimer's disease;	chr2:97777431	chr2:97664217~97703064:+
BRCA	cis	rs10838687	0.736	rs1449626	ENSG00000243802.2	RP11-390K5.1	3.59	0.000349	0.0183	0.15	0.11	Proinsulin levels;	chr11:47269208	chr11:47191181~47191542:-
BRCA	cis	rs6973609	0.627	rs1003248	ENSG00000271122.1	RP11-379H18.1	3.59	0.000349	0.0183	0.11	0.11	Obesity-related traits;	chr7:35570153	chr7:35695214~35699413:+
BRCA	cis	rs7636293	0.592	rs6439168	ENSG00000270773.1	RP13-685P2.7	-3.59	0.000349	0.0183	-0.15	-0.11	Height;	chr3:129332100	chr3:129345411~129346164:+
BRCA	cis	rs10943724	1	rs6915595	ENSG00000272129.1	RP11-250B2.6	3.59	0.000349	0.0183	0.15	0.11	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr6:80585414	chr6:80355424~80356859:+
BRCA	cis	rs4950322	0.542	rs3766520	ENSG00000227242.3	NBPF13P	-3.59	0.00035	0.0183	-0.16	-0.11	Protein quantitative trait loci;	chr1:147214658	chr1:147021320~147124525:-
BRCA	cis	rs1008375	1	rs11727312	ENSG00000249502.1	AC006160.5	-3.59	0.00035	0.0183	-0.13	-0.11	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17667562	chr4:17587467~17614571:-
BRCA	cis	rs801193	1	rs6958520	ENSG00000232546.1	RP11-458F8.1	-3.59	0.00035	0.0183	-0.09	-0.11	Aortic root size;	chr7:66686466	chr7:66848496~66858136:+
BRCA	cis	rs9341808	0.754	rs6907729	ENSG00000279022.1	RP11-250B2.4	-3.59	0.00035	0.0183	-0.12	-0.11	Sitting height ratio;	chr6:80295205	chr6:80440730~80441172:+
BRCA	cis	rs2274273	0.682	rs1187876	ENSG00000233924.1	AL160471.6	3.59	0.00035	0.0183	0.12	0.11	Protein biomarker;	chr14:55028481	chr14:55004813~55005687:-
BRCA	cis	rs2411233	1	rs11635288	ENSG00000259278.1	RP11-62C7.2	3.59	0.00035	0.0183	0.13	0.11	Platelet count;	chr15:38978127	chr15:39019233~39024918:+
BRCA	cis	rs10170310	0.938	rs11680891	ENSG00000241772.2	AC092620.2	-3.59	0.00035	0.0183	-0.16	-0.11	Response to antipsychotic treatment;	chr2:138506884	chr2:138569090~138574458:+
BRCA	cis	rs17092148	0.887	rs6058104	ENSG00000269202.1	RP4-614O4.12	3.59	0.00035	0.0183	0.15	0.11	Neuroticism;	chr20:34683248	chr20:35201747~35203288:-
BRCA	cis	rs7520050	0.966	rs11810993	ENSG00000234329.1	RP11-767N6.2	-3.59	0.00035	0.0183	-0.1	-0.11	Reticulocyte count;Red blood cell count;	chr1:46013121	chr1:45651039~45651826:-
BRCA	cis	rs1843834	0.574	rs6436499	ENSG00000274629.1	RP11-92F20.1	-3.59	0.00035	0.0183	-0.14	-0.11	IgE levels in asthmatics (D.p. specific);	chr2:224591834	chr2:224464682~224474500:+
BRCA	cis	rs10899021	0.512	rs10219168	ENSG00000279353.1	RP11-864N7.4	-3.59	0.00035	0.0183	-0.16	-0.11	Response to metformin (IC50);	chr11:74663408	chr11:74698231~74699658:-
BRCA	cis	rs11098499	0.618	rs35265692	ENSG00000260404.2	RP11-384K6.6	3.59	0.00035	0.0183	0.1	0.11	Corneal astigmatism;	chr4:119403980	chr4:118591773~118633729:+
BRCA	cis	rs16958440	0.581	rs11082564	ENSG00000267724.1	RP11-49K24.8	3.59	0.00035	0.0183	0.17	0.11	Sitting height ratio;	chr18:47132778	chr18:47105946~47108062:+
BRCA	cis	rs16958440	0.708	rs62096477	ENSG00000267724.1	RP11-49K24.8	3.59	0.00035	0.0183	0.17	0.11	Sitting height ratio;	chr18:47135939	chr18:47105946~47108062:+
BRCA	cis	rs10829156	0.945	rs8181345	ENSG00000225527.1	RP11-383B4.4	-3.59	0.00035	0.0183	-0.16	-0.11	Sudden cardiac arrest;	chr10:18678689	chr10:18531849~18533336:-
BRCA	cis	rs7267979	1	rs6115182	ENSG00000274414.1	RP5-965G21.4	3.59	0.00035	0.0183	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25429623	chr20:25239007~25245229:-
BRCA	cis	rs9992667	0.563	rs10026640	ENSG00000231160.8	KLF3-AS1	3.59	0.00035	0.0183	0.12	0.11	Eosinophil percentage of granulocytes;	chr4:38701352	chr4:38612701~38664883:-
BRCA	cis	rs4950322	0.57	rs72692963	ENSG00000237188.3	RP11-337C18.8	3.59	0.00035	0.0183	0.14	0.11	Protein quantitative trait loci;	chr1:147331090	chr1:147172771~147211568:+
BRCA	cis	rs4950322	0.518	rs72692965	ENSG00000237188.3	RP11-337C18.8	3.59	0.00035	0.0183	0.14	0.11	Protein quantitative trait loci;	chr1:147332085	chr1:147172771~147211568:+
BRCA	cis	rs4950322	0.518	rs72692968	ENSG00000237188.3	RP11-337C18.8	3.59	0.00035	0.0183	0.14	0.11	Protein quantitative trait loci;	chr1:147332884	chr1:147172771~147211568:+
BRCA	cis	rs4950322	0.518	rs72692970	ENSG00000237188.3	RP11-337C18.8	3.59	0.00035	0.0183	0.14	0.11	Protein quantitative trait loci;	chr1:147332887	chr1:147172771~147211568:+
BRCA	cis	rs4950322	0.57	rs72692971	ENSG00000237188.3	RP11-337C18.8	3.59	0.00035	0.0183	0.14	0.11	Protein quantitative trait loci;	chr1:147333088	chr1:147172771~147211568:+
BRCA	cis	rs4950322	0.57	rs72692973	ENSG00000237188.3	RP11-337C18.8	3.59	0.00035	0.0183	0.14	0.11	Protein quantitative trait loci;	chr1:147333281	chr1:147172771~147211568:+
BRCA	cis	rs4950322	0.57	rs72692975	ENSG00000237188.3	RP11-337C18.8	3.59	0.00035	0.0183	0.14	0.11	Protein quantitative trait loci;	chr1:147333506	chr1:147172771~147211568:+
BRCA	cis	rs910873	0.505	rs6058089	ENSG00000202150.1	RNU6-407P	-3.59	0.00035	0.0183	-0.16	-0.11	Melanoma;	chr20:34606453	chr20:35030317~35030420:-
BRCA	cis	rs7267979	1	rs2500432	ENSG00000277938.1	RP5-965G21.3	3.59	0.00035	0.0183	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25309876	chr20:25229150~25231933:+
BRCA	cis	rs804280	0.509	rs12719915	ENSG00000205879.4	FAM90A2P	-3.59	0.00035	0.0183	-0.13	-0.11	Myopia (pathological);	chr8:11928746	chr8:12172202~12178575:-
BRCA	cis	rs2749097	0.735	rs10493349	ENSG00000244256.3	RN7SL130P	-3.59	0.00035	0.0183	-0.16	-0.11	Alcohol consumption (transferrin glycosylation);	chr1:63690237	chr1:63655743~63656047:+
BRCA	cis	rs1208	1	rs1208	ENSG00000253671.1	RP11-806O11.1	-3.59	0.00035	0.0183	-0.13	-0.11	Insulin resistance/response;	chr8:18400806	chr8:17808941~17820868:+
BRCA	cis	rs7141336	0.791	rs12883490	ENSG00000258884.1	CTD-3035D6.2	3.59	0.00035	0.0183	0.14	0.11	Anxiety disorder;	chr14:90729028	chr14:90822365~90828128:-
BRCA	cis	rs7495132	0.688	rs3743405	ENSG00000245479.2	LINC01585	-3.59	0.00035	0.0183	-0.16	-0.11	Ulcerative colitis;Inflammatory bowel disease;	chr15:90625744	chr15:90660234~90664967:+
BRCA	cis	rs10883723	0.81	rs2296582	ENSG00000213061.2	PFN1P11	-3.59	0.00035	0.0183	-0.15	-0.11	Allergic disease (asthma, hay fever or eczema);	chr10:102484382	chr10:102838011~102845473:-
BRCA	cis	rs875971	0.929	rs10950041	ENSG00000229886.1	RP5-1132H15.3	3.59	0.00035	0.0183	0.12	0.11	Aortic root size;	chr7:66508888	chr7:66025126~66031544:-
BRCA	cis	rs6120849	0.754	rs6088686	ENSG00000202150.1	RNU6-407P	3.59	0.00035	0.0183	0.16	0.11	Protein C levels;	chr20:35035634	chr20:35030317~35030420:-
BRCA	cis	rs6120849	0.754	rs6120804	ENSG00000202150.1	RNU6-407P	3.59	0.00035	0.0183	0.16	0.11	Protein C levels;	chr20:35035898	chr20:35030317~35030420:-
BRCA	cis	rs6120849	0.707	rs6088690	ENSG00000202150.1	RNU6-407P	3.59	0.00035	0.0183	0.16	0.11	Protein C levels;	chr20:35045523	chr20:35030317~35030420:-
BRCA	cis	rs6120849	0.754	rs6088691	ENSG00000202150.1	RNU6-407P	3.59	0.00035	0.0183	0.16	0.11	Protein C levels;	chr20:35045955	chr20:35030317~35030420:-
BRCA	cis	rs6120849	0.754	rs6087666	ENSG00000202150.1	RNU6-407P	3.59	0.00035	0.0183	0.16	0.11	Protein C levels;	chr20:35052439	chr20:35030317~35030420:-
BRCA	cis	rs6120849	0.754	rs17319032	ENSG00000202150.1	RNU6-407P	3.59	0.00035	0.0183	0.16	0.11	Protein C levels;	chr20:35055493	chr20:35030317~35030420:-
BRCA	cis	rs7954584	0.567	rs1169071	ENSG00000212694.7	LINC01089	-3.59	0.00035	0.0183	-0.09	-0.11	Mean corpuscular volume;	chr12:121952178	chr12:121795267~121803906:-
BRCA	cis	rs7131987	0.903	rs2194519	ENSG00000257176.2	RP11-996F15.2	3.59	0.00035	0.0183	0.13	0.11	QT interval;	chr12:29270650	chr12:29280418~29317848:-
BRCA	cis	rs863345	0.604	rs11265008	ENSG00000229914.1	RP11-404O13.4	-3.59	0.00035	0.0183	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158528881	chr1:158195633~158196131:-
BRCA	cis	rs863345	0.604	rs11265010	ENSG00000229914.1	RP11-404O13.4	-3.59	0.00035	0.0183	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158529063	chr1:158195633~158196131:-
BRCA	cis	rs863345	0.604	rs12123305	ENSG00000229914.1	RP11-404O13.4	-3.59	0.00035	0.0183	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158529165	chr1:158195633~158196131:-
BRCA	cis	rs863345	0.604	rs12063320	ENSG00000229914.1	RP11-404O13.4	-3.59	0.00035	0.0183	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158529633	chr1:158195633~158196131:-
BRCA	cis	rs863345	0.604	rs12064489	ENSG00000229914.1	RP11-404O13.4	-3.59	0.00035	0.0183	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158529659	chr1:158195633~158196131:-
BRCA	cis	rs863345	0.625	rs12063360	ENSG00000229914.1	RP11-404O13.4	-3.59	0.00035	0.0183	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158529704	chr1:158195633~158196131:-
BRCA	cis	rs863345	0.604	rs10908665	ENSG00000229914.1	RP11-404O13.4	-3.59	0.00035	0.0183	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158530099	chr1:158195633~158196131:-
BRCA	cis	rs863345	0.625	rs12119672	ENSG00000229914.1	RP11-404O13.4	-3.59	0.00035	0.0183	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158530495	chr1:158195633~158196131:-
BRCA	cis	rs863345	0.604	rs12059669	ENSG00000229914.1	RP11-404O13.4	-3.59	0.00035	0.0183	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158531690	chr1:158195633~158196131:-
BRCA	cis	rs863345	0.604	rs10908670	ENSG00000229914.1	RP11-404O13.4	-3.59	0.00035	0.0183	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158532323	chr1:158195633~158196131:-
BRCA	cis	rs863345	0.565	rs10908671	ENSG00000229914.1	RP11-404O13.4	-3.59	0.00035	0.0183	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158532370	chr1:158195633~158196131:-
BRCA	cis	rs863345	0.604	rs12075228	ENSG00000229914.1	RP11-404O13.4	-3.59	0.00035	0.0183	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158532466	chr1:158195633~158196131:-
BRCA	cis	rs6918586	0.658	rs198819	ENSG00000272810.1	U91328.22	-3.59	0.00035	0.0183	-0.12	-0.11	Schizophrenia;	chr6:26124202	chr6:26013241~26013757:+
BRCA	cis	rs1348850	0.526	rs4144278	ENSG00000271825.1	RP11-337N6.2	3.59	0.00035	0.0183	0.19	0.11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177547650	chr2:177300600~177302006:+
BRCA	cis	rs17092148	0.887	rs4911431	ENSG00000250917.1	RP4-785G19.5	3.59	0.000351	0.0183	0.19	0.11	Neuroticism;	chr20:34570514	chr20:34234840~34281173:-
BRCA	cis	rs2562456	0.833	rs4321312	ENSG00000268117.1	VN1R84P	3.59	0.000351	0.0183	0.16	0.11	Pain;	chr19:21336614	chr19:21719801~21720035:-
BRCA	cis	rs4919694	1	rs78214351	ENSG00000236937.2	PTGES3P4	3.59	0.000351	0.0183	0.22	0.11	Arsenic metabolism;	chr10:103062931	chr10:102845595~102845950:+
BRCA	cis	rs2271404	1	rs2271404	ENSG00000227992.1	AC108463.2	3.59	0.000351	0.0183	0.17	0.11	Atopic dermatitis;	chr2:111246290	chr2:111203964~111206215:-
BRCA	cis	rs853679	0.882	rs3757188	ENSG00000204709.4	LINC01556	3.59	0.000351	0.0183	0.23	0.11	Depression;	chr6:28139579	chr6:28943877~28944537:+
BRCA	cis	rs61931739	0.5	rs34287388	ENSG00000258794.3	DUX4L27	3.59	0.000351	0.0183	0.16	0.11	Morning vs. evening chronotype;	chr12:34291691	chr12:34208415~34209675:-
BRCA	cis	rs564309	1	rs532465	ENSG00000212237.1	RNA5SP18	3.59	0.000351	0.0183	0.18	0.11	Hip circumference (psychosocial stress interaction);	chr1:228399791	chr1:228647912~228648032:-
BRCA	cis	rs9467773	1	rs6456734	ENSG00000224843.5	LINC00240	-3.59	0.000351	0.0183	-0.12	-0.11	Intelligence (multi-trait analysis);	chr6:26566737	chr6:26956992~27023924:+
BRCA	cis	rs6792584	0.504	rs6810165	ENSG00000241316.5	SUCLG2-AS1	-3.59	0.000351	0.0183	-0.11	-0.11	Corneal astigmatism;	chr3:67456549	chr3:67654697~67947713:+
BRCA	cis	rs7267979	1	rs6083844	ENSG00000274414.1	RP5-965G21.4	3.59	0.000351	0.0183	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25406196	chr20:25239007~25245229:-
BRCA	cis	rs716804	0.504	rs11042725	ENSG00000254554.1	RP11-351I24.1	3.59	0.000351	0.0183	0.14	0.11	Neuroticism;	chr11:10303778	chr11:10302657~10303704:-
BRCA	cis	rs1865760	0.963	rs9356991	ENSG00000272810.1	U91328.22	-3.59	0.000351	0.0183	-0.13	-0.11	Height;	chr6:25901530	chr6:26013241~26013757:+
BRCA	cis	rs4919694	0.615	rs78384860	ENSG00000213061.2	PFN1P11	3.59	0.000351	0.0183	0.24	0.11	Arsenic metabolism;	chr10:103243262	chr10:102838011~102845473:-
BRCA	cis	rs4819052	0.851	rs1999335	ENSG00000215447.6	BX322557.10	-3.59	0.000351	0.0183	-0.11	-0.11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250698	chr21:45288052~45291738:+
BRCA	cis	rs9467773	1	rs9357010	ENSG00000224843.5	LINC00240	-3.59	0.000351	0.0183	-0.12	-0.11	Intelligence (multi-trait analysis);	chr6:26527717	chr6:26956992~27023924:+
BRCA	cis	rs9650657	0.529	rs10108618	ENSG00000255020.1	AF131216.5	3.59	0.000351	0.0183	0.13	0.11	Neuroticism;	chr8:11095582	chr8:11345748~11347502:-
BRCA	cis	rs17684571	0.938	rs13192037	ENSG00000231441.1	RP11-472M19.2	3.59	0.000351	0.0183	0.18	0.11	Schizophrenia;	chr6:56689474	chr6:56844002~56864078:+
BRCA	cis	rs6480314	0.711	rs61854659	ENSG00000233590.1	RP11-153K11.3	-3.59	0.000351	0.0183	-0.18	-0.11	Optic nerve measurement (disc area);	chr10:68182967	chr10:68233251~68242379:-
BRCA	cis	rs6696239	0.911	rs28446171	ENSG00000215812.5	ZNF847P	3.59	0.000351	0.0183	0.15	0.11	Height;	chr1:227643475	chr1:227696892~227706699:-
BRCA	cis	rs660899	0.752	rs7511800	ENSG00000229431.1	RP1-92O14.6	-3.59	0.000351	0.0183	-0.12	-0.11	Hypertension risk in short sleep duration;	chr1:43748598	chr1:43385113~43389155:+
BRCA	cis	rs9863	0.794	rs7978610	ENSG00000270028.1	RP11-380L11.4	-3.59	0.000351	0.0183	-0.14	-0.11	White blood cell count;	chr12:123984025	chr12:123925461~123926083:-
BRCA	cis	rs11662721	0.938	rs45450492	ENSG00000264188.1	RP11-13N13.5	3.59	0.000351	0.0183	0.16	0.11	Phospholipid levels (plasma);	chr18:21527755	chr18:21661787~21662395:-
BRCA	cis	rs745109	0.882	rs72932310	ENSG00000273080.1	RP11-301O19.1	3.59	0.000351	0.0183	0.17	0.11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86485608	chr2:86195590~86196049:+
BRCA	cis	rs745109	0.882	rs72932311	ENSG00000273080.1	RP11-301O19.1	3.59	0.000351	0.0183	0.17	0.11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86485697	chr2:86195590~86196049:+
BRCA	cis	rs2836974	0.544	rs8128919	ENSG00000238141.2	BRWD1-AS1	3.59	0.000351	0.0183	0.12	0.11	Cognitive function;	chr21:39339936	chr21:39315707~39323218:+
BRCA	cis	rs17406451	0.759	rs7588221	ENSG00000234936.1	AC010883.5	3.59	0.000351	0.0184	0.11	0.11	Mitochondrial DNA levels;	chr2:43427177	chr2:43229573~43233394:+
BRCA	cis	rs2243480	1	rs1701758	ENSG00000226002.1	RP11-460N20.5	-3.59	0.000351	0.0184	-0.18	-0.11	Diabetic kidney disease;	chr7:66005214	chr7:65084103~65100232:+
BRCA	cis	rs10504130	0.518	rs6473654	ENSG00000272024.1	RP11-546K22.3	3.59	0.000351	0.0184	0.15	0.11	Venous thromboembolism (SNP x SNP interaction);	chr8:51758954	chr8:51950284~51950690:+
BRCA	cis	rs737008	0.922	rs11074957	ENSG00000262703.1	RP11-485G7.6	-3.59	0.000352	0.0184	-0.12	-0.11	Obesity-related traits;	chr16:11284294	chr16:11348143~11349321:-
BRCA	cis	rs9388451	0.626	rs9385383	ENSG00000237742.5	RP11-624M8.1	-3.59	0.000352	0.0184	-0.13	-0.11	Brugada syndrome;	chr6:125765144	chr6:125578558~125749190:-
BRCA	cis	rs863345	0.604	rs11265016	ENSG00000229914.1	RP11-404O13.4	-3.59	0.000352	0.0184	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158533995	chr1:158195633~158196131:-
BRCA	cis	rs863345	0.604	rs10908673	ENSG00000229914.1	RP11-404O13.4	-3.59	0.000352	0.0184	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158534118	chr1:158195633~158196131:-
BRCA	cis	rs863345	0.604	rs10908674	ENSG00000229914.1	RP11-404O13.4	-3.59	0.000352	0.0184	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158534130	chr1:158195633~158196131:-
BRCA	cis	rs863345	0.547	rs10908675	ENSG00000229914.1	RP11-404O13.4	-3.59	0.000352	0.0184	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158534339	chr1:158195633~158196131:-
BRCA	cis	rs863345	0.604	rs7518708	ENSG00000229914.1	RP11-404O13.4	-3.59	0.000352	0.0184	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158534484	chr1:158195633~158196131:-
BRCA	cis	rs863345	0.604	rs7533071	ENSG00000229914.1	RP11-404O13.4	-3.59	0.000352	0.0184	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158534689	chr1:158195633~158196131:-
BRCA	cis	rs863345	0.564	rs7540999	ENSG00000229914.1	RP11-404O13.4	-3.59	0.000352	0.0184	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158534780	chr1:158195633~158196131:-
BRCA	cis	rs1479090	0.805	rs6811980	ENSG00000250027.1	RP11-563E2.2	-3.59	0.000352	0.0184	-0.14	-0.11	Lung cancer;	chr4:163113378	chr4:163108785~163119965:+
BRCA	cis	rs7107174	1	rs2511170	ENSG00000251323.2	RP11-452H21.4	3.59	0.000352	0.0184	0.15	0.11	Testicular germ cell tumor;	chr11:78269536	chr11:78423982~78429836:-
BRCA	cis	rs17301013	0.932	rs12074753	ENSG00000200674.1	RN7SKP160	3.59	0.000352	0.0184	0.15	0.11	Systemic lupus erythematosus;	chr1:174565768	chr1:173791548~173791887:+
BRCA	cis	rs17301013	0.932	rs1016466	ENSG00000200674.1	RN7SKP160	3.59	0.000352	0.0184	0.15	0.11	Systemic lupus erythematosus;	chr1:174570652	chr1:173791548~173791887:+
BRCA	cis	rs17301013	0.932	rs10753086	ENSG00000200674.1	RN7SKP160	3.59	0.000352	0.0184	0.15	0.11	Systemic lupus erythematosus;	chr1:174580802	chr1:173791548~173791887:+
BRCA	cis	rs8180040	0.654	rs62246451	ENSG00000280667.1	Y_RNA	-3.59	0.000352	0.0184	-0.12	-0.11	Colorectal cancer;	chr3:47170142	chr3:47501083~47501182:+
BRCA	cis	rs8180040	0.627	rs58956475	ENSG00000280667.1	Y_RNA	-3.59	0.000352	0.0184	-0.12	-0.11	Colorectal cancer;	chr3:47183125	chr3:47501083~47501182:+
BRCA	cis	rs894157	0.92	rs8039002	ENSG00000259212.1	CTD-3065B20.2	-3.59	0.000352	0.0184	-0.2	-0.11	Obesity-related traits;	chr15:89599056	chr15:90595840~90596447:-
BRCA	cis	rs6750047	0.932	rs2116232	ENSG00000235848.3	RMDN2-AS1	-3.59	0.000352	0.0184	-0.14	-0.11	Cutaneous malignant melanoma;Melanoma;	chr2:38041575	chr2:37949911~38067041:-
BRCA	cis	rs4665809	0.816	rs2384359	ENSG00000231655.1	AC011742.3	3.59	0.000352	0.0184	0.17	0.11	Gut microbiome composition (summer);	chr2:26148495	chr2:26140263~26141264:-
BRCA	cis	rs11035577	0.632	rs6485131	ENSG00000279675.1	RP11-454H19.2	-3.59	0.000352	0.0184	-0.17	-0.11	Temperament (bipolar disorder);	chr11:39750621	chr11:40107244~40112599:-
BRCA	cis	rs11035577	0.632	rs6485132	ENSG00000279675.1	RP11-454H19.2	-3.59	0.000352	0.0184	-0.17	-0.11	Temperament (bipolar disorder);	chr11:39750673	chr11:40107244~40112599:-
BRCA	cis	rs6601530	0.564	rs7826189	ENSG00000248896.2	CTD-2135J3.3	3.59	0.000352	0.0184	0.13	0.11	Carotid intima media thickness;	chr8:10770350	chr8:10729314~10771392:+
BRCA	cis	rs10043775	1	rs10477376	ENSG00000251330.3	CTD-2283N19.1	3.59	0.000352	0.0184	0.13	0.11	Periodontal microbiota;	chr5:148405651	chr5:148430159~148430807:-
BRCA	cis	rs7020830	0.858	rs67036212	ENSG00000260100.1	RP11-220I1.5	-3.59	0.000352	0.0184	-0.14	-0.11	Schizophrenia;	chr9:37133541	chr9:37078813~37079776:-
BRCA	cis	rs8018967	1	rs8018967	ENSG00000258443.1	RP3-414A15.11	-3.59	0.000352	0.0184	-0.13	-0.11	Blood metabolite ratios;	chr14:73510230	chr14:73517233~73520648:-
BRCA	cis	rs16940212	0.618	rs16940174	ENSG00000259771.1	RP11-429D19.1	3.59	0.000352	0.0184	0.18	0.11	HDL cholesterol;HDL cholesterol levels;	chr15:58394139	chr15:59266720~59271162:-
BRCA	cis	rs1889642	0.701	rs1158596	ENSG00000227354.5	RBM26-AS1	3.59	0.000352	0.0184	0.12	0.11	Colonoscopy-negative controls vs population controls;	chr13:79774518	chr13:79406309~79424328:+
BRCA	cis	rs72772090	0.539	rs17405676	ENSG00000272109.1	CTD-2260A17.3	3.59	0.000352	0.0184	0.21	0.11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96846912	chr5:96804353~96806105:+
BRCA	cis	rs2274273	0.84	rs10142448	ENSG00000259318.1	RP11-454L9.2	-3.59	0.000352	0.0184	-0.09	-0.11	Protein biomarker;	chr14:55371390	chr14:55394940~55395233:-
BRCA	cis	rs6813195	0.642	rs6535849	ENSG00000245954.5	RP11-18H21.1	3.59	0.000352	0.0184	0.1	0.11	Type 2 diabetes;	chr4:152378963	chr4:152100754~152104720:+
BRCA	cis	rs6545883	0.524	rs2593631	ENSG00000270820.4	RP11-355B11.2	-3.59	0.000352	0.0184	-0.12	-0.11	Tuberculosis;	chr2:61345151	chr2:61471188~61484130:+
BRCA	cis	rs13272568	0.614	rs11776905	ENSG00000254352.1	RP11-578O24.2	-3.59	0.000352	0.0184	-0.14	-0.11	Bone mineral density;	chr8:78110421	chr8:78723796~78724136:-
BRCA	cis	rs875971	0.522	rs10807697	ENSG00000223473.2	GS1-124K5.3	3.59	0.000352	0.0184	0.08	0.11	Aortic root size;	chr7:65951183	chr7:66491049~66493566:-
BRCA	cis	rs10256972	0.713	rs10435026	ENSG00000199023.2	MIR339	-3.59	0.000352	0.0184	-0.14	-0.11	Endometriosis;Longevity;	chr7:1026312	chr7:1022935~1023045:-
BRCA	cis	rs1670533	1	rs6857085	ENSG00000251639.2	RP11-20I20.1	-3.59	0.000352	0.0184	-0.18	-0.11	Recombination rate (females);	chr4:1102132	chr4:1100016~1101558:-
BRCA	cis	rs6005807	0.719	rs2144922	ENSG00000272858.1	CTA-292E10.8	-3.59	0.000352	0.0184	-0.18	-0.11	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28527329	chr22:28814914~28815662:+
BRCA	cis	rs495337	0.76	rs6125825	ENSG00000229222.1	KRT18P4	-3.59	0.000352	0.0184	-0.14	-0.11	Psoriasis;	chr20:49937166	chr20:49956745~49958032:+
BRCA	cis	rs6840360	0.571	rs62327272	ENSG00000278978.1	RP11-164P12.5	-3.59	0.000352	0.0184	-0.13	-0.11	Intelligence (multi-trait analysis);	chr4:151623938	chr4:151669786~151670503:+
BRCA	cis	rs4919694	1	rs12268849	ENSG00000236937.2	PTGES3P4	3.59	0.000352	0.0184	0.21	0.11	Arsenic metabolism;	chr10:102977925	chr10:102845595~102845950:+
BRCA	cis	rs6696239	1	rs7549475	ENSG00000227711.2	RP11-275O4.5	3.59	0.000352	0.0184	0.15	0.11	Height;	chr1:227586999	chr1:227509028~227520477:-
BRCA	cis	rs17214007	0.877	rs4541094	ENSG00000260735.1	RP11-72I8.1	-3.59	0.000353	0.0184	-0.15	-0.11	Cognitive function;	chr16:15776878	chr16:15094411~15109197:+
BRCA	cis	rs4925540	0.519	rs4925613	ENSG00000215796.3	RP11-551G24.2	-3.59	0.000353	0.0184	-0.14	-0.11	Response to taxane treatment (docetaxel);	chr1:247073096	chr1:247042791~247044021:+
BRCA	cis	rs4925540	0.519	rs4925614	ENSG00000215796.3	RP11-551G24.2	-3.59	0.000353	0.0184	-0.14	-0.11	Response to taxane treatment (docetaxel);	chr1:247073261	chr1:247042791~247044021:+
BRCA	cis	rs2553218	0.934	rs8040774	ENSG00000274765.1	RP11-139H15.7	3.59	0.000353	0.0184	0.12	0.11	Immune response to smallpox vaccine (IL-6);	chr15:54578906	chr15:55343141~55343575:-
BRCA	cis	rs16852403	0.548	rs6685012	ENSG00000224687.1	RASAL2-AS1	3.59	0.000353	0.0184	0.14	0.11	Childhood ear infection;	chr1:178206166	chr1:178091508~178093984:-
BRCA	cis	rs6728642	0.519	rs7589232	ENSG00000273265.1	RP11-353K11.1	3.59	0.000353	0.0184	0.16	0.11	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:96900411	chr2:96812239~96813657:-
BRCA	cis	rs2455799	0.574	rs2455800	ENSG00000224728.1	AC090945.1	-3.59	0.000353	0.0184	-0.11	-0.11	Mean platelet volume;	chr3:15660082	chr3:15878047~15879571:+
BRCA	cis	rs10043775	0.831	rs12519039	ENSG00000251330.3	CTD-2283N19.1	-3.59	0.000353	0.0184	-0.14	-0.11	Periodontal microbiota;	chr5:148346786	chr5:148430159~148430807:-
BRCA	cis	rs75422866	0.867	rs73104103	ENSG00000276691.1	RP5-1057I20.5	3.59	0.000353	0.0184	0.23	0.11	Pneumonia;	chr12:47669604	chr12:47788426~47788971:+
BRCA	cis	rs7267979	0.586	rs6050439	ENSG00000276952.1	RP5-965G21.6	3.59	0.000353	0.0184	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25211695	chr20:25284915~25285588:-
BRCA	cis	rs7618501	1	rs9855505	ENSG00000228008.1	CTD-2330K9.3	-3.59	0.000353	0.0184	-0.11	-0.11	Intelligence (multi-trait analysis);	chr3:49754725	chr3:49903845~49916937:+
BRCA	cis	rs4462272	0.557	rs12784396	ENSG00000230224.1	PHBP9	3.59	0.000353	0.0184	0.1	0.11	Age-related hearing impairment (SNP x SNP interaction);	chr10:100267650	chr10:100248271~100249095:+
BRCA	cis	rs66887589	0.72	rs11724758	ENSG00000225892.3	RP11-384K6.2	3.59	0.000353	0.0184	0.1	0.11	Diastolic blood pressure;	chr4:119318723	chr4:118632274~118634759:+
BRCA	cis	rs10129255	1	rs11621409	ENSG00000211959.2	IGHV4-39	3.58	0.000353	0.0184	0.09	0.11	Kawasaki disease;	chr14:106695603	chr14:106421711~106422218:-
BRCA	cis	rs6708331	0.938	rs13000514	ENSG00000231024.1	AC092431.3	-3.58	0.000353	0.0184	-0.16	-0.11	Obesity-related traits;	chr2:70167884	chr2:69700192~69713847:-
BRCA	cis	rs7520050	0.966	rs6677007	ENSG00000234329.1	RP11-767N6.2	-3.58	0.000353	0.0184	-0.1	-0.11	Reticulocyte count;Red blood cell count;	chr1:45934918	chr1:45651039~45651826:-
BRCA	cis	rs7520050	0.966	rs4660898	ENSG00000234329.1	RP11-767N6.2	-3.58	0.000353	0.0184	-0.1	-0.11	Reticulocyte count;Red blood cell count;	chr1:45936499	chr1:45651039~45651826:-
BRCA	cis	rs2227564	0.729	rs2688615	ENSG00000279689.1	RP11-574K11.32	3.58	0.000353	0.0184	0.12	0.11	Crohn's disease;Inflammatory bowel disease;	chr10:73891741	chr10:73769264~73772862:-
BRCA	cis	rs10005067	0.967	rs4693906	ENSG00000249001.4	RP11-742B18.1	-3.58	0.000353	0.0184	-0.13	-0.11	Total body bone mineral density (age 30-45);	chr4:87901351	chr4:87568035~87733956:-
BRCA	cis	rs7577696	0.962	rs2235134	ENSG00000276334.1	AL133243.1	-3.58	0.000353	0.0184	-0.14	-0.11	Inflammatory biomarkers;	chr2:32107474	chr2:32521927~32523547:+
BRCA	cis	rs7267979	0.966	rs2387885	ENSG00000274414.1	RP5-965G21.4	3.58	0.000353	0.0184	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25434588	chr20:25239007~25245229:-
BRCA	cis	rs7267979	1	rs2424713	ENSG00000274414.1	RP5-965G21.4	-3.58	0.000353	0.0184	-0.13	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25437846	chr20:25239007~25245229:-
BRCA	cis	rs1007738	0.507	rs7940240	ENSG00000200376.1	RNU5E-10P	3.58	0.000353	0.0184	0.14	0.11	Bone mineral density (hip);	chr11:47181517	chr11:47576471~47576588:-
BRCA	cis	rs875971	0.522	rs1617484	ENSG00000223473.2	GS1-124K5.3	3.58	0.000353	0.0184	0.08	0.11	Aortic root size;	chr7:65998108	chr7:66491049~66493566:-
BRCA	cis	rs8114671	0.562	rs4911161	ENSG00000126005.14	MMP24-AS1	-3.58	0.000353	0.0184	-0.13	-0.11	Height;	chr20:34814428	chr20:35216462~35278131:-
BRCA	cis	rs789852	0.867	rs1773176	ENSG00000231770.4	TMEM44-AS1	-3.58	0.000353	0.0184	-0.19	-0.11	QT interval;	chr3:194595509	chr3:194584011~194590260:+
BRCA	cis	rs10849893	0.576	rs10849886	ENSG00000258435.1	RP11-711D18.2	-3.58	0.000353	0.0184	-0.12	-0.11	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr12:121449118	chr12:121391962~121399859:+
BRCA	cis	rs7089973	0.872	rs35010779	ENSG00000236799.1	RP11-383C6.2	-3.58	0.000353	0.0184	-0.14	-0.11	Bipolar disorder or attention deficit hyperactivity disorder;	chr10:114872057	chr10:114994657~114996593:+
BRCA	cis	rs7089973	0.872	rs35622181	ENSG00000236799.1	RP11-383C6.2	-3.58	0.000353	0.0184	-0.14	-0.11	Bipolar disorder or attention deficit hyperactivity disorder;	chr10:114872217	chr10:114994657~114996593:+
BRCA	cis	rs7089973	0.872	rs7074729	ENSG00000236799.1	RP11-383C6.2	-3.58	0.000353	0.0184	-0.14	-0.11	Bipolar disorder or attention deficit hyperactivity disorder;	chr10:114872498	chr10:114994657~114996593:+
BRCA	cis	rs11098499	0.82	rs28578366	ENSG00000260091.1	RP11-33B1.4	3.58	0.000353	0.0184	0.1	0.11	Corneal astigmatism;	chr4:119615750	chr4:119409333~119410233:+
BRCA	cis	rs524281	0.861	rs10791858	ENSG00000255557.1	RP11-770G2.2	3.58	0.000353	0.0184	0.15	0.11	Electroencephalogram traits;	chr11:66210925	chr11:65745729~65771585:+
BRCA	cis	rs524281	0.817	rs10791859	ENSG00000255557.1	RP11-770G2.2	3.58	0.000353	0.0184	0.15	0.11	Electroencephalogram traits;	chr11:66210982	chr11:65745729~65771585:+
BRCA	cis	rs9420	0.528	rs34052104	ENSG00000265566.2	RN7SL605P	-3.58	0.000353	0.0184	-0.16	-0.11	Schizophrenia;	chr11:57617046	chr11:57528085~57528365:-
BRCA	cis	rs11098499	0.863	rs6833334	ENSG00000260404.2	RP11-384K6.6	3.58	0.000353	0.0184	0.11	0.11	Corneal astigmatism;	chr4:119583072	chr4:118591773~118633729:+
BRCA	cis	rs3176789	0.767	rs2110451	ENSG00000256673.1	RP11-599J14.2	3.58	0.000353	0.0184	0.13	0.11	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9778751	chr12:9398355~9414851:-
BRCA	cis	rs11148252	0.74	rs9536052	ENSG00000198384.8	TPTE2P3	-3.58	0.000353	0.0184	-0.13	-0.11	Lewy body disease;	chr13:52386574	chr13:52522632~52586906:+
BRCA	cis	rs2412819	0.571	rs528764	ENSG00000201136.1	RNU6-353P	-3.58	0.000353	0.0184	-0.15	-0.11	Lung cancer;	chr15:43838650	chr15:43702363~43702470:+
BRCA	cis	rs2562456	0.558	rs62108173	ENSG00000268658.4	LINC00664	3.58	0.000353	0.0184	0.19	0.11	Pain;	chr19:21244386	chr19:21483374~21503238:+
BRCA	cis	rs10129255	0.912	rs61997792	ENSG00000211967.3	IGHV3-53	-3.58	0.000353	0.0184	-0.08	-0.11	Kawasaki disease;	chr14:106799304	chr14:106592676~106593347:-
BRCA	cis	rs495337	0.736	rs633829	ENSG00000224397.4	LINC01272	-3.58	0.000353	0.0184	-0.11	-0.11	Psoriasis;	chr20:49876754	chr20:50267486~50279795:+
BRCA	cis	rs12303914	0.676	rs3759272	ENSG00000256682.2	TAS2R12	3.58	0.000353	0.0184	0.13	0.11	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr12:10305588	chr12:10894943~10896952:-
BRCA	cis	rs7020830	0.789	rs17408112	ENSG00000230188.1	RP11-405L18.4	-3.58	0.000353	0.0184	-0.14	-0.11	Schizophrenia;	chr9:37114068	chr9:37490421~37490893:-
BRCA	cis	rs848490	0.851	rs1130039	ENSG00000214293.7	APTR	3.58	0.000353	0.0184	0.14	0.11	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77657810	chr7:77657660~77696265:-
BRCA	cis	rs71520386	0.846	rs17778126	ENSG00000179428.2	AC073072.5	3.58	0.000353	0.0184	0.15	0.11	Fibrinogen levels;	chr7:22779340	chr7:22725395~22727620:-
BRCA	cis	rs818427	0.964	rs1093677	ENSG00000279522.1	CTC-487M23.6	3.58	0.000353	0.0184	0.12	0.11	Total body bone mineral density;	chr5:112883003	chr5:112894933~112896531:+
BRCA	cis	rs9866825	0.967	rs6767747	ENSG00000227110.5	LMCD1-AS1	3.58	0.000353	0.0184	0.13	0.11	QT interval;	chr3:8204048	chr3:7952805~8611924:-
BRCA	cis	rs875971	0.862	rs1875057	ENSG00000271064.1	RP11-792A8.3	3.58	0.000353	0.0184	0.13	0.11	Aortic root size;	chr7:66266868	chr7:66748838~66749077:-
BRCA	cis	rs875971	0.862	rs6960446	ENSG00000271064.1	RP11-792A8.3	3.58	0.000353	0.0184	0.13	0.11	Aortic root size;	chr7:66268272	chr7:66748838~66749077:-
BRCA	cis	rs875971	0.789	rs10260426	ENSG00000271064.1	RP11-792A8.3	3.58	0.000353	0.0184	0.13	0.11	Aortic root size;	chr7:66271055	chr7:66748838~66749077:-
BRCA	cis	rs4805834	0.843	rs11671809	ENSG00000201388.1	SNORA68	-3.58	0.000353	0.0184	-0.18	-0.11	Creatinine levels;	chr19:32841610	chr19:32608337~32608469:-
BRCA	cis	rs55780018	0.645	rs73058939	ENSG00000224137.1	AC079767.4	3.58	0.000354	0.0184	0.09	0.11	Systolic blood pressure;	chr2:207638487	chr2:207662375~207667024:+
BRCA	cis	rs2305707	0.544	rs2445757	ENSG00000273674.3	CTD-2378E12.1	3.58	0.000354	0.0184	0.21	0.11	Height;	chr15:51297568	chr15:50839875~50908599:-
BRCA	cis	rs2305707	0.544	rs2470155	ENSG00000273674.3	CTD-2378E12.1	3.58	0.000354	0.0184	0.21	0.11	Height;	chr15:51298556	chr15:50839875~50908599:-
BRCA	cis	rs11892454	0.565	rs13422139	ENSG00000217643.1	PTGES3P2	-3.58	0.000354	0.0184	-0.12	-0.11	Heschl's gyrus morphology;	chr2:25843701	chr2:25822469~25822950:+
BRCA	cis	rs7824557	0.815	rs2736372	ENSG00000255020.1	AF131216.5	3.58	0.000354	0.0184	0.13	0.11	Retinal vascular caliber;	chr8:11248532	chr8:11345748~11347502:-
BRCA	cis	rs9868809	0.881	rs3821876	ENSG00000225399.4	RP11-3B7.1	-3.58	0.000354	0.0184	-0.18	-0.11	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48630961	chr3:49260085~49261316:+
BRCA	cis	rs7771547	0.519	rs9654588	ENSG00000224666.3	RP1-50J22.4	3.58	0.000354	0.0184	0.14	0.11	Platelet distribution width;	chr6:36396146	chr6:36386831~36393462:+
BRCA	cis	rs6754311	0.517	rs1469995	ENSG00000231890.6	DARS-AS1	-3.58	0.000354	0.0185	-0.16	-0.11	Mosquito bite size;	chr2:135784989	chr2:135985176~136022593:+
BRCA	cis	rs7339483	0.702	rs10411891	ENSG00000268442.1	CTD-2027I19.2	3.58	0.000354	0.0185	0.22	0.11	Discordance in emotional problems in monozygotic twins;	chr19:24185732	chr19:24162370~24163425:-
BRCA	cis	rs67073037	0.955	rs12611829	ENSG00000230730.1	AC074011.2	-3.58	0.000354	0.0185	-0.15	-0.11	Breast cancer;Breast cancer (estrogen-receptor negative);	chr2:28921590	chr2:28633282~28664540:-
BRCA	cis	rs67073037	0.955	rs12620680	ENSG00000230730.1	AC074011.2	-3.58	0.000354	0.0185	-0.15	-0.11	Breast cancer;Breast cancer (estrogen-receptor negative);	chr2:28921745	chr2:28633282~28664540:-
BRCA	cis	rs11098499	0.955	rs13113112	ENSG00000260091.1	RP11-33B1.4	-3.58	0.000354	0.0185	-0.1	-0.11	Corneal astigmatism;	chr4:119234885	chr4:119409333~119410233:+
BRCA	cis	rs8105895	0.935	rs7259971	ENSG00000269345.1	VN1R85P	3.58	0.000354	0.0185	0.16	0.11	Body mass index (change over time);	chr19:22054517	chr19:22174766~22175191:-
BRCA	cis	rs8105895	0.935	rs6511316	ENSG00000269345.1	VN1R85P	3.58	0.000354	0.0185	0.16	0.11	Body mass index (change over time);	chr19:22054827	chr19:22174766~22175191:-
BRCA	cis	rs8105895	0.935	rs10406553	ENSG00000269345.1	VN1R85P	3.58	0.000354	0.0185	0.16	0.11	Body mass index (change over time);	chr19:22054999	chr19:22174766~22175191:-
BRCA	cis	rs8105895	0.935	rs10406653	ENSG00000269345.1	VN1R85P	3.58	0.000354	0.0185	0.16	0.11	Body mass index (change over time);	chr19:22055221	chr19:22174766~22175191:-
BRCA	cis	rs8105895	0.935	rs10407250	ENSG00000269345.1	VN1R85P	3.58	0.000354	0.0185	0.16	0.11	Body mass index (change over time);	chr19:22055349	chr19:22174766~22175191:-
BRCA	cis	rs8105895	0.935	rs10412953	ENSG00000269345.1	VN1R85P	3.58	0.000354	0.0185	0.16	0.11	Body mass index (change over time);	chr19:22055680	chr19:22174766~22175191:-
BRCA	cis	rs8105895	0.935	rs4510150	ENSG00000269345.1	VN1R85P	3.58	0.000354	0.0185	0.16	0.11	Body mass index (change over time);	chr19:22056867	chr19:22174766~22175191:-
BRCA	cis	rs8105895	0.935	rs4542784	ENSG00000269345.1	VN1R85P	3.58	0.000354	0.0185	0.16	0.11	Body mass index (change over time);	chr19:22056949	chr19:22174766~22175191:-
BRCA	cis	rs8105895	0.935	rs4257328	ENSG00000269345.1	VN1R85P	3.58	0.000354	0.0185	0.16	0.11	Body mass index (change over time);	chr19:22057288	chr19:22174766~22175191:-
BRCA	cis	rs8105895	0.935	rs10404669	ENSG00000269345.1	VN1R85P	3.58	0.000354	0.0185	0.16	0.11	Body mass index (change over time);	chr19:22058416	chr19:22174766~22175191:-
BRCA	cis	rs8105895	0.877	rs9973249	ENSG00000269345.1	VN1R85P	3.58	0.000354	0.0185	0.16	0.11	Body mass index (change over time);	chr19:22059358	chr19:22174766~22175191:-
BRCA	cis	rs8105895	0.877	rs2163837	ENSG00000269345.1	VN1R85P	3.58	0.000354	0.0185	0.16	0.11	Body mass index (change over time);	chr19:22059434	chr19:22174766~22175191:-
BRCA	cis	rs8105895	0.935	rs2163835	ENSG00000269345.1	VN1R85P	3.58	0.000354	0.0185	0.16	0.11	Body mass index (change over time);	chr19:22059877	chr19:22174766~22175191:-
BRCA	cis	rs8105895	0.935	rs28857211	ENSG00000269345.1	VN1R85P	3.58	0.000354	0.0185	0.16	0.11	Body mass index (change over time);	chr19:22060302	chr19:22174766~22175191:-
BRCA	cis	rs8105895	0.935	rs28894669	ENSG00000269345.1	VN1R85P	3.58	0.000354	0.0185	0.16	0.11	Body mass index (change over time);	chr19:22060462	chr19:22174766~22175191:-
BRCA	cis	rs56046484	0.956	rs12908535	ENSG00000230373.7	GOLGA6L5P	3.58	0.000354	0.0185	0.17	0.11	Testicular germ cell tumor;	chr15:85058294	chr15:84507885~84516814:-
BRCA	cis	rs8024893	0.764	rs7178760	ENSG00000270055.1	CTD-3092A11.2	3.58	0.000354	0.0185	0.17	0.11	Red cell distribution width;	chr15:31239170	chr15:30487963~30490313:+
BRCA	cis	rs2998286	0.723	rs332126	ENSG00000237128.1	RP11-351M16.3	3.58	0.000354	0.0185	0.14	0.11	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28556866	chr10:28433008~28495813:-
BRCA	cis	rs2998286	0.723	rs332128	ENSG00000237128.1	RP11-351M16.3	3.58	0.000354	0.0185	0.14	0.11	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28559399	chr10:28433008~28495813:-
BRCA	cis	rs11039100	1	rs12792952	ENSG00000224295.2	AC087380.14	3.58	0.000354	0.0185	0.2	0.11	Peripheral arterial disease (traffic-related air pollution interaction);	chr11:5805583	chr11:5518441~5524955:-
BRCA	cis	rs2486012	0.678	rs3011218	ENSG00000237950.1	RP11-7O11.3	3.58	0.000354	0.0185	0.18	0.11	Intelligence (multi-trait analysis);	chr1:43837657	chr1:43944370~43946551:-
BRCA	cis	rs9470794	1	rs75192044	ENSG00000204110.6	RP1-153P14.8	-3.58	0.000354	0.0185	-0.23	-0.11	Type 2 diabetes;	chr6:38002699	chr6:37507348~37535616:+
BRCA	cis	rs6943931	1	rs9648283	ENSG00000230658.1	KLHL7-AS1	-3.58	0.000354	0.0185	-0.15	-0.11	Diabetic kidney disease;	chr7:22377349	chr7:23101228~23105703:-
BRCA	cis	rs17270561	0.609	rs9358885	ENSG00000272462.2	U91328.19	-3.58	0.000354	0.0185	-0.14	-0.11	Iron status biomarkers;	chr6:25757796	chr6:25992662~26001775:+
BRCA	cis	rs4589258	0.966	rs4463818	ENSG00000280367.1	RP11-121L10.2	3.58	0.000354	0.0185	0.13	0.11	Intelligence (multi-trait analysis);	chr11:90774204	chr11:90223153~90226538:+
BRCA	cis	rs172166	0.694	rs203876	ENSG00000219891.2	ZSCAN12P1	3.58	0.000354	0.0185	0.14	0.11	Cardiac Troponin-T levels;	chr6:28078895	chr6:28091154~28093664:+
BRCA	cis	rs62025270	0.688	rs10163064	ENSG00000259367.1	RP11-815J21.4	3.58	0.000354	0.0185	0.11	0.11	Idiopathic pulmonary fibrosis;	chr15:85734289	chr15:85619623~85670948:-
BRCA	cis	rs8180040	0.701	rs62248439	ENSG00000271161.1	BOLA2P2	-3.58	0.000354	0.0185	-0.12	-0.11	Colorectal cancer;	chr3:46954958	chr3:47499841~47500407:+
BRCA	cis	rs1355223	0.902	rs4465347	ENSG00000271369.1	RP11-350D17.3	-3.58	0.000354	0.0185	-0.13	-0.11	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34705786	chr11:34709600~34710161:+
BRCA	cis	rs1949733	1	rs1949733	ENSG00000251615.3	RP11-774O3.3	3.58	0.000354	0.0185	0.12	0.11	Response to antineoplastic agents;	chr4:8501632	chr4:8355090~8358338:-
BRCA	cis	rs911555	0.706	rs10129426	ENSG00000269940.1	RP11-73M18.7	3.58	0.000354	0.0185	0.11	0.11	Intelligence (multi-trait analysis);	chr14:103552118	chr14:103694560~103695170:+
BRCA	cis	rs73198271	0.74	rs1039911	ENSG00000233609.3	RP11-62H7.2	-3.58	0.000354	0.0185	-0.11	-0.11	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8790696	chr8:8961200~8979025:+
BRCA	cis	rs3767633	0.8	rs2341479	ENSG00000229808.1	RP11-456P18.2	-3.58	0.000354	0.0185	-0.19	-0.11	IgG glycosylation;	chr1:161915562	chr1:161890833~161892196:+
BRCA	cis	rs7903456	0.648	rs9420429	ENSG00000200253.1	RNU6-529P	3.58	0.000354	0.0185	0.14	0.11	Gout;Renal underexcretion gout;	chr10:87049058	chr10:87041238~87041341:-
BRCA	cis	rs4699052	1	rs6533059	ENSG00000251288.2	RP11-10L12.2	-3.58	0.000354	0.0185	-0.13	-0.11	Testicular germ cell tumor;	chr4:103212219	chr4:102751401~102752641:+
BRCA	cis	rs77106637	1	rs11605166	ENSG00000256633.1	RP11-169D4.2	3.58	0.000354	0.0185	0.15	0.11	Type 2 diabetes;	chr11:72958732	chr11:72584572~72587979:+
BRCA	cis	rs2243480	0.522	rs431168	ENSG00000275400.1	RP4-756H11.5	3.58	0.000354	0.0185	0.25	0.11	Diabetic kidney disease;	chr7:66046617	chr7:66553805~66554199:-
BRCA	cis	rs10800309	0.71	rs6696854	ENSG00000225217.1	HSPA7	3.58	0.000354	0.0185	0.13	0.11	Inflammatory bowel disease;Ulcerative colitis;	chr1:161494024	chr1:161606291~161608217:+
BRCA	cis	rs1355223	0.902	rs1597962	ENSG00000271369.1	RP11-350D17.3	-3.58	0.000354	0.0185	-0.13	-0.11	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34705625	chr11:34709600~34710161:+
BRCA	cis	rs7618501	1	rs1491986	ENSG00000228008.1	CTD-2330K9.3	-3.58	0.000354	0.0185	-0.1	-0.11	Intelligence (multi-trait analysis);	chr3:49701653	chr3:49903845~49916937:+
BRCA	cis	rs7131987	0.874	rs10843366	ENSG00000257176.2	RP11-996F15.2	-3.58	0.000354	0.0185	-0.13	-0.11	QT interval;	chr12:29254970	chr12:29280418~29317848:-
BRCA	cis	rs7131987	0.845	rs2042511	ENSG00000257176.2	RP11-996F15.2	-3.58	0.000354	0.0185	-0.13	-0.11	QT interval;	chr12:29255847	chr12:29280418~29317848:-
BRCA	cis	rs10876993	0.928	rs7136269	ENSG00000270039.1	RP11-571M6.17	3.58	0.000354	0.0185	0.15	0.11	Celiac disease or Rheumatoid arthritis;	chr12:57682154	chr12:57803838~57804415:+
BRCA	cis	rs865483	0.828	rs1016680	ENSG00000276054.1	RP11-378E13.3	-3.58	0.000354	0.0185	-0.15	-0.11	Monocyte count;	chr17:37514283	chr17:37386886~37387926:+
BRCA	cis	rs801193	1	rs3800812	ENSG00000275400.1	RP4-756H11.5	-3.58	0.000354	0.0185	-0.13	-0.11	Aortic root size;	chr7:66758474	chr7:66553805~66554199:-
BRCA	cis	rs801193	1	rs4279493	ENSG00000275400.1	RP4-756H11.5	-3.58	0.000354	0.0185	-0.13	-0.11	Aortic root size;	chr7:66761633	chr7:66553805~66554199:-
BRCA	cis	rs6142618	0.562	rs4911547	ENSG00000224452.1	RSL24D1P6	3.58	0.000354	0.0185	0.15	0.11	Inflammatory bowel disease;	chr20:32145670	chr20:32170390~32170790:-
BRCA	cis	rs465969	0.744	rs9400477	ENSG00000271789.1	RP5-1112D6.7	-3.58	0.000354	0.0185	-0.26	-0.11	Psoriasis;	chr6:111469440	chr6:111297126~111298510:+
BRCA	cis	rs2108622	0.727	rs62106156	ENSG00000214049.6	UCA1	3.58	0.000354	0.0185	0.16	0.11	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15869614	chr19:15828961~15836320:+
BRCA	cis	rs910873	0.505	rs2378249	ENSG00000202150.1	RNU6-407P	3.58	0.000354	0.0185	0.16	0.11	Melanoma;	chr20:34630286	chr20:35030317~35030420:-
BRCA	cis	rs1468333	0.567	rs2240334	ENSG00000206989.1	SNORD63	3.58	0.000354	0.0185	0.12	0.11	Resting heart rate;	chr5:138427926	chr5:138561043~138561110:-
BRCA	cis	rs911119	0.913	rs13038990	ENSG00000270001.1	RP11-218C14.8	-3.58	0.000354	0.0185	-0.14	-0.11	Chronic kidney disease;	chr20:23608416	chr20:23631826~23632316:-
BRCA	cis	rs4699052	0.963	rs6533066	ENSG00000251288.2	RP11-10L12.2	-3.58	0.000354	0.0185	-0.13	-0.11	Testicular germ cell tumor;	chr4:103242450	chr4:102751401~102752641:+
BRCA	cis	rs10043228	1	rs1592917	ENSG00000271918.1	CTD-2287O16.5	-3.58	0.000354	0.0185	-0.16	-0.11	Asthma or chronic obstructive pulmonary disease;	chr5:116233717	chr5:116083807~116085416:-
BRCA	cis	rs9470794	1	rs56114002	ENSG00000204110.6	RP1-153P14.8	-3.58	0.000354	0.0185	-0.17	-0.11	Type 2 diabetes;	chr6:38161265	chr6:37507348~37535616:+
BRCA	cis	rs1018697	1	rs7909612	ENSG00000236937.2	PTGES3P4	3.58	0.000354	0.0185	0.14	0.11	Colorectal adenoma (advanced);	chr10:102801699	chr10:102845595~102845950:+
BRCA	cis	rs295490	0.748	rs78230813	ENSG00000178631.7	ACTG1P1	-3.58	0.000355	0.0185	-0.23	-0.11	PR interval in Tripanosoma cruzi seropositivity;	chr3:139441345	chr3:139493809~139494937:+
BRCA	cis	rs72766638	0.895	rs55924785	ENSG00000235106.7	LINC00094	3.58	0.000355	0.0185	0.14	0.11	Mosquito bite size;	chr9:134064464	chr9:134025439~134034666:+
BRCA	cis	rs2031532	0.587	rs7317772	ENSG00000236577.1	SNRPGP14	3.58	0.000355	0.0185	0.13	0.11	Cardiac hypertrophy;	chr13:49468661	chr13:49488970~49489364:+
BRCA	cis	rs6142618	0.562	rs6142608	ENSG00000275576.1	RP5-836N17.4	-3.58	0.000355	0.0185	-0.12	-0.11	Inflammatory bowel disease;	chr20:32103140	chr20:32116171~32116629:+
BRCA	cis	rs72928364	0.86	rs13085636	ENSG00000256628.3	ZBTB11-AS1	3.58	0.000355	0.0185	0.22	0.11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:101078260	chr3:101676475~101679217:+
BRCA	cis	rs9287719	0.967	rs6432113	ENSG00000224177.5	LINC00570	-3.58	0.000355	0.0185	-0.13	-0.11	Prostate cancer;	chr2:10604763	chr2:11393981~11403077:+
BRCA	cis	rs11088226	0.681	rs2833903	ENSG00000186842.4	LINC00846	-3.58	0.000355	0.0185	-0.18	-0.11	Gastritis;	chr21:32568509	chr21:32572238~32575881:-
BRCA	cis	rs71566846	0.649	rs9464431	ENSG00000272541.1	XXbac-BPGBPG55C20.1	3.58	0.000355	0.0185	0.18	0.11	Coronary artery disease;	chr6:57277368	chr6:57855891~57856468:-
BRCA	cis	rs344364	0.511	rs1657134	ENSG00000219027.2	RPS3AP2	3.58	0.000355	0.0185	0.16	0.11	Glomerular filtration rate in chronic kidney disease;	chr16:1903126	chr16:1477830~1478583:+
BRCA	cis	rs344364	0.511	rs2906912	ENSG00000219027.2	RPS3AP2	3.58	0.000355	0.0185	0.16	0.11	Glomerular filtration rate in chronic kidney disease;	chr16:1903150	chr16:1477830~1478583:+
BRCA	cis	rs4819052	0.851	rs13050359	ENSG00000215447.6	BX322557.10	-3.58	0.000355	0.0185	-0.11	-0.11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45252756	chr21:45288052~45291738:+
BRCA	cis	rs1355223	0.902	rs1588353	ENSG00000271369.1	RP11-350D17.3	-3.58	0.000355	0.0185	-0.13	-0.11	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34709267	chr11:34709600~34710161:+
BRCA	cis	rs9295536	0.651	rs9460707	ENSG00000260455.1	NBAT1	-3.58	0.000355	0.0185	-0.12	-0.11	Neuroblastoma;	chr6:22137419	chr6:22134957~22147193:-
BRCA	cis	rs12723316	0.932	rs12754424	ENSG00000233008.4	RP11-475O6.1	-3.58	0.000355	0.0185	-0.21	-0.11	Schizophrenia;	chr1:83819890	chr1:83575776~83861023:-
BRCA	cis	rs1250259	0.519	rs34255697	ENSG00000225166.1	AC012462.2	-3.58	0.000355	0.0185	-0.14	-0.11	Coronary artery disease;Pulse pressure;	chr2:215401502	chr2:215453707~215463871:+
BRCA	cis	rs9635324	0.964	rs11633883	ENSG00000223313.1	RNU6-516P	3.58	0.000355	0.0185	0.14	0.11	Blood metabolite ratios;Blood metabolite levels;	chr15:40422202	chr15:40529570~40529673:+
BRCA	cis	rs3742264	0.656	rs9534258	ENSG00000235903.6	CPB2-AS1	3.58	0.000355	0.0185	0.13	0.11	Blood protein levels;	chr13:45946738	chr13:46052806~46113332:+
BRCA	cis	rs889956	0.68	rs9789665	ENSG00000233251.6	AC007743.1	-3.58	0.000355	0.0185	-0.13	-0.11	Educational attainment;	chr2:56992861	chr2:56173534~56185770:-
BRCA	cis	rs10876993	0.89	rs2619441	ENSG00000270039.1	RP11-571M6.17	3.58	0.000355	0.0185	0.15	0.11	Celiac disease or Rheumatoid arthritis;	chr12:57689232	chr12:57803838~57804415:+
BRCA	cis	rs1355223	0.902	rs1901831	ENSG00000271369.1	RP11-350D17.3	-3.58	0.000355	0.0185	-0.13	-0.11	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34703628	chr11:34709600~34710161:+
BRCA	cis	rs1355223	0.902	rs34610590	ENSG00000271369.1	RP11-350D17.3	-3.58	0.000355	0.0185	-0.13	-0.11	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34703893	chr11:34709600~34710161:+
BRCA	cis	rs6142618	0.562	rs6061159	ENSG00000275576.1	RP5-836N17.4	-3.58	0.000355	0.0185	-0.12	-0.11	Inflammatory bowel disease;	chr20:32104119	chr20:32116171~32116629:+
BRCA	cis	rs6142618	0.562	rs6142609	ENSG00000275576.1	RP5-836N17.4	-3.58	0.000355	0.0185	-0.12	-0.11	Inflammatory bowel disease;	chr20:32104232	chr20:32116171~32116629:+
BRCA	cis	rs10876993	0.928	rs1628552	ENSG00000270039.1	RP11-571M6.17	3.58	0.000355	0.0185	0.15	0.11	Celiac disease or Rheumatoid arthritis;	chr12:57688359	chr12:57803838~57804415:+
BRCA	cis	rs7789940	0.904	rs56919252	ENSG00000231087.2	FDPSP7	-3.58	0.000355	0.0185	-0.14	-0.11	Multiple sclerosis;	chr7:76308203	chr7:76968197~76969250:-
BRCA	cis	rs875971	1	rs12698523	ENSG00000272831.1	RP11-792A8.4	3.58	0.000355	0.0185	0.1	0.11	Aortic root size;	chr7:66503126	chr7:66739829~66740385:-
BRCA	cis	rs12468226	0.873	rs3181153	ENSG00000272966.1	RP11-686O6.1	-3.58	0.000355	0.0185	-0.18	-0.11	Urate levels;	chr2:202205155	chr2:202336739~202337200:+
BRCA	cis	rs4835473	0.864	rs17750354	ENSG00000246448.2	RP13-578N3.3	-3.58	0.000355	0.0185	-0.12	-0.11	Immature fraction of reticulocytes;	chr4:143737352	chr4:143700257~143865072:+
BRCA	cis	rs35520189	0.857	rs2466446	ENSG00000231747.1	AC079922.2	3.58	0.000355	0.0185	0.11	0.11	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:112865703	chr2:112621809~112622167:-
BRCA	cis	rs250518	0.926	rs7723498	ENSG00000271926.1	CTD-2376I4.1	3.58	0.000355	0.0185	0.15	0.11	Mean corpuscular hemoglobin concentration;	chr5:72791470	chr5:72953635~72954274:-
BRCA	cis	rs321358	0.731	rs7940380	ENSG00000271390.1	RP11-89C3.3	3.58	0.000355	0.0185	0.17	0.11	Body mass index;	chr11:111149974	chr11:111089870~111090368:-
BRCA	cis	rs8141529	0.702	rs5762870	ENSG00000226471.5	CTA-292E10.6	-3.58	0.000355	0.0185	-0.13	-0.11	Lymphocyte counts;	chr22:28865171	chr22:28800683~28848559:+
BRCA	cis	rs6893300	0.961	rs55827522	ENSG00000225051.5	HMGB3P22	3.58	0.000355	0.0185	0.15	0.11	Resting heart rate;	chr5:179750115	chr5:179679032~179694768:+
BRCA	cis	rs11892454	0.599	rs890681	ENSG00000217643.1	PTGES3P2	-3.58	0.000355	0.0185	-0.12	-0.11	Heschl's gyrus morphology;	chr2:25755618	chr2:25822469~25822950:+
BRCA	cis	rs7208859	0.623	rs11658022	ENSG00000276250.1	CTD-2349P21.12	-3.58	0.000356	0.0185	-0.19	-0.11	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30758341	chr17:30803654~30804077:+
BRCA	cis	rs2562456	0.833	rs2968076	ENSG00000268555.1	RP11-678G14.3	-3.58	0.000356	0.0185	-0.14	-0.11	Pain;	chr19:21454299	chr19:21570822~21587322:-
BRCA	cis	rs1722141	0.633	rs2132572	ENSG00000237471.1	AC073115.6	3.58	0.000356	0.0185	0.15	0.11	Sitting height ratio;	chr7:45921946	chr7:45969657~45980191:+
BRCA	cis	rs3764021	0.509	rs10772072	ENSG00000260423.1	RP13-735L24.1	-3.58	0.000356	0.0185	-0.13	-0.11	Type 1 diabetes;	chr12:9717335	chr12:9367464~9397617:+
BRCA	cis	rs9816784	0.566	rs11720913	ENSG00000207650.1	MIR570	3.58	0.000356	0.0185	0.14	0.11	Mean corpuscular hemoglobin;	chr3:196105689	chr3:195699401~195699497:+
BRCA	cis	rs7487075	0.828	rs7132228	ENSG00000274723.1	RP11-618L22.1	3.58	0.000356	0.0185	0.13	0.11	Itch intensity from mosquito bite;	chr12:46338178	chr12:46970504~46972155:+
BRCA	cis	rs7487075	0.893	rs4768116	ENSG00000274723.1	RP11-618L22.1	3.58	0.000356	0.0185	0.13	0.11	Itch intensity from mosquito bite;	chr12:46339247	chr12:46970504~46972155:+
BRCA	cis	rs739401	0.611	rs10833048	ENSG00000183562.3	CTC-343N3.1	-3.58	0.000356	0.0185	-0.12	-0.11	Longevity;	chr11:2998810	chr11:2989863~2991344:+
BRCA	cis	rs875971	0.825	rs6951503	ENSG00000229886.1	RP5-1132H15.3	-3.58	0.000356	0.0185	-0.13	-0.11	Aortic root size;	chr7:66253949	chr7:66025126~66031544:-
BRCA	cis	rs875971	1	rs6958271	ENSG00000229886.1	RP5-1132H15.3	3.58	0.000356	0.0185	0.12	0.11	Aortic root size;	chr7:66514344	chr7:66025126~66031544:-
BRCA	cis	rs875971	1	rs6958277	ENSG00000229886.1	RP5-1132H15.3	3.58	0.000356	0.0185	0.12	0.11	Aortic root size;	chr7:66514362	chr7:66025126~66031544:-
BRCA	cis	rs7903456	0.648	rs1923938	ENSG00000200253.1	RNU6-529P	3.58	0.000356	0.0185	0.14	0.11	Gout;Renal underexcretion gout;	chr10:87077623	chr10:87041238~87041341:-
BRCA	cis	rs41308713	0.606	rs77984335	ENSG00000196756.10	SNHG17	-3.58	0.000356	0.0185	-0.25	-0.11	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr20:38444643	chr20:38420588~38435353:-
BRCA	cis	rs11039100	1	rs12366070	ENSG00000224295.2	AC087380.14	3.58	0.000356	0.0185	0.21	0.11	Peripheral arterial disease (traffic-related air pollution interaction);	chr11:5807164	chr11:5518441~5524955:-
BRCA	cis	rs11039100	1	rs12362071	ENSG00000224295.2	AC087380.14	3.58	0.000356	0.0185	0.21	0.11	Peripheral arterial disease (traffic-related air pollution interaction);	chr11:5807220	chr11:5518441~5524955:-
BRCA	cis	rs17221829	0.733	rs11600976	ENSG00000280385.1	AP000648.5	-3.58	0.000356	0.0185	-0.13	-0.11	Anxiety in major depressive disorder;	chr11:89627674	chr11:90193614~90198120:+
BRCA	cis	rs2214681	0.967	rs12532290	ENSG00000273314.1	RP5-1136G13.2	3.58	0.000356	0.0185	0.13	0.11	Bone mineral density;	chr7:148009889	chr7:148696467~148698664:-
BRCA	cis	rs7246657	0.943	rs4801803	ENSG00000267470.4	ZNF571-AS1	-3.58	0.000356	0.0185	-0.15	-0.11	Coronary artery calcification;	chr19:37476021	chr19:37548914~37587348:+
BRCA	cis	rs6088590	1	rs11696546	ENSG00000276073.1	RP5-1125A11.7	-3.58	0.000356	0.0185	-0.13	-0.11	Coronary artery disease;	chr20:34865196	chr20:33985617~33988989:-
BRCA	cis	rs910316	0.737	rs175055	ENSG00000259138.1	RP11-950C14.7	-3.58	0.000356	0.0185	-0.11	-0.11	Height;	chr14:75022243	chr14:75127153~75136930:+
BRCA	cis	rs9329221	0.502	rs11777364	ENSG00000246477.3	AF131216.6	3.58	0.000356	0.0185	0.1	0.11	Neuroticism;	chr8:10431036	chr8:11315859~11325429:-
BRCA	cis	rs1850744	0.826	rs10939504	ENSG00000163612.10	FAM86KP	3.58	0.000356	0.0185	0.26	0.11	Economic and political preferences;	chr4:9765746	chr4:9153296~9165451:+
BRCA	cis	rs6736093	0.966	rs11674883	ENSG00000236307.2	EEF1E1P1	3.58	0.000356	0.0185	0.14	0.11	Coronary artery disease;	chr2:111955492	chr2:111887914~111888741:+
BRCA	cis	rs11992162	0.967	rs10088415	ENSG00000255052.4	FAM66D	3.58	0.000356	0.0186	0.14	0.11	Monocyte count;	chr8:11973316	chr8:12115782~12177550:+
BRCA	cis	rs8058578	1	rs7204278	ENSG00000275263.1	RP11-1072A3.4	-3.58	0.000356	0.0186	-0.14	-0.11	Multiple myeloma;	chr16:30718953	chr16:30956872~30957199:-
BRCA	cis	rs863345	0.604	rs10797021	ENSG00000176320.2	RP11-404O13.5	-3.58	0.000356	0.0186	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158520551	chr1:158197922~158203877:-
BRCA	cis	rs61931739	0.5	rs34080094	ENSG00000258794.3	DUX4L27	3.58	0.000356	0.0186	0.16	0.11	Morning vs. evening chronotype;	chr12:34395017	chr12:34208415~34209675:-
BRCA	cis	rs2562456	0.92	rs2650784	ENSG00000240522.1	RPL7AP10	3.58	0.000356	0.0186	0.12	0.11	Pain;	chr19:21483795	chr19:21149648~21150438:-
BRCA	cis	rs3747113	1	rs9624447	ENSG00000234928.1	AP000344.3	3.58	0.000356	0.0186	0.14	0.11	Gut microbiome composition (summer);	chr22:24285587	chr22:23433564~23435071:+
BRCA	cis	rs930395	0.514	rs6868779	ENSG00000251141.4	RP11-53O19.1	-3.58	0.000356	0.0186	-0.1	-0.11	Breast cancer;	chr5:44885898	chr5:44744900~44808777:-
BRCA	cis	rs4415084	0.652	rs10045264	ENSG00000251141.4	RP11-53O19.1	-3.58	0.000356	0.0186	-0.1	-0.11	Breast cancer;	chr5:44886330	chr5:44744900~44808777:-
BRCA	cis	rs7824557	0.815	rs958648	ENSG00000255020.1	AF131216.5	3.58	0.000356	0.0186	0.13	0.11	Retinal vascular caliber;	chr8:11246386	chr8:11345748~11347502:-
BRCA	cis	rs10761482	0.861	rs10761492	ENSG00000254271.1	RP11-131N11.4	3.58	0.000356	0.0186	0.15	0.11	Schizophrenia;	chr10:60349143	chr10:60734342~60741828:+
BRCA	cis	rs3755021	1	rs2305590	ENSG00000260742.1	RP11-366L5.1	3.58	0.000356	0.0186	0.16	0.11	Monocyte-lymphocyte ratio;	chr2:181481817	chr2:181887851~181891663:-
BRCA	cis	rs7267979	1	rs2257432	ENSG00000274414.1	RP5-965G21.4	-3.58	0.000356	0.0186	-0.13	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25290450	chr20:25239007~25245229:-
BRCA	cis	rs7267979	1	rs2258066	ENSG00000274414.1	RP5-965G21.4	-3.58	0.000356	0.0186	-0.13	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25290690	chr20:25239007~25245229:-
BRCA	cis	rs7267979	1	rs2258135	ENSG00000274414.1	RP5-965G21.4	-3.58	0.000356	0.0186	-0.13	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25291687	chr20:25239007~25245229:-
BRCA	cis	rs10838687	0.8	rs4752983	ENSG00000243802.2	RP11-390K5.1	3.58	0.000356	0.0186	0.15	0.11	Proinsulin levels;	chr11:47330587	chr11:47191181~47191542:-
BRCA	cis	rs10838687	0.8	rs3729805	ENSG00000243802.2	RP11-390K5.1	3.58	0.000356	0.0186	0.15	0.11	Proinsulin levels;	chr11:47331206	chr11:47191181~47191542:-
BRCA	cis	rs2832077	0.506	rs10222093	ENSG00000236056.1	GAPDHP14	3.58	0.000357	0.0186	0.13	0.11	Cognitive test performance;	chr21:28791196	chr21:29222321~29223257:+
BRCA	cis	rs35740288	0.787	rs2291048	ENSG00000259407.1	RP11-158M2.3	3.58	0.000357	0.0186	0.15	0.11	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85682427	chr15:85744109~85750281:-
BRCA	cis	rs1348850	0.837	rs4243388	ENSG00000280374.1	RP11-337N6.3	3.58	0.000357	0.0186	0.15	0.11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177419876	chr2:177317715~177318471:-
BRCA	cis	rs8180040	0.62	rs6442055	ENSG00000280667.1	Y_RNA	3.58	0.000357	0.0186	0.12	0.11	Colorectal cancer;	chr3:47069232	chr3:47501083~47501182:+
BRCA	cis	rs6714710	0.603	rs2278700	ENSG00000228486.8	LINC01125	-3.58	0.000357	0.0186	-0.1	-0.11	Posterior cortical atrophy and Alzheimer's disease;	chr2:97810919	chr2:97664217~97703064:+
BRCA	cis	rs6714710	0.603	rs78006955	ENSG00000228486.8	LINC01125	-3.58	0.000357	0.0186	-0.1	-0.11	Posterior cortical atrophy and Alzheimer's disease;	chr2:97839047	chr2:97664217~97703064:+
BRCA	cis	rs7267979	1	rs6050544	ENSG00000274414.1	RP5-965G21.4	3.58	0.000357	0.0186	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25339592	chr20:25239007~25245229:-
BRCA	cis	rs875971	1	rs1540651	ENSG00000230189.5	GS1-124K5.2	-3.58	0.000357	0.0186	-0.09	-0.11	Aortic root size;	chr7:66185134	chr7:66409143~66490059:-
BRCA	cis	rs2708977	0.665	rs772173	ENSG00000237510.6	AC008268.2	3.58	0.000357	0.0186	0.15	0.11	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96334658	chr2:95789654~95800166:+
BRCA	cis	rs35612822	0.556	rs784543	ENSG00000232485.2	AC098820.3	-3.58	0.000357	0.0186	-0.14	-0.11	Kidney disease (early stage) in type 1 diabetes;	chr2:216393080	chr2:216479030~216498761:-
BRCA	cis	rs10129255	0.556	rs9324093	ENSG00000253359.1	IGHV3-37	3.58	0.000357	0.0186	0.09	0.11	Kawasaki disease;	chr14:106683893	chr14:106396676~106397114:-
BRCA	cis	rs3099143	1	rs7172639	ENSG00000196274.5	Metazoa_SRP	-3.58	0.000357	0.0186	-0.16	-0.11	Recalcitrant atopic dermatitis;	chr15:76872947	chr15:76230048~76230390:-
BRCA	cis	rs3099143	1	rs7174048	ENSG00000196274.5	Metazoa_SRP	-3.58	0.000357	0.0186	-0.16	-0.11	Recalcitrant atopic dermatitis;	chr15:76873075	chr15:76230048~76230390:-
BRCA	cis	rs4950322	0.58	rs4950308	ENSG00000227242.3	NBPF13P	-3.58	0.000357	0.0186	-0.15	-0.11	Protein quantitative trait loci;	chr1:147120092	chr1:147021320~147124525:-
BRCA	cis	rs13256369	0.951	rs13270852	ENSG00000254153.1	CTA-398F10.2	3.58	0.000357	0.0186	0.15	0.11	Obesity-related traits;	chr8:8709343	chr8:8456909~8461337:-
BRCA	cis	rs78487399	0.808	rs17030925	ENSG00000234936.1	AC010883.5	3.58	0.000357	0.0186	0.17	0.11	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43486669	chr2:43229573~43233394:+
BRCA	cis	rs4700393	0.52	rs286158	ENSG00000272308.1	RP11-231G3.1	-3.58	0.000357	0.0186	-0.14	-0.11	Intelligence (multi-trait analysis);	chr5:60638426	chr5:60866457~60866935:-
BRCA	cis	rs28687655	0.681	rs7171289	ENSG00000260773.1	RP11-352G18.2	3.58	0.000357	0.0186	0.11	0.11	Mean corpuscular hemoglobin concentration;	chr15:65414231	chr15:66314914~66331703:-
BRCA	cis	rs2411233	0.967	rs7169140	ENSG00000259278.1	RP11-62C7.2	3.58	0.000357	0.0186	0.13	0.11	Platelet count;	chr15:38979064	chr15:39019233~39024918:+
BRCA	cis	rs2411233	1	rs7168969	ENSG00000259278.1	RP11-62C7.2	3.58	0.000357	0.0186	0.13	0.11	Platelet count;	chr15:38979092	chr15:39019233~39024918:+
BRCA	cis	rs4834770	1	rs10034579	ENSG00000178636.7	RP11-455G16.1	-3.58	0.000357	0.0186	-0.13	-0.11	Blood protein levels;	chr4:119322874	chr4:119192773~119212644:-
BRCA	cis	rs1400816	0.85	rs2037164	ENSG00000228389.1	AC068039.4	-3.58	0.000357	0.0186	-0.2	-0.11	Amyotrophic lateral sclerosis (sporadic);	chr2:171685728	chr2:171773482~171775844:+
BRCA	cis	rs8177876	0.597	rs1048194	ENSG00000261061.1	RP11-303E16.2	3.58	0.000357	0.0186	0.17	0.11	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81031097	chr16:81030770~81031485:+
BRCA	cis	rs11098499	0.826	rs4472123	ENSG00000250412.1	KLHL2P1	3.58	0.000357	0.0186	0.13	0.11	Corneal astigmatism;	chr4:119315475	chr4:119334329~119378233:+
BRCA	cis	rs7239883	0.5	rs16976273	ENSG00000267652.1	RP11-188I24.1	3.58	0.000357	0.0186	0.16	0.11	Waist circumference;Body mass index;	chr18:42515729	chr18:41789162~41789395:-
BRCA	cis	rs2562456	0.55	rs4809143	ENSG00000268555.1	RP11-678G14.3	3.58	0.000357	0.0186	0.16	0.11	Pain;	chr19:21589926	chr19:21570822~21587322:-
BRCA	cis	rs2562456	0.583	rs4809144	ENSG00000268555.1	RP11-678G14.3	3.58	0.000357	0.0186	0.16	0.11	Pain;	chr19:21589928	chr19:21570822~21587322:-
BRCA	cis	rs16958440	0.581	rs11082564	ENSG00000267800.1	RP11-49K24.5	-3.58	0.000357	0.0186	-0.2	-0.11	Sitting height ratio;	chr18:47132778	chr18:47137018~47137290:+
BRCA	cis	rs16958440	0.708	rs62096477	ENSG00000267800.1	RP11-49K24.5	-3.58	0.000357	0.0186	-0.2	-0.11	Sitting height ratio;	chr18:47135939	chr18:47137018~47137290:+
BRCA	cis	rs826838	0.586	rs1843903	ENSG00000257718.1	RP11-396F22.1	3.58	0.000357	0.0186	0.11	0.11	Heart rate;	chr12:38233722	chr12:38906451~38909592:+
BRCA	cis	rs316020	1	rs316009	ENSG00000251988.1	RNU4ATAC18P	-3.58	0.000357	0.0186	-0.21	-0.11	Blood metabolite ratios;	chr6:160254732	chr6:159720415~159720540:-
BRCA	cis	rs13434995	0.513	rs62305268	ENSG00000249700.7	SRD5A3-AS1	-3.58	0.000357	0.0186	-0.16	-0.11	Adiponectin levels;	chr4:55506991	chr4:55363971~55395847:-
BRCA	cis	rs13434995	0.513	rs62305270	ENSG00000249700.7	SRD5A3-AS1	-3.58	0.000357	0.0186	-0.16	-0.11	Adiponectin levels;	chr4:55507842	chr4:55363971~55395847:-
BRCA	cis	rs13434995	0.513	rs7681414	ENSG00000249700.7	SRD5A3-AS1	-3.58	0.000357	0.0186	-0.16	-0.11	Adiponectin levels;	chr4:55508890	chr4:55363971~55395847:-
BRCA	cis	rs13434995	0.513	rs62305271	ENSG00000249700.7	SRD5A3-AS1	-3.58	0.000357	0.0186	-0.16	-0.11	Adiponectin levels;	chr4:55509715	chr4:55363971~55395847:-
BRCA	cis	rs13434995	0.513	rs10462033	ENSG00000249700.7	SRD5A3-AS1	-3.58	0.000357	0.0186	-0.16	-0.11	Adiponectin levels;	chr4:55511552	chr4:55363971~55395847:-
BRCA	cis	rs13434995	0.513	rs1915905	ENSG00000249700.7	SRD5A3-AS1	-3.58	0.000357	0.0186	-0.16	-0.11	Adiponectin levels;	chr4:55512381	chr4:55363971~55395847:-
BRCA	cis	rs13434995	0.513	rs1522109	ENSG00000249700.7	SRD5A3-AS1	-3.58	0.000357	0.0186	-0.16	-0.11	Adiponectin levels;	chr4:55514403	chr4:55363971~55395847:-
BRCA	cis	rs6005451	1	rs12157480	ENSG00000225783.5	MIAT	-3.58	0.000357	0.0186	-0.14	-0.11	Prostate cancer (SNP x SNP interaction);	chr22:27454583	chr22:26646428~26676475:+
BRCA	cis	rs4388249	0.687	rs2301017	ENSG00000271849.1	CTC-332L22.1	-3.58	0.000357	0.0186	-0.15	-0.11	Schizophrenia;	chr5:109863696	chr5:109687802~109688329:-
BRCA	cis	rs2839186	0.934	rs2839194	ENSG00000215424.8	MCM3AP-AS1	3.58	0.000358	0.0186	0.1	0.11	Testicular germ cell tumor;	chr21:46279523	chr21:46229217~46259390:+
BRCA	cis	rs17092148	0.887	rs6059919	ENSG00000250917.1	RP4-785G19.5	3.58	0.000358	0.0186	0.19	0.11	Neuroticism;	chr20:34563741	chr20:34234840~34281173:-
BRCA	cis	rs6918586	0.658	rs198822	ENSG00000272462.2	U91328.19	-3.58	0.000358	0.0186	-0.12	-0.11	Schizophrenia;	chr6:26123311	chr6:25992662~26001775:+
BRCA	cis	rs6479874	0.92	rs7893612	ENSG00000223502.1	RP11-96B5.3	-3.58	0.000358	0.0186	-0.21	-0.11	Migraine;	chr10:51001698	chr10:51062579~51068553:-
BRCA	cis	rs6479874	1	rs6479841	ENSG00000223502.1	RP11-96B5.3	-3.58	0.000358	0.0186	-0.21	-0.11	Migraine;	chr10:51002206	chr10:51062579~51068553:-
BRCA	cis	rs2832077	0.527	rs11088095	ENSG00000176054.6	RPL23P2	-3.58	0.000358	0.0186	-0.12	-0.11	Cognitive test performance;	chr21:28850866	chr21:28997613~28998033:-
BRCA	cis	rs2832077	0.527	rs2142375	ENSG00000176054.6	RPL23P2	-3.58	0.000358	0.0186	-0.12	-0.11	Cognitive test performance;	chr21:28851420	chr21:28997613~28998033:-
BRCA	cis	rs801193	0.613	rs2659900	ENSG00000230189.5	GS1-124K5.2	3.58	0.000358	0.0186	0.09	0.11	Aortic root size;	chr7:66719456	chr7:66409143~66490059:-
BRCA	cis	rs11170468	0.722	rs10876457	ENSG00000257718.1	RP11-396F22.1	-3.58	0.000358	0.0186	-0.14	-0.11	Body mass index;	chr12:39059887	chr12:38906451~38909592:+
BRCA	cis	rs2998286	0.862	rs2790448	ENSG00000237128.1	RP11-351M16.3	3.58	0.000358	0.0186	0.14	0.11	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28512828	chr10:28433008~28495813:-
BRCA	cis	rs2998286	0.822	rs2807734	ENSG00000237128.1	RP11-351M16.3	3.58	0.000358	0.0186	0.14	0.11	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28513036	chr10:28433008~28495813:-
BRCA	cis	rs10456847	0.8	rs4562147	ENSG00000229700.1	RP1-130G2.1	-3.58	0.000358	0.0186	-0.13	-0.11	Chronic periodontitis (mean interproximal clinical attachment level);	chr6:19139738	chr6:20042455~20042940:-
BRCA	cis	rs1009077	0.61	rs2248236	ENSG00000245958.5	RP11-33B1.1	-3.58	0.000358	0.0186	-0.12	-0.11	Endometriosis;	chr4:119572782	chr4:119454791~119552025:+
BRCA	cis	rs1009077	0.61	rs2622499	ENSG00000245958.5	RP11-33B1.1	-3.58	0.000358	0.0186	-0.12	-0.11	Endometriosis;	chr4:119574695	chr4:119454791~119552025:+
BRCA	cis	rs1009077	0.61	rs2622500	ENSG00000245958.5	RP11-33B1.1	-3.58	0.000358	0.0186	-0.12	-0.11	Endometriosis;	chr4:119574951	chr4:119454791~119552025:+
BRCA	cis	rs1009077	0.61	rs12646525	ENSG00000245958.5	RP11-33B1.1	-3.58	0.000358	0.0186	-0.12	-0.11	Endometriosis;	chr4:119581306	chr4:119454791~119552025:+
BRCA	cis	rs1009077	0.61	rs12503853	ENSG00000245958.5	RP11-33B1.1	-3.58	0.000358	0.0186	-0.12	-0.11	Endometriosis;	chr4:119582008	chr4:119454791~119552025:+
BRCA	cis	rs6964587	0.839	rs11767135	ENSG00000188693.7	CYP51A1-AS1	3.58	0.000358	0.0186	0.12	0.11	Breast cancer;	chr7:91921931	chr7:92134604~92180725:+
BRCA	cis	rs6964587	0.869	rs13237856	ENSG00000188693.7	CYP51A1-AS1	3.58	0.000358	0.0186	0.12	0.11	Breast cancer;	chr7:91922474	chr7:92134604~92180725:+
BRCA	cis	rs115575488	0.85	rs116448534	ENSG00000236804.1	RPS3AP12	3.58	0.000358	0.0186	0.2	0.11	Lobe attachment (rater-scored or self-reported);	chr1:119144589	chr1:119126539~119127291:-
BRCA	cis	rs17597773	0.674	rs12073837	ENSG00000257551.1	HLX-AS1	-3.58	0.000358	0.0186	-0.13	-0.11	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220836863	chr1:220832763~220880140:-
BRCA	cis	rs8054556	0.967	rs12918652	ENSG00000261367.1	RP11-455F5.4	-3.58	0.000358	0.0186	-0.12	-0.11	Autism spectrum disorder or schizophrenia;	chr16:29953036	chr16:30107675~30110541:+
BRCA	cis	rs7172809	0.643	rs4886874	ENSG00000260139.5	CSPG4P13	3.58	0.000358	0.0186	0.13	0.11	Glucose homeostasis traits;	chr15:77545744	chr15:77894684~77904674:+
BRCA	cis	rs4243971	0.516	rs6057567	ENSG00000275576.1	RP5-836N17.4	-3.58	0.000358	0.0186	-0.12	-0.11	Inflammatory bowel disease;Crohn's disease;	chr20:32378588	chr20:32116171~32116629:+
BRCA	cis	rs17772222	1	rs7145588	ENSG00000258789.1	RP11-507K2.3	-3.58	0.000358	0.0186	-0.13	-0.11	Coronary artery calcification;	chr14:88360452	chr14:88551597~88552493:+
BRCA	cis	rs7824557	0.806	rs34171564	ENSG00000255046.1	RP11-297N6.4	3.58	0.000358	0.0186	0.13	0.11	Retinal vascular caliber;	chr8:11237837	chr8:11797928~11802568:-
BRCA	cis	rs930395	0.859	rs7716600	ENSG00000251141.4	RP11-53O19.1	-3.58	0.000358	0.0186	-0.12	-0.11	Breast cancer;	chr5:44874903	chr5:44744900~44808777:-
BRCA	cis	rs3812762	0.833	rs10500707	ENSG00000254860.4	TMEM9B-AS1	-3.58	0.000358	0.0186	-0.11	-0.11	Hypospadias;	chr11:8796033	chr11:8964675~8977527:+
BRCA	cis	rs12234571	0.793	rs4729658	ENSG00000214293.7	APTR	3.58	0.000358	0.0186	0.23	0.11	Obesity-related traits;	chr7:77728246	chr7:77657660~77696265:-
BRCA	cis	rs2055729	0.645	rs7828229	ENSG00000233609.3	RP11-62H7.2	-3.58	0.000358	0.0186	-0.12	-0.11	Multiple myeloma (hyperdiploidy);	chr8:9885331	chr8:8961200~8979025:+
BRCA	cis	rs4714291	0.963	rs2395543	ENSG00000180211.5	RP1-278E11.3	3.58	0.000358	0.0186	0.12	0.11	Strep throat;	chr6:39997281	chr6:39958414~39958833:-
BRCA	cis	rs6600671	0.899	rs6674392	ENSG00000275131.1	CH17-472G23.4	-3.58	0.000358	0.0186	-0.1	-0.11	Hip geometry;	chr1:121518864	chr1:120489625~120579190:-
BRCA	cis	rs3740713	1	rs1848048	ENSG00000256361.1	RP11-613F22.6	3.58	0.000358	0.0186	0.17	0.11	Amyotrophic lateral sclerosis (sporadic);	chr11:18447449	chr11:18511043~18511475:-
BRCA	cis	rs3740713	1	rs16935432	ENSG00000256361.1	RP11-613F22.6	3.58	0.000358	0.0186	0.17	0.11	Amyotrophic lateral sclerosis (sporadic);	chr11:18448940	chr11:18511043~18511475:-
BRCA	cis	rs3740713	1	rs73440625	ENSG00000256361.1	RP11-613F22.6	3.58	0.000358	0.0186	0.17	0.11	Amyotrophic lateral sclerosis (sporadic);	chr11:18449253	chr11:18511043~18511475:-
BRCA	cis	rs3740713	1	rs76599129	ENSG00000256361.1	RP11-613F22.6	3.58	0.000358	0.0186	0.17	0.11	Amyotrophic lateral sclerosis (sporadic);	chr11:18450080	chr11:18511043~18511475:-
BRCA	cis	rs853679	0.517	rs2281588	ENSG00000226314.6	ZNF192P1	-3.58	0.000358	0.0186	-0.17	-0.11	Depression;	chr6:28104824	chr6:28161781~28169594:+
BRCA	cis	rs801193	0.844	rs732465	ENSG00000273448.1	RP11-166O4.6	3.58	0.000358	0.0186	0.1	0.11	Aortic root size;	chr7:66533463	chr7:67333047~67334383:+
BRCA	cis	rs11700536	0.656	rs9978825	ENSG00000236663.1	AP001631.9	3.58	0.000358	0.0186	0.12	0.11	Interleukin-18 levels;	chr21:43149043	chr21:43140523~43141092:-
BRCA	cis	rs7927592	0.645	rs7950900	ENSG00000212093.1	AP000807.1	3.58	0.000358	0.0186	0.12	0.11	Total body bone mineral density;	chr11:68526077	chr11:68506083~68506166:-
BRCA	cis	rs7031325	0.819	rs10758801	ENSG00000225489.5	RP11-390F4.3	3.58	0.000358	0.0186	0.15	0.11	Systemic lupus erythematosus;	chr9:6657192	chr9:6716495~6727438:+
BRCA	cis	rs7712401	0.755	rs1870560	ENSG00000249996.1	RP11-359P5.1	3.58	0.000358	0.0187	0.13	0.11	Mean platelet volume;	chr5:122775515	chr5:123036271~123054667:+
BRCA	cis	rs9467773	1	rs10214634	ENSG00000224843.5	LINC00240	-3.58	0.000358	0.0187	-0.12	-0.11	Intelligence (multi-trait analysis);	chr6:26564354	chr6:26956992~27023924:+
BRCA	cis	rs481331	0.799	rs210269	ENSG00000273008.1	RP11-351D16.3	3.58	0.000358	0.0187	0.17	0.11	Systemic juvenile idiopathic arthritis;	chr10:42505999	chr10:43136824~43138334:-
BRCA	cis	rs863345	0.604	rs6666609	ENSG00000176320.2	RP11-404O13.5	-3.58	0.000358	0.0187	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158528334	chr1:158197922~158203877:-
BRCA	cis	rs6696239	0.956	rs6426470	ENSG00000215812.5	ZNF847P	3.58	0.000358	0.0187	0.15	0.11	Height;	chr1:227665920	chr1:227696892~227706699:-
BRCA	cis	rs801193	1	rs3778909	ENSG00000275400.1	RP4-756H11.5	-3.58	0.000358	0.0187	-0.13	-0.11	Aortic root size;	chr7:66790659	chr7:66553805~66554199:-
BRCA	cis	rs13326165	0.76	rs55965068	ENSG00000243224.1	RP5-1157M23.2	-3.58	0.000358	0.0187	-0.16	-0.11	HDL cholesterol levels;HDL cholesterol;	chr3:52320416	chr3:52239258~52241097:+
BRCA	cis	rs13108904	0.905	rs1680074	ENSG00000211482.1	AC092574.1	-3.58	0.000359	0.0187	-0.13	-0.11	Obesity-related traits;	chr4:1285833	chr4:409809~409915:+
BRCA	cis	rs6700559	0.692	rs2809342	ENSG00000260088.1	RP11-92G12.3	-3.58	0.000359	0.0187	-0.14	-0.11	Coronary artery disease;	chr1:200628522	chr1:200669507~200694250:+
BRCA	cis	rs7520050	0.966	rs785492	ENSG00000234329.1	RP11-767N6.2	-3.58	0.000359	0.0187	-0.1	-0.11	Reticulocyte count;Red blood cell count;	chr1:46117935	chr1:45651039~45651826:-
BRCA	cis	rs295490	0.748	rs77016755	ENSG00000178631.7	ACTG1P1	-3.58	0.000359	0.0187	-0.21	-0.11	PR interval in Tripanosoma cruzi seropositivity;	chr3:139392125	chr3:139493809~139494937:+
BRCA	cis	rs295490	0.748	rs61034702	ENSG00000178631.7	ACTG1P1	-3.58	0.000359	0.0187	-0.21	-0.11	PR interval in Tripanosoma cruzi seropositivity;	chr3:139395105	chr3:139493809~139494937:+
BRCA	cis	rs10744955	0.727	rs8035794	ENSG00000244879.4	GABPB1-AS1	-3.58	0.000359	0.0187	-0.12	-0.11	Lobe attachment (rater-scored or self-reported);	chr15:50157506	chr15:50354959~50372202:+
BRCA	cis	rs6714710	0.603	rs11123974	ENSG00000228486.8	LINC01125	-3.58	0.000359	0.0187	-0.1	-0.11	Posterior cortical atrophy and Alzheimer's disease;	chr2:97989519	chr2:97664217~97703064:+
BRCA	cis	rs7172677	0.711	rs8027552	ENSG00000260269.4	CTD-2323K18.1	-3.58	0.000359	0.0187	-0.15	-0.11	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75147052	chr15:75527150~75601205:-
BRCA	cis	rs62458065	0.513	rs7788809	ENSG00000273014.1	RP11-225B17.2	-3.58	0.000359	0.0187	-0.17	-0.11	Metabolite levels (HVA/MHPG ratio);	chr7:32513010	chr7:32758882~32759353:+
BRCA	cis	rs10043228	0.826	rs9326989	ENSG00000250015.1	CTC-339F2.2	3.58	0.000359	0.0187	0.14	0.11	Asthma or chronic obstructive pulmonary disease;	chr5:116137594	chr5:116302354~116304134:-
BRCA	cis	rs10043228	0.826	rs9326990	ENSG00000250015.1	CTC-339F2.2	3.58	0.000359	0.0187	0.14	0.11	Asthma or chronic obstructive pulmonary disease;	chr5:116138797	chr5:116302354~116304134:-
BRCA	cis	rs13256369	1	rs873063	ENSG00000254153.1	CTA-398F10.2	3.58	0.000359	0.0187	0.15	0.11	Obesity-related traits;	chr8:8714937	chr8:8456909~8461337:-
BRCA	cis	rs67696533	0.711	rs4911241	ENSG00000275576.1	RP5-836N17.4	-3.58	0.000359	0.0187	-0.13	-0.11	White blood cell count (basophil);Basophil percentage of granulocytes;Basophil percentage of white cells;	chr20:32552363	chr20:32116171~32116629:+
BRCA	cis	rs863345	0.647	rs923663	ENSG00000176320.2	RP11-404O13.5	3.58	0.000359	0.0187	0.12	0.11	Pneumococcal bacteremia;	chr1:158537942	chr1:158197922~158203877:-
BRCA	cis	rs7695732	0.703	rs7659904	ENSG00000270720.1	RP11-84C13.2	-3.58	0.000359	0.0187	-0.15	-0.11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr4:88997161	chr4:89119284~89119871:+
BRCA	cis	rs10129255	1	rs10129319	ENSG00000232216.1	IGHV3-43	3.58	0.000359	0.0187	0.09	0.11	Kawasaki disease;	chr14:106767996	chr14:106470264~106470800:-
BRCA	cis	rs7520050	0.966	rs4660317	ENSG00000281133.1	AL355480.3	3.58	0.000359	0.0187	0.13	0.11	Reticulocyte count;Red blood cell count;	chr1:45860554	chr1:45580892~45580996:-
BRCA	cis	rs7520050	0.966	rs10749860	ENSG00000281133.1	AL355480.3	3.58	0.000359	0.0187	0.13	0.11	Reticulocyte count;Red blood cell count;	chr1:45862538	chr1:45580892~45580996:-
BRCA	cis	rs7520050	0.931	rs6688365	ENSG00000281133.1	AL355480.3	3.58	0.000359	0.0187	0.13	0.11	Reticulocyte count;Red blood cell count;	chr1:45864212	chr1:45580892~45580996:-
BRCA	cis	rs7520050	0.966	rs6656992	ENSG00000281133.1	AL355480.3	3.58	0.000359	0.0187	0.13	0.11	Reticulocyte count;Red blood cell count;	chr1:45867396	chr1:45580892~45580996:-
BRCA	cis	rs7520050	0.966	rs61783220	ENSG00000281133.1	AL355480.3	3.58	0.000359	0.0187	0.13	0.11	Reticulocyte count;Red blood cell count;	chr1:45869640	chr1:45580892~45580996:-
BRCA	cis	rs7520050	0.966	rs7540325	ENSG00000281133.1	AL355480.3	3.58	0.000359	0.0187	0.13	0.11	Reticulocyte count;Red blood cell count;	chr1:45872545	chr1:45580892~45580996:-
BRCA	cis	rs7520050	1	rs7540699	ENSG00000281133.1	AL355480.3	3.58	0.000359	0.0187	0.13	0.11	Reticulocyte count;Red blood cell count;	chr1:45872913	chr1:45580892~45580996:-
BRCA	cis	rs7520050	0.966	rs4660319	ENSG00000281133.1	AL355480.3	3.58	0.000359	0.0187	0.13	0.11	Reticulocyte count;Red blood cell count;	chr1:45875951	chr1:45580892~45580996:-
BRCA	cis	rs7520050	0.931	rs11211213	ENSG00000281133.1	AL355480.3	3.58	0.000359	0.0187	0.13	0.11	Reticulocyte count;Red blood cell count;	chr1:45876845	chr1:45580892~45580996:-
BRCA	cis	rs1823874	0.677	rs1993295	ENSG00000259363.4	CTD-2054N24.2	3.58	0.000359	0.0187	0.13	0.11	IgG glycosylation;	chr15:99823332	chr15:99807023~99877148:+
BRCA	cis	rs7818688	0.929	rs28419772	ENSG00000245080.5	RP11-320N21.1	-3.58	0.000359	0.0187	-0.18	-0.11	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95009208	chr8:95066808~95073182:-
BRCA	cis	rs9393813	0.516	rs4713098	ENSG00000241549.7	GUSBP2	-3.58	0.000359	0.0187	-0.12	-0.11	Bipolar disorder;	chr6:27435826	chr6:26871484~26956554:-
BRCA	cis	rs2615061	0.808	rs12032511	ENSG00000229965.1	RP11-118H4.1	3.58	0.000359	0.0187	0.19	0.11	Monocyte count;	chr1:225767929	chr1:226438564~226439344:+
BRCA	cis	rs6479874	0.736	rs2816835	ENSG00000223502.1	RP11-96B5.3	3.58	0.000359	0.0187	0.19	0.11	Migraine;	chr10:50992874	chr10:51062579~51068553:-
BRCA	cis	rs75504410	0.579	rs3733315	ENSG00000231160.8	KLF3-AS1	-3.58	0.000359	0.0187	-0.15	-0.11	Sum eosinophil basophil counts;Eosinophil counts;	chr4:38630535	chr4:38612701~38664883:-
BRCA	cis	rs7914558	1	rs11191542	ENSG00000213277.3	MARCKSL1P1	3.58	0.000359	0.0187	0.12	0.11	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103064567	chr10:103175554~103176094:+
BRCA	cis	rs12468226	0.938	rs115418918	ENSG00000272966.1	RP11-686O6.1	3.58	0.000359	0.0187	0.18	0.11	Urate levels;	chr2:202315145	chr2:202336739~202337200:+
BRCA	cis	rs801193	1	rs2420824	ENSG00000273142.1	RP11-458F8.4	3.58	0.000359	0.0187	0.09	0.11	Aortic root size;	chr7:66666129	chr7:66902857~66906297:+
BRCA	cis	rs875971	1	rs709597	ENSG00000271064.1	RP11-792A8.3	3.58	0.000359	0.0187	0.13	0.11	Aortic root size;	chr7:66360996	chr7:66748838~66749077:-
BRCA	cis	rs10266483	0.883	rs683689	ENSG00000228653.2	HNRNPCP7	-3.58	0.000359	0.0187	-0.13	-0.11	Response to statin therapy;	chr7:64282165	chr7:64500825~64501729:+
BRCA	cis	rs11098499	0.863	rs1552095	ENSG00000260091.1	RP11-33B1.4	-3.58	0.000359	0.0187	-0.1	-0.11	Corneal astigmatism;	chr4:119539151	chr4:119409333~119410233:+
BRCA	cis	rs6696239	0.866	rs7536661	ENSG00000215812.5	ZNF847P	3.58	0.000359	0.0187	0.15	0.11	Height;	chr1:227683846	chr1:227696892~227706699:-
BRCA	cis	rs6943931	1	rs6964829	ENSG00000230658.1	KLHL7-AS1	-3.58	0.000359	0.0187	-0.14	-0.11	Diabetic kidney disease;	chr7:22375332	chr7:23101228~23105703:-
BRCA	cis	rs9470794	1	rs79532072	ENSG00000204110.6	RP1-153P14.8	-3.58	0.000359	0.0187	-0.23	-0.11	Type 2 diabetes;	chr6:38135781	chr6:37507348~37535616:+
BRCA	cis	rs4533267	0.957	rs62036215	ENSG00000270127.2	RP11-526I2.5	-3.58	0.000359	0.0187	-0.14	-0.11	Height;	chr15:100253578	chr15:100547765~100550153:-
BRCA	cis	rs1468333	0.537	rs4317313	ENSG00000206989.1	SNORD63	3.58	0.000359	0.0187	0.12	0.11	Resting heart rate;	chr5:138363903	chr5:138561043~138561110:-
BRCA	cis	rs1468333	0.598	rs4639219	ENSG00000206989.1	SNORD63	3.58	0.000359	0.0187	0.12	0.11	Resting heart rate;	chr5:138363931	chr5:138561043~138561110:-
BRCA	cis	rs10043775	0.831	rs4705248	ENSG00000251330.3	CTD-2283N19.1	-3.58	0.000359	0.0187	-0.14	-0.11	Periodontal microbiota;	chr5:148309258	chr5:148430159~148430807:-
BRCA	cis	rs875971	0.929	rs778692	ENSG00000272831.1	RP11-792A8.4	3.58	0.000359	0.0187	0.1	0.11	Aortic root size;	chr7:66407462	chr7:66739829~66740385:-
BRCA	cis	rs875971	1	rs4718343	ENSG00000272831.1	RP11-792A8.4	3.58	0.000359	0.0187	0.1	0.11	Aortic root size;	chr7:66409301	chr7:66739829~66740385:-
BRCA	cis	rs875971	1	rs1968225	ENSG00000272831.1	RP11-792A8.4	3.58	0.000359	0.0187	0.1	0.11	Aortic root size;	chr7:66409786	chr7:66739829~66740385:-
BRCA	cis	rs875971	1	rs6460295	ENSG00000272831.1	RP11-792A8.4	3.58	0.000359	0.0187	0.1	0.11	Aortic root size;	chr7:66417741	chr7:66739829~66740385:-
BRCA	cis	rs875971	0.964	rs6978721	ENSG00000272831.1	RP11-792A8.4	3.58	0.000359	0.0187	0.1	0.11	Aortic root size;	chr7:66418217	chr7:66739829~66740385:-
BRCA	cis	rs370915	0.928	rs433477	ENSG00000250971.1	RP11-696F12.1	-3.58	0.000359	0.0187	-0.11	-0.11	Gout;	chr4:186893712	chr4:187060099~187060930:+
BRCA	cis	rs67766926	1	rs10208155	ENSG00000237522.1	NONOP2	-3.58	0.000359	0.0187	-0.12	-0.11	Inflammatory skin disease;	chr2:60887904	chr2:60936819~60938049:-
BRCA	cis	rs7131987	0.903	rs10843367	ENSG00000273680.1	RP11-996F15.6	3.58	0.000359	0.0187	0.14	0.11	QT interval;	chr12:29255447	chr12:29332733~29333383:-
BRCA	cis	rs1003719	0.68	rs3737540	ENSG00000242553.1	AP001432.14	3.58	0.000359	0.0187	0.12	0.11	Eye color traits;	chr21:37150966	chr21:37221419~37237744:+
BRCA	cis	rs3743266	0.613	rs4775273	ENSG00000245534.5	RORA-AS1	3.58	0.000359	0.0187	0.13	0.11	Menarche (age at onset);	chr15:60446367	chr15:60479178~60630637:+
BRCA	cis	rs875971	0.505	rs1167385	ENSG00000223473.2	GS1-124K5.3	-3.58	0.000359	0.0187	-0.08	-0.11	Aortic root size;	chr7:66048321	chr7:66491049~66493566:-
BRCA	cis	rs754466	0.606	rs7084705	ENSG00000213514.2	RP11-428P16.2	3.58	0.000359	0.0187	0.15	0.11	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77836917	chr10:77730766~77734769:+
BRCA	cis	rs73201462	1	rs55925538	ENSG00000242551.2	POU5F1P6	3.58	0.00036	0.0187	0.19	0.11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128324034	chr3:128674735~128677005:-
BRCA	cis	rs73201462	1	rs73197388	ENSG00000242551.2	POU5F1P6	3.58	0.00036	0.0187	0.19	0.11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128325077	chr3:128674735~128677005:-
BRCA	cis	rs9457247	0.602	rs13204839	ENSG00000272549.1	RP11-351J23.2	-3.58	0.00036	0.0187	-0.12	-0.11	Crohn's disease;	chr6:167057631	chr6:167666840~167679270:-
BRCA	cis	rs9457247	0.602	rs6456152	ENSG00000272549.1	RP11-351J23.2	-3.58	0.00036	0.0187	-0.12	-0.11	Crohn's disease;	chr6:167058574	chr6:167666840~167679270:-
BRCA	cis	rs17756712	0.725	rs4335022	ENSG00000271911.1	RP11-532F6.5	3.58	0.00036	0.0187	0.19	0.11	Vertical cup-disc ratio;	chr6:596417	chr6:761675~780648:+
BRCA	cis	rs17756712	0.725	rs72835956	ENSG00000271911.1	RP11-532F6.5	3.58	0.00036	0.0187	0.19	0.11	Vertical cup-disc ratio;	chr6:597164	chr6:761675~780648:+
BRCA	cis	rs40067	1	rs372894	ENSG00000272523.1	LINC01023	3.58	0.00036	0.0187	0.12	0.11	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr5:108043678	chr5:108727825~108728260:-
BRCA	cis	rs8180040	1	rs8180040	ENSG00000280667.1	Y_RNA	3.58	0.00036	0.0187	0.12	0.11	Colorectal cancer;	chr3:47347457	chr3:47501083~47501182:+
BRCA	cis	rs448720	1	rs392452	ENSG00000260657.2	RP11-315D16.4	-3.58	0.00036	0.0187	-0.13	-0.11	Cognitive performance;	chr15:67914677	chr15:68267792~68277994:-
BRCA	cis	rs13434995	0.513	rs6846764	ENSG00000273257.1	RP11-177J6.1	3.58	0.00036	0.0187	0.16	0.11	Adiponectin levels;	chr4:55557322	chr4:55387949~55388271:+
BRCA	cis	rs13434995	0.513	rs6853506	ENSG00000273257.1	RP11-177J6.1	3.58	0.00036	0.0187	0.16	0.11	Adiponectin levels;	chr4:55558207	chr4:55387949~55388271:+
BRCA	cis	rs7487075	0.82	rs4238102	ENSG00000257261.4	RP11-96H19.1	3.58	0.00036	0.0187	0.12	0.11	Itch intensity from mosquito bite;	chr12:46332713	chr12:46383679~46876159:+
BRCA	cis	rs11673344	0.526	rs17305823	ENSG00000267422.1	CTD-2554C21.1	-3.58	0.00036	0.0187	-0.15	-0.11	Obesity-related traits;	chr19:37644145	chr19:37779686~37792865:+
BRCA	cis	rs4660456	0.556	rs823674	ENSG00000272145.1	NFYC-AS1	3.58	0.00036	0.0187	0.1	0.11	Platelet count;	chr1:40774799	chr1:40690380~40692066:-
BRCA	cis	rs873549	0.959	rs6604701	ENSG00000227925.1	RP11-191N8.2	3.58	0.00036	0.0187	0.13	0.11	Keloid;	chr1:222094158	chr1:221827666~221840666:-
BRCA	cis	rs873549	1	rs6604702	ENSG00000227925.1	RP11-191N8.2	3.58	0.00036	0.0187	0.13	0.11	Keloid;	chr1:222094181	chr1:221827666~221840666:-
BRCA	cis	rs873549	1	rs3910712	ENSG00000227925.1	RP11-191N8.2	3.58	0.00036	0.0187	0.13	0.11	Keloid;	chr1:222094609	chr1:221827666~221840666:-
BRCA	cis	rs873549	1	rs3910711	ENSG00000227925.1	RP11-191N8.2	3.58	0.00036	0.0187	0.13	0.11	Keloid;	chr1:222094622	chr1:221827666~221840666:-
BRCA	cis	rs6582630	0.548	rs8189608	ENSG00000257718.1	RP11-396F22.1	-3.58	0.00036	0.0187	-0.11	-0.11	Drug-induced liver injury (flucloxacillin);	chr12:37933973	chr12:38906451~38909592:+
BRCA	cis	rs7578361	0.879	rs16827092	ENSG00000231969.1	AC144449.1	3.58	0.00036	0.0187	0.17	0.11	Acute lymphoblastic leukemia (childhood);	chr2:149487781	chr2:149587196~149848233:+
BRCA	cis	rs875971	0.502	rs2465121	ENSG00000232559.3	GS1-124K5.12	-3.58	0.00036	0.0187	-0.15	-0.11	Aortic root size;	chr7:66156017	chr7:66554588~66576923:-
BRCA	cis	rs7561149	0.902	rs6715406	ENSG00000270574.1	RP11-171I2.2	-3.58	0.00036	0.0187	-0.15	-0.11	QT interval;	chr2:178785974	chr2:178578790~178580906:+
BRCA	cis	rs17507216	0.56	rs2871011	ENSG00000276710.3	CSPG4P8	-3.58	0.00036	0.0187	-0.11	-0.11	Excessive daytime sleepiness;	chr15:82560792	chr15:82459472~82477258:+
BRCA	cis	rs4589258	0.762	rs10437566	ENSG00000280367.1	RP11-121L10.2	3.58	0.00036	0.0187	0.13	0.11	Intelligence (multi-trait analysis);	chr11:90730718	chr11:90223153~90226538:+
BRCA	cis	rs6714710	0.627	rs6748124	ENSG00000228486.8	LINC01125	-3.58	0.00036	0.0187	-0.1	-0.11	Posterior cortical atrophy and Alzheimer's disease;	chr2:97902551	chr2:97664217~97703064:+
BRCA	cis	rs6714710	0.603	rs58546246	ENSG00000228486.8	LINC01125	-3.58	0.00036	0.0187	-0.1	-0.11	Posterior cortical atrophy and Alzheimer's disease;	chr2:97905360	chr2:97664217~97703064:+
BRCA	cis	rs10129255	1	rs10129407	ENSG00000253132.1	IGHV3-62	-3.58	0.00036	0.0187	-0.09	-0.11	Kawasaki disease;	chr14:106767956	chr14:106643142~106643585:-
BRCA	cis	rs863345	0.604	rs11265024	ENSG00000176320.2	RP11-404O13.5	-3.58	0.00036	0.0187	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158543465	chr1:158197922~158203877:-
BRCA	cis	rs6601327	0.551	rs13272424	ENSG00000233609.3	RP11-62H7.2	-3.58	0.00036	0.0187	-0.1	-0.11	Multiple myeloma (hyperdiploidy);	chr8:9717809	chr8:8961200~8979025:+
BRCA	cis	rs2692947	0.74	rs4907280	ENSG00000168992.4	OR7E102P	3.58	0.00036	0.0187	0.16	0.11	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95736378	chr2:95546531~95547545:+
BRCA	cis	rs9467773	1	rs9295695	ENSG00000224843.5	LINC00240	3.58	0.00036	0.0187	0.12	0.11	Intelligence (multi-trait analysis);	chr6:26528022	chr6:26956992~27023924:+
BRCA	cis	rs1334894	0.892	rs72911394	ENSG00000187762.5	HSPE1P11	3.58	0.00036	0.0187	0.26	0.11	Coronary artery disease;	chr6:35557387	chr6:35023522~35023831:+
BRCA	cis	rs1555133	0.625	rs6141665	ENSG00000275576.1	RP5-836N17.4	-3.58	0.00036	0.0187	-0.12	-0.11	Monocyte count;	chr20:32303438	chr20:32116171~32116629:+
BRCA	cis	rs61352607	1	rs11613352	ENSG00000259125.1	RP11-545N8.3	-3.58	0.00036	0.0187	-0.16	-0.11	Triglycerides;	chr12:57398797	chr12:57144620~57147619:-
BRCA	cis	rs875971	0.895	rs6460278	ENSG00000271064.1	RP11-792A8.3	3.58	0.00036	0.0187	0.13	0.11	Aortic root size;	chr7:66197749	chr7:66748838~66749077:-
BRCA	cis	rs875971	0.862	rs6460279	ENSG00000271064.1	RP11-792A8.3	3.58	0.00036	0.0187	0.13	0.11	Aortic root size;	chr7:66197774	chr7:66748838~66749077:-
BRCA	cis	rs875971	0.862	rs28491091	ENSG00000271064.1	RP11-792A8.3	3.58	0.00036	0.0187	0.13	0.11	Aortic root size;	chr7:66204077	chr7:66748838~66749077:-
BRCA	cis	rs10129255	0.913	rs10140943	ENSG00000253132.1	IGHV3-62	-3.58	0.00036	0.0187	-0.09	-0.11	Kawasaki disease;	chr14:106767441	chr14:106643142~106643585:-
BRCA	cis	rs6496667	0.533	rs2074584	ENSG00000259262.1	NDUFA3P4	3.58	0.00036	0.0187	0.12	0.11	Rheumatoid arthritis;	chr15:90466149	chr15:90385814~90386063:+
BRCA	cis	rs8103278	1	rs8102876	ENSG00000268423.3	AC011551.3	3.58	0.000361	0.0188	0.14	0.11	Coronary artery disease;	chr19:45829584	chr19:46547056~46600861:-
BRCA	cis	rs687432	0.924	rs7950003	ENSG00000265566.2	RN7SL605P	-3.58	0.000361	0.0188	-0.16	-0.11	Parkinson's disease;	chr11:57992464	chr11:57528085~57528365:-
BRCA	cis	rs17767294	0.708	rs6908688	ENSG00000219392.1	RP1-265C24.5	-3.58	0.000361	0.0188	-0.26	-0.11	Parkinson's disease;	chr6:27918273	chr6:28115628~28116551:+
BRCA	cis	rs4654783	0.505	rs7544210	ENSG00000271428.1	RP1-224A6.8	-3.58	0.000361	0.0188	-0.11	-0.11	Endometriosis;	chr1:22128649	chr1:22068340~22068827:-
BRCA	cis	rs75422866	0.867	rs73102188	ENSG00000276691.1	RP5-1057I20.5	3.58	0.000361	0.0188	0.23	0.11	Pneumonia;	chr12:47662993	chr12:47788426~47788971:+
BRCA	cis	rs75422866	0.867	rs73102195	ENSG00000276691.1	RP5-1057I20.5	3.58	0.000361	0.0188	0.23	0.11	Pneumonia;	chr12:47666309	chr12:47788426~47788971:+
BRCA	cis	rs75422866	0.867	rs73102201	ENSG00000276691.1	RP5-1057I20.5	3.58	0.000361	0.0188	0.23	0.11	Pneumonia;	chr12:47669269	chr12:47788426~47788971:+
BRCA	cis	rs75422866	0.867	rs73104104	ENSG00000276691.1	RP5-1057I20.5	3.58	0.000361	0.0188	0.23	0.11	Pneumonia;	chr12:47671986	chr12:47788426~47788971:+
BRCA	cis	rs75422866	0.867	rs73104111	ENSG00000276691.1	RP5-1057I20.5	3.58	0.000361	0.0188	0.23	0.11	Pneumonia;	chr12:47673994	chr12:47788426~47788971:+
BRCA	cis	rs250518	0.926	rs6452683	ENSG00000271926.1	CTD-2376I4.1	3.58	0.000361	0.0188	0.15	0.11	Mean corpuscular hemoglobin concentration;	chr5:72787076	chr5:72953635~72954274:-
BRCA	cis	rs925550	0.525	rs12648663	ENSG00000224786.1	CETN4P	-3.58	0.000361	0.0188	-0.17	-0.11	Primary biliary cholangitis;	chr4:122687542	chr4:122730548~122732193:-
BRCA	cis	rs12468226	0.679	rs6435133	ENSG00000272966.1	RP11-686O6.1	-3.58	0.000361	0.0188	-0.18	-0.11	Urate levels;	chr2:202209237	chr2:202336739~202337200:+
BRCA	cis	rs12468226	0.817	rs12693965	ENSG00000272966.1	RP11-686O6.1	-3.58	0.000361	0.0188	-0.18	-0.11	Urate levels;	chr2:202210188	chr2:202336739~202337200:+
BRCA	cis	rs12468226	0.873	rs3769817	ENSG00000272966.1	RP11-686O6.1	-3.58	0.000361	0.0188	-0.18	-0.11	Urate levels;	chr2:202214584	chr2:202336739~202337200:+
BRCA	cis	rs12468226	0.873	rs6435134	ENSG00000272966.1	RP11-686O6.1	-3.58	0.000361	0.0188	-0.18	-0.11	Urate levels;	chr2:202214857	chr2:202336739~202337200:+
BRCA	cis	rs12468226	0.817	rs6435135	ENSG00000272966.1	RP11-686O6.1	-3.58	0.000361	0.0188	-0.18	-0.11	Urate levels;	chr2:202217469	chr2:202336739~202337200:+
BRCA	cis	rs6787172	0.811	rs4510417	ENSG00000243025.1	MTAPP1	-3.58	0.000361	0.0188	-0.13	-0.11	Subjective well-being;	chr3:158491764	chr3:158609610~158610857:-
BRCA	cis	rs13326165	0.76	rs13059674	ENSG00000243224.1	RP5-1157M23.2	-3.58	0.000361	0.0188	-0.15	-0.11	HDL cholesterol levels;HDL cholesterol;	chr3:52337773	chr3:52239258~52241097:+
BRCA	cis	rs11098499	1	rs6837898	ENSG00000260404.2	RP11-384K6.6	3.58	0.000361	0.0188	0.11	0.11	Corneal astigmatism;	chr4:119257999	chr4:118591773~118633729:+
BRCA	cis	rs56281245	0.793	rs78466687	ENSG00000249363.1	CTB-78O21.1	3.58	0.000361	0.0188	0.24	0.11	Hepcidin levels;	chr5:145582918	chr5:145728360~145729349:-
BRCA	cis	rs896854	0.552	rs2515236	ENSG00000245080.5	RP11-320N21.1	-3.58	0.000361	0.0188	-0.14	-0.11	Type 2 diabetes;	chr8:94922679	chr8:95066808~95073182:-
BRCA	cis	rs8012947	0.651	rs74055634	ENSG00000257621.6	PSMA3-AS1	3.58	0.000361	0.0188	0.1	0.11	Alcohol consumption in current drinkers;	chr14:58361359	chr14:58265365~58298134:-
BRCA	cis	rs2243480	0.803	rs35480979	ENSG00000234585.5	CCT6P3	-3.58	0.000361	0.0188	-0.16	-0.11	Diabetic kidney disease;	chr7:65892097	chr7:65038354~65074713:+
BRCA	cis	rs2243480	1	rs35391607	ENSG00000234585.5	CCT6P3	-3.58	0.000361	0.0188	-0.16	-0.11	Diabetic kidney disease;	chr7:65895842	chr7:65038354~65074713:+
BRCA	cis	rs2243480	1	rs13220979	ENSG00000234585.5	CCT6P3	-3.58	0.000361	0.0188	-0.16	-0.11	Diabetic kidney disease;	chr7:65898217	chr7:65038354~65074713:+
BRCA	cis	rs2243480	1	rs34974928	ENSG00000234585.5	CCT6P3	-3.58	0.000361	0.0188	-0.16	-0.11	Diabetic kidney disease;	chr7:65899019	chr7:65038354~65074713:+
BRCA	cis	rs875971	0.862	rs10261398	ENSG00000273024.4	INTS4P2	3.58	0.000361	0.0188	0.12	0.11	Aortic root size;	chr7:66285177	chr7:65647864~65715661:+
BRCA	cis	rs875971	0.862	rs10224872	ENSG00000273024.4	INTS4P2	3.58	0.000361	0.0188	0.12	0.11	Aortic root size;	chr7:66294786	chr7:65647864~65715661:+
BRCA	cis	rs524281	0.773	rs2155030	ENSG00000255038.1	RP11-1167A19.2	-3.58	0.000361	0.0188	-0.17	-0.11	Electroencephalogram traits;	chr11:66263216	chr11:66067277~66069619:-
BRCA	cis	rs524281	0.773	rs2155031	ENSG00000255038.1	RP11-1167A19.2	-3.58	0.000361	0.0188	-0.17	-0.11	Electroencephalogram traits;	chr11:66263456	chr11:66067277~66069619:-
BRCA	cis	rs7829975	0.535	rs4841005	ENSG00000254153.1	CTA-398F10.2	-3.58	0.000361	0.0188	-0.13	-0.11	Mood instability;	chr8:8643720	chr8:8456909~8461337:-
BRCA	cis	rs10883723	0.81	rs7072351	ENSG00000213061.2	PFN1P11	-3.58	0.000361	0.0188	-0.15	-0.11	Allergic disease (asthma, hay fever or eczema);	chr10:102505290	chr10:102838011~102845473:-
BRCA	cis	rs3749237	0.964	rs7431078	ENSG00000225399.4	RP11-3B7.1	3.58	0.000361	0.0188	0.11	0.11	Resting heart rate;	chr3:49770757	chr3:49260085~49261316:+
BRCA	cis	rs67478160	0.619	rs12886363	ENSG00000269910.1	RP11-73M18.10	3.58	0.000361	0.0188	0.11	0.11	Schizophrenia;	chr14:103807449	chr14:103694516~103695050:-
BRCA	cis	rs75422866	0.867	rs73104152	ENSG00000276691.1	RP5-1057I20.5	3.58	0.000361	0.0188	0.23	0.11	Pneumonia;	chr12:47699091	chr12:47788426~47788971:+
BRCA	cis	rs75422866	0.867	rs73104155	ENSG00000276691.1	RP5-1057I20.5	3.58	0.000361	0.0188	0.23	0.11	Pneumonia;	chr12:47700790	chr12:47788426~47788971:+
BRCA	cis	rs559406	0.501	rs2542160	ENSG00000260302.1	RP11-973H7.1	-3.58	0.000361	0.0188	-0.14	-0.11	Psoriasis;	chr18:12789247	chr18:12774651~12775923:-
BRCA	cis	rs2562456	0.682	rs11085464	ENSG00000268119.4	CTD-2561J22.5	3.58	0.000361	0.0188	0.17	0.11	Pain;	chr19:21568976	chr19:21444241~21463908:-
BRCA	cis	rs13434995	0.513	rs1979604	ENSG00000273257.1	RP11-177J6.1	3.58	0.000361	0.0188	0.16	0.11	Adiponectin levels;	chr4:55552588	chr4:55387949~55388271:+
BRCA	cis	rs13434995	0.537	rs4865012	ENSG00000273257.1	RP11-177J6.1	3.58	0.000361	0.0188	0.16	0.11	Adiponectin levels;	chr4:55554619	chr4:55387949~55388271:+
BRCA	cis	rs4242434	0.854	rs3064	ENSG00000254064.1	CTD-2530N21.4	3.58	0.000361	0.0188	0.12	0.11	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);	chr8:22594175	chr8:22254576~22275162:-
BRCA	cis	rs2274273	0.682	rs7141975	ENSG00000233924.1	AL160471.6	-3.58	0.000362	0.0188	-0.13	-0.11	Protein biomarker;	chr14:55075498	chr14:55004813~55005687:-
BRCA	cis	rs10771431	0.782	rs10771415	ENSG00000214776.8	RP11-726G1.1	-3.58	0.000362	0.0188	-0.12	-0.11	Breast size;	chr12:9205627	chr12:9467552~9576275:+
BRCA	cis	rs11098499	0.909	rs28555550	ENSG00000260091.1	RP11-33B1.4	-3.58	0.000362	0.0188	-0.1	-0.11	Corneal astigmatism;	chr4:119289885	chr4:119409333~119410233:+
BRCA	cis	rs11098499	1	rs28419773	ENSG00000260091.1	RP11-33B1.4	-3.58	0.000362	0.0188	-0.1	-0.11	Corneal astigmatism;	chr4:119289906	chr4:119409333~119410233:+
BRCA	cis	rs12950390	0.853	rs12451815	ENSG00000234494.6	SP2-AS1	-3.58	0.000362	0.0188	-0.14	-0.11	IgG glycosylation;	chr17:47778590	chr17:47897330~47941410:-
BRCA	cis	rs6012564	1	rs2024959	ENSG00000230758.1	SNAP23P	3.58	0.000362	0.0188	0.13	0.11	Anger;	chr20:49078854	chr20:49038357~49038602:-
BRCA	cis	rs757978	1	rs11681497	ENSG00000223374.1	AC005104.3	3.58	0.000362	0.0188	0.15	0.11	Chronic lymphocytic leukemia;	chr2:241404918	chr2:241351340~241353104:-
BRCA	cis	rs656900	0.74	rs644315	ENSG00000261229.4	MTHFS	3.58	0.000362	0.0188	0.11	0.11	Cerebrospinal P-tau181p levels;	chr15:79821207	chr15:79843547~79897285:-
BRCA	cis	rs1018697	0.966	rs10748831	ENSG00000236937.2	PTGES3P4	3.58	0.000362	0.0188	0.14	0.11	Colorectal adenoma (advanced);	chr10:102798986	chr10:102845595~102845950:+
BRCA	cis	rs67073037	0.955	rs12620770	ENSG00000230730.1	AC074011.2	-3.58	0.000362	0.0188	-0.15	-0.11	Breast cancer;Breast cancer (estrogen-receptor negative);	chr2:28922026	chr2:28633282~28664540:-
BRCA	cis	rs1538138	1	rs1538138	ENSG00000224995.1	LINC01526	-3.58	0.000362	0.0188	-0.14	-0.11	Corneal structure;	chr6:82084877	chr6:81813286~81814157:-
BRCA	cis	rs1075265	0.783	rs805439	ENSG00000272156.1	RP11-477N3.1	-3.58	0.000362	0.0188	-0.11	-0.11	Chronotype;Morning vs. evening chronotype;	chr2:53829437	chr2:54082554~54085066:+
BRCA	cis	rs4932480	0.713	rs7168186	ENSG00000259677.1	RP11-493E3.1	3.58	0.000362	0.0188	0.14	0.11	Age-related macular degeneration (SNP x mitochondrial G12771A interaction);Advanced age-related macular degeneration;	chr15:89207729	chr15:89876540~89877285:+
BRCA	cis	rs2998286	0.862	rs2153300	ENSG00000237128.1	RP11-351M16.3	3.58	0.000362	0.0188	0.14	0.11	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28519041	chr10:28433008~28495813:-
BRCA	cis	rs4689592	0.503	rs4689064	ENSG00000245468.3	RP11-367J11.3	-3.58	0.000362	0.0188	-0.14	-0.11	Monocyte percentage of white cells;	chr4:7053876	chr4:7094571~7103385:-
BRCA	cis	rs36051895	0.664	rs3780373	ENSG00000237711.1	RP11-39K24.13	-3.58	0.000362	0.0188	-0.13	-0.11	Pediatric autoimmune diseases;	chr9:5098223	chr9:5100236~5101009:+
BRCA	cis	rs11122895	0.509	rs6708131	ENSG00000236307.2	EEF1E1P1	3.58	0.000362	0.0188	0.12	0.11	Allergic sensitization;	chr2:111688082	chr2:111887914~111888741:+
BRCA	cis	rs6480314	0.711	rs78671884	ENSG00000233590.1	RP11-153K11.3	-3.58	0.000362	0.0188	-0.18	-0.11	Optic nerve measurement (disc area);	chr10:68192669	chr10:68233251~68242379:-
BRCA	cis	rs6480314	0.711	rs61857181	ENSG00000233590.1	RP11-153K11.3	-3.58	0.000362	0.0188	-0.18	-0.11	Optic nerve measurement (disc area);	chr10:68193771	chr10:68233251~68242379:-
BRCA	cis	rs13434995	0.513	rs17722979	ENSG00000249700.7	SRD5A3-AS1	-3.58	0.000362	0.0188	-0.16	-0.11	Adiponectin levels;	chr4:55480244	chr4:55363971~55395847:-
BRCA	cis	rs11638815	0.775	rs34191802	ENSG00000279758.1	RP11-752G15.10	-3.58	0.000362	0.0188	-0.13	-0.11	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82730240	chr15:82738386~82739122:+
BRCA	cis	rs8054556	1	rs4583255	ENSG00000214725.6	CDIPT-AS1	-3.58	0.000362	0.0188	-0.14	-0.11	Autism spectrum disorder or schizophrenia;	chr16:29977620	chr16:29863593~29868053:+
BRCA	cis	rs6460942	0.597	rs17544637	ENSG00000226690.5	AC005281.1	3.58	0.000362	0.0188	0.21	0.11	Coronary artery disease;	chr7:12482245	chr7:12496429~12541910:+
BRCA	cis	rs9467773	0.62	rs2451741	ENSG00000224843.5	LINC00240	-3.58	0.000362	0.0188	-0.12	-0.11	Intelligence (multi-trait analysis);	chr6:26629176	chr6:26956992~27023924:+
BRCA	cis	rs55675132	0.548	rs17476878	ENSG00000226167.1	AP4B1-AS1	3.58	0.000362	0.0188	0.12	0.11	Schizophrenia;	chr1:114815435	chr1:113856635~113901237:+
BRCA	cis	rs7800418	0.775	rs740188	ENSG00000214870.7	AC004540.5	3.58	0.000362	0.0188	0.13	0.11	Cognitive function;	chr7:26555819	chr7:26398593~26494256:+
BRCA	cis	rs2229238	0.744	rs10752641	ENSG00000272030.1	RP1-178F15.4	3.58	0.000362	0.0188	0.14	0.11	Coronary heart disease;	chr1:154459566	chr1:153631438~153634397:-
BRCA	cis	rs6840360	0.571	rs6811676	ENSG00000270265.1	RP11-731D1.4	-3.58	0.000362	0.0188	-0.13	-0.11	Intelligence (multi-trait analysis);	chr4:151641574	chr4:151333775~151353224:-
BRCA	cis	rs2562456	0.833	rs516519	ENSG00000240522.1	RPL7AP10	3.58	0.000362	0.0188	0.12	0.11	Pain;	chr19:21298730	chr19:21149648~21150438:-
BRCA	cis	rs6088590	0.901	rs6087631	ENSG00000276073.1	RP5-1125A11.7	-3.58	0.000362	0.0188	-0.13	-0.11	Coronary artery disease;	chr20:34815706	chr20:33985617~33988989:-
BRCA	cis	rs73201462	1	rs2955130	ENSG00000242551.2	POU5F1P6	-3.58	0.000362	0.0188	-0.19	-0.11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128218971	chr3:128674735~128677005:-
BRCA	cis	rs4650943	0.503	rs10494495	ENSG00000227740.1	RP11-318C24.2	3.58	0.000362	0.0188	0.12	0.11	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in inactive individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr1:175977264	chr1:175904762~175920513:-
BRCA	cis	rs10191559	0.552	rs10930960	ENSG00000234663.4	AC104820.2	3.58	0.000362	0.0188	0.1	0.11	Red blood cell count;	chr2:181201261	chr2:181101932~181399559:+
BRCA	cis	rs10191559	0.552	rs4667141	ENSG00000234663.4	AC104820.2	3.58	0.000362	0.0188	0.1	0.11	Red blood cell count;	chr2:181201564	chr2:181101932~181399559:+
BRCA	cis	rs7620503	1	rs1463858	ENSG00000231574.4	RP11-91K9.1	3.58	0.000362	0.0188	0.12	0.11	Corneal structure;	chr3:177580339	chr3:177816865~177899224:+
BRCA	cis	rs12368653	0.701	rs238517	ENSG00000257159.1	RP11-58A17.3	-3.58	0.000363	0.0188	-0.13	-0.11	Multiple sclerosis;	chr12:57723954	chr12:57967058~57968399:+
BRCA	cis	rs514024	0.765	rs497632	ENSG00000225032.4	RP11-228B15.4	3.58	0.000363	0.0188	0.1	0.11	Eating disorders (purging via substances);	chr9:127713163	chr9:127816066~127822520:+
BRCA	cis	rs10943724	1	rs10943724	ENSG00000272129.1	RP11-250B2.6	3.58	0.000363	0.0188	0.15	0.11	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr6:80593088	chr6:80355424~80356859:+
BRCA	cis	rs490234	0.812	rs13300639	ENSG00000232630.1	PRPS1P2	-3.58	0.000363	0.0188	-0.12	-0.11	Mean arterial pressure;	chr9:125645019	chr9:125150653~125151589:+
BRCA	cis	rs251253	0.827	rs251251	ENSG00000253959.1	CTB-43E15.1	3.58	0.000363	0.0188	0.1	0.11	PR interval;	chr5:173059166	chr5:173642519~173658194:+
BRCA	cis	rs2562456	0.876	rs11085468	ENSG00000213976.4	CTD-2561J22.2	-3.58	0.000363	0.0188	-0.13	-0.11	Pain;	chr19:21569087	chr19:21382865~21387177:+
BRCA	cis	rs1348850	0.914	rs11893448	ENSG00000280374.1	RP11-337N6.3	3.58	0.000363	0.0188	0.15	0.11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177415285	chr2:177317715~177318471:-
BRCA	cis	rs6728515	1	rs6728515	ENSG00000232642.1	AC008073.7	3.58	0.000363	0.0188	0.18	0.11	Conotruncal heart defects (maternal effects);	chr2:23482004	chr2:24165884~24175005:-
BRCA	cis	rs2262909	0.962	rs17459246	ENSG00000279377.1	AC003973.3	-3.58	0.000363	0.0188	-0.16	-0.11	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;	chr19:22095319	chr19:21965708~21968529:-
BRCA	cis	rs9467773	0.967	rs9461267	ENSG00000261353.1	CTA-14H9.5	-3.58	0.000363	0.0188	-0.11	-0.11	Intelligence (multi-trait analysis);	chr6:26525227	chr6:26527063~26527404:+
BRCA	cis	rs12467847	1	rs12467847	ENSG00000231747.1	AC079922.2	-3.58	0.000363	0.0188	-0.11	-0.11	Response to amphetamines;	chr2:112933827	chr2:112621809~112622167:-
BRCA	cis	rs477895	0.713	rs11600867	ENSG00000256940.1	RP11-783K16.5	3.58	0.000363	0.0189	0.16	0.11	Mean platelet volume;	chr11:64204580	chr11:64245964~64248217:+
BRCA	cis	rs2439831	0.85	rs7169322	ENSG00000206991.1	RNU6-610P	-3.58	0.000363	0.0189	-0.18	-0.11	Lung cancer in ever smokers;	chr15:43838816	chr15:43637632~43637738:-
BRCA	cis	rs2439831	0.85	rs28707214	ENSG00000206991.1	RNU6-610P	-3.58	0.000363	0.0189	-0.18	-0.11	Lung cancer in ever smokers;	chr15:43839425	chr15:43637632~43637738:-
BRCA	cis	rs9810888	0.567	rs6762231	ENSG00000270941.1	RP5-966M1.5	3.58	0.000363	0.0189	0.13	0.11	Hypertension;Diastolic blood pressure;Systolic blood pressure;	chr3:53629163	chr3:52734735~52735013:+
BRCA	cis	rs6991838	0.584	rs7812446	ENSG00000272155.1	RP11-707M3.3	3.58	0.000363	0.0189	0.1	0.11	Intelligence (multi-trait analysis);	chr8:65593753	chr8:65714334~65714778:-
BRCA	cis	rs6991838	0.557	rs7812390	ENSG00000272155.1	RP11-707M3.3	3.58	0.000363	0.0189	0.1	0.11	Intelligence (multi-trait analysis);	chr8:65593982	chr8:65714334~65714778:-
BRCA	cis	rs853679	0.517	rs9393887	ENSG00000272009.1	RP1-313I6.12	-3.58	0.000363	0.0189	-0.16	-0.11	Depression;	chr6:28091242	chr6:28078792~28081130:-
BRCA	cis	rs6714710	0.58	rs57804205	ENSG00000228486.8	LINC01125	-3.58	0.000363	0.0189	-0.1	-0.11	Posterior cortical atrophy and Alzheimer's disease;	chr2:97838009	chr2:97664217~97703064:+
BRCA	cis	rs10843647	0.51	rs10843608	ENSG00000245614.3	DDX11-AS1	3.58	0.000363	0.0189	0.12	0.11	Glucose homeostasis traits;	chr12:30108338	chr12:31020763~31073847:-
BRCA	cis	rs613391	0.603	rs628225	ENSG00000265194.1	RP11-70L8.4	-3.58	0.000363	0.0189	-0.12	-0.11	Quantitative traits;	chr9:22741676	chr9:21858910~21861926:-
BRCA	cis	rs73072330	1	rs17729010	ENSG00000229759.1	MRPS18AP1	3.58	0.000363	0.0189	0.24	0.11	Stem cell growth factor beta levels;	chr3:47871213	chr3:48256350~48256938:-
BRCA	cis	rs801193	1	rs2659909	ENSG00000275400.1	RP4-756H11.5	-3.58	0.000363	0.0189	-0.12	-0.11	Aortic root size;	chr7:66695292	chr7:66553805~66554199:-
BRCA	cis	rs9959145	1	rs28815517	ENSG00000267108.1	RP11-861E21.1	3.58	0.000363	0.0189	0.19	0.11	Immune response to smallpox vaccine (IL-6);	chr18:12558747	chr18:12432897~12437635:+
BRCA	cis	rs7020830	0.898	rs13289199	ENSG00000230188.1	RP11-405L18.4	-3.58	0.000363	0.0189	-0.13	-0.11	Schizophrenia;	chr9:37278067	chr9:37490421~37490893:-
BRCA	cis	rs6774494	1	rs6774494	ENSG00000269889.1	RP11-816J6.3	3.58	0.000363	0.0189	0.15	0.11	Nasopharyngeal carcinoma;	chr3:169364845	chr3:169769649~169772043:+
BRCA	cis	rs11098499	0.644	rs3986377	ENSG00000249244.1	RP11-548H18.2	3.58	0.000363	0.0189	0.12	0.11	Corneal astigmatism;	chr4:119339115	chr4:119391831~119395335:-
BRCA	cis	rs10028773	0.556	rs4473640	ENSG00000249244.1	RP11-548H18.2	3.58	0.000363	0.0189	0.12	0.11	Educational attainment;	chr4:119339282	chr4:119391831~119395335:-
BRCA	cis	rs4243971	0.516	rs6141662	ENSG00000275576.1	RP5-836N17.4	-3.58	0.000363	0.0189	-0.12	-0.11	Inflammatory bowel disease;Crohn's disease;	chr20:32294357	chr20:32116171~32116629:+
BRCA	cis	rs3824867	0.92	rs7101772	ENSG00000280615.1	Y_RNA	3.58	0.000363	0.0189	0.13	0.11	Mean corpuscular hemoglobin;	chr11:47427827	chr11:47614898~47614994:-
BRCA	cis	rs2640806	0.67	rs28629440	ENSG00000253105.4	KB-1448A5.1	3.58	0.000363	0.0189	0.13	0.11	Obesity-related traits;	chr8:96313394	chr8:96371865~96387438:-
BRCA	cis	rs8040855	0.627	rs4980357	ENSG00000229212.6	RP11-561C5.4	-3.58	0.000363	0.0189	-0.15	-0.11	Bulimia nervosa;	chr15:85064878	chr15:85205440~85234795:-
BRCA	cis	rs8040855	0.627	rs4980356	ENSG00000229212.6	RP11-561C5.4	-3.58	0.000363	0.0189	-0.15	-0.11	Bulimia nervosa;	chr15:85064901	chr15:85205440~85234795:-
BRCA	cis	rs12724450	0.793	rs71622698	ENSG00000228126.1	FALEC	3.58	0.000363	0.0189	0.21	0.11	Blood protein levels;	chr1:150432497	chr1:150515757~150518032:+
BRCA	cis	rs337100	0.546	rs393099	ENSG00000263432.2	RN7SL689P	-3.58	0.000363	0.0189	-0.13	-0.11	Pulse pressure;	chr5:123137073	chr5:123022487~123022783:-
BRCA	cis	rs9400180	0.879	rs9386703	ENSG00000271734.1	RP1-111B22.3	-3.58	0.000363	0.0189	-0.15	-0.11	Major depressive disorder;	chr6:108059389	chr6:108030249~108030718:-
BRCA	cis	rs8180040	0.654	rs6766230	ENSG00000280667.1	Y_RNA	3.58	0.000363	0.0189	0.12	0.11	Colorectal cancer;	chr3:47154719	chr3:47501083~47501182:+
BRCA	cis	rs8180040	0.627	rs9821119	ENSG00000280667.1	Y_RNA	3.58	0.000363	0.0189	0.12	0.11	Colorectal cancer;	chr3:47156947	chr3:47501083~47501182:+
BRCA	cis	rs875971	0.66	rs10263935	ENSG00000273142.1	RP11-458F8.4	-3.58	0.000363	0.0189	-0.09	-0.11	Aortic root size;	chr7:66631041	chr7:66902857~66906297:+
BRCA	cis	rs56046484	0.956	rs34054841	ENSG00000230373.7	GOLGA6L5P	3.58	0.000363	0.0189	0.17	0.11	Testicular germ cell tumor;	chr15:85058115	chr15:84507885~84516814:-
BRCA	cis	rs17680741	0.697	rs12269333	ENSG00000225484.5	NUTM2B-AS1	-3.58	0.000363	0.0189	-0.18	-0.11	Coronary artery disease;	chr10:80507049	chr10:79663088~79826594:-
BRCA	cis	rs6120849	0.707	rs6120798	ENSG00000202150.1	RNU6-407P	3.58	0.000363	0.0189	0.16	0.11	Protein C levels;	chr20:35023019	chr20:35030317~35030420:-
BRCA	cis	rs4835473	0.932	rs6827971	ENSG00000249741.2	RP11-673E1.3	3.58	0.000363	0.0189	0.11	0.11	Immature fraction of reticulocytes;	chr4:143822126	chr4:143911514~143912053:-
BRCA	cis	rs7954584	0.616	rs10743185	ENSG00000212694.7	LINC01089	-3.58	0.000363	0.0189	-0.09	-0.11	Mean corpuscular volume;	chr12:121918529	chr12:121795267~121803906:-
BRCA	cis	rs9368481	0.761	rs4358615	ENSG00000224843.5	LINC00240	-3.58	0.000363	0.0189	-0.13	-0.11	Autism spectrum disorder or schizophrenia;	chr6:27030788	chr6:26956992~27023924:+
BRCA	cis	rs1635	0.826	rs4713159	ENSG00000216901.1	AL022393.7	3.58	0.000363	0.0189	0.26	0.11	Schizophrenia;	chr6:28315995	chr6:28176188~28176674:+
BRCA	cis	rs875971	0.895	rs12698520	ENSG00000229886.1	RP5-1132H15.3	3.58	0.000363	0.0189	0.12	0.11	Aortic root size;	chr7:66453720	chr7:66025126~66031544:-
BRCA	cis	rs61931739	0.5	rs3924704	ENSG00000258794.3	DUX4L27	3.58	0.000363	0.0189	0.16	0.11	Morning vs. evening chronotype;	chr12:34404898	chr12:34208415~34209675:-
BRCA	cis	rs4761702	0.527	rs12824664	ENSG00000257322.4	RP11-511B23.2	-3.58	0.000363	0.0189	-0.14	-0.11	Immature fraction of reticulocytes;	chr12:93343125	chr12:93003415~93215679:-
BRCA	cis	rs4449834	0.816	rs4738821	ENSG00000254432.1	RP11-33I11.2	-3.58	0.000364	0.0189	-0.15	-0.11	Sum eosinophil basophil counts;	chr8:60763977	chr8:60808735~60809606:-
BRCA	cis	rs17684571	0.872	rs34832779	ENSG00000231441.1	RP11-472M19.2	3.58	0.000364	0.0189	0.19	0.11	Schizophrenia;	chr6:56758350	chr6:56844002~56864078:+
BRCA	cis	rs2108622	0.727	rs62107770	ENSG00000214049.6	UCA1	3.58	0.000364	0.0189	0.16	0.11	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15874615	chr19:15828961~15836320:+
BRCA	cis	rs6840360	0.573	rs11099807	ENSG00000278978.1	RP11-164P12.5	-3.58	0.000364	0.0189	-0.12	-0.11	Intelligence (multi-trait analysis);	chr4:151348076	chr4:151669786~151670503:+
BRCA	cis	rs1949733	1	rs1357481	ENSG00000251615.3	RP11-774O3.3	-3.58	0.000364	0.0189	-0.12	-0.11	Response to antineoplastic agents;	chr4:8494494	chr4:8355090~8358338:-
BRCA	cis	rs739401	0.869	rs395188	ENSG00000183562.3	CTC-343N3.1	3.58	0.000364	0.0189	0.11	0.11	Longevity;	chr11:3051401	chr11:2989863~2991344:+
BRCA	cis	rs568617	1	rs641018	ENSG00000254614.2	AP003068.23	-3.58	0.000364	0.0189	-0.16	-0.11	Crohn's disease;	chr11:65887922	chr11:65177606~65181834:-
BRCA	cis	rs10197140	1	rs12468564	ENSG00000235721.1	AC013268.3	-3.58	0.000364	0.0189	-0.14	-0.11	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110852042	chr2:110007675~110010783:+
BRCA	cis	rs10197140	1	rs10197140	ENSG00000235721.1	AC013268.3	-3.58	0.000364	0.0189	-0.14	-0.11	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110852366	chr2:110007675~110010783:+
BRCA	cis	rs10197140	1	rs10193050	ENSG00000235721.1	AC013268.3	-3.58	0.000364	0.0189	-0.14	-0.11	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110853521	chr2:110007675~110010783:+
BRCA	cis	rs6968419	0.537	rs7811113	ENSG00000279086.1	RP11-667F14.1	-3.58	0.000364	0.0189	-0.11	-0.11	Intraocular pressure;	chr7:116160765	chr7:116209234~116211511:-
BRCA	cis	rs4263408	0.934	rs4975036	ENSG00000224097.5	RP11-472B18.1	3.58	0.000364	0.0189	0.13	0.11	Plasma amyloid beta peptide concentrations (ABx-40);	chr4:39713470	chr4:39480255~39481905:+
BRCA	cis	rs853679	0.607	rs35749575	ENSG00000216901.1	AL022393.7	3.58	0.000364	0.0189	0.29	0.11	Depression;	chr6:28147040	chr6:28176188~28176674:+
BRCA	cis	rs17801127	0.818	rs16825497	ENSG00000231969.1	AC144449.1	3.58	0.000364	0.0189	0.19	0.11	Liver enzyme levels (alanine transaminase);	chr2:149675672	chr2:149587196~149848233:+
BRCA	cis	rs2153535	0.562	rs10458225	ENSG00000251164.1	HULC	3.58	0.000364	0.0189	0.13	0.11	Motion sickness;	chr6:8385771	chr6:8652137~8653846:+
BRCA	cis	rs6490294	0.571	rs7970397	ENSG00000234608.6	MAPKAPK5-AS1	3.58	0.000364	0.0189	0.16	0.11	Mean platelet volume;	chr12:112142267	chr12:111839764~111842902:-
BRCA	cis	rs6121246	1	rs6121246	ENSG00000230613.1	HM13-AS1	3.58	0.000364	0.0189	0.16	0.11	Mean corpuscular hemoglobin;	chr20:31845549	chr20:31567707~31573263:-
BRCA	cis	rs7475343	0.612	rs61854729	ENSG00000224034.1	RP11-445P17.8	-3.58	0.000364	0.0189	-0.21	-0.11	Intelligence;	chr10:5190979	chr10:5266033~5271236:-
BRCA	cis	rs853679	0.546	rs34295134	ENSG00000241549.7	GUSBP2	3.58	0.000364	0.0189	0.2	0.11	Depression;	chr6:27860373	chr6:26871484~26956554:-
BRCA	cis	rs2803122	0.807	rs4977289	ENSG00000272842.1	RP11-513M16.7	-3.58	0.000364	0.0189	-0.11	-0.11	Pulse pressure;	chr9:19225190	chr9:19371386~19371945:-
BRCA	cis	rs10769025	0.519	rs80053551	ENSG00000244926.5	ALKBH3-AS1	-3.58	0.000364	0.0189	-0.17	-0.11	Gout;	chr11:44268995	chr11:43909292~43920944:-
BRCA	cis	rs12468226	0.938	rs114922024	ENSG00000272966.1	RP11-686O6.1	3.58	0.000364	0.0189	0.18	0.11	Urate levels;	chr2:202315958	chr2:202336739~202337200:+
BRCA	cis	rs12468226	0.938	rs77261109	ENSG00000272966.1	RP11-686O6.1	3.58	0.000364	0.0189	0.18	0.11	Urate levels;	chr2:202316233	chr2:202336739~202337200:+
BRCA	cis	rs12468226	0.938	rs12466003	ENSG00000272966.1	RP11-686O6.1	3.58	0.000364	0.0189	0.18	0.11	Urate levels;	chr2:202317317	chr2:202336739~202337200:+
BRCA	cis	rs2031532	0.569	rs6561526	ENSG00000236577.1	SNRPGP14	3.58	0.000364	0.0189	0.13	0.11	Cardiac hypertrophy;	chr13:49492388	chr13:49488970~49489364:+
BRCA	cis	rs13126694	0.744	rs9968557	ENSG00000251073.1	NUDT19P5	3.58	0.000364	0.0189	0.11	0.11	Blood osmolality (transformed sodium);	chr4:158098673	chr4:158182825~158183393:+
BRCA	cis	rs60871478	0.838	rs7789321	ENSG00000237181.1	AC147651.4	-3.58	0.000364	0.0189	-0.12	-0.11	Cerebrospinal P-tau181p levels;	chr7:761340	chr7:603185~608482:+
BRCA	cis	rs80226907	0.634	rs75855839	ENSG00000186615.9	KTN1-AS1	-3.58	0.000364	0.0189	-0.24	-0.11	Mean platelet volume;	chr14:55452377	chr14:55499278~55580110:-
BRCA	cis	rs9650657	0.623	rs11250065	ENSG00000154316.13	TDH	3.58	0.000364	0.0189	0.14	0.11	Neuroticism;	chr8:10742871	chr8:11339637~11368452:+
BRCA	cis	rs848490	0.928	rs55919387	ENSG00000214293.7	APTR	3.58	0.000364	0.0189	0.14	0.11	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77686304	chr7:77657660~77696265:-
BRCA	cis	rs10484434	0.792	rs9689245	ENSG00000272810.1	U91328.22	3.58	0.000364	0.0189	0.16	0.11	HIV-1 viral setpoint;	chr6:26050617	chr6:26013241~26013757:+
BRCA	cis	rs1538970	0.924	rs11211117	ENSG00000281133.1	AL355480.3	-3.58	0.000364	0.0189	-0.15	-0.11	Platelet count;	chr1:45464574	chr1:45580892~45580996:-
BRCA	cis	rs8141529	0.748	rs7287918	ENSG00000226471.5	CTA-292E10.6	-3.58	0.000364	0.0189	-0.13	-0.11	Lymphocyte counts;	chr22:28885722	chr22:28800683~28848559:+
BRCA	cis	rs316020	1	rs316010	ENSG00000251988.1	RNU4ATAC18P	-3.58	0.000364	0.0189	-0.2	-0.11	Blood metabolite ratios;	chr6:160253525	chr6:159720415~159720540:-
BRCA	cis	rs2278034	0.578	rs881753	ENSG00000207650.1	MIR570	-3.58	0.000365	0.0189	-0.12	-0.11	Bronchopulmonary dysplasia;	chr3:195879899	chr3:195699401~195699497:+
BRCA	cis	rs6044112	1	rs6044112	ENSG00000273998.1	RP4-777L9.2	3.58	0.000365	0.0189	0.18	0.11	Response to taxane treatment (docetaxel);	chr20:16555769	chr20:16576068~16579615:+
BRCA	cis	rs2692947	0.864	rs2579518	ENSG00000232931.4	LINC00342	3.58	0.000365	0.0189	0.12	0.11	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96009511	chr2:95807118~95816215:-
BRCA	cis	rs748404	0.666	rs10518812	ENSG00000166763.7	STRCP1	-3.58	0.000365	0.0189	-0.16	-0.11	Lung cancer;	chr15:43360739	chr15:43699488~43718184:-
BRCA	cis	rs6991838	0.584	rs7823840	ENSG00000272155.1	RP11-707M3.3	3.58	0.000365	0.0189	0.1	0.11	Intelligence (multi-trait analysis);	chr8:65606766	chr8:65714334~65714778:-
BRCA	cis	rs6918586	0.636	rs198817	ENSG00000272810.1	U91328.22	-3.58	0.000365	0.0189	-0.12	-0.11	Schizophrenia;	chr6:26126296	chr6:26013241~26013757:+
BRCA	cis	rs2496589	1	rs9496639	ENSG00000217648.1	RP1-95L4.4	-3.58	0.000365	0.0189	-0.17	-0.11	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);	chr6:143447371	chr6:143342246~143343383:+
BRCA	cis	rs6601530	0.504	rs736669	ENSG00000248896.2	CTD-2135J3.3	-3.58	0.000365	0.0189	-0.13	-0.11	Carotid intima media thickness;	chr8:10763790	chr8:10729314~10771392:+
BRCA	cis	rs8073060	0.544	rs2626626	ENSG00000267554.1	RP11-686D22.10	-3.58	0.000365	0.0189	-0.12	-0.11	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35699698	chr17:35470069~35470628:-
BRCA	cis	rs9952980	0.621	rs1462149	ENSG00000266968.2	RP11-116O18.1	-3.58	0.000365	0.0189	-0.13	-0.11	Breast cancer;	chr18:45339960	chr18:45646153~45647937:+
BRCA	cis	rs7267979	1	rs2482943	ENSG00000274973.1	RP13-401N8.7	3.58	0.000365	0.0189	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25399957	chr20:25845497~25845862:+
BRCA	cis	rs6068583	0.86	rs6068585	ENSG00000197670.6	RP4-724E16.2	-3.58	0.000365	0.0189	-0.15	-0.11	Colorectal adenoma (advanced);	chr20:53575358	chr20:53552770~53575863:+
BRCA	cis	rs2274273	0.745	rs748017	ENSG00000259318.1	RP11-454L9.2	3.58	0.000365	0.0189	0.09	0.11	Protein biomarker;	chr14:55075582	chr14:55394940~55395233:-
BRCA	cis	rs12744310	0.502	rs12725272	ENSG00000235358.1	RP11-399E6.1	3.58	0.000365	0.0189	0.14	0.11	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41324190	chr1:41242373~41284861:+
BRCA	cis	rs8114671	0.551	rs4911162	ENSG00000261582.1	RP4-614O4.11	-3.58	0.000365	0.0189	-0.1	-0.11	Height;	chr20:34823622	chr20:35267885~35280043:-
BRCA	cis	rs10504130	0.569	rs12680128	ENSG00000272076.1	RP11-11C20.3	3.58	0.000365	0.0189	0.16	0.11	Venous thromboembolism (SNP x SNP interaction);	chr8:51766683	chr8:51810110~51810681:-
BRCA	cis	rs801193	0.967	rs34356500	ENSG00000232546.1	RP11-458F8.1	-3.58	0.000365	0.0189	-0.09	-0.11	Aortic root size;	chr7:66771620	chr7:66848496~66858136:+
BRCA	cis	rs1008375	0.931	rs979823	ENSG00000249502.1	AC006160.5	-3.58	0.000365	0.0189	-0.12	-0.11	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17698553	chr4:17587467~17614571:-
BRCA	cis	rs2243480	0.901	rs1701759	ENSG00000226002.1	RP11-460N20.5	-3.58	0.000365	0.0189	-0.18	-0.11	Diabetic kidney disease;	chr7:66005945	chr7:65084103~65100232:+
BRCA	cis	rs4243971	0.516	rs6141687	ENSG00000277692.1	RP11-358N2.2	-3.58	0.000365	0.0189	-0.12	-0.11	Inflammatory bowel disease;Crohn's disease;	chr20:32351737	chr20:32355053~32355734:+
BRCA	cis	rs4415084	1	rs6884702	ENSG00000272335.1	RP11-53O19.3	3.58	0.000365	0.019	0.1	0.11	Breast cancer;	chr5:44682487	chr5:44826076~44828592:+
BRCA	cis	rs818427	0.71	rs1966477	ENSG00000279522.1	CTC-487M23.6	-3.58	0.000365	0.019	-0.12	-0.11	Total body bone mineral density;	chr5:112837089	chr5:112894933~112896531:+
BRCA	cis	rs7176093	0.874	rs9635397	ENSG00000259295.5	CSPG4P12	-3.58	0.000365	0.019	-0.14	-0.11	Aging traits;	chr15:85802759	chr15:85191438~85213905:+
BRCA	cis	rs12701220	0.894	rs12701406	ENSG00000224079.1	AC091729.7	3.58	0.000365	0.019	0.17	0.11	Bronchopulmonary dysplasia;	chr7:1010647	chr7:1074450~1078036:+
BRCA	cis	rs4835473	0.643	rs34680080	ENSG00000246448.2	RP13-578N3.3	-3.58	0.000365	0.019	-0.13	-0.11	Immature fraction of reticulocytes;	chr4:143797290	chr4:143700257~143865072:+
BRCA	cis	rs6696239	1	rs6696239	ENSG00000227711.2	RP11-275O4.5	-3.58	0.000365	0.019	-0.15	-0.11	Height;	chr1:227562367	chr1:227509028~227520477:-
BRCA	cis	rs1949733	1	rs3103067	ENSG00000205959.3	RP11-689P11.2	-3.58	0.000365	0.019	-0.11	-0.11	Response to antineoplastic agents;	chr4:8509496	chr4:8482270~8512610:+
BRCA	cis	rs34792	0.524	rs34629185	ENSG00000275910.1	RP11-680G24.6	-3.58	0.000365	0.019	-0.14	-0.11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15517597	chr16:15015828~15016390:-
BRCA	cis	rs12612619	0.579	rs6756245	ENSG00000229122.1	AGBL5-IT1	3.58	0.000365	0.019	0.12	0.11	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:26860621	chr2:27061038~27061815:+
BRCA	cis	rs2736345	0.788	rs2618476	ENSG00000255354.1	RP11-148O21.2	-3.58	0.000365	0.019	-0.11	-0.11	Systemic lupus erythematosus;Sjögren's syndrome;	chr8:11495032	chr8:11558466~11560020:-
BRCA	cis	rs7487075	0.893	rs2408508	ENSG00000274723.1	RP11-618L22.1	3.58	0.000365	0.019	0.13	0.11	Itch intensity from mosquito bite;	chr12:46336817	chr12:46970504~46972155:+
BRCA	cis	rs889122	0.765	rs889162	ENSG00000267289.1	CTD-2623N2.11	3.58	0.000365	0.019	0.16	0.11	Menarche (age at onset);	chr19:9841240	chr19:9834079~9835013:-
BRCA	cis	rs34773007	0.518	rs66468832	ENSG00000232709.1	MARK2P9	3.58	0.000365	0.019	0.15	0.11	Type 2 diabetes;	chr10:92955087	chr10:92418667~92420875:+
BRCA	cis	rs875971	0.66	rs10263935	ENSG00000265600.1	AC006480.1	-3.58	0.000366	0.019	-0.13	-0.11	Aortic root size;	chr7:66631041	chr7:67356680~67356779:+
BRCA	cis	rs72766638	0.895	rs11795079	ENSG00000235106.7	LINC00094	3.58	0.000366	0.019	0.15	0.11	Mosquito bite size;	chr9:134065012	chr9:134025439~134034666:+
BRCA	cis	rs10129255	1	rs11621409	ENSG00000211958.2	IGHV3-38	3.58	0.000366	0.019	0.09	0.11	Kawasaki disease;	chr14:106695603	chr14:106410493~106411021:-
BRCA	cis	rs2041840	0.538	rs3821142	ENSG00000272054.1	RP11-423P10.2	-3.58	0.000366	0.019	-0.09	-0.11	Chronic lymphocytic leukemia;	chr2:37348144	chr2:37208875~37212677:+
BRCA	cis	rs74233809	1	rs11191453	ENSG00000236937.2	PTGES3P4	3.58	0.000366	0.019	0.24	0.11	Birth weight;	chr10:102900095	chr10:102845595~102845950:+
BRCA	cis	rs6545883	0.507	rs12478192	ENSG00000270820.4	RP11-355B11.2	-3.58	0.000366	0.019	-0.12	-0.11	Tuberculosis;	chr2:61364040	chr2:61471188~61484130:+
BRCA	cis	rs2657888	0.528	rs12304519	ENSG00000257576.1	RP11-153M3.1	-3.58	0.000366	0.019	-0.14	-0.11	Adiponectin levels;	chr12:56480738	chr12:56511002~56512703:+
BRCA	cis	rs7267979	0.934	rs2257464	ENSG00000274414.1	RP5-965G21.4	-3.58	0.000366	0.019	-0.13	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25285236	chr20:25239007~25245229:-
BRCA	cis	rs56046484	0.956	rs34105012	ENSG00000230373.7	GOLGA6L5P	3.58	0.000366	0.019	0.17	0.11	Testicular germ cell tumor;	chr15:85048455	chr15:84507885~84516814:-
BRCA	cis	rs6545883	0.929	rs9679557	ENSG00000273302.1	RP11-493E12.2	3.58	0.000366	0.019	0.1	0.11	Tuberculosis;	chr2:61482214	chr2:61199979~61200769:+
BRCA	cis	rs7487075	0.619	rs10785629	ENSG00000257261.4	RP11-96H19.1	3.58	0.000366	0.019	0.12	0.11	Itch intensity from mosquito bite;	chr12:46460944	chr12:46383679~46876159:+
BRCA	cis	rs6772849	0.896	rs4857859	ENSG00000207088.1	SNORA7B	-3.58	0.000366	0.019	-0.14	-0.11	Monocyte percentage of white cells;Monocyte count;	chr3:128629171	chr3:129397210~129397348:-
BRCA	cis	rs1371614	0.523	rs4233714	ENSG00000272148.1	RP11-195B17.1	-3.58	0.000366	0.019	-0.12	-0.11	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26958586	chr2:27062428~27062907:-
BRCA	cis	rs2602836	0.83	rs2602874	ENSG00000272777.1	RP11-571L19.8	-3.58	0.000366	0.019	-0.11	-0.11	HDL cholesterol;HDL cholesterol levels;	chr4:99118245	chr4:99067256~99068125:-
BRCA	cis	rs875971	0.755	rs76288834	ENSG00000229886.1	RP5-1132H15.3	-3.58	0.000366	0.019	-0.12	-0.11	Aortic root size;	chr7:66604815	chr7:66025126~66031544:-
BRCA	cis	rs4665809	0.878	rs4665826	ENSG00000231655.1	AC011742.3	-3.58	0.000366	0.019	-0.17	-0.11	Gut microbiome composition (summer);	chr2:26144634	chr2:26140263~26141264:-
BRCA	cis	rs10411161	0.702	rs11879319	ENSG00000269483.1	AC006272.1	3.58	0.000366	0.019	0.18	0.11	Breast cancer;	chr19:51886339	chr19:51839924~51843324:-
BRCA	cis	rs11035577	0.57	rs10837252	ENSG00000279675.1	RP11-454H19.2	-3.58	0.000366	0.019	-0.17	-0.11	Temperament (bipolar disorder);	chr11:39761958	chr11:40107244~40112599:-
BRCA	cis	rs11035577	0.632	rs10837253	ENSG00000279675.1	RP11-454H19.2	-3.58	0.000366	0.019	-0.17	-0.11	Temperament (bipolar disorder);	chr11:39761971	chr11:40107244~40112599:-
BRCA	cis	rs4516970	1	rs7752664	ENSG00000237927.1	RP3-393E18.2	3.58	0.000366	0.019	0.28	0.11	Iron status biomarkers;	chr6:159798003	chr6:159586955~159589169:-
BRCA	cis	rs6012564	0.788	rs6095404	ENSG00000227431.4	CSE1L-AS1	3.58	0.000366	0.019	0.13	0.11	Anger;	chr20:49040144	chr20:49040463~49046044:-
BRCA	cis	rs17014483	0.749	rs3017899	ENSG00000248019.2	FAM13A-AS1	-3.58	0.000366	0.019	-0.14	-0.11	Post bronchodilator FEV1/FVC ratio;	chr4:88722846	chr4:88709789~88730103:+
BRCA	cis	rs4664293	0.647	rs6756502	ENSG00000224152.1	AC009506.1	3.58	0.000366	0.019	0.12	0.11	Monocyte percentage of white cells;	chr2:159698072	chr2:159615296~159617082:+
BRCA	cis	rs2841277	0.708	rs10083374	ENSG00000258701.1	LINC00638	3.58	0.000366	0.019	0.12	0.11	Rheumatoid arthritis;	chr14:104936657	chr14:104821201~104823718:+
BRCA	cis	rs9437689	0.566	rs1146465	ENSG00000235501.4	RP4-639F20.1	-3.58	0.000366	0.019	-0.13	-0.11	Phospholipid levels (plasma);	chr1:94936057	chr1:94927566~94963270:+
BRCA	cis	rs2400362	0.618	rs7007683	ENSG00000254162.1	RP11-48B3.3	-3.58	0.000366	0.019	-0.12	-0.11	Glucocorticoid-induced osteonecrosis (age 10 years and older);	chr8:80928640	chr8:80535006~80539135:-
BRCA	cis	rs4713118	0.868	rs9468220	ENSG00000280107.1	AL022393.9	3.58	0.000366	0.019	0.16	0.11	Parkinson's disease;	chr6:27765197	chr6:28170845~28172521:+
BRCA	cis	rs4869313	0.668	rs2549797	ENSG00000248734.2	CTD-2260A17.1	-3.57	0.000366	0.019	-0.11	-0.11	Pediatric autoimmune diseases;	chr5:96909814	chr5:96784777~96785999:+
BRCA	cis	rs1122794	1	rs1122794	ENSG00000268836.1	LA16c-OS12.2	-3.57	0.000366	0.019	-0.13	-0.11	Mean corpuscular hemoglobin;Red blood cell traits;	chr16:259156	chr16:185748~186294:-
BRCA	cis	rs77457752	0.525	rs10961293	ENSG00000270547.4	LINC01235	3.57	0.000366	0.019	0.19	0.11	Breast cancer;	chr9:13894251	chr9:13406380~13433053:-
BRCA	cis	rs7020830	0.898	rs12554874	ENSG00000230188.1	RP11-405L18.4	-3.57	0.000366	0.019	-0.14	-0.11	Schizophrenia;	chr9:37073905	chr9:37490421~37490893:-
BRCA	cis	rs4835473	0.932	rs35164917	ENSG00000246448.2	RP13-578N3.3	3.57	0.000366	0.019	0.12	0.11	Immature fraction of reticulocytes;	chr4:143748891	chr4:143700257~143865072:+
BRCA	cis	rs4478858	0.735	rs6676354	ENSG00000223907.1	LINC01226	-3.57	0.000366	0.019	-0.13	-0.11	Alcohol dependence;	chr1:31327899	chr1:31518435~31524245:+
BRCA	cis	rs733592	0.929	rs4760678	ENSG00000273765.1	RP11-370I10.11	-3.57	0.000367	0.019	-0.13	-0.11	Plateletcrit;	chr12:48067798	chr12:48360920~48361377:+
BRCA	cis	rs733592	0.965	rs1978161	ENSG00000273765.1	RP11-370I10.11	-3.57	0.000367	0.019	-0.13	-0.11	Plateletcrit;	chr12:48073938	chr12:48360920~48361377:+
BRCA	cis	rs4950322	0.518	rs56151278	ENSG00000230832.3	RP11-325P15.2	-3.57	0.000367	0.019	-0.17	-0.11	Protein quantitative trait loci;	chr1:147117421	chr1:147082338~147083578:-
BRCA	cis	rs11088226	0.681	rs2833912	ENSG00000186842.4	LINC00846	-3.57	0.000367	0.019	-0.18	-0.11	Gastritis;	chr21:32577512	chr21:32572238~32575881:-
BRCA	cis	rs11088226	0.681	rs9622	ENSG00000186842.4	LINC00846	-3.57	0.000367	0.019	-0.18	-0.11	Gastritis;	chr21:32578758	chr21:32572238~32575881:-
BRCA	cis	rs10198628	0.685	rs10198180	ENSG00000264370.1	MIR3125	3.57	0.000367	0.019	0.13	0.11	Pericardial fat;Pericardial adipose tissue adjusted for height and weight;	chr2:12796064	chr2:12737367~12737444:+
BRCA	cis	rs2243480	1	rs313831	ENSG00000237026.1	RP11-328P23.2	3.57	0.000367	0.019	0.21	0.11	Diabetic kidney disease;	chr7:66086239	chr7:65235790~65236723:-
BRCA	cis	rs11892454	0.599	rs55946759	ENSG00000217643.1	PTGES3P2	-3.57	0.000367	0.019	-0.12	-0.11	Heschl's gyrus morphology;	chr2:25745953	chr2:25822469~25822950:+
BRCA	cis	rs7267979	0.706	rs6037069	ENSG00000231081.1	RP4-760C5.3	-3.57	0.000367	0.019	-0.14	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25253530	chr20:26008791~26010531:-
BRCA	cis	rs672059	1	rs547905	ENSG00000224468.3	RP11-181K3.4	-3.57	0.000367	0.019	-0.12	-0.11	Hypertriglyceridemia;	chr1:183188789	chr1:183138402~183141282:-
BRCA	cis	rs68170813	0.617	rs10464499	ENSG00000241764.3	AC002467.7	3.57	0.000367	0.019	0.19	0.11	Coronary artery disease;	chr7:107497126	chr7:107742817~107744581:-
BRCA	cis	rs68170813	0.617	rs12535761	ENSG00000241764.3	AC002467.7	3.57	0.000367	0.019	0.19	0.11	Coronary artery disease;	chr7:107498830	chr7:107742817~107744581:-
BRCA	cis	rs9868809	0.881	rs2276850	ENSG00000225399.4	RP11-3B7.1	-3.57	0.000367	0.019	-0.18	-0.11	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48632215	chr3:49260085~49261316:+
BRCA	cis	rs9868809	0.881	rs34368826	ENSG00000225399.4	RP11-3B7.1	-3.57	0.000367	0.019	-0.18	-0.11	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48633394	chr3:49260085~49261316:+
BRCA	cis	rs2832077	0.943	rs2832084	ENSG00000215533.7	LINC00189	3.57	0.000367	0.019	0.16	0.11	Cognitive test performance;	chr21:28782476	chr21:29193480~29288205:+
BRCA	cis	rs2640806	0.505	rs7818838	ENSG00000253105.4	KB-1448A5.1	3.57	0.000367	0.019	0.13	0.11	Obesity-related traits;	chr8:96347051	chr8:96371865~96387438:-
BRCA	cis	rs7267979	1	rs2257982	ENSG00000274414.1	RP5-965G21.4	-3.57	0.000367	0.019	-0.13	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25288994	chr20:25239007~25245229:-
BRCA	cis	rs7267979	1	rs2257985	ENSG00000274414.1	RP5-965G21.4	-3.57	0.000367	0.019	-0.13	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25289107	chr20:25239007~25245229:-
BRCA	cis	rs7267979	1	rs2257988	ENSG00000274414.1	RP5-965G21.4	-3.57	0.000367	0.019	-0.13	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25289367	chr20:25239007~25245229:-
BRCA	cis	rs7267979	0.966	rs6050532	ENSG00000274414.1	RP5-965G21.4	3.57	0.000367	0.019	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25328157	chr20:25239007~25245229:-
BRCA	cis	rs61931739	0.5	rs7488438	ENSG00000258794.3	DUX4L27	3.57	0.000367	0.019	0.16	0.11	Morning vs. evening chronotype;	chr12:34378424	chr12:34208415~34209675:-
BRCA	cis	rs10761482	0.861	rs7089563	ENSG00000254271.1	RP11-131N11.4	3.57	0.000367	0.019	0.15	0.11	Schizophrenia;	chr10:60350140	chr10:60734342~60741828:+
BRCA	cis	rs10761482	0.861	rs7073512	ENSG00000254271.1	RP11-131N11.4	3.57	0.000367	0.019	0.15	0.11	Schizophrenia;	chr10:60350168	chr10:60734342~60741828:+
BRCA	cis	rs10761482	0.861	rs719095	ENSG00000254271.1	RP11-131N11.4	3.57	0.000367	0.019	0.15	0.11	Schizophrenia;	chr10:60351191	chr10:60734342~60741828:+
BRCA	cis	rs13434995	0.513	rs6554282	ENSG00000273257.1	RP11-177J6.1	3.57	0.000367	0.019	0.16	0.11	Adiponectin levels;	chr4:55519812	chr4:55387949~55388271:+
BRCA	cis	rs13434995	0.513	rs6554283	ENSG00000273257.1	RP11-177J6.1	3.57	0.000367	0.019	0.16	0.11	Adiponectin levels;	chr4:55521053	chr4:55387949~55388271:+
BRCA	cis	rs13434995	0.513	rs1546004	ENSG00000273257.1	RP11-177J6.1	3.57	0.000367	0.019	0.16	0.11	Adiponectin levels;	chr4:55521612	chr4:55387949~55388271:+
BRCA	cis	rs13434995	0.513	rs4865006	ENSG00000273257.1	RP11-177J6.1	3.57	0.000367	0.019	0.16	0.11	Adiponectin levels;	chr4:55526112	chr4:55387949~55388271:+
BRCA	cis	rs6095360	0.625	rs2426132	ENSG00000222365.1	SNORD12B	-3.57	0.000367	0.019	-0.11	-0.11	Intelligence (multi-trait analysis);	chr20:49106590	chr20:49280319~49280409:+
BRCA	cis	rs2692947	0.537	rs11164050	ENSG00000168992.4	OR7E102P	3.57	0.000367	0.019	0.15	0.11	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95686703	chr2:95546531~95547545:+
BRCA	cis	rs9992667	0.516	rs13328049	ENSG00000231160.8	KLF3-AS1	3.57	0.000367	0.019	0.12	0.11	Eosinophil percentage of granulocytes;	chr4:38701452	chr4:38612701~38664883:-
BRCA	cis	rs10875943	0.751	rs56222401	ENSG00000258101.2	RP11-977B10.2	3.57	0.000367	0.019	0.15	0.11	Prostate cancer;	chr12:49278931	chr12:49232790~49264756:-
BRCA	cis	rs72775230	0.68	rs72775234	ENSG00000233990.1	RP11-401E9.3	-3.57	0.000367	0.019	-0.2	-0.11	Conotruncal heart defects (inherited effects);	chr10:8516361	chr10:7833618~7833957:-
BRCA	cis	rs10043228	0.702	rs6866938	ENSG00000250015.1	CTC-339F2.2	3.57	0.000367	0.019	0.13	0.11	Asthma or chronic obstructive pulmonary disease;	chr5:116292420	chr5:116302354~116304134:-
BRCA	cis	rs3755605	0.728	rs16847919	ENSG00000242578.1	RP11-469J4.3	3.57	0.000367	0.019	0.13	0.11	Testicular germ cell tumor;	chr3:170174510	chr3:170410512~170418615:+
BRCA	cis	rs7481311	0.956	rs11030075	ENSG00000245573.6	BDNF-AS	-3.57	0.000367	0.019	-0.13	-0.11	Weight;Body mass index;	chr11:27605749	chr11:27506838~27698174:+
BRCA	cis	rs962856	0.575	rs6740919	ENSG00000236780.4	AC078941.1	-3.57	0.000367	0.019	-0.15	-0.11	Pancreatic cancer;	chr2:67392923	chr2:67123357~67215319:-
BRCA	cis	rs17483466	0.628	rs6730256	ENSG00000175772.10	LINC01106	-3.57	0.000367	0.019	-0.24	-0.11	Chronic lymphocytic leukemia;	chr2:111014234	chr2:110375138~110384442:-
BRCA	cis	rs1979679	0.918	rs11049513	ENSG00000244712.1	RP11-874G11.1	-3.57	0.000367	0.019	-0.16	-0.11	Ossification of the posterior longitudinal ligament of the spine;	chr12:28297218	chr12:28564678~28565141:-
BRCA	cis	rs687432	0.885	rs7121128	ENSG00000265566.2	RN7SL605P	-3.57	0.000367	0.019	-0.15	-0.11	Parkinson's disease;	chr11:57976459	chr11:57528085~57528365:-
BRCA	cis	rs1008375	0.931	rs10939734	ENSG00000249502.1	AC006160.5	-3.57	0.000367	0.019	-0.13	-0.11	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17569086	chr4:17587467~17614571:-
BRCA	cis	rs2562456	0.52	rs279793	ENSG00000268081.1	RP11-678G14.2	3.57	0.000367	0.019	0.19	0.11	Pain;	chr19:21272972	chr19:21554640~21569237:-
BRCA	cis	rs7598759	0.966	rs6754426	ENSG00000281035.1	AC017104.3	-3.57	0.000367	0.0191	-0.12	-0.11	Noise-induced hearing loss;	chr2:231458068	chr2:231456417~231456557:-
BRCA	cis	rs1143633	0.537	rs4447608	ENSG00000231747.1	AC079922.2	3.57	0.000367	0.0191	0.1	0.11	Allergic disease (asthma, hay fever or eczema);	chr2:112848380	chr2:112621809~112622167:-
BRCA	cis	rs8013055	0.796	rs4075105	ENSG00000253364.1	RP11-731F5.2	-3.57	0.000367	0.0191	-0.14	-0.11	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);	chr14:105533894	chr14:105644496~105649057:-
BRCA	cis	rs938554	0.694	rs4697700	ENSG00000250413.1	RP11-448G15.1	-3.57	0.000367	0.0191	-0.16	-0.11	Blood metabolite levels;	chr4:9944168	chr4:10006482~10009725:+
BRCA	cis	rs6120849	0.754	rs11167253	ENSG00000202150.1	RNU6-407P	3.57	0.000368	0.0191	0.16	0.11	Protein C levels;	chr20:35026646	chr20:35030317~35030420:-
BRCA	cis	rs6120849	0.707	rs6120799	ENSG00000202150.1	RNU6-407P	3.57	0.000368	0.0191	0.16	0.11	Protein C levels;	chr20:35027152	chr20:35030317~35030420:-
BRCA	cis	rs6120849	0.754	rs6088682	ENSG00000202150.1	RNU6-407P	3.57	0.000368	0.0191	0.16	0.11	Protein C levels;	chr20:35027899	chr20:35030317~35030420:-
BRCA	cis	rs6120849	0.754	rs13433216	ENSG00000202150.1	RNU6-407P	3.57	0.000368	0.0191	0.16	0.11	Protein C levels;	chr20:35028498	chr20:35030317~35030420:-
BRCA	cis	rs12438356	0.686	rs2047823	ENSG00000259222.2	RP11-809H16.5	-3.57	0.000368	0.0191	-0.17	-0.11	CTACK levels;	chr15:69215828	chr15:69080879~69099987:+
BRCA	cis	rs2617170	0.922	rs2250877	ENSG00000245648.1	RP11-277P12.20	3.57	0.000368	0.0191	0.14	0.11	Behcet's disease;	chr12:10393659	chr12:10363769~10398506:+
BRCA	cis	rs4557020	0.967	rs4429513	ENSG00000162997.14	PRORSD1P	-3.57	0.000368	0.0191	-0.12	-0.11	Myopia (pathological);	chr2:54481924	chr2:55282319~55284522:+
BRCA	cis	rs3781913	0.874	rs12363065	ENSG00000215841.3	RP11-800A3.2	3.57	0.000368	0.0191	0.13	0.11	Rheumatoid arthritis;	chr11:72659855	chr11:73214998~73215913:-
BRCA	cis	rs11673344	0.864	rs1533736	ENSG00000267005.1	AC002984.2	3.57	0.000368	0.0191	0.15	0.11	Obesity-related traits;	chr19:37164074	chr19:36173406~36173853:-
BRCA	cis	rs1075265	0.836	rs11687324	ENSG00000272156.1	RP11-477N3.1	-3.57	0.000368	0.0191	-0.11	-0.11	Chronotype;Morning vs. evening chronotype;	chr2:54046589	chr2:54082554~54085066:+
BRCA	cis	rs17221829	0.537	rs7933470	ENSG00000280385.1	AP000648.5	-3.57	0.000368	0.0191	-0.13	-0.11	Anxiety in major depressive disorder;	chr11:89643795	chr11:90193614~90198120:+
BRCA	cis	rs17221829	0.536	rs7943784	ENSG00000280385.1	AP000648.5	-3.57	0.000368	0.0191	-0.13	-0.11	Anxiety in major depressive disorder;	chr11:89644142	chr11:90193614~90198120:+
BRCA	cis	rs13113518	0.51	rs3749473	ENSG00000273257.1	RP11-177J6.1	3.57	0.000368	0.0191	0.15	0.11	Height;	chr4:55428461	chr4:55387949~55388271:+
BRCA	cis	rs9287719	0.967	rs10929682	ENSG00000224177.5	LINC00570	3.57	0.000368	0.0191	0.13	0.11	Prostate cancer;	chr2:10592063	chr2:11393981~11403077:+
BRCA	cis	rs12681366	1	rs66787185	ENSG00000253175.1	RP11-267M23.6	3.57	0.000368	0.0191	0.13	0.11	Nonsyndromic cleft lip with cleft palate;	chr8:94365254	chr8:94565036~94565715:+
BRCA	cis	rs1865760	0.566	rs2858993	ENSG00000272462.2	U91328.19	-3.57	0.000368	0.0191	-0.13	-0.11	Height;	chr6:26087628	chr6:25992662~26001775:+
BRCA	cis	rs875971	0.505	rs6955582	ENSG00000232546.1	RP11-458F8.1	-3.57	0.000368	0.0191	-0.09	-0.11	Aortic root size;	chr7:65966699	chr7:66848496~66858136:+
BRCA	cis	rs1476670	0.565	rs2428965	ENSG00000236200.4	KDM4A-AS1	3.57	0.000368	0.0191	0.12	0.11	Eotaxin levels;	chr1:44037237	chr1:43699765~43708138:-
BRCA	cis	rs67073037	0.91	rs66604446	ENSG00000230730.1	AC074011.2	-3.57	0.000368	0.0191	-0.15	-0.11	Breast cancer;Breast cancer (estrogen-receptor negative);	chr2:28897064	chr2:28633282~28664540:-
BRCA	cis	rs67073037	0.955	rs66768547	ENSG00000230730.1	AC074011.2	-3.57	0.000368	0.0191	-0.15	-0.11	Breast cancer;Breast cancer (estrogen-receptor negative);	chr2:28897250	chr2:28633282~28664540:-
BRCA	cis	rs77741769	0.7	rs7969196	ENSG00000277423.1	RP11-173P15.9	3.57	0.000368	0.0191	0.14	0.11	Mean corpuscular volume;	chr12:120939853	chr12:120703867~120704282:+
BRCA	cis	rs7267979	0.932	rs6037125	ENSG00000274973.1	RP13-401N8.7	-3.57	0.000368	0.0191	-0.12	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25482746	chr20:25845497~25845862:+
BRCA	cis	rs4388249	1	rs67906234	ENSG00000271849.1	CTC-332L22.1	-3.57	0.000368	0.0191	-0.18	-0.11	Schizophrenia;	chr5:109730081	chr5:109687802~109688329:-
BRCA	cis	rs11662721	0.938	rs116238971	ENSG00000264188.1	RP11-13N13.5	3.57	0.000368	0.0191	0.16	0.11	Phospholipid levels (plasma);	chr18:21564889	chr18:21661787~21662395:-
BRCA	cis	rs2562456	0.833	rs62110428	ENSG00000268117.1	VN1R84P	3.57	0.000368	0.0191	0.17	0.11	Pain;	chr19:21430854	chr19:21719801~21720035:-
BRCA	cis	rs2391285	0.566	rs4483061	ENSG00000280255.1	RP5-1007F24.1	3.57	0.000368	0.0191	0.16	0.11	Post bronchodilator FEV1/FVC ratio;	chr7:26567879	chr7:26538378~26541048:+
BRCA	cis	rs2243480	1	rs313832	ENSG00000237026.1	RP11-328P23.2	3.57	0.000368	0.0191	0.21	0.11	Diabetic kidney disease;	chr7:66085904	chr7:65235790~65236723:-
BRCA	cis	rs6088590	0.603	rs6579186	ENSG00000269202.1	RP4-614O4.12	-3.57	0.000368	0.0191	-0.11	-0.11	Coronary artery disease;	chr20:34694394	chr20:35201747~35203288:-
BRCA	cis	rs2017387	0.515	rs157550	ENSG00000161643.11	SIGLEC16	-3.57	0.000368	0.0191	-0.22	-0.11	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50036114	chr19:49969673~49975814:+
BRCA	cis	rs10986311	0.775	rs6478658	ENSG00000227200.1	RP11-121A14.3	-3.57	0.000368	0.0191	-0.12	-0.11	Vitiligo;	chr9:124365531	chr9:124262876~124265809:+
BRCA	cis	rs2839186	0.843	rs17182671	ENSG00000215424.8	MCM3AP-AS1	3.57	0.000368	0.0191	0.1	0.11	Testicular germ cell tumor;	chr21:46276324	chr21:46229217~46259390:+
BRCA	cis	rs2839186	0.739	rs7282763	ENSG00000215424.8	MCM3AP-AS1	3.57	0.000368	0.0191	0.1	0.11	Testicular germ cell tumor;	chr21:46276886	chr21:46229217~46259390:+
BRCA	cis	rs10876993	0.855	rs1689585	ENSG00000270039.1	RP11-571M6.17	-3.57	0.000368	0.0191	-0.15	-0.11	Celiac disease or Rheumatoid arthritis;	chr12:57686357	chr12:57803838~57804415:+
BRCA	cis	rs6142618	0.562	rs4911548	ENSG00000224452.1	RSL24D1P6	3.57	0.000368	0.0191	0.15	0.11	Inflammatory bowel disease;	chr20:32147536	chr20:32170390~32170790:-
BRCA	cis	rs6142618	0.562	rs6142621	ENSG00000224452.1	RSL24D1P6	3.57	0.000368	0.0191	0.15	0.11	Inflammatory bowel disease;	chr20:32148004	chr20:32170390~32170790:-
BRCA	cis	rs12681366	0.762	rs7831073	ENSG00000253175.1	RP11-267M23.6	3.57	0.000368	0.0191	0.13	0.11	Nonsyndromic cleft lip with cleft palate;	chr8:94342138	chr8:94565036~94565715:+
BRCA	cis	rs11098403	0.719	rs11562857	ENSG00000225892.3	RP11-384K6.2	3.57	0.000368	0.0191	0.11	0.11	Schizophrenia;	chr4:117812710	chr4:118632274~118634759:+
BRCA	cis	rs525304	1	rs525304	ENSG00000279459.1	RP11-826F13.1	3.57	0.000368	0.0191	0.13	0.11	Response to fenofibrate (adiponectin levels);	chr11:70660101	chr11:70603304~70604859:+
BRCA	cis	rs75804782	0.641	rs41264155	ENSG00000186235.9	AC016757.3	3.57	0.000368	0.0191	0.25	0.11	Chronotype;Morning vs. evening chronotype;	chr2:238433455	chr2:238224552~238231677:-
BRCA	cis	rs2288884	0.505	rs4988334	ENSG00000275055.1	CTC-471J1.11	-3.57	0.000368	0.0191	-0.16	-0.11	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:51965745	chr19:52049007~52049754:+
BRCA	cis	rs970548	1	rs12257549	ENSG00000230869.1	CTGLF10P	3.57	0.000368	0.0191	0.14	0.11	Total cholesterol levels;HDL cholesterol;HDL cholesterol levels;Cholesterol, total;	chr10:45534183	chr10:45678692~45700532:+
BRCA	cis	rs17301013	0.861	rs332770	ENSG00000200674.1	RN7SKP160	3.57	0.000368	0.0191	0.15	0.11	Systemic lupus erythematosus;	chr1:174681511	chr1:173791548~173791887:+
BRCA	cis	rs7267979	1	rs6115146	ENSG00000276952.1	RP5-965G21.6	-3.57	0.000368	0.0191	-0.13	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25323871	chr20:25284915~25285588:-
BRCA	cis	rs7267979	0.934	rs6037085	ENSG00000276952.1	RP5-965G21.6	-3.57	0.000368	0.0191	-0.13	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25324566	chr20:25284915~25285588:-
BRCA	cis	rs875971	0.522	rs34973832	ENSG00000223473.2	GS1-124K5.3	3.57	0.000368	0.0191	0.08	0.11	Aortic root size;	chr7:65931217	chr7:66491049~66493566:-
BRCA	cis	rs7474896	1	rs12766567	ENSG00000120555.12	SEPT7P9	3.57	0.000368	0.0191	0.2	0.11	Obesity (extreme);	chr10:37746294	chr10:38383069~38402916:-
BRCA	cis	rs9467773	0.565	rs4343916	ENSG00000261353.1	CTA-14H9.5	-3.57	0.000368	0.0191	-0.12	-0.11	Intelligence (multi-trait analysis);	chr6:26522447	chr6:26527063~26527404:+
BRCA	cis	rs1009077	0.627	rs3775846	ENSG00000245958.5	RP11-33B1.1	3.57	0.000368	0.0191	0.16	0.11	Endometriosis;	chr4:119511372	chr4:119454791~119552025:+
BRCA	cis	rs4622329	0.615	rs7137913	ENSG00000257202.1	RP11-512N21.3	3.57	0.000369	0.0191	0.13	0.11	Systemic lupus erythematosus;	chr12:101897599	chr12:101923410~101924719:-
BRCA	cis	rs11247915	0.54	rs11582416	ENSG00000238084.4	RP3-469D22.1	3.57	0.000369	0.0191	0.14	0.11	Obesity-related traits;	chr1:26351230	chr1:25398721~25399198:+
BRCA	cis	rs8105895	0.877	rs2359833	ENSG00000269345.1	VN1R85P	3.57	0.000369	0.0191	0.16	0.11	Body mass index (change over time);	chr19:22059419	chr19:22174766~22175191:-
BRCA	cis	rs2615061	0.808	rs12025085	ENSG00000229965.1	RP11-118H4.1	3.57	0.000369	0.0191	0.19	0.11	Monocyte count;	chr1:225767970	chr1:226438564~226439344:+
BRCA	cis	rs13098911	0.54	rs13059238	ENSG00000223552.1	RP11-24F11.2	-3.57	0.000369	0.0191	-0.18	-0.11	Celiac disease;	chr3:45966333	chr3:46364955~46407059:-
BRCA	cis	rs1670533	0.872	rs935969	ENSG00000251639.2	RP11-20I20.1	3.57	0.000369	0.0191	0.17	0.11	Recombination rate (females);	chr4:1068800	chr4:1100016~1101558:-
BRCA	cis	rs809367	1	rs647416	ENSG00000151303.11	RP11-96C23.13	-3.57	0.000369	0.0191	-0.22	-0.11	Parental extreme longevity (95 years and older);	chr10:87986811	chr10:86992406~87010203:+
BRCA	cis	rs875971	0.862	rs778724	ENSG00000106610.13	STAG3L4	-3.57	0.000369	0.0191	-0.15	-0.11	Aortic root size;	chr7:66364304	chr7:67302621~67321526:+
BRCA	cis	rs76963786	1	rs1259728	ENSG00000255760.1	RP11-428G5.5	-3.57	0.000369	0.0191	-0.14	-0.11	Interleukin-9 levels;	chr12:31877081	chr12:31877079~31887203:-
BRCA	cis	rs7520050	0.966	rs6661910	ENSG00000281133.1	AL355480.3	3.57	0.000369	0.0191	0.13	0.11	Reticulocyte count;Red blood cell count;	chr1:45824960	chr1:45580892~45580996:-
BRCA	cis	rs2333021	0.934	rs12879195	ENSG00000258408.1	NT5CP2	3.57	0.000369	0.0191	0.12	0.11	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:73006248	chr14:73539221~73539781:-
BRCA	cis	rs13401620	0.827	rs55654325	ENSG00000229326.3	AC069154.4	-3.57	0.000369	0.0191	-0.15	-0.11	Breast size;	chr2:119829527	chr2:119698623~119700151:+
BRCA	cis	rs13094143	0.519	rs17461279	ENSG00000279862.1	RP11-423E7.2	3.57	0.000369	0.0191	0.16	0.11	Monokine induced by gamma interferon levels;	chr3:172263915	chr3:172301654~172303052:-
BRCA	cis	rs1949733	1	rs2631740	ENSG00000205959.3	RP11-689P11.2	3.57	0.000369	0.0191	0.11	0.11	Response to antineoplastic agents;	chr4:8482379	chr4:8482270~8512610:+
BRCA	cis	rs12724450	0.793	rs74124686	ENSG00000228126.1	FALEC	3.57	0.000369	0.0191	0.21	0.11	Blood protein levels;	chr1:150444145	chr1:150515757~150518032:+
BRCA	cis	rs10129255	0.957	rs8009464	ENSG00000231475.3	IGHV4-31	-3.57	0.000369	0.0191	-0.08	-0.11	Kawasaki disease;	chr14:106777611	chr14:106349283~106349792:-
BRCA	cis	rs7203315	0.778	rs1448239	ENSG00000260468.1	LINC01290	-3.57	0.000369	0.0191	-0.17	-0.11	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr16:10093578	chr16:10514842~10528202:-
BRCA	cis	rs875971	1	rs11974264	ENSG00000230189.5	GS1-124K5.2	-3.57	0.000369	0.0191	-0.09	-0.11	Aortic root size;	chr7:66182595	chr7:66409143~66490059:-
BRCA	cis	rs3136202	0.684	rs12448998	ENSG00000242307.1	RPS26P52	3.57	0.000369	0.0191	0.14	0.11	Conduct disorder (symptom count);	chr16:13982400	chr16:13922332~13922679:-
BRCA	cis	rs7520050	0.966	rs785479	ENSG00000234329.1	RP11-767N6.2	-3.57	0.000369	0.0191	-0.1	-0.11	Reticulocyte count;Red blood cell count;	chr1:46026472	chr1:45651039~45651826:-
BRCA	cis	rs9844666	0.512	rs9819440	ENSG00000273486.1	RP11-731C17.2	-3.57	0.000369	0.0191	-0.13	-0.11	Height;	chr3:135944640	chr3:136837338~136839021:-
BRCA	cis	rs10876993	0.928	rs1689587	ENSG00000270039.1	RP11-571M6.17	3.57	0.000369	0.0191	0.15	0.11	Celiac disease or Rheumatoid arthritis;	chr12:57681615	chr12:57803838~57804415:+
BRCA	cis	rs7520050	0.966	rs4073846	ENSG00000281133.1	AL355480.3	-3.57	0.000369	0.0191	-0.13	-0.11	Reticulocyte count;Red blood cell count;	chr1:45997209	chr1:45580892~45580996:-
BRCA	cis	rs4560672	0.627	rs1744171	ENSG00000218226.1	TATDN2P2	-3.57	0.000369	0.0191	-0.16	-0.11	Smoking quantity;	chr6:158086151	chr6:158609706~158621636:-
BRCA	cis	rs10043775	1	rs4274968	ENSG00000251330.3	CTD-2283N19.1	-3.57	0.000369	0.0191	-0.13	-0.11	Periodontal microbiota;	chr5:148446027	chr5:148430159~148430807:-
BRCA	cis	rs10043775	1	rs6884076	ENSG00000251330.3	CTD-2283N19.1	-3.57	0.000369	0.0191	-0.13	-0.11	Periodontal microbiota;	chr5:148447171	chr5:148430159~148430807:-
BRCA	cis	rs10266483	0.739	rs55747800	ENSG00000271550.1	BNIP3P11	-3.57	0.000369	0.0191	-0.16	-0.11	Response to statin therapy;	chr7:64410105	chr7:64678954~64687393:-
BRCA	cis	rs10266483	0.774	rs56055804	ENSG00000271550.1	BNIP3P11	-3.57	0.000369	0.0191	-0.16	-0.11	Response to statin therapy;	chr7:64410423	chr7:64678954~64687393:-
BRCA	cis	rs8058578	1	rs8048448	ENSG00000280211.1	RP11-2C24.3	3.57	0.000369	0.0191	0.12	0.11	Multiple myeloma;	chr16:30680887	chr16:30773532~30776033:-
BRCA	cis	rs1635	0.826	rs79567170	ENSG00000216901.1	AL022393.7	3.57	0.000369	0.0191	0.26	0.11	Schizophrenia;	chr6:28312280	chr6:28176188~28176674:+
BRCA	cis	rs4761702	0.524	rs12581099	ENSG00000257322.4	RP11-511B23.2	-3.57	0.000369	0.0191	-0.17	-0.11	Immature fraction of reticulocytes;	chr12:93333720	chr12:93003415~93215679:-
BRCA	cis	rs687432	0.887	rs12807528	ENSG00000265566.2	RN7SL605P	-3.57	0.000369	0.0191	-0.15	-0.11	Parkinson's disease;	chr11:57958176	chr11:57528085~57528365:-
BRCA	cis	rs7520050	0.966	rs1707340	ENSG00000234329.1	RP11-767N6.2	-3.57	0.000369	0.0191	-0.1	-0.11	Reticulocyte count;Red blood cell count;	chr1:46049270	chr1:45651039~45651826:-
BRCA	cis	rs7520050	1	rs785473	ENSG00000234329.1	RP11-767N6.2	-3.57	0.000369	0.0191	-0.1	-0.11	Reticulocyte count;Red blood cell count;	chr1:46051191	chr1:45651039~45651826:-
BRCA	cis	rs7520050	0.931	rs785472	ENSG00000234329.1	RP11-767N6.2	-3.57	0.000369	0.0191	-0.1	-0.11	Reticulocyte count;Red blood cell count;	chr1:46052616	chr1:45651039~45651826:-
BRCA	cis	rs2274273	0.87	rs7153612	ENSG00000259318.1	RP11-454L9.2	3.57	0.000369	0.0191	0.09	0.11	Protein biomarker;	chr14:55322044	chr14:55394940~55395233:-
BRCA	cis	rs9287719	0.967	rs4470306	ENSG00000224177.5	LINC00570	3.57	0.000369	0.0191	0.13	0.11	Prostate cancer;	chr2:10603872	chr2:11393981~11403077:+
BRCA	cis	rs7045881	0.696	rs7871097	ENSG00000254396.1	RP11-56F10.3	3.57	0.000369	0.0191	0.16	0.11	Schizophrenia;	chr9:26917693	chr9:27102630~27104728:+
BRCA	cis	rs6040449	0.847	rs2207105	ENSG00000235036.4	RP5-1099D15.1	-3.57	0.000369	0.0191	-0.12	-0.11	Relative hand skill;	chr20:11250705	chr20:10612861~10614229:-
BRCA	cis	rs4950322	0.634	rs7542951	ENSG00000237188.3	RP11-337C18.8	3.57	0.000369	0.0191	0.14	0.11	Protein quantitative trait loci;	chr1:147340308	chr1:147172771~147211568:+
BRCA	cis	rs7903456	0.648	rs9420432	ENSG00000200253.1	RNU6-529P	3.57	0.000369	0.0191	0.14	0.11	Gout;Renal underexcretion gout;	chr10:87072473	chr10:87041238~87041341:-
BRCA	cis	rs1816213	1	rs13014941	ENSG00000273466.1	RP11-548H3.1	-3.57	0.000369	0.0191	-0.24	-0.11	Diastolic blood pressure;	chr2:218789975	chr2:218633256~218634014:-
BRCA	cis	rs771767	0.539	rs771773	ENSG00000244119.1	PDCL3P4	3.57	0.000369	0.0191	0.11	0.11	Multiple sclerosis;	chr3:102034561	chr3:101712472~101713191:+
BRCA	cis	rs4835473	0.932	rs17018238	ENSG00000246448.2	RP13-578N3.3	-3.57	0.000369	0.0191	-0.12	-0.11	Immature fraction of reticulocytes;	chr4:143782737	chr4:143700257~143865072:+
BRCA	cis	rs7829975	0.806	rs2428	ENSG00000233609.3	RP11-62H7.2	3.57	0.000369	0.0191	0.1	0.11	Mood instability;	chr8:8783635	chr8:8961200~8979025:+
BRCA	cis	rs748404	0.666	rs12907870	ENSG00000166763.7	STRCP1	3.57	0.000369	0.0191	0.16	0.11	Lung cancer;	chr15:43453971	chr15:43699488~43718184:-
BRCA	cis	rs7615952	0.604	rs9837847	ENSG00000241288.6	RP11-379B18.5	-3.57	0.000369	0.0191	-0.19	-0.11	Blood pressure (smoking interaction);	chr3:125905076	chr3:125827238~125916384:-
BRCA	cis	rs8058578	1	rs8058578	ENSG00000275263.1	RP11-1072A3.4	-3.57	0.00037	0.0191	-0.14	-0.11	Multiple myeloma;	chr16:30714927	chr16:30956872~30957199:-
BRCA	cis	rs61931739	0.534	rs1608912	ENSG00000258794.3	DUX4L27	3.57	0.00037	0.0191	0.15	0.11	Morning vs. evening chronotype;	chr12:33855639	chr12:34208415~34209675:-
BRCA	cis	rs8099594	0.64	rs6507906	ENSG00000266696.1	RP11-30L3.2	3.57	0.00037	0.0191	0.13	0.11	Height;	chr18:49408635	chr18:49205912~49208781:+
BRCA	cis	rs4927850	1	rs7627706	ENSG00000273009.1	RP11-352G9.1	-3.57	0.00037	0.0191	-0.13	-0.11	Pancreatic cancer;	chr3:196026482	chr3:195913078~195913683:-
BRCA	cis	rs4927850	0.881	rs7630489	ENSG00000273009.1	RP11-352G9.1	-3.57	0.00037	0.0191	-0.13	-0.11	Pancreatic cancer;	chr3:196026530	chr3:195913078~195913683:-
BRCA	cis	rs4927850	1	rs7627868	ENSG00000273009.1	RP11-352G9.1	-3.57	0.00037	0.0191	-0.13	-0.11	Pancreatic cancer;	chr3:196026602	chr3:195913078~195913683:-
BRCA	cis	rs1129187	0.902	rs6907751	ENSG00000220614.1	RP11-480N24.4	3.57	0.00037	0.0191	0.12	0.11	Alzheimer's disease in APOE e4+ carriers;	chr6:42977112	chr6:43328134~43328476:+
BRCA	cis	rs539096	0.83	rs2842183	ENSG00000236200.4	KDM4A-AS1	3.57	0.00037	0.0192	0.13	0.11	Intelligence (multi-trait analysis);	chr1:43554723	chr1:43699765~43708138:-
BRCA	cis	rs911555	0.519	rs8014069	ENSG00000244691.1	RPL10AP1	-3.57	0.00037	0.0192	-0.14	-0.11	Intelligence (multi-trait analysis);	chr14:103537974	chr14:103412119~103412761:-
BRCA	cis	rs595244	1	rs363820	ENSG00000259705.1	RP11-227D13.1	-3.57	0.00037	0.0192	-0.18	-0.11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48436833	chr15:48645951~48652016:+
BRCA	cis	rs4892230	1	rs4892230	ENSG00000276934.1	RP11-231E4.5	3.57	0.00037	0.0192	0.14	0.11	Mononucleosis;	chr18:74488337	chr18:74504766~74505248:+
BRCA	cis	rs12887734	0.524	rs12588797	ENSG00000269940.1	RP11-73M18.7	-3.57	0.00037	0.0192	-0.12	-0.11	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103833683	chr14:103694560~103695170:+
BRCA	cis	rs4388249	1	rs1370957	ENSG00000271849.1	CTC-332L22.1	-3.57	0.00037	0.0192	-0.18	-0.11	Schizophrenia;	chr5:109726259	chr5:109687802~109688329:-
BRCA	cis	rs2391285	0.609	rs4722610	ENSG00000280255.1	RP5-1007F24.1	-3.57	0.00037	0.0192	-0.16	-0.11	Post bronchodilator FEV1/FVC ratio;	chr7:26558412	chr7:26538378~26541048:+
BRCA	cis	rs10744955	0.679	rs4775867	ENSG00000244879.4	GABPB1-AS1	-3.57	0.00037	0.0192	-0.11	-0.11	Lobe attachment (rater-scored or self-reported);	chr15:50165065	chr15:50354959~50372202:+
BRCA	cis	rs7714670	0.704	rs12653477	ENSG00000184084.7	CTD-2372A4.1	-3.57	0.00037	0.0192	-0.13	-0.11	Venous thromboembolism (SNP x SNP interaction);	chr5:73794264	chr5:73803296~73803599:-
BRCA	cis	rs4650943	0.503	rs10913117	ENSG00000227740.1	RP11-318C24.2	-3.57	0.00037	0.0192	-0.12	-0.11	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in inactive individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr1:175983072	chr1:175904762~175920513:-
BRCA	cis	rs1075265	0.836	rs1363063	ENSG00000272156.1	RP11-477N3.1	-3.57	0.00037	0.0192	-0.11	-0.11	Chronotype;Morning vs. evening chronotype;	chr2:54047433	chr2:54082554~54085066:+
BRCA	cis	rs1334894	0.818	rs72899794	ENSG00000187762.5	HSPE1P11	3.57	0.00037	0.0192	0.26	0.11	Coronary artery disease;	chr6:35547457	chr6:35023522~35023831:+
BRCA	cis	rs1334894	0.901	rs72899796	ENSG00000187762.5	HSPE1P11	3.57	0.00037	0.0192	0.26	0.11	Coronary artery disease;	chr6:35547659	chr6:35023522~35023831:+
BRCA	cis	rs801193	0.967	rs2420827	ENSG00000272831.1	RP11-792A8.4	-3.57	0.00037	0.0192	-0.1	-0.11	Aortic root size;	chr7:66682114	chr7:66739829~66740385:-
BRCA	cis	rs3781264	0.848	rs10882422	ENSG00000268894.5	PLCE1-AS1	3.57	0.00037	0.0192	0.14	0.11	Esophageal cancer and gastric cancer;	chr10:94313806	chr10:94279277~94287478:-
BRCA	cis	rs7307902	0.518	rs739856	ENSG00000280054.1	RP1-197B17.7	-3.57	0.00037	0.0192	-0.14	-0.11	Obesity-related traits;	chr12:47574240	chr12:47728151~47730598:-
BRCA	cis	rs4237845	0.78	rs3751331	ENSG00000270039.1	RP11-571M6.17	-3.57	0.00037	0.0192	-0.15	-0.11	Intelligence (multi-trait analysis);	chr12:57896495	chr12:57803838~57804415:+
BRCA	cis	rs4713118	0.516	rs6931858	ENSG00000261839.1	RP1-265C24.8	3.57	0.00037	0.0192	0.15	0.11	Parkinson's disease;	chr6:28110633	chr6:28136849~28139678:+
BRCA	cis	rs1009077	0.61	rs12648259	ENSG00000245958.5	RP11-33B1.1	-3.57	0.00037	0.0192	-0.12	-0.11	Endometriosis;	chr4:119583024	chr4:119454791~119552025:+
BRCA	cis	rs7819412	0.668	rs920047	ENSG00000255020.1	AF131216.5	3.57	0.00037	0.0192	0.13	0.11	Triglycerides;	chr8:11229966	chr8:11345748~11347502:-
BRCA	cis	rs6088580	0.524	rs6088575	ENSG00000279253.1	RP4-614O4.13	-3.57	0.00037	0.0192	-0.14	-0.11	Glomerular filtration rate (creatinine);	chr20:34685599	chr20:35262727~35264187:-
BRCA	cis	rs6918586	0.532	rs198800	ENSG00000272462.2	U91328.19	-3.57	0.00037	0.0192	-0.12	-0.11	Schizophrenia;	chr6:26139705	chr6:25992662~26001775:+
BRCA	cis	rs754466	0.606	rs12356375	ENSG00000213514.2	RP11-428P16.2	3.57	0.00037	0.0192	0.15	0.11	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77834756	chr10:77730766~77734769:+
BRCA	cis	rs251253	0.765	rs171725	ENSG00000253959.1	CTB-43E15.1	3.57	0.00037	0.0192	0.1	0.11	PR interval;	chr5:173143217	chr5:173642519~173658194:+
BRCA	cis	rs7267979	1	rs1888999	ENSG00000274414.1	RP5-965G21.4	-3.57	0.00037	0.0192	-0.13	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25311212	chr20:25239007~25245229:-
BRCA	cis	rs2692947	0.77	rs2315421	ENSG00000232931.4	LINC00342	3.57	0.00037	0.0192	0.11	0.11	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95831768	chr2:95807118~95816215:-
BRCA	cis	rs7260598	1	rs17304569	ENSG00000268442.1	CTD-2027I19.2	3.57	0.00037	0.0192	0.17	0.11	Response to taxane treatment (placlitaxel);	chr19:24058103	chr19:24162370~24163425:-
BRCA	cis	rs295490	0.748	rs77342235	ENSG00000178631.7	ACTG1P1	-3.57	0.00037	0.0192	-0.23	-0.11	PR interval in Tripanosoma cruzi seropositivity;	chr3:139419212	chr3:139493809~139494937:+
BRCA	cis	rs1208	0.777	rs13270123	ENSG00000253671.1	RP11-806O11.1	-3.57	0.00037	0.0192	-0.13	-0.11	Insulin resistance/response;	chr8:18413538	chr8:17808941~17820868:+
BRCA	cis	rs11668609	0.515	rs61308481	ENSG00000268442.1	CTD-2027I19.2	3.57	0.00037	0.0192	0.19	0.11	Response to taxane treatment (docetaxel);	chr19:23882545	chr19:24162370~24163425:-
BRCA	cis	rs7260598	0.539	rs59175483	ENSG00000268442.1	CTD-2027I19.2	3.57	0.00037	0.0192	0.19	0.11	Response to taxane treatment (placlitaxel);	chr19:23882740	chr19:24162370~24163425:-
BRCA	cis	rs17361889	0.633	rs1918267	ENSG00000229108.1	MEOX2-AS1	3.57	0.00037	0.0192	0.13	0.11	Pediatric bone mineral content (hip);	chr7:16231700	chr7:15688378~15695491:+
BRCA	cis	rs6596100	0.915	rs3088225	ENSG00000248648.1	RP11-485M7.1	-3.57	0.00037	0.0192	-0.14	-0.11	Breast cancer;	chr5:133051568	chr5:133003119~133003365:+
BRCA	cis	rs467650	0.509	rs183628	ENSG00000248489.1	CTD-2007H13.3	3.57	0.00037	0.0192	0.12	0.11	Venous thromboembolism (SNP x SNP interaction);	chr5:98643787	chr5:98929171~98995013:+
BRCA	cis	rs10005067	0.967	rs28684711	ENSG00000249001.4	RP11-742B18.1	-3.57	0.00037	0.0192	-0.13	-0.11	Total body bone mineral density (age 30-45);	chr4:87905306	chr4:87568035~87733956:-
BRCA	cis	rs6460942	0.908	rs73301032	ENSG00000226690.5	AC005281.1	3.57	0.00037	0.0192	0.2	0.11	Coronary artery disease;	chr7:12217173	chr7:12496429~12541910:+
BRCA	cis	rs6696239	0.869	rs61824940	ENSG00000215812.5	ZNF847P	3.57	0.000371	0.0192	0.15	0.11	Height;	chr1:227642791	chr1:227696892~227706699:-
BRCA	cis	rs703842	0.585	rs10877022	ENSG00000270039.1	RP11-571M6.17	-3.57	0.000371	0.0192	-0.16	-0.11	Multiple sclerosis;	chr12:57830154	chr12:57803838~57804415:+
BRCA	cis	rs863345	0.604	rs2873593	ENSG00000229914.1	RP11-404O13.4	-3.57	0.000371	0.0192	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158534921	chr1:158195633~158196131:-
BRCA	cis	rs6991838	0.557	rs67046768	ENSG00000272155.1	RP11-707M3.3	3.57	0.000371	0.0192	0.1	0.11	Intelligence (multi-trait analysis);	chr8:65577486	chr8:65714334~65714778:-
BRCA	cis	rs943466	0.911	rs73746509	ENSG00000223837.2	BRD2-IT1	3.57	0.000371	0.0192	0.14	0.11	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;	chr6:33762048	chr6:32970232~32970886:+
BRCA	cis	rs8012947	0.565	rs4901852	ENSG00000257621.6	PSMA3-AS1	3.57	0.000371	0.0192	0.09	0.11	Alcohol consumption in current drinkers;	chr14:58355211	chr14:58265365~58298134:-
BRCA	cis	rs91731	0.85	rs1427854	ENSG00000249572.1	CTD-2203K17.1	3.57	0.000371	0.0192	0.23	0.11	Lung function (FVC);	chr5:33259288	chr5:33424025~33440619:-
BRCA	cis	rs6005807	0.688	rs9625475	ENSG00000272858.1	CTA-292E10.8	3.57	0.000371	0.0192	0.2	0.11	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28445851	chr22:28814914~28815662:+
BRCA	cis	rs911119	1	rs2016161	ENSG00000270001.1	RP11-218C14.8	3.57	0.000371	0.0192	0.14	0.11	Chronic kidney disease;	chr20:23640537	chr20:23631826~23632316:-
BRCA	cis	rs295490	0.748	rs79854429	ENSG00000178631.7	ACTG1P1	-3.57	0.000371	0.0192	-0.21	-0.11	PR interval in Tripanosoma cruzi seropositivity;	chr3:139512550	chr3:139493809~139494937:+
BRCA	cis	rs4272720	0.95	rs56027486	ENSG00000228754.1	RP11-534L6.3	-3.57	0.000371	0.0192	-0.16	-0.11	Platelet count;Plateletcrit;	chr10:49067487	chr10:48745545~48746128:-
BRCA	cis	rs62064224	0.589	rs8069673	ENSG00000279781.1	RP11-466A19.7	-3.57	0.000371	0.0192	-0.13	-0.11	Schizophrenia;	chr17:32334231	chr17:32518322~32518934:-
BRCA	cis	rs733592	0.894	rs886589	ENSG00000273765.1	RP11-370I10.11	-3.57	0.000371	0.0192	-0.13	-0.11	Plateletcrit;	chr12:48083414	chr12:48360920~48361377:+
BRCA	cis	rs11673344	0.704	rs826262	ENSG00000267422.1	CTD-2554C21.1	3.57	0.000371	0.0192	0.14	0.11	Obesity-related traits;	chr19:36928540	chr19:37779686~37792865:+
BRCA	cis	rs4950322	0.518	rs55697094	ENSG00000230832.3	RP11-325P15.2	-3.57	0.000371	0.0192	-0.17	-0.11	Protein quantitative trait loci;	chr1:147121205	chr1:147082338~147083578:-
BRCA	cis	rs7819412	0.668	rs2409714	ENSG00000254866.2	DEFB109P3	3.57	0.000371	0.0192	0.14	0.11	Triglycerides;	chr8:11152608	chr8:12150895~12151134:-
BRCA	cis	rs8114671	0.562	rs2889861	ENSG00000261582.1	RP4-614O4.11	-3.57	0.000371	0.0192	-0.1	-0.11	Height;	chr20:34817861	chr20:35267885~35280043:-
BRCA	cis	rs2274273	0.837	rs59871474	ENSG00000259318.1	RP11-454L9.2	3.57	0.000371	0.0192	0.09	0.11	Protein biomarker;	chr14:55312645	chr14:55394940~55395233:-
BRCA	cis	rs4865762	0.514	rs2652546	ENSG00000247796.2	CTD-2366F13.1	3.57	0.000371	0.0192	0.12	0.11	Intraocular pressure;	chr5:53141088	chr5:53109842~53115126:+
BRCA	cis	rs67478160	0.643	rs12880821	ENSG00000269910.1	RP11-73M18.10	3.57	0.000371	0.0192	0.11	0.11	Schizophrenia;	chr14:103809712	chr14:103694516~103695050:-
BRCA	cis	rs4835473	0.801	rs76574827	ENSG00000246448.2	RP13-578N3.3	-3.57	0.000371	0.0192	-0.12	-0.11	Immature fraction of reticulocytes;	chr4:143737303	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.832	rs62337616	ENSG00000246448.2	RP13-578N3.3	-3.57	0.000371	0.0192	-0.12	-0.11	Immature fraction of reticulocytes;	chr4:143737307	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.832	rs66717029	ENSG00000246448.2	RP13-578N3.3	-3.57	0.000371	0.0192	-0.12	-0.11	Immature fraction of reticulocytes;	chr4:143737318	chr4:143700257~143865072:+
BRCA	cis	rs7487075	0.893	rs12317787	ENSG00000257261.4	RP11-96H19.1	3.57	0.000371	0.0192	0.12	0.11	Itch intensity from mosquito bite;	chr12:46342946	chr12:46383679~46876159:+
BRCA	cis	rs4805834	0.843	rs79689188	ENSG00000201388.1	SNORA68	3.57	0.000371	0.0192	0.19	0.11	Creatinine levels;	chr19:32890573	chr19:32608337~32608469:-
BRCA	cis	rs2625529	0.689	rs12161990	ENSG00000261187.1	RP11-1007O24.2	3.57	0.000371	0.0192	0.12	0.11	Red blood cell count;	chr15:71910099	chr15:72465128~72466262:-
BRCA	cis	rs12701220	0.894	rs12539012	ENSG00000224079.1	AC091729.7	3.57	0.000371	0.0192	0.17	0.11	Bronchopulmonary dysplasia;	chr7:1012497	chr7:1074450~1078036:+
BRCA	cis	rs7735319	0.565	rs10071675	ENSG00000249572.1	CTD-2203K17.1	3.57	0.000371	0.0192	0.14	0.11	Systolic blood pressure;	chr5:33080307	chr5:33424025~33440619:-
BRCA	cis	rs10035650	0.589	rs10476615	ENSG00000243806.1	RPL7P18	-3.57	0.000371	0.0192	-0.14	-0.11	Cancer;	chr5:94728298	chr5:94825961~94826694:-
BRCA	cis	rs73201462	1	rs13095660	ENSG00000242551.2	POU5F1P6	3.57	0.000371	0.0192	0.19	0.11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128129313	chr3:128674735~128677005:-
BRCA	cis	rs73201462	0.708	rs6788497	ENSG00000242551.2	POU5F1P6	3.57	0.000371	0.0192	0.19	0.11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128129545	chr3:128674735~128677005:-
BRCA	cis	rs73201462	1	rs6439116	ENSG00000242551.2	POU5F1P6	3.57	0.000371	0.0192	0.19	0.11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128130224	chr3:128674735~128677005:-
BRCA	cis	rs13059975	1	rs13059975	ENSG00000242551.2	POU5F1P6	3.57	0.000371	0.0192	0.19	0.11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128130841	chr3:128674735~128677005:-
BRCA	cis	rs73201462	1	rs11714619	ENSG00000242551.2	POU5F1P6	3.57	0.000371	0.0192	0.19	0.11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128131233	chr3:128674735~128677005:-
BRCA	cis	rs2422052	0.766	rs1583330	ENSG00000236255.1	AC009404.2	-3.57	0.000371	0.0192	-0.11	-0.11	Mosquito bite size;	chr2:117892452	chr2:117833937~117841658:+
BRCA	cis	rs6430585	0.591	rs12466487	ENSG00000231890.6	DARS-AS1	3.57	0.000371	0.0192	0.18	0.11	Corneal structure;	chr2:135649508	chr2:135985176~136022593:+
BRCA	cis	rs6866344	0.601	rs4419608	ENSG00000170089.14	RP11-423H2.1	-3.57	0.000371	0.0192	-0.16	-0.11	Neutrophil percentage of white cells;	chr5:178670048	chr5:177809407~177950732:+
BRCA	cis	rs1124769	0.57	rs1903588	ENSG00000259298.1	RP11-562A8.4	-3.57	0.000371	0.0192	-0.1	-0.11	Cognitive performance;	chr15:50851849	chr15:50497195~50498744:-
BRCA	cis	rs16852403	0.517	rs10494512	ENSG00000224687.1	RASAL2-AS1	3.57	0.000371	0.0192	0.13	0.11	Childhood ear infection;	chr1:178282545	chr1:178091508~178093984:-
BRCA	cis	rs4622329	0.595	rs7978722	ENSG00000257202.1	RP11-512N21.3	3.57	0.000371	0.0192	0.13	0.11	Systemic lupus erythematosus;	chr12:101895174	chr12:101923410~101924719:-
BRCA	cis	rs17684571	0.938	rs62412528	ENSG00000231441.1	RP11-472M19.2	3.57	0.000371	0.0192	0.17	0.11	Schizophrenia;	chr6:56693587	chr6:56844002~56864078:+
BRCA	cis	rs2905347	0.895	rs2961281	ENSG00000232949.1	AC002480.4	-3.57	0.000371	0.0192	-0.13	-0.11	Major depression and alcohol dependence;	chr7:22600673	chr7:22589705~22591622:+
BRCA	cis	rs8114671	0.836	rs6142280	ENSG00000261582.1	RP4-614O4.11	3.57	0.000371	0.0192	0.11	0.11	Height;	chr20:35034439	chr20:35267885~35280043:-
BRCA	cis	rs11764932	0.838	rs12669299	ENSG00000229108.1	MEOX2-AS1	-3.57	0.000371	0.0192	-0.13	-0.11	Kidney function decline traits;	chr7:15699419	chr7:15688378~15695491:+
BRCA	cis	rs12303914	0.962	rs4102739	ENSG00000256682.2	TAS2R12	3.57	0.000371	0.0192	0.13	0.11	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr12:10327909	chr12:10894943~10896952:-
BRCA	cis	rs11892454	0.599	rs66878742	ENSG00000217643.1	PTGES3P2	-3.57	0.000371	0.0192	-0.12	-0.11	Heschl's gyrus morphology;	chr2:25787398	chr2:25822469~25822950:+
BRCA	cis	rs875971	0.895	rs7788984	ENSG00000273448.1	RP11-166O4.6	3.57	0.000371	0.0192	0.1	0.11	Aortic root size;	chr7:66450629	chr7:67333047~67334383:+
BRCA	cis	rs6429082	0.51	rs2789369	ENSG00000230026.2	RP11-382D8.5	-3.57	0.000371	0.0192	-0.12	-0.11	Adiposity;	chr1:235340200	chr1:235361153~235362540:+
BRCA	cis	rs35520189	0.961	rs13008855	ENSG00000231747.1	AC079922.2	3.57	0.000371	0.0192	0.12	0.11	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:112851991	chr2:112621809~112622167:-
BRCA	cis	rs17345786	0.911	rs10936707	ENSG00000256628.3	ZBTB11-AS1	3.57	0.000371	0.0192	0.15	0.11	Colonoscopy-negative controls vs population controls;	chr3:101605219	chr3:101676475~101679217:+
BRCA	cis	rs3749237	1	rs11710675	ENSG00000225399.4	RP11-3B7.1	3.57	0.000372	0.0192	0.11	0.11	Resting heart rate;	chr3:49714467	chr3:49260085~49261316:+
BRCA	cis	rs7246967	0.673	rs427709	ENSG00000198153.8	ZNF849P	-3.57	0.000372	0.0192	-0.17	-0.11	Bronchopulmonary dysplasia;	chr19:22815361	chr19:22685167~22686732:+
BRCA	cis	rs7246967	0.736	rs2617779	ENSG00000198153.8	ZNF849P	-3.57	0.000372	0.0192	-0.17	-0.11	Bronchopulmonary dysplasia;	chr19:22815519	chr19:22685167~22686732:+
BRCA	cis	rs61931739	0.534	rs11052973	ENSG00000258794.3	DUX4L27	3.57	0.000372	0.0192	0.16	0.11	Morning vs. evening chronotype;	chr12:33876773	chr12:34208415~34209675:-
BRCA	cis	rs61931739	0.534	rs11052974	ENSG00000258794.3	DUX4L27	3.57	0.000372	0.0192	0.16	0.11	Morning vs. evening chronotype;	chr12:33876942	chr12:34208415~34209675:-
BRCA	cis	rs539096	0.83	rs11580074	ENSG00000236200.4	KDM4A-AS1	-3.57	0.000372	0.0192	-0.14	-0.11	Intelligence (multi-trait analysis);	chr1:43558813	chr1:43699765~43708138:-
BRCA	cis	rs28489187	0.706	rs233127	ENSG00000223653.4	RP11-131L23.1	3.57	0.000372	0.0192	0.12	0.11	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85328118	chr1:85276715~85448124:+
BRCA	cis	rs6840360	0.571	rs72730104	ENSG00000270265.1	RP11-731D1.4	-3.57	0.000372	0.0192	-0.13	-0.11	Intelligence (multi-trait analysis);	chr4:151622705	chr4:151333775~151353224:-
BRCA	cis	rs1245541	0.595	rs1668155	ENSG00000226701.1	RP11-570G20.1	3.57	0.000372	0.0192	0.12	0.11	Insulin-like growth factors;	chr10:72098381	chr10:72189941~72190576:+
BRCA	cis	rs10411262	0.506	rs6509291	ENSG00000245598.5	DACT3-AS1	-3.57	0.000372	0.0192	-0.15	-0.11	Tonsillectomy;	chr19:46683704	chr19:46660364~46677447:+
BRCA	cis	rs10129255	0.957	rs28887506	ENSG00000211958.2	IGHV3-38	3.57	0.000372	0.0192	0.09	0.11	Kawasaki disease;	chr14:106785589	chr14:106410493~106411021:-
BRCA	cis	rs7474896	0.507	rs2474555	ENSG00000226578.1	RP11-258F22.1	-3.57	0.000372	0.0192	-0.15	-0.11	Obesity (extreme);	chr10:38176292	chr10:37775371~37784131:-
BRCA	cis	rs7412746	0.658	rs8444	ENSG00000224800.1	RP11-235D19.2	-3.57	0.000372	0.0192	-0.14	-0.11	Melanoma;	chr1:150966095	chr1:150881236~150881683:-
BRCA	cis	rs1878931	0.582	rs10048083	ENSG00000263280.1	LA16c-325D7.2	3.57	0.000372	0.0192	0.12	0.11	Body mass index (adult);	chr16:3367465	chr16:2866348~2867618:-
BRCA	cis	rs17772222	1	rs61977049	ENSG00000258789.1	RP11-507K2.3	-3.57	0.000372	0.0192	-0.13	-0.11	Coronary artery calcification;	chr14:88360656	chr14:88551597~88552493:+
BRCA	cis	rs6431644	0.694	rs626110	ENSG00000224287.2	MSL3P1	3.57	0.000372	0.0192	0.13	0.11	Left atrial antero-posterior diameter;	chr2:233853834	chr2:233865437~233868444:-
BRCA	cis	rs7246657	0.525	rs10405238	ENSG00000267470.4	ZNF571-AS1	3.57	0.000372	0.0193	0.16	0.11	Coronary artery calcification;	chr19:36997153	chr19:37548914~37587348:+
BRCA	cis	rs8054556	1	rs4788204	ENSG00000183604.13	SMG1P5	-3.57	0.000372	0.0193	-0.1	-0.11	Autism spectrum disorder or schizophrenia;	chr16:29983897	chr16:30267553~30335374:-
BRCA	cis	rs853679	0.546	rs175597	ENSG00000216901.1	AL022393.7	3.57	0.000372	0.0193	0.22	0.11	Depression;	chr6:27842848	chr6:28176188~28176674:+
BRCA	cis	rs2031532	0.587	rs7991226	ENSG00000236577.1	SNRPGP14	3.57	0.000372	0.0193	0.12	0.11	Cardiac hypertrophy;	chr13:49458157	chr13:49488970~49489364:+
BRCA	cis	rs10771431	0.81	rs10771418	ENSG00000278635.1	CTD-2318O12.1	3.57	0.000372	0.0193	0.11	0.11	Breast size;	chr12:9206399	chr12:9415641~9416718:+
BRCA	cis	rs12681366	0.762	rs3019148	ENSG00000253175.1	RP11-267M23.6	3.57	0.000372	0.0193	0.12	0.11	Nonsyndromic cleft lip with cleft palate;	chr8:94417407	chr8:94565036~94565715:+
BRCA	cis	rs17711722	0.565	rs4275112	ENSG00000226002.1	RP11-460N20.5	-3.57	0.000372	0.0193	-0.12	-0.11	Calcium levels;	chr7:65733651	chr7:65084103~65100232:+
BRCA	cis	rs9918079	0.524	rs4235379	ENSG00000214846.4	RP11-115L11.1	3.57	0.000372	0.0193	0.14	0.11	Obesity-related traits;	chr4:15657655	chr4:15730962~15731627:-
BRCA	cis	rs12474201	0.822	rs897530	ENSG00000279254.1	RP11-536C12.1	-3.57	0.000372	0.0193	-0.14	-0.11	Height;	chr2:46721011	chr2:46668870~46670778:+
BRCA	cis	rs7119	0.7	rs60701760	ENSG00000259362.2	RP11-307C19.1	3.57	0.000372	0.0193	0.14	0.11	Type 2 diabetes;	chr15:77595810	chr15:77525540~77534110:+
BRCA	cis	rs875971	1	rs6963646	ENSG00000230189.5	GS1-124K5.2	-3.57	0.000372	0.0193	-0.09	-0.11	Aortic root size;	chr7:66220780	chr7:66409143~66490059:-
BRCA	cis	rs11098499	0.863	rs59732491	ENSG00000260404.2	RP11-384K6.6	3.57	0.000372	0.0193	0.11	0.11	Corneal astigmatism;	chr4:119568433	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.863	rs11723090	ENSG00000260404.2	RP11-384K6.6	3.57	0.000372	0.0193	0.11	0.11	Corneal astigmatism;	chr4:119569437	chr4:118591773~118633729:+
BRCA	cis	rs7259376	0.936	rs8108630	ENSG00000269345.1	VN1R85P	3.57	0.000372	0.0193	0.13	0.11	Menopause (age at onset);	chr19:22352375	chr19:22174766~22175191:-
BRCA	cis	rs9309473	0.519	rs2421545	ENSG00000230002.2	ALMS1-IT1	-3.57	0.000372	0.0193	-0.13	-0.11	Metabolite levels;	chr2:73412348	chr2:73456764~73459484:+
BRCA	cis	rs873549	1	rs10863688	ENSG00000227925.1	RP11-191N8.2	3.57	0.000372	0.0193	0.13	0.11	Keloid;	chr1:222093432	chr1:221827666~221840666:-
BRCA	cis	rs17270561	0.609	rs1892255	ENSG00000272462.2	U91328.19	-3.57	0.000372	0.0193	-0.14	-0.11	Iron status biomarkers;	chr6:25750126	chr6:25992662~26001775:+
BRCA	cis	rs17270561	0.609	rs1892254	ENSG00000272462.2	U91328.19	-3.57	0.000372	0.0193	-0.14	-0.11	Iron status biomarkers;	chr6:25750302	chr6:25992662~26001775:+
BRCA	cis	rs1005277	0.563	rs2800550	ENSG00000276805.1	RP11-291L22.6	3.57	0.000372	0.0193	0.12	0.11	Extrinsic epigenetic age acceleration;	chr10:38194001	chr10:38451030~38451785:+
BRCA	cis	rs2562456	0.876	rs11085467	ENSG00000240522.1	RPL7AP10	-3.57	0.000372	0.0193	-0.12	-0.11	Pain;	chr19:21569041	chr19:21149648~21150438:-
BRCA	cis	rs7172677	0.737	rs7179426	ENSG00000260269.4	CTD-2323K18.1	-3.57	0.000372	0.0193	-0.15	-0.11	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75149147	chr15:75527150~75601205:-
BRCA	cis	rs7267979	0.866	rs2424698	ENSG00000277938.1	RP5-965G21.3	3.57	0.000372	0.0193	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25275470	chr20:25229150~25231933:+
BRCA	cis	rs10944	0.598	rs650304	ENSG00000253558.1	CTD-2179L22.1	-3.57	0.000373	0.0193	-0.13	-0.11	Blood and toenail selenium levels;	chr5:78980069	chr5:78041879~78044138:-
BRCA	cis	rs10944	0.598	rs559088	ENSG00000253558.1	CTD-2179L22.1	-3.57	0.000373	0.0193	-0.13	-0.11	Blood and toenail selenium levels;	chr5:78980108	chr5:78041879~78044138:-
BRCA	cis	rs7267979	1	rs11087521	ENSG00000274973.1	RP13-401N8.7	-3.57	0.000373	0.0193	-0.13	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25460012	chr20:25845497~25845862:+
BRCA	cis	rs17169635	0.601	rs1377297	ENSG00000272941.1	RP11-134L10.1	-3.57	0.000373	0.0193	-0.11	-0.11	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);	chr7:134861368	chr7:135168403~135169547:+
BRCA	cis	rs8180040	0.966	rs13079098	ENSG00000271161.1	BOLA2P2	3.57	0.000373	0.0193	0.12	0.11	Colorectal cancer;	chr3:47401373	chr3:47499841~47500407:+
BRCA	cis	rs875971	0.964	rs778723	ENSG00000271064.1	RP11-792A8.3	-3.57	0.000373	0.0193	-0.13	-0.11	Aortic root size;	chr7:66364510	chr7:66748838~66749077:-
BRCA	cis	rs2803122	0.967	rs10757040	ENSG00000272842.1	RP11-513M16.7	-3.57	0.000373	0.0193	-0.11	-0.11	Pulse pressure;	chr9:19241849	chr9:19371386~19371945:-
BRCA	cis	rs2803122	0.934	rs2175378	ENSG00000272842.1	RP11-513M16.7	-3.57	0.000373	0.0193	-0.11	-0.11	Pulse pressure;	chr9:19241965	chr9:19371386~19371945:-
BRCA	cis	rs7618501	1	rs6446295	ENSG00000228008.1	CTD-2330K9.3	3.57	0.000373	0.0193	0.1	0.11	Intelligence (multi-trait analysis);	chr3:49771630	chr3:49903845~49916937:+
BRCA	cis	rs916888	0.773	rs9896243	ENSG00000262881.1	RP11-669E14.4	-3.57	0.000373	0.0193	-0.13	-0.11	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:45907670~45910779:-
BRCA	cis	rs782590	0.533	rs2008040	ENSG00000272606.1	RP11-554J4.1	-3.57	0.000373	0.0193	-0.12	-0.11	Metabolic syndrome;	chr2:55460154	chr2:55617909~55618373:+
BRCA	cis	rs2243480	1	rs464895	ENSG00000237026.1	RP11-328P23.2	3.57	0.000373	0.0193	0.22	0.11	Diabetic kidney disease;	chr7:66062119	chr7:65235790~65236723:-
BRCA	cis	rs7259376	0.936	rs6511344	ENSG00000269345.1	VN1R85P	3.57	0.000373	0.0193	0.13	0.11	Menopause (age at onset);	chr19:22352871	chr19:22174766~22175191:-
BRCA	cis	rs38055	0.668	rs2112876	ENSG00000247796.2	CTD-2366F13.1	3.57	0.000373	0.0193	0.15	0.11	Acne (severe);	chr5:53182885	chr5:53109842~53115126:+
BRCA	cis	rs321358	0.731	rs17460676	ENSG00000271390.1	RP11-89C3.3	3.57	0.000373	0.0193	0.16	0.11	Body mass index;	chr11:111166625	chr11:111089870~111090368:-
BRCA	cis	rs6545883	0.965	rs1562308	ENSG00000212978.6	AC016747.3	3.57	0.000373	0.0193	0.15	0.11	Tuberculosis;	chr2:61541286	chr2:61141592~61144969:-
BRCA	cis	rs7818688	1	rs28651964	ENSG00000245080.5	RP11-320N21.1	-3.57	0.000373	0.0193	-0.19	-0.11	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95014553	chr8:95066808~95073182:-
BRCA	cis	rs4689592	0.587	rs3822269	ENSG00000245468.3	RP11-367J11.3	3.57	0.000373	0.0193	0.12	0.11	Monocyte percentage of white cells;	chr4:7068174	chr4:7094571~7103385:-
BRCA	cis	rs295490	0.748	rs78103472	ENSG00000178631.7	ACTG1P1	-3.57	0.000373	0.0193	-0.23	-0.11	PR interval in Tripanosoma cruzi seropositivity;	chr3:139433304	chr3:139493809~139494937:+
BRCA	cis	rs2243480	1	rs73142166	ENSG00000226767.1	RP11-328P23.3	-3.57	0.000373	0.0193	-0.19	-0.11	Diabetic kidney disease;	chr7:65910845	chr7:65508773~65508944:-
BRCA	cis	rs259282	0.514	rs10420153	ENSG00000267475.1	CTD-2538C1.2	3.57	0.000373	0.0193	0.14	0.11	Schizophrenia;	chr19:32622051	chr19:32687089~32691750:-
BRCA	cis	rs5758659	0.652	rs129857	ENSG00000270083.1	RP1-257I20.14	-3.57	0.000373	0.0193	-0.12	-0.11	Cognitive function;	chr22:42003682	chr22:42089630~42090028:-
BRCA	cis	rs812925	0.537	rs778153	ENSG00000270820.4	RP11-355B11.2	-3.57	0.000373	0.0193	-0.12	-0.11	Immature fraction of reticulocytes;	chr2:61381517	chr2:61471188~61484130:+
BRCA	cis	rs7771547	0.692	rs9296192	ENSG00000224666.3	RP1-50J22.4	3.57	0.000373	0.0193	0.12	0.11	Platelet distribution width;	chr6:36633426	chr6:36386831~36393462:+
BRCA	cis	rs3755605	0.728	rs61672237	ENSG00000242578.1	RP11-469J4.3	3.57	0.000373	0.0193	0.13	0.11	Testicular germ cell tumor;	chr3:170086549	chr3:170410512~170418615:+
BRCA	cis	rs3740713	1	rs35593189	ENSG00000256361.1	RP11-613F22.6	3.57	0.000373	0.0193	0.17	0.11	Amyotrophic lateral sclerosis (sporadic);	chr11:18446831	chr11:18511043~18511475:-
BRCA	cis	rs4927850	1	rs7630875	ENSG00000185485.13	SDHAP1	3.57	0.000373	0.0193	0.11	0.11	Pancreatic cancer;	chr3:196026895	chr3:195959748~195990318:-
BRCA	cis	rs6088580	0.524	rs6088569	ENSG00000279253.1	RP4-614O4.13	3.57	0.000373	0.0193	0.13	0.11	Glomerular filtration rate (creatinine);	chr20:34680395	chr20:35262727~35264187:-
BRCA	cis	rs6490294	0.528	rs60690688	ENSG00000257624.1	RP1-128M12.3	3.57	0.000373	0.0193	0.18	0.11	Mean platelet volume;	chr12:112104179	chr12:112000739~112000985:-
BRCA	cis	rs453301	0.571	rs330048	ENSG00000233609.3	RP11-62H7.2	-3.57	0.000373	0.0193	-0.1	-0.11	Joint mobility (Beighton score);	chr8:9229768	chr8:8961200~8979025:+
BRCA	cis	rs115344852	0.585	rs1016069	ENSG00000220721.1	OR1F12	3.57	0.000373	0.0193	0.14	0.11	Epithelial ovarian cancer;	chr6:28472641	chr6:28073316~28074233:+
BRCA	cis	rs10838634	1	rs73456126	ENSG00000280615.1	Y_RNA	-3.57	0.000373	0.0193	-0.19	-0.11	Schizophrenia;	chr11:46793235	chr11:47614898~47614994:-
BRCA	cis	rs10838634	1	rs56311746	ENSG00000280615.1	Y_RNA	-3.57	0.000373	0.0193	-0.19	-0.11	Schizophrenia;	chr11:46796493	chr11:47614898~47614994:-
BRCA	cis	rs10838634	1	rs7111760	ENSG00000280615.1	Y_RNA	-3.57	0.000373	0.0193	-0.19	-0.11	Schizophrenia;	chr11:46806723	chr11:47614898~47614994:-
BRCA	cis	rs10838634	1	rs7123729	ENSG00000280615.1	Y_RNA	-3.57	0.000373	0.0193	-0.19	-0.11	Schizophrenia;	chr11:46809025	chr11:47614898~47614994:-
BRCA	cis	rs10838634	1	rs7108147	ENSG00000280615.1	Y_RNA	-3.57	0.000373	0.0193	-0.19	-0.11	Schizophrenia;	chr11:46809297	chr11:47614898~47614994:-
BRCA	cis	rs4243971	0.516	rs6141302	ENSG00000275576.1	RP5-836N17.4	-3.57	0.000373	0.0193	-0.12	-0.11	Inflammatory bowel disease;Crohn's disease;	chr20:32396436	chr20:32116171~32116629:+
BRCA	cis	rs3796352	1	rs35174175	ENSG00000280417.1	RP11-5O17.1	-3.57	0.000373	0.0193	-0.21	-0.11	Immune reponse to smallpox (secreted IL-2);	chr3:53007493	chr3:53046166~53048122:+
BRCA	cis	rs3796352	1	rs11713859	ENSG00000280417.1	RP11-5O17.1	-3.57	0.000373	0.0193	-0.21	-0.11	Immune reponse to smallpox (secreted IL-2);	chr3:53008064	chr3:53046166~53048122:+
BRCA	cis	rs2274273	0.624	rs10129505	ENSG00000259318.1	RP11-454L9.2	3.57	0.000373	0.0193	0.1	0.11	Protein biomarker;	chr14:55309657	chr14:55394940~55395233:-
BRCA	cis	rs4908769	0.66	rs301801	ENSG00000270282.1	RP5-1115A15.2	3.57	0.000373	0.0193	0.12	0.11	Allergy;	chr1:8435885	chr1:8512653~8513021:+
BRCA	cis	rs8062405	0.54	rs480400	ENSG00000275441.1	RP11-666O2.2	3.57	0.000374	0.0193	0.1	0.11	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28563294	chr16:28553709~28554140:-
BRCA	cis	rs7871395	1	rs2031970	ENSG00000225460.1	RP13-93L13.1	3.57	0.000374	0.0193	0.13	0.11	Nonsyndromic cleft lip with cleft palate;	chr9:89589257	chr9:89472237~89472692:+
BRCA	cis	rs988913	0.723	rs4715515	ENSG00000261116.1	RP3-523K23.2	-3.57	0.000374	0.0193	-0.13	-0.11	Menarche (age at onset);	chr6:55103646	chr6:54943167~54945099:+
BRCA	cis	rs12681366	0.708	rs1813167	ENSG00000253175.1	RP11-267M23.6	-3.57	0.000374	0.0193	-0.12	-0.11	Nonsyndromic cleft lip with cleft palate;	chr8:94336525	chr8:94565036~94565715:+
BRCA	cis	rs2422052	0.527	rs2276695	ENSG00000236255.1	AC009404.2	-3.57	0.000374	0.0193	-0.11	-0.11	Mosquito bite size;	chr2:118057292	chr2:117833937~117841658:+
BRCA	cis	rs7954584	0.583	rs10770186	ENSG00000212694.7	LINC01089	-3.57	0.000374	0.0193	-0.09	-0.11	Mean corpuscular volume;	chr12:121923506	chr12:121795267~121803906:-
BRCA	cis	rs4073582	0.595	rs801739	ENSG00000255320.1	RP11-755F10.1	-3.57	0.000374	0.0193	-0.14	-0.11	Gout;	chr11:66155118	chr11:66244840~66246239:-
BRCA	cis	rs875971	0.964	rs6978429	ENSG00000272831.1	RP11-792A8.4	3.57	0.000374	0.0193	0.1	0.11	Aortic root size;	chr7:66494889	chr7:66739829~66740385:-
BRCA	cis	rs875971	1	rs4718357	ENSG00000272831.1	RP11-792A8.4	3.57	0.000374	0.0193	0.1	0.11	Aortic root size;	chr7:66495891	chr7:66739829~66740385:-
BRCA	cis	rs2562456	0.793	rs7259708	ENSG00000268555.1	RP11-678G14.3	3.57	0.000374	0.0193	0.14	0.11	Pain;	chr19:21567846	chr19:21570822~21587322:-
BRCA	cis	rs7045881	0.696	rs12002259	ENSG00000254396.1	RP11-56F10.3	3.57	0.000374	0.0193	0.16	0.11	Schizophrenia;	chr9:26918232	chr9:27102630~27104728:+
BRCA	cis	rs7045881	0.696	rs12002260	ENSG00000254396.1	RP11-56F10.3	3.57	0.000374	0.0193	0.16	0.11	Schizophrenia;	chr9:26918234	chr9:27102630~27104728:+
BRCA	cis	rs4664293	0.632	rs2059697	ENSG00000226266.5	AC009961.3	3.57	0.000374	0.0193	0.13	0.11	Monocyte percentage of white cells;	chr2:159799079	chr2:159670708~159712435:-
BRCA	cis	rs10911902	0.643	rs6667940	ENSG00000229739.2	RP11-295K2.3	-3.57	0.000374	0.0193	-0.15	-0.11	Schizophrenia;	chr1:186350448	chr1:186435161~186470291:+
BRCA	cis	rs13427251	0.868	rs1901284	ENSG00000231822.1	AC019097.7	3.57	0.000374	0.0193	0.11	0.11	Chronic sinus infection;	chr2:99529578	chr2:99102018~99102752:+
BRCA	cis	rs1559040	1	rs72800725	ENSG00000233266.1	HMGB1P31	-3.57	0.000374	0.0193	-0.19	-0.11	Sudden cardiac arrest;	chr2:54074000	chr2:54051334~54051760:+
BRCA	cis	rs875971	0.895	rs778700	ENSG00000271064.1	RP11-792A8.3	-3.57	0.000374	0.0193	-0.13	-0.11	Aortic root size;	chr7:66401463	chr7:66748838~66749077:-
BRCA	cis	rs875971	1	rs778699	ENSG00000271064.1	RP11-792A8.3	-3.57	0.000374	0.0193	-0.13	-0.11	Aortic root size;	chr7:66403303	chr7:66748838~66749077:-
BRCA	cis	rs875971	0.508	rs10950045	ENSG00000273448.1	RP11-166O4.6	-3.57	0.000374	0.0193	-0.1	-0.11	Aortic root size;	chr7:66601386	chr7:67333047~67334383:+
BRCA	cis	rs801193	0.839	rs6968619	ENSG00000273448.1	RP11-166O4.6	-3.57	0.000374	0.0193	-0.1	-0.11	Aortic root size;	chr7:66603880	chr7:67333047~67334383:+
BRCA	cis	rs801193	0.805	rs12532355	ENSG00000273448.1	RP11-166O4.6	-3.57	0.000374	0.0193	-0.1	-0.11	Aortic root size;	chr7:66605597	chr7:67333047~67334383:+
BRCA	cis	rs9400180	0.959	rs57236857	ENSG00000271734.1	RP1-111B22.3	-3.57	0.000374	0.0193	-0.14	-0.11	Major depressive disorder;	chr6:108041297	chr6:108030249~108030718:-
BRCA	cis	rs7200543	1	rs16966947	ENSG00000207425.1	Y_RNA	-3.57	0.000374	0.0193	-0.13	-0.11	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15047188	chr16:14915457~14915556:-
BRCA	cis	rs300890	0.651	rs300913	ENSG00000250326.1	RP11-284M14.1	-3.57	0.000374	0.0193	-0.13	-0.11	Nasopharyngeal carcinoma;	chr4:143355490	chr4:142933195~143184861:-
BRCA	cis	rs17767294	0.708	rs72847377	ENSG00000272009.1	RP1-313I6.12	-3.57	0.000374	0.0193	-0.28	-0.11	Parkinson's disease;	chr6:27898411	chr6:28078792~28081130:-
BRCA	cis	rs9866825	0.846	rs6798676	ENSG00000227110.5	LMCD1-AS1	3.57	0.000374	0.0193	0.13	0.11	QT interval;	chr3:8219676	chr3:7952805~8611924:-
BRCA	cis	rs875971	0.638	rs35986979	ENSG00000275400.1	RP4-756H11.5	3.57	0.000374	0.0193	0.13	0.11	Aortic root size;	chr7:66624003	chr7:66553805~66554199:-
BRCA	cis	rs8098244	0.894	rs6507894	ENSG00000265752.2	RP11-403A21.1	3.57	0.000374	0.0194	0.13	0.11	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23758312	chr18:23957754~23982556:-
BRCA	cis	rs9918079	0.56	rs6449153	ENSG00000214846.4	RP11-115L11.1	3.57	0.000374	0.0194	0.14	0.11	Obesity-related traits;	chr4:15629593	chr4:15730962~15731627:-
BRCA	cis	rs2991971	0.747	rs2492841	ENSG00000280836.1	AL355480.1	-3.57	0.000374	0.0194	-0.13	-0.11	High light scatter reticulocyte count;	chr1:45429219	chr1:45581219~45581321:-
BRCA	cis	rs2985334	0.81	rs150088	ENSG00000237934.1	RP11-467D18.2	-3.57	0.000374	0.0194	-0.14	-0.11	Amyotrophic lateral sclerosis (sporadic);	chr1:28936021	chr1:29223933~29224816:+
BRCA	cis	rs2998286	0.723	rs332121	ENSG00000237128.1	RP11-351M16.3	3.57	0.000374	0.0194	0.14	0.11	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28552285	chr10:28433008~28495813:-
BRCA	cis	rs2998286	0.572	rs332124	ENSG00000237128.1	RP11-351M16.3	3.57	0.000374	0.0194	0.14	0.11	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28553545	chr10:28433008~28495813:-
BRCA	cis	rs10876993	0.928	rs1689586	ENSG00000270039.1	RP11-571M6.17	3.57	0.000374	0.0194	0.15	0.11	Celiac disease or Rheumatoid arthritis;	chr12:57685803	chr12:57803838~57804415:+
BRCA	cis	rs10838634	1	rs7102474	ENSG00000280615.1	Y_RNA	-3.57	0.000374	0.0194	-0.19	-0.11	Schizophrenia;	chr11:46811542	chr11:47614898~47614994:-
BRCA	cis	rs11892454	0.533	rs7592985	ENSG00000217643.1	PTGES3P2	-3.57	0.000374	0.0194	-0.12	-0.11	Heschl's gyrus morphology;	chr2:25877358	chr2:25822469~25822950:+
BRCA	cis	rs2411233	1	rs8028719	ENSG00000259278.1	RP11-62C7.2	3.57	0.000375	0.0194	0.13	0.11	Platelet count;	chr15:38978581	chr15:39019233~39024918:+
BRCA	cis	rs2411233	0.967	rs6492849	ENSG00000259278.1	RP11-62C7.2	3.57	0.000375	0.0194	0.13	0.11	Platelet count;	chr15:38978886	chr15:39019233~39024918:+
BRCA	cis	rs2411233	1	rs7168645	ENSG00000259278.1	RP11-62C7.2	3.57	0.000375	0.0194	0.13	0.11	Platelet count;	chr15:38978964	chr15:39019233~39024918:+
BRCA	cis	rs16852403	0.571	rs11800119	ENSG00000224687.1	RASAL2-AS1	3.57	0.000375	0.0194	0.14	0.11	Childhood ear infection;	chr1:178175838	chr1:178091508~178093984:-
BRCA	cis	rs7267979	0.903	rs6132819	ENSG00000274414.1	RP5-965G21.4	-3.57	0.000375	0.0194	-0.13	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25237982	chr20:25239007~25245229:-
BRCA	cis	rs3755021	1	rs2305589	ENSG00000260742.1	RP11-366L5.1	3.57	0.000375	0.0194	0.16	0.11	Monocyte-lymphocyte ratio;	chr2:181482210	chr2:181887851~181891663:-
BRCA	cis	rs9341808	0.519	rs676311	ENSG00000233967.5	RP11-250B2.3	-3.57	0.000375	0.0194	-0.12	-0.11	Sitting height ratio;	chr6:80280033	chr6:80443344~80465927:+
BRCA	cis	rs1552244	0.572	rs3894322	ENSG00000269894.1	RP11-1020A11.1	-3.57	0.000375	0.0194	-0.14	-0.11	Alzheimer's disease;	chr3:10127281	chr3:9935706~9936258:+
BRCA	cis	rs1552244	0.572	rs3894323	ENSG00000269894.1	RP11-1020A11.1	-3.57	0.000375	0.0194	-0.14	-0.11	Alzheimer's disease;	chr3:10127283	chr3:9935706~9936258:+
BRCA	cis	rs13434995	0.513	rs73236142	ENSG00000273257.1	RP11-177J6.1	-3.57	0.000375	0.0194	-0.16	-0.11	Adiponectin levels;	chr4:55446143	chr4:55387949~55388271:+
BRCA	cis	rs28595532	1	rs17258106	ENSG00000248213.3	CICP16	3.57	0.000375	0.0194	0.23	0.11	Cannabis dependence symptom count;	chr4:118754251	chr4:118635970~118638782:-
BRCA	cis	rs10129255	0.518	rs10150460	ENSG00000211964.3	IGHV3-48	3.57	0.000375	0.0194	0.07	0.11	Kawasaki disease;	chr14:106677179	chr14:106537810~106538344:-
BRCA	cis	rs7572733	0.935	rs10189897	ENSG00000231621.1	AC013264.2	3.57	0.000375	0.0194	0.1	0.11	Dermatomyositis;	chr2:197948686	chr2:197197991~197199273:+
BRCA	cis	rs875971	0.628	rs6974355	ENSG00000230189.5	GS1-124K5.2	3.57	0.000375	0.0194	0.09	0.11	Aortic root size;	chr7:66376994	chr7:66409143~66490059:-
BRCA	cis	rs10864907	0.837	rs6747618	ENSG00000231747.1	AC079922.2	-3.57	0.000375	0.0194	-0.1	-0.11	Pulmonary function;	chr2:112952776	chr2:112621809~112622167:-
BRCA	cis	rs3930017	0.513	rs3930018	ENSG00000225726.1	AC007000.10	-3.57	0.000375	0.0194	-0.13	-0.11	Body mass index;	chr7:77091318	chr7:77071751~77072237:-
BRCA	cis	rs13434995	0.842	rs9790448	ENSG00000249700.7	SRD5A3-AS1	-3.57	0.000375	0.0194	-0.17	-0.11	Adiponectin levels;	chr4:55592918	chr4:55363971~55395847:-
BRCA	cis	rs1124769	0.57	rs1903589	ENSG00000259298.1	RP11-562A8.4	-3.57	0.000375	0.0194	-0.1	-0.11	Cognitive performance;	chr15:50852087	chr15:50497195~50498744:-
BRCA	cis	rs7968440	0.736	rs10735827	ENSG00000272368.2	RP4-605O3.4	3.57	0.000375	0.0194	0.11	0.11	Fibrinogen;	chr12:50788629	chr12:50112197~50165618:+
BRCA	cis	rs7412746	0.588	rs10305664	ENSG00000224800.1	RP11-235D19.2	-3.57	0.000375	0.0194	-0.14	-0.11	Melanoma;	chr1:150867210	chr1:150881236~150881683:-
BRCA	cis	rs1560104	0.709	rs2217271	ENSG00000259876.1	CTD-3037G24.4	3.57	0.000375	0.0194	0.12	0.11	Obesity-related traits;	chr16:12610623	chr16:12556353~12557694:-
BRCA	cis	rs5758511	0.773	rs7288749	ENSG00000233903.2	Z83851.4	3.57	0.000375	0.0194	0.16	0.11	Birth weight;	chr22:41960426	chr22:42276355~42277052:+
BRCA	cis	rs2625529	0.824	rs11072338	ENSG00000260037.4	CTD-2524L6.3	-3.57	0.000375	0.0194	-0.16	-0.11	Red blood cell count;	chr15:71953106	chr15:71818396~71823384:+
BRCA	cis	rs10883723	1	rs10883723	ENSG00000213061.2	PFN1P11	-3.57	0.000375	0.0194	-0.15	-0.11	Allergic disease (asthma, hay fever or eczema);	chr10:102466075	chr10:102838011~102845473:-
BRCA	cis	rs4950322	0.571	rs4373796	ENSG00000237188.3	RP11-337C18.8	3.57	0.000375	0.0194	0.14	0.11	Protein quantitative trait loci;	chr1:147316747	chr1:147172771~147211568:+
BRCA	cis	rs4950322	0.543	rs4568882	ENSG00000237188.3	RP11-337C18.8	3.57	0.000375	0.0194	0.14	0.11	Protein quantitative trait loci;	chr1:147316885	chr1:147172771~147211568:+
BRCA	cis	rs4950322	0.543	rs2883323	ENSG00000237188.3	RP11-337C18.8	3.57	0.000375	0.0194	0.14	0.11	Protein quantitative trait loci;	chr1:147316995	chr1:147172771~147211568:+
BRCA	cis	rs4950322	0.543	rs2883324	ENSG00000237188.3	RP11-337C18.8	3.57	0.000375	0.0194	0.14	0.11	Protein quantitative trait loci;	chr1:147317157	chr1:147172771~147211568:+
BRCA	cis	rs7412746	0.658	rs1027699	ENSG00000231073.1	RP11-316M1.3	3.57	0.000375	0.0194	0.12	0.11	Melanoma;	chr1:150839236	chr1:150973123~150975534:+
BRCA	cis	rs875971	0.862	rs2901152	ENSG00000271064.1	RP11-792A8.3	3.57	0.000375	0.0194	0.13	0.11	Aortic root size;	chr7:66300017	chr7:66748838~66749077:-
BRCA	cis	rs6546537	0.911	rs13027712	ENSG00000231024.1	AC092431.3	3.57	0.000375	0.0194	0.16	0.11	Serum thyroid-stimulating hormone levels;	chr2:69664235	chr2:69700192~69713847:-
BRCA	cis	rs6546537	0.868	rs62133967	ENSG00000231024.1	AC092431.3	3.57	0.000375	0.0194	0.16	0.11	Serum thyroid-stimulating hormone levels;	chr2:69664576	chr2:69700192~69713847:-
BRCA	cis	rs11673344	0.832	rs112380313	ENSG00000267682.1	CTD-3220F14.2	-3.57	0.000375	0.0194	-0.1	-0.11	Obesity-related traits;	chr19:37027979	chr19:37337236~37337743:+
BRCA	cis	rs721917	0.607	rs4319455	ENSG00000225484.5	NUTM2B-AS1	-3.57	0.000375	0.0194	-0.14	-0.11	Chronic obstructive pulmonary disease;	chr10:79979389	chr10:79663088~79826594:-
BRCA	cis	rs6964587	1	rs6950470	ENSG00000188693.7	CYP51A1-AS1	-3.57	0.000375	0.0194	-0.12	-0.11	Breast cancer;	chr7:92051327	chr7:92134604~92180725:+
BRCA	cis	rs6964587	1	rs926192	ENSG00000188693.7	CYP51A1-AS1	-3.57	0.000375	0.0194	-0.12	-0.11	Breast cancer;	chr7:92042539	chr7:92134604~92180725:+
BRCA	cis	rs8067545	0.611	rs12603372	ENSG00000270091.1	RP11-78O7.2	-3.57	0.000375	0.0194	-0.11	-0.11	Schizophrenia;	chr17:20278253	chr17:19896590~19897287:-
BRCA	cis	rs4713118	0.662	rs149946	ENSG00000216901.1	AL022393.7	-3.57	0.000375	0.0194	-0.16	-0.11	Parkinson's disease;	chr6:28002253	chr6:28176188~28176674:+
BRCA	cis	rs7048146	0.899	rs884919	ENSG00000213539.4	YBX1P6	3.57	0.000375	0.0194	0.12	0.11	Vascular brain injury;	chr9:109585693	chr9:109532830~109534332:-
BRCA	cis	rs1912124	0.92	rs17337098	ENSG00000271983.1	RP11-28H5.2	3.57	0.000375	0.0194	0.21	0.11	Peripheral arterial disease (traffic-related air pollution interaction);	chr15:81186388	chr15:80693216~80693707:-
BRCA	cis	rs35306767	0.855	rs11253499	ENSG00000229869.1	RP11-363N22.2	-3.57	0.000375	0.0194	-0.17	-0.11	Eosinophil percentage of granulocytes;	chr10:898150	chr10:933026~942743:+
BRCA	cis	rs9868809	0.881	rs3806694	ENSG00000225399.4	RP11-3B7.1	-3.57	0.000375	0.0194	-0.18	-0.11	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48634901	chr3:49260085~49261316:+
BRCA	cis	rs718433	0.584	rs8015812	ENSG00000211778.2	TRAV4	-3.57	0.000376	0.0194	-0.08	-0.11	Intraocular pressure;	chr14:21746791	chr14:21736152~21736982:+
BRCA	cis	rs4950322	0.518	rs4950306	ENSG00000230832.3	RP11-325P15.2	-3.57	0.000376	0.0194	-0.17	-0.11	Protein quantitative trait loci;	chr1:147117838	chr1:147082338~147083578:-
BRCA	cis	rs9921338	0.961	rs4356497	ENSG00000263080.1	RP11-485G7.5	-3.57	0.000376	0.0194	-0.16	-0.11	Vein graft stenosis in coronary artery bypass grafting;	chr16:11320339	chr16:11341809~11345211:-
BRCA	cis	rs7260538	0.933	rs1987236	ENSG00000268034.1	AC005795.1	3.57	0.000376	0.0194	0.12	0.11	DDT metabolite (p,p'-DDE levels);	chr19:41003128	chr19:41506152~41506898:+
BRCA	cis	rs9816784	0.576	rs12631246	ENSG00000207650.1	MIR570	3.57	0.000376	0.0194	0.14	0.11	Mean corpuscular hemoglobin;	chr3:196094713	chr3:195699401~195699497:+
BRCA	cis	rs6498068	0.594	rs1875929	ENSG00000279662.1	RP11-609N14.4	-3.57	0.000376	0.0194	-0.13	-0.11	Metabolite levels (MHPG);	chr16:10528202	chr16:10445309~10449747:-
BRCA	cis	rs4761470	0.511	rs1880935	ENSG00000258365.1	RP11-1105G2.3	-3.57	0.000376	0.0194	-0.19	-0.11	Estradiol plasma levels (breast cancer);	chr12:94278134	chr12:94277758~94282844:-
BRCA	cis	rs4761470	0.511	rs4761601	ENSG00000258365.1	RP11-1105G2.3	-3.57	0.000376	0.0194	-0.19	-0.11	Estradiol plasma levels (breast cancer);	chr12:94278226	chr12:94277758~94282844:-
BRCA	cis	rs77686669	1	rs77686669	ENSG00000242294.5	STAG3L5P	3.57	0.000376	0.0194	0.09	0.11	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr7:100146949	chr7:100336079~100351900:+
BRCA	cis	rs8141529	0.748	rs2064261	ENSG00000226471.5	CTA-292E10.6	-3.57	0.000376	0.0194	-0.13	-0.11	Lymphocyte counts;	chr22:28891742	chr22:28800683~28848559:+
BRCA	cis	rs4243971	0.516	rs6141659	ENSG00000277692.1	RP11-358N2.2	3.57	0.000376	0.0194	0.12	0.11	Inflammatory bowel disease;Crohn's disease;	chr20:32284466	chr20:32355053~32355734:+
BRCA	cis	rs13401620	0.871	rs4480992	ENSG00000229326.3	AC069154.4	3.57	0.000376	0.0194	0.14	0.11	Breast size;	chr2:119951741	chr2:119698623~119700151:+
BRCA	cis	rs3749237	0.964	rs34522271	ENSG00000225399.4	RP11-3B7.1	3.57	0.000376	0.0194	0.11	0.11	Resting heart rate;	chr3:49771084	chr3:49260085~49261316:+
BRCA	cis	rs2032314	0.527	rs8133280	ENSG00000237945.6	LINC00649	-3.57	0.000376	0.0194	-0.18	-0.11	Red blood cell traits;	chr21:33952284	chr21:33915534~33977691:+
BRCA	cis	rs863345	0.604	rs1342946	ENSG00000176320.2	RP11-404O13.5	-3.57	0.000376	0.0194	-0.11	-0.11	Pneumococcal bacteremia;	chr1:158483397	chr1:158197922~158203877:-
BRCA	cis	rs7520050	1	rs12143096	ENSG00000226957.1	RP4-533D7.4	3.57	0.000376	0.0194	0.12	0.11	Reticulocyte count;Red blood cell count;	chr1:46004091	chr1:46046818~46048368:+
BRCA	cis	rs10838634	1	rs3136489	ENSG00000280615.1	Y_RNA	-3.57	0.000376	0.0194	-0.23	-0.11	Schizophrenia;	chr11:46734103	chr11:47614898~47614994:-
BRCA	cis	rs745109	0.882	rs1518812	ENSG00000273080.1	RP11-301O19.1	3.57	0.000376	0.0194	0.17	0.11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86488573	chr2:86195590~86196049:+
BRCA	cis	rs6801044	0.741	rs823511	ENSG00000272792.1	RP11-141C7.4	-3.57	0.000376	0.0194	-0.16	-0.11	Creatinine levels in ischemic stroke;	chr3:195536070	chr3:195639990~195640460:+
BRCA	cis	rs6942407	0.546	rs2108272	ENSG00000224046.1	AC005076.5	-3.57	0.000376	0.0194	-0.16	-0.11	Food allergy;	chr7:87176083	chr7:87151423~87152420:-
BRCA	cis	rs7308116	0.967	rs7303096	ENSG00000274395.1	RP11-554D14.8	-3.57	0.000376	0.0194	-0.12	-0.11	Pelvic organ prolapse (moderate/severe);	chr12:107805253	chr12:107835541~107836555:-
BRCA	cis	rs11764932	1	rs11764932	ENSG00000229108.1	MEOX2-AS1	3.57	0.000376	0.0194	0.12	0.11	Kidney function decline traits;	chr7:15693493	chr7:15688378~15695491:+
BRCA	cis	rs13153459	0.594	rs2330570	ENSG00000279557.1	CTD-2210P15.3	-3.57	0.000376	0.0194	-0.2	-0.11	Parkinson's disease;	chr5:44531253	chr5:43586367~43587543:-
BRCA	cis	rs4805834	0.841	rs11084672	ENSG00000201388.1	SNORA68	3.57	0.000376	0.0194	0.19	0.11	Creatinine levels;	chr19:32862451	chr19:32608337~32608469:-
BRCA	cis	rs4805834	0.764	rs11668597	ENSG00000201388.1	SNORA68	3.57	0.000376	0.0194	0.19	0.11	Creatinine levels;	chr19:32863498	chr19:32608337~32608469:-
BRCA	cis	rs6714710	0.58	rs55886305	ENSG00000228486.8	LINC01125	-3.57	0.000376	0.0194	-0.1	-0.11	Posterior cortical atrophy and Alzheimer's disease;	chr2:97879198	chr2:97664217~97703064:+
BRCA	cis	rs13118159	0.771	rs13117476	ENSG00000254094.1	AC078852.1	-3.57	0.000376	0.0194	-0.12	-0.11	Longevity;	chr4:1340933	chr4:1356581~1358075:+
BRCA	cis	rs875971	0.767	rs61348003	ENSG00000271064.1	RP11-792A8.3	-3.57	0.000376	0.0194	-0.13	-0.11	Aortic root size;	chr7:66540947	chr7:66748838~66749077:-
BRCA	cis	rs875971	0.825	rs801202	ENSG00000271064.1	RP11-792A8.3	3.57	0.000376	0.0194	0.13	0.11	Aortic root size;	chr7:66558942	chr7:66748838~66749077:-
BRCA	cis	rs7246657	0.525	rs10410594	ENSG00000267470.4	ZNF571-AS1	3.57	0.000376	0.0194	0.16	0.11	Coronary artery calcification;	chr19:36986856	chr19:37548914~37587348:+
BRCA	cis	rs728478	1	rs9913367	ENSG00000266992.1	DHX40P1	3.57	0.000376	0.0194	0.13	0.11	QT interval;	chr17:59370661	chr17:59976009~60002384:-
BRCA	cis	rs7520050	1	rs12143096	ENSG00000281133.1	AL355480.3	3.57	0.000376	0.0194	0.13	0.11	Reticulocyte count;Red blood cell count;	chr1:46004091	chr1:45580892~45580996:-
BRCA	cis	rs957448	1	rs12680965	ENSG00000261437.1	RP11-22C11.2	3.57	0.000376	0.0194	0.12	0.11	Nonsyndromic cleft lip with cleft palate;	chr8:94554069	chr8:94637285~94639467:-
BRCA	cis	rs853679	0.599	rs149943	ENSG00000216901.1	AL022393.7	3.57	0.000376	0.0194	0.22	0.11	Depression;	chr6:28034610	chr6:28176188~28176674:+
BRCA	cis	rs6545883	0.929	rs7561229	ENSG00000212978.6	AC016747.3	3.57	0.000376	0.0194	0.15	0.11	Tuberculosis;	chr2:61510855	chr2:61141592~61144969:-
BRCA	cis	rs4950322	0.58	rs17355419	ENSG00000227242.3	NBPF13P	-3.57	0.000376	0.0194	-0.15	-0.11	Protein quantitative trait loci;	chr1:147110094	chr1:147021320~147124525:-
BRCA	cis	rs4950322	0.58	rs72706428	ENSG00000227242.3	NBPF13P	-3.57	0.000376	0.0194	-0.15	-0.11	Protein quantitative trait loci;	chr1:147110219	chr1:147021320~147124525:-
BRCA	cis	rs4950322	0.563	rs61838944	ENSG00000227242.3	NBPF13P	-3.57	0.000376	0.0194	-0.15	-0.11	Protein quantitative trait loci;	chr1:147110275	chr1:147021320~147124525:-
BRCA	cis	rs539096	0.874	rs2842175	ENSG00000236200.4	KDM4A-AS1	3.57	0.000376	0.0194	0.14	0.11	Intelligence (multi-trait analysis);	chr1:43557944	chr1:43699765~43708138:-
BRCA	cis	rs4148883	0.675	rs34511427	ENSG00000272777.1	RP11-571L19.8	-3.57	0.000376	0.0194	-0.11	-0.11	Alcohol dependence;	chr4:99184248	chr4:99067256~99068125:-
BRCA	cis	rs16950303	0.661	rs73439648	ENSG00000265496.3	MIR1539	3.57	0.000376	0.0194	0.21	0.11	Height;	chr18:49057974	chr18:49487339~49491878:+
BRCA	cis	rs3770752	0.823	rs10190959	ENSG00000272054.1	RP11-423P10.2	-3.57	0.000376	0.0194	-0.1	-0.11	Schizophrenia;	chr2:37312433	chr2:37208875~37212677:+
BRCA	cis	rs10129255	0.83	rs61997609	ENSG00000211967.3	IGHV3-53	-3.57	0.000376	0.0194	-0.08	-0.11	Kawasaki disease;	chr14:106692376	chr14:106592676~106593347:-
BRCA	cis	rs3858526	0.883	rs10769333	ENSG00000224295.2	AC087380.14	3.57	0.000376	0.0194	0.16	0.11	DNA methylation (variation);	chr11:5918455	chr11:5518441~5524955:-
BRCA	cis	rs2744375	1	rs2744373	ENSG00000261189.1	RP3-512B11.3	3.57	0.000376	0.0194	0.17	0.11	Resting heart rate;	chr6:7554294	chr6:7540451~7541338:-
BRCA	cis	rs10849893	0.554	rs10849888	ENSG00000258435.1	RP11-711D18.2	-3.57	0.000376	0.0194	-0.12	-0.11	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr12:121454983	chr12:121391962~121399859:+
BRCA	cis	rs6714710	0.603	rs11681535	ENSG00000228486.8	LINC01125	-3.57	0.000376	0.0194	-0.1	-0.11	Posterior cortical atrophy and Alzheimer's disease;	chr2:97872486	chr2:97664217~97703064:+
BRCA	cis	rs6678639	0.522	rs9793989	ENSG00000225154.2	RP11-184J23.2	3.57	0.000377	0.0195	0.16	0.11	Blood metabolite ratios;	chr1:47031066	chr1:47074778~47075979:-
BRCA	cis	rs2346177	0.811	rs4953373	ENSG00000279254.1	RP11-536C12.1	-3.57	0.000377	0.0195	-0.13	-0.11	HDL cholesterol;	chr2:46425006	chr2:46668870~46670778:+
BRCA	cis	rs6496044	0.568	rs2880764	ENSG00000259630.2	CTD-2262B20.1	-3.57	0.000377	0.0195	-0.13	-0.11	Interstitial lung disease;	chr15:85513177	chr15:85415228~85415633:+
BRCA	cis	rs1075265	0.84	rs805309	ENSG00000272156.1	RP11-477N3.1	-3.57	0.000377	0.0195	-0.11	-0.11	Chronotype;Morning vs. evening chronotype;	chr2:53968877	chr2:54082554~54085066:+
BRCA	cis	rs61869271	0.688	rs881192	ENSG00000236799.1	RP11-383C6.2	-3.57	0.000377	0.0195	-0.13	-0.11	Tonsillectomy;	chr10:114947026	chr10:114994657~114996593:+
BRCA	cis	rs6600671	0.934	rs11249429	ENSG00000223345.3	HIST2H2BA	-3.57	0.000377	0.0195	-0.13	-0.11	Hip geometry;	chr1:121549282	chr1:121108210~121117257:-
BRCA	cis	rs7015630	0.738	rs34642426	ENSG00000251136.7	RP11-37B2.1	-3.57	0.000377	0.0195	-0.13	-0.11	Inflammatory bowel disease;Crohn's disease;	chr8:89842618	chr8:89609409~89757727:-
BRCA	cis	rs4950322	0.518	rs61838936	ENSG00000230832.3	RP11-325P15.2	-3.57	0.000377	0.0195	-0.18	-0.11	Protein quantitative trait loci;	chr1:147098422	chr1:147082338~147083578:-
BRCA	cis	rs9807841	0.617	rs2360944	ENSG00000267100.1	ILF3-AS1	3.57	0.000377	0.0195	0.11	0.11	Inflammatory skin disease;	chr19:10659298	chr19:10651862~10653844:-
BRCA	cis	rs11673344	0.838	rs111827672	ENSG00000267682.1	CTD-3220F14.2	-3.57	0.000377	0.0195	-0.11	-0.11	Obesity-related traits;	chr19:37158964	chr19:37337236~37337743:+
BRCA	cis	rs17214007	0.877	rs11075280	ENSG00000260735.1	RP11-72I8.1	-3.57	0.000377	0.0195	-0.15	-0.11	Cognitive function;	chr16:15776630	chr16:15094411~15109197:+
BRCA	cis	rs7208859	0.623	rs73269923	ENSG00000276250.1	CTD-2349P21.12	-3.57	0.000377	0.0195	-0.18	-0.11	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775553	chr17:30803654~30804077:+
BRCA	cis	rs748404	0.666	rs60018990	ENSG00000201136.1	RNU6-353P	3.57	0.000377	0.0195	0.16	0.11	Lung cancer;	chr15:43504606	chr15:43702363~43702470:+
BRCA	cis	rs4865762	0.535	rs254605	ENSG00000247796.2	CTD-2366F13.1	3.57	0.000377	0.0195	0.12	0.11	Intraocular pressure;	chr5:53147803	chr5:53109842~53115126:+
BRCA	cis	rs595244	0.908	rs35349206	ENSG00000259705.1	RP11-227D13.1	3.57	0.000377	0.0195	0.17	0.11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48433982	chr15:48645951~48652016:+
BRCA	cis	rs6490294	0.528	rs60690688	ENSG00000234608.6	MAPKAPK5-AS1	3.57	0.000377	0.0195	0.16	0.11	Mean platelet volume;	chr12:112104179	chr12:111839764~111842902:-
BRCA	cis	rs1501138	0.636	rs203447	ENSG00000263327.5	TAPT1-AS1	-3.57	0.000377	0.0195	-0.14	-0.11	Systemic juvenile idiopathic arthritis;	chr4:16255644	chr4:16226685~16320140:+
BRCA	cis	rs10875746	0.768	rs12305182	ENSG00000273765.1	RP11-370I10.11	-3.57	0.000377	0.0195	-0.15	-0.11	Longevity (90 years and older);	chr12:48027624	chr12:48360920~48361377:+
BRCA	cis	rs77633900	0.614	rs280033	ENSG00000196274.5	Metazoa_SRP	3.57	0.000377	0.0195	0.16	0.11	Glioma;Non-glioblastoma glioma;	chr15:76730758	chr15:76230048~76230390:-
BRCA	cis	rs4713118	0.869	rs9468214	ENSG00000219392.1	RP1-265C24.5	-3.57	0.000377	0.0195	-0.16	-0.11	Parkinson's disease;	chr6:27745520	chr6:28115628~28116551:+
BRCA	cis	rs10043228	1	rs12332658	ENSG00000271918.1	CTD-2287O16.5	-3.57	0.000377	0.0195	-0.14	-0.11	Asthma or chronic obstructive pulmonary disease;	chr5:116209909	chr5:116083807~116085416:-
BRCA	cis	rs4835473	0.932	rs35655934	ENSG00000246448.2	RP13-578N3.3	-3.57	0.000377	0.0195	-0.12	-0.11	Immature fraction of reticulocytes;	chr4:143734697	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.897	rs35515006	ENSG00000246448.2	RP13-578N3.3	-3.57	0.000377	0.0195	-0.12	-0.11	Immature fraction of reticulocytes;	chr4:143734705	chr4:143700257~143865072:+
BRCA	cis	rs962856	0.537	rs676245	ENSG00000236780.4	AC078941.1	3.57	0.000377	0.0195	0.13	0.11	Pancreatic cancer;	chr2:67454716	chr2:67123357~67215319:-
BRCA	cis	rs2836974	0.604	rs2854727	ENSG00000238141.2	BRWD1-AS1	3.57	0.000377	0.0195	0.12	0.11	Cognitive function;	chr21:39341861	chr21:39315707~39323218:+
BRCA	cis	rs1204660	1	rs1204660	ENSG00000199676.1	Y_RNA	3.57	0.000377	0.0195	0.19	0.11	Venous thromboembolism (SNP x SNP interaction);	chr20:35405288	chr20:35853252~35853364:-
BRCA	cis	rs4908769	0.66	rs10779702	ENSG00000232912.4	RP5-1115A15.1	-3.57	0.000377	0.0195	-0.12	-0.11	Allergy;	chr1:8363450	chr1:8424645~8434838:+
BRCA	cis	rs6432852	0.516	rs2304002	ENSG00000235192.1	AC009495.2	3.57	0.000377	0.0195	0.11	0.11	Diabetic kidney disease;	chr2:165857585	chr2:165794851~165810010:+
BRCA	cis	rs61931739	0.5	rs11053212	ENSG00000258794.3	DUX4L27	3.57	0.000377	0.0195	0.16	0.11	Morning vs. evening chronotype;	chr12:34313181	chr12:34208415~34209675:-
BRCA	cis	rs61931739	0.5	rs11053213	ENSG00000258794.3	DUX4L27	3.57	0.000377	0.0195	0.16	0.11	Morning vs. evening chronotype;	chr12:34313460	chr12:34208415~34209675:-
BRCA	cis	rs1455244	0.81	rs8083560	ENSG00000267533.1	RP11-815J4.7	-3.57	0.000377	0.0195	-0.14	-0.11	Schizophrenia;	chr18:11462681	chr18:12067173~12068417:-
BRCA	cis	rs1046491	1	rs62085926	ENSG00000264964.1	RP11-888D10.3	3.57	0.000378	0.0195	0.22	0.11	Scarlet fever;	chr18:9212641	chr18:9315194~9334441:-
BRCA	cis	rs1046491	1	rs11661921	ENSG00000264964.1	RP11-888D10.3	3.57	0.000378	0.0195	0.22	0.11	Scarlet fever;	chr18:9214150	chr18:9315194~9334441:-
BRCA	cis	rs1046491	1	rs11872176	ENSG00000264964.1	RP11-888D10.3	3.57	0.000378	0.0195	0.22	0.11	Scarlet fever;	chr18:9218600	chr18:9315194~9334441:-
BRCA	cis	rs1005277	0.579	rs2749612	ENSG00000276805.1	RP11-291L22.6	3.57	0.000378	0.0195	0.12	0.11	Extrinsic epigenetic age acceleration;	chr10:38199682	chr10:38451030~38451785:+
BRCA	cis	rs16950303	1	rs16950303	ENSG00000264269.1	RP11-15F12.1	3.57	0.000378	0.0195	0.22	0.11	Height;	chr18:49055989	chr18:49023703~49048474:+
BRCA	cis	rs1555133	0.584	rs4911093	ENSG00000275576.1	RP5-836N17.4	-3.57	0.000378	0.0195	-0.12	-0.11	Monocyte count;	chr20:32430560	chr20:32116171~32116629:+
BRCA	cis	rs7577696	0.853	rs212699	ENSG00000276334.1	AL133243.1	3.57	0.000378	0.0195	0.14	0.11	Inflammatory biomarkers;	chr2:32218450	chr2:32521927~32523547:+
BRCA	cis	rs7577696	0.853	rs212701	ENSG00000276334.1	AL133243.1	3.57	0.000378	0.0195	0.14	0.11	Inflammatory biomarkers;	chr2:32218985	chr2:32521927~32523547:+
BRCA	cis	rs561341	1	rs498391	ENSG00000265798.5	RP11-271K11.5	3.57	0.000378	0.0195	0.19	0.11	Hip circumference adjusted for BMI;	chr17:32001685	chr17:31038575~31059121:-
BRCA	cis	rs6771316	1	rs17009384	ENSG00000241163.6	LINC00877	3.57	0.000378	0.0195	0.16	0.11	Venous thromboembolism (SNP x SNP interaction);	chr3:72093380	chr3:72035300~72279503:-
BRCA	cis	rs2243480	0.803	rs160649	ENSG00000237026.1	RP11-328P23.2	3.57	0.000378	0.0195	0.21	0.11	Diabetic kidney disease;	chr7:66078212	chr7:65235790~65236723:-
BRCA	cis	rs2243480	1	rs160648	ENSG00000237026.1	RP11-328P23.2	3.57	0.000378	0.0195	0.21	0.11	Diabetic kidney disease;	chr7:66078397	chr7:65235790~65236723:-
BRCA	cis	rs1865760	0.929	rs2876693	ENSG00000272810.1	U91328.22	-3.57	0.000378	0.0195	-0.13	-0.11	Height;	chr6:25954206	chr6:26013241~26013757:+
BRCA	cis	rs9287719	0.967	rs6706542	ENSG00000224177.5	LINC00570	3.57	0.000378	0.0195	0.13	0.11	Prostate cancer;	chr2:10602365	chr2:11393981~11403077:+
BRCA	cis	rs9287719	0.967	rs2287061	ENSG00000224177.5	LINC00570	3.57	0.000378	0.0195	0.13	0.11	Prostate cancer;	chr2:10603027	chr2:11393981~11403077:+
BRCA	cis	rs9287719	0.967	rs2287062	ENSG00000224177.5	LINC00570	3.57	0.000378	0.0195	0.13	0.11	Prostate cancer;	chr2:10603065	chr2:11393981~11403077:+
BRCA	cis	rs9287719	0.935	rs1309	ENSG00000224177.5	LINC00570	3.57	0.000378	0.0195	0.13	0.11	Prostate cancer;	chr2:10603420	chr2:11393981~11403077:+
BRCA	cis	rs9287719	0.967	rs3815521	ENSG00000224177.5	LINC00570	3.57	0.000378	0.0195	0.13	0.11	Prostate cancer;	chr2:10603528	chr2:11393981~11403077:+
BRCA	cis	rs9287719	0.967	rs10929686	ENSG00000224177.5	LINC00570	3.57	0.000378	0.0195	0.13	0.11	Prostate cancer;	chr2:10603579	chr2:11393981~11403077:+
BRCA	cis	rs9287719	0.967	rs4613248	ENSG00000224177.5	LINC00570	3.57	0.000378	0.0195	0.13	0.11	Prostate cancer;	chr2:10603925	chr2:11393981~11403077:+
BRCA	cis	rs9287719	0.967	rs10191883	ENSG00000224177.5	LINC00570	3.57	0.000378	0.0195	0.13	0.11	Prostate cancer;	chr2:10604010	chr2:11393981~11403077:+
BRCA	cis	rs9287719	0.934	rs4629131	ENSG00000224177.5	LINC00570	3.57	0.000378	0.0195	0.13	0.11	Prostate cancer;	chr2:10604033	chr2:11393981~11403077:+
BRCA	cis	rs9287719	0.901	rs4555317	ENSG00000224177.5	LINC00570	3.57	0.000378	0.0195	0.13	0.11	Prostate cancer;	chr2:10604121	chr2:11393981~11403077:+
BRCA	cis	rs9287719	0.967	rs4555318	ENSG00000224177.5	LINC00570	3.57	0.000378	0.0195	0.13	0.11	Prostate cancer;	chr2:10604169	chr2:11393981~11403077:+
BRCA	cis	rs9287719	0.934	rs4622695	ENSG00000224177.5	LINC00570	3.57	0.000378	0.0195	0.13	0.11	Prostate cancer;	chr2:10604201	chr2:11393981~11403077:+
BRCA	cis	rs9287719	0.934	rs6432111	ENSG00000224177.5	LINC00570	3.57	0.000378	0.0195	0.13	0.11	Prostate cancer;	chr2:10604494	chr2:11393981~11403077:+
BRCA	cis	rs17801127	0.901	rs13026469	ENSG00000231969.1	AC144449.1	3.57	0.000378	0.0195	0.19	0.11	Liver enzyme levels (alanine transaminase);	chr2:149698874	chr2:149587196~149848233:+
BRCA	cis	rs17801127	0.901	rs13011748	ENSG00000231969.1	AC144449.1	3.57	0.000378	0.0195	0.19	0.11	Liver enzyme levels (alanine transaminase);	chr2:149699081	chr2:149587196~149848233:+
BRCA	cis	rs897984	0.542	rs11865038	ENSG00000232748.3	RP11-196G11.6	-3.57	0.000378	0.0195	-0.13	-0.11	Dementia with Lewy bodies;	chr16:31083850	chr16:31056460~31062803:+
BRCA	cis	rs897984	0.542	rs11864806	ENSG00000232748.3	RP11-196G11.6	-3.57	0.000378	0.0195	-0.13	-0.11	Dementia with Lewy bodies;	chr16:31083883	chr16:31056460~31062803:+
BRCA	cis	rs897984	0.542	rs7199949	ENSG00000232748.3	RP11-196G11.6	-3.57	0.000378	0.0195	-0.13	-0.11	Dementia with Lewy bodies;	chr16:31084843	chr16:31056460~31062803:+
BRCA	cis	rs3617	0.572	rs2245538	ENSG00000279144.1	RP11-894J14.2	3.57	0.000378	0.0195	0.14	0.11	Red blood cell count;Autism spectrum disorder or schizophrenia;	chr3:52818044	chr3:52848085~52848553:-
BRCA	cis	rs9467773	1	rs6925895	ENSG00000224843.5	LINC00240	-3.57	0.000378	0.0195	-0.12	-0.11	Intelligence (multi-trait analysis);	chr6:26571937	chr6:26956992~27023924:+
BRCA	cis	rs863345	0.604	rs11264999	ENSG00000176320.2	RP11-404O13.5	-3.57	0.000378	0.0195	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158519070	chr1:158197922~158203877:-
BRCA	cis	rs17801127	0.818	rs34272267	ENSG00000231969.1	AC144449.1	3.57	0.000378	0.0195	0.19	0.11	Liver enzyme levels (alanine transaminase);	chr2:149679511	chr2:149587196~149848233:+
BRCA	cis	rs10938353	0.906	rs2348343	ENSG00000273369.1	RP11-700J17.1	-3.57	0.000378	0.0195	-0.13	-0.11	Body mass index;	chr4:44586034	chr4:44693946~44694386:-
BRCA	cis	rs12468226	1	rs16839090	ENSG00000272966.1	RP11-686O6.1	3.57	0.000378	0.0195	0.18	0.11	Urate levels;	chr2:202348338	chr2:202336739~202337200:+
BRCA	cis	rs733175	0.599	rs6856396	ENSG00000250413.1	RP11-448G15.1	-3.57	0.000378	0.0195	-0.2	-0.11	Psychosis and Alzheimer's disease;	chr4:10029539	chr4:10006482~10009725:+
BRCA	cis	rs970548	0.954	rs61854123	ENSG00000230869.1	CTGLF10P	3.57	0.000378	0.0195	0.14	0.11	Total cholesterol levels;HDL cholesterol;HDL cholesterol levels;Cholesterol, total;	chr10:45570003	chr10:45678692~45700532:+
BRCA	cis	rs952623	0.649	rs6952464	ENSG00000227191.5	TRGC2	3.57	0.000378	0.0195	0.1	0.11	Intelligence (multi-trait analysis);	chr7:39036727	chr7:38239580~38368091:-
BRCA	cis	rs9309711	0.544	rs9309712	ENSG00000271868.1	RP11-1293J14.1	-3.57	0.000378	0.0195	-0.15	-0.11	Neurofibrillary tangles;	chr2:3487556	chr2:3496956~3497428:+
BRCA	cis	rs60871478	0.735	rs4721501	ENSG00000237181.1	AC147651.4	3.57	0.000378	0.0195	0.12	0.11	Cerebrospinal P-tau181p levels;	chr7:822529	chr7:603185~608482:+
BRCA	cis	rs17135159	0.917	rs12779983	ENSG00000273001.1	RP11-118K6.3	-3.57	0.000378	0.0195	-0.14	-0.11	Reading and spelling;	chr10:3365469	chr10:3065424~3066001:-
BRCA	cis	rs17684571	0.938	rs34724718	ENSG00000231441.1	RP11-472M19.2	3.57	0.000378	0.0195	0.15	0.11	Schizophrenia;	chr6:56693024	chr6:56844002~56864078:+
BRCA	cis	rs249954	0.512	rs703767	ENSG00000260136.4	CTD-2270L9.4	3.57	0.000378	0.0195	0.11	0.11	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr16:23650318	chr16:23452758~23457606:+
BRCA	cis	rs7520050	0.966	rs12409773	ENSG00000226957.1	RP4-533D7.4	3.57	0.000378	0.0195	0.12	0.11	Reticulocyte count;Red blood cell count;	chr1:45893159	chr1:46046818~46048368:+
BRCA	cis	rs7520050	1	rs12410070	ENSG00000226957.1	RP4-533D7.4	3.57	0.000378	0.0195	0.12	0.11	Reticulocyte count;Red blood cell count;	chr1:45893210	chr1:46046818~46048368:+
BRCA	cis	rs7520050	0.966	rs12410071	ENSG00000226957.1	RP4-533D7.4	3.57	0.000378	0.0195	0.12	0.11	Reticulocyte count;Red blood cell count;	chr1:45893214	chr1:46046818~46048368:+
BRCA	cis	rs8067545	0.75	rs4925077	ENSG00000270091.1	RP11-78O7.2	-3.57	0.000378	0.0195	-0.1	-0.11	Schizophrenia;	chr17:20078963	chr17:19896590~19897287:-
BRCA	cis	rs2562456	0.917	rs2681377	ENSG00000268705.1	BNIP3P26	-3.57	0.000378	0.0195	-0.12	-0.11	Pain;	chr19:21533718	chr19:21521343~21521896:-
BRCA	cis	rs11148252	0.74	rs3803264	ENSG00000281106.1	LINC00282	-3.57	0.000378	0.0195	-0.13	-0.11	Lewy body disease;	chr13:52397758	chr13:51813347~51845175:-
BRCA	cis	rs2692947	0.599	rs7561198	ENSG00000168992.4	OR7E102P	-3.57	0.000378	0.0195	-0.16	-0.11	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96109233	chr2:95546531~95547545:+
BRCA	cis	rs2692947	0.702	rs2312955	ENSG00000168992.4	OR7E102P	-3.57	0.000378	0.0195	-0.16	-0.11	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96111420	chr2:95546531~95547545:+
BRCA	cis	rs1178127	0.719	rs1178171	ENSG00000232821.1	AC003986.6	3.57	0.000378	0.0195	0.14	0.11	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);	chr7:18754723	chr7:19112474~19114271:+
BRCA	cis	rs36051895	0.664	rs3780373	ENSG00000236254.1	MTND4P14	-3.57	0.000378	0.0195	-0.13	-0.11	Pediatric autoimmune diseases;	chr9:5098223	chr9:5107937~5109290:+
BRCA	cis	rs7520050	0.966	rs1707336	ENSG00000226957.1	RP4-533D7.4	3.57	0.000378	0.0195	0.12	0.11	Reticulocyte count;Red blood cell count;	chr1:46027788	chr1:46046818~46048368:+
BRCA	cis	rs10864907	0.837	rs10221977	ENSG00000231747.1	AC079922.2	-3.57	0.000378	0.0195	-0.1	-0.11	Pulmonary function;	chr2:112939699	chr2:112621809~112622167:-
BRCA	cis	rs7267979	0.932	rs449370	ENSG00000204556.4	CTD-2514C3.1	3.57	0.000378	0.0195	0.15	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25470544	chr20:26018832~26020684:+
BRCA	cis	rs736801	0.78	rs12521868	ENSG00000233006.5	AC034220.3	-3.57	0.000378	0.0195	-0.09	-0.11	Mosquito bite size;Breast cancer;	chr5:132448701	chr5:132311285~132369916:-
BRCA	cis	rs2108622	0.683	rs56228205	ENSG00000214049.6	UCA1	3.57	0.000378	0.0195	0.16	0.11	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871163	chr19:15828961~15836320:+
BRCA	cis	rs877819	0.697	rs7101184	ENSG00000228403.1	RP11-563N6.6	-3.57	0.000379	0.0195	-0.12	-0.11	Systemic lupus erythematosus;	chr10:48838278	chr10:48878022~48878649:+
BRCA	cis	rs877819	0.697	rs7074067	ENSG00000228403.1	RP11-563N6.6	-3.57	0.000379	0.0195	-0.12	-0.11	Systemic lupus erythematosus;	chr10:48838279	chr10:48878022~48878649:+
BRCA	cis	rs11098499	0.955	rs1511018	ENSG00000225892.3	RP11-384K6.2	3.57	0.000379	0.0195	0.11	0.11	Corneal astigmatism;	chr4:119240425	chr4:118632274~118634759:+
BRCA	cis	rs7267979	1	rs6138572	ENSG00000274973.1	RP13-401N8.7	-3.57	0.000379	0.0195	-0.13	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25455298	chr20:25845497~25845862:+
BRCA	cis	rs7267979	1	rs6138575	ENSG00000274973.1	RP13-401N8.7	-3.57	0.000379	0.0195	-0.13	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25458316	chr20:25845497~25845862:+
BRCA	cis	rs9467773	0.526	rs10946817	ENSG00000124549.13	BTN2A3P	-3.57	0.000379	0.0195	-0.11	-0.11	Intelligence (multi-trait analysis);	chr6:26363828	chr6:26421391~26432383:+
BRCA	cis	rs875971	0.83	rs587360	ENSG00000230189.5	GS1-124K5.2	3.57	0.000379	0.0195	0.09	0.11	Aortic root size;	chr7:66057711	chr7:66409143~66490059:-
BRCA	cis	rs6854137	0.904	rs13124822	ENSG00000214676.4	RPL9P16	-3.57	0.000379	0.0195	-0.13	-0.11	Vein graft stenosis in coronary artery bypass grafting;	chr4:168816561	chr4:168755816~168756382:+
BRCA	cis	rs2562456	0.652	rs62110214	ENSG00000268555.1	RP11-678G14.3	3.57	0.000379	0.0195	0.15	0.11	Pain;	chr19:21592406	chr19:21570822~21587322:-
BRCA	cis	rs875971	0.862	rs1981799	ENSG00000229886.1	RP5-1132H15.3	3.57	0.000379	0.0195	0.12	0.11	Aortic root size;	chr7:66490572	chr7:66025126~66031544:-
BRCA	cis	rs28489187	0.706	rs233057	ENSG00000223653.4	RP11-131L23.1	3.57	0.000379	0.0195	0.12	0.11	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85333172	chr1:85276715~85448124:+
BRCA	cis	rs28489187	0.706	rs233058	ENSG00000223653.4	RP11-131L23.1	3.57	0.000379	0.0195	0.12	0.11	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85333182	chr1:85276715~85448124:+
BRCA	cis	rs28489187	0.706	rs233059	ENSG00000223653.4	RP11-131L23.1	3.57	0.000379	0.0195	0.12	0.11	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85333253	chr1:85276715~85448124:+
BRCA	cis	rs28489187	0.706	rs233060	ENSG00000223653.4	RP11-131L23.1	3.57	0.000379	0.0195	0.12	0.11	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85333260	chr1:85276715~85448124:+
BRCA	cis	rs3753275	0.624	rs4908773	ENSG00000270282.1	RP5-1115A15.2	3.57	0.000379	0.0195	0.15	0.11	Educational attainment;	chr1:8709669	chr1:8512653~8513021:+
BRCA	cis	rs72692916	0.536	rs2296096	ENSG00000225706.1	PTPRD-AS1	3.57	0.000379	0.0195	0.25	0.11	Midgestational circulating levels of PCBs (fetal genetic effect);	chr9:8449502	chr9:8858130~8862255:+
BRCA	cis	rs748404	1	rs17779494	ENSG00000205771.5	CATSPER2P1	3.57	0.000379	0.0196	0.16	0.11	Lung cancer;	chr15:43287025	chr15:43726918~43747094:-
BRCA	cis	rs10744955	0.727	rs8042657	ENSG00000244879.4	GABPB1-AS1	-3.57	0.000379	0.0196	-0.11	-0.11	Lobe attachment (rater-scored or self-reported);	chr15:50160504	chr15:50354959~50372202:+
BRCA	cis	rs6840360	0.571	rs62327272	ENSG00000270265.1	RP11-731D1.4	-3.57	0.000379	0.0196	-0.13	-0.11	Intelligence (multi-trait analysis);	chr4:151623938	chr4:151333775~151353224:-
BRCA	cis	rs6964587	0.904	rs6465339	ENSG00000188693.7	CYP51A1-AS1	3.57	0.000379	0.0196	0.12	0.11	Breast cancer;	chr7:91941476	chr7:92134604~92180725:+
BRCA	cis	rs8141529	0.748	rs1318025	ENSG00000226471.5	CTA-292E10.6	-3.57	0.000379	0.0196	-0.13	-0.11	Lymphocyte counts;	chr22:28887769	chr22:28800683~28848559:+
BRCA	cis	rs12303914	0.775	rs7313418	ENSG00000256682.2	TAS2R12	3.57	0.000379	0.0196	0.13	0.11	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr12:10316426	chr12:10894943~10896952:-
BRCA	cis	rs6840360	0.571	rs72730104	ENSG00000278978.1	RP11-164P12.5	-3.57	0.000379	0.0196	-0.13	-0.11	Intelligence (multi-trait analysis);	chr4:151622705	chr4:151669786~151670503:+
BRCA	cis	rs2286503	0.646	rs17147344	ENSG00000226329.2	AC005682.6	3.57	0.000379	0.0196	0.11	0.11	Fibrinogen;	chr7:22841237	chr7:22863874~22881350:-
BRCA	cis	rs10070219	0.505	rs10071916	ENSG00000248445.4	SEMA6A-AS1	-3.57	0.000379	0.0196	-0.15	-0.11	3-hydroxypropylmercapturic acid levels in smokers;	chr5:117352842	chr5:116447547~116508276:+
BRCA	cis	rs9467773	1	rs6932156	ENSG00000224843.5	LINC00240	-3.57	0.000379	0.0196	-0.12	-0.11	Intelligence (multi-trait analysis);	chr6:26571278	chr6:26956992~27023924:+
BRCA	cis	rs9467773	1	rs6924838	ENSG00000224843.5	LINC00240	-3.57	0.000379	0.0196	-0.12	-0.11	Intelligence (multi-trait analysis);	chr6:26571528	chr6:26956992~27023924:+
BRCA	cis	rs4919694	1	rs3740394	ENSG00000236937.2	PTGES3P4	3.57	0.000379	0.0196	0.22	0.11	Arsenic metabolism;	chr10:102874717	chr10:102845595~102845950:+
BRCA	cis	rs1009077	0.61	rs7684899	ENSG00000245958.5	RP11-33B1.1	-3.57	0.000379	0.0196	-0.12	-0.11	Endometriosis;	chr4:119600474	chr4:119454791~119552025:+
BRCA	cis	rs2841277	0.645	rs28380382	ENSG00000258701.1	LINC00638	3.57	0.000379	0.0196	0.12	0.11	Rheumatoid arthritis;	chr14:104944490	chr14:104821201~104823718:+
BRCA	cis	rs877819	0.583	rs2620880	ENSG00000278561.1	PTPN20CP	-3.57	0.000379	0.0196	-0.13	-0.11	Systemic lupus erythematosus;	chr10:48877383	chr10:48064308~48119455:-
BRCA	cis	rs4925386	0.625	rs3810550	ENSG00000233017.2	RP5-908M14.5	-3.57	0.000379	0.0196	-0.16	-0.11	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62337061	chr20:62427827~62447621:+
BRCA	cis	rs10412972	0.697	rs12978299	ENSG00000273837.1	LLNLR-470E3.1	-3.57	0.000379	0.0196	-0.14	-0.11	Plasma plasminogen levels;	chr19:51651145	chr19:51639478~51639931:-
BRCA	cis	rs4662750	0.619	rs2244042	ENSG00000272789.1	RP11-286H15.1	3.57	0.000379	0.0196	0.11	0.11	Renal cell carcinoma;	chr2:127647423	chr2:127625997~127626848:-
BRCA	cis	rs9614461	0.702	rs2294202	ENSG00000226328.5	NUP50-AS1	-3.57	0.000379	0.0196	-0.18	-0.11	Tonsillectomy;	chr22:45342446	chr22:45133020~45163781:-
BRCA	cis	rs7520050	0.966	rs785495	ENSG00000234329.1	RP11-767N6.2	-3.57	0.000379	0.0196	-0.1	-0.11	Reticulocyte count;Red blood cell count;	chr1:46122215	chr1:45651039~45651826:-
BRCA	cis	rs11098499	0.908	rs9995234	ENSG00000260091.1	RP11-33B1.4	-3.57	0.000379	0.0196	-0.1	-0.11	Corneal astigmatism;	chr4:119400672	chr4:119409333~119410233:+
BRCA	cis	rs1670533	1	rs7669622	ENSG00000251639.2	RP11-20I20.1	3.57	0.000379	0.0196	0.18	0.11	Recombination rate (females);	chr4:1064871	chr4:1100016~1101558:-
BRCA	cis	rs2839186	0.967	rs17176131	ENSG00000215424.8	MCM3AP-AS1	3.57	0.000379	0.0196	0.1	0.11	Testicular germ cell tumor;	chr21:46285323	chr21:46229217~46259390:+
BRCA	cis	rs170557	0.573	rs12750599	ENSG00000203706.7	SERTAD4-AS1	-3.57	0.000379	0.0196	-0.13	-0.11	Alopecia areata;	chr1:209999889	chr1:210231456~210234047:-
BRCA	cis	rs6600671	0.934	rs11249431	ENSG00000223345.3	HIST2H2BA	-3.57	0.00038	0.0196	-0.14	-0.11	Hip geometry;	chr1:121544405	chr1:121108210~121117257:-
BRCA	cis	rs11098499	0.644	rs10050092	ENSG00000225892.3	RP11-384K6.2	3.57	0.00038	0.0196	0.11	0.11	Corneal astigmatism;	chr4:119610930	chr4:118632274~118634759:+
BRCA	cis	rs8049367	0.684	rs759274	ENSG00000267077.1	RP11-127I20.5	-3.57	0.00038	0.0196	-0.11	-0.11	Nonsyndromic cleft lip with or without cleft palate;	chr16:3917410	chr16:4795265~4796532:-
BRCA	cis	rs875971	0.929	rs12535036	ENSG00000272831.1	RP11-792A8.4	3.57	0.00038	0.0196	0.1	0.11	Aortic root size;	chr7:66499076	chr7:66739829~66740385:-
BRCA	cis	rs875971	1	rs6970030	ENSG00000272831.1	RP11-792A8.4	3.57	0.00038	0.0196	0.1	0.11	Aortic root size;	chr7:66503692	chr7:66739829~66740385:-
BRCA	cis	rs875971	0.928	rs6970357	ENSG00000272831.1	RP11-792A8.4	3.57	0.00038	0.0196	0.1	0.11	Aortic root size;	chr7:66503891	chr7:66739829~66740385:-
BRCA	cis	rs9467773	1	rs1535277	ENSG00000224843.5	LINC00240	-3.57	0.00038	0.0196	-0.12	-0.11	Intelligence (multi-trait analysis);	chr6:26567574	chr6:26956992~27023924:+
BRCA	cis	rs9467773	1	rs1884948	ENSG00000224843.5	LINC00240	-3.57	0.00038	0.0196	-0.12	-0.11	Intelligence (multi-trait analysis);	chr6:26567760	chr6:26956992~27023924:+
BRCA	cis	rs9467773	1	rs1884949	ENSG00000224843.5	LINC00240	-3.57	0.00038	0.0196	-0.12	-0.11	Intelligence (multi-trait analysis);	chr6:26567839	chr6:26956992~27023924:+
BRCA	cis	rs9467773	1	rs9467796	ENSG00000224843.5	LINC00240	-3.57	0.00038	0.0196	-0.12	-0.11	Intelligence (multi-trait analysis);	chr6:26568183	chr6:26956992~27023924:+
BRCA	cis	rs9467773	1	rs9467797	ENSG00000224843.5	LINC00240	-3.57	0.00038	0.0196	-0.12	-0.11	Intelligence (multi-trait analysis);	chr6:26568245	chr6:26956992~27023924:+
BRCA	cis	rs9467773	1	rs1078679	ENSG00000224843.5	LINC00240	-3.57	0.00038	0.0196	-0.12	-0.11	Intelligence (multi-trait analysis);	chr6:26568513	chr6:26956992~27023924:+
BRCA	cis	rs6733011	0.502	rs6542847	ENSG00000273306.1	RP11-527J8.1	3.57	0.00038	0.0196	0.11	0.11	Bipolar disorder;	chr2:98957008	chr2:99405218~99405843:+
BRCA	cis	rs321358	0.731	rs536579	ENSG00000271390.1	RP11-89C3.3	3.57	0.00038	0.0196	0.17	0.11	Body mass index;	chr11:111145748	chr11:111089870~111090368:-
BRCA	cis	rs13434995	0.945	rs55849318	ENSG00000273257.1	RP11-177J6.1	-3.57	0.00038	0.0196	-0.18	-0.11	Adiponectin levels;	chr4:55615826	chr4:55387949~55388271:+
BRCA	cis	rs2412980	0.59	rs4482600	ENSG00000232530.1	RP1-102K2.6	-3.57	0.00038	0.0196	-0.22	-0.11	Dialysis-related mortality;	chr22:30183897	chr22:30239194~30240538:+
BRCA	cis	rs11642862	1	rs111954099	ENSG00000261487.1	AC135048.13	-3.57	0.00038	0.0196	-0.2	-0.11	Tonsillectomy;	chr16:30778302	chr16:30948386~30956511:+
BRCA	cis	rs1538970	0.781	rs10890330	ENSG00000281133.1	AL355480.3	-3.57	0.00038	0.0196	-0.15	-0.11	Platelet count;	chr1:45454734	chr1:45580892~45580996:-
BRCA	cis	rs8058578	1	rs13338946	ENSG00000275263.1	RP11-1072A3.4	-3.57	0.00038	0.0196	-0.14	-0.11	Multiple myeloma;	chr16:30689537	chr16:30956872~30957199:-
BRCA	cis	rs3805389	0.504	rs1873090	ENSG00000249700.7	SRD5A3-AS1	-3.57	0.00038	0.0196	-0.17	-0.11	Waist-to-hip ratio adjusted for body mass index;	chr4:55605237	chr4:55363971~55395847:-
BRCA	cis	rs875971	1	rs12532998	ENSG00000272831.1	RP11-792A8.4	3.57	0.00038	0.0196	0.1	0.11	Aortic root size;	chr7:66502472	chr7:66739829~66740385:-
BRCA	cis	rs74233809	1	rs12220743	ENSG00000236937.2	PTGES3P4	3.57	0.00038	0.0196	0.23	0.11	Birth weight;	chr10:103092155	chr10:102845595~102845950:+
BRCA	cis	rs8023401	0.938	rs71467654	ENSG00000274654.1	CTD-3247H4.2	3.57	0.00038	0.0196	0.16	0.11	Spherical equivalent (joint analysis main effects and education interaction);	chr15:48521862	chr15:48528980~48529728:-
BRCA	cis	rs1005277	0.563	rs2505216	ENSG00000276805.1	RP11-291L22.6	3.57	0.00038	0.0196	0.12	0.11	Extrinsic epigenetic age acceleration;	chr10:38193902	chr10:38451030~38451785:+
BRCA	cis	rs1730008	1	rs2693546	ENSG00000279311.1	RP11-170K4.2	-3.57	0.00038	0.0196	-0.13	-0.11	Lobe attachment (rater-scored or self-reported);	chr3:158185186	chr3:158869898~158871821:+
BRCA	cis	rs17209837	1	rs7802555	ENSG00000224046.1	AC005076.5	3.57	0.00038	0.0196	0.16	0.11	Gallbladder cancer;	chr7:87501034	chr7:87151423~87152420:-
BRCA	cis	rs801193	0.569	rs11761542	ENSG00000265600.1	AC006480.1	-3.57	0.00038	0.0196	-0.13	-0.11	Aortic root size;	chr7:66753209	chr7:67356680~67356779:+
BRCA	cis	rs930395	1	rs930395	ENSG00000248779.1	RP11-53O19.2	3.57	0.00038	0.0196	0.12	0.11	Breast cancer;	chr5:44822356	chr5:44752949~44765744:+
BRCA	cis	rs6490294	0.528	rs77211491	ENSG00000257624.1	RP1-128M12.3	3.57	0.00038	0.0196	0.2	0.11	Mean platelet volume;	chr12:111884974	chr12:112000739~112000985:-
BRCA	cis	rs801193	0.967	rs2707841	ENSG00000232546.1	RP11-458F8.1	-3.57	0.00038	0.0196	-0.09	-0.11	Aortic root size;	chr7:66692033	chr7:66848496~66858136:+
BRCA	cis	rs801193	1	rs4717310	ENSG00000232546.1	RP11-458F8.1	-3.57	0.00038	0.0196	-0.09	-0.11	Aortic root size;	chr7:66696020	chr7:66848496~66858136:+
BRCA	cis	rs7267979	0.932	rs1985737	ENSG00000277938.1	RP5-965G21.3	3.57	0.00038	0.0196	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25610832	chr20:25229150~25231933:+
BRCA	cis	rs11887277	0.505	rs4665905	ENSG00000272148.1	RP11-195B17.1	-3.57	0.00038	0.0196	-0.13	-0.11	Obesity-related traits;	chr2:26774622	chr2:27062428~27062907:-
BRCA	cis	rs853679	0.76	rs9468317	ENSG00000261839.1	RP1-265C24.8	3.57	0.00038	0.0196	0.16	0.11	Depression;	chr6:28230678	chr6:28136849~28139678:+
BRCA	cis	rs7412746	0.658	rs6660845	ENSG00000224800.1	RP11-235D19.2	-3.57	0.00038	0.0196	-0.14	-0.11	Melanoma;	chr1:150868590	chr1:150881236~150881683:-
BRCA	cis	rs6813195	0.716	rs2054757	ENSG00000245954.5	RP11-18H21.1	3.57	0.00038	0.0196	0.1	0.11	Type 2 diabetes;	chr4:152564767	chr4:152100754~152104720:+
BRCA	cis	rs6480314	0.764	rs7898034	ENSG00000233590.1	RP11-153K11.3	3.57	0.00038	0.0196	0.17	0.11	Optic nerve measurement (disc area);	chr10:68217859	chr10:68233251~68242379:-
BRCA	cis	rs60871478	0.635	rs4311567	ENSG00000237181.1	AC147651.4	-3.56	0.00038	0.0196	-0.12	-0.11	Cerebrospinal P-tau181p levels;	chr7:752658	chr7:603185~608482:+
BRCA	cis	rs4689592	0.503	rs66885632	ENSG00000245468.3	RP11-367J11.3	-3.56	0.00038	0.0196	-0.14	-0.11	Monocyte percentage of white cells;	chr4:7052011	chr4:7094571~7103385:-
BRCA	cis	rs9341808	0.754	rs9294173	ENSG00000233967.5	RP11-250B2.3	3.56	0.000381	0.0196	0.11	0.11	Sitting height ratio;	chr6:80281913	chr6:80443344~80465927:+
BRCA	cis	rs875971	1	rs11974264	ENSG00000272831.1	RP11-792A8.4	-3.56	0.000381	0.0196	-0.1	-0.11	Aortic root size;	chr7:66182595	chr7:66739829~66740385:-
BRCA	cis	rs10838634	1	rs59197251	ENSG00000280615.1	Y_RNA	-3.56	0.000381	0.0196	-0.19	-0.11	Schizophrenia;	chr11:46823298	chr11:47614898~47614994:-
BRCA	cis	rs2642442	0.962	rs2807834	ENSG00000257551.1	HLX-AS1	3.56	0.000381	0.0196	0.12	0.11	Cholesterol, total;LDL cholesterol;	chr1:220797251	chr1:220832763~220880140:-
BRCA	cis	rs7020830	0.861	rs2291589	ENSG00000230188.1	RP11-405L18.4	-3.56	0.000381	0.0196	-0.14	-0.11	Schizophrenia;	chr9:37079664	chr9:37490421~37490893:-
BRCA	cis	rs10911902	0.602	rs6425024	ENSG00000229739.2	RP11-295K2.3	-3.56	0.000381	0.0196	-0.16	-0.11	Schizophrenia;	chr1:186305001	chr1:186435161~186470291:+
BRCA	cis	rs10911902	0.602	rs2273778	ENSG00000229739.2	RP11-295K2.3	-3.56	0.000381	0.0196	-0.16	-0.11	Schizophrenia;	chr1:186305027	chr1:186435161~186470291:+
BRCA	cis	rs10911902	0.602	rs2273777	ENSG00000229739.2	RP11-295K2.3	-3.56	0.000381	0.0196	-0.16	-0.11	Schizophrenia;	chr1:186305043	chr1:186435161~186470291:+
BRCA	cis	rs4835473	0.932	rs13147386	ENSG00000246448.2	RP13-578N3.3	3.56	0.000381	0.0196	0.12	0.11	Immature fraction of reticulocytes;	chr4:143736586	chr4:143700257~143865072:+
BRCA	cis	rs801193	1	rs17566701	ENSG00000272831.1	RP11-792A8.4	3.56	0.000381	0.0196	0.1	0.11	Aortic root size;	chr7:66728196	chr7:66739829~66740385:-
BRCA	cis	rs11098499	0.657	rs10434028	ENSG00000225892.3	RP11-384K6.2	3.56	0.000381	0.0196	0.11	0.11	Corneal astigmatism;	chr4:119373309	chr4:118632274~118634759:+
BRCA	cis	rs6088580	0.524	rs6088564	ENSG00000261582.1	RP4-614O4.11	3.56	0.000381	0.0196	0.11	0.11	Glomerular filtration rate (creatinine);	chr20:34661640	chr20:35267885~35280043:-
BRCA	cis	rs6088580	0.524	rs11167241	ENSG00000261582.1	RP4-614O4.11	3.56	0.000381	0.0196	0.11	0.11	Glomerular filtration rate (creatinine);	chr20:34663031	chr20:35267885~35280043:-
BRCA	cis	rs6088580	0.505	rs6142219	ENSG00000261582.1	RP4-614O4.11	3.56	0.000381	0.0196	0.11	0.11	Glomerular filtration rate (creatinine);	chr20:34668541	chr20:35267885~35280043:-
BRCA	cis	rs6710503	0.692	rs2083389	ENSG00000224165.4	DNAJC27-AS1	3.56	0.000381	0.0196	0.13	0.11	Lung cancer in ever smokers;Breast cancer;	chr2:24744855	chr2:24971390~25039694:+
BRCA	cis	rs17301013	0.932	rs67967476	ENSG00000200674.1	RN7SKP160	3.56	0.000381	0.0196	0.15	0.11	Systemic lupus erythematosus;	chr1:174616119	chr1:173791548~173791887:+
BRCA	cis	rs7712401	0.791	rs6595409	ENSG00000249996.1	RP11-359P5.1	3.56	0.000381	0.0196	0.13	0.11	Mean platelet volume;	chr5:122778061	chr5:123036271~123054667:+
BRCA	cis	rs1348850	0.914	rs3902850	ENSG00000280374.1	RP11-337N6.3	3.56	0.000381	0.0196	0.15	0.11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177451171	chr2:177317715~177318471:-
BRCA	cis	rs10005067	0.967	rs4693905	ENSG00000249001.4	RP11-742B18.1	3.56	0.000381	0.0196	0.13	0.11	Total body bone mineral density (age 30-45);	chr4:87901297	chr4:87568035~87733956:-
BRCA	cis	rs67766926	1	rs10209620	ENSG00000237522.1	NONOP2	-3.56	0.000381	0.0196	-0.12	-0.11	Inflammatory skin disease;	chr2:60946806	chr2:60936819~60938049:-
BRCA	cis	rs2243480	0.908	rs55876148	ENSG00000226767.1	RP11-328P23.3	-3.56	0.000381	0.0196	-0.19	-0.11	Diabetic kidney disease;	chr7:65914813	chr7:65508773~65508944:-
BRCA	cis	rs6005807	0.719	rs73430118	ENSG00000272858.1	CTA-292E10.8	-3.56	0.000381	0.0196	-0.19	-0.11	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28517962	chr22:28814914~28815662:+
BRCA	cis	rs7260598	0.539	rs57061964	ENSG00000268442.1	CTD-2027I19.2	3.56	0.000381	0.0196	0.19	0.11	Response to taxane treatment (placlitaxel);	chr19:23883476	chr19:24162370~24163425:-
BRCA	cis	rs7260598	0.539	rs11670271	ENSG00000268442.1	CTD-2027I19.2	3.56	0.000381	0.0196	0.19	0.11	Response to taxane treatment (placlitaxel);	chr19:23883921	chr19:24162370~24163425:-
BRCA	cis	rs7260598	0.539	rs11670335	ENSG00000268442.1	CTD-2027I19.2	3.56	0.000381	0.0196	0.19	0.11	Response to taxane treatment (placlitaxel);	chr19:23884108	chr19:24162370~24163425:-
BRCA	cis	rs4478858	0.735	rs7547897	ENSG00000223907.1	LINC01226	-3.56	0.000381	0.0196	-0.13	-0.11	Alcohol dependence;	chr1:31324746	chr1:31518435~31524245:+
BRCA	cis	rs697003	0.52	rs7551341	ENSG00000231057.3	RP11-122M14.1	-3.56	0.000381	0.0196	-0.12	-0.11	Red cell distribution width;	chr1:211651551	chr1:211675762~211690103:+
BRCA	cis	rs12744310	0.502	rs2364531	ENSG00000235358.1	RP11-399E6.1	3.56	0.000381	0.0196	0.14	0.11	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41338544	chr1:41242373~41284861:+
BRCA	cis	rs911119	0.913	rs13043266	ENSG00000270001.1	RP11-218C14.8	-3.56	0.000381	0.0196	-0.15	-0.11	Chronic kidney disease;	chr20:23607490	chr20:23631826~23632316:-
BRCA	cis	rs2455799	0.573	rs924753	ENSG00000224728.1	AC090945.1	-3.56	0.000381	0.0196	-0.1	-0.11	Mean platelet volume;	chr3:15664617	chr3:15878047~15879571:+
BRCA	cis	rs16917546	1	rs16917546	ENSG00000238280.1	RP11-436D10.3	3.56	0.000381	0.0196	0.15	0.11	Basal cell carcinoma;	chr10:62637778	chr10:62793562~62805887:-
BRCA	cis	rs6696239	0.956	rs3942992	ENSG00000227711.2	RP11-275O4.5	3.56	0.000381	0.0196	0.15	0.11	Height;	chr1:227584695	chr1:227509028~227520477:-
BRCA	cis	rs4759375	1	rs10773003	ENSG00000235423.7	RP11-282O18.3	-3.56	0.000381	0.0196	-0.18	-0.11	HDL cholesterol;	chr12:123290580	chr12:123252030~123261483:-
BRCA	cis	rs875971	0.508	rs10258739	ENSG00000273448.1	RP11-166O4.6	-3.56	0.000381	0.0197	-0.1	-0.11	Aortic root size;	chr7:66597948	chr7:67333047~67334383:+
BRCA	cis	rs7267979	1	rs2482937	ENSG00000274973.1	RP13-401N8.7	3.56	0.000381	0.0197	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25360150	chr20:25845497~25845862:+
BRCA	cis	rs273909	0.622	rs2662314	ENSG00000233006.5	AC034220.3	-3.56	0.000381	0.0197	-0.11	-0.11	Coronary artery disease;	chr5:132289476	chr5:132311285~132369916:-
BRCA	cis	rs2998286	0.54	rs332158	ENSG00000237128.1	RP11-351M16.3	3.56	0.000381	0.0197	0.14	0.11	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28595433	chr10:28433008~28495813:-
BRCA	cis	rs9392653	0.924	rs449288	ENSG00000220685.3	RP11-530A18.1	3.56	0.000381	0.0197	0.15	0.11	Venous thromboembolism (SNP x SNP interaction);	chr6:5073954	chr6:5065795~5066982:-
BRCA	cis	rs4697263	0.671	rs13125327	ENSG00000237350.1	CDC42P6	-3.56	0.000381	0.0197	-0.14	-0.11	Age-related hearing impairment (SNP x SNP interaction);	chr4:22015595	chr4:22727375~22727950:-
BRCA	cis	rs11892454	0.565	rs10187156	ENSG00000217643.1	PTGES3P2	-3.56	0.000381	0.0197	-0.12	-0.11	Heschl's gyrus morphology;	chr2:25864526	chr2:25822469~25822950:+
BRCA	cis	rs3136441	1	rs60258676	ENSG00000200376.1	RNU5E-10P	-3.56	0.000381	0.0197	-0.16	-0.11	HDL cholesterol;	chr11:46876236	chr11:47576471~47576588:-
BRCA	cis	rs10838634	0.901	rs17787930	ENSG00000280615.1	Y_RNA	-3.56	0.000381	0.0197	-0.24	-0.11	Schizophrenia;	chr11:46936748	chr11:47614898~47614994:-
BRCA	cis	rs10838634	0.901	rs61899282	ENSG00000280615.1	Y_RNA	-3.56	0.000381	0.0197	-0.24	-0.11	Schizophrenia;	chr11:46955857	chr11:47614898~47614994:-
BRCA	cis	rs10838634	0.901	rs118016470	ENSG00000280615.1	Y_RNA	-3.56	0.000381	0.0197	-0.24	-0.11	Schizophrenia;	chr11:46960612	chr11:47614898~47614994:-
BRCA	cis	rs10838634	0.901	rs61899283	ENSG00000280615.1	Y_RNA	-3.56	0.000381	0.0197	-0.24	-0.11	Schizophrenia;	chr11:46961687	chr11:47614898~47614994:-
BRCA	cis	rs875971	0.545	rs1796217	ENSG00000273448.1	RP11-166O4.6	-3.56	0.000381	0.0197	-0.11	-0.11	Aortic root size;	chr7:66620931	chr7:67333047~67334383:+
BRCA	cis	rs3755021	1	rs17290351	ENSG00000260742.1	RP11-366L5.1	3.56	0.000382	0.0197	0.16	0.11	Monocyte-lymphocyte ratio;	chr2:181481148	chr2:181887851~181891663:-
BRCA	cis	rs875971	1	rs778706	ENSG00000271064.1	RP11-792A8.3	-3.56	0.000382	0.0197	-0.13	-0.11	Aortic root size;	chr7:66395437	chr7:66748838~66749077:-
BRCA	cis	rs8012947	0.545	rs1190980	ENSG00000257621.6	PSMA3-AS1	-3.56	0.000382	0.0197	-0.09	-0.11	Alcohol consumption in current drinkers;	chr14:58348088	chr14:58265365~58298134:-
BRCA	cis	rs11239930	1	rs11239930	ENSG00000227242.3	NBPF13P	-3.56	0.000382	0.0197	-0.12	-0.11	AIDS progression;	chr1:147089017	chr1:147021320~147124525:-
BRCA	cis	rs7578199	0.741	rs13011791	ENSG00000228989.1	AC133528.2	3.56	0.000382	0.0197	0.14	0.11	Chronic lymphocytic leukemia;	chr2:241462646	chr2:241690414~241694289:+
BRCA	cis	rs1730008	0.731	rs73166358	ENSG00000279311.1	RP11-170K4.2	3.56	0.000382	0.0197	0.14	0.11	Lobe attachment (rater-scored or self-reported);	chr3:158260004	chr3:158869898~158871821:+
BRCA	cis	rs952623	0.501	rs11973171	ENSG00000211694.2	TRGV10	3.56	0.000382	0.0197	0.1	0.11	Intelligence (multi-trait analysis);	chr7:39046921	chr7:38299811~38300322:-
BRCA	cis	rs62458065	0.64	rs28587905	ENSG00000229358.3	DPY19L1P1	-3.56	0.000382	0.0197	-0.16	-0.11	Metabolite levels (HVA/MHPG ratio);	chr7:32493442	chr7:32580949~32761787:-
BRCA	cis	rs1404100	0.51	rs2341683	ENSG00000249274.1	PDLIM1P4	3.56	0.000382	0.0197	0.12	0.11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:99069807	chr3:98782188~98783193:+
BRCA	cis	rs871012	0.502	rs62388483	ENSG00000251405.2	CTB-109A12.1	-3.56	0.000382	0.0197	-0.15	-0.11	IgG glycosylation;	chr5:157456829	chr5:157362615~157460078:-
BRCA	cis	rs2274459	1	rs3806107	ENSG00000249346.5	LINC01016	3.56	0.000382	0.0197	0.14	0.11	Obesity (extreme);	chr6:33799636	chr6:33867506~33896914:-
BRCA	cis	rs8099594	0.64	rs504246	ENSG00000266696.1	RP11-30L3.2	3.56	0.000382	0.0197	0.13	0.11	Height;	chr18:49332619	chr18:49205912~49208781:+
BRCA	cis	rs7412746	0.658	rs4970982	ENSG00000231073.1	RP11-316M1.3	3.56	0.000382	0.0197	0.12	0.11	Melanoma;	chr1:150892608	chr1:150973123~150975534:+
BRCA	cis	rs2274273	1	rs15870	ENSG00000259318.1	RP11-454L9.2	3.56	0.000382	0.0197	0.09	0.11	Protein biomarker;	chr14:55152593	chr14:55394940~55395233:-
BRCA	cis	rs7267979	1	rs2482930	ENSG00000274973.1	RP13-401N8.7	3.56	0.000382	0.0197	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25353479	chr20:25845497~25845862:+
BRCA	cis	rs6943931	1	rs58989721	ENSG00000230658.1	KLHL7-AS1	-3.56	0.000382	0.0197	-0.15	-0.11	Diabetic kidney disease;	chr7:22376300	chr7:23101228~23105703:-
BRCA	cis	rs6840360	0.571	rs12647566	ENSG00000270265.1	RP11-731D1.4	-3.56	0.000382	0.0197	-0.13	-0.11	Intelligence (multi-trait analysis);	chr4:151561373	chr4:151333775~151353224:-
BRCA	cis	rs10876993	0.89	rs799575	ENSG00000269903.1	RP11-571M6.18	3.56	0.000382	0.0197	0.14	0.11	Celiac disease or Rheumatoid arthritis;	chr12:57675324	chr12:57814494~57814926:+
BRCA	cis	rs10771431	0.597	rs10843144	ENSG00000256427.1	RP11-118B22.4	3.56	0.000382	0.0197	0.11	0.11	Breast size;	chr12:9204981	chr12:9246497~9257960:+
BRCA	cis	rs7131987	0.903	rs67517901	ENSG00000273680.1	RP11-996F15.6	3.56	0.000382	0.0197	0.14	0.11	QT interval;	chr12:29268413	chr12:29332733~29333383:-
BRCA	cis	rs2842992	0.83	rs1475123	ENSG00000207392.1	SNORA20	-3.56	0.000382	0.0197	-0.15	-0.11	Age-related macular degeneration (geographic atrophy);	chr6:159756975	chr6:159780250~159780381:-
BRCA	cis	rs718433	0.584	rs1002180	ENSG00000211778.2	TRAV4	-3.56	0.000382	0.0197	-0.08	-0.11	Intraocular pressure;	chr14:21748768	chr14:21736152~21736982:+
BRCA	cis	rs7500067	1	rs896625	ENSG00000259867.4	RP11-525K10.3	3.56	0.000382	0.0197	0.14	0.11	Breast cancer;	chr16:80613653	chr16:80155053~80563135:-
BRCA	cis	rs8040855	0.965	rs4843027	ENSG00000259774.1	RP11-182J1.13	-3.56	0.000382	0.0197	-0.13	-0.11	Bulimia nervosa;	chr15:85171892	chr15:84422618~84425882:+
BRCA	cis	rs6540731	1	rs6540731	ENSG00000226251.4	RP11-15I11.3	3.56	0.000382	0.0197	0.13	0.11	Intelligence (childhood);	chr1:212218821	chr1:212225278~212238977:-
BRCA	cis	rs10838634	1	rs3136480	ENSG00000280615.1	Y_RNA	-3.56	0.000382	0.0197	-0.23	-0.11	Schizophrenia;	chr11:46730298	chr11:47614898~47614994:-
BRCA	cis	rs7246657	0.525	rs10401417	ENSG00000267470.4	ZNF571-AS1	3.56	0.000382	0.0197	0.16	0.11	Coronary artery calcification;	chr19:36976638	chr19:37548914~37587348:+
BRCA	cis	rs875971	0.862	rs6952182	ENSG00000271064.1	RP11-792A8.3	3.56	0.000382	0.0197	0.13	0.11	Aortic root size;	chr7:66218330	chr7:66748838~66749077:-
BRCA	cis	rs11696845	0.626	rs4810439	ENSG00000276223.1	RP4-781B1.5	3.56	0.000382	0.0197	0.11	0.11	Obesity-related traits;	chr20:44749229	chr20:44746642~44747201:+
BRCA	cis	rs7267979	1	rs2500446	ENSG00000274973.1	RP13-401N8.7	3.56	0.000382	0.0197	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25359028	chr20:25845497~25845862:+
BRCA	cis	rs7618501	1	rs11716575	ENSG00000228008.1	CTD-2330K9.3	-3.56	0.000382	0.0197	-0.1	-0.11	Intelligence (multi-trait analysis);	chr3:49707457	chr3:49903845~49916937:+
BRCA	cis	rs7618501	1	rs4855867	ENSG00000228008.1	CTD-2330K9.3	-3.56	0.000382	0.0197	-0.1	-0.11	Intelligence (multi-trait analysis);	chr3:49708389	chr3:49903845~49916937:+
BRCA	cis	rs7618501	1	rs4855862	ENSG00000228008.1	CTD-2330K9.3	-3.56	0.000382	0.0197	-0.1	-0.11	Intelligence (multi-trait analysis);	chr3:49711400	chr3:49903845~49916937:+
BRCA	cis	rs7833787	0.929	rs7844317	ENSG00000254054.2	RP11-156K13.3	3.56	0.000382	0.0197	0.13	0.11	Obesity-related traits;	chr8:18839536	chr8:17905756~17907887:+
BRCA	cis	rs2304003	0.528	rs1023708	ENSG00000229195.1	AC009495.4	3.56	0.000382	0.0197	0.14	0.11	Social communication problems;	chr2:165863084	chr2:165794857~165846091:-
BRCA	cis	rs74233809	1	rs34747231	ENSG00000213061.2	PFN1P11	3.56	0.000382	0.0197	0.25	0.11	Birth weight;	chr10:103182487	chr10:102838011~102845473:-
BRCA	cis	rs1156327	0.826	rs4617844	ENSG00000188477.11	AC003003.5	-3.56	0.000382	0.0197	-0.29	-0.11	Periodontal disease-related phenotypes;	chr16:19313769	chr16:19285783~19310947:+
BRCA	cis	rs11992162	0.591	rs35657308	ENSG00000255020.1	AF131216.5	3.56	0.000382	0.0197	0.13	0.11	Monocyte count;	chr8:11946893	chr8:11345748~11347502:-
BRCA	cis	rs4372836	0.504	rs12185717	ENSG00000226833.4	AC097724.3	3.56	0.000382	0.0197	0.13	0.11	Body mass index;	chr2:28846685	chr2:28708953~28736205:-
BRCA	cis	rs1404100	0.51	rs1038272	ENSG00000249274.1	PDLIM1P4	3.56	0.000383	0.0197	0.12	0.11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:99067685	chr3:98782188~98783193:+
BRCA	cis	rs11085466	1	rs75079001	ENSG00000268081.1	RP11-678G14.2	-3.56	0.000383	0.0197	-0.17	-0.11	Colorectal or endometrial cancer;	chr19:21574573	chr19:21554640~21569237:-
BRCA	cis	rs11085466	0.948	rs11668453	ENSG00000268081.1	RP11-678G14.2	-3.56	0.000383	0.0197	-0.17	-0.11	Colorectal or endometrial cancer;	chr19:21576555	chr19:21554640~21569237:-
BRCA	cis	rs11085466	1	rs75211977	ENSG00000268081.1	RP11-678G14.2	-3.56	0.000383	0.0197	-0.17	-0.11	Colorectal or endometrial cancer;	chr19:21577399	chr19:21554640~21569237:-
BRCA	cis	rs3760982	0.585	rs61013802	ENSG00000267191.1	RP11-15A1.2	-3.56	0.000383	0.0197	-0.14	-0.11	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43787990	chr19:43902001~43926545:+
BRCA	cis	rs801193	0.569	rs4717315	ENSG00000271064.1	RP11-792A8.3	-3.56	0.000383	0.0197	-0.13	-0.11	Aortic root size;	chr7:66713338	chr7:66748838~66749077:-
BRCA	cis	rs1211609	0.685	rs11061330	ENSG00000279640.1	RP13-977J11.6	3.56	0.000383	0.0197	0.17	0.11	Macrophage Migration Inhibitory Factor levels;	chr12:131110018	chr12:132100013~132100820:-
BRCA	cis	rs860295	0.702	rs10908465	ENSG00000232093.1	RP11-307C12.11	3.56	0.000383	0.0197	0.12	0.11	Body mass index;	chr1:155419897	chr1:155045191~155046118:-
BRCA	cis	rs67073037	0.518	rs4666129	ENSG00000230730.1	AC074011.2	-3.56	0.000383	0.0197	-0.15	-0.11	Breast cancer;Breast cancer (estrogen-receptor negative);	chr2:28913270	chr2:28633282~28664540:-
BRCA	cis	rs7561149	0.902	rs6729746	ENSG00000270574.1	RP11-171I2.2	-3.56	0.000383	0.0197	-0.15	-0.11	QT interval;	chr2:178784622	chr2:178578790~178580906:+
BRCA	cis	rs7089973	0.872	rs35628210	ENSG00000236799.1	RP11-383C6.2	-3.56	0.000383	0.0197	-0.14	-0.11	Bipolar disorder or attention deficit hyperactivity disorder;	chr10:114870272	chr10:114994657~114996593:+
BRCA	cis	rs7789940	0.904	rs6953281	ENSG00000231087.2	FDPSP7	-3.56	0.000383	0.0197	-0.14	-0.11	Multiple sclerosis;	chr7:76317626	chr7:76968197~76969250:-
BRCA	cis	rs7789940	0.951	rs7787526	ENSG00000231087.2	FDPSP7	-3.56	0.000383	0.0197	-0.14	-0.11	Multiple sclerosis;	chr7:76318236	chr7:76968197~76969250:-
BRCA	cis	rs6988985	0.728	rs4310186	ENSG00000253741.1	CTD-2292P10.4	3.56	0.000383	0.0197	0.12	0.11	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;	chr8:142874831	chr8:142702252~142726973:-
BRCA	cis	rs73201462	1	rs34409786	ENSG00000242551.2	POU5F1P6	3.56	0.000383	0.0197	0.19	0.11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128169332	chr3:128674735~128677005:-
BRCA	cis	rs73201462	1	rs11706455	ENSG00000242551.2	POU5F1P6	3.56	0.000383	0.0197	0.19	0.11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128173148	chr3:128674735~128677005:-
BRCA	cis	rs4578769	0.722	rs55943912	ENSG00000265939.1	UBE2CP2	-3.56	0.000383	0.0197	-0.15	-0.11	Eosinophil percentage of white cells;	chr18:22938388	chr18:22900486~22900995:-
BRCA	cis	rs6496044	0.568	rs2880764	ENSG00000230373.7	GOLGA6L5P	3.56	0.000383	0.0197	0.12	0.11	Interstitial lung disease;	chr15:85513177	chr15:84507885~84516814:-
BRCA	cis	rs6142618	0.562	rs4911197	ENSG00000224452.1	RSL24D1P6	3.56	0.000383	0.0197	0.15	0.11	Inflammatory bowel disease;	chr20:32130490	chr20:32170390~32170790:-
BRCA	cis	rs4835473	0.932	rs66474962	ENSG00000246448.2	RP13-578N3.3	-3.56	0.000383	0.0197	-0.12	-0.11	Immature fraction of reticulocytes;	chr4:143735145	chr4:143700257~143865072:+
BRCA	cis	rs73201462	1	rs35145572	ENSG00000242551.2	POU5F1P6	3.56	0.000383	0.0197	0.19	0.11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128128575	chr3:128674735~128677005:-
BRCA	cis	rs7283707	0.681	rs75928396	ENSG00000270071.1	AP001172.2	-3.56	0.000383	0.0197	-0.15	-0.11	QRS complex (12-leadsum);	chr21:15889704	chr21:16291791~16308133:-
BRCA	cis	rs1178127	0.65	rs1178134	ENSG00000232821.1	AC003986.6	3.56	0.000383	0.0197	0.16	0.11	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);	chr7:18732607	chr7:19112474~19114271:+
BRCA	cis	rs7852462	0.802	rs67084970	ENSG00000203279.3	RP11-498P14.5	3.56	0.000383	0.0197	0.13	0.11	Barrett's esophagus  or Esophageal adenocarcinoma;Barrett's esophagus;	chr9:97542579	chr9:97200475~97238700:-
BRCA	cis	rs2425143	1	rs17093026	ENSG00000088340.14	FER1L4	3.56	0.000383	0.0197	0.17	0.11	Blood protein levels;	chr20:35730989	chr20:35558737~35607562:-
BRCA	cis	rs2288884	0.541	rs8107827	ENSG00000275055.1	CTC-471J1.11	-3.56	0.000383	0.0197	-0.16	-0.11	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:51962228	chr19:52049007~52049754:+
BRCA	cis	rs17221829	0.645	rs4753227	ENSG00000280385.1	AP000648.5	-3.56	0.000383	0.0197	-0.12	-0.11	Anxiety in major depressive disorder;	chr11:89635934	chr11:90193614~90198120:+
BRCA	cis	rs875971	0.929	rs6970860	ENSG00000272831.1	RP11-792A8.4	3.56	0.000383	0.0197	0.1	0.11	Aortic root size;	chr7:66511647	chr7:66739829~66740385:-
BRCA	cis	rs240993	0.516	rs240968	ENSG00000271789.1	RP5-1112D6.7	-3.56	0.000383	0.0197	-0.15	-0.11	Inflammatory skin disease;Psoriasis;	chr6:111311517	chr6:111297126~111298510:+
BRCA	cis	rs3805389	0.504	rs28416150	ENSG00000249700.7	SRD5A3-AS1	-3.56	0.000383	0.0197	-0.17	-0.11	Waist-to-hip ratio adjusted for body mass index;	chr4:55608211	chr4:55363971~55395847:-
BRCA	cis	rs739401	0.611	rs3782069	ENSG00000247473.2	CARS-AS1	3.56	0.000383	0.0197	0.13	0.11	Longevity;	chr11:3012045	chr11:3029009~3041260:+
BRCA	cis	rs35176054	0.73	rs34943195	ENSG00000280693.1	SH3PXD2A-AS1	-3.56	0.000383	0.0197	-0.2	-0.11	Atrial fibrillation;	chr10:103757733	chr10:103745966~103755423:+
BRCA	cis	rs8099594	0.64	rs9789092	ENSG00000266696.1	RP11-30L3.2	-3.56	0.000383	0.0197	-0.13	-0.11	Height;	chr18:49303096	chr18:49205912~49208781:+
BRCA	cis	rs2880765	0.835	rs56406982	ENSG00000230373.7	GOLGA6L5P	3.56	0.000383	0.0197	0.12	0.11	Coronary artery disease;	chr15:85493148	chr15:84507885~84516814:-
BRCA	cis	rs8030379	0.519	rs11259926	ENSG00000230373.7	GOLGA6L5P	-3.56	0.000383	0.0197	-0.13	-0.11	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83897496	chr15:84507885~84516814:-
BRCA	cis	rs2835345	0.531	rs2409816	ENSG00000233818.1	AP000695.4	3.56	0.000383	0.0197	0.11	0.11	Pulmonary function;	chr21:36453663	chr21:36445731~36532408:+
BRCA	cis	rs17784882	0.524	rs7433300	ENSG00000271161.1	BOLA2P2	3.56	0.000383	0.0197	0.12	0.11	QT interval;	chr3:47079150	chr3:47499841~47500407:+
BRCA	cis	rs4650943	0.503	rs10753112	ENSG00000227740.1	RP11-318C24.2	3.56	0.000383	0.0197	0.12	0.11	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in inactive individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr1:175989851	chr1:175904762~175920513:-
BRCA	cis	rs6963495	0.585	rs1728653	ENSG00000272604.1	RP11-251G23.5	3.56	0.000383	0.0198	0.14	0.11	Bipolar disorder (body mass index interaction);	chr7:105550888	chr7:105571083~105573660:+
BRCA	cis	rs930395	0.514	rs34501299	ENSG00000248779.1	RP11-53O19.2	-3.56	0.000383	0.0198	-0.1	-0.11	Breast cancer;	chr5:44912977	chr5:44752949~44765744:+
BRCA	cis	rs13256369	1	rs7004438	ENSG00000233609.3	RP11-62H7.2	3.56	0.000383	0.0198	0.12	0.11	Obesity-related traits;	chr8:8716869	chr8:8961200~8979025:+
BRCA	cis	rs10005067	0.904	rs17783044	ENSG00000249001.4	RP11-742B18.1	-3.56	0.000383	0.0198	-0.13	-0.11	Total body bone mineral density (age 30-45);	chr4:87903936	chr4:87568035~87733956:-
BRCA	cis	rs794185	0.806	rs711637	ENSG00000231249.1	ITPR1-AS1	-3.56	0.000384	0.0198	-0.12	-0.11	Multiple sclerosis--Brain Glutamate Levels;	chr3:4445582	chr3:4490891~4493163:-
BRCA	cis	rs801193	1	rs2003301	ENSG00000232546.1	RP11-458F8.1	3.56	0.000384	0.0198	0.09	0.11	Aortic root size;	chr7:66682669	chr7:66848496~66858136:+
BRCA	cis	rs7577696	0.85	rs3769606	ENSG00000276334.1	AL133243.1	-3.56	0.000384	0.0198	-0.14	-0.11	Inflammatory biomarkers;	chr2:32092481	chr2:32521927~32523547:+
BRCA	cis	rs6964587	0.692	rs4729025	ENSG00000188693.7	CYP51A1-AS1	-3.56	0.000384	0.0198	-0.12	-0.11	Breast cancer;	chr7:92218190	chr7:92134604~92180725:+
BRCA	cis	rs2839186	0.786	rs7409792	ENSG00000215424.8	MCM3AP-AS1	3.56	0.000384	0.0198	0.1	0.11	Testicular germ cell tumor;	chr21:46271815	chr21:46229217~46259390:+
BRCA	cis	rs2554380	0.628	rs919069	ENSG00000259570.1	RP11-671M22.4	3.56	0.000384	0.0198	0.14	0.11	Height;	chr15:83775776	chr15:84394512~84395514:+
BRCA	cis	rs55780018	0.614	rs10183085	ENSG00000224137.1	AC079767.4	3.56	0.000384	0.0198	0.09	0.11	Systolic blood pressure;	chr2:207643671	chr2:207662375~207667024:+
BRCA	cis	rs13113518	0.51	rs6858749	ENSG00000273257.1	RP11-177J6.1	3.56	0.000384	0.0198	0.14	0.11	Height;	chr4:55424270	chr4:55387949~55388271:+
BRCA	cis	rs17428076	0.918	rs62183765	ENSG00000228389.1	AC068039.4	-3.56	0.000384	0.0198	-0.16	-0.11	Myopia;	chr2:171975512	chr2:171773482~171775844:+
BRCA	cis	rs6600671	0.764	rs6600673	ENSG00000275538.1	RNVU1-19	3.56	0.000384	0.0198	0.13	0.11	Hip geometry;	chr1:121426988	chr1:120850819~120850985:-
BRCA	cis	rs2835872	0.828	rs2835838	ENSG00000230366.8	DSCR9	-3.56	0.000384	0.0198	-0.14	-0.11	Electroencephalographic traits in alcoholism;	chr21:37618692	chr21:37208503~37221736:+
BRCA	cis	rs983392	0.792	rs540170	ENSG00000275344.1	MIR6503	-3.56	0.000384	0.0198	-0.11	-0.11	Alzheimer's disease (late onset);	chr11:60112565	chr11:60209071~60209156:-
BRCA	cis	rs848490	0.889	rs11763798	ENSG00000214293.7	APTR	3.56	0.000384	0.0198	0.13	0.11	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77605323	chr7:77657660~77696265:-
BRCA	cis	rs9437689	0.591	rs1146460	ENSG00000235501.4	RP4-639F20.1	-3.56	0.000384	0.0198	-0.13	-0.11	Phospholipid levels (plasma);	chr1:94943364	chr1:94927566~94963270:+
BRCA	cis	rs7267979	0.932	rs4280527	ENSG00000274973.1	RP13-401N8.7	-3.56	0.000384	0.0198	-0.12	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25563378	chr20:25845497~25845862:+
BRCA	cis	rs10504130	0.53	rs4292674	ENSG00000272076.1	RP11-11C20.3	3.56	0.000384	0.0198	0.16	0.11	Venous thromboembolism (SNP x SNP interaction);	chr8:51767212	chr8:51810110~51810681:-
BRCA	cis	rs10504130	0.569	rs4292675	ENSG00000272076.1	RP11-11C20.3	3.56	0.000384	0.0198	0.16	0.11	Venous thromboembolism (SNP x SNP interaction);	chr8:51767414	chr8:51810110~51810681:-
BRCA	cis	rs10504130	0.569	rs76746661	ENSG00000272076.1	RP11-11C20.3	3.56	0.000384	0.0198	0.16	0.11	Venous thromboembolism (SNP x SNP interaction);	chr8:51769206	chr8:51810110~51810681:-
BRCA	cis	rs10504130	0.66	rs79691523	ENSG00000272076.1	RP11-11C20.3	3.56	0.000384	0.0198	0.16	0.11	Venous thromboembolism (SNP x SNP interaction);	chr8:51772173	chr8:51810110~51810681:-
BRCA	cis	rs4919669	0.591	rs10883731	ENSG00000213277.3	MARCKSL1P1	3.56	0.000384	0.0198	0.19	0.11	Mean arterial pressure (long-term average);Systolic blood pressure (long-term average);	chr10:102533370	chr10:103175554~103176094:+
BRCA	cis	rs7267979	1	rs6050544	ENSG00000274973.1	RP13-401N8.7	3.56	0.000384	0.0198	0.12	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25339592	chr20:25845497~25845862:+
BRCA	cis	rs8180040	0.726	rs4234465	ENSG00000260236.1	RP11-708J19.1	3.56	0.000384	0.0198	0.1	0.11	Colorectal cancer;	chr3:46985395	chr3:47379089~47380999:-
BRCA	cis	rs863345	0.625	rs7534112	ENSG00000229914.1	RP11-404O13.4	-3.56	0.000384	0.0198	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158562275	chr1:158195633~158196131:-
BRCA	cis	rs853679	0.882	rs2743555	ENSG00000216901.1	AL022393.7	3.56	0.000384	0.0198	0.19	0.11	Depression;	chr6:28273304	chr6:28176188~28176674:+
BRCA	cis	rs35304300	1	rs17068850	ENSG00000225177.4	RP11-390P2.4	3.56	0.000384	0.0198	0.13	0.11	Mean platelet volume;	chr6:139533783	chr6:138692548~138697288:+
BRCA	cis	rs7620503	0.659	rs11715199	ENSG00000228561.2	RP11-114M1.1	-3.56	0.000384	0.0198	-0.14	-0.11	Corneal structure;	chr3:177556691	chr3:177683627~177691250:+
BRCA	cis	rs11098499	0.863	rs11098532	ENSG00000260404.2	RP11-384K6.6	3.56	0.000384	0.0198	0.11	0.11	Corneal astigmatism;	chr4:119569571	chr4:118591773~118633729:+
BRCA	cis	rs875971	0.862	rs1167390	ENSG00000223473.2	GS1-124K5.3	-3.56	0.000384	0.0198	-0.09	-0.11	Aortic root size;	chr7:66110906	chr7:66491049~66493566:-
BRCA	cis	rs875971	0.862	rs35034167	ENSG00000223473.2	GS1-124K5.3	-3.56	0.000384	0.0198	-0.09	-0.11	Aortic root size;	chr7:66115179	chr7:66491049~66493566:-
BRCA	cis	rs1499614	0.522	rs13247442	ENSG00000275400.1	RP4-756H11.5	3.56	0.000384	0.0198	0.25	0.11	Gout;	chr7:66723871	chr7:66553805~66554199:-
BRCA	cis	rs7975161	1	rs7960443	ENSG00000257681.1	RP11-341G23.4	-3.56	0.000384	0.0198	-0.15	-0.11	Toenail selenium levels;	chr12:104251585	chr12:103746315~103768858:-
BRCA	cis	rs654950	0.934	rs662999	ENSG00000230638.4	RP11-486B10.4	-3.56	0.000384	0.0198	-0.14	-0.11	Airway imaging phenotypes;	chr1:41535489	chr1:41542069~41544310:+
BRCA	cis	rs7267979	1	rs2258719	ENSG00000274973.1	RP13-401N8.7	-3.56	0.000384	0.0198	-0.13	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25295207	chr20:25845497~25845862:+
BRCA	cis	rs1865760	1	rs6910174	ENSG00000272810.1	U91328.22	-3.56	0.000384	0.0198	-0.13	-0.11	Height;	chr6:25904186	chr6:26013241~26013757:+
BRCA	cis	rs2599510	0.783	rs2710630	ENSG00000276517.1	AL133243.2	3.56	0.000384	0.0198	0.13	0.11	Interleukin-18 levels;	chr2:32540930	chr2:32526504~32529507:+
BRCA	cis	rs115575488	0.85	rs78664615	ENSG00000231365.4	RP11-418J17.1	3.56	0.000384	0.0198	0.21	0.11	Lobe attachment (rater-scored or self-reported);	chr1:119102543	chr1:119140396~119275973:+
BRCA	cis	rs7487075	0.893	rs1492894	ENSG00000257261.4	RP11-96H19.1	3.56	0.000384	0.0198	0.12	0.11	Itch intensity from mosquito bite;	chr12:46334885	chr12:46383679~46876159:+
BRCA	cis	rs8114671	0.562	rs6088635	ENSG00000279253.1	RP4-614O4.13	-3.56	0.000384	0.0198	-0.13	-0.11	Height;	chr20:34878698	chr20:35262727~35264187:-
BRCA	cis	rs11083846	0.913	rs4802322	ENSG00000268423.3	AC011551.3	-3.56	0.000384	0.0198	-0.15	-0.11	Chronic lymphocytic leukemia;	chr19:46739735	chr19:46547056~46600861:-
BRCA	cis	rs7267979	0.833	rs6138556	ENSG00000274973.1	RP13-401N8.7	-3.56	0.000384	0.0198	-0.13	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25262674	chr20:25845497~25845862:+
BRCA	cis	rs875971	0.929	rs34406470	ENSG00000272831.1	RP11-792A8.4	3.56	0.000384	0.0198	0.1	0.11	Aortic root size;	chr7:66464969	chr7:66739829~66740385:-
BRCA	cis	rs4664293	0.625	rs2114625	ENSG00000224152.1	AC009506.1	-3.56	0.000384	0.0198	-0.12	-0.11	Monocyte percentage of white cells;	chr2:159687297	chr2:159615296~159617082:+
BRCA	cis	rs10504130	1	rs58561048	ENSG00000272076.1	RP11-11C20.3	3.56	0.000384	0.0198	0.19	0.11	Venous thromboembolism (SNP x SNP interaction);	chr8:51789982	chr8:51810110~51810681:-
BRCA	cis	rs10504130	1	rs11778849	ENSG00000272076.1	RP11-11C20.3	3.56	0.000384	0.0198	0.19	0.11	Venous thromboembolism (SNP x SNP interaction);	chr8:51795694	chr8:51810110~51810681:-
BRCA	cis	rs11088226	0.681	rs2833902	ENSG00000186842.4	LINC00846	-3.56	0.000385	0.0198	-0.18	-0.11	Gastritis;	chr21:32568148	chr21:32572238~32575881:-
BRCA	cis	rs875971	0.862	rs4718319	ENSG00000273024.4	INTS4P2	3.56	0.000385	0.0198	0.12	0.11	Aortic root size;	chr7:66187797	chr7:65647864~65715661:+
BRCA	cis	rs875971	0.723	rs28391294	ENSG00000273024.4	INTS4P2	3.56	0.000385	0.0198	0.12	0.11	Aortic root size;	chr7:66189328	chr7:65647864~65715661:+
BRCA	cis	rs875971	0.83	rs6967708	ENSG00000273024.4	INTS4P2	3.56	0.000385	0.0198	0.12	0.11	Aortic root size;	chr7:66192326	chr7:65647864~65715661:+
BRCA	cis	rs875971	0.895	rs7782806	ENSG00000273024.4	INTS4P2	3.56	0.000385	0.0198	0.12	0.11	Aortic root size;	chr7:66192910	chr7:65647864~65715661:+
BRCA	cis	rs9549260	0.604	rs9532587	ENSG00000168852.11	TPTE2P5	3.56	0.000385	0.0198	0.13	0.11	Red blood cell count;	chr13:40728558	chr13:40822296~40921749:-
BRCA	cis	rs4763879	0.778	rs2895989	ENSG00000256582.1	RP11-75L1.1	-3.56	0.000385	0.0198	-0.11	-0.11	Type 1 diabetes;	chr12:9688735	chr12:9704077~9709350:+
BRCA	cis	rs7954584	0.635	rs7309024	ENSG00000212694.7	LINC01089	-3.56	0.000385	0.0198	-0.08	-0.11	Mean corpuscular volume;	chr12:121900428	chr12:121795267~121803906:-
BRCA	cis	rs253959	0.545	rs712579	ENSG00000272265.1	CTD-2287O16.4	-3.56	0.000385	0.0198	-0.13	-0.11	Bipolar disorder and schizophrenia;	chr5:116314839	chr5:116078110~116078570:-
BRCA	cis	rs2573652	1	rs2581365	ENSG00000254744.3	CTD-3076O17.1	-3.56	0.000385	0.0198	-0.13	-0.11	Height;	chr15:99973113	chr15:99970215~99974010:+
BRCA	cis	rs17801127	0.901	rs13030023	ENSG00000231969.1	AC144449.1	3.56	0.000385	0.0198	0.19	0.11	Liver enzyme levels (alanine transaminase);	chr2:149653337	chr2:149587196~149848233:+
BRCA	cis	rs1371614	0.589	rs527267	ENSG00000229122.1	AGBL5-IT1	-3.56	0.000385	0.0198	-0.12	-0.11	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26896787	chr2:27061038~27061815:+
BRCA	cis	rs875971	1	rs778726	ENSG00000271064.1	RP11-792A8.3	-3.56	0.000385	0.0198	-0.13	-0.11	Aortic root size;	chr7:66363744	chr7:66748838~66749077:-
BRCA	cis	rs875971	0.767	rs1695815	ENSG00000271064.1	RP11-792A8.3	-3.56	0.000385	0.0198	-0.13	-0.11	Aortic root size;	chr7:66366357	chr7:66748838~66749077:-
BRCA	cis	rs875971	1	rs778685	ENSG00000271064.1	RP11-792A8.3	-3.56	0.000385	0.0198	-0.13	-0.11	Aortic root size;	chr7:66371189	chr7:66748838~66749077:-
BRCA	cis	rs875971	0.929	rs778682	ENSG00000271064.1	RP11-792A8.3	-3.56	0.000385	0.0198	-0.13	-0.11	Aortic root size;	chr7:66372947	chr7:66748838~66749077:-
BRCA	cis	rs875971	0.964	rs11765965	ENSG00000271064.1	RP11-792A8.3	-3.56	0.000385	0.0198	-0.13	-0.11	Aortic root size;	chr7:66377234	chr7:66748838~66749077:-
BRCA	cis	rs2039553	0.552	rs1414110	ENSG00000227354.5	RBM26-AS1	-3.56	0.000385	0.0198	-0.12	-0.11	Pancreatic cancer;	chr13:79750788	chr13:79406309~79424328:+
BRCA	cis	rs2274273	0.967	rs10137409	ENSG00000259318.1	RP11-454L9.2	3.56	0.000385	0.0198	0.09	0.11	Protein biomarker;	chr14:55144723	chr14:55394940~55395233:-
BRCA	cis	rs10771431	0.597	rs3759275	ENSG00000256427.1	RP11-118B22.4	3.56	0.000385	0.0198	0.11	0.11	Breast size;	chr12:9201232	chr12:9246497~9257960:+
BRCA	cis	rs10771431	0.597	rs3759274	ENSG00000256427.1	RP11-118B22.4	3.56	0.000385	0.0198	0.11	0.11	Breast size;	chr12:9201279	chr12:9246497~9257960:+
BRCA	cis	rs10771431	0.597	rs10771412	ENSG00000256427.1	RP11-118B22.4	3.56	0.000385	0.0198	0.11	0.11	Breast size;	chr12:9201757	chr12:9246497~9257960:+
BRCA	cis	rs10771431	0.597	rs10771413	ENSG00000256427.1	RP11-118B22.4	3.56	0.000385	0.0198	0.11	0.11	Breast size;	chr12:9201817	chr12:9246497~9257960:+
BRCA	cis	rs875971	0.862	rs801195	ENSG00000271064.1	RP11-792A8.3	3.56	0.000385	0.0198	0.13	0.11	Aortic root size;	chr7:66561128	chr7:66748838~66749077:-
BRCA	cis	rs11048434	0.518	rs759469	ENSG00000111788.10	RP11-22B23.1	-3.56	0.000385	0.0198	-0.1	-0.11	Sjögren's syndrome;	chr12:9023108	chr12:9277235~9313241:+
BRCA	cis	rs9309473	0.687	rs6706235	ENSG00000230002.2	ALMS1-IT1	3.56	0.000385	0.0198	0.13	0.11	Metabolite levels;	chr2:73386430	chr2:73456764~73459484:+
BRCA	cis	rs4243971	0.516	rs2281542	ENSG00000277692.1	RP11-358N2.2	-3.56	0.000385	0.0198	-0.12	-0.11	Inflammatory bowel disease;Crohn's disease;	chr20:32427840	chr20:32355053~32355734:+
BRCA	cis	rs6490294	0.571	rs2272308	ENSG00000234608.6	MAPKAPK5-AS1	3.56	0.000385	0.0198	0.16	0.11	Mean platelet volume;	chr12:112163446	chr12:111839764~111842902:-
BRCA	cis	rs67696533	0.62	rs911529	ENSG00000235217.6	TSPY26P	-3.56	0.000385	0.0198	-0.14	-0.11	White blood cell count (basophil);Basophil percentage of granulocytes;Basophil percentage of white cells;	chr20:32559137	chr20:32186477~32190527:-
BRCA	cis	rs1914816	0.941	rs2460151	ENSG00000196274.5	Metazoa_SRP	3.56	0.000385	0.0198	0.14	0.11	Response to tocilizumab in rheumatoid arthritis;	chr15:76195166	chr15:76230048~76230390:-
BRCA	cis	rs853679	0.599	rs149990	ENSG00000216901.1	AL022393.7	3.56	0.000385	0.0198	0.22	0.11	Depression;	chr6:28030480	chr6:28176188~28176674:+
BRCA	cis	rs4243971	0.516	rs4911223	ENSG00000275576.1	RP5-836N17.4	-3.56	0.000385	0.0198	-0.12	-0.11	Inflammatory bowel disease;Crohn's disease;	chr20:32373538	chr20:32116171~32116629:+
BRCA	cis	rs7829975	0.606	rs11776838	ENSG00000253981.4	ALG1L13P	-3.56	0.000385	0.0198	-0.12	-0.11	Mood instability;	chr8:8937291	chr8:8236003~8244667:-
BRCA	cis	rs6991838	0.584	rs34494846	ENSG00000272155.1	RP11-707M3.3	3.56	0.000386	0.0198	0.1	0.11	Intelligence (multi-trait analysis);	chr8:65602397	chr8:65714334~65714778:-
BRCA	cis	rs4919687	0.55	rs10748828	ENSG00000236937.2	PTGES3P4	-3.56	0.000386	0.0198	-0.15	-0.11	Colorectal cancer;	chr10:102697037	chr10:102845595~102845950:+
BRCA	cis	rs10421328	0.848	rs867616	ENSG00000267419.1	CTC-559E9.6	-3.56	0.000386	0.0198	-0.15	-0.11	Parental longevity (combined parental age at death);	chr19:19646873	chr19:19776602~19834927:+
BRCA	cis	rs6142618	0.543	rs6141639	ENSG00000275576.1	RP5-836N17.4	-3.56	0.000386	0.0198	-0.12	-0.11	Inflammatory bowel disease;	chr20:32222473	chr20:32116171~32116629:+
BRCA	cis	rs739401	0.527	rs418832	ENSG00000247473.2	CARS-AS1	3.56	0.000386	0.0198	0.13	0.11	Longevity;	chr11:3051006	chr11:3029009~3041260:+
BRCA	cis	rs6088580	0.524	rs6088552	ENSG00000279253.1	RP4-614O4.13	3.56	0.000386	0.0198	0.13	0.11	Glomerular filtration rate (creatinine);	chr20:34638687	chr20:35262727~35264187:-
BRCA	cis	rs11170468	0.621	rs11170842	ENSG00000257718.1	RP11-396F22.1	-3.56	0.000386	0.0198	-0.14	-0.11	Body mass index;	chr12:39135437	chr12:38906451~38909592:+
BRCA	cis	rs6545883	0.929	rs1838978	ENSG00000273302.1	RP11-493E12.2	-3.56	0.000386	0.0198	-0.1	-0.11	Tuberculosis;	chr2:61313788	chr2:61199979~61200769:+
BRCA	cis	rs1949733	1	rs2688223	ENSG00000205959.3	RP11-689P11.2	-3.56	0.000386	0.0198	-0.11	-0.11	Response to antineoplastic agents;	chr4:8469671	chr4:8482270~8512610:+
BRCA	cis	rs7572733	0.935	rs10931796	ENSG00000231621.1	AC013264.2	-3.56	0.000386	0.0199	-0.1	-0.11	Dermatomyositis;	chr2:197975937	chr2:197197991~197199273:+
BRCA	cis	rs970548	0.954	rs10466245	ENSG00000230869.1	CTGLF10P	3.56	0.000386	0.0199	0.14	0.11	Total cholesterol levels;HDL cholesterol;HDL cholesterol levels;Cholesterol, total;	chr10:45536299	chr10:45678692~45700532:+
BRCA	cis	rs10005067	0.967	rs6845452	ENSG00000249001.4	RP11-742B18.1	3.56	0.000386	0.0199	0.13	0.11	Total body bone mineral density (age 30-45);	chr4:87901855	chr4:87568035~87733956:-
BRCA	cis	rs442309	1	rs224148	ENSG00000238280.1	RP11-436D10.3	-3.56	0.000386	0.0199	-0.14	-0.11	Vogt-Koyanagi-Harada syndrome;	chr10:62726879	chr10:62793562~62805887:-
BRCA	cis	rs442309	1	rs224149	ENSG00000238280.1	RP11-436D10.3	-3.56	0.000386	0.0199	-0.14	-0.11	Vogt-Koyanagi-Harada syndrome;	chr10:62727313	chr10:62793562~62805887:-
BRCA	cis	rs74233809	1	rs11191582	ENSG00000236937.2	PTGES3P4	3.56	0.000386	0.0199	0.26	0.11	Birth weight;	chr10:103153896	chr10:102845595~102845950:+
BRCA	cis	rs875971	0.756	rs4718328	ENSG00000223473.2	GS1-124K5.3	-3.56	0.000386	0.0199	-0.08	-0.11	Aortic root size;	chr7:66228350	chr7:66491049~66493566:-
BRCA	cis	rs8180040	0.934	rs4858811	ENSG00000280667.1	Y_RNA	-3.56	0.000386	0.0199	-0.12	-0.11	Colorectal cancer;	chr3:47439034	chr3:47501083~47501182:+
BRCA	cis	rs1635	0.826	rs742107	ENSG00000216901.1	AL022393.7	3.56	0.000386	0.0199	0.25	0.11	Schizophrenia;	chr6:28322937	chr6:28176188~28176674:+
BRCA	cis	rs9425766	0.54	rs2294492	ENSG00000200674.1	RN7SKP160	3.56	0.000386	0.0199	0.14	0.11	Life satisfaction;	chr1:174157884	chr1:173791548~173791887:+
BRCA	cis	rs8040855	0.599	rs6496800	ENSG00000259416.2	RP11-158M2.5	-3.56	0.000386	0.0199	-0.13	-0.11	Bulimia nervosa;	chr15:85185055	chr15:85754941~85756237:-
BRCA	cis	rs2243480	1	rs34815098	ENSG00000234585.5	CCT6P3	-3.56	0.000386	0.0199	-0.16	-0.11	Diabetic kidney disease;	chr7:65827267	chr7:65038354~65074713:+
BRCA	cis	rs2243480	1	rs35735127	ENSG00000234585.5	CCT6P3	-3.56	0.000386	0.0199	-0.16	-0.11	Diabetic kidney disease;	chr7:65835436	chr7:65038354~65074713:+
BRCA	cis	rs2243480	0.901	rs35256305	ENSG00000234585.5	CCT6P3	-3.56	0.000386	0.0199	-0.16	-0.11	Diabetic kidney disease;	chr7:65841418	chr7:65038354~65074713:+
BRCA	cis	rs2243480	0.803	rs34004500	ENSG00000234585.5	CCT6P3	-3.56	0.000386	0.0199	-0.16	-0.11	Diabetic kidney disease;	chr7:65847191	chr7:65038354~65074713:+
BRCA	cis	rs2243480	1	rs35825738	ENSG00000234585.5	CCT6P3	-3.56	0.000386	0.0199	-0.16	-0.11	Diabetic kidney disease;	chr7:65853040	chr7:65038354~65074713:+
BRCA	cis	rs2391285	0.609	rs1029555	ENSG00000214870.7	AC004540.5	3.56	0.000386	0.0199	0.16	0.11	Post bronchodilator FEV1/FVC ratio;	chr7:26547477	chr7:26398593~26494256:+
BRCA	cis	rs875971	0.862	rs1612452	ENSG00000223473.2	GS1-124K5.3	-3.56	0.000386	0.0199	-0.09	-0.11	Aortic root size;	chr7:66108909	chr7:66491049~66493566:-
BRCA	cis	rs2154319	0.943	rs17358122	ENSG00000230638.4	RP11-486B10.4	-3.56	0.000386	0.0199	-0.18	-0.11	Height;	chr1:41225651	chr1:41542069~41544310:+
BRCA	cis	rs1383484	0.798	rs1871731	ENSG00000230373.7	GOLGA6L5P	-3.56	0.000386	0.0199	-0.13	-0.11	Height;	chr15:83869280	chr15:84507885~84516814:-
BRCA	cis	rs925550	0.932	rs12501008	ENSG00000224786.1	CETN4P	-3.56	0.000386	0.0199	-0.18	-0.11	Primary biliary cholangitis;	chr4:122676285	chr4:122730548~122732193:-
BRCA	cis	rs17711722	0.727	rs2658585	ENSG00000273142.1	RP11-458F8.4	-3.56	0.000386	0.0199	-0.1	-0.11	Calcium levels;	chr7:65996954	chr7:66902857~66906297:+
BRCA	cis	rs2120243	0.533	rs1500921	ENSG00000244515.1	KRT18P34	-3.56	0.000386	0.0199	-0.13	-0.11	Hepatocellular carcinoma in hepatitis B infection;	chr3:157337638	chr3:157162663~157163932:-
BRCA	cis	rs2120243	0.533	rs62278578	ENSG00000244515.1	KRT18P34	-3.56	0.000386	0.0199	-0.13	-0.11	Hepatocellular carcinoma in hepatitis B infection;	chr3:157338078	chr3:157162663~157163932:-
BRCA	cis	rs1916284	0.901	rs9811706	ENSG00000239831.1	RNF7P1	3.56	0.000386	0.0199	0.13	0.11	Prostate cancer (SNP x SNP interaction);	chr3:57415209	chr3:57519669~57520010:-
BRCA	cis	rs17695224	0.545	rs8109098	ENSG00000269483.1	AC006272.1	3.56	0.000386	0.0199	0.13	0.11	HDL cholesterol;HDL cholesterol levels;	chr19:51825363	chr19:51839924~51843324:-
BRCA	cis	rs9468199	0.523	rs9468152	ENSG00000271755.1	RP1-153G14.4	-3.56	0.000386	0.0199	-0.17	-0.11	Parkinson's disease;	chr6:27525127	chr6:27404010~27406964:-
BRCA	cis	rs11673344	0.566	rs1545755	ENSG00000233527.7	ZNF529-AS1	3.56	0.000386	0.0199	0.12	0.11	Obesity-related traits;	chr19:37490607	chr19:36573070~36594708:+
BRCA	cis	rs2439831	0.85	rs3816792	ENSG00000206991.1	RNU6-610P	3.56	0.000386	0.0199	0.17	0.11	Lung cancer in ever smokers;	chr15:43824788	chr15:43637632~43637738:-
BRCA	cis	rs61160187	0.582	rs55814394	ENSG00000272308.1	RP11-231G3.1	-3.56	0.000386	0.0199	-0.12	-0.11	Educational attainment (years of education);Educational attainment (college completion);	chr5:61014107	chr5:60866457~60866935:-
BRCA	cis	rs6977955	1	rs6977955	ENSG00000234336.5	JAZF1-AS1	3.56	0.000386	0.0199	0.15	0.11	Allergic disease (asthma, hay fever or eczema);	chr7:28117268	chr7:28180322~28243917:+
BRCA	cis	rs7771547	0.855	rs4713987	ENSG00000224666.3	RP1-50J22.4	3.56	0.000386	0.0199	0.12	0.11	Platelet distribution width;	chr6:36631233	chr6:36386831~36393462:+
BRCA	cis	rs7111546	0.791	rs78969307	ENSG00000246225.5	RP11-17A1.3	3.56	0.000386	0.0199	0.19	0.11	Dialysis-related mortality;	chr11:22850803	chr11:22829380~22945393:+
BRCA	cis	rs6714710	0.603	rs6757357	ENSG00000228486.8	LINC01125	-3.56	0.000386	0.0199	-0.1	-0.11	Posterior cortical atrophy and Alzheimer's disease;	chr2:97875287	chr2:97664217~97703064:+
BRCA	cis	rs11783469	0.524	rs2235116	ENSG00000253390.1	CTC-756D1.2	3.56	0.000386	0.0199	0.16	0.11	Reticulocyte count;	chr8:23479897	chr8:23458601~23484971:+
BRCA	cis	rs58235267	0.553	rs1025132	ENSG00000242412.1	DBIL5P2	-3.56	0.000387	0.0199	-0.14	-0.11	Prostate-specific antigen levels (conditioned on lead SNPs);	chr2:63133504	chr2:63117851~63119542:-
BRCA	cis	rs8114671	0.562	rs2076667	ENSG00000279253.1	RP4-614O4.13	-3.56	0.000387	0.0199	-0.12	-0.11	Height;	chr20:34919161	chr20:35262727~35264187:-
BRCA	cis	rs860295	0.812	rs4278368	ENSG00000246203.2	RP11-29H23.5	-3.56	0.000387	0.0199	-0.12	-0.11	Body mass index;	chr1:155752766	chr1:155614726~155660245:-
BRCA	cis	rs1466788	0.895	rs481420	ENSG00000224965.1	KCNC4-AS1	3.56	0.000387	0.0199	0.13	0.11	Blood metabolite levels;	chr1:110066139	chr1:110208834~110209987:-
BRCA	cis	rs6599077	0.616	rs9883358	ENSG00000223797.4	ENTPD3-AS1	3.56	0.000387	0.0199	0.13	0.11	Sleep-related phenotypes;	chr3:40134140	chr3:40313802~40453329:-
BRCA	cis	rs17345786	0.906	rs59359251	ENSG00000244119.1	PDCL3P4	3.56	0.000387	0.0199	0.1	0.11	Colonoscopy-negative controls vs population controls;	chr3:101427518	chr3:101712472~101713191:+
BRCA	cis	rs6142618	0.562	rs6061159	ENSG00000277692.1	RP11-358N2.2	-3.56	0.000387	0.0199	-0.12	-0.11	Inflammatory bowel disease;	chr20:32104119	chr20:32355053~32355734:+
BRCA	cis	rs6142618	0.562	rs6142609	ENSG00000277692.1	RP11-358N2.2	-3.56	0.000387	0.0199	-0.12	-0.11	Inflammatory bowel disease;	chr20:32104232	chr20:32355053~32355734:+
BRCA	cis	rs12887734	0.524	rs4906364	ENSG00000269910.1	RP11-73M18.10	3.56	0.000387	0.0199	0.12	0.11	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103748005	chr14:103694516~103695050:-
BRCA	cis	rs4713118	0.869	rs6902689	ENSG00000219392.1	RP1-265C24.5	-3.56	0.000387	0.0199	-0.16	-0.11	Parkinson's disease;	chr6:27741662	chr6:28115628~28116551:+
BRCA	cis	rs870355	1	rs870355	ENSG00000204282.4	TNRC6C-AS1	3.56	0.000387	0.0199	0.12	0.11	Vitiligo;	chr17:78170115	chr17:78107398~78111799:-
BRCA	cis	rs2562456	0.917	rs2650793	ENSG00000268119.4	CTD-2561J22.5	-3.56	0.000387	0.0199	-0.16	-0.11	Pain;	chr19:21493313	chr19:21444241~21463908:-
BRCA	cis	rs10838634	1	rs12277006	ENSG00000280615.1	Y_RNA	-3.56	0.000387	0.0199	-0.19	-0.11	Schizophrenia;	chr11:46848771	chr11:47614898~47614994:-
BRCA	cis	rs7487075	0.554	rs12229299	ENSG00000274723.1	RP11-618L22.1	3.56	0.000387	0.0199	0.14	0.11	Itch intensity from mosquito bite;	chr12:46691110	chr12:46970504~46972155:+
BRCA	cis	rs875971	0.862	rs2420174	ENSG00000273024.4	INTS4P2	3.56	0.000387	0.0199	0.12	0.11	Aortic root size;	chr7:66180374	chr7:65647864~65715661:+
BRCA	cis	rs875971	0.862	rs2420173	ENSG00000273024.4	INTS4P2	3.56	0.000387	0.0199	0.12	0.11	Aortic root size;	chr7:66180412	chr7:65647864~65715661:+
BRCA	cis	rs792448	0.534	rs66912346	ENSG00000226251.4	RP11-15I11.3	-3.56	0.000387	0.0199	-0.15	-0.11	White blood cell count (basophil);	chr1:212444178	chr1:212225278~212238977:-
BRCA	cis	rs9400180	0.879	rs2187913	ENSG00000271734.1	RP1-111B22.3	-3.56	0.000387	0.0199	-0.15	-0.11	Major depressive disorder;	chr6:108033979	chr6:108030249~108030718:-
BRCA	cis	rs9400180	0.84	rs9386697	ENSG00000271734.1	RP1-111B22.3	-3.56	0.000387	0.0199	-0.15	-0.11	Major depressive disorder;	chr6:108035577	chr6:108030249~108030718:-
BRCA	cis	rs600550	0.588	rs10897049	ENSG00000275344.1	MIR6503	3.56	0.000387	0.0199	0.12	0.11	Lipoprotein-associated phospholipase A2 activity and mass;	chr11:60333108	chr11:60209071~60209156:-
BRCA	cis	rs66887589	0.807	rs9799664	ENSG00000260404.2	RP11-384K6.6	3.56	0.000387	0.0199	0.09	0.11	Diastolic blood pressure;	chr4:119405523	chr4:118591773~118633729:+
BRCA	cis	rs1884752	1	rs1884751	ENSG00000278816.1	RP5-1116H23.4	-3.56	0.000387	0.0199	-0.12	-0.11	Anti-saccade response;	chr20:5416682	chr20:5061037~5061340:-
BRCA	cis	rs7781557	0.64	rs6968036	ENSG00000239969.4	RP11-163E9.2	-3.56	0.000387	0.0199	-0.18	-0.11	Colorectal adenoma (advanced);	chr7:102915473	chr7:102364162~102380633:+
BRCA	cis	rs8073060	0.559	rs72829925	ENSG00000267554.1	RP11-686D22.10	3.56	0.000387	0.0199	0.12	0.11	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35722759	chr17:35470069~35470628:-
BRCA	cis	rs9868809	0.881	rs6773261	ENSG00000225399.4	RP11-3B7.1	-3.56	0.000387	0.0199	-0.17	-0.11	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48637631	chr3:49260085~49261316:+
BRCA	cis	rs1865760	1	rs9348698	ENSG00000272810.1	U91328.22	-3.56	0.000387	0.0199	-0.13	-0.11	Height;	chr6:25929461	chr6:26013241~26013757:+
BRCA	cis	rs962856	1	rs6710832	ENSG00000236605.1	AC023115.4	3.56	0.000387	0.0199	0.13	0.11	Pancreatic cancer;	chr2:67374810	chr2:67324627~67325304:+
BRCA	cis	rs6142618	0.562	rs6142608	ENSG00000277692.1	RP11-358N2.2	-3.56	0.000387	0.0199	-0.12	-0.11	Inflammatory bowel disease;	chr20:32103140	chr20:32355053~32355734:+
BRCA	cis	rs2274273	0.84	rs1045002	ENSG00000259318.1	RP11-454L9.2	3.56	0.000387	0.0199	0.09	0.11	Protein biomarker;	chr14:55351799	chr14:55394940~55395233:-
BRCA	cis	rs863345	0.604	rs7549581	ENSG00000229914.1	RP11-404O13.4	-3.56	0.000387	0.0199	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158519914	chr1:158195633~158196131:-
BRCA	cis	rs863345	0.604	rs7512592	ENSG00000229914.1	RP11-404O13.4	-3.56	0.000387	0.0199	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158520155	chr1:158195633~158196131:-
BRCA	cis	rs863345	0.604	rs10797018	ENSG00000229914.1	RP11-404O13.4	-3.56	0.000387	0.0199	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158520322	chr1:158195633~158196131:-
BRCA	cis	rs863345	0.527	rs10797019	ENSG00000229914.1	RP11-404O13.4	-3.56	0.000387	0.0199	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158520431	chr1:158195633~158196131:-
BRCA	cis	rs863345	0.604	rs10797020	ENSG00000229914.1	RP11-404O13.4	-3.56	0.000387	0.0199	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158520534	chr1:158195633~158196131:-
BRCA	cis	rs863345	0.625	rs10489833	ENSG00000229914.1	RP11-404O13.4	-3.56	0.000387	0.0199	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158520661	chr1:158195633~158196131:-
BRCA	cis	rs863345	0.604	rs11265003	ENSG00000229914.1	RP11-404O13.4	-3.56	0.000387	0.0199	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158520841	chr1:158195633~158196131:-
BRCA	cis	rs863345	0.604	rs950260	ENSG00000229914.1	RP11-404O13.4	-3.56	0.000387	0.0199	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158521730	chr1:158195633~158196131:-
BRCA	cis	rs863345	0.604	rs7518808	ENSG00000229914.1	RP11-404O13.4	-3.56	0.000387	0.0199	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158522030	chr1:158195633~158196131:-
BRCA	cis	rs9659323	0.931	rs113197996	ENSG00000231365.4	RP11-418J17.1	-3.56	0.000387	0.0199	-0.13	-0.11	Body mass index;	chr1:118979803	chr1:119140396~119275973:+
BRCA	cis	rs11098499	0.863	rs10004484	ENSG00000260091.1	RP11-33B1.4	-3.56	0.000387	0.0199	-0.1	-0.11	Corneal astigmatism;	chr4:119521273	chr4:119409333~119410233:+
BRCA	cis	rs3743102	1	rs3803383	ENSG00000259315.1	RP11-752G15.9	3.56	0.000387	0.0199	0.15	0.11	Colorectal adenoma (advanced);	chr15:82754741	chr15:82725873~82738904:-
BRCA	cis	rs10266483	0.705	rs599522	ENSG00000227986.1	TRIM60P18	-3.56	0.000387	0.0199	-0.12	-0.11	Response to statin therapy;	chr7:64298104	chr7:64355078~64356199:+
BRCA	cis	rs2554380	0.943	rs2585049	ENSG00000225151.9	GOLGA2P7	3.56	0.000388	0.0199	0.16	0.11	Height;	chr15:83684121	chr15:84199311~84230136:-
BRCA	cis	rs7819412	0.875	rs6981523	ENSG00000154316.13	TDH	3.56	0.000388	0.0199	0.14	0.11	Triglycerides;	chr8:11204283	chr8:11339637~11368452:+
BRCA	cis	rs2562456	0.917	rs2562466	ENSG00000268705.1	BNIP3P26	-3.56	0.000388	0.0199	-0.12	-0.11	Pain;	chr19:21531402	chr19:21521343~21521896:-
BRCA	cis	rs875971	0.706	rs1643374	ENSG00000272831.1	RP11-792A8.4	3.56	0.000388	0.0199	0.1	0.11	Aortic root size;	chr7:66407695	chr7:66739829~66740385:-
BRCA	cis	rs6142618	0.562	rs4911550	ENSG00000224452.1	RSL24D1P6	3.56	0.000388	0.0199	0.15	0.11	Inflammatory bowel disease;	chr20:32151639	chr20:32170390~32170790:-
BRCA	cis	rs1355223	0.902	rs2185700	ENSG00000271369.1	RP11-350D17.3	-3.56	0.000388	0.0199	-0.13	-0.11	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34702657	chr11:34709600~34710161:+
BRCA	cis	rs11122895	0.509	rs55937046	ENSG00000236307.2	EEF1E1P1	3.56	0.000388	0.0199	0.12	0.11	Allergic sensitization;	chr2:111689719	chr2:111887914~111888741:+
BRCA	cis	rs10838634	1	rs6485700	ENSG00000280615.1	Y_RNA	3.56	0.000388	0.0199	0.19	0.11	Schizophrenia;	chr11:46854382	chr11:47614898~47614994:-
BRCA	cis	rs2836950	0.52	rs8130240	ENSG00000235701.1	PCBP2P1	-3.56	0.000388	0.0199	-0.13	-0.11	Menarche (age at onset);	chr21:39166182	chr21:39171130~39172106:-
BRCA	cis	rs17801127	0.818	rs848219	ENSG00000231969.1	AC144449.1	3.56	0.000388	0.0199	0.17	0.11	Liver enzyme levels (alanine transaminase);	chr2:149685494	chr2:149587196~149848233:+
BRCA	cis	rs13434995	0.513	rs55885973	ENSG00000273257.1	RP11-177J6.1	-3.56	0.000388	0.0199	-0.16	-0.11	Adiponectin levels;	chr4:55480054	chr4:55387949~55388271:+
BRCA	cis	rs7160336	1	rs2300191	ENSG00000259065.1	RP5-1021I20.1	3.56	0.000388	0.0199	0.12	0.11	Blood protein levels;	chr14:74114818	chr14:73787360~73803270:+
BRCA	cis	rs6545883	0.507	rs2442025	ENSG00000270820.4	RP11-355B11.2	-3.56	0.000388	0.0199	-0.12	-0.11	Tuberculosis;	chr2:61344310	chr2:61471188~61484130:+
BRCA	cis	rs2148307	0.523	rs10828135	ENSG00000228339.1	AMD1P1	-3.56	0.000388	0.0199	-0.14	-0.11	Photic sneeze reflex;	chr10:20808283	chr10:20350049~20351100:+
BRCA	cis	rs10129255	0.957	rs17113284	ENSG00000211967.3	IGHV3-53	3.56	0.000388	0.02	0.08	0.11	Kawasaki disease;	chr14:106684476	chr14:106592676~106593347:-
BRCA	cis	rs875971	0.862	rs4718330	ENSG00000223473.2	GS1-124K5.3	-3.56	0.000388	0.02	-0.08	-0.11	Aortic root size;	chr7:66250256	chr7:66491049~66493566:-
BRCA	cis	rs8105895	1	rs79846980	ENSG00000269345.1	VN1R85P	3.56	0.000388	0.02	0.17	0.11	Body mass index (change over time);	chr19:21958541	chr19:22174766~22175191:-
BRCA	cis	rs6593122	0.565	rs10234270	ENSG00000235454.1	HAUS6P3	-3.56	0.000388	0.02	-0.14	-0.11	Vaccine-related adverse events;	chr7:54117976	chr7:53862233~53863339:+
BRCA	cis	rs7324021	0.867	rs7997502	ENSG00000238286.1	SLC35E1P1	-3.56	0.000388	0.02	-0.21	-0.11	Gut microbiome composition (winter);	chr13:20027416	chr13:20607268~20608131:+
BRCA	cis	rs3781264	0.848	rs10509670	ENSG00000268894.5	PLCE1-AS1	3.56	0.000388	0.02	0.14	0.11	Esophageal cancer and gastric cancer;	chr10:94308190	chr10:94279277~94287478:-
BRCA	cis	rs2065415	1	rs2065415	ENSG00000229720.1	RP3-495K2.2	3.56	0.000388	0.02	0.17	0.11	Warfarin maintenance dose;	chr6:169037250	chr6:169034197~169035642:-
BRCA	cis	rs863345	0.604	rs1873511	ENSG00000229914.1	RP11-404O13.4	-3.56	0.000388	0.02	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158491576	chr1:158195633~158196131:-
BRCA	cis	rs7954584	0.52	rs1169096	ENSG00000274292.1	RP11-347I19.7	3.56	0.000388	0.02	0.09	0.11	Mean corpuscular volume;	chr12:122027930	chr12:121800797~121803403:+
BRCA	cis	rs3755605	0.52	rs481781	ENSG00000242578.1	RP11-469J4.3	3.56	0.000388	0.02	0.13	0.11	Testicular germ cell tumor;	chr3:170222257	chr3:170410512~170418615:+
BRCA	cis	rs613391	0.603	rs565595	ENSG00000265194.1	RP11-70L8.4	-3.56	0.000388	0.02	-0.12	-0.11	Quantitative traits;	chr9:22724189	chr9:21858910~21861926:-
BRCA	cis	rs867371	0.656	rs2665103	ENSG00000276710.3	CSPG4P8	3.56	0.000388	0.02	0.11	0.11	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82140374	chr15:82459472~82477258:+
BRCA	cis	rs13118159	0.55	rs1137789	ENSG00000273179.1	RP11-20I20.4	3.56	0.000388	0.02	0.12	0.11	Longevity;	chr4:1388010	chr4:1167778~1168174:+
BRCA	cis	rs4415084	1	rs6861560	ENSG00000272335.1	RP11-53O19.3	3.56	0.000388	0.02	0.1	0.11	Breast cancer;	chr5:44708276	chr5:44826076~44828592:+
BRCA	cis	rs8054556	1	rs7190185	ENSG00000261367.1	RP11-455F5.4	-3.56	0.000388	0.02	-0.12	-0.11	Autism spectrum disorder or schizophrenia;	chr16:29951031	chr16:30107675~30110541:+
BRCA	cis	rs17684571	0.872	rs11961141	ENSG00000231441.1	RP11-472M19.2	3.56	0.000388	0.02	0.16	0.11	Schizophrenia;	chr6:56717580	chr6:56844002~56864078:+
BRCA	cis	rs17684571	0.81	rs60498201	ENSG00000231441.1	RP11-472M19.2	3.56	0.000388	0.02	0.16	0.11	Schizophrenia;	chr6:56718021	chr6:56844002~56864078:+
BRCA	cis	rs7618501	1	rs35261599	ENSG00000228008.1	CTD-2330K9.3	-3.56	0.000388	0.02	-0.1	-0.11	Intelligence (multi-trait analysis);	chr3:49735803	chr3:49903845~49916937:+
BRCA	cis	rs9341808	0.754	rs9294173	ENSG00000279022.1	RP11-250B2.4	3.56	0.000389	0.02	0.12	0.11	Sitting height ratio;	chr6:80281913	chr6:80440730~80441172:+
BRCA	cis	rs718948	0.673	rs718947	ENSG00000199466.1	Y_RNA	3.56	0.000389	0.02	0.13	0.11	Body mass index;	chr10:125050580	chr10:124766196~124766297:+
BRCA	cis	rs4919694	0.901	rs74376228	ENSG00000236937.2	PTGES3P4	3.56	0.000389	0.02	0.24	0.11	Arsenic metabolism;	chr10:102917905	chr10:102845595~102845950:+
BRCA	cis	rs12303914	0.802	rs7301715	ENSG00000256682.2	TAS2R12	3.56	0.000389	0.02	0.13	0.11	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr12:10316507	chr12:10894943~10896952:-
BRCA	cis	rs12303914	0.802	rs7316530	ENSG00000256682.2	TAS2R12	3.56	0.000389	0.02	0.13	0.11	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr12:10316512	chr12:10894943~10896952:-
BRCA	cis	rs10043228	1	rs77856716	ENSG00000271918.1	CTD-2287O16.5	-3.56	0.000389	0.02	-0.16	-0.11	Asthma or chronic obstructive pulmonary disease;	chr5:116229963	chr5:116083807~116085416:-
BRCA	cis	rs4427176	0.765	rs17150478	ENSG00000233609.3	RP11-62H7.2	-3.56	0.000389	0.02	-0.14	-0.11	Mosquito bite size;	chr8:9783524	chr8:8961200~8979025:+
BRCA	cis	rs80226907	0.831	rs17742621	ENSG00000258413.1	RP11-665C16.6	-3.56	0.000389	0.02	-0.27	-0.11	Mean platelet volume;	chr14:55387006	chr14:55262767~55272075:-
BRCA	cis	rs6012564	1	rs3092374	ENSG00000222365.1	SNORD12B	-3.56	0.000389	0.02	-0.12	-0.11	Anger;	chr20:49047407	chr20:49280319~49280409:+
BRCA	cis	rs2882667	0.964	rs11958050	ENSG00000242683.1	CTB-46B19.1	3.56	0.000389	0.02	0.12	0.11	Age-related hearing impairment (SNP x SNP interaction);	chr5:138966139	chr5:139035148~139035987:-
BRCA	cis	rs4819052	0.807	rs4819047	ENSG00000215447.6	BX322557.10	-3.56	0.000389	0.02	-0.11	-0.11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245224	chr21:45288052~45291738:+
BRCA	cis	rs372883	0.532	rs425989	ENSG00000176054.6	RPL23P2	-3.56	0.000389	0.02	-0.11	-0.11	Pancreatic cancer;	chr21:29342954	chr21:28997613~28998033:-
BRCA	cis	rs5758659	0.679	rs134870	ENSG00000270083.1	RP1-257I20.14	3.56	0.000389	0.02	0.12	0.11	Cognitive function;	chr22:42256311	chr22:42089630~42090028:-
BRCA	cis	rs448720	0.935	rs9796591	ENSG00000260657.2	RP11-315D16.4	-3.56	0.000389	0.02	-0.13	-0.11	Cognitive performance;	chr15:67905497	chr15:68267792~68277994:-
BRCA	cis	rs3781264	0.595	rs10786161	ENSG00000268894.5	PLCE1-AS1	-3.56	0.000389	0.02	-0.15	-0.11	Esophageal cancer and gastric cancer;	chr10:94347914	chr10:94279277~94287478:-
BRCA	cis	rs875971	0.862	rs6460306	ENSG00000271064.1	RP11-792A8.3	3.56	0.000389	0.02	0.13	0.11	Aortic root size;	chr7:66595806	chr7:66748838~66749077:-
BRCA	cis	rs11088226	0.681	rs2833901	ENSG00000186842.4	LINC00846	-3.56	0.000389	0.02	-0.18	-0.11	Gastritis;	chr21:32567008	chr21:32572238~32575881:-
BRCA	cis	rs7674212	0.51	rs6856593	ENSG00000246560.2	RP11-10L12.4	3.56	0.000389	0.02	0.12	0.11	Type 2 diabetes;	chr4:103256542	chr4:102828055~102844075:+
BRCA	cis	rs7221109	1	rs7221109	ENSG00000224244.1	AC090283.3	3.56	0.000389	0.02	0.12	0.11	Type 1 diabetes;	chr17:40614034	chr17:40687038~40689360:-
BRCA	cis	rs9840812	0.637	rs667920	ENSG00000273486.1	RP11-731C17.2	3.56	0.000389	0.02	0.14	0.11	Fibrinogen levels;	chr3:136350630	chr3:136837338~136839021:-
BRCA	cis	rs2089222	1	rs2089222	ENSG00000196668.3	LINC00173	3.56	0.000389	0.02	0.19	0.11	Acute lymphoblastic leukemia (childhood);	chr12:116564853	chr12:116533422~116536518:+
BRCA	cis	rs1193	0.802	rs12714203	ENSG00000266931.1	RP11-1252D15.1	-3.56	0.000389	0.02	-0.13	-0.11	High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;High light scatter reticulocyte count;	chr2:86766651	chr2:87055658~87055800:-
BRCA	cis	rs964611	0.882	rs79379792	ENSG00000259488.2	RP11-154J22.1	-3.56	0.000389	0.02	-0.14	-0.11	Metabolite levels (Pyroglutamine);	chr15:48351980	chr15:48312353~48331856:-
BRCA	cis	rs964611	0.882	rs13380180	ENSG00000259488.2	RP11-154J22.1	-3.56	0.000389	0.02	-0.14	-0.11	Metabolite levels (Pyroglutamine);	chr15:48352572	chr15:48312353~48331856:-
BRCA	cis	rs964611	0.882	rs13379705	ENSG00000259488.2	RP11-154J22.1	-3.56	0.000389	0.02	-0.14	-0.11	Metabolite levels (Pyroglutamine);	chr15:48352611	chr15:48312353~48331856:-
BRCA	cis	rs7620503	0.613	rs11715814	ENSG00000228221.4	LINC00578	3.56	0.000389	0.02	0.14	0.11	Corneal structure;	chr3:177562207	chr3:177441921~177752305:+
BRCA	cis	rs6480314	0.711	rs61857176	ENSG00000233590.1	RP11-153K11.3	-3.56	0.000389	0.02	-0.18	-0.11	Optic nerve measurement (disc area);	chr10:68186207	chr10:68233251~68242379:-
BRCA	cis	rs6480314	0.711	rs61857177	ENSG00000233590.1	RP11-153K11.3	-3.56	0.000389	0.02	-0.18	-0.11	Optic nerve measurement (disc area);	chr10:68187015	chr10:68233251~68242379:-
BRCA	cis	rs80226907	1	rs78962984	ENSG00000258413.1	RP11-665C16.6	-3.56	0.000389	0.02	-0.28	-0.11	Mean platelet volume;	chr14:55377501	chr14:55262767~55272075:-
BRCA	cis	rs80226907	1	rs117343607	ENSG00000258413.1	RP11-665C16.6	-3.56	0.000389	0.02	-0.28	-0.11	Mean platelet volume;	chr14:55378893	chr14:55262767~55272075:-
BRCA	cis	rs80226907	0.803	rs75434949	ENSG00000258413.1	RP11-665C16.6	-3.56	0.000389	0.02	-0.28	-0.11	Mean platelet volume;	chr14:55379795	chr14:55262767~55272075:-
BRCA	cis	rs80226907	1	rs77790976	ENSG00000258413.1	RP11-665C16.6	-3.56	0.000389	0.02	-0.28	-0.11	Mean platelet volume;	chr14:55380807	chr14:55262767~55272075:-
BRCA	cis	rs80226907	1	rs79908604	ENSG00000258413.1	RP11-665C16.6	-3.56	0.000389	0.02	-0.28	-0.11	Mean platelet volume;	chr14:55381123	chr14:55262767~55272075:-
BRCA	cis	rs80226907	1	rs74324636	ENSG00000258413.1	RP11-665C16.6	-3.56	0.000389	0.02	-0.28	-0.11	Mean platelet volume;	chr14:55381535	chr14:55262767~55272075:-
BRCA	cis	rs80226907	1	rs80089534	ENSG00000258413.1	RP11-665C16.6	-3.56	0.000389	0.02	-0.28	-0.11	Mean platelet volume;	chr14:55381748	chr14:55262767~55272075:-
BRCA	cis	rs80226907	1	rs77450776	ENSG00000258413.1	RP11-665C16.6	-3.56	0.000389	0.02	-0.28	-0.11	Mean platelet volume;	chr14:55382751	chr14:55262767~55272075:-
BRCA	cis	rs80226907	1	rs78837103	ENSG00000258413.1	RP11-665C16.6	-3.56	0.000389	0.02	-0.28	-0.11	Mean platelet volume;	chr14:55384018	chr14:55262767~55272075:-
BRCA	cis	rs80226907	1	rs112231368	ENSG00000258413.1	RP11-665C16.6	-3.56	0.000389	0.02	-0.28	-0.11	Mean platelet volume;	chr14:55384037	chr14:55262767~55272075:-
BRCA	cis	rs10005067	0.901	rs17715954	ENSG00000249001.4	RP11-742B18.1	-3.56	0.000389	0.02	-0.13	-0.11	Total body bone mineral density (age 30-45);	chr4:87909565	chr4:87568035~87733956:-
BRCA	cis	rs8023401	0.882	rs11855166	ENSG00000274654.1	CTD-3247H4.2	3.56	0.000389	0.02	0.15	0.11	Spherical equivalent (joint analysis main effects and education interaction);	chr15:48506078	chr15:48528980~48529728:-
BRCA	cis	rs1414896	0.646	rs965314	ENSG00000226835.1	RP11-148B18.3	-3.56	0.000389	0.02	-0.12	-0.11	Non-alcoholic fatty liver disease histology (AST);	chr1:95168166	chr1:94333267~94334848:+
BRCA	cis	rs2692947	0.655	rs4605406	ENSG00000168992.4	OR7E102P	3.56	0.000389	0.02	0.16	0.11	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95917987	chr2:95546531~95547545:+
BRCA	cis	rs11892454	0.712	rs66524787	ENSG00000217643.1	PTGES3P2	-3.56	0.000389	0.02	-0.12	-0.11	Heschl's gyrus morphology;	chr2:25725008	chr2:25822469~25822950:+
BRCA	cis	rs10504229	0.593	rs4738567	ENSG00000253523.1	RP11-1112C15.2	-3.56	0.000389	0.02	-0.15	-0.11	Developmental language disorder (linguistic errors);	chr8:57084474	chr8:58031334~58032682:-
BRCA	cis	rs68170813	0.652	rs116894096	ENSG00000241764.3	AC002467.7	3.56	0.000389	0.02	0.19	0.11	Coronary artery disease;	chr7:107538032	chr7:107742817~107744581:-
BRCA	cis	rs6747972	1	rs6747972	ENSG00000236259.1	AC017083.2	-3.56	0.000389	0.02	-0.13	-0.11	Restless legs syndrome;	chr2:67843093	chr2:68125265~68125747:+
BRCA	cis	rs524281	0.637	rs7126075	ENSG00000255038.1	RP11-1167A19.2	-3.56	0.000389	0.02	-0.16	-0.11	Electroencephalogram traits;	chr11:66173092	chr11:66067277~66069619:-
BRCA	cis	rs524281	0.861	rs2177054	ENSG00000255038.1	RP11-1167A19.2	-3.56	0.000389	0.02	-0.16	-0.11	Electroencephalogram traits;	chr11:66177141	chr11:66067277~66069619:-
BRCA	cis	rs12724450	1	rs12724450	ENSG00000228126.1	FALEC	3.56	0.000389	0.02	0.2	0.11	Blood protein levels;	chr1:150508095	chr1:150515757~150518032:+
BRCA	cis	rs2562456	0.833	rs2968076	ENSG00000268119.4	CTD-2561J22.5	-3.56	0.000389	0.02	-0.16	-0.11	Pain;	chr19:21454299	chr19:21444241~21463908:-
BRCA	cis	rs16940212	0.618	rs166359	ENSG00000259771.1	RP11-429D19.1	3.56	0.000389	0.02	0.18	0.11	HDL cholesterol;HDL cholesterol levels;	chr15:58395410	chr15:59266720~59271162:-
BRCA	cis	rs17801127	0.748	rs6436389	ENSG00000231969.1	AC144449.1	-3.56	0.000389	0.02	-0.18	-0.11	Liver enzyme levels (alanine transaminase);	chr2:149691760	chr2:149587196~149848233:+
BRCA	cis	rs11098499	0.82	rs28578366	ENSG00000225892.3	RP11-384K6.2	-3.56	0.00039	0.02	-0.11	-0.11	Corneal astigmatism;	chr4:119615750	chr4:118632274~118634759:+
BRCA	cis	rs7520050	0.966	rs7556615	ENSG00000281133.1	AL355480.3	3.56	0.00039	0.02	0.13	0.11	Reticulocyte count;Red blood cell count;	chr1:45995697	chr1:45580892~45580996:-
BRCA	cis	rs7572733	0.935	rs1607376	ENSG00000231621.1	AC013264.2	-3.56	0.00039	0.02	-0.1	-0.11	Dermatomyositis;	chr2:197963190	chr2:197197991~197199273:+
BRCA	cis	rs7620503	0.571	rs6443468	ENSG00000277241.1	RP11-114M1.3	3.56	0.00039	0.02	0.13	0.11	Corneal structure;	chr3:177565231	chr3:177700346~177701072:-
BRCA	cis	rs2880765	0.835	rs7178991	ENSG00000259630.2	CTD-2262B20.1	-3.56	0.00039	0.02	-0.13	-0.11	Coronary artery disease;	chr15:85507713	chr15:85415228~85415633:+
BRCA	cis	rs8180040	1	rs1076394	ENSG00000260236.1	RP11-708J19.1	-3.56	0.00039	0.02	-0.1	-0.11	Colorectal cancer;	chr3:47281291	chr3:47379089~47380999:-
BRCA	cis	rs8180040	0.966	rs17476234	ENSG00000260236.1	RP11-708J19.1	-3.56	0.00039	0.02	-0.1	-0.11	Colorectal cancer;	chr3:47284808	chr3:47379089~47380999:-
BRCA	cis	rs7089973	0.966	rs12772800	ENSG00000236799.1	RP11-383C6.2	-3.56	0.00039	0.02	-0.14	-0.11	Bipolar disorder or attention deficit hyperactivity disorder;	chr10:114871203	chr10:114994657~114996593:+
BRCA	cis	rs7267979	1	rs6515651	ENSG00000277938.1	RP5-965G21.3	-3.56	0.00039	0.02	-0.13	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25433903	chr20:25229150~25231933:+
BRCA	cis	rs1007738	0.542	rs2279438	ENSG00000200376.1	RNU5E-10P	3.56	0.00039	0.02	0.14	0.11	Bone mineral density (hip);	chr11:47182624	chr11:47576471~47576588:-
BRCA	cis	rs2411233	1	rs8034438	ENSG00000259278.1	RP11-62C7.2	3.56	0.00039	0.02	0.13	0.11	Platelet count;	chr15:38986708	chr15:39019233~39024918:+
BRCA	cis	rs7487075	0.859	rs956910	ENSG00000274723.1	RP11-618L22.1	3.56	0.00039	0.02	0.13	0.11	Itch intensity from mosquito bite;	chr12:46366005	chr12:46970504~46972155:+
BRCA	cis	rs494453	0.557	rs2473842	ENSG00000227811.2	FAM212B-AS1	-3.56	0.00039	0.02	-0.13	-0.11	Osteoporosis-related phenotypes;	chr1:111684778	chr1:111739841~111747798:+
BRCA	cis	rs7618915	0.501	rs2289247	ENSG00000243224.1	RP5-1157M23.2	-3.56	0.00039	0.02	-0.12	-0.11	Bipolar disorder;	chr3:52693241	chr3:52239258~52241097:+
BRCA	cis	rs295490	0.667	rs78684868	ENSG00000178631.7	ACTG1P1	-3.56	0.00039	0.02	-0.21	-0.11	PR interval in Tripanosoma cruzi seropositivity;	chr3:139485651	chr3:139493809~139494937:+
BRCA	cis	rs2880765	0.835	rs6497206	ENSG00000230373.7	GOLGA6L5P	3.56	0.00039	0.02	0.12	0.11	Coronary artery disease;	chr15:85485994	chr15:84507885~84516814:-
BRCA	cis	rs4478858	0.735	rs10798843	ENSG00000223907.1	LINC01226	-3.56	0.00039	0.02	-0.13	-0.11	Alcohol dependence;	chr1:31324247	chr1:31518435~31524245:+
BRCA	cis	rs4478858	0.735	rs7526095	ENSG00000223907.1	LINC01226	-3.56	0.00039	0.02	-0.13	-0.11	Alcohol dependence;	chr1:31324734	chr1:31518435~31524245:+
BRCA	cis	rs4478858	0.735	rs6681286	ENSG00000223907.1	LINC01226	-3.56	0.00039	0.02	-0.13	-0.11	Alcohol dependence;	chr1:31326537	chr1:31518435~31524245:+
BRCA	cis	rs4478858	0.698	rs4949204	ENSG00000223907.1	LINC01226	-3.56	0.00039	0.02	-0.13	-0.11	Alcohol dependence;	chr1:31327568	chr1:31518435~31524245:+
BRCA	cis	rs4478858	0.735	rs4949205	ENSG00000223907.1	LINC01226	-3.56	0.00039	0.02	-0.13	-0.11	Alcohol dependence;	chr1:31327732	chr1:31518435~31524245:+
BRCA	cis	rs4478858	0.735	rs6687819	ENSG00000223907.1	LINC01226	-3.56	0.00039	0.02	-0.13	-0.11	Alcohol dependence;	chr1:31328265	chr1:31518435~31524245:+
BRCA	cis	rs4478858	0.698	rs7543348	ENSG00000223907.1	LINC01226	-3.56	0.00039	0.02	-0.13	-0.11	Alcohol dependence;	chr1:31331958	chr1:31518435~31524245:+
BRCA	cis	rs4478858	0.698	rs11802155	ENSG00000223907.1	LINC01226	-3.56	0.00039	0.02	-0.13	-0.11	Alcohol dependence;	chr1:31332165	chr1:31518435~31524245:+
BRCA	cis	rs4478858	0.735	rs12126725	ENSG00000223907.1	LINC01226	-3.56	0.00039	0.02	-0.13	-0.11	Alcohol dependence;	chr1:31333006	chr1:31518435~31524245:+
BRCA	cis	rs4478858	0.735	rs68008576	ENSG00000223907.1	LINC01226	-3.56	0.00039	0.02	-0.13	-0.11	Alcohol dependence;	chr1:31333058	chr1:31518435~31524245:+
BRCA	cis	rs4478858	0.735	rs11582342	ENSG00000223907.1	LINC01226	-3.56	0.00039	0.02	-0.13	-0.11	Alcohol dependence;	chr1:31337834	chr1:31518435~31524245:+
BRCA	cis	rs4478858	0.735	rs34960310	ENSG00000223907.1	LINC01226	-3.56	0.00039	0.02	-0.13	-0.11	Alcohol dependence;	chr1:31343350	chr1:31518435~31524245:+
BRCA	cis	rs4478858	0.735	rs10914361	ENSG00000223907.1	LINC01226	-3.56	0.00039	0.02	-0.13	-0.11	Alcohol dependence;	chr1:31344695	chr1:31518435~31524245:+
BRCA	cis	rs4478858	0.735	rs4531329	ENSG00000223907.1	LINC01226	-3.56	0.00039	0.02	-0.13	-0.11	Alcohol dependence;	chr1:31344963	chr1:31518435~31524245:+
BRCA	cis	rs4478858	0.709	rs3766296	ENSG00000223907.1	LINC01226	-3.56	0.00039	0.02	-0.13	-0.11	Alcohol dependence;	chr1:31347376	chr1:31518435~31524245:+
BRCA	cis	rs9392556	0.829	rs620484	ENSG00000230648.1	RP3-406P24.3	3.56	0.00039	0.02	0.14	0.11	Blood metabolite levels;	chr6:4113977	chr6:4018843~4021215:-
BRCA	cis	rs61160187	0.582	rs10939879	ENSG00000272308.1	RP11-231G3.1	-3.56	0.00039	0.02	-0.12	-0.11	Educational attainment (years of education);Educational attainment (college completion);	chr5:61019996	chr5:60866457~60866935:-
BRCA	cis	rs10876993	0.89	rs2640630	ENSG00000270039.1	RP11-571M6.17	3.56	0.00039	0.02	0.14	0.11	Celiac disease or Rheumatoid arthritis;	chr12:57673484	chr12:57803838~57804415:+
BRCA	cis	rs6929812	0.613	rs9468140	ENSG00000204789.4	ZNF204P	3.56	0.00039	0.02	0.14	0.11	Neuroticism (multi-trait analysis);	chr6:27503736	chr6:27357825~27360221:-
BRCA	cis	rs7954584	0.611	rs3887885	ENSG00000212694.7	LINC01089	-3.56	0.00039	0.02	-0.08	-0.11	Mean corpuscular volume;	chr12:121898580	chr12:121795267~121803906:-
BRCA	cis	rs10995356	0.844	rs12218430	ENSG00000238280.1	RP11-436D10.3	-3.56	0.00039	0.02	-0.14	-0.11	Temperament;	chr10:62931881	chr10:62793562~62805887:-
BRCA	cis	rs330048	0.545	rs11249913	ENSG00000233609.3	RP11-62H7.2	-3.56	0.00039	0.02	-0.11	-0.11	Systemic lupus erythematosus;	chr8:9286011	chr8:8961200~8979025:+
BRCA	cis	rs4648045	0.796	rs4648058	ENSG00000246560.2	RP11-10L12.4	3.56	0.00039	0.02	0.12	0.11	Lymphocyte percentage of white cells;	chr4:102594434	chr4:102828055~102844075:+
BRCA	cis	rs1005277	0.54	rs7903942	ENSG00000226578.1	RP11-258F22.1	3.56	0.00039	0.02	0.12	0.11	Extrinsic epigenetic age acceleration;	chr10:37640348	chr10:37775371~37784131:-
BRCA	cis	rs2274273	0.624	rs7151754	ENSG00000259318.1	RP11-454L9.2	3.56	0.00039	0.02	0.1	0.11	Protein biomarker;	chr14:55321783	chr14:55394940~55395233:-
BRCA	cis	rs10838634	1	rs61897308	ENSG00000280615.1	Y_RNA	-3.56	0.00039	0.02	-0.23	-0.11	Schizophrenia;	chr11:46812701	chr11:47614898~47614994:-
BRCA	cis	rs10876993	0.928	rs2640636	ENSG00000270039.1	RP11-571M6.17	3.56	0.00039	0.02	0.15	0.11	Celiac disease or Rheumatoid arthritis;	chr12:57683761	chr12:57803838~57804415:+
BRCA	cis	rs10876993	0.928	rs2640637	ENSG00000270039.1	RP11-571M6.17	3.56	0.00039	0.02	0.15	0.11	Celiac disease or Rheumatoid arthritis;	chr12:57683803	chr12:57803838~57804415:+
BRCA	cis	rs875971	0.83	rs12673450	ENSG00000223473.2	GS1-124K5.3	3.56	0.00039	0.02	0.09	0.11	Aortic root size;	chr7:66544233	chr7:66491049~66493566:-
BRCA	cis	rs863345	0.604	rs12044283	ENSG00000229914.1	RP11-404O13.4	-3.56	0.00039	0.02	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158494043	chr1:158195633~158196131:-
BRCA	cis	rs863345	0.604	rs12044288	ENSG00000229914.1	RP11-404O13.4	-3.56	0.00039	0.02	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158494073	chr1:158195633~158196131:-
BRCA	cis	rs863345	0.604	rs2051450	ENSG00000229914.1	RP11-404O13.4	-3.56	0.00039	0.02	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158494272	chr1:158195633~158196131:-
BRCA	cis	rs10129255	0.913	rs10140943	ENSG00000232216.1	IGHV3-43	3.56	0.00039	0.02	0.09	0.11	Kawasaki disease;	chr14:106767441	chr14:106470264~106470800:-
BRCA	cis	rs7520050	0.902	rs7514192	ENSG00000234329.1	RP11-767N6.2	-3.56	0.00039	0.02	-0.1	-0.11	Reticulocyte count;Red blood cell count;	chr1:45783305	chr1:45651039~45651826:-
BRCA	cis	rs11098499	0.863	rs1010740	ENSG00000225892.3	RP11-384K6.2	-3.56	0.00039	0.0201	-0.11	-0.11	Corneal astigmatism;	chr4:119542254	chr4:118632274~118634759:+
BRCA	cis	rs1400816	0.85	rs2028671	ENSG00000228389.1	AC068039.4	3.56	0.00039	0.0201	0.2	0.11	Amyotrophic lateral sclerosis (sporadic);	chr2:171987925	chr2:171773482~171775844:+
BRCA	cis	rs7618501	1	rs7618501	ENSG00000228008.1	CTD-2330K9.3	-3.56	0.00039	0.0201	-0.1	-0.11	Intelligence (multi-trait analysis);	chr3:49735214	chr3:49903845~49916937:+
BRCA	cis	rs7618501	1	rs7618519	ENSG00000228008.1	CTD-2330K9.3	-3.56	0.00039	0.0201	-0.1	-0.11	Intelligence (multi-trait analysis);	chr3:49735275	chr3:49903845~49916937:+
BRCA	cis	rs593531	0.513	rs7120394	ENSG00000280269.1	AP000577.2	3.56	0.00039	0.0201	0.14	0.11	Neuroticism;	chr11:74323428	chr11:74204869~74205746:+
BRCA	cis	rs654950	0.776	rs2759252	ENSG00000230638.4	RP11-486B10.4	3.56	0.00039	0.0201	0.15	0.11	Airway imaging phenotypes;	chr1:41556183	chr1:41542069~41544310:+
BRCA	cis	rs12594515	0.548	rs12912226	ENSG00000259200.1	RP11-718O11.1	-3.56	0.00039	0.0201	-0.14	-0.11	Weight;Waist circumference;	chr15:45693510	chr15:45705078~45931069:+
BRCA	cis	rs55894533	0.597	rs2645408	ENSG00000255046.1	RP11-297N6.4	-3.56	0.000391	0.0201	-0.13	-0.11	Leprosy;	chr8:11888849	chr8:11797928~11802568:-
BRCA	cis	rs17711722	0.727	rs35850374	ENSG00000227113.2	RP11-460N20.4	3.56	0.000391	0.0201	0.11	0.11	Calcium levels;	chr7:65892789	chr7:65075023~65078780:+
BRCA	cis	rs2071426	0.755	rs1934952	ENSG00000273450.1	RP11-76P2.4	-3.56	0.000391	0.0201	-0.14	-0.11	Blood metabolite levels;	chr10:95037743	chr10:94314907~94315327:-
BRCA	cis	rs375066	0.935	rs368089	ENSG00000278917.1	RP11-15A1.4	-3.56	0.000391	0.0201	-0.13	-0.11	Breast cancer;	chr19:43894932	chr19:43891233~43895411:+
BRCA	cis	rs2562456	0.833	rs552800	ENSG00000240522.1	RPL7AP10	3.56	0.000391	0.0201	0.12	0.11	Pain;	chr19:21301840	chr19:21149648~21150438:-
BRCA	cis	rs10463316	0.817	rs906679	ENSG00000260581.1	CTB-113P19.4	3.56	0.000391	0.0201	0.13	0.11	Metabolite levels (Pyroglutamine);	chr5:151399741	chr5:151652275~151655449:+
BRCA	cis	rs7520050	0.902	rs4626927	ENSG00000234329.1	RP11-767N6.2	-3.56	0.000391	0.0201	-0.1	-0.11	Reticulocyte count;Red blood cell count;	chr1:45782973	chr1:45651039~45651826:-
BRCA	cis	rs7048146	0.899	rs7861587	ENSG00000213539.4	YBX1P6	3.56	0.000391	0.0201	0.12	0.11	Vascular brain injury;	chr9:109584316	chr9:109532830~109534332:-
BRCA	cis	rs9425766	0.679	rs4650989	ENSG00000200674.1	RN7SKP160	3.56	0.000391	0.0201	0.14	0.11	Life satisfaction;	chr1:174289739	chr1:173791548~173791887:+
BRCA	cis	rs656900	0.669	rs665629	ENSG00000259548.1	RP11-38G5.2	3.56	0.000391	0.0201	0.13	0.11	Cerebrospinal P-tau181p levels;	chr15:79826889	chr15:79832466~79833554:-
BRCA	cis	rs943466	0.911	rs111352628	ENSG00000223837.2	BRD2-IT1	3.56	0.000391	0.0201	0.14	0.11	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;	chr6:33774713	chr6:32970232~32970886:+
BRCA	cis	rs801193	0.904	rs4718405	ENSG00000265600.1	AC006480.1	-3.56	0.000391	0.0201	-0.13	-0.11	Aortic root size;	chr7:66789659	chr7:67356680~67356779:+
BRCA	cis	rs6545883	0.929	rs3732171	ENSG00000212978.6	AC016747.3	3.56	0.000391	0.0201	0.15	0.11	Tuberculosis;	chr2:61522555	chr2:61141592~61144969:-
BRCA	cis	rs2839186	0.9	rs2839196	ENSG00000239415.1	AP001469.9	3.56	0.000391	0.0201	0.12	0.11	Testicular germ cell tumor;	chr21:46288123	chr21:46251549~46254133:-
BRCA	cis	rs13256369	1	rs10103769	ENSG00000254153.1	CTA-398F10.2	3.56	0.000391	0.0201	0.15	0.11	Obesity-related traits;	chr8:8715526	chr8:8456909~8461337:-
BRCA	cis	rs6942407	0.546	rs10228392	ENSG00000224046.1	AC005076.5	-3.56	0.000391	0.0201	-0.16	-0.11	Food allergy;	chr7:87170357	chr7:87151423~87152420:-
BRCA	cis	rs3219474	0.614	rs114562368	ENSG00000280836.1	AL355480.1	-3.56	0.000391	0.0201	-0.24	-0.11	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:45433506	chr1:45581219~45581321:-
BRCA	cis	rs2573652	1	rs2581345	ENSG00000254744.3	CTD-3076O17.1	-3.56	0.000391	0.0201	-0.13	-0.11	Height;	chr15:99974086	chr15:99970215~99974010:+
BRCA	cis	rs71566846	0.579	rs13210430	ENSG00000272541.1	XXbac-BPGBPG55C20.1	-3.56	0.000391	0.0201	-0.18	-0.11	Coronary artery disease;	chr6:57279854	chr6:57855891~57856468:-
BRCA	cis	rs17772222	1	rs12587386	ENSG00000258789.1	RP11-507K2.3	-3.56	0.000391	0.0201	-0.13	-0.11	Coronary artery calcification;	chr14:88361420	chr14:88551597~88552493:+
BRCA	cis	rs11892454	0.527	rs13022069	ENSG00000217643.1	PTGES3P2	-3.56	0.000391	0.0201	-0.12	-0.11	Heschl's gyrus morphology;	chr2:25844817	chr2:25822469~25822950:+
BRCA	cis	rs863345	0.604	rs2157687	ENSG00000176320.2	RP11-404O13.5	-3.56	0.000391	0.0201	-0.11	-0.11	Pneumococcal bacteremia;	chr1:158523210	chr1:158197922~158203877:-
BRCA	cis	rs863345	0.548	rs1032352	ENSG00000176320.2	RP11-404O13.5	-3.56	0.000391	0.0201	-0.11	-0.11	Pneumococcal bacteremia;	chr1:158523364	chr1:158197922~158203877:-
BRCA	cis	rs721917	0.646	rs2819096	ENSG00000242600.5	MBL1P	3.56	0.000391	0.0201	0.13	0.11	Chronic obstructive pulmonary disease;	chr10:79947857	chr10:79904898~79950336:+
BRCA	cis	rs10844706	0.699	rs10772079	ENSG00000256673.1	RP11-599J14.2	-3.56	0.000391	0.0201	-0.13	-0.11	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9721798	chr12:9398355~9414851:-
BRCA	cis	rs3820068	0.581	rs12385690	ENSG00000237301.1	RP4-680D5.2	-3.56	0.000391	0.0201	-0.14	-0.11	Systolic blood pressure;	chr1:15606437	chr1:15586136~15603626:-
BRCA	cis	rs871012	0.502	rs11951889	ENSG00000251405.2	CTB-109A12.1	-3.56	0.000392	0.0201	-0.15	-0.11	IgG glycosylation;	chr5:157449776	chr5:157362615~157460078:-
BRCA	cis	rs3617	0.599	rs12487379	ENSG00000242142.1	SERBP1P3	3.56	0.000392	0.0201	0.13	0.11	Red blood cell count;Autism spectrum disorder or schizophrenia;	chr3:52861769	chr3:53064283~53065091:-
BRCA	cis	rs4849845	0.637	rs62168279	ENSG00000223549.1	MTND5P28	3.56	0.000392	0.0201	0.13	0.11	Mean platelet volume;	chr2:120269195	chr2:120215181~120217279:+
BRCA	cis	rs10883723	0.962	rs11191294	ENSG00000213061.2	PFN1P11	-3.56	0.000392	0.0201	-0.15	-0.11	Allergic disease (asthma, hay fever or eczema);	chr10:102466080	chr10:102838011~102845473:-
BRCA	cis	rs2688482	0.557	rs2550236	ENSG00000242086.7	LINC00969	3.56	0.000392	0.0201	0.15	0.11	Lung disease severity in cystic fibrosis;	chr3:195795450	chr3:195658062~195739964:+
BRCA	cis	rs2562456	0.793	rs7259708	ENSG00000268119.4	CTD-2561J22.5	3.56	0.000392	0.0201	0.17	0.11	Pain;	chr19:21567846	chr19:21444241~21463908:-
BRCA	cis	rs9866825	0.935	rs1386963	ENSG00000227110.5	LMCD1-AS1	3.56	0.000392	0.0201	0.13	0.11	QT interval;	chr3:8204618	chr3:7952805~8611924:-
BRCA	cis	rs863345	0.527	rs7514555	ENSG00000229914.1	RP11-404O13.4	-3.56	0.000392	0.0201	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158475348	chr1:158195633~158196131:-
BRCA	cis	rs863345	0.604	rs11264976	ENSG00000229914.1	RP11-404O13.4	-3.56	0.000392	0.0201	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158477137	chr1:158195633~158196131:-
BRCA	cis	rs863345	0.604	rs11264977	ENSG00000229914.1	RP11-404O13.4	-3.56	0.000392	0.0201	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158478062	chr1:158195633~158196131:-
BRCA	cis	rs10838634	1	rs4128315	ENSG00000280615.1	Y_RNA	-3.56	0.000392	0.0201	-0.19	-0.11	Schizophrenia;	chr11:46815651	chr11:47614898~47614994:-
BRCA	cis	rs10838634	1	rs7106323	ENSG00000280615.1	Y_RNA	-3.56	0.000392	0.0201	-0.19	-0.11	Schizophrenia;	chr11:46821290	chr11:47614898~47614994:-
BRCA	cis	rs10838634	1	rs12287376	ENSG00000280615.1	Y_RNA	-3.56	0.000392	0.0201	-0.19	-0.11	Schizophrenia;	chr11:46835508	chr11:47614898~47614994:-
BRCA	cis	rs3740393	0.562	rs11191393	ENSG00000213277.3	MARCKSL1P1	-3.56	0.000392	0.0201	-0.16	-0.11	Microalbuminuria;	chr10:102767673	chr10:103175554~103176094:+
BRCA	cis	rs17270561	0.609	rs17267614	ENSG00000272462.2	U91328.19	-3.56	0.000392	0.0201	-0.14	-0.11	Iron status biomarkers;	chr6:25729799	chr6:25992662~26001775:+
BRCA	cis	rs12738007	0.84	rs1565714	ENSG00000277916.1	uc_338	3.56	0.000392	0.0201	0.09	0.11	Schizophrenia;	chr1:29247851	chr1:29171285~29171453:-
BRCA	cis	rs6446731	0.734	rs7675084	ENSG00000261643.1	RP11-529E10.6	-3.56	0.000392	0.0201	-0.12	-0.11	Mean platelet volume;	chr4:3272181	chr4:3503597~3504457:-
BRCA	cis	rs7572733	0.935	rs7571869	ENSG00000231621.1	AC013264.2	-3.56	0.000392	0.0201	-0.1	-0.11	Dermatomyositis;	chr2:197976891	chr2:197197991~197199273:+
BRCA	cis	rs735860	0.763	rs1346603	ENSG00000271367.1	RP3-483K16.4	-3.56	0.000392	0.0201	-0.11	-0.11	Glaucoma;	chr6:53284464	chr6:53350158~53350705:+
BRCA	cis	rs8030379	1	rs4842838	ENSG00000176700.18	SCAND2P	3.56	0.000392	0.0201	0.1	0.11	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83913372	chr15:84631451~84647478:+
BRCA	cis	rs2333021	0.934	rs7155380	ENSG00000259015.1	RP11-109N23.6	3.56	0.000392	0.0201	0.11	0.11	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:73014626	chr14:72960595~72961993:+
BRCA	cis	rs2562456	0.561	rs12610883	ENSG00000268555.1	RP11-678G14.3	3.56	0.000392	0.0201	0.14	0.11	Pain;	chr19:21567257	chr19:21570822~21587322:-
BRCA	cis	rs2562456	0.837	rs11085462	ENSG00000268555.1	RP11-678G14.3	3.56	0.000392	0.0201	0.14	0.11	Pain;	chr19:21567449	chr19:21570822~21587322:-
BRCA	cis	rs7267979	1	rs13038834	ENSG00000274973.1	RP13-401N8.7	-3.56	0.000392	0.0201	-0.13	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25460797	chr20:25845497~25845862:+
BRCA	cis	rs877819	0.697	rs10776650	ENSG00000228403.1	RP11-563N6.6	-3.56	0.000392	0.0201	-0.12	-0.11	Systemic lupus erythematosus;	chr10:48839229	chr10:48878022~48878649:+
BRCA	cis	rs2408955	0.504	rs11168441	ENSG00000226413.2	OR8T1P	-3.56	0.000392	0.0201	-0.25	-0.11	Glycated hemoglobin levels;	chr12:48182271	chr12:48442030~48442947:-
BRCA	cis	rs74233809	1	rs12219304	ENSG00000236937.2	PTGES3P4	3.56	0.000392	0.0201	0.24	0.11	Birth weight;	chr10:103171827	chr10:102845595~102845950:+
BRCA	cis	rs6504622	0.755	rs34774205	ENSG00000263142.4	LRRC37A17P	-3.56	0.000392	0.0201	-0.09	-0.11	Orofacial clefts;	chr17:47083453	chr17:46978481~47054569:+
BRCA	cis	rs8180040	0.966	rs11130137	ENSG00000276925.1	RP11-708J19.3	-3.56	0.000392	0.0201	-0.13	-0.11	Colorectal cancer;	chr3:47537348	chr3:47469777~47469987:+
BRCA	cis	rs10819083	0.681	rs7875710	ENSG00000232630.1	PRPS1P2	-3.56	0.000392	0.0201	-0.11	-0.11	Squamous cell lung carcinoma;	chr9:125835113	chr9:125150653~125151589:+
BRCA	cis	rs17507216	0.591	rs7163848	ENSG00000276710.3	CSPG4P8	-3.56	0.000392	0.0201	-0.15	-0.11	Excessive daytime sleepiness;	chr15:82729563	chr15:82459472~82477258:+
BRCA	cis	rs957448	0.507	rs1984711	ENSG00000254315.1	RP11-267M23.3	3.56	0.000392	0.0201	0.14	0.11	Nonsyndromic cleft lip with cleft palate;	chr8:94600276	chr8:94533628~94534391:+
BRCA	cis	rs860818	1	rs858252	ENSG00000230658.1	KLHL7-AS1	-3.56	0.000392	0.0201	-0.28	-0.11	Initial pursuit acceleration;	chr7:23178253	chr7:23101228~23105703:-
BRCA	cis	rs860818	1	rs858250	ENSG00000230658.1	KLHL7-AS1	-3.56	0.000392	0.0201	-0.28	-0.11	Initial pursuit acceleration;	chr7:23178941	chr7:23101228~23105703:-
BRCA	cis	rs699371	0.525	rs1156021	ENSG00000259005.1	RP3-449M8.6	3.56	0.000392	0.0201	0.13	0.11	Height;	chr14:74432889	chr14:74474007~74474864:-
BRCA	cis	rs4415084	1	rs4419600	ENSG00000272335.1	RP11-53O19.3	3.56	0.000392	0.0201	0.1	0.11	Breast cancer;	chr5:44678432	chr5:44826076~44828592:+
BRCA	cis	rs3824867	0.92	rs7105907	ENSG00000280615.1	Y_RNA	3.56	0.000392	0.0201	0.13	0.11	Mean corpuscular hemoglobin;	chr11:47428767	chr11:47614898~47614994:-
BRCA	cis	rs3824867	0.92	rs9734013	ENSG00000280615.1	Y_RNA	3.56	0.000392	0.0201	0.13	0.11	Mean corpuscular hemoglobin;	chr11:47429966	chr11:47614898~47614994:-
BRCA	cis	rs3824867	0.92	rs9919526	ENSG00000280615.1	Y_RNA	3.56	0.000392	0.0201	0.13	0.11	Mean corpuscular hemoglobin;	chr11:47430072	chr11:47614898~47614994:-
BRCA	cis	rs875971	0.755	rs76288834	ENSG00000273024.4	INTS4P2	3.56	0.000392	0.0201	0.12	0.11	Aortic root size;	chr7:66604815	chr7:65647864~65715661:+
BRCA	cis	rs2274273	0.624	rs7154796	ENSG00000259318.1	RP11-454L9.2	3.56	0.000392	0.0201	0.1	0.11	Protein biomarker;	chr14:55304740	chr14:55394940~55395233:-
BRCA	cis	rs77320796	1	rs11207138	ENSG00000259943.1	RP1-39G22.7	3.56	0.000392	0.0201	0.11	0.11	Platelet count;	chr1:39926485	chr1:40256427~40257967:-
BRCA	cis	rs313426	0.5	rs4754960	ENSG00000260966.1	RP11-690D19.3	3.56	0.000392	0.0201	0.13	0.11	Toenail selenium levels;	chr11:103541415	chr11:103050687~103055799:-
BRCA	cis	rs61160187	0.582	rs1471488	ENSG00000272308.1	RP11-231G3.1	-3.56	0.000392	0.0201	-0.12	-0.11	Educational attainment (years of education);Educational attainment (college completion);	chr5:60990270	chr5:60866457~60866935:-
BRCA	cis	rs1876206	0.554	rs585256	ENSG00000274654.1	CTD-3247H4.2	3.56	0.000392	0.0201	0.13	0.11	Breast cancer;	chr15:48607548	chr15:48528980~48529728:-
BRCA	cis	rs2835872	0.965	rs2835850	ENSG00000228677.1	TTC3-AS1	-3.56	0.000392	0.0201	-0.14	-0.11	Electroencephalographic traits in alcoholism;	chr21:37640675	chr21:37187666~37193926:-
BRCA	cis	rs4243971	0.516	rs11699120	ENSG00000275576.1	RP5-836N17.4	-3.56	0.000393	0.0201	-0.12	-0.11	Inflammatory bowel disease;Crohn's disease;	chr20:32361172	chr20:32116171~32116629:+
BRCA	cis	rs7592578	0.599	rs62180992	ENSG00000272979.1	RP11-647K16.1	-3.56	0.000393	0.0201	-0.18	-0.11	Diastolic blood pressure;	chr2:190421006	chr2:190454092~190454521:-
BRCA	cis	rs754466	0.58	rs10762765	ENSG00000213514.2	RP11-428P16.2	3.56	0.000393	0.0201	0.15	0.11	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77806649	chr10:77730766~77734769:+
BRCA	cis	rs7577696	0.924	rs11124277	ENSG00000276334.1	AL133243.1	-3.56	0.000393	0.0201	-0.14	-0.11	Inflammatory biomarkers;	chr2:32095301	chr2:32521927~32523547:+
BRCA	cis	rs7712401	0.686	rs154511	ENSG00000251538.4	RP11-166A12.1	3.56	0.000393	0.0201	0.12	0.11	Mean platelet volume;	chr5:122859859	chr5:122628952~122730685:-
BRCA	cis	rs11893307	0.566	rs62179714	ENSG00000235852.1	AC005540.3	3.56	0.000393	0.0201	0.14	0.11	Mean platelet volume;	chr2:190702815	chr2:190880797~190882059:-
BRCA	cis	rs6001482	0.533	rs12484704	ENSG00000223350.2	IGLV9-49	-3.56	0.000393	0.0201	-0.11	-0.11	Diastolic blood pressure;	chr22:22228856	chr22:22343187~22343732:+
BRCA	cis	rs1816752	0.905	rs7571	ENSG00000273628.1	RP11-756A22.7	3.56	0.000393	0.0201	0.14	0.11	Obesity-related traits;	chr13:24426479	chr13:24933006~24936796:+
BRCA	cis	rs240993	0.812	rs9374262	ENSG00000271789.1	RP5-1112D6.7	3.56	0.000393	0.0201	0.15	0.11	Inflammatory skin disease;Psoriasis;	chr6:111553772	chr6:111297126~111298510:+
BRCA	cis	rs875971	0.862	rs801194	ENSG00000271064.1	RP11-792A8.3	3.56	0.000393	0.0201	0.13	0.11	Aortic root size;	chr7:66563508	chr7:66748838~66749077:-
BRCA	cis	rs3916	0.911	rs12829722	ENSG00000277423.1	RP11-173P15.9	-3.56	0.000393	0.0201	-0.15	-0.11	Urinary metabolites (H-NMR features);	chr12:120717819	chr12:120703867~120704282:+
BRCA	cis	rs35520189	0.961	rs13008855	ENSG00000274877.1	RP11-65I12.1	3.56	0.000393	0.0202	0.16	0.11	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:112851991	chr2:113237595~113240825:+
BRCA	cis	rs4714291	0.962	rs847744	ENSG00000180211.5	RP1-278E11.3	3.56	0.000393	0.0202	0.12	0.11	Strep throat;	chr6:40117506	chr6:39958414~39958833:-
BRCA	cis	rs9868809	0.505	rs73080312	ENSG00000270441.1	RP11-694I15.7	3.56	0.000393	0.0202	0.26	0.11	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48700414	chr3:49140086~49160851:-
BRCA	cis	rs11098499	0.954	rs10031483	ENSG00000225892.3	RP11-384K6.2	3.56	0.000393	0.0202	0.11	0.11	Corneal astigmatism;	chr4:119501481	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.954	rs10031665	ENSG00000225892.3	RP11-384K6.2	3.56	0.000393	0.0202	0.11	0.11	Corneal astigmatism;	chr4:119501697	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.954	rs3733523	ENSG00000225892.3	RP11-384K6.2	3.56	0.000393	0.0202	0.11	0.11	Corneal astigmatism;	chr4:119502564	chr4:118632274~118634759:+
BRCA	cis	rs7944584	0.511	rs10838731	ENSG00000280615.1	Y_RNA	3.56	0.000393	0.0202	0.14	0.11	Fasting blood glucose;Fasting blood glucose (BMI interaction);	chr11:47585583	chr11:47614898~47614994:-
BRCA	cis	rs324126	0.78	rs11084155	ENSG00000277977.1	CTD-3018O17.5	3.56	0.000393	0.0202	0.13	0.11	Colonoscopy-negative controls vs population controls;	chr19:52383613	chr19:52392659~52392755:+
BRCA	cis	rs324126	0.752	rs11084156	ENSG00000277977.1	CTD-3018O17.5	3.56	0.000393	0.0202	0.13	0.11	Colonoscopy-negative controls vs population controls;	chr19:52383634	chr19:52392659~52392755:+
BRCA	cis	rs603446	0.901	rs180344	ENSG00000246100.3	LINC00900	-3.56	0.000393	0.0202	-0.12	-0.11	Triglycerides;	chr11:116742468	chr11:115754248~115760627:-
BRCA	cis	rs11773103	0.881	rs11771569	ENSG00000224046.1	AC005076.5	3.56	0.000393	0.0202	0.23	0.11	Bipolar disorder or major depressive disorder (combined);	chr7:87208752	chr7:87151423~87152420:-
BRCA	cis	rs10975870	0.847	rs10815486	ENSG00000232946.1	RP11-390F4.2	3.56	0.000393	0.0202	0.14	0.11	Body mass index;	chr9:6942110	chr9:6675284~6675614:+
BRCA	cis	rs2216824	1	rs80198396	ENSG00000278908.1	RP11-523J2.1	3.56	0.000393	0.0202	0.19	0.11	Oropharynx cancer;	chr2:30882719	chr2:30677762~30679895:+
BRCA	cis	rs1005277	0.505	rs1208689	ENSG00000273019.1	RP11-508N22.13	-3.56	0.000393	0.0202	-0.13	-0.11	Extrinsic epigenetic age acceleration;	chr10:37808847	chr10:38149968~38150293:+
BRCA	cis	rs71520386	0.846	rs35247857	ENSG00000179428.2	AC073072.5	3.56	0.000393	0.0202	0.15	0.11	Fibrinogen levels;	chr7:22780901	chr7:22725395~22727620:-
BRCA	cis	rs863345	0.604	rs1894040	ENSG00000229914.1	RP11-404O13.4	3.56	0.000393	0.0202	0.12	0.11	Pneumococcal bacteremia;	chr1:158486546	chr1:158195633~158196131:-
BRCA	cis	rs17214007	0.877	rs11644832	ENSG00000279866.1	CTB-193M12.4	3.56	0.000393	0.0202	0.16	0.11	Cognitive function;	chr16:15778891	chr16:15704410~15705984:+
BRCA	cis	rs17214007	0.877	rs11645883	ENSG00000279866.1	CTB-193M12.4	3.56	0.000393	0.0202	0.16	0.11	Cognitive function;	chr16:15778950	chr16:15704410~15705984:+
BRCA	cis	rs13434995	0.513	rs13134079	ENSG00000249700.7	SRD5A3-AS1	3.56	0.000393	0.0202	0.16	0.11	Adiponectin levels;	chr4:55542021	chr4:55363971~55395847:-
BRCA	cis	rs11673344	0.698	rs56161518	ENSG00000267682.1	CTD-3220F14.2	-3.56	0.000393	0.0202	-0.11	-0.11	Obesity-related traits;	chr19:36978555	chr19:37337236~37337743:+
BRCA	cis	rs9287719	0.81	rs7601748	ENSG00000224177.5	LINC00570	3.56	0.000393	0.0202	0.13	0.11	Prostate cancer;	chr2:10645320	chr2:11393981~11403077:+
BRCA	cis	rs73201462	1	rs11716941	ENSG00000242551.2	POU5F1P6	-3.56	0.000393	0.0202	-0.19	-0.11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128156531	chr3:128674735~128677005:-
BRCA	cis	rs12118297	1	rs17129944	ENSG00000261737.1	RP4-612B15.3	-3.56	0.000393	0.0202	-0.16	-0.11	Breast cancer;	chr1:87307088	chr1:86703502~86704462:-
BRCA	cis	rs1008375	0.966	rs6839660	ENSG00000249502.1	AC006160.5	-3.56	0.000393	0.0202	-0.12	-0.11	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17666364	chr4:17587467~17614571:-
BRCA	cis	rs7824557	0.591	rs2736282	ENSG00000255046.1	RP11-297N6.4	-3.56	0.000393	0.0202	-0.13	-0.11	Retinal vascular caliber;	chr8:11367971	chr8:11797928~11802568:-
BRCA	cis	rs427943	0.646	rs7281757	ENSG00000184274.3	LINC00315	-3.56	0.000393	0.0202	-0.15	-0.11	Body mass index;	chr21:45216246	chr21:45300245~45305257:-
BRCA	cis	rs11892454	0.565	rs10191905	ENSG00000217643.1	PTGES3P2	-3.56	0.000393	0.0202	-0.12	-0.11	Heschl's gyrus morphology;	chr2:25795975	chr2:25822469~25822950:+
BRCA	cis	rs7746199	0.673	rs35501037	ENSG00000216901.1	AL022393.7	3.56	0.000393	0.0202	0.27	0.11	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27771787	chr6:28176188~28176674:+
BRCA	cis	rs10971721	0.584	rs10971938	ENSG00000279489.1	RP11-392A14.8	-3.56	0.000393	0.0202	-0.21	-0.11	Body mass index;	chr9:34120722	chr9:35001913~35003663:+
BRCA	cis	rs853679	0.546	rs200953	ENSG00000216901.1	AL022393.7	3.56	0.000393	0.0202	0.21	0.11	Depression;	chr6:27869489	chr6:28176188~28176674:+
BRCA	cis	rs62458065	0.85	rs62458099	ENSG00000273014.1	RP11-225B17.2	-3.56	0.000393	0.0202	-0.17	-0.11	Metabolite levels (HVA/MHPG ratio);	chr7:32432783	chr7:32758882~32759353:+
BRCA	cis	rs62458065	0.85	rs62458100	ENSG00000273014.1	RP11-225B17.2	-3.56	0.000393	0.0202	-0.17	-0.11	Metabolite levels (HVA/MHPG ratio);	chr7:32433530	chr7:32758882~32759353:+
BRCA	cis	rs4650943	0.508	rs10913143	ENSG00000227740.1	RP11-318C24.2	3.56	0.000393	0.0202	0.11	0.11	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in inactive individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr1:176142623	chr1:175904762~175920513:-
BRCA	cis	rs11673344	0.704	rs510757	ENSG00000267422.1	CTD-2554C21.1	-3.56	0.000394	0.0202	-0.14	-0.11	Obesity-related traits;	chr19:36931900	chr19:37779686~37792865:+
BRCA	cis	rs67478160	0.643	rs8005594	ENSG00000269910.1	RP11-73M18.10	3.56	0.000394	0.0202	0.1	0.11	Schizophrenia;	chr14:103813552	chr14:103694516~103695050:-
BRCA	cis	rs12477438	0.953	rs3851334	ENSG00000231822.1	AC019097.7	-3.56	0.000394	0.0202	-0.14	-0.11	Chronic sinus infection;	chr2:99178241	chr2:99102018~99102752:+
BRCA	cis	rs72928364	0.858	rs16843198	ENSG00000256628.3	ZBTB11-AS1	-3.56	0.000394	0.0202	-0.2	-0.11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:101064231	chr3:101676475~101679217:+
BRCA	cis	rs3862030	0.503	rs6584505	ENSG00000213061.2	PFN1P11	-3.56	0.000394	0.0202	-0.15	-0.11	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr10:102494655	chr10:102838011~102845473:-
BRCA	cis	rs40067	1	rs288151	ENSG00000272523.1	LINC01023	3.56	0.000394	0.0202	0.12	0.11	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr5:108041637	chr5:108727825~108728260:-
BRCA	cis	rs10771431	0.597	rs7976807	ENSG00000256673.1	RP11-599J14.2	3.56	0.000394	0.0202	0.12	0.11	Breast size;	chr12:9199863	chr12:9398355~9414851:-
BRCA	cis	rs2462686	0.93	rs2462687	ENSG00000229628.1	AC073115.7	3.56	0.000394	0.0202	0.13	0.11	Major depressive disorder;	chr7:45942707	chr7:45990905~46000898:+
BRCA	cis	rs4767841	0.935	rs3213625	ENSG00000248636.5	RP11-768F21.1	-3.56	0.000394	0.0202	-0.14	-0.11	Urgency urinary incontinence;	chr12:119720724	chr12:119387987~119668079:-
BRCA	cis	rs4767841	0.935	rs3213626	ENSG00000248636.5	RP11-768F21.1	-3.56	0.000394	0.0202	-0.14	-0.11	Urgency urinary incontinence;	chr12:119720736	chr12:119387987~119668079:-
BRCA	cis	rs10944	0.598	rs594686	ENSG00000253558.1	CTD-2179L22.1	-3.56	0.000394	0.0202	-0.13	-0.11	Blood and toenail selenium levels;	chr5:78979945	chr5:78041879~78044138:-
BRCA	cis	rs34792	0.688	rs153786	ENSG00000275910.1	RP11-680G24.6	-3.56	0.000394	0.0202	-0.13	-0.11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15499857	chr16:15015828~15016390:-
BRCA	cis	rs56046484	0.871	rs7177110	ENSG00000259774.1	RP11-182J1.13	3.56	0.000394	0.0202	0.17	0.11	Testicular germ cell tumor;	chr15:85128524	chr15:84422618~84425882:+
BRCA	cis	rs17711722	0.701	rs55773927	ENSG00000227113.2	RP11-460N20.4	3.56	0.000394	0.0202	0.11	0.11	Calcium levels;	chr7:65872915	chr7:65075023~65078780:+
BRCA	cis	rs721917	0.506	rs2758555	ENSG00000225484.5	NUTM2B-AS1	-3.56	0.000394	0.0202	-0.15	-0.11	Chronic obstructive pulmonary disease;	chr10:79931278	chr10:79663088~79826594:-
BRCA	cis	rs10782582	0.593	rs4646960	ENSG00000181227.3	RP4-682C21.2	3.56	0.000394	0.0202	0.11	0.11	Daytime sleep phenotypes;	chr1:75745418	chr1:75743423~75744776:-
BRCA	cis	rs7267979	1	rs1888997	ENSG00000274973.1	RP13-401N8.7	3.56	0.000394	0.0202	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25318352	chr20:25845497~25845862:+
BRCA	cis	rs10043775	0.958	rs12717974	ENSG00000251330.3	CTD-2283N19.1	-3.56	0.000394	0.0202	-0.13	-0.11	Periodontal microbiota;	chr5:148449614	chr5:148430159~148430807:-
BRCA	cis	rs2905347	0.755	rs2961288	ENSG00000232949.1	AC002480.4	-3.56	0.000394	0.0202	-0.13	-0.11	Major depression and alcohol dependence;	chr7:22625510	chr7:22589705~22591622:+
BRCA	cis	rs8098244	0.603	rs1711455	ENSG00000265752.2	RP11-403A21.1	3.56	0.000394	0.0202	0.12	0.11	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23695207	chr18:23957754~23982556:-
BRCA	cis	rs5742933	1	rs1966729	ENSG00000253559.1	OSGEPL1-AS1	-3.56	0.000394	0.0202	-0.15	-0.11	Ferritin levels;	chr2:189721105	chr2:189762704~189765556:+
BRCA	cis	rs13126694	0.65	rs6536287	ENSG00000248429.4	RP11-597D13.9	-3.56	0.000394	0.0202	-0.1	-0.11	Blood osmolality (transformed sodium);	chr4:157921400	chr4:158170752~158202877:+
BRCA	cis	rs1865760	0.964	rs6932113	ENSG00000272810.1	U91328.22	-3.56	0.000394	0.0202	-0.13	-0.11	Height;	chr6:25912870	chr6:26013241~26013757:+
BRCA	cis	rs6452790	0.529	rs1569187	ENSG00000247828.6	TMEM161B-AS1	-3.56	0.000394	0.0202	-0.14	-0.11	Cognitive function;	chr5:87960989	chr5:88268895~88436685:+
BRCA	cis	rs2243480	1	rs316330	ENSG00000229180.5	GS1-124K5.11	3.56	0.000394	0.0202	0.15	0.11	Diabetic kidney disease;	chr7:66140385	chr7:66526088~66542624:-
BRCA	cis	rs2853668	1	rs2853668	ENSG00000232615.4	CTD-2012J19.1	-3.56	0.000394	0.0202	-0.14	-0.11	Nasopharyngeal carcinoma;	chr5:1299910	chr5:1614836~1616334:+
BRCA	cis	rs8098244	0.861	rs8099617	ENSG00000265752.2	RP11-403A21.1	3.56	0.000394	0.0202	0.13	0.11	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23828815	chr18:23957754~23982556:-
BRCA	cis	rs4415084	0.716	rs7703497	ENSG00000248779.1	RP11-53O19.2	3.56	0.000394	0.0202	0.1	0.11	Breast cancer;	chr5:44856926	chr5:44752949~44765744:+
BRCA	cis	rs4869313	0.668	rs1216569	ENSG00000248734.2	CTD-2260A17.1	3.56	0.000394	0.0202	0.11	0.11	Pediatric autoimmune diseases;	chr5:96926830	chr5:96784777~96785999:+
BRCA	cis	rs6071166	0.683	rs6071145	ENSG00000224635.1	RP4-564F22.5	-3.56	0.000394	0.0202	-0.13	-0.11	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38699933	chr20:38406011~38416797:-
BRCA	cis	rs2154319	0.887	rs9439033	ENSG00000230638.4	RP11-486B10.4	-3.56	0.000394	0.0202	-0.18	-0.11	Height;	chr1:41060351	chr1:41542069~41544310:+
BRCA	cis	rs2243480	1	rs781156	ENSG00000226767.1	RP11-328P23.3	-3.56	0.000394	0.0202	-0.19	-0.11	Diabetic kidney disease;	chr7:66014154	chr7:65508773~65508944:-
BRCA	cis	rs2243480	1	rs451396	ENSG00000226767.1	RP11-328P23.3	-3.56	0.000394	0.0202	-0.19	-0.11	Diabetic kidney disease;	chr7:66019087	chr7:65508773~65508944:-
BRCA	cis	rs2243480	1	rs1715235	ENSG00000226767.1	RP11-328P23.3	-3.56	0.000394	0.0202	-0.19	-0.11	Diabetic kidney disease;	chr7:66023407	chr7:65508773~65508944:-
BRCA	cis	rs7729723	0.591	rs4835796	ENSG00000253404.1	AC034243.1	-3.56	0.000394	0.0202	-0.14	-0.11	Amyotrophic lateral sclerosis (C9orf72 mutation interaction);	chr5:138446426	chr5:138744434~138753309:-
BRCA	cis	rs2832077	0.943	rs2832091	ENSG00000236056.1	GAPDHP14	3.56	0.000394	0.0202	0.16	0.11	Cognitive test performance;	chr21:28790533	chr21:29222321~29223257:+
BRCA	cis	rs10464366	0.798	rs6945380	ENSG00000233306.2	TRGV2	3.56	0.000395	0.0202	0.1	0.11	IgG glycosylation;	chr7:39075615	chr7:38362864~38363518:-
BRCA	cis	rs1670533	1	rs7685541	ENSG00000251639.2	RP11-20I20.1	3.56	0.000395	0.0202	0.18	0.11	Recombination rate (females);	chr4:1064713	chr4:1100016~1101558:-
BRCA	cis	rs10838634	1	rs7115986	ENSG00000280615.1	Y_RNA	-3.56	0.000395	0.0202	-0.19	-0.11	Schizophrenia;	chr11:46807624	chr11:47614898~47614994:-
BRCA	cis	rs3753275	0.69	rs10864355	ENSG00000232912.4	RP5-1115A15.1	3.56	0.000395	0.0202	0.14	0.11	Educational attainment;	chr1:8506241	chr1:8424645~8434838:+
BRCA	cis	rs375066	0.935	rs421512	ENSG00000278917.1	RP11-15A1.4	-3.56	0.000395	0.0202	-0.13	-0.11	Breast cancer;	chr19:43911428	chr19:43891233~43895411:+
BRCA	cis	rs4713118	0.662	rs9380046	ENSG00000226314.6	ZNF192P1	-3.56	0.000395	0.0202	-0.16	-0.11	Parkinson's disease;	chr6:28062721	chr6:28161781~28169594:+
BRCA	cis	rs6500637	0.591	rs2075466	ENSG00000267077.1	RP11-127I20.5	3.56	0.000395	0.0202	0.12	0.11	Cancer;	chr16:4822969	chr16:4795265~4796532:-
BRCA	cis	rs38055	0.846	rs454780	ENSG00000247796.2	CTD-2366F13.1	-3.56	0.000395	0.0202	-0.12	-0.11	Acne (severe);	chr5:53282178	chr5:53109842~53115126:+
BRCA	cis	rs2216824	0.908	rs76790836	ENSG00000278908.1	RP11-523J2.1	3.56	0.000395	0.0202	0.19	0.11	Oropharynx cancer;	chr2:30884093	chr2:30677762~30679895:+
BRCA	cis	rs9785234	0.793	rs10819948	ENSG00000175611.10	LINC00476	3.56	0.000395	0.0202	0.13	0.11	Glomerular filtration rate in chronic kidney disease;	chr9:96171481	chr9:95759231~95875977:-
BRCA	cis	rs7267979	0.565	rs13040726	ENSG00000274973.1	RP13-401N8.7	3.56	0.000395	0.0202	0.12	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25579245	chr20:25845497~25845862:+
BRCA	cis	rs4533720	0.578	rs13114716	ENSG00000248546.3	ANP32C	-3.56	0.000395	0.0202	-0.12	-0.11	Urinary uromodulin levels;	chr4:164047925	chr4:164197007~164197711:-
BRCA	cis	rs2835345	0.563	rs58602880	ENSG00000214914.3	RPL23AP3	-3.55	0.000395	0.0202	-0.15	-0.11	Pulmonary function;	chr21:36454610	chr21:36016079~36016546:-
BRCA	cis	rs9788721	1	rs10519203	ENSG00000261762.1	RP11-650L12.2	3.55	0.000395	0.0202	0.13	0.11	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78521704	chr15:78589123~78591276:-
BRCA	cis	rs10883723	0.81	rs17782574	ENSG00000213061.2	PFN1P11	-3.55	0.000395	0.0203	-0.15	-0.11	Allergic disease (asthma, hay fever or eczema);	chr10:102519637	chr10:102838011~102845473:-
BRCA	cis	rs875971	1	rs11971949	ENSG00000272831.1	RP11-792A8.4	-3.55	0.000395	0.0203	-0.1	-0.11	Aortic root size;	chr7:66161027	chr7:66739829~66740385:-
BRCA	cis	rs10504130	0.569	rs12679983	ENSG00000272076.1	RP11-11C20.3	3.55	0.000395	0.0203	0.16	0.11	Venous thromboembolism (SNP x SNP interaction);	chr8:51765596	chr8:51810110~51810681:-
BRCA	cis	rs890448	0.796	rs6816400	ENSG00000254531.1	FLJ20021	3.55	0.000395	0.0203	0.13	0.11	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101367295	chr4:101347780~101348883:+
BRCA	cis	rs7618501	1	rs11130218	ENSG00000228008.1	CTD-2330K9.3	-3.55	0.000395	0.0203	-0.1	-0.11	Intelligence (multi-trait analysis);	chr3:49714939	chr3:49903845~49916937:+
BRCA	cis	rs7267979	1	rs6083804	ENSG00000274414.1	RP5-965G21.4	3.55	0.000395	0.0203	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25336424	chr20:25239007~25245229:-
BRCA	cis	rs7267979	1	rs4815405	ENSG00000274414.1	RP5-965G21.4	3.55	0.000395	0.0203	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25336856	chr20:25239007~25245229:-
BRCA	cis	rs7267979	1	rs6050542	ENSG00000274414.1	RP5-965G21.4	3.55	0.000395	0.0203	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25338243	chr20:25239007~25245229:-
BRCA	cis	rs9967417	0.523	rs7506068	ENSG00000266696.1	RP11-30L3.2	3.55	0.000395	0.0203	0.12	0.11	Height;	chr18:49358279	chr18:49205912~49208781:+
BRCA	cis	rs7267979	1	rs6076336	ENSG00000274414.1	RP5-965G21.4	3.55	0.000395	0.0203	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25338576	chr20:25239007~25245229:-
BRCA	cis	rs470089	1	rs138118	ENSG00000261251.1	RP3-388M5.9	3.55	0.000395	0.0203	0.15	0.11	Type 2 diabetes (dietary heme iron intake interaction);	chr22:43868622	chr22:43812456~43817394:+
BRCA	cis	rs2562456	0.833	rs62109229	ENSG00000240522.1	RPL7AP10	-3.55	0.000395	0.0203	-0.13	-0.11	Pain;	chr19:21354380	chr19:21149648~21150438:-
BRCA	cis	rs2562456	0.833	rs11670815	ENSG00000240522.1	RPL7AP10	-3.55	0.000395	0.0203	-0.13	-0.11	Pain;	chr19:21356515	chr19:21149648~21150438:-
BRCA	cis	rs2562456	0.833	rs11666540	ENSG00000240522.1	RPL7AP10	-3.55	0.000395	0.0203	-0.13	-0.11	Pain;	chr19:21356550	chr19:21149648~21150438:-
BRCA	cis	rs2562456	0.833	rs11667361	ENSG00000240522.1	RPL7AP10	-3.55	0.000395	0.0203	-0.13	-0.11	Pain;	chr19:21356580	chr19:21149648~21150438:-
BRCA	cis	rs1816752	0.749	rs77832754	ENSG00000273628.1	RP11-756A22.7	3.55	0.000395	0.0203	0.13	0.11	Obesity-related traits;	chr13:24416016	chr13:24933006~24936796:+
BRCA	cis	rs11122895	0.527	rs10186692	ENSG00000236307.2	EEF1E1P1	3.55	0.000395	0.0203	0.12	0.11	Allergic sensitization;	chr2:111686719	chr2:111887914~111888741:+
BRCA	cis	rs6714710	0.603	rs13023980	ENSG00000228486.8	LINC01125	-3.55	0.000395	0.0203	-0.1	-0.11	Posterior cortical atrophy and Alzheimer's disease;	chr2:97886524	chr2:97664217~97703064:+
BRCA	cis	rs17826219	0.789	rs4794873	ENSG00000280069.1	CTD-2349P21.3	-3.55	0.000395	0.0203	-0.16	-0.11	Body mass index;	chr17:30421334	chr17:30738182~30740275:+
BRCA	cis	rs330048	0.545	rs11774353	ENSG00000254153.1	CTA-398F10.2	3.55	0.000395	0.0203	0.14	0.11	Systemic lupus erythematosus;	chr8:9295617	chr8:8456909~8461337:-
BRCA	cis	rs7302981	0.692	rs1979702	ENSG00000272368.2	RP4-605O3.4	-3.55	0.000395	0.0203	-0.11	-0.11	Systolic blood pressure;	chr12:50068864	chr12:50112197~50165618:+
BRCA	cis	rs6142618	0.562	rs2281360	ENSG00000224452.1	RSL24D1P6	3.55	0.000395	0.0203	0.15	0.11	Inflammatory bowel disease;	chr20:32139026	chr20:32170390~32170790:-
BRCA	cis	rs754466	0.58	rs10824575	ENSG00000213514.2	RP11-428P16.2	3.55	0.000395	0.0203	0.15	0.11	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77789289	chr10:77730766~77734769:+
BRCA	cis	rs4819052	0.851	rs1999333	ENSG00000215447.6	BX322557.10	-3.55	0.000395	0.0203	-0.11	-0.11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250486	chr21:45288052~45291738:+
BRCA	cis	rs875971	0.706	rs1643374	ENSG00000232546.1	RP11-458F8.1	-3.55	0.000396	0.0203	-0.09	-0.11	Aortic root size;	chr7:66407695	chr7:66848496~66858136:+
BRCA	cis	rs7914558	1	rs8139	ENSG00000213277.3	MARCKSL1P1	3.55	0.000396	0.0203	0.12	0.11	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103088366	chr10:103175554~103176094:+
BRCA	cis	rs6840360	0.593	rs28602726	ENSG00000270265.1	RP11-731D1.4	-3.55	0.000396	0.0203	-0.13	-0.11	Intelligence (multi-trait analysis);	chr4:151578636	chr4:151333775~151353224:-
BRCA	cis	rs758324	0.717	rs7720910	ENSG00000279370.1	RP1-247F3.1	-3.55	0.000396	0.0203	-0.15	-0.11	Alzheimer's disease in APOE e4- carriers;	chr5:132024654	chr5:131261321~131261607:-
BRCA	cis	rs524281	0.817	rs7115081	ENSG00000255557.1	RP11-770G2.2	3.55	0.000396	0.0203	0.15	0.11	Electroencephalogram traits;	chr11:66086070	chr11:65745729~65771585:+
BRCA	cis	rs524281	0.861	rs11227403	ENSG00000255557.1	RP11-770G2.2	3.55	0.000396	0.0203	0.15	0.11	Electroencephalogram traits;	chr11:66090957	chr11:65745729~65771585:+
BRCA	cis	rs524281	0.861	rs1862005	ENSG00000255557.1	RP11-770G2.2	3.55	0.000396	0.0203	0.15	0.11	Electroencephalogram traits;	chr11:66095931	chr11:65745729~65771585:+
BRCA	cis	rs524281	0.861	rs7935336	ENSG00000255557.1	RP11-770G2.2	3.55	0.000396	0.0203	0.15	0.11	Electroencephalogram traits;	chr11:66097854	chr11:65745729~65771585:+
BRCA	cis	rs524281	0.861	rs11227409	ENSG00000255557.1	RP11-770G2.2	3.55	0.000396	0.0203	0.15	0.11	Electroencephalogram traits;	chr11:66103467	chr11:65745729~65771585:+
BRCA	cis	rs524281	0.861	rs11227410	ENSG00000255557.1	RP11-770G2.2	3.55	0.000396	0.0203	0.15	0.11	Electroencephalogram traits;	chr11:66105925	chr11:65745729~65771585:+
BRCA	cis	rs1816213	1	rs61500159	ENSG00000273466.1	RP11-548H3.1	-3.55	0.000396	0.0203	-0.23	-0.11	Diastolic blood pressure;	chr2:218749049	chr2:218633256~218634014:-
BRCA	cis	rs4950322	0.57	rs72691012	ENSG00000237188.3	RP11-337C18.8	3.55	0.000396	0.0203	0.14	0.11	Protein quantitative trait loci;	chr1:147239751	chr1:147172771~147211568:+
BRCA	cis	rs4835473	0.932	rs34525847	ENSG00000246448.2	RP13-578N3.3	-3.55	0.000396	0.0203	-0.12	-0.11	Immature fraction of reticulocytes;	chr4:143734970	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.932	rs35277115	ENSG00000246448.2	RP13-578N3.3	-3.55	0.000396	0.0203	-0.12	-0.11	Immature fraction of reticulocytes;	chr4:143735001	chr4:143700257~143865072:+
BRCA	cis	rs931127	0.719	rs2127507	ENSG00000245532.5	NEAT1	-3.55	0.000396	0.0203	-0.09	-0.11	Systemic lupus erythematosus;	chr11:65686959	chr11:65422774~65445540:+
BRCA	cis	rs10043775	0.793	rs3749689	ENSG00000251330.3	CTD-2283N19.1	-3.55	0.000396	0.0203	-0.13	-0.11	Periodontal microbiota;	chr5:148314481	chr5:148430159~148430807:-
BRCA	cis	rs17123764	0.892	rs1317131	ENSG00000257464.1	RP11-161H23.8	-3.55	0.000396	0.0203	-0.2	-0.11	Intelligence (multi-trait analysis);	chr12:49711383	chr12:49442424~49442652:-
BRCA	cis	rs987724	0.593	rs4680317	ENSG00000240875.4	LINC00886	3.55	0.000396	0.0203	0.13	0.11	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156938964	chr3:156747346~156817062:-
BRCA	cis	rs9400180	0.84	rs9320251	ENSG00000271734.1	RP1-111B22.3	-3.55	0.000396	0.0203	-0.15	-0.11	Major depressive disorder;	chr6:108053511	chr6:108030249~108030718:-
BRCA	cis	rs9400180	0.84	rs6938614	ENSG00000271734.1	RP1-111B22.3	-3.55	0.000396	0.0203	-0.15	-0.11	Major depressive disorder;	chr6:108053546	chr6:108030249~108030718:-
BRCA	cis	rs4374383	0.606	rs17042094	ENSG00000243389.1	AC012442.5	-3.55	0.000396	0.0203	-0.14	-0.11	Hepatitis C induced liver fibrosis;	chr2:111956460	chr2:112589040~112614431:+
BRCA	cis	rs9650657	0.504	rs7813802	ENSG00000254866.2	DEFB109P3	-3.55	0.000396	0.0203	-0.14	-0.11	Neuroticism;	chr8:11176467	chr8:12150895~12151134:-
BRCA	cis	rs35123781	1	rs601728	ENSG00000250635.1	CTD-3224K15.2	-3.55	0.000396	0.0203	-0.12	-0.11	Schizophrenia;	chr5:139677491	chr5:139648999~139649728:-
BRCA	cis	rs10129255	0.957	rs8009948	ENSG00000274576.2	IGHV2-70	3.55	0.000396	0.0203	0.11	0.11	Kawasaki disease;	chr14:106805607	chr14:106770577~106771020:-
BRCA	cis	rs28489187	0.66	rs6576767	ENSG00000223653.4	RP11-131L23.1	-3.55	0.000396	0.0203	-0.12	-0.11	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85410633	chr1:85276715~85448124:+
BRCA	cis	rs7542375	0.683	rs11587049	ENSG00000272823.1	RP11-295M18.6	3.55	0.000396	0.0203	0.13	0.11	Obesity-related traits;	chr1:220926544	chr1:220828676~220829211:-
BRCA	cis	rs56046484	0.956	rs35204319	ENSG00000230373.7	GOLGA6L5P	3.55	0.000396	0.0203	0.17	0.11	Testicular germ cell tumor;	chr15:85107246	chr15:84507885~84516814:-
BRCA	cis	rs16846053	0.605	rs62188818	ENSG00000227403.1	AC009299.3	3.55	0.000396	0.0203	0.27	0.11	Blood osmolality (transformed sodium);	chr2:161899685	chr2:161244739~161249050:+
BRCA	cis	rs6012564	1	rs2252259	ENSG00000230758.1	SNAP23P	-3.55	0.000396	0.0203	-0.13	-0.11	Anger;	chr20:49046286	chr20:49038357~49038602:-
BRCA	cis	rs7020830	0.898	rs308492	ENSG00000230188.1	RP11-405L18.4	-3.55	0.000396	0.0203	-0.13	-0.11	Schizophrenia;	chr9:37298023	chr9:37490421~37490893:-
BRCA	cis	rs283610	0.695	rs157554	ENSG00000249149.2	RP11-79P5.3	-3.55	0.000396	0.0203	-0.15	-0.11	Obesity-related traits;	chr5:73943871	chr5:73382384~73410509:+
BRCA	cis	rs6714710	0.603	rs12104810	ENSG00000228486.8	LINC01125	-3.55	0.000396	0.0203	-0.1	-0.11	Posterior cortical atrophy and Alzheimer's disease;	chr2:97827195	chr2:97664217~97703064:+
BRCA	cis	rs12413361	0.967	rs2994653	ENSG00000272914.1	RP11-330O11.3	-3.55	0.000396	0.0203	-0.13	-0.11	Height;	chr10:30835310	chr10:30831828~30833387:-
BRCA	cis	rs35520189	0.754	rs1143629	ENSG00000274877.1	RP11-65I12.1	3.55	0.000396	0.0203	0.15	0.11	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:112835941	chr2:113237595~113240825:+
BRCA	cis	rs67073037	0.869	rs11677485	ENSG00000230730.1	AC074011.2	-3.55	0.000396	0.0203	-0.15	-0.11	Breast cancer;Breast cancer (estrogen-receptor negative);	chr2:28923228	chr2:28633282~28664540:-
BRCA	cis	rs7020830	0.825	rs10973248	ENSG00000230188.1	RP11-405L18.4	-3.55	0.000397	0.0203	-0.13	-0.11	Schizophrenia;	chr9:37197771	chr9:37490421~37490893:-
BRCA	cis	rs8098244	0.894	rs8099763	ENSG00000265752.2	RP11-403A21.1	3.55	0.000397	0.0203	0.13	0.11	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23829100	chr18:23957754~23982556:-
BRCA	cis	rs12220238	0.915	rs11000948	ENSG00000213731.2	RAB5CP1	3.55	0.000397	0.0203	0.17	0.11	Soluble interleukin-2 receptor subunit alpha;	chr10:74271963	chr10:74423435~74424014:-
BRCA	cis	rs4849845	0.598	rs3933620	ENSG00000236878.1	AC012363.7	3.55	0.000397	0.0203	0.13	0.11	Mean platelet volume;	chr2:120277360	chr2:120211054~120211715:+
BRCA	cis	rs4869313	0.66	rs2549800	ENSG00000248734.2	CTD-2260A17.1	-3.55	0.000397	0.0203	-0.11	-0.11	Pediatric autoimmune diseases;	chr5:96913930	chr5:96784777~96785999:+
BRCA	cis	rs984222	1	rs984222	ENSG00000231365.4	RP11-418J17.1	-3.55	0.000397	0.0203	-0.13	-0.11	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:118961220	chr1:119140396~119275973:+
BRCA	cis	rs2839186	0.681	rs13047198	ENSG00000215424.8	MCM3AP-AS1	3.55	0.000397	0.0203	0.1	0.11	Testicular germ cell tumor;	chr21:46281921	chr21:46229217~46259390:+
BRCA	cis	rs34779708	0.658	rs4934715	ENSG00000269952.1	RP11-324I22.3	-3.55	0.000397	0.0203	-0.15	-0.11	Inflammatory bowel disease;Crohn's disease;	chr10:35076064	chr10:35210416~35210750:+
BRCA	cis	rs12310956	0.532	rs10844707	ENSG00000258794.3	DUX4L27	3.55	0.000397	0.0203	0.16	0.11	Morning vs. evening chronotype;	chr12:33783154	chr12:34208415~34209675:-
BRCA	cis	rs9287719	0.967	rs715247	ENSG00000224177.5	LINC00570	3.55	0.000397	0.0203	0.13	0.11	Prostate cancer;	chr2:10596165	chr2:11393981~11403077:+
BRCA	cis	rs9287719	0.967	rs715246	ENSG00000224177.5	LINC00570	3.55	0.000397	0.0203	0.13	0.11	Prostate cancer;	chr2:10596229	chr2:11393981~11403077:+
BRCA	cis	rs9287719	0.967	rs2010073	ENSG00000224177.5	LINC00570	3.55	0.000397	0.0203	0.13	0.11	Prostate cancer;	chr2:10596352	chr2:11393981~11403077:+
BRCA	cis	rs9287719	0.967	rs2010080	ENSG00000224177.5	LINC00570	3.55	0.000397	0.0203	0.13	0.11	Prostate cancer;	chr2:10596426	chr2:11393981~11403077:+
BRCA	cis	rs9287719	0.901	rs6432109	ENSG00000224177.5	LINC00570	3.55	0.000397	0.0203	0.13	0.11	Prostate cancer;	chr2:10596695	chr2:11393981~11403077:+
BRCA	cis	rs9287719	0.934	rs6432110	ENSG00000224177.5	LINC00570	3.55	0.000397	0.0203	0.13	0.11	Prostate cancer;	chr2:10597892	chr2:11393981~11403077:+
BRCA	cis	rs9287719	0.967	rs7605461	ENSG00000224177.5	LINC00570	3.55	0.000397	0.0203	0.13	0.11	Prostate cancer;	chr2:10598008	chr2:11393981~11403077:+
BRCA	cis	rs9287719	0.967	rs7593496	ENSG00000224177.5	LINC00570	3.55	0.000397	0.0203	0.13	0.11	Prostate cancer;	chr2:10598050	chr2:11393981~11403077:+
BRCA	cis	rs9287719	0.967	rs7608498	ENSG00000224177.5	LINC00570	3.55	0.000397	0.0203	0.13	0.11	Prostate cancer;	chr2:10598302	chr2:11393981~11403077:+
BRCA	cis	rs9287719	0.967	rs7582775	ENSG00000224177.5	LINC00570	3.55	0.000397	0.0203	0.13	0.11	Prostate cancer;	chr2:10598323	chr2:11393981~11403077:+
BRCA	cis	rs9287719	0.967	rs6750891	ENSG00000224177.5	LINC00570	3.55	0.000397	0.0203	0.13	0.11	Prostate cancer;	chr2:10598437	chr2:11393981~11403077:+
BRCA	cis	rs9287719	0.967	rs6733416	ENSG00000224177.5	LINC00570	3.55	0.000397	0.0203	0.13	0.11	Prostate cancer;	chr2:10598558	chr2:11393981~11403077:+
BRCA	cis	rs9287719	0.967	rs6751398	ENSG00000224177.5	LINC00570	3.55	0.000397	0.0203	0.13	0.11	Prostate cancer;	chr2:10598846	chr2:11393981~11403077:+
BRCA	cis	rs9287719	0.901	rs13034017	ENSG00000224177.5	LINC00570	3.55	0.000397	0.0203	0.13	0.11	Prostate cancer;	chr2:10599466	chr2:11393981~11403077:+
BRCA	cis	rs9287719	0.967	rs13034061	ENSG00000224177.5	LINC00570	3.55	0.000397	0.0203	0.13	0.11	Prostate cancer;	chr2:10599525	chr2:11393981~11403077:+
BRCA	cis	rs9287719	0.935	rs7600495	ENSG00000224177.5	LINC00570	3.55	0.000397	0.0203	0.13	0.11	Prostate cancer;	chr2:10599674	chr2:11393981~11403077:+
BRCA	cis	rs9287719	0.967	rs7600587	ENSG00000224177.5	LINC00570	3.55	0.000397	0.0203	0.13	0.11	Prostate cancer;	chr2:10599725	chr2:11393981~11403077:+
BRCA	cis	rs9287719	0.839	rs7600695	ENSG00000224177.5	LINC00570	3.55	0.000397	0.0203	0.13	0.11	Prostate cancer;	chr2:10599819	chr2:11393981~11403077:+
BRCA	cis	rs9287719	0.967	rs7587114	ENSG00000224177.5	LINC00570	3.55	0.000397	0.0203	0.13	0.11	Prostate cancer;	chr2:10599837	chr2:11393981~11403077:+
BRCA	cis	rs9287719	0.967	rs7600728	ENSG00000224177.5	LINC00570	3.55	0.000397	0.0203	0.13	0.11	Prostate cancer;	chr2:10599873	chr2:11393981~11403077:+
BRCA	cis	rs9287719	0.967	rs7600820	ENSG00000224177.5	LINC00570	3.55	0.000397	0.0203	0.13	0.11	Prostate cancer;	chr2:10599918	chr2:11393981~11403077:+
BRCA	cis	rs9287719	0.967	rs7587231	ENSG00000224177.5	LINC00570	3.55	0.000397	0.0203	0.13	0.11	Prostate cancer;	chr2:10599967	chr2:11393981~11403077:+
BRCA	cis	rs2832077	0.527	rs9980449	ENSG00000176054.6	RPL23P2	-3.55	0.000397	0.0203	-0.12	-0.11	Cognitive test performance;	chr21:28852567	chr21:28997613~28998033:-
BRCA	cis	rs13256369	1	rs4840351	ENSG00000254153.1	CTA-398F10.2	3.55	0.000397	0.0203	0.15	0.11	Obesity-related traits;	chr8:8715638	chr8:8456909~8461337:-
BRCA	cis	rs3770752	0.836	rs34819784	ENSG00000272054.1	RP11-423P10.2	-3.55	0.000397	0.0203	-0.1	-0.11	Schizophrenia;	chr2:37263889	chr2:37208875~37212677:+
BRCA	cis	rs2380205	0.517	rs12767690	ENSG00000232807.2	RP11-536K7.3	3.55	0.000397	0.0203	0.12	0.11	Breast cancer;	chr10:5926008	chr10:5934270~5945900:-
BRCA	cis	rs11187837	0.803	rs79193572	ENSG00000273450.1	RP11-76P2.4	3.55	0.000397	0.0203	0.25	0.11	Sudden cardiac arrest;	chr10:94359956	chr10:94314907~94315327:-
BRCA	cis	rs10739695	0.87	rs7038732	ENSG00000225032.4	RP11-228B15.4	-3.55	0.000397	0.0203	-0.1	-0.11	Monocyte percentage of white cells;	chr9:127764264	chr9:127816066~127822520:+
BRCA	cis	rs672059	1	rs659307	ENSG00000224468.3	RP11-181K3.4	-3.55	0.000397	0.0203	-0.12	-0.11	Hypertriglyceridemia;	chr1:183193943	chr1:183138402~183141282:-
BRCA	cis	rs6964587	0.934	rs6973792	ENSG00000188693.7	CYP51A1-AS1	-3.55	0.000397	0.0203	-0.12	-0.11	Breast cancer;	chr7:92120484	chr7:92134604~92180725:+
BRCA	cis	rs6068583	0.86	rs6063965	ENSG00000197670.6	RP4-724E16.2	-3.55	0.000397	0.0203	-0.15	-0.11	Colorectal adenoma (advanced);	chr20:53574661	chr20:53552770~53575863:+
BRCA	cis	rs8180040	0.726	rs2385867	ENSG00000276925.1	RP11-708J19.3	-3.55	0.000397	0.0203	-0.12	-0.11	Colorectal cancer;	chr3:47017833	chr3:47469777~47469987:+
BRCA	cis	rs931127	0.666	rs7932857	ENSG00000245532.5	NEAT1	-3.55	0.000397	0.0203	-0.09	-0.11	Systemic lupus erythematosus;	chr11:65690022	chr11:65422774~65445540:+
BRCA	cis	rs2617170	0.922	rs2617149	ENSG00000245648.1	RP11-277P12.20	-3.55	0.000397	0.0203	-0.14	-0.11	Behcet's disease;	chr12:10375734	chr12:10363769~10398506:+
BRCA	cis	rs13401620	0.626	rs12471141	ENSG00000229326.3	AC069154.4	3.55	0.000397	0.0203	0.14	0.11	Breast size;	chr2:120066173	chr2:119698623~119700151:+
BRCA	cis	rs11867129	1	rs4787277	ENSG00000279031.1	LA16c-360H6.1	-3.55	0.000397	0.0203	-0.18	-0.11	RR interval (tricyclic/tetracyclic antidepressant use interaction);	chr16:2318168	chr16:3292879~3293403:+
BRCA	cis	rs806795	0.605	rs6935954	ENSG00000241549.7	GUSBP2	-3.55	0.000397	0.0203	-0.13	-0.11	Mosquito bite size;	chr6:26255223	chr6:26871484~26956554:-
BRCA	cis	rs9635324	1	rs10518693	ENSG00000223313.1	RNU6-516P	3.55	0.000397	0.0204	0.13	0.11	Blood metabolite ratios;Blood metabolite levels;	chr15:40407823	chr15:40529570~40529673:+
BRCA	cis	rs13108904	0.935	rs2293633	ENSG00000211482.1	AC092574.1	3.55	0.000397	0.0204	0.12	0.11	Obesity-related traits;	chr4:1297852	chr4:409809~409915:+
BRCA	cis	rs73242632	1	rs10002090	ENSG00000269949.1	RP11-738E22.3	3.55	0.000397	0.0204	0.25	0.11	Congenital heart disease (maternal effect);	chr4:56993426	chr4:56960927~56961373:-
BRCA	cis	rs36051895	0.589	rs17492549	ENSG00000237711.1	RP11-39K24.13	-3.55	0.000398	0.0204	-0.13	-0.11	Pediatric autoimmune diseases;	chr9:5202830	chr9:5100236~5101009:+
BRCA	cis	rs1008375	0.932	rs11935124	ENSG00000249502.1	AC006160.5	3.55	0.000398	0.0204	0.13	0.11	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17666577	chr4:17587467~17614571:-
BRCA	cis	rs6918586	0.658	rs198828	ENSG00000272810.1	U91328.22	-3.55	0.000398	0.0204	-0.12	-0.11	Schizophrenia;	chr6:26119231	chr6:26013241~26013757:+
BRCA	cis	rs7705502	0.779	rs56176106	ENSG00000251144.1	CTD-2532K18.2	-3.55	0.000398	0.0204	-0.14	-0.11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for body mass index;	chr5:173869893	chr5:174820027~174826324:+
BRCA	cis	rs7705502	0.78	rs55959485	ENSG00000251144.1	CTD-2532K18.2	-3.55	0.000398	0.0204	-0.14	-0.11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for body mass index;	chr5:173870048	chr5:174820027~174826324:+
BRCA	cis	rs7705502	0.58	rs72810955	ENSG00000251144.1	CTD-2532K18.2	-3.55	0.000398	0.0204	-0.14	-0.11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for body mass index;	chr5:173870299	chr5:174820027~174826324:+
BRCA	cis	rs10838634	1	rs11822959	ENSG00000280615.1	Y_RNA	-3.55	0.000398	0.0204	-0.19	-0.11	Schizophrenia;	chr11:46785003	chr11:47614898~47614994:-
BRCA	cis	rs7267979	0.873	rs7453	ENSG00000231081.1	RP4-760C5.3	-3.55	0.000398	0.0204	-0.14	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25226438	chr20:26008791~26010531:-
BRCA	cis	rs7267979	0.966	rs6050611	ENSG00000276952.1	RP5-965G21.6	3.55	0.000398	0.0204	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25433783	chr20:25284915~25285588:-
BRCA	cis	rs35123781	0.654	rs356443	ENSG00000249526.1	CTB-35F21.1	3.55	0.000398	0.0204	0.14	0.11	Schizophrenia;	chr5:139698244	chr5:139684645~139745010:+
BRCA	cis	rs7759001	0.681	rs13212050	ENSG00000237154.2	MCFD2P1	3.55	0.000398	0.0204	0.13	0.11	Glomerular filtration rate (creatinine);	chr6:27511830	chr6:27407697~27407996:+
BRCA	cis	rs4835473	0.897	rs35598237	ENSG00000246448.2	RP13-578N3.3	-3.55	0.000398	0.0204	-0.12	-0.11	Immature fraction of reticulocytes;	chr4:143735961	chr4:143700257~143865072:+
BRCA	cis	rs1371614	0.61	rs3820822	ENSG00000272148.1	RP11-195B17.1	-3.55	0.000398	0.0204	-0.12	-0.11	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26932994	chr2:27062428~27062907:-
BRCA	cis	rs17221829	0.71	rs1844198	ENSG00000280385.1	AP000648.5	-3.55	0.000398	0.0204	-0.12	-0.11	Anxiety in major depressive disorder;	chr11:89655019	chr11:90193614~90198120:+
BRCA	cis	rs6914598	0.876	rs59596472	ENSG00000240869.3	RN7SL128P	-3.55	0.000398	0.0204	-0.15	-0.11	Cutaneous malignant melanoma;Melanoma;	chr6:21155781	chr6:20421583~20421887:-
BRCA	cis	rs1722141	0.598	rs2453849	ENSG00000237471.1	AC073115.6	3.55	0.000398	0.0204	0.15	0.11	Sitting height ratio;	chr7:45935066	chr7:45969657~45980191:+
BRCA	cis	rs1730008	0.618	rs60295840	ENSG00000279311.1	RP11-170K4.2	3.55	0.000398	0.0204	0.13	0.11	Lobe attachment (rater-scored or self-reported);	chr3:158526211	chr3:158869898~158871821:+
BRCA	cis	rs2832077	0.527	rs59730679	ENSG00000176054.6	RPL23P2	-3.55	0.000398	0.0204	-0.12	-0.11	Cognitive test performance;	chr21:28853922	chr21:28997613~28998033:-
BRCA	cis	rs2692947	0.537	rs2320170	ENSG00000232931.4	LINC00342	-3.55	0.000398	0.0204	-0.12	-0.11	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95574025	chr2:95807118~95816215:-
BRCA	cis	rs9467773	0.565	rs6925047	ENSG00000261353.1	CTA-14H9.5	-3.55	0.000398	0.0204	-0.12	-0.11	Intelligence (multi-trait analysis);	chr6:26521207	chr6:26527063~26527404:+
BRCA	cis	rs73222236	0.825	rs7612160	ENSG00000239213.4	NCK1-AS1	3.55	0.000398	0.0204	0.12	0.11	Coronary artery disease;	chr3:136553963	chr3:136841726~136862054:-
BRCA	cis	rs9650657	0.623	rs7004253	ENSG00000248896.2	CTD-2135J3.3	-3.55	0.000398	0.0204	-0.13	-0.11	Neuroticism;	chr8:10743347	chr8:10729314~10771392:+
BRCA	cis	rs2153535	0.561	rs9328474	ENSG00000251164.1	HULC	-3.55	0.000398	0.0204	-0.13	-0.11	Motion sickness;	chr6:8506770	chr6:8652137~8653846:+
BRCA	cis	rs4849845	0.598	rs11690576	ENSG00000236878.1	AC012363.7	-3.55	0.000398	0.0204	-0.13	-0.11	Mean platelet volume;	chr2:120262224	chr2:120211054~120211715:+
BRCA	cis	rs4835473	0.897	rs17693780	ENSG00000246448.2	RP13-578N3.3	-3.55	0.000398	0.0204	-0.12	-0.11	Immature fraction of reticulocytes;	chr4:143737563	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.897	rs35556180	ENSG00000246448.2	RP13-578N3.3	-3.55	0.000398	0.0204	-0.12	-0.11	Immature fraction of reticulocytes;	chr4:143737595	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.897	rs35377051	ENSG00000246448.2	RP13-578N3.3	-3.55	0.000398	0.0204	-0.12	-0.11	Immature fraction of reticulocytes;	chr4:143737627	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.864	rs17018131	ENSG00000246448.2	RP13-578N3.3	-3.55	0.000398	0.0204	-0.12	-0.11	Immature fraction of reticulocytes;	chr4:143737647	chr4:143700257~143865072:+
BRCA	cis	rs6918586	0.658	rs198829	ENSG00000272810.1	U91328.22	-3.55	0.000398	0.0204	-0.12	-0.11	Schizophrenia;	chr6:26118665	chr6:26013241~26013757:+
BRCA	cis	rs7712401	0.791	rs9327279	ENSG00000263432.2	RN7SL689P	3.55	0.000398	0.0204	0.12	0.11	Mean platelet volume;	chr5:122786465	chr5:123022487~123022783:-
BRCA	cis	rs9527	0.622	rs12779263	ENSG00000236937.2	PTGES3P4	3.55	0.000398	0.0204	0.15	0.11	Arsenic metabolism;	chr10:103126776	chr10:102845595~102845950:+
BRCA	cis	rs972578	0.715	rs13433641	ENSG00000274717.1	RP1-47A17.1	-3.55	0.000398	0.0204	-0.13	-0.11	Mean platelet volume;	chr22:42872003	chr22:42791814~42794313:-
BRCA	cis	rs7246657	0.525	rs997516	ENSG00000267470.4	ZNF571-AS1	3.55	0.000398	0.0204	0.16	0.11	Coronary artery calcification;	chr19:36983362	chr19:37548914~37587348:+
BRCA	cis	rs1040	0.646	rs9505938	ENSG00000226445.1	XXyac-YX65C7_A.2	-3.55	0.000399	0.0204	-0.12	-0.11	Joint mobility (Beighton score);	chr6:169211837	chr6:169213254~169239565:+
BRCA	cis	rs9333290	0.893	rs17334303	ENSG00000259915.2	RP11-410E4.1	3.55	0.000399	0.0204	0.15	0.11	Urinary albumin-to-creatinine ratio in non-diabetics;Urinary albumin-to-creatinine ratio;	chr2:186681979	chr2:186354570~186356773:-
BRCA	cis	rs9333290	0.893	rs13027560	ENSG00000259915.2	RP11-410E4.1	3.55	0.000399	0.0204	0.15	0.11	Urinary albumin-to-creatinine ratio in non-diabetics;Urinary albumin-to-creatinine ratio;	chr2:186682185	chr2:186354570~186356773:-
BRCA	cis	rs1642645	0.793	rs642579	ENSG00000228452.1	RP5-994D16.9	-3.55	0.000399	0.0204	-0.15	-0.11	Left ventricular obstructive tract defect (maternal effect);	chr1:41965726	chr1:42775813~42776790:-
BRCA	cis	rs6498068	0.594	rs12996	ENSG00000279662.1	RP11-609N14.4	-3.55	0.000399	0.0204	-0.13	-0.11	Metabolite levels (MHPG);	chr16:10529447	chr16:10445309~10449747:-
BRCA	cis	rs6964587	1	rs7791138	ENSG00000188693.7	CYP51A1-AS1	-3.55	0.000399	0.0204	-0.12	-0.11	Breast cancer;	chr7:92057475	chr7:92134604~92180725:+
BRCA	cis	rs2274273	0.624	rs7159824	ENSG00000259318.1	RP11-454L9.2	3.55	0.000399	0.0204	0.1	0.11	Protein biomarker;	chr14:55305818	chr14:55394940~55395233:-
BRCA	cis	rs2599510	0.744	rs4952212	ENSG00000276517.1	AL133243.2	3.55	0.000399	0.0204	0.13	0.11	Interleukin-18 levels;	chr2:32393425	chr2:32526504~32529507:+
BRCA	cis	rs970548	0.69	rs12269352	ENSG00000237840.5	FAM21FP	3.55	0.000399	0.0204	0.13	0.11	Total cholesterol levels;HDL cholesterol;HDL cholesterol levels;Cholesterol, total;	chr10:45560198	chr10:45706431~45727231:-
BRCA	cis	rs4742903	0.935	rs10120101	ENSG00000270332.1	SMC2-AS1	3.55	0.000399	0.0204	0.12	0.11	Breast cancer;High-grade serous ovarian cancer;	chr9:104238628	chr9:104080024~104093073:-
BRCA	cis	rs62025270	0.593	rs62022926	ENSG00000259416.2	RP11-158M2.5	-3.55	0.000399	0.0204	-0.17	-0.11	Idiopathic pulmonary fibrosis;	chr15:85696261	chr15:85754941~85756237:-
BRCA	cis	rs4886920	0.802	rs7164558	ENSG00000260776.4	RP11-114H24.2	-3.55	0.000399	0.0204	-0.13	-0.11	Neuroticism;	chr15:77854040	chr15:77914217~77926846:-
BRCA	cis	rs13326165	0.709	rs6796333	ENSG00000243224.1	RP5-1157M23.2	-3.55	0.000399	0.0204	-0.15	-0.11	HDL cholesterol levels;HDL cholesterol;	chr3:52325662	chr3:52239258~52241097:+
BRCA	cis	rs2562456	0.917	rs2650805	ENSG00000240522.1	RPL7AP10	3.55	0.000399	0.0204	0.12	0.11	Pain;	chr19:21505137	chr19:21149648~21150438:-
BRCA	cis	rs7267979	1	rs2474777	ENSG00000125804.12	FAM182A	-3.55	0.000399	0.0204	-0.14	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25291997	chr20:26054655~26086917:+
BRCA	cis	rs654950	0.875	rs687835	ENSG00000230638.4	RP11-486B10.4	-3.55	0.000399	0.0204	-0.14	-0.11	Airway imaging phenotypes;	chr1:41533233	chr1:41542069~41544310:+
BRCA	cis	rs17801127	0.748	rs6747199	ENSG00000231969.1	AC144449.1	3.55	0.000399	0.0204	0.19	0.11	Liver enzyme levels (alanine transaminase);	chr2:149676139	chr2:149587196~149848233:+
BRCA	cis	rs863345	0.604	rs1873510	ENSG00000229914.1	RP11-404O13.4	-3.55	0.000399	0.0204	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158491628	chr1:158195633~158196131:-
BRCA	cis	rs6120849	0.754	rs6120797	ENSG00000202150.1	RNU6-407P	3.55	0.000399	0.0204	0.16	0.11	Protein C levels;	chr20:35018199	chr20:35030317~35030420:-
BRCA	cis	rs6120849	0.754	rs6119560	ENSG00000202150.1	RNU6-407P	3.55	0.000399	0.0204	0.16	0.11	Protein C levels;	chr20:35019174	chr20:35030317~35030420:-
BRCA	cis	rs7020830	0.931	rs13288178	ENSG00000260100.1	RP11-220I1.5	-3.55	0.000399	0.0204	-0.14	-0.11	Schizophrenia;	chr9:37107802	chr9:37078813~37079776:-
BRCA	cis	rs826838	0.616	rs11182893	ENSG00000257718.1	RP11-396F22.1	-3.55	0.000399	0.0204	-0.11	-0.11	Heart rate;	chr12:38233913	chr12:38906451~38909592:+
BRCA	cis	rs2665103	0.715	rs7403041	ENSG00000280753.1	AC044907.1	3.55	0.000399	0.0204	0.1	0.11	Intelligence (multi-trait analysis);	chr15:82287841	chr15:82847870~82847998:-
BRCA	cis	rs7781557	1	rs7781557	ENSG00000239969.4	RP11-163E9.2	3.55	0.000399	0.0204	0.18	0.11	Colorectal adenoma (advanced);	chr7:102841444	chr7:102364162~102380633:+
BRCA	cis	rs36051895	0.664	rs10117501	ENSG00000236254.1	MTND4P14	-3.55	0.000399	0.0204	-0.13	-0.11	Pediatric autoimmune diseases;	chr9:5094246	chr9:5107937~5109290:+
BRCA	cis	rs6929812	0.613	rs13215560	ENSG00000271755.1	RP1-153G14.4	3.55	0.000399	0.0204	0.13	0.11	Neuroticism (multi-trait analysis);	chr6:27514160	chr6:27404010~27406964:-
BRCA	cis	rs9287719	0.967	rs4519489	ENSG00000224177.5	LINC00570	3.55	0.000399	0.0204	0.13	0.11	Prostate cancer;	chr2:10598961	chr2:11393981~11403077:+
BRCA	cis	rs9287719	0.967	rs4453662	ENSG00000224177.5	LINC00570	3.55	0.000399	0.0204	0.13	0.11	Prostate cancer;	chr2:10599002	chr2:11393981~11403077:+
BRCA	cis	rs295490	0.748	rs1602626	ENSG00000178631.7	ACTG1P1	3.55	0.000399	0.0204	0.21	0.11	PR interval in Tripanosoma cruzi seropositivity;	chr3:139364928	chr3:139493809~139494937:+
BRCA	cis	rs6708331	0.504	rs2169837	ENSG00000231024.1	AC092431.3	-3.55	0.000399	0.0204	-0.14	-0.11	Obesity-related traits;	chr2:70324775	chr2:69700192~69713847:-
BRCA	cis	rs4449834	0.816	rs7012450	ENSG00000254432.1	RP11-33I11.2	-3.55	0.000399	0.0204	-0.15	-0.11	Sum eosinophil basophil counts;	chr8:60754868	chr8:60808735~60809606:-
BRCA	cis	rs12900463	0.813	rs306198	ENSG00000259295.5	CSPG4P12	-3.55	0.000399	0.0204	-0.16	-0.11	Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine);	chr15:84862138	chr15:85191438~85213905:+
BRCA	cis	rs2281603	0.951	rs12385918	ENSG00000259116.1	RP11-973N13.4	-3.55	0.000399	0.0204	-0.11	-0.11	Lymphocyte counts;	chr14:64533227	chr14:64514154~64540368:-
BRCA	cis	rs10782582	0.569	rs74090722	ENSG00000181227.3	RP4-682C21.2	3.55	0.000399	0.0204	0.11	0.11	Daytime sleep phenotypes;	chr1:75731577	chr1:75743423~75744776:-
BRCA	cis	rs4978813	0.5	rs7870600	ENSG00000213539.4	YBX1P6	-3.55	0.000399	0.0204	-0.12	-0.11	Plantar warts;	chr9:109535950	chr9:109532830~109534332:-
BRCA	cis	rs13401620	0.871	rs66532914	ENSG00000229326.3	AC069154.4	-3.55	0.000399	0.0204	-0.15	-0.11	Breast size;	chr2:119925053	chr2:119698623~119700151:+
BRCA	cis	rs983392	0.679	rs7128450	ENSG00000275344.1	MIR6503	3.55	0.000399	0.0204	0.11	0.11	Alzheimer's disease (late onset);	chr11:60263797	chr11:60209071~60209156:-
BRCA	cis	rs983392	0.679	rs10736701	ENSG00000275344.1	MIR6503	3.55	0.000399	0.0204	0.11	0.11	Alzheimer's disease (late onset);	chr11:60264003	chr11:60209071~60209156:-
BRCA	cis	rs35304300	1	rs17068822	ENSG00000225177.4	RP11-390P2.4	3.55	0.000399	0.0204	0.13	0.11	Mean platelet volume;	chr6:139528783	chr6:138692548~138697288:+
BRCA	cis	rs1404100	0.51	rs2140573	ENSG00000249274.1	PDLIM1P4	3.55	0.000399	0.0204	0.12	0.11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:99071376	chr3:98782188~98783193:+
BRCA	cis	rs848490	0.888	rs56100966	ENSG00000214293.7	APTR	3.55	0.000399	0.0204	0.14	0.11	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77661233	chr7:77657660~77696265:-
BRCA	cis	rs10876993	0.928	rs774890	ENSG00000270039.1	RP11-571M6.17	3.55	0.000399	0.0204	0.14	0.11	Celiac disease or Rheumatoid arthritis;	chr12:57674605	chr12:57803838~57804415:+
BRCA	cis	rs10129255	0.5	rs2105991	ENSG00000211976.2	IGHV3-73	-3.55	0.000399	0.0204	-0.08	-0.11	Kawasaki disease;	chr14:106682022	chr14:106802694~106803233:-
BRCA	cis	rs6088580	0.601	rs6059827	ENSG00000269202.1	RP4-614O4.12	-3.55	0.000399	0.0204	-0.11	-0.11	Glomerular filtration rate (creatinine);	chr20:34428552	chr20:35201747~35203288:-
BRCA	cis	rs9500256	0.934	rs1343391	ENSG00000272316.1	XXbac-BPGBPG55C20.2	3.55	0.000399	0.0204	0.09	0.11	Eosinophilic esophagitis (pediatric);	chr6:58017876	chr6:57908560~57913911:-
BRCA	cis	rs2274273	0.901	rs12050099	ENSG00000259318.1	RP11-454L9.2	3.55	0.000399	0.0204	0.09	0.11	Protein biomarker;	chr14:55297613	chr14:55394940~55395233:-
BRCA	cis	rs801193	1	rs2707836	ENSG00000232546.1	RP11-458F8.1	-3.55	0.000399	0.0204	-0.09	-0.11	Aortic root size;	chr7:66695448	chr7:66848496~66858136:+
BRCA	cis	rs801193	0.844	rs7779971	ENSG00000232546.1	RP11-458F8.1	-3.55	0.000399	0.0204	-0.09	-0.11	Aortic root size;	chr7:66696803	chr7:66848496~66858136:+
BRCA	cis	rs62229266	0.804	rs2835241	ENSG00000214914.3	RPL23AP3	-3.55	4e-04	0.0204	-0.13	-0.11	Mitral valve prolapse;	chr21:36039082	chr21:36016079~36016546:-
BRCA	cis	rs4478858	0.735	rs6676682	ENSG00000223907.1	LINC01226	-3.55	4e-04	0.0204	-0.13	-0.11	Alcohol dependence;	chr1:31336969	chr1:31518435~31524245:+
BRCA	cis	rs8180040	0.701	rs13066214	ENSG00000280667.1	Y_RNA	3.55	4e-04	0.0204	0.12	0.11	Colorectal cancer;	chr3:46992447	chr3:47501083~47501182:+
BRCA	cis	rs11098499	0.863	rs17050695	ENSG00000250412.1	KLHL2P1	3.55	4e-04	0.0204	0.13	0.11	Corneal astigmatism;	chr4:119568372	chr4:119334329~119378233:+
BRCA	cis	rs6545883	0.965	rs7591345	ENSG00000212978.6	AC016747.3	3.55	4e-04	0.0204	0.15	0.11	Tuberculosis;	chr2:61502506	chr2:61141592~61144969:-
BRCA	cis	rs875971	1	rs7792762	ENSG00000272831.1	RP11-792A8.4	3.55	4e-04	0.0204	0.1	0.11	Aortic root size;	chr7:66539151	chr7:66739829~66740385:-
BRCA	cis	rs7818688	1	rs6651272	ENSG00000245080.5	RP11-320N21.1	3.55	4e-04	0.0205	0.19	0.11	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95035705	chr8:95066808~95073182:-
BRCA	cis	rs6088580	0.524	rs6088567	ENSG00000126005.14	MMP24-AS1	3.55	4e-04	0.0205	0.13	0.11	Glomerular filtration rate (creatinine);	chr20:34676068	chr20:35216462~35278131:-
BRCA	cis	rs6088580	0.524	rs6088568	ENSG00000126005.14	MMP24-AS1	3.55	4e-04	0.0205	0.13	0.11	Glomerular filtration rate (creatinine);	chr20:34678167	chr20:35216462~35278131:-
BRCA	cis	rs6088580	0.524	rs1321306	ENSG00000126005.14	MMP24-AS1	3.55	4e-04	0.0205	0.13	0.11	Glomerular filtration rate (creatinine);	chr20:34678575	chr20:35216462~35278131:-
BRCA	cis	rs952623	0.501	rs1000869	ENSG00000211694.2	TRGV10	3.55	4e-04	0.0205	0.1	0.11	Intelligence (multi-trait analysis);	chr7:39042627	chr7:38299811~38300322:-
BRCA	cis	rs10129255	0.957	rs11846893	ENSG00000231475.3	IGHV4-31	-3.55	4e-04	0.0205	-0.08	-0.11	Kawasaki disease;	chr14:106779068	chr14:106349283~106349792:-
BRCA	cis	rs9329221	0.537	rs1351876	ENSG00000272267.2	RP11-375N15.2	3.55	4e-04	0.0205	0.13	0.11	Neuroticism;	chr8:10127267	chr8:9555144~9556520:-
BRCA	cis	rs9341808	0.727	rs4706834	ENSG00000279022.1	RP11-250B2.4	3.55	4e-04	0.0205	0.12	0.11	Sitting height ratio;	chr6:80302888	chr6:80440730~80441172:+
BRCA	cis	rs6456156	0.774	rs6930998	ENSG00000272549.1	RP11-351J23.2	3.55	4e-04	0.0205	0.11	0.11	Primary biliary cholangitis;	chr6:167113452	chr6:167666840~167679270:-
BRCA	cis	rs61931739	0.5	rs11053201	ENSG00000258794.3	DUX4L27	3.55	4e-04	0.0205	0.16	0.11	Morning vs. evening chronotype;	chr12:34300968	chr12:34208415~34209675:-
BRCA	cis	rs61931739	0.5	rs28692887	ENSG00000258794.3	DUX4L27	3.55	4e-04	0.0205	0.16	0.11	Morning vs. evening chronotype;	chr12:34304140	chr12:34208415~34209675:-
BRCA	cis	rs61931739	0.5	rs28624237	ENSG00000258794.3	DUX4L27	3.55	4e-04	0.0205	0.16	0.11	Morning vs. evening chronotype;	chr12:34304236	chr12:34208415~34209675:-
BRCA	cis	rs75422866	0.867	rs35044089	ENSG00000276691.1	RP5-1057I20.5	3.55	4e-04	0.0205	0.23	0.11	Pneumonia;	chr12:47610881	chr12:47788426~47788971:+
BRCA	cis	rs75422866	0.867	rs78912815	ENSG00000276691.1	RP5-1057I20.5	3.55	4e-04	0.0205	0.23	0.11	Pneumonia;	chr12:47612065	chr12:47788426~47788971:+
BRCA	cis	rs2991971	0.967	rs2275276	ENSG00000281133.1	AL355480.3	3.55	4e-04	0.0205	0.13	0.11	High light scatter reticulocyte count;	chr1:45508256	chr1:45580892~45580996:-
BRCA	cis	rs754133	1	rs754133	ENSG00000257534.1	RP11-834C11.10	3.55	4e-04	0.0205	0.13	0.11	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);	chr12:54025136	chr12:54162065~54164452:-
BRCA	cis	rs7260598	0.642	rs67908565	ENSG00000268442.1	CTD-2027I19.2	3.55	4e-04	0.0205	0.17	0.11	Response to taxane treatment (placlitaxel);	chr19:23998579	chr19:24162370~24163425:-
BRCA	cis	rs6733011	0.502	rs6542847	ENSG00000226791.5	AC109826.1	3.55	4e-04	0.0205	0.13	0.11	Bipolar disorder;	chr2:98957008	chr2:98761938~98772920:-
BRCA	cis	rs3816183	0.585	rs10195899	ENSG00000226491.1	FTOP1	-3.55	4e-04	0.0205	-0.13	-0.11	Hypospadias;	chr2:42654394	chr2:42797225~42798712:-
BRCA	cis	rs11673344	0.704	rs1644710	ENSG00000267422.1	CTD-2554C21.1	3.55	4e-04	0.0205	0.14	0.11	Obesity-related traits;	chr19:36926160	chr19:37779686~37792865:+
BRCA	cis	rs2301573	0.584	rs62267596	ENSG00000271270.4	TMCC1-AS1	-3.55	4e-04	0.0205	-0.24	-0.11	Hip circumference;	chr3:129630381	chr3:129893871~129918575:+
BRCA	cis	rs7020830	0.931	rs9775431	ENSG00000230188.1	RP11-405L18.4	-3.55	4e-04	0.0205	-0.13	-0.11	Schizophrenia;	chr9:37130436	chr9:37490421~37490893:-
BRCA	cis	rs2692947	0.77	rs12471925	ENSG00000168992.4	OR7E102P	3.55	4e-04	0.0205	0.16	0.11	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95889774	chr2:95546531~95547545:+
BRCA	cis	rs16950303	0.661	rs12456273	ENSG00000264269.1	RP11-15F12.1	3.55	4e-04	0.0205	0.22	0.11	Height;	chr18:49058381	chr18:49023703~49048474:+
BRCA	cis	rs10986311	0.722	rs944339	ENSG00000227200.1	RP11-121A14.3	-3.55	4e-04	0.0205	-0.12	-0.11	Vitiligo;	chr9:124278699	chr9:124262876~124265809:+
BRCA	cis	rs9420	0.528	rs7102271	ENSG00000265566.2	RN7SL605P	-3.55	4e-04	0.0205	-0.15	-0.11	Schizophrenia;	chr11:57629352	chr11:57528085~57528365:-
BRCA	cis	rs2562456	0.876	rs11085467	ENSG00000268119.4	CTD-2561J22.5	3.55	4e-04	0.0205	0.16	0.11	Pain;	chr19:21569041	chr19:21444241~21463908:-
BRCA	cis	rs2108622	0.727	rs55954696	ENSG00000214049.6	UCA1	3.55	4e-04	0.0205	0.16	0.11	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15870995	chr19:15828961~15836320:+
BRCA	cis	rs752590	0.623	rs72831810	ENSG00000189223.12	PAX8-AS1	3.55	4e-04	0.0205	0.24	0.11	Mucinous ovarian carcinoma;	chr2:113221787	chr2:113211522~113276581:+
BRCA	cis	rs1005277	0.522	rs289645	ENSG00000099251.13	HSD17B7P2	3.55	4e-04	0.0205	0.12	0.11	Extrinsic epigenetic age acceleration;	chr10:37654714	chr10:38356380~38378505:+
BRCA	cis	rs6487679	0.526	rs972111	ENSG00000256069.6	A2MP1	3.55	4e-04	0.0205	0.12	0.11	Non-alcoholic fatty liver disease histology (AST);	chr12:9221777	chr12:9228533~9275817:-
BRCA	cis	rs10056811	0.51	rs10058171	ENSG00000271815.1	CTD-2235C13.3	-3.55	4e-04	0.0205	-0.19	-0.11	Coronary artery disease;	chr5:75112166	chr5:75363760~75364242:+
BRCA	cis	rs10911902	0.567	rs76557279	ENSG00000229739.2	RP11-295K2.3	-3.55	4e-04	0.0205	-0.15	-0.11	Schizophrenia;	chr1:186344161	chr1:186435161~186470291:+
BRCA	cis	rs9287719	0.967	rs4668691	ENSG00000224177.5	LINC00570	3.55	4e-04	0.0205	0.13	0.11	Prostate cancer;	chr2:10600368	chr2:11393981~11403077:+
BRCA	cis	rs9287719	0.934	rs10181806	ENSG00000224177.5	LINC00570	3.55	4e-04	0.0205	0.13	0.11	Prostate cancer;	chr2:10601015	chr2:11393981~11403077:+
BRCA	cis	rs9287719	0.967	rs11687023	ENSG00000224177.5	LINC00570	3.55	4e-04	0.0205	0.13	0.11	Prostate cancer;	chr2:10601286	chr2:11393981~11403077:+
BRCA	cis	rs9287719	0.967	rs10454738	ENSG00000224177.5	LINC00570	3.55	4e-04	0.0205	0.13	0.11	Prostate cancer;	chr2:10601923	chr2:11393981~11403077:+
BRCA	cis	rs4388249	1	rs13157374	ENSG00000271849.1	CTC-332L22.1	-3.55	4e-04	0.0205	-0.17	-0.11	Schizophrenia;	chr5:109782503	chr5:109687802~109688329:-
BRCA	cis	rs17092148	1	rs6088594	ENSG00000202150.1	RNU6-407P	-3.55	4e-04	0.0205	-0.16	-0.11	Neuroticism;	chr20:34755354	chr20:35030317~35030420:-
BRCA	cis	rs910316	1	rs175442	ENSG00000259138.1	RP11-950C14.7	-3.55	4e-04	0.0205	-0.11	-0.11	Height;	chr14:75136861	chr14:75127153~75136930:+
BRCA	cis	rs9494145	0.68	rs4895441	ENSG00000236703.1	MYB-AS1	3.55	4e-04	0.0205	0.11	0.11	Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count;	chr6:135105435	chr6:135195083~135195995:-
BRCA	cis	rs962856	0.576	rs642046	ENSG00000236780.4	AC078941.1	3.55	4e-04	0.0205	0.14	0.11	Pancreatic cancer;	chr2:67461003	chr2:67123357~67215319:-
BRCA	cis	rs8180040	0.966	rs60369822	ENSG00000280667.1	Y_RNA	-3.55	4e-04	0.0205	-0.12	-0.11	Colorectal cancer;	chr3:47438245	chr3:47501083~47501182:+
BRCA	cis	rs7578361	0.918	rs10203060	ENSG00000231969.1	AC144449.1	3.55	4e-04	0.0205	0.17	0.11	Acute lymphoblastic leukemia (childhood);	chr2:149521505	chr2:149587196~149848233:+
BRCA	cis	rs7618501	1	rs9859153	ENSG00000228008.1	CTD-2330K9.3	3.55	0.000401	0.0205	0.1	0.11	Intelligence (multi-trait analysis);	chr3:49769652	chr3:49903845~49916937:+
BRCA	cis	rs647097	0.961	rs633286	ENSG00000265962.1	GACAT2	3.55	0.000401	0.0205	0.13	0.11	Chronic obstructive pulmonary disease;	chr18:8809275	chr18:8695856~8707621:-
BRCA	cis	rs67311347	0.544	rs2887965	ENSG00000199906.1	RNU5B-2P	3.55	0.000401	0.0205	0.11	0.11	Renal cell carcinoma;	chr3:40292663	chr3:40498891~40499003:-
BRCA	cis	rs4718428	0.607	rs66954441	ENSG00000229886.1	RP5-1132H15.3	3.55	0.000401	0.0205	0.13	0.11	Corneal structure;	chr7:66904222	chr7:66025126~66031544:-
BRCA	cis	rs739401	0.611	rs12284275	ENSG00000183562.3	CTC-343N3.1	-3.55	0.000401	0.0205	-0.12	-0.11	Longevity;	chr11:3003154	chr11:2989863~2991344:+
BRCA	cis	rs1040	0.625	rs9505936	ENSG00000226445.1	XXyac-YX65C7_A.2	-3.55	0.000401	0.0205	-0.12	-0.11	Joint mobility (Beighton score);	chr6:169211724	chr6:169213254~169239565:+
BRCA	cis	rs1040	0.625	rs9505937	ENSG00000226445.1	XXyac-YX65C7_A.2	-3.55	0.000401	0.0205	-0.12	-0.11	Joint mobility (Beighton score);	chr6:169211725	chr6:169213254~169239565:+
BRCA	cis	rs4372836	0.541	rs6710080	ENSG00000226833.4	AC097724.3	3.55	0.000401	0.0205	0.13	0.11	Body mass index;	chr2:28767109	chr2:28708953~28736205:-
BRCA	cis	rs4372836	0.505	rs6710082	ENSG00000226833.4	AC097724.3	3.55	0.000401	0.0205	0.13	0.11	Body mass index;	chr2:28767111	chr2:28708953~28736205:-
BRCA	cis	rs1865760	0.713	rs6928951	ENSG00000272462.2	U91328.19	-3.55	0.000401	0.0205	-0.13	-0.11	Height;	chr6:25995326	chr6:25992662~26001775:+
BRCA	cis	rs4713118	0.662	rs9380045	ENSG00000226314.6	ZNF192P1	-3.55	0.000401	0.0205	-0.16	-0.11	Parkinson's disease;	chr6:28057501	chr6:28161781~28169594:+
BRCA	cis	rs7267979	1	rs12428	ENSG00000231081.1	RP4-760C5.3	3.55	0.000401	0.0205	0.14	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25453185	chr20:26008791~26010531:-
BRCA	cis	rs4865762	0.514	rs251336	ENSG00000247796.2	CTD-2366F13.1	3.55	0.000401	0.0205	0.12	0.11	Intraocular pressure;	chr5:53135558	chr5:53109842~53115126:+
BRCA	cis	rs897984	0.513	rs17839568	ENSG00000232748.3	RP11-196G11.6	-3.55	0.000401	0.0205	-0.13	-0.11	Dementia with Lewy bodies;	chr16:31088462	chr16:31056460~31062803:+
BRCA	cis	rs1479090	0.762	rs11100479	ENSG00000250027.1	RP11-563E2.2	-3.55	0.000401	0.0205	-0.14	-0.11	Lung cancer;	chr4:163091749	chr4:163108785~163119965:+
BRCA	cis	rs17406451	0.819	rs6739313	ENSG00000234936.1	AC010883.5	3.55	0.000401	0.0205	0.11	0.11	Mitochondrial DNA levels;	chr2:43418536	chr2:43229573~43233394:+
BRCA	cis	rs7572733	0.935	rs7558450	ENSG00000231621.1	AC013264.2	-3.55	0.000401	0.0205	-0.1	-0.11	Dermatomyositis;	chr2:197973042	chr2:197197991~197199273:+
BRCA	cis	rs7429990	0.901	rs6442091	ENSG00000199476.1	Y_RNA	3.55	0.000401	0.0205	0.15	0.11	Educational attainment (years of education);	chr3:48001568	chr3:48288587~48288694:+
BRCA	cis	rs7429990	0.965	rs4858810	ENSG00000199476.1	Y_RNA	3.55	0.000401	0.0205	0.15	0.11	Educational attainment (years of education);	chr3:48002247	chr3:48288587~48288694:+
BRCA	cis	rs2297363	1	rs3777411	ENSG00000216480.2	RP3-393E18.1	3.55	0.000401	0.0205	0.14	0.11	Total cholesterol levels;Blood protein levels;	chr6:160055913	chr6:159526062~159526527:-
BRCA	cis	rs875971	0.522	rs709604	ENSG00000232546.1	RP11-458F8.1	3.55	0.000401	0.0205	0.09	0.11	Aortic root size;	chr7:66032447	chr7:66848496~66858136:+
BRCA	cis	rs7829975	0.533	rs13274028	ENSG00000233609.3	RP11-62H7.2	3.55	0.000401	0.0205	0.1	0.11	Mood instability;	chr8:8871683	chr8:8961200~8979025:+
BRCA	cis	rs7089973	0.872	rs7072356	ENSG00000236799.1	RP11-383C6.2	-3.55	0.000401	0.0205	-0.14	-0.11	Bipolar disorder or attention deficit hyperactivity disorder;	chr10:114874892	chr10:114994657~114996593:+
BRCA	cis	rs7089973	0.872	rs11818114	ENSG00000236799.1	RP11-383C6.2	-3.55	0.000401	0.0205	-0.14	-0.11	Bipolar disorder or attention deficit hyperactivity disorder;	chr10:114875119	chr10:114994657~114996593:+
BRCA	cis	rs7089973	0.872	rs11818115	ENSG00000236799.1	RP11-383C6.2	-3.55	0.000401	0.0205	-0.14	-0.11	Bipolar disorder or attention deficit hyperactivity disorder;	chr10:114875132	chr10:114994657~114996593:+
BRCA	cis	rs7089973	0.836	rs12765350	ENSG00000236799.1	RP11-383C6.2	-3.55	0.000401	0.0205	-0.14	-0.11	Bipolar disorder or attention deficit hyperactivity disorder;	chr10:114875546	chr10:114994657~114996593:+
BRCA	cis	rs8105895	0.935	rs8110969	ENSG00000269345.1	VN1R85P	3.55	0.000401	0.0205	0.16	0.11	Body mass index (change over time);	chr19:22057420	chr19:22174766~22175191:-
BRCA	cis	rs11448612	1	rs11448612	ENSG00000214293.7	APTR	-3.55	0.000401	0.0205	-0.13	-0.11	Facial morphology (factor 23);	chr7:77633271	chr7:77657660~77696265:-
BRCA	cis	rs10744955	0.727	rs6493413	ENSG00000244879.4	GABPB1-AS1	-3.55	0.000401	0.0205	-0.11	-0.11	Lobe attachment (rater-scored or self-reported);	chr15:50165538	chr15:50354959~50372202:+
BRCA	cis	rs2935776	0.52	rs1979443	ENSG00000253796.1	RP11-1084E5.1	-3.55	0.000401	0.0205	-0.11	-0.11	Cerebrospinal T-tau levels;	chr8:108583483	chr8:108895029~109063417:-
BRCA	cis	rs10838634	1	rs3136496	ENSG00000280615.1	Y_RNA	-3.55	0.000401	0.0205	-0.23	-0.11	Schizophrenia;	chr11:46736487	chr11:47614898~47614994:-
BRCA	cis	rs10838634	0.901	rs3136500	ENSG00000280615.1	Y_RNA	-3.55	0.000401	0.0205	-0.23	-0.11	Schizophrenia;	chr11:46736833	chr11:47614898~47614994:-
BRCA	cis	rs6120849	0.662	rs6060300	ENSG00000202150.1	RNU6-407P	3.55	0.000401	0.0205	0.16	0.11	Protein C levels;	chr20:35193167	chr20:35030317~35030420:-
BRCA	cis	rs11877825	0.826	rs1893228	ENSG00000265728.1	RP11-883A18.3	-3.55	0.000401	0.0205	-0.15	-0.11	Gut microbiota (bacterial taxa);	chr18:10578875	chr18:10594590~10604798:+
BRCA	cis	rs4835473	0.778	rs6856553	ENSG00000249741.2	RP11-673E1.3	3.55	0.000401	0.0205	0.11	0.11	Immature fraction of reticulocytes;	chr4:143825973	chr4:143911514~143912053:-
BRCA	cis	rs4835473	0.868	rs11737787	ENSG00000249741.2	RP11-673E1.3	3.55	0.000401	0.0205	0.11	0.11	Immature fraction of reticulocytes;	chr4:143826498	chr4:143911514~143912053:-
BRCA	cis	rs8038465	0.615	rs6495074	ENSG00000260898.4	ADPGK-AS1	3.55	0.000401	0.0205	0.12	0.11	Liver enzyme levels (gamma-glutamyl transferase);	chr15:73666672	chr15:72782835~72798199:+
BRCA	cis	rs875971	0.862	rs709596	ENSG00000271064.1	RP11-792A8.3	-3.55	0.000401	0.0205	-0.13	-0.11	Aortic root size;	chr7:66360926	chr7:66748838~66749077:-
BRCA	cis	rs7267979	0.903	rs6115118	ENSG00000231081.1	RP4-760C5.3	-3.55	0.000401	0.0205	-0.14	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25266098	chr20:26008791~26010531:-
BRCA	cis	rs7267979	0.903	rs1118963	ENSG00000231081.1	RP4-760C5.3	-3.55	0.000401	0.0205	-0.14	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25266813	chr20:26008791~26010531:-
BRCA	cis	rs13401620	0.752	rs1470482	ENSG00000229326.3	AC069154.4	3.55	0.000402	0.0205	0.14	0.11	Breast size;	chr2:119999012	chr2:119698623~119700151:+
BRCA	cis	rs7620503	1	rs6777561	ENSG00000228561.2	RP11-114M1.1	3.55	0.000402	0.0205	0.13	0.11	Corneal structure;	chr3:177587410	chr3:177683627~177691250:+
BRCA	cis	rs875971	0.862	rs1167390	ENSG00000273024.4	INTS4P2	3.55	0.000402	0.0205	0.12	0.11	Aortic root size;	chr7:66110906	chr7:65647864~65715661:+
BRCA	cis	rs875971	0.862	rs35034167	ENSG00000273024.4	INTS4P2	3.55	0.000402	0.0205	0.12	0.11	Aortic root size;	chr7:66115179	chr7:65647864~65715661:+
BRCA	cis	rs34779708	0.966	rs4934737	ENSG00000269952.1	RP11-324I22.3	-3.55	0.000402	0.0205	-0.15	-0.11	Inflammatory bowel disease;Crohn's disease;	chr10:35223871	chr10:35210416~35210750:+
BRCA	cis	rs4449834	0.851	rs9298042	ENSG00000254432.1	RP11-33I11.2	-3.55	0.000402	0.0205	-0.15	-0.11	Sum eosinophil basophil counts;	chr8:60795760	chr8:60808735~60809606:-
BRCA	cis	rs12967678	1	rs12967678	ENSG00000260302.1	RP11-973H7.1	3.55	0.000402	0.0205	0.21	0.11	Selective IgA deficiency;	chr18:12805389	chr18:12774651~12775923:-
BRCA	cis	rs891378	1	rs4844592	ENSG00000274245.1	RP11-357P18.2	-3.55	0.000402	0.0205	-0.14	-0.11	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207327866	chr1:207372559~207373252:+
BRCA	cis	rs13434995	0.513	rs7665846	ENSG00000273257.1	RP11-177J6.1	3.55	0.000402	0.0205	0.16	0.11	Adiponectin levels;	chr4:55573078	chr4:55387949~55388271:+
BRCA	cis	rs3768617	0.706	rs8179460	ENSG00000224468.3	RP11-181K3.4	-3.55	0.000402	0.0205	-0.12	-0.11	Fuchs's corneal dystrophy;	chr1:183087087	chr1:183138402~183141282:-
BRCA	cis	rs7735319	0.565	rs10056456	ENSG00000249572.1	CTD-2203K17.1	3.55	0.000402	0.0205	0.14	0.11	Systolic blood pressure;	chr5:33087339	chr5:33424025~33440619:-
BRCA	cis	rs73198271	0.74	rs10105920	ENSG00000233609.3	RP11-62H7.2	3.55	0.000402	0.0205	0.11	0.11	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8791227	chr8:8961200~8979025:+
BRCA	cis	rs62025270	0.632	rs56153788	ENSG00000259416.2	RP11-158M2.5	-3.55	0.000402	0.0205	-0.17	-0.11	Idiopathic pulmonary fibrosis;	chr15:85627761	chr15:85754941~85756237:-
BRCA	cis	rs11085466	0.948	rs76881507	ENSG00000268081.1	RP11-678G14.2	-3.55	0.000402	0.0205	-0.17	-0.11	Colorectal or endometrial cancer;	chr19:21579387	chr19:21554640~21569237:-
BRCA	cis	rs6701713	0.84	rs6656401	ENSG00000274245.1	RP11-357P18.2	3.55	0.000402	0.0205	0.18	0.11	Alzheimer's disease (late onset);	chr1:207518704	chr1:207372559~207373252:+
BRCA	cis	rs58521262	0.585	rs2927367	ENSG00000241282.1	RPL34P33	3.55	0.000402	0.0205	0.15	0.11	Testicular germ cell tumor;	chr19:23047317	chr19:22699352~22699685:+
BRCA	cis	rs801193	0.569	rs2659907	ENSG00000265600.1	AC006480.1	-3.55	0.000402	0.0205	-0.13	-0.11	Aortic root size;	chr7:66699045	chr7:67356680~67356779:+
BRCA	cis	rs7824557	0.806	rs7007394	ENSG00000255046.1	RP11-297N6.4	3.55	0.000402	0.0205	0.13	0.11	Retinal vascular caliber;	chr8:11237057	chr8:11797928~11802568:-
BRCA	cis	rs3015497	0.637	rs7493755	ENSG00000259113.1	RP11-406H23.2	-3.55	0.000402	0.0205	-0.12	-0.11	Mean platelet volume;	chr14:50706307	chr14:50448807~50456742:+
BRCA	cis	rs2489715	0.7	rs2419674	ENSG00000185904.10	LINC00839	-3.55	0.000402	0.0205	-0.13	-0.11	Helix rolling;	chr10:42428607	chr10:42475543~42495336:+
BRCA	cis	rs7267979	1	rs2424710	ENSG00000274973.1	RP13-401N8.7	-3.55	0.000402	0.0206	-0.13	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25303250	chr20:25845497~25845862:+
BRCA	cis	rs13401620	0.827	rs7600358	ENSG00000229326.3	AC069154.4	3.55	0.000402	0.0206	0.15	0.11	Breast size;	chr2:119945396	chr2:119698623~119700151:+
BRCA	cis	rs12411860	0.929	rs12569464	ENSG00000226200.5	SGMS1-AS1	-3.55	0.000402	0.0206	-0.1	-0.11	Blood protein levels;	chr10:50274514	chr10:50624951~50641451:+
BRCA	cis	rs9311474	0.629	rs4282054	ENSG00000222345.1	SNORD19	3.55	0.000402	0.0206	0.11	0.11	Electroencephalogram traits;	chr3:52532049	chr3:52691378~52691453:+
BRCA	cis	rs6854137	0.553	rs10014274	ENSG00000214676.4	RPL9P16	-3.55	0.000402	0.0206	-0.13	-0.11	Vein graft stenosis in coronary artery bypass grafting;	chr4:168784146	chr4:168755816~168756382:+
BRCA	cis	rs7267979	1	rs6037086	ENSG00000274414.1	RP5-965G21.4	3.55	0.000402	0.0206	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25325702	chr20:25239007~25245229:-
BRCA	cis	rs7267979	0.966	rs2482923	ENSG00000274414.1	RP5-965G21.4	3.55	0.000402	0.0206	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25328345	chr20:25239007~25245229:-
BRCA	cis	rs2404602	0.692	rs1867197	ENSG00000274515.1	CTD-2026K11.5	3.55	0.000402	0.0206	0.12	0.11	Blood metabolite levels;	chr15:76617690	chr15:75645020~75645442:+
BRCA	cis	rs2496589	0.609	rs11155297	ENSG00000229036.6	VDAC1P8	-3.55	0.000402	0.0206	-0.14	-0.11	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);	chr6:143503967	chr6:143490424~143506406:+
BRCA	cis	rs4073416	0.872	rs7156078	ENSG00000276116.2	FUT8-AS1	3.55	0.000402	0.0206	0.11	0.11	N-glycan levels;	chr14:65771983	chr14:65411170~65412690:-
BRCA	cis	rs911186	0.812	rs35454259	ENSG00000216901.1	AL022393.7	3.55	0.000402	0.0206	0.17	0.11	Autism spectrum disorder or schizophrenia;	chr6:27286696	chr6:28176188~28176674:+
BRCA	cis	rs7411387	1	rs7411387	ENSG00000234020.1	CHIAP3	3.55	0.000402	0.0206	0.13	0.11	Interferon alpha levels in systemic lupus erythematosus;	chr1:111294513	chr1:111353275~111367409:-
BRCA	cis	rs62458065	0.64	rs79619897	ENSG00000273014.1	RP11-225B17.2	-3.55	0.000402	0.0206	-0.17	-0.11	Metabolite levels (HVA/MHPG ratio);	chr7:32475207	chr7:32758882~32759353:+
BRCA	cis	rs6964587	1	rs2282970	ENSG00000188693.7	CYP51A1-AS1	-3.55	0.000402	0.0206	-0.12	-0.11	Breast cancer;	chr7:91954967	chr7:92134604~92180725:+
BRCA	cis	rs7487075	0.619	rs10880973	ENSG00000257261.4	RP11-96H19.1	3.55	0.000402	0.0206	0.12	0.11	Itch intensity from mosquito bite;	chr12:46459426	chr12:46383679~46876159:+
BRCA	cis	rs6088590	1	rs6119512	ENSG00000276073.1	RP5-1125A11.7	-3.55	0.000402	0.0206	-0.13	-0.11	Coronary artery disease;	chr20:34719100	chr20:33985617~33988989:-
BRCA	cis	rs77633900	0.614	rs280028	ENSG00000196274.5	Metazoa_SRP	3.55	0.000402	0.0206	0.16	0.11	Glioma;Non-glioblastoma glioma;	chr15:76739125	chr15:76230048~76230390:-
BRCA	cis	rs897984	0.542	rs3751855	ENSG00000232748.3	RP11-196G11.6	-3.55	0.000402	0.0206	-0.13	-0.11	Dementia with Lewy bodies;	chr16:31079888	chr16:31056460~31062803:+
BRCA	cis	rs6142618	0.562	rs2235902	ENSG00000224452.1	RSL24D1P6	3.55	0.000402	0.0206	0.15	0.11	Inflammatory bowel disease;	chr20:32133547	chr20:32170390~32170790:-
BRCA	cis	rs2952768	1	rs2709397	ENSG00000224137.1	AC079767.4	-3.55	0.000402	0.0206	-0.1	-0.11	Opioid sensitivity;	chr2:207627845	chr2:207662375~207667024:+
BRCA	cis	rs6929812	0.577	rs2294309	ENSG00000271755.1	RP1-153G14.4	3.55	0.000402	0.0206	0.12	0.11	Neuroticism (multi-trait analysis);	chr6:27516037	chr6:27404010~27406964:-
BRCA	cis	rs4478858	0.735	rs6685728	ENSG00000223907.1	LINC01226	-3.55	0.000402	0.0206	-0.13	-0.11	Alcohol dependence;	chr1:31329703	chr1:31518435~31524245:+
BRCA	cis	rs875971	1	rs11971949	ENSG00000230189.5	GS1-124K5.2	-3.55	0.000402	0.0206	-0.09	-0.11	Aortic root size;	chr7:66161027	chr7:66409143~66490059:-
BRCA	cis	rs7937682	0.632	rs11214029	ENSG00000176343.5	RPL37AP8	3.55	0.000402	0.0206	0.14	0.11	Primary sclerosing cholangitis;	chr11:111890506	chr11:111889199~111889474:-
BRCA	cis	rs10266483	0.661	rs608769	ENSG00000227986.1	TRIM60P18	-3.55	0.000403	0.0206	-0.12	-0.11	Response to statin therapy;	chr7:64292783	chr7:64355078~64356199:+
BRCA	cis	rs5758511	0.596	rs55644935	ENSG00000231261.1	HMGN2P10	-3.55	0.000403	0.0206	-0.15	-0.11	Birth weight;	chr22:42270063	chr22:41709225~41709489:-
BRCA	cis	rs4869313	0.642	rs2247650	ENSG00000248734.2	CTD-2260A17.1	-3.55	0.000403	0.0206	-0.11	-0.11	Pediatric autoimmune diseases;	chr5:96894046	chr5:96784777~96785999:+
BRCA	cis	rs6460942	0.841	rs6968277	ENSG00000226690.5	AC005281.1	3.55	0.000403	0.0206	0.18	0.11	Coronary artery disease;	chr7:12404169	chr7:12496429~12541910:+
BRCA	cis	rs6714710	0.58	rs57681139	ENSG00000228486.8	LINC01125	-3.55	0.000403	0.0206	-0.1	-0.11	Posterior cortical atrophy and Alzheimer's disease;	chr2:97838010	chr2:97664217~97703064:+
BRCA	cis	rs6714710	0.58	rs1838797	ENSG00000228486.8	LINC01125	-3.55	0.000403	0.0206	-0.1	-0.11	Posterior cortical atrophy and Alzheimer's disease;	chr2:97838109	chr2:97664217~97703064:+
BRCA	cis	rs4589258	0.843	rs7128572	ENSG00000280367.1	RP11-121L10.2	3.55	0.000403	0.0206	0.13	0.11	Intelligence (multi-trait analysis);	chr11:90749821	chr11:90223153~90226538:+
BRCA	cis	rs4589258	1	rs4462299	ENSG00000280367.1	RP11-121L10.2	3.55	0.000403	0.0206	0.13	0.11	Intelligence (multi-trait analysis);	chr11:90750106	chr11:90223153~90226538:+
BRCA	cis	rs1113500	0.575	rs1781070	ENSG00000230489.1	VAV3-AS1	3.55	0.000403	0.0206	0.12	0.11	Growth-regulated protein alpha levels;	chr1:108027076	chr1:107964443~107994607:+
BRCA	cis	rs17684571	0.751	rs13203681	ENSG00000231441.1	RP11-472M19.2	3.55	0.000403	0.0206	0.17	0.11	Schizophrenia;	chr6:56841361	chr6:56844002~56864078:+
BRCA	cis	rs17684571	0.751	rs36094082	ENSG00000231441.1	RP11-472M19.2	3.55	0.000403	0.0206	0.17	0.11	Schizophrenia;	chr6:56842153	chr6:56844002~56864078:+
BRCA	cis	rs62025270	0.632	rs16943251	ENSG00000259367.1	RP11-815J21.4	3.55	0.000403	0.0206	0.1	0.11	Idiopathic pulmonary fibrosis;	chr15:85692004	chr15:85619623~85670948:-
BRCA	cis	rs10905065	0.766	rs11598374	ENSG00000215267.7	AKR1C7P	-3.55	0.000403	0.0206	-0.14	-0.11	Menopause (age at onset);	chr10:5785023	chr10:5275173~5288470:-
BRCA	cis	rs853679	0.517	rs9368555	ENSG00000226314.6	ZNF192P1	-3.55	0.000403	0.0206	-0.17	-0.11	Depression;	chr6:28141189	chr6:28161781~28169594:+
BRCA	cis	rs853679	0.517	rs9393893	ENSG00000226314.6	ZNF192P1	-3.55	0.000403	0.0206	-0.17	-0.11	Depression;	chr6:28141484	chr6:28161781~28169594:+
BRCA	cis	rs875971	0.838	rs2173570	ENSG00000272831.1	RP11-792A8.4	-3.55	0.000403	0.0206	-0.1	-0.11	Aortic root size;	chr7:66297976	chr7:66739829~66740385:-
BRCA	cis	rs9467773	0.596	rs3001369	ENSG00000224843.5	LINC00240	-3.55	0.000403	0.0206	-0.12	-0.11	Intelligence (multi-trait analysis);	chr6:26670741	chr6:26956992~27023924:+
BRCA	cis	rs2274273	1	rs10149435	ENSG00000233924.1	AL160471.6	-3.55	0.000403	0.0206	-0.12	-0.11	Protein biomarker;	chr14:55160771	chr14:55004813~55005687:-
BRCA	cis	rs10504130	0.569	rs71513549	ENSG00000272076.1	RP11-11C20.3	3.55	0.000403	0.0206	0.16	0.11	Venous thromboembolism (SNP x SNP interaction);	chr8:51770326	chr8:51810110~51810681:-
BRCA	cis	rs10504130	0.502	rs4321994	ENSG00000272076.1	RP11-11C20.3	3.55	0.000403	0.0206	0.16	0.11	Venous thromboembolism (SNP x SNP interaction);	chr8:51771680	chr8:51810110~51810681:-
BRCA	cis	rs7267979	1	rs2424716	ENSG00000277938.1	RP5-965G21.3	3.55	0.000403	0.0206	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25442902	chr20:25229150~25231933:+
BRCA	cis	rs7267979	1	rs761025	ENSG00000277938.1	RP5-965G21.3	3.55	0.000403	0.0206	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25446332	chr20:25229150~25231933:+
BRCA	cis	rs7695732	0.869	rs1795738	ENSG00000270720.1	RP11-84C13.2	-3.55	0.000403	0.0206	-0.15	-0.11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr4:89009283	chr4:89119284~89119871:+
BRCA	cis	rs6991838	0.584	rs4737221	ENSG00000272155.1	RP11-707M3.3	3.55	0.000403	0.0206	0.1	0.11	Intelligence (multi-trait analysis);	chr8:65569075	chr8:65714334~65714778:-
BRCA	cis	rs7618501	1	rs7372730	ENSG00000228008.1	CTD-2330K9.3	-3.55	0.000403	0.0206	-0.1	-0.11	Intelligence (multi-trait analysis);	chr3:49753249	chr3:49903845~49916937:+
BRCA	cis	rs7959452	0.59	rs6581889	ENSG00000274979.1	RP11-1143G9.5	-3.55	0.000403	0.0206	-0.12	-0.11	Blood protein levels;	chr12:69363649	chr12:69326574~69331882:-
BRCA	cis	rs7959452	0.59	rs11177619	ENSG00000274979.1	RP11-1143G9.5	-3.55	0.000403	0.0206	-0.12	-0.11	Blood protein levels;	chr12:69365091	chr12:69326574~69331882:-
BRCA	cis	rs7959452	0.532	rs2291005	ENSG00000274979.1	RP11-1143G9.5	-3.55	0.000403	0.0206	-0.12	-0.11	Blood protein levels;	chr12:69370608	chr12:69326574~69331882:-
BRCA	cis	rs7959452	0.59	rs11177628	ENSG00000274979.1	RP11-1143G9.5	-3.55	0.000403	0.0206	-0.12	-0.11	Blood protein levels;	chr12:69371641	chr12:69326574~69331882:-
BRCA	cis	rs7959452	0.562	rs11177630	ENSG00000274979.1	RP11-1143G9.5	-3.55	0.000403	0.0206	-0.12	-0.11	Blood protein levels;	chr12:69374183	chr12:69326574~69331882:-
BRCA	cis	rs4869313	0.668	rs2548526	ENSG00000248734.2	CTD-2260A17.1	-3.55	0.000403	0.0206	-0.11	-0.11	Pediatric autoimmune diseases;	chr5:96909913	chr5:96784777~96785999:+
BRCA	cis	rs4869313	0.642	rs2548525	ENSG00000248734.2	CTD-2260A17.1	-3.55	0.000403	0.0206	-0.11	-0.11	Pediatric autoimmune diseases;	chr5:96910188	chr5:96784777~96785999:+
BRCA	cis	rs4869313	0.668	rs2549798	ENSG00000248734.2	CTD-2260A17.1	-3.55	0.000403	0.0206	-0.11	-0.11	Pediatric autoimmune diseases;	chr5:96910199	chr5:96784777~96785999:+
BRCA	cis	rs4869313	0.668	rs2549799	ENSG00000248734.2	CTD-2260A17.1	-3.55	0.000403	0.0206	-0.11	-0.11	Pediatric autoimmune diseases;	chr5:96910206	chr5:96784777~96785999:+
BRCA	cis	rs4869313	0.668	rs2113191	ENSG00000248734.2	CTD-2260A17.1	-3.55	0.000403	0.0206	-0.11	-0.11	Pediatric autoimmune diseases;	chr5:96910634	chr5:96784777~96785999:+
BRCA	cis	rs4869313	0.694	rs2548524	ENSG00000248734.2	CTD-2260A17.1	-3.55	0.000403	0.0206	-0.11	-0.11	Pediatric autoimmune diseases;	chr5:96910897	chr5:96784777~96785999:+
BRCA	cis	rs4869313	0.668	rs2548523	ENSG00000248734.2	CTD-2260A17.1	-3.55	0.000403	0.0206	-0.11	-0.11	Pediatric autoimmune diseases;	chr5:96911236	chr5:96784777~96785999:+
BRCA	cis	rs4869313	0.617	rs1363975	ENSG00000248734.2	CTD-2260A17.1	-3.55	0.000403	0.0206	-0.11	-0.11	Pediatric autoimmune diseases;	chr5:96913182	chr5:96784777~96785999:+
BRCA	cis	rs4869313	0.668	rs2255546	ENSG00000248734.2	CTD-2260A17.1	-3.55	0.000403	0.0206	-0.11	-0.11	Pediatric autoimmune diseases;	chr5:96913411	chr5:96784777~96785999:+
BRCA	cis	rs4869313	0.668	rs2255633	ENSG00000248734.2	CTD-2260A17.1	-3.55	0.000403	0.0206	-0.11	-0.11	Pediatric autoimmune diseases;	chr5:96913619	chr5:96784777~96785999:+
BRCA	cis	rs4869313	0.642	rs2255634	ENSG00000248734.2	CTD-2260A17.1	-3.55	0.000403	0.0206	-0.11	-0.11	Pediatric autoimmune diseases;	chr5:96913647	chr5:96784777~96785999:+
BRCA	cis	rs4869313	0.668	rs2255637	ENSG00000248734.2	CTD-2260A17.1	-3.55	0.000403	0.0206	-0.11	-0.11	Pediatric autoimmune diseases;	chr5:96913674	chr5:96784777~96785999:+
BRCA	cis	rs2555155	0.808	rs11604960	ENSG00000254595.1	CTD-2010I16.1	3.55	0.000403	0.0206	0.12	0.11	DNA methylation (variation);	chr11:6507389	chr11:6488186~6489377:-
BRCA	cis	rs2562456	0.917	rs2562468	ENSG00000268705.1	BNIP3P26	-3.55	0.000403	0.0206	-0.12	-0.11	Pain;	chr19:21532048	chr19:21521343~21521896:-
BRCA	cis	rs2562456	0.917	rs2562471	ENSG00000268705.1	BNIP3P26	-3.55	0.000403	0.0206	-0.12	-0.11	Pain;	chr19:21533017	chr19:21521343~21521896:-
BRCA	cis	rs4703129	1	rs1550809	ENSG00000246763.5	RGMB-AS1	-3.55	0.000403	0.0206	-0.13	-0.11	Asperger disorder;	chr5:98556811	chr5:98769618~98773469:-
BRCA	cis	rs13401620	0.917	rs56369236	ENSG00000229326.3	AC069154.4	-3.55	0.000404	0.0206	-0.15	-0.11	Breast size;	chr2:119775012	chr2:119698623~119700151:+
BRCA	cis	rs7208859	0.673	rs2433	ENSG00000264538.5	SUZ12P1	-3.55	0.000404	0.0206	-0.17	-0.11	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30899210	chr17:30709299~30790908:+
BRCA	cis	rs7190551	0.51	rs12596702	ENSG00000260979.1	RP11-77H9.8	3.55	0.000404	0.0206	0.15	0.11	Platelet distribution width;	chr16:8997029	chr16:8962706~8966990:+
BRCA	cis	rs8180040	0.966	rs11130129	ENSG00000280667.1	Y_RNA	-3.55	0.000404	0.0206	-0.12	-0.11	Colorectal cancer;	chr3:47448395	chr3:47501083~47501182:+
BRCA	cis	rs4266144	0.563	rs61124401	ENSG00000241770.1	RP11-555M1.3	-3.55	0.000404	0.0206	-0.16	-0.11	Coronary artery disease;	chr3:157123130	chr3:157163452~157169133:+
BRCA	cis	rs10504130	0.932	rs80143499	ENSG00000272076.1	RP11-11C20.3	3.55	0.000404	0.0206	0.19	0.11	Venous thromboembolism (SNP x SNP interaction);	chr8:51808915	chr8:51810110~51810681:-
BRCA	cis	rs10504130	0.932	rs79612913	ENSG00000272076.1	RP11-11C20.3	3.55	0.000404	0.0206	0.19	0.11	Venous thromboembolism (SNP x SNP interaction);	chr8:51808916	chr8:51810110~51810681:-
BRCA	cis	rs10504130	1	rs75257860	ENSG00000272076.1	RP11-11C20.3	3.55	0.000404	0.0206	0.19	0.11	Venous thromboembolism (SNP x SNP interaction);	chr8:51811887	chr8:51810110~51810681:-
BRCA	cis	rs10504130	1	rs79299366	ENSG00000272076.1	RP11-11C20.3	3.55	0.000404	0.0206	0.19	0.11	Venous thromboembolism (SNP x SNP interaction);	chr8:51812800	chr8:51810110~51810681:-
BRCA	cis	rs250518	0.926	rs11953054	ENSG00000271926.1	CTD-2376I4.1	3.55	0.000404	0.0206	0.15	0.11	Mean corpuscular hemoglobin concentration;	chr5:72746876	chr5:72953635~72954274:-
BRCA	cis	rs9307551	0.602	rs7697040	ENSG00000244002.1	RP11-162K6.1	-3.55	0.000404	0.0206	-0.17	-0.11	Refractive error;	chr4:79644498	chr4:80161129~80162011:+
BRCA	cis	rs1075265	0.563	rs2692536	ENSG00000272156.1	RP11-477N3.1	-3.55	0.000404	0.0206	-0.12	-0.11	Chronotype;Morning vs. evening chronotype;	chr2:53788266	chr2:54082554~54085066:+
BRCA	cis	rs4953911	1	rs12618392	ENSG00000224043.6	CCNT2-AS1	3.55	0.000404	0.0206	0.15	0.11	Multiple sclerosis (severity);	chr2:134309531	chr2:134735464~134918710:-
BRCA	cis	rs67696533	0.588	rs6141743	ENSG00000275576.1	RP5-836N17.4	-3.55	0.000404	0.0206	-0.13	-0.11	White blood cell count (basophil);Basophil percentage of granulocytes;Basophil percentage of white cells;	chr20:32519596	chr20:32116171~32116629:+
BRCA	cis	rs8114671	0.562	rs4911164	ENSG00000126005.14	MMP24-AS1	-3.55	0.000404	0.0206	-0.13	-0.11	Height;	chr20:34891685	chr20:35216462~35278131:-
BRCA	cis	rs4713118	0.869	rs9461405	ENSG00000219392.1	RP1-265C24.5	-3.55	0.000404	0.0206	-0.15	-0.11	Parkinson's disease;	chr6:27751596	chr6:28115628~28116551:+
BRCA	cis	rs745109	0.816	rs59255035	ENSG00000273080.1	RP11-301O19.1	3.55	0.000404	0.0206	0.17	0.11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86479570	chr2:86195590~86196049:+
BRCA	cis	rs8114671	0.562	rs6087651	ENSG00000279253.1	RP4-614O4.13	-3.55	0.000404	0.0206	-0.12	-0.11	Height;	chr20:34930550	chr20:35262727~35264187:-
BRCA	cis	rs8114671	0.562	rs6119545	ENSG00000279253.1	RP4-614O4.13	-3.55	0.000404	0.0206	-0.12	-0.11	Height;	chr20:34935066	chr20:35262727~35264187:-
BRCA	cis	rs36051895	0.554	rs7856773	ENSG00000237711.1	RP11-39K24.13	-3.55	0.000404	0.0206	-0.13	-0.11	Pediatric autoimmune diseases;	chr9:5204705	chr9:5100236~5101009:+
BRCA	cis	rs4767841	1	rs10849691	ENSG00000248636.5	RP11-768F21.1	-3.55	0.000404	0.0206	-0.14	-0.11	Urgency urinary incontinence;	chr12:119716449	chr12:119387987~119668079:-
BRCA	cis	rs6496932	0.635	rs67659163	ENSG00000259630.2	CTD-2262B20.1	-3.55	0.000404	0.0206	-0.14	-0.11	Central corneal thickness;Corneal structure;	chr15:85387673	chr15:85415228~85415633:+
BRCA	cis	rs2299587	0.554	rs7815429	ENSG00000253671.1	RP11-806O11.1	-3.55	0.000404	0.0206	-0.13	-0.11	Economic and political preferences;	chr8:17879848	chr8:17808941~17820868:+
BRCA	cis	rs2836974	0.583	rs2735307	ENSG00000238141.2	BRWD1-AS1	3.55	0.000404	0.0206	0.12	0.11	Cognitive function;	chr21:39341432	chr21:39315707~39323218:+
BRCA	cis	rs2274273	0.588	rs7155054	ENSG00000259318.1	RP11-454L9.2	3.55	0.000404	0.0206	0.1	0.11	Protein biomarker;	chr14:55283944	chr14:55394940~55395233:-
BRCA	cis	rs739401	0.588	rs10219272	ENSG00000247473.2	CARS-AS1	3.55	0.000404	0.0206	0.12	0.11	Longevity;	chr11:2999559	chr11:3029009~3041260:+
BRCA	cis	rs9467773	1	rs4871	ENSG00000224843.5	LINC00240	-3.55	0.000404	0.0206	-0.12	-0.11	Intelligence (multi-trait analysis);	chr6:26545404	chr6:26956992~27023924:+
BRCA	cis	rs10208649	0.908	rs11889527	ENSG00000272156.1	RP11-477N3.1	3.55	0.000404	0.0206	0.22	0.11	Body mass index;	chr2:53999178	chr2:54082554~54085066:+
BRCA	cis	rs240993	0.516	rs181294	ENSG00000271789.1	RP5-1112D6.7	-3.55	0.000404	0.0206	-0.15	-0.11	Inflammatory skin disease;Psoriasis;	chr6:111298999	chr6:111297126~111298510:+
BRCA	cis	rs10744955	0.727	rs2414032	ENSG00000244879.4	GABPB1-AS1	-3.55	0.000404	0.0206	-0.11	-0.11	Lobe attachment (rater-scored or self-reported);	chr15:50166464	chr15:50354959~50372202:+
BRCA	cis	rs713587	0.806	rs6737082	ENSG00000224165.4	DNAJC27-AS1	-3.55	0.000404	0.0207	-0.12	-0.11	Body mass index in non-asthmatics;	chr2:24915171	chr2:24971390~25039694:+
BRCA	cis	rs1914816	1	rs2456075	ENSG00000259422.1	RP11-593F23.1	3.55	0.000404	0.0207	0.16	0.11	Response to tocilizumab in rheumatoid arthritis;	chr15:76263645	chr15:76174891~76181486:-
BRCA	cis	rs7111546	0.791	rs76432525	ENSG00000246225.5	RP11-17A1.3	3.55	0.000404	0.0207	0.19	0.11	Dialysis-related mortality;	chr11:22849681	chr11:22829380~22945393:+
BRCA	cis	rs7011507	1	rs6997499	ENSG00000279881.1	RP11-513O13.1	3.55	0.000404	0.0207	0.16	0.11	Inflammatory bowel disease;Ulcerative colitis;	chr8:48278424	chr8:48428143~48431041:-
BRCA	cis	rs4713118	0.662	rs9468274	ENSG00000226314.6	ZNF192P1	-3.55	0.000404	0.0207	-0.16	-0.11	Parkinson's disease;	chr6:28058299	chr6:28161781~28169594:+
BRCA	cis	rs4713118	0.662	rs9468275	ENSG00000226314.6	ZNF192P1	-3.55	0.000404	0.0207	-0.16	-0.11	Parkinson's disease;	chr6:28058358	chr6:28161781~28169594:+
BRCA	cis	rs4713118	0.662	rs9468276	ENSG00000226314.6	ZNF192P1	-3.55	0.000404	0.0207	-0.16	-0.11	Parkinson's disease;	chr6:28059910	chr6:28161781~28169594:+
BRCA	cis	rs4713118	0.662	rs9468277	ENSG00000226314.6	ZNF192P1	-3.55	0.000404	0.0207	-0.16	-0.11	Parkinson's disease;	chr6:28060612	chr6:28161781~28169594:+
BRCA	cis	rs4713118	0.662	rs9468278	ENSG00000226314.6	ZNF192P1	-3.55	0.000404	0.0207	-0.16	-0.11	Parkinson's disease;	chr6:28060704	chr6:28161781~28169594:+
BRCA	cis	rs4713118	0.662	rs13218430	ENSG00000226314.6	ZNF192P1	-3.55	0.000404	0.0207	-0.16	-0.11	Parkinson's disease;	chr6:28062059	chr6:28161781~28169594:+
BRCA	cis	rs9400180	0.879	rs4946895	ENSG00000271734.1	RP1-111B22.3	-3.55	0.000404	0.0207	-0.15	-0.11	Major depressive disorder;	chr6:108047677	chr6:108030249~108030718:-
BRCA	cis	rs7520050	0.966	rs4545281	ENSG00000234329.1	RP11-767N6.2	-3.55	0.000404	0.0207	-0.1	-0.11	Reticulocyte count;Red blood cell count;	chr1:45894382	chr1:45651039~45651826:-
BRCA	cis	rs6011674	1	rs75824619	ENSG00000273821.1	RP5-963E22.6	3.55	0.000405	0.0207	0.21	0.11	Response to cytadine analogues (cytosine arabinoside);	chr20:63225119	chr20:63218041~63218502:+
BRCA	cis	rs7259811	0.851	rs2870102	ENSG00000268266.1	AC003005.2	3.55	0.000405	0.0207	0.15	0.11	Western dietary pattern;	chr19:56712920	chr19:57477649~57482996:+
BRCA	cis	rs2360027	0.599	rs17257958	ENSG00000231365.4	RP11-418J17.1	-3.55	0.000405	0.0207	-0.14	-0.11	Tonsillectomy;	chr1:118537880	chr1:119140396~119275973:+
BRCA	cis	rs3011225	0.738	rs7542434	ENSG00000237950.1	RP11-7O11.3	-3.55	0.000405	0.0207	-0.15	-0.11	Amyotrophic lateral sclerosis (age of onset);	chr1:43843215	chr1:43944370~43946551:-
BRCA	cis	rs7577894	0.506	rs6743114	ENSG00000272606.1	RP11-554J4.1	3.55	0.000405	0.0207	0.12	0.11	Amyotrophic lateral sclerosis;	chr2:55847390	chr2:55617909~55618373:+
BRCA	cis	rs4650943	0.586	rs2455750	ENSG00000227740.1	RP11-318C24.2	3.55	0.000405	0.0207	0.11	0.11	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in inactive individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr1:176305980	chr1:175904762~175920513:-
BRCA	cis	rs875971	0.895	rs4718349	ENSG00000229886.1	RP5-1132H15.3	3.55	0.000405	0.0207	0.12	0.11	Aortic root size;	chr7:66444024	chr7:66025126~66031544:-
BRCA	cis	rs875971	1	rs2042133	ENSG00000229886.1	RP5-1132H15.3	3.55	0.000405	0.0207	0.12	0.11	Aortic root size;	chr7:66466935	chr7:66025126~66031544:-
BRCA	cis	rs875971	0.964	rs2161065	ENSG00000229886.1	RP5-1132H15.3	3.55	0.000405	0.0207	0.12	0.11	Aortic root size;	chr7:66467918	chr7:66025126~66031544:-
BRCA	cis	rs875971	0.862	rs12698521	ENSG00000229886.1	RP5-1132H15.3	3.55	0.000405	0.0207	0.12	0.11	Aortic root size;	chr7:66474502	chr7:66025126~66031544:-
BRCA	cis	rs9952980	0.573	rs28732974	ENSG00000266968.2	RP11-116O18.1	-3.55	0.000405	0.0207	-0.14	-0.11	Breast cancer;	chr18:45324022	chr18:45646153~45647937:+
BRCA	cis	rs7103648	1	rs7103648	ENSG00000280615.1	Y_RNA	3.55	0.000405	0.0207	0.13	0.11	Systolic blood pressure;Diastolic blood pressure;	chr11:47440232	chr11:47614898~47614994:-
BRCA	cis	rs7103648	0.932	rs7104036	ENSG00000280615.1	Y_RNA	3.55	0.000405	0.0207	0.13	0.11	Systolic blood pressure;Diastolic blood pressure;	chr11:47440589	chr11:47614898~47614994:-
BRCA	cis	rs1823913	0.614	rs1947457	ENSG00000280083.1	RP11-317J9.1	-3.55	0.000405	0.0207	-0.2	-0.11	Obesity-related traits;	chr2:191298970	chr2:191154118~191156070:-
BRCA	cis	rs6490294	0.528	rs79761579	ENSG00000257624.1	RP1-128M12.3	3.55	0.000405	0.0207	0.2	0.11	Mean platelet volume;	chr12:112021081	chr12:112000739~112000985:-
BRCA	cis	rs295490	0.748	rs17560106	ENSG00000178631.7	ACTG1P1	-3.55	0.000405	0.0207	-0.21	-0.11	PR interval in Tripanosoma cruzi seropositivity;	chr3:139461388	chr3:139493809~139494937:+
BRCA	cis	rs2109514	0.542	rs1011442	ENSG00000237813.3	AC002066.1	3.55	0.000405	0.0207	0.14	0.11	Prevalent atrial fibrillation;	chr7:116448247	chr7:116238260~116499465:-
BRCA	cis	rs67478160	0.595	rs2295146	ENSG00000269910.1	RP11-73M18.10	3.55	0.000405	0.0207	0.11	0.11	Schizophrenia;	chr14:103733019	chr14:103694516~103695050:-
BRCA	cis	rs4835473	0.9	rs67600034	ENSG00000246448.2	RP13-578N3.3	-3.55	0.000405	0.0207	-0.12	-0.11	Immature fraction of reticulocytes;	chr4:143734670	chr4:143700257~143865072:+
BRCA	cis	rs6743226	0.603	rs3755324	ENSG00000266621.1	AC104841.1	3.55	0.000405	0.0207	0.13	0.11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in non-smokers;	chr2:241263805	chr2:241245202~241245299:-
BRCA	cis	rs733175	0.857	rs10018663	ENSG00000250413.1	RP11-448G15.1	-3.55	0.000405	0.0207	-0.17	-0.11	Psychosis and Alzheimer's disease;	chr4:10003173	chr4:10006482~10009725:+
BRCA	cis	rs8030605	0.704	rs55759746	ENSG00000277245.1	RP11-48G14.3	3.55	0.000405	0.0207	0.23	0.11	Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;	chr15:56333954	chr15:56447120~56447697:+
BRCA	cis	rs8141529	0.748	rs715531	ENSG00000272858.1	CTA-292E10.8	-3.55	0.000405	0.0207	-0.14	-0.11	Lymphocyte counts;	chr22:28886691	chr22:28814914~28815662:+
BRCA	cis	rs17221829	0.733	rs72971005	ENSG00000280385.1	AP000648.5	-3.55	0.000405	0.0207	-0.13	-0.11	Anxiety in major depressive disorder;	chr11:89625244	chr11:90193614~90198120:+
BRCA	cis	rs2191566	1	rs2356549	ENSG00000266921.1	RP11-15A1.7	-3.55	0.000405	0.0207	-0.14	-0.11	Acute lymphoblastic leukemia (childhood);	chr19:44007050	chr19:43996896~44002836:-
BRCA	cis	rs524281	0.861	rs10791855	ENSG00000255038.1	RP11-1167A19.2	-3.55	0.000405	0.0207	-0.16	-0.11	Electroencephalogram traits;	chr11:66196266	chr11:66067277~66069619:-
BRCA	cis	rs6015450	1	rs80271186	ENSG00000228340.4	MIR646HG	3.55	0.000405	0.0207	0.22	0.11	Hypertension;Blood pressure;Systolic blood pressure;Diastolic blood pressure;	chr20:59151068	chr20:60087840~60527458:+
BRCA	cis	rs9921338	0.632	rs80945	ENSG00000262636.1	CTD-3088G3.4	-3.55	0.000405	0.0207	-0.19	-0.11	Vein graft stenosis in coronary artery bypass grafting;	chr16:11249263	chr16:11380859~11381118:-
BRCA	cis	rs848490	0.962	rs11764879	ENSG00000214293.7	APTR	3.55	0.000405	0.0207	0.14	0.11	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77703950	chr7:77657660~77696265:-
BRCA	cis	rs6840360	0.55	rs6836343	ENSG00000270265.1	RP11-731D1.4	-3.55	0.000405	0.0207	-0.13	-0.11	Intelligence (multi-trait analysis);	chr4:151576412	chr4:151333775~151353224:-
BRCA	cis	rs6840360	0.571	rs4696270	ENSG00000270265.1	RP11-731D1.4	-3.55	0.000405	0.0207	-0.13	-0.11	Intelligence (multi-trait analysis);	chr4:151577137	chr4:151333775~151353224:-
BRCA	cis	rs6914598	0.876	rs6915161	ENSG00000240869.3	RN7SL128P	-3.55	0.000405	0.0207	-0.16	-0.11	Cutaneous malignant melanoma;Melanoma;	chr6:21163980	chr6:20421583~20421887:-
BRCA	cis	rs488400	0.558	rs361163	ENSG00000251603.1	RP11-164P12.4	3.55	0.000405	0.0207	0.11	0.11	Trans fatty acid levels;	chr4:151878731	chr4:151667224~151670502:+
BRCA	cis	rs77633900	0.614	rs280001	ENSG00000196274.5	Metazoa_SRP	3.55	0.000406	0.0207	0.16	0.11	Glioma;Non-glioblastoma glioma;	chr15:76711225	chr15:76230048~76230390:-
BRCA	cis	rs10090774	0.965	rs12680723	ENSG00000280303.2	ERICD	-3.55	0.000406	0.0207	-0.13	-0.11	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140984704	chr8:140636281~140638283:+
BRCA	cis	rs2252790	0.64	rs1128261	ENSG00000233558.1	RP3-486I3.4	-3.55	0.000406	0.0207	-0.13	-0.11	Fast beta electroencephalogram;	chr6:116277690	chr6:116258493~116259115:-
BRCA	cis	rs7311936	1	rs7302734	ENSG00000269980.1	RP11-282O18.7	-3.55	0.000406	0.0207	-0.13	-0.11	Vertical cup-disc ratio;	chr12:124151796	chr12:123262060~123262402:+
BRCA	cis	rs3020264	0.586	rs3020265	ENSG00000249898.6	CTD-2541M15.1	3.55	0.000406	0.0207	0.13	0.11	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 24 weeks);	chr8:6631400	chr8:6618475~6708209:-
BRCA	cis	rs911119	0.913	rs6048926	ENSG00000270001.1	RP11-218C14.8	-3.55	0.000406	0.0207	-0.14	-0.11	Chronic kidney disease;	chr20:23600350	chr20:23631826~23632316:-
BRCA	cis	rs11039100	0.85	rs34930440	ENSG00000224295.2	AC087380.14	3.55	0.000406	0.0207	0.21	0.11	Peripheral arterial disease (traffic-related air pollution interaction);	chr11:5812927	chr11:5518441~5524955:-
BRCA	cis	rs11039100	0.85	rs35990969	ENSG00000224295.2	AC087380.14	3.55	0.000406	0.0207	0.21	0.11	Peripheral arterial disease (traffic-related air pollution interaction);	chr11:5813012	chr11:5518441~5524955:-
BRCA	cis	rs11039100	0.85	rs35746872	ENSG00000224295.2	AC087380.14	3.55	0.000406	0.0207	0.21	0.11	Peripheral arterial disease (traffic-related air pollution interaction);	chr11:5813105	chr11:5518441~5524955:-
BRCA	cis	rs8180040	1	rs553989	ENSG00000276925.1	RP11-708J19.3	3.55	0.000406	0.0207	0.12	0.11	Colorectal cancer;	chr3:47358838	chr3:47469777~47469987:+
BRCA	cis	rs75422866	0.867	rs73102140	ENSG00000276691.1	RP5-1057I20.5	3.55	0.000406	0.0207	0.23	0.11	Pneumonia;	chr12:47647497	chr12:47788426~47788971:+
BRCA	cis	rs75422866	0.867	rs73102148	ENSG00000276691.1	RP5-1057I20.5	3.55	0.000406	0.0207	0.23	0.11	Pneumonia;	chr12:47648013	chr12:47788426~47788971:+
BRCA	cis	rs75422866	0.867	rs73102151	ENSG00000276691.1	RP5-1057I20.5	3.55	0.000406	0.0207	0.23	0.11	Pneumonia;	chr12:47648023	chr12:47788426~47788971:+
BRCA	cis	rs7412746	0.634	rs2124952	ENSG00000231073.1	RP11-316M1.3	3.55	0.000406	0.0207	0.12	0.11	Melanoma;	chr1:150951298	chr1:150973123~150975534:+
BRCA	cis	rs34779708	0.931	rs11010130	ENSG00000269952.1	RP11-324I22.3	-3.55	0.000406	0.0207	-0.15	-0.11	Inflammatory bowel disease;Crohn's disease;	chr10:35224379	chr10:35210416~35210750:+
BRCA	cis	rs34779708	0.897	rs11010131	ENSG00000269952.1	RP11-324I22.3	-3.55	0.000406	0.0207	-0.15	-0.11	Inflammatory bowel disease;Crohn's disease;	chr10:35224388	chr10:35210416~35210750:+
BRCA	cis	rs9457247	0.534	rs9356551	ENSG00000227598.1	RP1-167A14.2	3.55	0.000406	0.0207	0.12	0.11	Crohn's disease;	chr6:166986857	chr6:166969626~166999065:-
BRCA	cis	rs1871744	0.746	rs6857600	ENSG00000246375.2	RP11-10L7.1	-3.55	0.000406	0.0207	-0.17	-0.11	Renal underexcretion gout;	chr4:88144923	chr4:88284942~88331421:+
BRCA	cis	rs10761482	0.861	rs4948406	ENSG00000254271.1	RP11-131N11.4	3.55	0.000406	0.0207	0.15	0.11	Schizophrenia;	chr10:60350388	chr10:60734342~60741828:+
BRCA	cis	rs7267979	0.966	rs2261698	ENSG00000274414.1	RP5-965G21.4	-3.55	0.000406	0.0207	-0.13	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25279274	chr20:25239007~25245229:-
BRCA	cis	rs1914816	0.878	rs2456078	ENSG00000259422.1	RP11-593F23.1	3.55	0.000406	0.0207	0.16	0.11	Response to tocilizumab in rheumatoid arthritis;	chr15:76266529	chr15:76174891~76181486:-
BRCA	cis	rs6840360	0.571	rs4696110	ENSG00000270265.1	RP11-731D1.4	-3.55	0.000406	0.0207	-0.12	-0.11	Intelligence (multi-trait analysis);	chr4:151750173	chr4:151333775~151353224:-
BRCA	cis	rs1816752	0.819	rs4770665	ENSG00000273628.1	RP11-756A22.7	3.55	0.000406	0.0207	0.13	0.11	Obesity-related traits;	chr13:24414810	chr13:24933006~24936796:+
BRCA	cis	rs564309	1	rs12061642	ENSG00000212237.1	RNA5SP18	3.55	0.000406	0.0207	0.21	0.11	Hip circumference (psychosocial stress interaction);	chr1:228398535	chr1:228647912~228648032:-
BRCA	cis	rs9381040	0.701	rs4711658	ENSG00000261068.2	RP11-7K24.3	3.55	0.000406	0.0207	0.15	0.11	Alzheimer's disease (late onset);	chr6:41195153	chr6:42092233~42094259:-
BRCA	cis	rs4722166	0.532	rs6461662	ENSG00000225541.1	AC002480.5	-3.55	0.000406	0.0207	-0.11	-0.11	Lung cancer;	chr7:22717470	chr7:22571607~22661792:-
BRCA	cis	rs35306767	0.903	rs12778891	ENSG00000229869.1	RP11-363N22.2	-3.55	0.000406	0.0207	-0.17	-0.11	Eosinophil percentage of granulocytes;	chr10:904190	chr10:933026~942743:+
BRCA	cis	rs4763879	0.502	rs11052552	ENSG00000214826.5	DDX12P	3.55	0.000406	0.0207	0.09	0.11	Type 1 diabetes;	chr12:9703362	chr12:9418673~9448229:-
BRCA	cis	rs875971	0.79	rs10257911	ENSG00000271064.1	RP11-792A8.3	3.55	0.000406	0.0207	0.13	0.11	Aortic root size;	chr7:66278783	chr7:66748838~66749077:-
BRCA	cis	rs7618501	1	rs11709680	ENSG00000228008.1	CTD-2330K9.3	-3.55	0.000407	0.0207	-0.1	-0.11	Intelligence (multi-trait analysis);	chr3:49707755	chr3:49903845~49916937:+
BRCA	cis	rs7618501	1	rs11130219	ENSG00000228008.1	CTD-2330K9.3	-3.55	0.000407	0.0207	-0.1	-0.11	Intelligence (multi-trait analysis);	chr3:49714994	chr3:49903845~49916937:+
BRCA	cis	rs7618501	1	rs34614773	ENSG00000228008.1	CTD-2330K9.3	-3.55	0.000407	0.0207	-0.1	-0.11	Intelligence (multi-trait analysis);	chr3:49715570	chr3:49903845~49916937:+
BRCA	cis	rs412658	0.67	rs1912576	ENSG00000269345.1	VN1R85P	3.55	0.000407	0.0207	0.14	0.11	Telomere length;	chr19:21938491	chr19:22174766~22175191:-
BRCA	cis	rs6088580	0.634	rs6059878	ENSG00000269202.1	RP4-614O4.12	-3.55	0.000407	0.0207	-0.11	-0.11	Glomerular filtration rate (creatinine);	chr20:34499361	chr20:35201747~35203288:-
BRCA	cis	rs6088580	0.601	rs6120668	ENSG00000269202.1	RP4-614O4.12	-3.55	0.000407	0.0207	-0.11	-0.11	Glomerular filtration rate (creatinine);	chr20:34511988	chr20:35201747~35203288:-
BRCA	cis	rs6088580	0.634	rs6059887	ENSG00000269202.1	RP4-614O4.12	-3.55	0.000407	0.0207	-0.11	-0.11	Glomerular filtration rate (creatinine);	chr20:34513297	chr20:35201747~35203288:-
BRCA	cis	rs6088580	0.634	rs6059892	ENSG00000269202.1	RP4-614O4.12	-3.55	0.000407	0.0207	-0.11	-0.11	Glomerular filtration rate (creatinine);	chr20:34517961	chr20:35201747~35203288:-
BRCA	cis	rs6088580	0.609	rs2378205	ENSG00000269202.1	RP4-614O4.12	-3.55	0.000407	0.0207	-0.11	-0.11	Glomerular filtration rate (creatinine);	chr20:34522998	chr20:35201747~35203288:-
BRCA	cis	rs1005277	0.505	rs200939	ENSG00000273019.1	RP11-508N22.13	-3.55	0.000407	0.0207	-0.13	-0.11	Extrinsic epigenetic age acceleration;	chr10:37850555	chr10:38149968~38150293:+
BRCA	cis	rs997295	0.57	rs7172298	ENSG00000259673.4	IQCH-AS1	3.55	0.000407	0.0207	0.12	0.11	Motion sickness;	chr15:67580645	chr15:67403619~67521844:-
BRCA	cis	rs613391	0.578	rs7874257	ENSG00000265194.1	RP11-70L8.4	-3.55	0.000407	0.0207	-0.11	-0.11	Quantitative traits;	chr9:22723026	chr9:21858910~21861926:-
BRCA	cis	rs6490294	0.571	rs6489830	ENSG00000234608.6	MAPKAPK5-AS1	3.55	0.000407	0.0207	0.16	0.11	Mean platelet volume;	chr12:112144736	chr12:111839764~111842902:-
BRCA	cis	rs6490294	0.571	rs12422864	ENSG00000234608.6	MAPKAPK5-AS1	3.55	0.000407	0.0207	0.16	0.11	Mean platelet volume;	chr12:112146397	chr12:111839764~111842902:-
BRCA	cis	rs2938670	1	rs2938670	ENSG00000261762.1	RP11-650L12.2	-3.55	0.000407	0.0208	-0.13	-0.11	Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;Post bronchodilator FEV1 in COPD;	chr15:78448346	chr15:78589123~78591276:-
BRCA	cis	rs1178968	1	rs12539763	ENSG00000174353.16	STAG3L3	3.55	0.000407	0.0208	0.14	0.11	Triglyceride levels;	chr7:73348420	chr7:72969696~73005922:-
BRCA	cis	rs36093844	0.8	rs17817331	ENSG00000279742.1	RP11-700A24.1	3.55	0.000407	0.0208	0.17	0.11	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85884295	chr11:85852557~85854943:-
BRCA	cis	rs73206853	0.563	rs56386451	ENSG00000277299.1	RP11-837J7.4	-3.55	0.000407	0.0208	-0.2	-0.11	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr12:110736711	chr12:109948389~109949029:+
BRCA	cis	rs7781266	0.739	rs11765450	ENSG00000226205.1	AC007790.4	-3.55	0.000407	0.0208	-0.16	-0.11	Educational attainment (college completion);	chr7:133384928	chr7:133732493~133733595:-
BRCA	cis	rs1061377	0.513	rs6840214	ENSG00000249685.1	RP11-360F5.3	-3.55	0.000407	0.0208	-0.14	-0.11	Uric acid levels;	chr4:39118999	chr4:39133913~39135608:+
BRCA	cis	rs6840360	0.571	rs4696275	ENSG00000278978.1	RP11-164P12.5	-3.55	0.000407	0.0208	-0.13	-0.11	Intelligence (multi-trait analysis);	chr4:151609829	chr4:151669786~151670503:+
BRCA	cis	rs80226907	0.634	rs79915691	ENSG00000186615.9	KTN1-AS1	-3.55	0.000407	0.0208	-0.24	-0.11	Mean platelet volume;	chr14:55440832	chr14:55499278~55580110:-
BRCA	cis	rs4073416	0.647	rs11158592	ENSG00000276116.2	FUT8-AS1	3.55	0.000407	0.0208	0.11	0.11	N-glycan levels;	chr14:65393250	chr14:65411170~65412690:-
BRCA	cis	rs4073416	0.647	rs11158593	ENSG00000276116.2	FUT8-AS1	3.55	0.000407	0.0208	0.11	0.11	N-glycan levels;	chr14:65393266	chr14:65411170~65412690:-
BRCA	cis	rs17597773	0.674	rs11118619	ENSG00000257551.1	HLX-AS1	-3.55	0.000407	0.0208	-0.13	-0.11	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220838921	chr1:220832763~220880140:-
BRCA	cis	rs67478160	0.619	rs3742365	ENSG00000269910.1	RP11-73M18.10	3.55	0.000407	0.0208	0.11	0.11	Schizophrenia;	chr14:103731914	chr14:103694516~103695050:-
BRCA	cis	rs8114671	0.562	rs6088636	ENSG00000261582.1	RP4-614O4.11	-3.55	0.000407	0.0208	-0.1	-0.11	Height;	chr20:34881943	chr20:35267885~35280043:-
BRCA	cis	rs713477	0.505	rs8019209	ENSG00000186615.9	KTN1-AS1	-3.55	0.000407	0.0208	-0.13	-0.11	Pediatric bone mineral content (femoral neck);	chr14:55424611	chr14:55499278~55580110:-
BRCA	cis	rs13401620	0.555	rs2018962	ENSG00000236878.1	AC012363.7	3.55	0.000407	0.0208	0.13	0.11	Breast size;	chr2:120217026	chr2:120211054~120211715:+
BRCA	cis	rs524281	0.773	rs79770412	ENSG00000255038.1	RP11-1167A19.2	-3.55	0.000407	0.0208	-0.17	-0.11	Electroencephalogram traits;	chr11:66277873	chr11:66067277~66069619:-
BRCA	cis	rs6545883	0.929	rs55806663	ENSG00000212978.6	AC016747.3	3.55	0.000407	0.0208	0.15	0.11	Tuberculosis;	chr2:61513352	chr2:61141592~61144969:-
BRCA	cis	rs6460942	0.915	rs17541464	ENSG00000226690.5	AC005281.1	3.55	0.000407	0.0208	0.19	0.11	Coronary artery disease;	chr7:12423049	chr7:12496429~12541910:+
BRCA	cis	rs739401	0.572	rs410820	ENSG00000247473.2	CARS-AS1	3.55	0.000407	0.0208	0.13	0.11	Longevity;	chr11:3058872	chr11:3029009~3041260:+
BRCA	cis	rs4950322	0.57	rs72691095	ENSG00000227242.3	NBPF13P	-3.55	0.000407	0.0208	-0.16	-0.11	Protein quantitative trait loci;	chr1:147298305	chr1:147021320~147124525:-
BRCA	cis	rs34779708	0.931	rs7079498	ENSG00000269952.1	RP11-324I22.3	-3.55	0.000407	0.0208	-0.15	-0.11	Inflammatory bowel disease;Crohn's disease;	chr10:35086416	chr10:35210416~35210750:+
BRCA	cis	rs2455799	0.574	rs2455801	ENSG00000224728.1	AC090945.1	-3.55	0.000407	0.0208	-0.1	-0.11	Mean platelet volume;	chr3:15660350	chr3:15878047~15879571:+
BRCA	cis	rs1455244	0.848	rs2282534	ENSG00000267533.1	RP11-815J4.7	-3.55	0.000407	0.0208	-0.14	-0.11	Schizophrenia;	chr18:11466336	chr18:12067173~12068417:-
BRCA	cis	rs495337	0.736	rs599195	ENSG00000224397.4	LINC01272	-3.55	0.000407	0.0208	-0.11	-0.11	Psoriasis;	chr20:49848258	chr20:50267486~50279795:+
BRCA	cis	rs11088226	0.681	rs1134747	ENSG00000186842.4	LINC00846	-3.55	0.000407	0.0208	-0.18	-0.11	Gastritis;	chr21:32566701	chr21:32572238~32575881:-
BRCA	cis	rs11088226	0.681	rs16989507	ENSG00000186842.4	LINC00846	-3.55	0.000407	0.0208	-0.18	-0.11	Gastritis;	chr21:32567199	chr21:32572238~32575881:-
BRCA	cis	rs7520050	0.966	rs34102169	ENSG00000281133.1	AL355480.3	3.55	0.000407	0.0208	0.13	0.11	Reticulocyte count;Red blood cell count;	chr1:45959192	chr1:45580892~45580996:-
BRCA	cis	rs6714900	0.888	rs2160783	ENSG00000234896.1	OR7E62P	3.55	0.000407	0.0208	0.14	0.11	Blood protein levels;	chr2:71056337	chr2:71055527~71056003:+
BRCA	cis	rs4820539	1	rs4822357	ENSG00000211647.1	IGLV5-48	-3.55	0.000407	0.0208	-0.09	-0.11	Bone mineral density;	chr22:23131044	chr22:22352940~22353433:+
BRCA	cis	rs36051895	0.664	rs17425637	ENSG00000237711.1	RP11-39K24.13	-3.55	0.000408	0.0208	-0.13	-0.11	Pediatric autoimmune diseases;	chr9:5110000	chr9:5100236~5101009:+
BRCA	cis	rs6696239	0.911	rs7538206	ENSG00000215812.5	ZNF847P	3.55	0.000408	0.0208	0.15	0.11	Height;	chr1:227689081	chr1:227696892~227706699:-
BRCA	cis	rs3816183	0.597	rs6758365	ENSG00000226491.1	FTOP1	-3.55	0.000408	0.0208	-0.13	-0.11	Hypospadias;	chr2:42599267	chr2:42797225~42798712:-
BRCA	cis	rs9584850	0.718	rs6491427	ENSG00000231194.1	FARP1-AS1	3.55	0.000408	0.0208	0.15	0.11	Neuroticism;	chr13:98460912	chr13:98435405~98435840:-
BRCA	cis	rs465969	1	rs465969	ENSG00000230177.1	RP5-1112D6.4	3.55	0.000408	0.0208	0.2	0.11	Psoriasis;	chr6:111334327	chr6:111277932~111278742:+
BRCA	cis	rs10043228	0.702	rs7711510	ENSG00000250015.1	CTC-339F2.2	3.55	0.000408	0.0208	0.12	0.11	Asthma or chronic obstructive pulmonary disease;	chr5:116296556	chr5:116302354~116304134:-
BRCA	cis	rs875971	1	rs12533997	ENSG00000229886.1	RP5-1132H15.3	3.55	0.000408	0.0208	0.12	0.11	Aortic root size;	chr7:66500390	chr7:66025126~66031544:-
BRCA	cis	rs7722600	1	rs60701788	ENSG00000253404.1	AC034243.1	-3.55	0.000408	0.0208	-0.18	-0.11	Heart rate;	chr5:137796825	chr5:138744434~138753309:-
BRCA	cis	rs34779708	0.966	rs10827487	ENSG00000269952.1	RP11-324I22.3	-3.55	0.000408	0.0208	-0.15	-0.11	Inflammatory bowel disease;Crohn's disease;	chr10:35117950	chr10:35210416~35210750:+
BRCA	cis	rs6964587	0.597	rs975707	ENSG00000188693.7	CYP51A1-AS1	-3.55	0.000408	0.0208	-0.12	-0.11	Breast cancer;	chr7:92245213	chr7:92134604~92180725:+
BRCA	cis	rs17767294	0.708	rs72848786	ENSG00000219392.1	RP1-265C24.5	-3.55	0.000408	0.0208	-0.29	-0.11	Parkinson's disease;	chr6:28012239	chr6:28115628~28116551:+
BRCA	cis	rs6545883	0.868	rs2518932	ENSG00000212978.6	AC016747.3	3.55	0.000408	0.0208	0.15	0.11	Tuberculosis;	chr2:61574142	chr2:61141592~61144969:-
BRCA	cis	rs6801044	0.65	rs823519	ENSG00000272792.1	RP11-141C7.4	3.55	0.000408	0.0208	0.17	0.11	Creatinine levels in ischemic stroke;	chr3:195544046	chr3:195639990~195640460:+
BRCA	cis	rs910316	1	rs7156105	ENSG00000259138.1	RP11-950C14.7	3.55	0.000408	0.0208	0.12	0.11	Height;	chr14:75075251	chr14:75127153~75136930:+
BRCA	cis	rs2998286	0.723	rs332154	ENSG00000237128.1	RP11-351M16.3	3.55	0.000408	0.0208	0.14	0.11	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28591465	chr10:28433008~28495813:-
BRCA	cis	rs2998286	0.723	rs332156	ENSG00000237128.1	RP11-351M16.3	3.55	0.000408	0.0208	0.14	0.11	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28593152	chr10:28433008~28495813:-
BRCA	cis	rs11662721	0.938	rs11664807	ENSG00000264188.1	RP11-13N13.5	3.55	0.000408	0.0208	0.16	0.11	Phospholipid levels (plasma);	chr18:21568625	chr18:21661787~21662395:-
BRCA	cis	rs7267979	1	rs2500424	ENSG00000274973.1	RP13-401N8.7	3.55	0.000408	0.0208	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25411333	chr20:25845497~25845862:+
BRCA	cis	rs72928364	0.86	rs62274066	ENSG00000256628.3	ZBTB11-AS1	3.55	0.000408	0.0208	0.22	0.11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:101082335	chr3:101676475~101679217:+
BRCA	cis	rs2400749	0.795	rs8018119	ENSG00000258521.1	RP11-638I2.9	-3.55	0.000408	0.0208	-0.11	-0.11	Alzheimer's disease (survival time);	chr14:99567910	chr14:100339832~100340554:+
BRCA	cis	rs787274	0.543	rs10739377	ENSG00000271631.1	RP11-408O19.5	-3.55	0.000408	0.0208	-0.18	-0.11	Age-related hearing impairment (SNP x SNP interaction);	chr9:112869318	chr9:112885158~112885767:+
BRCA	cis	rs9397240	0.789	rs10499303	ENSG00000235381.1	RP11-477D19.2	3.55	0.000408	0.0208	0.17	0.11	Life satisfaction;	chr6:155294105	chr6:155253139~155256724:-
BRCA	cis	rs7267979	0.966	rs4813557	ENSG00000274414.1	RP5-965G21.4	3.55	0.000408	0.0208	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25311909	chr20:25239007~25245229:-
BRCA	cis	rs7089973	0.872	rs3180654	ENSG00000236799.1	RP11-383C6.2	-3.55	0.000408	0.0208	-0.13	-0.11	Bipolar disorder or attention deficit hyperactivity disorder;	chr10:114855286	chr10:114994657~114996593:+
BRCA	cis	rs7089973	0.872	rs10490908	ENSG00000236799.1	RP11-383C6.2	-3.55	0.000408	0.0208	-0.13	-0.11	Bipolar disorder or attention deficit hyperactivity disorder;	chr10:114856403	chr10:114994657~114996593:+
BRCA	cis	rs8105895	0.935	rs62111039	ENSG00000269345.1	VN1R85P	3.55	0.000408	0.0208	0.17	0.11	Body mass index (change over time);	chr19:22104534	chr19:22174766~22175191:-
BRCA	cis	rs6991838	0.584	rs1053085	ENSG00000272155.1	RP11-707M3.3	3.55	0.000408	0.0208	0.1	0.11	Intelligence (multi-trait analysis);	chr8:65603753	chr8:65714334~65714778:-
BRCA	cis	rs6771316	0.524	rs60436497	ENSG00000241163.6	LINC00877	-3.55	0.000409	0.0208	-0.13	-0.11	Venous thromboembolism (SNP x SNP interaction);	chr3:72081288	chr3:72035300~72279503:-
BRCA	cis	rs58521262	1	rs62121598	ENSG00000268105.1	RP11-369G6.2	-3.55	0.000409	0.0208	-0.18	-0.11	Testicular germ cell tumor;	chr19:23033301	chr19:23125665~23128543:+
BRCA	cis	rs6012564	0.964	rs2064853	ENSG00000230758.1	SNAP23P	-3.55	0.000409	0.0208	-0.13	-0.11	Anger;	chr20:49058639	chr20:49038357~49038602:-
BRCA	cis	rs6840360	0.571	rs62327277	ENSG00000278978.1	RP11-164P12.5	-3.55	0.000409	0.0208	-0.13	-0.11	Intelligence (multi-trait analysis);	chr4:151634753	chr4:151669786~151670503:+
BRCA	cis	rs2574985	0.813	rs1203386	ENSG00000226200.5	SGMS1-AS1	-3.55	0.000409	0.0208	-0.11	-0.11	Subjective well-being;	chr10:50446871	chr10:50624951~50641451:+
BRCA	cis	rs801193	0.548	rs2109297	ENSG00000271064.1	RP11-792A8.3	3.55	0.000409	0.0208	0.13	0.11	Aortic root size;	chr7:66657397	chr7:66748838~66749077:-
BRCA	cis	rs4865762	0.514	rs2652547	ENSG00000247796.2	CTD-2366F13.1	3.55	0.000409	0.0208	0.12	0.11	Intraocular pressure;	chr5:53141110	chr5:53109842~53115126:+
BRCA	cis	rs2286492	1	rs2286492	ENSG00000230658.1	KLHL7-AS1	-3.55	0.000409	0.0208	-0.23	-0.11	Bipolar disorder;	chr7:22945391	chr7:23101228~23105703:-
BRCA	cis	rs34779708	0.966	rs17500582	ENSG00000269952.1	RP11-324I22.3	-3.55	0.000409	0.0208	-0.14	-0.11	Inflammatory bowel disease;Crohn's disease;	chr10:35209860	chr10:35210416~35210750:+
BRCA	cis	rs11098499	0.863	rs13140391	ENSG00000260404.2	RP11-384K6.6	3.55	0.000409	0.0208	0.1	0.11	Corneal astigmatism;	chr4:119582282	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.863	rs13140409	ENSG00000260404.2	RP11-384K6.6	3.55	0.000409	0.0208	0.1	0.11	Corneal astigmatism;	chr4:119582305	chr4:118591773~118633729:+
BRCA	cis	rs9951698	0.703	rs7234960	ENSG00000266969.1	RP11-773H22.4	3.55	0.000409	0.0208	0.15	0.11	Intelligence (multi-trait analysis);	chr18:13018072	chr18:12984694~12991173:-
BRCA	cis	rs17680741	0.697	rs2343550	ENSG00000225484.5	NUTM2B-AS1	-3.55	0.000409	0.0208	-0.18	-0.11	Coronary artery disease;	chr10:80504667	chr10:79663088~79826594:-
BRCA	cis	rs1558648	0.858	rs12996377	ENSG00000234389.1	AC007278.3	3.55	0.000409	0.0208	0.15	0.11	Serum protein levels (sST2);	chr2:102214018	chr2:102438713~102440475:+
BRCA	cis	rs12277962	1	rs740320	ENSG00000279837.1	RP11-504G3.2	3.55	0.000409	0.0208	0.13	0.11	Night sleep phenotypes;	chr11:17636973	chr11:18601882~18602649:+
BRCA	cis	rs11088226	0.645	rs78172258	ENSG00000186842.4	LINC00846	-3.55	0.000409	0.0208	-0.18	-0.11	Gastritis;	chr21:32564229	chr21:32572238~32575881:-
BRCA	cis	rs11088226	0.681	rs11702499	ENSG00000186842.4	LINC00846	-3.55	0.000409	0.0208	-0.18	-0.11	Gastritis;	chr21:32566255	chr21:32572238~32575881:-
BRCA	cis	rs11088226	0.681	rs11700670	ENSG00000186842.4	LINC00846	-3.55	0.000409	0.0208	-0.18	-0.11	Gastritis;	chr21:32566305	chr21:32572238~32575881:-
BRCA	cis	rs11088226	0.681	rs11700671	ENSG00000186842.4	LINC00846	-3.55	0.000409	0.0208	-0.18	-0.11	Gastritis;	chr21:32566311	chr21:32572238~32575881:-
BRCA	cis	rs832187	0.704	rs832195	ENSG00000224479.4	AC136289.1	-3.55	0.000409	0.0209	-0.13	-0.11	Schizophrenia;	chr3:63878936	chr3:63742293~63827445:-
BRCA	cis	rs1144333	0.737	rs1144339	ENSG00000181227.3	RP4-682C21.2	3.55	0.000409	0.0209	0.15	0.11	Attention function in attention deficit hyperactive disorder;	chr1:75814858	chr1:75743423~75744776:-
BRCA	cis	rs2108622	0.727	rs76984410	ENSG00000214049.6	UCA1	3.55	0.000409	0.0209	0.15	0.11	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871890	chr19:15828961~15836320:+
BRCA	cis	rs2108622	0.727	rs77780918	ENSG00000214049.6	UCA1	3.55	0.000409	0.0209	0.15	0.11	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871897	chr19:15828961~15836320:+
BRCA	cis	rs10838634	1	rs11824327	ENSG00000280615.1	Y_RNA	-3.55	0.000409	0.0209	-0.19	-0.11	Schizophrenia;	chr11:46843154	chr11:47614898~47614994:-
BRCA	cis	rs1424638	0.604	rs13024494	ENSG00000233251.6	AC007743.1	-3.55	0.000409	0.0209	-0.13	-0.11	Intelligence (multi-trait analysis);	chr2:57016301	chr2:56173534~56185770:-
BRCA	cis	rs10911902	0.643	rs28715477	ENSG00000229739.2	RP11-295K2.3	-3.55	0.000409	0.0209	-0.15	-0.11	Schizophrenia;	chr1:186326392	chr1:186435161~186470291:+
BRCA	cis	rs10911902	0.643	rs3766707	ENSG00000229739.2	RP11-295K2.3	-3.55	0.000409	0.0209	-0.15	-0.11	Schizophrenia;	chr1:186335955	chr1:186435161~186470291:+
BRCA	cis	rs3770752	0.86	rs11689794	ENSG00000272054.1	RP11-423P10.2	-3.55	0.000409	0.0209	-0.1	-0.11	Schizophrenia;	chr2:37323053	chr2:37208875~37212677:+
BRCA	cis	rs17092148	1	rs62211617	ENSG00000202150.1	RNU6-407P	-3.55	0.000409	0.0209	-0.16	-0.11	Neuroticism;	chr20:34812552	chr20:35030317~35030420:-
BRCA	cis	rs17092148	1	rs11699062	ENSG00000202150.1	RNU6-407P	-3.55	0.000409	0.0209	-0.16	-0.11	Neuroticism;	chr20:34812576	chr20:35030317~35030420:-
BRCA	cis	rs8141529	0.748	rs715531	ENSG00000226471.5	CTA-292E10.6	-3.55	0.000409	0.0209	-0.13	-0.11	Lymphocyte counts;	chr22:28886691	chr22:28800683~28848559:+
BRCA	cis	rs11892454	0.544	rs7591614	ENSG00000217643.1	PTGES3P2	-3.55	0.000409	0.0209	-0.12	-0.11	Heschl's gyrus morphology;	chr2:25780199	chr2:25822469~25822950:+
BRCA	cis	rs28489187	0.706	rs233071	ENSG00000223653.4	RP11-131L23.1	3.55	0.000409	0.0209	0.12	0.11	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85340322	chr1:85276715~85448124:+
BRCA	cis	rs863345	0.604	rs2873593	ENSG00000176320.2	RP11-404O13.5	-3.55	0.000409	0.0209	-0.11	-0.11	Pneumococcal bacteremia;	chr1:158534921	chr1:158197922~158203877:-
BRCA	cis	rs12428035	0.536	rs72636562	ENSG00000247400.3	DNAJC3-AS1	-3.55	0.000409	0.0209	-0.18	-0.11	Glomerular filtration rate (cystatin C);Response to statins (LDL cholesterol change);	chr13:95910513	chr13:95648733~95676925:-
BRCA	cis	rs4957325	0.733	rs4422570	ENSG00000250492.1	INTS6P1	3.55	0.000409	0.0209	0.19	0.11	Hemoglobin concentration;	chr5:40482240	chr5:39718984~39721513:-
BRCA	cis	rs8054556	0.787	rs3814877	ENSG00000214725.6	CDIPT-AS1	-3.55	0.000409	0.0209	-0.13	-0.11	Autism spectrum disorder or schizophrenia;	chr16:30031356	chr16:29863593~29868053:+
BRCA	cis	rs7618501	1	rs7374183	ENSG00000228008.1	CTD-2330K9.3	-3.55	0.000409	0.0209	-0.1	-0.11	Intelligence (multi-trait analysis);	chr3:49747700	chr3:49903845~49916937:+
BRCA	cis	rs4835473	0.932	rs4383567	ENSG00000246448.2	RP13-578N3.3	3.55	0.00041	0.0209	0.12	0.11	Immature fraction of reticulocytes;	chr4:143788873	chr4:143700257~143865072:+
BRCA	cis	rs11893307	0.537	rs1558473	ENSG00000235852.1	AC005540.3	3.55	0.00041	0.0209	0.14	0.11	Mean platelet volume;	chr2:190639338	chr2:190880797~190882059:-
BRCA	cis	rs7520050	0.897	rs4440807	ENSG00000281133.1	AL355480.3	3.55	0.00041	0.0209	0.13	0.11	Reticulocyte count;Red blood cell count;	chr1:46005206	chr1:45580892~45580996:-
BRCA	cis	rs2573652	1	rs2573651	ENSG00000254744.3	CTD-3076O17.1	-3.55	0.00041	0.0209	-0.13	-0.11	Height;	chr15:99973904	chr15:99970215~99974010:+
BRCA	cis	rs11877825	0.826	rs3748425	ENSG00000265728.1	RP11-883A18.3	-3.55	0.00041	0.0209	-0.15	-0.11	Gut microbiota (bacterial taxa);	chr18:10581765	chr18:10594590~10604798:+
BRCA	cis	rs7620503	1	rs6805429	ENSG00000231574.4	RP11-91K9.1	3.55	0.00041	0.0209	0.12	0.11	Corneal structure;	chr3:177581481	chr3:177816865~177899224:+
BRCA	cis	rs6545883	0.931	rs7557230	ENSG00000212978.6	AC016747.3	3.55	0.00041	0.0209	0.15	0.11	Tuberculosis;	chr2:61509517	chr2:61141592~61144969:-
BRCA	cis	rs7020830	0.898	rs12000309	ENSG00000230188.1	RP11-405L18.4	-3.55	0.00041	0.0209	-0.13	-0.11	Schizophrenia;	chr9:37230847	chr9:37490421~37490893:-
BRCA	cis	rs10005067	0.806	rs10013836	ENSG00000249001.4	RP11-742B18.1	-3.55	0.00041	0.0209	-0.13	-0.11	Total body bone mineral density (age 30-45);	chr4:87909480	chr4:87568035~87733956:-
BRCA	cis	rs6964587	1	rs12666179	ENSG00000188693.7	CYP51A1-AS1	3.55	0.00041	0.0209	0.12	0.11	Breast cancer;	chr7:91944796	chr7:92134604~92180725:+
BRCA	cis	rs6964587	1	rs417	ENSG00000188693.7	CYP51A1-AS1	3.55	0.00041	0.0209	0.12	0.11	Breast cancer;	chr7:91951807	chr7:92134604~92180725:+
BRCA	cis	rs7520050	0.966	rs7522601	ENSG00000234329.1	RP11-767N6.2	-3.55	0.00041	0.0209	-0.1	-0.11	Reticulocyte count;Red blood cell count;	chr1:45953349	chr1:45651039~45651826:-
BRCA	cis	rs7520050	0.966	rs10789487	ENSG00000234329.1	RP11-767N6.2	-3.55	0.00041	0.0209	-0.1	-0.11	Reticulocyte count;Red blood cell count;	chr1:45954549	chr1:45651039~45651826:-
BRCA	cis	rs846271	0.832	rs846272	ENSG00000224116.5	INHBA-AS1	3.55	0.00041	0.0209	0.13	0.11	IgG glycosylation;	chr7:41996746	chr7:41693916~41779388:+
BRCA	cis	rs8103278	1	rs9807819	ENSG00000268423.3	AC011551.3	3.55	0.00041	0.0209	0.13	0.11	Coronary artery disease;	chr19:45736340	chr19:46547056~46600861:-
BRCA	cis	rs8114671	0.562	rs1018447	ENSG00000261582.1	RP4-614O4.11	3.55	0.00041	0.0209	0.1	0.11	Height;	chr20:34813904	chr20:35267885~35280043:-
BRCA	cis	rs10043775	1	rs4472255	ENSG00000251330.3	CTD-2283N19.1	-3.55	0.00041	0.0209	-0.13	-0.11	Periodontal microbiota;	chr5:148446054	chr5:148430159~148430807:-
BRCA	cis	rs1823874	0.677	rs2168069	ENSG00000259363.4	CTD-2054N24.2	3.55	0.00041	0.0209	0.13	0.11	IgG glycosylation;	chr15:99823798	chr15:99807023~99877148:+
BRCA	cis	rs1468333	0.567	rs10045383	ENSG00000206989.1	SNORD63	3.54	0.00041	0.0209	0.12	0.11	Resting heart rate;	chr5:138353523	chr5:138561043~138561110:-
BRCA	cis	rs8141529	0.748	rs6519766	ENSG00000272858.1	CTA-292E10.8	3.54	0.00041	0.0209	0.14	0.11	Lymphocyte counts;	chr22:28874003	chr22:28814914~28815662:+
BRCA	cis	rs875971	0.895	rs3857684	ENSG00000229886.1	RP5-1132H15.3	3.54	0.00041	0.0209	0.12	0.11	Aortic root size;	chr7:66473171	chr7:66025126~66031544:-
BRCA	cis	rs36051895	0.603	rs10974972	ENSG00000237711.1	RP11-39K24.13	-3.54	0.00041	0.0209	-0.13	-0.11	Pediatric autoimmune diseases;	chr9:5130146	chr9:5100236~5101009:+
BRCA	cis	rs2011013	0.957	rs17370601	ENSG00000225151.9	GOLGA2P7	3.54	0.00041	0.0209	0.14	0.11	Sitting height ratio;	chr15:83948494	chr15:84199311~84230136:-
BRCA	cis	rs7577696	0.706	rs2268796	ENSG00000276334.1	AL133243.1	3.54	0.00041	0.0209	0.13	0.11	Inflammatory biomarkers;	chr2:31557210	chr2:32521927~32523547:+
BRCA	cis	rs564309	0.764	rs12096217	ENSG00000183929.7	DUSP5P1	3.54	0.00041	0.0209	0.25	0.11	Hip circumference (psychosocial stress interaction);	chr1:228346751	chr1:228650241~228651379:+
BRCA	cis	rs809367	1	rs809367	ENSG00000151303.11	RP11-96C23.13	3.54	0.00041	0.0209	0.16	0.11	Parental extreme longevity (95 years and older);	chr10:87982049	chr10:86992406~87010203:+
BRCA	cis	rs6480314	0.711	rs16925246	ENSG00000233590.1	RP11-153K11.3	3.54	0.00041	0.0209	0.18	0.11	Optic nerve measurement (disc area);	chr10:68188569	chr10:68233251~68242379:-
BRCA	cis	rs7487075	0.637	rs4438106	ENSG00000257261.4	RP11-96H19.1	3.54	0.00041	0.0209	0.12	0.11	Itch intensity from mosquito bite;	chr12:46321745	chr12:46383679~46876159:+
BRCA	cis	rs7487075	0.786	rs11183441	ENSG00000257261.4	RP11-96H19.1	3.54	0.00041	0.0209	0.12	0.11	Itch intensity from mosquito bite;	chr12:46322137	chr12:46383679~46876159:+
BRCA	cis	rs875971	1	rs7781698	ENSG00000271064.1	RP11-792A8.3	-3.54	0.00041	0.0209	-0.13	-0.11	Aortic root size;	chr7:66431325	chr7:66748838~66749077:-
BRCA	cis	rs10916772	0.618	rs78021092	ENSG00000236963.4	LINC01141	3.54	0.00041	0.0209	0.19	0.11	Psychosis proneness (perceptual aberration scale);	chr1:20368995	chr1:20360579~20431234:-
BRCA	cis	rs351365	0.502	rs351359	ENSG00000215866.6	LINC01356	-3.54	0.000411	0.0209	-0.12	-0.11	Pancreatic cancer;	chr1:112497655	chr1:112820170~112850643:-
BRCA	cis	rs3015497	0.673	rs7148925	ENSG00000259113.1	RP11-406H23.2	-3.54	0.000411	0.0209	-0.12	-0.11	Mean platelet volume;	chr14:50705992	chr14:50448807~50456742:+
BRCA	cis	rs3015497	0.637	rs4405473	ENSG00000259113.1	RP11-406H23.2	-3.54	0.000411	0.0209	-0.12	-0.11	Mean platelet volume;	chr14:50706029	chr14:50448807~50456742:+
BRCA	cis	rs7809799	0.571	rs66568021	ENSG00000244219.5	GS1-259H13.2	-3.54	0.000411	0.0209	-0.22	-0.11	Ulcerative colitis;	chr7:99345366	chr7:99598066~99610813:+
BRCA	cis	rs7809799	0.571	rs67909852	ENSG00000244219.5	GS1-259H13.2	-3.54	0.000411	0.0209	-0.22	-0.11	Ulcerative colitis;	chr7:99347303	chr7:99598066~99610813:+
BRCA	cis	rs924712	0.535	rs1393778	ENSG00000261116.1	RP3-523K23.2	3.54	0.000411	0.0209	0.13	0.11	Breast cancer;	chr6:54835751	chr6:54943167~54945099:+
BRCA	cis	rs7017914	0.967	rs17688313	ENSG00000246366.5	RP11-382J12.1	-3.54	0.000411	0.0209	-0.12	-0.11	Bone mineral density;	chr8:70771629	chr8:70608577~70663279:+
BRCA	cis	rs654950	0.775	rs28972757	ENSG00000230638.4	RP11-486B10.4	3.54	0.000411	0.0209	0.14	0.11	Airway imaging phenotypes;	chr1:41527342	chr1:41542069~41544310:+
BRCA	cis	rs4869313	0.846	rs10434709	ENSG00000248734.2	CTD-2260A17.1	-3.54	0.000411	0.0209	-0.11	-0.11	Pediatric autoimmune diseases;	chr5:96890070	chr5:96784777~96785999:+
BRCA	cis	rs853679	0.55	rs6901017	ENSG00000261839.1	RP1-265C24.8	3.54	0.000411	0.0209	0.14	0.11	Depression;	chr6:28184805	chr6:28136849~28139678:+
BRCA	cis	rs829883	0.622	rs7302630	ENSG00000227825.4	SLC9A7P1	-3.54	0.000411	0.0209	-0.15	-0.11	Colorectal adenoma (advanced);	chr12:98565799	chr12:98453835~98457145:-
BRCA	cis	rs4578769	0.729	rs12456891	ENSG00000273232.1	RP11-370A5.2	-3.54	0.000411	0.0209	-0.15	-0.11	Eosinophil percentage of white cells;	chr18:22830243	chr18:22882825~22883357:-
BRCA	cis	rs10761482	0.861	rs4948405	ENSG00000254271.1	RP11-131N11.4	3.54	0.000411	0.0209	0.15	0.11	Schizophrenia;	chr10:60348661	chr10:60734342~60741828:+
BRCA	cis	rs2797685	0.755	rs41402249	ENSG00000269925.1	RP3-467L1.6	-3.54	0.000411	0.0209	-0.16	-0.11	Crohn's disease;	chr1:7762663	chr1:7776383~7776775:+
BRCA	cis	rs10191559	0.541	rs13032688	ENSG00000234663.4	AC104820.2	3.54	0.000411	0.0209	0.1	0.11	Red blood cell count;	chr2:181208637	chr2:181101932~181399559:+
BRCA	cis	rs10191559	0.552	rs4441426	ENSG00000234663.4	AC104820.2	3.54	0.000411	0.0209	0.1	0.11	Red blood cell count;	chr2:181208692	chr2:181101932~181399559:+
BRCA	cis	rs10191559	0.552	rs4441427	ENSG00000234663.4	AC104820.2	3.54	0.000411	0.0209	0.1	0.11	Red blood cell count;	chr2:181208846	chr2:181101932~181399559:+
BRCA	cis	rs10191559	0.552	rs4473348	ENSG00000234663.4	AC104820.2	3.54	0.000411	0.0209	0.1	0.11	Red blood cell count;	chr2:181209015	chr2:181101932~181399559:+
BRCA	cis	rs10191559	0.507	rs4441429	ENSG00000234663.4	AC104820.2	3.54	0.000411	0.0209	0.1	0.11	Red blood cell count;	chr2:181209040	chr2:181101932~181399559:+
BRCA	cis	rs10191559	0.508	rs4666722	ENSG00000234663.4	AC104820.2	3.54	0.000411	0.0209	0.1	0.11	Red blood cell count;	chr2:181209241	chr2:181101932~181399559:+
BRCA	cis	rs10191559	0.507	rs6730853	ENSG00000234663.4	AC104820.2	3.54	0.000411	0.0209	0.1	0.11	Red blood cell count;	chr2:181210024	chr2:181101932~181399559:+
BRCA	cis	rs7103648	1	rs12292911	ENSG00000280615.1	Y_RNA	3.54	0.000411	0.0209	0.13	0.11	Systolic blood pressure;Diastolic blood pressure;	chr11:47427521	chr11:47614898~47614994:-
BRCA	cis	rs11892454	0.533	rs10193672	ENSG00000217643.1	PTGES3P2	-3.54	0.000411	0.0209	-0.12	-0.11	Heschl's gyrus morphology;	chr2:25881395	chr2:25822469~25822950:+
BRCA	cis	rs943466	1	rs11753083	ENSG00000223837.2	BRD2-IT1	3.54	0.000411	0.0209	0.14	0.11	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;	chr6:33793334	chr6:32970232~32970886:+
BRCA	cis	rs7735319	0.966	rs3860754	ENSG00000249572.1	CTD-2203K17.1	-3.54	0.000411	0.0209	-0.15	-0.11	Systolic blood pressure;	chr5:33149343	chr5:33424025~33440619:-
BRCA	cis	rs4835473	0.932	rs12509642	ENSG00000246448.2	RP13-578N3.3	-3.54	0.000411	0.0209	-0.12	-0.11	Immature fraction of reticulocytes;	chr4:143737080	chr4:143700257~143865072:+
BRCA	cis	rs6802315	0.573	rs7635993	ENSG00000272440.1	RP11-379F4.6	3.54	0.000411	0.0209	0.14	0.11	Periodontitis (CDC/AAP);	chr3:158742187	chr3:158695367~158695581:+
BRCA	cis	rs3093024	0.595	rs4412174	ENSG00000272549.1	RP11-351J23.2	-3.54	0.000411	0.0209	-0.11	-0.11	Rheumatoid arthritis;	chr6:167062578	chr6:167666840~167679270:-
BRCA	cis	rs3093024	0.595	rs4458654	ENSG00000272549.1	RP11-351J23.2	-3.54	0.000411	0.0209	-0.11	-0.11	Rheumatoid arthritis;	chr6:167062580	chr6:167666840~167679270:-
BRCA	cis	rs9309473	0.718	rs10175529	ENSG00000230002.2	ALMS1-IT1	3.54	0.000411	0.0209	0.13	0.11	Metabolite levels;	chr2:73378965	chr2:73456764~73459484:+
BRCA	cis	rs8114671	0.562	rs1060615	ENSG00000279253.1	RP4-614O4.13	3.54	0.000411	0.0209	0.12	0.11	Height;	chr20:34890578	chr20:35262727~35264187:-
BRCA	cis	rs7487075	0.859	rs3782904	ENSG00000274723.1	RP11-618L22.1	3.54	0.000411	0.0209	0.13	0.11	Itch intensity from mosquito bite;	chr12:46364202	chr12:46970504~46972155:+
BRCA	cis	rs17135159	0.917	rs12773260	ENSG00000273001.1	RP11-118K6.3	3.54	0.000411	0.0209	0.14	0.11	Reading and spelling;	chr10:3365137	chr10:3065424~3066001:-
BRCA	cis	rs848087	0.564	rs2774036	ENSG00000200385.1	SNORA42	3.54	0.000411	0.0209	0.09	0.11	Breast cancer;	chr14:36789499	chr14:37720425~37720561:+
BRCA	cis	rs801193	1	rs2659909	ENSG00000273142.1	RP11-458F8.4	-3.54	0.000411	0.0209	-0.09	-0.11	Aortic root size;	chr7:66695292	chr7:66902857~66906297:+
BRCA	cis	rs58521262	0.932	rs55774410	ENSG00000268105.1	RP11-369G6.2	-3.54	0.000411	0.0209	-0.18	-0.11	Testicular germ cell tumor;	chr19:23020694	chr19:23125665~23128543:+
BRCA	cis	rs7680126	0.5	rs4640669	ENSG00000250413.1	RP11-448G15.1	-3.54	0.000411	0.0209	-0.17	-0.11	Urate levels in obese individuals;Urate levels in lean individuals;Urate levels in overweight individuals;	chr4:10144109	chr4:10006482~10009725:+
BRCA	cis	rs11209261	0.602	rs6704179	ENSG00000232284.6	GNG12-AS1	3.54	0.000411	0.0209	0.12	0.11	Airflow obstruction;	chr1:68339176	chr1:67832303~68202987:+
BRCA	cis	rs7017914	0.967	rs1348535	ENSG00000246366.5	RP11-382J12.1	3.54	0.000411	0.0209	0.12	0.11	Bone mineral density;	chr8:70750506	chr8:70608577~70663279:+
BRCA	cis	rs60843830	0.928	rs55742348	ENSG00000223751.1	AC116609.2	3.54	0.000411	0.0209	0.15	0.11	Spherical equivalent (joint analysis main effects and education interaction);	chr2:217563	chr2:742488~747767:+
BRCA	cis	rs10771431	1	rs10771431	ENSG00000214776.8	RP11-726G1.1	-3.54	0.000411	0.0209	-0.12	-0.11	Breast size;	chr12:9228263	chr12:9467552~9576275:+
BRCA	cis	rs8103278	1	rs36091860	ENSG00000268423.3	AC011551.3	3.54	0.000411	0.021	0.14	0.11	Coronary artery disease;	chr19:45809622	chr19:46547056~46600861:-
BRCA	cis	rs12893668	0.703	rs729438	ENSG00000258914.1	CTD-2134A5.3	-3.54	0.000411	0.021	-0.15	-0.11	Reticulocyte count;	chr14:103626452	chr14:103875055~103877478:+
BRCA	cis	rs2274459	0.585	rs12664880	ENSG00000249346.5	LINC01016	3.54	0.000411	0.021	0.13	0.11	Obesity (extreme);	chr6:33812784	chr6:33867506~33896914:-
BRCA	cis	rs7089973	0.534	rs61869275	ENSG00000236799.1	RP11-383C6.2	-3.54	0.000411	0.021	-0.14	-0.11	Bipolar disorder or attention deficit hyperactivity disorder;	chr10:114989841	chr10:114994657~114996593:+
BRCA	cis	rs950027	0.549	rs1719250	ENSG00000259479.5	SORD2P	3.54	0.000412	0.021	0.14	0.11	Response to fenofibrate (adiponectin levels);	chr15:45317575	chr15:44826371~44884694:-
BRCA	cis	rs6940116	1	rs6940116	ENSG00000204789.4	ZNF204P	3.54	0.000412	0.021	0.18	0.11	Intelligence (multi-trait analysis);Autism spectrum disorder or schizophrenia;	chr6:27740953	chr6:27357825~27360221:-
BRCA	cis	rs61931739	0.5	rs11053203	ENSG00000258794.3	DUX4L27	3.54	0.000412	0.021	0.16	0.11	Morning vs. evening chronotype;	chr12:34303658	chr12:34208415~34209675:-
BRCA	cis	rs35146811	0.735	rs1637001	ENSG00000214313.7	AZGP1P1	-3.54	0.000412	0.021	-0.12	-0.11	Coronary artery disease;	chr7:100210528	chr7:99980762~99987535:+
BRCA	cis	rs17092148	0.887	rs6059937	ENSG00000202150.1	RNU6-407P	3.54	0.000412	0.021	0.16	0.11	Neuroticism;	chr20:34598396	chr20:35030317~35030420:-
BRCA	cis	rs62458065	0.85	rs7808992	ENSG00000273014.1	RP11-225B17.2	-3.54	0.000412	0.021	-0.17	-0.11	Metabolite levels (HVA/MHPG ratio);	chr7:32431065	chr7:32758882~32759353:+
BRCA	cis	rs4263408	1	rs7656037	ENSG00000224097.5	RP11-472B18.1	3.54	0.000412	0.021	0.13	0.11	Plasma amyloid beta peptide concentrations (ABx-40);	chr4:39716345	chr4:39480255~39481905:+
BRCA	cis	rs853679	0.713	rs200991	ENSG00000241549.7	GUSBP2	-3.54	0.000412	0.021	-0.16	-0.11	Depression;	chr6:27847716	chr6:26871484~26956554:-
BRCA	cis	rs1538970	0.924	rs11211118	ENSG00000281133.1	AL355480.3	-3.54	0.000412	0.021	-0.15	-0.11	Platelet count;	chr1:45464598	chr1:45580892~45580996:-
BRCA	cis	rs10043228	1	rs12514600	ENSG00000271918.1	CTD-2287O16.5	-3.54	0.000412	0.021	-0.16	-0.11	Asthma or chronic obstructive pulmonary disease;	chr5:116134958	chr5:116083807~116085416:-
BRCA	cis	rs4805834	0.764	rs12150890	ENSG00000201388.1	SNORA68	3.54	0.000412	0.021	0.19	0.11	Creatinine levels;	chr19:32864163	chr19:32608337~32608469:-
BRCA	cis	rs8114671	0.562	rs6087642	ENSG00000261582.1	RP4-614O4.11	-3.54	0.000412	0.021	-0.1	-0.11	Height;	chr20:34880503	chr20:35267885~35280043:-
BRCA	cis	rs7809799	0.571	rs67934834	ENSG00000244219.5	GS1-259H13.2	-3.54	0.000412	0.021	-0.23	-0.11	Ulcerative colitis;	chr7:99301841	chr7:99598066~99610813:+
BRCA	cis	rs6743226	0.626	rs59542139	ENSG00000266621.1	AC104841.1	3.54	0.000412	0.021	0.13	0.11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in non-smokers;	chr2:241274234	chr2:241245202~241245299:-
BRCA	cis	rs6743226	0.603	rs60515663	ENSG00000266621.1	AC104841.1	3.54	0.000412	0.021	0.13	0.11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in non-smokers;	chr2:241274843	chr2:241245202~241245299:-
BRCA	cis	rs2692947	0.77	rs72823920	ENSG00000168992.4	OR7E102P	3.54	0.000412	0.021	0.16	0.11	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95765128	chr2:95546531~95547545:+
BRCA	cis	rs2274273	0.934	rs17740741	ENSG00000259318.1	RP11-454L9.2	3.54	0.000412	0.021	0.09	0.11	Protein biomarker;	chr14:55295994	chr14:55394940~55395233:-
BRCA	cis	rs2274273	0.901	rs68046603	ENSG00000259318.1	RP11-454L9.2	3.54	0.000412	0.021	0.09	0.11	Protein biomarker;	chr14:55296085	chr14:55394940~55395233:-
BRCA	cis	rs875971	0.862	rs6964437	ENSG00000271064.1	RP11-792A8.3	3.54	0.000412	0.021	0.13	0.11	Aortic root size;	chr7:66221457	chr7:66748838~66749077:-
BRCA	cis	rs7176093	0.914	rs4843104	ENSG00000259295.5	CSPG4P12	3.54	0.000412	0.021	0.15	0.11	Aging traits;	chr15:85806808	chr15:85191438~85213905:+
BRCA	cis	rs6121246	0.657	rs74392247	ENSG00000230613.1	HM13-AS1	3.54	0.000412	0.021	0.19	0.11	Mean corpuscular hemoglobin;	chr20:31653934	chr20:31567707~31573263:-
BRCA	cis	rs7267979	0.933	rs1130694	ENSG00000274414.1	RP5-965G21.4	-3.54	0.000412	0.021	-0.13	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25295661	chr20:25239007~25245229:-
BRCA	cis	rs12468226	0.938	rs80282360	ENSG00000272966.1	RP11-686O6.1	3.54	0.000412	0.021	0.19	0.11	Urate levels;	chr2:202275121	chr2:202336739~202337200:+
BRCA	cis	rs11098403	0.753	rs4580714	ENSG00000225892.3	RP11-384K6.2	3.54	0.000412	0.021	0.11	0.11	Schizophrenia;	chr4:117856532	chr4:118632274~118634759:+
BRCA	cis	rs687432	0.847	rs12801976	ENSG00000265566.2	RN7SL605P	-3.54	0.000412	0.021	-0.15	-0.11	Parkinson's disease;	chr11:57971520	chr11:57528085~57528365:-
BRCA	cis	rs11098499	0.697	rs4560394	ENSG00000250412.1	KLHL2P1	3.54	0.000412	0.021	0.13	0.11	Corneal astigmatism;	chr4:119392280	chr4:119334329~119378233:+
BRCA	cis	rs8094794	0.744	rs16968192	ENSG00000267707.2	RP11-95O2.5	3.54	0.000412	0.021	0.16	0.11	Periodontal disease-related phenotypes;	chr18:36702616	chr18:37243776~37247506:+
BRCA	cis	rs56046484	0.912	rs12914674	ENSG00000230373.7	GOLGA6L5P	3.54	0.000412	0.021	0.17	0.11	Testicular germ cell tumor;	chr15:85119829	chr15:84507885~84516814:-
BRCA	cis	rs12686800	0.761	rs954197	ENSG00000236404.7	VLDLR-AS1	3.54	0.000412	0.021	0.14	0.11	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr9:2483942	chr9:2422702~2643359:-
BRCA	cis	rs1005277	0.602	rs1831315	ENSG00000276805.1	RP11-291L22.6	3.54	0.000412	0.021	0.12	0.11	Extrinsic epigenetic age acceleration;	chr10:38184425	chr10:38451030~38451785:+
BRCA	cis	rs68170813	0.652	rs117775624	ENSG00000241764.3	AC002467.7	3.54	0.000412	0.021	0.19	0.11	Coronary artery disease;	chr7:107483668	chr7:107742817~107744581:-
BRCA	cis	rs16849225	0.548	rs6748298	ENSG00000206869.1	SNORA70F	-3.54	0.000412	0.021	-0.13	-0.11	Systolic blood pressure;Blood pressure;	chr2:163977170	chr2:164687643~164687777:-
BRCA	cis	rs7520050	0.966	rs6695809	ENSG00000281133.1	AL355480.3	3.54	0.000412	0.021	0.13	0.11	Reticulocyte count;Red blood cell count;	chr1:45819789	chr1:45580892~45580996:-
BRCA	cis	rs9346455	0.614	rs1322759	ENSG00000199094.2	MIR30C2	3.54	0.000412	0.021	0.16	0.11	Antipsychotic drug-induced weight gain;Antipsychotic drug-induced weight gain (time interaction);	chr6:71303320	chr6:71376933~71377045:-
BRCA	cis	rs7267979	0.873	rs6037062	ENSG00000231081.1	RP4-760C5.3	-3.54	0.000412	0.021	-0.14	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25222256	chr20:26008791~26010531:-
BRCA	cis	rs8023401	0.938	rs7176364	ENSG00000274654.1	CTD-3247H4.2	3.54	0.000413	0.021	0.15	0.11	Spherical equivalent (joint analysis main effects and education interaction);	chr15:48487892	chr15:48528980~48529728:-
BRCA	cis	rs9863	0.931	rs35825716	ENSG00000270028.1	RP11-380L11.4	3.54	0.000413	0.021	0.14	0.11	White blood cell count;	chr12:123942977	chr12:123925461~123926083:-
BRCA	cis	rs10129255	0.5	rs4774008	ENSG00000211976.2	IGHV3-73	-3.54	0.000413	0.021	-0.08	-0.11	Kawasaki disease;	chr14:106681273	chr14:106802694~106803233:-
BRCA	cis	rs74233809	1	rs943037	ENSG00000213061.2	PFN1P11	3.54	0.000413	0.021	0.24	0.11	Birth weight;	chr10:103076162	chr10:102838011~102845473:-
BRCA	cis	rs2833693	0.661	rs10854355	ENSG00000261610.1	AP000265.1	3.54	0.000413	0.021	0.13	0.11	Temperament;	chr21:32167854	chr21:32259804~32261585:-
BRCA	cis	rs11098499	0.644	rs2389880	ENSG00000260091.1	RP11-33B1.4	-3.54	0.000413	0.021	-0.09	-0.11	Corneal astigmatism;	chr4:119638715	chr4:119409333~119410233:+
BRCA	cis	rs77320796	1	rs61781290	ENSG00000259943.1	RP1-39G22.7	3.54	0.000413	0.021	0.11	0.11	Platelet count;	chr1:39927488	chr1:40256427~40257967:-
BRCA	cis	rs873549	1	rs3910710	ENSG00000227925.1	RP11-191N8.2	3.54	0.000413	0.021	0.13	0.11	Keloid;	chr1:222094781	chr1:221827666~221840666:-
BRCA	cis	rs2841277	0.708	rs10083496	ENSG00000258701.1	LINC00638	3.54	0.000413	0.021	0.12	0.11	Rheumatoid arthritis;	chr14:104936449	chr14:104821201~104823718:+
BRCA	cis	rs875971	0.861	rs801215	ENSG00000271064.1	RP11-792A8.3	3.54	0.000413	0.021	0.13	0.11	Aortic root size;	chr7:66546951	chr7:66748838~66749077:-
BRCA	cis	rs6754311	0.517	rs1865452	ENSG00000231890.6	DARS-AS1	-3.54	0.000413	0.021	-0.16	-0.11	Mosquito bite size;	chr2:135781760	chr2:135985176~136022593:+
BRCA	cis	rs16944613	0.541	rs4566137	ENSG00000271396.1	RP11-697E2.9	-3.54	0.000413	0.021	-0.17	-0.11	Colorectal cancer;	chr15:90554732	chr15:90284376~90285580:-
BRCA	cis	rs4449834	1	rs7005873	ENSG00000254432.1	RP11-33I11.2	-3.54	0.000413	0.021	-0.14	-0.11	Sum eosinophil basophil counts;	chr8:60836334	chr8:60808735~60809606:-
BRCA	cis	rs1865760	0.573	rs7450342	ENSG00000272462.2	U91328.19	-3.54	0.000413	0.021	-0.13	-0.11	Height;	chr6:25919252	chr6:25992662~26001775:+
BRCA	cis	rs1865760	0.613	rs7749342	ENSG00000272462.2	U91328.19	-3.54	0.000413	0.021	-0.13	-0.11	Height;	chr6:25920037	chr6:25992662~26001775:+
BRCA	cis	rs2400362	0.752	rs4739772	ENSG00000260317.1	RP11-48B3.4	-3.54	0.000413	0.021	-0.14	-0.11	Glucocorticoid-induced osteonecrosis (age 10 years and older);	chr8:80930234	chr8:80541300~80543104:+
BRCA	cis	rs6918586	0.636	rs198816	ENSG00000272810.1	U91328.22	-3.54	0.000413	0.021	-0.12	-0.11	Schizophrenia;	chr6:26126956	chr6:26013241~26013757:+
BRCA	cis	rs40067	1	rs288157	ENSG00000272523.1	LINC01023	3.54	0.000413	0.021	0.12	0.11	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr5:108035193	chr5:108727825~108728260:-
BRCA	cis	rs1670533	1	rs13135215	ENSG00000251639.2	RP11-20I20.1	3.54	0.000413	0.021	0.17	0.11	Recombination rate (females);	chr4:1060576	chr4:1100016~1101558:-
BRCA	cis	rs1670533	1	rs13107058	ENSG00000251639.2	RP11-20I20.1	3.54	0.000413	0.021	0.17	0.11	Recombination rate (females);	chr4:1060591	chr4:1100016~1101558:-
BRCA	cis	rs1560104	0.709	rs9806858	ENSG00000259876.1	CTD-3037G24.4	3.54	0.000413	0.021	0.12	0.11	Obesity-related traits;	chr16:12610564	chr16:12556353~12557694:-
BRCA	cis	rs6918586	0.658	rs198814	ENSG00000272810.1	U91328.22	-3.54	0.000413	0.021	-0.12	-0.11	Schizophrenia;	chr6:26127531	chr6:26013241~26013757:+
BRCA	cis	rs1208	0.867	rs923796	ENSG00000253671.1	RP11-806O11.1	-3.54	0.000413	0.021	-0.13	-0.11	Insulin resistance/response;	chr8:18395899	chr8:17808941~17820868:+
BRCA	cis	rs6951245	0.572	rs79489623	ENSG00000229043.2	AC091729.9	-3.54	0.000413	0.021	-0.25	-0.11	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1005996	chr7:1160374~1165267:+
BRCA	cis	rs1144333	1	rs1144333	ENSG00000181227.3	RP4-682C21.2	3.54	0.000413	0.021	0.15	0.11	Attention function in attention deficit hyperactive disorder;	chr1:75809415	chr1:75743423~75744776:-
BRCA	cis	rs55675132	0.548	rs12120464	ENSG00000226167.1	AP4B1-AS1	3.54	0.000413	0.021	0.11	0.11	Schizophrenia;	chr1:114835070	chr1:113856635~113901237:+
BRCA	cis	rs6683273	0.72	rs16823783	ENSG00000272420.1	RP4-740C4.7	3.54	0.000413	0.021	0.19	0.11	QRS duration;	chr1:3280916	chr1:2363061~2363628:-
BRCA	cis	rs7943953	0.58	rs12419350	ENSG00000254717.2	GLYATL1P2	-3.54	0.000413	0.021	-0.15	-0.11	Odorant perception (&beta-ionone);	chr11:59331211	chr11:58878302~58893460:+
BRCA	cis	rs1510510	0.742	rs7594049	ENSG00000229915.1	AC016999.2	3.54	0.000413	0.021	0.17	0.11	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr2:238669814	chr2:238427077~238427729:-
BRCA	cis	rs2832191	0.545	rs2251381	ENSG00000232855.5	AF131217.1	-3.54	0.000413	0.021	-0.13	-0.11	Dental caries;	chr21:29158371	chr21:28439346~28674848:-
BRCA	cis	rs7176093	0.958	rs11855515	ENSG00000259295.5	CSPG4P12	-3.54	0.000413	0.021	-0.15	-0.11	Aging traits;	chr15:85835589	chr15:85191438~85213905:+
BRCA	cis	rs4713118	0.616	rs9348789	ENSG00000226314.6	ZNF192P1	-3.54	0.000414	0.021	-0.16	-0.11	Parkinson's disease;	chr6:28057708	chr6:28161781~28169594:+
BRCA	cis	rs6676180	0.555	rs871665	ENSG00000236804.1	RPS3AP12	-3.54	0.000414	0.0211	-0.12	-0.11	Monobrow;	chr1:119230040	chr1:119126539~119127291:-
BRCA	cis	rs1816752	0.633	rs8002387	ENSG00000273628.1	RP11-756A22.7	3.54	0.000414	0.0211	0.13	0.11	Obesity-related traits;	chr13:24416306	chr13:24933006~24936796:+
BRCA	cis	rs9392653	0.654	rs1246997	ENSG00000220685.3	RP11-530A18.1	-3.54	0.000414	0.0211	-0.15	-0.11	Venous thromboembolism (SNP x SNP interaction);	chr6:5059671	chr6:5065795~5066982:-
BRCA	cis	rs4386084	1	rs12148767	ENSG00000244879.4	GABPB1-AS1	-3.54	0.000414	0.0211	-0.13	-0.11	Basophil percentage of granulocytes;Basophil percentage of white cells;	chr15:49932114	chr15:50354959~50372202:+
BRCA	cis	rs6460942	0.778	rs74993124	ENSG00000226690.5	AC005281.1	3.54	0.000414	0.0211	0.19	0.11	Coronary artery disease;	chr7:12423291	chr7:12496429~12541910:+
BRCA	cis	rs6914598	0.876	rs9460600	ENSG00000240869.3	RN7SL128P	-3.54	0.000414	0.0211	-0.16	-0.11	Cutaneous malignant melanoma;Melanoma;	chr6:21151279	chr6:20421583~20421887:-
BRCA	cis	rs6012564	1	rs17632	ENSG00000230758.1	SNAP23P	3.54	0.000414	0.0211	0.13	0.11	Anger;	chr20:49096526	chr20:49038357~49038602:-
BRCA	cis	rs295490	0.748	rs74636199	ENSG00000178631.7	ACTG1P1	-3.54	0.000414	0.0211	-0.21	-0.11	PR interval in Tripanosoma cruzi seropositivity;	chr3:139493679	chr3:139493809~139494937:+
BRCA	cis	rs3750965	0.734	rs11604251	ENSG00000265539.1	MIR3164	3.54	0.000414	0.0211	0.13	0.11	Hair color;	chr11:69052961	chr11:69083176~69083258:+
BRCA	cis	rs10504130	1	rs58583070	ENSG00000272076.1	RP11-11C20.3	3.54	0.000414	0.0211	0.19	0.11	Venous thromboembolism (SNP x SNP interaction);	chr8:51775492	chr8:51810110~51810681:-
BRCA	cis	rs7481311	0.917	rs73430670	ENSG00000245573.6	BDNF-AS	-3.54	0.000414	0.0211	-0.13	-0.11	Weight;Body mass index;	chr11:27594083	chr11:27506838~27698174:+
BRCA	cis	rs9525927	0.625	rs9533803	ENSG00000227258.4	SMIM2-AS1	3.54	0.000414	0.0211	0.17	0.11	Dupuytren's disease;	chr13:44246472	chr13:44110451~44240517:+
BRCA	cis	rs526231	0.726	rs2288789	ENSG00000175749.11	EIF3KP1	3.54	0.000414	0.0211	0.15	0.11	Primary biliary cholangitis;	chr5:103264823	chr5:103032376~103033031:+
BRCA	cis	rs7520050	0.933	rs4504835	ENSG00000234329.1	RP11-767N6.2	-3.54	0.000414	0.0211	-0.1	-0.11	Reticulocyte count;Red blood cell count;	chr1:45989899	chr1:45651039~45651826:-
BRCA	cis	rs4869313	0.668	rs2548533	ENSG00000248734.2	CTD-2260A17.1	3.54	0.000414	0.0211	0.11	0.11	Pediatric autoimmune diseases;	chr5:96902697	chr5:96784777~96785999:+
BRCA	cis	rs8098244	1	rs4800514	ENSG00000265752.2	RP11-403A21.1	3.54	0.000414	0.0211	0.13	0.11	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23818150	chr18:23957754~23982556:-
BRCA	cis	rs13118159	0.509	rs4974554	ENSG00000273179.1	RP11-20I20.4	3.54	0.000414	0.0211	0.12	0.11	Longevity;	chr4:1363179	chr4:1167778~1168174:+
BRCA	cis	rs11098499	0.866	rs3756156	ENSG00000260091.1	RP11-33B1.4	-3.54	0.000414	0.0211	-0.1	-0.11	Corneal astigmatism;	chr4:119603686	chr4:119409333~119410233:+
BRCA	cis	rs9325144	0.56	rs11182979	ENSG00000257718.1	RP11-396F22.1	-3.54	0.000414	0.0211	-0.11	-0.11	Morning vs. evening chronotype;	chr12:38248760	chr12:38906451~38909592:+
BRCA	cis	rs7632954	0.567	rs6808372	ENSG00000227110.5	LMCD1-AS1	3.54	0.000414	0.0211	0.13	0.11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr3:8493007	chr3:7952805~8611924:-
BRCA	cis	rs11877825	0.685	rs2099871	ENSG00000265728.1	RP11-883A18.3	-3.54	0.000414	0.0211	-0.15	-0.11	Gut microbiota (bacterial taxa);	chr18:10578679	chr18:10594590~10604798:+
BRCA	cis	rs829883	0.622	rs4762498	ENSG00000227825.4	SLC9A7P1	-3.54	0.000414	0.0211	-0.15	-0.11	Colorectal adenoma (advanced);	chr12:98570959	chr12:98453835~98457145:-
BRCA	cis	rs10419113	0.668	rs2360535	ENSG00000268379.1	CTC-360J11.4	3.54	0.000414	0.0211	0.13	0.11	Pediatric bone mineral density (spine);	chr19:57668813	chr19:57175233~57177921:+
BRCA	cis	rs9309473	0.687	rs6747145	ENSG00000230002.2	ALMS1-IT1	3.54	0.000414	0.0211	0.13	0.11	Metabolite levels;	chr2:73382049	chr2:73456764~73459484:+
BRCA	cis	rs7620503	1	rs35168340	ENSG00000228561.2	RP11-114M1.1	3.54	0.000414	0.0211	0.13	0.11	Corneal structure;	chr3:177581264	chr3:177683627~177691250:+
BRCA	cis	rs7620503	0.918	rs34316712	ENSG00000228561.2	RP11-114M1.1	3.54	0.000414	0.0211	0.13	0.11	Corneal structure;	chr3:177581277	chr3:177683627~177691250:+
BRCA	cis	rs13434995	0.513	rs972446	ENSG00000249700.7	SRD5A3-AS1	3.54	0.000414	0.0211	0.16	0.11	Adiponectin levels;	chr4:55569581	chr4:55363971~55395847:-
BRCA	cis	rs13434995	0.513	rs11732481	ENSG00000249700.7	SRD5A3-AS1	3.54	0.000414	0.0211	0.16	0.11	Adiponectin levels;	chr4:55570212	chr4:55363971~55395847:-
BRCA	cis	rs8180040	1	rs2302278	ENSG00000280667.1	Y_RNA	-3.54	0.000414	0.0211	-0.12	-0.11	Colorectal cancer;	chr3:47319592	chr3:47501083~47501182:+
BRCA	cis	rs6600671	0.764	rs6600673	ENSG00000275131.1	CH17-472G23.4	-3.54	0.000414	0.0211	-0.1	-0.11	Hip geometry;	chr1:121426988	chr1:120489625~120579190:-
BRCA	cis	rs7781266	0.79	rs62472378	ENSG00000226205.1	AC007790.4	3.54	0.000415	0.0211	0.17	0.11	Educational attainment (college completion);	chr7:133424225	chr7:133732493~133733595:-
BRCA	cis	rs9291683	0.692	rs1558489	ENSG00000250413.1	RP11-448G15.1	3.54	0.000415	0.0211	0.14	0.11	Bone mineral density;	chr4:10323865	chr4:10006482~10009725:+
BRCA	cis	rs812925	0.571	rs3087898	ENSG00000271889.1	RP11-493E12.1	3.54	0.000415	0.0211	0.14	0.11	Immature fraction of reticulocytes;	chr2:61537939	chr2:61151433~61162105:-
BRCA	cis	rs1555322	1	rs6058219	ENSG00000279253.1	RP4-614O4.13	-3.54	0.000415	0.0211	-0.18	-0.11	Attention deficit hyperactivity disorder;	chr20:35271441	chr20:35262727~35264187:-
BRCA	cis	rs7487075	0.82	rs7134855	ENSG00000257261.4	RP11-96H19.1	3.54	0.000415	0.0211	0.12	0.11	Itch intensity from mosquito bite;	chr12:46317527	chr12:46383679~46876159:+
BRCA	cis	rs875971	0.825	rs28480509	ENSG00000271064.1	RP11-792A8.3	3.54	0.000415	0.0211	0.13	0.11	Aortic root size;	chr7:66634237	chr7:66748838~66749077:-
BRCA	cis	rs7267979	1	rs4815418	ENSG00000274414.1	RP5-965G21.4	3.54	0.000415	0.0211	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25401575	chr20:25239007~25245229:-
BRCA	cis	rs12761761	0.739	rs11146471	ENSG00000279982.1	RP11-45A17.3	-3.54	0.000415	0.0211	-0.14	-0.11	Intelligence (multi-trait analysis);Educational attainment (years of education);	chr10:131993114	chr10:131996738~131999846:+
BRCA	cis	rs12612619	0.695	rs10207670	ENSG00000272148.1	RP11-195B17.1	-3.54	0.000415	0.0211	-0.13	-0.11	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27020133	chr2:27062428~27062907:-
BRCA	cis	rs477895	0.653	rs11603212	ENSG00000256940.1	RP11-783K16.5	-3.54	0.000415	0.0211	-0.16	-0.11	Mean platelet volume;	chr11:64160338	chr11:64245964~64248217:+
BRCA	cis	rs2811403	0.792	rs2953124	ENSG00000270773.1	RP13-685P2.7	3.54	0.000415	0.0211	0.13	0.11	Basophil percentage of white cells;	chr3:128438208	chr3:129345411~129346164:+
BRCA	cis	rs2191566	0.691	rs4803673	ENSG00000266921.1	RP11-15A1.7	-3.54	0.000415	0.0211	-0.14	-0.11	Acute lymphoblastic leukemia (childhood);	chr19:44080403	chr19:43996896~44002836:-
BRCA	cis	rs12477438	0.52	rs7605843	ENSG00000231822.1	AC019097.7	3.54	0.000415	0.0211	0.12	0.11	Chronic sinus infection;	chr2:99195431	chr2:99102018~99102752:+
BRCA	cis	rs12477438	0.52	rs13798	ENSG00000231822.1	AC019097.7	3.54	0.000415	0.0211	0.12	0.11	Chronic sinus infection;	chr2:99197151	chr2:99102018~99102752:+
BRCA	cis	rs16940212	0.58	rs493987	ENSG00000259771.1	RP11-429D19.1	3.54	0.000415	0.0211	0.18	0.11	HDL cholesterol;HDL cholesterol levels;	chr15:58395707	chr15:59266720~59271162:-
BRCA	cis	rs4519046	0.66	rs2999224	ENSG00000273008.1	RP11-351D16.3	3.54	0.000415	0.0211	0.14	0.11	Hirschsprung disease;	chr10:43503318	chr10:43136824~43138334:-
BRCA	cis	rs7944584	0.837	rs11039149	ENSG00000200376.1	RNU5E-10P	3.54	0.000415	0.0211	0.16	0.11	Fasting blood glucose;Fasting blood glucose (BMI interaction);	chr11:47255124	chr11:47576471~47576588:-
BRCA	cis	rs910873	0.505	rs6058099	ENSG00000202150.1	RNU6-407P	3.54	0.000415	0.0211	0.16	0.11	Melanoma;	chr20:34661330	chr20:35030317~35030420:-
BRCA	cis	rs12612619	0.579	rs4552148	ENSG00000229122.1	AGBL5-IT1	-3.54	0.000415	0.0211	-0.12	-0.11	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:26857645	chr2:27061038~27061815:+
BRCA	cis	rs61160187	0.582	rs7723901	ENSG00000272308.1	RP11-231G3.1	-3.54	0.000415	0.0211	-0.12	-0.11	Educational attainment (years of education);Educational attainment (college completion);	chr5:60977163	chr5:60866457~60866935:-
BRCA	cis	rs10744955	0.702	rs12591392	ENSG00000244879.4	GABPB1-AS1	-3.54	0.000415	0.0211	-0.11	-0.11	Lobe attachment (rater-scored or self-reported);	chr15:50161192	chr15:50354959~50372202:+
BRCA	cis	rs7618501	1	rs7431106	ENSG00000228008.1	CTD-2330K9.3	3.54	0.000415	0.0211	0.1	0.11	Intelligence (multi-trait analysis);	chr3:49770941	chr3:49903845~49916937:+
BRCA	cis	rs997295	0.57	rs28730805	ENSG00000260657.2	RP11-315D16.4	3.54	0.000415	0.0211	0.13	0.11	Motion sickness;	chr15:67587080	chr15:68267792~68277994:-
BRCA	cis	rs72772090	0.634	rs12186366	ENSG00000272109.1	CTD-2260A17.3	3.54	0.000415	0.0211	0.2	0.11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96753146	chr5:96804353~96806105:+
BRCA	cis	rs10883723	0.962	rs1056741	ENSG00000213061.2	PFN1P11	-3.54	0.000415	0.0211	-0.15	-0.11	Allergic disease (asthma, hay fever or eczema);	chr10:102476883	chr10:102838011~102845473:-
BRCA	cis	rs9394169	0.592	rs4304152	ENSG00000224557.6	HLA-DPB2	-3.54	0.000415	0.0211	-0.13	-0.11	Essential tremor;	chr6:33755513	chr6:33112451~33129084:+
BRCA	cis	rs9619254	0.92	rs16990001	ENSG00000224050.1	RP1-90G24.6	3.54	0.000415	0.0211	0.17	0.11	Loneliness (multivariate analysis);	chr22:32204928	chr22:32273420~32277186:+
BRCA	cis	rs467650	0.529	rs1508791	ENSG00000246763.5	RGMB-AS1	-3.54	0.000415	0.0211	-0.12	-0.11	Venous thromboembolism (SNP x SNP interaction);	chr5:98660173	chr5:98769618~98773469:-
BRCA	cis	rs875971	0.577	rs34888281	ENSG00000232546.1	RP11-458F8.1	3.54	0.000415	0.0211	0.09	0.11	Aortic root size;	chr7:66120784	chr7:66848496~66858136:+
BRCA	cis	rs875971	1	rs937495	ENSG00000271064.1	RP11-792A8.3	3.54	0.000416	0.0211	0.13	0.11	Aortic root size;	chr7:66314811	chr7:66748838~66749077:-
BRCA	cis	rs875971	1	rs2036264	ENSG00000271064.1	RP11-792A8.3	3.54	0.000416	0.0211	0.13	0.11	Aortic root size;	chr7:66334917	chr7:66748838~66749077:-
BRCA	cis	rs875971	1	rs7783613	ENSG00000271064.1	RP11-792A8.3	3.54	0.000416	0.0211	0.13	0.11	Aortic root size;	chr7:66340274	chr7:66748838~66749077:-
BRCA	cis	rs7586085	0.874	rs11686403	ENSG00000229195.1	AC009495.4	-3.54	0.000416	0.0211	-0.13	-0.11	Total body bone mineral density;	chr2:165750483	chr2:165794857~165846091:-
BRCA	cis	rs7586085	0.874	rs13427924	ENSG00000229195.1	AC009495.4	-3.54	0.000416	0.0211	-0.13	-0.11	Total body bone mineral density;	chr2:165751236	chr2:165794857~165846091:-
BRCA	cis	rs7221109	0.71	rs1048572	ENSG00000224244.1	AC090283.3	-3.54	0.000416	0.0211	-0.12	-0.11	Type 1 diabetes;	chr17:40640990	chr17:40687038~40689360:-
BRCA	cis	rs9467773	0.626	rs6935803	ENSG00000124549.13	BTN2A3P	-3.54	0.000416	0.0211	-0.11	-0.11	Intelligence (multi-trait analysis);	chr6:26350267	chr6:26421391~26432383:+
BRCA	cis	rs9467773	0.626	rs6936006	ENSG00000124549.13	BTN2A3P	-3.54	0.000416	0.0211	-0.11	-0.11	Intelligence (multi-trait analysis);	chr6:26350337	chr6:26421391~26432383:+
BRCA	cis	rs7618501	1	rs57648519	ENSG00000228008.1	CTD-2330K9.3	3.54	0.000416	0.0211	0.1	0.11	Intelligence (multi-trait analysis);	chr3:49775736	chr3:49903845~49916937:+
BRCA	cis	rs7429990	0.932	rs6442101	ENSG00000228638.1	FCF1P2	3.54	0.000416	0.0211	0.12	0.11	Educational attainment (years of education);	chr3:48089403	chr3:48290793~48291375:-
BRCA	cis	rs7048146	0.832	rs10979945	ENSG00000213539.4	YBX1P6	3.54	0.000416	0.0211	0.12	0.11	Vascular brain injury;	chr9:109582456	chr9:109532830~109534332:-
BRCA	cis	rs7620503	1	rs6801659	ENSG00000228561.2	RP11-114M1.1	3.54	0.000416	0.0211	0.13	0.11	Corneal structure;	chr3:177580004	chr3:177683627~177691250:+
BRCA	cis	rs8054556	0.647	rs4787488	ENSG00000183604.13	SMG1P5	3.54	0.000416	0.0211	0.1	0.11	Autism spectrum disorder or schizophrenia;	chr16:29984482	chr16:30267553~30335374:-
BRCA	cis	rs7520050	0.902	rs4638056	ENSG00000234329.1	RP11-767N6.2	-3.54	0.000416	0.0211	-0.1	-0.11	Reticulocyte count;Red blood cell count;	chr1:45992481	chr1:45651039~45651826:-
BRCA	cis	rs7520050	0.931	rs11576305	ENSG00000234329.1	RP11-767N6.2	-3.54	0.000416	0.0211	-0.1	-0.11	Reticulocyte count;Red blood cell count;	chr1:45994374	chr1:45651039~45651826:-
BRCA	cis	rs8114671	0.836	rs6141526	ENSG00000261582.1	RP4-614O4.11	3.54	0.000416	0.0211	0.11	0.11	Height;	chr20:35027452	chr20:35267885~35280043:-
BRCA	cis	rs7660883	1	rs3775217	ENSG00000251411.1	RP11-397E7.4	3.54	0.000416	0.0211	0.12	0.11	HDL cholesterol levels;	chr4:87098315	chr4:86913266~86914817:-
BRCA	cis	rs8105895	0.935	rs1560717	ENSG00000269345.1	VN1R85P	3.54	0.000416	0.0211	0.17	0.11	Body mass index (change over time);	chr19:22109445	chr19:22174766~22175191:-
BRCA	cis	rs853679	0.517	rs7755442	ENSG00000272009.1	RP1-313I6.12	-3.54	0.000416	0.0211	-0.16	-0.11	Depression;	chr6:28071237	chr6:28078792~28081130:-
BRCA	cis	rs853679	0.517	rs55747925	ENSG00000272009.1	RP1-313I6.12	-3.54	0.000416	0.0211	-0.16	-0.11	Depression;	chr6:28076559	chr6:28078792~28081130:-
BRCA	cis	rs853679	0.517	rs34716816	ENSG00000272009.1	RP1-313I6.12	-3.54	0.000416	0.0211	-0.16	-0.11	Depression;	chr6:28078391	chr6:28078792~28081130:-
BRCA	cis	rs853679	0.517	rs9380049	ENSG00000272009.1	RP1-313I6.12	-3.54	0.000416	0.0211	-0.16	-0.11	Depression;	chr6:28080757	chr6:28078792~28081130:-
BRCA	cis	rs853679	0.517	rs9380050	ENSG00000272009.1	RP1-313I6.12	-3.54	0.000416	0.0211	-0.16	-0.11	Depression;	chr6:28080760	chr6:28078792~28081130:-
BRCA	cis	rs7520050	0.966	rs7556436	ENSG00000281133.1	AL355480.3	-3.54	0.000416	0.0211	-0.12	-0.11	Reticulocyte count;Red blood cell count;	chr1:45898208	chr1:45580892~45580996:-
BRCA	cis	rs9437689	1	rs4390223	ENSG00000235501.4	RP4-639F20.1	3.54	0.000416	0.0211	0.14	0.11	Phospholipid levels (plasma);	chr1:95091073	chr1:94927566~94963270:+
BRCA	cis	rs9437689	1	rs4309032	ENSG00000235501.4	RP4-639F20.1	3.54	0.000416	0.0211	0.14	0.11	Phospholipid levels (plasma);	chr1:95091212	chr1:94927566~94963270:+
BRCA	cis	rs9437689	1	rs12569207	ENSG00000235501.4	RP4-639F20.1	3.54	0.000416	0.0211	0.14	0.11	Phospholipid levels (plasma);	chr1:95093446	chr1:94927566~94963270:+
BRCA	cis	rs295490	0.748	rs78681436	ENSG00000178631.7	ACTG1P1	-3.54	0.000416	0.0211	-0.21	-0.11	PR interval in Tripanosoma cruzi seropositivity;	chr3:139510715	chr3:139493809~139494937:+
BRCA	cis	rs2124910	0.708	rs10853836	ENSG00000255441.1	CTD-2616J11.2	-3.54	0.000416	0.0211	-0.14	-0.11	Blood protein levels;	chr19:51525727	chr19:51415724~51417425:+
BRCA	cis	rs875971	1	rs1167612	ENSG00000230189.5	GS1-124K5.2	-3.54	0.000416	0.0211	-0.09	-0.11	Aortic root size;	chr7:66102989	chr7:66409143~66490059:-
BRCA	cis	rs8058578	1	rs3747481	ENSG00000274678.1	RP11-2C24.7	3.54	0.000416	0.0212	0.13	0.11	Multiple myeloma;	chr16:30655046	chr16:30821338~30821884:+
BRCA	cis	rs10005067	0.773	rs28738713	ENSG00000249001.4	RP11-742B18.1	-3.54	0.000416	0.0212	-0.13	-0.11	Total body bone mineral density (age 30-45);	chr4:87909095	chr4:87568035~87733956:-
BRCA	cis	rs7267979	0.866	rs6138609	ENSG00000277938.1	RP5-965G21.3	3.54	0.000416	0.0212	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25590349	chr20:25229150~25231933:+
BRCA	cis	rs4664293	0.737	rs1549579	ENSG00000224152.1	AC009506.1	-3.54	0.000416	0.0212	-0.12	-0.11	Monocyte percentage of white cells;	chr2:159812150	chr2:159615296~159617082:+
BRCA	cis	rs8180040	0.966	rs6792461	ENSG00000280667.1	Y_RNA	-3.54	0.000416	0.0212	-0.12	-0.11	Colorectal cancer;	chr3:47431678	chr3:47501083~47501182:+
BRCA	cis	rs73201462	1	rs67575175	ENSG00000242551.2	POU5F1P6	3.54	0.000416	0.0212	0.19	0.11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128161383	chr3:128674735~128677005:-
BRCA	cis	rs10761482	0.906	rs7093702	ENSG00000254271.1	RP11-131N11.4	3.54	0.000416	0.0212	0.15	0.11	Schizophrenia;	chr10:60333951	chr10:60734342~60741828:+
BRCA	cis	rs694419	0.934	rs12456150	ENSG00000278017.1	RP11-120K19.4	3.54	0.000416	0.0212	0.13	0.11	Serum albumin level;	chr18:62490357	chr18:62525919~62526325:-
BRCA	cis	rs564309	0.764	rs3795814	ENSG00000183929.7	DUSP5P1	3.54	0.000416	0.0212	0.21	0.11	Hip circumference (psychosocial stress interaction);	chr1:228356099	chr1:228650241~228651379:+
BRCA	cis	rs8180040	1	rs11714294	ENSG00000280667.1	Y_RNA	-3.54	0.000416	0.0212	-0.12	-0.11	Colorectal cancer;	chr3:47298233	chr3:47501083~47501182:+
BRCA	cis	rs7637701	0.967	rs12638253	ENSG00000240875.4	LINC00886	3.54	0.000416	0.0212	0.13	0.11	Breast cancer;	chr3:156908302	chr3:156747346~156817062:-
BRCA	cis	rs17801127	0.818	rs1724817	ENSG00000231969.1	AC144449.1	-3.54	0.000416	0.0212	-0.18	-0.11	Liver enzyme levels (alanine transaminase);	chr2:149690198	chr2:149587196~149848233:+
BRCA	cis	rs3617	0.572	rs2245538	ENSG00000243224.1	RP5-1157M23.2	-3.54	0.000416	0.0212	-0.12	-0.11	Red blood cell count;Autism spectrum disorder or schizophrenia;	chr3:52818044	chr3:52239258~52241097:+
BRCA	cis	rs2337406	0.925	rs11851094	ENSG00000280411.1	IGHV1-69-2	-3.54	0.000416	0.0212	-0.1	-0.11	Alzheimer's disease (late onset);	chr14:106688967	chr14:106762092~106762588:-
BRCA	cis	rs2880765	0.835	rs4842887	ENSG00000230373.7	GOLGA6L5P	3.54	0.000416	0.0212	0.12	0.11	Coronary artery disease;	chr15:85492579	chr15:84507885~84516814:-
BRCA	cis	rs11098499	0.691	rs10028773	ENSG00000260404.2	RP11-384K6.6	-3.54	0.000416	0.0212	-0.1	-0.11	Corneal astigmatism;	chr4:119344104	chr4:118591773~118633729:+
BRCA	cis	rs687432	0.924	rs66813766	ENSG00000265566.2	RN7SL605P	-3.54	0.000417	0.0212	-0.15	-0.11	Parkinson's disease;	chr11:57930782	chr11:57528085~57528365:-
BRCA	cis	rs116175783	0.557	rs62188123	ENSG00000235724.7	AC009299.2	3.54	0.000417	0.0212	0.17	0.11	Intelligence (multi-trait analysis);	chr2:161385335	chr2:161222785~161308303:-
BRCA	cis	rs12760731	0.72	rs10913535	ENSG00000213057.5	C1orf220	3.54	0.000417	0.0212	0.15	0.11	Obesity-related traits;	chr1:178333779	chr1:178542752~178548889:+
BRCA	cis	rs12760731	0.72	rs7548163	ENSG00000213057.5	C1orf220	3.54	0.000417	0.0212	0.15	0.11	Obesity-related traits;	chr1:178337560	chr1:178542752~178548889:+
BRCA	cis	rs12760731	0.72	rs16852717	ENSG00000213057.5	C1orf220	3.54	0.000417	0.0212	0.15	0.11	Obesity-related traits;	chr1:178340588	chr1:178542752~178548889:+
BRCA	cis	rs7176093	1	rs17641851	ENSG00000259295.5	CSPG4P12	-3.54	0.000417	0.0212	-0.15	-0.11	Aging traits;	chr15:85831354	chr15:85191438~85213905:+
BRCA	cis	rs17123764	0.892	rs74087113	ENSG00000257464.1	RP11-161H23.8	-3.54	0.000417	0.0212	-0.2	-0.11	Intelligence (multi-trait analysis);	chr12:49710321	chr12:49442424~49442652:-
BRCA	cis	rs17123764	0.892	rs1993398	ENSG00000257464.1	RP11-161H23.8	-3.54	0.000417	0.0212	-0.2	-0.11	Intelligence (multi-trait analysis);	chr12:49711631	chr12:49442424~49442652:-
BRCA	cis	rs2303319	0.504	rs62187752	ENSG00000227403.1	AC009299.3	3.54	0.000417	0.0212	0.29	0.11	Cognitive function;	chr2:161852523	chr2:161244739~161249050:+
BRCA	cis	rs875971	1	rs7781698	ENSG00000229886.1	RP5-1132H15.3	3.54	0.000417	0.0212	0.12	0.11	Aortic root size;	chr7:66431325	chr7:66025126~66031544:-
BRCA	cis	rs9425766	0.962	rs941989	ENSG00000200674.1	RN7SKP160	-3.54	0.000417	0.0212	-0.15	-0.11	Life satisfaction;	chr1:173912733	chr1:173791548~173791887:+
BRCA	cis	rs910316	0.737	rs175048	ENSG00000259138.1	RP11-950C14.7	-3.54	0.000417	0.0212	-0.11	-0.11	Height;	chr14:75013191	chr14:75127153~75136930:+
BRCA	cis	rs55962025	0.883	rs3755883	ENSG00000261643.1	RP11-529E10.6	3.54	0.000417	0.0212	0.14	0.11	Parental longevity (mother's age at death);	chr4:3221523	chr4:3503597~3504457:-
BRCA	cis	rs12915845	0.545	rs12911061	ENSG00000271997.1	RP11-97O12.6	-3.54	0.000417	0.0212	-0.09	-0.11	Menarche (age at onset);	chr15:88523404	chr15:88501944~88505787:-
BRCA	cis	rs2163813	1	rs17699333	ENSG00000270325.1	BNIP3P9	3.54	0.000417	0.0212	0.14	0.11	Toenail selenium levels;	chr19:19720735	chr19:19856975~19857527:+
BRCA	cis	rs6452790	0.529	rs11948248	ENSG00000247828.6	TMEM161B-AS1	-3.54	0.000417	0.0212	-0.15	-0.11	Cognitive function;	chr5:87973545	chr5:88268895~88436685:+
BRCA	cis	rs6452790	0.529	rs58414795	ENSG00000247828.6	TMEM161B-AS1	-3.54	0.000417	0.0212	-0.15	-0.11	Cognitive function;	chr5:87973704	chr5:88268895~88436685:+
BRCA	cis	rs6452790	0.529	rs59172908	ENSG00000247828.6	TMEM161B-AS1	-3.54	0.000417	0.0212	-0.15	-0.11	Cognitive function;	chr5:87973841	chr5:88268895~88436685:+
BRCA	cis	rs7267979	0.966	rs7270835	ENSG00000277938.1	RP5-965G21.3	3.54	0.000417	0.0212	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25454431	chr20:25229150~25231933:+
BRCA	cis	rs7267979	1	rs6115191	ENSG00000277938.1	RP5-965G21.3	3.54	0.000417	0.0212	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25459842	chr20:25229150~25231933:+
BRCA	cis	rs7267979	1	rs6107045	ENSG00000277938.1	RP5-965G21.3	3.54	0.000417	0.0212	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25461300	chr20:25229150~25231933:+
BRCA	cis	rs7267979	1	rs6107046	ENSG00000277938.1	RP5-965G21.3	3.54	0.000417	0.0212	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25461413	chr20:25229150~25231933:+
BRCA	cis	rs7267979	1	rs6107047	ENSG00000277938.1	RP5-965G21.3	3.54	0.000417	0.0212	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25461461	chr20:25229150~25231933:+
BRCA	cis	rs12467847	1	rs4387792	ENSG00000231747.1	AC079922.2	3.54	0.000417	0.0212	0.1	0.11	Response to amphetamines;	chr2:112933711	chr2:112621809~112622167:-
BRCA	cis	rs910873	1	rs17305573	ENSG00000250917.1	RP4-785G19.5	-3.54	0.000417	0.0212	-0.31	-0.11	Melanoma;	chr20:34592348	chr20:34234840~34281173:-
BRCA	cis	rs9346455	0.554	rs9346457	ENSG00000199094.2	MIR30C2	3.54	0.000417	0.0212	0.16	0.11	Antipsychotic drug-induced weight gain;Antipsychotic drug-induced weight gain (time interaction);	chr6:71299599	chr6:71376933~71377045:-
BRCA	cis	rs2055729	0.614	rs17150693	ENSG00000233609.3	RP11-62H7.2	3.54	0.000417	0.0212	0.12	0.11	Multiple myeloma (hyperdiploidy);	chr8:9884142	chr8:8961200~8979025:+
BRCA	cis	rs67340775	0.541	rs200965	ENSG00000241549.7	GUSBP2	3.54	0.000417	0.0212	0.16	0.11	Lung cancer in ever smokers;	chr6:27898606	chr6:26871484~26956554:-
BRCA	cis	rs4699052	1	rs7694190	ENSG00000251288.2	RP11-10L12.2	-3.54	0.000417	0.0212	-0.13	-0.11	Testicular germ cell tumor;	chr4:103246860	chr4:102751401~102752641:+
BRCA	cis	rs9457247	1	rs416131	ENSG00000227598.1	RP1-167A14.2	3.54	0.000417	0.0212	0.11	0.11	Crohn's disease;	chr6:166993056	chr6:166969626~166999065:-
BRCA	cis	rs6142618	0.562	rs6141646	ENSG00000275576.1	RP5-836N17.4	-3.54	0.000417	0.0212	-0.12	-0.11	Inflammatory bowel disease;	chr20:32244052	chr20:32116171~32116629:+
BRCA	cis	rs801193	0.569	rs2659893	ENSG00000265600.1	AC006480.1	-3.54	0.000417	0.0212	-0.13	-0.11	Aortic root size;	chr7:66735006	chr7:67356680~67356779:+
BRCA	cis	rs801193	0.569	rs2659892	ENSG00000265600.1	AC006480.1	-3.54	0.000417	0.0212	-0.13	-0.11	Aortic root size;	chr7:66735318	chr7:67356680~67356779:+
BRCA	cis	rs801193	0.569	rs2707847	ENSG00000265600.1	AC006480.1	-3.54	0.000417	0.0212	-0.13	-0.11	Aortic root size;	chr7:66737884	chr7:67356680~67356779:+
BRCA	cis	rs11168618	0.935	rs2114322	ENSG00000273765.1	RP11-370I10.11	-3.54	0.000417	0.0212	-0.13	-0.11	Adiponectin levels;	chr12:48557824	chr12:48360920~48361377:+
BRCA	cis	rs8098244	0.706	rs6508004	ENSG00000265752.2	RP11-403A21.1	3.54	0.000417	0.0212	0.12	0.11	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23884153	chr18:23957754~23982556:-
BRCA	cis	rs2400362	0.54	rs7015157	ENSG00000272518.1	RP11-26J3.3	-3.54	0.000417	0.0212	-0.12	-0.11	Glucocorticoid-induced osteonecrosis (age 10 years and older);	chr8:80952635	chr8:79956465~79957381:-
BRCA	cis	rs875971	0.83	rs427575	ENSG00000230189.5	GS1-124K5.2	3.54	0.000417	0.0212	0.09	0.11	Aortic root size;	chr7:66054232	chr7:66409143~66490059:-
BRCA	cis	rs56804039	1	rs17616779	ENSG00000233609.3	RP11-62H7.2	3.54	0.000417	0.0212	0.13	0.11	Cervical cancer;	chr8:8524864	chr8:8961200~8979025:+
BRCA	cis	rs1354774	0.505	rs16987929	ENSG00000228674.4	CTB-147C22.3	-3.54	0.000417	0.0212	-0.15	-0.11	Prostate-specific antigen levels;	chr19:50881997	chr19:50927079~50927571:-
BRCA	cis	rs7246657	0.943	rs6508733	ENSG00000267470.4	ZNF571-AS1	3.54	0.000417	0.0212	0.14	0.11	Coronary artery calcification;	chr19:37509646	chr19:37548914~37587348:+
BRCA	cis	rs4869313	0.668	rs1363977	ENSG00000248734.2	CTD-2260A17.1	-3.54	0.000417	0.0212	-0.11	-0.11	Pediatric autoimmune diseases;	chr5:96913003	chr5:96784777~96785999:+
BRCA	cis	rs911555	0.755	rs6575988	ENSG00000269940.1	RP11-73M18.7	-3.54	0.000417	0.0212	-0.12	-0.11	Intelligence (multi-trait analysis);	chr14:103434490	chr14:103694560~103695170:+
BRCA	cis	rs9534338	0.505	rs9534330	ENSG00000235903.6	CPB2-AS1	-3.54	0.000417	0.0212	-0.14	-0.11	Blood protein levels;	chr13:46116190	chr13:46052806~46113332:+
BRCA	cis	rs672059	1	rs575474	ENSG00000224468.3	RP11-181K3.4	-3.54	0.000417	0.0212	-0.12	-0.11	Hypertriglyceridemia;	chr1:183189464	chr1:183138402~183141282:-
BRCA	cis	rs495337	0.76	rs6125825	ENSG00000224397.4	LINC01272	-3.54	0.000417	0.0212	-0.11	-0.11	Psoriasis;	chr20:49937166	chr20:50267486~50279795:+
BRCA	cis	rs13136331	0.721	rs2627714	ENSG00000249001.4	RP11-742B18.1	3.54	0.000417	0.0212	0.15	0.11	Sitting height ratio;	chr4:87766541	chr4:87568035~87733956:-
BRCA	cis	rs8180040	0.62	rs6414435	ENSG00000260236.1	RP11-708J19.1	3.54	0.000417	0.0212	0.1	0.11	Colorectal cancer;	chr3:47079650	chr3:47379089~47380999:-
BRCA	cis	rs10916772	0.618	rs80024955	ENSG00000236963.4	LINC01141	3.54	0.000417	0.0212	0.19	0.11	Psychosis proneness (perceptual aberration scale);	chr1:20369973	chr1:20360579~20431234:-
BRCA	cis	rs7520050	0.966	rs11211241	ENSG00000226957.1	RP4-533D7.4	3.54	0.000417	0.0212	0.12	0.11	Reticulocyte count;Red blood cell count;	chr1:45987011	chr1:46046818~46048368:+
BRCA	cis	rs2704588	1	rs1458552	ENSG00000270720.1	RP11-84C13.2	-3.54	0.000418	0.0212	-0.16	-0.11	Longevity;	chr4:88915701	chr4:89119284~89119871:+
BRCA	cis	rs2274273	0.553	rs56166765	ENSG00000259318.1	RP11-454L9.2	3.54	0.000418	0.0212	0.1	0.11	Protein biomarker;	chr14:55271300	chr14:55394940~55395233:-
BRCA	cis	rs561341	1	rs497479	ENSG00000265798.5	RP11-271K11.5	3.54	0.000418	0.0212	0.19	0.11	Hip circumference adjusted for BMI;	chr17:32001586	chr17:31038575~31059121:-
BRCA	cis	rs34421088	0.548	rs2618443	ENSG00000254866.2	DEFB109P3	3.54	0.000418	0.0212	0.14	0.11	Neuroticism;	chr8:11527047	chr8:12150895~12151134:-
BRCA	cis	rs8040855	0.965	rs1961276	ENSG00000259774.1	RP11-182J1.13	3.54	0.000418	0.0212	0.13	0.11	Bulimia nervosa;	chr15:85170986	chr15:84422618~84425882:+
BRCA	cis	rs61931739	0.5	rs11519398	ENSG00000258794.3	DUX4L27	3.54	0.000418	0.0212	0.16	0.11	Morning vs. evening chronotype;	chr12:34320618	chr12:34208415~34209675:-
BRCA	cis	rs7578361	0.918	rs1196672	ENSG00000231969.1	AC144449.1	-3.54	0.000418	0.0212	-0.16	-0.11	Acute lymphoblastic leukemia (childhood);	chr2:149478589	chr2:149587196~149848233:+
BRCA	cis	rs710865	0.541	rs2073104	ENSG00000270728.1	RP4-657E11.10	-3.54	0.000418	0.0212	-0.13	-0.11	Brain structure;	chr1:19238156	chr1:19297080~19297903:+
BRCA	cis	rs16858210	0.607	rs57874587	ENSG00000234371.6	RPSAP31	3.54	0.000418	0.0212	0.16	0.11	Menopause (age at onset);	chr3:183866961	chr3:183884924~183888449:+
BRCA	cis	rs5758511	0.68	rs739146	ENSG00000231261.1	HMGN2P10	-3.54	0.000418	0.0212	-0.15	-0.11	Birth weight;	chr22:42264408	chr22:41709225~41709489:-
BRCA	cis	rs987724	0.515	rs6787457	ENSG00000244515.1	KRT18P34	-3.54	0.000418	0.0212	-0.17	-0.11	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156891157	chr3:157162663~157163932:-
BRCA	cis	rs10504390	0.656	rs17395816	ENSG00000200714.1	Y_RNA	-3.54	0.000418	0.0212	-0.25	-0.11	IgG glycosylation;	chr8:65722291	chr8:65592731~65592820:+
BRCA	cis	rs2486012	1	rs2906456	ENSG00000237950.1	RP11-7O11.3	-3.54	0.000418	0.0212	-0.19	-0.11	Intelligence (multi-trait analysis);	chr1:43875248	chr1:43944370~43946551:-
BRCA	cis	rs860295	0.812	rs10908481	ENSG00000246203.2	RP11-29H23.5	-3.54	0.000418	0.0212	-0.12	-0.11	Body mass index;	chr1:155743859	chr1:155614726~155660245:-
BRCA	cis	rs61931739	0.5	rs10844848	ENSG00000258794.3	DUX4L27	3.54	0.000418	0.0212	0.16	0.11	Morning vs. evening chronotype;	chr12:34256770	chr12:34208415~34209675:-
BRCA	cis	rs8058578	1	rs8058578	ENSG00000274678.1	RP11-2C24.7	3.54	0.000418	0.0212	0.13	0.11	Multiple myeloma;	chr16:30714927	chr16:30821338~30821884:+
BRCA	cis	rs7917772	0.636	rs2250580	ENSG00000236937.2	PTGES3P4	-3.54	0.000418	0.0212	-0.15	-0.11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;	chr10:102745930	chr10:102845595~102845950:+
BRCA	cis	rs4835473	0.9	rs35230778	ENSG00000246448.2	RP13-578N3.3	-3.54	0.000418	0.0212	-0.12	-0.11	Immature fraction of reticulocytes;	chr4:143734336	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.9	rs34772566	ENSG00000246448.2	RP13-578N3.3	-3.54	0.000418	0.0212	-0.12	-0.11	Immature fraction of reticulocytes;	chr4:143734355	chr4:143700257~143865072:+
BRCA	cis	rs12612619	0.695	rs10207670	ENSG00000229122.1	AGBL5-IT1	-3.54	0.000418	0.0212	-0.12	-0.11	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27020133	chr2:27061038~27061815:+
BRCA	cis	rs8030379	1	rs10906982	ENSG00000176700.18	SCAND2P	-3.54	0.000418	0.0213	-0.1	-0.11	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83899406	chr15:84631451~84647478:+
BRCA	cis	rs6893300	0.961	rs4700838	ENSG00000225051.5	HMGB3P22	3.54	0.000418	0.0213	0.15	0.11	Resting heart rate;	chr5:179758120	chr5:179679032~179694768:+
BRCA	cis	rs867371	0.762	rs1846910	ENSG00000278603.1	RP13-608F4.5	3.54	0.000418	0.0213	0.15	0.11	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82279439	chr15:82472203~82472426:+
BRCA	cis	rs826838	0.616	rs10880738	ENSG00000257718.1	RP11-396F22.1	-3.54	0.000418	0.0213	-0.11	-0.11	Heart rate;	chr12:38223960	chr12:38906451~38909592:+
BRCA	cis	rs826838	0.616	rs2387921	ENSG00000257718.1	RP11-396F22.1	-3.54	0.000418	0.0213	-0.11	-0.11	Heart rate;	chr12:38230965	chr12:38906451~38909592:+
BRCA	cis	rs826838	0.585	rs12296822	ENSG00000257718.1	RP11-396F22.1	-3.54	0.000418	0.0213	-0.11	-0.11	Heart rate;	chr12:38232027	chr12:38906451~38909592:+
BRCA	cis	rs826838	0.616	rs7977357	ENSG00000257718.1	RP11-396F22.1	-3.54	0.000418	0.0213	-0.11	-0.11	Heart rate;	chr12:38232206	chr12:38906451~38909592:+
BRCA	cis	rs826838	0.616	rs7966266	ENSG00000257718.1	RP11-396F22.1	-3.54	0.000418	0.0213	-0.11	-0.11	Heart rate;	chr12:38232336	chr12:38906451~38909592:+
BRCA	cis	rs12659622	0.85	rs12656926	ENSG00000250415.1	CTC-461F20.1	3.54	0.000418	0.0213	0.19	0.11	Obesity-related traits;	chr5:15662812	chr5:16617225~16621276:+
BRCA	cis	rs654950	0.934	rs641974	ENSG00000230638.4	RP11-486B10.4	3.54	0.000418	0.0213	0.14	0.11	Airway imaging phenotypes;	chr1:41536466	chr1:41542069~41544310:+
BRCA	cis	rs687432	0.924	rs56055377	ENSG00000265566.2	RN7SL605P	-3.54	0.000418	0.0213	-0.15	-0.11	Parkinson's disease;	chr11:57938146	chr11:57528085~57528365:-
BRCA	cis	rs17366136	1	rs17366136	ENSG00000232949.1	AC002480.4	-3.54	0.000418	0.0213	-0.12	-0.11	Coronary atherosclerosis (increased number of diseased vessels) (traffic exposure interaction);	chr7:22561508	chr7:22589705~22591622:+
BRCA	cis	rs7474896	0.832	rs12783666	ENSG00000120555.12	SEPT7P9	3.54	0.000419	0.0213	0.2	0.11	Obesity (extreme);	chr10:37728160	chr10:38383069~38402916:-
BRCA	cis	rs7809799	0.571	rs73163167	ENSG00000244219.5	GS1-259H13.2	-3.54	0.000419	0.0213	-0.22	-0.11	Ulcerative colitis;	chr7:99345463	chr7:99598066~99610813:+
BRCA	cis	rs7809799	0.571	rs111251485	ENSG00000244219.5	GS1-259H13.2	-3.54	0.000419	0.0213	-0.22	-0.11	Ulcerative colitis;	chr7:99360607	chr7:99598066~99610813:+
BRCA	cis	rs737008	0.922	rs2550475	ENSG00000262703.1	RP11-485G7.6	3.54	0.000419	0.0213	0.12	0.11	Obesity-related traits;	chr16:11278129	chr16:11348143~11349321:-
BRCA	cis	rs6964587	0.869	rs10256780	ENSG00000188693.7	CYP51A1-AS1	3.54	0.000419	0.0213	0.12	0.11	Breast cancer;	chr7:91897862	chr7:92134604~92180725:+
BRCA	cis	rs6964587	0.869	rs10241720	ENSG00000188693.7	CYP51A1-AS1	3.54	0.000419	0.0213	0.12	0.11	Breast cancer;	chr7:91898053	chr7:92134604~92180725:+
BRCA	cis	rs2562456	0.917	rs6511256	ENSG00000240522.1	RPL7AP10	3.54	0.000419	0.0213	0.12	0.11	Pain;	chr19:21510513	chr19:21149648~21150438:-
BRCA	cis	rs6088580	0.634	rs1890002	ENSG00000275784.1	RP5-1125A11.6	3.54	0.000419	0.0213	0.12	0.11	Glomerular filtration rate (creatinine);	chr20:34331413	chr20:33989480~33991818:-
BRCA	cis	rs11673344	0.583	rs10421436	ENSG00000267682.1	CTD-3220F14.2	3.54	0.000419	0.0213	0.09	0.11	Obesity-related traits;	chr19:37394601	chr19:37337236~37337743:+
BRCA	cis	rs863345	0.604	rs11264983	ENSG00000229914.1	RP11-404O13.4	-3.54	0.000419	0.0213	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158492428	chr1:158195633~158196131:-
BRCA	cis	rs863345	0.604	rs6664542	ENSG00000229914.1	RP11-404O13.4	-3.54	0.000419	0.0213	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158492641	chr1:158195633~158196131:-
BRCA	cis	rs3753275	0.624	rs6577525	ENSG00000230679.1	ENO1-AS1	-3.54	0.000419	0.0213	-0.16	-0.11	Educational attainment;	chr1:8797045	chr1:8878835~8879894:+
BRCA	cis	rs10197140	1	rs62159471	ENSG00000235721.1	AC013268.3	-3.54	0.000419	0.0213	-0.14	-0.11	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110857844	chr2:110007675~110010783:+
BRCA	cis	rs7722600	0.808	rs9327807	ENSG00000253404.1	AC034243.1	-3.54	0.000419	0.0213	-0.18	-0.11	Heart rate;	chr5:138014789	chr5:138744434~138753309:-
BRCA	cis	rs932316	0.825	rs56026359	ENSG00000272402.1	RP1-30M3.6	-3.54	0.000419	0.0213	-0.16	-0.11	Iron status biomarkers;	chr6:25666586	chr6:24706747~24707151:+
BRCA	cis	rs12317459	0.591	rs10862503	ENSG00000213270.5	RPL6P25	-3.54	0.000419	0.0213	-0.17	-0.11	Prostate cancer (SNP x SNP interaction);	chr12:82773021	chr12:83151331~83152190:+
BRCA	cis	rs10045504	1	rs10045504	ENSG00000249911.1	LINC01265	-3.54	0.000419	0.0213	-0.16	-0.11	Night sleep phenotypes;	chr5:38762186	chr5:38710367~38720273:-
BRCA	cis	rs3768617	0.624	rs34105373	ENSG00000224468.3	RP11-181K3.4	-3.54	0.000419	0.0213	-0.12	-0.11	Fuchs's corneal dystrophy;	chr1:183129252	chr1:183138402~183141282:-
BRCA	cis	rs2562456	0.752	rs7258562	ENSG00000268117.1	VN1R84P	3.54	0.000419	0.0213	0.16	0.11	Pain;	chr19:21331762	chr19:21719801~21720035:-
BRCA	cis	rs2018683	0.707	rs2391718	ENSG00000228421.2	AC005013.5	3.54	0.000419	0.0213	0.14	0.11	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28935371	chr7:28957667~28959345:+
BRCA	cis	rs1969253	0.803	rs843362	ENSG00000205955.4	HSP90AA5P	-3.54	0.000419	0.0213	-0.13	-0.11	Major depressive disorder;	chr3:184146241	chr3:184115352~184117898:+
BRCA	cis	rs2562456	0.833	rs2968078	ENSG00000268555.1	RP11-678G14.3	-3.54	0.000419	0.0213	-0.14	-0.11	Pain;	chr19:21458942	chr19:21570822~21587322:-
BRCA	cis	rs10829156	0.947	rs10764661	ENSG00000225527.1	RP11-383B4.4	-3.54	0.000419	0.0213	-0.16	-0.11	Sudden cardiac arrest;	chr10:18659018	chr10:18531849~18533336:-
BRCA	cis	rs875971	0.508	rs6947808	ENSG00000273448.1	RP11-166O4.6	-3.54	0.000419	0.0213	-0.1	-0.11	Aortic root size;	chr7:66580095	chr7:67333047~67334383:+
BRCA	cis	rs11035577	0.632	rs1531415	ENSG00000279675.1	RP11-454H19.2	-3.54	0.000419	0.0213	-0.16	-0.11	Temperament (bipolar disorder);	chr11:39777328	chr11:40107244~40112599:-
BRCA	cis	rs13063635	0.915	rs41289616	ENSG00000223552.1	RP11-24F11.2	-3.54	0.000419	0.0213	-0.18	-0.11	Eosinophil percentage of granulocytes;	chr3:45955771	chr3:46364955~46407059:-
BRCA	cis	rs10056811	0.5	rs67969809	ENSG00000271815.1	CTD-2235C13.3	-3.54	0.000419	0.0213	-0.16	-0.11	Coronary artery disease;	chr5:75617971	chr5:75363760~75364242:+
BRCA	cis	rs17014483	0.749	rs3017902	ENSG00000248019.2	FAM13A-AS1	-3.54	0.000419	0.0213	-0.14	-0.11	Post bronchodilator FEV1/FVC ratio;	chr4:88716931	chr4:88709789~88730103:+
BRCA	cis	rs17014483	0.749	rs3017900	ENSG00000248019.2	FAM13A-AS1	-3.54	0.000419	0.0213	-0.14	-0.11	Post bronchodilator FEV1/FVC ratio;	chr4:88718315	chr4:88709789~88730103:+
BRCA	cis	rs7267979	0.586	rs1007707	ENSG00000274414.1	RP5-965G21.4	-3.54	0.000419	0.0213	-0.13	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25209962	chr20:25239007~25245229:-
BRCA	cis	rs6141600	0.526	rs11696352	ENSG00000278035.1	RP11-234K24.6	3.54	0.000419	0.0213	0.15	0.11	Height;Hip circumference;	chr20:36162441	chr20:36233851~36234297:+
BRCA	cis	rs55675132	0.548	rs79671603	ENSG00000226167.1	AP4B1-AS1	3.54	0.000419	0.0213	0.11	0.11	Schizophrenia;	chr1:114835077	chr1:113856635~113901237:+
BRCA	cis	rs13256369	1	rs10098234	ENSG00000233609.3	RP11-62H7.2	3.54	0.000419	0.0213	0.11	0.11	Obesity-related traits;	chr8:8719182	chr8:8961200~8979025:+
BRCA	cis	rs34929064	0.718	rs34788132	ENSG00000179428.2	AC073072.5	-3.54	0.000419	0.0213	-0.16	-0.11	Major depression and alcohol dependence;	chr7:22699298	chr7:22725395~22727620:-
BRCA	cis	rs9788682	0.747	rs8042059	ENSG00000261762.1	RP11-650L12.2	-3.54	0.000419	0.0213	-0.13	-0.11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78615517	chr15:78589123~78591276:-
BRCA	cis	rs13401620	0.843	rs7601857	ENSG00000229326.3	AC069154.4	3.54	0.000419	0.0213	0.14	0.11	Breast size;	chr2:119791704	chr2:119698623~119700151:+
BRCA	cis	rs9990333	0.562	rs73210005	ENSG00000207650.1	MIR570	3.54	0.000419	0.0213	0.13	0.11	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196100441	chr3:195699401~195699497:+
BRCA	cis	rs4243971	0.516	rs6141666	ENSG00000275576.1	RP5-836N17.4	-3.54	0.000419	0.0213	-0.12	-0.11	Inflammatory bowel disease;Crohn's disease;	chr20:32307959	chr20:32116171~32116629:+
BRCA	cis	rs11671005	0.736	rs11668201	ENSG00000265272.2	RN7SL693P	3.54	0.000419	0.0213	0.16	0.11	Mean platelet volume;	chr19:58492265	chr19:58490797~58491075:+
BRCA	cis	rs6445967	0.569	rs7622497	ENSG00000244161.1	FLNB-AS1	3.54	0.000419	0.0213	0.1	0.11	Platelet count;	chr3:58296946	chr3:58162547~58170636:-
BRCA	cis	rs6840360	0.615	rs7695412	ENSG00000270265.1	RP11-731D1.4	-3.54	0.000419	0.0213	-0.13	-0.11	Intelligence (multi-trait analysis);	chr4:151566923	chr4:151333775~151353224:-
BRCA	cis	rs6071166	0.683	rs6027331	ENSG00000224635.1	RP4-564F22.5	-3.54	0.000419	0.0213	-0.13	-0.11	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38694540	chr20:38406011~38416797:-
BRCA	cis	rs185968827	1	rs185968827	ENSG00000231441.1	RP11-472M19.2	3.54	0.000419	0.0213	0.19	0.11	Alzheimer disease and age of onset;	chr6:56843712	chr6:56844002~56864078:+
BRCA	cis	rs6005807	0.843	rs7291268	ENSG00000272858.1	CTA-292E10.8	-3.54	0.000419	0.0213	-0.22	-0.11	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28501631	chr22:28814914~28815662:+
BRCA	cis	rs6997458	0.869	rs11261474	ENSG00000258256.1	RP11-219B4.5	-3.54	0.000419	0.0213	-0.13	-0.11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85382421	chr8:85222446~85245717:-
BRCA	cis	rs11035577	0.632	rs1979964	ENSG00000279675.1	RP11-454H19.2	-3.54	0.000419	0.0213	-0.17	-0.11	Temperament (bipolar disorder);	chr11:39776472	chr11:40107244~40112599:-
BRCA	cis	rs6840360	0.573	rs4696249	ENSG00000278978.1	RP11-164P12.5	-3.54	0.000419	0.0213	-0.12	-0.11	Intelligence (multi-trait analysis);	chr4:151343495	chr4:151669786~151670503:+
BRCA	cis	rs6840360	0.573	rs10024721	ENSG00000278978.1	RP11-164P12.5	-3.54	0.000419	0.0213	-0.12	-0.11	Intelligence (multi-trait analysis);	chr4:151344179	chr4:151669786~151670503:+
BRCA	cis	rs9400180	0.84	rs12174050	ENSG00000271734.1	RP1-111B22.3	-3.54	0.00042	0.0213	-0.15	-0.11	Major depressive disorder;	chr6:108066915	chr6:108030249~108030718:-
BRCA	cis	rs12468226	1	rs58288071	ENSG00000272966.1	RP11-686O6.1	3.54	0.00042	0.0213	0.19	0.11	Urate levels;	chr2:202350016	chr2:202336739~202337200:+
BRCA	cis	rs8105895	0.935	rs28635943	ENSG00000269345.1	VN1R85P	3.54	0.00042	0.0213	0.16	0.11	Body mass index (change over time);	chr19:22085910	chr19:22174766~22175191:-
BRCA	cis	rs73198271	0.74	rs1039910	ENSG00000233609.3	RP11-62H7.2	-3.54	0.00042	0.0213	-0.11	-0.11	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8790556	chr8:8961200~8979025:+
BRCA	cis	rs1667255	1	rs6506932	ENSG00000266521.1	RP11-650P15.1	3.54	0.00042	0.0213	0.13	0.11	Retinol levels;	chr18:31579987	chr18:31496645~31497195:-
BRCA	cis	rs12468226	0.873	rs6761131	ENSG00000272966.1	RP11-686O6.1	-3.54	0.00042	0.0213	-0.18	-0.11	Urate levels;	chr2:202237675	chr2:202336739~202337200:+
BRCA	cis	rs10895275	0.961	rs1820455	ENSG00000277459.1	RP11-732A21.3	-3.54	0.00042	0.0213	-0.12	-0.11	Migraine;	chr11:102221635	chr11:102109827~102110457:-
BRCA	cis	rs853679	0.567	rs6905380	ENSG00000220721.1	OR1F12	3.54	0.00042	0.0213	0.14	0.11	Depression;	chr6:28407125	chr6:28073316~28074233:+
BRCA	cis	rs4294134	0.608	rs11535258	ENSG00000223718.3	AC093107.7	3.54	0.00042	0.0213	0.16	0.11	Paget's disease;	chr7:135562799	chr7:135660039~135660647:+
BRCA	cis	rs1178127	0.759	rs11764116	ENSG00000232821.1	AC003986.6	3.54	0.00042	0.0213	0.15	0.11	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);	chr7:18760790	chr7:19112474~19114271:+
BRCA	cis	rs10844706	0.699	rs10772079	ENSG00000278635.1	CTD-2318O12.1	-3.54	0.00042	0.0213	-0.12	-0.11	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9721798	chr12:9415641~9416718:+
BRCA	cis	rs643177	0.888	rs6909442	ENSG00000226004.1	RP11-10J5.1	3.54	0.00042	0.0213	0.1	0.11	Psoriasis;Inflammatory skin disease;	chr6:137921350	chr6:137943079~137945802:-
BRCA	cis	rs2333021	0.711	rs34518714	ENSG00000259015.1	RP11-109N23.6	3.54	0.00042	0.0213	0.11	0.11	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:72992601	chr14:72960595~72961993:+
BRCA	cis	rs7647973	0.516	rs12490393	ENSG00000272434.1	RP13-131K19.6	-3.54	0.00042	0.0213	-0.13	-0.11	Menarche (age at onset);	chr3:49158699	chr3:49029316~49029706:+
BRCA	cis	rs4449834	1	rs4507803	ENSG00000254432.1	RP11-33I11.2	-3.54	0.00042	0.0213	-0.14	-0.11	Sum eosinophil basophil counts;	chr8:60831174	chr8:60808735~60809606:-
BRCA	cis	rs12726943	0.518	rs589873	ENSG00000229989.3	MIR181A1HG	3.54	0.00042	0.0213	0.17	0.11	Perceived unattractiveness to mosquitoes;	chr1:199427729	chr1:198807493~198937429:-
BRCA	cis	rs1376877	0.875	rs62183912	ENSG00000273456.1	RP11-686O6.2	3.54	0.00042	0.0213	0.1	0.11	Subclinical atherosclerosis traits (other);	chr2:203302651	chr2:202374932~202375604:-
BRCA	cis	rs67073037	0.955	rs11677283	ENSG00000230730.1	AC074011.2	-3.54	0.00042	0.0213	-0.15	-0.11	Breast cancer;Breast cancer (estrogen-receptor negative);	chr2:28928169	chr2:28633282~28664540:-
BRCA	cis	rs8180040	0.654	rs6773521	ENSG00000260236.1	RP11-708J19.1	-3.54	0.00042	0.0213	-0.1	-0.11	Colorectal cancer;	chr3:47192929	chr3:47379089~47380999:-
BRCA	cis	rs73206853	0.686	rs73194039	ENSG00000277299.1	RP11-837J7.4	-3.54	0.00042	0.0213	-0.2	-0.11	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr12:110741348	chr12:109948389~109949029:+
BRCA	cis	rs5758511	0.68	rs5758687	ENSG00000231261.1	HMGN2P10	-3.54	0.00042	0.0213	-0.15	-0.11	Birth weight;	chr22:42260582	chr22:41709225~41709489:-
BRCA	cis	rs516805	0.528	rs2684230	ENSG00000279453.1	RP3-425C14.4	-3.54	0.00042	0.0213	-0.14	-0.11	Lymphocyte counts;	chr6:122078062	chr6:122436789~122439223:-
BRCA	cis	rs11105468	0.524	rs10745520	ENSG00000270344.2	RP11-734K2.4	3.54	0.00042	0.0213	0.1	0.11	Febrile seizures (MMR vaccine-unrelated);Febrile seizures;Febrile seizures (MMR vaccine-related);	chr12:89966286	chr12:89525654~89548005:+
BRCA	cis	rs863345	0.604	rs6669271	ENSG00000229914.1	RP11-404O13.4	-3.54	0.00042	0.0213	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158502209	chr1:158195633~158196131:-
BRCA	cis	rs875971	0.543	rs801191	ENSG00000273448.1	RP11-166O4.6	-3.54	0.00042	0.0213	-0.1	-0.11	Aortic root size;	chr7:66567968	chr7:67333047~67334383:+
BRCA	cis	rs2638953	0.886	rs11049617	ENSG00000273989.1	RP11-425D17.2	-3.54	0.00042	0.0213	-0.17	-0.11	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28453344	chr12:28236227~28236828:+
BRCA	cis	rs2638953	0.924	rs11049618	ENSG00000273989.1	RP11-425D17.2	-3.54	0.00042	0.0213	-0.17	-0.11	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28453371	chr12:28236227~28236828:+
BRCA	cis	rs886774	0.803	rs4518	ENSG00000273055.1	CTB-13F3.1	-3.54	0.000421	0.0213	-0.11	-0.11	Ulcerative colitis;	chr7:107919746	chr7:107942116~107942740:+
BRCA	cis	rs1005277	0.54	rs1814077	ENSG00000099251.13	HSD17B7P2	3.54	0.000421	0.0213	0.12	0.11	Extrinsic epigenetic age acceleration;	chr10:37703090	chr10:38356380~38378505:+
BRCA	cis	rs17221829	0.617	rs11018677	ENSG00000280385.1	AP000648.5	-3.54	0.000421	0.0213	-0.13	-0.11	Anxiety in major depressive disorder;	chr11:89629652	chr11:90193614~90198120:+
BRCA	cis	rs17221829	0.733	rs11018679	ENSG00000280385.1	AP000648.5	-3.54	0.000421	0.0213	-0.13	-0.11	Anxiety in major depressive disorder;	chr11:89629701	chr11:90193614~90198120:+
BRCA	cis	rs4449834	0.816	rs11991467	ENSG00000254432.1	RP11-33I11.2	-3.54	0.000421	0.0213	-0.15	-0.11	Sum eosinophil basophil counts;	chr8:60766815	chr8:60808735~60809606:-
BRCA	cis	rs1424638	0.629	rs2865290	ENSG00000233251.6	AC007743.1	-3.54	0.000421	0.0214	-0.13	-0.11	Intelligence (multi-trait analysis);	chr2:57021110	chr2:56173534~56185770:-
BRCA	cis	rs2803122	0.84	rs10757036	ENSG00000272842.1	RP11-513M16.7	-3.54	0.000421	0.0214	-0.11	-0.11	Pulse pressure;	chr9:19236127	chr9:19371386~19371945:-
BRCA	cis	rs832540	0.83	rs252907	ENSG00000271828.1	CTD-2310F14.1	-3.54	0.000421	0.0214	-0.13	-0.11	Coronary artery disease;	chr5:56824819	chr5:56927874~56929573:+
BRCA	cis	rs7267979	1	rs884613	ENSG00000274414.1	RP5-965G21.4	3.54	0.000421	0.0214	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25307869	chr20:25239007~25245229:-
BRCA	cis	rs7267979	1	rs1888998	ENSG00000274414.1	RP5-965G21.4	3.54	0.000421	0.0214	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25311190	chr20:25239007~25245229:-
BRCA	cis	rs13108904	0.901	rs1680073	ENSG00000211482.1	AC092574.1	-3.54	0.000421	0.0214	-0.12	-0.11	Obesity-related traits;	chr4:1286549	chr4:409809~409915:+
BRCA	cis	rs3796352	0.568	rs11713376	ENSG00000275956.1	RP5-966M1.7	-3.54	0.000421	0.0214	-0.2	-0.11	Immune reponse to smallpox (secreted IL-2);	chr3:52924911	chr3:52732547~52733867:+
BRCA	cis	rs7520050	0.966	rs4073846	ENSG00000234329.1	RP11-767N6.2	3.54	0.000421	0.0214	0.1	0.11	Reticulocyte count;Red blood cell count;	chr1:45997209	chr1:45651039~45651826:-
BRCA	cis	rs1424638	0.655	rs2195493	ENSG00000233251.6	AC007743.1	-3.54	0.000421	0.0214	-0.13	-0.11	Intelligence (multi-trait analysis);	chr2:57015767	chr2:56173534~56185770:-
BRCA	cis	rs9818758	0.607	rs9990153	ENSG00000228350.1	CELSR3-AS1	-3.54	0.000421	0.0214	-0.22	-0.11	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49254450	chr3:48663776~48669174:+
BRCA	cis	rs7520050	0.743	rs61789988	ENSG00000281133.1	AL355480.3	3.54	0.000421	0.0214	0.13	0.11	Reticulocyte count;Red blood cell count;	chr1:45619570	chr1:45580892~45580996:-
BRCA	cis	rs7916410	0.505	rs11595406	ENSG00000226493.1	RP11-524O24.2	3.54	0.000421	0.0214	0.15	0.11	Optic disc area;	chr10:68185542	chr10:68499532~68499968:+
BRCA	cis	rs1971762	0.527	rs7972401	ENSG00000270175.1	RP11-793H13.11	-3.54	0.000421	0.0214	-0.09	-0.11	Height;	chr12:53546262	chr12:53500162~53500936:-
BRCA	cis	rs1790761	0.587	rs7934075	ENSG00000273819.1	ENPP7P7	-3.54	0.000421	0.0214	-0.13	-0.11	Mean corpuscular volume;	chr11:67528478	chr11:67812557~67873367:-
BRCA	cis	rs198426	0.849	rs2158505	ENSG00000243742.4	RPLP0P2	-3.54	0.000421	0.0214	-0.14	-0.11	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr11:61714460	chr11:61615036~61639449:+
BRCA	cis	rs7712401	0.525	rs193541	ENSG00000249996.1	RP11-359P5.1	3.54	0.000421	0.0214	0.13	0.11	Mean platelet volume;	chr5:122917609	chr5:123036271~123054667:+
BRCA	cis	rs783540	0.9	rs12916980	ENSG00000274376.3	ADAMTS7P1	-3.54	0.000421	0.0214	-0.12	-0.11	Schizophrenia;	chr15:82637696	chr15:82298553~82334609:+
BRCA	cis	rs875971	1	rs4717292	ENSG00000229886.1	RP5-1132H15.3	3.54	0.000421	0.0214	0.12	0.11	Aortic root size;	chr7:66430611	chr7:66025126~66031544:-
BRCA	cis	rs875971	1	rs35149210	ENSG00000229886.1	RP5-1132H15.3	3.54	0.000421	0.0214	0.12	0.11	Aortic root size;	chr7:66464938	chr7:66025126~66031544:-
BRCA	cis	rs10208649	1	rs72904915	ENSG00000272156.1	RP11-477N3.1	3.54	0.000421	0.0214	0.22	0.11	Body mass index;	chr2:54000213	chr2:54082554~54085066:+
BRCA	cis	rs7620503	1	rs1875095	ENSG00000277241.1	RP11-114M1.3	3.54	0.000421	0.0214	0.12	0.11	Corneal structure;	chr3:177585935	chr3:177700346~177701072:-
BRCA	cis	rs67073037	0.955	rs12471649	ENSG00000230730.1	AC074011.2	-3.54	0.000421	0.0214	-0.15	-0.11	Breast cancer;Breast cancer (estrogen-receptor negative);	chr2:28920559	chr2:28633282~28664540:-
BRCA	cis	rs12601721	0.531	rs2190980	ENSG00000273687.1	RP5-837J1.6	3.54	0.000421	0.0214	0.13	0.11	Macrophage inflammatory protein 1b levels;	chr17:34669734	chr17:35018660~35018991:+
BRCA	cis	rs12428035	0.764	rs72636556	ENSG00000247400.3	DNAJC3-AS1	-3.54	0.000421	0.0214	-0.18	-0.11	Glomerular filtration rate (cystatin C);Response to statins (LDL cholesterol change);	chr13:95898481	chr13:95648733~95676925:-
BRCA	cis	rs10266483	0.774	rs1404679	ENSG00000228653.2	HNRNPCP7	3.54	0.000421	0.0214	0.13	0.11	Response to statin therapy;	chr7:64358254	chr7:64500825~64501729:+
BRCA	cis	rs4714291	0.963	rs9369159	ENSG00000180211.5	RP1-278E11.3	3.54	0.000422	0.0214	0.12	0.11	Strep throat;	chr6:40031114	chr6:39958414~39958833:-
BRCA	cis	rs10510102	0.516	rs2420976	ENSG00000226864.1	ATE1-AS1	-3.54	0.000422	0.0214	-0.2	-0.11	Breast cancer;	chr10:121986932	chr10:121928312~121951965:+
BRCA	cis	rs875971	1	rs709595	ENSG00000271064.1	RP11-792A8.3	-3.54	0.000422	0.0214	-0.13	-0.11	Aortic root size;	chr7:66352346	chr7:66748838~66749077:-
BRCA	cis	rs875971	1	rs811880	ENSG00000271064.1	RP11-792A8.3	-3.54	0.000422	0.0214	-0.13	-0.11	Aortic root size;	chr7:66353659	chr7:66748838~66749077:-
BRCA	cis	rs17014483	0.749	rs2924936	ENSG00000248019.2	FAM13A-AS1	-3.54	0.000422	0.0214	-0.14	-0.11	Post bronchodilator FEV1/FVC ratio;	chr4:88720363	chr4:88709789~88730103:+
BRCA	cis	rs4835473	0.9	rs56084616	ENSG00000246448.2	RP13-578N3.3	-3.54	0.000422	0.0214	-0.12	-0.11	Immature fraction of reticulocytes;	chr4:143746697	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.966	rs11722639	ENSG00000246448.2	RP13-578N3.3	-3.54	0.000422	0.0214	-0.12	-0.11	Immature fraction of reticulocytes;	chr4:143746884	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.966	rs11722673	ENSG00000246448.2	RP13-578N3.3	-3.54	0.000422	0.0214	-0.12	-0.11	Immature fraction of reticulocytes;	chr4:143746946	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.932	rs6821979	ENSG00000246448.2	RP13-578N3.3	-3.54	0.000422	0.0214	-0.12	-0.11	Immature fraction of reticulocytes;	chr4:143748091	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.932	rs6838887	ENSG00000246448.2	RP13-578N3.3	-3.54	0.000422	0.0214	-0.12	-0.11	Immature fraction of reticulocytes;	chr4:143748130	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.932	rs1982392	ENSG00000246448.2	RP13-578N3.3	-3.54	0.000422	0.0214	-0.12	-0.11	Immature fraction of reticulocytes;	chr4:143748604	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.932	rs1982393	ENSG00000246448.2	RP13-578N3.3	-3.54	0.000422	0.0214	-0.12	-0.11	Immature fraction of reticulocytes;	chr4:143748736	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.932	rs9683880	ENSG00000246448.2	RP13-578N3.3	-3.54	0.000422	0.0214	-0.12	-0.11	Immature fraction of reticulocytes;	chr4:143748787	chr4:143700257~143865072:+
BRCA	cis	rs7520050	0.966	rs11211230	ENSG00000226957.1	RP4-533D7.4	3.54	0.000422	0.0214	0.12	0.11	Reticulocyte count;Red blood cell count;	chr1:45941095	chr1:46046818~46048368:+
BRCA	cis	rs801193	1	rs6975195	ENSG00000275400.1	RP4-756H11.5	3.54	0.000422	0.0214	0.12	0.11	Aortic root size;	chr7:66659787	chr7:66553805~66554199:-
BRCA	cis	rs2692947	0.667	rs4144055	ENSG00000168992.4	OR7E102P	3.54	0.000422	0.0214	0.15	0.11	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95982108	chr2:95546531~95547545:+
BRCA	cis	rs62247992	0.62	rs57549659	ENSG00000227245.1	RP11-136C24.2	3.54	0.000422	0.0214	0.16	0.11	Facial morphology (factor 15, philtrum width);	chr3:43096723	chr3:43087479~43088068:+
BRCA	cis	rs853679	0.546	rs493161	ENSG00000216676.2	RP1-15D7.1	-3.54	0.000422	0.0214	-0.2	-0.11	Depression;	chr6:27882936	chr6:27652602~27652825:-
BRCA	cis	rs672059	1	rs551569	ENSG00000224468.3	RP11-181K3.4	-3.54	0.000422	0.0214	-0.12	-0.11	Hypertriglyceridemia;	chr1:183189158	chr1:183138402~183141282:-
BRCA	cis	rs672059	1	rs1760624	ENSG00000224468.3	RP11-181K3.4	-3.54	0.000422	0.0214	-0.12	-0.11	Hypertriglyceridemia;	chr1:183189417	chr1:183138402~183141282:-
BRCA	cis	rs7267979	1	rs2500443	ENSG00000274973.1	RP13-401N8.7	3.54	0.000422	0.0214	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25350806	chr20:25845497~25845862:+
BRCA	cis	rs13434995	0.513	rs11240	ENSG00000249700.7	SRD5A3-AS1	-3.54	0.000422	0.0214	-0.16	-0.11	Adiponectin levels;	chr4:55453183	chr4:55363971~55395847:-
BRCA	cis	rs863345	0.625	rs4575081	ENSG00000176320.2	RP11-404O13.5	-3.54	0.000422	0.0214	-0.11	-0.11	Pneumococcal bacteremia;	chr1:158535047	chr1:158197922~158203877:-
BRCA	cis	rs61931739	0.517	rs11052964	ENSG00000258794.3	DUX4L27	3.54	0.000422	0.0214	0.16	0.11	Morning vs. evening chronotype;	chr12:33858061	chr12:34208415~34209675:-
BRCA	cis	rs7267979	0.932	rs1985737	ENSG00000274973.1	RP13-401N8.7	-3.54	0.000422	0.0214	-0.12	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25610832	chr20:25845497~25845862:+
BRCA	cis	rs10761482	0.861	rs10761489	ENSG00000254271.1	RP11-131N11.4	3.54	0.000422	0.0214	0.15	0.11	Schizophrenia;	chr10:60348846	chr10:60734342~60741828:+
BRCA	cis	rs10761482	0.861	rs10761490	ENSG00000254271.1	RP11-131N11.4	3.54	0.000422	0.0214	0.15	0.11	Schizophrenia;	chr10:60348908	chr10:60734342~60741828:+
BRCA	cis	rs9392556	0.829	rs689308	ENSG00000230648.1	RP3-406P24.3	3.54	0.000422	0.0214	0.14	0.11	Blood metabolite levels;	chr6:4127496	chr6:4018843~4021215:-
BRCA	cis	rs10131519	0.604	rs4905917	ENSG00000199082.1	MIR342	-3.54	0.000422	0.0214	-0.13	-0.11	Coronary artery disease;	chr14:99916855	chr14:100109655~100109753:+
BRCA	cis	rs6088580	0.634	rs4277599	ENSG00000275784.1	RP5-1125A11.6	3.54	0.000422	0.0214	0.12	0.11	Glomerular filtration rate (creatinine);	chr20:34421099	chr20:33989480~33991818:-
BRCA	cis	rs561341	0.941	rs8081016	ENSG00000265798.5	RP11-271K11.5	3.54	0.000422	0.0214	0.19	0.11	Hip circumference adjusted for BMI;	chr17:32004732	chr17:31038575~31059121:-
BRCA	cis	rs76798021	0.689	rs11721212	ENSG00000271976.1	RP11-884K10.7	3.54	0.000422	0.0214	0.13	0.11	Lung function (FEV1/FVC);	chr3:53605912	chr3:53858994~53861576:-
BRCA	cis	rs10894147	1	rs10750422	ENSG00000175773.11	RP11-121M22.1	3.54	0.000422	0.0214	0.17	0.11	Obesity-related traits;	chr11:129822685	chr11:130314993~130403657:+
BRCA	cis	rs7824557	0.767	rs28507159	ENSG00000154316.13	TDH	-3.54	0.000422	0.0214	-0.15	-0.11	Retinal vascular caliber;	chr8:11308567	chr8:11339637~11368452:+
BRCA	cis	rs1387259	0.619	rs7134565	ENSG00000257735.1	RP11-370I10.6	-3.54	0.000422	0.0214	-0.13	-0.11	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48236241	chr12:48350945~48442411:+
BRCA	cis	rs4787491	0.729	rs3814878	ENSG00000214725.6	CDIPT-AS1	-3.54	0.000422	0.0214	-0.13	-0.11	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30030645	chr16:29863593~29868053:+
BRCA	cis	rs9346455	0.614	rs58732838	ENSG00000199094.2	MIR30C2	3.54	0.000422	0.0214	0.16	0.11	Antipsychotic drug-induced weight gain;Antipsychotic drug-induced weight gain (time interaction);	chr6:71290793	chr6:71376933~71377045:-
BRCA	cis	rs9346455	0.614	rs9360445	ENSG00000199094.2	MIR30C2	3.54	0.000422	0.0214	0.16	0.11	Antipsychotic drug-induced weight gain;Antipsychotic drug-induced weight gain (time interaction);	chr6:71291163	chr6:71376933~71377045:-
BRCA	cis	rs12712133	0.514	rs10188022	ENSG00000234389.1	AC007278.3	-3.54	0.000422	0.0214	-0.11	-0.11	Primary biliary cholangitis;	chr2:102258406	chr2:102438713~102440475:+
BRCA	cis	rs1348850	0.914	rs6761593	ENSG00000280374.1	RP11-337N6.3	-3.54	0.000422	0.0214	-0.15	-0.11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177586872	chr2:177317715~177318471:-
BRCA	cis	rs4919669	0.668	rs10786700	ENSG00000213277.3	MARCKSL1P1	3.54	0.000422	0.0214	0.17	0.11	Mean arterial pressure (long-term average);Systolic blood pressure (long-term average);	chr10:102627978	chr10:103175554~103176094:+
BRCA	cis	rs7123876	0.504	rs1157343	ENSG00000202522.1	Y_RNA	3.54	0.000422	0.0214	0.09	0.11	Body mass index;	chr11:72718096	chr11:72766004~72766116:+
BRCA	cis	rs7229439	0.707	rs8085852	ENSG00000267414.1	RP11-456K23.1	-3.54	0.000422	0.0214	-0.12	-0.11	Antipsychotic drug-induced QTc interval change in schizophrenia;	chr18:45352100	chr18:44676927~44679717:-
BRCA	cis	rs4742903	0.904	rs10114234	ENSG00000270332.1	SMC2-AS1	-3.54	0.000422	0.0214	-0.12	-0.11	Breast cancer;High-grade serous ovarian cancer;	chr9:104241365	chr9:104080024~104093073:-
BRCA	cis	rs10035650	0.589	rs10076188	ENSG00000243806.1	RPL7P18	3.54	0.000423	0.0214	0.13	0.11	Cancer;	chr5:94726834	chr5:94825961~94826694:-
BRCA	cis	rs4415084	0.966	rs4571480	ENSG00000248464.1	FGF10-AS1	-3.54	0.000423	0.0214	-0.12	-0.11	Breast cancer;	chr5:44687086	chr5:44388732~44413989:+
BRCA	cis	rs372883	0.638	rs371432	ENSG00000176054.6	RPL23P2	-3.54	0.000423	0.0214	-0.12	-0.11	Pancreatic cancer;	chr21:29338555	chr21:28997613~28998033:-
BRCA	cis	rs7818688	1	rs73276406	ENSG00000245080.5	RP11-320N21.1	-3.54	0.000423	0.0214	-0.18	-0.11	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95009532	chr8:95066808~95073182:-
BRCA	cis	rs7818688	1	rs9297950	ENSG00000245080.5	RP11-320N21.1	-3.54	0.000423	0.0214	-0.18	-0.11	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95013431	chr8:95066808~95073182:-
BRCA	cis	rs7221109	0.533	rs7210983	ENSG00000224244.1	AC090283.3	3.54	0.000423	0.0214	0.12	0.11	Type 1 diabetes;	chr17:40660862	chr17:40687038~40689360:-
BRCA	cis	rs7520050	0.966	rs6668284	ENSG00000281133.1	AL355480.3	3.54	0.000423	0.0214	0.13	0.11	Reticulocyte count;Red blood cell count;	chr1:45888838	chr1:45580892~45580996:-
BRCA	cis	rs13256369	0.756	rs13280759	ENSG00000254153.1	CTA-398F10.2	3.54	0.000423	0.0214	0.15	0.11	Obesity-related traits;	chr8:8705485	chr8:8456909~8461337:-
BRCA	cis	rs477895	0.713	rs35095324	ENSG00000256940.1	RP11-783K16.5	3.54	0.000423	0.0214	0.15	0.11	Mean platelet volume;	chr11:64180940	chr11:64245964~64248217:+
BRCA	cis	rs1949733	1	rs3103071	ENSG00000205959.3	RP11-689P11.2	3.54	0.000423	0.0214	0.11	0.11	Response to antineoplastic agents;	chr4:8506852	chr4:8482270~8512610:+
BRCA	cis	rs7849585	0.928	rs7038554	ENSG00000273066.4	RP11-216L13.19	3.54	0.000423	0.0214	0.11	0.11	Height;	chr9:136243135	chr9:136799223~136810042:+
BRCA	cis	rs4950322	0.518	rs4950305	ENSG00000237188.3	RP11-337C18.8	3.54	0.000423	0.0214	0.13	0.11	Protein quantitative trait loci;	chr1:147117711	chr1:147172771~147211568:+
BRCA	cis	rs4449834	0.773	rs7009754	ENSG00000254432.1	RP11-33I11.2	-3.54	0.000423	0.0214	-0.14	-0.11	Sum eosinophil basophil counts;	chr8:60780329	chr8:60808735~60809606:-
BRCA	cis	rs4449834	0.851	rs6471901	ENSG00000254432.1	RP11-33I11.2	-3.54	0.000423	0.0214	-0.14	-0.11	Sum eosinophil basophil counts;	chr8:60780853	chr8:60808735~60809606:-
BRCA	cis	rs34217772	0.739	rs17181741	ENSG00000258636.1	CTD-2298J14.2	3.54	0.000423	0.0214	0.14	0.11	Myopia;	chr14:41839275	chr14:41587861~41604856:-
BRCA	cis	rs6439153	0.933	rs900381	ENSG00000242551.2	POU5F1P6	-3.54	0.000423	0.0215	-0.14	-0.11	Pneumococcal bacteremia;	chr3:128994612	chr3:128674735~128677005:-
BRCA	cis	rs853679	0.882	rs4713139	ENSG00000219392.1	RP1-265C24.5	-3.54	0.000423	0.0215	-0.23	-0.11	Depression;	chr6:28124907	chr6:28115628~28116551:+
BRCA	cis	rs4718428	0.705	rs28648401	ENSG00000229886.1	RP5-1132H15.3	3.54	0.000423	0.0215	0.13	0.11	Corneal structure;	chr7:66902145	chr7:66025126~66031544:-
BRCA	cis	rs7914558	0.966	rs943035	ENSG00000213277.3	MARCKSL1P1	3.54	0.000423	0.0215	0.12	0.11	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103079395	chr10:103175554~103176094:+
BRCA	cis	rs7914558	0.966	rs7921574	ENSG00000213277.3	MARCKSL1P1	3.54	0.000423	0.0215	0.12	0.11	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103081213	chr10:103175554~103176094:+
BRCA	cis	rs11083475	1	rs1808382	ENSG00000267892.1	CTD-2540F13.2	3.54	0.000423	0.0215	0.12	0.11	Heart rate;	chr19:38660394	chr19:38738284~38739863:+
BRCA	cis	rs683250	0.629	rs680562	ENSG00000254551.1	RP11-727A23.7	3.54	0.000423	0.0215	0.14	0.11	Subcortical brain region volumes;	chr11:83237847	chr11:83209431~83213379:-
BRCA	cis	rs4930561	0.765	rs7931502	ENSG00000184795.9	UNC93B5	3.54	0.000423	0.0215	0.12	0.11	Breast cancer in childhood cancer survivors;IgG glycosylation;	chr11:68192140	chr11:67711702~67716005:-
BRCA	cis	rs7412746	0.658	rs11204739	ENSG00000231073.1	RP11-316M1.3	3.54	0.000423	0.0215	0.12	0.11	Melanoma;	chr1:150893284	chr1:150973123~150975534:+
BRCA	cis	rs7618501	0.699	rs9821675	ENSG00000281433.1	Metazoa_SRP	-3.54	0.000423	0.0215	-0.11	-0.11	Intelligence (multi-trait analysis);	chr3:49865111	chr3:49320296~49320564:+
BRCA	cis	rs3781264	0.595	rs11187853	ENSG00000268894.5	PLCE1-AS1	-3.54	0.000423	0.0215	-0.15	-0.11	Esophageal cancer and gastric cancer;	chr10:94312471	chr10:94279277~94287478:-
BRCA	cis	rs7089973	0.872	rs7918253	ENSG00000236799.1	RP11-383C6.2	-3.54	0.000423	0.0215	-0.13	-0.11	Bipolar disorder or attention deficit hyperactivity disorder;	chr10:114854742	chr10:114994657~114996593:+
BRCA	cis	rs7089973	0.872	rs7918388	ENSG00000236799.1	RP11-383C6.2	-3.54	0.000423	0.0215	-0.13	-0.11	Bipolar disorder or attention deficit hyperactivity disorder;	chr10:114854804	chr10:114994657~114996593:+
BRCA	cis	rs12317459	1	rs11115388	ENSG00000213270.5	RPL6P25	-3.54	0.000423	0.0215	-0.16	-0.11	Prostate cancer (SNP x SNP interaction);	chr12:82767833	chr12:83151331~83152190:+
BRCA	cis	rs660899	0.857	rs10890280	ENSG00000229431.1	RP1-92O14.6	-3.54	0.000423	0.0215	-0.11	-0.11	Hypertension risk in short sleep duration;	chr1:43772547	chr1:43385113~43389155:+
BRCA	cis	rs2411233	1	rs8029263	ENSG00000259278.1	RP11-62C7.2	3.54	0.000423	0.0215	0.13	0.11	Platelet count;	chr15:39009045	chr15:39019233~39024918:+
BRCA	cis	rs9866825	0.902	rs12485848	ENSG00000227110.5	LMCD1-AS1	3.54	0.000423	0.0215	0.13	0.11	QT interval;	chr3:8206610	chr3:7952805~8611924:-
BRCA	cis	rs7709909	0.755	rs6883090	ENSG00000249655.1	CTC-325J23.2	3.54	0.000423	0.0215	0.12	0.11	HDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;	chr5:80680569	chr5:80630313~80631590:-
BRCA	cis	rs2985684	0.846	rs11157693	ENSG00000278009.1	RP11-649E7.8	3.54	0.000424	0.0215	0.15	0.11	Carotid intima media thickness;	chr14:49581708	chr14:49601011~49601124:-
BRCA	cis	rs2985684	0.846	rs10150624	ENSG00000278009.1	RP11-649E7.8	3.54	0.000424	0.0215	0.15	0.11	Carotid intima media thickness;	chr14:49584847	chr14:49601011~49601124:-
BRCA	cis	rs2985684	0.802	rs10150823	ENSG00000278009.1	RP11-649E7.8	3.54	0.000424	0.0215	0.15	0.11	Carotid intima media thickness;	chr14:49585033	chr14:49601011~49601124:-
BRCA	cis	rs2337406	1	rs3858878	ENSG00000280411.1	IGHV1-69-2	-3.54	0.000424	0.0215	-0.1	-0.11	Alzheimer's disease (late onset);	chr14:106688061	chr14:106762092~106762588:-
BRCA	cis	rs13272568	0.614	rs13278866	ENSG00000254352.1	RP11-578O24.2	-3.54	0.000424	0.0215	-0.14	-0.11	Bone mineral density;	chr8:78119700	chr8:78723796~78724136:-
BRCA	cis	rs11048434	0.518	rs4883206	ENSG00000256069.6	A2MP1	-3.54	0.000424	0.0215	-0.11	-0.11	Sjögren's syndrome;	chr12:9021169	chr12:9228533~9275817:-
BRCA	cis	rs4287000	0.615	rs11793637	ENSG00000227603.1	RP11-165J3.6	3.54	0.000424	0.0215	0.11	0.11	Itch intensity from mosquito bite adjusted by bite size;	chr9:93653617	chr9:93435332~93437121:-
BRCA	cis	rs4906332	1	rs8012127	ENSG00000259775.1	RP11-45P15.4	-3.54	0.000424	0.0215	-0.12	-0.11	Coronary artery disease;	chr14:103476425	chr14:103331674~103332367:-
BRCA	cis	rs4906332	1	rs78316803	ENSG00000259775.1	RP11-45P15.4	-3.54	0.000424	0.0215	-0.12	-0.11	Coronary artery disease;	chr14:103476526	chr14:103331674~103332367:-
BRCA	cis	rs4906332	1	rs17617832	ENSG00000259775.1	RP11-45P15.4	-3.54	0.000424	0.0215	-0.12	-0.11	Coronary artery disease;	chr14:103476803	chr14:103331674~103332367:-
BRCA	cis	rs4906332	1	rs11625172	ENSG00000259775.1	RP11-45P15.4	-3.54	0.000424	0.0215	-0.12	-0.11	Coronary artery disease;	chr14:103478575	chr14:103331674~103332367:-
BRCA	cis	rs11098499	0.739	rs9996382	ENSG00000225892.3	RP11-384K6.2	3.54	0.000424	0.0215	0.11	0.11	Corneal astigmatism;	chr4:119229857	chr4:118632274~118634759:+
BRCA	cis	rs983392	0.792	rs521952	ENSG00000275344.1	MIR6503	-3.54	0.000424	0.0215	-0.11	-0.11	Alzheimer's disease (late onset);	chr11:60102723	chr11:60209071~60209156:-
BRCA	cis	rs2562456	0.833	rs2562507	ENSG00000268555.1	RP11-678G14.3	-3.54	0.000424	0.0215	-0.14	-0.11	Pain;	chr19:21543535	chr19:21570822~21587322:-
BRCA	cis	rs672059	1	rs544352	ENSG00000224468.3	RP11-181K3.4	-3.54	0.000424	0.0215	-0.12	-0.11	Hypertriglyceridemia;	chr1:183188411	chr1:183138402~183141282:-
BRCA	cis	rs672059	1	rs546183	ENSG00000224468.3	RP11-181K3.4	-3.54	0.000424	0.0215	-0.12	-0.11	Hypertriglyceridemia;	chr1:183188618	chr1:183138402~183141282:-
BRCA	cis	rs672059	1	rs625917	ENSG00000224468.3	RP11-181K3.4	-3.54	0.000424	0.0215	-0.12	-0.11	Hypertriglyceridemia;	chr1:183188856	chr1:183138402~183141282:-
BRCA	cis	rs9614461	0.702	rs2294202	ENSG00000232363.1	RP1-102D24.5	-3.54	0.000424	0.0215	-0.19	-0.11	Tonsillectomy;	chr22:45342446	chr22:45435864~45448743:-
BRCA	cis	rs7120118	0.517	rs2290149	ENSG00000280615.1	Y_RNA	3.54	0.000424	0.0215	0.18	0.11	HDL cholesterol;	chr11:47324365	chr11:47614898~47614994:-
BRCA	cis	rs7267979	0.932	rs6132848	ENSG00000274414.1	RP5-965G21.4	-3.54	0.000424	0.0215	-0.13	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25581009	chr20:25239007~25245229:-
BRCA	cis	rs13256369	1	rs13256369	ENSG00000233609.3	RP11-62H7.2	3.54	0.000424	0.0215	0.11	0.11	Obesity-related traits;	chr8:8719869	chr8:8961200~8979025:+
BRCA	cis	rs7267979	1	rs6050559	ENSG00000274414.1	RP5-965G21.4	-3.54	0.000424	0.0215	-0.13	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25349279	chr20:25239007~25245229:-
BRCA	cis	rs58521262	0.516	rs10408398	ENSG00000268105.1	RP11-369G6.2	3.54	0.000424	0.0215	0.15	0.11	Testicular germ cell tumor;	chr19:22912624	chr19:23125665~23128543:+
BRCA	cis	rs17680741	0.657	rs12246432	ENSG00000225484.5	NUTM2B-AS1	-3.54	0.000424	0.0215	-0.18	-0.11	Coronary artery disease;	chr10:80510462	chr10:79663088~79826594:-
BRCA	cis	rs4388249	1	rs1866373	ENSG00000249068.1	CTC-287O8.1	3.54	0.000424	0.0215	0.16	0.11	Schizophrenia;	chr5:109704541	chr5:109840128~109840692:-
BRCA	cis	rs62025270	0.632	rs7163838	ENSG00000259367.1	RP11-815J21.4	3.54	0.000424	0.0215	0.1	0.11	Idiopathic pulmonary fibrosis;	chr15:85664390	chr15:85619623~85670948:-
BRCA	cis	rs7339483	0.702	rs28452037	ENSG00000268442.1	CTD-2027I19.2	3.54	0.000424	0.0215	0.23	0.11	Discordance in emotional problems in monozygotic twins;	chr19:24182757	chr19:24162370~24163425:-
BRCA	cis	rs801193	1	rs6958520	ENSG00000275400.1	RP4-756H11.5	-3.54	0.000424	0.0215	-0.12	-0.11	Aortic root size;	chr7:66686466	chr7:66553805~66554199:-
BRCA	cis	rs7267979	0.903	rs6107015	ENSG00000274414.1	RP5-965G21.4	-3.54	0.000424	0.0215	-0.13	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25236128	chr20:25239007~25245229:-
BRCA	cis	rs12310956	0.532	rs1589903	ENSG00000258794.3	DUX4L27	3.54	0.000424	0.0215	0.16	0.11	Morning vs. evening chronotype;	chr12:33790084	chr12:34208415~34209675:-
BRCA	cis	rs1670533	1	rs2290408	ENSG00000251639.2	RP11-20I20.1	-3.54	0.000424	0.0215	-0.17	-0.11	Recombination rate (females);	chr4:1073479	chr4:1100016~1101558:-
BRCA	cis	rs1443512	0.796	rs1822437	ENSG00000257534.1	RP11-834C11.10	3.54	0.000424	0.0215	0.13	0.11	Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-hip ratio;Waist-to-hip ratio adjusted for body mass index;	chr12:53946293	chr12:54162065~54164452:-
BRCA	cis	rs2905347	0.895	rs2961283	ENSG00000232949.1	AC002480.4	3.54	0.000424	0.0215	0.12	0.11	Major depression and alcohol dependence;	chr7:22600879	chr7:22589705~22591622:+
BRCA	cis	rs9308731	0.591	rs10439381	ENSG00000230499.1	AC108463.1	-3.54	0.000424	0.0215	-0.12	-0.11	Chronic lymphocytic leukemia;	chr2:111178882	chr2:111195963~111206494:+
BRCA	cis	rs875971	0.929	rs6970860	ENSG00000229886.1	RP5-1132H15.3	3.54	0.000424	0.0215	0.12	0.11	Aortic root size;	chr7:66511647	chr7:66025126~66031544:-
BRCA	cis	rs10411161	0.671	rs8105497	ENSG00000269349.1	CTD-3099C6.5	3.54	0.000424	0.0215	0.17	0.11	Breast cancer;	chr19:51847134	chr19:52511282~52512342:-
BRCA	cis	rs2108622	0.727	rs12609900	ENSG00000214049.6	UCA1	3.54	0.000424	0.0215	0.15	0.11	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871604	chr19:15828961~15836320:+
BRCA	cis	rs2108622	0.727	rs62107763	ENSG00000214049.6	UCA1	3.54	0.000424	0.0215	0.15	0.11	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871788	chr19:15828961~15836320:+
BRCA	cis	rs2108622	0.727	rs62107764	ENSG00000214049.6	UCA1	3.54	0.000424	0.0215	0.15	0.11	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871848	chr19:15828961~15836320:+
BRCA	cis	rs2108622	0.727	rs8101038	ENSG00000214049.6	UCA1	3.54	0.000424	0.0215	0.15	0.11	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15872054	chr19:15828961~15836320:+
BRCA	cis	rs17301013	0.932	rs1754355	ENSG00000234741.6	GAS5	-3.54	0.000424	0.0215	-0.11	-0.11	Systemic lupus erythematosus;	chr1:174807407	chr1:173863900~173868882:-
BRCA	cis	rs4948275	0.597	rs2650712	ENSG00000237233.2	TMEM26-AS1	-3.54	0.000424	0.0215	-0.13	-0.11	Night sleep phenotypes;	chr10:61605901	chr10:61452639~61481956:+
BRCA	cis	rs7412746	0.658	rs4970986	ENSG00000224800.1	RP11-235D19.2	-3.54	0.000425	0.0215	-0.14	-0.11	Melanoma;	chr1:150935479	chr1:150881236~150881683:-
BRCA	cis	rs7412746	0.658	rs59024312	ENSG00000224800.1	RP11-235D19.2	-3.54	0.000425	0.0215	-0.14	-0.11	Melanoma;	chr1:150936529	chr1:150881236~150881683:-
BRCA	cis	rs7412746	0.658	rs7528773	ENSG00000224800.1	RP11-235D19.2	-3.54	0.000425	0.0215	-0.14	-0.11	Melanoma;	chr1:150943399	chr1:150881236~150881683:-
BRCA	cis	rs12659622	0.92	rs78387238	ENSG00000250415.1	CTC-461F20.1	3.54	0.000425	0.0215	0.19	0.11	Obesity-related traits;	chr5:15649655	chr5:16617225~16621276:+
BRCA	cis	rs35520189	0.961	rs58788639	ENSG00000274877.1	RP11-65I12.1	-3.54	0.000425	0.0215	-0.16	-0.11	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:112869012	chr2:113237595~113240825:+
BRCA	cis	rs10876993	0.928	rs2169988	ENSG00000270039.1	RP11-571M6.17	3.54	0.000425	0.0215	0.14	0.11	Celiac disease or Rheumatoid arthritis;	chr12:57677382	chr12:57803838~57804415:+
BRCA	cis	rs7429990	0.932	rs34025851	ENSG00000199476.1	Y_RNA	-3.54	0.000425	0.0215	-0.15	-0.11	Educational attainment (years of education);	chr3:47912243	chr3:48288587~48288694:+
BRCA	cis	rs13256369	0.901	rs12679831	ENSG00000254153.1	CTA-398F10.2	3.54	0.000425	0.0215	0.15	0.11	Obesity-related traits;	chr8:8708901	chr8:8456909~8461337:-
BRCA	cis	rs13256369	0.901	rs12681327	ENSG00000254153.1	CTA-398F10.2	3.54	0.000425	0.0215	0.15	0.11	Obesity-related traits;	chr8:8708904	chr8:8456909~8461337:-
BRCA	cis	rs295490	0.748	rs61680644	ENSG00000178631.7	ACTG1P1	-3.54	0.000425	0.0215	-0.21	-0.11	PR interval in Tripanosoma cruzi seropositivity;	chr3:139455729	chr3:139493809~139494937:+
BRCA	cis	rs295490	0.667	rs79829464	ENSG00000178631.7	ACTG1P1	-3.54	0.000425	0.0215	-0.21	-0.11	PR interval in Tripanosoma cruzi seropositivity;	chr3:139456842	chr3:139493809~139494937:+
BRCA	cis	rs2154319	0.943	rs61774689	ENSG00000230638.4	RP11-486B10.4	-3.54	0.000425	0.0215	-0.18	-0.11	Height;	chr1:41219750	chr1:41542069~41544310:+
BRCA	cis	rs1446468	0.656	rs1470048	ENSG00000277998.1	RP11-452N17.1	-3.54	0.000425	0.0215	-0.1	-0.11	Blood pressure;Immunoglobulin A vasculitis;Mean arterial pressure;Diastolic blood pressure;Systolic blood pressure;	chr2:164256660	chr2:164573741~164574054:+
BRCA	cis	rs7267979	1	rs1077889	ENSG00000274414.1	RP5-965G21.4	-3.54	0.000425	0.0215	-0.13	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25287257	chr20:25239007~25245229:-
BRCA	cis	rs394563	0.601	rs439495	ENSG00000223701.3	RAET1E-AS1	-3.54	0.000425	0.0215	-0.14	-0.11	Dupuytren's disease;	chr6:149472088	chr6:149884431~149919508:+
BRCA	cis	rs28489187	0.706	rs233108	ENSG00000223653.4	RP11-131L23.1	3.54	0.000425	0.0215	0.12	0.11	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85316037	chr1:85276715~85448124:+
BRCA	cis	rs970548	0.688	rs1059696	ENSG00000230869.1	CTGLF10P	3.54	0.000425	0.0215	0.16	0.11	Total cholesterol levels;HDL cholesterol;HDL cholesterol levels;Cholesterol, total;	chr10:45438989	chr10:45678692~45700532:+
BRCA	cis	rs8180040	0.603	rs9854790	ENSG00000280667.1	Y_RNA	3.54	0.000425	0.0215	0.12	0.11	Colorectal cancer;	chr3:47059816	chr3:47501083~47501182:+
BRCA	cis	rs8180040	0.726	rs2061197	ENSG00000271161.1	BOLA2P2	-3.54	0.000425	0.0215	-0.12	-0.11	Colorectal cancer;	chr3:46959860	chr3:47499841~47500407:+
BRCA	cis	rs1722141	0.65	rs788711	ENSG00000237471.1	AC073115.6	3.54	0.000425	0.0215	0.14	0.11	Sitting height ratio;	chr7:45971115	chr7:45969657~45980191:+
BRCA	cis	rs7577696	0.85	rs11124276	ENSG00000276334.1	AL133243.1	-3.54	0.000425	0.0215	-0.13	-0.11	Inflammatory biomarkers;	chr2:32093359	chr2:32521927~32523547:+
BRCA	cis	rs4578769	0.765	rs61311054	ENSG00000273232.1	RP11-370A5.2	-3.54	0.000425	0.0215	-0.15	-0.11	Eosinophil percentage of white cells;	chr18:22906406	chr18:22882825~22883357:-
BRCA	cis	rs4820539	1	rs2157710	ENSG00000211650.2	IGLV5-45	-3.54	0.000425	0.0215	-0.09	-0.11	Bone mineral density;	chr22:23115299	chr22:22375986~22376505:+
BRCA	cis	rs11035577	0.57	rs7110727	ENSG00000279675.1	RP11-454H19.2	-3.54	0.000425	0.0215	-0.17	-0.11	Temperament (bipolar disorder);	chr11:39768282	chr11:40107244~40112599:-
BRCA	cis	rs11035577	0.632	rs7128280	ENSG00000279675.1	RP11-454H19.2	-3.54	0.000425	0.0215	-0.17	-0.11	Temperament (bipolar disorder);	chr11:39768381	chr11:40107244~40112599:-
BRCA	cis	rs6997458	0.742	rs3758077	ENSG00000258256.1	RP11-219B4.5	-3.54	0.000425	0.0215	-0.13	-0.11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85463274	chr8:85222446~85245717:-
BRCA	cis	rs875971	0.895	rs4145009	ENSG00000229886.1	RP5-1132H15.3	-3.54	0.000425	0.0215	-0.12	-0.11	Aortic root size;	chr7:66261628	chr7:66025126~66031544:-
BRCA	cis	rs13126694	0.71	rs9995402	ENSG00000251073.1	NUDT19P5	3.54	0.000425	0.0215	0.1	0.11	Blood osmolality (transformed sodium);	chr4:158105262	chr4:158182825~158183393:+
BRCA	cis	rs13126694	0.71	rs34237515	ENSG00000251073.1	NUDT19P5	3.54	0.000425	0.0215	0.1	0.11	Blood osmolality (transformed sodium);	chr4:158105607	chr4:158182825~158183393:+
BRCA	cis	rs6439153	0.743	rs71331685	ENSG00000242551.2	POU5F1P6	-3.54	0.000425	0.0215	-0.14	-0.11	Pneumococcal bacteremia;	chr3:128992582	chr3:128674735~128677005:-
BRCA	cis	rs10504130	0.569	rs60153173	ENSG00000272076.1	RP11-11C20.3	3.54	0.000425	0.0215	0.16	0.11	Venous thromboembolism (SNP x SNP interaction);	chr8:51778064	chr8:51810110~51810681:-
BRCA	cis	rs172166	0.694	rs203877	ENSG00000219891.2	ZSCAN12P1	3.54	0.000425	0.0215	0.13	0.11	Cardiac Troponin-T levels;	chr6:28080846	chr6:28091154~28093664:+
BRCA	cis	rs7577696	0.924	rs7566162	ENSG00000276334.1	AL133243.1	-3.54	0.000425	0.0215	-0.13	-0.11	Inflammatory biomarkers;	chr2:32099003	chr2:32521927~32523547:+
BRCA	cis	rs4950322	0.518	rs61838951	ENSG00000237188.3	RP11-337C18.8	3.54	0.000425	0.0216	0.13	0.11	Protein quantitative trait loci;	chr1:147116081	chr1:147172771~147211568:+
BRCA	cis	rs564309	0.867	rs12093491	ENSG00000212237.1	RNA5SP18	3.54	0.000425	0.0216	0.21	0.11	Hip circumference (psychosocial stress interaction);	chr1:228381797	chr1:228647912~228648032:-
BRCA	cis	rs10504130	0.696	rs11785805	ENSG00000272076.1	RP11-11C20.3	3.54	0.000425	0.0216	0.16	0.11	Venous thromboembolism (SNP x SNP interaction);	chr8:51929310	chr8:51810110~51810681:-
BRCA	cis	rs10129255	0.957	rs2007467	ENSG00000232216.1	IGHV3-43	-3.54	0.000425	0.0216	-0.09	-0.11	Kawasaki disease;	chr14:106771605	chr14:106470264~106470800:-
BRCA	cis	rs564309	1	rs12061642	ENSG00000183929.7	DUSP5P1	3.54	0.000426	0.0216	0.22	0.11	Hip circumference (psychosocial stress interaction);	chr1:228398535	chr1:228650241~228651379:+
BRCA	cis	rs950027	0.787	rs1153845	ENSG00000275672.1	GATM-AS1	3.54	0.000426	0.0216	0.13	0.11	Response to fenofibrate (adiponectin levels);	chr15:45432531	chr15:45378700~45380123:+
BRCA	cis	rs7829975	0.606	rs7819827	ENSG00000253981.4	ALG1L13P	-3.54	0.000426	0.0216	-0.12	-0.11	Mood instability;	chr8:8939545	chr8:8236003~8244667:-
BRCA	cis	rs7829975	0.573	rs7842359	ENSG00000253981.4	ALG1L13P	-3.54	0.000426	0.0216	-0.12	-0.11	Mood instability;	chr8:8939568	chr8:8236003~8244667:-
BRCA	cis	rs6929812	0.576	rs2064219	ENSG00000241549.7	GUSBP2	-3.54	0.000426	0.0216	-0.12	-0.11	Neuroticism (multi-trait analysis);	chr6:27408222	chr6:26871484~26956554:-
BRCA	cis	rs875971	0.638	rs7793569	ENSG00000232546.1	RP11-458F8.1	3.54	0.000426	0.0216	0.09	0.11	Aortic root size;	chr7:66651646	chr7:66848496~66858136:+
BRCA	cis	rs801193	1	rs3857688	ENSG00000232546.1	RP11-458F8.1	3.54	0.000426	0.0216	0.09	0.11	Aortic root size;	chr7:66662819	chr7:66848496~66858136:+
BRCA	cis	rs801193	1	rs2286684	ENSG00000232546.1	RP11-458F8.1	3.54	0.000426	0.0216	0.09	0.11	Aortic root size;	chr7:66664843	chr7:66848496~66858136:+
BRCA	cis	rs801193	0.935	rs2286683	ENSG00000232546.1	RP11-458F8.1	3.54	0.000426	0.0216	0.09	0.11	Aortic root size;	chr7:66664856	chr7:66848496~66858136:+
BRCA	cis	rs801193	1	rs10274773	ENSG00000232546.1	RP11-458F8.1	3.54	0.000426	0.0216	0.09	0.11	Aortic root size;	chr7:66668591	chr7:66848496~66858136:+
BRCA	cis	rs8098244	0.964	rs1268716	ENSG00000265752.2	RP11-403A21.1	-3.54	0.000426	0.0216	-0.14	-0.11	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23894863	chr18:23957754~23982556:-
BRCA	cis	rs8098244	0.964	rs1262341	ENSG00000265752.2	RP11-403A21.1	-3.54	0.000426	0.0216	-0.14	-0.11	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23895595	chr18:23957754~23982556:-
BRCA	cis	rs8098244	0.964	rs1258113	ENSG00000265752.2	RP11-403A21.1	-3.54	0.000426	0.0216	-0.14	-0.11	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23895680	chr18:23957754~23982556:-
BRCA	cis	rs8098244	0.964	rs1154226	ENSG00000265752.2	RP11-403A21.1	-3.54	0.000426	0.0216	-0.14	-0.11	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23901269	chr18:23957754~23982556:-
BRCA	cis	rs8098244	0.964	rs9961718	ENSG00000265752.2	RP11-403A21.1	3.54	0.000426	0.0216	0.14	0.11	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23893803	chr18:23957754~23982556:-
BRCA	cis	rs7412746	0.658	rs12090215	ENSG00000224800.1	RP11-235D19.2	-3.54	0.000426	0.0216	-0.14	-0.11	Melanoma;	chr1:150921184	chr1:150881236~150881683:-
BRCA	cis	rs7412746	0.658	rs72704682	ENSG00000224800.1	RP11-235D19.2	-3.54	0.000426	0.0216	-0.14	-0.11	Melanoma;	chr1:150925201	chr1:150881236~150881683:-
BRCA	cis	rs7412746	0.658	rs72704685	ENSG00000224800.1	RP11-235D19.2	-3.54	0.000426	0.0216	-0.14	-0.11	Melanoma;	chr1:150925211	chr1:150881236~150881683:-
BRCA	cis	rs4869313	0.668	rs7736466	ENSG00000248734.2	CTD-2260A17.1	3.54	0.000426	0.0216	0.11	0.11	Pediatric autoimmune diseases;	chr5:96954007	chr5:96784777~96785999:+
BRCA	cis	rs72647484	0.554	rs2744754	ENSG00000228397.1	RP1-224A6.3	-3.53	0.000426	0.0216	-0.29	-0.11	Colorectal cancer;	chr1:22249974	chr1:22023994~22024968:-
BRCA	cis	rs4865762	0.514	rs1823072	ENSG00000247796.2	CTD-2366F13.1	3.53	0.000426	0.0216	0.12	0.11	Intraocular pressure;	chr5:53133976	chr5:53109842~53115126:+
BRCA	cis	rs4865762	0.514	rs251337	ENSG00000247796.2	CTD-2366F13.1	3.53	0.000426	0.0216	0.12	0.11	Intraocular pressure;	chr5:53134576	chr5:53109842~53115126:+
BRCA	cis	rs11098499	0.82	rs2389885	ENSG00000250412.1	KLHL2P1	3.53	0.000426	0.0216	0.14	0.11	Corneal astigmatism;	chr4:119612776	chr4:119334329~119378233:+
BRCA	cis	rs240993	0.516	rs465646	ENSG00000271789.1	RP5-1112D6.7	-3.53	0.000426	0.0216	-0.16	-0.11	Inflammatory skin disease;Psoriasis;	chr6:111299555	chr6:111297126~111298510:+
BRCA	cis	rs806321	0.534	rs1269281	ENSG00000237152.3	DLEU7-AS1	3.53	0.000426	0.0216	0.14	0.11	Multiple sclerosis;	chr13:50316402	chr13:50807856~50849905:+
BRCA	cis	rs7172677	0.737	rs11072528	ENSG00000260269.4	CTD-2323K18.1	-3.53	0.000426	0.0216	-0.15	-0.11	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75144114	chr15:75527150~75601205:-
BRCA	cis	rs12723316	0.867	rs12735437	ENSG00000233008.4	RP11-475O6.1	-3.53	0.000426	0.0216	-0.2	-0.11	Schizophrenia;	chr1:83806966	chr1:83575776~83861023:-
BRCA	cis	rs7130284	0.748	rs12225280	ENSG00000134612.10	FOLH1B	-3.53	0.000426	0.0216	-0.23	-0.11	Homocysteine levels;	chr11:89464591	chr11:89639227~89698718:+
BRCA	cis	rs7339483	0.702	rs73031016	ENSG00000268442.1	CTD-2027I19.2	3.53	0.000426	0.0216	0.23	0.11	Discordance in emotional problems in monozygotic twins;	chr19:24182099	chr19:24162370~24163425:-
BRCA	cis	rs7620503	1	rs1463858	ENSG00000228561.2	RP11-114M1.1	3.53	0.000426	0.0216	0.13	0.11	Corneal structure;	chr3:177580339	chr3:177683627~177691250:+
BRCA	cis	rs73222236	0.825	rs56040643	ENSG00000239213.4	NCK1-AS1	3.53	0.000426	0.0216	0.12	0.11	Coronary artery disease;	chr3:136538621	chr3:136841726~136862054:-
BRCA	cis	rs8113308	0.752	rs11882377	ENSG00000269235.1	ZNF350-AS1	3.53	0.000426	0.0216	0.2	0.11	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:52000877	chr19:51949134~51981367:+
BRCA	cis	rs2749592	0.55	rs12255038	ENSG00000263064.2	RP11-291L22.7	-3.53	0.000426	0.0216	-0.14	-0.11	Age-related hearing impairment (SNP x SNP interaction);	chr10:37580404	chr10:38448689~38448949:+
BRCA	cis	rs4950322	0.518	rs4950305	ENSG00000230832.3	RP11-325P15.2	-3.53	0.000426	0.0216	-0.16	-0.11	Protein quantitative trait loci;	chr1:147117711	chr1:147082338~147083578:-
BRCA	cis	rs11671005	0.695	rs8106061	ENSG00000265272.2	RN7SL693P	3.53	0.000426	0.0216	0.16	0.11	Mean platelet volume;	chr19:58406623	chr19:58490797~58491075:+
BRCA	cis	rs420259	0.727	rs35585	ENSG00000260136.4	CTD-2270L9.4	-3.53	0.000426	0.0216	-0.1	-0.11	Bipolar disorder;	chr16:23665790	chr16:23452758~23457606:+
BRCA	cis	rs11892454	0.565	rs10174199	ENSG00000217643.1	PTGES3P2	-3.53	0.000426	0.0216	-0.12	-0.11	Heschl's gyrus morphology;	chr2:25810618	chr2:25822469~25822950:+
BRCA	cis	rs1555133	0.694	rs6141680	ENSG00000275576.1	RP5-836N17.4	-3.53	0.000426	0.0216	-0.12	-0.11	Monocyte count;	chr20:32341389	chr20:32116171~32116629:+
BRCA	cis	rs2585417	0.506	rs2616335	ENSG00000185834.10	RPL12P4	-3.53	0.000426	0.0216	-0.12	-0.11	Obesity-related traits;	chr20:54297902	chr20:55074644~55075140:+
BRCA	cis	rs7267979	1	rs11087520	ENSG00000204556.4	CTD-2514C3.1	-3.53	0.000427	0.0216	-0.15	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25456191	chr20:26018832~26020684:+
BRCA	cis	rs10005067	0.901	rs34268974	ENSG00000249001.4	RP11-742B18.1	-3.53	0.000427	0.0216	-0.13	-0.11	Total body bone mineral density (age 30-45);	chr4:87910307	chr4:87568035~87733956:-
BRCA	cis	rs7020830	0.898	rs308523	ENSG00000230188.1	RP11-405L18.4	-3.53	0.000427	0.0216	-0.13	-0.11	Schizophrenia;	chr9:37338788	chr9:37490421~37490893:-
BRCA	cis	rs1914816	0.941	rs2469544	ENSG00000196274.5	Metazoa_SRP	3.53	0.000427	0.0216	0.14	0.11	Response to tocilizumab in rheumatoid arthritis;	chr15:76192606	chr15:76230048~76230390:-
BRCA	cis	rs16893526	1	rs11961442	ENSG00000224995.1	LINC01526	-3.53	0.000427	0.0216	-0.21	-0.11	Coronary heart disease;	chr6:81797406	chr6:81813286~81814157:-
BRCA	cis	rs9400180	0.879	rs9374015	ENSG00000271734.1	RP1-111B22.3	-3.53	0.000427	0.0216	-0.15	-0.11	Major depressive disorder;	chr6:108065639	chr6:108030249~108030718:-
BRCA	cis	rs9400180	0.879	rs9374016	ENSG00000271734.1	RP1-111B22.3	-3.53	0.000427	0.0216	-0.15	-0.11	Major depressive disorder;	chr6:108065661	chr6:108030249~108030718:-
BRCA	cis	rs7267979	0.932	rs6107052	ENSG00000276952.1	RP5-965G21.6	3.53	0.000427	0.0216	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25550202	chr20:25284915~25285588:-
BRCA	cis	rs863345	0.604	rs10797021	ENSG00000229914.1	RP11-404O13.4	-3.53	0.000427	0.0216	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158520551	chr1:158195633~158196131:-
BRCA	cis	rs875971	0.545	rs316328	ENSG00000232559.3	GS1-124K5.12	-3.53	0.000427	0.0216	-0.14	-0.11	Aortic root size;	chr7:66143851	chr7:66554588~66576923:-
BRCA	cis	rs4950322	0.634	rs7542951	ENSG00000227242.3	NBPF13P	-3.53	0.000427	0.0216	-0.16	-0.11	Protein quantitative trait loci;	chr1:147340308	chr1:147021320~147124525:-
BRCA	cis	rs4869313	0.668	rs2549795	ENSG00000248734.2	CTD-2260A17.1	-3.53	0.000427	0.0216	-0.11	-0.11	Pediatric autoimmune diseases;	chr5:96908934	chr5:96784777~96785999:+
BRCA	cis	rs6088580	0.543	rs4911158	ENSG00000261582.1	RP4-614O4.11	3.53	0.000427	0.0216	0.11	0.11	Glomerular filtration rate (creatinine);	chr20:34651708	chr20:35267885~35280043:-
BRCA	cis	rs2554380	0.628	rs7175491	ENSG00000259570.1	RP11-671M22.4	3.53	0.000427	0.0216	0.14	0.11	Height;	chr15:83806187	chr15:84394512~84395514:+
BRCA	cis	rs7283707	0.581	rs2823513	ENSG00000270071.1	AP001172.2	-3.53	0.000427	0.0216	-0.14	-0.11	QRS complex (12-leadsum);	chr21:15862465	chr21:16291791~16308133:-
BRCA	cis	rs79387448	0.745	rs7572284	ENSG00000234389.1	AC007278.3	3.53	0.000427	0.0216	0.15	0.11	Gut microbiota (bacterial taxa);	chr2:102502964	chr2:102438713~102440475:+
BRCA	cis	rs7267979	0.966	rs2261795	ENSG00000204556.4	CTD-2514C3.1	-3.53	0.000427	0.0216	-0.15	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25282500	chr20:26018832~26020684:+
BRCA	cis	rs798766	1	rs7682402	ENSG00000244459.2	RP11-1398P2.1	-3.53	0.000427	0.0216	-0.14	-0.11	Urinary bladder cancer;Bladder cancer;	chr4:1741616	chr4:1574062~1580253:-
BRCA	cis	rs72482608	0.636	rs6667186	ENSG00000271811.1	RP1-79C4.4	3.53	0.000427	0.0216	0.12	0.11	Emphysema imaging phenotypes;	chr1:170890176	chr1:170667381~170669425:+
BRCA	cis	rs7239883	0.5	rs1583210	ENSG00000267652.1	RP11-188I24.1	3.53	0.000427	0.0216	0.16	0.11	Waist circumference;Body mass index;	chr18:42517652	chr18:41789162~41789395:-
BRCA	cis	rs7916663	0.522	rs3886147	ENSG00000225213.2	RP11-197M22.2	-3.53	0.000427	0.0216	-0.2	-0.11	Obesity-related traits;	chr10:16679381	chr10:16721352~16748377:-
BRCA	cis	rs7017914	0.934	rs1993862	ENSG00000246366.5	RP11-382J12.1	3.53	0.000427	0.0216	0.12	0.11	Bone mineral density;	chr8:70667127	chr8:70608577~70663279:+
BRCA	cis	rs1348850	0.914	rs1453370	ENSG00000280374.1	RP11-337N6.3	3.53	0.000427	0.0216	0.15	0.11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177462999	chr2:177317715~177318471:-
BRCA	cis	rs2333021	0.866	rs10133784	ENSG00000259015.1	RP11-109N23.6	3.53	0.000427	0.0216	0.11	0.11	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:73003328	chr14:72960595~72961993:+
BRCA	cis	rs4499344	0.73	rs377044	ENSG00000267475.1	CTD-2538C1.2	3.53	0.000427	0.0216	0.13	0.11	Mean platelet volume;	chr19:32615045	chr19:32687089~32691750:-
BRCA	cis	rs3011225	0.738	rs803677	ENSG00000237950.1	RP11-7O11.3	3.53	0.000427	0.0216	0.16	0.11	Amyotrophic lateral sclerosis (age of onset);	chr1:43886029	chr1:43944370~43946551:-
BRCA	cis	rs3011225	0.688	rs803676	ENSG00000237950.1	RP11-7O11.3	3.53	0.000427	0.0216	0.16	0.11	Amyotrophic lateral sclerosis (age of onset);	chr1:43886786	chr1:43944370~43946551:-
BRCA	cis	rs873549	0.785	rs7549980	ENSG00000227925.1	RP11-191N8.2	3.53	0.000427	0.0216	0.13	0.11	Keloid;	chr1:222095156	chr1:221827666~221840666:-
BRCA	cis	rs873549	1	rs7552392	ENSG00000227925.1	RP11-191N8.2	3.53	0.000427	0.0216	0.13	0.11	Keloid;	chr1:222095349	chr1:221827666~221840666:-
BRCA	cis	rs873549	1	rs6703147	ENSG00000227925.1	RP11-191N8.2	3.53	0.000427	0.0216	0.13	0.11	Keloid;	chr1:222095423	chr1:221827666~221840666:-
BRCA	cis	rs873549	1	rs6703389	ENSG00000227925.1	RP11-191N8.2	3.53	0.000427	0.0216	0.13	0.11	Keloid;	chr1:222095609	chr1:221827666~221840666:-
BRCA	cis	rs10916772	0.558	rs76883690	ENSG00000236963.4	LINC01141	3.53	0.000428	0.0216	0.19	0.11	Psychosis proneness (perceptual aberration scale);	chr1:20367341	chr1:20360579~20431234:-
BRCA	cis	rs3753275	0.69	rs9730025	ENSG00000270282.1	RP5-1115A15.2	3.53	0.000428	0.0216	0.16	0.11	Educational attainment;	chr1:8559014	chr1:8512653~8513021:+
BRCA	cis	rs6743226	0.603	rs62186419	ENSG00000266621.1	AC104841.1	3.53	0.000428	0.0216	0.13	0.11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in non-smokers;	chr2:241307450	chr2:241245202~241245299:-
BRCA	cis	rs6743226	0.557	rs62186420	ENSG00000266621.1	AC104841.1	3.53	0.000428	0.0216	0.13	0.11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in non-smokers;	chr2:241307460	chr2:241245202~241245299:-
BRCA	cis	rs72772090	0.539	rs72775810	ENSG00000272109.1	CTD-2260A17.3	3.53	0.000428	0.0216	0.21	0.11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96849604	chr5:96804353~96806105:+
BRCA	cis	rs56046484	0.956	rs35045545	ENSG00000230373.7	GOLGA6L5P	3.53	0.000428	0.0216	0.16	0.11	Testicular germ cell tumor;	chr15:85121720	chr15:84507885~84516814:-
BRCA	cis	rs6044112	0.718	rs6080286	ENSG00000273998.1	RP4-777L9.2	3.53	0.000428	0.0216	0.2	0.11	Response to taxane treatment (docetaxel);	chr20:16529379	chr20:16576068~16579615:+
BRCA	cis	rs6102185	0.624	rs6129697	ENSG00000229771.2	RP4-644L1.2	-3.53	0.000428	0.0216	-0.13	-0.11	IgG glycosylation;	chr20:40887371	chr20:40696499~40698616:-
BRCA	cis	rs6831352	0.879	rs1230154	ENSG00000260641.1	RP11-1299A16.3	3.53	0.000428	0.0216	0.15	0.11	Alcohol dependence;	chr4:99067508	chr4:98658904~98664550:+
BRCA	cis	rs1823874	0.71	rs56186545	ENSG00000259363.4	CTD-2054N24.2	3.53	0.000428	0.0216	0.13	0.11	IgG glycosylation;	chr15:99820554	chr15:99807023~99877148:+
BRCA	cis	rs2617170	0.885	rs7978962	ENSG00000245648.1	RP11-277P12.20	3.53	0.000428	0.0216	0.14	0.11	Behcet's disease;	chr12:10372225	chr12:10363769~10398506:+
BRCA	cis	rs7267979	0.966	rs3002698	ENSG00000274973.1	RP13-401N8.7	3.53	0.000428	0.0217	0.12	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25322743	chr20:25845497~25845862:+
BRCA	cis	rs10844706	0.73	rs12317499	ENSG00000278635.1	CTD-2318O12.1	-3.53	0.000428	0.0217	-0.12	-0.11	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9732764	chr12:9415641~9416718:+
BRCA	cis	rs4374383	0.884	rs6739294	ENSG00000243389.1	AC012442.5	3.53	0.000428	0.0217	0.14	0.11	Hepatitis C induced liver fibrosis;	chr2:111995303	chr2:112589040~112614431:+
BRCA	cis	rs853679	0.517	rs9380047	ENSG00000226314.6	ZNF192P1	-3.53	0.000428	0.0217	-0.16	-0.11	Depression;	chr6:28070115	chr6:28161781~28169594:+
BRCA	cis	rs2899832	0.5	rs77434119	ENSG00000258704.4	SRP54-AS1	3.53	0.000428	0.0217	0.25	0.11	Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:35204924	chr14:34920858~34982532:-
BRCA	cis	rs1040555	0.516	rs242547	ENSG00000260536.1	RP5-1085F17.4	3.53	0.000428	0.0217	0.14	0.11	Lymphocyte percentage of white cells;	chr20:32830775	chr20:32843128~32854257:-
BRCA	cis	rs7590720	0.819	rs1344694	ENSG00000230838.1	AC093850.2	-3.53	0.000428	0.0217	-0.1	-0.11	Alcohol dependence;	chr2:216028914	chr2:215718043~215719424:+
BRCA	cis	rs13326165	0.76	rs11711934	ENSG00000243224.1	RP5-1157M23.2	-3.53	0.000428	0.0217	-0.15	-0.11	HDL cholesterol levels;HDL cholesterol;	chr3:52324101	chr3:52239258~52241097:+
BRCA	cis	rs11892454	0.712	rs10181262	ENSG00000217643.1	PTGES3P2	-3.53	0.000428	0.0217	-0.12	-0.11	Heschl's gyrus morphology;	chr2:25726790	chr2:25822469~25822950:+
BRCA	cis	rs2640806	0.645	rs34545432	ENSG00000253105.4	KB-1448A5.1	3.53	0.000428	0.0217	0.13	0.11	Obesity-related traits;	chr8:96314443	chr8:96371865~96387438:-
BRCA	cis	rs3764021	0.506	rs11052372	ENSG00000256582.1	RP11-75L1.1	3.53	0.000428	0.0217	0.12	0.11	Type 1 diabetes;	chr12:9679363	chr12:9704077~9709350:+
BRCA	cis	rs1387259	0.64	rs10783243	ENSG00000257735.1	RP11-370I10.6	-3.53	0.000428	0.0217	-0.12	-0.11	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48259220	chr12:48350945~48442411:+
BRCA	cis	rs1046491	1	rs62085927	ENSG00000264964.1	RP11-888D10.3	3.53	0.000428	0.0217	0.22	0.11	Scarlet fever;	chr18:9232564	chr18:9315194~9334441:-
BRCA	cis	rs10421328	0.784	rs11667828	ENSG00000267419.1	CTC-559E9.6	3.53	0.000428	0.0217	0.12	0.11	Parental longevity (combined parental age at death);	chr19:19657665	chr19:19776602~19834927:+
BRCA	cis	rs6490294	0.571	rs57929857	ENSG00000257624.1	RP1-128M12.3	3.53	0.000428	0.0217	0.21	0.11	Mean platelet volume;	chr12:111995752	chr12:112000739~112000985:-
BRCA	cis	rs6545883	0.831	rs9309336	ENSG00000212978.6	AC016747.3	3.53	0.000428	0.0217	0.15	0.11	Tuberculosis;	chr2:61536030	chr2:61141592~61144969:-
BRCA	cis	rs10501293	1	rs10838010	ENSG00000252652.1	Y_RNA	3.53	0.000429	0.0217	0.13	0.11	Cognitive performance;	chr11:43101412	chr11:43331261~43331356:+
BRCA	cis	rs10501293	1	rs4755698	ENSG00000252652.1	Y_RNA	3.53	0.000429	0.0217	0.13	0.11	Cognitive performance;	chr11:43101986	chr11:43331261~43331356:+
BRCA	cis	rs910873	0.505	rs6059969	ENSG00000202150.1	RNU6-407P	3.53	0.000429	0.0217	0.16	0.11	Melanoma;	chr20:34657480	chr20:35030317~35030420:-
BRCA	cis	rs794185	0.561	rs304045	ENSG00000231249.1	ITPR1-AS1	-3.53	0.000429	0.0217	-0.12	-0.11	Multiple sclerosis--Brain Glutamate Levels;	chr3:4512367	chr3:4490891~4493163:-
BRCA	cis	rs875971	0.545	rs75840613	ENSG00000273448.1	RP11-166O4.6	3.53	0.000429	0.0217	0.11	0.11	Aortic root size;	chr7:66376399	chr7:67333047~67334383:+
BRCA	cis	rs4835473	0.838	rs6832094	ENSG00000249741.2	RP11-673E1.3	3.53	0.000429	0.0217	0.11	0.11	Immature fraction of reticulocytes;	chr4:143795388	chr4:143911514~143912053:-
BRCA	cis	rs875971	1	rs1981798	ENSG00000229886.1	RP5-1132H15.3	3.53	0.000429	0.0217	0.12	0.11	Aortic root size;	chr7:66489916	chr7:66025126~66031544:-
BRCA	cis	rs6430585	0.941	rs60963894	ENSG00000231890.6	DARS-AS1	-3.53	0.000429	0.0217	-0.16	-0.11	Corneal structure;	chr2:135782100	chr2:135985176~136022593:+
BRCA	cis	rs6430585	0.941	rs10496737	ENSG00000231890.6	DARS-AS1	-3.53	0.000429	0.0217	-0.16	-0.11	Corneal structure;	chr2:135782513	chr2:135985176~136022593:+
BRCA	cis	rs561341	1	rs498391	ENSG00000277511.1	CTD-2095E4.5	3.53	0.000429	0.0217	0.16	0.11	Hip circumference adjusted for BMI;	chr17:32001685	chr17:32127595~32128454:+
BRCA	cis	rs10241079	0.915	rs10237825	ENSG00000229628.1	AC073115.7	-3.53	0.000429	0.0217	-0.14	-0.11	Lobe attachment (rater-scored or self-reported);	chr7:46695556	chr7:45990905~46000898:+
BRCA	cis	rs957448	1	rs1023767	ENSG00000261437.1	RP11-22C11.2	3.53	0.000429	0.0217	0.11	0.11	Nonsyndromic cleft lip with cleft palate;	chr8:94518741	chr8:94637285~94639467:-
BRCA	cis	rs397969	0.573	rs203475	ENSG00000261033.1	RP11-209D14.2	-3.53	0.000429	0.0217	-0.16	-0.11	Platelet count;	chr17:19947662	chr17:20008051~20009234:-
BRCA	cis	rs4718428	0.662	rs34577323	ENSG00000275400.1	RP4-756H11.5	-3.53	0.000429	0.0217	-0.14	-0.11	Corneal structure;	chr7:66845054	chr7:66553805~66554199:-
BRCA	cis	rs55675132	0.548	rs3911878	ENSG00000226167.1	AP4B1-AS1	3.53	0.000429	0.0217	0.12	0.11	Schizophrenia;	chr1:114835784	chr1:113856635~113901237:+
BRCA	cis	rs17776563	0.639	rs11631914	ENSG00000261441.1	RP11-217B1.2	3.53	0.000429	0.0217	0.14	0.11	Thyroid hormone levels;	chr15:88571731	chr15:89335053~89336161:+
BRCA	cis	rs72615157	0.606	rs941288	ENSG00000242294.5	STAG3L5P	3.53	0.000429	0.0217	0.1	0.11	Lung function (FEV1/FVC);	chr7:100179185	chr7:100336079~100351900:+
BRCA	cis	rs2978263	1	rs2979495	ENSG00000272375.1	RP11-51J9.6	3.53	0.000429	0.0217	0.15	0.11	Cognitive performance;	chr8:30630710	chr8:30197404~30198048:+
BRCA	cis	rs10246939	0.505	rs6967189	ENSG00000270923.1	TAS2R6P	-3.53	0.000429	0.0217	-0.12	-0.11	Bitter taste perception;	chr7:141826220	chr7:141787815~141788640:+
BRCA	cis	rs2882667	0.964	rs67296915	ENSG00000242683.1	CTB-46B19.1	3.53	0.000429	0.0217	0.12	0.11	Age-related hearing impairment (SNP x SNP interaction);	chr5:138965910	chr5:139035148~139035987:-
BRCA	cis	rs6991838	0.584	rs1053087	ENSG00000272155.1	RP11-707M3.3	3.53	0.000429	0.0217	0.1	0.11	Intelligence (multi-trait analysis);	chr8:65603630	chr8:65714334~65714778:-
BRCA	cis	rs2744375	0.6	rs2744362	ENSG00000261189.1	RP3-512B11.3	3.53	0.000429	0.0217	0.14	0.11	Resting heart rate;	chr6:7550975	chr6:7540451~7541338:-
BRCA	cis	rs863345	0.604	rs949397	ENSG00000229914.1	RP11-404O13.4	-3.53	0.00043	0.0217	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158492161	chr1:158195633~158196131:-
BRCA	cis	rs863345	0.604	rs949398	ENSG00000229914.1	RP11-404O13.4	-3.53	0.00043	0.0217	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158492193	chr1:158195633~158196131:-
BRCA	cis	rs11673344	0.566	rs256735	ENSG00000233527.7	ZNF529-AS1	-3.53	0.00043	0.0217	-0.12	-0.11	Obesity-related traits;	chr19:37375141	chr19:36573070~36594708:+
BRCA	cis	rs673253	1	rs673253	ENSG00000229431.1	RP1-92O14.6	-3.53	0.00043	0.0217	-0.12	-0.11	Intelligence (multi-trait analysis);	chr1:43596483	chr1:43385113~43389155:+
BRCA	cis	rs12586478	0.538	rs12589642	ENSG00000205562.2	RP11-497E19.1	3.53	0.00043	0.0217	0.1	0.11	Post bronchodilator FEV1;	chr14:86311771	chr14:85524432~85529988:-
BRCA	cis	rs9457247	0.602	rs12209395	ENSG00000227598.1	RP1-167A14.2	-3.53	0.00043	0.0217	-0.12	-0.11	Crohn's disease;	chr6:167050426	chr6:166969626~166999065:-
BRCA	cis	rs3755605	0.728	rs6444895	ENSG00000242578.1	RP11-469J4.3	3.53	0.00043	0.0217	0.13	0.11	Testicular germ cell tumor;	chr3:170083870	chr3:170410512~170418615:+
BRCA	cis	rs4927850	0.723	rs7630825	ENSG00000224769.1	AC069213.1	3.53	0.00043	0.0217	0.15	0.11	Pancreatic cancer;	chr3:196026869	chr3:195614947~195620233:+
BRCA	cis	rs7221109	0.677	rs917593	ENSG00000224244.1	AC090283.3	3.53	0.00043	0.0217	0.12	0.11	Type 1 diabetes;	chr17:40660274	chr17:40687038~40689360:-
BRCA	cis	rs170557	0.597	rs6664500	ENSG00000203706.7	SERTAD4-AS1	-3.53	0.00043	0.0217	-0.13	-0.11	Alopecia areata;	chr1:209922950	chr1:210231456~210234047:-
BRCA	cis	rs4478858	0.647	rs12752761	ENSG00000229447.2	RP11-490K7.4	-3.53	0.00043	0.0217	-0.1	-0.11	Alcohol dependence;	chr1:31238041	chr1:31263245~31263681:-
BRCA	cis	rs6840360	0.571	rs12648420	ENSG00000270265.1	RP11-731D1.4	-3.53	0.00043	0.0217	-0.13	-0.11	Intelligence (multi-trait analysis);	chr4:151622282	chr4:151333775~151353224:-
BRCA	cis	rs4950322	0.57	rs72691093	ENSG00000227242.3	NBPF13P	-3.53	0.00043	0.0217	-0.16	-0.11	Protein quantitative trait loci;	chr1:147297977	chr1:147021320~147124525:-
BRCA	cis	rs4950322	0.57	rs76236344	ENSG00000227242.3	NBPF13P	-3.53	0.00043	0.0217	-0.16	-0.11	Protein quantitative trait loci;	chr1:147297989	chr1:147021320~147124525:-
BRCA	cis	rs4295623	0.531	rs2898295	ENSG00000255046.1	RP11-297N6.4	3.53	0.00043	0.0217	0.13	0.11	Morning vs. evening chronotype;	chr8:11738460	chr8:11797928~11802568:-
BRCA	cis	rs2562456	0.561	rs12610883	ENSG00000268119.4	CTD-2561J22.5	3.53	0.00043	0.0217	0.17	0.11	Pain;	chr19:21567257	chr19:21444241~21463908:-
BRCA	cis	rs2562456	0.837	rs11085462	ENSG00000268119.4	CTD-2561J22.5	3.53	0.00043	0.0217	0.17	0.11	Pain;	chr19:21567449	chr19:21444241~21463908:-
BRCA	cis	rs72928364	0.929	rs13059867	ENSG00000244119.1	PDCL3P4	3.53	0.00043	0.0217	0.14	0.11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:101046704	chr3:101712472~101713191:+
BRCA	cis	rs9308731	0.591	rs879623	ENSG00000230499.1	AC108463.1	-3.53	0.00043	0.0217	-0.12	-0.11	Chronic lymphocytic leukemia;	chr2:111189247	chr2:111195963~111206494:+
BRCA	cis	rs115575488	0.85	rs10494221	ENSG00000231365.4	RP11-418J17.1	3.53	0.00043	0.0217	0.2	0.11	Lobe attachment (rater-scored or self-reported);	chr1:119091601	chr1:119140396~119275973:+
BRCA	cis	rs9346455	0.614	rs58732838	ENSG00000279289.1	RP3-331H24.6	3.53	0.00043	0.0217	0.16	0.11	Antipsychotic drug-induced weight gain;Antipsychotic drug-induced weight gain (time interaction);	chr6:71290793	chr6:71386852~71390829:-
BRCA	cis	rs9346455	0.614	rs9360445	ENSG00000279289.1	RP3-331H24.6	3.53	0.00043	0.0217	0.16	0.11	Antipsychotic drug-induced weight gain;Antipsychotic drug-induced weight gain (time interaction);	chr6:71291163	chr6:71386852~71390829:-
BRCA	cis	rs853679	0.517	rs56310871	ENSG00000272009.1	RP1-313I6.12	-3.53	0.00043	0.0217	-0.16	-0.11	Depression;	chr6:28076704	chr6:28078792~28081130:-
BRCA	cis	rs758747	0.574	rs12933120	ENSG00000276754.1	RP11-461A8.5	3.53	0.00043	0.0218	0.18	0.11	Body mass index;	chr16:3584745	chr16:3686998~3687380:+
BRCA	cis	rs6854137	0.553	rs13110398	ENSG00000214676.4	RPL9P16	-3.53	0.00043	0.0218	-0.12	-0.11	Vein graft stenosis in coronary artery bypass grafting;	chr4:168781081	chr4:168755816~168756382:+
BRCA	cis	rs11673344	0.566	rs8109103	ENSG00000233527.7	ZNF529-AS1	3.53	0.00043	0.0218	0.12	0.11	Obesity-related traits;	chr19:37503209	chr19:36573070~36594708:+
BRCA	cis	rs62025270	1	rs62025270	ENSG00000259416.2	RP11-158M2.5	-3.53	0.00043	0.0218	-0.17	-0.11	Idiopathic pulmonary fibrosis;	chr15:85756967	chr15:85754941~85756237:-
BRCA	cis	rs75422866	0.867	rs73104115	ENSG00000276691.1	RP5-1057I20.5	3.53	0.00043	0.0218	0.23	0.11	Pneumonia;	chr12:47684843	chr12:47788426~47788971:+
BRCA	cis	rs75422866	0.867	rs73104116	ENSG00000276691.1	RP5-1057I20.5	3.53	0.00043	0.0218	0.23	0.11	Pneumonia;	chr12:47685023	chr12:47788426~47788971:+
BRCA	cis	rs2554380	0.628	rs7179507	ENSG00000259570.1	RP11-671M22.4	3.53	0.00043	0.0218	0.13	0.11	Height;	chr15:83804779	chr15:84394512~84395514:+
BRCA	cis	rs7267979	0.966	rs6037097	ENSG00000276952.1	RP5-965G21.6	3.53	0.00043	0.0218	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25366585	chr20:25284915~25285588:-
BRCA	cis	rs2504916	0.83	rs2504934	ENSG00000220305.1	HNRNPH1P1	3.53	0.00043	0.0218	0.15	0.11	Response to hepatitis C treatment;	chr6:160360634	chr6:159712801~159713985:-
BRCA	cis	rs6991838	0.584	rs7459944	ENSG00000272155.1	RP11-707M3.3	3.53	0.00043	0.0218	0.1	0.11	Intelligence (multi-trait analysis);	chr8:65566040	chr8:65714334~65714778:-
BRCA	cis	rs10916772	0.617	rs79793584	ENSG00000236963.4	LINC01141	3.53	0.00043	0.0218	0.19	0.11	Psychosis proneness (perceptual aberration scale);	chr1:20367649	chr1:20360579~20431234:-
BRCA	cis	rs7267979	0.528	rs34485039	ENSG00000274973.1	RP13-401N8.7	3.53	0.00043	0.0218	0.12	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25603127	chr20:25845497~25845862:+
BRCA	cis	rs3816183	0.958	rs4953665	ENSG00000226491.1	FTOP1	-3.53	0.00043	0.0218	-0.14	-0.11	Hypospadias;	chr2:42798901	chr2:42797225~42798712:-
BRCA	cis	rs13315871	0.929	rs71311852	ENSG00000272182.1	RP11-802O23.3	3.53	0.00043	0.0218	0.22	0.11	Cholesterol, total;	chr3:58313116	chr3:58428255~58428815:+
BRCA	cis	rs8114671	0.836	rs6060140	ENSG00000261582.1	RP4-614O4.11	-3.53	0.00043	0.0218	-0.11	-0.11	Height;	chr20:34978704	chr20:35267885~35280043:-
BRCA	cis	rs12586478	0.585	rs12885106	ENSG00000205562.2	RP11-497E19.1	-3.53	0.00043	0.0218	-0.1	-0.11	Post bronchodilator FEV1;	chr14:86321661	chr14:85524432~85529988:-
BRCA	cis	rs17301013	0.932	rs6683602	ENSG00000200674.1	RN7SKP160	3.53	0.00043	0.0218	0.14	0.11	Systemic lupus erythematosus;	chr1:174617615	chr1:173791548~173791887:+
BRCA	cis	rs17301013	0.932	rs6696197	ENSG00000200674.1	RN7SKP160	3.53	0.00043	0.0218	0.14	0.11	Systemic lupus erythematosus;	chr1:174617860	chr1:173791548~173791887:+
BRCA	cis	rs2333021	0.78	rs28619241	ENSG00000259015.1	RP11-109N23.6	3.53	0.00043	0.0218	0.11	0.11	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:72972902	chr14:72960595~72961993:+
BRCA	cis	rs2333021	0.78	rs12931	ENSG00000259015.1	RP11-109N23.6	3.53	0.00043	0.0218	0.11	0.11	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:72974156	chr14:72960595~72961993:+
BRCA	cis	rs801193	1	rs2659912	ENSG00000232546.1	RP11-458F8.1	-3.53	0.000431	0.0218	-0.09	-0.11	Aortic root size;	chr7:66693012	chr7:66848496~66858136:+
BRCA	cis	rs11098403	0.753	rs35385554	ENSG00000225892.3	RP11-384K6.2	3.53	0.000431	0.0218	0.11	0.11	Schizophrenia;	chr4:117854039	chr4:118632274~118634759:+
BRCA	cis	rs871012	0.502	rs17599812	ENSG00000251405.2	CTB-109A12.1	-3.53	0.000431	0.0218	-0.15	-0.11	IgG glycosylation;	chr5:157450982	chr5:157362615~157460078:-
BRCA	cis	rs3617	0.625	rs2240917	ENSG00000243224.1	RP5-1157M23.2	-3.53	0.000431	0.0218	-0.12	-0.11	Red blood cell count;Autism spectrum disorder or schizophrenia;	chr3:52817121	chr3:52239258~52241097:+
BRCA	cis	rs3764021	0.527	rs11052426	ENSG00000278635.1	CTD-2318O12.1	-3.53	0.000431	0.0218	-0.12	-0.11	Type 1 diabetes;	chr12:9688330	chr12:9415641~9416718:+
BRCA	cis	rs277939	0.967	rs277996	ENSG00000253366.3	RP11-589F5.4	-3.53	0.000431	0.0218	-0.12	-0.11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr5:71627141	chr5:70751184~70795914:+
BRCA	cis	rs4934494	0.727	rs1590566	ENSG00000235100.3	RP11-80H5.9	-3.53	0.000431	0.0218	-0.14	-0.11	Red blood cell count;	chr10:89778781	chr10:89667181~89699671:-
BRCA	cis	rs25645	0.502	rs8065126	ENSG00000266469.1	CTB-131K11.1	-3.53	0.000431	0.0218	-0.12	-0.11	Myeloid white cell count;	chr17:39942782	chr17:39401793~39406233:+
BRCA	cis	rs6487679	1	rs7298108	ENSG00000214776.8	RP11-726G1.1	3.53	0.000431	0.0218	0.15	0.11	Non-alcoholic fatty liver disease histology (AST);	chr12:9223572	chr12:9467552~9576275:+
BRCA	cis	rs10208649	0.908	rs11904365	ENSG00000272156.1	RP11-477N3.1	-3.53	0.000431	0.0218	-0.22	-0.11	Body mass index;	chr2:53998444	chr2:54082554~54085066:+
BRCA	cis	rs321358	0.731	rs1517578	ENSG00000271390.1	RP11-89C3.3	3.53	0.000431	0.0218	0.17	0.11	Body mass index;	chr11:111150750	chr11:111089870~111090368:-
BRCA	cis	rs2731006	0.901	rs2730991	ENSG00000257114.2	RP11-25I15.3	3.53	0.000431	0.0218	0.17	0.11	Panic disorder;	chr12:42762907	chr12:42692216~42717119:+
BRCA	cis	rs875971	0.545	rs313830	ENSG00000232559.3	GS1-124K5.12	-3.53	0.000431	0.0218	-0.15	-0.11	Aortic root size;	chr7:66086944	chr7:66554588~66576923:-
BRCA	cis	rs7267979	0.565	rs4815437	ENSG00000274973.1	RP13-401N8.7	3.53	0.000431	0.0218	0.12	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25604152	chr20:25845497~25845862:+
BRCA	cis	rs2562456	0.793	rs62110424	ENSG00000268117.1	VN1R84P	3.53	0.000431	0.0218	0.17	0.11	Pain;	chr19:21416835	chr19:21719801~21720035:-
BRCA	cis	rs12479064	0.604	rs11893359	ENSG00000231822.1	AC019097.7	-3.53	0.000431	0.0218	-0.13	-0.11	Chronic sinus infection;	chr2:99338145	chr2:99102018~99102752:+
BRCA	cis	rs13405728	0.618	rs12713013	ENSG00000202227.1	RNU6-282P	-3.53	0.000431	0.0218	-0.19	-0.11	Polycystic ovary syndrome;	chr2:48710015	chr2:48501922~48502024:-
BRCA	cis	rs6840360	0.582	rs4696259	ENSG00000251611.1	RP11-610P16.1	-3.53	0.000431	0.0218	-0.1	-0.11	Intelligence (multi-trait analysis);	chr4:151389636	chr4:151407551~151408835:-
BRCA	cis	rs35146811	0.695	rs1623264	ENSG00000214313.7	AZGP1P1	-3.53	0.000431	0.0218	-0.12	-0.11	Coronary artery disease;	chr7:100213581	chr7:99980762~99987535:+
BRCA	cis	rs2554380	0.628	rs6602993	ENSG00000176700.18	SCAND2P	-3.53	0.000431	0.0218	-0.11	-0.11	Height;	chr15:83813610	chr15:84631451~84647478:+
BRCA	cis	rs879564	0.893	rs7259918	ENSG00000205790.1	DPP9-AS1	-3.53	0.000431	0.0218	-0.1	-0.11	Thyroid peroxidase antibody positivity;	chr19:4755166	chr19:4679282~4685948:+
BRCA	cis	rs8014252	0.803	rs7158201	ENSG00000259158.2	ADAM20P1	3.53	0.000431	0.0218	0.17	0.11	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70543829	chr14:70468881~70483756:-
BRCA	cis	rs863345	0.608	rs11265013	ENSG00000229914.1	RP11-404O13.4	-3.53	0.000431	0.0218	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158529835	chr1:158195633~158196131:-
BRCA	cis	rs863345	0.535	rs12064570	ENSG00000229914.1	RP11-404O13.4	-3.53	0.000431	0.0218	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158529841	chr1:158195633~158196131:-
BRCA	cis	rs863345	0.535	rs12068285	ENSG00000229914.1	RP11-404O13.4	-3.53	0.000431	0.0218	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158529842	chr1:158195633~158196131:-
BRCA	cis	rs72819225	0.581	rs928118	ENSG00000228701.1	TNKS2-AS1	-3.53	0.000431	0.0218	-0.14	-0.11	Yeast infection;	chr10:91565289	chr10:91782839~91798291:-
BRCA	cis	rs2803122	0.838	rs10757033	ENSG00000272842.1	RP11-513M16.7	-3.53	0.000432	0.0218	-0.11	-0.11	Pulse pressure;	chr9:19223306	chr9:19371386~19371945:-
BRCA	cis	rs718433	0.636	rs2733765	ENSG00000256379.1	TRAV8-5	-3.53	0.000432	0.0218	-0.14	-0.11	Intraocular pressure;	chr14:21801037	chr14:21903077~21903598:+
BRCA	cis	rs9325144	0.56	rs7314632	ENSG00000257718.1	RP11-396F22.1	-3.53	0.000432	0.0218	-0.11	-0.11	Morning vs. evening chronotype;	chr12:38243177	chr12:38906451~38909592:+
BRCA	cis	rs875971	1	rs12533997	ENSG00000271064.1	RP11-792A8.3	-3.53	0.000432	0.0218	-0.13	-0.11	Aortic root size;	chr7:66500390	chr7:66748838~66749077:-
BRCA	cis	rs875971	0.862	rs28470208	ENSG00000273024.4	INTS4P2	3.53	0.000432	0.0218	0.12	0.11	Aortic root size;	chr7:66119713	chr7:65647864~65715661:+
BRCA	cis	rs3739034	0.938	rs6752536	ENSG00000224043.6	CCNT2-AS1	-3.53	0.000432	0.0218	-0.19	-0.11	Gut microbiome composition (winter);	chr2:134709928	chr2:134735464~134918710:-
BRCA	cis	rs6088580	0.524	rs6088564	ENSG00000126005.14	MMP24-AS1	3.53	0.000432	0.0218	0.13	0.11	Glomerular filtration rate (creatinine);	chr20:34661640	chr20:35216462~35278131:-
BRCA	cis	rs6088580	0.524	rs11167241	ENSG00000126005.14	MMP24-AS1	3.53	0.000432	0.0218	0.13	0.11	Glomerular filtration rate (creatinine);	chr20:34663031	chr20:35216462~35278131:-
BRCA	cis	rs6088580	0.505	rs6142219	ENSG00000126005.14	MMP24-AS1	3.53	0.000432	0.0218	0.13	0.11	Glomerular filtration rate (creatinine);	chr20:34668541	chr20:35216462~35278131:-
BRCA	cis	rs2952768	1	rs2709394	ENSG00000224137.1	AC079767.4	-3.53	0.000432	0.0218	-0.09	-0.11	Opioid sensitivity;	chr2:207627251	chr2:207662375~207667024:+
BRCA	cis	rs7618501	0.735	rs9876508	ENSG00000228008.1	CTD-2330K9.3	-3.53	0.000432	0.0218	-0.1	-0.11	Intelligence (multi-trait analysis);	chr3:49743411	chr3:49903845~49916937:+
BRCA	cis	rs7618501	0.722	rs9853458	ENSG00000228008.1	CTD-2330K9.3	-3.53	0.000432	0.0218	-0.1	-0.11	Intelligence (multi-trait analysis);	chr3:49745778	chr3:49903845~49916937:+
BRCA	cis	rs807669	0.586	rs5746671	ENSG00000223461.1	AC004471.9	-3.53	0.000432	0.0218	-0.12	-0.11	Metabolite levels;	chr22:19173386	chr22:19121529~19124503:+
BRCA	cis	rs3889199	0.74	rs7412276	ENSG00000272226.1	RP11-63G10.3	3.53	0.000432	0.0218	0.14	0.11	Pulse pressure;	chr1:59202049	chr1:58812808~58813342:-
BRCA	cis	rs2163813	1	rs17699333	ENSG00000275540.1	CTC-559E9.12	-3.53	0.000432	0.0218	-0.15	-0.11	Toenail selenium levels;	chr19:19720735	chr19:19740884~19750127:+
BRCA	cis	rs13401620	0.917	rs1982669	ENSG00000229326.3	AC069154.4	-3.53	0.000432	0.0218	-0.15	-0.11	Breast size;	chr2:119781763	chr2:119698623~119700151:+
BRCA	cis	rs4478858	0.595	rs4949387	ENSG00000223907.1	LINC01226	-3.53	0.000432	0.0218	-0.13	-0.11	Alcohol dependence;	chr1:31330593	chr1:31518435~31524245:+
BRCA	cis	rs12468226	0.938	rs114177656	ENSG00000272966.1	RP11-686O6.1	3.53	0.000432	0.0218	0.18	0.11	Urate levels;	chr2:202291596	chr2:202336739~202337200:+
BRCA	cis	rs35123781	1	rs673632	ENSG00000250635.1	CTD-3224K15.2	-3.53	0.000432	0.0218	-0.12	-0.11	Schizophrenia;	chr5:139677652	chr5:139648999~139649728:-
BRCA	cis	rs6696239	0.823	rs12124388	ENSG00000227711.2	RP11-275O4.5	-3.53	0.000432	0.0218	-0.15	-0.11	Height;	chr1:227683125	chr1:227509028~227520477:-
BRCA	cis	rs13136331	0.718	rs2627690	ENSG00000249001.4	RP11-742B18.1	3.53	0.000432	0.0218	0.14	0.11	Sitting height ratio;	chr4:87732464	chr4:87568035~87733956:-
BRCA	cis	rs17221829	0.673	rs10765225	ENSG00000280385.1	AP000648.5	-3.53	0.000432	0.0218	-0.12	-0.11	Anxiety in major depressive disorder;	chr11:89651820	chr11:90193614~90198120:+
BRCA	cis	rs7712401	0.791	rs1870559	ENSG00000249996.1	RP11-359P5.1	3.53	0.000432	0.0218	0.13	0.11	Mean platelet volume;	chr5:122781011	chr5:123036271~123054667:+
BRCA	cis	rs7712401	0.791	rs10059964	ENSG00000249996.1	RP11-359P5.1	3.53	0.000432	0.0218	0.13	0.11	Mean platelet volume;	chr5:122782598	chr5:123036271~123054667:+
BRCA	cis	rs28489187	0.706	rs233062	ENSG00000223653.4	RP11-131L23.1	3.53	0.000432	0.0218	0.12	0.11	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85334702	chr1:85276715~85448124:+
BRCA	cis	rs7943953	0.833	rs11602535	ENSG00000254717.2	GLYATL1P2	-3.53	0.000432	0.0218	-0.14	-0.11	Odorant perception (&beta-ionone);	chr11:59423026	chr11:58878302~58893460:+
BRCA	cis	rs1348850	0.874	rs1348848	ENSG00000280374.1	RP11-337N6.3	-3.53	0.000432	0.0218	-0.15	-0.11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177493505	chr2:177317715~177318471:-
BRCA	cis	rs4703129	0.967	rs4702979	ENSG00000246763.5	RGMB-AS1	-3.53	0.000432	0.0218	-0.13	-0.11	Asperger disorder;	chr5:98508688	chr5:98769618~98773469:-
BRCA	cis	rs4703129	0.967	rs4702980	ENSG00000246763.5	RGMB-AS1	-3.53	0.000432	0.0218	-0.13	-0.11	Asperger disorder;	chr5:98508704	chr5:98769618~98773469:-
BRCA	cis	rs687432	0.924	rs11600171	ENSG00000265566.2	RN7SL605P	-3.53	0.000432	0.0218	-0.15	-0.11	Parkinson's disease;	chr11:57933291	chr11:57528085~57528365:-
BRCA	cis	rs687432	0.924	rs34534719	ENSG00000265566.2	RN7SL605P	-3.53	0.000432	0.0218	-0.15	-0.11	Parkinson's disease;	chr11:57933395	chr11:57528085~57528365:-
BRCA	cis	rs687432	0.924	rs1510420	ENSG00000265566.2	RN7SL605P	-3.53	0.000432	0.0218	-0.15	-0.11	Parkinson's disease;	chr11:57933726	chr11:57528085~57528365:-
BRCA	cis	rs1046491	1	rs11661901	ENSG00000264964.1	RP11-888D10.3	3.53	0.000432	0.0218	0.22	0.11	Scarlet fever;	chr18:9250377	chr18:9315194~9334441:-
BRCA	cis	rs1046491	1	rs11664929	ENSG00000264964.1	RP11-888D10.3	3.53	0.000432	0.0218	0.22	0.11	Scarlet fever;	chr18:9250538	chr18:9315194~9334441:-
BRCA	cis	rs1046491	1	rs11081469	ENSG00000264964.1	RP11-888D10.3	3.53	0.000432	0.0218	0.22	0.11	Scarlet fever;	chr18:9276265	chr18:9315194~9334441:-
BRCA	cis	rs7259811	0.851	rs730845	ENSG00000268266.1	AC003005.2	-3.53	0.000432	0.0218	-0.15	-0.11	Western dietary pattern;	chr19:56713022	chr19:57477649~57482996:+
BRCA	cis	rs7520050	0.966	rs4376778	ENSG00000281133.1	AL355480.3	3.53	0.000432	0.0218	0.13	0.11	Reticulocyte count;Red blood cell count;	chr1:45823174	chr1:45580892~45580996:-
BRCA	cis	rs7520050	0.966	rs6672898	ENSG00000281133.1	AL355480.3	3.53	0.000432	0.0218	0.13	0.11	Reticulocyte count;Red blood cell count;	chr1:45824916	chr1:45580892~45580996:-
BRCA	cis	rs17092148	0.836	rs4911157	ENSG00000250917.1	RP4-785G19.5	3.53	0.000433	0.0219	0.18	0.11	Neuroticism;	chr20:34579271	chr20:34234840~34281173:-
BRCA	cis	rs4819052	0.918	rs34886433	ENSG00000223768.1	LINC00205	-3.53	0.000433	0.0219	-0.17	-0.11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260623	chr21:45293285~45297354:+
BRCA	cis	rs11039100	0.85	rs11039118	ENSG00000224295.2	AC087380.14	3.53	0.000433	0.0219	0.21	0.11	Peripheral arterial disease (traffic-related air pollution interaction);	chr11:5811371	chr11:5518441~5524955:-
BRCA	cis	rs11039100	0.681	rs11039120	ENSG00000224295.2	AC087380.14	3.53	0.000433	0.0219	0.21	0.11	Peripheral arterial disease (traffic-related air pollution interaction);	chr11:5811866	chr11:5518441~5524955:-
BRCA	cis	rs11039100	0.85	rs11039121	ENSG00000224295.2	AC087380.14	3.53	0.000433	0.0219	0.21	0.11	Peripheral arterial disease (traffic-related air pollution interaction);	chr11:5811931	chr11:5518441~5524955:-
BRCA	cis	rs11039100	0.85	rs12792985	ENSG00000224295.2	AC087380.14	3.53	0.000433	0.0219	0.21	0.11	Peripheral arterial disease (traffic-related air pollution interaction);	chr11:5812512	chr11:5518441~5524955:-
BRCA	cis	rs11039100	0.85	rs12792672	ENSG00000224295.2	AC087380.14	3.53	0.000433	0.0219	0.21	0.11	Peripheral arterial disease (traffic-related air pollution interaction);	chr11:5812708	chr11:5518441~5524955:-
BRCA	cis	rs11673344	0.704	rs1726719	ENSG00000267422.1	CTD-2554C21.1	3.53	0.000433	0.0219	0.14	0.11	Obesity-related traits;	chr19:36927130	chr19:37779686~37792865:+
BRCA	cis	rs7989336	0.625	rs9513122	ENSG00000226977.1	HMGN1P24	3.53	0.000433	0.0219	0.13	0.11	Obesity;	chr13:96348280	chr13:95809310~95809607:-
BRCA	cis	rs11673344	0.636	rs7255595	ENSG00000267682.1	CTD-3220F14.2	-3.53	0.000433	0.0219	-0.1	-0.11	Obesity-related traits;	chr19:36896260	chr19:37337236~37337743:+
BRCA	cis	rs1524976	0.6	rs1949843	ENSG00000272610.1	MAGI1-IT1	-3.53	0.000433	0.0219	-0.16	-0.11	PR interval;	chr3:65467333	chr3:65872815~65954558:-
BRCA	cis	rs1667255	1	rs4799581	ENSG00000266521.1	RP11-650P15.1	3.53	0.000433	0.0219	0.13	0.11	Retinol levels;	chr18:31581548	chr18:31496645~31497195:-
BRCA	cis	rs2562456	0.876	rs11085465	ENSG00000268555.1	RP11-678G14.3	-3.53	0.000433	0.0219	-0.14	-0.11	Pain;	chr19:21568988	chr19:21570822~21587322:-
BRCA	cis	rs7809799	0.85	rs10248890	ENSG00000242798.1	RP11-506M12.1	3.53	0.000433	0.0219	0.2	0.11	Ulcerative colitis;	chr7:99154761	chr7:100115214~100127139:-
BRCA	cis	rs7267979	1	rs10966	ENSG00000204556.4	CTD-2514C3.1	-3.53	0.000433	0.0219	-0.15	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25302308	chr20:26018832~26020684:+
BRCA	cis	rs4725617	0.822	rs4421280	ENSG00000229153.4	EPHA1-AS1	-3.53	0.000433	0.0219	-0.22	-0.11	Blood protein levels;	chr7:143406124	chr7:143407813~143523449:+
BRCA	cis	rs11603691	1	rs10896608	ENSG00000254662.1	RP11-872D17.4	-3.53	0.000433	0.0219	-0.22	-0.11	Low high density lipoprotein cholesterol levels;	chr11:57341437	chr11:57325603~57327958:+
BRCA	cis	rs77948430	0.881	rs17188957	ENSG00000255122.1	RP11-303G3.6	-3.53	0.000433	0.0219	-0.19	-0.11	Itch intensity from mosquito bite adjusted by bite size;	chr8:13241170	chr8:12580287~12581063:+
BRCA	cis	rs2904967	0.852	rs1858783	ENSG00000254614.2	AP003068.23	3.53	0.000433	0.0219	0.19	0.11	Mean corpuscular volume;	chr11:65275470	chr11:65177606~65181834:-
BRCA	cis	rs2803122	0.774	rs10757034	ENSG00000272842.1	RP11-513M16.7	-3.53	0.000433	0.0219	-0.11	-0.11	Pulse pressure;	chr9:19227805	chr9:19371386~19371945:-
BRCA	cis	rs4664293	0.967	rs7597482	ENSG00000224152.1	AC009506.1	-3.53	0.000433	0.0219	-0.12	-0.11	Monocyte percentage of white cells;	chr2:159690580	chr2:159615296~159617082:+
BRCA	cis	rs4664293	0.967	rs7597488	ENSG00000224152.1	AC009506.1	-3.53	0.000433	0.0219	-0.12	-0.11	Monocyte percentage of white cells;	chr2:159690585	chr2:159615296~159617082:+
BRCA	cis	rs17092148	0.887	rs932542	ENSG00000250917.1	RP4-785G19.5	3.53	0.000433	0.0219	0.18	0.11	Neuroticism;	chr20:34583564	chr20:34234840~34281173:-
BRCA	cis	rs17092148	0.887	rs6059931	ENSG00000250917.1	RP4-785G19.5	3.53	0.000433	0.0219	0.18	0.11	Neuroticism;	chr20:34587534	chr20:34234840~34281173:-
BRCA	cis	rs12887734	0.546	rs4906376	ENSG00000269910.1	RP11-73M18.10	3.53	0.000433	0.0219	0.12	0.11	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103805828	chr14:103694516~103695050:-
BRCA	cis	rs7712401	0.791	rs4835897	ENSG00000263432.2	RN7SL689P	3.53	0.000433	0.0219	0.12	0.11	Mean platelet volume;	chr5:122785809	chr5:123022487~123022783:-
BRCA	cis	rs2839398	1	rs2839398	ENSG00000227698.1	AP001619.2	-3.53	0.000433	0.0219	-0.2	-0.11	Parkinson's disease;	chr21:41866243	chr21:41874756~41877613:-
BRCA	cis	rs10266483	0.774	rs642909	ENSG00000228653.2	HNRNPCP7	-3.53	0.000433	0.0219	-0.13	-0.11	Response to statin therapy;	chr7:64309943	chr7:64500825~64501729:+
BRCA	cis	rs73219805	0.536	rs17055142	ENSG00000228451.3	SDAD1P1	3.53	0.000433	0.0219	0.25	0.11	Schizophrenia;	chr8:26344085	chr8:26379259~26382953:-
BRCA	cis	rs6446731	0.734	rs9996868	ENSG00000261643.1	RP11-529E10.6	-3.53	0.000433	0.0219	-0.12	-0.11	Mean platelet volume;	chr4:3273757	chr4:3503597~3504457:-
BRCA	cis	rs1670533	1	rs6839931	ENSG00000251639.2	RP11-20I20.1	3.53	0.000433	0.0219	0.17	0.11	Recombination rate (females);	chr4:1059384	chr4:1100016~1101558:-
BRCA	cis	rs6120849	0.754	rs6120790	ENSG00000202150.1	RNU6-407P	3.53	0.000433	0.0219	0.15	0.11	Protein C levels;	chr20:35011287	chr20:35030317~35030420:-
BRCA	cis	rs2832077	0.527	rs1048546	ENSG00000176054.6	RPL23P2	-3.53	0.000433	0.0219	-0.12	-0.11	Cognitive test performance;	chr21:28872555	chr21:28997613~28998033:-
BRCA	cis	rs6582630	0.538	rs12304844	ENSG00000257718.1	RP11-396F22.1	-3.53	0.000434	0.0219	-0.11	-0.11	Drug-induced liver injury (flucloxacillin);	chr12:37942068	chr12:38906451~38909592:+
BRCA	cis	rs6582630	0.538	rs12305104	ENSG00000257718.1	RP11-396F22.1	-3.53	0.000434	0.0219	-0.11	-0.11	Drug-induced liver injury (flucloxacillin);	chr12:37942551	chr12:38906451~38909592:+
BRCA	cis	rs12644436	0.526	rs10032322	ENSG00000249001.4	RP11-742B18.1	-3.53	0.000434	0.0219	-0.13	-0.11	HIV-1 viral setpoint;	chr4:87850173	chr4:87568035~87733956:-
BRCA	cis	rs62025270	0.632	rs62022918	ENSG00000259367.1	RP11-815J21.4	3.53	0.000434	0.0219	0.1	0.11	Idiopathic pulmonary fibrosis;	chr15:85675053	chr15:85619623~85670948:-
BRCA	cis	rs8060686	0.516	rs7193701	ENSG00000263126.1	CTC-479C5.10	3.53	0.000434	0.0219	0.1	0.11	HDL cholesterol;Metabolic syndrome;	chr16:68151257	chr16:67882461~67886367:+
BRCA	cis	rs375066	0.935	rs432454	ENSG00000278917.1	RP11-15A1.4	-3.53	0.000434	0.0219	-0.13	-0.11	Breast cancer;	chr19:43894679	chr19:43891233~43895411:+
BRCA	cis	rs74233809	1	rs11191531	ENSG00000236937.2	PTGES3P4	3.53	0.000434	0.0219	0.23	0.11	Birth weight;	chr10:103047141	chr10:102845595~102845950:+
BRCA	cis	rs10504130	0.666	rs7819892	ENSG00000228801.5	RP11-110G21.1	3.53	0.000434	0.0219	0.13	0.11	Venous thromboembolism (SNP x SNP interaction);	chr8:51932916	chr8:51899325~51947173:+
BRCA	cis	rs867186	0.925	rs1033799	ENSG00000126005.14	MMP24-AS1	-3.53	0.000434	0.0219	-0.17	-0.11	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35132230	chr20:35216462~35278131:-
BRCA	cis	rs56114371	0.777	rs200483	ENSG00000216676.2	RP1-15D7.1	-3.53	0.000434	0.0219	-0.18	-0.11	Breast cancer;	chr6:27807046	chr6:27652602~27652825:-
BRCA	cis	rs6087771	0.781	rs6089067	ENSG00000230613.1	HM13-AS1	3.53	0.000434	0.0219	0.15	0.11	Putamen volume;Subcortical brain region volumes;	chr20:31771091	chr20:31567707~31573263:-
BRCA	cis	rs2041840	0.961	rs4670687	ENSG00000272054.1	RP11-423P10.2	-3.53	0.000434	0.0219	-0.1	-0.11	Chronic lymphocytic leukemia;	chr2:37309370	chr2:37208875~37212677:+
BRCA	cis	rs7690839	1	rs10008568	ENSG00000270720.1	RP11-84C13.2	-3.53	0.000434	0.0219	-0.12	-0.11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr4:88933041	chr4:89119284~89119871:+
BRCA	cis	rs4916588	0.697	rs4916586	ENSG00000230732.4	AC127904.2	3.53	0.000434	0.0219	0.14	0.11	Night sleep phenotypes;	chr3:196933949	chr3:196912646~196914579:+
BRCA	cis	rs4388249	1	rs1866372	ENSG00000249068.1	CTC-287O8.1	3.53	0.000434	0.0219	0.16	0.11	Schizophrenia;	chr5:109704265	chr5:109840128~109840692:-
BRCA	cis	rs7520050	0.966	rs2275426	ENSG00000226957.1	RP4-533D7.4	3.53	0.000434	0.0219	0.12	0.11	Reticulocyte count;Red blood cell count;	chr1:46021880	chr1:46046818~46048368:+
BRCA	cis	rs62025270	0.632	rs7163838	ENSG00000259416.2	RP11-158M2.5	-3.53	0.000434	0.0219	-0.16	-0.11	Idiopathic pulmonary fibrosis;	chr15:85664390	chr15:85754941~85756237:-
BRCA	cis	rs875971	0.861	rs801215	ENSG00000265600.1	AC006480.1	3.53	0.000434	0.0219	0.13	0.11	Aortic root size;	chr7:66546951	chr7:67356680~67356779:+
BRCA	cis	rs9650657	0.601	rs10903330	ENSG00000154316.13	TDH	-3.53	0.000434	0.0219	-0.14	-0.11	Neuroticism;	chr8:10815594	chr8:11339637~11368452:+
BRCA	cis	rs6490294	0.571	rs7309841	ENSG00000234608.6	MAPKAPK5-AS1	3.53	0.000434	0.0219	0.16	0.11	Mean platelet volume;	chr12:112127249	chr12:111839764~111842902:-
BRCA	cis	rs6490294	0.571	rs7294753	ENSG00000234608.6	MAPKAPK5-AS1	3.53	0.000434	0.0219	0.16	0.11	Mean platelet volume;	chr12:112129646	chr12:111839764~111842902:-
BRCA	cis	rs6772849	0.93	rs1962040	ENSG00000207088.1	SNORA7B	-3.53	0.000434	0.0219	-0.14	-0.11	Monocyte percentage of white cells;Monocyte count;	chr3:128605318	chr3:129397210~129397348:-
BRCA	cis	rs1667255	1	rs1080093	ENSG00000266521.1	RP11-650P15.1	3.53	0.000434	0.0219	0.13	0.11	Retinol levels;	chr18:31593717	chr18:31496645~31497195:-
BRCA	cis	rs11098499	1	rs35643470	ENSG00000225892.3	RP11-384K6.2	3.53	0.000434	0.0219	0.11	0.11	Corneal astigmatism;	chr4:119263793	chr4:118632274~118634759:+
BRCA	cis	rs1008375	0.931	rs6837181	ENSG00000249502.1	AC006160.5	-3.53	0.000434	0.0219	-0.12	-0.11	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17699630	chr4:17587467~17614571:-
BRCA	cis	rs7647973	0.593	rs4855885	ENSG00000228008.1	CTD-2330K9.3	-3.53	0.000434	0.0219	-0.15	-0.11	Menarche (age at onset);	chr3:49652766	chr3:49903845~49916937:+
BRCA	cis	rs757978	1	rs7601738	ENSG00000223374.1	AC005104.3	-3.53	0.000434	0.0219	-0.14	-0.11	Chronic lymphocytic leukemia;	chr2:241436398	chr2:241351340~241353104:-
BRCA	cis	rs6696239	0.911	rs10916166	ENSG00000227711.2	RP11-275O4.5	-3.53	0.000434	0.0219	-0.15	-0.11	Height;	chr1:227569367	chr1:227509028~227520477:-
BRCA	cis	rs6696239	0.955	rs10916167	ENSG00000227711.2	RP11-275O4.5	-3.53	0.000434	0.0219	-0.15	-0.11	Height;	chr1:227573431	chr1:227509028~227520477:-
BRCA	cis	rs11892454	0.565	rs13418205	ENSG00000217643.1	PTGES3P2	-3.53	0.000435	0.0219	-0.12	-0.11	Heschl's gyrus morphology;	chr2:25827477	chr2:25822469~25822950:+
BRCA	cis	rs4374383	0.884	rs4303721	ENSG00000243389.1	AC012442.5	-3.53	0.000435	0.0219	-0.14	-0.11	Hepatitis C induced liver fibrosis;	chr2:112003457	chr2:112589040~112614431:+
BRCA	cis	rs6545883	0.525	rs1729662	ENSG00000270820.4	RP11-355B11.2	3.53	0.000435	0.0219	0.12	0.11	Tuberculosis;	chr2:61164170	chr2:61471188~61484130:+
BRCA	cis	rs812925	0.519	rs2922089	ENSG00000270820.4	RP11-355B11.2	-3.53	0.000435	0.0219	-0.12	-0.11	Immature fraction of reticulocytes;	chr2:61397994	chr2:61471188~61484130:+
BRCA	cis	rs1411478	1	rs12754041	ENSG00000243155.1	RP11-46A10.5	3.53	0.000435	0.0219	0.12	0.11	Menopause (age at onset);Progressive supranuclear palsy;	chr1:180988826	chr1:180944042~180976482:-
BRCA	cis	rs801193	0.839	rs12534943	ENSG00000273448.1	RP11-166O4.6	-3.53	0.000435	0.0219	-0.1	-0.11	Aortic root size;	chr7:66605533	chr7:67333047~67334383:+
BRCA	cis	rs67073037	0.956	rs12622122	ENSG00000230730.1	AC074011.2	-3.53	0.000435	0.0219	-0.15	-0.11	Breast cancer;Breast cancer (estrogen-receptor negative);	chr2:28888194	chr2:28633282~28664540:-
BRCA	cis	rs67073037	0.915	rs12622793	ENSG00000230730.1	AC074011.2	-3.53	0.000435	0.0219	-0.15	-0.11	Breast cancer;Breast cancer (estrogen-receptor negative);	chr2:28888240	chr2:28633282~28664540:-
BRCA	cis	rs74233809	1	rs11191587	ENSG00000236937.2	PTGES3P4	3.53	0.000435	0.0219	0.23	0.11	Birth weight;	chr10:103169959	chr10:102845595~102845950:+
BRCA	cis	rs17684571	0.872	rs35807277	ENSG00000231441.1	RP11-472M19.2	3.53	0.000435	0.0219	0.16	0.11	Schizophrenia;	chr6:56718783	chr6:56844002~56864078:+
BRCA	cis	rs977987	0.806	rs4887818	ENSG00000261476.1	RP11-77K12.3	-3.53	0.000435	0.0219	-0.12	-0.11	Dupuytren's disease;	chr16:75328097	chr16:75458252~75460017:-
BRCA	cis	rs7615952	0.512	rs34085484	ENSG00000248787.1	RP11-666A20.4	-3.53	0.000435	0.0219	-0.17	-0.11	Blood pressure (smoking interaction);	chr3:125825343	chr3:125908005~125910272:-
BRCA	cis	rs7615952	0.608	rs35668111	ENSG00000248787.1	RP11-666A20.4	-3.53	0.000435	0.0219	-0.17	-0.11	Blood pressure (smoking interaction);	chr3:125825792	chr3:125908005~125910272:-
BRCA	cis	rs2836974	0.583	rs2776306	ENSG00000238141.2	BRWD1-AS1	3.53	0.000435	0.022	0.12	0.11	Cognitive function;	chr21:39341828	chr21:39315707~39323218:+
BRCA	cis	rs3781264	0.595	rs10882424	ENSG00000268894.5	PLCE1-AS1	-3.53	0.000435	0.022	-0.14	-0.11	Esophageal cancer and gastric cancer;	chr10:94326321	chr10:94279277~94287478:-
BRCA	cis	rs10191773	0.589	rs72831641	ENSG00000237753.1	AC079922.3	3.53	0.000435	0.022	0.16	0.11	Yeast infection;	chr2:112198238	chr2:112641832~112645690:-
BRCA	cis	rs2243480	1	rs35396113	ENSG00000226767.1	RP11-328P23.3	-3.53	0.000435	0.022	-0.19	-0.11	Diabetic kidney disease;	chr7:66030474	chr7:65508773~65508944:-
BRCA	cis	rs2749592	0.513	rs1208708	ENSG00000120555.12	SEPT7P9	3.53	0.000435	0.022	0.13	0.11	Age-related hearing impairment (SNP x SNP interaction);	chr10:37796648	chr10:38383069~38402916:-
BRCA	cis	rs13068223	0.74	rs343999	ENSG00000241770.1	RP11-555M1.3	3.53	0.000435	0.022	0.14	0.11	Age-related hearing impairment (SNP x SNP interaction);	chr3:156734050	chr3:157163452~157169133:+
BRCA	cis	rs4650943	0.732	rs352311	ENSG00000227740.1	RP11-318C24.2	-3.53	0.000435	0.022	-0.11	-0.11	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in inactive individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr1:176289894	chr1:175904762~175920513:-
BRCA	cis	rs4650943	0.732	rs187085	ENSG00000227740.1	RP11-318C24.2	-3.53	0.000435	0.022	-0.11	-0.11	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in inactive individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr1:176290883	chr1:175904762~175920513:-
BRCA	cis	rs1455244	0.813	rs6505654	ENSG00000267533.1	RP11-815J4.7	-3.53	0.000435	0.022	-0.14	-0.11	Schizophrenia;	chr18:11466803	chr18:12067173~12068417:-
BRCA	cis	rs2360027	0.622	rs10923614	ENSG00000231365.4	RP11-418J17.1	-3.53	0.000435	0.022	-0.13	-0.11	Tonsillectomy;	chr1:118561834	chr1:119140396~119275973:+
BRCA	cis	rs9378688	0.654	rs2479011	ENSG00000244041.6	LINC01011	3.53	0.000435	0.022	0.15	0.11	Caudate nucleus volume;	chr6:2355515	chr6:2987967~2991173:+
BRCA	cis	rs2243480	1	rs316329	ENSG00000229180.5	GS1-124K5.11	3.53	0.000435	0.022	0.14	0.11	Diabetic kidney disease;	chr7:66143429	chr7:66526088~66542624:-
BRCA	cis	rs74233809	1	rs11191505	ENSG00000236937.2	PTGES3P4	3.53	0.000435	0.022	0.24	0.11	Birth weight;	chr10:103007134	chr10:102845595~102845950:+
BRCA	cis	rs6840360	0.571	rs62327271	ENSG00000278978.1	RP11-164P12.5	-3.53	0.000435	0.022	-0.13	-0.11	Intelligence (multi-trait analysis);	chr4:151614764	chr4:151669786~151670503:+
BRCA	cis	rs11892454	0.565	rs35926307	ENSG00000217643.1	PTGES3P2	-3.53	0.000435	0.022	-0.12	-0.11	Heschl's gyrus morphology;	chr2:25820663	chr2:25822469~25822950:+
BRCA	cis	rs2041840	1	rs2160392	ENSG00000272054.1	RP11-423P10.2	-3.53	0.000435	0.022	-0.1	-0.11	Chronic lymphocytic leukemia;	chr2:37300250	chr2:37208875~37212677:+
BRCA	cis	rs11098499	1	rs11726229	ENSG00000260091.1	RP11-33B1.4	-3.53	0.000435	0.022	-0.1	-0.11	Corneal astigmatism;	chr4:119290425	chr4:119409333~119410233:+
BRCA	cis	rs6015450	1	rs58754928	ENSG00000228340.4	MIR646HG	3.53	0.000436	0.022	0.21	0.11	Hypertension;Blood pressure;Systolic blood pressure;Diastolic blood pressure;	chr20:59150882	chr20:60087840~60527458:+
BRCA	cis	rs7208859	0.673	rs61348930	ENSG00000264538.5	SUZ12P1	-3.53	0.000436	0.022	-0.17	-0.11	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30894745	chr17:30709299~30790908:+
BRCA	cis	rs7208859	0.614	rs28758251	ENSG00000264538.5	SUZ12P1	-3.53	0.000436	0.022	-0.17	-0.11	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30896294	chr17:30709299~30790908:+
BRCA	cis	rs7208859	0.673	rs9899943	ENSG00000264538.5	SUZ12P1	-3.53	0.000436	0.022	-0.17	-0.11	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30896907	chr17:30709299~30790908:+
BRCA	cis	rs7208859	0.673	rs11080138	ENSG00000264538.5	SUZ12P1	-3.53	0.000436	0.022	-0.17	-0.11	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30897524	chr17:30709299~30790908:+
BRCA	cis	rs7208859	0.673	rs73265612	ENSG00000264538.5	SUZ12P1	-3.53	0.000436	0.022	-0.17	-0.11	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30898965	chr17:30709299~30790908:+
BRCA	cis	rs7208859	0.673	rs11658435	ENSG00000264538.5	SUZ12P1	-3.53	0.000436	0.022	-0.17	-0.11	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30901543	chr17:30709299~30790908:+
BRCA	cis	rs7208859	0.673	rs73265624	ENSG00000264538.5	SUZ12P1	-3.53	0.000436	0.022	-0.17	-0.11	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30905048	chr17:30709299~30790908:+
BRCA	cis	rs8023401	0.938	rs4775767	ENSG00000274654.1	CTD-3247H4.2	3.53	0.000436	0.022	0.15	0.11	Spherical equivalent (joint analysis main effects and education interaction);	chr15:48543922	chr15:48528980~48529728:-
BRCA	cis	rs2274273	0.745	rs8005399	ENSG00000259318.1	RP11-454L9.2	3.53	0.000436	0.022	0.09	0.11	Protein biomarker;	chr14:55076127	chr14:55394940~55395233:-
BRCA	cis	rs9847710	0.967	rs2564931	ENSG00000242849.2	ALDOAP1	3.53	0.000436	0.022	0.13	0.11	Ulcerative colitis;	chr3:52986543	chr3:52193170~52194785:+
BRCA	cis	rs7267979	1	rs3002702	ENSG00000276952.1	RP5-965G21.6	3.53	0.000436	0.022	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25288284	chr20:25284915~25285588:-
BRCA	cis	rs11673344	0.864	rs79407399	ENSG00000267309.1	CTD-2630F21.1	-3.53	0.000436	0.022	-0.14	-0.11	Obesity-related traits;	chr19:37000004	chr19:36489649~36491040:+
BRCA	cis	rs8141529	0.748	rs6005936	ENSG00000272858.1	CTA-292E10.8	-3.53	0.000436	0.022	-0.14	-0.11	Lymphocyte counts;	chr22:28893262	chr22:28814914~28815662:+
BRCA	cis	rs1987511	1	rs1987511	ENSG00000224034.1	RP11-445P17.8	-3.53	0.000436	0.022	-0.14	-0.11	Intelligence;	chr10:5306374	chr10:5266033~5271236:-
BRCA	cis	rs16986856	0.964	rs1865729	ENSG00000269696.1	AC007228.11	-3.53	0.000436	0.022	-0.13	-0.11	Obesity-related traits;	chr19:55987427	chr19:56545566~56567411:-
BRCA	cis	rs1455244	0.848	rs9303732	ENSG00000267533.1	RP11-815J4.7	-3.53	0.000436	0.022	-0.14	-0.11	Schizophrenia;	chr18:11465860	chr18:12067173~12068417:-
BRCA	cis	rs3805389	0.504	rs10000512	ENSG00000249700.7	SRD5A3-AS1	-3.53	0.000436	0.022	-0.17	-0.11	Waist-to-hip ratio adjusted for body mass index;	chr4:55602855	chr4:55363971~55395847:-
BRCA	cis	rs9296095	1	rs5745568	ENSG00000224796.1	RPL32P1	3.53	0.000436	0.022	0.13	0.11	Platelet count;	chr6:33580617	chr6:33079451~33079860:+
BRCA	cis	rs1730008	0.731	rs10936139	ENSG00000279311.1	RP11-170K4.2	3.53	0.000436	0.022	0.14	0.11	Lobe attachment (rater-scored or self-reported);	chr3:158421146	chr3:158869898~158871821:+
BRCA	cis	rs4781563	0.662	rs7200442	ENSG00000242307.1	RPS26P52	-3.53	0.000436	0.022	-0.14	-0.11	Bilirubin levels;	chr16:13909799	chr16:13922332~13922679:-
BRCA	cis	rs928391	1	rs928392	ENSG00000223356.1	RP11-66D17.5	-3.53	0.000436	0.022	-0.13	-0.11	Platelet count;	chr1:156801024	chr1:156712212~156713174:-
BRCA	cis	rs9400180	0.879	rs9398159	ENSG00000271734.1	RP1-111B22.3	-3.53	0.000436	0.022	-0.15	-0.11	Major depressive disorder;	chr6:108065166	chr6:108030249~108030718:-
BRCA	cis	rs875971	0.862	rs1612452	ENSG00000273024.4	INTS4P2	3.53	0.000436	0.022	0.12	0.11	Aortic root size;	chr7:66108909	chr7:65647864~65715661:+
BRCA	cis	rs4703129	1	rs1345572	ENSG00000246763.5	RGMB-AS1	-3.53	0.000436	0.022	-0.12	-0.11	Asperger disorder;	chr5:98536662	chr5:98769618~98773469:-
BRCA	cis	rs1949733	0.701	rs940136	ENSG00000250471.2	GMPSP1	3.53	0.000436	0.022	0.11	0.11	Response to antineoplastic agents;	chr4:8447265	chr4:8174421~8174999:+
BRCA	cis	rs295490	0.748	rs41399544	ENSG00000178631.7	ACTG1P1	-3.53	0.000436	0.022	-0.21	-0.11	PR interval in Tripanosoma cruzi seropositivity;	chr3:139356303	chr3:139493809~139494937:+
BRCA	cis	rs875971	1	rs3735148	ENSG00000273024.4	INTS4P2	-3.53	0.000436	0.022	-0.12	-0.11	Aortic root size;	chr7:66506022	chr7:65647864~65715661:+
BRCA	cis	rs10759883	0.539	rs10115110	ENSG00000225194.2	LINC00092	3.53	0.000436	0.022	0.11	0.11	Nicotine dependence;	chr9:96033023	chr9:96019732~96027965:-
BRCA	cis	rs9840812	0.769	rs1711171	ENSG00000273486.1	RP11-731C17.2	3.53	0.000436	0.022	0.14	0.11	Fibrinogen levels;	chr3:136301699	chr3:136837338~136839021:-
BRCA	cis	rs10266483	0.705	rs660228	ENSG00000228653.2	HNRNPCP7	-3.53	0.000436	0.022	-0.13	-0.11	Response to statin therapy;	chr7:64295867	chr7:64500825~64501729:+
BRCA	cis	rs875971	1	rs12698523	ENSG00000271064.1	RP11-792A8.3	-3.53	0.000436	0.022	-0.13	-0.11	Aortic root size;	chr7:66503126	chr7:66748838~66749077:-
BRCA	cis	rs752590	0.614	rs67626501	ENSG00000189223.12	PAX8-AS1	3.53	0.000436	0.022	0.2	0.11	Mucinous ovarian carcinoma;	chr2:113262802	chr2:113211522~113276581:+
BRCA	cis	rs997295	0.513	rs11635495	ENSG00000260657.2	RP11-315D16.4	3.53	0.000436	0.022	0.13	0.11	Motion sickness;	chr15:67512344	chr15:68267792~68277994:-
BRCA	cis	rs10761482	0.859	rs2199210	ENSG00000254271.1	RP11-131N11.4	3.53	0.000436	0.022	0.15	0.11	Schizophrenia;	chr10:60334994	chr10:60734342~60741828:+
BRCA	cis	rs2562456	0.92	rs2650784	ENSG00000213976.4	CTD-2561J22.2	3.53	0.000436	0.022	0.12	0.11	Pain;	chr19:21483795	chr19:21382865~21387177:+
BRCA	cis	rs1463132	0.636	rs12599024	ENSG00000229917.2	RPL7P46	3.53	0.000436	0.022	0.16	0.11	HIV-1 control;	chr16:10032616	chr16:11027024~11027763:+
BRCA	cis	rs8098244	0.603	rs3017550	ENSG00000265752.2	RP11-403A21.1	3.53	0.000436	0.022	0.12	0.11	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23696510	chr18:23957754~23982556:-
BRCA	cis	rs6142618	0.562	rs4911547	ENSG00000277692.1	RP11-358N2.2	-3.53	0.000436	0.022	-0.12	-0.11	Inflammatory bowel disease;	chr20:32145670	chr20:32355053~32355734:+
BRCA	cis	rs35306767	0.903	rs12763396	ENSG00000229869.1	RP11-363N22.2	-3.53	0.000436	0.022	-0.16	-0.11	Eosinophil percentage of granulocytes;	chr10:881417	chr10:933026~942743:+
BRCA	cis	rs35306767	0.903	rs11816064	ENSG00000229869.1	RP11-363N22.2	-3.53	0.000436	0.022	-0.16	-0.11	Eosinophil percentage of granulocytes;	chr10:885236	chr10:933026~942743:+
BRCA	cis	rs4985726	0.702	rs12603708	ENSG00000128438.9	TBC1D27	-3.53	0.000437	0.022	-0.1	-0.11	Non-albumin protein levels;	chr17:16943799	chr17:16922915~16934839:-
BRCA	cis	rs6866721	0.634	rs712614	ENSG00000249167.1	CTB-118N6.2	3.53	0.000437	0.022	0.13	0.11	Body mass index;	chr5:116885854	chr5:116574482~116591398:+
BRCA	cis	rs4942486	1	rs9534323	ENSG00000215515.2	IFIT1P1	-3.53	0.000437	0.022	-0.12	-0.11	LDL cholesterol levels;LDL cholesterol;	chr13:32376120	chr13:32384660~32386108:+
BRCA	cis	rs10944	0.598	rs1841991	ENSG00000253558.1	CTD-2179L22.1	3.53	0.000437	0.022	0.13	0.11	Blood and toenail selenium levels;	chr5:78980325	chr5:78041879~78044138:-
BRCA	cis	rs6095360	1	rs6512554	ENSG00000222365.1	SNORD12B	-3.53	0.000437	0.022	-0.12	-0.11	Intelligence (multi-trait analysis);	chr20:48916213	chr20:49280319~49280409:+
BRCA	cis	rs9457247	1	rs439553	ENSG00000227598.1	RP1-167A14.2	-3.53	0.000437	0.022	-0.11	-0.11	Crohn's disease;	chr6:166977724	chr6:166969626~166999065:-
BRCA	cis	rs873549	1	rs7546082	ENSG00000227925.1	RP11-191N8.2	-3.53	0.000437	0.022	-0.13	-0.11	Keloid;	chr1:222092759	chr1:221827666~221840666:-
BRCA	cis	rs9733	0.519	rs11807450	ENSG00000231073.1	RP11-316M1.3	3.53	0.000437	0.022	0.11	0.11	Tonsillectomy;	chr1:150705243	chr1:150973123~150975534:+
BRCA	cis	rs1046491	1	rs6506647	ENSG00000264964.1	RP11-888D10.3	3.53	0.000437	0.022	0.22	0.11	Scarlet fever;	chr18:9240901	chr18:9315194~9334441:-
BRCA	cis	rs7781266	0.79	rs62469961	ENSG00000226205.1	AC007790.4	3.53	0.000437	0.022	0.17	0.11	Educational attainment (college completion);	chr7:133466151	chr7:133732493~133733595:-
BRCA	cis	rs11098499	0.863	rs10004484	ENSG00000250412.1	KLHL2P1	3.53	0.000437	0.022	0.13	0.11	Corneal astigmatism;	chr4:119521273	chr4:119334329~119378233:+
BRCA	cis	rs948562	0.793	rs79170562	ENSG00000280010.1	AP001350.4	3.53	0.000437	0.022	0.21	0.11	Lymphoma;	chr11:58604081	chr11:58627435~58628528:+
BRCA	cis	rs6696239	1	rs12140848	ENSG00000215812.5	ZNF847P	3.53	0.000437	0.022	0.15	0.11	Height;	chr1:227589241	chr1:227696892~227706699:-
BRCA	cis	rs6696239	0.955	rs12129894	ENSG00000215812.5	ZNF847P	3.53	0.000437	0.022	0.15	0.11	Height;	chr1:227589287	chr1:227696892~227706699:-
BRCA	cis	rs7267979	0.844	rs6050477	ENSG00000125804.12	FAM182A	3.53	0.000437	0.022	0.15	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25240911	chr20:26054655~26086917:+
BRCA	cis	rs6964587	1	rs9785013	ENSG00000188693.7	CYP51A1-AS1	-3.53	0.000437	0.022	-0.12	-0.11	Breast cancer;	chr7:92044988	chr7:92134604~92180725:+
BRCA	cis	rs638893	0.528	rs521910	ENSG00000255422.1	AP002954.4	3.53	0.000437	0.022	0.17	0.11	Vitiligo;	chr11:118739920	chr11:118704607~118750263:+
BRCA	cis	rs9868809	0.772	rs13070798	ENSG00000225399.4	RP11-3B7.1	3.53	0.000437	0.022	0.14	0.11	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48668501	chr3:49260085~49261316:+
BRCA	cis	rs2839186	0.526	rs2839297	ENSG00000239415.1	AP001469.9	3.53	0.000437	0.022	0.11	0.11	Testicular germ cell tumor;	chr21:46501926	chr21:46251549~46254133:-
BRCA	cis	rs78545713	0.649	rs79988778	ENSG00000241549.7	GUSBP2	-3.53	0.000437	0.022	-0.18	-0.11	Iron status biomarkers (total iron binding capacity);	chr6:26210393	chr6:26871484~26956554:-
BRCA	cis	rs875971	1	rs12532998	ENSG00000271064.1	RP11-792A8.3	-3.53	0.000437	0.022	-0.13	-0.11	Aortic root size;	chr7:66502472	chr7:66748838~66749077:-
BRCA	cis	rs8114671	0.562	rs6058137	ENSG00000126005.14	MMP24-AS1	-3.53	0.000437	0.022	-0.13	-0.11	Height;	chr20:34887271	chr20:35216462~35278131:-
BRCA	cis	rs7015630	0.955	rs10096271	ENSG00000251136.7	RP11-37B2.1	-3.53	0.000437	0.022	-0.12	-0.11	Inflammatory bowel disease;Crohn's disease;	chr8:89863288	chr8:89609409~89757727:-
BRCA	cis	rs17489649	0.785	rs4957836	ENSG00000271849.1	CTC-332L22.1	3.53	0.000437	0.0221	0.14	0.11	Intelligence (multi-trait analysis);	chr5:109867341	chr5:109687802~109688329:-
BRCA	cis	rs6545883	0.929	rs12617911	ENSG00000212978.6	AC016747.3	3.53	0.000437	0.0221	0.15	0.11	Tuberculosis;	chr2:61513690	chr2:61141592~61144969:-
BRCA	cis	rs4763879	0.778	rs1056151	ENSG00000256582.1	RP11-75L1.1	-3.53	0.000437	0.0221	-0.11	-0.11	Type 1 diabetes;	chr12:9698427	chr12:9704077~9709350:+
BRCA	cis	rs68170813	0.652	rs17482494	ENSG00000241764.3	AC002467.7	3.53	0.000437	0.0221	0.19	0.11	Coronary artery disease;	chr7:107528042	chr7:107742817~107744581:-
BRCA	cis	rs68170813	0.652	rs17482543	ENSG00000241764.3	AC002467.7	3.53	0.000437	0.0221	0.19	0.11	Coronary artery disease;	chr7:107528729	chr7:107742817~107744581:-
BRCA	cis	rs68170813	0.652	rs74374590	ENSG00000241764.3	AC002467.7	3.53	0.000437	0.0221	0.19	0.11	Coronary artery disease;	chr7:107532025	chr7:107742817~107744581:-
BRCA	cis	rs68170813	0.617	rs117884147	ENSG00000241764.3	AC002467.7	3.53	0.000437	0.0221	0.19	0.11	Coronary artery disease;	chr7:107537148	chr7:107742817~107744581:-
BRCA	cis	rs68170813	0.652	rs75136686	ENSG00000241764.3	AC002467.7	3.53	0.000437	0.0221	0.19	0.11	Coronary artery disease;	chr7:107540504	chr7:107742817~107744581:-
BRCA	cis	rs68170813	0.617	rs76923959	ENSG00000241764.3	AC002467.7	3.53	0.000437	0.0221	0.19	0.11	Coronary artery disease;	chr7:107542470	chr7:107742817~107744581:-
BRCA	cis	rs2282526	0.615	rs162377	ENSG00000232124.1	AP001057.1	3.53	0.000437	0.0221	0.14	0.11	Mean corpuscular hemoglobin;	chr21:43506121	chr21:44201290~44202696:+
BRCA	cis	rs6693388	0.602	rs2999526	ENSG00000234614.1	AL450992.2	3.53	0.000437	0.0221	0.12	0.11	Blood metabolite ratios;	chr1:151979219	chr1:151841877~151850385:+
BRCA	cis	rs11892454	0.599	rs1076000	ENSG00000217643.1	PTGES3P2	-3.53	0.000438	0.0221	-0.12	-0.11	Heschl's gyrus morphology;	chr2:25754487	chr2:25822469~25822950:+
BRCA	cis	rs1005277	0.522	rs289643	ENSG00000099251.13	HSD17B7P2	3.53	0.000438	0.0221	0.12	0.11	Extrinsic epigenetic age acceleration;	chr10:37652566	chr10:38356380~38378505:+
BRCA	cis	rs910316	0.763	rs175036	ENSG00000259138.1	RP11-950C14.7	-3.53	0.000438	0.0221	-0.11	-0.11	Height;	chr14:74997592	chr14:75127153~75136930:+
BRCA	cis	rs910316	0.712	rs175037	ENSG00000259138.1	RP11-950C14.7	-3.53	0.000438	0.0221	-0.11	-0.11	Height;	chr14:74998335	chr14:75127153~75136930:+
BRCA	cis	rs7176093	1	rs72755349	ENSG00000259295.5	CSPG4P12	-3.53	0.000438	0.0221	-0.15	-0.11	Aging traits;	chr15:85821667	chr15:85191438~85213905:+
BRCA	cis	rs7520050	0.966	rs11211208	ENSG00000281133.1	AL355480.3	3.53	0.000438	0.0221	0.13	0.11	Reticulocyte count;Red blood cell count;	chr1:45868584	chr1:45580892~45580996:-
BRCA	cis	rs324126	0.78	rs62108318	ENSG00000277977.1	CTD-3018O17.5	3.53	0.000438	0.0221	0.13	0.11	Colonoscopy-negative controls vs population controls;	chr19:52380322	chr19:52392659~52392755:+
BRCA	cis	rs9868809	0.881	rs57334642	ENSG00000225399.4	RP11-3B7.1	-3.53	0.000438	0.0221	-0.18	-0.11	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48629362	chr3:49260085~49261316:+
BRCA	cis	rs9400180	0.879	rs12567	ENSG00000271734.1	RP1-111B22.3	-3.53	0.000438	0.0221	-0.15	-0.11	Major depressive disorder;	chr6:108043378	chr6:108030249~108030718:-
BRCA	cis	rs55675132	0.548	rs12138998	ENSG00000226167.1	AP4B1-AS1	3.53	0.000438	0.0221	0.11	0.11	Schizophrenia;	chr1:114834547	chr1:113856635~113901237:+
BRCA	cis	rs55675132	0.548	rs17274725	ENSG00000226167.1	AP4B1-AS1	3.53	0.000438	0.0221	0.11	0.11	Schizophrenia;	chr1:114834848	chr1:113856635~113901237:+
BRCA	cis	rs875971	1	rs1540651	ENSG00000272831.1	RP11-792A8.4	-3.53	0.000438	0.0221	-0.1	-0.11	Aortic root size;	chr7:66185134	chr7:66739829~66740385:-
BRCA	cis	rs1334894	0.901	rs72911380	ENSG00000187762.5	HSPE1P11	3.53	0.000438	0.0221	0.25	0.11	Coronary artery disease;	chr6:35551706	chr6:35023522~35023831:+
BRCA	cis	rs7560272	0.538	rs4852977	ENSG00000204872.3	NAT8B	3.53	0.000438	0.0221	0.15	0.11	Schizophrenia;	chr2:73711168	chr2:73700576~73701340:-
BRCA	cis	rs7487075	0.619	rs6582658	ENSG00000257261.4	RP11-96H19.1	3.53	0.000438	0.0221	0.12	0.11	Itch intensity from mosquito bite;	chr12:46462312	chr12:46383679~46876159:+
BRCA	cis	rs8062405	0.755	rs4149398	ENSG00000261766.1	RP11-22P6.2	-3.53	0.000438	0.0221	-0.11	-0.11	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28597617	chr16:28862166~28863340:-
BRCA	cis	rs928391	1	rs2644615	ENSG00000223356.1	RP11-66D17.5	-3.53	0.000438	0.0221	-0.14	-0.11	Platelet count;	chr1:156791826	chr1:156712212~156713174:-
BRCA	cis	rs10266483	0.515	rs6949304	ENSG00000227986.1	TRIM60P18	3.53	0.000438	0.0221	0.14	0.11	Response to statin therapy;	chr7:64257903	chr7:64355078~64356199:+
BRCA	cis	rs2976388	0.647	rs2244163	ENSG00000253196.1	RP11-706C16.7	3.53	0.000438	0.0221	0.1	0.11	Urinary tract infection frequency;	chr8:142703082	chr8:142763116~142766427:+
BRCA	cis	rs9467773	0.549	rs9467805	ENSG00000261353.1	CTA-14H9.5	-3.53	0.000438	0.0221	-0.11	-0.11	Intelligence (multi-trait analysis);	chr6:26583138	chr6:26527063~26527404:+
BRCA	cis	rs3739034	0.938	rs730946	ENSG00000224043.6	CCNT2-AS1	-3.53	0.000438	0.0221	-0.19	-0.11	Gut microbiome composition (winter);	chr2:134707679	chr2:134735464~134918710:-
BRCA	cis	rs7520050	0.902	rs7514192	ENSG00000281133.1	AL355480.3	3.53	0.000438	0.0221	0.13	0.11	Reticulocyte count;Red blood cell count;	chr1:45783305	chr1:45580892~45580996:-
BRCA	cis	rs1949733	0.675	rs2688219	ENSG00000250471.2	GMPSP1	3.53	0.000438	0.0221	0.11	0.11	Response to antineoplastic agents;	chr4:8442904	chr4:8174421~8174999:+
BRCA	cis	rs7267979	1	rs2424704	ENSG00000231081.1	RP4-760C5.3	-3.53	0.000438	0.0221	-0.14	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25293293	chr20:26008791~26010531:-
BRCA	cis	rs210142	1	rs210142	ENSG00000237398.1	HLA-DPA3	-3.53	0.000438	0.0221	-0.13	-0.11	Platelet count;Plateletcrit;Chronic lymphocytic leukemia;	chr6:33579060	chr6:33131216~33143325:-
BRCA	cis	rs210143	1	rs210143	ENSG00000237398.1	HLA-DPA3	-3.53	0.000438	0.0221	-0.13	-0.11	B-cell malignancies (chronic lymphocytic leukemia, Hodgkin lymphoma or multiple myeloma) (pleiotropy);Chronic lymphocytic leukemia;Neutrophil percentage of granulocytes;	chr6:33579153	chr6:33131216~33143325:-
BRCA	cis	rs4950322	0.563	rs6700783	ENSG00000237188.3	RP11-337C18.8	3.53	0.000438	0.0221	0.13	0.11	Protein quantitative trait loci;	chr1:147111987	chr1:147172771~147211568:+
BRCA	cis	rs733592	0.504	rs2261608	ENSG00000273765.1	RP11-370I10.11	3.53	0.000438	0.0221	0.13	0.11	Plateletcrit;	chr12:48327851	chr12:48360920~48361377:+
BRCA	cis	rs9650657	0.623	rs11250065	ENSG00000248896.2	CTD-2135J3.3	-3.53	0.000438	0.0221	-0.13	-0.11	Neuroticism;	chr8:10742871	chr8:10729314~10771392:+
BRCA	cis	rs12549902	1	rs12550613	ENSG00000254165.1	RP11-503E24.2	3.53	0.000438	0.0221	0.11	0.11	Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Corrected insulin response;Type 2 diabetes;	chr8:41652741	chr8:42537529~42538304:-
BRCA	cis	rs7267979	1	rs6050559	ENSG00000274973.1	RP13-401N8.7	-3.53	0.000438	0.0221	-0.12	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25349279	chr20:25845497~25845862:+
BRCA	cis	rs6772849	0.93	rs9868579	ENSG00000207088.1	SNORA7B	3.53	0.000439	0.0221	0.14	0.11	Monocyte percentage of white cells;Monocyte count;	chr3:128632211	chr3:129397210~129397348:-
BRCA	cis	rs9346455	1	rs9342830	ENSG00000279289.1	RP3-331H24.6	3.53	0.000439	0.0221	0.18	0.11	Antipsychotic drug-induced weight gain;Antipsychotic drug-induced weight gain (time interaction);	chr6:71315106	chr6:71386852~71390829:-
BRCA	cis	rs17221829	0.549	rs9666894	ENSG00000280385.1	AP000648.5	-3.53	0.000439	0.0221	-0.12	-0.11	Anxiety in major depressive disorder;	chr11:89625191	chr11:90193614~90198120:+
BRCA	cis	rs116175783	0.557	rs62188138	ENSG00000235724.7	AC009299.2	3.53	0.000439	0.0221	0.16	0.11	Intelligence (multi-trait analysis);	chr2:161410935	chr2:161222785~161308303:-
BRCA	cis	rs116175783	0.557	rs6710414	ENSG00000235724.7	AC009299.2	3.53	0.000439	0.0221	0.16	0.11	Intelligence (multi-trait analysis);	chr2:161412004	chr2:161222785~161308303:-
BRCA	cis	rs1208	0.965	rs4621844	ENSG00000253671.1	RP11-806O11.1	-3.53	0.000439	0.0221	-0.13	-0.11	Insulin resistance/response;	chr8:18397429	chr8:17808941~17820868:+
BRCA	cis	rs6071524	0.517	rs1474973	ENSG00000224635.1	RP4-564F22.5	-3.53	0.000439	0.0221	-0.13	-0.11	Autism spectrum disorder or schizophrenia;	chr20:38839802	chr20:38406011~38416797:-
BRCA	cis	rs718433	0.584	rs2075478	ENSG00000211778.2	TRAV4	-3.53	0.000439	0.0221	-0.08	-0.11	Intraocular pressure;	chr14:21749767	chr14:21736152~21736982:+
BRCA	cis	rs718433	0.584	rs2874142	ENSG00000211778.2	TRAV4	-3.53	0.000439	0.0221	-0.08	-0.11	Intraocular pressure;	chr14:21750036	chr14:21736152~21736982:+
BRCA	cis	rs11035577	0.516	rs4756529	ENSG00000279675.1	RP11-454H19.2	-3.53	0.000439	0.0221	-0.17	-0.11	Temperament (bipolar disorder);	chr11:39765911	chr11:40107244~40112599:-
BRCA	cis	rs2236231	0.513	rs10150890	ENSG00000259502.1	RP11-643G16.3	-3.53	0.000439	0.0221	-0.15	-0.11	Plasma kynurenine levels in major depressive disorder;	chr14:67597789	chr14:67610986~67613864:+
BRCA	cis	rs10419113	0.668	rs2360530	ENSG00000268379.1	CTC-360J11.4	3.53	0.000439	0.0221	0.13	0.11	Pediatric bone mineral density (spine);	chr19:57669785	chr19:57175233~57177921:+
BRCA	cis	rs9788682	0.747	rs2568485	ENSG00000261143.1	ADAMTS7P3	3.53	0.000439	0.0221	0.15	0.11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78459772	chr15:77976042~77993057:+
BRCA	cis	rs4557020	0.904	rs4671942	ENSG00000162997.14	PRORSD1P	-3.53	0.000439	0.0221	-0.12	-0.11	Myopia (pathological);	chr2:54486929	chr2:55282319~55284522:+
BRCA	cis	rs863345	0.604	rs1342953	ENSG00000229914.1	RP11-404O13.4	-3.53	0.000439	0.0221	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158494709	chr1:158195633~158196131:-
BRCA	cis	rs6084875	0.646	rs6076735	ENSG00000274949.1	RP5-1009E24.9	-3.53	0.000439	0.0221	-0.15	-0.11	Systemic lupus erythematosus;	chr20:4771362	chr20:3811384~3823882:+
BRCA	cis	rs4470077	1	rs10146352	ENSG00000258413.1	RP11-665C16.6	-3.53	0.000439	0.0221	-0.16	-0.11	Platelet count;	chr14:55430871	chr14:55262767~55272075:-
BRCA	cis	rs7985	0.725	rs1007476	ENSG00000225783.5	MIAT	3.53	0.000439	0.0221	0.09	0.11	Electroencephalogram traits;	chr22:26660685	chr22:26646428~26676475:+
BRCA	cis	rs694739	0.536	rs11231740	ENSG00000236935.1	AP003774.1	-3.53	0.000439	0.0221	-0.1	-0.11	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64279169	chr11:64325050~64329504:-
BRCA	cis	rs925550	0.867	rs309389	ENSG00000224786.1	CETN4P	-3.53	0.000439	0.0221	-0.18	-0.11	Primary biliary cholangitis;	chr4:122689551	chr4:122730548~122732193:-
BRCA	cis	rs7267979	0.932	rs6115215	ENSG00000274414.1	RP5-965G21.4	-3.53	0.000439	0.0221	-0.13	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25581864	chr20:25239007~25245229:-
BRCA	cis	rs5167	0.677	rs73047643	ENSG00000214855.8	APOC1P1	3.53	0.000439	0.0221	0.15	0.11	Blood protein levels;	chr19:44954136	chr19:44926804~44931386:+
BRCA	cis	rs957448	1	rs12678305	ENSG00000261437.1	RP11-22C11.2	3.53	0.000439	0.0221	0.11	0.11	Nonsyndromic cleft lip with cleft palate;	chr8:94508911	chr8:94637285~94639467:-
BRCA	cis	rs853679	1	rs10456362	ENSG00000216901.1	AL022393.7	-3.53	0.000439	0.0221	-0.18	-0.11	Depression;	chr6:28254038	chr6:28176188~28176674:+
BRCA	cis	rs2117445	0.581	rs12196014	ENSG00000270362.1	HMGN3-AS1	-3.53	0.000439	0.0221	-0.14	-0.11	Daytime sleep phenotypes;	chr6:79931130	chr6:79233718~79236797:+
BRCA	cis	rs2904967	0.929	rs592050	ENSG00000254614.2	AP003068.23	3.53	0.000439	0.0221	0.19	0.11	Mean corpuscular volume;	chr11:65262718	chr11:65177606~65181834:-
BRCA	cis	rs2904967	0.929	rs554122	ENSG00000254614.2	AP003068.23	3.53	0.000439	0.0221	0.19	0.11	Mean corpuscular volume;	chr11:65266403	chr11:65177606~65181834:-
BRCA	cis	rs2904967	0.852	rs488289	ENSG00000254614.2	AP003068.23	3.53	0.000439	0.0221	0.19	0.11	Mean corpuscular volume;	chr11:65271793	chr11:65177606~65181834:-
BRCA	cis	rs12549902	0.8	rs4736999	ENSG00000254165.1	RP11-503E24.2	3.53	0.000439	0.0221	0.11	0.11	Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Corrected insulin response;Type 2 diabetes;	chr8:41648633	chr8:42537529~42538304:-
BRCA	cis	rs1018697	0.966	rs6584526	ENSG00000236937.2	PTGES3P4	3.53	0.000439	0.0221	0.14	0.11	Colorectal adenoma (advanced);	chr10:102806484	chr10:102845595~102845950:+
BRCA	cis	rs10043228	1	rs62384678	ENSG00000250015.1	CTC-339F2.2	3.53	0.000439	0.0221	0.14	0.11	Asthma or chronic obstructive pulmonary disease;	chr5:116086991	chr5:116302354~116304134:-
BRCA	cis	rs4761702	0.857	rs1135400	ENSG00000258274.1	RP11-887P2.5	-3.53	0.000439	0.0221	-0.12	-0.11	Immature fraction of reticulocytes;	chr12:93315763	chr12:93707791~93737823:-
BRCA	cis	rs7520050	0.966	rs6701614	ENSG00000281133.1	AL355480.3	3.53	0.000439	0.0221	0.12	0.11	Reticulocyte count;Red blood cell count;	chr1:45843748	chr1:45580892~45580996:-
BRCA	cis	rs9844666	0.512	rs9839259	ENSG00000239213.4	NCK1-AS1	-3.53	0.000439	0.0221	-0.12	-0.11	Height;	chr3:135923495	chr3:136841726~136862054:-
BRCA	cis	rs8058578	1	rs8051050	ENSG00000275263.1	RP11-1072A3.4	-3.53	0.000439	0.0221	-0.14	-0.11	Multiple myeloma;	chr16:30676588	chr16:30956872~30957199:-
BRCA	cis	rs1799949	1	rs8070085	ENSG00000267151.3	RP11-100E5.2	-3.53	0.000439	0.0221	-0.13	-0.11	Menopause (age at onset);	chr17:43189967	chr17:43444707~43451200:+
BRCA	cis	rs875971	0.545	rs1638724	ENSG00000273448.1	RP11-166O4.6	-3.53	0.000439	0.0221	-0.11	-0.11	Aortic root size;	chr7:66575494	chr7:67333047~67334383:+
BRCA	cis	rs516805	0.528	rs2684235	ENSG00000279114.1	RP3-425C14.5	3.53	0.00044	0.0221	0.12	0.11	Lymphocyte counts;	chr6:122082083	chr6:122471923~122484161:+
BRCA	cis	rs80028505	0.908	rs56056710	ENSG00000271304.1	DPRXP2	3.53	0.00044	0.0221	0.21	0.11	Foot ulcer in diabetes and neuropathy;	chr6:36068575	chr6:35989515~35990436:-
BRCA	cis	rs80028505	0.908	rs58237753	ENSG00000271304.1	DPRXP2	3.53	0.00044	0.0221	0.21	0.11	Foot ulcer in diabetes and neuropathy;	chr6:36068578	chr6:35989515~35990436:-
BRCA	cis	rs17818399	0.547	rs7607633	ENSG00000279254.1	RP11-536C12.1	-3.53	0.00044	0.0222	-0.15	-0.11	Height;	chr2:46532288	chr2:46668870~46670778:+
BRCA	cis	rs13434995	0.513	rs1801260	ENSG00000273257.1	RP11-177J6.1	-3.53	0.00044	0.0222	-0.16	-0.11	Adiponectin levels;	chr4:55435202	chr4:55387949~55388271:+
BRCA	cis	rs13434995	0.513	rs17721215	ENSG00000273257.1	RP11-177J6.1	-3.53	0.00044	0.0222	-0.16	-0.11	Adiponectin levels;	chr4:55437620	chr4:55387949~55388271:+
BRCA	cis	rs55986470	0.817	rs6710301	ENSG00000186235.9	AC016757.3	-3.53	0.00044	0.0222	-0.19	-0.11	Chronotype;	chr2:238532667	chr2:238224552~238231677:-
BRCA	cis	rs62458065	0.925	rs10243243	ENSG00000273014.1	RP11-225B17.2	-3.53	0.00044	0.0222	-0.16	-0.11	Metabolite levels (HVA/MHPG ratio);	chr7:32421097	chr7:32758882~32759353:+
BRCA	cis	rs17345786	1	rs17345528	ENSG00000256628.3	ZBTB11-AS1	-3.53	0.00044	0.0222	-0.15	-0.11	Colonoscopy-negative controls vs population controls;	chr3:101575986	chr3:101676475~101679217:+
BRCA	cis	rs72615157	0.634	rs11762932	ENSG00000214313.7	AZGP1P1	3.53	0.00044	0.0222	0.13	0.11	Lung function (FEV1/FVC);	chr7:100195043	chr7:99980762~99987535:+
BRCA	cis	rs6964587	0.677	rs62467839	ENSG00000188693.7	CYP51A1-AS1	-3.53	0.00044	0.0222	-0.12	-0.11	Breast cancer;	chr7:92338057	chr7:92134604~92180725:+
BRCA	cis	rs6005807	0.719	rs134524	ENSG00000272858.1	CTA-292E10.8	3.53	0.00044	0.0222	0.2	0.11	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28377816	chr22:28814914~28815662:+
BRCA	cis	rs1949733	1	rs2631740	ENSG00000251615.3	RP11-774O3.3	3.53	0.00044	0.0222	0.12	0.11	Response to antineoplastic agents;	chr4:8482379	chr4:8355090~8358338:-
BRCA	cis	rs2688608	0.672	rs2688622	ENSG00000271816.1	BMS1P4	3.53	0.00044	0.0222	0.11	0.11	Inflammatory bowel disease;	chr10:73929223	chr10:73699151~73730487:-
BRCA	cis	rs2749592	0.505	rs7915670	ENSG00000263064.2	RP11-291L22.7	-3.53	0.00044	0.0222	-0.13	-0.11	Age-related hearing impairment (SNP x SNP interaction);	chr10:37581284	chr10:38448689~38448949:+
BRCA	cis	rs7226408	0.948	rs11662126	ENSG00000274849.1	RP11-49I11.4	3.53	0.00044	0.0222	0.2	0.11	Obesity-related traits;	chr18:36828355	chr18:36189824~36190272:+
BRCA	cis	rs2985684	0.948	rs2883437	ENSG00000278009.1	RP11-649E7.8	3.53	0.00044	0.0222	0.15	0.11	Carotid intima media thickness;	chr14:49564948	chr14:49601011~49601124:-
BRCA	cis	rs7520050	0.933	rs6666743	ENSG00000281133.1	AL355480.3	3.53	0.00044	0.0222	0.12	0.11	Reticulocyte count;Red blood cell count;	chr1:45845603	chr1:45580892~45580996:-
BRCA	cis	rs863345	0.604	rs975118	ENSG00000229914.1	RP11-404O13.4	-3.53	0.00044	0.0222	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158541655	chr1:158195633~158196131:-
BRCA	cis	rs2880765	0.677	rs7181410	ENSG00000230373.7	GOLGA6L5P	-3.53	0.00044	0.0222	-0.12	-0.11	Coronary artery disease;	chr15:85463104	chr15:84507885~84516814:-
BRCA	cis	rs11158026	0.603	rs12147796	ENSG00000233924.1	AL160471.6	-3.53	0.00044	0.0222	-0.13	-0.11	Parkinson's disease;	chr14:54941978	chr14:55004813~55005687:-
BRCA	cis	rs6500602	0.893	rs6500596	ENSG00000280063.1	RP11-295D4.3	3.53	0.00044	0.0222	0.09	0.11	Schizophrenia;	chr16:4420026	chr16:4346694~4348648:-
BRCA	cis	rs4363385	0.72	rs6665527	ENSG00000272654.1	RP11-422P24.11	3.53	0.00044	0.0222	0.12	0.11	Inflammatory skin disease;	chr1:152994533	chr1:153977743~153979160:+
BRCA	cis	rs5758511	0.731	rs58302269	ENSG00000231261.1	HMGN2P10	-3.53	0.00044	0.0222	-0.15	-0.11	Birth weight;	chr22:41955305	chr22:41709225~41709489:-
BRCA	cis	rs3805389	0.504	rs1873091	ENSG00000249700.7	SRD5A3-AS1	-3.53	0.00044	0.0222	-0.18	-0.11	Waist-to-hip ratio adjusted for body mass index;	chr4:55605266	chr4:55363971~55395847:-
BRCA	cis	rs3805389	0.504	rs17725110	ENSG00000249700.7	SRD5A3-AS1	-3.53	0.00044	0.0222	-0.18	-0.11	Waist-to-hip ratio adjusted for body mass index;	chr4:55605855	chr4:55363971~55395847:-
BRCA	cis	rs4689592	0.587	rs6825954	ENSG00000245468.3	RP11-367J11.3	3.53	0.00044	0.0222	0.12	0.11	Monocyte percentage of white cells;	chr4:7072499	chr4:7094571~7103385:-
BRCA	cis	rs7520050	0.933	rs11211203	ENSG00000281133.1	AL355480.3	3.53	0.00044	0.0222	0.12	0.11	Reticulocyte count;Red blood cell count;	chr1:45849920	chr1:45580892~45580996:-
BRCA	cis	rs7578035	0.5	rs17021941	ENSG00000231822.1	AC019097.7	-3.53	0.00044	0.0222	-0.12	-0.11	Bipolar disorder;	chr2:98767836	chr2:99102018~99102752:+
BRCA	cis	rs1411478	1	rs7528526	ENSG00000243155.1	RP11-46A10.5	3.53	0.00044	0.0222	0.12	0.11	Menopause (age at onset);Progressive supranuclear palsy;	chr1:180979438	chr1:180944042~180976482:-
BRCA	cis	rs6545883	0.929	rs2593627	ENSG00000273302.1	RP11-493E12.2	-3.53	0.00044	0.0222	-0.1	-0.11	Tuberculosis;	chr2:61391439	chr2:61199979~61200769:+
BRCA	cis	rs219780	0.898	rs219786	ENSG00000233818.1	AP000695.4	3.53	0.00044	0.0222	0.13	0.11	Kidney stones;	chr21:36459453	chr21:36445731~36532408:+
BRCA	cis	rs76798021	0.935	rs11713811	ENSG00000271976.1	RP11-884K10.7	3.53	0.00044	0.0222	0.15	0.11	Lung function (FEV1/FVC);	chr3:53659043	chr3:53858994~53861576:-
BRCA	cis	rs875971	1	rs3981131	ENSG00000273448.1	RP11-166O4.6	3.53	0.00044	0.0222	0.1	0.11	Aortic root size;	chr7:66486690	chr7:67333047~67334383:+
BRCA	cis	rs10129255	0.789	rs61997796	ENSG00000232216.1	IGHV3-43	3.53	0.00044	0.0222	0.09	0.11	Kawasaki disease;	chr14:106813798	chr14:106470264~106470800:-
BRCA	cis	rs699	0.545	rs2478535	ENSG00000228058.1	RP11-552D4.1	3.53	0.00044	0.0222	0.13	0.11	Coronary artery disease;	chr1:230692645	chr1:230002730~230007162:+
BRCA	cis	rs10197140	1	rs17465162	ENSG00000235721.1	AC013268.3	-3.53	0.00044	0.0222	-0.14	-0.11	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110855568	chr2:110007675~110010783:+
BRCA	cis	rs11170468	0.621	rs11170855	ENSG00000257718.1	RP11-396F22.1	-3.53	0.00044	0.0222	-0.14	-0.11	Body mass index;	chr12:39141303	chr12:38906451~38909592:+
BRCA	cis	rs9659323	1	rs9659323	ENSG00000231365.4	RP11-418J17.1	-3.53	0.00044	0.0222	-0.13	-0.11	Body mass index;	chr1:118961738	chr1:119140396~119275973:+
BRCA	cis	rs3824867	0.881	rs4752829	ENSG00000280615.1	Y_RNA	3.53	0.00044	0.0222	0.13	0.11	Mean corpuscular hemoglobin;	chr11:47375103	chr11:47614898~47614994:-
BRCA	cis	rs9856151	1	rs9855524	ENSG00000261167.1	RP11-517B11.7	-3.53	0.000441	0.0222	-0.12	-0.11	Body mass index;	chr3:131818190	chr3:131455126~131458598:-
BRCA	cis	rs2882667	0.69	rs13174008	ENSG00000242683.1	CTB-46B19.1	3.53	0.000441	0.0222	0.13	0.11	Age-related hearing impairment (SNP x SNP interaction);	chr5:138922220	chr5:139035148~139035987:-
BRCA	cis	rs360932	0.674	rs361147	ENSG00000270265.1	RP11-731D1.4	3.53	0.000441	0.0222	0.13	0.11	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr4:151969411	chr4:151333775~151353224:-
BRCA	cis	rs4703129	0.934	rs1978419	ENSG00000246763.5	RGMB-AS1	-3.53	0.000441	0.0222	-0.12	-0.11	Asperger disorder;	chr5:98532166	chr5:98769618~98773469:-
BRCA	cis	rs1008375	0.931	rs7435102	ENSG00000249502.1	AC006160.5	-3.53	0.000441	0.0222	-0.13	-0.11	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17569857	chr4:17587467~17614571:-
BRCA	cis	rs375066	0.935	rs425217	ENSG00000278917.1	RP11-15A1.4	-3.53	0.000441	0.0222	-0.13	-0.11	Breast cancer;	chr19:43889823	chr19:43891233~43895411:+
BRCA	cis	rs524281	0.648	rs10896089	ENSG00000255038.1	RP11-1167A19.2	-3.53	0.000441	0.0222	-0.16	-0.11	Electroencephalogram traits;	chr11:66168821	chr11:66067277~66069619:-
BRCA	cis	rs2554380	0.628	rs7177929	ENSG00000176700.18	SCAND2P	-3.53	0.000441	0.0222	-0.11	-0.11	Height;	chr15:83809927	chr15:84631451~84647478:+
BRCA	cis	rs17366136	1	rs17366136	ENSG00000232759.1	AC002480.3	-3.53	0.000441	0.0222	-0.12	-0.11	Coronary atherosclerosis (increased number of diseased vessels) (traffic exposure interaction);	chr7:22561508	chr7:22563337~22573996:+
BRCA	cis	rs7267979	0.933	rs2258728	ENSG00000276952.1	RP5-965G21.6	3.53	0.000441	0.0222	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25295707	chr20:25284915~25285588:-
BRCA	cis	rs2739330	0.828	rs5760108	ENSG00000228039.3	KB-1125A3.10	3.53	0.000441	0.0222	0.12	0.11	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23963780~23964374:+
BRCA	cis	rs6490294	0.528	rs78745958	ENSG00000257624.1	RP1-128M12.3	3.53	0.000441	0.0222	0.2	0.11	Mean platelet volume;	chr12:111990367	chr12:112000739~112000985:-
BRCA	cis	rs1670533	0.932	rs2045067	ENSG00000251639.2	RP11-20I20.1	3.53	0.000441	0.0222	0.17	0.11	Recombination rate (females);	chr4:1058567	chr4:1100016~1101558:-
BRCA	cis	rs72775230	0.891	rs72775231	ENSG00000233990.1	RP11-401E9.3	-3.53	0.000441	0.0222	-0.19	-0.11	Conotruncal heart defects (inherited effects);	chr10:8513235	chr10:7833618~7833957:-
BRCA	cis	rs3770752	0.836	rs3213745	ENSG00000272054.1	RP11-423P10.2	-3.53	0.000441	0.0222	-0.1	-0.11	Schizophrenia;	chr2:37231568	chr2:37208875~37212677:+
BRCA	cis	rs10266483	0.639	rs6952592	ENSG00000228653.2	HNRNPCP7	-3.53	0.000441	0.0222	-0.13	-0.11	Response to statin therapy;	chr7:64293667	chr7:64500825~64501729:+
BRCA	cis	rs7620503	1	rs6801849	ENSG00000231574.4	RP11-91K9.1	3.53	0.000441	0.0222	0.12	0.11	Corneal structure;	chr3:177580036	chr3:177816865~177899224:+
BRCA	cis	rs7660883	0.866	rs1674999	ENSG00000251411.1	RP11-397E7.4	-3.53	0.000441	0.0222	-0.12	-0.11	HDL cholesterol levels;	chr4:87106498	chr4:86913266~86914817:-
BRCA	cis	rs6088580	0.524	rs6088567	ENSG00000279253.1	RP4-614O4.13	3.53	0.000441	0.0222	0.12	0.11	Glomerular filtration rate (creatinine);	chr20:34676068	chr20:35262727~35264187:-
BRCA	cis	rs6088580	0.524	rs6088568	ENSG00000279253.1	RP4-614O4.13	3.53	0.000441	0.0222	0.12	0.11	Glomerular filtration rate (creatinine);	chr20:34678167	chr20:35262727~35264187:-
BRCA	cis	rs6088580	0.524	rs1321306	ENSG00000279253.1	RP4-614O4.13	3.53	0.000441	0.0222	0.12	0.11	Glomerular filtration rate (creatinine);	chr20:34678575	chr20:35262727~35264187:-
BRCA	cis	rs91731	0.92	rs268760	ENSG00000249572.1	CTD-2203K17.1	-3.53	0.000441	0.0222	-0.19	-0.11	Lung function (FVC);	chr5:33308459	chr5:33424025~33440619:-
BRCA	cis	rs7259811	0.539	rs4801364	ENSG00000268266.1	AC003005.2	-3.53	0.000441	0.0222	-0.14	-0.11	Western dietary pattern;	chr19:56712448	chr19:57477649~57482996:+
BRCA	cis	rs7267979	0.932	rs6115215	ENSG00000277938.1	RP5-965G21.3	3.53	0.000441	0.0222	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25581864	chr20:25229150~25231933:+
BRCA	cis	rs7036656	0.691	rs10757261	ENSG00000238271.2	IFNWP19	-3.53	0.000441	0.0222	-0.12	-0.11	White blood cell count;	chr9:21954954	chr9:21455484~21456049:+
BRCA	cis	rs11227306	0.934	rs7940691	ENSG00000254510.1	RP11-867G23.10	-3.53	0.000441	0.0222	-0.11	-0.11	DNA methylation (variation);	chr11:65873435	chr11:66409158~66417137:+
BRCA	cis	rs4819052	0.851	rs2838831	ENSG00000223768.1	LINC00205	-3.53	0.000441	0.0222	-0.15	-0.11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244860	chr21:45293285~45297354:+
BRCA	cis	rs875971	1	rs7789554	ENSG00000229886.1	RP5-1132H15.3	3.53	0.000441	0.0222	0.12	0.11	Aortic root size;	chr7:66481051	chr7:66025126~66031544:-
BRCA	cis	rs875971	1	rs4717300	ENSG00000229886.1	RP5-1132H15.3	3.53	0.000441	0.0222	0.12	0.11	Aortic root size;	chr7:66482393	chr7:66025126~66031544:-
BRCA	cis	rs875971	0.895	rs1974769	ENSG00000229886.1	RP5-1132H15.3	3.53	0.000441	0.0222	0.12	0.11	Aortic root size;	chr7:66485627	chr7:66025126~66031544:-
BRCA	cis	rs875971	0.895	rs6460300	ENSG00000229886.1	RP5-1132H15.3	3.53	0.000441	0.0222	0.12	0.11	Aortic root size;	chr7:66487937	chr7:66025126~66031544:-
BRCA	cis	rs875971	0.862	rs7803416	ENSG00000229886.1	RP5-1132H15.3	3.53	0.000441	0.0222	0.12	0.11	Aortic root size;	chr7:66489212	chr7:66025126~66031544:-
BRCA	cis	rs875971	0.964	rs2277911	ENSG00000229886.1	RP5-1132H15.3	3.53	0.000441	0.0222	0.12	0.11	Aortic root size;	chr7:66493638	chr7:66025126~66031544:-
BRCA	cis	rs7520050	0.966	rs7539932	ENSG00000281133.1	AL355480.3	3.53	0.000441	0.0222	0.12	0.11	Reticulocyte count;Red blood cell count;	chr1:45826682	chr1:45580892~45580996:-
BRCA	cis	rs7520050	0.966	rs61783200	ENSG00000281133.1	AL355480.3	3.53	0.000441	0.0222	0.12	0.11	Reticulocyte count;Red blood cell count;	chr1:45831731	chr1:45580892~45580996:-
BRCA	cis	rs875971	0.564	rs313804	ENSG00000230189.5	GS1-124K5.2	3.53	0.000441	0.0222	0.09	0.11	Aortic root size;	chr7:66049635	chr7:66409143~66490059:-
BRCA	cis	rs875971	0.662	rs448725	ENSG00000230189.5	GS1-124K5.2	3.53	0.000441	0.0222	0.09	0.11	Aortic root size;	chr7:66049641	chr7:66409143~66490059:-
BRCA	cis	rs2380205	0.517	rs7082434	ENSG00000232807.2	RP11-536K7.3	3.53	0.000441	0.0222	0.12	0.11	Breast cancer;	chr10:5906675	chr10:5934270~5945900:-
BRCA	cis	rs875971	0.929	rs34406470	ENSG00000271064.1	RP11-792A8.3	-3.53	0.000441	0.0222	-0.13	-0.11	Aortic root size;	chr7:66464969	chr7:66748838~66749077:-
BRCA	cis	rs6437061	0.737	rs3103295	ENSG00000223198.1	RNU2-22P	3.53	0.000442	0.0222	0.13	0.11	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);	chr2:232169762	chr2:231501990~231502201:-
BRCA	cis	rs4557020	0.904	rs4671219	ENSG00000203327.2	AC012358.7	-3.53	0.000442	0.0222	-0.11	-0.11	Myopia (pathological);	chr2:54496551	chr2:55214387~55216126:-
BRCA	cis	rs9333290	0.93	rs34980163	ENSG00000259915.2	RP11-410E4.1	-3.53	0.000442	0.0222	-0.16	-0.11	Urinary albumin-to-creatinine ratio in non-diabetics;Urinary albumin-to-creatinine ratio;	chr2:186636720	chr2:186354570~186356773:-
BRCA	cis	rs1555133	0.96	rs6141734	ENSG00000277692.1	RP11-358N2.2	-3.53	0.000442	0.0222	-0.12	-0.11	Monocyte count;	chr20:32486569	chr20:32355053~32355734:+
BRCA	cis	rs27434	0.529	rs34757	ENSG00000248734.2	CTD-2260A17.1	3.53	0.000442	0.0222	0.12	0.11	Ankylosing spondylitis;	chr5:96816885	chr5:96784777~96785999:+
BRCA	cis	rs4356203	0.543	rs214081	ENSG00000184669.7	OR7E14P	-3.53	0.000442	0.0222	-0.15	-0.11	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17278107	chr11:17013998~17053024:+
BRCA	cis	rs6500602	0.627	rs6500610	ENSG00000280063.1	RP11-295D4.3	3.53	0.000442	0.0222	0.09	0.11	Schizophrenia;	chr16:4479612	chr16:4346694~4348648:-
BRCA	cis	rs7656342	0.636	rs10012880	ENSG00000250342.1	SNRPCP16	3.53	0.000442	0.0222	0.12	0.11	Gut microbiota (bacterial taxa);	chr4:9833856	chr4:9051842~9052051:-
BRCA	cis	rs7267979	1	rs6115140	ENSG00000274973.1	RP13-401N8.7	-3.53	0.000442	0.0222	-0.12	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25304871	chr20:25845497~25845862:+
BRCA	cis	rs2236231	0.55	rs7152520	ENSG00000259502.1	RP11-643G16.3	-3.53	0.000442	0.0222	-0.15	-0.11	Plasma kynurenine levels in major depressive disorder;	chr14:67596657	chr14:67610986~67613864:+
BRCA	cis	rs6881634	0.501	rs17193552	ENSG00000253558.1	CTD-2179L22.1	-3.52	0.000442	0.0222	-0.13	-0.11	Hippocampal atrophy;	chr5:78471754	chr5:78041879~78044138:-
BRCA	cis	rs6787172	0.783	rs6441201	ENSG00000272087.1	RP11-379F4.7	3.52	0.000442	0.0223	0.13	0.11	Subjective well-being;	chr3:158460535	chr3:158693120~158693768:-
BRCA	cis	rs6787172	0.783	rs12496767	ENSG00000272087.1	RP11-379F4.7	3.52	0.000442	0.0223	0.13	0.11	Subjective well-being;	chr3:158461448	chr3:158693120~158693768:-
BRCA	cis	rs6565180	0.632	rs8050812	ENSG00000261332.1	RP11-297C4.1	-3.52	0.000442	0.0223	-0.15	-0.11	Tonsillectomy;	chr16:30374516	chr16:30498766~30499554:-
BRCA	cis	rs11168618	0.74	rs10506281	ENSG00000240399.1	RP1-228P16.1	-3.52	0.000442	0.0223	-0.11	-0.11	Adiponectin levels;	chr12:48529991	chr12:48054813~48055591:-
BRCA	cis	rs13434995	0.513	rs1048004	ENSG00000249700.7	SRD5A3-AS1	-3.52	0.000442	0.0223	-0.16	-0.11	Adiponectin levels;	chr4:55434042	chr4:55363971~55395847:-
BRCA	cis	rs67383717	0.527	rs12004422	ENSG00000236095.1	RP11-49O14.2	-3.52	0.000442	0.0223	-0.12	-0.11	Parkinson's disease (pesticide exposure interaction);	chr9:95873393	chr9:94900429~94904754:+
BRCA	cis	rs801193	1	rs7785213	ENSG00000275400.1	RP4-756H11.5	3.52	0.000442	0.0223	0.12	0.11	Aortic root size;	chr7:66673991	chr7:66553805~66554199:-
BRCA	cis	rs10501293	1	rs2862694	ENSG00000252652.1	Y_RNA	-3.52	0.000442	0.0223	-0.13	-0.11	Cognitive performance;	chr11:43043203	chr11:43331261~43331356:+
BRCA	cis	rs1039766	1	rs268878	ENSG00000227791.3	AC007365.4	-3.52	0.000442	0.0223	-0.16	-0.11	Lung adenocarcinoma;Lung cancer;	chr2:65270437	chr2:64665607~64666064:+
BRCA	cis	rs4478858	0.654	rs113490486	ENSG00000229447.2	RP11-490K7.4	-3.52	0.000442	0.0223	-0.1	-0.11	Alcohol dependence;	chr1:31240016	chr1:31263245~31263681:-
BRCA	cis	rs9796	0.689	rs28409432	ENSG00000223313.1	RNU6-516P	3.52	0.000442	0.0223	0.13	0.11	Menopause (age at onset);	chr15:41155256	chr15:40529570~40529673:+
BRCA	cis	rs10883723	0.81	rs7079810	ENSG00000213061.2	PFN1P11	-3.52	0.000442	0.0223	-0.15	-0.11	Allergic disease (asthma, hay fever or eczema);	chr10:102484126	chr10:102838011~102845473:-
BRCA	cis	rs4374383	0.631	rs1400323	ENSG00000243389.1	AC012442.5	3.52	0.000442	0.0223	0.14	0.11	Hepatitis C induced liver fibrosis;	chr2:111912884	chr2:112589040~112614431:+
BRCA	cis	rs4664293	0.667	rs3815876	ENSG00000226266.5	AC009961.3	-3.52	0.000442	0.0223	-0.13	-0.11	Monocyte percentage of white cells;	chr2:159783640	chr2:159670708~159712435:-
BRCA	cis	rs7520050	0.933	rs9787208	ENSG00000281133.1	AL355480.3	3.52	0.000442	0.0223	0.12	0.11	Reticulocyte count;Red blood cell count;	chr1:45848944	chr1:45580892~45580996:-
BRCA	cis	rs7520050	0.966	rs4076006	ENSG00000281133.1	AL355480.3	3.52	0.000442	0.0223	0.13	0.11	Reticulocyte count;Red blood cell count;	chr1:45972404	chr1:45580892~45580996:-
BRCA	cis	rs7520050	0.966	rs11211234	ENSG00000281133.1	AL355480.3	3.52	0.000442	0.0223	0.13	0.11	Reticulocyte count;Red blood cell count;	chr1:45973115	chr1:45580892~45580996:-
BRCA	cis	rs993804	0.571	rs6766372	ENSG00000264219.1	MIR4442	-3.52	0.000443	0.0223	-0.12	-0.11	Bipolar disorder and schizophrenia;	chr3:25069981	chr3:25664873~25664939:-
BRCA	cis	rs1710990	1	rs1710990	ENSG00000259165.1	DDX18P1	3.52	0.000443	0.0223	0.13	0.11	Intelligence (multi-trait analysis);	chr14:69108337	chr14:69083398~69085389:+
BRCA	cis	rs4372836	0.518	rs12472549	ENSG00000226833.4	AC097724.3	3.52	0.000443	0.0223	0.13	0.11	Body mass index;	chr2:28769138	chr2:28708953~28736205:-
BRCA	cis	rs9659323	1	rs12073056	ENSG00000231365.4	RP11-418J17.1	-3.52	0.000443	0.0223	-0.13	-0.11	Body mass index;	chr1:118965777	chr1:119140396~119275973:+
BRCA	cis	rs11662721	0.938	rs11662308	ENSG00000264188.1	RP11-13N13.5	3.52	0.000443	0.0223	0.15	0.11	Phospholipid levels (plasma);	chr18:21585516	chr18:21661787~21662395:-
BRCA	cis	rs11662721	0.938	rs75155754	ENSG00000264188.1	RP11-13N13.5	3.52	0.000443	0.0223	0.15	0.11	Phospholipid levels (plasma);	chr18:21595031	chr18:21661787~21662395:-
BRCA	cis	rs2832077	0.506	rs2832085	ENSG00000236056.1	GAPDHP14	3.52	0.000443	0.0223	0.13	0.11	Cognitive test performance;	chr21:28782936	chr21:29222321~29223257:+
BRCA	cis	rs2832191	0.692	rs2776240	ENSG00000215533.7	LINC00189	-3.52	0.000443	0.0223	-0.12	-0.11	Dental caries;	chr21:28938317	chr21:29193480~29288205:+
BRCA	cis	rs73198271	0.74	rs964771	ENSG00000254153.1	CTA-398F10.2	3.52	0.000443	0.0223	0.14	0.11	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8793429	chr8:8456909~8461337:-
BRCA	cis	rs1325195	0.881	rs10913690	ENSG00000232750.2	RP11-177A2.5	-3.52	0.000443	0.0223	-0.11	-0.11	IgE grass sensitization;	chr1:179097936	chr1:179035309~179035652:-
BRCA	cis	rs2555155	0.837	rs2723631	ENSG00000254595.1	CTD-2010I16.1	3.52	0.000443	0.0223	0.12	0.11	DNA methylation (variation);	chr11:6516500	chr11:6488186~6489377:-
BRCA	cis	rs2120243	0.504	rs114107407	ENSG00000244515.1	KRT18P34	-3.52	0.000443	0.0223	-0.13	-0.11	Hepatocellular carcinoma in hepatitis B infection;	chr3:157344846	chr3:157162663~157163932:-
BRCA	cis	rs28489187	0.683	rs2177461	ENSG00000223653.4	RP11-131L23.1	-3.52	0.000443	0.0223	-0.12	-0.11	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85396293	chr1:85276715~85448124:+
BRCA	cis	rs28489187	0.66	rs3949301	ENSG00000223653.4	RP11-131L23.1	-3.52	0.000443	0.0223	-0.12	-0.11	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85397700	chr1:85276715~85448124:+
BRCA	cis	rs7267979	0.903	rs6107015	ENSG00000274973.1	RP13-401N8.7	-3.52	0.000443	0.0223	-0.13	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25236128	chr20:25845497~25845862:+
BRCA	cis	rs91731	0.92	rs2967086	ENSG00000249572.1	CTD-2203K17.1	-3.52	0.000443	0.0223	-0.2	-0.11	Lung function (FVC);	chr5:33260950	chr5:33424025~33440619:-
BRCA	cis	rs6993270	0.779	rs6999724	ENSG00000245330.4	KB-1471A8.1	3.52	0.000443	0.0223	0.17	0.11	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr8:119908591	chr8:119867419~119874488:-
BRCA	cis	rs3770752	0.897	rs13015451	ENSG00000272054.1	RP11-423P10.2	-3.52	0.000443	0.0223	-0.1	-0.11	Schizophrenia;	chr2:37323942	chr2:37208875~37212677:+
BRCA	cis	rs91731	0.92	rs2967087	ENSG00000249572.1	CTD-2203K17.1	-3.52	0.000443	0.0223	-0.21	-0.11	Lung function (FVC);	chr5:33261145	chr5:33424025~33440619:-
BRCA	cis	rs8099594	0.565	rs4939849	ENSG00000266696.1	RP11-30L3.2	-3.52	0.000443	0.0223	-0.13	-0.11	Height;	chr18:49201252	chr18:49205912~49208781:+
BRCA	cis	rs7520050	0.933	rs6680211	ENSG00000281133.1	AL355480.3	3.52	0.000443	0.0223	0.12	0.11	Reticulocyte count;Red blood cell count;	chr1:45849335	chr1:45580892~45580996:-
BRCA	cis	rs3858526	0.839	rs10466484	ENSG00000224295.2	AC087380.14	3.52	0.000443	0.0223	0.15	0.11	DNA methylation (variation);	chr11:5922466	chr11:5518441~5524955:-
BRCA	cis	rs11673344	0.704	rs484001	ENSG00000267005.1	AC002984.2	3.52	0.000443	0.0223	0.13	0.11	Obesity-related traits;	chr19:36931320	chr19:36173406~36173853:-
BRCA	cis	rs8114671	0.562	rs4911163	ENSG00000261582.1	RP4-614O4.11	-3.52	0.000443	0.0223	-0.1	-0.11	Height;	chr20:34882891	chr20:35267885~35280043:-
BRCA	cis	rs875971	0.522	rs2949690	ENSG00000272831.1	RP11-792A8.4	-3.52	0.000443	0.0223	-0.1	-0.11	Aortic root size;	chr7:66018255	chr7:66739829~66740385:-
BRCA	cis	rs295490	0.831	rs3772871	ENSG00000178631.7	ACTG1P1	3.52	0.000443	0.0223	0.2	0.11	PR interval in Tripanosoma cruzi seropositivity;	chr3:139522774	chr3:139493809~139494937:+
BRCA	cis	rs7520050	0.902	rs4626927	ENSG00000281133.1	AL355480.3	3.52	0.000443	0.0223	0.13	0.11	Reticulocyte count;Red blood cell count;	chr1:45782973	chr1:45580892~45580996:-
BRCA	cis	rs72928364	1	rs17398421	ENSG00000244119.1	PDCL3P4	3.52	0.000443	0.0223	0.13	0.11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100954063	chr3:101712472~101713191:+
BRCA	cis	rs1790761	0.52	rs1551884	ENSG00000273819.1	ENPP7P7	-3.52	0.000443	0.0223	-0.14	-0.11	Mean corpuscular volume;	chr11:67632130	chr11:67812557~67873367:-
BRCA	cis	rs8054556	1	rs3814884	ENSG00000214725.6	CDIPT-AS1	-3.52	0.000443	0.0223	-0.13	-0.11	Autism spectrum disorder or schizophrenia;	chr16:29983415	chr16:29863593~29868053:+
BRCA	cis	rs687432	0.924	rs7121139	ENSG00000265566.2	RN7SL605P	-3.52	0.000443	0.0223	-0.16	-0.11	Parkinson's disease;	chr11:58015348	chr11:57528085~57528365:-
BRCA	cis	rs6840360	0.533	rs4696297	ENSG00000278978.1	RP11-164P12.5	3.52	0.000443	0.0223	0.12	0.11	Intelligence (multi-trait analysis);	chr4:151804686	chr4:151669786~151670503:+
BRCA	cis	rs2908197	0.788	rs6465111	ENSG00000205485.12	AC004980.7	3.52	0.000443	0.0223	0.12	0.11	3-hydroxypropylmercapturic acid levels in smokers;	chr7:76362061	chr7:76549360~76627982:+
BRCA	cis	rs495337	0.677	rs6012750	ENSG00000229222.1	KRT18P4	3.52	0.000443	0.0223	0.13	0.11	Psoriasis;	chr20:49814143	chr20:49956745~49958032:+
BRCA	cis	rs1987511	1	rs11253092	ENSG00000224034.1	RP11-445P17.8	-3.52	0.000443	0.0223	-0.14	-0.11	Intelligence;	chr10:5307132	chr10:5266033~5271236:-
BRCA	cis	rs2288327	0.818	rs3731751	ENSG00000271011.1	RP11-171I2.5	3.52	0.000443	0.0223	0.2	0.11	Atrial fibrillation;	chr2:178541158	chr2:178577103~178577622:+
BRCA	cis	rs253959	0.545	rs712600	ENSG00000272265.1	CTD-2287O16.4	-3.52	0.000443	0.0223	-0.12	-0.11	Bipolar disorder and schizophrenia;	chr5:116323198	chr5:116078110~116078570:-
BRCA	cis	rs6102185	0.572	rs6102201	ENSG00000229771.2	RP4-644L1.2	-3.52	0.000444	0.0223	-0.13	-0.11	IgG glycosylation;	chr20:40891166	chr20:40696499~40698616:-
BRCA	cis	rs7246657	0.943	rs2126977	ENSG00000267470.4	ZNF571-AS1	-3.52	0.000444	0.0223	-0.14	-0.11	Coronary artery calcification;	chr19:37504845	chr19:37548914~37587348:+
BRCA	cis	rs1730008	0.865	rs9811346	ENSG00000279311.1	RP11-170K4.2	-3.52	0.000444	0.0223	-0.12	-0.11	Lobe attachment (rater-scored or self-reported);	chr3:158162481	chr3:158869898~158871821:+
BRCA	cis	rs7267979	1	rs7018	ENSG00000274414.1	RP5-965G21.4	-3.52	0.000444	0.0223	-0.13	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25297625	chr20:25239007~25245229:-
BRCA	cis	rs6012564	0.963	rs6125551	ENSG00000227431.4	CSE1L-AS1	-3.52	0.000444	0.0223	-0.13	-0.11	Anger;	chr20:49103849	chr20:49040463~49046044:-
BRCA	cis	rs7618501	1	rs9872864	ENSG00000228008.1	CTD-2330K9.3	-3.52	0.000444	0.0223	-0.1	-0.11	Intelligence (multi-trait analysis);	chr3:49754590	chr3:49903845~49916937:+
BRCA	cis	rs6088590	1	rs11698977	ENSG00000276073.1	RP5-1125A11.7	-3.52	0.000444	0.0223	-0.13	-0.11	Coronary artery disease;	chr20:34861888	chr20:33985617~33988989:-
BRCA	cis	rs10129255	0.957	rs12590667	ENSG00000232216.1	IGHV3-43	-3.52	0.000444	0.0223	-0.08	-0.11	Kawasaki disease;	chr14:106779223	chr14:106470264~106470800:-
BRCA	cis	rs801193	0.935	rs3800820	ENSG00000275400.1	RP4-756H11.5	3.52	0.000444	0.0223	0.12	0.11	Aortic root size;	chr7:66682191	chr7:66553805~66554199:-
BRCA	cis	rs3753275	0.69	rs1463055	ENSG00000270282.1	RP5-1115A15.2	3.52	0.000444	0.0223	0.16	0.11	Educational attainment;	chr1:8561527	chr1:8512653~8513021:+
BRCA	cis	rs2243480	0.522	rs12698511	ENSG00000222364.1	RNU6-96P	-3.52	0.000444	0.0223	-0.24	-0.11	Diabetic kidney disease;	chr7:66009932	chr7:66395191~66395286:+
BRCA	cis	rs6751744	0.513	rs7563368	ENSG00000224152.1	AC009506.1	3.52	0.000444	0.0223	0.12	0.11	Dysphagia;	chr2:159600564	chr2:159615296~159617082:+
BRCA	cis	rs3743162	0.553	rs4842994	ENSG00000275120.1	RP11-182J1.17	-3.52	0.000444	0.0223	-0.15	-0.11	Alzheimer's disease (age of onset);	chr15:84872568	chr15:84599434~84606463:-
BRCA	cis	rs12096438	1	rs11806326	ENSG00000224183.1	SDHDP6	3.52	0.000444	0.0223	0.13	0.11	Platelet count;Mean platelet volume;	chr1:25572674	chr1:25294164~25294643:-
BRCA	cis	rs910316	0.726	rs175040	ENSG00000259138.1	RP11-950C14.7	-3.52	0.000444	0.0223	-0.11	-0.11	Height;	chr14:75002852	chr14:75127153~75136930:+
BRCA	cis	rs9733	0.526	rs6587542	ENSG00000224800.1	RP11-235D19.2	-3.52	0.000444	0.0223	-0.13	-0.11	Tonsillectomy;	chr1:150935225	chr1:150881236~150881683:-
BRCA	cis	rs6964587	1	rs7789492	ENSG00000188693.7	CYP51A1-AS1	-3.52	0.000444	0.0223	-0.12	-0.11	Breast cancer;	chr7:92039540	chr7:92134604~92180725:+
BRCA	cis	rs7208859	0.573	rs216443	ENSG00000214719.10	AC005562.1	-3.52	0.000444	0.0223	-0.21	-0.11	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30604853	chr17:30576464~30672789:+
BRCA	cis	rs7558911	0.51	rs3769825	ENSG00000230408.3	AC007163.6	-3.52	0.000444	0.0223	-0.11	-0.11	Chronic lymphocytic leukemia;	chr2:201246657	chr2:200780495~200812170:-
BRCA	cis	rs9303029	1	rs9898723	ENSG00000263321.1	RP11-388C12.5	-3.52	0.000444	0.0223	-0.15	-0.11	Protein quantitative trait loci;	chr17:82482031	chr17:82729164~82734143:-
BRCA	cis	rs58521262	0.546	rs1478458	ENSG00000268105.1	RP11-369G6.2	3.52	0.000444	0.0223	0.15	0.11	Testicular germ cell tumor;	chr19:22911499	chr19:23125665~23128543:+
BRCA	cis	rs13434995	0.513	rs13134079	ENSG00000273257.1	RP11-177J6.1	3.52	0.000444	0.0223	0.16	0.11	Adiponectin levels;	chr4:55542021	chr4:55387949~55388271:+
BRCA	cis	rs9527	0.637	rs7085104	ENSG00000213277.3	MARCKSL1P1	3.52	0.000444	0.0223	0.12	0.11	Arsenic metabolism;	chr10:102869116	chr10:103175554~103176094:+
BRCA	cis	rs7615952	0.576	rs1127717	ENSG00000248787.1	RP11-666A20.4	-3.52	0.000444	0.0223	-0.16	-0.11	Blood pressure (smoking interaction);	chr3:126107216	chr3:125908005~125910272:-
BRCA	cis	rs35740288	1	rs35740288	ENSG00000202081.1	RNU6-1280P	3.52	0.000444	0.0223	0.14	0.11	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85753854	chr15:85651522~85651628:-
BRCA	cis	rs35740288	1	rs17577449	ENSG00000202081.1	RNU6-1280P	3.52	0.000444	0.0223	0.14	0.11	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85753954	chr15:85651522~85651628:-
BRCA	cis	rs853679	0.567	rs7774981	ENSG00000220721.1	OR1F12	3.52	0.000444	0.0224	0.14	0.11	Depression;	chr6:28379133	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.567	rs7754960	ENSG00000220721.1	OR1F12	3.52	0.000444	0.0224	0.14	0.11	Depression;	chr6:28379168	chr6:28073316~28074233:+
BRCA	cis	rs41308713	0.681	rs8116426	ENSG00000224635.1	RP4-564F22.5	-3.52	0.000444	0.0224	-0.29	-0.11	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr20:38405996	chr20:38406011~38416797:-
BRCA	cis	rs41308713	0.786	rs8116471	ENSG00000224635.1	RP4-564F22.5	-3.52	0.000444	0.0224	-0.29	-0.11	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr20:38406047	chr20:38406011~38416797:-
BRCA	cis	rs75804782	0.641	rs72987304	ENSG00000186235.9	AC016757.3	3.52	0.000444	0.0224	0.24	0.11	Chronotype;Morning vs. evening chronotype;	chr2:238436891	chr2:238224552~238231677:-
BRCA	cis	rs6943931	1	rs9648282	ENSG00000230658.1	KLHL7-AS1	-3.52	0.000444	0.0224	-0.14	-0.11	Diabetic kidney disease;	chr7:22377344	chr7:23101228~23105703:-
BRCA	cis	rs3768617	0.727	rs12066735	ENSG00000224468.3	RP11-181K3.4	-3.52	0.000444	0.0224	-0.12	-0.11	Fuchs's corneal dystrophy;	chr1:183132316	chr1:183138402~183141282:-
BRCA	cis	rs561341	1	rs15654	ENSG00000277511.1	CTD-2095E4.5	3.52	0.000444	0.0224	0.16	0.11	Hip circumference adjusted for BMI;	chr17:31999341	chr17:32127595~32128454:+
BRCA	cis	rs561341	1	rs550923	ENSG00000277511.1	CTD-2095E4.5	3.52	0.000444	0.0224	0.16	0.11	Hip circumference adjusted for BMI;	chr17:31999994	chr17:32127595~32128454:+
BRCA	cis	rs7520050	0.966	rs10789475	ENSG00000281133.1	AL355480.3	3.52	0.000445	0.0224	0.12	0.11	Reticulocyte count;Red blood cell count;	chr1:45838505	chr1:45580892~45580996:-
BRCA	cis	rs12614435	0.512	rs16866420	ENSG00000270574.1	RP11-171I2.2	3.52	0.000445	0.0224	0.16	0.11	Atrial fibrillation;	chr2:178626508	chr2:178578790~178580906:+
BRCA	cis	rs459571	0.959	rs465535	ENSG00000235106.7	LINC00094	3.52	0.000445	0.0224	0.11	0.11	Platelet distribution width;	chr9:134045783	chr9:134025439~134034666:+
BRCA	cis	rs80226907	1	rs76997592	ENSG00000258413.1	RP11-665C16.6	-3.52	0.000445	0.0224	-0.28	-0.11	Mean platelet volume;	chr14:55372108	chr14:55262767~55272075:-
BRCA	cis	rs13108904	0.935	rs6853002	ENSG00000253399.1	AC078852.2	-3.52	0.000445	0.0224	-0.12	-0.11	Obesity-related traits;	chr4:1302203	chr4:1358479~1359461:+
BRCA	cis	rs10256972	0.721	rs4720249	ENSG00000199023.2	MIR339	-3.52	0.000445	0.0224	-0.14	-0.11	Endometriosis;Longevity;	chr7:1032927	chr7:1022935~1023045:-
BRCA	cis	rs2411233	0.934	rs1824492	ENSG00000259278.1	RP11-62C7.2	3.52	0.000445	0.0224	0.13	0.11	Platelet count;	chr15:38992312	chr15:39019233~39024918:+
BRCA	cis	rs4835473	0.897	rs17693768	ENSG00000246448.2	RP13-578N3.3	-3.52	0.000445	0.0224	-0.12	-0.11	Immature fraction of reticulocytes;	chr4:143737503	chr4:143700257~143865072:+
BRCA	cis	rs1119582	1	rs458314	ENSG00000279118.1	RP11-517I3.2	-3.52	0.000445	0.0224	-0.13	-0.11	Select biomarker traits;	chr5:125949388	chr5:126496279~126498604:+
BRCA	cis	rs8098244	0.894	rs9304391	ENSG00000265752.2	RP11-403A21.1	3.52	0.000445	0.0224	0.13	0.11	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23829811	chr18:23957754~23982556:-
BRCA	cis	rs9437689	0.934	rs10735790	ENSG00000235501.4	RP4-639F20.1	-3.52	0.000445	0.0224	-0.14	-0.11	Phospholipid levels (plasma);	chr1:95038121	chr1:94927566~94963270:+
BRCA	cis	rs7937890	1	rs7937890	ENSG00000254418.1	RP11-21L19.1	3.52	0.000445	0.0224	0.12	0.11	Mitochondrial DNA levels;	chr11:14374939	chr11:14262846~14273691:-
BRCA	cis	rs6585424	1	rs12769115	ENSG00000225484.5	NUTM2B-AS1	-3.52	0.000445	0.0224	-0.22	-0.11	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80173745	chr10:79663088~79826594:-
BRCA	cis	rs6088590	1	rs6087625	ENSG00000276073.1	RP5-1125A11.7	3.52	0.000445	0.0224	0.12	0.11	Coronary artery disease;	chr20:34754674	chr20:33985617~33988989:-
BRCA	cis	rs6545883	0.929	rs2264100	ENSG00000270820.4	RP11-355B11.2	3.52	0.000445	0.0224	0.13	0.11	Tuberculosis;	chr2:61443694	chr2:61471188~61484130:+
BRCA	cis	rs6484218	0.562	rs10840398	ENSG00000250041.2	CTD-2003C8.2	3.52	0.000445	0.0224	0.18	0.11	Schizophrenia, bipolar disorder and depression (combined);	chr11:10372613	chr11:10884885~10899322:-
BRCA	cis	rs848087	0.564	rs848112	ENSG00000200385.1	SNORA42	3.52	0.000445	0.0224	0.09	0.11	Breast cancer;	chr14:36784517	chr14:37720425~37720561:+
BRCA	cis	rs2235649	0.592	rs7197113	ENSG00000206630.1	SNORD60	-3.52	0.000445	0.0224	-0.14	-0.11	Blood metabolite levels;	chr16:1919482	chr16:2155023~2155105:-
BRCA	cis	rs9876781	0.53	rs11708617	ENSG00000199476.1	Y_RNA	-3.52	0.000445	0.0224	-0.15	-0.11	Longevity;	chr3:48354819	chr3:48288587~48288694:+
BRCA	cis	rs10792665	0.649	rs948182	ENSG00000254965.1	RP11-113K21.2	-3.52	0.000445	0.0224	-0.11	-0.11	Obesity-related traits;	chr11:83035189	chr11:83111060~83111442:-
BRCA	cis	rs875971	0.862	rs13226170	ENSG00000271064.1	RP11-792A8.3	-3.52	0.000445	0.0224	-0.13	-0.11	Aortic root size;	chr7:66534311	chr7:66748838~66749077:-
BRCA	cis	rs875971	0.862	rs2420611	ENSG00000271064.1	RP11-792A8.3	-3.52	0.000445	0.0224	-0.13	-0.11	Aortic root size;	chr7:66534333	chr7:66748838~66749077:-
BRCA	cis	rs718433	0.556	rs1569287	ENSG00000211778.2	TRAV4	-3.52	0.000445	0.0224	-0.08	-0.11	Intraocular pressure;	chr14:21747309	chr14:21736152~21736982:+
BRCA	cis	rs7818688	0.929	rs7812312	ENSG00000245080.5	RP11-320N21.1	-3.52	0.000445	0.0224	-0.18	-0.11	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95008172	chr8:95066808~95073182:-
BRCA	cis	rs324126	0.78	rs11084157	ENSG00000277977.1	CTD-3018O17.5	3.52	0.000445	0.0224	0.13	0.11	Colonoscopy-negative controls vs population controls;	chr19:52383652	chr19:52392659~52392755:+
BRCA	cis	rs324126	0.78	rs8104808	ENSG00000277977.1	CTD-3018O17.5	3.52	0.000445	0.0224	0.13	0.11	Colonoscopy-negative controls vs population controls;	chr19:52384174	chr19:52392659~52392755:+
BRCA	cis	rs324126	0.78	rs8104812	ENSG00000277977.1	CTD-3018O17.5	3.52	0.000445	0.0224	0.13	0.11	Colonoscopy-negative controls vs population controls;	chr19:52384184	chr19:52392659~52392755:+
BRCA	cis	rs10872587	0.657	rs11155459	ENSG00000235652.6	RP11-545I5.3	-3.52	0.000445	0.0224	-0.12	-0.11	Lobe attachment (rater-scored or self-reported);	chr6:146257615	chr6:145799409~145886585:+
BRCA	cis	rs7412746	0.634	rs2124952	ENSG00000224800.1	RP11-235D19.2	-3.52	0.000445	0.0224	-0.14	-0.11	Melanoma;	chr1:150951298	chr1:150881236~150881683:-
BRCA	cis	rs6142618	0.562	rs6061186	ENSG00000277692.1	RP11-358N2.2	-3.52	0.000445	0.0224	-0.12	-0.11	Inflammatory bowel disease;	chr20:32143937	chr20:32355053~32355734:+
BRCA	cis	rs4869313	0.721	rs193994	ENSG00000248734.2	CTD-2260A17.1	3.52	0.000445	0.0224	0.11	0.11	Pediatric autoimmune diseases;	chr5:96923019	chr5:96784777~96785999:+
BRCA	cis	rs7520050	0.931	rs6697557	ENSG00000281133.1	AL355480.3	3.52	0.000445	0.0224	0.12	0.11	Reticulocyte count;Red blood cell count;	chr1:45842137	chr1:45580892~45580996:-
BRCA	cis	rs848490	0.889	rs55689723	ENSG00000214293.7	APTR	3.52	0.000445	0.0224	0.13	0.11	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77616939	chr7:77657660~77696265:-
BRCA	cis	rs8030605	0.778	rs1579370	ENSG00000277245.1	RP11-48G14.3	-3.52	0.000445	0.0224	-0.23	-0.11	Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;	chr15:56292669	chr15:56447120~56447697:+
BRCA	cis	rs6964833	1	rs34324835	ENSG00000277072.3	STAG3L2	3.52	0.000445	0.0224	0.12	0.11	Menarche (age at onset);	chr7:74717986	chr7:74882163~74890610:-
BRCA	cis	rs4557020	0.836	rs4599153	ENSG00000162997.14	PRORSD1P	-3.52	0.000445	0.0224	-0.12	-0.11	Myopia (pathological);	chr2:54468800	chr2:55282319~55284522:+
BRCA	cis	rs78472555	0.661	rs2581474	ENSG00000259363.4	CTD-2054N24.2	-3.52	0.000445	0.0224	-0.15	-0.11	Post bronchodilator FEV1/FVC ratio in COPD;	chr15:99609573	chr15:99807023~99877148:+
BRCA	cis	rs6088580	0.601	rs6059872	ENSG00000269202.1	RP4-614O4.12	-3.52	0.000445	0.0224	-0.11	-0.11	Glomerular filtration rate (creatinine);	chr20:34494970	chr20:35201747~35203288:-
BRCA	cis	rs11931598	1	rs11931598	ENSG00000245748.1	RP11-367J11.2	3.52	0.000446	0.0224	0.11	0.11	Sum basophil neutrophil counts;Neutrophil count;Granulocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;	chr4:7045375	chr4:7030554~7046231:-
BRCA	cis	rs17192198	0.717	rs17192457	ENSG00000274021.1	RP11-823E8.3	-3.52	0.000446	0.0224	-0.16	-0.11	Diastolic blood pressure;	chr12:89933601	chr12:89351015~89353271:+
BRCA	cis	rs12501370	0.568	rs7656191	ENSG00000201736.1	RNA5SP160	3.52	0.000446	0.0224	0.14	0.11	Iris color (L* coordinate);	chr4:41121817	chr4:40990154~40990273:+
BRCA	cis	rs1823874	0.71	rs55947799	ENSG00000259363.4	CTD-2054N24.2	3.52	0.000446	0.0224	0.13	0.11	IgG glycosylation;	chr15:99820700	chr15:99807023~99877148:+
BRCA	cis	rs12317459	1	rs11115402	ENSG00000213270.5	RPL6P25	-3.52	0.000446	0.0224	-0.15	-0.11	Prostate cancer (SNP x SNP interaction);	chr12:82772695	chr12:83151331~83152190:+
BRCA	cis	rs16986856	0.964	rs2867235	ENSG00000269696.1	AC007228.11	3.52	0.000446	0.0224	0.13	0.11	Obesity-related traits;	chr19:55987256	chr19:56545566~56567411:-
BRCA	cis	rs2154319	0.887	rs2144788	ENSG00000230638.4	RP11-486B10.4	3.52	0.000446	0.0224	0.18	0.11	Height;	chr1:41066772	chr1:41542069~41544310:+
BRCA	cis	rs17767294	0.614	rs72850298	ENSG00000219392.1	RP1-265C24.5	-3.52	0.000446	0.0224	-0.3	-0.11	Parkinson's disease;	chr6:28254778	chr6:28115628~28116551:+
BRCA	cis	rs9467773	0.935	rs9461270	ENSG00000261353.1	CTA-14H9.5	-3.52	0.000446	0.0224	-0.11	-0.11	Intelligence (multi-trait analysis);	chr6:26543882	chr6:26527063~26527404:+
BRCA	cis	rs7959452	0.719	rs57954211	ENSG00000274979.1	RP11-1143G9.5	-3.52	0.000446	0.0224	-0.12	-0.11	Blood protein levels;	chr12:69354617	chr12:69326574~69331882:-
BRCA	cis	rs10986311	0.681	rs10818937	ENSG00000227200.1	RP11-121A14.3	-3.52	0.000446	0.0224	-0.14	-0.11	Vitiligo;	chr9:124253161	chr9:124262876~124265809:+
BRCA	cis	rs9467773	1	rs1884946	ENSG00000261353.1	CTA-14H9.5	-3.52	0.000446	0.0224	-0.11	-0.11	Intelligence (multi-trait analysis);	chr6:26545080	chr6:26527063~26527404:+
BRCA	cis	rs61931739	0.5	rs11053261	ENSG00000258794.3	DUX4L27	3.52	0.000446	0.0224	0.16	0.11	Morning vs. evening chronotype;	chr12:34377875	chr12:34208415~34209675:-
BRCA	cis	rs13401620	0.752	rs2166433	ENSG00000229326.3	AC069154.4	3.52	0.000446	0.0224	0.14	0.11	Breast size;	chr2:119983507	chr2:119698623~119700151:+
BRCA	cis	rs748404	0.666	rs16957715	ENSG00000201136.1	RNU6-353P	3.52	0.000446	0.0224	0.15	0.11	Lung cancer;	chr15:43416539	chr15:43702363~43702470:+
BRCA	cis	rs34792	0.554	rs2067063	ENSG00000275910.1	RP11-680G24.6	-3.52	0.000446	0.0224	-0.14	-0.11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15515106	chr16:15015828~15016390:-
BRCA	cis	rs6696239	0.911	rs10916166	ENSG00000215812.5	ZNF847P	3.52	0.000446	0.0224	0.15	0.11	Height;	chr1:227569367	chr1:227696892~227706699:-
BRCA	cis	rs6696239	0.955	rs10916167	ENSG00000215812.5	ZNF847P	3.52	0.000446	0.0224	0.15	0.11	Height;	chr1:227573431	chr1:227696892~227706699:-
BRCA	cis	rs748404	0.666	rs66629206	ENSG00000166763.7	STRCP1	3.52	0.000446	0.0224	0.16	0.11	Lung cancer;	chr15:43458804	chr15:43699488~43718184:-
BRCA	cis	rs8058578	1	rs8058578	ENSG00000280211.1	RP11-2C24.3	3.52	0.000446	0.0224	0.11	0.11	Multiple myeloma;	chr16:30714927	chr16:30773532~30776033:-
BRCA	cis	rs12681366	0.734	rs2046664	ENSG00000253175.1	RP11-267M23.6	3.52	0.000446	0.0224	0.12	0.11	Nonsyndromic cleft lip with cleft palate;	chr8:94375713	chr8:94565036~94565715:+
BRCA	cis	rs181553	0.532	rs2044550	ENSG00000266696.1	RP11-30L3.2	-3.52	0.000446	0.0224	-0.13	-0.11	Hip circumference adjusted for BMI;	chr18:49055730	chr18:49205912~49208781:+
BRCA	cis	rs17221829	0.673	rs11018676	ENSG00000280385.1	AP000648.5	-3.52	0.000447	0.0224	-0.12	-0.11	Anxiety in major depressive disorder;	chr11:89629560	chr11:90193614~90198120:+
BRCA	cis	rs1429524	0.813	rs6954645	ENSG00000243144.5	RP11-115N4.1	3.52	0.000447	0.0224	0.15	0.11	Ejection fraction in Tripanosoma cruzi seropositivity;	chr7:91297165	chr7:91311368~91515409:+
BRCA	cis	rs2952768	0.772	rs6748491	ENSG00000224137.1	AC079767.4	-3.52	0.000447	0.0224	-0.1	-0.11	Opioid sensitivity;	chr2:207626021	chr2:207662375~207667024:+
BRCA	cis	rs10129255	0.5	rs1024350	ENSG00000211964.3	IGHV3-48	-3.52	0.000447	0.0224	-0.07	-0.11	Kawasaki disease;	chr14:106685105	chr14:106537810~106538344:-
BRCA	cis	rs1039766	0.929	rs55843720	ENSG00000227791.3	AC007365.4	-3.52	0.000447	0.0224	-0.17	-0.11	Lung adenocarcinoma;Lung cancer;	chr2:65268436	chr2:64665607~64666064:+
BRCA	cis	rs67340775	0.541	rs200973	ENSG00000219392.1	RP1-265C24.5	-3.52	0.000447	0.0225	-0.18	-0.11	Lung cancer in ever smokers;	chr6:27890643	chr6:28115628~28116551:+
BRCA	cis	rs10208649	0.831	rs6545368	ENSG00000272156.1	RP11-477N3.1	3.52	0.000447	0.0225	0.17	0.11	Body mass index;	chr2:53813267	chr2:54082554~54085066:+
BRCA	cis	rs875971	0.929	rs12535036	ENSG00000271064.1	RP11-792A8.3	-3.52	0.000447	0.0225	-0.13	-0.11	Aortic root size;	chr7:66499076	chr7:66748838~66749077:-
BRCA	cis	rs875971	1	rs6970030	ENSG00000271064.1	RP11-792A8.3	-3.52	0.000447	0.0225	-0.13	-0.11	Aortic root size;	chr7:66503692	chr7:66748838~66749077:-
BRCA	cis	rs875971	0.928	rs6970357	ENSG00000271064.1	RP11-792A8.3	-3.52	0.000447	0.0225	-0.13	-0.11	Aortic root size;	chr7:66503891	chr7:66748838~66749077:-
BRCA	cis	rs9847710	1	rs4687697	ENSG00000242849.2	ALDOAP1	-3.52	0.000447	0.0225	-0.12	-0.11	Ulcerative colitis;	chr3:53056474	chr3:52193170~52194785:+
BRCA	cis	rs2692947	0.77	rs6719831	ENSG00000232931.4	LINC00342	3.52	0.000447	0.0225	0.11	0.11	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95836842	chr2:95807118~95816215:-
BRCA	cis	rs745109	0.882	rs17027270	ENSG00000273080.1	RP11-301O19.1	-3.52	0.000447	0.0225	-0.16	-0.11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86490746	chr2:86195590~86196049:+
BRCA	cis	rs4819052	0.851	rs875621	ENSG00000215447.6	BX322557.10	-3.52	0.000447	0.0225	-0.11	-0.11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45262380	chr21:45288052~45291738:+
BRCA	cis	rs7618915	1	rs3852064	ENSG00000239557.1	RP11-168J18.6	3.52	0.000447	0.0225	0.14	0.11	Bipolar disorder;	chr3:52315396	chr3:52373652~52374882:+
BRCA	cis	rs804280	0.509	rs12719915	ENSG00000154316.13	TDH	3.52	0.000447	0.0225	0.14	0.11	Myopia (pathological);	chr8:11928746	chr8:11339637~11368452:+
BRCA	cis	rs3735485	0.843	rs4724340	ENSG00000201772.1	SNORA5C	-3.52	0.000447	0.0225	-0.15	-0.11	White blood cell count;Sum basophil neutrophil counts;Neutrophil count;Granulocyte percentage of myeloid white cells;Monocyte percentage of white cells;Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Lymphocyte counts;	chr7:44995523	chr7:45104906~45105042:-
BRCA	cis	rs6736093	0.901	rs11675946	ENSG00000236307.2	EEF1E1P1	3.52	0.000447	0.0225	0.13	0.11	Coronary artery disease;	chr2:111985456	chr2:111887914~111888741:+
BRCA	cis	rs67478160	0.575	rs8014294	ENSG00000269910.1	RP11-73M18.10	3.52	0.000447	0.0225	0.1	0.11	Schizophrenia;	chr14:103856646	chr14:103694516~103695050:-
BRCA	cis	rs875971	0.658	rs432667	ENSG00000271064.1	RP11-792A8.3	-3.52	0.000447	0.0225	-0.13	-0.11	Aortic root size;	chr7:66049646	chr7:66748838~66749077:-
BRCA	cis	rs4763879	0.634	rs7974396	ENSG00000256582.1	RP11-75L1.1	-3.52	0.000447	0.0225	-0.11	-0.11	Type 1 diabetes;	chr12:9708101	chr12:9704077~9709350:+
BRCA	cis	rs4374383	0.884	rs4848933	ENSG00000243389.1	AC012442.5	-3.52	0.000447	0.0225	-0.14	-0.11	Hepatitis C induced liver fibrosis;	chr2:112004076	chr2:112589040~112614431:+
BRCA	cis	rs2554380	0.628	rs4843156	ENSG00000259570.1	RP11-671M22.4	3.52	0.000447	0.0225	0.14	0.11	Height;	chr15:83788593	chr15:84394512~84395514:+
BRCA	cis	rs6696239	0.956	rs6678802	ENSG00000215812.5	ZNF847P	3.52	0.000447	0.0225	0.15	0.11	Height;	chr1:227652030	chr1:227696892~227706699:-
BRCA	cis	rs6696239	0.911	rs10799437	ENSG00000215812.5	ZNF847P	3.52	0.000447	0.0225	0.15	0.11	Height;	chr1:227652145	chr1:227696892~227706699:-
BRCA	cis	rs10504130	1	rs16916865	ENSG00000272076.1	RP11-11C20.3	3.52	0.000447	0.0225	0.18	0.11	Venous thromboembolism (SNP x SNP interaction);	chr8:51833290	chr8:51810110~51810681:-
BRCA	cis	rs7520050	0.933	rs4504835	ENSG00000226957.1	RP4-533D7.4	3.52	0.000447	0.0225	0.12	0.11	Reticulocyte count;Red blood cell count;	chr1:45989899	chr1:46046818~46048368:+
BRCA	cis	rs9921338	0.887	rs6498183	ENSG00000263080.1	RP11-485G7.5	3.52	0.000447	0.0225	0.17	0.11	Vein graft stenosis in coronary artery bypass grafting;	chr16:11337051	chr16:11341809~11345211:-
BRCA	cis	rs806321	0.548	rs1269268	ENSG00000237152.3	DLEU7-AS1	3.52	0.000447	0.0225	0.14	0.11	Multiple sclerosis;	chr13:50333154	chr13:50807856~50849905:+
BRCA	cis	rs10005067	0.967	rs28630038	ENSG00000249001.4	RP11-742B18.1	-3.52	0.000447	0.0225	-0.13	-0.11	Total body bone mineral density (age 30-45);	chr4:87905343	chr4:87568035~87733956:-
BRCA	cis	rs6813195	0.554	rs10031972	ENSG00000245954.5	RP11-18H21.1	3.52	0.000447	0.0225	0.09	0.11	Type 2 diabetes;	chr4:152450612	chr4:152100754~152104720:+
BRCA	cis	rs12438356	0.881	rs883767	ENSG00000259222.2	RP11-809H16.5	-3.52	0.000448	0.0225	-0.18	-0.11	CTACK levels;	chr15:69280424	chr15:69080879~69099987:+
BRCA	cis	rs73198271	0.653	rs3827811	ENSG00000233609.3	RP11-62H7.2	-3.52	0.000448	0.0225	-0.11	-0.11	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8801528	chr8:8961200~8979025:+
BRCA	cis	rs6545883	0.894	rs12997538	ENSG00000273302.1	RP11-493E12.2	-3.52	0.000448	0.0225	-0.1	-0.11	Tuberculosis;	chr2:61337114	chr2:61199979~61200769:+
BRCA	cis	rs3764563	1	rs8107240	ENSG00000267594.5	CYP4F24P	-3.52	0.000448	0.0225	-0.2	-0.11	Inflammatory biomarkers;	chr19:15626582	chr19:15760241~15779909:-
BRCA	cis	rs3764563	0.66	rs8107923	ENSG00000267594.5	CYP4F24P	-3.52	0.000448	0.0225	-0.2	-0.11	Inflammatory biomarkers;	chr19:15627089	chr19:15760241~15779909:-
BRCA	cis	rs10744816	0.846	rs10850304	ENSG00000257817.1	RP4-601P9.2	-3.52	0.000448	0.0225	-0.14	-0.11	Obesity-related traits;	chr12:114282948	chr12:114713811~114767957:+
BRCA	cis	rs944990	0.793	rs10821159	ENSG00000227603.1	RP11-165J3.6	3.52	0.000448	0.0225	0.13	0.11	Body mass index;	chr9:93552115	chr9:93435332~93437121:-
BRCA	cis	rs713477	0.654	rs7143800	ENSG00000186615.9	KTN1-AS1	-3.52	0.000448	0.0225	-0.12	-0.11	Pediatric bone mineral content (femoral neck);	chr14:55451016	chr14:55499278~55580110:-
BRCA	cis	rs11048434	0.518	rs34651717	ENSG00000111788.10	RP11-22B23.1	3.52	0.000448	0.0225	0.1	0.11	Sjögren's syndrome;	chr12:9025154	chr12:9277235~9313241:+
BRCA	cis	rs11048434	0.518	rs35176717	ENSG00000111788.10	RP11-22B23.1	3.52	0.000448	0.0225	0.1	0.11	Sjögren's syndrome;	chr12:9025170	chr12:9277235~9313241:+
BRCA	cis	rs11048434	0.518	rs34533518	ENSG00000111788.10	RP11-22B23.1	3.52	0.000448	0.0225	0.1	0.11	Sjögren's syndrome;	chr12:9025302	chr12:9277235~9313241:+
BRCA	cis	rs4374383	0.884	rs1131244	ENSG00000243389.1	AC012442.5	-3.52	0.000448	0.0225	-0.14	-0.11	Hepatitis C induced liver fibrosis;	chr2:112008396	chr2:112589040~112614431:+
BRCA	cis	rs4374383	0.884	rs10210692	ENSG00000243389.1	AC012442.5	-3.52	0.000448	0.0225	-0.14	-0.11	Hepatitis C induced liver fibrosis;	chr2:112008685	chr2:112589040~112614431:+
BRCA	cis	rs465969	0.744	rs6939657	ENSG00000271789.1	RP5-1112D6.7	3.52	0.000448	0.0225	0.23	0.11	Psoriasis;	chr6:111521822	chr6:111297126~111298510:+
BRCA	cis	rs9400467	1	rs9400467	ENSG00000231889.6	TRAF3IP2-AS1	-3.52	0.000448	0.0225	-0.12	-0.11	Amino acid levels;Blood metabolite levels;	chr6:111102812	chr6:111483511~111598302:+
BRCA	cis	rs10501293	0.917	rs9645617	ENSG00000252652.1	Y_RNA	3.52	0.000448	0.0225	0.13	0.11	Cognitive performance;	chr11:43084070	chr11:43331261~43331356:+
BRCA	cis	rs8058578	1	rs8051050	ENSG00000274678.1	RP11-2C24.7	3.52	0.000448	0.0225	0.13	0.11	Multiple myeloma;	chr16:30676588	chr16:30821338~30821884:+
BRCA	cis	rs10501293	1	rs4755695	ENSG00000252652.1	Y_RNA	3.52	0.000448	0.0225	0.13	0.11	Cognitive performance;	chr11:43086794	chr11:43331261~43331356:+
BRCA	cis	rs11180559	0.534	rs1542570	ENSG00000257497.2	RP11-585P4.5	3.52	0.000448	0.0225	0.2	0.11	Daytime sleep phenotypes;	chr12:75604823	chr12:75483454~75489820:-
BRCA	cis	rs13434995	0.513	rs12509047	ENSG00000249700.7	SRD5A3-AS1	3.52	0.000448	0.0225	0.16	0.11	Adiponectin levels;	chr4:55545245	chr4:55363971~55395847:-
BRCA	cis	rs7735319	0.565	rs6864361	ENSG00000249572.1	CTD-2203K17.1	3.52	0.000448	0.0225	0.14	0.11	Systolic blood pressure;	chr5:33116096	chr5:33424025~33440619:-
BRCA	cis	rs7824557	0.806	rs6601574	ENSG00000255046.1	RP11-297N6.4	3.52	0.000448	0.0225	0.13	0.11	Retinal vascular caliber;	chr8:11237376	chr8:11797928~11802568:-
BRCA	cis	rs9527	0.59	rs12355120	ENSG00000269609.4	RPARP-AS1	-3.52	0.000448	0.0225	-0.1	-0.11	Arsenic metabolism;	chr10:103092409	chr10:102449817~102461106:+
BRCA	cis	rs4557020	0.901	rs4671937	ENSG00000203327.2	AC012358.7	-3.52	0.000448	0.0225	-0.11	-0.11	Myopia (pathological);	chr2:54465678	chr2:55214387~55216126:-
BRCA	cis	rs4243971	0.516	rs6141662	ENSG00000277692.1	RP11-358N2.2	-3.52	0.000448	0.0225	-0.12	-0.11	Inflammatory bowel disease;Crohn's disease;	chr20:32294357	chr20:32355053~32355734:+
BRCA	cis	rs16852403	0.619	rs10913509	ENSG00000224687.1	RASAL2-AS1	3.52	0.000448	0.0225	0.14	0.11	Childhood ear infection;	chr1:178153649	chr1:178091508~178093984:-
BRCA	cis	rs10838634	1	rs60940896	ENSG00000280615.1	Y_RNA	-3.52	0.000448	0.0225	-0.18	-0.11	Schizophrenia;	chr11:46849042	chr11:47614898~47614994:-
BRCA	cis	rs10838634	1	rs61898463	ENSG00000280615.1	Y_RNA	-3.52	0.000448	0.0225	-0.18	-0.11	Schizophrenia;	chr11:46851855	chr11:47614898~47614994:-
BRCA	cis	rs10838634	1	rs7938960	ENSG00000280615.1	Y_RNA	-3.52	0.000448	0.0225	-0.18	-0.11	Schizophrenia;	chr11:46855531	chr11:47614898~47614994:-
BRCA	cis	rs9921338	0.886	rs4780363	ENSG00000263080.1	RP11-485G7.5	-3.52	0.000448	0.0225	-0.16	-0.11	Vein graft stenosis in coronary artery bypass grafting;	chr16:11322034	chr16:11341809~11345211:-
BRCA	cis	rs943466	0.955	rs11757524	ENSG00000223837.2	BRD2-IT1	3.52	0.000448	0.0225	0.14	0.11	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;	chr6:33798435	chr6:32970232~32970886:+
BRCA	cis	rs1670533	0.932	rs13140341	ENSG00000251639.2	RP11-20I20.1	3.52	0.000448	0.0225	0.17	0.11	Recombination rate (females);	chr4:1060447	chr4:1100016~1101558:-
BRCA	cis	rs7737355	0.685	rs6872533	ENSG00000224431.1	AC063976.7	-3.52	0.000448	0.0225	-0.18	-0.11	Life satisfaction;	chr5:131315518	chr5:132199456~132203487:+
BRCA	cis	rs6601530	0.564	rs733395	ENSG00000248896.2	CTD-2135J3.3	3.52	0.000448	0.0225	0.13	0.11	Carotid intima media thickness;	chr8:10764450	chr8:10729314~10771392:+
BRCA	cis	rs728616	0.558	rs34268041	ENSG00000225484.5	NUTM2B-AS1	-3.52	0.000448	0.0225	-0.22	-0.11	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80388883	chr10:79663088~79826594:-
BRCA	cis	rs6964587	1	rs7802788	ENSG00000188693.7	CYP51A1-AS1	-3.52	0.000448	0.0225	-0.12	-0.11	Breast cancer;	chr7:92107560	chr7:92134604~92180725:+
BRCA	cis	rs10043228	0.826	rs9326989	ENSG00000271918.1	CTD-2287O16.5	-3.52	0.000448	0.0225	-0.14	-0.11	Asthma or chronic obstructive pulmonary disease;	chr5:116137594	chr5:116083807~116085416:-
BRCA	cis	rs10043228	0.826	rs9326990	ENSG00000271918.1	CTD-2287O16.5	-3.52	0.000448	0.0225	-0.14	-0.11	Asthma or chronic obstructive pulmonary disease;	chr5:116138797	chr5:116083807~116085416:-
BRCA	cis	rs7020830	0.825	rs66684257	ENSG00000230188.1	RP11-405L18.4	-3.52	0.000448	0.0225	-0.13	-0.11	Schizophrenia;	chr9:37199090	chr9:37490421~37490893:-
BRCA	cis	rs11897432	0.592	rs6743581	ENSG00000279873.2	LINC01126	3.52	0.000448	0.0225	0.11	0.11	DNA methylation (variation);	chr2:43389671	chr2:43227210~43228855:+
BRCA	cis	rs2562456	0.874	rs2562417	ENSG00000268119.4	CTD-2561J22.5	-3.52	0.000449	0.0225	-0.17	-0.11	Pain;	chr19:21528400	chr19:21444241~21463908:-
BRCA	cis	rs11098499	0.569	rs10023641	ENSG00000249244.1	RP11-548H18.2	3.52	0.000449	0.0225	0.12	0.11	Corneal astigmatism;	chr4:119337255	chr4:119391831~119395335:-
BRCA	cis	rs72819225	0.616	rs7477129	ENSG00000228701.1	TNKS2-AS1	3.52	0.000449	0.0225	0.14	0.11	Yeast infection;	chr10:91565229	chr10:91782839~91798291:-
BRCA	cis	rs875971	0.964	rs778721	ENSG00000271064.1	RP11-792A8.3	-3.52	0.000449	0.0225	-0.13	-0.11	Aortic root size;	chr7:66380410	chr7:66748838~66749077:-
BRCA	cis	rs10419113	0.641	rs12611312	ENSG00000268379.1	CTC-360J11.4	-3.52	0.000449	0.0225	-0.13	-0.11	Pediatric bone mineral density (spine);	chr19:57764436	chr19:57175233~57177921:+
BRCA	cis	rs8114671	0.562	rs6087641	ENSG00000261582.1	RP4-614O4.11	-3.52	0.000449	0.0225	-0.1	-0.11	Height;	chr20:34879914	chr20:35267885~35280043:-
BRCA	cis	rs74233809	1	rs35125602	ENSG00000236937.2	PTGES3P4	3.52	0.000449	0.0225	0.23	0.11	Birth weight;	chr10:102896282	chr10:102845595~102845950:+
BRCA	cis	rs11098499	0.78	rs7680914	ENSG00000260091.1	RP11-33B1.4	-3.52	0.000449	0.0225	-0.1	-0.11	Corneal astigmatism;	chr4:119641898	chr4:119409333~119410233:+
BRCA	cis	rs894734	0.567	rs7138907	ENSG00000228630.4	HOTAIR	-3.52	0.000449	0.0225	-0.13	-0.11	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs);	chr12:53930792	chr12:53962308~53974956:-
BRCA	cis	rs10761482	0.861	rs10733763	ENSG00000254271.1	RP11-131N11.4	3.52	0.000449	0.0225	0.15	0.11	Schizophrenia;	chr10:60349522	chr10:60734342~60741828:+
BRCA	cis	rs7020830	0.825	rs10973248	ENSG00000260100.1	RP11-220I1.5	-3.52	0.000449	0.0225	-0.13	-0.11	Schizophrenia;	chr9:37197771	chr9:37078813~37079776:-
BRCA	cis	rs7833790	0.654	rs7835342	ENSG00000254689.1	RP11-354A14.1	3.52	0.000449	0.0225	0.13	0.11	Diastolic blood pressure;	chr8:81785857	chr8:81885377~81923193:+
BRCA	cis	rs1383484	0.545	rs9329363	ENSG00000259728.4	LINC00933	-3.52	0.000449	0.0225	-0.13	-0.11	Height;	chr15:83974382	chr15:84570649~84580175:+
BRCA	cis	rs17014483	0.749	rs2924348	ENSG00000248019.2	FAM13A-AS1	-3.52	0.000449	0.0225	-0.14	-0.11	Post bronchodilator FEV1/FVC ratio;	chr4:88711759	chr4:88709789~88730103:+
BRCA	cis	rs11877825	1	rs11877825	ENSG00000265728.1	RP11-883A18.3	-3.52	0.000449	0.0225	-0.15	-0.11	Gut microbiota (bacterial taxa);	chr18:10566407	chr18:10594590~10604798:+
BRCA	cis	rs11877825	1	rs11877777	ENSG00000265728.1	RP11-883A18.3	-3.52	0.000449	0.0225	-0.15	-0.11	Gut microbiota (bacterial taxa);	chr18:10566408	chr18:10594590~10604798:+
BRCA	cis	rs6840360	0.541	rs4696251	ENSG00000278978.1	RP11-164P12.5	-3.52	0.000449	0.0225	-0.12	-0.11	Intelligence (multi-trait analysis);	chr4:151345174	chr4:151669786~151670503:+
BRCA	cis	rs16957304	1	rs16957304	ENSG00000280163.1	CTC-277H1.6	3.52	0.000449	0.0226	0.2	0.11	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);	chr16:67301066	chr16:67205175~67206849:-
BRCA	cis	rs17092148	0.887	rs6120684	ENSG00000202150.1	RNU6-407P	3.52	0.000449	0.0226	0.16	0.11	Neuroticism;	chr20:34591984	chr20:35030317~35030420:-
BRCA	cis	rs10129255	0.518	rs10150460	ENSG00000211976.2	IGHV3-73	3.52	0.000449	0.0226	0.08	0.11	Kawasaki disease;	chr14:106677179	chr14:106802694~106803233:-
BRCA	cis	rs748404	0.666	rs8027748	ENSG00000166763.7	STRCP1	3.52	0.000449	0.0226	0.16	0.11	Lung cancer;	chr15:43447622	chr15:43699488~43718184:-
BRCA	cis	rs1861628	0.512	rs6435953	ENSG00000229352.1	AC007563.3	3.52	0.000449	0.0226	0.17	0.11	Serum thyroid-stimulating hormone levels;Hypothyroidism;	chr2:216763364	chr2:216799608~216805335:+
BRCA	cis	rs28489187	0.617	rs233112	ENSG00000223653.4	RP11-131L23.1	-3.52	0.000449	0.0226	-0.12	-0.11	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85320068	chr1:85276715~85448124:+
BRCA	cis	rs2562456	0.682	rs11085464	ENSG00000268555.1	RP11-678G14.3	3.52	0.000449	0.0226	0.14	0.11	Pain;	chr19:21568976	chr19:21570822~21587322:-
BRCA	cis	rs28489187	0.73	rs233130	ENSG00000223653.4	RP11-131L23.1	3.52	0.000449	0.0226	0.12	0.11	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85329429	chr1:85276715~85448124:+
BRCA	cis	rs13160562	0.666	rs26481	ENSG00000248734.2	CTD-2260A17.1	3.52	0.000449	0.0226	0.12	0.11	Alcohol dependence;	chr5:96767648	chr5:96784777~96785999:+
BRCA	cis	rs6121246	0.954	rs73241710	ENSG00000230613.1	HM13-AS1	3.52	0.000449	0.0226	0.16	0.11	Mean corpuscular hemoglobin;	chr20:31837153	chr20:31567707~31573263:-
BRCA	cis	rs17680741	0.697	rs11185829	ENSG00000225484.5	NUTM2B-AS1	-3.52	0.000449	0.0226	-0.18	-0.11	Coronary artery disease;	chr10:80508094	chr10:79663088~79826594:-
BRCA	cis	rs11170468	0.621	rs7131887	ENSG00000257718.1	RP11-396F22.1	-3.52	0.000449	0.0226	-0.14	-0.11	Body mass index;	chr12:39112959	chr12:38906451~38909592:+
BRCA	cis	rs11955398	0.502	rs295559	ENSG00000272308.1	RP11-231G3.1	3.52	0.000449	0.0226	0.12	0.11	Intelligence (multi-trait analysis);	chr5:61105395	chr5:60866457~60866935:-
BRCA	cis	rs1133146	1	rs12971799	ENSG00000269001.1	ZNF818P	-3.52	0.000449	0.0226	-0.12	-0.11	Yu-Zhi constitution type in type 2 diabetes;	chr19:53163873	chr19:53212988~53213396:+
BRCA	cis	rs970548	0.69	rs10900222	ENSG00000237840.5	FAM21FP	3.52	0.000449	0.0226	0.13	0.11	Total cholesterol levels;HDL cholesterol;HDL cholesterol levels;Cholesterol, total;	chr10:45501918	chr10:45706431~45727231:-
BRCA	cis	rs13434995	0.513	rs62303711	ENSG00000249700.7	SRD5A3-AS1	-3.52	0.000449	0.0226	-0.16	-0.11	Adiponectin levels;	chr4:55458325	chr4:55363971~55395847:-
BRCA	cis	rs7943953	1	rs3862658	ENSG00000254717.2	GLYATL1P2	-3.52	0.000449	0.0226	-0.14	-0.11	Odorant perception (&beta-ionone);	chr11:59451053	chr11:58878302~58893460:+
BRCA	cis	rs9650657	0.623	rs11250066	ENSG00000248896.2	CTD-2135J3.3	-3.52	0.000449	0.0226	-0.13	-0.11	Neuroticism;	chr8:10742957	chr8:10729314~10771392:+
BRCA	cis	rs2832191	0.791	rs2832198	ENSG00000232855.5	AF131217.1	-3.52	0.000449	0.0226	-0.13	-0.11	Dental caries;	chr21:29125919	chr21:28439346~28674848:-
BRCA	cis	rs4819052	0.851	rs35560973	ENSG00000215447.6	BX322557.10	-3.52	0.000449	0.0226	-0.11	-0.11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45242658	chr21:45288052~45291738:+
BRCA	cis	rs7487075	0.558	rs7959095	ENSG00000274723.1	RP11-618L22.1	3.52	0.000449	0.0226	0.13	0.11	Itch intensity from mosquito bite;	chr12:46239545	chr12:46970504~46972155:+
BRCA	cis	rs10864907	0.754	rs3917356	ENSG00000231747.1	AC079922.2	3.52	0.000449	0.0226	0.1	0.11	Pulmonary function;	chr2:112834786	chr2:112621809~112622167:-
BRCA	cis	rs1670533	1	rs28562028	ENSG00000251639.2	RP11-20I20.1	3.52	0.000449	0.0226	0.17	0.11	Recombination rate (females);	chr4:1061327	chr4:1100016~1101558:-
BRCA	cis	rs5758511	0.773	rs7288749	ENSG00000226450.2	CYP2D8P	3.52	0.000449	0.0226	0.12	0.11	Birth weight;	chr22:41960426	chr22:42149886~42155001:-
BRCA	cis	rs75504410	0.579	rs191414	ENSG00000231160.8	KLF3-AS1	-3.52	0.000449	0.0226	-0.15	-0.11	Sum eosinophil basophil counts;Eosinophil counts;	chr4:38631676	chr4:38612701~38664883:-
BRCA	cis	rs757978	0.929	rs111943976	ENSG00000223374.1	AC005104.3	3.52	0.00045	0.0226	0.14	0.11	Chronic lymphocytic leukemia;	chr2:241439490	chr2:241351340~241353104:-
BRCA	cis	rs853679	0.567	rs3799499	ENSG00000220721.1	OR1F12	3.52	0.00045	0.0226	0.14	0.11	Depression;	chr6:28386473	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.567	rs2232427	ENSG00000220721.1	OR1F12	3.52	0.00045	0.0226	0.14	0.11	Depression;	chr6:28391932	chr6:28073316~28074233:+
BRCA	cis	rs4462272	0.557	rs11591741	ENSG00000230224.1	PHBP9	-3.52	0.00045	0.0226	-0.1	-0.11	Age-related hearing impairment (SNP x SNP interaction);	chr10:100216744	chr10:100248271~100249095:+
BRCA	cis	rs875971	0.895	rs12698520	ENSG00000271064.1	RP11-792A8.3	-3.52	0.00045	0.0226	-0.13	-0.11	Aortic root size;	chr7:66453720	chr7:66748838~66749077:-
BRCA	cis	rs78487399	0.808	rs13409687	ENSG00000234936.1	AC010883.5	3.52	0.00045	0.0226	0.16	0.11	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43474012	chr2:43229573~43233394:+
BRCA	cis	rs78487399	0.71	rs7561114	ENSG00000234936.1	AC010883.5	3.52	0.00045	0.0226	0.16	0.11	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43474812	chr2:43229573~43233394:+
BRCA	cis	rs78487399	0.71	rs7590220	ENSG00000234936.1	AC010883.5	3.52	0.00045	0.0226	0.16	0.11	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43475012	chr2:43229573~43233394:+
BRCA	cis	rs78487399	0.808	rs6731980	ENSG00000234936.1	AC010883.5	3.52	0.00045	0.0226	0.16	0.11	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43476044	chr2:43229573~43233394:+
BRCA	cis	rs71520386	0.898	rs12536091	ENSG00000226329.2	AC005682.6	-3.52	0.00045	0.0226	-0.13	-0.11	Fibrinogen levels;	chr7:22788581	chr7:22863874~22881350:-
BRCA	cis	rs2076295	0.503	rs1358903	ENSG00000261189.1	RP3-512B11.3	-3.52	0.00045	0.0226	-0.13	-0.11	Idiopathic pulmonary fibrosis;Interstitial lung disease;Chronic obstructive pulmonary disease;	chr6:7563906	chr6:7540451~7541338:-
BRCA	cis	rs13434995	0.513	rs1048004	ENSG00000273257.1	RP11-177J6.1	-3.52	0.00045	0.0226	-0.16	-0.11	Adiponectin levels;	chr4:55434042	chr4:55387949~55388271:+
BRCA	cis	rs889312	0.5	rs1867731	ENSG00000237705.1	AC008937.2	3.52	0.00045	0.0226	0.11	0.11	Breast cancer (early onset);Breast cancer;	chr5:56836288	chr5:56842016~56862164:-
BRCA	cis	rs1667255	1	rs1667244	ENSG00000266521.1	RP11-650P15.1	-3.52	0.00045	0.0226	-0.13	-0.11	Retinol levels;	chr18:31587942	chr18:31496645~31497195:-
BRCA	cis	rs2512987	1	rs2433420	ENSG00000254731.1	CTD-2005H7.1	-3.52	0.00045	0.0226	-0.12	-0.11	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr11:86703319	chr11:86703099~86714092:+
BRCA	cis	rs6067053	0.533	rs6067019	ENSG00000227431.4	CSE1L-AS1	3.52	0.00045	0.0226	0.13	0.11	Intelligence (multi-trait analysis);	chr20:49211989	chr20:49040463~49046044:-
BRCA	cis	rs7020830	0.861	rs6476622	ENSG00000230188.1	RP11-405L18.4	-3.52	0.00045	0.0226	-0.13	-0.11	Schizophrenia;	chr9:37308052	chr9:37490421~37490893:-
BRCA	cis	rs1876905	0.68	rs434034	ENSG00000255389.1	C6orf3	3.52	0.00045	0.0226	0.14	0.11	Mean corpuscular hemoglobin;	chr6:111204180	chr6:111599875~111602295:+
BRCA	cis	rs9921338	0.924	rs7204628	ENSG00000263080.1	RP11-485G7.5	3.52	0.00045	0.0226	0.16	0.11	Vein graft stenosis in coronary artery bypass grafting;	chr16:11350715	chr16:11341809~11345211:-
BRCA	cis	rs846271	1	rs846271	ENSG00000224116.5	INHBA-AS1	3.52	0.00045	0.0226	0.13	0.11	IgG glycosylation;	chr7:41997238	chr7:41693916~41779388:+
BRCA	cis	rs2625529	0.73	rs35713471	ENSG00000260037.4	CTD-2524L6.3	-3.52	0.00045	0.0226	-0.15	-0.11	Red blood cell count;	chr15:72167630	chr15:71818396~71823384:+
BRCA	cis	rs890448	0.796	rs6852377	ENSG00000254531.1	FLJ20021	3.52	0.00045	0.0226	0.13	0.11	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101365552	chr4:101347780~101348883:+
BRCA	cis	rs7520050	0.898	rs34175029	ENSG00000226957.1	RP4-533D7.4	3.52	0.00045	0.0226	0.12	0.11	Reticulocyte count;Red blood cell count;	chr1:46018199	chr1:46046818~46048368:+
BRCA	cis	rs9926296	0.715	rs467035	ENSG00000261373.1	VPS9D1-AS1	-3.52	0.00045	0.0226	-0.13	-0.11	Vitiligo;	chr16:89673877	chr16:89711856~89718165:+
BRCA	cis	rs7208859	0.673	rs3816780	ENSG00000250462.7	LRRC37BP1	-3.52	0.00045	0.0226	-0.2	-0.11	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30834340	chr17:30629680~30637466:+
BRCA	cis	rs2243480	0.901	rs3813708	ENSG00000226767.1	RP11-328P23.3	-3.52	0.00045	0.0226	-0.19	-0.11	Diabetic kidney disease;	chr7:65840645	chr7:65508773~65508944:-
BRCA	cis	rs1411478	0.84	rs11586493	ENSG00000243155.1	RP11-46A10.5	3.52	0.00045	0.0226	0.12	0.11	Menopause (age at onset);Progressive supranuclear palsy;	chr1:180992109	chr1:180944042~180976482:-
BRCA	cis	rs4835473	0.868	rs971391	ENSG00000246448.2	RP13-578N3.3	-3.52	0.00045	0.0226	-0.12	-0.11	Immature fraction of reticulocytes;	chr4:143751324	chr4:143700257~143865072:+
BRCA	cis	rs1670533	1	rs6858612	ENSG00000251639.2	RP11-20I20.1	3.52	0.00045	0.0226	0.17	0.11	Recombination rate (females);	chr4:1059565	chr4:1100016~1101558:-
BRCA	cis	rs4934494	0.822	rs3962370	ENSG00000235100.3	RP11-80H5.9	-3.52	0.00045	0.0226	-0.14	-0.11	Red blood cell count;	chr10:89777763	chr10:89667181~89699671:-
BRCA	cis	rs7103648	1	rs7947450	ENSG00000280615.1	Y_RNA	3.52	0.00045	0.0226	0.13	0.11	Systolic blood pressure;Diastolic blood pressure;	chr11:47408353	chr11:47614898~47614994:-
BRCA	cis	rs2411233	0.967	rs2164010	ENSG00000259278.1	RP11-62C7.2	-3.52	0.00045	0.0226	-0.13	-0.11	Platelet count;	chr15:38995251	chr15:39019233~39024918:+
BRCA	cis	rs863345	0.584	rs6672789	ENSG00000176320.2	RP11-404O13.5	-3.52	0.00045	0.0226	-0.11	-0.11	Pneumococcal bacteremia;	chr1:158527349	chr1:158197922~158203877:-
BRCA	cis	rs3760982	1	rs10405457	ENSG00000267191.1	RP11-15A1.2	-3.52	0.00045	0.0226	-0.14	-0.11	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43792430	chr19:43902001~43926545:+
BRCA	cis	rs863345	0.604	rs6699473	ENSG00000176320.2	RP11-404O13.5	-3.52	0.00045	0.0226	-0.11	-0.11	Pneumococcal bacteremia;	chr1:158525419	chr1:158197922~158203877:-
BRCA	cis	rs61931739	0.5	rs11053222	ENSG00000258794.3	DUX4L27	3.52	0.00045	0.0226	0.16	0.11	Morning vs. evening chronotype;	chr12:34328165	chr12:34208415~34209675:-
BRCA	cis	rs61931739	0.5	rs11053223	ENSG00000258794.3	DUX4L27	3.52	0.00045	0.0226	0.16	0.11	Morning vs. evening chronotype;	chr12:34329012	chr12:34208415~34209675:-
BRCA	cis	rs1008375	0.932	rs10009933	ENSG00000249502.1	AC006160.5	-3.52	0.000451	0.0226	-0.13	-0.11	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17668484	chr4:17587467~17614571:-
BRCA	cis	rs1889642	0.585	rs7324675	ENSG00000227354.5	RBM26-AS1	3.52	0.000451	0.0226	0.12	0.11	Colonoscopy-negative controls vs population controls;	chr13:79767810	chr13:79406309~79424328:+
BRCA	cis	rs417065	0.516	rs6661746	ENSG00000238290.1	RP11-431K24.1	-3.52	0.000451	0.0226	-0.14	-0.11	Psoriasis;	chr1:8208560	chr1:8026738~8122702:+
BRCA	cis	rs9467773	1	rs9467779	ENSG00000224843.5	LINC00240	3.52	0.000451	0.0226	0.12	0.11	Intelligence (multi-trait analysis);	chr6:26536459	chr6:26956992~27023924:+
BRCA	cis	rs2018683	0.739	rs10233884	ENSG00000228421.2	AC005013.5	3.52	0.000451	0.0226	0.14	0.11	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28932690	chr7:28957667~28959345:+
BRCA	cis	rs62344088	1	rs6872393	ENSG00000188242.4	PP7080	3.52	0.000451	0.0226	0.25	0.11	Asthma (childhood onset);	chr5:155739	chr5:466124~473098:-
BRCA	cis	rs7577894	0.967	rs6747885	ENSG00000272606.1	RP11-554J4.1	3.52	0.000451	0.0226	0.12	0.11	Amyotrophic lateral sclerosis;	chr2:55765874	chr2:55617909~55618373:+
BRCA	cis	rs28489187	0.683	rs6576764	ENSG00000223653.4	RP11-131L23.1	-3.52	0.000451	0.0226	-0.12	-0.11	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85400728	chr1:85276715~85448124:+
BRCA	cis	rs7267979	1	rs7019	ENSG00000274973.1	RP13-401N8.7	-3.52	0.000451	0.0226	-0.12	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25297642	chr20:25845497~25845862:+
BRCA	cis	rs4243971	0.516	rs933004	ENSG00000275576.1	RP5-836N17.4	-3.52	0.000451	0.0226	-0.12	-0.11	Inflammatory bowel disease;Crohn's disease;	chr20:32329704	chr20:32116171~32116629:+
BRCA	cis	rs524281	0.861	rs10896077	ENSG00000255557.1	RP11-770G2.2	3.52	0.000451	0.0226	0.15	0.11	Electroencephalogram traits;	chr11:66084262	chr11:65745729~65771585:+
BRCA	cis	rs875971	0.862	rs11765791	ENSG00000271064.1	RP11-792A8.3	-3.52	0.000451	0.0226	-0.13	-0.11	Aortic root size;	chr7:66471587	chr7:66748838~66749077:-
BRCA	cis	rs9949617	1	rs9949617	ENSG00000266495.1	RP11-17J14.2	3.52	0.000451	0.0226	0.2	0.11	Hypertriglyceridemia;	chr18:23299253	chr18:23257164~23260354:-
BRCA	cis	rs72928364	1	rs41386544	ENSG00000256628.3	ZBTB11-AS1	-3.52	0.000451	0.0226	-0.2	-0.11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:101040223	chr3:101676475~101679217:+
BRCA	cis	rs17345786	0.906	rs72944107	ENSG00000244119.1	PDCL3P4	3.52	0.000451	0.0226	0.1	0.11	Colonoscopy-negative controls vs population controls;	chr3:101478346	chr3:101712472~101713191:+
BRCA	cis	rs1850744	0.536	rs6843869	ENSG00000250342.1	SNRPCP16	-3.52	0.000451	0.0226	-0.22	-0.11	Economic and political preferences;	chr4:9632827	chr4:9051842~9052051:-
BRCA	cis	rs9807841	0.67	rs2360942	ENSG00000267100.1	ILF3-AS1	3.52	0.000451	0.0226	0.11	0.11	Inflammatory skin disease;	chr19:10670126	chr19:10651862~10653844:-
BRCA	cis	rs8054556	0.647	rs8048433	ENSG00000275371.1	RP11-455F5.6	-3.52	0.000451	0.0226	-0.11	-0.11	Autism spectrum disorder or schizophrenia;	chr16:29920272	chr16:30110895~30111955:+
BRCA	cis	rs17361889	0.752	rs56161298	ENSG00000229108.1	MEOX2-AS1	3.52	0.000451	0.0226	0.13	0.11	Pediatric bone mineral content (hip);	chr7:16215537	chr7:15688378~15695491:+
BRCA	cis	rs1670533	1	rs629261	ENSG00000251639.2	RP11-20I20.1	3.52	0.000451	0.0226	0.17	0.11	Recombination rate (females);	chr4:1092975	chr4:1100016~1101558:-
BRCA	cis	rs1670533	1	rs629260	ENSG00000251639.2	RP11-20I20.1	3.52	0.000451	0.0226	0.17	0.11	Recombination rate (females);	chr4:1092976	chr4:1100016~1101558:-
BRCA	cis	rs36093844	1	rs36093844	ENSG00000279742.1	RP11-700A24.1	3.52	0.000451	0.0226	0.14	0.11	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85865084	chr11:85852557~85854943:-
BRCA	cis	rs736408	0.812	rs9324	ENSG00000239557.1	RP11-168J18.6	3.52	0.000451	0.0226	0.14	0.11	Bipolar disorder;	chr3:52791569	chr3:52373652~52374882:+
BRCA	cis	rs875971	0.545	rs17138149	ENSG00000232559.3	GS1-124K5.12	3.52	0.000451	0.0226	0.14	0.11	Aortic root size;	chr7:66228193	chr7:66554588~66576923:-
BRCA	cis	rs6714710	0.603	rs6746768	ENSG00000228486.8	LINC01125	-3.52	0.000451	0.0226	-0.09	-0.11	Posterior cortical atrophy and Alzheimer's disease;	chr2:97850184	chr2:97664217~97703064:+
BRCA	cis	rs2191566	0.664	rs8105574	ENSG00000266921.1	RP11-15A1.7	-3.52	0.000451	0.0226	-0.14	-0.11	Acute lymphoblastic leukemia (childhood);	chr19:44084889	chr19:43996896~44002836:-
BRCA	cis	rs79387448	0.745	rs7601773	ENSG00000234389.1	AC007278.3	3.52	0.000451	0.0226	0.15	0.11	Gut microbiota (bacterial taxa);	chr2:102504024	chr2:102438713~102440475:+
BRCA	cis	rs8012947	0.565	rs7151036	ENSG00000257621.6	PSMA3-AS1	3.52	0.000451	0.0226	0.09	0.11	Alcohol consumption in current drinkers;	chr14:58356315	chr14:58265365~58298134:-
BRCA	cis	rs9863	0.898	rs11057400	ENSG00000270028.1	RP11-380L11.4	3.52	0.000451	0.0226	0.14	0.11	White blood cell count;	chr12:123940602	chr12:123925461~123926083:-
BRCA	cis	rs9467773	1	rs10484442	ENSG00000224843.5	LINC00240	-3.52	0.000451	0.0226	-0.12	-0.11	Intelligence (multi-trait analysis);	chr6:26555651	chr6:26956992~27023924:+
BRCA	cis	rs13434995	0.513	rs7676245	ENSG00000249700.7	SRD5A3-AS1	-3.52	0.000451	0.0226	-0.16	-0.11	Adiponectin levels;	chr4:55455150	chr4:55363971~55395847:-
BRCA	cis	rs3743266	0.613	rs1869485	ENSG00000245534.5	RORA-AS1	3.52	0.000451	0.0227	0.12	0.11	Menarche (age at onset);	chr15:60454406	chr15:60479178~60630637:+
BRCA	cis	rs3960554	0.808	rs11983987	ENSG00000205485.12	AC004980.7	-3.52	0.000451	0.0227	-0.14	-0.11	Eotaxin levels;	chr7:76028532	chr7:76549360~76627982:+
BRCA	cis	rs2832077	0.943	rs2832094	ENSG00000215533.7	LINC00189	3.52	0.000452	0.0227	0.16	0.11	Cognitive test performance;	chr21:28793588	chr21:29193480~29288205:+
BRCA	cis	rs7405404	0.913	rs11640541	ENSG00000276564.1	CTA-276F8.1	3.52	0.000452	0.0227	0.13	0.11	Bipolar disorder lithium response (categorical) or schizophrenia;Schizophrenia;	chr16:13652691	chr16:14150833~14153235:+
BRCA	cis	rs13315871	1	rs9819072	ENSG00000272182.1	RP11-802O23.3	3.52	0.000452	0.0227	0.22	0.11	Cholesterol, total;	chr3:58367920	chr3:58428255~58428815:+
BRCA	cis	rs13315871	1	rs9860970	ENSG00000272182.1	RP11-802O23.3	3.52	0.000452	0.0227	0.22	0.11	Cholesterol, total;	chr3:58368054	chr3:58428255~58428815:+
BRCA	cis	rs250518	0.926	rs4267846	ENSG00000271926.1	CTD-2376I4.1	3.52	0.000452	0.0227	0.14	0.11	Mean corpuscular hemoglobin concentration;	chr5:72735617	chr5:72953635~72954274:-
BRCA	cis	rs250518	0.926	rs2338788	ENSG00000271926.1	CTD-2376I4.1	3.52	0.000452	0.0227	0.14	0.11	Mean corpuscular hemoglobin concentration;	chr5:72737690	chr5:72953635~72954274:-
BRCA	cis	rs17014483	0.749	rs2860408	ENSG00000248019.2	FAM13A-AS1	-3.52	0.000452	0.0227	-0.14	-0.11	Post bronchodilator FEV1/FVC ratio;	chr4:88717881	chr4:88709789~88730103:+
BRCA	cis	rs13434995	0.513	rs12509047	ENSG00000273257.1	RP11-177J6.1	3.52	0.000452	0.0227	0.16	0.11	Adiponectin levels;	chr4:55545245	chr4:55387949~55388271:+
BRCA	cis	rs10043775	0.793	rs6886203	ENSG00000251330.3	CTD-2283N19.1	-3.52	0.000452	0.0227	-0.13	-0.11	Periodontal microbiota;	chr5:148317287	chr5:148430159~148430807:-
BRCA	cis	rs1208	0.741	rs67089637	ENSG00000253671.1	RP11-806O11.1	-3.52	0.000452	0.0227	-0.13	-0.11	Insulin resistance/response;	chr8:18413240	chr8:17808941~17820868:+
BRCA	cis	rs757978	1	rs80085676	ENSG00000223374.1	AC005104.3	3.52	0.000452	0.0227	0.15	0.11	Chronic lymphocytic leukemia;	chr2:241408492	chr2:241351340~241353104:-
BRCA	cis	rs6940638	0.688	rs9393795	ENSG00000124549.13	BTN2A3P	-3.52	0.000452	0.0227	-0.12	-0.11	Intelligence (multi-trait analysis);	chr6:27249940	chr6:26421391~26432383:+
BRCA	cis	rs4148883	0.629	rs10009145	ENSG00000272777.1	RP11-571L19.8	-3.52	0.000452	0.0227	-0.11	-0.11	Alcohol dependence;	chr4:99126778	chr4:99067256~99068125:-
BRCA	cis	rs4714291	1	rs1546965	ENSG00000180211.5	RP1-278E11.3	-3.52	0.000452	0.0227	-0.12	-0.11	Strep throat;	chr6:40031410	chr6:39958414~39958833:-
BRCA	cis	rs7620503	1	rs6801659	ENSG00000231574.4	RP11-91K9.1	3.52	0.000452	0.0227	0.12	0.11	Corneal structure;	chr3:177580004	chr3:177816865~177899224:+
BRCA	cis	rs930395	0.514	rs10063172	ENSG00000248779.1	RP11-53O19.2	-3.52	0.000452	0.0227	-0.1	-0.11	Breast cancer;	chr5:44930607	chr5:44752949~44765744:+
BRCA	cis	rs3755021	1	rs12479308	ENSG00000260742.1	RP11-366L5.1	3.52	0.000452	0.0227	0.15	0.11	Monocyte-lymphocyte ratio;	chr2:181483615	chr2:181887851~181891663:-
BRCA	cis	rs875971	0.522	rs7784623	ENSG00000227113.2	RP11-460N20.4	3.52	0.000452	0.0227	0.11	0.11	Aortic root size;	chr7:65930047	chr7:65075023~65078780:+
BRCA	cis	rs6012564	1	rs6122763	ENSG00000230758.1	SNAP23P	-3.52	0.000452	0.0227	-0.12	-0.11	Anger;	chr20:49181116	chr20:49038357~49038602:-
BRCA	cis	rs6582630	0.577	rs12312748	ENSG00000257718.1	RP11-396F22.1	-3.52	0.000452	0.0227	-0.11	-0.11	Drug-induced liver injury (flucloxacillin);	chr12:37949524	chr12:38906451~38909592:+
BRCA	cis	rs6696239	0.866	rs7536661	ENSG00000227711.2	RP11-275O4.5	-3.52	0.000452	0.0227	-0.15	-0.11	Height;	chr1:227683846	chr1:227509028~227520477:-
BRCA	cis	rs4718428	0.705	rs11028	ENSG00000229886.1	RP5-1132H15.3	3.52	0.000452	0.0227	0.13	0.11	Corneal structure;	chr7:66811230	chr7:66025126~66031544:-
BRCA	cis	rs6671200	0.85	rs259345	ENSG00000235501.4	RP4-639F20.1	3.52	0.000452	0.0227	0.23	0.11	Stearic acid (18:0) levels;	chr1:95264093	chr1:94927566~94963270:+
BRCA	cis	rs72772090	0.634	rs17401901	ENSG00000272109.1	CTD-2260A17.3	3.52	0.000452	0.0227	0.2	0.11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96756221	chr5:96804353~96806105:+
BRCA	cis	rs72772090	0.634	rs72773906	ENSG00000272109.1	CTD-2260A17.3	3.52	0.000452	0.0227	0.2	0.11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96756570	chr5:96804353~96806105:+
BRCA	cis	rs11098499	0.954	rs3733519	ENSG00000225892.3	RP11-384K6.2	3.52	0.000452	0.0227	0.11	0.11	Corneal astigmatism;	chr4:119502293	chr4:118632274~118634759:+
BRCA	cis	rs860295	0.702	rs56675301	ENSG00000232093.1	RP11-307C12.11	3.52	0.000452	0.0227	0.12	0.11	Body mass index;	chr1:155394536	chr1:155045191~155046118:-
BRCA	cis	rs6088580	0.634	rs2378133	ENSG00000275784.1	RP5-1125A11.6	3.52	0.000452	0.0227	0.12	0.11	Glomerular filtration rate (creatinine);	chr20:34331699	chr20:33989480~33991818:-
BRCA	cis	rs7943953	0.865	rs12791598	ENSG00000254717.2	GLYATL1P2	-3.52	0.000452	0.0227	-0.15	-0.11	Odorant perception (&beta-ionone);	chr11:59453679	chr11:58878302~58893460:+
BRCA	cis	rs3764563	0.877	rs4019751	ENSG00000267594.5	CYP4F24P	-3.52	0.000452	0.0227	-0.2	-0.11	Inflammatory biomarkers;	chr19:15629906	chr19:15760241~15779909:-
BRCA	cis	rs17221829	0.6	rs3881248	ENSG00000280385.1	AP000648.5	-3.52	0.000452	0.0227	-0.12	-0.11	Anxiety in major depressive disorder;	chr11:89629028	chr11:90193614~90198120:+
BRCA	cis	rs17221829	0.702	rs72971023	ENSG00000280385.1	AP000648.5	-3.52	0.000452	0.0227	-0.12	-0.11	Anxiety in major depressive disorder;	chr11:89630766	chr11:90193614~90198120:+
BRCA	cis	rs17221829	0.703	rs11018682	ENSG00000280385.1	AP000648.5	-3.52	0.000452	0.0227	-0.12	-0.11	Anxiety in major depressive disorder;	chr11:89631283	chr11:90193614~90198120:+
BRCA	cis	rs17221829	0.733	rs11018684	ENSG00000280385.1	AP000648.5	-3.52	0.000452	0.0227	-0.12	-0.11	Anxiety in major depressive disorder;	chr11:89631695	chr11:90193614~90198120:+
BRCA	cis	rs6743226	0.748	rs12620606	ENSG00000266621.1	AC104841.1	3.52	0.000452	0.0227	0.13	0.11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in non-smokers;	chr2:241214600	chr2:241245202~241245299:-
BRCA	cis	rs56046484	0.956	rs34889576	ENSG00000230373.7	GOLGA6L5P	3.52	0.000452	0.0227	0.16	0.11	Testicular germ cell tumor;	chr15:85121445	chr15:84507885~84516814:-
BRCA	cis	rs56046484	0.956	rs34076898	ENSG00000230373.7	GOLGA6L5P	3.52	0.000452	0.0227	0.16	0.11	Testicular germ cell tumor;	chr15:85121569	chr15:84507885~84516814:-
BRCA	cis	rs56046484	0.956	rs35533990	ENSG00000230373.7	GOLGA6L5P	3.52	0.000452	0.0227	0.16	0.11	Testicular germ cell tumor;	chr15:85121590	chr15:84507885~84516814:-
BRCA	cis	rs6997458	0.935	rs7824715	ENSG00000258256.1	RP11-219B4.5	-3.52	0.000452	0.0227	-0.13	-0.11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85366148	chr8:85222446~85245717:-
BRCA	cis	rs2400362	0.752	rs4739774	ENSG00000272518.1	RP11-26J3.3	-3.52	0.000452	0.0227	-0.13	-0.11	Glucocorticoid-induced osteonecrosis (age 10 years and older);	chr8:80935179	chr8:79956465~79957381:-
BRCA	cis	rs1044826	0.623	rs6798217	ENSG00000178631.7	ACTG1P1	3.52	0.000452	0.0227	0.14	0.11	Obesity-related traits;	chr3:139322399	chr3:139493809~139494937:+
BRCA	cis	rs736801	0.836	rs2522052	ENSG00000233006.5	AC034220.3	-3.52	0.000453	0.0227	-0.08	-0.11	Mosquito bite size;Breast cancer;	chr5:132462795	chr5:132311285~132369916:-
BRCA	cis	rs736801	0.808	rs2706403	ENSG00000233006.5	AC034220.3	-3.52	0.000453	0.0227	-0.08	-0.11	Mosquito bite size;Breast cancer;	chr5:132463320	chr5:132311285~132369916:-
BRCA	cis	rs736801	0.754	rs2706336	ENSG00000233006.5	AC034220.3	-3.52	0.000453	0.0227	-0.08	-0.11	Mosquito bite size;Breast cancer;	chr5:132464269	chr5:132311285~132369916:-
BRCA	cis	rs2832077	0.506	rs2832088	ENSG00000236056.1	GAPDHP14	3.52	0.000453	0.0227	0.13	0.11	Cognitive test performance;	chr21:28786298	chr21:29222321~29223257:+
BRCA	cis	rs1730008	1	rs699923	ENSG00000279311.1	RP11-170K4.2	-3.52	0.000453	0.0227	-0.12	-0.11	Lobe attachment (rater-scored or self-reported);	chr3:158223812	chr3:158869898~158871821:+
BRCA	cis	rs853679	1	rs1419183	ENSG00000216901.1	AL022393.7	3.52	0.000453	0.0227	0.18	0.11	Depression;	chr6:28275017	chr6:28176188~28176674:+
BRCA	cis	rs2835872	0.965	rs857975	ENSG00000228677.1	TTC3-AS1	3.52	0.000453	0.0227	0.14	0.11	Electroencephalographic traits in alcoholism;	chr21:37629311	chr21:37187666~37193926:-
BRCA	cis	rs9307551	0.741	rs13128134	ENSG00000250334.4	LINC00989	-3.52	0.000453	0.0227	-0.17	-0.11	Refractive error;	chr4:79551143	chr4:79492416~79576460:+
BRCA	cis	rs1389724	0.632	rs11102167	ENSG00000231346.4	LINC01160	-3.52	0.000453	0.0227	-0.14	-0.11	Schizophrenia;	chr1:110797380	chr1:111599655~111608723:-
BRCA	cis	rs2115630	0.754	rs12595321	ENSG00000259728.4	LINC00933	-3.52	0.000453	0.0227	-0.12	-0.11	P wave terminal force;	chr15:84788038	chr15:84570649~84580175:+
BRCA	cis	rs73201462	0.901	rs56050323	ENSG00000242551.2	POU5F1P6	3.52	0.000453	0.0227	0.19	0.11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128128455	chr3:128674735~128677005:-
BRCA	cis	rs7520050	0.966	rs11211199	ENSG00000281133.1	AL355480.3	3.52	0.000453	0.0227	0.12	0.11	Reticulocyte count;Red blood cell count;	chr1:45822197	chr1:45580892~45580996:-
BRCA	cis	rs8054556	0.967	rs7193532	ENSG00000214725.6	CDIPT-AS1	-3.52	0.000453	0.0227	-0.14	-0.11	Autism spectrum disorder or schizophrenia;	chr16:29951481	chr16:29863593~29868053:+
BRCA	cis	rs28489187	0.706	rs233074	ENSG00000223653.4	RP11-131L23.1	3.52	0.000453	0.0227	0.13	0.11	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85343382	chr1:85276715~85448124:+
BRCA	cis	rs2562456	0.792	rs2562398	ENSG00000268555.1	RP11-678G14.3	-3.52	0.000453	0.0227	-0.14	-0.11	Pain;	chr19:21540147	chr19:21570822~21587322:-
BRCA	cis	rs10819861	0.655	rs55821317	ENSG00000175611.10	LINC00476	3.52	0.000453	0.0227	0.12	0.11	Electrocardiographic traits;	chr9:96106090	chr9:95759231~95875977:-
BRCA	cis	rs2642442	1	rs2642442	ENSG00000257551.1	HLX-AS1	-3.52	0.000453	0.0227	-0.12	-0.11	Cholesterol, total;LDL cholesterol;	chr1:220800221	chr1:220832763~220880140:-
BRCA	cis	rs495337	0.965	rs4810999	ENSG00000229222.1	KRT18P4	-3.52	0.000453	0.0227	-0.14	-0.11	Psoriasis;	chr20:49964432	chr20:49956745~49958032:+
BRCA	cis	rs1555322	1	rs6058219	ENSG00000269202.1	RP4-614O4.12	-3.52	0.000453	0.0227	-0.15	-0.11	Attention deficit hyperactivity disorder;	chr20:35271441	chr20:35201747~35203288:-
BRCA	cis	rs7520050	0.966	rs10890354	ENSG00000281133.1	AL355480.3	3.52	0.000453	0.0227	0.12	0.11	Reticulocyte count;Red blood cell count;	chr1:45839675	chr1:45580892~45580996:-
BRCA	cis	rs2811403	0.792	rs2713584	ENSG00000270773.1	RP13-685P2.7	-3.52	0.000453	0.0227	-0.12	-0.11	Basophil percentage of white cells;	chr3:128439709	chr3:129345411~129346164:+
BRCA	cis	rs34779708	0.897	rs7897827	ENSG00000269952.1	RP11-324I22.3	-3.52	0.000453	0.0227	-0.14	-0.11	Inflammatory bowel disease;Crohn's disease;	chr10:35097309	chr10:35210416~35210750:+
BRCA	cis	rs61931739	0.5	rs11053218	ENSG00000258794.3	DUX4L27	-3.52	0.000453	0.0227	-0.16	-0.11	Morning vs. evening chronotype;	chr12:34321857	chr12:34208415~34209675:-
BRCA	cis	rs7520050	0.902	rs4638056	ENSG00000226957.1	RP4-533D7.4	3.52	0.000453	0.0227	0.12	0.11	Reticulocyte count;Red blood cell count;	chr1:45992481	chr1:46046818~46048368:+
BRCA	cis	rs7520050	0.931	rs11576305	ENSG00000226957.1	RP4-533D7.4	3.52	0.000453	0.0227	0.12	0.11	Reticulocyte count;Red blood cell count;	chr1:45994374	chr1:46046818~46048368:+
BRCA	cis	rs1047014	0.81	rs12528525	ENSG00000228412.5	RP4-625H18.2	-3.52	0.000453	0.0227	-0.14	-0.11	Height;	chr6:19831587	chr6:19802164~19804752:-
BRCA	cis	rs6012564	0.793	rs1043361	ENSG00000222365.1	SNORD12B	3.52	0.000453	0.0227	0.12	0.11	Anger;	chr20:49114621	chr20:49280319~49280409:+
BRCA	cis	rs78487399	0.808	rs79271345	ENSG00000234936.1	AC010883.5	3.52	0.000453	0.0227	0.17	0.11	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43518955	chr2:43229573~43233394:+
BRCA	cis	rs13434995	0.513	rs60097207	ENSG00000273257.1	RP11-177J6.1	-3.52	0.000453	0.0227	-0.17	-0.11	Adiponectin levels;	chr4:55406696	chr4:55387949~55388271:+
BRCA	cis	rs2274273	0.905	rs8007614	ENSG00000259318.1	RP11-454L9.2	3.52	0.000453	0.0227	0.09	0.11	Protein biomarker;	chr14:55119857	chr14:55394940~55395233:-
BRCA	cis	rs495337	1	rs6067293	ENSG00000229222.1	KRT18P4	-3.52	0.000453	0.0227	-0.14	-0.11	Psoriasis;	chr20:49965204	chr20:49956745~49958032:+
BRCA	cis	rs752010	0.644	rs6700390	ENSG00000230638.4	RP11-486B10.4	-3.52	0.000454	0.0227	-0.14	-0.11	Lupus nephritis in systemic lupus erythematosus;	chr1:41646883	chr1:41542069~41544310:+
BRCA	cis	rs6696239	0.956	rs10916173	ENSG00000227711.2	RP11-275O4.5	-3.52	0.000454	0.0227	-0.15	-0.11	Height;	chr1:227605545	chr1:227509028~227520477:-
BRCA	cis	rs7429990	0.965	rs4296617	ENSG00000199476.1	Y_RNA	3.52	0.000454	0.0227	0.15	0.11	Educational attainment (years of education);	chr3:48026818	chr3:48288587~48288694:+
BRCA	cis	rs78545713	0.536	rs78653353	ENSG00000241549.7	GUSBP2	-3.52	0.000454	0.0227	-0.18	-0.11	Iron status biomarkers (total iron binding capacity);	chr6:26208689	chr6:26871484~26956554:-
BRCA	cis	rs78545713	0.536	rs78759249	ENSG00000241549.7	GUSBP2	-3.52	0.000454	0.0227	-0.18	-0.11	Iron status biomarkers (total iron binding capacity);	chr6:26208728	chr6:26871484~26956554:-
BRCA	cis	rs2554380	0.628	rs2081541	ENSG00000259570.1	RP11-671M22.4	3.52	0.000454	0.0227	0.14	0.11	Height;	chr15:83774934	chr15:84394512~84395514:+
BRCA	cis	rs4869313	0.668	rs251344	ENSG00000248734.2	CTD-2260A17.1	3.52	0.000454	0.0227	0.11	0.11	Pediatric autoimmune diseases;	chr5:96923223	chr5:96784777~96785999:+
BRCA	cis	rs73201462	1	rs6783253	ENSG00000242551.2	POU5F1P6	3.52	0.000454	0.0227	0.19	0.11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128132718	chr3:128674735~128677005:-
BRCA	cis	rs4363385	0.693	rs821755	ENSG00000272654.1	RP11-422P24.11	3.52	0.000454	0.0227	0.11	0.11	Inflammatory skin disease;	chr1:153063769	chr1:153977743~153979160:+
BRCA	cis	rs12586478	0.561	rs8012090	ENSG00000205562.2	RP11-497E19.1	3.52	0.000454	0.0227	0.1	0.11	Post bronchodilator FEV1;	chr14:86311656	chr14:85524432~85529988:-
BRCA	cis	rs10771431	0.817	rs10843149	ENSG00000278635.1	CTD-2318O12.1	3.52	0.000454	0.0227	0.1	0.11	Breast size;	chr12:9209471	chr12:9415641~9416718:+
BRCA	cis	rs9393813	0.566	rs12662076	ENSG00000271755.1	RP1-153G14.4	3.52	0.000454	0.0227	0.13	0.11	Bipolar disorder;	chr6:27395358	chr6:27404010~27406964:-
BRCA	cis	rs27434	0.583	rs151908	ENSG00000248734.2	CTD-2260A17.1	3.52	0.000454	0.0227	0.12	0.11	Ankylosing spondylitis;	chr5:96820791	chr5:96784777~96785999:+
BRCA	cis	rs27434	0.583	rs151909	ENSG00000248734.2	CTD-2260A17.1	3.52	0.000454	0.0227	0.12	0.11	Ankylosing spondylitis;	chr5:96821185	chr5:96784777~96785999:+
BRCA	cis	rs8073060	0.586	rs72829922	ENSG00000267554.1	RP11-686D22.10	3.52	0.000454	0.0227	0.12	0.11	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35717790	chr17:35470069~35470628:-
BRCA	cis	rs8073060	0.586	rs72829923	ENSG00000267554.1	RP11-686D22.10	3.52	0.000454	0.0227	0.12	0.11	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35718070	chr17:35470069~35470628:-
BRCA	cis	rs8073060	0.586	rs4796104	ENSG00000267554.1	RP11-686D22.10	3.52	0.000454	0.0227	0.12	0.11	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35719813	chr17:35470069~35470628:-
BRCA	cis	rs8073060	0.586	rs72829927	ENSG00000267554.1	RP11-686D22.10	3.52	0.000454	0.0227	0.12	0.11	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35722973	chr17:35470069~35470628:-
BRCA	cis	rs8073060	0.586	rs9649	ENSG00000267554.1	RP11-686D22.10	3.52	0.000454	0.0227	0.12	0.11	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35723915	chr17:35470069~35470628:-
BRCA	cis	rs9392556	0.829	rs612022	ENSG00000230648.1	RP3-406P24.3	3.52	0.000454	0.0228	0.14	0.11	Blood metabolite levels;	chr6:4126682	chr6:4018843~4021215:-
BRCA	cis	rs9392556	0.829	rs676683	ENSG00000230648.1	RP3-406P24.3	3.52	0.000454	0.0228	0.14	0.11	Blood metabolite levels;	chr6:4127019	chr6:4018843~4021215:-
BRCA	cis	rs7636293	0.592	rs6439167	ENSG00000270773.1	RP13-685P2.7	-3.52	0.000454	0.0228	-0.14	-0.11	Height;	chr3:129331913	chr3:129345411~129346164:+
BRCA	cis	rs875971	0.545	rs10261710	ENSG00000232559.3	GS1-124K5.12	3.52	0.000454	0.0228	0.15	0.11	Aortic root size;	chr7:66249202	chr7:66554588~66576923:-
BRCA	cis	rs7615952	1	rs7616044	ENSG00000241288.6	RP11-379B18.5	-3.52	0.000454	0.0228	-0.15	-0.11	Blood pressure (smoking interaction);	chr3:125930511	chr3:125827238~125916384:-
BRCA	cis	rs2018683	0.707	rs4722878	ENSG00000228421.2	AC005013.5	3.52	0.000454	0.0228	0.14	0.11	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28933414	chr7:28957667~28959345:+
BRCA	cis	rs4934494	0.636	rs34408087	ENSG00000232229.4	LINC00865	-3.52	0.000454	0.0228	-0.17	-0.11	Red blood cell count;	chr10:89783794	chr10:89829510~89840861:+
BRCA	cis	rs970548	0.739	rs11239550	ENSG00000237840.5	FAM21FP	-3.52	0.000454	0.0228	-0.13	-0.11	Total cholesterol levels;HDL cholesterol;HDL cholesterol levels;Cholesterol, total;	chr10:45529281	chr10:45706431~45727231:-
BRCA	cis	rs80226907	0.539	rs17128484	ENSG00000186615.9	KTN1-AS1	-3.52	0.000454	0.0228	-0.21	-0.11	Mean platelet volume;	chr14:55438039	chr14:55499278~55580110:-
BRCA	cis	rs75804782	0.641	rs72983861	ENSG00000186235.9	AC016757.3	3.52	0.000454	0.0228	0.24	0.11	Chronotype;Morning vs. evening chronotype;	chr2:238417485	chr2:238224552~238231677:-
BRCA	cis	rs13256369	1	rs10088439	ENSG00000233609.3	RP11-62H7.2	3.52	0.000454	0.0228	0.11	0.11	Obesity-related traits;	chr8:8719189	chr8:8961200~8979025:+
BRCA	cis	rs8114671	0.562	rs2889861	ENSG00000279253.1	RP4-614O4.13	-3.52	0.000454	0.0228	-0.12	-0.11	Height;	chr20:34817861	chr20:35262727~35264187:-
BRCA	cis	rs11671005	0.611	rs56026876	ENSG00000265272.2	RN7SL693P	3.52	0.000454	0.0228	0.17	0.11	Mean platelet volume;	chr19:58494790	chr19:58490797~58491075:+
BRCA	cis	rs11239930	0.538	rs17160592	ENSG00000227242.3	NBPF13P	-3.52	0.000454	0.0228	-0.14	-0.11	AIDS progression;	chr1:147083644	chr1:147021320~147124525:-
BRCA	cis	rs11239930	0.538	rs56060937	ENSG00000227242.3	NBPF13P	-3.52	0.000454	0.0228	-0.14	-0.11	AIDS progression;	chr1:147083854	chr1:147021320~147124525:-
BRCA	cis	rs6490294	0.571	rs57168159	ENSG00000234608.6	MAPKAPK5-AS1	3.52	0.000454	0.0228	0.16	0.11	Mean platelet volume;	chr12:112189041	chr12:111839764~111842902:-
BRCA	cis	rs6860540	0.687	rs6871720	ENSG00000251405.2	CTB-109A12.1	-3.52	0.000454	0.0228	-0.15	-0.11	Inflammatory skin disease;	chr5:157447457	chr5:157362615~157460078:-
BRCA	cis	rs2573652	0.963	rs2573649	ENSG00000254744.3	CTD-3076O17.1	-3.52	0.000454	0.0228	-0.13	-0.11	Height;	chr15:99973835	chr15:99970215~99974010:+
BRCA	cis	rs12289961	0.681	rs11229313	ENSG00000265566.2	RN7SL605P	-3.52	0.000455	0.0228	-0.18	-0.11	Lymphoma;	chr11:58251236	chr11:57528085~57528365:-
BRCA	cis	rs6840360	0.509	rs62327273	ENSG00000270265.1	RP11-731D1.4	-3.52	0.000455	0.0228	-0.13	-0.11	Intelligence (multi-trait analysis);	chr4:151626442	chr4:151333775~151353224:-
BRCA	cis	rs6840360	0.571	rs4696276	ENSG00000278978.1	RP11-164P12.5	-3.52	0.000455	0.0228	-0.13	-0.11	Intelligence (multi-trait analysis);	chr4:151611530	chr4:151669786~151670503:+
BRCA	cis	rs6840360	0.571	rs62327270	ENSG00000278978.1	RP11-164P12.5	-3.52	0.000455	0.0228	-0.13	-0.11	Intelligence (multi-trait analysis);	chr4:151612466	chr4:151669786~151670503:+
BRCA	cis	rs7008867	1	rs6982144	ENSG00000253390.1	CTC-756D1.2	-3.52	0.000455	0.0228	-0.16	-0.11	Hip circumference adjusted for BMI;	chr8:23527278	chr8:23458601~23484971:+
BRCA	cis	rs1670533	0.769	rs6814833	ENSG00000251639.2	RP11-20I20.1	3.52	0.000455	0.0228	0.17	0.11	Recombination rate (females);	chr4:1063891	chr4:1100016~1101558:-
BRCA	cis	rs7000551	0.751	rs2449338	ENSG00000253125.1	RP11-459E5.1	3.52	0.000455	0.0228	0.1	0.11	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr8:22511719	chr8:22690150~22798616:+
BRCA	cis	rs9500256	0.655	rs12191043	ENSG00000272316.1	XXbac-BPGBPG55C20.2	3.52	0.000455	0.0228	0.1	0.11	Eosinophilic esophagitis (pediatric);	chr6:58020205	chr6:57908560~57913911:-
BRCA	cis	rs4698048	0.506	rs6833292	ENSG00000261490.1	RP11-448G15.3	-3.52	0.000455	0.0228	-0.09	-0.11	Skin aging (microtopography measurement);	chr4:10270805	chr4:10068089~10073019:-
BRCA	cis	rs7781557	0.64	rs6964296	ENSG00000239969.4	RP11-163E9.2	-3.52	0.000455	0.0228	-0.17	-0.11	Colorectal adenoma (advanced);	chr7:102932495	chr7:102364162~102380633:+
BRCA	cis	rs7208859	0.573	rs56031503	ENSG00000276250.1	CTD-2349P21.12	-3.52	0.000455	0.0228	-0.17	-0.11	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748647	chr17:30803654~30804077:+
BRCA	cis	rs68170813	0.652	rs8180747	ENSG00000241764.3	AC002467.7	3.52	0.000455	0.0228	0.19	0.11	Coronary artery disease;	chr7:107465863	chr7:107742817~107744581:-
BRCA	cis	rs36051895	0.589	rs12682672	ENSG00000237711.1	RP11-39K24.13	-3.52	0.000455	0.0228	-0.13	-0.11	Pediatric autoimmune diseases;	chr9:5187941	chr9:5100236~5101009:+
BRCA	cis	rs8058578	0.775	rs8046391	ENSG00000280211.1	RP11-2C24.3	3.52	0.000455	0.0228	0.11	0.11	Multiple myeloma;	chr16:30825327	chr16:30773532~30776033:-
BRCA	cis	rs860295	0.702	rs11264381	ENSG00000236675.1	MTX1P1	3.52	0.000455	0.0228	0.14	0.11	Body mass index;	chr1:155552781	chr1:155230975~155234325:+
BRCA	cis	rs4934494	0.834	rs3740033	ENSG00000235100.3	RP11-80H5.9	3.52	0.000455	0.0228	0.13	0.11	Red blood cell count;	chr10:89634639	chr10:89667181~89699671:-
BRCA	cis	rs7267979	0.932	rs6132848	ENSG00000277938.1	RP5-965G21.3	3.52	0.000455	0.0228	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25581009	chr20:25229150~25231933:+
BRCA	cis	rs801193	0.569	rs2659893	ENSG00000271064.1	RP11-792A8.3	-3.52	0.000455	0.0228	-0.13	-0.11	Aortic root size;	chr7:66735006	chr7:66748838~66749077:-
BRCA	cis	rs801193	0.569	rs2659892	ENSG00000271064.1	RP11-792A8.3	-3.52	0.000455	0.0228	-0.13	-0.11	Aortic root size;	chr7:66735318	chr7:66748838~66749077:-
BRCA	cis	rs801193	0.569	rs2707847	ENSG00000271064.1	RP11-792A8.3	-3.52	0.000455	0.0228	-0.13	-0.11	Aortic root size;	chr7:66737884	chr7:66748838~66749077:-
BRCA	cis	rs7833986	0.501	rs72653917	ENSG00000253603.1	CTA-397H3.3	-3.52	0.000455	0.0228	-0.16	-0.11	Height;	chr8:55980285	chr8:56074592~56075274:+
BRCA	cis	rs7097397	0.591	rs12768835	ENSG00000265018.5	CTGLF12P	-3.52	0.000455	0.0228	-0.14	-0.11	Systemic lupus erythematosus;	chr10:48768924	chr10:48009873~48031640:-
BRCA	cis	rs1916284	1	rs9857375	ENSG00000239831.1	RNF7P1	3.52	0.000455	0.0228	0.13	0.11	Prostate cancer (SNP x SNP interaction);	chr3:57411673	chr3:57519669~57520010:-
BRCA	cis	rs72634258	0.842	rs4908727	ENSG00000238290.1	RP11-431K24.1	-3.52	0.000455	0.0228	-0.16	-0.11	Inflammatory bowel disease;	chr1:8103062	chr1:8026738~8122702:+
BRCA	cis	rs10995240	1	rs10995240	ENSG00000238280.1	RP11-436D10.3	3.52	0.000455	0.0228	0.15	0.11	Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr10:62628871	chr10:62793562~62805887:-
BRCA	cis	rs28489187	0.706	rs233131	ENSG00000223653.4	RP11-131L23.1	3.52	0.000455	0.0228	0.12	0.11	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85329576	chr1:85276715~85448124:+
BRCA	cis	rs3805389	0.504	rs2412666	ENSG00000249700.7	SRD5A3-AS1	-3.52	0.000455	0.0228	-0.18	-0.11	Waist-to-hip ratio adjusted for body mass index;	chr4:55607192	chr4:55363971~55395847:-
BRCA	cis	rs875971	0.964	rs6978429	ENSG00000271064.1	RP11-792A8.3	-3.52	0.000455	0.0228	-0.13	-0.11	Aortic root size;	chr7:66494889	chr7:66748838~66749077:-
BRCA	cis	rs875971	1	rs4718357	ENSG00000271064.1	RP11-792A8.3	-3.52	0.000455	0.0228	-0.13	-0.11	Aortic root size;	chr7:66495891	chr7:66748838~66749077:-
BRCA	cis	rs7229439	0.737	rs11659929	ENSG00000267414.1	RP11-456K23.1	3.52	0.000455	0.0228	0.12	0.11	Antipsychotic drug-induced QTc interval change in schizophrenia;	chr18:45352149	chr18:44676927~44679717:-
BRCA	cis	rs2998286	0.723	rs332168	ENSG00000237128.1	RP11-351M16.3	3.52	0.000455	0.0228	0.14	0.11	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28607488	chr10:28433008~28495813:-
BRCA	cis	rs7474896	0.887	rs10827844	ENSG00000120555.12	SEPT7P9	3.52	0.000455	0.0228	0.19	0.11	Obesity (extreme);	chr10:38065366	chr10:38383069~38402916:-
BRCA	cis	rs2562456	1	rs2562456	ENSG00000213976.4	CTD-2561J22.2	-3.52	0.000455	0.0228	-0.12	-0.11	Pain;	chr19:21483408	chr19:21382865~21387177:+
BRCA	cis	rs13256369	0.756	rs13282580	ENSG00000254153.1	CTA-398F10.2	3.52	0.000455	0.0228	0.15	0.11	Obesity-related traits;	chr8:8705393	chr8:8456909~8461337:-
BRCA	cis	rs9796	0.653	rs28516683	ENSG00000223313.1	RNU6-516P	3.52	0.000455	0.0228	0.13	0.11	Menopause (age at onset);	chr15:41154447	chr15:40529570~40529673:+
BRCA	cis	rs2018683	0.707	rs2391718	ENSG00000233517.1	AC005162.5	-3.52	0.000455	0.0228	-0.13	-0.11	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28935371	chr7:28987028~28988899:+
BRCA	cis	rs875971	0.862	rs6964437	ENSG00000229886.1	RP5-1132H15.3	-3.52	0.000455	0.0228	-0.12	-0.11	Aortic root size;	chr7:66221457	chr7:66025126~66031544:-
BRCA	cis	rs1057510	0.79	rs16932801	ENSG00000257084.1	U47924.27	3.52	0.000456	0.0228	0.15	0.11	Myopia (pathological);	chr12:6611216	chr12:6963246~6964447:+
BRCA	cis	rs9923856	0.616	rs876476	ENSG00000263033.2	RP11-396B14.2	-3.52	0.000456	0.0228	-0.13	-0.11	Atopic dermatitis;Adult asthma;	chr16:11056391	chr16:11196177~11224969:+
BRCA	cis	rs863345	0.565	rs10908668	ENSG00000176320.2	RP11-404O13.5	-3.52	0.000456	0.0228	-0.11	-0.11	Pneumococcal bacteremia;	chr1:158532143	chr1:158197922~158203877:-
BRCA	cis	rs863345	0.526	rs10908669	ENSG00000176320.2	RP11-404O13.5	-3.52	0.000456	0.0228	-0.11	-0.11	Pneumococcal bacteremia;	chr1:158532148	chr1:158197922~158203877:-
BRCA	cis	rs812925	0.519	rs2694627	ENSG00000270820.4	RP11-355B11.2	-3.52	0.000456	0.0228	-0.12	-0.11	Immature fraction of reticulocytes;	chr2:61398371	chr2:61471188~61484130:+
BRCA	cis	rs2395128	0.667	rs10824247	ENSG00000213731.2	RAB5CP1	3.52	0.000456	0.0228	0.21	0.11	Ulcerative colitis;Inflammatory bowel disease;	chr10:74937602	chr10:74423435~74424014:-
BRCA	cis	rs7048146	0.899	rs13284486	ENSG00000213539.4	YBX1P6	3.52	0.000456	0.0228	0.12	0.11	Vascular brain injury;	chr9:109586658	chr9:109532830~109534332:-
BRCA	cis	rs875971	0.964	rs1643388	ENSG00000271064.1	RP11-792A8.3	-3.52	0.000456	0.0228	-0.13	-0.11	Aortic root size;	chr7:66379575	chr7:66748838~66749077:-
BRCA	cis	rs875971	1	rs778722	ENSG00000271064.1	RP11-792A8.3	-3.52	0.000456	0.0228	-0.13	-0.11	Aortic root size;	chr7:66379841	chr7:66748838~66749077:-
BRCA	cis	rs1538970	0.924	rs4660858	ENSG00000281133.1	AL355480.3	-3.52	0.000456	0.0228	-0.15	-0.11	Platelet count;	chr1:45470679	chr1:45580892~45580996:-
BRCA	cis	rs12760731	0.565	rs10913519	ENSG00000213057.5	C1orf220	3.52	0.000456	0.0228	0.16	0.11	Obesity-related traits;	chr1:178226959	chr1:178542752~178548889:+
BRCA	cis	rs9467773	1	rs1884946	ENSG00000224843.5	LINC00240	-3.52	0.000456	0.0228	-0.12	-0.11	Intelligence (multi-trait analysis);	chr6:26545080	chr6:26956992~27023924:+
BRCA	cis	rs7520050	0.751	rs592214	ENSG00000234329.1	RP11-767N6.2	-3.52	0.000456	0.0228	-0.1	-0.11	Reticulocyte count;Red blood cell count;	chr1:45558833	chr1:45651039~45651826:-
BRCA	cis	rs1018697	1	rs4919678	ENSG00000236937.2	PTGES3P4	3.52	0.000456	0.0228	0.14	0.11	Colorectal adenoma (advanced);	chr10:102794606	chr10:102845595~102845950:+
BRCA	cis	rs13136331	0.68	rs2732206	ENSG00000249001.4	RP11-742B18.1	3.52	0.000456	0.0228	0.15	0.11	Sitting height ratio;	chr4:87731352	chr4:87568035~87733956:-
BRCA	cis	rs16852403	0.583	rs10913506	ENSG00000224687.1	RASAL2-AS1	3.52	0.000456	0.0228	0.14	0.11	Childhood ear infection;	chr1:178123098	chr1:178091508~178093984:-
BRCA	cis	rs73222236	0.857	rs28396702	ENSG00000239213.4	NCK1-AS1	3.52	0.000456	0.0228	0.12	0.11	Coronary artery disease;	chr3:136448539	chr3:136841726~136862054:-
BRCA	cis	rs6951245	0.554	rs58210047	ENSG00000224079.1	AC091729.7	-3.52	0.000456	0.0228	-0.16	-0.11	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1109745	chr7:1074450~1078036:+
BRCA	cis	rs2833693	0.638	rs2409447	ENSG00000261610.1	AP000265.1	3.52	0.000456	0.0228	0.13	0.11	Temperament;	chr21:32173178	chr21:32259804~32261585:-
BRCA	cis	rs448720	1	rs7163687	ENSG00000260657.2	RP11-315D16.4	3.52	0.000456	0.0228	0.13	0.11	Cognitive performance;	chr15:67901611	chr15:68267792~68277994:-
BRCA	cis	rs35306767	0.903	rs12769431	ENSG00000229869.1	RP11-363N22.2	-3.52	0.000456	0.0228	-0.16	-0.11	Eosinophil percentage of granulocytes;	chr10:876693	chr10:933026~942743:+
BRCA	cis	rs875971	0.862	rs4718383	ENSG00000265600.1	AC006480.1	3.52	0.000456	0.0228	0.13	0.11	Aortic root size;	chr7:66643422	chr7:67356680~67356779:+
BRCA	cis	rs3740393	0.562	rs72845847	ENSG00000213277.3	MARCKSL1P1	3.52	0.000456	0.0228	0.15	0.11	Microalbuminuria;	chr10:102771849	chr10:103175554~103176094:+
BRCA	cis	rs8177876	0.749	rs11537	ENSG00000261141.1	RP11-303E16.5	3.52	0.000456	0.0228	0.19	0.11	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81046894	chr16:81055301~81056426:+
BRCA	cis	rs13136331	0.721	rs2627721	ENSG00000249001.4	RP11-742B18.1	3.52	0.000456	0.0228	0.15	0.11	Sitting height ratio;	chr4:87762277	chr4:87568035~87733956:-
BRCA	cis	rs13136331	0.721	rs2627717	ENSG00000249001.4	RP11-742B18.1	3.52	0.000456	0.0228	0.15	0.11	Sitting height ratio;	chr4:87763593	chr4:87568035~87733956:-
BRCA	cis	rs9467773	0.935	rs9461270	ENSG00000224843.5	LINC00240	-3.52	0.000456	0.0228	-0.12	-0.11	Intelligence (multi-trait analysis);	chr6:26543882	chr6:26956992~27023924:+
BRCA	cis	rs6832769	0.621	rs10033028	ENSG00000272969.1	RP11-528I4.2	-3.52	0.000456	0.0229	-0.13	-0.11	Personality dimensions;	chr4:55653709	chr4:55547112~55547889:+
BRCA	cis	rs4689592	0.503	rs3857180	ENSG00000245468.3	RP11-367J11.3	-3.52	0.000456	0.0229	-0.13	-0.11	Monocyte percentage of white cells;	chr4:7072172	chr4:7094571~7103385:-
BRCA	cis	rs8180040	1	rs553989	ENSG00000260236.1	RP11-708J19.1	-3.52	0.000456	0.0229	-0.1	-0.11	Colorectal cancer;	chr3:47358838	chr3:47379089~47380999:-
BRCA	cis	rs10181042	0.528	rs2564118	ENSG00000270820.4	RP11-355B11.2	3.52	0.000456	0.0229	0.12	0.11	Crohn's disease;	chr2:61006154	chr2:61471188~61484130:+
BRCA	cis	rs4622329	0.636	rs7975403	ENSG00000257202.1	RP11-512N21.3	3.52	0.000456	0.0229	0.13	0.11	Systemic lupus erythematosus;	chr12:101894749	chr12:101923410~101924719:-
BRCA	cis	rs4622329	0.615	rs7975321	ENSG00000257202.1	RP11-512N21.3	3.52	0.000456	0.0229	0.13	0.11	Systemic lupus erythematosus;	chr12:101894835	chr12:101923410~101924719:-
BRCA	cis	rs4622329	0.636	rs4764670	ENSG00000257202.1	RP11-512N21.3	3.52	0.000456	0.0229	0.13	0.11	Systemic lupus erythematosus;	chr12:101895089	chr12:101923410~101924719:-
BRCA	cis	rs4622329	0.615	rs4764672	ENSG00000257202.1	RP11-512N21.3	3.52	0.000456	0.0229	0.13	0.11	Systemic lupus erythematosus;	chr12:101895437	chr12:101923410~101924719:-
BRCA	cis	rs4622329	0.615	rs4764676	ENSG00000257202.1	RP11-512N21.3	3.52	0.000456	0.0229	0.13	0.11	Systemic lupus erythematosus;	chr12:101896179	chr12:101923410~101924719:-
BRCA	cis	rs4622329	0.615	rs7954630	ENSG00000257202.1	RP11-512N21.3	3.52	0.000456	0.0229	0.13	0.11	Systemic lupus erythematosus;	chr12:101896376	chr12:101923410~101924719:-
BRCA	cis	rs4622329	0.615	rs6539016	ENSG00000257202.1	RP11-512N21.3	3.52	0.000456	0.0229	0.13	0.11	Systemic lupus erythematosus;	chr12:101896459	chr12:101923410~101924719:-
BRCA	cis	rs964611	0.872	rs17350938	ENSG00000259488.2	RP11-154J22.1	-3.52	0.000456	0.0229	-0.16	-0.11	Metabolite levels (Pyroglutamine);	chr15:48297784	chr15:48312353~48331856:-
BRCA	cis	rs55883249	1	rs17362902	ENSG00000217258.2	AC007249.3	-3.52	0.000456	0.0229	-0.17	-0.11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:9628435	chr2:10452319~10455552:+
BRCA	cis	rs12908161	0.96	rs17599989	ENSG00000230373.7	GOLGA6L5P	-3.52	0.000456	0.0229	-0.13	-0.11	Schizophrenia;	chr15:84742305	chr15:84507885~84516814:-
BRCA	cis	rs7178375	0.607	rs71474639	ENSG00000259845.1	HERC2P10	3.52	0.000457	0.0229	0.18	0.11	Hypertriglyceridemia;	chr15:30921054	chr15:30815271~30844153:+
BRCA	cis	rs12681366	0.663	rs2921389	ENSG00000253175.1	RP11-267M23.6	3.52	0.000457	0.0229	0.12	0.11	Nonsyndromic cleft lip with cleft palate;	chr8:94454138	chr8:94565036~94565715:+
BRCA	cis	rs4788196	1	rs4788196	ENSG00000261367.1	RP11-455F5.4	-3.52	0.000457	0.0229	-0.12	-0.11	Pubertal anthropometrics;	chr16:29956113	chr16:30107675~30110541:+
BRCA	cis	rs1949733	0.656	rs2688243	ENSG00000250471.2	GMPSP1	3.52	0.000457	0.0229	0.11	0.11	Response to antineoplastic agents;	chr4:8434559	chr4:8174421~8174999:+
BRCA	cis	rs2731006	0.901	rs2678117	ENSG00000257114.2	RP11-25I15.3	3.52	0.000457	0.0229	0.17	0.11	Panic disorder;	chr12:42764681	chr12:42692216~42717119:+
BRCA	cis	rs17221829	0.739	rs72971036	ENSG00000280385.1	AP000648.5	-3.52	0.000457	0.0229	-0.12	-0.11	Anxiety in major depressive disorder;	chr11:89637384	chr11:90193614~90198120:+
BRCA	cis	rs1424638	0.655	rs2865291	ENSG00000233251.6	AC007743.1	-3.52	0.000457	0.0229	-0.13	-0.11	Intelligence (multi-trait analysis);	chr2:57021352	chr2:56173534~56185770:-
BRCA	cis	rs7267979	0.866	rs6138609	ENSG00000274414.1	RP5-965G21.4	-3.52	0.000457	0.0229	-0.13	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25590349	chr20:25239007~25245229:-
BRCA	cis	rs3889199	0.779	rs12746759	ENSG00000272226.1	RP11-63G10.3	3.52	0.000457	0.0229	0.14	0.11	Pulse pressure;	chr1:59201478	chr1:58812808~58813342:-
BRCA	cis	rs1008375	0.966	rs758483	ENSG00000249502.1	AC006160.5	3.52	0.000457	0.0229	0.13	0.11	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17701991	chr4:17587467~17614571:-
BRCA	cis	rs78587638	0.79	rs7605250	ENSG00000226856.4	AC093901.1	-3.52	0.000457	0.0229	-0.16	-0.11	Mosquito bite size;	chr2:118421301	chr2:118132128~118186386:-
BRCA	cis	rs9796	0.689	rs9888710	ENSG00000223313.1	RNU6-516P	3.52	0.000457	0.0229	0.13	0.11	Menopause (age at onset);	chr15:41153955	chr15:40529570~40529673:+
BRCA	cis	rs7520050	0.966	rs12409773	ENSG00000281133.1	AL355480.3	3.52	0.000457	0.0229	0.12	0.11	Reticulocyte count;Red blood cell count;	chr1:45893159	chr1:45580892~45580996:-
BRCA	cis	rs7520050	1	rs12410070	ENSG00000281133.1	AL355480.3	3.52	0.000457	0.0229	0.12	0.11	Reticulocyte count;Red blood cell count;	chr1:45893210	chr1:45580892~45580996:-
BRCA	cis	rs7520050	0.966	rs12410071	ENSG00000281133.1	AL355480.3	3.52	0.000457	0.0229	0.12	0.11	Reticulocyte count;Red blood cell count;	chr1:45893214	chr1:45580892~45580996:-
BRCA	cis	rs11148252	0.669	rs4884320	ENSG00000198384.8	TPTE2P3	3.52	0.000457	0.0229	0.13	0.11	Lewy body disease;	chr13:52432779	chr13:52522632~52586906:+
BRCA	cis	rs7520050	0.966	rs4660317	ENSG00000226957.1	RP4-533D7.4	3.52	0.000457	0.0229	0.12	0.11	Reticulocyte count;Red blood cell count;	chr1:45860554	chr1:46046818~46048368:+
BRCA	cis	rs7520050	0.966	rs10749860	ENSG00000226957.1	RP4-533D7.4	3.52	0.000457	0.0229	0.12	0.11	Reticulocyte count;Red blood cell count;	chr1:45862538	chr1:46046818~46048368:+
BRCA	cis	rs7520050	0.931	rs6688365	ENSG00000226957.1	RP4-533D7.4	3.52	0.000457	0.0229	0.12	0.11	Reticulocyte count;Red blood cell count;	chr1:45864212	chr1:46046818~46048368:+
BRCA	cis	rs7520050	0.966	rs6656992	ENSG00000226957.1	RP4-533D7.4	3.52	0.000457	0.0229	0.12	0.11	Reticulocyte count;Red blood cell count;	chr1:45867396	chr1:46046818~46048368:+
BRCA	cis	rs7520050	0.966	rs61783220	ENSG00000226957.1	RP4-533D7.4	3.52	0.000457	0.0229	0.12	0.11	Reticulocyte count;Red blood cell count;	chr1:45869640	chr1:46046818~46048368:+
BRCA	cis	rs7520050	0.966	rs7540325	ENSG00000226957.1	RP4-533D7.4	3.52	0.000457	0.0229	0.12	0.11	Reticulocyte count;Red blood cell count;	chr1:45872545	chr1:46046818~46048368:+
BRCA	cis	rs7520050	1	rs7540699	ENSG00000226957.1	RP4-533D7.4	3.52	0.000457	0.0229	0.12	0.11	Reticulocyte count;Red blood cell count;	chr1:45872913	chr1:46046818~46048368:+
BRCA	cis	rs7520050	0.966	rs4660319	ENSG00000226957.1	RP4-533D7.4	3.52	0.000457	0.0229	0.12	0.11	Reticulocyte count;Red blood cell count;	chr1:45875951	chr1:46046818~46048368:+
BRCA	cis	rs7520050	0.931	rs11211213	ENSG00000226957.1	RP4-533D7.4	3.52	0.000457	0.0229	0.12	0.11	Reticulocyte count;Red blood cell count;	chr1:45876845	chr1:46046818~46048368:+
BRCA	cis	rs8141529	0.748	rs5762882	ENSG00000226471.5	CTA-292E10.6	-3.52	0.000457	0.0229	-0.13	-0.11	Lymphocyte counts;	chr22:28894692	chr22:28800683~28848559:+
BRCA	cis	rs10191559	0.552	rs10194025	ENSG00000234663.4	AC104820.2	-3.52	0.000457	0.0229	-0.1	-0.11	Red blood cell count;	chr2:181207422	chr2:181101932~181399559:+
BRCA	cis	rs4713118	0.516	rs6931858	ENSG00000226314.6	ZNF192P1	-3.52	0.000457	0.0229	-0.16	-0.11	Parkinson's disease;	chr6:28110633	chr6:28161781~28169594:+
BRCA	cis	rs6840360	1	rs6846114	ENSG00000251611.1	RP11-610P16.1	3.52	0.000457	0.0229	0.1	0.11	Intelligence (multi-trait analysis);	chr4:151683406	chr4:151407551~151408835:-
BRCA	cis	rs7089973	0.526	rs1045657	ENSG00000236799.1	RP11-383C6.2	-3.52	0.000457	0.0229	-0.14	-0.11	Bipolar disorder or attention deficit hyperactivity disorder;	chr10:114977226	chr10:114994657~114996593:+
BRCA	cis	rs1670533	0.932	rs610218	ENSG00000251639.2	RP11-20I20.1	3.52	0.000457	0.0229	0.17	0.11	Recombination rate (females);	chr4:1086295	chr4:1100016~1101558:-
BRCA	cis	rs9527	0.637	rs11191424	ENSG00000213277.3	MARCKSL1P1	3.52	0.000457	0.0229	0.12	0.11	Arsenic metabolism;	chr10:102866129	chr10:103175554~103176094:+
BRCA	cis	rs7487075	0.859	rs7974529	ENSG00000274723.1	RP11-618L22.1	3.52	0.000457	0.0229	0.13	0.11	Itch intensity from mosquito bite;	chr12:46357605	chr12:46970504~46972155:+
BRCA	cis	rs6714710	0.603	rs17489454	ENSG00000228486.8	LINC01125	-3.52	0.000457	0.0229	-0.09	-0.11	Posterior cortical atrophy and Alzheimer's disease;	chr2:97790887	chr2:97664217~97703064:+
BRCA	cis	rs12073837	0.5	rs2807845	ENSG00000221571.3	RNU6ATAC35P	-3.52	0.000457	0.0229	-0.13	-0.11	F-cell distribution;	chr1:220822945	chr1:220825620~220826063:+
BRCA	cis	rs1998359	0.501	rs7147915	ENSG00000259087.4	RP11-356O9.2	-3.52	0.000457	0.0229	-0.1	-0.11	Self-reported allergy;	chr14:37687880	chr14:37556158~37567095:-
BRCA	cis	rs8028182	0.525	rs9920028	ENSG00000260206.1	CTD-2026K11.2	-3.52	0.000457	0.0229	-0.15	-0.11	Sudden cardiac arrest;	chr15:75635376	chr15:75636139~75639239:+
BRCA	cis	rs528808	1	rs528808	ENSG00000228439.4	TSTD3	-3.52	0.000458	0.0229	-0.17	-0.11	Age-related hearing impairment;	chr6:99656413	chr6:99520693~99531918:+
BRCA	cis	rs826838	0.559	rs1843891	ENSG00000257718.1	RP11-396F22.1	3.52	0.000458	0.0229	0.11	0.11	Heart rate;	chr12:38223216	chr12:38906451~38909592:+
BRCA	cis	rs91731	0.607	rs6450974	ENSG00000249572.1	CTD-2203K17.1	-3.52	0.000458	0.0229	-0.2	-0.11	Lung function (FVC);	chr5:33251713	chr5:33424025~33440619:-
BRCA	cis	rs7103648	0.695	rs11039290	ENSG00000280615.1	Y_RNA	3.52	0.000458	0.0229	0.14	0.11	Systolic blood pressure;Diastolic blood pressure;	chr11:47550727	chr11:47614898~47614994:-
BRCA	cis	rs249954	0.512	rs7588	ENSG00000260136.4	CTD-2270L9.4	3.52	0.000458	0.0229	0.11	0.11	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr16:23669844	chr16:23452758~23457606:+
BRCA	cis	rs66887589	0.56	rs9684327	ENSG00000260404.2	RP11-384K6.6	3.52	0.000458	0.0229	0.09	0.11	Diastolic blood pressure;	chr4:119444286	chr4:118591773~118633729:+
BRCA	cis	rs9788721	0.836	rs2656052	ENSG00000261762.1	RP11-650L12.2	-3.52	0.000458	0.0229	-0.13	-0.11	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78448590	chr15:78589123~78591276:-
BRCA	cis	rs10129255	1	rs11621409	ENSG00000274576.2	IGHV2-70	3.52	0.000458	0.0229	0.1	0.11	Kawasaki disease;	chr14:106695603	chr14:106770577~106771020:-
BRCA	cis	rs7586085	0.903	rs12692777	ENSG00000229195.1	AC009495.4	-3.52	0.000458	0.0229	-0.13	-0.11	Total body bone mineral density;	chr2:165766678	chr2:165794857~165846091:-
BRCA	cis	rs9346455	0.614	rs2273888	ENSG00000232295.6	RP11-154D6.1	-3.52	0.000458	0.0229	-0.16	-0.11	Antipsychotic drug-induced weight gain;Antipsychotic drug-induced weight gain (time interaction);	chr6:71296809	chr6:71221457~71328228:-
BRCA	cis	rs1816752	1	rs1816752	ENSG00000273628.1	RP11-756A22.7	3.52	0.000458	0.0229	0.14	0.11	Obesity-related traits;	chr13:24406811	chr13:24933006~24936796:+
BRCA	cis	rs2351088	0.536	rs17574591	ENSG00000231010.1	RP6-109B7.2	-3.52	0.000458	0.0229	-0.2	-0.11	Tonsillectomy;	chr22:45780034	chr22:46055740~46058160:-
BRCA	cis	rs7674212	0.556	rs6533039	ENSG00000248740.4	RP11-328K4.1	3.52	0.000458	0.0229	0.13	0.11	Type 2 diabetes;	chr4:102938381	chr4:103256159~103453658:+
BRCA	cis	rs36051895	0.664	rs7852755	ENSG00000236254.1	MTND4P14	-3.52	0.000458	0.0229	-0.13	-0.11	Pediatric autoimmune diseases;	chr9:5100862	chr9:5107937~5109290:+
BRCA	cis	rs4388249	1	rs13180361	ENSG00000249068.1	CTC-287O8.1	3.52	0.000458	0.0229	0.16	0.11	Schizophrenia;	chr5:109707287	chr5:109840128~109840692:-
BRCA	cis	rs11892454	0.565	rs10199550	ENSG00000217643.1	PTGES3P2	-3.52	0.000458	0.0229	-0.12	-0.11	Heschl's gyrus morphology;	chr2:25855662	chr2:25822469~25822950:+
BRCA	cis	rs4848143	0.64	rs4848677	ENSG00000236859.5	NIFK-AS1	-3.52	0.000458	0.0229	-0.12	-0.11	Capecitabine sensitivity;	chr2:121044106	chr2:121649650~121728208:+
BRCA	cis	rs7944584	0.511	rs10838725	ENSG00000280615.1	Y_RNA	3.52	0.000458	0.0229	0.14	0.11	Fasting blood glucose;Fasting blood glucose (BMI interaction);	chr11:47536319	chr11:47614898~47614994:-
BRCA	cis	rs7103648	0.695	rs10838726	ENSG00000280615.1	Y_RNA	3.52	0.000458	0.0229	0.14	0.11	Systolic blood pressure;Diastolic blood pressure;	chr11:47546792	chr11:47614898~47614994:-
BRCA	cis	rs7267979	0.586	rs6050445	ENSG00000276952.1	RP5-965G21.6	3.52	0.000458	0.0229	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25214758	chr20:25284915~25285588:-
BRCA	cis	rs8060686	0.516	rs7193701	ENSG00000260891.1	RP11-96D1.5	3.52	0.000458	0.0229	0.15	0.11	HDL cholesterol;Metabolic syndrome;	chr16:68151257	chr16:68212401~68221671:-
BRCA	cis	rs6429422	0.769	rs12723863	ENSG00000224727.1	FCF1P7	-3.52	0.000458	0.0229	-0.13	-0.11	Cognitive ability (multi-trait analysis);	chr1:243251389	chr1:243267257~243268119:-
BRCA	cis	rs8114671	0.836	rs62213676	ENSG00000261582.1	RP4-614O4.11	3.52	0.000458	0.0229	0.1	0.11	Height;	chr20:35024873	chr20:35267885~35280043:-
BRCA	cis	rs151234	0.741	rs10521145	ENSG00000259982.1	CDC37P1	3.52	0.000458	0.0229	0.19	0.11	Platelet distribution width;	chr16:28585563	chr16:28700294~28701540:-
BRCA	cis	rs4650943	0.503	rs7517503	ENSG00000227740.1	RP11-318C24.2	3.52	0.000458	0.0229	0.11	0.11	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in inactive individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr1:176123532	chr1:175904762~175920513:-
BRCA	cis	rs10759883	0.563	rs10819720	ENSG00000225194.2	LINC00092	3.52	0.000458	0.0229	0.11	0.11	Nicotine dependence;	chr9:96021506	chr9:96019732~96027965:-
BRCA	cis	rs875971	0.965	rs28682868	ENSG00000230189.5	GS1-124K5.2	-3.52	0.000458	0.0229	-0.09	-0.11	Aortic root size;	chr7:66224822	chr7:66409143~66490059:-
BRCA	cis	rs1126510	0.897	rs2229129	ENSG00000268423.3	AC011551.3	-3.52	0.000458	0.0229	-0.14	-0.11	Ulcerative colitis;	chr19:46621457	chr19:46547056~46600861:-
BRCA	cis	rs17428076	0.83	rs6704590	ENSG00000228389.1	AC068039.4	-3.52	0.000458	0.0229	-0.16	-0.11	Myopia;	chr2:172013647	chr2:171773482~171775844:+
BRCA	cis	rs4820539	1	rs5759598	ENSG00000211647.1	IGLV5-48	-3.52	0.000458	0.0229	-0.09	-0.11	Bone mineral density;	chr22:23138775	chr22:22352940~22353433:+
BRCA	cis	rs7635879	0.702	rs4687494	ENSG00000214146.2	RP11-699L21.1	3.52	0.000458	0.0229	0.13	0.11	Breastfeeding duration;	chr3:194010581	chr3:193957372~194003659:-
BRCA	cis	rs9341808	0.754	rs6916405	ENSG00000279022.1	RP11-250B2.4	3.52	0.000458	0.0229	0.12	0.11	Sitting height ratio;	chr6:80314471	chr6:80440730~80441172:+
BRCA	cis	rs9921338	0.509	rs28448519	ENSG00000262636.1	CTD-3088G3.4	-3.52	0.000458	0.0229	-0.15	-0.11	Vein graft stenosis in coronary artery bypass grafting;	chr16:11346126	chr16:11380859~11381118:-
BRCA	cis	rs91731	0.92	rs2934826	ENSG00000249572.1	CTD-2203K17.1	-3.52	0.000458	0.0229	-0.2	-0.11	Lung function (FVC);	chr5:33260882	chr5:33424025~33440619:-
BRCA	cis	rs1479090	0.722	rs11941116	ENSG00000250027.1	RP11-563E2.2	-3.52	0.000459	0.0229	-0.14	-0.11	Lung cancer;	chr4:163092755	chr4:163108785~163119965:+
BRCA	cis	rs1479090	0.762	rs1947794	ENSG00000250027.1	RP11-563E2.2	-3.52	0.000459	0.0229	-0.14	-0.11	Lung cancer;	chr4:163092815	chr4:163108785~163119965:+
BRCA	cis	rs7824557	0.67	rs2736381	ENSG00000254866.2	DEFB109P3	3.52	0.000459	0.0229	0.15	0.11	Retinal vascular caliber;	chr8:11275257	chr8:12150895~12151134:-
BRCA	cis	rs2512987	1	rs2512985	ENSG00000254731.1	CTD-2005H7.1	-3.52	0.000459	0.023	-0.12	-0.11	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr11:86703401	chr11:86703099~86714092:+
BRCA	cis	rs72928364	0.86	rs13081830	ENSG00000256628.3	ZBTB11-AS1	3.51	0.000459	0.023	0.22	0.11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:101072418	chr3:101676475~101679217:+
BRCA	cis	rs6496932	0.635	rs11632761	ENSG00000259630.2	CTD-2262B20.1	-3.51	0.000459	0.023	-0.14	-0.11	Central corneal thickness;Corneal structure;	chr15:85387562	chr15:85415228~85415633:+
BRCA	cis	rs7746082	0.627	rs6938089	ENSG00000219902.1	RPL35P3	3.51	0.000459	0.023	0.14	0.11	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr6:106022195	chr6:105302453~105302823:-
BRCA	cis	rs875971	0.862	rs6460282	ENSG00000271064.1	RP11-792A8.3	3.51	0.000459	0.023	0.13	0.11	Aortic root size;	chr7:66226259	chr7:66748838~66749077:-
BRCA	cis	rs7246657	0.943	rs8106839	ENSG00000267470.4	ZNF571-AS1	3.51	0.000459	0.023	0.14	0.11	Coronary artery calcification;	chr19:37467573	chr19:37548914~37587348:+
BRCA	cis	rs10005067	0.967	rs28620206	ENSG00000249001.4	RP11-742B18.1	-3.51	0.000459	0.023	-0.13	-0.11	Total body bone mineral density (age 30-45);	chr4:87897217	chr4:87568035~87733956:-
BRCA	cis	rs1046491	1	rs8086362	ENSG00000264964.1	RP11-888D10.3	3.51	0.000459	0.023	0.22	0.11	Scarlet fever;	chr18:9243963	chr18:9315194~9334441:-
BRCA	cis	rs2236231	0.55	rs11627686	ENSG00000259502.1	RP11-643G16.3	3.51	0.000459	0.023	0.15	0.11	Plasma kynurenine levels in major depressive disorder;	chr14:67596860	chr14:67610986~67613864:+
BRCA	cis	rs656900	0.647	rs1615963	ENSG00000259548.1	RP11-38G5.2	3.51	0.000459	0.023	0.12	0.11	Cerebrospinal P-tau181p levels;	chr15:79823484	chr15:79832466~79833554:-
BRCA	cis	rs1830951	0.611	rs1359567	ENSG00000243350.1	RP11-379F12.3	3.51	0.000459	0.023	0.1	0.11	Eosinophil counts;	chr10:8524838	chr10:8052242~8053449:-
BRCA	cis	rs13287066	0.651	rs10992716	ENSG00000203364.2	RP11-370F5.4	-3.51	0.000459	0.023	-0.11	-0.11	Intelligence (multi-trait analysis);	chr9:93372615	chr9:93147040~93148556:+
BRCA	cis	rs875971	0.545	rs10950029	ENSG00000232559.3	GS1-124K5.12	3.51	0.000459	0.023	0.14	0.11	Aortic root size;	chr7:66169334	chr7:66554588~66576923:-
BRCA	cis	rs654950	0.875	rs55865698	ENSG00000230638.4	RP11-486B10.4	3.51	0.000459	0.023	0.14	0.11	Airway imaging phenotypes;	chr1:41521087	chr1:41542069~41544310:+
BRCA	cis	rs12760731	0.72	rs10913544	ENSG00000213057.5	C1orf220	3.51	0.000459	0.023	0.15	0.11	Obesity-related traits;	chr1:178381845	chr1:178542752~178548889:+
BRCA	cis	rs10043775	1	rs9325095	ENSG00000251330.3	CTD-2283N19.1	-3.51	0.000459	0.023	-0.13	-0.11	Periodontal microbiota;	chr5:148405595	chr5:148430159~148430807:-
BRCA	cis	rs7903456	0.648	rs2296061	ENSG00000200253.1	RNU6-529P	3.51	0.000459	0.023	0.14	0.11	Gout;Renal underexcretion gout;	chr10:87068293	chr10:87041238~87041341:-
BRCA	cis	rs9425766	0.962	rs1322777	ENSG00000227373.4	RP11-160H22.5	3.51	0.000459	0.023	0.15	0.11	Life satisfaction;	chr1:173889962	chr1:174115300~174160004:-
BRCA	cis	rs67478160	0.529	rs12880413	ENSG00000269910.1	RP11-73M18.10	3.51	0.000459	0.023	0.1	0.11	Schizophrenia;	chr14:103801070	chr14:103694516~103695050:-
BRCA	cis	rs67478160	0.619	rs11623546	ENSG00000269910.1	RP11-73M18.10	3.51	0.000459	0.023	0.1	0.11	Schizophrenia;	chr14:103802761	chr14:103694516~103695050:-
BRCA	cis	rs67478160	0.619	rs55824307	ENSG00000269910.1	RP11-73M18.10	3.51	0.000459	0.023	0.1	0.11	Schizophrenia;	chr14:103804870	chr14:103694516~103695050:-
BRCA	cis	rs910316	0.687	rs11627442	ENSG00000259138.1	RP11-950C14.7	-3.51	0.000459	0.023	-0.12	-0.11	Height;	chr14:75202946	chr14:75127153~75136930:+
BRCA	cis	rs2191566	0.691	rs8104802	ENSG00000266921.1	RP11-15A1.7	-3.51	0.000459	0.023	-0.13	-0.11	Acute lymphoblastic leukemia (childhood);	chr19:44084816	chr19:43996896~44002836:-
BRCA	cis	rs1865760	0.532	rs2794719	ENSG00000272462.2	U91328.19	-3.51	0.000459	0.023	-0.13	-0.11	Height;	chr6:26088662	chr6:25992662~26001775:+
BRCA	cis	rs853679	0.517	rs6922063	ENSG00000226314.6	ZNF192P1	-3.51	0.000459	0.023	-0.16	-0.11	Depression;	chr6:28126588	chr6:28161781~28169594:+
BRCA	cis	rs853679	0.517	rs2275508	ENSG00000226314.6	ZNF192P1	-3.51	0.000459	0.023	-0.16	-0.11	Depression;	chr6:28126953	chr6:28161781~28169594:+
BRCA	cis	rs13315871	1	rs9844128	ENSG00000272182.1	RP11-802O23.3	3.51	0.000459	0.023	0.22	0.11	Cholesterol, total;	chr3:58405400	chr3:58428255~58428815:+
BRCA	cis	rs2070488	0.965	rs4679060	ENSG00000232439.1	RPL18AP7	-3.51	0.000459	0.023	-0.12	-0.11	Electrocardiographic conduction measures;	chr3:38494770	chr3:38526802~38527325:-
BRCA	cis	rs35520189	1	rs12053091	ENSG00000274877.1	RP11-65I12.1	-3.51	0.000459	0.023	-0.16	-0.11	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:112853203	chr2:113237595~113240825:+
BRCA	cis	rs875971	1	rs6958271	ENSG00000273448.1	RP11-166O4.6	3.51	0.000459	0.023	0.1	0.11	Aortic root size;	chr7:66514344	chr7:67333047~67334383:+
BRCA	cis	rs875971	1	rs6958277	ENSG00000273448.1	RP11-166O4.6	3.51	0.000459	0.023	0.1	0.11	Aortic root size;	chr7:66514362	chr7:67333047~67334383:+
BRCA	cis	rs875971	0.895	rs6460278	ENSG00000229886.1	RP5-1132H15.3	-3.51	0.000459	0.023	-0.12	-0.11	Aortic root size;	chr7:66197749	chr7:66025126~66031544:-
BRCA	cis	rs875971	0.862	rs6460279	ENSG00000229886.1	RP5-1132H15.3	-3.51	0.000459	0.023	-0.12	-0.11	Aortic root size;	chr7:66197774	chr7:66025126~66031544:-
BRCA	cis	rs875971	0.862	rs28491091	ENSG00000229886.1	RP5-1132H15.3	-3.51	0.000459	0.023	-0.12	-0.11	Aortic root size;	chr7:66204077	chr7:66025126~66031544:-
BRCA	cis	rs6951245	0.507	rs11976805	ENSG00000224079.1	AC091729.7	-3.51	0.00046	0.023	-0.15	-0.11	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1099080	chr7:1074450~1078036:+
BRCA	cis	rs6943931	1	rs6944521	ENSG00000230658.1	KLHL7-AS1	-3.51	0.00046	0.023	-0.14	-0.11	Diabetic kidney disease;	chr7:22375284	chr7:23101228~23105703:-
BRCA	cis	rs6943931	1	rs60037887	ENSG00000230658.1	KLHL7-AS1	-3.51	0.00046	0.023	-0.14	-0.11	Diabetic kidney disease;	chr7:22376183	chr7:23101228~23105703:-
BRCA	cis	rs6943931	1	rs60263888	ENSG00000230658.1	KLHL7-AS1	-3.51	0.00046	0.023	-0.14	-0.11	Diabetic kidney disease;	chr7:22376217	chr7:23101228~23105703:-
BRCA	cis	rs6943931	1	rs60447703	ENSG00000230658.1	KLHL7-AS1	-3.51	0.00046	0.023	-0.14	-0.11	Diabetic kidney disease;	chr7:22376292	chr7:23101228~23105703:-
BRCA	cis	rs6943931	1	rs73682633	ENSG00000230658.1	KLHL7-AS1	-3.51	0.00046	0.023	-0.14	-0.11	Diabetic kidney disease;	chr7:22376508	chr7:23101228~23105703:-
BRCA	cis	rs6943931	1	rs73079301	ENSG00000230658.1	KLHL7-AS1	-3.51	0.00046	0.023	-0.14	-0.11	Diabetic kidney disease;	chr7:22376688	chr7:23101228~23105703:-
BRCA	cis	rs875971	0.862	rs6460290	ENSG00000106610.13	STAG3L4	3.51	0.00046	0.023	0.14	0.11	Aortic root size;	chr7:66344119	chr7:67302621~67321526:+
BRCA	cis	rs1007738	0.542	rs901747	ENSG00000200376.1	RNU5E-10P	3.51	0.00046	0.023	0.14	0.11	Bone mineral density (hip);	chr11:47183430	chr11:47576471~47576588:-
BRCA	cis	rs9533799	1	rs9533798	ENSG00000227258.4	SMIM2-AS1	3.51	0.00046	0.023	0.14	0.11	Amyotrophic lateral sclerosis;	chr13:44228369	chr13:44110451~44240517:+
BRCA	cis	rs6714710	0.603	rs11678591	ENSG00000228486.8	LINC01125	-3.51	0.00046	0.023	-0.09	-0.11	Posterior cortical atrophy and Alzheimer's disease;	chr2:97924538	chr2:97664217~97703064:+
BRCA	cis	rs6943931	0.697	rs60398445	ENSG00000230658.1	KLHL7-AS1	-3.51	0.00046	0.023	-0.17	-0.11	Diabetic kidney disease;	chr7:22377474	chr7:23101228~23105703:-
BRCA	cis	rs12701220	0.901	rs12701708	ENSG00000224079.1	AC091729.7	3.51	0.00046	0.023	0.16	0.11	Bronchopulmonary dysplasia;	chr7:1050697	chr7:1074450~1078036:+
BRCA	cis	rs3015497	0.637	rs28888411	ENSG00000259113.1	RP11-406H23.2	-3.51	0.00046	0.023	-0.12	-0.11	Mean platelet volume;	chr14:50708951	chr14:50448807~50456742:+
BRCA	cis	rs875971	0.893	rs62465470	ENSG00000164669.11	INTS4P1	3.51	0.00046	0.023	0.13	0.11	Aortic root size;	chr7:66136231	chr7:65141225~65234216:+
BRCA	cis	rs6496932	0.635	rs11074191	ENSG00000259630.2	CTD-2262B20.1	-3.51	0.00046	0.023	-0.14	-0.11	Central corneal thickness;Corneal structure;	chr15:85388794	chr15:85415228~85415633:+
BRCA	cis	rs9457247	0.602	rs2157388	ENSG00000272549.1	RP11-351J23.2	-3.51	0.00046	0.023	-0.11	-0.11	Crohn's disease;	chr6:167068424	chr6:167666840~167679270:-
BRCA	cis	rs867371	0.762	rs12905578	ENSG00000278603.1	RP13-608F4.5	-3.51	0.00046	0.023	-0.15	-0.11	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82288923	chr15:82472203~82472426:+
BRCA	cis	rs11175492	1	rs12368761	ENSG00000243024.5	RPS11P6	-3.51	0.00046	0.023	-0.26	-0.11	Platelet count;	chr12:64682693	chr12:64222337~64397065:+
BRCA	cis	rs11686241	0.688	rs284538	ENSG00000241520.1	AC098820.4	-3.51	0.00046	0.023	-0.17	-0.11	Cancer;	chr2:216510924	chr2:216483032~216487196:-
BRCA	cis	rs9847710	1	rs13088455	ENSG00000242849.2	ALDOAP1	-3.51	0.00046	0.023	-0.12	-0.11	Ulcerative colitis;	chr3:53053466	chr3:52193170~52194785:+
BRCA	cis	rs4742903	0.527	rs7855137	ENSG00000270332.1	SMC2-AS1	3.51	0.00046	0.023	0.12	0.11	Breast cancer;High-grade serous ovarian cancer;	chr9:104229065	chr9:104080024~104093073:-
BRCA	cis	rs40067	1	rs288154	ENSG00000272523.1	LINC01023	3.51	0.00046	0.023	0.12	0.11	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr5:108039359	chr5:108727825~108728260:-
BRCA	cis	rs4713118	0.615	rs9348772	ENSG00000219392.1	RP1-265C24.5	-3.51	0.00046	0.023	-0.14	-0.11	Parkinson's disease;	chr6:27688311	chr6:28115628~28116551:+
BRCA	cis	rs8180040	0.62	rs9858443	ENSG00000280667.1	Y_RNA	3.51	0.00046	0.023	0.12	0.11	Colorectal cancer;	chr3:47044558	chr3:47501083~47501182:+
BRCA	cis	rs8180040	0.62	rs4683322	ENSG00000280667.1	Y_RNA	3.51	0.00046	0.023	0.12	0.11	Colorectal cancer;	chr3:47051699	chr3:47501083~47501182:+
BRCA	cis	rs11877825	0.826	rs8088116	ENSG00000265728.1	RP11-883A18.3	-3.51	0.00046	0.023	-0.15	-0.11	Gut microbiota (bacterial taxa);	chr18:10579882	chr18:10594590~10604798:+
BRCA	cis	rs4578769	0.959	rs3863525	ENSG00000273232.1	RP11-370A5.2	3.51	0.00046	0.023	0.14	0.11	Eosinophil percentage of white cells;	chr18:22898714	chr18:22882825~22883357:-
BRCA	cis	rs4578769	0.959	rs4800137	ENSG00000273232.1	RP11-370A5.2	3.51	0.00046	0.023	0.14	0.11	Eosinophil percentage of white cells;	chr18:22899721	chr18:22882825~22883357:-
BRCA	cis	rs7267979	0.745	rs6132845	ENSG00000277938.1	RP5-965G21.3	3.51	0.00046	0.023	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25567131	chr20:25229150~25231933:+
BRCA	cis	rs1670533	1	rs4690215	ENSG00000251639.2	RP11-20I20.1	3.51	0.00046	0.023	0.17	0.11	Recombination rate (females);	chr4:1060831	chr4:1100016~1101558:-
BRCA	cis	rs1670533	0.932	rs4690214	ENSG00000251639.2	RP11-20I20.1	3.51	0.00046	0.023	0.17	0.11	Recombination rate (females);	chr4:1060848	chr4:1100016~1101558:-
BRCA	cis	rs1670533	1	rs4690212	ENSG00000251639.2	RP11-20I20.1	3.51	0.00046	0.023	0.17	0.11	Recombination rate (females);	chr4:1061110	chr4:1100016~1101558:-
BRCA	cis	rs1670533	1	rs10902752	ENSG00000251639.2	RP11-20I20.1	3.51	0.00046	0.023	0.17	0.11	Recombination rate (females);	chr4:1062411	chr4:1100016~1101558:-
BRCA	cis	rs1670533	1	rs7673898	ENSG00000251639.2	RP11-20I20.1	3.51	0.00046	0.023	0.17	0.11	Recombination rate (females);	chr4:1062781	chr4:1100016~1101558:-
BRCA	cis	rs1670533	0.932	rs4690347	ENSG00000251639.2	RP11-20I20.1	3.51	0.00046	0.023	0.17	0.11	Recombination rate (females);	chr4:1063540	chr4:1100016~1101558:-
BRCA	cis	rs1670533	0.932	rs11731289	ENSG00000251639.2	RP11-20I20.1	3.51	0.00046	0.023	0.17	0.11	Recombination rate (females);	chr4:1063985	chr4:1100016~1101558:-
BRCA	cis	rs12915845	0.603	rs11073783	ENSG00000271997.1	RP11-97O12.6	-3.51	0.00046	0.023	-0.09	-0.11	Menarche (age at onset);	chr15:88500530	chr15:88501944~88505787:-
BRCA	cis	rs9868809	0.881	rs7620853	ENSG00000225399.4	RP11-3B7.1	-3.51	0.00046	0.023	-0.17	-0.11	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48629070	chr3:49260085~49261316:+
BRCA	cis	rs2274273	1	rs67805055	ENSG00000259318.1	RP11-454L9.2	3.51	0.00046	0.023	0.09	0.11	Protein biomarker;	chr14:55120834	chr14:55394940~55395233:-
BRCA	cis	rs28489187	0.683	rs12047422	ENSG00000223653.4	RP11-131L23.1	3.51	0.00046	0.023	0.13	0.11	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85383147	chr1:85276715~85448124:+
BRCA	cis	rs10191559	0.585	rs4233791	ENSG00000234663.4	AC104820.2	3.51	0.000461	0.023	0.1	0.11	Red blood cell count;	chr2:181197340	chr2:181101932~181399559:+
BRCA	cis	rs6601327	0.641	rs4129360	ENSG00000233609.3	RP11-62H7.2	-3.51	0.000461	0.023	-0.1	-0.11	Multiple myeloma (hyperdiploidy);	chr8:9715774	chr8:8961200~8979025:+
BRCA	cis	rs7487075	0.718	rs4768735	ENSG00000257261.4	RP11-96H19.1	-3.51	0.000461	0.023	-0.12	-0.11	Itch intensity from mosquito bite;	chr12:46550351	chr12:46383679~46876159:+
BRCA	cis	rs1348850	0.874	rs6742951	ENSG00000271825.1	RP11-337N6.2	3.51	0.000461	0.023	0.14	0.11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177476038	chr2:177300600~177302006:+
BRCA	cis	rs74233809	0.901	rs3824754	ENSG00000213061.2	PFN1P11	3.51	0.000461	0.023	0.23	0.11	Birth weight;	chr10:102854593	chr10:102838011~102845473:-
BRCA	cis	rs1007738	0.542	rs10838664	ENSG00000200376.1	RNU5E-10P	-3.51	0.000461	0.023	-0.14	-0.11	Bone mineral density (hip);	chr11:47182353	chr11:47576471~47576588:-
BRCA	cis	rs2692947	0.666	rs7566050	ENSG00000168992.4	OR7E102P	3.51	0.000461	0.023	0.15	0.11	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95960282	chr2:95546531~95547545:+
BRCA	cis	rs7520050	0.966	rs2275426	ENSG00000234329.1	RP11-767N6.2	-3.51	0.000461	0.023	-0.1	-0.11	Reticulocyte count;Red blood cell count;	chr1:46021880	chr1:45651039~45651826:-
BRCA	cis	rs6714710	0.603	rs1875699	ENSG00000228486.8	LINC01125	-3.51	0.000461	0.023	-0.09	-0.11	Posterior cortical atrophy and Alzheimer's disease;	chr2:97964261	chr2:97664217~97703064:+
BRCA	cis	rs875971	0.83	rs6976714	ENSG00000265600.1	AC006480.1	-3.51	0.000461	0.023	-0.13	-0.11	Aortic root size;	chr7:66426474	chr7:67356680~67356779:+
BRCA	cis	rs4578769	0.76	rs7227956	ENSG00000273232.1	RP11-370A5.2	3.51	0.000461	0.023	0.14	0.11	Eosinophil percentage of white cells;	chr18:22933855	chr18:22882825~22883357:-
BRCA	cis	rs848490	0.963	rs17385959	ENSG00000214293.7	APTR	3.51	0.000461	0.023	0.14	0.11	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77750439	chr7:77657660~77696265:-
BRCA	cis	rs6012564	1	rs755589	ENSG00000222365.1	SNORD12B	3.51	0.000461	0.0231	0.12	0.11	Anger;	chr20:49104848	chr20:49280319~49280409:+
BRCA	cis	rs9662633	1	rs6664760	ENSG00000227372.9	TP73-AS1	3.51	0.000461	0.0231	0.18	0.11	Visceral adipose tissue adjusted for BMI;	chr1:3731704	chr1:3735601~3747336:-
BRCA	cis	rs6743226	0.603	rs72484048	ENSG00000266621.1	AC104841.1	3.51	0.000461	0.0231	0.13	0.11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in non-smokers;	chr2:241287944	chr2:241245202~241245299:-
BRCA	cis	rs875971	0.522	rs1701760	ENSG00000227113.2	RP11-460N20.4	3.51	0.000461	0.0231	0.11	0.11	Aortic root size;	chr7:66008701	chr7:65075023~65078780:+
BRCA	cis	rs4950322	0.563	rs6686480	ENSG00000237188.3	RP11-337C18.8	3.51	0.000461	0.0231	0.13	0.11	Protein quantitative trait loci;	chr1:147111986	chr1:147172771~147211568:+
BRCA	cis	rs739401	0.572	rs12276060	ENSG00000247473.2	CARS-AS1	3.51	0.000461	0.0231	0.12	0.11	Longevity;	chr11:2994342	chr11:3029009~3041260:+
BRCA	cis	rs863345	0.604	rs10908666	ENSG00000229914.1	RP11-404O13.4	-3.51	0.000461	0.0231	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158530308	chr1:158195633~158196131:-
BRCA	cis	rs863345	0.564	rs10908667	ENSG00000229914.1	RP11-404O13.4	-3.51	0.000461	0.0231	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158530331	chr1:158195633~158196131:-
BRCA	cis	rs1075265	0.73	rs805391	ENSG00000272156.1	RP11-477N3.1	3.51	0.000461	0.0231	0.11	0.11	Chronotype;Morning vs. evening chronotype;	chr2:53877181	chr2:54082554~54085066:+
BRCA	cis	rs10782582	0.593	rs79552201	ENSG00000181227.3	RP4-682C21.2	3.51	0.000461	0.0231	0.11	0.11	Daytime sleep phenotypes;	chr1:75749812	chr1:75743423~75744776:-
BRCA	cis	rs73222236	0.825	rs9831321	ENSG00000239213.4	NCK1-AS1	-3.51	0.000461	0.0231	-0.12	-0.11	Coronary artery disease;	chr3:136423750	chr3:136841726~136862054:-
BRCA	cis	rs2274273	0.905	rs8007620	ENSG00000259318.1	RP11-454L9.2	3.51	0.000461	0.0231	0.09	0.11	Protein biomarker;	chr14:55119869	chr14:55394940~55395233:-
BRCA	cis	rs853679	0.607	rs34662244	ENSG00000216901.1	AL022393.7	3.51	0.000461	0.0231	0.29	0.11	Depression;	chr6:28106103	chr6:28176188~28176674:+
BRCA	cis	rs35952432	1	rs35952432	ENSG00000216901.1	AL022393.7	3.51	0.000461	0.0231	0.29	0.11	Lung cancer;	chr6:28107123	chr6:28176188~28176674:+
BRCA	cis	rs1941023	0.625	rs556448	ENSG00000254477.1	AP000640.10	3.51	0.000461	0.0231	0.13	0.11	Congenital heart disease (maternal effect);	chr11:60627708	chr11:59753015~59754975:-
BRCA	cis	rs7226408	0.842	rs62083176	ENSG00000267707.2	RP11-95O2.5	3.51	0.000461	0.0231	0.18	0.11	Obesity-related traits;	chr18:36744732	chr18:37243776~37247506:+
BRCA	cis	rs4713118	0.621	rs9295755	ENSG00000216901.1	AL022393.7	-3.51	0.000461	0.0231	-0.16	-0.11	Parkinson's disease;	chr6:28065396	chr6:28176188~28176674:+
BRCA	cis	rs860295	0.812	rs4278368	ENSG00000203761.5	MSTO2P	-3.51	0.000461	0.0231	-0.09	-0.11	Body mass index;	chr1:155752766	chr1:155745829~155750137:+
BRCA	cis	rs17301013	0.73	rs12060177	ENSG00000200674.1	RN7SKP160	3.51	0.000461	0.0231	0.14	0.11	Systemic lupus erythematosus;	chr1:174618545	chr1:173791548~173791887:+
BRCA	cis	rs8177876	0.822	rs12443549	ENSG00000261141.1	RP11-303E16.5	-3.51	0.000461	0.0231	-0.19	-0.11	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81070596	chr16:81055301~81056426:+
BRCA	cis	rs12705054	0.52	rs10281195	ENSG00000214142.2	RPL7P60	3.51	0.000461	0.0231	0.17	0.11	Facial emotion recognition (sad faces);	chr7:99264292	chr7:100139629~100140682:-
BRCA	cis	rs911119	0.913	rs6048923	ENSG00000270001.1	RP11-218C14.8	-3.51	0.000462	0.0231	-0.15	-0.11	Chronic kidney disease;	chr20:23597569	chr20:23631826~23632316:-
BRCA	cis	rs7267979	0.966	rs6083818	ENSG00000276952.1	RP5-965G21.6	-3.51	0.000462	0.0231	-0.13	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25365446	chr20:25284915~25285588:-
BRCA	cis	rs7267979	1	rs4815409	ENSG00000276952.1	RP5-965G21.6	-3.51	0.000462	0.0231	-0.13	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25366061	chr20:25284915~25285588:-
BRCA	cis	rs8073765	0.661	rs9915975	ENSG00000236088.8	COX10-AS1	3.51	0.000462	0.0231	0.14	0.11	Verbal memory performance (immediate recall change);	chr17:13728451	chr17:13756478~14069495:-
BRCA	cis	rs875971	0.862	rs1860469	ENSG00000265600.1	AC006480.1	3.51	0.000462	0.0231	0.13	0.11	Aortic root size;	chr7:66641888	chr7:67356680~67356779:+
BRCA	cis	rs934734	0.752	rs2661797	ENSG00000204929.10	AC074391.1	-3.51	0.000462	0.0231	-0.13	-0.11	Rheumatoid arthritis;	chr2:65406056	chr2:65436711~66084639:+
BRCA	cis	rs9951698	0.703	rs9964466	ENSG00000266969.1	RP11-773H22.4	3.51	0.000462	0.0231	0.14	0.11	Intelligence (multi-trait analysis);	chr18:13030384	chr18:12984694~12991173:-
BRCA	cis	rs258892	0.846	rs266441	ENSG00000272525.1	RP11-79P5.9	3.51	0.000462	0.0231	0.14	0.11	Small cell lung carcinoma;	chr5:72901850	chr5:73497550~73498293:-
BRCA	cis	rs6142102	0.961	rs4911405	ENSG00000206582.1	Y_RNA	-3.51	0.000462	0.0231	-0.14	-0.11	Skin pigmentation;	chr20:34087161	chr20:34526510~34526606:-
BRCA	cis	rs11792861	0.589	rs2176692	ENSG00000169253.3	RP11-220D10.1	3.51	0.000462	0.0231	0.13	0.11	Menarche (age at onset);	chr9:109165443	chr9:108626833~108627150:+
BRCA	cis	rs7020830	0.931	rs3802422	ENSG00000230188.1	RP11-405L18.4	-3.51	0.000462	0.0231	-0.13	-0.11	Schizophrenia;	chr9:37097175	chr9:37490421~37490893:-
BRCA	cis	rs2274273	0.745	rs748017	ENSG00000233924.1	AL160471.6	-3.51	0.000462	0.0231	-0.12	-0.11	Protein biomarker;	chr14:55075582	chr14:55004813~55005687:-
BRCA	cis	rs80028505	0.908	rs60909394	ENSG00000271304.1	DPRXP2	3.51	0.000462	0.0231	0.19	0.11	Foot ulcer in diabetes and neuropathy;	chr6:36087155	chr6:35989515~35990436:-
BRCA	cis	rs13256369	0.802	rs13281933	ENSG00000254153.1	CTA-398F10.2	3.51	0.000462	0.0231	0.15	0.11	Obesity-related traits;	chr8:8705155	chr8:8456909~8461337:-
BRCA	cis	rs11686241	1	rs13410848	ENSG00000241520.1	AC098820.4	3.51	0.000462	0.0231	0.17	0.11	Cancer;	chr2:216425920	chr2:216483032~216487196:-
BRCA	cis	rs875971	0.505	rs1167385	ENSG00000229180.5	GS1-124K5.11	-3.51	0.000462	0.0231	-0.09	-0.11	Aortic root size;	chr7:66048321	chr7:66526088~66542624:-
BRCA	cis	rs35306767	0.903	rs11253494	ENSG00000229869.1	RP11-363N22.2	-3.51	0.000462	0.0231	-0.16	-0.11	Eosinophil percentage of granulocytes;	chr10:891107	chr10:933026~942743:+
BRCA	cis	rs74233809	1	rs11191515	ENSG00000213061.2	PFN1P11	3.51	0.000462	0.0231	0.25	0.11	Birth weight;	chr10:103016770	chr10:102838011~102845473:-
BRCA	cis	rs1670533	1	rs652063	ENSG00000251639.2	RP11-20I20.1	3.51	0.000462	0.0231	0.17	0.11	Recombination rate (females);	chr4:1090349	chr4:1100016~1101558:-
BRCA	cis	rs1670533	0.818	rs643484	ENSG00000251639.2	RP11-20I20.1	3.51	0.000462	0.0231	0.17	0.11	Recombination rate (females);	chr4:1092038	chr4:1100016~1101558:-
BRCA	cis	rs4657482	0.606	rs3790665	ENSG00000236364.3	RP11-525G13.2	-3.51	0.000462	0.0231	-0.1	-0.11	Testicular germ cell tumor;	chr1:165900834	chr1:165890795~165900683:-
BRCA	cis	rs2856321	0.903	rs2860431	ENSG00000256651.1	RP11-144O23.8	-3.51	0.000462	0.0231	-0.11	-0.11	Height;	chr12:11713129	chr12:10831074~10832016:-
BRCA	cis	rs718433	0.584	rs7160973	ENSG00000211778.2	TRAV4	-3.51	0.000462	0.0231	-0.08	-0.11	Intraocular pressure;	chr14:21748391	chr14:21736152~21736982:+
BRCA	cis	rs10266483	0.545	rs114664455	ENSG00000227986.1	TRIM60P18	3.51	0.000462	0.0231	0.14	0.11	Response to statin therapy;	chr7:64263634	chr7:64355078~64356199:+
BRCA	cis	rs6445975	0.915	rs11130633	ENSG00000272360.1	RP11-359I18.5	3.51	0.000462	0.0231	0.12	0.11	Systemic lupus erythematosus;	chr3:58385065	chr3:58490830~58491291:-
BRCA	cis	rs5167	0.677	rs2238682	ENSG00000214855.8	APOC1P1	3.51	0.000462	0.0231	0.14	0.11	Blood protein levels;	chr19:44955336	chr19:44926804~44931386:+
BRCA	cis	rs4950322	0.542	rs56080828	ENSG00000227242.3	NBPF13P	-3.51	0.000462	0.0231	-0.15	-0.11	Protein quantitative trait loci;	chr1:147183447	chr1:147021320~147124525:-
BRCA	cis	rs3096277	0.955	rs403740	ENSG00000260228.4	RP11-483P21.2	3.51	0.000462	0.0231	0.15	0.11	Blood pressure;	chr16:83733528	chr16:83789967~83807834:-
BRCA	cis	rs988913	0.706	rs4296891	ENSG00000261116.1	RP3-523K23.2	-3.51	0.000462	0.0231	-0.13	-0.11	Menarche (age at onset);	chr6:55073395	chr6:54943167~54945099:+
BRCA	cis	rs7246967	0.608	rs2569725	ENSG00000198153.8	ZNF849P	-3.51	0.000462	0.0231	-0.16	-0.11	Bronchopulmonary dysplasia;	chr19:22833208	chr19:22685167~22686732:+
BRCA	cis	rs2025151	0.591	rs10990610	ENSG00000224848.1	RP11-535M15.1	3.51	0.000462	0.0231	0.18	0.11	Height;	chr9:96338431	chr9:96687056~96721121:+
BRCA	cis	rs17209837	0.607	rs2109505	ENSG00000224046.1	AC005076.5	3.51	0.000462	0.0231	0.14	0.11	Gallbladder cancer;	chr7:87450090	chr7:87151423~87152420:-
BRCA	cis	rs2952768	1	rs2551941	ENSG00000224137.1	AC079767.4	-3.51	0.000462	0.0231	-0.09	-0.11	Opioid sensitivity;	chr2:207627419	chr2:207662375~207667024:+
BRCA	cis	rs8114671	0.742	rs6058161	ENSG00000261582.1	RP4-614O4.11	3.51	0.000462	0.0231	0.1	0.11	Height;	chr20:35032223	chr20:35267885~35280043:-
BRCA	cis	rs6762	0.719	rs28655651	ENSG00000255108.1	AP006621.8	3.51	0.000462	0.0231	0.12	0.11	Mean platelet volume;	chr11:837121	chr11:823634~832883:-
BRCA	cis	rs10266483	0.545	rs73132069	ENSG00000227986.1	TRIM60P18	3.51	0.000463	0.0231	0.14	0.11	Response to statin therapy;	chr7:64258440	chr7:64355078~64356199:+
BRCA	cis	rs4272720	0.951	rs61850682	ENSG00000228754.1	RP11-534L6.3	-3.51	0.000463	0.0231	-0.15	-0.11	Platelet count;Plateletcrit;	chr10:49044213	chr10:48745545~48746128:-
BRCA	cis	rs361433	0.541	rs17163364	ENSG00000211720.3	TRBV11-1	3.51	0.000463	0.0231	0.19	0.11	Capecitabine sensitivity;	chr7:142491573	chr7:142407672~142408136:+
BRCA	cis	rs1119582	1	rs465730	ENSG00000279118.1	RP11-517I3.2	-3.51	0.000463	0.0231	-0.13	-0.11	Select biomarker traits;	chr5:125938798	chr5:126496279~126498604:+
BRCA	cis	rs75422866	0.867	rs79113930	ENSG00000276691.1	RP5-1057I20.5	3.51	0.000463	0.0231	0.23	0.11	Pneumonia;	chr12:47600628	chr12:47788426~47788971:+
BRCA	cis	rs2562456	0.874	rs2562417	ENSG00000268555.1	RP11-678G14.3	-3.51	0.000463	0.0231	-0.14	-0.11	Pain;	chr19:21528400	chr19:21570822~21587322:-
BRCA	cis	rs721917	0.525	rs2246111	ENSG00000225484.5	NUTM2B-AS1	-3.51	0.000463	0.0231	-0.15	-0.11	Chronic obstructive pulmonary disease;	chr10:79929985	chr10:79663088~79826594:-
BRCA	cis	rs561341	0.941	rs72825736	ENSG00000265798.5	RP11-271K11.5	3.51	0.000463	0.0231	0.19	0.11	Hip circumference adjusted for BMI;	chr17:32003267	chr17:31038575~31059121:-
BRCA	cis	rs1008375	0.866	rs2109518	ENSG00000249502.1	AC006160.5	-3.51	0.000463	0.0231	-0.13	-0.11	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17570539	chr4:17587467~17614571:-
BRCA	cis	rs67478160	0.595	rs12879501	ENSG00000269910.1	RP11-73M18.10	3.51	0.000463	0.0231	0.1	0.11	Schizophrenia;	chr14:103806297	chr14:103694516~103695050:-
BRCA	cis	rs8114671	0.562	rs8116657	ENSG00000126005.14	MMP24-AS1	-3.51	0.000463	0.0231	-0.13	-0.11	Height;	chr20:34888671	chr20:35216462~35278131:-
BRCA	cis	rs13401620	0.81	rs12477760	ENSG00000229326.3	AC069154.4	-3.51	0.000463	0.0231	-0.14	-0.11	Breast size;	chr2:119800891	chr2:119698623~119700151:+
BRCA	cis	rs832540	0.864	rs252908	ENSG00000271828.1	CTD-2310F14.1	-3.51	0.000463	0.0231	-0.13	-0.11	Coronary artery disease;	chr5:56824859	chr5:56927874~56929573:+
BRCA	cis	rs4589258	0.931	rs4550185	ENSG00000280367.1	RP11-121L10.2	3.51	0.000463	0.0231	0.13	0.11	Intelligence (multi-trait analysis);	chr11:90774882	chr11:90223153~90226538:+
BRCA	cis	rs7412746	0.611	rs7556661	ENSG00000224800.1	RP11-235D19.2	-3.51	0.000463	0.0231	-0.14	-0.11	Melanoma;	chr1:150919533	chr1:150881236~150881683:-
BRCA	cis	rs2274273	1	rs3825613	ENSG00000259318.1	RP11-454L9.2	3.51	0.000463	0.0231	0.09	0.11	Protein biomarker;	chr14:55126454	chr14:55394940~55395233:-
BRCA	cis	rs60843830	0.928	rs62114494	ENSG00000223751.1	AC116609.2	3.51	0.000463	0.0231	0.15	0.11	Spherical equivalent (joint analysis main effects and education interaction);	chr2:211317	chr2:742488~747767:+
BRCA	cis	rs853679	0.546	rs483143	ENSG00000216901.1	AL022393.7	3.51	0.000463	0.0231	0.21	0.11	Depression;	chr6:27878966	chr6:28176188~28176674:+
BRCA	cis	rs10266483	0.921	rs651934	ENSG00000228653.2	HNRNPCP7	-3.51	0.000463	0.0231	-0.13	-0.11	Response to statin therapy;	chr7:64283972	chr7:64500825~64501729:+
BRCA	cis	rs2692947	0.77	rs6719831	ENSG00000237510.6	AC008268.2	3.51	0.000463	0.0231	0.15	0.11	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95836842	chr2:95789654~95800166:+
BRCA	cis	rs1670533	1	rs7660779	ENSG00000251639.2	RP11-20I20.1	3.51	0.000463	0.0231	0.17	0.11	Recombination rate (females);	chr4:1082152	chr4:1100016~1101558:-
BRCA	cis	rs1479090	0.762	rs6829366	ENSG00000250027.1	RP11-563E2.2	-3.51	0.000463	0.0231	-0.14	-0.11	Lung cancer;	chr4:163133819	chr4:163108785~163119965:+
BRCA	cis	rs6460942	0.818	rs73299043	ENSG00000226690.5	AC005281.1	3.51	0.000463	0.0231	0.19	0.11	Coronary artery disease;	chr7:12211969	chr7:12496429~12541910:+
BRCA	cis	rs10486003	0.867	rs74362320	ENSG00000213455.3	AC091654.7	-3.51	0.000463	0.0231	-0.19	-0.11	Response to platinum-based agents;	chr7:97592134	chr7:98454119~98454617:-
BRCA	cis	rs613391	0.561	rs694541	ENSG00000265194.1	RP11-70L8.4	-3.51	0.000463	0.0231	-0.11	-0.11	Quantitative traits;	chr9:22722357	chr9:21858910~21861926:-
BRCA	cis	rs7103648	1	rs10838709	ENSG00000280615.1	Y_RNA	3.51	0.000463	0.0231	0.13	0.11	Systolic blood pressure;Diastolic blood pressure;	chr11:47425795	chr11:47614898~47614994:-
BRCA	cis	rs2333021	0.833	rs10141389	ENSG00000259015.1	RP11-109N23.6	3.51	0.000463	0.0231	0.11	0.11	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:73000413	chr14:72960595~72961993:+
BRCA	cis	rs11035577	0.632	rs1507650	ENSG00000279675.1	RP11-454H19.2	-3.51	0.000463	0.0232	-0.17	-0.11	Temperament (bipolar disorder);	chr11:39749476	chr11:40107244~40112599:-
BRCA	cis	rs13126694	0.682	rs4504305	ENSG00000251073.1	NUDT19P5	3.51	0.000464	0.0232	0.1	0.11	Blood osmolality (transformed sodium);	chr4:157982801	chr4:158182825~158183393:+
BRCA	cis	rs9467773	0.525	rs1535274	ENSG00000261353.1	CTA-14H9.5	-3.51	0.000464	0.0232	-0.11	-0.11	Intelligence (multi-trait analysis);	chr6:26520519	chr6:26527063~26527404:+
BRCA	cis	rs9925964	0.933	rs4889530	ENSG00000262766.1	RP11-196G11.4	-3.51	0.000464	0.0232	-0.09	-0.11	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31054597	chr16:31118078~31118747:+
BRCA	cis	rs718433	0.782	rs11157216	ENSG00000211778.2	TRAV4	-3.51	0.000464	0.0232	-0.08	-0.11	Intraocular pressure;	chr14:21773507	chr14:21736152~21736982:+
BRCA	cis	rs1437396	0.507	rs3791633	ENSG00000203327.2	AC012358.7	-3.51	0.000464	0.0232	-0.11	-0.11	Alcohol dependence;	chr2:55319591	chr2:55214387~55216126:-
BRCA	cis	rs1437396	0.526	rs3791634	ENSG00000203327.2	AC012358.7	-3.51	0.000464	0.0232	-0.11	-0.11	Alcohol dependence;	chr2:55319612	chr2:55214387~55216126:-
BRCA	cis	rs16846053	0.502	rs62188848	ENSG00000227403.1	AC009299.3	3.51	0.000464	0.0232	0.27	0.11	Blood osmolality (transformed sodium);	chr2:161920434	chr2:161244739~161249050:+
BRCA	cis	rs7404928	0.536	rs195995	ENSG00000260136.4	CTD-2270L9.4	-3.51	0.000464	0.0232	-0.1	-0.11	Rheumatoid arthritis;Primary biliary cholangitis;	chr16:23943078	chr16:23452758~23457606:+
BRCA	cis	rs13315871	1	rs12330157	ENSG00000272182.1	RP11-802O23.3	3.51	0.000464	0.0232	0.22	0.11	Cholesterol, total;	chr3:58378835	chr3:58428255~58428815:+
BRCA	cis	rs13315871	1	rs36097398	ENSG00000272182.1	RP11-802O23.3	3.51	0.000464	0.0232	0.22	0.11	Cholesterol, total;	chr3:58381603	chr3:58428255~58428815:+
BRCA	cis	rs13315871	1	rs13096020	ENSG00000272182.1	RP11-802O23.3	3.51	0.000464	0.0232	0.22	0.11	Cholesterol, total;	chr3:58382044	chr3:58428255~58428815:+
BRCA	cis	rs4869313	0.668	rs1981846	ENSG00000248734.2	CTD-2260A17.1	3.51	0.000464	0.0232	0.11	0.11	Pediatric autoimmune diseases;	chr5:96933158	chr5:96784777~96785999:+
BRCA	cis	rs6600671	0.899	rs11249432	ENSG00000275131.1	CH17-472G23.4	-3.51	0.000464	0.0232	-0.1	-0.11	Hip geometry;	chr1:121541678	chr1:120489625~120579190:-
BRCA	cis	rs7246657	0.508	rs1644702	ENSG00000267470.4	ZNF571-AS1	3.51	0.000464	0.0232	0.17	0.11	Coronary artery calcification;	chr19:37001005	chr19:37548914~37587348:+
BRCA	cis	rs656900	0.647	rs600671	ENSG00000259548.1	RP11-38G5.2	-3.51	0.000464	0.0232	-0.12	-0.11	Cerebrospinal P-tau181p levels;	chr15:79824890	chr15:79832466~79833554:-
BRCA	cis	rs10090774	0.965	rs7005021	ENSG00000280303.2	ERICD	3.51	0.000464	0.0232	0.13	0.11	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140859797	chr8:140636281~140638283:+
BRCA	cis	rs8105895	0.935	rs10406551	ENSG00000269345.1	VN1R85P	3.51	0.000464	0.0232	0.15	0.11	Body mass index (change over time);	chr19:22061718	chr19:22174766~22175191:-
BRCA	cis	rs8105895	0.935	rs10405613	ENSG00000269345.1	VN1R85P	3.51	0.000464	0.0232	0.15	0.11	Body mass index (change over time);	chr19:22061970	chr19:22174766~22175191:-
BRCA	cis	rs8105895	0.935	rs10405673	ENSG00000269345.1	VN1R85P	3.51	0.000464	0.0232	0.15	0.11	Body mass index (change over time);	chr19:22062088	chr19:22174766~22175191:-
BRCA	cis	rs8105895	0.935	rs10406485	ENSG00000269345.1	VN1R85P	3.51	0.000464	0.0232	0.15	0.11	Body mass index (change over time);	chr19:22062200	chr19:22174766~22175191:-
BRCA	cis	rs8105895	0.935	rs10406119	ENSG00000269345.1	VN1R85P	3.51	0.000464	0.0232	0.15	0.11	Body mass index (change over time);	chr19:22062207	chr19:22174766~22175191:-
BRCA	cis	rs8105895	0.935	rs10408150	ENSG00000269345.1	VN1R85P	3.51	0.000464	0.0232	0.15	0.11	Body mass index (change over time);	chr19:22062423	chr19:22174766~22175191:-
BRCA	cis	rs8105895	0.935	rs7251884	ENSG00000269345.1	VN1R85P	3.51	0.000464	0.0232	0.15	0.11	Body mass index (change over time);	chr19:22062728	chr19:22174766~22175191:-
BRCA	cis	rs8105895	0.935	rs7252023	ENSG00000269345.1	VN1R85P	3.51	0.000464	0.0232	0.15	0.11	Body mass index (change over time);	chr19:22062844	chr19:22174766~22175191:-
BRCA	cis	rs8105895	0.935	rs7252550	ENSG00000269345.1	VN1R85P	3.51	0.000464	0.0232	0.15	0.11	Body mass index (change over time);	chr19:22063215	chr19:22174766~22175191:-
BRCA	cis	rs8105895	0.935	rs10413784	ENSG00000269345.1	VN1R85P	3.51	0.000464	0.0232	0.15	0.11	Body mass index (change over time);	chr19:22063389	chr19:22174766~22175191:-
BRCA	cis	rs8105895	0.935	rs10407173	ENSG00000269345.1	VN1R85P	3.51	0.000464	0.0232	0.15	0.11	Body mass index (change over time);	chr19:22063861	chr19:22174766~22175191:-
BRCA	cis	rs8105895	0.935	rs8104144	ENSG00000269345.1	VN1R85P	3.51	0.000464	0.0232	0.15	0.11	Body mass index (change over time);	chr19:22064111	chr19:22174766~22175191:-
BRCA	cis	rs8105895	0.935	rs8103518	ENSG00000269345.1	VN1R85P	3.51	0.000464	0.0232	0.15	0.11	Body mass index (change over time);	chr19:22064150	chr19:22174766~22175191:-
BRCA	cis	rs8105895	0.935	rs8104630	ENSG00000269345.1	VN1R85P	3.51	0.000464	0.0232	0.15	0.11	Body mass index (change over time);	chr19:22064475	chr19:22174766~22175191:-
BRCA	cis	rs8105895	0.935	rs9653157	ENSG00000269345.1	VN1R85P	3.51	0.000464	0.0232	0.15	0.11	Body mass index (change over time);	chr19:22066688	chr19:22174766~22175191:-
BRCA	cis	rs8105895	0.935	rs9653142	ENSG00000269345.1	VN1R85P	3.51	0.000464	0.0232	0.15	0.11	Body mass index (change over time);	chr19:22066794	chr19:22174766~22175191:-
BRCA	cis	rs8105895	0.935	rs7247147	ENSG00000269345.1	VN1R85P	3.51	0.000464	0.0232	0.15	0.11	Body mass index (change over time);	chr19:22067056	chr19:22174766~22175191:-
BRCA	cis	rs8105895	0.935	rs7250905	ENSG00000269345.1	VN1R85P	3.51	0.000464	0.0232	0.15	0.11	Body mass index (change over time);	chr19:22067941	chr19:22174766~22175191:-
BRCA	cis	rs8105895	0.935	rs2043317	ENSG00000269345.1	VN1R85P	3.51	0.000464	0.0232	0.15	0.11	Body mass index (change over time);	chr19:22068294	chr19:22174766~22175191:-
BRCA	cis	rs8105895	0.935	rs2043316	ENSG00000269345.1	VN1R85P	3.51	0.000464	0.0232	0.15	0.11	Body mass index (change over time);	chr19:22068402	chr19:22174766~22175191:-
BRCA	cis	rs8105895	0.935	rs8108651	ENSG00000269345.1	VN1R85P	3.51	0.000464	0.0232	0.15	0.11	Body mass index (change over time);	chr19:22068662	chr19:22174766~22175191:-
BRCA	cis	rs8105895	0.935	rs10420019	ENSG00000269345.1	VN1R85P	3.51	0.000464	0.0232	0.15	0.11	Body mass index (change over time);	chr19:22069103	chr19:22174766~22175191:-
BRCA	cis	rs8105895	0.778	rs10401922	ENSG00000269345.1	VN1R85P	3.51	0.000464	0.0232	0.15	0.11	Body mass index (change over time);	chr19:22070450	chr19:22174766~22175191:-
BRCA	cis	rs8105895	0.935	rs10422289	ENSG00000269345.1	VN1R85P	3.51	0.000464	0.0232	0.15	0.11	Body mass index (change over time);	chr19:22073258	chr19:22174766~22175191:-
BRCA	cis	rs62025270	0.547	rs1026722	ENSG00000259762.1	RP11-158M2.4	3.51	0.000464	0.0232	0.14	0.11	Idiopathic pulmonary fibrosis;	chr15:85576168	chr15:85750336~85752901:-
BRCA	cis	rs2041840	0.521	rs4670193	ENSG00000272054.1	RP11-423P10.2	-3.51	0.000464	0.0232	-0.09	-0.11	Chronic lymphocytic leukemia;	chr2:37309345	chr2:37208875~37212677:+
BRCA	cis	rs787274	1	rs1891403	ENSG00000271631.1	RP11-408O19.5	3.51	0.000464	0.0232	0.18	0.11	Age-related hearing impairment (SNP x SNP interaction);	chr9:112764903	chr9:112885158~112885767:+
BRCA	cis	rs1250259	0.519	rs6435906	ENSG00000225166.1	AC012462.2	-3.51	0.000464	0.0232	-0.13	-0.11	Coronary artery disease;Pulse pressure;	chr2:215404917	chr2:215453707~215463871:+
BRCA	cis	rs1878931	0.624	rs39728	ENSG00000263280.1	LA16c-325D7.2	3.51	0.000464	0.0232	0.11	0.11	Body mass index (adult);	chr16:3403076	chr16:2866348~2867618:-
BRCA	cis	rs11892454	0.565	rs9309434	ENSG00000217643.1	PTGES3P2	3.51	0.000465	0.0232	0.12	0.11	Heschl's gyrus morphology;	chr2:25853557	chr2:25822469~25822950:+
BRCA	cis	rs9951698	0.703	rs6505776	ENSG00000266969.1	RP11-773H22.4	3.51	0.000465	0.0232	0.14	0.11	Intelligence (multi-trait analysis);	chr18:12984145	chr18:12984694~12991173:-
BRCA	cis	rs13113518	0.51	rs10049561	ENSG00000273257.1	RP11-177J6.1	3.51	0.000465	0.0232	0.14	0.11	Height;	chr4:55426623	chr4:55387949~55388271:+
BRCA	cis	rs12724450	0.546	rs34448981	ENSG00000228126.1	FALEC	3.51	0.000465	0.0232	0.2	0.11	Blood protein levels;	chr1:150463101	chr1:150515757~150518032:+
BRCA	cis	rs9341808	0.754	rs6916405	ENSG00000233967.5	RP11-250B2.3	3.51	0.000465	0.0232	0.11	0.11	Sitting height ratio;	chr6:80314471	chr6:80443344~80465927:+
BRCA	cis	rs495337	0.662	rs6020072	ENSG00000224397.4	LINC01272	3.51	0.000465	0.0232	0.11	0.11	Psoriasis;	chr20:49828917	chr20:50267486~50279795:+
BRCA	cis	rs4374383	1	rs4374383	ENSG00000243389.1	AC012442.5	-3.51	0.000465	0.0232	-0.14	-0.11	Hepatitis C induced liver fibrosis;	chr2:112013193	chr2:112589040~112614431:+
BRCA	cis	rs2562456	0.52	rs25760	ENSG00000268081.1	RP11-678G14.2	3.51	0.000465	0.0232	0.18	0.11	Pain;	chr19:21211375	chr19:21554640~21569237:-
BRCA	cis	rs787274	1	rs787276	ENSG00000271631.1	RP11-408O19.5	3.51	0.000465	0.0232	0.18	0.11	Age-related hearing impairment (SNP x SNP interaction);	chr9:112789611	chr9:112885158~112885767:+
BRCA	cis	rs787274	1	rs4979148	ENSG00000271631.1	RP11-408O19.5	3.51	0.000465	0.0232	0.18	0.11	Age-related hearing impairment (SNP x SNP interaction);	chr9:112791119	chr9:112885158~112885767:+
BRCA	cis	rs787274	1	rs4979150	ENSG00000271631.1	RP11-408O19.5	3.51	0.000465	0.0232	0.18	0.11	Age-related hearing impairment (SNP x SNP interaction);	chr9:112791222	chr9:112885158~112885767:+
BRCA	cis	rs787274	1	rs10759584	ENSG00000271631.1	RP11-408O19.5	3.51	0.000465	0.0232	0.18	0.11	Age-related hearing impairment (SNP x SNP interaction);	chr9:112792456	chr9:112885158~112885767:+
BRCA	cis	rs787274	1	rs4979153	ENSG00000271631.1	RP11-408O19.5	3.51	0.000465	0.0232	0.18	0.11	Age-related hearing impairment (SNP x SNP interaction);	chr9:112792704	chr9:112885158~112885767:+
BRCA	cis	rs1670533	1	rs11725984	ENSG00000251639.2	RP11-20I20.1	3.51	0.000465	0.0232	0.17	0.11	Recombination rate (females);	chr4:1093550	chr4:1100016~1101558:-
BRCA	cis	rs875971	0.571	rs160647	ENSG00000226767.1	RP11-328P23.3	-3.51	0.000465	0.0232	-0.14	-0.11	Aortic root size;	chr7:66089365	chr7:65508773~65508944:-
BRCA	cis	rs8114671	0.836	rs734308	ENSG00000261582.1	RP4-614O4.11	3.51	0.000465	0.0232	0.11	0.11	Height;	chr20:34984293	chr20:35267885~35280043:-
BRCA	cis	rs11892454	0.565	rs56397444	ENSG00000217643.1	PTGES3P2	-3.51	0.000465	0.0232	-0.12	-0.11	Heschl's gyrus morphology;	chr2:25804283	chr2:25822469~25822950:+
BRCA	cis	rs11892454	0.565	rs10207926	ENSG00000217643.1	PTGES3P2	-3.51	0.000465	0.0232	-0.12	-0.11	Heschl's gyrus morphology;	chr2:25806538	chr2:25822469~25822950:+
BRCA	cis	rs11892454	0.526	rs10210497	ENSG00000217643.1	PTGES3P2	-3.51	0.000465	0.0232	-0.12	-0.11	Heschl's gyrus morphology;	chr2:25806616	chr2:25822469~25822950:+
BRCA	cis	rs6696239	0.956	rs7540382	ENSG00000215812.5	ZNF847P	3.51	0.000465	0.0232	0.15	0.11	Height;	chr1:227692595	chr1:227696892~227706699:-
BRCA	cis	rs2908197	0.843	rs1076437	ENSG00000205485.12	AC004980.7	3.51	0.000465	0.0232	0.12	0.11	3-hydroxypropylmercapturic acid levels in smokers;	chr7:76310404	chr7:76549360~76627982:+
BRCA	cis	rs2898857	0.898	rs2240300	ENSG00000250948.1	RP11-1079K10.2	-3.51	0.000465	0.0232	-0.15	-0.11	Cancer;	chr17:49300159	chr17:49375380~49380094:+
BRCA	cis	rs11170468	0.621	rs7313545	ENSG00000257718.1	RP11-396F22.1	-3.51	0.000465	0.0232	-0.14	-0.11	Body mass index;	chr12:39116002	chr12:38906451~38909592:+
BRCA	cis	rs9650657	0.537	rs7016385	ENSG00000255046.1	RP11-297N6.4	-3.51	0.000465	0.0232	-0.13	-0.11	Neuroticism;	chr8:10921962	chr8:11797928~11802568:-
BRCA	cis	rs40067	1	rs288172	ENSG00000272523.1	LINC01023	-3.51	0.000465	0.0232	-0.12	-0.11	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr5:108017414	chr5:108727825~108728260:-
BRCA	cis	rs801193	0.548	rs2659891	ENSG00000265600.1	AC006480.1	-3.51	0.000465	0.0232	-0.13	-0.11	Aortic root size;	chr7:66736127	chr7:67356680~67356779:+
BRCA	cis	rs801193	0.548	rs7805152	ENSG00000265600.1	AC006480.1	-3.51	0.000465	0.0232	-0.13	-0.11	Aortic root size;	chr7:66744266	chr7:67356680~67356779:+
BRCA	cis	rs10181042	0.535	rs2441465	ENSG00000270820.4	RP11-355B11.2	3.51	0.000465	0.0232	0.12	0.11	Crohn's disease;	chr2:61084052	chr2:61471188~61484130:+
BRCA	cis	rs10045413	0.598	rs7735523	ENSG00000250167.1	CTC-321K16.1	-3.51	0.000465	0.0232	-0.13	-0.11	Age at smoking initiation in chronic obstructive pulmonary disease;	chr5:135609509	chr5:135559577~135634874:+
BRCA	cis	rs7615952	0.512	rs4679430	ENSG00000248787.1	RP11-666A20.4	-3.51	0.000465	0.0232	-0.16	-0.11	Blood pressure (smoking interaction);	chr3:125639049	chr3:125908005~125910272:-
BRCA	cis	rs7615952	0.512	rs34651730	ENSG00000248787.1	RP11-666A20.4	-3.51	0.000465	0.0232	-0.16	-0.11	Blood pressure (smoking interaction);	chr3:125639796	chr3:125908005~125910272:-
BRCA	cis	rs7615952	0.512	rs11929125	ENSG00000248787.1	RP11-666A20.4	-3.51	0.000465	0.0232	-0.16	-0.11	Blood pressure (smoking interaction);	chr3:125640599	chr3:125908005~125910272:-
BRCA	cis	rs7615952	0.512	rs2922175	ENSG00000248787.1	RP11-666A20.4	-3.51	0.000465	0.0232	-0.16	-0.11	Blood pressure (smoking interaction);	chr3:125642516	chr3:125908005~125910272:-
BRCA	cis	rs7267979	0.808	rs84816	ENSG00000274973.1	RP13-401N8.7	-3.51	0.000465	0.0232	-0.12	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25479283	chr20:25845497~25845862:+
BRCA	cis	rs7680126	0.596	rs17198547	ENSG00000250413.1	RP11-448G15.1	-3.51	0.000465	0.0232	-0.17	-0.11	Urate levels in obese individuals;Urate levels in lean individuals;Urate levels in overweight individuals;	chr4:10139795	chr4:10006482~10009725:+
BRCA	cis	rs2836950	0.52	rs1980407	ENSG00000235701.1	PCBP2P1	-3.51	0.000465	0.0232	-0.12	-0.11	Menarche (age at onset);	chr21:39172035	chr21:39171130~39172106:-
BRCA	cis	rs6696239	0.956	rs6672530	ENSG00000215812.5	ZNF847P	3.51	0.000465	0.0232	0.15	0.11	Height;	chr1:227583515	chr1:227696892~227706699:-
BRCA	cis	rs889312	0.5	rs832566	ENSG00000271828.1	CTD-2310F14.1	-3.51	0.000466	0.0232	-0.13	-0.11	Breast cancer (early onset);Breast cancer;	chr5:56855917	chr5:56927874~56929573:+
BRCA	cis	rs875971	0.651	rs313829	ENSG00000230189.5	GS1-124K5.2	-3.51	0.000466	0.0232	-0.09	-0.11	Aortic root size;	chr7:66087510	chr7:66409143~66490059:-
BRCA	cis	rs875971	0.964	rs6945019	ENSG00000271064.1	RP11-792A8.3	-3.51	0.000466	0.0232	-0.13	-0.11	Aortic root size;	chr7:66457471	chr7:66748838~66749077:-
BRCA	cis	rs7712401	0.791	rs3822367	ENSG00000249996.1	RP11-359P5.1	-3.51	0.000466	0.0232	-0.13	-0.11	Mean platelet volume;	chr5:122810577	chr5:123036271~123054667:+
BRCA	cis	rs875971	1	rs6961717	ENSG00000271064.1	RP11-792A8.3	3.51	0.000466	0.0232	0.12	0.11	Aortic root size;	chr7:66122550	chr7:66748838~66749077:-
BRCA	cis	rs71520386	0.898	rs12536144	ENSG00000226329.2	AC005682.6	-3.51	0.000466	0.0232	-0.13	-0.11	Fibrinogen levels;	chr7:22782890	chr7:22863874~22881350:-
BRCA	cis	rs62458065	1	rs979355	ENSG00000273014.1	RP11-225B17.2	3.51	0.000466	0.0232	0.16	0.11	Metabolite levels (HVA/MHPG ratio);	chr7:32424321	chr7:32758882~32759353:+
BRCA	cis	rs561341	1	rs576985	ENSG00000277511.1	CTD-2095E4.5	3.51	0.000466	0.0232	0.16	0.11	Hip circumference adjusted for BMI;	chr17:31996304	chr17:32127595~32128454:+
BRCA	cis	rs4950322	0.515	rs17160050	ENSG00000237188.3	RP11-337C18.8	3.51	0.000466	0.0232	0.13	0.11	Protein quantitative trait loci;	chr1:147255558	chr1:147172771~147211568:+
BRCA	cis	rs17092148	0.79	rs6087602	ENSG00000202150.1	RNU6-407P	3.51	0.000466	0.0232	0.16	0.11	Neuroticism;	chr20:34582885	chr20:35030317~35030420:-
BRCA	cis	rs687432	0.885	rs12803905	ENSG00000265566.2	RN7SL605P	-3.51	0.000466	0.0233	-0.15	-0.11	Parkinson's disease;	chr11:57966525	chr11:57528085~57528365:-
BRCA	cis	rs7824557	0.767	rs6985146	ENSG00000205879.4	FAM90A2P	3.51	0.000466	0.0233	0.14	0.11	Retinal vascular caliber;	chr8:11313212	chr8:12172202~12178575:-
BRCA	cis	rs17221829	0.673	rs11018700	ENSG00000280385.1	AP000648.5	-3.51	0.000466	0.0233	-0.12	-0.11	Anxiety in major depressive disorder;	chr11:89648898	chr11:90193614~90198120:+
BRCA	cis	rs1971762	0.545	rs10783586	ENSG00000270175.1	RP11-793H13.11	-3.51	0.000466	0.0233	-0.09	-0.11	Height;	chr12:53587037	chr12:53500162~53500936:-
BRCA	cis	rs8040855	0.599	rs2342123	ENSG00000259416.2	RP11-158M2.5	3.51	0.000466	0.0233	0.12	0.11	Bulimia nervosa;	chr15:85181918	chr15:85754941~85756237:-
BRCA	cis	rs1218582	0.772	rs10796934	ENSG00000232093.1	RP11-307C12.11	-3.51	0.000466	0.0233	-0.11	-0.11	Prostate cancer;	chr1:154877003	chr1:155045191~155046118:-
BRCA	cis	rs4415084	1	rs6874055	ENSG00000272335.1	RP11-53O19.3	3.51	0.000466	0.0233	0.1	0.11	Breast cancer;	chr5:44666863	chr5:44826076~44828592:+
BRCA	cis	rs17092148	0.887	rs2295443	ENSG00000202150.1	RNU6-407P	3.51	0.000466	0.0233	0.16	0.11	Neuroticism;	chr20:34586023	chr20:35030317~35030420:-
BRCA	cis	rs17092148	0.836	rs4564863	ENSG00000202150.1	RNU6-407P	3.51	0.000466	0.0233	0.16	0.11	Neuroticism;	chr20:34591563	chr20:35030317~35030420:-
BRCA	cis	rs17092148	0.887	rs6059936	ENSG00000202150.1	RNU6-407P	3.51	0.000466	0.0233	0.16	0.11	Neuroticism;	chr20:34596445	chr20:35030317~35030420:-
BRCA	cis	rs6747972	1	rs1820987	ENSG00000236259.1	AC017083.2	3.51	0.000466	0.0233	0.13	0.11	Restless legs syndrome;	chr2:67842735	chr2:68125265~68125747:+
BRCA	cis	rs4835473	0.864	rs5015762	ENSG00000246448.2	RP13-578N3.3	-3.51	0.000466	0.0233	-0.12	-0.11	Immature fraction of reticulocytes;	chr4:143737773	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.864	rs5015761	ENSG00000246448.2	RP13-578N3.3	-3.51	0.000466	0.0233	-0.12	-0.11	Immature fraction of reticulocytes;	chr4:143737791	chr4:143700257~143865072:+
BRCA	cis	rs9584850	0.834	rs9584855	ENSG00000231194.1	FARP1-AS1	-3.51	0.000466	0.0233	-0.14	-0.11	Neuroticism;	chr13:98466746	chr13:98435405~98435840:-
BRCA	cis	rs853679	0.546	rs200989	ENSG00000216676.2	RP1-15D7.1	-3.51	0.000466	0.0233	-0.19	-0.11	Depression;	chr6:27848664	chr6:27652602~27652825:-
BRCA	cis	rs7911264	0.739	rs6583827	ENSG00000232709.1	MARK2P9	-3.51	0.000466	0.0233	-0.14	-0.11	Inflammatory bowel disease;	chr10:92598266	chr10:92418667~92420875:+
BRCA	cis	rs7911264	0.739	rs7096101	ENSG00000232709.1	MARK2P9	-3.51	0.000466	0.0233	-0.14	-0.11	Inflammatory bowel disease;	chr10:92603171	chr10:92418667~92420875:+
BRCA	cis	rs7551222	0.683	rs898386	ENSG00000240219.1	RP11-430C7.5	3.51	0.000466	0.0233	0.13	0.11	Schizophrenia;	chr1:204610569	chr1:204626775~204629712:+
BRCA	cis	rs2813490	0.913	rs2747641	ENSG00000227627.1	RP1-101K10.6	3.51	0.000466	0.0233	0.13	0.11	Number of pregnancies;	chr6:152152702	chr6:152983750~152989223:+
BRCA	cis	rs924712	0.844	rs931766	ENSG00000261116.1	RP3-523K23.2	3.51	0.000466	0.0233	0.13	0.11	Breast cancer;	chr6:54862071	chr6:54943167~54945099:+
BRCA	cis	rs7170668	0.597	rs17493093	ENSG00000259134.4	LINC00924	3.51	0.000467	0.0233	0.12	0.11	Motion sickness;	chr15:95506447	chr15:95433095~95507847:+
BRCA	cis	rs7307902	0.518	rs739857	ENSG00000280054.1	RP1-197B17.7	-3.51	0.000467	0.0233	-0.14	-0.11	Obesity-related traits;	chr12:47574503	chr12:47728151~47730598:-
BRCA	cis	rs13068223	0.792	rs344034	ENSG00000241770.1	RP11-555M1.3	3.51	0.000467	0.0233	0.13	0.11	Age-related hearing impairment (SNP x SNP interaction);	chr3:156745215	chr3:157163452~157169133:+
BRCA	cis	rs7680126	0.536	rs4484299	ENSG00000250413.1	RP11-448G15.1	-3.51	0.000467	0.0233	-0.21	-0.11	Urate levels in obese individuals;Urate levels in lean individuals;Urate levels in overweight individuals;	chr4:10048827	chr4:10006482~10009725:+
BRCA	cis	rs6943931	1	rs12532078	ENSG00000230658.1	KLHL7-AS1	-3.51	0.000467	0.0233	-0.14	-0.11	Diabetic kidney disease;	chr7:22386379	chr7:23101228~23105703:-
BRCA	cis	rs4819052	0.851	rs9979545	ENSG00000215447.6	BX322557.10	-3.51	0.000467	0.0233	-0.11	-0.11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45259890	chr21:45288052~45291738:+
BRCA	cis	rs2562456	0.793	rs2650819	ENSG00000268119.4	CTD-2561J22.5	-3.51	0.000467	0.0233	-0.16	-0.11	Pain;	chr19:21456071	chr19:21444241~21463908:-
BRCA	cis	rs11719546	1	rs11719546	ENSG00000242551.2	POU5F1P6	3.51	0.000467	0.0233	0.18	0.11	Post bronchodilator FEV1;	chr3:128153759	chr3:128674735~128677005:-
BRCA	cis	rs3760982	0.585	rs62116964	ENSG00000266921.1	RP11-15A1.7	-3.51	0.000467	0.0233	-0.14	-0.11	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43787834	chr19:43996896~44002836:-
BRCA	cis	rs67478160	0.619	rs12885018	ENSG00000269910.1	RP11-73M18.10	3.51	0.000467	0.0233	0.1	0.11	Schizophrenia;	chr14:103807475	chr14:103694516~103695050:-
BRCA	cis	rs2307449	0.929	rs3940291	ENSG00000260123.1	RP11-326A19.4	3.51	0.000467	0.0233	0.13	0.11	Menopause (age at onset);	chr15:89286550	chr15:89041223~89082819:+
BRCA	cis	rs494453	0.6	rs565612	ENSG00000227811.2	FAM212B-AS1	-3.51	0.000467	0.0233	-0.13	-0.11	Osteoporosis-related phenotypes;	chr1:111677357	chr1:111739841~111747798:+
BRCA	cis	rs7267979	0.868	rs6138550	ENSG00000274973.1	RP13-401N8.7	-3.51	0.000467	0.0233	-0.12	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25242794	chr20:25845497~25845862:+
BRCA	cis	rs17345786	0.906	rs72940399	ENSG00000244119.1	PDCL3P4	3.51	0.000467	0.0233	0.1	0.11	Colonoscopy-negative controls vs population controls;	chr3:101403731	chr3:101712472~101713191:+
BRCA	cis	rs13113518	0.51	rs6858749	ENSG00000249700.7	SRD5A3-AS1	3.51	0.000467	0.0233	0.14	0.11	Height;	chr4:55424270	chr4:55363971~55395847:-
BRCA	cis	rs4835473	0.897	rs11100812	ENSG00000246448.2	RP13-578N3.3	3.51	0.000467	0.0233	0.12	0.11	Immature fraction of reticulocytes;	chr4:143790400	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.545	rs10022856	ENSG00000246448.2	RP13-578N3.3	3.51	0.000467	0.0233	0.12	0.11	Immature fraction of reticulocytes;	chr4:143793157	chr4:143700257~143865072:+
BRCA	cis	rs7267979	0.565	rs6107059	ENSG00000274973.1	RP13-401N8.7	3.51	0.000467	0.0233	0.12	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25611795	chr20:25845497~25845862:+
BRCA	cis	rs2446066	0.872	rs10876450	ENSG00000270175.1	RP11-793H13.11	3.51	0.000467	0.0233	0.12	0.11	Red blood cell count;	chr12:53417250	chr12:53500162~53500936:-
BRCA	cis	rs4622329	0.615	rs2176092	ENSG00000257202.1	RP11-512N21.3	-3.51	0.000467	0.0233	-0.13	-0.11	Systemic lupus erythematosus;	chr12:101893592	chr12:101923410~101924719:-
BRCA	cis	rs6732795	0.559	rs34081493	ENSG00000179818.12	PCBP1-AS1	3.51	0.000467	0.0233	0.14	0.11	Intraocular pressure;	chr2:69176750	chr2:69962263~70103220:-
BRCA	cis	rs8180040	0.62	rs7373821	ENSG00000260236.1	RP11-708J19.1	3.51	0.000467	0.0233	0.1	0.11	Colorectal cancer;	chr3:47038637	chr3:47379089~47380999:-
BRCA	cis	rs12723316	0.932	rs12728131	ENSG00000233008.4	RP11-475O6.1	-3.51	0.000467	0.0233	-0.21	-0.11	Schizophrenia;	chr1:83819166	chr1:83575776~83861023:-
BRCA	cis	rs7870753	0.578	rs7851198	ENSG00000224848.1	RP11-535M15.1	3.51	0.000467	0.0233	0.17	0.11	Height;	chr9:96370093	chr9:96687056~96721121:+
BRCA	cis	rs875971	0.564	rs313804	ENSG00000271064.1	RP11-792A8.3	-3.51	0.000467	0.0233	-0.13	-0.11	Aortic root size;	chr7:66049635	chr7:66748838~66749077:-
BRCA	cis	rs875971	0.662	rs448725	ENSG00000271064.1	RP11-792A8.3	-3.51	0.000467	0.0233	-0.13	-0.11	Aortic root size;	chr7:66049641	chr7:66748838~66749077:-
BRCA	cis	rs1555133	0.625	rs62206927	ENSG00000277692.1	RP11-358N2.2	-3.51	0.000467	0.0233	-0.12	-0.11	Monocyte count;	chr20:32411796	chr20:32355053~32355734:+
BRCA	cis	rs11098499	1	rs35643470	ENSG00000260404.2	RP11-384K6.6	3.51	0.000467	0.0233	0.1	0.11	Corneal astigmatism;	chr4:119263793	chr4:118591773~118633729:+
BRCA	cis	rs1005277	1	rs1005277	ENSG00000099251.13	HSD17B7P2	-3.51	0.000467	0.0233	-0.13	-0.11	Extrinsic epigenetic age acceleration;	chr10:37929331	chr10:38356380~38378505:+
BRCA	cis	rs9868809	0.649	rs3733086	ENSG00000225399.4	RP11-3B7.1	-3.51	0.000467	0.0233	-0.17	-0.11	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48662086	chr3:49260085~49261316:+
BRCA	cis	rs2041840	0.654	rs13022403	ENSG00000272054.1	RP11-423P10.2	-3.51	0.000467	0.0233	-0.11	-0.11	Chronic lymphocytic leukemia;	chr2:37186002	chr2:37208875~37212677:+
BRCA	cis	rs1712517	0.525	rs7911488	ENSG00000234699.1	RP11-225H22.4	3.51	0.000467	0.0233	0.14	0.11	Migraine;	chr10:103394332	chr10:103452846~103462695:+
BRCA	cis	rs72482608	0.596	rs3980705	ENSG00000271811.1	RP1-79C4.4	3.51	0.000467	0.0233	0.12	0.11	Emphysema imaging phenotypes;	chr1:170892693	chr1:170667381~170669425:+
BRCA	cis	rs10070219	0.505	rs62380373	ENSG00000248445.4	SEMA6A-AS1	-3.51	0.000467	0.0233	-0.14	-0.11	3-hydroxypropylmercapturic acid levels in smokers;	chr5:117352083	chr5:116447547~116508276:+
BRCA	cis	rs10070219	0.505	rs62380374	ENSG00000248445.4	SEMA6A-AS1	-3.51	0.000467	0.0233	-0.14	-0.11	3-hydroxypropylmercapturic acid levels in smokers;	chr5:117352154	chr5:116447547~116508276:+
BRCA	cis	rs10070219	0.505	rs62380375	ENSG00000248445.4	SEMA6A-AS1	-3.51	0.000467	0.0233	-0.14	-0.11	3-hydroxypropylmercapturic acid levels in smokers;	chr5:117352256	chr5:116447547~116508276:+
BRCA	cis	rs6964587	0.904	rs2023785	ENSG00000188693.7	CYP51A1-AS1	3.51	0.000467	0.0233	0.12	0.11	Breast cancer;	chr7:91918055	chr7:92134604~92180725:+
BRCA	cis	rs277939	0.967	rs277979	ENSG00000230847.4	RP11-195E2.1	-3.51	0.000467	0.0233	-0.13	-0.11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr5:71631859	chr5:71074225~71093193:-
BRCA	cis	rs6088580	0.524	rs6088569	ENSG00000126005.14	MMP24-AS1	3.51	0.000467	0.0233	0.13	0.11	Glomerular filtration rate (creatinine);	chr20:34680395	chr20:35216462~35278131:-
BRCA	cis	rs812925	0.555	rs12616433	ENSG00000273302.1	RP11-493E12.2	3.51	0.000467	0.0233	0.1	0.11	Immature fraction of reticulocytes;	chr2:61469353	chr2:61199979~61200769:+
BRCA	cis	rs10876993	0.928	rs2928053	ENSG00000270039.1	RP11-571M6.17	3.51	0.000467	0.0233	0.14	0.11	Celiac disease or Rheumatoid arthritis;	chr12:57669692	chr12:57803838~57804415:+
BRCA	cis	rs6918586	0.565	rs13196986	ENSG00000272810.1	U91328.22	3.51	0.000467	0.0233	0.13	0.11	Schizophrenia;	chr6:26090224	chr6:26013241~26013757:+
BRCA	cis	rs4388249	1	rs12189512	ENSG00000249068.1	CTC-287O8.1	3.51	0.000467	0.0233	0.16	0.11	Schizophrenia;	chr5:109714412	chr5:109840128~109840692:-
BRCA	cis	rs1730008	0.964	rs696715	ENSG00000279311.1	RP11-170K4.2	-3.51	0.000467	0.0233	-0.12	-0.11	Lobe attachment (rater-scored or self-reported);	chr3:158223444	chr3:158869898~158871821:+
BRCA	cis	rs8103278	1	rs9676288	ENSG00000268423.3	AC011551.3	3.51	0.000467	0.0233	0.13	0.11	Coronary artery disease;	chr19:45788802	chr19:46547056~46600861:-
BRCA	cis	rs17767294	0.614	rs72850302	ENSG00000219392.1	RP1-265C24.5	-3.51	0.000468	0.0233	-0.3	-0.11	Parkinson's disease;	chr6:28273621	chr6:28115628~28116551:+
BRCA	cis	rs8114671	0.562	rs6058120	ENSG00000261582.1	RP4-614O4.11	-3.51	0.000468	0.0233	-0.1	-0.11	Height;	chr20:34815026	chr20:35267885~35280043:-
BRCA	cis	rs1250259	0.542	rs13306359	ENSG00000225166.1	AC012462.2	-3.51	0.000468	0.0233	-0.13	-0.11	Coronary artery disease;Pulse pressure;	chr2:215404372	chr2:215453707~215463871:+
BRCA	cis	rs1250259	0.542	rs7589580	ENSG00000225166.1	AC012462.2	-3.51	0.000468	0.0233	-0.13	-0.11	Coronary artery disease;Pulse pressure;	chr2:215404531	chr2:215453707~215463871:+
BRCA	cis	rs10911902	0.602	rs74370445	ENSG00000229739.2	RP11-295K2.3	-3.51	0.000468	0.0233	-0.15	-0.11	Schizophrenia;	chr1:186380327	chr1:186435161~186470291:+
BRCA	cis	rs1424638	0.655	rs7420324	ENSG00000233251.6	AC007743.1	-3.51	0.000468	0.0233	-0.13	-0.11	Intelligence (multi-trait analysis);	chr2:57020938	chr2:56173534~56185770:-
BRCA	cis	rs4820539	0.966	rs2301554	ENSG00000211647.1	IGLV5-48	-3.51	0.000468	0.0233	-0.09	-0.11	Bone mineral density;	chr22:23142067	chr22:22352940~22353433:+
BRCA	cis	rs5997397	0.967	rs5752791	ENSG00000272858.1	CTA-292E10.8	3.51	0.000468	0.0233	0.13	0.11	Red cell distribution width;	chr22:28757559	chr22:28814914~28815662:+
BRCA	cis	rs3748682	0.821	rs71642605	ENSG00000252448.1	SNORA63	-3.51	0.000468	0.0233	-0.15	-0.11	Hypothyroidism;	chr1:37790755	chr1:37884237~37884317:+
BRCA	cis	rs12612435	0.64	rs6430634	ENSG00000226806.1	AC011893.3	-3.51	0.000468	0.0233	-0.12	-0.11	Takotsubo syndrome;	chr2:136379388	chr2:135820191~135823087:+
BRCA	cis	rs1348850	0.768	rs57681892	ENSG00000280374.1	RP11-337N6.3	3.51	0.000468	0.0233	0.15	0.11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177492917	chr2:177317715~177318471:-
BRCA	cis	rs7267979	1	rs6050555	ENSG00000276952.1	RP5-965G21.6	-3.51	0.000468	0.0233	-0.13	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25347907	chr20:25284915~25285588:-
BRCA	cis	rs3011225	0.738	rs3791075	ENSG00000237950.1	RP11-7O11.3	-3.51	0.000468	0.0233	-0.15	-0.11	Amyotrophic lateral sclerosis (age of onset);	chr1:43834854	chr1:43944370~43946551:-
BRCA	cis	rs3011225	0.738	rs12046114	ENSG00000237950.1	RP11-7O11.3	-3.51	0.000468	0.0233	-0.15	-0.11	Amyotrophic lateral sclerosis (age of onset);	chr1:43836148	chr1:43944370~43946551:-
BRCA	cis	rs1133146	0.967	rs8101962	ENSG00000269051.4	CTD-2245F17.3	3.51	0.000468	0.0234	0.12	0.11	Yu-Zhi constitution type in type 2 diabetes;	chr19:53177202	chr19:53197111~53211015:+
BRCA	cis	rs9457247	0.602	rs9457262	ENSG00000272549.1	RP11-351J23.2	-3.51	0.000468	0.0234	-0.11	-0.11	Crohn's disease;	chr6:167060197	chr6:167666840~167679270:-
BRCA	cis	rs8105895	0.877	rs7248305	ENSG00000269345.1	VN1R85P	3.51	0.000468	0.0234	0.15	0.11	Body mass index (change over time);	chr19:22067469	chr19:22174766~22175191:-
BRCA	cis	rs1941184	0.526	rs60094806	ENSG00000266521.1	RP11-650P15.1	-3.51	0.000468	0.0234	-0.14	-0.11	Parkinson's disease (age of onset);	chr18:31455475	chr18:31496645~31497195:-
BRCA	cis	rs1941184	0.526	rs61344982	ENSG00000266521.1	RP11-650P15.1	-3.51	0.000468	0.0234	-0.14	-0.11	Parkinson's disease (age of onset);	chr18:31455476	chr18:31496645~31497195:-
BRCA	cis	rs2360027	0.578	rs4659103	ENSG00000231365.4	RP11-418J17.1	-3.51	0.000468	0.0234	-0.14	-0.11	Tonsillectomy;	chr1:118558160	chr1:119140396~119275973:+
BRCA	cis	rs7829975	0.533	rs1039917	ENSG00000233609.3	RP11-62H7.2	3.51	0.000468	0.0234	0.1	0.11	Mood instability;	chr8:8861340	chr8:8961200~8979025:+
BRCA	cis	rs73201462	1	rs13071740	ENSG00000242551.2	POU5F1P6	3.51	0.000468	0.0234	0.19	0.11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128162725	chr3:128674735~128677005:-
BRCA	cis	rs73201462	1	rs13077790	ENSG00000242551.2	POU5F1P6	3.51	0.000468	0.0234	0.19	0.11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128163815	chr3:128674735~128677005:-
BRCA	cis	rs2839186	0.814	rs2276257	ENSG00000215424.8	MCM3AP-AS1	3.51	0.000468	0.0234	0.1	0.11	Testicular germ cell tumor;	chr21:46291315	chr21:46229217~46259390:+
BRCA	cis	rs988913	0.706	rs4521592	ENSG00000261116.1	RP3-523K23.2	-3.51	0.000469	0.0234	-0.13	-0.11	Menarche (age at onset);	chr6:55090481	chr6:54943167~54945099:+
BRCA	cis	rs8103278	1	rs7252126	ENSG00000268423.3	AC011551.3	3.51	0.000469	0.0234	0.13	0.11	Coronary artery disease;	chr19:45799116	chr19:46547056~46600861:-
BRCA	cis	rs2274273	0.84	rs72715769	ENSG00000259318.1	RP11-454L9.2	3.51	0.000469	0.0234	0.09	0.11	Protein biomarker;	chr14:55295711	chr14:55394940~55395233:-
BRCA	cis	rs7172809	0.643	rs61097729	ENSG00000260139.5	CSPG4P13	-3.51	0.000469	0.0234	-0.13	-0.11	Glucose homeostasis traits;	chr15:77542016	chr15:77894684~77904674:+
BRCA	cis	rs11175492	1	rs12368712	ENSG00000243024.5	RPS11P6	-3.51	0.000469	0.0234	-0.25	-0.11	Platelet count;	chr12:64682273	chr12:64222337~64397065:+
BRCA	cis	rs897984	0.511	rs7196726	ENSG00000275263.1	RP11-1072A3.4	-3.51	0.000469	0.0234	-0.13	-0.11	Dementia with Lewy bodies;	chr16:31080754	chr16:30956872~30957199:-
BRCA	cis	rs1577917	0.74	rs9344542	ENSG00000220563.1	PKMP3	3.51	0.000469	0.0234	0.11	0.11	Response to antipsychotic treatment;	chr6:85684187	chr6:85659892~85660606:-
BRCA	cis	rs6946131	0.571	rs2709310	ENSG00000235207.1	TUBBP6	-3.51	0.000469	0.0234	-0.13	-0.11	Systemic lupus erythematosus;	chr7:54781172	chr7:55645620~55646951:+
BRCA	cis	rs2278170	0.962	rs35390334	ENSG00000225101.4	OR52K3P	-3.51	0.000469	0.0234	-0.14	-0.11	Amyotrophic lateral sclerosis;	chr11:4464196	chr11:4474813~4475755:+
BRCA	cis	rs6964587	0.692	rs10236483	ENSG00000188693.7	CYP51A1-AS1	-3.51	0.000469	0.0234	-0.12	-0.11	Breast cancer;	chr7:92167982	chr7:92134604~92180725:+
BRCA	cis	rs873549	0.877	rs1530313	ENSG00000238042.4	RP11-815M8.1	3.51	0.000469	0.0234	0.13	0.11	Keloid;	chr1:222100668	chr1:221880981~221978523:-
BRCA	cis	rs873549	0.959	rs7524005	ENSG00000238042.4	RP11-815M8.1	3.51	0.000469	0.0234	0.13	0.11	Keloid;	chr1:222100977	chr1:221880981~221978523:-
BRCA	cis	rs873549	1	rs7555836	ENSG00000238042.4	RP11-815M8.1	3.51	0.000469	0.0234	0.13	0.11	Keloid;	chr1:222101090	chr1:221880981~221978523:-
BRCA	cis	rs7188697	0.922	rs37051	ENSG00000276259.1	RP11-481J2.4	-3.51	0.000469	0.0234	-0.12	-0.11	QT interval;	chr16:58524198	chr16:58522970~58523842:+
BRCA	cis	rs295490	0.748	rs78251555	ENSG00000178631.7	ACTG1P1	-3.51	0.000469	0.0234	-0.23	-0.11	PR interval in Tripanosoma cruzi seropositivity;	chr3:139460159	chr3:139493809~139494937:+
BRCA	cis	rs6600671	0.934	rs67718113	ENSG00000223345.3	HIST2H2BA	-3.51	0.000469	0.0234	-0.14	-0.11	Hip geometry;	chr1:121497112	chr1:121108210~121117257:-
BRCA	cis	rs1949733	1	rs1880023	ENSG00000205959.3	RP11-689P11.2	3.51	0.000469	0.0234	0.11	0.11	Response to antineoplastic agents;	chr4:8479104	chr4:8482270~8512610:+
BRCA	cis	rs801193	0.935	rs2659899	ENSG00000275400.1	RP4-756H11.5	-3.51	0.000469	0.0234	-0.12	-0.11	Aortic root size;	chr7:66721734	chr7:66553805~66554199:-
BRCA	cis	rs4950322	0.518	rs61838936	ENSG00000227242.3	NBPF13P	-3.51	0.000469	0.0234	-0.15	-0.11	Protein quantitative trait loci;	chr1:147098422	chr1:147021320~147124525:-
BRCA	cis	rs7405404	0.672	rs6498449	ENSG00000276564.1	CTA-276F8.1	3.51	0.000469	0.0234	0.12	0.11	Bipolar disorder lithium response (categorical) or schizophrenia;Schizophrenia;	chr16:13646036	chr16:14150833~14153235:+
BRCA	cis	rs34217772	0.603	rs17781325	ENSG00000258636.1	CTD-2298J14.2	3.51	0.000469	0.0234	0.14	0.11	Myopia;	chr14:41713161	chr14:41587861~41604856:-
BRCA	cis	rs3770752	0.866	rs74177070	ENSG00000272054.1	RP11-423P10.2	-3.51	0.000469	0.0234	-0.09	-0.11	Schizophrenia;	chr2:37299694	chr2:37208875~37212677:+
BRCA	cis	rs2235642	0.505	rs56359342	ENSG00000280062.1	LA16c-380F5.1	3.51	0.000469	0.0234	0.13	0.11	Coronary artery disease;	chr16:1604947	chr16:1530715~1533301:+
BRCA	cis	rs8114671	0.562	rs6120758	ENSG00000279253.1	RP4-614O4.13	-3.51	0.000469	0.0234	-0.12	-0.11	Height;	chr20:34904720	chr20:35262727~35264187:-
BRCA	cis	rs9393777	0.502	rs3823427	ENSG00000216901.1	AL022393.7	3.51	0.000469	0.0234	0.17	0.11	Intelligence (multi-trait analysis);	chr6:27288567	chr6:28176188~28176674:+
BRCA	cis	rs9325144	0.56	rs7980358	ENSG00000257718.1	RP11-396F22.1	3.51	0.000469	0.0234	0.11	0.11	Morning vs. evening chronotype;	chr12:38246594	chr12:38906451~38909592:+
BRCA	cis	rs17711722	0.727	rs35850374	ENSG00000229180.5	GS1-124K5.11	3.51	0.000469	0.0234	0.09	0.11	Calcium levels;	chr7:65892789	chr7:66526088~66542624:-
BRCA	cis	rs7615952	0.673	rs35955861	ENSG00000241288.6	RP11-379B18.5	-3.51	0.000469	0.0234	-0.18	-0.11	Blood pressure (smoking interaction);	chr3:125907358	chr3:125827238~125916384:-
BRCA	cis	rs12724450	0.793	rs34696422	ENSG00000228126.1	FALEC	3.51	0.00047	0.0234	0.2	0.11	Blood protein levels;	chr1:150407916	chr1:150515757~150518032:+
BRCA	cis	rs1468333	0.567	rs6861656	ENSG00000206989.1	SNORD63	3.51	0.00047	0.0234	0.12	0.11	Resting heart rate;	chr5:138331823	chr5:138561043~138561110:-
BRCA	cis	rs2562456	0.833	rs8106025	ENSG00000268119.4	CTD-2561J22.5	-3.51	0.00047	0.0234	-0.16	-0.11	Pain;	chr19:21451922	chr19:21444241~21463908:-
BRCA	cis	rs7474896	0.945	rs2749561	ENSG00000120555.12	SEPT7P9	-3.51	0.00047	0.0234	-0.19	-0.11	Obesity (extreme);	chr10:37909119	chr10:38383069~38402916:-
BRCA	cis	rs4650943	0.503	rs7553759	ENSG00000227740.1	RP11-318C24.2	3.51	0.00047	0.0234	0.11	0.11	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in inactive individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr1:176115310	chr1:175904762~175920513:-
BRCA	cis	rs9611565	0.694	rs106860	ENSG00000281538.1	RP4-669P10.20	3.51	0.00047	0.0234	0.14	0.11	Vitiligo;	chr22:41444403	chr22:42138060~42139726:+
BRCA	cis	rs34792	0.554	rs4597346	ENSG00000258354.1	MIR3180-1	-3.51	0.00047	0.0234	-0.14	-0.11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15529889	chr16:14909887~14911345:-
BRCA	cis	rs11098499	0.954	rs12510138	ENSG00000225892.3	RP11-384K6.2	3.51	0.00047	0.0234	0.11	0.11	Corneal astigmatism;	chr4:119502780	chr4:118632274~118634759:+
BRCA	cis	rs4243971	0.516	rs6141685	ENSG00000277692.1	RP11-358N2.2	-3.51	0.00047	0.0234	-0.12	-0.11	Inflammatory bowel disease;Crohn's disease;	chr20:32349772	chr20:32355053~32355734:+
BRCA	cis	rs7412746	0.658	rs57818453	ENSG00000224800.1	RP11-235D19.2	-3.51	0.00047	0.0234	-0.14	-0.11	Melanoma;	chr1:150790663	chr1:150881236~150881683:-
BRCA	cis	rs250518	0.926	rs3846644	ENSG00000271926.1	CTD-2376I4.1	3.51	0.00047	0.0234	0.14	0.11	Mean corpuscular hemoglobin concentration;	chr5:72727276	chr5:72953635~72954274:-
BRCA	cis	rs4388249	1	rs17638392	ENSG00000249068.1	CTC-287O8.1	3.51	0.00047	0.0234	0.16	0.11	Schizophrenia;	chr5:109716385	chr5:109840128~109840692:-
BRCA	cis	rs7577894	0.967	rs7560508	ENSG00000272606.1	RP11-554J4.1	3.51	0.00047	0.0234	0.12	0.11	Amyotrophic lateral sclerosis;	chr2:55775237	chr2:55617909~55618373:+
BRCA	cis	rs6600671	0.934	rs12060031	ENSG00000275131.1	CH17-472G23.4	3.51	0.00047	0.0234	0.1	0.11	Hip geometry;	chr1:121501652	chr1:120489625~120579190:-
BRCA	cis	rs6445975	0.666	rs12635366	ENSG00000272182.1	RP11-802O23.3	-3.51	0.00047	0.0234	-0.14	-0.11	Systemic lupus erythematosus;	chr3:58412739	chr3:58428255~58428815:+
BRCA	cis	rs10771431	0.817	rs17202253	ENSG00000278635.1	CTD-2318O12.1	3.51	0.00047	0.0234	0.1	0.11	Breast size;	chr12:9209254	chr12:9415641~9416718:+
BRCA	cis	rs324126	0.78	rs11084153	ENSG00000277977.1	CTD-3018O17.5	3.51	0.00047	0.0234	0.13	0.11	Colonoscopy-negative controls vs population controls;	chr19:52382142	chr19:52392659~52392755:+
BRCA	cis	rs324126	0.78	rs11084154	ENSG00000277977.1	CTD-3018O17.5	3.51	0.00047	0.0234	0.13	0.11	Colonoscopy-negative controls vs population controls;	chr19:52382168	chr19:52392659~52392755:+
BRCA	cis	rs6866721	0.634	rs1672491	ENSG00000249167.1	CTB-118N6.2	-3.51	0.00047	0.0234	-0.13	-0.11	Body mass index;	chr5:116887271	chr5:116574482~116591398:+
BRCA	cis	rs13326165	0.76	rs57441156	ENSG00000243224.1	RP5-1157M23.2	-3.51	0.00047	0.0234	-0.15	-0.11	HDL cholesterol levels;HDL cholesterol;	chr3:52320226	chr3:52239258~52241097:+
BRCA	cis	rs853679	0.517	rs9380058	ENSG00000226314.6	ZNF192P1	-3.51	0.00047	0.0234	-0.16	-0.11	Depression;	chr6:28159666	chr6:28161781~28169594:+
BRCA	cis	rs853679	0.517	rs9393898	ENSG00000226314.6	ZNF192P1	-3.51	0.00047	0.0234	-0.16	-0.11	Depression;	chr6:28162598	chr6:28161781~28169594:+
BRCA	cis	rs3739034	0.938	rs6747870	ENSG00000224043.6	CCNT2-AS1	3.51	0.00047	0.0234	0.19	0.11	Gut microbiome composition (winter);	chr2:134712199	chr2:134735464~134918710:-
BRCA	cis	rs6452524	0.508	rs256795	ENSG00000271862.1	RP11-343L5.2	-3.51	0.00047	0.0234	-0.13	-0.11	Hypertension (SNP x SNP interaction);	chr5:83001543	chr5:83049376~83050964:-
BRCA	cis	rs1061377	0.513	rs2566162	ENSG00000249685.1	RP11-360F5.3	3.51	0.00047	0.0234	0.15	0.11	Uric acid levels;	chr4:39126453	chr4:39133913~39135608:+
BRCA	cis	rs2274459	0.63	rs10947440	ENSG00000249346.5	LINC01016	3.51	0.00047	0.0234	0.11	0.11	Obesity (extreme);	chr6:33811939	chr6:33867506~33896914:-
BRCA	cis	rs6012564	0.927	rs932451	ENSG00000230758.1	SNAP23P	-3.51	0.00047	0.0234	-0.13	-0.11	Anger;	chr20:48957061	chr20:49038357~49038602:-
BRCA	cis	rs6801044	0.954	rs28564334	ENSG00000229178.1	AC069513.4	-3.51	0.00047	0.0234	-0.16	-0.11	Creatinine levels in ischemic stroke;	chr3:195560481	chr3:195655565~195657927:-
BRCA	cis	rs911119	0.913	rs6048922	ENSG00000270001.1	RP11-218C14.8	-3.51	0.00047	0.0234	-0.14	-0.11	Chronic kidney disease;	chr20:23597479	chr20:23631826~23632316:-
BRCA	cis	rs4589258	0.966	rs10765386	ENSG00000280367.1	RP11-121L10.2	3.51	0.00047	0.0234	0.13	0.11	Intelligence (multi-trait analysis);	chr11:90752813	chr11:90223153~90226538:+
BRCA	cis	rs4415084	0.652	rs11747159	ENSG00000248779.1	RP11-53O19.2	3.51	0.00047	0.0234	0.1	0.11	Breast cancer;	chr5:44737608	chr5:44752949~44765744:+
BRCA	cis	rs7804356	0.603	rs13234201	ENSG00000199085.2	MIR148A	3.51	0.00047	0.0234	0.13	0.11	Type 1 diabetes;	chr7:26738104	chr7:25949903~25950013:-
BRCA	cis	rs13118159	0.714	rs6843025	ENSG00000254094.1	AC078852.1	-3.51	0.00047	0.0234	-0.12	-0.11	Longevity;	chr4:1340630	chr4:1356581~1358075:+
BRCA	cis	rs12122100	0.689	rs12129419	ENSG00000206585.1	RNVU1-7	3.51	0.00047	0.0234	0.15	0.11	HIV-1 control;	chr1:147075155	chr1:148038753~148038916:-
BRCA	cis	rs74233809	1	rs11191505	ENSG00000213061.2	PFN1P11	3.51	0.00047	0.0234	0.24	0.11	Birth weight;	chr10:103007134	chr10:102838011~102845473:-
BRCA	cis	rs6840360	0.571	rs62327269	ENSG00000278978.1	RP11-164P12.5	-3.51	0.000471	0.0234	-0.13	-0.11	Intelligence (multi-trait analysis);	chr4:151606821	chr4:151669786~151670503:+
BRCA	cis	rs11108495	0.752	rs4643117	ENSG00000258177.1	RP11-394J1.2	3.51	0.000471	0.0234	0.13	0.11	Weight;	chr12:96416733	chr12:96222797~96223973:-
BRCA	cis	rs61869271	0.712	rs6585302	ENSG00000236799.1	RP11-383C6.2	-3.51	0.000471	0.0234	-0.13	-0.11	Tonsillectomy;	chr10:114923134	chr10:114994657~114996593:+
BRCA	cis	rs1348850	0.874	rs1348848	ENSG00000271825.1	RP11-337N6.2	-3.51	0.000471	0.0234	-0.14	-0.11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177493505	chr2:177300600~177302006:+
BRCA	cis	rs10193935	0.901	rs2374429	ENSG00000234362.4	AC104654.2	-3.51	0.000471	0.0235	-0.17	-0.11	Colonoscopy-negative controls vs population controls;	chr2:42450748	chr2:41931599~41933723:-
BRCA	cis	rs10132760	0.507	rs3899895	ENSG00000211778.2	TRAV4	-3.51	0.000471	0.0235	-0.08	-0.11	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;	chr14:21776159	chr14:21736152~21736982:+
BRCA	cis	rs911119	0.913	rs13037490	ENSG00000270001.1	RP11-218C14.8	-3.51	0.000471	0.0235	-0.15	-0.11	Chronic kidney disease;	chr20:23603088	chr20:23631826~23632316:-
BRCA	cis	rs7267979	0.933	rs2261109	ENSG00000274414.1	RP5-965G21.4	-3.51	0.000471	0.0235	-0.13	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25278564	chr20:25239007~25245229:-
BRCA	cis	rs7267979	0.966	rs2261720	ENSG00000274414.1	RP5-965G21.4	-3.51	0.000471	0.0235	-0.13	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25280005	chr20:25239007~25245229:-
BRCA	cis	rs1129187	0.72	rs9471972	ENSG00000220614.1	RP11-480N24.4	3.51	0.000471	0.0235	0.12	0.11	Alzheimer's disease in APOE e4+ carriers;	chr6:42947283	chr6:43328134~43328476:+
BRCA	cis	rs28489187	0.706	rs233067	ENSG00000223653.4	RP11-131L23.1	3.51	0.000471	0.0235	0.12	0.11	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85339295	chr1:85276715~85448124:+
BRCA	cis	rs8180040	0.726	rs2305638	ENSG00000260236.1	RP11-708J19.1	3.51	0.000471	0.0235	0.1	0.11	Colorectal cancer;	chr3:47005352	chr3:47379089~47380999:-
BRCA	cis	rs259282	0.589	rs6510271	ENSG00000267475.1	CTD-2538C1.2	3.51	0.000471	0.0235	0.13	0.11	Schizophrenia;	chr19:32626760	chr19:32687089~32691750:-
BRCA	cis	rs1865760	0.713	rs1130000	ENSG00000272462.2	U91328.19	-3.51	0.000471	0.0235	-0.13	-0.11	Height;	chr6:25985168	chr6:25992662~26001775:+
BRCA	cis	rs12887734	0.524	rs4900599	ENSG00000269940.1	RP11-73M18.7	3.51	0.000471	0.0235	0.12	0.11	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103817107	chr14:103694560~103695170:+
BRCA	cis	rs6142102	0.961	rs2268088	ENSG00000206582.1	Y_RNA	-3.51	0.000471	0.0235	-0.13	-0.11	Skin pigmentation;	chr20:34061258	chr20:34526510~34526606:-
BRCA	cis	rs6142102	0.961	rs2284388	ENSG00000206582.1	Y_RNA	-3.51	0.000471	0.0235	-0.13	-0.11	Skin pigmentation;	chr20:34067935	chr20:34526510~34526606:-
BRCA	cis	rs2518049	0.852	rs6601898	ENSG00000224034.1	RP11-445P17.8	3.51	0.000471	0.0235	0.2	0.11	Metabolic traits;	chr10:5076039	chr10:5266033~5271236:-
BRCA	cis	rs6430585	0.583	rs12475516	ENSG00000231890.6	DARS-AS1	-3.51	0.000471	0.0235	-0.15	-0.11	Corneal structure;	chr2:135803191	chr2:135985176~136022593:+
BRCA	cis	rs6430585	0.583	rs2304370	ENSG00000231890.6	DARS-AS1	-3.51	0.000471	0.0235	-0.15	-0.11	Corneal structure;	chr2:135804165	chr2:135985176~136022593:+
BRCA	cis	rs962856	0.729	rs1483350	ENSG00000236780.4	AC078941.1	3.51	0.000471	0.0235	0.14	0.11	Pancreatic cancer;	chr2:67292771	chr2:67123357~67215319:-
BRCA	cis	rs863345	0.604	rs10908656	ENSG00000229914.1	RP11-404O13.4	-3.51	0.000471	0.0235	-0.12	-0.11	Pneumococcal bacteremia;	chr1:158491226	chr1:158195633~158196131:-
BRCA	cis	rs2113818	0.541	rs4669885	ENSG00000264370.1	MIR3125	-3.51	0.000471	0.0235	-0.12	-0.11	Optic cup area;	chr2:12832893	chr2:12737367~12737444:+
BRCA	cis	rs17270561	0.666	rs12209856	ENSG00000272462.2	U91328.19	-3.51	0.000471	0.0235	-0.13	-0.11	Iron status biomarkers;	chr6:25793445	chr6:25992662~26001775:+
BRCA	cis	rs9921338	0.961	rs4315353	ENSG00000263080.1	RP11-485G7.5	-3.51	0.000471	0.0235	-0.16	-0.11	Vein graft stenosis in coronary artery bypass grafting;	chr16:11320303	chr16:11341809~11345211:-
BRCA	cis	rs7267979	0.932	rs2387891	ENSG00000274973.1	RP13-401N8.7	-3.51	0.000471	0.0235	-0.12	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25489692	chr20:25845497~25845862:+
BRCA	cis	rs6121246	0.609	rs6060843	ENSG00000230613.1	HM13-AS1	3.51	0.000471	0.0235	0.15	0.11	Mean corpuscular hemoglobin;	chr20:31709244	chr20:31567707~31573263:-
BRCA	cis	rs7959452	0.59	rs56054057	ENSG00000274979.1	RP11-1143G9.5	-3.51	0.000471	0.0235	-0.12	-0.11	Blood protein levels;	chr12:69382192	chr12:69326574~69331882:-
BRCA	cis	rs7959452	0.536	rs4761237	ENSG00000274979.1	RP11-1143G9.5	-3.51	0.000471	0.0235	-0.12	-0.11	Blood protein levels;	chr12:69382681	chr12:69326574~69331882:-
BRCA	cis	rs10129255	0.913	rs10140943	ENSG00000211967.3	IGHV3-53	-3.51	0.000471	0.0235	-0.08	-0.11	Kawasaki disease;	chr14:106767441	chr14:106592676~106593347:-
BRCA	cis	rs7246657	0.551	rs10404069	ENSG00000267470.4	ZNF571-AS1	3.51	0.000471	0.0235	0.16	0.11	Coronary artery calcification;	chr19:37147502	chr19:37548914~37587348:+
BRCA	cis	rs9584850	0.834	rs7985565	ENSG00000231194.1	FARP1-AS1	3.51	0.000471	0.0235	0.14	0.11	Neuroticism;	chr13:98461217	chr13:98435405~98435840:-
BRCA	cis	rs6500602	0.627	rs9938228	ENSG00000280063.1	RP11-295D4.3	3.51	0.000471	0.0235	0.09	0.11	Schizophrenia;	chr16:4480596	chr16:4346694~4348648:-
BRCA	cis	rs5997397	0.967	rs5762777	ENSG00000226471.5	CTA-292E10.6	-3.51	0.000471	0.0235	-0.12	-0.11	Red cell distribution width;	chr22:28754056	chr22:28800683~28848559:+
BRCA	cis	rs3770752	0.897	rs11680401	ENSG00000272054.1	RP11-423P10.2	-3.51	0.000471	0.0235	-0.09	-0.11	Schizophrenia;	chr2:37238595	chr2:37208875~37212677:+
BRCA	cis	rs4742903	0.967	rs7048372	ENSG00000270332.1	SMC2-AS1	3.51	0.000471	0.0235	0.12	0.11	Breast cancer;High-grade serous ovarian cancer;	chr9:104097457	chr9:104080024~104093073:-
BRCA	cis	rs4742903	0.967	rs10512325	ENSG00000270332.1	SMC2-AS1	3.51	0.000471	0.0235	0.12	0.11	Breast cancer;High-grade serous ovarian cancer;	chr9:104098910	chr9:104080024~104093073:-
BRCA	cis	rs4742903	0.935	rs10820602	ENSG00000270332.1	SMC2-AS1	3.51	0.000471	0.0235	0.12	0.11	Breast cancer;High-grade serous ovarian cancer;	chr9:104099001	chr9:104080024~104093073:-
BRCA	cis	rs863345	0.604	rs12118446	ENSG00000176320.2	RP11-404O13.5	-3.51	0.000471	0.0235	-0.11	-0.11	Pneumococcal bacteremia;	chr1:158526445	chr1:158197922~158203877:-
BRCA	cis	rs4699052	0.963	rs6533066	ENSG00000230069.3	LRRC37A15P	-3.51	0.000471	0.0235	-0.1	-0.11	Testicular germ cell tumor;	chr4:103242450	chr4:102727274~102730721:-
BRCA	cis	rs4950322	0.57	rs72691032	ENSG00000237188.3	RP11-337C18.8	3.51	0.000471	0.0235	0.14	0.11	Protein quantitative trait loci;	chr1:147261120	chr1:147172771~147211568:+
BRCA	cis	rs4950322	0.57	rs72691033	ENSG00000237188.3	RP11-337C18.8	3.51	0.000471	0.0235	0.14	0.11	Protein quantitative trait loci;	chr1:147261267	chr1:147172771~147211568:+
BRCA	cis	rs75804782	0.641	rs11885523	ENSG00000186235.9	AC016757.3	3.51	0.000471	0.0235	0.23	0.11	Chronotype;Morning vs. evening chronotype;	chr2:238435622	chr2:238224552~238231677:-
BRCA	cis	rs75804782	0.641	rs11904390	ENSG00000186235.9	AC016757.3	3.51	0.000471	0.0235	0.23	0.11	Chronotype;Morning vs. evening chronotype;	chr2:238436022	chr2:238224552~238231677:-
BRCA	cis	rs9921338	0.886	rs4780363	ENSG00000262636.1	CTD-3088G3.4	3.51	0.000471	0.0235	0.17	0.11	Vein graft stenosis in coronary artery bypass grafting;	chr16:11322034	chr16:11380859~11381118:-
BRCA	cis	rs6964587	0.692	rs12536220	ENSG00000188693.7	CYP51A1-AS1	-3.51	0.000471	0.0235	-0.12	-0.11	Breast cancer;	chr7:92176281	chr7:92134604~92180725:+
BRCA	cis	rs11955398	0.502	rs4700406	ENSG00000272308.1	RP11-231G3.1	-3.51	0.000471	0.0235	-0.12	-0.11	Intelligence (multi-trait analysis);	chr5:61070048	chr5:60866457~60866935:-
BRCA	cis	rs3770081	1	rs17027011	ENSG00000232504.4	ST3GAL5-AS1	3.51	0.000471	0.0235	0.25	0.11	Facial emotion recognition (sad faces);	chr2:86179433	chr2:85889280~85890980:+
BRCA	cis	rs2337406	0.539	rs2583292	ENSG00000211972.2	IGHV3-66	3.51	0.000471	0.0235	0.1	0.11	Alzheimer's disease (late onset);	chr14:106649040	chr14:106675017~106675544:-
BRCA	cis	rs9472155	1	rs7767550	ENSG00000220614.1	RP11-480N24.4	3.51	0.000472	0.0235	0.15	0.11	Vascular endothelial growth factor levels;	chr6:43931515	chr6:43328134~43328476:+
BRCA	cis	rs10819861	0.645	rs7045648	ENSG00000175611.10	LINC00476	3.51	0.000472	0.0235	0.11	0.11	Electrocardiographic traits;	chr9:96092757	chr9:95759231~95875977:-
BRCA	cis	rs9925964	0.869	rs2288004	ENSG00000262766.1	RP11-196G11.4	-3.51	0.000472	0.0235	-0.09	-0.11	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31042719	chr16:31118078~31118747:+
BRCA	cis	rs9784649	0.891	rs57762467	ENSG00000245662.2	RP11-184E9.1	3.51	0.000472	0.0235	0.17	0.11	Peripheral arterial disease (traffic-related air pollution interaction);	chr5:25025591	chr5:25190682~25306172:+
BRCA	cis	rs4662592	0.66	rs10754933	ENSG00000272789.1	RP11-286H15.1	-3.51	0.000472	0.0235	-0.12	-0.11	Antipsychotic drug-induced QTc interval change in schizophrenia;	chr2:128083443	chr2:127625997~127626848:-
BRCA	cis	rs718433	0.584	rs4982495	ENSG00000211778.2	TRAV4	-3.51	0.000472	0.0235	-0.08	-0.11	Intraocular pressure;	chr14:21752285	chr14:21736152~21736982:+
BRCA	cis	rs91731	0.651	rs2967088	ENSG00000249572.1	CTD-2203K17.1	-3.51	0.000472	0.0235	-0.2	-0.11	Lung function (FVC);	chr5:33273184	chr5:33424025~33440619:-
BRCA	cis	rs8114671	0.562	rs7263157	ENSG00000279253.1	RP4-614O4.13	-3.51	0.000472	0.0235	-0.13	-0.11	Height;	chr20:34871324	chr20:35262727~35264187:-
BRCA	cis	rs67478160	0.679	rs8011109	ENSG00000269910.1	RP11-73M18.10	3.51	0.000472	0.0235	0.1	0.11	Schizophrenia;	chr14:103813637	chr14:103694516~103695050:-
BRCA	cis	rs2834188	0.737	rs2834179	ENSG00000272659.1	AP000295.10	-3.51	0.000472	0.0235	-0.15	-0.11	Narcolepsy;	chr21:33307426	chr21:33309491~33310181:+
BRCA	cis	rs2243480	0.522	rs73150635	ENSG00000222364.1	RNU6-96P	-3.51	0.000472	0.0235	-0.25	-0.11	Diabetic kidney disease;	chr7:66507503	chr7:66395191~66395286:+
BRCA	cis	rs754466	0.58	rs12356063	ENSG00000213514.2	RP11-428P16.2	3.51	0.000472	0.0235	0.15	0.11	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77798373	chr10:77730766~77734769:+
BRCA	cis	rs4761470	0.577	rs35129588	ENSG00000258172.1	RP11-1105G2.4	-3.51	0.000472	0.0235	-0.15	-0.11	Estradiol plasma levels (breast cancer);	chr12:94297780	chr12:94272150~94277195:-
BRCA	cis	rs863345	0.604	rs59427353	ENSG00000176320.2	RP11-404O13.5	-3.51	0.000472	0.0235	-0.11	-0.11	Pneumococcal bacteremia;	chr1:158530831	chr1:158197922~158203877:-
BRCA	cis	rs863345	0.565	rs59188837	ENSG00000176320.2	RP11-404O13.5	-3.51	0.000472	0.0235	-0.11	-0.11	Pneumococcal bacteremia;	chr1:158530846	chr1:158197922~158203877:-
BRCA	cis	rs4650994	0.593	rs2811297	ENSG00000213057.5	C1orf220	-3.51	0.000472	0.0235	-0.1	-0.11	HDL cholesterol;HDL cholesterol levels;	chr1:178582337	chr1:178542752~178548889:+
BRCA	cis	rs7824557	0.628	rs7820301	ENSG00000255046.1	RP11-297N6.4	-3.51	0.000472	0.0235	-0.13	-0.11	Retinal vascular caliber;	chr8:11371163	chr8:11797928~11802568:-
BRCA	cis	rs3755605	0.664	rs1798239	ENSG00000242578.1	RP11-469J4.3	3.51	0.000472	0.0235	0.13	0.11	Testicular germ cell tumor;	chr3:170197165	chr3:170410512~170418615:+
BRCA	cis	rs2832077	0.943	rs2832097	ENSG00000232855.5	AF131217.1	-3.51	0.000472	0.0235	-0.16	-0.11	Cognitive test performance;	chr21:28801017	chr21:28439346~28674848:-
BRCA	cis	rs7429990	0.93	rs71323371	ENSG00000228638.1	FCF1P2	-3.51	0.000472	0.0235	-0.11	-0.11	Educational attainment (years of education);	chr3:47904327	chr3:48290793~48291375:-
BRCA	cis	rs3015497	0.741	rs7146084	ENSG00000259113.1	RP11-406H23.2	3.51	0.000472	0.0235	0.12	0.11	Mean platelet volume;	chr14:50696776	chr14:50448807~50456742:+
BRCA	cis	rs41464348	0.584	rs711235	ENSG00000279544.1	AL133243.4	3.51	0.000472	0.0235	0.13	0.11	Height;	chr2:33246442	chr2:32563328~32566436:+
BRCA	cis	rs149313	0.901	rs697976	ENSG00000272109.1	CTD-2260A17.3	-3.51	0.000472	0.0235	-0.13	-0.11	Blood protein levels;	chr5:96733063	chr5:96804353~96806105:+
BRCA	cis	rs1383484	0.798	rs28645965	ENSG00000230373.7	GOLGA6L5P	-3.51	0.000472	0.0235	-0.13	-0.11	Height;	chr15:83869893	chr15:84507885~84516814:-
BRCA	cis	rs1383484	0.798	rs28545666	ENSG00000230373.7	GOLGA6L5P	-3.51	0.000472	0.0235	-0.13	-0.11	Height;	chr15:83869959	chr15:84507885~84516814:-
BRCA	cis	rs875971	1	rs12532998	ENSG00000229886.1	RP5-1132H15.3	3.51	0.000472	0.0235	0.12	0.11	Aortic root size;	chr7:66502472	chr7:66025126~66031544:-
BRCA	cis	rs488400	0.676	rs165581	ENSG00000270265.1	RP11-731D1.4	-3.51	0.000472	0.0235	-0.14	-0.11	Trans fatty acid levels;	chr4:151868634	chr4:151333775~151353224:-
BRCA	cis	rs801193	0.569	rs35070132	ENSG00000106610.13	STAG3L4	-3.51	0.000472	0.0235	-0.15	-0.11	Aortic root size;	chr7:66773096	chr7:67302621~67321526:+
BRCA	cis	rs2274273	0.87	rs11625001	ENSG00000259318.1	RP11-454L9.2	3.51	0.000472	0.0235	0.09	0.11	Protein biomarker;	chr14:55291442	chr14:55394940~55395233:-
BRCA	cis	rs997295	0.57	rs28730805	ENSG00000259673.4	IQCH-AS1	3.51	0.000472	0.0235	0.12	0.11	Motion sickness;	chr15:67587080	chr15:67403619~67521844:-
BRCA	cis	rs7520050	0.966	rs946529	ENSG00000226957.1	RP4-533D7.4	3.51	0.000472	0.0235	0.12	0.11	Reticulocyte count;Red blood cell count;	chr1:46019876	chr1:46046818~46048368:+
BRCA	cis	rs2018683	0.677	rs2057956	ENSG00000228421.2	AC005013.5	3.51	0.000473	0.0235	0.14	0.11	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28933843	chr7:28957667~28959345:+
BRCA	cis	rs4657482	0.64	rs10918304	ENSG00000236364.3	RP11-525G13.2	-3.51	0.000473	0.0235	-0.1	-0.11	Testicular germ cell tumor;	chr1:165895450	chr1:165890795~165900683:-
BRCA	cis	rs10864907	0.806	rs10864908	ENSG00000231747.1	AC079922.2	-3.51	0.000473	0.0235	-0.1	-0.11	Pulmonary function;	chr2:112954919	chr2:112621809~112622167:-
BRCA	cis	rs12468226	1	rs74508472	ENSG00000272966.1	RP11-686O6.1	3.51	0.000473	0.0235	0.18	0.11	Urate levels;	chr2:202517290	chr2:202336739~202337200:+
BRCA	cis	rs2412819	0.559	rs8040336	ENSG00000275601.1	AC011330.13	-3.51	0.000473	0.0235	-0.12	-0.11	Lung cancer;	chr15:43761419	chr15:43642389~43643023:-
BRCA	cis	rs1865760	0.568	rs2032450	ENSG00000272462.2	U91328.19	-3.51	0.000473	0.0235	-0.13	-0.11	Height;	chr6:25992886	chr6:25992662~26001775:+
BRCA	cis	rs1865760	0.713	rs2013063	ENSG00000272462.2	U91328.19	-3.51	0.000473	0.0235	-0.13	-0.11	Height;	chr6:25993870	chr6:25992662~26001775:+
BRCA	cis	rs10035650	0.554	rs6879307	ENSG00000243806.1	RPL7P18	-3.51	0.000473	0.0235	-0.13	-0.11	Cancer;	chr5:94687383	chr5:94825961~94826694:-
BRCA	cis	rs10129255	1	rs10141557	ENSG00000232216.1	IGHV3-43	3.51	0.000473	0.0235	0.09	0.11	Kawasaki disease;	chr14:106767990	chr14:106470264~106470800:-
BRCA	cis	rs713477	0.524	rs2341538	ENSG00000186615.9	KTN1-AS1	3.51	0.000473	0.0235	0.13	0.11	Pediatric bone mineral content (femoral neck);	chr14:55428456	chr14:55499278~55580110:-
BRCA	cis	rs17406451	0.819	rs6747202	ENSG00000234936.1	AC010883.5	-3.51	0.000473	0.0235	-0.11	-0.11	Mitochondrial DNA levels;	chr2:43420428	chr2:43229573~43233394:+
BRCA	cis	rs2274273	0.87	rs67514154	ENSG00000259318.1	RP11-454L9.2	3.51	0.000473	0.0235	0.09	0.11	Protein biomarker;	chr14:55300664	chr14:55394940~55395233:-
BRCA	cis	rs258892	0.895	rs9293437	ENSG00000272525.1	RP11-79P5.9	-3.51	0.000473	0.0235	-0.13	-0.11	Small cell lung carcinoma;	chr5:72746078	chr5:73497550~73498293:-
BRCA	cis	rs6840360	1	rs7439465	ENSG00000251611.1	RP11-610P16.1	3.51	0.000473	0.0236	0.1	0.11	Intelligence (multi-trait analysis);	chr4:151673662	chr4:151407551~151408835:-
BRCA	cis	rs10421328	0.784	rs28635562	ENSG00000267419.1	CTC-559E9.6	-3.51	0.000473	0.0236	-0.12	-0.11	Parental longevity (combined parental age at death);	chr19:19658881	chr19:19776602~19834927:+
BRCA	cis	rs1730008	0.585	rs58891024	ENSG00000279311.1	RP11-170K4.2	3.51	0.000473	0.0236	0.13	0.11	Lobe attachment (rater-scored or self-reported);	chr3:158526636	chr3:158869898~158871821:+
BRCA	cis	rs2688608	0.672	rs2633321	ENSG00000271816.1	BMS1P4	3.51	0.000473	0.0236	0.11	0.11	Inflammatory bowel disease;	chr10:73933937	chr10:73699151~73730487:-
BRCA	cis	rs6813195	0.881	rs7669833	ENSG00000245954.5	RP11-18H21.1	3.51	0.000473	0.0236	0.1	0.11	Type 2 diabetes;	chr4:152592217	chr4:152100754~152104720:+
BRCA	cis	rs115575488	0.778	rs17023073	ENSG00000231365.4	RP11-418J17.1	3.51	0.000473	0.0236	0.19	0.11	Lobe attachment (rater-scored or self-reported);	chr1:119027128	chr1:119140396~119275973:+
BRCA	cis	rs375066	0.935	rs422457	ENSG00000278917.1	RP11-15A1.4	-3.51	0.000473	0.0236	-0.13	-0.11	Breast cancer;	chr19:43905259	chr19:43891233~43895411:+
BRCA	cis	rs67766926	0.537	rs17539345	ENSG00000237522.1	NONOP2	-3.51	0.000473	0.0236	-0.12	-0.11	Inflammatory skin disease;	chr2:61022966	chr2:60936819~60938049:-
BRCA	cis	rs13434995	0.588	rs114571142	ENSG00000273257.1	RP11-177J6.1	-3.51	0.000473	0.0236	-0.16	-0.11	Adiponectin levels;	chr4:55412991	chr4:55387949~55388271:+
BRCA	cis	rs11035577	0.57	rs4755520	ENSG00000279675.1	RP11-454H19.2	-3.51	0.000473	0.0236	-0.17	-0.11	Temperament (bipolar disorder);	chr11:39751085	chr11:40107244~40112599:-
BRCA	cis	rs12210905	0.622	rs116198502	ENSG00000272462.2	U91328.19	-3.51	0.000473	0.0236	-0.2	-0.11	Hip circumference adjusted for BMI;	chr6:26947236	chr6:25992662~26001775:+
BRCA	cis	rs853679	0.599	rs149949	ENSG00000216901.1	AL022393.7	3.51	0.000473	0.0236	0.21	0.11	Depression;	chr6:28043738	chr6:28176188~28176674:+
BRCA	cis	rs3764021	0.527	rs10844456	ENSG00000278635.1	CTD-2318O12.1	-3.51	0.000473	0.0236	-0.12	-0.11	Type 1 diabetes;	chr12:9689319	chr12:9415641~9416718:+
BRCA	cis	rs7829975	0.606	rs10112585	ENSG00000253981.4	ALG1L13P	-3.51	0.000473	0.0236	-0.12	-0.11	Mood instability;	chr8:8937520	chr8:8236003~8244667:-
BRCA	cis	rs2839186	0.596	rs4819217	ENSG00000215424.8	MCM3AP-AS1	3.51	0.000473	0.0236	0.1	0.11	Testicular germ cell tumor;	chr21:46224178	chr21:46229217~46259390:+
BRCA	cis	rs983392	0.692	rs580064	ENSG00000275344.1	MIR6503	-3.51	0.000474	0.0236	-0.11	-0.11	Alzheimer's disease (late onset);	chr11:60101646	chr11:60209071~60209156:-
BRCA	cis	rs11098403	0.753	rs9307443	ENSG00000225892.3	RP11-384K6.2	3.51	0.000474	0.0236	0.11	0.11	Schizophrenia;	chr4:117790128	chr4:118632274~118634759:+
BRCA	cis	rs11098403	0.798	rs9307444	ENSG00000225892.3	RP11-384K6.2	3.51	0.000474	0.0236	0.11	0.11	Schizophrenia;	chr4:117790188	chr4:118632274~118634759:+
BRCA	cis	rs7577696	0.785	rs3769602	ENSG00000276334.1	AL133243.1	-3.51	0.000474	0.0236	-0.14	-0.11	Inflammatory biomarkers;	chr2:32156760	chr2:32521927~32523547:+
BRCA	cis	rs16958440	0.541	rs62095459	ENSG00000280212.1	RP11-49K24.3	3.51	0.000474	0.0236	0.18	0.11	Sitting height ratio;	chr18:47095011	chr18:47076117~47076594:+
BRCA	cis	rs687432	0.924	rs61905309	ENSG00000265566.2	RN7SL605P	-3.51	0.000474	0.0236	-0.15	-0.11	Parkinson's disease;	chr11:57979102	chr11:57528085~57528365:-
BRCA	cis	rs35740288	0.77	rs11630286	ENSG00000259295.5	CSPG4P12	3.51	0.000474	0.0236	0.15	0.11	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85659298	chr15:85191438~85213905:+
BRCA	cis	rs7267979	0.966	rs2500433	ENSG00000274973.1	RP13-401N8.7	3.51	0.000474	0.0236	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25315699	chr20:25845497~25845862:+
BRCA	cis	rs7267979	0.966	rs2482948	ENSG00000274973.1	RP13-401N8.7	3.51	0.000474	0.0236	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25315863	chr20:25845497~25845862:+
BRCA	cis	rs13136331	0.642	rs2869681	ENSG00000249001.4	RP11-742B18.1	3.51	0.000474	0.0236	0.14	0.11	Sitting height ratio;	chr4:87699035	chr4:87568035~87733956:-
BRCA	cis	rs673253	0.686	rs3791136	ENSG00000229431.1	RP1-92O14.6	-3.51	0.000474	0.0236	-0.11	-0.11	Intelligence (multi-trait analysis);	chr1:43584276	chr1:43385113~43389155:+
BRCA	cis	rs3770081	1	rs3770066	ENSG00000232504.4	ST3GAL5-AS1	3.51	0.000474	0.0236	0.25	0.11	Facial emotion recognition (sad faces);	chr2:86165227	chr2:85889280~85890980:+
BRCA	cis	rs7620503	0.625	rs7620805	ENSG00000228561.2	RP11-114M1.1	3.51	0.000474	0.0236	0.14	0.11	Corneal structure;	chr3:177586637	chr3:177683627~177691250:+
BRCA	cis	rs1007738	0.542	rs11603373	ENSG00000200376.1	RNU5E-10P	-3.51	0.000474	0.0236	-0.14	-0.11	Bone mineral density (hip);	chr11:47181694	chr11:47576471~47576588:-
BRCA	cis	rs10944	0.598	rs595479	ENSG00000253558.1	CTD-2179L22.1	-3.51	0.000474	0.0236	-0.13	-0.11	Blood and toenail selenium levels;	chr5:78979828	chr5:78041879~78044138:-
BRCA	cis	rs13034020	0.641	rs35852308	ENSG00000271889.1	RP11-493E12.1	-3.51	0.000474	0.0236	-0.19	-0.11	Hodgkin's lymphoma;	chr2:60998428	chr2:61151433~61162105:-
BRCA	cis	rs2154319	0.79	rs213750	ENSG00000230638.4	RP11-486B10.4	3.51	0.000474	0.0236	0.18	0.11	Height;	chr1:41145142	chr1:41542069~41544310:+
BRCA	cis	rs2154319	0.836	rs213749	ENSG00000230638.4	RP11-486B10.4	3.51	0.000474	0.0236	0.18	0.11	Height;	chr1:41148218	chr1:41542069~41544310:+
BRCA	cis	rs656900	0.647	rs668641	ENSG00000259548.1	RP11-38G5.2	3.51	0.000474	0.0236	0.12	0.11	Cerebrospinal P-tau181p levels;	chr15:79826282	chr15:79832466~79833554:-
BRCA	cis	rs9287719	0.967	rs6721739	ENSG00000224177.5	LINC00570	-3.51	0.000474	0.0236	-0.13	-0.11	Prostate cancer;	chr2:10611120	chr2:11393981~11403077:+
BRCA	cis	rs4930561	0.739	rs10896303	ENSG00000255306.1	RP5-901A4.1	-3.51	0.000474	0.0236	-0.11	-0.11	Breast cancer in childhood cancer survivors;IgG glycosylation;	chr11:68206825	chr11:68024809~68030461:-
BRCA	cis	rs5167	0.583	rs7252480	ENSG00000214855.8	APOC1P1	3.51	0.000474	0.0236	0.14	0.11	Blood protein levels;	chr19:44955668	chr19:44926804~44931386:+
BRCA	cis	rs875971	0.638	rs6960778	ENSG00000275400.1	RP4-756H11.5	3.51	0.000474	0.0236	0.12	0.11	Aortic root size;	chr7:66606610	chr7:66553805~66554199:-
BRCA	cis	rs77741769	0.529	rs3213572	ENSG00000277423.1	RP11-173P15.9	3.51	0.000474	0.0236	0.13	0.11	Mean corpuscular volume;	chr12:120767275	chr12:120703867~120704282:+
BRCA	cis	rs490234	0.586	rs3122934	ENSG00000232630.1	PRPS1P2	3.51	0.000474	0.0236	0.11	0.11	Mean arterial pressure;	chr9:125391821	chr9:125150653~125151589:+
BRCA	cis	rs4865762	0.692	rs1374058	ENSG00000247796.2	CTD-2366F13.1	3.51	0.000474	0.0236	0.12	0.11	Intraocular pressure;	chr5:53131816	chr5:53109842~53115126:+
BRCA	cis	rs1005277	0.638	rs1005278	ENSG00000120555.12	SEPT7P9	-3.51	0.000474	0.0236	-0.13	-0.11	Extrinsic epigenetic age acceleration;	chr10:37929820	chr10:38383069~38402916:-
BRCA	cis	rs465969	1	rs9400478	ENSG00000230177.1	RP5-1112D6.4	-3.51	0.000474	0.0236	-0.28	-0.11	Psoriasis;	chr6:111478441	chr6:111277932~111278742:+
BRCA	cis	rs9378796	0.518	rs13196649	ENSG00000272248.1	RP3-406P24.4	-3.51	0.000475	0.0236	-0.17	-0.11	Mean platelet volume;	chr6:3435334	chr6:4018713~4019202:+
BRCA	cis	rs7520050	1	rs12143096	ENSG00000234329.1	RP11-767N6.2	-3.51	0.000475	0.0236	-0.1	-0.11	Reticulocyte count;Red blood cell count;	chr1:46004091	chr1:45651039~45651826:-
BRCA	cis	rs4835473	0.9	rs7683287	ENSG00000246448.2	RP13-578N3.3	-3.51	0.000475	0.0236	-0.12	-0.11	Immature fraction of reticulocytes;	chr4:143749270	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.712	rs2198000	ENSG00000246448.2	RP13-578N3.3	-3.51	0.000475	0.0236	-0.12	-0.11	Immature fraction of reticulocytes;	chr4:143750005	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.9	rs2198002	ENSG00000246448.2	RP13-578N3.3	-3.51	0.000475	0.0236	-0.12	-0.11	Immature fraction of reticulocytes;	chr4:143750028	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.932	rs6853460	ENSG00000246448.2	RP13-578N3.3	-3.51	0.000475	0.0236	-0.12	-0.11	Immature fraction of reticulocytes;	chr4:143750392	chr4:143700257~143865072:+
BRCA	cis	rs17270561	1	rs17270561	ENSG00000272462.2	U91328.19	3.51	0.000475	0.0236	0.15	0.11	Iron status biomarkers;	chr6:25820211	chr6:25992662~26001775:+
BRCA	cis	rs2304003	0.583	rs962501	ENSG00000229195.1	AC009495.4	3.51	0.000475	0.0236	0.13	0.11	Social communication problems;	chr2:165864741	chr2:165794857~165846091:-
BRCA	cis	rs600550	0.719	rs11230227	ENSG00000275344.1	MIR6503	3.51	0.000475	0.0236	0.12	0.11	Lipoprotein-associated phospholipase A2 activity and mass;	chr11:60274389	chr11:60209071~60209156:-
BRCA	cis	rs2412819	0.571	rs12443084	ENSG00000201136.1	RNU6-353P	-3.51	0.000475	0.0236	-0.15	-0.11	Lung cancer;	chr15:43748767	chr15:43702363~43702470:+
BRCA	cis	rs11874712	1	rs1800639	ENSG00000251939.1	RNU6-1278P	-3.51	0.000475	0.0236	-0.12	-0.11	Migraine - clinic-based;	chr18:46091274	chr18:46121615~46121721:-
BRCA	cis	rs10129255	0.957	rs8009464	ENSG00000211967.3	IGHV3-53	-3.51	0.000475	0.0236	-0.08	-0.11	Kawasaki disease;	chr14:106777611	chr14:106592676~106593347:-
BRCA	cis	rs4148883	0.675	rs28762430	ENSG00000272777.1	RP11-571L19.8	-3.51	0.000475	0.0236	-0.11	-0.11	Alcohol dependence;	chr4:99198100	chr4:99067256~99068125:-
BRCA	cis	rs1250259	0.519	rs13020766	ENSG00000225166.1	AC012462.2	-3.51	0.000475	0.0236	-0.13	-0.11	Coronary artery disease;Pulse pressure;	chr2:215411048	chr2:215453707~215463871:+
BRCA	cis	rs2562456	0.833	rs11666447	ENSG00000268117.1	VN1R84P	3.51	0.000475	0.0236	0.17	0.11	Pain;	chr19:21416270	chr19:21719801~21720035:-
BRCA	cis	rs826838	0.586	rs10785554	ENSG00000257718.1	RP11-396F22.1	3.51	0.000475	0.0236	0.11	0.11	Heart rate;	chr12:38234947	chr12:38906451~38909592:+
BRCA	cis	rs13434995	0.513	rs1801260	ENSG00000249700.7	SRD5A3-AS1	-3.51	0.000475	0.0236	-0.16	-0.11	Adiponectin levels;	chr4:55435202	chr4:55363971~55395847:-
BRCA	cis	rs13434995	0.513	rs17721215	ENSG00000249700.7	SRD5A3-AS1	-3.51	0.000475	0.0236	-0.16	-0.11	Adiponectin levels;	chr4:55437620	chr4:55363971~55395847:-
BRCA	cis	rs28489187	0.558	rs2474123	ENSG00000223653.4	RP11-131L23.1	3.51	0.000475	0.0236	0.12	0.11	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85361769	chr1:85276715~85448124:+
BRCA	cis	rs9785234	0.941	rs10819947	ENSG00000175611.10	LINC00476	-3.51	0.000475	0.0236	-0.13	-0.11	Glomerular filtration rate in chronic kidney disease;	chr9:96170406	chr9:95759231~95875977:-
BRCA	cis	rs9619254	0.92	rs16990001	ENSG00000242082.1	RP1-90G24.10	3.51	0.000475	0.0236	0.17	0.11	Loneliness (multivariate analysis);	chr22:32204928	chr22:32205115~32269666:+
BRCA	cis	rs2640806	0.505	rs17781856	ENSG00000253105.4	KB-1448A5.1	-3.51	0.000475	0.0236	-0.12	-0.11	Obesity-related traits;	chr8:96355322	chr8:96371865~96387438:-
BRCA	cis	rs7474896	1	rs35031837	ENSG00000120555.12	SEPT7P9	3.51	0.000475	0.0236	0.2	0.11	Obesity (extreme);	chr10:37645280	chr10:38383069~38402916:-
BRCA	cis	rs12413361	1	rs12413361	ENSG00000272914.1	RP11-330O11.3	-3.51	0.000475	0.0236	-0.13	-0.11	Height;	chr10:30838237	chr10:30831828~30833387:-
BRCA	cis	rs751728	0.643	rs12173787	ENSG00000224557.6	HLA-DPB2	-3.51	0.000475	0.0236	-0.13	-0.11	Crohn's disease;	chr6:33767694	chr6:33112451~33129084:+
BRCA	cis	rs60871478	0.636	rs7792072	ENSG00000237181.1	AC147651.4	3.51	0.000475	0.0236	0.12	0.11	Cerebrospinal P-tau181p levels;	chr7:846602	chr7:603185~608482:+
BRCA	cis	rs60871478	0.636	rs73045423	ENSG00000237181.1	AC147651.4	3.51	0.000475	0.0236	0.12	0.11	Cerebrospinal P-tau181p levels;	chr7:854315	chr7:603185~608482:+
BRCA	cis	rs2216824	1	rs12328717	ENSG00000278908.1	RP11-523J2.1	3.51	0.000475	0.0236	0.18	0.11	Oropharynx cancer;	chr2:30883373	chr2:30677762~30679895:+
BRCA	cis	rs11892454	0.565	rs12713680	ENSG00000217643.1	PTGES3P2	-3.51	0.000475	0.0236	-0.12	-0.11	Heschl's gyrus morphology;	chr2:25830974	chr2:25822469~25822950:+
BRCA	cis	rs7267979	0.966	rs2257233	ENSG00000276952.1	RP5-965G21.6	-3.51	0.000475	0.0236	-0.13	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25285348	chr20:25284915~25285588:-
BRCA	cis	rs17092148	1	rs6060047	ENSG00000202150.1	RNU6-407P	-3.51	0.000475	0.0236	-0.16	-0.11	Neuroticism;	chr20:34779597	chr20:35030317~35030420:-
BRCA	cis	rs11048434	0.518	rs7311509	ENSG00000256069.6	A2MP1	-3.51	0.000475	0.0236	-0.11	-0.11	Sjögren's syndrome;	chr12:9026438	chr12:9228533~9275817:-
BRCA	cis	rs2836950	0.545	rs11700813	ENSG00000235701.1	PCBP2P1	-3.51	0.000475	0.0236	-0.13	-0.11	Menarche (age at onset);	chr21:39145543	chr21:39171130~39172106:-
BRCA	cis	rs8073060	0.963	rs11080353	ENSG00000255987.1	TOMM20P2	3.51	0.000475	0.0236	0.1	0.11	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35544262	chr17:35514766~35515186:-
BRCA	cis	rs1730008	1	rs698975	ENSG00000279311.1	RP11-170K4.2	-3.51	0.000475	0.0236	-0.12	-0.11	Lobe attachment (rater-scored or self-reported);	chr3:158221590	chr3:158869898~158871821:+
BRCA	cis	rs7103648	0.864	rs10742802	ENSG00000280615.1	Y_RNA	3.51	0.000475	0.0236	0.13	0.11	Systolic blood pressure;Diastolic blood pressure;	chr11:47411174	chr11:47614898~47614994:-
BRCA	cis	rs890448	0.76	rs4699210	ENSG00000254531.1	FLJ20021	3.51	0.000475	0.0236	0.13	0.11	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101363829	chr4:101347780~101348883:+
BRCA	cis	rs4664293	0.801	rs7589771	ENSG00000224152.1	AC009506.1	-3.51	0.000475	0.0236	-0.12	-0.11	Monocyte percentage of white cells;	chr2:159727621	chr2:159615296~159617082:+
BRCA	cis	rs28489187	0.683	rs233050	ENSG00000223653.4	RP11-131L23.1	3.51	0.000475	0.0237	0.12	0.11	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85372110	chr1:85276715~85448124:+
BRCA	cis	rs62247992	0.698	rs11707627	ENSG00000227245.1	RP11-136C24.2	3.51	0.000476	0.0237	0.17	0.11	Facial morphology (factor 15, philtrum width);	chr3:43081731	chr3:43087479~43088068:+
BRCA	cis	rs7120118	0.517	rs11530168	ENSG00000280615.1	Y_RNA	3.51	0.000476	0.0237	0.18	0.11	HDL cholesterol;	chr11:47301435	chr11:47614898~47614994:-
BRCA	cis	rs10504130	0.569	rs6473653	ENSG00000253844.1	RP11-546K22.1	3.51	0.000476	0.0237	0.15	0.11	Venous thromboembolism (SNP x SNP interaction);	chr8:51757562	chr8:51961458~52022974:+
BRCA	cis	rs4711350	0.911	rs9461907	ENSG00000224557.6	HLA-DPB2	-3.51	0.000476	0.0237	-0.15	-0.11	Schizophrenia;	chr6:33759213	chr6:33112451~33129084:+
BRCA	cis	rs12723316	0.932	rs71652653	ENSG00000233008.4	RP11-475O6.1	-3.51	0.000476	0.0237	-0.21	-0.11	Schizophrenia;	chr1:83816903	chr1:83575776~83861023:-
BRCA	cis	rs2243480	1	rs73142122	ENSG00000226767.1	RP11-328P23.3	-3.51	0.000476	0.0237	-0.19	-0.11	Diabetic kidney disease;	chr7:65846311	chr7:65508773~65508944:-
BRCA	cis	rs2243480	0.901	rs73142137	ENSG00000226767.1	RP11-328P23.3	-3.51	0.000476	0.0237	-0.19	-0.11	Diabetic kidney disease;	chr7:65878455	chr7:65508773~65508944:-
BRCA	cis	rs2243480	1	rs13247184	ENSG00000226767.1	RP11-328P23.3	-3.51	0.000476	0.0237	-0.19	-0.11	Diabetic kidney disease;	chr7:65893941	chr7:65508773~65508944:-
BRCA	cis	rs2243480	1	rs35283677	ENSG00000226767.1	RP11-328P23.3	-3.51	0.000476	0.0237	-0.19	-0.11	Diabetic kidney disease;	chr7:65894246	chr7:65508773~65508944:-
BRCA	cis	rs2243480	1	rs35421653	ENSG00000226767.1	RP11-328P23.3	-3.51	0.000476	0.0237	-0.19	-0.11	Diabetic kidney disease;	chr7:65898442	chr7:65508773~65508944:-
BRCA	cis	rs12303914	0.502	rs61917597	ENSG00000256682.2	TAS2R12	3.51	0.000476	0.0237	0.15	0.11	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr12:10301504	chr12:10894943~10896952:-
BRCA	cis	rs1417569	0.546	rs2934649	ENSG00000237135.1	DDX10P1	-3.51	0.000476	0.0237	-0.15	-0.11	Tuberculosis;	chr10:30937490	chr10:30919012~30921235:-
BRCA	cis	rs13256369	0.851	rs13267036	ENSG00000254153.1	CTA-398F10.2	3.51	0.000476	0.0237	0.15	0.11	Obesity-related traits;	chr8:8709175	chr8:8456909~8461337:-
BRCA	cis	rs2018683	0.523	rs1499224	ENSG00000233517.1	AC005162.5	-3.51	0.000476	0.0237	-0.14	-0.11	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28989852	chr7:28987028~28988899:+
BRCA	cis	rs7954584	0.616	rs10743186	ENSG00000212694.7	LINC01089	-3.51	0.000476	0.0237	-0.08	-0.11	Mean corpuscular volume;	chr12:121918530	chr12:121795267~121803906:-
BRCA	cis	rs8180040	0.62	rs11720139	ENSG00000280667.1	Y_RNA	-3.51	0.000476	0.0237	-0.12	-0.11	Colorectal cancer;	chr3:46995266	chr3:47501083~47501182:+
BRCA	cis	rs4388249	1	rs3756597	ENSG00000249068.1	CTC-287O8.1	3.51	0.000476	0.0237	0.16	0.11	Schizophrenia;	chr5:109739808	chr5:109840128~109840692:-
BRCA	cis	rs4919694	1	rs77827514	ENSG00000236937.2	PTGES3P4	3.51	0.000476	0.0237	0.22	0.11	Arsenic metabolism;	chr10:103062252	chr10:102845595~102845950:+
BRCA	cis	rs17221829	0.764	rs12146462	ENSG00000280385.1	AP000648.5	-3.51	0.000476	0.0237	-0.12	-0.11	Anxiety in major depressive disorder;	chr11:89652206	chr11:90193614~90198120:+
BRCA	cis	rs6088580	0.524	rs6088564	ENSG00000279253.1	RP4-614O4.13	3.5	0.000476	0.0237	0.12	0.11	Glomerular filtration rate (creatinine);	chr20:34661640	chr20:35262727~35264187:-
BRCA	cis	rs6088580	0.524	rs11167241	ENSG00000279253.1	RP4-614O4.13	3.5	0.000476	0.0237	0.12	0.11	Glomerular filtration rate (creatinine);	chr20:34663031	chr20:35262727~35264187:-
BRCA	cis	rs6088580	0.505	rs6142219	ENSG00000279253.1	RP4-614O4.13	3.5	0.000476	0.0237	0.12	0.11	Glomerular filtration rate (creatinine);	chr20:34668541	chr20:35262727~35264187:-
BRCA	cis	rs16958440	0.708	rs62096465	ENSG00000280212.1	RP11-49K24.3	3.5	0.000476	0.0237	0.19	0.11	Sitting height ratio;	chr18:47103253	chr18:47076117~47076594:+
BRCA	cis	rs16958440	0.708	rs1434528	ENSG00000280212.1	RP11-49K24.3	3.5	0.000476	0.0237	0.19	0.11	Sitting height ratio;	chr18:47105952	chr18:47076117~47076594:+
BRCA	cis	rs10508774	0.5	rs17296289	ENSG00000273038.2	RP11-479G22.8	3.5	0.000476	0.0237	0.24	0.11	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32971771	chr10:32887255~32889311:-
BRCA	cis	rs3764021	0.527	rs17806710	ENSG00000278635.1	CTD-2318O12.1	-3.5	0.000476	0.0237	-0.12	-0.11	Type 1 diabetes;	chr12:9688368	chr12:9415641~9416718:+
BRCA	cis	rs13136331	0.721	rs2732175	ENSG00000249001.4	RP11-742B18.1	3.5	0.000476	0.0237	0.15	0.11	Sitting height ratio;	chr4:87761422	chr4:87568035~87733956:-
BRCA	cis	rs17489649	0.74	rs2217639	ENSG00000271849.1	CTC-332L22.1	3.5	0.000476	0.0237	0.14	0.11	Intelligence (multi-trait analysis);	chr5:109866693	chr5:109687802~109688329:-
BRCA	cis	rs6840360	0.615	rs113052419	ENSG00000270265.1	RP11-731D1.4	-3.5	0.000476	0.0237	-0.13	-0.11	Intelligence (multi-trait analysis);	chr4:151551856	chr4:151333775~151353224:-
BRCA	cis	rs10876993	0.893	rs1678504	ENSG00000270039.1	RP11-571M6.17	3.5	0.000476	0.0237	0.14	0.11	Celiac disease or Rheumatoid arthritis;	chr12:57691715	chr12:57803838~57804415:+
BRCA	cis	rs2832077	0.527	rs2250141	ENSG00000232855.5	AF131217.1	-3.5	0.000476	0.0237	-0.14	-0.11	Cognitive test performance;	chr21:28869662	chr21:28439346~28674848:-
BRCA	cis	rs524281	0.861	rs7931544	ENSG00000255038.1	RP11-1167A19.2	-3.5	0.000476	0.0237	-0.16	-0.11	Electroencephalogram traits;	chr11:66149563	chr11:66067277~66069619:-
BRCA	cis	rs860295	0.58	rs2282301	ENSG00000225082.2	DAP3P1	3.5	0.000476	0.0237	0.14	0.11	Body mass index;	chr1:155898834	chr1:155586644~155602197:+
BRCA	cis	rs10986311	1	rs748741	ENSG00000227200.1	RP11-121A14.3	3.5	0.000477	0.0237	0.13	0.11	Vitiligo;	chr9:124327496	chr9:124262876~124265809:+
BRCA	cis	rs2562456	0.833	rs4334427	ENSG00000268117.1	VN1R84P	3.5	0.000477	0.0237	0.16	0.11	Pain;	chr19:21338090	chr19:21719801~21720035:-
BRCA	cis	rs4388249	1	rs2284989	ENSG00000249068.1	CTC-287O8.1	3.5	0.000477	0.0237	0.16	0.11	Schizophrenia;	chr5:109740787	chr5:109840128~109840692:-
BRCA	cis	rs4388249	1	rs12656571	ENSG00000249068.1	CTC-287O8.1	3.5	0.000477	0.0237	0.16	0.11	Schizophrenia;	chr5:109742339	chr5:109840128~109840692:-
BRCA	cis	rs13326165	0.76	rs17052068	ENSG00000243224.1	RP5-1157M23.2	-3.5	0.000477	0.0237	-0.15	-0.11	HDL cholesterol levels;HDL cholesterol;	chr3:52318848	chr3:52239258~52241097:+
BRCA	cis	rs4460629	0.521	rs4361977	ENSG00000160766.13	GBAP1	-3.5	0.000477	0.0237	-0.11	-0.11	Serum magnesium levels;	chr1:155103603	chr1:155213821~155227422:-
BRCA	cis	rs73242632	1	rs2276896	ENSG00000269949.1	RP11-738E22.3	3.5	0.000477	0.0237	0.25	0.11	Congenital heart disease (maternal effect);	chr4:56978925	chr4:56960927~56961373:-
BRCA	cis	rs12723316	0.932	rs1010436	ENSG00000233008.4	RP11-475O6.1	-3.5	0.000477	0.0237	-0.21	-0.11	Schizophrenia;	chr1:83820893	chr1:83575776~83861023:-
BRCA	cis	rs10759883	0.539	rs10117340	ENSG00000225194.2	LINC00092	-3.5	0.000477	0.0237	-0.11	-0.11	Nicotine dependence;	chr9:96032530	chr9:96019732~96027965:-
BRCA	cis	rs36051895	0.664	rs3824433	ENSG00000236254.1	MTND4P14	-3.5	0.000477	0.0237	-0.12	-0.11	Pediatric autoimmune diseases;	chr9:5113577	chr9:5107937~5109290:+
BRCA	cis	rs11098499	0.754	rs878376	ENSG00000250412.1	KLHL2P1	3.5	0.000477	0.0237	0.12	0.11	Corneal astigmatism;	chr4:119316547	chr4:119334329~119378233:+
BRCA	cis	rs875971	1	rs2077593	ENSG00000271064.1	RP11-792A8.3	-3.5	0.000477	0.0237	-0.13	-0.11	Aortic root size;	chr7:66427543	chr7:66748838~66749077:-
BRCA	cis	rs875971	0.895	rs12531677	ENSG00000271064.1	RP11-792A8.3	3.5	0.000477	0.0237	0.13	0.11	Aortic root size;	chr7:66304099	chr7:66748838~66749077:-
BRCA	cis	rs875971	0.862	rs7798630	ENSG00000271064.1	RP11-792A8.3	3.5	0.000477	0.0237	0.13	0.11	Aortic root size;	chr7:66306492	chr7:66748838~66749077:-
BRCA	cis	rs12479064	0.724	rs4851203	ENSG00000231822.1	AC019097.7	-3.5	0.000477	0.0237	-0.12	-0.11	Chronic sinus infection;	chr2:99370469	chr2:99102018~99102752:+
BRCA	cis	rs7520050	0.933	rs6694340	ENSG00000281133.1	AL355480.3	3.5	0.000477	0.0237	0.12	0.11	Reticulocyte count;Red blood cell count;	chr1:45823744	chr1:45580892~45580996:-
BRCA	cis	rs6449502	0.92	rs4647078	ENSG00000215032.2	GNL3LP1	3.5	0.000477	0.0237	0.18	0.11	Mean platelet volume;	chr5:60921211	chr5:60891935~60893577:-
BRCA	cis	rs748404	0.666	rs514438	ENSG00000166763.7	STRCP1	3.5	0.000477	0.0237	0.15	0.11	Lung cancer;	chr15:43328245	chr15:43699488~43718184:-
BRCA	cis	rs1009077	0.578	rs2389863	ENSG00000245958.5	RP11-33B1.1	-3.5	0.000477	0.0237	-0.12	-0.11	Endometriosis;	chr4:119586509	chr4:119454791~119552025:+
BRCA	cis	rs1009077	0.531	rs10012485	ENSG00000245958.5	RP11-33B1.1	-3.5	0.000477	0.0237	-0.12	-0.11	Endometriosis;	chr4:119587143	chr4:119454791~119552025:+
BRCA	cis	rs1009077	0.61	rs28412979	ENSG00000245958.5	RP11-33B1.1	-3.5	0.000477	0.0237	-0.12	-0.11	Endometriosis;	chr4:119588726	chr4:119454791~119552025:+
BRCA	cis	rs1009077	0.61	rs13115778	ENSG00000245958.5	RP11-33B1.1	-3.5	0.000477	0.0237	-0.12	-0.11	Endometriosis;	chr4:119589380	chr4:119454791~119552025:+
BRCA	cis	rs1009077	0.61	rs7659250	ENSG00000245958.5	RP11-33B1.1	-3.5	0.000477	0.0237	-0.12	-0.11	Endometriosis;	chr4:119590820	chr4:119454791~119552025:+
BRCA	cis	rs1009077	0.61	rs6842674	ENSG00000245958.5	RP11-33B1.1	-3.5	0.000477	0.0237	-0.12	-0.11	Endometriosis;	chr4:119591353	chr4:119454791~119552025:+
BRCA	cis	rs7608910	0.93	rs4560096	ENSG00000237522.1	NONOP2	-3.5	0.000477	0.0237	-0.1	-0.11	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;	chr2:60977782	chr2:60936819~60938049:-
BRCA	cis	rs9990333	0.622	rs57783901	ENSG00000185485.13	SDHAP1	3.5	0.000477	0.0237	0.11	0.11	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196089486	chr3:195959748~195990318:-
BRCA	cis	rs875971	0.767	rs12668005	ENSG00000271064.1	RP11-792A8.3	-3.5	0.000477	0.0237	-0.13	-0.11	Aortic root size;	chr7:66444034	chr7:66748838~66749077:-
BRCA	cis	rs11035577	0.778	rs1507646	ENSG00000279675.1	RP11-454H19.2	-3.5	0.000477	0.0237	-0.18	-0.11	Temperament (bipolar disorder);	chr11:39795040	chr11:40107244~40112599:-
BRCA	cis	rs4908768	0.657	rs1353130	ENSG00000270282.1	RP5-1115A15.2	-3.5	0.000477	0.0237	-0.13	-0.11	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8762305	chr1:8512653~8513021:+
BRCA	cis	rs1511802	0.666	rs4862662	ENSG00000279943.1	FLJ38576	3.5	0.000477	0.0237	0.12	0.11	Blood protein levels;	chr4:186197508	chr4:186189032~186191490:-
BRCA	cis	rs2274273	0.624	rs68138420	ENSG00000259318.1	RP11-454L9.2	3.5	0.000477	0.0237	0.1	0.11	Protein biomarker;	chr14:55311249	chr14:55394940~55395233:-
BRCA	cis	rs8180040	0.62	rs9875235	ENSG00000260236.1	RP11-708J19.1	3.5	0.000477	0.0237	0.1	0.11	Colorectal cancer;	chr3:47042131	chr3:47379089~47380999:-
BRCA	cis	rs875971	0.895	rs7788984	ENSG00000229886.1	RP5-1132H15.3	3.5	0.000477	0.0237	0.12	0.11	Aortic root size;	chr7:66450629	chr7:66025126~66031544:-
BRCA	cis	rs4803750	1	rs4803750	ENSG00000266958.1	AC006126.3	-3.5	0.000478	0.0237	-0.27	-0.11	Lipid metabolism phenotypes;Age-related diseases, mortality and associated endophenotypes;Age-related disease endophenotypes;	chr19:44744370	chr19:45187388~45216933:+
BRCA	cis	rs6714710	0.58	rs11690737	ENSG00000228486.8	LINC01125	-3.5	0.000478	0.0237	-0.09	-0.11	Posterior cortical atrophy and Alzheimer's disease;	chr2:97845490	chr2:97664217~97703064:+
BRCA	cis	rs1437396	0.565	rs3111412	ENSG00000203327.2	AC012358.7	3.5	0.000478	0.0237	0.11	0.11	Alcohol dependence;	chr2:55362298	chr2:55214387~55216126:-
BRCA	cis	rs61869271	0.688	rs10885636	ENSG00000236799.1	RP11-383C6.2	-3.5	0.000478	0.0237	-0.13	-0.11	Tonsillectomy;	chr10:114953392	chr10:114994657~114996593:+
BRCA	cis	rs4835473	0.932	rs1839448	ENSG00000246448.2	RP13-578N3.3	3.5	0.000478	0.0237	0.12	0.11	Immature fraction of reticulocytes;	chr4:143752113	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.932	rs10021860	ENSG00000246448.2	RP13-578N3.3	3.5	0.000478	0.0237	0.12	0.11	Immature fraction of reticulocytes;	chr4:143754593	chr4:143700257~143865072:+
BRCA	cis	rs4654783	0.671	rs3765351	ENSG00000271428.1	RP1-224A6.8	3.5	0.000478	0.0237	0.11	0.11	Endometriosis;	chr1:22119498	chr1:22068340~22068827:-
BRCA	cis	rs61869271	0.65	rs2105001	ENSG00000236799.1	RP11-383C6.2	-3.5	0.000478	0.0237	-0.13	-0.11	Tonsillectomy;	chr10:114933684	chr10:114994657~114996593:+
BRCA	cis	rs2749592	0.513	rs9417249	ENSG00000099251.13	HSD17B7P2	-3.5	0.000478	0.0237	-0.12	-0.11	Age-related hearing impairment (SNP x SNP interaction);	chr10:37548227	chr10:38356380~38378505:+
BRCA	cis	rs7089973	0.526	rs17722042	ENSG00000236799.1	RP11-383C6.2	-3.5	0.000478	0.0238	-0.14	-0.11	Bipolar disorder or attention deficit hyperactivity disorder;	chr10:114978785	chr10:114994657~114996593:+
BRCA	cis	rs17597773	0.598	rs11118616	ENSG00000257551.1	HLX-AS1	-3.5	0.000478	0.0238	-0.13	-0.11	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220832314	chr1:220832763~220880140:-
BRCA	cis	rs1823874	0.71	rs1840298	ENSG00000259363.4	CTD-2054N24.2	3.5	0.000478	0.0238	0.13	0.11	IgG glycosylation;	chr15:99821889	chr15:99807023~99877148:+
BRCA	cis	rs13434995	0.513	rs17779627	ENSG00000273257.1	RP11-177J6.1	-3.5	0.000478	0.0238	-0.16	-0.11	Adiponectin levels;	chr4:55483775	chr4:55387949~55388271:+
BRCA	cis	rs67478160	0.643	rs12891175	ENSG00000269910.1	RP11-73M18.10	3.5	0.000478	0.0238	0.1	0.11	Schizophrenia;	chr14:103807829	chr14:103694516~103695050:-
BRCA	cis	rs67478160	0.595	rs12889993	ENSG00000269910.1	RP11-73M18.10	3.5	0.000478	0.0238	0.1	0.11	Schizophrenia;	chr14:103807957	chr14:103694516~103695050:-
BRCA	cis	rs10911902	0.643	rs2297226	ENSG00000229739.2	RP11-295K2.3	-3.5	0.000478	0.0238	-0.15	-0.11	Schizophrenia;	chr1:186374627	chr1:186435161~186470291:+
BRCA	cis	rs6500602	0.727	rs1477123	ENSG00000280063.1	RP11-295D4.3	3.5	0.000478	0.0238	0.08	0.11	Schizophrenia;	chr16:4510626	chr16:4346694~4348648:-
BRCA	cis	rs12324805	0.959	rs7178753	ENSG00000255769.6	GOLGA2P10	-3.5	0.000478	0.0238	-0.13	-0.11	Body mass index;	chr15:82062993	chr15:82472993~82513950:-
BRCA	cis	rs11673344	0.75	rs78241494	ENSG00000267682.1	CTD-3220F14.2	-3.5	0.000478	0.0238	-0.1	-0.11	Obesity-related traits;	chr19:37158846	chr19:37337236~37337743:+
BRCA	cis	rs801193	0.569	rs2659908	ENSG00000265600.1	AC006480.1	-3.5	0.000478	0.0238	-0.13	-0.11	Aortic root size;	chr7:66695835	chr7:67356680~67356779:+
BRCA	cis	rs2243480	1	rs1618893	ENSG00000275400.1	RP4-756H11.5	3.5	0.000478	0.0238	0.19	0.11	Diabetic kidney disease;	chr7:66631132	chr7:66553805~66554199:-
BRCA	cis	rs9437689	0.934	rs9661031	ENSG00000235501.4	RP4-639F20.1	-3.5	0.000478	0.0238	-0.14	-0.11	Phospholipid levels (plasma);	chr1:95039016	chr1:94927566~94963270:+
BRCA	cis	rs10197140	0.925	rs17545048	ENSG00000235721.1	AC013268.3	-3.5	0.000478	0.0238	-0.14	-0.11	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110901034	chr2:110007675~110010783:+
BRCA	cis	rs687432	0.924	rs12792638	ENSG00000213592.4	AP000662.9	-3.5	0.000478	0.0238	-0.14	-0.11	Parkinson's disease;	chr11:57983882	chr11:57718044~57718530:-
BRCA	cis	rs2251301	1	rs2736377	ENSG00000154316.13	TDH	3.5	0.000478	0.0238	0.19	0.11	Response to antipsychotic therapy (extrapyramidal side effects);	chr8:11261488	chr8:11339637~11368452:+
BRCA	cis	rs7172677	0.695	rs8029756	ENSG00000260269.4	CTD-2323K18.1	-3.5	0.000478	0.0238	-0.15	-0.11	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75143449	chr15:75527150~75601205:-
BRCA	cis	rs12141041	0.934	rs6670497	ENSG00000274642.1	CH17-472G23.1	-3.5	0.000478	0.0238	-0.13	-0.11	Blood metabolite levels;	chr1:119385346	chr1:120197085~120319680:+
BRCA	cis	rs801193	0.773	rs801207	ENSG00000273448.1	RP11-166O4.6	-3.5	0.000478	0.0238	-0.1	-0.11	Aortic root size;	chr7:66555603	chr7:67333047~67334383:+
BRCA	cis	rs10056811	0.527	rs55798253	ENSG00000271815.1	CTD-2235C13.3	-3.5	0.000478	0.0238	-0.19	-0.11	Coronary artery disease;	chr5:75085132	chr5:75363760~75364242:+
BRCA	cis	rs2835872	0.793	rs2835835	ENSG00000230366.8	DSCR9	-3.5	0.000478	0.0238	-0.14	-0.11	Electroencephalographic traits in alcoholism;	chr21:37616770	chr21:37208503~37221736:+
BRCA	cis	rs2835872	0.828	rs73220494	ENSG00000230366.8	DSCR9	-3.5	0.000478	0.0238	-0.14	-0.11	Electroencephalographic traits in alcoholism;	chr21:37616974	chr21:37208503~37221736:+
BRCA	cis	rs13434995	0.513	rs62305264	ENSG00000273257.1	RP11-177J6.1	-3.5	0.000478	0.0238	-0.16	-0.11	Adiponectin levels;	chr4:55502968	chr4:55387949~55388271:+
BRCA	cis	rs17301013	0.932	rs11804941	ENSG00000200674.1	RN7SKP160	-3.5	0.000478	0.0238	-0.14	-0.11	Systemic lupus erythematosus;	chr1:174624074	chr1:173791548~173791887:+
BRCA	cis	rs7705042	0.581	rs3899510	ENSG00000280047.1	CTC-463A16.1	-3.5	0.000478	0.0238	-0.13	-0.11	Asthma;	chr5:142171888	chr5:142165767~142168387:+
BRCA	cis	rs10129255	1	rs10129407	ENSG00000232216.1	IGHV3-43	3.5	0.000478	0.0238	0.09	0.11	Kawasaki disease;	chr14:106767956	chr14:106470264~106470800:-
BRCA	cis	rs17092148	0.636	rs6058107	ENSG00000269202.1	RP4-614O4.12	3.5	0.000478	0.0238	0.13	0.11	Neuroticism;	chr20:34700742	chr20:35201747~35203288:-
BRCA	cis	rs61869271	0.6	rs808411	ENSG00000236799.1	RP11-383C6.2	-3.5	0.000478	0.0238	-0.13	-0.11	Tonsillectomy;	chr10:115024879	chr10:114994657~114996593:+
BRCA	cis	rs1670533	0.685	rs56019586	ENSG00000251639.2	RP11-20I20.1	3.5	0.000478	0.0238	0.17	0.11	Recombination rate (females);	chr4:1066054	chr4:1100016~1101558:-
BRCA	cis	rs7656342	0.866	rs13124141	ENSG00000250342.1	SNRPCP16	-3.5	0.000478	0.0238	-0.12	-0.11	Gut microbiota (bacterial taxa);	chr4:9771613	chr4:9051842~9052051:-
BRCA	cis	rs1348850	0.914	rs7604673	ENSG00000271825.1	RP11-337N6.2	3.5	0.000478	0.0238	0.14	0.11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177527618	chr2:177300600~177302006:+
BRCA	cis	rs11039100	0.85	rs11039168	ENSG00000224295.2	AC087380.14	3.5	0.000478	0.0238	0.21	0.11	Peripheral arterial disease (traffic-related air pollution interaction);	chr11:5823493	chr11:5518441~5524955:-
BRCA	cis	rs2274273	0.84	rs28493647	ENSG00000259318.1	RP11-454L9.2	3.5	0.000478	0.0238	0.09	0.11	Protein biomarker;	chr14:55357745	chr14:55394940~55395233:-
BRCA	cis	rs2274273	0.84	rs17674463	ENSG00000259318.1	RP11-454L9.2	3.5	0.000478	0.0238	0.09	0.11	Protein biomarker;	chr14:55358145	chr14:55394940~55395233:-
BRCA	cis	rs4849845	0.612	rs3806491	ENSG00000223549.1	MTND5P28	3.5	0.000478	0.0238	0.13	0.11	Mean platelet volume;	chr2:120251099	chr2:120215181~120217279:+
BRCA	cis	rs8180040	0.654	rs1466740	ENSG00000260236.1	RP11-708J19.1	-3.5	0.000479	0.0238	-0.1	-0.11	Colorectal cancer;	chr3:47204393	chr3:47379089~47380999:-
BRCA	cis	rs12915845	0.545	rs1583794	ENSG00000271997.1	RP11-97O12.6	-3.5	0.000479	0.0238	-0.09	-0.11	Menarche (age at onset);	chr15:88533413	chr15:88501944~88505787:-
BRCA	cis	rs561341	1	rs550264	ENSG00000277511.1	CTD-2095E4.5	3.5	0.000479	0.0238	0.16	0.11	Hip circumference adjusted for BMI;	chr17:31990521	chr17:32127595~32128454:+
BRCA	cis	rs561341	1	rs111454793	ENSG00000277511.1	CTD-2095E4.5	3.5	0.000479	0.0238	0.16	0.11	Hip circumference adjusted for BMI;	chr17:31992248	chr17:32127595~32128454:+
BRCA	cis	rs561341	1	rs527256	ENSG00000277511.1	CTD-2095E4.5	3.5	0.000479	0.0238	0.16	0.11	Hip circumference adjusted for BMI;	chr17:31994274	chr17:32127595~32128454:+
BRCA	cis	rs561341	1	rs473356	ENSG00000277511.1	CTD-2095E4.5	3.5	0.000479	0.0238	0.16	0.11	Hip circumference adjusted for BMI;	chr17:31994743	chr17:32127595~32128454:+
BRCA	cis	rs721917	0.525	rs2819106	ENSG00000225484.5	NUTM2B-AS1	-3.5	0.000479	0.0238	-0.14	-0.11	Chronic obstructive pulmonary disease;	chr10:79926324	chr10:79663088~79826594:-
BRCA	cis	rs7520050	0.966	rs7556615	ENSG00000226957.1	RP4-533D7.4	3.5	0.000479	0.0238	0.12	0.11	Reticulocyte count;Red blood cell count;	chr1:45995697	chr1:46046818~46048368:+
BRCA	cis	rs7914558	0.932	rs4307650	ENSG00000213277.3	MARCKSL1P1	3.5	0.000479	0.0238	0.12	0.11	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103200095	chr10:103175554~103176094:+
BRCA	cis	rs11098499	0.863	rs3775858	ENSG00000250412.1	KLHL2P1	3.5	0.000479	0.0238	0.13	0.11	Corneal astigmatism;	chr4:119564873	chr4:119334329~119378233:+
BRCA	cis	rs2562456	0.833	rs55920089	ENSG00000240522.1	RPL7AP10	-3.5	0.000479	0.0238	-0.12	-0.11	Pain;	chr19:21337891	chr19:21149648~21150438:-
BRCA	cis	rs7079041	1	rs7079041	ENSG00000228816.1	AK3P5	3.5	0.000479	0.0238	0.12	0.11	Suicide in bipolar disorder;	chr10:32704340	chr10:32944481~32944999:+
BRCA	cis	rs9341808	0.617	rs9294170	ENSG00000279022.1	RP11-250B2.4	3.5	0.000479	0.0238	0.12	0.11	Sitting height ratio;	chr6:80104363	chr6:80440730~80441172:+
BRCA	cis	rs295490	0.748	rs115673919	ENSG00000178631.7	ACTG1P1	-3.5	0.000479	0.0238	-0.22	-0.11	PR interval in Tripanosoma cruzi seropositivity;	chr3:139489239	chr3:139493809~139494937:+
BRCA	cis	rs801193	0.569	rs7782587	ENSG00000265600.1	AC006480.1	-3.5	0.000479	0.0238	-0.13	-0.11	Aortic root size;	chr7:66701485	chr7:67356680~67356779:+
BRCA	cis	rs7636293	0.565	rs6763292	ENSG00000270773.1	RP13-685P2.7	3.5	0.000479	0.0238	0.15	0.11	Height;	chr3:129325862	chr3:129345411~129346164:+
BRCA	cis	rs2496589	0.889	rs9321908	ENSG00000218896.1	TUBB8P2	3.5	0.000479	0.0238	0.13	0.11	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);	chr6:143430477	chr6:143436216~143436710:+
BRCA	cis	rs2496589	0.791	rs9496623	ENSG00000218896.1	TUBB8P2	3.5	0.000479	0.0238	0.13	0.11	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);	chr6:143430488	chr6:143436216~143436710:+
BRCA	cis	rs2496589	0.791	rs9496624	ENSG00000218896.1	TUBB8P2	3.5	0.000479	0.0238	0.13	0.11	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);	chr6:143430490	chr6:143436216~143436710:+
BRCA	cis	rs2496589	0.824	rs9496625	ENSG00000218896.1	TUBB8P2	3.5	0.000479	0.0238	0.13	0.11	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);	chr6:143430496	chr6:143436216~143436710:+
BRCA	cis	rs3099143	1	rs3102710	ENSG00000196274.5	Metazoa_SRP	3.5	0.000479	0.0238	0.16	0.11	Recalcitrant atopic dermatitis;	chr15:76768807	chr15:76230048~76230390:-
BRCA	cis	rs3099143	1	rs3102709	ENSG00000196274.5	Metazoa_SRP	3.5	0.000479	0.0238	0.16	0.11	Recalcitrant atopic dermatitis;	chr15:76779919	chr15:76230048~76230390:-
BRCA	cis	rs7520050	0.966	rs11211241	ENSG00000281133.1	AL355480.3	3.5	0.000479	0.0238	0.13	0.11	Reticulocyte count;Red blood cell count;	chr1:45987011	chr1:45580892~45580996:-
BRCA	cis	rs4499344	0.73	rs417823	ENSG00000201388.1	SNORA68	3.5	0.000479	0.0238	0.13	0.11	Mean platelet volume;	chr19:32613655	chr19:32608337~32608469:-
BRCA	cis	rs61931739	0.5	rs7977194	ENSG00000258794.3	DUX4L27	3.5	0.000479	0.0238	0.16	0.11	Morning vs. evening chronotype;	chr12:34255524	chr12:34208415~34209675:-
BRCA	cis	rs7134599	0.561	rs10784670	ENSG00000236946.2	HNRNPA1P70	3.5	0.000479	0.0238	0.09	0.11	Inflammatory bowel disease;Ulcerative colitis;	chr12:68080315	chr12:68035767~68036853:+
BRCA	cis	rs74233809	1	rs12219027	ENSG00000213061.2	PFN1P11	3.5	0.000479	0.0238	0.23	0.11	Birth weight;	chr10:103051446	chr10:102838011~102845473:-
BRCA	cis	rs2333021	0.801	rs4903086	ENSG00000259015.1	RP11-109N23.6	3.5	0.000479	0.0238	0.11	0.11	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:72995605	chr14:72960595~72961993:+
BRCA	cis	rs2562456	0.833	rs56187954	ENSG00000240522.1	RPL7AP10	-3.5	0.000479	0.0238	-0.13	-0.11	Pain;	chr19:21345258	chr19:21149648~21150438:-
BRCA	cis	rs7172677	0.737	rs7163083	ENSG00000260269.4	CTD-2323K18.1	-3.5	0.000479	0.0238	-0.15	-0.11	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75149996	chr15:75527150~75601205:-
BRCA	cis	rs7520050	0.966	rs6661910	ENSG00000226957.1	RP4-533D7.4	3.5	0.000479	0.0238	0.12	0.11	Reticulocyte count;Red blood cell count;	chr1:45824960	chr1:46046818~46048368:+
BRCA	cis	rs10761482	0.769	rs990685	ENSG00000254271.1	RP11-131N11.4	3.5	0.000479	0.0238	0.15	0.11	Schizophrenia;	chr10:60338391	chr10:60734342~60741828:+
BRCA	cis	rs7267979	1	rs2482919	ENSG00000274973.1	RP13-401N8.7	3.5	0.000479	0.0238	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25319120	chr20:25845497~25845862:+
BRCA	cis	rs7020830	0.867	rs1472169	ENSG00000230188.1	RP11-405L18.4	-3.5	0.000479	0.0238	-0.13	-0.11	Schizophrenia;	chr9:37209399	chr9:37490421~37490893:-
BRCA	cis	rs11170468	1	rs7980487	ENSG00000257718.1	RP11-396F22.1	-3.5	0.000479	0.0238	-0.13	-0.11	Body mass index;	chr12:39033978	chr12:38906451~38909592:+
BRCA	cis	rs6866721	0.634	rs712613	ENSG00000249167.1	CTB-118N6.2	3.5	0.00048	0.0238	0.13	0.11	Body mass index;	chr5:116885775	chr5:116574482~116591398:+
BRCA	cis	rs2305707	0.611	rs2445753	ENSG00000273674.3	CTD-2378E12.1	3.5	0.00048	0.0238	0.21	0.11	Height;	chr15:51284346	chr15:50839875~50908599:-
BRCA	cis	rs6044112	0.619	rs6044021	ENSG00000273998.1	RP4-777L9.2	3.5	0.00048	0.0238	0.17	0.11	Response to taxane treatment (docetaxel);	chr20:16490104	chr20:16576068~16579615:+
BRCA	cis	rs2692947	0.711	rs34639392	ENSG00000237510.6	AC008268.2	3.5	0.00048	0.0238	0.15	0.11	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95843228	chr2:95789654~95800166:+
BRCA	cis	rs62229266	0.804	rs2835263	ENSG00000214914.3	RPL23AP3	-3.5	0.00048	0.0238	-0.13	-0.11	Mitral valve prolapse;	chr21:36057947	chr21:36016079~36016546:-
BRCA	cis	rs7267979	1	rs7268053	ENSG00000276952.1	RP5-965G21.6	-3.5	0.00048	0.0238	-0.13	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25347650	chr20:25284915~25285588:-
BRCA	cis	rs7267979	1	rs6083809	ENSG00000276952.1	RP5-965G21.6	-3.5	0.00048	0.0238	-0.13	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25348673	chr20:25284915~25285588:-
BRCA	cis	rs11573156	0.568	rs12042771	ENSG00000270728.1	RP4-657E11.10	3.5	0.00048	0.0238	0.13	0.11	Blood protein levels;	chr1:19963923	chr1:19297080~19297903:+
BRCA	cis	rs10191559	0.541	rs4667142	ENSG00000234663.4	AC104820.2	3.5	0.00048	0.0238	0.1	0.11	Red blood cell count;	chr2:181203926	chr2:181101932~181399559:+
BRCA	cis	rs1371614	0.61	rs12615509	ENSG00000229122.1	AGBL5-IT1	-3.5	0.00048	0.0238	-0.11	-0.11	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26875898	chr2:27061038~27061815:+
BRCA	cis	rs7267979	1	rs884613	ENSG00000274973.1	RP13-401N8.7	3.5	0.00048	0.0238	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25307869	chr20:25845497~25845862:+
BRCA	cis	rs7267979	1	rs1888998	ENSG00000274973.1	RP13-401N8.7	3.5	0.00048	0.0238	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25311190	chr20:25845497~25845862:+
BRCA	cis	rs62458065	0.568	rs62466415	ENSG00000273014.1	RP11-225B17.2	-3.5	0.00048	0.0238	-0.17	-0.11	Metabolite levels (HVA/MHPG ratio);	chr7:32478642	chr7:32758882~32759353:+
BRCA	cis	rs34217772	0.83	rs55718011	ENSG00000258636.1	CTD-2298J14.2	3.5	0.00048	0.0238	0.15	0.11	Myopia;	chr14:41746496	chr14:41587861~41604856:-
BRCA	cis	rs818427	0.71	rs187075	ENSG00000279522.1	CTC-487M23.6	-3.5	0.00048	0.0238	-0.12	-0.11	Total body bone mineral density;	chr5:112828541	chr5:112894933~112896531:+
BRCA	cis	rs6696239	0.911	rs7538206	ENSG00000227711.2	RP11-275O4.5	-3.5	0.00048	0.0238	-0.15	-0.11	Height;	chr1:227689081	chr1:227509028~227520477:-
BRCA	cis	rs2904967	0.778	rs77130160	ENSG00000254614.2	AP003068.23	3.5	0.00048	0.0238	0.27	0.11	Mean corpuscular volume;	chr11:65355223	chr11:65177606~65181834:-
BRCA	cis	rs10819861	0.679	rs10819868	ENSG00000175611.10	LINC00476	3.5	0.00048	0.0239	0.12	0.11	Electrocardiographic traits;	chr9:96109096	chr9:95759231~95875977:-
BRCA	cis	rs4243971	0.516	rs35290636	ENSG00000277692.1	RP11-358N2.2	-3.5	0.00048	0.0239	-0.12	-0.11	Inflammatory bowel disease;Crohn's disease;	chr20:32285000	chr20:32355053~32355734:+
BRCA	cis	rs17209837	1	rs67721532	ENSG00000224046.1	AC005076.5	3.5	0.00048	0.0239	0.17	0.11	Gallbladder cancer;	chr7:87455087	chr7:87151423~87152420:-
BRCA	cis	rs7660883	0.897	rs342469	ENSG00000251411.1	RP11-397E7.4	-3.5	0.00048	0.0239	-0.12	-0.11	HDL cholesterol levels;	chr4:87129402	chr4:86913266~86914817:-
BRCA	cis	rs2274273	0.624	rs7140628	ENSG00000259318.1	RP11-454L9.2	3.5	0.00048	0.0239	0.1	0.11	Protein biomarker;	chr14:55293963	chr14:55394940~55395233:-
BRCA	cis	rs55675132	0.548	rs12120506	ENSG00000226167.1	AP4B1-AS1	3.5	0.000481	0.0239	0.11	0.11	Schizophrenia;	chr1:114835156	chr1:113856635~113901237:+
BRCA	cis	rs3796352	1	rs11707780	ENSG00000280417.1	RP11-5O17.1	3.5	0.000481	0.0239	0.16	0.11	Immune reponse to smallpox (secreted IL-2);	chr3:53050310	chr3:53046166~53048122:+
BRCA	cis	rs875971	0.508	rs10242423	ENSG00000273448.1	RP11-166O4.6	-3.5	0.000481	0.0239	-0.1	-0.11	Aortic root size;	chr7:66594188	chr7:67333047~67334383:+
BRCA	cis	rs875971	0.508	rs10253883	ENSG00000273448.1	RP11-166O4.6	-3.5	0.000481	0.0239	-0.1	-0.11	Aortic root size;	chr7:66596151	chr7:67333047~67334383:+
BRCA	cis	rs875971	1	rs2087647	ENSG00000271064.1	RP11-792A8.3	3.5	0.000481	0.0239	0.12	0.11	Aortic root size;	chr7:66128201	chr7:66748838~66749077:-
BRCA	cis	rs1046491	0.901	rs8095601	ENSG00000264964.1	RP11-888D10.3	3.5	0.000481	0.0239	0.22	0.11	Scarlet fever;	chr18:9136157	chr18:9315194~9334441:-
BRCA	cis	rs763121	0.853	rs2076028	ENSG00000228274.3	RP3-508I15.9	-3.5	0.000481	0.0239	-0.13	-0.11	Menopause (age at onset);	chr22:38754445	chr22:38667585~38681820:-
BRCA	cis	rs417065	0.516	rs7548511	ENSG00000238290.1	RP11-431K24.1	-3.5	0.000481	0.0239	-0.14	-0.11	Psoriasis;	chr1:8207453	chr1:8026738~8122702:+
BRCA	cis	rs6120849	0.754	rs3818253	ENSG00000202150.1	RNU6-407P	3.5	0.000481	0.0239	0.15	0.11	Protein C levels;	chr20:35009073	chr20:35030317~35030420:-
BRCA	cis	rs12368653	0.651	rs2307097	ENSG00000257159.1	RP11-58A17.3	-3.5	0.000481	0.0239	-0.13	-0.11	Multiple sclerosis;	chr12:57802018	chr12:57967058~57968399:+
BRCA	cis	rs10266483	0.705	rs599522	ENSG00000228653.2	HNRNPCP7	-3.5	0.000481	0.0239	-0.13	-0.11	Response to statin therapy;	chr7:64298104	chr7:64500825~64501729:+
BRCA	cis	rs1555322	1	rs2425031	ENSG00000279253.1	RP4-614O4.13	-3.5	0.000481	0.0239	-0.17	-0.11	Attention deficit hyperactivity disorder;	chr20:35267481	chr20:35262727~35264187:-
BRCA	cis	rs17711722	0.701	rs55773927	ENSG00000232546.1	RP11-458F8.1	-3.5	0.000481	0.0239	-0.09	-0.11	Calcium levels;	chr7:65872915	chr7:66848496~66858136:+
BRCA	cis	rs9635324	1	rs10518693	ENSG00000259330.1	INAFM2	3.5	0.000481	0.0239	0.13	0.11	Blood metabolite ratios;Blood metabolite levels;	chr15:40407823	chr15:40325216~40326715:+
BRCA	cis	rs11892454	0.599	rs890680	ENSG00000217643.1	PTGES3P2	-3.5	0.000481	0.0239	-0.12	-0.11	Heschl's gyrus morphology;	chr2:25756509	chr2:25822469~25822950:+
BRCA	cis	rs295490	0.748	rs78652857	ENSG00000178631.7	ACTG1P1	-3.5	0.000481	0.0239	-0.22	-0.11	PR interval in Tripanosoma cruzi seropositivity;	chr3:139509107	chr3:139493809~139494937:+
BRCA	cis	rs4533251	0.8	rs4350538	ENSG00000273771.1	RP11-236L14.2	3.5	0.000481	0.0239	0.13	0.11	Attention deficit hyperactivity disorder and conduct disorder;	chr15:96718128	chr15:96080713~96084584:-
BRCA	cis	rs77633900	0.614	rs280014	ENSG00000196274.5	Metazoa_SRP	3.5	0.000481	0.0239	0.16	0.11	Glioma;Non-glioblastoma glioma;	chr15:76694549	chr15:76230048~76230390:-
BRCA	cis	rs997295	0.556	rs10468041	ENSG00000259673.4	IQCH-AS1	3.5	0.000481	0.0239	0.12	0.11	Motion sickness;	chr15:67480865	chr15:67403619~67521844:-
BRCA	cis	rs16831128	1	rs75122146	ENSG00000230992.3	FAM201B	-3.5	0.000481	0.0239	-0.15	-0.11	Conduct disorder;Conduct disorder (symptom count);	chr2:132390987	chr2:132352722~132353318:+
BRCA	cis	rs11711311	1	rs2566970	ENSG00000241529.3	RN7SL767P	3.5	0.000481	0.0239	0.13	0.11	IgG glycosylation;	chr3:113743276	chr3:113632704~113632998:+
BRCA	cis	rs9527	0.637	rs7096169	ENSG00000213277.3	MARCKSL1P1	3.5	0.000481	0.0239	0.12	0.11	Arsenic metabolism;	chr10:102858938	chr10:103175554~103176094:+
BRCA	cis	rs875971	0.522	rs4502988	ENSG00000229180.5	GS1-124K5.11	3.5	0.000481	0.0239	0.09	0.11	Aortic root size;	chr7:65832759	chr7:66526088~66542624:-
BRCA	cis	rs875971	1	rs6958484	ENSG00000271064.1	RP11-792A8.3	3.5	0.000481	0.0239	0.12	0.11	Aortic root size;	chr7:66134459	chr7:66748838~66749077:-
BRCA	cis	rs10027350	0.765	rs6838393	ENSG00000271172.1	RP11-660M5.1	3.5	0.000481	0.0239	0.13	0.11	Childhood ear infection;	chr4:25172629	chr4:25220403~25220913:+
BRCA	cis	rs6672530	0.518	rs1407718	ENSG00000227711.2	RP11-275O4.5	-3.5	0.000481	0.0239	-0.13	-0.11	Hip circumference adjusted for BMI;	chr1:227691562	chr1:227509028~227520477:-
BRCA	cis	rs301901	0.861	rs217797	ENSG00000272103.1	CTD-2653M23.3	3.5	0.000481	0.0239	0.13	0.11	Height;	chr5:37318193	chr5:36861736~36862217:-
BRCA	cis	rs2692947	0.537	rs1834135	ENSG00000232931.4	LINC00342	3.5	0.000481	0.0239	0.11	0.11	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95578477	chr2:95807118~95816215:-
BRCA	cis	rs2562456	0.833	rs55920089	ENSG00000268117.1	VN1R84P	3.5	0.000481	0.0239	0.16	0.11	Pain;	chr19:21337891	chr19:21719801~21720035:-
BRCA	cis	rs4835473	0.932	rs17018200	ENSG00000246448.2	RP13-578N3.3	-3.5	0.000482	0.0239	-0.12	-0.11	Immature fraction of reticulocytes;	chr4:143760866	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.932	rs11100805	ENSG00000246448.2	RP13-578N3.3	-3.5	0.000482	0.0239	-0.12	-0.11	Immature fraction of reticulocytes;	chr4:143760979	chr4:143700257~143865072:+
BRCA	cis	rs10864907	0.837	rs4254516	ENSG00000231747.1	AC079922.2	-3.5	0.000482	0.0239	-0.1	-0.11	Pulmonary function;	chr2:112944230	chr2:112621809~112622167:-
BRCA	cis	rs2057178	0.929	rs7121219	ENSG00000227160.2	THEM7P	3.5	0.000482	0.0239	0.19	0.11	Tuberculosis;	chr11:32320971	chr11:32112049~32343409:-
BRCA	cis	rs7620503	0.516	rs1566409	ENSG00000277241.1	RP11-114M1.3	3.5	0.000482	0.0239	0.13	0.11	Corneal structure;	chr3:177616400	chr3:177700346~177701072:-
BRCA	cis	rs6600671	1	rs4844616	ENSG00000270231.3	NBPF8P	3.5	0.000482	0.0239	0.12	0.11	Hip geometry;	chr1:121429348	chr1:120436353~120467739:+
BRCA	cis	rs9925964	0.933	rs9929899	ENSG00000262766.1	RP11-196G11.4	-3.5	0.000482	0.0239	-0.09	-0.11	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31051380	chr16:31118078~31118747:+
BRCA	cis	rs28489187	0.577	rs729655	ENSG00000223653.4	RP11-131L23.1	3.5	0.000482	0.0239	0.12	0.11	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85378934	chr1:85276715~85448124:+
BRCA	cis	rs12724450	0.793	rs58853199	ENSG00000228126.1	FALEC	3.5	0.000482	0.0239	0.2	0.11	Blood protein levels;	chr1:150405736	chr1:150515757~150518032:+
BRCA	cis	rs2380205	0.517	rs12785055	ENSG00000232807.2	RP11-536K7.3	3.5	0.000482	0.0239	0.12	0.11	Breast cancer;	chr10:5899167	chr10:5934270~5945900:-
BRCA	cis	rs7308116	1	rs7302944	ENSG00000274395.1	RP11-554D14.8	3.5	0.000482	0.0239	0.12	0.11	Pelvic organ prolapse (moderate/severe);	chr12:107805159	chr12:107835541~107836555:-
BRCA	cis	rs7705502	0.644	rs6882088	ENSG00000251144.1	CTD-2532K18.2	-3.5	0.000482	0.0239	-0.14	-0.11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for body mass index;	chr5:173867173	chr5:174820027~174826324:+
BRCA	cis	rs66887589	0.807	rs7694483	ENSG00000260404.2	RP11-384K6.6	3.5	0.000482	0.0239	0.09	0.11	Diastolic blood pressure;	chr4:119484774	chr4:118591773~118633729:+
BRCA	cis	rs1008375	0.932	rs1008894	ENSG00000249502.1	AC006160.5	3.5	0.000482	0.0239	0.12	0.11	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17703044	chr4:17587467~17614571:-
BRCA	cis	rs1865760	0.532	rs1061482	ENSG00000272462.2	U91328.19	-3.5	0.000482	0.0239	-0.13	-0.11	Height;	chr6:26086471	chr6:25992662~26001775:+
BRCA	cis	rs9392556	0.829	rs7166	ENSG00000230648.1	RP3-406P24.3	3.5	0.000482	0.0239	0.14	0.11	Blood metabolite levels;	chr6:4116028	chr6:4018843~4021215:-
BRCA	cis	rs8180040	0.577	rs12493425	ENSG00000280667.1	Y_RNA	3.5	0.000482	0.0239	0.12	0.11	Colorectal cancer;	chr3:47135456	chr3:47501083~47501182:+
BRCA	cis	rs6728642	0.908	rs7588921	ENSG00000275655.1	Metazoa_SRP	-3.5	0.000482	0.0239	-0.2	-0.11	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:97352698	chr2:97100587~97100874:+
BRCA	cis	rs9992667	0.516	rs10029476	ENSG00000231160.8	KLF3-AS1	3.5	0.000482	0.0239	0.11	0.11	Eosinophil percentage of granulocytes;	chr4:38702155	chr4:38612701~38664883:-
BRCA	cis	rs6801044	1	rs6801044	ENSG00000229178.1	AC069513.4	-3.5	0.000482	0.0239	-0.16	-0.11	Creatinine levels in ischemic stroke;	chr3:195562517	chr3:195655565~195657927:-
BRCA	cis	rs863345	0.604	rs6666805	ENSG00000176320.2	RP11-404O13.5	-3.5	0.000482	0.0239	-0.11	-0.11	Pneumococcal bacteremia;	chr1:158528515	chr1:158197922~158203877:-
BRCA	cis	rs863345	0.604	rs12120526	ENSG00000176320.2	RP11-404O13.5	-3.5	0.000482	0.0239	-0.11	-0.11	Pneumococcal bacteremia;	chr1:158528614	chr1:158197922~158203877:-
BRCA	cis	rs6840360	0.615	rs2120098	ENSG00000270265.1	RP11-731D1.4	-3.5	0.000482	0.0239	-0.13	-0.11	Intelligence (multi-trait analysis);	chr4:151536028	chr4:151333775~151353224:-
BRCA	cis	rs7487075	0.647	rs12580583	ENSG00000257261.4	RP11-96H19.1	3.5	0.000482	0.0239	0.11	0.11	Itch intensity from mosquito bite;	chr12:46313218	chr12:46383679~46876159:+
BRCA	cis	rs863345	0.504	rs857698	ENSG00000176320.2	RP11-404O13.5	-3.5	0.000482	0.0239	-0.11	-0.11	Pneumococcal bacteremia;	chr1:158591376	chr1:158197922~158203877:-
BRCA	cis	rs863345	0.504	rs2022386	ENSG00000176320.2	RP11-404O13.5	-3.5	0.000482	0.0239	-0.11	-0.11	Pneumococcal bacteremia;	chr1:158593286	chr1:158197922~158203877:-
BRCA	cis	rs863345	0.504	rs2482966	ENSG00000176320.2	RP11-404O13.5	-3.5	0.000482	0.0239	-0.11	-0.11	Pneumococcal bacteremia;	chr1:158593531	chr1:158197922~158203877:-
BRCA	cis	rs863345	0.504	rs857707	ENSG00000176320.2	RP11-404O13.5	-3.5	0.000482	0.0239	-0.11	-0.11	Pneumococcal bacteremia;	chr1:158594593	chr1:158197922~158203877:-
BRCA	cis	rs10129255	0.784	rs7147210	ENSG00000211958.2	IGHV3-38	3.5	0.000482	0.0239	0.09	0.11	Kawasaki disease;	chr14:106705271	chr14:106410493~106411021:-
BRCA	cis	rs7578361	0.918	rs6708520	ENSG00000231969.1	AC144449.1	3.5	0.000482	0.0239	0.17	0.11	Acute lymphoblastic leukemia (childhood);	chr2:149522030	chr2:149587196~149848233:+
BRCA	cis	rs7172677	0.737	rs11855234	ENSG00000260269.4	CTD-2323K18.1	-3.5	0.000482	0.0239	-0.15	-0.11	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75154493	chr15:75527150~75601205:-
BRCA	cis	rs875971	0.862	rs11984115	ENSG00000271064.1	RP11-792A8.3	3.5	0.000482	0.0239	0.13	0.11	Aortic root size;	chr7:66308872	chr7:66748838~66749077:-
BRCA	cis	rs12971120	0.891	rs71359051	ENSG00000276934.1	RP11-231E4.5	3.5	0.000483	0.0239	0.16	0.11	Refractive error;	chr18:74502488	chr18:74504766~74505248:+
BRCA	cis	rs853679	0.607	rs200489	ENSG00000216901.1	AL022393.7	3.5	0.000483	0.0239	0.21	0.11	Depression;	chr6:27830479	chr6:28176188~28176674:+
BRCA	cis	rs61160187	0.582	rs12516995	ENSG00000272308.1	RP11-231G3.1	-3.5	0.000483	0.0239	-0.12	-0.11	Educational attainment (years of education);Educational attainment (college completion);	chr5:61012447	chr5:60866457~60866935:-
BRCA	cis	rs2243480	1	rs1964692	ENSG00000226767.1	RP11-328P23.3	-3.5	0.000483	0.0239	-0.19	-0.11	Diabetic kidney disease;	chr7:65989196	chr7:65508773~65508944:-
BRCA	cis	rs416350	1	rs416350	ENSG00000256325.1	RP11-611O2.1	3.5	0.000483	0.0239	0.21	0.11	Temperament (bipolar disorder);	chr12:68385633	chr12:68828118~68828553:+
BRCA	cis	rs9807841	0.67	rs1982075	ENSG00000267100.1	ILF3-AS1	3.5	0.000483	0.0239	0.11	0.11	Inflammatory skin disease;	chr19:10677068	chr19:10651862~10653844:-
BRCA	cis	rs6545883	0.507	rs10169662	ENSG00000270820.4	RP11-355B11.2	-3.5	0.000483	0.0239	-0.11	-0.11	Tuberculosis;	chr2:61280801	chr2:61471188~61484130:+
BRCA	cis	rs11035577	0.632	rs10768539	ENSG00000279675.1	RP11-454H19.2	-3.5	0.000483	0.0239	-0.17	-0.11	Temperament (bipolar disorder);	chr11:39768084	chr11:40107244~40112599:-
BRCA	cis	rs17270561	0.609	rs7754296	ENSG00000272462.2	U91328.19	-3.5	0.000483	0.024	-0.14	-0.11	Iron status biomarkers;	chr6:25744650	chr6:25992662~26001775:+
BRCA	cis	rs8180040	0.629	rs7426969	ENSG00000280667.1	Y_RNA	3.5	0.000483	0.024	0.12	0.11	Colorectal cancer;	chr3:47049865	chr3:47501083~47501182:+
BRCA	cis	rs7487075	0.619	rs10748450	ENSG00000257261.4	RP11-96H19.1	3.5	0.000483	0.024	0.12	0.11	Itch intensity from mosquito bite;	chr12:46463319	chr12:46383679~46876159:+
BRCA	cis	rs6429422	0.763	rs3904685	ENSG00000224727.1	FCF1P7	-3.5	0.000483	0.024	-0.13	-0.11	Cognitive ability (multi-trait analysis);	chr1:243251410	chr1:243267257~243268119:-
BRCA	cis	rs10864907	0.806	rs11123152	ENSG00000231747.1	AC079922.2	-3.5	0.000483	0.024	-0.1	-0.11	Pulmonary function;	chr2:112949535	chr2:112621809~112622167:-
BRCA	cis	rs10864907	0.837	rs11123153	ENSG00000231747.1	AC079922.2	-3.5	0.000483	0.024	-0.1	-0.11	Pulmonary function;	chr2:112949537	chr2:112621809~112622167:-
BRCA	cis	rs2451932	0.807	rs384941	ENSG00000251050.1	RP11-168A11.4	3.5	0.000483	0.024	0.11	0.11	LDL peak particle diameter (total fat intake interaction);	chr5:80076584	chr5:80019609~80019920:+
BRCA	cis	rs8044995	0.563	rs8058517	ENSG00000280214.1	CTD-2012K14.5	3.5	0.000483	0.024	0.16	0.11	Schizophrenia;	chr16:68345957	chr16:67550815~67552935:-
BRCA	cis	rs349045	0.56	rs11083725	ENSG00000266921.1	RP11-15A1.7	3.5	0.000483	0.024	0.13	0.11	Reading or mathematical ability;	chr19:43796424	chr19:43996896~44002836:-
BRCA	cis	rs3858526	0.917	rs9284148	ENSG00000229534.1	HNRNPA1P53	3.5	0.000483	0.024	0.16	0.11	DNA methylation (variation);	chr11:5951955	chr11:5571247~5572192:-
BRCA	cis	rs853679	0.607	rs200489	ENSG00000216676.2	RP1-15D7.1	-3.5	0.000483	0.024	-0.19	-0.11	Depression;	chr6:27830479	chr6:27652602~27652825:-
BRCA	cis	rs1670533	0.872	rs13108222	ENSG00000251639.2	RP11-20I20.1	3.5	0.000483	0.024	0.17	0.11	Recombination rate (females);	chr4:1060468	chr4:1100016~1101558:-
BRCA	cis	rs2692947	0.537	rs4907274	ENSG00000232931.4	LINC00342	3.5	0.000483	0.024	0.12	0.11	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95697934	chr2:95807118~95816215:-
BRCA	cis	rs6840360	0.571	rs72728182	ENSG00000270265.1	RP11-731D1.4	-3.5	0.000483	0.024	-0.13	-0.11	Intelligence (multi-trait analysis);	chr4:151565875	chr4:151333775~151353224:-
BRCA	cis	rs6840360	0.571	rs4696098	ENSG00000270265.1	RP11-731D1.4	-3.5	0.000483	0.024	-0.13	-0.11	Intelligence (multi-trait analysis);	chr4:151567901	chr4:151333775~151353224:-
BRCA	cis	rs6840360	0.55	rs6816471	ENSG00000270265.1	RP11-731D1.4	-3.5	0.000483	0.024	-0.13	-0.11	Intelligence (multi-trait analysis);	chr4:151573717	chr4:151333775~151353224:-
BRCA	cis	rs10045413	0.598	rs1996255	ENSG00000250167.1	CTC-321K16.1	3.5	0.000483	0.024	0.13	0.11	Age at smoking initiation in chronic obstructive pulmonary disease;	chr5:135623786	chr5:135559577~135634874:+
BRCA	cis	rs344364	0.511	rs2982433	ENSG00000219027.2	RPS3AP2	3.5	0.000483	0.024	0.16	0.11	Glomerular filtration rate in chronic kidney disease;	chr16:1904507	chr16:1477830~1478583:+
BRCA	cis	rs12949688	0.967	rs12451748	ENSG00000262623.1	RP5-1107A17.2	-3.5	0.000483	0.024	-0.11	-0.11	Schizophrenia;	chr17:57744810	chr17:56951664~56952404:+
BRCA	cis	rs12949688	0.967	rs12451753	ENSG00000262623.1	RP5-1107A17.2	-3.5	0.000483	0.024	-0.11	-0.11	Schizophrenia;	chr17:57744853	chr17:56951664~56952404:+
BRCA	cis	rs2562456	0.754	rs55771551	ENSG00000268555.1	RP11-678G14.3	3.5	0.000483	0.024	0.14	0.11	Pain;	chr19:21563578	chr19:21570822~21587322:-
BRCA	cis	rs4921164	1	rs35675336	ENSG00000245812.2	RP11-175K6.1	-3.5	0.000483	0.024	-0.14	-0.11	Gut microbiome composition (winter);	chr5:159117927	chr5:159100483~159117478:+
BRCA	cis	rs11892454	0.565	rs13425195	ENSG00000217643.1	PTGES3P2	-3.5	0.000484	0.024	-0.12	-0.11	Heschl's gyrus morphology;	chr2:25859343	chr2:25822469~25822950:+
BRCA	cis	rs881375	0.9	rs1930786	ENSG00000238181.2	AHCYP2	-3.5	0.000484	0.024	-0.13	-0.11	Rheumatoid arthritis;	chr9:120929191	chr9:120720673~120721972:+
BRCA	cis	rs300890	0.689	rs7697838	ENSG00000250326.1	RP11-284M14.1	-3.5	0.000484	0.024	-0.12	-0.11	Nasopharyngeal carcinoma;	chr4:143326195	chr4:142933195~143184861:-
BRCA	cis	rs9951698	0.703	rs7241536	ENSG00000266969.1	RP11-773H22.4	3.5	0.000484	0.024	0.14	0.11	Intelligence (multi-trait analysis);	chr18:13033975	chr18:12984694~12991173:-
BRCA	cis	rs947583	0.588	rs2208574	ENSG00000231028.7	LINC00271	-3.5	0.000484	0.024	-0.11	-0.11	Phosphorus levels;	chr6:135754479	chr6:135497801~135716055:+
BRCA	cis	rs16958440	0.708	rs57468764	ENSG00000267800.1	RP11-49K24.5	-3.5	0.000484	0.024	-0.19	-0.11	Sitting height ratio;	chr18:47098485	chr18:47137018~47137290:+
BRCA	cis	rs17801127	0.748	rs13007543	ENSG00000231969.1	AC144449.1	3.5	0.000484	0.024	0.18	0.11	Liver enzyme levels (alanine transaminase);	chr2:149682573	chr2:149587196~149848233:+
BRCA	cis	rs1113500	0.787	rs10881501	ENSG00000230489.1	VAV3-AS1	-3.5	0.000484	0.024	-0.12	-0.11	Growth-regulated protein alpha levels;	chr1:108099123	chr1:107964443~107994607:+
BRCA	cis	rs13401620	0.871	rs59423169	ENSG00000229326.3	AC069154.4	-3.5	0.000484	0.024	-0.14	-0.11	Breast size;	chr2:119790070	chr2:119698623~119700151:+
BRCA	cis	rs11088226	0.758	rs2833864	ENSG00000186842.4	LINC00846	-3.5	0.000484	0.024	-0.17	-0.11	Gastritis;	chr21:32516083	chr21:32572238~32575881:-
BRCA	cis	rs1865760	0.929	rs1816546	ENSG00000272810.1	U91328.22	-3.5	0.000484	0.024	-0.13	-0.11	Height;	chr6:25938024	chr6:26013241~26013757:+
BRCA	cis	rs9467773	1	rs9295695	ENSG00000261353.1	CTA-14H9.5	3.5	0.000484	0.024	0.11	0.11	Intelligence (multi-trait analysis);	chr6:26528022	chr6:26527063~26527404:+
BRCA	cis	rs6973609	0.575	rs7776612	ENSG00000271122.1	RP11-379H18.1	3.5	0.000484	0.024	0.12	0.11	Obesity-related traits;	chr7:35549603	chr7:35695214~35699413:+
BRCA	cis	rs2109514	1	rs3919515	ENSG00000237813.3	AC002066.1	-3.5	0.000484	0.024	-0.13	-0.11	Prevalent atrial fibrillation;	chr7:116511730	chr7:116238260~116499465:-
BRCA	cis	rs7656342	0.836	rs10022923	ENSG00000250342.1	SNRPCP16	-3.5	0.000484	0.024	-0.12	-0.11	Gut microbiota (bacterial taxa);	chr4:9771814	chr4:9051842~9052051:-
BRCA	cis	rs360929	0.935	rs360915	ENSG00000245954.5	RP11-18H21.1	3.5	0.000484	0.024	0.12	0.11	Volumetric brain MRI;	chr4:151966727	chr4:152100754~152104720:+
BRCA	cis	rs17596685	1	rs168312	ENSG00000271216.1	LINC01050	3.5	0.000484	0.024	0.14	0.11	C-reactive protein levels;	chr13:42547624	chr13:42810366~42812562:-
BRCA	cis	rs3760982	0.585	rs67704568	ENSG00000266921.1	RP11-15A1.7	-3.5	0.000484	0.024	-0.14	-0.11	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43789867	chr19:43996896~44002836:-
BRCA	cis	rs875971	1	rs2420591	ENSG00000229886.1	RP5-1132H15.3	3.5	0.000484	0.024	0.12	0.11	Aortic root size;	chr7:66447394	chr7:66025126~66031544:-
BRCA	cis	rs375066	0.762	rs171238	ENSG00000267191.1	RP11-15A1.2	-3.5	0.000484	0.024	-0.14	-0.11	Breast cancer;	chr19:43875402	chr19:43902001~43926545:+
BRCA	cis	rs3096299	0.685	rs3803682	ENSG00000261118.1	RP11-104N10.1	3.5	0.000484	0.024	0.11	0.11	Multiple myeloma (IgH translocation);	chr16:89478228	chr16:89492017~89504460:-
BRCA	cis	rs4372836	0.658	rs56178008	ENSG00000226833.4	AC097724.3	-3.5	0.000484	0.024	-0.13	-0.11	Body mass index;	chr2:28875677	chr2:28708953~28736205:-
BRCA	cis	rs1468333	0.514	rs10515498	ENSG00000246323.2	RP11-325L7.1	-3.5	0.000484	0.024	-0.16	-0.11	Resting heart rate;	chr5:138250641	chr5:138032774~138037266:+
BRCA	cis	rs7487075	0.797	rs10880959	ENSG00000257261.4	RP11-96H19.1	3.5	0.000484	0.024	0.12	0.11	Itch intensity from mosquito bite;	chr12:46367344	chr12:46383679~46876159:+
BRCA	cis	rs1670533	1	rs6599278	ENSG00000251639.2	RP11-20I20.1	3.5	0.000484	0.024	0.17	0.11	Recombination rate (females);	chr4:1065010	chr4:1100016~1101558:-
BRCA	cis	rs2191566	0.691	rs56149185	ENSG00000266921.1	RP11-15A1.7	-3.5	0.000484	0.024	-0.13	-0.11	Acute lymphoblastic leukemia (childhood);	chr19:44083914	chr19:43996896~44002836:-
BRCA	cis	rs4713118	0.662	rs9357060	ENSG00000226314.6	ZNF192P1	-3.5	0.000484	0.024	-0.16	-0.11	Parkinson's disease;	chr6:28056708	chr6:28161781~28169594:+
BRCA	cis	rs4713118	0.662	rs9468271	ENSG00000226314.6	ZNF192P1	-3.5	0.000484	0.024	-0.16	-0.11	Parkinson's disease;	chr6:28056792	chr6:28161781~28169594:+
BRCA	cis	rs72720396	0.789	rs12048450	ENSG00000272931.1	RP5-943J3.2	-3.5	0.000484	0.024	-0.15	-0.11	Chronotype;Morning vs. evening chronotype;	chr1:90734103	chr1:89820174~89820868:-
BRCA	cis	rs6088590	0.687	rs6088580	ENSG00000269202.1	RP4-614O4.12	-3.5	0.000484	0.024	-0.11	-0.11	Coronary artery disease;	chr20:34697249	chr20:35201747~35203288:-
BRCA	cis	rs6088590	0.813	rs1884668	ENSG00000269202.1	RP4-614O4.12	-3.5	0.000484	0.024	-0.11	-0.11	Coronary artery disease;	chr20:34697710	chr20:35201747~35203288:-
BRCA	cis	rs13256369	0.851	rs13271698	ENSG00000254153.1	CTA-398F10.2	3.5	0.000484	0.024	0.15	0.11	Obesity-related traits;	chr8:8710029	chr8:8456909~8461337:-
BRCA	cis	rs2833693	0.513	rs2833756	ENSG00000261610.1	AP000265.1	-3.5	0.000484	0.024	-0.13	-0.11	Temperament;	chr21:32298033	chr21:32259804~32261585:-
BRCA	cis	rs12724450	0.793	rs12759551	ENSG00000228126.1	FALEC	3.5	0.000484	0.024	0.2	0.11	Blood protein levels;	chr1:150423187	chr1:150515757~150518032:+
BRCA	cis	rs11250098	0.547	rs2409764	ENSG00000255020.1	AF131216.5	-3.5	0.000484	0.024	-0.13	-0.11	Morning vs. evening chronotype;	chr8:11423764	chr8:11345748~11347502:-
BRCA	cis	rs875971	0.964	rs6978429	ENSG00000273024.4	INTS4P2	-3.5	0.000484	0.024	-0.12	-0.11	Aortic root size;	chr7:66494889	chr7:65647864~65715661:+
BRCA	cis	rs875971	1	rs4718357	ENSG00000273024.4	INTS4P2	-3.5	0.000484	0.024	-0.12	-0.11	Aortic root size;	chr7:66495891	chr7:65647864~65715661:+
BRCA	cis	rs875971	1	rs6957199	ENSG00000229886.1	RP5-1132H15.3	3.5	0.000484	0.024	0.12	0.11	Aortic root size;	chr7:66513532	chr7:66025126~66031544:-
BRCA	cis	rs9309473	0.607	rs2421489	ENSG00000230002.2	ALMS1-IT1	3.5	0.000485	0.024	0.13	0.11	Metabolite levels;	chr2:73366320	chr2:73456764~73459484:+
BRCA	cis	rs7520050	0.778	rs3014218	ENSG00000234329.1	RP11-767N6.2	-3.5	0.000485	0.024	-0.1	-0.11	Reticulocyte count;Red blood cell count;	chr1:45560656	chr1:45651039~45651826:-
BRCA	cis	rs4415084	1	rs920329	ENSG00000272335.1	RP11-53O19.3	3.5	0.000485	0.024	0.1	0.11	Breast cancer;	chr5:44702405	chr5:44826076~44828592:+
BRCA	cis	rs7520050	0.933	rs12565042	ENSG00000281133.1	AL355480.3	3.5	0.000485	0.024	0.12	0.11	Reticulocyte count;Red blood cell count;	chr1:45833438	chr1:45580892~45580996:-
BRCA	cis	rs944990	0.576	rs10992791	ENSG00000227603.1	RP11-165J3.6	3.5	0.000485	0.024	0.11	0.11	Body mass index;	chr9:93587851	chr9:93435332~93437121:-
BRCA	cis	rs7824557	0.836	rs1435278	ENSG00000154316.13	TDH	3.5	0.000485	0.024	0.15	0.11	Retinal vascular caliber;	chr8:11265520	chr8:11339637~11368452:+
BRCA	cis	rs2301573	0.584	rs12632461	ENSG00000271270.4	TMCC1-AS1	-3.5	0.000485	0.024	-0.23	-0.11	Hip circumference;	chr3:129703213	chr3:129893871~129918575:+
BRCA	cis	rs4803480	1	rs11882144	ENSG00000268355.1	AC006129.1	-3.5	0.000485	0.024	-0.15	-0.11	Schizophrenia;	chr19:41566244	chr19:41531206~41532174:+
BRCA	cis	rs1881509	0.702	rs4963079	ENSG00000233930.3	KRTAP5-AS1	-3.5	0.000485	0.024	-0.15	-0.11	Heroin dependence;	chr11:1414149	chr11:1571353~1599184:+
BRCA	cis	rs6088590	0.523	rs6088536	ENSG00000269202.1	RP4-614O4.12	-3.5	0.000485	0.024	-0.11	-0.11	Coronary artery disease;	chr20:34601302	chr20:35201747~35203288:-
BRCA	cis	rs250518	0.926	rs3916445	ENSG00000271926.1	CTD-2376I4.1	3.5	0.000485	0.024	0.14	0.11	Mean corpuscular hemoglobin concentration;	chr5:72773821	chr5:72953635~72954274:-
BRCA	cis	rs4648045	0.796	rs4648068	ENSG00000246560.2	RP11-10L12.4	3.5	0.000485	0.024	0.12	0.11	Lymphocyte percentage of white cells;	chr4:102597148	chr4:102828055~102844075:+
BRCA	cis	rs6887276	0.504	rs1003136	ENSG00000245937.6	LINC01184	3.5	0.000485	0.024	0.12	0.11	Height;	chr5:128012123	chr5:127940426~128083172:-
BRCA	cis	rs2154319	0.887	rs6670087	ENSG00000230638.4	RP11-486B10.4	-3.5	0.000485	0.024	-0.18	-0.11	Height;	chr1:41019774	chr1:41542069~41544310:+
BRCA	cis	rs2154319	0.887	rs6678816	ENSG00000230638.4	RP11-486B10.4	-3.5	0.000485	0.024	-0.18	-0.11	Height;	chr1:41019917	chr1:41542069~41544310:+
BRCA	cis	rs4805834	0.777	rs2016867	ENSG00000201388.1	SNORA68	-3.5	0.000485	0.024	-0.18	-0.11	Creatinine levels;	chr19:32919383	chr19:32608337~32608469:-
BRCA	cis	rs9982086	1	rs73897020	ENSG00000260583.1	AP000223.42	-3.5	0.000485	0.0241	-0.27	-0.11	Carboplatin disposition in epthelial ovarian cancer;	chr21:25643140	chr21:25582770~25583326:-
BRCA	cis	rs4276643	0.921	rs2685419	ENSG00000246339.5	EXTL3-AS1	3.5	0.000485	0.0241	0.11	0.11	Low vWF levels;	chr8:27948890	chr8:28696198~28701464:-
BRCA	cis	rs875971	0.862	rs801195	ENSG00000106610.13	STAG3L4	3.5	0.000485	0.0241	0.14	0.11	Aortic root size;	chr7:66561128	chr7:67302621~67321526:+
BRCA	cis	rs801193	1	rs7788576	ENSG00000275400.1	RP4-756H11.5	3.5	0.000485	0.0241	0.12	0.11	Aortic root size;	chr7:66683315	chr7:66553805~66554199:-
BRCA	cis	rs1348850	0.958	rs4893941	ENSG00000271825.1	RP11-337N6.2	3.5	0.000485	0.0241	0.14	0.11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177404803	chr2:177300600~177302006:+
BRCA	cis	rs4665809	0.878	rs35709953	ENSG00000231655.1	AC011742.3	-3.5	0.000485	0.0241	-0.18	-0.11	Gut microbiome composition (summer);	chr2:26112128	chr2:26140263~26141264:-
BRCA	cis	rs6012564	0.963	rs6125551	ENSG00000222365.1	SNORD12B	-3.5	0.000485	0.0241	-0.11	-0.11	Anger;	chr20:49103849	chr20:49280319~49280409:+
BRCA	cis	rs10129255	0.912	rs8009135	ENSG00000231475.3	IGHV4-31	-3.5	0.000485	0.0241	-0.08	-0.11	Kawasaki disease;	chr14:106777528	chr14:106349283~106349792:-
BRCA	cis	rs9287719	0.967	rs7592691	ENSG00000224177.5	LINC00570	3.5	0.000485	0.0241	0.13	0.11	Prostate cancer;	chr2:10597300	chr2:11393981~11403077:+
BRCA	cis	rs4388249	0.706	rs2301010	ENSG00000271849.1	CTC-332L22.1	3.5	0.000485	0.0241	0.19	0.11	Schizophrenia;	chr5:109796760	chr5:109687802~109688329:-
BRCA	cis	rs2018683	0.707	rs4722877	ENSG00000228421.2	AC005013.5	3.5	0.000485	0.0241	0.13	0.11	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28933289	chr7:28957667~28959345:+
BRCA	cis	rs1823874	0.71	rs2085087	ENSG00000259363.4	CTD-2054N24.2	3.5	0.000485	0.0241	0.13	0.11	IgG glycosylation;	chr15:99819938	chr15:99807023~99877148:+
BRCA	cis	rs7520050	0.966	rs11211230	ENSG00000234329.1	RP11-767N6.2	-3.5	0.000485	0.0241	-0.1	-0.11	Reticulocyte count;Red blood cell count;	chr1:45941095	chr1:45651039~45651826:-
BRCA	cis	rs10761482	0.861	rs10761486	ENSG00000254271.1	RP11-131N11.4	3.5	0.000485	0.0241	0.15	0.11	Schizophrenia;	chr10:60344545	chr10:60734342~60741828:+
BRCA	cis	rs10761482	0.861	rs10761487	ENSG00000254271.1	RP11-131N11.4	3.5	0.000485	0.0241	0.15	0.11	Schizophrenia;	chr10:60344551	chr10:60734342~60741828:+
BRCA	cis	rs1510510	0.643	rs13034392	ENSG00000186235.9	AC016757.3	-3.5	0.000486	0.0241	-0.18	-0.11	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr2:238619037	chr2:238224552~238231677:-
BRCA	cis	rs6545883	0.929	rs6545873	ENSG00000212978.6	AC016747.3	3.5	0.000486	0.0241	0.14	0.11	Tuberculosis;	chr2:61505877	chr2:61141592~61144969:-
BRCA	cis	rs17767294	0.708	rs72851182	ENSG00000219392.1	RP1-265C24.5	-3.5	0.000486	0.0241	-0.29	-0.11	Parkinson's disease;	chr6:28138921	chr6:28115628~28116551:+
BRCA	cis	rs17767294	0.708	rs75543204	ENSG00000219392.1	RP1-265C24.5	-3.5	0.000486	0.0241	-0.29	-0.11	Parkinson's disease;	chr6:28141038	chr6:28115628~28116551:+
BRCA	cis	rs4819052	0.851	rs12626188	ENSG00000223768.1	LINC00205	-3.5	0.000486	0.0241	-0.14	-0.11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45249343	chr21:45293285~45297354:+
BRCA	cis	rs11955398	0.62	rs6449512	ENSG00000272308.1	RP11-231G3.1	-3.5	0.000486	0.0241	-0.12	-0.11	Intelligence (multi-trait analysis);	chr5:60938415	chr5:60866457~60866935:-
BRCA	cis	rs12122100	0.742	rs12122092	ENSG00000244371.2	PFN1P8	3.5	0.000486	0.0241	0.13	0.11	HIV-1 control;	chr1:147037318	chr1:146957117~146957659:-
BRCA	cis	rs6494488	0.5	rs72742926	ENSG00000248415.1	GAPDHP61	-3.5	0.000486	0.0241	-0.24	-0.11	Coronary artery disease;	chr15:64572262	chr15:64528667~64529671:-
BRCA	cis	rs10761482	0.861	rs10761491	ENSG00000254271.1	RP11-131N11.4	3.5	0.000486	0.0241	0.15	0.11	Schizophrenia;	chr10:60348960	chr10:60734342~60741828:+
BRCA	cis	rs7176093	0.874	rs7172359	ENSG00000202081.1	RNU6-1280P	-3.5	0.000486	0.0241	-0.13	-0.11	Aging traits;	chr15:85803916	chr15:85651522~85651628:-
BRCA	cis	rs8073060	0.963	rs11080354	ENSG00000255987.1	TOMM20P2	-3.5	0.000486	0.0241	-0.1	-0.11	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35545388	chr17:35514766~35515186:-
BRCA	cis	rs11955398	0.502	rs248683	ENSG00000272308.1	RP11-231G3.1	-3.5	0.000486	0.0241	-0.12	-0.11	Intelligence (multi-trait analysis);	chr5:61064331	chr5:60866457~60866935:-
BRCA	cis	rs6943931	0.963	rs12531977	ENSG00000230658.1	KLHL7-AS1	-3.5	0.000486	0.0241	-0.14	-0.11	Diabetic kidney disease;	chr7:22385998	chr7:23101228~23105703:-
BRCA	cis	rs7520050	0.966	rs785464	ENSG00000234329.1	RP11-767N6.2	-3.5	0.000486	0.0241	-0.1	-0.11	Reticulocyte count;Red blood cell count;	chr1:46057417	chr1:45651039~45651826:-
BRCA	cis	rs2185341	0.536	rs10753536	ENSG00000218510.5	LINC00339	3.5	0.000486	0.0241	0.12	0.11	Amyotrophic lateral sclerosis;	chr1:22358758	chr1:22025188~22031223:+
BRCA	cis	rs1113500	0.787	rs10881502	ENSG00000230489.1	VAV3-AS1	3.5	0.000486	0.0241	0.12	0.11	Growth-regulated protein alpha levels;	chr1:108099197	chr1:107964443~107994607:+
BRCA	cis	rs9921338	0.961	rs4781069	ENSG00000263080.1	RP11-485G7.5	3.5	0.000486	0.0241	0.17	0.11	Vein graft stenosis in coronary artery bypass grafting;	chr16:11334905	chr16:11341809~11345211:-
BRCA	cis	rs4148883	0.689	rs1869458	ENSG00000272777.1	RP11-571L19.8	-3.5	0.000486	0.0241	-0.11	-0.11	Alcohol dependence;	chr4:99103577	chr4:99067256~99068125:-
BRCA	cis	rs4415084	1	rs10941677	ENSG00000272335.1	RP11-53O19.3	3.5	0.000486	0.0241	0.1	0.11	Breast cancer;	chr5:44662297	chr5:44826076~44828592:+
BRCA	cis	rs12468226	0.689	rs73989731	ENSG00000226261.1	AC064836.3	3.5	0.000486	0.0241	0.18	0.11	Urate levels;	chr2:202109309	chr2:202336024~202336727:-
BRCA	cis	rs9621305	0.8	rs5753766	ENSG00000237977.1	EIF4HP2	3.5	0.000486	0.0241	0.19	0.11	Intelligence;	chr22:31725640	chr22:30902219~30902781:+
BRCA	cis	rs2274273	0.624	rs66464079	ENSG00000259318.1	RP11-454L9.2	3.5	0.000486	0.0241	0.1	0.11	Protein biomarker;	chr14:55299446	chr14:55394940~55395233:-
BRCA	cis	rs67340775	0.541	rs200964	ENSG00000241549.7	GUSBP2	3.5	0.000486	0.0241	0.16	0.11	Lung cancer in ever smokers;	chr6:27899165	chr6:26871484~26956554:-
BRCA	cis	rs2023634	0.509	rs807741	ENSG00000241527.1	CA15P1	3.5	0.000486	0.0241	0.23	0.11	Metabolic traits;	chr22:19115785	chr22:19031564~19034564:-
BRCA	cis	rs2562456	0.793	rs7259396	ENSG00000240522.1	RPL7AP10	-3.5	0.000486	0.0241	-0.12	-0.11	Pain;	chr19:21340661	chr19:21149648~21150438:-
BRCA	cis	rs2562456	0.678	rs7260140	ENSG00000240522.1	RPL7AP10	-3.5	0.000486	0.0241	-0.12	-0.11	Pain;	chr19:21340723	chr19:21149648~21150438:-
BRCA	cis	rs2562456	0.833	rs11880624	ENSG00000240522.1	RPL7AP10	-3.5	0.000486	0.0241	-0.12	-0.11	Pain;	chr19:21341028	chr19:21149648~21150438:-
BRCA	cis	rs10761482	0.906	rs2199209	ENSG00000254271.1	RP11-131N11.4	3.5	0.000486	0.0241	0.15	0.11	Schizophrenia;	chr10:60334980	chr10:60734342~60741828:+
BRCA	cis	rs984222	0.838	rs10923724	ENSG00000231365.4	RP11-418J17.1	-3.5	0.000486	0.0241	-0.13	-0.11	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119004219	chr1:119140396~119275973:+
BRCA	cis	rs1479090	0.762	rs936564	ENSG00000250027.1	RP11-563E2.2	-3.5	0.000486	0.0241	-0.14	-0.11	Lung cancer;	chr4:163098611	chr4:163108785~163119965:+
BRCA	cis	rs1552244	0.572	rs67439440	ENSG00000269894.1	RP11-1020A11.1	-3.5	0.000486	0.0241	-0.14	-0.11	Alzheimer's disease;	chr3:10127819	chr3:9935706~9936258:+
BRCA	cis	rs4814894	0.716	rs4814895	ENSG00000236992.2	RPL12L3	3.5	0.000486	0.0241	0.12	0.11	Breast cancer;	chr20:19772996	chr20:19823443~19823943:-
BRCA	cis	rs10266483	0.881	rs636242	ENSG00000227986.1	TRIM60P18	-3.5	0.000486	0.0241	-0.12	-0.11	Response to statin therapy;	chr7:64284377	chr7:64355078~64356199:+
BRCA	cis	rs10266483	0.921	rs653746	ENSG00000227986.1	TRIM60P18	-3.5	0.000486	0.0241	-0.12	-0.11	Response to statin therapy;	chr7:64284399	chr7:64355078~64356199:+
BRCA	cis	rs7620503	1	rs6801849	ENSG00000228561.2	RP11-114M1.1	3.5	0.000486	0.0241	0.13	0.11	Corneal structure;	chr3:177580036	chr3:177683627~177691250:+
BRCA	cis	rs7520050	0.966	rs6680380	ENSG00000281133.1	AL355480.3	3.5	0.000486	0.0241	0.12	0.11	Reticulocyte count;Red blood cell count;	chr1:45834517	chr1:45580892~45580996:-
BRCA	cis	rs4363385	0.747	rs1413849	ENSG00000272654.1	RP11-422P24.11	3.5	0.000487	0.0241	0.11	0.11	Inflammatory skin disease;	chr1:152997757	chr1:153977743~153979160:+
BRCA	cis	rs4622329	0.615	rs7306175	ENSG00000257202.1	RP11-512N21.3	3.5	0.000487	0.0241	0.13	0.11	Systemic lupus erythematosus;	chr12:101900840	chr12:101923410~101924719:-
BRCA	cis	rs782590	0.574	rs12991445	ENSG00000272606.1	RP11-554J4.1	-3.5	0.000487	0.0241	-0.12	-0.11	Metabolic syndrome;	chr2:55448803	chr2:55617909~55618373:+
BRCA	cis	rs2439831	0.85	rs28684672	ENSG00000206991.1	RNU6-610P	-3.5	0.000487	0.0241	-0.18	-0.11	Lung cancer in ever smokers;	chr15:43815464	chr15:43637632~43637738:-
BRCA	cis	rs950169	0.519	rs7237	ENSG00000229212.6	RP11-561C5.4	-3.5	0.000487	0.0241	-0.14	-0.11	Schizophrenia;	chr15:84643346	chr15:85205440~85234795:-
BRCA	cis	rs2380205	0.689	rs12769593	ENSG00000232807.2	RP11-536K7.3	3.5	0.000487	0.0241	0.11	0.11	Breast cancer;	chr10:5856030	chr10:5934270~5945900:-
BRCA	cis	rs6943931	1	rs6960575	ENSG00000230658.1	KLHL7-AS1	-3.5	0.000487	0.0241	-0.14	-0.11	Diabetic kidney disease;	chr7:22378251	chr7:23101228~23105703:-
BRCA	cis	rs3760982	0.585	rs4803659	ENSG00000267191.1	RP11-15A1.2	-3.5	0.000487	0.0241	-0.14	-0.11	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43786083	chr19:43902001~43926545:+
BRCA	cis	rs801193	0.935	rs2659916	ENSG00000275400.1	RP4-756H11.5	-3.5	0.000487	0.0241	-0.12	-0.11	Aortic root size;	chr7:66686365	chr7:66553805~66554199:-
BRCA	cis	rs957448	1	rs10956915	ENSG00000261437.1	RP11-22C11.2	3.5	0.000487	0.0241	0.11	0.11	Nonsyndromic cleft lip with cleft palate;	chr8:94502362	chr8:94637285~94639467:-
BRCA	cis	rs2704588	1	rs1272570	ENSG00000270720.1	RP11-84C13.2	-3.5	0.000487	0.0241	-0.16	-0.11	Longevity;	chr4:88899764	chr4:89119284~89119871:+
BRCA	cis	rs12105510	0.608	rs62148700	ENSG00000270696.1	RP11-342K6.1	-3.5	0.000487	0.0241	-0.16	-0.11	Response to platinum-based chemotherapy (cisplatin);	chr2:75623114	chr2:75660462~75662208:+
BRCA	cis	rs654950	0.934	rs638859	ENSG00000230638.4	RP11-486B10.4	-3.5	0.000487	0.0241	-0.14	-0.11	Airway imaging phenotypes;	chr1:41535773	chr1:41542069~41544310:+
BRCA	cis	rs62458065	0.64	rs10271491	ENSG00000273014.1	RP11-225B17.2	-3.5	0.000487	0.0241	-0.17	-0.11	Metabolite levels (HVA/MHPG ratio);	chr7:32491053	chr7:32758882~32759353:+
BRCA	cis	rs1987511	1	rs61610073	ENSG00000224034.1	RP11-445P17.8	-3.5	0.000487	0.0241	-0.14	-0.11	Intelligence;	chr10:5306635	chr10:5266033~5271236:-
BRCA	cis	rs8042680	0.554	rs2301826	ENSG00000258725.1	PRC1-AS1	3.5	0.000487	0.0241	0.14	0.11	Type 2 diabetes;	chr15:90981967	chr15:90966345~90988624:+
BRCA	cis	rs17135159	1	rs11251866	ENSG00000273001.1	RP11-118K6.3	3.5	0.000487	0.0241	0.14	0.11	Reading and spelling;	chr10:3365088	chr10:3065424~3066001:-
BRCA	cis	rs17597773	0.674	rs1494372	ENSG00000257551.1	HLX-AS1	-3.5	0.000487	0.0241	-0.13	-0.11	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220841279	chr1:220832763~220880140:-
BRCA	cis	rs4272720	0.666	rs17011744	ENSG00000228754.1	RP11-534L6.3	-3.5	0.000487	0.0241	-0.13	-0.11	Platelet count;Plateletcrit;	chr10:49072989	chr10:48745545~48746128:-
BRCA	cis	rs7267979	0.903	rs6115118	ENSG00000274414.1	RP5-965G21.4	-3.5	0.000487	0.0241	-0.13	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25266098	chr20:25239007~25245229:-
BRCA	cis	rs7267979	0.903	rs1118963	ENSG00000274414.1	RP5-965G21.4	-3.5	0.000487	0.0241	-0.13	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25266813	chr20:25239007~25245229:-
BRCA	cis	rs11048434	0.535	rs2377680	ENSG00000256069.6	A2MP1	-3.5	0.000487	0.0241	-0.13	-0.11	Sjögren's syndrome;	chr12:9038809	chr12:9228533~9275817:-
BRCA	cis	rs829883	0.934	rs1641642	ENSG00000227825.4	SLC9A7P1	3.5	0.000487	0.0241	0.14	0.11	Colorectal adenoma (advanced);	chr12:98504948	chr12:98453835~98457145:-
BRCA	cis	rs1348850	0.561	rs1838890	ENSG00000271825.1	RP11-337N6.2	3.5	0.000487	0.0241	0.18	0.11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177546210	chr2:177300600~177302006:+
BRCA	cis	rs62344088	1	rs10065373	ENSG00000277812.1	AC021087.1	3.5	0.000487	0.0241	0.3	0.11	Asthma (childhood onset);	chr5:106704	chr5:262769~262881:+
BRCA	cis	rs7824557	0.767	rs6985460	ENSG00000205879.4	FAM90A2P	3.5	0.000487	0.0242	0.14	0.11	Retinal vascular caliber;	chr8:11313578	chr8:12172202~12178575:-
BRCA	cis	rs2274273	1	rs3742566	ENSG00000233924.1	AL160471.6	-3.5	0.000488	0.0242	-0.12	-0.11	Protein biomarker;	chr14:55129121	chr14:55004813~55005687:-
BRCA	cis	rs7586085	0.868	rs13430211	ENSG00000229195.1	AC009495.4	-3.5	0.000488	0.0242	-0.13	-0.11	Total body bone mineral density;	chr2:165766088	chr2:165794857~165846091:-
BRCA	cis	rs8130944	1	rs8130944	ENSG00000225731.1	AP001627.1	3.5	0.000488	0.0242	0.13	0.11	Perceived unattractiveness to mosquitoes;	chr21:42725797	chr21:42733594~42741758:-
BRCA	cis	rs4388249	1	rs3797695	ENSG00000249068.1	CTC-287O8.1	3.5	0.000488	0.0242	0.16	0.11	Schizophrenia;	chr5:109741816	chr5:109840128~109840692:-
BRCA	cis	rs6088580	0.634	rs6059890	ENSG00000269202.1	RP4-614O4.12	-3.5	0.000488	0.0242	-0.11	-0.11	Glomerular filtration rate (creatinine);	chr20:34513848	chr20:35201747~35203288:-
BRCA	cis	rs1670533	0.818	rs585735	ENSG00000251639.2	RP11-20I20.1	3.5	0.000488	0.0242	0.17	0.11	Recombination rate (females);	chr4:1086603	chr4:1100016~1101558:-
BRCA	cis	rs1119582	0.568	rs403676	ENSG00000279118.1	RP11-517I3.2	3.5	0.000488	0.0242	0.16	0.11	Select biomarker traits;	chr5:125866743	chr5:126496279~126498604:+
BRCA	cis	rs4879670	0.967	rs976163	ENSG00000236184.1	TCEA1P4	-3.5	0.000488	0.0242	-0.12	-0.11	Diabetic kidney disease;	chr9:33203944	chr9:32979560~32980403:-
BRCA	cis	rs849141	0.961	rs537124	ENSG00000234336.5	JAZF1-AS1	-3.5	0.000488	0.0242	-0.16	-0.11	Height;Hip circumference adjusted for BMI;	chr7:28163523	chr7:28180322~28243917:+
BRCA	cis	rs9816784	0.525	rs422772	ENSG00000207650.1	MIR570	3.5	0.000488	0.0242	0.14	0.11	Mean corpuscular hemoglobin;	chr3:196079601	chr3:195699401~195699497:+
BRCA	cis	rs8099594	0.64	rs487767	ENSG00000266696.1	RP11-30L3.2	3.5	0.000488	0.0242	0.13	0.11	Height;	chr18:49291622	chr18:49205912~49208781:+
BRCA	cis	rs1510510	0.757	rs12993655	ENSG00000186235.9	AC016757.3	-3.5	0.000488	0.0242	-0.17	-0.11	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr2:238623411	chr2:238224552~238231677:-
BRCA	cis	rs7607980	0.585	rs12692738	ENSG00000223318.1	RNA5SP111	3.5	0.000488	0.0242	0.13	0.11	Fasting blood insulin;Type 2 diabetes;Fasting blood insulin (BMI interaction);	chr2:164701742	chr2:164895677~164895777:-
BRCA	cis	rs1348850	0.914	rs9789582	ENSG00000280374.1	RP11-337N6.3	3.5	0.000488	0.0242	0.15	0.11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177465445	chr2:177317715~177318471:-
BRCA	cis	rs17711722	1	rs17711722	ENSG00000229180.5	GS1-124K5.11	-3.5	0.000488	0.0242	-0.09	-0.11	Calcium levels;	chr7:65806210	chr7:66526088~66542624:-
BRCA	cis	rs12477438	0.52	rs4402818	ENSG00000231822.1	AC019097.7	3.5	0.000488	0.0242	0.12	0.11	Chronic sinus infection;	chr2:99101145	chr2:99102018~99102752:+
BRCA	cis	rs6600671	0.693	rs1853731	ENSG00000275131.1	CH17-472G23.4	-3.5	0.000488	0.0242	-0.1	-0.11	Hip geometry;	chr1:121510262	chr1:120489625~120579190:-
BRCA	cis	rs2278170	1	rs11032361	ENSG00000225101.4	OR52K3P	-3.5	0.000488	0.0242	-0.14	-0.11	Amyotrophic lateral sclerosis;	chr11:4467000	chr11:4474813~4475755:+
BRCA	cis	rs1990950	1	rs1990950	ENSG00000251405.2	CTB-109A12.1	-3.5	0.000488	0.0242	-0.14	-0.11	Lung function (FEV1/FVC);	chr5:157493748	chr5:157362615~157460078:-
BRCA	cis	rs10044254	0.95	rs10051629	ENSG00000246214.1	RP11-260E18.1	-3.5	0.000488	0.0242	-0.14	-0.11	Asthma (corticosteroid response);	chr5:15779174	chr5:16615926~16629969:+
BRCA	cis	rs10044254	0.95	rs10066645	ENSG00000246214.1	RP11-260E18.1	-3.5	0.000488	0.0242	-0.14	-0.11	Asthma (corticosteroid response);	chr5:15779303	chr5:16615926~16629969:+
BRCA	cis	rs7959452	0.59	rs28778648	ENSG00000274979.1	RP11-1143G9.5	-3.5	0.000488	0.0242	-0.12	-0.11	Blood protein levels;	chr12:69378131	chr12:69326574~69331882:-
BRCA	cis	rs7959452	0.535	rs7133487	ENSG00000274979.1	RP11-1143G9.5	-3.5	0.000488	0.0242	-0.12	-0.11	Blood protein levels;	chr12:69380597	chr12:69326574~69331882:-
BRCA	cis	rs4703129	1	rs2052519	ENSG00000246763.5	RGMB-AS1	-3.5	0.000488	0.0242	-0.12	-0.11	Asperger disorder;	chr5:98535314	chr5:98769618~98773469:-
BRCA	cis	rs8091660	0.624	rs907547	ENSG00000278983.1	RP11-426J5.3	3.5	0.000488	0.0242	0.15	0.11	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48549725	chr18:48564795~48568342:+
BRCA	cis	rs853679	0.546	rs200948	ENSG00000216676.2	RP1-15D7.1	-3.5	0.000488	0.0242	-0.19	-0.11	Depression;	chr6:27867494	chr6:27652602~27652825:-
BRCA	cis	rs853679	0.546	rs200950	ENSG00000216676.2	RP1-15D7.1	-3.5	0.000488	0.0242	-0.19	-0.11	Depression;	chr6:27867994	chr6:27652602~27652825:-
BRCA	cis	rs28489187	0.666	rs233132	ENSG00000223653.4	RP11-131L23.1	3.5	0.000488	0.0242	0.12	0.11	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85330862	chr1:85276715~85448124:+
BRCA	cis	rs6545883	0.931	rs12713437	ENSG00000212978.6	AC016747.3	3.5	0.000488	0.0242	0.15	0.11	Tuberculosis;	chr2:61495769	chr2:61141592~61144969:-
BRCA	cis	rs5997397	0.967	rs5752791	ENSG00000226471.5	CTA-292E10.6	3.5	0.000488	0.0242	0.12	0.11	Red cell distribution width;	chr22:28757559	chr22:28800683~28848559:+
BRCA	cis	rs2303759	0.507	rs35042238	ENSG00000268686.1	AC010524.2	-3.5	0.000488	0.0242	-0.22	-0.11	Multiple sclerosis;	chr19:49369684	chr19:49368705~49388081:-
BRCA	cis	rs4499344	0.73	rs406470	ENSG00000201388.1	SNORA68	3.5	0.000488	0.0242	0.13	0.11	Mean platelet volume;	chr19:32613566	chr19:32608337~32608469:-
BRCA	cis	rs1030420	0.687	rs7014980	ENSG00000200714.1	Y_RNA	-3.5	0.000488	0.0242	-0.13	-0.11	Blood metabolite levels;	chr8:66446646	chr8:65592731~65592820:+
BRCA	cis	rs2562456	0.833	rs4644962	ENSG00000240522.1	RPL7AP10	-3.5	0.000488	0.0242	-0.12	-0.11	Pain;	chr19:21338125	chr19:21149648~21150438:-
BRCA	cis	rs6142618	0.562	rs6142614	ENSG00000275576.1	RP5-836N17.4	-3.5	0.000488	0.0242	-0.12	-0.11	Inflammatory bowel disease;	chr20:32124462	chr20:32116171~32116629:+
BRCA	cis	rs11992162	0.636	rs11250182	ENSG00000255020.1	AF131216.5	3.5	0.000488	0.0242	0.12	0.11	Monocyte count;	chr8:11950067	chr8:11345748~11347502:-
BRCA	cis	rs2555155	1	rs11040899	ENSG00000254595.1	CTD-2010I16.1	-3.5	0.000488	0.0242	-0.12	-0.11	DNA methylation (variation);	chr11:6498785	chr11:6488186~6489377:-
BRCA	cis	rs2243480	1	rs7794661	ENSG00000234585.5	CCT6P3	-3.5	0.000488	0.0242	-0.16	-0.11	Diabetic kidney disease;	chr7:65924743	chr7:65038354~65074713:+
BRCA	cis	rs7172809	0.643	rs16953967	ENSG00000260139.5	CSPG4P13	-3.5	0.000488	0.0242	-0.12	-0.11	Glucose homeostasis traits;	chr15:77544179	chr15:77894684~77904674:+
BRCA	cis	rs7267979	1	rs4815412	ENSG00000274414.1	RP5-965G21.4	-3.5	0.000488	0.0242	-0.13	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25369689	chr20:25239007~25245229:-
BRCA	cis	rs3816183	0.656	rs4953576	ENSG00000226491.1	FTOP1	-3.5	0.000489	0.0242	-0.14	-0.11	Hypospadias;	chr2:42708516	chr2:42797225~42798712:-
BRCA	cis	rs2148307	0.619	rs7078076	ENSG00000228339.1	AMD1P1	-3.5	0.000489	0.0242	-0.14	-0.11	Photic sneeze reflex;	chr10:20770782	chr10:20350049~20351100:+
BRCA	cis	rs17711722	0.701	rs781145	ENSG00000273142.1	RP11-458F8.4	-3.5	0.000489	0.0242	-0.09	-0.11	Calcium levels;	chr7:65975383	chr7:66902857~66906297:+
BRCA	cis	rs17221829	0.703	rs1962258	ENSG00000280385.1	AP000648.5	-3.5	0.000489	0.0242	-0.12	-0.11	Anxiety in major depressive disorder;	chr11:89647519	chr11:90193614~90198120:+
BRCA	cis	rs17221829	0.733	rs12421371	ENSG00000280385.1	AP000648.5	-3.5	0.000489	0.0242	-0.12	-0.11	Anxiety in major depressive disorder;	chr11:89647840	chr11:90193614~90198120:+
BRCA	cis	rs17221829	0.733	rs12421374	ENSG00000280385.1	AP000648.5	-3.5	0.000489	0.0242	-0.12	-0.11	Anxiety in major depressive disorder;	chr11:89647899	chr11:90193614~90198120:+
BRCA	cis	rs984222	0.775	rs2645294	ENSG00000231365.4	RP11-418J17.1	-3.5	0.000489	0.0242	-0.12	-0.11	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119031964	chr1:119140396~119275973:+
BRCA	cis	rs2274273	0.624	rs67386901	ENSG00000259318.1	RP11-454L9.2	3.5	0.000489	0.0242	0.1	0.11	Protein biomarker;	chr14:55290646	chr14:55394940~55395233:-
BRCA	cis	rs60843830	1	rs57542652	ENSG00000223751.1	AC116609.2	3.5	0.000489	0.0242	0.14	0.11	Spherical equivalent (joint analysis main effects and education interaction);	chr2:228088	chr2:742488~747767:+
BRCA	cis	rs3176789	0.767	rs1861090	ENSG00000256673.1	RP11-599J14.2	3.5	0.000489	0.0242	0.13	0.11	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9777083	chr12:9398355~9414851:-
BRCA	cis	rs10043775	0.793	rs1363704	ENSG00000251330.3	CTD-2283N19.1	-3.5	0.000489	0.0242	-0.12	-0.11	Periodontal microbiota;	chr5:148309883	chr5:148430159~148430807:-
BRCA	cis	rs10043775	0.793	rs10050560	ENSG00000251330.3	CTD-2283N19.1	-3.5	0.000489	0.0242	-0.12	-0.11	Periodontal microbiota;	chr5:148310137	chr5:148430159~148430807:-
BRCA	cis	rs4803480	0.678	rs3745936	ENSG00000268355.1	AC006129.1	-3.5	0.000489	0.0242	-0.14	-0.11	Schizophrenia;	chr19:41586462	chr19:41531206~41532174:+
BRCA	cis	rs721917	0.607	rs4319455	ENSG00000244733.5	RP11-506M13.3	-3.5	0.000489	0.0242	-0.13	-0.11	Chronic obstructive pulmonary disease;	chr10:79979389	chr10:79660891~79677996:+
BRCA	cis	rs1355223	0.902	rs35032224	ENSG00000271369.1	RP11-350D17.3	-3.5	0.000489	0.0242	-0.12	-0.11	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34676607	chr11:34709600~34710161:+
BRCA	cis	rs34975555	0.803	rs7007576	ENSG00000254054.2	RP11-156K13.3	-3.5	0.000489	0.0242	-0.17	-0.11	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:17974751	chr8:17905756~17907887:+
BRCA	cis	rs11098499	0.954	rs2389802	ENSG00000225892.3	RP11-384K6.2	3.5	0.000489	0.0242	0.11	0.11	Corneal astigmatism;	chr4:119404577	chr4:118632274~118634759:+
BRCA	cis	rs9973361	0.513	rs13399960	ENSG00000232411.1	AC009495.3	-3.5	0.000489	0.0242	-0.14	-0.11	Total body bone mineral density;	chr2:165842209	chr2:165833048~165839098:-
BRCA	cis	rs12282928	0.959	rs4980426	ENSG00000255197.4	RP11-750H9.5	3.5	0.000489	0.0242	0.1	0.11	Migraine - clinic-based;	chr11:48274467	chr11:47383148~47409190:-
BRCA	cis	rs1153858	0.887	rs28569043	ENSG00000275672.1	GATM-AS1	-3.5	0.000489	0.0242	-0.14	-0.11	Homoarginine levels;	chr15:45438728	chr15:45378700~45380123:+
BRCA	cis	rs6545883	0.899	rs1562309	ENSG00000212978.6	AC016747.3	3.5	0.000489	0.0242	0.15	0.11	Tuberculosis;	chr2:61542991	chr2:61141592~61144969:-
BRCA	cis	rs258892	0.895	rs13167768	ENSG00000272525.1	RP11-79P5.9	-3.5	0.000489	0.0242	-0.13	-0.11	Small cell lung carcinoma;	chr5:72738795	chr5:73497550~73498293:-
BRCA	cis	rs720064	0.537	rs2676106	ENSG00000265752.2	RP11-403A21.1	3.5	0.000489	0.0242	0.12	0.11	Strep throat;	chr18:23685075	chr18:23957754~23982556:-
BRCA	cis	rs853679	0.517	rs12174753	ENSG00000272009.1	RP1-313I6.12	-3.5	0.000489	0.0242	-0.16	-0.11	Depression;	chr6:28074687	chr6:28078792~28081130:-
BRCA	cis	rs12949688	0.967	rs7220397	ENSG00000262623.1	RP5-1107A17.2	-3.5	0.000489	0.0242	-0.11	-0.11	Schizophrenia;	chr17:57746161	chr17:56951664~56952404:+
BRCA	cis	rs12949688	0.967	rs8081251	ENSG00000262623.1	RP5-1107A17.2	-3.5	0.000489	0.0242	-0.11	-0.11	Schizophrenia;	chr17:57746672	chr17:56951664~56952404:+
BRCA	cis	rs748404	0.666	rs34633582	ENSG00000166763.7	STRCP1	3.5	0.000489	0.0242	0.15	0.11	Lung cancer;	chr15:43462683	chr15:43699488~43718184:-
BRCA	cis	rs35520189	0.857	rs6735739	ENSG00000231747.1	AC079922.2	3.5	0.000489	0.0242	0.11	0.11	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:112852309	chr2:112621809~112622167:-
BRCA	cis	rs6088590	0.687	rs13044899	ENSG00000269202.1	RP4-614O4.12	-3.5	0.00049	0.0242	-0.11	-0.11	Coronary artery disease;	chr20:34699274	chr20:35201747~35203288:-
BRCA	cis	rs6801605	0.963	rs6445607	ENSG00000271916.1	RP11-884K10.6	-3.5	0.00049	0.0242	-0.1	-0.11	Blood protein levels;	chr3:53843122	chr3:53797764~53798019:-
BRCA	cis	rs8114671	0.528	rs6119542	ENSG00000279253.1	RP4-614O4.13	-3.5	0.00049	0.0242	-0.12	-0.11	Height;	chr20:34896742	chr20:35262727~35264187:-
BRCA	cis	rs4657482	0.639	rs12045367	ENSG00000203307.2	RP11-375H19.2	-3.5	0.00049	0.0242	-0.14	-0.11	Testicular germ cell tumor;	chr1:165906735	chr1:166081183~166087483:+
BRCA	cis	rs9437689	1	rs4630159	ENSG00000235501.4	RP4-639F20.1	-3.5	0.00049	0.0242	-0.14	-0.11	Phospholipid levels (plasma);	chr1:95078122	chr1:94927566~94963270:+
BRCA	cis	rs1670533	1	rs1670534	ENSG00000251639.2	RP11-20I20.1	3.5	0.00049	0.0242	0.17	0.11	Recombination rate (females);	chr4:1093477	chr4:1100016~1101558:-
BRCA	cis	rs11098499	0.955	rs35434465	ENSG00000225892.3	RP11-384K6.2	3.5	0.00049	0.0242	0.11	0.11	Corneal astigmatism;	chr4:119248223	chr4:118632274~118634759:+
BRCA	cis	rs13325613	0.915	rs4473594	ENSG00000223552.1	RP11-24F11.2	3.5	0.00049	0.0242	0.19	0.11	Monocyte count;	chr3:46295865	chr3:46364955~46407059:-
BRCA	cis	rs2274273	0.773	rs10147765	ENSG00000259318.1	RP11-454L9.2	3.5	0.00049	0.0242	0.09	0.11	Protein biomarker;	chr14:55361108	chr14:55394940~55395233:-
BRCA	cis	rs1371614	0.513	rs13010712	ENSG00000229122.1	AGBL5-IT1	-3.5	0.00049	0.0242	-0.12	-0.11	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26864841	chr2:27061038~27061815:+
BRCA	cis	rs7636293	0.647	rs13095008	ENSG00000270773.1	RP13-685P2.7	3.5	0.00049	0.0242	0.15	0.11	Height;	chr3:129326057	chr3:129345411~129346164:+
BRCA	cis	rs12439619	0.693	rs7165536	ENSG00000259429.4	UBE2Q2P2	-3.5	0.00049	0.0243	-0.13	-0.11	Intelligence (multi-trait analysis);	chr15:82273743	chr15:82355142~82420075:+
BRCA	cis	rs7577894	0.967	rs1430198	ENSG00000272606.1	RP11-554J4.1	3.5	0.00049	0.0243	0.12	0.11	Amyotrophic lateral sclerosis;	chr2:55775269	chr2:55617909~55618373:+
BRCA	cis	rs6754311	0.517	rs1469996	ENSG00000231890.6	DARS-AS1	-3.5	0.00049	0.0243	-0.16	-0.11	Mosquito bite size;	chr2:135784990	chr2:135985176~136022593:+
BRCA	cis	rs6750795	0.518	rs1434519	ENSG00000223198.1	RNU2-22P	-3.5	0.00049	0.0243	-0.16	-0.11	Height;	chr2:231569050	chr2:231501990~231502201:-
BRCA	cis	rs3755605	0.728	rs11921468	ENSG00000242578.1	RP11-469J4.3	3.5	0.00049	0.0243	0.13	0.11	Testicular germ cell tumor;	chr3:170161570	chr3:170410512~170418615:+
BRCA	cis	rs875971	0.895	rs10755833	ENSG00000229886.1	RP5-1132H15.3	3.5	0.00049	0.0243	0.12	0.11	Aortic root size;	chr7:66448930	chr7:66025126~66031544:-
BRCA	cis	rs875971	0.895	rs1833495	ENSG00000229886.1	RP5-1132H15.3	3.5	0.00049	0.0243	0.12	0.11	Aortic root size;	chr7:66456608	chr7:66025126~66031544:-
BRCA	cis	rs875971	0.964	rs6945032	ENSG00000229886.1	RP5-1132H15.3	3.5	0.00049	0.0243	0.12	0.11	Aortic root size;	chr7:66457499	chr7:66025126~66031544:-
BRCA	cis	rs875971	0.929	rs12673810	ENSG00000229886.1	RP5-1132H15.3	3.5	0.00049	0.0243	0.12	0.11	Aortic root size;	chr7:66458866	chr7:66025126~66031544:-
BRCA	cis	rs875971	1	rs6961155	ENSG00000229886.1	RP5-1132H15.3	3.5	0.00049	0.0243	0.12	0.11	Aortic root size;	chr7:66468308	chr7:66025126~66031544:-
BRCA	cis	rs875971	1	rs7789768	ENSG00000229886.1	RP5-1132H15.3	3.5	0.00049	0.0243	0.12	0.11	Aortic root size;	chr7:66473993	chr7:66025126~66031544:-
BRCA	cis	rs875971	1	rs1363055	ENSG00000229886.1	RP5-1132H15.3	3.5	0.00049	0.0243	0.12	0.11	Aortic root size;	chr7:66478288	chr7:66025126~66031544:-
BRCA	cis	rs875971	0.964	rs9691480	ENSG00000229886.1	RP5-1132H15.3	3.5	0.00049	0.0243	0.12	0.11	Aortic root size;	chr7:66479319	chr7:66025126~66031544:-
BRCA	cis	rs875971	0.862	rs35378740	ENSG00000265600.1	AC006480.1	-3.5	0.00049	0.0243	-0.13	-0.11	Aortic root size;	chr7:66522725	chr7:67356680~67356779:+
BRCA	cis	rs2262909	0.962	rs11669110	ENSG00000279377.1	AC003973.3	-3.5	0.00049	0.0243	-0.15	-0.11	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;	chr19:22113683	chr19:21965708~21968529:-
BRCA	cis	rs74400468	0.529	rs10128322	ENSG00000272319.1	AL022345.7	3.5	0.00049	0.0243	0.23	0.11	Cannabis dependence symptom count;	chr10:42711252	chr10:42579724~42582772:+
BRCA	cis	rs4388249	1	rs12656748	ENSG00000249068.1	CTC-287O8.1	3.5	0.00049	0.0243	0.16	0.11	Schizophrenia;	chr5:109707528	chr5:109840128~109840692:-
BRCA	cis	rs7694379	0.704	rs13140105	ENSG00000251411.1	RP11-397E7.4	-3.5	0.00049	0.0243	-0.12	-0.11	Platelet count;	chr4:87256318	chr4:86913266~86914817:-
BRCA	cis	rs6943931	1	rs6942620	ENSG00000230658.1	KLHL7-AS1	-3.5	0.000491	0.0243	-0.14	-0.11	Diabetic kidney disease;	chr7:22378136	chr7:23101228~23105703:-
BRCA	cis	rs4699052	1	rs7661702	ENSG00000246560.2	RP11-10L12.4	3.5	0.000491	0.0243	0.11	0.11	Testicular germ cell tumor;	chr4:103218972	chr4:102828055~102844075:+
BRCA	cis	rs6545883	0.524	rs2694618	ENSG00000270820.4	RP11-355B11.2	3.5	0.000491	0.0243	0.11	0.11	Tuberculosis;	chr2:61309849	chr2:61471188~61484130:+
BRCA	cis	rs7260598	0.642	rs66750293	ENSG00000268442.1	CTD-2027I19.2	3.5	0.000491	0.0243	0.17	0.11	Response to taxane treatment (placlitaxel);	chr19:23997819	chr19:24162370~24163425:-
BRCA	cis	rs4835473	0.868	rs56115009	ENSG00000246448.2	RP13-578N3.3	-3.5	0.000491	0.0243	-0.12	-0.11	Immature fraction of reticulocytes;	chr4:143761073	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.9	rs10857406	ENSG00000246448.2	RP13-578N3.3	-3.5	0.000491	0.0243	-0.12	-0.11	Immature fraction of reticulocytes;	chr4:143761216	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.932	rs10857407	ENSG00000246448.2	RP13-578N3.3	-3.5	0.000491	0.0243	-0.12	-0.11	Immature fraction of reticulocytes;	chr4:143761226	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.932	rs10857408	ENSG00000246448.2	RP13-578N3.3	-3.5	0.000491	0.0243	-0.12	-0.11	Immature fraction of reticulocytes;	chr4:143761333	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.9	rs10857409	ENSG00000246448.2	RP13-578N3.3	-3.5	0.000491	0.0243	-0.12	-0.11	Immature fraction of reticulocytes;	chr4:143761461	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.932	rs10857410	ENSG00000246448.2	RP13-578N3.3	-3.5	0.000491	0.0243	-0.12	-0.11	Immature fraction of reticulocytes;	chr4:143761566	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.932	rs10857411	ENSG00000246448.2	RP13-578N3.3	-3.5	0.000491	0.0243	-0.12	-0.11	Immature fraction of reticulocytes;	chr4:143761599	chr4:143700257~143865072:+
BRCA	cis	rs72928364	0.86	rs34281790	ENSG00000256628.3	ZBTB11-AS1	3.5	0.000491	0.0243	0.22	0.11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:101071923	chr3:101676475~101679217:+
BRCA	cis	rs6840360	0.571	rs4696099	ENSG00000270265.1	RP11-731D1.4	-3.5	0.000491	0.0243	-0.13	-0.11	Intelligence (multi-trait analysis);	chr4:151580799	chr4:151333775~151353224:-
BRCA	cis	rs7267979	0.903	rs2474766	ENSG00000204556.4	CTD-2514C3.1	-3.5	0.000491	0.0243	-0.15	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25265517	chr20:26018832~26020684:+
BRCA	cis	rs7267979	0.903	rs2474769	ENSG00000204556.4	CTD-2514C3.1	-3.5	0.000491	0.0243	-0.15	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25268089	chr20:26018832~26020684:+
BRCA	cis	rs6840360	0.571	rs875668	ENSG00000278978.1	RP11-164P12.5	-3.5	0.000491	0.0243	-0.13	-0.11	Intelligence (multi-trait analysis);	chr4:151604509	chr4:151669786~151670503:+
BRCA	cis	rs4449834	0.851	rs4289855	ENSG00000254432.1	RP11-33I11.2	3.5	0.000491	0.0243	0.15	0.11	Sum eosinophil basophil counts;	chr8:60799811	chr8:60808735~60809606:-
BRCA	cis	rs7039247	0.659	rs12352824	ENSG00000281769.1	LINC01230	-3.5	0.000491	0.0243	-0.13	-0.11	Stem cell factor levels;	chr9:1267148	chr9:1045625~1048641:+
BRCA	cis	rs10750165	0.644	rs10790343	ENSG00000254854.1	CTD-2523D13.2	3.5	0.000491	0.0243	0.13	0.11	Aggressiveness in attention deficit hyperactivity disorder;	chr11:119759771	chr11:119729583~119739623:+
BRCA	cis	rs829883	0.659	rs12366950	ENSG00000227825.4	SLC9A7P1	-3.5	0.000491	0.0243	-0.15	-0.11	Colorectal adenoma (advanced);	chr12:98554122	chr12:98453835~98457145:-
BRCA	cis	rs2288327	0.73	rs16866358	ENSG00000271011.1	RP11-171I2.5	3.5	0.000491	0.0243	0.2	0.11	Atrial fibrillation;	chr2:178515369	chr2:178577103~178577622:+
BRCA	cis	rs2243480	0.901	rs2949697	ENSG00000226767.1	RP11-328P23.3	-3.5	0.000491	0.0243	-0.19	-0.11	Diabetic kidney disease;	chr7:65999249	chr7:65508773~65508944:-
BRCA	cis	rs8114671	0.562	rs6060064	ENSG00000126005.14	MMP24-AS1	3.5	0.000491	0.0243	0.12	0.11	Height;	chr20:34818536	chr20:35216462~35278131:-
BRCA	cis	rs977987	0.806	rs72787160	ENSG00000261476.1	RP11-77K12.3	-3.5	0.000491	0.0243	-0.12	-0.11	Dupuytren's disease;	chr16:75411264	chr16:75458252~75460017:-
BRCA	cis	rs4148883	0.504	rs4585310	ENSG00000246090.5	RP11-696N14.1	-3.5	0.000491	0.0243	-0.1	-0.11	Alcohol dependence;	chr4:99199076	chr4:99088857~99301356:+
BRCA	cis	rs13434995	0.513	rs2171617	ENSG00000273257.1	RP11-177J6.1	3.5	0.000491	0.0243	0.16	0.11	Adiponectin levels;	chr4:55591023	chr4:55387949~55388271:+
BRCA	cis	rs3755605	0.52	rs1082978	ENSG00000242578.1	RP11-469J4.3	3.5	0.000491	0.0243	0.13	0.11	Testicular germ cell tumor;	chr3:170219204	chr3:170410512~170418615:+
BRCA	cis	rs478304	0.53	rs11568300	ENSG00000255320.1	RP11-755F10.1	3.5	0.000491	0.0243	0.14	0.11	Acne (severe);	chr11:65657696	chr11:66244840~66246239:-
BRCA	cis	rs3770081	1	rs56104203	ENSG00000232504.4	ST3GAL5-AS1	3.5	0.000491	0.0243	0.26	0.11	Facial emotion recognition (sad faces);	chr2:86109133	chr2:85889280~85890980:+
BRCA	cis	rs6088590	0.582	rs6059909	ENSG00000269202.1	RP4-614O4.12	-3.5	0.000491	0.0243	-0.11	-0.11	Coronary artery disease;	chr20:34551887	chr20:35201747~35203288:-
BRCA	cis	rs1424638	0.655	rs11902758	ENSG00000233251.6	AC007743.1	-3.5	0.000491	0.0243	-0.13	-0.11	Intelligence (multi-trait analysis);	chr2:57025144	chr2:56173534~56185770:-
BRCA	cis	rs6496932	0.663	rs11074169	ENSG00000218052.5	ADAMTS7P4	-3.5	0.000491	0.0243	-0.12	-0.11	Central corneal thickness;Corneal structure;	chr15:85375721	chr15:85255369~85330334:-
BRCA	cis	rs10129255	0.518	rs11847766	ENSG00000211976.2	IGHV3-73	-3.5	0.000491	0.0243	-0.08	-0.11	Kawasaki disease;	chr14:106779186	chr14:106802694~106803233:-
BRCA	cis	rs8180040	0.932	rs62246474	ENSG00000260236.1	RP11-708J19.1	-3.5	0.000491	0.0243	-0.1	-0.11	Colorectal cancer;	chr3:47356640	chr3:47379089~47380999:-
BRCA	cis	rs56281245	0.793	rs1422651	ENSG00000249363.1	CTB-78O21.1	3.5	0.000491	0.0243	0.23	0.11	Hepcidin levels;	chr5:145576591	chr5:145728360~145729349:-
BRCA	cis	rs56281245	1	rs76357928	ENSG00000249363.1	CTB-78O21.1	3.5	0.000491	0.0243	0.23	0.11	Hepcidin levels;	chr5:145577584	chr5:145728360~145729349:-
BRCA	cis	rs11098499	0.566	rs17051356	ENSG00000250412.1	KLHL2P1	3.5	0.000491	0.0243	0.13	0.11	Corneal astigmatism;	chr4:119664153	chr4:119334329~119378233:+
BRCA	cis	rs2425143	1	rs2425141	ENSG00000088340.14	FER1L4	-3.5	0.000491	0.0243	-0.17	-0.11	Blood protein levels;	chr20:35762201	chr20:35558737~35607562:-
BRCA	cis	rs1193	0.837	rs2138397	ENSG00000266931.1	RP11-1252D15.1	-3.5	0.000491	0.0243	-0.13	-0.11	High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;High light scatter reticulocyte count;	chr2:86746926	chr2:87055658~87055800:-
BRCA	cis	rs848490	0.855	rs17155183	ENSG00000214293.7	APTR	3.5	0.000491	0.0243	0.13	0.11	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77571075	chr7:77657660~77696265:-
BRCA	cis	rs6452790	0.529	rs3910019	ENSG00000247828.6	TMEM161B-AS1	-3.5	0.000491	0.0243	-0.14	-0.11	Cognitive function;	chr5:87971470	chr5:88268895~88436685:+
BRCA	cis	rs6452790	0.529	rs10063680	ENSG00000247828.6	TMEM161B-AS1	-3.5	0.000491	0.0243	-0.14	-0.11	Cognitive function;	chr5:87972258	chr5:88268895~88436685:+
BRCA	cis	rs62458065	0.85	rs7785659	ENSG00000281332.1	LINC00997	-3.5	0.000491	0.0243	-0.16	-0.11	Metabolite levels (HVA/MHPG ratio);	chr7:32421403	chr7:32760279~32762924:+
BRCA	cis	rs6545883	0.965	rs2305156	ENSG00000212978.6	AC016747.3	3.5	0.000491	0.0243	0.15	0.11	Tuberculosis;	chr2:61502133	chr2:61141592~61144969:-
BRCA	cis	rs72928364	0.929	rs35850913	ENSG00000256628.3	ZBTB11-AS1	3.5	0.000491	0.0243	0.22	0.11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:101056236	chr3:101676475~101679217:+
BRCA	cis	rs561341	1	rs113115092	ENSG00000265798.5	RP11-271K11.5	3.5	0.000492	0.0243	0.18	0.11	Hip circumference adjusted for BMI;	chr17:31957145	chr17:31038575~31059121:-
BRCA	cis	rs561341	1	rs555629	ENSG00000265798.5	RP11-271K11.5	3.5	0.000492	0.0243	0.18	0.11	Hip circumference adjusted for BMI;	chr17:31967117	chr17:31038575~31059121:-
BRCA	cis	rs561341	0.769	rs559228	ENSG00000265798.5	RP11-271K11.5	3.5	0.000492	0.0243	0.18	0.11	Hip circumference adjusted for BMI;	chr17:31967508	chr17:31038575~31059121:-
BRCA	cis	rs561341	1	rs1681718	ENSG00000265798.5	RP11-271K11.5	3.5	0.000492	0.0243	0.18	0.11	Hip circumference adjusted for BMI;	chr17:31969426	chr17:31038575~31059121:-
BRCA	cis	rs1411478	0.967	rs4111520	ENSG00000243155.1	RP11-46A10.5	3.5	0.000492	0.0243	0.12	0.11	Menopause (age at onset);Progressive supranuclear palsy;	chr1:180989810	chr1:180944042~180976482:-
BRCA	cis	rs7824557	0.767	rs2164273	ENSG00000154316.13	TDH	-3.5	0.000492	0.0243	-0.15	-0.11	Retinal vascular caliber;	chr8:11310990	chr8:11339637~11368452:+
BRCA	cis	rs7267979	1	rs4815424	ENSG00000274414.1	RP5-965G21.4	3.5	0.000492	0.0243	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25409648	chr20:25239007~25245229:-
BRCA	cis	rs6866614	0.627	rs27437	ENSG00000233006.5	AC034220.3	3.5	0.000492	0.0243	0.08	0.11	Perceived unattractiveness to mosquitoes;	chr5:132101268	chr5:132311285~132369916:-
BRCA	cis	rs7112925	0.932	rs2282502	ENSG00000255517.5	CTD-3074O7.5	3.5	0.000492	0.0243	0.13	0.11	Height;	chr11:67066781	chr11:66473490~66480233:-
BRCA	cis	rs74233809	1	rs3781285	ENSG00000236937.2	PTGES3P4	3.5	0.000492	0.0243	0.24	0.11	Birth weight;	chr10:103065908	chr10:102845595~102845950:+
BRCA	cis	rs875971	1	rs3735148	ENSG00000229886.1	RP5-1132H15.3	3.5	0.000492	0.0243	0.12	0.11	Aortic root size;	chr7:66506022	chr7:66025126~66031544:-
BRCA	cis	rs4713118	0.869	rs9348775	ENSG00000219392.1	RP1-265C24.5	-3.5	0.000492	0.0243	-0.15	-0.11	Parkinson's disease;	chr6:27727550	chr6:28115628~28116551:+
BRCA	cis	rs12310956	0.532	rs7955514	ENSG00000258794.3	DUX4L27	3.5	0.000492	0.0243	0.16	0.11	Morning vs. evening chronotype;	chr12:33825802	chr12:34208415~34209675:-
BRCA	cis	rs863345	0.604	rs11265008	ENSG00000176320.2	RP11-404O13.5	-3.5	0.000492	0.0243	-0.11	-0.11	Pneumococcal bacteremia;	chr1:158528881	chr1:158197922~158203877:-
BRCA	cis	rs863345	0.604	rs11265010	ENSG00000176320.2	RP11-404O13.5	-3.5	0.000492	0.0243	-0.11	-0.11	Pneumococcal bacteremia;	chr1:158529063	chr1:158197922~158203877:-
BRCA	cis	rs863345	0.604	rs12123305	ENSG00000176320.2	RP11-404O13.5	-3.5	0.000492	0.0243	-0.11	-0.11	Pneumococcal bacteremia;	chr1:158529165	chr1:158197922~158203877:-
BRCA	cis	rs863345	0.604	rs12063320	ENSG00000176320.2	RP11-404O13.5	-3.5	0.000492	0.0243	-0.11	-0.11	Pneumococcal bacteremia;	chr1:158529633	chr1:158197922~158203877:-
BRCA	cis	rs863345	0.604	rs12064489	ENSG00000176320.2	RP11-404O13.5	-3.5	0.000492	0.0243	-0.11	-0.11	Pneumococcal bacteremia;	chr1:158529659	chr1:158197922~158203877:-
BRCA	cis	rs863345	0.625	rs12063360	ENSG00000176320.2	RP11-404O13.5	-3.5	0.000492	0.0243	-0.11	-0.11	Pneumococcal bacteremia;	chr1:158529704	chr1:158197922~158203877:-
BRCA	cis	rs863345	0.604	rs10908665	ENSG00000176320.2	RP11-404O13.5	-3.5	0.000492	0.0243	-0.11	-0.11	Pneumococcal bacteremia;	chr1:158530099	chr1:158197922~158203877:-
BRCA	cis	rs863345	0.625	rs12119672	ENSG00000176320.2	RP11-404O13.5	-3.5	0.000492	0.0243	-0.11	-0.11	Pneumococcal bacteremia;	chr1:158530495	chr1:158197922~158203877:-
BRCA	cis	rs863345	0.604	rs12059669	ENSG00000176320.2	RP11-404O13.5	-3.5	0.000492	0.0243	-0.11	-0.11	Pneumococcal bacteremia;	chr1:158531690	chr1:158197922~158203877:-
BRCA	cis	rs863345	0.604	rs10908670	ENSG00000176320.2	RP11-404O13.5	-3.5	0.000492	0.0243	-0.11	-0.11	Pneumococcal bacteremia;	chr1:158532323	chr1:158197922~158203877:-
BRCA	cis	rs863345	0.565	rs10908671	ENSG00000176320.2	RP11-404O13.5	-3.5	0.000492	0.0243	-0.11	-0.11	Pneumococcal bacteremia;	chr1:158532370	chr1:158197922~158203877:-
BRCA	cis	rs863345	0.604	rs12075228	ENSG00000176320.2	RP11-404O13.5	-3.5	0.000492	0.0243	-0.11	-0.11	Pneumococcal bacteremia;	chr1:158532466	chr1:158197922~158203877:-
BRCA	cis	rs7267979	1	rs404394	ENSG00000231081.1	RP4-760C5.3	-3.5	0.000492	0.0243	-0.14	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25467260	chr20:26008791~26010531:-
BRCA	cis	rs17027633	0.867	rs12097762	ENSG00000234020.1	CHIAP3	-3.5	0.000492	0.0243	-0.21	-0.11	Cerebrospinal fluid t-tau:AB1-42 ratio;	chr1:111418417	chr1:111353275~111367409:-
BRCA	cis	rs11764590	0.694	rs6461115	ENSG00000230914.2	AC004840.8	3.5	0.000492	0.0243	0.13	0.11	Neuroticism;	chr7:2064033	chr7:2384121~2388597:+
BRCA	cis	rs1401543	1	rs1007835	ENSG00000273486.1	RP11-731C17.2	3.5	0.000492	0.0243	0.14	0.11	Anticoagulant levels;	chr3:135849393	chr3:136837338~136839021:-
BRCA	cis	rs2227564	0.729	rs2633304	ENSG00000279689.1	RP11-574K11.32	3.5	0.000492	0.0243	0.12	0.11	Crohn's disease;Inflammatory bowel disease;	chr10:73890892	chr10:73769264~73772862:-
BRCA	cis	rs2227564	0.729	rs2688616	ENSG00000279689.1	RP11-574K11.32	3.5	0.000492	0.0243	0.12	0.11	Crohn's disease;Inflammatory bowel disease;	chr10:73890894	chr10:73769264~73772862:-
BRCA	cis	rs2346177	0.875	rs6726089	ENSG00000279254.1	RP11-536C12.1	-3.5	0.000492	0.0243	-0.13	-0.11	HDL cholesterol;	chr2:46418341	chr2:46668870~46670778:+
BRCA	cis	rs875971	1	rs1981798	ENSG00000271064.1	RP11-792A8.3	-3.5	0.000492	0.0243	-0.13	-0.11	Aortic root size;	chr7:66489916	chr7:66748838~66749077:-
BRCA	cis	rs958025	1	rs958025	ENSG00000261143.1	ADAMTS7P3	-3.5	0.000492	0.0243	-0.15	-0.11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78467006	chr15:77976042~77993057:+
BRCA	cis	rs9341808	0.727	rs9361599	ENSG00000233967.5	RP11-250B2.3	3.5	0.000492	0.0243	0.11	0.11	Sitting height ratio;	chr6:80315525	chr6:80443344~80465927:+
BRCA	cis	rs6490294	0.651	rs440	ENSG00000257624.1	RP1-128M12.3	3.5	0.000492	0.0244	0.15	0.11	Mean platelet volume;	chr12:111790910	chr12:112000739~112000985:-
BRCA	cis	rs8054556	1	rs3935873	ENSG00000214725.6	CDIPT-AS1	3.5	0.000492	0.0244	0.13	0.11	Autism spectrum disorder or schizophrenia;	chr16:30007179	chr16:29863593~29868053:+
BRCA	cis	rs6840360	0.533	rs11099829	ENSG00000278978.1	RP11-164P12.5	3.5	0.000493	0.0244	0.12	0.11	Intelligence (multi-trait analysis);	chr4:151806147	chr4:151669786~151670503:+
BRCA	cis	rs7660883	0.897	rs1037814	ENSG00000251411.1	RP11-397E7.4	-3.5	0.000493	0.0244	-0.12	-0.11	HDL cholesterol levels;	chr4:87128698	chr4:86913266~86914817:-
BRCA	cis	rs801193	0.569	rs2707824	ENSG00000265600.1	AC006480.1	-3.5	0.000493	0.0244	-0.13	-0.11	Aortic root size;	chr7:66724256	chr7:67356680~67356779:+
BRCA	cis	rs643177	1	rs643177	ENSG00000226004.1	RP11-10J5.1	-3.5	0.000493	0.0244	-0.1	-0.11	Psoriasis;Inflammatory skin disease;	chr6:137874556	chr6:137943079~137945802:-
BRCA	cis	rs539096	0.602	rs1143702	ENSG00000236200.4	KDM4A-AS1	-3.5	0.000493	0.0244	-0.12	-0.11	Intelligence (multi-trait analysis);	chr1:43621160	chr1:43699765~43708138:-
BRCA	cis	rs721917	0.525	rs7903576	ENSG00000278616.1	BEND3P3	-3.5	0.000493	0.0244	-0.1	-0.11	Chronic obstructive pulmonary disease;	chr10:79981386	chr10:79682997~79685436:+
BRCA	cis	rs4388249	1	rs1866372	ENSG00000271849.1	CTC-332L22.1	-3.5	0.000493	0.0244	-0.18	-0.11	Schizophrenia;	chr5:109704265	chr5:109687802~109688329:-
BRCA	cis	rs3732481	0.718	rs2222855	ENSG00000241560.4	ZBTB20-AS1	3.5	0.000493	0.0244	0.15	0.11	Mitochondrial DNA levels;	chr3:114721312	chr3:114351811~114388978:+
BRCA	cis	rs7172677	0.737	rs8029760	ENSG00000260269.4	CTD-2323K18.1	-3.5	0.000493	0.0244	-0.15	-0.11	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75143499	chr15:75527150~75601205:-
BRCA	cis	rs13108904	0.557	rs1250086	ENSG00000196810.4	CTBP1-AS2	-3.5	0.000493	0.0244	-0.13	-0.11	Obesity-related traits;	chr4:1254263	chr4:1249300~1288291:+
BRCA	cis	rs343496	0.877	rs340918	ENSG00000254017.1	IGHEP2	3.5	0.000493	0.0244	0.16	0.11	Asthma and hay fever;	chr9:6091048	chr9:5113549~5114804:+
BRCA	cis	rs9914544	0.689	rs8073236	ENSG00000264885.1	RP11-815I9.4	-3.5	0.000493	0.0244	-0.1	-0.11	Educational attainment (years of education);	chr17:18883869	chr17:18667629~18669461:-
BRCA	cis	rs17214007	0.877	rs10852376	ENSG00000279866.1	CTB-193M12.4	-3.5	0.000493	0.0244	-0.16	-0.11	Cognitive function;	chr16:15778216	chr16:15704410~15705984:+
BRCA	cis	rs250518	0.926	rs7709640	ENSG00000271926.1	CTD-2376I4.1	3.5	0.000493	0.0244	0.14	0.11	Mean corpuscular hemoglobin concentration;	chr5:72791653	chr5:72953635~72954274:-
BRCA	cis	rs8051149	0.652	rs9926829	ENSG00000261744.1	RP11-21B21.4	-3.5	0.000493	0.0244	-0.12	-0.11	Blood metabolite levels;	chr16:87849483	chr16:88512960~88531053:-
BRCA	cis	rs2337406	1	rs10459466	ENSG00000280411.1	IGHV1-69-2	-3.5	0.000493	0.0244	-0.11	-0.11	Alzheimer's disease (late onset);	chr14:106689255	chr14:106762092~106762588:-
BRCA	cis	rs6812193	0.518	rs28618267	ENSG00000271676.1	RP11-1E1.2	3.5	0.000493	0.0244	0.16	0.11	Parkinson's disease;	chr4:76270799	chr4:77112495~77113458:-
BRCA	cis	rs67073037	0.956	rs4666125	ENSG00000230730.1	AC074011.2	-3.5	0.000493	0.0244	-0.15	-0.11	Breast cancer;Breast cancer (estrogen-receptor negative);	chr2:28890057	chr2:28633282~28664540:-
BRCA	cis	rs7660883	0.86	rs10023050	ENSG00000251411.1	RP11-397E7.4	3.5	0.000493	0.0244	0.12	0.11	HDL cholesterol levels;	chr4:87143279	chr4:86913266~86914817:-
BRCA	cis	rs9311474	0.659	rs1133415	ENSG00000222345.1	SNORD19	3.5	0.000493	0.0244	0.11	0.11	Electroencephalogram traits;	chr3:52541815	chr3:52691378~52691453:+
BRCA	cis	rs7577894	0.507	rs1346787	ENSG00000272606.1	RP11-554J4.1	3.5	0.000493	0.0244	0.12	0.11	Amyotrophic lateral sclerosis;	chr2:55865477	chr2:55617909~55618373:+
BRCA	cis	rs1348850	0.747	rs1047884	ENSG00000280374.1	RP11-337N6.3	3.5	0.000493	0.0244	0.15	0.11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177623553	chr2:177317715~177318471:-
BRCA	cis	rs2243480	0.706	rs34466769	ENSG00000222364.1	RNU6-96P	-3.5	0.000493	0.0244	-0.17	-0.11	Diabetic kidney disease;	chr7:65988305	chr7:66395191~66395286:+
BRCA	cis	rs10129255	0.957	rs10136560	ENSG00000211959.2	IGHV4-39	3.5	0.000493	0.0244	0.08	0.11	Kawasaki disease;	chr14:106787630	chr14:106421711~106422218:-
BRCA	cis	rs9393777	0.546	rs9366673	ENSG00000241549.7	GUSBP2	3.5	0.000493	0.0244	0.15	0.11	Intelligence (multi-trait analysis);	chr6:26925550	chr6:26871484~26956554:-
BRCA	cis	rs875971	0.929	rs12535036	ENSG00000229886.1	RP5-1132H15.3	3.5	0.000493	0.0244	0.12	0.11	Aortic root size;	chr7:66499076	chr7:66025126~66031544:-
BRCA	cis	rs875971	1	rs6970030	ENSG00000229886.1	RP5-1132H15.3	3.5	0.000493	0.0244	0.12	0.11	Aortic root size;	chr7:66503692	chr7:66025126~66031544:-
BRCA	cis	rs875971	0.928	rs6970357	ENSG00000229886.1	RP5-1132H15.3	3.5	0.000493	0.0244	0.12	0.11	Aortic root size;	chr7:66503891	chr7:66025126~66031544:-
BRCA	cis	rs6545883	0.839	rs778764	ENSG00000212978.6	AC016747.3	3.5	0.000493	0.0244	0.14	0.11	Tuberculosis;	chr2:61558545	chr2:61141592~61144969:-
BRCA	cis	rs745109	0.882	rs6745875	ENSG00000273080.1	RP11-301O19.1	3.5	0.000493	0.0244	0.16	0.11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86503347	chr2:86195590~86196049:+
BRCA	cis	rs7578361	0.918	rs7569287	ENSG00000231969.1	AC144449.1	3.5	0.000493	0.0244	0.17	0.11	Acute lymphoblastic leukemia (childhood);	chr2:149523115	chr2:149587196~149848233:+
BRCA	cis	rs3764021	1	rs3764021	ENSG00000256594.6	RP11-705C15.2	3.5	0.000493	0.0244	0.13	0.11	Type 1 diabetes;	chr12:9681032	chr12:9633419~9658412:+
BRCA	cis	rs1538970	0.816	rs61788356	ENSG00000281133.1	AL355480.3	-3.5	0.000494	0.0244	-0.15	-0.11	Platelet count;	chr1:45541003	chr1:45580892~45580996:-
BRCA	cis	rs7239883	0.5	rs16976272	ENSG00000267652.1	RP11-188I24.1	3.5	0.000494	0.0244	0.16	0.11	Waist circumference;Body mass index;	chr18:42513342	chr18:41789162~41789395:-
BRCA	cis	rs4919687	0.55	rs12783444	ENSG00000236937.2	PTGES3P4	3.5	0.000494	0.0244	0.15	0.11	Colorectal cancer;	chr10:102720902	chr10:102845595~102845950:+
BRCA	cis	rs2905347	0.895	rs2905308	ENSG00000232949.1	AC002480.4	-3.5	0.000494	0.0244	-0.12	-0.11	Major depression and alcohol dependence;	chr7:22608575	chr7:22589705~22591622:+
BRCA	cis	rs131408	1	rs131408	ENSG00000244425.3	RN7SL268P	3.5	0.000494	0.0244	0.12	0.11	Peripheral artery disease;	chr22:23548649	chr22:23879493~23879790:-
BRCA	cis	rs3764021	0.527	rs10844537	ENSG00000260423.1	RP13-735L24.1	-3.5	0.000494	0.0244	-0.12	-0.11	Type 1 diabetes;	chr12:9709528	chr12:9367464~9397617:+
BRCA	cis	rs7586085	0.903	rs13431319	ENSG00000229195.1	AC009495.4	3.5	0.000494	0.0244	0.12	0.11	Total body bone mineral density;	chr2:165758067	chr2:165794857~165846091:-
BRCA	cis	rs6088580	0.524	rs4911437	ENSG00000279253.1	RP4-614O4.13	3.5	0.000494	0.0244	0.13	0.11	Glomerular filtration rate (creatinine);	chr20:34678345	chr20:35262727~35264187:-
BRCA	cis	rs889312	0.5	rs832570	ENSG00000237705.1	AC008937.2	3.49	0.000494	0.0244	0.11	0.11	Breast cancer (early onset);Breast cancer;	chr5:56860581	chr5:56842016~56862164:-
BRCA	cis	rs2692947	0.77	rs72492163	ENSG00000168992.4	OR7E102P	3.49	0.000494	0.0244	0.16	0.11	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95752068	chr2:95546531~95547545:+
BRCA	cis	rs5758511	0.633	rs5758690	ENSG00000231261.1	HMGN2P10	-3.49	0.000494	0.0244	-0.15	-0.11	Birth weight;	chr22:42272289	chr22:41709225~41709489:-
BRCA	cis	rs863345	0.604	rs11265016	ENSG00000176320.2	RP11-404O13.5	-3.49	0.000494	0.0244	-0.11	-0.11	Pneumococcal bacteremia;	chr1:158533995	chr1:158197922~158203877:-
BRCA	cis	rs863345	0.604	rs10908673	ENSG00000176320.2	RP11-404O13.5	-3.49	0.000494	0.0244	-0.11	-0.11	Pneumococcal bacteremia;	chr1:158534118	chr1:158197922~158203877:-
BRCA	cis	rs863345	0.604	rs10908674	ENSG00000176320.2	RP11-404O13.5	-3.49	0.000494	0.0244	-0.11	-0.11	Pneumococcal bacteremia;	chr1:158534130	chr1:158197922~158203877:-
BRCA	cis	rs863345	0.547	rs10908675	ENSG00000176320.2	RP11-404O13.5	-3.49	0.000494	0.0244	-0.11	-0.11	Pneumococcal bacteremia;	chr1:158534339	chr1:158197922~158203877:-
BRCA	cis	rs863345	0.604	rs7518708	ENSG00000176320.2	RP11-404O13.5	-3.49	0.000494	0.0244	-0.11	-0.11	Pneumococcal bacteremia;	chr1:158534484	chr1:158197922~158203877:-
BRCA	cis	rs863345	0.604	rs7533071	ENSG00000176320.2	RP11-404O13.5	-3.49	0.000494	0.0244	-0.11	-0.11	Pneumococcal bacteremia;	chr1:158534689	chr1:158197922~158203877:-
BRCA	cis	rs863345	0.564	rs7540999	ENSG00000176320.2	RP11-404O13.5	-3.49	0.000494	0.0244	-0.11	-0.11	Pneumococcal bacteremia;	chr1:158534780	chr1:158197922~158203877:-
BRCA	cis	rs2303319	0.504	rs1996265	ENSG00000227403.1	AC009299.3	-3.49	0.000494	0.0244	-0.28	-0.11	Cognitive function;	chr2:161843066	chr2:161244739~161249050:+
BRCA	cis	rs13434995	0.513	rs62305268	ENSG00000273257.1	RP11-177J6.1	-3.49	0.000494	0.0244	-0.16	-0.11	Adiponectin levels;	chr4:55506991	chr4:55387949~55388271:+
BRCA	cis	rs13434995	0.513	rs62305270	ENSG00000273257.1	RP11-177J6.1	-3.49	0.000494	0.0244	-0.16	-0.11	Adiponectin levels;	chr4:55507842	chr4:55387949~55388271:+
BRCA	cis	rs13434995	0.513	rs7681414	ENSG00000273257.1	RP11-177J6.1	-3.49	0.000494	0.0244	-0.16	-0.11	Adiponectin levels;	chr4:55508890	chr4:55387949~55388271:+
BRCA	cis	rs13434995	0.513	rs62305271	ENSG00000273257.1	RP11-177J6.1	-3.49	0.000494	0.0244	-0.16	-0.11	Adiponectin levels;	chr4:55509715	chr4:55387949~55388271:+
BRCA	cis	rs13434995	0.513	rs10462033	ENSG00000273257.1	RP11-177J6.1	-3.49	0.000494	0.0244	-0.16	-0.11	Adiponectin levels;	chr4:55511552	chr4:55387949~55388271:+
BRCA	cis	rs13434995	0.513	rs1915905	ENSG00000273257.1	RP11-177J6.1	-3.49	0.000494	0.0244	-0.16	-0.11	Adiponectin levels;	chr4:55512381	chr4:55387949~55388271:+
BRCA	cis	rs13434995	0.513	rs1522109	ENSG00000273257.1	RP11-177J6.1	-3.49	0.000494	0.0244	-0.16	-0.11	Adiponectin levels;	chr4:55514403	chr4:55387949~55388271:+
BRCA	cis	rs6040449	0.779	rs2223853	ENSG00000235036.4	RP5-1099D15.1	3.49	0.000494	0.0244	0.12	0.11	Relative hand skill;	chr20:11224235	chr20:10612861~10614229:-
BRCA	cis	rs5750830	0.594	rs1010170	ENSG00000280216.1	RP3-333H23.9	3.49	0.000494	0.0244	0.14	0.11	Intelligence (multi-trait analysis);	chr22:39382322	chr22:39379610~39380015:+
BRCA	cis	rs703108	0.752	rs4266963	ENSG00000279623.1	RP11-399C16.3	3.49	0.000494	0.0244	0.15	0.11	Monocyte percentage of white cells;	chr10:22055299	chr10:21865335~21865921:-
BRCA	cis	rs860295	0.557	rs11264372	ENSG00000232093.1	RP11-307C12.11	3.49	0.000494	0.0244	0.13	0.11	Body mass index;	chr1:155443139	chr1:155045191~155046118:-
BRCA	cis	rs4809760	0.692	rs8118160	ENSG00000224397.4	LINC01272	3.49	0.000494	0.0244	0.11	0.11	Gut microbiota (beta diversity);	chr20:49818099	chr20:50267486~50279795:+
BRCA	cis	rs12282928	0.959	rs4980427	ENSG00000255197.4	RP11-750H9.5	3.49	0.000495	0.0244	0.1	0.11	Migraine - clinic-based;	chr11:48274934	chr11:47383148~47409190:-
BRCA	cis	rs9388451	0.626	rs3734637	ENSG00000237742.5	RP11-624M8.1	-3.49	0.000495	0.0244	-0.13	-0.11	Brugada syndrome;	chr6:125760173	chr6:125578558~125749190:-
BRCA	cis	rs4835473	0.864	rs13117932	ENSG00000246448.2	RP13-578N3.3	-3.49	0.000495	0.0244	-0.12	-0.11	Immature fraction of reticulocytes;	chr4:143735873	chr4:143700257~143865072:+
BRCA	cis	rs4934494	0.723	rs17127001	ENSG00000232229.4	LINC00865	-3.49	0.000495	0.0245	-0.16	-0.11	Red blood cell count;	chr10:89762932	chr10:89829510~89840861:+
BRCA	cis	rs2688608	0.647	rs2461863	ENSG00000213731.2	RAB5CP1	-3.49	0.000495	0.0245	-0.12	-0.11	Inflammatory bowel disease;	chr10:73920478	chr10:74423435~74424014:-
BRCA	cis	rs8058578	1	rs3747481	ENSG00000275263.1	RP11-1072A3.4	-3.49	0.000495	0.0245	-0.14	-0.11	Multiple myeloma;	chr16:30655046	chr16:30956872~30957199:-
BRCA	cis	rs6928977	0.896	rs2614287	ENSG00000231028.7	LINC00271	3.49	0.000495	0.0245	0.11	0.11	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135371709	chr6:135497801~135716055:+
BRCA	cis	rs875971	0.505	rs2462573	ENSG00000229180.5	GS1-124K5.11	-3.49	0.000495	0.0245	-0.09	-0.11	Aortic root size;	chr7:66042405	chr7:66526088~66542624:-
BRCA	cis	rs62025270	0.688	rs7164373	ENSG00000259367.1	RP11-815J21.4	3.49	0.000495	0.0245	0.1	0.11	Idiopathic pulmonary fibrosis;	chr15:85722432	chr15:85619623~85670948:-
BRCA	cis	rs6500602	0.627	rs9934267	ENSG00000280063.1	RP11-295D4.3	3.49	0.000495	0.0245	0.08	0.11	Schizophrenia;	chr16:4484365	chr16:4346694~4348648:-
BRCA	cis	rs875971	0.929	rs12535036	ENSG00000273024.4	INTS4P2	-3.49	0.000495	0.0245	-0.12	-0.11	Aortic root size;	chr7:66499076	chr7:65647864~65715661:+
BRCA	cis	rs875971	1	rs6970030	ENSG00000273024.4	INTS4P2	-3.49	0.000495	0.0245	-0.12	-0.11	Aortic root size;	chr7:66503692	chr7:65647864~65715661:+
BRCA	cis	rs875971	0.928	rs6970357	ENSG00000273024.4	INTS4P2	-3.49	0.000495	0.0245	-0.12	-0.11	Aortic root size;	chr7:66503891	chr7:65647864~65715661:+
BRCA	cis	rs10908521	0.685	rs1998977	ENSG00000223356.1	RP11-66D17.5	3.49	0.000495	0.0245	0.13	0.11	Uric acid clearance;	chr1:156834329	chr1:156712212~156713174:-
BRCA	cis	rs959695	1	rs959695	ENSG00000253948.1	RP11-410L14.2	3.49	0.000495	0.0245	0.12	0.11	Hippocampal atrophy;	chr8:99822954	chr8:98996763~99013044:-
BRCA	cis	rs7632954	0.567	rs9813104	ENSG00000227110.5	LMCD1-AS1	3.49	0.000495	0.0245	0.13	0.11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr3:8492807	chr3:7952805~8611924:-
BRCA	cis	rs27434	0.583	rs34764	ENSG00000248734.2	CTD-2260A17.1	3.49	0.000495	0.0245	0.12	0.11	Ankylosing spondylitis;	chr5:96819526	chr5:96784777~96785999:+
BRCA	cis	rs2692947	0.832	rs2579519	ENSG00000232931.4	LINC00342	3.49	0.000495	0.0245	0.11	0.11	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96009418	chr2:95807118~95816215:-
BRCA	cis	rs2908197	0.843	rs2961041	ENSG00000205485.12	AC004980.7	3.49	0.000495	0.0245	0.12	0.11	3-hydroxypropylmercapturic acid levels in smokers;	chr7:76316627	chr7:76549360~76627982:+
BRCA	cis	rs2908197	0.843	rs2908193	ENSG00000205485.12	AC004980.7	3.49	0.000495	0.0245	0.12	0.11	3-hydroxypropylmercapturic acid levels in smokers;	chr7:76316628	chr7:76549360~76627982:+
BRCA	cis	rs1510272	0.69	rs10513491	ENSG00000243926.1	TIPARP-AS1	-3.49	0.000495	0.0245	-0.12	-0.11	Testicular germ cell tumor;	chr3:156602441	chr3:156671862~156674378:-
BRCA	cis	rs4243971	0.516	rs6141282	ENSG00000277692.1	RP11-358N2.2	-3.49	0.000495	0.0245	-0.12	-0.11	Inflammatory bowel disease;Crohn's disease;	chr20:32289514	chr20:32355053~32355734:+
BRCA	cis	rs4950322	0.57	rs111370771	ENSG00000237188.3	RP11-337C18.8	3.49	0.000495	0.0245	0.14	0.11	Protein quantitative trait loci;	chr1:147261420	chr1:147172771~147211568:+
BRCA	cis	rs17221829	0.645	rs11018705	ENSG00000280385.1	AP000648.5	-3.49	0.000495	0.0245	-0.12	-0.11	Anxiety in major depressive disorder;	chr11:89649532	chr11:90193614~90198120:+
BRCA	cis	rs745109	0.938	rs56875109	ENSG00000273080.1	RP11-301O19.1	3.49	0.000495	0.0245	0.16	0.11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86498246	chr2:86195590~86196049:+
BRCA	cis	rs875971	0.862	rs6978028	ENSG00000271064.1	RP11-792A8.3	-3.49	0.000495	0.0245	-0.13	-0.11	Aortic root size;	chr7:66421313	chr7:66748838~66749077:-
BRCA	cis	rs818427	1	rs382260	ENSG00000279522.1	CTC-487M23.6	3.49	0.000495	0.0245	0.12	0.11	Total body bone mineral density;	chr5:112874647	chr5:112894933~112896531:+
BRCA	cis	rs4930561	0.739	rs12225316	ENSG00000255306.1	RP5-901A4.1	-3.49	0.000495	0.0245	-0.11	-0.11	Breast cancer in childhood cancer survivors;IgG glycosylation;	chr11:68208536	chr11:68024809~68030461:-
BRCA	cis	rs11902236	0.534	rs12614762	ENSG00000188525.3	AC010969.1	-3.49	0.000495	0.0245	-0.12	-0.11	Prostate cancer;	chr2:9978849	chr2:10003158~10006030:-
BRCA	cis	rs7620503	0.721	rs11709335	ENSG00000277241.1	RP11-114M1.3	3.49	0.000495	0.0245	0.13	0.11	Corneal structure;	chr3:177591101	chr3:177700346~177701072:-
BRCA	cis	rs13256369	1	rs4840352	ENSG00000254153.1	CTA-398F10.2	3.49	0.000495	0.0245	0.15	0.11	Obesity-related traits;	chr8:8715998	chr8:8456909~8461337:-
BRCA	cis	rs801193	0.527	rs2707837	ENSG00000265600.1	AC006480.1	-3.49	0.000495	0.0245	-0.13	-0.11	Aortic root size;	chr7:66716086	chr7:67356680~67356779:+
BRCA	cis	rs6831256	0.583	rs10937929	ENSG00000261643.1	RP11-529E10.6	3.49	0.000496	0.0245	0.13	0.11	LDL cholesterol;Cholesterol, total;Triglycerides;Triglyceride levels;	chr4:3481310	chr4:3503597~3504457:-
BRCA	cis	rs6840360	0.571	rs62327277	ENSG00000270265.1	RP11-731D1.4	-3.49	0.000496	0.0245	-0.13	-0.11	Intelligence (multi-trait analysis);	chr4:151634753	chr4:151333775~151353224:-
BRCA	cis	rs6599077	0.95	rs11707830	ENSG00000223797.4	ENTPD3-AS1	3.49	0.000496	0.0245	0.14	0.11	Sleep-related phenotypes;	chr3:40069463	chr3:40313802~40453329:-
BRCA	cis	rs17331151	0.573	rs11718060	ENSG00000270941.1	RP5-966M1.5	-3.49	0.000496	0.0245	-0.19	-0.11	Immune reponse to smallpox (secreted IL-2);	chr3:52841530	chr3:52734735~52735013:+
BRCA	cis	rs4950322	0.58	rs7515160	ENSG00000227242.3	NBPF13P	-3.49	0.000496	0.0245	-0.15	-0.11	Protein quantitative trait loci;	chr1:147120714	chr1:147021320~147124525:-
BRCA	cis	rs465969	0.744	rs7758483	ENSG00000271789.1	RP5-1112D6.7	3.49	0.000496	0.0245	0.24	0.11	Psoriasis;	chr6:111467945	chr6:111297126~111298510:+
BRCA	cis	rs6088580	0.524	rs7269596	ENSG00000126005.14	MMP24-AS1	3.49	0.000496	0.0245	0.12	0.11	Glomerular filtration rate (creatinine);	chr20:34641259	chr20:35216462~35278131:-
BRCA	cis	rs7686660	0.517	rs10471102	ENSG00000250326.1	RP11-284M14.1	-3.49	0.000496	0.0245	-0.12	-0.11	Asthma;	chr4:143110859	chr4:142933195~143184861:-
BRCA	cis	rs73215715	0.517	rs10452944	ENSG00000238358.2	RP5-1121E10.2	3.49	0.000496	0.0245	0.15	0.11	Heschl's gyrus morphology;	chr7:90015975	chr7:90119299~90122890:-
BRCA	cis	rs952623	1	rs1918723	ENSG00000211694.2	TRGV10	3.49	0.000496	0.0245	0.09	0.11	Intelligence (multi-trait analysis);	chr7:38999461	chr7:38299811~38300322:-
BRCA	cis	rs2651244	0.965	rs12043275	ENSG00000229051.1	RP5-952N6.1	3.49	0.000496	0.0245	0.11	0.11	Inflammatory bowel disease;Ulcerative colitis;	chr1:70560578	chr1:70706453~70786468:+
BRCA	cis	rs308447	0.516	rs6815982	ENSG00000224786.1	CETN4P	-3.49	0.000496	0.0245	-0.16	-0.11	Perceived unattractiveness to mosquitoes;	chr4:122756317	chr4:122730548~122732193:-
BRCA	cis	rs738144	0.502	rs9611034	ENSG00000229598.1	PRDX3P1	-3.49	0.000496	0.0245	-0.11	-0.11	IgG glycosylation;	chr22:38834879	chr22:38722743~38723505:-
BRCA	cis	rs9788682	0.747	rs2656073	ENSG00000261143.1	ADAMTS7P3	-3.49	0.000496	0.0245	-0.15	-0.11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78449934	chr15:77976042~77993057:+
BRCA	cis	rs55883249	1	rs17453752	ENSG00000217258.2	AC007249.3	-3.49	0.000496	0.0245	-0.17	-0.11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:9626042	chr2:10452319~10455552:+
BRCA	cis	rs13256369	0.851	rs13258283	ENSG00000254153.1	CTA-398F10.2	3.49	0.000496	0.0245	0.15	0.11	Obesity-related traits;	chr8:8706120	chr8:8456909~8461337:-
BRCA	cis	rs13256369	0.851	rs13249700	ENSG00000254153.1	CTA-398F10.2	3.49	0.000496	0.0245	0.15	0.11	Obesity-related traits;	chr8:8706127	chr8:8456909~8461337:-
BRCA	cis	rs13256369	0.851	rs13255061	ENSG00000254153.1	CTA-398F10.2	3.49	0.000496	0.0245	0.15	0.11	Obesity-related traits;	chr8:8706324	chr8:8456909~8461337:-
BRCA	cis	rs13256369	0.851	rs12541477	ENSG00000254153.1	CTA-398F10.2	3.49	0.000496	0.0245	0.15	0.11	Obesity-related traits;	chr8:8706385	chr8:8456909~8461337:-
BRCA	cis	rs4703129	0.9	rs13152846	ENSG00000246763.5	RGMB-AS1	-3.49	0.000496	0.0245	-0.12	-0.11	Asperger disorder;	chr5:98557369	chr5:98769618~98773469:-
BRCA	cis	rs13315871	0.929	rs13080398	ENSG00000272182.1	RP11-802O23.3	3.49	0.000496	0.0245	0.22	0.11	Cholesterol, total;	chr3:58314555	chr3:58428255~58428815:+
BRCA	cis	rs13315871	0.929	rs9837903	ENSG00000272182.1	RP11-802O23.3	3.49	0.000496	0.0245	0.22	0.11	Cholesterol, total;	chr3:58316179	chr3:58428255~58428815:+
BRCA	cis	rs2574985	0.962	rs1203420	ENSG00000231345.3	BEND3P1	-3.49	0.000496	0.0245	-0.17	-0.11	Subjective well-being;	chr10:50423286	chr10:50655967~50660472:+
BRCA	cis	rs7020830	0.931	rs13295115	ENSG00000260100.1	RP11-220I1.5	-3.49	0.000496	0.0245	-0.14	-0.11	Schizophrenia;	chr9:37157967	chr9:37078813~37079776:-
BRCA	cis	rs875971	0.964	rs6978429	ENSG00000229886.1	RP5-1132H15.3	3.49	0.000496	0.0245	0.12	0.11	Aortic root size;	chr7:66494889	chr7:66025126~66031544:-
BRCA	cis	rs875971	1	rs4718357	ENSG00000229886.1	RP5-1132H15.3	3.49	0.000496	0.0245	0.12	0.11	Aortic root size;	chr7:66495891	chr7:66025126~66031544:-
BRCA	cis	rs4578769	0.918	rs9957390	ENSG00000273232.1	RP11-370A5.2	3.49	0.000496	0.0245	0.14	0.11	Eosinophil percentage of white cells;	chr18:22840421	chr18:22882825~22883357:-
BRCA	cis	rs7267979	1	rs6050617	ENSG00000231081.1	RP4-760C5.3	-3.49	0.000496	0.0245	-0.14	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25441012	chr20:26008791~26010531:-
BRCA	cis	rs7267979	0.933	rs2387887	ENSG00000231081.1	RP4-760C5.3	-3.49	0.000496	0.0245	-0.14	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25446445	chr20:26008791~26010531:-
BRCA	cis	rs7267979	1	rs6037121	ENSG00000231081.1	RP4-760C5.3	-3.49	0.000496	0.0245	-0.14	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25447675	chr20:26008791~26010531:-
BRCA	cis	rs7267979	1	rs1047171	ENSG00000231081.1	RP4-760C5.3	-3.49	0.000496	0.0245	-0.14	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25448150	chr20:26008791~26010531:-
BRCA	cis	rs7267979	1	rs6050629	ENSG00000231081.1	RP4-760C5.3	-3.49	0.000496	0.0245	-0.14	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25450044	chr20:26008791~26010531:-
BRCA	cis	rs7267979	1	rs6050630	ENSG00000231081.1	RP4-760C5.3	-3.49	0.000496	0.0245	-0.14	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25450109	chr20:26008791~26010531:-
BRCA	cis	rs6708331	0.941	rs10173259	ENSG00000231024.1	AC092431.3	-3.49	0.000496	0.0245	-0.15	-0.11	Obesity-related traits;	chr2:70140078	chr2:69700192~69713847:-
BRCA	cis	rs6866721	0.609	rs712616	ENSG00000249167.1	CTB-118N6.2	3.49	0.000496	0.0245	0.13	0.11	Body mass index;	chr5:116886130	chr5:116574482~116591398:+
BRCA	cis	rs9951698	0.667	rs567031	ENSG00000266969.1	RP11-773H22.4	3.49	0.000496	0.0245	0.14	0.11	Intelligence (multi-trait analysis);	chr18:13093775	chr18:12984694~12991173:-
BRCA	cis	rs7267979	1	rs6050632	ENSG00000231081.1	RP4-760C5.3	-3.49	0.000496	0.0245	-0.14	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25451965	chr20:26008791~26010531:-
BRCA	cis	rs4835473	0.932	rs34257944	ENSG00000246448.2	RP13-578N3.3	-3.49	0.000496	0.0245	-0.12	-0.11	Immature fraction of reticulocytes;	chr4:143736443	chr4:143700257~143865072:+
BRCA	cis	rs10911902	0.643	rs3736597	ENSG00000229739.2	RP11-295K2.3	-3.49	0.000496	0.0245	-0.15	-0.11	Schizophrenia;	chr1:186331918	chr1:186435161~186470291:+
BRCA	cis	rs3743266	0.613	rs12442393	ENSG00000245534.5	RORA-AS1	3.49	0.000497	0.0245	0.12	0.11	Menarche (age at onset);	chr15:60442261	chr15:60479178~60630637:+
BRCA	cis	rs4835473	0.838	rs4583708	ENSG00000246448.2	RP13-578N3.3	-3.49	0.000497	0.0245	-0.12	-0.11	Immature fraction of reticulocytes;	chr4:143735610	chr4:143700257~143865072:+
BRCA	cis	rs4650943	0.503	rs10913145	ENSG00000227740.1	RP11-318C24.2	3.49	0.000497	0.0245	0.11	0.11	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in inactive individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr1:176163466	chr1:175904762~175920513:-
BRCA	cis	rs516805	0.63	rs696650	ENSG00000279114.1	RP3-425C14.5	-3.49	0.000497	0.0245	-0.13	-0.11	Lymphocyte counts;	chr6:122261316	chr6:122471923~122484161:+
BRCA	cis	rs4078252	0.671	rs13183638	ENSG00000279522.1	CTC-487M23.6	-3.49	0.000497	0.0245	-0.12	-0.11	Response to cytadine analogues (cytosine arabinoside);	chr5:113114667	chr5:112894933~112896531:+
BRCA	cis	rs8099594	0.538	rs577081	ENSG00000266696.1	RP11-30L3.2	3.49	0.000497	0.0245	0.13	0.11	Height;	chr18:49314192	chr18:49205912~49208781:+
BRCA	cis	rs2712184	0.756	rs2712181	ENSG00000237930.1	AC007563.4	-3.49	0.000497	0.0245	-0.11	-0.11	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);	chr2:216790146	chr2:216785774~216786144:-
BRCA	cis	rs321358	0.895	rs17536059	ENSG00000271390.1	RP11-89C3.3	-3.49	0.000497	0.0245	-0.16	-0.11	Body mass index;	chr11:111086611	chr11:111089870~111090368:-
BRCA	cis	rs7246657	0.653	rs10414983	ENSG00000267470.4	ZNF571-AS1	3.49	0.000497	0.0245	0.16	0.11	Coronary artery calcification;	chr19:37174830	chr19:37548914~37587348:+
BRCA	cis	rs7246657	0.598	rs10405372	ENSG00000267470.4	ZNF571-AS1	3.49	0.000497	0.0245	0.16	0.11	Coronary artery calcification;	chr19:37177873	chr19:37548914~37587348:+
BRCA	cis	rs7246657	0.653	rs4805207	ENSG00000267470.4	ZNF571-AS1	3.49	0.000497	0.0245	0.16	0.11	Coronary artery calcification;	chr19:37182831	chr19:37548914~37587348:+
BRCA	cis	rs4308124	1	rs62160391	ENSG00000271590.1	RP11-181E10.3	3.49	0.000497	0.0245	0.11	0.11	Vitiligo;	chr2:111251258	chr2:111210995~111212476:-
BRCA	cis	rs1670533	1	rs11731320	ENSG00000251639.2	RP11-20I20.1	3.49	0.000497	0.0245	0.17	0.11	Recombination rate (females);	chr4:1064128	chr4:1100016~1101558:-
BRCA	cis	rs4415084	1	rs2165009	ENSG00000272335.1	RP11-53O19.3	3.49	0.000497	0.0245	0.1	0.11	Breast cancer;	chr5:44697814	chr5:44826076~44828592:+
BRCA	cis	rs13256369	1	rs873064	ENSG00000254153.1	CTA-398F10.2	3.49	0.000497	0.0245	0.15	0.11	Obesity-related traits;	chr8:8714870	chr8:8456909~8461337:-
BRCA	cis	rs10986311	0.814	rs7861040	ENSG00000227200.1	RP11-121A14.3	-3.49	0.000497	0.0245	-0.13	-0.11	Vitiligo;	chr9:124281856	chr9:124262876~124265809:+
BRCA	cis	rs673253	0.686	rs501299	ENSG00000229431.1	RP1-92O14.6	-3.49	0.000497	0.0245	-0.11	-0.11	Intelligence (multi-trait analysis);	chr1:43586163	chr1:43385113~43389155:+
BRCA	cis	rs875971	0.929	rs34406470	ENSG00000229886.1	RP5-1132H15.3	3.49	0.000497	0.0245	0.12	0.11	Aortic root size;	chr7:66464969	chr7:66025126~66031544:-
BRCA	cis	rs11673344	0.931	rs1234251	ENSG00000267682.1	CTD-3220F14.2	-3.49	0.000497	0.0245	-0.09	-0.11	Obesity-related traits;	chr19:37180354	chr19:37337236~37337743:+
BRCA	cis	rs875971	1	rs12532998	ENSG00000273024.4	INTS4P2	-3.49	0.000497	0.0245	-0.12	-0.11	Aortic root size;	chr7:66502472	chr7:65647864~65715661:+
BRCA	cis	rs7172689	1	rs67766197	ENSG00000271725.1	RP11-761I4.4	3.49	0.000497	0.0245	0.16	0.11	Inattentive symptoms;	chr15:81247610	chr15:81303215~81309391:-
BRCA	cis	rs7172689	1	rs59545248	ENSG00000271725.1	RP11-761I4.4	3.49	0.000497	0.0245	0.16	0.11	Inattentive symptoms;	chr15:81248089	chr15:81303215~81309391:-
BRCA	cis	rs1538138	0.955	rs7773801	ENSG00000224995.1	LINC01526	-3.49	0.000497	0.0245	-0.14	-0.11	Corneal structure;	chr6:82088876	chr6:81813286~81814157:-
BRCA	cis	rs2305707	0.544	rs936307	ENSG00000273674.3	CTD-2378E12.1	3.49	0.000497	0.0245	0.21	0.11	Height;	chr15:51287778	chr15:50839875~50908599:-
BRCA	cis	rs317865	0.867	rs73234625	ENSG00000263327.5	TAPT1-AS1	-3.49	0.000497	0.0245	-0.19	-0.11	Kidney disease (early stage) in type 1 diabetes;	chr4:16164583	chr4:16226685~16320140:+
BRCA	cis	rs683250	0.629	rs656515	ENSG00000254551.1	RP11-727A23.7	3.49	0.000497	0.0245	0.14	0.11	Subcortical brain region volumes;	chr11:83257666	chr11:83209431~83213379:-
BRCA	cis	rs12906542	0.516	rs4886992	ENSG00000259792.1	RP11-114H24.6	-3.49	0.000497	0.0245	-0.16	-0.11	Breast cancer;	chr15:78032887	chr15:77993405~77995289:+
BRCA	cis	rs7824557	0.652	rs12677504	ENSG00000154316.13	TDH	3.49	0.000497	0.0245	0.15	0.11	Retinal vascular caliber;	chr8:11275666	chr8:11339637~11368452:+
BRCA	cis	rs875971	1	rs709595	ENSG00000272831.1	RP11-792A8.4	3.49	0.000497	0.0245	0.1	0.11	Aortic root size;	chr7:66352346	chr7:66739829~66740385:-
BRCA	cis	rs875971	1	rs811880	ENSG00000272831.1	RP11-792A8.4	3.49	0.000497	0.0245	0.1	0.11	Aortic root size;	chr7:66353659	chr7:66739829~66740385:-
BRCA	cis	rs2524005	1	rs2524005	ENSG00000235238.1	SUMO2P1	3.49	0.000497	0.0246	0.15	0.11	Bipolar disorder and schizophrenia;	chr6:29931900	chr6:29636060~29636343:-
BRCA	cis	rs877819	0.697	rs6537581	ENSG00000228403.1	RP11-563N6.6	-3.49	0.000497	0.0246	-0.11	-0.11	Systemic lupus erythematosus;	chr10:48838075	chr10:48878022~48878649:+
BRCA	cis	rs7172809	0.561	rs28712147	ENSG00000260139.5	CSPG4P13	-3.49	0.000497	0.0246	-0.13	-0.11	Glucose homeostasis traits;	chr15:77552319	chr15:77894684~77904674:+
BRCA	cis	rs897984	0.542	rs7197717	ENSG00000275263.1	RP11-1072A3.4	-3.49	0.000497	0.0246	-0.13	-0.11	Dementia with Lewy bodies;	chr16:31071754	chr16:30956872~30957199:-
BRCA	cis	rs830124	0.929	rs10840627	ENSG00000272849.1	RP11-347I19.8	-3.49	0.000497	0.0246	-0.12	-0.11	Urinary metabolites;	chr12:121869674	chr12:121797511~121801972:+
BRCA	cis	rs4372836	0.543	rs11686412	ENSG00000226833.4	AC097724.3	3.49	0.000497	0.0246	0.13	0.11	Body mass index;	chr2:28769539	chr2:28708953~28736205:-
BRCA	cis	rs875971	0.862	rs6952182	ENSG00000229886.1	RP5-1132H15.3	-3.49	0.000497	0.0246	-0.12	-0.11	Aortic root size;	chr7:66218330	chr7:66025126~66031544:-
BRCA	cis	rs1816752	0.819	rs7985478	ENSG00000273628.1	RP11-756A22.7	3.49	0.000497	0.0246	0.13	0.11	Obesity-related traits;	chr13:24417135	chr13:24933006~24936796:+
BRCA	cis	rs853679	0.882	rs9380069	ENSG00000204709.4	LINC01556	3.49	0.000497	0.0246	0.2	0.11	Depression;	chr6:28235522	chr6:28943877~28944537:+
BRCA	cis	rs4819052	0.851	rs2838858	ENSG00000215447.6	BX322557.10	-3.49	0.000497	0.0246	-0.11	-0.11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45261178	chr21:45288052~45291738:+
BRCA	cis	rs8180040	0.654	rs11714373	ENSG00000280667.1	Y_RNA	-3.49	0.000497	0.0246	-0.12	-0.11	Colorectal cancer;	chr3:47173327	chr3:47501083~47501182:+
BRCA	cis	rs6565180	0.926	rs12446288	ENSG00000261332.1	RP11-297C4.1	3.49	0.000497	0.0246	0.14	0.11	Tonsillectomy;	chr16:30377388	chr16:30498766~30499554:-
BRCA	cis	rs7819412	0.668	rs2409714	ENSG00000255020.1	AF131216.5	3.49	0.000498	0.0246	0.13	0.11	Triglycerides;	chr8:11152608	chr8:11345748~11347502:-
BRCA	cis	rs9325144	0.513	rs7977596	ENSG00000257718.1	RP11-396F22.1	-3.49	0.000498	0.0246	-0.11	-0.11	Morning vs. evening chronotype;	chr12:38255265	chr12:38906451~38909592:+
BRCA	cis	rs9325144	0.56	rs12424821	ENSG00000257718.1	RP11-396F22.1	-3.49	0.000498	0.0246	-0.11	-0.11	Morning vs. evening chronotype;	chr12:38256149	chr12:38906451~38909592:+
BRCA	cis	rs524281	0.861	rs9645684	ENSG00000255557.1	RP11-770G2.2	3.49	0.000498	0.0246	0.15	0.11	Electroencephalogram traits;	chr11:66140493	chr11:65745729~65771585:+
BRCA	cis	rs9402743	0.632	rs6570040	ENSG00000231028.7	LINC00271	-3.49	0.000498	0.0246	-0.11	-0.11	Systemic lupus erythematosus;	chr6:135779557	chr6:135497801~135716055:+
BRCA	cis	rs7267979	1	rs2424712	ENSG00000231081.1	RP4-760C5.3	-3.49	0.000498	0.0246	-0.14	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25436306	chr20:26008791~26010531:-
BRCA	cis	rs7267979	0.966	rs2424714	ENSG00000231081.1	RP4-760C5.3	-3.49	0.000498	0.0246	-0.14	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25438045	chr20:26008791~26010531:-
BRCA	cis	rs7267979	0.966	rs2424715	ENSG00000231081.1	RP4-760C5.3	-3.49	0.000498	0.0246	-0.14	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25439441	chr20:26008791~26010531:-
BRCA	cis	rs1555133	0.694	rs3787373	ENSG00000277692.1	RP11-358N2.2	-3.49	0.000498	0.0246	-0.12	-0.11	Monocyte count;	chr20:32285519	chr20:32355053~32355734:+
BRCA	cis	rs7746199	0.736	rs34064842	ENSG00000216901.1	AL022393.7	3.49	0.000498	0.0246	0.27	0.11	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27720846	chr6:28176188~28176674:+
BRCA	cis	rs875971	1	rs6460296	ENSG00000271064.1	RP11-792A8.3	-3.49	0.000498	0.0246	-0.12	-0.11	Aortic root size;	chr7:66430152	chr7:66748838~66749077:-
BRCA	cis	rs8081187	0.71	rs17803815	ENSG00000276250.1	CTD-2349P21.12	-3.49	0.000498	0.0246	-0.21	-0.11	Breast cancer;	chr17:30376863	chr17:30803654~30804077:+
BRCA	cis	rs76798021	0.935	rs11712998	ENSG00000271976.1	RP11-884K10.7	3.49	0.000498	0.0246	0.14	0.11	Lung function (FEV1/FVC);	chr3:53654931	chr3:53858994~53861576:-
BRCA	cis	rs997295	0.57	rs60066681	ENSG00000259673.4	IQCH-AS1	3.49	0.000498	0.0246	0.12	0.11	Motion sickness;	chr15:67515738	chr15:67403619~67521844:-
BRCA	cis	rs6142102	0.961	rs4911401	ENSG00000206582.1	Y_RNA	-3.49	0.000498	0.0246	-0.13	-0.11	Skin pigmentation;	chr20:34066756	chr20:34526510~34526606:-
BRCA	cis	rs875971	1	rs1544549	ENSG00000230189.5	GS1-124K5.2	-3.49	0.000498	0.0246	-0.09	-0.11	Aortic root size;	chr7:66625676	chr7:66409143~66490059:-
BRCA	cis	rs300890	1	rs300893	ENSG00000250326.1	RP11-284M14.1	-3.49	0.000498	0.0246	-0.12	-0.11	Nasopharyngeal carcinoma;	chr4:143335963	chr4:142933195~143184861:-
BRCA	cis	rs300890	0.931	rs300892	ENSG00000250326.1	RP11-284M14.1	-3.49	0.000498	0.0246	-0.12	-0.11	Nasopharyngeal carcinoma;	chr4:143335998	chr4:142933195~143184861:-
BRCA	cis	rs891378	1	rs6700168	ENSG00000274245.1	RP11-357P18.2	3.49	0.000498	0.0246	0.14	0.11	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207329189	chr1:207372559~207373252:+
BRCA	cis	rs12586478	0.538	rs1505150	ENSG00000205562.2	RP11-497E19.1	3.49	0.000498	0.0246	0.1	0.11	Post bronchodilator FEV1;	chr14:86328740	chr14:85524432~85529988:-
BRCA	cis	rs875971	0.862	rs801194	ENSG00000106610.13	STAG3L4	3.49	0.000498	0.0246	0.14	0.11	Aortic root size;	chr7:66563508	chr7:67302621~67321526:+
BRCA	cis	rs877819	0.697	rs7912174	ENSG00000228403.1	RP11-563N6.6	3.49	0.000498	0.0246	0.11	0.11	Systemic lupus erythematosus;	chr10:48837426	chr10:48878022~48878649:+
BRCA	cis	rs6582630	0.555	rs7294313	ENSG00000257718.1	RP11-396F22.1	-3.49	0.000499	0.0246	-0.11	-0.11	Drug-induced liver injury (flucloxacillin);	chr12:37929801	chr12:38906451~38909592:+
BRCA	cis	rs17711722	0.701	rs4467826	ENSG00000223473.2	GS1-124K5.3	3.49	0.000499	0.0246	0.08	0.11	Calcium levels;	chr7:65903721	chr7:66491049~66493566:-
BRCA	cis	rs11858159	1	rs7496600	ENSG00000207279.1	SNORD116-24	-3.49	0.000499	0.0246	-0.11	-0.11	Platelet thrombus formation;	chr15:24570865	chr15:25094037~25094128:+
BRCA	cis	rs7954584	0.583	rs6486782	ENSG00000212694.7	LINC01089	-3.49	0.000499	0.0246	-0.08	-0.11	Mean corpuscular volume;	chr12:121921266	chr12:121795267~121803906:-
BRCA	cis	rs6600671	1	rs2319969	ENSG00000275131.1	CH17-472G23.4	-3.49	0.000499	0.0246	-0.1	-0.11	Hip geometry;	chr1:121465481	chr1:120489625~120579190:-
BRCA	cis	rs1005277	0.522	rs1208681	ENSG00000099251.13	HSD17B7P2	3.49	0.000499	0.0246	0.12	0.11	Extrinsic epigenetic age acceleration;	chr10:37804047	chr10:38356380~38378505:+
BRCA	cis	rs853679	0.546	rs175597	ENSG00000216676.2	RP1-15D7.1	-3.49	0.000499	0.0246	-0.19	-0.11	Depression;	chr6:27842848	chr6:27652602~27652825:-
BRCA	cis	rs28595532	1	rs11938970	ENSG00000248213.3	CICP16	-3.49	0.000499	0.0246	-0.18	-0.11	Cannabis dependence symptom count;	chr4:118738997	chr4:118635970~118638782:-
BRCA	cis	rs12760731	0.565	rs7550699	ENSG00000213057.5	C1orf220	3.49	0.000499	0.0246	0.16	0.11	Obesity-related traits;	chr1:178240449	chr1:178542752~178548889:+
BRCA	cis	rs9309473	0.632	rs11885217	ENSG00000163016.8	ALMS1P	3.49	0.000499	0.0246	0.13	0.11	Metabolite levels;	chr2:73326080	chr2:73644919~73685576:+
BRCA	cis	rs9863	0.931	rs6488914	ENSG00000269938.1	RP11-214K3.20	3.49	0.000499	0.0246	0.12	0.11	White blood cell count;	chr12:123963294	chr12:123968023~123968579:-
BRCA	cis	rs9788682	0.747	rs8042059	ENSG00000279373.1	RP11-650L12.4	-3.49	0.000499	0.0246	-0.14	-0.11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78615517	chr15:78537681~78538946:+
BRCA	cis	rs2929278	0.617	rs3986209	ENSG00000201136.1	RNU6-353P	-3.49	0.000499	0.0246	-0.15	-0.11	Schizophrenia;	chr15:43758675	chr15:43702363~43702470:+
BRCA	cis	rs78545713	0.649	rs11751062	ENSG00000241549.7	GUSBP2	-3.49	0.000499	0.0246	-0.18	-0.11	Iron status biomarkers (total iron binding capacity);	chr6:26215937	chr6:26871484~26956554:-
BRCA	cis	rs78545713	0.649	rs41266811	ENSG00000241549.7	GUSBP2	-3.49	0.000499	0.0246	-0.18	-0.11	Iron status biomarkers (total iron binding capacity);	chr6:26216428	chr6:26871484~26956554:-
BRCA	cis	rs654950	0.841	rs2759247	ENSG00000230638.4	RP11-486B10.4	3.49	0.000499	0.0246	0.14	0.11	Airway imaging phenotypes;	chr1:41526085	chr1:41542069~41544310:+
BRCA	cis	rs654950	0.841	rs2810549	ENSG00000230638.4	RP11-486B10.4	3.49	0.000499	0.0246	0.14	0.11	Airway imaging phenotypes;	chr1:41526090	chr1:41542069~41544310:+
BRCA	cis	rs6964587	0.869	rs405	ENSG00000188693.7	CYP51A1-AS1	3.49	0.000499	0.0246	0.12	0.11	Breast cancer;	chr7:91917013	chr7:92134604~92180725:+
BRCA	cis	rs875971	0.862	rs1981799	ENSG00000271064.1	RP11-792A8.3	-3.49	0.000499	0.0246	-0.12	-0.11	Aortic root size;	chr7:66490572	chr7:66748838~66749077:-
BRCA	cis	rs12724450	0.546	rs11801255	ENSG00000228126.1	FALEC	3.49	0.000499	0.0246	0.2	0.11	Blood protein levels;	chr1:150451824	chr1:150515757~150518032:+
BRCA	cis	rs4650943	0.503	rs12034255	ENSG00000227740.1	RP11-318C24.2	3.49	0.000499	0.0246	0.11	0.11	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in inactive individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr1:176156162	chr1:175904762~175920513:-
BRCA	cis	rs8114671	0.562	rs2378292	ENSG00000126005.14	MMP24-AS1	-3.49	0.000499	0.0246	-0.13	-0.11	Height;	chr20:34897375	chr20:35216462~35278131:-
BRCA	cis	rs10043228	1	rs12153717	ENSG00000271918.1	CTD-2287O16.5	-3.49	0.000499	0.0246	-0.16	-0.11	Asthma or chronic obstructive pulmonary disease;	chr5:116236217	chr5:116083807~116085416:-
BRCA	cis	rs17756712	0.725	rs17135234	ENSG00000272463.1	RP11-532F6.3	3.49	0.000499	0.0246	0.19	0.11	Vertical cup-disc ratio;	chr6:593109	chr6:708592~711405:-
BRCA	cis	rs7267979	0.586	rs1007708	ENSG00000274414.1	RP5-965G21.4	-3.49	0.000499	0.0246	-0.12	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25210323	chr20:25239007~25245229:-
BRCA	cis	rs9788721	0.836	rs2656065	ENSG00000261762.1	RP11-650L12.2	-3.49	0.000499	0.0246	-0.12	-0.11	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78458207	chr15:78589123~78591276:-
BRCA	cis	rs2346177	1	rs2346177	ENSG00000279254.1	RP11-536C12.1	3.49	0.000499	0.0246	0.13	0.11	HDL cholesterol;	chr2:46415110	chr2:46668870~46670778:+
BRCA	cis	rs13256369	0.802	rs12681326	ENSG00000254153.1	CTA-398F10.2	3.49	0.000499	0.0246	0.15	0.11	Obesity-related traits;	chr8:8708879	chr8:8456909~8461337:-
BRCA	cis	rs6460942	0.778	rs76030612	ENSG00000226690.5	AC005281.1	3.49	0.000499	0.0246	0.18	0.11	Coronary artery disease;	chr7:12423311	chr7:12496429~12541910:+
BRCA	cis	rs17711722	0.701	rs781143	ENSG00000273142.1	RP11-458F8.4	-3.49	5e-04	0.0247	-0.09	-0.11	Calcium levels;	chr7:65974892	chr7:66902857~66906297:+
BRCA	cis	rs11098403	0.753	rs12643746	ENSG00000225892.3	RP11-384K6.2	3.49	5e-04	0.0247	0.11	0.11	Schizophrenia;	chr4:117858644	chr4:118632274~118634759:+
BRCA	cis	rs6460942	0.597	rs10273045	ENSG00000226690.5	AC005281.1	3.49	5e-04	0.0247	0.21	0.11	Coronary artery disease;	chr7:12479745	chr7:12496429~12541910:+
BRCA	cis	rs732716	0.504	rs9352	ENSG00000267769.1	CTB-50L17.9	-3.49	5e-04	0.0247	-0.11	-0.11	Mean corpuscular volume;	chr19:4442339	chr19:4454014~4455286:+
BRCA	cis	rs8064024	0.599	rs1876359	ENSG00000267077.1	RP11-127I20.5	3.49	5e-04	0.0247	0.11	0.11	Cancer;	chr16:4880099	chr16:4795265~4796532:-
BRCA	cis	rs7620503	1	rs4273409	ENSG00000228561.2	RP11-114M1.1	3.49	5e-04	0.0247	0.13	0.11	Corneal structure;	chr3:177580997	chr3:177683627~177691250:+
BRCA	cis	rs7620503	1	rs36102700	ENSG00000228561.2	RP11-114M1.1	3.49	5e-04	0.0247	0.13	0.11	Corneal structure;	chr3:177581321	chr3:177683627~177691250:+
BRCA	cis	rs67478160	0.595	rs12433109	ENSG00000269910.1	RP11-73M18.10	3.49	5e-04	0.0247	0.11	0.11	Schizophrenia;	chr14:103730270	chr14:103694516~103695050:-
BRCA	cis	rs17345786	0.861	rs11707689	ENSG00000244119.1	PDCL3P4	3.49	5e-04	0.0247	0.1	0.11	Colonoscopy-negative controls vs population controls;	chr3:101367631	chr3:101712472~101713191:+
BRCA	cis	rs853679	1	rs11965538	ENSG00000216901.1	AL022393.7	3.49	5e-04	0.0247	0.18	0.11	Depression;	chr6:28272137	chr6:28176188~28176674:+
BRCA	cis	rs4886920	0.775	rs8032021	ENSG00000260776.4	RP11-114H24.2	-3.49	5e-04	0.0247	-0.13	-0.11	Neuroticism;	chr15:77855194	chr15:77914217~77926846:-
BRCA	cis	rs6012564	0.929	rs4810898	ENSG00000230758.1	SNAP23P	-3.49	5e-04	0.0247	-0.12	-0.11	Anger;	chr20:48937855	chr20:49038357~49038602:-
BRCA	cis	rs4243971	0.557	rs58921650	ENSG00000275576.1	RP5-836N17.4	-3.49	5e-04	0.0247	-0.12	-0.11	Inflammatory bowel disease;Crohn's disease;	chr20:32306100	chr20:32116171~32116629:+
BRCA	cis	rs875971	0.543	rs801191	ENSG00000265600.1	AC006480.1	3.49	5e-04	0.0247	0.13	0.11	Aortic root size;	chr7:66567968	chr7:67356680~67356779:+
BRCA	cis	rs9307239	0.533	rs1442485	ENSG00000246090.5	RP11-696N14.1	3.49	5e-04	0.0247	0.1	0.11	Alcohol dependence;	chr4:99385254	chr4:99088857~99301356:+
BRCA	cis	rs6479874	0.57	rs2816840	ENSG00000223502.1	RP11-96B5.3	-3.49	5e-04	0.0247	-0.19	-0.11	Migraine;	chr10:50988601	chr10:51062579~51068553:-
BRCA	cis	rs925946	0.518	rs10835201	ENSG00000245573.6	BDNF-AS	-3.49	5e-04	0.0247	-0.12	-0.11	Weight;Body mass index;	chr11:27596718	chr11:27506838~27698174:+
BRCA	cis	rs7131987	0.834	rs12228468	ENSG00000257176.2	RP11-996F15.2	3.49	5e-04	0.0247	0.13	0.11	QT interval;	chr12:29300677	chr12:29280418~29317848:-
BRCA	cis	rs1998359	0.862	rs55822659	ENSG00000259087.4	RP11-356O9.2	3.49	5e-04	0.0247	0.12	0.11	Self-reported allergy;	chr14:37702406	chr14:37556158~37567095:-
BRCA	cis	rs875971	1	rs3981131	ENSG00000230189.5	GS1-124K5.2	3.49	5e-04	0.0247	0.08	0.11	Aortic root size;	chr7:66486690	chr7:66409143~66490059:-
BRCA	cis	rs1479090	0.762	rs10031393	ENSG00000250027.1	RP11-563E2.2	-3.49	5e-04	0.0247	-0.14	-0.11	Lung cancer;	chr4:163099940	chr4:163108785~163119965:+
BRCA	cis	rs9381040	0.748	rs9357348	ENSG00000161912.16	ADCY10P1	3.49	5e-04	0.0247	0.12	0.11	Alzheimer's disease (late onset);	chr6:41186494	chr6:41101022~41140835:+
BRCA	cis	rs6964587	1	rs36021614	ENSG00000188693.7	CYP51A1-AS1	-3.49	5e-04	0.0247	-0.12	-0.11	Breast cancer;	chr7:92088176	chr7:92134604~92180725:+
BRCA	cis	rs7487075	0.893	rs4768115	ENSG00000257261.4	RP11-96H19.1	3.49	5e-04	0.0247	0.11	0.11	Itch intensity from mosquito bite;	chr12:46338736	chr12:46383679~46876159:+
BRCA	cis	rs7487075	0.893	rs4547171	ENSG00000257261.4	RP11-96H19.1	3.49	5e-04	0.0247	0.11	0.11	Itch intensity from mosquito bite;	chr12:46339609	chr12:46383679~46876159:+
BRCA	cis	rs7487075	0.828	rs2169030	ENSG00000257261.4	RP11-96H19.1	3.49	5e-04	0.0247	0.11	0.11	Itch intensity from mosquito bite;	chr12:46341273	chr12:46383679~46876159:+
BRCA	cis	rs6918586	0.658	rs198809	ENSG00000272810.1	U91328.22	-3.49	5e-04	0.0247	-0.12	-0.11	Schizophrenia;	chr6:26128538	chr6:26013241~26013757:+
BRCA	cis	rs12220238	0.915	rs11000945	ENSG00000213731.2	RAB5CP1	-3.49	5e-04	0.0247	-0.16	-0.11	Soluble interleukin-2 receptor subunit alpha;	chr10:74270981	chr10:74423435~74424014:-
BRCA	cis	rs9392556	0.829	rs853417	ENSG00000230648.1	RP3-406P24.3	3.49	5e-04	0.0247	0.14	0.11	Blood metabolite levels;	chr6:4112889	chr6:4018843~4021215:-
BRCA	cis	rs2803122	0.846	rs10757032	ENSG00000272842.1	RP11-513M16.7	-3.49	5e-04	0.0247	-0.11	-0.11	Pulse pressure;	chr9:19213350	chr9:19371386~19371945:-
BRCA	cis	rs875971	1	rs3981131	ENSG00000265600.1	AC006480.1	-3.49	0.000501	0.0247	-0.12	-0.11	Aortic root size;	chr7:66486690	chr7:67356680~67356779:+
BRCA	cis	rs17092148	0.848	rs6060030	ENSG00000202150.1	RNU6-407P	3.49	0.000501	0.0247	0.15	0.11	Neuroticism;	chr20:34752510	chr20:35030317~35030420:-
BRCA	cis	rs9816784	0.525	rs555412	ENSG00000207650.1	MIR570	3.49	0.000501	0.0247	0.14	0.11	Mean corpuscular hemoglobin;	chr3:196078047	chr3:195699401~195699497:+
BRCA	cis	rs337100	0.546	rs366769	ENSG00000263432.2	RN7SL689P	-3.49	0.000501	0.0247	-0.13	-0.11	Pulse pressure;	chr5:123136416	chr5:123022487~123022783:-
BRCA	cis	rs61776290	0.843	rs185864	ENSG00000271989.1	RP4-736L20.3	-3.49	0.000501	0.0247	-0.16	-0.11	Alcohol dependence (age at onset);	chr1:10627669	chr1:10429881~10430677:-
BRCA	cis	rs860295	0.756	rs7546258	ENSG00000246203.2	RP11-29H23.5	-3.49	0.000501	0.0247	-0.12	-0.11	Body mass index;	chr1:155728854	chr1:155614726~155660245:-
BRCA	cis	rs875971	0.756	rs2901210	ENSG00000106610.13	STAG3L4	3.49	0.000501	0.0247	0.14	0.11	Aortic root size;	chr7:66552518	chr7:67302621~67321526:+
BRCA	cis	rs6088580	0.66	rs6059893	ENSG00000269202.1	RP4-614O4.12	-3.49	0.000501	0.0247	-0.11	-0.11	Glomerular filtration rate (creatinine);	chr20:34518092	chr20:35201747~35203288:-
BRCA	cis	rs7824557	0.933	rs6601576	ENSG00000255046.1	RP11-297N6.4	3.49	0.000501	0.0247	0.13	0.11	Retinal vascular caliber;	chr8:11242766	chr8:11797928~11802568:-
BRCA	cis	rs9311474	0.629	rs13081028	ENSG00000222345.1	SNORD19	3.49	0.000501	0.0247	0.11	0.11	Electroencephalogram traits;	chr3:52521300	chr3:52691378~52691453:+
BRCA	cis	rs2765539	0.701	rs4659148	ENSG00000231365.4	RP11-418J17.1	-3.49	0.000501	0.0247	-0.14	-0.11	Waist-hip ratio;	chr1:119104071	chr1:119140396~119275973:+
BRCA	cis	rs17711722	0.64	rs13237956	ENSG00000232546.1	RP11-458F8.1	-3.49	0.000501	0.0247	-0.09	-0.11	Calcium levels;	chr7:65853042	chr7:66848496~66858136:+
BRCA	cis	rs875971	0.767	rs61348003	ENSG00000106610.13	STAG3L4	-3.49	0.000501	0.0247	-0.14	-0.11	Aortic root size;	chr7:66540947	chr7:67302621~67321526:+
BRCA	cis	rs875971	0.825	rs801202	ENSG00000106610.13	STAG3L4	3.49	0.000501	0.0247	0.14	0.11	Aortic root size;	chr7:66558942	chr7:67302621~67321526:+
BRCA	cis	rs7412746	0.658	rs897815	ENSG00000224800.1	RP11-235D19.2	3.49	0.000501	0.0247	0.14	0.11	Melanoma;	chr1:150906625	chr1:150881236~150881683:-
BRCA	cis	rs4588572	0.643	rs7716529	ENSG00000245556.2	SCAMP1-AS1	-3.49	0.000501	0.0247	-0.13	-0.11	Triglycerides;	chr5:78442813	chr5:78342365~78360507:-
BRCA	cis	rs2055729	0.645	rs12056944	ENSG00000233609.3	RP11-62H7.2	3.49	0.000501	0.0247	0.11	0.11	Multiple myeloma (hyperdiploidy);	chr8:9885015	chr8:8961200~8979025:+
BRCA	cis	rs875971	0.862	rs13226170	ENSG00000265600.1	AC006480.1	-3.49	0.000501	0.0247	-0.13	-0.11	Aortic root size;	chr7:66534311	chr7:67356680~67356779:+
BRCA	cis	rs875971	0.862	rs2420611	ENSG00000265600.1	AC006480.1	-3.49	0.000501	0.0247	-0.13	-0.11	Aortic root size;	chr7:66534333	chr7:67356680~67356779:+
BRCA	cis	rs10761482	0.701	rs12411733	ENSG00000254271.1	RP11-131N11.4	3.49	0.000501	0.0247	0.14	0.11	Schizophrenia;	chr10:60363288	chr10:60734342~60741828:+
BRCA	cis	rs7412746	0.634	rs7521592	ENSG00000224800.1	RP11-235D19.2	-3.49	0.000501	0.0247	-0.14	-0.11	Melanoma;	chr1:150849215	chr1:150881236~150881683:-
BRCA	cis	rs10056811	0.556	rs55810502	ENSG00000271815.1	CTD-2235C13.3	-3.49	0.000501	0.0247	-0.16	-0.11	Coronary artery disease;	chr5:75085134	chr5:75363760~75364242:+
BRCA	cis	rs10129255	0.5	rs6576230	ENSG00000211976.2	IGHV3-73	-3.49	0.000501	0.0247	-0.08	-0.11	Kawasaki disease;	chr14:106778539	chr14:106802694~106803233:-
BRCA	cis	rs481331	0.734	rs35917885	ENSG00000273008.1	RP11-351D16.3	-3.49	0.000501	0.0247	-0.14	-0.11	Systemic juvenile idiopathic arthritis;	chr10:42483589	chr10:43136824~43138334:-
BRCA	cis	rs853679	0.517	rs35193936	ENSG00000226314.6	ZNF192P1	-3.49	0.000501	0.0247	-0.16	-0.11	Depression;	chr6:28108492	chr6:28161781~28169594:+
BRCA	cis	rs875971	0.862	rs11763189	ENSG00000265600.1	AC006480.1	-3.49	0.000502	0.0247	-0.13	-0.11	Aortic root size;	chr7:66518542	chr7:67356680~67356779:+
BRCA	cis	rs2262909	0.924	rs4290587	ENSG00000279377.1	AC003973.3	3.49	0.000502	0.0247	0.15	0.11	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;	chr19:21981844	chr19:21965708~21968529:-
BRCA	cis	rs10486003	1	rs77479653	ENSG00000213455.3	AC091654.7	-3.49	0.000502	0.0247	-0.19	-0.11	Response to platinum-based agents;	chr7:97593618	chr7:98454119~98454617:-
BRCA	cis	rs131777	0.708	rs131749	ENSG00000272666.1	CTA-384D8.35	-3.49	0.000502	0.0247	-0.11	-0.11	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr22:50586195	chr22:50542305~50542906:-
BRCA	cis	rs9309473	0.607	rs1851546	ENSG00000230002.2	ALMS1-IT1	3.49	0.000502	0.0247	0.13	0.11	Metabolite levels;	chr2:73363999	chr2:73456764~73459484:+
BRCA	cis	rs1479090	0.651	rs4485770	ENSG00000250027.1	RP11-563E2.2	-3.49	0.000502	0.0247	-0.14	-0.11	Lung cancer;	chr4:163099023	chr4:163108785~163119965:+
BRCA	cis	rs10045413	0.598	rs7715321	ENSG00000250167.1	CTC-321K16.1	3.49	0.000502	0.0247	0.13	0.11	Age at smoking initiation in chronic obstructive pulmonary disease;	chr5:135609316	chr5:135559577~135634874:+
BRCA	cis	rs564309	0.867	rs12735877	ENSG00000212237.1	RNA5SP18	3.49	0.000502	0.0247	0.2	0.11	Hip circumference (psychosocial stress interaction);	chr1:228380500	chr1:228647912~228648032:-
BRCA	cis	rs3862030	0.5	rs11191327	ENSG00000213061.2	PFN1P11	-3.49	0.000502	0.0247	-0.15	-0.11	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr10:102544126	chr10:102838011~102845473:-
BRCA	cis	rs7777677	0.925	rs4726540	ENSG00000275158.1	TRBV12-5	3.49	0.000502	0.0247	0.1	0.11	Alcoholic chronic pancreatitis;	chr7:142658771	chr7:142580917~142581427:+
BRCA	cis	rs2411233	1	rs8040312	ENSG00000259278.1	RP11-62C7.2	-3.49	0.000502	0.0247	-0.13	-0.11	Platelet count;	chr15:38987902	chr15:39019233~39024918:+
BRCA	cis	rs1443512	0.812	rs1975472	ENSG00000228630.4	HOTAIR	-3.49	0.000502	0.0247	-0.14	-0.11	Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-hip ratio;Waist-to-hip ratio adjusted for body mass index;	chr12:53943299	chr12:53962308~53974956:-
BRCA	cis	rs801193	0.967	rs3800823	ENSG00000232546.1	RP11-458F8.1	3.49	0.000502	0.0247	0.09	0.11	Aortic root size;	chr7:66682123	chr7:66848496~66858136:+
BRCA	cis	rs13136331	0.642	rs1319917	ENSG00000249001.4	RP11-742B18.1	3.49	0.000502	0.0247	0.14	0.11	Sitting height ratio;	chr4:87707656	chr4:87568035~87733956:-
BRCA	cis	rs12681366	0.62	rs2930968	ENSG00000253175.1	RP11-267M23.6	3.49	0.000502	0.0248	0.12	0.11	Nonsyndromic cleft lip with cleft palate;	chr8:94450467	chr8:94565036~94565715:+
BRCA	cis	rs12681366	0.663	rs2930970	ENSG00000253175.1	RP11-267M23.6	3.49	0.000502	0.0248	0.12	0.11	Nonsyndromic cleft lip with cleft palate;	chr8:94452109	chr8:94565036~94565715:+
BRCA	cis	rs17711722	0.701	rs55773927	ENSG00000229180.5	GS1-124K5.11	3.49	0.000502	0.0248	0.09	0.11	Calcium levels;	chr7:65872915	chr7:66526088~66542624:-
BRCA	cis	rs10761482	0.861	rs10761484	ENSG00000254271.1	RP11-131N11.4	3.49	0.000502	0.0248	0.15	0.11	Schizophrenia;	chr10:60338700	chr10:60734342~60741828:+
BRCA	cis	rs4388249	1	rs12656763	ENSG00000249068.1	CTC-287O8.1	3.49	0.000502	0.0248	0.16	0.11	Schizophrenia;	chr5:109707482	chr5:109840128~109840692:-
BRCA	cis	rs7618501	0.933	rs3811695	ENSG00000228008.1	CTD-2330K9.3	-3.49	0.000502	0.0248	-0.1	-0.11	Intelligence (multi-trait analysis);	chr3:49724180	chr3:49903845~49916937:+
BRCA	cis	rs1466535	1	rs4759277	ENSG00000201579.1	RNU6-343P	3.49	0.000502	0.0248	0.12	0.11	Abdominal aortic aneurysm;	chr12:57139907	chr12:56588518~56588621:+
BRCA	cis	rs9436747	0.782	rs9436746	ENSG00000237852.1	RP4-630A11.3	-3.49	0.000502	0.0248	-0.13	-0.11	Myeloid white cell count;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;White blood cell count;Sum neutrophil eosinophil counts;	chr1:65442790	chr1:65486406~65494188:+
BRCA	cis	rs2337406	0.587	rs10129888	ENSG00000211972.2	IGHV3-66	3.49	0.000502	0.0248	0.1	0.11	Alzheimer's disease (late onset);	chr14:106647421	chr14:106675017~106675544:-
BRCA	cis	rs6696239	0.513	rs3010192	ENSG00000227711.2	RP11-275O4.5	-3.49	0.000502	0.0248	-0.13	-0.11	Height;	chr1:227615350	chr1:227509028~227520477:-
BRCA	cis	rs1008375	0.966	rs12503517	ENSG00000249502.1	AC006160.5	-3.49	0.000502	0.0248	-0.12	-0.11	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17697102	chr4:17587467~17614571:-
BRCA	cis	rs11673344	0.523	rs7258438	ENSG00000276846.1	CTD-3220F14.3	3.49	0.000502	0.0248	0.13	0.11	Obesity-related traits;	chr19:37032534	chr19:37314868~37315620:-
BRCA	cis	rs10761482	0.861	rs10994310	ENSG00000254271.1	RP11-131N11.4	-3.49	0.000502	0.0248	-0.15	-0.11	Schizophrenia;	chr10:60346411	chr10:60734342~60741828:+
BRCA	cis	rs6142618	0.562	rs4911548	ENSG00000277692.1	RP11-358N2.2	-3.49	0.000502	0.0248	-0.12	-0.11	Inflammatory bowel disease;	chr20:32147536	chr20:32355053~32355734:+
BRCA	cis	rs6142618	0.562	rs6142621	ENSG00000277692.1	RP11-358N2.2	-3.49	0.000502	0.0248	-0.12	-0.11	Inflammatory bowel disease;	chr20:32148004	chr20:32355053~32355734:+
BRCA	cis	rs2692947	0.537	rs11685849	ENSG00000232931.4	LINC00342	3.49	0.000503	0.0248	0.12	0.11	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95578056	chr2:95807118~95816215:-
BRCA	cis	rs2692947	0.537	rs11688045	ENSG00000232931.4	LINC00342	3.49	0.000503	0.0248	0.12	0.11	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95578057	chr2:95807118~95816215:-
BRCA	cis	rs80226907	0.614	rs111594243	ENSG00000258413.1	RP11-665C16.6	-3.49	0.000503	0.0248	-0.28	-0.11	Mean platelet volume;	chr14:55379353	chr14:55262767~55272075:-
BRCA	cis	rs687432	0.679	rs3853676	ENSG00000265566.2	RN7SL605P	-3.49	0.000503	0.0248	-0.14	-0.11	Parkinson's disease;	chr11:58126495	chr11:57528085~57528365:-
BRCA	cis	rs4839524	0.964	rs10924022	ENSG00000203865.8	ATP1A1-AS1	-3.49	0.000503	0.0248	-0.12	-0.11	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:116260109	chr1:116392247~116418622:-
BRCA	cis	rs2795502	1	rs3121278	ENSG00000185904.10	LINC00839	3.49	0.000503	0.0248	0.15	0.11	Blood protein levels;	chr10:42880198	chr10:42475543~42495336:+
BRCA	cis	rs2227564	0.729	rs2227551	ENSG00000271816.1	BMS1P4	3.49	0.000503	0.0248	0.11	0.11	Crohn's disease;Inflammatory bowel disease;	chr10:73909432	chr10:73699151~73730487:-
BRCA	cis	rs656900	0.669	rs7178799	ENSG00000259548.1	RP11-38G5.2	-3.49	0.000503	0.0248	-0.12	-0.11	Cerebrospinal P-tau181p levels;	chr15:79826981	chr15:79832466~79833554:-
BRCA	cis	rs1710990	0.819	rs1275415	ENSG00000259165.1	DDX18P1	3.49	0.000503	0.0248	0.12	0.11	Intelligence (multi-trait analysis);	chr14:69144993	chr14:69083398~69085389:+
BRCA	cis	rs11098499	0.863	rs10018280	ENSG00000250412.1	KLHL2P1	3.49	0.000503	0.0248	0.13	0.11	Corneal astigmatism;	chr4:119556984	chr4:119334329~119378233:+
BRCA	cis	rs11098499	0.863	rs6534141	ENSG00000250412.1	KLHL2P1	3.49	0.000503	0.0248	0.13	0.11	Corneal astigmatism;	chr4:119564068	chr4:119334329~119378233:+
BRCA	cis	rs11098499	0.863	rs2127823	ENSG00000250412.1	KLHL2P1	3.49	0.000503	0.0248	0.13	0.11	Corneal astigmatism;	chr4:119564515	chr4:119334329~119378233:+
BRCA	cis	rs2692947	0.666	rs10183151	ENSG00000168992.4	OR7E102P	-3.49	0.000503	0.0248	-0.15	-0.11	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96109038	chr2:95546531~95547545:+
BRCA	cis	rs4372836	0.704	rs966250	ENSG00000226833.4	AC097724.3	3.49	0.000503	0.0248	0.13	0.11	Body mass index;	chr2:28751273	chr2:28708953~28736205:-
BRCA	cis	rs10411161	0.752	rs10404812	ENSG00000269483.1	AC006272.1	3.49	0.000503	0.0248	0.18	0.11	Breast cancer;	chr19:51897438	chr19:51839924~51843324:-
BRCA	cis	rs6840360	0.615	rs4696267	ENSG00000270265.1	RP11-731D1.4	-3.49	0.000503	0.0248	-0.13	-0.11	Intelligence (multi-trait analysis);	chr4:151543348	chr4:151333775~151353224:-
BRCA	cis	rs6840360	0.615	rs4696268	ENSG00000270265.1	RP11-731D1.4	-3.49	0.000503	0.0248	-0.13	-0.11	Intelligence (multi-trait analysis);	chr4:151543571	chr4:151333775~151353224:-
BRCA	cis	rs6840360	0.615	rs10021407	ENSG00000270265.1	RP11-731D1.4	-3.49	0.000503	0.0248	-0.13	-0.11	Intelligence (multi-trait analysis);	chr4:151543850	chr4:151333775~151353224:-
BRCA	cis	rs6840360	0.615	rs58977077	ENSG00000270265.1	RP11-731D1.4	-3.49	0.000503	0.0248	-0.13	-0.11	Intelligence (multi-trait analysis);	chr4:151549087	chr4:151333775~151353224:-
BRCA	cis	rs6840360	0.554	rs62329088	ENSG00000270265.1	RP11-731D1.4	-3.49	0.000503	0.0248	-0.13	-0.11	Intelligence (multi-trait analysis);	chr4:151550137	chr4:151333775~151353224:-
BRCA	cis	rs6840360	0.615	rs66852535	ENSG00000270265.1	RP11-731D1.4	-3.49	0.000503	0.0248	-0.13	-0.11	Intelligence (multi-trait analysis);	chr4:151551075	chr4:151333775~151353224:-
BRCA	cis	rs6840360	0.593	rs10033405	ENSG00000270265.1	RP11-731D1.4	-3.49	0.000503	0.0248	-0.13	-0.11	Intelligence (multi-trait analysis);	chr4:151553337	chr4:151333775~151353224:-
BRCA	cis	rs6840360	0.615	rs4696096	ENSG00000270265.1	RP11-731D1.4	-3.49	0.000503	0.0248	-0.13	-0.11	Intelligence (multi-trait analysis);	chr4:151554235	chr4:151333775~151353224:-
BRCA	cis	rs6840360	0.615	rs1962910	ENSG00000270265.1	RP11-731D1.4	-3.49	0.000503	0.0248	-0.13	-0.11	Intelligence (multi-trait analysis);	chr4:151558240	chr4:151333775~151353224:-
BRCA	cis	rs11098499	0.863	rs9997631	ENSG00000250412.1	KLHL2P1	3.49	0.000503	0.0248	0.13	0.11	Corneal astigmatism;	chr4:119548840	chr4:119334329~119378233:+
BRCA	cis	rs943466	0.911	rs72880511	ENSG00000223837.2	BRD2-IT1	3.49	0.000503	0.0248	0.14	0.11	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;	chr6:33762043	chr6:32970232~32970886:+
BRCA	cis	rs35688236	1	rs35688236	ENSG00000236452.1	AC123023.1	3.49	0.000503	0.0248	0.15	0.11	Neuroticism;	chr3:34541501	chr3:34203244~34268811:+
BRCA	cis	rs61008539	0.893	rs4721502	ENSG00000237181.1	AC147651.4	3.49	0.000503	0.0248	0.09	0.11	Perceived unattractiveness to mosquitoes;	chr7:822549	chr7:603185~608482:+
BRCA	cis	rs7412746	0.658	rs3768016	ENSG00000224800.1	RP11-235D19.2	-3.49	0.000503	0.0248	-0.14	-0.11	Melanoma;	chr1:150837443	chr1:150881236~150881683:-
BRCA	cis	rs7412746	0.634	rs72704658	ENSG00000224800.1	RP11-235D19.2	-3.49	0.000503	0.0248	-0.14	-0.11	Melanoma;	chr1:150860534	chr1:150881236~150881683:-
BRCA	cis	rs11168618	0.74	rs4409884	ENSG00000240399.1	RP1-228P16.1	3.49	0.000503	0.0248	0.11	0.11	Adiponectin levels;	chr12:48533758	chr12:48054813~48055591:-
BRCA	cis	rs13401620	0.871	rs10192742	ENSG00000229326.3	AC069154.4	-3.49	0.000503	0.0248	-0.14	-0.11	Breast size;	chr2:119906041	chr2:119698623~119700151:+
BRCA	cis	rs12282928	0.959	rs1483122	ENSG00000255197.4	RP11-750H9.5	3.49	0.000503	0.0248	0.1	0.11	Migraine - clinic-based;	chr11:48305634	chr11:47383148~47409190:-
BRCA	cis	rs2704588	1	rs973680	ENSG00000270720.1	RP11-84C13.2	-3.49	0.000503	0.0248	-0.17	-0.11	Longevity;	chr4:88907467	chr4:89119284~89119871:+
BRCA	cis	rs1552244	0.572	rs59132826	ENSG00000269894.1	RP11-1020A11.1	-3.49	0.000503	0.0248	-0.14	-0.11	Alzheimer's disease;	chr3:10128041	chr3:9935706~9936258:+
BRCA	cis	rs1552244	0.572	rs58223482	ENSG00000269894.1	RP11-1020A11.1	-3.49	0.000503	0.0248	-0.14	-0.11	Alzheimer's disease;	chr3:10128062	chr3:9935706~9936258:+
BRCA	cis	rs1552244	0.572	rs113406084	ENSG00000269894.1	RP11-1020A11.1	-3.49	0.000503	0.0248	-0.14	-0.11	Alzheimer's disease;	chr3:10128506	chr3:9935706~9936258:+
BRCA	cis	rs853679	0.546	rs200952	ENSG00000216676.2	RP1-15D7.1	-3.49	0.000503	0.0248	-0.19	-0.11	Depression;	chr6:27869198	chr6:27652602~27652825:-
BRCA	cis	rs1348850	0.519	rs1527407	ENSG00000280374.1	RP11-337N6.3	3.49	0.000503	0.0248	0.15	0.11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177660902	chr2:177317715~177318471:-
BRCA	cis	rs1348850	0.519	rs1527406	ENSG00000280374.1	RP11-337N6.3	3.49	0.000503	0.0248	0.15	0.11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177660927	chr2:177317715~177318471:-
BRCA	cis	rs6696239	1	rs10799428	ENSG00000215812.5	ZNF847P	3.49	0.000503	0.0248	0.15	0.11	Height;	chr1:227610864	chr1:227696892~227706699:-
BRCA	cis	rs890448	0.796	rs13109704	ENSG00000254531.1	FLJ20021	3.49	0.000503	0.0248	0.13	0.11	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101365056	chr4:101347780~101348883:+
BRCA	cis	rs2031532	0.587	rs4942830	ENSG00000236577.1	SNRPGP14	3.49	0.000503	0.0248	0.12	0.11	Cardiac hypertrophy;	chr13:49445240	chr13:49488970~49489364:+
BRCA	cis	rs2832077	0.943	rs2832097	ENSG00000174680.8	GRIK1-AS1	3.49	0.000503	0.0248	0.12	0.11	Cognitive test performance;	chr21:28801017	chr21:29748175~29764002:+
BRCA	cis	rs6487679	0.526	rs972111	ENSG00000256427.1	RP11-118B22.4	3.49	0.000503	0.0248	0.12	0.11	Non-alcoholic fatty liver disease histology (AST);	chr12:9221777	chr12:9246497~9257960:+
BRCA	cis	rs12681366	0.762	rs7824722	ENSG00000253175.1	RP11-267M23.6	3.49	0.000503	0.0248	0.12	0.11	Nonsyndromic cleft lip with cleft palate;	chr8:94338623	chr8:94565036~94565715:+
BRCA	cis	rs875971	0.965	rs6971509	ENSG00000272831.1	RP11-792A8.4	-3.49	0.000503	0.0248	-0.1	-0.11	Aortic root size;	chr7:66249983	chr7:66739829~66740385:-
BRCA	cis	rs5750830	0.649	rs5750822	ENSG00000280216.1	RP3-333H23.9	-3.49	0.000503	0.0248	-0.13	-0.11	Intelligence (multi-trait analysis);	chr22:39430783	chr22:39379610~39380015:+
BRCA	cis	rs7637701	0.901	rs4680312	ENSG00000240875.4	LINC00886	-3.49	0.000503	0.0248	-0.13	-0.11	Breast cancer;	chr3:156888140	chr3:156747346~156817062:-
BRCA	cis	rs7637701	0.967	rs11712111	ENSG00000240875.4	LINC00886	-3.49	0.000503	0.0248	-0.13	-0.11	Breast cancer;	chr3:156891151	chr3:156747346~156817062:-
BRCA	cis	rs875971	0.54	rs781152	ENSG00000229180.5	GS1-124K5.11	3.49	0.000503	0.0248	0.09	0.11	Aortic root size;	chr7:66014585	chr7:66526088~66542624:-
BRCA	cis	rs17711722	0.727	rs781151	ENSG00000229180.5	GS1-124K5.11	3.49	0.000503	0.0248	0.09	0.11	Calcium levels;	chr7:66014891	chr7:66526088~66542624:-
BRCA	cis	rs18122	0.846	rs11885548	ENSG00000236780.4	AC078941.1	3.49	0.000504	0.0248	0.15	0.11	Waist-to-hip ratio adjusted for body mass index;	chr2:67401461	chr2:67123357~67215319:-
BRCA	cis	rs1912124	1	rs11639206	ENSG00000271983.1	RP11-28H5.2	3.49	0.000504	0.0248	0.21	0.11	Peripheral arterial disease (traffic-related air pollution interaction);	chr15:81206587	chr15:80693216~80693707:-
BRCA	cis	rs2562456	0.874	rs9304986	ENSG00000240522.1	RPL7AP10	3.49	0.000504	0.0248	0.12	0.11	Pain;	chr19:21499260	chr19:21149648~21150438:-
BRCA	cis	rs6801044	0.789	rs823526	ENSG00000272792.1	RP11-141C7.4	3.49	0.000504	0.0248	0.16	0.11	Creatinine levels in ischemic stroke;	chr3:195551478	chr3:195639990~195640460:+
BRCA	cis	rs863345	0.604	rs2317970	ENSG00000176320.2	RP11-404O13.5	-3.49	0.000504	0.0248	-0.11	-0.11	Pneumococcal bacteremia;	chr1:158534980	chr1:158197922~158203877:-
BRCA	cis	rs863345	0.604	rs2873594	ENSG00000176320.2	RP11-404O13.5	-3.49	0.000504	0.0248	-0.11	-0.11	Pneumococcal bacteremia;	chr1:158535000	chr1:158197922~158203877:-
BRCA	cis	rs73222236	0.825	rs9850383	ENSG00000239213.4	NCK1-AS1	3.49	0.000504	0.0248	0.12	0.11	Coronary artery disease;	chr3:136462601	chr3:136841726~136862054:-
BRCA	cis	rs4835473	0.9	rs13137885	ENSG00000246448.2	RP13-578N3.3	-3.49	0.000504	0.0248	-0.12	-0.11	Immature fraction of reticulocytes;	chr4:143734212	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.9	rs13105550	ENSG00000246448.2	RP13-578N3.3	-3.49	0.000504	0.0248	-0.12	-0.11	Immature fraction of reticulocytes;	chr4:143734220	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.9	rs13105571	ENSG00000246448.2	RP13-578N3.3	-3.49	0.000504	0.0248	-0.12	-0.11	Immature fraction of reticulocytes;	chr4:143734241	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.9	rs36083417	ENSG00000246448.2	RP13-578N3.3	-3.49	0.000504	0.0248	-0.12	-0.11	Immature fraction of reticulocytes;	chr4:143734253	chr4:143700257~143865072:+
BRCA	cis	rs7620503	1	rs35921520	ENSG00000228561.2	RP11-114M1.1	3.49	0.000504	0.0248	0.13	0.11	Corneal structure;	chr3:177581444	chr3:177683627~177691250:+
BRCA	cis	rs2216824	1	rs78599283	ENSG00000278908.1	RP11-523J2.1	3.49	0.000504	0.0248	0.19	0.11	Oropharynx cancer;	chr2:30883346	chr2:30677762~30679895:+
BRCA	cis	rs6714710	0.603	rs10432626	ENSG00000228486.8	LINC01125	-3.49	0.000504	0.0248	-0.09	-0.11	Posterior cortical atrophy and Alzheimer's disease;	chr2:97944690	chr2:97664217~97703064:+
BRCA	cis	rs12438356	0.571	rs8031212	ENSG00000259222.2	RP11-809H16.5	3.49	0.000504	0.0248	0.14	0.11	CTACK levels;	chr15:69144988	chr15:69080879~69099987:+
BRCA	cis	rs9467773	1	rs1321481	ENSG00000224843.5	LINC00240	-3.49	0.000504	0.0248	-0.12	-0.11	Intelligence (multi-trait analysis);	chr6:26537982	chr6:26956992~27023924:+
BRCA	cis	rs9467773	1	rs4713008	ENSG00000224843.5	LINC00240	-3.49	0.000504	0.0248	-0.12	-0.11	Intelligence (multi-trait analysis);	chr6:26538040	chr6:26956992~27023924:+
BRCA	cis	rs7824557	0.767	rs1897951	ENSG00000154316.13	TDH	-3.49	0.000504	0.0248	-0.15	-0.11	Retinal vascular caliber;	chr8:11312345	chr8:11339637~11368452:+
BRCA	cis	rs4886920	0.862	rs35020526	ENSG00000260776.4	RP11-114H24.2	-3.49	0.000504	0.0248	-0.13	-0.11	Neuroticism;	chr15:77845520	chr15:77914217~77926846:-
BRCA	cis	rs8105895	0.935	rs62111030	ENSG00000269345.1	VN1R85P	3.49	0.000504	0.0248	0.17	0.11	Body mass index (change over time);	chr19:22096573	chr19:22174766~22175191:-
BRCA	cis	rs8105895	0.935	rs62111032	ENSG00000269345.1	VN1R85P	3.49	0.000504	0.0248	0.17	0.11	Body mass index (change over time);	chr19:22098547	chr19:22174766~22175191:-
BRCA	cis	rs2274273	1	rs2274273	ENSG00000233924.1	AL160471.6	3.49	0.000504	0.0248	0.12	0.11	Protein biomarker;	chr14:55147918	chr14:55004813~55005687:-
BRCA	cis	rs9402743	0.632	rs7754830	ENSG00000231028.7	LINC00271	-3.49	0.000504	0.0248	-0.11	-0.11	Systemic lupus erythematosus;	chr6:135779904	chr6:135497801~135716055:+
BRCA	cis	rs28489187	0.706	rs423105	ENSG00000223653.4	RP11-131L23.1	3.49	0.000504	0.0248	0.12	0.11	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85330744	chr1:85276715~85448124:+
BRCA	cis	rs7260598	0.642	rs73023276	ENSG00000268442.1	CTD-2027I19.2	3.49	0.000505	0.0249	0.17	0.11	Response to taxane treatment (placlitaxel);	chr19:23976045	chr19:24162370~24163425:-
BRCA	cis	rs875971	0.66	rs801193	ENSG00000275400.1	RP4-756H11.5	3.49	0.000505	0.0249	0.12	0.11	Aortic root size;	chr7:66565625	chr7:66553805~66554199:-
BRCA	cis	rs1153858	1	rs10519022	ENSG00000275672.1	GATM-AS1	3.49	0.000505	0.0249	0.14	0.11	Homoarginine levels;	chr15:45371486	chr15:45378700~45380123:+
BRCA	cis	rs6964587	0.967	rs7783414	ENSG00000188693.7	CYP51A1-AS1	-3.49	0.000505	0.0249	-0.12	-0.11	Breast cancer;	chr7:92156643	chr7:92134604~92180725:+
BRCA	cis	rs1056107	0.933	rs7037658	ENSG00000266315.1	MIR4668	3.49	0.000505	0.0249	0.11	0.11	Colorectal cancer;	chr9:112309244	chr9:111932100~111932169:+
BRCA	cis	rs78487399	0.808	rs7561287	ENSG00000234936.1	AC010883.5	3.49	0.000505	0.0249	0.16	0.11	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43461932	chr2:43229573~43233394:+
BRCA	cis	rs10761482	0.813	rs10821735	ENSG00000254271.1	RP11-131N11.4	3.49	0.000505	0.0249	0.15	0.11	Schizophrenia;	chr10:60345222	chr10:60734342~60741828:+
BRCA	cis	rs10761482	0.861	rs10994309	ENSG00000254271.1	RP11-131N11.4	3.49	0.000505	0.0249	0.15	0.11	Schizophrenia;	chr10:60345439	chr10:60734342~60741828:+
BRCA	cis	rs10761482	0.817	rs2061484	ENSG00000254271.1	RP11-131N11.4	3.49	0.000505	0.0249	0.15	0.11	Schizophrenia;	chr10:60345740	chr10:60734342~60741828:+
BRCA	cis	rs9951698	0.667	rs6505775	ENSG00000266969.1	RP11-773H22.4	3.49	0.000505	0.0249	0.14	0.11	Intelligence (multi-trait analysis);	chr18:12978184	chr18:12984694~12991173:-
BRCA	cis	rs7943953	1	rs1901855	ENSG00000254717.2	GLYATL1P2	-3.49	0.000505	0.0249	-0.14	-0.11	Odorant perception (&beta-ionone);	chr11:59452324	chr11:58878302~58893460:+
BRCA	cis	rs9467773	1	rs1321480	ENSG00000261353.1	CTA-14H9.5	-3.49	0.000505	0.0249	-0.11	-0.11	Intelligence (multi-trait analysis);	chr6:26532514	chr6:26527063~26527404:+
BRCA	cis	rs737008	0.922	rs2550475	ENSG00000262636.1	CTD-3088G3.4	3.49	0.000505	0.0249	0.15	0.11	Obesity-related traits;	chr16:11278129	chr16:11380859~11381118:-
BRCA	cis	rs3780378	0.87	rs7034878	ENSG00000214190.2	RNF152P1	3.49	0.000505	0.0249	0.12	0.11	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;Eosinophil percentage of white cells;	chr9:5058991	chr9:5418373~5418976:-
BRCA	cis	rs2281603	0.762	rs10132794	ENSG00000259116.1	RP11-973N13.4	-3.49	0.000505	0.0249	-0.1	-0.11	Lymphocyte counts;	chr14:64581793	chr14:64514154~64540368:-
BRCA	cis	rs524281	0.861	rs10750779	ENSG00000255038.1	RP11-1167A19.2	-3.49	0.000505	0.0249	-0.16	-0.11	Electroencephalogram traits;	chr11:66207120	chr11:66067277~66069619:-
BRCA	cis	rs11700980	0.636	rs11701464	ENSG00000232855.5	AF131217.1	-3.49	0.000505	0.0249	-0.18	-0.11	QRS complex (12-leadsum);	chr21:28913070	chr21:28439346~28674848:-
BRCA	cis	rs801193	1	rs11773829	ENSG00000275400.1	RP4-756H11.5	3.49	0.000505	0.0249	0.12	0.11	Aortic root size;	chr7:66676087	chr7:66553805~66554199:-
BRCA	cis	rs4352251	0.841	rs6543036	ENSG00000212283.1	SNORD89	3.49	0.000505	0.0249	0.23	0.11	Adiponectin levels (BMI-adjusted);Adiponectin levels;	chr2:101357595	chr2:101272936~101273049:-
BRCA	cis	rs801193	0.967	rs2707841	ENSG00000275400.1	RP4-756H11.5	-3.49	0.000505	0.0249	-0.12	-0.11	Aortic root size;	chr7:66692033	chr7:66553805~66554199:-
BRCA	cis	rs801193	1	rs4717310	ENSG00000275400.1	RP4-756H11.5	-3.49	0.000505	0.0249	-0.12	-0.11	Aortic root size;	chr7:66696020	chr7:66553805~66554199:-
BRCA	cis	rs801193	0.569	rs2707824	ENSG00000271064.1	RP11-792A8.3	-3.49	0.000505	0.0249	-0.13	-0.11	Aortic root size;	chr7:66724256	chr7:66748838~66749077:-
BRCA	cis	rs13401620	0.917	rs11683731	ENSG00000229326.3	AC069154.4	-3.49	0.000505	0.0249	-0.14	-0.11	Breast size;	chr2:119793186	chr2:119698623~119700151:+
BRCA	cis	rs6866721	0.608	rs712610	ENSG00000249167.1	CTB-118N6.2	3.49	0.000505	0.0249	0.13	0.11	Body mass index;	chr5:116885505	chr5:116574482~116591398:+
BRCA	cis	rs9467773	0.967	rs6932865	ENSG00000224843.5	LINC00240	-3.49	0.000505	0.0249	-0.12	-0.11	Intelligence (multi-trait analysis);	chr6:26539938	chr6:26956992~27023924:+
BRCA	cis	rs9467773	1	rs6933176	ENSG00000224843.5	LINC00240	-3.49	0.000505	0.0249	-0.12	-0.11	Intelligence (multi-trait analysis);	chr6:26539950	chr6:26956992~27023924:+
BRCA	cis	rs13256369	0.802	rs13255789	ENSG00000254153.1	CTA-398F10.2	3.49	0.000505	0.0249	0.15	0.11	Obesity-related traits;	chr8:8705281	chr8:8456909~8461337:-
BRCA	cis	rs78487399	0.808	rs1388387	ENSG00000234936.1	AC010883.5	3.49	0.000505	0.0249	0.16	0.11	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43509830	chr2:43229573~43233394:+
BRCA	cis	rs1479090	0.722	rs9654227	ENSG00000250027.1	RP11-563E2.2	-3.49	0.000505	0.0249	-0.14	-0.11	Lung cancer;	chr4:163100413	chr4:163108785~163119965:+
BRCA	cis	rs1479090	0.762	rs4691070	ENSG00000250027.1	RP11-563E2.2	-3.49	0.000505	0.0249	-0.14	-0.11	Lung cancer;	chr4:163100678	chr4:163108785~163119965:+
BRCA	cis	rs2216824	1	rs75320989	ENSG00000278908.1	RP11-523J2.1	3.49	0.000506	0.0249	0.19	0.11	Oropharynx cancer;	chr2:30883900	chr2:30677762~30679895:+
BRCA	cis	rs3096299	0.967	rs2965932	ENSG00000222019.6	URAHP	3.49	0.000506	0.0249	0.1	0.11	Multiple myeloma (IgH translocation);	chr16:89410643	chr16:90039761~90047773:-
BRCA	cis	rs997295	0.57	rs7170299	ENSG00000259673.4	IQCH-AS1	3.49	0.000506	0.0249	0.12	0.11	Motion sickness;	chr15:67580380	chr15:67403619~67521844:-
BRCA	cis	rs6792584	0.629	rs12635531	ENSG00000241316.5	SUCLG2-AS1	3.49	0.000506	0.0249	0.11	0.11	Corneal astigmatism;	chr3:67452909	chr3:67654697~67947713:+
BRCA	cis	rs7520050	0.581	rs3855959	ENSG00000280836.1	AL355480.1	3.49	0.000506	0.0249	0.13	0.11	Reticulocyte count;Red blood cell count;	chr1:46168202	chr1:45581219~45581321:-
BRCA	cis	rs875971	0.54	rs736270	ENSG00000232546.1	RP11-458F8.1	-3.49	0.000506	0.0249	-0.09	-0.11	Aortic root size;	chr7:65963835	chr7:66848496~66858136:+
BRCA	cis	rs2108622	0.727	rs9305069	ENSG00000214049.6	UCA1	3.49	0.000506	0.0249	0.15	0.11	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15872576	chr19:15828961~15836320:+
BRCA	cis	rs2486012	1	rs2486007	ENSG00000237950.1	RP11-7O11.3	-3.49	0.000506	0.0249	-0.19	-0.11	Intelligence (multi-trait analysis);	chr1:43968941	chr1:43944370~43946551:-
BRCA	cis	rs11239537	1	rs11239537	ENSG00000237840.5	FAM21FP	3.49	0.000506	0.0249	0.13	0.11	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr10:45487060	chr10:45706431~45727231:-
BRCA	cis	rs970548	0.69	rs10900220	ENSG00000237840.5	FAM21FP	3.49	0.000506	0.0249	0.13	0.11	Total cholesterol levels;HDL cholesterol;HDL cholesterol levels;Cholesterol, total;	chr10:45488474	chr10:45706431~45727231:-
BRCA	cis	rs7474896	1	rs11011370	ENSG00000120555.12	SEPT7P9	3.49	0.000506	0.0249	0.2	0.11	Obesity (extreme);	chr10:37794090	chr10:38383069~38402916:-
BRCA	cis	rs7474896	1	rs11011372	ENSG00000120555.12	SEPT7P9	3.49	0.000506	0.0249	0.2	0.11	Obesity (extreme);	chr10:37798355	chr10:38383069~38402916:-
BRCA	cis	rs7474896	1	rs35951606	ENSG00000120555.12	SEPT7P9	3.49	0.000506	0.0249	0.2	0.11	Obesity (extreme);	chr10:37799419	chr10:38383069~38402916:-
BRCA	cis	rs7474896	1	rs3824584	ENSG00000120555.12	SEPT7P9	3.49	0.000506	0.0249	0.2	0.11	Obesity (extreme);	chr10:37802381	chr10:38383069~38402916:-
BRCA	cis	rs2236231	0.55	rs12890988	ENSG00000259502.1	RP11-643G16.3	-3.49	0.000506	0.0249	-0.15	-0.11	Plasma kynurenine levels in major depressive disorder;	chr14:67597240	chr14:67610986~67613864:+
BRCA	cis	rs10056811	0.538	rs56174528	ENSG00000271815.1	CTD-2235C13.3	-3.49	0.000506	0.0249	-0.19	-0.11	Coronary artery disease;	chr5:75104691	chr5:75363760~75364242:+
BRCA	cis	rs13434995	0.513	rs62303726	ENSG00000273257.1	RP11-177J6.1	-3.49	0.000506	0.0249	-0.16	-0.11	Adiponectin levels;	chr4:55490415	chr4:55387949~55388271:+
BRCA	cis	rs13434995	0.513	rs55729020	ENSG00000273257.1	RP11-177J6.1	-3.49	0.000506	0.0249	-0.16	-0.11	Adiponectin levels;	chr4:55491681	chr4:55387949~55388271:+
BRCA	cis	rs13434995	0.513	rs3805156	ENSG00000273257.1	RP11-177J6.1	-3.49	0.000506	0.0249	-0.16	-0.11	Adiponectin levels;	chr4:55497925	chr4:55387949~55388271:+
BRCA	cis	rs13434995	0.513	rs62303731	ENSG00000273257.1	RP11-177J6.1	-3.49	0.000506	0.0249	-0.16	-0.11	Adiponectin levels;	chr4:55499667	chr4:55387949~55388271:+
BRCA	cis	rs13434995	0.513	rs62303732	ENSG00000273257.1	RP11-177J6.1	-3.49	0.000506	0.0249	-0.16	-0.11	Adiponectin levels;	chr4:55499868	chr4:55387949~55388271:+
BRCA	cis	rs13434995	0.513	rs56196624	ENSG00000273257.1	RP11-177J6.1	-3.49	0.000506	0.0249	-0.16	-0.11	Adiponectin levels;	chr4:55500340	chr4:55387949~55388271:+
BRCA	cis	rs13434995	0.513	rs62305265	ENSG00000273257.1	RP11-177J6.1	-3.49	0.000506	0.0249	-0.16	-0.11	Adiponectin levels;	chr4:55503474	chr4:55387949~55388271:+
BRCA	cis	rs2243480	1	rs3885839	ENSG00000226767.1	RP11-328P23.3	-3.49	0.000506	0.0249	-0.19	-0.11	Diabetic kidney disease;	chr7:65825416	chr7:65508773~65508944:-
BRCA	cis	rs453301	0.686	rs6748	ENSG00000254153.1	CTA-398F10.2	-3.49	0.000506	0.0249	-0.13	-0.11	Joint mobility (Beighton score);	chr8:9033292	chr8:8456909~8461337:-
BRCA	cis	rs875971	0.862	rs28470208	ENSG00000223473.2	GS1-124K5.3	-3.49	0.000506	0.0249	-0.08	-0.11	Aortic root size;	chr7:66119713	chr7:66491049~66493566:-
BRCA	cis	rs6490294	0.528	rs77030808	ENSG00000257624.1	RP1-128M12.3	3.49	0.000506	0.0249	0.2	0.11	Mean platelet volume;	chr12:111891224	chr12:112000739~112000985:-
BRCA	cis	rs34779708	1	rs12769189	ENSG00000269952.1	RP11-324I22.3	-3.49	0.000506	0.0249	-0.15	-0.11	Inflammatory bowel disease;Crohn's disease;	chr10:35110740	chr10:35210416~35210750:+
BRCA	cis	rs62244186	0.711	rs6778410	ENSG00000214820.3	MPRIPP1	3.49	0.000506	0.0249	0.12	0.11	Depressive symptoms;	chr3:44702501	chr3:44579938~44581026:-
BRCA	cis	rs600550	0.719	rs11230222	ENSG00000275344.1	MIR6503	3.49	0.000506	0.0249	0.12	0.11	Lipoprotein-associated phospholipase A2 activity and mass;	chr11:60268392	chr11:60209071~60209156:-
BRCA	cis	rs987724	0.555	rs9866373	ENSG00000240875.4	LINC00886	-3.49	0.000506	0.0249	-0.13	-0.11	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156901961	chr3:156747346~156817062:-
BRCA	cis	rs4908769	0.624	rs1763838	ENSG00000232912.4	RP5-1115A15.1	3.49	0.000506	0.0249	0.11	0.11	Allergy;	chr1:8413271	chr1:8424645~8434838:+
BRCA	cis	rs875971	0.862	rs13232191	ENSG00000271064.1	RP11-792A8.3	-3.49	0.000506	0.0249	-0.13	-0.11	Aortic root size;	chr7:66521661	chr7:66748838~66749077:-
BRCA	cis	rs875971	0.862	rs10950043	ENSG00000271064.1	RP11-792A8.3	-3.49	0.000506	0.0249	-0.13	-0.11	Aortic root size;	chr7:66523623	chr7:66748838~66749077:-
BRCA	cis	rs875971	0.862	rs17747530	ENSG00000271064.1	RP11-792A8.3	-3.49	0.000506	0.0249	-0.13	-0.11	Aortic root size;	chr7:66529742	chr7:66748838~66749077:-
BRCA	cis	rs875971	0.862	rs13536	ENSG00000271064.1	RP11-792A8.3	3.49	0.000506	0.0249	0.13	0.11	Aortic root size;	chr7:66554203	chr7:66748838~66749077:-
BRCA	cis	rs875971	0.862	rs801209	ENSG00000271064.1	RP11-792A8.3	3.49	0.000506	0.0249	0.13	0.11	Aortic root size;	chr7:66554403	chr7:66748838~66749077:-
BRCA	cis	rs875971	0.862	rs801206	ENSG00000271064.1	RP11-792A8.3	3.49	0.000506	0.0249	0.13	0.11	Aortic root size;	chr7:66556979	chr7:66748838~66749077:-
BRCA	cis	rs875971	0.862	rs801204	ENSG00000271064.1	RP11-792A8.3	3.49	0.000506	0.0249	0.13	0.11	Aortic root size;	chr7:66557934	chr7:66748838~66749077:-
BRCA	cis	rs875971	0.862	rs801203	ENSG00000271064.1	RP11-792A8.3	3.49	0.000506	0.0249	0.13	0.11	Aortic root size;	chr7:66558025	chr7:66748838~66749077:-
BRCA	cis	rs2154319	0.836	rs2749419	ENSG00000230638.4	RP11-486B10.4	3.49	0.000506	0.0249	0.18	0.11	Height;	chr1:41085769	chr1:41542069~41544310:+
BRCA	cis	rs10504130	1	rs61326367	ENSG00000272076.1	RP11-11C20.3	3.49	0.000506	0.0249	0.19	0.11	Venous thromboembolism (SNP x SNP interaction);	chr8:51775466	chr8:51810110~51810681:-
BRCA	cis	rs17345786	1	rs997739	ENSG00000256628.3	ZBTB11-AS1	3.49	0.000506	0.0249	0.15	0.11	Colonoscopy-negative controls vs population controls;	chr3:101595096	chr3:101676475~101679217:+
BRCA	cis	rs6840360	0.615	rs6535822	ENSG00000270265.1	RP11-731D1.4	-3.49	0.000506	0.0249	-0.12	-0.11	Intelligence (multi-trait analysis);	chr4:151758570	chr4:151333775~151353224:-
BRCA	cis	rs77633900	0.614	rs280008	ENSG00000196274.5	Metazoa_SRP	3.49	0.000506	0.0249	0.16	0.11	Glioma;Non-glioblastoma glioma;	chr15:76719474	chr15:76230048~76230390:-
BRCA	cis	rs10463316	0.817	rs10052992	ENSG00000260581.1	CTB-113P19.4	3.49	0.000506	0.0249	0.12	0.11	Metabolite levels (Pyroglutamine);	chr5:151409041	chr5:151652275~151655449:+
BRCA	cis	rs11711311	0.747	rs9882193	ENSG00000241529.3	RN7SL767P	3.49	0.000506	0.0249	0.12	0.11	IgG glycosylation;	chr3:113630604	chr3:113632704~113632998:+
BRCA	cis	rs72928364	0.858	rs66598219	ENSG00000256628.3	ZBTB11-AS1	3.49	0.000507	0.0249	0.21	0.11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:101060591	chr3:101676475~101679217:+
BRCA	cis	rs739401	0.611	rs402276	ENSG00000183562.3	CTC-343N3.1	-3.49	0.000507	0.0249	-0.11	-0.11	Longevity;	chr11:3030174	chr11:2989863~2991344:+
BRCA	cis	rs17711722	1	rs17711722	ENSG00000227113.2	RP11-460N20.4	-3.49	0.000507	0.0249	-0.11	-0.11	Calcium levels;	chr7:65806210	chr7:65075023~65078780:+
BRCA	cis	rs6671200	0.573	rs6666528	ENSG00000226026.4	RP11-57H12.3	-3.49	0.000507	0.0249	-0.16	-0.11	Stearic acid (18:0) levels;	chr1:95231934	chr1:95163219~95233982:-
BRCA	cis	rs4908769	0.588	rs2784737	ENSG00000232912.4	RP5-1115A15.1	-3.49	0.000507	0.0249	-0.12	-0.11	Allergy;	chr1:8403116	chr1:8424645~8434838:+
BRCA	cis	rs6912958	0.535	rs242283	ENSG00000272008.1	RP11-393I2.4	-3.49	0.000507	0.0249	-0.12	-0.11	Monocyte percentage of white cells;	chr6:87321213	chr6:87151159~87155285:-
BRCA	cis	rs748404	0.666	rs12905220	ENSG00000166763.7	STRCP1	3.49	0.000507	0.0249	0.15	0.11	Lung cancer;	chr15:43465641	chr15:43699488~43718184:-
BRCA	cis	rs8105895	0.877	rs28822164	ENSG00000269345.1	VN1R85P	3.49	0.000507	0.0249	0.15	0.11	Body mass index (change over time);	chr19:22062306	chr19:22174766~22175191:-
BRCA	cis	rs4691139	0.588	rs7680569	ENSG00000248632.1	RP11-366M4.11	3.49	0.000507	0.0249	0.12	0.11	Ovarian cancer in BRCA1 mutation carriers;	chr4:164978073	chr4:164968587~164970002:-
BRCA	cis	rs875971	0.666	rs13242072	ENSG00000232546.1	RP11-458F8.1	3.49	0.000507	0.0249	0.09	0.11	Aortic root size;	chr7:66301001	chr7:66848496~66858136:+
BRCA	cis	rs875971	1	rs4718307	ENSG00000271064.1	RP11-792A8.3	3.49	0.000507	0.0249	0.12	0.11	Aortic root size;	chr7:66146001	chr7:66748838~66749077:-
BRCA	cis	rs875971	1	rs7801282	ENSG00000271064.1	RP11-792A8.3	3.49	0.000507	0.0249	0.12	0.11	Aortic root size;	chr7:66148700	chr7:66748838~66749077:-
BRCA	cis	rs34792	0.554	rs12708796	ENSG00000275910.1	RP11-680G24.6	-3.49	0.000507	0.0249	-0.13	-0.11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15535980	chr16:15015828~15016390:-
BRCA	cis	rs6496932	0.874	rs11074061	ENSG00000259774.1	RP11-182J1.13	3.49	0.000507	0.0249	0.16	0.11	Central corneal thickness;Corneal structure;	chr15:85274962	chr15:84422618~84425882:+
BRCA	cis	rs7267979	0.899	rs442834	ENSG00000204556.4	CTD-2514C3.1	-3.49	0.000507	0.0249	-0.14	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25477460	chr20:26018832~26020684:+
BRCA	cis	rs495337	0.736	rs596195	ENSG00000224397.4	LINC01272	-3.49	0.000507	0.0249	-0.11	-0.11	Psoriasis;	chr20:49858231	chr20:50267486~50279795:+
BRCA	cis	rs60871478	0.73	rs62432226	ENSG00000237181.1	AC147651.4	-3.49	0.000507	0.025	-0.12	-0.11	Cerebrospinal P-tau181p levels;	chr7:753336	chr7:603185~608482:+
BRCA	cis	rs8180040	0.593	rs12715421	ENSG00000280667.1	Y_RNA	3.49	0.000507	0.025	0.12	0.11	Colorectal cancer;	chr3:47043369	chr3:47501083~47501182:+
BRCA	cis	rs1823874	0.71	rs4246297	ENSG00000259363.4	CTD-2054N24.2	3.49	0.000507	0.025	0.13	0.11	IgG glycosylation;	chr15:99826723	chr15:99807023~99877148:+
BRCA	cis	rs2638953	0.962	rs11049611	ENSG00000273989.1	RP11-425D17.2	-3.49	0.000507	0.025	-0.16	-0.11	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28447311	chr12:28236227~28236828:+
BRCA	cis	rs7020830	0.898	rs2047010	ENSG00000230188.1	RP11-405L18.4	-3.49	0.000507	0.025	-0.13	-0.11	Schizophrenia;	chr9:37077950	chr9:37490421~37490893:-
BRCA	cis	rs6914598	0.876	rs6941714	ENSG00000240869.3	RN7SL128P	3.49	0.000507	0.025	0.15	0.11	Cutaneous malignant melanoma;Melanoma;	chr6:21164897	chr6:20421583~20421887:-
BRCA	cis	rs2411233	1	rs2411234	ENSG00000259278.1	RP11-62C7.2	3.49	0.000507	0.025	0.13	0.11	Platelet count;	chr15:38982616	chr15:39019233~39024918:+
BRCA	cis	rs6565180	0.963	rs4787642	ENSG00000261332.1	RP11-297C4.1	-3.49	0.000507	0.025	-0.14	-0.11	Tonsillectomy;	chr16:30348087	chr16:30498766~30499554:-
BRCA	cis	rs3136202	0.684	rs187613	ENSG00000242307.1	RPS26P52	3.49	0.000507	0.025	0.14	0.11	Conduct disorder (symptom count);	chr16:13980739	chr16:13922332~13922679:-
BRCA	cis	rs818427	0.737	rs411356	ENSG00000279522.1	CTC-487M23.6	-3.49	0.000508	0.025	-0.12	-0.11	Total body bone mineral density;	chr5:112836522	chr5:112894933~112896531:+
BRCA	cis	rs9467773	0.596	rs2451750	ENSG00000261353.1	CTA-14H9.5	-3.49	0.000508	0.025	-0.11	-0.11	Intelligence (multi-trait analysis);	chr6:26646351	chr6:26527063~26527404:+
BRCA	cis	rs9467773	0.596	rs2451751	ENSG00000261353.1	CTA-14H9.5	-3.49	0.000508	0.025	-0.11	-0.11	Intelligence (multi-trait analysis);	chr6:26646486	chr6:26527063~26527404:+
BRCA	cis	rs4272720	0.901	rs7905715	ENSG00000228754.1	RP11-534L6.3	-3.49	0.000508	0.025	-0.16	-0.11	Platelet count;Plateletcrit;	chr10:49173186	chr10:48745545~48746128:-
BRCA	cis	rs1865760	1	rs7770139	ENSG00000272810.1	U91328.22	-3.49	0.000508	0.025	-0.13	-0.11	Height;	chr6:25925595	chr6:26013241~26013757:+
BRCA	cis	rs875971	1	rs12698523	ENSG00000229886.1	RP5-1132H15.3	3.49	0.000508	0.025	0.12	0.11	Aortic root size;	chr7:66503126	chr7:66025126~66031544:-
BRCA	cis	rs1670533	0.932	rs6599276	ENSG00000251639.2	RP11-20I20.1	3.49	0.000508	0.025	0.17	0.11	Recombination rate (females);	chr4:1063039	chr4:1100016~1101558:-
BRCA	cis	rs308447	0.516	rs13142203	ENSG00000224786.1	CETN4P	3.49	0.000508	0.025	0.16	0.11	Perceived unattractiveness to mosquitoes;	chr4:122757847	chr4:122730548~122732193:-
BRCA	cis	rs10501293	0.956	rs10768918	ENSG00000252652.1	Y_RNA	3.49	0.000508	0.025	0.13	0.11	Cognitive performance;	chr11:43112931	chr11:43331261~43331356:+
BRCA	cis	rs6452790	0.529	rs10078703	ENSG00000247828.6	TMEM161B-AS1	-3.49	0.000508	0.025	-0.14	-0.11	Cognitive function;	chr5:87972416	chr5:88268895~88436685:+
BRCA	cis	rs4869313	0.642	rs1216565	ENSG00000248734.2	CTD-2260A17.1	3.49	0.000508	0.025	0.11	0.11	Pediatric autoimmune diseases;	chr5:96930175	chr5:96784777~96785999:+
BRCA	cis	rs7267979	0.933	rs2258728	ENSG00000204556.4	CTD-2514C3.1	-3.49	0.000508	0.025	-0.15	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25295707	chr20:26018832~26020684:+
BRCA	cis	rs2562456	0.682	rs11085464	ENSG00000240522.1	RPL7AP10	-3.49	0.000508	0.025	-0.12	-0.11	Pain;	chr19:21568976	chr19:21149648~21150438:-
BRCA	cis	rs748404	0.666	rs12906481	ENSG00000166763.7	STRCP1	3.49	0.000508	0.025	0.16	0.11	Lung cancer;	chr15:43467356	chr15:43699488~43718184:-
BRCA	cis	rs748404	0.666	rs35958032	ENSG00000166763.7	STRCP1	3.49	0.000508	0.025	0.16	0.11	Lung cancer;	chr15:43494397	chr15:43699488~43718184:-
BRCA	cis	rs2320614	0.806	rs17471740	ENSG00000250027.1	RP11-563E2.2	-3.49	0.000508	0.025	-0.12	-0.11	Lung adenocarcinoma;	chr4:163179124	chr4:163108785~163119965:+
BRCA	cis	rs637571	0.524	rs674363	ENSG00000255320.1	RP11-755F10.1	3.49	0.000508	0.025	0.14	0.11	Eosinophil percentage of white cells;	chr11:65931663	chr11:66244840~66246239:-
BRCA	cis	rs8181477	1	rs11014504	ENSG00000240291.1	RP11-499P20.2	-3.49	0.000508	0.025	-0.1	-0.11	Obesity-related traits;	chr10:18495059	chr10:18513115~18545651:-
BRCA	cis	rs9341808	0.754	rs9352817	ENSG00000233967.5	RP11-250B2.3	3.49	0.000508	0.025	0.11	0.11	Sitting height ratio;	chr6:80316162	chr6:80443344~80465927:+
BRCA	cis	rs8141529	0.719	rs5762880	ENSG00000226471.5	CTA-292E10.6	-3.49	0.000508	0.025	-0.13	-0.11	Lymphocyte counts;	chr22:28891828	chr22:28800683~28848559:+
BRCA	cis	rs2274273	0.805	rs28612464	ENSG00000259318.1	RP11-454L9.2	3.49	0.000508	0.025	0.09	0.11	Protein biomarker;	chr14:55349693	chr14:55394940~55395233:-
BRCA	cis	rs2274273	0.773	rs28430823	ENSG00000259318.1	RP11-454L9.2	3.49	0.000508	0.025	0.09	0.11	Protein biomarker;	chr14:55349842	chr14:55394940~55395233:-
BRCA	cis	rs2274273	0.87	rs17741831	ENSG00000259318.1	RP11-454L9.2	3.49	0.000508	0.025	0.09	0.11	Protein biomarker;	chr14:55349997	chr14:55394940~55395233:-
BRCA	cis	rs8180040	1	rs2159400	ENSG00000260236.1	RP11-708J19.1	-3.49	0.000508	0.025	-0.1	-0.11	Colorectal cancer;	chr3:47334400	chr3:47379089~47380999:-
BRCA	cis	rs6840360	0.55	rs7675818	ENSG00000270265.1	RP11-731D1.4	-3.49	0.000508	0.025	-0.12	-0.11	Intelligence (multi-trait analysis);	chr4:151769625	chr4:151333775~151353224:-
BRCA	cis	rs6840360	0.593	rs7654294	ENSG00000270265.1	RP11-731D1.4	-3.49	0.000508	0.025	-0.12	-0.11	Intelligence (multi-trait analysis);	chr4:151769823	chr4:151333775~151353224:-
BRCA	cis	rs7834765	0.747	rs1354503	ENSG00000248690.5	HAS2-AS1	3.49	0.000508	0.025	0.12	0.11	Lupus nephritis in systemic lupus erythematosus;	chr8:121260260	chr8:121639293~121644693:+
BRCA	cis	rs6088590	0.71	rs6059992	ENSG00000275784.1	RP5-1125A11.6	-3.49	0.000508	0.025	-0.12	-0.11	Coronary artery disease;	chr20:34694471	chr20:33989480~33991818:-
BRCA	cis	rs1865760	0.566	rs9379825	ENSG00000272462.2	U91328.19	-3.49	0.000508	0.025	-0.13	-0.11	Height;	chr6:26083643	chr6:25992662~26001775:+
BRCA	cis	rs1865760	0.566	rs9467672	ENSG00000272462.2	U91328.19	-3.49	0.000508	0.025	-0.13	-0.11	Height;	chr6:26083676	chr6:25992662~26001775:+
BRCA	cis	rs1865760	0.566	rs9295688	ENSG00000272462.2	U91328.19	-3.49	0.000508	0.025	-0.13	-0.11	Height;	chr6:26083989	chr6:25992662~26001775:+
BRCA	cis	rs6142618	0.562	rs4911543	ENSG00000275576.1	RP5-836N17.4	-3.49	0.000508	0.025	-0.12	-0.11	Inflammatory bowel disease;	chr20:32107342	chr20:32116171~32116629:+
BRCA	cis	rs2823962	0.892	rs11700811	ENSG00000270093.1	AP000473.8	-3.49	0.000508	0.025	-0.11	-0.11	Amyotrophic lateral sclerosis;	chr21:16659142	chr21:16643529~16645065:+
BRCA	cis	rs11892454	0.599	rs56121630	ENSG00000217643.1	PTGES3P2	-3.49	0.000508	0.025	-0.12	-0.11	Heschl's gyrus morphology;	chr2:25777485	chr2:25822469~25822950:+
BRCA	cis	rs2880765	0.835	rs6497202	ENSG00000230373.7	GOLGA6L5P	3.49	0.000508	0.025	0.11	0.11	Coronary artery disease;	chr15:85478144	chr15:84507885~84516814:-
BRCA	cis	rs6840360	0.573	rs11099806	ENSG00000278978.1	RP11-164P12.5	-3.49	0.000508	0.025	-0.12	-0.11	Intelligence (multi-trait analysis);	chr4:151347964	chr4:151669786~151670503:+
BRCA	cis	rs6582630	0.621	rs10880656	ENSG00000257718.1	RP11-396F22.1	-3.49	0.000508	0.025	-0.11	-0.11	Drug-induced liver injury (flucloxacillin);	chr12:38177418	chr12:38906451~38909592:+
BRCA	cis	rs794185	0.592	rs304010	ENSG00000231249.1	ITPR1-AS1	3.49	0.000508	0.025	0.13	0.11	Multiple sclerosis--Brain Glutamate Levels;	chr3:4518579	chr3:4490891~4493163:-
BRCA	cis	rs7735319	0.584	rs6890760	ENSG00000249572.1	CTD-2203K17.1	3.49	0.000508	0.025	0.13	0.11	Systolic blood pressure;	chr5:33103000	chr5:33424025~33440619:-
BRCA	cis	rs10043775	0.793	rs1862431	ENSG00000251330.3	CTD-2283N19.1	-3.49	0.000508	0.025	-0.12	-0.11	Periodontal microbiota;	chr5:148313860	chr5:148430159~148430807:-
BRCA	cis	rs6490294	0.571	rs7973898	ENSG00000234608.6	MAPKAPK5-AS1	3.49	0.000508	0.025	0.16	0.11	Mean platelet volume;	chr12:112178363	chr12:111839764~111842902:-
BRCA	cis	rs10761482	0.861	rs2061486	ENSG00000254271.1	RP11-131N11.4	3.49	0.000508	0.025	0.15	0.11	Schizophrenia;	chr10:60346158	chr10:60734342~60741828:+
BRCA	cis	rs7246657	0.653	rs10406612	ENSG00000267470.4	ZNF571-AS1	3.49	0.000508	0.025	0.16	0.11	Coronary artery calcification;	chr19:37225709	chr19:37548914~37587348:+
BRCA	cis	rs34217772	0.83	rs57130262	ENSG00000258636.1	CTD-2298J14.2	3.49	0.000508	0.025	0.15	0.11	Myopia;	chr14:41746601	chr14:41587861~41604856:-
BRCA	cis	rs875971	0.862	rs1981799	ENSG00000273024.4	INTS4P2	-3.49	0.000509	0.025	-0.12	-0.11	Aortic root size;	chr7:66490572	chr7:65647864~65715661:+
BRCA	cis	rs875971	0.83	rs809025	ENSG00000265600.1	AC006480.1	-3.49	0.000509	0.025	-0.13	-0.11	Aortic root size;	chr7:66384832	chr7:67356680~67356779:+
BRCA	cis	rs1555133	0.625	rs6141671	ENSG00000275576.1	RP5-836N17.4	-3.49	0.000509	0.025	-0.12	-0.11	Monocyte count;	chr20:32317768	chr20:32116171~32116629:+
BRCA	cis	rs4243971	0.516	rs4911216	ENSG00000275576.1	RP5-836N17.4	-3.49	0.000509	0.025	-0.12	-0.11	Inflammatory bowel disease;Crohn's disease;	chr20:32322107	chr20:32116171~32116629:+
BRCA	cis	rs4243971	0.516	rs4911217	ENSG00000275576.1	RP5-836N17.4	-3.49	0.000509	0.025	-0.12	-0.11	Inflammatory bowel disease;Crohn's disease;	chr20:32322148	chr20:32116171~32116629:+
BRCA	cis	rs4243971	0.516	rs56012551	ENSG00000275576.1	RP5-836N17.4	-3.49	0.000509	0.025	-0.12	-0.11	Inflammatory bowel disease;Crohn's disease;	chr20:32323312	chr20:32116171~32116629:+
BRCA	cis	rs4243971	0.516	rs56366536	ENSG00000275576.1	RP5-836N17.4	-3.49	0.000509	0.025	-0.12	-0.11	Inflammatory bowel disease;Crohn's disease;	chr20:32323462	chr20:32116171~32116629:+
BRCA	cis	rs1555133	0.624	rs55647947	ENSG00000275576.1	RP5-836N17.4	-3.49	0.000509	0.025	-0.12	-0.11	Monocyte count;	chr20:32323583	chr20:32116171~32116629:+
BRCA	cis	rs4243971	0.516	rs13043343	ENSG00000275576.1	RP5-836N17.4	-3.49	0.000509	0.025	-0.12	-0.11	Inflammatory bowel disease;Crohn's disease;	chr20:32324404	chr20:32116171~32116629:+
BRCA	cis	rs4243971	0.516	rs2024952	ENSG00000275576.1	RP5-836N17.4	-3.49	0.000509	0.025	-0.12	-0.11	Inflammatory bowel disease;Crohn's disease;	chr20:32326149	chr20:32116171~32116629:+
BRCA	cis	rs4243971	0.516	rs3746606	ENSG00000275576.1	RP5-836N17.4	-3.49	0.000509	0.025	-0.12	-0.11	Inflammatory bowel disease;Crohn's disease;	chr20:32326903	chr20:32116171~32116629:+
BRCA	cis	rs1468333	0.537	rs13184188	ENSG00000206989.1	SNORD63	3.49	0.000509	0.025	0.12	0.11	Resting heart rate;	chr5:138453830	chr5:138561043~138561110:-
BRCA	cis	rs6901004	0.803	rs354524	ENSG00000271789.1	RP5-1112D6.7	3.49	0.000509	0.025	0.12	0.11	Blood metabolite levels;	chr6:111186906	chr6:111297126~111298510:+
BRCA	cis	rs27434	0.583	rs40091	ENSG00000248734.2	CTD-2260A17.1	3.49	0.000509	0.025	0.12	0.11	Ankylosing spondylitis;	chr5:96819216	chr5:96784777~96785999:+
BRCA	cis	rs2400749	0.739	rs4268691	ENSG00000258521.1	RP11-638I2.9	-3.49	0.000509	0.025	-0.11	-0.11	Alzheimer's disease (survival time);	chr14:99568570	chr14:100339832~100340554:+
BRCA	cis	rs10761482	0.817	rs4948404	ENSG00000254271.1	RP11-131N11.4	3.49	0.000509	0.025	0.15	0.11	Schizophrenia;	chr10:60348444	chr10:60734342~60741828:+
BRCA	cis	rs10761482	0.768	rs3919830	ENSG00000254271.1	RP11-131N11.4	3.49	0.000509	0.025	0.15	0.11	Schizophrenia;	chr10:60348447	chr10:60734342~60741828:+
BRCA	cis	rs875971	1	rs12533997	ENSG00000273024.4	INTS4P2	-3.49	0.000509	0.025	-0.12	-0.11	Aortic root size;	chr7:66500390	chr7:65647864~65715661:+
BRCA	cis	rs425277	0.583	rs4648807	ENSG00000182873.5	RP11-181G12.2	-3.49	0.000509	0.025	-0.1	-0.11	Height;	chr1:2109459	chr1:2181794~2184389:-
BRCA	cis	rs72772090	0.539	rs72773969	ENSG00000272109.1	CTD-2260A17.3	3.49	0.000509	0.025	0.22	0.11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96809493	chr5:96804353~96806105:+
BRCA	cis	rs987724	0.555	rs12629380	ENSG00000240875.4	LINC00886	-3.49	0.000509	0.025	-0.13	-0.11	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156898291	chr3:156747346~156817062:-
BRCA	cis	rs4819052	0.808	rs2246697	ENSG00000223768.1	LINC00205	-3.49	0.000509	0.025	-0.14	-0.11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45270084	chr21:45293285~45297354:+
BRCA	cis	rs4819052	0.819	rs7279136	ENSG00000223768.1	LINC00205	-3.49	0.000509	0.025	-0.14	-0.11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45272372	chr21:45293285~45297354:+
BRCA	cis	rs4819052	0.788	rs4819051	ENSG00000223768.1	LINC00205	-3.49	0.000509	0.025	-0.14	-0.11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45273213	chr21:45293285~45297354:+
BRCA	cis	rs4819052	0.819	rs8134084	ENSG00000223768.1	LINC00205	-3.49	0.000509	0.025	-0.14	-0.11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45273380	chr21:45293285~45297354:+
BRCA	cis	rs4819052	0.851	rs7276828	ENSG00000223768.1	LINC00205	-3.49	0.000509	0.025	-0.14	-0.11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45275124	chr21:45293285~45297354:+
BRCA	cis	rs4819052	0.851	rs7281263	ENSG00000223768.1	LINC00205	-3.49	0.000509	0.025	-0.14	-0.11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45275691	chr21:45293285~45297354:+
BRCA	cis	rs4819052	0.851	rs914214	ENSG00000223768.1	LINC00205	-3.49	0.000509	0.025	-0.14	-0.11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45277905	chr21:45293285~45297354:+
BRCA	cis	rs867371	0.82	rs7164362	ENSG00000276710.3	CSPG4P8	-3.49	0.000509	0.025	-0.12	-0.11	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82194401	chr15:82459472~82477258:+
BRCA	cis	rs10256972	0.758	rs11979275	ENSG00000199023.2	MIR339	-3.49	0.000509	0.025	-0.13	-0.11	Endometriosis;Longevity;	chr7:1029699	chr7:1022935~1023045:-
BRCA	cis	rs10256972	0.758	rs11980081	ENSG00000199023.2	MIR339	-3.49	0.000509	0.025	-0.13	-0.11	Endometriosis;Longevity;	chr7:1029736	chr7:1022935~1023045:-
BRCA	cis	rs6495122	0.501	rs7167261	ENSG00000260269.4	CTD-2323K18.1	3.49	0.000509	0.025	0.14	0.11	Diastolic blood pressure;Coffee consumption;Caffeine consumption;	chr15:75051466	chr15:75527150~75601205:-
BRCA	cis	rs4148883	0.689	rs1311621	ENSG00000272777.1	RP11-571L19.8	-3.49	0.000509	0.025	-0.11	-0.11	Alcohol dependence;	chr4:99092867	chr4:99067256~99068125:-
BRCA	cis	rs6088590	0.931	rs12625149	ENSG00000276073.1	RP5-1125A11.7	3.49	0.000509	0.025	0.13	0.11	Coronary artery disease;	chr20:34838009	chr20:33985617~33988989:-
BRCA	cis	rs911119	0.866	rs2405393	ENSG00000270001.1	RP11-218C14.8	-3.49	0.000509	0.025	-0.14	-0.11	Chronic kidney disease;	chr20:23588755	chr20:23631826~23632316:-
BRCA	cis	rs911119	0.866	rs4346460	ENSG00000270001.1	RP11-218C14.8	-3.49	0.000509	0.025	-0.14	-0.11	Chronic kidney disease;	chr20:23588763	chr20:23631826~23632316:-
BRCA	cis	rs7824557	0.806	rs6601573	ENSG00000255046.1	RP11-297N6.4	3.49	0.000509	0.025	0.13	0.11	Retinal vascular caliber;	chr8:11237242	chr8:11797928~11802568:-
BRCA	cis	rs10501293	1	rs12222341	ENSG00000252652.1	Y_RNA	3.49	0.000509	0.025	0.13	0.11	Cognitive performance;	chr11:43105172	chr11:43331261~43331356:+
BRCA	cis	rs10129255	0.957	rs12590735	ENSG00000211958.2	IGHV3-38	3.49	0.000509	0.025	0.08	0.11	Kawasaki disease;	chr14:106779660	chr14:106410493~106411021:-
BRCA	cis	rs67180937	0.553	rs2936020	ENSG00000225265.1	TAF1A-AS1	-3.49	0.000509	0.025	-0.14	-0.11	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222655754	chr1:222589825~222593032:+
BRCA	cis	rs2562456	0.752	rs7258562	ENSG00000240522.1	RPL7AP10	-3.49	0.000509	0.025	-0.12	-0.11	Pain;	chr19:21331762	chr19:21149648~21150438:-
BRCA	cis	rs7577696	0.853	rs430759	ENSG00000276334.1	AL133243.1	-3.49	0.000509	0.025	-0.13	-0.11	Inflammatory biomarkers;	chr2:32222799	chr2:32521927~32523547:+
BRCA	cis	rs253959	0.545	rs712599	ENSG00000248445.4	SEMA6A-AS1	-3.49	0.000509	0.025	-0.1	-0.11	Bipolar disorder and schizophrenia;	chr5:116323068	chr5:116447547~116508276:+
BRCA	cis	rs9325144	0.56	rs61929893	ENSG00000257718.1	RP11-396F22.1	-3.49	0.000509	0.025	-0.11	-0.11	Morning vs. evening chronotype;	chr12:38259564	chr12:38906451~38909592:+
BRCA	cis	rs9325144	0.56	rs10785573	ENSG00000257718.1	RP11-396F22.1	-3.49	0.000509	0.025	-0.11	-0.11	Morning vs. evening chronotype;	chr12:38260364	chr12:38906451~38909592:+
BRCA	cis	rs16893526	1	rs11969940	ENSG00000224995.1	LINC01526	-3.49	0.000509	0.0251	-0.2	-0.11	Coronary heart disease;	chr6:81795771	chr6:81813286~81814157:-
BRCA	cis	rs6479874	1	rs7080757	ENSG00000223502.1	RP11-96B5.3	-3.49	0.000509	0.0251	-0.2	-0.11	Migraine;	chr10:50999793	chr10:51062579~51068553:-
BRCA	cis	rs875971	1	rs11971949	ENSG00000271064.1	RP11-792A8.3	3.49	0.00051	0.0251	0.13	0.11	Aortic root size;	chr7:66161027	chr7:66748838~66749077:-
BRCA	cis	rs7829975	0.564	rs2921060	ENSG00000233609.3	RP11-62H7.2	-3.49	0.00051	0.0251	-0.1	-0.11	Mood instability;	chr8:8460307	chr8:8961200~8979025:+
BRCA	cis	rs73201462	0.708	rs11709725	ENSG00000242551.2	POU5F1P6	3.49	0.00051	0.0251	0.18	0.11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128139090	chr3:128674735~128677005:-
BRCA	cis	rs9990333	1	rs9990333	ENSG00000224769.1	AC069213.1	-3.49	0.00051	0.0251	-0.15	-0.11	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196100334	chr3:195614947~195620233:+
BRCA	cis	rs3764021	0.527	rs10844537	ENSG00000278635.1	CTD-2318O12.1	-3.49	0.00051	0.0251	-0.12	-0.11	Type 1 diabetes;	chr12:9709528	chr12:9415641~9416718:+
BRCA	cis	rs6696239	0.956	rs1995019	ENSG00000215812.5	ZNF847P	3.49	0.00051	0.0251	0.15	0.11	Height;	chr1:227580096	chr1:227696892~227706699:-
BRCA	cis	rs34217772	0.83	rs58644188	ENSG00000258636.1	CTD-2298J14.2	3.49	0.00051	0.0251	0.15	0.11	Myopia;	chr14:41745351	chr14:41587861~41604856:-
BRCA	cis	rs34217772	0.771	rs57676929	ENSG00000258636.1	CTD-2298J14.2	3.49	0.00051	0.0251	0.15	0.11	Myopia;	chr14:41745826	chr14:41587861~41604856:-
BRCA	cis	rs2281603	0.951	rs1982440	ENSG00000259116.1	RP11-973N13.4	-3.49	0.00051	0.0251	-0.1	-0.11	Lymphocyte counts;	chr14:64494049	chr14:64514154~64540368:-
BRCA	cis	rs7615952	0.512	rs2979334	ENSG00000248787.1	RP11-666A20.4	-3.49	0.00051	0.0251	-0.16	-0.11	Blood pressure (smoking interaction);	chr3:125639980	chr3:125908005~125910272:-
BRCA	cis	rs7615952	0.512	rs11921452	ENSG00000248787.1	RP11-666A20.4	-3.49	0.00051	0.0251	-0.16	-0.11	Blood pressure (smoking interaction);	chr3:125640906	chr3:125908005~125910272:-
BRCA	cis	rs10484434	0.818	rs11759668	ENSG00000272810.1	U91328.22	3.49	0.00051	0.0251	0.15	0.11	HIV-1 viral setpoint;	chr6:26014261	chr6:26013241~26013757:+
BRCA	cis	rs9549328	0.756	rs2993291	ENSG00000267868.1	RP11-120K24.3	3.49	0.00051	0.0251	0.15	0.11	Systolic blood pressure;	chr13:112999532	chr13:112964835~112966131:-
BRCA	cis	rs962856	0.619	rs7592026	ENSG00000236605.1	AC023115.4	-3.49	0.00051	0.0251	-0.14	-0.11	Pancreatic cancer;	chr2:67368007	chr2:67324627~67325304:+
BRCA	cis	rs10504130	0.569	rs12676345	ENSG00000272076.1	RP11-11C20.3	3.49	0.00051	0.0251	0.15	0.11	Venous thromboembolism (SNP x SNP interaction);	chr8:51773249	chr8:51810110~51810681:-
BRCA	cis	rs10198628	1	rs7558700	ENSG00000264370.1	MIR3125	3.49	0.00051	0.0251	0.12	0.11	Pericardial fat;Pericardial adipose tissue adjusted for height and weight;	chr2:12829767	chr2:12737367~12737444:+
BRCA	cis	rs721917	0.506	rs2819102	ENSG00000225484.5	NUTM2B-AS1	-3.49	0.00051	0.0251	-0.14	-0.11	Chronic obstructive pulmonary disease;	chr10:79928914	chr10:79663088~79826594:-
BRCA	cis	rs4919694	1	rs7099987	ENSG00000236937.2	PTGES3P4	3.49	0.00051	0.0251	0.22	0.11	Arsenic metabolism;	chr10:103048169	chr10:102845595~102845950:+
BRCA	cis	rs10266483	0.921	rs651934	ENSG00000271550.1	BNIP3P11	3.49	0.00051	0.0251	0.14	0.11	Response to statin therapy;	chr7:64283972	chr7:64678954~64687393:-
BRCA	cis	rs875971	0.895	rs7788984	ENSG00000271064.1	RP11-792A8.3	-3.49	0.00051	0.0251	-0.13	-0.11	Aortic root size;	chr7:66450629	chr7:66748838~66749077:-
BRCA	cis	rs4699052	0.963	rs2085978	ENSG00000246560.2	RP11-10L12.4	3.49	0.00051	0.0251	0.11	0.11	Testicular germ cell tumor;	chr4:103272457	chr4:102828055~102844075:+
BRCA	cis	rs6840360	0.533	rs13145446	ENSG00000270265.1	RP11-731D1.4	3.49	0.00051	0.0251	0.13	0.11	Intelligence (multi-trait analysis);	chr4:151807883	chr4:151333775~151353224:-
BRCA	cis	rs6840360	0.533	rs13121178	ENSG00000270265.1	RP11-731D1.4	3.49	0.00051	0.0251	0.13	0.11	Intelligence (multi-trait analysis);	chr4:151807895	chr4:151333775~151353224:-
BRCA	cis	rs11098499	0.954	rs12502423	ENSG00000225892.3	RP11-384K6.2	3.49	0.00051	0.0251	0.11	0.11	Corneal astigmatism;	chr4:119503017	chr4:118632274~118634759:+
BRCA	cis	rs11250097	0.507	rs2409779	ENSG00000255020.1	AF131216.5	3.49	0.00051	0.0251	0.13	0.11	Neuroticism;	chr8:11453831	chr8:11345748~11347502:-
BRCA	cis	rs7267979	0.866	rs437635	ENSG00000204556.4	CTD-2514C3.1	-3.49	0.00051	0.0251	-0.14	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25476252	chr20:26018832~26020684:+
BRCA	cis	rs7267979	0.932	rs417110	ENSG00000204556.4	CTD-2514C3.1	-3.49	0.00051	0.0251	-0.14	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25477661	chr20:26018832~26020684:+
BRCA	cis	rs7267979	0.932	rs449703	ENSG00000204556.4	CTD-2514C3.1	-3.49	0.00051	0.0251	-0.14	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25477923	chr20:26018832~26020684:+
BRCA	cis	rs853679	0.76	rs11962305	ENSG00000261839.1	RP1-265C24.8	3.49	0.00051	0.0251	0.16	0.11	Depression;	chr6:28232159	chr6:28136849~28139678:+
BRCA	cis	rs1387259	0.619	rs2130095	ENSG00000257735.1	RP11-370I10.6	-3.49	0.00051	0.0251	-0.12	-0.11	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48244972	chr12:48350945~48442411:+
BRCA	cis	rs2243480	1	rs13310597	ENSG00000229180.5	GS1-124K5.11	3.49	0.00051	0.0251	0.15	0.11	Diabetic kidney disease;	chr7:66133553	chr7:66526088~66542624:-
BRCA	cis	rs801193	1	rs2003301	ENSG00000275400.1	RP4-756H11.5	3.49	0.00051	0.0251	0.12	0.11	Aortic root size;	chr7:66682669	chr7:66553805~66554199:-
BRCA	cis	rs7911264	0.739	rs10882091	ENSG00000232709.1	MARK2P9	-3.49	0.00051	0.0251	-0.14	-0.11	Inflammatory bowel disease;	chr10:92614620	chr10:92418667~92420875:+
BRCA	cis	rs875971	0.83	rs778711	ENSG00000271064.1	RP11-792A8.3	-3.49	0.00051	0.0251	-0.13	-0.11	Aortic root size;	chr7:66386670	chr7:66748838~66749077:-
BRCA	cis	rs875971	0.862	rs1083554	ENSG00000271064.1	RP11-792A8.3	-3.49	0.00051	0.0251	-0.13	-0.11	Aortic root size;	chr7:66387354	chr7:66748838~66749077:-
BRCA	cis	rs875971	0.862	rs778707	ENSG00000271064.1	RP11-792A8.3	-3.49	0.00051	0.0251	-0.13	-0.11	Aortic root size;	chr7:66392040	chr7:66748838~66749077:-
BRCA	cis	rs875971	0.862	rs778705	ENSG00000271064.1	RP11-792A8.3	-3.49	0.00051	0.0251	-0.13	-0.11	Aortic root size;	chr7:66396128	chr7:66748838~66749077:-
BRCA	cis	rs875971	0.862	rs778697	ENSG00000271064.1	RP11-792A8.3	-3.49	0.00051	0.0251	-0.13	-0.11	Aortic root size;	chr7:66405439	chr7:66748838~66749077:-
BRCA	cis	rs875971	0.798	rs7789615	ENSG00000271064.1	RP11-792A8.3	-3.49	0.00051	0.0251	-0.13	-0.11	Aortic root size;	chr7:66413674	chr7:66748838~66749077:-
BRCA	cis	rs12682352	0.602	rs635594	ENSG00000233609.3	RP11-62H7.2	-3.49	0.00051	0.0251	-0.1	-0.11	Neuroticism;	chr8:8755877	chr8:8961200~8979025:+
BRCA	cis	rs1969253	0.803	rs843357	ENSG00000205955.4	HSP90AA5P	-3.49	0.00051	0.0251	-0.13	-0.11	Major depressive disorder;	chr3:184143962	chr3:184115352~184117898:+
BRCA	cis	rs4919687	0.55	rs7904396	ENSG00000213061.2	PFN1P11	3.49	0.000511	0.0251	0.15	0.11	Colorectal cancer;	chr10:102697081	chr10:102838011~102845473:-
BRCA	cis	rs875971	0.862	rs1643375	ENSG00000265600.1	AC006480.1	-3.49	0.000511	0.0251	-0.13	-0.11	Aortic root size;	chr7:66407690	chr7:67356680~67356779:+
BRCA	cis	rs40067	1	rs288144	ENSG00000272523.1	LINC01023	-3.49	0.000511	0.0251	-0.12	-0.11	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr5:108059533	chr5:108727825~108728260:-
BRCA	cis	rs2153535	0.585	rs9405400	ENSG00000251164.1	HULC	-3.49	0.000511	0.0251	-0.13	-0.11	Motion sickness;	chr6:8606895	chr6:8652137~8653846:+
BRCA	cis	rs6445967	1	rs11713627	ENSG00000272182.1	RP11-802O23.3	3.49	0.000511	0.0251	0.12	0.11	Platelet count;	chr3:58321219	chr3:58428255~58428815:+
BRCA	cis	rs6812193	0.518	rs10019829	ENSG00000271676.1	RP11-1E1.2	-3.49	0.000511	0.0251	-0.15	-0.11	Parkinson's disease;	chr4:76266905	chr4:77112495~77113458:-
BRCA	cis	rs8062405	0.755	rs4788076	ENSG00000261766.1	RP11-22P6.2	-3.49	0.000511	0.0251	-0.11	-0.11	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28558684	chr16:28862166~28863340:-
BRCA	cis	rs7267979	1	rs11087521	ENSG00000231081.1	RP4-760C5.3	-3.49	0.000511	0.0251	-0.14	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25460012	chr20:26008791~26010531:-
BRCA	cis	rs17014483	0.749	rs2924935	ENSG00000248019.2	FAM13A-AS1	-3.49	0.000511	0.0251	-0.14	-0.11	Post bronchodilator FEV1/FVC ratio;	chr4:88719416	chr4:88709789~88730103:+
BRCA	cis	rs7259376	0.936	rs11085524	ENSG00000269345.1	VN1R85P	3.49	0.000511	0.0251	0.13	0.11	Menopause (age at onset);	chr19:22353620	chr19:22174766~22175191:-
BRCA	cis	rs2216824	1	rs74933881	ENSG00000278908.1	RP11-523J2.1	3.49	0.000511	0.0251	0.19	0.11	Oropharynx cancer;	chr2:30883270	chr2:30677762~30679895:+
BRCA	cis	rs2216824	1	rs78196671	ENSG00000278908.1	RP11-523J2.1	3.49	0.000511	0.0251	0.19	0.11	Oropharynx cancer;	chr2:30883310	chr2:30677762~30679895:+
BRCA	cis	rs2216824	1	rs79975330	ENSG00000278908.1	RP11-523J2.1	3.49	0.000511	0.0251	0.19	0.11	Oropharynx cancer;	chr2:30883958	chr2:30677762~30679895:+
BRCA	cis	rs2216824	0.818	rs74423600	ENSG00000278908.1	RP11-523J2.1	3.49	0.000511	0.0251	0.19	0.11	Oropharynx cancer;	chr2:30884094	chr2:30677762~30679895:+
BRCA	cis	rs7771547	0.855	rs9366911	ENSG00000224666.3	RP1-50J22.4	-3.49	0.000511	0.0251	-0.12	-0.11	Platelet distribution width;	chr6:36621563	chr6:36386831~36393462:+
BRCA	cis	rs10246939	0.505	rs34726057	ENSG00000270923.1	TAS2R6P	-3.49	0.000511	0.0251	-0.12	-0.11	Bitter taste perception;	chr7:141832117	chr7:141787815~141788640:+
BRCA	cis	rs1348850	0.914	rs1348849	ENSG00000280374.1	RP11-337N6.3	3.49	0.000511	0.0251	0.14	0.11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177493344	chr2:177317715~177318471:-
BRCA	cis	rs930395	0.514	rs7703618	ENSG00000248779.1	RP11-53O19.2	-3.49	0.000511	0.0251	-0.1	-0.11	Breast cancer;	chr5:44914477	chr5:44752949~44765744:+
BRCA	cis	rs3760982	0.585	rs68073292	ENSG00000266921.1	RP11-15A1.7	-3.49	0.000511	0.0251	-0.14	-0.11	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43787249	chr19:43996896~44002836:-
BRCA	cis	rs2425143	1	rs2425143	ENSG00000088340.14	FER1L4	-3.49	0.000511	0.0251	-0.17	-0.11	Blood protein levels;	chr20:35762744	chr20:35558737~35607562:-
BRCA	cis	rs17801127	0.515	rs35188572	ENSG00000231969.1	AC144449.1	3.49	0.000511	0.0251	0.21	0.11	Liver enzyme levels (alanine transaminase);	chr2:149891071	chr2:149587196~149848233:+
BRCA	cis	rs3096299	0.632	rs8051537	ENSG00000259877.2	RP11-46C24.7	-3.49	0.000511	0.0251	-0.1	-0.11	Multiple myeloma (IgH translocation);	chr16:89477976	chr16:89215211~89217653:-
BRCA	cis	rs8054556	0.647	rs4788211	ENSG00000183604.13	SMG1P5	-3.49	0.000511	0.0251	-0.1	-0.11	Autism spectrum disorder or schizophrenia;	chr16:30004244	chr16:30267553~30335374:-
BRCA	cis	rs10129255	0.957	rs11847726	ENSG00000211958.2	IGHV3-38	3.49	0.000511	0.0251	0.08	0.11	Kawasaki disease;	chr14:106779116	chr14:106410493~106411021:-
BRCA	cis	rs1208	0.777	rs1799929	ENSG00000253671.1	RP11-806O11.1	3.49	0.000511	0.0251	0.13	0.11	Insulin resistance/response;	chr8:18400484	chr8:17808941~17820868:+
BRCA	cis	rs7695732	0.703	rs1961979	ENSG00000270720.1	RP11-84C13.2	-3.49	0.000511	0.0251	-0.14	-0.11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr4:89001286	chr4:89119284~89119871:+
BRCA	cis	rs7781266	0.64	rs62472376	ENSG00000226205.1	AC007790.4	3.49	0.000511	0.0251	0.16	0.11	Educational attainment (college completion);	chr7:133415522	chr7:133732493~133733595:-
BRCA	cis	rs13315871	1	rs11708590	ENSG00000272182.1	RP11-802O23.3	-3.49	0.000511	0.0251	-0.21	-0.11	Cholesterol, total;	chr3:58350908	chr3:58428255~58428815:+
BRCA	cis	rs7577696	0.539	rs2280972	ENSG00000276334.1	AL133243.1	-3.49	0.000511	0.0251	-0.16	-0.11	Inflammatory biomarkers;	chr2:32152892	chr2:32521927~32523547:+
BRCA	cis	rs925946	0.518	rs10835197	ENSG00000245573.6	BDNF-AS	-3.49	0.000511	0.0251	-0.13	-0.11	Weight;Body mass index;	chr11:27585996	chr11:27506838~27698174:+
BRCA	cis	rs6993270	0.779	rs59151115	ENSG00000245330.4	KB-1471A8.1	-3.49	0.000511	0.0251	-0.17	-0.11	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr8:119909776	chr8:119867419~119874488:-
BRCA	cis	rs739401	0.527	rs423236	ENSG00000183562.3	CTC-343N3.1	-3.49	0.000511	0.0251	-0.11	-0.11	Longevity;	chr11:3044686	chr11:2989863~2991344:+
BRCA	cis	rs316577	1	rs316577	ENSG00000248126.1	CTD-2012J19.2	-3.49	0.000511	0.0251	-0.13	-0.11	Cannabis use (initiation);	chr5:2294574	chr5:1598127~1598247:+
BRCA	cis	rs7943953	0.865	rs34882977	ENSG00000254717.2	GLYATL1P2	-3.49	0.000512	0.0251	-0.15	-0.11	Odorant perception (&beta-ionone);	chr11:59448081	chr11:58878302~58893460:+
BRCA	cis	rs875971	0.862	rs13232191	ENSG00000265600.1	AC006480.1	-3.49	0.000512	0.0251	-0.13	-0.11	Aortic root size;	chr7:66521661	chr7:67356680~67356779:+
BRCA	cis	rs875971	0.862	rs10950043	ENSG00000265600.1	AC006480.1	-3.49	0.000512	0.0251	-0.13	-0.11	Aortic root size;	chr7:66523623	chr7:67356680~67356779:+
BRCA	cis	rs875971	0.862	rs17747530	ENSG00000265600.1	AC006480.1	-3.49	0.000512	0.0251	-0.13	-0.11	Aortic root size;	chr7:66529742	chr7:67356680~67356779:+
BRCA	cis	rs875971	0.862	rs13536	ENSG00000265600.1	AC006480.1	3.49	0.000512	0.0251	0.13	0.11	Aortic root size;	chr7:66554203	chr7:67356680~67356779:+
BRCA	cis	rs875971	0.862	rs801209	ENSG00000265600.1	AC006480.1	3.49	0.000512	0.0251	0.13	0.11	Aortic root size;	chr7:66554403	chr7:67356680~67356779:+
BRCA	cis	rs875971	0.862	rs801206	ENSG00000265600.1	AC006480.1	3.49	0.000512	0.0251	0.13	0.11	Aortic root size;	chr7:66556979	chr7:67356680~67356779:+
BRCA	cis	rs875971	0.862	rs801204	ENSG00000265600.1	AC006480.1	3.49	0.000512	0.0251	0.13	0.11	Aortic root size;	chr7:66557934	chr7:67356680~67356779:+
BRCA	cis	rs875971	0.862	rs801203	ENSG00000265600.1	AC006480.1	3.49	0.000512	0.0251	0.13	0.11	Aortic root size;	chr7:66558025	chr7:67356680~67356779:+
BRCA	cis	rs1982963	0.95	rs2645750	ENSG00000277050.1	RP11-102G14.1	-3.49	0.000512	0.0251	-0.13	-0.11	Waist-to-hip ratio adjusted for body mass index;	chr14:52036074	chr14:51637348~51637947:-
BRCA	cis	rs7020830	0.898	rs2790063	ENSG00000230188.1	RP11-405L18.4	-3.49	0.000512	0.0251	-0.13	-0.11	Schizophrenia;	chr9:37287408	chr9:37490421~37490893:-
BRCA	cis	rs7267979	1	rs6050626	ENSG00000231081.1	RP4-760C5.3	-3.49	0.000512	0.0251	-0.14	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25447625	chr20:26008791~26010531:-
BRCA	cis	rs4326844	0.845	rs11559982	ENSG00000249388.1	RP11-834C11.6	-3.49	0.000512	0.0251	-0.14	-0.11	Platelet count;	chr12:54317790	chr12:54082118~54102693:+
BRCA	cis	rs2333021	0.649	rs2333016	ENSG00000259015.1	RP11-109N23.6	3.49	0.000512	0.0251	0.12	0.11	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:72993209	chr14:72960595~72961993:+
BRCA	cis	rs62025270	0.522	rs16943120	ENSG00000259367.1	RP11-815J21.4	3.49	0.000512	0.0251	0.1	0.11	Idiopathic pulmonary fibrosis;	chr15:85683066	chr15:85619623~85670948:-
BRCA	cis	rs6088580	0.634	rs6087587	ENSG00000269202.1	RP4-614O4.12	-3.49	0.000512	0.0251	-0.11	-0.11	Glomerular filtration rate (creatinine);	chr20:34470823	chr20:35201747~35203288:-
BRCA	cis	rs10759883	0.563	rs690286	ENSG00000225194.2	LINC00092	3.49	0.000512	0.0251	0.11	0.11	Nicotine dependence;	chr9:96034685	chr9:96019732~96027965:-
BRCA	cis	rs9467773	1	rs9393729	ENSG00000261353.1	CTA-14H9.5	-3.49	0.000512	0.0251	-0.11	-0.11	Intelligence (multi-trait analysis);	chr6:26513938	chr6:26527063~26527404:+
BRCA	cis	rs1437396	0.609	rs2589065	ENSG00000203327.2	AC012358.7	3.49	0.000512	0.0251	0.11	0.11	Alcohol dependence;	chr2:55330911	chr2:55214387~55216126:-
BRCA	cis	rs8058578	1	rs8048448	ENSG00000274678.1	RP11-2C24.7	3.49	0.000512	0.0251	0.13	0.11	Multiple myeloma;	chr16:30680887	chr16:30821338~30821884:+
BRCA	cis	rs6463739	0.785	rs6463740	ENSG00000219545.8	UMAD1	-3.49	0.000512	0.0251	-0.11	-0.11	Small cell lung carcinoma;	chr7:7867221	chr7:7640711~8004059:+
BRCA	cis	rs1865760	1	rs1865760	ENSG00000272810.1	U91328.22	-3.49	0.000512	0.0251	-0.13	-0.11	Height;	chr6:25916751	chr6:26013241~26013757:+
BRCA	cis	rs4578769	0.569	rs9951157	ENSG00000265943.1	RP11-739L10.1	3.49	0.000512	0.0251	0.14	0.11	Eosinophil percentage of white cells;	chr18:22974173	chr18:22699481~22933764:-
BRCA	cis	rs9341808	0.718	rs3828754	ENSG00000279022.1	RP11-250B2.4	3.49	0.000512	0.0251	0.12	0.11	Sitting height ratio;	chr6:80190923	chr6:80440730~80441172:+
BRCA	cis	rs9341808	0.718	rs10943696	ENSG00000279022.1	RP11-250B2.4	3.49	0.000512	0.0251	0.12	0.11	Sitting height ratio;	chr6:80191555	chr6:80440730~80441172:+
BRCA	cis	rs9341808	0.718	rs6910201	ENSG00000279022.1	RP11-250B2.4	3.49	0.000512	0.0251	0.12	0.11	Sitting height ratio;	chr6:80195221	chr6:80440730~80441172:+
BRCA	cis	rs875971	0.862	rs35378740	ENSG00000271064.1	RP11-792A8.3	-3.49	0.000512	0.0251	-0.13	-0.11	Aortic root size;	chr7:66522725	chr7:66748838~66749077:-
BRCA	cis	rs36093844	0.752	rs17744675	ENSG00000279742.1	RP11-700A24.1	3.49	0.000512	0.0251	0.16	0.11	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85882863	chr11:85852557~85854943:-
BRCA	cis	rs12724450	0.793	rs12747619	ENSG00000228126.1	FALEC	3.49	0.000512	0.0251	0.2	0.11	Blood protein levels;	chr1:150414667	chr1:150515757~150518032:+
BRCA	cis	rs4648045	0.789	rs230509	ENSG00000246560.2	RP11-10L12.4	-3.49	0.000512	0.0251	-0.13	-0.11	Lymphocyte percentage of white cells;	chr4:102557108	chr4:102828055~102844075:+
BRCA	cis	rs2991971	0.782	rs10789463	ENSG00000281133.1	AL355480.3	-3.49	0.000512	0.0252	-0.13	-0.11	High light scatter reticulocyte count;	chr1:45462176	chr1:45580892~45580996:-
BRCA	cis	rs1670533	1	rs2100411	ENSG00000251639.2	RP11-20I20.1	3.49	0.000512	0.0252	0.17	0.11	Recombination rate (females);	chr4:1080624	chr4:1100016~1101558:-
BRCA	cis	rs1670533	1	rs1670533	ENSG00000251639.2	RP11-20I20.1	3.49	0.000512	0.0252	0.17	0.11	Recombination rate (females);	chr4:1084399	chr4:1100016~1101558:-
BRCA	cis	rs875971	0.825	rs7384021	ENSG00000271064.1	RP11-792A8.3	3.49	0.000512	0.0252	0.13	0.11	Aortic root size;	chr7:66612917	chr7:66748838~66749077:-
BRCA	cis	rs9400180	0.879	rs17069185	ENSG00000271734.1	RP1-111B22.3	-3.49	0.000512	0.0252	-0.14	-0.11	Major depressive disorder;	chr6:108026951	chr6:108030249~108030718:-
BRCA	cis	rs4819052	0.819	rs13046807	ENSG00000223768.1	LINC00205	-3.49	0.000512	0.0252	-0.14	-0.11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45252371	chr21:45293285~45297354:+
BRCA	cis	rs7487075	0.82	rs4238102	ENSG00000274723.1	RP11-618L22.1	3.49	0.000512	0.0252	0.13	0.11	Itch intensity from mosquito bite;	chr12:46332713	chr12:46970504~46972155:+
BRCA	cis	rs17095355	0.892	rs7085888	ENSG00000203497.2	PDCD4-AS1	3.49	0.000512	0.0252	0.15	0.11	Biliary atresia;	chr10:109954172	chr10:110869868~110872233:-
BRCA	cis	rs10761482	0.861	rs1903204	ENSG00000254271.1	RP11-131N11.4	3.49	0.000512	0.0252	0.15	0.11	Schizophrenia;	chr10:60340473	chr10:60734342~60741828:+
BRCA	cis	rs10761482	0.769	rs10740024	ENSG00000254271.1	RP11-131N11.4	3.49	0.000512	0.0252	0.15	0.11	Schizophrenia;	chr10:60341082	chr10:60734342~60741828:+
BRCA	cis	rs10761482	0.861	rs1473404	ENSG00000254271.1	RP11-131N11.4	3.49	0.000512	0.0252	0.15	0.11	Schizophrenia;	chr10:60342558	chr10:60734342~60741828:+
BRCA	cis	rs10761482	0.861	rs10761485	ENSG00000254271.1	RP11-131N11.4	3.49	0.000512	0.0252	0.15	0.11	Schizophrenia;	chr10:60342902	chr10:60734342~60741828:+
BRCA	cis	rs10761482	0.813	rs2061487	ENSG00000254271.1	RP11-131N11.4	3.49	0.000512	0.0252	0.15	0.11	Schizophrenia;	chr10:60343084	chr10:60734342~60741828:+
BRCA	cis	rs10761482	0.861	rs2061488	ENSG00000254271.1	RP11-131N11.4	3.49	0.000512	0.0252	0.15	0.11	Schizophrenia;	chr10:60343408	chr10:60734342~60741828:+
BRCA	cis	rs10761482	0.813	rs2061489	ENSG00000254271.1	RP11-131N11.4	3.49	0.000512	0.0252	0.15	0.11	Schizophrenia;	chr10:60343438	chr10:60734342~60741828:+
BRCA	cis	rs10761482	0.861	rs4456215	ENSG00000254271.1	RP11-131N11.4	3.49	0.000512	0.0252	0.15	0.11	Schizophrenia;	chr10:60343491	chr10:60734342~60741828:+
BRCA	cis	rs3764021	0.527	rs10844456	ENSG00000256594.6	RP11-705C15.2	3.49	0.000512	0.0252	0.14	0.11	Type 1 diabetes;	chr12:9689319	chr12:9633419~9658412:+
BRCA	cis	rs2898290	0.5	rs11998678	ENSG00000254948.1	OR7E158P	3.49	0.000512	0.0252	0.13	0.11	Systolic blood pressure;	chr8:11972641	chr8:11919900~11920809:-
BRCA	cis	rs875971	0.508	rs10258739	ENSG00000265600.1	AC006480.1	3.49	0.000512	0.0252	0.13	0.11	Aortic root size;	chr7:66597948	chr7:67356680~67356779:+
BRCA	cis	rs12216545	0.695	rs10276888	ENSG00000244151.1	RP11-148K1.12	-3.49	0.000512	0.0252	-0.09	-0.11	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150533238	chr7:151074742~151076530:-
BRCA	cis	rs495337	0.699	rs6020074	ENSG00000224397.4	LINC01272	3.49	0.000513	0.0252	0.11	0.11	Psoriasis;	chr20:49832122	chr20:50267486~50279795:+
BRCA	cis	rs2998286	0.636	rs332112	ENSG00000237128.1	RP11-351M16.3	-3.49	0.000513	0.0252	-0.13	-0.11	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28633879	chr10:28433008~28495813:-
BRCA	cis	rs3764021	0.527	rs3764022	ENSG00000278635.1	CTD-2318O12.1	-3.49	0.000513	0.0252	-0.12	-0.11	Type 1 diabetes;	chr12:9680928	chr12:9415641~9416718:+
BRCA	cis	rs853679	0.546	rs200954	ENSG00000216676.2	RP1-15D7.1	-3.49	0.000513	0.0252	-0.19	-0.11	Depression;	chr6:27870986	chr6:27652602~27652825:-
BRCA	cis	rs7267979	0.903	rs6115109	ENSG00000231081.1	RP4-760C5.3	-3.48	0.000513	0.0252	-0.14	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25259031	chr20:26008791~26010531:-
BRCA	cis	rs7267979	0.833	rs4619688	ENSG00000231081.1	RP4-760C5.3	-3.48	0.000513	0.0252	-0.14	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25263465	chr20:26008791~26010531:-
BRCA	cis	rs2961333	1	rs2961333	ENSG00000243635.1	RP11-281P11.1	-3.48	0.000513	0.0252	-0.18	-0.11	Pediatric bone mineral content (femoral neck);	chr3:104508518	chr3:104502700~104503266:+
BRCA	cis	rs2961333	1	rs2961216	ENSG00000243635.1	RP11-281P11.1	-3.48	0.000513	0.0252	-0.18	-0.11	Pediatric bone mineral content (femoral neck);	chr3:104508948	chr3:104502700~104503266:+
BRCA	cis	rs2961333	1	rs2961332	ENSG00000243635.1	RP11-281P11.1	-3.48	0.000513	0.0252	-0.18	-0.11	Pediatric bone mineral content (femoral neck);	chr3:104509967	chr3:104502700~104503266:+
BRCA	cis	rs2961333	1	rs2961353	ENSG00000243635.1	RP11-281P11.1	-3.48	0.000513	0.0252	-0.18	-0.11	Pediatric bone mineral content (femoral neck);	chr3:104510981	chr3:104502700~104503266:+
BRCA	cis	rs7829975	0.567	rs6601273	ENSG00000253981.4	ALG1L13P	-3.48	0.000513	0.0252	-0.12	-0.11	Mood instability;	chr8:8939009	chr8:8236003~8244667:-
BRCA	cis	rs1008375	0.932	rs7677212	ENSG00000249502.1	AC006160.5	3.48	0.000513	0.0252	0.12	0.11	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17674309	chr4:17587467~17614571:-
BRCA	cis	rs17407555	0.909	rs2868939	ENSG00000251087.3	ALG1L3P	-3.48	0.000513	0.0252	-0.17	-0.11	Schizophrenia (age at onset);	chr4:10313297	chr4:9703754~9710812:-
BRCA	cis	rs6439699	1	rs60246781	ENSG00000273486.1	RP11-731C17.2	3.48	0.000513	0.0252	0.15	0.11	Intelligence (multi-trait analysis);	chr3:137291161	chr3:136837338~136839021:-
BRCA	cis	rs5742933	0.948	rs2264018	ENSG00000253559.1	OSGEPL1-AS1	-3.48	0.000513	0.0252	-0.15	-0.11	Ferritin levels;	chr2:189712052	chr2:189762704~189765556:+
BRCA	cis	rs73206853	0.62	rs111354540	ENSG00000277299.1	RP11-837J7.4	-3.48	0.000513	0.0252	-0.2	-0.11	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr12:110712497	chr12:109948389~109949029:+
BRCA	cis	rs8180040	0.647	rs57756484	ENSG00000260236.1	RP11-708J19.1	-3.48	0.000513	0.0252	-0.1	-0.11	Colorectal cancer;	chr3:47197843	chr3:47379089~47380999:-
BRCA	cis	rs6142618	0.562	rs6061186	ENSG00000224452.1	RSL24D1P6	3.48	0.000513	0.0252	0.14	0.11	Inflammatory bowel disease;	chr20:32143937	chr20:32170390~32170790:-
BRCA	cis	rs875971	1	rs2077593	ENSG00000272831.1	RP11-792A8.4	3.48	0.000513	0.0252	0.1	0.11	Aortic root size;	chr7:66427543	chr7:66739829~66740385:-
BRCA	cis	rs11098499	0.754	rs66900435	ENSG00000250412.1	KLHL2P1	3.48	0.000513	0.0252	0.12	0.11	Corneal astigmatism;	chr4:119328270	chr4:119334329~119378233:+
BRCA	cis	rs78472555	0.69	rs2570817	ENSG00000259363.4	CTD-2054N24.2	-3.48	0.000513	0.0252	-0.14	-0.11	Post bronchodilator FEV1/FVC ratio in COPD;	chr15:99659516	chr15:99807023~99877148:+
BRCA	cis	rs6142102	0.961	rs8123521	ENSG00000206582.1	Y_RNA	-3.48	0.000513	0.0252	-0.13	-0.11	Skin pigmentation;	chr20:34081079	chr20:34526510~34526606:-
BRCA	cis	rs801193	0.773	rs801207	ENSG00000265600.1	AC006480.1	3.48	0.000513	0.0252	0.13	0.11	Aortic root size;	chr7:66555603	chr7:67356680~67356779:+
BRCA	cis	rs7487075	0.82	rs4768113	ENSG00000257261.4	RP11-96H19.1	3.48	0.000513	0.0252	0.11	0.11	Itch intensity from mosquito bite;	chr12:46314253	chr12:46383679~46876159:+
BRCA	cis	rs3018712	0.532	rs28551086	ENSG00000251637.5	RP11-119D9.1	-3.48	0.000513	0.0252	-0.2	-0.11	Total body bone mineral density;	chr11:68633271	chr11:67886477~67906350:+
BRCA	cis	rs67073037	1	rs4407214	ENSG00000230730.1	AC074011.2	-3.48	0.000513	0.0252	-0.15	-0.11	Breast cancer;Breast cancer (estrogen-receptor negative);	chr2:28895392	chr2:28633282~28664540:-
BRCA	cis	rs4767841	1	rs2996027	ENSG00000248636.5	RP11-768F21.1	-3.48	0.000513	0.0252	-0.13	-0.11	Urgency urinary incontinence;	chr12:119726478	chr12:119387987~119668079:-
BRCA	cis	rs2562456	0.917	rs10420016	ENSG00000268705.1	BNIP3P26	-3.48	0.000513	0.0252	-0.12	-0.11	Pain;	chr19:21505800	chr19:21521343~21521896:-
BRCA	cis	rs2692947	0.63	rs1168966	ENSG00000168992.4	OR7E102P	3.48	0.000513	0.0252	0.15	0.11	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96132771	chr2:95546531~95547545:+
BRCA	cis	rs11239544	1	rs11239544	ENSG00000237840.5	FAM21FP	3.48	0.000513	0.0252	0.14	0.11	Cholesterol, total;	chr10:45512085	chr10:45706431~45727231:-
BRCA	cis	rs9866825	0.934	rs1386962	ENSG00000227110.5	LMCD1-AS1	-3.48	0.000513	0.0252	-0.13	-0.11	QT interval;	chr3:8204813	chr3:7952805~8611924:-
BRCA	cis	rs10911902	0.643	rs3766703	ENSG00000229739.2	RP11-295K2.3	-3.48	0.000513	0.0252	-0.15	-0.11	Schizophrenia;	chr1:186346575	chr1:186435161~186470291:+
BRCA	cis	rs2692947	0.702	rs6717101	ENSG00000232931.4	LINC00342	3.48	0.000513	0.0252	0.11	0.11	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95839804	chr2:95807118~95816215:-
BRCA	cis	rs7429990	0.965	rs319696	ENSG00000199476.1	Y_RNA	-3.48	0.000513	0.0252	-0.14	-0.11	Educational attainment (years of education);	chr3:47902371	chr3:48288587~48288694:+
BRCA	cis	rs8050907	1	rs11862083	ENSG00000280063.1	RP11-295D4.3	-3.48	0.000513	0.0252	-0.16	-0.11	Obesity-related traits;	chr16:4599719	chr16:4346694~4348648:-
BRCA	cis	rs806321	0.534	rs1269274	ENSG00000237152.3	DLEU7-AS1	3.48	0.000514	0.0252	0.14	0.11	Multiple sclerosis;	chr13:50321502	chr13:50807856~50849905:+
BRCA	cis	rs801193	0.569	rs2659908	ENSG00000271064.1	RP11-792A8.3	-3.48	0.000514	0.0252	-0.13	-0.11	Aortic root size;	chr7:66695835	chr7:66748838~66749077:-
BRCA	cis	rs12468226	0.689	rs73989733	ENSG00000226261.1	AC064836.3	3.48	0.000514	0.0252	0.18	0.11	Urate levels;	chr2:202115241	chr2:202336024~202336727:-
BRCA	cis	rs1865760	1	rs6905887	ENSG00000272810.1	U91328.22	-3.48	0.000514	0.0252	-0.13	-0.11	Height;	chr6:25911875	chr6:26013241~26013757:+
BRCA	cis	rs7487075	0.619	rs4077707	ENSG00000257261.4	RP11-96H19.1	3.48	0.000514	0.0252	0.12	0.11	Itch intensity from mosquito bite;	chr12:46464715	chr12:46383679~46876159:+
BRCA	cis	rs1119582	0.636	rs418786	ENSG00000279118.1	RP11-517I3.2	3.48	0.000514	0.0252	0.15	0.11	Select biomarker traits;	chr5:125867220	chr5:126496279~126498604:+
BRCA	cis	rs1823874	0.71	rs4965543	ENSG00000259363.4	CTD-2054N24.2	3.48	0.000514	0.0252	0.13	0.11	IgG glycosylation;	chr15:99821050	chr15:99807023~99877148:+
BRCA	cis	rs13434995	0.513	rs6554291	ENSG00000249700.7	SRD5A3-AS1	-3.48	0.000514	0.0252	-0.15	-0.11	Adiponectin levels;	chr4:55571204	chr4:55363971~55395847:-
BRCA	cis	rs6696239	0.911	rs10753436	ENSG00000215812.5	ZNF847P	3.48	0.000514	0.0252	0.15	0.11	Height;	chr1:227609163	chr1:227696892~227706699:-
BRCA	cis	rs7647973	0.925	rs6446257	ENSG00000272434.1	RP13-131K19.6	3.48	0.000514	0.0252	0.14	0.11	Menarche (age at onset);	chr3:49216059	chr3:49029316~49029706:+
BRCA	cis	rs6449502	0.541	rs13163684	ENSG00000251279.1	CTC-436P18.1	3.48	0.000514	0.0252	0.24	0.11	Mean platelet volume;	chr5:61148444	chr5:61162070~61232040:+
BRCA	cis	rs863345	0.604	rs1342948	ENSG00000176320.2	RP11-404O13.5	-3.48	0.000514	0.0252	-0.11	-0.11	Pneumococcal bacteremia;	chr1:158493504	chr1:158197922~158203877:-
BRCA	cis	rs11931598	0.514	rs10937779	ENSG00000245748.1	RP11-367J11.2	3.48	0.000514	0.0252	0.11	0.11	Sum basophil neutrophil counts;Neutrophil count;Granulocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;	chr4:7037599	chr4:7030554~7046231:-
BRCA	cis	rs1348850	0.567	rs2222711	ENSG00000280374.1	RP11-337N6.3	3.48	0.000514	0.0252	0.15	0.11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177669382	chr2:177317715~177318471:-
BRCA	cis	rs875971	0.628	rs6974355	ENSG00000232546.1	RP11-458F8.1	-3.48	0.000514	0.0252	-0.09	-0.11	Aortic root size;	chr7:66376994	chr7:66848496~66858136:+
BRCA	cis	rs206936	0.706	rs57622072	ENSG00000276404.1	MIR6835	-3.48	0.000514	0.0252	-0.13	-0.11	Body mass index;	chr6:34336847	chr6:34240673~34240736:+
BRCA	cis	rs34792	0.525	rs12708795	ENSG00000275910.1	RP11-680G24.6	-3.48	0.000514	0.0252	-0.13	-0.11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15533861	chr16:15015828~15016390:-
BRCA	cis	rs4819052	0.851	rs4819049	ENSG00000215447.6	BX322557.10	-3.48	0.000514	0.0252	-0.11	-0.11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45253171	chr21:45288052~45291738:+
BRCA	cis	rs4243971	0.516	rs14353	ENSG00000275576.1	RP5-836N17.4	-3.48	0.000514	0.0252	-0.12	-0.11	Inflammatory bowel disease;Crohn's disease;	chr20:32334595	chr20:32116171~32116629:+
BRCA	cis	rs9333290	0.93	rs2084448	ENSG00000259915.2	RP11-410E4.1	3.48	0.000514	0.0252	0.14	0.11	Urinary albumin-to-creatinine ratio in non-diabetics;Urinary albumin-to-creatinine ratio;	chr2:186665793	chr2:186354570~186356773:-
BRCA	cis	rs745109	0.882	rs11899532	ENSG00000273080.1	RP11-301O19.1	3.48	0.000514	0.0252	0.16	0.11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86495893	chr2:86195590~86196049:+
BRCA	cis	rs873549	1	rs7517086	ENSG00000227925.1	RP11-191N8.2	3.48	0.000514	0.0252	0.12	0.11	Keloid;	chr1:222097983	chr1:221827666~221840666:-
BRCA	cis	rs4795519	0.778	rs55901274	ENSG00000266527.1	RP11-138P22.1	3.48	0.000514	0.0252	0.13	0.11	Chronic myeloid leukemia;	chr17:27079073	chr17:27874645~27881237:+
BRCA	cis	rs35306767	0.903	rs11813210	ENSG00000229869.1	RP11-363N22.2	-3.48	0.000514	0.0253	-0.16	-0.11	Eosinophil percentage of granulocytes;	chr10:873856	chr10:933026~942743:+
BRCA	cis	rs1555322	1	rs2425034	ENSG00000269202.1	RP4-614O4.12	-3.48	0.000515	0.0253	-0.15	-0.11	Attention deficit hyperactivity disorder;	chr20:35268011	chr20:35201747~35203288:-
BRCA	cis	rs1555322	0.858	rs2425035	ENSG00000269202.1	RP4-614O4.12	-3.48	0.000515	0.0253	-0.15	-0.11	Attention deficit hyperactivity disorder;	chr20:35268016	chr20:35201747~35203288:-
BRCA	cis	rs7697932	0.521	rs2866186	ENSG00000245322.5	RP11-15B17.1	3.48	0.000515	0.0253	0.13	0.11	Renal cell carcinoma;	chr4:100153163	chr4:99950006~100195099:+
BRCA	cis	rs4925540	0.962	rs7549105	ENSG00000215796.3	RP11-551G24.2	-3.48	0.000515	0.0253	-0.13	-0.11	Response to taxane treatment (docetaxel);	chr1:247041754	chr1:247042791~247044021:+
BRCA	cis	rs8098244	0.928	rs11082828	ENSG00000265752.2	RP11-403A21.1	3.48	0.000515	0.0253	0.14	0.11	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23881681	chr18:23957754~23982556:-
BRCA	cis	rs1046491	0.803	rs11081459	ENSG00000264964.1	RP11-888D10.3	3.48	0.000515	0.0253	0.22	0.11	Scarlet fever;	chr18:9107817	chr18:9315194~9334441:-
BRCA	cis	rs6866721	0.608	rs712611	ENSG00000249167.1	CTB-118N6.2	3.48	0.000515	0.0253	0.13	0.11	Body mass index;	chr5:116885556	chr5:116574482~116591398:+
BRCA	cis	rs6866721	0.608	rs712612	ENSG00000249167.1	CTB-118N6.2	3.48	0.000515	0.0253	0.13	0.11	Body mass index;	chr5:116885639	chr5:116574482~116591398:+
BRCA	cis	rs8099594	0.614	rs577979	ENSG00000266696.1	RP11-30L3.2	-3.48	0.000515	0.0253	-0.13	-0.11	Height;	chr18:49315817	chr18:49205912~49208781:+
BRCA	cis	rs6088580	0.634	rs6059868	ENSG00000269202.1	RP4-614O4.12	-3.48	0.000515	0.0253	-0.11	-0.11	Glomerular filtration rate (creatinine);	chr20:34491655	chr20:35201747~35203288:-
BRCA	cis	rs7259811	0.539	rs4630665	ENSG00000268266.1	AC003005.2	-3.48	0.000515	0.0253	-0.14	-0.11	Western dietary pattern;	chr19:56712720	chr19:57477649~57482996:+
BRCA	cis	rs2386661	0.523	rs2386663	ENSG00000231483.1	RP11-336A10.5	3.48	0.000515	0.0253	0.13	0.11	Breast cancer;	chr10:5610776	chr10:5608475~5610793:-
BRCA	cis	rs6964587	0.692	rs2027950	ENSG00000188693.7	CYP51A1-AS1	3.48	0.000515	0.0253	0.12	0.11	Breast cancer;	chr7:92234386	chr7:92134604~92180725:+
BRCA	cis	rs3781264	0.595	rs11187881	ENSG00000268894.5	PLCE1-AS1	-3.48	0.000515	0.0253	-0.14	-0.11	Esophageal cancer and gastric cancer;	chr10:94335697	chr10:94279277~94287478:-
BRCA	cis	rs977987	0.806	rs4887823	ENSG00000280152.1	RP11-331F4.5	-3.48	0.000515	0.0253	-0.11	-0.11	Dupuytren's disease;	chr16:75399176	chr16:75245994~75250077:-
BRCA	cis	rs13315871	1	rs71311868	ENSG00000272182.1	RP11-802O23.3	3.48	0.000515	0.0253	0.22	0.11	Cholesterol, total;	chr3:58407147	chr3:58428255~58428815:+
BRCA	cis	rs73242632	0.881	rs55734441	ENSG00000269949.1	RP11-738E22.3	3.48	0.000515	0.0253	0.24	0.11	Congenital heart disease (maternal effect);	chr4:56967551	chr4:56960927~56961373:-
BRCA	cis	rs7714670	0.736	rs2962278	ENSG00000184084.7	CTD-2372A4.1	-3.48	0.000515	0.0253	-0.13	-0.11	Venous thromboembolism (SNP x SNP interaction);	chr5:73798133	chr5:73803296~73803599:-
BRCA	cis	rs2562456	0.724	rs58001930	ENSG00000268555.1	RP11-678G14.3	3.48	0.000515	0.0253	0.14	0.11	Pain;	chr19:21560061	chr19:21570822~21587322:-
BRCA	cis	rs10266483	1	rs1960321	ENSG00000227986.1	TRIM60P18	-3.48	0.000515	0.0253	-0.11	-0.11	Response to statin therapy;	chr7:64270906	chr7:64355078~64356199:+
BRCA	cis	rs4869313	0.668	rs2548536	ENSG00000248734.2	CTD-2260A17.1	-3.48	0.000515	0.0253	-0.11	-0.11	Pediatric autoimmune diseases;	chr5:96896698	chr5:96784777~96785999:+
BRCA	cis	rs875971	0.522	rs1917563	ENSG00000272831.1	RP11-792A8.4	-3.48	0.000515	0.0253	-0.1	-0.11	Aortic root size;	chr7:65950660	chr7:66739829~66740385:-
BRCA	cis	rs76798021	0.554	rs55999888	ENSG00000271976.1	RP11-884K10.7	3.48	0.000515	0.0253	0.12	0.11	Lung function (FEV1/FVC);	chr3:53607554	chr3:53858994~53861576:-
BRCA	cis	rs11209261	0.602	rs4369263	ENSG00000232284.6	GNG12-AS1	3.48	0.000515	0.0253	0.12	0.11	Airflow obstruction;	chr1:68336221	chr1:67832303~68202987:+
BRCA	cis	rs6714710	0.603	rs7583868	ENSG00000228486.8	LINC01125	-3.48	0.000515	0.0253	-0.09	-0.11	Posterior cortical atrophy and Alzheimer's disease;	chr2:97971909	chr2:97664217~97703064:+
BRCA	cis	rs496300	0.899	rs672948	ENSG00000237989.1	AP001046.5	-3.48	0.000515	0.0253	-0.11	-0.11	Metabolic syndrome;	chr21:43373568	chr21:43358147~43362349:-
BRCA	cis	rs7520050	0.902	rs1355642	ENSG00000281133.1	AL355480.3	3.48	0.000515	0.0253	0.12	0.11	Reticulocyte count;Red blood cell count;	chr1:46133231	chr1:45580892~45580996:-
BRCA	cis	rs970548	0.954	rs11239536	ENSG00000237840.5	FAM21FP	3.48	0.000515	0.0253	0.14	0.11	Total cholesterol levels;HDL cholesterol;HDL cholesterol levels;Cholesterol, total;	chr10:45483150	chr10:45706431~45727231:-
BRCA	cis	rs910873	1	rs910873	ENSG00000269202.1	RP4-614O4.12	-3.48	0.000515	0.0253	-0.24	-0.11	Melanoma;	chr20:34583968	chr20:35201747~35203288:-
BRCA	cis	rs853679	0.517	rs36078605	ENSG00000226314.6	ZNF192P1	-3.48	0.000515	0.0253	-0.16	-0.11	Depression;	chr6:28110254	chr6:28161781~28169594:+
BRCA	cis	rs10838687	0.8	rs2290146	ENSG00000243802.2	RP11-390K5.1	3.48	0.000515	0.0253	0.15	0.11	Proinsulin levels;	chr11:47331947	chr11:47191181~47191542:-
BRCA	cis	rs2154319	0.887	rs1740615	ENSG00000230638.4	RP11-486B10.4	3.48	0.000516	0.0253	0.18	0.11	Height;	chr1:41072844	chr1:41542069~41544310:+
BRCA	cis	rs3136202	0.643	rs8060706	ENSG00000242307.1	RPS26P52	3.48	0.000516	0.0253	0.14	0.11	Conduct disorder (symptom count);	chr16:13981554	chr16:13922332~13922679:-
BRCA	cis	rs7951911	0.915	rs7131423	ENSG00000254427.1	RP11-430H10.1	3.48	0.000516	0.0253	0.23	0.11	IgG glycosylation;	chr11:45077084	chr11:45355371~45366121:+
BRCA	cis	rs12411860	1	rs13376768	ENSG00000226200.5	SGMS1-AS1	-3.48	0.000516	0.0253	-0.1	-0.11	Blood protein levels;	chr10:50273395	chr10:50624951~50641451:+
BRCA	cis	rs4948102	0.691	rs4470984	ENSG00000226278.1	PSPHP1	-3.48	0.000516	0.0253	-0.12	-0.11	Plasma homocysteine levels (post-methionine load test);	chr7:55965865	chr7:55764797~55773288:+
BRCA	cis	rs301901	1	rs158622	ENSG00000272103.1	CTD-2653M23.3	-3.48	0.000516	0.0253	-0.13	-0.11	Height;	chr5:36887793	chr5:36861736~36862217:-
BRCA	cis	rs4713118	0.868	rs760587	ENSG00000280107.1	AL022393.9	-3.48	0.000516	0.0253	-0.16	-0.11	Parkinson's disease;	chr6:27772521	chr6:28170845~28172521:+
BRCA	cis	rs8030605	0.704	rs11632260	ENSG00000277245.1	RP11-48G14.3	3.48	0.000516	0.0253	0.23	0.11	Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;	chr15:56309620	chr15:56447120~56447697:+
BRCA	cis	rs875971	0.862	rs778702	ENSG00000265600.1	AC006480.1	-3.48	0.000516	0.0253	-0.13	-0.11	Aortic root size;	chr7:66399848	chr7:67356680~67356779:+
BRCA	cis	rs7837791	0.647	rs7843283	ENSG00000242970.2	AC068522.4	-3.48	0.000516	0.0253	-0.14	-0.11	Refractive error;	chr8:59254955	chr8:58588420~58588764:-
BRCA	cis	rs7837791	0.647	rs7015454	ENSG00000242970.2	AC068522.4	-3.48	0.000516	0.0253	-0.14	-0.11	Refractive error;	chr8:59255456	chr8:58588420~58588764:-
BRCA	cis	rs12210905	0.688	rs12195783	ENSG00000272009.1	RP1-313I6.12	-3.48	0.000516	0.0253	-0.24	-0.11	Hip circumference adjusted for BMI;	chr6:27476566	chr6:28078792~28081130:-
BRCA	cis	rs4657482	0.962	rs9887956	ENSG00000236364.3	RP11-525G13.2	3.48	0.000516	0.0253	0.09	0.11	Testicular germ cell tumor;	chr1:165879976	chr1:165890795~165900683:-
BRCA	cis	rs277939	0.967	rs277978	ENSG00000230847.4	RP11-195E2.1	-3.48	0.000516	0.0253	-0.13	-0.11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr5:71630732	chr5:71074225~71093193:-
BRCA	cis	rs2836950	0.565	rs8134214	ENSG00000235701.1	PCBP2P1	-3.48	0.000516	0.0253	-0.12	-0.11	Menarche (age at onset);	chr21:39170441	chr21:39171130~39172106:-
BRCA	cis	rs875971	1	rs4717292	ENSG00000271064.1	RP11-792A8.3	-3.48	0.000516	0.0253	-0.12	-0.11	Aortic root size;	chr7:66430611	chr7:66748838~66749077:-
BRCA	cis	rs875971	1	rs35149210	ENSG00000271064.1	RP11-792A8.3	-3.48	0.000516	0.0253	-0.12	-0.11	Aortic root size;	chr7:66464938	chr7:66748838~66749077:-
BRCA	cis	rs7487075	0.893	rs1471223	ENSG00000274723.1	RP11-618L22.1	-3.48	0.000516	0.0253	-0.12	-0.11	Itch intensity from mosquito bite;	chr12:46333987	chr12:46970504~46972155:+
BRCA	cis	rs13434995	0.513	rs73236142	ENSG00000249700.7	SRD5A3-AS1	-3.48	0.000516	0.0253	-0.16	-0.11	Adiponectin levels;	chr4:55446143	chr4:55363971~55395847:-
BRCA	cis	rs6943931	0.963	rs57080842	ENSG00000230658.1	KLHL7-AS1	-3.48	0.000516	0.0253	-0.14	-0.11	Diabetic kidney disease;	chr7:22379796	chr7:23101228~23105703:-
BRCA	cis	rs9392556	0.829	rs2783073	ENSG00000230648.1	RP3-406P24.3	3.48	0.000516	0.0253	0.14	0.11	Blood metabolite levels;	chr6:4118440	chr6:4018843~4021215:-
BRCA	cis	rs8180040	0.62	rs6768722	ENSG00000260236.1	RP11-708J19.1	3.48	0.000516	0.0253	0.1	0.11	Colorectal cancer;	chr3:47037622	chr3:47379089~47380999:-
BRCA	cis	rs8180040	0.62	rs11715121	ENSG00000260236.1	RP11-708J19.1	-3.48	0.000516	0.0253	-0.1	-0.11	Colorectal cancer;	chr3:47031131	chr3:47379089~47380999:-
BRCA	cis	rs8180040	0.62	rs11709660	ENSG00000260236.1	RP11-708J19.1	-3.48	0.000516	0.0253	-0.1	-0.11	Colorectal cancer;	chr3:47033437	chr3:47379089~47380999:-
BRCA	cis	rs4934494	0.768	rs1926139	ENSG00000232229.4	LINC00865	-3.48	0.000516	0.0253	-0.16	-0.11	Red blood cell count;	chr10:89753395	chr10:89829510~89840861:+
BRCA	cis	rs4934494	0.727	rs55823491	ENSG00000232229.4	LINC00865	-3.48	0.000516	0.0253	-0.16	-0.11	Red blood cell count;	chr10:89757598	chr10:89829510~89840861:+
BRCA	cis	rs4934494	0.727	rs12570750	ENSG00000232229.4	LINC00865	-3.48	0.000516	0.0253	-0.16	-0.11	Red blood cell count;	chr10:89761273	chr10:89829510~89840861:+
BRCA	cis	rs1193	0.837	rs2138396	ENSG00000266931.1	RP11-1252D15.1	-3.48	0.000516	0.0253	-0.13	-0.11	High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;High light scatter reticulocyte count;	chr2:86752599	chr2:87055658~87055800:-
BRCA	cis	rs3739034	0.941	rs948583	ENSG00000224043.6	CCNT2-AS1	-3.48	0.000516	0.0253	-0.17	-0.11	Gut microbiome composition (winter);	chr2:134725843	chr2:134735464~134918710:-
BRCA	cis	rs6822297	0.745	rs7666651	ENSG00000240005.4	RP11-293A21.1	3.48	0.000517	0.0253	0.13	0.11	Obesity-related traits;	chr4:26904814	chr4:26859806~26860599:-
BRCA	cis	rs11992162	0.591	rs4240678	ENSG00000255020.1	AF131216.5	3.48	0.000517	0.0253	0.12	0.11	Monocyte count;	chr8:11944917	chr8:11345748~11347502:-
BRCA	cis	rs7520050	0.902	rs4626927	ENSG00000226957.1	RP4-533D7.4	3.48	0.000517	0.0253	0.12	0.11	Reticulocyte count;Red blood cell count;	chr1:45782973	chr1:46046818~46048368:+
BRCA	cis	rs1414896	0.669	rs11165345	ENSG00000226835.1	RP11-148B18.3	3.48	0.000517	0.0253	0.12	0.11	Non-alcoholic fatty liver disease histology (AST);	chr1:95227082	chr1:94333267~94334848:+
BRCA	cis	rs6496932	0.874	rs11074061	ENSG00000259295.5	CSPG4P12	3.48	0.000517	0.0253	0.17	0.11	Central corneal thickness;Corneal structure;	chr15:85274962	chr15:85191438~85213905:+
BRCA	cis	rs987724	0.515	rs453219	ENSG00000244515.1	KRT18P34	-3.48	0.000517	0.0253	-0.16	-0.11	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156856463	chr3:157162663~157163932:-
BRCA	cis	rs249954	0.512	rs249870	ENSG00000260136.4	CTD-2270L9.4	3.48	0.000517	0.0253	0.11	0.11	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr16:23654857	chr16:23452758~23457606:+
BRCA	cis	rs875971	1	rs6956179	ENSG00000271064.1	RP11-792A8.3	3.48	0.000517	0.0253	0.12	0.11	Aortic root size;	chr7:66341672	chr7:66748838~66749077:-
BRCA	cis	rs9921338	0.961	rs7199821	ENSG00000263080.1	RP11-485G7.5	3.48	0.000517	0.0253	0.17	0.11	Vein graft stenosis in coronary artery bypass grafting;	chr16:11331154	chr16:11341809~11345211:-
BRCA	cis	rs1670533	1	rs13134921	ENSG00000251639.2	RP11-20I20.1	3.48	0.000517	0.0253	0.17	0.11	Recombination rate (females);	chr4:1060389	chr4:1100016~1101558:-
BRCA	cis	rs1670533	0.932	rs13106586	ENSG00000251639.2	RP11-20I20.1	3.48	0.000517	0.0253	0.17	0.11	Recombination rate (females);	chr4:1060394	chr4:1100016~1101558:-
BRCA	cis	rs1437396	0.609	rs2576704	ENSG00000203327.2	AC012358.7	3.48	0.000517	0.0253	0.11	0.11	Alcohol dependence;	chr2:55327462	chr2:55214387~55216126:-
BRCA	cis	rs1437396	0.609	rs2576716	ENSG00000203327.2	AC012358.7	3.48	0.000517	0.0253	0.11	0.11	Alcohol dependence;	chr2:55331475	chr2:55214387~55216126:-
BRCA	cis	rs7919656	0.626	rs2663041	ENSG00000278561.1	PTPN20CP	-3.48	0.000517	0.0253	-0.13	-0.11	Clinically amyopathic dermatomyositis;	chr10:48899492	chr10:48064308~48119455:-
BRCA	cis	rs3735485	0.722	rs3801407	ENSG00000272556.1	RP11-638I8.1	-3.48	0.000517	0.0253	-0.13	-0.11	White blood cell count;Sum basophil neutrophil counts;Neutrophil count;Granulocyte percentage of myeloid white cells;Monocyte percentage of white cells;Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Lymphocyte counts;	chr7:45103904	chr7:45814602~45815263:+
BRCA	cis	rs34792	0.637	rs1684547	ENSG00000275910.1	RP11-680G24.6	-3.48	0.000517	0.0253	-0.12	-0.11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15480604	chr16:15015828~15016390:-
BRCA	cis	rs7246657	0.525	rs1667351	ENSG00000267470.4	ZNF571-AS1	3.48	0.000517	0.0254	0.14	0.11	Coronary artery calcification;	chr19:36987125	chr19:37548914~37587348:+
BRCA	cis	rs78487399	0.808	rs13417883	ENSG00000234936.1	AC010883.5	3.48	0.000517	0.0254	0.16	0.11	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43473015	chr2:43229573~43233394:+
BRCA	cis	rs2274273	1	rs1047556	ENSG00000233924.1	AL160471.6	-3.48	0.000517	0.0254	-0.12	-0.11	Protein biomarker;	chr14:55133564	chr14:55004813~55005687:-
BRCA	cis	rs10792665	0.649	rs4619175	ENSG00000254965.1	RP11-113K21.2	-3.48	0.000517	0.0254	-0.11	-0.11	Obesity-related traits;	chr11:83029987	chr11:83111060~83111442:-
BRCA	cis	rs4698790	0.635	rs13129180	ENSG00000249965.2	CDC42P4	3.48	0.000517	0.0254	0.13	0.11	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);	chr4:109765257	chr4:109555170~109555732:+
BRCA	cis	rs889122	0.68	rs1077220	ENSG00000270614.1	CTC-325H20.7	3.48	0.000517	0.0254	0.13	0.11	Menarche (age at onset);	chr19:9836241	chr19:9348106~9348703:-
BRCA	cis	rs2154319	0.887	rs6698511	ENSG00000230638.4	RP11-486B10.4	3.48	0.000517	0.0254	0.18	0.11	Height;	chr1:41079478	chr1:41542069~41544310:+
BRCA	cis	rs11098499	0.863	rs1155576	ENSG00000250412.1	KLHL2P1	3.48	0.000517	0.0254	0.13	0.11	Corneal astigmatism;	chr4:119529004	chr4:119334329~119378233:+
BRCA	cis	rs2400362	0.793	rs1438227	ENSG00000272518.1	RP11-26J3.3	-3.48	0.000517	0.0254	-0.13	-0.11	Glucocorticoid-induced osteonecrosis (age 10 years and older);	chr8:80957358	chr8:79956465~79957381:-
BRCA	cis	rs9400467	0.537	rs12214886	ENSG00000255389.1	C6orf3	3.48	0.000517	0.0254	0.16	0.11	Amino acid levels;Blood metabolite levels;	chr6:111178878	chr6:111599875~111602295:+
BRCA	cis	rs6813195	0.642	rs4696318	ENSG00000245954.5	RP11-18H21.1	3.48	0.000517	0.0254	0.09	0.11	Type 2 diabetes;	chr4:152381454	chr4:152100754~152104720:+
BRCA	cis	rs6088590	0.735	rs2273684	ENSG00000269202.1	RP4-614O4.12	3.48	0.000517	0.0254	0.11	0.11	Coronary artery disease;	chr20:34941963	chr20:35201747~35203288:-
BRCA	cis	rs2274273	0.84	rs943590	ENSG00000259318.1	RP11-454L9.2	3.48	0.000517	0.0254	0.09	0.11	Protein biomarker;	chr14:55271878	chr14:55394940~55395233:-
BRCA	cis	rs2243480	1	rs1618893	ENSG00000228409.4	CCT6P1	3.48	0.000518	0.0254	0.14	0.11	Diabetic kidney disease;	chr7:66631132	chr7:65751142~65763354:+
BRCA	cis	rs687432	0.887	rs34015013	ENSG00000265566.2	RN7SL605P	-3.48	0.000518	0.0254	-0.15	-0.11	Parkinson's disease;	chr11:58001390	chr11:57528085~57528365:-
BRCA	cis	rs794185	0.561	rs420944	ENSG00000231249.1	ITPR1-AS1	3.48	0.000518	0.0254	0.12	0.11	Multiple sclerosis--Brain Glutamate Levels;	chr3:4513704	chr3:4490891~4493163:-
BRCA	cis	rs7520050	0.902	rs7514192	ENSG00000226957.1	RP4-533D7.4	3.48	0.000518	0.0254	0.12	0.11	Reticulocyte count;Red blood cell count;	chr1:45783305	chr1:46046818~46048368:+
BRCA	cis	rs16975963	0.644	rs73031321	ENSG00000276846.1	CTD-3220F14.3	-3.48	0.000518	0.0254	-0.15	-0.11	Longevity;	chr19:37549956	chr19:37314868~37315620:-
BRCA	cis	rs11239930	0.517	rs4950354	ENSG00000227242.3	NBPF13P	-3.48	0.000518	0.0254	-0.14	-0.11	AIDS progression;	chr1:147082674	chr1:147021320~147124525:-
BRCA	cis	rs11239930	0.538	rs4950355	ENSG00000227242.3	NBPF13P	-3.48	0.000518	0.0254	-0.14	-0.11	AIDS progression;	chr1:147082700	chr1:147021320~147124525:-
BRCA	cis	rs10197140	1	rs17465210	ENSG00000235721.1	AC013268.3	-3.48	0.000518	0.0254	-0.14	-0.11	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110858410	chr2:110007675~110010783:+
BRCA	cis	rs2562456	0.754	rs58338799	ENSG00000240522.1	RPL7AP10	-3.48	0.000518	0.0254	-0.12	-0.11	Pain;	chr19:21339009	chr19:21149648~21150438:-
BRCA	cis	rs6121246	0.609	rs1009453	ENSG00000230613.1	HM13-AS1	3.48	0.000518	0.0254	0.15	0.11	Mean corpuscular hemoglobin;	chr20:31817037	chr20:31567707~31573263:-
BRCA	cis	rs13021401	0.656	rs342071	ENSG00000228950.1	AC023137.2	3.48	0.000518	0.0254	0.13	0.11	Systemic sclerosis;	chr2:20485421	chr2:20451042~20452947:+
BRCA	cis	rs72827839	0.846	rs16953461	ENSG00000263412.1	RP5-890E16.2	-3.48	0.000518	0.0254	-0.14	-0.11	Ease of getting up in the morning;	chr17:48184374	chr17:48045141~48048073:-
BRCA	cis	rs2333021	0.624	rs56282258	ENSG00000259015.1	RP11-109N23.6	3.48	0.000518	0.0254	0.12	0.11	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:72992221	chr14:72960595~72961993:+
BRCA	cis	rs4657482	0.962	rs10918303	ENSG00000236364.3	RP11-525G13.2	-3.48	0.000518	0.0254	-0.1	-0.11	Testicular germ cell tumor;	chr1:165883992	chr1:165890795~165900683:-
BRCA	cis	rs258892	1	rs258886	ENSG00000272525.1	RP11-79P5.9	-3.48	0.000518	0.0254	-0.12	-0.11	Small cell lung carcinoma;	chr5:73007961	chr5:73497550~73498293:-
BRCA	cis	rs35275482	0.541	rs7165175	ENSG00000259238.1	RP11-361D15.2	-3.48	0.000518	0.0254	-0.14	-0.11	Gut microbiota (bacterial taxa);	chr15:59814792	chr15:59688517~59689418:+
BRCA	cis	rs10043775	1	rs10068216	ENSG00000251330.3	CTD-2283N19.1	3.48	0.000518	0.0254	0.13	0.11	Periodontal microbiota;	chr5:148393755	chr5:148430159~148430807:-
BRCA	cis	rs9467773	1	rs9467791	ENSG00000224843.5	LINC00240	3.48	0.000518	0.0254	0.12	0.11	Intelligence (multi-trait analysis);	chr6:26562258	chr6:26956992~27023924:+
BRCA	cis	rs11673344	0.704	rs1644711	ENSG00000267422.1	CTD-2554C21.1	3.48	0.000518	0.0254	0.14	0.11	Obesity-related traits;	chr19:36926420	chr19:37779686~37792865:+
BRCA	cis	rs11673344	0.704	rs485034	ENSG00000267422.1	CTD-2554C21.1	3.48	0.000518	0.0254	0.14	0.11	Obesity-related traits;	chr19:36931455	chr19:37779686~37792865:+
BRCA	cis	rs11673344	0.704	rs517110	ENSG00000267422.1	CTD-2554C21.1	3.48	0.000518	0.0254	0.14	0.11	Obesity-related traits;	chr19:36931492	chr19:37779686~37792865:+
BRCA	cis	rs561341	0.943	rs508566	ENSG00000277511.1	CTD-2095E4.5	3.48	0.000518	0.0254	0.16	0.11	Hip circumference adjusted for BMI;	chr17:31962842	chr17:32127595~32128454:+
BRCA	cis	rs17092148	0.887	rs2378199	ENSG00000202150.1	RNU6-407P	3.48	0.000518	0.0254	0.16	0.11	Neuroticism;	chr20:34598676	chr20:35030317~35030420:-
BRCA	cis	rs12900413	0.603	rs12905689	ENSG00000259212.1	CTD-3065B20.2	3.48	0.000518	0.0254	0.13	0.11	Coronary artery aneurysm in Kawasaki disease;	chr15:89758112	chr15:90595840~90596447:-
BRCA	cis	rs863345	0.604	rs6697656	ENSG00000176320.2	RP11-404O13.5	-3.48	0.000518	0.0254	-0.11	-0.11	Pneumococcal bacteremia;	chr1:158550947	chr1:158197922~158203877:-
BRCA	cis	rs4835473	0.838	rs34819068	ENSG00000249741.2	RP11-673E1.3	3.48	0.000518	0.0254	0.11	0.11	Immature fraction of reticulocytes;	chr4:143787330	chr4:143911514~143912053:-
BRCA	cis	rs10876993	0.89	rs774891	ENSG00000270039.1	RP11-571M6.17	3.48	0.000518	0.0254	0.14	0.11	Celiac disease or Rheumatoid arthritis;	chr12:57674788	chr12:57803838~57804415:+
BRCA	cis	rs1144333	1	rs60144605	ENSG00000181227.3	RP4-682C21.2	-3.48	0.000518	0.0254	-0.15	-0.11	Attention function in attention deficit hyperactive disorder;	chr1:75894014	chr1:75743423~75744776:-
BRCA	cis	rs7508	0.511	rs2237853	ENSG00000253944.1	RP11-156K13.1	-3.48	0.000518	0.0254	-0.16	-0.11	Atrial fibrillation;	chr8:18020371	chr8:17801345~17861069:+
BRCA	cis	rs2692947	0.77	rs58730124	ENSG00000168992.4	OR7E102P	3.48	0.000518	0.0254	0.16	0.11	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95747590	chr2:95546531~95547545:+
BRCA	cis	rs7412746	0.634	rs3754212	ENSG00000224800.1	RP11-235D19.2	-3.48	0.000518	0.0254	-0.14	-0.11	Melanoma;	chr1:150765724	chr1:150881236~150881683:-
BRCA	cis	rs875971	0.862	rs6962717	ENSG00000265600.1	AC006480.1	-3.48	0.000519	0.0254	-0.13	-0.11	Aortic root size;	chr7:66418748	chr7:67356680~67356779:+
BRCA	cis	rs739401	0.611	rs2301140	ENSG00000247473.2	CARS-AS1	3.48	0.000519	0.0254	0.13	0.11	Longevity;	chr11:3001399	chr11:3029009~3041260:+
BRCA	cis	rs3096299	0.606	rs8052103	ENSG00000260630.5	SNAI3-AS1	3.48	0.000519	0.0254	0.14	0.11	Multiple myeloma (IgH translocation);	chr16:89474835	chr16:88663298~88687186:+
BRCA	cis	rs911119	0.866	rs4815223	ENSG00000270001.1	RP11-218C14.8	-3.48	0.000519	0.0254	-0.14	-0.11	Chronic kidney disease;	chr20:23596475	chr20:23631826~23632316:-
BRCA	cis	rs16939607	0.908	rs16939613	ENSG00000254352.1	RP11-578O24.2	-3.48	0.000519	0.0254	-0.18	-0.11	White blood cell count;	chr8:78124542	chr8:78723796~78724136:-
BRCA	cis	rs10504130	0.569	rs12678646	ENSG00000272076.1	RP11-11C20.3	3.48	0.000519	0.0254	0.15	0.11	Venous thromboembolism (SNP x SNP interaction);	chr8:51755611	chr8:51810110~51810681:-
BRCA	cis	rs728478	0.845	rs7207830	ENSG00000265638.1	AC005702.3	3.48	0.000519	0.0254	0.13	0.11	QT interval;	chr17:59402382	chr17:60042694~60042772:-
BRCA	cis	rs3011225	0.738	rs3791076	ENSG00000237950.1	RP11-7O11.3	-3.48	0.000519	0.0254	-0.16	-0.11	Amyotrophic lateral sclerosis (age of onset);	chr1:43849250	chr1:43944370~43946551:-
BRCA	cis	rs2191566	0.576	rs393536	ENSG00000266921.1	RP11-15A1.7	3.48	0.000519	0.0254	0.14	0.11	Acute lymphoblastic leukemia (childhood);	chr19:43988866	chr19:43996896~44002836:-
BRCA	cis	rs7615952	0.673	rs35001498	ENSG00000241288.6	RP11-379B18.5	-3.48	0.000519	0.0254	-0.18	-0.11	Blood pressure (smoking interaction);	chr3:125909801	chr3:125827238~125916384:-
BRCA	cis	rs2935776	0.68	rs1909023	ENSG00000253796.1	RP11-1084E5.1	3.48	0.000519	0.0254	0.13	0.11	Cerebrospinal T-tau levels;	chr8:108645687	chr8:108895029~109063417:-
BRCA	cis	rs4073416	0.647	rs10138570	ENSG00000276116.2	FUT8-AS1	3.48	0.000519	0.0254	0.11	0.11	N-glycan levels;	chr14:65393320	chr14:65411170~65412690:-
BRCA	cis	rs2839186	0.77	rs2280956	ENSG00000215424.8	MCM3AP-AS1	-3.48	0.000519	0.0254	-0.1	-0.11	Testicular germ cell tumor;	chr21:46222409	chr21:46229217~46259390:+
BRCA	cis	rs2823962	0.892	rs1119222	ENSG00000270093.1	AP000473.8	3.48	0.000519	0.0254	0.1	0.11	Amyotrophic lateral sclerosis;	chr21:16658445	chr21:16643529~16645065:+
BRCA	cis	rs6671200	0.541	rs7555339	ENSG00000228852.5	RP11-57H12.5	-3.48	0.000519	0.0254	-0.14	-0.11	Stearic acid (18:0) levels;	chr1:95226023	chr1:95243167~95278940:-
BRCA	cis	rs8114671	0.562	rs2889861	ENSG00000126005.14	MMP24-AS1	-3.48	0.000519	0.0254	-0.12	-0.11	Height;	chr20:34817861	chr20:35216462~35278131:-
BRCA	cis	rs62005083	0.541	rs61059815	ENSG00000259065.1	RP5-1021I20.1	-3.48	0.000519	0.0254	-0.16	-0.11	Mean corpuscular volume;	chr14:74069762	chr14:73787360~73803270:+
BRCA	cis	rs1730008	0.835	rs6802443	ENSG00000279311.1	RP11-170K4.2	-3.48	0.000519	0.0254	-0.12	-0.11	Lobe attachment (rater-scored or self-reported);	chr3:158170649	chr3:158869898~158871821:+
BRCA	cis	rs1383484	0.606	rs9329364	ENSG00000259728.4	LINC00933	-3.48	0.000519	0.0254	-0.13	-0.11	Height;	chr15:83974490	chr15:84570649~84580175:+
BRCA	cis	rs4713118	0.588	rs200994	ENSG00000280107.1	AL022393.9	3.48	0.000519	0.0254	0.16	0.11	Parkinson's disease;	chr6:27846035	chr6:28170845~28172521:+
BRCA	cis	rs7131987	0.834	rs1989478	ENSG00000275476.1	RP11-996F15.4	-3.48	0.000519	0.0254	-0.12	-0.11	QT interval;	chr12:29289296	chr12:29277397~29277882:-
BRCA	cis	rs7903456	0.648	rs9421576	ENSG00000200253.1	RNU6-529P	3.48	0.000519	0.0254	0.14	0.11	Gout;Renal underexcretion gout;	chr10:87069444	chr10:87041238~87041341:-
BRCA	cis	rs9425766	0.679	rs4650945	ENSG00000200674.1	RN7SKP160	-3.48	0.000519	0.0255	-0.14	-0.11	Life satisfaction;	chr1:174114966	chr1:173791548~173791887:+
BRCA	cis	rs1411478	1	rs1411478	ENSG00000243155.1	RP11-46A10.5	3.48	0.000519	0.0255	0.12	0.11	Menopause (age at onset);Progressive supranuclear palsy;	chr1:180993146	chr1:180944042~180976482:-
BRCA	cis	rs7267979	1	rs6037086	ENSG00000274973.1	RP13-401N8.7	3.48	0.000519	0.0255	0.12	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25325702	chr20:25845497~25845862:+
BRCA	cis	rs7267979	0.966	rs2482923	ENSG00000274973.1	RP13-401N8.7	3.48	0.000519	0.0255	0.12	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25328345	chr20:25845497~25845862:+
BRCA	cis	rs2274273	0.624	rs7152390	ENSG00000259318.1	RP11-454L9.2	3.48	0.000519	0.0255	0.1	0.11	Protein biomarker;	chr14:55344983	chr14:55394940~55395233:-
BRCA	cis	rs7577894	0.934	rs6723918	ENSG00000272606.1	RP11-554J4.1	3.48	0.000519	0.0255	0.12	0.11	Amyotrophic lateral sclerosis;	chr2:55777004	chr2:55617909~55618373:+
BRCA	cis	rs10944	0.598	rs1717570	ENSG00000253558.1	CTD-2179L22.1	3.48	0.000519	0.0255	0.13	0.11	Blood and toenail selenium levels;	chr5:78980651	chr5:78041879~78044138:-
BRCA	cis	rs7577894	0.967	rs6742316	ENSG00000272606.1	RP11-554J4.1	3.48	0.000519	0.0255	0.12	0.11	Amyotrophic lateral sclerosis;	chr2:55776853	chr2:55617909~55618373:+
BRCA	cis	rs6429422	0.613	rs12749011	ENSG00000224727.1	FCF1P7	-3.48	0.000519	0.0255	-0.13	-0.11	Cognitive ability (multi-trait analysis);	chr1:243245861	chr1:243267257~243268119:-
BRCA	cis	rs8098244	0.603	rs1788813	ENSG00000265752.2	RP11-403A21.1	3.48	0.000519	0.0255	0.12	0.11	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23701204	chr18:23957754~23982556:-
BRCA	cis	rs10129255	1	rs10129255	ENSG00000232216.1	IGHV3-43	-3.48	0.000519	0.0255	-0.09	-0.11	Kawasaki disease;	chr14:106767970	chr14:106470264~106470800:-
BRCA	cis	rs34217772	0.83	rs60081458	ENSG00000258636.1	CTD-2298J14.2	3.48	0.000519	0.0255	0.15	0.11	Myopia;	chr14:41746599	chr14:41587861~41604856:-
BRCA	cis	rs3764021	0.509	rs10772070	ENSG00000256594.6	RP11-705C15.2	3.48	0.00052	0.0255	0.15	0.11	Type 1 diabetes;	chr12:9717320	chr12:9633419~9658412:+
BRCA	cis	rs6964587	0.626	rs2269810	ENSG00000188693.7	CYP51A1-AS1	3.48	0.00052	0.0255	0.11	0.11	Breast cancer;	chr7:91879523	chr7:92134604~92180725:+
BRCA	cis	rs2882667	0.893	rs7717375	ENSG00000242683.1	CTB-46B19.1	3.48	0.00052	0.0255	0.12	0.11	Age-related hearing impairment (SNP x SNP interaction);	chr5:138955716	chr5:139035148~139035987:-
BRCA	cis	rs7267979	0.868	rs6138553	ENSG00000274973.1	RP13-401N8.7	-3.48	0.00052	0.0255	-0.12	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25258597	chr20:25845497~25845862:+
BRCA	cis	rs6582630	0.576	rs4882375	ENSG00000257718.1	RP11-396F22.1	-3.48	0.00052	0.0255	-0.11	-0.11	Drug-induced liver injury (flucloxacillin);	chr12:37978137	chr12:38906451~38909592:+
BRCA	cis	rs78487399	0.808	rs10169346	ENSG00000234936.1	AC010883.5	3.48	0.00052	0.0255	0.16	0.11	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43513966	chr2:43229573~43233394:+
BRCA	cis	rs875971	1	rs12698523	ENSG00000273024.4	INTS4P2	-3.48	0.00052	0.0255	-0.12	-0.11	Aortic root size;	chr7:66503126	chr7:65647864~65715661:+
BRCA	cis	rs6437061	0.737	rs3103296	ENSG00000223198.1	RNU2-22P	-3.48	0.00052	0.0255	-0.13	-0.11	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);	chr2:232169785	chr2:231501990~231502201:-
BRCA	cis	rs160451	0.811	rs218945	ENSG00000251136.7	RP11-37B2.1	-3.48	0.00052	0.0255	-0.11	-0.11	Leprosy;	chr8:89701884	chr8:89609409~89757727:-
BRCA	cis	rs7267979	1	rs2500404	ENSG00000274414.1	RP5-965G21.4	3.48	0.00052	0.0255	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25379122	chr20:25239007~25245229:-
BRCA	cis	rs7267979	1	rs2500405	ENSG00000274414.1	RP5-965G21.4	3.48	0.00052	0.0255	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25380190	chr20:25239007~25245229:-
BRCA	cis	rs7267979	1	rs2482941	ENSG00000274414.1	RP5-965G21.4	3.48	0.00052	0.0255	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25380580	chr20:25239007~25245229:-
BRCA	cis	rs7267979	0.903	rs2500423	ENSG00000274414.1	RP5-965G21.4	3.48	0.00052	0.0255	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25394246	chr20:25239007~25245229:-
BRCA	cis	rs12819124	0.502	rs10875718	ENSG00000257735.1	RP11-370I10.6	3.48	0.00052	0.0255	0.13	0.11	Glycated hemoglobin levels;	chr12:48017319	chr12:48350945~48442411:+
BRCA	cis	rs860295	0.702	rs11264366	ENSG00000236675.1	MTX1P1	-3.48	0.00052	0.0255	-0.13	-0.11	Body mass index;	chr1:155365620	chr1:155230975~155234325:+
BRCA	cis	rs6997458	0.904	rs1532424	ENSG00000258256.1	RP11-219B4.5	-3.48	0.00052	0.0255	-0.13	-0.11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85355963	chr8:85222446~85245717:-
BRCA	cis	rs7874244	0.953	rs7868737	ENSG00000214190.2	RNF152P1	3.48	0.00052	0.0255	0.15	0.11	Red blood cell count;	chr9:4843672	chr9:5418373~5418976:-
BRCA	cis	rs6921919	0.806	rs213230	ENSG00000220721.1	OR1F12	3.48	0.00052	0.0255	0.14	0.11	Autism spectrum disorder or schizophrenia;	chr6:28362487	chr6:28073316~28074233:+
BRCA	cis	rs6943931	1	rs6960583	ENSG00000230658.1	KLHL7-AS1	-3.48	0.00052	0.0255	-0.14	-0.11	Diabetic kidney disease;	chr7:22378219	chr7:23101228~23105703:-
BRCA	cis	rs2274273	0.87	rs66696758	ENSG00000259318.1	RP11-454L9.2	3.48	0.00052	0.0255	0.09	0.11	Protein biomarker;	chr14:55299791	chr14:55394940~55395233:-
BRCA	cis	rs2274273	0.87	rs7153645	ENSG00000259318.1	RP11-454L9.2	3.48	0.00052	0.0255	0.09	0.11	Protein biomarker;	chr14:55304800	chr14:55394940~55395233:-
BRCA	cis	rs1555133	0.652	rs6141304	ENSG00000275576.1	RP5-836N17.4	-3.48	0.00052	0.0255	-0.12	-0.11	Monocyte count;	chr20:32401407	chr20:32116171~32116629:+
BRCA	cis	rs6984305	0.541	rs17716118	ENSG00000253774.1	CTD-3023L14.1	3.48	0.00052	0.0255	0.19	0.11	Liver enzyme levels (alkaline phosphatase);	chr8:9322624	chr8:8559894~8562124:+
BRCA	cis	rs970548	0.739	rs10793620	ENSG00000237840.5	FAM21FP	3.48	0.00052	0.0255	0.13	0.11	Total cholesterol levels;HDL cholesterol;HDL cholesterol levels;Cholesterol, total;	chr10:45591835	chr10:45706431~45727231:-
BRCA	cis	rs13315871	1	rs9821570	ENSG00000272182.1	RP11-802O23.3	3.48	0.00052	0.0255	0.21	0.11	Cholesterol, total;	chr3:58350192	chr3:58428255~58428815:+
BRCA	cis	rs12826942	0.765	rs17592014	ENSG00000257225.1	RP11-328C8.4	-3.48	0.00052	0.0255	-0.17	-0.11	Coronary artery disease;	chr12:42156345	chr12:42459366~42466128:+
BRCA	cis	rs7045881	0.696	rs10511793	ENSG00000254396.1	RP11-56F10.3	3.48	0.00052	0.0255	0.16	0.11	Schizophrenia;	chr9:26924623	chr9:27102630~27104728:+
BRCA	cis	rs73222236	0.679	rs66810260	ENSG00000239213.4	NCK1-AS1	3.48	0.00052	0.0255	0.12	0.11	Coronary artery disease;	chr3:136574215	chr3:136841726~136862054:-
BRCA	cis	rs1005277	0.522	rs11011343	ENSG00000099251.13	HSD17B7P2	3.48	0.00052	0.0255	0.12	0.11	Extrinsic epigenetic age acceleration;	chr10:37713770	chr10:38356380~38378505:+
BRCA	cis	rs2562456	0.833	rs4644962	ENSG00000268117.1	VN1R84P	3.48	0.00052	0.0255	0.16	0.11	Pain;	chr19:21338125	chr19:21719801~21720035:-
BRCA	cis	rs801193	0.548	rs2659904	ENSG00000230189.5	GS1-124K5.2	3.48	0.00052	0.0255	0.09	0.11	Aortic root size;	chr7:66713615	chr7:66409143~66490059:-
BRCA	cis	rs3096299	0.933	rs2965934	ENSG00000259877.2	RP11-46C24.7	-3.48	0.00052	0.0255	-0.1	-0.11	Multiple myeloma (IgH translocation);	chr16:89414821	chr16:89215211~89217653:-
BRCA	cis	rs1411478	1	rs7516739	ENSG00000243155.1	RP11-46A10.5	3.48	0.00052	0.0255	0.11	0.11	Menopause (age at onset);Progressive supranuclear palsy;	chr1:180979370	chr1:180944042~180976482:-
BRCA	cis	rs11662721	0.938	rs45579846	ENSG00000264188.1	RP11-13N13.5	3.48	0.000521	0.0255	0.15	0.11	Phospholipid levels (plasma);	chr18:21529804	chr18:21661787~21662395:-
BRCA	cis	rs7943953	0.686	rs1453547	ENSG00000254717.2	GLYATL1P2	-3.48	0.000521	0.0255	-0.15	-0.11	Odorant perception (&beta-ionone);	chr11:59422439	chr11:58878302~58893460:+
BRCA	cis	rs2562456	0.833	rs4334427	ENSG00000240522.1	RPL7AP10	-3.48	0.000521	0.0255	-0.12	-0.11	Pain;	chr19:21338090	chr19:21149648~21150438:-
BRCA	cis	rs6452790	0.529	rs55940342	ENSG00000247828.6	TMEM161B-AS1	-3.48	0.000521	0.0255	-0.15	-0.11	Cognitive function;	chr5:87983558	chr5:88268895~88436685:+
BRCA	cis	rs6452790	0.529	rs11957225	ENSG00000247828.6	TMEM161B-AS1	-3.48	0.000521	0.0255	-0.15	-0.11	Cognitive function;	chr5:87988692	chr5:88268895~88436685:+
BRCA	cis	rs13126694	0.744	rs10049927	ENSG00000251073.1	NUDT19P5	3.48	0.000521	0.0255	0.1	0.11	Blood osmolality (transformed sodium);	chr4:157998056	chr4:158182825~158183393:+
BRCA	cis	rs793571	0.779	rs8035628	ENSG00000259250.1	RP11-50C13.1	3.48	0.000521	0.0255	0.15	0.11	Schizophrenia;	chr15:58885201	chr15:58587507~58591676:+
BRCA	cis	rs4648045	0.796	rs4648058	ENSG00000251288.2	RP11-10L12.2	-3.48	0.000521	0.0255	-0.13	-0.11	Lymphocyte percentage of white cells;	chr4:102594434	chr4:102751401~102752641:+
BRCA	cis	rs300890	1	rs624189	ENSG00000250326.1	RP11-284M14.1	-3.48	0.000521	0.0255	-0.12	-0.11	Nasopharyngeal carcinoma;	chr4:143324210	chr4:142933195~143184861:-
BRCA	cis	rs2991971	0.967	rs7526665	ENSG00000280836.1	AL355480.1	3.48	0.000521	0.0255	0.12	0.11	High light scatter reticulocyte count;	chr1:45540160	chr1:45581219~45581321:-
BRCA	cis	rs2991971	0.967	rs644915	ENSG00000280836.1	AL355480.1	3.48	0.000521	0.0255	0.12	0.11	High light scatter reticulocyte count;	chr1:45541330	chr1:45581219~45581321:-
BRCA	cis	rs11121152	1	rs11121152	ENSG00000270282.1	RP5-1115A15.2	-3.48	0.000521	0.0255	-0.12	-0.11	Inflammatory skin disease;	chr1:8297161	chr1:8512653~8513021:+
BRCA	cis	rs875971	0.862	rs778680	ENSG00000265600.1	AC006480.1	-3.48	0.000521	0.0255	-0.13	-0.11	Aortic root size;	chr7:66375427	chr7:67356680~67356779:+
BRCA	cis	rs875971	0.862	rs11769079	ENSG00000265600.1	AC006480.1	-3.48	0.000521	0.0255	-0.13	-0.11	Aortic root size;	chr7:66377141	chr7:67356680~67356779:+
BRCA	cis	rs875971	0.862	rs1695820	ENSG00000265600.1	AC006480.1	-3.48	0.000521	0.0255	-0.13	-0.11	Aortic root size;	chr7:66379576	chr7:67356680~67356779:+
BRCA	cis	rs7267979	0.903	rs6050481	ENSG00000274973.1	RP13-401N8.7	-3.48	0.000521	0.0255	-0.12	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25243944	chr20:25845497~25845862:+
BRCA	cis	rs7267979	0.834	rs6115100	ENSG00000274973.1	RP13-401N8.7	-3.48	0.000521	0.0255	-0.12	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25245302	chr20:25845497~25845862:+
BRCA	cis	rs4272720	0.951	rs61850684	ENSG00000228754.1	RP11-534L6.3	-3.48	0.000521	0.0255	-0.15	-0.11	Platelet count;Plateletcrit;	chr10:49044891	chr10:48745545~48746128:-
BRCA	cis	rs7267979	1	rs2027003	ENSG00000274414.1	RP5-965G21.4	3.48	0.000521	0.0255	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25369862	chr20:25239007~25245229:-
BRCA	cis	rs7267979	1	rs2027004	ENSG00000274414.1	RP5-965G21.4	3.48	0.000521	0.0255	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25369982	chr20:25239007~25245229:-
BRCA	cis	rs7267979	0.934	rs2500399	ENSG00000274414.1	RP5-965G21.4	3.48	0.000521	0.0255	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25374058	chr20:25239007~25245229:-
BRCA	cis	rs138777	0.892	rs4821387	ENSG00000273176.1	RP3-510H16.3	-3.48	0.000521	0.0255	-0.13	-0.11	Total cholesterol levels;Cholesterol, total;	chr22:35273448	chr22:35298838~35299541:-
BRCA	cis	rs7267979	0.868	rs6138553	ENSG00000231081.1	RP4-760C5.3	-3.48	0.000521	0.0255	-0.14	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25258597	chr20:26008791~26010531:-
BRCA	cis	rs2108622	0.727	rs7254940	ENSG00000214049.6	UCA1	3.48	0.000521	0.0255	0.15	0.11	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15873698	chr19:15828961~15836320:+
BRCA	cis	rs7267979	1	rs6076339	ENSG00000231081.1	RP4-760C5.3	3.48	0.000521	0.0255	0.14	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25368076	chr20:26008791~26010531:-
BRCA	cis	rs71520386	0.583	rs35322907	ENSG00000179428.2	AC073072.5	3.48	0.000521	0.0255	0.12	0.11	Fibrinogen levels;	chr7:22806592	chr7:22725395~22727620:-
BRCA	cis	rs10129255	0.913	rs10140943	ENSG00000211958.2	IGHV3-38	3.48	0.000521	0.0255	0.09	0.11	Kawasaki disease;	chr14:106767441	chr14:106410493~106411021:-
BRCA	cis	rs4435363	1	rs4435363	ENSG00000268423.3	AC011551.3	3.48	0.000521	0.0255	0.19	0.11	Immature fraction of reticulocytes;P wave terminal force;	chr19:46569138	chr19:46547056~46600861:-
BRCA	cis	rs28530618	0.564	rs4911248	ENSG00000198547.7	C20orf203	3.48	0.000521	0.0255	0.12	0.11	Birth weight;	chr20:32626432	chr20:32631652~32673941:-
BRCA	cis	rs9534338	0.505	rs11342	ENSG00000235903.6	CPB2-AS1	3.48	0.000521	0.0255	0.13	0.11	Blood protein levels;	chr13:46126507	chr13:46052806~46113332:+
BRCA	cis	rs2274273	0.901	rs10140801	ENSG00000259318.1	RP11-454L9.2	3.48	0.000521	0.0255	0.09	0.11	Protein biomarker;	chr14:55263686	chr14:55394940~55395233:-
BRCA	cis	rs4243971	0.516	rs6141670	ENSG00000275576.1	RP5-836N17.4	-3.48	0.000521	0.0255	-0.12	-0.11	Inflammatory bowel disease;Crohn's disease;	chr20:32314976	chr20:32116171~32116629:+
BRCA	cis	rs2364403	0.715	rs12081057	ENSG00000225082.2	DAP3P1	-3.48	0.000522	0.0255	-0.2	-0.11	Amyotrophic lateral sclerosis (age of onset);	chr1:155952404	chr1:155586644~155602197:+
BRCA	cis	rs13315871	0.929	rs4560319	ENSG00000272182.1	RP11-802O23.3	3.48	0.000522	0.0255	0.21	0.11	Cholesterol, total;	chr3:58400547	chr3:58428255~58428815:+
BRCA	cis	rs6964587	0.626	rs4422709	ENSG00000188693.7	CYP51A1-AS1	3.48	0.000522	0.0255	0.11	0.11	Breast cancer;	chr7:91881654	chr7:92134604~92180725:+
BRCA	cis	rs2835872	0.828	rs111576572	ENSG00000230366.8	DSCR9	-3.48	0.000522	0.0255	-0.14	-0.11	Electroencephalographic traits in alcoholism;	chr21:37617262	chr21:37208503~37221736:+
BRCA	cis	rs7577696	0.741	rs2300702	ENSG00000276334.1	AL133243.1	3.48	0.000522	0.0256	0.13	0.11	Inflammatory biomarkers;	chr2:31562948	chr2:32521927~32523547:+
BRCA	cis	rs5758511	0.68	rs56111723	ENSG00000231261.1	HMGN2P10	-3.48	0.000522	0.0256	-0.15	-0.11	Birth weight;	chr22:42268877	chr22:41709225~41709489:-
BRCA	cis	rs13256369	0.851	rs13254997	ENSG00000254153.1	CTA-398F10.2	3.48	0.000522	0.0256	0.15	0.11	Obesity-related traits;	chr8:8706243	chr8:8456909~8461337:-
BRCA	cis	rs4449834	0.781	rs10093135	ENSG00000254432.1	RP11-33I11.2	-3.48	0.000522	0.0256	-0.14	-0.11	Sum eosinophil basophil counts;	chr8:60744388	chr8:60808735~60809606:-
BRCA	cis	rs7618501	0.966	rs9882639	ENSG00000228008.1	CTD-2330K9.3	3.48	0.000522	0.0256	0.1	0.11	Intelligence (multi-trait analysis);	chr3:49762042	chr3:49903845~49916937:+
BRCA	cis	rs7618501	1	rs60205400	ENSG00000228008.1	CTD-2330K9.3	3.48	0.000522	0.0256	0.1	0.11	Intelligence (multi-trait analysis);	chr3:49762839	chr3:49903845~49916937:+
BRCA	cis	rs7618501	0.933	rs6809431	ENSG00000228008.1	CTD-2330K9.3	3.48	0.000522	0.0256	0.1	0.11	Intelligence (multi-trait analysis);	chr3:49766686	chr3:49903845~49916937:+
BRCA	cis	rs6088580	0.524	rs6088567	ENSG00000261582.1	RP4-614O4.11	3.48	0.000522	0.0256	0.1	0.11	Glomerular filtration rate (creatinine);	chr20:34676068	chr20:35267885~35280043:-
BRCA	cis	rs6088580	0.524	rs6088568	ENSG00000261582.1	RP4-614O4.11	3.48	0.000522	0.0256	0.1	0.11	Glomerular filtration rate (creatinine);	chr20:34678167	chr20:35267885~35280043:-
BRCA	cis	rs6088580	0.524	rs1321306	ENSG00000261582.1	RP4-614O4.11	3.48	0.000522	0.0256	0.1	0.11	Glomerular filtration rate (creatinine);	chr20:34678575	chr20:35267885~35280043:-
BRCA	cis	rs2585417	0.535	rs2185849	ENSG00000185834.10	RPL12P4	-3.48	0.000522	0.0256	-0.11	-0.11	Obesity-related traits;	chr20:54296758	chr20:55074644~55075140:+
BRCA	cis	rs2991971	0.967	rs937291	ENSG00000281133.1	AL355480.3	3.48	0.000522	0.0256	0.12	0.11	High light scatter reticulocyte count;	chr1:45491367	chr1:45580892~45580996:-
BRCA	cis	rs4795519	0.614	rs16972661	ENSG00000265646.2	TUFMP1	3.48	0.000522	0.0256	0.15	0.11	Chronic myeloid leukemia;	chr17:27071011	chr17:27082690~27084036:-
BRCA	cis	rs3743266	0.613	rs1063100	ENSG00000245534.5	RORA-AS1	3.48	0.000522	0.0256	0.12	0.11	Menarche (age at onset);	chr15:60442498	chr15:60479178~60630637:+
BRCA	cis	rs28602670	1	rs28602670	ENSG00000261143.1	ADAMTS7P3	-3.48	0.000522	0.0256	-0.15	-0.11	Post bronchodilator FEV1;	chr15:78475825	chr15:77976042~77993057:+
BRCA	cis	rs9341808	0.69	rs6930534	ENSG00000279022.1	RP11-250B2.4	3.48	0.000522	0.0256	0.12	0.11	Sitting height ratio;	chr6:80186333	chr6:80440730~80441172:+
BRCA	cis	rs934734	0.563	rs11126034	ENSG00000237979.1	AC007389.1	-3.48	0.000522	0.0256	-0.13	-0.11	Rheumatoid arthritis;	chr2:65353087	chr2:65500993~65502138:-
BRCA	cis	rs4449834	0.851	rs4581092	ENSG00000254432.1	RP11-33I11.2	-3.48	0.000522	0.0256	-0.14	-0.11	Sum eosinophil basophil counts;	chr8:60792752	chr8:60808735~60809606:-
BRCA	cis	rs2882667	0.69	rs3763016	ENSG00000242683.1	CTB-46B19.1	3.48	0.000522	0.0256	0.13	0.11	Age-related hearing impairment (SNP x SNP interaction);	chr5:138935043	chr5:139035148~139035987:-
BRCA	cis	rs35146811	0.735	rs1043915	ENSG00000214313.7	AZGP1P1	3.48	0.000522	0.0256	0.11	0.11	Coronary artery disease;	chr7:100202222	chr7:99980762~99987535:+
BRCA	cis	rs2346177	0.875	rs12986585	ENSG00000279254.1	RP11-536C12.1	-3.48	0.000522	0.0256	-0.12	-0.11	HDL cholesterol;	chr2:46416982	chr2:46668870~46670778:+
BRCA	cis	rs2274273	0.686	rs68083077	ENSG00000259318.1	RP11-454L9.2	3.48	0.000522	0.0256	0.1	0.11	Protein biomarker;	chr14:55107710	chr14:55394940~55395233:-
BRCA	cis	rs7520050	0.966	rs4076006	ENSG00000226957.1	RP4-533D7.4	3.48	0.000522	0.0256	0.12	0.11	Reticulocyte count;Red blood cell count;	chr1:45972404	chr1:46046818~46048368:+
BRCA	cis	rs7520050	0.966	rs11211234	ENSG00000226957.1	RP4-533D7.4	3.48	0.000522	0.0256	0.12	0.11	Reticulocyte count;Red blood cell count;	chr1:45973115	chr1:46046818~46048368:+
BRCA	cis	rs9329221	0.935	rs6601450	ENSG00000154316.13	TDH	-3.48	0.000522	0.0256	-0.13	-0.11	Neuroticism;	chr8:10385591	chr8:11339637~11368452:+
BRCA	cis	rs1411478	1	rs6665134	ENSG00000243155.1	RP11-46A10.5	3.48	0.000522	0.0256	0.11	0.11	Menopause (age at onset);Progressive supranuclear palsy;	chr1:180980492	chr1:180944042~180976482:-
BRCA	cis	rs687432	0.885	rs7949741	ENSG00000265566.2	RN7SL605P	-3.48	0.000522	0.0256	-0.15	-0.11	Parkinson's disease;	chr11:57992295	chr11:57528085~57528365:-
BRCA	cis	rs687432	0.924	rs12802044	ENSG00000265566.2	RN7SL605P	-3.48	0.000522	0.0256	-0.15	-0.11	Parkinson's disease;	chr11:57993211	chr11:57528085~57528365:-
BRCA	cis	rs7620503	0.613	rs11720644	ENSG00000228221.4	LINC00578	-3.48	0.000522	0.0256	-0.14	-0.11	Corneal structure;	chr3:177559917	chr3:177441921~177752305:+
BRCA	cis	rs2197308	0.549	rs10785517	ENSG00000257718.1	RP11-396F22.1	3.48	0.000522	0.0256	0.11	0.11	Morning vs. evening chronotype;	chr12:38184190	chr12:38906451~38909592:+
BRCA	cis	rs2638953	0.853	rs10843191	ENSG00000273989.1	RP11-425D17.2	-3.48	0.000522	0.0256	-0.16	-0.11	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28507594	chr12:28236227~28236828:+
BRCA	cis	rs8114671	0.527	rs6088650	ENSG00000261582.1	RP4-614O4.11	3.48	0.000522	0.0256	0.1	0.11	Height;	chr20:34926662	chr20:35267885~35280043:-
BRCA	cis	rs875971	0.862	rs6947339	ENSG00000271064.1	RP11-792A8.3	-3.48	0.000522	0.0256	-0.13	-0.11	Aortic root size;	chr7:66423483	chr7:66748838~66749077:-
BRCA	cis	rs477895	0.653	rs11606544	ENSG00000256940.1	RP11-783K16.5	3.48	0.000522	0.0256	0.15	0.11	Mean platelet volume;	chr11:64129429	chr11:64245964~64248217:+
BRCA	cis	rs6964587	0.626	rs4729011	ENSG00000188693.7	CYP51A1-AS1	3.48	0.000523	0.0256	0.12	0.11	Breast cancer;	chr7:91886105	chr7:92134604~92180725:+
BRCA	cis	rs4970988	0.556	rs2280078	ENSG00000203804.4	ADAMTSL4-AS1	-3.48	0.000523	0.0256	-0.11	-0.11	Urate levels;	chr1:150627705	chr1:150560202~150574552:-
BRCA	cis	rs7917772	0.503	rs10883732	ENSG00000213061.2	PFN1P11	-3.48	0.000523	0.0256	-0.15	-0.11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;	chr10:102533704	chr10:102838011~102845473:-
BRCA	cis	rs7917772	0.503	rs10748825	ENSG00000213061.2	PFN1P11	-3.48	0.000523	0.0256	-0.15	-0.11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;	chr10:102533852	chr10:102838011~102845473:-
BRCA	cis	rs7917772	0.503	rs7893155	ENSG00000213061.2	PFN1P11	-3.48	0.000523	0.0256	-0.15	-0.11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;	chr10:102534471	chr10:102838011~102845473:-
BRCA	cis	rs7917772	0.503	rs7914389	ENSG00000213061.2	PFN1P11	-3.48	0.000523	0.0256	-0.15	-0.11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;	chr10:102535645	chr10:102838011~102845473:-
BRCA	cis	rs7917772	0.503	rs7915589	ENSG00000213061.2	PFN1P11	-3.48	0.000523	0.0256	-0.15	-0.11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;	chr10:102539507	chr10:102838011~102845473:-
BRCA	cis	rs7917772	0.503	rs7100753	ENSG00000213061.2	PFN1P11	-3.48	0.000523	0.0256	-0.15	-0.11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;	chr10:102541222	chr10:102838011~102845473:-
BRCA	cis	rs7917772	0.503	rs11191326	ENSG00000213061.2	PFN1P11	-3.48	0.000523	0.0256	-0.15	-0.11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;	chr10:102543202	chr10:102838011~102845473:-
BRCA	cis	rs4650943	0.503	rs10913148	ENSG00000227740.1	RP11-318C24.2	3.48	0.000523	0.0256	0.11	0.11	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in inactive individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr1:176179650	chr1:175904762~175920513:-
BRCA	cis	rs300703	0.542	rs300697	ENSG00000228643.1	AC079779.4	-3.48	0.000523	0.0256	-0.18	-0.11	Blood protein levels;	chr2:184496	chr2:286419~301515:+
BRCA	cis	rs17772222	0.516	rs1006259	ENSG00000258789.1	RP11-507K2.3	-3.48	0.000523	0.0256	-0.12	-0.11	Coronary artery calcification;	chr14:88339759	chr14:88551597~88552493:+
BRCA	cis	rs73201462	1	rs2687730	ENSG00000242551.2	POU5F1P6	3.48	0.000523	0.0256	0.18	0.11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128196614	chr3:128674735~128677005:-
BRCA	cis	rs2251381	0.606	rs8129515	ENSG00000232855.5	AF131217.1	-3.48	0.000523	0.0256	-0.14	-0.11	Selective IgA deficiency;	chr21:29147846	chr21:28439346~28674848:-
BRCA	cis	rs1018697	1	rs7911528	ENSG00000236937.2	PTGES3P4	3.48	0.000523	0.0256	0.14	0.11	Colorectal adenoma (advanced);	chr10:102791810	chr10:102845595~102845950:+
BRCA	cis	rs8040855	0.627	rs62019482	ENSG00000229212.6	RP11-561C5.4	-3.48	0.000523	0.0256	-0.15	-0.11	Bulimia nervosa;	chr15:85071796	chr15:85205440~85234795:-
BRCA	cis	rs28489187	0.706	rs233095	ENSG00000223653.4	RP11-131L23.1	3.48	0.000523	0.0256	0.12	0.11	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85359133	chr1:85276715~85448124:+
BRCA	cis	rs999943	0.774	rs10947421	ENSG00000224557.6	HLA-DPB2	-3.48	0.000523	0.0256	-0.14	-0.11	Obesity (extreme);	chr6:33643501	chr6:33112451~33129084:+
BRCA	cis	rs999943	0.846	rs10947422	ENSG00000224557.6	HLA-DPB2	-3.48	0.000523	0.0256	-0.14	-0.11	Obesity (extreme);	chr6:33643574	chr6:33112451~33129084:+
BRCA	cis	rs6456156	0.742	rs3093026	ENSG00000272549.1	RP11-351J23.2	-3.48	0.000523	0.0256	-0.11	-0.11	Primary biliary cholangitis;	chr6:167119202	chr6:167666840~167679270:-
BRCA	cis	rs8054556	1	rs4788197	ENSG00000183604.13	SMG1P5	-3.48	0.000523	0.0256	-0.1	-0.11	Autism spectrum disorder or schizophrenia;	chr16:29959513	chr16:30267553~30335374:-
BRCA	cis	rs8054556	1	rs4788198	ENSG00000183604.13	SMG1P5	-3.48	0.000523	0.0256	-0.1	-0.11	Autism spectrum disorder or schizophrenia;	chr16:29959514	chr16:30267553~30335374:-
BRCA	cis	rs2985684	0.948	rs4900925	ENSG00000258568.1	RHOQP1	-3.48	0.000523	0.0256	-0.13	-0.11	Carotid intima media thickness;	chr14:49545607	chr14:49599994~49600572:+
BRCA	cis	rs6445967	1	rs12633655	ENSG00000272182.1	RP11-802O23.3	3.48	0.000523	0.0256	0.12	0.11	Platelet count;	chr3:58320594	chr3:58428255~58428815:+
BRCA	cis	rs6445967	1	rs11712758	ENSG00000272182.1	RP11-802O23.3	3.48	0.000523	0.0256	0.12	0.11	Platelet count;	chr3:58320852	chr3:58428255~58428815:+
BRCA	cis	rs6772849	0.93	rs68090762	ENSG00000207088.1	SNORA7B	-3.48	0.000523	0.0256	-0.13	-0.11	Monocyte percentage of white cells;Monocyte count;	chr3:128625064	chr3:129397210~129397348:-
BRCA	cis	rs72928364	0.929	rs13060849	ENSG00000256628.3	ZBTB11-AS1	3.48	0.000523	0.0256	0.21	0.11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:101054639	chr3:101676475~101679217:+
BRCA	cis	rs72928364	0.929	rs13065684	ENSG00000256628.3	ZBTB11-AS1	3.48	0.000523	0.0256	0.21	0.11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:101054894	chr3:101676475~101679217:+
BRCA	cis	rs7172677	0.737	rs7169545	ENSG00000260269.4	CTD-2323K18.1	-3.48	0.000523	0.0256	-0.15	-0.11	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75143782	chr15:75527150~75601205:-
BRCA	cis	rs2154319	0.887	rs6669542	ENSG00000230638.4	RP11-486B10.4	3.48	0.000523	0.0256	0.18	0.11	Height;	chr1:41060098	chr1:41542069~41544310:+
BRCA	cis	rs5758659	0.714	rs2284087	ENSG00000182057.4	OGFRP1	-3.48	0.000523	0.0256	-0.12	-0.11	Cognitive function;	chr22:42089667	chr22:42269753~42275196:+
BRCA	cis	rs61931739	0.534	rs73103090	ENSG00000258794.3	DUX4L27	3.48	0.000523	0.0256	0.15	0.11	Morning vs. evening chronotype;	chr12:33945866	chr12:34208415~34209675:-
BRCA	cis	rs6951643	0.967	rs727903	ENSG00000224138.1	AC000123.4	-3.48	0.000523	0.0256	-0.13	-0.11	Creutzfeldt-Jakob disease (sporadic);	chr7:126738788	chr7:127350128~127351523:+
BRCA	cis	rs61931739	0.5	rs11053249	ENSG00000258794.3	DUX4L27	3.48	0.000523	0.0256	0.15	0.11	Morning vs. evening chronotype;	chr12:34365899	chr12:34208415~34209675:-
BRCA	cis	rs6914598	0.876	rs9465977	ENSG00000240869.3	RN7SL128P	-3.48	0.000523	0.0256	-0.15	-0.11	Cutaneous malignant melanoma;Melanoma;	chr6:21160828	chr6:20421583~20421887:-
BRCA	cis	rs4934494	0.727	rs36019294	ENSG00000232229.4	LINC00865	-3.48	0.000523	0.0256	-0.16	-0.11	Red blood cell count;	chr10:89777822	chr10:89829510~89840861:+
BRCA	cis	rs875971	0.825	rs28480509	ENSG00000265600.1	AC006480.1	3.48	0.000523	0.0256	0.13	0.11	Aortic root size;	chr7:66634237	chr7:67356680~67356779:+
BRCA	cis	rs7620503	0.613	rs11715627	ENSG00000228221.4	LINC00578	3.48	0.000523	0.0256	0.14	0.11	Corneal structure;	chr3:177567399	chr3:177441921~177752305:+
BRCA	cis	rs35740288	0.77	rs35348278	ENSG00000259295.5	CSPG4P12	3.48	0.000523	0.0256	0.15	0.11	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85657109	chr15:85191438~85213905:+
BRCA	cis	rs7487075	0.619	rs9669404	ENSG00000257261.4	RP11-96H19.1	-3.48	0.000523	0.0256	-0.12	-0.11	Itch intensity from mosquito bite;	chr12:46405180	chr12:46383679~46876159:+
BRCA	cis	rs6672530	0.518	rs1323022	ENSG00000227711.2	RP11-275O4.5	3.48	0.000524	0.0256	0.12	0.11	Hip circumference adjusted for BMI;	chr1:227688435	chr1:227509028~227520477:-
BRCA	cis	rs1455244	0.813	rs7231219	ENSG00000267533.1	RP11-815J4.7	-3.48	0.000524	0.0256	-0.14	-0.11	Schizophrenia;	chr18:11466857	chr18:12067173~12068417:-
BRCA	cis	rs7620503	0.959	rs2863014	ENSG00000228561.2	RP11-114M1.1	3.48	0.000524	0.0256	0.13	0.11	Corneal structure;	chr3:177585404	chr3:177683627~177691250:+
BRCA	cis	rs55788414	0.932	rs9929253	ENSG00000166473.15	PKD1L2	-3.48	0.000524	0.0256	-0.19	-0.11	Left ventricular obstructive tract defect (maternal effect);	chr16:81148036	chr16:81100875~81220370:-
BRCA	cis	rs875971	0.522	rs1917563	ENSG00000232546.1	RP11-458F8.1	3.48	0.000524	0.0256	0.09	0.11	Aortic root size;	chr7:65950660	chr7:66848496~66858136:+
BRCA	cis	rs952623	0.501	rs12671046	ENSG00000211694.2	TRGV10	-3.48	0.000524	0.0256	-0.09	-0.11	Intelligence (multi-trait analysis);	chr7:39042266	chr7:38299811~38300322:-
BRCA	cis	rs60871478	0.679	rs6962050	ENSG00000237181.1	AC147651.4	-3.48	0.000524	0.0256	-0.12	-0.11	Cerebrospinal P-tau181p levels;	chr7:777564	chr7:603185~608482:+
BRCA	cis	rs8073060	0.586	rs226090	ENSG00000267554.1	RP11-686D22.10	-3.48	0.000524	0.0256	-0.12	-0.11	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35707040	chr17:35470069~35470628:-
BRCA	cis	rs4699052	0.662	rs1516732	ENSG00000230069.3	LRRC37A15P	-3.48	0.000524	0.0256	-0.1	-0.11	Testicular germ cell tumor;	chr4:103329997	chr4:102727274~102730721:-
BRCA	cis	rs6121246	0.609	rs6060627	ENSG00000230613.1	HM13-AS1	3.48	0.000524	0.0256	0.14	0.11	Mean corpuscular hemoglobin;	chr20:31674356	chr20:31567707~31573263:-
BRCA	cis	rs2243480	1	rs313809	ENSG00000226767.1	RP11-328P23.3	-3.48	0.000524	0.0256	-0.19	-0.11	Diabetic kidney disease;	chr7:66034996	chr7:65508773~65508944:-
BRCA	cis	rs6600671	0.899	rs2319971	ENSG00000223345.3	HIST2H2BA	3.48	0.000524	0.0256	0.13	0.11	Hip geometry;	chr1:121485184	chr1:121108210~121117257:-
BRCA	cis	rs881375	0.967	rs7864019	ENSG00000238181.2	AHCYP2	-3.48	0.000524	0.0256	-0.13	-0.11	Rheumatoid arthritis;	chr9:120930590	chr9:120720673~120721972:+
BRCA	cis	rs2832270	0.915	rs2832260	ENSG00000176054.6	RPL23P2	-3.48	0.000524	0.0256	-0.23	-0.11	Response to mTOR inhibitor (everolimus);	chr21:29212486	chr21:28997613~28998033:-
BRCA	cis	rs6545883	0.929	rs7606167	ENSG00000212978.6	AC016747.3	3.48	0.000524	0.0256	0.14	0.11	Tuberculosis;	chr2:61515519	chr2:61141592~61144969:-
BRCA	cis	rs1355223	0.867	rs2281908	ENSG00000271369.1	RP11-350D17.3	-3.48	0.000524	0.0256	-0.13	-0.11	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34662031	chr11:34709600~34710161:+
BRCA	cis	rs2274273	0.84	rs66486619	ENSG00000259318.1	RP11-454L9.2	3.48	0.000524	0.0256	0.09	0.11	Protein biomarker;	chr14:55402837	chr14:55394940~55395233:-
BRCA	cis	rs783540	0.843	rs28374463	ENSG00000274376.3	ADAMTS7P1	-3.48	0.000524	0.0256	-0.12	-0.11	Schizophrenia;	chr15:82630613	chr15:82298553~82334609:+
BRCA	cis	rs2034650	0.612	rs7165636	ENSG00000223313.1	RNU6-516P	3.48	0.000524	0.0256	0.13	0.11	Interstitial lung disease;	chr15:40400484	chr15:40529570~40529673:+
BRCA	cis	rs1823874	0.71	rs56160817	ENSG00000259363.4	CTD-2054N24.2	3.48	0.000524	0.0256	0.13	0.11	IgG glycosylation;	chr15:99820472	chr15:99807023~99877148:+
BRCA	cis	rs2154319	0.887	rs61779269	ENSG00000230638.4	RP11-486B10.4	-3.48	0.000524	0.0257	-0.18	-0.11	Height;	chr1:41199784	chr1:41542069~41544310:+
BRCA	cis	rs2154319	0.887	rs61779270	ENSG00000230638.4	RP11-486B10.4	-3.48	0.000524	0.0257	-0.18	-0.11	Height;	chr1:41205234	chr1:41542069~41544310:+
BRCA	cis	rs7429990	0.965	rs184388	ENSG00000199476.1	Y_RNA	-3.48	0.000524	0.0257	-0.14	-0.11	Educational attainment (years of education);	chr3:47898136	chr3:48288587~48288694:+
BRCA	cis	rs910316	1	rs13099	ENSG00000259138.1	RP11-950C14.7	-3.48	0.000524	0.0257	-0.11	-0.11	Height;	chr14:75132452	chr14:75127153~75136930:+
BRCA	cis	rs987724	0.515	rs344079	ENSG00000244515.1	KRT18P34	-3.48	0.000524	0.0257	-0.16	-0.11	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156837783	chr3:157162663~157163932:-
BRCA	cis	rs987724	0.515	rs344080	ENSG00000244515.1	KRT18P34	-3.48	0.000524	0.0257	-0.16	-0.11	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156837996	chr3:157162663~157163932:-
BRCA	cis	rs987724	0.515	rs344082	ENSG00000244515.1	KRT18P34	-3.48	0.000524	0.0257	-0.16	-0.11	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156838290	chr3:157162663~157163932:-
BRCA	cis	rs987724	0.515	rs344084	ENSG00000244515.1	KRT18P34	-3.48	0.000524	0.0257	-0.16	-0.11	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156838591	chr3:157162663~157163932:-
BRCA	cis	rs74233809	1	rs79237883	ENSG00000213061.2	PFN1P11	3.48	0.000524	0.0257	0.24	0.11	Birth weight;	chr10:103181189	chr10:102838011~102845473:-
BRCA	cis	rs4699052	1	rs6533060	ENSG00000230069.3	LRRC37A15P	-3.48	0.000524	0.0257	-0.1	-0.11	Testicular germ cell tumor;	chr4:103218839	chr4:102727274~102730721:-
BRCA	cis	rs2274273	0.805	rs11628437	ENSG00000259318.1	RP11-454L9.2	3.48	0.000524	0.0257	0.09	0.11	Protein biomarker;	chr14:55308750	chr14:55394940~55395233:-
BRCA	cis	rs2991971	0.729	rs10890328	ENSG00000280836.1	AL355480.1	-3.48	0.000524	0.0257	-0.13	-0.11	High light scatter reticulocyte count;	chr1:45439711	chr1:45581219~45581321:-
BRCA	cis	rs8180040	0.739	rs4683320	ENSG00000260236.1	RP11-708J19.1	3.48	0.000524	0.0257	0.09	0.11	Colorectal cancer;	chr3:47111502	chr3:47379089~47380999:-
BRCA	cis	rs651907	0.737	rs9844218	ENSG00000256628.3	ZBTB11-AS1	-3.48	0.000525	0.0257	-0.14	-0.11	Colorectal cancer;	chr3:101866139	chr3:101676475~101679217:+
BRCA	cis	rs875971	0.54	rs1723268	ENSG00000227113.2	RP11-460N20.4	3.48	0.000525	0.0257	0.11	0.11	Aortic root size;	chr7:66008093	chr7:65075023~65078780:+
BRCA	cis	rs3750965	0.959	rs4930264	ENSG00000259799.1	RP11-554A11.9	3.48	0.000525	0.0257	0.13	0.11	Hair color;	chr11:69084713	chr11:69155910~69159752:+
BRCA	cis	rs516805	0.665	rs517427	ENSG00000279114.1	RP3-425C14.5	-3.48	0.000525	0.0257	-0.14	-0.11	Lymphocyte counts;	chr6:122291180	chr6:122471923~122484161:+
BRCA	cis	rs7229439	0.737	rs11659929	ENSG00000279319.1	RP11-693M3.1	3.48	0.000525	0.0257	0.12	0.11	Antipsychotic drug-induced QTc interval change in schizophrenia;	chr18:45352149	chr18:44986109~44989203:+
BRCA	cis	rs1348850	0.914	rs10497503	ENSG00000271825.1	RP11-337N6.2	3.48	0.000525	0.0257	0.14	0.11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177507011	chr2:177300600~177302006:+
BRCA	cis	rs4366055	1	rs4366055	ENSG00000261437.1	RP11-22C11.2	3.48	0.000525	0.0257	0.11	0.11	Body mass index;	chr8:94495100	chr8:94637285~94639467:-
BRCA	cis	rs890448	0.796	rs7668224	ENSG00000254531.1	FLJ20021	3.48	0.000525	0.0257	0.13	0.11	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101363270	chr4:101347780~101348883:+
BRCA	cis	rs890448	0.796	rs4699211	ENSG00000254531.1	FLJ20021	3.48	0.000525	0.0257	0.13	0.11	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101363878	chr4:101347780~101348883:+
BRCA	cis	rs977987	0.806	rs11862582	ENSG00000280152.1	RP11-331F4.5	-3.48	0.000525	0.0257	-0.11	-0.11	Dupuytren's disease;	chr16:75397397	chr16:75245994~75250077:-
BRCA	cis	rs16950303	0.661	rs73439648	ENSG00000264269.1	RP11-15F12.1	3.48	0.000525	0.0257	0.22	0.11	Height;	chr18:49057974	chr18:49023703~49048474:+
BRCA	cis	rs2562456	0.724	rs58001930	ENSG00000268705.1	BNIP3P26	3.48	0.000525	0.0257	0.12	0.11	Pain;	chr19:21560061	chr19:21521343~21521896:-
BRCA	cis	rs10876993	0.928	rs2640631	ENSG00000269903.1	RP11-571M6.18	3.48	0.000525	0.0257	0.13	0.11	Celiac disease or Rheumatoid arthritis;	chr12:57673749	chr12:57814494~57814926:+
BRCA	cis	rs7267979	0.899	rs6115213	ENSG00000274414.1	RP5-965G21.4	-3.48	0.000525	0.0257	-0.13	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25569736	chr20:25239007~25245229:-
BRCA	cis	rs2921036	0.529	rs2979192	ENSG00000253981.4	ALG1L13P	3.48	0.000525	0.0257	0.13	0.11	Neuroticism;	chr8:8480637	chr8:8236003~8244667:-
BRCA	cis	rs17767294	0.708	rs79956881	ENSG00000219392.1	RP1-265C24.5	-3.48	0.000525	0.0257	-0.3	-0.11	Parkinson's disease;	chr6:28062372	chr6:28115628~28116551:+
BRCA	cis	rs11877825	0.813	rs34276557	ENSG00000265728.1	RP11-883A18.3	-3.48	0.000525	0.0257	-0.15	-0.11	Gut microbiota (bacterial taxa);	chr18:10571008	chr18:10594590~10604798:+
BRCA	cis	rs9341808	0.718	rs9352801	ENSG00000279022.1	RP11-250B2.4	3.48	0.000525	0.0257	0.12	0.11	Sitting height ratio;	chr6:80107751	chr6:80440730~80441172:+
BRCA	cis	rs7188861	0.681	rs72773819	ENSG00000262636.1	CTD-3088G3.4	3.48	0.000525	0.0257	0.21	0.11	HDL cholesterol;	chr16:11312935	chr16:11380859~11381118:-
BRCA	cis	rs6439699	0.941	rs13067731	ENSG00000273486.1	RP11-731C17.2	3.48	0.000525	0.0257	0.14	0.11	Intelligence (multi-trait analysis);	chr3:137271149	chr3:136837338~136839021:-
BRCA	cis	rs4819052	0.851	rs9754134	ENSG00000223768.1	LINC00205	-3.48	0.000525	0.0257	-0.15	-0.11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45241836	chr21:45293285~45297354:+
BRCA	cis	rs709400	0.628	rs6575983	ENSG00000260285.1	RP11-600F24.7	3.48	0.000525	0.0257	0.1	0.11	Body mass index;	chr14:103403512	chr14:103525010~103529072:-
BRCA	cis	rs991427	0.908	rs12320366	ENSG00000258100.1	RP11-121E16.1	-3.48	0.000525	0.0257	-0.14	-0.11	Systolic blood pressure (alcohol consumption interaction);	chr12:91056207	chr12:91362196~91368606:+
BRCA	cis	rs12317459	1	rs73356363	ENSG00000213270.5	RPL6P25	-3.48	0.000525	0.0257	-0.16	-0.11	Prostate cancer (SNP x SNP interaction);	chr12:82766564	chr12:83151331~83152190:+
BRCA	cis	rs10129255	0.957	rs11847726	ENSG00000231475.3	IGHV4-31	-3.48	0.000525	0.0257	-0.08	-0.11	Kawasaki disease;	chr14:106779116	chr14:106349283~106349792:-
BRCA	cis	rs17221829	0.733	rs117029483	ENSG00000280385.1	AP000648.5	-3.48	0.000525	0.0257	-0.12	-0.11	Anxiety in major depressive disorder;	chr11:89632750	chr11:90193614~90198120:+
BRCA	cis	rs17221829	0.733	rs10830304	ENSG00000280385.1	AP000648.5	-3.48	0.000525	0.0257	-0.12	-0.11	Anxiety in major depressive disorder;	chr11:89633586	chr11:90193614~90198120:+
BRCA	cis	rs911119	0.913	rs4815222	ENSG00000270001.1	RP11-218C14.8	3.48	0.000525	0.0257	0.14	0.11	Chronic kidney disease;	chr20:23596327	chr20:23631826~23632316:-
BRCA	cis	rs8180040	0.654	rs6773521	ENSG00000280667.1	Y_RNA	-3.48	0.000525	0.0257	-0.12	-0.11	Colorectal cancer;	chr3:47192929	chr3:47501083~47501182:+
BRCA	cis	rs28489187	0.66	rs4949900	ENSG00000223653.4	RP11-131L23.1	-3.48	0.000525	0.0257	-0.12	-0.11	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85395351	chr1:85276715~85448124:+
BRCA	cis	rs10911902	0.643	rs78468398	ENSG00000229739.2	RP11-295K2.3	-3.48	0.000525	0.0257	-0.15	-0.11	Schizophrenia;	chr1:186315149	chr1:186435161~186470291:+
BRCA	cis	rs1730008	0.964	rs699928	ENSG00000279311.1	RP11-170K4.2	-3.48	0.000526	0.0257	-0.12	-0.11	Lobe attachment (rater-scored or self-reported);	chr3:158214061	chr3:158869898~158871821:+
BRCA	cis	rs481331	0.866	rs11499093	ENSG00000273008.1	RP11-351D16.3	3.48	0.000526	0.0257	0.13	0.11	Systemic juvenile idiopathic arthritis;	chr10:42487342	chr10:43136824~43138334:-
BRCA	cis	rs9467773	1	rs4713006	ENSG00000261353.1	CTA-14H9.5	-3.48	0.000526	0.0257	-0.11	-0.11	Intelligence (multi-trait analysis);	chr6:26519644	chr6:26527063~26527404:+
BRCA	cis	rs751728	0.626	rs57150921	ENSG00000224557.6	HLA-DPB2	-3.48	0.000526	0.0257	-0.12	-0.11	Crohn's disease;	chr6:33769741	chr6:33112451~33129084:+
BRCA	cis	rs8058578	1	rs13338946	ENSG00000274678.1	RP11-2C24.7	3.48	0.000526	0.0257	0.13	0.11	Multiple myeloma;	chr16:30689537	chr16:30821338~30821884:+
BRCA	cis	rs3916	0.955	rs35525135	ENSG00000277423.1	RP11-173P15.9	-3.48	0.000526	0.0257	-0.14	-0.11	Urinary metabolites (H-NMR features);	chr12:120702261	chr12:120703867~120704282:+
BRCA	cis	rs4713118	0.513	rs149954	ENSG00000219891.2	ZSCAN12P1	3.48	0.000526	0.0257	0.13	0.11	Parkinson's disease;	chr6:28067468	chr6:28091154~28093664:+
BRCA	cis	rs600231	0.708	rs602838	ENSG00000254614.2	AP003068.23	3.48	0.000526	0.0257	0.14	0.11	Bone mineral density;	chr11:65485776	chr11:65177606~65181834:-
BRCA	cis	rs11098499	0.754	rs17595608	ENSG00000250412.1	KLHL2P1	3.48	0.000526	0.0257	0.12	0.11	Corneal astigmatism;	chr4:119329351	chr4:119334329~119378233:+
BRCA	cis	rs875971	0.929	rs778692	ENSG00000273024.4	INTS4P2	-3.48	0.000526	0.0257	-0.12	-0.11	Aortic root size;	chr7:66407462	chr7:65647864~65715661:+
BRCA	cis	rs875971	1	rs4718343	ENSG00000273024.4	INTS4P2	-3.48	0.000526	0.0257	-0.12	-0.11	Aortic root size;	chr7:66409301	chr7:65647864~65715661:+
BRCA	cis	rs875971	1	rs1968225	ENSG00000273024.4	INTS4P2	-3.48	0.000526	0.0257	-0.12	-0.11	Aortic root size;	chr7:66409786	chr7:65647864~65715661:+
BRCA	cis	rs875971	1	rs6460295	ENSG00000273024.4	INTS4P2	-3.48	0.000526	0.0257	-0.12	-0.11	Aortic root size;	chr7:66417741	chr7:65647864~65715661:+
BRCA	cis	rs875971	0.964	rs6978721	ENSG00000273024.4	INTS4P2	-3.48	0.000526	0.0257	-0.12	-0.11	Aortic root size;	chr7:66418217	chr7:65647864~65715661:+
BRCA	cis	rs863345	0.604	rs1578761	ENSG00000176320.2	RP11-404O13.5	-3.48	0.000526	0.0257	-0.11	-0.11	Pneumococcal bacteremia;	chr1:158527782	chr1:158197922~158203877:-
BRCA	cis	rs72634258	0.554	rs7556518	ENSG00000269925.1	RP3-467L1.6	3.48	0.000526	0.0257	0.18	0.11	Inflammatory bowel disease;	chr1:7787786	chr1:7776383~7776775:+
BRCA	cis	rs7089973	0.641	rs12772737	ENSG00000236799.1	RP11-383C6.2	-3.48	0.000526	0.0257	-0.14	-0.11	Bipolar disorder or attention deficit hyperactivity disorder;	chr10:114981742	chr10:114994657~114996593:+
BRCA	cis	rs2908197	0.843	rs2961040	ENSG00000205485.12	AC004980.7	3.48	0.000526	0.0257	0.12	0.11	3-hydroxypropylmercapturic acid levels in smokers;	chr7:76317446	chr7:76549360~76627982:+
BRCA	cis	rs9467773	1	rs6910899	ENSG00000261353.1	CTA-14H9.5	-3.48	0.000526	0.0257	-0.11	-0.11	Intelligence (multi-trait analysis);	chr6:26524111	chr6:26527063~26527404:+
BRCA	cis	rs2154319	0.887	rs7525193	ENSG00000230638.4	RP11-486B10.4	3.48	0.000526	0.0257	0.18	0.11	Height;	chr1:41055040	chr1:41542069~41544310:+
BRCA	cis	rs16945612	0.826	rs274540	ENSG00000260922.1	RP11-538I12.3	3.48	0.000526	0.0257	0.21	0.11	Bone mineral density;	chr16:77387154	chr16:77234877~77290934:+
BRCA	cis	rs2638953	0.671	rs11049352	ENSG00000247934.4	RP11-967K21.1	-3.48	0.000526	0.0257	-0.16	-0.11	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28113832	chr12:28163298~28190738:-
BRCA	cis	rs13256369	0.851	rs13256611	ENSG00000254153.1	CTA-398F10.2	3.48	0.000526	0.0257	0.15	0.11	Obesity-related traits;	chr8:8706831	chr8:8456909~8461337:-
BRCA	cis	rs28489187	0.643	rs997251	ENSG00000223653.4	RP11-131L23.1	3.48	0.000526	0.0257	0.12	0.11	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85379684	chr1:85276715~85448124:+
BRCA	cis	rs10838634	0.803	rs118012321	ENSG00000280615.1	Y_RNA	-3.48	0.000526	0.0257	-0.23	-0.11	Schizophrenia;	chr11:47098515	chr11:47614898~47614994:-
BRCA	cis	rs4578769	0.55	rs9953702	ENSG00000265943.1	RP11-739L10.1	3.48	0.000526	0.0257	0.14	0.11	Eosinophil percentage of white cells;	chr18:22971001	chr18:22699481~22933764:-
BRCA	cis	rs74233809	1	rs11191515	ENSG00000236937.2	PTGES3P4	3.48	0.000526	0.0257	0.24	0.11	Birth weight;	chr10:103016770	chr10:102845595~102845950:+
BRCA	cis	rs16940212	0.618	rs261301	ENSG00000259771.1	RP11-429D19.1	3.48	0.000526	0.0257	0.17	0.11	HDL cholesterol;HDL cholesterol levels;	chr15:58394740	chr15:59266720~59271162:-
BRCA	cis	rs12220238	0.778	rs10824216	ENSG00000213731.2	RAB5CP1	-3.48	0.000526	0.0257	-0.17	-0.11	Soluble interleukin-2 receptor subunit alpha;	chr10:74649452	chr10:74423435~74424014:-
BRCA	cis	rs11035577	0.632	rs7950939	ENSG00000279675.1	RP11-454H19.2	-3.48	0.000526	0.0257	-0.16	-0.11	Temperament (bipolar disorder);	chr11:39763889	chr11:40107244~40112599:-
BRCA	cis	rs8114671	0.562	rs2378294	ENSG00000261582.1	RP4-614O4.11	-3.48	0.000526	0.0257	-0.1	-0.11	Height;	chr20:34912575	chr20:35267885~35280043:-
BRCA	cis	rs875971	0.522	rs4718286	ENSG00000227113.2	RP11-460N20.4	3.48	0.000527	0.0257	0.11	0.11	Aortic root size;	chr7:65827777	chr7:65075023~65078780:+
BRCA	cis	rs17711722	0.585	rs6942660	ENSG00000227113.2	RP11-460N20.4	3.48	0.000527	0.0257	0.11	0.11	Calcium levels;	chr7:65837419	chr7:65075023~65078780:+
BRCA	cis	rs2562456	0.876	rs11085465	ENSG00000213976.4	CTD-2561J22.2	3.48	0.000527	0.0257	0.13	0.11	Pain;	chr19:21568988	chr19:21382865~21387177:+
BRCA	cis	rs11892454	0.565	rs2891480	ENSG00000217643.1	PTGES3P2	-3.48	0.000527	0.0257	-0.12	-0.11	Heschl's gyrus morphology;	chr2:25861328	chr2:25822469~25822950:+
BRCA	cis	rs4703129	1	rs13166309	ENSG00000246763.5	RGMB-AS1	-3.48	0.000527	0.0257	-0.12	-0.11	Asperger disorder;	chr5:98558169	chr5:98769618~98773469:-
BRCA	cis	rs17756712	0.725	rs17135357	ENSG00000272463.1	RP11-532F6.3	3.48	0.000527	0.0258	0.19	0.11	Vertical cup-disc ratio;	chr6:602983	chr6:708592~711405:-
BRCA	cis	rs4388249	0.948	rs34364676	ENSG00000271849.1	CTC-332L22.1	-3.48	0.000527	0.0258	-0.17	-0.11	Schizophrenia;	chr5:109760822	chr5:109687802~109688329:-
BRCA	cis	rs4388249	1	rs34961375	ENSG00000271849.1	CTC-332L22.1	-3.48	0.000527	0.0258	-0.17	-0.11	Schizophrenia;	chr5:109761009	chr5:109687802~109688329:-
BRCA	cis	rs8114671	0.836	rs6142284	ENSG00000261582.1	RP4-614O4.11	3.48	0.000527	0.0258	0.1	0.11	Height;	chr20:35053564	chr20:35267885~35280043:-
BRCA	cis	rs875971	0.508	rs6947808	ENSG00000265600.1	AC006480.1	3.48	0.000527	0.0258	0.13	0.11	Aortic root size;	chr7:66580095	chr7:67356680~67356779:+
BRCA	cis	rs56046484	0.956	rs35885781	ENSG00000259630.2	CTD-2262B20.1	-3.48	0.000527	0.0258	-0.18	-0.11	Testicular germ cell tumor;	chr15:85047852	chr15:85415228~85415633:+
BRCA	cis	rs2191566	0.691	rs55771992	ENSG00000266921.1	RP11-15A1.7	-3.48	0.000527	0.0258	-0.13	-0.11	Acute lymphoblastic leukemia (childhood);	chr19:44084125	chr19:43996896~44002836:-
BRCA	cis	rs2191566	0.691	rs56182773	ENSG00000266921.1	RP11-15A1.7	-3.48	0.000527	0.0258	-0.13	-0.11	Acute lymphoblastic leukemia (childhood);	chr19:44084172	chr19:43996896~44002836:-
BRCA	cis	rs397969	0.596	rs12450857	ENSG00000261033.1	RP11-209D14.2	-3.48	0.000527	0.0258	-0.15	-0.11	Platelet count;	chr17:19991935	chr17:20008051~20009234:-
BRCA	cis	rs6696239	0.956	rs12133625	ENSG00000215812.5	ZNF847P	3.48	0.000527	0.0258	0.15	0.11	Height;	chr1:227656481	chr1:227696892~227706699:-
BRCA	cis	rs1005277	0.577	rs4934906	ENSG00000099251.13	HSD17B7P2	3.48	0.000527	0.0258	0.12	0.11	Extrinsic epigenetic age acceleration;	chr10:37726100	chr10:38356380~38378505:+
BRCA	cis	rs539096	0.624	rs653953	ENSG00000236200.4	KDM4A-AS1	-3.48	0.000527	0.0258	-0.12	-0.11	Intelligence (multi-trait analysis);	chr1:43617344	chr1:43699765~43708138:-
BRCA	cis	rs6601327	0.518	rs13264850	ENSG00000233609.3	RP11-62H7.2	-3.48	0.000527	0.0258	-0.1	-0.11	Multiple myeloma (hyperdiploidy);	chr8:9717821	chr8:8961200~8979025:+
BRCA	cis	rs10246939	0.505	rs10952508	ENSG00000270923.1	TAS2R6P	-3.48	0.000527	0.0258	-0.12	-0.11	Bitter taste perception;	chr7:141879415	chr7:141787815~141788640:+
BRCA	cis	rs6997458	0.904	rs725605	ENSG00000258256.1	RP11-219B4.5	-3.48	0.000527	0.0258	-0.12	-0.11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85354657	chr8:85222446~85245717:-
BRCA	cis	rs6678639	0.522	rs2292059	ENSG00000225154.2	RP11-184J23.2	3.48	0.000527	0.0258	0.16	0.11	Blood metabolite ratios;	chr1:47039045	chr1:47074778~47075979:-
BRCA	cis	rs4819052	0.851	rs914218	ENSG00000223768.1	LINC00205	-3.48	0.000527	0.0258	-0.14	-0.11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45278530	chr21:45293285~45297354:+
BRCA	cis	rs6887276	0.538	rs35897671	ENSG00000245937.6	LINC01184	-3.48	0.000527	0.0258	-0.12	-0.11	Height;	chr5:128014053	chr5:127940426~128083172:-
BRCA	cis	rs9863	0.861	rs10846579	ENSG00000256596.1	RP11-522N14.2	3.48	0.000527	0.0258	0.14	0.11	White blood cell count;	chr12:123922856	chr12:124206228~124209018:+
BRCA	cis	rs9863	0.861	rs11057394	ENSG00000256596.1	RP11-522N14.2	3.48	0.000527	0.0258	0.14	0.11	White blood cell count;	chr12:123923129	chr12:124206228~124209018:+
BRCA	cis	rs9863	0.861	rs12809125	ENSG00000256596.1	RP11-522N14.2	3.48	0.000527	0.0258	0.14	0.11	White blood cell count;	chr12:123923444	chr12:124206228~124209018:+
BRCA	cis	rs4819052	0.851	rs9977178	ENSG00000223768.1	LINC00205	-3.48	0.000527	0.0258	-0.14	-0.11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244616	chr21:45293285~45297354:+
BRCA	cis	rs11098499	0.754	rs938056	ENSG00000250412.1	KLHL2P1	3.48	0.000527	0.0258	0.12	0.11	Corneal astigmatism;	chr4:119316298	chr4:119334329~119378233:+
BRCA	cis	rs4908769	0.624	rs2708630	ENSG00000232912.4	RP5-1115A15.1	-3.48	0.000527	0.0258	-0.12	-0.11	Allergy;	chr1:8387344	chr1:8424645~8434838:+
BRCA	cis	rs1912124	1	rs68020982	ENSG00000259343.4	TMC3-AS1	3.48	0.000527	0.0258	0.25	0.11	Peripheral arterial disease (traffic-related air pollution interaction);	chr15:81222170	chr15:81324377~81362037:+
BRCA	cis	rs2380205	0.517	rs12774228	ENSG00000238266.1	LINC00707	3.48	0.000527	0.0258	0.11	0.11	Breast cancer;	chr10:5935312	chr10:6779598~6842906:+
BRCA	cis	rs62025270	0.632	rs56153788	ENSG00000259367.1	RP11-815J21.4	3.48	0.000528	0.0258	0.1	0.11	Idiopathic pulmonary fibrosis;	chr15:85627761	chr15:85619623~85670948:-
BRCA	cis	rs4243971	0.516	rs6141285	ENSG00000277692.1	RP11-358N2.2	-3.48	0.000528	0.0258	-0.12	-0.11	Inflammatory bowel disease;Crohn's disease;	chr20:32304631	chr20:32355053~32355734:+
BRCA	cis	rs3750965	0.839	rs921670	ENSG00000265539.1	MIR3164	-3.48	0.000528	0.0258	-0.13	-0.11	Hair color;	chr11:69104171	chr11:69083176~69083258:+
BRCA	cis	rs6429082	0.838	rs4659520	ENSG00000230026.2	RP11-382D8.5	3.48	0.000528	0.0258	0.12	0.11	Adiposity;	chr1:235412006	chr1:235361153~235362540:+
BRCA	cis	rs721917	0.525	rs7903576	ENSG00000225484.5	NUTM2B-AS1	-3.48	0.000528	0.0258	-0.14	-0.11	Chronic obstructive pulmonary disease;	chr10:79981386	chr10:79663088~79826594:-
BRCA	cis	rs12438356	0.686	rs28787715	ENSG00000259222.2	RP11-809H16.5	-3.48	0.000528	0.0258	-0.16	-0.11	CTACK levels;	chr15:69221382	chr15:69080879~69099987:+
BRCA	cis	rs11893307	0.509	rs62182902	ENSG00000235852.1	AC005540.3	3.48	0.000528	0.0258	0.14	0.11	Mean platelet volume;	chr2:190638041	chr2:190880797~190882059:-
BRCA	cis	rs58521262	0.66	rs62120789	ENSG00000268105.1	RP11-369G6.2	-3.48	0.000528	0.0258	-0.18	-0.11	Testicular germ cell tumor;	chr19:22868506	chr19:23125665~23128543:+
BRCA	cis	rs4363385	0.51	rs11205187	ENSG00000231416.1	RP11-422P24.9	3.48	0.000528	0.0258	0.12	0.11	Inflammatory skin disease;	chr1:153080847	chr1:153995632~153995960:+
BRCA	cis	rs875971	0.862	rs2024192	ENSG00000271064.1	RP11-792A8.3	3.48	0.000528	0.0258	0.13	0.11	Aortic root size;	chr7:66576460	chr7:66748838~66749077:-
BRCA	cis	rs8180040	0.62	rs11917361	ENSG00000280667.1	Y_RNA	-3.48	0.000528	0.0258	-0.12	-0.11	Colorectal cancer;	chr3:47029007	chr3:47501083~47501182:+
BRCA	cis	rs10843647	1	rs909014	ENSG00000245614.3	DDX11-AS1	-3.48	0.000528	0.0258	-0.12	-0.11	Glucose homeostasis traits;	chr12:30182128	chr12:31020763~31073847:-
BRCA	cis	rs62344088	1	rs9986162	ENSG00000277812.1	AC021087.1	3.48	0.000528	0.0258	0.3	0.11	Asthma (childhood onset);	chr5:107396	chr5:262769~262881:+
BRCA	cis	rs7914558	0.966	rs11191438	ENSG00000272912.1	RP11-724N1.1	-3.48	0.000528	0.0258	-0.12	-0.11	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102878107	chr10:102914585~102915404:+
BRCA	cis	rs10838634	1	rs7118097	ENSG00000280615.1	Y_RNA	-3.48	0.000528	0.0258	-0.18	-0.11	Schizophrenia;	chr11:46799349	chr11:47614898~47614994:-
BRCA	cis	rs10838634	1	rs7129622	ENSG00000280615.1	Y_RNA	-3.48	0.000528	0.0258	-0.18	-0.11	Schizophrenia;	chr11:46807345	chr11:47614898~47614994:-
BRCA	cis	rs7429990	0.965	rs34750113	ENSG00000199476.1	Y_RNA	-3.48	0.000528	0.0258	-0.15	-0.11	Educational attainment (years of education);	chr3:47944902	chr3:48288587~48288694:+
BRCA	cis	rs875971	0.862	rs801195	ENSG00000265600.1	AC006480.1	3.48	0.000528	0.0258	0.13	0.11	Aortic root size;	chr7:66561128	chr7:67356680~67356779:+
BRCA	cis	rs2625529	0.878	rs2929511	ENSG00000261187.1	RP11-1007O24.2	3.48	0.000528	0.0258	0.12	0.11	Red blood cell count;	chr15:71939341	chr15:72465128~72466262:-
BRCA	cis	rs12807809	0.945	rs1939214	ENSG00000254941.1	RP11-677M14.5	3.48	0.000528	0.0258	0.15	0.11	Schizophrenia;	chr11:124735394	chr11:124807822~124808269:-
BRCA	cis	rs2998286	0.813	rs2790431	ENSG00000237128.1	RP11-351M16.3	3.48	0.000528	0.0258	0.15	0.11	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28500266	chr10:28433008~28495813:-
BRCA	cis	rs7577696	0.962	rs212746	ENSG00000276334.1	AL133243.1	3.48	0.000528	0.0258	0.13	0.11	Inflammatory biomarkers;	chr2:32187998	chr2:32521927~32523547:+
BRCA	cis	rs909674	0.541	rs5750816	ENSG00000280216.1	RP3-333H23.9	3.48	0.000528	0.0258	0.13	0.11	IgG fucosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG digalactosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG glycosylation;	chr22:39414374	chr22:39379610~39380015:+
BRCA	cis	rs6142618	0.562	rs1321415	ENSG00000277692.1	RP11-358N2.2	-3.48	0.000528	0.0258	-0.12	-0.11	Inflammatory bowel disease;	chr20:32156415	chr20:32355053~32355734:+
BRCA	cis	rs2018683	0.523	rs4513881	ENSG00000233517.1	AC005162.5	3.48	0.000529	0.0258	0.14	0.11	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28985794	chr7:28987028~28988899:+
BRCA	cis	rs494453	0.6	rs474860	ENSG00000227811.2	FAM212B-AS1	-3.48	0.000529	0.0258	-0.13	-0.11	Osteoporosis-related phenotypes;	chr1:111672590	chr1:111739841~111747798:+
BRCA	cis	rs10761482	0.813	rs4291629	ENSG00000254271.1	RP11-131N11.4	3.48	0.000529	0.0258	0.15	0.11	Schizophrenia;	chr10:60345000	chr10:60734342~60741828:+
BRCA	cis	rs4718428	0.705	rs62465692	ENSG00000275400.1	RP4-756H11.5	-3.48	0.000529	0.0258	-0.14	-0.11	Corneal structure;	chr7:66830758	chr7:66553805~66554199:-
BRCA	cis	rs3617	0.572	rs2256332	ENSG00000279144.1	RP11-894J14.2	-3.48	0.000529	0.0258	-0.13	-0.11	Red blood cell count;Autism spectrum disorder or schizophrenia;	chr3:52821849	chr3:52848085~52848553:-
BRCA	cis	rs2333021	0.649	rs12893375	ENSG00000259015.1	RP11-109N23.6	3.48	0.000529	0.0258	0.12	0.11	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:72990559	chr14:72960595~72961993:+
BRCA	cis	rs877819	0.667	rs7916558	ENSG00000228403.1	RP11-563N6.6	-3.48	0.000529	0.0258	-0.12	-0.11	Systemic lupus erythematosus;	chr10:48863564	chr10:48878022~48878649:+
BRCA	cis	rs7267979	0.934	rs4815423	ENSG00000274414.1	RP5-965G21.4	3.48	0.000529	0.0258	0.12	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25406885	chr20:25239007~25245229:-
BRCA	cis	rs11673344	0.698	rs56161518	ENSG00000267260.1	CTD-2162K18.4	-3.48	0.000529	0.0258	-0.17	-0.11	Obesity-related traits;	chr19:36978555	chr19:36773153~36777078:+
BRCA	cis	rs2262909	0.962	rs1526884	ENSG00000279377.1	AC003973.3	-3.48	0.000529	0.0258	-0.15	-0.11	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;	chr19:22120849	chr19:21965708~21968529:-
BRCA	cis	rs10090774	0.965	rs2665883	ENSG00000280303.2	ERICD	3.48	0.000529	0.0258	0.13	0.11	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140995814	chr8:140636281~140638283:+
BRCA	cis	rs6088580	0.634	rs6088508	ENSG00000269202.1	RP4-614O4.12	-3.48	0.000529	0.0258	-0.11	-0.11	Glomerular filtration rate (creatinine);	chr20:34472276	chr20:35201747~35203288:-
BRCA	cis	rs8180040	0.603	rs9854790	ENSG00000260236.1	RP11-708J19.1	3.48	0.000529	0.0258	0.1	0.11	Colorectal cancer;	chr3:47059816	chr3:47379089~47380999:-
BRCA	cis	rs886427	0.838	rs4149782	ENSG00000262482.1	LA16c-321D4.2	-3.48	0.000529	0.0258	-0.13	-0.11	Metabolic syndrome;	chr16:2977295	chr16:2939714~2954276:-
BRCA	cis	rs7572644	0.568	rs11127133	ENSG00000223522.1	AC093690.1	-3.48	0.000529	0.0258	-0.12	-0.11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:28135612	chr2:28307691~28310459:-
BRCA	cis	rs1538970	0.781	rs12049503	ENSG00000280836.1	AL355480.1	-3.48	0.000529	0.0258	-0.15	-0.11	Platelet count;	chr1:45555884	chr1:45581219~45581321:-
BRCA	cis	rs17711722	0.701	rs781145	ENSG00000227113.2	RP11-460N20.4	3.48	0.000529	0.0259	0.11	0.11	Calcium levels;	chr7:65975383	chr7:65075023~65078780:+
BRCA	cis	rs9868809	0.772	rs2302295	ENSG00000225399.4	RP11-3B7.1	-3.48	0.000529	0.0259	-0.15	-0.11	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48652677	chr3:49260085~49261316:+
BRCA	cis	rs1865760	1	rs7757666	ENSG00000272810.1	U91328.22	-3.48	0.000529	0.0259	-0.13	-0.11	Height;	chr6:25902398	chr6:26013241~26013757:+
BRCA	cis	rs1865760	1	rs6910138	ENSG00000272810.1	U91328.22	-3.48	0.000529	0.0259	-0.13	-0.11	Height;	chr6:25904124	chr6:26013241~26013757:+
BRCA	cis	rs6964587	0.81	rs408	ENSG00000188693.7	CYP51A1-AS1	3.48	0.000529	0.0259	0.12	0.11	Breast cancer;	chr7:91926970	chr7:92134604~92180725:+
BRCA	cis	rs871012	0.542	rs951958	ENSG00000251405.2	CTB-109A12.1	-3.48	0.000529	0.0259	-0.15	-0.11	IgG glycosylation;	chr5:157462089	chr5:157362615~157460078:-
BRCA	cis	rs860295	0.665	rs12028416	ENSG00000236675.1	MTX1P1	-3.48	0.00053	0.0259	-0.13	-0.11	Body mass index;	chr1:155431370	chr1:155230975~155234325:+
BRCA	cis	rs860295	0.629	rs12026638	ENSG00000236675.1	MTX1P1	-3.48	0.00053	0.0259	-0.13	-0.11	Body mass index;	chr1:155431469	chr1:155230975~155234325:+
BRCA	cis	rs948562	0.744	rs11229481	ENSG00000255299.4	RP11-655C2.3	-3.48	0.00053	0.0259	-0.13	-0.11	Lymphoma;	chr11:58464426	chr11:58497888~58505758:-
BRCA	cis	rs948562	0.744	rs11229484	ENSG00000255299.4	RP11-655C2.3	-3.48	0.00053	0.0259	-0.13	-0.11	Lymphoma;	chr11:58464724	chr11:58497888~58505758:-
BRCA	cis	rs1730008	0.731	rs73172105	ENSG00000279311.1	RP11-170K4.2	3.48	0.00053	0.0259	0.14	0.11	Lobe attachment (rater-scored or self-reported);	chr3:158426434	chr3:158869898~158871821:+
BRCA	cis	rs1730008	0.731	rs12496934	ENSG00000279311.1	RP11-170K4.2	3.48	0.00053	0.0259	0.14	0.11	Lobe attachment (rater-scored or self-reported);	chr3:158431772	chr3:158869898~158871821:+
BRCA	cis	rs2811415	0.597	rs13093679	ENSG00000242551.2	POU5F1P6	3.48	0.00053	0.0259	0.15	0.11	Lung function (FEV1/FVC);	chr3:128007162	chr3:128674735~128677005:-
BRCA	cis	rs1635	0.826	rs4711167	ENSG00000216901.1	AL022393.7	-3.48	0.00053	0.0259	-0.25	-0.11	Schizophrenia;	chr6:28327111	chr6:28176188~28176674:+
BRCA	cis	rs3755132	0.568	rs16862882	ENSG00000214657.4	RP11-120J4.1	3.48	0.00053	0.0259	0.18	0.11	Wilms tumor;	chr2:15668508	chr2:15869939~15870243:+
BRCA	cis	rs4835473	0.932	rs6853676	ENSG00000246448.2	RP13-578N3.3	-3.48	0.00053	0.0259	-0.12	-0.11	Immature fraction of reticulocytes;	chr4:143750495	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.932	rs6848393	ENSG00000246448.2	RP13-578N3.3	-3.48	0.00053	0.0259	-0.12	-0.11	Immature fraction of reticulocytes;	chr4:143750537	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.932	rs971390	ENSG00000246448.2	RP13-578N3.3	-3.48	0.00053	0.0259	-0.12	-0.11	Immature fraction of reticulocytes;	chr4:143751264	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.932	rs971392	ENSG00000246448.2	RP13-578N3.3	-3.48	0.00053	0.0259	-0.12	-0.11	Immature fraction of reticulocytes;	chr4:143751384	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.838	rs35978782	ENSG00000246448.2	RP13-578N3.3	-3.48	0.00053	0.0259	-0.12	-0.11	Immature fraction of reticulocytes;	chr4:143751713	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.932	rs34060266	ENSG00000246448.2	RP13-578N3.3	-3.48	0.00053	0.0259	-0.12	-0.11	Immature fraction of reticulocytes;	chr4:143751766	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.932	rs35300159	ENSG00000246448.2	RP13-578N3.3	-3.48	0.00053	0.0259	-0.12	-0.11	Immature fraction of reticulocytes;	chr4:143751768	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.932	rs13139419	ENSG00000246448.2	RP13-578N3.3	-3.48	0.00053	0.0259	-0.12	-0.11	Immature fraction of reticulocytes;	chr4:143751862	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.868	rs13106052	ENSG00000246448.2	RP13-578N3.3	-3.48	0.00053	0.0259	-0.12	-0.11	Immature fraction of reticulocytes;	chr4:143751995	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.932	rs13134401	ENSG00000246448.2	RP13-578N3.3	-3.48	0.00053	0.0259	-0.12	-0.11	Immature fraction of reticulocytes;	chr4:143752008	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.932	rs13106287	ENSG00000246448.2	RP13-578N3.3	-3.48	0.00053	0.0259	-0.12	-0.11	Immature fraction of reticulocytes;	chr4:143752091	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.932	rs13134679	ENSG00000246448.2	RP13-578N3.3	-3.48	0.00053	0.0259	-0.12	-0.11	Immature fraction of reticulocytes;	chr4:143752187	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.932	rs13108134	ENSG00000246448.2	RP13-578N3.3	-3.48	0.00053	0.0259	-0.12	-0.11	Immature fraction of reticulocytes;	chr4:143752213	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.9	rs34406317	ENSG00000246448.2	RP13-578N3.3	-3.48	0.00053	0.0259	-0.12	-0.11	Immature fraction of reticulocytes;	chr4:143752237	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.932	rs35863996	ENSG00000246448.2	RP13-578N3.3	-3.48	0.00053	0.0259	-0.12	-0.11	Immature fraction of reticulocytes;	chr4:143752260	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.932	rs6836896	ENSG00000246448.2	RP13-578N3.3	-3.48	0.00053	0.0259	-0.12	-0.11	Immature fraction of reticulocytes;	chr4:143752404	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.932	rs2874983	ENSG00000246448.2	RP13-578N3.3	-3.48	0.00053	0.0259	-0.12	-0.11	Immature fraction of reticulocytes;	chr4:143752589	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.932	rs2874984	ENSG00000246448.2	RP13-578N3.3	-3.48	0.00053	0.0259	-0.12	-0.11	Immature fraction of reticulocytes;	chr4:143752622	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.9	rs2323192	ENSG00000246448.2	RP13-578N3.3	-3.48	0.00053	0.0259	-0.12	-0.11	Immature fraction of reticulocytes;	chr4:143752646	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.932	rs2323193	ENSG00000246448.2	RP13-578N3.3	-3.48	0.00053	0.0259	-0.12	-0.11	Immature fraction of reticulocytes;	chr4:143752812	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.932	rs34152627	ENSG00000246448.2	RP13-578N3.3	-3.48	0.00053	0.0259	-0.12	-0.11	Immature fraction of reticulocytes;	chr4:143753205	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.932	rs35670108	ENSG00000246448.2	RP13-578N3.3	-3.48	0.00053	0.0259	-0.12	-0.11	Immature fraction of reticulocytes;	chr4:143753280	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.9	rs6832005	ENSG00000246448.2	RP13-578N3.3	-3.48	0.00053	0.0259	-0.12	-0.11	Immature fraction of reticulocytes;	chr4:143754284	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.838	rs55963933	ENSG00000246448.2	RP13-578N3.3	-3.48	0.00053	0.0259	-0.12	-0.11	Immature fraction of reticulocytes;	chr4:143755048	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.9	rs34790336	ENSG00000246448.2	RP13-578N3.3	-3.48	0.00053	0.0259	-0.12	-0.11	Immature fraction of reticulocytes;	chr4:143755284	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.932	rs35740243	ENSG00000246448.2	RP13-578N3.3	-3.48	0.00053	0.0259	-0.12	-0.11	Immature fraction of reticulocytes;	chr4:143755395	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.932	rs4395452	ENSG00000246448.2	RP13-578N3.3	-3.48	0.00053	0.0259	-0.12	-0.11	Immature fraction of reticulocytes;	chr4:143755678	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.741	rs6537180	ENSG00000246448.2	RP13-578N3.3	-3.48	0.00053	0.0259	-0.12	-0.11	Immature fraction of reticulocytes;	chr4:143755984	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.741	rs6537181	ENSG00000246448.2	RP13-578N3.3	-3.48	0.00053	0.0259	-0.12	-0.11	Immature fraction of reticulocytes;	chr4:143755995	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.9	rs6814065	ENSG00000246448.2	RP13-578N3.3	-3.48	0.00053	0.0259	-0.12	-0.11	Immature fraction of reticulocytes;	chr4:143756233	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.9	rs6816347	ENSG00000246448.2	RP13-578N3.3	-3.48	0.00053	0.0259	-0.12	-0.11	Immature fraction of reticulocytes;	chr4:143756674	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.808	rs6847256	ENSG00000246448.2	RP13-578N3.3	-3.48	0.00053	0.0259	-0.12	-0.11	Immature fraction of reticulocytes;	chr4:143757032	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.868	rs57413073	ENSG00000246448.2	RP13-578N3.3	-3.48	0.00053	0.0259	-0.12	-0.11	Immature fraction of reticulocytes;	chr4:143757852	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.932	rs34732468	ENSG00000246448.2	RP13-578N3.3	-3.48	0.00053	0.0259	-0.12	-0.11	Immature fraction of reticulocytes;	chr4:143758009	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.932	rs12510395	ENSG00000246448.2	RP13-578N3.3	-3.48	0.00053	0.0259	-0.12	-0.11	Immature fraction of reticulocytes;	chr4:143758107	chr4:143700257~143865072:+
BRCA	cis	rs16958440	0.708	rs62096462	ENSG00000267800.1	RP11-49K24.5	-3.48	0.00053	0.0259	-0.19	-0.11	Sitting height ratio;	chr18:47098808	chr18:47137018~47137290:+
BRCA	cis	rs2486012	0.737	rs6691988	ENSG00000237950.1	RP11-7O11.3	-3.48	0.00053	0.0259	-0.16	-0.11	Intelligence (multi-trait analysis);	chr1:43788731	chr1:43944370~43946551:-
BRCA	cis	rs1411478	0.967	rs57113693	ENSG00000243155.1	RP11-46A10.5	3.48	0.00053	0.0259	0.11	0.11	Menopause (age at onset);Progressive supranuclear palsy;	chr1:180983158	chr1:180944042~180976482:-
BRCA	cis	rs1979679	0.959	rs75757272	ENSG00000244712.1	RP11-874G11.1	-3.48	0.00053	0.0259	-0.16	-0.11	Ossification of the posterior longitudinal ligament of the spine;	chr12:28251809	chr12:28564678~28565141:-
BRCA	cis	rs259067	0.904	rs746486	ENSG00000271043.2	MTRNR2L2	3.48	0.00053	0.0259	0.15	0.11	Obesity;	chr5:79802363	chr5:80650000~80650086:-
BRCA	cis	rs2562456	0.833	rs62110429	ENSG00000268117.1	VN1R84P	3.48	0.00053	0.0259	0.17	0.11	Pain;	chr19:21430984	chr19:21719801~21720035:-
BRCA	cis	rs7944584	0.879	rs11039182	ENSG00000200376.1	RNU5E-10P	3.48	0.00053	0.0259	0.15	0.11	Fasting blood glucose;Fasting blood glucose (BMI interaction);	chr11:47325172	chr11:47576471~47576588:-
BRCA	cis	rs10782582	0.593	rs17647178	ENSG00000181227.3	RP4-682C21.2	3.48	0.00053	0.0259	0.11	0.11	Daytime sleep phenotypes;	chr1:75744839	chr1:75743423~75744776:-
BRCA	cis	rs61931739	0.5	rs7977186	ENSG00000258794.3	DUX4L27	3.48	0.00053	0.0259	0.15	0.11	Morning vs. evening chronotype;	chr12:34278551	chr12:34208415~34209675:-
BRCA	cis	rs35306767	0.903	rs11812523	ENSG00000229869.1	RP11-363N22.2	-3.48	0.00053	0.0259	-0.16	-0.11	Eosinophil percentage of granulocytes;	chr10:869698	chr10:933026~942743:+
BRCA	cis	rs35306767	0.903	rs35567307	ENSG00000229869.1	RP11-363N22.2	-3.48	0.00053	0.0259	-0.16	-0.11	Eosinophil percentage of granulocytes;	chr10:869864	chr10:933026~942743:+
BRCA	cis	rs721917	0.506	rs2758556	ENSG00000225484.5	NUTM2B-AS1	3.48	0.00053	0.0259	0.14	0.11	Chronic obstructive pulmonary disease;	chr10:79931229	chr10:79663088~79826594:-
BRCA	cis	rs7647973	0.626	rs9824435	ENSG00000281433.1	Metazoa_SRP	-3.48	0.00053	0.0259	-0.14	-0.11	Menarche (age at onset);	chr3:49636910	chr3:49320296~49320564:+
BRCA	cis	rs964611	0.882	rs12909148	ENSG00000259488.2	RP11-154J22.1	3.48	0.00053	0.0259	0.13	0.11	Metabolite levels (Pyroglutamine);	chr15:48356800	chr15:48312353~48331856:-
BRCA	cis	rs2638953	0.64	rs1511548	ENSG00000273989.1	RP11-425D17.2	-3.48	0.00053	0.0259	-0.15	-0.11	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28579057	chr12:28236227~28236828:+
BRCA	cis	rs6964587	0.743	rs33993294	ENSG00000188693.7	CYP51A1-AS1	-3.48	0.00053	0.0259	-0.12	-0.11	Breast cancer;	chr7:92369341	chr7:92134604~92180725:+
BRCA	cis	rs3770752	0.836	rs3755195	ENSG00000272054.1	RP11-423P10.2	-3.48	0.00053	0.0259	-0.1	-0.11	Schizophrenia;	chr2:37232527	chr2:37208875~37212677:+
BRCA	cis	rs1355223	0.902	rs1258464	ENSG00000271369.1	RP11-350D17.3	-3.48	0.00053	0.0259	-0.12	-0.11	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34709949	chr11:34709600~34710161:+
BRCA	cis	rs80226907	1	rs76480089	ENSG00000258413.1	RP11-665C16.6	-3.48	0.00053	0.0259	-0.28	-0.11	Mean platelet volume;	chr14:55365894	chr14:55262767~55272075:-
BRCA	cis	rs2109514	1	rs7795510	ENSG00000237813.3	AC002066.1	3.48	0.00053	0.0259	0.13	0.11	Prevalent atrial fibrillation;	chr7:116516907	chr7:116238260~116499465:-
BRCA	cis	rs4974559	0.739	rs28573879	ENSG00000253399.1	AC078852.2	3.48	0.000531	0.0259	0.16	0.11	Systolic blood pressure;	chr4:1292122	chr4:1358479~1359461:+
BRCA	cis	rs8180040	0.654	rs9837343	ENSG00000280667.1	Y_RNA	3.48	0.000531	0.0259	0.12	0.11	Colorectal cancer;	chr3:47135898	chr3:47501083~47501182:+
BRCA	cis	rs17361889	0.752	rs62440451	ENSG00000229108.1	MEOX2-AS1	3.48	0.000531	0.0259	0.12	0.11	Pediatric bone mineral content (hip);	chr7:16259676	chr7:15688378~15695491:+
BRCA	cis	rs17027633	0.867	rs2050607	ENSG00000234020.1	CHIAP3	-3.48	0.000531	0.0259	-0.21	-0.11	Cerebrospinal fluid t-tau:AB1-42 ratio;	chr1:111418185	chr1:111353275~111367409:-
BRCA	cis	rs7267979	1	rs6515651	ENSG00000204556.4	CTD-2514C3.1	3.48	0.000531	0.0259	0.14	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25433903	chr20:26018832~26020684:+
BRCA	cis	rs6494488	0.5	rs72742925	ENSG00000248415.1	GAPDHP61	-3.48	0.000531	0.0259	-0.24	-0.11	Coronary artery disease;	chr15:64571104	chr15:64528667~64529671:-
BRCA	cis	rs6494488	0.5	rs72742927	ENSG00000248415.1	GAPDHP61	-3.48	0.000531	0.0259	-0.24	-0.11	Coronary artery disease;	chr15:64574106	chr15:64528667~64529671:-
BRCA	cis	rs6494488	0.5	rs72742928	ENSG00000248415.1	GAPDHP61	-3.48	0.000531	0.0259	-0.24	-0.11	Coronary artery disease;	chr15:64576281	chr15:64528667~64529671:-
BRCA	cis	rs6494488	0.5	rs72742931	ENSG00000248415.1	GAPDHP61	-3.48	0.000531	0.0259	-0.24	-0.11	Coronary artery disease;	chr15:64579797	chr15:64528667~64529671:-
BRCA	cis	rs6494488	0.5	rs72742934	ENSG00000248415.1	GAPDHP61	-3.48	0.000531	0.0259	-0.24	-0.11	Coronary artery disease;	chr15:64583524	chr15:64528667~64529671:-
BRCA	cis	rs987724	0.593	rs9867621	ENSG00000240875.4	LINC00886	-3.48	0.000531	0.0259	-0.12	-0.11	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156896774	chr3:156747346~156817062:-
BRCA	cis	rs4805834	0.843	rs73036807	ENSG00000201388.1	SNORA68	3.48	0.000531	0.0259	0.18	0.11	Creatinine levels;	chr19:32843119	chr19:32608337~32608469:-
BRCA	cis	rs6456156	0.792	rs7775443	ENSG00000272549.1	RP11-351J23.2	3.48	0.000531	0.0259	0.11	0.11	Primary biliary cholangitis;	chr6:167099764	chr6:167666840~167679270:-
BRCA	cis	rs9863	0.931	rs11057401	ENSG00000270028.1	RP11-380L11.4	3.48	0.000531	0.0259	0.14	0.11	White blood cell count;	chr12:123942759	chr12:123925461~123926083:-
BRCA	cis	rs13434995	0.589	rs499110	ENSG00000273257.1	RP11-177J6.1	-3.48	0.000531	0.0259	-0.16	-0.11	Adiponectin levels;	chr4:55381628	chr4:55387949~55388271:+
BRCA	cis	rs6540556	0.723	rs1415542	ENSG00000236136.1	ADORA2BP1	-3.48	0.000531	0.0259	-0.14	-0.11	Red blood cell count;	chr1:209728765	chr1:209744373~209745214:+
BRCA	cis	rs1411478	0.967	rs59145927	ENSG00000243155.1	RP11-46A10.5	3.48	0.000531	0.0259	0.11	0.11	Menopause (age at onset);Progressive supranuclear palsy;	chr1:180983159	chr1:180944042~180976482:-
BRCA	cis	rs2991971	0.967	rs6661321	ENSG00000281133.1	AL355480.3	3.48	0.000531	0.0259	0.12	0.11	High light scatter reticulocyte count;	chr1:45488927	chr1:45580892~45580996:-
BRCA	cis	rs12761761	0.696	rs61865660	ENSG00000279982.1	RP11-45A17.3	-3.48	0.000531	0.0259	-0.15	-0.11	Intelligence (multi-trait analysis);Educational attainment (years of education);	chr10:131996967	chr10:131996738~131999846:+
BRCA	cis	rs6088590	1	rs6088595	ENSG00000275784.1	RP5-1125A11.6	-3.48	0.000531	0.0259	-0.13	-0.11	Coronary artery disease;	chr20:34770696	chr20:33989480~33991818:-
BRCA	cis	rs7267979	1	rs2297496	ENSG00000274414.1	RP5-965G21.4	3.48	0.000531	0.0259	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25315151	chr20:25239007~25245229:-
BRCA	cis	rs6696239	1	rs6698409	ENSG00000215812.5	ZNF847P	3.48	0.000531	0.0259	0.15	0.11	Height;	chr1:227580657	chr1:227696892~227706699:-
BRCA	cis	rs6840360	0.571	rs4696278	ENSG00000270265.1	RP11-731D1.4	-3.48	0.000532	0.0259	-0.13	-0.11	Intelligence (multi-trait analysis);	chr4:151637826	chr4:151333775~151353224:-
BRCA	cis	rs6840360	0.571	rs4696279	ENSG00000270265.1	RP11-731D1.4	-3.48	0.000532	0.0259	-0.13	-0.11	Intelligence (multi-trait analysis);	chr4:151639297	chr4:151333775~151353224:-
BRCA	cis	rs6439699	0.76	rs1478322	ENSG00000273486.1	RP11-731C17.2	3.48	0.000532	0.0259	0.14	0.11	Intelligence (multi-trait analysis);	chr3:137242426	chr3:136837338~136839021:-
BRCA	cis	rs6108958	0.838	rs2876228	ENSG00000235036.4	RP5-1099D15.1	-3.48	0.000532	0.0259	-0.12	-0.11	Gut microbiome composition (summer);	chr20:11436244	chr20:10612861~10614229:-
BRCA	cis	rs9664222	1	rs9664222	ENSG00000213613.2	RP11-380G5.3	3.48	0.000532	0.0259	0.16	0.11	Longevity;	chr10:87578876	chr10:87945502~87946024:+
BRCA	cis	rs13434995	0.513	rs62309729	ENSG00000273257.1	RP11-177J6.1	-3.48	0.000532	0.0259	-0.16	-0.11	Adiponectin levels;	chr4:55536679	chr4:55387949~55388271:+
BRCA	cis	rs27434	0.583	rs34762	ENSG00000248734.2	CTD-2260A17.1	3.48	0.000532	0.0259	0.12	0.11	Ankylosing spondylitis;	chr5:96818263	chr5:96784777~96785999:+
BRCA	cis	rs7781557	1	rs11496066	ENSG00000239969.4	RP11-163E9.2	-3.48	0.000532	0.0259	-0.17	-0.11	Colorectal adenoma (advanced);	chr7:102845807	chr7:102364162~102380633:+
BRCA	cis	rs863345	0.604	rs6674656	ENSG00000176320.2	RP11-404O13.5	-3.48	0.000532	0.0259	-0.11	-0.11	Pneumococcal bacteremia;	chr1:158525641	chr1:158197922~158203877:-
BRCA	cis	rs863345	0.584	rs10797023	ENSG00000176320.2	RP11-404O13.5	-3.48	0.000532	0.0259	-0.11	-0.11	Pneumococcal bacteremia;	chr1:158527289	chr1:158197922~158203877:-
BRCA	cis	rs863345	0.584	rs10797024	ENSG00000176320.2	RP11-404O13.5	-3.48	0.000532	0.0259	-0.11	-0.11	Pneumococcal bacteremia;	chr1:158527373	chr1:158197922~158203877:-
BRCA	cis	rs863345	0.584	rs6657638	ENSG00000176320.2	RP11-404O13.5	-3.48	0.000532	0.0259	-0.11	-0.11	Pneumococcal bacteremia;	chr1:158527394	chr1:158197922~158203877:-
BRCA	cis	rs863345	0.604	rs6670343	ENSG00000176320.2	RP11-404O13.5	-3.48	0.000532	0.0259	-0.11	-0.11	Pneumococcal bacteremia;	chr1:158527468	chr1:158197922~158203877:-
BRCA	cis	rs34421088	0.506	rs7813424	ENSG00000154316.13	TDH	-3.48	0.000532	0.0259	-0.15	-0.11	Neuroticism;	chr8:11287008	chr8:11339637~11368452:+
BRCA	cis	rs13421350	0.579	rs59476799	ENSG00000225205.4	AC093818.1	-3.48	0.000532	0.0259	-0.19	-0.11	Diabetic kidney disease;	chr2:172511591	chr2:172480840~172556596:-
BRCA	cis	rs2941484	0.509	rs2383937	ENSG00000254023.1	PKMP4	3.48	0.000532	0.0259	0.12	0.11	Urate levels;	chr8:75592712	chr8:75376709~75377014:+
BRCA	cis	rs11048434	0.518	rs1805707	ENSG00000111788.10	RP11-22B23.1	3.48	0.000532	0.0259	0.1	0.11	Sjögren's syndrome;	chr12:9029110	chr12:9277235~9313241:+
BRCA	cis	rs801193	0.569	rs4717315	ENSG00000265600.1	AC006480.1	-3.48	0.000532	0.0259	-0.13	-0.11	Aortic root size;	chr7:66713338	chr7:67356680~67356779:+
BRCA	cis	rs11098499	0.863	rs6858592	ENSG00000250412.1	KLHL2P1	3.48	0.000532	0.0259	0.13	0.11	Corneal astigmatism;	chr4:119537537	chr4:119334329~119378233:+
BRCA	cis	rs4388249	1	rs12654396	ENSG00000271849.1	CTC-332L22.1	-3.48	0.000532	0.0259	-0.17	-0.11	Schizophrenia;	chr5:109700097	chr5:109687802~109688329:-
BRCA	cis	rs6792584	0.543	rs4327406	ENSG00000241316.5	SUCLG2-AS1	3.48	0.000532	0.0259	0.11	0.11	Corneal astigmatism;	chr3:67458430	chr3:67654697~67947713:+
BRCA	cis	rs8040855	0.579	rs4843029	ENSG00000259416.2	RP11-158M2.5	-3.48	0.000532	0.0259	-0.12	-0.11	Bulimia nervosa;	chr15:85182164	chr15:85754941~85756237:-
BRCA	cis	rs13230714	0.858	rs714429	ENSG00000170356.8	OR2A20P	3.48	0.000532	0.0259	0.15	0.11	Breast cancer;	chr7:144456641	chr7:144250045~144252957:-
BRCA	cis	rs6496932	0.676	rs7183651	ENSG00000218052.5	ADAMTS7P4	-3.48	0.000532	0.026	-0.11	-0.11	Central corneal thickness;Corneal structure;	chr15:85352490	chr15:85255369~85330334:-
BRCA	cis	rs6044112	1	rs6080301	ENSG00000273998.1	RP4-777L9.2	3.48	0.000532	0.026	0.17	0.11	Response to taxane treatment (docetaxel);	chr20:16555021	chr20:16576068~16579615:+
BRCA	cis	rs4835473	0.9	rs35419968	ENSG00000246448.2	RP13-578N3.3	-3.47	0.000532	0.026	-0.12	-0.11	Immature fraction of reticulocytes;	chr4:143734583	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.868	rs66634585	ENSG00000246448.2	RP13-578N3.3	-3.47	0.000532	0.026	-0.12	-0.11	Immature fraction of reticulocytes;	chr4:143734608	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.868	rs35016507	ENSG00000246448.2	RP13-578N3.3	-3.47	0.000532	0.026	-0.12	-0.11	Immature fraction of reticulocytes;	chr4:143734617	chr4:143700257~143865072:+
BRCA	cis	rs7267979	1	rs2424716	ENSG00000204556.4	CTD-2514C3.1	-3.47	0.000532	0.026	-0.14	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25442902	chr20:26018832~26020684:+
BRCA	cis	rs7267979	1	rs761025	ENSG00000204556.4	CTD-2514C3.1	-3.47	0.000532	0.026	-0.14	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25446332	chr20:26018832~26020684:+
BRCA	cis	rs7620503	0.506	rs2242401	ENSG00000277241.1	RP11-114M1.3	3.47	0.000532	0.026	0.13	0.11	Corneal structure;	chr3:177620492	chr3:177700346~177701072:-
BRCA	cis	rs17095355	0.818	rs6584970	ENSG00000203876.8	ADD3-AS1	-3.47	0.000532	0.026	-0.15	-0.11	Biliary atresia;	chr10:110088062	chr10:109940104~110008381:-
BRCA	cis	rs2985684	0.948	rs12897941	ENSG00000278009.1	RP11-649E7.8	3.47	0.000532	0.026	0.15	0.11	Carotid intima media thickness;	chr14:49549983	chr14:49601011~49601124:-
BRCA	cis	rs4648045	0.765	rs230511	ENSG00000246560.2	RP11-10L12.4	-3.47	0.000532	0.026	-0.13	-0.11	Lymphocyte percentage of white cells;	chr4:102553611	chr4:102828055~102844075:+
BRCA	cis	rs524281	0.861	rs2177053	ENSG00000255038.1	RP11-1167A19.2	-3.47	0.000532	0.026	-0.15	-0.11	Electroencephalogram traits;	chr11:66198674	chr11:66067277~66069619:-
BRCA	cis	rs853679	0.546	rs200996	ENSG00000216901.1	AL022393.7	3.47	0.000532	0.026	0.21	0.11	Depression;	chr6:27844050	chr6:28176188~28176674:+
BRCA	cis	rs3105593	1	rs4775893	ENSG00000259298.1	RP11-562A8.4	3.47	0.000532	0.026	0.09	0.11	QT interval;	chr15:50606498	chr15:50497195~50498744:-
BRCA	cis	rs11209261	0.602	rs9803835	ENSG00000232284.6	GNG12-AS1	3.47	0.000532	0.026	0.12	0.11	Airflow obstruction;	chr1:68336778	chr1:67832303~68202987:+
BRCA	cis	rs11047510	0.73	rs12296947	ENSG00000164845.15	FAM86FP	3.47	0.000532	0.026	0.17	0.11	Exploratory eye movement dysfunction in schizophrenia (responsive search score);	chr12:8847892	chr12:8232512~8242948:-
BRCA	cis	rs1193	1	rs2367378	ENSG00000266931.1	RP11-1252D15.1	-3.47	0.000532	0.026	-0.13	-0.11	High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;High light scatter reticulocyte count;	chr2:86771090	chr2:87055658~87055800:-
BRCA	cis	rs1193	1	rs10201422	ENSG00000266931.1	RP11-1252D15.1	-3.47	0.000532	0.026	-0.13	-0.11	High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;High light scatter reticulocyte count;	chr2:86772048	chr2:87055658~87055800:-
BRCA	cis	rs2835872	0.965	rs857946	ENSG00000230366.8	DSCR9	-3.47	0.000532	0.026	-0.14	-0.11	Electroencephalographic traits in alcoholism;	chr21:37637001	chr21:37208503~37221736:+
BRCA	cis	rs2191566	0.691	rs8105315	ENSG00000266921.1	RP11-15A1.7	-3.47	0.000532	0.026	-0.13	-0.11	Acute lymphoblastic leukemia (childhood);	chr19:44084633	chr19:43996896~44002836:-
BRCA	cis	rs2191566	0.691	rs8104437	ENSG00000266921.1	RP11-15A1.7	-3.47	0.000532	0.026	-0.13	-0.11	Acute lymphoblastic leukemia (childhood);	chr19:44084636	chr19:43996896~44002836:-
BRCA	cis	rs6429422	0.769	rs12097743	ENSG00000224727.1	FCF1P7	-3.47	0.000533	0.026	-0.13	-0.11	Cognitive ability (multi-trait analysis);	chr1:243248084	chr1:243267257~243268119:-
BRCA	cis	rs4819052	0.851	rs4819040	ENSG00000215447.6	BX322557.10	-3.47	0.000533	0.026	-0.11	-0.11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239847	chr21:45288052~45291738:+
BRCA	cis	rs7520050	0.931	rs6686134	ENSG00000226957.1	RP4-533D7.4	3.47	0.000533	0.026	0.11	0.11	Reticulocyte count;Red blood cell count;	chr1:45912596	chr1:46046818~46048368:+
BRCA	cis	rs17345786	0.906	rs56171035	ENSG00000244119.1	PDCL3P4	3.47	0.000533	0.026	0.1	0.11	Colonoscopy-negative controls vs population controls;	chr3:101392264	chr3:101712472~101713191:+
BRCA	cis	rs9341808	0.718	rs35447745	ENSG00000279022.1	RP11-250B2.4	3.47	0.000533	0.026	0.12	0.11	Sitting height ratio;	chr6:80107031	chr6:80440730~80441172:+
BRCA	cis	rs2274273	0.868	rs9919926	ENSG00000259318.1	RP11-454L9.2	3.47	0.000533	0.026	0.09	0.11	Protein biomarker;	chr14:55347172	chr14:55394940~55395233:-
BRCA	cis	rs2018683	0.707	rs917219	ENSG00000228421.2	AC005013.5	3.47	0.000533	0.026	0.13	0.11	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28935726	chr7:28957667~28959345:+
BRCA	cis	rs4763879	0.634	rs12424826	ENSG00000256582.1	RP11-75L1.1	-3.47	0.000533	0.026	-0.11	-0.11	Type 1 diabetes;	chr12:9701981	chr12:9704077~9709350:+
BRCA	cis	rs6005807	0.64	rs2013784	ENSG00000272858.1	CTA-292E10.8	3.47	0.000533	0.026	0.18	0.11	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28527945	chr22:28814914~28815662:+
BRCA	cis	rs13118159	0.55	rs2336081	ENSG00000273179.1	RP11-20I20.4	-3.47	0.000533	0.026	-0.12	-0.11	Longevity;	chr4:1356534	chr4:1167778~1168174:+
BRCA	cis	rs6671200	0.607	rs10874908	ENSG00000226026.4	RP11-57H12.3	-3.47	0.000533	0.026	-0.16	-0.11	Stearic acid (18:0) levels;	chr1:95238595	chr1:95163219~95233982:-
BRCA	cis	rs7267979	1	rs6115146	ENSG00000204556.4	CTD-2514C3.1	3.47	0.000533	0.026	0.14	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25323871	chr20:26018832~26020684:+
BRCA	cis	rs7267979	0.934	rs6037085	ENSG00000204556.4	CTD-2514C3.1	3.47	0.000533	0.026	0.14	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25324566	chr20:26018832~26020684:+
BRCA	cis	rs6764184	1	rs10470696	ENSG00000244161.1	FLNB-AS1	3.47	0.000533	0.026	0.09	0.11	Optic cup area;Vertical cup-disc ratio;	chr3:58015261	chr3:58162547~58170636:-
BRCA	cis	rs7172677	0.737	rs8025412	ENSG00000260269.4	CTD-2323K18.1	-3.47	0.000533	0.026	-0.15	-0.11	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75151692	chr15:75527150~75601205:-
BRCA	cis	rs875971	0.862	rs6460302	ENSG00000265600.1	AC006480.1	-3.47	0.000533	0.026	-0.13	-0.11	Aortic root size;	chr7:66495270	chr7:67356680~67356779:+
BRCA	cis	rs787274	1	rs787298	ENSG00000271631.1	RP11-408O19.5	3.47	0.000533	0.026	0.18	0.11	Age-related hearing impairment (SNP x SNP interaction);	chr9:112779926	chr9:112885158~112885767:+
BRCA	cis	rs8046148	0.617	rs9927260	ENSG00000260381.2	RP11-429P3.5	3.47	0.000533	0.026	0.19	0.11	Testicular germ cell tumor;	chr16:50035317	chr16:50100339~50121943:-
BRCA	cis	rs4478858	0.66	rs10798844	ENSG00000260386.4	LINC01225	-3.47	0.000533	0.026	-0.13	-0.11	Alcohol dependence;	chr1:31346281	chr1:31500085~31540885:+
BRCA	cis	rs1334894	0.901	rs7768598	ENSG00000187762.5	HSPE1P11	-3.47	0.000533	0.026	-0.24	-0.11	Coronary artery disease;	chr6:35552874	chr6:35023522~35023831:+
BRCA	cis	rs6812193	0.518	rs17236179	ENSG00000271676.1	RP11-1E1.2	3.47	0.000533	0.026	0.15	0.11	Parkinson's disease;	chr4:76265489	chr4:77112495~77113458:-
BRCA	cis	rs7560272	0.723	rs13386124	ENSG00000230002.2	ALMS1-IT1	3.47	0.000533	0.026	0.13	0.11	Schizophrenia;	chr2:73544568	chr2:73456764~73459484:+
BRCA	cis	rs1912124	1	rs66540250	ENSG00000259343.4	TMC3-AS1	3.47	0.000533	0.026	0.25	0.11	Peripheral arterial disease (traffic-related air pollution interaction);	chr15:81221137	chr15:81324377~81362037:+
BRCA	cis	rs2380205	0.517	rs6602330	ENSG00000232807.2	RP11-536K7.3	3.47	0.000533	0.026	0.11	0.11	Breast cancer;	chr10:5902270	chr10:5934270~5945900:-
BRCA	cis	rs17684571	0.872	rs13219942	ENSG00000231441.1	RP11-472M19.2	3.47	0.000533	0.026	0.19	0.11	Schizophrenia;	chr6:56713977	chr6:56844002~56864078:+
BRCA	cis	rs17684571	0.872	rs35326806	ENSG00000231441.1	RP11-472M19.2	3.47	0.000533	0.026	0.19	0.11	Schizophrenia;	chr6:56714216	chr6:56844002~56864078:+
BRCA	cis	rs17214007	0.597	rs11649126	ENSG00000261819.1	RP11-680G24.4	3.47	0.000533	0.026	0.19	0.11	Cognitive function;	chr16:15626390	chr16:14988259~14990160:-
BRCA	cis	rs1722141	0.634	rs1723960	ENSG00000237471.1	AC073115.6	3.47	0.000533	0.026	0.14	0.11	Sitting height ratio;	chr7:46017247	chr7:45969657~45980191:+
BRCA	cis	rs1193	1	rs1193	ENSG00000266931.1	RP11-1252D15.1	-3.47	0.000533	0.026	-0.13	-0.11	High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;High light scatter reticulocyte count;	chr2:86775106	chr2:87055658~87055800:-
BRCA	cis	rs8030605	0.778	rs2249183	ENSG00000277245.1	RP11-48G14.3	-3.47	0.000533	0.026	-0.2	-0.11	Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;	chr15:56264953	chr15:56447120~56447697:+
BRCA	cis	rs3011225	0.738	rs2527777	ENSG00000237950.1	RP11-7O11.3	-3.47	0.000533	0.026	-0.16	-0.11	Amyotrophic lateral sclerosis (age of onset);	chr1:43879124	chr1:43944370~43946551:-
BRCA	cis	rs1437396	0.526	rs6545487	ENSG00000203327.2	AC012358.7	-3.47	0.000533	0.026	-0.11	-0.11	Alcohol dependence;	chr2:55313028	chr2:55214387~55216126:-
BRCA	cis	rs997295	0.535	rs11630854	ENSG00000259673.4	IQCH-AS1	3.47	0.000533	0.026	0.12	0.11	Motion sickness;	chr15:67565778	chr15:67403619~67521844:-
BRCA	cis	rs67478160	0.572	rs8016014	ENSG00000269910.1	RP11-73M18.10	3.47	0.000533	0.026	0.1	0.11	Schizophrenia;	chr14:103827461	chr14:103694516~103695050:-
BRCA	cis	rs73186030	0.925	rs1801725	ENSG00000272758.4	RP11-299J3.8	3.47	0.000533	0.026	0.17	0.11	Serum parathyroid hormone levels;	chr3:122284910	chr3:122416207~122443180:+
BRCA	cis	rs1009077	0.709	rs10004865	ENSG00000249244.1	RP11-548H18.2	-3.47	0.000534	0.026	-0.15	-0.11	Endometriosis;	chr4:119745118	chr4:119391831~119395335:-
BRCA	cis	rs853679	0.517	rs4713145	ENSG00000226314.6	ZNF192P1	-3.47	0.000534	0.026	-0.16	-0.11	Depression;	chr6:28139049	chr6:28161781~28169594:+
BRCA	cis	rs7474896	0.616	rs2474561	ENSG00000272983.1	RP11-508N22.12	3.47	0.000534	0.026	0.14	0.11	Obesity (extreme);	chr10:38084616	chr10:38137337~38144399:+
BRCA	cis	rs7824557	0.767	rs11250127	ENSG00000154316.13	TDH	-3.47	0.000534	0.026	-0.15	-0.11	Retinal vascular caliber;	chr8:11312700	chr8:11339637~11368452:+
BRCA	cis	rs7985	0.901	rs736690	ENSG00000225783.5	MIAT	-3.47	0.000534	0.026	-0.09	-0.11	Electroencephalogram traits;	chr22:26678805	chr22:26646428~26676475:+
BRCA	cis	rs3760982	0.546	rs73048681	ENSG00000267191.1	RP11-15A1.2	-3.47	0.000534	0.026	-0.15	-0.11	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43785793	chr19:43902001~43926545:+
BRCA	cis	rs6088580	0.524	rs6087616	ENSG00000261582.1	RP4-614O4.11	3.47	0.000534	0.026	0.1	0.11	Glomerular filtration rate (creatinine);	chr20:34675229	chr20:35267885~35280043:-
BRCA	cis	rs875971	0.929	rs4122249	ENSG00000271064.1	RP11-792A8.3	-3.47	0.000534	0.026	-0.12	-0.11	Aortic root size;	chr7:66455949	chr7:66748838~66749077:-
BRCA	cis	rs997295	0.535	rs11630854	ENSG00000260657.2	RP11-315D16.4	3.47	0.000534	0.026	0.13	0.11	Motion sickness;	chr15:67565778	chr15:68267792~68277994:-
BRCA	cis	rs4714291	0.963	rs1721412	ENSG00000180211.5	RP1-278E11.3	3.47	0.000534	0.026	0.12	0.11	Strep throat;	chr6:40132867	chr6:39958414~39958833:-
BRCA	cis	rs9457247	0.588	rs35171809	ENSG00000227598.1	RP1-167A14.2	-3.47	0.000534	0.026	-0.11	-0.11	Crohn's disease;	chr6:167019278	chr6:166969626~166999065:-
BRCA	cis	rs7520050	0.966	rs4076006	ENSG00000234329.1	RP11-767N6.2	-3.47	0.000534	0.026	-0.1	-0.11	Reticulocyte count;Red blood cell count;	chr1:45972404	chr1:45651039~45651826:-
BRCA	cis	rs7520050	0.966	rs11211234	ENSG00000234329.1	RP11-767N6.2	-3.47	0.000534	0.026	-0.1	-0.11	Reticulocyte count;Red blood cell count;	chr1:45973115	chr1:45651039~45651826:-
BRCA	cis	rs1670533	1	rs10003009	ENSG00000251639.2	RP11-20I20.1	3.47	0.000534	0.026	0.17	0.11	Recombination rate (females);	chr4:1057061	chr4:1100016~1101558:-
BRCA	cis	rs35520189	0.591	rs34027384	ENSG00000189223.12	PAX8-AS1	-3.47	0.000534	0.026	-0.17	-0.11	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:112940517	chr2:113211522~113276581:+
BRCA	cis	rs875971	1	rs2420591	ENSG00000271064.1	RP11-792A8.3	-3.47	0.000534	0.026	-0.12	-0.11	Aortic root size;	chr7:66447394	chr7:66748838~66749077:-
BRCA	cis	rs62025270	0.632	rs111906684	ENSG00000259367.1	RP11-815J21.4	3.47	0.000534	0.026	0.1	0.11	Idiopathic pulmonary fibrosis;	chr15:85678705	chr15:85619623~85670948:-
BRCA	cis	rs12310956	0.532	rs11052952	ENSG00000258794.3	DUX4L27	3.47	0.000534	0.026	0.15	0.11	Morning vs. evening chronotype;	chr12:33835113	chr12:34208415~34209675:-
BRCA	cis	rs12310956	0.532	rs35366144	ENSG00000258794.3	DUX4L27	3.47	0.000534	0.026	0.15	0.11	Morning vs. evening chronotype;	chr12:33839065	chr12:34208415~34209675:-
BRCA	cis	rs9863	0.861	rs11057397	ENSG00000270028.1	RP11-380L11.4	3.47	0.000534	0.026	0.14	0.11	White blood cell count;	chr12:123935181	chr12:123925461~123926083:-
BRCA	cis	rs13136331	0.684	rs1054627	ENSG00000249001.4	RP11-742B18.1	-3.47	0.000534	0.026	-0.15	-0.11	Sitting height ratio;	chr4:87811540	chr4:87568035~87733956:-
BRCA	cis	rs875971	0.756	rs2901210	ENSG00000265600.1	AC006480.1	3.47	0.000534	0.026	0.13	0.11	Aortic root size;	chr7:66552518	chr7:67356680~67356779:+
BRCA	cis	rs853679	0.517	rs9393890	ENSG00000226314.6	ZNF192P1	-3.47	0.000534	0.0261	-0.16	-0.11	Depression;	chr6:28096077	chr6:28161781~28169594:+
BRCA	cis	rs853679	0.517	rs9366715	ENSG00000226314.6	ZNF192P1	-3.47	0.000534	0.0261	-0.16	-0.11	Depression;	chr6:28096855	chr6:28161781~28169594:+
BRCA	cis	rs2562456	0.833	rs62107547	ENSG00000240522.1	RPL7AP10	-3.47	0.000534	0.0261	-0.12	-0.11	Pain;	chr19:21341245	chr19:21149648~21150438:-
BRCA	cis	rs7914558	1	rs7920251	ENSG00000213277.3	MARCKSL1P1	3.47	0.000535	0.0261	0.12	0.11	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103190440	chr10:103175554~103176094:+
BRCA	cis	rs4878639	0.512	rs10814332	ENSG00000235387.1	LINC00961	-3.47	0.000535	0.0261	-0.12	-0.11	IgG glycosylation;	chr9:36124562	chr9:35909483~35911686:+
BRCA	cis	rs4805834	0.92	rs7253595	ENSG00000201388.1	SNORA68	3.47	0.000535	0.0261	0.18	0.11	Creatinine levels;	chr19:32917047	chr19:32608337~32608469:-
BRCA	cis	rs7682317	0.664	rs7671167	ENSG00000270720.1	RP11-84C13.2	3.47	0.000535	0.0261	0.12	0.11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr4:88962828	chr4:89119284~89119871:+
BRCA	cis	rs2692947	0.711	rs34639392	ENSG00000232931.4	LINC00342	3.47	0.000535	0.0261	0.11	0.11	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95843228	chr2:95807118~95816215:-
BRCA	cis	rs17796831	0.965	rs11851274	ENSG00000205562.2	RP11-497E19.1	-3.47	0.000535	0.0261	-0.11	-0.11	Lobe attachment (rater-scored or self-reported);	chr14:85325608	chr14:85524432~85529988:-
BRCA	cis	rs931127	0.719	rs2127507	ENSG00000255557.1	RP11-770G2.2	3.47	0.000535	0.0261	0.12	0.11	Systemic lupus erythematosus;	chr11:65686959	chr11:65745729~65771585:+
BRCA	cis	rs11892454	0.599	rs34357652	ENSG00000217643.1	PTGES3P2	-3.47	0.000535	0.0261	-0.12	-0.11	Heschl's gyrus morphology;	chr2:25776544	chr2:25822469~25822950:+
BRCA	cis	rs11892454	0.599	rs17680961	ENSG00000217643.1	PTGES3P2	-3.47	0.000535	0.0261	-0.12	-0.11	Heschl's gyrus morphology;	chr2:25777655	chr2:25822469~25822950:+
BRCA	cis	rs11892454	0.523	rs13004909	ENSG00000217643.1	PTGES3P2	-3.47	0.000535	0.0261	-0.12	-0.11	Heschl's gyrus morphology;	chr2:25779436	chr2:25822469~25822950:+
BRCA	cis	rs8180040	0.522	rs749512	ENSG00000280667.1	Y_RNA	-3.47	0.000535	0.0261	-0.12	-0.11	Colorectal cancer;	chr3:46994410	chr3:47501083~47501182:+
BRCA	cis	rs4374383	0.631	rs10175316	ENSG00000243389.1	AC012442.5	3.47	0.000535	0.0261	0.13	0.11	Hepatitis C induced liver fibrosis;	chr2:111912297	chr2:112589040~112614431:+
BRCA	cis	rs453301	0.658	rs6983877	ENSG00000253981.4	ALG1L13P	-3.47	0.000535	0.0261	-0.12	-0.11	Joint mobility (Beighton score);	chr8:9047129	chr8:8236003~8244667:-
BRCA	cis	rs35365539	1	rs35365539	ENSG00000228008.1	CTD-2330K9.3	-3.47	0.000535	0.0261	-0.1	-0.11	Blood protein levels;	chr3:49756914	chr3:49903845~49916937:+
BRCA	cis	rs748404	0.666	rs12906017	ENSG00000166763.7	STRCP1	3.47	0.000535	0.0261	0.16	0.11	Lung cancer;	chr15:43504710	chr15:43699488~43718184:-
BRCA	cis	rs7122937	0.648	rs12576156	ENSG00000235027.1	AC068580.6	-3.47	0.000535	0.0261	-0.14	-0.11	QT interval;	chr11:2477588	chr11:1760348~1762486:+
BRCA	cis	rs4950322	0.542	rs3766519	ENSG00000230832.3	RP11-325P15.2	-3.47	0.000535	0.0261	-0.17	-0.11	Protein quantitative trait loci;	chr1:147214802	chr1:147082338~147083578:-
BRCA	cis	rs7267979	1	rs398036	ENSG00000204556.4	CTD-2514C3.1	-3.47	0.000535	0.0261	-0.14	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25459214	chr20:26018832~26020684:+
BRCA	cis	rs7267979	1	rs397119	ENSG00000204556.4	CTD-2514C3.1	-3.47	0.000535	0.0261	-0.14	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25459551	chr20:26018832~26020684:+
BRCA	cis	rs313426	0.541	rs2408680	ENSG00000260966.1	RP11-690D19.3	3.47	0.000535	0.0261	0.13	0.11	Toenail selenium levels;	chr11:103541703	chr11:103050687~103055799:-
BRCA	cis	rs313426	0.5	rs2122773	ENSG00000260966.1	RP11-690D19.3	3.47	0.000535	0.0261	0.13	0.11	Toenail selenium levels;	chr11:103542141	chr11:103050687~103055799:-
BRCA	cis	rs313426	0.529	rs35365294	ENSG00000260966.1	RP11-690D19.3	3.47	0.000535	0.0261	0.13	0.11	Toenail selenium levels;	chr11:103542982	chr11:103050687~103055799:-
BRCA	cis	rs12477438	1	rs995617	ENSG00000231822.1	AC019097.7	3.47	0.000535	0.0261	0.14	0.11	Chronic sinus infection;	chr2:99241441	chr2:99102018~99102752:+
BRCA	cis	rs1670533	1	rs6852850	ENSG00000251639.2	RP11-20I20.1	3.47	0.000535	0.0261	0.17	0.11	Recombination rate (females);	chr4:1059069	chr4:1100016~1101558:-
BRCA	cis	rs12049351	0.943	rs6687883	ENSG00000229367.1	HMGN2P19	-3.47	0.000535	0.0261	-0.16	-0.11	Circulating myeloperoxidase levels (plasma);	chr1:229582109	chr1:229570532~229570796:+
BRCA	cis	rs1421334	0.679	rs2080720	ENSG00000253961.1	RP11-363L24.3	-3.47	0.000535	0.0261	-0.12	-0.11	Intelligence (multi-trait analysis);	chr8:30983815	chr8:31167078~31177167:-
BRCA	cis	rs950169	0.58	rs11634322	ENSG00000230373.7	GOLGA6L5P	-3.47	0.000535	0.0261	-0.13	-0.11	Schizophrenia;	chr15:84628978	chr15:84507885~84516814:-
BRCA	cis	rs10501293	0.917	rs10768914	ENSG00000252652.1	Y_RNA	3.47	0.000535	0.0261	0.12	0.11	Cognitive performance;	chr11:43080713	chr11:43331261~43331356:+
BRCA	cis	rs1250259	0.542	rs7592898	ENSG00000225166.1	AC012462.2	-3.47	0.000535	0.0261	-0.13	-0.11	Coronary artery disease;Pulse pressure;	chr2:215407089	chr2:215453707~215463871:+
BRCA	cis	rs849141	0.89	rs860263	ENSG00000234336.5	JAZF1-AS1	-3.47	0.000535	0.0261	-0.16	-0.11	Height;Hip circumference adjusted for BMI;	chr7:28142727	chr7:28180322~28243917:+
BRCA	cis	rs7818688	0.932	rs10111154	ENSG00000245080.5	RP11-320N21.1	-3.47	0.000535	0.0261	-0.17	-0.11	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95028659	chr8:95066808~95073182:-
BRCA	cis	rs2832270	0.562	rs73193803	ENSG00000176054.6	RPL23P2	-3.47	0.000535	0.0261	-0.2	-0.11	Response to mTOR inhibitor (everolimus);	chr21:29157005	chr21:28997613~28998033:-
BRCA	cis	rs74233809	1	rs79668541	ENSG00000236937.2	PTGES3P4	3.47	0.000535	0.0261	0.24	0.11	Birth weight;	chr10:103034147	chr10:102845595~102845950:+
BRCA	cis	rs7932354	0.583	rs3136447	ENSG00000200376.1	RNU5E-10P	-3.47	0.000535	0.0261	-0.14	-0.11	Bone mineral density (hip);Bone mineral density;	chr11:46722818	chr11:47576471~47576588:-
BRCA	cis	rs863345	0.604	rs4276920	ENSG00000229914.1	RP11-404O13.4	-3.47	0.000536	0.0261	-0.11	-0.11	Pneumococcal bacteremia;	chr1:158535182	chr1:158195633~158196131:-
BRCA	cis	rs4919694	1	rs12246689	ENSG00000236937.2	PTGES3P4	3.47	0.000536	0.0261	0.22	0.11	Arsenic metabolism;	chr10:103057274	chr10:102845595~102845950:+
BRCA	cis	rs7647973	0.593	rs1799844	ENSG00000281433.1	Metazoa_SRP	-3.47	0.000536	0.0261	-0.14	-0.11	Menarche (age at onset);	chr3:49810209	chr3:49320296~49320564:+
BRCA	cis	rs34779708	0.966	rs11010129	ENSG00000269952.1	RP11-324I22.3	-3.47	0.000536	0.0261	-0.14	-0.11	Inflammatory bowel disease;Crohn's disease;	chr10:35221894	chr10:35210416~35210750:+
BRCA	cis	rs2554380	0.628	rs4843156	ENSG00000176700.18	SCAND2P	-3.47	0.000536	0.0261	-0.11	-0.11	Height;	chr15:83788593	chr15:84631451~84647478:+
BRCA	cis	rs58383906	0.543	rs2196553	ENSG00000235904.1	RBMS3-AS3	-3.47	0.000536	0.0261	-0.11	-0.11	Type 2 diabetes (age of onset);	chr3:29213873	chr3:29264194~29290726:-
BRCA	cis	rs11671005	0.693	rs11668757	ENSG00000269473.1	CTD-2619J13.19	3.47	0.000536	0.0261	0.16	0.11	Mean platelet volume;	chr19:58416932	chr19:58440448~58445849:+
BRCA	cis	rs7894407	0.623	rs10883846	ENSG00000213061.2	PFN1P11	-3.47	0.000536	0.0261	-0.15	-0.11	White matter hyperintensity burden;	chr10:103198487	chr10:102838011~102845473:-
BRCA	cis	rs7520050	0.966	rs7515491	ENSG00000281133.1	AL355480.3	3.47	0.000536	0.0261	0.12	0.11	Reticulocyte count;Red blood cell count;	chr1:45889407	chr1:45580892~45580996:-
BRCA	cis	rs4699052	0.963	rs4699057	ENSG00000251288.2	RP11-10L12.2	3.47	0.000536	0.0261	0.13	0.11	Testicular germ cell tumor;	chr4:103249966	chr4:102751401~102752641:+
BRCA	cis	rs7107174	1	rs7101429	ENSG00000251323.2	RP11-452H21.4	3.47	0.000536	0.0261	0.16	0.11	Testicular germ cell tumor;	chr11:78281921	chr11:78423982~78429836:-
BRCA	cis	rs11638815	0.859	rs12437785	ENSG00000279758.1	RP11-752G15.10	-3.47	0.000536	0.0261	-0.12	-0.11	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82718605	chr15:82738386~82739122:+
BRCA	cis	rs10838634	1	rs7945548	ENSG00000280615.1	Y_RNA	-3.47	0.000536	0.0261	-0.18	-0.11	Schizophrenia;	chr11:46878729	chr11:47614898~47614994:-
BRCA	cis	rs881375	0.933	rs7021206	ENSG00000238181.2	AHCYP2	3.47	0.000536	0.0261	0.13	0.11	Rheumatoid arthritis;	chr9:120921879	chr9:120720673~120721972:+
BRCA	cis	rs4689592	0.622	rs2276968	ENSG00000245468.3	RP11-367J11.3	3.47	0.000536	0.0261	0.12	0.11	Monocyte percentage of white cells;	chr4:7068391	chr4:7094571~7103385:-
BRCA	cis	rs10844706	0.669	rs10772102	ENSG00000278635.1	CTD-2318O12.1	-3.47	0.000536	0.0261	-0.12	-0.11	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9744357	chr12:9415641~9416718:+
BRCA	cis	rs10043228	1	rs79889615	ENSG00000250015.1	CTC-339F2.2	3.47	0.000536	0.0261	0.16	0.11	Asthma or chronic obstructive pulmonary disease;	chr5:116255595	chr5:116302354~116304134:-
BRCA	cis	rs863345	0.604	rs4276920	ENSG00000176320.2	RP11-404O13.5	-3.47	0.000536	0.0261	-0.11	-0.11	Pneumococcal bacteremia;	chr1:158535182	chr1:158197922~158203877:-
BRCA	cis	rs2153535	0.585	rs1041279	ENSG00000251164.1	HULC	-3.47	0.000536	0.0261	-0.13	-0.11	Motion sickness;	chr6:8650293	chr6:8652137~8653846:+
BRCA	cis	rs10518325	1	rs10518325	ENSG00000249244.1	RP11-548H18.2	3.47	0.000536	0.0261	0.22	0.11	Perioperative myocardial infarction in coronary artery bypass surgery;	chr4:118796479	chr4:119391831~119395335:-
BRCA	cis	rs875971	0.789	rs7808013	ENSG00000271064.1	RP11-792A8.3	3.47	0.000536	0.0261	0.13	0.11	Aortic root size;	chr7:66606209	chr7:66748838~66749077:-
BRCA	cis	rs35520189	0.625	rs12614316	ENSG00000231747.1	AC079922.2	-3.47	0.000536	0.0261	-0.11	-0.11	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:112947826	chr2:112621809~112622167:-
BRCA	cis	rs524281	0.861	rs2293121	ENSG00000255038.1	RP11-1167A19.2	-3.47	0.000536	0.0261	-0.15	-0.11	Electroencephalogram traits;	chr11:66193876	chr11:66067277~66069619:-
BRCA	cis	rs524281	0.814	rs10896098	ENSG00000255038.1	RP11-1167A19.2	-3.47	0.000536	0.0261	-0.15	-0.11	Electroencephalogram traits;	chr11:66200945	chr11:66067277~66069619:-
BRCA	cis	rs12496230	0.794	rs9813067	ENSG00000272610.1	MAGI1-IT1	-3.47	0.000536	0.0261	-0.13	-0.11	Type 2 diabetes;	chr3:66812220	chr3:65872815~65954558:-
BRCA	cis	rs4831760	0.783	rs11787043	ENSG00000250483.1	PPM1AP1	3.47	0.000536	0.0261	0.15	0.11	Pulmonary function decline;	chr8:15567358	chr8:15806149~15807283:-
BRCA	cis	rs8062405	1	rs12325113	ENSG00000261766.1	RP11-22P6.2	-3.47	0.000536	0.0261	-0.11	-0.11	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28837347	chr16:28862166~28863340:-
BRCA	cis	rs56163509	1	rs56163509	ENSG00000261766.1	RP11-22P6.2	-3.47	0.000536	0.0261	-0.11	-0.11	Tonsillectomy;Mean corpuscular volume;	chr16:28853150	chr16:28862166~28863340:-
BRCA	cis	rs6142102	0.961	rs2235597	ENSG00000206582.1	Y_RNA	-3.47	0.000536	0.0261	-0.13	-0.11	Skin pigmentation;	chr20:34077808	chr20:34526510~34526606:-
BRCA	cis	rs1730008	0.585	rs7617666	ENSG00000279311.1	RP11-170K4.2	3.47	0.000536	0.0261	0.12	0.11	Lobe attachment (rater-scored or self-reported);	chr3:158321223	chr3:158869898~158871821:+
BRCA	cis	rs2304003	0.583	rs1023706	ENSG00000229195.1	AC009495.4	3.47	0.000536	0.0261	0.13	0.11	Social communication problems;	chr2:165863636	chr2:165794857~165846091:-
BRCA	cis	rs1124769	0.719	rs11070833	ENSG00000274528.1	CTD-2650P22.2	3.47	0.000536	0.0261	0.13	0.11	Cognitive performance;	chr15:51087164	chr15:52017167~52018032:-
BRCA	cis	rs6453278	0.732	rs6868455	ENSG00000250802.5	ZBED3-AS1	3.47	0.000536	0.0261	0.16	0.11	Autism;	chr5:77102798	chr5:77086740~77166909:+
BRCA	cis	rs6500602	0.826	rs9925719	ENSG00000280063.1	RP11-295D4.3	3.47	0.000536	0.0261	0.09	0.11	Schizophrenia;	chr16:4411860	chr16:4346694~4348648:-
BRCA	cis	rs2692947	0.832	rs2579550	ENSG00000232931.4	LINC00342	3.47	0.000536	0.0261	0.12	0.11	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96076196	chr2:95807118~95816215:-
BRCA	cis	rs2692947	0.8	rs2692936	ENSG00000232931.4	LINC00342	3.47	0.000536	0.0261	0.12	0.11	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96079981	chr2:95807118~95816215:-
BRCA	cis	rs3755605	0.728	rs11915943	ENSG00000242578.1	RP11-469J4.3	3.47	0.000537	0.0261	0.12	0.11	Testicular germ cell tumor;	chr3:170163562	chr3:170410512~170418615:+
BRCA	cis	rs4819052	0.765	rs2838852	ENSG00000223768.1	LINC00205	-3.47	0.000537	0.0261	-0.14	-0.11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45257122	chr21:45293285~45297354:+
BRCA	cis	rs7520050	0.751	rs592214	ENSG00000281133.1	AL355480.3	3.47	0.000537	0.0261	0.12	0.11	Reticulocyte count;Red blood cell count;	chr1:45558833	chr1:45580892~45580996:-
BRCA	cis	rs7561149	0.736	rs1027138	ENSG00000270574.1	RP11-171I2.2	-3.47	0.000537	0.0261	-0.15	-0.11	QT interval;	chr2:178858292	chr2:178578790~178580906:+
BRCA	cis	rs2785946	0.697	rs9316716	ENSG00000136149.6	RPL13AP25	3.47	0.000537	0.0261	0.09	0.11	Amyotrophic lateral sclerosis;	chr13:54386109	chr13:54440704~54441315:-
BRCA	cis	rs10411161	0.702	rs79180893	ENSG00000268095.1	ZNF649-AS1	3.47	0.000537	0.0261	0.19	0.11	Breast cancer;	chr19:51892362	chr19:51888025~51900463:+
BRCA	cis	rs10411161	0.702	rs11879436	ENSG00000268095.1	ZNF649-AS1	3.47	0.000537	0.0261	0.19	0.11	Breast cancer;	chr19:51894562	chr19:51888025~51900463:+
BRCA	cis	rs10411161	0.702	rs10420224	ENSG00000268095.1	ZNF649-AS1	3.47	0.000537	0.0261	0.19	0.11	Breast cancer;	chr19:51895702	chr19:51888025~51900463:+
BRCA	cis	rs10411161	0.702	rs75647161	ENSG00000268095.1	ZNF649-AS1	3.47	0.000537	0.0261	0.19	0.11	Breast cancer;	chr19:51895731	chr19:51888025~51900463:+
BRCA	cis	rs10411161	0.702	rs17778790	ENSG00000268095.1	ZNF649-AS1	3.47	0.000537	0.0261	0.19	0.11	Breast cancer;	chr19:51896306	chr19:51888025~51900463:+
BRCA	cis	rs12531458	0.967	rs11773650	ENSG00000249978.1	TRGV7	3.47	0.000537	0.0262	0.09	0.11	Educational attainment (years of education);	chr7:39072266	chr7:38335041~38335514:-
BRCA	cis	rs6449502	0.92	rs11951504	ENSG00000215032.2	GNL3LP1	3.47	0.000537	0.0262	0.19	0.11	Mean platelet volume;	chr5:61076611	chr5:60891935~60893577:-
BRCA	cis	rs1113500	0.814	rs12039712	ENSG00000230489.1	VAV3-AS1	-3.47	0.000537	0.0262	-0.12	-0.11	Growth-regulated protein alpha levels;	chr1:108098577	chr1:107964443~107994607:+
BRCA	cis	rs1075265	0.729	rs7571086	ENSG00000272156.1	RP11-477N3.1	-3.47	0.000537	0.0262	-0.11	-0.11	Chronotype;Morning vs. evening chronotype;	chr2:54007899	chr2:54082554~54085066:+
BRCA	cis	rs9876781	0.56	rs2362451	ENSG00000244380.1	RP11-24C3.2	-3.47	0.000537	0.0262	-0.12	-0.11	Longevity;	chr3:48358338	chr3:48440352~48446656:-
BRCA	cis	rs4356203	0.87	rs7936310	ENSG00000184669.7	OR7E14P	3.47	0.000537	0.0262	0.14	0.11	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17248741	chr11:17013998~17053024:+
BRCA	cis	rs6600671	1	rs1856572	ENSG00000270231.3	NBPF8P	3.47	0.000537	0.0262	0.11	0.11	Hip geometry;	chr1:121427719	chr1:120436353~120467739:+
BRCA	cis	rs910873	0.505	rs2378249	ENSG00000250917.1	RP4-785G19.5	3.47	0.000537	0.0262	0.18	0.11	Melanoma;	chr20:34630286	chr20:34234840~34281173:-
BRCA	cis	rs6840360	0.593	rs10016160	ENSG00000270265.1	RP11-731D1.4	-3.47	0.000537	0.0262	-0.12	-0.11	Intelligence (multi-trait analysis);	chr4:151772846	chr4:151333775~151353224:-
BRCA	cis	rs2412819	0.597	rs514311	ENSG00000201136.1	RNU6-353P	3.47	0.000537	0.0262	0.15	0.11	Lung cancer;	chr15:43869376	chr15:43702363~43702470:+
BRCA	cis	rs6893300	0.785	rs55654737	ENSG00000225051.5	HMGB3P22	3.47	0.000537	0.0262	0.14	0.11	Resting heart rate;	chr5:179791841	chr5:179679032~179694768:+
BRCA	cis	rs10849893	0.595	rs6489811	ENSG00000272849.1	RP11-347I19.8	-3.47	0.000537	0.0262	-0.08	-0.11	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr12:121455823	chr12:121797511~121801972:+
BRCA	cis	rs11790994	0.915	rs1335050	ENSG00000175611.10	LINC00476	3.47	0.000537	0.0262	0.18	0.11	Inattentive symptoms;	chr9:95664357	chr9:95759231~95875977:-
BRCA	cis	rs10411161	0.702	rs892039	ENSG00000268095.1	ZNF649-AS1	3.47	0.000537	0.0262	0.19	0.11	Breast cancer;	chr19:51893288	chr19:51888025~51900463:+
BRCA	cis	rs10411161	0.702	rs2867319	ENSG00000268095.1	ZNF649-AS1	3.47	0.000537	0.0262	0.19	0.11	Breast cancer;	chr19:51893907	chr19:51888025~51900463:+
BRCA	cis	rs1865760	1	rs3799372	ENSG00000272810.1	U91328.22	-3.47	0.000537	0.0262	-0.13	-0.11	Height;	chr6:25922083	chr6:26013241~26013757:+
BRCA	cis	rs1865760	0.963	rs1540273	ENSG00000272810.1	U91328.22	-3.47	0.000537	0.0262	-0.13	-0.11	Height;	chr6:25923930	chr6:26013241~26013757:+
BRCA	cis	rs1865760	1	rs9358895	ENSG00000272810.1	U91328.22	-3.47	0.000537	0.0262	-0.13	-0.11	Height;	chr6:25924427	chr6:26013241~26013757:+
BRCA	cis	rs11673344	0.566	rs185369	ENSG00000233527.7	ZNF529-AS1	-3.47	0.000537	0.0262	-0.12	-0.11	Obesity-related traits;	chr19:37376137	chr19:36573070~36594708:+
BRCA	cis	rs7165170	0.554	rs7175560	ENSG00000245479.2	LINC01585	-3.47	0.000537	0.0262	-0.14	-0.11	Crohn's disease;Inflammatory bowel disease;	chr15:90606847	chr15:90660234~90664967:+
BRCA	cis	rs6570726	0.526	rs9376928	ENSG00000270638.1	RP3-466P17.1	-3.47	0.000537	0.0262	-0.12	-0.11	Lobe attachment (rater-scored or self-reported);	chr6:145403267	chr6:145735570~145737218:+
BRCA	cis	rs10129255	0.957	rs10136817	ENSG00000231475.3	IGHV4-31	-3.47	0.000537	0.0262	-0.09	-0.11	Kawasaki disease;	chr14:106787730	chr14:106349283~106349792:-
BRCA	cis	rs7712401	0.791	rs4835897	ENSG00000249996.1	RP11-359P5.1	3.47	0.000537	0.0262	0.12	0.11	Mean platelet volume;	chr5:122785809	chr5:123036271~123054667:+
BRCA	cis	rs11673344	0.77	rs34729406	ENSG00000267682.1	CTD-3220F14.2	-3.47	0.000537	0.0262	-0.1	-0.11	Obesity-related traits;	chr19:37012764	chr19:37337236~37337743:+
BRCA	cis	rs2514805	0.803	rs2513789	ENSG00000253585.1	KB-1184D12.1	3.47	0.000537	0.0262	0.19	0.11	Diisocyanate-induced asthma;	chr8:94115885	chr8:94097764~94104322:-
BRCA	cis	rs6728642	1	rs116171118	ENSG00000279791.1	RP11-499E14.1	-3.47	0.000537	0.0262	-0.23	-0.11	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:97029299	chr2:97094935~97097433:+
BRCA	cis	rs1823874	0.581	rs11855419	ENSG00000254744.3	CTD-3076O17.1	3.47	0.000537	0.0262	0.13	0.11	IgG glycosylation;	chr15:99787275	chr15:99970215~99974010:+
BRCA	cis	rs2832191	0.74	rs2832175	ENSG00000236056.1	GAPDHP14	3.47	0.000538	0.0262	0.12	0.11	Dental caries;	chr21:29103285	chr21:29222321~29223257:+
BRCA	cis	rs832540	0.931	rs2591960	ENSG00000271828.1	CTD-2310F14.1	-3.47	0.000538	0.0262	-0.13	-0.11	Coronary artery disease;	chr5:56942984	chr5:56927874~56929573:+
BRCA	cis	rs673253	0.638	rs3791140	ENSG00000229431.1	RP1-92O14.6	-3.47	0.000538	0.0262	-0.11	-0.11	Intelligence (multi-trait analysis);	chr1:43586107	chr1:43385113~43389155:+
BRCA	cis	rs7615952	0.512	rs2979351	ENSG00000248787.1	RP11-666A20.4	-3.47	0.000538	0.0262	-0.16	-0.11	Blood pressure (smoking interaction);	chr3:125644755	chr3:125908005~125910272:-
BRCA	cis	rs4664293	0.764	rs1425044	ENSG00000226266.5	AC009961.3	-3.47	0.000538	0.0262	-0.12	-0.11	Monocyte percentage of white cells;	chr2:159618426	chr2:159670708~159712435:-
BRCA	cis	rs8141529	0.719	rs9625619	ENSG00000226471.5	CTA-292E10.6	-3.47	0.000538	0.0262	-0.13	-0.11	Lymphocyte counts;	chr22:28876340	chr22:28800683~28848559:+
BRCA	cis	rs979233	0.935	rs13166285	ENSG00000188850.9	RP11-159F24.2	3.47	0.000538	0.0262	0.13	0.11	Systemic lupus erythematosus;	chr5:42529446	chr5:43336164~43348716:+
BRCA	cis	rs8180040	0.62	rs11707736	ENSG00000280667.1	Y_RNA	-3.47	0.000538	0.0262	-0.12	-0.11	Colorectal cancer;	chr3:47028014	chr3:47501083~47501182:+
BRCA	cis	rs763121	0.889	rs6001209	ENSG00000280216.1	RP3-333H23.9	3.47	0.000538	0.0262	0.13	0.11	Menopause (age at onset);	chr22:38725247	chr22:39379610~39380015:+
BRCA	cis	rs4713118	0.786	rs200503	ENSG00000280107.1	AL022393.9	-3.47	0.000538	0.0262	-0.15	-0.11	Parkinson's disease;	chr6:27818104	chr6:28170845~28172521:+
BRCA	cis	rs4713118	0.786	rs200502	ENSG00000280107.1	AL022393.9	-3.47	0.000538	0.0262	-0.15	-0.11	Parkinson's disease;	chr6:27820284	chr6:28170845~28172521:+
BRCA	cis	rs35520189	0.857	rs2708914	ENSG00000231747.1	AC079922.2	3.47	0.000538	0.0262	0.11	0.11	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:112869657	chr2:112621809~112622167:-
BRCA	cis	rs6601327	0.641	rs6601350	ENSG00000233609.3	RP11-62H7.2	-3.47	0.000538	0.0262	-0.1	-0.11	Multiple myeloma (hyperdiploidy);	chr8:9716446	chr8:8961200~8979025:+
BRCA	cis	rs337100	0.572	rs387435	ENSG00000263432.2	RN7SL689P	3.47	0.000538	0.0262	0.13	0.11	Pulse pressure;	chr5:123138001	chr5:123022487~123022783:-
BRCA	cis	rs1466535	1	rs4367982	ENSG00000201579.1	RNU6-343P	3.47	0.000538	0.0262	0.12	0.11	Abdominal aortic aneurysm;	chr12:57137849	chr12:56588518~56588621:+
BRCA	cis	rs72775230	0.68	rs17389232	ENSG00000233990.1	RP11-401E9.3	-3.47	0.000538	0.0262	-0.19	-0.11	Conotruncal heart defects (inherited effects);	chr10:8516870	chr10:7833618~7833957:-
BRCA	cis	rs72775230	0.733	rs11596712	ENSG00000233990.1	RP11-401E9.3	-3.47	0.000538	0.0262	-0.19	-0.11	Conotruncal heart defects (inherited effects);	chr10:8517293	chr10:7833618~7833957:-
BRCA	cis	rs4927850	1	rs7625570	ENSG00000273009.1	RP11-352G9.1	-3.47	0.000538	0.0262	-0.13	-0.11	Pancreatic cancer;	chr3:196020527	chr3:195913078~195913683:-
BRCA	cis	rs9486719	1	rs12208449	ENSG00000233797.1	UFL1-AS1	-3.47	0.000538	0.0262	-0.16	-0.11	Coronary artery disease;Migraine;	chr6:96455377	chr6:96358374~96521669:-
BRCA	cis	rs2333021	0.649	rs12881153	ENSG00000259015.1	RP11-109N23.6	3.47	0.000538	0.0262	0.12	0.11	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:72993647	chr14:72960595~72961993:+
BRCA	cis	rs6088580	0.524	rs2378251	ENSG00000261582.1	RP4-614O4.11	3.47	0.000538	0.0262	0.1	0.11	Glomerular filtration rate (creatinine);	chr20:34688946	chr20:35267885~35280043:-
BRCA	cis	rs9949617	0.538	rs28455497	ENSG00000266495.1	RP11-17J14.2	3.47	0.000538	0.0262	0.17	0.11	Hypertriglyceridemia;	chr18:23330067	chr18:23257164~23260354:-
BRCA	cis	rs6943931	1	rs73682636	ENSG00000230658.1	KLHL7-AS1	-3.47	0.000539	0.0262	-0.14	-0.11	Diabetic kidney disease;	chr7:22376568	chr7:23101228~23105703:-
BRCA	cis	rs6545883	0.929	rs7563678	ENSG00000212978.6	AC016747.3	-3.47	0.000539	0.0262	-0.14	-0.11	Tuberculosis;	chr2:61514676	chr2:61141592~61144969:-
BRCA	cis	rs7165170	0.549	rs6496689	ENSG00000271396.1	RP11-697E2.9	3.47	0.000539	0.0262	0.14	0.11	Crohn's disease;Inflammatory bowel disease;	chr15:90553683	chr15:90284376~90285580:-
BRCA	cis	rs648090	0.914	rs3016694	ENSG00000254509.1	RP11-677M14.6	3.47	0.000539	0.0262	0.11	0.11	Testicular germ cell tumor;	chr11:125189794	chr11:124791228~124791660:+
BRCA	cis	rs829883	0.659	rs11109528	ENSG00000227825.4	SLC9A7P1	-3.47	0.000539	0.0262	-0.14	-0.11	Colorectal adenoma (advanced);	chr12:98557584	chr12:98453835~98457145:-
BRCA	cis	rs6088580	0.57	rs6058057	ENSG00000269202.1	RP4-614O4.12	-3.47	0.000539	0.0262	-0.11	-0.11	Glomerular filtration rate (creatinine);	chr20:34477478	chr20:35201747~35203288:-
BRCA	cis	rs6743226	0.603	rs11678750	ENSG00000266621.1	AC104841.1	3.47	0.000539	0.0262	0.13	0.11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in non-smokers;	chr2:241261504	chr2:241245202~241245299:-
BRCA	cis	rs7781266	0.739	rs6949831	ENSG00000226205.1	AC007790.4	-3.47	0.000539	0.0262	-0.16	-0.11	Educational attainment (college completion);	chr7:133396716	chr7:133732493~133733595:-
BRCA	cis	rs5742933	1	rs16831925	ENSG00000253559.1	OSGEPL1-AS1	-3.47	0.000539	0.0262	-0.15	-0.11	Ferritin levels;	chr2:189731178	chr2:189762704~189765556:+
BRCA	cis	rs10829156	0.773	rs7909552	ENSG00000225527.1	RP11-383B4.4	-3.47	0.000539	0.0262	-0.14	-0.11	Sudden cardiac arrest;	chr10:18620407	chr10:18531849~18533336:-
BRCA	cis	rs853679	0.517	rs9380056	ENSG00000226314.6	ZNF192P1	-3.47	0.000539	0.0262	-0.16	-0.11	Depression;	chr6:28136698	chr6:28161781~28169594:+
BRCA	cis	rs853679	0.517	rs9380057	ENSG00000226314.6	ZNF192P1	-3.47	0.000539	0.0262	-0.16	-0.11	Depression;	chr6:28136856	chr6:28161781~28169594:+
BRCA	cis	rs853679	0.517	rs6941992	ENSG00000226314.6	ZNF192P1	-3.47	0.000539	0.0262	-0.16	-0.11	Depression;	chr6:28138363	chr6:28161781~28169594:+
BRCA	cis	rs4713118	0.516	rs4713142	ENSG00000226314.6	ZNF192P1	-3.47	0.000539	0.0262	-0.16	-0.11	Parkinson's disease;	chr6:28138569	chr6:28161781~28169594:+
BRCA	cis	rs853679	0.517	rs4713143	ENSG00000226314.6	ZNF192P1	-3.47	0.000539	0.0262	-0.16	-0.11	Depression;	chr6:28138981	chr6:28161781~28169594:+
BRCA	cis	rs853679	0.517	rs4713144	ENSG00000226314.6	ZNF192P1	-3.47	0.000539	0.0262	-0.16	-0.11	Depression;	chr6:28139012	chr6:28161781~28169594:+
BRCA	cis	rs4835473	0.9	rs7687976	ENSG00000246448.2	RP13-578N3.3	-3.47	0.000539	0.0262	-0.12	-0.11	Immature fraction of reticulocytes;	chr4:143749171	chr4:143700257~143865072:+
BRCA	cis	rs875971	0.862	rs2024192	ENSG00000265600.1	AC006480.1	3.47	0.000539	0.0262	0.13	0.11	Aortic root size;	chr7:66576460	chr7:67356680~67356779:+
BRCA	cis	rs2243480	1	rs160655	ENSG00000237026.1	RP11-328P23.2	3.47	0.000539	0.0262	0.2	0.11	Diabetic kidney disease;	chr7:66068227	chr7:65235790~65236723:-
BRCA	cis	rs74233809	1	rs11191593	ENSG00000213061.2	PFN1P11	3.47	0.000539	0.0262	0.23	0.11	Birth weight;	chr10:103179458	chr10:102838011~102845473:-
BRCA	cis	rs911555	0.57	rs11625397	ENSG00000269940.1	RP11-73M18.7	-3.47	0.000539	0.0262	-0.11	-0.11	Intelligence (multi-trait analysis);	chr14:103561220	chr14:103694560~103695170:+
BRCA	cis	rs6812193	0.518	rs10025494	ENSG00000271676.1	RP11-1E1.2	-3.47	0.000539	0.0262	-0.15	-0.11	Parkinson's disease;	chr4:76268227	chr4:77112495~77113458:-
BRCA	cis	rs6058526	1	rs66773564	ENSG00000275576.1	RP5-836N17.4	3.47	0.000539	0.0262	0.17	0.11	Chronic obstructive pulmonary disease;	chr20:32116987	chr20:32116171~32116629:+
BRCA	cis	rs6828577	0.56	rs2631147	ENSG00000245958.5	RP11-33B1.1	3.47	0.000539	0.0262	0.1	0.11	Perioperative myocardial infarction in coronary artery bypass surgery;	chr4:118534699	chr4:119454791~119552025:+
BRCA	cis	rs801193	0.636	rs10233806	ENSG00000230189.5	GS1-124K5.2	-3.47	0.000539	0.0262	-0.09	-0.11	Aortic root size;	chr7:66653261	chr7:66409143~66490059:-
BRCA	cis	rs3805389	0.504	rs28756087	ENSG00000249700.7	SRD5A3-AS1	-3.47	0.000539	0.0263	-0.17	-0.11	Waist-to-hip ratio adjusted for body mass index;	chr4:55601940	chr4:55363971~55395847:-
BRCA	cis	rs3805389	0.504	rs28713371	ENSG00000249700.7	SRD5A3-AS1	-3.47	0.000539	0.0263	-0.17	-0.11	Waist-to-hip ratio adjusted for body mass index;	chr4:55602255	chr4:55363971~55395847:-
BRCA	cis	rs3805389	0.504	rs10011801	ENSG00000249700.7	SRD5A3-AS1	-3.47	0.000539	0.0263	-0.17	-0.11	Waist-to-hip ratio adjusted for body mass index;	chr4:55602567	chr4:55363971~55395847:-
BRCA	cis	rs10043775	0.75	rs2112759	ENSG00000251330.3	CTD-2283N19.1	-3.47	0.000539	0.0263	-0.12	-0.11	Periodontal microbiota;	chr5:148324688	chr5:148430159~148430807:-
BRCA	cis	rs6951245	0.554	rs11544331	ENSG00000224079.1	AC091729.7	-3.47	0.000539	0.0263	-0.16	-0.11	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1091775	chr7:1074450~1078036:+
BRCA	cis	rs6545883	1	rs6545883	ENSG00000212978.6	AC016747.3	3.47	0.000539	0.0263	0.14	0.11	Tuberculosis;	chr2:61545122	chr2:61141592~61144969:-
BRCA	cis	rs10043228	0.826	rs12514785	ENSG00000271918.1	CTD-2287O16.5	-3.47	0.000539	0.0263	-0.15	-0.11	Asthma or chronic obstructive pulmonary disease;	chr5:116139040	chr5:116083807~116085416:-
BRCA	cis	rs875971	0.964	rs12668936	ENSG00000271064.1	RP11-792A8.3	-3.47	0.000539	0.0263	-0.12	-0.11	Aortic root size;	chr7:66449417	chr7:66748838~66749077:-
BRCA	cis	rs2055729	0.645	rs62489486	ENSG00000233609.3	RP11-62H7.2	3.47	0.000539	0.0263	0.12	0.11	Multiple myeloma (hyperdiploidy);	chr8:9884415	chr8:8961200~8979025:+
BRCA	cis	rs10129255	0.536	rs3944157	ENSG00000253359.1	IGHV3-37	3.47	0.000539	0.0263	0.09	0.11	Kawasaki disease;	chr14:106682286	chr14:106396676~106397114:-
BRCA	cis	rs28489187	0.597	rs506082	ENSG00000223653.4	RP11-131L23.1	-3.47	0.000539	0.0263	-0.12	-0.11	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85433532	chr1:85276715~85448124:+
BRCA	cis	rs3764021	0.527	rs12227655	ENSG00000260423.1	RP13-735L24.1	-3.47	0.000539	0.0263	-0.12	-0.11	Type 1 diabetes;	chr12:9715652	chr12:9367464~9397617:+
BRCA	cis	rs3764021	0.506	rs12228641	ENSG00000260423.1	RP13-735L24.1	-3.47	0.000539	0.0263	-0.12	-0.11	Type 1 diabetes;	chr12:9715680	chr12:9367464~9397617:+
BRCA	cis	rs10170310	0.872	rs62161711	ENSG00000241772.2	AC092620.2	-3.47	0.00054	0.0263	-0.15	-0.11	Response to antipsychotic treatment;	chr2:138501652	chr2:138569090~138574458:+
BRCA	cis	rs4879656	0.705	rs10813910	ENSG00000225693.1	LAGE3P1	-3.47	0.00054	0.0263	-0.13	-0.11	Menopause (age at onset);	chr9:32965209	chr9:33019682~33020165:-
BRCA	cis	rs4363385	0.51	rs10888528	ENSG00000231416.1	RP11-422P24.9	-3.47	0.00054	0.0263	-0.12	-0.11	Inflammatory skin disease;	chr1:153078040	chr1:153995632~153995960:+
BRCA	cis	rs13118159	0.742	rs34947293	ENSG00000254094.1	AC078852.1	-3.47	0.00054	0.0263	-0.11	-0.11	Longevity;	chr4:1341246	chr4:1356581~1358075:+
BRCA	cis	rs16858210	0.607	rs953419	ENSG00000234371.6	RPSAP31	-3.47	0.00054	0.0263	-0.15	-0.11	Menopause (age at onset);	chr3:183868095	chr3:183884924~183888449:+
BRCA	cis	rs8105895	0.935	rs62112362	ENSG00000269345.1	VN1R85P	3.47	0.00054	0.0263	0.17	0.11	Body mass index (change over time);	chr19:22110311	chr19:22174766~22175191:-
BRCA	cis	rs875971	0.862	rs4718377	ENSG00000223473.2	GS1-124K5.3	-3.47	0.00054	0.0263	-0.08	-0.11	Aortic root size;	chr7:66584691	chr7:66491049~66493566:-
BRCA	cis	rs875971	0.862	rs10278014	ENSG00000223473.2	GS1-124K5.3	-3.47	0.00054	0.0263	-0.08	-0.11	Aortic root size;	chr7:66586277	chr7:66491049~66493566:-
BRCA	cis	rs3781264	0.595	rs7096037	ENSG00000268894.5	PLCE1-AS1	-3.47	0.00054	0.0263	-0.14	-0.11	Esophageal cancer and gastric cancer;	chr10:94329950	chr10:94279277~94287478:-
BRCA	cis	rs7572733	0.935	rs11675025	ENSG00000231621.1	AC013264.2	-3.47	0.00054	0.0263	-0.1	-0.11	Dermatomyositis;	chr2:197973591	chr2:197197991~197199273:+
BRCA	cis	rs987724	0.613	rs1384538	ENSG00000240875.4	LINC00886	-3.47	0.00054	0.0263	-0.12	-0.11	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156977820	chr3:156747346~156817062:-
BRCA	cis	rs16846053	0.786	rs62188794	ENSG00000227403.1	AC009299.3	3.47	0.00054	0.0263	0.26	0.11	Blood osmolality (transformed sodium);	chr2:161884073	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.605	rs62188795	ENSG00000227403.1	AC009299.3	3.47	0.00054	0.0263	0.26	0.11	Blood osmolality (transformed sodium);	chr2:161884497	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.605	rs62188796	ENSG00000227403.1	AC009299.3	3.47	0.00054	0.0263	0.26	0.11	Blood osmolality (transformed sodium);	chr2:161884652	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.605	rs72881073	ENSG00000227403.1	AC009299.3	3.47	0.00054	0.0263	0.26	0.11	Blood osmolality (transformed sodium);	chr2:161885247	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.605	rs62188798	ENSG00000227403.1	AC009299.3	3.47	0.00054	0.0263	0.26	0.11	Blood osmolality (transformed sodium);	chr2:161886388	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.605	rs72865206	ENSG00000227403.1	AC009299.3	3.47	0.00054	0.0263	0.26	0.11	Blood osmolality (transformed sodium);	chr2:161886752	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.502	rs115848314	ENSG00000227403.1	AC009299.3	3.47	0.00054	0.0263	0.26	0.11	Blood osmolality (transformed sodium);	chr2:161888991	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.605	rs58909484	ENSG00000227403.1	AC009299.3	3.47	0.00054	0.0263	0.26	0.11	Blood osmolality (transformed sodium);	chr2:161891599	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.605	rs62188810	ENSG00000227403.1	AC009299.3	3.47	0.00054	0.0263	0.26	0.11	Blood osmolality (transformed sodium);	chr2:161892568	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.605	rs72865220	ENSG00000227403.1	AC009299.3	3.47	0.00054	0.0263	0.26	0.11	Blood osmolality (transformed sodium);	chr2:161893161	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.605	rs62188811	ENSG00000227403.1	AC009299.3	3.47	0.00054	0.0263	0.26	0.11	Blood osmolality (transformed sodium);	chr2:161893795	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.539	rs1343883	ENSG00000227403.1	AC009299.3	3.47	0.00054	0.0263	0.26	0.11	Blood osmolality (transformed sodium);	chr2:161894164	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.605	rs4146952	ENSG00000227403.1	AC009299.3	3.47	0.00054	0.0263	0.26	0.11	Blood osmolality (transformed sodium);	chr2:161897136	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.605	rs62188816	ENSG00000227403.1	AC009299.3	3.47	0.00054	0.0263	0.26	0.11	Blood osmolality (transformed sodium);	chr2:161897645	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.605	rs62188817	ENSG00000227403.1	AC009299.3	3.47	0.00054	0.0263	0.26	0.11	Blood osmolality (transformed sodium);	chr2:161897715	chr2:161244739~161249050:+
BRCA	cis	rs10043775	0.75	rs4705249	ENSG00000251330.3	CTD-2283N19.1	-3.47	0.00054	0.0263	-0.12	-0.11	Periodontal microbiota;	chr5:148309451	chr5:148430159~148430807:-
BRCA	cis	rs11866815	0.557	rs12599449	ENSG00000260807.5	RP11-161M6.2	-3.47	0.00054	0.0263	-0.17	-0.11	Body mass index;	chr16:347269	chr16:975761~981596:-
BRCA	cis	rs4699052	0.507	rs6533085	ENSG00000248740.4	RP11-328K4.1	3.47	0.00054	0.0263	0.13	0.11	Testicular germ cell tumor;	chr4:103360429	chr4:103256159~103453658:+
BRCA	cis	rs6545883	0.929	rs778140	ENSG00000273302.1	RP11-493E12.2	3.47	0.00054	0.0263	0.1	0.11	Tuberculosis;	chr2:61455841	chr2:61199979~61200769:+
BRCA	cis	rs2562456	0.793	rs7259396	ENSG00000268117.1	VN1R84P	3.47	0.00054	0.0263	0.16	0.11	Pain;	chr19:21340661	chr19:21719801~21720035:-
BRCA	cis	rs2562456	0.678	rs7260140	ENSG00000268117.1	VN1R84P	3.47	0.00054	0.0263	0.16	0.11	Pain;	chr19:21340723	chr19:21719801~21720035:-
BRCA	cis	rs2562456	0.833	rs11880624	ENSG00000268117.1	VN1R84P	3.47	0.00054	0.0263	0.16	0.11	Pain;	chr19:21341028	chr19:21719801~21720035:-
BRCA	cis	rs1009077	0.61	rs6822275	ENSG00000245958.5	RP11-33B1.1	-3.47	0.00054	0.0263	-0.12	-0.11	Endometriosis;	chr4:119588472	chr4:119454791~119552025:+
BRCA	cis	rs2301573	1	rs10934887	ENSG00000239437.3	RN7SL752P	3.47	0.00054	0.0263	0.2	0.11	Hip circumference;	chr3:129585463	chr3:129591349~129591635:+
BRCA	cis	rs875971	0.522	rs4718286	ENSG00000229180.5	GS1-124K5.11	3.47	0.00054	0.0263	0.09	0.11	Aortic root size;	chr7:65827777	chr7:66526088~66542624:-
BRCA	cis	rs17711722	0.585	rs6942660	ENSG00000229180.5	GS1-124K5.11	3.47	0.00054	0.0263	0.09	0.11	Calcium levels;	chr7:65837419	chr7:66526088~66542624:-
BRCA	cis	rs1348850	0.526	rs6723014	ENSG00000271825.1	RP11-337N6.2	3.47	0.00054	0.0263	0.18	0.11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177545858	chr2:177300600~177302006:+
BRCA	cis	rs113835537	0.529	rs75003264	ENSG00000214659.4	KRT8P26	3.47	0.00054	0.0263	0.16	0.11	Airway imaging phenotypes;	chr11:66488628	chr11:65726939~65728214:+
BRCA	cis	rs801193	0.527	rs2707837	ENSG00000271064.1	RP11-792A8.3	-3.47	0.00054	0.0263	-0.13	-0.11	Aortic root size;	chr7:66716086	chr7:66748838~66749077:-
BRCA	cis	rs5758511	0.773	rs73165164	ENSG00000233903.2	Z83851.4	3.47	0.00054	0.0263	0.16	0.11	Birth weight;	chr22:41959545	chr22:42276355~42277052:+
BRCA	cis	rs2811415	0.597	rs9821500	ENSG00000242551.2	POU5F1P6	3.47	0.00054	0.0263	0.15	0.11	Lung function (FEV1/FVC);	chr3:128016086	chr3:128674735~128677005:-
BRCA	cis	rs881375	0.967	rs10739579	ENSG00000238181.2	AHCYP2	-3.47	0.00054	0.0263	-0.13	-0.11	Rheumatoid arthritis;	chr9:120932510	chr9:120720673~120721972:+
BRCA	cis	rs2235682	0.862	rs9622424	ENSG00000237668.1	RPS15AP38	3.47	0.00054	0.0263	0.12	0.11	Airway responsiveness in chronic obstructive pulmonary disease;	chr22:36588260	chr22:36421273~36421644:-
BRCA	cis	rs2400362	0.838	rs2028814	ENSG00000260317.1	RP11-48B3.4	3.47	0.00054	0.0263	0.14	0.11	Glucocorticoid-induced osteonecrosis (age 10 years and older);	chr8:80958616	chr8:80541300~80543104:+
BRCA	cis	rs2333021	0.934	rs4903092	ENSG00000258408.1	NT5CP2	3.47	0.00054	0.0263	0.11	0.11	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:73013017	chr14:73539221~73539781:-
BRCA	cis	rs28489187	0.706	rs233099	ENSG00000223653.4	RP11-131L23.1	3.47	0.00054	0.0263	0.12	0.11	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85360511	chr1:85276715~85448124:+
BRCA	cis	rs9307551	0.741	rs10025630	ENSG00000250334.4	LINC00989	-3.47	0.00054	0.0263	-0.17	-0.11	Refractive error;	chr4:79551641	chr4:79492416~79576460:+
BRCA	cis	rs9788721	0.836	rs2568494	ENSG00000261762.1	RP11-650L12.2	-3.47	0.00054	0.0263	-0.12	-0.11	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78448622	chr15:78589123~78591276:-
BRCA	cis	rs7267979	0.933	rs2424708	ENSG00000274973.1	RP13-401N8.7	-3.47	0.00054	0.0263	-0.12	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25300762	chr20:25845497~25845862:+
BRCA	cis	rs10202231	0.781	rs9309322	ENSG00000237522.1	NONOP2	-3.47	0.00054	0.0263	-0.1	-0.11	Response to antipsychotic treatment;	chr2:60214049	chr2:60936819~60938049:-
BRCA	cis	rs17597773	0.635	rs1494368	ENSG00000257551.1	HLX-AS1	-3.47	0.00054	0.0263	-0.13	-0.11	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220830826	chr1:220832763~220880140:-
BRCA	cis	rs7267979	1	rs7267979	ENSG00000274414.1	RP5-965G21.4	-3.47	0.00054	0.0263	-0.13	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25317451	chr20:25239007~25245229:-
BRCA	cis	rs4578769	0.959	rs9955664	ENSG00000273232.1	RP11-370A5.2	3.47	0.000541	0.0263	0.14	0.11	Eosinophil percentage of white cells;	chr18:22901330	chr18:22882825~22883357:-
BRCA	cis	rs13401620	0.871	rs12464639	ENSG00000229326.3	AC069154.4	-3.47	0.000541	0.0263	-0.14	-0.11	Breast size;	chr2:119909451	chr2:119698623~119700151:+
BRCA	cis	rs875971	0.862	rs6944374	ENSG00000223473.2	GS1-124K5.3	-3.47	0.000541	0.0263	-0.08	-0.11	Aortic root size;	chr7:66221942	chr7:66491049~66493566:-
BRCA	cis	rs4388249	1	rs2301000	ENSG00000249068.1	CTC-287O8.1	3.47	0.000541	0.0263	0.15	0.11	Schizophrenia;	chr5:109751735	chr5:109840128~109840692:-
BRCA	cis	rs4388249	0.95	rs724214	ENSG00000249068.1	CTC-287O8.1	3.47	0.000541	0.0263	0.15	0.11	Schizophrenia;	chr5:109752655	chr5:109840128~109840692:-
BRCA	cis	rs875971	1	rs7789554	ENSG00000272831.1	RP11-792A8.4	3.47	0.000541	0.0263	0.1	0.11	Aortic root size;	chr7:66481051	chr7:66739829~66740385:-
BRCA	cis	rs875971	1	rs4717300	ENSG00000272831.1	RP11-792A8.4	3.47	0.000541	0.0263	0.1	0.11	Aortic root size;	chr7:66482393	chr7:66739829~66740385:-
BRCA	cis	rs875971	0.895	rs1974769	ENSG00000272831.1	RP11-792A8.4	3.47	0.000541	0.0263	0.1	0.11	Aortic root size;	chr7:66485627	chr7:66739829~66740385:-
BRCA	cis	rs875971	0.895	rs6460300	ENSG00000272831.1	RP11-792A8.4	3.47	0.000541	0.0263	0.1	0.11	Aortic root size;	chr7:66487937	chr7:66739829~66740385:-
BRCA	cis	rs875971	0.862	rs7803416	ENSG00000272831.1	RP11-792A8.4	3.47	0.000541	0.0263	0.1	0.11	Aortic root size;	chr7:66489212	chr7:66739829~66740385:-
BRCA	cis	rs875971	0.964	rs2277911	ENSG00000272831.1	RP11-792A8.4	3.47	0.000541	0.0263	0.1	0.11	Aortic root size;	chr7:66493638	chr7:66739829~66740385:-
BRCA	cis	rs17092148	0.887	rs6058104	ENSG00000250917.1	RP4-785G19.5	3.47	0.000541	0.0263	0.18	0.11	Neuroticism;	chr20:34683248	chr20:34234840~34281173:-
BRCA	cis	rs250585	1	rs4968013	ENSG00000280039.1	CTD-2270L9.3	-3.47	0.000541	0.0263	-0.12	-0.11	Egg allergy;	chr16:23501271	chr16:23412380~23416680:+
BRCA	cis	rs12474201	0.894	rs34401107	ENSG00000279254.1	RP11-536C12.1	-3.47	0.000541	0.0263	-0.13	-0.11	Height;	chr2:46745629	chr2:46668870~46670778:+
BRCA	cis	rs35520189	0.796	rs1143627	ENSG00000274877.1	RP11-65I12.1	3.47	0.000541	0.0263	0.14	0.11	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:112836810	chr2:113237595~113240825:+
BRCA	cis	rs1670533	1	rs6852155	ENSG00000251639.2	RP11-20I20.1	3.47	0.000541	0.0263	0.17	0.11	Recombination rate (females);	chr4:1073850	chr4:1100016~1101558:-
BRCA	cis	rs10761482	0.861	rs1814117	ENSG00000254271.1	RP11-131N11.4	3.47	0.000541	0.0263	0.15	0.11	Schizophrenia;	chr10:60340139	chr10:60734342~60741828:+
BRCA	cis	rs10761482	0.861	rs2893830	ENSG00000254271.1	RP11-131N11.4	3.47	0.000541	0.0263	0.15	0.11	Schizophrenia;	chr10:60340187	chr10:60734342~60741828:+
BRCA	cis	rs9650657	0.589	rs6985109	ENSG00000255020.1	AF131216.5	-3.47	0.000541	0.0263	-0.12	-0.11	Neuroticism;	chr8:10904075	chr8:11345748~11347502:-
BRCA	cis	rs12496230	0.794	rs7638057	ENSG00000272610.1	MAGI1-IT1	-3.47	0.000541	0.0263	-0.13	-0.11	Type 2 diabetes;	chr3:66812294	chr3:65872815~65954558:-
BRCA	cis	rs12496230	0.794	rs7645370	ENSG00000272610.1	MAGI1-IT1	-3.47	0.000541	0.0263	-0.13	-0.11	Type 2 diabetes;	chr3:66812469	chr3:65872815~65954558:-
BRCA	cis	rs12496230	0.794	rs7642618	ENSG00000272610.1	MAGI1-IT1	-3.47	0.000541	0.0263	-0.13	-0.11	Type 2 diabetes;	chr3:66812578	chr3:65872815~65954558:-
BRCA	cis	rs9816784	0.525	rs41301371	ENSG00000207650.1	MIR570	3.47	0.000541	0.0263	0.13	0.11	Mean corpuscular hemoglobin;	chr3:196072696	chr3:195699401~195699497:+
BRCA	cis	rs10771431	0.597	rs10843142	ENSG00000214776.8	RP11-726G1.1	-3.47	0.000541	0.0263	-0.12	-0.11	Breast size;	chr12:9204906	chr12:9467552~9576275:+
BRCA	cis	rs977987	0.806	rs766521	ENSG00000280152.1	RP11-331F4.5	3.47	0.000541	0.0263	0.11	0.11	Dupuytren's disease;	chr16:75390256	chr16:75245994~75250077:-
BRCA	cis	rs72615157	0.716	rs75779608	ENSG00000214313.7	AZGP1P1	-3.47	0.000541	0.0263	-0.14	-0.11	Lung function (FEV1/FVC);	chr7:100171334	chr7:99980762~99987535:+
BRCA	cis	rs11031096	0.738	rs9937	ENSG00000224513.2	AC109309.4	-3.47	0.000541	0.0263	-0.13	-0.11	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr11:4138227	chr11:3226061~3232838:+
BRCA	cis	rs17221829	0.626	rs10830305	ENSG00000280385.1	AP000648.5	-3.47	0.000541	0.0263	-0.12	-0.11	Anxiety in major depressive disorder;	chr11:89633626	chr11:90193614~90198120:+
BRCA	cis	rs17221829	0.562	rs10830306	ENSG00000280385.1	AP000648.5	-3.47	0.000541	0.0263	-0.12	-0.11	Anxiety in major depressive disorder;	chr11:89633811	chr11:90193614~90198120:+
BRCA	cis	rs17221829	0.733	rs11018689	ENSG00000280385.1	AP000648.5	-3.47	0.000541	0.0263	-0.12	-0.11	Anxiety in major depressive disorder;	chr11:89634623	chr11:90193614~90198120:+
BRCA	cis	rs17221829	0.673	rs4753228	ENSG00000280385.1	AP000648.5	-3.47	0.000541	0.0263	-0.12	-0.11	Anxiety in major depressive disorder;	chr11:89635989	chr11:90193614~90198120:+
BRCA	cis	rs17221829	0.733	rs12363392	ENSG00000280385.1	AP000648.5	-3.47	0.000541	0.0263	-0.12	-0.11	Anxiety in major depressive disorder;	chr11:89637430	chr11:90193614~90198120:+
BRCA	cis	rs17221829	0.733	rs10765222	ENSG00000280385.1	AP000648.5	-3.47	0.000541	0.0263	-0.12	-0.11	Anxiety in major depressive disorder;	chr11:89638941	chr11:90193614~90198120:+
BRCA	cis	rs17221829	0.733	rs7942295	ENSG00000280385.1	AP000648.5	-3.47	0.000541	0.0263	-0.12	-0.11	Anxiety in major depressive disorder;	chr11:89639173	chr11:90193614~90198120:+
BRCA	cis	rs17221829	0.733	rs7945304	ENSG00000280385.1	AP000648.5	-3.47	0.000541	0.0263	-0.12	-0.11	Anxiety in major depressive disorder;	chr11:89639356	chr11:90193614~90198120:+
BRCA	cis	rs17221829	0.703	rs17818747	ENSG00000280385.1	AP000648.5	-3.47	0.000541	0.0263	-0.12	-0.11	Anxiety in major depressive disorder;	chr11:89640522	chr11:90193614~90198120:+
BRCA	cis	rs17221829	0.673	rs12364712	ENSG00000280385.1	AP000648.5	-3.47	0.000541	0.0263	-0.12	-0.11	Anxiety in major depressive disorder;	chr11:89640679	chr11:90193614~90198120:+
BRCA	cis	rs17221829	0.645	rs4002142	ENSG00000280385.1	AP000648.5	-3.47	0.000541	0.0263	-0.12	-0.11	Anxiety in major depressive disorder;	chr11:89640845	chr11:90193614~90198120:+
BRCA	cis	rs17221829	0.668	rs12364732	ENSG00000280385.1	AP000648.5	-3.47	0.000541	0.0263	-0.12	-0.11	Anxiety in major depressive disorder;	chr11:89640886	chr11:90193614~90198120:+
BRCA	cis	rs17221829	0.614	rs2388202	ENSG00000280385.1	AP000648.5	-3.47	0.000541	0.0263	-0.12	-0.11	Anxiety in major depressive disorder;	chr11:89641063	chr11:90193614~90198120:+
BRCA	cis	rs17221829	0.528	rs4561217	ENSG00000280385.1	AP000648.5	-3.47	0.000541	0.0263	-0.12	-0.11	Anxiety in major depressive disorder;	chr11:89642097	chr11:90193614~90198120:+
BRCA	cis	rs17221829	0.627	rs10830315	ENSG00000280385.1	AP000648.5	-3.47	0.000541	0.0263	-0.12	-0.11	Anxiety in major depressive disorder;	chr11:89642406	chr11:90193614~90198120:+
BRCA	cis	rs17221829	0.525	rs9804670	ENSG00000280385.1	AP000648.5	-3.47	0.000541	0.0263	-0.12	-0.11	Anxiety in major depressive disorder;	chr11:89642633	chr11:90193614~90198120:+
BRCA	cis	rs17221829	0.645	rs9804648	ENSG00000280385.1	AP000648.5	-3.47	0.000541	0.0263	-0.12	-0.11	Anxiety in major depressive disorder;	chr11:89642672	chr11:90193614~90198120:+
BRCA	cis	rs17221829	0.733	rs1844199	ENSG00000280385.1	AP000648.5	-3.47	0.000541	0.0263	-0.12	-0.11	Anxiety in major depressive disorder;	chr11:89643200	chr11:90193614~90198120:+
BRCA	cis	rs17221829	0.589	rs7930747	ENSG00000280385.1	AP000648.5	-3.47	0.000541	0.0263	-0.12	-0.11	Anxiety in major depressive disorder;	chr11:89643992	chr11:90193614~90198120:+
BRCA	cis	rs17221829	0.703	rs7944552	ENSG00000280385.1	AP000648.5	-3.47	0.000541	0.0263	-0.12	-0.11	Anxiety in major depressive disorder;	chr11:89644040	chr11:90193614~90198120:+
BRCA	cis	rs34792	0.554	rs12919246	ENSG00000275910.1	RP11-680G24.6	-3.47	0.000541	0.0263	-0.13	-0.11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15533103	chr16:15015828~15016390:-
BRCA	cis	rs8114671	0.836	rs2425012	ENSG00000261582.1	RP4-614O4.11	3.47	0.000541	0.0263	0.1	0.11	Height;	chr20:34994152	chr20:35267885~35280043:-
BRCA	cis	rs4243971	0.516	rs6141664	ENSG00000277692.1	RP11-358N2.2	-3.47	0.000541	0.0263	-0.12	-0.11	Inflammatory bowel disease;Crohn's disease;	chr20:32300565	chr20:32355053~32355734:+
BRCA	cis	rs72772090	0.539	rs11750464	ENSG00000272109.1	CTD-2260A17.3	-3.47	0.000541	0.0263	-0.2	-0.11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96777327	chr5:96804353~96806105:+
BRCA	cis	rs737008	1	rs737008	ENSG00000262636.1	CTD-3088G3.4	-3.47	0.000541	0.0263	-0.15	-0.11	Obesity-related traits;	chr16:11281009	chr16:11380859~11381118:-
BRCA	cis	rs11098499	0.739	rs4833612	ENSG00000249244.1	RP11-548H18.2	-3.47	0.000541	0.0263	-0.13	-0.11	Corneal astigmatism;	chr4:119226441	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.739	rs10013032	ENSG00000249244.1	RP11-548H18.2	-3.47	0.000541	0.0263	-0.13	-0.11	Corneal astigmatism;	chr4:119228264	chr4:119391831~119395335:-
BRCA	cis	rs16846053	0.605	rs62188807	ENSG00000227403.1	AC009299.3	3.47	0.000541	0.0263	0.26	0.11	Blood osmolality (transformed sodium);	chr2:161889698	chr2:161244739~161249050:+
BRCA	cis	rs9329221	0.736	rs34381075	ENSG00000154316.13	TDH	-3.47	0.000541	0.0263	-0.14	-0.11	Neuroticism;	chr8:10386275	chr8:11339637~11368452:+
BRCA	cis	rs10129255	0.5	rs6576225	ENSG00000211976.2	IGHV3-73	-3.47	0.000542	0.0263	-0.08	-0.11	Kawasaki disease;	chr14:106778120	chr14:106802694~106803233:-
BRCA	cis	rs10129255	0.5	rs6576226	ENSG00000211976.2	IGHV3-73	-3.47	0.000542	0.0263	-0.08	-0.11	Kawasaki disease;	chr14:106778135	chr14:106802694~106803233:-
BRCA	cis	rs7707921	0.505	rs12516434	ENSG00000251374.1	RPS23P5	-3.47	0.000542	0.0263	-0.14	-0.11	Breast cancer;	chr5:82132253	chr5:82265157~82265259:-
BRCA	cis	rs4372836	0.543	rs10204329	ENSG00000226833.4	AC097724.3	3.47	0.000542	0.0263	0.13	0.11	Body mass index;	chr2:28775211	chr2:28708953~28736205:-
BRCA	cis	rs10761482	0.861	rs2061490	ENSG00000254271.1	RP11-131N11.4	3.47	0.000542	0.0263	0.15	0.11	Schizophrenia;	chr10:60343904	chr10:60734342~60741828:+
BRCA	cis	rs10761482	0.861	rs2061491	ENSG00000254271.1	RP11-131N11.4	3.47	0.000542	0.0263	0.15	0.11	Schizophrenia;	chr10:60343917	chr10:60734342~60741828:+
BRCA	cis	rs11992162	1	rs7460395	ENSG00000254866.2	DEFB109P3	-3.47	0.000542	0.0263	-0.14	-0.11	Monocyte count;	chr8:11977866	chr8:12150895~12151134:-
BRCA	cis	rs875971	1	rs778696	ENSG00000273024.4	INTS4P2	-3.47	0.000542	0.0263	-0.12	-0.11	Aortic root size;	chr7:66405826	chr7:65647864~65715661:+
BRCA	cis	rs875971	1	rs778694	ENSG00000273024.4	INTS4P2	-3.47	0.000542	0.0263	-0.12	-0.11	Aortic root size;	chr7:66406571	chr7:65647864~65715661:+
BRCA	cis	rs875971	1	rs4718344	ENSG00000273024.4	INTS4P2	-3.47	0.000542	0.0263	-0.12	-0.11	Aortic root size;	chr7:66409394	chr7:65647864~65715661:+
BRCA	cis	rs875971	0.737	rs7803424	ENSG00000273024.4	INTS4P2	-3.47	0.000542	0.0263	-0.12	-0.11	Aortic root size;	chr7:66415618	chr7:65647864~65715661:+
BRCA	cis	rs875971	0.83	rs7799834	ENSG00000273024.4	INTS4P2	-3.47	0.000542	0.0263	-0.12	-0.11	Aortic root size;	chr7:66415707	chr7:65647864~65715661:+
BRCA	cis	rs875971	0.756	rs4718328	ENSG00000229886.1	RP5-1132H15.3	-3.47	0.000542	0.0263	-0.12	-0.11	Aortic root size;	chr7:66228350	chr7:66025126~66031544:-
BRCA	cis	rs1421334	0.679	rs2160935	ENSG00000254109.4	RBPMS-AS1	-3.47	0.000542	0.0264	-0.15	-0.11	Intelligence (multi-trait analysis);	chr8:30983135	chr8:30382119~30385401:-
BRCA	cis	rs11673344	0.704	rs1667384	ENSG00000267422.1	CTD-2554C21.1	3.47	0.000542	0.0264	0.14	0.11	Obesity-related traits;	chr19:36925852	chr19:37779686~37792865:+
BRCA	cis	rs4699052	0.893	rs4699058	ENSG00000246560.2	RP11-10L12.4	3.47	0.000542	0.0264	0.11	0.11	Testicular germ cell tumor;	chr4:103250164	chr4:102828055~102844075:+
BRCA	cis	rs7520050	0.902	rs4638056	ENSG00000281133.1	AL355480.3	3.47	0.000542	0.0264	0.12	0.11	Reticulocyte count;Red blood cell count;	chr1:45992481	chr1:45580892~45580996:-
BRCA	cis	rs7520050	0.931	rs11576305	ENSG00000281133.1	AL355480.3	3.47	0.000542	0.0264	0.12	0.11	Reticulocyte count;Red blood cell count;	chr1:45994374	chr1:45580892~45580996:-
BRCA	cis	rs2638953	0.925	rs11049598	ENSG00000273989.1	RP11-425D17.2	-3.47	0.000542	0.0264	-0.16	-0.11	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28436160	chr12:28236227~28236828:+
BRCA	cis	rs990171	0.538	rs7591872	ENSG00000234389.1	AC007278.3	3.47	0.000542	0.0264	0.11	0.11	Lymphocyte counts;	chr2:102496182	chr2:102438713~102440475:+
BRCA	cis	rs7131987	0.903	rs11050152	ENSG00000257176.2	RP11-996F15.2	-3.47	0.000542	0.0264	-0.13	-0.11	QT interval;	chr12:29251491	chr12:29280418~29317848:-
BRCA	cis	rs3743102	0.527	rs117959961	ENSG00000259429.4	UBE2Q2P2	3.47	0.000542	0.0264	0.16	0.11	Colorectal adenoma (advanced);	chr15:82671143	chr15:82355142~82420075:+
BRCA	cis	rs6500602	0.826	rs11076830	ENSG00000280063.1	RP11-295D4.3	3.47	0.000542	0.0264	0.09	0.11	Schizophrenia;	chr16:4410048	chr16:4346694~4348648:-
BRCA	cis	rs709400	0.628	rs4906321	ENSG00000260285.1	RP11-600F24.7	3.47	0.000542	0.0264	0.1	0.11	Body mass index;	chr14:103412545	chr14:103525010~103529072:-
BRCA	cis	rs11098499	0.913	rs67073020	ENSG00000260404.2	RP11-384K6.6	3.47	0.000542	0.0264	0.1	0.11	Corneal astigmatism;	chr4:119231402	chr4:118591773~118633729:+
BRCA	cis	rs11673344	0.642	rs12462487	ENSG00000267422.1	CTD-2554C21.1	3.47	0.000542	0.0264	0.14	0.11	Obesity-related traits;	chr19:37311211	chr19:37779686~37792865:+
BRCA	cis	rs2657888	0.628	rs2638285	ENSG00000257576.1	RP11-153M3.1	3.47	0.000542	0.0264	0.13	0.11	Adiponectin levels;	chr12:56492577	chr12:56511002~56512703:+
BRCA	cis	rs10129255	0.957	rs8009073	ENSG00000211958.2	IGHV3-38	3.47	0.000542	0.0264	0.08	0.11	Kawasaki disease;	chr14:106777278	chr14:106410493~106411021:-
BRCA	cis	rs881375	0.933	rs7031096	ENSG00000238181.2	AHCYP2	-3.47	0.000542	0.0264	-0.13	-0.11	Rheumatoid arthritis;	chr9:120932664	chr9:120720673~120721972:+
BRCA	cis	rs881375	0.967	rs10739580	ENSG00000238181.2	AHCYP2	-3.47	0.000542	0.0264	-0.13	-0.11	Rheumatoid arthritis;	chr9:120933004	chr9:120720673~120721972:+
BRCA	cis	rs4622329	0.636	rs7974969	ENSG00000257202.1	RP11-512N21.3	3.47	0.000542	0.0264	0.12	0.11	Systemic lupus erythematosus;	chr12:101894645	chr12:101923410~101924719:-
BRCA	cis	rs259282	0.562	rs2021772	ENSG00000267475.1	CTD-2538C1.2	3.47	0.000542	0.0264	0.13	0.11	Schizophrenia;	chr19:32616745	chr19:32687089~32691750:-
BRCA	cis	rs10819861	0.547	rs10760781	ENSG00000175611.10	LINC00476	3.47	0.000542	0.0264	0.12	0.11	Electrocardiographic traits;	chr9:96110549	chr9:95759231~95875977:-
BRCA	cis	rs1443512	0.812	rs2044210	ENSG00000228630.4	HOTAIR	-3.47	0.000542	0.0264	-0.13	-0.11	Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-hip ratio;Waist-to-hip ratio adjusted for body mass index;	chr12:53941749	chr12:53962308~53974956:-
BRCA	cis	rs886427	0.517	rs12918697	ENSG00000262959.2	LA16c-321D4.1	3.47	0.000542	0.0264	0.15	0.11	Metabolic syndrome;	chr16:2952850	chr16:2922662~2923202:-
BRCA	cis	rs4787491	0.704	rs35605010	ENSG00000275371.1	RP11-455F5.6	-3.47	0.000542	0.0264	-0.1	-0.11	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30022107	chr16:30110895~30111955:+
BRCA	cis	rs4687718	0.528	rs10510763	ENSG00000274967.1	Y_RNA	-3.47	0.000542	0.0264	-0.15	-0.11	QRS duration;	chr3:53363454	chr3:53290640~53290751:+
BRCA	cis	rs524281	0.861	rs7946917	ENSG00000255038.1	RP11-1167A19.2	-3.47	0.000543	0.0264	-0.15	-0.11	Electroencephalogram traits;	chr11:66189106	chr11:66067277~66069619:-
BRCA	cis	rs524281	0.861	rs10896094	ENSG00000255038.1	RP11-1167A19.2	-3.47	0.000543	0.0264	-0.15	-0.11	Electroencephalogram traits;	chr11:66191735	chr11:66067277~66069619:-
BRCA	cis	rs1424638	0.61	rs11903900	ENSG00000233251.6	AC007743.1	-3.47	0.000543	0.0264	-0.13	-0.11	Intelligence (multi-trait analysis);	chr2:57001264	chr2:56173534~56185770:-
BRCA	cis	rs957448	1	rs7829886	ENSG00000261437.1	RP11-22C11.2	3.47	0.000543	0.0264	0.11	0.11	Nonsyndromic cleft lip with cleft palate;	chr8:94485160	chr8:94637285~94639467:-
BRCA	cis	rs4886920	0.862	rs4886531	ENSG00000260776.4	RP11-114H24.2	-3.47	0.000543	0.0264	-0.13	-0.11	Neuroticism;	chr15:77852400	chr15:77914217~77926846:-
BRCA	cis	rs9921338	0.636	rs56069754	ENSG00000262636.1	CTD-3088G3.4	-3.47	0.000543	0.0264	-0.17	-0.11	Vein graft stenosis in coronary artery bypass grafting;	chr16:11268783	chr16:11380859~11381118:-
BRCA	cis	rs1424638	0.639	rs1808569	ENSG00000233251.6	AC007743.1	-3.47	0.000543	0.0264	-0.13	-0.11	Intelligence (multi-trait analysis);	chr2:57022538	chr2:56173534~56185770:-
BRCA	cis	rs17221829	0.616	rs75627051	ENSG00000280385.1	AP000648.5	-3.47	0.000543	0.0264	-0.12	-0.11	Anxiety in major depressive disorder;	chr11:89627735	chr11:90193614~90198120:+
BRCA	cis	rs9905704	0.681	rs1468540	ENSG00000265148.4	BZRAP1-AS1	-3.47	0.000543	0.0264	-0.13	-0.11	Testicular germ cell tumor;	chr17:58484581	chr17:58325450~58415766:+
BRCA	cis	rs4835473	0.932	rs1993015	ENSG00000246448.2	RP13-578N3.3	-3.47	0.000543	0.0264	-0.12	-0.11	Immature fraction of reticulocytes;	chr4:143760202	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.9	rs1993016	ENSG00000246448.2	RP13-578N3.3	-3.47	0.000543	0.0264	-0.12	-0.11	Immature fraction of reticulocytes;	chr4:143760217	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.932	rs1993017	ENSG00000246448.2	RP13-578N3.3	-3.47	0.000543	0.0264	-0.12	-0.11	Immature fraction of reticulocytes;	chr4:143760285	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.9	rs1375983	ENSG00000246448.2	RP13-578N3.3	-3.47	0.000543	0.0264	-0.12	-0.11	Immature fraction of reticulocytes;	chr4:143760423	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.932	rs1375984	ENSG00000246448.2	RP13-578N3.3	-3.47	0.000543	0.0264	-0.12	-0.11	Immature fraction of reticulocytes;	chr4:143760510	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.932	rs1375985	ENSG00000246448.2	RP13-578N3.3	-3.47	0.000543	0.0264	-0.12	-0.11	Immature fraction of reticulocytes;	chr4:143760556	chr4:143700257~143865072:+
BRCA	cis	rs11039100	0.85	rs11039115	ENSG00000224295.2	AC087380.14	3.47	0.000543	0.0264	0.2	0.11	Peripheral arterial disease (traffic-related air pollution interaction);	chr11:5810149	chr11:5518441~5524955:-
BRCA	cis	rs11039100	0.85	rs11039116	ENSG00000224295.2	AC087380.14	3.47	0.000543	0.0264	0.2	0.11	Peripheral arterial disease (traffic-related air pollution interaction);	chr11:5810321	chr11:5518441~5524955:-
BRCA	cis	rs911119	0.913	rs6106685	ENSG00000270001.1	RP11-218C14.8	-3.47	0.000543	0.0264	-0.14	-0.11	Chronic kidney disease;	chr20:23600975	chr20:23631826~23632316:-
BRCA	cis	rs7577894	1	rs7577894	ENSG00000272606.1	RP11-554J4.1	-3.47	0.000543	0.0264	-0.12	-0.11	Amyotrophic lateral sclerosis;	chr2:55781769	chr2:55617909~55618373:+
BRCA	cis	rs10186876	0.965	rs11684838	ENSG00000223658.6	AC011242.6	-3.47	0.000543	0.0264	-0.13	-0.11	Hand grip strength;	chr2:44023016	chr2:43675380~43676322:-
BRCA	cis	rs6012564	0.893	rs6066909	ENSG00000230758.1	SNAP23P	3.47	0.000543	0.0264	0.13	0.11	Anger;	chr20:48913376	chr20:49038357~49038602:-
BRCA	cis	rs7917772	0.503	rs11191328	ENSG00000213061.2	PFN1P11	-3.47	0.000543	0.0264	-0.15	-0.11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;	chr10:102545428	chr10:102838011~102845473:-
BRCA	cis	rs2985334	1	rs2993715	ENSG00000237934.1	RP11-467D18.2	-3.47	0.000543	0.0264	-0.13	-0.11	Amyotrophic lateral sclerosis (sporadic);	chr1:29029538	chr1:29223933~29224816:+
BRCA	cis	rs58847541	0.584	rs56804846	ENSG00000243498.2	UBA52P5	-3.47	0.000543	0.0264	-0.21	-0.11	Breast cancer;	chr8:123568903	chr8:123236852~123237062:+
BRCA	cis	rs7267979	1	rs2482919	ENSG00000274414.1	RP5-965G21.4	3.47	0.000543	0.0264	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25319120	chr20:25239007~25245229:-
BRCA	cis	rs987724	0.515	rs6441101	ENSG00000244515.1	KRT18P34	-3.47	0.000543	0.0264	-0.16	-0.11	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156875409	chr3:157162663~157163932:-
BRCA	cis	rs1348850	0.519	rs1544002	ENSG00000280374.1	RP11-337N6.3	3.47	0.000543	0.0264	0.15	0.11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177664806	chr2:177317715~177318471:-
BRCA	cis	rs11642862	1	rs11642466	ENSG00000260082.1	RP11-2C24.5	-3.47	0.000543	0.0264	-0.2	-0.11	Tonsillectomy;	chr16:30770621	chr16:30821068~30822110:-
BRCA	cis	rs7590268	0.577	rs6715054	ENSG00000279873.2	LINC01126	3.47	0.000543	0.0264	0.12	0.11	Orofacial clefts;	chr2:43396893	chr2:43227210~43228855:+
BRCA	cis	rs13136331	0.684	rs1903798	ENSG00000249001.4	RP11-742B18.1	-3.47	0.000543	0.0264	-0.15	-0.11	Sitting height ratio;	chr4:87798866	chr4:87568035~87733956:-
BRCA	cis	rs863345	0.604	rs1578763	ENSG00000176320.2	RP11-404O13.5	-3.47	0.000543	0.0264	-0.11	-0.11	Pneumococcal bacteremia;	chr1:158527624	chr1:158197922~158203877:-
BRCA	cis	rs863345	0.604	rs1578762	ENSG00000176320.2	RP11-404O13.5	-3.47	0.000543	0.0264	-0.11	-0.11	Pneumococcal bacteremia;	chr1:158527650	chr1:158197922~158203877:-
BRCA	cis	rs80226907	1	rs41299199	ENSG00000258413.1	RP11-665C16.6	-3.47	0.000543	0.0264	-0.28	-0.11	Mean platelet volume;	chr14:55369272	chr14:55262767~55272075:-
BRCA	cis	rs875971	0.516	rs6945322	ENSG00000232546.1	RP11-458F8.1	-3.47	0.000543	0.0264	-0.09	-0.11	Aortic root size;	chr7:65871069	chr7:66848496~66858136:+
BRCA	cis	rs2425143	0.908	rs6060491	ENSG00000088340.14	FER1L4	3.47	0.000543	0.0264	0.15	0.11	Blood protein levels;	chr20:35587178	chr20:35558737~35607562:-
BRCA	cis	rs6141600	0.526	rs73101486	ENSG00000278035.1	RP11-234K24.6	3.47	0.000543	0.0264	0.15	0.11	Height;Hip circumference;	chr20:36172015	chr20:36233851~36234297:+
BRCA	cis	rs11662721	0.938	rs3017643	ENSG00000264188.1	RP11-13N13.5	3.47	0.000543	0.0264	0.14	0.11	Phospholipid levels (plasma);	chr18:21625180	chr18:21661787~21662395:-
BRCA	cis	rs13126694	0.744	rs7682867	ENSG00000251073.1	NUDT19P5	3.47	0.000543	0.0264	0.1	0.11	Blood osmolality (transformed sodium);	chr4:158026735	chr4:158182825~158183393:+
BRCA	cis	rs10782582	0.532	rs78106188	ENSG00000181227.3	RP4-682C21.2	3.47	0.000543	0.0264	0.11	0.11	Daytime sleep phenotypes;	chr1:75672151	chr1:75743423~75744776:-
BRCA	cis	rs10826995	0.808	rs211307	ENSG00000228816.1	AK3P5	3.47	0.000543	0.0264	0.15	0.11	Pulse pressure;	chr10:32060310	chr10:32944481~32944999:+
BRCA	cis	rs80028505	0.908	rs79062678	ENSG00000271304.1	DPRXP2	3.47	0.000543	0.0264	0.2	0.11	Foot ulcer in diabetes and neuropathy;	chr6:36090426	chr6:35989515~35990436:-
BRCA	cis	rs4415084	0.716	rs4596389	ENSG00000272335.1	RP11-53O19.3	3.47	0.000543	0.0264	0.1	0.11	Breast cancer;	chr5:44836454	chr5:44826076~44828592:+
BRCA	cis	rs61869271	0.712	rs10885634	ENSG00000236799.1	RP11-383C6.2	-3.47	0.000544	0.0264	-0.13	-0.11	Tonsillectomy;	chr10:114940677	chr10:114994657~114996593:+
BRCA	cis	rs875971	0.964	rs12668936	ENSG00000272831.1	RP11-792A8.4	3.47	0.000544	0.0264	0.1	0.11	Aortic root size;	chr7:66449417	chr7:66739829~66740385:-
BRCA	cis	rs7267979	1	rs2482940	ENSG00000274414.1	RP5-965G21.4	3.47	0.000544	0.0264	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25369194	chr20:25239007~25245229:-
BRCA	cis	rs7221109	0.56	rs758630	ENSG00000224244.1	AC090283.3	-3.47	0.000544	0.0264	-0.12	-0.11	Type 1 diabetes;	chr17:40713053	chr17:40687038~40689360:-
BRCA	cis	rs890448	0.796	rs4574415	ENSG00000254531.1	FLJ20021	3.47	0.000544	0.0264	0.13	0.11	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101361276	chr4:101347780~101348883:+
BRCA	cis	rs7267979	1	rs6083828	ENSG00000204556.4	CTD-2514C3.1	3.47	0.000544	0.0264	0.14	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25389282	chr20:26018832~26020684:+
BRCA	cis	rs6427908	1	rs6427908	ENSG00000249007.1	RP11-510N19.5	-3.47	0.000544	0.0264	-0.16	-0.11	Itch intensity from mosquito bite adjusted by bite size;	chr1:201459957	chr1:202011370~202015657:+
BRCA	cis	rs7084921	0.608	rs11596211	ENSG00000233690.1	EBAG9P1	3.47	0.000544	0.0264	0.13	0.11	Bone mineral density;	chr10:100080362	chr10:99697407~99697949:-
BRCA	cis	rs7520050	0.933	rs4504835	ENSG00000281133.1	AL355480.3	3.47	0.000544	0.0264	0.12	0.11	Reticulocyte count;Red blood cell count;	chr1:45989899	chr1:45580892~45580996:-
BRCA	cis	rs890448	0.796	rs10433982	ENSG00000254531.1	FLJ20021	3.47	0.000544	0.0264	0.13	0.11	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101362741	chr4:101347780~101348883:+
BRCA	cis	rs300890	0.841	rs6840603	ENSG00000250326.1	RP11-284M14.1	-3.47	0.000544	0.0264	-0.12	-0.11	Nasopharyngeal carcinoma;	chr4:143306423	chr4:142933195~143184861:-
BRCA	cis	rs55675132	0.548	rs75634202	ENSG00000226167.1	AP4B1-AS1	3.47	0.000544	0.0264	0.11	0.11	Schizophrenia;	chr1:114832843	chr1:113856635~113901237:+
BRCA	cis	rs853679	0.542	rs9393892	ENSG00000226314.6	ZNF192P1	-3.47	0.000544	0.0264	-0.16	-0.11	Depression;	chr6:28113616	chr6:28161781~28169594:+
BRCA	cis	rs11671005	0.735	rs12986387	ENSG00000265272.2	RN7SL693P	3.47	0.000544	0.0264	0.15	0.11	Mean platelet volume;	chr19:58415848	chr19:58490797~58491075:+
BRCA	cis	rs11671005	0.735	rs11667723	ENSG00000265272.2	RN7SL693P	3.47	0.000544	0.0264	0.15	0.11	Mean platelet volume;	chr19:58416122	chr19:58490797~58491075:+
BRCA	cis	rs11671005	0.735	rs11668789	ENSG00000265272.2	RN7SL693P	3.47	0.000544	0.0264	0.15	0.11	Mean platelet volume;	chr19:58416942	chr19:58490797~58491075:+
BRCA	cis	rs2692947	0.77	rs2315417	ENSG00000237510.6	AC008268.2	3.47	0.000544	0.0264	0.14	0.11	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95834541	chr2:95789654~95800166:+
BRCA	cis	rs6545883	0.965	rs2305155	ENSG00000212978.6	AC016747.3	3.47	0.000544	0.0264	0.14	0.11	Tuberculosis;	chr2:61502123	chr2:61141592~61144969:-
BRCA	cis	rs8054556	1	rs3814880	ENSG00000214725.6	CDIPT-AS1	-3.47	0.000544	0.0264	-0.13	-0.11	Autism spectrum disorder or schizophrenia;	chr16:30006574	chr16:29863593~29868053:+
BRCA	cis	rs17301013	0.932	rs7542389	ENSG00000200674.1	RN7SKP160	3.47	0.000544	0.0264	0.14	0.11	Systemic lupus erythematosus;	chr1:174565104	chr1:173791548~173791887:+
BRCA	cis	rs324126	0.78	rs1993531	ENSG00000277977.1	CTD-3018O17.5	3.47	0.000544	0.0264	0.13	0.11	Colonoscopy-negative controls vs population controls;	chr19:52381633	chr19:52392659~52392755:+
BRCA	cis	rs4578769	0.765	rs9949825	ENSG00000273232.1	RP11-370A5.2	-3.47	0.000544	0.0264	-0.15	-0.11	Eosinophil percentage of white cells;	chr18:22806055	chr18:22882825~22883357:-
BRCA	cis	rs10958369	0.871	rs10958370	ENSG00000260484.1	RP11-1081M5.2	3.47	0.000544	0.0264	0.12	0.11	Response to antineoplastic agents;	chr8:53505150	chr8:53388701~53390872:-
BRCA	cis	rs7487075	0.619	rs6582657	ENSG00000273015.2	RP11-352M15.2	-3.47	0.000544	0.0264	-0.11	-0.11	Itch intensity from mosquito bite;	chr12:46462236	chr12:45718046~45727775:-
BRCA	cis	rs1865760	0.534	rs72834629	ENSG00000272462.2	U91328.19	-3.47	0.000544	0.0264	-0.14	-0.11	Height;	chr6:26022804	chr6:25992662~26001775:+
BRCA	cis	rs875971	1	rs2220626	ENSG00000271064.1	RP11-792A8.3	3.47	0.000544	0.0264	0.13	0.11	Aortic root size;	chr7:66081075	chr7:66748838~66749077:-
BRCA	cis	rs3892630	0.5	rs6510301	ENSG00000267475.1	CTD-2538C1.2	-3.47	0.000544	0.0265	-0.16	-0.11	Red blood cell traits;	chr19:32868885	chr19:32687089~32691750:-
BRCA	cis	rs7193541	0.684	rs4888262	ENSG00000262904.1	TMPOP2	-3.47	0.000544	0.0265	-0.11	-0.11	Multiple myeloma;	chr16:74636560	chr16:74667506~74668706:+
BRCA	cis	rs7308116	1	rs7964384	ENSG00000274395.1	RP11-554D14.8	-3.47	0.000544	0.0265	-0.12	-0.11	Pelvic organ prolapse (moderate/severe);	chr12:107804631	chr12:107835541~107836555:-
BRCA	cis	rs7308116	0.967	rs6539360	ENSG00000274395.1	RP11-554D14.8	-3.47	0.000544	0.0265	-0.12	-0.11	Pelvic organ prolapse (moderate/severe);	chr12:107804942	chr12:107835541~107836555:-
BRCA	cis	rs7520050	0.966	rs34102169	ENSG00000226957.1	RP4-533D7.4	3.47	0.000544	0.0265	0.12	0.11	Reticulocyte count;Red blood cell count;	chr1:45959192	chr1:46046818~46048368:+
BRCA	cis	rs9959145	1	rs78908311	ENSG00000267199.1	RP11-861E21.2	3.47	0.000544	0.0265	0.18	0.11	Immune response to smallpox vaccine (IL-6);	chr18:12688279	chr18:12438890~12448205:+
BRCA	cis	rs1823874	0.71	rs3919790	ENSG00000259363.4	CTD-2054N24.2	3.47	0.000544	0.0265	0.13	0.11	IgG glycosylation;	chr15:99821130	chr15:99807023~99877148:+
BRCA	cis	rs17192198	0.599	rs7957774	ENSG00000270344.2	RP11-734K2.4	-3.47	0.000544	0.0265	-0.12	-0.11	Diastolic blood pressure;	chr12:89754627	chr12:89525654~89548005:+
BRCA	cis	rs873549	1	rs2378519	ENSG00000238042.4	RP11-815M8.1	3.47	0.000544	0.0265	0.12	0.11	Keloid;	chr1:222100526	chr1:221880981~221978523:-
BRCA	cis	rs687432	0.688	rs7130381	ENSG00000265566.2	RN7SL605P	-3.47	0.000545	0.0265	-0.14	-0.11	Parkinson's disease;	chr11:58126971	chr11:57528085~57528365:-
BRCA	cis	rs9467773	1	rs1321481	ENSG00000261353.1	CTA-14H9.5	-3.47	0.000545	0.0265	-0.11	-0.11	Intelligence (multi-trait analysis);	chr6:26537982	chr6:26527063~26527404:+
BRCA	cis	rs9467773	1	rs4713008	ENSG00000261353.1	CTA-14H9.5	-3.47	0.000545	0.0265	-0.11	-0.11	Intelligence (multi-trait analysis);	chr6:26538040	chr6:26527063~26527404:+
BRCA	cis	rs4533720	0.569	rs13149496	ENSG00000248546.3	ANP32C	-3.47	0.000545	0.0265	-0.12	-0.11	Urinary uromodulin levels;	chr4:164030523	chr4:164197007~164197711:-
BRCA	cis	rs2135507	0.501	rs7657237	ENSG00000250057.1	RP11-576N17.5	-3.47	0.000545	0.0265	-0.16	-0.11	Juvenile osteochondritis dissecans;	chr4:82674085	chr4:83233512~83247213:-
BRCA	cis	rs9693857	0.518	rs35589912	ENSG00000233609.3	RP11-62H7.2	-3.47	0.000545	0.0265	-0.11	-0.11	Systolic blood pressure;	chr8:9420478	chr8:8961200~8979025:+
BRCA	cis	rs357394	0.901	rs11981141	ENSG00000243099.1	AC020983.5	3.47	0.000545	0.0265	0.19	0.11	Pulmonary function;	chr7:138399768	chr7:138688980~138689522:+
BRCA	cis	rs7176093	0.846	rs10163127	ENSG00000259295.5	CSPG4P12	-3.47	0.000545	0.0265	-0.13	-0.11	Aging traits;	chr15:85802077	chr15:85191438~85213905:+
BRCA	cis	rs6088590	0.648	rs6058105	ENSG00000269202.1	RP4-614O4.12	-3.47	0.000545	0.0265	-0.11	-0.11	Coronary artery disease;	chr20:34683915	chr20:35201747~35203288:-
BRCA	cis	rs944990	0.557	rs10821164	ENSG00000227603.1	RP11-165J3.6	3.47	0.000545	0.0265	0.11	0.11	Body mass index;	chr9:93584947	chr9:93435332~93437121:-
BRCA	cis	rs5742933	0.948	rs6434365	ENSG00000253559.1	OSGEPL1-AS1	-3.47	0.000545	0.0265	-0.15	-0.11	Ferritin levels;	chr2:189707695	chr2:189762704~189765556:+
BRCA	cis	rs6736093	1	rs4848861	ENSG00000243389.1	AC012442.5	3.47	0.000545	0.0265	0.15	0.11	Coronary artery disease;	chr2:111911258	chr2:112589040~112614431:+
BRCA	cis	rs9863	0.896	rs12824567	ENSG00000270028.1	RP11-380L11.4	3.47	0.000545	0.0265	0.14	0.11	White blood cell count;	chr12:124010656	chr12:123925461~123926083:-
BRCA	cis	rs2243480	1	rs316313	ENSG00000229180.5	GS1-124K5.11	3.47	0.000545	0.0265	0.15	0.11	Diabetic kidney disease;	chr7:66128561	chr7:66526088~66542624:-
BRCA	cis	rs2243480	1	rs316312	ENSG00000229180.5	GS1-124K5.11	3.47	0.000545	0.0265	0.15	0.11	Diabetic kidney disease;	chr7:66131504	chr7:66526088~66542624:-
BRCA	cis	rs2243480	1	rs419603	ENSG00000229180.5	GS1-124K5.11	3.47	0.000545	0.0265	0.15	0.11	Diabetic kidney disease;	chr7:66132354	chr7:66526088~66542624:-
BRCA	cis	rs7267979	1	rs6050561	ENSG00000276952.1	RP5-965G21.6	-3.47	0.000545	0.0265	-0.13	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25354219	chr20:25284915~25285588:-
BRCA	cis	rs7267979	1	rs6083813	ENSG00000276952.1	RP5-965G21.6	-3.47	0.000545	0.0265	-0.13	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25357035	chr20:25284915~25285588:-
BRCA	cis	rs673253	0.686	rs6698389	ENSG00000229431.1	RP1-92O14.6	-3.47	0.000545	0.0265	-0.11	-0.11	Intelligence (multi-trait analysis);	chr1:43585903	chr1:43385113~43389155:+
BRCA	cis	rs9921338	0.961	rs77552156	ENSG00000263080.1	RP11-485G7.5	3.47	0.000545	0.0265	0.17	0.11	Vein graft stenosis in coronary artery bypass grafting;	chr16:11332542	chr16:11341809~11345211:-
BRCA	cis	rs6866721	0.634	rs712615	ENSG00000249167.1	CTB-118N6.2	3.47	0.000545	0.0265	0.13	0.11	Body mass index;	chr5:116885938	chr5:116574482~116591398:+
BRCA	cis	rs6120849	0.663	rs13041792	ENSG00000276073.1	RP5-1125A11.7	-3.47	0.000545	0.0265	-0.15	-0.11	Protein C levels;	chr20:34957252	chr20:33985617~33988989:-
BRCA	cis	rs8028182	0.636	rs28432989	ENSG00000246877.1	DNM1P35	3.47	0.000545	0.0265	0.14	0.11	Sudden cardiac arrest;	chr15:75475956	chr15:75727670~75738623:-
BRCA	cis	rs13256369	0.851	rs11786125	ENSG00000254153.1	CTA-398F10.2	3.47	0.000545	0.0265	0.15	0.11	Obesity-related traits;	chr8:8707060	chr8:8456909~8461337:-
BRCA	cis	rs4415084	1	rs2165009	ENSG00000248464.1	FGF10-AS1	3.47	0.000545	0.0265	0.12	0.11	Breast cancer;	chr5:44697814	chr5:44388732~44413989:+
BRCA	cis	rs10191559	0.507	rs4254470	ENSG00000234663.4	AC104820.2	3.47	0.000545	0.0265	0.1	0.11	Red blood cell count;	chr2:181213850	chr2:181101932~181399559:+
BRCA	cis	rs10191559	0.552	rs6723271	ENSG00000234663.4	AC104820.2	3.47	0.000545	0.0265	0.1	0.11	Red blood cell count;	chr2:181215656	chr2:181101932~181399559:+
BRCA	cis	rs911555	0.755	rs6575988	ENSG00000269958.1	RP11-73M18.8	-3.47	0.000546	0.0265	-0.12	-0.11	Intelligence (multi-trait analysis);	chr14:103434490	chr14:103696353~103697163:+
BRCA	cis	rs9467773	1	rs6940053	ENSG00000224843.5	LINC00240	-3.47	0.000546	0.0265	-0.12	-0.11	Intelligence (multi-trait analysis);	chr6:26561894	chr6:26956992~27023924:+
BRCA	cis	rs10876993	0.928	rs1678540	ENSG00000270039.1	RP11-571M6.17	3.47	0.000546	0.0265	0.14	0.11	Celiac disease or Rheumatoid arthritis;	chr12:57671219	chr12:57803838~57804415:+
BRCA	cis	rs6840360	0.55	rs7689266	ENSG00000270265.1	RP11-731D1.4	-3.47	0.000546	0.0265	-0.13	-0.11	Intelligence (multi-trait analysis);	chr4:151639896	chr4:151333775~151353224:-
BRCA	cis	rs7577696	0.853	rs212758	ENSG00000276334.1	AL133243.1	-3.47	0.000546	0.0265	-0.14	-0.11	Inflammatory biomarkers;	chr2:32200913	chr2:32521927~32523547:+
BRCA	cis	rs2692947	0.759	rs2949885	ENSG00000168992.4	OR7E102P	3.47	0.000546	0.0265	0.15	0.11	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95996667	chr2:95546531~95547545:+
BRCA	cis	rs61008539	0.815	rs6960062	ENSG00000237181.1	AC147651.4	3.47	0.000546	0.0265	0.09	0.11	Perceived unattractiveness to mosquitoes;	chr7:845028	chr7:603185~608482:+
BRCA	cis	rs875971	0.964	rs778735	ENSG00000271064.1	RP11-792A8.3	-3.47	0.000546	0.0265	-0.12	-0.11	Aortic root size;	chr7:66349822	chr7:66748838~66749077:-
BRCA	cis	rs10464366	0.843	rs1525798	ENSG00000233306.2	TRGV2	3.47	0.000546	0.0265	0.1	0.11	IgG glycosylation;	chr7:39072980	chr7:38362864~38363518:-
BRCA	cis	rs11902236	0.545	rs59715119	ENSG00000188525.3	AC010969.1	-3.47	0.000546	0.0265	-0.12	-0.11	Prostate cancer;	chr2:9979488	chr2:10003158~10006030:-
BRCA	cis	rs7267979	0.966	rs2387885	ENSG00000231081.1	RP4-760C5.3	3.47	0.000546	0.0265	0.14	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25434588	chr20:26008791~26010531:-
BRCA	cis	rs7267979	1	rs2424713	ENSG00000231081.1	RP4-760C5.3	-3.47	0.000546	0.0265	-0.14	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25437846	chr20:26008791~26010531:-
BRCA	cis	rs9467773	0.967	rs6932865	ENSG00000261353.1	CTA-14H9.5	-3.47	0.000546	0.0265	-0.11	-0.11	Intelligence (multi-trait analysis);	chr6:26539938	chr6:26527063~26527404:+
BRCA	cis	rs9467773	1	rs6933176	ENSG00000261353.1	CTA-14H9.5	-3.47	0.000546	0.0265	-0.11	-0.11	Intelligence (multi-trait analysis);	chr6:26539950	chr6:26527063~26527404:+
BRCA	cis	rs7246657	0.524	rs28542490	ENSG00000267470.4	ZNF571-AS1	3.47	0.000546	0.0265	0.16	0.11	Coronary artery calcification;	chr19:36965682	chr19:37548914~37587348:+
BRCA	cis	rs67766926	0.953	rs13422089	ENSG00000237522.1	NONOP2	-3.47	0.000546	0.0265	-0.12	-0.11	Inflammatory skin disease;	chr2:60889106	chr2:60936819~60938049:-
BRCA	cis	rs7013415	0.563	rs11775093	ENSG00000253317.1	RP11-142A23.1	-3.47	0.000546	0.0265	-0.13	-0.11	Gout;	chr8:72126075	chr8:72196334~72202269:+
BRCA	cis	rs948562	0.744	rs4313600	ENSG00000255299.4	RP11-655C2.3	-3.47	0.000546	0.0265	-0.13	-0.11	Lymphoma;	chr11:58463748	chr11:58497888~58505758:-
BRCA	cis	rs948562	0.69	rs11229480	ENSG00000255299.4	RP11-655C2.3	-3.47	0.000546	0.0265	-0.13	-0.11	Lymphoma;	chr11:58464209	chr11:58497888~58505758:-
BRCA	cis	rs875971	0.825	rs10281499	ENSG00000271064.1	RP11-792A8.3	3.47	0.000546	0.0265	0.13	0.11	Aortic root size;	chr7:66583979	chr7:66748838~66749077:-
BRCA	cis	rs10799445	0.527	rs10799435	ENSG00000227711.2	RP11-275O4.5	-3.47	0.000546	0.0265	-0.13	-0.11	Height;	chr1:227636221	chr1:227509028~227520477:-
BRCA	cis	rs6456156	0.766	rs150112	ENSG00000227598.1	RP1-167A14.2	3.47	0.000546	0.0265	0.11	0.11	Primary biliary cholangitis;	chr6:167096390	chr6:166969626~166999065:-
BRCA	cis	rs736408	0.812	rs1076425	ENSG00000242142.1	SERBP1P3	3.47	0.000546	0.0265	0.13	0.11	Bipolar disorder;	chr3:52791446	chr3:53064283~53065091:-
BRCA	cis	rs7520050	0.966	rs11211199	ENSG00000226957.1	RP4-533D7.4	3.47	0.000546	0.0265	0.11	0.11	Reticulocyte count;Red blood cell count;	chr1:45822197	chr1:46046818~46048368:+
BRCA	cis	rs2150410	0.831	rs8131150	ENSG00000232608.1	TIMM9P2	3.47	0.000546	0.0265	0.21	0.11	Temperament (bipolar disorder);	chr21:39305389	chr21:39216624~39217506:+
BRCA	cis	rs4386084	1	rs12904014	ENSG00000244879.4	GABPB1-AS1	-3.47	0.000546	0.0265	-0.13	-0.11	Basophil percentage of granulocytes;Basophil percentage of white cells;	chr15:49939548	chr15:50354959~50372202:+
BRCA	cis	rs12817211	0.699	rs7975894	ENSG00000272368.2	RP4-605O3.4	3.47	0.000546	0.0265	0.15	0.11	Colorectal or endometrial cancer;	chr12:50390529	chr12:50112197~50165618:+
BRCA	cis	rs8054556	0.935	rs4788203	ENSG00000183604.13	SMG1P5	-3.47	0.000546	0.0265	-0.11	-0.11	Autism spectrum disorder or schizophrenia;	chr16:29967506	chr16:30267553~30335374:-
BRCA	cis	rs35740288	0.58	rs34526042	ENSG00000202081.1	RNU6-1280P	3.47	0.000546	0.0265	0.15	0.11	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85796725	chr15:85651522~85651628:-
BRCA	cis	rs9467773	1	rs6940188	ENSG00000224843.5	LINC00240	-3.47	0.000546	0.0265	-0.12	-0.11	Intelligence (multi-trait analysis);	chr6:26561801	chr6:26956992~27023924:+
BRCA	cis	rs6496932	0.635	rs11632761	ENSG00000218052.5	ADAMTS7P4	-3.47	0.000546	0.0265	-0.12	-0.11	Central corneal thickness;Corneal structure;	chr15:85387562	chr15:85255369~85330334:-
BRCA	cis	rs11098499	0.863	rs1383532	ENSG00000225892.3	RP11-384K6.2	-3.47	0.000546	0.0265	-0.11	-0.11	Corneal astigmatism;	chr4:119513249	chr4:118632274~118634759:+
BRCA	cis	rs897984	0.609	rs35468353	ENSG00000275263.1	RP11-1072A3.4	-3.47	0.000546	0.0265	-0.13	-0.11	Dementia with Lewy bodies;	chr16:31045112	chr16:30956872~30957199:-
BRCA	cis	rs897984	0.609	rs11862744	ENSG00000275263.1	RP11-1072A3.4	-3.47	0.000546	0.0265	-0.13	-0.11	Dementia with Lewy bodies;	chr16:31046479	chr16:30956872~30957199:-
BRCA	cis	rs12760731	0.582	rs6658398	ENSG00000213057.5	C1orf220	3.47	0.000546	0.0265	0.14	0.11	Obesity-related traits;	chr1:178589746	chr1:178542752~178548889:+
BRCA	cis	rs7008867	1	rs7010306	ENSG00000253390.1	CTC-756D1.2	-3.47	0.000546	0.0265	-0.15	-0.11	Hip circumference adjusted for BMI;	chr8:23525895	chr8:23458601~23484971:+
BRCA	cis	rs890448	0.76	rs7687487	ENSG00000254531.1	FLJ20021	3.47	0.000546	0.0265	0.13	0.11	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101362824	chr4:101347780~101348883:+
BRCA	cis	rs6964587	1	rs10488510	ENSG00000188693.7	CYP51A1-AS1	-3.47	0.000546	0.0265	-0.12	-0.11	Breast cancer;	chr7:92030911	chr7:92134604~92180725:+
BRCA	cis	rs910316	1	rs175449	ENSG00000259138.1	RP11-950C14.7	-3.47	0.000546	0.0265	-0.11	-0.11	Height;	chr14:75124143	chr14:75127153~75136930:+
BRCA	cis	rs910316	0.935	rs175448	ENSG00000259138.1	RP11-950C14.7	-3.47	0.000546	0.0265	-0.11	-0.11	Height;	chr14:75124368	chr14:75127153~75136930:+
BRCA	cis	rs999943	0.846	rs10947420	ENSG00000224557.6	HLA-DPB2	-3.47	0.000546	0.0265	-0.14	-0.11	Obesity (extreme);	chr6:33643284	chr6:33112451~33129084:+
BRCA	cis	rs1555321	0.679	rs743168	ENSG00000273038.2	RP11-479G22.8	3.47	0.000547	0.0265	0.13	0.11	Coronary artery disease;	chr10:33215955	chr10:32887255~32889311:-
BRCA	cis	rs2055375	0.54	rs159362	ENSG00000272308.1	RP11-231G3.1	-3.47	0.000547	0.0265	-0.13	-0.11	Intelligence (multi-trait analysis);	chr5:61226625	chr5:60866457~60866935:-
BRCA	cis	rs12477438	1	rs17760953	ENSG00000231822.1	AC019097.7	-3.47	0.000547	0.0265	-0.13	-0.11	Chronic sinus infection;	chr2:99243400	chr2:99102018~99102752:+
BRCA	cis	rs6429422	0.769	rs6689352	ENSG00000224727.1	FCF1P7	-3.47	0.000547	0.0265	-0.13	-0.11	Cognitive ability (multi-trait analysis);	chr1:243244480	chr1:243267257~243268119:-
BRCA	cis	rs7520050	0.807	rs12025621	ENSG00000281133.1	AL355480.3	3.47	0.000547	0.0265	0.12	0.11	Reticulocyte count;Red blood cell count;	chr1:45762719	chr1:45580892~45580996:-
BRCA	cis	rs41369048	0.858	rs2784273	ENSG00000257551.1	HLX-AS1	-3.47	0.000547	0.0265	-0.15	-0.11	Eosinophil counts;Sum eosinophil basophil counts;	chr1:220907744	chr1:220832763~220880140:-
BRCA	cis	rs13256369	0.802	rs11249888	ENSG00000254153.1	CTA-398F10.2	3.47	0.000547	0.0265	0.15	0.11	Obesity-related traits;	chr8:8707424	chr8:8456909~8461337:-
BRCA	cis	rs13256369	0.851	rs11249889	ENSG00000254153.1	CTA-398F10.2	3.47	0.000547	0.0265	0.15	0.11	Obesity-related traits;	chr8:8707482	chr8:8456909~8461337:-
BRCA	cis	rs2839186	0.632	rs17176110	ENSG00000215424.8	MCM3AP-AS1	3.47	0.000547	0.0265	0.1	0.11	Testicular germ cell tumor;	chr21:46286621	chr21:46229217~46259390:+
BRCA	cis	rs564309	1	rs505129	ENSG00000212237.1	RNA5SP18	3.47	0.000547	0.0266	0.18	0.11	Hip circumference (psychosocial stress interaction);	chr1:228399128	chr1:228647912~228648032:-
BRCA	cis	rs838721	1	rs706848	ENSG00000259793.1	RP11-400N9.1	-3.47	0.000547	0.0266	-0.09	-0.11	Total body bone mineral density;	chr2:233391273	chr2:233351132~233353416:-
BRCA	cis	rs8114671	0.836	rs4911461	ENSG00000261582.1	RP4-614O4.11	3.47	0.000547	0.0266	0.1	0.11	Height;	chr20:35042190	chr20:35267885~35280043:-
BRCA	cis	rs10411161	1	rs72626249	ENSG00000269483.1	AC006272.1	3.47	0.000547	0.0266	0.18	0.11	Breast cancer;	chr19:51861622	chr19:51839924~51843324:-
BRCA	cis	rs7246657	0.653	rs10425441	ENSG00000267470.4	ZNF571-AS1	3.47	0.000547	0.0266	0.16	0.11	Coronary artery calcification;	chr19:37179746	chr19:37548914~37587348:+
BRCA	cis	rs2143606	0.743	rs2143607	ENSG00000223891.4	OSER1-AS1	-3.47	0.000547	0.0266	-0.11	-0.11	Granulocyte percentage of myeloid white cells;	chr20:44210072	chr20:44210960~44226027:+
BRCA	cis	rs3749237	0.964	rs2234385	ENSG00000225399.4	RP11-3B7.1	3.47	0.000547	0.0266	0.1	0.11	Resting heart rate;	chr3:49808608	chr3:49260085~49261316:+
BRCA	cis	rs3749237	0.964	rs1799843	ENSG00000225399.4	RP11-3B7.1	3.47	0.000547	0.0266	0.1	0.11	Resting heart rate;	chr3:49812290	chr3:49260085~49261316:+
BRCA	cis	rs300890	0.729	rs11100787	ENSG00000250326.1	RP11-284M14.1	3.47	0.000547	0.0266	0.12	0.11	Nasopharyngeal carcinoma;	chr4:143391139	chr4:142933195~143184861:-
BRCA	cis	rs494453	0.71	rs2477429	ENSG00000227811.2	FAM212B-AS1	-3.47	0.000547	0.0266	-0.15	-0.11	Osteoporosis-related phenotypes;	chr1:111663807	chr1:111739841~111747798:+
BRCA	cis	rs7520050	0.966	rs7524495	ENSG00000281133.1	AL355480.3	3.47	0.000547	0.0266	0.12	0.11	Reticulocyte count;Red blood cell count;	chr1:45801260	chr1:45580892~45580996:-
BRCA	cis	rs250518	0.888	rs6870112	ENSG00000271926.1	CTD-2376I4.1	3.47	0.000547	0.0266	0.14	0.11	Mean corpuscular hemoglobin concentration;	chr5:72725093	chr5:72953635~72954274:-
BRCA	cis	rs1424638	0.535	rs12373686	ENSG00000233251.6	AC007743.1	-3.47	0.000547	0.0266	-0.13	-0.11	Intelligence (multi-trait analysis);	chr2:56992773	chr2:56173534~56185770:-
BRCA	cis	rs863345	0.604	rs7548349	ENSG00000176320.2	RP11-404O13.5	-3.47	0.000547	0.0266	-0.11	-0.11	Pneumococcal bacteremia;	chr1:158523936	chr1:158197922~158203877:-
BRCA	cis	rs4906332	1	rs2065015	ENSG00000259775.1	RP11-45P15.4	3.47	0.000547	0.0266	0.12	0.11	Coronary artery disease;	chr14:103437724	chr14:103331674~103332367:-
BRCA	cis	rs12477602	1	rs34047945	ENSG00000272966.1	RP11-686O6.1	3.47	0.000547	0.0266	0.18	0.11	Intelligence (multi-trait analysis);	chr2:202391532	chr2:202336739~202337200:+
BRCA	cis	rs250518	0.926	rs7734796	ENSG00000271926.1	CTD-2376I4.1	3.47	0.000547	0.0266	0.14	0.11	Mean corpuscular hemoglobin concentration;	chr5:72781261	chr5:72953635~72954274:-
BRCA	cis	rs7537765	1	rs17037452	ENSG00000242349.4	NPPA-AS1	-3.47	0.000547	0.0266	-0.16	-0.11	QRS complex (12-leadsum);	chr1:11835618	chr1:11841017~11848079:+
BRCA	cis	rs250585	0.588	rs250567	ENSG00000260136.4	CTD-2270L9.4	-3.47	0.000547	0.0266	-0.18	-0.11	Egg allergy;	chr16:23383078	chr16:23452758~23457606:+
BRCA	cis	rs2154319	0.673	rs2011981	ENSG00000230638.4	RP11-486B10.4	3.47	0.000547	0.0266	0.18	0.11	Height;	chr1:41075181	chr1:41542069~41544310:+
BRCA	cis	rs2154319	0.887	rs2024859	ENSG00000230638.4	RP11-486B10.4	3.47	0.000547	0.0266	0.18	0.11	Height;	chr1:41096613	chr1:41542069~41544310:+
BRCA	cis	rs7615952	0.611	rs9681518	ENSG00000241288.6	RP11-379B18.5	-3.47	0.000547	0.0266	-0.18	-0.11	Blood pressure (smoking interaction);	chr3:125896287	chr3:125827238~125916384:-
BRCA	cis	rs17684571	0.938	rs16888118	ENSG00000231441.1	RP11-472M19.2	3.47	0.000547	0.0266	0.15	0.11	Schizophrenia;	chr6:56687838	chr6:56844002~56864078:+
BRCA	cis	rs2214681	1	rs2214681	ENSG00000273314.1	RP5-1136G13.2	3.47	0.000548	0.0266	0.12	0.11	Bone mineral density;	chr7:148005600	chr7:148696467~148698664:-
BRCA	cis	rs4805834	0.843	rs17272197	ENSG00000201388.1	SNORA68	3.47	0.000548	0.0266	0.18	0.11	Creatinine levels;	chr19:32838238	chr19:32608337~32608469:-
BRCA	cis	rs4805834	0.843	rs11668337	ENSG00000201388.1	SNORA68	3.47	0.000548	0.0266	0.18	0.11	Creatinine levels;	chr19:32838864	chr19:32608337~32608469:-
BRCA	cis	rs892961	1	rs892961	ENSG00000279801.1	RP11-75C10.6	3.47	0.000548	0.0266	0.14	0.11	Airflow obstruction;	chr17:77404018	chr17:77444704~77447167:+
BRCA	cis	rs13326165	0.76	rs55997317	ENSG00000243224.1	RP5-1157M23.2	-3.47	0.000548	0.0266	-0.15	-0.11	HDL cholesterol levels;HDL cholesterol;	chr3:52316729	chr3:52239258~52241097:+
BRCA	cis	rs987360	0.585	rs7664023	ENSG00000248869.4	RP11-138I17.1	3.47	0.000548	0.0266	0.11	0.11	Temperament;	chr4:137263610	chr4:136796722~137212799:-
BRCA	cis	rs8040855	0.599	rs6496792	ENSG00000259416.2	RP11-158M2.5	-3.47	0.000548	0.0266	-0.12	-0.11	Bulimia nervosa;	chr15:85182514	chr15:85754941~85756237:-
BRCA	cis	rs8040855	0.599	rs6496793	ENSG00000259416.2	RP11-158M2.5	-3.47	0.000548	0.0266	-0.12	-0.11	Bulimia nervosa;	chr15:85182515	chr15:85754941~85756237:-
BRCA	cis	rs8040855	0.599	rs6496795	ENSG00000259416.2	RP11-158M2.5	-3.47	0.000548	0.0266	-0.12	-0.11	Bulimia nervosa;	chr15:85182622	chr15:85754941~85756237:-
BRCA	cis	rs45509595	0.749	rs401763	ENSG00000241549.7	GUSBP2	3.47	0.000548	0.0266	0.19	0.11	Breast cancer;	chr6:27814750	chr6:26871484~26956554:-
BRCA	cis	rs45509595	0.659	rs390764	ENSG00000241549.7	GUSBP2	3.47	0.000548	0.0266	0.19	0.11	Breast cancer;	chr6:27814757	chr6:26871484~26956554:-
BRCA	cis	rs45509595	0.841	rs401754	ENSG00000241549.7	GUSBP2	3.47	0.000548	0.0266	0.19	0.11	Breast cancer;	chr6:27814760	chr6:26871484~26956554:-
BRCA	cis	rs12949688	0.967	rs9910446	ENSG00000262623.1	RP5-1107A17.2	-3.47	0.000548	0.0266	-0.11	-0.11	Schizophrenia;	chr17:57744124	chr17:56951664~56952404:+
BRCA	cis	rs875971	1	rs6979382	ENSG00000273448.1	RP11-166O4.6	3.47	0.000548	0.0266	0.1	0.11	Aortic root size;	chr7:66421388	chr7:67333047~67334383:+
BRCA	cis	rs875971	1	rs6961990	ENSG00000273448.1	RP11-166O4.6	3.47	0.000548	0.0266	0.1	0.11	Aortic root size;	chr7:66423583	chr7:67333047~67334383:+
BRCA	cis	rs8040855	0.627	rs12904238	ENSG00000229212.6	RP11-561C5.4	-3.47	0.000548	0.0266	-0.14	-0.11	Bulimia nervosa;	chr15:85096610	chr15:85205440~85234795:-
BRCA	cis	rs739401	0.572	rs739399	ENSG00000247473.2	CARS-AS1	3.47	0.000548	0.0266	0.12	0.11	Longevity;	chr11:2995222	chr11:3029009~3041260:+
BRCA	cis	rs8114671	0.562	rs959829	ENSG00000126005.14	MMP24-AS1	3.47	0.000548	0.0266	0.13	0.11	Height;	chr20:34758244	chr20:35216462~35278131:-
BRCA	cis	rs2120991	1	rs11170737	ENSG00000250742.1	RP11-834C11.4	-3.47	0.000548	0.0266	-0.13	-0.11	Biliary atresia;	chr12:53885820	chr12:54126098~54132843:+
BRCA	cis	rs4974559	0.739	rs28444605	ENSG00000253399.1	AC078852.2	3.47	0.000548	0.0266	0.16	0.11	Systolic blood pressure;	chr4:1296493	chr4:1358479~1359461:+
BRCA	cis	rs7520050	0.966	rs12139630	ENSG00000226957.1	RP4-533D7.4	3.47	0.000548	0.0266	0.11	0.11	Reticulocyte count;Red blood cell count;	chr1:45885263	chr1:46046818~46048368:+
BRCA	cis	rs4478858	0.647	rs10798835	ENSG00000229447.2	RP11-490K7.4	-3.47	0.000548	0.0266	-0.1	-0.11	Alcohol dependence;	chr1:31236208	chr1:31263245~31263681:-
BRCA	cis	rs8180040	0.701	rs7617689	ENSG00000271161.1	BOLA2P2	-3.47	0.000548	0.0266	-0.11	-0.11	Colorectal cancer;	chr3:46954952	chr3:47499841~47500407:+
BRCA	cis	rs17756712	0.725	rs9504483	ENSG00000271911.1	RP11-532F6.5	3.47	0.000548	0.0266	0.17	0.11	Vertical cup-disc ratio;	chr6:620222	chr6:761675~780648:+
BRCA	cis	rs709400	0.628	rs7155014	ENSG00000258851.1	RP11-894P9.2	-3.47	0.000548	0.0266	-0.12	-0.11	Body mass index;	chr14:103397633	chr14:103553421~103561877:+
BRCA	cis	rs7338174	0.655	rs9316535	ENSG00000243406.5	MRPS31P5	3.47	0.000548	0.0266	0.17	0.11	Mitochondrial DNA levels;	chr13:51329329	chr13:52167709~52194465:-
BRCA	cis	rs11700980	1	rs2832058	ENSG00000232855.5	AF131217.1	3.47	0.000548	0.0266	0.21	0.11	QRS complex (12-leadsum);	chr21:28760912	chr21:28439346~28674848:-
BRCA	cis	rs61931739	0.5	rs11053166	ENSG00000258794.3	DUX4L27	-3.47	0.000548	0.0266	-0.15	-0.11	Morning vs. evening chronotype;	chr12:34232963	chr12:34208415~34209675:-
BRCA	cis	rs6671200	0.607	rs2296308	ENSG00000226026.4	RP11-57H12.3	3.47	0.000548	0.0266	0.16	0.11	Stearic acid (18:0) levels;	chr1:95244383	chr1:95163219~95233982:-
BRCA	cis	rs4650943	0.503	rs10753117	ENSG00000227740.1	RP11-318C24.2	3.47	0.000548	0.0266	0.11	0.11	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in inactive individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr1:176050793	chr1:175904762~175920513:-
BRCA	cis	rs4650943	0.503	rs10798444	ENSG00000227740.1	RP11-318C24.2	3.47	0.000548	0.0266	0.11	0.11	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in inactive individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr1:176051224	chr1:175904762~175920513:-
BRCA	cis	rs36051895	0.623	rs10975023	ENSG00000237711.1	RP11-39K24.13	3.47	0.000548	0.0266	0.13	0.11	Pediatric autoimmune diseases;	chr9:5239549	chr9:5100236~5101009:+
BRCA	cis	rs10844706	0.669	rs10844682	ENSG00000278635.1	CTD-2318O12.1	3.47	0.000548	0.0266	0.12	0.11	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9747028	chr12:9415641~9416718:+
BRCA	cis	rs4243971	0.516	rs1467479	ENSG00000224452.1	RSL24D1P6	3.47	0.000548	0.0266	0.15	0.11	Inflammatory bowel disease;Crohn's disease;	chr20:32442766	chr20:32170390~32170790:-
BRCA	cis	rs4589258	1	rs5009703	ENSG00000280367.1	RP11-121L10.2	3.47	0.000549	0.0266	0.12	0.11	Intelligence (multi-trait analysis);	chr11:90754676	chr11:90223153~90226538:+
BRCA	cis	rs73201462	0.908	rs2811388	ENSG00000242551.2	POU5F1P6	3.47	0.000549	0.0266	0.18	0.11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128299604	chr3:128674735~128677005:-
BRCA	cis	rs11047510	0.73	rs11047578	ENSG00000164845.15	FAM86FP	3.47	0.000549	0.0266	0.17	0.11	Exploratory eye movement dysfunction in schizophrenia (responsive search score);	chr12:8849393	chr12:8232512~8242948:-
BRCA	cis	rs2312236	0.714	rs12566727	ENSG00000225171.2	DUTP6	-3.47	0.000549	0.0266	-0.15	-0.11	Post-traumatic stress disorder;	chr1:166753917	chr1:166868748~166869209:+
BRCA	cis	rs9921338	0.887	rs13330151	ENSG00000263080.1	RP11-485G7.5	3.47	0.000549	0.0266	0.17	0.11	Vein graft stenosis in coronary artery bypass grafting;	chr16:11308542	chr16:11341809~11345211:-
BRCA	cis	rs1348850	0.914	rs3902850	ENSG00000271825.1	RP11-337N6.2	3.47	0.000549	0.0266	0.14	0.11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177451171	chr2:177300600~177302006:+
BRCA	cis	rs3764563	1	rs4646530	ENSG00000267594.5	CYP4F24P	3.47	0.000549	0.0266	0.2	0.11	Inflammatory biomarkers;	chr19:15624428	chr19:15760241~15779909:-
BRCA	cis	rs3770081	1	rs12620810	ENSG00000232504.4	ST3GAL5-AS1	3.47	0.000549	0.0266	0.26	0.11	Facial emotion recognition (sad faces);	chr2:86164358	chr2:85889280~85890980:+
BRCA	cis	rs9470794	1	rs56030069	ENSG00000204110.6	RP1-153P14.8	-3.47	0.000549	0.0266	-0.2	-0.11	Type 2 diabetes;	chr6:38161339	chr6:37507348~37535616:+
BRCA	cis	rs9470794	1	rs59693994	ENSG00000204110.6	RP1-153P14.8	-3.47	0.000549	0.0266	-0.2	-0.11	Type 2 diabetes;	chr6:38162147	chr6:37507348~37535616:+
BRCA	cis	rs12971120	0.891	rs12968731	ENSG00000276934.1	RP11-231E4.5	3.47	0.000549	0.0266	0.16	0.11	Refractive error;	chr18:74502473	chr18:74504766~74505248:+
BRCA	cis	rs7176093	1	rs72755344	ENSG00000259295.5	CSPG4P12	-3.47	0.000549	0.0266	-0.15	-0.11	Aging traits;	chr15:85820620	chr15:85191438~85213905:+
BRCA	cis	rs9388451	0.839	rs3799711	ENSG00000237742.5	RP11-624M8.1	3.47	0.000549	0.0266	0.13	0.11	Brugada syndrome;	chr6:125754167	chr6:125578558~125749190:-
BRCA	cis	rs2574985	0.813	rs1203405	ENSG00000226200.5	SGMS1-AS1	-3.47	0.000549	0.0266	-0.11	-0.11	Subjective well-being;	chr10:50438969	chr10:50624951~50641451:+
BRCA	cis	rs757978	1	rs2074771	ENSG00000223374.1	AC005104.3	3.47	0.000549	0.0266	0.14	0.11	Chronic lymphocytic leukemia;	chr2:241411529	chr2:241351340~241353104:-
BRCA	cis	rs68170813	0.652	rs76742243	ENSG00000241764.3	AC002467.7	3.47	0.000549	0.0266	0.19	0.11	Coronary artery disease;	chr7:107503757	chr7:107742817~107744581:-
BRCA	cis	rs1348850	0.914	rs6710575	ENSG00000271825.1	RP11-337N6.2	3.47	0.000549	0.0266	0.14	0.11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177512583	chr2:177300600~177302006:+
BRCA	cis	rs66561647	0.661	rs890442	ENSG00000207110.1	RNU1-106P	-3.47	0.000549	0.0266	-0.13	-0.11	Hemoglobin concentration;	chr8:127918961	chr8:127999131~127999294:+
BRCA	cis	rs4902562	0.838	rs6573823	ENSG00000258837.1	CTD-2566J3.1	-3.47	0.000549	0.0266	-0.13	-0.11	Systemic lupus erythematosus;	chr14:68266915	chr14:68125004~68130196:-
BRCA	cis	rs7772486	0.875	rs1331645	ENSG00000270638.1	RP3-466P17.1	3.47	0.000549	0.0266	0.12	0.11	Lobe attachment (rater-scored or self-reported);	chr6:146077271	chr6:145735570~145737218:+
BRCA	cis	rs12147450	1	rs17112431	ENSG00000259162.1	RP11-203M5.6	-3.47	0.000549	0.0267	-0.13	-0.11	Response to antipsychotic therapy (extrapyramidal side effects);	chr14:20489331	chr14:20437982~20441268:+
BRCA	cis	rs3749237	0.964	rs11717463	ENSG00000225399.4	RP11-3B7.1	3.47	0.000549	0.0267	0.11	0.11	Resting heart rate;	chr3:49771548	chr3:49260085~49261316:+
BRCA	cis	rs75757892	0.621	rs1983851	ENSG00000236512.1	RP3-336K20__B.2	3.47	0.000549	0.0267	0.18	0.11	Hematocrit;Red blood cell count;	chr6:7293309	chr6:7620422~7620878:+
BRCA	cis	rs75757892	0.588	rs77454875	ENSG00000236512.1	RP3-336K20__B.2	3.47	0.000549	0.0267	0.18	0.11	Hematocrit;Red blood cell count;	chr6:7294122	chr6:7620422~7620878:+
BRCA	cis	rs10501293	0.956	rs11037235	ENSG00000252652.1	Y_RNA	3.47	0.000549	0.0267	0.13	0.11	Cognitive performance;	chr11:43078831	chr11:43331261~43331356:+
BRCA	cis	rs8114671	0.562	rs4911447	ENSG00000261582.1	RP4-614O4.11	-3.47	0.00055	0.0267	-0.1	-0.11	Height;	chr20:34891642	chr20:35267885~35280043:-
BRCA	cis	rs11673344	0.503	rs1829603	ENSG00000276846.1	CTD-3220F14.3	3.47	0.00055	0.0267	0.12	0.11	Obesity-related traits;	chr19:37065396	chr19:37314868~37315620:-
BRCA	cis	rs875971	0.861	rs801215	ENSG00000106610.13	STAG3L4	3.47	0.00055	0.0267	0.14	0.11	Aortic root size;	chr7:66546951	chr7:67302621~67321526:+
BRCA	cis	rs925946	0.518	rs12361806	ENSG00000245573.6	BDNF-AS	-3.47	0.00055	0.0267	-0.13	-0.11	Weight;Body mass index;	chr11:27598022	chr11:27506838~27698174:+
BRCA	cis	rs9325144	0.56	rs11183150	ENSG00000257718.1	RP11-396F22.1	-3.47	0.00055	0.0267	-0.11	-0.11	Morning vs. evening chronotype;	chr12:38280896	chr12:38906451~38909592:+
BRCA	cis	rs897984	0.609	rs35468353	ENSG00000260267.1	RP11-452L6.5	3.47	0.00055	0.0267	0.1	0.11	Dementia with Lewy bodies;	chr16:31045112	chr16:31456711~31459736:-
BRCA	cis	rs897984	0.609	rs11862744	ENSG00000260267.1	RP11-452L6.5	3.47	0.00055	0.0267	0.1	0.11	Dementia with Lewy bodies;	chr16:31046479	chr16:31456711~31459736:-
BRCA	cis	rs10792665	0.512	rs7104905	ENSG00000254965.1	RP11-113K21.2	-3.47	0.00055	0.0267	-0.11	-0.11	Obesity-related traits;	chr11:82899097	chr11:83111060~83111442:-
BRCA	cis	rs9611565	0.625	rs9607819	ENSG00000237037.8	NDUFA6-AS1	3.47	0.00055	0.0267	0.15	0.11	Vitiligo;	chr22:41562858	chr22:42090931~42137742:+
BRCA	cis	rs6601327	0.898	rs1458942	ENSG00000253426.4	RP11-10A14.4	3.47	0.00055	0.0267	0.12	0.11	Multiple myeloma (hyperdiploidy);	chr8:9549092	chr8:9151742~9168136:+
BRCA	cis	rs77437330	0.73	rs2269618	ENSG00000272356.1	RP5-1112D6.8	-3.47	0.00055	0.0267	-0.23	-0.11	Skin pigmentation;	chr6:111719463	chr6:111309203~111313517:+
BRCA	cis	rs6964587	0.869	rs7810391	ENSG00000188693.7	CYP51A1-AS1	3.47	0.00055	0.0267	0.12	0.11	Breast cancer;	chr7:91890913	chr7:92134604~92180725:+
BRCA	cis	rs6964587	0.869	rs7778667	ENSG00000188693.7	CYP51A1-AS1	3.47	0.00055	0.0267	0.12	0.11	Breast cancer;	chr7:91891502	chr7:92134604~92180725:+
BRCA	cis	rs516805	0.706	rs1034060	ENSG00000279114.1	RP3-425C14.5	3.47	0.00055	0.0267	0.13	0.11	Lymphocyte counts;	chr6:122319181	chr6:122471923~122484161:+
BRCA	cis	rs7520050	0.778	rs12404197	ENSG00000281133.1	AL355480.3	3.47	0.00055	0.0267	0.12	0.11	Reticulocyte count;Red blood cell count;	chr1:45766748	chr1:45580892~45580996:-
BRCA	cis	rs7520050	0.801	rs6703960	ENSG00000281133.1	AL355480.3	3.47	0.00055	0.0267	0.12	0.11	Reticulocyte count;Red blood cell count;	chr1:45767051	chr1:45580892~45580996:-
BRCA	cis	rs13136331	0.641	rs2627685	ENSG00000249001.4	RP11-742B18.1	3.47	0.00055	0.0267	0.15	0.11	Sitting height ratio;	chr4:87736640	chr4:87568035~87733956:-
BRCA	cis	rs897984	0.52	rs4889614	ENSG00000280211.1	RP11-2C24.3	-3.47	0.00055	0.0267	-0.11	-0.11	Dementia with Lewy bodies;	chr16:30850814	chr16:30773532~30776033:-
BRCA	cis	rs1334894	1	rs72911397	ENSG00000187762.5	HSPE1P11	3.47	0.00055	0.0267	0.25	0.11	Coronary artery disease;	chr6:35558044	chr6:35023522~35023831:+
BRCA	cis	rs448720	0.967	rs338357	ENSG00000260657.2	RP11-315D16.4	-3.47	0.00055	0.0267	-0.13	-0.11	Cognitive performance;	chr15:67902334	chr15:68267792~68277994:-
BRCA	cis	rs739401	0.611	rs10833048	ENSG00000247473.2	CARS-AS1	3.47	0.00055	0.0267	0.12	0.11	Longevity;	chr11:2998810	chr11:3029009~3041260:+
BRCA	cis	rs11931598	0.702	rs10937780	ENSG00000245748.1	RP11-367J11.2	-3.47	0.00055	0.0267	-0.11	-0.11	Sum basophil neutrophil counts;Neutrophil count;Granulocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;	chr4:7047115	chr4:7030554~7046231:-
BRCA	cis	rs6142618	0.562	rs4911550	ENSG00000277692.1	RP11-358N2.2	-3.47	0.00055	0.0267	-0.12	-0.11	Inflammatory bowel disease;	chr20:32151639	chr20:32355053~32355734:+
BRCA	cis	rs2411233	1	rs7184047	ENSG00000259278.1	RP11-62C7.2	3.47	0.00055	0.0267	0.13	0.11	Platelet count;	chr15:38984939	chr15:39019233~39024918:+
BRCA	cis	rs2243480	1	rs781150	ENSG00000226767.1	RP11-328P23.3	-3.47	0.00055	0.0267	-0.18	-0.11	Diabetic kidney disease;	chr7:66015986	chr7:65508773~65508944:-
BRCA	cis	rs2243480	1	rs313798	ENSG00000226767.1	RP11-328P23.3	-3.47	0.00055	0.0267	-0.18	-0.11	Diabetic kidney disease;	chr7:66028044	chr7:65508773~65508944:-
BRCA	cis	rs27434	0.66	rs26493	ENSG00000248734.2	CTD-2260A17.1	3.47	0.00055	0.0267	0.15	0.11	Ankylosing spondylitis;	chr5:96819615	chr5:96784777~96785999:+
BRCA	cis	rs2836974	0.545	rs3167757	ENSG00000238141.2	BRWD1-AS1	3.47	0.00055	0.0267	0.12	0.11	Cognitive function;	chr21:39342552	chr21:39315707~39323218:+
BRCA	cis	rs4363385	0.667	rs73014331	ENSG00000272654.1	RP11-422P24.11	3.47	0.00055	0.0267	0.11	0.11	Inflammatory skin disease;	chr1:152992057	chr1:153977743~153979160:+
BRCA	cis	rs4650943	0.503	rs10913131	ENSG00000227740.1	RP11-318C24.2	3.47	0.00055	0.0267	0.11	0.11	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in inactive individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr1:176067035	chr1:175904762~175920513:-
BRCA	cis	rs344364	0.511	rs2917519	ENSG00000219027.2	RPS3AP2	3.47	0.00055	0.0267	0.16	0.11	Glomerular filtration rate in chronic kidney disease;	chr16:1900478	chr16:1477830~1478583:+
BRCA	cis	rs344364	0.511	rs2982455	ENSG00000219027.2	RPS3AP2	3.47	0.00055	0.0267	0.16	0.11	Glomerular filtration rate in chronic kidney disease;	chr16:1900497	chr16:1477830~1478583:+
BRCA	cis	rs997295	0.57	rs11632574	ENSG00000259673.4	IQCH-AS1	3.47	0.00055	0.0267	0.12	0.11	Motion sickness;	chr15:67560067	chr15:67403619~67521844:-
BRCA	cis	rs7649443	0.959	rs34121928	ENSG00000243339.3	RN7SL738P	-3.47	0.00055	0.0267	-0.15	-0.11	Nonsyndromic cleft lip with cleft palate;	chr3:197275998	chr3:196399911~196400207:+
BRCA	cis	rs7520050	0.966	rs12144263	ENSG00000226957.1	RP4-533D7.4	3.47	0.00055	0.0267	0.11	0.11	Reticulocyte count;Red blood cell count;	chr1:45886774	chr1:46046818~46048368:+
BRCA	cis	rs7339483	0.85	rs8108185	ENSG00000269416.4	LINC01224	3.47	0.000551	0.0267	0.21	0.11	Discordance in emotional problems in monozygotic twins;	chr19:24239371	chr19:23399233~23416075:-
BRCA	cis	rs7339483	0.867	rs10406126	ENSG00000269416.4	LINC01224	3.47	0.000551	0.0267	0.21	0.11	Discordance in emotional problems in monozygotic twins;	chr19:24241263	chr19:23399233~23416075:-
BRCA	cis	rs2835872	0.965	rs2154553	ENSG00000228677.1	TTC3-AS1	3.47	0.000551	0.0267	0.14	0.11	Electroencephalographic traits in alcoholism;	chr21:37632199	chr21:37187666~37193926:-
BRCA	cis	rs8180040	1	rs11130127	ENSG00000260236.1	RP11-708J19.1	-3.47	0.000551	0.0267	-0.1	-0.11	Colorectal cancer;	chr3:47357303	chr3:47379089~47380999:-
BRCA	cis	rs752010	0.714	rs7515948	ENSG00000230638.4	RP11-486B10.4	-3.47	0.000551	0.0267	-0.13	-0.11	Lupus nephritis in systemic lupus erythematosus;	chr1:41613375	chr1:41542069~41544310:+
BRCA	cis	rs10761482	0.69	rs4406773	ENSG00000254271.1	RP11-131N11.4	3.47	0.000551	0.0267	0.15	0.11	Schizophrenia;	chr10:60344816	chr10:60734342~60741828:+
BRCA	cis	rs10761482	0.728	rs4290174	ENSG00000254271.1	RP11-131N11.4	3.47	0.000551	0.0267	0.15	0.11	Schizophrenia;	chr10:60344825	chr10:60734342~60741828:+
BRCA	cis	rs7200786	0.565	rs41369	ENSG00000274038.1	RP11-66H6.4	-3.47	0.000551	0.0267	-0.12	-0.11	Systemic lupus erythematosus;Multiple sclerosis;	chr16:11160855	chr16:11056556~11057034:+
BRCA	cis	rs999943	0.846	rs2274200	ENSG00000224557.6	HLA-DPB2	-3.47	0.000551	0.0267	-0.15	-0.11	Obesity (extreme);	chr6:33657919	chr6:33112451~33129084:+
BRCA	cis	rs787274	0.867	rs787279	ENSG00000271631.1	RP11-408O19.5	3.47	0.000551	0.0267	0.18	0.11	Age-related hearing impairment (SNP x SNP interaction);	chr9:112777234	chr9:112885158~112885767:+
BRCA	cis	rs36093844	0.626	rs11234517	ENSG00000279742.1	RP11-700A24.1	3.47	0.000551	0.0267	0.14	0.11	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:86020533	chr11:85852557~85854943:-
BRCA	cis	rs12900413	0.603	rs2351493	ENSG00000259212.1	CTD-3065B20.2	3.47	0.000551	0.0267	0.13	0.11	Coronary artery aneurysm in Kawasaki disease;	chr15:89756305	chr15:90595840~90596447:-
BRCA	cis	rs10043775	0.789	rs10037318	ENSG00000251330.3	CTD-2283N19.1	-3.47	0.000551	0.0267	-0.13	-0.11	Periodontal microbiota;	chr5:148377030	chr5:148430159~148430807:-
BRCA	cis	rs7000551	0.751	rs1116084	ENSG00000253125.1	RP11-459E5.1	3.47	0.000551	0.0267	0.11	0.11	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr8:22537796	chr8:22690150~22798616:+
BRCA	cis	rs6582630	0.576	rs2387836	ENSG00000257718.1	RP11-396F22.1	3.47	0.000551	0.0267	0.11	0.11	Drug-induced liver injury (flucloxacillin);	chr12:38166268	chr12:38906451~38909592:+
BRCA	cis	rs6701713	0.959	rs1408078	ENSG00000274245.1	RP11-357P18.2	-3.47	0.000551	0.0267	-0.17	-0.11	Alzheimer's disease (late onset);	chr1:207627210	chr1:207372559~207373252:+
BRCA	cis	rs13256369	0.755	rs12680167	ENSG00000254153.1	CTA-398F10.2	3.47	0.000551	0.0267	0.15	0.11	Obesity-related traits;	chr8:8704957	chr8:8456909~8461337:-
BRCA	cis	rs7267979	1	rs4815406	ENSG00000276952.1	RP5-965G21.6	-3.47	0.000551	0.0267	-0.13	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25360680	chr20:25284915~25285588:-
BRCA	cis	rs10181042	0.565	rs1177233	ENSG00000270820.4	RP11-355B11.2	-3.47	0.000551	0.0267	-0.12	-0.11	Crohn's disease;	chr2:61034999	chr2:61471188~61484130:+
BRCA	cis	rs35176054	0.73	rs7093473	ENSG00000280693.1	SH3PXD2A-AS1	3.47	0.000551	0.0267	0.17	0.11	Atrial fibrillation;	chr10:103775573	chr10:103745966~103755423:+
BRCA	cis	rs10266483	0.705	rs1111649	ENSG00000227986.1	TRIM60P18	-3.47	0.000551	0.0267	-0.12	-0.11	Response to statin therapy;	chr7:64296435	chr7:64355078~64356199:+
BRCA	cis	rs7636293	0.592	rs10934881	ENSG00000270773.1	RP13-685P2.7	3.47	0.000551	0.0267	0.14	0.11	Height;	chr3:129324739	chr3:129345411~129346164:+
BRCA	cis	rs875971	0.965	rs9969301	ENSG00000271064.1	RP11-792A8.3	3.47	0.000551	0.0267	0.12	0.11	Aortic root size;	chr7:66316668	chr7:66748838~66749077:-
BRCA	cis	rs787274	0.867	rs1361719	ENSG00000271631.1	RP11-408O19.5	3.47	0.000551	0.0267	0.18	0.11	Age-related hearing impairment (SNP x SNP interaction);	chr9:112773296	chr9:112885158~112885767:+
BRCA	cis	rs787274	1	rs2645993	ENSG00000271631.1	RP11-408O19.5	3.47	0.000551	0.0267	0.18	0.11	Age-related hearing impairment (SNP x SNP interaction);	chr9:112773987	chr9:112885158~112885767:+
BRCA	cis	rs787274	0.681	rs787284	ENSG00000271631.1	RP11-408O19.5	3.47	0.000551	0.0267	0.18	0.11	Age-related hearing impairment (SNP x SNP interaction);	chr9:112775760	chr9:112885158~112885767:+
BRCA	cis	rs74233809	1	rs10883815	ENSG00000236937.2	PTGES3P4	3.47	0.000551	0.0267	0.23	0.11	Birth weight;	chr10:102979422	chr10:102845595~102845950:+
BRCA	cis	rs74233809	1	rs112390216	ENSG00000236937.2	PTGES3P4	3.47	0.000551	0.0267	0.23	0.11	Birth weight;	chr10:102981274	chr10:102845595~102845950:+
BRCA	cis	rs4805834	0.841	rs6510304	ENSG00000201388.1	SNORA68	-3.47	0.000551	0.0267	-0.18	-0.11	Creatinine levels;	chr19:32905321	chr19:32608337~32608469:-
BRCA	cis	rs4805834	0.92	rs2082424	ENSG00000201388.1	SNORA68	-3.47	0.000551	0.0267	-0.18	-0.11	Creatinine levels;	chr19:32907383	chr19:32608337~32608469:-
BRCA	cis	rs8114671	0.562	rs6087643	ENSG00000279253.1	RP4-614O4.13	-3.47	0.000551	0.0267	-0.12	-0.11	Height;	chr20:34886659	chr20:35262727~35264187:-
BRCA	cis	rs7572733	0.935	rs13394871	ENSG00000231621.1	AC013264.2	-3.47	0.000551	0.0267	-0.1	-0.11	Dermatomyositis;	chr2:197981613	chr2:197197991~197199273:+
BRCA	cis	rs1865760	1	rs2071299	ENSG00000272810.1	U91328.22	-3.47	0.000551	0.0267	-0.13	-0.11	Height;	chr6:25914573	chr6:26013241~26013757:+
BRCA	cis	rs1865760	1	rs2071298	ENSG00000272810.1	U91328.22	-3.47	0.000551	0.0267	-0.13	-0.11	Height;	chr6:25914673	chr6:26013241~26013757:+
BRCA	cis	rs1865760	0.964	rs1324084	ENSG00000272810.1	U91328.22	-3.47	0.000551	0.0267	-0.13	-0.11	Height;	chr6:25914906	chr6:26013241~26013757:+
BRCA	cis	rs10464366	0.843	rs6957662	ENSG00000233306.2	TRGV2	3.47	0.000551	0.0267	0.1	0.11	IgG glycosylation;	chr7:39071229	chr7:38362864~38363518:-
BRCA	cis	rs10464366	0.843	rs4723819	ENSG00000233306.2	TRGV2	3.47	0.000551	0.0267	0.1	0.11	IgG glycosylation;	chr7:39071641	chr7:38362864~38363518:-
BRCA	cis	rs801193	0.844	rs732465	ENSG00000265600.1	AC006480.1	-3.47	0.000551	0.0267	-0.13	-0.11	Aortic root size;	chr7:66533463	chr7:67356680~67356779:+
BRCA	cis	rs613391	0.508	rs10965431	ENSG00000265194.1	RP11-70L8.4	-3.47	0.000552	0.0267	-0.11	-0.11	Quantitative traits;	chr9:22725850	chr9:21858910~21861926:-
BRCA	cis	rs1865760	0.713	rs7766342	ENSG00000272462.2	U91328.19	-3.47	0.000552	0.0267	-0.13	-0.11	Height;	chr6:25990446	chr6:25992662~26001775:+
BRCA	cis	rs1865760	0.713	rs9461229	ENSG00000272462.2	U91328.19	-3.47	0.000552	0.0267	-0.13	-0.11	Height;	chr6:25992051	chr6:25992662~26001775:+
BRCA	cis	rs10129255	0.826	rs7150693	ENSG00000211958.2	IGHV3-38	3.47	0.000552	0.0267	0.09	0.11	Kawasaki disease;	chr14:106705382	chr14:106410493~106411021:-
BRCA	cis	rs10129255	0.869	rs7150549	ENSG00000211958.2	IGHV3-38	3.47	0.000552	0.0267	0.09	0.11	Kawasaki disease;	chr14:106705441	chr14:106410493~106411021:-
BRCA	cis	rs3781264	0.595	rs11187876	ENSG00000268894.5	PLCE1-AS1	-3.47	0.000552	0.0267	-0.14	-0.11	Esophageal cancer and gastric cancer;	chr10:94330382	chr10:94279277~94287478:-
BRCA	cis	rs3753275	0.64	rs6577498	ENSG00000270282.1	RP5-1115A15.2	3.47	0.000552	0.0267	0.16	0.11	Educational attainment;	chr1:8548765	chr1:8512653~8513021:+
BRCA	cis	rs875971	0.577	rs34888281	ENSG00000272831.1	RP11-792A8.4	-3.47	0.000552	0.0267	-0.1	-0.11	Aortic root size;	chr7:66120784	chr7:66739829~66740385:-
BRCA	cis	rs5758511	0.773	rs62240997	ENSG00000233903.2	Z83851.4	3.47	0.000552	0.0267	0.16	0.11	Birth weight;	chr22:41958563	chr22:42276355~42277052:+
BRCA	cis	rs67340775	0.834	rs13218875	ENSG00000216901.1	AL022393.7	3.47	0.000552	0.0267	0.28	0.11	Lung cancer in ever smokers;	chr6:27916234	chr6:28176188~28176674:+
BRCA	cis	rs7412746	0.621	rs72704656	ENSG00000224800.1	RP11-235D19.2	-3.47	0.000552	0.0267	-0.14	-0.11	Melanoma;	chr1:150855831	chr1:150881236~150881683:-
BRCA	cis	rs1730008	0.731	rs11719124	ENSG00000279311.1	RP11-170K4.2	3.47	0.000552	0.0267	0.14	0.11	Lobe attachment (rater-scored or self-reported);	chr3:158425937	chr3:158869898~158871821:+
BRCA	cis	rs6918586	0.658	rs198830	ENSG00000272462.2	U91328.19	-3.47	0.000552	0.0267	-0.12	-0.11	Schizophrenia;	chr6:26118018	chr6:25992662~26001775:+
BRCA	cis	rs6912958	0.525	rs59322	ENSG00000272008.1	RP11-393I2.4	-3.46	0.000552	0.0268	-0.12	-0.11	Monocyte percentage of white cells;	chr6:87310803	chr6:87151159~87155285:-
BRCA	cis	rs17301013	0.932	rs1653627	ENSG00000200674.1	RN7SKP160	-3.46	0.000552	0.0268	-0.14	-0.11	Systemic lupus erythematosus;	chr1:174771879	chr1:173791548~173791887:+
BRCA	cis	rs12234571	1	rs73374113	ENSG00000214293.7	APTR	3.46	0.000552	0.0268	0.21	0.11	Obesity-related traits;	chr7:77732629	chr7:77657660~77696265:-
BRCA	cis	rs12234571	1	rs12672657	ENSG00000214293.7	APTR	3.46	0.000552	0.0268	0.21	0.11	Obesity-related traits;	chr7:77733091	chr7:77657660~77696265:-
BRCA	cis	rs4974559	0.739	rs6599298	ENSG00000253399.1	AC078852.2	3.46	0.000552	0.0268	0.16	0.11	Systolic blood pressure;	chr4:1304334	chr4:1358479~1359461:+
BRCA	cis	rs2688608	0.725	rs2688623	ENSG00000213731.2	RAB5CP1	-3.46	0.000552	0.0268	-0.12	-0.11	Inflammatory bowel disease;	chr10:73929857	chr10:74423435~74424014:-
BRCA	cis	rs524281	0.861	rs10750780	ENSG00000255038.1	RP11-1167A19.2	-3.46	0.000552	0.0268	-0.15	-0.11	Electroencephalogram traits;	chr11:66207121	chr11:66067277~66069619:-
BRCA	cis	rs983392	0.709	rs2162254	ENSG00000275344.1	MIR6503	3.46	0.000552	0.0268	0.11	0.11	Alzheimer's disease (late onset);	chr11:60272444	chr11:60209071~60209156:-
BRCA	cis	rs4916495	0.874	rs1105977	ENSG00000228413.1	AC024937.2	3.46	0.000552	0.0268	0.14	0.11	Lobe attachment (rater-scored or self-reported);	chr3:196202381	chr3:196044695~196045254:+
BRCA	cis	rs9467773	1	rs767471	ENSG00000224843.5	LINC00240	-3.46	0.000552	0.0268	-0.12	-0.11	Intelligence (multi-trait analysis);	chr6:26557626	chr6:26956992~27023924:+
BRCA	cis	rs4981053	0.644	rs1958710	ENSG00000259001.3	RPPH1	3.46	0.000552	0.0268	0.12	0.11	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr14:20057023	chr14:20343048~20343685:-
BRCA	cis	rs4919694	1	rs112809537	ENSG00000236937.2	PTGES3P4	3.46	0.000552	0.0268	0.22	0.11	Arsenic metabolism;	chr10:102910589	chr10:102845595~102845950:+
BRCA	cis	rs4919694	0.901	rs12251035	ENSG00000236937.2	PTGES3P4	3.46	0.000552	0.0268	0.22	0.11	Arsenic metabolism;	chr10:102911702	chr10:102845595~102845950:+
BRCA	cis	rs62025270	0.547	rs338540	ENSG00000259762.1	RP11-158M2.4	3.46	0.000552	0.0268	0.13	0.11	Idiopathic pulmonary fibrosis;	chr15:85652500	chr15:85750336~85752901:-
BRCA	cis	rs2880765	0.835	rs11074276	ENSG00000230373.7	GOLGA6L5P	3.46	0.000552	0.0268	0.11	0.11	Coronary artery disease;	chr15:85487132	chr15:84507885~84516814:-
BRCA	cis	rs2880765	0.835	rs7164106	ENSG00000230373.7	GOLGA6L5P	3.46	0.000552	0.0268	0.11	0.11	Coronary artery disease;	chr15:85489359	chr15:84507885~84516814:-
BRCA	cis	rs2880765	0.835	rs1872074	ENSG00000230373.7	GOLGA6L5P	3.46	0.000552	0.0268	0.11	0.11	Coronary artery disease;	chr15:85489953	chr15:84507885~84516814:-
BRCA	cis	rs7296418	0.961	rs4148862	ENSG00000280389.1	RP11-512M8.11	-3.46	0.000552	0.0268	-0.14	-0.11	Platelet count;	chr12:123084072	chr12:122255119~122260274:-
BRCA	cis	rs6496932	0.913	rs7403354	ENSG00000259774.1	RP11-182J1.13	3.46	0.000552	0.0268	0.15	0.11	Central corneal thickness;Corneal structure;	chr15:85277624	chr15:84422618~84425882:+
BRCA	cis	rs61160187	0.582	rs1479645	ENSG00000272308.1	RP11-231G3.1	-3.46	0.000553	0.0268	-0.12	-0.11	Educational attainment (years of education);Educational attainment (college completion);	chr5:61023904	chr5:60866457~60866935:-
BRCA	cis	rs7267979	1	rs7020	ENSG00000274414.1	RP5-965G21.4	-3.46	0.000553	0.0268	-0.12	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25297964	chr20:25239007~25245229:-
BRCA	cis	rs6943931	1	rs9648285	ENSG00000230658.1	KLHL7-AS1	-3.46	0.000553	0.0268	-0.14	-0.11	Diabetic kidney disease;	chr7:22377686	chr7:23101228~23105703:-
BRCA	cis	rs6943931	1	rs12535102	ENSG00000230658.1	KLHL7-AS1	-3.46	0.000553	0.0268	-0.14	-0.11	Diabetic kidney disease;	chr7:22377970	chr7:23101228~23105703:-
BRCA	cis	rs8114671	0.562	rs1060615	ENSG00000261582.1	RP4-614O4.11	3.46	0.000553	0.0268	0.1	0.11	Height;	chr20:34890578	chr20:35267885~35280043:-
BRCA	cis	rs4742903	0.545	rs4394453	ENSG00000270332.1	SMC2-AS1	3.46	0.000553	0.0268	0.12	0.11	Breast cancer;High-grade serous ovarian cancer;	chr9:104231233	chr9:104080024~104093073:-
BRCA	cis	rs10191559	0.507	rs4441428	ENSG00000234663.4	AC104820.2	3.46	0.000553	0.0268	0.1	0.11	Red blood cell count;	chr2:181208938	chr2:181101932~181399559:+
BRCA	cis	rs12723316	0.932	rs36120300	ENSG00000233008.4	RP11-475O6.1	-3.46	0.000553	0.0268	-0.2	-0.11	Schizophrenia;	chr1:83813456	chr1:83575776~83861023:-
BRCA	cis	rs12723316	0.932	rs76880990	ENSG00000233008.4	RP11-475O6.1	-3.46	0.000553	0.0268	-0.2	-0.11	Schizophrenia;	chr1:83813596	chr1:83575776~83861023:-
BRCA	cis	rs2731006	0.857	rs2678119	ENSG00000257114.2	RP11-25I15.3	3.46	0.000553	0.0268	0.17	0.11	Panic disorder;	chr12:42762202	chr12:42692216~42717119:+
BRCA	cis	rs875971	0.66	rs2013222	ENSG00000265600.1	AC006480.1	3.46	0.000553	0.0268	0.12	0.11	Aortic root size;	chr7:66570949	chr7:67356680~67356779:+
BRCA	cis	rs6120849	0.586	rs2025096	ENSG00000276073.1	RP5-1125A11.7	-3.46	0.000553	0.0268	-0.15	-0.11	Protein C levels;	chr20:34952197	chr20:33985617~33988989:-
BRCA	cis	rs4974559	0.69	rs28641665	ENSG00000253399.1	AC078852.2	3.46	0.000553	0.0268	0.16	0.11	Systolic blood pressure;	chr4:1294993	chr4:1358479~1359461:+
BRCA	cis	rs7405404	0.913	rs11642229	ENSG00000276564.1	CTA-276F8.1	3.46	0.000553	0.0268	0.13	0.11	Bipolar disorder lithium response (categorical) or schizophrenia;Schizophrenia;	chr16:13653435	chr16:14150833~14153235:+
BRCA	cis	rs6840360	0.554	rs10222838	ENSG00000270265.1	RP11-731D1.4	-3.46	0.000553	0.0268	-0.12	-0.11	Intelligence (multi-trait analysis);	chr4:151768947	chr4:151333775~151353224:-
BRCA	cis	rs6840360	0.593	rs10222925	ENSG00000270265.1	RP11-731D1.4	-3.46	0.000553	0.0268	-0.12	-0.11	Intelligence (multi-trait analysis);	chr4:151769063	chr4:151333775~151353224:-
BRCA	cis	rs2229238	0.911	rs59239860	ENSG00000272030.1	RP1-178F15.4	-3.46	0.000553	0.0268	-0.16	-0.11	Coronary heart disease;	chr1:154519631	chr1:153631438~153634397:-
BRCA	cis	rs4575098	0.681	rs10797093	ENSG00000232879.2	RP11-544M22.3	-3.46	0.000553	0.0268	-0.12	-0.11	Monocyte percentage of white cells;	chr1:161133655	chr1:161034834~161035006:+
BRCA	cis	rs4575098	0.626	rs11265557	ENSG00000232879.2	RP11-544M22.3	-3.46	0.000553	0.0268	-0.12	-0.11	Monocyte percentage of white cells;	chr1:161136564	chr1:161034834~161035006:+
BRCA	cis	rs9341808	0.718	rs2322636	ENSG00000279022.1	RP11-250B2.4	3.46	0.000553	0.0268	0.12	0.11	Sitting height ratio;	chr6:80187719	chr6:80440730~80441172:+
BRCA	cis	rs875971	0.502	rs2946580	ENSG00000232559.3	GS1-124K5.12	-3.46	0.000553	0.0268	-0.15	-0.11	Aortic root size;	chr7:66066855	chr7:66554588~66576923:-
BRCA	cis	rs7103648	1	rs10838705	ENSG00000280615.1	Y_RNA	3.46	0.000553	0.0268	0.12	0.11	Systolic blood pressure;Diastolic blood pressure;	chr11:47403380	chr11:47614898~47614994:-
BRCA	cis	rs7200786	0.565	rs10852330	ENSG00000274038.1	RP11-66H6.4	-3.46	0.000553	0.0268	-0.12	-0.11	Systemic lupus erythematosus;Multiple sclerosis;	chr16:11122201	chr16:11056556~11057034:+
BRCA	cis	rs13063635	0.764	rs4683166	ENSG00000226933.1	NRBF2P2	-3.46	0.000553	0.0268	-0.15	-0.11	Eosinophil percentage of granulocytes;	chr3:46047849	chr3:46023296~46024156:+
BRCA	cis	rs74233809	1	rs75970938	ENSG00000236937.2	PTGES3P4	3.46	0.000553	0.0268	0.24	0.11	Birth weight;	chr10:103033891	chr10:102845595~102845950:+
BRCA	cis	rs2811415	0.597	rs9869012	ENSG00000242551.2	POU5F1P6	3.46	0.000553	0.0268	0.15	0.11	Lung function (FEV1/FVC);	chr3:128009820	chr3:128674735~128677005:-
BRCA	cis	rs55962025	0.846	rs363066	ENSG00000261643.1	RP11-529E10.6	-3.46	0.000553	0.0268	-0.14	-0.11	Parental longevity (mother's age at death);	chr4:3134226	chr4:3503597~3504457:-
BRCA	cis	rs11098499	0.863	rs1383532	ENSG00000260091.1	RP11-33B1.4	3.46	0.000553	0.0268	0.1	0.11	Corneal astigmatism;	chr4:119513249	chr4:119409333~119410233:+
BRCA	cis	rs7200543	1	rs3803575	ENSG00000270580.4	PKD1P6	3.46	0.000553	0.0268	0.12	0.11	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15044590	chr16:15104723~15131601:-
BRCA	cis	rs910873	0.505	rs6087607	ENSG00000269202.1	RP4-614O4.12	3.46	0.000553	0.0268	0.15	0.11	Melanoma;	chr20:34609685	chr20:35201747~35203288:-
BRCA	cis	rs10761482	1	rs1340652	ENSG00000254271.1	RP11-131N11.4	-3.46	0.000553	0.0268	-0.15	-0.11	Schizophrenia;	chr10:60318445	chr10:60734342~60741828:+
BRCA	cis	rs67340775	0.541	rs200968	ENSG00000241549.7	GUSBP2	3.46	0.000553	0.0268	0.16	0.11	Lung cancer in ever smokers;	chr6:27891790	chr6:26871484~26956554:-
BRCA	cis	rs7267979	0.899	rs2104734	ENSG00000274414.1	RP5-965G21.4	-3.46	0.000553	0.0268	-0.12	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25546032	chr20:25239007~25245229:-
BRCA	cis	rs16852403	0.548	rs2225586	ENSG00000224687.1	RASAL2-AS1	3.46	0.000554	0.0268	0.13	0.11	Childhood ear infection;	chr1:178234997	chr1:178091508~178093984:-
BRCA	cis	rs875971	0.964	rs697969	ENSG00000230189.5	GS1-124K5.2	-3.46	0.000554	0.0268	-0.09	-0.11	Aortic root size;	chr7:66093491	chr7:66409143~66490059:-
BRCA	cis	rs875971	1	rs1182882	ENSG00000230189.5	GS1-124K5.2	-3.46	0.000554	0.0268	-0.09	-0.11	Aortic root size;	chr7:66097076	chr7:66409143~66490059:-
BRCA	cis	rs983392	0.792	rs502419	ENSG00000275344.1	MIR6503	-3.46	0.000554	0.0268	-0.11	-0.11	Alzheimer's disease (late onset);	chr11:60098702	chr11:60209071~60209156:-
BRCA	cis	rs7520050	0.966	rs34102169	ENSG00000234329.1	RP11-767N6.2	-3.46	0.000554	0.0268	-0.1	-0.11	Reticulocyte count;Red blood cell count;	chr1:45959192	chr1:45651039~45651826:-
BRCA	cis	rs739401	0.572	rs384490	ENSG00000247473.2	CARS-AS1	3.46	0.000554	0.0268	0.12	0.11	Longevity;	chr11:3057655	chr11:3029009~3041260:+
BRCA	cis	rs754133	0.963	rs12319419	ENSG00000250451.4	HOXC-AS1	-3.46	0.000554	0.0268	-0.14	-0.11	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);	chr12:54026992	chr12:53999022~54000010:-
BRCA	cis	rs59482735	1	rs59482735	ENSG00000238181.2	AHCYP2	-3.46	0.000554	0.0268	-0.14	-0.11	Prostate-specific antigen levels;	chr9:120881148	chr9:120720673~120721972:+
BRCA	cis	rs10457838	0.742	rs6911677	ENSG00000236591.1	RP11-162J8.3	-3.46	0.000554	0.0268	-0.15	-0.11	Post-traumatic stress disorder;	chr6:149006087	chr6:149027700~149032573:-
BRCA	cis	rs6918586	0.615	rs198824	ENSG00000272462.2	U91328.19	-3.46	0.000554	0.0268	-0.12	-0.11	Schizophrenia;	chr6:26122555	chr6:25992662~26001775:+
BRCA	cis	rs6918586	0.658	rs198821	ENSG00000272462.2	U91328.19	-3.46	0.000554	0.0268	-0.12	-0.11	Schizophrenia;	chr6:26123401	chr6:25992662~26001775:+
BRCA	cis	rs7131987	0.903	rs10843367	ENSG00000257176.2	RP11-996F15.2	-3.46	0.000554	0.0268	-0.13	-0.11	QT interval;	chr12:29255447	chr12:29280418~29317848:-
BRCA	cis	rs8040855	0.579	rs6496797	ENSG00000259416.2	RP11-158M2.5	-3.46	0.000554	0.0268	-0.12	-0.11	Bulimia nervosa;	chr15:85183624	chr15:85754941~85756237:-
BRCA	cis	rs7267979	0.816	rs1044573	ENSG00000125804.12	FAM182A	-3.46	0.000554	0.0268	-0.14	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25226018	chr20:26054655~26086917:+
BRCA	cis	rs16893526	0.649	rs9353030	ENSG00000224995.1	LINC01526	-3.46	0.000554	0.0268	-0.17	-0.11	Coronary heart disease;	chr6:81811662	chr6:81813286~81814157:-
BRCA	cis	rs6743226	0.603	rs11675957	ENSG00000266621.1	AC104841.1	-3.46	0.000554	0.0268	-0.13	-0.11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in non-smokers;	chr2:241269377	chr2:241245202~241245299:-
BRCA	cis	rs6430585	0.941	rs6708957	ENSG00000231890.6	DARS-AS1	-3.46	0.000554	0.0268	-0.16	-0.11	Corneal structure;	chr2:135762473	chr2:135985176~136022593:+
BRCA	cis	rs3770752	0.897	rs12616151	ENSG00000272054.1	RP11-423P10.2	-3.46	0.000554	0.0268	-0.09	-0.11	Schizophrenia;	chr2:37318060	chr2:37208875~37212677:+
BRCA	cis	rs4742903	0.904	rs7028408	ENSG00000270332.1	SMC2-AS1	3.46	0.000554	0.0268	0.12	0.11	Breast cancer;High-grade serous ovarian cancer;	chr9:104097530	chr9:104080024~104093073:-
BRCA	cis	rs13315871	0.79	rs13071148	ENSG00000272182.1	RP11-802O23.3	3.46	0.000554	0.0268	0.21	0.11	Cholesterol, total;	chr3:58325111	chr3:58428255~58428815:+
BRCA	cis	rs957448	0.948	rs1470153	ENSG00000261437.1	RP11-22C11.2	3.46	0.000554	0.0268	0.11	0.11	Nonsyndromic cleft lip with cleft palate;	chr8:94514587	chr8:94637285~94639467:-
BRCA	cis	rs16950303	1	rs16950303	ENSG00000265496.3	MIR1539	3.46	0.000554	0.0268	0.2	0.11	Height;	chr18:49055989	chr18:49487339~49491878:+
BRCA	cis	rs2562456	0.558	rs62108173	ENSG00000268081.1	RP11-678G14.2	3.46	0.000554	0.0268	0.18	0.11	Pain;	chr19:21244386	chr19:21554640~21569237:-
BRCA	cis	rs66887589	0.592	rs62320740	ENSG00000250412.1	KLHL2P1	3.46	0.000554	0.0268	0.12	0.11	Diastolic blood pressure;	chr4:119358331	chr4:119334329~119378233:+
BRCA	cis	rs4835473	0.932	rs13129702	ENSG00000246448.2	RP13-578N3.3	3.46	0.000554	0.0269	0.12	0.11	Immature fraction of reticulocytes;	chr4:143785132	chr4:143700257~143865072:+
BRCA	cis	rs11671005	0.735	rs3764532	ENSG00000265272.2	RN7SL693P	3.46	0.000554	0.0269	0.15	0.11	Mean platelet volume;	chr19:58417855	chr19:58490797~58491075:+
BRCA	cis	rs6964587	0.869	rs7793946	ENSG00000188693.7	CYP51A1-AS1	3.46	0.000554	0.0269	0.12	0.11	Breast cancer;	chr7:91891314	chr7:92134604~92180725:+
BRCA	cis	rs3764021	0.527	rs11052426	ENSG00000256594.6	RP11-705C15.2	3.46	0.000554	0.0269	0.14	0.11	Type 1 diabetes;	chr12:9688330	chr12:9633419~9658412:+
BRCA	cis	rs6431644	0.694	rs501145	ENSG00000224287.2	MSL3P1	3.46	0.000554	0.0269	0.13	0.11	Left atrial antero-posterior diameter;	chr2:233854252	chr2:233865437~233868444:-
BRCA	cis	rs561341	0.943	rs508566	ENSG00000265798.5	RP11-271K11.5	3.46	0.000555	0.0269	0.18	0.11	Hip circumference adjusted for BMI;	chr17:31962842	chr17:31038575~31059121:-
BRCA	cis	rs2243480	0.764	rs2460423	ENSG00000229180.5	GS1-124K5.11	3.46	0.000555	0.0269	0.15	0.11	Diabetic kidney disease;	chr7:66136229	chr7:66526088~66542624:-
BRCA	cis	rs259282	0.851	rs174083	ENSG00000267475.1	CTD-2538C1.2	3.46	0.000555	0.0269	0.14	0.11	Schizophrenia;	chr19:32650274	chr19:32687089~32691750:-
BRCA	cis	rs78472555	0.566	rs4408523	ENSG00000259363.4	CTD-2054N24.2	-3.46	0.000555	0.0269	-0.14	-0.11	Post bronchodilator FEV1/FVC ratio in COPD;	chr15:99681682	chr15:99807023~99877148:+
BRCA	cis	rs6732160	0.588	rs13394018	ENSG00000230002.2	ALMS1-IT1	3.46	0.000555	0.0269	0.13	0.11	Intelligence (multi-trait analysis);	chr2:73145477	chr2:73456764~73459484:+
BRCA	cis	rs6918586	0.658	rs198803	ENSG00000272810.1	U91328.22	-3.46	0.000555	0.0269	-0.12	-0.11	Schizophrenia;	chr6:26134824	chr6:26013241~26013757:+
BRCA	cis	rs4664293	0.51	rs747707	ENSG00000230783.1	AC009961.2	3.46	0.000555	0.0269	0.13	0.11	Monocyte percentage of white cells;	chr2:159609003	chr2:159689217~159690291:-
BRCA	cis	rs9843304	0.616	rs4681177	ENSG00000244503.1	RP11-278L15.6	3.46	0.000555	0.0269	0.14	0.11	Gallstone disease;	chr3:149485213	chr3:149494660~149495995:+
BRCA	cis	rs10483282	1	rs11849215	ENSG00000258657.4	RP11-104E19.1	-3.46	0.000555	0.0269	-0.13	-0.11	Alcohol dependence;	chr14:23777584	chr14:24595723~24657774:+
BRCA	cis	rs58521262	0.729	rs7255375	ENSG00000268105.1	RP11-369G6.2	-3.46	0.000555	0.0269	-0.18	-0.11	Testicular germ cell tumor;	chr19:22877293	chr19:23125665~23128543:+
BRCA	cis	rs683250	0.661	rs2510474	ENSG00000254551.1	RP11-727A23.7	-3.46	0.000555	0.0269	-0.13	-0.11	Subcortical brain region volumes;	chr11:83412686	chr11:83209431~83213379:-
BRCA	cis	rs4388249	1	rs11960226	ENSG00000271849.1	CTC-332L22.1	-3.46	0.000555	0.0269	-0.17	-0.11	Schizophrenia;	chr5:109747980	chr5:109687802~109688329:-
BRCA	cis	rs4388249	0.95	rs3797693	ENSG00000271849.1	CTC-332L22.1	-3.46	0.000555	0.0269	-0.17	-0.11	Schizophrenia;	chr5:109750314	chr5:109687802~109688329:-
BRCA	cis	rs8099594	0.565	rs7240563	ENSG00000266696.1	RP11-30L3.2	3.46	0.000555	0.0269	0.12	0.11	Height;	chr18:49236812	chr18:49205912~49208781:+
BRCA	cis	rs72615157	0.612	rs7786505	ENSG00000214313.7	AZGP1P1	-3.46	0.000555	0.0269	-0.13	-0.11	Lung function (FEV1/FVC);	chr7:100219962	chr7:99980762~99987535:+
BRCA	cis	rs703842	0.616	rs7489290	ENSG00000270039.1	RP11-571M6.17	-3.46	0.000555	0.0269	-0.15	-0.11	Multiple sclerosis;	chr12:57834805	chr12:57803838~57804415:+
BRCA	cis	rs11088226	0.681	rs1015047	ENSG00000186842.4	LINC00846	-3.46	0.000555	0.0269	-0.17	-0.11	Gastritis;	chr21:32577113	chr21:32572238~32575881:-
BRCA	cis	rs11168618	0.846	rs7974213	ENSG00000273765.1	RP11-370I10.11	-3.46	0.000555	0.0269	-0.12	-0.11	Adiponectin levels;	chr12:48487709	chr12:48360920~48361377:+
BRCA	cis	rs6924995	0.956	rs7742617	ENSG00000218073.1	RP1-13D10.2	-3.46	0.000555	0.0269	-0.14	-0.11	Response to statins (LDL cholesterol change);	chr6:16156573	chr6:16160926~16161411:+
BRCA	cis	rs2243480	1	rs10807702	ENSG00000275400.1	RP4-756H11.5	3.46	0.000555	0.0269	0.19	0.11	Diabetic kidney disease;	chr7:66302856	chr7:66553805~66554199:-
BRCA	cis	rs10819861	0.621	rs7025349	ENSG00000175611.10	LINC00476	-3.46	0.000555	0.0269	-0.11	-0.11	Electrocardiographic traits;	chr9:96085409	chr9:95759231~95875977:-
BRCA	cis	rs6012564	0.927	rs6019570	ENSG00000230758.1	SNAP23P	-3.46	0.000555	0.0269	-0.12	-0.11	Anger;	chr20:48983153	chr20:49038357~49038602:-
BRCA	cis	rs77948430	0.881	rs17188957	ENSG00000250794.2	ALG1L12P	-3.46	0.000555	0.0269	-0.22	-0.11	Itch intensity from mosquito bite adjusted by bite size;	chr8:13241170	chr8:12421032~12425000:+
BRCA	cis	rs12724450	0.793	rs56214117	ENSG00000228126.1	FALEC	3.46	0.000555	0.0269	0.2	0.11	Blood protein levels;	chr1:150448149	chr1:150515757~150518032:+
BRCA	cis	rs7586085	0.868	rs2113841	ENSG00000229195.1	AC009495.4	-3.46	0.000556	0.0269	-0.13	-0.11	Total body bone mineral density;	chr2:165765599	chr2:165794857~165846091:-
BRCA	cis	rs34779708	0.966	rs17591857	ENSG00000269952.1	RP11-324I22.3	3.46	0.000556	0.0269	0.14	0.11	Inflammatory bowel disease;Crohn's disease;	chr10:35210115	chr10:35210416~35210750:+
BRCA	cis	rs7781266	0.79	rs1038630	ENSG00000226205.1	AC007790.4	-3.46	0.000556	0.0269	-0.16	-0.11	Educational attainment (college completion);	chr7:133465067	chr7:133732493~133733595:-
BRCA	cis	rs440932	1	rs365309	ENSG00000233609.3	RP11-62H7.2	-3.46	0.000556	0.0269	-0.11	-0.11	High light scatter reticulocyte percentage of red cells;	chr8:9169430	chr8:8961200~8979025:+
BRCA	cis	rs2243480	1	rs1723270	ENSG00000226767.1	RP11-328P23.3	-3.46	0.000556	0.0269	-0.18	-0.11	Diabetic kidney disease;	chr7:66004843	chr7:65508773~65508944:-
BRCA	cis	rs12030196	0.871	rs12080311	ENSG00000230812.4	LINC01358	-3.46	0.000556	0.0269	-0.12	-0.11	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr1:58987662	chr1:59020387~59044614:+
BRCA	cis	rs4911253	0.527	rs853859	ENSG00000260536.1	RP5-1085F17.4	3.46	0.000556	0.0269	0.14	0.11	Lymphocyte counts;	chr20:32814463	chr20:32843128~32854257:-
BRCA	cis	rs13126694	0.71	rs6847800	ENSG00000251073.1	NUDT19P5	3.46	0.000556	0.0269	0.1	0.11	Blood osmolality (transformed sodium);	chr4:158011724	chr4:158182825~158183393:+
BRCA	cis	rs7954584	0.531	rs1154514	ENSG00000272849.1	RP11-347I19.8	-3.46	0.000556	0.0269	-0.09	-0.11	Mean corpuscular volume;	chr12:121936982	chr12:121797511~121801972:+
BRCA	cis	rs9377188	0.556	rs2500520	ENSG00000219433.2	RP11-350J20.4	3.46	0.000556	0.0269	0.14	0.11	Cancer;	chr6:148979316	chr6:149794763~149795746:+
BRCA	cis	rs2408955	0.542	rs7975632	ENSG00000257735.1	RP11-370I10.6	3.46	0.000556	0.0269	0.14	0.11	Glycated hemoglobin levels;	chr12:48049265	chr12:48350945~48442411:+
BRCA	cis	rs2422052	1	rs2422052	ENSG00000236255.1	AC009404.2	-3.46	0.000556	0.0269	-0.11	-0.11	Mosquito bite size;	chr2:117894188	chr2:117833937~117841658:+
BRCA	cis	rs875971	0.767	rs12668005	ENSG00000223473.2	GS1-124K5.3	3.46	0.000556	0.0269	0.08	0.11	Aortic root size;	chr7:66444034	chr7:66491049~66493566:-
BRCA	cis	rs10454142	0.731	rs11680719	ENSG00000272663.1	RP11-191L17.1	-3.46	0.000556	0.0269	-0.12	-0.11	Sex hormone-binding globulin levels;	chr2:48430704	chr2:48440043~48440597:-
BRCA	cis	rs35520189	0.592	rs12471839	ENSG00000231747.1	AC079922.2	-3.46	0.000556	0.0269	-0.11	-0.11	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:112954912	chr2:112621809~112622167:-
BRCA	cis	rs11209261	0.517	rs9436376	ENSG00000232284.6	GNG12-AS1	3.46	0.000556	0.0269	0.12	0.11	Airflow obstruction;	chr1:68340797	chr1:67832303~68202987:+
BRCA	cis	rs60515486	0.527	rs56756748	ENSG00000243802.2	RP11-390K5.1	3.46	0.000556	0.0269	0.16	0.11	Lymphocyte counts;	chr11:47371017	chr11:47191181~47191542:-
BRCA	cis	rs9324022	0.858	rs1004573	ENSG00000271198.1	VDAC3P1	-3.46	0.000556	0.0269	-0.18	-0.11	Plateletcrit;	chr14:100711898	chr14:99964529~99965378:+
BRCA	cis	rs3096299	0.632	rs8051537	ENSG00000261118.1	RP11-104N10.1	3.46	0.000556	0.0269	0.11	0.11	Multiple myeloma (IgH translocation);	chr16:89477976	chr16:89492017~89504460:-
BRCA	cis	rs2251666	0.765	rs17771656	ENSG00000267077.1	RP11-127I20.5	3.46	0.000556	0.0269	0.13	0.11	Cancer;	chr16:4878256	chr16:4795265~4796532:-
BRCA	cis	rs4950322	0.744	rs2353987	ENSG00000237188.3	RP11-337C18.8	3.46	0.000556	0.0269	0.13	0.11	Protein quantitative trait loci;	chr1:147355845	chr1:147172771~147211568:+
BRCA	cis	rs13118159	0.836	rs2276903	ENSG00000254094.1	AC078852.1	-3.46	0.000556	0.0269	-0.11	-0.11	Longevity;	chr4:1349617	chr4:1356581~1358075:+
BRCA	cis	rs9923856	0.695	rs723586	ENSG00000263033.2	RP11-396B14.2	-3.46	0.000556	0.0269	-0.13	-0.11	Atopic dermatitis;Adult asthma;	chr16:11004522	chr16:11196177~11224969:+
BRCA	cis	rs361433	0.541	rs11982016	ENSG00000211720.3	TRBV11-1	3.46	0.000556	0.0269	0.17	0.11	Capecitabine sensitivity;	chr7:142504387	chr7:142407672~142408136:+
BRCA	cis	rs2312236	0.673	rs12073480	ENSG00000225171.2	DUTP6	-3.46	0.000556	0.0269	-0.15	-0.11	Post-traumatic stress disorder;	chr1:166742161	chr1:166868748~166869209:+
BRCA	cis	rs8180040	0.587	rs1466741	ENSG00000260236.1	RP11-708J19.1	-3.46	0.000556	0.0269	-0.1	-0.11	Colorectal cancer;	chr3:47205724	chr3:47379089~47380999:-
BRCA	cis	rs2243480	1	rs12698509	ENSG00000234585.5	CCT6P3	-3.46	0.000556	0.0269	-0.16	-0.11	Diabetic kidney disease;	chr7:65953889	chr7:65038354~65074713:+
BRCA	cis	rs10191559	0.552	rs4374330	ENSG00000234663.4	AC104820.2	3.46	0.000556	0.0269	0.09	0.11	Red blood cell count;	chr2:181193705	chr2:181101932~181399559:+
BRCA	cis	rs10782582	0.593	rs17848068	ENSG00000181227.3	RP4-682C21.2	3.46	0.000556	0.0269	0.11	0.11	Daytime sleep phenotypes;	chr1:75724531	chr1:75743423~75744776:-
BRCA	cis	rs4671400	0.543	rs62152274	ENSG00000270820.4	RP11-355B11.2	-3.46	0.000557	0.0269	-0.14	-0.11	3-hydroxypropylmercapturic acid levels in smokers;	chr2:61272453	chr2:61471188~61484130:+
BRCA	cis	rs4761470	0.637	rs11107531	ENSG00000258365.1	RP11-1105G2.3	-3.46	0.000557	0.0269	-0.14	-0.11	Estradiol plasma levels (breast cancer);	chr12:94407545	chr12:94277758~94282844:-
BRCA	cis	rs13256369	0.755	rs12550057	ENSG00000254153.1	CTA-398F10.2	3.46	0.000557	0.0269	0.15	0.11	Obesity-related traits;	chr8:8704758	chr8:8456909~8461337:-
BRCA	cis	rs1018697	1	rs4919677	ENSG00000236937.2	PTGES3P4	3.46	0.000557	0.027	0.14	0.11	Colorectal adenoma (advanced);	chr10:102794547	chr10:102845595~102845950:+
BRCA	cis	rs9467773	0.595	rs12525810	ENSG00000224843.5	LINC00240	-3.46	0.000557	0.027	-0.12	-0.11	Intelligence (multi-trait analysis);	chr6:26623283	chr6:26956992~27023924:+
BRCA	cis	rs7267979	1	rs2027003	ENSG00000274973.1	RP13-401N8.7	3.46	0.000557	0.027	0.12	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25369862	chr20:25845497~25845862:+
BRCA	cis	rs7267979	1	rs2027004	ENSG00000274973.1	RP13-401N8.7	3.46	0.000557	0.027	0.12	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25369982	chr20:25845497~25845862:+
BRCA	cis	rs7267979	0.934	rs2500399	ENSG00000274973.1	RP13-401N8.7	3.46	0.000557	0.027	0.12	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25374058	chr20:25845497~25845862:+
BRCA	cis	rs17767294	0.708	rs72846777	ENSG00000219392.1	RP1-265C24.5	-3.46	0.000557	0.027	-0.29	-0.11	Parkinson's disease;	chr6:28147032	chr6:28115628~28116551:+
BRCA	cis	rs17767294	0.708	rs62620226	ENSG00000219392.1	RP1-265C24.5	-3.46	0.000557	0.027	-0.29	-0.11	Parkinson's disease;	chr6:28153500	chr6:28115628~28116551:+
BRCA	cis	rs17767294	0.708	rs72846788	ENSG00000219392.1	RP1-265C24.5	-3.46	0.000557	0.027	-0.29	-0.11	Parkinson's disease;	chr6:28163065	chr6:28115628~28116551:+
BRCA	cis	rs17767294	0.708	rs72846792	ENSG00000219392.1	RP1-265C24.5	-3.46	0.000557	0.027	-0.29	-0.11	Parkinson's disease;	chr6:28165533	chr6:28115628~28116551:+
BRCA	cis	rs17767294	0.708	rs74756732	ENSG00000219392.1	RP1-265C24.5	-3.46	0.000557	0.027	-0.29	-0.11	Parkinson's disease;	chr6:28184769	chr6:28115628~28116551:+
BRCA	cis	rs9467773	0.549	rs9461273	ENSG00000261353.1	CTA-14H9.5	3.46	0.000557	0.027	0.11	0.11	Intelligence (multi-trait analysis);	chr6:26584298	chr6:26527063~26527404:+
BRCA	cis	rs687432	0.924	rs11608016	ENSG00000265566.2	RN7SL605P	-3.46	0.000557	0.027	-0.15	-0.11	Parkinson's disease;	chr11:58007013	chr11:57528085~57528365:-
BRCA	cis	rs55986470	0.67	rs56313033	ENSG00000186235.9	AC016757.3	3.46	0.000557	0.027	0.23	0.11	Chronotype;	chr2:238437561	chr2:238224552~238231677:-
BRCA	cis	rs17711722	0.727	rs35850374	ENSG00000232546.1	RP11-458F8.1	-3.46	0.000557	0.027	-0.09	-0.11	Calcium levels;	chr7:65892789	chr7:66848496~66858136:+
BRCA	cis	rs6088590	0.648	rs6059991	ENSG00000276073.1	RP5-1125A11.7	-3.46	0.000557	0.027	-0.12	-0.11	Coronary artery disease;	chr20:34693032	chr20:33985617~33988989:-
BRCA	cis	rs9333290	0.866	rs9753297	ENSG00000259915.2	RP11-410E4.1	-3.46	0.000557	0.027	-0.15	-0.11	Urinary albumin-to-creatinine ratio in non-diabetics;Urinary albumin-to-creatinine ratio;	chr2:186649083	chr2:186354570~186356773:-
BRCA	cis	rs1009077	0.579	rs10021460	ENSG00000245958.5	RP11-33B1.1	-3.46	0.000557	0.027	-0.11	-0.11	Endometriosis;	chr4:119595464	chr4:119454791~119552025:+
BRCA	cis	rs4849845	0.598	rs11690576	ENSG00000223549.1	MTND5P28	-3.46	0.000557	0.027	-0.12	-0.11	Mean platelet volume;	chr2:120262224	chr2:120215181~120217279:+
BRCA	cis	rs6433921	0.964	rs11680383	ENSG00000260742.1	RP11-366L5.1	3.46	0.000557	0.027	0.13	0.11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;	chr2:181554422	chr2:181887851~181891663:-
BRCA	cis	rs12517906	0.848	rs10903267	ENSG00000250900.5	CTC-338M12.6	3.46	0.000557	0.027	0.14	0.11	Weight;Body mass index;	chr5:180744716	chr5:181195496~181203103:+
BRCA	cis	rs2148307	0.55	rs11594318	ENSG00000228339.1	AMD1P1	-3.46	0.000557	0.027	-0.14	-0.11	Photic sneeze reflex;	chr10:20806158	chr10:20350049~20351100:+
BRCA	cis	rs987724	0.515	rs344087	ENSG00000244515.1	KRT18P34	-3.46	0.000557	0.027	-0.16	-0.11	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156842608	chr3:157162663~157163932:-
BRCA	cis	rs9467773	0.967	rs6941022	ENSG00000224843.5	LINC00240	-3.46	0.000557	0.027	-0.12	-0.11	Intelligence (multi-trait analysis);	chr6:26553303	chr6:26956992~27023924:+
BRCA	cis	rs9467773	1	rs2224380	ENSG00000224843.5	LINC00240	-3.46	0.000557	0.027	-0.12	-0.11	Intelligence (multi-trait analysis);	chr6:26553715	chr6:26956992~27023924:+
BRCA	cis	rs9467773	1	rs6930120	ENSG00000224843.5	LINC00240	-3.46	0.000557	0.027	-0.12	-0.11	Intelligence (multi-trait analysis);	chr6:26555256	chr6:26956992~27023924:+
BRCA	cis	rs10479542	0.583	rs4131080	ENSG00000273549.1	Metazoa_SRP	-3.46	0.000558	0.027	-0.13	-0.11	Lung cancer;	chr5:179617291	chr5:179629151~179629410:+
BRCA	cis	rs1005277	0.505	rs10827835	ENSG00000273019.1	RP11-508N22.13	3.46	0.000558	0.027	0.12	0.11	Extrinsic epigenetic age acceleration;	chr10:37861781	chr10:38149968~38150293:+
BRCA	cis	rs875971	0.651	rs2420596	ENSG00000223473.2	GS1-124K5.3	3.46	0.000558	0.027	0.08	0.11	Aortic root size;	chr7:66450996	chr7:66491049~66493566:-
BRCA	cis	rs875971	0.52	rs2420597	ENSG00000223473.2	GS1-124K5.3	3.46	0.000558	0.027	0.08	0.11	Aortic root size;	chr7:66450999	chr7:66491049~66493566:-
BRCA	cis	rs12477438	1	rs12477438	ENSG00000231822.1	AC019097.7	-3.46	0.000558	0.027	-0.13	-0.11	Chronic sinus infection;	chr2:99224622	chr2:99102018~99102752:+
BRCA	cis	rs7267979	0.966	rs6083817	ENSG00000276952.1	RP5-965G21.6	-3.46	0.000558	0.027	-0.13	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25363362	chr20:25284915~25285588:-
BRCA	cis	rs7267979	1	rs6050564	ENSG00000276952.1	RP5-965G21.6	-3.46	0.000558	0.027	-0.13	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25363595	chr20:25284915~25285588:-
BRCA	cis	rs7911264	0.739	rs10786050	ENSG00000232709.1	MARK2P9	-3.46	0.000558	0.027	-0.14	-0.11	Inflammatory bowel disease;	chr10:92607473	chr10:92418667~92420875:+
BRCA	cis	rs13126694	0.744	rs28635553	ENSG00000251073.1	NUDT19P5	3.46	0.000558	0.027	0.1	0.11	Blood osmolality (transformed sodium);	chr4:158010962	chr4:158182825~158183393:+
BRCA	cis	rs1193	0.837	rs1878109	ENSG00000266931.1	RP11-1252D15.1	-3.46	0.000558	0.027	-0.13	-0.11	High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;High light scatter reticulocyte count;	chr2:86755753	chr2:87055658~87055800:-
BRCA	cis	rs4849845	0.637	rs4077564	ENSG00000223549.1	MTND5P28	3.46	0.000558	0.027	0.12	0.11	Mean platelet volume;	chr2:120246665	chr2:120215181~120217279:+
BRCA	cis	rs10844706	0.699	rs11052750	ENSG00000278635.1	CTD-2318O12.1	-3.46	0.000558	0.027	-0.11	-0.11	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9735090	chr12:9415641~9416718:+
BRCA	cis	rs17192198	0.66	rs1554393	ENSG00000270344.2	RP11-734K2.4	3.46	0.000558	0.027	0.11	0.11	Diastolic blood pressure;	chr12:89754295	chr12:89525654~89548005:+
BRCA	cis	rs7208859	0.623	rs7503335	ENSG00000276250.1	CTD-2349P21.12	-3.46	0.000558	0.027	-0.16	-0.11	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30746944	chr17:30803654~30804077:+
BRCA	cis	rs930395	0.514	rs9791056	ENSG00000248779.1	RP11-53O19.2	-3.46	0.000558	0.027	-0.1	-0.11	Breast cancer;	chr5:44903789	chr5:44752949~44765744:+
BRCA	cis	rs9905704	0.587	rs2003537	ENSG00000265148.4	BZRAP1-AS1	-3.46	0.000558	0.027	-0.14	-0.11	Testicular germ cell tumor;	chr17:58534510	chr17:58325450~58415766:+
BRCA	cis	rs17741049	0.881	rs73688699	ENSG00000260493.1	RP11-219B4.7	-3.46	0.000558	0.027	-0.25	-0.11	Blood protein levels;	chr8:85274330	chr8:85172077~85177062:-
BRCA	cis	rs62458065	0.513	rs10268803	ENSG00000273014.1	RP11-225B17.2	-3.46	0.000558	0.027	-0.16	-0.11	Metabolite levels (HVA/MHPG ratio);	chr7:32508223	chr7:32758882~32759353:+
BRCA	cis	rs72647484	0.558	rs2744697	ENSG00000228397.1	RP1-224A6.3	-3.46	0.000558	0.027	-0.29	-0.11	Colorectal cancer;	chr1:22257162	chr1:22023994~22024968:-
BRCA	cis	rs72647484	0.642	rs72647481	ENSG00000228397.1	RP1-224A6.3	-3.46	0.000558	0.027	-0.29	-0.11	Colorectal cancer;	chr1:22258225	chr1:22023994~22024968:-
BRCA	cis	rs11662586	1	rs7243921	ENSG00000267270.4	PARD6G-AS1	-3.46	0.000558	0.027	-0.14	-0.11	Exploratory eye movement dysfunction in schizophrenia (responsive search score);	chr18:79935237	chr18:80147924~80178432:+
BRCA	cis	rs977987	0.778	rs1109341	ENSG00000261476.1	RP11-77K12.3	-3.46	0.000558	0.027	-0.12	-0.11	Dupuytren's disease;	chr16:75411707	chr16:75458252~75460017:-
BRCA	cis	rs6696239	0.513	rs2935146	ENSG00000227711.2	RP11-275O4.5	-3.46	0.000558	0.027	-0.12	-0.11	Height;	chr1:227598332	chr1:227509028~227520477:-
BRCA	cis	rs6696239	0.513	rs2999744	ENSG00000227711.2	RP11-275O4.5	-3.46	0.000558	0.027	-0.12	-0.11	Height;	chr1:227599667	chr1:227509028~227520477:-
BRCA	cis	rs10944	0.598	rs688286	ENSG00000253558.1	CTD-2179L22.1	-3.46	0.000558	0.027	-0.13	-0.11	Blood and toenail selenium levels;	chr5:78980842	chr5:78041879~78044138:-
BRCA	cis	rs7520050	0.966	rs1768816	ENSG00000234329.1	RP11-767N6.2	-3.46	0.000558	0.027	-0.1	-0.11	Reticulocyte count;Red blood cell count;	chr1:46062927	chr1:45651039~45651826:-
BRCA	cis	rs2657888	0.628	rs2638334	ENSG00000257576.1	RP11-153M3.1	3.46	0.000558	0.027	0.13	0.11	Adiponectin levels;	chr12:56488744	chr12:56511002~56512703:+
BRCA	cis	rs1670533	1	rs688785	ENSG00000251639.2	RP11-20I20.1	3.46	0.000558	0.027	0.17	0.11	Recombination rate (females);	chr4:1088919	chr4:1100016~1101558:-
BRCA	cis	rs1670533	0.746	rs688008	ENSG00000251639.2	RP11-20I20.1	3.46	0.000558	0.027	0.17	0.11	Recombination rate (females);	chr4:1089041	chr4:1100016~1101558:-
BRCA	cis	rs1670533	1	rs676561	ENSG00000251639.2	RP11-20I20.1	3.46	0.000558	0.027	0.17	0.11	Recombination rate (females);	chr4:1089324	chr4:1100016~1101558:-
BRCA	cis	rs2839186	0.565	rs2839183	ENSG00000228137.1	AP001469.7	-3.46	0.000559	0.027	-0.11	-0.11	Testicular germ cell tumor;	chr21:46267230	chr21:46246890~46247682:+
BRCA	cis	rs4835473	0.932	rs2218791	ENSG00000246448.2	RP13-578N3.3	-3.46	0.000559	0.027	-0.12	-0.11	Immature fraction of reticulocytes;	chr4:143749300	chr4:143700257~143865072:+
BRCA	cis	rs7339483	1	rs10410193	ENSG00000269416.4	LINC01224	3.46	0.000559	0.027	0.21	0.11	Discordance in emotional problems in monozygotic twins;	chr19:24219116	chr19:23399233~23416075:-
BRCA	cis	rs6942407	0.546	rs2286268	ENSG00000224046.1	AC005076.5	-3.46	0.000559	0.027	-0.15	-0.11	Food allergy;	chr7:87219069	chr7:87151423~87152420:-
BRCA	cis	rs35306767	0.903	rs12254002	ENSG00000229869.1	RP11-363N22.2	3.46	0.000559	0.027	0.16	0.11	Eosinophil percentage of granulocytes;	chr10:883193	chr10:933026~942743:+
BRCA	cis	rs7267979	1	rs6115153	ENSG00000276952.1	RP5-965G21.6	-3.46	0.000559	0.027	-0.13	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25344931	chr20:25284915~25285588:-
BRCA	cis	rs875971	0.638	rs7793569	ENSG00000275400.1	RP4-756H11.5	3.46	0.000559	0.027	0.12	0.11	Aortic root size;	chr7:66651646	chr7:66553805~66554199:-
BRCA	cis	rs801193	1	rs3857688	ENSG00000275400.1	RP4-756H11.5	3.46	0.000559	0.027	0.12	0.11	Aortic root size;	chr7:66662819	chr7:66553805~66554199:-
BRCA	cis	rs801193	1	rs2286684	ENSG00000275400.1	RP4-756H11.5	3.46	0.000559	0.027	0.12	0.11	Aortic root size;	chr7:66664843	chr7:66553805~66554199:-
BRCA	cis	rs801193	0.935	rs2286683	ENSG00000275400.1	RP4-756H11.5	3.46	0.000559	0.027	0.12	0.11	Aortic root size;	chr7:66664856	chr7:66553805~66554199:-
BRCA	cis	rs801193	1	rs10274773	ENSG00000275400.1	RP4-756H11.5	3.46	0.000559	0.027	0.12	0.11	Aortic root size;	chr7:66668591	chr7:66553805~66554199:-
BRCA	cis	rs8038465	0.638	rs7495543	ENSG00000260898.4	ADPGK-AS1	3.46	0.000559	0.027	0.12	0.11	Liver enzyme levels (gamma-glutamyl transferase);	chr15:73662792	chr15:72782835~72798199:+
BRCA	cis	rs7103648	0.966	rs10769263	ENSG00000280615.1	Y_RNA	3.46	0.000559	0.027	0.13	0.11	Systolic blood pressure;Diastolic blood pressure;	chr11:47395632	chr11:47614898~47614994:-
BRCA	cis	rs8062405	1	rs12443881	ENSG00000261766.1	RP11-22P6.2	-3.46	0.000559	0.027	-0.11	-0.11	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28830456	chr16:28862166~28863340:-
BRCA	cis	rs6545883	0.929	rs10190332	ENSG00000273302.1	RP11-493E12.2	-3.46	0.000559	0.027	-0.1	-0.11	Tuberculosis;	chr2:61392132	chr2:61199979~61200769:+
BRCA	cis	rs6696239	0.956	rs2172936	ENSG00000227711.2	RP11-275O4.5	-3.46	0.000559	0.027	-0.15	-0.11	Height;	chr1:227596547	chr1:227509028~227520477:-
BRCA	cis	rs6696239	0.956	rs9726691	ENSG00000227711.2	RP11-275O4.5	-3.46	0.000559	0.027	-0.15	-0.11	Height;	chr1:227597923	chr1:227509028~227520477:-
BRCA	cis	rs7819412	0.595	rs2409712	ENSG00000254507.2	RP11-481A20.10	3.46	0.000559	0.027	0.13	0.11	Triglycerides;	chr8:11129327	chr8:12003400~12004082:-
BRCA	cis	rs13401620	0.871	rs10165049	ENSG00000229326.3	AC069154.4	-3.46	0.000559	0.027	-0.14	-0.11	Breast size;	chr2:119794420	chr2:119698623~119700151:+
BRCA	cis	rs12612420	0.534	rs12999182	ENSG00000225953.2	SATB2-AS1	3.46	0.000559	0.027	0.17	0.11	Exercise (leisure time);	chr2:200269252	chr2:199457700~199476935:+
BRCA	cis	rs2274273	0.588	rs9919923	ENSG00000259318.1	RP11-454L9.2	3.46	0.000559	0.027	0.1	0.11	Protein biomarker;	chr14:55347181	chr14:55394940~55395233:-
BRCA	cis	rs2274273	0.588	rs9919932	ENSG00000259318.1	RP11-454L9.2	3.46	0.000559	0.027	0.1	0.11	Protein biomarker;	chr14:55347362	chr14:55394940~55395233:-
BRCA	cis	rs875971	0.658	rs432667	ENSG00000230189.5	GS1-124K5.2	3.46	0.000559	0.027	0.09	0.11	Aortic root size;	chr7:66049646	chr7:66409143~66490059:-
BRCA	cis	rs2585417	0.535	rs2153964	ENSG00000185834.10	RPL12P4	-3.46	0.000559	0.027	-0.11	-0.11	Obesity-related traits;	chr20:54296976	chr20:55074644~55075140:+
BRCA	cis	rs2585417	0.535	rs2153965	ENSG00000185834.10	RPL12P4	-3.46	0.000559	0.027	-0.11	-0.11	Obesity-related traits;	chr20:54296996	chr20:55074644~55075140:+
BRCA	cis	rs4356203	0.87	rs1979603	ENSG00000184669.7	OR7E14P	-3.46	0.000559	0.027	-0.14	-0.11	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17261839	chr11:17013998~17053024:+
BRCA	cis	rs7264396	0.563	rs6058322	ENSG00000088340.14	FER1L4	3.46	0.000559	0.027	0.15	0.11	Total cholesterol levels;	chr20:35779355	chr20:35558737~35607562:-
BRCA	cis	rs2574985	0.925	rs1203418	ENSG00000231345.3	BEND3P1	-3.46	0.000559	0.0271	-0.18	-0.11	Subjective well-being;	chr10:50418827	chr10:50655967~50660472:+
BRCA	cis	rs205391	0.544	rs398889	ENSG00000275807.1	RP11-1348G14.8	3.46	0.000559	0.0271	0.15	0.11	Obesity-related traits;	chr16:28032176	chr16:28822431~28823969:-
BRCA	cis	rs1411478	1	rs4652545	ENSG00000243155.1	RP11-46A10.5	3.46	0.000559	0.0271	0.11	0.11	Menopause (age at onset);Progressive supranuclear palsy;	chr1:180978472	chr1:180944042~180976482:-
BRCA	cis	rs13393800	0.806	rs2276559	ENSG00000237126.7	AC073254.1	-3.46	0.000559	0.0271	-0.14	-0.11	Height;	chr2:232586453	chr2:232580948~232611971:-
BRCA	cis	rs6545883	0.503	rs1665272	ENSG00000270820.4	RP11-355B11.2	3.46	0.000559	0.0271	0.12	0.11	Tuberculosis;	chr2:61152151	chr2:61471188~61484130:+
BRCA	cis	rs2833693	1	rs2833695	ENSG00000261610.1	AP000265.1	3.46	0.000559	0.0271	0.14	0.11	Temperament;	chr21:32181819	chr21:32259804~32261585:-
BRCA	cis	rs738144	0.502	rs9611034	ENSG00000228274.3	RP3-508I15.9	-3.46	0.000559	0.0271	-0.13	-0.11	IgG glycosylation;	chr22:38834879	chr22:38667585~38681820:-
BRCA	cis	rs2625529	0.73	rs2957725	ENSG00000261187.1	RP11-1007O24.2	3.46	0.00056	0.0271	0.12	0.11	Red blood cell count;	chr15:71955864	chr15:72465128~72466262:-
BRCA	cis	rs74501188	0.56	rs7724016	ENSG00000281357.1	ARRDC3-AS1	-3.46	0.00056	0.0271	-0.12	-0.11	Small cell lung carcinoma;	chr5:90922072	chr5:91380349~91439085:+
BRCA	cis	rs7955516	0.781	rs10770642	ENSG00000255910.1	RP11-405A12.2	-3.46	0.00056	0.0271	-0.11	-0.11	Adiponectin levels;	chr12:20340848	chr12:19775451~20009937:+
BRCA	cis	rs16858210	0.607	rs60244260	ENSG00000234371.6	RPSAP31	3.46	0.00056	0.0271	0.16	0.11	Menopause (age at onset);	chr3:183852946	chr3:183884924~183888449:+
BRCA	cis	rs6429422	0.736	rs6662991	ENSG00000224727.1	FCF1P7	-3.46	0.00056	0.0271	-0.13	-0.11	Cognitive ability (multi-trait analysis);	chr1:243246906	chr1:243267257~243268119:-
BRCA	cis	rs7259376	0.902	rs12610462	ENSG00000269345.1	VN1R85P	3.46	0.00056	0.0271	0.12	0.11	Menopause (age at onset);	chr19:22368660	chr19:22174766~22175191:-
BRCA	cis	rs7259376	0.936	rs16999064	ENSG00000269345.1	VN1R85P	3.46	0.00056	0.0271	0.12	0.11	Menopause (age at onset);	chr19:22369800	chr19:22174766~22175191:-
BRCA	cis	rs7777677	0.925	rs4726542	ENSG00000275158.1	TRBV12-5	3.46	0.00056	0.0271	0.1	0.11	Alcoholic chronic pancreatitis;	chr7:142659516	chr7:142580917~142581427:+
BRCA	cis	rs10043775	0.793	rs6892647	ENSG00000251330.3	CTD-2283N19.1	-3.46	0.00056	0.0271	-0.12	-0.11	Periodontal microbiota;	chr5:148331933	chr5:148430159~148430807:-
BRCA	cis	rs10266483	0.545	rs12540100	ENSG00000228014.1	ZNF680P1	-3.46	0.00056	0.0271	-0.16	-0.11	Response to statin therapy;	chr7:64289924	chr7:64469185~64470653:+
BRCA	cis	rs9545308	0.897	rs9545315	ENSG00000227676.3	LINC01068	-3.46	0.00056	0.0271	-0.14	-0.11	Nonsyndromic cleft lip with cleft palate;	chr13:80070878	chr13:79566727~79571436:+
BRCA	cis	rs6678639	0.522	rs17102977	ENSG00000225154.2	RP11-184J23.2	-3.46	0.00056	0.0271	-0.16	-0.11	Blood metabolite ratios;	chr1:47029933	chr1:47074778~47075979:-
BRCA	cis	rs8054556	1	rs8054556	ENSG00000214725.6	CDIPT-AS1	-3.46	0.00056	0.0271	-0.13	-0.11	Autism spectrum disorder or schizophrenia;	chr16:29946895	chr16:29863593~29868053:+
BRCA	cis	rs4950322	0.802	rs72694705	ENSG00000237188.3	RP11-337C18.8	3.46	0.00056	0.0271	0.14	0.11	Protein quantitative trait loci;	chr1:147362313	chr1:147172771~147211568:+
BRCA	cis	rs1635	0.655	rs10484542	ENSG00000216901.1	AL022393.7	3.46	0.00056	0.0271	0.23	0.11	Schizophrenia;	chr6:28341976	chr6:28176188~28176674:+
BRCA	cis	rs12701220	0.857	rs1057558	ENSG00000224079.1	AC091729.7	3.46	0.00056	0.0271	0.15	0.11	Bronchopulmonary dysplasia;	chr7:1022730	chr7:1074450~1078036:+
BRCA	cis	rs2645424	1	rs962366	ENSG00000269899.1	RP11-589N15.2	3.46	0.00056	0.0271	0.12	0.11	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);	chr8:11826894	chr8:11846154~11846391:-
BRCA	cis	rs55675132	0.548	rs79783412	ENSG00000226167.1	AP4B1-AS1	3.46	0.00056	0.0271	0.11	0.11	Schizophrenia;	chr1:114830857	chr1:113856635~113901237:+
BRCA	cis	rs55675132	0.548	rs75587174	ENSG00000226167.1	AP4B1-AS1	3.46	0.00056	0.0271	0.11	0.11	Schizophrenia;	chr1:114830886	chr1:113856635~113901237:+
BRCA	cis	rs465969	0.744	rs3851228	ENSG00000271789.1	RP5-1112D6.7	-3.46	0.00056	0.0271	-0.21	-0.11	Psoriasis;	chr6:111526988	chr6:111297126~111298510:+
BRCA	cis	rs4713118	0.662	rs156744	ENSG00000226314.6	ZNF192P1	-3.46	0.00056	0.0271	-0.16	-0.11	Parkinson's disease;	chr6:27999496	chr6:28161781~28169594:+
BRCA	cis	rs4713118	0.662	rs149947	ENSG00000226314.6	ZNF192P1	-3.46	0.00056	0.0271	-0.16	-0.11	Parkinson's disease;	chr6:28004655	chr6:28161781~28169594:+
BRCA	cis	rs4907240	0.731	rs11900310	ENSG00000230606.9	AC159540.1	-3.46	0.00056	0.0271	-0.13	-0.11	Event-related brain oscillations;	chr2:96476093	chr2:97416165~97433527:-
BRCA	cis	rs12468226	1	rs7565875	ENSG00000272966.1	RP11-686O6.1	3.46	0.00056	0.0271	0.17	0.11	Urate levels;	chr2:202516412	chr2:202336739~202337200:+
BRCA	cis	rs6743226	0.603	rs3771343	ENSG00000266621.1	AC104841.1	3.46	0.00056	0.0271	0.13	0.11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in non-smokers;	chr2:241264871	chr2:241245202~241245299:-
BRCA	cis	rs7020830	0.931	rs1388978	ENSG00000230188.1	RP11-405L18.4	-3.46	0.00056	0.0271	-0.13	-0.11	Schizophrenia;	chr9:37144065	chr9:37490421~37490893:-
BRCA	cis	rs875971	0.862	rs1981799	ENSG00000272831.1	RP11-792A8.4	3.46	0.000561	0.0271	0.1	0.11	Aortic root size;	chr7:66490572	chr7:66739829~66740385:-
BRCA	cis	rs160451	0.811	rs218943	ENSG00000251136.7	RP11-37B2.1	-3.46	0.000561	0.0271	-0.11	-0.11	Leprosy;	chr8:89701113	chr8:89609409~89757727:-
BRCA	cis	rs17035270	0.891	rs17429654	ENSG00000249885.1	ARHGEF38-IT1	3.46	0.000561	0.0271	0.14	0.11	Coronary artery disease;	chr4:105103424	chr4:105561591~105570238:+
BRCA	cis	rs718433	0.556	rs2075477	ENSG00000211778.2	TRAV4	-3.46	0.000561	0.0271	-0.08	-0.11	Intraocular pressure;	chr14:21749072	chr14:21736152~21736982:+
BRCA	cis	rs7674212	0.507	rs223413	ENSG00000248740.4	RP11-328K4.1	-3.46	0.000561	0.0271	-0.13	-0.11	Type 2 diabetes;	chr4:102811709	chr4:103256159~103453658:+
BRCA	cis	rs67340775	0.541	rs200966	ENSG00000219392.1	RP1-265C24.5	-3.46	0.000561	0.0271	-0.18	-0.11	Lung cancer in ever smokers;	chr6:27894374	chr6:28115628~28116551:+
BRCA	cis	rs7959452	0.59	rs11177643	ENSG00000274979.1	RP11-1143G9.5	-3.46	0.000561	0.0271	-0.11	-0.11	Blood protein levels;	chr12:69391932	chr12:69326574~69331882:-
BRCA	cis	rs11098403	0.753	rs4392571	ENSG00000225892.3	RP11-384K6.2	3.46	0.000561	0.0271	0.11	0.11	Schizophrenia;	chr4:117846167	chr4:118632274~118634759:+
BRCA	cis	rs12949688	0.934	rs12449409	ENSG00000262623.1	RP5-1107A17.2	-3.46	0.000561	0.0271	-0.11	-0.11	Schizophrenia;	chr17:57745106	chr17:56951664~56952404:+
BRCA	cis	rs1143633	0.579	rs4849132	ENSG00000231747.1	AC079922.2	3.46	0.000561	0.0271	0.1	0.11	Allergic disease (asthma, hay fever or eczema);	chr2:112915894	chr2:112621809~112622167:-
BRCA	cis	rs2554380	0.628	rs6602990	ENSG00000176700.18	SCAND2P	-3.46	0.000561	0.0271	-0.11	-0.11	Height;	chr15:83783470	chr15:84631451~84647478:+
BRCA	cis	rs219780	0.768	rs219784	ENSG00000233818.1	AP000695.4	3.46	0.000561	0.0271	0.12	0.11	Kidney stones;	chr21:36459569	chr21:36445731~36532408:+
BRCA	cis	rs4925386	0.84	rs6143035	ENSG00000275437.1	RP5-908M14.10	-3.46	0.000561	0.0271	-0.12	-0.11	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62345644	chr20:62402236~62405935:-
BRCA	cis	rs2832270	1	rs2832272	ENSG00000273464.1	RP11-313P22.1	3.46	0.000561	0.0271	0.19	0.11	Response to mTOR inhibitor (everolimus);	chr21:29225082	chr21:29657406~29657831:+
BRCA	cis	rs931127	0.692	rs7934517	ENSG00000255557.1	RP11-770G2.2	3.46	0.000561	0.0271	0.12	0.11	Systemic lupus erythematosus;	chr11:65678202	chr11:65745729~65771585:+
BRCA	cis	rs12122100	0.696	rs12752148	ENSG00000229828.2	PDE4DIP1	-3.46	0.000561	0.0271	-0.15	-0.11	HIV-1 control;	chr1:147085526	chr1:148080598~148093883:+
BRCA	cis	rs7914558	1	rs67908413	ENSG00000213277.3	MARCKSL1P1	3.46	0.000561	0.0271	0.12	0.11	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103005232	chr10:103175554~103176094:+
BRCA	cis	rs9287719	0.967	rs6748036	ENSG00000224177.5	LINC00570	3.46	0.000561	0.0271	0.12	0.11	Prostate cancer;	chr2:10577363	chr2:11393981~11403077:+
BRCA	cis	rs17761864	0.881	rs17834563	ENSG00000262333.1	HNRNPA1P16	3.46	0.000561	0.0271	0.12	0.11	Esophageal cancer (squamous cell);	chr17:2269416	chr17:2306761~2307715:+
BRCA	cis	rs2657888	0.529	rs12316930	ENSG00000257576.1	RP11-153M3.1	-3.46	0.000561	0.0271	-0.14	-0.11	Adiponectin levels;	chr12:56492032	chr12:56511002~56512703:+
BRCA	cis	rs12122100	0.651	rs12743228	ENSG00000278811.3	LINC00624	-3.46	0.000561	0.0271	-0.14	-0.11	HIV-1 control;	chr1:147076727	chr1:147258885~147517875:-
BRCA	cis	rs6601327	0.613	rs11785458	ENSG00000233609.3	RP11-62H7.2	-3.46	0.000561	0.0271	-0.1	-0.11	Multiple myeloma (hyperdiploidy);	chr8:9649300	chr8:8961200~8979025:+
BRCA	cis	rs4650943	0.503	rs6678628	ENSG00000227740.1	RP11-318C24.2	3.46	0.000561	0.0271	0.11	0.11	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in inactive individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr1:176094588	chr1:175904762~175920513:-
BRCA	cis	rs4650943	0.503	rs6678812	ENSG00000227740.1	RP11-318C24.2	3.46	0.000561	0.0271	0.11	0.11	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in inactive individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr1:176094735	chr1:175904762~175920513:-
BRCA	cis	rs4243971	0.516	rs6141700	ENSG00000275576.1	RP5-836N17.4	-3.46	0.000561	0.0271	-0.12	-0.11	Inflammatory bowel disease;Crohn's disease;	chr20:32394763	chr20:32116171~32116629:+
BRCA	cis	rs1555133	0.543	rs13043838	ENSG00000275576.1	RP5-836N17.4	-3.46	0.000561	0.0271	-0.12	-0.11	Monocyte count;	chr20:32396999	chr20:32116171~32116629:+
BRCA	cis	rs477895	0.713	rs11601024	ENSG00000256940.1	RP11-783K16.5	3.46	0.000561	0.0271	0.15	0.11	Mean platelet volume;	chr11:64175602	chr11:64245964~64248217:+
BRCA	cis	rs4671400	0.516	rs1809028	ENSG00000212978.6	AC016747.3	3.46	0.000561	0.0271	0.18	0.11	3-hydroxypropylmercapturic acid levels in smokers;	chr2:61186588	chr2:61141592~61144969:-
BRCA	cis	rs1616122	0.606	rs1193238	ENSG00000229519.2	RP11-58A11.2	3.46	0.000561	0.0271	0.12	0.11	Periodontal microbiota;	chr1:7466311	chr1:6547905~6548619:+
BRCA	cis	rs561341	1	rs501312	ENSG00000265798.5	RP11-271K11.5	3.46	0.000562	0.0271	0.18	0.11	Hip circumference adjusted for BMI;	chr17:32002047	chr17:31038575~31059121:-
BRCA	cis	rs10045413	0.598	rs13171268	ENSG00000250167.1	CTC-321K16.1	3.46	0.000562	0.0271	0.13	0.11	Age at smoking initiation in chronic obstructive pulmonary disease;	chr5:135619695	chr5:135559577~135634874:+
BRCA	cis	rs2154319	0.887	rs2064740	ENSG00000230638.4	RP11-486B10.4	3.46	0.000562	0.0271	0.18	0.11	Height;	chr1:41048478	chr1:41542069~41544310:+
BRCA	cis	rs2154319	0.79	rs2363096	ENSG00000230638.4	RP11-486B10.4	3.46	0.000562	0.0271	0.18	0.11	Height;	chr1:41049277	chr1:41542069~41544310:+
BRCA	cis	rs4842666	0.528	rs7302816	ENSG00000270344.2	RP11-734K2.4	-3.46	0.000562	0.0271	-0.12	-0.11	Blood pressure;	chr12:89556543	chr12:89525654~89548005:+
BRCA	cis	rs6893300	0.961	rs11739042	ENSG00000225051.5	HMGB3P22	3.46	0.000562	0.0272	0.14	0.11	Resting heart rate;	chr5:179755494	chr5:179679032~179694768:+
BRCA	cis	rs1870634	0.541	rs4997087	ENSG00000273008.1	RP11-351D16.3	-3.46	0.000562	0.0272	-0.13	-0.11	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;	chr10:43999917	chr10:43136824~43138334:-
BRCA	cis	rs7935829	0.536	rs611267	ENSG00000275344.1	MIR6503	3.46	0.000562	0.0272	0.11	0.11	Fibrinogen levels;	chr11:60237795	chr11:60209071~60209156:-
BRCA	cis	rs9314986	1	rs1590501	ENSG00000232489.1	MFAP1P1	-3.46	0.000562	0.0272	-0.13	-0.11	Biliary atresia;	chr13:29882170	chr13:30541643~30542897:-
BRCA	cis	rs7134599	0.561	rs7134731	ENSG00000203585.3	RP11-542B15.1	3.46	0.000562	0.0272	0.11	0.11	Inflammatory bowel disease;Ulcerative colitis;	chr12:68076278	chr12:67519829~67567126:+
BRCA	cis	rs8114671	0.527	rs2295352	ENSG00000126005.14	MMP24-AS1	3.46	0.000562	0.0272	0.12	0.11	Height;	chr20:34732251	chr20:35216462~35278131:-
BRCA	cis	rs4699052	1	rs4699052	ENSG00000230069.3	LRRC37A15P	-3.46	0.000562	0.0272	-0.1	-0.11	Testicular germ cell tumor;	chr4:103216633	chr4:102727274~102730721:-
BRCA	cis	rs950169	0.545	rs4842841	ENSG00000176700.18	SCAND2P	-3.46	0.000562	0.0272	-0.12	-0.11	Schizophrenia;	chr15:83972373	chr15:84631451~84647478:+
BRCA	cis	rs10139154	0.889	rs229155	ENSG00000250365.5	CTD-2213F21.2	3.46	0.000562	0.0272	0.13	0.11	Amyotrophic lateral sclerosis;	chr14:30634685	chr14:31420286~31452883:+
BRCA	cis	rs910316	0.967	rs4899549	ENSG00000259138.1	RP11-950C14.7	-3.46	0.000562	0.0272	-0.11	-0.11	Height;	chr14:75180791	chr14:75127153~75136930:+
BRCA	cis	rs910316	0.967	rs4899550	ENSG00000259138.1	RP11-950C14.7	-3.46	0.000562	0.0272	-0.11	-0.11	Height;	chr14:75180963	chr14:75127153~75136930:+
BRCA	cis	rs2278170	0.923	rs11032354	ENSG00000225101.4	OR52K3P	-3.46	0.000562	0.0272	-0.14	-0.11	Amyotrophic lateral sclerosis;	chr11:4465947	chr11:4474813~4475755:+
BRCA	cis	rs1552172	0.853	rs2004659	ENSG00000234367.1	PFN1P3	-3.46	0.000562	0.0272	-0.12	-0.11	Breast cancer;	chr1:145846884	chr1:145407772~145408173:+
BRCA	cis	rs359466	0.938	rs12188193	ENSG00000254164.1	CTB-33O18.2	-3.46	0.000562	0.0272	-0.17	-0.11	QRS complex (Sokolow-Lyon);	chr5:173909682	chr5:173574938~173576275:+
BRCA	cis	rs9650657	0.538	rs11250093	ENSG00000255046.1	RP11-297N6.4	-3.46	0.000562	0.0272	-0.13	-0.11	Neuroticism;	chr8:10941318	chr8:11797928~11802568:-
BRCA	cis	rs8098244	0.928	rs1893290	ENSG00000265752.2	RP11-403A21.1	3.46	0.000562	0.0272	0.14	0.11	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23862657	chr18:23957754~23982556:-
BRCA	cis	rs1411478	1	rs6425657	ENSG00000243155.1	RP11-46A10.5	3.46	0.000563	0.0272	0.11	0.11	Menopause (age at onset);Progressive supranuclear palsy;	chr1:180987769	chr1:180944042~180976482:-
BRCA	cis	rs875971	0.862	rs11773628	ENSG00000265600.1	AC006480.1	3.46	0.000563	0.0272	0.13	0.11	Aortic root size;	chr7:66517644	chr7:67356680~67356779:+
BRCA	cis	rs7914558	1	rs1926030	ENSG00000213277.3	MARCKSL1P1	3.46	0.000563	0.0272	0.12	0.11	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103095899	chr10:103175554~103176094:+
BRCA	cis	rs6546537	0.826	rs2704443	ENSG00000231024.1	AC092431.3	3.46	0.000563	0.0272	0.15	0.11	Serum thyroid-stimulating hormone levels;	chr2:69662206	chr2:69700192~69713847:-
BRCA	cis	rs10761482	0.861	rs2061492	ENSG00000254271.1	RP11-131N11.4	3.46	0.000563	0.0272	0.15	0.11	Schizophrenia;	chr10:60344258	chr10:60734342~60741828:+
BRCA	cis	rs10129255	0.957	rs17113284	ENSG00000211958.2	IGHV3-38	-3.46	0.000563	0.0272	-0.08	-0.11	Kawasaki disease;	chr14:106684476	chr14:106410493~106411021:-
BRCA	cis	rs6772849	0.896	rs35535737	ENSG00000207088.1	SNORA7B	-3.46	0.000563	0.0272	-0.13	-0.11	Monocyte percentage of white cells;Monocyte count;	chr3:128664563	chr3:129397210~129397348:-
BRCA	cis	rs7200543	0.883	rs4985148	ENSG00000270580.4	PKD1P6	3.46	0.000563	0.0272	0.12	0.11	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15053931	chr16:15104723~15131601:-
BRCA	cis	rs875971	1	rs4717292	ENSG00000273024.4	INTS4P2	-3.46	0.000563	0.0272	-0.12	-0.11	Aortic root size;	chr7:66430611	chr7:65647864~65715661:+
BRCA	cis	rs875971	1	rs35149210	ENSG00000273024.4	INTS4P2	-3.46	0.000563	0.0272	-0.12	-0.11	Aortic root size;	chr7:66464938	chr7:65647864~65715661:+
BRCA	cis	rs35547463	1	rs35547463	ENSG00000279311.1	RP11-170K4.2	-3.46	0.000563	0.0272	-0.12	-0.11	Lobe attachment (rater-scored or self-reported);	chr3:158215041	chr3:158869898~158871821:+
BRCA	cis	rs1730008	1	rs698984	ENSG00000279311.1	RP11-170K4.2	-3.46	0.000563	0.0272	-0.12	-0.11	Lobe attachment (rater-scored or self-reported);	chr3:158216283	chr3:158869898~158871821:+
BRCA	cis	rs1730008	0.964	rs698983	ENSG00000279311.1	RP11-170K4.2	-3.46	0.000563	0.0272	-0.12	-0.11	Lobe attachment (rater-scored or self-reported);	chr3:158216406	chr3:158869898~158871821:+
BRCA	cis	rs1730008	1	rs699926	ENSG00000279311.1	RP11-170K4.2	-3.46	0.000563	0.0272	-0.12	-0.11	Lobe attachment (rater-scored or self-reported);	chr3:158217682	chr3:158869898~158871821:+
BRCA	cis	rs1730008	0.964	rs699925	ENSG00000279311.1	RP11-170K4.2	-3.46	0.000563	0.0272	-0.12	-0.11	Lobe attachment (rater-scored or self-reported);	chr3:158217815	chr3:158869898~158871821:+
BRCA	cis	rs1730008	1	rs698982	ENSG00000279311.1	RP11-170K4.2	-3.46	0.000563	0.0272	-0.12	-0.11	Lobe attachment (rater-scored or self-reported);	chr3:158219393	chr3:158869898~158871821:+
BRCA	cis	rs1730008	1	rs698981	ENSG00000279311.1	RP11-170K4.2	-3.46	0.000563	0.0272	-0.12	-0.11	Lobe attachment (rater-scored or self-reported);	chr3:158219442	chr3:158869898~158871821:+
BRCA	cis	rs1730008	1	rs698979	ENSG00000279311.1	RP11-170K4.2	-3.46	0.000563	0.0272	-0.12	-0.11	Lobe attachment (rater-scored or self-reported);	chr3:158220150	chr3:158869898~158871821:+
BRCA	cis	rs6732795	0.559	rs4299364	ENSG00000179818.12	PCBP1-AS1	3.46	0.000563	0.0272	0.13	0.11	Intraocular pressure;	chr2:69171131	chr2:69962263~70103220:-
BRCA	cis	rs853679	0.598	rs9380054	ENSG00000226314.6	ZNF192P1	-3.46	0.000563	0.0272	-0.16	-0.11	Depression;	chr6:28099759	chr6:28161781~28169594:+
BRCA	cis	rs4713118	0.547	rs2116981	ENSG00000226314.6	ZNF192P1	-3.46	0.000563	0.0272	-0.16	-0.11	Parkinson's disease;	chr6:28100173	chr6:28161781~28169594:+
BRCA	cis	rs853679	0.517	rs9368552	ENSG00000226314.6	ZNF192P1	-3.46	0.000563	0.0272	-0.16	-0.11	Depression;	chr6:28100648	chr6:28161781~28169594:+
BRCA	cis	rs853679	0.542	rs34131763	ENSG00000226314.6	ZNF192P1	-3.46	0.000563	0.0272	-0.16	-0.11	Depression;	chr6:28107222	chr6:28161781~28169594:+
BRCA	cis	rs8103278	1	rs7258283	ENSG00000268423.3	AC011551.3	3.46	0.000563	0.0272	0.13	0.11	Coronary artery disease;	chr19:45832253	chr19:46547056~46600861:-
BRCA	cis	rs6600671	0.934	rs11249431	ENSG00000275131.1	CH17-472G23.4	3.46	0.000563	0.0272	0.1	0.11	Hip geometry;	chr1:121544405	chr1:120489625~120579190:-
BRCA	cis	rs2243480	1	rs387676	ENSG00000229180.5	GS1-124K5.11	3.46	0.000563	0.0272	0.15	0.11	Diabetic kidney disease;	chr7:66133233	chr7:66526088~66542624:-
BRCA	cis	rs9921338	0.961	rs11545336	ENSG00000263080.1	RP11-485G7.5	3.46	0.000563	0.0272	0.17	0.11	Vein graft stenosis in coronary artery bypass grafting;	chr16:11345639	chr16:11341809~11345211:-
BRCA	cis	rs6088590	0.687	rs73106933	ENSG00000276073.1	RP5-1125A11.7	-3.46	0.000563	0.0272	-0.12	-0.11	Coronary artery disease;	chr20:34699621	chr20:33985617~33988989:-
BRCA	cis	rs4759375	0.915	rs7954704	ENSG00000256092.2	RP13-942N8.1	3.46	0.000563	0.0272	0.17	0.11	HDL cholesterol;	chr12:123326824	chr12:123363868~123366113:+
BRCA	cis	rs2625529	0.586	rs2306489	ENSG00000261187.1	RP11-1007O24.2	3.46	0.000563	0.0272	0.11	0.11	Red blood cell count;	chr15:71935130	chr15:72465128~72466262:-
BRCA	cis	rs10044254	0.95	rs2938831	ENSG00000246214.1	RP11-260E18.1	3.46	0.000563	0.0272	0.14	0.11	Asthma (corticosteroid response);	chr5:15766210	chr5:16615926~16629969:+
BRCA	cis	rs4835473	0.9	rs35311036	ENSG00000246448.2	RP13-578N3.3	-3.46	0.000563	0.0272	-0.12	-0.11	Immature fraction of reticulocytes;	chr4:143734397	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.9	rs35906127	ENSG00000246448.2	RP13-578N3.3	-3.46	0.000563	0.0272	-0.12	-0.11	Immature fraction of reticulocytes;	chr4:143734400	chr4:143700257~143865072:+
BRCA	cis	rs951005	0.572	rs7024727	ENSG00000228352.2	RP11-537H15.3	-3.46	0.000563	0.0272	-0.17	-0.11	Rheumatoid arthritis;	chr9:34730398	chr9:34084332~34096225:+
BRCA	cis	rs2274273	0.934	rs10144418	ENSG00000259318.1	RP11-454L9.2	3.46	0.000563	0.0272	0.09	0.11	Protein biomarker;	chr14:55350990	chr14:55394940~55395233:-
BRCA	cis	rs970548	0.862	rs10900230	ENSG00000237840.5	FAM21FP	3.46	0.000563	0.0272	0.14	0.11	Total cholesterol levels;HDL cholesterol;HDL cholesterol levels;Cholesterol, total;	chr10:45634941	chr10:45706431~45727231:-
BRCA	cis	rs4919687	0.55	rs12775883	ENSG00000236937.2	PTGES3P4	3.46	0.000563	0.0272	0.15	0.11	Colorectal cancer;	chr10:102725544	chr10:102845595~102845950:+
BRCA	cis	rs10070219	0.505	rs72812601	ENSG00000248445.4	SEMA6A-AS1	-3.46	0.000563	0.0272	-0.14	-0.11	3-hydroxypropylmercapturic acid levels in smokers;	chr5:117352333	chr5:116447547~116508276:+
BRCA	cis	rs2911132	0.511	rs3198304	ENSG00000272109.1	CTD-2260A17.3	-3.46	0.000563	0.0272	-0.15	-0.11	Urate levels (BMI interaction);	chr5:96775524	chr5:96804353~96806105:+
BRCA	cis	rs1670533	1	rs641987	ENSG00000251639.2	RP11-20I20.1	3.46	0.000564	0.0272	0.17	0.11	Recombination rate (females);	chr4:1083754	chr4:1100016~1101558:-
BRCA	cis	rs11048434	0.518	rs759469	ENSG00000256069.6	A2MP1	3.46	0.000564	0.0272	0.11	0.11	Sjögren's syndrome;	chr12:9023108	chr12:9228533~9275817:-
BRCA	cis	rs6693567	0.565	rs4926395	ENSG00000237976.1	RP11-126K1.6	3.46	0.000564	0.0272	0.12	0.11	Migraine;	chr1:150432822	chr1:151346967~151348027:+
BRCA	cis	rs17014483	0.749	rs2972030	ENSG00000248019.2	FAM13A-AS1	-3.46	0.000564	0.0272	-0.14	-0.11	Post bronchodilator FEV1/FVC ratio;	chr4:88709878	chr4:88709789~88730103:+
BRCA	cis	rs1193	0.837	rs10186663	ENSG00000266931.1	RP11-1252D15.1	-3.46	0.000564	0.0272	-0.13	-0.11	High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;High light scatter reticulocyte count;	chr2:86751970	chr2:87055658~87055800:-
BRCA	cis	rs1193	0.837	rs2887012	ENSG00000266931.1	RP11-1252D15.1	-3.46	0.000564	0.0272	-0.13	-0.11	High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;High light scatter reticulocyte count;	chr2:86752294	chr2:87055658~87055800:-
BRCA	cis	rs66887589	0.616	rs11098498	ENSG00000260091.1	RP11-33B1.4	-3.46	0.000564	0.0272	-0.09	-0.11	Diastolic blood pressure;	chr4:119265964	chr4:119409333~119410233:+
BRCA	cis	rs3864261	0.515	rs12186995	ENSG00000251613.3	CTC-347C20.1	-3.46	0.000564	0.0272	-0.13	-0.11	Discordance in emotional problems in monozygotic twins;	chr5:73039500	chr5:72687112~72762727:-
BRCA	cis	rs16944613	0.541	rs6496690	ENSG00000259212.1	CTD-3065B20.2	3.46	0.000564	0.0272	0.16	0.11	Colorectal cancer;	chr15:90554169	chr15:90595840~90596447:-
BRCA	cis	rs27434	0.583	rs34759	ENSG00000248734.2	CTD-2260A17.1	3.46	0.000564	0.0272	0.12	0.11	Ankylosing spondylitis;	chr5:96817430	chr5:96784777~96785999:+
BRCA	cis	rs7773456	0.576	rs6924929	ENSG00000217379.2	RP11-254A17.1	3.46	0.000564	0.0272	0.13	0.11	Lupus nephritis in systemic lupus erythematosus;	chr6:19812381	chr6:19143695~19144160:+
BRCA	cis	rs687432	0.627	rs4939180	ENSG00000213592.4	AP000662.9	3.46	0.000564	0.0272	0.13	0.11	Parkinson's disease;	chr11:58095944	chr11:57718044~57718530:-
BRCA	cis	rs2154319	0.887	rs11555079	ENSG00000230638.4	RP11-486B10.4	-3.46	0.000564	0.0272	-0.18	-0.11	Height;	chr1:41028077	chr1:41542069~41544310:+
BRCA	cis	rs9959145	1	rs17595746	ENSG00000267199.1	RP11-861E21.2	3.46	0.000564	0.0272	0.18	0.11	Immune response to smallpox vaccine (IL-6);	chr18:12707859	chr18:12438890~12448205:+
BRCA	cis	rs2832191	0.716	rs1984012	ENSG00000236056.1	GAPDHP14	-3.46	0.000564	0.0272	-0.12	-0.11	Dental caries;	chr21:29020151	chr21:29222321~29223257:+
BRCA	cis	rs6840360	0.571	rs11736116	ENSG00000270265.1	RP11-731D1.4	-3.46	0.000564	0.0272	-0.13	-0.11	Intelligence (multi-trait analysis);	chr4:151610664	chr4:151333775~151353224:-
BRCA	cis	rs6430585	0.941	rs12469551	ENSG00000231890.6	DARS-AS1	3.46	0.000564	0.0272	0.15	0.11	Corneal structure;	chr2:135752442	chr2:135985176~136022593:+
BRCA	cis	rs12681366	0.734	rs2931633	ENSG00000253175.1	RP11-267M23.6	3.46	0.000564	0.0272	0.12	0.11	Nonsyndromic cleft lip with cleft palate;	chr8:94410492	chr8:94565036~94565715:+
BRCA	cis	rs10844706	0.669	rs10844682	ENSG00000256594.6	RP11-705C15.2	-3.46	0.000564	0.0272	-0.14	-0.11	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9747028	chr12:9633419~9658412:+
BRCA	cis	rs9513593	0.579	rs12860697	ENSG00000218502.3	H2AFZP3	3.46	0.000564	0.0272	0.17	0.11	Psoriasis;	chr13:99160711	chr13:99215372~99215758:-
BRCA	cis	rs783540	0.935	rs2278355	ENSG00000274376.3	ADAMTS7P1	3.46	0.000564	0.0272	0.12	0.11	Schizophrenia;	chr15:82662403	chr15:82298553~82334609:+
BRCA	cis	rs2811415	0.597	rs9809497	ENSG00000242551.2	POU5F1P6	3.46	0.000564	0.0273	0.15	0.11	Lung function (FEV1/FVC);	chr3:128063671	chr3:128674735~128677005:-
BRCA	cis	rs58521262	0.52	rs7253127	ENSG00000268105.1	RP11-369G6.2	-3.46	0.000564	0.0273	-0.18	-0.11	Testicular germ cell tumor;	chr19:22849568	chr19:23125665~23128543:+
BRCA	cis	rs58521262	0.607	rs62120774	ENSG00000268105.1	RP11-369G6.2	-3.46	0.000564	0.0273	-0.18	-0.11	Testicular germ cell tumor;	chr19:22855558	chr19:23125665~23128543:+
BRCA	cis	rs61931739	0.5	rs12832312	ENSG00000258794.3	DUX4L27	3.46	0.000564	0.0273	0.16	0.11	Morning vs. evening chronotype;	chr12:33878264	chr12:34208415~34209675:-
BRCA	cis	rs8114671	0.836	rs6120778	ENSG00000261582.1	RP4-614O4.11	-3.46	0.000565	0.0273	-0.1	-0.11	Height;	chr20:34977366	chr20:35267885~35280043:-
BRCA	cis	rs7131987	0.903	rs7302129	ENSG00000257176.2	RP11-996F15.2	-3.46	0.000565	0.0273	-0.13	-0.11	QT interval;	chr12:29262347	chr12:29280418~29317848:-
BRCA	cis	rs1348850	0.914	rs4893950	ENSG00000280374.1	RP11-337N6.3	3.46	0.000565	0.0273	0.14	0.11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177440157	chr2:177317715~177318471:-
BRCA	cis	rs6496932	0.663	rs11074169	ENSG00000259630.2	CTD-2262B20.1	-3.46	0.000565	0.0273	-0.14	-0.11	Central corneal thickness;Corneal structure;	chr15:85375721	chr15:85415228~85415633:+
BRCA	cis	rs889312	0.5	rs252906	ENSG00000237705.1	AC008937.2	3.46	0.000565	0.0273	0.11	0.11	Breast cancer (early onset);Breast cancer;	chr5:56823363	chr5:56842016~56862164:-
BRCA	cis	rs1730008	0.618	rs62287897	ENSG00000279311.1	RP11-170K4.2	3.46	0.000565	0.0273	0.13	0.11	Lobe attachment (rater-scored or self-reported);	chr3:158522082	chr3:158869898~158871821:+
BRCA	cis	rs6088590	0.687	rs8115656	ENSG00000276073.1	RP5-1125A11.7	-3.46	0.000565	0.0273	-0.12	-0.11	Coronary artery disease;	chr20:34694976	chr20:33985617~33988989:-
BRCA	cis	rs2835872	0.965	rs857976	ENSG00000228677.1	TTC3-AS1	-3.46	0.000565	0.0273	-0.14	-0.11	Electroencephalographic traits in alcoholism;	chr21:37628875	chr21:37187666~37193926:-
BRCA	cis	rs1018697	1	rs7088711	ENSG00000236937.2	PTGES3P4	-3.46	0.000565	0.0273	-0.14	-0.11	Colorectal adenoma (advanced);	chr10:102799509	chr10:102845595~102845950:+
BRCA	cis	rs6088580	0.634	rs1205338	ENSG00000275784.1	RP5-1125A11.6	3.46	0.000565	0.0273	0.12	0.11	Glomerular filtration rate (creatinine);	chr20:34337819	chr20:33989480~33991818:-
BRCA	cis	rs853679	0.517	rs9393891	ENSG00000226314.6	ZNF192P1	-3.46	0.000565	0.0273	-0.16	-0.11	Depression;	chr6:28111382	chr6:28161781~28169594:+
BRCA	cis	rs853679	0.517	rs9468286	ENSG00000226314.6	ZNF192P1	-3.46	0.000565	0.0273	-0.16	-0.11	Depression;	chr6:28111650	chr6:28161781~28169594:+
BRCA	cis	rs853679	0.517	rs9380055	ENSG00000226314.6	ZNF192P1	-3.46	0.000565	0.0273	-0.16	-0.11	Depression;	chr6:28113851	chr6:28161781~28169594:+
BRCA	cis	rs853679	0.517	rs9368553	ENSG00000226314.6	ZNF192P1	-3.46	0.000565	0.0273	-0.16	-0.11	Depression;	chr6:28114487	chr6:28161781~28169594:+
BRCA	cis	rs853679	0.517	rs9368554	ENSG00000226314.6	ZNF192P1	-3.46	0.000565	0.0273	-0.16	-0.11	Depression;	chr6:28114933	chr6:28161781~28169594:+
BRCA	cis	rs853679	0.517	rs4713137	ENSG00000226314.6	ZNF192P1	-3.46	0.000565	0.0273	-0.16	-0.11	Depression;	chr6:28115743	chr6:28161781~28169594:+
BRCA	cis	rs853679	0.517	rs9348793	ENSG00000226314.6	ZNF192P1	-3.46	0.000565	0.0273	-0.16	-0.11	Depression;	chr6:28116411	chr6:28161781~28169594:+
BRCA	cis	rs4713118	0.586	rs6905516	ENSG00000226314.6	ZNF192P1	-3.46	0.000565	0.0273	-0.16	-0.11	Parkinson's disease;	chr6:28118700	chr6:28161781~28169594:+
BRCA	cis	rs4713118	0.586	rs6905522	ENSG00000226314.6	ZNF192P1	-3.46	0.000565	0.0273	-0.16	-0.11	Parkinson's disease;	chr6:28118701	chr6:28161781~28169594:+
BRCA	cis	rs4713118	0.586	rs9468290	ENSG00000226314.6	ZNF192P1	-3.46	0.000565	0.0273	-0.16	-0.11	Parkinson's disease;	chr6:28119896	chr6:28161781~28169594:+
BRCA	cis	rs801193	1	rs2707836	ENSG00000275400.1	RP4-756H11.5	-3.46	0.000565	0.0273	-0.12	-0.11	Aortic root size;	chr7:66695448	chr7:66553805~66554199:-
BRCA	cis	rs801193	0.844	rs7779971	ENSG00000275400.1	RP4-756H11.5	-3.46	0.000565	0.0273	-0.12	-0.11	Aortic root size;	chr7:66696803	chr7:66553805~66554199:-
BRCA	cis	rs10995356	0.802	rs1509953	ENSG00000238280.1	RP11-436D10.3	-3.46	0.000565	0.0273	-0.14	-0.11	Temperament;	chr10:62975980	chr10:62793562~62805887:-
BRCA	cis	rs987724	0.593	rs11707914	ENSG00000240875.4	LINC00886	-3.46	0.000565	0.0273	-0.13	-0.11	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156829982	chr3:156747346~156817062:-
BRCA	cis	rs72772090	0.539	rs17481759	ENSG00000272109.1	CTD-2260A17.3	3.46	0.000565	0.0273	0.21	0.11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96778991	chr5:96804353~96806105:+
BRCA	cis	rs8030136	0.645	rs11161135	ENSG00000275529.1	SNORD116-4	-3.46	0.000565	0.0273	-0.14	-0.11	Periodontitis (DPAL);	chr15:24746797	chr15:25059538~25059633:+
BRCA	cis	rs6714710	0.603	rs34502870	ENSG00000228486.8	LINC01125	-3.46	0.000565	0.0273	-0.09	-0.11	Posterior cortical atrophy and Alzheimer's disease;	chr2:97789466	chr2:97664217~97703064:+
BRCA	cis	rs4950322	0.57	rs72691090	ENSG00000227242.3	NBPF13P	-3.46	0.000565	0.0273	-0.15	-0.11	Protein quantitative trait loci;	chr1:147297884	chr1:147021320~147124525:-
BRCA	cis	rs8141529	0.702	rs469990	ENSG00000226471.5	CTA-292E10.6	-3.46	0.000565	0.0273	-0.12	-0.11	Lymphocyte counts;	chr22:28908212	chr22:28800683~28848559:+
BRCA	cis	rs9467773	1	rs9357010	ENSG00000261353.1	CTA-14H9.5	-3.46	0.000565	0.0273	-0.11	-0.11	Intelligence (multi-trait analysis);	chr6:26527717	chr6:26527063~26527404:+
BRCA	cis	rs1555133	0.625	rs6141665	ENSG00000277692.1	RP11-358N2.2	-3.46	0.000565	0.0273	-0.12	-0.11	Monocyte count;	chr20:32303438	chr20:32355053~32355734:+
BRCA	cis	rs2998286	0.862	rs946594	ENSG00000237128.1	RP11-351M16.3	3.46	0.000565	0.0273	0.13	0.11	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28503318	chr10:28433008~28495813:-
BRCA	cis	rs17169635	0.879	rs3800737	ENSG00000272941.1	RP11-134L10.1	3.46	0.000565	0.0273	0.12	0.11	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);	chr7:134853124	chr7:135168403~135169547:+
BRCA	cis	rs3105593	1	rs1395297	ENSG00000259618.1	RP11-562A8.5	-3.46	0.000565	0.0273	-0.12	-0.11	QT interval;	chr15:50586312	chr15:50494018~50497080:-
BRCA	cis	rs1383484	1	rs1383484	ENSG00000259728.4	LINC00933	-3.46	0.000565	0.0273	-0.13	-0.11	Height;	chr15:83854003	chr15:84570649~84580175:+
BRCA	cis	rs10129255	0.872	rs1858683	ENSG00000211959.2	IGHV4-39	3.46	0.000565	0.0273	0.08	0.11	Kawasaki disease;	chr14:106670217	chr14:106421711~106422218:-
BRCA	cis	rs10256972	0.758	rs4723649	ENSG00000199023.2	MIR339	-3.46	0.000565	0.0273	-0.13	-0.11	Endometriosis;Longevity;	chr7:1032269	chr7:1022935~1023045:-
BRCA	cis	rs2692947	0.732	rs56847058	ENSG00000168992.4	OR7E102P	3.46	0.000565	0.0273	0.15	0.11	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95741145	chr2:95546531~95547545:+
BRCA	cis	rs28489187	0.683	rs6671599	ENSG00000223653.4	RP11-131L23.1	-3.46	0.000565	0.0273	-0.12	-0.11	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85393174	chr1:85276715~85448124:+
BRCA	cis	rs35740288	0.58	rs34635893	ENSG00000202081.1	RNU6-1280P	3.46	0.000565	0.0273	0.15	0.11	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85797017	chr15:85651522~85651628:-
BRCA	cis	rs1499614	0.901	rs3936	ENSG00000229180.5	GS1-124K5.11	3.46	0.000565	0.0273	0.15	0.11	Gout;	chr7:66661502	chr7:66526088~66542624:-
BRCA	cis	rs8103278	1	rs8108864	ENSG00000268423.3	AC011551.3	3.46	0.000565	0.0273	0.13	0.11	Coronary artery disease;	chr19:45798413	chr19:46547056~46600861:-
BRCA	cis	rs7267979	0.966	rs454723	ENSG00000277938.1	RP5-965G21.3	3.46	0.000565	0.0273	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25458292	chr20:25229150~25231933:+
BRCA	cis	rs10911902	0.643	rs75490185	ENSG00000229739.2	RP11-295K2.3	-3.46	0.000565	0.0273	-0.15	-0.11	Schizophrenia;	chr1:186366319	chr1:186435161~186470291:+
BRCA	cis	rs10911902	0.643	rs112738913	ENSG00000229739.2	RP11-295K2.3	-3.46	0.000565	0.0273	-0.15	-0.11	Schizophrenia;	chr1:186367231	chr1:186435161~186470291:+
BRCA	cis	rs2412819	0.571	rs10163069	ENSG00000201136.1	RNU6-353P	-3.46	0.000565	0.0273	-0.15	-0.11	Lung cancer;	chr15:43755372	chr15:43702363~43702470:+
BRCA	cis	rs2411233	1	rs892402	ENSG00000259278.1	RP11-62C7.2	3.46	0.000566	0.0273	0.13	0.11	Platelet count;	chr15:38982894	chr15:39019233~39024918:+
BRCA	cis	rs11673344	0.58	rs320881	ENSG00000267422.1	CTD-2554C21.1	3.46	0.000566	0.0273	0.14	0.11	Obesity-related traits;	chr19:37246948	chr19:37779686~37792865:+
BRCA	cis	rs67478160	0.595	rs2295146	ENSG00000269940.1	RP11-73M18.7	3.46	0.000566	0.0273	0.11	0.11	Schizophrenia;	chr14:103733019	chr14:103694560~103695170:+
BRCA	cis	rs2243480	1	rs35058610	ENSG00000234585.5	CCT6P3	-3.46	0.000566	0.0273	-0.16	-0.11	Diabetic kidney disease;	chr7:65925938	chr7:65038354~65074713:+
BRCA	cis	rs748404	0.666	rs55748552	ENSG00000166763.7	STRCP1	3.46	0.000566	0.0273	0.15	0.11	Lung cancer;	chr15:43359428	chr15:43699488~43718184:-
BRCA	cis	rs748404	0.63	rs35278805	ENSG00000166763.7	STRCP1	3.46	0.000566	0.0273	0.15	0.11	Lung cancer;	chr15:43361124	chr15:43699488~43718184:-
BRCA	cis	rs2562456	0.833	rs62109229	ENSG00000268117.1	VN1R84P	3.46	0.000566	0.0273	0.16	0.11	Pain;	chr19:21354380	chr19:21719801~21720035:-
BRCA	cis	rs2562456	0.833	rs11670815	ENSG00000268117.1	VN1R84P	3.46	0.000566	0.0273	0.16	0.11	Pain;	chr19:21356515	chr19:21719801~21720035:-
BRCA	cis	rs2562456	0.833	rs11666540	ENSG00000268117.1	VN1R84P	3.46	0.000566	0.0273	0.16	0.11	Pain;	chr19:21356550	chr19:21719801~21720035:-
BRCA	cis	rs2562456	0.833	rs11667361	ENSG00000268117.1	VN1R84P	3.46	0.000566	0.0273	0.16	0.11	Pain;	chr19:21356580	chr19:21719801~21720035:-
BRCA	cis	rs3755605	0.697	rs6766729	ENSG00000242578.1	RP11-469J4.3	3.46	0.000566	0.0273	0.13	0.11	Testicular germ cell tumor;	chr3:170188156	chr3:170410512~170418615:+
BRCA	cis	rs11098499	0.698	rs4422403	ENSG00000249244.1	RP11-548H18.2	3.46	0.000566	0.0273	0.12	0.11	Corneal astigmatism;	chr4:119337039	chr4:119391831~119395335:-
BRCA	cis	rs6479874	0.57	rs2245995	ENSG00000223502.1	RP11-96B5.3	-3.46	0.000566	0.0273	-0.19	-0.11	Migraine;	chr10:50989403	chr10:51062579~51068553:-
BRCA	cis	rs7260598	0.892	rs60186040	ENSG00000268442.1	CTD-2027I19.2	3.46	0.000566	0.0273	0.17	0.11	Response to taxane treatment (placlitaxel);	chr19:24024068	chr19:24162370~24163425:-
BRCA	cis	rs12477438	1	rs6542873	ENSG00000231822.1	AC019097.7	-3.46	0.000566	0.0273	-0.13	-0.11	Chronic sinus infection;	chr2:99208502	chr2:99102018~99102752:+
BRCA	cis	rs10229583	1	rs10229583	ENSG00000273270.1	RP11-212P7.2	-3.46	0.000566	0.0273	-0.13	-0.11	Type 2 diabetes;	chr7:127606849	chr7:128524016~128531069:-
BRCA	cis	rs17741873	0.779	rs10509346	ENSG00000272589.1	ZSWIM8-AS1	3.46	0.000566	0.0273	0.15	0.11	Paclitaxel disposition in epithelial ovarian cancer;	chr10:73836256	chr10:73796514~73801399:-
BRCA	cis	rs11098499	0.73	rs78971550	ENSG00000225892.3	RP11-384K6.2	3.46	0.000566	0.0273	0.11	0.11	Corneal astigmatism;	chr4:119359886	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.645	rs78422072	ENSG00000225892.3	RP11-384K6.2	3.46	0.000566	0.0273	0.11	0.11	Corneal astigmatism;	chr4:119359887	chr4:118632274~118634759:+
BRCA	cis	rs10838687	0.673	rs77532017	ENSG00000243802.2	RP11-390K5.1	3.46	0.000566	0.0273	0.15	0.11	Proinsulin levels;	chr11:47262766	chr11:47191181~47191542:-
BRCA	cis	rs875971	0.83	rs778711	ENSG00000265600.1	AC006480.1	-3.46	0.000566	0.0273	-0.13	-0.11	Aortic root size;	chr7:66386670	chr7:67356680~67356779:+
BRCA	cis	rs875971	0.862	rs1083554	ENSG00000265600.1	AC006480.1	-3.46	0.000566	0.0273	-0.13	-0.11	Aortic root size;	chr7:66387354	chr7:67356680~67356779:+
BRCA	cis	rs875971	0.862	rs778707	ENSG00000265600.1	AC006480.1	-3.46	0.000566	0.0273	-0.13	-0.11	Aortic root size;	chr7:66392040	chr7:67356680~67356779:+
BRCA	cis	rs875971	0.862	rs778705	ENSG00000265600.1	AC006480.1	-3.46	0.000566	0.0273	-0.13	-0.11	Aortic root size;	chr7:66396128	chr7:67356680~67356779:+
BRCA	cis	rs875971	0.862	rs778697	ENSG00000265600.1	AC006480.1	-3.46	0.000566	0.0273	-0.13	-0.11	Aortic root size;	chr7:66405439	chr7:67356680~67356779:+
BRCA	cis	rs875971	0.798	rs7789615	ENSG00000265600.1	AC006480.1	-3.46	0.000566	0.0273	-0.13	-0.11	Aortic root size;	chr7:66413674	chr7:67356680~67356779:+
BRCA	cis	rs12043302	0.529	rs11578279	ENSG00000225077.2	LINC00337	-3.46	0.000566	0.0273	-0.21	-0.11	Gestational age at birth in labor-initiated deliveries (child effect);	chr1:6838455	chr1:6236240~6239444:+
BRCA	cis	rs10744816	0.846	rs10774743	ENSG00000257817.1	RP4-601P9.2	-3.46	0.000566	0.0273	-0.13	-0.11	Obesity-related traits;	chr12:114286859	chr12:114713811~114767957:+
BRCA	cis	rs17655565	0.904	rs3809172	ENSG00000257830.1	RP11-845M18.7	3.46	0.000566	0.0273	0.2	0.11	Plasma amyloid beta peptide concentrations (ABx-42);	chr12:52301414	chr12:52274647~52279156:-
BRCA	cis	rs2562456	0.754	rs58338799	ENSG00000268117.1	VN1R84P	3.46	0.000566	0.0273	0.16	0.11	Pain;	chr19:21339009	chr19:21719801~21720035:-
BRCA	cis	rs984222	0.967	rs984225	ENSG00000231365.4	RP11-418J17.1	-3.46	0.000566	0.0273	-0.12	-0.11	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:118961661	chr1:119140396~119275973:+
BRCA	cis	rs984222	0.967	rs10923712	ENSG00000231365.4	RP11-418J17.1	-3.46	0.000566	0.0273	-0.12	-0.11	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:118962811	chr1:119140396~119275973:+
BRCA	cis	rs4388249	0.95	rs35342188	ENSG00000249068.1	CTC-287O8.1	3.46	0.000566	0.0273	0.15	0.11	Schizophrenia;	chr5:109755916	chr5:109840128~109840692:-
BRCA	cis	rs4388249	0.95	rs17638690	ENSG00000249068.1	CTC-287O8.1	3.46	0.000566	0.0273	0.15	0.11	Schizophrenia;	chr5:109756113	chr5:109840128~109840692:-
BRCA	cis	rs8180040	1	rs807931	ENSG00000276925.1	RP11-708J19.3	-3.46	0.000566	0.0273	-0.12	-0.11	Colorectal cancer;	chr3:47347827	chr3:47469777~47469987:+
BRCA	cis	rs9467773	0.869	rs1796521	ENSG00000224843.5	LINC00240	3.46	0.000566	0.0273	0.12	0.11	Intelligence (multi-trait analysis);	chr6:26421164	chr6:26956992~27023924:+
BRCA	cis	rs7267979	1	rs2500404	ENSG00000274973.1	RP13-401N8.7	3.46	0.000566	0.0273	0.12	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25379122	chr20:25845497~25845862:+
BRCA	cis	rs7267979	1	rs2500405	ENSG00000274973.1	RP13-401N8.7	3.46	0.000566	0.0273	0.12	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25380190	chr20:25845497~25845862:+
BRCA	cis	rs7267979	1	rs2482941	ENSG00000274973.1	RP13-401N8.7	3.46	0.000566	0.0273	0.12	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25380580	chr20:25845497~25845862:+
BRCA	cis	rs7267979	0.903	rs2500423	ENSG00000274973.1	RP13-401N8.7	3.46	0.000566	0.0273	0.12	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25394246	chr20:25845497~25845862:+
BRCA	cis	rs10844682	0.603	rs10844673	ENSG00000256673.1	RP11-599J14.2	-3.46	0.000566	0.0273	-0.14	-0.11	Monocyte percentage of white cells;	chr12:9744969	chr12:9398355~9414851:-
BRCA	cis	rs4919669	0.668	rs4919666	ENSG00000213277.3	MARCKSL1P1	3.46	0.000566	0.0273	0.17	0.11	Mean arterial pressure (long-term average);Systolic blood pressure (long-term average);	chr10:102624272	chr10:103175554~103176094:+
BRCA	cis	rs11098499	0.644	rs10009566	ENSG00000260091.1	RP11-33B1.4	-3.46	0.000566	0.0273	-0.09	-0.11	Corneal astigmatism;	chr4:119637453	chr4:119409333~119410233:+
BRCA	cis	rs910316	1	rs10136948	ENSG00000259138.1	RP11-950C14.7	3.46	0.000566	0.0273	0.11	0.11	Height;	chr14:75044372	chr14:75127153~75136930:+
BRCA	cis	rs2070488	0.775	rs1073506	ENSG00000229589.1	ACVR2B-AS1	-3.46	0.000566	0.0273	-0.11	-0.11	Electrocardiographic conduction measures;	chr3:38524744	chr3:38451027~38454820:-
BRCA	cis	rs1468333	0.724	rs10054835	ENSG00000206989.1	SNORD63	3.46	0.000566	0.0273	0.12	0.11	Resting heart rate;	chr5:138283083	chr5:138561043~138561110:-
BRCA	cis	rs7800418	0.698	rs10248571	ENSG00000280255.1	RP5-1007F24.1	3.46	0.000566	0.0273	0.12	0.11	Cognitive function;	chr7:26551966	chr7:26538378~26541048:+
BRCA	cis	rs8180040	0.726	rs34344887	ENSG00000260236.1	RP11-708J19.1	3.46	0.000566	0.0273	0.09	0.11	Colorectal cancer;	chr3:47000671	chr3:47379089~47380999:-
BRCA	cis	rs4499344	0.556	rs259227	ENSG00000267475.1	CTD-2538C1.2	3.46	0.000567	0.0273	0.15	0.11	Mean platelet volume;	chr19:32643885	chr19:32687089~32691750:-
BRCA	cis	rs495337	0.73	rs648095	ENSG00000224397.4	LINC01272	-3.46	0.000567	0.0273	-0.11	-0.11	Psoriasis;	chr20:49877641	chr20:50267486~50279795:+
BRCA	cis	rs1912124	1	rs72744137	ENSG00000259343.4	TMC3-AS1	3.46	0.000567	0.0273	0.25	0.11	Peripheral arterial disease (traffic-related air pollution interaction);	chr15:81221240	chr15:81324377~81362037:+
BRCA	cis	rs1045529	0.524	rs34251783	ENSG00000254153.1	CTA-398F10.2	-3.46	0.000567	0.0273	-0.13	-0.11	Myopia (pathological);Myopia;	chr8:9033866	chr8:8456909~8461337:-
BRCA	cis	rs6452790	0.529	rs3910028	ENSG00000247828.6	TMEM161B-AS1	-3.46	0.000567	0.0273	-0.14	-0.11	Cognitive function;	chr5:87974366	chr5:88268895~88436685:+
BRCA	cis	rs4819052	0.819	rs34818688	ENSG00000223768.1	LINC00205	-3.46	0.000567	0.0273	-0.14	-0.11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45252501	chr21:45293285~45297354:+
BRCA	cis	rs2749592	0.513	rs1208708	ENSG00000226578.1	RP11-258F22.1	-3.46	0.000567	0.0273	-0.12	-0.11	Age-related hearing impairment (SNP x SNP interaction);	chr10:37796648	chr10:37775371~37784131:-
BRCA	cis	rs7520050	0.933	rs6656022	ENSG00000226957.1	RP4-533D7.4	3.46	0.000567	0.0273	0.12	0.11	Reticulocyte count;Red blood cell count;	chr1:45928643	chr1:46046818~46048368:+
BRCA	cis	rs7267979	0.866	rs2424698	ENSG00000274414.1	RP5-965G21.4	-3.46	0.000567	0.0273	-0.13	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25275470	chr20:25239007~25245229:-
BRCA	cis	rs2976388	1	rs1045574	ENSG00000261693.1	RP13-467H17.1	-3.46	0.000567	0.0273	-0.11	-0.11	Urinary tract infection frequency;	chr8:142682540	chr8:142403652~142407028:+
BRCA	cis	rs2302063	0.627	rs1682802	ENSG00000267138.1	AC005954.3	-3.46	0.000567	0.0273	-0.13	-0.11	Glucose homeostasis traits;	chr19:3158118	chr19:3754620~3756659:-
BRCA	cis	rs2832270	0.562	rs17814339	ENSG00000176054.6	RPL23P2	-3.46	0.000567	0.0273	-0.19	-0.11	Response to mTOR inhibitor (everolimus);	chr21:29171122	chr21:28997613~28998033:-
BRCA	cis	rs2191566	0.54	rs436739	ENSG00000266921.1	RP11-15A1.7	3.46	0.000567	0.0274	0.14	0.11	Acute lymphoblastic leukemia (childhood);	chr19:43991401	chr19:43996896~44002836:-
BRCA	cis	rs875971	0.929	rs778712	ENSG00000272831.1	RP11-792A8.4	3.46	0.000567	0.0274	0.1	0.11	Aortic root size;	chr7:66384991	chr7:66739829~66740385:-
BRCA	cis	rs863345	0.565	rs2051665	ENSG00000176320.2	RP11-404O13.5	-3.46	0.000567	0.0274	-0.11	-0.11	Pneumococcal bacteremia;	chr1:158537367	chr1:158197922~158203877:-
BRCA	cis	rs863345	0.526	rs2051666	ENSG00000176320.2	RP11-404O13.5	-3.46	0.000567	0.0274	-0.11	-0.11	Pneumococcal bacteremia;	chr1:158537370	chr1:158197922~158203877:-
BRCA	cis	rs4819052	0.851	rs7279182	ENSG00000215447.6	BX322557.10	-3.46	0.000567	0.0274	-0.11	-0.11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45236197	chr21:45288052~45291738:+
BRCA	cis	rs10504229	0.593	rs12216730	ENSG00000253523.1	RP11-1112C15.2	-3.46	0.000567	0.0274	-0.15	-0.11	Developmental language disorder (linguistic errors);	chr8:57091335	chr8:58031334~58032682:-
BRCA	cis	rs987724	0.593	rs9853479	ENSG00000240875.4	LINC00886	-3.46	0.000567	0.0274	-0.13	-0.11	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156966135	chr3:156747346~156817062:-
BRCA	cis	rs10819083	0.666	rs10760401	ENSG00000232630.1	PRPS1P2	-3.46	0.000567	0.0274	-0.11	-0.11	Squamous cell lung carcinoma;	chr9:125776562	chr9:125150653~125151589:+
BRCA	cis	rs34217772	0.83	rs61992396	ENSG00000258636.1	CTD-2298J14.2	3.46	0.000567	0.0274	0.14	0.11	Myopia;	chr14:41743794	chr14:41587861~41604856:-
BRCA	cis	rs34217772	0.83	rs61992397	ENSG00000258636.1	CTD-2298J14.2	3.46	0.000567	0.0274	0.14	0.11	Myopia;	chr14:41744059	chr14:41587861~41604856:-
BRCA	cis	rs34217772	0.783	rs61992398	ENSG00000258636.1	CTD-2298J14.2	3.46	0.000567	0.0274	0.14	0.11	Myopia;	chr14:41744578	chr14:41587861~41604856:-
BRCA	cis	rs34217772	0.83	rs61992399	ENSG00000258636.1	CTD-2298J14.2	3.46	0.000567	0.0274	0.14	0.11	Myopia;	chr14:41744786	chr14:41587861~41604856:-
BRCA	cis	rs34217772	0.83	rs61992400	ENSG00000258636.1	CTD-2298J14.2	3.46	0.000567	0.0274	0.14	0.11	Myopia;	chr14:41744838	chr14:41587861~41604856:-
BRCA	cis	rs73242632	1	rs41344750	ENSG00000269949.1	RP11-738E22.3	3.46	0.000567	0.0274	0.24	0.11	Congenital heart disease (maternal effect);	chr4:56964047	chr4:56960927~56961373:-
BRCA	cis	rs67478160	0.704	rs12894254	ENSG00000269910.1	RP11-73M18.10	3.46	0.000567	0.0274	0.1	0.11	Schizophrenia;	chr14:103824612	chr14:103694516~103695050:-
BRCA	cis	rs6142618	0.523	rs2377473	ENSG00000275576.1	RP5-836N17.4	-3.46	0.000567	0.0274	-0.12	-0.11	Inflammatory bowel disease;	chr20:32262445	chr20:32116171~32116629:+
BRCA	cis	rs74233809	1	rs74444347	ENSG00000213061.2	PFN1P11	3.46	0.000567	0.0274	0.23	0.11	Birth weight;	chr10:103009518	chr10:102838011~102845473:-
BRCA	cis	rs74233809	1	rs12221335	ENSG00000213061.2	PFN1P11	3.46	0.000567	0.0274	0.23	0.11	Birth weight;	chr10:103009635	chr10:102838011~102845473:-
BRCA	cis	rs745109	0.882	rs72932336	ENSG00000273080.1	RP11-301O19.1	3.46	0.000567	0.0274	0.16	0.11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86501968	chr2:86195590~86196049:+
BRCA	cis	rs2832191	0.692	rs8134627	ENSG00000236056.1	GAPDHP14	3.46	0.000567	0.0274	0.12	0.11	Dental caries;	chr21:28976747	chr21:29222321~29223257:+
BRCA	cis	rs1355223	0.872	rs12785367	ENSG00000271369.1	RP11-350D17.3	-3.46	0.000567	0.0274	-0.12	-0.11	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34693722	chr11:34709600~34710161:+
BRCA	cis	rs1355223	0.902	rs11819839	ENSG00000271369.1	RP11-350D17.3	-3.46	0.000567	0.0274	-0.12	-0.11	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34694231	chr11:34709600~34710161:+
BRCA	cis	rs7656342	0.686	rs1464258	ENSG00000250342.1	SNRPCP16	3.46	0.000568	0.0274	0.12	0.11	Gut microbiota (bacterial taxa);	chr4:9832483	chr4:9051842~9052051:-
BRCA	cis	rs6943931	1	rs73682635	ENSG00000230658.1	KLHL7-AS1	-3.46	0.000568	0.0274	-0.14	-0.11	Diabetic kidney disease;	chr7:22376556	chr7:23101228~23105703:-
BRCA	cis	rs11673344	0.504	rs2385374	ENSG00000276846.1	CTD-3220F14.3	3.46	0.000568	0.0274	0.12	0.11	Obesity-related traits;	chr19:37092115	chr19:37314868~37315620:-
BRCA	cis	rs6088580	0.524	rs6088565	ENSG00000279253.1	RP4-614O4.13	3.46	0.000568	0.0274	0.13	0.11	Glomerular filtration rate (creatinine);	chr20:34667182	chr20:35262727~35264187:-
BRCA	cis	rs1790761	0.52	rs7124513	ENSG00000273819.1	ENPP7P7	-3.46	0.000568	0.0274	-0.13	-0.11	Mean corpuscular volume;	chr11:67628243	chr11:67812557~67873367:-
BRCA	cis	rs8022179	0.566	rs959083	ENSG00000244691.1	RPL10AP1	-3.46	0.000568	0.0274	-0.16	-0.11	Monocyte count;	chr14:103356350	chr14:103412119~103412761:-
BRCA	cis	rs2113818	0.511	rs4669889	ENSG00000264370.1	MIR3125	-3.46	0.000568	0.0274	-0.12	-0.11	Optic cup area;	chr2:12840465	chr2:12737367~12737444:+
BRCA	cis	rs2599510	0.811	rs2710628	ENSG00000276517.1	AL133243.2	-3.46	0.000568	0.0274	-0.13	-0.11	Interleukin-18 levels;	chr2:32533286	chr2:32526504~32529507:+
BRCA	cis	rs6840360	0.571	rs11940881	ENSG00000278978.1	RP11-164P12.5	-3.46	0.000568	0.0274	-0.13	-0.11	Intelligence (multi-trait analysis);	chr4:151579898	chr4:151669786~151670503:+
BRCA	cis	rs10043775	0.793	rs7730707	ENSG00000251330.3	CTD-2283N19.1	-3.46	0.000568	0.0274	-0.12	-0.11	Periodontal microbiota;	chr5:148331188	chr5:148430159~148430807:-
BRCA	cis	rs62458065	0.85	rs6462362	ENSG00000281332.1	LINC00997	-3.46	0.000568	0.0274	-0.16	-0.11	Metabolite levels (HVA/MHPG ratio);	chr7:32425121	chr7:32760279~32762924:+
BRCA	cis	rs1979679	0.578	rs2127316	ENSG00000247934.4	RP11-967K21.1	-3.46	0.000568	0.0274	-0.13	-0.11	Ossification of the posterior longitudinal ligament of the spine;	chr12:28121472	chr12:28163298~28190738:-
BRCA	cis	rs6585424	1	rs12777867	ENSG00000225484.5	NUTM2B-AS1	-3.46	0.000568	0.0274	-0.22	-0.11	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80175774	chr10:79663088~79826594:-
BRCA	cis	rs10181042	0.565	rs1177234	ENSG00000273302.1	RP11-493E12.2	3.46	0.000568	0.0274	0.1	0.11	Crohn's disease;	chr2:61032928	chr2:61199979~61200769:+
BRCA	cis	rs7103648	1	rs11039225	ENSG00000280615.1	Y_RNA	3.46	0.000568	0.0274	0.12	0.11	Systolic blood pressure;Diastolic blood pressure;	chr11:47409048	chr11:47614898~47614994:-
BRCA	cis	rs35146811	0.735	rs11767968	ENSG00000214313.7	AZGP1P1	3.46	0.000568	0.0274	0.11	0.11	Coronary artery disease;	chr7:100193348	chr7:99980762~99987535:+
BRCA	cis	rs9329221	0.662	rs9650650	ENSG00000154316.13	TDH	-3.46	0.000568	0.0274	-0.14	-0.11	Neuroticism;	chr8:10390466	chr8:11339637~11368452:+
BRCA	cis	rs910873	0.505	rs6087607	ENSG00000250917.1	RP4-785G19.5	3.46	0.000568	0.0274	0.18	0.11	Melanoma;	chr20:34609685	chr20:34234840~34281173:-
BRCA	cis	rs3617	0.625	rs2239548	ENSG00000243224.1	RP5-1157M23.2	-3.46	0.000568	0.0274	-0.11	-0.11	Red blood cell count;Autism spectrum disorder or schizophrenia;	chr3:52820170	chr3:52239258~52241097:+
BRCA	cis	rs7773456	0.533	rs9350190	ENSG00000217379.2	RP11-254A17.1	3.46	0.000568	0.0274	0.13	0.11	Lupus nephritis in systemic lupus erythematosus;	chr6:19811429	chr6:19143695~19144160:+
BRCA	cis	rs10129255	1	rs11621409	ENSG00000232216.1	IGHV3-43	3.46	0.000568	0.0274	0.09	0.11	Kawasaki disease;	chr14:106695603	chr14:106470264~106470800:-
BRCA	cis	rs4950322	0.58	rs17359629	ENSG00000230832.3	RP11-325P15.2	-3.46	0.000568	0.0274	-0.16	-0.11	Protein quantitative trait loci;	chr1:147121537	chr1:147082338~147083578:-
BRCA	cis	rs12438356	0.686	rs12101761	ENSG00000259222.2	RP11-809H16.5	-3.46	0.000568	0.0274	-0.16	-0.11	CTACK levels;	chr15:69218794	chr15:69080879~69099987:+
BRCA	cis	rs3820068	0.58	rs34426856	ENSG00000237301.1	RP4-680D5.2	-3.46	0.000568	0.0274	-0.14	-0.11	Systolic blood pressure;	chr1:15679820	chr1:15586136~15603626:-
BRCA	cis	rs55704346	0.713	rs11940059	ENSG00000281501.1	SEPSECS-AS1	-3.46	0.000568	0.0274	-0.12	-0.11	Tonsillectomy;	chr4:25227200	chr4:25160641~25201440:+
BRCA	cis	rs6840360	0.571	rs11931934	ENSG00000270265.1	RP11-731D1.4	-3.46	0.000568	0.0274	-0.13	-0.11	Intelligence (multi-trait analysis);	chr4:151630930	chr4:151333775~151353224:-
BRCA	cis	rs9549328	0.765	rs1317506	ENSG00000235280.2	MCF2L-AS1	3.46	0.000568	0.0274	0.15	0.11	Systolic blood pressure;	chr13:112976829	chr13:112967484~112968824:-
BRCA	cis	rs2446066	0.872	rs10876455	ENSG00000250133.2	HOXC-AS2	3.46	0.000568	0.0274	0.19	0.11	Red blood cell count;	chr12:53431541	chr12:53993810~53996785:-
BRCA	cis	rs11098499	0.863	rs10013305	ENSG00000225892.3	RP11-384K6.2	3.46	0.000568	0.0274	0.11	0.11	Corneal astigmatism;	chr4:119529269	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.863	rs3775849	ENSG00000225892.3	RP11-384K6.2	3.46	0.000568	0.0274	0.11	0.11	Corneal astigmatism;	chr4:119529753	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.818	rs7688802	ENSG00000225892.3	RP11-384K6.2	3.46	0.000568	0.0274	0.11	0.11	Corneal astigmatism;	chr4:119530513	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.863	rs7695620	ENSG00000225892.3	RP11-384K6.2	3.46	0.000568	0.0274	0.11	0.11	Corneal astigmatism;	chr4:119531621	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.863	rs12502389	ENSG00000225892.3	RP11-384K6.2	3.46	0.000568	0.0274	0.11	0.11	Corneal astigmatism;	chr4:119533036	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.821	rs3775852	ENSG00000225892.3	RP11-384K6.2	3.46	0.000568	0.0274	0.11	0.11	Corneal astigmatism;	chr4:119533401	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.82	rs6534140	ENSG00000225892.3	RP11-384K6.2	3.46	0.000568	0.0274	0.11	0.11	Corneal astigmatism;	chr4:119534156	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.863	rs7657849	ENSG00000225892.3	RP11-384K6.2	3.46	0.000568	0.0274	0.11	0.11	Corneal astigmatism;	chr4:119534339	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.863	rs10034450	ENSG00000225892.3	RP11-384K6.2	3.46	0.000568	0.0274	0.11	0.11	Corneal astigmatism;	chr4:119534494	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.863	rs1480939	ENSG00000225892.3	RP11-384K6.2	3.46	0.000568	0.0274	0.11	0.11	Corneal astigmatism;	chr4:119535772	chr4:118632274~118634759:+
BRCA	cis	rs28489187	0.683	rs6704103	ENSG00000223653.4	RP11-131L23.1	-3.46	0.000569	0.0274	-0.12	-0.11	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85402974	chr1:85276715~85448124:+
BRCA	cis	rs28489187	0.683	rs11161611	ENSG00000223653.4	RP11-131L23.1	-3.46	0.000569	0.0274	-0.12	-0.11	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85402996	chr1:85276715~85448124:+
BRCA	cis	rs2288884	0.537	rs4145658	ENSG00000268282.1	CTD-2620I22.2	-3.46	0.000569	0.0274	-0.13	-0.11	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52085465	chr19:53004040~53005150:+
BRCA	cis	rs9419788	1	rs9419788	ENSG00000273450.1	RP11-76P2.4	-3.46	0.000569	0.0274	-0.14	-0.11	Personality traits in bipolar disorder;	chr10:94253948	chr10:94314907~94315327:-
BRCA	cis	rs875971	0.825	rs801202	ENSG00000265600.1	AC006480.1	3.46	0.000569	0.0274	0.13	0.11	Aortic root size;	chr7:66558942	chr7:67356680~67356779:+
BRCA	cis	rs875971	0.767	rs61348003	ENSG00000265600.1	AC006480.1	-3.46	0.000569	0.0274	-0.13	-0.11	Aortic root size;	chr7:66540947	chr7:67356680~67356779:+
BRCA	cis	rs1971762	0.504	rs1843318	ENSG00000270175.1	RP11-793H13.11	-3.46	0.000569	0.0274	-0.09	-0.11	Height;	chr12:53564293	chr12:53500162~53500936:-
BRCA	cis	rs1400816	0.85	rs2292814	ENSG00000228389.1	AC068039.4	-3.46	0.000569	0.0274	-0.2	-0.11	Amyotrophic lateral sclerosis (sporadic);	chr2:171730057	chr2:171773482~171775844:+
BRCA	cis	rs4835473	0.932	rs12513130	ENSG00000246448.2	RP13-578N3.3	-3.46	0.000569	0.0274	-0.12	-0.11	Immature fraction of reticulocytes;	chr4:143758666	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.868	rs7681891	ENSG00000246448.2	RP13-578N3.3	-3.46	0.000569	0.0274	-0.12	-0.11	Immature fraction of reticulocytes;	chr4:143759289	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.771	rs34069296	ENSG00000246448.2	RP13-578N3.3	-3.46	0.000569	0.0274	-0.12	-0.11	Immature fraction of reticulocytes;	chr4:143759656	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.897	rs7687915	ENSG00000246448.2	RP13-578N3.3	-3.46	0.000569	0.0274	-0.12	-0.11	Immature fraction of reticulocytes;	chr4:143759801	chr4:143700257~143865072:+
BRCA	cis	rs2692947	0.655	rs60090597	ENSG00000168992.4	OR7E102P	3.46	0.000569	0.0274	0.15	0.11	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95740518	chr2:95546531~95547545:+
BRCA	cis	rs8031584	0.672	rs17815726	ENSG00000259845.1	HERC2P10	-3.46	0.000569	0.0274	-0.14	-0.11	Huntington's disease progression;	chr15:31021049	chr15:30815271~30844153:+
BRCA	cis	rs4671400	0.571	rs62152275	ENSG00000270820.4	RP11-355B11.2	-3.46	0.000569	0.0274	-0.14	-0.11	3-hydroxypropylmercapturic acid levels in smokers;	chr2:61275103	chr2:61471188~61484130:+
BRCA	cis	rs7267979	0.509	rs6115218	ENSG00000204556.4	CTD-2514C3.1	-3.46	0.000569	0.0274	-0.15	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25585849	chr20:26018832~26020684:+
BRCA	cis	rs4849845	0.584	rs3896630	ENSG00000223549.1	MTND5P28	3.46	0.000569	0.0274	0.12	0.11	Mean platelet volume;	chr2:120279442	chr2:120215181~120217279:+
BRCA	cis	rs4849845	0.637	rs13022486	ENSG00000223549.1	MTND5P28	3.46	0.000569	0.0274	0.12	0.11	Mean platelet volume;	chr2:120281035	chr2:120215181~120217279:+
BRCA	cis	rs12681366	0.708	rs2445699	ENSG00000253175.1	RP11-267M23.6	-3.46	0.000569	0.0274	-0.12	-0.11	Nonsyndromic cleft lip with cleft palate;	chr8:94334289	chr8:94565036~94565715:+
BRCA	cis	rs1119582	1	rs186610	ENSG00000279118.1	RP11-517I3.2	-3.46	0.000569	0.0274	-0.13	-0.11	Select biomarker traits;	chr5:125942057	chr5:126496279~126498604:+
BRCA	cis	rs13315871	1	rs11715445	ENSG00000272182.1	RP11-802O23.3	3.46	0.000569	0.0274	0.22	0.11	Cholesterol, total;	chr3:58358161	chr3:58428255~58428815:+
BRCA	cis	rs4388249	1	rs2269201	ENSG00000249068.1	CTC-287O8.1	3.46	0.000569	0.0274	0.15	0.11	Schizophrenia;	chr5:109716958	chr5:109840128~109840692:-
BRCA	cis	rs4388249	0.898	rs2269203	ENSG00000249068.1	CTC-287O8.1	3.46	0.000569	0.0274	0.15	0.11	Schizophrenia;	chr5:109717432	chr5:109840128~109840692:-
BRCA	cis	rs9900497	0.536	rs4646785	ENSG00000189343.7	RPS2P46	-3.46	0.000569	0.0274	-0.14	-0.11	Response to paliperidone in schizophrenia (CGI-S score);	chr17:19748589	chr17:19445970~19446852:-
BRCA	cis	rs2140773	0.692	rs12467052	ENSG00000244384.3	RN7SL359P	3.46	0.000569	0.0274	0.11	0.11	Liver enzyme levels (gamma-glutamyl transferase);	chr2:232642551	chr2:232649849~232650136:+
BRCA	cis	rs2031532	0.565	rs11619265	ENSG00000236577.1	SNRPGP14	3.46	0.000569	0.0274	0.12	0.11	Cardiac hypertrophy;	chr13:49483497	chr13:49488970~49489364:+
BRCA	cis	rs524281	0.861	rs11227415	ENSG00000255038.1	RP11-1167A19.2	3.46	0.000569	0.0275	0.15	0.11	Electroencephalogram traits;	chr11:66117988	chr11:66067277~66069619:-
BRCA	cis	rs3770752	0.866	rs2888434	ENSG00000272054.1	RP11-423P10.2	-3.46	0.00057	0.0275	-0.09	-0.11	Schizophrenia;	chr2:37238763	chr2:37208875~37212677:+
BRCA	cis	rs3770752	0.828	rs11124569	ENSG00000272054.1	RP11-423P10.2	-3.46	0.00057	0.0275	-0.09	-0.11	Schizophrenia;	chr2:37239539	chr2:37208875~37212677:+
BRCA	cis	rs4869313	0.668	rs2549791	ENSG00000248734.2	CTD-2260A17.1	-3.46	0.00057	0.0275	-0.11	-0.11	Pediatric autoimmune diseases;	chr5:96906738	chr5:96784777~96785999:+
BRCA	cis	rs4869313	0.668	rs2549792	ENSG00000248734.2	CTD-2260A17.1	-3.46	0.00057	0.0275	-0.11	-0.11	Pediatric autoimmune diseases;	chr5:96906758	chr5:96784777~96785999:+
BRCA	cis	rs13126694	0.682	rs6536288	ENSG00000251073.1	NUDT19P5	-3.46	0.00057	0.0275	-0.1	-0.11	Blood osmolality (transformed sodium);	chr4:157949748	chr4:158182825~158183393:+
BRCA	cis	rs9650657	0.655	rs10093774	ENSG00000255046.1	RP11-297N6.4	-3.46	0.00057	0.0275	-0.12	-0.11	Neuroticism;	chr8:10845783	chr8:11797928~11802568:-
BRCA	cis	rs4388249	1	rs11241032	ENSG00000249068.1	CTC-287O8.1	3.46	0.00057	0.0275	0.15	0.11	Schizophrenia;	chr5:109723507	chr5:109840128~109840692:-
BRCA	cis	rs2288884	0.537	rs16983434	ENSG00000267927.1	CTD-2525I3.2	3.46	0.00057	0.0275	0.14	0.11	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52088180	chr19:52171158~52177002:+
BRCA	cis	rs2688608	0.839	rs2633311	ENSG00000213731.2	RAB5CP1	3.46	0.00057	0.0275	0.12	0.11	Inflammatory bowel disease;	chr10:73838341	chr10:74423435~74424014:-
BRCA	cis	rs6445975	0.628	rs7231	ENSG00000273493.1	RP11-80H18.4	3.46	0.00057	0.0275	0.15	0.11	Systemic lupus erythematosus;	chr3:58427738	chr3:58329965~58330118:+
BRCA	cis	rs6012953	0.874	rs6063534	ENSG00000231715.1	COX6CP2	3.46	0.00057	0.0275	0.11	0.11	Vitiligo;	chr20:50572631	chr20:50479767~50479991:+
BRCA	cis	rs826838	0.586	rs10880753	ENSG00000257718.1	RP11-396F22.1	-3.46	0.00057	0.0275	-0.11	-0.11	Heart rate;	chr12:38234345	chr12:38906451~38909592:+
BRCA	cis	rs826838	0.616	rs10880754	ENSG00000257718.1	RP11-396F22.1	-3.46	0.00057	0.0275	-0.11	-0.11	Heart rate;	chr12:38234352	chr12:38906451~38909592:+
BRCA	cis	rs6012564	1	rs2295028	ENSG00000230758.1	SNAP23P	-3.46	0.00057	0.0275	-0.12	-0.11	Anger;	chr20:48966421	chr20:49038357~49038602:-
BRCA	cis	rs34792	0.688	rs153782	ENSG00000275910.1	RP11-680G24.6	3.46	0.00057	0.0275	0.12	0.11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15507763	chr16:15015828~15016390:-
BRCA	cis	rs1466788	0.895	rs3754443	ENSG00000224965.1	KCNC4-AS1	3.46	0.00057	0.0275	0.13	0.11	Blood metabolite levels;	chr1:110066666	chr1:110208834~110209987:-
BRCA	cis	rs672059	0.966	rs492228	ENSG00000224468.3	RP11-181K3.4	-3.46	0.00057	0.0275	-0.11	-0.11	Hypertriglyceridemia;	chr1:183187341	chr1:183138402~183141282:-
BRCA	cis	rs672059	1	rs652753	ENSG00000224468.3	RP11-181K3.4	-3.46	0.00057	0.0275	-0.11	-0.11	Hypertriglyceridemia;	chr1:183187434	chr1:183138402~183141282:-
BRCA	cis	rs672059	1	rs638781	ENSG00000224468.3	RP11-181K3.4	-3.46	0.00057	0.0275	-0.11	-0.11	Hypertriglyceridemia;	chr1:183188223	chr1:183138402~183141282:-
BRCA	cis	rs6142102	0.961	rs6120519	ENSG00000206582.1	Y_RNA	-3.46	0.00057	0.0275	-0.13	-0.11	Skin pigmentation;	chr20:34100307	chr20:34526510~34526606:-
BRCA	cis	rs16858210	0.607	rs59321941	ENSG00000234371.6	RPSAP31	3.46	0.00057	0.0275	0.16	0.11	Menopause (age at onset);	chr3:183853236	chr3:183884924~183888449:+
BRCA	cis	rs12444795	0.755	rs741692	ENSG00000267077.1	RP11-127I20.5	3.46	0.00057	0.0275	0.15	0.11	Cancer;	chr16:4812424	chr16:4795265~4796532:-
BRCA	cis	rs875971	0.964	rs778708	ENSG00000272831.1	RP11-792A8.4	3.46	0.000571	0.0275	0.1	0.11	Aortic root size;	chr7:66391332	chr7:66739829~66740385:-
BRCA	cis	rs9503598	0.521	rs4959834	ENSG00000266750.1	MIR4645	3.46	0.000571	0.0275	0.12	0.11	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr6:3436457	chr6:2854031~2854107:-
BRCA	cis	rs8130944	0.822	rs1515756	ENSG00000225731.1	AP001627.1	3.46	0.000571	0.0275	0.13	0.11	Perceived unattractiveness to mosquitoes;	chr21:42694660	chr21:42733594~42741758:-
BRCA	cis	rs4499344	0.519	rs259226	ENSG00000267475.1	CTD-2538C1.2	3.46	0.000571	0.0275	0.15	0.11	Mean platelet volume;	chr19:32644059	chr19:32687089~32691750:-
BRCA	cis	rs4819052	0.684	rs914216	ENSG00000223768.1	LINC00205	-3.46	0.000571	0.0275	-0.14	-0.11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45278383	chr21:45293285~45297354:+
BRCA	cis	rs9535495	0.931	rs1841676	ENSG00000237152.3	DLEU7-AS1	3.46	0.000571	0.0275	0.13	0.11	High light scatter reticulocyte count;Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;	chr13:50825622	chr13:50807856~50849905:+
BRCA	cis	rs80226907	0.634	rs713474	ENSG00000186615.9	KTN1-AS1	-3.46	0.000571	0.0275	-0.22	-0.11	Mean platelet volume;	chr14:55437818	chr14:55499278~55580110:-
BRCA	cis	rs10844706	0.666	rs10844609	ENSG00000256594.6	RP11-705C15.2	3.46	0.000571	0.0275	0.14	0.11	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9723909	chr12:9633419~9658412:+
BRCA	cis	rs11642862	1	rs111954099	ENSG00000260082.1	RP11-2C24.5	-3.46	0.000571	0.0275	-0.19	-0.11	Tonsillectomy;	chr16:30778302	chr16:30821068~30822110:-
BRCA	cis	rs6600671	1	rs4844607	ENSG00000223345.3	HIST2H2BA	-3.46	0.000571	0.0275	-0.13	-0.11	Hip geometry;	chr1:121442201	chr1:121108210~121117257:-
BRCA	cis	rs13217239	0.646	rs7768407	ENSG00000124549.13	BTN2A3P	3.46	0.000571	0.0275	0.11	0.11	Schizophrenia;	chr6:27049016	chr6:26421391~26432383:+
BRCA	cis	rs1865760	1	rs6938233	ENSG00000272810.1	U91328.22	-3.46	0.000571	0.0275	-0.12	-0.11	Height;	chr6:25913849	chr6:26013241~26013757:+
BRCA	cis	rs11673344	0.543	rs1818748	ENSG00000276846.1	CTD-3220F14.3	3.46	0.000571	0.0275	0.12	0.11	Obesity-related traits;	chr19:37065416	chr19:37314868~37315620:-
BRCA	cis	rs7943953	0.865	rs7932593	ENSG00000254717.2	GLYATL1P2	-3.46	0.000571	0.0275	-0.15	-0.11	Odorant perception (&beta-ionone);	chr11:59454206	chr11:58878302~58893460:+
BRCA	cis	rs7943953	0.865	rs7932937	ENSG00000254717.2	GLYATL1P2	-3.46	0.000571	0.0275	-0.15	-0.11	Odorant perception (&beta-ionone);	chr11:59454663	chr11:58878302~58893460:+
BRCA	cis	rs11673344	0.832	rs11540540	ENSG00000267682.1	CTD-3220F14.2	-3.46	0.000571	0.0275	-0.1	-0.11	Obesity-related traits;	chr19:37129629	chr19:37337236~37337743:+
BRCA	cis	rs830124	0.866	rs11043226	ENSG00000272849.1	RP11-347I19.8	-3.46	0.000571	0.0275	-0.12	-0.11	Urinary metabolites;	chr12:121869380	chr12:121797511~121801972:+
BRCA	cis	rs849141	0.925	rs1029534	ENSG00000234336.5	JAZF1-AS1	-3.46	0.000571	0.0275	-0.16	-0.11	Height;Hip circumference adjusted for BMI;	chr7:28149464	chr7:28180322~28243917:+
BRCA	cis	rs6733011	0.542	rs6542860	ENSG00000273306.1	RP11-527J8.1	3.46	0.000571	0.0275	0.11	0.11	Bipolar disorder;	chr2:99062913	chr2:99405218~99405843:+
BRCA	cis	rs561341	0.882	rs2521594	ENSG00000265798.5	RP11-271K11.5	3.46	0.000571	0.0275	0.18	0.11	Hip circumference adjusted for BMI;	chr17:31975068	chr17:31038575~31059121:-
BRCA	cis	rs518600	1	rs518600	ENSG00000276334.1	AL133243.1	3.46	0.000571	0.0275	0.13	0.11	Interleukin-18 levels;	chr2:31629385	chr2:32521927~32523547:+
BRCA	cis	rs17836934	0.525	rs7303123	ENSG00000270344.2	RP11-734K2.4	-3.46	0.000571	0.0275	-0.1	-0.11	Total body bone mineral density;	chr12:89975574	chr12:89525654~89548005:+
BRCA	cis	rs17836934	0.525	rs10777216	ENSG00000270344.2	RP11-734K2.4	-3.46	0.000571	0.0275	-0.1	-0.11	Total body bone mineral density;	chr12:89976239	chr12:89525654~89548005:+
BRCA	cis	rs3096299	0.658	rs34590044	ENSG00000261118.1	RP11-104N10.1	3.46	0.000571	0.0275	0.11	0.11	Multiple myeloma (IgH translocation);	chr16:89476749	chr16:89492017~89504460:-
BRCA	cis	rs9976876	0.9	rs4817728	ENSG00000231106.2	LINC01436	3.46	0.000571	0.0275	0.12	0.11	Total body bone mineral density;	chr21:35571936	chr21:36005338~36007838:+
BRCA	cis	rs11662721	0.938	rs12960229	ENSG00000264188.1	RP11-13N13.5	-3.46	0.000571	0.0275	-0.14	-0.11	Phospholipid levels (plasma);	chr18:21542677	chr18:21661787~21662395:-
BRCA	cis	rs7512898	0.51	rs10920054	ENSG00000260088.1	RP11-92G12.3	-3.46	0.000571	0.0275	-0.15	-0.11	Electrocardiographic conduction measures;	chr1:200861312	chr1:200669507~200694250:+
BRCA	cis	rs7520050	0.966	rs6668284	ENSG00000226957.1	RP4-533D7.4	3.46	0.000571	0.0275	0.11	0.11	Reticulocyte count;Red blood cell count;	chr1:45888838	chr1:46046818~46048368:+
BRCA	cis	rs4865762	0.595	rs454858	ENSG00000247796.2	CTD-2366F13.1	3.46	0.000572	0.0275	0.11	0.11	Intraocular pressure;	chr5:53247761	chr5:53109842~53115126:+
BRCA	cis	rs2574985	0.962	rs1203421	ENSG00000231345.3	BEND3P1	-3.46	0.000572	0.0275	-0.17	-0.11	Subjective well-being;	chr10:50424012	chr10:50655967~50660472:+
BRCA	cis	rs7829975	0.688	rs7826654	ENSG00000173295.6	FAM86B3P	3.46	0.000572	0.0275	0.11	0.11	Mood instability;	chr8:8521596	chr8:8228595~8244865:+
BRCA	cis	rs7829975	0.688	rs7826660	ENSG00000173295.6	FAM86B3P	3.46	0.000572	0.0275	0.11	0.11	Mood instability;	chr8:8521597	chr8:8228595~8244865:+
BRCA	cis	rs6599077	0.616	rs11716640	ENSG00000223797.4	ENTPD3-AS1	3.46	0.000572	0.0275	0.13	0.11	Sleep-related phenotypes;	chr3:40133841	chr3:40313802~40453329:-
BRCA	cis	rs8062405	0.755	rs12447461	ENSG00000261766.1	RP11-22P6.2	-3.46	0.000572	0.0275	-0.11	-0.11	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28571620	chr16:28862166~28863340:-
BRCA	cis	rs8062405	0.755	rs111693583	ENSG00000261766.1	RP11-22P6.2	-3.46	0.000572	0.0275	-0.11	-0.11	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28572289	chr16:28862166~28863340:-
BRCA	cis	rs6545883	0.894	rs6760075	ENSG00000273302.1	RP11-493E12.2	-3.46	0.000572	0.0275	-0.1	-0.11	Tuberculosis;	chr2:61385746	chr2:61199979~61200769:+
BRCA	cis	rs6088590	1	rs6087632	ENSG00000276073.1	RP5-1125A11.7	-3.46	0.000572	0.0275	-0.12	-0.11	Coronary artery disease;	chr20:34819901	chr20:33985617~33988989:-
BRCA	cis	rs6088590	0.931	rs6088617	ENSG00000276073.1	RP5-1125A11.7	-3.46	0.000572	0.0275	-0.12	-0.11	Coronary artery disease;	chr20:34820233	chr20:33985617~33988989:-
BRCA	cis	rs12446632	0.941	rs8054079	ENSG00000261195.1	CTD-2380F24.1	3.46	0.000572	0.0275	0.17	0.11	Hip circumference;Body mass index (joint analysis main effects and smoking interaction);BMI in smokers;Menarche (age at onset);Obesity;Childhood body mass index;Waist circumference;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Body mass index;	chr16:19964085	chr16:19761172~19766099:-
BRCA	cis	rs4703129	1	rs6865579	ENSG00000246763.5	RGMB-AS1	-3.46	0.000572	0.0275	-0.12	-0.11	Asperger disorder;	chr5:98532425	chr5:98769618~98773469:-
BRCA	cis	rs6500602	0.626	rs7665	ENSG00000280063.1	RP11-295D4.3	3.46	0.000572	0.0275	0.08	0.11	Schizophrenia;	chr16:4512511	chr16:4346694~4348648:-
BRCA	cis	rs13381277	0.764	rs8082880	ENSG00000266256.1	LINC00683	-3.46	0.000572	0.0276	-0.17	-0.11	Dental caries;	chr18:76607560	chr18:76615212~76625940:+
BRCA	cis	rs8103278	1	rs8108590	ENSG00000268423.3	AC011551.3	3.46	0.000572	0.0276	0.13	0.11	Coronary artery disease;	chr19:45798362	chr19:46547056~46600861:-
BRCA	cis	rs4713118	0.513	rs1225591	ENSG00000219891.2	ZSCAN12P1	3.46	0.000572	0.0276	0.14	0.11	Parkinson's disease;	chr6:28180974	chr6:28091154~28093664:+
BRCA	cis	rs11239930	0.517	rs2477568	ENSG00000227242.3	NBPF13P	3.46	0.000572	0.0276	0.14	0.11	AIDS progression;	chr1:147076244	chr1:147021320~147124525:-
BRCA	cis	rs10838687	0.8	rs7124958	ENSG00000243802.2	RP11-390K5.1	3.46	0.000572	0.0276	0.15	0.11	Proinsulin levels;	chr11:47325709	chr11:47191181~47191542:-
BRCA	cis	rs38055	0.558	rs72762377	ENSG00000247796.2	CTD-2366F13.1	3.46	0.000572	0.0276	0.14	0.11	Acne (severe);	chr5:53253057	chr5:53109842~53115126:+
BRCA	cis	rs13315871	1	rs13060489	ENSG00000272182.1	RP11-802O23.3	3.46	0.000572	0.0276	0.22	0.11	Cholesterol, total;	chr3:58353560	chr3:58428255~58428815:+
BRCA	cis	rs863345	0.584	rs1117125	ENSG00000176320.2	RP11-404O13.5	-3.46	0.000572	0.0276	-0.11	-0.11	Pneumococcal bacteremia;	chr1:158539606	chr1:158197922~158203877:-
BRCA	cis	rs752010	0.967	rs10890151	ENSG00000230638.4	RP11-486B10.4	-3.46	0.000572	0.0276	-0.13	-0.11	Lupus nephritis in systemic lupus erythematosus;	chr1:41636172	chr1:41542069~41544310:+
BRCA	cis	rs977987	0.527	rs62059844	ENSG00000280152.1	RP11-331F4.5	-3.46	0.000572	0.0276	-0.11	-0.11	Dupuytren's disease;	chr16:75395839	chr16:75245994~75250077:-
BRCA	cis	rs875971	0.545	rs316328	ENSG00000226767.1	RP11-328P23.3	-3.46	0.000572	0.0276	-0.12	-0.11	Aortic root size;	chr7:66143851	chr7:65508773~65508944:-
BRCA	cis	rs6500637	0.58	rs2660243	ENSG00000267077.1	RP11-127I20.5	-3.46	0.000572	0.0276	-0.11	-0.11	Cancer;	chr16:4891396	chr16:4795265~4796532:-
BRCA	cis	rs72819225	0.616	rs10881923	ENSG00000228701.1	TNKS2-AS1	3.46	0.000572	0.0276	0.14	0.11	Yeast infection;	chr10:91569029	chr10:91782839~91798291:-
BRCA	cis	rs6015450	0.702	rs75339815	ENSG00000228340.4	MIR646HG	3.46	0.000572	0.0276	0.21	0.11	Hypertension;Blood pressure;Systolic blood pressure;Diastolic blood pressure;	chr20:59150034	chr20:60087840~60527458:+
BRCA	cis	rs2555155	0.775	rs10769696	ENSG00000254595.1	CTD-2010I16.1	-3.46	0.000572	0.0276	-0.12	-0.11	DNA methylation (variation);	chr11:6525884	chr11:6488186~6489377:-
BRCA	cis	rs35306767	0.953	rs11253520	ENSG00000232656.6	IDI2-AS1	3.46	0.000572	0.0276	0.13	0.11	Eosinophil percentage of granulocytes;	chr10:930021	chr10:1022666~1044201:+
BRCA	cis	rs7308116	0.645	rs10861833	ENSG00000257951.1	RP11-554D14.4	3.46	0.000572	0.0276	0.13	0.11	Pelvic organ prolapse (moderate/severe);	chr12:107902358	chr12:107881242~107883382:+
BRCA	cis	rs875971	0.862	rs6460282	ENSG00000223473.2	GS1-124K5.3	-3.46	0.000572	0.0276	-0.08	-0.11	Aortic root size;	chr7:66226259	chr7:66491049~66493566:-
BRCA	cis	rs2109514	0.74	rs12706089	ENSG00000237813.3	AC002066.1	-3.45	0.000573	0.0276	-0.13	-0.11	Prevalent atrial fibrillation;	chr7:116444313	chr7:116238260~116499465:-
BRCA	cis	rs2262909	1	rs2359821	ENSG00000279377.1	AC003973.3	3.45	0.000573	0.0276	0.15	0.11	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;	chr19:22025512	chr19:21965708~21968529:-
BRCA	cis	rs2262909	1	rs2017962	ENSG00000279377.1	AC003973.3	3.45	0.000573	0.0276	0.15	0.11	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;	chr19:22025949	chr19:21965708~21968529:-
BRCA	cis	rs1730008	0.661	rs17627933	ENSG00000279311.1	RP11-170K4.2	3.45	0.000573	0.0276	0.13	0.11	Lobe attachment (rater-scored or self-reported);	chr3:158417468	chr3:158869898~158871821:+
BRCA	cis	rs524281	0.861	rs10791858	ENSG00000255038.1	RP11-1167A19.2	-3.45	0.000573	0.0276	-0.15	-0.11	Electroencephalogram traits;	chr11:66210925	chr11:66067277~66069619:-
BRCA	cis	rs524281	0.817	rs10791859	ENSG00000255038.1	RP11-1167A19.2	-3.45	0.000573	0.0276	-0.15	-0.11	Electroencephalogram traits;	chr11:66210982	chr11:66067277~66069619:-
BRCA	cis	rs9788682	0.642	rs2568483	ENSG00000261143.1	ADAMTS7P3	-3.45	0.000573	0.0276	-0.14	-0.11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78460001	chr15:77976042~77993057:+
BRCA	cis	rs875971	0.545	rs4441996	ENSG00000232559.3	GS1-124K5.12	-3.45	0.000573	0.0276	-0.14	-0.11	Aortic root size;	chr7:66123233	chr7:66554588~66576923:-
BRCA	cis	rs4664293	0.715	rs13002625	ENSG00000226266.5	AC009961.3	3.45	0.000573	0.0276	0.13	0.11	Monocyte percentage of white cells;	chr2:159648114	chr2:159670708~159712435:-
BRCA	cis	rs7103648	0.864	rs10769264	ENSG00000280615.1	Y_RNA	3.45	0.000573	0.0276	0.12	0.11	Systolic blood pressure;Diastolic blood pressure;	chr11:47401789	chr11:47614898~47614994:-
BRCA	cis	rs7781557	0.64	rs7779854	ENSG00000239969.4	RP11-163E9.2	-3.45	0.000573	0.0276	-0.17	-0.11	Colorectal adenoma (advanced);	chr7:102911135	chr7:102364162~102380633:+
BRCA	cis	rs12575642	0.66	rs58632573	ENSG00000256940.1	RP11-783K16.5	3.45	0.000573	0.0276	0.15	0.11	Attention deficit hyperactivity disorder;	chr11:64128827	chr11:64245964~64248217:+
BRCA	cis	rs2991971	0.967	rs10789465	ENSG00000281133.1	AL355480.3	3.45	0.000573	0.0276	0.12	0.11	High light scatter reticulocyte count;	chr1:45506087	chr1:45580892~45580996:-
BRCA	cis	rs4927850	0.957	rs4927851	ENSG00000185485.13	SDHAP1	3.45	0.000573	0.0276	0.11	0.11	Pancreatic cancer;	chr3:196024982	chr3:195959748~195990318:-
BRCA	cis	rs957448	0.687	rs10104041	ENSG00000254315.1	RP11-267M23.3	3.45	0.000573	0.0276	0.13	0.11	Nonsyndromic cleft lip with cleft palate;	chr8:94559374	chr8:94533628~94534391:+
BRCA	cis	rs10129255	0.872	rs8015406	ENSG00000211958.2	IGHV3-38	3.45	0.000573	0.0276	0.09	0.11	Kawasaki disease;	chr14:106670611	chr14:106410493~106411021:-
BRCA	cis	rs2288327	1	rs890578	ENSG00000271011.1	RP11-171I2.5	3.45	0.000573	0.0276	0.18	0.11	Atrial fibrillation;	chr2:178549906	chr2:178577103~178577622:+
BRCA	cis	rs4372836	0.602	rs11685682	ENSG00000226833.4	AC097724.3	-3.45	0.000573	0.0276	-0.13	-0.11	Body mass index;	chr2:28833935	chr2:28708953~28736205:-
BRCA	cis	rs2055729	0.645	rs12544019	ENSG00000233609.3	RP11-62H7.2	3.45	0.000573	0.0276	0.12	0.11	Multiple myeloma (hyperdiploidy);	chr8:9885068	chr8:8961200~8979025:+
BRCA	cis	rs9635324	0.927	rs17733719	ENSG00000223313.1	RNU6-516P	3.45	0.000573	0.0276	0.13	0.11	Blood metabolite ratios;Blood metabolite levels;	chr15:40428587	chr15:40529570~40529673:+
BRCA	cis	rs9785234	0.941	rs7862977	ENSG00000175611.10	LINC00476	3.45	0.000573	0.0276	0.13	0.11	Glomerular filtration rate in chronic kidney disease;	chr9:96170467	chr9:95759231~95875977:-
BRCA	cis	rs2243480	0.901	rs35087093	ENSG00000234585.5	CCT6P3	-3.45	0.000573	0.0276	-0.16	-0.11	Diabetic kidney disease;	chr7:65940221	chr7:65038354~65074713:+
BRCA	cis	rs9866825	0.935	rs5001961	ENSG00000227110.5	LMCD1-AS1	3.45	0.000573	0.0276	0.13	0.11	QT interval;	chr3:8205888	chr3:7952805~8611924:-
BRCA	cis	rs10844706	0.699	rs11052717	ENSG00000256594.6	RP11-705C15.2	3.45	0.000573	0.0276	0.14	0.11	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9726217	chr12:9633419~9658412:+
BRCA	cis	rs1642645	0.872	rs1408948	ENSG00000228452.1	RP5-994D16.9	3.45	0.000573	0.0276	0.14	0.11	Left ventricular obstructive tract defect (maternal effect);	chr1:41952035	chr1:42775813~42776790:-
BRCA	cis	rs6714710	0.603	rs35424768	ENSG00000228486.8	LINC01125	-3.45	0.000573	0.0276	-0.09	-0.11	Posterior cortical atrophy and Alzheimer's disease;	chr2:97779190	chr2:97664217~97703064:+
BRCA	cis	rs6714710	0.603	rs13020776	ENSG00000228486.8	LINC01125	-3.45	0.000573	0.0276	-0.09	-0.11	Posterior cortical atrophy and Alzheimer's disease;	chr2:97786290	chr2:97664217~97703064:+
BRCA	cis	rs7520050	0.645	rs1768809	ENSG00000234329.1	RP11-767N6.2	-3.45	0.000573	0.0276	-0.1	-0.11	Reticulocyte count;Red blood cell count;	chr1:46037164	chr1:45651039~45651826:-
BRCA	cis	rs28489187	0.505	rs7525786	ENSG00000223653.4	RP11-131L23.1	-3.45	0.000573	0.0276	-0.12	-0.11	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85418393	chr1:85276715~85448124:+
BRCA	cis	rs12216125	0.554	rs6942196	ENSG00000272462.2	U91328.19	-3.45	0.000573	0.0276	-0.13	-0.11	Iron status biomarkers;	chr6:26072576	chr6:25992662~26001775:+
BRCA	cis	rs72928364	0.86	rs13081830	ENSG00000244119.1	PDCL3P4	3.45	0.000574	0.0276	0.14	0.11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:101072418	chr3:101712472~101713191:+
BRCA	cis	rs4805834	0.843	rs11668777	ENSG00000201388.1	SNORA68	3.45	0.000574	0.0276	0.19	0.11	Creatinine levels;	chr19:32863283	chr19:32608337~32608469:-
BRCA	cis	rs7824557	0.707	rs3808518	ENSG00000255046.1	RP11-297N6.4	3.45	0.000574	0.0276	0.13	0.11	Retinal vascular caliber;	chr8:11285763	chr8:11797928~11802568:-
BRCA	cis	rs853679	0.546	rs200953	ENSG00000241549.7	GUSBP2	3.45	0.000574	0.0276	0.19	0.11	Depression;	chr6:27869489	chr6:26871484~26956554:-
BRCA	cis	rs27434	0.539	rs40604	ENSG00000248734.2	CTD-2260A17.1	3.45	0.000574	0.0276	0.12	0.11	Ankylosing spondylitis;	chr5:96820197	chr5:96784777~96785999:+
BRCA	cis	rs8180040	0.967	rs4858890	ENSG00000280667.1	Y_RNA	-3.45	0.000574	0.0276	-0.12	-0.11	Colorectal cancer;	chr3:47363966	chr3:47501083~47501182:+
BRCA	cis	rs10832139	0.553	rs61884784	ENSG00000255074.1	RP11-140L24.3	3.45	0.000574	0.0276	0.16	0.11	P wave terminal force;	chr11:13926070	chr11:14440787~14441677:+
BRCA	cis	rs2243480	1	rs781149	ENSG00000226767.1	RP11-328P23.3	-3.45	0.000574	0.0276	-0.18	-0.11	Diabetic kidney disease;	chr7:66016297	chr7:65508773~65508944:-
BRCA	cis	rs2243480	0.901	rs58207111	ENSG00000226767.1	RP11-328P23.3	-3.45	0.000574	0.0276	-0.18	-0.11	Diabetic kidney disease;	chr7:66021736	chr7:65508773~65508944:-
BRCA	cis	rs6452790	0.529	rs10053088	ENSG00000247828.6	TMEM161B-AS1	-3.45	0.000574	0.0276	-0.14	-0.11	Cognitive function;	chr5:87974550	chr5:88268895~88436685:+
BRCA	cis	rs6452790	0.529	rs3906609	ENSG00000247828.6	TMEM161B-AS1	-3.45	0.000574	0.0276	-0.14	-0.11	Cognitive function;	chr5:87975311	chr5:88268895~88436685:+
BRCA	cis	rs6452790	0.529	rs3915320	ENSG00000247828.6	TMEM161B-AS1	-3.45	0.000574	0.0276	-0.14	-0.11	Cognitive function;	chr5:87975359	chr5:88268895~88436685:+
BRCA	cis	rs1009077	0.61	rs2389866	ENSG00000245958.5	RP11-33B1.1	-3.45	0.000574	0.0276	-0.11	-0.11	Endometriosis;	chr4:119594108	chr4:119454791~119552025:+
BRCA	cis	rs1009077	0.579	rs10032993	ENSG00000245958.5	RP11-33B1.1	-3.45	0.000574	0.0276	-0.11	-0.11	Endometriosis;	chr4:119595462	chr4:119454791~119552025:+
BRCA	cis	rs1009077	0.504	rs9998919	ENSG00000245958.5	RP11-33B1.1	-3.45	0.000574	0.0276	-0.11	-0.11	Endometriosis;	chr4:119595538	chr4:119454791~119552025:+
BRCA	cis	rs10501293	0.746	rs1544871	ENSG00000252652.1	Y_RNA	-3.45	0.000574	0.0276	-0.13	-0.11	Cognitive performance;	chr11:43032572	chr11:43331261~43331356:+
BRCA	cis	rs7656342	0.808	rs6815039	ENSG00000250342.1	SNRPCP16	-3.45	0.000574	0.0276	-0.12	-0.11	Gut microbiota (bacterial taxa);	chr4:9776185	chr4:9051842~9052051:-
BRCA	cis	rs7103648	0.695	rs7933019	ENSG00000280615.1	Y_RNA	3.45	0.000574	0.0276	0.14	0.11	Systolic blood pressure;Diastolic blood pressure;	chr11:47487585	chr11:47614898~47614994:-
BRCA	cis	rs11098499	0.691	rs10010355	ENSG00000225892.3	RP11-384K6.2	3.45	0.000574	0.0276	0.1	0.11	Corneal astigmatism;	chr4:119339888	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.691	rs9307471	ENSG00000225892.3	RP11-384K6.2	3.45	0.000574	0.0276	0.1	0.11	Corneal astigmatism;	chr4:119340107	chr4:118632274~118634759:+
BRCA	cis	rs7520050	0.966	rs4660321	ENSG00000281133.1	AL355480.3	3.45	0.000574	0.0276	0.12	0.11	Reticulocyte count;Red blood cell count;	chr1:45901088	chr1:45580892~45580996:-
BRCA	cis	rs7520050	0.931	rs6698247	ENSG00000281133.1	AL355480.3	3.45	0.000574	0.0276	0.12	0.11	Reticulocyte count;Red blood cell count;	chr1:45905814	chr1:45580892~45580996:-
BRCA	cis	rs7520050	0.966	rs6675946	ENSG00000281133.1	AL355480.3	3.45	0.000574	0.0276	0.12	0.11	Reticulocyte count;Red blood cell count;	chr1:45906102	chr1:45580892~45580996:-
BRCA	cis	rs7520050	0.931	rs7526678	ENSG00000281133.1	AL355480.3	3.45	0.000574	0.0276	0.12	0.11	Reticulocyte count;Red blood cell count;	chr1:45908487	chr1:45580892~45580996:-
BRCA	cis	rs1122401	1	rs1122400	ENSG00000280159.1	CTD-2591A1.1	3.45	0.000574	0.0276	0.14	0.11	Smoking initiation;	chr5:54580172	chr5:54643557~54645987:+
BRCA	cis	rs11035577	0.632	rs7945701	ENSG00000279675.1	RP11-454H19.2	-3.45	0.000574	0.0276	-0.16	-0.11	Temperament (bipolar disorder);	chr11:39767548	chr11:40107244~40112599:-
BRCA	cis	rs2018683	0.707	rs2057957	ENSG00000228421.2	AC005013.5	-3.45	0.000574	0.0276	-0.13	-0.11	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28935009	chr7:28957667~28959345:+
BRCA	cis	rs7020830	0.83	rs308499	ENSG00000230188.1	RP11-405L18.4	-3.45	0.000574	0.0276	-0.13	-0.11	Schizophrenia;	chr9:37348062	chr9:37490421~37490893:-
BRCA	cis	rs1355023	0.547	rs9384582	ENSG00000231628.1	RP3-355L5.4	-3.45	0.000574	0.0276	-0.11	-0.11	Age-related macular degeneration;	chr6:105773532	chr6:105279016~105281755:+
BRCA	cis	rs35306767	0.903	rs10904577	ENSG00000229869.1	RP11-363N22.2	-3.45	0.000574	0.0276	-0.16	-0.11	Eosinophil percentage of granulocytes;	chr10:876137	chr10:933026~942743:+
BRCA	cis	rs4819052	0.851	rs7276591	ENSG00000215447.6	BX322557.10	-3.45	0.000574	0.0277	-0.11	-0.11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260241	chr21:45288052~45291738:+
BRCA	cis	rs6460942	0.915	rs62447640	ENSG00000226690.5	AC005281.1	3.45	0.000574	0.0277	0.21	0.11	Coronary artery disease;	chr7:12448656	chr7:12496429~12541910:+
BRCA	cis	rs7259811	0.892	rs62133210	ENSG00000268266.1	AC003005.2	3.45	0.000574	0.0277	0.14	0.11	Western dietary pattern;	chr19:56714741	chr19:57477649~57482996:+
BRCA	cis	rs561341	0.783	rs512698	ENSG00000265798.5	RP11-271K11.5	3.45	0.000575	0.0277	0.18	0.11	Hip circumference adjusted for BMI;	chr17:31965488	chr17:31038575~31059121:-
BRCA	cis	rs11858159	0.902	rs61995200	ENSG00000207279.1	SNORD116-24	-3.45	0.000575	0.0277	-0.11	-0.11	Platelet thrombus formation;	chr15:24570034	chr15:25094037~25094128:+
BRCA	cis	rs3760982	0.565	rs3786956	ENSG00000266921.1	RP11-15A1.7	-3.45	0.000575	0.0277	-0.14	-0.11	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43782677	chr19:43996896~44002836:-
BRCA	cis	rs55675132	0.548	rs76034359	ENSG00000226167.1	AP4B1-AS1	3.45	0.000575	0.0277	0.11	0.11	Schizophrenia;	chr1:114832427	chr1:113856635~113901237:+
BRCA	cis	rs703842	0.616	rs4760171	ENSG00000257159.1	RP11-58A17.3	3.45	0.000575	0.0277	0.13	0.11	Multiple sclerosis;	chr12:57832121	chr12:57967058~57968399:+
BRCA	cis	rs17711722	0.675	rs6947132	ENSG00000227113.2	RP11-460N20.4	-3.45	0.000575	0.0277	-0.11	-0.11	Calcium levels;	chr7:65808508	chr7:65075023~65078780:+
BRCA	cis	rs9393813	0.528	rs4713109	ENSG00000204789.4	ZNF204P	3.45	0.000575	0.0277	0.13	0.11	Bipolar disorder;	chr6:27508489	chr6:27357825~27360221:-
BRCA	cis	rs4415084	0.966	rs16901937	ENSG00000248464.1	FGF10-AS1	3.45	0.000575	0.0277	0.12	0.11	Breast cancer;	chr5:44709039	chr5:44388732~44413989:+
BRCA	cis	rs875971	1	rs697970	ENSG00000272831.1	RP11-792A8.4	-3.45	0.000575	0.0277	-0.1	-0.11	Aortic root size;	chr7:66095065	chr7:66739829~66740385:-
BRCA	cis	rs4218	0.689	rs73418863	ENSG00000259732.1	RP11-59H7.3	-3.45	0.000575	0.0277	-0.13	-0.11	Social communication problems;	chr15:59098923	chr15:59121034~59133250:+
BRCA	cis	rs2562456	0.833	rs56187954	ENSG00000268117.1	VN1R84P	3.45	0.000575	0.0277	0.16	0.11	Pain;	chr19:21345258	chr19:21719801~21720035:-
BRCA	cis	rs11887277	0.557	rs35103404	ENSG00000272148.1	RP11-195B17.1	-3.45	0.000575	0.0277	-0.13	-0.11	Obesity-related traits;	chr2:26749198	chr2:27062428~27062907:-
BRCA	cis	rs17345786	0.861	rs17402964	ENSG00000244119.1	PDCL3P4	3.45	0.000575	0.0277	0.1	0.11	Colonoscopy-negative controls vs population controls;	chr3:101349101	chr3:101712472~101713191:+
BRCA	cis	rs9437689	0.966	rs4339907	ENSG00000235501.4	RP4-639F20.1	3.45	0.000575	0.0277	0.14	0.11	Phospholipid levels (plasma);	chr1:95067910	chr1:94927566~94963270:+
BRCA	cis	rs8114671	0.562	rs6087644	ENSG00000126005.14	MMP24-AS1	-3.45	0.000575	0.0277	-0.13	-0.11	Height;	chr20:34893114	chr20:35216462~35278131:-
BRCA	cis	rs4835473	0.932	rs1006406	ENSG00000246448.2	RP13-578N3.3	-3.45	0.000575	0.0277	-0.12	-0.11	Immature fraction of reticulocytes;	chr4:143761710	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.932	rs1562776	ENSG00000246448.2	RP13-578N3.3	-3.45	0.000575	0.0277	-0.12	-0.11	Immature fraction of reticulocytes;	chr4:143761999	chr4:143700257~143865072:+
BRCA	cis	rs7703051	0.786	rs7730495	ENSG00000271815.1	CTD-2235C13.3	-3.45	0.000575	0.0277	-0.14	-0.11	Age-related diseases, mortality and associated endophenotypes;LDL cholesterol;Age-related disease endophenotypes;	chr5:75315408	chr5:75363760~75364242:+
BRCA	cis	rs991427	0.908	rs10859104	ENSG00000258100.1	RP11-121E16.1	-3.45	0.000575	0.0277	-0.14	-0.11	Systolic blood pressure (alcohol consumption interaction);	chr12:91067889	chr12:91362196~91368606:+
BRCA	cis	rs7487075	0.897	rs2897968	ENSG00000274723.1	RP11-618L22.1	3.45	0.000575	0.0277	0.14	0.11	Itch intensity from mosquito bite;	chr12:46369903	chr12:46970504~46972155:+
BRCA	cis	rs4950322	0.512	rs10736839	ENSG00000237188.3	RP11-337C18.8	-3.45	0.000575	0.0277	-0.11	-0.11	Protein quantitative trait loci;	chr1:147370431	chr1:147172771~147211568:+
BRCA	cis	rs875971	0.862	rs6978028	ENSG00000265600.1	AC006480.1	-3.45	0.000575	0.0277	-0.13	-0.11	Aortic root size;	chr7:66421313	chr7:67356680~67356779:+
BRCA	cis	rs3864261	0.515	rs57149385	ENSG00000251613.3	CTC-347C20.1	-3.45	0.000576	0.0277	-0.13	-0.11	Discordance in emotional problems in monozygotic twins;	chr5:73060354	chr5:72687112~72762727:-
BRCA	cis	rs3864261	0.515	rs10942539	ENSG00000251613.3	CTC-347C20.1	-3.45	0.000576	0.0277	-0.13	-0.11	Discordance in emotional problems in monozygotic twins;	chr5:73061259	chr5:72687112~72762727:-
BRCA	cis	rs78545713	0.536	rs11755618	ENSG00000241549.7	GUSBP2	3.45	0.000576	0.0277	0.18	0.11	Iron status biomarkers (total iron binding capacity);	chr6:26215574	chr6:26871484~26956554:-
BRCA	cis	rs875971	0.964	rs778735	ENSG00000273448.1	RP11-166O4.6	3.45	0.000576	0.0277	0.1	0.11	Aortic root size;	chr7:66349822	chr7:67333047~67334383:+
BRCA	cis	rs259282	0.538	rs6510270	ENSG00000267475.1	CTD-2538C1.2	3.45	0.000576	0.0277	0.13	0.11	Schizophrenia;	chr19:32623608	chr19:32687089~32691750:-
BRCA	cis	rs4557020	1	rs4557020	ENSG00000162997.14	PRORSD1P	-3.45	0.000576	0.0277	-0.11	-0.11	Myopia (pathological);	chr2:54491044	chr2:55282319~55284522:+
BRCA	cis	rs27434	0.583	rs34760	ENSG00000248734.2	CTD-2260A17.1	3.45	0.000576	0.0277	0.12	0.11	Ankylosing spondylitis;	chr5:96817788	chr5:96784777~96785999:+
BRCA	cis	rs6582630	0.562	rs35080195	ENSG00000257718.1	RP11-396F22.1	-3.45	0.000576	0.0277	-0.11	-0.11	Drug-induced liver injury (flucloxacillin);	chr12:37917064	chr12:38906451~38909592:+
BRCA	cis	rs9296095	0.796	rs3846855	ENSG00000224796.1	RPL32P1	3.45	0.000576	0.0277	0.13	0.11	Platelet count;	chr6:33588100	chr6:33079451~33079860:+
BRCA	cis	rs11892454	0.599	rs7605347	ENSG00000217643.1	PTGES3P2	-3.45	0.000576	0.0277	-0.12	-0.11	Heschl's gyrus morphology;	chr2:25780361	chr2:25822469~25822950:+
BRCA	cis	rs6012564	1	rs2426109	ENSG00000230758.1	SNAP23P	-3.45	0.000576	0.0277	-0.12	-0.11	Anger;	chr20:49046090	chr20:49038357~49038602:-
BRCA	cis	rs6832769	0.643	rs10003211	ENSG00000272969.1	RP11-528I4.2	-3.45	0.000576	0.0277	-0.13	-0.11	Personality dimensions;	chr4:55651165	chr4:55547112~55547889:+
BRCA	cis	rs2562456	0.754	rs55771551	ENSG00000268705.1	BNIP3P26	3.45	0.000576	0.0277	0.12	0.11	Pain;	chr19:21563578	chr19:21521343~21521896:-
BRCA	cis	rs7308116	1	rs7134568	ENSG00000240441.1	RP11-864J10.2	-3.45	0.000576	0.0277	-0.12	-0.11	Pelvic organ prolapse (moderate/severe);	chr12:107805973	chr12:107719599~107720133:+
BRCA	cis	rs875971	0.862	rs11765791	ENSG00000223473.2	GS1-124K5.3	3.45	0.000576	0.0277	0.08	0.11	Aortic root size;	chr7:66471587	chr7:66491049~66493566:-
BRCA	cis	rs6570726	0.526	rs72994723	ENSG00000270638.1	RP3-466P17.1	-3.45	0.000576	0.0277	-0.12	-0.11	Lobe attachment (rater-scored or self-reported);	chr6:145401812	chr6:145735570~145737218:+
BRCA	cis	rs911555	0.57	rs11625397	ENSG00000269910.1	RP11-73M18.10	-3.45	0.000576	0.0277	-0.1	-0.11	Intelligence (multi-trait analysis);	chr14:103561220	chr14:103694516~103695050:-
BRCA	cis	rs36051895	0.589	rs6476948	ENSG00000237711.1	RP11-39K24.13	-3.45	0.000576	0.0277	-0.13	-0.11	Pediatric autoimmune diseases;	chr9:5204404	chr9:5100236~5101009:+
BRCA	cis	rs7826238	0.502	rs10503377	ENSG00000254153.1	CTA-398F10.2	3.45	0.000576	0.0277	0.14	0.11	Systolic blood pressure;	chr8:8520912	chr8:8456909~8461337:-
BRCA	cis	rs6696239	0.513	rs4653514	ENSG00000227711.2	RP11-275O4.5	3.45	0.000576	0.0277	0.12	0.11	Height;	chr1:227565381	chr1:227509028~227520477:-
BRCA	cis	rs2638953	0.888	rs10843189	ENSG00000273989.1	RP11-425D17.2	-3.45	0.000577	0.0277	-0.16	-0.11	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28506985	chr12:28236227~28236828:+
BRCA	cis	rs7259376	0.936	rs7255829	ENSG00000269345.1	VN1R85P	3.45	0.000577	0.0277	0.12	0.11	Menopause (age at onset);	chr19:22354509	chr19:22174766~22175191:-
BRCA	cis	rs7590268	0.707	rs35805220	ENSG00000279873.2	LINC01126	3.45	0.000577	0.0277	0.13	0.11	Orofacial clefts;	chr2:43335660	chr2:43227210~43228855:+
BRCA	cis	rs2439831	0.85	rs3825783	ENSG00000206991.1	RNU6-610P	-3.45	0.000577	0.0277	-0.18	-0.11	Lung cancer in ever smokers;	chr15:43810111	chr15:43637632~43637738:-
BRCA	cis	rs875971	0.964	rs12668936	ENSG00000229886.1	RP5-1132H15.3	3.45	0.000577	0.0277	0.12	0.11	Aortic root size;	chr7:66449417	chr7:66025126~66031544:-
BRCA	cis	rs11673344	0.642	rs12462708	ENSG00000267422.1	CTD-2554C21.1	-3.45	0.000577	0.0277	-0.14	-0.11	Obesity-related traits;	chr19:37306676	chr19:37779686~37792865:+
BRCA	cis	rs10759883	0.539	rs7847393	ENSG00000225194.2	LINC00092	3.45	0.000577	0.0277	0.11	0.11	Nicotine dependence;	chr9:96033431	chr9:96019732~96027965:-
BRCA	cis	rs4237845	0.788	rs6581157	ENSG00000270039.1	RP11-571M6.17	-3.45	0.000577	0.0277	-0.15	-0.11	Intelligence (multi-trait analysis);	chr12:57895010	chr12:57803838~57804415:+
BRCA	cis	rs875971	0.964	rs60193905	ENSG00000273024.4	INTS4P2	-3.45	0.000577	0.0277	-0.12	-0.11	Aortic root size;	chr7:66506273	chr7:65647864~65715661:+
BRCA	cis	rs3747113	0.954	rs2298378	ENSG00000234928.1	AP000344.3	3.45	0.000577	0.0277	0.14	0.11	Gut microbiome composition (summer);	chr22:24323637	chr22:23433564~23435071:+
BRCA	cis	rs875971	0.898	rs6977501	ENSG00000272831.1	RP11-792A8.4	-3.45	0.000577	0.0277	-0.1	-0.11	Aortic root size;	chr7:66228355	chr7:66739829~66740385:-
BRCA	cis	rs7260598	0.901	rs7251567	ENSG00000268442.1	CTD-2027I19.2	3.45	0.000577	0.0277	0.17	0.11	Response to taxane treatment (placlitaxel);	chr19:24034489	chr19:24162370~24163425:-
BRCA	cis	rs7267979	0.966	rs7270835	ENSG00000231081.1	RP4-760C5.3	-3.45	0.000577	0.0277	-0.14	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25454431	chr20:26008791~26010531:-
BRCA	cis	rs7267979	1	rs6115191	ENSG00000231081.1	RP4-760C5.3	-3.45	0.000577	0.0277	-0.14	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25459842	chr20:26008791~26010531:-
BRCA	cis	rs7267979	1	rs6107045	ENSG00000231081.1	RP4-760C5.3	-3.45	0.000577	0.0277	-0.14	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25461300	chr20:26008791~26010531:-
BRCA	cis	rs7267979	1	rs6107046	ENSG00000231081.1	RP4-760C5.3	-3.45	0.000577	0.0277	-0.14	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25461413	chr20:26008791~26010531:-
BRCA	cis	rs7267979	1	rs6107047	ENSG00000231081.1	RP4-760C5.3	-3.45	0.000577	0.0277	-0.14	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25461461	chr20:26008791~26010531:-
BRCA	cis	rs17756712	0.725	rs3823130	ENSG00000271911.1	RP11-532F6.5	3.45	0.000577	0.0278	0.19	0.11	Vertical cup-disc ratio;	chr6:594012	chr6:761675~780648:+
BRCA	cis	rs71520386	0.632	rs10253651	ENSG00000179428.2	AC073072.5	3.45	0.000577	0.0278	0.12	0.11	Fibrinogen levels;	chr7:22830564	chr7:22725395~22727620:-
BRCA	cis	rs8040855	0.599	rs4577058	ENSG00000259416.2	RP11-158M2.5	-3.45	0.000577	0.0278	-0.12	-0.11	Bulimia nervosa;	chr15:85183227	chr15:85754941~85756237:-
BRCA	cis	rs943466	1	rs6921487	ENSG00000223837.2	BRD2-IT1	3.45	0.000577	0.0278	0.13	0.11	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;	chr6:33781516	chr6:32970232~32970886:+
BRCA	cis	rs4374383	0.631	rs1607060	ENSG00000243389.1	AC012442.5	3.45	0.000577	0.0278	0.13	0.11	Hepatitis C induced liver fibrosis;	chr2:111913350	chr2:112589040~112614431:+
BRCA	cis	rs530081	0.659	rs500903	ENSG00000274184.1	RP11-158H5.8	3.45	0.000577	0.0278	0.13	0.11	Lobe attachment (rater-scored or self-reported);	chr18:35113339	chr18:35268218~35270238:+
BRCA	cis	rs8062405	1	rs62037369	ENSG00000261766.1	RP11-22P6.2	-3.45	0.000577	0.0278	-0.11	-0.11	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28872520	chr16:28862166~28863340:-
BRCA	cis	rs8062405	0.965	rs7359397	ENSG00000261766.1	RP11-22P6.2	-3.45	0.000577	0.0278	-0.11	-0.11	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28874338	chr16:28862166~28863340:-
BRCA	cis	rs16852403	0.861	rs6662255	ENSG00000224687.1	RASAL2-AS1	3.45	0.000577	0.0278	0.13	0.11	Childhood ear infection;	chr1:178070948	chr1:178091508~178093984:-
BRCA	cis	rs2625529	0.526	rs6494997	ENSG00000260037.4	CTD-2524L6.3	3.45	0.000577	0.0278	0.13	0.11	Red blood cell count;	chr15:72268301	chr15:71818396~71823384:+
BRCA	cis	rs74233809	1	rs11191551	ENSG00000236937.2	PTGES3P4	3.45	0.000577	0.0278	0.23	0.11	Birth weight;	chr10:103091078	chr10:102845595~102845950:+
BRCA	cis	rs74233809	1	rs17094683	ENSG00000236937.2	PTGES3P4	3.45	0.000577	0.0278	0.23	0.11	Birth weight;	chr10:103091544	chr10:102845595~102845950:+
BRCA	cis	rs7048146	0.899	rs4978836	ENSG00000213539.4	YBX1P6	3.45	0.000577	0.0278	0.12	0.11	Vascular brain injury;	chr9:109576701	chr9:109532830~109534332:-
BRCA	cis	rs2574985	0.813	rs1203407	ENSG00000226200.5	SGMS1-AS1	-3.45	0.000577	0.0278	-0.11	-0.11	Subjective well-being;	chr10:50438213	chr10:50624951~50641451:+
BRCA	cis	rs4449834	0.781	rs4738818	ENSG00000254432.1	RP11-33I11.2	-3.45	0.000577	0.0278	-0.14	-0.11	Sum eosinophil basophil counts;	chr8:60708335	chr8:60808735~60809606:-
BRCA	cis	rs2562456	0.876	rs10424079	ENSG00000240522.1	RPL7AP10	-3.45	0.000577	0.0278	-0.12	-0.11	Pain;	chr19:21406377	chr19:21149648~21150438:-
BRCA	cis	rs10761256	0.778	rs7028306	ENSG00000227603.1	RP11-165J3.6	3.45	0.000577	0.0278	0.11	0.11	Itch intensity from mosquito bite adjusted by bite size;	chr9:93663801	chr9:93435332~93437121:-
BRCA	cis	rs10761256	0.806	rs10761254	ENSG00000227603.1	RP11-165J3.6	3.45	0.000577	0.0278	0.11	0.11	Itch intensity from mosquito bite adjusted by bite size;	chr9:93664062	chr9:93435332~93437121:-
BRCA	cis	rs613391	0.555	rs497100	ENSG00000265194.1	RP11-70L8.4	-3.45	0.000577	0.0278	-0.11	-0.11	Quantitative traits;	chr9:22747409	chr9:21858910~21861926:-
BRCA	cis	rs8058578	0.775	rs8046391	ENSG00000260082.1	RP11-2C24.5	3.45	0.000577	0.0278	0.12	0.11	Multiple myeloma;	chr16:30825327	chr16:30821068~30822110:-
BRCA	cis	rs830124	1	rs1947826	ENSG00000272849.1	RP11-347I19.8	-3.45	0.000577	0.0278	-0.12	-0.11	Urinary metabolites;	chr12:121868064	chr12:121797511~121801972:+
BRCA	cis	rs830124	1	rs2101017	ENSG00000272849.1	RP11-347I19.8	-3.45	0.000577	0.0278	-0.12	-0.11	Urinary metabolites;	chr12:121868951	chr12:121797511~121801972:+
BRCA	cis	rs1008375	0.931	rs6449326	ENSG00000249502.1	AC006160.5	-3.45	0.000578	0.0278	-0.12	-0.11	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17698167	chr4:17587467~17614571:-
BRCA	cis	rs6142618	0.562	rs3787369	ENSG00000275576.1	RP5-836N17.4	-3.45	0.000578	0.0278	-0.13	-0.11	Inflammatory bowel disease;	chr20:32152631	chr20:32116171~32116629:+
BRCA	cis	rs11098499	0.818	rs55825515	ENSG00000260404.2	RP11-384K6.6	3.45	0.000578	0.0278	0.1	0.11	Corneal astigmatism;	chr4:119565247	chr4:118591773~118633729:+
BRCA	cis	rs2301573	0.584	rs62265604	ENSG00000271270.4	TMCC1-AS1	-3.45	0.000578	0.0278	-0.23	-0.11	Hip circumference;	chr3:129894308	chr3:129893871~129918575:+
BRCA	cis	rs16950303	0.661	rs73439668	ENSG00000265496.3	MIR1539	3.45	0.000578	0.0278	0.21	0.11	Height;	chr18:49068480	chr18:49487339~49491878:+
BRCA	cis	rs1056107	0.933	rs10981354	ENSG00000266315.1	MIR4668	3.45	0.000578	0.0278	0.11	0.11	Colorectal cancer;	chr9:112308436	chr9:111932100~111932169:+
BRCA	cis	rs10761482	0.813	rs4948407	ENSG00000254271.1	RP11-131N11.4	3.45	0.000578	0.0278	0.15	0.11	Schizophrenia;	chr10:60350441	chr10:60734342~60741828:+
BRCA	cis	rs10761482	0.859	rs4948408	ENSG00000254271.1	RP11-131N11.4	3.45	0.000578	0.0278	0.15	0.11	Schizophrenia;	chr10:60350455	chr10:60734342~60741828:+
BRCA	cis	rs4648045	0.894	rs11097789	ENSG00000246560.2	RP11-10L12.4	3.45	0.000578	0.0278	0.13	0.11	Lymphocyte percentage of white cells;	chr4:102581605	chr4:102828055~102844075:+
BRCA	cis	rs11702148	0.552	rs9977929	ENSG00000231355.1	AP000302.58	3.45	0.000578	0.0278	0.13	0.11	Mean corpuscular hemoglobin;	chr21:33501409	chr21:33482499~33484258:-
BRCA	cis	rs2400749	0.635	rs12883395	ENSG00000258521.1	RP11-638I2.9	-3.45	0.000578	0.0278	-0.1	-0.11	Alzheimer's disease (survival time);	chr14:99552519	chr14:100339832~100340554:+
BRCA	cis	rs2400749	0.611	rs12884667	ENSG00000258521.1	RP11-638I2.9	-3.45	0.000578	0.0278	-0.1	-0.11	Alzheimer's disease (survival time);	chr14:99552542	chr14:100339832~100340554:+
BRCA	cis	rs2400749	0.635	rs12883400	ENSG00000258521.1	RP11-638I2.9	-3.45	0.000578	0.0278	-0.1	-0.11	Alzheimer's disease (survival time);	chr14:99552567	chr14:100339832~100340554:+
BRCA	cis	rs2400749	0.588	rs12884693	ENSG00000258521.1	RP11-638I2.9	-3.45	0.000578	0.0278	-0.1	-0.11	Alzheimer's disease (survival time);	chr14:99552587	chr14:100339832~100340554:+
BRCA	cis	rs2400749	0.635	rs12883531	ENSG00000258521.1	RP11-638I2.9	-3.45	0.000578	0.0278	-0.1	-0.11	Alzheimer's disease (survival time);	chr14:99552597	chr14:100339832~100340554:+
BRCA	cis	rs2400749	0.685	rs12887707	ENSG00000258521.1	RP11-638I2.9	-3.45	0.000578	0.0278	-0.1	-0.11	Alzheimer's disease (survival time);	chr14:99552627	chr14:100339832~100340554:+
BRCA	cis	rs2400749	0.685	rs12888032	ENSG00000258521.1	RP11-638I2.9	-3.45	0.000578	0.0278	-0.1	-0.11	Alzheimer's disease (survival time);	chr14:99552640	chr14:100339832~100340554:+
BRCA	cis	rs6943931	1	rs9648280	ENSG00000230658.1	KLHL7-AS1	-3.45	0.000578	0.0278	-0.14	-0.11	Diabetic kidney disease;	chr7:22377195	chr7:23101228~23105703:-
BRCA	cis	rs853679	0.517	rs17711344	ENSG00000272009.1	RP1-313I6.12	3.45	0.000578	0.0278	0.15	0.11	Depression;	chr6:28109824	chr6:28078792~28081130:-
BRCA	cis	rs495337	1	rs2281216	ENSG00000229222.1	KRT18P4	-3.45	0.000578	0.0278	-0.13	-0.11	Psoriasis;	chr20:49951966	chr20:49956745~49958032:+
BRCA	cis	rs2645424	0.686	rs2294140	ENSG00000269899.1	RP11-589N15.2	-3.45	0.000578	0.0278	-0.12	-0.11	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);	chr8:11848168	chr8:11846154~11846391:-
BRCA	cis	rs524281	0.861	rs7941431	ENSG00000255038.1	RP11-1167A19.2	-3.45	0.000578	0.0278	-0.15	-0.11	Electroencephalogram traits;	chr11:66192686	chr11:66067277~66069619:-
BRCA	cis	rs10777288	0.513	rs1920761	ENSG00000258100.1	RP11-121E16.1	3.45	0.000578	0.0278	0.14	0.11	Pulmonary function (smoking interaction);	chr12:90993533	chr12:91362196~91368606:+
BRCA	cis	rs10777288	0.561	rs1920757	ENSG00000258100.1	RP11-121E16.1	3.45	0.000578	0.0278	0.14	0.11	Pulmonary function (smoking interaction);	chr12:90994145	chr12:91362196~91368606:+
BRCA	cis	rs6964587	1	rs2075881	ENSG00000188693.7	CYP51A1-AS1	-3.45	0.000578	0.0278	-0.12	-0.11	Breast cancer;	chr7:92105238	chr7:92134604~92180725:+
BRCA	cis	rs6964587	1	rs7785971	ENSG00000188693.7	CYP51A1-AS1	-3.45	0.000578	0.0278	-0.12	-0.11	Breast cancer;	chr7:92107480	chr7:92134604~92180725:+
BRCA	cis	rs4657482	0.606	rs3790655	ENSG00000236364.3	RP11-525G13.2	-3.45	0.000578	0.0278	-0.09	-0.11	Testicular germ cell tumor;	chr1:165893086	chr1:165890795~165900683:-
BRCA	cis	rs4237845	0.735	rs11172375	ENSG00000270039.1	RP11-571M6.17	-3.45	0.000578	0.0278	-0.15	-0.11	Intelligence (multi-trait analysis);	chr12:57897791	chr12:57803838~57804415:+
BRCA	cis	rs7296418	0.961	rs1727307	ENSG00000280389.1	RP11-512M8.11	-3.45	0.000578	0.0278	-0.14	-0.11	Platelet count;	chr12:123091195	chr12:122255119~122260274:-
BRCA	cis	rs1730008	1	rs827141	ENSG00000279311.1	RP11-170K4.2	3.45	0.000578	0.0278	0.12	0.11	Lobe attachment (rater-scored or self-reported);	chr3:158205662	chr3:158869898~158871821:+
BRCA	cis	rs13315871	0.929	rs71311853	ENSG00000272182.1	RP11-802O23.3	3.45	0.000578	0.0278	0.21	0.11	Cholesterol, total;	chr3:58333425	chr3:58428255~58428815:+
BRCA	cis	rs10820912	1	rs10992148	ENSG00000225460.1	RP13-93L13.1	3.45	0.000578	0.0278	0.11	0.11	Left atrial antero-posterior diameter;	chr9:90113342	chr9:89472237~89472692:+
BRCA	cis	rs4575098	0.681	rs11591206	ENSG00000232879.2	RP11-544M22.3	-3.45	0.000578	0.0278	-0.12	-0.11	Monocyte percentage of white cells;	chr1:161141573	chr1:161034834~161035006:+
BRCA	cis	rs853679	0.546	rs200981	ENSG00000241549.7	GUSBP2	3.45	0.000578	0.0278	0.19	0.11	Depression;	chr6:27865396	chr6:26871484~26956554:-
BRCA	cis	rs91731	0.79	rs7706830	ENSG00000249572.1	CTD-2203K17.1	3.45	0.000579	0.0278	0.19	0.11	Lung function (FVC);	chr5:33228805	chr5:33424025~33440619:-
BRCA	cis	rs9467773	0.967	rs1535276	ENSG00000261353.1	CTA-14H9.5	-3.45	0.000579	0.0278	-0.11	-0.11	Intelligence (multi-trait analysis);	chr6:26520713	chr6:26527063~26527404:+
BRCA	cis	rs7283707	0.681	rs7277807	ENSG00000270071.1	AP001172.2	3.45	0.000579	0.0278	0.14	0.11	QRS complex (12-leadsum);	chr21:15727779	chr21:16291791~16308133:-
BRCA	cis	rs885518	0.636	rs10811612	ENSG00000240498.5	CDKN2B-AS1	3.45	0.000579	0.0278	0.27	0.11	Lung adenocarcinoma;	chr9:21774168	chr9:21994778~22121097:+
BRCA	cis	rs7412746	0.611	rs4970931	ENSG00000224800.1	RP11-235D19.2	-3.45	0.000579	0.0278	-0.13	-0.11	Melanoma;	chr1:150938251	chr1:150881236~150881683:-
BRCA	cis	rs9733	0.503	rs7556451	ENSG00000224800.1	RP11-235D19.2	-3.45	0.000579	0.0278	-0.13	-0.11	Tonsillectomy;	chr1:150940666	chr1:150881236~150881683:-
BRCA	cis	rs7412746	0.611	rs2271076	ENSG00000224800.1	RP11-235D19.2	-3.45	0.000579	0.0278	-0.13	-0.11	Melanoma;	chr1:150944181	chr1:150881236~150881683:-
BRCA	cis	rs8094794	0.744	rs16968184	ENSG00000267707.2	RP11-95O2.5	3.45	0.000579	0.0278	0.15	0.11	Periodontal disease-related phenotypes;	chr18:36700658	chr18:37243776~37247506:+
BRCA	cis	rs875971	0.862	rs709596	ENSG00000106610.13	STAG3L4	-3.45	0.000579	0.0278	-0.14	-0.11	Aortic root size;	chr7:66360926	chr7:67302621~67321526:+
BRCA	cis	rs1005277	0.691	rs2474558	ENSG00000099251.13	HSD17B7P2	-3.45	0.000579	0.0278	-0.12	-0.11	Extrinsic epigenetic age acceleration;	chr10:38197213	chr10:38356380~38378505:+
BRCA	cis	rs3015497	0.637	rs7156129	ENSG00000259113.1	RP11-406H23.2	-3.45	0.000579	0.0278	-0.12	-0.11	Mean platelet volume;	chr14:50710705	chr14:50448807~50456742:+
BRCA	cis	rs672059	0.934	rs641057	ENSG00000224468.3	RP11-181K3.4	-3.45	0.000579	0.0278	-0.11	-0.11	Hypertriglyceridemia;	chr1:183187724	chr1:183138402~183141282:-
BRCA	cis	rs2625529	0.824	rs12903484	ENSG00000260037.4	CTD-2524L6.3	-3.45	0.000579	0.0278	-0.15	-0.11	Red blood cell count;	chr15:72007140	chr15:71818396~71823384:+
BRCA	cis	rs1823874	0.677	rs2100446	ENSG00000259363.4	CTD-2054N24.2	3.45	0.000579	0.0278	0.13	0.11	IgG glycosylation;	chr15:99820169	chr15:99807023~99877148:+
BRCA	cis	rs875971	1	rs6460296	ENSG00000273024.4	INTS4P2	-3.45	0.000579	0.0278	-0.12	-0.11	Aortic root size;	chr7:66430152	chr7:65647864~65715661:+
BRCA	cis	rs9863	0.931	rs2178663	ENSG00000270028.1	RP11-380L11.4	3.45	0.000579	0.0278	0.13	0.11	White blood cell count;	chr12:123949358	chr12:123925461~123926083:-
BRCA	cis	rs11098499	0.863	rs3733525	ENSG00000225892.3	RP11-384K6.2	3.45	0.000579	0.0278	0.11	0.11	Corneal astigmatism;	chr4:119525893	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.863	rs3775847	ENSG00000225892.3	RP11-384K6.2	3.45	0.000579	0.0278	0.11	0.11	Corneal astigmatism;	chr4:119526487	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.863	rs3775848	ENSG00000225892.3	RP11-384K6.2	3.45	0.000579	0.0278	0.11	0.11	Corneal astigmatism;	chr4:119526569	chr4:118632274~118634759:+
BRCA	cis	rs11098403	0.753	rs4401519	ENSG00000225892.3	RP11-384K6.2	3.45	0.000579	0.0278	0.11	0.11	Schizophrenia;	chr4:117853216	chr4:118632274~118634759:+
BRCA	cis	rs6088590	1	rs10048849	ENSG00000276073.1	RP5-1125A11.7	-3.45	0.000579	0.0278	-0.12	-0.11	Coronary artery disease;	chr20:34831877	chr20:33985617~33988989:-
BRCA	cis	rs6088590	1	rs6088607	ENSG00000276073.1	RP5-1125A11.7	-3.45	0.000579	0.0278	-0.12	-0.11	Coronary artery disease;	chr20:34790930	chr20:33985617~33988989:-
BRCA	cis	rs1499614	1	rs1267818	ENSG00000229180.5	GS1-124K5.11	3.45	0.000579	0.0278	0.15	0.11	Gout;	chr7:66642037	chr7:66526088~66542624:-
BRCA	cis	rs9309473	0.519	rs2178154	ENSG00000230002.2	ALMS1-IT1	-3.45	0.000579	0.0278	-0.12	-0.11	Metabolite levels;	chr2:73434610	chr2:73456764~73459484:+
BRCA	cis	rs709400	0.663	rs11623869	ENSG00000258851.1	RP11-894P9.2	-3.45	0.000579	0.0278	-0.13	-0.11	Body mass index;	chr14:103417296	chr14:103553421~103561877:+
BRCA	cis	rs2625529	0.652	rs1481862	ENSG00000261187.1	RP11-1007O24.2	3.45	0.000579	0.0279	0.11	0.11	Red blood cell count;	chr15:71953307	chr15:72465128~72466262:-
BRCA	cis	rs6452790	0.529	rs7444401	ENSG00000247828.6	TMEM161B-AS1	-3.45	0.000579	0.0279	-0.14	-0.11	Cognitive function;	chr5:87978125	chr5:88268895~88436685:+
BRCA	cis	rs6452790	0.529	rs3910026	ENSG00000247828.6	TMEM161B-AS1	-3.45	0.000579	0.0279	-0.14	-0.11	Cognitive function;	chr5:87980456	chr5:88268895~88436685:+
BRCA	cis	rs4388249	1	rs3819904	ENSG00000271849.1	CTC-332L22.1	-3.45	0.000579	0.0279	-0.17	-0.11	Schizophrenia;	chr5:109699795	chr5:109687802~109688329:-
BRCA	cis	rs10504130	1	rs16916961	ENSG00000272076.1	RP11-11C20.3	3.45	0.000579	0.0279	0.18	0.11	Venous thromboembolism (SNP x SNP interaction);	chr8:51918618	chr8:51810110~51810681:-
BRCA	cis	rs8180040	0.726	rs2061197	ENSG00000280667.1	Y_RNA	-3.45	0.000579	0.0279	-0.12	-0.11	Colorectal cancer;	chr3:46959860	chr3:47501083~47501182:+
BRCA	cis	rs11088226	0.681	rs2833899	ENSG00000186842.4	LINC00846	-3.45	0.000579	0.0279	-0.18	-0.11	Gastritis;	chr21:32560953	chr21:32572238~32575881:-
BRCA	cis	rs7412746	0.611	rs72704679	ENSG00000224800.1	RP11-235D19.2	-3.45	0.00058	0.0279	-0.13	-0.11	Melanoma;	chr1:150925001	chr1:150881236~150881683:-
BRCA	cis	rs5167	0.601	rs73047694	ENSG00000214855.8	APOC1P1	3.45	0.00058	0.0279	0.14	0.11	Blood protein levels;	chr19:44994594	chr19:44926804~44931386:+
BRCA	cis	rs478304	0.593	rs9666878	ENSG00000255557.1	RP11-770G2.2	-3.45	0.00058	0.0279	-0.12	-0.11	Acne (severe);	chr11:65708345	chr11:65745729~65771585:+
BRCA	cis	rs890448	0.965	rs17031366	ENSG00000254531.1	FLJ20021	-3.45	0.00058	0.0279	-0.13	-0.11	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101503642	chr4:101347780~101348883:+
BRCA	cis	rs10876993	0.928	rs813854	ENSG00000269903.1	RP11-571M6.18	3.45	0.00058	0.0279	0.13	0.11	Celiac disease or Rheumatoid arthritis;	chr12:57677564	chr12:57814494~57814926:+
BRCA	cis	rs72720396	0.694	rs6689362	ENSG00000272931.1	RP5-943J3.2	3.45	0.00058	0.0279	0.13	0.11	Chronotype;Morning vs. evening chronotype;	chr1:90737694	chr1:89820174~89820868:-
BRCA	cis	rs987724	0.593	rs13088978	ENSG00000240875.4	LINC00886	-3.45	0.00058	0.0279	-0.12	-0.11	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156951007	chr3:156747346~156817062:-
BRCA	cis	rs11662721	0.938	rs116826070	ENSG00000264188.1	RP11-13N13.5	3.45	0.00058	0.0279	0.15	0.11	Phospholipid levels (plasma);	chr18:21579391	chr18:21661787~21662395:-
BRCA	cis	rs6088590	1	rs6088590	ENSG00000276073.1	RP5-1125A11.7	-3.45	0.00058	0.0279	-0.12	-0.11	Coronary artery disease;	chr20:34725762	chr20:33985617~33988989:-
BRCA	cis	rs10504130	1	rs11780891	ENSG00000272076.1	RP11-11C20.3	3.45	0.00058	0.0279	0.18	0.11	Venous thromboembolism (SNP x SNP interaction);	chr8:51762067	chr8:51810110~51810681:-
BRCA	cis	rs10844706	0.699	rs10844635	ENSG00000278635.1	CTD-2318O12.1	-3.45	0.00058	0.0279	-0.11	-0.11	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9735313	chr12:9415641~9416718:+
BRCA	cis	rs10844706	0.699	rs10844637	ENSG00000278635.1	CTD-2318O12.1	-3.45	0.00058	0.0279	-0.11	-0.11	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9735495	chr12:9415641~9416718:+
BRCA	cis	rs10844706	0.699	rs10844638	ENSG00000278635.1	CTD-2318O12.1	-3.45	0.00058	0.0279	-0.11	-0.11	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9735800	chr12:9415641~9416718:+
BRCA	cis	rs61352607	1	rs7971133	ENSG00000259125.1	RP11-545N8.3	-3.45	0.00058	0.0279	-0.15	-0.11	Triglycerides;	chr12:57376315	chr12:57144620~57147619:-
BRCA	cis	rs13315871	1	rs11710058	ENSG00000272182.1	RP11-802O23.3	3.45	0.00058	0.0279	0.21	0.11	Cholesterol, total;	chr3:58397321	chr3:58428255~58428815:+
BRCA	cis	rs13315871	1	rs13317835	ENSG00000272182.1	RP11-802O23.3	3.45	0.00058	0.0279	0.21	0.11	Cholesterol, total;	chr3:58397548	chr3:58428255~58428815:+
BRCA	cis	rs7674212	0.531	rs7665026	ENSG00000248740.4	RP11-328K4.1	3.45	0.00058	0.0279	0.13	0.11	Type 2 diabetes;	chr4:103015491	chr4:103256159~103453658:+
BRCA	cis	rs56281245	0.793	rs17103610	ENSG00000249363.1	CTB-78O21.1	-3.45	0.00058	0.0279	-0.21	-0.11	Hepcidin levels;	chr5:145675163	chr5:145728360~145729349:-
BRCA	cis	rs360932	0.55	rs360909	ENSG00000270265.1	RP11-731D1.4	-3.45	0.00058	0.0279	-0.13	-0.11	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr4:151975014	chr4:151333775~151353224:-
BRCA	cis	rs2839186	1	rs2839186	ENSG00000215424.8	MCM3AP-AS1	3.45	0.00058	0.0279	0.09	0.11	Testicular germ cell tumor;	chr21:46270154	chr21:46229217~46259390:+
BRCA	cis	rs10883723	0.738	rs715438	ENSG00000213061.2	PFN1P11	-3.45	0.00058	0.0279	-0.15	-0.11	Allergic disease (asthma, hay fever or eczema);	chr10:102498546	chr10:102838011~102845473:-
BRCA	cis	rs7267979	0.932	rs1541061	ENSG00000274414.1	RP5-965G21.4	-3.45	0.00058	0.0279	-0.12	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25540421	chr20:25239007~25245229:-
BRCA	cis	rs1376877	0.934	rs11693128	ENSG00000273456.1	RP11-686O6.2	3.45	0.00058	0.0279	0.1	0.11	Subclinical atherosclerosis traits (other);	chr2:203251178	chr2:202374932~202375604:-
BRCA	cis	rs6088580	0.524	rs1853056	ENSG00000261582.1	RP4-614O4.11	3.45	0.00058	0.0279	0.1	0.11	Glomerular filtration rate (creatinine);	chr20:34674254	chr20:35267885~35280043:-
BRCA	cis	rs4722585	0.533	rs3753097	ENSG00000273237.1	CTB-119C2.1	-3.45	0.00058	0.0279	-0.13	-0.11	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);	chr7:26158587	chr7:26173533~26174945:-
BRCA	cis	rs6840360	0.55	rs4696269	ENSG00000270265.1	RP11-731D1.4	-3.45	0.00058	0.0279	-0.13	-0.11	Intelligence (multi-trait analysis);	chr4:151560552	chr4:151333775~151353224:-
BRCA	cis	rs17482078	0.885	rs10045403	ENSG00000272109.1	CTD-2260A17.3	-3.45	0.000581	0.0279	-0.16	-0.11	Behcet's disease;Blood protein levels;	chr5:96812030	chr5:96804353~96806105:+
BRCA	cis	rs76917914	1	rs874610	ENSG00000236896.1	RP11-535C21.3	3.45	0.000581	0.0279	0.14	0.11	Immature fraction of reticulocytes;	chr9:98020413	chr9:97986551~97987656:-
BRCA	cis	rs13256369	1	rs12550458	ENSG00000254153.1	CTA-398F10.2	3.45	0.000581	0.0279	0.15	0.11	Obesity-related traits;	chr8:8710322	chr8:8456909~8461337:-
BRCA	cis	rs10198628	1	rs4669888	ENSG00000264370.1	MIR3125	-3.45	0.000581	0.0279	-0.12	-0.11	Pericardial fat;Pericardial adipose tissue adjusted for height and weight;	chr2:12840388	chr2:12737367~12737444:+
BRCA	cis	rs875971	1	rs7792762	ENSG00000229886.1	RP5-1132H15.3	3.45	0.000581	0.0279	0.12	0.11	Aortic root size;	chr7:66539151	chr7:66025126~66031544:-
BRCA	cis	rs801193	0.967	rs2707849	ENSG00000232546.1	RP11-458F8.1	-3.45	0.000581	0.0279	-0.09	-0.11	Aortic root size;	chr7:66687725	chr7:66848496~66858136:+
BRCA	cis	rs873549	1	rs1348270	ENSG00000227925.1	RP11-191N8.2	3.45	0.000581	0.0279	0.12	0.11	Keloid;	chr1:222096919	chr1:221827666~221840666:-
BRCA	cis	rs10792320	0.565	rs79502317	ENSG00000244176.1	RP11-810P12.1	-3.45	0.000581	0.0279	-0.18	-0.11	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr11:61968664	chr11:62011751~62012602:-
BRCA	cis	rs10944	0.572	rs688180	ENSG00000253558.1	CTD-2179L22.1	-3.45	0.000581	0.0279	-0.13	-0.11	Blood and toenail selenium levels;	chr5:78980924	chr5:78041879~78044138:-
BRCA	cis	rs56322409	1	rs12359272	ENSG00000226688.5	ENTPD1-AS1	3.45	0.000581	0.0279	0.13	0.11	Blood metabolite levels;	chr10:95605406	chr10:95753206~96090238:-
BRCA	cis	rs1334894	0.892	rs72913412	ENSG00000187762.5	HSPE1P11	3.45	0.000581	0.0279	0.25	0.11	Coronary artery disease;	chr6:35568877	chr6:35023522~35023831:+
BRCA	cis	rs10838634	1	rs56331152	ENSG00000280615.1	Y_RNA	-3.45	0.000581	0.0279	-0.18	-0.11	Schizophrenia;	chr11:46863465	chr11:47614898~47614994:-
BRCA	cis	rs4648045	0.894	rs230542	ENSG00000246560.2	RP11-10L12.4	-3.45	0.000581	0.0279	-0.13	-0.11	Lymphocyte percentage of white cells;	chr4:102577298	chr4:102828055~102844075:+
BRCA	cis	rs2976388	0.609	rs1469811	ENSG00000253196.1	RP11-706C16.7	3.45	0.000581	0.0279	0.1	0.11	Urinary tract infection frequency;	chr8:142706581	chr8:142763116~142766427:+
BRCA	cis	rs4744901	1	rs12344522	ENSG00000278910.2	BANCR	3.45	0.000581	0.0279	0.19	0.11	Schizophrenia;	chr9:69499585	chr9:69296682~69306977:-
BRCA	cis	rs11239930	0.517	rs685741	ENSG00000227242.3	NBPF13P	-3.45	0.000581	0.0279	-0.14	-0.11	AIDS progression;	chr1:147074503	chr1:147021320~147124525:-
BRCA	cis	rs7103648	0.966	rs874896	ENSG00000280615.1	Y_RNA	3.45	0.000581	0.0279	0.12	0.11	Systolic blood pressure;Diastolic blood pressure;	chr11:47397402	chr11:47614898~47614994:-
BRCA	cis	rs2638953	0.853	rs11049635	ENSG00000273989.1	RP11-425D17.2	-3.45	0.000581	0.0279	-0.16	-0.11	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28464293	chr12:28236227~28236828:+
BRCA	cis	rs375066	0.762	rs17656688	ENSG00000267191.1	RP11-15A1.2	3.45	0.000581	0.0279	0.14	0.11	Breast cancer;	chr19:43920925	chr19:43902001~43926545:+
BRCA	cis	rs8114671	0.562	rs6088642	ENSG00000261582.1	RP4-614O4.11	-3.45	0.000581	0.0279	-0.1	-0.11	Height;	chr20:34895383	chr20:35267885~35280043:-
BRCA	cis	rs11250098	0.547	rs2409764	ENSG00000251402.3	FAM90A25P	3.45	0.000581	0.0279	0.13	0.11	Morning vs. evening chronotype;	chr8:11423764	chr8:12415080~12418090:-
BRCA	cis	rs2262909	0.849	rs2666447	ENSG00000279377.1	AC003973.3	3.45	0.000581	0.0279	0.15	0.11	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;	chr19:21950066	chr19:21965708~21968529:-
BRCA	cis	rs324126	0.78	rs11084150	ENSG00000277977.1	CTD-3018O17.5	-3.45	0.000581	0.0279	-0.13	-0.11	Colonoscopy-negative controls vs population controls;	chr19:52381851	chr19:52392659~52392755:+
BRCA	cis	rs7649443	0.959	rs35112822	ENSG00000243339.3	RN7SL738P	-3.45	0.000581	0.0279	-0.15	-0.11	Nonsyndromic cleft lip with cleft palate;	chr3:197249598	chr3:196399911~196400207:+
BRCA	cis	rs10761482	0.861	rs10821733	ENSG00000254271.1	RP11-131N11.4	3.45	0.000581	0.0279	0.15	0.11	Schizophrenia;	chr10:60343647	chr10:60734342~60741828:+
BRCA	cis	rs10761482	0.813	rs10821734	ENSG00000254271.1	RP11-131N11.4	3.45	0.000581	0.0279	0.15	0.11	Schizophrenia;	chr10:60343654	chr10:60734342~60741828:+
BRCA	cis	rs2274273	1	rs1047556	ENSG00000259318.1	RP11-454L9.2	3.45	0.000581	0.0279	0.09	0.11	Protein biomarker;	chr14:55133564	chr14:55394940~55395233:-
BRCA	cis	rs752010	0.655	rs10890145	ENSG00000230638.4	RP11-486B10.4	-3.45	0.000582	0.0279	-0.14	-0.11	Lupus nephritis in systemic lupus erythematosus;	chr1:41620619	chr1:41542069~41544310:+
BRCA	cis	rs10761482	0.954	rs10994305	ENSG00000254271.1	RP11-131N11.4	3.45	0.000582	0.0279	0.15	0.11	Schizophrenia;	chr10:60326241	chr10:60734342~60741828:+
BRCA	cis	rs2154319	0.887	rs1740610	ENSG00000230638.4	RP11-486B10.4	3.45	0.000582	0.0279	0.18	0.11	Height;	chr1:41037008	chr1:41542069~41544310:+
BRCA	cis	rs2154319	0.887	rs7518880	ENSG00000230638.4	RP11-486B10.4	3.45	0.000582	0.0279	0.18	0.11	Height;	chr1:41038148	chr1:41542069~41544310:+
BRCA	cis	rs2154319	0.836	rs9326087	ENSG00000230638.4	RP11-486B10.4	3.45	0.000582	0.0279	0.18	0.11	Height;	chr1:41038523	chr1:41542069~41544310:+
BRCA	cis	rs2154319	0.887	rs10489522	ENSG00000230638.4	RP11-486B10.4	3.45	0.000582	0.0279	0.18	0.11	Height;	chr1:41038770	chr1:41542069~41544310:+
BRCA	cis	rs11098499	0.754	rs9999724	ENSG00000250412.1	KLHL2P1	3.45	0.000582	0.0279	0.12	0.11	Corneal astigmatism;	chr4:119318789	chr4:119334329~119378233:+
BRCA	cis	rs7200543	0.883	rs4985148	ENSG00000207425.1	Y_RNA	-3.45	0.000582	0.028	-0.13	-0.11	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15053931	chr16:14915457~14915556:-
BRCA	cis	rs7131987	0.834	rs12228468	ENSG00000273680.1	RP11-996F15.6	-3.45	0.000582	0.028	-0.13	-0.11	QT interval;	chr12:29300677	chr12:29332733~29333383:-
BRCA	cis	rs2337406	0.587	rs10139664	ENSG00000211972.2	IGHV3-66	3.45	0.000582	0.028	0.1	0.11	Alzheimer's disease (late onset);	chr14:106647254	chr14:106675017~106675544:-
BRCA	cis	rs7824557	0.767	rs7837036	ENSG00000154316.13	TDH	-3.45	0.000582	0.028	-0.15	-0.11	Retinal vascular caliber;	chr8:11317980	chr8:11339637~11368452:+
BRCA	cis	rs854765	0.647	rs854790	ENSG00000154874.13	CCDC144B	-3.45	0.000582	0.028	-0.13	-0.11	Total body bone mineral density;	chr17:18125004	chr17:18537800~18625617:-
BRCA	cis	rs68170813	0.617	rs17486	ENSG00000241764.3	AC002467.7	3.45	0.000582	0.028	0.19	0.11	Coronary artery disease;	chr7:107472445	chr7:107742817~107744581:-
BRCA	cis	rs68170813	0.652	rs17481621	ENSG00000241764.3	AC002467.7	3.45	0.000582	0.028	0.19	0.11	Coronary artery disease;	chr7:107473407	chr7:107742817~107744581:-
BRCA	cis	rs7405404	0.913	rs2157065	ENSG00000276564.1	CTA-276F8.1	3.45	0.000582	0.028	0.13	0.11	Bipolar disorder lithium response (categorical) or schizophrenia;Schizophrenia;	chr16:13654986	chr16:14150833~14153235:+
BRCA	cis	rs6840360	1	rs2278304	ENSG00000278978.1	RP11-164P12.5	3.45	0.000582	0.028	0.12	0.11	Intelligence (multi-trait analysis);	chr4:151672257	chr4:151669786~151670503:+
BRCA	cis	rs748404	0.666	rs16957730	ENSG00000166763.7	STRCP1	3.45	0.000582	0.028	0.15	0.11	Lung cancer;	chr15:43438288	chr15:43699488~43718184:-
BRCA	cis	rs4713118	0.588	rs200994	ENSG00000241549.7	GUSBP2	-3.45	0.000582	0.028	-0.14	-0.11	Parkinson's disease;	chr6:27846035	chr6:26871484~26956554:-
BRCA	cis	rs2154319	0.887	rs17357954	ENSG00000230638.4	RP11-486B10.4	-3.45	0.000582	0.028	-0.18	-0.11	Height;	chr1:41021665	chr1:41542069~41544310:+
BRCA	cis	rs801193	0.569	rs7782587	ENSG00000271064.1	RP11-792A8.3	-3.45	0.000582	0.028	-0.12	-0.11	Aortic root size;	chr7:66701485	chr7:66748838~66749077:-
BRCA	cis	rs561341	1	rs548957	ENSG00000265798.5	RP11-271K11.5	3.45	0.000582	0.028	0.18	0.11	Hip circumference adjusted for BMI;	chr17:31975392	chr17:31038575~31059121:-
BRCA	cis	rs561341	1	rs484175	ENSG00000265798.5	RP11-271K11.5	3.45	0.000582	0.028	0.18	0.11	Hip circumference adjusted for BMI;	chr17:31982022	chr17:31038575~31059121:-
BRCA	cis	rs561341	0.941	rs4525554	ENSG00000265798.5	RP11-271K11.5	3.45	0.000582	0.028	0.18	0.11	Hip circumference adjusted for BMI;	chr17:31985800	chr17:31038575~31059121:-
BRCA	cis	rs36051895	0.603	rs10123980	ENSG00000237711.1	RP11-39K24.13	-3.45	0.000582	0.028	-0.12	-0.11	Pediatric autoimmune diseases;	chr9:5130363	chr9:5100236~5101009:+
BRCA	cis	rs4363385	0.531	rs11205188	ENSG00000231416.1	RP11-422P24.9	3.45	0.000582	0.028	0.12	0.11	Inflammatory skin disease;	chr1:153081169	chr1:153995632~153995960:+
BRCA	cis	rs2346177	0.875	rs1447565	ENSG00000279254.1	RP11-536C12.1	-3.45	0.000582	0.028	-0.12	-0.11	HDL cholesterol;	chr2:46416543	chr2:46668870~46670778:+
BRCA	cis	rs6696239	0.956	rs7540382	ENSG00000227711.2	RP11-275O4.5	-3.45	0.000583	0.028	-0.15	-0.11	Height;	chr1:227692595	chr1:227509028~227520477:-
BRCA	cis	rs9467773	1	rs2393670	ENSG00000261353.1	CTA-14H9.5	-3.45	0.000583	0.028	-0.11	-0.11	Intelligence (multi-trait analysis);	chr6:26535313	chr6:26527063~26527404:+
BRCA	cis	rs7267979	1	rs2482927	ENSG00000274414.1	RP5-965G21.4	3.45	0.000583	0.028	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25346515	chr20:25239007~25245229:-
BRCA	cis	rs7165170	0.554	rs10438437	ENSG00000245479.2	LINC01585	-3.45	0.000583	0.028	-0.14	-0.11	Crohn's disease;Inflammatory bowel disease;	chr15:90612753	chr15:90660234~90664967:+
BRCA	cis	rs17776563	0.664	rs12593758	ENSG00000261441.1	RP11-217B1.2	3.45	0.000583	0.028	0.14	0.11	Thyroid hormone levels;	chr15:88568488	chr15:89335053~89336161:+
BRCA	cis	rs2342371	1	rs13094241	ENSG00000239122.1	RNU2-11P	3.45	0.000583	0.028	0.13	0.11	Fat distribution (HIV);	chr3:196464022	chr3:195928589~195928775:-
BRCA	cis	rs11892454	0.599	rs28562485	ENSG00000217643.1	PTGES3P2	-3.45	0.000583	0.028	-0.12	-0.11	Heschl's gyrus morphology;	chr2:25776342	chr2:25822469~25822950:+
BRCA	cis	rs9467773	1	rs9393731	ENSG00000261353.1	CTA-14H9.5	-3.45	0.000583	0.028	-0.11	-0.11	Intelligence (multi-trait analysis);	chr6:26529146	chr6:26527063~26527404:+
BRCA	cis	rs4927850	0.918	rs4361313	ENSG00000185485.13	SDHAP1	3.45	0.000583	0.028	0.11	0.11	Pancreatic cancer;	chr3:196025389	chr3:195959748~195990318:-
BRCA	cis	rs9467773	1	rs11756120	ENSG00000261353.1	CTA-14H9.5	-3.45	0.000583	0.028	-0.11	-0.11	Intelligence (multi-trait analysis);	chr6:26529580	chr6:26527063~26527404:+
BRCA	cis	rs9467773	1	rs9393732	ENSG00000261353.1	CTA-14H9.5	-3.45	0.000583	0.028	-0.11	-0.11	Intelligence (multi-trait analysis);	chr6:26530670	chr6:26527063~26527404:+
BRCA	cis	rs9467773	0.967	rs9358954	ENSG00000261353.1	CTA-14H9.5	-3.45	0.000583	0.028	-0.11	-0.11	Intelligence (multi-trait analysis);	chr6:26530950	chr6:26527063~26527404:+
BRCA	cis	rs9467773	1	rs10946834	ENSG00000261353.1	CTA-14H9.5	-3.45	0.000583	0.028	-0.11	-0.11	Intelligence (multi-trait analysis);	chr6:26533436	chr6:26527063~26527404:+
BRCA	cis	rs9467773	1	rs10946835	ENSG00000261353.1	CTA-14H9.5	-3.45	0.000583	0.028	-0.11	-0.11	Intelligence (multi-trait analysis);	chr6:26533529	chr6:26527063~26527404:+
BRCA	cis	rs9467773	1	rs9467778	ENSG00000261353.1	CTA-14H9.5	-3.45	0.000583	0.028	-0.11	-0.11	Intelligence (multi-trait analysis);	chr6:26534515	chr6:26527063~26527404:+
BRCA	cis	rs11098499	0.913	rs67073020	ENSG00000225892.3	RP11-384K6.2	3.45	0.000583	0.028	0.11	0.11	Corneal astigmatism;	chr4:119231402	chr4:118632274~118634759:+
BRCA	cis	rs597539	0.652	rs1249474	ENSG00000255741.1	RP11-757G1.5	-3.45	0.000583	0.028	-0.14	-0.11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68887306	chr11:68941503~68942852:-
BRCA	cis	rs4925540	1	rs1112137	ENSG00000215796.3	RP11-551G24.2	-3.45	0.000583	0.028	-0.12	-0.11	Response to taxane treatment (docetaxel);	chr1:247052073	chr1:247042791~247044021:+
BRCA	cis	rs13126694	0.633	rs4388135	ENSG00000251073.1	NUDT19P5	3.45	0.000583	0.028	0.1	0.11	Blood osmolality (transformed sodium);	chr4:158093301	chr4:158182825~158183393:+
BRCA	cis	rs67385638	0.862	rs11036641	ENSG00000225101.4	OR52K3P	3.45	0.000583	0.028	0.15	0.11	Hemoglobin levels;	chr11:5289348	chr11:4474813~4475755:+
BRCA	cis	rs875971	0.505	rs2462573	ENSG00000227113.2	RP11-460N20.4	-3.45	0.000583	0.028	-0.11	-0.11	Aortic root size;	chr7:66042405	chr7:65075023~65078780:+
BRCA	cis	rs9584850	0.834	rs7339274	ENSG00000231194.1	FARP1-AS1	-3.45	0.000583	0.028	-0.14	-0.11	Neuroticism;	chr13:98468018	chr13:98435405~98435840:-
BRCA	cis	rs853679	0.517	rs9468298	ENSG00000226314.6	ZNF192P1	-3.45	0.000583	0.028	-0.16	-0.11	Depression;	chr6:28154567	chr6:28161781~28169594:+
BRCA	cis	rs853679	0.517	rs9295759	ENSG00000226314.6	ZNF192P1	-3.45	0.000583	0.028	-0.16	-0.11	Depression;	chr6:28156691	chr6:28161781~28169594:+
BRCA	cis	rs853679	0.517	rs9348796	ENSG00000226314.6	ZNF192P1	-3.45	0.000583	0.028	-0.16	-0.11	Depression;	chr6:28158424	chr6:28161781~28169594:+
BRCA	cis	rs853679	0.517	rs11552219	ENSG00000226314.6	ZNF192P1	-3.45	0.000583	0.028	-0.16	-0.11	Depression;	chr6:28159056	chr6:28161781~28169594:+
BRCA	cis	rs853679	0.517	rs9357066	ENSG00000226314.6	ZNF192P1	-3.45	0.000583	0.028	-0.16	-0.11	Depression;	chr6:28162053	chr6:28161781~28169594:+
BRCA	cis	rs9866825	0.967	rs3856897	ENSG00000227110.5	LMCD1-AS1	3.45	0.000583	0.028	0.13	0.11	QT interval;	chr3:8205813	chr3:7952805~8611924:-
BRCA	cis	rs5742933	1	rs6717922	ENSG00000253559.1	OSGEPL1-AS1	-3.45	0.000583	0.028	-0.15	-0.11	Ferritin levels;	chr2:189721497	chr2:189762704~189765556:+
BRCA	cis	rs1334894	1	rs72913405	ENSG00000187762.5	HSPE1P11	3.45	0.000583	0.028	0.25	0.11	Coronary artery disease;	chr6:35562285	chr6:35023522~35023831:+
BRCA	cis	rs1334894	0.792	rs56318292	ENSG00000187762.5	HSPE1P11	3.45	0.000583	0.028	0.25	0.11	Coronary artery disease;	chr6:35563386	chr6:35023522~35023831:+
BRCA	cis	rs6430585	0.527	rs57530667	ENSG00000231890.6	DARS-AS1	-3.45	0.000583	0.028	-0.17	-0.11	Corneal structure;	chr2:135686768	chr2:135985176~136022593:+
BRCA	cis	rs6430585	0.527	rs12465544	ENSG00000231890.6	DARS-AS1	-3.45	0.000583	0.028	-0.17	-0.11	Corneal structure;	chr2:135694106	chr2:135985176~136022593:+
BRCA	cis	rs7578199	0.779	rs17387035	ENSG00000228989.1	AC133528.2	3.45	0.000583	0.028	0.13	0.11	Chronic lymphocytic leukemia;	chr2:241454588	chr2:241690414~241694289:+
BRCA	cis	rs17197037	0.545	rs17792617	ENSG00000277734.3	TRAC	-3.45	0.000583	0.028	-0.07	-0.11	Bipolar disorder;	chr14:21315725	chr14:22281105~22552155:+
BRCA	cis	rs11098499	0.691	rs17009144	ENSG00000225892.3	RP11-384K6.2	-3.45	0.000583	0.028	-0.1	-0.11	Corneal astigmatism;	chr4:119349640	chr4:118632274~118634759:+
BRCA	cis	rs3760982	0.546	rs73048681	ENSG00000266921.1	RP11-15A1.7	-3.45	0.000583	0.028	-0.15	-0.11	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43785793	chr19:43996896~44002836:-
BRCA	cis	rs6012953	0.874	rs1885176	ENSG00000231715.1	COX6CP2	-3.45	0.000583	0.028	-0.11	-0.11	Vitiligo;	chr20:50558752	chr20:50479767~50479991:+
BRCA	cis	rs890448	0.796	rs10433981	ENSG00000254531.1	FLJ20021	3.45	0.000583	0.028	0.12	0.11	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101362432	chr4:101347780~101348883:+
BRCA	cis	rs4781563	0.588	rs185297	ENSG00000242307.1	RPS26P52	3.45	0.000583	0.028	0.15	0.11	Bilirubin levels;	chr16:13969520	chr16:13922332~13922679:-
BRCA	cis	rs4781563	0.544	rs254936	ENSG00000242307.1	RPS26P52	3.45	0.000583	0.028	0.15	0.11	Bilirubin levels;	chr16:13969727	chr16:13922332~13922679:-
BRCA	cis	rs12682352	0.715	rs332039	ENSG00000253130.1	CTD-3023L14.2	-3.45	0.000583	0.028	-0.12	-0.11	Neuroticism;	chr8:8866141	chr8:8561391~8569688:+
BRCA	cis	rs8058578	1	rs13338946	ENSG00000280211.1	RP11-2C24.3	3.45	0.000584	0.028	0.11	0.11	Multiple myeloma;	chr16:30689537	chr16:30773532~30776033:-
BRCA	cis	rs7267979	0.565	rs6076364	ENSG00000274973.1	RP13-401N8.7	3.45	0.000584	0.028	0.12	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25576165	chr20:25845497~25845862:+
BRCA	cis	rs875971	0.505	rs1167386	ENSG00000227113.2	RP11-460N20.4	-3.45	0.000584	0.028	-0.11	-0.11	Aortic root size;	chr7:66048109	chr7:65075023~65078780:+
BRCA	cis	rs9863	0.931	rs11057407	ENSG00000270028.1	RP11-380L11.4	3.45	0.000584	0.028	0.14	0.11	White blood cell count;	chr12:123965282	chr12:123925461~123926083:-
BRCA	cis	rs28489187	0.643	rs233054	ENSG00000223653.4	RP11-131L23.1	3.45	0.000584	0.028	0.12	0.11	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85374508	chr1:85276715~85448124:+
BRCA	cis	rs6495122	0.501	rs12101482	ENSG00000260269.4	CTD-2323K18.1	3.45	0.000584	0.028	0.13	0.11	Diastolic blood pressure;Coffee consumption;Caffeine consumption;	chr15:75052443	chr15:75527150~75601205:-
BRCA	cis	rs6840360	0.571	rs55808836	ENSG00000270265.1	RP11-731D1.4	-3.45	0.000584	0.028	-0.13	-0.11	Intelligence (multi-trait analysis);	chr4:151633839	chr4:151333775~151353224:-
BRCA	cis	rs6840360	0.571	rs11726892	ENSG00000270265.1	RP11-731D1.4	-3.45	0.000584	0.028	-0.13	-0.11	Intelligence (multi-trait analysis);	chr4:151633954	chr4:151333775~151353224:-
BRCA	cis	rs17214007	0.597	rs11649126	ENSG00000260735.1	RP11-72I8.1	-3.45	0.000584	0.028	-0.16	-0.11	Cognitive function;	chr16:15626390	chr16:15094411~15109197:+
BRCA	cis	rs9400180	0.959	rs7662	ENSG00000271734.1	RP1-111B22.3	-3.45	0.000584	0.028	-0.13	-0.11	Major depressive disorder;	chr6:108042902	chr6:108030249~108030718:-
BRCA	cis	rs17014483	0.749	rs3017905	ENSG00000248019.2	FAM13A-AS1	-3.45	0.000584	0.028	-0.13	-0.11	Post bronchodilator FEV1/FVC ratio;	chr4:88710981	chr4:88709789~88730103:+
BRCA	cis	rs794185	0.532	rs304046	ENSG00000231249.1	ITPR1-AS1	-3.45	0.000584	0.028	-0.12	-0.11	Multiple sclerosis--Brain Glutamate Levels;	chr3:4512822	chr3:4490891~4493163:-
BRCA	cis	rs12474201	0.925	rs17822294	ENSG00000279254.1	RP11-536C12.1	-3.45	0.000584	0.028	-0.14	-0.11	Height;	chr2:46732865	chr2:46668870~46670778:+
BRCA	cis	rs6426833	0.716	rs10916667	ENSG00000117242.7	PINK1-AS	-3.45	0.000584	0.028	-0.13	-0.11	Ulcerative colitis;Inflammatory bowel disease;	chr1:19900544	chr1:20642657~20652193:-
BRCA	cis	rs357618	0.531	rs7723079	ENSG00000249035.5	CTB-113P19.1	-3.45	0.000584	0.028	-0.13	-0.11	Basophil percentage of white cells;	chr5:151507055	chr5:151676945~151724782:+
BRCA	cis	rs6545883	0.56	rs11677775	ENSG00000270820.4	RP11-355B11.2	-3.45	0.000584	0.028	-0.11	-0.11	Tuberculosis;	chr2:61275975	chr2:61471188~61484130:+
BRCA	cis	rs7647973	0.626	rs62262722	ENSG00000228008.1	CTD-2330K9.3	3.45	0.000584	0.028	0.15	0.11	Menarche (age at onset);	chr3:49731986	chr3:49903845~49916937:+
BRCA	cis	rs6943931	1	rs60318095	ENSG00000230658.1	KLHL7-AS1	-3.45	0.000584	0.028	-0.14	-0.11	Diabetic kidney disease;	chr7:22377023	chr7:23101228~23105703:-
BRCA	cis	rs13315871	0.929	rs71311854	ENSG00000272182.1	RP11-802O23.3	3.45	0.000584	0.028	0.21	0.11	Cholesterol, total;	chr3:58333432	chr3:58428255~58428815:+
BRCA	cis	rs950776	0.642	rs12905641	ENSG00000261762.1	RP11-650L12.2	-3.45	0.000584	0.028	-0.12	-0.11	Sudden cardiac arrest;	chr15:78672020	chr15:78589123~78591276:-
BRCA	cis	rs4819052	0.851	rs7279011	ENSG00000215447.6	BX322557.10	-3.45	0.000584	0.028	-0.11	-0.11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45236080	chr21:45288052~45291738:+
BRCA	cis	rs7267979	1	rs6132835	ENSG00000231081.1	RP4-760C5.3	-3.45	0.000584	0.028	-0.14	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25454031	chr20:26008791~26010531:-
BRCA	cis	rs7267979	0.933	rs11699203	ENSG00000231081.1	RP4-760C5.3	-3.45	0.000584	0.028	-0.14	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25454533	chr20:26008791~26010531:-
BRCA	cis	rs7267979	0.933	rs6138571	ENSG00000231081.1	RP4-760C5.3	-3.45	0.000584	0.028	-0.14	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25454752	chr20:26008791~26010531:-
BRCA	cis	rs7267979	0.966	rs416745	ENSG00000231081.1	RP4-760C5.3	-3.45	0.000584	0.028	-0.14	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25458232	chr20:26008791~26010531:-
BRCA	cis	rs7267979	1	rs447722	ENSG00000231081.1	RP4-760C5.3	-3.45	0.000584	0.028	-0.14	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25462874	chr20:26008791~26010531:-
BRCA	cis	rs7267979	1	rs422424	ENSG00000231081.1	RP4-760C5.3	-3.45	0.000584	0.028	-0.14	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25464810	chr20:26008791~26010531:-
BRCA	cis	rs7267979	1	rs422844	ENSG00000231081.1	RP4-760C5.3	-3.45	0.000584	0.028	-0.14	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25464955	chr20:26008791~26010531:-
BRCA	cis	rs7267979	1	rs401166	ENSG00000231081.1	RP4-760C5.3	-3.45	0.000584	0.028	-0.14	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25465672	chr20:26008791~26010531:-
BRCA	cis	rs2113818	0.568	rs10197989	ENSG00000264370.1	MIR3125	-3.45	0.000584	0.028	-0.12	-0.11	Optic cup area;	chr2:12795856	chr2:12737367~12737444:+
BRCA	cis	rs321358	0.731	rs484021	ENSG00000271390.1	RP11-89C3.3	3.45	0.000584	0.028	0.16	0.11	Body mass index;	chr11:111136353	chr11:111089870~111090368:-
BRCA	cis	rs321358	0.731	rs7112075	ENSG00000271390.1	RP11-89C3.3	3.45	0.000584	0.028	0.16	0.11	Body mass index;	chr11:111136407	chr11:111089870~111090368:-
BRCA	cis	rs6918586	0.658	rs198813	ENSG00000272810.1	U91328.22	-3.45	0.000584	0.028	-0.12	-0.11	Schizophrenia;	chr6:26127998	chr6:26013241~26013757:+
BRCA	cis	rs80226907	0.539	rs79257991	ENSG00000186615.9	KTN1-AS1	-3.45	0.000584	0.028	-0.22	-0.11	Mean platelet volume;	chr14:55438030	chr14:55499278~55580110:-
BRCA	cis	rs12050794	0.671	rs62022788	ENSG00000260037.4	CTD-2524L6.3	3.45	0.000584	0.028	0.13	0.11	Metabolite levels (HVA/MHPG ratio);	chr15:72266985	chr15:71818396~71823384:+
BRCA	cis	rs2148307	0.787	rs3758601	ENSG00000228339.1	AMD1P1	-3.45	0.000584	0.028	-0.13	-0.11	Photic sneeze reflex;	chr10:20808840	chr10:20350049~20351100:+
BRCA	cis	rs801193	0.742	rs9969300	ENSG00000230189.5	GS1-124K5.2	-3.45	0.000584	0.028	-0.08	-0.11	Aortic root size;	chr7:66316659	chr7:66409143~66490059:-
BRCA	cis	rs7412746	0.658	rs7521719	ENSG00000224800.1	RP11-235D19.2	-3.45	0.000584	0.0281	-0.13	-0.11	Melanoma;	chr1:150940658	chr1:150881236~150881683:-
BRCA	cis	rs3805389	0.504	rs56288855	ENSG00000249700.7	SRD5A3-AS1	-3.45	0.000585	0.0281	-0.17	-0.11	Waist-to-hip ratio adjusted for body mass index;	chr4:55603178	chr4:55363971~55395847:-
BRCA	cis	rs6142102	0.961	rs2235596	ENSG00000206582.1	Y_RNA	3.45	0.000585	0.0281	0.12	0.11	Skin pigmentation;	chr20:34096503	chr20:34526510~34526606:-
BRCA	cis	rs660899	0.894	rs11810109	ENSG00000229431.1	RP1-92O14.6	-3.45	0.000585	0.0281	-0.12	-0.11	Hypertension risk in short sleep duration;	chr1:43721141	chr1:43385113~43389155:+
BRCA	cis	rs12906542	0.516	rs10444863	ENSG00000259792.1	RP11-114H24.6	-3.45	0.000585	0.0281	-0.16	-0.11	Breast cancer;	chr15:78066495	chr15:77993405~77995289:+
BRCA	cis	rs7260598	1	rs7254349	ENSG00000268442.1	CTD-2027I19.2	3.45	0.000585	0.0281	0.17	0.11	Response to taxane treatment (placlitaxel);	chr19:24047541	chr19:24162370~24163425:-
BRCA	cis	rs6496044	0.547	rs7173125	ENSG00000259630.2	CTD-2262B20.1	3.45	0.000585	0.0281	0.13	0.11	Interstitial lung disease;	chr15:85512214	chr15:85415228~85415633:+
BRCA	cis	rs6044112	1	rs6044111	ENSG00000273998.1	RP4-777L9.2	3.45	0.000585	0.0281	0.17	0.11	Response to taxane treatment (docetaxel);	chr20:16555679	chr20:16576068~16579615:+
BRCA	cis	rs10484434	0.818	rs62394555	ENSG00000216331.1	HIST1H1PS1	3.45	0.000585	0.0281	0.18	0.11	HIV-1 viral setpoint;	chr6:26071861	chr6:26195566~26195771:+
BRCA	cis	rs728616	0.558	rs72817596	ENSG00000225484.5	NUTM2B-AS1	-3.45	0.000585	0.0281	-0.22	-0.11	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80391838	chr10:79663088~79826594:-
BRCA	cis	rs28829049	0.861	rs10492996	ENSG00000270728.1	RP4-657E11.10	-3.45	0.000585	0.0281	-0.11	-0.11	QRS duration in Tripanosoma cruzi seropositivity;	chr1:19039058	chr1:19297080~19297903:+
BRCA	cis	rs11098499	0.754	rs1980027	ENSG00000250412.1	KLHL2P1	3.45	0.000585	0.0281	0.12	0.11	Corneal astigmatism;	chr4:119330422	chr4:119334329~119378233:+
BRCA	cis	rs2998286	0.723	rs332146	ENSG00000237128.1	RP11-351M16.3	3.45	0.000585	0.0281	0.14	0.11	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28580255	chr10:28433008~28495813:-
BRCA	cis	rs12141041	0.967	rs7513419	ENSG00000274642.1	CH17-472G23.1	-3.45	0.000585	0.0281	-0.13	-0.11	Blood metabolite levels;	chr1:119376691	chr1:120197085~120319680:+
BRCA	cis	rs875971	0.54	rs1723268	ENSG00000232546.1	RP11-458F8.1	-3.45	0.000585	0.0281	-0.09	-0.11	Aortic root size;	chr7:66008093	chr7:66848496~66858136:+
BRCA	cis	rs9311474	0.632	rs6445528	ENSG00000222345.1	SNORD19	-3.45	0.000585	0.0281	-0.11	-0.11	Electroencephalogram traits;	chr3:52538431	chr3:52691378~52691453:+
BRCA	cis	rs806321	0.534	rs1149870	ENSG00000237152.3	DLEU7-AS1	3.45	0.000585	0.0281	0.13	0.11	Multiple sclerosis;	chr13:50325616	chr13:50807856~50849905:+
BRCA	cis	rs13434995	0.536	rs62303712	ENSG00000273257.1	RP11-177J6.1	-3.45	0.000585	0.0281	-0.16	-0.11	Adiponectin levels;	chr4:55460484	chr4:55387949~55388271:+
BRCA	cis	rs300890	0.597	rs2055730	ENSG00000250326.1	RP11-284M14.1	3.45	0.000585	0.0281	0.13	0.11	Nasopharyngeal carcinoma;	chr4:143367500	chr4:142933195~143184861:-
BRCA	cis	rs2882667	0.893	rs10054796	ENSG00000242683.1	CTB-46B19.1	3.45	0.000585	0.0281	0.12	0.11	Age-related hearing impairment (SNP x SNP interaction);	chr5:138958655	chr5:139035148~139035987:-
BRCA	cis	rs2882667	0.893	rs10069961	ENSG00000242683.1	CTB-46B19.1	3.45	0.000585	0.0281	0.12	0.11	Age-related hearing impairment (SNP x SNP interaction);	chr5:138958879	chr5:139035148~139035987:-
BRCA	cis	rs2836950	0.565	rs2836931	ENSG00000235701.1	PCBP2P1	-3.45	0.000585	0.0281	-0.12	-0.11	Menarche (age at onset);	chr21:39174643	chr21:39171130~39172106:-
BRCA	cis	rs9341808	0.69	rs9448909	ENSG00000279022.1	RP11-250B2.4	3.45	0.000585	0.0281	0.12	0.11	Sitting height ratio;	chr6:80199314	chr6:80440730~80441172:+
BRCA	cis	rs80093141	0.706	rs12437035	ENSG00000271424.1	RP11-647O20.1	3.45	0.000585	0.0281	0.15	0.11	Common carotid intima-media thickness in HIV infection;	chr14:38899362	chr14:39370279~39370756:-
BRCA	cis	rs7267979	1	rs2258201	ENSG00000274414.1	RP5-965G21.4	-3.45	0.000585	0.0281	-0.12	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25291854	chr20:25239007~25245229:-
BRCA	cis	rs34779708	0.966	rs11599606	ENSG00000269952.1	RP11-324I22.3	-3.45	0.000585	0.0281	-0.14	-0.11	Inflammatory bowel disease;Crohn's disease;	chr10:35117698	chr10:35210416~35210750:+
BRCA	cis	rs1424638	0.681	rs2115605	ENSG00000233251.6	AC007743.1	-3.45	0.000585	0.0281	-0.12	-0.11	Intelligence (multi-trait analysis);	chr2:57011753	chr2:56173534~56185770:-
BRCA	cis	rs873549	0.883	rs6604700	ENSG00000238042.4	RP11-815M8.1	3.45	0.000585	0.0281	0.12	0.11	Keloid;	chr1:222093982	chr1:221880981~221978523:-
BRCA	cis	rs35146811	0.66	rs3779046	ENSG00000214313.7	AZGP1P1	3.45	0.000586	0.0281	0.11	0.11	Coronary artery disease;	chr7:100181620	chr7:99980762~99987535:+
BRCA	cis	rs35146811	0.66	rs3779045	ENSG00000214313.7	AZGP1P1	3.45	0.000586	0.0281	0.11	0.11	Coronary artery disease;	chr7:100181636	chr7:99980762~99987535:+
BRCA	cis	rs35146811	0.7	rs4729579	ENSG00000214313.7	AZGP1P1	3.45	0.000586	0.0281	0.11	0.11	Coronary artery disease;	chr7:100182659	chr7:99980762~99987535:+
BRCA	cis	rs35146811	0.7	rs7788301	ENSG00000214313.7	AZGP1P1	3.45	0.000586	0.0281	0.11	0.11	Coronary artery disease;	chr7:100185130	chr7:99980762~99987535:+
BRCA	cis	rs35146811	0.735	rs2272344	ENSG00000214313.7	AZGP1P1	3.45	0.000586	0.0281	0.11	0.11	Coronary artery disease;	chr7:100189196	chr7:99980762~99987535:+
BRCA	cis	rs35146811	0.735	rs11764176	ENSG00000214313.7	AZGP1P1	3.45	0.000586	0.0281	0.11	0.11	Coronary artery disease;	chr7:100189341	chr7:99980762~99987535:+
BRCA	cis	rs35146811	0.735	rs6948729	ENSG00000214313.7	AZGP1P1	3.45	0.000586	0.0281	0.11	0.11	Coronary artery disease;	chr7:100189749	chr7:99980762~99987535:+
BRCA	cis	rs875971	0.862	rs880166	ENSG00000223473.2	GS1-124K5.3	-3.45	0.000586	0.0281	-0.08	-0.11	Aortic root size;	chr7:66205775	chr7:66491049~66493566:-
BRCA	cis	rs9341808	0.718	rs2179842	ENSG00000233967.5	RP11-250B2.3	3.45	0.000586	0.0281	0.11	0.11	Sitting height ratio;	chr6:80269336	chr6:80443344~80465927:+
BRCA	cis	rs2243480	1	rs313807	ENSG00000226767.1	RP11-328P23.3	-3.45	0.000586	0.0281	-0.18	-0.11	Diabetic kidney disease;	chr7:66034494	chr7:65508773~65508944:-
BRCA	cis	rs3177980	0.639	rs12064636	ENSG00000239494.2	RN7SL333P	-3.45	0.000586	0.0281	-0.1	-0.11	Amyotrophic lateral sclerosis;	chr1:169838480	chr1:169859756~169860052:+
BRCA	cis	rs59721556	0.918	rs17825229	ENSG00000258917.1	ZMYND19P1	3.45	0.000586	0.0281	0.15	0.11	Response to paliperidone in schizophrenia (Multivariate);Response to paliperidone in schizophrenia (CGI-S score);Response to paliperidone in schizophrenia (PANSS score);Red cell distribution width;Response to paliperidone in schizophrenia (positive Marder score);	chr14:77651831	chr14:77696591~77697377:+
BRCA	cis	rs59721556	0.918	rs77320936	ENSG00000258917.1	ZMYND19P1	3.45	0.000586	0.0281	0.15	0.11	Response to paliperidone in schizophrenia (Multivariate);Response to paliperidone in schizophrenia (CGI-S score);Response to paliperidone in schizophrenia (PANSS score);Red cell distribution width;Response to paliperidone in schizophrenia (positive Marder score);	chr14:77652166	chr14:77696591~77697377:+
BRCA	cis	rs1113500	0.748	rs1781048	ENSG00000230489.1	VAV3-AS1	-3.45	0.000586	0.0281	-0.13	-0.11	Growth-regulated protein alpha levels;	chr1:108012428	chr1:107964443~107994607:+
BRCA	cis	rs7829975	0.623	rs10092965	ENSG00000173295.6	FAM86B3P	3.45	0.000586	0.0281	0.11	0.11	Mood instability;	chr8:8515975	chr8:8228595~8244865:+
BRCA	cis	rs6714710	0.663	rs71429376	ENSG00000228486.8	LINC01125	-3.45	0.000586	0.0281	-0.09	-0.11	Posterior cortical atrophy and Alzheimer's disease;	chr2:97917949	chr2:97664217~97703064:+
BRCA	cis	rs2031532	0.544	rs3764089	ENSG00000236577.1	SNRPGP14	3.45	0.000586	0.0281	0.12	0.11	Cardiac hypertrophy;	chr13:49489102	chr13:49488970~49489364:+
BRCA	cis	rs2803122	0.967	rs4977519	ENSG00000272842.1	RP11-513M16.7	-3.45	0.000586	0.0281	-0.11	-0.11	Pulse pressure;	chr9:19241204	chr9:19371386~19371945:-
BRCA	cis	rs4578769	0.959	rs7226652	ENSG00000273232.1	RP11-370A5.2	3.45	0.000586	0.0281	0.14	0.11	Eosinophil percentage of white cells;	chr18:22904043	chr18:22882825~22883357:-
BRCA	cis	rs2892838	1	rs2892838	ENSG00000237773.4	AC003075.4	-3.45	0.000586	0.0281	-0.13	-0.11	Caffeine metabolism (plasma 1,7-dimethylxanthine (paraxanthine) to 1,3,7-trimethylxanthine (caffeine) ratio);Caffeine metabolism (plasma 1,3,7-trimethylxanthine (caffeine) level);	chr7:17285000	chr7:17279834~17299357:-
BRCA	cis	rs6545883	0.868	rs7608483	ENSG00000273302.1	RP11-493E12.2	3.45	0.000586	0.0281	0.1	0.11	Tuberculosis;	chr2:61609100	chr2:61199979~61200769:+
BRCA	cis	rs6452790	0.529	rs6876396	ENSG00000247828.6	TMEM161B-AS1	-3.45	0.000586	0.0281	-0.14	-0.11	Cognitive function;	chr5:87979726	chr5:88268895~88436685:+
BRCA	cis	rs8114671	0.562	rs6088622	ENSG00000126005.14	MMP24-AS1	-3.45	0.000586	0.0281	-0.12	-0.11	Height;	chr20:34832174	chr20:35216462~35278131:-
BRCA	cis	rs13256369	0.901	rs13251887	ENSG00000254153.1	CTA-398F10.2	3.45	0.000586	0.0281	0.15	0.11	Obesity-related traits;	chr8:8711168	chr8:8456909~8461337:-
BRCA	cis	rs910873	0.505	rs6058099	ENSG00000250917.1	RP4-785G19.5	3.45	0.000586	0.0281	0.18	0.11	Melanoma;	chr20:34661330	chr20:34234840~34281173:-
BRCA	cis	rs10056811	0.538	rs4632781	ENSG00000271815.1	CTD-2235C13.3	-3.45	0.000586	0.0281	-0.19	-0.11	Coronary artery disease;	chr5:75080833	chr5:75363760~75364242:+
BRCA	cis	rs7512552	0.839	rs1498308	ENSG00000223945.2	RP11-458I7.1	3.45	0.000586	0.0281	0.11	0.11	Allergic disease (asthma, hay fever or eczema);Atopic dermatitis;	chr1:150322682	chr1:150053864~150055034:+
BRCA	cis	rs3748682	0.821	rs12030690	ENSG00000252448.1	SNORA63	-3.45	0.000586	0.0281	-0.14	-0.11	Hypothyroidism;	chr1:37792335	chr1:37884237~37884317:+
BRCA	cis	rs7267979	0.903	rs6115109	ENSG00000274973.1	RP13-401N8.7	-3.45	0.000586	0.0281	-0.12	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25259031	chr20:25845497~25845862:+
BRCA	cis	rs7267979	0.833	rs4619688	ENSG00000274973.1	RP13-401N8.7	-3.45	0.000586	0.0281	-0.12	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25263465	chr20:25845497~25845862:+
BRCA	cis	rs8105895	0.935	rs7247228	ENSG00000269345.1	VN1R85P	3.45	0.000586	0.0281	0.15	0.11	Body mass index (change over time);	chr19:22067334	chr19:22174766~22175191:-
BRCA	cis	rs2106139	1	rs7287561	ENSG00000185065.6	AC000068.5	-3.45	0.000586	0.0281	-0.23	-0.11	IgG glycosylation;	chr22:19574189	chr22:19447893~19450105:+
BRCA	cis	rs12438356	1	rs7166136	ENSG00000259222.2	RP11-809H16.5	-3.45	0.000587	0.0281	-0.17	-0.11	CTACK levels;	chr15:69296238	chr15:69080879~69099987:+
BRCA	cis	rs6813195	0.642	rs2406600	ENSG00000245954.5	RP11-18H21.1	3.45	0.000587	0.0281	0.09	0.11	Type 2 diabetes;	chr4:152389254	chr4:152100754~152104720:+
BRCA	cis	rs875971	0.895	rs4718349	ENSG00000271064.1	RP11-792A8.3	-3.45	0.000587	0.0281	-0.12	-0.11	Aortic root size;	chr7:66444024	chr7:66748838~66749077:-
BRCA	cis	rs875971	1	rs2042133	ENSG00000271064.1	RP11-792A8.3	-3.45	0.000587	0.0281	-0.12	-0.11	Aortic root size;	chr7:66466935	chr7:66748838~66749077:-
BRCA	cis	rs875971	0.964	rs2161065	ENSG00000271064.1	RP11-792A8.3	-3.45	0.000587	0.0281	-0.12	-0.11	Aortic root size;	chr7:66467918	chr7:66748838~66749077:-
BRCA	cis	rs875971	0.862	rs12698521	ENSG00000271064.1	RP11-792A8.3	-3.45	0.000587	0.0281	-0.12	-0.11	Aortic root size;	chr7:66474502	chr7:66748838~66749077:-
BRCA	cis	rs7894407	0.856	rs10883855	ENSG00000213061.2	PFN1P11	3.45	0.000587	0.0281	0.14	0.11	White matter hyperintensity burden;	chr10:103332690	chr10:102838011~102845473:-
BRCA	cis	rs6696239	0.956	rs2172936	ENSG00000215812.5	ZNF847P	3.45	0.000587	0.0281	0.15	0.11	Height;	chr1:227596547	chr1:227696892~227706699:-
BRCA	cis	rs6696239	0.956	rs9726691	ENSG00000215812.5	ZNF847P	3.45	0.000587	0.0281	0.15	0.11	Height;	chr1:227597923	chr1:227696892~227706699:-
BRCA	cis	rs8180040	0.739	rs11719306	ENSG00000260236.1	RP11-708J19.1	3.45	0.000587	0.0281	0.09	0.11	Colorectal cancer;	chr3:47142692	chr3:47379089~47380999:-
BRCA	cis	rs9311474	0.629	rs11709284	ENSG00000222345.1	SNORD19	3.45	0.000587	0.0281	0.11	0.11	Electroencephalogram traits;	chr3:52525689	chr3:52691378~52691453:+
BRCA	cis	rs74233809	1	rs11191502	ENSG00000213061.2	PFN1P11	3.45	0.000587	0.0281	0.23	0.11	Birth weight;	chr10:103005737	chr10:102838011~102845473:-
BRCA	cis	rs3764021	0.527	rs17806710	ENSG00000256594.6	RP11-705C15.2	3.45	0.000587	0.0281	0.14	0.11	Type 1 diabetes;	chr12:9688368	chr12:9633419~9658412:+
BRCA	cis	rs56046484	0.871	rs62021230	ENSG00000259630.2	CTD-2262B20.1	-3.45	0.000587	0.0281	-0.18	-0.11	Testicular germ cell tumor;	chr15:85040721	chr15:85415228~85415633:+
BRCA	cis	rs4869313	0.643	rs1423568	ENSG00000248734.2	CTD-2260A17.1	-3.45	0.000587	0.0282	-0.11	-0.11	Pediatric autoimmune diseases;	chr5:96903590	chr5:96784777~96785999:+
BRCA	cis	rs4869313	0.617	rs2161658	ENSG00000248734.2	CTD-2260A17.1	-3.45	0.000587	0.0282	-0.11	-0.11	Pediatric autoimmune diseases;	chr5:96903941	chr5:96784777~96785999:+
BRCA	cis	rs4869313	0.668	rs2548531	ENSG00000248734.2	CTD-2260A17.1	-3.45	0.000587	0.0282	-0.11	-0.11	Pediatric autoimmune diseases;	chr5:96904009	chr5:96784777~96785999:+
BRCA	cis	rs4869313	0.668	rs2549786	ENSG00000248734.2	CTD-2260A17.1	-3.45	0.000587	0.0282	-0.11	-0.11	Pediatric autoimmune diseases;	chr5:96904010	chr5:96784777~96785999:+
BRCA	cis	rs4869313	0.668	rs2549788	ENSG00000248734.2	CTD-2260A17.1	-3.45	0.000587	0.0282	-0.11	-0.11	Pediatric autoimmune diseases;	chr5:96904682	chr5:96784777~96785999:+
BRCA	cis	rs12122100	0.651	rs12737860	ENSG00000278811.3	LINC00624	-3.45	0.000587	0.0282	-0.13	-0.11	HIV-1 control;	chr1:147074795	chr1:147258885~147517875:-
BRCA	cis	rs4699052	0.963	rs56144793	ENSG00000230069.3	LRRC37A15P	-3.45	0.000587	0.0282	-0.1	-0.11	Testicular germ cell tumor;	chr4:103229496	chr4:102727274~102730721:-
BRCA	cis	rs7590268	0.636	rs33979934	ENSG00000279873.2	LINC01126	3.45	0.000587	0.0282	0.12	0.11	Orofacial clefts;	chr2:43398045	chr2:43227210~43228855:+
BRCA	cis	rs4927850	0.881	rs7624638	ENSG00000273009.1	RP11-352G9.1	-3.45	0.000587	0.0282	-0.13	-0.11	Pancreatic cancer;	chr3:196021858	chr3:195913078~195913683:-
BRCA	cis	rs77106637	0.932	rs17244499	ENSG00000256633.1	RP11-169D4.2	-3.45	0.000587	0.0282	-0.14	-0.11	Type 2 diabetes;	chr11:72918901	chr11:72584572~72587979:+
BRCA	cis	rs806321	0.51	rs1262867	ENSG00000237152.3	DLEU7-AS1	3.45	0.000587	0.0282	0.14	0.11	Multiple sclerosis;	chr13:50316911	chr13:50807856~50849905:+
BRCA	cis	rs4795519	0.736	rs2061895	ENSG00000266527.1	RP11-138P22.1	3.45	0.000587	0.0282	0.13	0.11	Chronic myeloid leukemia;	chr17:27081770	chr17:27874645~27881237:+
BRCA	cis	rs9481169	0.85	rs13210247	ENSG00000272356.1	RP5-1112D6.8	3.45	0.000587	0.0282	0.19	0.11	Inflammatory skin disease;	chr6:111601517	chr6:111309203~111313517:+
BRCA	cis	rs9650657	0.623	rs10091636	ENSG00000248896.2	CTD-2135J3.3	-3.45	0.000587	0.0282	-0.12	-0.11	Neuroticism;	chr8:10745456	chr8:10729314~10771392:+
BRCA	cis	rs9650657	0.54	rs10094732	ENSG00000248896.2	CTD-2135J3.3	-3.45	0.000587	0.0282	-0.12	-0.11	Neuroticism;	chr8:10745505	chr8:10729314~10771392:+
BRCA	cis	rs4650943	0.503	rs10753118	ENSG00000227740.1	RP11-318C24.2	3.45	0.000587	0.0282	0.11	0.11	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in inactive individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr1:176074666	chr1:175904762~175920513:-
BRCA	cis	rs1986116	0.773	rs4903538	ENSG00000258819.1	RP11-7F17.3	3.45	0.000588	0.0282	0.17	0.11	Sleep quality;	chr14:77050478	chr14:77069180~77076344:-
BRCA	cis	rs1368882	1	rs1368882	ENSG00000225183.1	RP4-758J24.4	-3.45	0.000588	0.0282	-0.13	-0.11	Non-substance related behavioral disinhibition;	chr1:54641346	chr1:54089856~54090093:+
BRCA	cis	rs875971	0.964	rs6945019	ENSG00000229886.1	RP5-1132H15.3	3.45	0.000588	0.0282	0.12	0.11	Aortic root size;	chr7:66457471	chr7:66025126~66031544:-
BRCA	cis	rs748404	0.666	rs72709879	ENSG00000201136.1	RNU6-353P	3.45	0.000588	0.0282	0.15	0.11	Lung cancer;	chr15:43507777	chr15:43702363~43702470:+
BRCA	cis	rs7773456	0.533	rs9368127	ENSG00000217379.2	RP11-254A17.1	3.45	0.000588	0.0282	0.13	0.11	Lupus nephritis in systemic lupus erythematosus;	chr6:19811760	chr6:19143695~19144160:+
BRCA	cis	rs11098499	1	rs6849889	ENSG00000260404.2	RP11-384K6.6	3.45	0.000588	0.0282	0.1	0.11	Corneal astigmatism;	chr4:119265193	chr4:118591773~118633729:+
BRCA	cis	rs11673344	0.838	rs55856280	ENSG00000267682.1	CTD-3220F14.2	-3.45	0.000588	0.0282	-0.1	-0.11	Obesity-related traits;	chr19:37150747	chr19:37337236~37337743:+
BRCA	cis	rs7520050	0.931	rs6686134	ENSG00000281133.1	AL355480.3	3.45	0.000588	0.0282	0.12	0.11	Reticulocyte count;Red blood cell count;	chr1:45912596	chr1:45580892~45580996:-
BRCA	cis	rs490234	0.812	rs10121109	ENSG00000232630.1	PRPS1P2	-3.45	0.000588	0.0282	-0.11	-0.11	Mean arterial pressure;	chr9:125692927	chr9:125150653~125151589:+
BRCA	cis	rs8073060	0.855	rs12150450	ENSG00000255987.1	TOMM20P2	3.45	0.000588	0.0282	0.1	0.11	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35541877	chr17:35514766~35515186:-
BRCA	cis	rs7412746	0.658	rs12068264	ENSG00000224800.1	RP11-235D19.2	-3.45	0.000588	0.0282	-0.14	-0.11	Melanoma;	chr1:150754853	chr1:150881236~150881683:-
BRCA	cis	rs72819225	0.616	rs1411121	ENSG00000228701.1	TNKS2-AS1	3.45	0.000588	0.0282	0.13	0.11	Yeast infection;	chr10:91565670	chr10:91782839~91798291:-
BRCA	cis	rs873549	1	rs11118946	ENSG00000227925.1	RP11-191N8.2	3.45	0.000588	0.0282	0.12	0.11	Keloid;	chr1:222096451	chr1:221827666~221840666:-
BRCA	cis	rs873549	1	rs11118947	ENSG00000227925.1	RP11-191N8.2	3.45	0.000588	0.0282	0.12	0.11	Keloid;	chr1:222096463	chr1:221827666~221840666:-
BRCA	cis	rs13118159	0.573	rs7664763	ENSG00000273179.1	RP11-20I20.4	3.45	0.000588	0.0282	0.12	0.11	Longevity;	chr4:1358517	chr4:1167778~1168174:+
BRCA	cis	rs886774	0.707	rs3735602	ENSG00000273055.1	CTB-13F3.1	-3.45	0.000588	0.0282	-0.11	-0.11	Ulcerative colitis;	chr7:107923141	chr7:107942116~107942740:+
BRCA	cis	rs751728	0.664	rs2395402	ENSG00000224557.6	HLA-DPB2	-3.45	0.000588	0.0282	-0.12	-0.11	Crohn's disease;	chr6:33785896	chr6:33112451~33129084:+
BRCA	cis	rs2400749	0.685	rs12372919	ENSG00000258521.1	RP11-638I2.9	3.45	0.000588	0.0282	0.1	0.11	Alzheimer's disease (survival time);	chr14:99551024	chr14:100339832~100340554:+
BRCA	cis	rs494453	0.557	rs508594	ENSG00000227811.2	FAM212B-AS1	3.45	0.000588	0.0282	0.13	0.11	Osteoporosis-related phenotypes;	chr1:111622549	chr1:111739841~111747798:+
BRCA	cis	rs654950	0.841	rs676383	ENSG00000230881.1	RP11-486B10.3	3.45	0.000588	0.0282	0.11	0.11	Airway imaging phenotypes;	chr1:41528082	chr1:41535443~41535868:+
BRCA	cis	rs72772090	0.71	rs17479052	ENSG00000272109.1	CTD-2260A17.3	3.45	0.000588	0.0282	0.2	0.11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96729932	chr5:96804353~96806105:+
BRCA	cis	rs10129255	0.957	rs11847726	ENSG00000211967.3	IGHV3-53	-3.45	0.000588	0.0282	-0.08	-0.11	Kawasaki disease;	chr14:106779116	chr14:106592676~106593347:-
BRCA	cis	rs7647973	0.593	rs62262730	ENSG00000228008.1	CTD-2330K9.3	3.45	0.000588	0.0282	0.14	0.11	Menarche (age at onset);	chr3:49770841	chr3:49903845~49916937:+
BRCA	cis	rs875971	0.862	rs2909688	ENSG00000106610.13	STAG3L4	-3.45	0.000588	0.0282	-0.14	-0.11	Aortic root size;	chr7:66376625	chr7:67302621~67321526:+
BRCA	cis	rs3731714	1	rs3731714	ENSG00000201499.1	RNU6-312P	3.45	0.000588	0.0282	0.13	0.11	Trans fatty acid levels;	chr2:201196097	chr2:200881715~200881821:-
BRCA	cis	rs6142618	0.562	rs6142622	ENSG00000275576.1	RP5-836N17.4	-3.45	0.000588	0.0282	-0.12	-0.11	Inflammatory bowel disease;	chr20:32151175	chr20:32116171~32116629:+
BRCA	cis	rs9304742	0.854	rs11084211	ENSG00000241015.2	TPM3P9	-3.45	0.000588	0.0282	-0.14	-0.11	Psoriasis;	chr19:52957608	chr19:53431984~53444670:+
BRCA	cis	rs3092566	1	rs3092566	ENSG00000227431.4	CSE1L-AS1	-3.45	0.000589	0.0282	-0.12	-0.11	Intelligence (multi-trait analysis);	chr20:48882633	chr20:49040463~49046044:-
BRCA	cis	rs12439619	0.508	rs11856561	ENSG00000276710.3	CSPG4P8	-3.45	0.000589	0.0282	-0.11	-0.11	Intelligence (multi-trait analysis);	chr15:82161415	chr15:82459472~82477258:+
BRCA	cis	rs2625529	0.816	rs8025504	ENSG00000260037.4	CTD-2524L6.3	-3.45	0.000589	0.0282	-0.15	-0.11	Red blood cell count;	chr15:72002416	chr15:71818396~71823384:+
BRCA	cis	rs13326165	0.76	rs11706001	ENSG00000243224.1	RP5-1157M23.2	-3.45	0.000589	0.0282	-0.15	-0.11	HDL cholesterol levels;HDL cholesterol;	chr3:52338112	chr3:52239258~52241097:+
BRCA	cis	rs10843647	0.51	rs10843604	ENSG00000245614.3	DDX11-AS1	3.45	0.000589	0.0282	0.12	0.11	Glucose homeostasis traits;	chr12:30102207	chr12:31020763~31073847:-
BRCA	cis	rs11098499	0.863	rs1480940	ENSG00000225892.3	RP11-384K6.2	3.45	0.000589	0.0282	0.11	0.11	Corneal astigmatism;	chr4:119536527	chr4:118632274~118634759:+
BRCA	cis	rs36051895	0.664	rs3824433	ENSG00000237711.1	RP11-39K24.13	-3.45	0.000589	0.0282	-0.12	-0.11	Pediatric autoimmune diseases;	chr9:5113577	chr9:5100236~5101009:+
BRCA	cis	rs55962025	0.883	rs362336	ENSG00000261643.1	RP11-529E10.6	3.45	0.000589	0.0282	0.13	0.11	Parental longevity (mother's age at death);	chr4:3212105	chr4:3503597~3504457:-
BRCA	cis	rs875971	1	rs7789554	ENSG00000271064.1	RP11-792A8.3	-3.45	0.000589	0.0282	-0.12	-0.11	Aortic root size;	chr7:66481051	chr7:66748838~66749077:-
BRCA	cis	rs875971	1	rs4717300	ENSG00000271064.1	RP11-792A8.3	-3.45	0.000589	0.0282	-0.12	-0.11	Aortic root size;	chr7:66482393	chr7:66748838~66749077:-
BRCA	cis	rs875971	0.895	rs1974769	ENSG00000271064.1	RP11-792A8.3	-3.45	0.000589	0.0282	-0.12	-0.11	Aortic root size;	chr7:66485627	chr7:66748838~66749077:-
BRCA	cis	rs875971	0.895	rs6460300	ENSG00000271064.1	RP11-792A8.3	-3.45	0.000589	0.0282	-0.12	-0.11	Aortic root size;	chr7:66487937	chr7:66748838~66749077:-
BRCA	cis	rs875971	0.862	rs7803416	ENSG00000271064.1	RP11-792A8.3	-3.45	0.000589	0.0282	-0.12	-0.11	Aortic root size;	chr7:66489212	chr7:66748838~66749077:-
BRCA	cis	rs875971	0.964	rs2277911	ENSG00000271064.1	RP11-792A8.3	-3.45	0.000589	0.0282	-0.12	-0.11	Aortic root size;	chr7:66493638	chr7:66748838~66749077:-
BRCA	cis	rs7332672	0.651	rs7983415	ENSG00000218502.3	H2AFZP3	-3.45	0.000589	0.0282	-0.12	-0.11	Eosinophil counts;	chr13:99128159	chr13:99215372~99215758:-
BRCA	cis	rs7339483	0.618	rs2009596	ENSG00000268442.1	CTD-2027I19.2	3.45	0.000589	0.0282	0.2	0.11	Discordance in emotional problems in monozygotic twins;	chr19:24170300	chr19:24162370~24163425:-
BRCA	cis	rs7339483	0.618	rs2116965	ENSG00000268442.1	CTD-2027I19.2	3.45	0.000589	0.0282	0.2	0.11	Discordance in emotional problems in monozygotic twins;	chr19:24171056	chr19:24162370~24163425:-
BRCA	cis	rs58521262	0.66	rs57042530	ENSG00000268105.1	RP11-369G6.2	-3.45	0.000589	0.0282	-0.18	-0.11	Testicular germ cell tumor;	chr19:22851778	chr19:23125665~23128543:+
BRCA	cis	rs1865760	0.566	rs9295686	ENSG00000272462.2	U91328.19	-3.45	0.00059	0.0283	-0.12	-0.11	Height;	chr6:26081755	chr6:25992662~26001775:+
BRCA	cis	rs1865760	0.532	rs9295687	ENSG00000272462.2	U91328.19	-3.45	0.00059	0.0283	-0.12	-0.11	Height;	chr6:26082482	chr6:25992662~26001775:+
BRCA	cis	rs1865760	0.566	rs4529296	ENSG00000272462.2	U91328.19	-3.45	0.00059	0.0283	-0.12	-0.11	Height;	chr6:26082907	chr6:25992662~26001775:+
BRCA	cis	rs1865760	0.566	rs1971509	ENSG00000272462.2	U91328.19	-3.45	0.00059	0.0283	-0.12	-0.11	Height;	chr6:26085549	chr6:25992662~26001775:+
BRCA	cis	rs1865760	0.532	rs2006736	ENSG00000272462.2	U91328.19	-3.45	0.00059	0.0283	-0.12	-0.11	Height;	chr6:26085789	chr6:25992662~26001775:+
BRCA	cis	rs1865760	0.566	rs1800702	ENSG00000272462.2	U91328.19	-3.45	0.00059	0.0283	-0.12	-0.11	Height;	chr6:26086235	chr6:25992662~26001775:+
BRCA	cis	rs1865760	0.566	rs2794720	ENSG00000272462.2	U91328.19	-3.45	0.00059	0.0283	-0.12	-0.11	Height;	chr6:26086974	chr6:25992662~26001775:+
BRCA	cis	rs683250	0.661	rs2507852	ENSG00000254551.1	RP11-727A23.7	3.45	0.00059	0.0283	0.14	0.11	Subcortical brain region volumes;	chr11:83411509	chr11:83209431~83213379:-
BRCA	cis	rs6840360	0.571	rs7678080	ENSG00000270265.1	RP11-731D1.4	-3.45	0.00059	0.0283	-0.13	-0.11	Intelligence (multi-trait analysis);	chr4:151636198	chr4:151333775~151353224:-
BRCA	cis	rs4849845	0.598	rs3889223	ENSG00000236878.1	AC012363.7	3.45	0.00059	0.0283	0.12	0.11	Mean platelet volume;	chr2:120266856	chr2:120211054~120211715:+
BRCA	cis	rs4849845	0.573	rs33971369	ENSG00000236878.1	AC012363.7	3.45	0.00059	0.0283	0.12	0.11	Mean platelet volume;	chr2:120267411	chr2:120211054~120211715:+
BRCA	cis	rs7931462	0.655	rs6483208	ENSG00000255445.1	RP11-573M3.3	-3.45	0.00059	0.0283	-0.17	-0.11	DNA methylation (parent-of-origin);	chr11:92972678	chr11:93152075~93152750:+
BRCA	cis	rs6907629	0.776	rs1999375	ENSG00000280057.1	RP1-168L15.6	-3.45	0.00059	0.0283	-0.12	-0.11	Asthma (childhood onset);	chr6:167163210	chr6:166388136~166389920:+
BRCA	cis	rs2835872	0.93	rs857974	ENSG00000228677.1	TTC3-AS1	3.45	0.00059	0.0283	0.14	0.11	Electroencephalographic traits in alcoholism;	chr21:37633439	chr21:37187666~37193926:-
BRCA	cis	rs16893526	0.649	rs1931629	ENSG00000224995.1	LINC01526	-3.45	0.00059	0.0283	-0.17	-0.11	Coronary heart disease;	chr6:81810760	chr6:81813286~81814157:-
BRCA	cis	rs16893526	0.649	rs1931628	ENSG00000224995.1	LINC01526	-3.45	0.00059	0.0283	-0.17	-0.11	Coronary heart disease;	chr6:81810812	chr6:81813286~81814157:-
BRCA	cis	rs16893526	0.649	rs1931627	ENSG00000224995.1	LINC01526	-3.45	0.00059	0.0283	-0.17	-0.11	Coronary heart disease;	chr6:81810851	chr6:81813286~81814157:-
BRCA	cis	rs11621710	0.798	rs10132769	ENSG00000226677.3	IGBP1P1	3.45	0.00059	0.0283	0.13	0.11	Granulocyte percentage of myeloid white cells;	chr14:35107252	chr14:34939324~34940332:+
BRCA	cis	rs6593122	0.628	rs10227819	ENSG00000235454.1	HAUS6P3	-3.45	0.00059	0.0283	-0.14	-0.11	Vaccine-related adverse events;	chr7:54117550	chr7:53862233~53863339:+
BRCA	cis	rs2486012	1	rs3011230	ENSG00000237950.1	RP11-7O11.3	-3.45	0.00059	0.0283	-0.19	-0.11	Intelligence (multi-trait analysis);	chr1:43874983	chr1:43944370~43946551:-
BRCA	cis	rs4950322	0.542	rs3766520	ENSG00000230832.3	RP11-325P15.2	-3.45	0.00059	0.0283	-0.17	-0.11	Protein quantitative trait loci;	chr1:147214658	chr1:147082338~147083578:-
BRCA	cis	rs9341808	0.622	rs684283	ENSG00000233967.5	RP11-250B2.3	-3.45	0.00059	0.0283	-0.11	-0.11	Sitting height ratio;	chr6:80257600	chr6:80443344~80465927:+
BRCA	cis	rs7520050	0.966	rs7522601	ENSG00000281133.1	AL355480.3	3.45	0.00059	0.0283	0.12	0.11	Reticulocyte count;Red blood cell count;	chr1:45953349	chr1:45580892~45580996:-
BRCA	cis	rs7520050	0.966	rs10789487	ENSG00000281133.1	AL355480.3	3.45	0.00059	0.0283	0.12	0.11	Reticulocyte count;Red blood cell count;	chr1:45954549	chr1:45580892~45580996:-
BRCA	cis	rs748404	0.666	rs35160541	ENSG00000166763.7	STRCP1	3.45	0.00059	0.0283	0.15	0.11	Lung cancer;	chr15:43365601	chr15:43699488~43718184:-
BRCA	cis	rs13088281	1	rs13088281	ENSG00000242142.1	SERBP1P3	3.45	0.00059	0.0283	0.19	0.11	Immune reponse to smallpox (secreted IL-2);	chr3:53113560	chr3:53064283~53065091:-
BRCA	cis	rs6840360	0.615	rs9884167	ENSG00000270265.1	RP11-731D1.4	-3.45	0.00059	0.0283	-0.12	-0.11	Intelligence (multi-trait analysis);	chr4:151549647	chr4:151333775~151353224:-
BRCA	cis	rs1056107	0.933	rs4979099	ENSG00000266315.1	MIR4668	3.45	0.00059	0.0283	0.11	0.11	Colorectal cancer;	chr9:112319336	chr9:111932100~111932169:+
BRCA	cis	rs11673344	0.864	rs79407399	ENSG00000267682.1	CTD-3220F14.2	-3.45	0.00059	0.0283	-0.1	-0.11	Obesity-related traits;	chr19:37000004	chr19:37337236~37337743:+
BRCA	cis	rs2898857	1	rs2898857	ENSG00000250948.1	RP11-1079K10.2	3.45	0.00059	0.0283	0.15	0.11	Cancer;	chr17:49278661	chr17:49375380~49380094:+
BRCA	cis	rs10419113	0.641	rs12610315	ENSG00000268379.1	CTC-360J11.4	3.45	0.00059	0.0283	0.12	0.11	Pediatric bone mineral density (spine);	chr19:57765288	chr19:57175233~57177921:+
BRCA	cis	rs950169	0.58	rs17532346	ENSG00000230373.7	GOLGA6L5P	-3.45	0.00059	0.0283	-0.13	-0.11	Schizophrenia;	chr15:84628264	chr15:84507885~84516814:-
BRCA	cis	rs713477	0.692	rs8019270	ENSG00000186615.9	KTN1-AS1	-3.45	0.00059	0.0283	-0.12	-0.11	Pediatric bone mineral content (femoral neck);	chr14:55440454	chr14:55499278~55580110:-
BRCA	cis	rs7339483	1	rs10420480	ENSG00000269416.4	LINC01224	3.45	0.00059	0.0283	0.21	0.11	Discordance in emotional problems in monozygotic twins;	chr19:24245149	chr19:23399233~23416075:-
BRCA	cis	rs4849845	0.637	rs11688038	ENSG00000236878.1	AC012363.7	3.45	0.00059	0.0283	0.12	0.11	Mean platelet volume;	chr2:120269006	chr2:120211054~120211715:+
BRCA	cis	rs6499755	0.712	rs31116	ENSG00000245694.7	CRNDE	3.45	0.00059	0.0283	0.13	0.11	Hypospadias;	chr16:55346918	chr16:54918863~54929189:-
BRCA	cis	rs2518049	0.904	rs2398186	ENSG00000224034.1	RP11-445P17.8	3.45	0.00059	0.0283	0.2	0.11	Metabolic traits;	chr10:5080378	chr10:5266033~5271236:-
BRCA	cis	rs10504130	0.696	rs75833886	ENSG00000272076.1	RP11-11C20.3	3.45	0.00059	0.0283	0.16	0.11	Venous thromboembolism (SNP x SNP interaction);	chr8:51929844	chr8:51810110~51810681:-
BRCA	cis	rs10504130	0.696	rs17284746	ENSG00000272076.1	RP11-11C20.3	3.45	0.00059	0.0283	0.16	0.11	Venous thromboembolism (SNP x SNP interaction);	chr8:51930320	chr8:51810110~51810681:-
BRCA	cis	rs3096299	0.967	rs2911257	ENSG00000261118.1	RP11-104N10.1	3.45	0.00059	0.0283	0.11	0.11	Multiple myeloma (IgH translocation);	chr16:89417726	chr16:89492017~89504460:-
BRCA	cis	rs1131351	0.62	rs11895809	ENSG00000234378.1	AC098828.2	-3.45	0.00059	0.0283	-0.12	-0.11	Seasonality;	chr2:20199293	chr2:20063856~20106829:-
BRCA	cis	rs910316	1	rs175443	ENSG00000259138.1	RP11-950C14.7	-3.45	0.00059	0.0283	-0.11	-0.11	Height;	chr14:75135260	chr14:75127153~75136930:+
BRCA	cis	rs76248362	0.786	rs9507178	ENSG00000205861.10	C1QTNF9B-AS1	3.45	0.00059	0.0283	0.28	0.11	3-hydroxypropylmercapturic acid levels in smokers;	chr13:23862659	chr13:23888889~23897263:+
BRCA	cis	rs4376189	0.614	rs11132338	ENSG00000233110.1	RP11-301L8.2	-3.45	0.00059	0.0283	-0.18	-0.11	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr4:185717293	chr4:185587909~185594003:+
BRCA	cis	rs16940212	0.618	rs447794	ENSG00000259771.1	RP11-429D19.1	3.45	0.00059	0.0283	0.17	0.11	HDL cholesterol;HDL cholesterol levels;	chr15:58394439	chr15:59266720~59271162:-
BRCA	cis	rs7617480	0.519	rs6790914	ENSG00000225399.4	RP11-3B7.1	3.45	0.000591	0.0283	0.1	0.11	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:49168885	chr3:49260085~49261316:+
BRCA	cis	rs2386661	0.522	rs11258044	ENSG00000242147.1	RP13-463N16.6	3.45	0.000591	0.0283	0.13	0.11	Breast cancer;	chr10:5602429	chr10:5594991~5596118:-
BRCA	cis	rs74233809	1	rs11191580	ENSG00000213061.2	PFN1P11	-3.45	0.000591	0.0283	-0.24	-0.11	Birth weight;	chr10:103146454	chr10:102838011~102845473:-
BRCA	cis	rs2832077	0.527	rs1048546	ENSG00000232855.5	AF131217.1	3.45	0.000591	0.0283	0.13	0.11	Cognitive test performance;	chr21:28872555	chr21:28439346~28674848:-
BRCA	cis	rs2400362	0.838	rs4739609	ENSG00000260317.1	RP11-48B3.4	-3.45	0.000591	0.0283	-0.14	-0.11	Glucocorticoid-induced osteonecrosis (age 10 years and older);	chr8:80958987	chr8:80541300~80543104:+
BRCA	cis	rs68170813	0.652	rs7784906	ENSG00000241764.3	AC002467.7	3.45	0.000591	0.0283	0.18	0.11	Coronary artery disease;	chr7:107507941	chr7:107742817~107744581:-
BRCA	cis	rs68170813	0.652	rs56949084	ENSG00000241764.3	AC002467.7	3.45	0.000591	0.0283	0.18	0.11	Coronary artery disease;	chr7:107516942	chr7:107742817~107744581:-
BRCA	cis	rs68170813	0.652	rs6976759	ENSG00000241764.3	AC002467.7	3.45	0.000591	0.0283	0.18	0.11	Coronary artery disease;	chr7:107518061	chr7:107742817~107744581:-
BRCA	cis	rs7572733	0.935	rs1850633	ENSG00000231621.1	AC013264.2	-3.45	0.000591	0.0283	-0.1	-0.11	Dermatomyositis;	chr2:197964858	chr2:197197991~197199273:+
BRCA	cis	rs9863	0.931	rs34180676	ENSG00000270028.1	RP11-380L11.4	3.45	0.000591	0.0283	0.13	0.11	White blood cell count;	chr12:123946972	chr12:123925461~123926083:-
BRCA	cis	rs9863	0.931	rs7955815	ENSG00000270028.1	RP11-380L11.4	3.45	0.000591	0.0283	0.13	0.11	White blood cell count;	chr12:123948159	chr12:123925461~123926083:-
BRCA	cis	rs2744375	0.6	rs2237102	ENSG00000261189.1	RP3-512B11.3	3.45	0.000591	0.0283	0.13	0.11	Resting heart rate;	chr6:7551912	chr6:7540451~7541338:-
BRCA	cis	rs7412746	0.658	rs11204723	ENSG00000224800.1	RP11-235D19.2	-3.45	0.000591	0.0283	-0.13	-0.11	Melanoma;	chr1:150759142	chr1:150881236~150881683:-
BRCA	cis	rs853679	0.542	rs6934769	ENSG00000226314.6	ZNF192P1	-3.45	0.000591	0.0283	-0.16	-0.11	Depression;	chr6:28123153	chr6:28161781~28169594:+
BRCA	cis	rs853679	0.517	rs17711801	ENSG00000226314.6	ZNF192P1	-3.45	0.000591	0.0283	-0.16	-0.11	Depression;	chr6:28124529	chr6:28161781~28169594:+
BRCA	cis	rs4713118	0.527	rs9461433	ENSG00000226314.6	ZNF192P1	-3.45	0.000591	0.0283	-0.16	-0.11	Parkinson's disease;	chr6:28127394	chr6:28161781~28169594:+
BRCA	cis	rs853679	0.517	rs9468292	ENSG00000226314.6	ZNF192P1	-3.45	0.000591	0.0283	-0.16	-0.11	Depression;	chr6:28127577	chr6:28161781~28169594:+
BRCA	cis	rs9888739	0.8	rs7193268	ENSG00000261245.2	RP11-120K18.3	3.45	0.000591	0.0283	0.14	0.11	Systemic lupus erythematosus;	chr16:31329676	chr16:31361278~31361695:-
BRCA	cis	rs1823874	0.71	rs67068917	ENSG00000259363.4	CTD-2054N24.2	3.45	0.000591	0.0283	0.13	0.11	IgG glycosylation;	chr15:99822310	chr15:99807023~99877148:+
BRCA	cis	rs13108904	0.901	rs4974594	ENSG00000253399.1	AC078852.2	3.45	0.000591	0.0283	0.12	0.11	Obesity-related traits;	chr4:1306692	chr4:1358479~1359461:+
BRCA	cis	rs12741884	0.526	rs2807326	ENSG00000228397.1	RP1-224A6.3	-3.45	0.000591	0.0283	-0.14	-0.11	TB-LM or TBLH-BMD (pleiotropy);Bone mineral density (paediatric, total body less head);	chr1:22237000	chr1:22023994~22024968:-
BRCA	cis	rs8098244	0.861	rs9962023	ENSG00000265752.2	RP11-403A21.1	-3.45	0.000591	0.0283	-0.12	-0.11	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23833905	chr18:23957754~23982556:-
BRCA	cis	rs9325144	0.56	rs11183046	ENSG00000257718.1	RP11-396F22.1	-3.45	0.000591	0.0283	-0.11	-0.11	Morning vs. evening chronotype;	chr12:38261468	chr12:38906451~38909592:+
BRCA	cis	rs875971	0.825	rs4587224	ENSG00000223473.2	GS1-124K5.3	-3.45	0.000591	0.0283	-0.08	-0.11	Aortic root size;	chr7:66271195	chr7:66491049~66493566:-
BRCA	cis	rs875971	0.792	rs6971752	ENSG00000223473.2	GS1-124K5.3	-3.45	0.000591	0.0283	-0.08	-0.11	Aortic root size;	chr7:66272999	chr7:66491049~66493566:-
BRCA	cis	rs875971	0.862	rs10950033	ENSG00000223473.2	GS1-124K5.3	-3.45	0.000591	0.0283	-0.08	-0.11	Aortic root size;	chr7:66274686	chr7:66491049~66493566:-
BRCA	cis	rs875971	0.862	rs11760844	ENSG00000223473.2	GS1-124K5.3	-3.45	0.000591	0.0283	-0.08	-0.11	Aortic root size;	chr7:66274896	chr7:66491049~66493566:-
BRCA	cis	rs8141529	0.748	rs5752826	ENSG00000226471.5	CTA-292E10.6	-3.45	0.000591	0.0283	-0.13	-0.11	Lymphocyte counts;	chr22:28873820	chr22:28800683~28848559:+
BRCA	cis	rs11773103	1	rs73204819	ENSG00000224046.1	AC005076.5	3.45	0.000591	0.0283	0.19	0.11	Bipolar disorder or major depressive disorder (combined);	chr7:87141009	chr7:87151423~87152420:-
BRCA	cis	rs4759375	1	rs9669295	ENSG00000256092.2	RP13-942N8.1	3.45	0.000591	0.0283	0.17	0.11	HDL cholesterol;	chr12:123358123	chr12:123363868~123366113:+
BRCA	cis	rs247833	0.585	rs13336427	ENSG00000278716.1	LA16c-352F7.1	3.45	0.000592	0.0283	0.18	0.11	Monocyte count;	chr16:84557170	chr16:85489813~85490831:+
BRCA	cis	rs875971	1	rs778710	ENSG00000272831.1	RP11-792A8.4	3.45	0.000592	0.0283	0.09	0.11	Aortic root size;	chr7:66389847	chr7:66739829~66740385:-
BRCA	cis	rs7620503	0.571	rs6443468	ENSG00000231574.4	RP11-91K9.1	3.45	0.000592	0.0283	0.13	0.11	Corneal structure;	chr3:177565231	chr3:177816865~177899224:+
BRCA	cis	rs10129255	0.913	rs28861466	ENSG00000211958.2	IGHV3-38	3.45	0.000592	0.0283	0.09	0.11	Kawasaki disease;	chr14:106718572	chr14:106410493~106411021:-
BRCA	cis	rs965469	1	rs6037590	ENSG00000215063.3	RPL21P2	3.45	0.000592	0.0283	0.14	0.11	IFN-related cytopenia;	chr20:3393438	chr20:4059633~4060113:-
BRCA	cis	rs951005	0.572	rs7029213	ENSG00000228352.2	RP11-537H15.3	-3.45	0.000592	0.0283	-0.17	-0.11	Rheumatoid arthritis;	chr9:34731619	chr9:34084332~34096225:+
BRCA	cis	rs2640806	0.645	rs7824518	ENSG00000253105.4	KB-1448A5.1	3.45	0.000592	0.0283	0.12	0.11	Obesity-related traits;	chr8:96318523	chr8:96371865~96387438:-
BRCA	cis	rs2108225	0.837	rs6959729	ENSG00000231006.1	RPL7P32	-3.45	0.000592	0.0283	-0.1	-0.11	Ulcerative colitis;	chr7:107805735	chr7:108510233~108510976:+
BRCA	cis	rs997295	0.529	rs12592315	ENSG00000270964.1	RP11-502I4.3	-3.45	0.000592	0.0283	-0.12	-0.11	Motion sickness;	chr15:67747928	chr15:67541072~67542604:-
BRCA	cis	rs875971	1	rs11974264	ENSG00000271064.1	RP11-792A8.3	3.45	0.000592	0.0283	0.12	0.11	Aortic root size;	chr7:66182595	chr7:66748838~66749077:-
BRCA	cis	rs875971	0.508	rs10258739	ENSG00000271064.1	RP11-792A8.3	3.45	0.000592	0.0283	0.12	0.11	Aortic root size;	chr7:66597948	chr7:66748838~66749077:-
BRCA	cis	rs7620503	0.571	rs6443468	ENSG00000228561.2	RP11-114M1.1	3.45	0.000592	0.0283	0.14	0.11	Corneal structure;	chr3:177565231	chr3:177683627~177691250:+
BRCA	cis	rs61931739	0.534	rs11052979	ENSG00000258794.3	DUX4L27	3.45	0.000592	0.0283	0.15	0.11	Morning vs. evening chronotype;	chr12:33882839	chr12:34208415~34209675:-
BRCA	cis	rs7339483	0.541	rs10413875	ENSG00000267886.1	CTD-2291D10.4	3.45	0.000592	0.0283	0.19	0.11	Discordance in emotional problems in monozygotic twins;	chr19:24047012	chr19:23075201~23100361:+
BRCA	cis	rs467650	0.509	rs27391	ENSG00000248489.1	CTD-2007H13.3	3.45	0.000592	0.0283	0.12	0.11	Venous thromboembolism (SNP x SNP interaction);	chr5:98644719	chr5:98929171~98995013:+
BRCA	cis	rs4869313	0.607	rs2549789	ENSG00000248734.2	CTD-2260A17.1	-3.45	0.000592	0.0283	-0.11	-0.11	Pediatric autoimmune diseases;	chr5:96906566	chr5:96784777~96785999:+
BRCA	cis	rs4869313	0.668	rs2549790	ENSG00000248734.2	CTD-2260A17.1	-3.45	0.000592	0.0283	-0.11	-0.11	Pediatric autoimmune diseases;	chr5:96906708	chr5:96784777~96785999:+
BRCA	cis	rs4869313	0.617	rs33934033	ENSG00000248734.2	CTD-2260A17.1	-3.45	0.000592	0.0283	-0.11	-0.11	Pediatric autoimmune diseases;	chr5:96907162	chr5:96784777~96785999:+
BRCA	cis	rs4869313	0.668	rs17087165	ENSG00000248734.2	CTD-2260A17.1	-3.45	0.000592	0.0283	-0.11	-0.11	Pediatric autoimmune diseases;	chr5:96907277	chr5:96784777~96785999:+
BRCA	cis	rs8180040	0.62	rs6442055	ENSG00000260236.1	RP11-708J19.1	3.45	0.000592	0.0283	0.1	0.11	Colorectal cancer;	chr3:47069232	chr3:47379089~47380999:-
BRCA	cis	rs61542988	0.57	rs7781074	ENSG00000226329.2	AC005682.6	-3.45	0.000592	0.0284	-0.12	-0.11	Fibrinogen levels;	chr7:22786741	chr7:22863874~22881350:-
BRCA	cis	rs10043228	0.826	rs62384693	ENSG00000250015.1	CTC-339F2.2	3.45	0.000592	0.0284	0.13	0.11	Asthma or chronic obstructive pulmonary disease;	chr5:116097784	chr5:116302354~116304134:-
BRCA	cis	rs10043228	1	rs62384697	ENSG00000250015.1	CTC-339F2.2	3.45	0.000592	0.0284	0.13	0.11	Asthma or chronic obstructive pulmonary disease;	chr5:116102587	chr5:116302354~116304134:-
BRCA	cis	rs7727544	0.526	rs4705908	ENSG00000233006.5	AC034220.3	3.45	0.000592	0.0284	0.08	0.11	Blood metabolite levels;	chr5:132011827	chr5:132311285~132369916:-
BRCA	cis	rs2262909	0.853	rs56207853	ENSG00000279377.1	AC003973.3	-3.45	0.000592	0.0284	-0.15	-0.11	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;	chr19:22109555	chr19:21965708~21968529:-
BRCA	cis	rs3735485	0.738	rs62458150	ENSG00000201772.1	SNORA5C	3.45	0.000592	0.0284	0.14	0.11	White blood cell count;Sum basophil neutrophil counts;Neutrophil count;Granulocyte percentage of myeloid white cells;Monocyte percentage of white cells;Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Lymphocyte counts;	chr7:45061447	chr7:45104906~45105042:-
BRCA	cis	rs3735485	0.738	rs10279523	ENSG00000201772.1	SNORA5C	3.45	0.000592	0.0284	0.14	0.11	White blood cell count;Sum basophil neutrophil counts;Neutrophil count;Granulocyte percentage of myeloid white cells;Monocyte percentage of white cells;Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Lymphocyte counts;	chr7:45062046	chr7:45104906~45105042:-
BRCA	cis	rs3735485	0.738	rs10253578	ENSG00000201772.1	SNORA5C	3.45	0.000592	0.0284	0.14	0.11	White blood cell count;Sum basophil neutrophil counts;Neutrophil count;Granulocyte percentage of myeloid white cells;Monocyte percentage of white cells;Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Lymphocyte counts;	chr7:45062459	chr7:45104906~45105042:-
BRCA	cis	rs875971	0.83	rs778715	ENSG00000106610.13	STAG3L4	-3.45	0.000592	0.0284	-0.14	-0.11	Aortic root size;	chr7:66384222	chr7:67302621~67321526:+
BRCA	cis	rs12681366	0.734	rs16916796	ENSG00000253175.1	RP11-267M23.6	3.45	0.000592	0.0284	0.12	0.11	Nonsyndromic cleft lip with cleft palate;	chr8:94390001	chr8:94565036~94565715:+
BRCA	cis	rs11098499	0.526	rs10026625	ENSG00000250412.1	KLHL2P1	3.45	0.000592	0.0284	0.12	0.11	Corneal astigmatism;	chr4:119358981	chr4:119334329~119378233:+
BRCA	cis	rs7824557	0.564	rs2736295	ENSG00000254866.2	DEFB109P3	-3.45	0.000592	0.0284	-0.14	-0.11	Retinal vascular caliber;	chr8:11377271	chr8:12150895~12151134:-
BRCA	cis	rs7647973	0.621	rs3774800	ENSG00000226913.1	BSN-AS2	3.45	0.000592	0.0284	0.11	0.11	Menarche (age at onset);	chr3:49297335	chr3:49549306~49554366:-
BRCA	cis	rs8030605	0.704	rs3848113	ENSG00000277245.1	RP11-48G14.3	3.45	0.000592	0.0284	0.23	0.11	Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;	chr15:56435178	chr15:56447120~56447697:+
BRCA	cis	rs8133974	0.941	rs41360844	ENSG00000225555.1	AP000320.6	-3.45	0.000593	0.0284	-0.21	-0.11	Sum eosinophil basophil counts;Eosinophil counts;Eosinophil percentage of granulocytes;	chr21:35109174	chr21:34370802~34375348:-
BRCA	cis	rs863345	0.564	rs11265014	ENSG00000229914.1	RP11-404O13.4	-3.45	0.000593	0.0284	-0.11	-0.11	Pneumococcal bacteremia;	chr1:158533431	chr1:158195633~158196131:-
BRCA	cis	rs863345	0.604	rs11265015	ENSG00000229914.1	RP11-404O13.4	-3.45	0.000593	0.0284	-0.11	-0.11	Pneumococcal bacteremia;	chr1:158533462	chr1:158195633~158196131:-
BRCA	cis	rs11175492	1	rs77164989	ENSG00000243024.5	RPS11P6	-3.45	0.000593	0.0284	-0.25	-0.11	Platelet count;	chr12:64669556	chr12:64222337~64397065:+
BRCA	cis	rs703108	0.731	rs7898954	ENSG00000223984.1	HNRNPRP1	3.45	0.000593	0.0284	0.13	0.11	Monocyte percentage of white cells;	chr10:22034717	chr10:21624592~21626286:-
BRCA	cis	rs2657888	0.529	rs71459376	ENSG00000257576.1	RP11-153M3.1	-3.45	0.000593	0.0284	-0.14	-0.11	Adiponectin levels;	chr12:56495355	chr12:56511002~56512703:+
BRCA	cis	rs11671005	0.735	rs3826684	ENSG00000269600.1	AC016629.3	-3.45	0.000593	0.0284	-0.16	-0.11	Mean platelet volume;	chr19:58407338	chr19:58593896~58599355:-
BRCA	cis	rs11671005	0.735	rs3826683	ENSG00000269600.1	AC016629.3	-3.45	0.000593	0.0284	-0.16	-0.11	Mean platelet volume;	chr19:58407366	chr19:58593896~58599355:-
BRCA	cis	rs11671005	0.735	rs3826681	ENSG00000269600.1	AC016629.3	-3.45	0.000593	0.0284	-0.16	-0.11	Mean platelet volume;	chr19:58407397	chr19:58593896~58599355:-
BRCA	cis	rs4950322	0.518	rs61838936	ENSG00000237188.3	RP11-337C18.8	3.45	0.000593	0.0284	0.13	0.11	Protein quantitative trait loci;	chr1:147098422	chr1:147172771~147211568:+
BRCA	cis	rs7103648	0.966	rs1377416	ENSG00000280615.1	Y_RNA	3.45	0.000593	0.0284	0.12	0.11	Systolic blood pressure;Diastolic blood pressure;	chr11:47395195	chr11:47614898~47614994:-
BRCA	cis	rs654950	0.783	rs668359	ENSG00000230881.1	RP11-486B10.3	3.45	0.000593	0.0284	0.11	0.11	Airway imaging phenotypes;	chr1:41537754	chr1:41535443~41535868:+
BRCA	cis	rs4660456	0.596	rs1534956	ENSG00000272145.1	NFYC-AS1	-3.45	0.000593	0.0284	-0.1	-0.11	Platelet count;	chr1:40720771	chr1:40690380~40692066:-
BRCA	cis	rs9990333	0.544	rs112577972	ENSG00000207650.1	MIR570	3.45	0.000593	0.0284	0.13	0.11	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196098278	chr3:195699401~195699497:+
BRCA	cis	rs1949733	0.628	rs2688231	ENSG00000205959.3	RP11-689P11.2	-3.45	0.000593	0.0284	-0.1	-0.11	Response to antineoplastic agents;	chr4:8489254	chr4:8482270~8512610:+
BRCA	cis	rs12285276	0.576	rs2593756	ENSG00000205106.4	DKFZp779M0652	3.45	0.000593	0.0284	0.14	0.11	Visceral fat;	chr11:45746850	chr11:45771432~45772358:+
BRCA	cis	rs7615952	0.576	rs2276726	ENSG00000248787.1	RP11-666A20.4	-3.45	0.000593	0.0284	-0.15	-0.11	Blood pressure (smoking interaction);	chr3:126107444	chr3:125908005~125910272:-
BRCA	cis	rs9948	0.655	rs17119562	ENSG00000230606.9	AC159540.1	3.45	0.000593	0.0284	0.22	0.11	Erectile dysfunction and prostate cancer treatment;	chr2:96716107	chr2:97416165~97433527:-
BRCA	cis	rs2836950	0.545	rs2836959	ENSG00000235701.1	PCBP2P1	-3.45	0.000593	0.0284	-0.12	-0.11	Menarche (age at onset);	chr21:39251742	chr21:39171130~39172106:-
BRCA	cis	rs11098403	0.687	rs62325879	ENSG00000225892.3	RP11-384K6.2	3.45	0.000593	0.0284	0.11	0.11	Schizophrenia;	chr4:117832531	chr4:118632274~118634759:+
BRCA	cis	rs3781264	0.595	rs10882430	ENSG00000268894.5	PLCE1-AS1	-3.45	0.000593	0.0284	-0.14	-0.11	Esophageal cancer and gastric cancer;	chr10:94330915	chr10:94279277~94287478:-
BRCA	cis	rs72928364	1	rs34719725	ENSG00000244119.1	PDCL3P4	3.45	0.000593	0.0284	0.13	0.11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100958648	chr3:101712472~101713191:+
BRCA	cis	rs6696239	1	rs6696239	ENSG00000215812.5	ZNF847P	3.45	0.000593	0.0284	0.15	0.11	Height;	chr1:227562367	chr1:227696892~227706699:-
BRCA	cis	rs1912124	1	rs72744134	ENSG00000259343.4	TMC3-AS1	3.45	0.000593	0.0284	0.24	0.11	Peripheral arterial disease (traffic-related air pollution interaction);	chr15:81218367	chr15:81324377~81362037:+
BRCA	cis	rs1912124	1	rs72744136	ENSG00000259343.4	TMC3-AS1	3.45	0.000593	0.0284	0.24	0.11	Peripheral arterial disease (traffic-related air pollution interaction);	chr15:81219367	chr15:81324377~81362037:+
BRCA	cis	rs6736093	0.966	rs3761699	ENSG00000236307.2	EEF1E1P1	-3.45	0.000593	0.0284	-0.13	-0.11	Coronary artery disease;	chr2:111947713	chr2:111887914~111888741:+
BRCA	cis	rs16858210	0.648	rs57604063	ENSG00000234371.6	RPSAP31	3.45	0.000593	0.0284	0.16	0.11	Menopause (age at onset);	chr3:183860901	chr3:183884924~183888449:+
BRCA	cis	rs3816183	0.756	rs4953669	ENSG00000226491.1	FTOP1	3.45	0.000593	0.0284	0.13	0.11	Hypospadias;	chr2:42842836	chr2:42797225~42798712:-
BRCA	cis	rs950027	0.62	rs1346267	ENSG00000275672.1	GATM-AS1	-3.45	0.000593	0.0284	-0.13	-0.11	Response to fenofibrate (adiponectin levels);	chr15:45398791	chr15:45378700~45380123:+
BRCA	cis	rs56046484	0.956	rs12904410	ENSG00000230373.7	GOLGA6L5P	3.45	0.000593	0.0284	0.16	0.11	Testicular germ cell tumor;	chr15:85066557	chr15:84507885~84516814:-
BRCA	cis	rs9341808	0.718	rs9361584	ENSG00000279022.1	RP11-250B2.4	3.45	0.000593	0.0284	0.12	0.11	Sitting height ratio;	chr6:80110229	chr6:80440730~80441172:+
BRCA	cis	rs6545883	0.826	rs1186697	ENSG00000273302.1	RP11-493E12.2	3.45	0.000594	0.0284	0.1	0.11	Tuberculosis;	chr2:61434282	chr2:61199979~61200769:+
BRCA	cis	rs7259376	0.905	rs11879791	ENSG00000269345.1	VN1R85P	3.45	0.000594	0.0284	0.12	0.11	Menopause (age at onset);	chr19:22354137	chr19:22174766~22175191:-
BRCA	cis	rs7259376	0.936	rs59598661	ENSG00000269345.1	VN1R85P	3.45	0.000594	0.0284	0.12	0.11	Menopause (age at onset);	chr19:22354227	chr19:22174766~22175191:-
BRCA	cis	rs4703129	1	rs11241847	ENSG00000246763.5	RGMB-AS1	3.45	0.000594	0.0284	0.12	0.11	Asperger disorder;	chr5:98526278	chr5:98769618~98773469:-
BRCA	cis	rs875971	0.756	rs2901210	ENSG00000271064.1	RP11-792A8.3	3.44	0.000594	0.0284	0.13	0.11	Aortic root size;	chr7:66552518	chr7:66748838~66749077:-
BRCA	cis	rs2380205	0.689	rs907690	ENSG00000232807.2	RP11-536K7.3	3.44	0.000594	0.0284	0.11	0.11	Breast cancer;	chr10:5859404	chr10:5934270~5945900:-
BRCA	cis	rs597539	0.615	rs583182	ENSG00000255741.1	RP11-757G1.5	-3.44	0.000594	0.0284	-0.14	-0.11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68911166	chr11:68941503~68942852:-
BRCA	cis	rs10139154	1	rs7154847	ENSG00000258640.3	RPL21P5	3.44	0.000594	0.0284	0.13	0.11	Amyotrophic lateral sclerosis;	chr14:30590763	chr14:31111569~31112239:-
BRCA	cis	rs6496932	0.635	rs28559998	ENSG00000218052.5	ADAMTS7P4	-3.44	0.000594	0.0284	-0.11	-0.11	Central corneal thickness;Corneal structure;	chr15:85360605	chr15:85255369~85330334:-
BRCA	cis	rs6496932	0.635	rs8023859	ENSG00000218052.5	ADAMTS7P4	-3.44	0.000594	0.0284	-0.11	-0.11	Central corneal thickness;Corneal structure;	chr15:85361540	chr15:85255369~85330334:-
BRCA	cis	rs300890	1	rs300890	ENSG00000250326.1	RP11-284M14.1	-3.44	0.000594	0.0284	-0.12	-0.11	Nasopharyngeal carcinoma;	chr4:143328617	chr4:142933195~143184861:-
BRCA	cis	rs300890	1	rs300891	ENSG00000250326.1	RP11-284M14.1	-3.44	0.000594	0.0284	-0.12	-0.11	Nasopharyngeal carcinoma;	chr4:143329058	chr4:142933195~143184861:-
BRCA	cis	rs7037266	0.892	rs35433789	ENSG00000232946.1	RP11-390F4.2	-3.44	0.000594	0.0284	-0.13	-0.11	Menarche (age at onset);	chr9:6942910	chr9:6675284~6675614:+
BRCA	cis	rs3617	0.625	rs2240917	ENSG00000279144.1	RP11-894J14.2	3.44	0.000594	0.0284	0.13	0.11	Red blood cell count;Autism spectrum disorder or schizophrenia;	chr3:52817121	chr3:52848085~52848553:-
BRCA	cis	rs4795519	0.778	rs11080057	ENSG00000266527.1	RP11-138P22.1	3.44	0.000594	0.0284	0.13	0.11	Chronic myeloid leukemia;	chr17:27079757	chr17:27874645~27881237:+
BRCA	cis	rs4795519	0.677	rs3933803	ENSG00000266527.1	RP11-138P22.1	3.44	0.000594	0.0284	0.13	0.11	Chronic myeloid leukemia;	chr17:27081441	chr17:27874645~27881237:+
BRCA	cis	rs4388249	1	rs2284990	ENSG00000249068.1	CTC-287O8.1	3.44	0.000594	0.0284	0.15	0.11	Schizophrenia;	chr5:109743666	chr5:109840128~109840692:-
BRCA	cis	rs4388249	1	rs2300997	ENSG00000249068.1	CTC-287O8.1	3.44	0.000594	0.0284	0.15	0.11	Schizophrenia;	chr5:109746893	chr5:109840128~109840692:-
BRCA	cis	rs478304	0.654	rs12289836	ENSG00000255320.1	RP11-755F10.1	-3.44	0.000594	0.0284	-0.14	-0.11	Acne (severe);	chr11:65669417	chr11:66244840~66246239:-
BRCA	cis	rs10792665	0.724	rs10898068	ENSG00000246067.6	RAB30-AS1	-3.44	0.000594	0.0284	-0.11	-0.11	Obesity-related traits;	chr11:82999847	chr11:83072066~83106719:+
BRCA	cis	rs253959	0.545	rs712600	ENSG00000271918.1	CTD-2287O16.5	-3.44	0.000594	0.0284	-0.09	-0.11	Bipolar disorder and schizophrenia;	chr5:116323198	chr5:116083807~116085416:-
BRCA	cis	rs10043228	1	rs7727882	ENSG00000248445.4	SEMA6A-AS1	-3.44	0.000594	0.0284	-0.15	-0.11	Asthma or chronic obstructive pulmonary disease;	chr5:116278810	chr5:116447547~116508276:+
BRCA	cis	rs9368481	0.761	rs7775041	ENSG00000224843.5	LINC00240	3.44	0.000594	0.0284	0.13	0.11	Autism spectrum disorder or schizophrenia;	chr6:27041733	chr6:26956992~27023924:+
BRCA	cis	rs8105895	0.867	rs62111037	ENSG00000269345.1	VN1R85P	3.44	0.000594	0.0284	0.17	0.11	Body mass index (change over time);	chr19:22103761	chr19:22174766~22175191:-
BRCA	cis	rs8105895	0.935	rs7254050	ENSG00000269345.1	VN1R85P	3.44	0.000594	0.0284	0.17	0.11	Body mass index (change over time);	chr19:22103939	chr19:22174766~22175191:-
BRCA	cis	rs1979679	0.686	rs4348940	ENSG00000244712.1	RP11-874G11.1	3.44	0.000594	0.0284	0.17	0.11	Ossification of the posterior longitudinal ligament of the spine;	chr12:28437804	chr12:28564678~28565141:-
BRCA	cis	rs910873	1	rs910873	ENSG00000250917.1	RP4-785G19.5	-3.44	0.000595	0.0284	-0.3	-0.11	Melanoma;	chr20:34583968	chr20:34234840~34281173:-
BRCA	cis	rs875971	0.54	rs1723268	ENSG00000272831.1	RP11-792A8.4	3.44	0.000595	0.0284	0.1	0.11	Aortic root size;	chr7:66008093	chr7:66739829~66740385:-
BRCA	cis	rs10844706	1	rs10844706	ENSG00000278635.1	CTD-2318O12.1	-3.44	0.000595	0.0284	-0.11	-0.11	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9757536	chr12:9415641~9416718:+
BRCA	cis	rs10876993	0.928	rs2169988	ENSG00000269903.1	RP11-571M6.18	3.44	0.000595	0.0285	0.13	0.11	Celiac disease or Rheumatoid arthritis;	chr12:57677382	chr12:57814494~57814926:+
BRCA	cis	rs17784882	0.521	rs11713693	ENSG00000271161.1	BOLA2P2	-3.44	0.000595	0.0285	-0.12	-0.11	QT interval;	chr3:47033416	chr3:47499841~47500407:+
BRCA	cis	rs7914558	0.901	rs35525740	ENSG00000213277.3	MARCKSL1P1	3.44	0.000595	0.0285	0.12	0.11	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103181355	chr10:103175554~103176094:+
BRCA	cis	rs7914558	0.869	rs10883842	ENSG00000213277.3	MARCKSL1P1	3.44	0.000595	0.0285	0.12	0.11	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103181832	chr10:103175554~103176094:+
BRCA	cis	rs7267979	0.527	rs6083891	ENSG00000274973.1	RP13-401N8.7	3.44	0.000595	0.0285	0.12	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25593636	chr20:25845497~25845862:+
BRCA	cis	rs9807841	0.643	rs4435370	ENSG00000267100.1	ILF3-AS1	3.44	0.000595	0.0285	0.11	0.11	Inflammatory skin disease;	chr19:10663947	chr19:10651862~10653844:-
BRCA	cis	rs6005807	0.719	rs2881496	ENSG00000272858.1	CTA-292E10.8	3.44	0.000595	0.0285	0.18	0.11	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28525277	chr22:28814914~28815662:+
BRCA	cis	rs9341808	0.727	rs1324120	ENSG00000279022.1	RP11-250B2.4	3.44	0.000595	0.0285	0.12	0.11	Sitting height ratio;	chr6:80266408	chr6:80440730~80441172:+
BRCA	cis	rs2904967	0.568	rs2904966	ENSG00000254501.1	AP003068.9	3.44	0.000595	0.0285	0.2	0.11	Mean corpuscular volume;	chr11:65323256	chr11:65110714~65111695:-
BRCA	cis	rs709400	0.659	rs7160366	ENSG00000258851.1	RP11-894P9.2	-3.44	0.000595	0.0285	-0.13	-0.11	Body mass index;	chr14:103477800	chr14:103553421~103561877:+
BRCA	cis	rs6824218	1	rs6824218	ENSG00000270720.1	RP11-84C13.2	3.44	0.000595	0.0285	0.12	0.11	Post bronchodilator FEV1;	chr4:88919919	chr4:89119284~89119871:+
BRCA	cis	rs7208859	0.524	rs73988172	ENSG00000276250.1	CTD-2349P21.12	-3.44	0.000595	0.0285	-0.16	-0.11	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759314	chr17:30803654~30804077:+
BRCA	cis	rs2243480	0.901	rs2456483	ENSG00000226767.1	RP11-328P23.3	-3.44	0.000595	0.0285	-0.18	-0.11	Diabetic kidney disease;	chr7:65996588	chr7:65508773~65508944:-
BRCA	cis	rs2243480	1	rs1701750	ENSG00000226767.1	RP11-328P23.3	-3.44	0.000595	0.0285	-0.18	-0.11	Diabetic kidney disease;	chr7:66002158	chr7:65508773~65508944:-
BRCA	cis	rs875971	0.862	rs6955837	ENSG00000271064.1	RP11-792A8.3	3.44	0.000595	0.0285	0.13	0.11	Aortic root size;	chr7:66578155	chr7:66748838~66749077:-
BRCA	cis	rs853679	0.517	rs9393896	ENSG00000226314.6	ZNF192P1	-3.44	0.000595	0.0285	-0.16	-0.11	Depression;	chr6:28159925	chr6:28161781~28169594:+
BRCA	cis	rs853679	0.517	rs9393897	ENSG00000226314.6	ZNF192P1	-3.44	0.000595	0.0285	-0.16	-0.11	Depression;	chr6:28159932	chr6:28161781~28169594:+
BRCA	cis	rs889312	0.5	rs866223	ENSG00000271828.1	CTD-2310F14.1	-3.44	0.000595	0.0285	-0.13	-0.11	Breast cancer (early onset);Breast cancer;	chr5:56829526	chr5:56927874~56929573:+
BRCA	cis	rs860295	0.676	rs11264374	ENSG00000236675.1	MTX1P1	-3.44	0.000595	0.0285	-0.13	-0.11	Body mass index;	chr1:155451721	chr1:155230975~155234325:+
BRCA	cis	rs7615952	0.543	rs4645102	ENSG00000241288.6	RP11-379B18.5	-3.44	0.000595	0.0285	-0.13	-0.11	Blood pressure (smoking interaction);	chr3:125705597	chr3:125827238~125916384:-
BRCA	cis	rs863345	0.625	rs6663286	ENSG00000229914.1	RP11-404O13.4	-3.44	0.000595	0.0285	-0.11	-0.11	Pneumococcal bacteremia;	chr1:158503935	chr1:158195633~158196131:-
BRCA	cis	rs10844706	0.699	rs11052752	ENSG00000278635.1	CTD-2318O12.1	-3.44	0.000595	0.0285	-0.12	-0.11	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9735222	chr12:9415641~9416718:+
BRCA	cis	rs2274273	1	rs7140872	ENSG00000233924.1	AL160471.6	-3.44	0.000595	0.0285	-0.12	-0.11	Protein biomarker;	chr14:55146026	chr14:55004813~55005687:-
BRCA	cis	rs1865760	1	rs3830057	ENSG00000272810.1	U91328.22	-3.44	0.000595	0.0285	-0.12	-0.11	Height;	chr6:25918282	chr6:26013241~26013757:+
BRCA	cis	rs4950322	0.57	rs4593887	ENSG00000237188.3	RP11-337C18.8	3.44	0.000595	0.0285	0.13	0.11	Protein quantitative trait loci;	chr1:147234246	chr1:147172771~147211568:+
BRCA	cis	rs16849225	0.526	rs11691032	ENSG00000206869.1	SNORA70F	-3.44	0.000596	0.0285	-0.13	-0.11	Systolic blood pressure;Blood pressure;	chr2:163932003	chr2:164687643~164687777:-
BRCA	cis	rs7695732	0.752	rs1849597	ENSG00000270720.1	RP11-84C13.2	-3.44	0.000596	0.0285	-0.14	-0.11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr4:89013399	chr4:89119284~89119871:+
BRCA	cis	rs17201317	0.609	rs6983904	ENSG00000207399.1	RNU6-1011P	3.44	0.000596	0.0285	0.15	0.11	Small vessel stroke;	chr8:103106319	chr8:103384961~103385067:+
BRCA	cis	rs7404928	0.557	rs195990	ENSG00000260136.4	CTD-2270L9.4	-3.44	0.000596	0.0285	-0.09	-0.11	Rheumatoid arthritis;Primary biliary cholangitis;	chr16:23935064	chr16:23452758~23457606:+
BRCA	cis	rs8073060	0.586	rs4795086	ENSG00000267554.1	RP11-686D22.10	3.44	0.000596	0.0285	0.11	0.11	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35715171	chr17:35470069~35470628:-
BRCA	cis	rs10739695	0.51	rs10819309	ENSG00000273186.1	RP11-339B21.10	3.44	0.000596	0.0285	0.13	0.11	Monocyte percentage of white cells;	chr9:127819444	chr9:128431598~128432006:+
BRCA	cis	rs7208859	0.673	rs2269915	ENSG00000264538.5	SUZ12P1	-3.44	0.000596	0.0285	-0.16	-0.11	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30906326	chr17:30709299~30790908:+
BRCA	cis	rs7208859	0.673	rs2269916	ENSG00000264538.5	SUZ12P1	-3.44	0.000596	0.0285	-0.16	-0.11	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30906745	chr17:30709299~30790908:+
BRCA	cis	rs7208859	0.673	rs11649765	ENSG00000264538.5	SUZ12P1	-3.44	0.000596	0.0285	-0.16	-0.11	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30906870	chr17:30709299~30790908:+
BRCA	cis	rs7773456	0.74	rs4140625	ENSG00000217379.2	RP11-254A17.1	3.44	0.000596	0.0285	0.12	0.11	Lupus nephritis in systemic lupus erythematosus;	chr6:19818109	chr6:19143695~19144160:+
BRCA	cis	rs6088590	0.687	rs6088580	ENSG00000276073.1	RP5-1125A11.7	-3.44	0.000596	0.0285	-0.12	-0.11	Coronary artery disease;	chr20:34697249	chr20:33985617~33988989:-
BRCA	cis	rs6088590	0.813	rs1884668	ENSG00000276073.1	RP5-1125A11.7	-3.44	0.000596	0.0285	-0.12	-0.11	Coronary artery disease;	chr20:34697710	chr20:33985617~33988989:-
BRCA	cis	rs17685	0.884	rs6978677	ENSG00000205485.12	AC004980.7	-3.44	0.000596	0.0285	-0.12	-0.11	Coffee consumption (cups per day);Coffee consumption;	chr7:76006922	chr7:76549360~76627982:+
BRCA	cis	rs739496	0.947	rs28362508	ENSG00000257624.1	RP1-128M12.3	3.44	0.000596	0.0285	0.15	0.11	Platelet count;	chr12:111446611	chr12:112000739~112000985:-
BRCA	cis	rs3764021	0.527	rs10844503	ENSG00000278635.1	CTD-2318O12.1	-3.44	0.000596	0.0285	-0.12	-0.11	Type 1 diabetes;	chr12:9701660	chr12:9415641~9416718:+
BRCA	cis	rs2991971	0.901	rs11211122	ENSG00000281133.1	AL355480.3	3.44	0.000596	0.0285	0.13	0.11	High light scatter reticulocyte count;	chr1:45488978	chr1:45580892~45580996:-
BRCA	cis	rs6121246	0.954	rs7266148	ENSG00000230613.1	HM13-AS1	3.44	0.000596	0.0285	0.16	0.11	Mean corpuscular hemoglobin;	chr20:31843267	chr20:31567707~31573263:-
BRCA	cis	rs875971	0.862	rs4718319	ENSG00000223473.2	GS1-124K5.3	-3.44	0.000596	0.0285	-0.08	-0.11	Aortic root size;	chr7:66187797	chr7:66491049~66493566:-
BRCA	cis	rs875971	0.723	rs28391294	ENSG00000223473.2	GS1-124K5.3	-3.44	0.000596	0.0285	-0.08	-0.11	Aortic root size;	chr7:66189328	chr7:66491049~66493566:-
BRCA	cis	rs875971	0.83	rs6967708	ENSG00000223473.2	GS1-124K5.3	-3.44	0.000596	0.0285	-0.08	-0.11	Aortic root size;	chr7:66192326	chr7:66491049~66493566:-
BRCA	cis	rs875971	0.895	rs7782806	ENSG00000223473.2	GS1-124K5.3	-3.44	0.000596	0.0285	-0.08	-0.11	Aortic root size;	chr7:66192910	chr7:66491049~66493566:-
BRCA	cis	rs7267979	1	rs6115153	ENSG00000231081.1	RP4-760C5.3	3.44	0.000596	0.0285	0.14	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25344931	chr20:26008791~26010531:-
BRCA	cis	rs6430585	0.527	rs59413285	ENSG00000231890.6	DARS-AS1	-3.44	0.000596	0.0285	-0.16	-0.11	Corneal structure;	chr2:135686615	chr2:135985176~136022593:+
BRCA	cis	rs6430585	0.527	rs62168833	ENSG00000231890.6	DARS-AS1	-3.44	0.000596	0.0285	-0.16	-0.11	Corneal structure;	chr2:135691684	chr2:135985176~136022593:+
BRCA	cis	rs875971	0.964	rs12668936	ENSG00000273024.4	INTS4P2	-3.44	0.000596	0.0285	-0.12	-0.11	Aortic root size;	chr7:66449417	chr7:65647864~65715661:+
BRCA	cis	rs2288327	0.818	rs16866373	ENSG00000271011.1	RP11-171I2.5	3.44	0.000596	0.0285	0.2	0.11	Atrial fibrillation;	chr2:178527353	chr2:178577103~178577622:+
BRCA	cis	rs9374013	0.564	rs77674548	ENSG00000271734.1	RP1-111B22.3	-3.44	0.000596	0.0285	-0.14	-0.11	Major depressive disorder;	chr6:108031475	chr6:108030249~108030718:-
BRCA	cis	rs13401620	0.827	rs55824303	ENSG00000229326.3	AC069154.4	-3.44	0.000596	0.0285	-0.15	-0.11	Breast size;	chr2:119845977	chr2:119698623~119700151:+
BRCA	cis	rs7267979	0.744	rs6050463	ENSG00000204556.4	CTD-2514C3.1	-3.44	0.000596	0.0285	-0.14	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25228354	chr20:26018832~26020684:+
BRCA	cis	rs6696239	0.513	rs4653853	ENSG00000227711.2	RP11-275O4.5	3.44	0.000596	0.0285	0.12	0.11	Height;	chr1:227563901	chr1:227509028~227520477:-
BRCA	cis	rs4925540	0.928	rs10924895	ENSG00000215796.3	RP11-551G24.2	-3.44	0.000596	0.0285	-0.13	-0.11	Response to taxane treatment (docetaxel);	chr1:247033301	chr1:247042791~247044021:+
BRCA	cis	rs11642862	1	rs74483355	ENSG00000260082.1	RP11-2C24.5	-3.44	0.000596	0.0285	-0.2	-0.11	Tonsillectomy;	chr16:30825109	chr16:30821068~30822110:-
BRCA	cis	rs7299940	0.967	rs10848243	ENSG00000256299.1	RP11-989F5.3	-3.44	0.000596	0.0285	-0.11	-0.11	Panic disorder;	chr12:130894769	chr12:130810821~130812622:-
BRCA	cis	rs6088580	0.668	rs1205340	ENSG00000275784.1	RP5-1125A11.6	3.44	0.000596	0.0285	0.11	0.11	Glomerular filtration rate (creatinine);	chr20:34336065	chr20:33989480~33991818:-
BRCA	cis	rs948562	0.657	rs11229574	ENSG00000255299.4	RP11-655C2.3	-3.44	0.000596	0.0285	-0.13	-0.11	Lymphoma;	chr11:58667837	chr11:58497888~58505758:-
BRCA	cis	rs72928364	1	rs73143088	ENSG00000244119.1	PDCL3P4	3.44	0.000596	0.0285	0.13	0.11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100953743	chr3:101712472~101713191:+
BRCA	cis	rs801193	1	rs7782320	ENSG00000275400.1	RP4-756H11.5	-3.44	0.000597	0.0285	-0.12	-0.11	Aortic root size;	chr7:66712111	chr7:66553805~66554199:-
BRCA	cis	rs4819052	0.851	rs28622522	ENSG00000223768.1	LINC00205	-3.44	0.000597	0.0285	-0.14	-0.11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45256684	chr21:45293285~45297354:+
BRCA	cis	rs745109	0.882	rs1030887	ENSG00000273080.1	RP11-301O19.1	3.44	0.000597	0.0285	0.16	0.11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86528529	chr2:86195590~86196049:+
BRCA	cis	rs4657482	0.606	rs4657490	ENSG00000236364.3	RP11-525G13.2	-3.44	0.000597	0.0285	-0.1	-0.11	Testicular germ cell tumor;	chr1:165900453	chr1:165890795~165900683:-
BRCA	cis	rs7201929	1	rs7201929	ENSG00000278665.1	RP11-666O2.4	3.44	0.000597	0.0285	0.12	0.11	QT interval;	chr16:28860645	chr16:28599241~28601881:-
BRCA	cis	rs1559040	0.932	rs28368466	ENSG00000233266.1	HMGB1P31	-3.44	0.000597	0.0285	-0.18	-0.11	Sudden cardiac arrest;	chr2:54061824	chr2:54051334~54051760:+
BRCA	cis	rs748404	0.666	rs35326382	ENSG00000166763.7	STRCP1	3.44	0.000597	0.0285	0.15	0.11	Lung cancer;	chr15:43338686	chr15:43699488~43718184:-
BRCA	cis	rs7254232	0.961	rs10853783	ENSG00000211513.4	MIR320E	-3.44	0.000597	0.0285	-0.13	-0.11	Chronic periodontitis;	chr19:47289867	chr19:46709271~46709382:-
BRCA	cis	rs952623	0.501	rs12670003	ENSG00000211694.2	TRGV10	3.44	0.000597	0.0285	0.09	0.11	Intelligence (multi-trait analysis);	chr7:39044053	chr7:38299811~38300322:-
BRCA	cis	rs4934494	0.727	rs67827533	ENSG00000232229.4	LINC00865	-3.44	0.000597	0.0285	-0.16	-0.11	Red blood cell count;	chr10:89745626	chr10:89829510~89840861:+
BRCA	cis	rs11239930	0.517	rs685741	ENSG00000237188.3	RP11-337C18.8	3.44	0.000597	0.0285	0.12	0.11	AIDS progression;	chr1:147074503	chr1:147172771~147211568:+
BRCA	cis	rs4449834	0.81	rs10109193	ENSG00000254432.1	RP11-33I11.2	-3.44	0.000597	0.0285	-0.14	-0.11	Sum eosinophil basophil counts;	chr8:60798925	chr8:60808735~60809606:-
BRCA	cis	rs4699052	0.928	rs2126473	ENSG00000230069.3	LRRC37A15P	-3.44	0.000597	0.0285	-0.1	-0.11	Testicular germ cell tumor;	chr4:103220376	chr4:102727274~102730721:-
BRCA	cis	rs4699052	0.963	rs6816055	ENSG00000230069.3	LRRC37A15P	-3.44	0.000597	0.0285	-0.1	-0.11	Testicular germ cell tumor;	chr4:103222003	chr4:102727274~102730721:-
BRCA	cis	rs12612619	0.579	rs6753540	ENSG00000229122.1	AGBL5-IT1	-3.44	0.000597	0.0285	-0.11	-0.11	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:26857266	chr2:27061038~27061815:+
BRCA	cis	rs7703051	0.833	rs2878417	ENSG00000271815.1	CTD-2235C13.3	-3.44	0.000597	0.0285	-0.13	-0.11	Age-related diseases, mortality and associated endophenotypes;LDL cholesterol;Age-related disease endophenotypes;	chr5:75321437	chr5:75363760~75364242:+
BRCA	cis	rs7200543	1	rs55727637	ENSG00000270580.4	PKD1P6	3.44	0.000597	0.0285	0.12	0.11	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15051395	chr16:15104723~15131601:-
BRCA	cis	rs1018697	0.966	rs11191396	ENSG00000236937.2	PTGES3P4	3.44	0.000597	0.0286	0.14	0.11	Colorectal adenoma (advanced);	chr10:102793108	chr10:102845595~102845950:+
BRCA	cis	rs490234	0.932	rs577026	ENSG00000232630.1	PRPS1P2	-3.44	0.000597	0.0286	-0.1	-0.11	Mean arterial pressure;	chr9:125578744	chr9:125150653~125151589:+
BRCA	cis	rs4415084	1	rs6871484	ENSG00000272335.1	RP11-53O19.3	3.44	0.000597	0.0286	0.1	0.11	Breast cancer;	chr5:44676203	chr5:44826076~44828592:+
BRCA	cis	rs11239930	0.538	rs630630	ENSG00000227242.3	NBPF13P	-3.44	0.000597	0.0286	-0.13	-0.11	AIDS progression;	chr1:147080377	chr1:147021320~147124525:-
BRCA	cis	rs11239930	0.538	rs618575	ENSG00000227242.3	NBPF13P	-3.44	0.000597	0.0286	-0.13	-0.11	AIDS progression;	chr1:147080759	chr1:147021320~147124525:-
BRCA	cis	rs7048146	0.899	rs4595205	ENSG00000213539.4	YBX1P6	3.44	0.000597	0.0286	0.12	0.11	Vascular brain injury;	chr9:109575965	chr9:109532830~109534332:-
BRCA	cis	rs4662592	0.522	rs10928812	ENSG00000229758.2	DYNLT3P2	-3.44	0.000597	0.0286	-0.13	-0.11	Antipsychotic drug-induced QTc interval change in schizophrenia;	chr2:128211888	chr2:128199901~128200195:+
BRCA	cis	rs3735485	0.76	rs10232306	ENSG00000201772.1	SNORA5C	-3.44	0.000597	0.0286	-0.14	-0.11	White blood cell count;Sum basophil neutrophil counts;Neutrophil count;Granulocyte percentage of myeloid white cells;Monocyte percentage of white cells;Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Lymphocyte counts;	chr7:44987137	chr7:45104906~45105042:-
BRCA	cis	rs3735485	0.8	rs1859489	ENSG00000201772.1	SNORA5C	-3.44	0.000597	0.0286	-0.14	-0.11	White blood cell count;Sum basophil neutrophil counts;Neutrophil count;Granulocyte percentage of myeloid white cells;Monocyte percentage of white cells;Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Lymphocyte counts;	chr7:44988209	chr7:45104906~45105042:-
BRCA	cis	rs62103177	0.525	rs8086024	ENSG00000278075.1	RP11-248M19.1	-3.44	0.000597	0.0286	-0.17	-0.11	Opioid sensitivity;	chr18:79986623	chr18:79900555~79900903:-
BRCA	cis	rs4699052	0.963	rs11097801	ENSG00000230069.3	LRRC37A15P	-3.44	0.000598	0.0286	-0.1	-0.11	Testicular germ cell tumor;	chr4:103229166	chr4:102727274~102730721:-
BRCA	cis	rs62458065	0.64	rs4141788	ENSG00000229358.3	DPY19L1P1	-3.44	0.000598	0.0286	-0.15	-0.11	Metabolite levels (HVA/MHPG ratio);	chr7:32479652	chr7:32580949~32761787:-
BRCA	cis	rs11992162	0.591	rs35657308	ENSG00000154316.13	TDH	3.44	0.000598	0.0286	0.13	0.11	Monocyte count;	chr8:11946893	chr8:11339637~11368452:+
BRCA	cis	rs6918586	1	rs6918586	ENSG00000216331.1	HIST1H1PS1	3.44	0.000598	0.0286	0.14	0.11	Schizophrenia;	chr6:26097156	chr6:26195566~26195771:+
BRCA	cis	rs875971	0.83	rs778715	ENSG00000265600.1	AC006480.1	-3.44	0.000598	0.0286	-0.13	-0.11	Aortic root size;	chr7:66384222	chr7:67356680~67356779:+
BRCA	cis	rs898097	0.625	rs2125479	ENSG00000263063.1	RP11-388C12.1	-3.44	0.000598	0.0286	-0.11	-0.11	Breast cancer;	chr17:82932386	chr17:82713908~82716255:-
BRCA	cis	rs6088590	1	rs3787222	ENSG00000276073.1	RP5-1125A11.7	-3.44	0.000598	0.0286	-0.12	-0.11	Coronary artery disease;	chr20:34745236	chr20:33985617~33988989:-
BRCA	cis	rs4664293	0.51	rs890096	ENSG00000230783.1	AC009961.2	3.44	0.000598	0.0286	0.13	0.11	Monocyte percentage of white cells;	chr2:159604849	chr2:159689217~159690291:-
BRCA	cis	rs12282928	0.7	rs2047815	ENSG00000255197.4	RP11-750H9.5	-3.44	0.000598	0.0286	-0.1	-0.11	Migraine - clinic-based;	chr11:48178345	chr11:47383148~47409190:-
BRCA	cis	rs910316	0.967	rs175451	ENSG00000259138.1	RP11-950C14.7	-3.44	0.000598	0.0286	-0.11	-0.11	Height;	chr14:75123026	chr14:75127153~75136930:+
BRCA	cis	rs7020830	0.825	rs13297152	ENSG00000260100.1	RP11-220I1.5	-3.44	0.000598	0.0286	-0.13	-0.11	Schizophrenia;	chr9:37075626	chr9:37078813~37079776:-
BRCA	cis	rs28489187	0.643	rs2011825	ENSG00000223653.4	RP11-131L23.1	3.44	0.000598	0.0286	0.12	0.11	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85378988	chr1:85276715~85448124:+
BRCA	cis	rs11673344	0.764	rs569371	ENSG00000267682.1	CTD-3220F14.2	-3.44	0.000598	0.0286	-0.09	-0.11	Obesity-related traits;	chr19:36963095	chr19:37337236~37337743:+
BRCA	cis	rs713477	0.505	rs9635232	ENSG00000186615.9	KTN1-AS1	-3.44	0.000598	0.0286	-0.13	-0.11	Pediatric bone mineral content (femoral neck);	chr14:55421162	chr14:55499278~55580110:-
BRCA	cis	rs875971	0.862	rs6947339	ENSG00000106610.13	STAG3L4	-3.44	0.000598	0.0286	-0.14	-0.11	Aortic root size;	chr7:66423483	chr7:67302621~67321526:+
BRCA	cis	rs12282928	0.699	rs4752916	ENSG00000255197.4	RP11-750H9.5	-3.44	0.000598	0.0286	-0.1	-0.11	Migraine - clinic-based;	chr11:48207236	chr11:47383148~47409190:-
BRCA	cis	rs6964587	0.869	rs406	ENSG00000188693.7	CYP51A1-AS1	3.44	0.000598	0.0286	0.12	0.11	Breast cancer;	chr7:91917212	chr7:92134604~92180725:+
BRCA	cis	rs12906542	0.516	rs76398134	ENSG00000259792.1	RP11-114H24.6	-3.44	0.000598	0.0286	-0.16	-0.11	Breast cancer;	chr15:77996385	chr15:77993405~77995289:+
BRCA	cis	rs1950832	0.723	rs12323457	ENSG00000258636.1	CTD-2298J14.2	-3.44	0.000598	0.0286	-0.12	-0.11	Urate levels in obese individuals;	chr14:41703150	chr14:41587861~41604856:-
BRCA	cis	rs9863	0.804	rs80270210	ENSG00000270028.1	RP11-380L11.4	3.44	0.000598	0.0286	0.14	0.11	White blood cell count;	chr12:123962850	chr12:123925461~123926083:-
BRCA	cis	rs2839186	0.967	rs9637172	ENSG00000215424.8	MCM3AP-AS1	3.44	0.000598	0.0286	0.09	0.11	Testicular germ cell tumor;	chr21:46265873	chr21:46229217~46259390:+
BRCA	cis	rs6142102	0.961	rs4911407	ENSG00000206582.1	Y_RNA	-3.44	0.000598	0.0286	-0.13	-0.11	Skin pigmentation;	chr20:34095759	chr20:34526510~34526606:-
BRCA	cis	rs3015497	0.637	rs6572692	ENSG00000259113.1	RP11-406H23.2	3.44	0.000598	0.0286	0.12	0.11	Mean platelet volume;	chr14:50710021	chr14:50448807~50456742:+
BRCA	cis	rs6012564	0.806	rs4810903	ENSG00000230758.1	SNAP23P	-3.44	0.000598	0.0286	-0.12	-0.11	Anger;	chr20:48982668	chr20:49038357~49038602:-
BRCA	cis	rs4981053	0.644	rs2150324	ENSG00000259001.3	RPPH1	-3.44	0.000598	0.0286	-0.12	-0.11	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr14:20057674	chr14:20343048~20343685:-
BRCA	cis	rs6901317	1	rs6901317	ENSG00000231628.1	RP3-355L5.4	-3.44	0.000598	0.0286	-0.1	-0.11	Beard thickness;	chr6:105588276	chr6:105279016~105281755:+
BRCA	cis	rs9437689	0.966	rs12751774	ENSG00000235501.4	RP4-639F20.1	3.44	0.000598	0.0286	0.13	0.11	Phospholipid levels (plasma);	chr1:95082137	chr1:94927566~94963270:+
BRCA	cis	rs9467773	1	rs9461271	ENSG00000224843.5	LINC00240	-3.44	0.000599	0.0286	-0.12	-0.11	Intelligence (multi-trait analysis);	chr6:26554740	chr6:26956992~27023924:+
BRCA	cis	rs6943931	1	rs73079300	ENSG00000230658.1	KLHL7-AS1	-3.44	0.000599	0.0286	-0.14	-0.11	Diabetic kidney disease;	chr7:22376554	chr7:23101228~23105703:-
BRCA	cis	rs867371	0.929	rs1045508	ENSG00000276710.3	CSPG4P8	3.44	0.000599	0.0286	0.11	0.11	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82157565	chr15:82459472~82477258:+
BRCA	cis	rs2692947	0.726	rs13009727	ENSG00000232931.4	LINC00342	-3.44	0.000599	0.0286	-0.11	-0.11	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96104135	chr2:95807118~95816215:-
BRCA	cis	rs1878931	0.507	rs67218524	ENSG00000263280.1	LA16c-325D7.2	-3.44	0.000599	0.0286	-0.11	-0.11	Body mass index (adult);	chr16:3353057	chr16:2866348~2867618:-
BRCA	cis	rs56046484	0.956	rs35045545	ENSG00000259630.2	CTD-2262B20.1	-3.44	0.000599	0.0286	-0.18	-0.11	Testicular germ cell tumor;	chr15:85121720	chr15:85415228~85415633:+
BRCA	cis	rs9341808	0.718	rs9443734	ENSG00000279022.1	RP11-250B2.4	3.44	0.000599	0.0286	0.12	0.11	Sitting height ratio;	chr6:80110576	chr6:80440730~80441172:+
BRCA	cis	rs853679	0.55	rs1237875	ENSG00000261839.1	RP1-265C24.8	-3.44	0.000599	0.0286	-0.14	-0.11	Depression;	chr6:28205232	chr6:28136849~28139678:+
BRCA	cis	rs17213965	0.561	rs8048091	ENSG00000275910.1	RP11-680G24.6	-3.44	0.000599	0.0286	-0.14	-0.11	Waist-hip ratio;	chr16:15787633	chr16:15015828~15016390:-
BRCA	cis	rs2489715	0.7	rs2247391	ENSG00000185904.10	LINC00839	-3.44	0.000599	0.0286	-0.13	-0.11	Helix rolling;	chr10:42395290	chr10:42475543~42495336:+
BRCA	cis	rs4654783	0.521	rs59709264	ENSG00000271428.1	RP1-224A6.8	3.44	0.000599	0.0286	0.11	0.11	Endometriosis;	chr1:22122832	chr1:22068340~22068827:-
BRCA	cis	rs875971	1	rs2420820	ENSG00000229886.1	RP5-1132H15.3	-3.44	0.000599	0.0286	-0.12	-0.11	Aortic root size;	chr7:66626920	chr7:66025126~66031544:-
BRCA	cis	rs7620503	1	rs6808260	ENSG00000228561.2	RP11-114M1.1	3.44	0.000599	0.0286	0.12	0.11	Corneal structure;	chr3:177582044	chr3:177683627~177691250:+
BRCA	cis	rs62458065	1	rs6462363	ENSG00000273014.1	RP11-225B17.2	-3.44	0.000599	0.0286	-0.16	-0.11	Metabolite levels (HVA/MHPG ratio);	chr7:32425147	chr7:32758882~32759353:+
BRCA	cis	rs6545883	0.929	rs2694625	ENSG00000273302.1	RP11-493E12.2	-3.44	0.000599	0.0286	-0.1	-0.11	Tuberculosis;	chr2:61388920	chr2:61199979~61200769:+
BRCA	cis	rs853679	0.607	rs72846780	ENSG00000216901.1	AL022393.7	3.44	0.000599	0.0286	0.28	0.11	Depression;	chr6:28151277	chr6:28176188~28176674:+
BRCA	cis	rs853679	0.607	rs13205911	ENSG00000216901.1	AL022393.7	3.44	0.000599	0.0286	0.28	0.11	Depression;	chr6:28156336	chr6:28176188~28176674:+
BRCA	cis	rs853679	0.607	rs13197176	ENSG00000216901.1	AL022393.7	3.44	0.000599	0.0286	0.28	0.11	Depression;	chr6:28161454	chr6:28176188~28176674:+
BRCA	cis	rs853679	0.607	rs13201308	ENSG00000216901.1	AL022393.7	3.44	0.000599	0.0286	0.28	0.11	Depression;	chr6:28162311	chr6:28176188~28176674:+
BRCA	cis	rs853679	0.607	rs34505829	ENSG00000216901.1	AL022393.7	3.44	0.000599	0.0286	0.28	0.11	Depression;	chr6:28165461	chr6:28176188~28176674:+
BRCA	cis	rs853679	0.607	rs35098436	ENSG00000216901.1	AL022393.7	3.44	0.000599	0.0286	0.28	0.11	Depression;	chr6:28166443	chr6:28176188~28176674:+
BRCA	cis	rs853679	0.607	rs72846794	ENSG00000216901.1	AL022393.7	3.44	0.000599	0.0286	0.28	0.11	Depression;	chr6:28169721	chr6:28176188~28176674:+
BRCA	cis	rs853679	0.607	rs13217984	ENSG00000216901.1	AL022393.7	3.44	0.000599	0.0286	0.28	0.11	Depression;	chr6:28171932	chr6:28176188~28176674:+
BRCA	cis	rs853679	0.505	rs35781323	ENSG00000216901.1	AL022393.7	3.44	0.000599	0.0286	0.28	0.11	Depression;	chr6:28177054	chr6:28176188~28176674:+
BRCA	cis	rs11662721	0.938	rs11665314	ENSG00000264188.1	RP11-13N13.5	3.44	0.000599	0.0286	0.14	0.11	Phospholipid levels (plasma);	chr18:21664015	chr18:21661787~21662395:-
BRCA	cis	rs875971	0.862	rs801194	ENSG00000265600.1	AC006480.1	3.44	0.000599	0.0286	0.13	0.11	Aortic root size;	chr7:66563508	chr7:67356680~67356779:+
BRCA	cis	rs875971	0.862	rs6952182	ENSG00000223473.2	GS1-124K5.3	-3.44	0.000599	0.0286	-0.08	-0.11	Aortic root size;	chr7:66218330	chr7:66491049~66493566:-
BRCA	cis	rs4372836	0.729	rs10166861	ENSG00000226833.4	AC097724.3	3.44	0.000599	0.0286	0.12	0.11	Body mass index;	chr2:28838245	chr2:28708953~28736205:-
BRCA	cis	rs9346455	1	rs12055385	ENSG00000199094.2	MIR30C2	3.44	0.000599	0.0286	0.17	0.11	Antipsychotic drug-induced weight gain;Antipsychotic drug-induced weight gain (time interaction);	chr6:71287086	chr6:71376933~71377045:-
BRCA	cis	rs11035577	0.57	rs2861720	ENSG00000279675.1	RP11-454H19.2	3.44	0.000599	0.0286	0.16	0.11	Temperament (bipolar disorder);	chr11:39762285	chr11:40107244~40112599:-
BRCA	cis	rs34975555	0.803	rs2299598	ENSG00000254054.2	RP11-156K13.3	-3.44	0.000599	0.0286	-0.16	-0.11	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:17978890	chr8:17905756~17907887:+
BRCA	cis	rs13126694	0.71	rs6848159	ENSG00000251073.1	NUDT19P5	-3.44	0.000599	0.0286	-0.1	-0.11	Blood osmolality (transformed sodium);	chr4:158051130	chr4:158182825~158183393:+
BRCA	cis	rs67696533	0.6	rs6141745	ENSG00000235217.6	TSPY26P	-3.44	0.000599	0.0286	-0.13	-0.11	White blood cell count (basophil);Basophil percentage of granulocytes;Basophil percentage of white cells;	chr20:32521002	chr20:32186477~32190527:-
BRCA	cis	rs2562456	0.958	rs2562508	ENSG00000268555.1	RP11-678G14.3	-3.44	0.000599	0.0286	-0.14	-0.11	Pain;	chr19:21543479	chr19:21570822~21587322:-
BRCA	cis	rs8058578	0.887	rs28421305	ENSG00000280211.1	RP11-2C24.3	3.44	0.000599	0.0286	0.11	0.11	Multiple myeloma;	chr16:30826807	chr16:30773532~30776033:-
BRCA	cis	rs10744816	0.875	rs11614542	ENSG00000257817.1	RP4-601P9.2	-3.44	0.000599	0.0286	-0.13	-0.11	Obesity-related traits;	chr12:114283533	chr12:114713811~114767957:+
BRCA	cis	rs10744816	0.875	rs12813238	ENSG00000257817.1	RP4-601P9.2	-3.44	0.000599	0.0286	-0.13	-0.11	Obesity-related traits;	chr12:114284019	chr12:114713811~114767957:+
BRCA	cis	rs875971	0.54	rs4717275	ENSG00000272831.1	RP11-792A8.4	-3.44	6e-04	0.0286	-0.1	-0.11	Aortic root size;	chr7:65800193	chr7:66739829~66740385:-
BRCA	cis	rs80226907	0.708	rs77658582	ENSG00000258413.1	RP11-665C16.6	-3.44	6e-04	0.0286	-0.27	-0.11	Mean platelet volume;	chr14:55291663	chr14:55262767~55272075:-
BRCA	cis	rs80226907	1	rs80148613	ENSG00000258413.1	RP11-665C16.6	-3.44	6e-04	0.0286	-0.27	-0.11	Mean platelet volume;	chr14:55294534	chr14:55262767~55272075:-
BRCA	cis	rs80226907	1	rs113289681	ENSG00000258413.1	RP11-665C16.6	-3.44	6e-04	0.0286	-0.27	-0.11	Mean platelet volume;	chr14:55295265	chr14:55262767~55272075:-
BRCA	cis	rs6088580	0.524	rs6088569	ENSG00000261582.1	RP4-614O4.11	3.44	6e-04	0.0286	0.1	0.11	Glomerular filtration rate (creatinine);	chr20:34680395	chr20:35267885~35280043:-
BRCA	cis	rs977987	0.806	rs2285225	ENSG00000280152.1	RP11-331F4.5	-3.44	6e-04	0.0286	-0.11	-0.11	Dupuytren's disease;	chr16:75395354	chr16:75245994~75250077:-
BRCA	cis	rs7735319	0.688	rs62368019	ENSG00000249572.1	CTD-2203K17.1	3.44	6e-04	0.0287	0.16	0.11	Systolic blood pressure;	chr5:33167549	chr5:33424025~33440619:-
BRCA	cis	rs739496	0.615	rs4646777	ENSG00000257624.1	RP1-128M12.3	3.44	6e-04	0.0287	0.15	0.11	Platelet count;	chr12:111792232	chr12:112000739~112000985:-
BRCA	cis	rs6012953	1	rs6063533	ENSG00000231715.1	COX6CP2	-3.44	6e-04	0.0287	-0.11	-0.11	Vitiligo;	chr20:50542862	chr20:50479767~50479991:+
BRCA	cis	rs72772090	0.539	rs11741100	ENSG00000272109.1	CTD-2260A17.3	3.44	6e-04	0.0287	0.2	0.11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96777541	chr5:96804353~96806105:+
BRCA	cis	rs1005277	0.505	rs200931	ENSG00000273019.1	RP11-508N22.13	-3.44	6e-04	0.0287	-0.13	-0.11	Extrinsic epigenetic age acceleration;	chr10:37839506	chr10:38149968~38150293:+
BRCA	cis	rs7267979	0.966	rs6083855	ENSG00000231081.1	RP4-760C5.3	3.44	6e-04	0.0287	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25424482	chr20:26008791~26010531:-
BRCA	cis	rs7267979	1	rs4815426	ENSG00000231081.1	RP4-760C5.3	3.44	6e-04	0.0287	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25424550	chr20:26008791~26010531:-
BRCA	cis	rs853679	0.607	rs200489	ENSG00000241549.7	GUSBP2	3.44	6e-04	0.0287	0.19	0.11	Depression;	chr6:27830479	chr6:26871484~26956554:-
BRCA	cis	rs875971	0.965	rs6971509	ENSG00000271064.1	RP11-792A8.3	3.44	6e-04	0.0287	0.12	0.11	Aortic root size;	chr7:66249983	chr7:66748838~66749077:-
BRCA	cis	rs34792	0.853	rs1684546	ENSG00000258354.1	MIR3180-1	3.44	6e-04	0.0287	0.13	0.11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15466568	chr16:14909887~14911345:-
BRCA	cis	rs7267979	0.932	rs6138600	ENSG00000274414.1	RP5-965G21.4	-3.44	6e-04	0.0287	-0.12	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25540710	chr20:25239007~25245229:-
BRCA	cis	rs2638953	0.672	rs10843203	ENSG00000273989.1	RP11-425D17.2	-3.44	6e-04	0.0287	-0.16	-0.11	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28563555	chr12:28236227~28236828:+
BRCA	cis	rs875971	0.964	rs778723	ENSG00000272831.1	RP11-792A8.4	3.44	6e-04	0.0287	0.09	0.11	Aortic root size;	chr7:66364510	chr7:66739829~66740385:-
BRCA	cis	rs7165170	0.554	rs12903655	ENSG00000245479.2	LINC01585	-3.44	6e-04	0.0287	-0.14	-0.11	Crohn's disease;Inflammatory bowel disease;	chr15:90605398	chr15:90660234~90664967:+
BRCA	cis	rs40067	1	rs288164	ENSG00000272523.1	LINC01023	3.44	6e-04	0.0287	0.12	0.11	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr5:108023011	chr5:108727825~108728260:-
BRCA	cis	rs1878931	0.582	rs9635562	ENSG00000279568.1	RP11-20I23.5	3.44	6e-04	0.0287	0.11	0.11	Body mass index (adult);	chr16:3366689	chr16:2575628~2577373:-
BRCA	cis	rs2411233	1	rs12911831	ENSG00000259278.1	RP11-62C7.2	3.44	6e-04	0.0287	0.13	0.11	Platelet count;	chr15:38980022	chr15:39019233~39024918:+
BRCA	cis	rs2411233	0.935	rs13379944	ENSG00000259278.1	RP11-62C7.2	3.44	6e-04	0.0287	0.13	0.11	Platelet count;	chr15:38980256	chr15:39019233~39024918:+
BRCA	cis	rs2411233	0.967	rs12916430	ENSG00000259278.1	RP11-62C7.2	3.44	6e-04	0.0287	0.13	0.11	Platelet count;	chr15:38980337	chr15:39019233~39024918:+
BRCA	cis	rs2411233	1	rs12708392	ENSG00000259278.1	RP11-62C7.2	3.44	6e-04	0.0287	0.13	0.11	Platelet count;	chr15:38980363	chr15:39019233~39024918:+
BRCA	cis	rs875971	0.862	rs2420174	ENSG00000229886.1	RP5-1132H15.3	-3.44	0.000601	0.0287	-0.12	-0.11	Aortic root size;	chr7:66180374	chr7:66025126~66031544:-
BRCA	cis	rs875971	0.862	rs2420173	ENSG00000229886.1	RP5-1132H15.3	-3.44	0.000601	0.0287	-0.12	-0.11	Aortic root size;	chr7:66180412	chr7:66025126~66031544:-
BRCA	cis	rs2625529	0.652	rs2957736	ENSG00000261187.1	RP11-1007O24.2	3.44	0.000601	0.0287	0.11	0.11	Red blood cell count;	chr15:71973003	chr15:72465128~72466262:-
BRCA	cis	rs561341	1	rs501312	ENSG00000277511.1	CTD-2095E4.5	3.44	0.000601	0.0287	0.16	0.11	Hip circumference adjusted for BMI;	chr17:32002047	chr17:32127595~32128454:+
BRCA	cis	rs5167	0.743	rs57204168	ENSG00000214855.8	APOC1P1	3.44	0.000601	0.0287	0.13	0.11	Blood protein levels;	chr19:44993518	chr19:44926804~44931386:+
BRCA	cis	rs561341	0.941	rs72825736	ENSG00000277511.1	CTD-2095E4.5	3.44	0.000601	0.0287	0.16	0.11	Hip circumference adjusted for BMI;	chr17:32003267	chr17:32127595~32128454:+
BRCA	cis	rs67478160	0.643	rs34813623	ENSG00000269910.1	RP11-73M18.10	3.44	0.000601	0.0287	0.1	0.11	Schizophrenia;	chr14:103796957	chr14:103694516~103695050:-
BRCA	cis	rs67478160	0.608	rs34066659	ENSG00000269910.1	RP11-73M18.10	3.44	0.000601	0.0287	0.1	0.11	Schizophrenia;	chr14:103797090	chr14:103694516~103695050:-
BRCA	cis	rs8009147	1	rs8009147	ENSG00000269910.1	RP11-73M18.10	3.44	0.000601	0.0287	0.1	0.11	Autism spectrum disorder or schizophrenia;	chr14:103798325	chr14:103694516~103695050:-
BRCA	cis	rs67478160	0.643	rs7147171	ENSG00000269910.1	RP11-73M18.10	3.44	0.000601	0.0287	0.1	0.11	Schizophrenia;	chr14:103798520	chr14:103694516~103695050:-
BRCA	cis	rs490234	0.756	rs1398142	ENSG00000232630.1	PRPS1P2	-3.44	0.000601	0.0287	-0.1	-0.11	Mean arterial pressure;	chr9:125464433	chr9:125150653~125151589:+
BRCA	cis	rs6040449	0.887	rs726867	ENSG00000235036.4	RP5-1099D15.1	3.44	0.000601	0.0287	0.12	0.11	Relative hand skill;	chr20:11247049	chr20:10612861~10614229:-
BRCA	cis	rs9307551	0.645	rs7655446	ENSG00000250334.4	LINC00989	-3.44	0.000601	0.0287	-0.17	-0.11	Refractive error;	chr4:79499947	chr4:79492416~79576460:+
BRCA	cis	rs10838687	0.673	rs2290148	ENSG00000243802.2	RP11-390K5.1	3.44	0.000601	0.0287	0.15	0.11	Proinsulin levels;	chr11:47324594	chr11:47191181~47191542:-
BRCA	cis	rs2562456	0.833	rs2928211	ENSG00000240522.1	RPL7AP10	3.44	0.000601	0.0287	0.12	0.11	Pain;	chr19:21358495	chr19:21149648~21150438:-
BRCA	cis	rs2446066	0.872	rs3741651	ENSG00000270175.1	RP11-793H13.11	-3.44	0.000601	0.0287	-0.12	-0.11	Red blood cell count;	chr12:53383387	chr12:53500162~53500936:-
BRCA	cis	rs6545883	0.929	rs3821222	ENSG00000273302.1	RP11-493E12.2	3.44	0.000601	0.0287	0.1	0.11	Tuberculosis;	chr2:61486391	chr2:61199979~61200769:+
BRCA	cis	rs2562456	0.833	rs2562416	ENSG00000268117.1	VN1R84P	3.44	0.000601	0.0287	0.16	0.11	Pain;	chr19:21430609	chr19:21719801~21720035:-
BRCA	cis	rs4873772	0.773	rs10109113	ENSG00000253330.1	RP11-697N18.3	-3.44	0.000601	0.0287	-0.14	-0.11	Lobe attachment (rater-scored or self-reported);	chr8:47475519	chr8:47511034~47512141:-
BRCA	cis	rs875971	1	rs1540651	ENSG00000271064.1	RP11-792A8.3	3.44	0.000601	0.0287	0.12	0.11	Aortic root size;	chr7:66185134	chr7:66748838~66749077:-
BRCA	cis	rs875971	0.54	rs781152	ENSG00000232546.1	RP11-458F8.1	-3.44	0.000601	0.0287	-0.09	-0.11	Aortic root size;	chr7:66014585	chr7:66848496~66858136:+
BRCA	cis	rs17711722	0.727	rs781151	ENSG00000232546.1	RP11-458F8.1	-3.44	0.000601	0.0287	-0.09	-0.11	Calcium levels;	chr7:66014891	chr7:66848496~66858136:+
BRCA	cis	rs7267979	0.966	rs2500433	ENSG00000274414.1	RP5-965G21.4	3.44	0.000601	0.0287	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25315699	chr20:25239007~25245229:-
BRCA	cis	rs7267979	0.966	rs2482948	ENSG00000274414.1	RP5-965G21.4	3.44	0.000601	0.0287	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25315863	chr20:25239007~25245229:-
BRCA	cis	rs910316	0.737	rs2098251	ENSG00000259138.1	RP11-950C14.7	3.44	0.000602	0.0287	0.11	0.11	Height;	chr14:75025993	chr14:75127153~75136930:+
BRCA	cis	rs910316	0.664	rs2098252	ENSG00000259138.1	RP11-950C14.7	3.44	0.000602	0.0287	0.11	0.11	Height;	chr14:75026029	chr14:75127153~75136930:+
BRCA	cis	rs9951698	0.703	rs8088313	ENSG00000266969.1	RP11-773H22.4	3.44	0.000602	0.0287	0.14	0.11	Intelligence (multi-trait analysis);	chr18:12977207	chr18:12984694~12991173:-
BRCA	cis	rs801193	0.569	rs11761542	ENSG00000271064.1	RP11-792A8.3	-3.44	0.000602	0.0287	-0.13	-0.11	Aortic root size;	chr7:66753209	chr7:66748838~66749077:-
BRCA	cis	rs10911902	0.643	rs16825150	ENSG00000229739.2	RP11-295K2.3	-3.44	0.000602	0.0287	-0.15	-0.11	Schizophrenia;	chr1:186306628	chr1:186435161~186470291:+
BRCA	cis	rs7267979	0.789	rs2260197	ENSG00000274414.1	RP5-965G21.4	-3.44	0.000602	0.0287	-0.13	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25303707	chr20:25239007~25245229:-
BRCA	cis	rs13136331	0.68	rs2732171	ENSG00000249001.4	RP11-742B18.1	3.44	0.000602	0.0287	0.14	0.11	Sitting height ratio;	chr4:87734832	chr4:87568035~87733956:-
BRCA	cis	rs62025270	0.688	rs7182210	ENSG00000259367.1	RP11-815J21.4	3.44	0.000602	0.0287	0.1	0.11	Idiopathic pulmonary fibrosis;	chr15:85722551	chr15:85619623~85670948:-
BRCA	cis	rs10760158	0.8	rs10818525	ENSG00000235865.2	GSN-AS1	3.44	0.000602	0.0287	0.09	0.11	Pulse pressure;	chr9:121289999	chr9:121280768~121285530:-
BRCA	cis	rs4718428	0.705	rs13220977	ENSG00000229886.1	RP5-1132H15.3	-3.44	0.000602	0.0287	-0.13	-0.11	Corneal structure;	chr7:66872661	chr7:66025126~66031544:-
BRCA	cis	rs897984	0.609	rs12445650	ENSG00000260267.1	RP11-452L6.5	3.44	0.000602	0.0287	0.1	0.11	Dementia with Lewy bodies;	chr16:31033576	chr16:31456711~31459736:-
BRCA	cis	rs2243480	1	rs34933526	ENSG00000234585.5	CCT6P3	-3.44	0.000602	0.0288	-0.16	-0.11	Diabetic kidney disease;	chr7:65918212	chr7:65038354~65074713:+
BRCA	cis	rs2243480	1	rs6949812	ENSG00000234585.5	CCT6P3	-3.44	0.000602	0.0288	-0.16	-0.11	Diabetic kidney disease;	chr7:65922114	chr7:65038354~65074713:+
BRCA	cis	rs2243480	1	rs6970243	ENSG00000234585.5	CCT6P3	-3.44	0.000602	0.0288	-0.16	-0.11	Diabetic kidney disease;	chr7:65923503	chr7:65038354~65074713:+
BRCA	cis	rs2243480	0.708	rs35310401	ENSG00000234585.5	CCT6P3	-3.44	0.000602	0.0288	-0.16	-0.11	Diabetic kidney disease;	chr7:65925372	chr7:65038354~65074713:+
BRCA	cis	rs2243480	0.831	rs7806717	ENSG00000234585.5	CCT6P3	3.44	0.000602	0.0288	0.16	0.11	Diabetic kidney disease;	chr7:65928187	chr7:65038354~65074713:+
BRCA	cis	rs4631830	0.9	rs11006274	ENSG00000204177.9	BMS1P1	3.44	0.000602	0.0288	0.1	0.11	Prostate-specific antigen levels;	chr10:46055531	chr10:46786674~46811989:+
BRCA	cis	rs875971	0.895	rs10755833	ENSG00000272831.1	RP11-792A8.4	3.44	0.000602	0.0288	0.1	0.11	Aortic root size;	chr7:66448930	chr7:66739829~66740385:-
BRCA	cis	rs875971	0.895	rs1833495	ENSG00000272831.1	RP11-792A8.4	3.44	0.000602	0.0288	0.1	0.11	Aortic root size;	chr7:66456608	chr7:66739829~66740385:-
BRCA	cis	rs875971	0.964	rs6945032	ENSG00000272831.1	RP11-792A8.4	3.44	0.000602	0.0288	0.1	0.11	Aortic root size;	chr7:66457499	chr7:66739829~66740385:-
BRCA	cis	rs875971	0.929	rs12673810	ENSG00000272831.1	RP11-792A8.4	3.44	0.000602	0.0288	0.1	0.11	Aortic root size;	chr7:66458866	chr7:66739829~66740385:-
BRCA	cis	rs875971	1	rs6961155	ENSG00000272831.1	RP11-792A8.4	3.44	0.000602	0.0288	0.1	0.11	Aortic root size;	chr7:66468308	chr7:66739829~66740385:-
BRCA	cis	rs875971	1	rs7789768	ENSG00000272831.1	RP11-792A8.4	3.44	0.000602	0.0288	0.1	0.11	Aortic root size;	chr7:66473993	chr7:66739829~66740385:-
BRCA	cis	rs875971	1	rs1363055	ENSG00000272831.1	RP11-792A8.4	3.44	0.000602	0.0288	0.1	0.11	Aortic root size;	chr7:66478288	chr7:66739829~66740385:-
BRCA	cis	rs875971	0.964	rs9691480	ENSG00000272831.1	RP11-792A8.4	3.44	0.000602	0.0288	0.1	0.11	Aortic root size;	chr7:66479319	chr7:66739829~66740385:-
BRCA	cis	rs8054556	1	rs4787486	ENSG00000183604.13	SMG1P5	-3.44	0.000602	0.0288	-0.1	-0.11	Autism spectrum disorder or schizophrenia;	chr16:29966241	chr16:30267553~30335374:-
BRCA	cis	rs9437689	1	rs9437812	ENSG00000235501.4	RP4-639F20.1	3.44	0.000602	0.0288	0.13	0.11	Phospholipid levels (plasma);	chr1:95081509	chr1:94927566~94963270:+
BRCA	cis	rs603446	0.61	rs1263058	ENSG00000280143.1	AP000892.6	3.44	0.000602	0.0288	0.1	0.11	Triglycerides;	chr11:116704839	chr11:117204967~117210292:+
BRCA	cis	rs2562456	0.833	rs2562507	ENSG00000268119.4	CTD-2561J22.5	-3.44	0.000603	0.0288	-0.16	-0.11	Pain;	chr19:21543535	chr19:21444241~21463908:-
BRCA	cis	rs7618501	0.966	rs7372966	ENSG00000228008.1	CTD-2330K9.3	-3.44	0.000603	0.0288	-0.1	-0.11	Intelligence (multi-trait analysis);	chr3:49751536	chr3:49903845~49916937:+
BRCA	cis	rs4578769	0.681	rs72887615	ENSG00000273232.1	RP11-370A5.2	-3.44	0.000603	0.0288	-0.15	-0.11	Eosinophil percentage of white cells;	chr18:22928638	chr18:22882825~22883357:-
BRCA	cis	rs683257	0.852	rs9495861	ENSG00000234147.1	RP3-460G2.2	3.44	0.000603	0.0288	0.23	0.11	Facial emotion recognition (angry faces);	chr6:140900922	chr6:140845958~140852924:-
BRCA	cis	rs2148307	0.619	rs7069805	ENSG00000228339.1	AMD1P1	3.44	0.000603	0.0288	0.13	0.11	Photic sneeze reflex;	chr10:20769667	chr10:20350049~20351100:+
BRCA	cis	rs8054556	1	rs12921996	ENSG00000214725.6	CDIPT-AS1	-3.44	0.000603	0.0288	-0.13	-0.11	Autism spectrum disorder or schizophrenia;	chr16:30000297	chr16:29863593~29868053:+
BRCA	cis	rs863345	0.604	rs2873595	ENSG00000176320.2	RP11-404O13.5	-3.44	0.000603	0.0288	-0.11	-0.11	Pneumococcal bacteremia;	chr1:158538592	chr1:158197922~158203877:-
BRCA	cis	rs4499344	0.73	rs2545357	ENSG00000201388.1	SNORA68	3.44	0.000603	0.0288	0.12	0.11	Mean platelet volume;	chr19:32613704	chr19:32608337~32608469:-
BRCA	cis	rs2278034	0.578	rs881753	ENSG00000272792.1	RP11-141C7.4	3.44	0.000603	0.0288	0.13	0.11	Bronchopulmonary dysplasia;	chr3:195879899	chr3:195639990~195640460:+
BRCA	cis	rs848490	0.855	rs55860308	ENSG00000214293.7	APTR	3.44	0.000603	0.0288	0.13	0.11	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77616657	chr7:77657660~77696265:-
BRCA	cis	rs11098403	0.687	rs12646271	ENSG00000225892.3	RP11-384K6.2	-3.44	0.000603	0.0288	-0.1	-0.11	Schizophrenia;	chr4:117831480	chr4:118632274~118634759:+
BRCA	cis	rs7200786	0.692	rs7206912	ENSG00000274038.1	RP11-66H6.4	-3.44	0.000603	0.0288	-0.12	-0.11	Systemic lupus erythematosus;Multiple sclerosis;	chr16:11150801	chr16:11056556~11057034:+
BRCA	cis	rs2839186	0.559	rs2277826	ENSG00000215424.8	MCM3AP-AS1	-3.44	0.000603	0.0288	-0.1	-0.11	Testicular germ cell tumor;	chr21:46219578	chr21:46229217~46259390:+
BRCA	cis	rs983392	0.679	rs7930318	ENSG00000275344.1	MIR6503	3.44	0.000603	0.0288	0.11	0.11	Alzheimer's disease (late onset);	chr11:60265898	chr11:60209071~60209156:-
BRCA	cis	rs6500602	0.702	rs6500606	ENSG00000280063.1	RP11-295D4.3	-3.44	0.000603	0.0288	-0.08	-0.11	Schizophrenia;	chr16:4452513	chr16:4346694~4348648:-
BRCA	cis	rs62229266	0.835	rs998384	ENSG00000214914.3	RPL23AP3	3.44	0.000603	0.0288	0.13	0.11	Mitral valve prolapse;	chr21:36073228	chr21:36016079~36016546:-
BRCA	cis	rs58521262	0.932	rs56025038	ENSG00000268105.1	RP11-369G6.2	-3.44	0.000603	0.0288	-0.18	-0.11	Testicular germ cell tumor;	chr19:23037049	chr19:23125665~23128543:+
BRCA	cis	rs58521262	0.789	rs55925020	ENSG00000268105.1	RP11-369G6.2	-3.44	0.000603	0.0288	-0.18	-0.11	Testicular germ cell tumor;	chr19:22884778	chr19:23125665~23128543:+
BRCA	cis	rs2412819	0.571	rs2930531	ENSG00000201136.1	RNU6-353P	-3.44	0.000603	0.0288	-0.15	-0.11	Lung cancer;	chr15:43829372	chr15:43702363~43702470:+
BRCA	cis	rs13256369	0.851	rs11249890	ENSG00000254153.1	CTA-398F10.2	3.44	0.000603	0.0288	0.15	0.11	Obesity-related traits;	chr8:8707735	chr8:8456909~8461337:-
BRCA	cis	rs4449834	0.781	rs7836586	ENSG00000254432.1	RP11-33I11.2	-3.44	0.000603	0.0288	-0.14	-0.11	Sum eosinophil basophil counts;	chr8:60743131	chr8:60808735~60809606:-
BRCA	cis	rs11148252	0.846	rs7323666	ENSG00000272281.5	TPTE2P2	-3.44	0.000603	0.0288	-0.1	-0.11	Lewy body disease;	chr13:52431923	chr13:52219344~52334277:-
BRCA	cis	rs7188697	0.922	rs37053	ENSG00000276259.1	RP11-481J2.4	-3.44	0.000603	0.0288	-0.12	-0.11	QT interval;	chr16:58524803	chr16:58522970~58523842:+
BRCA	cis	rs375066	0.762	rs17713001	ENSG00000267191.1	RP11-15A1.2	3.44	0.000604	0.0288	0.14	0.11	Breast cancer;	chr19:43917073	chr19:43902001~43926545:+
BRCA	cis	rs375066	0.762	rs2284245	ENSG00000267191.1	RP11-15A1.2	3.44	0.000604	0.0288	0.14	0.11	Breast cancer;	chr19:43918437	chr19:43902001~43926545:+
BRCA	cis	rs875971	0.893	rs62465470	ENSG00000223473.2	GS1-124K5.3	-3.44	0.000604	0.0288	-0.08	-0.11	Aortic root size;	chr7:66136231	chr7:66491049~66493566:-
BRCA	cis	rs4372836	0.543	rs6747852	ENSG00000226833.4	AC097724.3	3.44	0.000604	0.0288	0.13	0.11	Body mass index;	chr2:28786974	chr2:28708953~28736205:-
BRCA	cis	rs10883723	0.668	rs12414407	ENSG00000213061.2	PFN1P11	3.44	0.000604	0.0288	0.14	0.11	Allergic disease (asthma, hay fever or eczema);	chr10:102627262	chr10:102838011~102845473:-
BRCA	cis	rs9467773	0.62	rs2101582	ENSG00000261353.1	CTA-14H9.5	-3.44	0.000604	0.0288	-0.11	-0.11	Intelligence (multi-trait analysis);	chr6:26622506	chr6:26527063~26527404:+
BRCA	cis	rs1865760	0.688	rs1436310	ENSG00000272462.2	U91328.19	-3.44	0.000604	0.0288	-0.13	-0.11	Height;	chr6:25969730	chr6:25992662~26001775:+
BRCA	cis	rs10792665	0.724	rs10898069	ENSG00000246067.6	RAB30-AS1	-3.44	0.000604	0.0288	-0.11	-0.11	Obesity-related traits;	chr11:83000167	chr11:83072066~83106719:+
BRCA	cis	rs71520386	0.632	rs10279864	ENSG00000179428.2	AC073072.5	3.44	0.000604	0.0288	0.12	0.11	Fibrinogen levels;	chr7:22824205	chr7:22725395~22727620:-
BRCA	cis	rs6600671	0.967	rs4844613	ENSG00000223345.3	HIST2H2BA	3.44	0.000604	0.0288	0.13	0.11	Hip geometry;	chr1:121431913	chr1:121108210~121117257:-
BRCA	cis	rs3755132	0.568	rs876718	ENSG00000214657.4	RP11-120J4.1	-3.44	0.000604	0.0288	-0.19	-0.11	Wilms tumor;	chr2:15668811	chr2:15869939~15870243:+
BRCA	cis	rs9341808	0.718	rs9448908	ENSG00000279022.1	RP11-250B2.4	3.44	0.000604	0.0288	0.12	0.11	Sitting height ratio;	chr6:80188352	chr6:80440730~80441172:+
BRCA	cis	rs875971	0.862	rs11763189	ENSG00000106610.13	STAG3L4	-3.44	0.000604	0.0288	-0.14	-0.11	Aortic root size;	chr7:66518542	chr7:67302621~67321526:+
BRCA	cis	rs818427	0.964	rs151976	ENSG00000279522.1	CTC-487M23.6	3.44	0.000604	0.0288	0.12	0.11	Total body bone mineral density;	chr5:112900751	chr5:112894933~112896531:+
BRCA	cis	rs10246939	0.579	rs13232651	ENSG00000270923.1	TAS2R6P	-3.44	0.000604	0.0288	-0.11	-0.11	Bitter taste perception;	chr7:141862624	chr7:141787815~141788640:+
BRCA	cis	rs13217239	0.574	rs9366680	ENSG00000124549.13	BTN2A3P	3.44	0.000604	0.0288	0.11	0.11	Schizophrenia;	chr6:27038344	chr6:26421391~26432383:+
BRCA	cis	rs875971	0.862	rs2909688	ENSG00000271064.1	RP11-792A8.3	-3.44	0.000604	0.0288	-0.13	-0.11	Aortic root size;	chr7:66376625	chr7:66748838~66749077:-
BRCA	cis	rs6088580	0.505	rs6141503	ENSG00000279253.1	RP4-614O4.13	3.44	0.000604	0.0288	0.12	0.11	Glomerular filtration rate (creatinine);	chr20:34686665	chr20:35262727~35264187:-
BRCA	cis	rs6102185	0.549	rs6029415	ENSG00000229771.2	RP4-644L1.2	-3.44	0.000604	0.0288	-0.13	-0.11	IgG glycosylation;	chr20:40889551	chr20:40696499~40698616:-
BRCA	cis	rs9346455	1	rs9342828	ENSG00000279289.1	RP3-331H24.6	3.44	0.000604	0.0288	0.17	0.11	Antipsychotic drug-induced weight gain;Antipsychotic drug-induced weight gain (time interaction);	chr6:71283954	chr6:71386852~71390829:-
BRCA	cis	rs1635	0.655	rs16893975	ENSG00000216901.1	AL022393.7	-3.44	0.000604	0.0288	-0.24	-0.11	Schizophrenia;	chr6:28334501	chr6:28176188~28176674:+
BRCA	cis	rs7520050	0.808	rs11211195	ENSG00000281133.1	AL355480.3	3.44	0.000604	0.0288	0.12	0.11	Reticulocyte count;Red blood cell count;	chr1:45816623	chr1:45580892~45580996:-
BRCA	cis	rs7520050	0.808	rs11211196	ENSG00000281133.1	AL355480.3	3.44	0.000604	0.0288	0.12	0.11	Reticulocyte count;Red blood cell count;	chr1:45816624	chr1:45580892~45580996:-
BRCA	cis	rs67766926	0.953	rs10185028	ENSG00000237522.1	NONOP2	-3.44	0.000604	0.0288	-0.11	-0.11	Inflammatory skin disease;	chr2:60891604	chr2:60936819~60938049:-
BRCA	cis	rs8023401	0.507	rs35026266	ENSG00000259705.1	RP11-227D13.1	3.44	0.000604	0.0288	0.12	0.11	Spherical equivalent (joint analysis main effects and education interaction);	chr15:48476847	chr15:48645951~48652016:+
BRCA	cis	rs7818688	0.697	rs3802191	ENSG00000253528.2	RP11-347C18.4	3.44	0.000604	0.0288	0.16	0.11	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94975356	chr8:94974573~94974853:-
BRCA	cis	rs897984	0.609	rs12445650	ENSG00000275263.1	RP11-1072A3.4	-3.44	0.000605	0.0288	-0.12	-0.11	Dementia with Lewy bodies;	chr16:31033576	chr16:30956872~30957199:-
BRCA	cis	rs2625529	0.668	rs8192431	ENSG00000260037.4	CTD-2524L6.3	-3.44	0.000605	0.0288	-0.15	-0.11	Red blood cell count;	chr15:72200011	chr15:71818396~71823384:+
BRCA	cis	rs315135	0.73	rs9668668	ENSG00000274979.1	RP11-1143G9.5	-3.44	0.000605	0.0288	-0.16	-0.11	Response to diuretic therapy;	chr12:69311076	chr12:69326574~69331882:-
BRCA	cis	rs7020830	0.861	rs13289001	ENSG00000230188.1	RP11-405L18.4	-3.44	0.000605	0.0288	-0.13	-0.11	Schizophrenia;	chr9:37311595	chr9:37490421~37490893:-
BRCA	cis	rs11008222	0.935	rs11008223	ENSG00000272381.1	RP11-192P3.4	3.44	0.000605	0.0288	0.13	0.11	Congenital left-sided heart lesions (maternal effect);	chr10:30754148	chr10:31187883~31261910:+
BRCA	cis	rs4950322	0.57	rs72691004	ENSG00000237188.3	RP11-337C18.8	3.44	0.000605	0.0288	0.13	0.11	Protein quantitative trait loci;	chr1:147234309	chr1:147172771~147211568:+
BRCA	cis	rs6545883	0.868	rs6752938	ENSG00000212978.6	AC016747.3	3.44	0.000605	0.0288	0.14	0.11	Tuberculosis;	chr2:61614453	chr2:61141592~61144969:-
BRCA	cis	rs73222236	0.825	rs9853387	ENSG00000239213.4	NCK1-AS1	3.44	0.000605	0.0288	0.12	0.11	Coronary artery disease;	chr3:136320146	chr3:136841726~136862054:-
BRCA	cis	rs9863	0.931	rs3186071	ENSG00000270028.1	RP11-380L11.4	3.44	0.000605	0.0288	0.13	0.11	White blood cell count;	chr12:123944732	chr12:123925461~123926083:-
BRCA	cis	rs7260598	0.681	rs62114776	ENSG00000268442.1	CTD-2027I19.2	3.44	0.000605	0.0288	0.17	0.11	Response to taxane treatment (placlitaxel);	chr19:24054513	chr19:24162370~24163425:-
BRCA	cis	rs2031532	0.587	rs7995283	ENSG00000236577.1	SNRPGP14	3.44	0.000605	0.0288	0.12	0.11	Cardiac hypertrophy;	chr13:49470449	chr13:49488970~49489364:+
BRCA	cis	rs4851551	0.543	rs62156407	ENSG00000234389.1	AC007278.3	3.44	0.000605	0.0288	0.2	0.11	Blood protein levels;	chr2:102208162	chr2:102438713~102440475:+
BRCA	cis	rs5758511	0.68	rs5758681	ENSG00000231261.1	HMGN2P10	-3.44	0.000605	0.0288	-0.15	-0.11	Birth weight;	chr22:42249085	chr22:41709225~41709489:-
BRCA	cis	rs1552244	0.572	rs7645667	ENSG00000269894.1	RP11-1020A11.1	-3.44	0.000605	0.0288	-0.14	-0.11	Alzheimer's disease;	chr3:10115653	chr3:9935706~9936258:+
BRCA	cis	rs984222	0.617	rs1891222	ENSG00000231365.4	RP11-418J17.1	-3.44	0.000605	0.0288	-0.13	-0.11	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119208379	chr1:119140396~119275973:+
BRCA	cis	rs13256369	0.708	rs10903310	ENSG00000233609.3	RP11-62H7.2	-3.44	0.000605	0.0288	-0.12	-0.11	Obesity-related traits;	chr8:8732177	chr8:8961200~8979025:+
BRCA	cis	rs17767294	0.614	rs72850298	ENSG00000272009.1	RP1-313I6.12	-3.44	0.000605	0.0289	-0.28	-0.11	Parkinson's disease;	chr6:28254778	chr6:28078792~28081130:-
BRCA	cis	rs7045881	0.696	rs7024415	ENSG00000254396.1	RP11-56F10.3	3.44	0.000605	0.0289	0.16	0.11	Schizophrenia;	chr9:26809430	chr9:27102630~27104728:+
BRCA	cis	rs6012564	0.893	rs6019516	ENSG00000230758.1	SNAP23P	-3.44	0.000605	0.0289	-0.13	-0.11	Anger;	chr20:48913613	chr20:49038357~49038602:-
BRCA	cis	rs6964587	1	rs10245095	ENSG00000188693.7	CYP51A1-AS1	-3.44	0.000605	0.0289	-0.12	-0.11	Breast cancer;	chr7:92081531	chr7:92134604~92180725:+
BRCA	cis	rs1354774	0.505	rs8103659	ENSG00000228674.4	CTB-147C22.3	-3.44	0.000605	0.0289	-0.14	-0.11	Prostate-specific antigen levels;	chr19:50882146	chr19:50927079~50927571:-
BRCA	cis	rs9325389	0.648	rs12630378	ENSG00000239122.1	RNU2-11P	-3.44	0.000605	0.0289	-0.15	-0.11	Facial morphology (factor 17, height of vermillion upper lip);	chr3:195832418	chr3:195928589~195928775:-
BRCA	cis	rs1075265	0.933	rs2287642	ENSG00000272156.1	RP11-477N3.1	-3.44	0.000605	0.0289	-0.11	-0.11	Chronotype;Morning vs. evening chronotype;	chr2:54108447	chr2:54082554~54085066:+
BRCA	cis	rs6088590	0.71	rs6059992	ENSG00000269202.1	RP4-614O4.12	-3.44	0.000605	0.0289	-0.11	-0.11	Coronary artery disease;	chr20:34694471	chr20:35201747~35203288:-
BRCA	cis	rs7914558	1	rs10786740	ENSG00000213277.3	MARCKSL1P1	3.44	0.000605	0.0289	0.12	0.11	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103175836	chr10:103175554~103176094:+
BRCA	cis	rs6452790	0.529	rs10055827	ENSG00000247828.6	TMEM161B-AS1	-3.44	0.000605	0.0289	-0.14	-0.11	Cognitive function;	chr5:87970557	chr5:88268895~88436685:+
BRCA	cis	rs12681366	0.663	rs2043987	ENSG00000253175.1	RP11-267M23.6	3.44	0.000605	0.0289	0.12	0.11	Nonsyndromic cleft lip with cleft palate;	chr8:94457465	chr8:94565036~94565715:+
BRCA	cis	rs7959452	0.557	rs7980883	ENSG00000274979.1	RP11-1143G9.5	-3.44	0.000605	0.0289	-0.11	-0.11	Blood protein levels;	chr12:69385134	chr12:69326574~69331882:-
BRCA	cis	rs7412746	0.658	rs4537557	ENSG00000224800.1	RP11-235D19.2	-3.44	0.000605	0.0289	-0.13	-0.11	Melanoma;	chr1:150761960	chr1:150881236~150881683:-
BRCA	cis	rs7412746	0.658	rs2864869	ENSG00000224800.1	RP11-235D19.2	-3.44	0.000605	0.0289	-0.13	-0.11	Melanoma;	chr1:150762179	chr1:150881236~150881683:-
BRCA	cis	rs736408	0.812	rs6778329	ENSG00000242142.1	SERBP1P3	3.44	0.000605	0.0289	0.12	0.11	Bipolar disorder;	chr3:52790594	chr3:53064283~53065091:-
BRCA	cis	rs9341808	0.718	rs9359408	ENSG00000279022.1	RP11-250B2.4	3.44	0.000606	0.0289	0.12	0.11	Sitting height ratio;	chr6:80110415	chr6:80440730~80441172:+
BRCA	cis	rs7267979	1	rs448396	ENSG00000231081.1	RP4-760C5.3	-3.44	0.000606	0.0289	-0.14	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25459633	chr20:26008791~26010531:-
BRCA	cis	rs12234571	1	rs111703270	ENSG00000214293.7	APTR	3.44	0.000606	0.0289	0.22	0.11	Obesity-related traits;	chr7:77740119	chr7:77657660~77696265:-
BRCA	cis	rs4657482	0.572	rs4656466	ENSG00000236364.3	RP11-525G13.2	-3.44	0.000606	0.0289	-0.1	-0.11	Testicular germ cell tumor;	chr1:165900130	chr1:165890795~165900683:-
BRCA	cis	rs258892	0.895	rs9654412	ENSG00000272525.1	RP11-79P5.9	-3.44	0.000606	0.0289	-0.13	-0.11	Small cell lung carcinoma;	chr5:72744832	chr5:73497550~73498293:-
BRCA	cis	rs11673344	0.9	rs11671112	ENSG00000267682.1	CTD-3220F14.2	-3.44	0.000606	0.0289	-0.1	-0.11	Obesity-related traits;	chr19:37169384	chr19:37337236~37337743:+
BRCA	cis	rs7520050	0.897	rs4440807	ENSG00000234329.1	RP11-767N6.2	-3.44	0.000606	0.0289	-0.1	-0.11	Reticulocyte count;Red blood cell count;	chr1:46005206	chr1:45651039~45651826:-
BRCA	cis	rs3096299	0.685	rs4785675	ENSG00000261118.1	RP11-104N10.1	3.44	0.000606	0.0289	0.11	0.11	Multiple myeloma (IgH translocation);	chr16:89473566	chr16:89492017~89504460:-
BRCA	cis	rs62458065	0.513	rs787216	ENSG00000273014.1	RP11-225B17.2	-3.44	0.000606	0.0289	-0.16	-0.11	Metabolite levels (HVA/MHPG ratio);	chr7:32539279	chr7:32758882~32759353:+
BRCA	cis	rs62458065	0.513	rs702831	ENSG00000273014.1	RP11-225B17.2	-3.44	0.000606	0.0289	-0.16	-0.11	Metabolite levels (HVA/MHPG ratio);	chr7:32540103	chr7:32758882~32759353:+
BRCA	cis	rs62458065	0.513	rs787220	ENSG00000273014.1	RP11-225B17.2	-3.44	0.000606	0.0289	-0.16	-0.11	Metabolite levels (HVA/MHPG ratio);	chr7:32541527	chr7:32758882~32759353:+
BRCA	cis	rs875971	0.505	rs1167386	ENSG00000229180.5	GS1-124K5.11	-3.44	0.000606	0.0289	-0.09	-0.11	Aortic root size;	chr7:66048109	chr7:66526088~66542624:-
BRCA	cis	rs4835473	0.838	rs6832094	ENSG00000246448.2	RP13-578N3.3	-3.44	0.000606	0.0289	-0.12	-0.11	Immature fraction of reticulocytes;	chr4:143795388	chr4:143700257~143865072:+
BRCA	cis	rs7131987	0.621	rs3782506	ENSG00000273680.1	RP11-996F15.6	-3.44	0.000606	0.0289	-0.13	-0.11	QT interval;	chr12:29292489	chr12:29332733~29333383:-
BRCA	cis	rs6490294	0.571	rs12312538	ENSG00000257624.1	RP1-128M12.3	3.44	0.000606	0.0289	0.17	0.11	Mean platelet volume;	chr12:112051717	chr12:112000739~112000985:-
BRCA	cis	rs988913	0.723	rs4715520	ENSG00000261116.1	RP3-523K23.2	3.44	0.000606	0.0289	0.13	0.11	Menarche (age at onset);	chr6:55131197	chr6:54943167~54945099:+
BRCA	cis	rs952623	0.649	rs17171519	ENSG00000227191.5	TRGC2	3.44	0.000606	0.0289	0.1	0.11	Intelligence (multi-trait analysis);	chr7:39020712	chr7:38239580~38368091:-
BRCA	cis	rs2555155	0.87	rs2723644	ENSG00000254595.1	CTD-2010I16.1	3.44	0.000606	0.0289	0.12	0.11	DNA methylation (variation);	chr11:6521787	chr11:6488186~6489377:-
BRCA	cis	rs9467773	0.967	rs7753565	ENSG00000224843.5	LINC00240	-3.44	0.000606	0.0289	-0.12	-0.11	Intelligence (multi-trait analysis);	chr6:26559784	chr6:26956992~27023924:+
BRCA	cis	rs72772090	0.539	rs55996659	ENSG00000272109.1	CTD-2260A17.3	3.44	0.000606	0.0289	0.21	0.11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96778446	chr5:96804353~96806105:+
BRCA	cis	rs4578769	0.681	rs6507455	ENSG00000273232.1	RP11-370A5.2	3.44	0.000606	0.0289	0.15	0.11	Eosinophil percentage of white cells;	chr18:23032669	chr18:22882825~22883357:-
BRCA	cis	rs853679	0.607	rs67040724	ENSG00000216901.1	AL022393.7	3.44	0.000606	0.0289	0.27	0.11	Depression;	chr6:27937731	chr6:28176188~28176674:+
BRCA	cis	rs2562456	0.833	rs62107547	ENSG00000268117.1	VN1R84P	3.44	0.000606	0.0289	0.16	0.11	Pain;	chr19:21341245	chr19:21719801~21720035:-
BRCA	cis	rs3805389	0.504	rs62308708	ENSG00000249700.7	SRD5A3-AS1	-3.44	0.000606	0.0289	-0.17	-0.11	Waist-to-hip ratio adjusted for body mass index;	chr4:55626177	chr4:55363971~55395847:-
BRCA	cis	rs3735485	0.843	rs4563792	ENSG00000201772.1	SNORA5C	-3.44	0.000606	0.0289	-0.14	-0.11	White blood cell count;Sum basophil neutrophil counts;Neutrophil count;Granulocyte percentage of myeloid white cells;Monocyte percentage of white cells;Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Lymphocyte counts;	chr7:44997045	chr7:45104906~45105042:-
BRCA	cis	rs11673344	0.615	rs2921561	ENSG00000267422.1	CTD-2554C21.1	3.44	0.000606	0.0289	0.13	0.11	Obesity-related traits;	chr19:37348969	chr19:37779686~37792865:+
BRCA	cis	rs61864810	1	rs61864810	ENSG00000274723.1	RP11-618L22.1	3.44	0.000606	0.0289	0.13	0.11	Itch intensity from mosquito bite;	chr12:46288226	chr12:46970504~46972155:+
BRCA	cis	rs7208859	0.573	rs55661352	ENSG00000276250.1	CTD-2349P21.12	-3.44	0.000606	0.0289	-0.18	-0.11	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30718610	chr17:30803654~30804077:+
BRCA	cis	rs7267979	1	rs6138572	ENSG00000231081.1	RP4-760C5.3	-3.44	0.000607	0.0289	-0.14	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25455298	chr20:26008791~26010531:-
BRCA	cis	rs7267979	1	rs6138575	ENSG00000231081.1	RP4-760C5.3	-3.44	0.000607	0.0289	-0.14	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25458316	chr20:26008791~26010531:-
BRCA	cis	rs11035577	0.632	rs2861770	ENSG00000279675.1	RP11-454H19.2	-3.44	0.000607	0.0289	-0.17	-0.11	Temperament (bipolar disorder);	chr11:39746821	chr11:40107244~40112599:-
BRCA	cis	rs11035577	0.632	rs1507651	ENSG00000279675.1	RP11-454H19.2	-3.44	0.000607	0.0289	-0.17	-0.11	Temperament (bipolar disorder);	chr11:39747755	chr11:40107244~40112599:-
BRCA	cis	rs11035577	0.632	rs7114822	ENSG00000279675.1	RP11-454H19.2	-3.44	0.000607	0.0289	-0.17	-0.11	Temperament (bipolar disorder);	chr11:39748031	chr11:40107244~40112599:-
BRCA	cis	rs11035577	0.632	rs1507649	ENSG00000279675.1	RP11-454H19.2	-3.44	0.000607	0.0289	-0.17	-0.11	Temperament (bipolar disorder);	chr11:39749520	chr11:40107244~40112599:-
BRCA	cis	rs7267979	0.527	rs6076369	ENSG00000274973.1	RP13-401N8.7	3.44	0.000607	0.0289	0.12	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25596147	chr20:25845497~25845862:+
BRCA	cis	rs7923837	0.656	rs6583826	ENSG00000232709.1	MARK2P9	-3.44	0.000607	0.0289	-0.13	-0.11	Multiple sclerosis;Body mass index;	chr10:92588073	chr10:92418667~92420875:+
BRCA	cis	rs2985684	0.894	rs4581611	ENSG00000278009.1	RP11-649E7.8	3.44	0.000607	0.0289	0.15	0.11	Carotid intima media thickness;	chr14:49576802	chr14:49601011~49601124:-
BRCA	cis	rs853679	0.517	rs56364346	ENSG00000272009.1	RP1-313I6.12	-3.44	0.000607	0.0289	-0.15	-0.11	Depression;	chr6:28082984	chr6:28078792~28081130:-
BRCA	cis	rs853679	0.517	rs9357061	ENSG00000272009.1	RP1-313I6.12	-3.44	0.000607	0.0289	-0.15	-0.11	Depression;	chr6:28083994	chr6:28078792~28081130:-
BRCA	cis	rs853679	0.517	rs9368550	ENSG00000272009.1	RP1-313I6.12	-3.44	0.000607	0.0289	-0.15	-0.11	Depression;	chr6:28084025	chr6:28078792~28081130:-
BRCA	cis	rs853679	0.542	rs2295594	ENSG00000272009.1	RP1-313I6.12	-3.44	0.000607	0.0289	-0.15	-0.11	Depression;	chr6:28085319	chr6:28078792~28081130:-
BRCA	cis	rs17192198	0.904	rs73200994	ENSG00000258302.2	RP11-981P6.1	-3.44	0.000607	0.0289	-0.15	-0.11	Diastolic blood pressure;	chr12:89767689	chr12:89561129~89594878:+
BRCA	cis	rs6456156	0.692	rs9457270	ENSG00000272549.1	RP11-351J23.2	-3.44	0.000607	0.0289	-0.11	-0.11	Primary biliary cholangitis;	chr6:167099440	chr6:167666840~167679270:-
BRCA	cis	rs17684571	0.872	rs34812826	ENSG00000231441.1	RP11-472M19.2	3.44	0.000607	0.0289	0.16	0.11	Schizophrenia;	chr6:56721893	chr6:56844002~56864078:+
BRCA	cis	rs7578361	0.918	rs6714859	ENSG00000231969.1	AC144449.1	3.44	0.000607	0.0289	0.17	0.11	Acute lymphoblastic leukemia (childhood);	chr2:149521785	chr2:149587196~149848233:+
BRCA	cis	rs11098403	0.753	rs10006167	ENSG00000225892.3	RP11-384K6.2	3.44	0.000607	0.0289	0.11	0.11	Schizophrenia;	chr4:117845960	chr4:118632274~118634759:+
BRCA	cis	rs10484434	0.792	rs7757646	ENSG00000216331.1	HIST1H1PS1	3.44	0.000607	0.0289	0.18	0.11	HIV-1 viral setpoint;	chr6:26064151	chr6:26195566~26195771:+
BRCA	cis	rs10819861	0.645	rs7862829	ENSG00000175611.10	LINC00476	3.44	0.000607	0.0289	0.11	0.11	Electrocardiographic traits;	chr9:96094462	chr9:95759231~95875977:-
BRCA	cis	rs662138	1	rs662138	ENSG00000213073.4	RP11-288H12.3	-3.44	0.000607	0.0289	-0.14	-0.11	Metabolic traits;Blood metabolite levels;	chr6:160143444	chr6:160093082~160096212:+
BRCA	cis	rs3760982	0.813	rs8111664	ENSG00000267191.1	RP11-15A1.2	3.44	0.000607	0.0289	0.14	0.11	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43790940	chr19:43902001~43926545:+
BRCA	cis	rs12893668	0.703	rs729438	ENSG00000258534.1	CTD-2134A5.4	-3.44	0.000607	0.0289	-0.14	-0.11	Reticulocyte count;	chr14:103626452	chr14:103854366~103880111:-
BRCA	cis	rs2638953	0.853	rs10506036	ENSG00000273989.1	RP11-425D17.2	3.44	0.000607	0.029	0.16	0.11	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28497632	chr12:28236227~28236828:+
BRCA	cis	rs8114671	0.804	rs6060139	ENSG00000261582.1	RP4-614O4.11	-3.44	0.000607	0.029	-0.1	-0.11	Height;	chr20:34978696	chr20:35267885~35280043:-
BRCA	cis	rs826838	0.585	rs4363678	ENSG00000257718.1	RP11-396F22.1	3.44	0.000607	0.029	0.11	0.11	Heart rate;	chr12:38230712	chr12:38906451~38909592:+
BRCA	cis	rs13315871	1	rs9864824	ENSG00000272182.1	RP11-802O23.3	-3.44	0.000608	0.029	-0.21	-0.11	Cholesterol, total;	chr3:58409108	chr3:58428255~58428815:+
BRCA	cis	rs10487112	0.695	rs11563531	ENSG00000235436.9	DPY19L2P4	3.44	0.000608	0.029	0.11	0.11	Perceived unattractiveness to mosquitoes;	chr7:90517922	chr7:90119400~90125600:+
BRCA	cis	rs10923574	0.597	rs10923576	ENSG00000231365.4	RP11-418J17.1	-3.44	0.000608	0.029	-0.13	-0.11	Breast cancer;Folding of antihelix;	chr1:118500269	chr1:119140396~119275973:+
BRCA	cis	rs990171	0.538	rs6543155	ENSG00000234389.1	AC007278.3	3.44	0.000608	0.029	0.11	0.11	Lymphocyte counts;	chr2:102498436	chr2:102438713~102440475:+
BRCA	cis	rs2455826	0.874	rs2455853	ENSG00000224728.1	AC090945.1	-3.44	0.000608	0.029	-0.11	-0.11	Inflammatory skin disease;	chr3:15648518	chr3:15878047~15879571:+
BRCA	cis	rs12681963	0.614	rs16876663	ENSG00000248159.1	HSPA8P11	3.44	0.000608	0.029	0.26	0.11	Migraine;	chr8:30202182	chr8:30237382~30240997:+
BRCA	cis	rs12681963	0.688	rs73234780	ENSG00000248159.1	HSPA8P11	3.44	0.000608	0.029	0.26	0.11	Migraine;	chr8:30202239	chr8:30237382~30240997:+
BRCA	cis	rs12681963	0.614	rs73234781	ENSG00000248159.1	HSPA8P11	3.44	0.000608	0.029	0.26	0.11	Migraine;	chr8:30202242	chr8:30237382~30240997:+
BRCA	cis	rs12681963	0.614	rs7001629	ENSG00000248159.1	HSPA8P11	3.44	0.000608	0.029	0.26	0.11	Migraine;	chr8:30203273	chr8:30237382~30240997:+
BRCA	cis	rs754466	0.606	rs56402185	ENSG00000213514.2	RP11-428P16.2	3.44	0.000608	0.029	0.14	0.11	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77826090	chr10:77730766~77734769:+
BRCA	cis	rs1005277	0.579	rs1614236	ENSG00000276805.1	RP11-291L22.6	3.44	0.000608	0.029	0.12	0.11	Extrinsic epigenetic age acceleration;	chr10:38214068	chr10:38451030~38451785:+
BRCA	cis	rs1005277	0.579	rs2749616	ENSG00000276805.1	RP11-291L22.6	3.44	0.000608	0.029	0.12	0.11	Extrinsic epigenetic age acceleration;	chr10:38222065	chr10:38451030~38451785:+
BRCA	cis	rs875971	1	rs7789554	ENSG00000273024.4	INTS4P2	-3.44	0.000608	0.029	-0.12	-0.11	Aortic root size;	chr7:66481051	chr7:65647864~65715661:+
BRCA	cis	rs875971	1	rs4717300	ENSG00000273024.4	INTS4P2	-3.44	0.000608	0.029	-0.12	-0.11	Aortic root size;	chr7:66482393	chr7:65647864~65715661:+
BRCA	cis	rs875971	0.895	rs1974769	ENSG00000273024.4	INTS4P2	-3.44	0.000608	0.029	-0.12	-0.11	Aortic root size;	chr7:66485627	chr7:65647864~65715661:+
BRCA	cis	rs875971	0.895	rs6460300	ENSG00000273024.4	INTS4P2	-3.44	0.000608	0.029	-0.12	-0.11	Aortic root size;	chr7:66487937	chr7:65647864~65715661:+
BRCA	cis	rs875971	0.862	rs7803416	ENSG00000273024.4	INTS4P2	-3.44	0.000608	0.029	-0.12	-0.11	Aortic root size;	chr7:66489212	chr7:65647864~65715661:+
BRCA	cis	rs875971	0.964	rs2277911	ENSG00000273024.4	INTS4P2	-3.44	0.000608	0.029	-0.12	-0.11	Aortic root size;	chr7:66493638	chr7:65647864~65715661:+
BRCA	cis	rs9635963	0.883	rs11083004	ENSG00000264924.1	RP11-799B12.2	-3.44	0.000608	0.029	-0.14	-0.11	Protein quantitative trait loci;	chr18:24186147	chr18:24113637~24121003:-
BRCA	cis	rs9393813	0.528	rs4713109	ENSG00000271755.1	RP1-153G14.4	3.44	0.000608	0.029	0.12	0.11	Bipolar disorder;	chr6:27508489	chr6:27404010~27406964:-
BRCA	cis	rs74233809	1	rs943037	ENSG00000236937.2	PTGES3P4	3.44	0.000608	0.029	0.23	0.11	Birth weight;	chr10:103076162	chr10:102845595~102845950:+
BRCA	cis	rs7620503	1	rs1463857	ENSG00000228561.2	RP11-114M1.1	3.44	0.000608	0.029	0.12	0.11	Corneal structure;	chr3:177580539	chr3:177683627~177691250:+
BRCA	cis	rs875971	1	rs2420591	ENSG00000272831.1	RP11-792A8.4	3.44	0.000608	0.029	0.1	0.11	Aortic root size;	chr7:66447394	chr7:66739829~66740385:-
BRCA	cis	rs1916284	1	rs9846190	ENSG00000239831.1	RNF7P1	3.44	0.000608	0.029	0.13	0.11	Prostate cancer (SNP x SNP interaction);	chr3:57409310	chr3:57519669~57520010:-
BRCA	cis	rs1916284	0.934	rs7625549	ENSG00000239831.1	RNF7P1	3.44	0.000608	0.029	0.13	0.11	Prostate cancer (SNP x SNP interaction);	chr3:57410552	chr3:57519669~57520010:-
BRCA	cis	rs7260598	1	rs62117633	ENSG00000268442.1	CTD-2027I19.2	3.44	0.000608	0.029	0.17	0.11	Response to taxane treatment (placlitaxel);	chr19:24036672	chr19:24162370~24163425:-
BRCA	cis	rs7267979	0.903	rs6115118	ENSG00000274973.1	RP13-401N8.7	-3.44	0.000608	0.029	-0.12	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25266098	chr20:25845497~25845862:+
BRCA	cis	rs7267979	0.903	rs1118963	ENSG00000274973.1	RP13-401N8.7	-3.44	0.000608	0.029	-0.12	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25266813	chr20:25845497~25845862:+
BRCA	cis	rs2120991	1	rs7133819	ENSG00000250742.1	RP11-834C11.4	-3.44	0.000608	0.029	-0.13	-0.11	Biliary atresia;	chr12:53868972	chr12:54126098~54132843:+
BRCA	cis	rs10761482	0.683	rs4488150	ENSG00000254271.1	RP11-131N11.4	3.44	0.000608	0.029	0.15	0.11	Schizophrenia;	chr10:60345160	chr10:60734342~60741828:+
BRCA	cis	rs4919669	0.668	rs17114810	ENSG00000213277.3	MARCKSL1P1	3.44	0.000608	0.029	0.17	0.11	Mean arterial pressure (long-term average);Systolic blood pressure (long-term average);	chr10:102631788	chr10:103175554~103176094:+
BRCA	cis	rs7267979	1	rs2482931	ENSG00000274414.1	RP5-965G21.4	3.44	0.000608	0.029	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25353809	chr20:25239007~25245229:-
BRCA	cis	rs875971	0.516	rs6945322	ENSG00000227113.2	RP11-460N20.4	3.44	0.000608	0.029	0.11	0.11	Aortic root size;	chr7:65871069	chr7:65075023~65078780:+
BRCA	cis	rs36093844	0.752	rs17744699	ENSG00000279742.1	RP11-700A24.1	-3.44	0.000608	0.029	-0.17	-0.11	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85886120	chr11:85852557~85854943:-
BRCA	cis	rs36093844	0.752	rs17817343	ENSG00000279742.1	RP11-700A24.1	-3.44	0.000608	0.029	-0.17	-0.11	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85887269	chr11:85852557~85854943:-
BRCA	cis	rs748404	0.666	rs7176923	ENSG00000205771.5	CATSPER2P1	-3.44	0.000608	0.029	-0.16	-0.11	Lung cancer;	chr15:43317679	chr15:43726918~43747094:-
BRCA	cis	rs240993	0.516	rs369594	ENSG00000271789.1	RP5-1112D6.7	-3.44	0.000608	0.029	-0.14	-0.11	Inflammatory skin disease;Psoriasis;	chr6:111303197	chr6:111297126~111298510:+
BRCA	cis	rs1823874	0.677	rs56096943	ENSG00000259363.4	CTD-2054N24.2	3.44	0.000608	0.029	0.13	0.11	IgG glycosylation;	chr15:99820513	chr15:99807023~99877148:+
BRCA	cis	rs1424638	0.589	rs12713328	ENSG00000233251.6	AC007743.1	-3.44	0.000608	0.029	-0.12	-0.11	Intelligence (multi-trait analysis);	chr2:57060483	chr2:56173534~56185770:-
BRCA	cis	rs987724	0.574	rs9812895	ENSG00000240875.4	LINC00886	-3.44	0.000609	0.029	-0.12	-0.11	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156886370	chr3:156747346~156817062:-
BRCA	cis	rs1916284	1	rs1916284	ENSG00000239831.1	RNF7P1	3.44	0.000609	0.029	0.13	0.11	Prostate cancer (SNP x SNP interaction);	chr3:57409039	chr3:57519669~57520010:-
BRCA	cis	rs10820912	1	rs10992147	ENSG00000225460.1	RP13-93L13.1	3.44	0.000609	0.029	0.11	0.11	Left atrial antero-posterior diameter;	chr9:90113303	chr9:89472237~89472692:+
BRCA	cis	rs875971	0.895	rs3857684	ENSG00000273024.4	INTS4P2	-3.44	0.000609	0.029	-0.12	-0.11	Aortic root size;	chr7:66473171	chr7:65647864~65715661:+
BRCA	cis	rs1005277	0.522	rs289647	ENSG00000273019.1	RP11-508N22.13	-3.44	0.000609	0.029	-0.12	-0.11	Extrinsic epigenetic age acceleration;	chr10:37679350	chr10:38149968~38150293:+
BRCA	cis	rs73222236	0.787	rs6782151	ENSG00000239213.4	NCK1-AS1	3.44	0.000609	0.029	0.12	0.11	Coronary artery disease;	chr3:136616953	chr3:136841726~136862054:-
BRCA	cis	rs11694172	1	rs11694172	ENSG00000226261.1	AC064836.3	-3.44	0.000609	0.029	-0.14	-0.11	Cholesterol, total;	chr2:202667581	chr2:202336024~202336727:-
BRCA	cis	rs77320796	1	rs3103780	ENSG00000259943.1	RP1-39G22.7	3.44	0.000609	0.029	0.11	0.11	Platelet count;	chr1:39929497	chr1:40256427~40257967:-
BRCA	cis	rs7959452	0.558	rs1478464	ENSG00000274979.1	RP11-1143G9.5	-3.44	0.000609	0.029	-0.12	-0.11	Blood protein levels;	chr12:69386009	chr12:69326574~69331882:-
BRCA	cis	rs2904524	1	rs77397439	ENSG00000257613.1	LINC01481	-3.44	0.000609	0.029	-0.18	-0.11	Amyotrophic lateral sclerosis (age of onset);	chr12:70313566	chr12:70219132~70221862:-
BRCA	cis	rs2904524	1	rs58828627	ENSG00000257613.1	LINC01481	-3.44	0.000609	0.029	-0.18	-0.11	Amyotrophic lateral sclerosis (age of onset);	chr12:70317513	chr12:70219132~70221862:-
BRCA	cis	rs2904524	1	rs1404124	ENSG00000257613.1	LINC01481	-3.44	0.000609	0.029	-0.18	-0.11	Amyotrophic lateral sclerosis (age of onset);	chr12:70319519	chr12:70219132~70221862:-
BRCA	cis	rs1953600	0.521	rs7067644	ENSG00000237523.1	LINC00857	-3.44	0.000609	0.029	-0.11	-0.11	Sarcoidosis;	chr10:80164489	chr10:80207710~80219657:+
BRCA	cis	rs4374383	0.631	rs884448	ENSG00000243389.1	AC012442.5	-3.44	0.000609	0.029	-0.14	-0.11	Hepatitis C induced liver fibrosis;	chr2:111942751	chr2:112589040~112614431:+
BRCA	cis	rs17374749	0.601	rs13320144	ENSG00000273486.1	RP11-731C17.2	-3.44	0.000609	0.029	-0.13	-0.11	Anxiety in major depressive disorder;	chr3:137103637	chr3:136837338~136839021:-
BRCA	cis	rs8130944	0.859	rs756577	ENSG00000225731.1	AP001627.1	3.44	0.000609	0.029	0.13	0.11	Perceived unattractiveness to mosquitoes;	chr21:42698213	chr21:42733594~42741758:-
BRCA	cis	rs10958605	0.624	rs2980813	ENSG00000254143.1	RP11-470M17.2	-3.44	0.000609	0.029	-0.13	-0.11	Parkinson's disease (motor and cognition);	chr8:40192491	chr8:40161458~40172612:+
BRCA	cis	rs34217772	0.83	rs61992395	ENSG00000258636.1	CTD-2298J14.2	3.44	0.000609	0.029	0.14	0.11	Myopia;	chr14:41743612	chr14:41587861~41604856:-
BRCA	cis	rs1865760	0.566	rs2051544	ENSG00000272462.2	U91328.19	-3.44	0.000609	0.029	-0.13	-0.11	Height;	chr6:26070865	chr6:25992662~26001775:+
BRCA	cis	rs763121	0.853	rs5750673	ENSG00000273076.1	RP3-508I15.22	3.44	0.000609	0.029	0.12	0.11	Menopause (age at onset);	chr22:38714119	chr22:38743495~38743910:+
BRCA	cis	rs875971	0.895	rs10755833	ENSG00000271064.1	RP11-792A8.3	-3.44	0.000609	0.029	-0.12	-0.11	Aortic root size;	chr7:66448930	chr7:66748838~66749077:-
BRCA	cis	rs875971	0.895	rs1833495	ENSG00000271064.1	RP11-792A8.3	-3.44	0.000609	0.029	-0.12	-0.11	Aortic root size;	chr7:66456608	chr7:66748838~66749077:-
BRCA	cis	rs875971	0.964	rs6945032	ENSG00000271064.1	RP11-792A8.3	-3.44	0.000609	0.029	-0.12	-0.11	Aortic root size;	chr7:66457499	chr7:66748838~66749077:-
BRCA	cis	rs875971	0.929	rs12673810	ENSG00000271064.1	RP11-792A8.3	-3.44	0.000609	0.029	-0.12	-0.11	Aortic root size;	chr7:66458866	chr7:66748838~66749077:-
BRCA	cis	rs875971	1	rs6961155	ENSG00000271064.1	RP11-792A8.3	-3.44	0.000609	0.029	-0.12	-0.11	Aortic root size;	chr7:66468308	chr7:66748838~66749077:-
BRCA	cis	rs875971	1	rs7789768	ENSG00000271064.1	RP11-792A8.3	-3.44	0.000609	0.029	-0.12	-0.11	Aortic root size;	chr7:66473993	chr7:66748838~66749077:-
BRCA	cis	rs875971	1	rs1363055	ENSG00000271064.1	RP11-792A8.3	-3.44	0.000609	0.029	-0.12	-0.11	Aortic root size;	chr7:66478288	chr7:66748838~66749077:-
BRCA	cis	rs875971	0.964	rs9691480	ENSG00000271064.1	RP11-792A8.3	-3.44	0.000609	0.029	-0.12	-0.11	Aortic root size;	chr7:66479319	chr7:66748838~66749077:-
BRCA	cis	rs8180040	1	rs8180040	ENSG00000260236.1	RP11-708J19.1	3.44	0.000609	0.029	0.09	0.11	Colorectal cancer;	chr3:47347457	chr3:47379089~47380999:-
BRCA	cis	rs17192198	0.762	rs17783015	ENSG00000258302.2	RP11-981P6.1	-3.44	0.000609	0.029	-0.14	-0.11	Diastolic blood pressure;	chr12:89837609	chr12:89561129~89594878:+
BRCA	cis	rs2333021	0.649	rs8022470	ENSG00000259015.1	RP11-109N23.6	3.44	0.000609	0.029	0.12	0.11	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:73005293	chr14:72960595~72961993:+
BRCA	cis	rs3748682	0.861	rs2291297	ENSG00000212541.1	RNU6-510P	-3.44	0.000609	0.029	-0.15	-0.11	Hypothyroidism;	chr1:37806988	chr1:37991462~37991569:+
BRCA	cis	rs12637928	0.507	rs7610787	ENSG00000206532.2	RP11-553A10.1	-3.44	0.000609	0.029	-0.13	-0.11	Neuroticism;	chr3:110600060	chr3:110888384~110893476:-
BRCA	cis	rs4435363	1	rs8105727	ENSG00000268423.3	AC011551.3	3.44	0.000609	0.029	0.18	0.11	Immature fraction of reticulocytes;P wave terminal force;	chr19:46563387	chr19:46547056~46600861:-
BRCA	cis	rs863345	0.584	rs10908676	ENSG00000229914.1	RP11-404O13.4	-3.44	0.000609	0.029	-0.11	-0.11	Pneumococcal bacteremia;	chr1:158536373	chr1:158195633~158196131:-
BRCA	cis	rs56046484	1	rs12911330	ENSG00000230373.7	GOLGA6L5P	3.44	0.000609	0.029	0.16	0.11	Testicular germ cell tumor;	chr15:85087103	chr15:84507885~84516814:-
BRCA	cis	rs56046484	0.956	rs34919315	ENSG00000230373.7	GOLGA6L5P	3.44	0.000609	0.029	0.16	0.11	Testicular germ cell tumor;	chr15:85088675	chr15:84507885~84516814:-
BRCA	cis	rs7615952	0.512	rs2979336	ENSG00000248787.1	RP11-666A20.4	-3.44	0.000609	0.029	-0.16	-0.11	Blood pressure (smoking interaction);	chr3:125638626	chr3:125908005~125910272:-
BRCA	cis	rs295490	0.748	rs58060926	ENSG00000178631.7	ACTG1P1	-3.44	0.000609	0.029	-0.21	-0.11	PR interval in Tripanosoma cruzi seropositivity;	chr3:139356577	chr3:139493809~139494937:+
BRCA	cis	rs295490	0.748	rs78116750	ENSG00000178631.7	ACTG1P1	-3.44	0.000609	0.029	-0.21	-0.11	PR interval in Tripanosoma cruzi seropositivity;	chr3:139356886	chr3:139493809~139494937:+
BRCA	cis	rs295490	0.748	rs74365525	ENSG00000178631.7	ACTG1P1	-3.44	0.000609	0.029	-0.21	-0.11	PR interval in Tripanosoma cruzi seropositivity;	chr3:139357107	chr3:139493809~139494937:+
BRCA	cis	rs295490	0.667	rs80049554	ENSG00000178631.7	ACTG1P1	-3.44	0.000609	0.029	-0.21	-0.11	PR interval in Tripanosoma cruzi seropositivity;	chr3:139357161	chr3:139493809~139494937:+
BRCA	cis	rs295490	0.748	rs2307031	ENSG00000178631.7	ACTG1P1	-3.44	0.000609	0.029	-0.21	-0.11	PR interval in Tripanosoma cruzi seropositivity;	chr3:139357978	chr3:139493809~139494937:+
BRCA	cis	rs295490	0.915	rs79695313	ENSG00000178631.7	ACTG1P1	-3.44	0.000609	0.029	-0.21	-0.11	PR interval in Tripanosoma cruzi seropositivity;	chr3:139358335	chr3:139493809~139494937:+
BRCA	cis	rs6490294	0.904	rs11066098	ENSG00000234608.6	MAPKAPK5-AS1	3.44	0.000609	0.029	0.13	0.11	Mean platelet volume;	chr12:111950324	chr12:111839764~111842902:-
BRCA	cis	rs10501293	1	rs4495880	ENSG00000252652.1	Y_RNA	3.44	0.000609	0.029	0.13	0.11	Cognitive performance;	chr11:43112076	chr11:43331261~43331356:+
BRCA	cis	rs72772090	0.71	rs17400741	ENSG00000272109.1	CTD-2260A17.3	3.44	0.000609	0.029	0.2	0.11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96730872	chr5:96804353~96806105:+
BRCA	cis	rs6593122	0.583	rs12534272	ENSG00000235454.1	HAUS6P3	-3.44	0.00061	0.029	-0.14	-0.11	Vaccine-related adverse events;	chr7:54118369	chr7:53862233~53863339:+
BRCA	cis	rs6593122	0.628	rs12534275	ENSG00000235454.1	HAUS6P3	-3.44	0.00061	0.029	-0.14	-0.11	Vaccine-related adverse events;	chr7:54118422	chr7:53862233~53863339:+
BRCA	cis	rs6593122	0.651	rs1916971	ENSG00000235454.1	HAUS6P3	-3.44	0.00061	0.029	-0.14	-0.11	Vaccine-related adverse events;	chr7:54118501	chr7:53862233~53863339:+
BRCA	cis	rs8098244	0.603	rs1711457	ENSG00000265752.2	RP11-403A21.1	3.44	0.00061	0.029	0.11	0.11	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23699494	chr18:23957754~23982556:-
BRCA	cis	rs2836950	0.565	rs2836930	ENSG00000235701.1	PCBP2P1	-3.44	0.00061	0.029	-0.12	-0.11	Menarche (age at onset);	chr21:39173730	chr21:39171130~39172106:-
BRCA	cis	rs2305707	0.544	rs2470177	ENSG00000273674.3	CTD-2378E12.1	3.44	0.00061	0.029	0.19	0.11	Height;	chr15:51292788	chr15:50839875~50908599:-
BRCA	cis	rs2243480	1	rs1167613	ENSG00000226767.1	RP11-328P23.3	-3.44	0.00061	0.029	-0.18	-0.11	Diabetic kidney disease;	chr7:66022452	chr7:65508773~65508944:-
BRCA	cis	rs2243480	1	rs313799	ENSG00000226767.1	RP11-328P23.3	-3.44	0.00061	0.029	-0.18	-0.11	Diabetic kidney disease;	chr7:66029343	chr7:65508773~65508944:-
BRCA	cis	rs2562456	0.876	rs62110163	ENSG00000268555.1	RP11-678G14.3	3.44	0.00061	0.029	0.14	0.11	Pain;	chr19:21546020	chr19:21570822~21587322:-
BRCA	cis	rs2562456	0.761	rs35008138	ENSG00000268555.1	RP11-678G14.3	3.44	0.00061	0.029	0.14	0.11	Pain;	chr19:21548822	chr19:21570822~21587322:-
BRCA	cis	rs2562456	0.833	rs2681388	ENSG00000268555.1	RP11-678G14.3	3.44	0.00061	0.029	0.14	0.11	Pain;	chr19:21549451	chr19:21570822~21587322:-
BRCA	cis	rs2562456	0.876	rs2681370	ENSG00000268555.1	RP11-678G14.3	3.44	0.00061	0.029	0.14	0.11	Pain;	chr19:21554036	chr19:21570822~21587322:-
BRCA	cis	rs2562456	0.876	rs11668606	ENSG00000268555.1	RP11-678G14.3	3.44	0.00061	0.029	0.14	0.11	Pain;	chr19:21554618	chr19:21570822~21587322:-
BRCA	cis	rs2562456	0.876	rs2681395	ENSG00000268555.1	RP11-678G14.3	3.44	0.00061	0.029	0.14	0.11	Pain;	chr19:21555338	chr19:21570822~21587322:-
BRCA	cis	rs17027633	1	rs3767607	ENSG00000234020.1	CHIAP3	-3.44	0.00061	0.029	-0.2	-0.11	Cerebrospinal fluid t-tau:AB1-42 ratio;	chr1:111415066	chr1:111353275~111367409:-
BRCA	cis	rs987724	0.515	rs4680309	ENSG00000244515.1	KRT18P34	-3.44	0.00061	0.029	-0.16	-0.11	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156865807	chr3:157162663~157163932:-
BRCA	cis	rs987724	0.515	rs2874488	ENSG00000244515.1	KRT18P34	-3.44	0.00061	0.029	-0.16	-0.11	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156868027	chr3:157162663~157163932:-
BRCA	cis	rs987724	0.515	rs6765353	ENSG00000244515.1	KRT18P34	-3.44	0.00061	0.029	-0.16	-0.11	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156868755	chr3:157162663~157163932:-
BRCA	cis	rs987724	0.515	rs7638330	ENSG00000244515.1	KRT18P34	-3.44	0.00061	0.029	-0.16	-0.11	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156869976	chr3:157162663~157163932:-
BRCA	cis	rs71520386	0.632	rs10254365	ENSG00000179428.2	AC073072.5	3.44	0.00061	0.029	0.12	0.11	Fibrinogen levels;	chr7:22825135	chr7:22725395~22727620:-
BRCA	cis	rs801193	0.66	rs2659897	ENSG00000271064.1	RP11-792A8.3	3.44	0.00061	0.029	0.12	0.11	Aortic root size;	chr7:66722728	chr7:66748838~66749077:-
BRCA	cis	rs4427176	0.654	rs11991621	ENSG00000233609.3	RP11-62H7.2	-3.44	0.00061	0.0291	-0.12	-0.11	Mosquito bite size;	chr8:9549072	chr8:8961200~8979025:+
BRCA	cis	rs613391	0.522	rs593909	ENSG00000265194.1	RP11-70L8.4	-3.44	0.00061	0.0291	-0.11	-0.11	Quantitative traits;	chr9:22730878	chr9:21858910~21861926:-
BRCA	cis	rs8114671	0.836	rs745849	ENSG00000261582.1	RP4-614O4.11	3.44	0.00061	0.0291	0.1	0.11	Height;	chr20:34984375	chr20:35267885~35280043:-
BRCA	cis	rs875971	0.862	rs1968126	ENSG00000271064.1	RP11-792A8.3	3.44	0.00061	0.0291	0.13	0.11	Aortic root size;	chr7:66592017	chr7:66748838~66749077:-
BRCA	cis	rs467650	0.549	rs162676	ENSG00000246763.5	RGMB-AS1	-3.44	0.00061	0.0291	-0.12	-0.11	Venous thromboembolism (SNP x SNP interaction);	chr5:98655799	chr5:98769618~98773469:-
BRCA	cis	rs875971	0.505	rs1167385	ENSG00000227113.2	RP11-460N20.4	-3.44	0.00061	0.0291	-0.11	-0.11	Aortic root size;	chr7:66048321	chr7:65075023~65078780:+
BRCA	cis	rs9437689	0.899	rs6687388	ENSG00000235501.4	RP4-639F20.1	3.44	0.00061	0.0291	0.13	0.11	Phospholipid levels (plasma);	chr1:95049568	chr1:94927566~94963270:+
BRCA	cis	rs7824557	0.507	rs7010590	ENSG00000154316.13	TDH	-3.44	0.00061	0.0291	-0.14	-0.11	Retinal vascular caliber;	chr8:11205373	chr8:11339637~11368452:+
BRCA	cis	rs11887277	0.586	rs828264	ENSG00000272148.1	RP11-195B17.1	-3.44	0.00061	0.0291	-0.12	-0.11	Obesity-related traits;	chr2:26771899	chr2:27062428~27062907:-
BRCA	cis	rs1982963	0.587	rs2516593	ENSG00000277050.1	RP11-102G14.1	-3.44	0.00061	0.0291	-0.11	-0.11	Waist-to-hip ratio adjusted for body mass index;	chr14:52036651	chr14:51637348~51637947:-
BRCA	cis	rs1982963	0.639	rs2749875	ENSG00000277050.1	RP11-102G14.1	-3.44	0.00061	0.0291	-0.11	-0.11	Waist-to-hip ratio adjusted for body mass index;	chr14:52036678	chr14:51637348~51637947:-
BRCA	cis	rs7258465	1	rs4808133	ENSG00000273654.1	CTB-52I2.4	-3.44	0.00061	0.0291	-0.13	-0.11	Breast cancer;	chr19:18497708	chr19:18022403~18032099:+
BRCA	cis	rs7258465	1	rs4808134	ENSG00000273654.1	CTB-52I2.4	-3.44	0.00061	0.0291	-0.13	-0.11	Breast cancer;	chr19:18497769	chr19:18022403~18032099:+
BRCA	cis	rs886774	0.866	rs4348408	ENSG00000273055.1	CTB-13F3.1	-3.44	0.00061	0.0291	-0.11	-0.11	Ulcerative colitis;	chr7:107868828	chr7:107942116~107942740:+
BRCA	cis	rs8098244	0.737	rs1154237	ENSG00000265752.2	RP11-403A21.1	-3.44	0.00061	0.0291	-0.14	-0.11	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23935225	chr18:23957754~23982556:-
BRCA	cis	rs73201462	0.901	rs34749881	ENSG00000242551.2	POU5F1P6	3.44	0.00061	0.0291	0.18	0.11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128151426	chr3:128674735~128677005:-
BRCA	cis	rs73201462	1	rs11711710	ENSG00000242551.2	POU5F1P6	3.44	0.00061	0.0291	0.18	0.11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128153663	chr3:128674735~128677005:-
BRCA	cis	rs2288327	0.75	rs16866465	ENSG00000271011.1	RP11-171I2.5	3.44	0.000611	0.0291	0.19	0.11	Atrial fibrillation;	chr2:178718769	chr2:178577103~178577622:+
BRCA	cis	rs2640806	0.645	rs28441183	ENSG00000253105.4	KB-1448A5.1	3.44	0.000611	0.0291	0.13	0.11	Obesity-related traits;	chr8:96315066	chr8:96371865~96387438:-
BRCA	cis	rs2640806	0.645	rs28588175	ENSG00000253105.4	KB-1448A5.1	3.44	0.000611	0.0291	0.13	0.11	Obesity-related traits;	chr8:96315067	chr8:96371865~96387438:-
BRCA	cis	rs7520050	0.966	rs6680380	ENSG00000226957.1	RP4-533D7.4	3.44	0.000611	0.0291	0.11	0.11	Reticulocyte count;Red blood cell count;	chr1:45834517	chr1:46046818~46048368:+
BRCA	cis	rs55883249	1	rs17453724	ENSG00000217258.2	AC007249.3	3.44	0.000611	0.0291	0.16	0.11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:9623872	chr2:10452319~10455552:+
BRCA	cis	rs10911902	0.688	rs113019508	ENSG00000229739.2	RP11-295K2.3	-3.44	0.000611	0.0291	-0.15	-0.11	Schizophrenia;	chr1:186349685	chr1:186435161~186470291:+
BRCA	cis	rs16846053	0.605	rs62188820	ENSG00000227403.1	AC009299.3	3.44	0.000611	0.0291	0.26	0.11	Blood osmolality (transformed sodium);	chr2:161905025	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.605	rs72865241	ENSG00000227403.1	AC009299.3	3.44	0.000611	0.0291	0.26	0.11	Blood osmolality (transformed sodium);	chr2:161905524	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.539	rs62188821	ENSG00000227403.1	AC009299.3	3.44	0.000611	0.0291	0.26	0.11	Blood osmolality (transformed sodium);	chr2:161906449	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.605	rs55931021	ENSG00000227403.1	AC009299.3	3.44	0.000611	0.0291	0.26	0.11	Blood osmolality (transformed sodium);	chr2:161907986	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.605	rs72865255	ENSG00000227403.1	AC009299.3	3.44	0.000611	0.0291	0.26	0.11	Blood osmolality (transformed sodium);	chr2:161909249	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.54	rs72865256	ENSG00000227403.1	AC009299.3	3.44	0.000611	0.0291	0.26	0.11	Blood osmolality (transformed sodium);	chr2:161909252	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.605	rs72865260	ENSG00000227403.1	AC009299.3	3.44	0.000611	0.0291	0.26	0.11	Blood osmolality (transformed sodium);	chr2:161910741	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.605	rs72865262	ENSG00000227403.1	AC009299.3	3.44	0.000611	0.0291	0.26	0.11	Blood osmolality (transformed sodium);	chr2:161910782	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.605	rs62188825	ENSG00000227403.1	AC009299.3	3.44	0.000611	0.0291	0.26	0.11	Blood osmolality (transformed sodium);	chr2:161910943	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.605	rs62188826	ENSG00000227403.1	AC009299.3	3.44	0.000611	0.0291	0.26	0.11	Blood osmolality (transformed sodium);	chr2:161911143	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.605	rs62188827	ENSG00000227403.1	AC009299.3	3.44	0.000611	0.0291	0.26	0.11	Blood osmolality (transformed sodium);	chr2:161911698	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.685	rs62188838	ENSG00000227403.1	AC009299.3	3.44	0.000611	0.0291	0.26	0.11	Blood osmolality (transformed sodium);	chr2:161915131	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.605	rs62188839	ENSG00000227403.1	AC009299.3	3.44	0.000611	0.0291	0.26	0.11	Blood osmolality (transformed sodium);	chr2:161915158	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.605	rs55693861	ENSG00000227403.1	AC009299.3	3.44	0.000611	0.0291	0.26	0.11	Blood osmolality (transformed sodium);	chr2:161916006	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.605	rs62188842	ENSG00000227403.1	AC009299.3	3.44	0.000611	0.0291	0.26	0.11	Blood osmolality (transformed sodium);	chr2:161916600	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.605	rs1913809	ENSG00000227403.1	AC009299.3	3.44	0.000611	0.0291	0.26	0.11	Blood osmolality (transformed sodium);	chr2:161917849	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.502	rs56399725	ENSG00000227403.1	AC009299.3	3.44	0.000611	0.0291	0.26	0.11	Blood osmolality (transformed sodium);	chr2:161918616	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.605	rs62188845	ENSG00000227403.1	AC009299.3	3.44	0.000611	0.0291	0.26	0.11	Blood osmolality (transformed sodium);	chr2:161918729	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.605	rs72865282	ENSG00000227403.1	AC009299.3	3.44	0.000611	0.0291	0.26	0.11	Blood osmolality (transformed sodium);	chr2:161918879	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.605	rs72865285	ENSG00000227403.1	AC009299.3	3.44	0.000611	0.0291	0.26	0.11	Blood osmolality (transformed sodium);	chr2:161919122	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.605	rs62188846	ENSG00000227403.1	AC009299.3	3.44	0.000611	0.0291	0.26	0.11	Blood osmolality (transformed sodium);	chr2:161919351	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.581	rs62188849	ENSG00000227403.1	AC009299.3	3.44	0.000611	0.0291	0.26	0.11	Blood osmolality (transformed sodium);	chr2:161921111	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.605	rs62188850	ENSG00000227403.1	AC009299.3	3.44	0.000611	0.0291	0.26	0.11	Blood osmolality (transformed sodium);	chr2:161922804	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.605	rs62188851	ENSG00000227403.1	AC009299.3	3.44	0.000611	0.0291	0.26	0.11	Blood osmolality (transformed sodium);	chr2:161922940	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.605	rs62188852	ENSG00000227403.1	AC009299.3	3.44	0.000611	0.0291	0.26	0.11	Blood osmolality (transformed sodium);	chr2:161923410	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.605	rs72865298	ENSG00000227403.1	AC009299.3	3.44	0.000611	0.0291	0.26	0.11	Blood osmolality (transformed sodium);	chr2:161924263	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.605	rs72867006	ENSG00000227403.1	AC009299.3	3.44	0.000611	0.0291	0.26	0.11	Blood osmolality (transformed sodium);	chr2:161929148	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.605	rs58510689	ENSG00000227403.1	AC009299.3	3.44	0.000611	0.0291	0.26	0.11	Blood osmolality (transformed sodium);	chr2:161931385	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.605	rs57300571	ENSG00000227403.1	AC009299.3	3.44	0.000611	0.0291	0.26	0.11	Blood osmolality (transformed sodium);	chr2:161931599	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.605	rs61358430	ENSG00000227403.1	AC009299.3	3.44	0.000611	0.0291	0.26	0.11	Blood osmolality (transformed sodium);	chr2:161931747	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.605	rs72867014	ENSG00000227403.1	AC009299.3	3.44	0.000611	0.0291	0.26	0.11	Blood osmolality (transformed sodium);	chr2:161931986	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.605	rs60702957	ENSG00000227403.1	AC009299.3	3.44	0.000611	0.0291	0.26	0.11	Blood osmolality (transformed sodium);	chr2:161933126	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.605	rs62189660	ENSG00000227403.1	AC009299.3	3.44	0.000611	0.0291	0.26	0.11	Blood osmolality (transformed sodium);	chr2:161933491	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.605	rs59699314	ENSG00000227403.1	AC009299.3	3.44	0.000611	0.0291	0.26	0.11	Blood osmolality (transformed sodium);	chr2:161933588	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.685	rs62189662	ENSG00000227403.1	AC009299.3	3.44	0.000611	0.0291	0.26	0.11	Blood osmolality (transformed sodium);	chr2:161933642	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.605	rs56160038	ENSG00000227403.1	AC009299.3	3.44	0.000611	0.0291	0.26	0.11	Blood osmolality (transformed sodium);	chr2:161934332	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.581	rs56378636	ENSG00000227403.1	AC009299.3	3.44	0.000611	0.0291	0.26	0.11	Blood osmolality (transformed sodium);	chr2:161934482	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.685	rs62189666	ENSG00000227403.1	AC009299.3	3.44	0.000611	0.0291	0.26	0.11	Blood osmolality (transformed sodium);	chr2:161935902	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.605	rs62189667	ENSG00000227403.1	AC009299.3	3.44	0.000611	0.0291	0.26	0.11	Blood osmolality (transformed sodium);	chr2:161936527	chr2:161244739~161249050:+
BRCA	cis	rs7829975	0.686	rs907180	ENSG00000233609.3	RP11-62H7.2	3.44	0.000611	0.0291	0.1	0.11	Mood instability;	chr8:8845317	chr8:8961200~8979025:+
BRCA	cis	rs4388249	0.95	rs35342188	ENSG00000271849.1	CTC-332L22.1	-3.44	0.000611	0.0291	-0.17	-0.11	Schizophrenia;	chr5:109755916	chr5:109687802~109688329:-
BRCA	cis	rs4388249	0.95	rs17638690	ENSG00000271849.1	CTC-332L22.1	-3.44	0.000611	0.0291	-0.17	-0.11	Schizophrenia;	chr5:109756113	chr5:109687802~109688329:-
BRCA	cis	rs8098244	0.964	rs7243993	ENSG00000265752.2	RP11-403A21.1	3.44	0.000611	0.0291	0.14	0.11	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23869438	chr18:23957754~23982556:-
BRCA	cis	rs8098244	0.964	rs7229663	ENSG00000265752.2	RP11-403A21.1	3.44	0.000611	0.0291	0.14	0.11	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23869480	chr18:23957754~23982556:-
BRCA	cis	rs11615866	1	rs10492090	ENSG00000202318.1	Y_RNA	-3.44	0.000611	0.0291	-0.18	-0.11	Neuropathic pain in type 2 diabetes;	chr12:5282227	chr12:6234345~6234455:-
BRCA	cis	rs2562456	0.793	rs2650819	ENSG00000268555.1	RP11-678G14.3	-3.44	0.000611	0.0291	-0.14	-0.11	Pain;	chr19:21456071	chr19:21570822~21587322:-
BRCA	cis	rs4372836	0.729	rs7567861	ENSG00000226833.4	AC097724.3	3.44	0.000611	0.0291	0.12	0.11	Body mass index;	chr2:28812983	chr2:28708953~28736205:-
BRCA	cis	rs2076295	0.503	rs1358904	ENSG00000261189.1	RP3-512B11.3	-3.44	0.000611	0.0291	-0.13	-0.11	Idiopathic pulmonary fibrosis;Interstitial lung disease;Chronic obstructive pulmonary disease;	chr6:7564228	chr6:7540451~7541338:-
BRCA	cis	rs6964587	0.967	rs10231496	ENSG00000188693.7	CYP51A1-AS1	-3.44	0.000611	0.0291	-0.12	-0.11	Breast cancer;	chr7:92111818	chr7:92134604~92180725:+
BRCA	cis	rs11723261	0.621	rs7440274	ENSG00000250892.1	RP11-1365D11.1	3.44	0.000611	0.0291	0.17	0.11	Immune response to smallpox vaccine (IL-6);	chr4:161923	chr4:201409~205009:-
BRCA	cis	rs73108077	1	rs73108009	ENSG00000277112.2	RP11-755J8.1	-3.44	0.000611	0.0291	-0.22	-0.11	Red blood cell density in sickle cell anemia;	chr20:31390409	chr20:30681825~30723932:-
BRCA	cis	rs6433921	1	rs10754994	ENSG00000260742.1	RP11-366L5.1	-3.44	0.000611	0.0291	-0.13	-0.11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;	chr2:181556160	chr2:181887851~181891663:-
BRCA	cis	rs12282928	0.885	rs4472898	ENSG00000255197.4	RP11-750H9.5	3.44	0.000611	0.0291	0.1	0.11	Migraine - clinic-based;	chr11:48239431	chr11:47383148~47409190:-
BRCA	cis	rs9866825	0.967	rs6774769	ENSG00000227110.5	LMCD1-AS1	-3.44	0.000611	0.0291	-0.13	-0.11	QT interval;	chr3:8206208	chr3:7952805~8611924:-
BRCA	cis	rs2904524	1	rs74768022	ENSG00000257613.1	LINC01481	-3.44	0.000611	0.0291	-0.18	-0.11	Amyotrophic lateral sclerosis (age of onset);	chr12:70333874	chr12:70219132~70221862:-
BRCA	cis	rs2904524	1	rs17107996	ENSG00000257613.1	LINC01481	-3.44	0.000611	0.0291	-0.18	-0.11	Amyotrophic lateral sclerosis (age of onset);	chr12:70334297	chr12:70219132~70221862:-
BRCA	cis	rs2904524	1	rs74823021	ENSG00000257613.1	LINC01481	-3.44	0.000611	0.0291	-0.18	-0.11	Amyotrophic lateral sclerosis (age of onset);	chr12:70334627	chr12:70219132~70221862:-
BRCA	cis	rs11887277	0.507	rs1368892	ENSG00000272148.1	RP11-195B17.1	-3.44	0.000611	0.0291	-0.12	-0.11	Obesity-related traits;	chr2:26831683	chr2:27062428~27062907:-
BRCA	cis	rs3755605	0.52	rs1082975	ENSG00000242578.1	RP11-469J4.3	3.44	0.000611	0.0291	0.13	0.11	Testicular germ cell tumor;	chr3:170221724	chr3:170410512~170418615:+
BRCA	cis	rs6600671	1	rs7532615	ENSG00000223345.3	HIST2H2BA	-3.44	0.000611	0.0291	-0.12	-0.11	Hip geometry;	chr1:121430980	chr1:121108210~121117257:-
BRCA	cis	rs739496	0.947	rs34368158	ENSG00000257624.1	RP1-128M12.3	3.44	0.000612	0.0291	0.15	0.11	Platelet count;	chr12:111408224	chr12:112000739~112000985:-
BRCA	cis	rs17197037	0.545	rs8010980	ENSG00000277734.3	TRAC	-3.44	0.000612	0.0291	-0.07	-0.11	Bipolar disorder;	chr14:21318343	chr14:22281105~22552155:+
BRCA	cis	rs1411478	1	rs3747957	ENSG00000243155.1	RP11-46A10.5	3.44	0.000612	0.0291	0.11	0.11	Menopause (age at onset);Progressive supranuclear palsy;	chr1:180984717	chr1:180944042~180976482:-
BRCA	cis	rs4578769	0.959	rs4800430	ENSG00000273232.1	RP11-370A5.2	3.44	0.000612	0.0291	0.14	0.11	Eosinophil percentage of white cells;	chr18:22803299	chr18:22882825~22883357:-
BRCA	cis	rs6088580	0.634	rs4911420	ENSG00000269202.1	RP4-614O4.12	3.44	0.000612	0.0291	0.11	0.11	Glomerular filtration rate (creatinine);	chr20:34410848	chr20:35201747~35203288:-
BRCA	cis	rs3753275	0.624	rs10864364	ENSG00000230679.1	ENO1-AS1	-3.44	0.000612	0.0291	-0.15	-0.11	Educational attainment;	chr1:8707721	chr1:8878835~8879894:+
BRCA	cis	rs4650943	0.9	rs4233166	ENSG00000227740.1	RP11-318C24.2	-3.44	0.000612	0.0291	-0.11	-0.11	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in inactive individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr1:176442065	chr1:175904762~175920513:-
BRCA	cis	rs2154319	0.836	rs213768	ENSG00000230638.4	RP11-486B10.4	3.44	0.000612	0.0291	0.18	0.11	Height;	chr1:41152770	chr1:41542069~41544310:+
BRCA	cis	rs60871478	0.588	rs56205589	ENSG00000237181.1	AC147651.4	3.44	0.000612	0.0291	0.12	0.11	Cerebrospinal P-tau181p levels;	chr7:870782	chr7:603185~608482:+
BRCA	cis	rs250518	0.926	rs3846650	ENSG00000271926.1	CTD-2376I4.1	3.44	0.000612	0.0291	0.14	0.11	Mean corpuscular hemoglobin concentration;	chr5:72768560	chr5:72953635~72954274:-
BRCA	cis	rs17092148	0.836	rs6059910	ENSG00000202150.1	RNU6-407P	3.44	0.000612	0.0291	0.15	0.11	Neuroticism;	chr20:34554303	chr20:35030317~35030420:-
BRCA	cis	rs61931739	0.534	rs4931775	ENSG00000258794.3	DUX4L27	3.44	0.000612	0.0291	0.15	0.11	Morning vs. evening chronotype;	chr12:33897794	chr12:34208415~34209675:-
BRCA	cis	rs61931739	0.517	rs7975714	ENSG00000258794.3	DUX4L27	3.44	0.000612	0.0291	0.15	0.11	Morning vs. evening chronotype;	chr12:33902676	chr12:34208415~34209675:-
BRCA	cis	rs61931739	0.517	rs7960878	ENSG00000258794.3	DUX4L27	3.44	0.000612	0.0291	0.15	0.11	Morning vs. evening chronotype;	chr12:33902710	chr12:34208415~34209675:-
BRCA	cis	rs61931739	0.517	rs1843738	ENSG00000258794.3	DUX4L27	3.44	0.000612	0.0291	0.15	0.11	Morning vs. evening chronotype;	chr12:33904000	chr12:34208415~34209675:-
BRCA	cis	rs61931739	0.5	rs11052990	ENSG00000258794.3	DUX4L27	3.44	0.000612	0.0291	0.15	0.11	Morning vs. evening chronotype;	chr12:33905712	chr12:34208415~34209675:-
BRCA	cis	rs2985684	0.841	rs12894785	ENSG00000258568.1	RHOQP1	3.44	0.000612	0.0291	0.13	0.11	Carotid intima media thickness;	chr14:49583037	chr14:49599994~49600572:+
BRCA	cis	rs8105895	0.867	rs12151358	ENSG00000269345.1	VN1R85P	3.44	0.000612	0.0291	0.17	0.11	Body mass index (change over time);	chr19:22099806	chr19:22174766~22175191:-
BRCA	cis	rs7020830	0.867	rs1339553	ENSG00000230188.1	RP11-405L18.4	-3.44	0.000612	0.0291	-0.13	-0.11	Schizophrenia;	chr9:37266126	chr9:37490421~37490893:-
BRCA	cis	rs6840360	0.571	rs12648420	ENSG00000278978.1	RP11-164P12.5	-3.44	0.000612	0.0291	-0.13	-0.11	Intelligence (multi-trait analysis);	chr4:151622282	chr4:151669786~151670503:+
BRCA	cis	rs8105895	0.935	rs8108976	ENSG00000269345.1	VN1R85P	3.44	0.000613	0.0291	0.15	0.11	Body mass index (change over time);	chr19:22068899	chr19:22174766~22175191:-
BRCA	cis	rs56281245	0.793	rs74796977	ENSG00000249363.1	CTB-78O21.1	3.44	0.000613	0.0291	0.22	0.11	Hepcidin levels;	chr5:145577124	chr5:145728360~145729349:-
BRCA	cis	rs36051895	0.664	rs3780372	ENSG00000237711.1	RP11-39K24.13	-3.44	0.000613	0.0292	-0.13	-0.11	Pediatric autoimmune diseases;	chr9:5097544	chr9:5100236~5101009:+
BRCA	cis	rs2985684	0.74	rs2883438	ENSG00000258568.1	RHOQP1	3.44	0.000613	0.0292	0.13	0.11	Carotid intima media thickness;	chr14:49577674	chr14:49599994~49600572:+
BRCA	cis	rs4869313	0.668	rs6874656	ENSG00000248734.2	CTD-2260A17.1	-3.44	0.000613	0.0292	-0.11	-0.11	Pediatric autoimmune diseases;	chr5:96898671	chr5:96784777~96785999:+
BRCA	cis	rs4699052	1	rs7694190	ENSG00000230069.3	LRRC37A15P	-3.44	0.000613	0.0292	-0.1	-0.11	Testicular germ cell tumor;	chr4:103246860	chr4:102727274~102730721:-
BRCA	cis	rs2041840	0.53	rs3845783	ENSG00000272054.1	RP11-423P10.2	3.44	0.000613	0.0292	0.1	0.11	Chronic lymphocytic leukemia;	chr2:37174881	chr2:37208875~37212677:+
BRCA	cis	rs58521262	0.729	rs58977014	ENSG00000268105.1	RP11-369G6.2	-3.44	0.000613	0.0292	-0.18	-0.11	Testicular germ cell tumor;	chr19:22879427	chr19:23125665~23128543:+
BRCA	cis	rs7405404	0.672	rs1126144	ENSG00000276564.1	CTA-276F8.1	-3.44	0.000613	0.0292	-0.12	-0.11	Bipolar disorder lithium response (categorical) or schizophrenia;Schizophrenia;	chr16:13640009	chr16:14150833~14153235:+
BRCA	cis	rs1039766	1	rs268870	ENSG00000227791.3	AC007365.4	-3.44	0.000613	0.0292	-0.16	-0.11	Lung adenocarcinoma;Lung cancer;	chr2:65256415	chr2:64665607~64666064:+
BRCA	cis	rs4930561	0.714	rs7950451	ENSG00000255306.1	RP5-901A4.1	-3.44	0.000613	0.0292	-0.11	-0.11	Breast cancer in childhood cancer survivors;IgG glycosylation;	chr11:68194939	chr11:68024809~68030461:-
BRCA	cis	rs4930561	0.714	rs7950452	ENSG00000255306.1	RP5-901A4.1	-3.44	0.000613	0.0292	-0.11	-0.11	Breast cancer in childhood cancer survivors;IgG glycosylation;	chr11:68194940	chr11:68024809~68030461:-
BRCA	cis	rs4930561	0.765	rs34493482	ENSG00000255306.1	RP5-901A4.1	-3.44	0.000613	0.0292	-0.11	-0.11	Breast cancer in childhood cancer survivors;IgG glycosylation;	chr11:68202041	chr11:68024809~68030461:-
BRCA	cis	rs62458065	0.713	rs62463968	ENSG00000281332.1	LINC00997	-3.44	0.000613	0.0292	-0.16	-0.11	Metabolite levels (HVA/MHPG ratio);	chr7:32461630	chr7:32760279~32762924:+
BRCA	cis	rs36051895	0.589	rs62543574	ENSG00000237711.1	RP11-39K24.13	-3.44	0.000613	0.0292	-0.13	-0.11	Pediatric autoimmune diseases;	chr9:5204090	chr9:5100236~5101009:+
BRCA	cis	rs1401999	0.898	rs9876143	ENSG00000223882.1	ABCC5-AS1	-3.44	0.000613	0.0292	-0.12	-0.11	Anterior chamber depth;	chr3:184013574	chr3:184006338~184011419:+
BRCA	cis	rs7246967	0.611	rs2617780	ENSG00000198153.8	ZNF849P	-3.44	0.000613	0.0292	-0.2	-0.11	Bronchopulmonary dysplasia;	chr19:22809388	chr19:22685167~22686732:+
BRCA	cis	rs1466788	0.932	rs3768469	ENSG00000224965.1	KCNC4-AS1	3.44	0.000613	0.0292	0.12	0.11	Blood metabolite levels;	chr1:110071778	chr1:110208834~110209987:-
BRCA	cis	rs2478118	0.509	rs7093277	ENSG00000273474.1	RP11-295P9.12	-3.44	0.000613	0.0292	-0.1	-0.11	Lupus nephritis in systemic lupus erythematosus;	chr10:13668897	chr10:13675646~13675990:+
BRCA	cis	rs748404	0.589	rs62020612	ENSG00000166763.7	STRCP1	3.44	0.000613	0.0292	0.15	0.11	Lung cancer;	chr15:43525881	chr15:43699488~43718184:-
BRCA	cis	rs1144333	1	rs5745392	ENSG00000181227.3	RP4-682C21.2	-3.44	0.000613	0.0292	-0.15	-0.11	Attention function in attention deficit hyperactive disorder;	chr1:75841124	chr1:75743423~75744776:-
BRCA	cis	rs875971	0.862	rs9791712	ENSG00000265600.1	AC006480.1	3.44	0.000613	0.0292	0.13	0.11	Aortic root size;	chr7:66640176	chr7:67356680~67356779:+
BRCA	cis	rs875971	0.862	rs9791713	ENSG00000265600.1	AC006480.1	3.44	0.000613	0.0292	0.13	0.11	Aortic root size;	chr7:66640211	chr7:67356680~67356779:+
BRCA	cis	rs987724	0.593	rs10212230	ENSG00000240875.4	LINC00886	-3.44	0.000613	0.0292	-0.12	-0.11	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156973164	chr3:156747346~156817062:-
BRCA	cis	rs3755605	0.664	rs6809704	ENSG00000242578.1	RP11-469J4.3	3.44	0.000613	0.0292	0.13	0.11	Testicular germ cell tumor;	chr3:170194960	chr3:170410512~170418615:+
BRCA	cis	rs3755605	0.662	rs6797517	ENSG00000242578.1	RP11-469J4.3	3.44	0.000613	0.0292	0.13	0.11	Testicular germ cell tumor;	chr3:170195044	chr3:170410512~170418615:+
BRCA	cis	rs3760982	0.967	rs12463346	ENSG00000267191.1	RP11-15A1.2	-3.44	0.000613	0.0292	-0.13	-0.11	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43788092	chr19:43902001~43926545:+
BRCA	cis	rs7188697	0.922	rs246258	ENSG00000276259.1	RP11-481J2.4	3.44	0.000613	0.0292	0.12	0.11	QT interval;	chr16:58545370	chr16:58522970~58523842:+
BRCA	cis	rs7264396	0.563	rs2425136	ENSG00000088340.14	FER1L4	-3.44	0.000614	0.0292	-0.15	-0.11	Total cholesterol levels;	chr20:35756860	chr20:35558737~35607562:-
BRCA	cis	rs10411161	0.702	rs7247017	ENSG00000268095.1	ZNF649-AS1	3.44	0.000614	0.0292	0.19	0.11	Breast cancer;	chr19:51888516	chr19:51888025~51900463:+
BRCA	cis	rs10411161	0.702	rs7256926	ENSG00000268095.1	ZNF649-AS1	3.44	0.000614	0.0292	0.19	0.11	Breast cancer;	chr19:51888735	chr19:51888025~51900463:+
BRCA	cis	rs45509595	0.841	rs9368531	ENSG00000241549.7	GUSBP2	3.44	0.000614	0.0292	0.19	0.11	Breast cancer;	chr6:27814094	chr6:26871484~26956554:-
BRCA	cis	rs45509595	0.841	rs2747054	ENSG00000241549.7	GUSBP2	3.44	0.000614	0.0292	0.19	0.11	Breast cancer;	chr6:27815581	chr6:26871484~26956554:-
BRCA	cis	rs984222	0.967	rs10802069	ENSG00000231365.4	RP11-418J17.1	-3.44	0.000614	0.0292	-0.13	-0.11	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:118974734	chr1:119140396~119275973:+
BRCA	cis	rs1421334	0.781	rs11778607	ENSG00000253961.1	RP11-363L24.3	3.44	0.000614	0.0292	0.12	0.11	Intelligence (multi-trait analysis);	chr8:30982052	chr8:31167078~31177167:-
BRCA	cis	rs2243480	0.901	rs1701759	ENSG00000226767.1	RP11-328P23.3	-3.44	0.000614	0.0292	-0.18	-0.11	Diabetic kidney disease;	chr7:66005945	chr7:65508773~65508944:-
BRCA	cis	rs739401	0.566	rs7931504	ENSG00000247473.2	CARS-AS1	3.44	0.000614	0.0292	0.12	0.11	Longevity;	chr11:3005482	chr11:3029009~3041260:+
BRCA	cis	rs7339483	0.702	rs13344859	ENSG00000269416.4	LINC01224	3.44	0.000614	0.0292	0.23	0.11	Discordance in emotional problems in monozygotic twins;	chr19:24187286	chr19:23399233~23416075:-
BRCA	cis	rs875971	0.666	rs13242072	ENSG00000230189.5	GS1-124K5.2	-3.44	0.000614	0.0292	-0.08	-0.11	Aortic root size;	chr7:66301001	chr7:66409143~66490059:-
BRCA	cis	rs2911132	0.628	rs2032890	ENSG00000251000.1	AC008592.3	3.44	0.000614	0.0292	0.13	0.11	Urate levels (BMI interaction);	chr5:96785448	chr5:95834424~95835046:-
BRCA	cis	rs7239883	0.5	rs60232560	ENSG00000267652.1	RP11-188I24.1	3.44	0.000614	0.0292	0.15	0.11	Waist circumference;Body mass index;	chr18:42511494	chr18:41789162~41789395:-
BRCA	cis	rs12413361	0.967	rs2994655	ENSG00000237135.1	DDX10P1	3.44	0.000614	0.0292	0.12	0.11	Height;	chr10:30836579	chr10:30919012~30921235:-
BRCA	cis	rs1131351	0.61	rs2881925	ENSG00000234378.1	AC098828.2	3.44	0.000614	0.0292	0.12	0.11	Seasonality;	chr2:20190933	chr2:20063856~20106829:-
BRCA	cis	rs7267979	0.844	rs6050477	ENSG00000274414.1	RP5-965G21.4	3.44	0.000614	0.0292	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25240911	chr20:25239007~25245229:-
BRCA	cis	rs13126694	0.744	rs7691516	ENSG00000251073.1	NUDT19P5	3.44	0.000614	0.0292	0.1	0.11	Blood osmolality (transformed sodium);	chr4:158073326	chr4:158182825~158183393:+
BRCA	cis	rs9951698	0.703	rs692964	ENSG00000266969.1	RP11-773H22.4	3.44	0.000614	0.0292	0.14	0.11	Intelligence (multi-trait analysis);	chr18:13094133	chr18:12984694~12991173:-
BRCA	cis	rs7590268	0.806	rs12477823	ENSG00000279873.2	LINC01126	3.44	0.000614	0.0292	0.13	0.11	Orofacial clefts;	chr2:43393181	chr2:43227210~43228855:+
BRCA	cis	rs853679	0.599	rs156743	ENSG00000216901.1	AL022393.7	3.44	0.000614	0.0292	0.21	0.11	Depression;	chr6:27999311	chr6:28176188~28176674:+
BRCA	cis	rs881375	1	rs1609810	ENSG00000238181.2	AHCYP2	-3.44	0.000614	0.0292	-0.13	-0.11	Rheumatoid arthritis;	chr9:120880073	chr9:120720673~120721972:+
BRCA	cis	rs910316	1	rs12889472	ENSG00000259138.1	RP11-950C14.7	3.44	0.000614	0.0292	0.11	0.11	Height;	chr14:75077276	chr14:75127153~75136930:+
BRCA	cis	rs6586111	1	rs4934371	ENSG00000226659.1	RP11-137H2.4	3.44	0.000614	0.0292	0.14	0.11	Capecitabine sensitivity;	chr10:80613039	chr10:80529597~80535942:-
BRCA	cis	rs4819052	0.851	rs28616694	ENSG00000223768.1	LINC00205	-3.44	0.000614	0.0292	-0.14	-0.11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45254871	chr21:45293285~45297354:+
BRCA	cis	rs13153459	0.602	rs72748092	ENSG00000279557.1	CTD-2210P15.3	-3.44	0.000614	0.0292	-0.2	-0.11	Parkinson's disease;	chr5:44518995	chr5:43586367~43587543:-
BRCA	cis	rs2411233	1	rs9920253	ENSG00000259278.1	RP11-62C7.2	3.44	0.000614	0.0292	0.12	0.11	Platelet count;	chr15:38981333	chr15:39019233~39024918:+
BRCA	cis	rs2411233	0.967	rs9920221	ENSG00000259278.1	RP11-62C7.2	3.44	0.000614	0.0292	0.12	0.11	Platelet count;	chr15:38981465	chr15:39019233~39024918:+
BRCA	cis	rs12760731	0.92	rs16852934	ENSG00000213057.5	C1orf220	3.44	0.000614	0.0292	0.14	0.11	Obesity-related traits;	chr1:178510155	chr1:178542752~178548889:+
BRCA	cis	rs4767841	0.935	rs904655	ENSG00000248636.5	RP11-768F21.1	-3.44	0.000614	0.0292	-0.13	-0.11	Urgency urinary incontinence;	chr12:119752074	chr12:119387987~119668079:-
BRCA	cis	rs6728642	0.908	rs9973669	ENSG00000275655.1	Metazoa_SRP	-3.44	0.000614	0.0292	-0.21	-0.11	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:97013357	chr2:97100587~97100874:+
BRCA	cis	rs732765	0.657	rs8016513	ENSG00000270000.1	RP3-449M8.9	-3.44	0.000614	0.0292	-0.17	-0.11	Non-small cell lung cancer;	chr14:74771558	chr14:74471930~74472360:-
BRCA	cis	rs4665809	0.877	rs35224700	ENSG00000231655.1	AC011742.3	-3.44	0.000614	0.0292	-0.18	-0.11	Gut microbiome composition (summer);	chr2:26075168	chr2:26140263~26141264:-
BRCA	cis	rs8064024	0.56	rs741769	ENSG00000267077.1	RP11-127I20.5	3.44	0.000614	0.0292	0.11	0.11	Cancer;	chr16:4886204	chr16:4795265~4796532:-
BRCA	cis	rs853679	0.55	rs1233707	ENSG00000261839.1	RP1-265C24.8	3.44	0.000614	0.0292	0.14	0.11	Depression;	chr6:28205175	chr6:28136849~28139678:+
BRCA	cis	rs4332037	0.802	rs12113633	ENSG00000273230.1	RP11-1246C19.1	3.44	0.000615	0.0292	0.17	0.11	Bipolar disorder;	chr7:1893300	chr7:1464497~1467522:-
BRCA	cis	rs4761470	0.577	rs35129588	ENSG00000258365.1	RP11-1105G2.3	-3.44	0.000615	0.0292	-0.14	-0.11	Estradiol plasma levels (breast cancer);	chr12:94297780	chr12:94277758~94282844:-
BRCA	cis	rs6600671	1	rs11249350	ENSG00000223345.3	HIST2H2BA	3.44	0.000615	0.0292	0.13	0.11	Hip geometry;	chr1:121436587	chr1:121108210~121117257:-
BRCA	cis	rs2835345	0.511	rs57583267	ENSG00000233818.1	AP000695.4	3.44	0.000615	0.0292	0.12	0.11	Pulmonary function;	chr21:36445230	chr21:36445731~36532408:+
BRCA	cis	rs6540731	0.521	rs10779572	ENSG00000229983.1	RP11-15I11.2	-3.44	0.000615	0.0292	-0.12	-0.11	Intelligence (childhood);	chr1:212181070	chr1:212168207~212190259:+
BRCA	cis	rs1865760	1	rs7739966	ENSG00000272810.1	U91328.22	-3.44	0.000615	0.0292	-0.12	-0.11	Height;	chr6:25905812	chr6:26013241~26013757:+
BRCA	cis	rs1865760	1	rs56118523	ENSG00000272810.1	U91328.22	-3.44	0.000615	0.0292	-0.12	-0.11	Height;	chr6:25908747	chr6:26013241~26013757:+
BRCA	cis	rs1865760	1	rs12209482	ENSG00000272810.1	U91328.22	-3.44	0.000615	0.0292	-0.12	-0.11	Height;	chr6:25909001	chr6:26013241~26013757:+
BRCA	cis	rs7267979	1	rs6050609	ENSG00000231081.1	RP4-760C5.3	3.44	0.000615	0.0292	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25431115	chr20:26008791~26010531:-
BRCA	cis	rs1348850	0.914	rs2060929	ENSG00000280374.1	RP11-337N6.3	3.44	0.000615	0.0292	0.14	0.11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177415303	chr2:177317715~177318471:-
BRCA	cis	rs977987	0.806	rs4888411	ENSG00000261476.1	RP11-77K12.3	-3.44	0.000615	0.0292	-0.12	-0.11	Dupuytren's disease;	chr16:75409285	chr16:75458252~75460017:-
BRCA	cis	rs12893668	0.703	rs2403197	ENSG00000258534.1	CTD-2134A5.4	3.44	0.000615	0.0292	0.14	0.11	Reticulocyte count;	chr14:103587427	chr14:103854366~103880111:-
BRCA	cis	rs10819083	0.666	rs10760400	ENSG00000232630.1	PRPS1P2	-3.44	0.000615	0.0292	-0.11	-0.11	Squamous cell lung carcinoma;	chr9:125761990	chr9:125150653~125151589:+
BRCA	cis	rs35146811	0.538	rs3823642	ENSG00000214313.7	AZGP1P1	3.44	0.000615	0.0292	0.11	0.11	Coronary artery disease;	chr7:100198449	chr7:99980762~99987535:+
BRCA	cis	rs91731	0.92	rs7723475	ENSG00000249572.1	CTD-2203K17.1	3.44	0.000615	0.0292	0.2	0.11	Lung function (FVC);	chr5:33232213	chr5:33424025~33440619:-
BRCA	cis	rs12724450	0.793	rs11799813	ENSG00000228126.1	FALEC	3.44	0.000615	0.0292	0.2	0.11	Blood protein levels;	chr1:150363264	chr1:150515757~150518032:+
BRCA	cis	rs13315871	1	rs9864325	ENSG00000272182.1	RP11-802O23.3	3.44	0.000615	0.0292	0.21	0.11	Cholesterol, total;	chr3:58351119	chr3:58428255~58428815:+
BRCA	cis	rs16852403	0.583	rs12071903	ENSG00000224687.1	RASAL2-AS1	3.44	0.000615	0.0292	0.14	0.11	Childhood ear infection;	chr1:178126669	chr1:178091508~178093984:-
BRCA	cis	rs12135894	0.562	rs6688969	ENSG00000266075.2	RN7SL574P	-3.44	0.000615	0.0292	-0.13	-0.11	Mean corpuscular volume;	chr1:3826827	chr1:3782815~3783111:+
BRCA	cis	rs6012953	1	rs6020586	ENSG00000231715.1	COX6CP2	3.44	0.000615	0.0292	0.11	0.11	Vitiligo;	chr20:50539126	chr20:50479767~50479991:+
BRCA	cis	rs6088590	0.707	rs67159833	ENSG00000269202.1	RP4-614O4.12	-3.44	0.000615	0.0292	-0.12	-0.11	Coronary artery disease;	chr20:34900276	chr20:35201747~35203288:-
BRCA	cis	rs6600671	0.764	rs6600673	ENSG00000227082.1	CH17-437K3.1	-3.44	0.000615	0.0293	-0.13	-0.11	Hip geometry;	chr1:121426988	chr1:121396754~121463129:+
BRCA	cis	rs7546	0.504	rs2075637	ENSG00000267077.1	RP11-127I20.5	-3.44	0.000615	0.0293	-0.11	-0.11	Cancer;	chr16:4888279	chr16:4795265~4796532:-
BRCA	cis	rs7713065	1	rs3857440	ENSG00000202533.1	Y_RNA	3.44	0.000615	0.0293	0.11	0.11	Lung function (FEV1/FVC);	chr5:132458377	chr5:132468147~132468257:+
BRCA	cis	rs16917546	0.967	rs10995243	ENSG00000238280.1	RP11-436D10.3	3.44	0.000615	0.0293	0.14	0.11	Basal cell carcinoma;	chr10:62631448	chr10:62793562~62805887:-
BRCA	cis	rs6997458	0.742	rs10095352	ENSG00000258256.1	RP11-219B4.5	-3.44	0.000615	0.0293	-0.12	-0.11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85460203	chr8:85222446~85245717:-
BRCA	cis	rs952623	0.649	rs6462887	ENSG00000227191.5	TRGC2	3.44	0.000615	0.0293	0.1	0.11	Intelligence (multi-trait analysis);	chr7:39028036	chr7:38239580~38368091:-
BRCA	cis	rs988913	0.678	rs4490665	ENSG00000261116.1	RP3-523K23.2	-3.44	0.000615	0.0293	-0.13	-0.11	Menarche (age at onset);	chr6:55126019	chr6:54943167~54945099:+
BRCA	cis	rs988913	0.678	rs9367615	ENSG00000261116.1	RP3-523K23.2	-3.44	0.000615	0.0293	-0.13	-0.11	Menarche (age at onset);	chr6:55126485	chr6:54943167~54945099:+
BRCA	cis	rs2262909	0.962	rs2017521	ENSG00000279377.1	AC003973.3	3.44	0.000615	0.0293	0.15	0.11	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;	chr19:21943336	chr19:21965708~21968529:-
BRCA	cis	rs2262909	1	rs2175366	ENSG00000279377.1	AC003973.3	3.44	0.000615	0.0293	0.15	0.11	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;	chr19:21945477	chr19:21965708~21968529:-
BRCA	cis	rs10844706	0.699	rs10844615	ENSG00000256594.6	RP11-705C15.2	3.44	0.000616	0.0293	0.14	0.11	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9725646	chr12:9633419~9658412:+
BRCA	cis	rs7112925	0.966	rs11602157	ENSG00000255517.5	CTD-3074O7.5	3.44	0.000616	0.0293	0.13	0.11	Height;	chr11:67059848	chr11:66473490~66480233:-
BRCA	cis	rs6490294	0.571	rs7295294	ENSG00000257624.1	RP1-128M12.3	3.44	0.000616	0.0293	0.17	0.11	Mean platelet volume;	chr12:112027089	chr12:112000739~112000985:-
BRCA	cis	rs17711722	0.727	rs1880555	ENSG00000229180.5	GS1-124K5.11	3.44	0.000616	0.0293	0.09	0.11	Calcium levels;	chr7:65967580	chr7:66526088~66542624:-
BRCA	cis	rs875971	0.862	rs10274883	ENSG00000271064.1	RP11-792A8.3	3.44	0.000616	0.0293	0.13	0.11	Aortic root size;	chr7:66651104	chr7:66748838~66749077:-
BRCA	cis	rs9287719	0.967	rs6744599	ENSG00000224177.5	LINC00570	-3.44	0.000616	0.0293	-0.12	-0.11	Prostate cancer;	chr2:10606887	chr2:11393981~11403077:+
BRCA	cis	rs7960483	0.627	rs4277177	ENSG00000258096.1	RP11-474P2.2	3.44	0.000616	0.0293	0.12	0.11	Hypertension (SNP x SNP interaction);	chr12:45548488	chr12:46371463~46373778:+
BRCA	cis	rs62103177	0.608	rs4799115	ENSG00000267270.4	PARD6G-AS1	-3.44	0.000616	0.0293	-0.17	-0.11	Opioid sensitivity;	chr18:79976365	chr18:80147924~80178432:+
BRCA	cis	rs4950322	0.547	rs56864370	ENSG00000230832.3	RP11-325P15.2	-3.44	0.000616	0.0293	-0.16	-0.11	Protein quantitative trait loci;	chr1:147111847	chr1:147082338~147083578:-
BRCA	cis	rs4578769	0.842	rs7243256	ENSG00000273232.1	RP11-370A5.2	3.43	0.000616	0.0293	0.14	0.11	Eosinophil percentage of white cells;	chr18:22936411	chr18:22882825~22883357:-
BRCA	cis	rs4578769	0.842	rs9966323	ENSG00000273232.1	RP11-370A5.2	3.43	0.000616	0.0293	0.14	0.11	Eosinophil percentage of white cells;	chr18:22936418	chr18:22882825~22883357:-
BRCA	cis	rs6019512	0.625	rs6012556	ENSG00000227431.4	CSE1L-AS1	-3.43	0.000616	0.0293	-0.12	-0.11	Intelligence (multi-trait analysis);	chr20:48911906	chr20:49040463~49046044:-
BRCA	cis	rs2041840	1	rs2540977	ENSG00000272054.1	RP11-423P10.2	-3.43	0.000616	0.0293	-0.1	-0.11	Chronic lymphocytic leukemia;	chr2:37235085	chr2:37208875~37212677:+
BRCA	cis	rs9866825	0.967	rs12487337	ENSG00000227110.5	LMCD1-AS1	3.43	0.000616	0.0293	0.13	0.11	QT interval;	chr3:8206021	chr3:7952805~8611924:-
BRCA	cis	rs72793342	0.651	rs8050463	ENSG00000235560.3	AC002310.12	3.43	0.000616	0.0293	0.14	0.11	RANTES levels;	chr16:30542838	chr16:30534752~30537144:+
BRCA	cis	rs12310956	0.532	rs11052948	ENSG00000258794.3	DUX4L27	3.43	0.000616	0.0293	0.15	0.11	Morning vs. evening chronotype;	chr12:33829038	chr12:34208415~34209675:-
BRCA	cis	rs897984	0.609	rs17839567	ENSG00000260267.1	RP11-452L6.5	3.43	0.000616	0.0293	0.1	0.11	Dementia with Lewy bodies;	chr16:31046624	chr16:31456711~31459736:-
BRCA	cis	rs4781563	0.636	rs836876	ENSG00000242307.1	RPS26P52	3.43	0.000616	0.0293	0.16	0.11	Bilirubin levels;	chr16:13973146	chr16:13922332~13922679:-
BRCA	cis	rs6585424	0.85	rs61860036	ENSG00000225484.5	NUTM2B-AS1	-3.43	0.000616	0.0293	-0.22	-0.11	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80175103	chr10:79663088~79826594:-
BRCA	cis	rs11892454	0.599	rs7609372	ENSG00000217643.1	PTGES3P2	-3.43	0.000616	0.0293	-0.12	-0.11	Heschl's gyrus morphology;	chr2:25746694	chr2:25822469~25822950:+
BRCA	cis	rs34467563	0.67	rs6990150	ENSG00000253105.4	KB-1448A5.1	3.43	0.000616	0.0293	0.13	0.11	Lobe attachment (rater-scored or self-reported);	chr8:96356394	chr8:96371865~96387438:-
BRCA	cis	rs2310173	0.575	rs13022757	ENSG00000281162.1	LINC01127	-3.43	0.000616	0.0293	-0.11	-0.11	Ulcerative colitis;Ankylosing spondylitis;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr2:101997084	chr2:101962056~101987167:+
BRCA	cis	rs10782582	0.545	rs12138018	ENSG00000181227.3	RP4-682C21.2	3.43	0.000616	0.0293	0.11	0.11	Daytime sleep phenotypes;	chr1:75721109	chr1:75743423~75744776:-
BRCA	cis	rs8012947	0.545	rs1190980	ENSG00000180189.10	HMGB1P14	-3.43	0.000616	0.0293	-0.12	-0.11	Alcohol consumption in current drinkers;	chr14:58348088	chr14:58284773~58285363:+
BRCA	cis	rs8094794	0.744	rs28578323	ENSG00000267707.2	RP11-95O2.5	3.43	0.000616	0.0293	0.15	0.11	Periodontal disease-related phenotypes;	chr18:36708097	chr18:37243776~37247506:+
BRCA	cis	rs11170468	0.621	rs61939205	ENSG00000257718.1	RP11-396F22.1	-3.43	0.000616	0.0293	-0.13	-0.11	Body mass index;	chr12:39133062	chr12:38906451~38909592:+
BRCA	cis	rs10799445	0.508	rs10916165	ENSG00000227711.2	RP11-275O4.5	3.43	0.000616	0.0293	0.12	0.11	Height;	chr1:227567234	chr1:227509028~227520477:-
BRCA	cis	rs6493487	0.512	rs12324214	ENSG00000259298.1	RP11-562A8.4	3.43	0.000616	0.0293	0.12	0.11	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr15:50827284	chr15:50497195~50498744:-
BRCA	cis	rs10829156	1	rs10829156	ENSG00000240291.1	RP11-499P20.2	3.43	0.000616	0.0293	0.12	0.11	Sudden cardiac arrest;	chr10:18661626	chr10:18513115~18545651:-
BRCA	cis	rs6570726	0.526	rs4896805	ENSG00000270638.1	RP3-466P17.1	-3.43	0.000617	0.0293	-0.12	-0.11	Lobe attachment (rater-scored or self-reported);	chr6:145414293	chr6:145735570~145737218:+
BRCA	cis	rs12118297	0.882	rs6689223	ENSG00000261737.1	RP4-612B15.3	-3.43	0.000617	0.0293	-0.16	-0.11	Breast cancer;	chr1:87301704	chr1:86703502~86704462:-
BRCA	cis	rs875971	0.862	rs3893216	ENSG00000106610.13	STAG3L4	3.43	0.000617	0.0293	0.14	0.11	Aortic root size;	chr7:66325720	chr7:67302621~67321526:+
BRCA	cis	rs875971	0.862	rs6958294	ENSG00000106610.13	STAG3L4	3.43	0.000617	0.0293	0.14	0.11	Aortic root size;	chr7:66329809	chr7:67302621~67321526:+
BRCA	cis	rs875971	0.862	rs2088655	ENSG00000106610.13	STAG3L4	3.43	0.000617	0.0293	0.14	0.11	Aortic root size;	chr7:66330724	chr7:67302621~67321526:+
BRCA	cis	rs875971	0.895	rs10447522	ENSG00000106610.13	STAG3L4	3.43	0.000617	0.0293	0.14	0.11	Aortic root size;	chr7:66331087	chr7:67302621~67321526:+
BRCA	cis	rs7695732	0.7	rs62306390	ENSG00000270720.1	RP11-84C13.2	3.43	0.000617	0.0293	0.14	0.11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr4:89110177	chr4:89119284~89119871:+
BRCA	cis	rs6012564	1	rs56131635	ENSG00000230758.1	SNAP23P	3.43	0.000617	0.0293	0.12	0.11	Anger;	chr20:49157806	chr20:49038357~49038602:-
BRCA	cis	rs34779708	0.931	rs11010125	ENSG00000269952.1	RP11-324I22.3	-3.43	0.000617	0.0293	-0.14	-0.11	Inflammatory bowel disease;Crohn's disease;	chr10:35214025	chr10:35210416~35210750:+
BRCA	cis	rs9437689	0.966	rs6687450	ENSG00000235501.4	RP4-639F20.1	-3.43	0.000617	0.0293	-0.13	-0.11	Phospholipid levels (plasma);	chr1:95015020	chr1:94927566~94963270:+
BRCA	cis	rs2664588	0.613	rs6125186	ENSG00000276923.1	RP11-321P16.1	3.43	0.000617	0.0293	0.14	0.11	Cerebrospinal fluid AB1-42 levels;	chr20:47953547	chr20:48073869~48074188:+
BRCA	cis	rs62025270	0.688	rs62022939	ENSG00000259416.2	RP11-158M2.5	-3.43	0.000617	0.0293	-0.16	-0.11	Idiopathic pulmonary fibrosis;	chr15:85707651	chr15:85754941~85756237:-
BRCA	cis	rs8180040	0.587	rs1466741	ENSG00000280667.1	Y_RNA	-3.43	0.000617	0.0293	-0.12	-0.11	Colorectal cancer;	chr3:47205724	chr3:47501083~47501182:+
BRCA	cis	rs783540	0.967	rs4779044	ENSG00000274376.3	ADAMTS7P1	3.43	0.000617	0.0293	0.12	0.11	Schizophrenia;	chr15:82670601	chr15:82298553~82334609:+
BRCA	cis	rs75757892	0.621	rs111582393	ENSG00000236512.1	RP3-336K20__B.2	3.43	0.000617	0.0293	0.18	0.11	Hematocrit;Red blood cell count;	chr6:7291200	chr6:7620422~7620878:+
BRCA	cis	rs2880765	0.835	rs4514633	ENSG00000230373.7	GOLGA6L5P	3.43	0.000617	0.0293	0.11	0.11	Coronary artery disease;	chr15:85497786	chr15:84507885~84516814:-
BRCA	cis	rs2274273	1	rs3742566	ENSG00000259318.1	RP11-454L9.2	3.43	0.000617	0.0293	0.09	0.11	Protein biomarker;	chr14:55129121	chr14:55394940~55395233:-
BRCA	cis	rs987724	0.593	rs9871817	ENSG00000240875.4	LINC00886	-3.43	0.000617	0.0293	-0.12	-0.11	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156893887	chr3:156747346~156817062:-
BRCA	cis	rs6142618	0.562	rs6141277	ENSG00000275576.1	RP5-836N17.4	-3.43	0.000617	0.0293	-0.12	-0.11	Inflammatory bowel disease;	chr20:32243354	chr20:32116171~32116629:+
BRCA	cis	rs8180040	1	rs1024037	ENSG00000260236.1	RP11-708J19.1	-3.43	0.000617	0.0293	-0.1	-0.11	Colorectal cancer;	chr3:47276959	chr3:47379089~47380999:-
BRCA	cis	rs7712401	0.791	rs6872932	ENSG00000249996.1	RP11-359P5.1	3.43	0.000617	0.0293	0.12	0.11	Mean platelet volume;	chr5:122809941	chr5:123036271~123054667:+
BRCA	cis	rs6683273	0.72	rs16823783	ENSG00000272235.1	RP11-22L13.1	-3.43	0.000617	0.0293	-0.21	-0.11	QRS duration;	chr1:3280916	chr1:3306636~3310096:-
BRCA	cis	rs1466788	0.965	rs6674413	ENSG00000224965.1	KCNC4-AS1	3.43	0.000617	0.0293	0.13	0.11	Blood metabolite levels;	chr1:110082488	chr1:110208834~110209987:-
BRCA	cis	rs17756712	0.57	rs1122256	ENSG00000272485.1	RP11-284J1.1	3.43	0.000617	0.0293	0.15	0.11	Vertical cup-disc ratio;	chr6:611969	chr6:774747~780214:-
BRCA	cis	rs792448	0.534	rs66912346	ENSG00000224535.1	RP11-61J19.2	3.43	0.000618	0.0293	0.13	0.11	White blood cell count (basophil);	chr1:212444178	chr1:212466816~212467743:-
BRCA	cis	rs3816183	0.585	rs2374435	ENSG00000226491.1	FTOP1	-3.43	0.000618	0.0293	-0.13	-0.11	Hypospadias;	chr2:42631616	chr2:42797225~42798712:-
BRCA	cis	rs5167	0.601	rs892131	ENSG00000214855.8	APOC1P1	3.43	0.000618	0.0294	0.14	0.11	Blood protein levels;	chr19:44993738	chr19:44926804~44931386:+
BRCA	cis	rs62247992	0.546	rs9840881	ENSG00000227245.1	RP11-136C24.2	-3.43	0.000618	0.0294	-0.15	-0.11	Facial morphology (factor 15, philtrum width);	chr3:43126243	chr3:43087479~43088068:+
BRCA	cis	rs11892454	0.599	rs77262249	ENSG00000217643.1	PTGES3P2	-3.43	0.000618	0.0294	-0.12	-0.11	Heschl's gyrus morphology;	chr2:25786534	chr2:25822469~25822950:+
BRCA	cis	rs4243971	0.516	rs4575791	ENSG00000275576.1	RP5-836N17.4	-3.43	0.000618	0.0294	-0.12	-0.11	Inflammatory bowel disease;Crohn's disease;	chr20:32388501	chr20:32116171~32116629:+
BRCA	cis	rs6714710	0.603	rs2044458	ENSG00000228486.8	LINC01125	-3.43	0.000618	0.0294	-0.09	-0.11	Posterior cortical atrophy and Alzheimer's disease;	chr2:97761049	chr2:97664217~97703064:+
BRCA	cis	rs6445967	1	rs12688	ENSG00000272182.1	RP11-802O23.3	3.43	0.000618	0.0294	0.12	0.11	Platelet count;	chr3:58319352	chr3:58428255~58428815:+
BRCA	cis	rs3820068	0.58	rs7556473	ENSG00000237301.1	RP4-680D5.2	3.43	0.000618	0.0294	0.14	0.11	Systolic blood pressure;	chr1:15670363	chr1:15586136~15603626:-
BRCA	cis	rs1348850	0.874	rs2166558	ENSG00000271825.1	RP11-337N6.2	3.43	0.000618	0.0294	0.14	0.11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177508924	chr2:177300600~177302006:+
BRCA	cis	rs9991779	0.562	rs2117809	ENSG00000272870.1	RP11-798M19.6	3.43	0.000618	0.0294	0.19	0.11	Pediatric bone mineral content (hip);	chr4:174076614	chr4:173363780~173370446:-
BRCA	cis	rs801193	0.569	rs881285	ENSG00000271064.1	RP11-792A8.3	3.43	0.000618	0.0294	0.13	0.11	Aortic root size;	chr7:66654433	chr7:66748838~66749077:-
BRCA	cis	rs12681366	0.683	rs1379246	ENSG00000253175.1	RP11-267M23.6	-3.43	0.000618	0.0294	-0.12	-0.11	Nonsyndromic cleft lip with cleft palate;	chr8:94361073	chr8:94565036~94565715:+
BRCA	cis	rs17301013	0.761	rs332805	ENSG00000200674.1	RN7SKP160	3.43	0.000618	0.0294	0.14	0.11	Systemic lupus erythematosus;	chr1:174652487	chr1:173791548~173791887:+
BRCA	cis	rs6600671	1	rs10903159	ENSG00000223345.3	HIST2H2BA	3.43	0.000618	0.0294	0.13	0.11	Hip geometry;	chr1:121440138	chr1:121108210~121117257:-
BRCA	cis	rs752010	0.714	rs7513753	ENSG00000230638.4	RP11-486B10.4	-3.43	0.000618	0.0294	-0.13	-0.11	Lupus nephritis in systemic lupus erythematosus;	chr1:41613561	chr1:41542069~41544310:+
BRCA	cis	rs240993	0.812	rs9398272	ENSG00000271789.1	RP5-1112D6.7	3.43	0.000618	0.0294	0.14	0.11	Inflammatory skin disease;Psoriasis;	chr6:111522345	chr6:111297126~111298510:+
BRCA	cis	rs911119	0.913	rs6048928	ENSG00000270001.1	RP11-218C14.8	-3.43	0.000618	0.0294	-0.14	-0.11	Chronic kidney disease;	chr20:23605351	chr20:23631826~23632316:-
BRCA	cis	rs10843647	0.967	rs7311104	ENSG00000245614.3	DDX11-AS1	-3.43	0.000618	0.0294	-0.12	-0.11	Glucose homeostasis traits;	chr12:30181649	chr12:31020763~31073847:-
BRCA	cis	rs10843647	1	rs4931287	ENSG00000245614.3	DDX11-AS1	-3.43	0.000618	0.0294	-0.12	-0.11	Glucose homeostasis traits;	chr12:30181767	chr12:31020763~31073847:-
BRCA	cis	rs10843647	1	rs909013	ENSG00000245614.3	DDX11-AS1	-3.43	0.000618	0.0294	-0.12	-0.11	Glucose homeostasis traits;	chr12:30181821	chr12:31020763~31073847:-
BRCA	cis	rs10843647	0.935	rs1318325	ENSG00000245614.3	DDX11-AS1	-3.43	0.000618	0.0294	-0.12	-0.11	Glucose homeostasis traits;	chr12:30182189	chr12:31020763~31073847:-
BRCA	cis	rs2625529	0.668	rs35206011	ENSG00000260037.4	CTD-2524L6.3	-3.43	0.000619	0.0294	-0.15	-0.11	Red blood cell count;	chr15:72247153	chr15:71818396~71823384:+
BRCA	cis	rs295490	0.748	rs77347345	ENSG00000178631.7	ACTG1P1	-3.43	0.000619	0.0294	-0.21	-0.11	PR interval in Tripanosoma cruzi seropositivity;	chr3:139459863	chr3:139493809~139494937:+
BRCA	cis	rs4879656	0.545	rs1537254	ENSG00000236184.1	TCEA1P4	-3.43	0.000619	0.0294	-0.14	-0.11	Menopause (age at onset);	chr9:33004341	chr9:32979560~32980403:-
BRCA	cis	rs9287719	0.967	rs6735074	ENSG00000224177.5	LINC00570	-3.43	0.000619	0.0294	-0.12	-0.11	Prostate cancer;	chr2:10594640	chr2:11393981~11403077:+
BRCA	cis	rs17213965	0.561	rs9929598	ENSG00000275910.1	RP11-680G24.6	-3.43	0.000619	0.0294	-0.13	-0.11	Waist-hip ratio;	chr16:15786153	chr16:15015828~15016390:-
BRCA	cis	rs972578	0.791	rs738383	ENSG00000237037.8	NDUFA6-AS1	3.43	0.000619	0.0294	0.11	0.11	Mean platelet volume;	chr22:42919387	chr22:42090931~42137742:+
BRCA	cis	rs1023500	0.505	rs134874	ENSG00000226450.2	CYP2D8P	3.43	0.000619	0.0294	0.1	0.11	Schizophrenia;	chr22:42265138	chr22:42149886~42155001:-
BRCA	cis	rs2688608	0.623	rs2633317	ENSG00000213731.2	RAB5CP1	-3.43	0.000619	0.0294	-0.12	-0.11	Inflammatory bowel disease;	chr10:73930510	chr10:74423435~74424014:-
BRCA	cis	rs1823874	0.677	rs4381582	ENSG00000259363.4	CTD-2054N24.2	3.43	0.000619	0.0294	0.13	0.11	IgG glycosylation;	chr15:99820308	chr15:99807023~99877148:+
BRCA	cis	rs6545883	0.929	rs6545877	ENSG00000212978.6	AC016747.3	3.43	0.000619	0.0294	0.14	0.11	Tuberculosis;	chr2:61514812	chr2:61141592~61144969:-
BRCA	cis	rs10750165	0.875	rs11217496	ENSG00000254428.1	RP11-110I1.11	-3.43	0.000619	0.0294	-0.08	-0.11	Aggressiveness in attention deficit hyperactivity disorder;	chr11:119778247	chr11:119003742~119004893:-
BRCA	cis	rs6791479	0.966	rs1152864	ENSG00000236182.1	RP11-297K7.1	-3.43	0.000619	0.0294	-0.12	-0.11	Squamous cell carcinoma;	chr3:189492176	chr3:188989382~188990135:-
BRCA	cis	rs28489187	0.683	rs2892888	ENSG00000223653.4	RP11-131L23.1	-3.43	0.000619	0.0294	-0.12	-0.11	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85400464	chr1:85276715~85448124:+
BRCA	cis	rs2154319	0.836	rs7553037	ENSG00000230638.4	RP11-486B10.4	3.43	0.000619	0.0294	0.18	0.11	Height;	chr1:41041729	chr1:41542069~41544310:+
BRCA	cis	rs7487075	0.619	rs10748448	ENSG00000257261.4	RP11-96H19.1	3.43	0.000619	0.0294	0.12	0.11	Itch intensity from mosquito bite;	chr12:46409555	chr12:46383679~46876159:+
BRCA	cis	rs10129255	0.701	rs2005643	ENSG00000231475.3	IGHV4-31	-3.43	0.000619	0.0294	-0.08	-0.11	Kawasaki disease;	chr14:106676288	chr14:106349283~106349792:-
BRCA	cis	rs875971	0.83	rs6950137	ENSG00000223473.2	GS1-124K5.3	3.43	0.000619	0.0294	0.08	0.11	Aortic root size;	chr7:66511623	chr7:66491049~66493566:-
BRCA	cis	rs748404	0.666	rs12913977	ENSG00000166763.7	STRCP1	3.43	0.000619	0.0294	0.15	0.11	Lung cancer;	chr15:43438913	chr15:43699488~43718184:-
BRCA	cis	rs748404	0.666	rs12914122	ENSG00000166763.7	STRCP1	3.43	0.000619	0.0294	0.15	0.11	Lung cancer;	chr15:43438956	chr15:43699488~43718184:-
BRCA	cis	rs748404	0.666	rs34697113	ENSG00000166763.7	STRCP1	3.43	0.000619	0.0294	0.15	0.11	Lung cancer;	chr15:43442041	chr15:43699488~43718184:-
BRCA	cis	rs36051895	0.589	rs4560849	ENSG00000237711.1	RP11-39K24.13	-3.43	0.000619	0.0294	-0.13	-0.11	Pediatric autoimmune diseases;	chr9:5203866	chr9:5100236~5101009:+
BRCA	cis	rs9437689	0.902	rs10874902	ENSG00000235501.4	RP4-639F20.1	-3.43	0.000619	0.0294	-0.13	-0.11	Phospholipid levels (plasma);	chr1:95040705	chr1:94927566~94963270:+
BRCA	cis	rs3892630	0.588	rs28787932	ENSG00000267567.1	CTD-2538C1.3	3.43	0.000619	0.0294	0.16	0.11	Red blood cell traits;	chr19:32735323	chr19:32718298~32719595:-
BRCA	cis	rs3755605	0.635	rs6797319	ENSG00000242578.1	RP11-469J4.3	3.43	0.000619	0.0294	0.13	0.11	Testicular germ cell tumor;	chr3:170194821	chr3:170410512~170418615:+
BRCA	cis	rs1455244	0.848	rs1455247	ENSG00000267533.1	RP11-815J4.7	-3.43	0.000619	0.0294	-0.13	-0.11	Schizophrenia;	chr18:11469842	chr18:12067173~12068417:-
BRCA	cis	rs8114671	0.527	rs2295352	ENSG00000261582.1	RP4-614O4.11	3.43	0.000619	0.0294	0.1	0.11	Height;	chr20:34732251	chr20:35267885~35280043:-
BRCA	cis	rs875971	0.965	rs10267430	ENSG00000271064.1	RP11-792A8.3	3.43	0.000619	0.0294	0.12	0.11	Aortic root size;	chr7:66278036	chr7:66748838~66749077:-
BRCA	cis	rs2573652	1	rs2581341	ENSG00000254744.3	CTD-3076O17.1	-3.43	0.00062	0.0294	-0.13	-0.11	Height;	chr15:99974289	chr15:99970215~99974010:+
BRCA	cis	rs2625529	0.526	rs11634622	ENSG00000260037.4	CTD-2524L6.3	3.43	0.00062	0.0294	0.13	0.11	Red blood cell count;	chr15:72269986	chr15:71818396~71823384:+
BRCA	cis	rs12468226	0.872	rs115187557	ENSG00000272966.1	RP11-686O6.1	3.43	0.00062	0.0294	0.18	0.11	Urate levels;	chr2:202495351	chr2:202336739~202337200:+
BRCA	cis	rs1941023	0.64	rs716562	ENSG00000255355.1	AP000640.2	-3.43	0.00062	0.0294	-0.13	-0.11	Congenital heart disease (maternal effect);	chr11:60544983	chr11:59669312~59676041:+
BRCA	cis	rs3118867	0.808	rs3118873	ENSG00000204446.4	C9orf170	3.43	0.00062	0.0294	0.1	0.11	Blood pressure;	chr9:87649411	chr9:87148644~87159556:+
BRCA	cis	rs17123764	0.786	rs10506288	ENSG00000257464.1	RP11-161H23.8	3.43	0.00062	0.0294	0.19	0.11	Intelligence (multi-trait analysis);	chr12:49766347	chr12:49442424~49442652:-
BRCA	cis	rs853679	0.546	rs200995	ENSG00000216676.2	RP1-15D7.1	3.43	0.00062	0.0294	0.19	0.11	Depression;	chr6:27845916	chr6:27652602~27652825:-
BRCA	cis	rs875971	0.895	rs3857684	ENSG00000271064.1	RP11-792A8.3	-3.43	0.00062	0.0294	-0.12	-0.11	Aortic root size;	chr7:66473171	chr7:66748838~66749077:-
BRCA	cis	rs11673344	0.615	rs2921561	ENSG00000267682.1	CTD-3220F14.2	-3.43	0.00062	0.0294	-0.09	-0.11	Obesity-related traits;	chr19:37348969	chr19:37337236~37337743:+
BRCA	cis	rs987724	0.537	rs9847187	ENSG00000240875.4	LINC00886	-3.43	0.00062	0.0294	-0.12	-0.11	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156873356	chr3:156747346~156817062:-
BRCA	cis	rs987724	0.593	rs2321290	ENSG00000240875.4	LINC00886	-3.43	0.00062	0.0294	-0.12	-0.11	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156873765	chr3:156747346~156817062:-
BRCA	cis	rs987724	0.593	rs17382070	ENSG00000240875.4	LINC00886	-3.43	0.00062	0.0294	-0.12	-0.11	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156890754	chr3:156747346~156817062:-
BRCA	cis	rs2108622	0.727	rs7251296	ENSG00000267218.2	AC005336.5	3.43	0.00062	0.0294	0.12	0.11	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15872926	chr19:15902300~15903238:-
BRCA	cis	rs2692947	0.759	rs1917890	ENSG00000232931.4	LINC00342	3.43	0.00062	0.0294	0.11	0.11	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96006253	chr2:95807118~95816215:-
BRCA	cis	rs8030605	0.704	rs72740574	ENSG00000277245.1	RP11-48G14.3	3.43	0.00062	0.0294	0.23	0.11	Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;	chr15:56344809	chr15:56447120~56447697:+
BRCA	cis	rs1555133	0.558	rs6141306	ENSG00000275576.1	RP5-836N17.4	-3.43	0.00062	0.0294	-0.12	-0.11	Monocyte count;	chr20:32421489	chr20:32116171~32116629:+
BRCA	cis	rs1555133	0.558	rs6141307	ENSG00000275576.1	RP5-836N17.4	-3.43	0.00062	0.0294	-0.12	-0.11	Monocyte count;	chr20:32421490	chr20:32116171~32116629:+
BRCA	cis	rs1555133	0.694	rs6141309	ENSG00000275576.1	RP5-836N17.4	-3.43	0.00062	0.0294	-0.12	-0.11	Monocyte count;	chr20:32423541	chr20:32116171~32116629:+
BRCA	cis	rs3764021	0.527	rs3764022	ENSG00000256594.6	RP11-705C15.2	3.43	0.00062	0.0294	0.14	0.11	Type 1 diabetes;	chr12:9680928	chr12:9633419~9658412:+
BRCA	cis	rs2154319	0.887	rs4660500	ENSG00000230638.4	RP11-486B10.4	3.43	0.00062	0.0295	0.18	0.11	Height;	chr1:41058997	chr1:41542069~41544310:+
BRCA	cis	rs1005277	0.579	rs1740737	ENSG00000276805.1	RP11-291L22.6	3.43	0.00062	0.0295	0.12	0.11	Extrinsic epigenetic age acceleration;	chr10:38210437	chr10:38451030~38451785:+
BRCA	cis	rs72928364	1	rs17399603	ENSG00000256628.3	ZBTB11-AS1	3.43	0.00062	0.0295	0.2	0.11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:101017295	chr3:101676475~101679217:+
BRCA	cis	rs2599510	0.84	rs466146	ENSG00000276517.1	AL133243.2	-3.43	0.00062	0.0295	-0.12	-0.11	Interleukin-18 levels;	chr2:32314167	chr2:32526504~32529507:+
BRCA	cis	rs875971	0.862	rs4718319	ENSG00000229886.1	RP5-1132H15.3	-3.43	0.00062	0.0295	-0.12	-0.11	Aortic root size;	chr7:66187797	chr7:66025126~66031544:-
BRCA	cis	rs875971	0.723	rs28391294	ENSG00000229886.1	RP5-1132H15.3	-3.43	0.00062	0.0295	-0.12	-0.11	Aortic root size;	chr7:66189328	chr7:66025126~66031544:-
BRCA	cis	rs875971	0.83	rs6967708	ENSG00000229886.1	RP5-1132H15.3	-3.43	0.00062	0.0295	-0.12	-0.11	Aortic root size;	chr7:66192326	chr7:66025126~66031544:-
BRCA	cis	rs875971	0.895	rs7782806	ENSG00000229886.1	RP5-1132H15.3	-3.43	0.00062	0.0295	-0.12	-0.11	Aortic root size;	chr7:66192910	chr7:66025126~66031544:-
BRCA	cis	rs7586085	0.874	rs62174820	ENSG00000229195.1	AC009495.4	-3.43	0.00062	0.0295	-0.13	-0.11	Total body bone mineral density;	chr2:165760157	chr2:165794857~165846091:-
BRCA	cis	rs1401999	0.864	rs4148563	ENSG00000223882.1	ABCC5-AS1	-3.43	0.00062	0.0295	-0.12	-0.11	Anterior chamber depth;	chr3:184008211	chr3:184006338~184011419:+
BRCA	cis	rs853679	0.513	rs9468296	ENSG00000226314.6	ZNF192P1	-3.43	0.00062	0.0295	-0.16	-0.11	Depression;	chr6:28145952	chr6:28161781~28169594:+
BRCA	cis	rs11098499	0.722	rs17595727	ENSG00000249244.1	RP11-548H18.2	-3.43	0.000621	0.0295	-0.12	-0.11	Corneal astigmatism;	chr4:119340919	chr4:119391831~119395335:-
BRCA	cis	rs875971	0.964	rs6945019	ENSG00000273448.1	RP11-166O4.6	3.43	0.000621	0.0295	0.1	0.11	Aortic root size;	chr7:66457471	chr7:67333047~67334383:+
BRCA	cis	rs6918586	0.557	rs198827	ENSG00000272462.2	U91328.19	-3.43	0.000621	0.0295	-0.12	-0.11	Schizophrenia;	chr6:26120774	chr6:25992662~26001775:+
BRCA	cis	rs6600671	1	rs6600671	ENSG00000231429.2	RP11-343N15.2	3.43	0.000621	0.0295	0.13	0.11	Hip geometry;	chr1:121458637	chr1:121412719~121429274:+
BRCA	cis	rs4415084	1	rs13156930	ENSG00000272335.1	RP11-53O19.3	3.43	0.000621	0.0295	0.1	0.11	Breast cancer;	chr5:44697933	chr5:44826076~44828592:+
BRCA	cis	rs875971	0.862	rs778686	ENSG00000265600.1	AC006480.1	-3.43	0.000621	0.0295	-0.13	-0.11	Aortic root size;	chr7:66370923	chr7:67356680~67356779:+
BRCA	cis	rs4950322	0.515	rs72691016	ENSG00000227242.3	NBPF13P	-3.43	0.000621	0.0295	-0.14	-0.11	Protein quantitative trait loci;	chr1:147245375	chr1:147021320~147124525:-
BRCA	cis	rs911119	0.657	rs6114214	ENSG00000270001.1	RP11-218C14.8	-3.43	0.000621	0.0295	-0.15	-0.11	Chronic kidney disease;	chr20:23647287	chr20:23631826~23632316:-
BRCA	cis	rs11219769	0.729	rs4337053	ENSG00000245498.5	RP11-677M14.7	-3.43	0.000621	0.0295	-0.13	-0.11	Blood protein levels;	chr11:124732967	chr11:124800450~124834487:+
BRCA	cis	rs1730008	1	rs827142	ENSG00000279311.1	RP11-170K4.2	-3.43	0.000621	0.0295	-0.12	-0.11	Lobe attachment (rater-scored or self-reported);	chr3:158205992	chr3:158869898~158871821:+
BRCA	cis	rs27434	0.583	rs149431	ENSG00000248734.2	CTD-2260A17.1	3.43	0.000621	0.0295	0.12	0.11	Ankylosing spondylitis;	chr5:96821838	chr5:96784777~96785999:+
BRCA	cis	rs27434	0.583	rs151954	ENSG00000248734.2	CTD-2260A17.1	3.43	0.000621	0.0295	0.12	0.11	Ankylosing spondylitis;	chr5:96821986	chr5:96784777~96785999:+
BRCA	cis	rs27434	0.583	rs193482	ENSG00000248734.2	CTD-2260A17.1	3.43	0.000621	0.0295	0.12	0.11	Ankylosing spondylitis;	chr5:96822143	chr5:96784777~96785999:+
BRCA	cis	rs27434	0.583	rs149544	ENSG00000248734.2	CTD-2260A17.1	3.43	0.000621	0.0295	0.12	0.11	Ankylosing spondylitis;	chr5:96822151	chr5:96784777~96785999:+
BRCA	cis	rs6452790	0.529	rs6452762	ENSG00000247828.6	TMEM161B-AS1	-3.43	0.000621	0.0295	-0.14	-0.11	Cognitive function;	chr5:87965976	chr5:88268895~88436685:+
BRCA	cis	rs6452790	0.529	rs7708292	ENSG00000247828.6	TMEM161B-AS1	-3.43	0.000621	0.0295	-0.14	-0.11	Cognitive function;	chr5:87966023	chr5:88268895~88436685:+
BRCA	cis	rs1971762	0.545	rs10747675	ENSG00000270175.1	RP11-793H13.11	3.43	0.000621	0.0295	0.09	0.11	Height;	chr12:53606247	chr12:53500162~53500936:-
BRCA	cis	rs6696239	0.513	rs3010193	ENSG00000227711.2	RP11-275O4.5	-3.43	0.000621	0.0295	-0.12	-0.11	Height;	chr1:227610621	chr1:227509028~227520477:-
BRCA	cis	rs875971	1	rs778706	ENSG00000273024.4	INTS4P2	-3.43	0.000621	0.0295	-0.12	-0.11	Aortic root size;	chr7:66395437	chr7:65647864~65715661:+
BRCA	cis	rs6840360	0.571	rs7685697	ENSG00000270265.1	RP11-731D1.4	-3.43	0.000621	0.0295	-0.13	-0.11	Intelligence (multi-trait analysis);	chr4:151637697	chr4:151333775~151353224:-
BRCA	cis	rs6840360	0.593	rs10022023	ENSG00000270265.1	RP11-731D1.4	-3.43	0.000621	0.0295	-0.13	-0.11	Intelligence (multi-trait analysis);	chr4:151639579	chr4:151333775~151353224:-
BRCA	cis	rs6708331	0.941	rs10173330	ENSG00000231024.1	AC092431.3	-3.43	0.000621	0.0295	-0.15	-0.11	Obesity-related traits;	chr2:70139981	chr2:69700192~69713847:-
BRCA	cis	rs4803480	0.578	rs7252454	ENSG00000269800.1	PLEKHA3P1	-3.43	0.000621	0.0295	-0.14	-0.11	Schizophrenia;	chr19:41527343	chr19:41521043~41521989:-
BRCA	cis	rs2243480	1	rs1723267	ENSG00000226767.1	RP11-328P23.3	-3.43	0.000621	0.0295	-0.18	-0.11	Diabetic kidney disease;	chr7:66008327	chr7:65508773~65508944:-
BRCA	cis	rs4878639	0.606	rs11790288	ENSG00000281649.1	EBLN3	-3.43	0.000621	0.0295	-0.1	-0.11	IgG glycosylation;	chr9:36118474	chr9:37079857~37090507:+
BRCA	cis	rs875971	0.862	rs778684	ENSG00000265600.1	AC006480.1	-3.43	0.000621	0.0295	-0.13	-0.11	Aortic root size;	chr7:66371416	chr7:67356680~67356779:+
BRCA	cis	rs7267979	0.932	rs2260997	ENSG00000277938.1	RP5-965G21.3	-3.43	0.000621	0.0295	-0.13	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25275630	chr20:25229150~25231933:+
BRCA	cis	rs12637928	0.507	rs1512533	ENSG00000206532.2	RP11-553A10.1	-3.43	0.000621	0.0295	-0.13	-0.11	Neuroticism;	chr3:110598150	chr3:110888384~110893476:-
BRCA	cis	rs4713118	0.513	rs9368547	ENSG00000219891.2	ZSCAN12P1	3.43	0.000621	0.0295	0.13	0.11	Parkinson's disease;	chr6:28060289	chr6:28091154~28093664:+
BRCA	cis	rs4713118	0.513	rs183244	ENSG00000219891.2	ZSCAN12P1	3.43	0.000621	0.0295	0.13	0.11	Parkinson's disease;	chr6:28064060	chr6:28091154~28093664:+
BRCA	cis	rs240764	0.619	rs10872623	ENSG00000220695.1	RP1-121G13.3	-3.43	0.000621	0.0295	-0.12	-0.11	Neuroticism;	chr6:100717171	chr6:100530276~100531052:+
BRCA	cis	rs13315871	1	rs4367085	ENSG00000272182.1	RP11-802O23.3	3.43	0.000621	0.0295	0.21	0.11	Cholesterol, total;	chr3:58403508	chr3:58428255~58428815:+
BRCA	cis	rs6445975	0.666	rs12635366	ENSG00000272360.1	RP11-359I18.5	-3.43	0.000621	0.0295	-0.13	-0.11	Systemic lupus erythematosus;	chr3:58412739	chr3:58490830~58491291:-
BRCA	cis	rs1510510	0.867	rs10190297	ENSG00000229915.1	AC016999.2	3.43	0.000621	0.0295	0.18	0.11	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr2:238601722	chr2:238427077~238427729:-
BRCA	cis	rs66887589	0.616	rs10032299	ENSG00000260091.1	RP11-33B1.4	-3.43	0.000621	0.0295	-0.09	-0.11	Diastolic blood pressure;	chr4:119285264	chr4:119409333~119410233:+
BRCA	cis	rs10504130	0.569	rs13265006	ENSG00000272076.1	RP11-11C20.3	3.43	0.000621	0.0295	0.15	0.11	Venous thromboembolism (SNP x SNP interaction);	chr8:51877963	chr8:51810110~51810681:-
BRCA	cis	rs10504130	0.597	rs34058697	ENSG00000272076.1	RP11-11C20.3	3.43	0.000621	0.0295	0.15	0.11	Venous thromboembolism (SNP x SNP interaction);	chr8:51882392	chr8:51810110~51810681:-
BRCA	cis	rs1987511	1	rs7071555	ENSG00000224034.1	RP11-445P17.8	-3.43	0.000621	0.0295	-0.14	-0.11	Intelligence;	chr10:5303015	chr10:5266033~5271236:-
BRCA	cis	rs1987511	1	rs4448600	ENSG00000224034.1	RP11-445P17.8	-3.43	0.000621	0.0295	-0.14	-0.11	Intelligence;	chr10:5303605	chr10:5266033~5271236:-
BRCA	cis	rs11673344	0.734	rs1234250	ENSG00000267422.1	CTD-2554C21.1	-3.43	0.000621	0.0295	-0.14	-0.11	Obesity-related traits;	chr19:37199518	chr19:37779686~37792865:+
BRCA	cis	rs66887589	0.807	rs13134517	ENSG00000260404.2	RP11-384K6.6	3.43	0.000621	0.0295	0.09	0.11	Diastolic blood pressure;	chr4:119484107	chr4:118591773~118633729:+
BRCA	cis	rs66887589	0.837	rs6534135	ENSG00000260404.2	RP11-384K6.6	3.43	0.000621	0.0295	0.09	0.11	Diastolic blood pressure;	chr4:119485147	chr4:118591773~118633729:+
BRCA	cis	rs7487075	0.859	rs2307061	ENSG00000257261.4	RP11-96H19.1	3.43	0.000621	0.0295	0.12	0.11	Itch intensity from mosquito bite;	chr12:46364711	chr12:46383679~46876159:+
BRCA	cis	rs4499344	0.556	rs438268	ENSG00000267475.1	CTD-2538C1.2	3.43	0.000621	0.0295	0.15	0.11	Mean platelet volume;	chr19:32618998	chr19:32687089~32691750:-
BRCA	cis	rs3760982	0.585	rs11673534	ENSG00000266921.1	RP11-15A1.7	-3.43	0.000621	0.0295	-0.13	-0.11	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43794732	chr19:43996896~44002836:-
BRCA	cis	rs3760982	0.585	rs11673490	ENSG00000266921.1	RP11-15A1.7	-3.43	0.000621	0.0295	-0.13	-0.11	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43794733	chr19:43996896~44002836:-
BRCA	cis	rs3760982	0.585	rs11083724	ENSG00000266921.1	RP11-15A1.7	-3.43	0.000621	0.0295	-0.13	-0.11	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43794836	chr19:43996896~44002836:-
BRCA	cis	rs17711722	0.701	rs781143	ENSG00000227113.2	RP11-460N20.4	3.43	0.000621	0.0295	0.11	0.11	Calcium levels;	chr7:65974892	chr7:65075023~65078780:+
BRCA	cis	rs4449834	0.775	rs7842389	ENSG00000254432.1	RP11-33I11.2	-3.43	0.000622	0.0295	-0.14	-0.11	Sum eosinophil basophil counts;	chr8:60772635	chr8:60808735~60809606:-
BRCA	cis	rs2243480	1	rs1701758	ENSG00000226767.1	RP11-328P23.3	-3.43	0.000622	0.0295	-0.18	-0.11	Diabetic kidney disease;	chr7:66005214	chr7:65508773~65508944:-
BRCA	cis	rs1710990	0.819	rs1710989	ENSG00000259165.1	DDX18P1	3.43	0.000622	0.0295	0.12	0.11	Intelligence (multi-trait analysis);	chr14:69114519	chr14:69083398~69085389:+
BRCA	cis	rs10266483	0.545	rs116760071	ENSG00000228014.1	ZNF680P1	3.43	0.000622	0.0295	0.15	0.11	Response to statin therapy;	chr7:64289082	chr7:64469185~64470653:+
BRCA	cis	rs10129255	1	rs61997605	ENSG00000211958.2	IGHV3-38	3.43	0.000622	0.0295	0.09	0.11	Kawasaki disease;	chr14:106678368	chr14:106410493~106411021:-
BRCA	cis	rs875971	1	rs2077593	ENSG00000273024.4	INTS4P2	-3.43	0.000622	0.0295	-0.12	-0.11	Aortic root size;	chr7:66427543	chr7:65647864~65715661:+
BRCA	cis	rs7824557	0.767	rs6991606	ENSG00000154316.13	TDH	-3.43	0.000622	0.0295	-0.15	-0.11	Retinal vascular caliber;	chr8:11318650	chr8:11339637~11368452:+
BRCA	cis	rs2599510	0.811	rs2754523	ENSG00000276517.1	AL133243.2	-3.43	0.000622	0.0295	-0.13	-0.11	Interleukin-18 levels;	chr2:32612043	chr2:32526504~32529507:+
BRCA	cis	rs6142102	0.886	rs6142098	ENSG00000206582.1	Y_RNA	-3.43	0.000622	0.0295	-0.12	-0.11	Skin pigmentation;	chr20:34100488	chr20:34526510~34526606:-
BRCA	cis	rs7781266	0.79	rs7778778	ENSG00000226205.1	AC007790.4	3.43	0.000622	0.0295	0.15	0.11	Educational attainment (college completion);	chr7:133418835	chr7:133732493~133733595:-
BRCA	cis	rs1208	0.899	rs1390358	ENSG00000253671.1	RP11-806O11.1	3.43	0.000622	0.0295	0.12	0.11	Insulin resistance/response;	chr8:18395245	chr8:17808941~17820868:+
BRCA	cis	rs2832191	0.716	rs7284006	ENSG00000236056.1	GAPDHP14	-3.43	0.000622	0.0295	-0.12	-0.11	Dental caries;	chr21:29102865	chr21:29222321~29223257:+
BRCA	cis	rs897984	0.571	rs7184567	ENSG00000260267.1	RP11-452L6.5	3.43	0.000622	0.0295	0.1	0.11	Dementia with Lewy bodies;	chr16:31009757	chr16:31456711~31459736:-
BRCA	cis	rs11098499	0.575	rs9996586	ENSG00000260404.2	RP11-384K6.6	3.43	0.000622	0.0295	0.09	0.11	Corneal astigmatism;	chr4:119405787	chr4:118591773~118633729:+
BRCA	cis	rs4819052	0.851	rs34101026	ENSG00000223768.1	LINC00205	-3.43	0.000622	0.0295	-0.14	-0.11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45242285	chr21:45293285~45297354:+
BRCA	cis	rs4819052	0.851	rs2838828	ENSG00000223768.1	LINC00205	-3.43	0.000622	0.0295	-0.14	-0.11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45243508	chr21:45293285~45297354:+
BRCA	cis	rs4819052	0.851	rs13049337	ENSG00000223768.1	LINC00205	-3.43	0.000622	0.0295	-0.14	-0.11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45243545	chr21:45293285~45297354:+
BRCA	cis	rs10995356	0.872	rs10761684	ENSG00000238280.1	RP11-436D10.3	-3.43	0.000622	0.0295	-0.14	-0.11	Temperament;	chr10:62960604	chr10:62793562~62805887:-
BRCA	cis	rs2243480	1	rs34136756	ENSG00000234585.5	CCT6P3	-3.43	0.000622	0.0295	-0.16	-0.11	Diabetic kidney disease;	chr7:65916269	chr7:65038354~65074713:+
BRCA	cis	rs875971	0.522	rs1917563	ENSG00000223473.2	GS1-124K5.3	-3.43	0.000622	0.0295	-0.08	-0.11	Aortic root size;	chr7:65950660	chr7:66491049~66493566:-
BRCA	cis	rs564309	0.681	rs1188483	ENSG00000183929.7	DUSP5P1	-3.43	0.000622	0.0295	-0.2	-0.11	Hip circumference (psychosocial stress interaction);	chr1:228430387	chr1:228650241~228651379:+
BRCA	cis	rs6545883	0.965	rs6545872	ENSG00000212978.6	AC016747.3	3.43	0.000622	0.0295	0.14	0.11	Tuberculosis;	chr2:61497433	chr2:61141592~61144969:-
BRCA	cis	rs9973361	1	rs9973899	ENSG00000232411.1	AC009495.3	-3.43	0.000622	0.0295	-0.15	-0.11	Total body bone mineral density;	chr2:165861072	chr2:165833048~165839098:-
BRCA	cis	rs9341808	0.718	rs4437429	ENSG00000279022.1	RP11-250B2.4	3.43	0.000622	0.0295	0.12	0.11	Sitting height ratio;	chr6:80118875	chr6:80440730~80441172:+
BRCA	cis	rs965469	1	rs6051806	ENSG00000215063.3	RPL21P2	3.43	0.000622	0.0295	0.14	0.11	IFN-related cytopenia;	chr20:3369672	chr20:4059633~4060113:-
BRCA	cis	rs7487075	0.79	rs11183527	ENSG00000257261.4	RP11-96H19.1	3.43	0.000622	0.0295	0.12	0.11	Itch intensity from mosquito bite;	chr12:46552580	chr12:46383679~46876159:+
BRCA	cis	rs1510510	0.742	rs12692235	ENSG00000229915.1	AC016999.2	3.43	0.000622	0.0295	0.17	0.11	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr2:238637065	chr2:238427077~238427729:-
BRCA	cis	rs7829975	0.572	rs7005000	ENSG00000253981.4	ALG1L13P	-3.43	0.000622	0.0295	-0.12	-0.11	Mood instability;	chr8:8939092	chr8:8236003~8244667:-
BRCA	cis	rs875971	0.54	rs781152	ENSG00000230189.5	GS1-124K5.2	3.43	0.000622	0.0295	0.09	0.11	Aortic root size;	chr7:66014585	chr7:66409143~66490059:-
BRCA	cis	rs17711722	0.727	rs781151	ENSG00000230189.5	GS1-124K5.2	3.43	0.000622	0.0295	0.09	0.11	Calcium levels;	chr7:66014891	chr7:66409143~66490059:-
BRCA	cis	rs6813195	0.642	rs7673175	ENSG00000245954.5	RP11-18H21.1	3.43	0.000622	0.0295	0.09	0.11	Type 2 diabetes;	chr4:152380064	chr4:152100754~152104720:+
BRCA	cis	rs8054556	1	rs4787489	ENSG00000214725.6	CDIPT-AS1	-3.43	0.000622	0.0295	-0.13	-0.11	Autism spectrum disorder or schizophrenia;	chr16:29984559	chr16:29863593~29868053:+
BRCA	cis	rs7412746	0.634	rs12096831	ENSG00000224800.1	RP11-235D19.2	-3.43	0.000622	0.0295	-0.13	-0.11	Melanoma;	chr1:150891637	chr1:150881236~150881683:-
BRCA	cis	rs801193	1	rs2659912	ENSG00000275400.1	RP4-756H11.5	-3.43	0.000622	0.0295	-0.12	-0.11	Aortic root size;	chr7:66693012	chr7:66553805~66554199:-
BRCA	cis	rs4073416	0.738	rs11851576	ENSG00000276116.2	FUT8-AS1	3.43	0.000622	0.0295	0.11	0.11	N-glycan levels;	chr14:65433565	chr14:65411170~65412690:-
BRCA	cis	rs687432	0.887	rs11601663	ENSG00000265566.2	RN7SL605P	-3.43	0.000622	0.0295	-0.15	-0.11	Parkinson's disease;	chr11:58005834	chr11:57528085~57528365:-
BRCA	cis	rs897984	0.572	rs112906665	ENSG00000260267.1	RP11-452L6.5	3.43	0.000623	0.0295	0.1	0.11	Dementia with Lewy bodies;	chr16:31028818	chr16:31456711~31459736:-
BRCA	cis	rs13126694	0.71	rs13137826	ENSG00000251073.1	NUDT19P5	3.43	0.000623	0.0295	0.1	0.11	Blood osmolality (transformed sodium);	chr4:158001354	chr4:158182825~158183393:+
BRCA	cis	rs812925	0.519	rs10199672	ENSG00000270820.4	RP11-355B11.2	-3.43	0.000623	0.0295	-0.11	-0.11	Immature fraction of reticulocytes;	chr2:61400499	chr2:61471188~61484130:+
BRCA	cis	rs10246939	0.579	rs17133534	ENSG00000270923.1	TAS2R6P	-3.43	0.000623	0.0295	-0.11	-0.11	Bitter taste perception;	chr7:141860855	chr7:141787815~141788640:+
BRCA	cis	rs17092148	0.848	rs6060030	ENSG00000250917.1	RP4-785G19.5	3.43	0.000623	0.0295	0.17	0.11	Neuroticism;	chr20:34752510	chr20:34234840~34281173:-
BRCA	cis	rs10844706	0.699	rs10844633	ENSG00000278635.1	CTD-2318O12.1	-3.43	0.000623	0.0295	-0.11	-0.11	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9734790	chr12:9415641~9416718:+
BRCA	cis	rs17291845	0.519	rs12920152	ENSG00000277559.1	RP11-434E6.4	3.43	0.000623	0.0296	0.18	0.11	Information processing speed;	chr16:55244512	chr16:54290965~54292422:+
BRCA	cis	rs1949733	0.701	rs1880024	ENSG00000250471.2	GMPSP1	3.43	0.000623	0.0296	0.11	0.11	Response to antineoplastic agents;	chr4:8452912	chr4:8174421~8174999:+
BRCA	cis	rs3735485	0.678	rs1132130	ENSG00000201772.1	SNORA5C	3.43	0.000623	0.0296	0.14	0.11	White blood cell count;Sum basophil neutrophil counts;Neutrophil count;Granulocyte percentage of myeloid white cells;Monocyte percentage of white cells;Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Lymphocyte counts;	chr7:45080649	chr7:45104906~45105042:-
BRCA	cis	rs219780	0.821	rs219777	ENSG00000233818.1	AP000695.4	3.43	0.000623	0.0296	0.12	0.11	Kidney stones;	chr21:36462423	chr21:36445731~36532408:+
BRCA	cis	rs6487679	1	rs7298108	ENSG00000256069.6	A2MP1	-3.43	0.000623	0.0296	-0.13	-0.11	Non-alcoholic fatty liver disease histology (AST);	chr12:9223572	chr12:9228533~9275817:-
BRCA	cis	rs7560272	0.723	rs13386124	ENSG00000272702.1	RP11-44N22.3	3.43	0.000623	0.0296	0.11	0.11	Schizophrenia;	chr2:73544568	chr2:73113018~73115907:+
BRCA	cis	rs7412746	0.658	rs3768016	ENSG00000231073.1	RP11-316M1.3	3.43	0.000623	0.0296	0.11	0.11	Melanoma;	chr1:150837443	chr1:150973123~150975534:+
BRCA	cis	rs2991971	0.967	rs12743512	ENSG00000281133.1	AL355480.3	-3.43	0.000623	0.0296	-0.12	-0.11	High light scatter reticulocyte count;	chr1:45488361	chr1:45580892~45580996:-
BRCA	cis	rs748404	0.626	rs35992154	ENSG00000166763.7	STRCP1	3.43	0.000623	0.0296	0.15	0.11	Lung cancer;	chr15:43345669	chr15:43699488~43718184:-
BRCA	cis	rs137699	0.652	rs2413589	ENSG00000280216.1	RP3-333H23.9	3.43	0.000623	0.0296	0.14	0.11	IgG glycosylation;	chr22:39359684	chr22:39379610~39380015:+
BRCA	cis	rs4722585	0.533	rs2049843	ENSG00000273237.1	CTB-119C2.1	-3.43	0.000624	0.0296	-0.13	-0.11	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);	chr7:26157343	chr7:26173533~26174945:-
BRCA	cis	rs4950322	0.518	rs4950304	ENSG00000237188.3	RP11-337C18.8	3.43	0.000624	0.0296	0.13	0.11	Protein quantitative trait loci;	chr1:147116685	chr1:147172771~147211568:+
BRCA	cis	rs76798021	0.81	rs11709171	ENSG00000271976.1	RP11-884K10.7	3.43	0.000624	0.0296	0.14	0.11	Lung function (FEV1/FVC);	chr3:53635877	chr3:53858994~53861576:-
BRCA	cis	rs9346455	0.614	rs9364151	ENSG00000199094.2	MIR30C2	3.43	0.000624	0.0296	0.15	0.11	Antipsychotic drug-induced weight gain;Antipsychotic drug-induced weight gain (time interaction);	chr6:71287368	chr6:71376933~71377045:-
BRCA	cis	rs9346455	0.614	rs2208845	ENSG00000199094.2	MIR30C2	3.43	0.000624	0.0296	0.15	0.11	Antipsychotic drug-induced weight gain;Antipsychotic drug-induced weight gain (time interaction);	chr6:71287575	chr6:71376933~71377045:-
BRCA	cis	rs1865760	1	rs3752421	ENSG00000272810.1	U91328.22	-3.43	0.000624	0.0296	-0.12	-0.11	Height;	chr6:25918460	chr6:26013241~26013757:+
BRCA	cis	rs3764021	0.509	rs10772072	ENSG00000256594.6	RP11-705C15.2	3.43	0.000624	0.0296	0.14	0.11	Type 1 diabetes;	chr12:9717335	chr12:9633419~9658412:+
BRCA	cis	rs7103648	0.63	rs7120548	ENSG00000280615.1	Y_RNA	3.43	0.000624	0.0296	0.14	0.11	Systolic blood pressure;Diastolic blood pressure;	chr11:47641380	chr11:47614898~47614994:-
BRCA	cis	rs12149695	0.735	rs11641348	ENSG00000259940.2	CTD-3203P2.1	-3.43	0.000624	0.0296	-0.13	-0.11	Gut microbiota (bacterial taxa);	chr16:27233765	chr16:27213308~27214993:-
BRCA	cis	rs7636839	0.504	rs9825172	ENSG00000236182.1	RP11-297K7.1	-3.43	0.000624	0.0296	-0.12	-0.11	EGFR mutation-positive lung adenocarcinoma;	chr3:189617453	chr3:188989382~188990135:-
BRCA	cis	rs2243480	1	rs34703416	ENSG00000226767.1	RP11-328P23.3	-3.43	0.000624	0.0296	-0.18	-0.11	Diabetic kidney disease;	chr7:65835655	chr7:65508773~65508944:-
BRCA	cis	rs10504130	0.932	rs16916856	ENSG00000272076.1	RP11-11C20.3	3.43	0.000624	0.0296	0.18	0.11	Venous thromboembolism (SNP x SNP interaction);	chr8:51826590	chr8:51810110~51810681:-
BRCA	cis	rs5167	0.566	rs934427	ENSG00000214855.8	APOC1P1	3.43	0.000624	0.0296	0.14	0.11	Blood protein levels;	chr19:44975559	chr19:44926804~44931386:+
BRCA	cis	rs2554380	0.628	rs7175491	ENSG00000176700.18	SCAND2P	-3.43	0.000624	0.0296	-0.11	-0.11	Height;	chr15:83806187	chr15:84631451~84647478:+
BRCA	cis	rs9311474	0.597	rs6778735	ENSG00000222345.1	SNORD19	3.43	0.000624	0.0296	0.11	0.11	Electroencephalogram traits;	chr3:52531084	chr3:52691378~52691453:+
BRCA	cis	rs875971	0.825	rs10281499	ENSG00000223473.2	GS1-124K5.3	-3.43	0.000624	0.0296	-0.08	-0.11	Aortic root size;	chr7:66583979	chr7:66491049~66493566:-
BRCA	cis	rs595982	0.546	rs12461075	ENSG00000235191.1	NUCB1-AS1	3.43	0.000624	0.0296	0.14	0.11	Red cell distribution width;	chr19:48896564	chr19:48910930~48918891:-
BRCA	cis	rs763121	0.962	rs2071887	ENSG00000273076.1	RP3-508I15.22	3.43	0.000624	0.0296	0.11	0.11	Menopause (age at onset);	chr22:38483005	chr22:38743495~38743910:+
BRCA	cis	rs875971	1	rs4717292	ENSG00000272831.1	RP11-792A8.4	3.43	0.000624	0.0296	0.09	0.11	Aortic root size;	chr7:66430611	chr7:66739829~66740385:-
BRCA	cis	rs875971	1	rs35149210	ENSG00000272831.1	RP11-792A8.4	3.43	0.000624	0.0296	0.09	0.11	Aortic root size;	chr7:66464938	chr7:66739829~66740385:-
BRCA	cis	rs875971	0.862	rs2909688	ENSG00000265600.1	AC006480.1	-3.43	0.000624	0.0296	-0.13	-0.11	Aortic root size;	chr7:66376625	chr7:67356680~67356779:+
BRCA	cis	rs1865760	1	rs9467636	ENSG00000272810.1	U91328.22	-3.43	0.000624	0.0296	-0.12	-0.11	Height;	chr6:25919321	chr6:26013241~26013757:+
BRCA	cis	rs1865760	1	rs9358893	ENSG00000272810.1	U91328.22	-3.43	0.000624	0.0296	-0.12	-0.11	Height;	chr6:25921533	chr6:26013241~26013757:+
BRCA	cis	rs72772090	0.539	rs11747179	ENSG00000272109.1	CTD-2260A17.3	3.43	0.000624	0.0296	0.2	0.11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96777265	chr5:96804353~96806105:+
BRCA	cis	rs6496932	0.755	rs6497021	ENSG00000259630.2	CTD-2262B20.1	-3.43	0.000624	0.0296	-0.14	-0.11	Central corneal thickness;Corneal structure;	chr15:85353036	chr15:85415228~85415633:+
BRCA	cis	rs853679	0.517	rs1947863	ENSG00000226314.6	ZNF192P1	-3.43	0.000624	0.0296	-0.16	-0.11	Depression;	chr6:28131566	chr6:28161781~28169594:+
BRCA	cis	rs2131877	1	rs2131877	ENSG00000230266.1	XXYLT1-AS2	-3.43	0.000625	0.0296	-0.12	-0.11	Non-small cell lung cancer;	chr3:195137645	chr3:195147871~195152790:+
BRCA	cis	rs3796619	1	rs3796619	ENSG00000272588.1	RP11-440L14.4	-3.43	0.000625	0.0296	-0.11	-0.11	Recombination rate (males);	chr4:1101493	chr4:757022~757740:-
BRCA	cis	rs12310956	0.532	rs1525897	ENSG00000258794.3	DUX4L27	3.43	0.000625	0.0296	0.15	0.11	Morning vs. evening chronotype;	chr12:33788098	chr12:34208415~34209675:-
BRCA	cis	rs11673344	0.801	rs76806623	ENSG00000267682.1	CTD-3220F14.2	-3.43	0.000625	0.0296	-0.1	-0.11	Obesity-related traits;	chr19:37132525	chr19:37337236~37337743:+
BRCA	cis	rs4363385	0.693	rs76987906	ENSG00000272654.1	RP11-422P24.11	3.43	0.000625	0.0296	0.11	0.11	Inflammatory skin disease;	chr1:152992054	chr1:153977743~153979160:+
BRCA	cis	rs2835872	0.793	rs73220482	ENSG00000230366.8	DSCR9	-3.43	0.000625	0.0296	-0.14	-0.11	Electroencephalographic traits in alcoholism;	chr21:37613984	chr21:37208503~37221736:+
BRCA	cis	rs875971	0.508	rs6947808	ENSG00000271064.1	RP11-792A8.3	3.43	0.000625	0.0296	0.12	0.11	Aortic root size;	chr7:66580095	chr7:66748838~66749077:-
BRCA	cis	rs3824344	0.507	rs10814501	ENSG00000281649.1	EBLN3	-3.43	0.000625	0.0296	-0.09	-0.11	Intelligence;	chr9:37019307	chr9:37079857~37090507:+
BRCA	cis	rs2835872	0.932	rs73222345	ENSG00000230366.8	DSCR9	-3.43	0.000625	0.0296	-0.14	-0.11	Electroencephalographic traits in alcoholism;	chr21:37664267	chr21:37208503~37221736:+
BRCA	cis	rs9650657	0.623	rs6601514	ENSG00000154316.13	TDH	3.43	0.000625	0.0296	0.13	0.11	Neuroticism;	chr8:10743771	chr8:11339637~11368452:+
BRCA	cis	rs2304003	1	rs2304003	ENSG00000235192.1	AC009495.2	3.43	0.000625	0.0296	0.13	0.11	Social communication problems;	chr2:165857571	chr2:165794851~165810010:+
BRCA	cis	rs4664293	0.51	rs6731277	ENSG00000230783.1	AC009961.2	3.43	0.000625	0.0296	0.13	0.11	Monocyte percentage of white cells;	chr2:159610606	chr2:159689217~159690291:-
BRCA	cis	rs7664683	1	rs2054394	ENSG00000230069.3	LRRC37A15P	3.43	0.000625	0.0296	0.17	0.11	Erythrocyte cadmium concentration in never smokers;	chr4:102347606	chr4:102727274~102730721:-
BRCA	cis	rs1499614	0.803	rs1796229	ENSG00000229180.5	GS1-124K5.11	3.43	0.000625	0.0296	0.15	0.11	Gout;	chr7:66654674	chr7:66526088~66542624:-
BRCA	cis	rs1056107	0.866	rs4979093	ENSG00000266315.1	MIR4668	3.43	0.000625	0.0296	0.11	0.11	Colorectal cancer;	chr9:112275820	chr9:111932100~111932169:+
BRCA	cis	rs787274	1	rs787301	ENSG00000271631.1	RP11-408O19.5	-3.43	0.000625	0.0296	-0.18	-0.11	Age-related hearing impairment (SNP x SNP interaction);	chr9:112780457	chr9:112885158~112885767:+
BRCA	cis	rs1348850	0.914	rs3813259	ENSG00000271825.1	RP11-337N6.2	3.43	0.000625	0.0296	0.13	0.11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177392486	chr2:177300600~177302006:+
BRCA	cis	rs3764021	0.527	rs10844427	ENSG00000278635.1	CTD-2318O12.1	-3.43	0.000625	0.0296	-0.12	-0.11	Type 1 diabetes;	chr12:9681798	chr12:9415641~9416718:+
BRCA	cis	rs1528472	0.836	rs1614271	ENSG00000276533.1	RP11-139H15.5	3.43	0.000625	0.0296	0.12	0.11	Urinary albumin-to-creatinine ratio;Urinary albumin-to-creatinine ratio in non-diabetics;	chr15:55019187	chr15:55288849~55289346:-
BRCA	cis	rs5758511	0.689	rs17002947	ENSG00000230107.1	CTA-126B4.7	3.43	0.000625	0.0296	0.15	0.11	Birth weight;	chr22:42292526	chr22:42438023~42446195:+
BRCA	cis	rs7246657	0.943	rs34603719	ENSG00000267470.4	ZNF571-AS1	3.43	0.000625	0.0296	0.15	0.11	Coronary artery calcification;	chr19:37303626	chr19:37548914~37587348:+
BRCA	cis	rs3753275	0.684	rs6577532	ENSG00000232912.4	RP5-1115A15.1	3.43	0.000625	0.0296	0.13	0.11	Educational attainment;	chr1:8839246	chr1:8424645~8434838:+
BRCA	cis	rs8054556	0.633	rs12928610	ENSG00000183604.13	SMG1P5	-3.43	0.000625	0.0296	-0.1	-0.11	Autism spectrum disorder or schizophrenia;	chr16:30004701	chr16:30267553~30335374:-
BRCA	cis	rs4713118	0.587	rs61471148	ENSG00000226314.6	ZNF192P1	-3.43	0.000626	0.0297	-0.16	-0.11	Parkinson's disease;	chr6:28069254	chr6:28161781~28169594:+
BRCA	cis	rs10090774	0.71	rs4413752	ENSG00000280303.2	ERICD	-3.43	0.000626	0.0297	-0.12	-0.11	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140678873	chr8:140636281~140638283:+
BRCA	cis	rs860295	0.702	rs11264381	ENSG00000232093.1	RP11-307C12.11	-3.43	0.000626	0.0297	-0.12	-0.11	Body mass index;	chr1:155552781	chr1:155045191~155046118:-
BRCA	cis	rs875971	0.862	rs908915	ENSG00000229886.1	RP5-1132H15.3	-3.43	0.000626	0.0297	-0.12	-0.11	Aortic root size;	chr7:66149664	chr7:66025126~66031544:-
BRCA	cis	rs78487399	0.808	rs13405076	ENSG00000234936.1	AC010883.5	3.43	0.000626	0.0297	0.16	0.11	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43508214	chr2:43229573~43233394:+
BRCA	cis	rs2562456	0.876	rs62110163	ENSG00000268119.4	CTD-2561J22.5	3.43	0.000626	0.0297	0.16	0.11	Pain;	chr19:21546020	chr19:21444241~21463908:-
BRCA	cis	rs2562456	0.761	rs35008138	ENSG00000268119.4	CTD-2561J22.5	3.43	0.000626	0.0297	0.16	0.11	Pain;	chr19:21548822	chr19:21444241~21463908:-
BRCA	cis	rs2562456	0.833	rs2681388	ENSG00000268119.4	CTD-2561J22.5	3.43	0.000626	0.0297	0.16	0.11	Pain;	chr19:21549451	chr19:21444241~21463908:-
BRCA	cis	rs2562456	0.876	rs2681370	ENSG00000268119.4	CTD-2561J22.5	3.43	0.000626	0.0297	0.16	0.11	Pain;	chr19:21554036	chr19:21444241~21463908:-
BRCA	cis	rs2562456	0.876	rs11668606	ENSG00000268119.4	CTD-2561J22.5	3.43	0.000626	0.0297	0.16	0.11	Pain;	chr19:21554618	chr19:21444241~21463908:-
BRCA	cis	rs2562456	0.876	rs2681395	ENSG00000268119.4	CTD-2561J22.5	3.43	0.000626	0.0297	0.16	0.11	Pain;	chr19:21555338	chr19:21444241~21463908:-
BRCA	cis	rs67073037	0.955	rs4371318	ENSG00000230730.1	AC074011.2	-3.43	0.000626	0.0297	-0.14	-0.11	Breast cancer;Breast cancer (estrogen-receptor negative);	chr2:28933494	chr2:28633282~28664540:-
BRCA	cis	rs801193	0.569	rs2659907	ENSG00000271064.1	RP11-792A8.3	-3.43	0.000626	0.0297	-0.12	-0.11	Aortic root size;	chr7:66699045	chr7:66748838~66749077:-
BRCA	cis	rs12530845	1	rs12540325	ENSG00000223718.3	AC093107.7	3.43	0.000626	0.0297	0.16	0.11	Red blood cell traits;	chr7:135649363	chr7:135660039~135660647:+
BRCA	cis	rs9287719	0.967	rs4669593	ENSG00000224177.5	LINC00570	3.43	0.000626	0.0297	0.12	0.11	Prostate cancer;	chr2:10561782	chr2:11393981~11403077:+
BRCA	cis	rs9287719	0.967	rs3814388	ENSG00000224177.5	LINC00570	3.43	0.000626	0.0297	0.12	0.11	Prostate cancer;	chr2:10561973	chr2:11393981~11403077:+
BRCA	cis	rs875971	0.862	rs6955837	ENSG00000223473.2	GS1-124K5.3	-3.43	0.000626	0.0297	-0.08	-0.11	Aortic root size;	chr7:66578155	chr7:66491049~66493566:-
BRCA	cis	rs6439699	0.941	rs13068466	ENSG00000273486.1	RP11-731C17.2	3.43	0.000626	0.0297	0.14	0.11	Intelligence (multi-trait analysis);	chr3:137271599	chr3:136837338~136839021:-
BRCA	cis	rs9311474	0.629	rs7639267	ENSG00000222345.1	SNORD19	3.43	0.000626	0.0297	0.11	0.11	Electroencephalogram traits;	chr3:52534789	chr3:52691378~52691453:+
BRCA	cis	rs561341	1	rs542132	ENSG00000265798.5	RP11-271K11.5	3.43	0.000626	0.0297	0.18	0.11	Hip circumference adjusted for BMI;	chr17:31980174	chr17:31038575~31059121:-
BRCA	cis	rs12220238	0.915	rs11001003	ENSG00000213731.2	RAB5CP1	-3.43	0.000626	0.0297	-0.17	-0.11	Soluble interleukin-2 receptor subunit alpha;	chr10:74340186	chr10:74423435~74424014:-
BRCA	cis	rs4787951	0.56	rs3024530	ENSG00000259940.2	CTD-3203P2.1	3.43	0.000626	0.0297	0.12	0.11	Eosinophil percentage of white cells;	chr16:27339366	chr16:27213308~27214993:-
BRCA	cis	rs6696239	1	rs10799428	ENSG00000227711.2	RP11-275O4.5	-3.43	0.000626	0.0297	-0.15	-0.11	Height;	chr1:227610864	chr1:227509028~227520477:-
BRCA	cis	rs9467773	0.62	rs2504600	ENSG00000261353.1	CTA-14H9.5	-3.43	0.000626	0.0297	-0.11	-0.11	Intelligence (multi-trait analysis);	chr6:26648106	chr6:26527063~26527404:+
BRCA	cis	rs9467773	0.62	rs2130657	ENSG00000261353.1	CTA-14H9.5	-3.43	0.000626	0.0297	-0.11	-0.11	Intelligence (multi-trait analysis);	chr6:26650598	chr6:26527063~26527404:+
BRCA	cis	rs9467773	0.62	rs2498351	ENSG00000261353.1	CTA-14H9.5	-3.43	0.000626	0.0297	-0.11	-0.11	Intelligence (multi-trait analysis);	chr6:26659414	chr6:26527063~26527404:+
BRCA	cis	rs9467773	0.62	rs2504566	ENSG00000261353.1	CTA-14H9.5	-3.43	0.000626	0.0297	-0.11	-0.11	Intelligence (multi-trait analysis);	chr6:26660260	chr6:26527063~26527404:+
BRCA	cis	rs7829975	0.688	rs6601703	ENSG00000173295.6	FAM86B3P	3.43	0.000626	0.0297	0.11	0.11	Mood instability;	chr8:8522714	chr8:8228595~8244865:+
BRCA	cis	rs6490294	0.571	rs6489824	ENSG00000257624.1	RP1-128M12.3	3.43	0.000626	0.0297	0.17	0.11	Mean platelet volume;	chr12:112030613	chr12:112000739~112000985:-
BRCA	cis	rs2287838	0.901	rs5004102	ENSG00000267289.1	CTD-2623N2.11	-3.43	0.000626	0.0297	-0.12	-0.11	Sleep duration;	chr19:9871658	chr19:9834079~9835013:-
BRCA	cis	rs17767294	0.708	rs115714358	ENSG00000219392.1	RP1-265C24.5	-3.43	0.000626	0.0297	-0.29	-0.11	Parkinson's disease;	chr6:27996554	chr6:28115628~28116551:+
BRCA	cis	rs6490294	0.8	rs78783055	ENSG00000257624.1	RP1-128M12.3	3.43	0.000626	0.0297	0.15	0.11	Mean platelet volume;	chr12:111795691	chr12:112000739~112000985:-
BRCA	cis	rs4650943	0.503	rs7534058	ENSG00000227740.1	RP11-318C24.2	3.43	0.000626	0.0297	0.11	0.11	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in inactive individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr1:176055184	chr1:175904762~175920513:-
BRCA	cis	rs74233809	0.901	rs4409766	ENSG00000236937.2	PTGES3P4	3.43	0.000627	0.0297	0.2	0.11	Birth weight;	chr10:102856906	chr10:102845595~102845950:+
BRCA	cis	rs6964587	0.692	rs2374550	ENSG00000188693.7	CYP51A1-AS1	-3.43	0.000627	0.0297	-0.11	-0.11	Breast cancer;	chr7:92191673	chr7:92134604~92180725:+
BRCA	cis	rs2835345	1	rs2835345	ENSG00000279365.1	KB-176G8.1	3.43	0.000627	0.0297	0.15	0.11	Pulmonary function;	chr21:36429136	chr21:36485867~36487760:+
BRCA	cis	rs4378999	0.8	rs4286453	ENSG00000273356.1	RP11-804H8.6	3.43	0.000627	0.0297	0.18	0.11	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;	chr3:51104928	chr3:50669989~50672048:+
BRCA	cis	rs4578769	0.959	rs1031651	ENSG00000273232.1	RP11-370A5.2	3.43	0.000627	0.0297	0.14	0.11	Eosinophil percentage of white cells;	chr18:22915716	chr18:22882825~22883357:-
BRCA	cis	rs4578769	0.959	rs4800439	ENSG00000273232.1	RP11-370A5.2	3.43	0.000627	0.0297	0.14	0.11	Eosinophil percentage of white cells;	chr18:22920492	chr18:22882825~22883357:-
BRCA	cis	rs4578769	0.959	rs8096389	ENSG00000273232.1	RP11-370A5.2	3.43	0.000627	0.0297	0.14	0.11	Eosinophil percentage of white cells;	chr18:22921952	chr18:22882825~22883357:-
BRCA	cis	rs4578769	0.959	rs9949696	ENSG00000273232.1	RP11-370A5.2	3.43	0.000627	0.0297	0.14	0.11	Eosinophil percentage of white cells;	chr18:22923688	chr18:22882825~22883357:-
BRCA	cis	rs4578769	0.959	rs930910	ENSG00000273232.1	RP11-370A5.2	3.43	0.000627	0.0297	0.14	0.11	Eosinophil percentage of white cells;	chr18:22930178	chr18:22882825~22883357:-
BRCA	cis	rs983392	0.617	rs667897	ENSG00000275344.1	MIR6503	3.43	0.000627	0.0297	0.11	0.11	Alzheimer's disease (late onset);	chr11:60169506	chr11:60209071~60209156:-
BRCA	cis	rs10838634	0.901	rs16938534	ENSG00000280615.1	Y_RNA	-3.43	0.000627	0.0297	-0.18	-0.11	Schizophrenia;	chr11:46865833	chr11:47614898~47614994:-
BRCA	cis	rs2762353	0.526	rs3936052	ENSG00000272462.2	U91328.19	-3.43	0.000627	0.0297	-0.12	-0.11	Blood metabolite levels;	chr6:25715306	chr6:25992662~26001775:+
BRCA	cis	rs7267979	1	rs453329	ENSG00000276952.1	RP5-965G21.6	3.43	0.000627	0.0297	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25459957	chr20:25284915~25285588:-
BRCA	cis	rs8054556	0.669	rs12931955	ENSG00000183604.13	SMG1P5	-3.43	0.000627	0.0297	-0.1	-0.11	Autism spectrum disorder or schizophrenia;	chr16:30001745	chr16:30267553~30335374:-
BRCA	cis	rs2640806	0.645	rs3735987	ENSG00000253105.4	KB-1448A5.1	3.43	0.000627	0.0297	0.12	0.11	Obesity-related traits;	chr8:96320433	chr8:96371865~96387438:-
BRCA	cis	rs2191566	0.576	rs396148	ENSG00000266921.1	RP11-15A1.7	3.43	0.000627	0.0297	0.13	0.11	Acute lymphoblastic leukemia (childhood);	chr19:43990396	chr19:43996896~44002836:-
BRCA	cis	rs6997458	0.742	rs7841178	ENSG00000258256.1	RP11-219B4.5	3.43	0.000627	0.0297	0.12	0.11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85425690	chr8:85222446~85245717:-
BRCA	cis	rs6012564	0.928	rs8118105	ENSG00000230758.1	SNAP23P	3.43	0.000627	0.0297	0.12	0.11	Anger;	chr20:49182127	chr20:49038357~49038602:-
BRCA	cis	rs6964587	0.843	rs56075286	ENSG00000188693.7	CYP51A1-AS1	-3.43	0.000627	0.0297	-0.12	-0.11	Breast cancer;	chr7:92102204	chr7:92134604~92180725:+
BRCA	cis	rs4849845	0.704	rs4848580	ENSG00000223549.1	MTND5P28	-3.43	0.000627	0.0297	-0.12	-0.11	Mean platelet volume;	chr2:120243541	chr2:120215181~120217279:+
BRCA	cis	rs964611	1	rs8037626	ENSG00000259488.2	RP11-154J22.1	-3.43	0.000627	0.0297	-0.14	-0.11	Metabolite levels (Pyroglutamine);	chr15:48314149	chr15:48312353~48331856:-
BRCA	cis	rs7712401	0.791	rs4836244	ENSG00000263432.2	RN7SL689P	3.43	0.000627	0.0297	0.12	0.11	Mean platelet volume;	chr5:122780537	chr5:123022487~123022783:-
BRCA	cis	rs950881	0.601	rs3771164	ENSG00000234389.1	AC007278.3	3.43	0.000627	0.0297	0.12	0.11	Allergy;	chr2:102375326	chr2:102438713~102440475:+
BRCA	cis	rs4950322	0.748	rs17360812	ENSG00000227242.3	NBPF13P	3.43	0.000627	0.0297	0.15	0.11	Protein quantitative trait loci;	chr1:147355010	chr1:147021320~147124525:-
BRCA	cis	rs80168506	0.748	rs7571939	ENSG00000196096.3	AC079610.2	3.43	0.000627	0.0297	0.2	0.11	Selective IgA deficiency;	chr2:213185232	chr2:213276552~213284205:-
BRCA	cis	rs7709909	0.755	rs32950	ENSG00000249655.1	CTC-325J23.2	3.43	0.000627	0.0297	0.11	0.11	HDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;	chr5:80722425	chr5:80630313~80631590:-
BRCA	cis	rs2652822	0.935	rs12148069	ENSG00000259459.4	RP11-321G12.1	-3.43	0.000627	0.0297	-0.1	-0.11	Metabolic traits;	chr15:63151593	chr15:63390136~63438320:+
BRCA	cis	rs8180040	0.62	rs749511	ENSG00000260236.1	RP11-708J19.1	-3.43	0.000627	0.0297	-0.09	-0.11	Colorectal cancer;	chr3:46994245	chr3:47379089~47380999:-
BRCA	cis	rs2991971	1	rs518365	ENSG00000280836.1	AL355480.1	3.43	0.000627	0.0297	0.12	0.11	High light scatter reticulocyte count;	chr1:45544980	chr1:45581219~45581321:-
BRCA	cis	rs4925540	1	rs12122290	ENSG00000215796.3	RP11-551G24.2	-3.43	0.000627	0.0297	-0.12	-0.11	Response to taxane treatment (docetaxel);	chr1:247052508	chr1:247042791~247044021:+
BRCA	cis	rs4925540	0.89	rs12118487	ENSG00000215796.3	RP11-551G24.2	-3.43	0.000627	0.0297	-0.12	-0.11	Response to taxane treatment (docetaxel);	chr1:247052540	chr1:247042791~247044021:+
BRCA	cis	rs911119	0.913	rs6036465	ENSG00000270001.1	RP11-218C14.8	-3.43	0.000627	0.0297	-0.13	-0.11	Chronic kidney disease;	chr20:23607366	chr20:23631826~23632316:-
BRCA	cis	rs875971	1	rs778710	ENSG00000273024.4	INTS4P2	-3.43	0.000627	0.0297	-0.11	-0.11	Aortic root size;	chr7:66389847	chr7:65647864~65715661:+
BRCA	cis	rs1376877	0.934	rs56317341	ENSG00000273456.1	RP11-686O6.2	3.43	0.000628	0.0297	0.1	0.11	Subclinical atherosclerosis traits (other);	chr2:203246025	chr2:202374932~202375604:-
BRCA	cis	rs4906332	1	rs12879663	ENSG00000259775.1	RP11-45P15.4	-3.43	0.000628	0.0297	-0.12	-0.11	Coronary artery disease;	chr14:103407878	chr14:103331674~103332367:-
BRCA	cis	rs1018697	1	rs7086400	ENSG00000236937.2	PTGES3P4	3.43	0.000628	0.0297	0.14	0.11	Colorectal adenoma (advanced);	chr10:102802340	chr10:102845595~102845950:+
BRCA	cis	rs80226907	1	rs78610369	ENSG00000258413.1	RP11-665C16.6	-3.43	0.000628	0.0297	-0.27	-0.11	Mean platelet volume;	chr14:55298346	chr14:55262767~55272075:-
BRCA	cis	rs80226907	1	rs117960693	ENSG00000258413.1	RP11-665C16.6	-3.43	0.000628	0.0297	-0.27	-0.11	Mean platelet volume;	chr14:55298642	chr14:55262767~55272075:-
BRCA	cis	rs80226907	1	rs76104714	ENSG00000258413.1	RP11-665C16.6	-3.43	0.000628	0.0297	-0.27	-0.11	Mean platelet volume;	chr14:55299069	chr14:55262767~55272075:-
BRCA	cis	rs80226907	0.901	rs76761568	ENSG00000258413.1	RP11-665C16.6	-3.43	0.000628	0.0297	-0.27	-0.11	Mean platelet volume;	chr14:55302353	chr14:55262767~55272075:-
BRCA	cis	rs80226907	1	rs112815650	ENSG00000258413.1	RP11-665C16.6	-3.43	0.000628	0.0297	-0.27	-0.11	Mean platelet volume;	chr14:55304545	chr14:55262767~55272075:-
BRCA	cis	rs294588	0.543	rs297945	ENSG00000250061.4	RP11-541P9.3	-3.43	0.000628	0.0297	-0.13	-0.11	Aging;	chr5:163563467	chr5:163012265~163437326:-
BRCA	cis	rs3764021	0.527	rs10844503	ENSG00000260423.1	RP13-735L24.1	-3.43	0.000628	0.0297	-0.12	-0.11	Type 1 diabetes;	chr12:9701660	chr12:9367464~9397617:+
BRCA	cis	rs1018697	1	rs2150928	ENSG00000236937.2	PTGES3P4	3.43	0.000628	0.0297	0.14	0.11	Colorectal adenoma (advanced);	chr10:102791228	chr10:102845595~102845950:+
BRCA	cis	rs2625529	0.53	rs2959930	ENSG00000260037.4	CTD-2524L6.3	-3.43	0.000628	0.0297	-0.14	-0.11	Red blood cell count;	chr15:72306273	chr15:71818396~71823384:+
BRCA	cis	rs7839435	1	rs11776293	ENSG00000234770.1	GULOP	-3.43	0.000628	0.0298	-0.17	-0.11	Lung adenocarcinoma;	chr8:27560912	chr8:27560274~27589073:+
BRCA	cis	rs2307022	0.671	rs9889191	ENSG00000279693.1	RP11-71L14.3	-3.43	0.000628	0.0298	-0.11	-0.11	Body mass index;	chr16:68343945	chr16:68367325~68370262:-
BRCA	cis	rs752010	0.695	rs11210508	ENSG00000230638.4	RP11-486B10.4	-3.43	0.000628	0.0298	-0.13	-0.11	Lupus nephritis in systemic lupus erythematosus;	chr1:41641264	chr1:41542069~41544310:+
BRCA	cis	rs67478160	0.704	rs12894254	ENSG00000269940.1	RP11-73M18.7	3.43	0.000628	0.0298	0.11	0.11	Schizophrenia;	chr14:103824612	chr14:103694560~103695170:+
BRCA	cis	rs4648045	0.535	rs4698861	ENSG00000251288.2	RP11-10L12.2	3.43	0.000628	0.0298	0.14	0.11	Lymphocyte percentage of white cells;	chr4:102624330	chr4:102751401~102752641:+
BRCA	cis	rs10129255	0.957	rs12590735	ENSG00000211967.3	IGHV3-53	-3.43	0.000628	0.0298	-0.08	-0.11	Kawasaki disease;	chr14:106779660	chr14:106592676~106593347:-
BRCA	cis	rs875971	0.895	rs778700	ENSG00000273024.4	INTS4P2	-3.43	0.000628	0.0298	-0.12	-0.11	Aortic root size;	chr7:66401463	chr7:65647864~65715661:+
BRCA	cis	rs875971	1	rs778699	ENSG00000273024.4	INTS4P2	-3.43	0.000628	0.0298	-0.12	-0.11	Aortic root size;	chr7:66403303	chr7:65647864~65715661:+
BRCA	cis	rs7709909	0.653	rs40139	ENSG00000249655.1	CTC-325J23.2	3.43	0.000628	0.0298	0.11	0.11	HDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;	chr5:80738016	chr5:80630313~80631590:-
BRCA	cis	rs344364	0.511	rs911391	ENSG00000219027.2	RPS3AP2	3.43	0.000628	0.0298	0.16	0.11	Glomerular filtration rate in chronic kidney disease;	chr16:1897015	chr16:1477830~1478583:+
BRCA	cis	rs60822569	1	rs60822569	ENSG00000249388.1	RP11-834C11.6	-3.43	0.000628	0.0298	-0.14	-0.11	Mean platelet volume;	chr12:54323724	chr12:54082118~54102693:+
BRCA	cis	rs2625529	0.824	rs16953769	ENSG00000260037.4	CTD-2524L6.3	-3.43	0.000628	0.0298	-0.15	-0.11	Red blood cell count;	chr15:72170984	chr15:71818396~71823384:+
BRCA	cis	rs4865762	0.514	rs152944	ENSG00000247796.2	CTD-2366F13.1	3.43	0.000629	0.0298	0.12	0.11	Intraocular pressure;	chr5:53135013	chr5:53109842~53115126:+
BRCA	cis	rs863345	0.604	rs4584390	ENSG00000229914.1	RP11-404O13.4	-3.43	0.000629	0.0298	-0.11	-0.11	Pneumococcal bacteremia;	chr1:158536185	chr1:158195633~158196131:-
BRCA	cis	rs6964587	0.773	rs12536421	ENSG00000188693.7	CYP51A1-AS1	-3.43	0.000629	0.0298	-0.12	-0.11	Breast cancer;	chr7:92378906	chr7:92134604~92180725:+
BRCA	cis	rs4805834	0.764	rs11668595	ENSG00000201388.1	SNORA68	3.43	0.000629	0.0298	0.19	0.11	Creatinine levels;	chr19:32863495	chr19:32608337~32608469:-
BRCA	cis	rs2832191	0.791	rs7283853	ENSG00000232855.5	AF131217.1	3.43	0.000629	0.0298	0.12	0.11	Dental caries;	chr21:29126194	chr21:28439346~28674848:-
BRCA	cis	rs10129255	0.957	rs2013423	ENSG00000253936.1	IGHV3-63	3.43	0.000629	0.0298	0.09	0.11	Kawasaki disease;	chr14:106690675	chr14:106652237~106652681:-
BRCA	cis	rs10129255	0.957	rs56134540	ENSG00000253936.1	IGHV3-63	3.43	0.000629	0.0298	0.09	0.11	Kawasaki disease;	chr14:106691290	chr14:106652237~106652681:-
BRCA	cis	rs7474896	1	rs10827823	ENSG00000120555.12	SEPT7P9	3.43	0.000629	0.0298	0.19	0.11	Obesity (extreme);	chr10:37750453	chr10:38383069~38402916:-
BRCA	cis	rs7267979	0.932	rs433352	ENSG00000204556.4	CTD-2514C3.1	3.43	0.000629	0.0298	0.14	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25487356	chr20:26018832~26020684:+
BRCA	cis	rs4713118	0.516	rs7739216	ENSG00000226314.6	ZNF192P1	-3.43	0.000629	0.0298	-0.16	-0.11	Parkinson's disease;	chr6:28112168	chr6:28161781~28169594:+
BRCA	cis	rs853679	0.517	rs35512245	ENSG00000226314.6	ZNF192P1	-3.43	0.000629	0.0298	-0.16	-0.11	Depression;	chr6:28112175	chr6:28161781~28169594:+
BRCA	cis	rs4243971	0.557	rs58921650	ENSG00000277692.1	RP11-358N2.2	-3.43	0.000629	0.0298	-0.12	-0.11	Inflammatory bowel disease;Crohn's disease;	chr20:32306100	chr20:32355053~32355734:+
BRCA	cis	rs6088590	0.687	rs8115656	ENSG00000269202.1	RP4-614O4.12	-3.43	0.000629	0.0298	-0.11	-0.11	Coronary artery disease;	chr20:34694976	chr20:35201747~35203288:-
BRCA	cis	rs7554547	0.791	rs1321073	ENSG00000242349.4	NPPA-AS1	-3.43	0.000629	0.0298	-0.11	-0.11	Nonsyndromic cleft lip with cleft palate;	chr1:11891569	chr1:11841017~11848079:+
BRCA	cis	rs987724	0.593	rs9875585	ENSG00000240875.4	LINC00886	-3.43	0.000629	0.0298	-0.12	-0.11	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156963334	chr3:156747346~156817062:-
BRCA	cis	rs34792	0.688	rs153782	ENSG00000260872.1	RP11-680G24.5	3.43	0.000629	0.0298	0.11	0.11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15507763	chr16:15018106~15020488:-
BRCA	cis	rs6840360	1	rs17360475	ENSG00000278978.1	RP11-164P12.5	3.43	0.000629	0.0298	0.12	0.11	Intelligence (multi-trait analysis);	chr4:151750488	chr4:151669786~151670503:+
BRCA	cis	rs7487075	0.82	rs12310125	ENSG00000274723.1	RP11-618L22.1	3.43	0.000629	0.0298	0.12	0.11	Itch intensity from mosquito bite;	chr12:46299371	chr12:46970504~46972155:+
BRCA	cis	rs564309	0.764	rs3795814	ENSG00000212237.1	RNA5SP18	3.43	0.000629	0.0298	0.19	0.11	Hip circumference (psychosocial stress interaction);	chr1:228356099	chr1:228647912~228648032:-
BRCA	cis	rs999943	0.846	rs9366826	ENSG00000224557.6	HLA-DPB2	-3.43	0.000629	0.0298	-0.14	-0.11	Obesity (extreme);	chr6:33651407	chr6:33112451~33129084:+
BRCA	cis	rs2439831	0.85	rs11856795	ENSG00000206991.1	RNU6-610P	-3.43	0.000629	0.0298	-0.17	-0.11	Lung cancer in ever smokers;	chr15:43868384	chr15:43637632~43637738:-
BRCA	cis	rs28489187	0.706	rs72724606	ENSG00000223653.4	RP11-131L23.1	3.43	0.000629	0.0298	0.12	0.11	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85384563	chr1:85276715~85448124:+
BRCA	cis	rs10504130	0.74	rs17277222	ENSG00000272024.1	RP11-546K22.3	3.43	0.000629	0.0298	0.2	0.11	Venous thromboembolism (SNP x SNP interaction);	chr8:51654801	chr8:51950284~51950690:+
BRCA	cis	rs7712401	0.791	rs1531340	ENSG00000249996.1	RP11-359P5.1	3.43	0.00063	0.0298	0.12	0.11	Mean platelet volume;	chr5:122772322	chr5:123036271~123054667:+
BRCA	cis	rs6015450	1	rs16982520	ENSG00000228340.4	MIR646HG	-3.43	0.00063	0.0298	-0.18	-0.11	Hypertension;Blood pressure;Systolic blood pressure;Diastolic blood pressure;	chr20:59183665	chr20:60087840~60527458:+
BRCA	cis	rs17406451	0.788	rs7609003	ENSG00000234936.1	AC010883.5	-3.43	0.00063	0.0298	-0.1	-0.11	Mitochondrial DNA levels;	chr2:43478723	chr2:43229573~43233394:+
BRCA	cis	rs8180040	0.966	rs13079098	ENSG00000260236.1	RP11-708J19.1	3.43	0.00063	0.0298	0.1	0.11	Colorectal cancer;	chr3:47401373	chr3:47379089~47380999:-
BRCA	cis	rs4919669	0.623	rs2298278	ENSG00000213277.3	MARCKSL1P1	3.43	0.00063	0.0298	0.17	0.11	Mean arterial pressure (long-term average);Systolic blood pressure (long-term average);	chr10:102630546	chr10:103175554~103176094:+
BRCA	cis	rs6600671	0.902	rs2222371	ENSG00000275131.1	CH17-472G23.4	3.43	0.00063	0.0298	0.1	0.11	Hip geometry;	chr1:121547320	chr1:120489625~120579190:-
BRCA	cis	rs7267979	0.932	rs1985737	ENSG00000274414.1	RP5-965G21.4	-3.43	0.00063	0.0298	-0.12	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25610832	chr20:25239007~25245229:-
BRCA	cis	rs6696239	0.513	rs3010186	ENSG00000227711.2	RP11-275O4.5	-3.43	0.00063	0.0298	-0.12	-0.11	Height;	chr1:227587125	chr1:227509028~227520477:-
BRCA	cis	rs2832191	0.716	rs1543652	ENSG00000236056.1	GAPDHP14	-3.43	0.00063	0.0298	-0.12	-0.11	Dental caries;	chr21:29075679	chr21:29222321~29223257:+
BRCA	cis	rs970548	0.643	rs12765320	ENSG00000239883.7	PARPG1	3.43	0.00063	0.0298	0.1	0.11	Total cholesterol levels;HDL cholesterol;HDL cholesterol levels;Cholesterol, total;	chr10:45435357	chr10:45854093~45972154:-
BRCA	cis	rs2050392	0.517	rs656600	ENSG00000224473.1	CCND3P1	3.43	0.00063	0.0298	0.14	0.11	Inflammatory bowel disease;	chr10:30476725	chr10:30403197~30403776:-
BRCA	cis	rs875971	0.862	rs6964437	ENSG00000223473.2	GS1-124K5.3	-3.43	0.00063	0.0298	-0.08	-0.11	Aortic root size;	chr7:66221457	chr7:66491049~66493566:-
BRCA	cis	rs1865760	0.963	rs3846838	ENSG00000272810.1	U91328.22	-3.43	0.00063	0.0298	-0.12	-0.11	Height;	chr6:25911547	chr6:26013241~26013757:+
BRCA	cis	rs7429990	0.965	rs9854454	ENSG00000280173.1	RP11-447D11.3	-3.43	0.00063	0.0298	-0.09	-0.11	Educational attainment (years of education);	chr3:47971307	chr3:47346950~47349073:+
BRCA	cis	rs11671005	0.735	rs3826682	ENSG00000269600.1	AC016629.3	-3.43	0.00063	0.0298	-0.16	-0.11	Mean platelet volume;	chr19:58407381	chr19:58593896~58599355:-
BRCA	cis	rs74233809	1	rs12411886	ENSG00000213061.2	PFN1P11	3.43	0.00063	0.0298	0.25	0.11	Birth weight;	chr10:102925542	chr10:102838011~102845473:-
BRCA	cis	rs2239547	0.522	rs2581801	ENSG00000279144.1	RP11-894J14.2	-3.43	0.00063	0.0298	-0.14	-0.11	Schizophrenia;	chr3:52938891	chr3:52848085~52848553:-
BRCA	cis	rs10876993	1	rs10876993	ENSG00000270039.1	RP11-571M6.17	3.43	0.00063	0.0298	0.14	0.11	Celiac disease or Rheumatoid arthritis;	chr12:57668884	chr12:57803838~57804415:+
BRCA	cis	rs13420028	0.628	rs2315385	ENSG00000230992.3	FAM201B	-3.43	0.00063	0.0298	-0.12	-0.11	Hypertension (SNP x SNP interaction);	chr2:132424921	chr2:132352722~132353318:+
BRCA	cis	rs490234	0.702	rs12553882	ENSG00000232630.1	PRPS1P2	-3.43	0.00063	0.0298	-0.11	-0.11	Mean arterial pressure;	chr9:125432765	chr9:125150653~125151589:+
BRCA	cis	rs613391	0.561	rs471112	ENSG00000265194.1	RP11-70L8.4	-3.43	0.00063	0.0298	-0.11	-0.11	Quantitative traits;	chr9:22720808	chr9:21858910~21861926:-
BRCA	cis	rs17801127	0.901	rs16827290	ENSG00000231969.1	AC144449.1	3.43	0.00063	0.0298	0.19	0.11	Liver enzyme levels (alanine transaminase);	chr2:149652761	chr2:149587196~149848233:+
BRCA	cis	rs9393813	0.528	rs9468141	ENSG00000204789.4	ZNF204P	3.43	0.00063	0.0298	0.13	0.11	Bipolar disorder;	chr6:27506748	chr6:27357825~27360221:-
BRCA	cis	rs1528472	0.836	rs1690366	ENSG00000276533.1	RP11-139H15.5	3.43	0.00063	0.0298	0.12	0.11	Urinary albumin-to-creatinine ratio;Urinary albumin-to-creatinine ratio in non-diabetics;	chr15:55019365	chr15:55288849~55289346:-
BRCA	cis	rs2562456	0.682	rs11085464	ENSG00000268705.1	BNIP3P26	3.43	0.00063	0.0298	0.12	0.11	Pain;	chr19:21568976	chr19:21521343~21521896:-
BRCA	cis	rs853679	0.517	rs9393885	ENSG00000272009.1	RP1-313I6.12	-3.43	0.000631	0.0298	-0.15	-0.11	Depression;	chr6:28082231	chr6:28078792~28081130:-
BRCA	cis	rs853679	0.517	rs9393886	ENSG00000272009.1	RP1-313I6.12	-3.43	0.000631	0.0298	-0.15	-0.11	Depression;	chr6:28082261	chr6:28078792~28081130:-
BRCA	cis	rs4713118	0.515	rs9368549	ENSG00000272009.1	RP1-313I6.12	-3.43	0.000631	0.0298	-0.15	-0.11	Parkinson's disease;	chr6:28082269	chr6:28078792~28081130:-
BRCA	cis	rs4533720	0.569	rs6536772	ENSG00000248546.3	ANP32C	-3.43	0.000631	0.0299	-0.12	-0.11	Urinary uromodulin levels;	chr4:164029012	chr4:164197007~164197711:-
BRCA	cis	rs7833790	0.7	rs7834483	ENSG00000254689.1	RP11-354A14.1	3.43	0.000631	0.0299	0.13	0.11	Diastolic blood pressure;	chr8:81792593	chr8:81885377~81923193:+
BRCA	cis	rs73222236	0.825	rs7621017	ENSG00000239213.4	NCK1-AS1	3.43	0.000631	0.0299	0.12	0.11	Coronary artery disease;	chr3:136553387	chr3:136841726~136862054:-
BRCA	cis	rs4908769	0.624	rs301791	ENSG00000232912.4	RP5-1115A15.1	-3.43	0.000631	0.0299	-0.11	-0.11	Allergy;	chr1:8408312	chr1:8424645~8434838:+
BRCA	cis	rs10129255	1	rs10141557	ENSG00000211967.3	IGHV3-53	-3.43	0.000631	0.0299	-0.08	-0.11	Kawasaki disease;	chr14:106767990	chr14:106592676~106593347:-
BRCA	cis	rs4835473	0.932	rs4835305	ENSG00000246448.2	RP13-578N3.3	-3.43	0.000631	0.0299	-0.12	-0.11	Immature fraction of reticulocytes;	chr4:143823646	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.932	rs11721700	ENSG00000246448.2	RP13-578N3.3	-3.43	0.000631	0.0299	-0.12	-0.11	Immature fraction of reticulocytes;	chr4:143824264	chr4:143700257~143865072:+
BRCA	cis	rs17197037	0.545	rs7147689	ENSG00000277734.3	TRAC	-3.43	0.000631	0.0299	-0.07	-0.11	Bipolar disorder;	chr14:21318697	chr14:22281105~22552155:+
BRCA	cis	rs2904967	0.703	rs2904982	ENSG00000254501.1	AP003068.9	-3.43	0.000631	0.0299	-0.22	-0.11	Mean corpuscular volume;	chr11:65236830	chr11:65110714~65111695:-
BRCA	cis	rs736408	0.812	rs2270197	ENSG00000242142.1	SERBP1P3	3.43	0.000631	0.0299	0.13	0.11	Bipolar disorder;	chr3:52790079	chr3:53064283~53065091:-
BRCA	cis	rs901683	0.85	rs73291122	ENSG00000230869.1	CTGLF10P	-3.43	0.000631	0.0299	-0.24	-0.11	Mean corpuscular volume;Red blood cell traits;	chr10:45603955	chr10:45678692~45700532:+
BRCA	cis	rs1670533	1	rs11735663	ENSG00000251639.2	RP11-20I20.1	3.43	0.000631	0.0299	0.17	0.11	Recombination rate (females);	chr4:1058057	chr4:1100016~1101558:-
BRCA	cis	rs35306767	0.903	rs17159970	ENSG00000229869.1	RP11-363N22.2	-3.43	0.000631	0.0299	-0.16	-0.11	Eosinophil percentage of granulocytes;	chr10:889661	chr10:933026~942743:+
BRCA	cis	rs12517906	1	rs11249745	ENSG00000280161.1	CTC-205M6.1	-3.43	0.000631	0.0299	-0.15	-0.11	Weight;Body mass index;	chr5:180744399	chr5:180810401~180811384:+
BRCA	cis	rs3760982	0.585	rs67773424	ENSG00000266921.1	RP11-15A1.7	-3.43	0.000631	0.0299	-0.13	-0.11	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43789842	chr19:43996896~44002836:-
BRCA	cis	rs8114671	0.836	rs2038504	ENSG00000261582.1	RP4-614O4.11	3.43	0.000631	0.0299	0.1	0.11	Height;	chr20:35060384	chr20:35267885~35280043:-
BRCA	cis	rs8114671	0.836	rs2104083	ENSG00000261582.1	RP4-614O4.11	3.43	0.000631	0.0299	0.1	0.11	Height;	chr20:35061330	chr20:35267885~35280043:-
BRCA	cis	rs8114671	0.839	rs2104084	ENSG00000261582.1	RP4-614O4.11	3.43	0.000631	0.0299	0.1	0.11	Height;	chr20:35061414	chr20:35267885~35280043:-
BRCA	cis	rs11711311	0.712	rs10804510	ENSG00000241529.3	RN7SL767P	-3.43	0.000631	0.0299	-0.12	-0.11	IgG glycosylation;	chr3:113621853	chr3:113632704~113632998:+
BRCA	cis	rs11098499	0.754	rs714899	ENSG00000250412.1	KLHL2P1	3.43	0.000631	0.0299	0.12	0.11	Corneal astigmatism;	chr4:119321880	chr4:119334329~119378233:+
BRCA	cis	rs2562456	0.793	rs62110424	ENSG00000268705.1	BNIP3P26	3.43	0.000631	0.0299	0.13	0.11	Pain;	chr19:21416835	chr19:21521343~21521896:-
BRCA	cis	rs10129255	1	rs10129407	ENSG00000253763.1	IGHV3-6	3.43	0.000631	0.0299	0.1	0.11	Kawasaki disease;	chr14:106767956	chr14:106055549~106055998:-
BRCA	cis	rs13126694	0.778	rs13106004	ENSG00000251073.1	NUDT19P5	3.43	0.000631	0.0299	0.1	0.11	Blood osmolality (transformed sodium);	chr4:158104532	chr4:158182825~158183393:+
BRCA	cis	rs13126694	0.744	rs13106234	ENSG00000251073.1	NUDT19P5	3.43	0.000631	0.0299	0.1	0.11	Blood osmolality (transformed sodium);	chr4:158104618	chr4:158182825~158183393:+
BRCA	cis	rs61931739	0.5	rs2389269	ENSG00000258794.3	DUX4L27	3.43	0.000631	0.0299	0.15	0.11	Morning vs. evening chronotype;	chr12:33881244	chr12:34208415~34209675:-
BRCA	cis	rs875971	0.965	rs7794930	ENSG00000272831.1	RP11-792A8.4	-3.43	0.000631	0.0299	-0.09	-0.11	Aortic root size;	chr7:66313559	chr7:66739829~66740385:-
BRCA	cis	rs848490	0.889	rs11761707	ENSG00000214293.7	APTR	-3.43	0.000632	0.0299	-0.13	-0.11	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77608867	chr7:77657660~77696265:-
BRCA	cis	rs10129255	0.536	rs17113249	ENSG00000211964.3	IGHV3-48	-3.43	0.000632	0.0299	-0.07	-0.11	Kawasaki disease;	chr14:106678273	chr14:106537810~106538344:-
BRCA	cis	rs11098499	0.691	rs10028773	ENSG00000260091.1	RP11-33B1.4	3.43	0.000632	0.0299	0.09	0.11	Corneal astigmatism;	chr4:119344104	chr4:119409333~119410233:+
BRCA	cis	rs897984	0.572	rs112906665	ENSG00000275263.1	RP11-1072A3.4	-3.43	0.000632	0.0299	-0.12	-0.11	Dementia with Lewy bodies;	chr16:31028818	chr16:30956872~30957199:-
BRCA	cis	rs7487075	0.619	rs6582657	ENSG00000257261.4	RP11-96H19.1	3.43	0.000632	0.0299	0.12	0.11	Itch intensity from mosquito bite;	chr12:46462236	chr12:46383679~46876159:+
BRCA	cis	rs9457247	1	rs408087	ENSG00000227598.1	RP1-167A14.2	-3.43	0.000632	0.0299	-0.11	-0.11	Crohn's disease;	chr6:166985464	chr6:166969626~166999065:-
BRCA	cis	rs2562456	0.874	rs2562408	ENSG00000268705.1	BNIP3P26	-3.43	0.000632	0.0299	-0.12	-0.11	Pain;	chr19:21527079	chr19:21521343~21521896:-
BRCA	cis	rs1250248	0.536	rs1053238	ENSG00000225166.1	AC012462.2	-3.43	0.000632	0.0299	-0.13	-0.11	Total cholesterol levels;	chr2:215404486	chr2:215453707~215463871:+
BRCA	cis	rs67073037	0.955	rs3924272	ENSG00000230730.1	AC074011.2	-3.43	0.000632	0.0299	-0.14	-0.11	Breast cancer;Breast cancer (estrogen-receptor negative);	chr2:28944812	chr2:28633282~28664540:-
BRCA	cis	rs751728	0.664	rs12196293	ENSG00000224557.6	HLA-DPB2	-3.43	0.000632	0.0299	-0.12	-0.11	Crohn's disease;	chr6:33781374	chr6:33112451~33129084:+
BRCA	cis	rs751728	0.664	rs12190029	ENSG00000224557.6	HLA-DPB2	-3.43	0.000632	0.0299	-0.12	-0.11	Crohn's disease;	chr6:33781375	chr6:33112451~33129084:+
BRCA	cis	rs56114371	0.777	rs200481	ENSG00000216901.1	AL022393.7	3.43	0.000632	0.0299	0.2	0.11	Breast cancer;	chr6:27806054	chr6:28176188~28176674:+
BRCA	cis	rs495337	1	rs4809769	ENSG00000229222.1	KRT18P4	-3.43	0.000632	0.0299	-0.13	-0.11	Psoriasis;	chr20:49962627	chr20:49956745~49958032:+
BRCA	cis	rs687432	0.718	rs10896687	ENSG00000265566.2	RN7SL605P	-3.43	0.000632	0.0299	-0.13	-0.11	Parkinson's disease;	chr11:58019373	chr11:57528085~57528365:-
BRCA	cis	rs17221829	0.739	rs7945443	ENSG00000280385.1	AP000648.5	-3.43	0.000632	0.0299	-0.12	-0.11	Anxiety in major depressive disorder;	chr11:89639454	chr11:90193614~90198120:+
BRCA	cis	rs17221829	0.574	rs2773245	ENSG00000280385.1	AP000648.5	-3.43	0.000632	0.0299	-0.12	-0.11	Anxiety in major depressive disorder;	chr11:89639458	chr11:90193614~90198120:+
BRCA	cis	rs875971	0.862	rs880166	ENSG00000229886.1	RP5-1132H15.3	-3.43	0.000632	0.0299	-0.12	-0.11	Aortic root size;	chr7:66205775	chr7:66025126~66031544:-
BRCA	cis	rs793571	0.779	rs28641638	ENSG00000259250.1	RP11-50C13.1	-3.43	0.000632	0.0299	-0.16	-0.11	Schizophrenia;	chr15:58923034	chr15:58587507~58591676:+
BRCA	cis	rs10129255	0.518	rs7143784	ENSG00000211964.3	IGHV3-48	-3.43	0.000632	0.0299	-0.07	-0.11	Kawasaki disease;	chr14:106687277	chr14:106537810~106538344:-
BRCA	cis	rs13401620	0.871	rs11689019	ENSG00000229326.3	AC069154.4	-3.43	0.000632	0.0299	-0.15	-0.11	Breast size;	chr2:119871922	chr2:119698623~119700151:+
BRCA	cis	rs986417	0.818	rs1010051	ENSG00000258670.1	RP11-1042B17.3	-3.43	0.000632	0.0299	-0.19	-0.11	Gut microbiota (bacterial taxa);	chr14:60536270	chr14:60515119~60554916:+
BRCA	cis	rs986417	0.748	rs1955691	ENSG00000258670.1	RP11-1042B17.3	-3.43	0.000632	0.0299	-0.19	-0.11	Gut microbiota (bacterial taxa);	chr14:60537410	chr14:60515119~60554916:+
BRCA	cis	rs986417	0.818	rs2351173	ENSG00000258670.1	RP11-1042B17.3	-3.43	0.000632	0.0299	-0.19	-0.11	Gut microbiota (bacterial taxa);	chr14:60542037	chr14:60515119~60554916:+
BRCA	cis	rs7267979	1	rs1888999	ENSG00000274973.1	RP13-401N8.7	-3.43	0.000632	0.0299	-0.12	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25311212	chr20:25845497~25845862:+
BRCA	cis	rs7674212	0.531	rs4698876	ENSG00000248740.4	RP11-328K4.1	3.43	0.000632	0.0299	0.12	0.11	Type 2 diabetes;	chr4:103012410	chr4:103256159~103453658:+
BRCA	cis	rs9467773	0.967	rs9295694	ENSG00000261353.1	CTA-14H9.5	-3.43	0.000632	0.0299	-0.11	-0.11	Intelligence (multi-trait analysis);	chr6:26512766	chr6:26527063~26527404:+
BRCA	cis	rs9467773	0.967	rs9467775	ENSG00000261353.1	CTA-14H9.5	-3.43	0.000632	0.0299	-0.11	-0.11	Intelligence (multi-trait analysis);	chr6:26513207	chr6:26527063~26527404:+
BRCA	cis	rs6095360	0.966	rs13037557	ENSG00000222365.1	SNORD12B	-3.43	0.000632	0.0299	-0.12	-0.11	Intelligence (multi-trait analysis);	chr20:48918053	chr20:49280319~49280409:+
BRCA	cis	rs7818688	0.697	rs17665737	ENSG00000245080.5	RP11-320N21.1	-3.43	0.000632	0.0299	-0.18	-0.11	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94974078	chr8:95066808~95073182:-
BRCA	cis	rs818427	0.927	rs469760	ENSG00000279522.1	CTC-487M23.6	3.43	0.000632	0.0299	0.12	0.11	Total body bone mineral density;	chr5:112909080	chr5:112894933~112896531:+
BRCA	cis	rs7267979	0.932	rs449370	ENSG00000231081.1	RP4-760C5.3	3.43	0.000632	0.0299	0.14	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25470544	chr20:26008791~26010531:-
BRCA	cis	rs295490	0.748	rs77995988	ENSG00000178631.7	ACTG1P1	-3.43	0.000632	0.0299	-0.22	-0.11	PR interval in Tripanosoma cruzi seropositivity;	chr3:139456686	chr3:139493809~139494937:+
BRCA	cis	rs10043775	0.793	rs7702440	ENSG00000251330.3	CTD-2283N19.1	-3.43	0.000632	0.0299	-0.12	-0.11	Periodontal microbiota;	chr5:148325222	chr5:148430159~148430807:-
BRCA	cis	rs8060686	0.516	rs7193701	ENSG00000279649.1	RP11-96D1.8	3.43	0.000632	0.0299	0.09	0.11	HDL cholesterol;Metabolic syndrome;	chr16:68151257	chr16:68290087~68292790:-
BRCA	cis	rs9782955	1	rs6673237	ENSG00000207181.1	SNORA14B	-3.43	0.000632	0.0299	-0.13	-0.11	Systemic lupus erythematosus;	chr1:235877829	chr1:235127803~235127937:-
BRCA	cis	rs1046491	1	rs12454497	ENSG00000264964.1	RP11-888D10.3	3.43	0.000632	0.0299	0.22	0.11	Scarlet fever;	chr18:9224441	chr18:9315194~9334441:-
BRCA	cis	rs524281	0.861	rs10791854	ENSG00000255038.1	RP11-1167A19.2	-3.43	0.000633	0.0299	-0.15	-0.11	Electroencephalogram traits;	chr11:66196072	chr11:66067277~66069619:-
BRCA	cis	rs2625529	0.652	rs2278987	ENSG00000261187.1	RP11-1007O24.2	3.43	0.000633	0.0299	0.11	0.11	Red blood cell count;	chr15:72117428	chr15:72465128~72466262:-
BRCA	cis	rs1075265	0.704	rs805405	ENSG00000272156.1	RP11-477N3.1	-3.43	0.000633	0.0299	-0.11	-0.11	Chronotype;Morning vs. evening chronotype;	chr2:53891014	chr2:54082554~54085066:+
BRCA	cis	rs1371614	0.632	rs4665929	ENSG00000272148.1	RP11-195B17.1	-3.43	0.000633	0.0299	-0.12	-0.11	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26932981	chr2:27062428~27062907:-
BRCA	cis	rs7520050	0.966	rs6677007	ENSG00000226957.1	RP4-533D7.4	3.43	0.000633	0.0299	0.11	0.11	Reticulocyte count;Red blood cell count;	chr1:45934918	chr1:46046818~46048368:+
BRCA	cis	rs7520050	0.966	rs4660898	ENSG00000226957.1	RP4-533D7.4	3.43	0.000633	0.0299	0.11	0.11	Reticulocyte count;Red blood cell count;	chr1:45936499	chr1:46046818~46048368:+
BRCA	cis	rs897984	0.542	rs73530203	ENSG00000275263.1	RP11-1072A3.4	-3.43	0.000633	0.0299	-0.13	-0.11	Dementia with Lewy bodies;	chr16:31088538	chr16:30956872~30957199:-
BRCA	cis	rs875971	0.862	rs4149461	ENSG00000223473.2	GS1-124K5.3	-3.43	0.000633	0.0299	-0.08	-0.11	Aortic root size;	chr7:66279745	chr7:66491049~66493566:-
BRCA	cis	rs12701220	0.744	rs10499317	ENSG00000224079.1	AC091729.7	3.43	0.000633	0.0299	0.15	0.11	Bronchopulmonary dysplasia;	chr7:972467	chr7:1074450~1078036:+
BRCA	cis	rs58521262	0.592	rs11671459	ENSG00000268105.1	RP11-369G6.2	-3.43	0.000633	0.03	-0.18	-0.11	Testicular germ cell tumor;	chr19:22840945	chr19:23125665~23128543:+
BRCA	cis	rs9951698	0.667	rs9961669	ENSG00000266969.1	RP11-773H22.4	3.43	0.000633	0.03	0.14	0.11	Intelligence (multi-trait analysis);	chr18:13020882	chr18:12984694~12991173:-
BRCA	cis	rs2562456	0.917	rs10420016	ENSG00000240522.1	RPL7AP10	3.43	0.000633	0.03	0.12	0.11	Pain;	chr19:21505800	chr19:21149648~21150438:-
BRCA	cis	rs16862426	1	rs16862426	ENSG00000270728.1	RP4-657E11.10	3.43	0.000633	0.03	0.22	0.11	Methotrexate phramacokinetics (acute lymphoblastic leukemia);	chr1:18995001	chr1:19297080~19297903:+
BRCA	cis	rs10458771	0.92	rs7087535	ENSG00000223482.6	NUTM2A-AS1	-3.43	0.000633	0.03	-0.2	-0.11	Amyotrophic lateral sclerosis (sporadic);	chr10:86396775	chr10:87203875~87342612:-
BRCA	cis	rs2749592	0.55	rs7917262	ENSG00000263064.2	RP11-291L22.7	-3.43	0.000633	0.03	-0.13	-0.11	Age-related hearing impairment (SNP x SNP interaction);	chr10:37585674	chr10:38448689~38448949:+
BRCA	cis	rs71520386	0.632	rs35353454	ENSG00000179428.2	AC073072.5	3.43	0.000633	0.03	0.12	0.11	Fibrinogen levels;	chr7:22822120	chr7:22725395~22727620:-
BRCA	cis	rs801193	1	rs2659909	ENSG00000265600.1	AC006480.1	-3.43	0.000633	0.03	-0.12	-0.11	Aortic root size;	chr7:66695292	chr7:67356680~67356779:+
BRCA	cis	rs2360027	0.599	rs2202578	ENSG00000231365.4	RP11-418J17.1	-3.43	0.000633	0.03	-0.13	-0.11	Tonsillectomy;	chr1:118543849	chr1:119140396~119275973:+
BRCA	cis	rs4906332	1	rs4900574	ENSG00000259775.1	RP11-45P15.4	3.43	0.000633	0.03	0.12	0.11	Coronary artery disease;	chr14:103412687	chr14:103331674~103332367:-
BRCA	cis	rs2562456	0.561	rs12610883	ENSG00000268705.1	BNIP3P26	3.43	0.000633	0.03	0.12	0.11	Pain;	chr19:21567257	chr19:21521343~21521896:-
BRCA	cis	rs2562456	0.837	rs11085462	ENSG00000268705.1	BNIP3P26	3.43	0.000633	0.03	0.12	0.11	Pain;	chr19:21567449	chr19:21521343~21521896:-
BRCA	cis	rs2274273	0.84	rs3742569	ENSG00000259318.1	RP11-454L9.2	3.43	0.000633	0.03	0.09	0.11	Protein biomarker;	chr14:55351988	chr14:55394940~55395233:-
BRCA	cis	rs889312	1	rs889312	ENSG00000271828.1	CTD-2310F14.1	-3.43	0.000633	0.03	-0.13	-0.11	Breast cancer (early onset);Breast cancer;	chr5:56736057	chr5:56927874~56929573:+
BRCA	cis	rs4767841	0.935	rs3956827	ENSG00000248636.5	RP11-768F21.1	-3.43	0.000633	0.03	-0.13	-0.11	Urgency urinary incontinence;	chr12:119751727	chr12:119387987~119668079:-
BRCA	cis	rs10045413	0.598	rs56402736	ENSG00000250167.1	CTC-321K16.1	3.43	0.000633	0.03	0.13	0.11	Age at smoking initiation in chronic obstructive pulmonary disease;	chr5:135617865	chr5:135559577~135634874:+
BRCA	cis	rs1843834	0.539	rs6739735	ENSG00000274629.1	RP11-92F20.1	3.43	0.000633	0.03	0.14	0.11	IgE levels in asthmatics (D.p. specific);	chr2:224540536	chr2:224464682~224474500:+
BRCA	cis	rs3770752	0.836	rs4998429	ENSG00000272054.1	RP11-423P10.2	-3.43	0.000633	0.03	-0.09	-0.11	Schizophrenia;	chr2:37237287	chr2:37208875~37212677:+
BRCA	cis	rs4713118	0.869	rs6922574	ENSG00000219392.1	RP1-265C24.5	-3.43	0.000633	0.03	-0.15	-0.11	Parkinson's disease;	chr6:27725224	chr6:28115628~28116551:+
BRCA	cis	rs3136202	0.684	rs1651196	ENSG00000242307.1	RPS26P52	3.43	0.000633	0.03	0.14	0.11	Conduct disorder (symptom count);	chr16:13976536	chr16:13922332~13922679:-
BRCA	cis	rs8114671	0.562	rs6120758	ENSG00000261582.1	RP4-614O4.11	-3.43	0.000633	0.03	-0.1	-0.11	Height;	chr20:34904720	chr20:35267885~35280043:-
BRCA	cis	rs6439153	0.933	rs1871951	ENSG00000242551.2	POU5F1P6	-3.43	0.000633	0.03	-0.14	-0.11	Pneumococcal bacteremia;	chr3:129001644	chr3:128674735~128677005:-
BRCA	cis	rs957448	1	rs2381885	ENSG00000261437.1	RP11-22C11.2	3.43	0.000634	0.03	0.11	0.11	Nonsyndromic cleft lip with cleft palate;	chr8:94499974	chr8:94637285~94639467:-
BRCA	cis	rs1865760	0.865	rs1436306	ENSG00000272810.1	U91328.22	-3.43	0.000634	0.03	-0.12	-0.11	Height;	chr6:25948193	chr6:26013241~26013757:+
BRCA	cis	rs853679	0.546	rs200949	ENSG00000241549.7	GUSBP2	3.43	0.000634	0.03	0.18	0.11	Depression;	chr6:27867657	chr6:26871484~26956554:-
BRCA	cis	rs7267979	1	rs6115182	ENSG00000231081.1	RP4-760C5.3	3.43	0.000634	0.03	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25429623	chr20:26008791~26010531:-
BRCA	cis	rs11671005	0.651	rs11878203	ENSG00000265272.2	RN7SL693P	3.43	0.000634	0.03	0.15	0.11	Mean platelet volume;	chr19:58408683	chr19:58490797~58491075:+
BRCA	cis	rs2899832	0.5	rs76872729	ENSG00000258704.4	SRP54-AS1	3.43	0.000634	0.03	0.24	0.11	Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:35213695	chr14:34920858~34982532:-
BRCA	cis	rs2899832	0.5	rs74925268	ENSG00000258704.4	SRP54-AS1	3.43	0.000634	0.03	0.24	0.11	Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:35221947	chr14:34920858~34982532:-
BRCA	cis	rs10129255	0.957	rs12590667	ENSG00000231475.3	IGHV4-31	3.43	0.000634	0.03	0.08	0.11	Kawasaki disease;	chr14:106779223	chr14:106349283~106349792:-
BRCA	cis	rs3099143	0.908	rs3102716	ENSG00000196274.5	Metazoa_SRP	3.43	0.000634	0.03	0.15	0.11	Recalcitrant atopic dermatitis;	chr15:76758662	chr15:76230048~76230390:-
BRCA	cis	rs60871478	1	rs34761279	ENSG00000237181.1	AC147651.4	-3.43	0.000634	0.03	-0.11	-0.11	Cerebrospinal P-tau181p levels;	chr7:754834	chr7:603185~608482:+
BRCA	cis	rs6452790	0.529	rs10074247	ENSG00000247828.6	TMEM161B-AS1	-3.43	0.000634	0.03	-0.14	-0.11	Cognitive function;	chr5:87977267	chr5:88268895~88436685:+
BRCA	cis	rs6693567	0.565	rs832621	ENSG00000237976.1	RP11-126K1.6	3.43	0.000634	0.03	0.11	0.11	Migraine;	chr1:150420433	chr1:151346967~151348027:+
BRCA	cis	rs13416342	0.681	rs11126163	ENSG00000236259.1	AC017083.2	3.43	0.000634	0.03	0.12	0.11	Breast cancer;	chr2:67861036	chr2:68125265~68125747:+
BRCA	cis	rs10043775	1	rs4349707	ENSG00000251330.3	CTD-2283N19.1	-3.43	0.000634	0.03	-0.13	-0.11	Periodontal microbiota;	chr5:148408875	chr5:148430159~148430807:-
BRCA	cis	rs8180040	0.587	rs62246398	ENSG00000260236.1	RP11-708J19.1	-3.43	0.000634	0.03	-0.1	-0.11	Colorectal cancer;	chr3:47024713	chr3:47379089~47380999:-
BRCA	cis	rs2880765	0.835	rs4360875	ENSG00000230373.7	GOLGA6L5P	3.43	0.000634	0.03	0.11	0.11	Coronary artery disease;	chr15:85497163	chr15:84507885~84516814:-
BRCA	cis	rs6142102	1	rs2378078	ENSG00000228265.4	RALY-AS1	-3.43	0.000634	0.03	-0.12	-0.11	Skin pigmentation;	chr20:34126922	chr20:33983052~33994357:-
BRCA	cis	rs875971	1	rs1565531	ENSG00000271064.1	RP11-792A8.3	3.43	0.000634	0.03	0.12	0.11	Aortic root size;	chr7:66198126	chr7:66748838~66749077:-
BRCA	cis	rs7742824	1	rs73429745	ENSG00000219222.1	RP11-480N24.3	3.43	0.000634	0.03	0.13	0.11	Major depressive disorder;	chr6:44133685	chr6:43310231~43310357:+
BRCA	cis	rs1401999	0.898	rs4148561	ENSG00000223882.1	ABCC5-AS1	-3.43	0.000634	0.03	-0.12	-0.11	Anterior chamber depth;	chr3:184008591	chr3:184006338~184011419:+
BRCA	cis	rs4835473	0.778	rs6856553	ENSG00000246448.2	RP13-578N3.3	-3.43	0.000634	0.03	-0.12	-0.11	Immature fraction of reticulocytes;	chr4:143825973	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.868	rs11737787	ENSG00000246448.2	RP13-578N3.3	-3.43	0.000634	0.03	-0.12	-0.11	Immature fraction of reticulocytes;	chr4:143826498	chr4:143700257~143865072:+
BRCA	cis	rs2898279	0.872	rs7830445	ENSG00000255354.1	RP11-148O21.2	-3.43	0.000634	0.03	-0.1	-0.11	Small cell lung carcinoma;	chr8:11444552	chr8:11558466~11560020:-
BRCA	cis	rs875971	0.505	rs1723275	ENSG00000229180.5	GS1-124K5.11	-3.43	0.000634	0.03	-0.09	-0.11	Aortic root size;	chr7:66039646	chr7:66526088~66542624:-
BRCA	cis	rs4742903	0.967	rs2274725	ENSG00000270332.1	SMC2-AS1	3.43	0.000635	0.03	0.12	0.11	Breast cancer;High-grade serous ovarian cancer;	chr9:104102289	chr9:104080024~104093073:-
BRCA	cis	rs6964587	1	rs6960867	ENSG00000244055.1	AC007566.10	-3.43	0.000635	0.03	-0.1	-0.11	Breast cancer;	chr7:92083384	chr7:92457564~92491610:+
BRCA	cis	rs11671005	0.735	rs11668814	ENSG00000265272.2	RN7SL693P	3.43	0.000635	0.03	0.15	0.11	Mean platelet volume;	chr19:58435466	chr19:58490797~58491075:+
BRCA	cis	rs875971	0.825	rs1000464	ENSG00000229886.1	RP5-1132H15.3	-3.43	0.000635	0.03	-0.12	-0.11	Aortic root size;	chr7:66312922	chr7:66025126~66031544:-
BRCA	cis	rs10129255	0.957	rs10138532	ENSG00000231475.3	IGHV4-31	-3.43	0.000635	0.03	-0.09	-0.11	Kawasaki disease;	chr14:106803901	chr14:106349283~106349792:-
BRCA	cis	rs2924679	1	rs3019587	ENSG00000250508.1	RP11-757G1.6	3.43	0.000635	0.03	0.26	0.11	Obesity-related traits;	chr11:68802174	chr11:68870664~68874542:+
BRCA	cis	rs2274273	0.686	rs17253695	ENSG00000259318.1	RP11-454L9.2	-3.43	0.000635	0.03	-0.09	-0.11	Protein biomarker;	chr14:55107892	chr14:55394940~55395233:-
BRCA	cis	rs2439831	0.85	rs61390361	ENSG00000206991.1	RNU6-610P	-3.43	0.000635	0.03	-0.17	-0.11	Lung cancer in ever smokers;	chr15:43867644	chr15:43637632~43637738:-
BRCA	cis	rs36051895	0.589	rs6476947	ENSG00000237711.1	RP11-39K24.13	-3.43	0.000635	0.03	-0.13	-0.11	Pediatric autoimmune diseases;	chr9:5204279	chr9:5100236~5101009:+
BRCA	cis	rs7259811	0.892	rs66528367	ENSG00000268266.1	AC003005.2	3.43	0.000635	0.03	0.14	0.11	Western dietary pattern;	chr19:56714551	chr19:57477649~57482996:+
BRCA	cis	rs11686241	1	rs11886806	ENSG00000241520.1	AC098820.4	-3.43	0.000635	0.03	-0.16	-0.11	Cancer;	chr2:216424552	chr2:216483032~216487196:-
BRCA	cis	rs11700980	0.636	rs116306600	ENSG00000232855.5	AF131217.1	3.43	0.000635	0.03	0.19	0.11	QRS complex (12-leadsum);	chr21:28860220	chr21:28439346~28674848:-
BRCA	cis	rs7917772	0.532	rs10748829	ENSG00000236937.2	PTGES3P4	3.43	0.000635	0.03	0.15	0.11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;	chr10:102767487	chr10:102845595~102845950:+
BRCA	cis	rs11671005	0.735	rs35652377	ENSG00000265272.2	RN7SL693P	3.43	0.000635	0.03	0.15	0.11	Mean platelet volume;	chr19:58417833	chr19:58490797~58491075:+
BRCA	cis	rs11671005	0.735	rs3088284	ENSG00000265272.2	RN7SL693P	3.43	0.000635	0.03	0.15	0.11	Mean platelet volume;	chr19:58418060	chr19:58490797~58491075:+
BRCA	cis	rs11671005	0.735	rs12981649	ENSG00000265272.2	RN7SL693P	3.43	0.000635	0.03	0.15	0.11	Mean platelet volume;	chr19:58418676	chr19:58490797~58491075:+
BRCA	cis	rs6973609	0.554	rs1600016	ENSG00000271122.1	RP11-379H18.1	3.43	0.000635	0.03	0.13	0.11	Obesity-related traits;	chr7:35566102	chr7:35695214~35699413:+
BRCA	cis	rs7520050	0.933	rs6656022	ENSG00000281133.1	AL355480.3	3.43	0.000635	0.03	0.12	0.11	Reticulocyte count;Red blood cell count;	chr1:45928643	chr1:45580892~45580996:-
BRCA	cis	rs2333021	1	rs2333021	ENSG00000258408.1	NT5CP2	3.43	0.000635	0.03	0.11	0.11	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:73017676	chr14:73539221~73539781:-
BRCA	cis	rs1434538	0.935	rs3796443	ENSG00000271474.1	RP11-710C12.1	3.43	0.000635	0.03	0.13	0.11	Coronary artery disease;	chr4:95140358	chr4:95549129~95552457:+
BRCA	cis	rs34421088	0.548	rs2618443	ENSG00000227888.4	FAM66A	-3.43	0.000635	0.03	-0.13	-0.11	Neuroticism;	chr8:11527047	chr8:12362019~12388296:+
BRCA	cis	rs2153535	0.585	rs7762631	ENSG00000251164.1	HULC	3.43	0.000635	0.03	0.13	0.11	Motion sickness;	chr6:8635339	chr6:8652137~8653846:+
BRCA	cis	rs7520050	0.778	rs3014216	ENSG00000281133.1	AL355480.3	-3.43	0.000635	0.03	-0.12	-0.11	Reticulocyte count;Red blood cell count;	chr1:45570088	chr1:45580892~45580996:-
BRCA	cis	rs11587682	0.76	rs12145082	ENSG00000228126.1	FALEC	3.43	0.000636	0.0301	0.14	0.11	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr1:150491050	chr1:150515757~150518032:+
BRCA	cis	rs10864907	0.837	rs10178396	ENSG00000231747.1	AC079922.2	-3.43	0.000636	0.0301	-0.09	-0.11	Pulmonary function;	chr2:112941478	chr2:112621809~112622167:-
BRCA	cis	rs13256369	1	rs9329166	ENSG00000233609.3	RP11-62H7.2	3.43	0.000636	0.0301	0.11	0.11	Obesity-related traits;	chr8:8719145	chr8:8961200~8979025:+
BRCA	cis	rs7572733	0.967	rs976179	ENSG00000231621.1	AC013264.2	3.43	0.000636	0.0301	0.1	0.11	Dermatomyositis;	chr2:198015654	chr2:197197991~197199273:+
BRCA	cis	rs6696239	0.911	rs12129213	ENSG00000215812.5	ZNF847P	3.43	0.000636	0.0301	0.15	0.11	Height;	chr1:227698506	chr1:227696892~227706699:-
BRCA	cis	rs7412746	0.611	rs11204747	ENSG00000224800.1	RP11-235D19.2	3.43	0.000636	0.0301	0.13	0.11	Melanoma;	chr1:150954676	chr1:150881236~150881683:-
BRCA	cis	rs2243480	1	rs937108	ENSG00000234585.5	CCT6P3	-3.43	0.000636	0.0301	-0.16	-0.11	Diabetic kidney disease;	chr7:65963465	chr7:65038354~65074713:+
BRCA	cis	rs8133974	1	rs6517275	ENSG00000225555.1	AP000320.6	3.43	0.000636	0.0301	0.2	0.11	Sum eosinophil basophil counts;Eosinophil counts;Eosinophil percentage of granulocytes;	chr21:35079268	chr21:34370802~34375348:-
BRCA	cis	rs1424638	0.629	rs4586668	ENSG00000233251.6	AC007743.1	-3.43	0.000636	0.0301	-0.12	-0.11	Intelligence (multi-trait analysis);	chr2:57021031	chr2:56173534~56185770:-
BRCA	cis	rs1348850	0.914	rs12104588	ENSG00000271825.1	RP11-337N6.2	3.43	0.000636	0.0301	0.14	0.11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177388947	chr2:177300600~177302006:+
BRCA	cis	rs2072499	0.932	rs3001790	ENSG00000232519.2	RP11-29H23.4	-3.43	0.000636	0.0301	-0.13	-0.11	Testicular germ cell tumor;	chr1:156195499	chr1:155609776~155610380:-
BRCA	cis	rs875971	1	rs778696	ENSG00000272831.1	RP11-792A8.4	3.43	0.000636	0.0301	0.09	0.11	Aortic root size;	chr7:66405826	chr7:66739829~66740385:-
BRCA	cis	rs875971	1	rs778694	ENSG00000272831.1	RP11-792A8.4	3.43	0.000636	0.0301	0.09	0.11	Aortic root size;	chr7:66406571	chr7:66739829~66740385:-
BRCA	cis	rs875971	1	rs4718344	ENSG00000272831.1	RP11-792A8.4	3.43	0.000636	0.0301	0.09	0.11	Aortic root size;	chr7:66409394	chr7:66739829~66740385:-
BRCA	cis	rs875971	0.737	rs7803424	ENSG00000272831.1	RP11-792A8.4	3.43	0.000636	0.0301	0.09	0.11	Aortic root size;	chr7:66415618	chr7:66739829~66740385:-
BRCA	cis	rs875971	0.83	rs7799834	ENSG00000272831.1	RP11-792A8.4	3.43	0.000636	0.0301	0.09	0.11	Aortic root size;	chr7:66415707	chr7:66739829~66740385:-
BRCA	cis	rs11035577	0.632	rs10768536	ENSG00000279675.1	RP11-454H19.2	-3.43	0.000636	0.0301	-0.16	-0.11	Temperament (bipolar disorder);	chr11:39766683	chr11:40107244~40112599:-
BRCA	cis	rs7705502	0.779	rs6864880	ENSG00000251144.1	CTD-2532K18.2	-3.43	0.000636	0.0301	-0.13	-0.11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for body mass index;	chr5:173871223	chr5:174820027~174826324:+
BRCA	cis	rs7705502	0.709	rs6869803	ENSG00000251144.1	CTD-2532K18.2	-3.43	0.000636	0.0301	-0.13	-0.11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for body mass index;	chr5:173871822	chr5:174820027~174826324:+
BRCA	cis	rs7017914	0.811	rs4272413	ENSG00000246366.5	RP11-382J12.1	3.43	0.000636	0.0301	0.12	0.11	Bone mineral density;	chr8:70723952	chr8:70608577~70663279:+
BRCA	cis	rs3892630	0.588	rs12610342	ENSG00000267567.1	CTD-2538C1.3	3.43	0.000636	0.0301	0.16	0.11	Red blood cell traits;	chr19:32759784	chr19:32718298~32719595:-
BRCA	cis	rs9863	0.896	rs77112003	ENSG00000270028.1	RP11-380L11.4	3.43	0.000636	0.0301	0.13	0.11	White blood cell count;	chr12:124002996	chr12:123925461~123926083:-
BRCA	cis	rs16917546	1	rs7090073	ENSG00000238280.1	RP11-436D10.3	3.43	0.000636	0.0301	0.14	0.11	Basal cell carcinoma;	chr10:62663745	chr10:62793562~62805887:-
BRCA	cis	rs9309473	0.519	rs6746971	ENSG00000230002.2	ALMS1-IT1	3.43	0.000636	0.0301	0.12	0.11	Metabolite levels;	chr2:73442334	chr2:73456764~73459484:+
BRCA	cis	rs1056107	0.933	rs10116045	ENSG00000266315.1	MIR4668	3.43	0.000636	0.0301	0.11	0.11	Colorectal cancer;	chr9:112285580	chr9:111932100~111932169:+
BRCA	cis	rs1056107	0.933	rs6477908	ENSG00000266315.1	MIR4668	3.43	0.000636	0.0301	0.11	0.11	Colorectal cancer;	chr9:112285627	chr9:111932100~111932169:+
BRCA	cis	rs258892	0.895	rs9293450	ENSG00000272525.1	RP11-79P5.9	-3.43	0.000636	0.0301	-0.13	-0.11	Small cell lung carcinoma;	chr5:72772649	chr5:73497550~73498293:-
BRCA	cis	rs7760535	0.656	rs7766190	ENSG00000231889.6	TRAF3IP2-AS1	3.43	0.000636	0.0301	0.1	0.11	Metabolic traits;	chr6:111583863	chr6:111483511~111598302:+
BRCA	cis	rs4648045	0.796	rs12509403	ENSG00000251288.2	RP11-10L12.2	-3.43	0.000636	0.0301	-0.13	-0.11	Lymphocyte percentage of white cells;	chr4:102604193	chr4:102751401~102752641:+
BRCA	cis	rs4272720	0.901	rs17011755	ENSG00000228754.1	RP11-534L6.3	-3.43	0.000636	0.0301	-0.15	-0.11	Platelet count;Plateletcrit;	chr10:49079527	chr10:48745545~48746128:-
BRCA	cis	rs6540556	0.682	rs932335	ENSG00000236136.1	ADORA2BP1	-3.43	0.000636	0.0301	-0.13	-0.11	Red blood cell count;	chr1:209732389	chr1:209744373~209745214:+
BRCA	cis	rs6088580	0.634	rs6059905	ENSG00000269202.1	RP4-614O4.12	-3.43	0.000636	0.0301	-0.11	-0.11	Glomerular filtration rate (creatinine);	chr20:34539142	chr20:35201747~35203288:-
BRCA	cis	rs6012953	0.845	rs2904270	ENSG00000231715.1	COX6CP2	-3.43	0.000636	0.0301	-0.11	-0.11	Vitiligo;	chr20:50568735	chr20:50479767~50479991:+
BRCA	cis	rs7474896	1	rs2749564	ENSG00000120555.12	SEPT7P9	-3.43	0.000637	0.0301	-0.19	-0.11	Obesity (extreme);	chr10:37889887	chr10:38383069~38402916:-
BRCA	cis	rs1982963	0.95	rs2645749	ENSG00000277050.1	RP11-102G14.1	-3.43	0.000637	0.0301	-0.13	-0.11	Waist-to-hip ratio adjusted for body mass index;	chr14:52036077	chr14:51637348~51637947:-
BRCA	cis	rs6840360	0.593	rs6855883	ENSG00000270265.1	RP11-731D1.4	-3.43	0.000637	0.0301	-0.12	-0.11	Intelligence (multi-trait analysis);	chr4:151767845	chr4:151333775~151353224:-
BRCA	cis	rs875971	0.862	rs4718330	ENSG00000229886.1	RP5-1132H15.3	-3.43	0.000637	0.0301	-0.12	-0.11	Aortic root size;	chr7:66250256	chr7:66025126~66031544:-
BRCA	cis	rs2904967	0.866	rs526502	ENSG00000254614.2	AP003068.23	-3.43	0.000637	0.0301	-0.18	-0.11	Mean corpuscular volume;	chr11:65259119	chr11:65177606~65181834:-
BRCA	cis	rs4835473	0.932	rs13152209	ENSG00000246448.2	RP13-578N3.3	3.43	0.000637	0.0301	0.12	0.11	Immature fraction of reticulocytes;	chr4:143776088	chr4:143700257~143865072:+
BRCA	cis	rs7429990	1	rs1665982	ENSG00000280173.1	RP11-447D11.3	-3.43	0.000637	0.0301	-0.1	-0.11	Educational attainment (years of education);	chr3:47863589	chr3:47346950~47349073:+
BRCA	cis	rs1115240	0.502	rs8009979	ENSG00000262119.1	RP11-483C6.1	-3.43	0.000637	0.0301	-0.12	-0.11	Educational attainment (years of education);	chr14:26653507	chr14:26592747~26594517:-
BRCA	cis	rs453301	0.686	rs3989373	ENSG00000173295.6	FAM86B3P	-3.43	0.000637	0.0301	-0.11	-0.11	Joint mobility (Beighton score);	chr8:9053798	chr8:8228595~8244865:+
BRCA	cis	rs9400180	0.918	rs723861	ENSG00000271734.1	RP1-111B22.3	-3.43	0.000637	0.0301	-0.13	-0.11	Major depressive disorder;	chr6:108052799	chr6:108030249~108030718:-
BRCA	cis	rs6601327	1	rs6601327	ENSG00000233609.3	RP11-62H7.2	-3.43	0.000637	0.0301	-0.1	-0.11	Multiple myeloma (hyperdiploidy);	chr8:9538022	chr8:8961200~8979025:+
BRCA	cis	rs6012953	0.817	rs16995294	ENSG00000231715.1	COX6CP2	-3.43	0.000637	0.0301	-0.11	-0.11	Vitiligo;	chr20:50564808	chr20:50479767~50479991:+
BRCA	cis	rs11098403	0.753	rs12640486	ENSG00000225892.3	RP11-384K6.2	3.43	0.000637	0.0301	0.11	0.11	Schizophrenia;	chr4:117849505	chr4:118632274~118634759:+
BRCA	cis	rs9611565	0.659	rs9611610	ENSG00000281538.1	RP4-669P10.20	3.43	0.000637	0.0301	0.14	0.11	Vitiligo;	chr22:41553255	chr22:42138060~42139726:+
BRCA	cis	rs10170310	1	rs6720716	ENSG00000241772.2	AC092620.2	-3.43	0.000637	0.0301	-0.15	-0.11	Response to antipsychotic treatment;	chr2:138511232	chr2:138569090~138574458:+
BRCA	cis	rs359466	0.938	rs359413	ENSG00000254164.1	CTB-33O18.2	-3.43	0.000637	0.0301	-0.17	-0.11	QRS complex (Sokolow-Lyon);	chr5:173917175	chr5:173574938~173576275:+
BRCA	cis	rs11874712	1	rs3765636	ENSG00000251939.1	RNU6-1278P	-3.43	0.000637	0.0301	-0.12	-0.11	Migraine - clinic-based;	chr18:46073694	chr18:46121615~46121721:-
BRCA	cis	rs6005807	0.92	rs73437900	ENSG00000272858.1	CTA-292E10.8	-3.43	0.000637	0.0301	-0.21	-0.11	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28361318	chr22:28814914~28815662:+
BRCA	cis	rs7020830	0.931	rs7034554	ENSG00000230188.1	RP11-405L18.4	-3.43	0.000637	0.0301	-0.13	-0.11	Schizophrenia;	chr9:37081304	chr9:37490421~37490893:-
BRCA	cis	rs9287719	0.967	rs12464817	ENSG00000224177.5	LINC00570	3.43	0.000637	0.0301	0.12	0.11	Prostate cancer;	chr2:10567086	chr2:11393981~11403077:+
BRCA	cis	rs13113518	0.51	rs11732723	ENSG00000273257.1	RP11-177J6.1	-3.43	0.000637	0.0301	-0.14	-0.11	Height;	chr4:55424391	chr4:55387949~55388271:+
BRCA	cis	rs4820539	0.966	rs5996470	ENSG00000211647.1	IGLV5-48	-3.43	0.000637	0.0301	-0.08	-0.11	Bone mineral density;	chr22:23141068	chr22:22352940~22353433:+
BRCA	cis	rs10995356	0.844	rs10822098	ENSG00000238280.1	RP11-436D10.3	-3.43	0.000637	0.0301	-0.14	-0.11	Temperament;	chr10:62957155	chr10:62793562~62805887:-
BRCA	cis	rs11877825	0.826	rs9675768	ENSG00000265728.1	RP11-883A18.3	-3.43	0.000637	0.0301	-0.15	-0.11	Gut microbiota (bacterial taxa);	chr18:10571712	chr18:10594590~10604798:+
BRCA	cis	rs10838634	1	rs7115038	ENSG00000280615.1	Y_RNA	3.43	0.000637	0.0301	0.18	0.11	Schizophrenia;	chr11:46876241	chr11:47614898~47614994:-
BRCA	cis	rs10838634	1	rs11039015	ENSG00000280615.1	Y_RNA	3.43	0.000637	0.0301	0.18	0.11	Schizophrenia;	chr11:46876314	chr11:47614898~47614994:-
BRCA	cis	rs4386084	1	rs4349086	ENSG00000244879.4	GABPB1-AS1	-3.43	0.000637	0.0301	-0.13	-0.11	Basophil percentage of granulocytes;Basophil percentage of white cells;	chr15:49930250	chr15:50354959~50372202:+
BRCA	cis	rs875971	0.577	rs35072105	ENSG00000232546.1	RP11-458F8.1	3.43	0.000637	0.0301	0.09	0.11	Aortic root size;	chr7:66144830	chr7:66848496~66858136:+
BRCA	cis	rs7615952	0.576	rs2276729	ENSG00000248787.1	RP11-666A20.4	-3.43	0.000637	0.0301	-0.16	-0.11	Blood pressure (smoking interaction);	chr3:126107371	chr3:125908005~125910272:-
BRCA	cis	rs9341808	0.754	rs1324121	ENSG00000279022.1	RP11-250B2.4	3.43	0.000637	0.0301	0.12	0.11	Sitting height ratio;	chr6:80236360	chr6:80440730~80441172:+
BRCA	cis	rs4835473	0.897	rs7681903	ENSG00000246448.2	RP13-578N3.3	-3.43	0.000637	0.0301	-0.12	-0.11	Immature fraction of reticulocytes;	chr4:143759326	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.897	rs7656753	ENSG00000246448.2	RP13-578N3.3	-3.43	0.000637	0.0301	-0.12	-0.11	Immature fraction of reticulocytes;	chr4:143759414	chr4:143700257~143865072:+
BRCA	cis	rs9303029	1	rs9898723	ENSG00000279744.1	RP13-20L14.10	-3.43	0.000637	0.0301	-0.12	-0.11	Protein quantitative trait loci;	chr17:82482031	chr17:82462601~82464255:+
BRCA	cis	rs7267979	1	rs2482940	ENSG00000274973.1	RP13-401N8.7	3.43	0.000637	0.0301	0.12	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25369194	chr20:25845497~25845862:+
BRCA	cis	rs6088580	0.634	rs3736762	ENSG00000269202.1	RP4-614O4.12	-3.43	0.000638	0.0301	-0.11	-0.11	Glomerular filtration rate (creatinine);	chr20:34449531	chr20:35201747~35203288:-
BRCA	cis	rs6088580	0.634	rs6058051	ENSG00000269202.1	RP4-614O4.12	-3.43	0.000638	0.0301	-0.11	-0.11	Glomerular filtration rate (creatinine);	chr20:34457057	chr20:35201747~35203288:-
BRCA	cis	rs6460942	0.659	rs28366613	ENSG00000226690.5	AC005281.1	3.43	0.000638	0.0301	0.21	0.11	Coronary artery disease;	chr7:12472541	chr7:12496429~12541910:+
BRCA	cis	rs7546	0.504	rs2075636	ENSG00000267077.1	RP11-127I20.5	-3.43	0.000638	0.0301	-0.11	-0.11	Cancer;	chr16:4888320	chr16:4795265~4796532:-
BRCA	cis	rs7131987	0.903	rs7308125	ENSG00000257176.2	RP11-996F15.2	-3.43	0.000638	0.0301	-0.13	-0.11	QT interval;	chr12:29272278	chr12:29280418~29317848:-
BRCA	cis	rs7254232	0.96	rs10853782	ENSG00000211513.4	MIR320E	-3.43	0.000638	0.0301	-0.13	-0.11	Chronic periodontitis;	chr19:47289852	chr19:46709271~46709382:-
BRCA	cis	rs8040855	0.576	rs62022528	ENSG00000259774.1	RP11-182J1.13	3.43	0.000638	0.0301	0.15	0.11	Bulimia nervosa;	chr15:84992030	chr15:84422618~84425882:+
BRCA	cis	rs28489187	0.683	rs67611930	ENSG00000223653.4	RP11-131L23.1	3.43	0.000638	0.0301	0.12	0.11	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85380909	chr1:85276715~85448124:+
BRCA	cis	rs16958440	0.708	rs62096462	ENSG00000267724.1	RP11-49K24.8	3.43	0.000638	0.0301	0.16	0.11	Sitting height ratio;	chr18:47098808	chr18:47105946~47108062:+
BRCA	cis	rs987724	0.593	rs9289973	ENSG00000240875.4	LINC00886	-3.43	0.000638	0.0301	-0.12	-0.11	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156960726	chr3:156747346~156817062:-
BRCA	cis	rs2446066	0.872	rs3741651	ENSG00000257379.1	RP11-793H13.8	3.43	0.000638	0.0301	0.16	0.11	Red blood cell count;	chr12:53383387	chr12:53441741~53467528:+
BRCA	cis	rs10777288	0.561	rs1920764	ENSG00000258100.1	RP11-121E16.1	3.43	0.000638	0.0301	0.14	0.11	Pulmonary function (smoking interaction);	chr12:90991705	chr12:91362196~91368606:+
BRCA	cis	rs1348850	0.789	rs2197611	ENSG00000271825.1	RP11-337N6.2	3.43	0.000638	0.0301	0.14	0.11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177504308	chr2:177300600~177302006:+
BRCA	cis	rs4499344	0.623	rs259278	ENSG00000267475.1	CTD-2538C1.2	3.43	0.000638	0.0301	0.14	0.11	Mean platelet volume;	chr19:32670220	chr19:32687089~32691750:-
BRCA	cis	rs9437689	0.714	rs1246349	ENSG00000228971.2	RP11-286B14.1	3.43	0.000638	0.0301	0.12	0.11	Phospholipid levels (plasma);	chr1:94972214	chr1:95510116~95782342:+
BRCA	cis	rs2803122	0.871	rs10481512	ENSG00000272842.1	RP11-513M16.7	-3.43	0.000638	0.0301	-0.11	-0.11	Pulse pressure;	chr9:19230741	chr9:19371386~19371945:-
BRCA	cis	rs4978813	0.5	rs12685609	ENSG00000213539.4	YBX1P6	-3.43	0.000638	0.0301	-0.12	-0.11	Plantar warts;	chr9:109536303	chr9:109532830~109534332:-
BRCA	cis	rs6500395	1	rs9924078	ENSG00000280067.1	CTD-2600H12.2	-3.43	0.000638	0.0301	-0.1	-0.11	Response to tocilizumab in rheumatoid arthritis;	chr16:48524007	chr16:48343755~48346058:-
BRCA	cis	rs2625529	0.59	rs3803471	ENSG00000260037.4	CTD-2524L6.3	-3.43	0.000638	0.0301	-0.15	-0.11	Red blood cell count;	chr15:72208445	chr15:71818396~71823384:+
BRCA	cis	rs11098499	0.863	rs34868248	ENSG00000225892.3	RP11-384K6.2	3.43	0.000638	0.0301	0.11	0.11	Corneal astigmatism;	chr4:119521275	chr4:118632274~118634759:+
BRCA	cis	rs2512987	1	rs2512987	ENSG00000254731.1	CTD-2005H7.1	-3.43	0.000638	0.0301	-0.12	-0.11	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr11:86703240	chr11:86703099~86714092:+
BRCA	cis	rs8114671	0.836	rs6058154	ENSG00000261582.1	RP4-614O4.11	3.43	0.000638	0.0301	0.1	0.11	Height;	chr20:34998031	chr20:35267885~35280043:-
BRCA	cis	rs6914598	0.876	rs67645673	ENSG00000240869.3	RN7SL128P	-3.43	0.000638	0.0302	-0.15	-0.11	Cutaneous malignant melanoma;Melanoma;	chr6:21156785	chr6:20421583~20421887:-
BRCA	cis	rs7937682	1	rs7937682	ENSG00000230911.1	PPIHP1	-3.43	0.000638	0.0302	-0.15	-0.11	Primary sclerosing cholangitis;	chr11:111709215	chr11:112029858~112030367:-
BRCA	cis	rs6142618	0.562	rs3746604	ENSG00000275576.1	RP5-836N17.4	-3.43	0.000638	0.0302	-0.12	-0.11	Inflammatory bowel disease;	chr20:32191327	chr20:32116171~32116629:+
BRCA	cis	rs9863	0.861	rs77020228	ENSG00000270028.1	RP11-380L11.4	3.43	0.000639	0.0302	0.14	0.11	White blood cell count;	chr12:123933925	chr12:123925461~123926083:-
BRCA	cis	rs7071275	0.6	rs11200050	ENSG00000226864.1	ATE1-AS1	-3.43	0.000639	0.0302	-0.21	-0.11	Dupuytren's disease;	chr10:121640871	chr10:121928312~121951965:+
BRCA	cis	rs7098100	0.781	rs1243180	ENSG00000231920.1	NEBL-AS1	-3.43	0.000639	0.0302	-0.12	-0.11	Breast cancer;	chr10:21626690	chr10:21174014~21175048:+
BRCA	cis	rs2842992	0.789	rs4235925	ENSG00000207392.1	SNORA20	-3.43	0.000639	0.0302	-0.14	-0.11	Age-related macular degeneration (geographic atrophy);	chr6:159781828	chr6:159780250~159780381:-
BRCA	cis	rs2625529	0.761	rs16956444	ENSG00000260037.4	CTD-2524L6.3	-3.43	0.000639	0.0302	-0.15	-0.11	Red blood cell count;	chr15:71978894	chr15:71818396~71823384:+
BRCA	cis	rs10129255	0.53	rs11624912	ENSG00000211964.3	IGHV3-48	-3.43	0.000639	0.0302	-0.07	-0.11	Kawasaki disease;	chr14:106673891	chr14:106537810~106538344:-
BRCA	cis	rs17684571	0.872	rs35494794	ENSG00000231441.1	RP11-472M19.2	3.43	0.000639	0.0302	0.18	0.11	Schizophrenia;	chr6:56716124	chr6:56844002~56864078:+
BRCA	cis	rs4819052	0.851	rs35871601	ENSG00000223768.1	LINC00205	-3.43	0.000639	0.0302	-0.14	-0.11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45255299	chr21:45293285~45297354:+
BRCA	cis	rs7560272	0.723	rs4852927	ENSG00000230002.2	ALMS1-IT1	-3.43	0.000639	0.0302	-0.12	-0.11	Schizophrenia;	chr2:73414429	chr2:73456764~73459484:+
BRCA	cis	rs7260598	0.539	rs61693040	ENSG00000268442.1	CTD-2027I19.2	3.43	0.000639	0.0302	0.18	0.11	Response to taxane treatment (placlitaxel);	chr19:23883370	chr19:24162370~24163425:-
BRCA	cis	rs1401999	0.932	rs4148557	ENSG00000223882.1	ABCC5-AS1	-3.42	0.000639	0.0302	-0.12	-0.11	Anterior chamber depth;	chr3:184015996	chr3:184006338~184011419:+
BRCA	cis	rs6012953	0.874	rs734589	ENSG00000231715.1	COX6CP2	-3.42	0.000639	0.0302	-0.11	-0.11	Vitiligo;	chr20:50562384	chr20:50479767~50479991:+
BRCA	cis	rs1730008	0.731	rs12493128	ENSG00000279311.1	RP11-170K4.2	3.42	0.000639	0.0302	0.13	0.11	Lobe attachment (rater-scored or self-reported);	chr3:158448308	chr3:158869898~158871821:+
BRCA	cis	rs863345	0.604	rs7544134	ENSG00000176320.2	RP11-404O13.5	-3.42	0.000639	0.0302	-0.11	-0.11	Pneumococcal bacteremia;	chr1:158505631	chr1:158197922~158203877:-
BRCA	cis	rs2638953	0.64	rs11049718	ENSG00000273989.1	RP11-425D17.2	-3.42	0.000639	0.0302	-0.16	-0.11	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28565739	chr12:28236227~28236828:+
BRCA	cis	rs324126	0.78	rs62108319	ENSG00000277977.1	CTD-3018O17.5	3.42	0.000639	0.0302	0.13	0.11	Colonoscopy-negative controls vs population controls;	chr19:52380577	chr19:52392659~52392755:+
BRCA	cis	rs324126	0.78	rs62108320	ENSG00000277977.1	CTD-3018O17.5	3.42	0.000639	0.0302	0.13	0.11	Colonoscopy-negative controls vs population controls;	chr19:52380770	chr19:52392659~52392755:+
BRCA	cis	rs324126	0.752	rs62108321	ENSG00000277977.1	CTD-3018O17.5	3.42	0.000639	0.0302	0.13	0.11	Colonoscopy-negative controls vs population controls;	chr19:52380825	chr19:52392659~52392755:+
BRCA	cis	rs2109514	1	rs2109514	ENSG00000237813.3	AC002066.1	3.42	0.000639	0.0302	0.13	0.11	Prevalent atrial fibrillation;	chr7:116519907	chr7:116238260~116499465:-
BRCA	cis	rs2109514	0.967	rs55883210	ENSG00000237813.3	AC002066.1	3.42	0.000639	0.0302	0.13	0.11	Prevalent atrial fibrillation;	chr7:116520470	chr7:116238260~116499465:-
BRCA	cis	rs600550	0.719	rs12421663	ENSG00000275344.1	MIR6503	3.42	0.000639	0.0302	0.11	0.11	Lipoprotein-associated phospholipase A2 activity and mass;	chr11:60268077	chr11:60209071~60209156:-
BRCA	cis	rs1046491	1	rs1034486	ENSG00000264964.1	RP11-888D10.3	-3.42	0.000639	0.0302	-0.21	-0.11	Scarlet fever;	chr18:9251238	chr18:9315194~9334441:-
BRCA	cis	rs5750830	0.649	rs5750811	ENSG00000273096.1	RP3-508I15.20	3.42	0.000639	0.0302	0.12	0.11	Intelligence (multi-trait analysis);	chr22:39397061	chr22:38736610~38736792:-
BRCA	cis	rs2832191	0.655	rs2247110	ENSG00000236056.1	GAPDHP14	3.42	0.000639	0.0302	0.12	0.11	Dental caries;	chr21:28951566	chr21:29222321~29223257:+
BRCA	cis	rs881375	0.967	rs1930781	ENSG00000238181.2	AHCYP2	-3.42	0.000639	0.0302	-0.13	-0.11	Rheumatoid arthritis;	chr9:120925556	chr9:120720673~120721972:+
BRCA	cis	rs881375	0.967	rs2416806	ENSG00000238181.2	AHCYP2	-3.42	0.000639	0.0302	-0.13	-0.11	Rheumatoid arthritis;	chr9:120928014	chr9:120720673~120721972:+
BRCA	cis	rs6540556	0.723	rs9430014	ENSG00000236136.1	ADORA2BP1	-3.42	0.000639	0.0302	-0.13	-0.11	Red blood cell count;	chr1:209732027	chr1:209744373~209745214:+
BRCA	cis	rs16975963	0.644	rs59426132	ENSG00000276846.1	CTD-3220F14.3	-3.42	0.000639	0.0302	-0.15	-0.11	Longevity;	chr19:37601869	chr19:37314868~37315620:-
BRCA	cis	rs4819052	0.851	rs2236445	ENSG00000215447.6	BX322557.10	-3.42	0.000639	0.0302	-0.11	-0.11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258538	chr21:45288052~45291738:+
BRCA	cis	rs8103278	1	rs11671524	ENSG00000268423.3	AC011551.3	3.42	0.000639	0.0302	0.13	0.11	Coronary artery disease;	chr19:45823908	chr19:46547056~46600861:-
BRCA	cis	rs3760982	0.585	rs67648499	ENSG00000266921.1	RP11-15A1.7	-3.42	0.000639	0.0302	-0.13	-0.11	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43789903	chr19:43996896~44002836:-
BRCA	cis	rs875971	0.929	rs778712	ENSG00000229886.1	RP5-1132H15.3	3.42	0.000639	0.0302	0.12	0.11	Aortic root size;	chr7:66384991	chr7:66025126~66031544:-
BRCA	cis	rs11587682	0.76	rs72698868	ENSG00000228126.1	FALEC	3.42	0.000639	0.0302	0.14	0.11	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr1:150495338	chr1:150515757~150518032:+
BRCA	cis	rs11587682	0.76	rs72698870	ENSG00000228126.1	FALEC	3.42	0.000639	0.0302	0.14	0.11	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr1:150495341	chr1:150515757~150518032:+
BRCA	cis	rs16975963	0.644	rs112666969	ENSG00000276846.1	CTD-3220F14.3	-3.42	0.000639	0.0302	-0.15	-0.11	Longevity;	chr19:37556743	chr19:37314868~37315620:-
BRCA	cis	rs28489187	0.706	rs233091	ENSG00000223653.4	RP11-131L23.1	3.42	0.000639	0.0302	0.12	0.11	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85357361	chr1:85276715~85448124:+
BRCA	cis	rs2625529	0.824	rs2415121	ENSG00000261187.1	RP11-1007O24.2	-3.42	0.00064	0.0302	-0.11	-0.11	Red blood cell count;	chr15:71841677	chr15:72465128~72466262:-
BRCA	cis	rs6430585	0.527	rs62168830	ENSG00000231890.6	DARS-AS1	-3.42	0.00064	0.0302	-0.16	-0.11	Corneal structure;	chr2:135686330	chr2:135985176~136022593:+
BRCA	cis	rs936094	0.597	rs7437425	ENSG00000271817.2	U3	3.42	0.00064	0.0302	0.14	0.11	Acute lymphoblastic leukemia (childhood);	chr4:158519224	chr4:158700691~158700909:+
BRCA	cis	rs2199351	0.687	rs111899753	ENSG00000250129.4	RP11-265F19.1	-3.42	0.00064	0.0302	-0.18	-0.11	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr3:131884791	chr3:131053317~131072339:-
BRCA	cis	rs495337	1	rs653423	ENSG00000229222.1	KRT18P4	-3.42	0.00064	0.0302	-0.13	-0.11	Psoriasis;	chr20:49897637	chr20:49956745~49958032:+
BRCA	cis	rs4713118	0.629	rs203889	ENSG00000226314.6	ZNF192P1	-3.42	0.00064	0.0302	-0.16	-0.11	Parkinson's disease;	chr6:28053997	chr6:28161781~28169594:+
BRCA	cis	rs12477602	0.938	rs17271400	ENSG00000272966.1	RP11-686O6.1	3.42	0.00064	0.0302	0.17	0.11	Intelligence (multi-trait analysis);	chr2:202405127	chr2:202336739~202337200:+
BRCA	cis	rs4388249	0.904	rs3776932	ENSG00000249068.1	CTC-287O8.1	3.42	0.00064	0.0302	0.14	0.11	Schizophrenia;	chr5:109850287	chr5:109840128~109840692:-
BRCA	cis	rs17014483	0.749	rs3017897	ENSG00000248019.2	FAM13A-AS1	-3.42	0.00064	0.0302	-0.13	-0.11	Post bronchodilator FEV1/FVC ratio;	chr4:88725555	chr4:88709789~88730103:+
BRCA	cis	rs875971	0.895	rs7788984	ENSG00000230189.5	GS1-124K5.2	3.42	0.00064	0.0302	0.08	0.11	Aortic root size;	chr7:66450629	chr7:66409143~66490059:-
BRCA	cis	rs7712401	0.791	rs4836244	ENSG00000249996.1	RP11-359P5.1	3.42	0.00064	0.0302	0.12	0.11	Mean platelet volume;	chr5:122780537	chr5:123036271~123054667:+
BRCA	cis	rs875971	0.619	rs2302918	ENSG00000275400.1	RP4-756H11.5	-3.42	0.00064	0.0302	-0.12	-0.11	Aortic root size;	chr7:66535945	chr7:66553805~66554199:-
BRCA	cis	rs12505328	0.593	rs4695839	ENSG00000213370.3	RANP6	3.42	0.00064	0.0302	0.14	0.11	Chin dimples;	chr4:173438788	chr4:173633728~173634371:-
BRCA	cis	rs1865760	0.927	rs6915834	ENSG00000272810.1	U91328.22	-3.42	0.00064	0.0302	-0.12	-0.11	Height;	chr6:25935199	chr6:26013241~26013757:+
BRCA	cis	rs11905172	0.554	rs34329220	ENSG00000275576.1	RP5-836N17.4	3.42	0.00064	0.0302	0.18	0.11	Chronic obstructive pulmonary disease;	chr20:32353700	chr20:32116171~32116629:+
BRCA	cis	rs1056107	0.931	rs10481637	ENSG00000266315.1	MIR4668	3.42	0.00064	0.0302	0.11	0.11	Colorectal cancer;	chr9:112334457	chr9:111932100~111932169:+
BRCA	cis	rs7267979	0.932	rs1985737	ENSG00000276952.1	RP5-965G21.6	3.42	0.00064	0.0302	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25610832	chr20:25284915~25285588:-
BRCA	cis	rs1401999	0.898	rs4148564	ENSG00000223882.1	ABCC5-AS1	-3.42	0.00064	0.0302	-0.12	-0.11	Anterior chamber depth;	chr3:184008194	chr3:184006338~184011419:+
BRCA	cis	rs10198628	1	rs7558818	ENSG00000264370.1	MIR3125	3.42	0.00064	0.0302	0.12	0.11	Pericardial fat;Pericardial adipose tissue adjusted for height and weight;	chr2:12829846	chr2:12737367~12737444:+
BRCA	cis	rs11098499	0.739	rs7441137	ENSG00000249244.1	RP11-548H18.2	-3.42	0.00064	0.0302	-0.13	-0.11	Corneal astigmatism;	chr4:119212066	chr4:119391831~119395335:-
BRCA	cis	rs3735485	0.678	rs62457083	ENSG00000201772.1	SNORA5C	3.42	0.00064	0.0302	0.14	0.11	White blood cell count;Sum basophil neutrophil counts;Neutrophil count;Granulocyte percentage of myeloid white cells;Monocyte percentage of white cells;Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Lymphocyte counts;	chr7:45112593	chr7:45104906~45105042:-
BRCA	cis	rs910316	0.935	rs11159119	ENSG00000259138.1	RP11-950C14.7	-3.42	0.000641	0.0302	-0.11	-0.11	Height;	chr14:75170264	chr14:75127153~75136930:+
BRCA	cis	rs12493885	0.505	rs357489	ENSG00000243069.6	ARHGEF26-AS1	3.42	0.000641	0.0302	0.14	0.11	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr3:154166728	chr3:154024401~154121332:-
BRCA	cis	rs4664293	0.528	rs56027129	ENSG00000230783.1	AC009961.2	3.42	0.000641	0.0302	0.13	0.11	Monocyte percentage of white cells;	chr2:159600091	chr2:159689217~159690291:-
BRCA	cis	rs1914816	0.941	rs2460146	ENSG00000259422.1	RP11-593F23.1	3.42	0.000641	0.0302	0.16	0.11	Response to tocilizumab in rheumatoid arthritis;	chr15:76262414	chr15:76174891~76181486:-
BRCA	cis	rs10070219	0.536	rs62380371	ENSG00000248445.4	SEMA6A-AS1	-3.42	0.000641	0.0302	-0.14	-0.11	3-hydroxypropylmercapturic acid levels in smokers;	chr5:117351525	chr5:116447547~116508276:+
BRCA	cis	rs875971	0.798	rs12698522	ENSG00000106610.13	STAG3L4	-3.42	0.000641	0.0302	-0.14	-0.11	Aortic root size;	chr7:66502354	chr7:67302621~67321526:+
BRCA	cis	rs875971	0.83	rs28714531	ENSG00000106610.13	STAG3L4	-3.42	0.000641	0.0302	-0.14	-0.11	Aortic root size;	chr7:66503250	chr7:67302621~67321526:+
BRCA	cis	rs875971	0.862	rs12698526	ENSG00000106610.13	STAG3L4	-3.42	0.000641	0.0302	-0.14	-0.11	Aortic root size;	chr7:66504118	chr7:67302621~67321526:+
BRCA	cis	rs4660456	0.913	rs2780952	ENSG00000272145.1	NFYC-AS1	-3.42	0.000641	0.0302	-0.12	-0.11	Platelet count;	chr1:40689711	chr1:40690380~40692066:-
BRCA	cis	rs1730008	0.865	rs827804	ENSG00000279311.1	RP11-170K4.2	-3.42	0.000641	0.0302	-0.11	-0.11	Lobe attachment (rater-scored or self-reported);	chr3:158202434	chr3:158869898~158871821:+
BRCA	cis	rs6840360	0.55	rs11723438	ENSG00000278978.1	RP11-164P12.5	3.42	0.000641	0.0302	0.13	0.11	Intelligence (multi-trait analysis);	chr4:151610649	chr4:151669786~151670503:+
BRCA	cis	rs45535039	0.506	rs2511856	ENSG00000255239.1	AP002954.6	3.42	0.000641	0.0302	0.13	0.11	Plateletcrit;	chr11:119273438	chr11:118688039~118690600:-
BRCA	cis	rs1878931	0.582	rs9635562	ENSG00000263280.1	LA16c-325D7.2	3.42	0.000641	0.0302	0.11	0.11	Body mass index (adult);	chr16:3366689	chr16:2866348~2867618:-
BRCA	cis	rs12505328	0.593	rs880960	ENSG00000213370.3	RANP6	3.42	0.000641	0.0302	0.14	0.11	Chin dimples;	chr4:173441258	chr4:173633728~173634371:-
BRCA	cis	rs12887734	0.569	rs66953418	ENSG00000269910.1	RP11-73M18.10	3.42	0.000641	0.0303	0.11	0.11	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103805133	chr14:103694516~103695050:-
BRCA	cis	rs17801127	0.901	rs1017151	ENSG00000231969.1	AC144449.1	3.42	0.000641	0.0303	0.18	0.11	Liver enzyme levels (alanine transaminase);	chr2:149684159	chr2:149587196~149848233:+
BRCA	cis	rs946836	0.695	rs10890506	ENSG00000224805.2	LINC00853	-3.42	0.000641	0.0303	-0.12	-0.11	White matter integrity;	chr1:47829361	chr1:47179250~47180339:+
BRCA	cis	rs1941023	0.967	rs10897085	ENSG00000254477.1	AP000640.10	3.42	0.000641	0.0303	0.13	0.11	Congenital heart disease (maternal effect);	chr11:60541484	chr11:59753015~59754975:-
BRCA	cis	rs8114671	0.562	rs6120739	ENSG00000261582.1	RP4-614O4.11	-3.42	0.000641	0.0303	-0.1	-0.11	Height;	chr20:34817424	chr20:35267885~35280043:-
BRCA	cis	rs72775230	0.647	rs72775259	ENSG00000233990.1	RP11-401E9.3	-3.42	0.000641	0.0303	-0.18	-0.11	Conotruncal heart defects (inherited effects);	chr10:8525290	chr10:7833618~7833957:-
BRCA	cis	rs34779708	0.966	rs17591781	ENSG00000269952.1	RP11-324I22.3	-3.42	0.000641	0.0303	-0.14	-0.11	Inflammatory bowel disease;Crohn's disease;	chr10:35209610	chr10:35210416~35210750:+
BRCA	cis	rs7312933	0.612	rs10785334	ENSG00000257225.1	RP11-328C8.4	3.42	0.000642	0.0303	0.14	0.11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42226575	chr12:42459366~42466128:+
BRCA	cis	rs1376303	0.558	rs12533180	ENSG00000205763.12	RP9P	3.42	0.000642	0.0303	0.18	0.11	Intelligence (multi-trait analysis);	chr7:32904520	chr7:32916815~32943176:-
BRCA	cis	rs9949617	0.851	rs67124903	ENSG00000266495.1	RP11-17J14.2	3.42	0.000642	0.0303	0.19	0.11	Hypertriglyceridemia;	chr18:23297331	chr18:23257164~23260354:-
BRCA	cis	rs11098499	0.913	rs35271032	ENSG00000260404.2	RP11-384K6.6	3.42	0.000642	0.0303	0.1	0.11	Corneal astigmatism;	chr4:119235504	chr4:118591773~118633729:+
BRCA	cis	rs9467773	0.596	rs3001369	ENSG00000261353.1	CTA-14H9.5	-3.42	0.000642	0.0303	-0.11	-0.11	Intelligence (multi-trait analysis);	chr6:26670741	chr6:26527063~26527404:+
BRCA	cis	rs875971	0.862	rs6947339	ENSG00000265600.1	AC006480.1	-3.42	0.000642	0.0303	-0.13	-0.11	Aortic root size;	chr7:66423483	chr7:67356680~67356779:+
BRCA	cis	rs1046491	1	rs34322928	ENSG00000264964.1	RP11-888D10.3	3.42	0.000642	0.0303	0.21	0.11	Scarlet fever;	chr18:9259396	chr18:9315194~9334441:-
BRCA	cis	rs2262909	0.925	rs404822	ENSG00000279377.1	AC003973.3	3.42	0.000642	0.0303	0.15	0.11	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;	chr19:22033165	chr19:21965708~21968529:-
BRCA	cis	rs713477	0.654	rs61976568	ENSG00000186615.9	KTN1-AS1	-3.42	0.000642	0.0303	-0.12	-0.11	Pediatric bone mineral content (femoral neck);	chr14:55439500	chr14:55499278~55580110:-
BRCA	cis	rs988913	0.678	rs10434833	ENSG00000261116.1	RP3-523K23.2	-3.42	0.000642	0.0303	-0.13	-0.11	Menarche (age at onset);	chr6:55118585	chr6:54943167~54945099:+
BRCA	cis	rs10501293	1	rs7111028	ENSG00000252652.1	Y_RNA	-3.42	0.000642	0.0303	-0.13	-0.11	Cognitive performance;	chr11:43038966	chr11:43331261~43331356:+
BRCA	cis	rs10501293	1	rs10768913	ENSG00000252652.1	Y_RNA	-3.42	0.000642	0.0303	-0.13	-0.11	Cognitive performance;	chr11:43039200	chr11:43331261~43331356:+
BRCA	cis	rs35306767	0.903	rs12264711	ENSG00000229869.1	RP11-363N22.2	-3.42	0.000642	0.0303	-0.16	-0.11	Eosinophil percentage of granulocytes;	chr10:883585	chr10:933026~942743:+
BRCA	cis	rs2811403	0.792	rs2981037	ENSG00000270773.1	RP13-685P2.7	3.42	0.000642	0.0303	0.12	0.11	Basophil percentage of white cells;	chr3:128439320	chr3:129345411~129346164:+
BRCA	cis	rs2204008	0.505	rs11182550	ENSG00000257718.1	RP11-396F22.1	3.42	0.000642	0.0303	0.11	0.11	Bladder cancer;	chr12:38176259	chr12:38906451~38909592:+
BRCA	cis	rs34779708	0.966	rs17591163	ENSG00000269952.1	RP11-324I22.3	-3.42	0.000642	0.0303	-0.15	-0.11	Inflammatory bowel disease;Crohn's disease;	chr10:35176351	chr10:35210416~35210750:+
BRCA	cis	rs875971	1	rs2420168	ENSG00000271064.1	RP11-792A8.3	3.42	0.000642	0.0303	0.12	0.11	Aortic root size;	chr7:66165644	chr7:66748838~66749077:-
BRCA	cis	rs11239930	0.538	rs3011810	ENSG00000227242.3	NBPF13P	-3.42	0.000642	0.0303	-0.13	-0.11	AIDS progression;	chr1:147082079	chr1:147021320~147124525:-
BRCA	cis	rs10783487	0.749	rs17126283	ENSG00000257542.4	OR7E47P	3.42	0.000642	0.0303	0.13	0.11	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr12:52090859	chr12:52079696~52108261:+
BRCA	cis	rs11686241	0.872	rs16856226	ENSG00000232485.2	AC098820.3	3.42	0.000643	0.0303	0.15	0.11	Cancer;	chr2:216484954	chr2:216479030~216498761:-
BRCA	cis	rs17301013	0.9	rs1754351	ENSG00000200674.1	RN7SKP160	-3.42	0.000643	0.0303	-0.14	-0.11	Systemic lupus erythematosus;	chr1:174762458	chr1:173791548~173791887:+
BRCA	cis	rs13034020	0.522	rs72809436	ENSG00000237522.1	NONOP2	3.42	0.000643	0.0303	0.13	0.11	Hodgkin's lymphoma;	chr2:61024010	chr2:60936819~60938049:-
BRCA	cis	rs2301573	1	rs11707404	ENSG00000271270.4	TMCC1-AS1	-3.42	0.000643	0.0303	-0.21	-0.11	Hip circumference;	chr3:129587361	chr3:129893871~129918575:+
BRCA	cis	rs6088590	0.502	rs6059861	ENSG00000269202.1	RP4-614O4.12	-3.42	0.000643	0.0303	-0.11	-0.11	Coronary artery disease;	chr20:34480758	chr20:35201747~35203288:-
BRCA	cis	rs875971	0.508	rs10242423	ENSG00000271064.1	RP11-792A8.3	3.42	0.000643	0.0303	0.12	0.11	Aortic root size;	chr7:66594188	chr7:66748838~66749077:-
BRCA	cis	rs875971	0.508	rs10253883	ENSG00000271064.1	RP11-792A8.3	3.42	0.000643	0.0303	0.12	0.11	Aortic root size;	chr7:66596151	chr7:66748838~66749077:-
BRCA	cis	rs6840360	0.571	rs4696273	ENSG00000278978.1	RP11-164P12.5	-3.42	0.000643	0.0303	-0.13	-0.11	Intelligence (multi-trait analysis);	chr4:151607325	chr4:151669786~151670503:+
BRCA	cis	rs6840360	0.571	rs4696274	ENSG00000278978.1	RP11-164P12.5	-3.42	0.000643	0.0303	-0.13	-0.11	Intelligence (multi-trait analysis);	chr4:151607326	chr4:151669786~151670503:+
BRCA	cis	rs6840360	0.571	rs4696101	ENSG00000278978.1	RP11-164P12.5	-3.42	0.000643	0.0303	-0.13	-0.11	Intelligence (multi-trait analysis);	chr4:151607361	chr4:151669786~151670503:+
BRCA	cis	rs950881	0.867	rs10197862	ENSG00000234389.1	AC007278.3	3.42	0.000643	0.0303	0.13	0.11	Allergy;	chr2:102350089	chr2:102438713~102440475:+
BRCA	cis	rs4819052	0.851	rs2838865	ENSG00000223768.1	LINC00205	-3.42	0.000643	0.0303	-0.14	-0.11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45292384	chr21:45293285~45297354:+
BRCA	cis	rs7959452	0.527	rs4761157	ENSG00000274979.1	RP11-1143G9.5	-3.42	0.000643	0.0303	-0.11	-0.11	Blood protein levels;	chr12:69387127	chr12:69326574~69331882:-
BRCA	cis	rs7959452	0.59	rs10878974	ENSG00000274979.1	RP11-1143G9.5	-3.42	0.000643	0.0303	-0.11	-0.11	Blood protein levels;	chr12:69387748	chr12:69326574~69331882:-
BRCA	cis	rs875971	0.964	rs60193905	ENSG00000273448.1	RP11-166O4.6	3.42	0.000643	0.0303	0.1	0.11	Aortic root size;	chr7:66506273	chr7:67333047~67334383:+
BRCA	cis	rs2411233	1	rs13380305	ENSG00000259278.1	RP11-62C7.2	3.42	0.000643	0.0303	0.12	0.11	Platelet count;	chr15:38980178	chr15:39019233~39024918:+
BRCA	cis	rs17767294	0.614	rs72850302	ENSG00000272009.1	RP1-313I6.12	-3.42	0.000643	0.0303	-0.28	-0.11	Parkinson's disease;	chr6:28273621	chr6:28078792~28081130:-
BRCA	cis	rs10129255	0.957	rs12590735	ENSG00000253132.1	IGHV3-62	-3.42	0.000643	0.0303	-0.08	-0.11	Kawasaki disease;	chr14:106779660	chr14:106643142~106643585:-
BRCA	cis	rs957448	0.698	rs116348949	ENSG00000254315.1	RP11-267M23.3	3.42	0.000643	0.0303	0.13	0.11	Nonsyndromic cleft lip with cleft palate;	chr8:94557488	chr8:94533628~94534391:+
BRCA	cis	rs7520050	0.966	rs11211241	ENSG00000234329.1	RP11-767N6.2	-3.42	0.000643	0.0303	-0.1	-0.11	Reticulocyte count;Red blood cell count;	chr1:45987011	chr1:45651039~45651826:-
BRCA	cis	rs6545883	0.965	rs3771258	ENSG00000212978.6	AC016747.3	3.42	0.000643	0.0303	0.14	0.11	Tuberculosis;	chr2:61537005	chr2:61141592~61144969:-
BRCA	cis	rs875971	0.862	rs2420174	ENSG00000223473.2	GS1-124K5.3	-3.42	0.000643	0.0303	-0.08	-0.11	Aortic root size;	chr7:66180374	chr7:66491049~66493566:-
BRCA	cis	rs875971	0.862	rs2420173	ENSG00000223473.2	GS1-124K5.3	-3.42	0.000643	0.0303	-0.08	-0.11	Aortic root size;	chr7:66180412	chr7:66491049~66493566:-
BRCA	cis	rs4718428	0.672	rs36038499	ENSG00000275400.1	RP4-756H11.5	-3.42	0.000643	0.0303	-0.13	-0.11	Corneal structure;	chr7:66824628	chr7:66553805~66554199:-
BRCA	cis	rs10760158	0.865	rs2239696	ENSG00000235865.2	GSN-AS1	3.42	0.000643	0.0303	0.09	0.11	Pulse pressure;	chr9:121266877	chr9:121280768~121285530:-
BRCA	cis	rs10457838	0.778	rs6903827	ENSG00000236591.1	RP11-162J8.3	-3.42	0.000643	0.0303	-0.14	-0.11	Post-traumatic stress disorder;	chr6:149082333	chr6:149027700~149032573:-
BRCA	cis	rs2625529	0.73	rs3759900	ENSG00000260037.4	CTD-2524L6.3	3.42	0.000643	0.0304	0.13	0.11	Red blood cell count;	chr15:72159486	chr15:71818396~71823384:+
BRCA	cis	rs317865	0.737	rs73234642	ENSG00000263327.5	TAPT1-AS1	-3.42	0.000644	0.0304	-0.18	-0.11	Kidney disease (early stage) in type 1 diabetes;	chr4:16185107	chr4:16226685~16320140:+
BRCA	cis	rs317865	0.737	rs73234644	ENSG00000263327.5	TAPT1-AS1	-3.42	0.000644	0.0304	-0.18	-0.11	Kidney disease (early stage) in type 1 diabetes;	chr4:16189038	chr4:16226685~16320140:+
BRCA	cis	rs317865	0.737	rs73234648	ENSG00000263327.5	TAPT1-AS1	-3.42	0.000644	0.0304	-0.18	-0.11	Kidney disease (early stage) in type 1 diabetes;	chr4:16191979	chr4:16226685~16320140:+
BRCA	cis	rs8023401	0.938	rs2413907	ENSG00000274654.1	CTD-3247H4.2	3.42	0.000644	0.0304	0.15	0.11	Spherical equivalent (joint analysis main effects and education interaction);	chr15:48520910	chr15:48528980~48529728:-
BRCA	cis	rs4243971	0.516	rs6141295	ENSG00000277692.1	RP11-358N2.2	-3.42	0.000644	0.0304	-0.12	-0.11	Inflammatory bowel disease;Crohn's disease;	chr20:32368199	chr20:32355053~32355734:+
BRCA	cis	rs911119	0.866	rs6048920	ENSG00000270001.1	RP11-218C14.8	-3.42	0.000644	0.0304	-0.14	-0.11	Chronic kidney disease;	chr20:23596207	chr20:23631826~23632316:-
BRCA	cis	rs2154319	0.836	rs6669737	ENSG00000230638.4	RP11-486B10.4	3.42	0.000644	0.0304	0.18	0.11	Height;	chr1:41060218	chr1:41542069~41544310:+
BRCA	cis	rs681524	1	rs681524	ENSG00000254851.1	RP11-109L13.1	-3.42	0.000644	0.0304	-0.28	-0.11	Hearing function;	chr11:116877598	chr11:117135528~117138582:+
BRCA	cis	rs11763147	1	rs11763147	ENSG00000223473.2	GS1-124K5.3	-3.42	0.000644	0.0304	-0.08	-0.11	Corneal structure;	chr7:65861834	chr7:66491049~66493566:-
BRCA	cis	rs2154319	0.887	rs213753	ENSG00000230638.4	RP11-486B10.4	3.42	0.000644	0.0304	0.18	0.11	Height;	chr1:41141659	chr1:41542069~41544310:+
BRCA	cis	rs7339483	0.618	rs4986348	ENSG00000268442.1	CTD-2027I19.2	3.42	0.000644	0.0304	0.2	0.11	Discordance in emotional problems in monozygotic twins;	chr19:24179688	chr19:24162370~24163425:-
BRCA	cis	rs8105895	0.733	rs62111029	ENSG00000269345.1	VN1R85P	3.42	0.000644	0.0304	0.17	0.11	Body mass index (change over time);	chr19:22093799	chr19:22174766~22175191:-
BRCA	cis	rs8105895	0.935	rs959908	ENSG00000269345.1	VN1R85P	3.42	0.000644	0.0304	0.17	0.11	Body mass index (change over time);	chr19:22099091	chr19:22174766~22175191:-
BRCA	cis	rs8105895	0.935	rs62111034	ENSG00000269345.1	VN1R85P	3.42	0.000644	0.0304	0.17	0.11	Body mass index (change over time);	chr19:22101918	chr19:22174766~22175191:-
BRCA	cis	rs4281086	0.599	rs11250025	ENSG00000280294.1	RP11-177H2.1	3.42	0.000644	0.0304	0.13	0.11	Obesity-related traits;	chr8:10536523	chr8:10856085~10859436:-
BRCA	cis	rs1165668	0.785	rs2439624	ENSG00000257681.1	RP11-341G23.4	-3.42	0.000644	0.0304	-0.13	-0.11	Coronary heart disease (SNP X SNP interaction);	chr12:103919937	chr12:103746315~103768858:-
BRCA	cis	rs7487075	0.897	rs10880960	ENSG00000257261.4	RP11-96H19.1	3.42	0.000644	0.0304	0.12	0.11	Itch intensity from mosquito bite;	chr12:46368046	chr12:46383679~46876159:+
BRCA	cis	rs943466	1	rs12524768	ENSG00000223837.2	BRD2-IT1	3.42	0.000644	0.0304	0.13	0.11	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;	chr6:33792701	chr6:32970232~32970886:+
BRCA	cis	rs943466	1	rs7755323	ENSG00000223837.2	BRD2-IT1	3.42	0.000644	0.0304	0.13	0.11	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;	chr6:33793382	chr6:32970232~32970886:+
BRCA	cis	rs3820068	0.603	rs7537618	ENSG00000237301.1	RP4-680D5.2	-3.42	0.000644	0.0304	-0.14	-0.11	Systolic blood pressure;	chr1:15651187	chr1:15586136~15603626:-
BRCA	cis	rs3820068	0.603	rs7529759	ENSG00000237301.1	RP4-680D5.2	-3.42	0.000644	0.0304	-0.14	-0.11	Systolic blood pressure;	chr1:15651382	chr1:15586136~15603626:-
BRCA	cis	rs3770752	0.897	rs7570547	ENSG00000272054.1	RP11-423P10.2	-3.42	0.000644	0.0304	-0.09	-0.11	Schizophrenia;	chr2:37323647	chr2:37208875~37212677:+
BRCA	cis	rs7142881	0.815	rs2165814	ENSG00000258648.1	UBE2CP1	-3.42	0.000644	0.0304	-0.12	-0.11	Response to iloperidone treatment (QT prolongation);	chr14:31624038	chr14:30683045~30683598:-
BRCA	cis	rs875971	1	rs3735148	ENSG00000271064.1	RP11-792A8.3	-3.42	0.000644	0.0304	-0.12	-0.11	Aortic root size;	chr7:66506022	chr7:66748838~66749077:-
BRCA	cis	rs7246657	0.722	rs16958863	ENSG00000267470.4	ZNF571-AS1	3.42	0.000644	0.0304	0.14	0.11	Coronary artery calcification;	chr19:37633334	chr19:37548914~37587348:+
BRCA	cis	rs13315871	0.929	rs11706920	ENSG00000272182.1	RP11-802O23.3	3.42	0.000644	0.0304	0.21	0.11	Cholesterol, total;	chr3:58293945	chr3:58428255~58428815:+
BRCA	cis	rs801193	1	rs10234018	ENSG00000229180.5	GS1-124K5.11	-3.42	0.000644	0.0304	-0.09	-0.11	Aortic root size;	chr7:66681297	chr7:66526088~66542624:-
BRCA	cis	rs7487075	0.859	rs7961994	ENSG00000257261.4	RP11-96H19.1	3.42	0.000644	0.0304	0.12	0.11	Itch intensity from mosquito bite;	chr12:46361329	chr12:46383679~46876159:+
BRCA	cis	rs801193	1	rs2659906	ENSG00000275400.1	RP4-756H11.5	-3.42	0.000645	0.0304	-0.12	-0.11	Aortic root size;	chr7:66700323	chr7:66553805~66554199:-
BRCA	cis	rs4664293	0.631	rs13019272	ENSG00000230783.1	AC009961.2	-3.42	0.000645	0.0304	-0.13	-0.11	Monocyte percentage of white cells;	chr2:159802352	chr2:159689217~159690291:-
BRCA	cis	rs8114671	0.562	rs6087644	ENSG00000261582.1	RP4-614O4.11	-3.42	0.000645	0.0304	-0.11	-0.11	Height;	chr20:34893114	chr20:35267885~35280043:-
BRCA	cis	rs1046491	0.901	rs12454936	ENSG00000264964.1	RP11-888D10.3	3.42	0.000645	0.0304	0.22	0.11	Scarlet fever;	chr18:9134440	chr18:9315194~9334441:-
BRCA	cis	rs7917772	0.503	rs2031602	ENSG00000213061.2	PFN1P11	-3.42	0.000645	0.0304	-0.14	-0.11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;	chr10:102548198	chr10:102838011~102845473:-
BRCA	cis	rs6593122	0.628	rs10230947	ENSG00000235454.1	HAUS6P3	3.42	0.000645	0.0304	0.14	0.11	Vaccine-related adverse events;	chr7:54117592	chr7:53862233~53863339:+
BRCA	cis	rs910873	1	rs56020497	ENSG00000250917.1	RP4-785G19.5	-3.42	0.000645	0.0304	-0.3	-0.11	Melanoma;	chr20:34578666	chr20:34234840~34281173:-
BRCA	cis	rs16958440	0.708	rs62096465	ENSG00000267800.1	RP11-49K24.5	-3.42	0.000645	0.0304	-0.19	-0.11	Sitting height ratio;	chr18:47103253	chr18:47137018~47137290:+
BRCA	cis	rs16958440	0.708	rs1434528	ENSG00000267800.1	RP11-49K24.5	-3.42	0.000645	0.0304	-0.19	-0.11	Sitting height ratio;	chr18:47105952	chr18:47137018~47137290:+
BRCA	cis	rs7560272	0.695	rs780393	ENSG00000230002.2	ALMS1-IT1	-3.42	0.000645	0.0304	-0.12	-0.11	Schizophrenia;	chr2:73474542	chr2:73456764~73459484:+
BRCA	cis	rs2411233	1	rs2411232	ENSG00000259278.1	RP11-62C7.2	3.42	0.000645	0.0304	0.12	0.11	Platelet count;	chr15:38982550	chr15:39019233~39024918:+
BRCA	cis	rs2411233	1	rs2411233	ENSG00000259278.1	RP11-62C7.2	3.42	0.000645	0.0304	0.12	0.11	Platelet count;	chr15:38982551	chr15:39019233~39024918:+
BRCA	cis	rs4865762	0.514	rs254618	ENSG00000247796.2	CTD-2366F13.1	3.42	0.000645	0.0304	0.12	0.11	Intraocular pressure;	chr5:53150665	chr5:53109842~53115126:+
BRCA	cis	rs7070797	0.518	rs2244860	ENSG00000237233.2	TMEM26-AS1	3.42	0.000645	0.0304	0.14	0.11	Takotsubo syndrome;	chr10:61761329	chr10:61452639~61481956:+
BRCA	cis	rs9341808	0.718	rs2179842	ENSG00000279022.1	RP11-250B2.4	3.42	0.000645	0.0304	0.12	0.11	Sitting height ratio;	chr6:80269336	chr6:80440730~80441172:+
BRCA	cis	rs61869271	0.688	rs11196995	ENSG00000236799.1	RP11-383C6.2	-3.42	0.000645	0.0304	-0.12	-0.11	Tonsillectomy;	chr10:114931968	chr10:114994657~114996593:+
BRCA	cis	rs7520050	0.966	rs12049588	ENSG00000234329.1	RP11-767N6.2	-3.42	0.000645	0.0304	-0.1	-0.11	Reticulocyte count;Red blood cell count;	chr1:46006750	chr1:45651039~45651826:-
BRCA	cis	rs7520050	0.966	rs12021587	ENSG00000234329.1	RP11-767N6.2	-3.42	0.000645	0.0304	-0.1	-0.11	Reticulocyte count;Red blood cell count;	chr1:46007087	chr1:45651039~45651826:-
BRCA	cis	rs8062405	0.755	rs62034358	ENSG00000261766.1	RP11-22P6.2	-3.42	0.000645	0.0304	-0.11	-0.11	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576276	chr16:28862166~28863340:-
BRCA	cis	rs8062405	0.755	rs12445823	ENSG00000261766.1	RP11-22P6.2	-3.42	0.000645	0.0304	-0.11	-0.11	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576728	chr16:28862166~28863340:-
BRCA	cis	rs8062405	0.723	rs12445744	ENSG00000261766.1	RP11-22P6.2	-3.42	0.000645	0.0304	-0.11	-0.11	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28577074	chr16:28862166~28863340:-
BRCA	cis	rs8062405	0.755	rs4787455	ENSG00000261766.1	RP11-22P6.2	-3.42	0.000645	0.0304	-0.11	-0.11	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28578134	chr16:28862166~28863340:-
BRCA	cis	rs2414095	0.527	rs11633715	ENSG00000259378.1	DCAF13P3	3.42	0.000646	0.0304	0.14	0.11	Follicule stimulating hormone;Total body bone mineral density;Hormone measurements;	chr15:51247646	chr15:50944663~50945996:+
BRCA	cis	rs875971	1	rs3981131	ENSG00000229886.1	RP5-1132H15.3	3.42	0.000646	0.0304	0.11	0.11	Aortic root size;	chr7:66486690	chr7:66025126~66031544:-
BRCA	cis	rs6088590	0.561	rs6087605	ENSG00000269202.1	RP4-614O4.12	-3.42	0.000646	0.0304	-0.11	-0.11	Coronary artery disease;	chr20:34592820	chr20:35201747~35203288:-
BRCA	cis	rs687432	0.887	rs11601202	ENSG00000265566.2	RN7SL605P	-3.42	0.000646	0.0304	-0.15	-0.11	Parkinson's disease;	chr11:58005688	chr11:57528085~57528365:-
BRCA	cis	rs1208	0.777	rs7826755	ENSG00000253671.1	RP11-806O11.1	-3.42	0.000646	0.0304	-0.12	-0.11	Insulin resistance/response;	chr8:18412557	chr8:17808941~17820868:+
BRCA	cis	rs853679	0.546	rs200990	ENSG00000241549.7	GUSBP2	3.42	0.000646	0.0304	0.19	0.11	Depression;	chr6:27848045	chr6:26871484~26956554:-
BRCA	cis	rs561341	0.882	rs2428337	ENSG00000265798.5	RP11-271K11.5	3.42	0.000646	0.0305	0.18	0.11	Hip circumference adjusted for BMI;	chr17:31972448	chr17:31038575~31059121:-
BRCA	cis	rs8113308	0.752	rs8113758	ENSG00000269235.1	ZNF350-AS1	3.42	0.000646	0.0305	0.18	0.11	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51990054	chr19:51949134~51981367:+
BRCA	cis	rs875971	0.862	rs1875057	ENSG00000223473.2	GS1-124K5.3	-3.42	0.000646	0.0305	-0.08	-0.11	Aortic root size;	chr7:66266868	chr7:66491049~66493566:-
BRCA	cis	rs875971	0.862	rs6960446	ENSG00000223473.2	GS1-124K5.3	-3.42	0.000646	0.0305	-0.08	-0.11	Aortic root size;	chr7:66268272	chr7:66491049~66493566:-
BRCA	cis	rs875971	0.789	rs10260426	ENSG00000223473.2	GS1-124K5.3	-3.42	0.000646	0.0305	-0.08	-0.11	Aortic root size;	chr7:66271055	chr7:66491049~66493566:-
BRCA	cis	rs2411233	1	rs2411230	ENSG00000259278.1	RP11-62C7.2	3.42	0.000646	0.0305	0.12	0.11	Platelet count;	chr15:38982408	chr15:39019233~39024918:+
BRCA	cis	rs10986311	0.637	rs10760361	ENSG00000214593.3	RP11-65N13.6	3.42	0.000646	0.0305	0.12	0.11	Vitiligo;	chr9:124415987	chr9:125263845~125264090:-
BRCA	cis	rs7267979	1	rs7268053	ENSG00000231081.1	RP4-760C5.3	3.42	0.000646	0.0305	0.14	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25347650	chr20:26008791~26010531:-
BRCA	cis	rs7267979	1	rs6083809	ENSG00000231081.1	RP4-760C5.3	3.42	0.000646	0.0305	0.14	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25348673	chr20:26008791~26010531:-
BRCA	cis	rs2562456	0.837	rs62110205	ENSG00000213976.4	CTD-2561J22.2	-3.42	0.000646	0.0305	-0.13	-0.11	Pain;	chr19:21577269	chr19:21382865~21387177:+
BRCA	cis	rs9875589	0.509	rs7636901	ENSG00000228242.5	AC093495.4	3.42	0.000646	0.0305	0.08	0.11	Ovarian reserve;	chr3:13989458	chr3:14144637~14165978:+
BRCA	cis	rs1865760	0.892	rs2328903	ENSG00000272810.1	U91328.22	-3.42	0.000646	0.0305	-0.12	-0.11	Height;	chr6:25935537	chr6:26013241~26013757:+
BRCA	cis	rs1865760	0.892	rs6456705	ENSG00000272810.1	U91328.22	-3.42	0.000646	0.0305	-0.12	-0.11	Height;	chr6:25935828	chr6:26013241~26013757:+
BRCA	cis	rs7833790	0.654	rs6415652	ENSG00000254689.1	RP11-354A14.1	3.42	0.000646	0.0305	0.13	0.11	Diastolic blood pressure;	chr8:81790022	chr8:81885377~81923193:+
BRCA	cis	rs7833790	0.632	rs6415653	ENSG00000254689.1	RP11-354A14.1	3.42	0.000646	0.0305	0.13	0.11	Diastolic blood pressure;	chr8:81790301	chr8:81885377~81923193:+
BRCA	cis	rs2948294	0.588	rs4840913	ENSG00000233609.3	RP11-62H7.2	3.42	0.000646	0.0305	0.11	0.11	Red cell distribution width;	chr8:8259384	chr8:8961200~8979025:+
BRCA	cis	rs1008375	0.966	rs10939758	ENSG00000249502.1	AC006160.5	-3.42	0.000646	0.0305	-0.12	-0.11	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17696632	chr4:17587467~17614571:-
BRCA	cis	rs73201462	1	rs73192978	ENSG00000242551.2	POU5F1P6	3.42	0.000646	0.0305	0.18	0.11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128149432	chr3:128674735~128677005:-
BRCA	cis	rs73201462	1	rs73192979	ENSG00000242551.2	POU5F1P6	3.42	0.000646	0.0305	0.18	0.11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128149478	chr3:128674735~128677005:-
BRCA	cis	rs12368653	0.651	rs2277326	ENSG00000257159.1	RP11-58A17.3	3.42	0.000646	0.0305	0.13	0.11	Multiple sclerosis;	chr12:57808636	chr12:57967058~57968399:+
BRCA	cis	rs6728642	1	rs17037402	ENSG00000279791.1	RP11-499E14.1	-3.42	0.000646	0.0305	-0.22	-0.11	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:97358816	chr2:97094935~97097433:+
BRCA	cis	rs2904524	1	rs78509050	ENSG00000257613.1	LINC01481	-3.42	0.000646	0.0305	-0.18	-0.11	Amyotrophic lateral sclerosis (age of onset);	chr12:70359589	chr12:70219132~70221862:-
BRCA	cis	rs2904524	1	rs75899653	ENSG00000257613.1	LINC01481	-3.42	0.000646	0.0305	-0.18	-0.11	Amyotrophic lateral sclerosis (age of onset);	chr12:70359894	chr12:70219132~70221862:-
BRCA	cis	rs7487075	0.859	rs7960147	ENSG00000257261.4	RP11-96H19.1	3.42	0.000646	0.0305	0.12	0.11	Itch intensity from mosquito bite;	chr12:46357671	chr12:46383679~46876159:+
BRCA	cis	rs9325144	0.56	rs1825802	ENSG00000257718.1	RP11-396F22.1	-3.42	0.000646	0.0305	-0.1	-0.11	Morning vs. evening chronotype;	chr12:38256539	chr12:38906451~38909592:+
BRCA	cis	rs9325144	0.56	rs7971313	ENSG00000257718.1	RP11-396F22.1	-3.42	0.000646	0.0305	-0.1	-0.11	Morning vs. evening chronotype;	chr12:38259611	chr12:38906451~38909592:+
BRCA	cis	rs2288884	0.559	rs11084130	ENSG00000269235.1	ZNF350-AS1	3.42	0.000646	0.0305	0.14	0.11	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52009443	chr19:51949134~51981367:+
BRCA	cis	rs7680126	0.633	rs887732	ENSG00000250413.1	RP11-448G15.1	3.42	0.000647	0.0305	0.18	0.11	Urate levels in obese individuals;Urate levels in lean individuals;Urate levels in overweight individuals;	chr4:10181493	chr4:10006482~10009725:+
BRCA	cis	rs6490294	0.904	rs11066098	ENSG00000257624.1	RP1-128M12.3	3.42	0.000647	0.0305	0.14	0.11	Mean platelet volume;	chr12:111950324	chr12:112000739~112000985:-
BRCA	cis	rs4664293	0.546	rs12469866	ENSG00000224152.1	AC009506.1	3.42	0.000647	0.0305	0.12	0.11	Monocyte percentage of white cells;	chr2:159766119	chr2:159615296~159617082:+
BRCA	cis	rs10266483	0.883	rs683689	ENSG00000227986.1	TRIM60P18	-3.42	0.000647	0.0305	-0.11	-0.11	Response to statin therapy;	chr7:64282165	chr7:64355078~64356199:+
BRCA	cis	rs72615157	0.613	rs56089143	ENSG00000214313.7	AZGP1P1	-3.42	0.000647	0.0305	-0.12	-0.11	Lung function (FEV1/FVC);	chr7:100222221	chr7:99980762~99987535:+
BRCA	cis	rs12549902	0.8	rs7825337	ENSG00000254165.1	RP11-503E24.2	3.42	0.000647	0.0305	0.11	0.11	Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Corrected insulin response;Type 2 diabetes;	chr8:41649718	chr8:42537529~42538304:-
BRCA	cis	rs3749237	1	rs11717256	ENSG00000225399.4	RP11-3B7.1	3.42	0.000647	0.0305	0.1	0.11	Resting heart rate;	chr3:49831087	chr3:49260085~49261316:+
BRCA	cis	rs709400	0.628	rs1989565	ENSG00000258851.1	RP11-894P9.2	3.42	0.000647	0.0305	0.12	0.11	Body mass index;	chr14:103395856	chr14:103553421~103561877:+
BRCA	cis	rs12723316	0.867	rs2143757	ENSG00000233008.4	RP11-475O6.1	-3.42	0.000647	0.0305	-0.2	-0.11	Schizophrenia;	chr1:83801108	chr1:83575776~83861023:-
BRCA	cis	rs72720396	0.789	rs10922910	ENSG00000272931.1	RP5-943J3.2	-3.42	0.000647	0.0305	-0.14	-0.11	Chronotype;Morning vs. evening chronotype;	chr1:90734305	chr1:89820174~89820868:-
BRCA	cis	rs11175492	1	rs118069463	ENSG00000243024.5	RPS11P6	-3.42	0.000647	0.0305	-0.25	-0.11	Platelet count;	chr12:64672119	chr12:64222337~64397065:+
BRCA	cis	rs11175492	1	rs77906229	ENSG00000243024.5	RPS11P6	-3.42	0.000647	0.0305	-0.25	-0.11	Platelet count;	chr12:64672764	chr12:64222337~64397065:+
BRCA	cis	rs4648045	0.861	rs230539	ENSG00000246560.2	RP11-10L12.4	-3.42	0.000647	0.0305	-0.12	-0.11	Lymphocyte percentage of white cells;	chr4:102574375	chr4:102828055~102844075:+
BRCA	cis	rs7520050	1	rs785511	ENSG00000234329.1	RP11-767N6.2	-3.42	0.000647	0.0305	-0.1	-0.11	Reticulocyte count;Red blood cell count;	chr1:46068826	chr1:45651039~45651826:-
BRCA	cis	rs7520050	0.966	rs809775	ENSG00000234329.1	RP11-767N6.2	-3.42	0.000647	0.0305	-0.1	-0.11	Reticulocyte count;Red blood cell count;	chr1:46072368	chr1:45651039~45651826:-
BRCA	cis	rs7112925	0.608	rs5006008	ENSG00000255038.1	RP11-1167A19.2	3.42	0.000647	0.0305	0.14	0.11	Height;	chr11:67063089	chr11:66067277~66069619:-
BRCA	cis	rs17767294	0.708	rs72848792	ENSG00000219392.1	RP1-265C24.5	-3.42	0.000647	0.0305	-0.29	-0.11	Parkinson's disease;	chr6:28029878	chr6:28115628~28116551:+
BRCA	cis	rs9468199	0.505	rs72848793	ENSG00000219392.1	RP1-265C24.5	-3.42	0.000647	0.0305	-0.29	-0.11	Parkinson's disease;	chr6:28031800	chr6:28115628~28116551:+
BRCA	cis	rs56046484	0.871	rs12900736	ENSG00000259630.2	CTD-2262B20.1	-3.42	0.000647	0.0305	-0.18	-0.11	Testicular germ cell tumor;	chr15:85014909	chr15:85415228~85415633:+
BRCA	cis	rs56046484	0.871	rs12904958	ENSG00000259630.2	CTD-2262B20.1	-3.42	0.000647	0.0305	-0.18	-0.11	Testicular germ cell tumor;	chr15:85014956	chr15:85415228~85415633:+
BRCA	cis	rs56046484	0.871	rs34493704	ENSG00000259630.2	CTD-2262B20.1	-3.42	0.000647	0.0305	-0.18	-0.11	Testicular germ cell tumor;	chr15:85015539	chr15:85415228~85415633:+
BRCA	cis	rs7426380	0.524	rs6545526	ENSG00000272606.1	RP11-554J4.1	3.42	0.000647	0.0305	0.12	0.11	Intraocular pressure;	chr2:55828301	chr2:55617909~55618373:+
BRCA	cis	rs6500602	0.701	rs4785971	ENSG00000280063.1	RP11-295D4.3	3.42	0.000647	0.0305	0.08	0.11	Schizophrenia;	chr16:4527089	chr16:4346694~4348648:-
BRCA	cis	rs12468226	0.873	rs2350358	ENSG00000272966.1	RP11-686O6.1	-3.42	0.000647	0.0305	-0.17	-0.11	Urate levels;	chr2:202199771	chr2:202336739~202337200:+
BRCA	cis	rs7267979	1	rs6050565	ENSG00000231081.1	RP4-760C5.3	3.42	0.000647	0.0305	0.13	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25366927	chr20:26008791~26010531:-
BRCA	cis	rs860295	0.702	rs12041534	ENSG00000203761.5	MSTO2P	3.42	0.000647	0.0305	0.09	0.11	Body mass index;	chr1:155437305	chr1:155745829~155750137:+
BRCA	cis	rs4927850	1	rs7614767	ENSG00000273009.1	RP11-352G9.1	-3.42	0.000647	0.0305	-0.12	-0.11	Pancreatic cancer;	chr3:196026580	chr3:195913078~195913683:-
BRCA	cis	rs1376877	0.934	rs62183874	ENSG00000273456.1	RP11-686O6.2	3.42	0.000647	0.0305	0.1	0.11	Subclinical atherosclerosis traits (other);	chr2:203241441	chr2:202374932~202375604:-
BRCA	cis	rs7258465	0.931	rs7249020	ENSG00000273654.1	CTB-52I2.4	-3.42	0.000647	0.0305	-0.13	-0.11	Breast cancer;	chr19:18497337	chr19:18022403~18032099:+
BRCA	cis	rs2562456	0.876	rs11085465	ENSG00000240522.1	RPL7AP10	3.42	0.000647	0.0305	0.12	0.11	Pain;	chr19:21568988	chr19:21149648~21150438:-
BRCA	cis	rs9329221	0.662	rs13254942	ENSG00000154316.13	TDH	3.42	0.000648	0.0305	0.14	0.11	Neuroticism;	chr8:10400168	chr8:11339637~11368452:+
BRCA	cis	rs875971	0.505	rs1723275	ENSG00000227113.2	RP11-460N20.4	-3.42	0.000648	0.0305	-0.11	-0.11	Aortic root size;	chr7:66039646	chr7:65075023~65078780:+
BRCA	cis	rs4499344	0.589	rs259233	ENSG00000267475.1	CTD-2538C1.2	3.42	0.000648	0.0305	0.15	0.11	Mean platelet volume;	chr19:32636094	chr19:32687089~32691750:-
BRCA	cis	rs4499344	0.556	rs259231	ENSG00000267475.1	CTD-2538C1.2	3.42	0.000648	0.0305	0.15	0.11	Mean platelet volume;	chr19:32638161	chr19:32687089~32691750:-
BRCA	cis	rs1670533	0.872	rs11727135	ENSG00000251639.2	RP11-20I20.1	3.42	0.000648	0.0305	0.16	0.11	Recombination rate (females);	chr4:1058015	chr4:1100016~1101558:-
BRCA	cis	rs1670533	0.872	rs11727136	ENSG00000251639.2	RP11-20I20.1	3.42	0.000648	0.0305	0.16	0.11	Recombination rate (females);	chr4:1058016	chr4:1100016~1101558:-
BRCA	cis	rs11673344	0.77	rs7257135	ENSG00000267682.1	CTD-3220F14.2	-3.42	0.000648	0.0305	-0.1	-0.11	Obesity-related traits;	chr19:37088726	chr19:37337236~37337743:+
BRCA	cis	rs11790994	1	rs11790994	ENSG00000175611.10	LINC00476	3.42	0.000648	0.0305	0.17	0.11	Inattentive symptoms;	chr9:95666984	chr9:95759231~95875977:-
BRCA	cis	rs11673344	0.734	rs2551047	ENSG00000267422.1	CTD-2554C21.1	3.42	0.000648	0.0305	0.14	0.11	Obesity-related traits;	chr19:36935174	chr19:37779686~37792865:+
BRCA	cis	rs11673344	0.704	rs551717	ENSG00000267422.1	CTD-2554C21.1	3.42	0.000648	0.0305	0.14	0.11	Obesity-related traits;	chr19:36936977	chr19:37779686~37792865:+
BRCA	cis	rs11673344	0.704	rs826290	ENSG00000267422.1	CTD-2554C21.1	3.42	0.000648	0.0305	0.14	0.11	Obesity-related traits;	chr19:36937543	chr19:37779686~37792865:+
BRCA	cis	rs11673344	0.67	rs505717	ENSG00000267422.1	CTD-2554C21.1	3.42	0.000648	0.0305	0.14	0.11	Obesity-related traits;	chr19:36939414	chr19:37779686~37792865:+
BRCA	cis	rs11673344	0.704	rs544543	ENSG00000267422.1	CTD-2554C21.1	3.42	0.000648	0.0305	0.14	0.11	Obesity-related traits;	chr19:36939921	chr19:37779686~37792865:+
BRCA	cis	rs11673344	0.67	rs568654	ENSG00000267422.1	CTD-2554C21.1	3.42	0.000648	0.0305	0.14	0.11	Obesity-related traits;	chr19:36940285	chr19:37779686~37792865:+
BRCA	cis	rs7267979	0.833	rs6138556	ENSG00000274414.1	RP5-965G21.4	-3.42	0.000648	0.0305	-0.13	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25262674	chr20:25239007~25245229:-
BRCA	cis	rs11031096	0.738	rs1980412	ENSG00000224513.2	AC109309.4	-3.42	0.000648	0.0305	-0.13	-0.11	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr11:4127718	chr11:3226061~3232838:+
BRCA	cis	rs860295	0.702	rs10908465	ENSG00000236675.1	MTX1P1	-3.42	0.000648	0.0305	-0.13	-0.11	Body mass index;	chr1:155419897	chr1:155230975~155234325:+
BRCA	cis	rs7620503	1	rs4555562	ENSG00000228561.2	RP11-114M1.1	3.42	0.000648	0.0305	0.12	0.11	Corneal structure;	chr3:177580775	chr3:177683627~177691250:+
BRCA	cis	rs7620503	1	rs4257602	ENSG00000228561.2	RP11-114M1.1	3.42	0.000648	0.0305	0.12	0.11	Corneal structure;	chr3:177580907	chr3:177683627~177691250:+
BRCA	cis	rs7620503	1	rs4290846	ENSG00000228561.2	RP11-114M1.1	3.42	0.000648	0.0305	0.12	0.11	Corneal structure;	chr3:177581146	chr3:177683627~177691250:+
BRCA	cis	rs4648045	0.894	rs230500	ENSG00000246560.2	RP11-10L12.4	3.42	0.000648	0.0305	0.12	0.11	Lymphocyte percentage of white cells;	chr4:102570567	chr4:102828055~102844075:+
BRCA	cis	rs13315871	1	rs11717423	ENSG00000272182.1	RP11-802O23.3	3.42	0.000648	0.0305	0.21	0.11	Cholesterol, total;	chr3:58344450	chr3:58428255~58428815:+
BRCA	cis	rs1865760	0.566	rs1539183	ENSG00000272462.2	U91328.19	-3.42	0.000648	0.0305	-0.12	-0.11	Height;	chr6:26074823	chr6:25992662~26001775:+
BRCA	cis	rs1823874	0.677	rs2100447	ENSG00000259363.4	CTD-2054N24.2	3.42	0.000648	0.0305	0.13	0.11	IgG glycosylation;	chr15:99820188	chr15:99807023~99877148:+
BRCA	cis	rs6809441	0.591	rs2291758	ENSG00000231873.1	RP11-761N21.1	3.42	0.000648	0.0305	0.12	0.11	Alcohol dependence;	chr3:41463375	chr3:40766207~40862626:+
BRCA	cis	rs12644436	0.526	rs9998083	ENSG00000249001.4	RP11-742B18.1	-3.42	0.000648	0.0305	-0.13	-0.11	HIV-1 viral setpoint;	chr4:87850239	chr4:87568035~87733956:-
BRCA	cis	rs7649443	0.959	rs3915512	ENSG00000243339.3	RN7SL738P	-3.42	0.000648	0.0305	-0.15	-0.11	Nonsyndromic cleft lip with cleft palate;	chr3:197295369	chr3:196399911~196400207:+
BRCA	cis	rs317865	0.737	rs73234629	ENSG00000263327.5	TAPT1-AS1	-3.42	0.000648	0.0305	-0.18	-0.11	Kidney disease (early stage) in type 1 diabetes;	chr4:16168153	chr4:16226685~16320140:+
BRCA	cis	rs561341	1	rs497479	ENSG00000277511.1	CTD-2095E4.5	3.42	0.000648	0.0305	0.16	0.11	Hip circumference adjusted for BMI;	chr17:32001586	chr17:32127595~32128454:+
BRCA	cis	rs907500	0.666	rs522894	ENSG00000232630.1	PRPS1P2	-3.42	0.000648	0.0305	-0.14	-0.11	Itch intensity from mosquito bite adjusted by bite size;	chr9:125537326	chr9:125150653~125151589:+
BRCA	cis	rs4415084	1	rs12515012	ENSG00000272335.1	RP11-53O19.3	3.42	0.000648	0.0305	0.1	0.11	Breast cancer;	chr5:44694433	chr5:44826076~44828592:+
BRCA	cis	rs7954584	0.531	rs1154514	ENSG00000212694.7	LINC01089	-3.42	0.000648	0.0305	-0.08	-0.11	Mean corpuscular volume;	chr12:121936982	chr12:121795267~121803906:-
BRCA	cis	rs7267979	1	rs7343481	ENSG00000204556.4	CTD-2514C3.1	3.42	0.000648	0.0305	0.14	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25319477	chr20:26018832~26020684:+
BRCA	cis	rs2153535	0.764	rs12190361	ENSG00000251164.1	HULC	3.42	0.000648	0.0305	0.13	0.11	Motion sickness;	chr6:8377079	chr6:8652137~8653846:+
BRCA	cis	rs11250097	0.549	rs11778177	ENSG00000255020.1	AF131216.5	3.42	0.000649	0.0305	0.13	0.11	Neuroticism;	chr8:11452853	chr8:11345748~11347502:-
BRCA	cis	rs8030605	0.778	rs72740579	ENSG00000277245.1	RP11-48G14.3	3.42	0.000649	0.0305	0.23	0.11	Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;	chr15:56347840	chr15:56447120~56447697:+
BRCA	cis	rs17711722	0.701	rs781145	ENSG00000232546.1	RP11-458F8.1	-3.42	0.000649	0.0306	-0.09	-0.11	Calcium levels;	chr7:65975383	chr7:66848496~66858136:+
BRCA	cis	rs748404	0.666	rs7180812	ENSG00000166763.7	STRCP1	3.42	0.000649	0.0306	0.15	0.11	Lung cancer;	chr15:43403033	chr15:43699488~43718184:-
BRCA	cis	rs2333021	0.78	rs12887074	ENSG00000259015.1	RP11-109N23.6	3.42	0.000649	0.0306	0.11	0.11	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:72981132	chr14:72960595~72961993:+
BRCA	cis	rs11671005	0.693	rs34230465	ENSG00000265272.2	RN7SL693P	3.42	0.000649	0.0306	0.15	0.11	Mean platelet volume;	chr19:58432209	chr19:58490797~58491075:+
BRCA	cis	rs6088590	0.523	rs6058084	ENSG00000269202.1	RP4-614O4.12	-3.42	0.000649	0.0306	-0.11	-0.11	Coronary artery disease;	chr20:34596000	chr20:35201747~35203288:-
BRCA	cis	rs3198697	0.663	rs12928099	ENSG00000260735.1	RP11-72I8.1	-3.42	0.000649	0.0306	-0.14	-0.11	Triglycerides;	chr16:15056648	chr16:15094411~15109197:+
BRCA	cis	rs2348418	0.715	rs1355471	ENSG00000244712.1	RP11-874G11.1	-3.42	0.000649	0.0306	-0.13	-0.11	Lung function (FEV1);Lung function (FVC);	chr12:28568792	chr12:28564678~28565141:-
BRCA	cis	rs867529	0.695	rs335115	ENSG00000253497.1	IGKV1-13	3.42	0.000649	0.0306	0.1	0.11	Height;	chr2:88728129	chr2:89045995~89046466:-
BRCA	cis	rs6452790	0.543	rs7700867	ENSG00000247828.6	TMEM161B-AS1	-3.42	0.000649	0.0306	-0.15	-0.11	Cognitive function;	chr5:88043876	chr5:88268895~88436685:+
BRCA	cis	rs2688608	0.592	rs7923045	ENSG00000242288.9	RP11-464F9.1	3.42	0.000649	0.0306	0.13	0.11	Inflammatory bowel disease;	chr10:73727740	chr10:73674295~73730466:-
BRCA	cis	rs1468333	0.724	rs7726580	ENSG00000206989.1	SNORD63	-3.42	0.000649	0.0306	-0.11	-0.11	Resting heart rate;	chr5:138272977	chr5:138561043~138561110:-
BRCA	cis	rs28595532	1	rs41455648	ENSG00000248213.3	CICP16	-3.42	0.000649	0.0306	-0.21	-0.11	Cannabis dependence symptom count;	chr4:118796875	chr4:118635970~118638782:-
BRCA	cis	rs2692947	0.566	rs11676901	ENSG00000168992.4	OR7E102P	3.42	0.000649	0.0306	0.15	0.11	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95704823	chr2:95546531~95547545:+
BRCA	cis	rs45544231	0.544	rs1123428	ENSG00000279427.1	RP11-132F7.2	3.42	0.000649	0.0306	0.12	0.11	Restless legs syndrome;	chr16:52543923	chr16:52436772~52437474:-
BRCA	cis	rs801193	0.548	rs2659904	ENSG00000271064.1	RP11-792A8.3	-3.42	0.000649	0.0306	-0.12	-0.11	Aortic root size;	chr7:66713615	chr7:66748838~66749077:-
BRCA	cis	rs1998359	0.651	rs177852	ENSG00000259087.4	RP11-356O9.2	3.42	0.000649	0.0306	0.11	0.11	Self-reported allergy;	chr14:37642665	chr14:37556158~37567095:-
BRCA	cis	rs12310956	0.532	rs1906134	ENSG00000258794.3	DUX4L27	3.42	0.000649	0.0306	0.15	0.11	Morning vs. evening chronotype;	chr12:33804200	chr12:34208415~34209675:-
BRCA	cis	rs12310956	0.515	rs1830086	ENSG00000258794.3	DUX4L27	3.42	0.000649	0.0306	0.15	0.11	Morning vs. evening chronotype;	chr12:33805939	chr12:34208415~34209675:-
BRCA	cis	rs12310956	0.532	rs1525904	ENSG00000258794.3	DUX4L27	3.42	0.000649	0.0306	0.15	0.11	Morning vs. evening chronotype;	chr12:33809513	chr12:34208415~34209675:-
BRCA	cis	rs12310956	0.532	rs10506119	ENSG00000258794.3	DUX4L27	3.42	0.000649	0.0306	0.15	0.11	Morning vs. evening chronotype;	chr12:33810749	chr12:34208415~34209675:-
BRCA	cis	rs12310956	0.532	rs11052930	ENSG00000258794.3	DUX4L27	3.42	0.000649	0.0306	0.15	0.11	Morning vs. evening chronotype;	chr12:33811889	chr12:34208415~34209675:-
BRCA	cis	rs13126694	0.744	rs28477319	ENSG00000251073.1	NUDT19P5	3.42	0.000649	0.0306	0.1	0.11	Blood osmolality (transformed sodium);	chr4:158095785	chr4:158182825~158183393:+
BRCA	cis	rs6831352	0.589	rs1133483	ENSG00000246090.5	RP11-696N14.1	3.42	0.00065	0.0306	0.1	0.11	Alcohol dependence;	chr4:99102772	chr4:99088857~99301356:+
BRCA	cis	rs687432	0.774	rs1155858	ENSG00000213592.4	AP000662.9	-3.42	0.00065	0.0306	-0.15	-0.11	Parkinson's disease;	chr11:58122474	chr11:57718044~57718530:-
BRCA	cis	rs1670533	1	rs10026482	ENSG00000251639.2	RP11-20I20.1	3.42	0.00065	0.0306	0.17	0.11	Recombination rate (females);	chr4:1057340	chr4:1100016~1101558:-
BRCA	cis	rs8023401	0.938	rs16960997	ENSG00000274654.1	CTD-3247H4.2	3.42	0.00065	0.0306	0.14	0.11	Spherical equivalent (joint analysis main effects and education interaction);	chr15:48482130	chr15:48528980~48529728:-
BRCA	cis	rs3743102	0.591	rs17841171	ENSG00000259429.4	UBE2Q2P2	-3.42	0.00065	0.0306	-0.15	-0.11	Colorectal adenoma (advanced);	chr15:82689636	chr15:82355142~82420075:+
BRCA	cis	rs13098911	0.54	rs4388012	ENSG00000223552.1	RP11-24F11.2	-3.42	0.00065	0.0306	-0.18	-0.11	Celiac disease;	chr3:45955009	chr3:46364955~46407059:-
BRCA	cis	rs7131987	0.801	rs6487804	ENSG00000275476.1	RP11-996F15.4	-3.42	0.00065	0.0306	-0.12	-0.11	QT interval;	chr12:29302001	chr12:29277397~29277882:-
BRCA	cis	rs10129255	0.913	rs28861466	ENSG00000253132.1	IGHV3-62	-3.42	0.00065	0.0306	-0.09	-0.11	Kawasaki disease;	chr14:106718572	chr14:106643142~106643585:-
BRCA	cis	rs903552	0.8	rs6598479	ENSG00000270127.2	RP11-526I2.5	-3.42	0.00065	0.0306	-0.17	-0.11	Diabetic kidney disease;	chr15:101465708	chr15:100547765~100550153:-
BRCA	cis	rs7190551	0.51	rs4985077	ENSG00000260979.1	RP11-77H9.8	-3.42	0.00065	0.0306	-0.14	-0.11	Platelet distribution width;	chr16:8998088	chr16:8962706~8966990:+
BRCA	cis	rs9467773	1	rs6925703	ENSG00000261353.1	CTA-14H9.5	-3.42	0.00065	0.0306	-0.11	-0.11	Intelligence (multi-trait analysis);	chr6:26521361	chr6:26527063~26527404:+
BRCA	cis	rs2999052	0.542	rs729847	ENSG00000250796.1	RP11-723O4.3	3.42	0.00065	0.0306	0.14	0.11	Hypospadias;	chr3:128391927	chr3:128869624~128870026:+
BRCA	cis	rs7649443	0.876	rs62282106	ENSG00000243339.3	RN7SL738P	-3.42	0.00065	0.0306	-0.15	-0.11	Nonsyndromic cleft lip with cleft palate;	chr3:197270277	chr3:196399911~196400207:+
BRCA	cis	rs35306767	0.903	rs35968821	ENSG00000229869.1	RP11-363N22.2	-3.42	0.00065	0.0306	-0.16	-0.11	Eosinophil percentage of granulocytes;	chr10:864285	chr10:933026~942743:+
BRCA	cis	rs3805389	0.504	rs17781708	ENSG00000273257.1	RP11-177J6.1	3.42	0.00065	0.0306	0.17	0.11	Waist-to-hip ratio adjusted for body mass index;	chr4:55614902	chr4:55387949~55388271:+
BRCA	cis	rs7412746	0.658	rs2230061	ENSG00000224800.1	RP11-235D19.2	-3.42	0.00065	0.0306	-0.13	-0.11	Melanoma;	chr1:150755063	chr1:150881236~150881683:-
BRCA	cis	rs12477602	0.938	rs74182351	ENSG00000272966.1	RP11-686O6.1	3.42	0.00065	0.0306	0.17	0.11	Intelligence (multi-trait analysis);	chr2:202407298	chr2:202336739~202337200:+
BRCA	cis	rs801193	0.591	rs721717	ENSG00000271064.1	RP11-792A8.3	3.42	0.00065	0.0306	0.13	0.11	Aortic root size;	chr7:66665305	chr7:66748838~66749077:-
BRCA	cis	rs2018683	0.707	rs1021689	ENSG00000228421.2	AC005013.5	3.42	0.00065	0.0306	0.13	0.11	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28934606	chr7:28957667~28959345:+
BRCA	cis	rs656900	0.715	rs1870576	ENSG00000261229.4	MTHFS	-3.42	0.00065	0.0306	-0.1	-0.11	Cerebrospinal P-tau181p levels;	chr15:79814786	chr15:79843547~79897285:-
BRCA	cis	rs6012564	0.893	rs6012555	ENSG00000230758.1	SNAP23P	-3.42	0.00065	0.0306	-0.13	-0.11	Anger;	chr20:48911205	chr20:49038357~49038602:-
BRCA	cis	rs11098499	0.863	rs17050695	ENSG00000225892.3	RP11-384K6.2	3.42	0.00065	0.0306	0.1	0.11	Corneal astigmatism;	chr4:119568372	chr4:118632274~118634759:+
BRCA	cis	rs9287719	0.967	rs7570118	ENSG00000224177.5	LINC00570	3.42	0.00065	0.0306	0.12	0.11	Prostate cancer;	chr2:10577881	chr2:11393981~11403077:+
BRCA	cis	rs7560272	0.723	rs2421548	ENSG00000230002.2	ALMS1-IT1	-3.42	0.00065	0.0306	-0.12	-0.11	Schizophrenia;	chr2:73414112	chr2:73456764~73459484:+
BRCA	cis	rs7560272	0.723	rs12995433	ENSG00000230002.2	ALMS1-IT1	-3.42	0.00065	0.0306	-0.12	-0.11	Schizophrenia;	chr2:73414198	chr2:73456764~73459484:+
BRCA	cis	rs9437689	1	rs9437689	ENSG00000235501.4	RP4-639F20.1	3.42	0.00065	0.0306	0.13	0.11	Phospholipid levels (plasma);	chr1:95083980	chr1:94927566~94963270:+
BRCA	cis	rs9437689	1	rs9437813	ENSG00000235501.4	RP4-639F20.1	3.42	0.00065	0.0306	0.13	0.11	Phospholipid levels (plasma);	chr1:95084357	chr1:94927566~94963270:+
BRCA	cis	rs9437689	1	rs4949965	ENSG00000235501.4	RP4-639F20.1	3.42	0.00065	0.0306	0.13	0.11	Phospholipid levels (plasma);	chr1:95085681	chr1:94927566~94963270:+
BRCA	cis	rs11082321	0.867	rs45464097	ENSG00000266850.1	RP11-370A5.1	-3.42	0.00065	0.0306	-0.2	-0.11	Breast cancer;	chr18:23189085	chr18:22723491~22907721:-
BRCA	cis	rs7264396	0.563	rs6060592	ENSG00000088340.14	FER1L4	-3.42	0.00065	0.0306	-0.15	-0.11	Total cholesterol levels;	chr20:35764492	chr20:35558737~35607562:-
BRCA	cis	rs35740288	0.539	rs34362339	ENSG00000259407.1	RP11-158M2.3	-3.42	0.00065	0.0306	-0.14	-0.11	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85794397	chr15:85744109~85750281:-
BRCA	cis	rs73201462	1	rs2687723	ENSG00000242551.2	POU5F1P6	3.42	0.00065	0.0306	0.18	0.11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128146716	chr3:128674735~128677005:-
BRCA	cis	rs2422052	0.729	rs967252	ENSG00000236255.1	AC009404.2	-3.42	0.000651	0.0306	-0.11	-0.11	Mosquito bite size;	chr2:117885916	chr2:117833937~117841658:+
BRCA	cis	rs7824557	0.724	rs2572398	ENSG00000248896.2	CTD-2135J3.3	3.42	0.000651	0.0306	0.13	0.11	Retinal vascular caliber;	chr8:11320584	chr8:10729314~10771392:+
BRCA	cis	rs7637230	0.945	rs7612823	ENSG00000244119.1	PDCL3P4	-3.42	0.000651	0.0306	-0.11	-0.11	Psoriasis vulgaris;Psoriasis;	chr3:101895079	chr3:101712472~101713191:+
BRCA	cis	rs12411860	0.927	rs56174375	ENSG00000226200.5	SGMS1-AS1	-3.42	0.000651	0.0306	-0.1	-0.11	Blood protein levels;	chr10:50274361	chr10:50624951~50641451:+
BRCA	cis	rs6012564	1	rs6125539	ENSG00000230758.1	SNAP23P	3.42	0.000651	0.0306	0.13	0.11	Anger;	chr20:49087273	chr20:49038357~49038602:-
BRCA	cis	rs3845817	0.51	rs6717426	ENSG00000237979.1	AC007389.1	-3.42	0.000651	0.0306	-0.12	-0.11	Bipolar disorder;	chr2:65554277	chr2:65500993~65502138:-
BRCA	cis	rs4345206	0.677	rs13124853	ENSG00000251687.1	RP11-181K12.2	-3.42	0.000651	0.0306	-0.12	-0.11	Coronary artery disease;	chr4:145863622	chr4:145833118~145839580:+
BRCA	cis	rs9341808	0.718	rs3805920	ENSG00000279022.1	RP11-250B2.4	3.42	0.000651	0.0306	0.12	0.11	Sitting height ratio;	chr6:80183028	chr6:80440730~80441172:+
BRCA	cis	rs13136331	0.68	rs2732169	ENSG00000249001.4	RP11-742B18.1	3.42	0.000651	0.0306	0.14	0.11	Sitting height ratio;	chr4:87735281	chr4:87568035~87733956:-
BRCA	cis	rs72928364	0.86	rs34281790	ENSG00000244119.1	PDCL3P4	3.42	0.000651	0.0306	0.14	0.11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:101071923	chr3:101712472~101713191:+
BRCA	cis	rs9847710	0.967	rs2564938	ENSG00000242849.2	ALDOAP1	3.42	0.000651	0.0306	0.12	0.11	Ulcerative colitis;	chr3:52992368	chr3:52193170~52194785:+
BRCA	cis	rs4950322	0.512	rs2883318	ENSG00000237188.3	RP11-337C18.8	3.42	0.000651	0.0306	0.11	0.11	Protein quantitative trait loci;	chr1:147377422	chr1:147172771~147211568:+
BRCA	cis	rs4622329	0.572	rs7956803	ENSG00000257202.1	RP11-512N21.3	3.42	0.000651	0.0306	0.12	0.11	Systemic lupus erythematosus;	chr12:101900084	chr12:101923410~101924719:-
BRCA	cis	rs8121203	1	rs73897240	ENSG00000213950.2	RPS10P2	-3.42	0.000651	0.0306	-0.24	-0.11	Peripheral arterial disease (traffic-related air pollution interaction);	chr20:15058098	chr20:14757563~14758056:+
BRCA	cis	rs642743	0.576	rs1545111	ENSG00000266852.2	MIR4482	3.42	0.000651	0.0306	0.14	0.11	Left ventricular obstructive tract defect (maternal effect);	chr10:104209298	chr10:104268336~104268405:-
BRCA	cis	rs12220238	0.822	rs73286281	ENSG00000213731.2	RAB5CP1	-3.42	0.000651	0.0306	-0.16	-0.11	Soluble interleukin-2 receptor subunit alpha;	chr10:74323579	chr10:74423435~74424014:-
BRCA	cis	rs1005277	0.505	rs200936	ENSG00000273019.1	RP11-508N22.13	-3.42	0.000651	0.0306	-0.12	-0.11	Extrinsic epigenetic age acceleration;	chr10:37846007	chr10:38149968~38150293:+
BRCA	cis	rs1005277	0.505	rs200937	ENSG00000273019.1	RP11-508N22.13	-3.42	0.000651	0.0306	-0.12	-0.11	Extrinsic epigenetic age acceleration;	chr10:37846844	chr10:38149968~38150293:+
BRCA	cis	rs2243480	1	rs316322	ENSG00000229180.5	GS1-124K5.11	3.42	0.000651	0.0307	0.14	0.11	Diabetic kidney disease;	chr7:66146246	chr7:66526088~66542624:-
BRCA	cis	rs9437689	0.591	rs7518326	ENSG00000235501.4	RP4-639F20.1	-3.42	0.000651	0.0307	-0.13	-0.11	Phospholipid levels (plasma);	chr1:94957735	chr1:94927566~94963270:+
BRCA	cis	rs13104971	0.505	rs11726290	ENSG00000248494.1	LNX1-AS2	3.42	0.000651	0.0307	0.15	0.11	Lifetime average cigarettes per day in chronic obstructive pulmonary disease;	chr4:52954915	chr4:53592956~53604047:+
BRCA	cis	rs3864261	0.515	rs55769858	ENSG00000272525.1	RP11-79P5.9	3.42	0.000651	0.0307	0.11	0.11	Discordance in emotional problems in monozygotic twins;	chr5:72984937	chr5:73497550~73498293:-
BRCA	cis	rs2403083	0.522	rs2403087	ENSG00000258256.1	RP11-219B4.5	-3.42	0.000651	0.0307	-0.14	-0.11	Plasma amyloid beta peptide concentrations (ABx-40);	chr8:85124266	chr8:85222446~85245717:-
BRCA	cis	rs6460942	0.915	rs62447639	ENSG00000226690.5	AC005281.1	3.42	0.000651	0.0307	0.21	0.11	Coronary artery disease;	chr7:12447177	chr7:12496429~12541910:+
BRCA	cis	rs6088580	0.634	rs6058073	ENSG00000269202.1	RP4-614O4.12	-3.42	0.000651	0.0307	-0.11	-0.11	Glomerular filtration rate (creatinine);	chr20:34528678	chr20:35201747~35203288:-
BRCA	cis	rs909674	0.541	rs5757655	ENSG00000280216.1	RP3-333H23.9	3.42	0.000651	0.0307	0.13	0.11	IgG fucosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG digalactosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG glycosylation;	chr22:39401173	chr22:39379610~39380015:+
BRCA	cis	rs10191559	0.552	rs11889566	ENSG00000234663.4	AC104820.2	3.42	0.000651	0.0307	0.09	0.11	Red blood cell count;	chr2:181228474	chr2:181101932~181399559:+
BRCA	cis	rs1075265	0.87	rs7569214	ENSG00000272156.1	RP11-477N3.1	-3.42	0.000651	0.0307	-0.11	-0.11	Chronotype;Morning vs. evening chronotype;	chr2:53989049	chr2:54082554~54085066:+
BRCA	cis	rs9437689	0.966	rs11165299	ENSG00000235501.4	RP4-639F20.1	3.42	0.000652	0.0307	0.13	0.11	Phospholipid levels (plasma);	chr1:95079300	chr1:94927566~94963270:+
BRCA	cis	rs863345	0.565	rs7551497	ENSG00000229914.1	RP11-404O13.4	-3.42	0.000652	0.0307	-0.11	-0.11	Pneumococcal bacteremia;	chr1:158475135	chr1:158195633~158196131:-
BRCA	cis	rs4660214	0.666	rs625384	ENSG00000182109.6	RP11-69E11.4	3.42	0.000652	0.0307	0.12	0.11	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39427421	chr1:39522280~39546187:-
BRCA	cis	rs911119	0.913	rs6048924	ENSG00000270001.1	RP11-218C14.8	-3.42	0.000652	0.0307	-0.13	-0.11	Chronic kidney disease;	chr20:23598359	chr20:23631826~23632316:-
BRCA	cis	rs12893668	0.572	rs2273175	ENSG00000258914.1	CTD-2134A5.3	3.42	0.000652	0.0307	0.14	0.11	Reticulocyte count;	chr14:103693804	chr14:103875055~103877478:+
BRCA	cis	rs7252981	0.632	rs8113682	ENSG00000267419.1	CTC-559E9.6	3.42	0.000652	0.0307	0.12	0.11	Perceived unattractiveness to mosquitoes;	chr19:19632921	chr19:19776602~19834927:+
BRCA	cis	rs1400816	0.85	rs6433313	ENSG00000228389.1	AC068039.4	3.42	0.000652	0.0307	0.19	0.11	Amyotrophic lateral sclerosis (sporadic);	chr2:171801186	chr2:171773482~171775844:+
BRCA	cis	rs1008375	0.932	rs13109475	ENSG00000249502.1	AC006160.5	3.42	0.000652	0.0307	0.12	0.11	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17675942	chr4:17587467~17614571:-
BRCA	cis	rs12496230	0.794	rs34113192	ENSG00000272610.1	MAGI1-IT1	-3.42	0.000652	0.0307	-0.13	-0.11	Type 2 diabetes;	chr3:66813244	chr3:65872815~65954558:-
BRCA	cis	rs13401620	0.626	rs12471141	ENSG00000236878.1	AC012363.7	3.42	0.000652	0.0307	0.13	0.11	Breast size;	chr2:120066173	chr2:120211054~120211715:+
BRCA	cis	rs13315871	0.929	rs79813245	ENSG00000272182.1	RP11-802O23.3	3.42	0.000652	0.0307	0.21	0.11	Cholesterol, total;	chr3:58332748	chr3:58428255~58428815:+
BRCA	cis	rs76206723	1	rs17171696	ENSG00000233225.3	AC004987.9	3.42	0.000652	0.0307	0.19	0.11	Pulse pressure;	chr7:40359594	chr7:39833571~39834718:+
BRCA	cis	rs34779708	0.931	rs11596502	ENSG00000269952.1	RP11-324I22.3	-3.42	0.000652	0.0307	-0.14	-0.11	Inflammatory bowel disease;Crohn's disease;	chr10:35098259	chr10:35210416~35210750:+
BRCA	cis	rs613391	0.561	rs590268	ENSG00000265194.1	RP11-70L8.4	-3.42	0.000652	0.0307	-0.11	-0.11	Quantitative traits;	chr9:22720861	chr9:21858910~21861926:-
BRCA	cis	rs4415084	0.716	rs6868232	ENSG00000272335.1	RP11-53O19.3	3.42	0.000652	0.0307	0.1	0.11	Breast cancer;	chr5:44827578	chr5:44826076~44828592:+
BRCA	cis	rs944990	0.538	rs10821166	ENSG00000227603.1	RP11-165J3.6	3.42	0.000652	0.0307	0.11	0.11	Body mass index;	chr9:93589641	chr9:93435332~93437121:-
BRCA	cis	rs863345	0.604	rs6666609	ENSG00000229914.1	RP11-404O13.4	-3.42	0.000652	0.0307	-0.11	-0.11	Pneumococcal bacteremia;	chr1:158528334	chr1:158195633~158196131:-
BRCA	cis	rs40067	1	rs288232	ENSG00000272523.1	LINC01023	3.42	0.000652	0.0307	0.12	0.11	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr5:108083847	chr5:108727825~108728260:-
BRCA	cis	rs9341808	0.6	rs668329	ENSG00000233967.5	RP11-250B2.3	-3.42	0.000652	0.0307	-0.11	-0.11	Sitting height ratio;	chr6:80258861	chr6:80443344~80465927:+
BRCA	cis	rs886774	0.866	rs12668766	ENSG00000273055.1	CTB-13F3.1	-3.42	0.000652	0.0307	-0.11	-0.11	Ulcerative colitis;	chr7:107876264	chr7:107942116~107942740:+
BRCA	cis	rs9527	0.615	rs11191485	ENSG00000236937.2	PTGES3P4	3.42	0.000652	0.0307	0.14	0.11	Arsenic metabolism;	chr10:102970059	chr10:102845595~102845950:+
BRCA	cis	rs6840360	0.615	rs2406973	ENSG00000278978.1	RP11-164P12.5	3.42	0.000652	0.0307	0.12	0.11	Intelligence (multi-trait analysis);	chr4:151687187	chr4:151669786~151670503:+
BRCA	cis	rs10923574	0.521	rs6699115	ENSG00000231365.4	RP11-418J17.1	-3.42	0.000653	0.0307	-0.13	-0.11	Breast cancer;Folding of antihelix;	chr1:118522959	chr1:119140396~119275973:+
BRCA	cis	rs930395	0.514	rs10041518	ENSG00000248779.1	RP11-53O19.2	-3.42	0.000653	0.0307	-0.1	-0.11	Breast cancer;	chr5:44927304	chr5:44752949~44765744:+
BRCA	cis	rs17684571	0.872	rs34429594	ENSG00000231441.1	RP11-472M19.2	3.42	0.000653	0.0307	0.16	0.11	Schizophrenia;	chr6:56714954	chr6:56844002~56864078:+
BRCA	cis	rs860295	0.702	rs10796946	ENSG00000236675.1	MTX1P1	-3.42	0.000653	0.0307	-0.13	-0.11	Body mass index;	chr1:155459699	chr1:155230975~155234325:+
BRCA	cis	rs860295	0.676	rs10908466	ENSG00000236675.1	MTX1P1	-3.42	0.000653	0.0307	-0.13	-0.11	Body mass index;	chr1:155459934	chr1:155230975~155234325:+
BRCA	cis	rs4819052	0.851	rs13047104	ENSG00000223768.1	LINC00205	-3.42	0.000653	0.0307	-0.14	-0.11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45253647	chr21:45293285~45297354:+
BRCA	cis	rs890448	0.796	rs6845368	ENSG00000254531.1	FLJ20021	-3.42	0.000653	0.0307	-0.12	-0.11	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101364742	chr4:101347780~101348883:+
BRCA	cis	rs17711722	0.727	rs2658585	ENSG00000232546.1	RP11-458F8.1	-3.42	0.000653	0.0307	-0.09	-0.11	Calcium levels;	chr7:65996954	chr7:66848496~66858136:+
BRCA	cis	rs58521262	0.585	rs2927367	ENSG00000267920.1	SNX6P1	-3.42	0.000653	0.0307	-0.14	-0.11	Testicular germ cell tumor;	chr19:23047317	chr19:23126569~23127792:-
BRCA	cis	rs7246760	0.867	rs7259075	ENSG00000267106.4	ZNF561-AS1	3.42	0.000653	0.0307	0.2	0.11	Pursuit maintenance gain;	chr19:9668100	chr19:9621291~9645896:+
BRCA	cis	rs7246760	0.867	rs35416342	ENSG00000267106.4	ZNF561-AS1	3.42	0.000653	0.0307	0.2	0.11	Pursuit maintenance gain;	chr19:9668382	chr19:9621291~9645896:+
BRCA	cis	rs7246760	0.867	rs12461215	ENSG00000267106.4	ZNF561-AS1	3.42	0.000653	0.0307	0.2	0.11	Pursuit maintenance gain;	chr19:9671785	chr19:9621291~9645896:+
BRCA	cis	rs7246760	0.867	rs1115825	ENSG00000267106.4	ZNF561-AS1	3.42	0.000653	0.0307	0.2	0.11	Pursuit maintenance gain;	chr19:9675445	chr19:9621291~9645896:+
BRCA	cis	rs7246760	0.867	rs59616842	ENSG00000267106.4	ZNF561-AS1	3.42	0.000653	0.0307	0.2	0.11	Pursuit maintenance gain;	chr19:9681569	chr19:9621291~9645896:+
BRCA	cis	rs7246760	0.867	rs66464474	ENSG00000267106.4	ZNF561-AS1	3.42	0.000653	0.0307	0.2	0.11	Pursuit maintenance gain;	chr19:9684473	chr19:9621291~9645896:+
BRCA	cis	rs7246760	0.737	rs60584926	ENSG00000267106.4	ZNF561-AS1	3.42	0.000653	0.0307	0.2	0.11	Pursuit maintenance gain;	chr19:9686338	chr19:9621291~9645896:+
BRCA	cis	rs7959452	0.562	rs10878975	ENSG00000274979.1	RP11-1143G9.5	-3.42	0.000653	0.0307	-0.11	-0.11	Blood protein levels;	chr12:69388264	chr12:69326574~69331882:-
BRCA	cis	rs7959452	0.557	rs899224	ENSG00000274979.1	RP11-1143G9.5	-3.42	0.000653	0.0307	-0.11	-0.11	Blood protein levels;	chr12:69390994	chr12:69326574~69331882:-
BRCA	cis	rs6517329	0.61	rs11088339	ENSG00000231106.2	LINC01436	3.42	0.000653	0.0307	0.12	0.11	Schizophrenia;	chr21:36126696	chr21:36005338~36007838:+
BRCA	cis	rs61931739	0.5	rs11053274	ENSG00000258794.3	DUX4L27	3.42	0.000653	0.0307	0.15	0.11	Morning vs. evening chronotype;	chr12:34394670	chr12:34208415~34209675:-
BRCA	cis	rs6120849	0.901	rs11696967	ENSG00000202150.1	RNU6-407P	3.42	0.000653	0.0307	0.14	0.11	Protein C levels;	chr20:35155806	chr20:35030317~35030420:-
BRCA	cis	rs7674212	0.531	rs4699048	ENSG00000248740.4	RP11-328K4.1	3.42	0.000653	0.0307	0.12	0.11	Type 2 diabetes;	chr4:103005570	chr4:103256159~103453658:+
BRCA	cis	rs2041840	1	rs2160393	ENSG00000272054.1	RP11-423P10.2	-3.42	0.000653	0.0307	-0.1	-0.11	Chronic lymphocytic leukemia;	chr2:37289807	chr2:37208875~37212677:+
BRCA	cis	rs660899	0.894	rs2270972	ENSG00000229431.1	RP1-92O14.6	-3.42	0.000653	0.0307	-0.11	-0.11	Hypertension risk in short sleep duration;	chr1:43692458	chr1:43385113~43389155:+
BRCA	cis	rs8114671	0.869	rs66535333	ENSG00000261582.1	RP4-614O4.11	3.42	0.000653	0.0307	0.1	0.11	Height;	chr20:35068863	chr20:35267885~35280043:-
BRCA	cis	rs8114671	0.869	rs1544047	ENSG00000261582.1	RP4-614O4.11	3.42	0.000653	0.0307	0.1	0.11	Height;	chr20:35082950	chr20:35267885~35280043:-
BRCA	cis	rs8114671	0.836	rs17404569	ENSG00000261582.1	RP4-614O4.11	3.42	0.000653	0.0307	0.1	0.11	Height;	chr20:35086274	chr20:35267885~35280043:-
BRCA	cis	rs78587638	0.843	rs77925536	ENSG00000226856.4	AC093901.1	-3.42	0.000653	0.0307	-0.19	-0.11	Mosquito bite size;	chr2:118407485	chr2:118132128~118186386:-
BRCA	cis	rs6494488	0.5	rs72744739	ENSG00000259635.1	AC100830.3	-3.42	0.000653	0.0307	-0.24	-0.11	Coronary artery disease;	chr15:64757727	chr15:64701248~64719602:+
BRCA	cis	rs6494488	0.5	rs72744741	ENSG00000259635.1	AC100830.3	-3.42	0.000653	0.0307	-0.24	-0.11	Coronary artery disease;	chr15:64758315	chr15:64701248~64719602:+
BRCA	cis	rs6088580	0.634	rs6059860	ENSG00000269202.1	RP4-614O4.12	-3.42	0.000653	0.0307	-0.11	-0.11	Glomerular filtration rate (creatinine);	chr20:34476025	chr20:35201747~35203288:-
BRCA	cis	rs7520050	0.966	rs12564541	ENSG00000281133.1	AL355480.3	3.42	0.000653	0.0307	0.12	0.11	Reticulocyte count;Red blood cell count;	chr1:45914565	chr1:45580892~45580996:-
BRCA	cis	rs7914558	0.505	rs12260436	ENSG00000213061.2	PFN1P11	3.42	0.000653	0.0307	0.15	0.11	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102981357	chr10:102838011~102845473:-
BRCA	cis	rs1437396	0.609	rs2589102	ENSG00000203327.2	AC012358.7	3.42	0.000654	0.0307	0.11	0.11	Alcohol dependence;	chr2:55357587	chr2:55214387~55216126:-
BRCA	cis	rs13118159	0.55	rs4974612	ENSG00000211482.1	AC092574.1	3.42	0.000654	0.0307	0.14	0.11	Longevity;	chr4:1370755	chr4:409809~409915:+
BRCA	cis	rs673253	0.662	rs61769611	ENSG00000229431.1	RP1-92O14.6	-3.42	0.000654	0.0307	-0.11	-0.11	Intelligence (multi-trait analysis);	chr1:43563242	chr1:43385113~43389155:+
BRCA	cis	rs9951698	0.703	rs10221326	ENSG00000266969.1	RP11-773H22.4	3.42	0.000654	0.0307	0.14	0.11	Intelligence (multi-trait analysis);	chr18:13036035	chr18:12984694~12991173:-
BRCA	cis	rs2625529	0.73	rs6494990	ENSG00000261187.1	RP11-1007O24.2	3.42	0.000654	0.0307	0.11	0.11	Red blood cell count;	chr15:72108733	chr15:72465128~72466262:-
BRCA	cis	rs12612435	0.91	rs12612433	ENSG00000226806.1	AC011893.3	-3.42	0.000654	0.0307	-0.13	-0.11	Takotsubo syndrome;	chr2:136347967	chr2:135820191~135823087:+
BRCA	cis	rs2832191	0.716	rs2249028	ENSG00000236056.1	GAPDHP14	-3.42	0.000654	0.0308	-0.12	-0.11	Dental caries;	chr21:28993001	chr21:29222321~29223257:+
BRCA	cis	rs7267979	0.744	rs6050464	ENSG00000274414.1	RP5-965G21.4	-3.42	0.000654	0.0308	-0.12	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25228663	chr20:25239007~25245229:-
BRCA	cis	rs875971	0.798	rs57739047	ENSG00000223473.2	GS1-124K5.3	3.42	0.000654	0.0308	0.08	0.11	Aortic root size;	chr7:66507579	chr7:66491049~66493566:-
BRCA	cis	rs516805	0.528	rs2816088	ENSG00000279453.1	RP3-425C14.4	-3.42	0.000654	0.0308	-0.14	-0.11	Lymphocyte counts;	chr6:122081706	chr6:122436789~122439223:-
BRCA	cis	rs1979679	0.553	rs10459089	ENSG00000278733.1	RP11-425D17.1	3.42	0.000654	0.0308	0.13	0.11	Ossification of the posterior longitudinal ligament of the spine;	chr12:28115957	chr12:28185625~28186190:-
BRCA	cis	rs853679	0.517	rs4711164	ENSG00000226314.6	ZNF192P1	-3.42	0.000654	0.0308	-0.16	-0.11	Depression;	chr6:28147378	chr6:28161781~28169594:+
BRCA	cis	rs853679	0.517	rs4711165	ENSG00000226314.6	ZNF192P1	-3.42	0.000654	0.0308	-0.16	-0.11	Depression;	chr6:28147406	chr6:28161781~28169594:+
BRCA	cis	rs853679	0.517	rs4713148	ENSG00000226314.6	ZNF192P1	-3.42	0.000654	0.0308	-0.16	-0.11	Depression;	chr6:28148143	chr6:28161781~28169594:+
BRCA	cis	rs853679	0.517	rs9348794	ENSG00000226314.6	ZNF192P1	-3.42	0.000654	0.0308	-0.16	-0.11	Depression;	chr6:28149979	chr6:28161781~28169594:+
BRCA	cis	rs853679	0.517	rs9295758	ENSG00000226314.6	ZNF192P1	-3.42	0.000654	0.0308	-0.16	-0.11	Depression;	chr6:28152885	chr6:28161781~28169594:+
BRCA	cis	rs853679	0.517	rs17774663	ENSG00000226314.6	ZNF192P1	-3.42	0.000654	0.0308	-0.16	-0.11	Depression;	chr6:28153120	chr6:28161781~28169594:+
BRCA	cis	rs7914558	0.902	rs3736922	ENSG00000272912.1	RP11-724N1.1	3.42	0.000654	0.0308	0.12	0.11	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103090875	chr10:102914585~102915404:+
BRCA	cis	rs7824557	0.606	rs2736273	ENSG00000255020.1	AF131216.5	-3.42	0.000654	0.0308	-0.12	-0.11	Retinal vascular caliber;	chr8:11342429	chr8:11345748~11347502:-
BRCA	cis	rs2262909	1	rs436039	ENSG00000279377.1	AC003973.3	3.42	0.000654	0.0308	0.15	0.11	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;	chr19:22032071	chr19:21965708~21968529:-
BRCA	cis	rs1005277	0.505	rs7069702	ENSG00000273019.1	RP11-508N22.13	3.42	0.000654	0.0308	0.12	0.11	Extrinsic epigenetic age acceleration;	chr10:37958431	chr10:38149968~38150293:+
BRCA	cis	rs7267979	0.586	rs6050429	ENSG00000274414.1	RP5-965G21.4	-3.42	0.000654	0.0308	-0.12	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25202422	chr20:25239007~25245229:-
BRCA	cis	rs2911132	0.564	rs1057569	ENSG00000272109.1	CTD-2260A17.3	-3.42	0.000654	0.0308	-0.15	-0.11	Urate levels (BMI interaction);	chr5:96773906	chr5:96804353~96806105:+
BRCA	cis	rs10844706	0.699	rs11052751	ENSG00000278635.1	CTD-2318O12.1	-3.42	0.000654	0.0308	-0.11	-0.11	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9735136	chr12:9415641~9416718:+
BRCA	cis	rs11902236	0.545	rs3791759	ENSG00000188525.3	AC010969.1	-3.42	0.000654	0.0308	-0.12	-0.11	Prostate cancer;	chr2:9979751	chr2:10003158~10006030:-
BRCA	cis	rs4687717	0.689	rs2306569	ENSG00000274967.1	Y_RNA	3.42	0.000654	0.0308	0.13	0.11	Blood metabolite levels;Blood metabolite ratios;	chr3:53240586	chr3:53290640~53290751:+
BRCA	cis	rs9341808	0.718	rs9443735	ENSG00000279022.1	RP11-250B2.4	3.42	0.000654	0.0308	0.12	0.11	Sitting height ratio;	chr6:80110757	chr6:80440730~80441172:+
BRCA	cis	rs8114671	0.935	rs6058198	ENSG00000126005.14	MMP24-AS1	-3.42	0.000654	0.0308	-0.13	-0.11	Height;	chr20:35160450	chr20:35216462~35278131:-
BRCA	cis	rs1005277	0.505	rs13503	ENSG00000273019.1	RP11-508N22.13	3.42	0.000654	0.0308	0.12	0.11	Extrinsic epigenetic age acceleration;	chr10:37950915	chr10:38149968~38150293:+
BRCA	cis	rs4908769	0.624	rs3765971	ENSG00000232912.4	RP5-1115A15.1	-3.42	0.000654	0.0308	-0.11	-0.11	Allergy;	chr1:8385300	chr1:8424645~8434838:+
BRCA	cis	rs997295	0.57	rs11632574	ENSG00000260657.2	RP11-315D16.4	3.42	0.000654	0.0308	0.13	0.11	Motion sickness;	chr15:67560067	chr15:68267792~68277994:-
BRCA	cis	rs10043775	0.793	rs17719763	ENSG00000251330.3	CTD-2283N19.1	-3.42	0.000654	0.0308	-0.12	-0.11	Periodontal microbiota;	chr5:148332899	chr5:148430159~148430807:-
BRCA	cis	rs2262909	0.962	rs11673195	ENSG00000279377.1	AC003973.3	-3.42	0.000655	0.0308	-0.15	-0.11	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;	chr19:22131012	chr19:21965708~21968529:-
BRCA	cis	rs875971	0.66	rs2013222	ENSG00000272831.1	RP11-792A8.4	-3.42	0.000655	0.0308	-0.09	-0.11	Aortic root size;	chr7:66570949	chr7:66739829~66740385:-
BRCA	cis	rs3770752	0.836	rs2300893	ENSG00000272054.1	RP11-423P10.2	-3.42	0.000655	0.0308	-0.09	-0.11	Schizophrenia;	chr2:37254839	chr2:37208875~37212677:+
BRCA	cis	rs9419702	0.76	rs11156443	ENSG00000234311.1	RP11-432J24.3	3.42	0.000655	0.0308	0.18	0.11	Survival in rectal cancer;	chr10:131703837	chr10:132433733~132441484:-
BRCA	cis	rs7586085	0.874	rs13422985	ENSG00000229195.1	AC009495.4	3.42	0.000655	0.0308	0.12	0.11	Total body bone mineral density;	chr2:165764126	chr2:165794857~165846091:-
BRCA	cis	rs889122	0.659	rs62106799	ENSG00000267289.1	CTD-2623N2.11	3.42	0.000655	0.0308	0.16	0.11	Menarche (age at onset);	chr19:9874359	chr19:9834079~9835013:-
BRCA	cis	rs8038465	0.638	rs12594175	ENSG00000260898.4	ADPGK-AS1	3.42	0.000655	0.0308	0.11	0.11	Liver enzyme levels (gamma-glutamyl transferase);	chr15:73680845	chr15:72782835~72798199:+
BRCA	cis	rs687432	0.851	rs6591444	ENSG00000265566.2	RN7SL605P	-3.42	0.000655	0.0308	-0.14	-0.11	Parkinson's disease;	chr11:57956587	chr11:57528085~57528365:-
BRCA	cis	rs4848143	0.64	rs730309	ENSG00000236859.5	NIFK-AS1	-3.42	0.000655	0.0308	-0.12	-0.11	Capecitabine sensitivity;	chr2:121045180	chr2:121649650~121728208:+
BRCA	cis	rs4787491	0.704	rs66467443	ENSG00000275371.1	RP11-455F5.6	-3.42	0.000655	0.0308	-0.1	-0.11	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30039173	chr16:30110895~30111955:+
BRCA	cis	rs2108225	0.837	rs6958729	ENSG00000231006.1	RPL7P32	3.42	0.000655	0.0308	0.1	0.11	Ulcerative colitis;	chr7:107810766	chr7:108510233~108510976:+
BRCA	cis	rs10419113	0.628	rs9304795	ENSG00000268379.1	CTC-360J11.4	3.42	0.000655	0.0308	0.12	0.11	Pediatric bone mineral density (spine);	chr19:57666177	chr19:57175233~57177921:+
BRCA	cis	rs2400362	0.793	rs1438227	ENSG00000260317.1	RP11-48B3.4	-3.42	0.000655	0.0308	-0.14	-0.11	Glucocorticoid-induced osteonecrosis (age 10 years and older);	chr8:80957358	chr8:80541300~80543104:+
BRCA	cis	rs8023401	0.872	rs11858693	ENSG00000274654.1	CTD-3247H4.2	3.42	0.000655	0.0308	0.16	0.11	Spherical equivalent (joint analysis main effects and education interaction);	chr15:48602711	chr15:48528980~48529728:-
BRCA	cis	rs5758511	0.731	rs5751186	ENSG00000233903.2	Z83851.4	-3.42	0.000655	0.0308	-0.15	-0.11	Birth weight;	chr22:41953706	chr22:42276355~42277052:+
BRCA	cis	rs4388249	1	rs3819904	ENSG00000249068.1	CTC-287O8.1	3.42	0.000655	0.0308	0.15	0.11	Schizophrenia;	chr5:109699795	chr5:109840128~109840692:-
BRCA	cis	rs4648045	0.894	rs230540	ENSG00000246560.2	RP11-10L12.4	-3.42	0.000655	0.0308	-0.12	-0.11	Lymphocyte percentage of white cells;	chr4:102575510	chr4:102828055~102844075:+
BRCA	cis	rs575018	0.918	rs542877	ENSG00000247877.5	CTD-2001C12.1	-3.42	0.000655	0.0308	-0.14	-0.11	Response to radiotherapy in cancer (late toxicity);	chr5:101085261	chr5:100449754~100535262:-
BRCA	cis	rs10883723	0.81	rs7094751	ENSG00000213061.2	PFN1P11	-3.42	0.000656	0.0308	-0.14	-0.11	Allergic disease (asthma, hay fever or eczema);	chr10:102515061	chr10:102838011~102845473:-
BRCA	cis	rs10883723	0.81	rs1884929	ENSG00000213061.2	PFN1P11	-3.42	0.000656	0.0308	-0.14	-0.11	Allergic disease (asthma, hay fever or eczema);	chr10:102515661	chr10:102838011~102845473:-
BRCA	cis	rs6828577	0.862	rs298995	ENSG00000225892.3	RP11-384K6.2	-3.42	0.000656	0.0308	-0.1	-0.11	Perioperative myocardial infarction in coronary artery bypass surgery;	chr4:118704118	chr4:118632274~118634759:+
BRCA	cis	rs4648045	0.861	rs1585215	ENSG00000246560.2	RP11-10L12.4	3.42	0.000656	0.0308	0.13	0.11	Lymphocyte percentage of white cells;	chr4:102523317	chr4:102828055~102844075:+
BRCA	cis	rs163574	1	rs163574	ENSG00000271870.1	RP11-97C16.1	3.42	0.000656	0.0308	0.14	0.11	Basophil percentage of granulocytes;White blood cell count (basophil);	chr3:3055243	chr3:3152942~3153435:+
BRCA	cis	rs10129255	1	rs10141557	ENSG00000253763.1	IGHV3-6	3.42	0.000656	0.0308	0.1	0.11	Kawasaki disease;	chr14:106767990	chr14:106055549~106055998:-
BRCA	cis	rs6545883	0.811	rs778753	ENSG00000212978.6	AC016747.3	3.42	0.000656	0.0308	0.14	0.11	Tuberculosis;	chr2:61553065	chr2:61141592~61144969:-
BRCA	cis	rs11773103	0.786	rs56365880	ENSG00000224046.1	AC005076.5	3.42	0.000656	0.0308	0.17	0.11	Bipolar disorder or major depressive disorder (combined);	chr7:87126354	chr7:87151423~87152420:-
BRCA	cis	rs7829975	0.533	rs13274028	ENSG00000173295.6	FAM86B3P	3.42	0.000656	0.0308	0.11	0.11	Mood instability;	chr8:8871683	chr8:8228595~8244865:+
BRCA	cis	rs6142102	0.961	rs6087557	ENSG00000206582.1	Y_RNA	-3.42	0.000656	0.0308	-0.12	-0.11	Skin pigmentation;	chr20:34110469	chr20:34526510~34526606:-
BRCA	cis	rs7267979	0.903	rs6115109	ENSG00000274414.1	RP5-965G21.4	-3.42	0.000656	0.0308	-0.13	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25259031	chr20:25239007~25245229:-
BRCA	cis	rs7267979	0.833	rs4619688	ENSG00000274414.1	RP5-965G21.4	-3.42	0.000656	0.0308	-0.13	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25263465	chr20:25239007~25245229:-
BRCA	cis	rs8180040	0.654	rs62246451	ENSG00000260236.1	RP11-708J19.1	-3.42	0.000656	0.0308	-0.1	-0.11	Colorectal cancer;	chr3:47170142	chr3:47379089~47380999:-
BRCA	cis	rs8180040	0.627	rs58956475	ENSG00000260236.1	RP11-708J19.1	-3.42	0.000656	0.0308	-0.1	-0.11	Colorectal cancer;	chr3:47183125	chr3:47379089~47380999:-
BRCA	cis	rs6445975	0.715	rs3773007	ENSG00000272360.1	RP11-359I18.5	-3.42	0.000656	0.0308	-0.11	-0.11	Systemic lupus erythematosus;	chr3:58283839	chr3:58490830~58491291:-
BRCA	cis	rs6142618	0.562	rs6089193	ENSG00000277692.1	RP11-358N2.2	-3.42	0.000656	0.0308	-0.11	-0.11	Inflammatory bowel disease;	chr20:32141685	chr20:32355053~32355734:+
BRCA	cis	rs860295	0.756	rs7546258	ENSG00000232093.1	RP11-307C12.11	3.42	0.000656	0.0308	0.12	0.11	Body mass index;	chr1:155728854	chr1:155045191~155046118:-
BRCA	cis	rs10777288	0.561	rs1920744	ENSG00000258100.1	RP11-121E16.1	3.42	0.000656	0.0308	0.13	0.11	Pulmonary function (smoking interaction);	chr12:91008935	chr12:91362196~91368606:+
BRCA	cis	rs875971	0.862	rs778736	ENSG00000106610.13	STAG3L4	-3.42	0.000656	0.0308	-0.14	-0.11	Aortic root size;	chr7:66348861	chr7:67302621~67321526:+
BRCA	cis	rs3805389	0.504	rs62308708	ENSG00000273257.1	RP11-177J6.1	-3.42	0.000656	0.0308	-0.18	-0.11	Waist-to-hip ratio adjusted for body mass index;	chr4:55626177	chr4:55387949~55388271:+
BRCA	cis	rs9650657	0.623	rs7004066	ENSG00000248896.2	CTD-2135J3.3	-3.42	0.000656	0.0308	-0.13	-0.11	Neuroticism;	chr8:10743233	chr8:10729314~10771392:+
BRCA	cis	rs2832191	0.791	rs2832196	ENSG00000232855.5	AF131217.1	3.42	0.000656	0.0308	0.12	0.11	Dental caries;	chr21:29125091	chr21:28439346~28674848:-
BRCA	cis	rs853679	0.517	rs9357063	ENSG00000272009.1	RP1-313I6.12	-3.42	0.000657	0.0309	-0.15	-0.11	Depression;	chr6:28092227	chr6:28078792~28081130:-
BRCA	cis	rs13153459	1	rs10054457	ENSG00000279557.1	CTD-2210P15.3	-3.42	0.000657	0.0309	-0.16	-0.11	Parkinson's disease;	chr5:44575931	chr5:43586367~43587543:-
BRCA	cis	rs687432	0.688	rs61902769	ENSG00000265566.2	RN7SL605P	-3.42	0.000657	0.0309	-0.14	-0.11	Parkinson's disease;	chr11:58125187	chr11:57528085~57528365:-
BRCA	cis	rs36051895	0.664	rs10117501	ENSG00000237711.1	RP11-39K24.13	-3.42	0.000657	0.0309	-0.13	-0.11	Pediatric autoimmune diseases;	chr9:5094246	chr9:5100236~5101009:+
BRCA	cis	rs2834256	0.527	rs9983905	ENSG00000231355.1	AP000302.58	3.42	0.000657	0.0309	0.13	0.11	Red cell distribution width;	chr21:33494551	chr21:33482499~33484258:-
BRCA	cis	rs875971	0.895	rs3857684	ENSG00000272831.1	RP11-792A8.4	3.42	0.000657	0.0309	0.09	0.11	Aortic root size;	chr7:66473171	chr7:66739829~66740385:-
BRCA	cis	rs7246967	0.673	rs7258098	ENSG00000241282.1	RPL34P33	3.42	0.000657	0.0309	0.2	0.11	Bronchopulmonary dysplasia;	chr19:22873927	chr19:22699352~22699685:+
BRCA	cis	rs2692947	0.537	rs11682182	ENSG00000168992.4	OR7E102P	3.42	0.000657	0.0309	0.14	0.11	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95712462	chr2:95546531~95547545:+
BRCA	cis	rs17221829	0.733	rs10765227	ENSG00000280385.1	AP000648.5	-3.42	0.000657	0.0309	-0.12	-0.11	Anxiety in major depressive disorder;	chr11:89651948	chr11:90193614~90198120:+
BRCA	cis	rs17221829	0.733	rs10765228	ENSG00000280385.1	AP000648.5	-3.42	0.000657	0.0309	-0.12	-0.11	Anxiety in major depressive disorder;	chr11:89651964	chr11:90193614~90198120:+
BRCA	cis	rs3748682	0.808	rs12728438	ENSG00000212541.1	RNU6-510P	-3.42	0.000657	0.0309	-0.15	-0.11	Hypothyroidism;	chr1:37883728	chr1:37991462~37991569:+
BRCA	cis	rs6840360	0.593	rs867800	ENSG00000270265.1	RP11-731D1.4	-3.42	0.000657	0.0309	-0.12	-0.11	Intelligence (multi-trait analysis);	chr4:151770318	chr4:151333775~151353224:-
BRCA	cis	rs853679	0.517	rs2273564	ENSG00000272009.1	RP1-313I6.12	-3.42	0.000657	0.0309	-0.15	-0.11	Depression;	chr6:28089816	chr6:28078792~28081130:-
BRCA	cis	rs853679	0.517	rs1853097	ENSG00000272009.1	RP1-313I6.12	-3.42	0.000657	0.0309	-0.15	-0.11	Depression;	chr6:28090857	chr6:28078792~28081130:-
BRCA	cis	rs853679	0.517	rs9393888	ENSG00000272009.1	RP1-313I6.12	-3.42	0.000657	0.0309	-0.15	-0.11	Depression;	chr6:28091439	chr6:28078792~28081130:-
BRCA	cis	rs853679	0.517	rs3734573	ENSG00000272009.1	RP1-313I6.12	-3.42	0.000657	0.0309	-0.15	-0.11	Depression;	chr6:28091659	chr6:28078792~28081130:-
BRCA	cis	rs853679	0.517	rs3823180	ENSG00000272009.1	RP1-313I6.12	-3.42	0.000657	0.0309	-0.15	-0.11	Depression;	chr6:28093966	chr6:28078792~28081130:-
BRCA	cis	rs853679	0.517	rs9368551	ENSG00000272009.1	RP1-313I6.12	-3.42	0.000657	0.0309	-0.15	-0.11	Depression;	chr6:28094014	chr6:28078792~28081130:-
BRCA	cis	rs2882667	0.69	rs288012	ENSG00000242683.1	CTB-46B19.1	-3.42	0.000657	0.0309	-0.12	-0.11	Age-related hearing impairment (SNP x SNP interaction);	chr5:138860584	chr5:139035148~139035987:-
BRCA	cis	rs757978	1	rs73116394	ENSG00000223374.1	AC005104.3	3.42	0.000657	0.0309	0.14	0.11	Chronic lymphocytic leukemia;	chr2:241428500	chr2:241351340~241353104:-
BRCA	cis	rs757978	1	rs73116396	ENSG00000223374.1	AC005104.3	3.42	0.000657	0.0309	0.14	0.11	Chronic lymphocytic leukemia;	chr2:241429278	chr2:241351340~241353104:-
BRCA	cis	rs7636293	0.551	rs9858960	ENSG00000270773.1	RP13-685P2.7	3.42	0.000657	0.0309	0.14	0.11	Height;	chr3:129324182	chr3:129345411~129346164:+
BRCA	cis	rs1555133	0.625	rs6141696	ENSG00000277692.1	RP11-358N2.2	-3.42	0.000657	0.0309	-0.12	-0.11	Monocyte count;	chr20:32381800	chr20:32355053~32355734:+
BRCA	cis	rs4243971	0.537	rs6141697	ENSG00000277692.1	RP11-358N2.2	-3.42	0.000657	0.0309	-0.12	-0.11	Inflammatory bowel disease;Crohn's disease;	chr20:32381803	chr20:32355053~32355734:+
BRCA	cis	rs4243971	0.516	rs6141299	ENSG00000277692.1	RP11-358N2.2	-3.42	0.000657	0.0309	-0.12	-0.11	Inflammatory bowel disease;Crohn's disease;	chr20:32382267	chr20:32355053~32355734:+
BRCA	cis	rs516805	0.528	rs2684235	ENSG00000279453.1	RP3-425C14.4	3.42	0.000657	0.0309	0.14	0.11	Lymphocyte counts;	chr6:122082083	chr6:122436789~122439223:-
BRCA	cis	rs12282928	0.959	rs1393791	ENSG00000255197.4	RP11-750H9.5	3.42	0.000657	0.0309	0.1	0.11	Migraine - clinic-based;	chr11:48242631	chr11:47383148~47409190:-
BRCA	cis	rs875971	0.522	rs34973832	ENSG00000227113.2	RP11-460N20.4	3.42	0.000657	0.0309	0.11	0.11	Aortic root size;	chr7:65931217	chr7:65075023~65078780:+
BRCA	cis	rs10419113	0.701	rs10403317	ENSG00000268379.1	CTC-360J11.4	3.42	0.000657	0.0309	0.12	0.11	Pediatric bone mineral density (spine);	chr19:57680115	chr19:57175233~57177921:+
BRCA	cis	rs4713118	0.869	rs7773070	ENSG00000219392.1	RP1-265C24.5	-3.42	0.000657	0.0309	-0.15	-0.11	Parkinson's disease;	chr6:27761048	chr6:28115628~28116551:+
BRCA	cis	rs2904967	0.703	rs2957111	ENSG00000254614.2	AP003068.23	-3.42	0.000657	0.0309	-0.23	-0.11	Mean corpuscular volume;	chr11:65235976	chr11:65177606~65181834:-
BRCA	cis	rs13434995	0.588	rs114571142	ENSG00000249700.7	SRD5A3-AS1	-3.42	0.000657	0.0309	-0.15	-0.11	Adiponectin levels;	chr4:55412991	chr4:55363971~55395847:-
BRCA	cis	rs7259376	0.936	rs1975173	ENSG00000269345.1	VN1R85P	3.42	0.000657	0.0309	0.13	0.11	Menopause (age at onset);	chr19:22351736	chr19:22174766~22175191:-
BRCA	cis	rs4819052	0.851	rs2838842	ENSG00000223768.1	LINC00205	-3.42	0.000657	0.0309	-0.14	-0.11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45249302	chr21:45293285~45297354:+
BRCA	cis	rs6840360	0.967	rs10049728	ENSG00000278978.1	RP11-164P12.5	-3.42	0.000657	0.0309	-0.12	-0.11	Intelligence (multi-trait analysis);	chr4:151750969	chr4:151669786~151670503:+
BRCA	cis	rs6840360	0.967	rs7684350	ENSG00000278978.1	RP11-164P12.5	-3.42	0.000657	0.0309	-0.12	-0.11	Intelligence (multi-trait analysis);	chr4:151751730	chr4:151669786~151670503:+
BRCA	cis	rs3764021	0.527	rs11052426	ENSG00000260423.1	RP13-735L24.1	-3.42	0.000657	0.0309	-0.12	-0.11	Type 1 diabetes;	chr12:9688330	chr12:9367464~9397617:+
BRCA	cis	rs7809799	1	rs4454228	ENSG00000242798.1	RP11-506M12.1	3.42	0.000657	0.0309	0.18	0.11	Ulcerative colitis;	chr7:99155535	chr7:100115214~100127139:-
BRCA	cis	rs17345786	1	rs3804775	ENSG00000256628.3	ZBTB11-AS1	3.42	0.000657	0.0309	0.15	0.11	Colonoscopy-negative controls vs population controls;	chr3:101587663	chr3:101676475~101679217:+
BRCA	cis	rs2439831	0.85	rs28858500	ENSG00000206991.1	RNU6-610P	-3.42	0.000658	0.0309	-0.17	-0.11	Lung cancer in ever smokers;	chr15:43864744	chr15:43637632~43637738:-
BRCA	cis	rs6828577	0.56	rs2631147	ENSG00000248280.1	RP11-33B1.2	3.42	0.000658	0.0309	0.11	0.11	Perioperative myocardial infarction in coronary artery bypass surgery;	chr4:118534699	chr4:119440561~119450157:-
BRCA	cis	rs6724465	0.636	rs6436119	ENSG00000272644.1	RP11-33O4.1	3.42	0.000658	0.0309	0.16	0.11	Height;	chr2:219154306	chr2:219069354~219069809:-
BRCA	cis	rs6912958	0.703	rs9362427	ENSG00000272008.1	RP11-393I2.4	-3.42	0.000658	0.0309	-0.11	-0.11	Monocyte percentage of white cells;	chr6:87387916	chr6:87151159~87155285:-
BRCA	cis	rs12190007	0.508	rs9406321	ENSG00000227508.5	FLJ38122	3.42	0.000658	0.0309	0.11	0.11	Obesity-related traits;	chr6:169326746	chr6:170272474~170279887:+
BRCA	cis	rs1437396	0.657	rs6725124	ENSG00000203327.2	AC012358.7	-3.42	0.000658	0.0309	-0.11	-0.11	Alcohol dependence;	chr2:55404161	chr2:55214387~55216126:-
BRCA	cis	rs13434995	0.513	rs6851971	ENSG00000239040.1	Y_RNA	-3.42	0.000658	0.0309	-0.12	-0.11	Adiponectin levels;	chr4:55561897	chr4:55412636~55412738:+
BRCA	cis	rs11088226	1	rs11088226	ENSG00000186842.4	LINC00846	-3.42	0.000658	0.0309	-0.16	-0.11	Gastritis;	chr21:32553221	chr21:32572238~32575881:-
BRCA	cis	rs12505328	0.593	rs880962	ENSG00000213370.3	RANP6	3.42	0.000658	0.0309	0.14	0.11	Chin dimples;	chr4:173441050	chr4:173633728~173634371:-
BRCA	cis	rs12505328	0.593	rs880961	ENSG00000213370.3	RANP6	3.42	0.000658	0.0309	0.14	0.11	Chin dimples;	chr4:173441101	chr4:173633728~173634371:-
BRCA	cis	rs7000551	0.68	rs28546543	ENSG00000254272.1	RP11-382J24.2	-3.42	0.000658	0.0309	-0.13	-0.11	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr8:22457359	chr8:22492631~22493044:+
BRCA	cis	rs881375	1	rs10818480	ENSG00000238181.2	AHCYP2	-3.42	0.000658	0.0309	-0.13	-0.11	Rheumatoid arthritis;	chr9:120880892	chr9:120720673~120721972:+
BRCA	cis	rs748404	0.626	rs62021176	ENSG00000166763.7	STRCP1	3.42	0.000658	0.0309	0.15	0.11	Lung cancer;	chr15:43388014	chr15:43699488~43718184:-
BRCA	cis	rs12505749	0.542	rs17086853	ENSG00000270147.1	RP11-646I6.6	-3.42	0.000658	0.0309	-0.12	-0.11	Airflow obstruction;	chr4:56486153	chr4:56396312~56396871:+
BRCA	cis	rs875971	0.862	rs6978028	ENSG00000106610.13	STAG3L4	-3.42	0.000658	0.0309	-0.14	-0.11	Aortic root size;	chr7:66421313	chr7:67302621~67321526:+
BRCA	cis	rs6600671	1	rs2185281	ENSG00000223345.3	HIST2H2BA	3.42	0.000658	0.0309	0.13	0.11	Hip geometry;	chr1:121438132	chr1:121108210~121117257:-
BRCA	cis	rs875971	0.929	rs6970860	ENSG00000273024.4	INTS4P2	-3.42	0.000658	0.0309	-0.12	-0.11	Aortic root size;	chr7:66511647	chr7:65647864~65715661:+
BRCA	cis	rs9834975	0.875	rs4678191	ENSG00000242531.1	RP11-299J3.6	-3.42	0.000658	0.0309	-0.1	-0.11	Diastolic blood pressure;	chr3:122402391	chr3:122416882~122417012:-
BRCA	cis	rs34421088	0.576	rs2572432	ENSG00000255046.1	RP11-297N6.4	3.42	0.000658	0.0309	0.13	0.11	Neuroticism;	chr8:11244214	chr8:11797928~11802568:-
BRCA	cis	rs4499344	0.768	rs10411319	ENSG00000201388.1	SNORA68	3.42	0.000659	0.0309	0.12	0.11	Mean platelet volume;	chr19:32611899	chr19:32608337~32608469:-
BRCA	cis	rs2688608	0.698	rs2633313	ENSG00000271816.1	BMS1P4	3.42	0.000659	0.0309	0.1	0.11	Inflammatory bowel disease;	chr10:73924107	chr10:73699151~73730487:-
BRCA	cis	rs17711722	0.727	rs1880555	ENSG00000227113.2	RP11-460N20.4	3.42	0.000659	0.0309	0.11	0.11	Calcium levels;	chr7:65967580	chr7:65075023~65078780:+
BRCA	cis	rs11874712	1	rs7235373	ENSG00000251939.1	RNU6-1278P	-3.42	0.000659	0.0309	-0.12	-0.11	Migraine - clinic-based;	chr18:46073797	chr18:46121615~46121721:-
BRCA	cis	rs7089973	0.61	rs34461950	ENSG00000236799.1	RP11-383C6.2	-3.42	0.000659	0.0309	-0.14	-0.11	Bipolar disorder or attention deficit hyperactivity disorder;	chr10:114968514	chr10:114994657~114996593:+
BRCA	cis	rs34779708	0.966	rs2045918	ENSG00000269952.1	RP11-324I22.3	-3.42	0.000659	0.0309	-0.14	-0.11	Inflammatory bowel disease;Crohn's disease;	chr10:35129589	chr10:35210416~35210750:+
BRCA	cis	rs34779708	0.966	rs4294520	ENSG00000269952.1	RP11-324I22.3	-3.42	0.000659	0.0309	-0.14	-0.11	Inflammatory bowel disease;Crohn's disease;	chr10:35133578	chr10:35210416~35210750:+
BRCA	cis	rs683250	0.598	rs7933220	ENSG00000255234.4	RP11-727A23.10	3.42	0.000659	0.0309	0.13	0.11	Subcortical brain region volumes;	chr11:83307732	chr11:83286128~83423516:+
BRCA	cis	rs7590720	1	rs4674048	ENSG00000230838.1	AC093850.2	-3.42	0.000659	0.0309	-0.1	-0.11	Alcohol dependence;	chr2:216035300	chr2:215718043~215719424:+
BRCA	cis	rs739401	0.572	rs404629	ENSG00000247473.2	CARS-AS1	3.42	0.000659	0.0309	0.12	0.11	Longevity;	chr11:3055795	chr11:3029009~3041260:+
BRCA	cis	rs2835345	0.563	rs60511692	ENSG00000214914.3	RPL23AP3	-3.42	0.000659	0.0309	-0.14	-0.11	Pulmonary function;	chr21:36454091	chr21:36016079~36016546:-
BRCA	cis	rs7781266	0.842	rs10954417	ENSG00000226205.1	AC007790.4	-3.42	0.000659	0.0309	-0.14	-0.11	Educational attainment (college completion);	chr7:133515768	chr7:133732493~133733595:-
BRCA	cis	rs74233809	1	rs11191531	ENSG00000213061.2	PFN1P11	3.42	0.000659	0.0309	0.23	0.11	Birth weight;	chr10:103047141	chr10:102838011~102845473:-
BRCA	cis	rs739496	0.501	rs441	ENSG00000257624.1	RP1-128M12.3	3.42	0.000659	0.0309	0.15	0.11	Platelet count;	chr12:111791045	chr12:112000739~112000985:-
BRCA	cis	rs10819861	0.621	rs7046587	ENSG00000175611.10	LINC00476	3.42	0.000659	0.031	0.11	0.11	Electrocardiographic traits;	chr9:96085105	chr9:95759231~95875977:-
BRCA	cis	rs4974559	0.895	rs12646130	ENSG00000253399.1	AC078852.2	3.42	0.000659	0.031	0.16	0.11	Systolic blood pressure;	chr4:1336742	chr4:1358479~1359461:+
BRCA	cis	rs72772090	0.539	rs114006288	ENSG00000272109.1	CTD-2260A17.3	3.42	0.000659	0.031	0.21	0.11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96782300	chr5:96804353~96806105:+
BRCA	cis	rs72772090	0.539	rs72773932	ENSG00000272109.1	CTD-2260A17.3	3.42	0.000659	0.031	0.21	0.11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96782444	chr5:96804353~96806105:+
BRCA	cis	rs72772090	0.539	rs11750934	ENSG00000272109.1	CTD-2260A17.3	3.42	0.000659	0.031	0.21	0.11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96782783	chr5:96804353~96806105:+
BRCA	cis	rs72772090	0.539	rs11738810	ENSG00000272109.1	CTD-2260A17.3	3.42	0.000659	0.031	0.21	0.11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96783351	chr5:96804353~96806105:+
BRCA	cis	rs72772090	0.539	rs11748519	ENSG00000272109.1	CTD-2260A17.3	3.42	0.000659	0.031	0.21	0.11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96783624	chr5:96804353~96806105:+
BRCA	cis	rs8073060	0.963	rs11080354	ENSG00000267554.1	RP11-686D22.10	-3.42	0.000659	0.031	-0.09	-0.11	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35545388	chr17:35470069~35470628:-
BRCA	cis	rs2069837	0.551	rs73684321	ENSG00000179428.2	AC073072.5	-3.42	0.000659	0.031	-0.14	-0.11	Longevity;	chr7:22734971	chr7:22725395~22727620:-
BRCA	cis	rs6600671	0.934	rs7528274	ENSG00000275131.1	CH17-472G23.4	-3.42	0.000659	0.031	-0.1	-0.11	Hip geometry;	chr1:121545103	chr1:120489625~120579190:-
BRCA	cis	rs9341808	0.718	rs11962614	ENSG00000279022.1	RP11-250B2.4	3.42	0.000659	0.031	0.12	0.11	Sitting height ratio;	chr6:80113589	chr6:80440730~80441172:+
BRCA	cis	rs9341808	0.718	rs12208016	ENSG00000279022.1	RP11-250B2.4	3.42	0.000659	0.031	0.12	0.11	Sitting height ratio;	chr6:80113846	chr6:80440730~80441172:+
BRCA	cis	rs9341808	0.718	rs9448886	ENSG00000279022.1	RP11-250B2.4	3.42	0.000659	0.031	0.12	0.11	Sitting height ratio;	chr6:80116184	chr6:80440730~80441172:+
BRCA	cis	rs9341808	0.683	rs9359409	ENSG00000279022.1	RP11-250B2.4	3.42	0.000659	0.031	0.12	0.11	Sitting height ratio;	chr6:80117180	chr6:80440730~80441172:+
BRCA	cis	rs1730008	1	rs827145	ENSG00000279311.1	RP11-170K4.2	-3.42	0.00066	0.031	-0.12	-0.11	Lobe attachment (rater-scored or self-reported);	chr3:158207123	chr3:158869898~158871821:+
BRCA	cis	rs1730008	0.927	rs827146	ENSG00000279311.1	RP11-170K4.2	-3.42	0.00066	0.031	-0.12	-0.11	Lobe attachment (rater-scored or self-reported);	chr3:158207762	chr3:158869898~158871821:+
BRCA	cis	rs1730008	1	rs866657	ENSG00000279311.1	RP11-170K4.2	-3.42	0.00066	0.031	-0.12	-0.11	Lobe attachment (rater-scored or self-reported);	chr3:158208937	chr3:158869898~158871821:+
BRCA	cis	rs1730008	1	rs1730099	ENSG00000279311.1	RP11-170K4.2	-3.42	0.00066	0.031	-0.12	-0.11	Lobe attachment (rater-scored or self-reported);	chr3:158209455	chr3:158869898~158871821:+
BRCA	cis	rs1730008	1	rs1729998	ENSG00000279311.1	RP11-170K4.2	-3.42	0.00066	0.031	-0.12	-0.11	Lobe attachment (rater-scored or self-reported);	chr3:158210235	chr3:158869898~158871821:+
BRCA	cis	rs1730008	1	rs1724666	ENSG00000279311.1	RP11-170K4.2	-3.42	0.00066	0.031	-0.12	-0.11	Lobe attachment (rater-scored or self-reported);	chr3:158211919	chr3:158869898~158871821:+
BRCA	cis	rs1730008	1	rs2682407	ENSG00000279311.1	RP11-170K4.2	-3.42	0.00066	0.031	-0.12	-0.11	Lobe attachment (rater-scored or self-reported);	chr3:158212320	chr3:158869898~158871821:+
BRCA	cis	rs12468226	1	rs76528043	ENSG00000272966.1	RP11-686O6.1	3.42	0.00066	0.031	0.18	0.11	Urate levels;	chr2:202466116	chr2:202336739~202337200:+
BRCA	cis	rs12468226	1	rs12468226	ENSG00000272966.1	RP11-686O6.1	3.42	0.00066	0.031	0.18	0.11	Urate levels;	chr2:202472278	chr2:202336739~202337200:+
BRCA	cis	rs2439831	0.85	rs12441984	ENSG00000206991.1	RNU6-610P	-3.42	0.00066	0.031	-0.17	-0.11	Lung cancer in ever smokers;	chr15:43834087	chr15:43637632~43637738:-
BRCA	cis	rs1005277	0.505	rs200910	ENSG00000273019.1	RP11-508N22.13	-3.42	0.00066	0.031	-0.12	-0.11	Extrinsic epigenetic age acceleration;	chr10:37819248	chr10:38149968~38150293:+
BRCA	cis	rs1862618	0.671	rs2034244	ENSG00000271828.1	CTD-2310F14.1	-3.42	0.00066	0.031	-0.13	-0.11	Initial pursuit acceleration;	chr5:56946947	chr5:56927874~56929573:+
BRCA	cis	rs4974559	0.739	rs10032327	ENSG00000253399.1	AC078852.2	3.42	0.00066	0.031	0.16	0.11	Systolic blood pressure;	chr4:1329749	chr4:1358479~1359461:+
BRCA	cis	rs7572733	0.935	rs10931797	ENSG00000231621.1	AC013264.2	-3.42	0.00066	0.031	-0.1	-0.11	Dermatomyositis;	chr2:197976069	chr2:197197991~197199273:+
BRCA	cis	rs7649443	0.918	rs7619429	ENSG00000243339.3	RN7SL738P	-3.42	0.00066	0.031	-0.15	-0.11	Nonsyndromic cleft lip with cleft palate;	chr3:197272219	chr3:196399911~196400207:+
BRCA	cis	rs7649443	0.959	rs1073726	ENSG00000243339.3	RN7SL738P	-3.42	0.00066	0.031	-0.15	-0.11	Nonsyndromic cleft lip with cleft palate;	chr3:197274137	chr3:196399911~196400207:+
BRCA	cis	rs62458065	1	rs6462364	ENSG00000273014.1	RP11-225B17.2	-3.42	0.00066	0.031	-0.16	-0.11	Metabolite levels (HVA/MHPG ratio);	chr7:32425164	chr7:32758882~32759353:+
BRCA	cis	rs8180040	0.62	rs56217494	ENSG00000260236.1	RP11-708J19.1	-3.42	0.00066	0.031	-0.1	-0.11	Colorectal cancer;	chr3:47006962	chr3:47379089~47380999:-
BRCA	cis	rs10782582	0.593	rs77208152	ENSG00000181227.3	RP4-682C21.2	3.42	0.00066	0.031	0.11	0.11	Daytime sleep phenotypes;	chr1:75658570	chr1:75743423~75744776:-
BRCA	cis	rs947583	0.573	rs12191817	ENSG00000231028.7	LINC00271	-3.42	0.00066	0.031	-0.12	-0.11	Phosphorus levels;	chr6:135702608	chr6:135497801~135716055:+
BRCA	cis	rs67478160	0.619	rs12878682	ENSG00000269910.1	RP11-73M18.10	3.42	0.00066	0.031	0.1	0.11	Schizophrenia;	chr14:103767290	chr14:103694516~103695050:-
BRCA	cis	rs67478160	0.644	rs7159810	ENSG00000269910.1	RP11-73M18.10	3.42	0.00066	0.031	0.1	0.11	Schizophrenia;	chr14:103827780	chr14:103694516~103695050:-
BRCA	cis	rs11088226	1	rs2833888	ENSG00000186842.4	LINC00846	-3.42	0.00066	0.031	-0.17	-0.11	Gastritis;	chr21:32555250	chr21:32572238~32575881:-
BRCA	cis	rs1376877	0.837	rs7573079	ENSG00000273456.1	RP11-686O6.2	3.42	0.00066	0.031	0.1	0.11	Subclinical atherosclerosis traits (other);	chr2:203062828	chr2:202374932~202375604:-
BRCA	cis	rs7608910	1	rs7608697	ENSG00000237522.1	NONOP2	-3.42	0.00066	0.031	-0.1	-0.11	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;	chr2:60977506	chr2:60936819~60938049:-
BRCA	cis	rs952623	0.501	rs11972294	ENSG00000211694.2	TRGV10	3.42	0.00066	0.031	0.09	0.11	Intelligence (multi-trait analysis);	chr7:39046143	chr7:38299811~38300322:-
BRCA	cis	rs2562456	0.876	rs62110163	ENSG00000268705.1	BNIP3P26	3.42	0.00066	0.031	0.12	0.11	Pain;	chr19:21546020	chr19:21521343~21521896:-
BRCA	cis	rs2562456	0.761	rs35008138	ENSG00000268705.1	BNIP3P26	3.42	0.00066	0.031	0.12	0.11	Pain;	chr19:21548822	chr19:21521343~21521896:-
BRCA	cis	rs2562456	0.833	rs2681388	ENSG00000268705.1	BNIP3P26	3.42	0.00066	0.031	0.12	0.11	Pain;	chr19:21549451	chr19:21521343~21521896:-
BRCA	cis	rs2562456	0.876	rs2681370	ENSG00000268705.1	BNIP3P26	3.42	0.00066	0.031	0.12	0.11	Pain;	chr19:21554036	chr19:21521343~21521896:-
BRCA	cis	rs2562456	0.876	rs11668606	ENSG00000268705.1	BNIP3P26	3.42	0.00066	0.031	0.12	0.11	Pain;	chr19:21554618	chr19:21521343~21521896:-
BRCA	cis	rs2562456	0.876	rs2681395	ENSG00000268705.1	BNIP3P26	3.42	0.00066	0.031	0.12	0.11	Pain;	chr19:21555338	chr19:21521343~21521896:-
BRCA	cis	rs12692738	0.626	rs3769893	ENSG00000223318.1	RNA5SP111	3.42	0.00066	0.031	0.13	0.11	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);	chr2:164751514	chr2:164895677~164895777:-
BRCA	cis	rs875971	0.628	rs6974355	ENSG00000232559.3	GS1-124K5.12	3.42	0.00066	0.031	0.13	0.11	Aortic root size;	chr7:66376994	chr7:66554588~66576923:-
BRCA	cis	rs6540556	0.723	rs9430012	ENSG00000236136.1	ADORA2BP1	-3.42	0.00066	0.031	-0.14	-0.11	Red blood cell count;	chr1:209727270	chr1:209744373~209745214:+
BRCA	cis	rs801193	0.967	rs2707849	ENSG00000275400.1	RP4-756H11.5	-3.42	0.00066	0.031	-0.12	-0.11	Aortic root size;	chr7:66687725	chr7:66553805~66554199:-
BRCA	cis	rs875971	1	rs709597	ENSG00000273448.1	RP11-166O4.6	-3.42	0.00066	0.031	-0.1	-0.11	Aortic root size;	chr7:66360996	chr7:67333047~67334383:+
BRCA	cis	rs34779708	0.966	rs35814343	ENSG00000269952.1	RP11-324I22.3	-3.42	0.00066	0.031	-0.14	-0.11	Inflammatory bowel disease;Crohn's disease;	chr10:35138786	chr10:35210416~35210750:+
BRCA	cis	rs10411161	0.702	rs1433081	ENSG00000269483.1	AC006272.1	3.42	0.00066	0.031	0.18	0.11	Breast cancer;	chr19:51887457	chr19:51839924~51843324:-
BRCA	cis	rs6671200	0.607	rs2147587	ENSG00000226026.4	RP11-57H12.3	-3.42	0.00066	0.031	-0.16	-0.11	Stearic acid (18:0) levels;	chr1:95249328	chr1:95163219~95233982:-
BRCA	cis	rs7712401	0.755	rs13172043	ENSG00000249996.1	RP11-359P5.1	3.42	0.00066	0.031	0.12	0.11	Mean platelet volume;	chr5:122849064	chr5:123036271~123054667:+
BRCA	cis	rs494453	0.6	rs474077	ENSG00000227811.2	FAM212B-AS1	-3.42	0.00066	0.031	-0.13	-0.11	Osteoporosis-related phenotypes;	chr1:111652592	chr1:111739841~111747798:+
BRCA	cis	rs9470794	1	rs11751937	ENSG00000204110.6	RP1-153P14.8	-3.42	0.00066	0.031	-0.21	-0.11	Type 2 diabetes;	chr6:38162677	chr6:37507348~37535616:+
BRCA	cis	rs7824557	0.606	rs1435277	ENSG00000255020.1	AF131216.5	-3.42	0.00066	0.031	-0.12	-0.11	Retinal vascular caliber;	chr8:11339461	chr8:11345748~11347502:-
BRCA	cis	rs2041840	0.692	rs6706672	ENSG00000272054.1	RP11-423P10.2	-3.42	0.00066	0.031	-0.1	-0.11	Chronic lymphocytic leukemia;	chr2:37172208	chr2:37208875~37212677:+
BRCA	cis	rs896655	0.631	rs1335511	ENSG00000229298.1	TUBB8P1	3.42	0.00066	0.031	0.11	0.11	Coronary artery disease;	chr9:21757917	chr9:21811621~21812347:-
BRCA	cis	rs3015497	0.663	rs12434932	ENSG00000259113.1	RP11-406H23.2	-3.42	0.00066	0.031	-0.12	-0.11	Mean platelet volume;	chr14:50690896	chr14:50448807~50456742:+
BRCA	cis	rs787274	1	rs1361720	ENSG00000271631.1	RP11-408O19.5	3.42	0.00066	0.031	0.18	0.11	Age-related hearing impairment (SNP x SNP interaction);	chr9:112773299	chr9:112885158~112885767:+
BRCA	cis	rs7917772	0.503	rs2031601	ENSG00000213061.2	PFN1P11	-3.42	0.00066	0.031	-0.14	-0.11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;	chr10:102548307	chr10:102838011~102845473:-
BRCA	cis	rs7283707	0.681	rs2823498	ENSG00000270071.1	AP001172.2	-3.42	0.00066	0.031	-0.17	-0.11	QRS complex (12-leadsum);	chr21:15810564	chr21:16291791~16308133:-
BRCA	cis	rs7695732	0.7	rs17015027	ENSG00000270720.1	RP11-84C13.2	-3.42	0.000661	0.031	-0.14	-0.11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr4:89113535	chr4:89119284~89119871:+
BRCA	cis	rs2274273	1	rs72718804	ENSG00000259318.1	RP11-454L9.2	3.42	0.000661	0.031	0.09	0.11	Protein biomarker;	chr14:55163892	chr14:55394940~55395233:-
BRCA	cis	rs9437689	0.934	rs4847220	ENSG00000235501.4	RP4-639F20.1	-3.42	0.000661	0.031	-0.13	-0.11	Phospholipid levels (plasma);	chr1:94998429	chr1:94927566~94963270:+
BRCA	cis	rs12282928	0.743	rs2202249	ENSG00000255197.4	RP11-750H9.5	3.42	0.000661	0.031	0.1	0.11	Migraine - clinic-based;	chr11:48179034	chr11:47383148~47409190:-
BRCA	cis	rs2638953	0.962	rs11494780	ENSG00000273989.1	RP11-425D17.2	-3.42	0.000661	0.031	-0.16	-0.11	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28402269	chr12:28236227~28236828:+
BRCA	cis	rs2638953	0.962	rs11049574	ENSG00000273989.1	RP11-425D17.2	-3.42	0.000661	0.031	-0.16	-0.11	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28406130	chr12:28236227~28236828:+
BRCA	cis	rs2638953	0.962	rs10506033	ENSG00000273989.1	RP11-425D17.2	-3.42	0.000661	0.031	-0.16	-0.11	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28415032	chr12:28236227~28236828:+
BRCA	cis	rs80130819	0.818	rs10783238	ENSG00000226413.2	OR8T1P	3.42	0.000661	0.031	0.19	0.11	Prostate cancer;	chr12:48210549	chr12:48442030~48442947:-
BRCA	cis	rs2694528	0.686	rs6864253	ENSG00000272308.1	RP11-231G3.1	-3.42	0.000661	0.031	-0.19	-0.11	Parkinson's disease;	chr5:60566916	chr5:60866457~60866935:-
BRCA	cis	rs4869313	0.694	rs2910787	ENSG00000248734.2	CTD-2260A17.1	-3.42	0.000661	0.031	-0.11	-0.11	Pediatric autoimmune diseases;	chr5:96938519	chr5:96784777~96785999:+
BRCA	cis	rs6142102	0.602	rs2268086	ENSG00000228265.4	RALY-AS1	3.42	0.000661	0.031	0.11	0.11	Skin pigmentation;	chr20:34060932	chr20:33983052~33994357:-
BRCA	cis	rs76206723	1	rs10234636	ENSG00000233225.3	AC004987.9	-3.42	0.000661	0.031	-0.17	-0.11	Pulse pressure;	chr7:40388018	chr7:39833571~39834718:+
BRCA	cis	rs7037266	0.963	rs7850286	ENSG00000232946.1	RP11-390F4.2	-3.42	0.000661	0.031	-0.13	-0.11	Menarche (age at onset);	chr9:6942877	chr9:6675284~6675614:+
BRCA	cis	rs7520050	0.966	rs11211208	ENSG00000226957.1	RP4-533D7.4	3.42	0.000661	0.031	0.11	0.11	Reticulocyte count;Red blood cell count;	chr1:45868584	chr1:46046818~46048368:+
BRCA	cis	rs613391	0.702	rs1448773	ENSG00000279670.1	RP11-70L8.5	-3.42	0.000661	0.031	-0.13	-0.11	Quantitative traits;	chr9:22705548	chr9:21892188~21893857:+
BRCA	cis	rs2148307	0.55	rs72785564	ENSG00000228339.1	AMD1P1	-3.42	0.000661	0.031	-0.14	-0.11	Photic sneeze reflex;	chr10:20805348	chr10:20350049~20351100:+
BRCA	cis	rs6708331	1	rs6708331	ENSG00000231024.1	AC092431.3	-3.42	0.000661	0.031	-0.14	-0.11	Obesity-related traits;	chr2:70141791	chr2:69700192~69713847:-
BRCA	cis	rs1466921	0.501	rs7164793	ENSG00000278603.1	RP13-608F4.5	3.42	0.000661	0.031	0.13	0.11	Left superior temporal gyrus thickness (schizophrenia interaction);	chr15:82076660	chr15:82472203~82472426:+
BRCA	cis	rs17711722	0.675	rs6947132	ENSG00000229180.5	GS1-124K5.11	-3.42	0.000661	0.031	-0.09	-0.11	Calcium levels;	chr7:65808508	chr7:66526088~66542624:-
BRCA	cis	rs1466788	1	rs1869596	ENSG00000224965.1	KCNC4-AS1	3.42	0.000661	0.031	0.12	0.11	Blood metabolite levels;	chr1:110081482	chr1:110208834~110209987:-
BRCA	cis	rs1046491	0.901	rs12968060	ENSG00000264964.1	RP11-888D10.3	3.42	0.000661	0.031	0.22	0.11	Scarlet fever;	chr18:9123947	chr18:9315194~9334441:-
BRCA	cis	rs4919669	0.719	rs11818043	ENSG00000213277.3	MARCKSL1P1	3.42	0.000661	0.031	0.17	0.11	Mean arterial pressure (long-term average);Systolic blood pressure (long-term average);	chr10:102631870	chr10:103175554~103176094:+
BRCA	cis	rs1165668	1	rs2583282	ENSG00000257681.1	RP11-341G23.4	-3.42	0.000661	0.031	-0.13	-0.11	Coronary heart disease (SNP X SNP interaction);	chr12:103919801	chr12:103746315~103768858:-
BRCA	cis	rs10129255	0.5	rs1024350	ENSG00000211976.2	IGHV3-73	-3.42	0.000661	0.031	-0.08	-0.11	Kawasaki disease;	chr14:106685105	chr14:106802694~106803233:-
BRCA	cis	rs911555	0.723	rs6575986	ENSG00000269940.1	RP11-73M18.7	3.42	0.000661	0.031	0.11	0.11	Intelligence (multi-trait analysis);	chr14:103420334	chr14:103694560~103695170:+
BRCA	cis	rs11874712	0.965	rs8083998	ENSG00000251939.1	RNU6-1278P	-3.42	0.000661	0.031	-0.11	-0.11	Migraine - clinic-based;	chr18:46093178	chr18:46121615~46121721:-
BRCA	cis	rs11874712	1	rs9945751	ENSG00000251939.1	RNU6-1278P	-3.42	0.000661	0.031	-0.11	-0.11	Migraine - clinic-based;	chr18:46093299	chr18:46121615~46121721:-
BRCA	cis	rs11874712	1	rs9945606	ENSG00000251939.1	RNU6-1278P	-3.42	0.000661	0.031	-0.11	-0.11	Migraine - clinic-based;	chr18:46093359	chr18:46121615~46121721:-
BRCA	cis	rs875971	0.862	rs11984115	ENSG00000106610.13	STAG3L4	3.42	0.000662	0.031	0.14	0.11	Aortic root size;	chr7:66308872	chr7:67302621~67321526:+
BRCA	cis	rs10129255	0.957	rs8009948	ENSG00000231475.3	IGHV4-31	-3.42	0.000662	0.031	-0.09	-0.11	Kawasaki disease;	chr14:106805607	chr14:106349283~106349792:-
BRCA	cis	rs17102884	0.506	rs887746	ENSG00000279594.1	RP11-950C14.10	-3.42	0.000662	0.031	-0.12	-0.11	Neuroticism;	chr14:74937114	chr14:75011269~75012851:-
BRCA	cis	rs9467773	1	rs2393670	ENSG00000224843.5	LINC00240	-3.42	0.000662	0.031	-0.12	-0.11	Intelligence (multi-trait analysis);	chr6:26535313	chr6:26956992~27023924:+
BRCA	cis	rs9467773	1	rs11756120	ENSG00000224843.5	LINC00240	-3.42	0.000662	0.0311	-0.12	-0.11	Intelligence (multi-trait analysis);	chr6:26529580	chr6:26956992~27023924:+
BRCA	cis	rs9467773	1	rs9393732	ENSG00000224843.5	LINC00240	-3.42	0.000662	0.0311	-0.12	-0.11	Intelligence (multi-trait analysis);	chr6:26530670	chr6:26956992~27023924:+
BRCA	cis	rs9467773	0.967	rs9358954	ENSG00000224843.5	LINC00240	-3.42	0.000662	0.0311	-0.12	-0.11	Intelligence (multi-trait analysis);	chr6:26530950	chr6:26956992~27023924:+
BRCA	cis	rs9467773	1	rs10946834	ENSG00000224843.5	LINC00240	-3.42	0.000662	0.0311	-0.12	-0.11	Intelligence (multi-trait analysis);	chr6:26533436	chr6:26956992~27023924:+
BRCA	cis	rs9467773	1	rs10946835	ENSG00000224843.5	LINC00240	-3.42	0.000662	0.0311	-0.12	-0.11	Intelligence (multi-trait analysis);	chr6:26533529	chr6:26956992~27023924:+
BRCA	cis	rs9467773	1	rs9467778	ENSG00000224843.5	LINC00240	-3.42	0.000662	0.0311	-0.12	-0.11	Intelligence (multi-trait analysis);	chr6:26534515	chr6:26956992~27023924:+
BRCA	cis	rs9467773	1	rs9393731	ENSG00000224843.5	LINC00240	-3.42	0.000662	0.0311	-0.12	-0.11	Intelligence (multi-trait analysis);	chr6:26529146	chr6:26956992~27023924:+
BRCA	cis	rs72775230	0.733	rs72775250	ENSG00000233990.1	RP11-401E9.3	-3.42	0.000662	0.0311	-0.18	-0.11	Conotruncal heart defects (inherited effects);	chr10:8521502	chr10:7833618~7833957:-
BRCA	cis	rs12949688	0.967	rs1990231	ENSG00000262623.1	RP5-1107A17.2	-3.42	0.000662	0.0311	-0.11	-0.11	Schizophrenia;	chr17:57743641	chr17:56951664~56952404:+
BRCA	cis	rs2625529	0.526	rs7179942	ENSG00000260037.4	CTD-2524L6.3	3.42	0.000662	0.0311	0.13	0.11	Red blood cell count;	chr15:72270733	chr15:71818396~71823384:+
BRCA	cis	rs11992186	0.597	rs77717027	ENSG00000233609.3	RP11-62H7.2	-3.42	0.000662	0.0311	-0.1	-0.11	Neuroticism;	chr8:8734122	chr8:8961200~8979025:+
BRCA	cis	rs7429990	0.965	rs4858881	ENSG00000199476.1	Y_RNA	3.42	0.000662	0.0311	0.14	0.11	Educational attainment (years of education);	chr3:48082306	chr3:48288587~48288694:+
BRCA	cis	rs7412746	0.611	rs12085336	ENSG00000231073.1	RP11-316M1.3	3.42	0.000662	0.0311	0.11	0.11	Melanoma;	chr1:150803304	chr1:150973123~150975534:+
BRCA	cis	rs11098499	0.562	rs13101722	ENSG00000249244.1	RP11-548H18.2	-3.42	0.000662	0.0311	-0.12	-0.11	Corneal astigmatism;	chr4:119634820	chr4:119391831~119395335:-
BRCA	cis	rs3893377	1	rs73224677	ENSG00000214846.4	RP11-115L11.1	3.42	0.000662	0.0311	0.15	0.11	Current cigarettes per day in chronic obstructive pulmonary disease;	chr4:15741834	chr4:15730962~15731627:-
BRCA	cis	rs9329221	0.868	rs7831557	ENSG00000255020.1	AF131216.5	3.42	0.000662	0.0311	0.13	0.11	Neuroticism;	chr8:10422718	chr8:11345748~11347502:-
BRCA	cis	rs79387448	0.745	rs7575867	ENSG00000234389.1	AC007278.3	3.42	0.000662	0.0311	0.14	0.11	Gut microbiota (bacterial taxa);	chr2:102503720	chr2:102438713~102440475:+
BRCA	cis	rs7697932	0.521	rs2866187	ENSG00000245322.5	RP11-15B17.1	3.42	0.000662	0.0311	0.13	0.11	Renal cell carcinoma;	chr4:100160466	chr4:99950006~100195099:+
BRCA	cis	rs863345	0.564	rs7515245	ENSG00000176320.2	RP11-404O13.5	-3.42	0.000662	0.0311	-0.11	-0.11	Pneumococcal bacteremia;	chr1:158524320	chr1:158197922~158203877:-
BRCA	cis	rs863345	0.604	rs10797022	ENSG00000176320.2	RP11-404O13.5	-3.42	0.000662	0.0311	-0.11	-0.11	Pneumococcal bacteremia;	chr1:158524403	chr1:158197922~158203877:-
BRCA	cis	rs853679	0.666	rs200956	ENSG00000219392.1	RP1-265C24.5	-3.42	0.000662	0.0311	-0.18	-0.11	Depression;	chr6:27871968	chr6:28115628~28116551:+
BRCA	cis	rs2839186	0.934	rs17176520	ENSG00000215424.8	MCM3AP-AS1	3.42	0.000662	0.0311	0.09	0.11	Testicular germ cell tumor;	chr21:46262167	chr21:46229217~46259390:+
BRCA	cis	rs7520050	0.966	rs9429183	ENSG00000234329.1	RP11-767N6.2	-3.41	0.000662	0.0311	-0.1	-0.11	Reticulocyte count;Red blood cell count;	chr1:46058910	chr1:45651039~45651826:-
BRCA	cis	rs10028773	0.515	rs9994488	ENSG00000249244.1	RP11-548H18.2	3.41	0.000662	0.0311	0.12	0.11	Educational attainment;	chr4:119666626	chr4:119391831~119395335:-
BRCA	cis	rs9457247	0.905	rs377232	ENSG00000227598.1	RP1-167A14.2	-3.41	0.000663	0.0311	-0.11	-0.11	Crohn's disease;	chr6:166996150	chr6:166969626~166999065:-
BRCA	cis	rs6741148	1	rs80339560	ENSG00000232973.10	CYP1B1-AS1	3.41	0.000663	0.0311	0.22	0.11	Erectile dysfunction and prostate cancer treatment;	chr2:38033805	chr2:38073447~38231651:+
BRCA	cis	rs9333290	0.93	rs11685758	ENSG00000259915.2	RP11-410E4.1	3.41	0.000663	0.0311	0.14	0.11	Urinary albumin-to-creatinine ratio in non-diabetics;Urinary albumin-to-creatinine ratio;	chr2:186668641	chr2:186354570~186356773:-
BRCA	cis	rs13315871	0.929	rs11130627	ENSG00000272182.1	RP11-802O23.3	3.41	0.000663	0.0311	0.21	0.11	Cholesterol, total;	chr3:58330022	chr3:58428255~58428815:+
BRCA	cis	rs931127	0.719	rs7949980	ENSG00000255557.1	RP11-770G2.2	3.41	0.000663	0.0311	0.12	0.11	Systemic lupus erythematosus;	chr11:65678479	chr11:65745729~65771585:+
BRCA	cis	rs10782582	0.593	rs11578480	ENSG00000181227.3	RP4-682C21.2	3.41	0.000663	0.0311	0.11	0.11	Daytime sleep phenotypes;	chr1:75743304	chr1:75743423~75744776:-
BRCA	cis	rs7804356	0.626	rs13234336	ENSG00000199085.2	MIR148A	3.41	0.000663	0.0311	0.13	0.11	Type 1 diabetes;	chr7:26738230	chr7:25949903~25950013:-
BRCA	cis	rs10129255	0.957	rs10137980	ENSG00000211967.3	IGHV3-53	-3.41	0.000663	0.0311	-0.07	-0.11	Kawasaki disease;	chr14:106775735	chr14:106592676~106593347:-
BRCA	cis	rs249954	0.512	rs249867	ENSG00000260136.4	CTD-2270L9.4	3.41	0.000663	0.0311	0.11	0.11	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr16:23657247	chr16:23452758~23457606:+
BRCA	cis	rs2288327	0.915	rs12614435	ENSG00000271011.1	RP11-171I2.5	3.41	0.000663	0.0311	0.18	0.11	Atrial fibrillation;	chr2:178624999	chr2:178577103~178577622:+
BRCA	cis	rs17228212	1	rs10152307	ENSG00000270964.1	RP11-502I4.3	-3.41	0.000663	0.0311	-0.14	-0.11	Coronary heart disease;	chr15:67152160	chr15:67541072~67542604:-
BRCA	cis	rs9959145	1	rs78543731	ENSG00000267199.1	RP11-861E21.2	3.41	0.000663	0.0311	0.18	0.11	Immune response to smallpox vaccine (IL-6);	chr18:12665565	chr18:12438890~12448205:+
BRCA	cis	rs4950322	0.518	rs11811023	ENSG00000227242.3	NBPF13P	3.41	0.000663	0.0311	0.13	0.11	Protein quantitative trait loci;	chr1:147109536	chr1:147021320~147124525:-
BRCA	cis	rs7824557	0.564	rs13260727	ENSG00000255020.1	AF131216.5	-3.41	0.000663	0.0311	-0.13	-0.11	Retinal vascular caliber;	chr8:11375351	chr8:11345748~11347502:-
BRCA	cis	rs4074961	0.509	rs4653300	ENSG00000233621.1	LINC01137	-3.41	0.000663	0.0311	-0.11	-0.11	Axial length;	chr1:37558453	chr1:37454879~37474411:-
BRCA	cis	rs889956	0.652	rs12615090	ENSG00000233251.6	AC007743.1	-3.41	0.000663	0.0311	-0.12	-0.11	Educational attainment;	chr2:57020196	chr2:56173534~56185770:-
BRCA	cis	rs74233809	1	rs12411886	ENSG00000236937.2	PTGES3P4	3.41	0.000663	0.0311	0.24	0.11	Birth weight;	chr10:102925542	chr10:102845595~102845950:+
BRCA	cis	rs11603691	1	rs518272	ENSG00000254662.1	RP11-872D17.4	-3.41	0.000663	0.0311	-0.23	-0.11	Low high density lipoprotein cholesterol levels;	chr11:57250083	chr11:57325603~57327958:+
BRCA	cis	rs6088580	0.634	rs6120650	ENSG00000269202.1	RP4-614O4.12	-3.41	0.000663	0.0311	-0.11	-0.11	Glomerular filtration rate (creatinine);	chr20:34452168	chr20:35201747~35203288:-
BRCA	cis	rs11098499	0.866	rs6847778	ENSG00000225892.3	RP11-384K6.2	3.41	0.000663	0.0311	0.1	0.11	Corneal astigmatism;	chr4:119372427	chr4:118632274~118634759:+
BRCA	cis	rs11671005	0.735	rs11667591	ENSG00000265272.2	RN7SL693P	3.41	0.000663	0.0311	0.15	0.11	Mean platelet volume;	chr19:58426270	chr19:58490797~58491075:+
BRCA	cis	rs1334894	0.901	rs12529688	ENSG00000187762.5	HSPE1P11	3.41	0.000663	0.0311	0.25	0.11	Coronary artery disease;	chr6:35545148	chr6:35023522~35023831:+
BRCA	cis	rs1009077	0.597	rs28378775	ENSG00000249244.1	RP11-548H18.2	-3.41	0.000663	0.0311	-0.14	-0.11	Endometriosis;	chr4:119761309	chr4:119391831~119395335:-
BRCA	cis	rs9400180	0.765	rs9386696	ENSG00000271734.1	RP1-111B22.3	-3.41	0.000663	0.0311	-0.14	-0.11	Major depressive disorder;	chr6:108030553	chr6:108030249~108030718:-
BRCA	cis	rs7308116	0.967	rs6539364	ENSG00000274395.1	RP11-554D14.8	-3.41	0.000663	0.0311	-0.12	-0.11	Pelvic organ prolapse (moderate/severe);	chr12:107807530	chr12:107835541~107836555:-
BRCA	cis	rs2599510	0.811	rs2243844	ENSG00000276517.1	AL133243.2	-3.41	0.000663	0.0311	-0.13	-0.11	Interleukin-18 levels;	chr2:32550917	chr2:32526504~32529507:+
BRCA	cis	rs17711722	0.64	rs13237956	ENSG00000229180.5	GS1-124K5.11	3.41	0.000663	0.0311	0.09	0.11	Calcium levels;	chr7:65853042	chr7:66526088~66542624:-
BRCA	cis	rs10875746	0.859	rs12305647	ENSG00000273765.1	RP11-370I10.11	-3.41	0.000663	0.0311	-0.14	-0.11	Longevity (90 years and older);	chr12:48189178	chr12:48360920~48361377:+
BRCA	cis	rs9527	0.615	rs10883810	ENSG00000236937.2	PTGES3P4	3.41	0.000663	0.0311	0.14	0.11	Arsenic metabolism;	chr10:102967467	chr10:102845595~102845950:+
BRCA	cis	rs9527	0.615	rs10883811	ENSG00000236937.2	PTGES3P4	3.41	0.000663	0.0311	0.14	0.11	Arsenic metabolism;	chr10:102967522	chr10:102845595~102845950:+
BRCA	cis	rs984222	0.967	rs1409157	ENSG00000231365.4	RP11-418J17.1	-3.41	0.000664	0.0311	-0.12	-0.11	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:118961864	chr1:119140396~119275973:+
BRCA	cis	rs7487075	0.619	rs12832777	ENSG00000257261.4	RP11-96H19.1	3.41	0.000664	0.0311	0.13	0.11	Itch intensity from mosquito bite;	chr12:46437346	chr12:46383679~46876159:+
BRCA	cis	rs2882667	0.654	rs884469	ENSG00000242683.1	CTB-46B19.1	-3.41	0.000664	0.0311	-0.12	-0.11	Age-related hearing impairment (SNP x SNP interaction);	chr5:138820270	chr5:139035148~139035987:-
BRCA	cis	rs77741769	0.571	rs3883901	ENSG00000277423.1	RP11-173P15.9	-3.41	0.000664	0.0311	-0.12	-0.11	Mean corpuscular volume;	chr12:120818717	chr12:120703867~120704282:+
BRCA	cis	rs11239930	0.56	rs632334	ENSG00000227242.3	NBPF13P	-3.41	0.000664	0.0311	-0.13	-0.11	AIDS progression;	chr1:147079972	chr1:147021320~147124525:-
BRCA	cis	rs6692729	0.966	rs6674701	ENSG00000242861.1	RP11-285F7.2	3.41	0.000664	0.0311	0.1	0.11	Electrodermal activity;	chr1:226819481	chr1:225840883~225846522:-
BRCA	cis	rs7131987	0.903	rs7970390	ENSG00000257599.1	OVCH1-AS1	-3.41	0.000664	0.0311	-0.13	-0.11	QT interval;	chr12:29245722	chr12:29389294~29487488:+
BRCA	cis	rs703108	0.752	rs4437938	ENSG00000279623.1	RP11-399C16.3	3.41	0.000664	0.0311	0.16	0.11	Monocyte percentage of white cells;	chr10:22052492	chr10:21865335~21865921:-
BRCA	cis	rs6840360	0.55	rs12651635	ENSG00000270265.1	RP11-731D1.4	-3.41	0.000664	0.0311	-0.13	-0.11	Intelligence (multi-trait analysis);	chr4:151636634	chr4:151333775~151353224:-
BRCA	cis	rs875971	0.522	rs2008188	ENSG00000229180.5	GS1-124K5.11	3.41	0.000664	0.0311	0.09	0.11	Aortic root size;	chr7:65964026	chr7:66526088~66542624:-
BRCA	cis	rs1250259	0.519	rs2372544	ENSG00000225166.1	AC012462.2	-3.41	0.000664	0.0311	-0.13	-0.11	Coronary artery disease;Pulse pressure;	chr2:215399547	chr2:215453707~215463871:+
BRCA	cis	rs530081	0.531	rs580924	ENSG00000257267.2	ZNF271P	3.41	0.000664	0.0311	0.12	0.11	Lobe attachment (rater-scored or self-reported);	chr18:35188820	chr18:35290282~35310766:+
BRCA	cis	rs490234	0.841	rs477813	ENSG00000232630.1	PRPS1P2	3.41	0.000664	0.0311	0.1	0.11	Mean arterial pressure;	chr9:125654595	chr9:125150653~125151589:+
BRCA	cis	rs59721556	0.918	rs17825235	ENSG00000258917.1	ZMYND19P1	3.41	0.000664	0.0311	0.15	0.11	Response to paliperidone in schizophrenia (Multivariate);Response to paliperidone in schizophrenia (CGI-S score);Response to paliperidone in schizophrenia (PANSS score);Red cell distribution width;Response to paliperidone in schizophrenia (positive Marder score);	chr14:77652957	chr14:77696591~77697377:+
BRCA	cis	rs59721556	0.918	rs76264090	ENSG00000258917.1	ZMYND19P1	3.41	0.000664	0.0311	0.15	0.11	Response to paliperidone in schizophrenia (Multivariate);Response to paliperidone in schizophrenia (CGI-S score);Response to paliperidone in schizophrenia (PANSS score);Red cell distribution width;Response to paliperidone in schizophrenia (positive Marder score);	chr14:77652964	chr14:77696591~77697377:+
BRCA	cis	rs17684571	0.872	rs34587484	ENSG00000231441.1	RP11-472M19.2	3.41	0.000664	0.0311	0.18	0.11	Schizophrenia;	chr6:56742926	chr6:56844002~56864078:+
BRCA	cis	rs17684571	0.872	rs34465210	ENSG00000231441.1	RP11-472M19.2	3.41	0.000664	0.0311	0.18	0.11	Schizophrenia;	chr6:56742930	chr6:56844002~56864078:+
BRCA	cis	rs12681366	0.734	rs4735288	ENSG00000253175.1	RP11-267M23.6	3.41	0.000664	0.0311	0.12	0.11	Nonsyndromic cleft lip with cleft palate;	chr8:94354316	chr8:94565036~94565715:+
BRCA	cis	rs62458065	0.85	rs10273165	ENSG00000281332.1	LINC00997	-3.41	0.000664	0.0311	-0.16	-0.11	Metabolite levels (HVA/MHPG ratio);	chr7:32421228	chr7:32760279~32762924:+
BRCA	cis	rs16852403	0.548	rs7547504	ENSG00000224687.1	RASAL2-AS1	3.41	0.000664	0.0311	0.13	0.11	Childhood ear infection;	chr1:178232177	chr1:178091508~178093984:-
BRCA	cis	rs16852403	0.548	rs3748788	ENSG00000224687.1	RASAL2-AS1	3.41	0.000664	0.0311	0.13	0.11	Childhood ear infection;	chr1:178233672	chr1:178091508~178093984:-
BRCA	cis	rs10883723	0.737	rs11191312	ENSG00000213061.2	PFN1P11	-3.41	0.000664	0.0311	-0.16	-0.11	Allergic disease (asthma, hay fever or eczema);	chr10:102518844	chr10:102838011~102845473:-
BRCA	cis	rs3808502	0.516	rs6983727	ENSG00000255020.1	AF131216.5	-3.41	0.000664	0.0311	-0.13	-0.11	Neuroticism;	chr8:11558303	chr8:11345748~11347502:-
BRCA	cis	rs7632954	0.935	rs6770049	ENSG00000227110.5	LMCD1-AS1	3.41	0.000664	0.0311	0.12	0.11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr3:8480702	chr3:7952805~8611924:-
BRCA	cis	rs79387448	0.505	rs17027327	ENSG00000234389.1	AC007278.3	3.41	0.000664	0.0311	0.14	0.11	Gut microbiota (bacterial taxa);	chr2:102506054	chr2:102438713~102440475:+
BRCA	cis	rs3924048	0.559	rs6541039	ENSG00000221340.1	RNU6ATAC18P	3.41	0.000664	0.0312	0.13	0.11	Optic cup area;	chr1:12566232	chr1:12569972~12570072:-
BRCA	cis	rs1383484	0.761	rs11259923	ENSG00000230373.7	GOLGA6L5P	-3.41	0.000664	0.0312	-0.13	-0.11	Height;	chr15:83866952	chr15:84507885~84516814:-
BRCA	cis	rs13353361	0.702	rs17036138	ENSG00000279254.1	RP11-536C12.1	3.41	0.000664	0.0312	0.24	0.11	Initial pursuit acceleration;	chr2:47025725	chr2:46668870~46670778:+
BRCA	cis	rs9341808	0.519	rs660888	ENSG00000233967.5	RP11-250B2.3	3.41	0.000664	0.0312	0.11	0.11	Sitting height ratio;	chr6:80273495	chr6:80443344~80465927:+
BRCA	cis	rs6754311	0.517	rs60453613	ENSG00000231890.6	DARS-AS1	-3.41	0.000664	0.0312	-0.15	-0.11	Mosquito bite size;	chr2:135769550	chr2:135985176~136022593:+
BRCA	cis	rs4243971	0.516	rs4575791	ENSG00000277692.1	RP11-358N2.2	-3.41	0.000664	0.0312	-0.12	-0.11	Inflammatory bowel disease;Crohn's disease;	chr20:32388501	chr20:32355053~32355734:+
BRCA	cis	rs2562456	0.917	rs2681392	ENSG00000240522.1	RPL7AP10	3.41	0.000664	0.0312	0.12	0.11	Pain;	chr19:21513185	chr19:21149648~21150438:-
BRCA	cis	rs9378796	0.518	rs13213207	ENSG00000272248.1	RP3-406P24.4	-3.41	0.000665	0.0312	-0.17	-0.11	Mean platelet volume;	chr6:3438831	chr6:4018713~4019202:+
BRCA	cis	rs721917	0.525	rs10788338	ENSG00000280355.1	RP11-119F19.5	-3.41	0.000665	0.0312	-0.11	-0.11	Chronic obstructive pulmonary disease;	chr10:79973266	chr10:79681973~79684094:-
BRCA	cis	rs9527	0.59	rs7894959	ENSG00000236937.2	PTGES3P4	3.41	0.000665	0.0312	0.14	0.11	Arsenic metabolism;	chr10:102996425	chr10:102845595~102845950:+
BRCA	cis	rs1348850	0.914	rs7591807	ENSG00000271825.1	RP11-337N6.2	3.41	0.000665	0.0312	0.13	0.11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177388258	chr2:177300600~177302006:+
BRCA	cis	rs875971	0.965	rs7794930	ENSG00000271064.1	RP11-792A8.3	3.41	0.000665	0.0312	0.12	0.11	Aortic root size;	chr7:66313559	chr7:66748838~66749077:-
BRCA	cis	rs854765	0.52	rs9899355	ENSG00000154874.13	CCDC144B	-3.41	0.000665	0.0312	-0.13	-0.11	Total body bone mineral density;	chr17:17994929	chr17:18537800~18625617:-
BRCA	cis	rs9307551	0.741	rs4101007	ENSG00000250334.4	LINC00989	-3.41	0.000665	0.0312	-0.17	-0.11	Refractive error;	chr4:79490540	chr4:79492416~79576460:+
BRCA	cis	rs9307551	0.741	rs880988	ENSG00000250334.4	LINC00989	-3.41	0.000665	0.0312	-0.17	-0.11	Refractive error;	chr4:79494318	chr4:79492416~79576460:+
BRCA	cis	rs40067	0.908	rs288161	ENSG00000272523.1	LINC01023	3.41	0.000665	0.0312	0.12	0.11	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr5:108027853	chr5:108727825~108728260:-
BRCA	cis	rs4415084	0.804	rs9292913	ENSG00000248779.1	RP11-53O19.2	-3.41	0.000665	0.0312	-0.1	-0.11	Breast cancer;	chr5:44870777	chr5:44752949~44765744:+
BRCA	cis	rs875971	0.83	rs4718358	ENSG00000230189.5	GS1-124K5.2	3.41	0.000665	0.0312	0.08	0.11	Aortic root size;	chr7:66508681	chr7:66409143~66490059:-
BRCA	cis	rs4650994	0.593	rs12568310	ENSG00000213057.5	C1orf220	-3.41	0.000665	0.0312	-0.1	-0.11	HDL cholesterol;HDL cholesterol levels;	chr1:178545487	chr1:178542752~178548889:+
BRCA	cis	rs1015362	0.54	rs2050209	ENSG00000275784.1	RP5-1125A11.6	3.41	0.000665	0.0312	0.14	0.11	Freckles;Red vs. non-red hair color;Skin sensitivity to sun;Burning and freckling;	chr20:33897730	chr20:33989480~33991818:-
BRCA	cis	rs10266483	0.96	rs679883	ENSG00000271550.1	BNIP3P11	-3.41	0.000665	0.0312	-0.13	-0.11	Response to statin therapy;	chr7:64289990	chr7:64678954~64687393:-
BRCA	cis	rs979233	0.935	rs33956936	ENSG00000188850.9	RP11-159F24.2	3.41	0.000665	0.0312	0.12	0.11	Systemic lupus erythematosus;	chr5:42521617	chr5:43336164~43348716:+
BRCA	cis	rs2694917	0.68	rs1043011	ENSG00000257576.1	RP11-153M3.1	3.41	0.000665	0.0312	0.17	0.11	Blood metabolite ratios;	chr12:56471256	chr12:56511002~56512703:+
BRCA	cis	rs12480328	1	rs73909842	ENSG00000228663.1	PSMD10P1	3.41	0.000665	0.0312	0.19	0.11	Prostate cancer;	chr20:50934277	chr20:50913731~50914411:+
BRCA	cis	rs7578361	0.918	rs7369134	ENSG00000231969.1	AC144449.1	-3.41	0.000665	0.0312	-0.16	-0.11	Acute lymphoblastic leukemia (childhood);	chr2:149516740	chr2:149587196~149848233:+
BRCA	cis	rs6490294	0.528	rs12580175	ENSG00000257624.1	RP1-128M12.3	3.41	0.000665	0.0312	0.19	0.11	Mean platelet volume;	chr12:111926708	chr12:112000739~112000985:-
BRCA	cis	rs6490294	0.528	rs61012856	ENSG00000257624.1	RP1-128M12.3	3.41	0.000665	0.0312	0.19	0.11	Mean platelet volume;	chr12:111927687	chr12:112000739~112000985:-
BRCA	cis	rs6490294	0.528	rs59131168	ENSG00000257624.1	RP1-128M12.3	3.41	0.000665	0.0312	0.19	0.11	Mean platelet volume;	chr12:111930559	chr12:112000739~112000985:-
BRCA	cis	rs1348850	0.914	rs1453370	ENSG00000271825.1	RP11-337N6.2	3.41	0.000665	0.0312	0.14	0.11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177462999	chr2:177300600~177302006:+
BRCA	cis	rs2342371	0.756	rs3973	ENSG00000273013.1	CTD-2002J20.1	3.41	0.000665	0.0312	0.15	0.11	Fat distribution (HIV);	chr3:196397407	chr3:196474801~196475394:+
BRCA	cis	rs12681366	0.663	rs2919662	ENSG00000253175.1	RP11-267M23.6	3.41	0.000665	0.0312	0.12	0.11	Nonsyndromic cleft lip with cleft palate;	chr8:94458044	chr8:94565036~94565715:+
BRCA	cis	rs12681366	0.663	rs2919660	ENSG00000253175.1	RP11-267M23.6	3.41	0.000665	0.0312	0.12	0.11	Nonsyndromic cleft lip with cleft palate;	chr8:94458469	chr8:94565036~94565715:+
BRCA	cis	rs12681366	0.663	rs1561648	ENSG00000253175.1	RP11-267M23.6	3.41	0.000665	0.0312	0.12	0.11	Nonsyndromic cleft lip with cleft palate;	chr8:94462209	chr8:94565036~94565715:+
BRCA	cis	rs7618501	1	rs7372725	ENSG00000228008.1	CTD-2330K9.3	-3.41	0.000665	0.0312	-0.1	-0.11	Intelligence (multi-trait analysis);	chr3:49753111	chr3:49903845~49916937:+
BRCA	cis	rs875971	0.965	rs9969301	ENSG00000272831.1	RP11-792A8.4	-3.41	0.000665	0.0312	-0.09	-0.11	Aortic root size;	chr7:66316668	chr7:66739829~66740385:-
BRCA	cis	rs6121246	0.609	rs2377317	ENSG00000230613.1	HM13-AS1	-3.41	0.000665	0.0312	-0.14	-0.11	Mean corpuscular hemoglobin;	chr20:31814699	chr20:31567707~31573263:-
BRCA	cis	rs73201462	0.808	rs34689870	ENSG00000242551.2	POU5F1P6	3.41	0.000665	0.0312	0.18	0.11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128141636	chr3:128674735~128677005:-
BRCA	cis	rs73201462	1	rs34817706	ENSG00000242551.2	POU5F1P6	3.41	0.000665	0.0312	0.18	0.11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128142215	chr3:128674735~128677005:-
BRCA	cis	rs6800225	1	rs6800225	ENSG00000242551.2	POU5F1P6	3.41	0.000665	0.0312	0.18	0.11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128143335	chr3:128674735~128677005:-
BRCA	cis	rs7911264	0.703	rs7894183	ENSG00000232709.1	MARK2P9	-3.41	0.000665	0.0312	-0.13	-0.11	Inflammatory bowel disease;	chr10:92622283	chr10:92418667~92420875:+
BRCA	cis	rs2562456	0.793	rs7259708	ENSG00000268705.1	BNIP3P26	3.41	0.000666	0.0312	0.12	0.11	Pain;	chr19:21567846	chr19:21521343~21521896:-
BRCA	cis	rs6142102	0.961	rs6119447	ENSG00000206582.1	Y_RNA	-3.41	0.000666	0.0312	-0.12	-0.11	Skin pigmentation;	chr20:34080770	chr20:34526510~34526606:-
BRCA	cis	rs4703129	0.967	rs13166458	ENSG00000246763.5	RGMB-AS1	-3.41	0.000666	0.0312	-0.12	-0.11	Asperger disorder;	chr5:98558262	chr5:98769618~98773469:-
BRCA	cis	rs62025270	0.593	rs7166540	ENSG00000259367.1	RP11-815J21.4	3.41	0.000666	0.0312	0.1	0.11	Idiopathic pulmonary fibrosis;	chr15:85700854	chr15:85619623~85670948:-
BRCA	cis	rs7637230	0.945	rs7652038	ENSG00000244119.1	PDCL3P4	-3.41	0.000666	0.0312	-0.11	-0.11	Psoriasis vulgaris;Psoriasis;	chr3:101894589	chr3:101712472~101713191:+
BRCA	cis	rs3749237	1	rs2291542	ENSG00000225399.4	RP11-3B7.1	3.41	0.000666	0.0312	0.1	0.11	Resting heart rate;	chr3:49714152	chr3:49260085~49261316:+
BRCA	cis	rs875971	0.545	rs73136346	ENSG00000226767.1	RP11-328P23.3	-3.41	0.000666	0.0312	-0.13	-0.11	Aortic root size;	chr7:66101095	chr7:65508773~65508944:-
BRCA	cis	rs801193	0.935	rs11772264	ENSG00000275400.1	RP4-756H11.5	-3.41	0.000666	0.0312	-0.12	-0.11	Aortic root size;	chr7:66711400	chr7:66553805~66554199:-
BRCA	cis	rs7620503	1	rs7645281	ENSG00000228561.2	RP11-114M1.1	3.41	0.000666	0.0312	0.12	0.11	Corneal structure;	chr3:177587048	chr3:177683627~177691250:+
BRCA	cis	rs27434	0.561	rs151910	ENSG00000248734.2	CTD-2260A17.1	3.41	0.000666	0.0312	0.12	0.11	Ankylosing spondylitis;	chr5:96821253	chr5:96784777~96785999:+
BRCA	cis	rs34792	0.76	rs153808	ENSG00000263065.1	AF001548.6	3.41	0.000666	0.0312	0.13	0.11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15464485	chr16:15741151~15741791:+
BRCA	cis	rs2882667	0.69	rs13158360	ENSG00000242683.1	CTB-46B19.1	3.41	0.000666	0.0312	0.12	0.11	Age-related hearing impairment (SNP x SNP interaction);	chr5:138922488	chr5:139035148~139035987:-
BRCA	cis	rs6142102	1	rs2378078	ENSG00000206582.1	Y_RNA	-3.41	0.000666	0.0312	-0.13	-0.11	Skin pigmentation;	chr20:34126922	chr20:34526510~34526606:-
BRCA	cis	rs7103648	0.669	rs10437655	ENSG00000280615.1	Y_RNA	3.41	0.000666	0.0312	0.12	0.11	Systolic blood pressure;Diastolic blood pressure;	chr11:47370397	chr11:47614898~47614994:-
BRCA	cis	rs78587638	0.79	rs74813157	ENSG00000226856.4	AC093901.1	-3.41	0.000666	0.0312	-0.18	-0.11	Mosquito bite size;	chr2:118423459	chr2:118132128~118186386:-
BRCA	cis	rs7259811	0.501	rs10411649	ENSG00000268266.1	AC003005.2	-3.41	0.000666	0.0312	-0.13	-0.11	Western dietary pattern;	chr19:56712107	chr19:57477649~57482996:+
BRCA	cis	rs4927850	0.958	rs1975582	ENSG00000185485.13	SDHAP1	3.41	0.000666	0.0312	0.11	0.11	Pancreatic cancer;	chr3:196024568	chr3:195959748~195990318:-
BRCA	cis	rs72928364	0.929	rs13074729	ENSG00000256628.3	ZBTB11-AS1	3.41	0.000666	0.0312	0.19	0.11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:101046740	chr3:101676475~101679217:+
BRCA	cis	rs74233809	1	rs12413046	ENSG00000213061.2	PFN1P11	3.41	0.000666	0.0312	0.24	0.11	Birth weight;	chr10:103111447	chr10:102838011~102845473:-
BRCA	cis	rs74233809	1	rs10883832	ENSG00000213061.2	PFN1P11	3.41	0.000666	0.0312	0.24	0.11	Birth weight;	chr10:103111522	chr10:102838011~102845473:-
BRCA	cis	rs6088590	1	rs28542147	ENSG00000276073.1	RP5-1125A11.7	-3.41	0.000666	0.0312	-0.12	-0.11	Coronary artery disease;	chr20:34788520	chr20:33985617~33988989:-
BRCA	cis	rs8073060	0.963	rs11080353	ENSG00000267554.1	RP11-686D22.10	3.41	0.000667	0.0312	0.09	0.11	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35544262	chr17:35470069~35470628:-
BRCA	cis	rs2625529	0.652	rs2957734	ENSG00000261187.1	RP11-1007O24.2	3.41	0.000667	0.0312	0.11	0.11	Red blood cell count;	chr15:71969044	chr15:72465128~72466262:-
BRCA	cis	rs7520050	0.931	rs11211198	ENSG00000281133.1	AL355480.3	3.41	0.000667	0.0312	0.12	0.11	Reticulocyte count;Red blood cell count;	chr1:45817001	chr1:45580892~45580996:-
BRCA	cis	rs7520050	0.966	rs10890352	ENSG00000281133.1	AL355480.3	3.41	0.000667	0.0312	0.12	0.11	Reticulocyte count;Red blood cell count;	chr1:45817956	chr1:45580892~45580996:-
BRCA	cis	rs7520050	0.966	rs6700597	ENSG00000281133.1	AL355480.3	3.41	0.000667	0.0312	0.12	0.11	Reticulocyte count;Red blood cell count;	chr1:45818574	chr1:45580892~45580996:-
BRCA	cis	rs2412819	0.571	rs495880	ENSG00000201136.1	RNU6-353P	-3.41	0.000667	0.0312	-0.15	-0.11	Lung cancer;	chr15:43855067	chr15:43702363~43702470:+
BRCA	cis	rs10460009	1	rs10460009	ENSG00000263606.1	RP11-737O24.3	-3.41	0.000667	0.0312	-0.19	-0.11	Type 2 diabetes;	chr18:2948031	chr18:2945550~2946890:-
BRCA	cis	rs7787531	0.908	rs613068	ENSG00000281896.1	RP11-274B21.13	-3.41	0.000667	0.0312	-0.1	-0.11	Tuberculosis;	chr7:129488881	chr7:128617865~128625905:+
BRCA	cis	rs1466788	0.932	rs12137237	ENSG00000224965.1	KCNC4-AS1	3.41	0.000667	0.0312	0.12	0.11	Blood metabolite levels;	chr1:110078395	chr1:110208834~110209987:-
BRCA	cis	rs1075265	0.84	rs2884254	ENSG00000272156.1	RP11-477N3.1	-3.41	0.000667	0.0312	-0.11	-0.11	Chronotype;Morning vs. evening chronotype;	chr2:53979326	chr2:54082554~54085066:+
BRCA	cis	rs10843647	0.904	rs12831025	ENSG00000245614.3	DDX11-AS1	-3.41	0.000667	0.0312	-0.12	-0.11	Glucose homeostasis traits;	chr12:30183434	chr12:31020763~31073847:-
BRCA	cis	rs11098499	0.954	rs3733524	ENSG00000225892.3	RP11-384K6.2	3.41	0.000667	0.0312	0.11	0.11	Corneal astigmatism;	chr4:119502574	chr4:118632274~118634759:+
BRCA	cis	rs875622	0.556	rs4808047	ENSG00000280332.1	CTD-2013N17.6	-3.41	0.000667	0.0312	-0.11	-0.11	White matter integrity;Neutrophil percentage of white cells;	chr19:16417023	chr19:16356329~16358327:-
BRCA	cis	rs9467773	1	rs9467782	ENSG00000261353.1	CTA-14H9.5	-3.41	0.000667	0.0313	-0.11	-0.11	Intelligence (multi-trait analysis);	chr6:26542545	chr6:26527063~26527404:+
BRCA	cis	rs7017914	1	rs13253842	ENSG00000246366.5	RP11-382J12.1	3.41	0.000667	0.0313	0.11	0.11	Bone mineral density;	chr8:70713268	chr8:70608577~70663279:+
BRCA	cis	rs7017914	0.967	rs13254908	ENSG00000246366.5	RP11-382J12.1	3.41	0.000667	0.0313	0.11	0.11	Bone mineral density;	chr8:70713863	chr8:70608577~70663279:+
BRCA	cis	rs7017914	0.967	rs13264669	ENSG00000246366.5	RP11-382J12.1	3.41	0.000667	0.0313	0.11	0.11	Bone mineral density;	chr8:70714537	chr8:70608577~70663279:+
BRCA	cis	rs7017914	0.967	rs34508469	ENSG00000246366.5	RP11-382J12.1	3.41	0.000667	0.0313	0.11	0.11	Bone mineral density;	chr8:70716228	chr8:70608577~70663279:+
BRCA	cis	rs7017914	0.934	rs56043721	ENSG00000246366.5	RP11-382J12.1	3.41	0.000667	0.0313	0.11	0.11	Bone mineral density;	chr8:70718192	chr8:70608577~70663279:+
BRCA	cis	rs11671005	0.779	rs3794970	ENSG00000265272.2	RN7SL693P	-3.41	0.000667	0.0313	-0.16	-0.11	Mean platelet volume;	chr19:58474893	chr19:58490797~58491075:+
BRCA	cis	rs9341808	0.718	rs12203867	ENSG00000279022.1	RP11-250B2.4	3.41	0.000667	0.0313	0.12	0.11	Sitting height ratio;	chr6:80111116	chr6:80440730~80441172:+
BRCA	cis	rs4869313	0.502	rs1230381	ENSG00000248734.2	CTD-2260A17.1	3.41	0.000667	0.0313	0.11	0.11	Pediatric autoimmune diseases;	chr5:96918505	chr5:96784777~96785999:+
BRCA	cis	rs11874712	1	rs8089150	ENSG00000251939.1	RNU6-1278P	-3.41	0.000667	0.0313	-0.11	-0.11	Migraine - clinic-based;	chr18:46094334	chr18:46121615~46121721:-
BRCA	cis	rs11874712	1	rs28699609	ENSG00000251939.1	RNU6-1278P	-3.41	0.000667	0.0313	-0.11	-0.11	Migraine - clinic-based;	chr18:46094913	chr18:46121615~46121721:-
BRCA	cis	rs11874712	1	rs7244950	ENSG00000251939.1	RNU6-1278P	-3.41	0.000667	0.0313	-0.11	-0.11	Migraine - clinic-based;	chr18:46096557	chr18:46121615~46121721:-
BRCA	cis	rs2562456	0.755	rs1879234	ENSG00000268705.1	BNIP3P26	-3.41	0.000667	0.0313	-0.12	-0.11	Pain;	chr19:21521677	chr19:21521343~21521896:-
BRCA	cis	rs10875943	0.751	rs11168962	ENSG00000258101.2	RP11-977B10.2	3.41	0.000667	0.0313	0.14	0.11	Prostate cancer;	chr12:49278956	chr12:49232790~49264756:-
BRCA	cis	rs3755605	0.728	rs10936614	ENSG00000242578.1	RP11-469J4.3	-3.41	0.000667	0.0313	-0.12	-0.11	Testicular germ cell tumor;	chr3:170162296	chr3:170410512~170418615:+
BRCA	cis	rs3764021	0.509	rs10772071	ENSG00000256594.6	RP11-705C15.2	3.41	0.000667	0.0313	0.14	0.11	Type 1 diabetes;	chr12:9717324	chr12:9633419~9658412:+
BRCA	cis	rs875971	0.862	rs7786892	ENSG00000223473.2	GS1-124K5.3	-3.41	0.000667	0.0313	-0.08	-0.11	Aortic root size;	chr7:66163889	chr7:66491049~66493566:-
BRCA	cis	rs12282928	0.921	rs7479951	ENSG00000255197.4	RP11-750H9.5	3.41	0.000667	0.0313	0.1	0.11	Migraine - clinic-based;	chr11:48273956	chr11:47383148~47409190:-
BRCA	cis	rs7267979	0.899	rs2179459	ENSG00000274973.1	RP13-401N8.7	-3.41	0.000667	0.0313	-0.12	-0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25475505	chr20:25845497~25845862:+
BRCA	cis	rs853679	0.882	rs9461432	ENSG00000219392.1	RP1-265C24.5	-3.41	0.000667	0.0313	-0.22	-0.11	Depression;	chr6:28119105	chr6:28115628~28116551:+
BRCA	cis	rs13401620	0.843	rs13401264	ENSG00000229326.3	AC069154.4	-3.41	0.000667	0.0313	-0.14	-0.11	Breast size;	chr2:119761756	chr2:119698623~119700151:+
BRCA	cis	rs9847710	0.67	rs36051354	ENSG00000242849.2	ALDOAP1	3.41	0.000667	0.0313	0.13	0.11	Ulcerative colitis;	chr3:52951996	chr3:52193170~52194785:+
BRCA	cis	rs2842992	0.724	rs15982	ENSG00000207392.1	SNORA20	-3.41	0.000667	0.0313	-0.13	-0.11	Age-related macular degeneration (geographic atrophy);	chr6:159778655	chr6:159780250~159780381:-
BRCA	cis	rs2262909	1	rs2078089	ENSG00000279377.1	AC003973.3	3.41	0.000668	0.0313	0.15	0.11	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;	chr19:22026951	chr19:21965708~21968529:-
BRCA	cis	rs13108904	0.557	rs1680033	ENSG00000196810.4	CTBP1-AS2	-3.41	0.000668	0.0313	-0.13	-0.11	Obesity-related traits;	chr4:1249616	chr4:1249300~1288291:+
BRCA	cis	rs11035577	0.632	rs10837249	ENSG00000279675.1	RP11-454H19.2	-3.41	0.000668	0.0313	-0.16	-0.11	Temperament (bipolar disorder);	chr11:39761926	chr11:40107244~40112599:-
BRCA	cis	rs11035577	0.57	rs10837250	ENSG00000279675.1	RP11-454H19.2	-3.41	0.000668	0.0313	-0.16	-0.11	Temperament (bipolar disorder);	chr11:39761936	chr11:40107244~40112599:-
BRCA	cis	rs11035577	0.632	rs10837251	ENSG00000279675.1	RP11-454H19.2	-3.41	0.000668	0.0313	-0.16	-0.11	Temperament (bipolar disorder);	chr11:39761938	chr11:40107244~40112599:-
BRCA	cis	rs7808935	0.589	rs38517	ENSG00000234336.5	JAZF1-AS1	-3.41	0.000668	0.0313	-0.16	-0.11	Prostate cancer;	chr7:27990867	chr7:28180322~28243917:+
BRCA	cis	rs801193	0.66	rs1962050	ENSG00000230358.3	RP11-166O4.1	3.41	0.000668	0.0313	0.13	0.11	Aortic root size;	chr7:66775021	chr7:67279778~67286230:+
BRCA	cis	rs4950322	0.563	rs6700783	ENSG00000230832.3	RP11-325P15.2	-3.41	0.000668	0.0313	-0.16	-0.11	Protein quantitative trait loci;	chr1:147111987	chr1:147082338~147083578:-
BRCA	cis	rs1799949	1	rs8070085	ENSG00000188825.12	LINC00910	3.41	0.000668	0.0313	0.1	0.11	Menopause (age at onset);	chr17:43189967	chr17:43369845~43389199:-
BRCA	cis	rs27434	0.583	rs28129	ENSG00000248734.2	CTD-2260A17.1	3.41	0.000668	0.0313	0.12	0.11	Ankylosing spondylitis;	chr5:96819815	chr5:96784777~96785999:+
BRCA	cis	rs27434	0.583	rs468130	ENSG00000248734.2	CTD-2260A17.1	3.41	0.000668	0.0313	0.12	0.11	Ankylosing spondylitis;	chr5:96820326	chr5:96784777~96785999:+
BRCA	cis	rs3825942	0.568	rs9944214	ENSG00000261801.4	LOXL1-AS1	3.41	0.000668	0.0313	0.12	0.11	Glaucoma (exfoliation);	chr15:73939516	chr15:73908071~73928248:-
BRCA	cis	rs921968	0.643	rs2278530	ENSG00000273466.1	RP11-548H3.1	3.41	0.000668	0.0313	0.11	0.11	Mean corpuscular hemoglobin concentration;	chr2:218636410	chr2:218633256~218634014:-
BRCA	cis	rs2835872	0.965	rs1787331	ENSG00000228677.1	TTC3-AS1	3.41	0.000668	0.0313	0.13	0.11	Electroencephalographic traits in alcoholism;	chr21:37631223	chr21:37187666~37193926:-
BRCA	cis	rs875971	0.558	rs4433015	ENSG00000232559.3	GS1-124K5.12	-3.41	0.000668	0.0313	-0.12	-0.11	Aortic root size;	chr7:66174736	chr7:66554588~66576923:-
BRCA	cis	rs7701440	0.512	rs2055375	ENSG00000272308.1	RP11-231G3.1	3.41	0.000668	0.0313	0.12	0.11	Educational attainment;	chr5:61235393	chr5:60866457~60866935:-
BRCA	cis	rs977987	0.778	rs4888413	ENSG00000261476.1	RP11-77K12.3	-3.41	0.000668	0.0313	-0.11	-0.11	Dupuytren's disease;	chr16:75409325	chr16:75458252~75460017:-
BRCA	cis	rs977987	0.778	rs8057849	ENSG00000261476.1	RP11-77K12.3	-3.41	0.000668	0.0313	-0.11	-0.11	Dupuytren's disease;	chr16:75409918	chr16:75458252~75460017:-
BRCA	cis	rs7188697	0.848	rs40187	ENSG00000276259.1	RP11-481J2.4	-3.41	0.000668	0.0313	-0.12	-0.11	QT interval;	chr16:58522662	chr16:58522970~58523842:+
BRCA	cis	rs62247992	0.698	rs7619872	ENSG00000227245.1	RP11-136C24.2	3.41	0.000668	0.0313	0.15	0.11	Facial morphology (factor 15, philtrum width);	chr3:43074678	chr3:43087479~43088068:+
BRCA	cis	rs11671005	0.779	rs55875034	ENSG00000265272.2	RN7SL693P	3.41	0.000668	0.0313	0.16	0.11	Mean platelet volume;	chr19:58472191	chr19:58490797~58491075:+
BRCA	cis	rs17741049	0.881	rs73688702	ENSG00000260493.1	RP11-219B4.7	-3.41	0.000668	0.0313	-0.24	-0.11	Blood protein levels;	chr8:85284898	chr8:85172077~85177062:-
BRCA	cis	rs11848070	1	rs11848070	ENSG00000258571.1	PTTG4P	-3.41	0.000668	0.0313	-0.14	-0.11	Alzheimer's disease (late onset);	chr14:71040884	chr14:71085482~71085833:-
BRCA	cis	rs8058578	1	rs7204278	ENSG00000274678.1	RP11-2C24.7	3.41	0.000669	0.0313	0.13	0.11	Multiple myeloma;	chr16:30718953	chr16:30821338~30821884:+
BRCA	cis	rs16950303	0.661	rs73439668	ENSG00000264269.1	RP11-15F12.1	3.41	0.000669	0.0313	0.22	0.11	Height;	chr18:49068480	chr18:49023703~49048474:+
BRCA	cis	rs4388249	1	rs2301000	ENSG00000271849.1	CTC-332L22.1	-3.41	0.000669	0.0313	-0.17	-0.11	Schizophrenia;	chr5:109751735	chr5:109687802~109688329:-
BRCA	cis	rs4388249	0.95	rs724214	ENSG00000271849.1	CTC-332L22.1	-3.41	0.000669	0.0313	-0.17	-0.11	Schizophrenia;	chr5:109752655	chr5:109687802~109688329:-
BRCA	cis	rs7917772	0.636	rs7911747	ENSG00000236937.2	PTGES3P4	3.41	0.000669	0.0313	0.15	0.11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;	chr10:102769133	chr10:102845595~102845950:+
BRCA	cis	rs3735485	0.8	rs7385926	ENSG00000201772.1	SNORA5C	-3.41	0.000669	0.0313	-0.14	-0.11	White blood cell count;Sum basophil neutrophil counts;Neutrophil count;Granulocyte percentage of myeloid white cells;Monocyte percentage of white cells;Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Lymphocyte counts;	chr7:45023229	chr7:45104906~45105042:-
BRCA	cis	rs6964587	0.839	rs10808086	ENSG00000188693.7	CYP51A1-AS1	-3.41	0.000669	0.0313	-0.11	-0.11	Breast cancer;	chr7:91818201	chr7:92134604~92180725:+
BRCA	cis	rs7089973	0.966	rs749649	ENSG00000236799.1	RP11-383C6.2	-3.41	0.000669	0.0313	-0.13	-0.11	Bipolar disorder or attention deficit hyperactivity disorder;	chr10:114882240	chr10:114994657~114996593:+
BRCA	cis	rs11642862	1	rs11645175	ENSG00000260082.1	RP11-2C24.5	-3.41	0.000669	0.0313	-0.2	-0.11	Tonsillectomy;	chr16:30791978	chr16:30821068~30822110:-
BRCA	cis	rs60678552	0.642	rs11754913	ENSG00000237021.2	RP3-486I3.7	3.41	0.000669	0.0313	0.19	0.11	Heschl's gyrus morphology;	chr6:116321517	chr6:116254207~116256743:+
BRCA	cis	rs8105895	0.935	rs62112364	ENSG00000269345.1	VN1R85P	3.41	0.000669	0.0313	0.16	0.11	Body mass index (change over time);	chr19:22112101	chr19:22174766~22175191:-
BRCA	cis	rs8114671	0.528	rs6119542	ENSG00000261582.1	RP4-614O4.11	-3.41	0.000669	0.0313	-0.1	-0.11	Height;	chr20:34896742	chr20:35267885~35280043:-
BRCA	cis	rs801193	0.844	rs732465	ENSG00000271064.1	RP11-792A8.3	-3.41	0.000669	0.0313	-0.12	-0.11	Aortic root size;	chr7:66533463	chr7:66748838~66749077:-
BRCA	cis	rs2985684	0.894	rs4900927	ENSG00000258568.1	RHOQP1	3.41	0.000669	0.0313	0.13	0.11	Carotid intima media thickness;	chr14:49552023	chr14:49599994~49600572:+
BRCA	cis	rs13420028	0.585	rs2241764	ENSG00000230992.3	FAM201B	-3.41	0.000669	0.0313	-0.12	-0.11	Hypertension (SNP x SNP interaction);	chr2:132417191	chr2:132352722~132353318:+
BRCA	cis	rs881375	0.967	rs1014529	ENSG00000238181.2	AHCYP2	-3.41	0.000669	0.0313	-0.13	-0.11	Rheumatoid arthritis;	chr9:120922665	chr9:120720673~120721972:+
BRCA	cis	rs72772090	0.539	rs10515248	ENSG00000272109.1	CTD-2260A17.3	3.41	0.000669	0.0313	0.2	0.11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96776301	chr5:96804353~96806105:+
BRCA	cis	rs72772090	0.539	rs56213813	ENSG00000272109.1	CTD-2260A17.3	3.41	0.000669	0.0313	0.2	0.11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96776580	chr5:96804353~96806105:+
BRCA	cis	rs72772090	0.52	rs56325109	ENSG00000272109.1	CTD-2260A17.3	3.41	0.000669	0.0313	0.2	0.11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96776591	chr5:96804353~96806105:+
BRCA	cis	rs72772090	0.539	rs11747148	ENSG00000272109.1	CTD-2260A17.3	3.41	0.000669	0.0313	0.2	0.11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96777159	chr5:96804353~96806105:+
BRCA	cis	rs875971	1	rs12533997	ENSG00000272831.1	RP11-792A8.4	3.41	0.000669	0.0313	0.09	0.11	Aortic root size;	chr7:66500390	chr7:66739829~66740385:-
BRCA	cis	rs9392556	0.829	rs7757606	ENSG00000230648.1	RP3-406P24.3	3.41	0.000669	0.0313	0.13	0.11	Blood metabolite levels;	chr6:4119470	chr6:4018843~4021215:-
BRCA	cis	rs873549	1	rs753962	ENSG00000227925.1	RP11-191N8.2	3.41	0.000669	0.0313	0.12	0.11	Keloid;	chr1:222099722	chr1:221827666~221840666:-
BRCA	cis	rs875971	0.83	rs778711	ENSG00000106610.13	STAG3L4	-3.41	0.000669	0.0313	-0.14	-0.11	Aortic root size;	chr7:66386670	chr7:67302621~67321526:+
BRCA	cis	rs875971	0.862	rs1083554	ENSG00000106610.13	STAG3L4	-3.41	0.000669	0.0313	-0.14	-0.11	Aortic root size;	chr7:66387354	chr7:67302621~67321526:+
BRCA	cis	rs875971	0.862	rs778707	ENSG00000106610.13	STAG3L4	-3.41	0.000669	0.0313	-0.14	-0.11	Aortic root size;	chr7:66392040	chr7:67302621~67321526:+
BRCA	cis	rs875971	0.862	rs778705	ENSG00000106610.13	STAG3L4	-3.41	0.000669	0.0313	-0.14	-0.11	Aortic root size;	chr7:66396128	chr7:67302621~67321526:+
BRCA	cis	rs875971	0.862	rs778697	ENSG00000106610.13	STAG3L4	-3.41	0.000669	0.0313	-0.14	-0.11	Aortic root size;	chr7:66405439	chr7:67302621~67321526:+
BRCA	cis	rs875971	0.798	rs7789615	ENSG00000106610.13	STAG3L4	-3.41	0.000669	0.0313	-0.14	-0.11	Aortic root size;	chr7:66413674	chr7:67302621~67321526:+
BRCA	cis	rs4865762	0.514	rs171710	ENSG00000247796.2	CTD-2366F13.1	3.41	0.000669	0.0313	0.12	0.11	Intraocular pressure;	chr5:53147401	chr5:53109842~53115126:+
BRCA	cis	rs6671200	0.607	rs2296308	ENSG00000228852.5	RP11-57H12.5	3.41	0.000669	0.0313	0.13	0.11	Stearic acid (18:0) levels;	chr1:95244383	chr1:95243167~95278940:-
BRCA	cis	rs7919656	0.626	rs2943245	ENSG00000278561.1	PTPN20CP	-3.41	0.000669	0.0313	-0.13	-0.11	Clinically amyopathic dermatomyositis;	chr10:48894711	chr10:48064308~48119455:-
BRCA	cis	rs12477602	0.938	rs71425937	ENSG00000272966.1	RP11-686O6.1	3.41	0.000669	0.0313	0.17	0.11	Intelligence (multi-trait analysis);	chr2:202382526	chr2:202336739~202337200:+
BRCA	cis	rs35275482	0.541	rs1437483	ENSG00000259238.1	RP11-361D15.2	-3.41	0.00067	0.0314	-0.13	-0.11	Gut microbiota (bacterial taxa);	chr15:59817724	chr15:59688517~59689418:+
BRCA	cis	rs4272720	0.755	rs11813727	ENSG00000228754.1	RP11-534L6.3	-3.41	0.00067	0.0314	-0.16	-0.11	Platelet count;Plateletcrit;	chr10:49008404	chr10:48745545~48746128:-
BRCA	cis	rs875971	0.522	rs6960048	ENSG00000227113.2	RP11-460N20.4	3.41	0.00067	0.0314	0.11	0.11	Aortic root size;	chr7:65943052	chr7:65075023~65078780:+
BRCA	cis	rs13118159	0.55	rs4974612	ENSG00000196810.4	CTBP1-AS2	3.41	0.00067	0.0314	0.13	0.11	Longevity;	chr4:1370755	chr4:1249300~1288291:+
BRCA	cis	rs4703129	1	rs6868590	ENSG00000246763.5	RGMB-AS1	-3.41	0.00067	0.0314	-0.12	-0.11	Asperger disorder;	chr5:98531274	chr5:98769618~98773469:-
BRCA	cis	rs7259811	0.961	rs7259808	ENSG00000268266.1	AC003005.2	3.41	0.00067	0.0314	0.14	0.11	Western dietary pattern;	chr19:56713645	chr19:57477649~57482996:+
BRCA	cis	rs7259811	1	rs7259811	ENSG00000268266.1	AC003005.2	3.41	0.00067	0.0314	0.14	0.11	Western dietary pattern;	chr19:56713651	chr19:57477649~57482996:+
BRCA	cis	rs7712401	0.755	rs27740	ENSG00000263432.2	RN7SL689P	-3.41	0.00067	0.0314	-0.12	-0.11	Mean platelet volume;	chr5:122869077	chr5:123022487~123022783:-
BRCA	cis	rs17331151	0.573	rs11626	ENSG00000270941.1	RP5-966M1.5	-3.41	0.00067	0.0314	-0.17	-0.11	Immune reponse to smallpox (secreted IL-2);	chr3:52839968	chr3:52734735~52735013:+
BRCA	cis	rs4962416	0.916	rs12769019	ENSG00000224023.9	FLJ37035	-3.41	0.00067	0.0314	-0.13	-0.11	Prostate cancer (SNP x SNP interaction);Prostate cancer;	chr10:125008758	chr10:125700436~125719566:-
BRCA	cis	rs1642645	0.872	rs689277	ENSG00000228452.1	RP5-994D16.9	3.41	0.00067	0.0314	0.13	0.11	Left ventricular obstructive tract defect (maternal effect);	chr1:41984700	chr1:42775813~42776790:-
BRCA	cis	rs2287838	0.967	rs11085425	ENSG00000267289.1	CTD-2623N2.11	-3.41	0.00067	0.0314	-0.13	-0.11	Sleep duration;	chr19:9867979	chr19:9834079~9835013:-
BRCA	cis	rs17027633	1	rs1419092	ENSG00000234020.1	CHIAP3	-3.41	0.00067	0.0314	-0.21	-0.11	Cerebrospinal fluid t-tau:AB1-42 ratio;	chr1:111419587	chr1:111353275~111367409:-
BRCA	cis	rs453301	0.571	rs330048	ENSG00000253981.4	ALG1L13P	-3.41	0.00067	0.0314	-0.12	-0.11	Joint mobility (Beighton score);	chr8:9229768	chr8:8236003~8244667:-
BRCA	cis	rs11048434	0.518	rs2377679	ENSG00000256427.1	RP11-118B22.4	-3.41	0.00067	0.0314	-0.11	-0.11	Sjögren's syndrome;	chr12:9023874	chr12:9246497~9257960:+
BRCA	cis	rs9646944	0.501	rs12712144	ENSG00000234389.1	AC007278.3	3.41	0.00067	0.0314	0.12	0.11	Blood protein levels;	chr2:102379140	chr2:102438713~102440475:+
BRCA	cis	rs9646944	0.501	rs3213733	ENSG00000234389.1	AC007278.3	3.41	0.00067	0.0314	0.12	0.11	Blood protein levels;	chr2:102381424	chr2:102438713~102440475:+
BRCA	cis	rs2337406	1	rs17113257	ENSG00000280411.1	IGHV1-69-2	-3.41	0.00067	0.0314	-0.09	-0.11	Alzheimer's disease (late onset);	chr14:106679574	chr14:106762092~106762588:-
BRCA	cis	rs4665809	0.938	rs35844686	ENSG00000231655.1	AC011742.3	-3.41	0.00067	0.0314	-0.18	-0.11	Gut microbiome composition (summer);	chr2:26082080	chr2:26140263~26141264:-
BRCA	cis	rs56011263	0.687	rs4690293	ENSG00000249592.4	RP11-440L14.1	-3.41	0.00067	0.0314	-0.12	-0.11	White blood cell count;	chr4:712312	chr4:762387~781849:-
BRCA	cis	rs8127691	0.967	rs4635612	ENSG00000225331.1	AP001055.6	3.41	0.00067	0.0314	0.13	0.11	Inflammatory bowel disease;	chr21:44196080	chr21:44158740~44160076:-
BRCA	cis	rs3011225	0.738	rs7552219	ENSG00000237950.1	RP11-7O11.3	-3.41	0.00067	0.0314	-0.15	-0.11	Amyotrophic lateral sclerosis (age of onset);	chr1:43846675	chr1:43944370~43946551:-
BRCA	cis	rs7620503	1	rs6443474	ENSG00000228561.2	RP11-114M1.1	3.41	0.00067	0.0314	0.12	0.11	Corneal structure;	chr3:177587336	chr3:177683627~177691250:+
BRCA	cis	rs10129255	0.957	rs10136817	ENSG00000211967.3	IGHV3-53	-3.41	0.00067	0.0314	-0.08	-0.11	Kawasaki disease;	chr14:106787730	chr14:106592676~106593347:-
BRCA	cis	rs10916248	0.569	rs7528528	ENSG00000232628.4	RP11-365O16.3	-3.41	0.00067	0.0314	-0.12	-0.11	QT interval (drug interaction);	chr1:224077615	chr1:224208747~224213279:-
BRCA	cis	rs91731	0.92	rs1813313	ENSG00000249572.1	CTD-2203K17.1	-3.41	0.00067	0.0314	-0.2	-0.11	Lung function (FVC);	chr5:33271878	chr5:33424025~33440619:-
BRCA	cis	rs91731	0.92	rs2331187	ENSG00000249572.1	CTD-2203K17.1	-3.41	0.00067	0.0314	-0.2	-0.11	Lung function (FVC);	chr5:33272590	chr5:33424025~33440619:-
BRCA	cis	rs7131987	0.868	rs11050151	ENSG00000257599.1	OVCH1-AS1	-3.41	0.00067	0.0314	-0.13	-0.11	QT interval;	chr12:29250075	chr12:29389294~29487488:+
BRCA	cis	rs1354774	0.505	rs61044983	ENSG00000197588.8	KLKP1	-3.41	0.00067	0.0314	-0.11	-0.11	Prostate-specific antigen levels;	chr19:50893666	chr19:50882096~50896398:-
BRCA	cis	rs56046484	0.871	rs71397837	ENSG00000259630.2	CTD-2262B20.1	-3.41	0.00067	0.0314	-0.18	-0.11	Testicular germ cell tumor;	chr15:85020330	chr15:85415228~85415633:+
BRCA	cis	rs56046484	0.871	rs62021203	ENSG00000259630.2	CTD-2262B20.1	-3.41	0.00067	0.0314	-0.18	-0.11	Testicular germ cell tumor;	chr15:85020846	chr15:85415228~85415633:+
BRCA	cis	rs4356203	0.905	rs214937	ENSG00000184669.7	OR7E14P	3.41	0.000671	0.0314	0.14	0.11	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17168005	chr11:17013998~17053024:+
BRCA	cis	rs7487075	0.893	rs12317787	ENSG00000274723.1	RP11-618L22.1	3.41	0.000671	0.0314	0.12	0.11	Itch intensity from mosquito bite;	chr12:46342946	chr12:46970504~46972155:+
BRCA	cis	rs9393813	0.528	rs6911865	ENSG00000271755.1	RP1-153G14.4	3.41	0.000671	0.0314	0.12	0.11	Bipolar disorder;	chr6:27502999	chr6:27404010~27406964:-
BRCA	cis	rs694739	0.536	rs671976	ENSG00000236935.1	AP003774.1	3.41	0.000671	0.0314	0.09	0.11	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64278557	chr11:64325050~64329504:-
BRCA	cis	rs962856	0.575	rs612624	ENSG00000236605.1	AC023115.4	3.41	0.000671	0.0314	0.13	0.11	Pancreatic cancer;	chr2:67430179	chr2:67324627~67325304:+
BRCA	cis	rs897984	0.542	rs11864839	ENSG00000232748.3	RP11-196G11.6	-3.41	0.000671	0.0314	-0.12	-0.11	Dementia with Lewy bodies;	chr16:31083930	chr16:31056460~31062803:+
BRCA	cis	rs259282	0.538	rs12151311	ENSG00000267475.1	CTD-2538C1.2	3.41	0.000671	0.0314	0.13	0.11	Schizophrenia;	chr19:32621801	chr19:32687089~32691750:-
BRCA	cis	rs4078252	0.627	rs11241193	ENSG00000279522.1	CTC-487M23.6	-3.41	0.000671	0.0314	-0.12	-0.11	Response to cytadine analogues (cytosine arabinoside);	chr5:113115736	chr5:112894933~112896531:+
BRCA	cis	rs9393813	0.528	rs9468141	ENSG00000271755.1	RP1-153G14.4	3.41	0.000671	0.0314	0.12	0.11	Bipolar disorder;	chr6:27506748	chr6:27404010~27406964:-
BRCA	cis	rs2070488	0.804	rs7372452	ENSG00000229589.1	ACVR2B-AS1	3.41	0.000671	0.0314	0.12	0.11	Electrocardiographic conduction measures;	chr3:38402807	chr3:38451027~38454820:-
BRCA	cis	rs2153535	0.585	rs7765238	ENSG00000251164.1	HULC	3.41	0.000671	0.0314	0.12	0.11	Motion sickness;	chr6:8632560	chr6:8652137~8653846:+
BRCA	cis	rs10129255	1	rs11627342	ENSG00000211958.2	IGHV3-38	3.41	0.000671	0.0314	0.09	0.11	Kawasaki disease;	chr14:106675823	chr14:106410493~106411021:-
BRCA	cis	rs6840360	0.571	rs11932059	ENSG00000278978.1	RP11-164P12.5	-3.41	0.000671	0.0314	-0.12	-0.11	Intelligence (multi-trait analysis);	chr4:151603344	chr4:151669786~151670503:+
BRCA	cis	rs2031532	0.544	rs35980977	ENSG00000236577.1	SNRPGP14	3.41	0.000671	0.0314	0.12	0.11	Cardiac hypertrophy;	chr13:49483800	chr13:49488970~49489364:+
BRCA	cis	rs4950322	0.518	rs61838938	ENSG00000237188.3	RP11-337C18.8	3.41	0.000671	0.0314	0.12	0.11	Protein quantitative trait loci;	chr1:147105943	chr1:147172771~147211568:+
BRCA	cis	rs4950322	0.529	rs11809327	ENSG00000237188.3	RP11-337C18.8	3.41	0.000671	0.0314	0.12	0.11	Protein quantitative trait loci;	chr1:147106679	chr1:147172771~147211568:+
BRCA	cis	rs4950322	0.563	rs11809328	ENSG00000237188.3	RP11-337C18.8	3.41	0.000671	0.0314	0.12	0.11	Protein quantitative trait loci;	chr1:147106681	chr1:147172771~147211568:+
BRCA	cis	rs875971	1	rs6956179	ENSG00000273448.1	RP11-166O4.6	-3.41	0.000671	0.0314	-0.09	-0.11	Aortic root size;	chr7:66341672	chr7:67333047~67334383:+
BRCA	cis	rs4699052	0.739	rs6855777	ENSG00000230069.3	LRRC37A15P	3.41	0.000671	0.0314	0.1	0.11	Testicular germ cell tumor;	chr4:103321207	chr4:102727274~102730721:-
BRCA	cis	rs1371614	0.632	rs10196501	ENSG00000272148.1	RP11-195B17.1	3.41	0.000671	0.0314	0.12	0.11	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26924404	chr2:27062428~27062907:-
BRCA	cis	rs17345786	0.954	rs17508319	ENSG00000256628.3	ZBTB11-AS1	3.41	0.000671	0.0314	0.14	0.11	Colonoscopy-negative controls vs population controls;	chr3:101600059	chr3:101676475~101679217:+
BRCA	cis	rs2795502	1	rs2185717	ENSG00000185904.10	LINC00839	3.41	0.000671	0.0314	0.15	0.11	Blood protein levels;	chr10:42848427	chr10:42475543~42495336:+
BRCA	cis	rs875971	1	rs778710	ENSG00000229886.1	RP5-1132H15.3	3.41	0.000671	0.0314	0.12	0.11	Aortic root size;	chr7:66389847	chr7:66025126~66031544:-
BRCA	cis	rs34217772	0.771	rs61992377	ENSG00000258636.1	CTD-2298J14.2	3.41	0.000671	0.0314	0.14	0.11	Myopia;	chr14:41738205	chr14:41587861~41604856:-
BRCA	cis	rs10129255	1	rs9324091	ENSG00000211958.2	IGHV3-38	3.41	0.000672	0.0314	0.08	0.11	Kawasaki disease;	chr14:106676625	chr14:106410493~106411021:-
BRCA	cis	rs6671200	0.607	rs3767315	ENSG00000226026.4	RP11-57H12.3	-3.41	0.000672	0.0314	-0.16	-0.11	Stearic acid (18:0) levels;	chr1:95240416	chr1:95163219~95233982:-
BRCA	cis	rs3960554	0.808	rs78478514	ENSG00000205485.12	AC004980.7	-3.41	0.000672	0.0314	-0.14	-0.11	Eotaxin levels;	chr7:76026578	chr7:76549360~76627982:+
BRCA	cis	rs7697932	0.521	rs7654712	ENSG00000245322.5	RP11-15B17.1	3.41	0.000672	0.0314	0.13	0.11	Renal cell carcinoma;	chr4:100160920	chr4:99950006~100195099:+
BRCA	cis	rs2289328	0.882	rs7164581	ENSG00000259211.1	RP11-64K12.8	-3.41	0.000672	0.0314	-0.14	-0.11	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr15:40352897	chr15:40464193~40466726:-
BRCA	cis	rs2016266	0.502	rs34745537	ENSG00000257379.1	RP11-793H13.8	-3.41	0.000672	0.0314	-0.12	-0.11	Bone mineral density;Bone mineral density (spine);	chr12:53241651	chr12:53441741~53467528:+
BRCA	cis	rs9393813	0.516	rs4711152	ENSG00000241549.7	GUSBP2	3.41	0.000672	0.0314	0.11	0.11	Bipolar disorder;	chr6:27412423	chr6:26871484~26956554:-
BRCA	cis	rs11138902	0.533	rs11139065	ENSG00000236801.1	RPL24P8	3.41	0.000672	0.0314	0.09	0.11	Intelligence (multi-trait analysis);Cognitive ability;Intelligence;	chr9:69517766	chr9:70217195~70217668:+
BRCA	cis	rs3219474	0.502	rs41343546	ENSG00000280836.1	AL355480.1	-3.41	0.000672	0.0314	-0.21	-0.11	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:45442591	chr1:45581219~45581321:-
BRCA	cis	rs10876993	0.928	rs7136269	ENSG00000269903.1	RP11-571M6.18	3.41	0.000672	0.0314	0.13	0.11	Celiac disease or Rheumatoid arthritis;	chr12:57682154	chr12:57814494~57814926:+
BRCA	cis	rs36051895	0.603	rs10123980	ENSG00000236254.1	MTND4P14	-3.41	0.000672	0.0314	-0.12	-0.11	Pediatric autoimmune diseases;	chr9:5130363	chr9:5107937~5109290:+
BRCA	cis	rs853679	0.599	rs202906	ENSG00000280107.1	AL022393.9	3.41	0.000672	0.0314	0.2	0.11	Depression;	chr6:28043874	chr6:28170845~28172521:+
BRCA	cis	rs9393813	0.528	rs6911865	ENSG00000204789.4	ZNF204P	3.41	0.000672	0.0314	0.13	0.11	Bipolar disorder;	chr6:27502999	chr6:27357825~27360221:-
BRCA	cis	rs6772849	0.768	rs4521246	ENSG00000242551.2	POU5F1P6	3.41	0.000672	0.0314	0.14	0.11	Monocyte percentage of white cells;Monocyte count;	chr3:128702323	chr3:128674735~128677005:-
BRCA	cis	rs875971	0.895	rs10755833	ENSG00000273024.4	INTS4P2	-3.41	0.000672	0.0314	-0.12	-0.11	Aortic root size;	chr7:66448930	chr7:65647864~65715661:+
BRCA	cis	rs875971	0.895	rs1833495	ENSG00000273024.4	INTS4P2	-3.41	0.000672	0.0314	-0.12	-0.11	Aortic root size;	chr7:66456608	chr7:65647864~65715661:+
BRCA	cis	rs875971	0.964	rs6945032	ENSG00000273024.4	INTS4P2	-3.41	0.000672	0.0314	-0.12	-0.11	Aortic root size;	chr7:66457499	chr7:65647864~65715661:+
BRCA	cis	rs875971	0.929	rs12673810	ENSG00000273024.4	INTS4P2	-3.41	0.000672	0.0314	-0.12	-0.11	Aortic root size;	chr7:66458866	chr7:65647864~65715661:+
BRCA	cis	rs875971	1	rs6961155	ENSG00000273024.4	INTS4P2	-3.41	0.000672	0.0314	-0.12	-0.11	Aortic root size;	chr7:66468308	chr7:65647864~65715661:+
BRCA	cis	rs875971	1	rs7789768	ENSG00000273024.4	INTS4P2	-3.41	0.000672	0.0314	-0.12	-0.11	Aortic root size;	chr7:66473993	chr7:65647864~65715661:+
BRCA	cis	rs875971	1	rs1363055	ENSG00000273024.4	INTS4P2	-3.41	0.000672	0.0314	-0.12	-0.11	Aortic root size;	chr7:66478288	chr7:65647864~65715661:+
BRCA	cis	rs875971	0.964	rs9691480	ENSG00000273024.4	INTS4P2	-3.41	0.000672	0.0314	-0.12	-0.11	Aortic root size;	chr7:66479319	chr7:65647864~65715661:+
BRCA	cis	rs889122	0.765	rs10425422	ENSG00000267289.1	CTD-2623N2.11	3.41	0.000672	0.0314	0.14	0.11	Menarche (age at onset);	chr19:9872345	chr19:9834079~9835013:-
BRCA	cis	rs6736093	1	rs6736093	ENSG00000236307.2	EEF1E1P1	3.41	0.000672	0.0314	0.13	0.11	Coronary artery disease;	chr2:111897665	chr2:111887914~111888741:+
BRCA	cis	rs1555133	0.625	rs6141691	ENSG00000277692.1	RP11-358N2.2	-3.41	0.000672	0.0314	-0.12	-0.11	Monocyte count;	chr20:32375123	chr20:32355053~32355734:+
BRCA	cis	rs10771431	0.782	rs10771415	ENSG00000256673.1	RP11-599J14.2	3.41	0.000672	0.0314	0.11	0.11	Breast size;	chr12:9205627	chr12:9398355~9414851:-
BRCA	cis	rs56046484	0.956	rs17540501	ENSG00000230373.7	GOLGA6L5P	3.41	0.000672	0.0315	0.16	0.11	Testicular germ cell tumor;	chr15:85094870	chr15:84507885~84516814:-
BRCA	cis	rs3748656	1	rs1106287	ENSG00000273483.1	RP4-671G15.2	3.41	0.000672	0.0315	0.14	0.11	Hip circumference adjusted for BMI;	chr1:112699500	chr1:112517799~112518441:-
BRCA	cis	rs10958369	1	rs10958369	ENSG00000260484.1	RP11-1081M5.2	3.41	0.000672	0.0315	0.12	0.11	Response to antineoplastic agents;	chr8:53497648	chr8:53388701~53390872:-
BRCA	cis	rs9564692	0.625	rs723918	ENSG00000229427.1	ANKRD26P4	3.41	0.000672	0.0315	0.12	0.11	Advanced age-related macular degeneration;	chr13:31142310	chr13:31311289~31312921:+
BRCA	cis	rs13393800	1	rs12617363	ENSG00000237126.7	AC073254.1	-3.41	0.000672	0.0315	-0.14	-0.11	Height;	chr2:232575586	chr2:232580948~232611971:-
BRCA	cis	rs12692738	0.572	rs401131	ENSG00000223318.1	RNA5SP111	3.41	0.000672	0.0315	0.13	0.11	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);	chr2:164752884	chr2:164895677~164895777:-
BRCA	cis	rs60871478	0.636	rs10245785	ENSG00000237181.1	AC147651.4	3.41	0.000672	0.0315	0.12	0.11	Cerebrospinal P-tau181p levels;	chr7:854785	chr7:603185~608482:+
BRCA	cis	rs2124910	0.815	rs2864103	ENSG00000255441.1	CTD-2616J11.2	-3.41	0.000672	0.0315	-0.12	-0.11	Blood protein levels;	chr19:51527070	chr19:51415724~51417425:+
BRCA	cis	rs875971	0.838	rs2173570	ENSG00000271064.1	RP11-792A8.3	3.41	0.000672	0.0315	0.12	0.11	Aortic root size;	chr7:66297976	chr7:66748838~66749077:-
BRCA	cis	rs9818758	0.607	rs55873331	ENSG00000270441.1	RP11-694I15.7	3.41	0.000672	0.0315	0.24	0.11	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49559622	chr3:49140086~49160851:-
BRCA	cis	rs8127691	0.935	rs2876932	ENSG00000225331.1	AP001055.6	3.41	0.000672	0.0315	0.13	0.11	Inflammatory bowel disease;	chr21:44198653	chr21:44158740~44160076:-
BRCA	cis	rs853679	0.517	rs9468297	ENSG00000226314.6	ZNF192P1	-3.41	0.000672	0.0315	-0.16	-0.11	Depression;	chr6:28151096	chr6:28161781~28169594:+
BRCA	cis	rs9467773	1	rs9467787	ENSG00000224843.5	LINC00240	-3.41	0.000673	0.0315	-0.12	-0.11	Intelligence (multi-trait analysis);	chr6:26556541	chr6:26956992~27023924:+
BRCA	cis	rs4072705	0.646	rs10120967	ENSG00000236643.1	RP11-175D17.3	-3.41	0.000673	0.0315	-0.13	-0.11	Menarche (age at onset);	chr9:124481855	chr9:124770123~124772927:+
BRCA	cis	rs1998359	0.953	rs12147542	ENSG00000259087.4	RP11-356O9.2	3.41	0.000673	0.0315	0.12	0.11	Self-reported allergy;	chr14:37662546	chr14:37556158~37567095:-
BRCA	cis	rs6801044	0.741	rs823517	ENSG00000272792.1	RP11-141C7.4	3.41	0.000673	0.0315	0.16	0.11	Creatinine levels in ischemic stroke;	chr3:195541837	chr3:195639990~195640460:+
BRCA	cis	rs8062405	0.755	rs55792032	ENSG00000261766.1	RP11-22P6.2	-3.41	0.000673	0.0315	-0.1	-0.11	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28588090	chr16:28862166~28863340:-
BRCA	cis	rs962856	0.619	rs6731934	ENSG00000236605.1	AC023115.4	3.41	0.000673	0.0315	0.14	0.11	Pancreatic cancer;	chr2:67332421	chr2:67324627~67325304:+
BRCA	cis	rs2154319	0.887	rs9439035	ENSG00000230638.4	RP11-486B10.4	3.41	0.000673	0.0315	0.18	0.11	Height;	chr1:41074593	chr1:41542069~41544310:+
BRCA	cis	rs2154319	0.673	rs2011982	ENSG00000230638.4	RP11-486B10.4	3.41	0.000673	0.0315	0.18	0.11	Height;	chr1:41075189	chr1:41542069~41544310:+
BRCA	cis	rs2154319	0.836	rs6674290	ENSG00000230638.4	RP11-486B10.4	3.41	0.000673	0.0315	0.18	0.11	Height;	chr1:41095560	chr1:41542069~41544310:+
BRCA	cis	rs2154319	0.887	rs2024860	ENSG00000230638.4	RP11-486B10.4	3.41	0.000673	0.0315	0.18	0.11	Height;	chr1:41096571	chr1:41542069~41544310:+
BRCA	cis	rs875971	1	rs2420591	ENSG00000273024.4	INTS4P2	-3.41	0.000673	0.0315	-0.12	-0.11	Aortic root size;	chr7:66447394	chr7:65647864~65715661:+
BRCA	cis	rs3105593	1	rs1395297	ENSG00000259298.1	RP11-562A8.4	-3.41	0.000673	0.0315	-0.09	-0.11	QT interval;	chr15:50586312	chr15:50497195~50498744:-
BRCA	cis	rs61931739	0.5	rs7489270	ENSG00000258794.3	DUX4L27	3.41	0.000673	0.0315	0.15	0.11	Morning vs. evening chronotype;	chr12:34279127	chr12:34208415~34209675:-
BRCA	cis	rs61931739	0.5	rs11053189	ENSG00000258794.3	DUX4L27	3.41	0.000673	0.0315	0.15	0.11	Morning vs. evening chronotype;	chr12:34280520	chr12:34208415~34209675:-
BRCA	cis	rs61931739	0.5	rs11053193	ENSG00000258794.3	DUX4L27	3.41	0.000673	0.0315	0.15	0.11	Morning vs. evening chronotype;	chr12:34285903	chr12:34208415~34209675:-
BRCA	cis	rs4930103	0.935	rs4930101	ENSG00000230080.2	AC139143.2	3.41	0.000673	0.0315	0.12	0.11	DNA methylation (variation);DNA methylation (parent-of-origin);	chr11:2000629	chr11:1802889~1804095:-
BRCA	cis	rs74233809	1	rs12219901	ENSG00000213061.2	PFN1P11	3.41	0.000673	0.0315	0.23	0.11	Birth weight;	chr10:103081210	chr10:102838011~102845473:-
BRCA	cis	rs74233809	1	rs10458729	ENSG00000213061.2	PFN1P11	3.41	0.000673	0.0315	0.23	0.11	Birth weight;	chr10:103081722	chr10:102838011~102845473:-
BRCA	cis	rs6088580	0.524	rs6087616	ENSG00000126005.14	MMP24-AS1	3.41	0.000673	0.0315	0.12	0.11	Glomerular filtration rate (creatinine);	chr20:34675229	chr20:35216462~35278131:-
BRCA	cis	rs2400749	0.83	rs6575733	ENSG00000258521.1	RP11-638I2.9	3.41	0.000673	0.0315	0.1	0.11	Alzheimer's disease (survival time);	chr14:99565040	chr14:100339832~100340554:+
BRCA	cis	rs2400749	0.798	rs12432298	ENSG00000258521.1	RP11-638I2.9	-3.41	0.000673	0.0315	-0.1	-0.11	Alzheimer's disease (survival time);	chr14:99566477	chr14:100339832~100340554:+
BRCA	cis	rs2400749	0.83	rs11160527	ENSG00000258521.1	RP11-638I2.9	-3.41	0.000673	0.0315	-0.1	-0.11	Alzheimer's disease (survival time);	chr14:99566662	chr14:100339832~100340554:+
BRCA	cis	rs2400749	0.83	rs11627095	ENSG00000258521.1	RP11-638I2.9	3.41	0.000673	0.0315	0.1	0.11	Alzheimer's disease (survival time);	chr14:99566819	chr14:100339832~100340554:+
BRCA	cis	rs2400749	0.83	rs10873506	ENSG00000258521.1	RP11-638I2.9	-3.41	0.000673	0.0315	-0.1	-0.11	Alzheimer's disease (survival time);	chr14:99566885	chr14:100339832~100340554:+
BRCA	cis	rs2400749	0.83	rs9671899	ENSG00000258521.1	RP11-638I2.9	-3.41	0.000673	0.0315	-0.1	-0.11	Alzheimer's disease (survival time);	chr14:99567292	chr14:100339832~100340554:+
BRCA	cis	rs2832191	0.791	rs2832197	ENSG00000232855.5	AF131217.1	3.41	0.000673	0.0315	0.12	0.11	Dental caries;	chr21:29125469	chr21:28439346~28674848:-
BRCA	cis	rs2832191	0.791	rs57721945	ENSG00000232855.5	AF131217.1	3.41	0.000673	0.0315	0.12	0.11	Dental caries;	chr21:29126423	chr21:28439346~28674848:-
BRCA	cis	rs2657888	1	rs2657888	ENSG00000257576.1	RP11-153M3.1	3.41	0.000673	0.0315	0.12	0.11	Adiponectin levels;	chr12:56544599	chr12:56511002~56512703:+
BRCA	cis	rs17385675	1	rs16838482	ENSG00000273209.1	RP11-107N15.1	3.41	0.000673	0.0315	0.16	0.11	Response to antipsychotic treatment;	chr2:201949699	chr2:202032770~202033537:-
BRCA	cis	rs62458065	0.64	rs4141788	ENSG00000273014.1	RP11-225B17.2	-3.41	0.000673	0.0315	-0.17	-0.11	Metabolite levels (HVA/MHPG ratio);	chr7:32479652	chr7:32758882~32759353:+
BRCA	cis	rs7104764	1	rs6598061	ENSG00000254910.1	RP11-326C3.7	-3.41	0.000673	0.0315	-0.12	-0.11	Menarche (age at onset);	chr11:243853	chr11:310139~311141:-
BRCA	cis	rs7104764	1	rs10902112	ENSG00000254910.1	RP11-326C3.7	-3.41	0.000673	0.0315	-0.12	-0.11	Menarche (age at onset);	chr11:244106	chr11:310139~311141:-
BRCA	cis	rs7104764	0.917	rs7107362	ENSG00000254910.1	RP11-326C3.7	-3.41	0.000673	0.0315	-0.12	-0.11	Menarche (age at onset);	chr11:244108	chr11:310139~311141:-
BRCA	cis	rs7104764	1	rs7128044	ENSG00000254910.1	RP11-326C3.7	-3.41	0.000673	0.0315	-0.12	-0.11	Menarche (age at onset);	chr11:244115	chr11:310139~311141:-
BRCA	cis	rs7104764	0.957	rs7116130	ENSG00000254910.1	RP11-326C3.7	-3.41	0.000673	0.0315	-0.12	-0.11	Menarche (age at onset);	chr11:244129	chr11:310139~311141:-
BRCA	cis	rs7104764	1	rs7128029	ENSG00000254910.1	RP11-326C3.7	-3.41	0.000673	0.0315	-0.12	-0.11	Menarche (age at onset);	chr11:244141	chr11:310139~311141:-
BRCA	cis	rs7104764	1	rs1128320	ENSG00000254910.1	RP11-326C3.7	-3.41	0.000673	0.0315	-0.12	-0.11	Menarche (age at onset);	chr11:244167	chr11:310139~311141:-
BRCA	cis	rs7104764	0.957	rs1128321	ENSG00000254910.1	RP11-326C3.7	-3.41	0.000673	0.0315	-0.12	-0.11	Menarche (age at onset);	chr11:244171	chr11:310139~311141:-
BRCA	cis	rs875971	0.79	rs10257911	ENSG00000223473.2	GS1-124K5.3	-3.41	0.000673	0.0315	-0.08	-0.11	Aortic root size;	chr7:66278783	chr7:66491049~66493566:-
BRCA	cis	rs13393800	1	rs13393800	ENSG00000237126.7	AC073254.1	-3.41	0.000673	0.0315	-0.14	-0.11	Height;	chr2:232577381	chr2:232580948~232611971:-
BRCA	cis	rs34734847	1	rs10431385	ENSG00000274029.1	RP11-340F14.6	-3.41	0.000674	0.0315	-0.12	-0.11	Mean corpuscular volume;	chr12:120691079	chr12:121190868~121191518:+
BRCA	cis	rs2832191	0.72	rs2832200	ENSG00000232855.5	AF131217.1	3.41	0.000674	0.0315	0.12	0.11	Dental caries;	chr21:29126844	chr21:28439346~28674848:-
BRCA	cis	rs2832191	0.791	rs28633762	ENSG00000232855.5	AF131217.1	3.41	0.000674	0.0315	0.12	0.11	Dental caries;	chr21:29127749	chr21:28439346~28674848:-
BRCA	cis	rs1524976	1	rs4688240	ENSG00000272610.1	MAGI1-IT1	3.41	0.000674	0.0315	0.17	0.11	PR interval;	chr3:65536717	chr3:65872815~65954558:-
BRCA	cis	rs10198628	0.713	rs4669876	ENSG00000264370.1	MIR3125	-3.41	0.000674	0.0315	-0.13	-0.11	Pericardial fat;Pericardial adipose tissue adjusted for height and weight;	chr2:12778174	chr2:12737367~12737444:+
BRCA	cis	rs2911132	0.511	rs7063	ENSG00000272109.1	CTD-2260A17.3	-3.41	0.000674	0.0315	-0.15	-0.11	Urate levels (BMI interaction);	chr5:96774507	chr5:96804353~96806105:+
BRCA	cis	rs1795240	0.818	rs2281003	ENSG00000231424.2	RP1-45C12.1	-3.41	0.000674	0.0315	-0.12	-0.11	Lentiform nucleus volume;	chr1:171137570	chr1:171247580~171251794:-
BRCA	cis	rs950881	0.932	rs3771180	ENSG00000234389.1	AC007278.3	3.41	0.000674	0.0315	0.13	0.11	Allergy;	chr2:102337157	chr2:102438713~102440475:+
BRCA	cis	rs950881	0.932	rs72823646	ENSG00000234389.1	AC007278.3	3.41	0.000674	0.0315	0.13	0.11	Allergy;	chr2:102337753	chr2:102438713~102440475:+
BRCA	cis	rs950881	0.932	rs13431828	ENSG00000234389.1	AC007278.3	3.41	0.000674	0.0315	0.13	0.11	Allergy;	chr2:102338193	chr2:102438713~102440475:+
BRCA	cis	rs950881	0.932	rs13408569	ENSG00000234389.1	AC007278.3	3.41	0.000674	0.0315	0.13	0.11	Allergy;	chr2:102338596	chr2:102438713~102440475:+
BRCA	cis	rs6822297	0.841	rs28454570	ENSG00000240005.4	RP11-293A21.1	3.41	0.000674	0.0315	0.12	0.11	Obesity-related traits;	chr4:26947373	chr4:26859806~26860599:-
BRCA	cis	rs2704588	1	rs2704606	ENSG00000270720.1	RP11-84C13.2	3.41	0.000674	0.0315	0.16	0.11	Longevity;	chr4:88914302	chr4:89119284~89119871:+
BRCA	cis	rs3748682	0.861	rs28420383	ENSG00000212541.1	RNU6-510P	-3.41	0.000674	0.0315	-0.15	-0.11	Hypothyroidism;	chr1:37880733	chr1:37991462~37991569:+
BRCA	cis	rs10170310	1	rs12691947	ENSG00000241772.2	AC092620.2	-3.41	0.000674	0.0315	-0.15	-0.11	Response to antipsychotic treatment;	chr2:138506901	chr2:138569090~138574458:+
BRCA	cis	rs875971	1	rs1167612	ENSG00000273024.4	INTS4P2	3.41	0.000674	0.0315	0.12	0.11	Aortic root size;	chr7:66102989	chr7:65647864~65715661:+
BRCA	cis	rs6942407	0.546	rs4728686	ENSG00000224046.1	AC005076.5	-3.41	0.000674	0.0315	-0.15	-0.11	Food allergy;	chr7:87185468	chr7:87151423~87152420:-
BRCA	cis	rs4578769	0.569	rs12605341	ENSG00000265943.1	RP11-739L10.1	-3.41	0.000674	0.0315	-0.14	-0.11	Eosinophil percentage of white cells;	chr18:22803011	chr18:22699481~22933764:-
BRCA	cis	rs2625529	0.689	rs12898728	ENSG00000261187.1	RP11-1007O24.2	-3.41	0.000674	0.0315	-0.11	-0.11	Red blood cell count;	chr15:71820512	chr15:72465128~72466262:-
BRCA	cis	rs6581612	0.756	rs2173456	ENSG00000255693.1	RP11-766N7.3	3.41	0.000674	0.0315	0.16	0.11	Hippocampal volume;	chr12:65117572	chr12:64883394~64977522:+
BRCA	cis	rs9457247	0.534	rs9366078	ENSG00000227598.1	RP1-167A14.2	3.41	0.000674	0.0315	0.11	0.11	Crohn's disease;	chr6:166986024	chr6:166969626~166999065:-
BRCA	cis	rs61542988	0.57	rs10950919	ENSG00000226329.2	AC005682.6	3.41	0.000674	0.0315	0.11	0.11	Fibrinogen levels;	chr7:22794202	chr7:22863874~22881350:-
BRCA	cis	rs713477	0.631	rs7145182	ENSG00000186615.9	KTN1-AS1	-3.41	0.000674	0.0315	-0.12	-0.11	Pediatric bone mineral content (femoral neck);	chr14:55438513	chr14:55499278~55580110:-
BRCA	cis	rs10864907	0.742	rs11123154	ENSG00000231747.1	AC079922.2	-3.41	0.000674	0.0315	-0.1	-0.11	Pulmonary function;	chr2:112975854	chr2:112621809~112622167:-
BRCA	cis	rs11158026	0.757	rs56206440	ENSG00000233924.1	AL160471.6	-3.41	0.000675	0.0315	-0.12	-0.11	Parkinson's disease;	chr14:54984168	chr14:55004813~55005687:-
BRCA	cis	rs375066	0.71	rs11881193	ENSG00000267191.1	RP11-15A1.2	3.41	0.000675	0.0315	0.14	0.11	Breast cancer;	chr19:43917364	chr19:43902001~43926545:+
BRCA	cis	rs3858526	0.514	rs4595572	ENSG00000224295.2	AC087380.14	3.41	0.000675	0.0315	0.13	0.11	DNA methylation (variation);	chr11:5842815	chr11:5518441~5524955:-
BRCA	cis	rs2018683	0.707	rs1021690	ENSG00000228421.2	AC005013.5	3.41	0.000675	0.0315	0.13	0.11	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28934871	chr7:28957667~28959345:+
BRCA	cis	rs2018683	0.707	rs1021691	ENSG00000228421.2	AC005013.5	3.41	0.000675	0.0315	0.13	0.11	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28934879	chr7:28957667~28959345:+
BRCA	cis	rs8114671	0.836	rs2425006	ENSG00000261582.1	RP4-614O4.11	3.41	0.000675	0.0315	0.1	0.11	Height;	chr20:34983425	chr20:35267885~35280043:-
BRCA	cis	rs7149337	0.752	rs8021773	ENSG00000258955.1	LINC00519	-3.41	0.000675	0.0315	-0.12	-0.11	Cancer;	chr14:51224810	chr14:51304416~51328386:-
BRCA	cis	rs1348850	0.526	rs7588049	ENSG00000271825.1	RP11-337N6.2	-3.41	0.000675	0.0315	-0.19	-0.11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177526050	chr2:177300600~177302006:+
BRCA	cis	rs3820068	0.608	rs12092485	ENSG00000237301.1	RP4-680D5.2	-3.41	0.000675	0.0315	-0.14	-0.11	Systolic blood pressure;	chr1:15721543	chr1:15586136~15603626:-
BRCA	cis	rs2342406	0.825	rs1026061	ENSG00000259439.2	RP11-89K21.1	3.41	0.000675	0.0315	0.17	0.11	Myopia;	chr2:44914872	chr2:44921077~44939199:-
BRCA	cis	rs930395	0.859	rs7716600	ENSG00000248779.1	RP11-53O19.2	-3.41	0.000675	0.0315	-0.12	-0.11	Breast cancer;	chr5:44874903	chr5:44752949~44765744:+
BRCA	cis	rs11250097	0.549	rs11784897	ENSG00000255020.1	AF131216.5	3.41	0.000675	0.0315	0.13	0.11	Neuroticism;	chr8:11452933	chr8:11345748~11347502:-
BRCA	cis	rs9633740	1	rs7900536	ENSG00000226659.1	RP11-137H2.4	-3.41	0.000675	0.0315	-0.17	-0.11	Post bronchodilator FEV1;	chr10:80493945	chr10:80529597~80535942:-
BRCA	cis	rs3764021	0.87	rs7970116	ENSG00000256594.6	RP11-705C15.2	-3.41	0.000675	0.0315	-0.12	-0.11	Type 1 diabetes;	chr12:9727518	chr12:9633419~9658412:+
BRCA	cis	rs3770752	0.836	rs11124574	ENSG00000272054.1	RP11-423P10.2	3.41	0.000675	0.0315	0.09	0.11	Schizophrenia;	chr2:37272146	chr2:37208875~37212677:+
BRCA	cis	rs14027	0.921	rs16893113	ENSG00000245330.4	KB-1471A8.1	3.41	0.000675	0.0316	0.15	0.11	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119756447	chr8:119867419~119874488:-
BRCA	cis	rs14027	0.921	rs2326377	ENSG00000245330.4	KB-1471A8.1	3.41	0.000675	0.0316	0.15	0.11	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119756696	chr8:119867419~119874488:-
BRCA	cis	rs14027	0.921	rs13257002	ENSG00000245330.4	KB-1471A8.1	3.41	0.000675	0.0316	0.15	0.11	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119757489	chr8:119867419~119874488:-
BRCA	cis	rs14027	0.921	rs62526565	ENSG00000245330.4	KB-1471A8.1	3.41	0.000675	0.0316	0.15	0.11	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119759301	chr8:119867419~119874488:-
BRCA	cis	rs7975161	1	rs7975161	ENSG00000257681.1	RP11-341G23.4	3.41	0.000675	0.0316	0.15	0.11	Toenail selenium levels;	chr12:104251627	chr12:103746315~103768858:-
BRCA	cis	rs11711311	0.747	rs7638449	ENSG00000241529.3	RN7SL767P	-3.41	0.000675	0.0316	-0.12	-0.11	IgG glycosylation;	chr3:113624799	chr3:113632704~113632998:+
BRCA	cis	rs7172689	0.908	rs4076201	ENSG00000273920.1	RP11-761I4.5	-3.41	0.000675	0.0316	-0.15	-0.11	Inattentive symptoms;	chr15:81279962	chr15:81335577~81336119:+
BRCA	cis	rs1484642	0.53	rs17151071	ENSG00000272505.1	RP11-981G7.6	3.41	0.000675	0.0316	0.15	0.11	Bipolar disorder and schizophrenia;	chr8:10099162	chr8:10486807~10489666:+
BRCA	cis	rs2455799	0.573	rs2255248	ENSG00000224728.1	AC090945.1	3.41	0.000675	0.0316	0.1	0.11	Mean platelet volume;	chr3:15713342	chr3:15878047~15879571:+
BRCA	cis	rs12220238	0.915	rs11001014	ENSG00000213731.2	RAB5CP1	3.41	0.000675	0.0316	0.16	0.11	Soluble interleukin-2 receptor subunit alpha;	chr10:74369074	chr10:74423435~74424014:-
BRCA	cis	rs7267979	0.966	rs6037083	ENSG00000274414.1	RP5-965G21.4	3.41	0.000675	0.0316	0.12	0.11	Liver enzyme levels (alkaline phosphatase);	chr20:25309907	chr20:25239007~25245229:-
BRCA	cis	rs11175492	0.92	rs112204838	ENSG00000243024.5	RPS11P6	-3.41	0.000675	0.0316	-0.25	-0.11	Platelet count;	chr12:64679383	chr12:64222337~64397065:+
BRCA	cis	rs7412746	0.611	rs4970984	ENSG00000224800.1	RP11-235D19.2	-3.41	0.000675	0.0316	-0.13	-0.11	Melanoma;	chr1:150914901	chr1:150881236~150881683:-
BRCA	cis	rs2216824	1	rs10184608	ENSG00000278908.1	RP11-523J2.1	3.41	0.000675	0.0316	0.18	0.11	Oropharynx cancer;	chr2:30884315	chr2:30677762~30679895:+
BRCA	cis	rs4374383	0.631	rs1400322	ENSG00000243389.1	AC012442.5	-3.41	0.000675	0.0316	-0.13	-0.11	Hepatitis C induced liver fibrosis;	chr2:111912608	chr2:112589040~112614431:+
BRCA	cis	rs875971	1	rs6958271	ENSG00000271064.1	RP11-792A8.3	-3.41	0.000675	0.0316	-0.12	-0.11	Aortic root size;	chr7:66514344	chr7:66748838~66749077:-
BRCA	cis	rs875971	1	rs6958277	ENSG00000271064.1	RP11-792A8.3	-3.41	0.000675	0.0316	-0.12	-0.11	Aortic root size;	chr7:66514362	chr7:66748838~66749077:-
BRCA	cis	rs4819052	0.851	rs2838843	ENSG00000223768.1	LINC00205	-3.41	0.000675	0.0316	-0.14	-0.11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45249369	chr21:45293285~45297354:+
BRCA	cis	rs9921338	0.961	rs7187870	ENSG00000263080.1	RP11-485G7.5	3.41	0.000675	0.0316	0.16	0.11	Vein graft stenosis in coronary artery bypass grafting;	chr16:11338062	chr16:11341809~11345211:-
BRCA	cis	rs11683197	0.901	rs11678749	ENSG00000237979.1	AC007389.1	-3.41	0.000675	0.0316	-0.14	-0.11	Visceral fat;	chr2:64800964	chr2:65500993~65502138:-
BRCA	cis	rs2834256	0.527	rs9983901	ENSG00000231355.1	AP000302.58	3.41	0.000675	0.0316	0.13	0.11	Red cell distribution width;	chr21:33494546	chr21:33482499~33484258:-
BRCA	cis	rs6802315	0.712	rs7615751	ENSG00000272440.1	RP11-379F4.6	3.41	0.000675	0.0316	0.13	0.11	Periodontitis (CDC/AAP);	chr3:158792041	chr3:158695367~158695581:+
BRCA	cis	rs8025790	0.508	rs4776370	ENSG00000270964.1	RP11-502I4.3	-3.41	0.000676	0.0316	-0.13	-0.11	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Body mass index;	chr15:67612173	chr15:67541072~67542604:-
BRCA	cis	rs7551222	0.75	rs898387	ENSG00000240219.1	RP11-430C7.5	-3.41	0.000676	0.0316	-0.13	-0.11	Schizophrenia;	chr1:204610245	chr1:204626775~204629712:+
BRCA	cis	rs1865760	0.827	rs9295680	ENSG00000272810.1	U91328.22	-3.41	0.000676	0.0316	-0.12	-0.11	Height;	chr6:25943875	chr6:26013241~26013757:+
BRCA	cis	rs1865760	0.827	rs9295681	ENSG00000272810.1	U91328.22	-3.41	0.000676	0.0316	-0.12	-0.11	Height;	chr6:25943889	chr6:26013241~26013757:+
BRCA	cis	rs10958369	0.541	rs1477956	ENSG00000274295.1	RP11-1081M5.3	3.41	0.000676	0.0316	0.13	0.11	Response to antineoplastic agents;	chr8:53522667	chr8:53394215~53394795:+
BRCA	cis	rs757081	0.658	rs214075	ENSG00000272034.1	SNORD14A	-3.41	0.000676	0.0316	-0.11	-0.11	Systolic blood pressure;	chr11:17278870	chr11:17074654~17074744:-
BRCA	cis	rs4713118	0.513	rs149955	ENSG00000219891.2	ZSCAN12P1	3.41	0.000676	0.0316	0.13	0.11	Parkinson's disease;	chr6:28068447	chr6:28091154~28093664:+
BRCA	cis	rs6142102	0.961	rs2284389	ENSG00000206582.1	Y_RNA	-3.41	0.000676	0.0316	-0.12	-0.11	Skin pigmentation;	chr20:34069035	chr20:34526510~34526606:-
BRCA	cis	rs11790131	0.742	rs12336917	ENSG00000272842.1	RP11-513M16.7	3.41	0.000676	0.0316	0.13	0.11	Liver fibrosis severity in HIV/hepatitis C co-infection;	chr9:19471207	chr9:19371386~19371945:-
BRCA	cis	rs11587682	0.76	rs12731738	ENSG00000228126.1	FALEC	3.41	0.000676	0.0316	0.14	0.11	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr1:150496098	chr1:150515757~150518032:+
BRCA	cis	rs11587682	0.76	rs1343965	ENSG00000228126.1	FALEC	3.41	0.000676	0.0316	0.14	0.11	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr1:150496366	chr1:150515757~150518032:+
BRCA	cis	rs6964587	0.61	rs2888850	ENSG00000188693.7	CYP51A1-AS1	-3.41	0.000676	0.0316	-0.11	-0.11	Breast cancer;	chr7:91800713	chr7:92134604~92180725:+
BRCA	cis	rs1371614	0.632	rs4665929	ENSG00000229122.1	AGBL5-IT1	-3.41	0.000676	0.0316	-0.11	-0.11	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26932981	chr2:27061038~27061815:+
BRCA	cis	rs7020830	0.894	rs12337316	ENSG00000230188.1	RP11-405L18.4	-3.41	0.000676	0.0316	-0.13	-0.11	Schizophrenia;	chr9:37148108	chr9:37490421~37490893:-
BRCA	cis	rs943466	1	rs2395400	ENSG00000223837.2	BRD2-IT1	3.41	0.000676	0.0316	0.13	0.11	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;	chr6:33802299	chr6:32970232~32970886:+
BRCA	cis	rs12460587	0.622	rs7247612	ENSG00000268282.1	CTD-2620I22.2	-3.41	0.000676	0.0316	-0.13	-0.11	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52082336	chr19:53004040~53005150:+
BRCA	cis	rs7771547	0.855	rs9368942	ENSG00000224666.3	RP1-50J22.4	3.41	0.000676	0.0316	0.11	0.11	Platelet distribution width;	chr6:36598736	chr6:36386831~36393462:+
BRCA	cis	rs875971	0.964	rs55748098	ENSG00000271064.1	RP11-792A8.3	3.41	0.000676	0.0316	0.12	0.11	Aortic root size;	chr7:66298631	chr7:66748838~66749077:-
BRCA	cis	rs2411233	1	rs2411231	ENSG00000259278.1	RP11-62C7.2	3.41	0.000676	0.0316	0.12	0.11	Platelet count;	chr15:38982469	chr15:39019233~39024918:+
BRCA	cis	rs72775230	0.68	rs72775236	ENSG00000233990.1	RP11-401E9.3	-3.41	0.000676	0.0316	-0.19	-0.11	Conotruncal heart defects (inherited effects);	chr10:8516952	chr10:7833618~7833957:-
BRCA	cis	rs2108622	0.727	rs8104311	ENSG00000214049.6	UCA1	3.41	0.000676	0.0316	0.15	0.11	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871950	chr19:15828961~15836320:+
BRCA	cis	rs4865762	0.595	rs251505	ENSG00000247796.2	CTD-2366F13.1	3.41	0.000676	0.0316	0.11	0.11	Intraocular pressure;	chr5:53248259	chr5:53109842~53115126:+
BRCA	cis	rs7017914	0.967	rs7825446	ENSG00000246366.5	RP11-382J12.1	3.41	0.000676	0.0316	0.12	0.11	Bone mineral density;	chr8:70751939	chr8:70608577~70663279:+
BRCA	cis	rs875971	0.929	rs10950041	ENSG00000273024.4	INTS4P2	-3.41	0.000676	0.0316	-0.11	-0.11	Aortic root size;	chr7:66508888	chr7:65647864~65715661:+
BRCA	cis	rs72683786	0.623	rs9644448	ENSG00000280303.2	ERICD	3.41	0.000676	0.0316	0.17	0.11	Mean corpuscular hemoglobin;	chr8:140805075	chr8:140636281~140638283:+
BRCA	cis	rs5758511	0.773	rs1894714	ENSG00000233903.2	Z83851.4	-3.41	0.000676	0.0316	-0.15	-0.11	Birth weight;	chr22:41953130	chr22:42276355~42277052:+
BRCA	cis	rs7429990	0.932	rs34025851	ENSG00000228638.1	FCF1P2	-3.41	0.000676	0.0316	-0.11	-0.11	Educational attainment (years of education);	chr3:47912243	chr3:48290793~48291375:-
BRCA	cis	rs801193	0.839	rs12534943	ENSG00000265600.1	AC006480.1	3.41	0.000676	0.0316	0.12	0.11	Aortic root size;	chr7:66605533	chr7:67356680~67356779:+
BRCA	cis	rs7824557	0.592	rs2572371	ENSG00000255046.1	RP11-297N6.4	-3.41	0.000676	0.0316	-0.12	-0.11	Retinal vascular caliber;	chr8:11366284	chr8:11797928~11802568:-
BRCA	cis	rs12612435	0.736	rs13004954	ENSG00000226806.1	AC011893.3	3.41	0.000677	0.0316	0.13	0.11	Takotsubo syndrome;	chr2:136391545	chr2:135820191~135823087:+
BRCA	cis	rs4363385	0.51	rs6661063	ENSG00000231416.1	RP11-422P24.9	3.41	0.000677	0.0316	0.11	0.11	Inflammatory skin disease;	chr1:153063572	chr1:153995632~153995960:+
BRCA	cis	rs875971	1	rs778696	ENSG00000229886.1	RP5-1132H15.3	3.41	0.000677	0.0316	0.12	0.11	Aortic root size;	chr7:66405826	chr7:66025126~66031544:-
BRCA	cis	rs875971	1	rs778694	ENSG00000229886.1	RP5-1132H15.3	3.41	0.000677	0.0316	0.12	0.11	Aortic root size;	chr7:66406571	chr7:66025126~66031544:-
BRCA	cis	rs875971	1	rs4718344	ENSG00000229886.1	RP5-1132H15.3	3.41	0.000677	0.0316	0.12	0.11	Aortic root size;	chr7:66409394	chr7:66025126~66031544:-
BRCA	cis	rs875971	0.737	rs7803424	ENSG00000229886.1	RP5-1132H15.3	3.41	0.000677	0.0316	0.12	0.11	Aortic root size;	chr7:66415618	chr7:66025126~66031544:-
BRCA	cis	rs875971	0.83	rs7799834	ENSG00000229886.1	RP5-1132H15.3	3.41	0.000677	0.0316	0.12	0.11	Aortic root size;	chr7:66415707	chr7:66025126~66031544:-
BRCA	cis	rs10043228	1	rs10062350	ENSG00000250015.1	CTC-339F2.2	3.41	0.000677	0.0316	0.15	0.11	Asthma or chronic obstructive pulmonary disease;	chr5:116117800	chr5:116302354~116304134:-
BRCA	cis	rs7818688	1	rs16917224	ENSG00000245080.5	RP11-320N21.1	-3.41	0.000677	0.0316	-0.18	-0.11	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95017882	chr8:95066808~95073182:-
BRCA	cis	rs1790761	0.587	rs4930430	ENSG00000273819.1	ENPP7P7	3.41	0.000677	0.0316	0.12	0.11	Mean corpuscular volume;	chr11:67526727	chr11:67812557~67873367:-
BRCA	cis	rs736801	0.808	rs4705950	ENSG00000233006.5	AC034220.3	3.41	0.000677	0.0316	0.08	0.11	Mosquito bite size;Breast cancer;	chr5:132457594	chr5:132311285~132369916:-
BRCA	cis	rs3764021	0.527	rs10844456	ENSG00000260423.1	RP13-735L24.1	-3.41	0.000677	0.0316	-0.12	-0.11	Type 1 diabetes;	chr12:9689319	chr12:9367464~9397617:+
BRCA	cis	rs863345	0.604	rs975118	ENSG00000176320.2	RP11-404O13.5	-3.41	0.000677	0.0316	-0.11	-0.11	Pneumococcal bacteremia;	chr1:158541655	chr1:158197922~158203877:-
BRCA	cis	rs703108	0.956	rs1170492	ENSG00000279623.1	RP11-399C16.3	-3.41	0.000677	0.0316	-0.15	-0.11	Monocyte percentage of white cells;	chr10:22216874	chr10:21865335~21865921:-
BRCA	cis	rs7474896	1	rs61859667	ENSG00000120555.12	SEPT7P9	3.41	0.000677	0.0316	0.19	0.11	Obesity (extreme);	chr10:37727451	chr10:38383069~38402916:-
BRCA	cis	rs10782582	0.593	rs12132750	ENSG00000181227.3	RP4-682C21.2	3.41	0.000677	0.0316	0.11	0.11	Daytime sleep phenotypes;	chr1:75670537	chr1:75743423~75744776:-
BRCA	cis	rs1178127	0.58	rs17139840	ENSG00000232821.1	AC003986.6	3.41	0.000677	0.0316	0.15	0.11	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);	chr7:18760980	chr7:19112474~19114271:+
BRCA	cis	rs2615061	0.935	rs61849046	ENSG00000229965.1	RP11-118H4.1	3.41	0.000677	0.0316	0.19	0.11	Monocyte count;	chr1:225743096	chr1:226438564~226439344:+
BRCA	cis	rs2615061	0.872	rs12042778	ENSG00000229965.1	RP11-118H4.1	3.41	0.000677	0.0316	0.19	0.11	Monocyte count;	chr1:225744363	chr1:226438564~226439344:+
BRCA	cis	rs2615061	0.872	rs12025075	ENSG00000229965.1	RP11-118H4.1	3.41	0.000677	0.0316	0.19	0.11	Monocyte count;	chr1:225744364	chr1:226438564~226439344:+
BRCA	cis	rs2615061	0.872	rs12025267	ENSG00000229965.1	RP11-118H4.1	3.41	0.000677	0.0316	0.19	0.11	Monocyte count;	chr1:225744984	chr1:226438564~226439344:+
BRCA	cis	rs6963495	0.818	rs73192125	ENSG00000223886.3	RP11-251G23.2	3.41	0.000677	0.0316	0.15	0.11	Bipolar disorder (body mass index interaction);	chr7:105534621	chr7:105530209~105530671:+
BRCA	cis	rs889122	0.531	rs8113425	ENSG00000267289.1	CTD-2623N2.11	-3.41	0.000677	0.0316	-0.12	-0.11	Menarche (age at onset);	chr19:9889630	chr19:9834079~9835013:-
BRCA	cis	rs2489715	0.7	rs2419678	ENSG00000185904.10	LINC00839	3.41	0.000677	0.0316	0.13	0.11	Helix rolling;	chr10:42396574	chr10:42475543~42495336:+
BRCA	cis	rs8023401	0.938	rs35011719	ENSG00000274654.1	CTD-3247H4.2	3.41	0.000677	0.0316	0.15	0.11	Spherical equivalent (joint analysis main effects and education interaction);	chr15:48520186	chr15:48528980~48529728:-
BRCA	cis	rs3739034	0.938	rs62171395	ENSG00000224043.6	CCNT2-AS1	-3.41	0.000677	0.0316	-0.18	-0.11	Gut microbiome composition (winter);	chr2:134719265	chr2:134735464~134918710:-
BRCA	cis	rs17801127	0.901	rs6708629	ENSG00000231969.1	AC144449.1	3.41	0.000677	0.0316	0.18	0.11	Liver enzyme levels (alanine transaminase);	chr2:149685243	chr2:149587196~149848233:+
BRCA	cis	rs12489946	0.818	rs7626738	ENSG00000239213.4	NCK1-AS1	-3.41	0.000677	0.0317	-0.17	-0.11	Initial pursuit acceleration;	chr3:137069440	chr3:136841726~136862054:-
BRCA	cis	rs2274273	1	rs10149435	ENSG00000259318.1	RP11-454L9.2	3.41	0.000677	0.0317	0.09	0.11	Protein biomarker;	chr14:55160771	chr14:55394940~55395233:-
BRCA	cis	rs1707322	0.789	rs7540578	ENSG00000226957.1	RP4-533D7.4	-3.41	0.000678	0.0317	-0.12	-0.11	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45786472	chr1:46046818~46048368:+
BRCA	cis	rs1009077	0.61	rs3756154	ENSG00000245958.5	RP11-33B1.1	-3.41	0.000678	0.0317	-0.11	-0.11	Endometriosis;	chr4:119597174	chr4:119454791~119552025:+
BRCA	cis	rs10043775	0.831	rs67468705	ENSG00000251330.3	CTD-2283N19.1	-3.41	0.000678	0.0317	-0.12	-0.11	Periodontal microbiota;	chr5:148322659	chr5:148430159~148430807:-
BRCA	cis	rs873549	1	rs2378519	ENSG00000227925.1	RP11-191N8.2	3.41	0.000678	0.0317	0.12	0.11	Keloid;	chr1:222100526	chr1:221827666~221840666:-
BRCA	cis	rs10191559	0.552	rs4432411	ENSG00000234663.4	AC104820.2	3.41	0.000678	0.0317	0.09	0.11	Red blood cell count;	chr2:181204277	chr2:181101932~181399559:+
BRCA	cis	rs2043112	0.691	rs10064513	ENSG00000249911.1	LINC01265	3.41	0.000678	0.0317	0.12	0.11	Obesity-related traits;	chr5:39081373	chr5:38710367~38720273:-
BRCA	cis	rs6142102	1	rs4911412	ENSG00000206582.1	Y_RNA	-3.41	0.000678	0.0317	-0.13	-0.11	Skin pigmentation;	chr20:34128629	chr20:34526510~34526606:-
BRCA	cis	rs524281	0.861	rs10896081	ENSG00000255038.1	RP11-1167A19.2	-3.41	0.000678	0.0317	-0.15	-0.11	Electroencephalogram traits;	chr11:66112883	chr11:66067277~66069619:-
BRCA	cis	rs875971	0.929	rs10950041	ENSG00000272831.1	RP11-792A8.4	3.41	0.000678	0.0317	0.09	0.11	Aortic root size;	chr7:66508888	chr7:66739829~66740385:-
BRCA	cis	rs8040855	0.627	rs35668291	ENSG00000229212.6	RP11-561C5.4	-3.41	0.000678	0.0317	-0.14	-0.11	Bulimia nervosa;	chr15:85109582	chr15:85205440~85234795:-
BRCA	cis	rs60432013	0.584	rs3764167	ENSG00000211813.2	TRAV34	3.41	0.000678	0.0317	0.18	0.11	Red cell distribution width;	chr14:23050766	chr14:22207522~22208129:+
BRCA	cis	rs8180040	0.932	rs62246474	ENSG00000280667.1	Y_RNA	-3.41	0.000678	0.0317	-0.12	-0.11	Colorectal cancer;	chr3:47356640	chr3:47501083~47501182:+
BRCA	cis	rs1348850	0.831	rs7606235	ENSG00000271825.1	RP11-337N6.2	3.41	0.000678	0.0317	0.14	0.11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177536560	chr2:177300600~177302006:+
BRCA	cis	rs1979679	0.879	rs980920	ENSG00000244712.1	RP11-874G11.1	-3.41	0.000678	0.0317	-0.15	-0.11	Ossification of the posterior longitudinal ligament of the spine;	chr12:28316178	chr12:28564678~28565141:-
BRCA	cis	rs897984	0.568	rs4889653	ENSG00000274678.1	RP11-2C24.7	-3.41	0.000678	0.0317	-0.13	-0.11	Dementia with Lewy bodies;	chr16:30884392	chr16:30821338~30821884:+
BRCA	cis	rs62458065	0.568	rs62466415	ENSG00000229358.3	DPY19L1P1	-3.41	0.000679	0.0317	-0.15	-0.11	Metabolite levels (HVA/MHPG ratio);	chr7:32478642	chr7:32580949~32761787:-
BRCA	cis	rs2333021	0.711	rs34518714	ENSG00000258408.1	NT5CP2	3.41	0.000679	0.0317	0.11	0.11	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:72992601	chr14:73539221~73539781:-
BRCA	cis	rs7618915	0.501	rs2289247	ENSG00000222345.1	SNORD19	3.41	0.000679	0.0317	0.11	0.11	Bipolar disorder;	chr3:52693241	chr3:52691378~52691453:+
BRCA	cis	rs10782582	0.593	rs11163915	ENSG00000181227.3	RP4-682C21.2	3.41	0.000679	0.0317	0.11	0.11	Daytime sleep phenotypes;	chr1:75664514	chr1:75743423~75744776:-
BRCA	cis	rs7594648	0.782	rs1517468	ENSG00000226383.4	AC093375.1	3.41	0.000679	0.0317	0.15	0.11	Age-related hearing impairment;	chr2:155643695	chr2:156011617~156024613:-
BRCA	cis	rs8114671	0.562	rs4911450	ENSG00000279253.1	RP4-614O4.13	-3.41	0.000679	0.0317	-0.12	-0.11	Height;	chr20:34924603	chr20:35262727~35264187:-
BRCA	cis	rs2280018	0.963	rs11075255	ENSG00000258354.1	MIR3180-1	-3.41	0.000679	0.0317	-0.13	-0.11	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15072375	chr16:14909887~14911345:-
BRCA	cis	rs860295	0.812	rs10908481	ENSG00000203761.5	MSTO2P	-3.41	0.000679	0.0317	-0.09	-0.11	Body mass index;	chr1:155743859	chr1:155745829~155750137:+
BRCA	cis	rs12887734	0.524	rs4900599	ENSG00000269910.1	RP11-73M18.10	3.41	0.000679	0.0317	0.11	0.11	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103817107	chr14:103694516~103695050:-
BRCA	cis	rs9807841	0.67	rs8099926	ENSG00000267100.1	ILF3-AS1	3.41	0.000679	0.0317	0.11	0.11	Inflammatory skin disease;	chr19:10667971	chr19:10651862~10653844:-
BRCA	cis	rs17711722	0.64	rs13237956	ENSG00000227113.2	RP11-460N20.4	3.41	0.000679	0.0317	0.11	0.11	Calcium levels;	chr7:65853042	chr7:65075023~65078780:+
BRCA	cis	rs10876993	0.928	rs1628552	ENSG00000269903.1	RP11-571M6.18	3.41	0.000679	0.0317	0.13	0.11	Celiac disease or Rheumatoid arthritis;	chr12:57688359	chr12:57814494~57814926:+
BRCA	cis	rs4908769	0.66	rs172531	ENSG00000232912.4	RP5-1115A15.1	-3.41	0.000679	0.0317	-0.11	-0.11	Allergy;	chr1:8435530	chr1:8424645~8434838:+
BRCA	cis	rs4819052	0.959	rs9976074	ENSG00000184274.3	LINC00315	-3.41	0.000679	0.0317	-0.15	-0.1	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45235723	chr21:45300245~45305257:-
BRCA	cis	rs6142618	0.523	rs4911087	ENSG00000275576.1	RP5-836N17.4	-3.41	0.000679	0.0317	-0.12	-0.1	Inflammatory bowel disease;	chr20:32256733	chr20:32116171~32116629:+
BRCA	cis	rs2243480	0.803	rs36127118	ENSG00000229180.5	GS1-124K5.11	3.41	0.000679	0.0317	0.14	0.1	Diabetic kidney disease;	chr7:66100518	chr7:66526088~66542624:-
BRCA	cis	rs8180040	0.545	rs9311403	ENSG00000280667.1	Y_RNA	3.41	0.000679	0.0317	0.12	0.1	Colorectal cancer;	chr3:47097388	chr3:47501083~47501182:+
BRCA	cis	rs10782582	0.593	rs11801414	ENSG00000181227.3	RP4-682C21.2	3.41	0.000679	0.0317	0.11	0.1	Daytime sleep phenotypes;	chr1:75658832	chr1:75743423~75744776:-
BRCA	cis	rs10782582	0.593	rs11802717	ENSG00000181227.3	RP4-682C21.2	3.41	0.000679	0.0317	0.11	0.1	Daytime sleep phenotypes;	chr1:75658963	chr1:75743423~75744776:-
BRCA	cis	rs10782582	0.569	rs4549990	ENSG00000181227.3	RP4-682C21.2	3.41	0.000679	0.0317	0.11	0.1	Daytime sleep phenotypes;	chr1:75659390	chr1:75743423~75744776:-
BRCA	cis	rs12726943	0.518	rs589873	ENSG00000236468.1	RP11-104D3.2	3.41	0.000679	0.0317	0.13	0.1	Perceived unattractiveness to mosquitoes;	chr1:199427729	chr1:199387141~199388475:+
BRCA	cis	rs1949733	0.628	rs1543246	ENSG00000250471.2	GMPSP1	3.41	0.000679	0.0317	0.11	0.1	Response to antineoplastic agents;	chr4:8503182	chr4:8174421~8174999:+
BRCA	cis	rs74233809	1	rs11191519	ENSG00000213061.2	PFN1P11	3.41	0.000679	0.0317	0.23	0.1	Birth weight;	chr10:103025161	chr10:102838011~102845473:-
BRCA	cis	rs55883249	1	rs55883249	ENSG00000217258.2	AC007249.3	3.41	0.000679	0.0317	0.16	0.1	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:9601406	chr2:10452319~10455552:+
BRCA	cis	rs4557020	0.901	rs4671937	ENSG00000162997.14	PRORSD1P	-3.41	0.000679	0.0317	-0.12	-0.1	Myopia (pathological);	chr2:54465678	chr2:55282319~55284522:+
BRCA	cis	rs875971	0.862	rs13226170	ENSG00000106610.13	STAG3L4	-3.41	0.000679	0.0317	-0.14	-0.1	Aortic root size;	chr7:66534311	chr7:67302621~67321526:+
BRCA	cis	rs875971	0.862	rs2420611	ENSG00000106610.13	STAG3L4	-3.41	0.000679	0.0317	-0.14	-0.1	Aortic root size;	chr7:66534333	chr7:67302621~67321526:+
BRCA	cis	rs1998359	0.953	rs1022804	ENSG00000259087.4	RP11-356O9.2	3.41	0.000679	0.0317	0.12	0.1	Self-reported allergy;	chr14:37711608	chr14:37556158~37567095:-
BRCA	cis	rs1348850	0.872	rs2084233	ENSG00000280374.1	RP11-337N6.3	3.41	0.000679	0.0317	0.14	0.1	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177466478	chr2:177317715~177318471:-
BRCA	cis	rs7259376	0.936	rs12608491	ENSG00000269345.1	VN1R85P	3.41	0.000679	0.0317	0.12	0.1	Menopause (age at onset);	chr19:22358825	chr19:22174766~22175191:-
BRCA	cis	rs2899832	0.5	rs75053077	ENSG00000258704.4	SRP54-AS1	3.41	0.000679	0.0317	0.25	0.1	Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:35274986	chr14:34920858~34982532:-
BRCA	cis	rs8002861	0.935	rs7318147	ENSG00000237361.2	TUSC8	-3.41	0.000679	0.0317	-0.14	-0.1	Leprosy;	chr13:43871017	chr13:44400250~44405984:-
BRCA	cis	rs875971	0.862	rs6460307	ENSG00000273024.4	INTS4P2	-3.41	0.000679	0.0317	-0.12	-0.1	Aortic root size;	chr7:66595884	chr7:65647864~65715661:+
BRCA	cis	rs2072510	0.683	rs2246973	ENSG00000237774.3	RP11-129B9.1	3.41	0.00068	0.0317	0.12	0.1	Metabolite levels (small molecules and protein measures);	chr12:96034097	chr12:95125760~95126389:+
BRCA	cis	rs10005067	0.935	rs12509080	ENSG00000249001.4	RP11-742B18.1	-3.41	0.00068	0.0317	-0.12	-0.1	Total body bone mineral density (age 30-45);	chr4:87896660	chr4:87568035~87733956:-
BRCA	cis	rs2439831	0.702	rs9989313	ENSG00000206991.1	RNU6-610P	-3.41	0.00068	0.0317	-0.17	-0.1	Lung cancer in ever smokers;	chr15:43860619	chr15:43637632~43637738:-
BRCA	cis	rs12959333	0.527	rs12709679	ENSG00000257267.2	ZNF271P	-3.41	0.00068	0.0317	-0.14	-0.1	Post bronchodilator FEV1;	chr18:35689830	chr18:35290282~35310766:+
BRCA	cis	rs4805834	0.843	rs73036814	ENSG00000201388.1	SNORA68	3.41	0.00068	0.0317	0.17	0.1	Creatinine levels;	chr19:32852710	chr19:32608337~32608469:-
BRCA	cis	rs6545883	0.507	rs6545855	ENSG00000270820.4	RP11-355B11.2	-3.41	0.00068	0.0317	-0.11	-0.1	Tuberculosis;	chr2:61305725	chr2:61471188~61484130:+
BRCA	cis	rs7188861	0.681	rs12922090	ENSG00000262636.1	CTD-3088G3.4	3.41	0.00068	0.0317	0.21	0.1	HDL cholesterol;	chr16:11321260	chr16:11380859~11381118:-
BRCA	cis	rs875971	0.862	rs6460306	ENSG00000106610.13	STAG3L4	3.41	0.00068	0.0317	0.14	0.1	Aortic root size;	chr7:66595806	chr7:67302621~67321526:+
BRCA	cis	rs9813712	0.953	rs9847910	ENSG00000228252.7	COL6A4P2	3.41	0.00068	0.0317	0.14	0.1	Response to amphetamines;	chr3:130248174	chr3:130212823~130273806:+
BRCA	cis	rs12724450	0.546	rs71622689	ENSG00000228126.1	FALEC	3.41	0.00068	0.0317	0.19	0.1	Blood protein levels;	chr1:150307169	chr1:150515757~150518032:+
BRCA	cis	rs12724450	0.793	rs4845	ENSG00000228126.1	FALEC	3.41	0.00068	0.0317	0.19	0.1	Blood protein levels;	chr1:150308116	chr1:150515757~150518032:+
BRCA	cis	rs4759375	0.92	rs28786830	ENSG00000256092.2	RP13-942N8.1	3.41	0.00068	0.0317	0.17	0.1	HDL cholesterol;	chr12:123375925	chr12:123363868~123366113:+
BRCA	cis	rs2274273	1	rs66871576	ENSG00000233924.1	AL160471.6	-3.41	0.00068	0.0317	-0.12	-0.1	Protein biomarker;	chr14:55162332	chr14:55004813~55005687:-
BRCA	cis	rs17741049	0.881	rs55702127	ENSG00000260493.1	RP11-219B4.7	-3.41	0.00068	0.0318	-0.24	-0.1	Blood protein levels;	chr8:85282258	chr8:85172077~85177062:-
BRCA	cis	rs45509595	0.822	rs200484	ENSG00000241549.7	GUSBP2	3.41	0.00068	0.0318	0.18	0.1	Breast cancer;	chr6:27807896	chr6:26871484~26956554:-
BRCA	cis	rs9906595	1	rs9906595	ENSG00000277182.1	CTB-58E17.5	-3.41	0.00068	0.0318	-0.21	-0.1	Obesity-related traits;	chr17:38945127	chr17:38749360~38751457:+
BRCA	cis	rs4578769	0.84	rs12232566	ENSG00000265939.1	UBE2CP2	-3.41	0.00068	0.0318	-0.13	-0.1	Eosinophil percentage of white cells;	chr18:22897295	chr18:22900486~22900995:-
BRCA	cis	rs1816752	0.837	rs7139748	ENSG00000273628.1	RP11-756A22.7	3.41	0.00068	0.0318	0.13	0.1	Obesity-related traits;	chr13:24411531	chr13:24933006~24936796:+
BRCA	cis	rs3099143	1	rs3099137	ENSG00000196274.5	Metazoa_SRP	3.41	0.00068	0.0318	0.15	0.1	Recalcitrant atopic dermatitis;	chr15:76831285	chr15:76230048~76230390:-
BRCA	cis	rs3099143	1	rs3110378	ENSG00000196274.5	Metazoa_SRP	3.41	0.00068	0.0318	0.15	0.1	Recalcitrant atopic dermatitis;	chr15:76835642	chr15:76230048~76230390:-
BRCA	cis	rs11239930	0.517	rs492243	ENSG00000227242.3	NBPF13P	-3.41	0.00068	0.0318	-0.13	-0.1	AIDS progression;	chr1:147077930	chr1:147021320~147124525:-
BRCA	cis	rs1816752	0.905	rs9581026	ENSG00000273628.1	RP11-756A22.7	3.41	0.00068	0.0318	0.13	0.1	Obesity-related traits;	chr13:24423788	chr13:24933006~24936796:+
BRCA	cis	rs10739695	0.935	rs10739694	ENSG00000225032.4	RP11-228B15.4	3.41	0.00068	0.0318	0.09	0.1	Monocyte percentage of white cells;	chr9:127764326	chr9:127816066~127822520:+
BRCA	cis	rs801193	0.901	rs4273746	ENSG00000232546.1	RP11-458F8.1	3.41	0.000681	0.0318	0.09	0.1	Aortic root size;	chr7:66836124	chr7:66848496~66858136:+
BRCA	cis	rs77320796	0.953	rs77692382	ENSG00000226745.2	RP11-115D7.3	-3.41	0.000681	0.0318	-0.17	-0.1	Platelet count;	chr1:39941043	chr1:40132764~40133448:+
BRCA	cis	rs997295	0.57	rs737226	ENSG00000259673.4	IQCH-AS1	3.41	0.000681	0.0318	0.12	0.1	Motion sickness;	chr15:67548435	chr15:67403619~67521844:-
BRCA	cis	rs6914598	0.876	rs9460603	ENSG00000240869.3	RN7SL128P	-3.41	0.000681	0.0318	-0.15	-0.1	Cutaneous malignant melanoma;Melanoma;	chr6:21164958	chr6:20421583~20421887:-
BRCA	cis	rs7520050	0.872	rs2486445	ENSG00000234329.1	RP11-767N6.2	-3.41	0.000681	0.0318	-0.1	-0.1	Reticulocyte count;Red blood cell count;	chr1:46139697	chr1:45651039~45651826:-
BRCA	cis	rs7660883	0.897	rs2125787	ENSG00000251411.1	RP11-397E7.4	3.41	0.000681	0.0318	0.11	0.1	HDL cholesterol levels;	chr4:87075471	chr4:86913266~86914817:-
BRCA	cis	rs10504130	0.569	rs34364864	ENSG00000272076.1	RP11-11C20.3	3.41	0.000681	0.0318	0.15	0.1	Venous thromboembolism (SNP x SNP interaction);	chr8:51817086	chr8:51810110~51810681:-
BRCA	cis	rs1468333	0.667	rs113260319	ENSG00000206989.1	SNORD63	3.41	0.000681	0.0318	0.12	0.1	Resting heart rate;	chr5:138407024	chr5:138561043~138561110:-
BRCA	cis	rs8040855	0.627	rs17541051	ENSG00000229212.6	RP11-561C5.4	-3.41	0.000681	0.0318	-0.14	-0.1	Bulimia nervosa;	chr15:85106122	chr15:85205440~85234795:-
BRCA	cis	rs13401620	0.917	rs7606911	ENSG00000229326.3	AC069154.4	3.41	0.000681	0.0318	0.14	0.1	Breast size;	chr2:119815963	chr2:119698623~119700151:+
BRCA	cis	rs9467711	0.79	rs13198716	ENSG00000241549.7	GUSBP2	-3.41	0.000681	0.0318	-0.23	-0.1	Autism spectrum disorder or schizophrenia;	chr6:26581807	chr6:26871484~26956554:-
BRCA	cis	rs8023401	0.938	rs12909238	ENSG00000274654.1	CTD-3247H4.2	3.41	0.000681	0.0318	0.15	0.1	Spherical equivalent (joint analysis main effects and education interaction);	chr15:48489186	chr15:48528980~48529728:-
BRCA	cis	rs58521262	0.729	rs11667539	ENSG00000268105.1	RP11-369G6.2	-3.41	0.000681	0.0318	-0.17	-0.1	Testicular germ cell tumor;	chr19:22879889	chr19:23125665~23128543:+
BRCA	cis	rs7833986	0.534	rs72653928	ENSG00000253603.1	CTA-397H3.3	-3.41	0.000681	0.0318	-0.15	-0.1	Height;	chr8:55995176	chr8:56074592~56075274:+
BRCA	cis	rs7267979	1	rs2257991	ENSG00000204556.4	CTD-2514C3.1	3.41	0.000681	0.0318	0.14	0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25289703	chr20:26018832~26020684:+
BRCA	cis	rs8180040	0.593	rs4018905	ENSG00000280667.1	Y_RNA	3.41	0.000681	0.0318	0.12	0.1	Colorectal cancer;	chr3:47096680	chr3:47501083~47501182:+
BRCA	cis	rs7914558	1	rs4917996	ENSG00000213277.3	MARCKSL1P1	3.41	0.000681	0.0318	0.12	0.1	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103166072	chr10:103175554~103176094:+
BRCA	cis	rs7914558	1	rs6584540	ENSG00000213277.3	MARCKSL1P1	3.41	0.000681	0.0318	0.12	0.1	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103167877	chr10:103175554~103176094:+
BRCA	cis	rs7914558	1	rs7081075	ENSG00000213277.3	MARCKSL1P1	3.41	0.000681	0.0318	0.12	0.1	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103169434	chr10:103175554~103176094:+
BRCA	cis	rs6693567	0.565	rs11205373	ENSG00000237976.1	RP11-126K1.6	3.41	0.000681	0.0318	0.11	0.1	Migraine;	chr1:150432232	chr1:151346967~151348027:+
BRCA	cis	rs7267979	1	rs2482931	ENSG00000274973.1	RP13-401N8.7	3.41	0.000682	0.0318	0.12	0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25353809	chr20:25845497~25845862:+
BRCA	cis	rs860295	0.557	rs11264372	ENSG00000203761.5	MSTO2P	-3.41	0.000682	0.0318	-0.1	-0.1	Body mass index;	chr1:155443139	chr1:155745829~155750137:+
BRCA	cis	rs2148307	0.893	rs7070831	ENSG00000228339.1	AMD1P1	-3.41	0.000682	0.0318	-0.12	-0.1	Photic sneeze reflex;	chr10:20794506	chr10:20350049~20351100:+
BRCA	cis	rs2835872	0.832	rs857978	ENSG00000228677.1	TTC3-AS1	3.41	0.000682	0.0318	0.14	0.1	Electroencephalographic traits in alcoholism;	chr21:37625824	chr21:37187666~37193926:-
BRCA	cis	rs34975555	0.568	rs12056521	ENSG00000254054.2	RP11-156K13.3	3.41	0.000682	0.0318	0.15	0.1	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:17965790	chr8:17905756~17907887:+
BRCA	cis	rs13256369	1	rs13282915	ENSG00000254153.1	CTA-398F10.2	3.41	0.000682	0.0318	0.14	0.1	Obesity-related traits;	chr8:8713381	chr8:8456909~8461337:-
BRCA	cis	rs8141529	0.702	rs8137262	ENSG00000226471.5	CTA-292E10.6	-3.41	0.000682	0.0318	-0.12	-0.1	Lymphocyte counts;	chr22:28896147	chr22:28800683~28848559:+
BRCA	cis	rs7252981	0.632	rs8101679	ENSG00000267419.1	CTC-559E9.6	3.41	0.000682	0.0318	0.12	0.1	Perceived unattractiveness to mosquitoes;	chr19:19623068	chr19:19776602~19834927:+
BRCA	cis	rs6144337	1	rs6144337	ENSG00000243802.2	RP11-390K5.1	3.41	0.000682	0.0318	0.15	0.1	Lymphocyte percentage of white cells;	chr11:47262763	chr11:47191181~47191542:-
BRCA	cis	rs748404	0.666	rs17780417	ENSG00000166763.7	STRCP1	3.41	0.000682	0.0318	0.15	0.1	Lung cancer;	chr15:43347264	chr15:43699488~43718184:-
BRCA	cis	rs9611565	0.512	rs5758464	ENSG00000281538.1	RP4-669P10.20	-3.41	0.000682	0.0318	-0.15	-0.1	Vitiligo;	chr22:41775296	chr22:42138060~42139726:+
BRCA	cis	rs4759375	0.92	rs7972811	ENSG00000256092.2	RP13-942N8.1	3.41	0.000682	0.0318	0.17	0.1	HDL cholesterol;	chr12:123336233	chr12:123363868~123366113:+
BRCA	cis	rs67385638	0.802	rs72872555	ENSG00000225101.4	OR52K3P	3.41	0.000682	0.0318	0.15	0.1	Hemoglobin levels;	chr11:5288939	chr11:4474813~4475755:+
BRCA	cis	rs728616	0.867	rs723191	ENSG00000242600.5	MBL1P	3.41	0.000682	0.0318	0.24	0.1	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79948164	chr10:79904898~79950336:+
BRCA	cis	rs7520050	0.966	rs11211230	ENSG00000281133.1	AL355480.3	3.41	0.000682	0.0318	0.12	0.1	Reticulocyte count;Red blood cell count;	chr1:45941095	chr1:45580892~45580996:-
BRCA	cis	rs8180040	0.62	rs9858443	ENSG00000260236.1	RP11-708J19.1	3.41	0.000682	0.0318	0.09	0.1	Colorectal cancer;	chr3:47044558	chr3:47379089~47380999:-
BRCA	cis	rs8180040	0.62	rs4683322	ENSG00000260236.1	RP11-708J19.1	3.41	0.000682	0.0318	0.09	0.1	Colorectal cancer;	chr3:47051699	chr3:47379089~47380999:-
BRCA	cis	rs637571	0.726	rs669371	ENSG00000255320.1	RP11-755F10.1	3.41	0.000682	0.0318	0.14	0.1	Eosinophil percentage of white cells;	chr11:65906682	chr11:66244840~66246239:-
BRCA	cis	rs7267979	1	rs2474777	ENSG00000274973.1	RP13-401N8.7	-3.41	0.000682	0.0318	-0.12	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25291997	chr20:25845497~25845862:+
BRCA	cis	rs6439699	0.699	rs1600136	ENSG00000273486.1	RP11-731C17.2	3.41	0.000682	0.0318	0.13	0.1	Intelligence (multi-trait analysis);	chr3:137261097	chr3:136837338~136839021:-
BRCA	cis	rs654950	0.776	rs2759252	ENSG00000230881.1	RP11-486B10.3	3.41	0.000682	0.0318	0.11	0.1	Airway imaging phenotypes;	chr1:41556183	chr1:41535443~41535868:+
BRCA	cis	rs17123764	0.71	rs57191490	ENSG00000257464.1	RP11-161H23.8	-3.41	0.000682	0.0318	-0.18	-0.1	Intelligence (multi-trait analysis);	chr12:49671106	chr12:49442424~49442652:-
BRCA	cis	rs6545883	0.965	rs11887205	ENSG00000212978.6	AC016747.3	3.41	0.000682	0.0318	0.14	0.1	Tuberculosis;	chr2:61547338	chr2:61141592~61144969:-
BRCA	cis	rs7637701	0.773	rs7623691	ENSG00000240875.4	LINC00886	3.41	0.000682	0.0318	0.12	0.1	Breast cancer;	chr3:156790921	chr3:156747346~156817062:-
BRCA	cis	rs6964833	1	rs4717906	ENSG00000277072.3	STAG3L2	3.41	0.000682	0.0318	0.11	0.1	Menarche (age at onset);	chr7:74671923	chr7:74882163~74890610:-
BRCA	cis	rs16917546	0.967	rs10995246	ENSG00000238280.1	RP11-436D10.3	3.41	0.000682	0.0318	0.14	0.1	Basal cell carcinoma;	chr10:62632086	chr10:62793562~62805887:-
BRCA	cis	rs10266483	0.705	rs1111649	ENSG00000228653.2	HNRNPCP7	-3.41	0.000682	0.0318	-0.13	-0.1	Response to statin therapy;	chr7:64296435	chr7:64500825~64501729:+
BRCA	cis	rs8114671	0.562	rs3746450	ENSG00000261582.1	RP4-614O4.11	-3.41	0.000682	0.0318	-0.1	-0.1	Height;	chr20:34920785	chr20:35267885~35280043:-
BRCA	cis	rs8114671	0.562	rs6087649	ENSG00000261582.1	RP4-614O4.11	-3.41	0.000682	0.0318	-0.1	-0.1	Height;	chr20:34922859	chr20:35267885~35280043:-
BRCA	cis	rs8114671	0.562	rs4911449	ENSG00000261582.1	RP4-614O4.11	-3.41	0.000682	0.0318	-0.1	-0.1	Height;	chr20:34924433	chr20:35267885~35280043:-
BRCA	cis	rs2749097	0.735	rs10889438	ENSG00000244256.3	RN7SL130P	-3.41	0.000682	0.0318	-0.15	-0.1	Alcohol consumption (transferrin glycosylation);	chr1:63695232	chr1:63655743~63656047:+
BRCA	cis	rs875971	0.522	rs2949690	ENSG00000227113.2	RP11-460N20.4	-3.41	0.000682	0.0318	-0.11	-0.1	Aortic root size;	chr7:66018255	chr7:65075023~65078780:+
BRCA	cis	rs35520189	0.591	rs12623837	ENSG00000231747.1	AC079922.2	-3.41	0.000682	0.0318	-0.11	-0.1	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:112944891	chr2:112621809~112622167:-
BRCA	cis	rs2832191	0.716	rs9983051	ENSG00000236056.1	GAPDHP14	-3.41	0.000682	0.0318	-0.12	-0.1	Dental caries;	chr21:28999569	chr21:29222321~29223257:+
BRCA	cis	rs12234571	0.744	rs17157284	ENSG00000214293.7	APTR	3.41	0.000683	0.0318	0.22	0.1	Obesity-related traits;	chr7:77750413	chr7:77657660~77696265:-
BRCA	cis	rs875971	1	rs1544549	ENSG00000229886.1	RP5-1132H15.3	-3.41	0.000683	0.0318	-0.12	-0.1	Aortic root size;	chr7:66625676	chr7:66025126~66031544:-
BRCA	cis	rs4919687	0.55	rs12259058	ENSG00000236937.2	PTGES3P4	3.41	0.000683	0.0318	0.15	0.1	Colorectal cancer;	chr10:102725042	chr10:102845595~102845950:+
BRCA	cis	rs10464366	0.843	rs13242209	ENSG00000233306.2	TRGV2	3.41	0.000683	0.0318	0.1	0.1	IgG glycosylation;	chr7:39070641	chr7:38362864~38363518:-
BRCA	cis	rs6009527	1	rs4315635	ENSG00000273192.1	CITF22-1A6.3	3.41	0.000683	0.0318	0.11	0.1	Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid);	chr22:49175604	chr22:49902228~49904576:+
BRCA	cis	rs7495132	0.646	rs4932359	ENSG00000245479.2	LINC01585	-3.41	0.000683	0.0318	-0.15	-0.1	Ulcerative colitis;Inflammatory bowel disease;	chr15:90628992	chr15:90660234~90664967:+
BRCA	cis	rs72928364	1	rs41386544	ENSG00000244119.1	PDCL3P4	-3.41	0.000683	0.0318	-0.13	-0.1	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:101040223	chr3:101712472~101713191:+
BRCA	cis	rs6500602	0.893	rs4786489	ENSG00000280063.1	RP11-295D4.3	3.41	0.000683	0.0318	0.08	0.1	Schizophrenia;	chr16:4435526	chr16:4346694~4348648:-
BRCA	cis	rs9500256	0.903	rs726783	ENSG00000272316.1	XXbac-BPGBPG55C20.2	3.41	0.000683	0.0319	0.09	0.1	Eosinophilic esophagitis (pediatric);	chr6:58006583	chr6:57908560~57913911:-
BRCA	cis	rs8180040	0.629	rs7426969	ENSG00000260236.1	RP11-708J19.1	3.41	0.000683	0.0319	0.09	0.1	Colorectal cancer;	chr3:47049865	chr3:47379089~47380999:-
BRCA	cis	rs924712	0.644	rs2134539	ENSG00000261116.1	RP3-523K23.2	3.41	0.000683	0.0319	0.13	0.1	Breast cancer;	chr6:54993436	chr6:54943167~54945099:+
BRCA	cis	rs16917546	0.967	rs10995239	ENSG00000238280.1	RP11-436D10.3	3.41	0.000683	0.0319	0.14	0.1	Basal cell carcinoma;	chr10:62628605	chr10:62793562~62805887:-
BRCA	cis	rs7339483	0.618	rs4986346	ENSG00000268442.1	CTD-2027I19.2	3.41	0.000683	0.0319	0.2	0.1	Discordance in emotional problems in monozygotic twins;	chr19:24175288	chr19:24162370~24163425:-
BRCA	cis	rs26868	0.766	rs30995	ENSG00000262362.1	LA16c-380H5.2	3.41	0.000683	0.0319	0.12	0.1	Height;	chr16:2198016	chr16:3003431~3005101:-
BRCA	cis	rs897984	0.542	rs11864839	ENSG00000279196.1	RP11-1072A3.3	3.41	0.000683	0.0319	0.11	0.1	Dementia with Lewy bodies;	chr16:31083930	chr16:30984630~30988270:-
BRCA	cis	rs17228212	1	rs731874	ENSG00000270964.1	RP11-502I4.3	-3.41	0.000683	0.0319	-0.14	-0.1	Coronary heart disease;	chr15:67154493	chr15:67541072~67542604:-
BRCA	cis	rs10266483	0.881	rs636242	ENSG00000271550.1	BNIP3P11	3.41	0.000683	0.0319	0.14	0.1	Response to statin therapy;	chr7:64284377	chr7:64678954~64687393:-
BRCA	cis	rs10266483	0.921	rs653746	ENSG00000271550.1	BNIP3P11	3.41	0.000683	0.0319	0.14	0.1	Response to statin therapy;	chr7:64284399	chr7:64678954~64687393:-
BRCA	cis	rs9646944	0.501	rs11687768	ENSG00000234389.1	AC007278.3	3.41	0.000683	0.0319	0.12	0.1	Blood protein levels;	chr2:102409278	chr2:102438713~102440475:+
BRCA	cis	rs4699052	0.893	rs4699058	ENSG00000251288.2	RP11-10L12.2	-3.41	0.000683	0.0319	-0.12	-0.1	Testicular germ cell tumor;	chr4:103250164	chr4:102751401~102752641:+
BRCA	cis	rs77106637	0.932	rs74439784	ENSG00000256633.1	RP11-169D4.2	3.41	0.000683	0.0319	0.14	0.1	Type 2 diabetes;	chr11:72938351	chr11:72584572~72587979:+
BRCA	cis	rs60871478	0.636	rs6976929	ENSG00000237181.1	AC147651.4	3.41	0.000683	0.0319	0.12	0.1	Cerebrospinal P-tau181p levels;	chr7:861745	chr7:603185~608482:+
BRCA	cis	rs35275482	1	rs6494147	ENSG00000259238.1	RP11-361D15.2	-3.41	0.000683	0.0319	-0.15	-0.1	Gut microbiota (bacterial taxa);	chr15:59809993	chr15:59688517~59689418:+
BRCA	cis	rs7561149	0.768	rs883894	ENSG00000270574.1	RP11-171I2.2	-3.41	0.000683	0.0319	-0.15	-0.1	QT interval;	chr2:178860008	chr2:178578790~178580906:+
BRCA	cis	rs4835473	0.932	rs13119602	ENSG00000246448.2	RP13-578N3.3	-3.41	0.000683	0.0319	-0.12	-0.1	Immature fraction of reticulocytes;	chr4:143736621	chr4:143700257~143865072:+
BRCA	cis	rs62025270	0.632	rs62022920	ENSG00000259367.1	RP11-815J21.4	3.41	0.000683	0.0319	0.1	0.1	Idiopathic pulmonary fibrosis;	chr15:85680159	chr15:85619623~85670948:-
BRCA	cis	rs873549	0.877	rs1530313	ENSG00000227925.1	RP11-191N8.2	3.41	0.000683	0.0319	0.12	0.1	Keloid;	chr1:222100668	chr1:221827666~221840666:-
BRCA	cis	rs873549	0.959	rs7524005	ENSG00000227925.1	RP11-191N8.2	3.41	0.000683	0.0319	0.12	0.1	Keloid;	chr1:222100977	chr1:221827666~221840666:-
BRCA	cis	rs873549	1	rs7555836	ENSG00000227925.1	RP11-191N8.2	3.41	0.000683	0.0319	0.12	0.1	Keloid;	chr1:222101090	chr1:221827666~221840666:-
BRCA	cis	rs7412746	0.658	rs7526489	ENSG00000224800.1	RP11-235D19.2	-3.41	0.000683	0.0319	-0.13	-0.1	Melanoma;	chr1:150753762	chr1:150881236~150881683:-
BRCA	cis	rs34792	0.637	rs1684547	ENSG00000258354.1	MIR3180-1	-3.41	0.000684	0.0319	-0.13	-0.1	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15480604	chr16:14909887~14911345:-
BRCA	cis	rs12724450	0.793	rs7517003	ENSG00000228126.1	FALEC	3.41	0.000684	0.0319	0.19	0.1	Blood protein levels;	chr1:150310123	chr1:150515757~150518032:+
BRCA	cis	rs62458065	1	rs79538247	ENSG00000273014.1	RP11-225B17.2	-3.41	0.000684	0.0319	-0.16	-0.1	Metabolite levels (HVA/MHPG ratio);	chr7:32428180	chr7:32758882~32759353:+
BRCA	cis	rs7824557	0.767	rs6985146	ENSG00000154316.13	TDH	-3.41	0.000684	0.0319	-0.14	-0.1	Retinal vascular caliber;	chr8:11313212	chr8:11339637~11368452:+
BRCA	cis	rs934734	0.752	rs1039764	ENSG00000204929.10	AC074391.1	-3.41	0.000684	0.0319	-0.13	-0.1	Rheumatoid arthritis;	chr2:65387479	chr2:65436711~66084639:+
BRCA	cis	rs2227564	0.678	rs2242256	ENSG00000279689.1	RP11-574K11.32	-3.41	0.000684	0.0319	-0.12	-0.1	Crohn's disease;Inflammatory bowel disease;	chr10:73837788	chr10:73769264~73772862:-
BRCA	cis	rs2227564	0.678	rs2242257	ENSG00000279689.1	RP11-574K11.32	-3.41	0.000684	0.0319	-0.12	-0.1	Crohn's disease;Inflammatory bowel disease;	chr10:73837847	chr10:73769264~73772862:-
BRCA	cis	rs12915845	0.584	rs7403482	ENSG00000271997.1	RP11-97O12.6	-3.41	0.000684	0.0319	-0.09	-0.1	Menarche (age at onset);	chr15:88519478	chr15:88501944~88505787:-
BRCA	cis	rs11170468	0.722	rs61937656	ENSG00000257718.1	RP11-396F22.1	-3.41	0.000684	0.0319	-0.12	-0.1	Body mass index;	chr12:39089700	chr12:38906451~38909592:+
BRCA	cis	rs801193	0.548	rs6975044	ENSG00000271064.1	RP11-792A8.3	-3.41	0.000684	0.0319	-0.12	-0.1	Aortic root size;	chr7:66762495	chr7:66748838~66749077:-
BRCA	cis	rs4878712	0.743	rs6476656	ENSG00000230188.1	RP11-405L18.4	3.41	0.000684	0.0319	0.12	0.1	HIV-1 susceptibility;	chr9:37663813	chr9:37490421~37490893:-
BRCA	cis	rs6893300	0.961	rs62406219	ENSG00000225051.5	HMGB3P22	3.41	0.000684	0.0319	0.14	0.1	Resting heart rate;	chr5:179784628	chr5:179679032~179694768:+
BRCA	cis	rs9381040	0.701	rs6933231	ENSG00000161912.16	ADCY10P1	3.41	0.000684	0.0319	0.12	0.1	Alzheimer's disease (late onset);	chr6:41195962	chr6:41101022~41140835:+
BRCA	cis	rs1355223	0.902	rs286861	ENSG00000271369.1	RP11-350D17.3	-3.41	0.000684	0.0319	-0.12	-0.1	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34696877	chr11:34709600~34710161:+
BRCA	cis	rs7578361	0.918	rs6756703	ENSG00000231969.1	AC144449.1	-3.41	0.000684	0.0319	-0.16	-0.1	Acute lymphoblastic leukemia (childhood);	chr2:149512450	chr2:149587196~149848233:+
BRCA	cis	rs7578361	0.918	rs10204886	ENSG00000231969.1	AC144449.1	-3.41	0.000684	0.0319	-0.16	-0.1	Acute lymphoblastic leukemia (childhood);	chr2:149512726	chr2:149587196~149848233:+
BRCA	cis	rs7258465	1	rs10411009	ENSG00000273654.1	CTB-52I2.4	-3.41	0.000684	0.0319	-0.13	-0.1	Breast cancer;	chr19:18495456	chr19:18022403~18032099:+
BRCA	cis	rs7947761	0.953	rs17095426	ENSG00000255059.1	AP000620.1	3.41	0.000684	0.0319	0.13	0.1	Coronary artery disease;	chr11:100767872	chr11:100666459~100666962:+
BRCA	cis	rs7646881	0.504	rs7617304	ENSG00000240207.5	RP11-379F4.4	-3.41	0.000684	0.0319	-0.14	-0.1	Tetralogy of Fallot;	chr3:158745312	chr3:158732263~158784070:+
BRCA	cis	rs1865760	0.865	rs9467650	ENSG00000272810.1	U91328.22	-3.41	0.000684	0.0319	-0.12	-0.1	Height;	chr6:25958007	chr6:26013241~26013757:+
BRCA	cis	rs8073060	0.586	rs2011897	ENSG00000267554.1	RP11-686D22.10	3.41	0.000684	0.0319	0.11	0.1	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35727389	chr17:35470069~35470628:-
BRCA	cis	rs7412746	0.658	rs2275235	ENSG00000224800.1	RP11-235D19.2	-3.41	0.000684	0.0319	-0.13	-0.1	Melanoma;	chr1:150757803	chr1:150881236~150881683:-
BRCA	cis	rs2243480	1	rs431076	ENSG00000229180.5	GS1-124K5.11	3.41	0.000685	0.0319	0.14	0.1	Diabetic kidney disease;	chr7:66135333	chr7:66526088~66542624:-
BRCA	cis	rs2243480	1	rs2460422	ENSG00000229180.5	GS1-124K5.11	3.41	0.000685	0.0319	0.14	0.1	Diabetic kidney disease;	chr7:66136518	chr7:66526088~66542624:-
BRCA	cis	rs2243480	1	rs316334	ENSG00000229180.5	GS1-124K5.11	3.41	0.000685	0.0319	0.14	0.1	Diabetic kidney disease;	chr7:66137139	chr7:66526088~66542624:-
BRCA	cis	rs7520050	0.966	rs10890354	ENSG00000226957.1	RP4-533D7.4	3.41	0.000685	0.0319	0.11	0.1	Reticulocyte count;Red blood cell count;	chr1:45839675	chr1:46046818~46048368:+
BRCA	cis	rs2832191	0.791	rs2832181	ENSG00000232855.5	AF131217.1	3.41	0.000685	0.0319	0.12	0.1	Dental caries;	chr21:29109050	chr21:28439346~28674848:-
BRCA	cis	rs60871478	0.73	rs13222476	ENSG00000237181.1	AC147651.4	-3.41	0.000685	0.0319	-0.12	-0.1	Cerebrospinal P-tau181p levels;	chr7:786993	chr7:603185~608482:+
BRCA	cis	rs10777288	0.561	rs60536787	ENSG00000258100.1	RP11-121E16.1	3.41	0.000685	0.0319	0.14	0.1	Pulmonary function (smoking interaction);	chr12:90995179	chr12:91362196~91368606:+
BRCA	cis	rs875971	0.522	rs1617484	ENSG00000229180.5	GS1-124K5.11	3.41	0.000685	0.0319	0.09	0.1	Aortic root size;	chr7:65998108	chr7:66526088~66542624:-
BRCA	cis	rs12477602	0.938	rs3942565	ENSG00000272966.1	RP11-686O6.1	3.41	0.000685	0.0319	0.17	0.1	Intelligence (multi-trait analysis);	chr2:202410875	chr2:202336739~202337200:+
BRCA	cis	rs13008689	0.967	rs13009356	ENSG00000236790.4	LINC00299	3.41	0.000685	0.0319	0.13	0.1	Longevity;	chr2:8390392	chr2:8007771~8383621:-
BRCA	cis	rs2574985	0.813	rs3011787	ENSG00000226200.5	SGMS1-AS1	-3.41	0.000685	0.0319	-0.11	-0.1	Subjective well-being;	chr10:50479563	chr10:50624951~50641451:+
BRCA	cis	rs6490294	0.571	rs7309841	ENSG00000257624.1	RP1-128M12.3	3.41	0.000685	0.0319	0.17	0.1	Mean platelet volume;	chr12:112127249	chr12:112000739~112000985:-
BRCA	cis	rs6490294	0.571	rs7294753	ENSG00000257624.1	RP1-128M12.3	3.41	0.000685	0.0319	0.17	0.1	Mean platelet volume;	chr12:112129646	chr12:112000739~112000985:-
BRCA	cis	rs67766926	0.587	rs17539290	ENSG00000237522.1	NONOP2	-3.41	0.000685	0.0319	-0.12	-0.1	Inflammatory skin disease;	chr2:61020375	chr2:60936819~60938049:-
BRCA	cis	rs687432	0.885	rs1113334	ENSG00000265566.2	RN7SL605P	-3.41	0.000685	0.0319	-0.15	-0.1	Parkinson's disease;	chr11:57975861	chr11:57528085~57528365:-
BRCA	cis	rs687432	0.924	rs1113335	ENSG00000265566.2	RN7SL605P	-3.41	0.000685	0.0319	-0.15	-0.1	Parkinson's disease;	chr11:57975977	chr11:57528085~57528365:-
BRCA	cis	rs7781266	0.79	rs17597439	ENSG00000226205.1	AC007790.4	3.41	0.000685	0.0319	0.16	0.1	Educational attainment (college completion);	chr7:133475978	chr7:133732493~133733595:-
BRCA	cis	rs74233809	1	rs5011520	ENSG00000236937.2	PTGES3P4	3.41	0.000685	0.0319	0.22	0.1	Birth weight;	chr10:102937759	chr10:102845595~102845950:+
BRCA	cis	rs74233809	1	rs10883808	ENSG00000236937.2	PTGES3P4	3.41	0.000685	0.0319	0.22	0.1	Birth weight;	chr10:102961369	chr10:102845595~102845950:+
BRCA	cis	rs74233809	1	rs11191479	ENSG00000236937.2	PTGES3P4	3.41	0.000685	0.0319	0.22	0.1	Birth weight;	chr10:102963863	chr10:102845595~102845950:+
BRCA	cis	rs1075265	0.935	rs6545384	ENSG00000272156.1	RP11-477N3.1	-3.41	0.000685	0.032	-0.11	-0.1	Chronotype;Morning vs. evening chronotype;	chr2:54073927	chr2:54082554~54085066:+
BRCA	cis	rs4468007	0.865	rs4308812	ENSG00000261534.1	RP11-244O19.1	-3.41	0.000685	0.032	-0.11	-0.1	Educational attainment;	chr9:121850999	chr9:121815674~121819452:-
BRCA	cis	rs7520050	0.966	rs61102033	ENSG00000281133.1	AL355480.3	3.41	0.000685	0.032	0.12	0.1	Reticulocyte count;Red blood cell count;	chr1:45916769	chr1:45580892~45580996:-
BRCA	cis	rs73201462	1	rs13077913	ENSG00000242551.2	POU5F1P6	3.41	0.000685	0.032	0.18	0.1	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128163761	chr3:128674735~128677005:-
BRCA	cis	rs13434995	0.513	rs17776975	ENSG00000273257.1	RP11-177J6.1	-3.41	0.000685	0.032	-0.16	-0.1	Adiponectin levels;	chr4:55410728	chr4:55387949~55388271:+
BRCA	cis	rs12893668	0.603	rs61637848	ENSG00000258914.1	CTD-2134A5.3	3.41	0.000685	0.032	0.14	0.1	Reticulocyte count;	chr14:103629694	chr14:103875055~103877478:+
BRCA	cis	rs1479090	0.762	rs9992504	ENSG00000250027.1	RP11-563E2.2	-3.41	0.000686	0.032	-0.14	-0.1	Lung cancer;	chr4:163098463	chr4:163108785~163119965:+
BRCA	cis	rs755249	0.567	rs4660543	ENSG00000243970.1	PPIEL	3.41	0.000686	0.032	0.15	0.1	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39213318	chr1:39531838~39558707:-
BRCA	cis	rs993804	0.528	rs13064047	ENSG00000264219.1	MIR4442	3.41	0.000686	0.032	0.12	0.1	Bipolar disorder and schizophrenia;	chr3:25040597	chr3:25664873~25664939:-
BRCA	cis	rs6095360	0.625	rs2426132	ENSG00000227431.4	CSE1L-AS1	-3.41	0.000686	0.032	-0.12	-0.1	Intelligence (multi-trait analysis);	chr20:49106590	chr20:49040463~49046044:-
BRCA	cis	rs4835473	0.932	rs34697602	ENSG00000246448.2	RP13-578N3.3	-3.41	0.000686	0.032	-0.12	-0.1	Immature fraction of reticulocytes;	chr4:143762499	chr4:143700257~143865072:+
BRCA	cis	rs3087591	0.879	rs59015798	ENSG00000263531.1	RP13-753N3.1	3.41	0.000686	0.032	0.14	0.1	Hip circumference;	chr17:31253864	chr17:30863921~30864940:-
BRCA	cis	rs11642862	1	rs112234000	ENSG00000260082.1	RP11-2C24.5	-3.41	0.000686	0.032	-0.19	-0.1	Tonsillectomy;	chr16:30767487	chr16:30821068~30822110:-
BRCA	cis	rs11642862	1	rs75500538	ENSG00000260082.1	RP11-2C24.5	-3.41	0.000686	0.032	-0.19	-0.1	Tonsillectomy;	chr16:30771128	chr16:30821068~30822110:-
BRCA	cis	rs2904524	1	rs17108038	ENSG00000257613.1	LINC01481	-3.41	0.000686	0.032	-0.18	-0.1	Amyotrophic lateral sclerosis (age of onset);	chr12:70347828	chr12:70219132~70221862:-
BRCA	cis	rs2908197	0.662	rs917423	ENSG00000205485.12	AC004980.7	3.41	0.000686	0.032	0.11	0.1	3-hydroxypropylmercapturic acid levels in smokers;	chr7:76355400	chr7:76549360~76627982:+
BRCA	cis	rs2554380	0.628	rs919069	ENSG00000176700.18	SCAND2P	-3.41	0.000686	0.032	-0.11	-0.1	Height;	chr15:83775776	chr15:84631451~84647478:+
BRCA	cis	rs2154490	0.821	rs2832395	ENSG00000176054.6	RPL23P2	3.41	0.000686	0.032	0.12	0.1	Glucocorticoid-induced osteonecrosis;	chr21:29548320	chr21:28997613~28998033:-
BRCA	cis	rs7487075	0.82	rs2408505	ENSG00000274723.1	RP11-618L22.1	3.41	0.000686	0.032	0.12	0.1	Itch intensity from mosquito bite;	chr12:46324041	chr12:46970504~46972155:+
BRCA	cis	rs6964587	0.755	rs13229505	ENSG00000188693.7	CYP51A1-AS1	-3.41	0.000686	0.032	-0.12	-0.1	Breast cancer;	chr7:91815365	chr7:92134604~92180725:+
BRCA	cis	rs3780486	0.629	rs10971439	ENSG00000233554.4	B4GALT1-AS1	3.41	0.000686	0.032	0.15	0.1	IgG glycosylation;	chr9:33180815	chr9:33166975~33179983:+
BRCA	cis	rs2625529	0.652	rs11634608	ENSG00000261187.1	RP11-1007O24.2	3.41	0.000686	0.032	0.11	0.1	Red blood cell count;	chr15:71963377	chr15:72465128~72466262:-
BRCA	cis	rs4622329	0.615	rs7136688	ENSG00000257202.1	RP11-512N21.3	3.41	0.000686	0.032	0.12	0.1	Systemic lupus erythematosus;	chr12:101900716	chr12:101923410~101924719:-
BRCA	cis	rs4622329	0.615	rs7305951	ENSG00000257202.1	RP11-512N21.3	3.41	0.000686	0.032	0.12	0.1	Systemic lupus erythematosus;	chr12:101900723	chr12:101923410~101924719:-
BRCA	cis	rs240764	0.579	rs6937520	ENSG00000220695.1	RP1-121G13.3	-3.41	0.000686	0.032	-0.12	-0.1	Neuroticism;	chr6:100725859	chr6:100530276~100531052:+
BRCA	cis	rs2154319	0.887	rs61780439	ENSG00000230638.4	RP11-486B10.4	-3.41	0.000686	0.032	-0.18	-0.1	Height;	chr1:41024505	chr1:41542069~41544310:+
BRCA	cis	rs875971	0.862	rs6460290	ENSG00000223473.2	GS1-124K5.3	-3.41	0.000686	0.032	-0.08	-0.1	Aortic root size;	chr7:66344119	chr7:66491049~66493566:-
BRCA	cis	rs6599077	0.95	rs67594343	ENSG00000223797.4	ENTPD3-AS1	3.41	0.000686	0.032	0.13	0.1	Sleep-related phenotypes;	chr3:40065407	chr3:40313802~40453329:-
BRCA	cis	rs7259811	0.886	rs56003639	ENSG00000268266.1	AC003005.2	3.41	0.000686	0.032	0.14	0.1	Western dietary pattern;	chr19:56713643	chr19:57477649~57482996:+
BRCA	cis	rs4657482	0.607	rs473222	ENSG00000203307.2	RP11-375H19.2	3.41	0.000687	0.032	0.14	0.1	Testicular germ cell tumor;	chr1:165907341	chr1:166081183~166087483:+
BRCA	cis	rs2625529	0.73	rs2957737	ENSG00000261187.1	RP11-1007O24.2	3.41	0.000687	0.032	0.12	0.1	Red blood cell count;	chr15:71973069	chr15:72465128~72466262:-
BRCA	cis	rs7819412	0.595	rs10106914	ENSG00000254507.2	RP11-481A20.10	3.41	0.000687	0.032	0.13	0.1	Triglycerides;	chr8:11130141	chr8:12003400~12004082:-
BRCA	cis	rs952623	0.649	rs12538487	ENSG00000227191.5	TRGC2	3.41	0.000687	0.032	0.09	0.1	Intelligence (multi-trait analysis);	chr7:39035780	chr7:38239580~38368091:-
BRCA	cis	rs2574985	0.813	rs1203394	ENSG00000226200.5	SGMS1-AS1	-3.41	0.000687	0.032	-0.11	-0.1	Subjective well-being;	chr10:50443000	chr10:50624951~50641451:+
BRCA	cis	rs2574985	0.813	rs1203393	ENSG00000226200.5	SGMS1-AS1	-3.41	0.000687	0.032	-0.11	-0.1	Subjective well-being;	chr10:50444327	chr10:50624951~50641451:+
BRCA	cis	rs57502260	0.704	rs17149179	ENSG00000212093.1	AP000807.1	3.41	0.000687	0.032	0.18	0.1	Total body bone mineral density (age 45-60);	chr11:68584254	chr11:68506083~68506166:-
BRCA	cis	rs4934494	0.911	rs7081788	ENSG00000232229.4	LINC00865	-3.4	0.000687	0.032	-0.15	-0.1	Red blood cell count;	chr10:89648999	chr10:89829510~89840861:+
BRCA	cis	rs10924970	0.967	rs12731177	ENSG00000230026.2	RP11-382D8.5	-3.4	0.000687	0.032	-0.11	-0.1	Asthma;	chr1:235299858	chr1:235361153~235362540:+
BRCA	cis	rs1018697	1	rs7092346	ENSG00000236937.2	PTGES3P4	3.4	0.000687	0.032	0.13	0.1	Colorectal adenoma (advanced);	chr10:102800007	chr10:102845595~102845950:+
BRCA	cis	rs17818399	0.547	rs13020299	ENSG00000279254.1	RP11-536C12.1	-3.4	0.000687	0.032	-0.13	-0.1	Height;	chr2:46531578	chr2:46668870~46670778:+
BRCA	cis	rs9534288	0.742	rs7337140	ENSG00000235903.6	CPB2-AS1	-3.4	0.000687	0.032	-0.15	-0.1	Blood protein levels;	chr13:46067346	chr13:46052806~46113332:+
BRCA	cis	rs10911902	0.643	rs16825243	ENSG00000229739.2	RP11-295K2.3	-3.4	0.000687	0.032	-0.14	-0.1	Schizophrenia;	chr1:186357769	chr1:186435161~186470291:+
BRCA	cis	rs875971	0.862	rs2024192	ENSG00000106610.13	STAG3L4	3.4	0.000687	0.032	0.14	0.1	Aortic root size;	chr7:66576460	chr7:67302621~67321526:+
BRCA	cis	rs1865760	0.566	rs9348706	ENSG00000272462.2	U91328.19	-3.4	0.000687	0.032	-0.12	-0.1	Height;	chr6:26065253	chr6:25992662~26001775:+
BRCA	cis	rs2985334	0.849	rs204060	ENSG00000237934.1	RP11-467D18.2	-3.4	0.000687	0.032	-0.13	-0.1	Amyotrophic lateral sclerosis (sporadic);	chr1:28953114	chr1:29223933~29224816:+
BRCA	cis	rs875971	1	rs10215948	ENSG00000271064.1	RP11-792A8.3	3.4	0.000687	0.032	0.12	0.1	Aortic root size;	chr7:66282799	chr7:66748838~66749077:-
BRCA	cis	rs875971	0.619	rs2302918	ENSG00000271064.1	RP11-792A8.3	-3.4	0.000687	0.032	-0.12	-0.1	Aortic root size;	chr7:66535945	chr7:66748838~66749077:-
BRCA	cis	rs7722600	1	rs3756687	ENSG00000253404.1	AC034243.1	-3.4	0.000687	0.032	-0.16	-0.1	Heart rate;	chr5:137866004	chr5:138744434~138753309:-
BRCA	cis	rs7267979	1	rs4815406	ENSG00000231081.1	RP4-760C5.3	3.4	0.000687	0.032	0.13	0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25360680	chr20:26008791~26010531:-
BRCA	cis	rs884843	1	rs884843	ENSG00000207741.1	MIR590	3.4	0.000687	0.032	0.09	0.1	Pulse pressure;	chr7:74031459	chr7:74191198~74191294:+
BRCA	cis	rs1642645	0.872	rs661428	ENSG00000228452.1	RP5-994D16.9	-3.4	0.000687	0.032	-0.14	-0.1	Left ventricular obstructive tract defect (maternal effect);	chr1:41985847	chr1:42775813~42776790:-
BRCA	cis	rs4356203	0.905	rs7938820	ENSG00000184669.7	OR7E14P	3.4	0.000688	0.032	0.13	0.1	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17055905	chr11:17013998~17053024:+
BRCA	cis	rs931127	0.719	rs2170082	ENSG00000245532.5	NEAT1	-3.4	0.000688	0.032	-0.09	-0.1	Systemic lupus erythematosus;	chr11:65687324	chr11:65422774~65445540:+
BRCA	cis	rs7412746	0.658	rs11581757	ENSG00000224800.1	RP11-235D19.2	-3.4	0.000688	0.032	-0.13	-0.1	Melanoma;	chr1:150919768	chr1:150881236~150881683:-
BRCA	cis	rs62458065	0.85	rs62458066	ENSG00000281332.1	LINC00997	-3.4	0.000688	0.032	-0.16	-0.1	Metabolite levels (HVA/MHPG ratio);	chr7:32424872	chr7:32760279~32762924:+
BRCA	cis	rs3735485	0.678	rs10258996	ENSG00000201772.1	SNORA5C	3.4	0.000688	0.032	0.14	0.1	White blood cell count;Sum basophil neutrophil counts;Neutrophil count;Granulocyte percentage of myeloid white cells;Monocyte percentage of white cells;Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Lymphocyte counts;	chr7:45116289	chr7:45104906~45105042:-
BRCA	cis	rs11047510	0.824	rs112142854	ENSG00000164845.15	FAM86FP	3.4	0.000688	0.032	0.18	0.1	Exploratory eye movement dysfunction in schizophrenia (responsive search score);	chr12:8846630	chr12:8232512~8242948:-
BRCA	cis	rs11587682	0.76	rs7552883	ENSG00000228126.1	FALEC	3.4	0.000688	0.032	0.14	0.1	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr1:150493446	chr1:150515757~150518032:+
BRCA	cis	rs11587682	0.76	rs11811950	ENSG00000228126.1	FALEC	3.4	0.000688	0.032	0.14	0.1	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr1:150494082	chr1:150515757~150518032:+
BRCA	cis	rs6545883	0.929	rs1186700	ENSG00000273302.1	RP11-493E12.2	3.4	0.000688	0.032	0.1	0.1	Tuberculosis;	chr2:61436237	chr2:61199979~61200769:+
BRCA	cis	rs7017914	0.967	rs7842851	ENSG00000246366.5	RP11-382J12.1	3.4	0.000688	0.032	0.11	0.1	Bone mineral density;	chr8:70751570	chr8:70608577~70663279:+
BRCA	cis	rs9925964	0.967	rs889548	ENSG00000262766.1	RP11-196G11.4	3.4	0.000688	0.032	0.09	0.1	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31126391	chr16:31118078~31118747:+
BRCA	cis	rs12468226	0.689	rs60584169	ENSG00000226261.1	AC064836.3	3.4	0.000688	0.032	0.17	0.1	Urate levels;	chr2:202111695	chr2:202336024~202336727:-
BRCA	cis	rs8180040	0.764	rs4682852	ENSG00000260236.1	RP11-708J19.1	3.4	0.000688	0.0321	0.09	0.1	Colorectal cancer;	chr3:47136282	chr3:47379089~47380999:-
BRCA	cis	rs931127	0.692	rs7934517	ENSG00000245532.5	NEAT1	-3.4	0.000688	0.0321	-0.09	-0.1	Systemic lupus erythematosus;	chr11:65678202	chr11:65422774~65445540:+
BRCA	cis	rs6681460	0.966	rs4655506	ENSG00000248458.2	RP4-598P13.1	3.4	0.000688	0.0321	0.11	0.1	Presence of antiphospholipid antibodies;	chr1:66685128	chr1:66665864~66677027:-
BRCA	cis	rs1730008	0.731	rs2139696	ENSG00000279311.1	RP11-170K4.2	3.4	0.000688	0.0321	0.13	0.1	Lobe attachment (rater-scored or self-reported);	chr3:158253363	chr3:158869898~158871821:+
BRCA	cis	rs9828082	0.961	rs2102649	ENSG00000228956.7	SATB1-AS1	-3.4	0.000688	0.0321	-0.11	-0.1	Neuroticism;	chr3:18581798	chr3:18445024~18920401:+
BRCA	cis	rs8040855	0.627	rs12909971	ENSG00000259774.1	RP11-182J1.13	3.4	0.000688	0.0321	0.14	0.1	Bulimia nervosa;	chr15:85045767	chr15:84422618~84425882:+
BRCA	cis	rs4078252	0.671	rs13184187	ENSG00000279522.1	CTC-487M23.6	-3.4	0.000688	0.0321	-0.12	-0.1	Response to cytadine analogues (cytosine arabinoside);	chr5:113114769	chr5:112894933~112896531:+
BRCA	cis	rs4078252	0.671	rs12188482	ENSG00000279522.1	CTC-487M23.6	-3.4	0.000688	0.0321	-0.12	-0.1	Response to cytadine analogues (cytosine arabinoside);	chr5:113114812	chr5:112894933~112896531:+
BRCA	cis	rs344364	0.511	rs1742462	ENSG00000219027.2	RPS3AP2	3.4	0.000688	0.0321	0.16	0.1	Glomerular filtration rate in chronic kidney disease;	chr16:1896061	chr16:1477830~1478583:+
BRCA	cis	rs6593122	0.628	rs1404207	ENSG00000235454.1	HAUS6P3	-3.4	0.000688	0.0321	-0.14	-0.1	Vaccine-related adverse events;	chr7:54115554	chr7:53862233~53863339:+
BRCA	cis	rs9392653	0.654	rs1246999	ENSG00000220685.3	RP11-530A18.1	-3.4	0.000688	0.0321	-0.15	-0.1	Venous thromboembolism (SNP x SNP interaction);	chr6:5060563	chr6:5065795~5066982:-
BRCA	cis	rs6832769	0.643	rs1488939	ENSG00000272969.1	RP11-528I4.2	-3.4	0.000688	0.0321	-0.13	-0.1	Personality dimensions;	chr4:55652977	chr4:55547112~55547889:+
BRCA	cis	rs10883723	0.81	rs7094366	ENSG00000213061.2	PFN1P11	-3.4	0.000688	0.0321	-0.14	-0.1	Allergic disease (asthma, hay fever or eczema);	chr10:102514973	chr10:102838011~102845473:-
BRCA	cis	rs875971	0.83	rs6976714	ENSG00000106610.13	STAG3L4	-3.4	0.000689	0.0321	-0.14	-0.1	Aortic root size;	chr7:66426474	chr7:67302621~67321526:+
BRCA	cis	rs11673344	0.8	rs826323	ENSG00000267422.1	CTD-2554C21.1	3.4	0.000689	0.0321	0.13	0.1	Obesity-related traits;	chr19:37014051	chr19:37779686~37792865:+
BRCA	cis	rs17695224	0.565	rs7253182	ENSG00000269483.1	AC006272.1	3.4	0.000689	0.0321	0.13	0.1	HDL cholesterol;HDL cholesterol levels;	chr19:51808838	chr19:51839924~51843324:-
BRCA	cis	rs14027	0.921	rs13270831	ENSG00000245330.4	KB-1471A8.1	3.4	0.000689	0.0321	0.15	0.1	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119755071	chr8:119867419~119874488:-
BRCA	cis	rs198846	0.542	rs198839	ENSG00000272810.1	U91328.22	-3.4	0.000689	0.0321	-0.13	-0.1	Mean corpuscular volume;Mean corpuscular hemoglobin concentration;Hemoglobin levels;Hemoglobin;Glycated hemoglobin levels;Blood pressure;	chr6:26112392	chr6:26013241~26013757:+
BRCA	cis	rs17818399	0.749	rs13000560	ENSG00000279254.1	RP11-536C12.1	-3.4	0.000689	0.0321	-0.14	-0.1	Height;	chr2:46563858	chr2:46668870~46670778:+
BRCA	cis	rs3764021	0.527	rs10844427	ENSG00000256594.6	RP11-705C15.2	3.4	0.000689	0.0321	0.14	0.1	Type 1 diabetes;	chr12:9681798	chr12:9633419~9658412:+
BRCA	cis	rs11673344	0.665	rs74435359	ENSG00000267682.1	CTD-3220F14.2	-3.4	0.000689	0.0321	-0.1	-0.1	Obesity-related traits;	chr19:36955252	chr19:37337236~37337743:+
BRCA	cis	rs11673344	0.523	rs2891766	ENSG00000276846.1	CTD-3220F14.3	3.4	0.000689	0.0321	0.12	0.1	Obesity-related traits;	chr19:37037057	chr19:37314868~37315620:-
BRCA	cis	rs7829975	0.688	rs7837587	ENSG00000173295.6	FAM86B3P	3.4	0.000689	0.0321	0.11	0.1	Mood instability;	chr8:8521482	chr8:8228595~8244865:+
BRCA	cis	rs3764021	0.527	rs3764022	ENSG00000260423.1	RP13-735L24.1	-3.4	0.000689	0.0321	-0.12	-0.1	Type 1 diabetes;	chr12:9680928	chr12:9367464~9397617:+
BRCA	cis	rs2554380	0.628	rs7179507	ENSG00000176700.18	SCAND2P	-3.4	0.000689	0.0321	-0.1	-0.1	Height;	chr15:83804779	chr15:84631451~84647478:+
BRCA	cis	rs7577696	0.813	rs212723	ENSG00000276334.1	AL133243.1	3.4	0.000689	0.0321	0.13	0.1	Inflammatory biomarkers;	chr2:32242079	chr2:32521927~32523547:+
BRCA	cis	rs12477438	0.871	rs62156364	ENSG00000231822.1	AC019097.7	-3.4	0.000689	0.0321	-0.13	-0.1	Chronic sinus infection;	chr2:99078634	chr2:99102018~99102752:+
BRCA	cis	rs10838687	0.736	rs2279238	ENSG00000243802.2	RP11-390K5.1	3.4	0.000689	0.0321	0.15	0.1	Proinsulin levels;	chr11:47260473	chr11:47191181~47191542:-
BRCA	cis	rs2880765	0.835	rs7178991	ENSG00000189136.7	UBE2Q2P1	3.4	0.000689	0.0321	0.09	0.1	Coronary artery disease;	chr15:85507713	chr15:84526781~84571216:-
BRCA	cis	rs7259376	0.875	rs6511345	ENSG00000269345.1	VN1R85P	3.4	0.000689	0.0321	0.12	0.1	Menopause (age at onset);	chr19:22354634	chr19:22174766~22175191:-
BRCA	cis	rs1969253	0.712	rs3792305	ENSG00000205955.4	HSP90AA5P	-3.4	0.000689	0.0321	-0.13	-0.1	Major depressive disorder;	chr3:184187189	chr3:184115352~184117898:+
BRCA	cis	rs10266483	1	rs10266483	ENSG00000227986.1	TRIM60P18	-3.4	0.000689	0.0321	-0.11	-0.1	Response to statin therapy;	chr7:64272953	chr7:64355078~64356199:+
BRCA	cis	rs11098403	0.753	rs4833553	ENSG00000225892.3	RP11-384K6.2	3.4	0.000689	0.0321	0.11	0.1	Schizophrenia;	chr4:117844055	chr4:118632274~118634759:+
BRCA	cis	rs4415084	0.652	rs10473376	ENSG00000248779.1	RP11-53O19.2	-3.4	0.000689	0.0321	-0.1	-0.1	Breast cancer;	chr5:44931126	chr5:44752949~44765744:+
BRCA	cis	rs930395	0.514	rs10473377	ENSG00000248779.1	RP11-53O19.2	-3.4	0.000689	0.0321	-0.1	-0.1	Breast cancer;	chr5:44931144	chr5:44752949~44765744:+
BRCA	cis	rs1424638	0.655	rs3930761	ENSG00000233251.6	AC007743.1	-3.4	0.000689	0.0321	-0.12	-0.1	Intelligence (multi-trait analysis);	chr2:57021970	chr2:56173534~56185770:-
BRCA	cis	rs853679	0.882	rs9468300	ENSG00000219392.1	RP1-265C24.5	-3.4	0.000689	0.0321	-0.22	-0.1	Depression;	chr6:28159062	chr6:28115628~28116551:+
BRCA	cis	rs9646944	0.531	rs17027029	ENSG00000234389.1	AC007278.3	3.4	0.000689	0.0321	0.12	0.1	Blood protein levels;	chr2:102374188	chr2:102438713~102440475:+
BRCA	cis	rs1007738	0.542	rs4752970	ENSG00000200376.1	RNU5E-10P	3.4	0.00069	0.0321	0.14	0.1	Bone mineral density (hip);	chr11:47187431	chr11:47576471~47576588:-
BRCA	cis	rs7005380	1	rs10955943	ENSG00000279347.1	RP11-85I17.2	3.4	0.00069	0.0321	0.11	0.1	Interstitial lung disease;	chr8:119931903	chr8:119838736~119840385:-
BRCA	cis	rs12612435	0.955	rs7589839	ENSG00000226806.1	AC011893.3	-3.4	0.00069	0.0321	-0.13	-0.1	Takotsubo syndrome;	chr2:136348068	chr2:135820191~135823087:+
BRCA	cis	rs7713065	1	rs7713065	ENSG00000202533.1	Y_RNA	-3.4	0.00069	0.0321	-0.11	-0.1	Lung function (FEV1/FVC);	chr5:132452642	chr5:132468147~132468257:+
BRCA	cis	rs875971	0.895	rs4718349	ENSG00000273024.4	INTS4P2	-3.4	0.00069	0.0321	-0.11	-0.1	Aortic root size;	chr7:66444024	chr7:65647864~65715661:+
BRCA	cis	rs875971	1	rs2042133	ENSG00000273024.4	INTS4P2	-3.4	0.00069	0.0321	-0.11	-0.1	Aortic root size;	chr7:66466935	chr7:65647864~65715661:+
BRCA	cis	rs875971	0.964	rs2161065	ENSG00000273024.4	INTS4P2	-3.4	0.00069	0.0321	-0.11	-0.1	Aortic root size;	chr7:66467918	chr7:65647864~65715661:+
BRCA	cis	rs875971	0.862	rs12698521	ENSG00000273024.4	INTS4P2	-3.4	0.00069	0.0321	-0.11	-0.1	Aortic root size;	chr7:66474502	chr7:65647864~65715661:+
BRCA	cis	rs7267979	0.966	rs6083817	ENSG00000231081.1	RP4-760C5.3	3.4	0.00069	0.0321	0.13	0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25363362	chr20:26008791~26010531:-
BRCA	cis	rs7267979	1	rs6050564	ENSG00000231081.1	RP4-760C5.3	3.4	0.00069	0.0321	0.13	0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25363595	chr20:26008791~26010531:-
BRCA	cis	rs875971	0.862	rs7796162	ENSG00000223473.2	GS1-124K5.3	-3.4	0.00069	0.0321	-0.08	-0.1	Aortic root size;	chr7:66280771	chr7:66491049~66493566:-
BRCA	cis	rs36051895	0.664	rs3780370	ENSG00000237711.1	RP11-39K24.13	-3.4	0.00069	0.0321	-0.13	-0.1	Pediatric autoimmune diseases;	chr9:5095167	chr9:5100236~5101009:+
BRCA	cis	rs539096	0.83	rs3000761	ENSG00000236200.4	KDM4A-AS1	3.4	0.00069	0.0321	0.12	0.1	Intelligence (multi-trait analysis);	chr1:43560418	chr1:43699765~43708138:-
BRCA	cis	rs72720396	1	rs72720396	ENSG00000272931.1	RP5-943J3.2	-3.4	0.00069	0.0321	-0.15	-0.1	Chronotype;Morning vs. evening chronotype;	chr1:90726025	chr1:89820174~89820868:-
BRCA	cis	rs1113500	0.58	rs1781058	ENSG00000230489.1	VAV3-AS1	-3.4	0.00069	0.0321	-0.12	-0.1	Growth-regulated protein alpha levels;	chr1:108021437	chr1:107964443~107994607:+
BRCA	cis	rs7259376	0.902	rs7248242	ENSG00000269345.1	VN1R85P	-3.4	0.00069	0.0321	-0.12	-0.1	Menopause (age at onset);	chr19:22393192	chr19:22174766~22175191:-
BRCA	cis	rs2638953	0.671	rs10843097	ENSG00000247934.4	RP11-967K21.1	-3.4	0.00069	0.0321	-0.15	-0.1	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28114106	chr12:28163298~28190738:-
BRCA	cis	rs2243480	1	rs67728539	ENSG00000226767.1	RP11-328P23.3	-3.4	0.00069	0.0321	-0.18	-0.1	Diabetic kidney disease;	chr7:65913137	chr7:65508773~65508944:-
BRCA	cis	rs853679	0.517	rs4713141	ENSG00000226314.6	ZNF192P1	-3.4	0.00069	0.0321	-0.16	-0.1	Depression;	chr6:28133900	chr6:28161781~28169594:+
BRCA	cis	rs11098499	0.955	rs1511019	ENSG00000225892.3	RP11-384K6.2	3.4	0.00069	0.0321	0.11	0.1	Corneal astigmatism;	chr4:119244852	chr4:118632274~118634759:+
BRCA	cis	rs7165170	0.719	rs5011651	ENSG00000245479.2	LINC01585	3.4	0.00069	0.0321	0.13	0.1	Crohn's disease;Inflammatory bowel disease;	chr15:90623381	chr15:90660234~90664967:+
BRCA	cis	rs4287000	0.585	rs4403473	ENSG00000227603.1	RP11-165J3.6	3.4	0.00069	0.0321	0.11	0.1	Itch intensity from mosquito bite adjusted by bite size;	chr9:93636892	chr9:93435332~93437121:-
BRCA	cis	rs875971	0.862	rs13232191	ENSG00000106610.13	STAG3L4	-3.4	0.00069	0.0321	-0.14	-0.1	Aortic root size;	chr7:66521661	chr7:67302621~67321526:+
BRCA	cis	rs875971	0.862	rs10950043	ENSG00000106610.13	STAG3L4	-3.4	0.00069	0.0321	-0.14	-0.1	Aortic root size;	chr7:66523623	chr7:67302621~67321526:+
BRCA	cis	rs875971	0.862	rs17747530	ENSG00000106610.13	STAG3L4	-3.4	0.00069	0.0321	-0.14	-0.1	Aortic root size;	chr7:66529742	chr7:67302621~67321526:+
BRCA	cis	rs875971	0.862	rs13536	ENSG00000106610.13	STAG3L4	3.4	0.00069	0.0321	0.14	0.1	Aortic root size;	chr7:66554203	chr7:67302621~67321526:+
BRCA	cis	rs875971	0.862	rs801209	ENSG00000106610.13	STAG3L4	3.4	0.00069	0.0321	0.14	0.1	Aortic root size;	chr7:66554403	chr7:67302621~67321526:+
BRCA	cis	rs875971	0.862	rs801206	ENSG00000106610.13	STAG3L4	3.4	0.00069	0.0321	0.14	0.1	Aortic root size;	chr7:66556979	chr7:67302621~67321526:+
BRCA	cis	rs875971	0.862	rs801204	ENSG00000106610.13	STAG3L4	3.4	0.00069	0.0321	0.14	0.1	Aortic root size;	chr7:66557934	chr7:67302621~67321526:+
BRCA	cis	rs875971	0.862	rs801203	ENSG00000106610.13	STAG3L4	3.4	0.00069	0.0321	0.14	0.1	Aortic root size;	chr7:66558025	chr7:67302621~67321526:+
BRCA	cis	rs9557207	1	rs9300539	ENSG00000231194.1	FARP1-AS1	-3.4	0.00069	0.0321	-0.15	-0.1	Inflammatory bowel disease;Peripheral arterial disease (traffic-related air pollution interaction);	chr13:99352915	chr13:98435405~98435840:-
BRCA	cis	rs6840360	0.593	rs1429558	ENSG00000270265.1	RP11-731D1.4	-3.4	0.00069	0.0321	-0.12	-0.1	Intelligence (multi-trait analysis);	chr4:151764254	chr4:151333775~151353224:-
BRCA	cis	rs3790268	0.527	rs6112466	ENSG00000179447.2	RP5-1027G4.3	3.4	0.000691	0.0322	0.19	0.1	Matrix metalloproteinase levels;	chr20:19574059	chr20:19242302~19284596:-
BRCA	cis	rs2908197	0.663	rs7802264	ENSG00000205485.12	AC004980.7	3.4	0.000691	0.0322	0.11	0.1	3-hydroxypropylmercapturic acid levels in smokers;	chr7:76356465	chr7:76549360~76627982:+
BRCA	cis	rs10829156	0.898	rs7095666	ENSG00000225527.1	RP11-383B4.4	3.4	0.000691	0.0322	0.14	0.1	Sudden cardiac arrest;	chr10:18650538	chr10:18531849~18533336:-
BRCA	cis	rs875971	1	rs9986696	ENSG00000271064.1	RP11-792A8.3	3.4	0.000691	0.0322	0.12	0.1	Aortic root size;	chr7:66239589	chr7:66748838~66749077:-
BRCA	cis	rs3770752	0.866	rs10177176	ENSG00000272054.1	RP11-423P10.2	-3.4	0.000691	0.0322	-0.09	-0.1	Schizophrenia;	chr2:37290902	chr2:37208875~37212677:+
BRCA	cis	rs4730250	0.711	rs117026964	ENSG00000241764.3	AC002467.7	3.4	0.000691	0.0322	0.19	0.1	Osteoarthritis;	chr7:107423211	chr7:107742817~107744581:-
BRCA	cis	rs68170813	0.652	rs763386	ENSG00000241764.3	AC002467.7	3.4	0.000691	0.0322	0.18	0.1	Coronary artery disease;	chr7:107556278	chr7:107742817~107744581:-
BRCA	cis	rs68170813	0.652	rs6958969	ENSG00000241764.3	AC002467.7	3.4	0.000691	0.0322	0.18	0.1	Coronary artery disease;	chr7:107557310	chr7:107742817~107744581:-
BRCA	cis	rs897984	0.542	rs750952	ENSG00000275263.1	RP11-1072A3.4	-3.4	0.000691	0.0322	-0.12	-0.1	Dementia with Lewy bodies;	chr16:31082633	chr16:30956872~30957199:-
BRCA	cis	rs6671200	0.607	rs7528790	ENSG00000226026.4	RP11-57H12.3	-3.4	0.000691	0.0322	-0.16	-0.1	Stearic acid (18:0) levels;	chr1:95243518	chr1:95163219~95233982:-
BRCA	cis	rs4713118	0.513	rs149950	ENSG00000219891.2	ZSCAN12P1	3.4	0.000691	0.0322	0.13	0.1	Parkinson's disease;	chr6:28065261	chr6:28091154~28093664:+
BRCA	cis	rs4713118	0.513	rs149951	ENSG00000219891.2	ZSCAN12P1	3.4	0.000691	0.0322	0.13	0.1	Parkinson's disease;	chr6:28065309	chr6:28091154~28093664:+
BRCA	cis	rs16852403	0.502	rs6682970	ENSG00000224687.1	RASAL2-AS1	3.4	0.000691	0.0322	0.13	0.1	Childhood ear infection;	chr1:178201385	chr1:178091508~178093984:-
BRCA	cis	rs6452790	0.543	rs10440679	ENSG00000247828.6	TMEM161B-AS1	-3.4	0.000691	0.0322	-0.15	-0.1	Cognitive function;	chr5:88078544	chr5:88268895~88436685:+
BRCA	cis	rs2276314	1	rs62101367	ENSG00000267627.4	RP11-905K4.1	-3.4	0.000691	0.0322	-0.14	-0.1	Endometriosis;Drug-induced torsades de pointes;	chr18:35970921	chr18:35951803~35966118:-
BRCA	cis	rs6801044	0.741	rs2641362	ENSG00000272792.1	RP11-141C7.4	3.4	0.000691	0.0322	0.16	0.1	Creatinine levels in ischemic stroke;	chr3:195530358	chr3:195639990~195640460:+
BRCA	cis	rs6801044	0.741	rs2686435	ENSG00000272792.1	RP11-141C7.4	3.4	0.000691	0.0322	0.16	0.1	Creatinine levels in ischemic stroke;	chr3:195530359	chr3:195639990~195640460:+
BRCA	cis	rs7712401	0.755	rs1545697	ENSG00000249996.1	RP11-359P5.1	3.4	0.000691	0.0322	0.12	0.1	Mean platelet volume;	chr5:122766582	chr5:123036271~123054667:+
BRCA	cis	rs875971	0.522	rs2949690	ENSG00000229180.5	GS1-124K5.11	-3.4	0.000691	0.0322	-0.09	-0.1	Aortic root size;	chr7:66018255	chr7:66526088~66542624:-
BRCA	cis	rs17345786	0.861	rs74768235	ENSG00000244119.1	PDCL3P4	3.4	0.000691	0.0322	0.1	0.1	Colonoscopy-negative controls vs population controls;	chr3:101423977	chr3:101712472~101713191:+
BRCA	cis	rs875971	0.798	rs57739047	ENSG00000265600.1	AC006480.1	-3.4	0.000691	0.0322	-0.13	-0.1	Aortic root size;	chr7:66507579	chr7:67356680~67356779:+
BRCA	cis	rs38055	0.537	rs56296560	ENSG00000247796.2	CTD-2366F13.1	3.4	0.000691	0.0322	0.12	0.1	Acne (severe);	chr5:53255681	chr5:53109842~53115126:+
BRCA	cis	rs9457247	0.602	rs12209395	ENSG00000272549.1	RP11-351J23.2	-3.4	0.000691	0.0322	-0.11	-0.1	Crohn's disease;	chr6:167050426	chr6:167666840~167679270:-
BRCA	cis	rs846271	0.8	rs6463083	ENSG00000224116.5	INHBA-AS1	-3.4	0.000692	0.0322	-0.13	-0.1	IgG glycosylation;	chr7:41995537	chr7:41693916~41779388:+
BRCA	cis	rs2832191	0.703	rs2853827	ENSG00000236056.1	GAPDHP14	-3.4	0.000692	0.0322	-0.12	-0.1	Dental caries;	chr21:29071275	chr21:29222321~29223257:+
BRCA	cis	rs2235544	0.565	rs928443	ENSG00000198711.5	SSBP3-AS1	3.4	0.000692	0.0322	0.11	0.1	Thyroid hormone levels;Multiple myeloma (hyperdiploidy);	chr1:54007843	chr1:54236440~54239063:+
BRCA	cis	rs875971	1	rs6957199	ENSG00000271064.1	RP11-792A8.3	-3.4	0.000692	0.0322	-0.12	-0.1	Aortic root size;	chr7:66513532	chr7:66748838~66749077:-
BRCA	cis	rs9409565	0.787	rs11789704	ENSG00000232063.1	RP11-307E17.8	3.4	0.000692	0.0322	0.11	0.1	Colorectal cancer (alcohol consumption interaction);	chr9:94471126	chr9:94332476~94360948:+
BRCA	cis	rs259282	0.538	rs8105481	ENSG00000267475.1	CTD-2538C1.2	3.4	0.000692	0.0322	0.13	0.1	Schizophrenia;	chr19:32627189	chr19:32687089~32691750:-
BRCA	cis	rs6672530	0.5	rs10799434	ENSG00000227711.2	RP11-275O4.5	-3.4	0.000692	0.0322	-0.12	-0.1	Hip circumference adjusted for BMI;	chr1:227635214	chr1:227509028~227520477:-
BRCA	cis	rs6672530	0.5	rs10916187	ENSG00000227711.2	RP11-275O4.5	-3.4	0.000692	0.0322	-0.12	-0.1	Hip circumference adjusted for BMI;	chr1:227635217	chr1:227509028~227520477:-
BRCA	cis	rs1411478	1	rs7553330	ENSG00000243155.1	RP11-46A10.5	3.4	0.000692	0.0322	0.11	0.1	Menopause (age at onset);Progressive supranuclear palsy;	chr1:180986879	chr1:180944042~180976482:-
BRCA	cis	rs3767633	0.925	rs2499856	ENSG00000229808.1	RP11-456P18.2	3.4	0.000692	0.0322	0.18	0.1	IgG glycosylation;	chr1:161956847	chr1:161890833~161892196:+
BRCA	cis	rs875971	0.522	rs2949690	ENSG00000232559.3	GS1-124K5.12	-3.4	0.000692	0.0322	-0.12	-0.1	Aortic root size;	chr7:66018255	chr7:66554588~66576923:-
BRCA	cis	rs2274273	0.901	rs7147136	ENSG00000259318.1	RP11-454L9.2	3.4	0.000692	0.0322	0.09	0.1	Protein biomarker;	chr14:55359970	chr14:55394940~55395233:-
BRCA	cis	rs950881	0.932	rs13408661	ENSG00000234389.1	AC007278.3	3.4	0.000692	0.0322	0.13	0.1	Allergy;	chr2:102338622	chr2:102438713~102440475:+
BRCA	cis	rs4835473	0.868	rs35243309	ENSG00000246448.2	RP13-578N3.3	-3.4	0.000692	0.0322	-0.12	-0.1	Immature fraction of reticulocytes;	chr4:143755116	chr4:143700257~143865072:+
BRCA	cis	rs5742933	1	rs4667306	ENSG00000253559.1	OSGEPL1-AS1	-3.4	0.000692	0.0322	-0.15	-0.1	Ferritin levels;	chr2:189725630	chr2:189762704~189765556:+
BRCA	cis	rs17684571	0.938	rs71564849	ENSG00000231441.1	RP11-472M19.2	3.4	0.000692	0.0322	0.17	0.1	Schizophrenia;	chr6:56709421	chr6:56844002~56864078:+
BRCA	cis	rs12148488	0.966	rs12899062	ENSG00000260269.4	CTD-2323K18.1	3.4	0.000692	0.0322	0.13	0.1	Caffeine consumption;	chr15:75055300	chr15:75527150~75601205:-
BRCA	cis	rs9392653	1	rs9392650	ENSG00000220685.3	RP11-530A18.1	-3.4	0.000692	0.0322	-0.14	-0.1	Venous thromboembolism (SNP x SNP interaction);	chr6:5070426	chr6:5065795~5066982:-
BRCA	cis	rs16852403	0.548	rs28760457	ENSG00000224687.1	RASAL2-AS1	3.4	0.000692	0.0322	0.13	0.1	Childhood ear infection;	chr1:178205350	chr1:178091508~178093984:-
BRCA	cis	rs12149695	0.872	rs4787415	ENSG00000259940.2	CTD-3203P2.1	3.4	0.000692	0.0322	0.13	0.1	Gut microbiota (bacterial taxa);	chr16:27239885	chr16:27213308~27214993:-
BRCA	cis	rs7649443	0.959	rs6779689	ENSG00000243339.3	RN7SL738P	-3.4	0.000692	0.0322	-0.15	-0.1	Nonsyndromic cleft lip with cleft palate;	chr3:197287302	chr3:196399911~196400207:+
BRCA	cis	rs7405404	0.672	rs7404413	ENSG00000276564.1	CTA-276F8.1	3.4	0.000692	0.0322	0.12	0.1	Bipolar disorder lithium response (categorical) or schizophrenia;Schizophrenia;	chr16:13645328	chr16:14150833~14153235:+
BRCA	cis	rs9470794	0.915	rs56390138	ENSG00000204110.6	RP1-153P14.8	-3.4	0.000692	0.0322	-0.18	-0.1	Type 2 diabetes;	chr6:38032690	chr6:37507348~37535616:+
BRCA	cis	rs13326165	0.76	rs6445386	ENSG00000243224.1	RP5-1157M23.2	-3.4	0.000692	0.0322	-0.15	-0.1	HDL cholesterol levels;HDL cholesterol;	chr3:52316196	chr3:52239258~52241097:+
BRCA	cis	rs7267979	0.833	rs6138556	ENSG00000204556.4	CTD-2514C3.1	-3.4	0.000692	0.0322	-0.15	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25262674	chr20:26018832~26020684:+
BRCA	cis	rs1208	0.899	rs35149886	ENSG00000253671.1	RP11-806O11.1	-3.4	0.000692	0.0322	-0.12	-0.1	Insulin resistance/response;	chr8:18394299	chr8:17808941~17820868:+
BRCA	cis	rs10958369	0.613	rs7812717	ENSG00000274295.1	RP11-1081M5.3	3.4	0.000692	0.0322	0.13	0.1	Response to antineoplastic agents;	chr8:53521362	chr8:53394215~53394795:+
BRCA	cis	rs13434995	0.513	rs17722979	ENSG00000273257.1	RP11-177J6.1	-3.4	0.000692	0.0322	-0.15	-0.1	Adiponectin levels;	chr4:55480244	chr4:55387949~55388271:+
BRCA	cis	rs71007656	1	rs71007656	ENSG00000273019.1	RP11-508N22.13	-3.4	0.000693	0.0322	-0.12	-0.1	Extrinsic epigenetic age acceleration;	chr10:37681922	chr10:38149968~38150293:+
BRCA	cis	rs2665103	0.715	rs11639440	ENSG00000280753.1	AC044907.1	-3.4	0.000693	0.0322	-0.1	-0.1	Intelligence (multi-trait analysis);	chr15:82278705	chr15:82847870~82847998:-
BRCA	cis	rs7712401	0.692	rs9327273	ENSG00000263432.2	RN7SL689P	3.4	0.000693	0.0322	0.12	0.1	Mean platelet volume;	chr5:122737855	chr5:123022487~123022783:-
BRCA	cis	rs4499344	0.521	rs259222	ENSG00000267475.1	CTD-2538C1.2	3.4	0.000693	0.0322	0.14	0.1	Mean platelet volume;	chr19:32645989	chr19:32687089~32691750:-
BRCA	cis	rs7577696	0.711	rs385076	ENSG00000276334.1	AL133243.1	3.4	0.000693	0.0322	0.13	0.1	Inflammatory biomarkers;	chr2:32264782	chr2:32521927~32523547:+
BRCA	cis	rs7267979	1	rs6050561	ENSG00000231081.1	RP4-760C5.3	3.4	0.000693	0.0322	0.13	0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25354219	chr20:26008791~26010531:-
BRCA	cis	rs7267979	1	rs6083813	ENSG00000231081.1	RP4-760C5.3	3.4	0.000693	0.0322	0.13	0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25357035	chr20:26008791~26010531:-
BRCA	cis	rs34792	0.626	rs153784	ENSG00000260872.1	RP11-680G24.5	-3.4	0.000693	0.0322	-0.12	-0.1	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15508734	chr16:15018106~15020488:-
BRCA	cis	rs72772090	0.539	rs3335	ENSG00000272109.1	CTD-2260A17.3	3.4	0.000693	0.0322	0.2	0.1	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96779366	chr5:96804353~96806105:+
BRCA	cis	rs72772090	0.539	rs3334	ENSG00000272109.1	CTD-2260A17.3	3.4	0.000693	0.0322	0.2	0.1	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96779381	chr5:96804353~96806105:+
BRCA	cis	rs7789940	0.81	rs12533978	ENSG00000231087.2	FDPSP7	-3.4	0.000693	0.0322	-0.14	-0.1	Multiple sclerosis;	chr7:76314035	chr7:76968197~76969250:-
BRCA	cis	rs10411161	0.81	rs17778711	ENSG00000275055.1	CTC-471J1.11	-3.4	0.000693	0.0322	-0.19	-0.1	Breast cancer;	chr19:51882047	chr19:52049007~52049754:+
BRCA	cis	rs10486003	1	rs6963652	ENSG00000213455.3	AC091654.7	-3.4	0.000693	0.0322	-0.18	-0.1	Response to platinum-based agents;	chr7:97587894	chr7:98454119~98454617:-
BRCA	cis	rs36051895	0.659	rs10283730	ENSG00000236254.1	MTND4P14	-3.4	0.000693	0.0322	-0.13	-0.1	Pediatric autoimmune diseases;	chr9:5073289	chr9:5107937~5109290:+
BRCA	cis	rs35520189	0.591	rs12995439	ENSG00000189223.12	PAX8-AS1	-3.4	0.000693	0.0322	-0.16	-0.1	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:112946069	chr2:113211522~113276581:+
BRCA	cis	rs8180040	0.726	rs7610636	ENSG00000280667.1	Y_RNA	-3.4	0.000693	0.0322	-0.12	-0.1	Colorectal cancer;	chr3:47022946	chr3:47501083~47501182:+
BRCA	cis	rs1577917	0.538	rs6454483	ENSG00000220563.1	PKMP3	3.4	0.000693	0.0322	0.1	0.1	Response to antipsychotic treatment;	chr6:85708565	chr6:85659892~85660606:-
BRCA	cis	rs8103278	1	rs7256192	ENSG00000268423.3	AC011551.3	3.4	0.000693	0.0322	0.13	0.1	Coronary artery disease;	chr19:45835234	chr19:46547056~46600861:-
BRCA	cis	rs979233	0.502	rs10059251	ENSG00000249779.1	RP11-447H19.3	-3.4	0.000693	0.0323	-0.14	-0.1	Systemic lupus erythematosus;	chr5:42330543	chr5:43206709~43207811:+
BRCA	cis	rs4648045	0.964	rs11723120	ENSG00000246560.2	RP11-10L12.4	3.4	0.000693	0.0323	0.12	0.1	Lymphocyte percentage of white cells;	chr4:102581394	chr4:102828055~102844075:+
BRCA	cis	rs9467773	0.62	rs9461275	ENSG00000261353.1	CTA-14H9.5	-3.4	0.000693	0.0323	-0.1	-0.1	Intelligence (multi-trait analysis);	chr6:26590573	chr6:26527063~26527404:+
BRCA	cis	rs7615952	0.673	rs9821905	ENSG00000241288.6	RP11-379B18.5	3.4	0.000693	0.0323	0.18	0.1	Blood pressure (smoking interaction);	chr3:125902007	chr3:125827238~125916384:-
BRCA	cis	rs337100	0.546	rs416015	ENSG00000263432.2	RN7SL689P	3.4	0.000693	0.0323	0.12	0.1	Pulse pressure;	chr5:123133429	chr5:123022487~123022783:-
BRCA	cis	rs12893668	0.514	rs3212090	ENSG00000258914.1	CTD-2134A5.3	3.4	0.000693	0.0323	0.14	0.1	Reticulocyte count;	chr14:103702526	chr14:103875055~103877478:+
BRCA	cis	rs3760982	0.585	rs1386502	ENSG00000266921.1	RP11-15A1.7	-3.4	0.000693	0.0323	-0.13	-0.1	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43789204	chr19:43996896~44002836:-
BRCA	cis	rs2811415	0.597	rs9848345	ENSG00000242551.2	POU5F1P6	3.4	0.000693	0.0323	0.14	0.1	Lung function (FEV1/FVC);	chr3:128060377	chr3:128674735~128677005:-
BRCA	cis	rs2811415	0.597	rs2304018	ENSG00000242551.2	POU5F1P6	3.4	0.000693	0.0323	0.14	0.1	Lung function (FEV1/FVC);	chr3:128060463	chr3:128674735~128677005:-
BRCA	cis	rs2811415	0.597	rs9849210	ENSG00000242551.2	POU5F1P6	3.4	0.000693	0.0323	0.14	0.1	Lung function (FEV1/FVC);	chr3:128060790	chr3:128674735~128677005:-
BRCA	cis	rs2811415	0.627	rs9289325	ENSG00000242551.2	POU5F1P6	3.4	0.000693	0.0323	0.14	0.1	Lung function (FEV1/FVC);	chr3:128060850	chr3:128674735~128677005:-
BRCA	cis	rs7267979	0.586	rs6050431	ENSG00000274414.1	RP5-965G21.4	-3.4	0.000693	0.0323	-0.12	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25203272	chr20:25239007~25245229:-
BRCA	cis	rs7267979	0.586	rs6050432	ENSG00000274414.1	RP5-965G21.4	-3.4	0.000693	0.0323	-0.12	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25203392	chr20:25239007~25245229:-
BRCA	cis	rs1376877	0.87	rs11683120	ENSG00000273456.1	RP11-686O6.2	3.4	0.000693	0.0323	0.1	0.1	Subclinical atherosclerosis traits (other);	chr2:203264588	chr2:202374932~202375604:-
BRCA	cis	rs2337406	1	rs4774173	ENSG00000280411.1	IGHV1-69-2	-3.4	0.000693	0.0323	-0.09	-0.1	Alzheimer's disease (late onset);	chr14:106682029	chr14:106762092~106762588:-
BRCA	cis	rs2712431	0.554	rs2010054	ENSG00000261159.1	RP11-723O4.9	-3.4	0.000693	0.0323	-0.11	-0.1	Monocyte chemoattractant protein-1 levels;	chr3:128586459	chr3:128859716~128860526:-
BRCA	cis	rs2880765	0.835	rs7168860	ENSG00000230373.7	GOLGA6L5P	3.4	0.000694	0.0323	0.11	0.1	Coronary artery disease;	chr15:85493799	chr15:84507885~84516814:-
BRCA	cis	rs925946	0.518	rs73430668	ENSG00000245573.6	BDNF-AS	-3.4	0.000694	0.0323	-0.13	-0.1	Weight;Body mass index;	chr11:27591872	chr11:27506838~27698174:+
BRCA	cis	rs564309	0.681	rs1188489	ENSG00000183929.7	DUSP5P1	-3.4	0.000694	0.0323	-0.2	-0.1	Hip circumference (psychosocial stress interaction);	chr1:228434071	chr1:228650241~228651379:+
BRCA	cis	rs8030379	1	rs11259936	ENSG00000176700.18	SCAND2P	3.4	0.000694	0.0323	0.09	0.1	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83911830	chr15:84631451~84647478:+
BRCA	cis	rs4742903	0.933	rs10820608	ENSG00000270332.1	SMC2-AS1	3.4	0.000694	0.0323	0.11	0.1	Breast cancer;High-grade serous ovarian cancer;	chr9:104128559	chr9:104080024~104093073:-
BRCA	cis	rs2832191	0.765	rs2832162	ENSG00000215533.7	LINC00189	-3.4	0.000694	0.0323	-0.12	-0.1	Dental caries;	chr21:29089487	chr21:29193480~29288205:+
BRCA	cis	rs930395	0.514	rs7703618	ENSG00000272335.1	RP11-53O19.3	-3.4	0.000694	0.0323	-0.1	-0.1	Breast cancer;	chr5:44914477	chr5:44826076~44828592:+
BRCA	cis	rs34421088	0.603	rs10086064	ENSG00000250794.2	ALG1L12P	-3.4	0.000694	0.0323	-0.13	-0.1	Neuroticism;	chr8:11726332	chr8:12421032~12425000:+
BRCA	cis	rs10043228	1	rs62384253	ENSG00000271918.1	CTD-2287O16.5	-3.4	0.000694	0.0323	-0.15	-0.1	Asthma or chronic obstructive pulmonary disease;	chr5:116227718	chr5:116083807~116085416:-
BRCA	cis	rs7620503	0.959	rs2863015	ENSG00000228561.2	RP11-114M1.1	3.4	0.000694	0.0323	0.12	0.1	Corneal structure;	chr3:177585391	chr3:177683627~177691250:+
BRCA	cis	rs7258465	1	rs10403249	ENSG00000273654.1	CTB-52I2.4	-3.4	0.000694	0.0323	-0.13	-0.1	Breast cancer;	chr19:18494132	chr19:18022403~18032099:+
BRCA	cis	rs1642645	0.606	rs638734	ENSG00000228452.1	RP5-994D16.9	-3.4	0.000694	0.0323	-0.14	-0.1	Left ventricular obstructive tract defect (maternal effect);	chr1:41994910	chr1:42775813~42776790:-
BRCA	cis	rs860295	0.812	rs3820594	ENSG00000203761.5	MSTO2P	-3.4	0.000694	0.0323	-0.09	-0.1	Body mass index;	chr1:155859720	chr1:155745829~155750137:+
BRCA	cis	rs6724465	0.673	rs77397607	ENSG00000272644.1	RP11-33O4.1	3.4	0.000694	0.0323	0.17	0.1	Height;	chr2:219157074	chr2:219069354~219069809:-
BRCA	cis	rs3889199	0.74	rs12741039	ENSG00000272226.1	RP11-63G10.3	3.4	0.000694	0.0323	0.14	0.1	Pulse pressure;	chr1:59207521	chr1:58812808~58813342:-
BRCA	cis	rs3916	0.911	rs7313271	ENSG00000277423.1	RP11-173P15.9	-3.4	0.000694	0.0323	-0.14	-0.1	Urinary metabolites (H-NMR features);	chr12:120714864	chr12:120703867~120704282:+
BRCA	cis	rs7818688	1	rs16917233	ENSG00000245080.5	RP11-320N21.1	3.4	0.000694	0.0323	0.17	0.1	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:95032739	chr8:95066808~95073182:-
BRCA	cis	rs1348850	0.526	rs2293475	ENSG00000271825.1	RP11-337N6.2	-3.4	0.000694	0.0323	-0.17	-0.1	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177543169	chr2:177300600~177302006:+
BRCA	cis	rs58521262	0.729	rs7246529	ENSG00000268105.1	RP11-369G6.2	-3.4	0.000694	0.0323	-0.18	-0.1	Testicular germ cell tumor;	chr19:22882321	chr19:23125665~23128543:+
BRCA	cis	rs2278170	0.962	rs11032355	ENSG00000225101.4	OR52K3P	-3.4	0.000694	0.0323	-0.14	-0.1	Amyotrophic lateral sclerosis;	chr11:4466159	chr11:4474813~4475755:+
BRCA	cis	rs34779708	0.931	rs34876468	ENSG00000269952.1	RP11-324I22.3	-3.4	0.000695	0.0323	-0.14	-0.1	Inflammatory bowel disease;Crohn's disease;	chr10:35135522	chr10:35210416~35210750:+
BRCA	cis	rs4578769	0.765	rs1584428	ENSG00000273232.1	RP11-370A5.2	3.4	0.000695	0.0323	0.15	0.1	Eosinophil percentage of white cells;	chr18:22807886	chr18:22882825~22883357:-
BRCA	cis	rs9457247	1	rs400063	ENSG00000227598.1	RP1-167A14.2	-3.4	0.000695	0.0323	-0.11	-0.1	Crohn's disease;	chr6:166973104	chr6:166969626~166999065:-
BRCA	cis	rs2625529	0.818	rs2246225	ENSG00000260037.4	CTD-2524L6.3	3.4	0.000695	0.0323	0.15	0.1	Red blood cell count;	chr15:71822889	chr15:71818396~71823384:+
BRCA	cis	rs2692947	0.696	rs2576437	ENSG00000232931.4	LINC00342	3.4	0.000695	0.0323	0.11	0.1	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96134678	chr2:95807118~95816215:-
BRCA	cis	rs9847710	0.967	rs2581778	ENSG00000275956.1	RP5-966M1.7	-3.4	0.000695	0.0323	-0.12	-0.1	Ulcerative colitis;	chr3:53021295	chr3:52732547~52733867:+
BRCA	cis	rs7127307	0.573	rs12419147	ENSG00000254703.2	SENCR	-3.4	0.000695	0.0323	-0.1	-0.1	Atopic dermatitis;	chr11:128295232	chr11:128691672~128696023:-
BRCA	cis	rs2640806	0.645	rs17781008	ENSG00000253105.4	KB-1448A5.1	-3.4	0.000695	0.0323	-0.12	-0.1	Obesity-related traits;	chr8:96325428	chr8:96371865~96387438:-
BRCA	cis	rs6430553	0.929	rs6714498	ENSG00000226806.1	AC011893.3	-3.4	0.000695	0.0323	-0.11	-0.1	Blood metabolite levels;	chr2:134893196	chr2:135820191~135823087:+
BRCA	cis	rs977987	0.778	rs4888412	ENSG00000261476.1	RP11-77K12.3	-3.4	0.000695	0.0323	-0.11	-0.1	Dupuytren's disease;	chr16:75409298	chr16:75458252~75460017:-
BRCA	cis	rs27434	0.583	rs151911	ENSG00000248734.2	CTD-2260A17.1	3.4	0.000695	0.0323	0.12	0.1	Ankylosing spondylitis;	chr5:96821381	chr5:96784777~96785999:+
BRCA	cis	rs1056107	0.933	rs7047691	ENSG00000266315.1	MIR4668	3.4	0.000695	0.0323	0.11	0.1	Colorectal cancer;	chr9:112289887	chr9:111932100~111932169:+
BRCA	cis	rs7200543	1	rs35574015	ENSG00000207425.1	Y_RNA	-3.4	0.000695	0.0323	-0.13	-0.1	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15052204	chr16:14915457~14915556:-
BRCA	cis	rs1161098	1	rs1161098	ENSG00000203585.3	RP11-542B15.1	3.4	0.000695	0.0323	0.14	0.1	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr12:67453680	chr12:67519829~67567126:+
BRCA	cis	rs6028335	0.674	rs3829696	ENSG00000274825.1	RP4-616B8.5	3.4	0.000695	0.0323	0.13	0.1	Alcohol and nicotine co-dependence;	chr20:39006061	chr20:38955910~38956547:+
BRCA	cis	rs6964587	1	rs3753108	ENSG00000188693.7	CYP51A1-AS1	-3.4	0.000695	0.0323	-0.11	-0.1	Breast cancer;	chr7:92000670	chr7:92134604~92180725:+
BRCA	cis	rs12922040	1	rs2075516	ENSG00000207425.1	Y_RNA	-3.4	0.000695	0.0323	-0.12	-0.1	Serum uric acid levels in response to allopurinol in gout;	chr16:15775668	chr16:14915457~14915556:-
BRCA	cis	rs879568	0.836	rs4477795	ENSG00000278986.1	RP11-723J4.3	-3.4	0.000695	0.0323	-0.12	-0.1	QRS duration;	chr18:36712403	chr18:35972151~35973916:+
BRCA	cis	rs6918586	0.658	rs198830	ENSG00000272810.1	U91328.22	-3.4	0.000695	0.0323	-0.11	-0.1	Schizophrenia;	chr6:26118018	chr6:26013241~26013757:+
BRCA	cis	rs910873	0.505	rs6059969	ENSG00000250917.1	RP4-785G19.5	3.4	0.000695	0.0323	0.18	0.1	Melanoma;	chr20:34657480	chr20:34234840~34281173:-
BRCA	cis	rs10838634	0.706	rs11039012	ENSG00000280615.1	Y_RNA	3.4	0.000695	0.0323	0.18	0.1	Schizophrenia;	chr11:46861767	chr11:47614898~47614994:-
BRCA	cis	rs9287719	0.967	rs10206225	ENSG00000224177.5	LINC00570	3.4	0.000695	0.0323	0.12	0.1	Prostate cancer;	chr2:10618531	chr2:11393981~11403077:+
BRCA	cis	rs34779708	0.897	rs16935880	ENSG00000269952.1	RP11-324I22.3	-3.4	0.000695	0.0323	-0.14	-0.1	Inflammatory bowel disease;Crohn's disease;	chr10:35126540	chr10:35210416~35210750:+
BRCA	cis	rs34779708	0.966	rs4934730	ENSG00000269952.1	RP11-324I22.3	-3.4	0.000695	0.0323	-0.14	-0.1	Inflammatory bowel disease;Crohn's disease;	chr10:35126627	chr10:35210416~35210750:+
BRCA	cis	rs613391	0.561	rs10811762	ENSG00000265194.1	RP11-70L8.4	-3.4	0.000695	0.0323	-0.11	-0.1	Quantitative traits;	chr9:22716471	chr9:21858910~21861926:-
BRCA	cis	rs6942407	0.546	rs2108271	ENSG00000224046.1	AC005076.5	-3.4	0.000695	0.0323	-0.15	-0.1	Food allergy;	chr7:87176056	chr7:87151423~87152420:-
BRCA	cis	rs6942407	0.546	rs7810647	ENSG00000224046.1	AC005076.5	-3.4	0.000695	0.0323	-0.15	-0.1	Food allergy;	chr7:87176645	chr7:87151423~87152420:-
BRCA	cis	rs17507216	1	rs17356118	ENSG00000276710.3	CSPG4P8	-3.4	0.000695	0.0323	-0.13	-0.1	Excessive daytime sleepiness;	chr15:82569149	chr15:82459472~82477258:+
BRCA	cis	rs1008375	0.966	rs6837664	ENSG00000249502.1	AC006160.5	-3.4	0.000696	0.0323	-0.12	-0.1	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17696212	chr4:17587467~17614571:-
BRCA	cis	rs6121246	0.559	rs6060950	ENSG00000230613.1	HM13-AS1	3.4	0.000696	0.0323	0.14	0.1	Mean corpuscular hemoglobin;	chr20:31790228	chr20:31567707~31573263:-
BRCA	cis	rs7735319	0.565	rs3860753	ENSG00000249572.1	CTD-2203K17.1	3.4	0.000696	0.0323	0.13	0.1	Systolic blood pressure;	chr5:33114872	chr5:33424025~33440619:-
BRCA	cis	rs2274273	1	rs4644	ENSG00000233924.1	AL160471.6	-3.4	0.000696	0.0323	-0.12	-0.1	Protein biomarker;	chr14:55138217	chr14:55004813~55005687:-
BRCA	cis	rs13008689	1	rs13008689	ENSG00000236790.4	LINC00299	-3.4	0.000696	0.0323	-0.12	-0.1	Longevity;	chr2:8390126	chr2:8007771~8383621:-
BRCA	cis	rs7267979	0.966	rs454723	ENSG00000276952.1	RP5-965G21.6	3.4	0.000696	0.0323	0.13	0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25458292	chr20:25284915~25285588:-
BRCA	cis	rs5742933	0.948	rs10195109	ENSG00000253559.1	OSGEPL1-AS1	3.4	0.000696	0.0323	0.14	0.1	Ferritin levels;	chr2:189704465	chr2:189762704~189765556:+
BRCA	cis	rs8123073	0.744	rs6058885	ENSG00000260257.2	RP5-1085F17.3	3.4	0.000696	0.0324	0.18	0.1	Attention deficit hyperactivity disorder (combined symptoms);	chr20:32780142	chr20:32856621~32858751:+
BRCA	cis	rs6517329	0.524	rs13047406	ENSG00000230212.5	AP000688.14	3.4	0.000696	0.0324	0.13	0.1	Schizophrenia;	chr21:36132840	chr21:36069642~36126640:-
BRCA	cis	rs853679	0.517	rs9368556	ENSG00000226314.6	ZNF192P1	-3.4	0.000696	0.0324	-0.16	-0.1	Depression;	chr6:28163375	chr6:28161781~28169594:+
BRCA	cis	rs853679	0.517	rs9368557	ENSG00000226314.6	ZNF192P1	-3.4	0.000696	0.0324	-0.16	-0.1	Depression;	chr6:28163759	chr6:28161781~28169594:+
BRCA	cis	rs853679	0.517	rs9380059	ENSG00000226314.6	ZNF192P1	-3.4	0.000696	0.0324	-0.16	-0.1	Depression;	chr6:28164580	chr6:28161781~28169594:+
BRCA	cis	rs853679	0.517	rs9380060	ENSG00000226314.6	ZNF192P1	-3.4	0.000696	0.0324	-0.16	-0.1	Depression;	chr6:28164825	chr6:28161781~28169594:+
BRCA	cis	rs853679	0.517	rs35227624	ENSG00000226314.6	ZNF192P1	-3.4	0.000696	0.0324	-0.16	-0.1	Depression;	chr6:28164948	chr6:28161781~28169594:+
BRCA	cis	rs853679	0.517	rs9380061	ENSG00000226314.6	ZNF192P1	-3.4	0.000696	0.0324	-0.16	-0.1	Depression;	chr6:28165025	chr6:28161781~28169594:+
BRCA	cis	rs853679	0.517	rs9368558	ENSG00000226314.6	ZNF192P1	-3.4	0.000696	0.0324	-0.16	-0.1	Depression;	chr6:28165528	chr6:28161781~28169594:+
BRCA	cis	rs7208859	0.573	rs11654035	ENSG00000276250.1	CTD-2349P21.12	-3.4	0.000696	0.0324	-0.17	-0.1	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809408	chr17:30803654~30804077:+
BRCA	cis	rs3805389	0.504	rs17725163	ENSG00000249700.7	SRD5A3-AS1	3.4	0.000696	0.0324	0.17	0.1	Waist-to-hip ratio adjusted for body mass index;	chr4:55609280	chr4:55363971~55395847:-
BRCA	cis	rs654950	0.875	rs600109	ENSG00000230881.1	RP11-486B10.3	3.4	0.000696	0.0324	0.11	0.1	Airway imaging phenotypes;	chr1:41532575	chr1:41535443~41535868:+
BRCA	cis	rs10995356	0.844	rs10761685	ENSG00000238280.1	RP11-436D10.3	3.4	0.000696	0.0324	0.14	0.1	Temperament;	chr10:62990651	chr10:62793562~62805887:-
BRCA	cis	rs2615061	0.872	rs12021809	ENSG00000229965.1	RP11-118H4.1	3.4	0.000696	0.0324	0.19	0.1	Monocyte count;	chr1:225754080	chr1:226438564~226439344:+
BRCA	cis	rs6696239	0.956	rs10916173	ENSG00000215812.5	ZNF847P	3.4	0.000696	0.0324	0.15	0.1	Height;	chr1:227605545	chr1:227696892~227706699:-
BRCA	cis	rs4950322	0.518	rs61838951	ENSG00000230832.3	RP11-325P15.2	-3.4	0.000696	0.0324	-0.16	-0.1	Protein quantitative trait loci;	chr1:147116081	chr1:147082338~147083578:-
BRCA	cis	rs12887734	0.546	rs12886637	ENSG00000269940.1	RP11-73M18.7	-3.4	0.000696	0.0324	-0.12	-0.1	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103756555	chr14:103694560~103695170:+
BRCA	cis	rs1046491	0.901	rs35587943	ENSG00000264964.1	RP11-888D10.3	3.4	0.000696	0.0324	0.21	0.1	Scarlet fever;	chr18:9105524	chr18:9315194~9334441:-
BRCA	cis	rs4714291	1	rs847769	ENSG00000180211.5	RP1-278E11.3	3.4	0.000696	0.0324	0.12	0.1	Strep throat;	chr6:40082432	chr6:39958414~39958833:-
BRCA	cis	rs10986311	0.832	rs7875898	ENSG00000227200.1	RP11-121A14.3	-3.4	0.000696	0.0324	-0.12	-0.1	Vitiligo;	chr9:124378244	chr9:124262876~124265809:+
BRCA	cis	rs6496044	0.568	rs2880765	ENSG00000259630.2	CTD-2262B20.1	3.4	0.000696	0.0324	0.12	0.1	Interstitial lung disease;	chr15:85513231	chr15:85415228~85415633:+
BRCA	cis	rs2911132	0.511	rs13160562	ENSG00000272109.1	CTD-2260A17.3	-3.4	0.000696	0.0324	-0.15	-0.1	Urate levels (BMI interaction);	chr5:96775667	chr5:96804353~96806105:+
BRCA	cis	rs7713972	0.588	rs2055646	ENSG00000250492.1	INTS6P1	-3.4	0.000696	0.0324	-0.2	-0.1	Blood protein levels;	chr5:40574840	chr5:39718984~39721513:-
BRCA	cis	rs3743102	1	rs3803383	ENSG00000278603.1	RP13-608F4.5	-3.4	0.000696	0.0324	-0.19	-0.1	Colorectal adenoma (advanced);	chr15:82754741	chr15:82472203~82472426:+
BRCA	cis	rs7649443	0.959	rs62282105	ENSG00000243339.3	RN7SL738P	-3.4	0.000696	0.0324	-0.15	-0.1	Nonsyndromic cleft lip with cleft palate;	chr3:197251848	chr3:196399911~196400207:+
BRCA	cis	rs9990333	0.544	rs11915082	ENSG00000273009.1	RP11-352G9.1	-3.4	0.000696	0.0324	-0.13	-0.1	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196082268	chr3:195913078~195913683:-
BRCA	cis	rs4478858	0.735	rs12563669	ENSG00000229447.2	RP11-490K7.4	-3.4	0.000696	0.0324	-0.1	-0.1	Alcohol dependence;	chr1:31385220	chr1:31263245~31263681:-
BRCA	cis	rs66887589	0.774	rs9307477	ENSG00000260404.2	RP11-384K6.6	3.4	0.000696	0.0324	0.09	0.1	Diastolic blood pressure;	chr4:119500654	chr4:118591773~118633729:+
BRCA	cis	rs13434995	0.513	rs6554291	ENSG00000273257.1	RP11-177J6.1	-3.4	0.000696	0.0324	-0.15	-0.1	Adiponectin levels;	chr4:55571204	chr4:55387949~55388271:+
BRCA	cis	rs12477438	0.52	rs7604557	ENSG00000231822.1	AC019097.7	3.4	0.000697	0.0324	0.11	0.1	Chronic sinus infection;	chr2:99131366	chr2:99102018~99102752:+
BRCA	cis	rs12477438	0.52	rs11685759	ENSG00000231822.1	AC019097.7	3.4	0.000697	0.0324	0.11	0.1	Chronic sinus infection;	chr2:99149754	chr2:99102018~99102752:+
BRCA	cis	rs12477438	0.52	rs11123765	ENSG00000231822.1	AC019097.7	3.4	0.000697	0.0324	0.11	0.1	Chronic sinus infection;	chr2:99151601	chr2:99102018~99102752:+
BRCA	cis	rs12477438	0.501	rs2632260	ENSG00000231822.1	AC019097.7	3.4	0.000697	0.0324	0.11	0.1	Chronic sinus infection;	chr2:99155127	chr2:99102018~99102752:+
BRCA	cis	rs7182621	1	rs7182621	ENSG00000182397.13	DNM1P46	-3.4	0.000697	0.0324	-0.11	-0.1	Colonoscopy-negative controls vs population controls;	chr15:99884400	chr15:99790156~99806927:-
BRCA	cis	rs495337	0.736	rs568124	ENSG00000224397.4	LINC01272	-3.4	0.000697	0.0324	-0.11	-0.1	Psoriasis;	chr20:49867588	chr20:50267486~50279795:+
BRCA	cis	rs8127691	1	rs762421	ENSG00000225331.1	AP001055.6	-3.4	0.000697	0.0324	-0.13	-0.1	Inflammatory bowel disease;	chr21:44195678	chr21:44158740~44160076:-
BRCA	cis	rs7829975	0.686	rs907180	ENSG00000253981.4	ALG1L13P	3.4	0.000697	0.0324	0.11	0.1	Mood instability;	chr8:8845317	chr8:8236003~8244667:-
BRCA	cis	rs748404	0.589	rs62020616	ENSG00000201136.1	RNU6-353P	3.4	0.000697	0.0324	0.15	0.1	Lung cancer;	chr15:43558554	chr15:43702363~43702470:+
BRCA	cis	rs748404	0.626	rs60367691	ENSG00000201136.1	RNU6-353P	3.4	0.000697	0.0324	0.15	0.1	Lung cancer;	chr15:43559201	chr15:43702363~43702470:+
BRCA	cis	rs910873	0.505	rs7261964	ENSG00000250917.1	RP4-785G19.5	3.4	0.000697	0.0324	0.18	0.1	Melanoma;	chr20:34617207	chr20:34234840~34281173:-
BRCA	cis	rs8114671	0.562	rs4911450	ENSG00000126005.14	MMP24-AS1	-3.4	0.000697	0.0324	-0.13	-0.1	Height;	chr20:34924603	chr20:35216462~35278131:-
BRCA	cis	rs417065	0.516	rs11121131	ENSG00000238290.1	RP11-431K24.1	-3.4	0.000697	0.0324	-0.14	-0.1	Psoriasis;	chr1:8212171	chr1:8026738~8122702:+
BRCA	cis	rs875971	0.83	rs6950137	ENSG00000265600.1	AC006480.1	-3.4	0.000697	0.0324	-0.13	-0.1	Aortic root size;	chr7:66511623	chr7:67356680~67356779:+
BRCA	cis	rs6801044	0.789	rs823526	ENSG00000229178.1	AC069513.4	3.4	0.000697	0.0324	0.15	0.1	Creatinine levels in ischemic stroke;	chr3:195551478	chr3:195655565~195657927:-
BRCA	cis	rs875971	1	rs10257427	ENSG00000271064.1	RP11-792A8.3	3.4	0.000697	0.0324	0.12	0.1	Aortic root size;	chr7:66278221	chr7:66748838~66749077:-
BRCA	cis	rs2899832	0.568	rs8017676	ENSG00000258738.1	RP11-73E17.2	3.4	0.000697	0.0324	0.2	0.1	Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:35293460	chr14:34874343~34876459:+
BRCA	cis	rs8114671	0.562	rs8117491	ENSG00000126005.14	MMP24-AS1	-3.4	0.000697	0.0324	-0.13	-0.1	Height;	chr20:34922317	chr20:35216462~35278131:-
BRCA	cis	rs6854137	0.553	rs17614715	ENSG00000214676.4	RPL9P16	3.4	0.000697	0.0324	0.12	0.1	Vein graft stenosis in coronary artery bypass grafting;	chr4:168780427	chr4:168755816~168756382:+
BRCA	cis	rs4957325	0.789	rs6876228	ENSG00000250492.1	INTS6P1	3.4	0.000697	0.0324	0.18	0.1	Hemoglobin concentration;	chr5:40480297	chr5:39718984~39721513:-
BRCA	cis	rs2916733	0.818	rs2920660	ENSG00000246089.3	RP11-115C21.2	-3.4	0.000697	0.0324	-0.15	-0.1	Epirubicin-induced leukopenia;	chr8:6462126	chr8:6403551~6407142:-
BRCA	cis	rs1538970	0.924	rs1007858	ENSG00000281133.1	AL355480.3	-3.4	0.000697	0.0324	-0.14	-0.1	Platelet count;	chr1:45446333	chr1:45580892~45580996:-
BRCA	cis	rs8060686	0.516	rs7193701	ENSG00000280163.1	CTC-277H1.6	3.4	0.000697	0.0324	0.14	0.1	HDL cholesterol;Metabolic syndrome;	chr16:68151257	chr16:67205175~67206849:-
BRCA	cis	rs8114671	0.562	rs6088646	ENSG00000261582.1	RP4-614O4.11	-3.4	0.000697	0.0324	-0.1	-0.1	Height;	chr20:34918134	chr20:35267885~35280043:-
BRCA	cis	rs8114671	0.562	rs6120763	ENSG00000261582.1	RP4-614O4.11	-3.4	0.000697	0.0324	-0.1	-0.1	Height;	chr20:34918597	chr20:35267885~35280043:-
BRCA	cis	rs76963786	0.685	rs2800000	ENSG00000201563.1	Y_RNA	3.4	0.000697	0.0324	0.15	0.1	Interleukin-9 levels;	chr12:31883189	chr12:32705403~32705506:-
BRCA	cis	rs875971	0.767	rs1643394	ENSG00000265600.1	AC006480.1	-3.4	0.000698	0.0324	-0.13	-0.1	Aortic root size;	chr7:66371107	chr7:67356680~67356779:+
BRCA	cis	rs6964587	0.626	rs10266424	ENSG00000188693.7	CYP51A1-AS1	3.4	0.000698	0.0324	0.11	0.1	Breast cancer;	chr7:91873914	chr7:92134604~92180725:+
BRCA	cis	rs80028505	0.808	rs61195139	ENSG00000271304.1	DPRXP2	3.4	0.000698	0.0324	0.2	0.1	Foot ulcer in diabetes and neuropathy;	chr6:36078449	chr6:35989515~35990436:-
BRCA	cis	rs6081569	1	rs6081569	ENSG00000179447.2	RP5-1027G4.3	-3.4	0.000698	0.0324	-0.13	-0.1	Mean platelet volume;	chr20:19323142	chr20:19242302~19284596:-
BRCA	cis	rs2692947	0.567	rs4907276	ENSG00000232931.4	LINC00342	-3.4	0.000698	0.0324	-0.11	-0.1	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95725361	chr2:95807118~95816215:-
BRCA	cis	rs4908769	0.624	rs1763839	ENSG00000232912.4	RP5-1115A15.1	3.4	0.000698	0.0324	0.11	0.1	Allergy;	chr1:8413276	chr1:8424645~8434838:+
BRCA	cis	rs977987	0.806	rs4888404	ENSG00000280152.1	RP11-331F4.5	-3.4	0.000698	0.0324	-0.11	-0.1	Dupuytren's disease;	chr16:75394199	chr16:75245994~75250077:-
BRCA	cis	rs7819412	0.521	rs4451268	ENSG00000154316.13	TDH	3.4	0.000698	0.0324	0.14	0.1	Triglycerides;	chr8:11177350	chr8:11339637~11368452:+
BRCA	cis	rs2908197	0.737	rs10230188	ENSG00000205485.12	AC004980.7	3.4	0.000698	0.0324	0.11	0.1	3-hydroxypropylmercapturic acid levels in smokers;	chr7:76351555	chr7:76549360~76627982:+
BRCA	cis	rs9951698	0.703	rs1786984	ENSG00000266969.1	RP11-773H22.4	3.4	0.000698	0.0324	0.14	0.1	Intelligence (multi-trait analysis);	chr18:13154355	chr18:12984694~12991173:-
BRCA	cis	rs1003719	0.715	rs762139	ENSG00000273210.1	AP001437.1	3.4	0.000698	0.0324	0.11	0.1	Eye color traits;	chr21:37196174	chr21:37365477~37365932:-
BRCA	cis	rs17361889	0.727	rs1527209	ENSG00000229108.1	MEOX2-AS1	3.4	0.000698	0.0324	0.12	0.1	Pediatric bone mineral content (hip);	chr7:16241462	chr7:15688378~15695491:+
BRCA	cis	rs1466788	1	rs10857811	ENSG00000224965.1	KCNC4-AS1	-3.4	0.000698	0.0324	-0.12	-0.1	Blood metabolite levels;	chr1:110075066	chr1:110208834~110209987:-
BRCA	cis	rs4478858	0.806	rs6686845	ENSG00000229447.2	RP11-490K7.4	-3.4	0.000698	0.0324	-0.1	-0.1	Alcohol dependence;	chr1:31235949	chr1:31263245~31263681:-
BRCA	cis	rs1555133	0.558	rs6141306	ENSG00000277692.1	RP11-358N2.2	-3.4	0.000698	0.0324	-0.12	-0.1	Monocyte count;	chr20:32421489	chr20:32355053~32355734:+
BRCA	cis	rs1555133	0.558	rs6141307	ENSG00000277692.1	RP11-358N2.2	-3.4	0.000698	0.0324	-0.12	-0.1	Monocyte count;	chr20:32421490	chr20:32355053~32355734:+
BRCA	cis	rs1555133	0.694	rs6141309	ENSG00000277692.1	RP11-358N2.2	-3.4	0.000698	0.0324	-0.12	-0.1	Monocyte count;	chr20:32423541	chr20:32355053~32355734:+
BRCA	cis	rs344364	0.511	rs911392	ENSG00000219027.2	RPS3AP2	3.4	0.000698	0.0324	0.15	0.1	Glomerular filtration rate in chronic kidney disease;	chr16:1897258	chr16:1477830~1478583:+
BRCA	cis	rs68170813	0.652	rs11532774	ENSG00000241764.3	AC002467.7	3.4	0.000698	0.0324	0.18	0.1	Coronary artery disease;	chr7:107561134	chr7:107742817~107744581:-
BRCA	cis	rs863345	0.604	rs11265024	ENSG00000229914.1	RP11-404O13.4	-3.4	0.000698	0.0324	-0.11	-0.1	Pneumococcal bacteremia;	chr1:158543465	chr1:158195633~158196131:-
BRCA	cis	rs587847	0.895	rs28507799	ENSG00000259225.5	RP11-1008C21.1	-3.4	0.000698	0.0324	-0.12	-0.1	Intraocular pressure;	chr15:37338004	chr15:37984766~38062340:+
BRCA	cis	rs4713118	0.587	rs9393899	ENSG00000226314.6	ZNF192P1	-3.4	0.000698	0.0324	-0.16	-0.1	Parkinson's disease;	chr6:28165750	chr6:28161781~28169594:+
BRCA	cis	rs1009077	0.61	rs7670921	ENSG00000245958.5	RP11-33B1.1	-3.4	0.000698	0.0324	-0.11	-0.1	Endometriosis;	chr4:119597867	chr4:119454791~119552025:+
BRCA	cis	rs11098499	0.604	rs2389887	ENSG00000250412.1	KLHL2P1	3.4	0.000698	0.0324	0.13	0.1	Corneal astigmatism;	chr4:119649489	chr4:119334329~119378233:+
BRCA	cis	rs11098499	0.604	rs34278750	ENSG00000250412.1	KLHL2P1	3.4	0.000698	0.0324	0.13	0.1	Corneal astigmatism;	chr4:119649981	chr4:119334329~119378233:+
BRCA	cis	rs938554	0.692	rs6449213	ENSG00000250413.1	RP11-448G15.1	3.4	0.000698	0.0324	0.17	0.1	Blood metabolite levels;	chr4:9992591	chr4:10006482~10009725:+
BRCA	cis	rs875971	0.522	rs2008188	ENSG00000272831.1	RP11-792A8.4	3.4	0.000699	0.0324	0.09	0.1	Aortic root size;	chr7:65964026	chr7:66739829~66740385:-
BRCA	cis	rs763121	0.889	rs6001209	ENSG00000273076.1	RP3-508I15.22	-3.4	0.000699	0.0324	-0.11	-0.1	Menopause (age at onset);	chr22:38725247	chr22:38743495~38743910:+
BRCA	cis	rs4873772	0.738	rs4873446	ENSG00000253330.1	RP11-697N18.3	-3.4	0.000699	0.0325	-0.14	-0.1	Lobe attachment (rater-scored or self-reported);	chr8:47533902	chr8:47511034~47512141:-
BRCA	cis	rs1510510	0.867	rs12692232	ENSG00000229915.1	AC016999.2	3.4	0.000699	0.0325	0.18	0.1	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr2:238599897	chr2:238427077~238427729:-
BRCA	cis	rs7267979	0.933	rs2258728	ENSG00000274414.1	RP5-965G21.4	-3.4	0.000699	0.0325	-0.12	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25295707	chr20:25239007~25245229:-
BRCA	cis	rs2011503	0.509	rs11668721	ENSG00000267419.1	CTC-559E9.6	-3.4	0.000699	0.0325	-0.15	-0.1	Bipolar disorder;	chr19:19650107	chr19:19776602~19834927:+
BRCA	cis	rs854765	0.624	rs9899634	ENSG00000197815.4	RP1-253P7.4	3.4	0.000699	0.0325	0.08	0.1	Total body bone mineral density;	chr17:17824629	chr17:17858227~17860041:+
BRCA	cis	rs7520050	0.966	rs4376778	ENSG00000226957.1	RP4-533D7.4	3.4	0.000699	0.0325	0.11	0.1	Reticulocyte count;Red blood cell count;	chr1:45823174	chr1:46046818~46048368:+
BRCA	cis	rs7520050	0.966	rs6672898	ENSG00000226957.1	RP4-533D7.4	3.4	0.000699	0.0325	0.11	0.1	Reticulocyte count;Red blood cell count;	chr1:45824916	chr1:46046818~46048368:+
BRCA	cis	rs7812879	0.929	rs2250788	ENSG00000255354.1	RP11-148O21.2	-3.4	0.000699	0.0325	-0.12	-0.1	Systemic lupus erythematosus;	chr8:11494547	chr8:11558466~11560020:-
BRCA	cis	rs2108622	0.727	rs7251296	ENSG00000214049.6	UCA1	3.4	0.000699	0.0325	0.15	0.1	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15872926	chr19:15828961~15836320:+
BRCA	cis	rs73195822	0.614	rs7975139	ENSG00000277299.1	RP11-837J7.4	-3.4	0.000699	0.0325	-0.17	-0.1	Itch intensity from mosquito bite;	chr12:110783326	chr12:109948389~109949029:+
BRCA	cis	rs613391	0.522	rs1992926	ENSG00000265194.1	RP11-70L8.4	-3.4	0.000699	0.0325	-0.11	-0.1	Quantitative traits;	chr9:22730294	chr9:21858910~21861926:-
BRCA	cis	rs3808502	0.549	rs7831039	ENSG00000255046.1	RP11-297N6.4	3.4	0.000699	0.0325	0.13	0.1	Neuroticism;	chr8:11570128	chr8:11797928~11802568:-
BRCA	cis	rs4835473	0.932	rs12513087	ENSG00000246448.2	RP13-578N3.3	-3.4	0.000699	0.0325	-0.12	-0.1	Immature fraction of reticulocytes;	chr4:143758551	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.932	rs12513119	ENSG00000246448.2	RP13-578N3.3	-3.4	0.000699	0.0325	-0.12	-0.1	Immature fraction of reticulocytes;	chr4:143758619	chr4:143700257~143865072:+
BRCA	cis	rs3820068	0.603	rs6696286	ENSG00000237301.1	RP4-680D5.2	-3.4	0.000699	0.0325	-0.13	-0.1	Systolic blood pressure;	chr1:15642275	chr1:15586136~15603626:-
BRCA	cis	rs7045881	0.877	rs7032967	ENSG00000254396.1	RP11-56F10.3	3.4	0.000699	0.0325	0.15	0.1	Schizophrenia;	chr9:26804137	chr9:27102630~27104728:+
BRCA	cis	rs3764021	0.506	rs10844468	ENSG00000278635.1	CTD-2318O12.1	-3.4	0.000699	0.0325	-0.12	-0.1	Type 1 diabetes;	chr12:9690799	chr12:9415641~9416718:+
BRCA	cis	rs4886920	1	rs4886920	ENSG00000260776.4	RP11-114H24.2	-3.4	0.000699	0.0325	-0.13	-0.1	Neuroticism;	chr15:77821710	chr15:77914217~77926846:-
BRCA	cis	rs17680741	0.542	rs35521186	ENSG00000225484.5	NUTM2B-AS1	-3.4	0.000699	0.0325	-0.18	-0.1	Coronary artery disease;	chr10:80484325	chr10:79663088~79826594:-
BRCA	cis	rs2573652	1	rs2727198	ENSG00000254744.3	CTD-3076O17.1	-3.4	0.000699	0.0325	-0.12	-0.1	Height;	chr15:99973517	chr15:99970215~99974010:+
BRCA	cis	rs9900280	1	rs8081267	ENSG00000178082.6	TWF1P1	-3.4	0.000699	0.0325	-0.12	-0.1	Mean platelet volume;	chr17:29436892	chr17:29203426~29204474:-
BRCA	cis	rs2562456	0.876	rs2359144	ENSG00000240522.1	RPL7AP10	-3.4	0.000699	0.0325	-0.12	-0.1	Pain;	chr19:21407834	chr19:21149648~21150438:-
BRCA	cis	rs2562456	0.876	rs4638726	ENSG00000240522.1	RPL7AP10	-3.4	0.000699	0.0325	-0.12	-0.1	Pain;	chr19:21409710	chr19:21149648~21150438:-
BRCA	cis	rs2562456	0.755	rs1879234	ENSG00000240522.1	RPL7AP10	3.4	0.000699	0.0325	0.12	0.1	Pain;	chr19:21521677	chr19:21149648~21150438:-
BRCA	cis	rs10936602	0.52	rs12486767	ENSG00000269984.1	RP11-362K14.5	3.4	7e-04	0.0325	0.09	0.1	Renal cell carcinoma;	chr3:169832971	chr3:169777192~169780334:-
BRCA	cis	rs2108225	0.967	rs7785790	ENSG00000231006.1	RPL7P32	3.4	7e-04	0.0325	0.1	0.1	Ulcerative colitis;	chr7:107809451	chr7:108510233~108510976:+
BRCA	cis	rs12530845	0.943	rs60858457	ENSG00000223718.3	AC093107.7	3.4	7e-04	0.0325	0.18	0.1	Red blood cell traits;	chr7:135652170	chr7:135660039~135660647:+
BRCA	cis	rs7948661	1	rs9332846	ENSG00000255239.1	AP002954.6	-3.4	7e-04	0.0325	-0.23	-0.1	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr11:118506808	chr11:118688039~118690600:-
BRCA	cis	rs6142102	0.961	rs909884	ENSG00000206582.1	Y_RNA	-3.4	7e-04	0.0325	-0.13	-0.1	Skin pigmentation;	chr20:34058257	chr20:34526510~34526606:-
BRCA	cis	rs7918232	0.567	rs11015463	ENSG00000236983.1	LINC00614	3.4	7e-04	0.0325	0.13	0.1	Breast cancer;	chr10:27030329	chr10:26943323~26944418:-
BRCA	cis	rs13126694	0.744	rs4521391	ENSG00000251073.1	NUDT19P5	3.4	7e-04	0.0325	0.1	0.1	Blood osmolality (transformed sodium);	chr4:158017310	chr4:158182825~158183393:+
BRCA	cis	rs35306767	0.903	rs11253495	ENSG00000229869.1	RP11-363N22.2	-3.4	7e-04	0.0325	-0.16	-0.1	Eosinophil percentage of granulocytes;	chr10:891124	chr10:933026~942743:+
BRCA	cis	rs67478160	0.654	rs11628240	ENSG00000269910.1	RP11-73M18.10	3.4	7e-04	0.0325	0.1	0.1	Schizophrenia;	chr14:103751798	chr14:103694516~103695050:-
BRCA	cis	rs6121246	0.559	rs6119728	ENSG00000230613.1	HM13-AS1	3.4	7e-04	0.0325	0.14	0.1	Mean corpuscular hemoglobin;	chr20:31825318	chr20:31567707~31573263:-
BRCA	cis	rs10129255	0.957	rs8009073	ENSG00000231475.3	IGHV4-31	-3.4	7e-04	0.0325	-0.08	-0.1	Kawasaki disease;	chr14:106777278	chr14:106349283~106349792:-
BRCA	cis	rs910873	0.505	rs6059961	ENSG00000250917.1	RP4-785G19.5	3.4	7e-04	0.0325	0.18	0.1	Melanoma;	chr20:34643686	chr20:34234840~34281173:-
BRCA	cis	rs58847541	0.584	rs60114686	ENSG00000243498.2	UBA52P5	-3.4	7e-04	0.0325	-0.21	-0.1	Breast cancer;	chr8:123569315	chr8:123236852~123237062:+
BRCA	cis	rs10129255	0.957	rs10136817	ENSG00000211959.2	IGHV4-39	3.4	7e-04	0.0325	0.08	0.1	Kawasaki disease;	chr14:106787730	chr14:106421711~106422218:-
BRCA	cis	rs911555	0.755	rs4143998	ENSG00000269940.1	RP11-73M18.7	3.4	7e-04	0.0325	0.11	0.1	Intelligence (multi-trait analysis);	chr14:103488910	chr14:103694560~103695170:+
BRCA	cis	rs911555	0.755	rs1138400	ENSG00000269940.1	RP11-73M18.7	3.4	7e-04	0.0325	0.11	0.1	Intelligence (multi-trait analysis);	chr14:103490496	chr14:103694560~103695170:+
BRCA	cis	rs4805834	0.843	rs11671987	ENSG00000201388.1	SNORA68	3.4	7e-04	0.0325	0.18	0.1	Creatinine levels;	chr19:32841406	chr19:32608337~32608469:-
BRCA	cis	rs7894407	0.629	rs11598702	ENSG00000213061.2	PFN1P11	-3.4	0.000701	0.0325	-0.15	-0.1	White matter hyperintensity burden;	chr10:103138228	chr10:102838011~102845473:-
BRCA	cis	rs76382185	0.622	rs34467663	ENSG00000235795.1	RP11-421L21.2	3.4	0.000701	0.0325	0.2	0.1	Lymphocyte counts;	chr1:100774706	chr1:100995473~100996260:+
BRCA	cis	rs1670533	1	rs2045065	ENSG00000251639.2	RP11-20I20.1	3.4	0.000701	0.0325	0.16	0.1	Recombination rate (females);	chr4:1058700	chr4:1100016~1101558:-
BRCA	cis	rs3755605	0.728	rs11718963	ENSG00000242578.1	RP11-469J4.3	3.4	0.000701	0.0325	0.12	0.1	Testicular germ cell tumor;	chr3:170184973	chr3:170410512~170418615:+
BRCA	cis	rs4805834	0.777	rs11671229	ENSG00000201388.1	SNORA68	3.4	0.000701	0.0325	0.18	0.1	Creatinine levels;	chr19:32816211	chr19:32608337~32608469:-
BRCA	cis	rs10838687	0.8	rs10769253	ENSG00000243802.2	RP11-390K5.1	3.4	0.000701	0.0325	0.15	0.1	Proinsulin levels;	chr11:47340788	chr11:47191181~47191542:-
BRCA	cis	rs6951643	0.782	rs6975541	ENSG00000224138.1	AC000123.4	3.4	0.000701	0.0325	0.12	0.1	Creutzfeldt-Jakob disease (sporadic);	chr7:126871966	chr7:127350128~127351523:+
BRCA	cis	rs10197140	0.925	rs11123227	ENSG00000235721.1	AC013268.3	-3.4	0.000701	0.0325	-0.14	-0.1	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110890437	chr2:110007675~110010783:+
BRCA	cis	rs1015213	1	rs6990124	ENSG00000253475.1	RP11-110G21.2	-3.4	0.000701	0.0325	-0.19	-0.1	Glaucoma (primary angle closure);	chr8:51975588	chr8:51895957~51896374:-
BRCA	cis	rs875971	0.862	rs35378740	ENSG00000106610.13	STAG3L4	-3.4	0.000701	0.0325	-0.14	-0.1	Aortic root size;	chr7:66522725	chr7:67302621~67321526:+
BRCA	cis	rs875971	0.862	rs11765791	ENSG00000106610.13	STAG3L4	-3.4	0.000701	0.0325	-0.14	-0.1	Aortic root size;	chr7:66471587	chr7:67302621~67321526:+
BRCA	cis	rs11686241	1	rs2271334	ENSG00000241520.1	AC098820.4	3.4	0.000701	0.0325	0.16	0.1	Cancer;	chr2:216432627	chr2:216483032~216487196:-
BRCA	cis	rs11686241	1	rs11686241	ENSG00000241520.1	AC098820.4	3.4	0.000701	0.0325	0.16	0.1	Cancer;	chr2:216433482	chr2:216483032~216487196:-
BRCA	cis	rs6517329	0.649	rs2242798	ENSG00000231106.2	LINC01436	3.4	0.000701	0.0325	0.12	0.1	Schizophrenia;	chr21:36120583	chr21:36005338~36007838:+
BRCA	cis	rs67696533	0.711	rs6119897	ENSG00000275576.1	RP5-836N17.4	3.4	0.000701	0.0326	0.12	0.1	White blood cell count (basophil);Basophil percentage of granulocytes;Basophil percentage of white cells;	chr20:32557613	chr20:32116171~32116629:+
BRCA	cis	rs10411161	0.752	rs4584941	ENSG00000269483.1	AC006272.1	3.4	0.000701	0.0326	0.19	0.1	Breast cancer;	chr19:51888888	chr19:51839924~51843324:-
BRCA	cis	rs6942407	0.592	rs757961	ENSG00000224046.1	AC005076.5	-3.4	0.000701	0.0326	-0.15	-0.1	Food allergy;	chr7:87220194	chr7:87151423~87152420:-
BRCA	cis	rs6942407	0.592	rs886787	ENSG00000224046.1	AC005076.5	-3.4	0.000701	0.0326	-0.15	-0.1	Food allergy;	chr7:87220894	chr7:87151423~87152420:-
BRCA	cis	rs6942407	0.592	rs4728689	ENSG00000224046.1	AC005076.5	-3.4	0.000701	0.0326	-0.15	-0.1	Food allergy;	chr7:87221781	chr7:87151423~87152420:-
BRCA	cis	rs6942407	0.592	rs10085726	ENSG00000224046.1	AC005076.5	-3.4	0.000701	0.0326	-0.15	-0.1	Food allergy;	chr7:87222081	chr7:87151423~87152420:-
BRCA	cis	rs9341808	0.754	rs9341811	ENSG00000279022.1	RP11-250B2.4	3.4	0.000701	0.0326	0.12	0.1	Sitting height ratio;	chr6:80272984	chr6:80440730~80441172:+
BRCA	cis	rs2811415	0.597	rs35944498	ENSG00000242551.2	POU5F1P6	3.4	0.000702	0.0326	0.15	0.1	Lung function (FEV1/FVC);	chr3:128012819	chr3:128674735~128677005:-
BRCA	cis	rs2811415	0.597	rs9814296	ENSG00000242551.2	POU5F1P6	3.4	0.000702	0.0326	0.15	0.1	Lung function (FEV1/FVC);	chr3:128013185	chr3:128674735~128677005:-
BRCA	cis	rs11587682	0.67	rs11580810	ENSG00000228126.1	FALEC	3.4	0.000702	0.0326	0.14	0.1	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr1:150435247	chr1:150515757~150518032:+
BRCA	cis	rs7712401	0.791	rs9327279	ENSG00000249996.1	RP11-359P5.1	3.4	0.000702	0.0326	0.12	0.1	Mean platelet volume;	chr5:122786465	chr5:123036271~123054667:+
BRCA	cis	rs2242330	0.798	rs28414931	ENSG00000250075.4	RP11-584P21.2	3.4	0.000702	0.0326	0.13	0.1	Parkinson's disease;	chr4:67570858	chr4:67417305~67468251:-
BRCA	cis	rs2880765	0.835	rs4536419	ENSG00000259630.2	CTD-2262B20.1	-3.4	0.000702	0.0326	-0.12	-0.1	Coronary artery disease;	chr15:85496240	chr15:85415228~85415633:+
BRCA	cis	rs875971	0.505	rs6955582	ENSG00000227113.2	RP11-460N20.4	3.4	0.000702	0.0326	0.11	0.1	Aortic root size;	chr7:65966699	chr7:65075023~65078780:+
BRCA	cis	rs987724	0.593	rs10936040	ENSG00000240875.4	LINC00886	-3.4	0.000702	0.0326	-0.12	-0.1	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156959236	chr3:156747346~156817062:-
BRCA	cis	rs26949	0.526	rs6887637	ENSG00000251279.1	CTC-436P18.1	3.4	0.000702	0.0326	0.13	0.1	Intelligence (multi-trait analysis);	chr5:60739813	chr5:61162070~61232040:+
BRCA	cis	rs952623	0.649	rs13242896	ENSG00000227191.5	TRGC2	3.4	0.000702	0.0326	0.09	0.1	Intelligence (multi-trait analysis);	chr7:39030462	chr7:38239580~38368091:-
BRCA	cis	rs8103278	1	rs725660	ENSG00000268423.3	AC011551.3	3.4	0.000702	0.0326	0.13	0.1	Coronary artery disease;	chr19:45759028	chr19:46547056~46600861:-
BRCA	cis	rs860295	0.702	rs11264375	ENSG00000236675.1	MTX1P1	3.4	0.000702	0.0326	0.12	0.1	Body mass index;	chr1:155454274	chr1:155230975~155234325:+
BRCA	cis	rs2832191	0.692	rs2245734	ENSG00000236056.1	GAPDHP14	-3.4	0.000702	0.0326	-0.12	-0.1	Dental caries;	chr21:28987644	chr21:29222321~29223257:+
BRCA	cis	rs889312	0.5	rs252905	ENSG00000237705.1	AC008937.2	3.4	0.000702	0.0326	0.11	0.1	Breast cancer (early onset);Breast cancer;	chr5:56823048	chr5:56842016~56862164:-
BRCA	cis	rs11035577	0.64	rs7951467	ENSG00000279675.1	RP11-454H19.2	-3.4	0.000702	0.0326	-0.18	-0.1	Temperament (bipolar disorder);	chr11:39791947	chr11:40107244~40112599:-
BRCA	cis	rs875971	0.522	rs4502988	ENSG00000227113.2	RP11-460N20.4	3.4	0.000702	0.0326	0.11	0.1	Aortic root size;	chr7:65832759	chr7:65075023~65078780:+
BRCA	cis	rs853679	0.517	rs9393895	ENSG00000226314.6	ZNF192P1	-3.4	0.000702	0.0326	-0.16	-0.1	Depression;	chr6:28159843	chr6:28161781~28169594:+
BRCA	cis	rs7267979	0.745	rs6132845	ENSG00000274973.1	RP13-401N8.7	-3.4	0.000702	0.0326	-0.12	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25567131	chr20:25845497~25845862:+
BRCA	cis	rs9863	0.861	rs3802999	ENSG00000270028.1	RP11-380L11.4	3.4	0.000702	0.0326	0.14	0.1	White blood cell count;	chr12:123929551	chr12:123925461~123926083:-
BRCA	cis	rs17711722	0.727	rs2658585	ENSG00000227113.2	RP11-460N20.4	3.4	0.000702	0.0326	0.11	0.1	Calcium levels;	chr7:65996954	chr7:65075023~65078780:+
BRCA	cis	rs4557020	0.904	rs7578287	ENSG00000162997.14	PRORSD1P	-3.4	0.000702	0.0326	-0.11	-0.1	Myopia (pathological);	chr2:54484092	chr2:55282319~55284522:+
BRCA	cis	rs875971	0.508	rs10950045	ENSG00000265600.1	AC006480.1	3.4	0.000702	0.0326	0.12	0.1	Aortic root size;	chr7:66601386	chr7:67356680~67356779:+
BRCA	cis	rs801193	0.839	rs6968619	ENSG00000265600.1	AC006480.1	3.4	0.000702	0.0326	0.12	0.1	Aortic root size;	chr7:66603880	chr7:67356680~67356779:+
BRCA	cis	rs801193	0.805	rs12532355	ENSG00000265600.1	AC006480.1	3.4	0.000702	0.0326	0.12	0.1	Aortic root size;	chr7:66605597	chr7:67356680~67356779:+
BRCA	cis	rs12282928	0.917	rs7115127	ENSG00000255197.4	RP11-750H9.5	3.4	0.000702	0.0326	0.1	0.1	Migraine - clinic-based;	chr11:48254338	chr11:47383148~47409190:-
BRCA	cis	rs1496653	0.591	rs71317817	ENSG00000206728.1	Y_RNA	3.4	0.000702	0.0326	0.21	0.1	Type 2 diabetes;	chr3:23210024	chr3:23273807~23273910:+
BRCA	cis	rs36051895	0.559	rs7868706	ENSG00000237711.1	RP11-39K24.13	-3.4	0.000702	0.0326	-0.12	-0.1	Pediatric autoimmune diseases;	chr9:5210936	chr9:5100236~5101009:+
BRCA	cis	rs7781557	1	rs17474893	ENSG00000170409.7	CTA-313A17.2	3.4	0.000702	0.0326	0.18	0.1	Colorectal adenoma (advanced);	chr7:102840310	chr7:102327256~102329530:-
BRCA	cis	rs9828082	0.961	rs13060349	ENSG00000228956.7	SATB1-AS1	3.4	0.000702	0.0326	0.11	0.1	Neuroticism;	chr3:18574694	chr3:18445024~18920401:+
BRCA	cis	rs10129255	0.785	rs10150044	ENSG00000211967.3	IGHV3-53	-3.4	0.000702	0.0326	-0.07	-0.1	Kawasaki disease;	chr14:106775695	chr14:106592676~106593347:-
BRCA	cis	rs55675132	0.548	rs75733320	ENSG00000226167.1	AP4B1-AS1	3.4	0.000702	0.0326	0.11	0.1	Schizophrenia;	chr1:114831199	chr1:113856635~113901237:+
BRCA	cis	rs7178572	0.625	rs12905285	ENSG00000259362.2	RP11-307C19.1	-3.4	0.000702	0.0326	-0.13	-0.1	Type 2 diabetes;	chr15:77553470	chr15:77525540~77534110:+
BRCA	cis	rs987724	0.593	rs9878585	ENSG00000240875.4	LINC00886	-3.4	0.000702	0.0326	-0.12	-0.1	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156952028	chr3:156747346~156817062:-
BRCA	cis	rs987724	0.574	rs2874492	ENSG00000240875.4	LINC00886	-3.4	0.000702	0.0326	-0.12	-0.1	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156953387	chr3:156747346~156817062:-
BRCA	cis	rs10005067	0.967	rs28532955	ENSG00000249001.4	RP11-742B18.1	-3.4	0.000703	0.0326	-0.12	-0.1	Total body bone mineral density (age 30-45);	chr4:87897131	chr4:87568035~87733956:-
BRCA	cis	rs2333021	0.78	rs2806042	ENSG00000259015.1	RP11-109N23.6	-3.4	0.000703	0.0326	-0.11	-0.1	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:72947939	chr14:72960595~72961993:+
BRCA	cis	rs4835473	0.932	rs7356305	ENSG00000246448.2	RP13-578N3.3	3.4	0.000703	0.0326	0.12	0.1	Immature fraction of reticulocytes;	chr4:143737850	chr4:143700257~143865072:+
BRCA	cis	rs13353361	0.702	rs56200787	ENSG00000279254.1	RP11-536C12.1	-3.4	0.000703	0.0326	-0.26	-0.1	Initial pursuit acceleration;	chr2:47025362	chr2:46668870~46670778:+
BRCA	cis	rs6964587	0.869	rs10242792	ENSG00000188693.7	CYP51A1-AS1	-3.4	0.000703	0.0326	-0.12	-0.1	Breast cancer;	chr7:91862789	chr7:92134604~92180725:+
BRCA	cis	rs58521262	0.729	rs7256784	ENSG00000268105.1	RP11-369G6.2	-3.4	0.000703	0.0326	-0.18	-0.1	Testicular germ cell tumor;	chr19:22880924	chr19:23125665~23128543:+
BRCA	cis	rs654950	0.875	rs2759248	ENSG00000230638.4	RP11-486B10.4	3.4	0.000703	0.0326	0.13	0.1	Airway imaging phenotypes;	chr1:41525124	chr1:41542069~41544310:+
BRCA	cis	rs2243480	0.522	rs431168	ENSG00000222364.1	RNU6-96P	-3.4	0.000703	0.0326	-0.24	-0.1	Diabetic kidney disease;	chr7:66046617	chr7:66395191~66395286:+
BRCA	cis	rs806321	0.534	rs1149865	ENSG00000237152.3	DLEU7-AS1	3.4	0.000703	0.0326	0.13	0.1	Multiple sclerosis;	chr13:50327967	chr13:50807856~50849905:+
BRCA	cis	rs73206853	0.62	rs73194038	ENSG00000277299.1	RP11-837J7.4	-3.4	0.000703	0.0326	-0.2	-0.1	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr12:110734534	chr12:109948389~109949029:+
BRCA	cis	rs7130284	0.881	rs59754221	ENSG00000134612.10	FOLH1B	3.4	0.000703	0.0326	0.23	0.1	Homocysteine levels;	chr11:89466020	chr11:89639227~89698718:+
BRCA	cis	rs2811415	0.597	rs3774796	ENSG00000242551.2	POU5F1P6	-3.4	0.000703	0.0326	-0.14	-0.1	Lung function (FEV1/FVC);	chr3:128061630	chr3:128674735~128677005:-
BRCA	cis	rs12220238	0.915	rs12217890	ENSG00000213731.2	RAB5CP1	-3.4	0.000703	0.0326	-0.16	-0.1	Soluble interleukin-2 receptor subunit alpha;	chr10:74264738	chr10:74423435~74424014:-
BRCA	cis	rs977987	0.806	rs4887824	ENSG00000261476.1	RP11-77K12.3	-3.4	0.000703	0.0326	-0.11	-0.1	Dupuytren's disease;	chr16:75407715	chr16:75458252~75460017:-
BRCA	cis	rs494526	0.521	rs11198726	ENSG00000229272.1	RP11-498J9.2	3.4	0.000703	0.0326	0.13	0.1	Alcoholic chronic pancreatitis;	chr10:119006786	chr10:119003536~119003884:-
BRCA	cis	rs67340775	0.541	rs200979	ENSG00000241549.7	GUSBP2	3.4	0.000703	0.0326	0.16	0.1	Lung cancer in ever smokers;	chr6:27884579	chr6:26871484~26956554:-
BRCA	cis	rs259282	0.538	rs6510272	ENSG00000267475.1	CTD-2538C1.2	3.4	0.000703	0.0326	0.13	0.1	Schizophrenia;	chr19:32626936	chr19:32687089~32691750:-
BRCA	cis	rs7481311	0.872	rs4922787	ENSG00000245573.6	BDNF-AS	3.4	0.000703	0.0326	0.13	0.1	Weight;Body mass index;	chr11:27486355	chr11:27506838~27698174:+
BRCA	cis	rs875971	0.895	rs12698520	ENSG00000273024.4	INTS4P2	-3.4	0.000703	0.0326	-0.11	-0.1	Aortic root size;	chr7:66453720	chr7:65647864~65715661:+
BRCA	cis	rs67073037	0.955	rs67612857	ENSG00000230730.1	AC074011.2	-3.4	0.000703	0.0326	-0.14	-0.1	Breast cancer;Breast cancer (estrogen-receptor negative);	chr2:28938841	chr2:28633282~28664540:-
BRCA	cis	rs66887589	0.837	rs7661498	ENSG00000260404.2	RP11-384K6.6	3.4	0.000703	0.0326	0.09	0.1	Diastolic blood pressure;	chr4:119486953	chr4:118591773~118633729:+
BRCA	cis	rs2354432	0.607	rs7553584	ENSG00000226015.2	CCT8P1	-3.4	0.000703	0.0326	-0.2	-0.1	Mitochondrial DNA levels;	chr1:147221837	chr1:147203276~147204932:-
BRCA	cis	rs10911902	0.643	rs34585917	ENSG00000229739.2	RP11-295K2.3	-3.4	0.000703	0.0326	-0.15	-0.1	Schizophrenia;	chr1:186317650	chr1:186435161~186470291:+
BRCA	cis	rs1411478	1	rs4652547	ENSG00000243155.1	RP11-46A10.5	3.4	0.000703	0.0326	0.11	0.1	Menopause (age at onset);Progressive supranuclear palsy;	chr1:180984953	chr1:180944042~180976482:-
BRCA	cis	rs1411478	1	rs4652548	ENSG00000243155.1	RP11-46A10.5	3.4	0.000703	0.0326	0.11	0.1	Menopause (age at onset);Progressive supranuclear palsy;	chr1:180984994	chr1:180944042~180976482:-
BRCA	cis	rs7781266	0.79	rs73148993	ENSG00000226205.1	AC007790.4	3.4	0.000703	0.0326	0.16	0.1	Educational attainment (college completion);	chr7:133493656	chr7:133732493~133733595:-
BRCA	cis	rs7709377	0.595	rs27125	ENSG00000272265.1	CTD-2287O16.4	3.4	0.000704	0.0326	0.12	0.1	Metabolite levels  (X-11787);	chr5:116302058	chr5:116078110~116078570:-
BRCA	cis	rs4702718	0.616	rs267978	ENSG00000272324.4	CTD-2154B17.4	3.4	0.000704	0.0326	0.13	0.1	Obesity-related traits;	chr5:10719692	chr5:10761065~10770294:+
BRCA	cis	rs2991971	0.967	rs11211130	ENSG00000281133.1	AL355480.3	3.4	0.000704	0.0326	0.12	0.1	High light scatter reticulocyte count;	chr1:45521180	chr1:45580892~45580996:-
BRCA	cis	rs3770752	0.866	rs3770759	ENSG00000272054.1	RP11-423P10.2	-3.4	0.000704	0.0326	-0.09	-0.1	Schizophrenia;	chr2:37290123	chr2:37208875~37212677:+
BRCA	cis	rs8115445	0.515	rs12626070	ENSG00000214535.3	RPS15AP1	3.4	0.000704	0.0326	0.14	0.1	Pediatric bone mineral content (radius);	chr20:21440673	chr20:21166206~21166596:-
BRCA	cis	rs1113500	0.575	rs1781067	ENSG00000230489.1	VAV3-AS1	-3.4	0.000704	0.0326	-0.12	-0.1	Growth-regulated protein alpha levels;	chr1:108025389	chr1:107964443~107994607:+
BRCA	cis	rs7520050	0.933	rs11211203	ENSG00000226957.1	RP4-533D7.4	3.4	0.000704	0.0326	0.11	0.1	Reticulocyte count;Red blood cell count;	chr1:45849920	chr1:46046818~46048368:+
BRCA	cis	rs4356203	0.87	rs214900	ENSG00000184669.7	OR7E14P	3.4	0.000704	0.0326	0.13	0.1	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17206215	chr11:17013998~17053024:+
BRCA	cis	rs258892	0.793	rs61141607	ENSG00000272525.1	RP11-79P5.9	-3.4	0.000704	0.0326	-0.13	-0.1	Small cell lung carcinoma;	chr5:72761056	chr5:73497550~73498293:-
BRCA	cis	rs4981053	0.622	rs2150327	ENSG00000259001.3	RPPH1	3.4	0.000704	0.0326	0.12	0.1	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr14:20059311	chr14:20343048~20343685:-
BRCA	cis	rs4981053	0.644	rs1958715	ENSG00000259001.3	RPPH1	3.4	0.000704	0.0326	0.12	0.1	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr14:20060048	chr14:20343048~20343685:-
BRCA	cis	rs4981053	0.644	rs1958716	ENSG00000259001.3	RPPH1	3.4	0.000704	0.0326	0.12	0.1	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr14:20060162	chr14:20343048~20343685:-
BRCA	cis	rs10129255	0.957	rs10142918	ENSG00000211958.2	IGHV3-38	3.4	0.000704	0.0327	0.08	0.1	Kawasaki disease;	chr14:106782206	chr14:106410493~106411021:-
BRCA	cis	rs12900413	0.603	rs2118848	ENSG00000259212.1	CTD-3065B20.2	3.4	0.000704	0.0327	0.13	0.1	Coronary artery aneurysm in Kawasaki disease;	chr15:89759272	chr15:90595840~90596447:-
BRCA	cis	rs67766926	0.951	rs10174032	ENSG00000237522.1	NONOP2	-3.4	0.000704	0.0327	-0.11	-0.1	Inflammatory skin disease;	chr2:60951790	chr2:60936819~60938049:-
BRCA	cis	rs4934494	0.911	rs34486602	ENSG00000232229.4	LINC00865	-3.4	0.000704	0.0327	-0.15	-0.1	Red blood cell count;	chr10:89655895	chr10:89829510~89840861:+
BRCA	cis	rs962856	0.619	rs11890682	ENSG00000236605.1	AC023115.4	3.4	0.000704	0.0327	0.14	0.1	Pancreatic cancer;	chr2:67362453	chr2:67324627~67325304:+
BRCA	cis	rs9341808	0.65	rs6909546	ENSG00000279022.1	RP11-250B2.4	3.4	0.000704	0.0327	0.12	0.1	Sitting height ratio;	chr6:80160206	chr6:80440730~80441172:+
BRCA	cis	rs7943953	0.714	rs1453549	ENSG00000254717.2	GLYATL1P2	-3.4	0.000704	0.0327	-0.15	-0.1	Odorant perception (&beta-ionone);	chr11:59425889	chr11:58878302~58893460:+
BRCA	cis	rs7943953	0.714	rs1349777	ENSG00000254717.2	GLYATL1P2	-3.4	0.000704	0.0327	-0.15	-0.1	Odorant perception (&beta-ionone);	chr11:59426842	chr11:58878302~58893460:+
BRCA	cis	rs7943953	0.714	rs7935959	ENSG00000254717.2	GLYATL1P2	-3.4	0.000704	0.0327	-0.15	-0.1	Odorant perception (&beta-ionone);	chr11:59427314	chr11:58878302~58893460:+
BRCA	cis	rs7943953	0.714	rs1453552	ENSG00000254717.2	GLYATL1P2	-3.4	0.000704	0.0327	-0.15	-0.1	Odorant perception (&beta-ionone);	chr11:59428711	chr11:58878302~58893460:+
BRCA	cis	rs7943953	0.714	rs12785234	ENSG00000254717.2	GLYATL1P2	-3.4	0.000704	0.0327	-0.15	-0.1	Odorant perception (&beta-ionone);	chr11:59429468	chr11:58878302~58893460:+
BRCA	cis	rs7943953	0.714	rs61901576	ENSG00000254717.2	GLYATL1P2	-3.4	0.000704	0.0327	-0.15	-0.1	Odorant perception (&beta-ionone);	chr11:59431298	chr11:58878302~58893460:+
BRCA	cis	rs10754283	0.557	rs1215508	ENSG00000231613.1	RP5-943J3.1	3.4	0.000704	0.0327	0.12	0.1	Amyotrophic lateral sclerosis (sporadic);	chr1:89623138	chr1:89788914~89790492:+
BRCA	cis	rs6840360	0.571	rs12650655	ENSG00000270265.1	RP11-731D1.4	-3.4	0.000704	0.0327	-0.12	-0.1	Intelligence (multi-trait analysis);	chr4:151634923	chr4:151333775~151353224:-
BRCA	cis	rs2640806	0.645	rs11782979	ENSG00000253105.4	KB-1448A5.1	3.4	0.000704	0.0327	0.13	0.1	Obesity-related traits;	chr8:96314888	chr8:96371865~96387438:-
BRCA	cis	rs1048886	0.872	rs9455181	ENSG00000271967.1	RP11-134K13.4	-3.4	0.000704	0.0327	-0.15	-0.1	Type 2 diabetes;	chr6:70593014	chr6:70596438~70596980:+
BRCA	cis	rs2357982	0.828	rs1267082	ENSG00000227403.1	AC009299.3	-3.4	0.000704	0.0327	-0.15	-0.1	Presence of antiphospholipid antibodies;	chr2:161123371	chr2:161244739~161249050:+
BRCA	cis	rs12220238	0.822	rs11000979	ENSG00000213731.2	RAB5CP1	-3.4	0.000704	0.0327	-0.16	-0.1	Soluble interleukin-2 receptor subunit alpha;	chr10:74308107	chr10:74423435~74424014:-
BRCA	cis	rs11098499	0.754	rs10213554	ENSG00000250412.1	KLHL2P1	-3.4	0.000704	0.0327	-0.12	-0.1	Corneal astigmatism;	chr4:119339630	chr4:119334329~119378233:+
BRCA	cis	rs9467773	1	rs9467782	ENSG00000224843.5	LINC00240	-3.4	0.000704	0.0327	-0.12	-0.1	Intelligence (multi-trait analysis);	chr6:26542545	chr6:26956992~27023924:+
BRCA	cis	rs8114671	0.967	rs3746427	ENSG00000279253.1	RP4-614O4.13	-3.4	0.000704	0.0327	-0.12	-0.1	Height;	chr20:35142661	chr20:35262727~35264187:-
BRCA	cis	rs10129255	1	rs4612959	ENSG00000253132.1	IGHV3-62	-3.4	0.000705	0.0327	-0.08	-0.1	Kawasaki disease;	chr14:106767055	chr14:106643142~106643585:-
BRCA	cis	rs801193	0.548	rs2659891	ENSG00000106610.13	STAG3L4	-3.4	0.000705	0.0327	-0.14	-0.1	Aortic root size;	chr7:66736127	chr7:67302621~67321526:+
BRCA	cis	rs801193	0.548	rs7805152	ENSG00000106610.13	STAG3L4	-3.4	0.000705	0.0327	-0.14	-0.1	Aortic root size;	chr7:66744266	chr7:67302621~67321526:+
BRCA	cis	rs7649443	0.917	rs6782876	ENSG00000243339.3	RN7SL738P	-3.4	0.000705	0.0327	-0.15	-0.1	Nonsyndromic cleft lip with cleft palate;	chr3:197294275	chr3:196399911~196400207:+
BRCA	cis	rs7578361	0.801	rs12464848	ENSG00000231969.1	AC144449.1	-3.4	0.000705	0.0327	-0.16	-0.1	Acute lymphoblastic leukemia (childhood);	chr2:149500912	chr2:149587196~149848233:+
BRCA	cis	rs7578361	0.838	rs12467943	ENSG00000231969.1	AC144449.1	-3.4	0.000705	0.0327	-0.16	-0.1	Acute lymphoblastic leukemia (childhood);	chr2:149500914	chr2:149587196~149848233:+
BRCA	cis	rs4835473	0.9	rs935732	ENSG00000246448.2	RP13-578N3.3	-3.4	0.000705	0.0327	-0.12	-0.1	Immature fraction of reticulocytes;	chr4:143759164	chr4:143700257~143865072:+
BRCA	cis	rs13401620	0.587	rs12620471	ENSG00000236878.1	AC012363.7	-3.4	0.000705	0.0327	-0.13	-0.1	Breast size;	chr2:120064042	chr2:120211054~120211715:+
BRCA	cis	rs9467773	0.62	rs2451711	ENSG00000261353.1	CTA-14H9.5	-3.4	0.000705	0.0327	-0.1	-0.1	Intelligence (multi-trait analysis);	chr6:26662882	chr6:26527063~26527404:+
BRCA	cis	rs12135191	0.523	rs7525169	ENSG00000229795.2	RPS21P1	3.4	0.000705	0.0327	0.13	0.1	Urate levels (BMI interaction);	chr1:236322349	chr1:235432985~235433231:+
BRCA	cis	rs66887589	0.616	rs6822808	ENSG00000260091.1	RP11-33B1.4	-3.4	0.000705	0.0327	-0.09	-0.1	Diastolic blood pressure;	chr4:119296210	chr4:119409333~119410233:+
BRCA	cis	rs10759883	0.539	rs689744	ENSG00000225194.2	LINC00092	3.4	0.000705	0.0327	0.11	0.1	Nicotine dependence;	chr9:96040417	chr9:96019732~96027965:-
BRCA	cis	rs2657888	0.628	rs2638335	ENSG00000257576.1	RP11-153M3.1	-3.4	0.000705	0.0327	-0.13	-0.1	Adiponectin levels;	chr12:56486888	chr12:56511002~56512703:+
BRCA	cis	rs7308116	0.967	rs7967585	ENSG00000274395.1	RP11-554D14.8	-3.4	0.000705	0.0327	-0.12	-0.1	Pelvic organ prolapse (moderate/severe);	chr12:107803062	chr12:107835541~107836555:-
BRCA	cis	rs11148252	0.583	rs9536048	ENSG00000272281.5	TPTE2P2	-3.4	0.000705	0.0327	-0.11	-0.1	Lewy body disease;	chr13:52384653	chr13:52219344~52334277:-
BRCA	cis	rs1949733	0.656	rs2631762	ENSG00000250471.2	GMPSP1	3.4	0.000705	0.0327	0.11	0.1	Response to antineoplastic agents;	chr4:8421395	chr4:8174421~8174999:+
BRCA	cis	rs17711722	0.74	rs7809991	ENSG00000227113.2	RP11-460N20.4	3.4	0.000705	0.0327	0.11	0.1	Calcium levels;	chr7:65941231	chr7:65075023~65078780:+
BRCA	cis	rs3760982	1	rs4802200	ENSG00000267191.1	RP11-15A1.2	-3.4	0.000705	0.0327	-0.13	-0.1	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43785366	chr19:43902001~43926545:+
BRCA	cis	rs1998359	0.953	rs9671863	ENSG00000259087.4	RP11-356O9.2	3.4	0.000705	0.0327	0.12	0.1	Self-reported allergy;	chr14:37658670	chr14:37556158~37567095:-
BRCA	cis	rs1830951	0.611	rs7093770	ENSG00000243350.1	RP11-379F12.3	3.4	0.000705	0.0327	0.1	0.1	Eosinophil counts;	chr10:8525166	chr10:8052242~8053449:-
BRCA	cis	rs12612420	0.591	rs883999	ENSG00000225953.2	SATB2-AS1	-3.4	0.000705	0.0327	-0.19	-0.1	Exercise (leisure time);	chr2:200338387	chr2:199457700~199476935:+
BRCA	cis	rs2154319	0.887	rs6600366	ENSG00000230638.4	RP11-486B10.4	3.4	0.000706	0.0327	0.18	0.1	Height;	chr1:41093940	chr1:41542069~41544310:+
BRCA	cis	rs3105593	1	rs3848129	ENSG00000259298.1	RP11-562A8.4	3.4	0.000706	0.0327	0.09	0.1	QT interval;	chr15:50599867	chr15:50497195~50498744:-
BRCA	cis	rs6964587	0.626	rs2188841	ENSG00000188693.7	CYP51A1-AS1	3.4	0.000706	0.0327	0.11	0.1	Breast cancer;	chr7:91893327	chr7:92134604~92180725:+
BRCA	cis	rs36051895	0.664	rs28378223	ENSG00000236254.1	MTND4P14	-3.4	0.000706	0.0327	-0.12	-0.1	Pediatric autoimmune diseases;	chr9:5113087	chr9:5107937~5109290:+
BRCA	cis	rs3947	0.789	rs1293322	ENSG00000255046.1	RP11-297N6.4	-3.4	0.000706	0.0327	-0.14	-0.1	Blood protein levels;	chr8:11835129	chr8:11797928~11802568:-
BRCA	cis	rs2562456	0.876	rs11085465	ENSG00000268705.1	BNIP3P26	-3.4	0.000706	0.0327	-0.11	-0.1	Pain;	chr19:21568988	chr19:21521343~21521896:-
BRCA	cis	rs10985070	0.507	rs12551347	ENSG00000238181.2	AHCYP2	-3.4	0.000706	0.0327	-0.13	-0.1	Rheumatoid arthritis;	chr9:121174316	chr9:120720673~120721972:+
BRCA	cis	rs846271	0.872	rs846288	ENSG00000224116.5	INHBA-AS1	3.4	0.000706	0.0327	0.12	0.1	IgG glycosylation;	chr7:42027282	chr7:41693916~41779388:+
BRCA	cis	rs6088580	0.505	rs6141503	ENSG00000126005.14	MMP24-AS1	3.4	0.000706	0.0327	0.12	0.1	Glomerular filtration rate (creatinine);	chr20:34686665	chr20:35216462~35278131:-
BRCA	cis	rs7267979	0.586	rs6083776	ENSG00000274414.1	RP5-965G21.4	-3.4	0.000706	0.0327	-0.12	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25205480	chr20:25239007~25245229:-
BRCA	cis	rs7267979	0.586	rs1473695	ENSG00000274414.1	RP5-965G21.4	-3.4	0.000706	0.0327	-0.12	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25206329	chr20:25239007~25245229:-
BRCA	cis	rs2274273	1	rs7493394	ENSG00000233924.1	AL160471.6	-3.4	0.000706	0.0327	-0.12	-0.1	Protein biomarker;	chr14:55151037	chr14:55004813~55005687:-
BRCA	cis	rs7246967	0.866	rs62120785	ENSG00000241282.1	RPL34P33	3.4	0.000706	0.0327	0.19	0.1	Bronchopulmonary dysplasia;	chr19:22861997	chr19:22699352~22699685:+
BRCA	cis	rs6991838	0.584	rs14213	ENSG00000272155.1	RP11-707M3.3	-3.4	0.000706	0.0327	-0.1	-0.1	Intelligence (multi-trait analysis);	chr8:65602719	chr8:65714334~65714778:-
BRCA	cis	rs6460942	0.908	rs967126	ENSG00000226690.5	AC005281.1	3.4	0.000706	0.0327	0.19	0.1	Coronary artery disease;	chr7:12197674	chr7:12496429~12541910:+
BRCA	cis	rs10463316	0.817	rs7713109	ENSG00000260581.1	CTB-113P19.4	3.4	0.000706	0.0327	0.12	0.1	Metabolite levels (Pyroglutamine);	chr5:151409723	chr5:151652275~151655449:+
BRCA	cis	rs7824557	0.591	rs2043510	ENSG00000255046.1	RP11-297N6.4	3.4	0.000706	0.0327	0.13	0.1	Retinal vascular caliber;	chr8:11367659	chr8:11797928~11802568:-
BRCA	cis	rs2243480	1	rs2257790	ENSG00000229180.5	GS1-124K5.11	3.4	0.000706	0.0327	0.14	0.1	Diabetic kidney disease;	chr7:66135463	chr7:66526088~66542624:-
BRCA	cis	rs490234	0.776	rs10115455	ENSG00000232630.1	PRPS1P2	-3.4	0.000706	0.0327	-0.11	-0.1	Mean arterial pressure;	chr9:125696571	chr9:125150653~125151589:+
BRCA	cis	rs1056107	0.933	rs3808879	ENSG00000266315.1	MIR4668	3.4	0.000707	0.0328	0.11	0.1	Colorectal cancer;	chr9:112299198	chr9:111932100~111932169:+
BRCA	cis	rs28472312	0.862	rs11150623	ENSG00000259982.1	CDC37P1	3.4	0.000707	0.0328	0.14	0.1	Intelligence (multi-trait analysis);	chr16:28869680	chr16:28700294~28701540:-
BRCA	cis	rs1401543	1	rs9682721	ENSG00000273486.1	RP11-731C17.2	-3.4	0.000707	0.0328	-0.13	-0.1	Anticoagulant levels;	chr3:135845176	chr3:136837338~136839021:-
BRCA	cis	rs7520050	0.966	rs7539932	ENSG00000226957.1	RP4-533D7.4	3.4	0.000707	0.0328	0.11	0.1	Reticulocyte count;Red blood cell count;	chr1:45826682	chr1:46046818~46048368:+
BRCA	cis	rs7520050	0.966	rs61783200	ENSG00000226957.1	RP4-533D7.4	3.4	0.000707	0.0328	0.11	0.1	Reticulocyte count;Red blood cell count;	chr1:45831731	chr1:46046818~46048368:+
BRCA	cis	rs7165170	0.719	rs5011652	ENSG00000245479.2	LINC01585	3.4	0.000707	0.0328	0.13	0.1	Crohn's disease;Inflammatory bowel disease;	chr15:90623376	chr15:90660234~90664967:+
BRCA	cis	rs27434	0.529	rs42443	ENSG00000248734.2	CTD-2260A17.1	3.4	0.000707	0.0328	0.12	0.1	Ankylosing spondylitis;	chr5:96820521	chr5:96784777~96785999:+
BRCA	cis	rs7590268	0.666	rs12473294	ENSG00000279873.2	LINC01126	3.4	0.000707	0.0328	0.12	0.1	Orofacial clefts;	chr2:43410335	chr2:43227210~43228855:+
BRCA	cis	rs2274273	0.837	rs8008119	ENSG00000259318.1	RP11-454L9.2	3.4	0.000707	0.0328	0.09	0.1	Protein biomarker;	chr14:55364510	chr14:55394940~55395233:-
BRCA	cis	rs6433921	1	rs12693280	ENSG00000260742.1	RP11-366L5.1	-3.4	0.000707	0.0328	-0.13	-0.1	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;	chr2:181559991	chr2:181887851~181891663:-
BRCA	cis	rs3735485	0.678	rs10229955	ENSG00000201772.1	SNORA5C	3.4	0.000707	0.0328	0.14	0.1	White blood cell count;Sum basophil neutrophil counts;Neutrophil count;Granulocyte percentage of myeloid white cells;Monocyte percentage of white cells;Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Lymphocyte counts;	chr7:45116568	chr7:45104906~45105042:-
BRCA	cis	rs2262909	0.889	rs61268244	ENSG00000279377.1	AC003973.3	-3.4	0.000707	0.0328	-0.15	-0.1	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;	chr19:22127328	chr19:21965708~21968529:-
BRCA	cis	rs7520050	0.931	rs11211189	ENSG00000281133.1	AL355480.3	3.4	0.000707	0.0328	0.12	0.1	Reticulocyte count;Red blood cell count;	chr1:45795912	chr1:45580892~45580996:-
BRCA	cis	rs7520050	0.966	rs12411269	ENSG00000281133.1	AL355480.3	3.4	0.000707	0.0328	0.12	0.1	Reticulocyte count;Red blood cell count;	chr1:45805380	chr1:45580892~45580996:-
BRCA	cis	rs7714670	0.736	rs2973545	ENSG00000184084.7	CTD-2372A4.1	-3.4	0.000707	0.0328	-0.12	-0.1	Venous thromboembolism (SNP x SNP interaction);	chr5:73798384	chr5:73803296~73803599:-
BRCA	cis	rs6496932	0.802	rs8038403	ENSG00000259630.2	CTD-2262B20.1	3.4	0.000707	0.0328	0.13	0.1	Central corneal thickness;Corneal structure;	chr15:85313364	chr15:85415228~85415633:+
BRCA	cis	rs7487075	0.619	rs7485599	ENSG00000257261.4	RP11-96H19.1	3.4	0.000707	0.0328	0.13	0.1	Itch intensity from mosquito bite;	chr12:46436696	chr12:46383679~46876159:+
BRCA	cis	rs7487075	0.578	rs4768716	ENSG00000257261.4	RP11-96H19.1	3.4	0.000707	0.0328	0.13	0.1	Itch intensity from mosquito bite;	chr12:46437375	chr12:46383679~46876159:+
BRCA	cis	rs7487075	0.578	rs4768122	ENSG00000257261.4	RP11-96H19.1	3.4	0.000707	0.0328	0.13	0.1	Itch intensity from mosquito bite;	chr12:46438551	chr12:46383679~46876159:+
BRCA	cis	rs7520050	0.966	rs6701614	ENSG00000226957.1	RP4-533D7.4	3.4	0.000707	0.0328	0.11	0.1	Reticulocyte count;Red blood cell count;	chr1:45843748	chr1:46046818~46048368:+
BRCA	cis	rs6095360	1	rs6512554	ENSG00000227431.4	CSE1L-AS1	-3.4	0.000707	0.0328	-0.13	-0.1	Intelligence (multi-trait analysis);	chr20:48916213	chr20:49040463~49046044:-
BRCA	cis	rs6504622	0.577	rs197925	ENSG00000260075.1	NSFP1	3.4	0.000707	0.0328	0.12	0.1	Orofacial clefts;	chr17:46933355	chr17:46372855~46487141:+
BRCA	cis	rs4849845	0.653	rs3933618	ENSG00000223549.1	MTND5P28	3.4	0.000707	0.0328	0.12	0.1	Mean platelet volume;	chr2:120277976	chr2:120215181~120217279:+
BRCA	cis	rs2841277	0.802	rs2841269	ENSG00000258701.1	LINC00638	3.4	0.000707	0.0328	0.11	0.1	Rheumatoid arthritis;	chr14:104919812	chr14:104821201~104823718:+
BRCA	cis	rs7812879	0.516	rs12543308	ENSG00000254866.2	DEFB109P3	3.4	0.000707	0.0328	0.16	0.1	Systemic lupus erythematosus;	chr8:11451284	chr8:12150895~12151134:-
BRCA	cis	rs6710503	0.632	rs62144583	ENSG00000224165.4	DNAJC27-AS1	3.4	0.000707	0.0328	0.14	0.1	Lung cancer in ever smokers;Breast cancer;	chr2:24780609	chr2:24971390~25039694:+
BRCA	cis	rs12681366	0.734	rs10102496	ENSG00000253175.1	RP11-267M23.6	3.4	0.000707	0.0328	0.12	0.1	Nonsyndromic cleft lip with cleft palate;	chr8:94385953	chr8:94565036~94565715:+
BRCA	cis	rs12681366	0.734	rs16916788	ENSG00000253175.1	RP11-267M23.6	3.4	0.000707	0.0328	0.12	0.1	Nonsyndromic cleft lip with cleft palate;	chr8:94387390	chr8:94565036~94565715:+
BRCA	cis	rs6600671	1	rs7532615	ENSG00000270231.3	NBPF8P	-3.4	0.000707	0.0328	-0.11	-0.1	Hip geometry;	chr1:121430980	chr1:120436353~120467739:+
BRCA	cis	rs12411860	0.821	rs930324	ENSG00000226200.5	SGMS1-AS1	-3.4	0.000708	0.0328	-0.1	-0.1	Blood protein levels;	chr10:50273112	chr10:50624951~50641451:+
BRCA	cis	rs2562456	0.917	rs2681389	ENSG00000240522.1	RPL7AP10	3.4	0.000708	0.0328	0.12	0.1	Pain;	chr19:21509773	chr19:21149648~21150438:-
BRCA	cis	rs2880765	0.805	rs11858817	ENSG00000230373.7	GOLGA6L5P	3.4	0.000708	0.0328	0.11	0.1	Coronary artery disease;	chr15:85488029	chr15:84507885~84516814:-
BRCA	cis	rs2880765	0.835	rs28874135	ENSG00000230373.7	GOLGA6L5P	3.4	0.000708	0.0328	0.11	0.1	Coronary artery disease;	chr15:85488272	chr15:84507885~84516814:-
BRCA	cis	rs2880765	0.835	rs11633604	ENSG00000230373.7	GOLGA6L5P	3.4	0.000708	0.0328	0.11	0.1	Coronary artery disease;	chr15:85488348	chr15:84507885~84516814:-
BRCA	cis	rs1949733	0.701	rs2631754	ENSG00000250471.2	GMPSP1	3.4	0.000708	0.0328	0.11	0.1	Response to antineoplastic agents;	chr4:8447506	chr4:8174421~8174999:+
BRCA	cis	rs2243480	1	rs35046236	ENSG00000234585.5	CCT6P3	-3.4	0.000708	0.0328	-0.15	-0.1	Diabetic kidney disease;	chr7:65943626	chr7:65038354~65074713:+
BRCA	cis	rs2243480	1	rs36068983	ENSG00000234585.5	CCT6P3	-3.4	0.000708	0.0328	-0.15	-0.1	Diabetic kidney disease;	chr7:65944004	chr7:65038354~65074713:+
BRCA	cis	rs2243480	1	rs68189316	ENSG00000234585.5	CCT6P3	-3.4	0.000708	0.0328	-0.15	-0.1	Diabetic kidney disease;	chr7:65944182	chr7:65038354~65074713:+
BRCA	cis	rs4388249	1	rs11960226	ENSG00000249068.1	CTC-287O8.1	3.4	0.000708	0.0328	0.15	0.1	Schizophrenia;	chr5:109747980	chr5:109840128~109840692:-
BRCA	cis	rs4388249	0.95	rs3797693	ENSG00000249068.1	CTC-287O8.1	3.4	0.000708	0.0328	0.15	0.1	Schizophrenia;	chr5:109750314	chr5:109840128~109840692:-
BRCA	cis	rs867371	0.614	rs7183805	ENSG00000276710.3	CSPG4P8	-3.4	0.000708	0.0328	-0.12	-0.1	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82247090	chr15:82459472~82477258:+
BRCA	cis	rs7572733	0.691	rs11684176	ENSG00000231621.1	AC013264.2	-3.4	0.000708	0.0328	-0.1	-0.1	Dermatomyositis;	chr2:198090050	chr2:197197991~197199273:+
BRCA	cis	rs375066	0.935	rs376032	ENSG00000278917.1	RP11-15A1.4	-3.4	0.000708	0.0328	-0.12	-0.1	Breast cancer;	chr19:43903412	chr19:43891233~43895411:+
BRCA	cis	rs739496	0.615	rs59905228	ENSG00000266370.1	MIR3657	3.4	0.000708	0.0328	0.13	0.1	Platelet count;	chr12:111743422	chr12:112037599~112037715:-
BRCA	cis	rs295490	0.748	rs17335312	ENSG00000178631.7	ACTG1P1	-3.4	0.000708	0.0328	-0.21	-0.1	PR interval in Tripanosoma cruzi seropositivity;	chr3:139356544	chr3:139493809~139494937:+
BRCA	cis	rs7078003	0.706	rs2297644	ENSG00000231025.1	RP11-175O19.4	-3.4	0.000708	0.0328	-0.16	-0.1	Metabolite levels (small molecules and protein measures);	chr10:97599982	chr10:96992450~96995959:+
BRCA	cis	rs875971	0.862	rs709596	ENSG00000223473.2	GS1-124K5.3	3.4	0.000708	0.0328	0.08	0.1	Aortic root size;	chr7:66360926	chr7:66491049~66493566:-
BRCA	cis	rs10761482	0.861	rs10821728	ENSG00000254271.1	RP11-131N11.4	3.4	0.000708	0.0328	0.15	0.1	Schizophrenia;	chr10:60339377	chr10:60734342~60741828:+
BRCA	cis	rs58521262	1	rs62124389	ENSG00000268105.1	RP11-369G6.2	-3.4	0.000708	0.0328	-0.17	-0.1	Testicular germ cell tumor;	chr19:22996716	chr19:23125665~23128543:+
BRCA	cis	rs504458	0.645	rs2808111	ENSG00000237505.5	PKN2-AS1	-3.4	0.000708	0.0328	-0.16	-0.1	Childhood ear infection;	chr1:88378628	chr1:88537513~88685204:-
BRCA	cis	rs7520050	0.931	rs6697557	ENSG00000226957.1	RP4-533D7.4	3.4	0.000708	0.0328	0.11	0.1	Reticulocyte count;Red blood cell count;	chr1:45842137	chr1:46046818~46048368:+
BRCA	cis	rs67766926	0.587	rs12713431	ENSG00000237522.1	NONOP2	3.4	0.000708	0.0328	0.12	0.1	Inflammatory skin disease;	chr2:61022541	chr2:60936819~60938049:-
BRCA	cis	rs8023401	0.938	rs7167026	ENSG00000274654.1	CTD-3247H4.2	3.4	0.000708	0.0328	0.15	0.1	Spherical equivalent (joint analysis main effects and education interaction);	chr15:48512899	chr15:48528980~48529728:-
BRCA	cis	rs4950322	0.57	rs79810882	ENSG00000230832.3	RP11-325P15.2	-3.4	0.000708	0.0328	-0.17	-0.1	Protein quantitative trait loci;	chr1:147235575	chr1:147082338~147083578:-
BRCA	cis	rs3796352	0.527	rs11715498	ENSG00000270941.1	RP5-966M1.5	-3.4	0.000708	0.0328	-0.18	-0.1	Immune reponse to smallpox (secreted IL-2);	chr3:52909535	chr3:52734735~52735013:+
BRCA	cis	rs36051895	0.659	rs10283730	ENSG00000237711.1	RP11-39K24.13	-3.4	0.000708	0.0328	-0.13	-0.1	Pediatric autoimmune diseases;	chr9:5073289	chr9:5100236~5101009:+
BRCA	cis	rs990171	0.538	rs7566063	ENSG00000234389.1	AC007278.3	3.4	0.000708	0.0328	0.11	0.1	Lymphocyte counts;	chr2:102496106	chr2:102438713~102440475:+
BRCA	cis	rs10843647	0.967	rs4931284	ENSG00000245614.3	DDX11-AS1	-3.4	0.000708	0.0328	-0.12	-0.1	Glucose homeostasis traits;	chr12:30181369	chr12:31020763~31073847:-
BRCA	cis	rs10843647	0.967	rs4931286	ENSG00000245614.3	DDX11-AS1	-3.4	0.000708	0.0328	-0.12	-0.1	Glucose homeostasis traits;	chr12:30181464	chr12:31020763~31073847:-
BRCA	cis	rs10843647	0.967	rs7295022	ENSG00000245614.3	DDX11-AS1	-3.4	0.000708	0.0328	-0.12	-0.1	Glucose homeostasis traits;	chr12:30181518	chr12:31020763~31073847:-
BRCA	cis	rs6964587	0.839	rs13229273	ENSG00000188693.7	CYP51A1-AS1	-3.4	0.000708	0.0328	-0.12	-0.1	Breast cancer;	chr7:91815158	chr7:92134604~92180725:+
BRCA	cis	rs7660883	0.866	rs342468	ENSG00000251411.1	RP11-397E7.4	-3.4	0.000709	0.0328	-0.11	-0.1	HDL cholesterol levels;	chr4:87130756	chr4:86913266~86914817:-
BRCA	cis	rs6088580	0.505	rs6141503	ENSG00000261582.1	RP4-614O4.11	3.4	0.000709	0.0328	0.1	0.1	Glomerular filtration rate (creatinine);	chr20:34686665	chr20:35267885~35280043:-
BRCA	cis	rs3764021	0.527	rs17806710	ENSG00000260423.1	RP13-735L24.1	-3.4	0.000709	0.0328	-0.12	-0.1	Type 1 diabetes;	chr12:9688368	chr12:9367464~9397617:+
BRCA	cis	rs7267979	1	rs2258563	ENSG00000274414.1	RP5-965G21.4	-3.4	0.000709	0.0328	-0.12	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25292799	chr20:25239007~25245229:-
BRCA	cis	rs8130944	0.893	rs2839577	ENSG00000225731.1	AP001627.1	3.4	0.000709	0.0328	0.12	0.1	Perceived unattractiveness to mosquitoes;	chr21:42731323	chr21:42733594~42741758:-
BRCA	cis	rs4699052	1	rs6533060	ENSG00000246560.2	RP11-10L12.4	3.4	0.000709	0.0329	0.11	0.1	Testicular germ cell tumor;	chr4:103218839	chr4:102828055~102844075:+
BRCA	cis	rs67478160	0.643	rs11160762	ENSG00000269910.1	RP11-73M18.10	-3.4	0.000709	0.0329	-0.1	-0.1	Schizophrenia;	chr14:103788746	chr14:103694516~103695050:-
BRCA	cis	rs10208712	0.637	rs7557140	ENSG00000242282.5	AC108488.4	3.4	0.000709	0.0329	0.11	0.1	Restless legs syndrome;	chr2:4067327	chr2:3531813~3536873:-
BRCA	cis	rs1466788	1	rs4838890	ENSG00000224965.1	KCNC4-AS1	3.4	0.000709	0.0329	0.12	0.1	Blood metabolite levels;	chr1:110074057	chr1:110208834~110209987:-
BRCA	cis	rs7560272	0.723	rs780391	ENSG00000230002.2	ALMS1-IT1	-3.4	0.000709	0.0329	-0.12	-0.1	Schizophrenia;	chr2:73476777	chr2:73456764~73459484:+
BRCA	cis	rs1712517	0.524	rs4917384	ENSG00000234699.1	RP11-225H22.4	-3.4	0.000709	0.0329	-0.13	-0.1	Migraine;	chr10:103236031	chr10:103452846~103462695:+
BRCA	cis	rs1376877	0.87	rs4261698	ENSG00000273456.1	RP11-686O6.2	3.4	0.000709	0.0329	0.1	0.1	Subclinical atherosclerosis traits (other);	chr2:203256236	chr2:202374932~202375604:-
BRCA	cis	rs2274273	1	rs15870	ENSG00000233924.1	AL160471.6	-3.4	0.000709	0.0329	-0.12	-0.1	Protein biomarker;	chr14:55152593	chr14:55004813~55005687:-
BRCA	cis	rs10761482	0.861	rs10821730	ENSG00000254271.1	RP11-131N11.4	-3.4	0.000709	0.0329	-0.15	-0.1	Schizophrenia;	chr10:60339513	chr10:60734342~60741828:+
BRCA	cis	rs687432	0.774	rs7120102	ENSG00000213592.4	AP000662.9	-3.4	0.000709	0.0329	-0.15	-0.1	Parkinson's disease;	chr11:58100658	chr11:57718044~57718530:-
BRCA	cis	rs1411478	1	rs1044595	ENSG00000243155.1	RP11-46A10.5	3.4	0.00071	0.0329	0.11	0.1	Menopause (age at onset);Progressive supranuclear palsy;	chr1:180974393	chr1:180944042~180976482:-
BRCA	cis	rs613391	0.561	rs682908	ENSG00000265194.1	RP11-70L8.4	-3.4	0.00071	0.0329	-0.11	-0.1	Quantitative traits;	chr9:22721975	chr9:21858910~21861926:-
BRCA	cis	rs7578361	0.918	rs10209100	ENSG00000231969.1	AC144449.1	3.4	0.00071	0.0329	0.16	0.1	Acute lymphoblastic leukemia (childhood);	chr2:149520601	chr2:149587196~149848233:+
BRCA	cis	rs17711722	0.727	rs1880555	ENSG00000232559.3	GS1-124K5.12	3.4	0.00071	0.0329	0.12	0.1	Calcium levels;	chr7:65967580	chr7:66554588~66576923:-
BRCA	cis	rs875971	0.83	rs4718358	ENSG00000271064.1	RP11-792A8.3	-3.4	0.00071	0.0329	-0.12	-0.1	Aortic root size;	chr7:66508681	chr7:66748838~66749077:-
BRCA	cis	rs2113818	0.514	rs7584581	ENSG00000264370.1	MIR3125	3.4	0.00071	0.0329	0.12	0.1	Optic cup area;	chr2:12829861	chr2:12737367~12737444:+
BRCA	cis	rs6582630	0.533	rs11181379	ENSG00000257718.1	RP11-396F22.1	3.4	0.00071	0.0329	0.1	0.1	Drug-induced liver injury (flucloxacillin);	chr12:37938579	chr12:38906451~38909592:+
BRCA	cis	rs2154319	1	rs61774708	ENSG00000230638.4	RP11-486B10.4	-3.4	0.00071	0.0329	-0.18	-0.1	Height;	chr1:41249135	chr1:41542069~41544310:+
BRCA	cis	rs2154319	1	rs74714120	ENSG00000230638.4	RP11-486B10.4	-3.4	0.00071	0.0329	-0.18	-0.1	Height;	chr1:41249206	chr1:41542069~41544310:+
BRCA	cis	rs879568	0.874	rs16968220	ENSG00000278986.1	RP11-723J4.3	-3.4	0.00071	0.0329	-0.12	-0.1	QRS duration;	chr18:36711234	chr18:35972151~35973916:+
BRCA	cis	rs1383484	1	rs28612730	ENSG00000259728.4	LINC00933	-3.4	0.00071	0.0329	-0.13	-0.1	Height;	chr15:83842454	chr15:84570649~84580175:+
BRCA	cis	rs11098499	0.955	rs13114751	ENSG00000260404.2	RP11-384K6.6	3.4	0.00071	0.0329	0.1	0.1	Corneal astigmatism;	chr4:119235462	chr4:118591773~118633729:+
BRCA	cis	rs1528472	0.836	rs1728875	ENSG00000276533.1	RP11-139H15.5	3.4	0.00071	0.0329	0.12	0.1	Urinary albumin-to-creatinine ratio;Urinary albumin-to-creatinine ratio in non-diabetics;	chr15:55025321	chr15:55288849~55289346:-
BRCA	cis	rs7660883	0.897	rs236995	ENSG00000251411.1	RP11-397E7.4	3.4	0.00071	0.0329	0.11	0.1	HDL cholesterol levels;	chr4:87079271	chr4:86913266~86914817:-
BRCA	cis	rs4730430	0.537	rs7781181	ENSG00000226965.1	AC003088.1	3.4	0.00071	0.0329	0.12	0.1	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr7:110498786	chr7:110432239~110534754:-
BRCA	cis	rs6545883	0.929	rs2593625	ENSG00000270820.4	RP11-355B11.2	3.4	0.00071	0.0329	0.12	0.1	Tuberculosis;	chr2:61441634	chr2:61471188~61484130:+
BRCA	cis	rs739401	0.611	rs12284275	ENSG00000247473.2	CARS-AS1	3.4	0.00071	0.0329	0.12	0.1	Longevity;	chr11:3003154	chr11:3029009~3041260:+
BRCA	cis	rs1730008	0.691	rs113849803	ENSG00000279311.1	RP11-170K4.2	3.4	0.00071	0.0329	0.13	0.1	Lobe attachment (rater-scored or self-reported);	chr3:158394189	chr3:158869898~158871821:+
BRCA	cis	rs539096	0.83	rs2494995	ENSG00000236200.4	KDM4A-AS1	3.4	0.00071	0.0329	0.13	0.1	Intelligence (multi-trait analysis);	chr1:43556632	chr1:43699765~43708138:-
BRCA	cis	rs6582630	0.615	rs10880642	ENSG00000257718.1	RP11-396F22.1	-3.4	0.00071	0.0329	-0.1	-0.1	Drug-induced liver injury (flucloxacillin);	chr12:38160350	chr12:38906451~38909592:+
BRCA	cis	rs1018697	1	rs7092051	ENSG00000236937.2	PTGES3P4	3.4	0.00071	0.0329	0.13	0.1	Colorectal adenoma (advanced);	chr10:102799720	chr10:102845595~102845950:+
BRCA	cis	rs2243480	1	rs464895	ENSG00000229180.5	GS1-124K5.11	3.4	0.00071	0.0329	0.15	0.1	Diabetic kidney disease;	chr7:66062119	chr7:66526088~66542624:-
BRCA	cis	rs6854137	0.553	rs924511	ENSG00000214676.4	RPL9P16	-3.4	0.00071	0.0329	-0.12	-0.1	Vein graft stenosis in coronary artery bypass grafting;	chr4:168781813	chr4:168755816~168756382:+
BRCA	cis	rs10771431	0.935	rs1117735	ENSG00000214776.8	RP11-726G1.1	-3.4	0.00071	0.0329	-0.11	-0.1	Breast size;	chr12:9220132	chr12:9467552~9576275:+
BRCA	cis	rs8099594	0.55	rs8088875	ENSG00000266696.1	RP11-30L3.2	3.4	0.00071	0.0329	0.12	0.1	Height;	chr18:49415109	chr18:49205912~49208781:+
BRCA	cis	rs4703129	1	rs62367545	ENSG00000246763.5	RGMB-AS1	-3.4	0.00071	0.0329	-0.12	-0.1	Asperger disorder;	chr5:98538071	chr5:98769618~98773469:-
BRCA	cis	rs67696533	0.62	rs911529	ENSG00000275576.1	RP5-836N17.4	-3.4	0.00071	0.0329	-0.13	-0.1	White blood cell count (basophil);Basophil percentage of granulocytes;Basophil percentage of white cells;	chr20:32559137	chr20:32116171~32116629:+
BRCA	cis	rs4908769	0.627	rs2252865	ENSG00000232912.4	RP5-1115A15.1	-3.4	0.00071	0.0329	-0.11	-0.1	Allergy;	chr1:8362616	chr1:8424645~8434838:+
BRCA	cis	rs3796619	1	rs55741287	ENSG00000272588.1	RP11-440L14.4	-3.4	0.00071	0.0329	-0.11	-0.1	Recombination rate (males);	chr4:1100882	chr4:757022~757740:-
BRCA	cis	rs6671200	0.831	rs71654413	ENSG00000226026.4	RP11-57H12.3	3.4	0.00071	0.0329	0.22	0.1	Stearic acid (18:0) levels;	chr1:95141532	chr1:95163219~95233982:-
BRCA	cis	rs6671200	1	rs34396223	ENSG00000228852.5	RP11-57H12.5	3.4	0.00071	0.0329	0.19	0.1	Stearic acid (18:0) levels;	chr1:95232272	chr1:95243167~95278940:-
BRCA	cis	rs4243971	0.516	rs6141294	ENSG00000277692.1	RP11-358N2.2	-3.4	0.00071	0.0329	-0.12	-0.1	Inflammatory bowel disease;Crohn's disease;	chr20:32365359	chr20:32355053~32355734:+
BRCA	cis	rs4243971	0.516	rs2295454	ENSG00000277692.1	RP11-358N2.2	-3.4	0.00071	0.0329	-0.12	-0.1	Inflammatory bowel disease;Crohn's disease;	chr20:32366492	chr20:32355053~32355734:+
BRCA	cis	rs68170813	0.617	rs6964395	ENSG00000241764.3	AC002467.7	3.4	0.00071	0.0329	0.19	0.1	Coronary artery disease;	chr7:107440222	chr7:107742817~107744581:-
BRCA	cis	rs12554020	0.786	rs79469056	ENSG00000227603.1	RP11-165J3.6	3.4	0.00071	0.0329	0.18	0.1	Schizophrenia;	chr9:93453807	chr9:93435332~93437121:-
BRCA	cis	rs12554020	0.786	rs12554164	ENSG00000227603.1	RP11-165J3.6	3.4	0.00071	0.0329	0.18	0.1	Schizophrenia;	chr9:93456677	chr9:93435332~93437121:-
BRCA	cis	rs6088580	0.634	rs6120666	ENSG00000269202.1	RP4-614O4.12	-3.4	0.00071	0.0329	-0.11	-0.1	Glomerular filtration rate (creatinine);	chr20:34502913	chr20:35201747~35203288:-
BRCA	cis	rs875971	0.522	rs10807697	ENSG00000227113.2	RP11-460N20.4	3.4	0.000711	0.0329	0.11	0.1	Aortic root size;	chr7:65951183	chr7:65075023~65078780:+
BRCA	cis	rs34929064	0.525	rs1880243	ENSG00000179428.2	AC073072.5	-3.4	0.000711	0.0329	-0.14	-0.1	Major depression and alcohol dependence;	chr7:22720036	chr7:22725395~22727620:-
BRCA	cis	rs7267979	0.565	rs4815432	ENSG00000274973.1	RP13-401N8.7	3.4	0.000711	0.0329	0.12	0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25575767	chr20:25845497~25845862:+
BRCA	cis	rs12505328	0.593	rs11132986	ENSG00000213370.3	RANP6	3.4	0.000711	0.0329	0.13	0.1	Chin dimples;	chr4:173450630	chr4:173633728~173634371:-
BRCA	cis	rs4713118	0.868	rs10484401	ENSG00000219392.1	RP1-265C24.5	3.4	0.000711	0.0329	0.16	0.1	Parkinson's disease;	chr6:27778811	chr6:28115628~28116551:+
BRCA	cis	rs11887277	0.507	rs12105076	ENSG00000272148.1	RP11-195B17.1	-3.4	0.000711	0.0329	-0.12	-0.1	Obesity-related traits;	chr2:26819097	chr2:27062428~27062907:-
BRCA	cis	rs7660883	1	rs3775221	ENSG00000251411.1	RP11-397E7.4	3.4	0.000711	0.0329	0.12	0.1	HDL cholesterol levels;	chr4:87090641	chr4:86913266~86914817:-
BRCA	cis	rs2777491	0.574	rs11635906	ENSG00000247556.5	OIP5-AS1	3.4	0.000711	0.0329	0.12	0.1	Ulcerative colitis;	chr15:41487062	chr15:41283990~41309737:+
BRCA	cis	rs4819052	0.885	rs28576202	ENSG00000223768.1	LINC00205	-3.4	0.000711	0.0329	-0.14	-0.1	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45254769	chr21:45293285~45297354:+
BRCA	cis	rs62025270	0.632	rs62022919	ENSG00000259416.2	RP11-158M2.5	-3.4	0.000711	0.0329	-0.16	-0.1	Idiopathic pulmonary fibrosis;	chr15:85675079	chr15:85754941~85756237:-
BRCA	cis	rs3742264	0.656	rs6561275	ENSG00000235903.6	CPB2-AS1	-3.4	0.000711	0.0329	-0.12	-0.1	Blood protein levels;	chr13:45944164	chr13:46052806~46113332:+
BRCA	cis	rs11892454	0.565	rs35430508	ENSG00000217643.1	PTGES3P2	-3.4	0.000711	0.0329	-0.12	-0.1	Heschl's gyrus morphology;	chr2:25814668	chr2:25822469~25822950:+
BRCA	cis	rs860295	0.557	rs915181	ENSG00000225082.2	DAP3P1	-3.4	0.000711	0.0329	-0.14	-0.1	Body mass index;	chr1:155944981	chr1:155586644~155602197:+
BRCA	cis	rs17836934	0.525	rs6538214	ENSG00000270344.2	RP11-734K2.4	-3.4	0.000711	0.0329	-0.1	-0.1	Total body bone mineral density;	chr12:89995520	chr12:89525654~89548005:+
BRCA	cis	rs10246939	0.553	rs34894166	ENSG00000270923.1	TAS2R6P	-3.4	0.000711	0.0329	-0.11	-0.1	Bitter taste perception;	chr7:141852158	chr7:141787815~141788640:+
BRCA	cis	rs860295	0.812	rs12081192	ENSG00000232093.1	RP11-307C12.11	3.4	0.000711	0.0329	0.12	0.1	Body mass index;	chr1:155768253	chr1:155045191~155046118:-
BRCA	cis	rs7487075	0.859	rs4768698	ENSG00000274723.1	RP11-618L22.1	-3.4	0.000711	0.0329	-0.12	-0.1	Itch intensity from mosquito bite;	chr12:46355305	chr12:46970504~46972155:+
BRCA	cis	rs35740288	0.77	rs17635450	ENSG00000259295.5	CSPG4P12	-3.4	0.000711	0.0329	-0.14	-0.1	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85655818	chr15:85191438~85213905:+
BRCA	cis	rs6943931	0.857	rs10950902	ENSG00000230658.1	KLHL7-AS1	-3.4	0.000711	0.0329	-0.14	-0.1	Diabetic kidney disease;	chr7:22380497	chr7:23101228~23105703:-
BRCA	cis	rs6943931	0.963	rs10950903	ENSG00000230658.1	KLHL7-AS1	-3.4	0.000711	0.0329	-0.14	-0.1	Diabetic kidney disease;	chr7:22380533	chr7:23101228~23105703:-
BRCA	cis	rs1376877	0.902	rs56102300	ENSG00000273456.1	RP11-686O6.2	3.4	0.000712	0.0329	0.1	0.1	Subclinical atherosclerosis traits (other);	chr2:203260545	chr2:202374932~202375604:-
BRCA	cis	rs6828577	0.955	rs13134170	ENSG00000281731.1	RP11-384K6.8	-3.4	0.000712	0.0329	-0.12	-0.1	Perioperative myocardial infarction in coronary artery bypass surgery;	chr4:118760720	chr4:118664087~118685341:-
BRCA	cis	rs1018697	1	rs1018696	ENSG00000236937.2	PTGES3P4	3.4	0.000712	0.0329	0.13	0.1	Colorectal adenoma (advanced);	chr10:102789309	chr10:102845595~102845950:+
BRCA	cis	rs718433	0.584	rs4982496	ENSG00000211778.2	TRAV4	-3.4	0.000712	0.0329	-0.07	-0.1	Intraocular pressure;	chr14:21752353	chr14:21736152~21736982:+
BRCA	cis	rs324126	0.78	rs62108317	ENSG00000277977.1	CTD-3018O17.5	3.4	0.000712	0.0329	0.12	0.1	Colonoscopy-negative controls vs population controls;	chr19:52380230	chr19:52392659~52392755:+
BRCA	cis	rs7020830	0.898	rs12000309	ENSG00000260100.1	RP11-220I1.5	-3.4	0.000712	0.0329	-0.13	-0.1	Schizophrenia;	chr9:37230847	chr9:37078813~37079776:-
BRCA	cis	rs359466	0.938	rs359415	ENSG00000253768.1	CTB-33O18.1	-3.4	0.000712	0.0329	-0.16	-0.1	QRS complex (Sokolow-Lyon);	chr5:173918484	chr5:173562478~173573199:+
BRCA	cis	rs9309711	0.506	rs9284794	ENSG00000271868.1	RP11-1293J14.1	-3.4	0.000712	0.0329	-0.14	-0.1	Neurofibrillary tangles;	chr2:3488281	chr2:3496956~3497428:+
BRCA	cis	rs2274273	1	rs2274273	ENSG00000259318.1	RP11-454L9.2	-3.4	0.000712	0.0329	-0.09	-0.1	Protein biomarker;	chr14:55147918	chr14:55394940~55395233:-
BRCA	cis	rs2017387	0.572	rs157547	ENSG00000161643.11	SIGLEC16	-3.4	0.000712	0.0329	-0.2	-0.1	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:49991825	chr19:49969673~49975814:+
BRCA	cis	rs12122100	0.651	rs12126527	ENSG00000278811.3	LINC00624	-3.4	0.000712	0.0329	-0.13	-0.1	HIV-1 control;	chr1:147079710	chr1:147258885~147517875:-
BRCA	cis	rs6894268	0.722	rs6422331	ENSG00000244945.1	RP11-1379J22.2	3.4	0.000712	0.0329	0.11	0.1	Eating disorders;	chr5:179575950	chr5:179595904~179603741:-
BRCA	cis	rs875971	0.862	rs1983372	ENSG00000223473.2	GS1-124K5.3	-3.4	0.000712	0.033	-0.08	-0.1	Aortic root size;	chr7:66146364	chr7:66491049~66493566:-
BRCA	cis	rs4578769	0.918	rs8089471	ENSG00000273232.1	RP11-370A5.2	3.4	0.000712	0.033	0.14	0.1	Eosinophil percentage of white cells;	chr18:22892994	chr18:22882825~22883357:-
BRCA	cis	rs6028335	0.61	rs3752291	ENSG00000274825.1	RP4-616B8.5	-3.4	0.000712	0.033	-0.13	-0.1	Alcohol and nicotine co-dependence;	chr20:38941761	chr20:38955910~38956547:+
BRCA	cis	rs7308116	0.967	rs7952838	ENSG00000274395.1	RP11-554D14.8	-3.4	0.000712	0.033	-0.11	-0.1	Pelvic organ prolapse (moderate/severe);	chr12:107803258	chr12:107835541~107836555:-
BRCA	cis	rs1414896	0.646	rs12135093	ENSG00000226835.1	RP11-148B18.3	3.4	0.000712	0.033	0.11	0.1	Non-alcoholic fatty liver disease histology (AST);	chr1:95208490	chr1:94333267~94334848:+
BRCA	cis	rs848490	0.889	rs68153348	ENSG00000214293.7	APTR	3.4	0.000712	0.033	0.13	0.1	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77589017	chr7:77657660~77696265:-
BRCA	cis	rs59721556	0.918	rs2886122	ENSG00000258917.1	ZMYND19P1	3.39	0.000712	0.033	0.15	0.1	Response to paliperidone in schizophrenia (Multivariate);Response to paliperidone in schizophrenia (CGI-S score);Response to paliperidone in schizophrenia (PANSS score);Red cell distribution width;Response to paliperidone in schizophrenia (positive Marder score);	chr14:77651029	chr14:77696591~77697377:+
BRCA	cis	rs8062405	0.755	rs56209193	ENSG00000261766.1	RP11-22P6.2	-3.39	0.000712	0.033	-0.1	-0.1	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28574315	chr16:28862166~28863340:-
BRCA	cis	rs11158026	0.603	rs8020545	ENSG00000233924.1	AL160471.6	-3.39	0.000712	0.033	-0.12	-0.1	Parkinson's disease;	chr14:54942352	chr14:55004813~55005687:-
BRCA	cis	rs11158026	0.574	rs8019390	ENSG00000233924.1	AL160471.6	-3.39	0.000712	0.033	-0.12	-0.1	Parkinson's disease;	chr14:54942366	chr14:55004813~55005687:-
BRCA	cis	rs490049	1	rs490049	ENSG00000277386.1	RP11-141M1.4	3.39	0.000712	0.033	0.23	0.1	Diabetic kidney disease;	chr13:32990725	chr13:33336216~33336716:-
BRCA	cis	rs9341808	0.667	rs2490251	ENSG00000233967.5	RP11-250B2.3	3.39	0.000712	0.033	0.11	0.1	Sitting height ratio;	chr6:80185447	chr6:80443344~80465927:+
BRCA	cis	rs1065852	0.526	rs8138080	ENSG00000273366.1	CTA-989H11.1	-3.39	0.000712	0.033	-0.14	-0.1	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42000367	chr22:42278188~42278846:+
BRCA	cis	rs11035577	0.632	rs6485134	ENSG00000279675.1	RP11-454H19.2	-3.39	0.000712	0.033	-0.16	-0.1	Temperament (bipolar disorder);	chr11:39755255	chr11:40107244~40112599:-
BRCA	cis	rs11035577	0.632	rs7107633	ENSG00000279675.1	RP11-454H19.2	-3.39	0.000712	0.033	-0.16	-0.1	Temperament (bipolar disorder);	chr11:39756366	chr11:40107244~40112599:-
BRCA	cis	rs11673344	0.642	rs55926714	ENSG00000267422.1	CTD-2554C21.1	3.39	0.000713	0.033	0.14	0.1	Obesity-related traits;	chr19:37307974	chr19:37779686~37792865:+
BRCA	cis	rs863345	0.604	rs11264991	ENSG00000229914.1	RP11-404O13.4	-3.39	0.000713	0.033	-0.11	-0.1	Pneumococcal bacteremia;	chr1:158503071	chr1:158195633~158196131:-
BRCA	cis	rs12893668	0.543	rs1799796	ENSG00000258914.1	CTD-2134A5.3	3.39	0.000713	0.033	0.14	0.1	Reticulocyte count;	chr14:103699590	chr14:103875055~103877478:+
BRCA	cis	rs1376877	0.902	rs62183907	ENSG00000273456.1	RP11-686O6.2	3.39	0.000713	0.033	0.1	0.1	Subclinical atherosclerosis traits (other);	chr2:203277805	chr2:202374932~202375604:-
BRCA	cis	rs11008222	1	rs10826864	ENSG00000272381.1	RP11-192P3.4	3.39	0.000713	0.033	0.12	0.1	Congenital left-sided heart lesions (maternal effect);	chr10:30755280	chr10:31187883~31261910:+
BRCA	cis	rs2274273	0.967	rs8013027	ENSG00000259318.1	RP11-454L9.2	3.39	0.000713	0.033	0.09	0.1	Protein biomarker;	chr14:55144222	chr14:55394940~55395233:-
BRCA	cis	rs1039766	1	rs72822431	ENSG00000227791.3	AC007365.4	3.39	0.000713	0.033	0.16	0.1	Lung adenocarcinoma;Lung cancer;	chr2:65294682	chr2:64665607~64666064:+
BRCA	cis	rs2880765	0.835	rs7180923	ENSG00000259630.2	CTD-2262B20.1	-3.39	0.000713	0.033	-0.12	-0.1	Coronary artery disease;	chr15:85507659	chr15:85415228~85415633:+
BRCA	cis	rs17711722	0.701	rs781143	ENSG00000232546.1	RP11-458F8.1	-3.39	0.000713	0.033	-0.09	-0.1	Calcium levels;	chr7:65974892	chr7:66848496~66858136:+
BRCA	cis	rs1146509	0.504	rs2022032	ENSG00000260464.1	RP4-561L24.3	-3.39	0.000713	0.033	-0.12	-0.1	QRS duration in Tripanosoma cruzi seropositivity;	chr1:94562563	chr1:93847174~93848939:+
BRCA	cis	rs7104764	1	rs2272565	ENSG00000254910.1	RP11-326C3.7	-3.39	0.000713	0.033	-0.12	-0.1	Menarche (age at onset);	chr11:244414	chr11:310139~311141:-
BRCA	cis	rs10043228	1	rs12517508	ENSG00000250015.1	CTC-339F2.2	3.39	0.000713	0.033	0.13	0.1	Asthma or chronic obstructive pulmonary disease;	chr5:116087877	chr5:116302354~116304134:-
BRCA	cis	rs6582630	0.599	rs7967598	ENSG00000257718.1	RP11-396F22.1	-3.39	0.000713	0.033	-0.1	-0.1	Drug-induced liver injury (flucloxacillin);	chr12:38146958	chr12:38906451~38909592:+
BRCA	cis	rs9341808	0.683	rs7771449	ENSG00000279022.1	RP11-250B2.4	3.39	0.000713	0.033	0.12	0.1	Sitting height ratio;	chr6:80210260	chr6:80440730~80441172:+
BRCA	cis	rs7191700	0.509	rs416603	ENSG00000262636.1	CTD-3088G3.4	-3.39	0.000713	0.033	-0.14	-0.1	Multiple sclerosis;	chr16:11270222	chr16:11380859~11381118:-
BRCA	cis	rs80028505	0.908	rs7748078	ENSG00000271304.1	DPRXP2	3.39	0.000714	0.033	0.2	0.1	Foot ulcer in diabetes and neuropathy;	chr6:36080233	chr6:35989515~35990436:-
BRCA	cis	rs80028505	0.71	rs80032177	ENSG00000271304.1	DPRXP2	3.39	0.000714	0.033	0.2	0.1	Foot ulcer in diabetes and neuropathy;	chr6:36081939	chr6:35989515~35990436:-
BRCA	cis	rs12787909	1	rs12787909	ENSG00000207185.1	RNU6-1157P	3.39	0.000714	0.033	0.22	0.1	Lipoprotein (a) - cholesterol levels;	chr11:117675767	chr11:118593988~118594093:+
BRCA	cis	rs13118159	0.509	rs7688922	ENSG00000211482.1	AC092574.1	3.39	0.000714	0.033	0.14	0.1	Longevity;	chr4:1367223	chr4:409809~409915:+
BRCA	cis	rs2562456	0.833	rs2928211	ENSG00000268119.4	CTD-2561J22.5	-3.39	0.000714	0.033	-0.16	-0.1	Pain;	chr19:21358495	chr19:21444241~21463908:-
BRCA	cis	rs13434995	0.589	rs496055	ENSG00000273257.1	RP11-177J6.1	-3.39	0.000714	0.033	-0.16	-0.1	Adiponectin levels;	chr4:55383670	chr4:55387949~55388271:+
BRCA	cis	rs792448	0.743	rs351377	ENSG00000226251.4	RP11-15I11.3	-3.39	0.000714	0.033	-0.13	-0.1	White blood cell count (basophil);	chr1:212252429	chr1:212225278~212238977:-
BRCA	cis	rs9990333	0.862	rs6806599	ENSG00000252620.1	RNU6ATAC24P	-3.39	0.000714	0.033	-0.11	-0.1	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196089280	chr3:195523087~195523221:-
BRCA	cis	rs3176789	0.515	rs7309875	ENSG00000256673.1	RP11-599J14.2	3.39	0.000714	0.033	0.12	0.1	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9768344	chr12:9398355~9414851:-
BRCA	cis	rs7520050	0.966	rs12405451	ENSG00000226957.1	RP4-533D7.4	3.39	0.000714	0.033	0.11	0.1	Reticulocyte count;Red blood cell count;	chr1:45918654	chr1:46046818~46048368:+
BRCA	cis	rs6840360	0.573	rs7692939	ENSG00000278978.1	RP11-164P12.5	-3.39	0.000714	0.033	-0.11	-0.1	Intelligence (multi-trait analysis);	chr4:151337303	chr4:151669786~151670503:+
BRCA	cis	rs6545883	0.929	rs6705235	ENSG00000273302.1	RP11-493E12.2	3.39	0.000714	0.033	0.1	0.1	Tuberculosis;	chr2:61486445	chr2:61199979~61200769:+
BRCA	cis	rs1800813	0.515	rs34148754	ENSG00000248494.1	LNX1-AS2	3.39	0.000714	0.033	0.16	0.1	Corneal curvature;	chr4:54190882	chr4:53592956~53604047:+
BRCA	cis	rs7103648	0.838	rs2293576	ENSG00000255520.1	RP11-390K5.3	-3.39	0.000714	0.033	-0.13	-0.1	Systolic blood pressure;Diastolic blood pressure;	chr11:47413435	chr11:47123104~47130801:-
BRCA	cis	rs4820803	1	rs4820803	ENSG00000226471.5	CTA-292E10.6	3.39	0.000714	0.033	0.15	0.1	Breast cancer;	chr22:29273659	chr22:28800683~28848559:+
BRCA	cis	rs13434995	0.513	rs62303681	ENSG00000273257.1	RP11-177J6.1	-3.39	0.000714	0.033	-0.16	-0.1	Adiponectin levels;	chr4:55403812	chr4:55387949~55388271:+
BRCA	cis	rs6012564	1	rs3092720	ENSG00000230758.1	SNAP23P	-3.39	0.000714	0.0331	-0.12	-0.1	Anger;	chr20:49023929	chr20:49038357~49038602:-
BRCA	cis	rs17123764	0.818	rs2303305	ENSG00000257464.1	RP11-161H23.8	3.39	0.000714	0.0331	0.18	0.1	Intelligence (multi-trait analysis);	chr12:49558885	chr12:49442424~49442652:-
BRCA	cis	rs6142102	0.886	rs4911147	ENSG00000206582.1	Y_RNA	-3.39	0.000714	0.0331	-0.13	-0.1	Skin pigmentation;	chr20:34079801	chr20:34526510~34526606:-
BRCA	cis	rs2803122	0.936	rs10117865	ENSG00000272842.1	RP11-513M16.7	-3.39	0.000715	0.0331	-0.11	-0.1	Pulse pressure;	chr9:19314433	chr9:19371386~19371945:-
BRCA	cis	rs6600671	0.967	rs4844613	ENSG00000270231.3	NBPF8P	3.39	0.000715	0.0331	0.11	0.1	Hip geometry;	chr1:121431913	chr1:120436353~120467739:+
BRCA	cis	rs812925	0.519	rs2463099	ENSG00000273302.1	RP11-493E12.2	-3.39	0.000715	0.0331	-0.09	-0.1	Immature fraction of reticulocytes;	chr2:61391176	chr2:61199979~61200769:+
BRCA	cis	rs2836974	0.666	rs4818015	ENSG00000238141.2	BRWD1-AS1	3.39	0.000715	0.0331	0.12	0.1	Cognitive function;	chr21:39303567	chr21:39315707~39323218:+
BRCA	cis	rs9584850	0.834	rs3803253	ENSG00000231194.1	FARP1-AS1	3.39	0.000715	0.0331	0.14	0.1	Neuroticism;	chr13:98464895	chr13:98435405~98435840:-
BRCA	cis	rs74665712	0.515	rs4532498	ENSG00000232400.1	RAD17P1	3.39	0.000715	0.0331	0.11	0.1	Residual cognition;	chr7:16917605	chr7:16864267~16866308:-
BRCA	cis	rs9467773	1	rs1321480	ENSG00000224843.5	LINC00240	-3.39	0.000715	0.0331	-0.12	-0.1	Intelligence (multi-trait analysis);	chr6:26532514	chr6:26956992~27023924:+
BRCA	cis	rs886774	0.774	rs4564	ENSG00000273055.1	CTB-13F3.1	-3.39	0.000715	0.0331	-0.11	-0.1	Ulcerative colitis;	chr7:107919466	chr7:107942116~107942740:+
BRCA	cis	rs4835473	0.897	rs34380794	ENSG00000246448.2	RP13-578N3.3	-3.39	0.000715	0.0331	-0.12	-0.1	Immature fraction of reticulocytes;	chr4:143735800	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.75	rs56372690	ENSG00000246448.2	RP13-578N3.3	-3.39	0.000715	0.0331	-0.12	-0.1	Immature fraction of reticulocytes;	chr4:143735816	chr4:143700257~143865072:+
BRCA	cis	rs17655565	1	rs76413558	ENSG00000257830.1	RP11-845M18.7	3.39	0.000715	0.0331	0.19	0.1	Plasma amyloid beta peptide concentrations (ABx-42);	chr12:52300372	chr12:52274647~52279156:-
BRCA	cis	rs2108225	0.837	rs7810937	ENSG00000231006.1	RPL7P32	-3.39	0.000715	0.0331	-0.1	-0.1	Ulcerative colitis;	chr7:107807055	chr7:108510233~108510976:+
BRCA	cis	rs8040855	0.627	rs11637512	ENSG00000229212.6	RP11-561C5.4	-3.39	0.000715	0.0331	-0.14	-0.1	Bulimia nervosa;	chr15:85105528	chr15:85205440~85234795:-
BRCA	cis	rs7020830	0.861	rs13295981	ENSG00000260100.1	RP11-220I1.5	-3.39	0.000715	0.0331	-0.13	-0.1	Schizophrenia;	chr9:37330070	chr9:37078813~37079776:-
BRCA	cis	rs17741049	0.737	rs59712590	ENSG00000260493.1	RP11-219B4.7	-3.39	0.000715	0.0331	-0.24	-0.1	Blood protein levels;	chr8:85262702	chr8:85172077~85177062:-
BRCA	cis	rs7636839	0.504	rs28632188	ENSG00000236182.1	RP11-297K7.1	-3.39	0.000716	0.0331	-0.12	-0.1	EGFR mutation-positive lung adenocarcinoma;	chr3:189620050	chr3:188989382~188990135:-
BRCA	cis	rs7267979	1	rs2258769	ENSG00000274414.1	RP5-965G21.4	-3.39	0.000716	0.0331	-0.12	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25296044	chr20:25239007~25245229:-
BRCA	cis	rs4714291	0.963	rs1721409	ENSG00000180211.5	RP1-278E11.3	3.39	0.000716	0.0331	0.11	0.1	Strep throat;	chr6:40144700	chr6:39958414~39958833:-
BRCA	cis	rs10819083	0.691	rs6478712	ENSG00000232630.1	PRPS1P2	-3.39	0.000716	0.0331	-0.1	-0.1	Squamous cell lung carcinoma;	chr9:125752329	chr9:125150653~125151589:+
BRCA	cis	rs6840360	0.571	rs1473305	ENSG00000278978.1	RP11-164P12.5	-3.39	0.000716	0.0331	-0.12	-0.1	Intelligence (multi-trait analysis);	chr4:151590569	chr4:151669786~151670503:+
BRCA	cis	rs6840360	0.571	rs62329101	ENSG00000278978.1	RP11-164P12.5	-3.39	0.000716	0.0331	-0.12	-0.1	Intelligence (multi-trait analysis);	chr4:151591087	chr4:151669786~151670503:+
BRCA	cis	rs6840360	0.571	rs4696100	ENSG00000278978.1	RP11-164P12.5	-3.39	0.000716	0.0331	-0.12	-0.1	Intelligence (multi-trait analysis);	chr4:151593090	chr4:151669786~151670503:+
BRCA	cis	rs17228212	1	rs11630297	ENSG00000270964.1	RP11-502I4.3	-3.39	0.000716	0.0331	-0.14	-0.1	Coronary heart disease;	chr15:67151626	chr15:67541072~67542604:-
BRCA	cis	rs9341808	0.718	rs3805922	ENSG00000279022.1	RP11-250B2.4	3.39	0.000716	0.0331	0.12	0.1	Sitting height ratio;	chr6:80182272	chr6:80440730~80441172:+
BRCA	cis	rs4243971	0.516	rs6141689	ENSG00000277692.1	RP11-358N2.2	-3.39	0.000716	0.0331	-0.12	-0.1	Inflammatory bowel disease;Crohn's disease;	chr20:32363324	chr20:32355053~32355734:+
BRCA	cis	rs67073037	0.955	rs11695230	ENSG00000230730.1	AC074011.2	-3.39	0.000716	0.0331	-0.13	-0.1	Breast cancer;Breast cancer (estrogen-receptor negative);	chr2:28907274	chr2:28633282~28664540:-
BRCA	cis	rs8098244	0.516	rs2960586	ENSG00000265752.2	RP11-403A21.1	3.39	0.000716	0.0331	0.11	0.1	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23690207	chr18:23957754~23982556:-
BRCA	cis	rs6840360	0.571	rs11723395	ENSG00000278978.1	RP11-164P12.5	-3.39	0.000716	0.0331	-0.12	-0.1	Intelligence (multi-trait analysis);	chr4:151603039	chr4:151669786~151670503:+
BRCA	cis	rs1555322	1	rs2425031	ENSG00000269202.1	RP4-614O4.12	-3.39	0.000716	0.0331	-0.15	-0.1	Attention deficit hyperactivity disorder;	chr20:35267481	chr20:35201747~35203288:-
BRCA	cis	rs826838	0.616	rs9668847	ENSG00000257718.1	RP11-396F22.1	3.39	0.000716	0.0331	0.1	0.1	Heart rate;	chr12:38220867	chr12:38906451~38909592:+
BRCA	cis	rs826838	0.616	rs4619214	ENSG00000257718.1	RP11-396F22.1	3.39	0.000716	0.0331	0.1	0.1	Heart rate;	chr12:38220902	chr12:38906451~38909592:+
BRCA	cis	rs826838	0.616	rs4418873	ENSG00000257718.1	RP11-396F22.1	3.39	0.000716	0.0331	0.1	0.1	Heart rate;	chr12:38231671	chr12:38906451~38909592:+
BRCA	cis	rs2277027	1	rs1422795	ENSG00000251405.2	CTB-109A12.1	-3.39	0.000716	0.0331	-0.14	-0.1	Pulmonary function;Pulmonary function (smoking interaction);	chr5:157509356	chr5:157362615~157460078:-
BRCA	cis	rs970548	0.69	rs1982796	ENSG00000237840.5	FAM21FP	3.39	0.000716	0.0331	0.13	0.1	Total cholesterol levels;HDL cholesterol;HDL cholesterol levels;Cholesterol, total;	chr10:45547125	chr10:45706431~45727231:-
BRCA	cis	rs2880765	0.835	rs4842886	ENSG00000230373.7	GOLGA6L5P	3.39	0.000716	0.0331	0.11	0.1	Coronary artery disease;	chr15:85492542	chr15:84507885~84516814:-
BRCA	cis	rs2400749	0.712	rs56362111	ENSG00000258521.1	RP11-638I2.9	3.39	0.000717	0.0331	0.1	0.1	Alzheimer's disease (survival time);	chr14:99564075	chr14:100339832~100340554:+
BRCA	cis	rs11233413	1	rs2127361	ENSG00000255503.1	RP11-113K21.4	-3.39	0.000717	0.0331	-0.12	-0.1	Economic and political preferences (feminism/equality);	chr11:83005476	chr11:83072402~83097196:-
BRCA	cis	rs3847687	1	rs78233646	ENSG00000250208.5	FZD10-AS1	3.39	0.000717	0.0331	0.13	0.1	Longevity;	chr12:131035625	chr12:130144315~130162256:-
BRCA	cis	rs7246657	0.941	rs67293224	ENSG00000267470.4	ZNF571-AS1	3.39	0.000717	0.0331	0.15	0.1	Coronary artery calcification;	chr19:37312346	chr19:37548914~37587348:+
BRCA	cis	rs7260598	0.535	rs13343732	ENSG00000268442.1	CTD-2027I19.2	3.39	0.000717	0.0331	0.15	0.1	Response to taxane treatment (placlitaxel);	chr19:23928479	chr19:24162370~24163425:-
BRCA	cis	rs2243480	1	rs7456042	ENSG00000226767.1	RP11-328P23.3	-3.39	0.000717	0.0331	-0.18	-0.1	Diabetic kidney disease;	chr7:65834791	chr7:65508773~65508944:-
BRCA	cis	rs2243480	1	rs73142121	ENSG00000226767.1	RP11-328P23.3	-3.39	0.000717	0.0331	-0.18	-0.1	Diabetic kidney disease;	chr7:65846219	chr7:65508773~65508944:-
BRCA	cis	rs2243480	1	rs34702770	ENSG00000226767.1	RP11-328P23.3	-3.39	0.000717	0.0331	-0.18	-0.1	Diabetic kidney disease;	chr7:65879836	chr7:65508773~65508944:-
BRCA	cis	rs2243480	1	rs34637256	ENSG00000226767.1	RP11-328P23.3	-3.39	0.000717	0.0331	-0.18	-0.1	Diabetic kidney disease;	chr7:65895144	chr7:65508773~65508944:-
BRCA	cis	rs35146811	0.735	rs2528900	ENSG00000214313.7	AZGP1P1	-3.39	0.000717	0.0331	-0.11	-0.1	Coronary artery disease;	chr7:100207696	chr7:99980762~99987535:+
BRCA	cis	rs4927850	0.752	rs7618864	ENSG00000271662.1	RP11-141C7.3	-3.39	0.000717	0.0332	-0.13	-0.1	Pancreatic cancer;	chr3:196022690	chr3:195650146~195651472:-
BRCA	cis	rs806321	0.534	rs1269278	ENSG00000237152.3	DLEU7-AS1	3.39	0.000717	0.0332	0.13	0.1	Multiple sclerosis;	chr13:50318177	chr13:50807856~50849905:+
BRCA	cis	rs875971	0.825	rs66981195	ENSG00000223473.2	GS1-124K5.3	-3.39	0.000717	0.0332	-0.08	-0.1	Aortic root size;	chr7:66614048	chr7:66491049~66493566:-
BRCA	cis	rs875971	0.862	rs3926380	ENSG00000223473.2	GS1-124K5.3	-3.39	0.000717	0.0332	-0.08	-0.1	Aortic root size;	chr7:66615658	chr7:66491049~66493566:-
BRCA	cis	rs875971	0.825	rs1860472	ENSG00000223473.2	GS1-124K5.3	-3.39	0.000717	0.0332	-0.08	-0.1	Aortic root size;	chr7:66617736	chr7:66491049~66493566:-
BRCA	cis	rs12612435	0.64	rs4954607	ENSG00000226806.1	AC011893.3	-3.39	0.000717	0.0332	-0.12	-0.1	Takotsubo syndrome;	chr2:136378112	chr2:135820191~135823087:+
BRCA	cis	rs2692947	0.537	rs12478605	ENSG00000237510.6	AC008268.2	3.39	0.000717	0.0332	0.15	0.1	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95711330	chr2:95789654~95800166:+
BRCA	cis	rs4927850	1	rs10881563	ENSG00000185485.13	SDHAP1	3.39	0.000717	0.0332	0.11	0.1	Pancreatic cancer;	chr3:196023354	chr3:195959748~195990318:-
BRCA	cis	rs7119	0.7	rs57471224	ENSG00000259362.2	RP11-307C19.1	3.39	0.000717	0.0332	0.13	0.1	Type 2 diabetes;	chr15:77595827	chr15:77525540~77534110:+
BRCA	cis	rs10504130	0.569	rs11775611	ENSG00000272076.1	RP11-11C20.3	3.39	0.000717	0.0332	0.15	0.1	Venous thromboembolism (SNP x SNP interaction);	chr8:51907714	chr8:51810110~51810681:-
BRCA	cis	rs6120849	0.615	rs11167248	ENSG00000276073.1	RP5-1125A11.7	-3.39	0.000717	0.0332	-0.15	-0.1	Protein C levels;	chr20:34950918	chr20:33985617~33988989:-
BRCA	cis	rs1178127	0.765	rs1178129	ENSG00000232821.1	AC003986.6	3.39	0.000718	0.0332	0.15	0.1	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);	chr7:18728711	chr7:19112474~19114271:+
BRCA	cis	rs6432852	0.966	rs10211165	ENSG00000232411.1	AC009495.3	3.39	0.000718	0.0332	0.12	0.1	Diabetic kidney disease;	chr2:165897158	chr2:165833048~165839098:-
BRCA	cis	rs7660883	0.897	rs342467	ENSG00000251411.1	RP11-397E7.4	-3.39	0.000718	0.0332	-0.11	-0.1	HDL cholesterol levels;	chr4:87131067	chr4:86913266~86914817:-
BRCA	cis	rs1865760	1	rs3799371	ENSG00000272810.1	U91328.22	3.39	0.000718	0.0332	0.12	0.1	Height;	chr6:25912588	chr6:26013241~26013757:+
BRCA	cis	rs66887589	0.66	rs4833613	ENSG00000250950.1	RP11-33B1.3	3.39	0.000718	0.0332	0.12	0.1	Diastolic blood pressure;	chr4:119229001	chr4:119456350~119457277:+
BRCA	cis	rs12489946	0.818	rs12496949	ENSG00000239213.4	NCK1-AS1	-3.39	0.000718	0.0332	-0.16	-0.1	Initial pursuit acceleration;	chr3:137062947	chr3:136841726~136862054:-
BRCA	cis	rs3018712	0.505	rs7102308	ENSG00000251637.5	RP11-119D9.1	3.39	0.000718	0.0332	0.18	0.1	Total body bone mineral density;	chr11:68645762	chr11:67886477~67906350:+
BRCA	cis	rs4955793	0.579	rs77242698	ENSG00000260743.1	RP11-255C15.3	3.39	0.000718	0.0332	0.23	0.1	Post-traumatic stress disorder (asjusted for relatedness);	chr3:179137833	chr3:179340322~179341887:+
BRCA	cis	rs1820460	0.959	rs2193354	ENSG00000258136.1	RP11-864J10.4	3.39	0.000718	0.0332	0.11	0.1	Cognitive performance;	chr12:107303988	chr12:107736555~107759968:+
BRCA	cis	rs17209837	1	rs7802783	ENSG00000224046.1	AC005076.5	-3.39	0.000718	0.0332	-0.15	-0.1	Gallbladder cancer;	chr7:87501081	chr7:87151423~87152420:-
BRCA	cis	rs344364	0.518	rs1657129	ENSG00000219027.2	RPS3AP2	3.39	0.000718	0.0332	0.16	0.1	Glomerular filtration rate in chronic kidney disease;	chr16:1895825	chr16:1477830~1478583:+
BRCA	cis	rs344364	0.511	rs1742463	ENSG00000219027.2	RPS3AP2	3.39	0.000718	0.0332	0.16	0.1	Glomerular filtration rate in chronic kidney disease;	chr16:1896109	chr16:1477830~1478583:+
BRCA	cis	rs10514758	0.744	rs72947727	ENSG00000242880.1	RP11-190P13.2	3.39	0.000718	0.0332	0.25	0.1	Urate levels in obese individuals;	chr3:115170850	chr3:115251196~115285347:+
BRCA	cis	rs10819861	0.645	rs10819810	ENSG00000175611.10	LINC00476	3.39	0.000718	0.0332	0.11	0.1	Electrocardiographic traits;	chr9:96087629	chr9:95759231~95875977:-
BRCA	cis	rs17711722	0.74	rs7809991	ENSG00000232546.1	RP11-458F8.1	-3.39	0.000718	0.0332	-0.09	-0.1	Calcium levels;	chr7:65941231	chr7:66848496~66858136:+
BRCA	cis	rs1912124	1	rs950071	ENSG00000259343.4	TMC3-AS1	3.39	0.000718	0.0332	0.24	0.1	Peripheral arterial disease (traffic-related air pollution interaction);	chr15:81226479	chr15:81324377~81362037:+
BRCA	cis	rs2998286	0.862	rs2993981	ENSG00000237128.1	RP11-351M16.3	3.39	0.000718	0.0332	0.13	0.1	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28506552	chr10:28433008~28495813:-
BRCA	cis	rs2998286	0.862	rs2993982	ENSG00000237128.1	RP11-351M16.3	3.39	0.000718	0.0332	0.13	0.1	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28506559	chr10:28433008~28495813:-
BRCA	cis	rs12468226	1	rs75040639	ENSG00000272966.1	RP11-686O6.1	3.39	0.000718	0.0332	0.18	0.1	Urate levels;	chr2:202486973	chr2:202336739~202337200:+
BRCA	cis	rs12282928	0.67	rs4752810	ENSG00000255197.4	RP11-750H9.5	3.39	0.000718	0.0332	0.1	0.1	Migraine - clinic-based;	chr11:48202508	chr11:47383148~47409190:-
BRCA	cis	rs12282928	0.699	rs7940877	ENSG00000255197.4	RP11-750H9.5	3.39	0.000718	0.0332	0.1	0.1	Migraine - clinic-based;	chr11:48204128	chr11:47383148~47409190:-
BRCA	cis	rs12282928	0.67	rs7941311	ENSG00000255197.4	RP11-750H9.5	3.39	0.000718	0.0332	0.1	0.1	Migraine - clinic-based;	chr11:48204287	chr11:47383148~47409190:-
BRCA	cis	rs4372836	0.518	rs1128416	ENSG00000226833.4	AC097724.3	3.39	0.000718	0.0332	0.12	0.1	Body mass index;	chr2:28778825	chr2:28708953~28736205:-
BRCA	cis	rs4372836	0.543	rs6742291	ENSG00000226833.4	AC097724.3	3.39	0.000718	0.0332	0.12	0.1	Body mass index;	chr2:28784483	chr2:28708953~28736205:-
BRCA	cis	rs2243480	1	rs464895	ENSG00000226767.1	RP11-328P23.3	-3.39	0.000719	0.0332	-0.19	-0.1	Diabetic kidney disease;	chr7:66062119	chr7:65508773~65508944:-
BRCA	cis	rs829880	0.789	rs1096146	ENSG00000227825.4	SLC9A7P1	3.39	0.000719	0.0332	0.12	0.1	Colonoscopy-negative controls vs population controls;	chr12:98457188	chr12:98453835~98457145:-
BRCA	cis	rs35740288	0.539	rs11629991	ENSG00000259407.1	RP11-158M2.3	-3.39	0.000719	0.0332	-0.14	-0.1	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85793433	chr15:85744109~85750281:-
BRCA	cis	rs875971	0.522	rs10807697	ENSG00000232546.1	RP11-458F8.1	-3.39	0.000719	0.0332	-0.09	-0.1	Aortic root size;	chr7:65951183	chr7:66848496~66858136:+
BRCA	cis	rs4622329	0.636	rs4764836	ENSG00000257202.1	RP11-512N21.3	3.39	0.000719	0.0332	0.12	0.1	Systemic lupus erythematosus;	chr12:101893925	chr12:101923410~101924719:-
BRCA	cis	rs77741769	0.571	rs11065283	ENSG00000277423.1	RP11-173P15.9	-3.39	0.000719	0.0332	-0.12	-0.1	Mean corpuscular volume;	chr12:120828650	chr12:120703867~120704282:+
BRCA	cis	rs17209837	0.607	rs4148821	ENSG00000224046.1	AC005076.5	3.39	0.000719	0.0332	0.14	0.1	Gallbladder cancer;	chr7:87450286	chr7:87151423~87152420:-
BRCA	cis	rs4699052	1	rs7661702	ENSG00000230069.3	LRRC37A15P	-3.39	0.000719	0.0332	-0.1	-0.1	Testicular germ cell tumor;	chr4:103218972	chr4:102727274~102730721:-
BRCA	cis	rs2278170	0.962	rs11032359	ENSG00000225101.4	OR52K3P	-3.39	0.000719	0.0332	-0.14	-0.1	Amyotrophic lateral sclerosis;	chr11:4466621	chr11:4474813~4475755:+
BRCA	cis	rs7927592	0.956	rs7106259	ENSG00000254610.1	RP5-903G2.2	-3.39	0.000719	0.0332	-0.14	-0.1	Total body bone mineral density;	chr11:68531044	chr11:67934563~67939774:-
BRCA	cis	rs7656342	0.665	rs10939600	ENSG00000250342.1	SNRPCP16	3.39	0.000719	0.0332	0.12	0.1	Gut microbiota (bacterial taxa);	chr4:9885307	chr4:9051842~9052051:-
BRCA	cis	rs7267979	1	rs4815411	ENSG00000276952.1	RP5-965G21.6	-3.39	0.000719	0.0332	-0.13	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25369587	chr20:25284915~25285588:-
BRCA	cis	rs5752223	1	rs5752213	ENSG00000230637.2	CTA-246H3.8	3.39	0.000719	0.0332	0.28	0.1	Trans fatty acid levels;	chr22:25800741	chr22:25327252~25339975:+
BRCA	cis	rs7238033	1	rs2298718	ENSG00000267193.4	RP11-116O18.3	-3.39	0.000719	0.0332	-0.11	-0.1	Bladder cancer;	chr18:45736573	chr18:45669367~45747215:-
BRCA	cis	rs4805834	0.622	rs3746024	ENSG00000201388.1	SNORA68	3.39	0.000719	0.0332	0.15	0.1	Creatinine levels;	chr19:32826784	chr19:32608337~32608469:-
BRCA	cis	rs8031584	0.697	rs8036176	ENSG00000269930.1	RP11-932O9.9	-3.39	0.000719	0.0332	-0.13	-0.1	Huntington's disease progression;	chr15:30883066	chr15:30616958~30617749:+
BRCA	cis	rs2274273	0.967	rs10137409	ENSG00000233924.1	AL160471.6	-3.39	0.000719	0.0332	-0.12	-0.1	Protein biomarker;	chr14:55144723	chr14:55004813~55005687:-
BRCA	cis	rs7267979	1	rs2257420	ENSG00000274414.1	RP5-965G21.4	-3.39	0.000719	0.0332	-0.12	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25295254	chr20:25239007~25245229:-
BRCA	cis	rs12477438	0.52	rs6717723	ENSG00000231822.1	AC019097.7	3.39	0.000719	0.0332	0.11	0.1	Chronic sinus infection;	chr2:99140467	chr2:99102018~99102752:+
BRCA	cis	rs180730	0.752	rs6857653	ENSG00000251609.2	SETP12	3.39	0.000719	0.0332	0.18	0.1	Fasting plasma glucose;	chr4:120925764	chr4:120895494~120897083:-
BRCA	cis	rs9325144	0.541	rs7303395	ENSG00000257718.1	RP11-396F22.1	-3.39	0.000719	0.0332	-0.11	-0.1	Morning vs. evening chronotype;	chr12:38270322	chr12:38906451~38909592:+
BRCA	cis	rs9325144	0.56	rs6582561	ENSG00000257718.1	RP11-396F22.1	-3.39	0.000719	0.0332	-0.11	-0.1	Morning vs. evening chronotype;	chr12:38273019	chr12:38906451~38909592:+
BRCA	cis	rs755249	0.529	rs3768299	ENSG00000243970.1	PPIEL	3.39	0.000719	0.0332	0.15	0.1	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39391520	chr1:39531838~39558707:-
BRCA	cis	rs875971	0.755	rs10228885	ENSG00000106610.13	STAG3L4	3.39	0.000719	0.0332	0.14	0.1	Aortic root size;	chr7:66315542	chr7:67302621~67321526:+
BRCA	cis	rs62458065	0.85	rs7785999	ENSG00000281332.1	LINC00997	-3.39	0.00072	0.0332	-0.15	-0.1	Metabolite levels (HVA/MHPG ratio);	chr7:32421650	chr7:32760279~32762924:+
BRCA	cis	rs71520386	0.632	rs10269414	ENSG00000179428.2	AC073072.5	3.39	0.00072	0.0332	0.12	0.1	Fibrinogen levels;	chr7:22816674	chr7:22725395~22727620:-
BRCA	cis	rs71520386	0.632	rs2286500	ENSG00000179428.2	AC073072.5	3.39	0.00072	0.0332	0.12	0.1	Fibrinogen levels;	chr7:22817185	chr7:22725395~22727620:-
BRCA	cis	rs7824557	0.614	rs2736277	ENSG00000255020.1	AF131216.5	3.39	0.00072	0.0332	0.12	0.1	Retinal vascular caliber;	chr8:11361384	chr8:11345748~11347502:-
BRCA	cis	rs7662987	0.517	rs2924580	ENSG00000260641.1	RP11-1299A16.3	3.39	0.00072	0.0332	0.15	0.1	Smoking initiation;	chr4:99111017	chr4:98658904~98664550:+
BRCA	cis	rs9863	0.861	rs12317176	ENSG00000256596.1	RP11-522N14.2	3.39	0.00072	0.0333	0.14	0.1	White blood cell count;	chr12:123920171	chr12:124206228~124209018:+
BRCA	cis	rs465969	1	rs9400478	ENSG00000271789.1	RP5-1112D6.7	-3.39	0.00072	0.0333	-0.27	-0.1	Psoriasis;	chr6:111478441	chr6:111297126~111298510:+
BRCA	cis	rs1437396	0.565	rs2864830	ENSG00000203327.2	AC012358.7	3.39	0.00072	0.0333	0.11	0.1	Alcohol dependence;	chr2:55358828	chr2:55214387~55216126:-
BRCA	cis	rs11673344	0.503	rs1667370	ENSG00000276846.1	CTD-3220F14.3	3.39	0.00072	0.0333	0.12	0.1	Obesity-related traits;	chr19:36999318	chr19:37314868~37315620:-
BRCA	cis	rs1766786	0.925	rs1361207	ENSG00000231365.4	RP11-418J17.1	-3.39	0.00072	0.0333	-0.2	-0.1	Chin dimples;	chr1:118913608	chr1:119140396~119275973:+
BRCA	cis	rs34779708	0.931	rs4934724	ENSG00000269952.1	RP11-324I22.3	-3.39	0.00072	0.0333	-0.14	-0.1	Inflammatory bowel disease;Crohn's disease;	chr10:35104741	chr10:35210416~35210750:+
BRCA	cis	rs11587682	0.76	rs1011546	ENSG00000228126.1	FALEC	3.39	0.00072	0.0333	0.14	0.1	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr1:150443499	chr1:150515757~150518032:+
BRCA	cis	rs10129255	0.957	rs10142859	ENSG00000211958.2	IGHV3-38	3.39	0.00072	0.0333	0.08	0.1	Kawasaki disease;	chr14:106782238	chr14:106410493~106411021:-
BRCA	cis	rs61542988	0.797	rs4329182	ENSG00000226329.2	AC005682.6	3.39	0.00072	0.0333	0.11	0.1	Fibrinogen levels;	chr7:22843002	chr7:22863874~22881350:-
BRCA	cis	rs61542988	0.756	rs5013587	ENSG00000226329.2	AC005682.6	3.39	0.00072	0.0333	0.11	0.1	Fibrinogen levels;	chr7:22843041	chr7:22863874~22881350:-
BRCA	cis	rs7937127	0.696	rs56388058	ENSG00000254907.1	RP11-484D2.2	3.39	0.00072	0.0333	0.2	0.1	Fibrinogen levels;	chr11:43512927	chr11:43328748~43359296:-
BRCA	cis	rs13108904	0.875	rs1732099	ENSG00000211482.1	AC092574.1	-3.39	0.00072	0.0333	-0.12	-0.1	Obesity-related traits;	chr4:1288908	chr4:409809~409915:+
BRCA	cis	rs2559856	0.967	rs2695290	ENSG00000274560.1	RP11-285E23.2	-3.39	0.000721	0.0333	-0.11	-0.1	Blood protein levels;	chr12:101694066	chr12:101696002~101696450:-
BRCA	cis	rs7020830	0.823	rs7019699	ENSG00000230188.1	RP11-405L18.4	-3.39	0.000721	0.0333	-0.13	-0.1	Schizophrenia;	chr9:37125084	chr9:37490421~37490893:-
BRCA	cis	rs7020830	0.931	rs7027473	ENSG00000230188.1	RP11-405L18.4	-3.39	0.000721	0.0333	-0.13	-0.1	Schizophrenia;	chr9:37132465	chr9:37490421~37490893:-
BRCA	cis	rs6942407	0.546	rs2074757	ENSG00000224046.1	AC005076.5	-3.39	0.000721	0.0333	-0.15	-0.1	Food allergy;	chr7:87164805	chr7:87151423~87152420:-
BRCA	cis	rs875971	0.895	rs12531677	ENSG00000106610.13	STAG3L4	3.39	0.000721	0.0333	0.14	0.1	Aortic root size;	chr7:66304099	chr7:67302621~67321526:+
BRCA	cis	rs875971	0.862	rs7798630	ENSG00000106610.13	STAG3L4	3.39	0.000721	0.0333	0.14	0.1	Aortic root size;	chr7:66306492	chr7:67302621~67321526:+
BRCA	cis	rs11239930	0.517	rs493000	ENSG00000227242.3	NBPF13P	-3.39	0.000721	0.0333	-0.13	-0.1	AIDS progression;	chr1:147077979	chr1:147021320~147124525:-
BRCA	cis	rs4950322	0.57	rs17356184	ENSG00000227242.3	NBPF13P	-3.39	0.000721	0.0333	-0.15	-0.1	Protein quantitative trait loci;	chr1:147262943	chr1:147021320~147124525:-
BRCA	cis	rs4950322	0.57	rs4950392	ENSG00000227242.3	NBPF13P	-3.39	0.000721	0.0333	-0.15	-0.1	Protein quantitative trait loci;	chr1:147264889	chr1:147021320~147124525:-
BRCA	cis	rs9813712	0.953	rs7619208	ENSG00000228252.7	COL6A4P2	-3.39	0.000721	0.0333	-0.14	-0.1	Response to amphetamines;	chr3:130258163	chr3:130212823~130273806:+
BRCA	cis	rs960902	1	rs10204024	ENSG00000224891.1	AC007899.3	3.39	0.000721	0.0333	0.12	0.1	Response to TNF-alpha inhibitors in rheumatoid arthritis;	chr2:37504886	chr2:37148530~37149304:+
BRCA	cis	rs6545883	0.929	rs2593626	ENSG00000270820.4	RP11-355B11.2	3.39	0.000721	0.0333	0.12	0.1	Tuberculosis;	chr2:61438049	chr2:61471188~61484130:+
BRCA	cis	rs6545883	0.929	rs2592352	ENSG00000270820.4	RP11-355B11.2	3.39	0.000721	0.0333	0.12	0.1	Tuberculosis;	chr2:61438201	chr2:61471188~61484130:+
BRCA	cis	rs4805834	0.719	rs11670575	ENSG00000201388.1	SNORA68	3.39	0.000721	0.0333	0.17	0.1	Creatinine levels;	chr19:32840638	chr19:32608337~32608469:-
BRCA	cis	rs8030136	0.645	rs11853976	ENSG00000275529.1	SNORD116-4	3.39	0.000721	0.0333	0.14	0.1	Periodontitis (DPAL);	chr15:24745040	chr15:25059538~25059633:+
BRCA	cis	rs4865762	0.512	rs7707949	ENSG00000247796.2	CTD-2366F13.1	3.39	0.000721	0.0333	0.12	0.1	Intraocular pressure;	chr5:53216806	chr5:53109842~53115126:+
BRCA	cis	rs972578	0.765	rs4822208	ENSG00000230319.1	AL022476.2	3.39	0.000721	0.0333	0.11	0.1	Mean platelet volume;	chr22:42865217	chr22:43038585~43052366:+
BRCA	cis	rs8062405	0.54	rs151226	ENSG00000275441.1	RP11-666O2.2	3.39	0.000721	0.0333	0.09	0.1	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28538502	chr16:28553709~28554140:-
BRCA	cis	rs72647484	0.643	rs2807335	ENSG00000228397.1	RP1-224A6.3	-3.39	0.000721	0.0333	-0.28	-0.1	Colorectal cancer;	chr1:22247271	chr1:22023994~22024968:-
BRCA	cis	rs2400749	0.712	rs55977094	ENSG00000258521.1	RP11-638I2.9	3.39	0.000721	0.0333	0.1	0.1	Alzheimer's disease (survival time);	chr14:99564303	chr14:100339832~100340554:+
BRCA	cis	rs2400749	0.712	rs8016113	ENSG00000258521.1	RP11-638I2.9	-3.39	0.000721	0.0333	-0.1	-0.1	Alzheimer's disease (survival time);	chr14:99564216	chr14:100339832~100340554:+
BRCA	cis	rs7131987	0.565	rs7976667	ENSG00000273680.1	RP11-996F15.6	3.39	0.000722	0.0333	0.12	0.1	QT interval;	chr12:29273098	chr12:29332733~29333383:-
BRCA	cis	rs875971	0.862	rs6971059	ENSG00000223473.2	GS1-124K5.3	-3.39	0.000722	0.0333	-0.08	-0.1	Aortic root size;	chr7:66602045	chr7:66491049~66493566:-
BRCA	cis	rs4435363	0.624	rs2099362	ENSG00000268423.3	AC011551.3	3.39	0.000722	0.0333	0.15	0.1	Immature fraction of reticulocytes;P wave terminal force;	chr19:46565124	chr19:46547056~46600861:-
BRCA	cis	rs687432	0.887	rs11601663	ENSG00000213592.4	AP000662.9	-3.39	0.000722	0.0333	-0.15	-0.1	Parkinson's disease;	chr11:58005834	chr11:57718044~57718530:-
BRCA	cis	rs3764021	0.527	rs2114870	ENSG00000256594.6	RP11-705C15.2	3.39	0.000722	0.0333	0.14	0.1	Type 1 diabetes;	chr12:9670544	chr12:9633419~9658412:+
BRCA	cis	rs9392556	0.829	rs659025	ENSG00000230648.1	RP3-406P24.3	3.39	0.000722	0.0333	0.13	0.1	Blood metabolite levels;	chr6:4118817	chr6:4018843~4021215:-
BRCA	cis	rs1056107	0.933	rs10759546	ENSG00000266315.1	MIR4668	3.39	0.000722	0.0333	0.11	0.1	Colorectal cancer;	chr9:112260664	chr9:111932100~111932169:+
BRCA	cis	rs3760982	0.565	rs8104300	ENSG00000266921.1	RP11-15A1.7	-3.39	0.000722	0.0333	-0.13	-0.1	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43788992	chr19:43996896~44002836:-
BRCA	cis	rs11587682	0.806	rs12726415	ENSG00000228126.1	FALEC	3.39	0.000722	0.0333	0.14	0.1	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr1:150430137	chr1:150515757~150518032:+
BRCA	cis	rs1005277	0.579	rs1780116	ENSG00000276805.1	RP11-291L22.6	3.39	0.000722	0.0333	0.11	0.1	Extrinsic epigenetic age acceleration;	chr10:38237693	chr10:38451030~38451785:+
BRCA	cis	rs1005277	0.579	rs1780121	ENSG00000276805.1	RP11-291L22.6	3.39	0.000722	0.0333	0.11	0.1	Extrinsic epigenetic age acceleration;	chr10:38240509	chr10:38451030~38451785:+
BRCA	cis	rs10492096	1	rs11064218	ENSG00000276718.1	RP1-102E24.10	-3.39	0.000722	0.0333	-0.14	-0.1	Hip geometry;	chr12:6477095	chr12:6466537~6467135:+
BRCA	cis	rs1193	0.913	rs13297	ENSG00000266931.1	RP11-1252D15.1	-3.39	0.000722	0.0333	-0.12	-0.1	High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;High light scatter reticulocyte count;	chr2:86775583	chr2:87055658~87055800:-
BRCA	cis	rs736408	0.736	rs4687550	ENSG00000242142.1	SERBP1P3	3.39	0.000722	0.0333	0.12	0.1	Bipolar disorder;	chr3:52789414	chr3:53064283~53065091:-
BRCA	cis	rs7520050	0.778	rs3014218	ENSG00000281133.1	AL355480.3	3.39	0.000722	0.0333	0.12	0.1	Reticulocyte count;Red blood cell count;	chr1:45560656	chr1:45580892~45580996:-
BRCA	cis	rs12282928	0.7	rs10838817	ENSG00000255197.4	RP11-750H9.5	3.39	0.000722	0.0334	0.1	0.1	Migraine - clinic-based;	chr11:48178713	chr11:47383148~47409190:-
BRCA	cis	rs6582630	0.56	rs11504462	ENSG00000257718.1	RP11-396F22.1	-3.39	0.000722	0.0334	-0.11	-0.1	Drug-induced liver injury (flucloxacillin);	chr12:38046577	chr12:38906451~38909592:+
BRCA	cis	rs2380205	0.517	rs12360409	ENSG00000238266.1	LINC00707	-3.39	0.000722	0.0334	-0.11	-0.1	Breast cancer;	chr10:5933835	chr10:6779598~6842906:+
BRCA	cis	rs17711722	0.74	rs7809991	ENSG00000272831.1	RP11-792A8.4	3.39	0.000723	0.0334	0.09	0.1	Calcium levels;	chr7:65941231	chr7:66739829~66740385:-
BRCA	cis	rs10895275	0.961	rs17097547	ENSG00000277459.1	RP11-732A21.3	-3.39	0.000723	0.0334	-0.11	-0.1	Migraine;	chr11:102224158	chr11:102109827~102110457:-
BRCA	cis	rs9876781	0.507	rs1824362	ENSG00000199476.1	Y_RNA	3.39	0.000723	0.0334	0.13	0.1	Longevity;	chr3:48360459	chr3:48288587~48288694:+
BRCA	cis	rs2985684	0.894	rs8005990	ENSG00000258568.1	RHOQP1	3.39	0.000723	0.0334	0.13	0.1	Carotid intima media thickness;	chr14:49555530	chr14:49599994~49600572:+
BRCA	cis	rs7959452	0.59	rs7968629	ENSG00000274979.1	RP11-1143G9.5	-3.39	0.000723	0.0334	-0.11	-0.1	Blood protein levels;	chr12:69389077	chr12:69326574~69331882:-
BRCA	cis	rs11874712	0.899	rs11664764	ENSG00000251939.1	RNU6-1278P	-3.39	0.000723	0.0334	-0.11	-0.1	Migraine - clinic-based;	chr18:46095398	chr18:46121615~46121721:-
BRCA	cis	rs80168506	0.748	rs10168328	ENSG00000196096.3	AC079610.2	3.39	0.000723	0.0334	0.2	0.1	Selective IgA deficiency;	chr2:213180566	chr2:213276552~213284205:-
BRCA	cis	rs8040855	0.931	rs11855471	ENSG00000259774.1	RP11-182J1.13	-3.39	0.000723	0.0334	-0.12	-0.1	Bulimia nervosa;	chr15:85175976	chr15:84422618~84425882:+
BRCA	cis	rs10129255	0.833	rs61997797	ENSG00000253132.1	IGHV3-62	-3.39	0.000723	0.0334	-0.08	-0.1	Kawasaki disease;	chr14:106815190	chr14:106643142~106643585:-
BRCA	cis	rs258892	0.895	rs13181437	ENSG00000272525.1	RP11-79P5.9	-3.39	0.000723	0.0334	-0.13	-0.1	Small cell lung carcinoma;	chr5:72755830	chr5:73497550~73498293:-
BRCA	cis	rs2991971	0.934	rs11211129	ENSG00000281133.1	AL355480.3	3.39	0.000723	0.0334	0.12	0.1	High light scatter reticulocyte count;	chr1:45517408	chr1:45580892~45580996:-
BRCA	cis	rs2496589	0.929	rs9496637	ENSG00000217648.1	RP1-95L4.4	3.39	0.000723	0.0334	0.15	0.1	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);	chr6:143446149	chr6:143342246~143343383:+
BRCA	cis	rs1466788	1	rs10127539	ENSG00000224965.1	KCNC4-AS1	3.39	0.000723	0.0334	0.12	0.1	Blood metabolite levels;	chr1:110077495	chr1:110208834~110209987:-
BRCA	cis	rs6963495	0.818	rs711430	ENSG00000223886.3	RP11-251G23.2	3.39	0.000723	0.0334	0.14	0.1	Bipolar disorder (body mass index interaction);	chr7:105527522	chr7:105530209~105530671:+
BRCA	cis	rs6893300	0.922	rs62406187	ENSG00000225051.5	HMGB3P22	3.39	0.000723	0.0334	0.14	0.1	Resting heart rate;	chr5:179758685	chr5:179679032~179694768:+
BRCA	cis	rs10420951	0.617	rs8101992	ENSG00000243455.3	RPS18P13	-3.39	0.000723	0.0334	-0.16	-0.1	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr19:18503613	chr19:18048637~18049090:+
BRCA	cis	rs3924048	0.559	rs4075303	ENSG00000221340.1	RNU6ATAC18P	3.39	0.000723	0.0334	0.13	0.1	Optic cup area;	chr1:12566564	chr1:12569972~12570072:-
BRCA	cis	rs7914558	1	rs7896547	ENSG00000213277.3	MARCKSL1P1	3.39	0.000723	0.0334	0.12	0.1	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103107201	chr10:103175554~103176094:+
BRCA	cis	rs17192198	0.571	rs2030932	ENSG00000270344.2	RP11-734K2.4	3.39	0.000723	0.0334	0.11	0.1	Diastolic blood pressure;	chr12:89735885	chr12:89525654~89548005:+
BRCA	cis	rs962856	0.619	rs6714988	ENSG00000236605.1	AC023115.4	3.39	0.000723	0.0334	0.14	0.1	Pancreatic cancer;	chr2:67368657	chr2:67324627~67325304:+
BRCA	cis	rs2548724	0.716	rs10515326	ENSG00000175749.11	EIF3KP1	3.39	0.000723	0.0334	0.15	0.1	Type 2 diabetes;	chr5:102478044	chr5:103032376~103033031:+
BRCA	cis	rs2842992	0.915	rs2758350	ENSG00000207392.1	SNORA20	-3.39	0.000723	0.0334	-0.14	-0.1	Age-related macular degeneration (geographic atrophy);	chr6:159697024	chr6:159780250~159780381:-
BRCA	cis	rs4713118	0.869	rs6914924	ENSG00000219392.1	RP1-265C24.5	-3.39	0.000723	0.0334	-0.15	-0.1	Parkinson's disease;	chr6:27743751	chr6:28115628~28116551:+
BRCA	cis	rs9392556	0.829	rs643232	ENSG00000272248.1	RP3-406P24.4	3.39	0.000723	0.0334	0.13	0.1	Blood metabolite levels;	chr6:4122015	chr6:4018713~4019202:+
BRCA	cis	rs11035577	0.632	rs10837248	ENSG00000279675.1	RP11-454H19.2	-3.39	0.000723	0.0334	-0.16	-0.1	Temperament (bipolar disorder);	chr11:39761887	chr11:40107244~40112599:-
BRCA	cis	rs673253	0.557	rs34898652	ENSG00000229431.1	RP1-92O14.6	-3.39	0.000723	0.0334	-0.11	-0.1	Intelligence (multi-trait analysis);	chr1:43508420	chr1:43385113~43389155:+
BRCA	cis	rs7308116	0.967	rs7486294	ENSG00000274395.1	RP11-554D14.8	-3.39	0.000724	0.0334	-0.11	-0.1	Pelvic organ prolapse (moderate/severe);	chr12:107804248	chr12:107835541~107836555:-
BRCA	cis	rs3018066	0.831	rs6842919	ENSG00000249635.1	RP11-710F7.3	3.39	0.000724	0.0334	0.12	0.1	Cancer;	chr4:106037013	chr4:106003317~106022478:-
BRCA	cis	rs4835473	0.932	rs10030428	ENSG00000246448.2	RP13-578N3.3	3.39	0.000724	0.0334	0.12	0.1	Immature fraction of reticulocytes;	chr4:143762699	chr4:143700257~143865072:+
BRCA	cis	rs6545883	0.801	rs778142	ENSG00000273302.1	RP11-493E12.2	3.39	0.000724	0.0334	0.1	0.1	Tuberculosis;	chr2:61454293	chr2:61199979~61200769:+
BRCA	cis	rs7017914	0.934	rs6987313	ENSG00000246366.5	RP11-382J12.1	3.39	0.000724	0.0334	0.11	0.1	Bone mineral density;	chr8:70658754	chr8:70608577~70663279:+
BRCA	cis	rs7017914	0.902	rs35580034	ENSG00000246366.5	RP11-382J12.1	3.39	0.000724	0.0334	0.11	0.1	Bone mineral density;	chr8:70659838	chr8:70608577~70663279:+
BRCA	cis	rs11671005	0.779	rs3794971	ENSG00000265272.2	RN7SL693P	3.39	0.000724	0.0334	0.16	0.1	Mean platelet volume;	chr19:58474499	chr19:58490797~58491075:+
BRCA	cis	rs2638953	0.962	rs11049586	ENSG00000273989.1	RP11-425D17.2	-3.39	0.000724	0.0334	-0.16	-0.1	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28418028	chr12:28236227~28236828:+
BRCA	cis	rs2638953	0.962	rs11049588	ENSG00000273989.1	RP11-425D17.2	-3.39	0.000724	0.0334	-0.16	-0.1	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28418628	chr12:28236227~28236828:+
BRCA	cis	rs2638953	0.925	rs10843166	ENSG00000273989.1	RP11-425D17.2	-3.39	0.000724	0.0334	-0.16	-0.1	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28422811	chr12:28236227~28236828:+
BRCA	cis	rs4869313	0.668	rs2548522	ENSG00000248734.2	CTD-2260A17.1	-3.39	0.000724	0.0334	-0.11	-0.1	Pediatric autoimmune diseases;	chr5:96914753	chr5:96784777~96785999:+
BRCA	cis	rs6517329	0.649	rs11088338	ENSG00000231106.2	LINC01436	3.39	0.000724	0.0334	0.12	0.1	Schizophrenia;	chr21:36122719	chr21:36005338~36007838:+
BRCA	cis	rs9325144	0.56	rs7980635	ENSG00000257718.1	RP11-396F22.1	-3.39	0.000724	0.0334	-0.11	-0.1	Morning vs. evening chronotype;	chr12:38274553	chr12:38906451~38909592:+
BRCA	cis	rs72772090	0.539	rs72773942	ENSG00000272109.1	CTD-2260A17.3	3.39	0.000724	0.0334	0.2	0.1	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96787663	chr5:96804353~96806105:+
BRCA	cis	rs12724450	0.793	rs12735903	ENSG00000228126.1	FALEC	3.39	0.000724	0.0334	0.2	0.1	Blood protein levels;	chr1:150386609	chr1:150515757~150518032:+
BRCA	cis	rs36051895	0.622	rs10974952	ENSG00000236254.1	MTND4P14	-3.39	0.000724	0.0334	-0.13	-0.1	Pediatric autoimmune diseases;	chr9:5079828	chr9:5107937~5109290:+
BRCA	cis	rs372883	0.935	rs1153294	ENSG00000236056.1	GAPDHP14	-3.39	0.000724	0.0334	-0.11	-0.1	Pancreatic cancer;	chr21:29328775	chr21:29222321~29223257:+
BRCA	cis	rs2288327	0.673	rs35504893	ENSG00000270574.1	RP11-171I2.2	3.39	0.000724	0.0334	0.17	0.1	Atrial fibrillation;	chr2:178556567	chr2:178578790~178580906:+
BRCA	cis	rs2904967	1	rs630055	ENSG00000254614.2	AP003068.23	-3.39	0.000724	0.0334	-0.18	-0.1	Mean corpuscular volume;	chr11:65320062	chr11:65177606~65181834:-
BRCA	cis	rs1555133	0.92	rs4911235	ENSG00000275576.1	RP5-836N17.4	-3.39	0.000724	0.0334	-0.12	-0.1	Monocyte count;	chr20:32490803	chr20:32116171~32116629:+
BRCA	cis	rs7202877	0.61	rs4536500	ENSG00000261783.1	RP11-252K23.2	3.39	0.000724	0.0334	0.18	0.1	Type 1 diabetes;Type 2 diabetes;	chr16:75309299	chr16:75379818~75381260:-
BRCA	cis	rs10129255	0.536	rs6576201	ENSG00000232216.1	IGHV3-43	-3.39	0.000724	0.0334	-0.08	-0.1	Kawasaki disease;	chr14:106683696	chr14:106470264~106470800:-
BRCA	cis	rs9467711	0.659	rs34605993	ENSG00000241549.7	GUSBP2	3.39	0.000725	0.0334	0.23	0.1	Autism spectrum disorder or schizophrenia;	chr6:26454135	chr6:26871484~26956554:-
BRCA	cis	rs79387448	0.745	rs59694233	ENSG00000234389.1	AC007278.3	3.39	0.000725	0.0334	0.14	0.1	Gut microbiota (bacterial taxa);	chr2:102500062	chr2:102438713~102440475:+
BRCA	cis	rs1816752	0.87	rs8000215	ENSG00000273628.1	RP11-756A22.7	3.39	0.000725	0.0334	0.13	0.1	Obesity-related traits;	chr13:24435648	chr13:24933006~24936796:+
BRCA	cis	rs10043775	1	rs7727161	ENSG00000251330.3	CTD-2283N19.1	-3.39	0.000725	0.0334	-0.12	-0.1	Periodontal microbiota;	chr5:148452923	chr5:148430159~148430807:-
BRCA	cis	rs337100	0.546	rs589928	ENSG00000263432.2	RN7SL689P	-3.39	0.000725	0.0334	-0.13	-0.1	Pulse pressure;	chr5:123144623	chr5:123022487~123022783:-
BRCA	cis	rs10501293	1	rs6485394	ENSG00000252652.1	Y_RNA	3.39	0.000725	0.0334	0.13	0.1	Cognitive performance;	chr11:43058491	chr11:43331261~43331356:+
BRCA	cis	rs6142618	0.523	rs6141651	ENSG00000275576.1	RP5-836N17.4	-3.39	0.000725	0.0334	-0.12	-0.1	Inflammatory bowel disease;	chr20:32263518	chr20:32116171~32116629:+
BRCA	cis	rs2908197	0.737	rs6465097	ENSG00000205485.12	AC004980.7	3.39	0.000725	0.0334	0.11	0.1	3-hydroxypropylmercapturic acid levels in smokers;	chr7:76343597	chr7:76549360~76627982:+
BRCA	cis	rs2288327	0.818	rs2303539	ENSG00000271011.1	RP11-171I2.5	3.39	0.000725	0.0335	0.2	0.1	Atrial fibrillation;	chr2:178538866	chr2:178577103~178577622:+
BRCA	cis	rs6439153	0.933	rs6799008	ENSG00000242551.2	POU5F1P6	-3.39	0.000725	0.0335	-0.13	-0.1	Pneumococcal bacteremia;	chr3:128998544	chr3:128674735~128677005:-
BRCA	cis	rs4919669	0.668	rs10786700	ENSG00000226009.1	KCNIP2-AS1	3.39	0.000725	0.0335	0.18	0.1	Mean arterial pressure (long-term average);Systolic blood pressure (long-term average);	chr10:102627978	chr10:101819078~101828779:+
BRCA	cis	rs11587682	0.76	rs34906632	ENSG00000228126.1	FALEC	3.39	0.000725	0.0335	0.14	0.1	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr1:150440047	chr1:150515757~150518032:+
BRCA	cis	rs11587682	0.806	rs35322831	ENSG00000228126.1	FALEC	3.39	0.000725	0.0335	0.14	0.1	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr1:150440268	chr1:150515757~150518032:+
BRCA	cis	rs11587682	0.806	rs3862206	ENSG00000228126.1	FALEC	3.39	0.000725	0.0335	0.14	0.1	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr1:150443155	chr1:150515757~150518032:+
BRCA	cis	rs56281245	0.793	rs115474497	ENSG00000249363.1	CTB-78O21.1	3.39	0.000725	0.0335	0.21	0.1	Hepcidin levels;	chr5:145647180	chr5:145728360~145729349:-
BRCA	cis	rs56281245	0.793	rs116041479	ENSG00000249363.1	CTB-78O21.1	3.39	0.000725	0.0335	0.21	0.1	Hepcidin levels;	chr5:145647330	chr5:145728360~145729349:-
BRCA	cis	rs56281245	0.793	rs79899757	ENSG00000249363.1	CTB-78O21.1	3.39	0.000725	0.0335	0.21	0.1	Hepcidin levels;	chr5:145650043	chr5:145728360~145729349:-
BRCA	cis	rs360932	0.734	rs360928	ENSG00000270265.1	RP11-731D1.4	3.39	0.000725	0.0335	0.12	0.1	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr4:151986429	chr4:151333775~151353224:-
BRCA	cis	rs613391	0.522	rs1667083	ENSG00000265194.1	RP11-70L8.4	-3.39	0.000725	0.0335	-0.11	-0.1	Quantitative traits;	chr9:22730548	chr9:21858910~21861926:-
BRCA	cis	rs613391	0.522	rs1470616	ENSG00000265194.1	RP11-70L8.4	-3.39	0.000725	0.0335	-0.11	-0.1	Quantitative traits;	chr9:22730733	chr9:21858910~21861926:-
BRCA	cis	rs344364	0.511	rs2982446	ENSG00000219027.2	RPS3AP2	3.39	0.000725	0.0335	0.16	0.1	Glomerular filtration rate in chronic kidney disease;	chr16:1897152	chr16:1477830~1478583:+
BRCA	cis	rs7474896	1	rs2753878	ENSG00000120555.12	SEPT7P9	-3.39	0.000725	0.0335	-0.18	-0.1	Obesity (extreme);	chr10:37882576	chr10:38383069~38402916:-
BRCA	cis	rs7474896	1	rs2738223	ENSG00000120555.12	SEPT7P9	-3.39	0.000725	0.0335	-0.18	-0.1	Obesity (extreme);	chr10:37896970	chr10:38383069~38402916:-
BRCA	cis	rs2357982	0.556	rs7568166	ENSG00000227403.1	AC009299.3	-3.39	0.000725	0.0335	-0.18	-0.1	Presence of antiphospholipid antibodies;	chr2:161033481	chr2:161244739~161249050:+
BRCA	cis	rs875971	0.825	rs66981195	ENSG00000271064.1	RP11-792A8.3	3.39	0.000725	0.0335	0.12	0.1	Aortic root size;	chr7:66614048	chr7:66748838~66749077:-
BRCA	cis	rs875971	0.862	rs3926380	ENSG00000271064.1	RP11-792A8.3	3.39	0.000725	0.0335	0.12	0.1	Aortic root size;	chr7:66615658	chr7:66748838~66749077:-
BRCA	cis	rs875971	0.825	rs1860472	ENSG00000271064.1	RP11-792A8.3	3.39	0.000725	0.0335	0.12	0.1	Aortic root size;	chr7:66617736	chr7:66748838~66749077:-
BRCA	cis	rs7267979	1	rs6050598	ENSG00000274414.1	RP5-965G21.4	-3.39	0.000726	0.0335	-0.12	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25416621	chr20:25239007~25245229:-
BRCA	cis	rs10129255	0.828	rs10140989	ENSG00000211959.2	IGHV4-39	3.39	0.000726	0.0335	0.08	0.1	Kawasaki disease;	chr14:106668657	chr14:106421711~106422218:-
BRCA	cis	rs11110077	0.545	rs7306985	ENSG00000238105.6	GOLGA2P5	3.39	0.000726	0.0335	0.13	0.1	Response to antipsychotic treatment in schizophrenia (working memory);	chr12:100006857	chr12:100156357~100173659:-
BRCA	cis	rs9467773	0.62	rs3800303	ENSG00000261353.1	CTA-14H9.5	-3.39	0.000726	0.0335	-0.1	-0.1	Intelligence (multi-trait analysis);	chr6:26597960	chr6:26527063~26527404:+
BRCA	cis	rs4631830	0.965	rs4306255	ENSG00000204177.9	BMS1P1	-3.39	0.000726	0.0335	-0.1	-0.1	Prostate-specific antigen levels;	chr10:46053378	chr10:46786674~46811989:+
BRCA	cis	rs6121246	0.909	rs6089070	ENSG00000230613.1	HM13-AS1	-3.39	0.000726	0.0335	-0.17	-0.1	Mean corpuscular hemoglobin;	chr20:31789970	chr20:31567707~31573263:-
BRCA	cis	rs7487075	0.859	rs7968173	ENSG00000257261.4	RP11-96H19.1	-3.39	0.000726	0.0335	-0.12	-0.1	Itch intensity from mosquito bite;	chr12:46365234	chr12:46383679~46876159:+
BRCA	cis	rs7474896	0.778	rs12571785	ENSG00000120555.12	SEPT7P9	3.39	0.000726	0.0335	0.2	0.1	Obesity (extreme);	chr10:37922471	chr10:38383069~38402916:-
BRCA	cis	rs7474896	0.725	rs11011405	ENSG00000120555.12	SEPT7P9	3.39	0.000726	0.0335	0.2	0.1	Obesity (extreme);	chr10:37926673	chr10:38383069~38402916:-
BRCA	cis	rs2337406	1	rs1961901	ENSG00000280411.1	IGHV1-69-2	-3.39	0.000726	0.0335	-0.09	-0.1	Alzheimer's disease (late onset);	chr14:106680856	chr14:106762092~106762588:-
BRCA	cis	rs2348114	0.609	rs7584595	ENSG00000238829.1	RNU7-45P	3.39	0.000726	0.0335	0.19	0.1	Intelligence;	chr2:200727928	chr2:201141904~201141966:+
BRCA	cis	rs1348850	0.914	rs10170667	ENSG00000280374.1	RP11-337N6.3	3.39	0.000726	0.0335	0.14	0.1	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177472150	chr2:177317715~177318471:-
BRCA	cis	rs7017914	0.967	rs1477944	ENSG00000246366.5	RP11-382J12.1	3.39	0.000726	0.0335	0.11	0.1	Bone mineral density;	chr8:70703365	chr8:70608577~70663279:+
BRCA	cis	rs7017914	0.967	rs17760497	ENSG00000246366.5	RP11-382J12.1	3.39	0.000726	0.0335	0.11	0.1	Bone mineral density;	chr8:70704810	chr8:70608577~70663279:+
BRCA	cis	rs4648045	0.765	rs3774967	ENSG00000251288.2	RP11-10L12.2	-3.39	0.000726	0.0335	-0.13	-0.1	Lymphocyte percentage of white cells;	chr4:102604774	chr4:102751401~102752641:+
BRCA	cis	rs10129255	0.957	rs11847726	ENSG00000253132.1	IGHV3-62	-3.39	0.000726	0.0335	-0.08	-0.1	Kawasaki disease;	chr14:106779116	chr14:106643142~106643585:-
BRCA	cis	rs6939532	0.522	rs13218591	ENSG00000124549.13	BTN2A3P	-3.39	0.000726	0.0335	-0.11	-0.1	Autism spectrum disorder or schizophrenia;	chr6:26376604	chr6:26421391~26432383:+
BRCA	cis	rs4148883	0.737	rs13148577	ENSG00000272777.1	RP11-571L19.8	-3.39	0.000726	0.0335	-0.11	-0.1	Alcohol dependence;	chr4:99139685	chr4:99067256~99068125:-
BRCA	cis	rs11662586	1	rs12605316	ENSG00000278000.1	AC139100.4	-3.39	0.000726	0.0335	-0.13	-0.1	Exploratory eye movement dysfunction in schizophrenia (responsive search score);	chr18:79933600	chr18:80161752~80162413:+
BRCA	cis	rs3799379	0.53	rs10456045	ENSG00000124549.13	BTN2A3P	3.39	0.000726	0.0335	0.12	0.1	Intelligence (multi-trait analysis);	chr6:26404730	chr6:26421391~26432383:+
BRCA	cis	rs9843304	0.616	rs34783865	ENSG00000244503.1	RP11-278L15.6	3.39	0.000726	0.0335	0.14	0.1	Gallstone disease;	chr3:149488005	chr3:149494660~149495995:+
BRCA	cis	rs2276314	0.857	rs6507158	ENSG00000267627.4	RP11-905K4.1	-3.39	0.000726	0.0335	-0.13	-0.1	Endometriosis;Drug-induced torsades de pointes;	chr18:36056103	chr18:35951803~35966118:-
BRCA	cis	rs2692947	0.77	rs2579552	ENSG00000232931.4	LINC00342	3.39	0.000726	0.0335	0.12	0.1	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96071335	chr2:95807118~95816215:-
BRCA	cis	rs830124	0.866	rs4760099	ENSG00000272849.1	RP11-347I19.8	-3.39	0.000726	0.0335	-0.11	-0.1	Urinary metabolites;	chr12:121880817	chr12:121797511~121801972:+
BRCA	cis	rs7246657	1	rs12709812	ENSG00000267470.4	ZNF571-AS1	-3.39	0.000726	0.0335	-0.14	-0.1	Coronary artery calcification;	chr19:37303948	chr19:37548914~37587348:+
BRCA	cis	rs1178127	0.682	rs727851	ENSG00000232821.1	AC003986.6	3.39	0.000726	0.0335	0.14	0.1	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);	chr7:18747194	chr7:19112474~19114271:+
BRCA	cis	rs875971	0.929	rs778712	ENSG00000273024.4	INTS4P2	-3.39	0.000727	0.0335	-0.11	-0.1	Aortic root size;	chr7:66384991	chr7:65647864~65715661:+
BRCA	cis	rs7487075	0.859	rs7968283	ENSG00000274723.1	RP11-618L22.1	3.39	0.000727	0.0335	0.13	0.1	Itch intensity from mosquito bite;	chr12:46365353	chr12:46970504~46972155:+
BRCA	cis	rs2617170	0.883	rs1351111	ENSG00000245648.1	RP11-277P12.20	3.39	0.000727	0.0335	0.14	0.1	Behcet's disease;	chr12:10402849	chr12:10363769~10398506:+
BRCA	cis	rs10484434	0.901	rs1800758	ENSG00000272810.1	U91328.22	3.39	0.000727	0.0335	0.17	0.1	HIV-1 viral setpoint;	chr6:26093008	chr6:26013241~26013757:+
BRCA	cis	rs9921338	0.961	rs9937269	ENSG00000263080.1	RP11-485G7.5	-3.39	0.000727	0.0335	-0.15	-0.1	Vein graft stenosis in coronary artery bypass grafting;	chr16:11322822	chr16:11341809~11345211:-
BRCA	cis	rs8114671	0.562	rs6088635	ENSG00000261582.1	RP4-614O4.11	-3.39	0.000727	0.0335	-0.1	-0.1	Height;	chr20:34878698	chr20:35267885~35280043:-
BRCA	cis	rs7149337	1	rs8006432	ENSG00000258955.1	LINC00519	-3.39	0.000727	0.0335	-0.11	-0.1	Cancer;	chr14:51264588	chr14:51304416~51328386:-
BRCA	cis	rs10877839	0.618	rs1901240	ENSG00000257354.2	RP11-631N16.2	-3.39	0.000727	0.0335	-0.09	-0.1	IgG glycosylation;	chr12:62397325	chr12:62602752~62622213:+
BRCA	cis	rs488400	0.558	rs361163	ENSG00000278978.1	RP11-164P12.5	3.39	0.000727	0.0335	0.13	0.1	Trans fatty acid levels;	chr4:151878731	chr4:151669786~151670503:+
BRCA	cis	rs8040855	0.658	rs12909111	ENSG00000229212.6	RP11-561C5.4	-3.39	0.000727	0.0335	-0.13	-0.1	Bulimia nervosa;	chr15:85061095	chr15:85205440~85234795:-
BRCA	cis	rs6840360	0.593	rs1429559	ENSG00000270265.1	RP11-731D1.4	-3.39	0.000727	0.0335	-0.12	-0.1	Intelligence (multi-trait analysis);	chr4:151760800	chr4:151333775~151353224:-
BRCA	cis	rs6840360	0.593	rs1366907	ENSG00000270265.1	RP11-731D1.4	-3.39	0.000727	0.0335	-0.12	-0.1	Intelligence (multi-trait analysis);	chr4:151761597	chr4:151333775~151353224:-
BRCA	cis	rs17756712	0.725	rs998777	ENSG00000272463.1	RP11-532F6.3	3.39	0.000727	0.0335	0.18	0.1	Vertical cup-disc ratio;	chr6:610431	chr6:708592~711405:-
BRCA	cis	rs1056107	0.933	rs10981350	ENSG00000266315.1	MIR4668	3.39	0.000727	0.0335	0.11	0.1	Colorectal cancer;	chr9:112304611	chr9:111932100~111932169:+
BRCA	cis	rs11098499	0.863	rs12498539	ENSG00000260404.2	RP11-384K6.6	3.39	0.000727	0.0335	0.1	0.1	Corneal astigmatism;	chr4:119547215	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.863	rs3822194	ENSG00000260404.2	RP11-384K6.6	3.39	0.000727	0.0335	0.1	0.1	Corneal astigmatism;	chr4:119550493	chr4:118591773~118633729:+
BRCA	cis	rs12681366	0.708	rs2470718	ENSG00000253175.1	RP11-267M23.6	-3.39	0.000727	0.0335	-0.11	-0.1	Nonsyndromic cleft lip with cleft palate;	chr8:94346849	chr8:94565036~94565715:+
BRCA	cis	rs875971	0.964	rs778735	ENSG00000230189.5	GS1-124K5.2	3.39	0.000727	0.0335	0.08	0.1	Aortic root size;	chr7:66349822	chr7:66409143~66490059:-
BRCA	cis	rs6490294	0.528	rs12423689	ENSG00000257624.1	RP1-128M12.3	3.39	0.000727	0.0335	0.19	0.1	Mean platelet volume;	chr12:111965331	chr12:112000739~112000985:-
BRCA	cis	rs6490294	0.528	rs12423699	ENSG00000257624.1	RP1-128M12.3	3.39	0.000727	0.0335	0.19	0.1	Mean platelet volume;	chr12:111965357	chr12:112000739~112000985:-
BRCA	cis	rs67478160	0.643	rs6575999	ENSG00000269910.1	RP11-73M18.10	3.39	0.000727	0.0335	0.1	0.1	Schizophrenia;	chr14:103784272	chr14:103694516~103695050:-
BRCA	cis	rs6088590	0.561	rs6059932	ENSG00000269202.1	RP4-614O4.12	-3.39	0.000727	0.0335	-0.11	-0.1	Coronary artery disease;	chr20:34587662	chr20:35201747~35203288:-
BRCA	cis	rs9303280	0.617	rs6503525	ENSG00000278834.1	RP11-458J1.1	-3.39	0.000727	0.0335	-0.1	-0.1	Self-reported allergy;	chr17:39938921	chr17:40648300~40649718:+
BRCA	cis	rs10761256	0.778	rs3750358	ENSG00000227603.1	RP11-165J3.6	3.39	0.000727	0.0335	0.11	0.1	Itch intensity from mosquito bite adjusted by bite size;	chr9:93662856	chr9:93435332~93437121:-
BRCA	cis	rs10838687	0.736	rs7118396	ENSG00000243802.2	RP11-390K5.1	3.39	0.000727	0.0335	0.15	0.1	Proinsulin levels;	chr11:47248385	chr11:47191181~47191542:-
BRCA	cis	rs1005277	0.522	rs289650	ENSG00000273019.1	RP11-508N22.13	-3.39	0.000728	0.0336	-0.12	-0.1	Extrinsic epigenetic age acceleration;	chr10:37686577	chr10:38149968~38150293:+
BRCA	cis	rs748802	0.704	rs10491554	ENSG00000231393.1	RP11-331F9.3	3.39	0.000728	0.0336	0.13	0.1	Resting heart rate;	chr9:35910693	chr9:35642514~35643517:+
BRCA	cis	rs948562	0.681	rs11229573	ENSG00000255299.4	RP11-655C2.3	3.39	0.000728	0.0336	0.12	0.1	Lymphoma;	chr11:58667095	chr11:58497888~58505758:-
BRCA	cis	rs1383484	0.545	rs7171383	ENSG00000259728.4	LINC00933	-3.39	0.000728	0.0336	-0.13	-0.1	Height;	chr15:83976087	chr15:84570649~84580175:+
BRCA	cis	rs7520050	0.966	rs4545281	ENSG00000226957.1	RP4-533D7.4	3.39	0.000728	0.0336	0.11	0.1	Reticulocyte count;Red blood cell count;	chr1:45894382	chr1:46046818~46048368:+
BRCA	cis	rs9333029	0.643	rs2405336	ENSG00000225154.2	RP11-184J23.2	-3.39	0.000728	0.0336	-0.14	-0.1	Blood metabolite levels;	chr1:46852408	chr1:47074778~47075979:-
BRCA	cis	rs2904804	0.555	rs4300303	ENSG00000224251.5	RP11-499O7.7	3.39	0.000728	0.0336	0.11	0.1	Economic and political preferences (immigration/crime);	chr10:4944761	chr10:4995488~4997380:+
BRCA	cis	rs9925964	0.967	rs2855475	ENSG00000262766.1	RP11-196G11.4	3.39	0.000728	0.0336	0.09	0.1	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31136227	chr16:31118078~31118747:+
BRCA	cis	rs1046491	0.901	rs8090297	ENSG00000264964.1	RP11-888D10.3	3.39	0.000728	0.0336	0.21	0.1	Scarlet fever;	chr18:9117290	chr18:9315194~9334441:-
BRCA	cis	rs1046491	0.901	rs41274300	ENSG00000264964.1	RP11-888D10.3	3.39	0.000728	0.0336	0.21	0.1	Scarlet fever;	chr18:9119491	chr18:9315194~9334441:-
BRCA	cis	rs1046491	0.901	rs12454025	ENSG00000264964.1	RP11-888D10.3	3.39	0.000728	0.0336	0.21	0.1	Scarlet fever;	chr18:9123494	chr18:9315194~9334441:-
BRCA	cis	rs1046491	0.901	rs12966444	ENSG00000264964.1	RP11-888D10.3	3.39	0.000728	0.0336	0.21	0.1	Scarlet fever;	chr18:9123634	chr18:9315194~9334441:-
BRCA	cis	rs1046491	0.901	rs12966775	ENSG00000264964.1	RP11-888D10.3	3.39	0.000728	0.0336	0.21	0.1	Scarlet fever;	chr18:9123862	chr18:9315194~9334441:-
BRCA	cis	rs1046491	0.901	rs36125741	ENSG00000264964.1	RP11-888D10.3	3.39	0.000728	0.0336	0.21	0.1	Scarlet fever;	chr18:9125539	chr18:9315194~9334441:-
BRCA	cis	rs1046491	0.901	rs12457429	ENSG00000264964.1	RP11-888D10.3	3.39	0.000728	0.0336	0.21	0.1	Scarlet fever;	chr18:9125848	chr18:9315194~9334441:-
BRCA	cis	rs1046491	0.901	rs12457266	ENSG00000264964.1	RP11-888D10.3	3.39	0.000728	0.0336	0.21	0.1	Scarlet fever;	chr18:9125853	chr18:9315194~9334441:-
BRCA	cis	rs1046491	0.901	rs35849084	ENSG00000264964.1	RP11-888D10.3	3.39	0.000728	0.0336	0.21	0.1	Scarlet fever;	chr18:9127798	chr18:9315194~9334441:-
BRCA	cis	rs1046491	0.803	rs11872481	ENSG00000264964.1	RP11-888D10.3	3.39	0.000728	0.0336	0.21	0.1	Scarlet fever;	chr18:9128455	chr18:9315194~9334441:-
BRCA	cis	rs2337406	1	rs4774172	ENSG00000280411.1	IGHV1-69-2	-3.39	0.000728	0.0336	-0.09	-0.1	Alzheimer's disease (late onset);	chr14:106681320	chr14:106762092~106762588:-
BRCA	cis	rs12234571	1	rs17157676	ENSG00000214293.7	APTR	3.39	0.000728	0.0336	0.21	0.1	Obesity-related traits;	chr7:77778063	chr7:77657660~77696265:-
BRCA	cis	rs35740288	0.77	rs11631660	ENSG00000259295.5	CSPG4P12	-3.39	0.000728	0.0336	-0.14	-0.1	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85672181	chr15:85191438~85213905:+
BRCA	cis	rs642743	0.554	rs11599497	ENSG00000266852.2	MIR4482	-3.39	0.000728	0.0336	-0.14	-0.1	Left ventricular obstructive tract defect (maternal effect);	chr10:104205753	chr10:104268336~104268405:-
BRCA	cis	rs6500602	0.673	rs4786512	ENSG00000280063.1	RP11-295D4.3	3.39	0.000728	0.0336	0.08	0.1	Schizophrenia;	chr16:4523039	chr16:4346694~4348648:-
BRCA	cis	rs3743102	1	rs3743102	ENSG00000278603.1	RP13-608F4.5	3.39	0.000728	0.0336	0.17	0.1	Colorectal adenoma (advanced);	chr15:82758642	chr15:82472203~82472426:+
BRCA	cis	rs4805834	0.843	rs17206261	ENSG00000201388.1	SNORA68	3.39	0.000728	0.0336	0.18	0.1	Creatinine levels;	chr19:32866193	chr19:32608337~32608469:-
BRCA	cis	rs7259376	0.936	rs10454118	ENSG00000269345.1	VN1R85P	-3.39	0.000728	0.0336	-0.12	-0.1	Menopause (age at onset);	chr19:22376803	chr19:22174766~22175191:-
BRCA	cis	rs2811415	0.597	rs11708842	ENSG00000242551.2	POU5F1P6	3.39	0.000728	0.0336	0.14	0.1	Lung function (FEV1/FVC);	chr3:128071782	chr3:128674735~128677005:-
BRCA	cis	rs76206723	1	rs79841539	ENSG00000233225.3	AC004987.9	3.39	0.000728	0.0336	0.19	0.1	Pulse pressure;	chr7:40361113	chr7:39833571~39834718:+
BRCA	cis	rs76206723	1	rs80157425	ENSG00000233225.3	AC004987.9	3.39	0.000728	0.0336	0.19	0.1	Pulse pressure;	chr7:40362454	chr7:39833571~39834718:+
BRCA	cis	rs186166891	1	rs186166891	ENSG00000233225.3	AC004987.9	3.39	0.000728	0.0336	0.19	0.1	Migraine;	chr7:40367277	chr7:39833571~39834718:+
BRCA	cis	rs17818399	0.547	rs7607308	ENSG00000279254.1	RP11-536C12.1	-3.39	0.000728	0.0336	-0.13	-0.1	Height;	chr2:46531965	chr2:46668870~46670778:+
BRCA	cis	rs56046484	0.912	rs12914674	ENSG00000259630.2	CTD-2262B20.1	-3.39	0.000728	0.0336	-0.17	-0.1	Testicular germ cell tumor;	chr15:85119829	chr15:85415228~85415633:+
BRCA	cis	rs2154319	0.831	rs213761	ENSG00000230638.4	RP11-486B10.4	3.39	0.000728	0.0336	0.18	0.1	Height;	chr1:41125462	chr1:41542069~41544310:+
BRCA	cis	rs2154319	0.887	rs213756	ENSG00000230638.4	RP11-486B10.4	3.39	0.000728	0.0336	0.18	0.1	Height;	chr1:41129409	chr1:41542069~41544310:+
BRCA	cis	rs2154319	0.836	rs213755	ENSG00000230638.4	RP11-486B10.4	3.39	0.000728	0.0336	0.18	0.1	Height;	chr1:41129493	chr1:41542069~41544310:+
BRCA	cis	rs897984	0.683	rs729482	ENSG00000275263.1	RP11-1072A3.4	-3.39	0.000729	0.0336	-0.13	-0.1	Dementia with Lewy bodies;	chr16:31005649	chr16:30956872~30957199:-
BRCA	cis	rs7520050	0.966	rs7522601	ENSG00000226957.1	RP4-533D7.4	3.39	0.000729	0.0336	0.11	0.1	Reticulocyte count;Red blood cell count;	chr1:45953349	chr1:46046818~46048368:+
BRCA	cis	rs7520050	0.966	rs10789487	ENSG00000226957.1	RP4-533D7.4	3.39	0.000729	0.0336	0.11	0.1	Reticulocyte count;Red blood cell count;	chr1:45954549	chr1:46046818~46048368:+
BRCA	cis	rs6691170	1	rs6691170	ENSG00000238042.4	RP11-815M8.1	-3.39	0.000729	0.0336	-0.11	-0.1	Colorectal cancer;	chr1:221872104	chr1:221880981~221978523:-
BRCA	cis	rs6586163	0.546	rs12359362	ENSG00000261438.1	RP11-399O19.9	-3.39	0.000729	0.0336	-0.1	-0.1	Chronic lymphocytic leukemia;	chr10:88993388	chr10:89015836~89017059:+
BRCA	cis	rs13126694	0.659	rs28514324	ENSG00000251073.1	NUDT19P5	3.39	0.000729	0.0336	0.1	0.1	Blood osmolality (transformed sodium);	chr4:158092778	chr4:158182825~158183393:+
BRCA	cis	rs198426	0.776	rs198434	ENSG00000243742.4	RPLP0P2	-3.39	0.000729	0.0336	-0.13	-0.1	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr11:61715945	chr11:61615036~61639449:+
BRCA	cis	rs4243971	0.516	rs1412998	ENSG00000277692.1	RP11-358N2.2	-3.39	0.000729	0.0336	-0.12	-0.1	Inflammatory bowel disease;Crohn's disease;	chr20:32355017	chr20:32355053~32355734:+
BRCA	cis	rs4415084	1	rs4415084	ENSG00000248779.1	RP11-53O19.2	3.39	0.000729	0.0336	0.1	0.1	Breast cancer;	chr5:44662413	chr5:44752949~44765744:+
BRCA	cis	rs3736986	1	rs7041383	ENSG00000215283.3	HMGB3P24	3.39	0.000729	0.0336	0.19	0.1	Bipolar disorder (inflammation and infection response interaction);	chr9:36204915	chr9:36303499~36304924:-
BRCA	cis	rs2299587	0.519	rs3850746	ENSG00000253944.1	RP11-156K13.1	3.39	0.000729	0.0336	0.13	0.1	Economic and political preferences;	chr8:17930027	chr8:17801345~17861069:+
BRCA	cis	rs17014483	0.749	rs2860422	ENSG00000248019.2	FAM13A-AS1	-3.39	0.000729	0.0336	-0.13	-0.1	Post bronchodilator FEV1/FVC ratio;	chr4:88723780	chr4:88709789~88730103:+
BRCA	cis	rs62289301	0.531	rs10212901	ENSG00000249234.1	RP11-452J21.2	-3.39	0.000729	0.0336	-0.12	-0.1	Joint mobility (Beighton score);	chr4:15415708	chr4:16178939~16183120:+
BRCA	cis	rs6988985	0.728	rs1134095	ENSG00000253741.1	CTD-2292P10.4	3.39	0.000729	0.0336	0.12	0.1	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;	chr8:142872874	chr8:142702252~142726973:-
BRCA	cis	rs4765663	0.725	rs10848608	ENSG00000243663.1	RPS4XP14	-3.39	0.000729	0.0336	-0.13	-0.1	Aortic root size;	chr12:2069763	chr12:1757231~1758011:-
BRCA	cis	rs11700980	0.901	rs2832064	ENSG00000232855.5	AF131217.1	3.39	0.000729	0.0336	0.21	0.1	QRS complex (12-leadsum);	chr21:28762914	chr21:28439346~28674848:-
BRCA	cis	rs2638953	0.849	rs10843172	ENSG00000273989.1	RP11-425D17.2	-3.39	0.000729	0.0336	-0.16	-0.1	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28452300	chr12:28236227~28236828:+
BRCA	cis	rs1998359	1	rs61987980	ENSG00000259087.4	RP11-356O9.2	3.39	0.000729	0.0336	0.12	0.1	Self-reported allergy;	chr14:37625233	chr14:37556158~37567095:-
BRCA	cis	rs13126694	0.744	rs7656059	ENSG00000251073.1	NUDT19P5	3.39	0.000729	0.0336	0.1	0.1	Blood osmolality (transformed sodium);	chr4:158080386	chr4:158182825~158183393:+
BRCA	cis	rs11673344	0.523	rs17206540	ENSG00000276846.1	CTD-3220F14.3	3.39	0.000729	0.0336	0.12	0.1	Obesity-related traits;	chr19:37069009	chr19:37314868~37315620:-
BRCA	cis	rs4415084	1	rs2218081	ENSG00000272335.1	RP11-53O19.3	3.39	0.000729	0.0336	0.1	0.1	Breast cancer;	chr5:44705038	chr5:44826076~44828592:+
BRCA	cis	rs755249	0.501	rs2484749	ENSG00000182109.6	RP11-69E11.4	-3.39	0.000729	0.0336	-0.13	-0.1	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39293283	chr1:39522280~39546187:-
BRCA	cis	rs4356203	0.905	rs6486354	ENSG00000184669.7	OR7E14P	-3.39	0.000729	0.0336	-0.13	-0.1	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17178561	chr11:17013998~17053024:+
BRCA	cis	rs360932	0.674	rs360914	ENSG00000270265.1	RP11-731D1.4	3.39	0.00073	0.0336	0.12	0.1	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr4:151965690	chr4:151333775~151353224:-
BRCA	cis	rs3796352	0.527	rs11716506	ENSG00000270941.1	RP5-966M1.5	-3.39	0.00073	0.0336	-0.18	-0.1	Immune reponse to smallpox (secreted IL-2);	chr3:52910312	chr3:52734735~52735013:+
BRCA	cis	rs10876993	0.928	rs774890	ENSG00000269903.1	RP11-571M6.18	3.39	0.00073	0.0336	0.13	0.1	Celiac disease or Rheumatoid arthritis;	chr12:57674605	chr12:57814494~57814926:+
BRCA	cis	rs12724450	0.793	rs34233130	ENSG00000228126.1	FALEC	3.39	0.00073	0.0336	0.2	0.1	Blood protein levels;	chr1:150477290	chr1:150515757~150518032:+
BRCA	cis	rs1376877	0.967	rs62183915	ENSG00000273456.1	RP11-686O6.2	3.39	0.00073	0.0336	0.1	0.1	Subclinical atherosclerosis traits (other);	chr2:203316198	chr2:202374932~202375604:-
BRCA	cis	rs8114671	0.562	rs6088653	ENSG00000261582.1	RP4-614O4.11	-3.39	0.00073	0.0336	-0.1	-0.1	Height;	chr20:34932518	chr20:35267885~35280043:-
BRCA	cis	rs34792	0.688	rs170168	ENSG00000260872.1	RP11-680G24.5	-3.39	0.00073	0.0336	-0.11	-0.1	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15507138	chr16:15018106~15020488:-
BRCA	cis	rs1129187	0.902	rs6907751	ENSG00000272223.1	RP1-20C7.6	3.39	0.00073	0.0336	0.12	0.1	Alzheimer's disease in APOE e4+ carriers;	chr6:42977112	chr6:43033897~43034405:-
BRCA	cis	rs6088590	1	rs6058111	ENSG00000276073.1	RP5-1125A11.7	-3.39	0.00073	0.0336	-0.12	-0.1	Coronary artery disease;	chr20:34723195	chr20:33985617~33988989:-
BRCA	cis	rs1949733	0.701	rs940134	ENSG00000250471.2	GMPSP1	3.39	0.00073	0.0336	0.11	0.1	Response to antineoplastic agents;	chr4:8453143	chr4:8174421~8174999:+
BRCA	cis	rs1949733	0.701	rs871768	ENSG00000250471.2	GMPSP1	3.39	0.00073	0.0336	0.11	0.1	Response to antineoplastic agents;	chr4:8453211	chr4:8174421~8174999:+
BRCA	cis	rs875971	0.862	rs4718377	ENSG00000271064.1	RP11-792A8.3	3.39	0.00073	0.0336	0.12	0.1	Aortic root size;	chr7:66584691	chr7:66748838~66749077:-
BRCA	cis	rs875971	0.862	rs10278014	ENSG00000271064.1	RP11-792A8.3	3.39	0.00073	0.0336	0.12	0.1	Aortic root size;	chr7:66586277	chr7:66748838~66749077:-
BRCA	cis	rs10191559	0.552	rs4666725	ENSG00000234663.4	AC104820.2	3.39	0.00073	0.0336	0.09	0.1	Red blood cell count;	chr2:181218536	chr2:181101932~181399559:+
BRCA	cis	rs72928364	1	rs35974360	ENSG00000244119.1	PDCL3P4	3.39	0.00073	0.0336	0.13	0.1	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:101038441	chr3:101712472~101713191:+
BRCA	cis	rs11175492	1	rs11175488	ENSG00000243024.5	RPS11P6	-3.39	0.00073	0.0336	-0.25	-0.1	Platelet count;	chr12:64639355	chr12:64222337~64397065:+
BRCA	cis	rs10266483	0.545	rs1812912	ENSG00000227986.1	TRIM60P18	3.39	0.00073	0.0336	0.13	0.1	Response to statin therapy;	chr7:64282891	chr7:64355078~64356199:+
BRCA	cis	rs12303914	0.676	rs3759270	ENSG00000256682.2	TAS2R12	-3.39	0.00073	0.0336	-0.13	-0.1	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr12:10306592	chr12:10894943~10896952:-
BRCA	cis	rs4950322	0.512	rs12409455	ENSG00000237188.3	RP11-337C18.8	3.39	0.00073	0.0336	0.11	0.1	Protein quantitative trait loci;	chr1:147378563	chr1:147172771~147211568:+
BRCA	cis	rs11887277	0.902	rs12991828	ENSG00000229122.1	AGBL5-IT1	3.39	0.00073	0.0336	0.12	0.1	Obesity-related traits;	chr2:26859691	chr2:27061038~27061815:+
BRCA	cis	rs2154319	0.887	rs213745	ENSG00000230638.4	RP11-486B10.4	3.39	0.00073	0.0336	0.18	0.1	Height;	chr1:41165657	chr1:41542069~41544310:+
BRCA	cis	rs2154319	0.887	rs61781831	ENSG00000230638.4	RP11-486B10.4	-3.39	0.00073	0.0336	-0.18	-0.1	Height;	chr1:41168110	chr1:41542069~41544310:+
BRCA	cis	rs2154319	0.887	rs61781832	ENSG00000230638.4	RP11-486B10.4	-3.39	0.00073	0.0336	-0.18	-0.1	Height;	chr1:41171252	chr1:41542069~41544310:+
BRCA	cis	rs58521262	0.729	rs11669667	ENSG00000268105.1	RP11-369G6.2	-3.39	0.00073	0.0337	-0.18	-0.1	Testicular germ cell tumor;	chr19:22881596	chr19:23125665~23128543:+
BRCA	cis	rs11079159	0.959	rs3794752	ENSG00000279059.1	RP11-257O5.2	-3.39	0.00073	0.0337	-0.11	-0.1	QRS duration;	chr17:55305468	chr17:54956760~54958426:-
BRCA	cis	rs12105510	0.608	rs13033867	ENSG00000270696.1	RP11-342K6.1	-3.39	0.00073	0.0337	-0.15	-0.1	Response to platinum-based chemotherapy (cisplatin);	chr2:75625652	chr2:75660462~75662208:+
BRCA	cis	rs6445975	1	rs7653734	ENSG00000272360.1	RP11-359I18.5	3.39	0.00073	0.0337	0.12	0.1	Systemic lupus erythematosus;	chr3:58387158	chr3:58490830~58491291:-
BRCA	cis	rs6593122	0.628	rs10281043	ENSG00000235454.1	HAUS6P3	-3.39	0.00073	0.0337	-0.14	-0.1	Vaccine-related adverse events;	chr7:54115160	chr7:53862233~53863339:+
BRCA	cis	rs1333657	1	rs1333657	ENSG00000216368.2	RP3-486D24.1	-3.39	0.00073	0.0337	-0.12	-0.1	Orofacial clefts;	chr6:10296103	chr6:10118452~10119253:+
BRCA	cis	rs1843834	0.539	rs10177898	ENSG00000274629.1	RP11-92F20.1	-3.39	0.000731	0.0337	-0.13	-0.1	IgE levels in asthmatics (D.p. specific);	chr2:224572835	chr2:224464682~224474500:+
BRCA	cis	rs6696239	0.911	rs56950588	ENSG00000227711.2	RP11-275O4.5	-3.39	0.000731	0.0337	-0.14	-0.1	Height;	chr1:227680773	chr1:227509028~227520477:-
BRCA	cis	rs9646944	0.501	rs10181785	ENSG00000234389.1	AC007278.3	3.39	0.000731	0.0337	0.12	0.1	Blood protein levels;	chr2:102408814	chr2:102438713~102440475:+
BRCA	cis	rs9646944	0.54	rs12712148	ENSG00000234389.1	AC007278.3	3.39	0.000731	0.0337	0.12	0.1	Blood protein levels;	chr2:102409087	chr2:102438713~102440475:+
BRCA	cis	rs4919669	0.668	rs7086898	ENSG00000213277.3	MARCKSL1P1	3.39	0.000731	0.0337	0.17	0.1	Mean arterial pressure (long-term average);Systolic blood pressure (long-term average);	chr10:102626395	chr10:103175554~103176094:+
BRCA	cis	rs931127	0.666	rs7932857	ENSG00000255557.1	RP11-770G2.2	3.39	0.000731	0.0337	0.12	0.1	Systemic lupus erythematosus;	chr11:65690022	chr11:65745729~65771585:+
BRCA	cis	rs1722141	0.633	rs903889	ENSG00000237471.1	AC073115.6	-3.39	0.000731	0.0337	-0.14	-0.1	Sitting height ratio;	chr7:45925396	chr7:45969657~45980191:+
BRCA	cis	rs875971	0.862	rs778720	ENSG00000223473.2	GS1-124K5.3	-3.39	0.000731	0.0337	-0.08	-0.1	Aortic root size;	chr7:66381288	chr7:66491049~66493566:-
BRCA	cis	rs6988985	0.728	rs1134096	ENSG00000253741.1	CTD-2292P10.4	-3.39	0.000731	0.0337	-0.12	-0.1	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;	chr8:142872807	chr8:142702252~142726973:-
BRCA	cis	rs748404	0.666	rs16957680	ENSG00000166763.7	STRCP1	3.39	0.000731	0.0337	0.15	0.1	Lung cancer;	chr15:43396207	chr15:43699488~43718184:-
BRCA	cis	rs73198271	0.583	rs11781985	ENSG00000233609.3	RP11-62H7.2	3.39	0.000731	0.0337	0.11	0.1	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8732273	chr8:8961200~8979025:+
BRCA	cis	rs9928842	0.771	rs2870471	ENSG00000261783.1	RP11-252K23.2	-3.39	0.000731	0.0337	-0.17	-0.1	Alcoholic chronic pancreatitis;	chr16:75240384	chr16:75379818~75381260:-
BRCA	cis	rs10876993	0.928	rs1678540	ENSG00000269903.1	RP11-571M6.18	3.39	0.000731	0.0337	0.13	0.1	Celiac disease or Rheumatoid arthritis;	chr12:57671219	chr12:57814494~57814926:+
BRCA	cis	rs600231	0.708	rs1784100	ENSG00000254614.2	AP003068.23	3.39	0.000731	0.0337	0.14	0.1	Bone mineral density;	chr11:65481756	chr11:65177606~65181834:-
BRCA	cis	rs755249	0.501	rs1889830	ENSG00000182109.6	RP11-69E11.4	-3.39	0.000731	0.0337	-0.13	-0.1	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39264500	chr1:39522280~39546187:-
BRCA	cis	rs7914558	1	rs1890184	ENSG00000272912.1	RP11-724N1.1	-3.39	0.000731	0.0337	-0.12	-0.1	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102988702	chr10:102914585~102915404:+
BRCA	cis	rs4908769	0.624	rs2120461	ENSG00000221083.1	SNORA77	-3.39	0.000731	0.0337	-0.11	-0.1	Allergy;	chr1:8387662	chr1:8511795~8511919:-
BRCA	cis	rs7260598	0.818	rs11666653	ENSG00000268442.1	CTD-2027I19.2	3.39	0.000731	0.0337	0.17	0.1	Response to taxane treatment (placlitaxel);	chr19:24037440	chr19:24162370~24163425:-
BRCA	cis	rs6840360	0.571	rs7692700	ENSG00000270265.1	RP11-731D1.4	-3.39	0.000731	0.0337	-0.13	-0.1	Intelligence (multi-trait analysis);	chr4:151631645	chr4:151333775~151353224:-
BRCA	cis	rs7267979	1	rs4815420	ENSG00000231081.1	RP4-760C5.3	3.39	0.000731	0.0337	0.13	0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25403343	chr20:26008791~26010531:-
BRCA	cis	rs875971	0.898	rs6977501	ENSG00000271064.1	RP11-792A8.3	3.39	0.000731	0.0337	0.12	0.1	Aortic root size;	chr7:66228355	chr7:66748838~66749077:-
BRCA	cis	rs6946131	0.593	rs2464963	ENSG00000235207.1	TUBBP6	-3.39	0.000731	0.0337	-0.13	-0.1	Systemic lupus erythematosus;	chr7:54778408	chr7:55645620~55646951:+
BRCA	cis	rs6946131	0.593	rs2464965	ENSG00000235207.1	TUBBP6	-3.39	0.000731	0.0337	-0.13	-0.1	Systemic lupus erythematosus;	chr7:54778541	chr7:55645620~55646951:+
BRCA	cis	rs832540	0.866	rs832579	ENSG00000271828.1	CTD-2310F14.1	-3.39	0.000731	0.0337	-0.13	-0.1	Coronary artery disease;	chr5:56869116	chr5:56927874~56929573:+
BRCA	cis	rs7620503	0.613	rs11720644	ENSG00000277241.1	RP11-114M1.3	-3.39	0.000732	0.0337	-0.13	-0.1	Corneal structure;	chr3:177559917	chr3:177700346~177701072:-
BRCA	cis	rs7649443	0.797	rs35665404	ENSG00000243339.3	RN7SL738P	-3.39	0.000732	0.0337	-0.15	-0.1	Nonsyndromic cleft lip with cleft palate;	chr3:197254900	chr3:196399911~196400207:+
BRCA	cis	rs6840360	0.571	rs4696271	ENSG00000278978.1	RP11-164P12.5	-3.39	0.000732	0.0337	-0.12	-0.1	Intelligence (multi-trait analysis);	chr4:151587966	chr4:151669786~151670503:+
BRCA	cis	rs10761256	0.806	rs10761252	ENSG00000227603.1	RP11-165J3.6	3.39	0.000732	0.0337	0.11	0.1	Itch intensity from mosquito bite adjusted by bite size;	chr9:93662019	chr9:93435332~93437121:-
BRCA	cis	rs879500	0.653	rs8093441	ENSG00000266296.1	ARIH2P1	3.39	0.000732	0.0337	0.15	0.1	Lung function (FVC);	chr18:28505534	chr18:28651732~28653208:+
BRCA	cis	rs7267979	1	rs2258617	ENSG00000274414.1	RP5-965G21.4	-3.39	0.000732	0.0337	-0.12	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25293682	chr20:25239007~25245229:-
BRCA	cis	rs6676180	0.555	rs12060730	ENSG00000236804.1	RPS3AP12	-3.39	0.000732	0.0337	-0.12	-0.1	Monobrow;	chr1:119228079	chr1:119126539~119127291:-
BRCA	cis	rs1670533	1	rs7679432	ENSG00000251639.2	RP11-20I20.1	3.39	0.000732	0.0337	0.17	0.1	Recombination rate (females);	chr4:1056733	chr4:1100016~1101558:-
BRCA	cis	rs1670533	0.932	rs9992925	ENSG00000251639.2	RP11-20I20.1	3.39	0.000732	0.0337	0.17	0.1	Recombination rate (females);	chr4:1057121	chr4:1100016~1101558:-
BRCA	cis	rs1670533	1	rs2290411	ENSG00000251639.2	RP11-20I20.1	3.39	0.000732	0.0337	0.17	0.1	Recombination rate (females);	chr4:1057289	chr4:1100016~1101558:-
BRCA	cis	rs9467773	0.935	rs4573	ENSG00000224843.5	LINC00240	-3.39	0.000732	0.0337	-0.12	-0.1	Intelligence (multi-trait analysis);	chr6:26546580	chr6:26956992~27023924:+
BRCA	cis	rs10838687	0.8	rs7928073	ENSG00000243802.2	RP11-390K5.1	3.39	0.000732	0.0337	0.15	0.1	Proinsulin levels;	chr11:47340306	chr11:47191181~47191542:-
BRCA	cis	rs12468226	1	rs116635509	ENSG00000272966.1	RP11-686O6.1	3.39	0.000732	0.0337	0.18	0.1	Urate levels;	chr2:202460027	chr2:202336739~202337200:+
BRCA	cis	rs9400180	0.84	rs9374006	ENSG00000271734.1	RP1-111B22.3	-3.39	0.000732	0.0337	-0.14	-0.1	Major depressive disorder;	chr6:108034328	chr6:108030249~108030718:-
BRCA	cis	rs875971	0.862	rs908915	ENSG00000223473.2	GS1-124K5.3	-3.39	0.000732	0.0337	-0.08	-0.1	Aortic root size;	chr7:66149664	chr7:66491049~66493566:-
BRCA	cis	rs3105593	1	rs4775893	ENSG00000259618.1	RP11-562A8.5	3.39	0.000732	0.0337	0.11	0.1	QT interval;	chr15:50606498	chr15:50494018~50497080:-
BRCA	cis	rs9392556	0.765	rs613709	ENSG00000230648.1	RP3-406P24.3	3.39	0.000732	0.0337	0.13	0.1	Blood metabolite levels;	chr6:4120449	chr6:4018843~4021215:-
BRCA	cis	rs7267979	0.932	rs928121	ENSG00000274973.1	RP13-401N8.7	-3.39	0.000732	0.0337	-0.12	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25554182	chr20:25845497~25845862:+
BRCA	cis	rs4809760	0.935	rs6020083	ENSG00000224397.4	LINC01272	3.39	0.000732	0.0337	0.1	0.1	Gut microbiota (beta diversity);	chr20:49845825	chr20:50267486~50279795:+
BRCA	cis	rs875971	0.929	rs6970860	ENSG00000273448.1	RP11-166O4.6	3.39	0.000732	0.0337	0.09	0.1	Aortic root size;	chr7:66511647	chr7:67333047~67334383:+
BRCA	cis	rs16852403	1	rs16852403	ENSG00000224687.1	RASAL2-AS1	3.39	0.000732	0.0337	0.14	0.1	Childhood ear infection;	chr1:178070091	chr1:178091508~178093984:-
BRCA	cis	rs2836950	0.772	rs62222988	ENSG00000235701.1	PCBP2P1	-3.39	0.000732	0.0337	-0.13	-0.1	Menarche (age at onset);	chr21:39197582	chr21:39171130~39172106:-
BRCA	cis	rs7520050	0.581	rs6671303	ENSG00000280836.1	AL355480.1	-3.39	0.000732	0.0337	-0.12	-0.1	Reticulocyte count;Red blood cell count;	chr1:46163981	chr1:45581219~45581321:-
BRCA	cis	rs10911902	0.643	rs16825185	ENSG00000229739.2	RP11-295K2.3	-3.39	0.000733	0.0337	-0.14	-0.1	Schizophrenia;	chr1:186337932	chr1:186435161~186470291:+
BRCA	cis	rs2041840	1	rs10177970	ENSG00000272054.1	RP11-423P10.2	3.39	0.000733	0.0337	0.1	0.1	Chronic lymphocytic leukemia;	chr2:37285825	chr2:37208875~37212677:+
BRCA	cis	rs34779708	0.966	rs12260130	ENSG00000269952.1	RP11-324I22.3	-3.39	0.000733	0.0337	-0.14	-0.1	Inflammatory bowel disease;Crohn's disease;	chr10:35178743	chr10:35210416~35210750:+
BRCA	cis	rs2562456	0.833	rs8106025	ENSG00000268555.1	RP11-678G14.3	-3.39	0.000733	0.0337	-0.13	-0.1	Pain;	chr19:21451922	chr19:21570822~21587322:-
BRCA	cis	rs4865762	0.512	rs6873915	ENSG00000247796.2	CTD-2366F13.1	3.39	0.000733	0.0337	0.12	0.1	Intraocular pressure;	chr5:53214634	chr5:53109842~53115126:+
BRCA	cis	rs6600671	0.764	rs6600673	ENSG00000231429.2	RP11-343N15.2	-3.39	0.000733	0.0337	-0.13	-0.1	Hip geometry;	chr1:121426988	chr1:121412719~121429274:+
BRCA	cis	rs6088580	0.524	rs6088560	ENSG00000126005.14	MMP24-AS1	3.39	0.000733	0.0337	0.12	0.1	Glomerular filtration rate (creatinine);	chr20:34640745	chr20:35216462~35278131:-
BRCA	cis	rs8114671	0.836	rs6142294	ENSG00000261582.1	RP4-614O4.11	3.39	0.000733	0.0337	0.1	0.1	Height;	chr20:35083694	chr20:35267885~35280043:-
BRCA	cis	rs61160187	0.673	rs10062240	ENSG00000272308.1	RP11-231G3.1	3.39	0.000733	0.0337	0.12	0.1	Educational attainment (years of education);Educational attainment (college completion);	chr5:60782585	chr5:60866457~60866935:-
BRCA	cis	rs6772849	0.896	rs9816260	ENSG00000207088.1	SNORA7B	-3.39	0.000733	0.0337	-0.13	-0.1	Monocyte percentage of white cells;Monocyte count;	chr3:128633240	chr3:129397210~129397348:-
BRCA	cis	rs875971	0.666	rs13242072	ENSG00000272831.1	RP11-792A8.4	-3.39	0.000733	0.0338	-0.09	-0.1	Aortic root size;	chr7:66301001	chr7:66739829~66740385:-
BRCA	cis	rs10761256	0.806	rs10992836	ENSG00000227603.1	RP11-165J3.6	3.39	0.000733	0.0338	0.11	0.1	Itch intensity from mosquito bite adjusted by bite size;	chr9:93660138	chr9:93435332~93437121:-
BRCA	cis	rs283610	0.77	rs438768	ENSG00000249149.2	RP11-79P5.3	3.39	0.000733	0.0338	0.13	0.1	Obesity-related traits;	chr5:73964093	chr5:73382384~73410509:+
BRCA	cis	rs4699052	1	rs6533059	ENSG00000246560.2	RP11-10L12.4	3.39	0.000733	0.0338	0.11	0.1	Testicular germ cell tumor;	chr4:103212219	chr4:102828055~102844075:+
BRCA	cis	rs8127691	1	rs743479	ENSG00000225331.1	AP001055.6	3.39	0.000733	0.0338	0.13	0.1	Inflammatory bowel disease;	chr21:44192067	chr21:44158740~44160076:-
BRCA	cis	rs12468226	0.938	rs116109808	ENSG00000272966.1	RP11-686O6.1	3.39	0.000733	0.0338	0.18	0.1	Urate levels;	chr2:202287356	chr2:202336739~202337200:+
BRCA	cis	rs12468226	0.873	rs78175596	ENSG00000272966.1	RP11-686O6.1	3.39	0.000733	0.0338	0.18	0.1	Urate levels;	chr2:202287993	chr2:202336739~202337200:+
BRCA	cis	rs12468226	0.938	rs74454549	ENSG00000272966.1	RP11-686O6.1	3.39	0.000733	0.0338	0.18	0.1	Urate levels;	chr2:202288044	chr2:202336739~202337200:+
BRCA	cis	rs7412746	0.586	rs2864882	ENSG00000224800.1	RP11-235D19.2	-3.39	0.000733	0.0338	-0.13	-0.1	Melanoma;	chr1:150910561	chr1:150881236~150881683:-
BRCA	cis	rs683250	0.701	rs10898127	ENSG00000254551.1	RP11-727A23.7	-3.39	0.000733	0.0338	-0.12	-0.1	Subcortical brain region volumes;	chr11:83497082	chr11:83209431~83213379:-
BRCA	cis	rs2360027	0.599	rs11590971	ENSG00000231365.4	RP11-418J17.1	3.39	0.000733	0.0338	0.13	0.1	Tonsillectomy;	chr1:118557264	chr1:119140396~119275973:+
BRCA	cis	rs2400749	0.712	rs4900434	ENSG00000258521.1	RP11-638I2.9	3.39	0.000733	0.0338	0.1	0.1	Alzheimer's disease (survival time);	chr14:99564636	chr14:100339832~100340554:+
BRCA	cis	rs2795502	0.882	rs2744091	ENSG00000185904.10	LINC00839	-3.39	0.000733	0.0338	-0.15	-0.1	Blood protein levels;	chr10:42843993	chr10:42475543~42495336:+
BRCA	cis	rs6964587	0.692	rs418	ENSG00000188693.7	CYP51A1-AS1	3.39	0.000733	0.0338	0.11	0.1	Breast cancer;	chr7:91954020	chr7:92134604~92180725:+
BRCA	cis	rs9796	0.558	rs7166905	ENSG00000223313.1	RNU6-516P	3.39	0.000733	0.0338	0.12	0.1	Menopause (age at onset);	chr15:41222678	chr15:40529570~40529673:+
BRCA	cis	rs1387259	0.64	rs10783243	ENSG00000226413.2	OR8T1P	-3.39	0.000733	0.0338	-0.13	-0.1	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48259220	chr12:48442030~48442947:-
BRCA	cis	rs1510510	0.867	rs12619578	ENSG00000229915.1	AC016999.2	3.39	0.000733	0.0338	0.17	0.1	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr2:238606780	chr2:238427077~238427729:-
BRCA	cis	rs7412746	0.611	rs9661876	ENSG00000224800.1	RP11-235D19.2	-3.39	0.000733	0.0338	-0.13	-0.1	Melanoma;	chr1:150938435	chr1:150881236~150881683:-
BRCA	cis	rs4356203	0.905	rs7927240	ENSG00000184669.7	OR7E14P	-3.39	0.000734	0.0338	-0.14	-0.1	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17056681	chr11:17013998~17053024:+
BRCA	cis	rs9379945	1	rs9379945	ENSG00000241549.7	GUSBP2	3.39	0.000734	0.0338	0.17	0.1	Intelligence (multi-trait analysis);	chr6:26940052	chr6:26871484~26956554:-
BRCA	cis	rs2899832	0.5	rs112733905	ENSG00000258704.4	SRP54-AS1	3.39	0.000734	0.0338	0.25	0.1	Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:35275875	chr14:34920858~34982532:-
BRCA	cis	rs4703129	0.967	rs1478456	ENSG00000246763.5	RGMB-AS1	-3.39	0.000734	0.0338	-0.12	-0.1	Asperger disorder;	chr5:98526748	chr5:98769618~98773469:-
BRCA	cis	rs11073619	0.803	rs7180895	ENSG00000259728.4	LINC00933	3.39	0.000734	0.0338	0.19	0.1	Positive affect;	chr15:84614489	chr15:84570649~84580175:+
BRCA	cis	rs6533014	1	rs6533014	ENSG00000248161.4	RP11-499E18.1	3.39	0.000734	0.0338	0.13	0.1	Homeostasis model assessment of beta-cell function (dietary factor interaction);	chr4:102428583	chr4:102418602~102450010:-
BRCA	cis	rs7617773	0.78	rs13079728	ENSG00000228350.1	CELSR3-AS1	3.39	0.000734	0.0338	0.15	0.1	Coronary artery disease;	chr3:48297870	chr3:48663776~48669174:+
BRCA	cis	rs321358	0.731	rs559757	ENSG00000271390.1	RP11-89C3.3	3.39	0.000734	0.0338	0.16	0.1	Body mass index;	chr11:111136885	chr11:111089870~111090368:-
BRCA	cis	rs321358	0.731	rs560503	ENSG00000271390.1	RP11-89C3.3	3.39	0.000734	0.0338	0.16	0.1	Body mass index;	chr11:111136911	chr11:111089870~111090368:-
BRCA	cis	rs321358	0.731	rs514347	ENSG00000271390.1	RP11-89C3.3	3.39	0.000734	0.0338	0.16	0.1	Body mass index;	chr11:111137333	chr11:111089870~111090368:-
BRCA	cis	rs321358	0.731	rs565152	ENSG00000271390.1	RP11-89C3.3	3.39	0.000734	0.0338	0.16	0.1	Body mass index;	chr11:111137443	chr11:111089870~111090368:-
BRCA	cis	rs1400816	0.85	rs3821096	ENSG00000228389.1	AC068039.4	3.39	0.000734	0.0338	0.19	0.1	Amyotrophic lateral sclerosis (sporadic);	chr2:171807510	chr2:171773482~171775844:+
BRCA	cis	rs1018697	1	rs11191397	ENSG00000236937.2	PTGES3P4	3.39	0.000734	0.0338	0.13	0.1	Colorectal adenoma (advanced);	chr10:102798517	chr10:102845595~102845950:+
BRCA	cis	rs911119	0.913	rs13043610	ENSG00000270001.1	RP11-218C14.8	-3.39	0.000734	0.0338	-0.14	-0.1	Chronic kidney disease;	chr20:23606304	chr20:23631826~23632316:-
BRCA	cis	rs4631830	0.932	rs4581397	ENSG00000204177.9	BMS1P1	-3.39	0.000734	0.0338	-0.1	-0.1	Prostate-specific antigen levels;	chr10:46063455	chr10:46786674~46811989:+
BRCA	cis	rs875971	0.862	rs6460307	ENSG00000223473.2	GS1-124K5.3	3.39	0.000734	0.0338	0.08	0.1	Aortic root size;	chr7:66595884	chr7:66491049~66493566:-
BRCA	cis	rs4787491	0.729	rs4788213	ENSG00000275371.1	RP11-455F5.6	-3.39	0.000734	0.0338	-0.1	-0.1	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30023203	chr16:30110895~30111955:+
BRCA	cis	rs4787491	0.679	rs7204852	ENSG00000275371.1	RP11-455F5.6	-3.39	0.000734	0.0338	-0.1	-0.1	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30028857	chr16:30110895~30111955:+
BRCA	cis	rs4787491	0.729	rs12446378	ENSG00000275371.1	RP11-455F5.6	-3.39	0.000734	0.0338	-0.1	-0.1	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30031789	chr16:30110895~30111955:+
BRCA	cis	rs6708331	0.941	rs7609359	ENSG00000231024.1	AC092431.3	-3.39	0.000734	0.0338	-0.14	-0.1	Obesity-related traits;	chr2:70131844	chr2:69700192~69713847:-
BRCA	cis	rs6708331	0.941	rs7595262	ENSG00000231024.1	AC092431.3	-3.39	0.000734	0.0338	-0.14	-0.1	Obesity-related traits;	chr2:70131865	chr2:69700192~69713847:-
BRCA	cis	rs4449834	0.781	rs730085	ENSG00000254432.1	RP11-33I11.2	-3.39	0.000734	0.0338	-0.13	-0.1	Sum eosinophil basophil counts;	chr8:60739055	chr8:60808735~60809606:-
BRCA	cis	rs10838634	1	rs3136439	ENSG00000280615.1	Y_RNA	-3.39	0.000734	0.0338	-0.2	-0.1	Schizophrenia;	chr11:46721585	chr11:47614898~47614994:-
BRCA	cis	rs3796352	1	rs11717619	ENSG00000252768.1	RNU6-856P	-3.39	0.000734	0.0338	-0.19	-0.1	Immune reponse to smallpox (secreted IL-2);	chr3:52969163	chr3:52551846~52551943:-
BRCA	cis	rs11673344	0.764	rs10403679	ENSG00000267309.1	CTD-2630F21.1	-3.39	0.000734	0.0338	-0.12	-0.1	Obesity-related traits;	chr19:36980810	chr19:36489649~36491040:+
BRCA	cis	rs8040855	0.965	rs6496766	ENSG00000230373.7	GOLGA6L5P	-3.39	0.000734	0.0338	-0.11	-0.1	Bulimia nervosa;	chr15:85159144	chr15:84507885~84516814:-
BRCA	cis	rs4631830	0.9	rs7075009	ENSG00000204177.9	BMS1P1	-3.39	0.000734	0.0338	-0.1	-0.1	Prostate-specific antigen levels;	chr10:46051679	chr10:46786674~46811989:+
BRCA	cis	rs5742933	0.948	rs6434363	ENSG00000253559.1	OSGEPL1-AS1	-3.39	0.000734	0.0338	-0.14	-0.1	Ferritin levels;	chr2:189707565	chr2:189762704~189765556:+
BRCA	cis	rs7017914	0.967	rs6999739	ENSG00000246366.5	RP11-382J12.1	3.39	0.000734	0.0338	0.11	0.1	Bone mineral density;	chr8:70724977	chr8:70608577~70663279:+
BRCA	cis	rs10504130	0.696	rs79069311	ENSG00000272076.1	RP11-11C20.3	3.39	0.000734	0.0338	0.16	0.1	Venous thromboembolism (SNP x SNP interaction);	chr8:51926891	chr8:51810110~51810681:-
BRCA	cis	rs10504130	0.696	rs60796336	ENSG00000272076.1	RP11-11C20.3	3.39	0.000734	0.0338	0.16	0.1	Venous thromboembolism (SNP x SNP interaction);	chr8:51928310	chr8:51810110~51810681:-
BRCA	cis	rs4759375	1	rs12366872	ENSG00000256092.2	RP13-942N8.1	-3.39	0.000734	0.0338	-0.16	-0.1	HDL cholesterol;	chr12:123320174	chr12:123363868~123366113:+
BRCA	cis	rs11098499	0.739	rs4833612	ENSG00000225892.3	RP11-384K6.2	-3.39	0.000734	0.0338	-0.1	-0.1	Corneal astigmatism;	chr4:119226441	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.739	rs10013032	ENSG00000225892.3	RP11-384K6.2	-3.39	0.000734	0.0338	-0.1	-0.1	Corneal astigmatism;	chr4:119228264	chr4:118632274~118634759:+
BRCA	cis	rs11673344	0.523	rs6510585	ENSG00000276846.1	CTD-3220F14.3	3.39	0.000735	0.0338	0.12	0.1	Obesity-related traits;	chr19:37063081	chr19:37314868~37315620:-
BRCA	cis	rs7267979	0.868	rs6138553	ENSG00000274414.1	RP5-965G21.4	-3.39	0.000735	0.0338	-0.13	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25258597	chr20:25239007~25245229:-
BRCA	cis	rs5762752	0.521	rs695709	ENSG00000235954.5	TTC28-AS1	-3.39	0.000735	0.0338	-0.12	-0.1	Optic disc area;	chr22:28516867	chr22:27919376~28008581:+
BRCA	cis	rs10129255	0.912	rs8009135	ENSG00000211958.2	IGHV3-38	3.39	0.000735	0.0338	0.08	0.1	Kawasaki disease;	chr14:106777528	chr14:106410493~106411021:-
BRCA	cis	rs7044106	0.791	rs4617229	ENSG00000270917.1	RP11-27I1.6	-3.39	0.000735	0.0338	-0.14	-0.1	Hip circumference adjusted for BMI;	chr9:120718418	chr9:120812475~120812845:-
BRCA	cis	rs4819052	0.851	rs8127834	ENSG00000223768.1	LINC00205	-3.39	0.000735	0.0338	-0.14	-0.1	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45276194	chr21:45293285~45297354:+
BRCA	cis	rs10129255	0.872	rs8015406	ENSG00000211959.2	IGHV4-39	3.39	0.000735	0.0338	0.08	0.1	Kawasaki disease;	chr14:106670611	chr14:106421711~106422218:-
BRCA	cis	rs1178127	0.719	rs1178174	ENSG00000232821.1	AC003986.6	3.39	0.000735	0.0338	0.14	0.1	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);	chr7:18757397	chr7:19112474~19114271:+
BRCA	cis	rs2717463	0.723	rs896202	ENSG00000239473.1	RPL7P38	-3.39	0.000735	0.0338	-0.14	-0.1	Positive affect;	chr12:80363869	chr12:80028893~80029631:+
BRCA	cis	rs4831760	1	rs354511	ENSG00000250483.1	PPM1AP1	3.39	0.000735	0.0338	0.13	0.1	Pulmonary function decline;	chr8:15676935	chr8:15806149~15807283:-
BRCA	cis	rs67340775	0.541	rs200965	ENSG00000219392.1	RP1-265C24.5	-3.39	0.000735	0.0338	-0.18	-0.1	Lung cancer in ever smokers;	chr6:27898606	chr6:28115628~28116551:+
BRCA	cis	rs6914598	0.917	rs6456399	ENSG00000240869.3	RN7SL128P	-3.39	0.000735	0.0338	-0.15	-0.1	Cutaneous malignant melanoma;Melanoma;	chr6:21154942	chr6:20421583~20421887:-
BRCA	cis	rs11035577	0.632	rs10430975	ENSG00000279675.1	RP11-454H19.2	-3.39	0.000735	0.0338	-0.16	-0.1	Temperament (bipolar disorder);	chr11:39761623	chr11:40107244~40112599:-
BRCA	cis	rs804280	0.525	rs1004712	ENSG00000254866.2	DEFB109P3	-3.39	0.000735	0.0338	-0.13	-0.1	Myopia (pathological);	chr8:11764784	chr8:12150895~12151134:-
BRCA	cis	rs2416257	0.673	rs6876020	ENSG00000249619.1	HMGN1P13	3.39	0.000735	0.0338	0.17	0.1	Eosinophil counts;	chr5:111132649	chr5:111572102~111572239:-
BRCA	cis	rs6752107	0.791	rs3792106	ENSG00000251485.1	AC068134.10	3.39	0.000736	0.0338	0.11	0.1	Inflammatory bowel disease;Crohn's disease;	chr2:233282094	chr2:232343116~232343903:+
BRCA	cis	rs7267979	0.932	rs6107052	ENSG00000274973.1	RP13-401N8.7	-3.39	0.000736	0.0339	-0.12	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25550202	chr20:25845497~25845862:+
BRCA	cis	rs1348850	0.608	rs2364845	ENSG00000227098.1	AC073636.1	3.39	0.000736	0.0339	0.13	0.1	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177361512	chr2:176845993~176849428:-
BRCA	cis	rs66887589	0.592	rs28580295	ENSG00000250412.1	KLHL2P1	3.39	0.000736	0.0339	0.11	0.1	Diastolic blood pressure;	chr4:119357718	chr4:119334329~119378233:+
BRCA	cis	rs13401620	0.626	rs12471141	ENSG00000223549.1	MTND5P28	3.39	0.000736	0.0339	0.13	0.1	Breast size;	chr2:120066173	chr2:120215181~120217279:+
BRCA	cis	rs801193	1	rs13239306	ENSG00000273142.1	RP11-458F8.4	3.39	0.000736	0.0339	0.09	0.1	Aortic root size;	chr7:66671030	chr7:66902857~66906297:+
BRCA	cis	rs875971	1	rs55962648	ENSG00000271064.1	RP11-792A8.3	3.39	0.000736	0.0339	0.12	0.1	Aortic root size;	chr7:66160764	chr7:66748838~66749077:-
BRCA	cis	rs1124769	0.57	rs2574757	ENSG00000259298.1	RP11-562A8.4	3.39	0.000736	0.0339	0.1	0.1	Cognitive performance;	chr15:50846263	chr15:50497195~50498744:-
BRCA	cis	rs853679	0.517	rs9357065	ENSG00000226314.6	ZNF192P1	-3.39	0.000736	0.0339	-0.16	-0.1	Depression;	chr6:28161802	chr6:28161781~28169594:+
BRCA	cis	rs4415084	1	rs13155752	ENSG00000272335.1	RP11-53O19.3	3.39	0.000736	0.0339	0.1	0.1	Breast cancer;	chr5:44680585	chr5:44826076~44828592:+
BRCA	cis	rs4356203	0.905	rs536628	ENSG00000184669.7	OR7E14P	-3.39	0.000736	0.0339	-0.13	-0.1	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17186545	chr11:17013998~17053024:+
BRCA	cis	rs7789940	1	rs7789940	ENSG00000231087.2	FDPSP7	-3.39	0.000736	0.0339	-0.14	-0.1	Multiple sclerosis;	chr7:76321913	chr7:76968197~76969250:-
BRCA	cis	rs4578769	0.765	rs898000	ENSG00000273232.1	RP11-370A5.2	-3.39	0.000736	0.0339	-0.15	-0.1	Eosinophil percentage of white cells;	chr18:22929109	chr18:22882825~22883357:-
BRCA	cis	rs718433	0.682	rs7150263	ENSG00000211778.2	TRAV4	-3.39	0.000736	0.0339	-0.08	-0.1	Intraocular pressure;	chr14:21794012	chr14:21736152~21736982:+
BRCA	cis	rs1479090	0.762	rs4691069	ENSG00000250027.1	RP11-563E2.2	-3.39	0.000736	0.0339	-0.14	-0.1	Lung cancer;	chr4:163099663	chr4:163108785~163119965:+
BRCA	cis	rs6126019	1	rs6126019	ENSG00000231715.1	COX6CP2	3.39	0.000736	0.0339	0.11	0.1	Hematocrit;Red blood cell count;	chr20:50485053	chr20:50479767~50479991:+
BRCA	cis	rs17256082	0.748	rs6721622	ENSG00000226853.2	AC010894.3	3.39	0.000736	0.0339	0.12	0.1	Glycated hemoglobin levels;	chr2:174371288	chr2:174487389~174488386:+
BRCA	cis	rs709400	0.628	rs4906321	ENSG00000258851.1	RP11-894P9.2	-3.39	0.000736	0.0339	-0.12	-0.1	Body mass index;	chr14:103412545	chr14:103553421~103561877:+
BRCA	cis	rs2070074	1	rs2070074	ENSG00000260947.1	RP11-384P7.7	3.39	0.000736	0.0339	0.19	0.1	CTACK levels;	chr9:34649445	chr9:33697459~33700986:+
BRCA	cis	rs7772486	0.875	rs6914813	ENSG00000270638.1	RP3-466P17.1	3.39	0.000736	0.0339	0.12	0.1	Lobe attachment (rater-scored or self-reported);	chr6:146076662	chr6:145735570~145737218:+
BRCA	cis	rs13434995	0.513	rs880358	ENSG00000273257.1	RP11-177J6.1	-3.39	0.000736	0.0339	-0.16	-0.1	Adiponectin levels;	chr4:55410311	chr4:55387949~55388271:+
BRCA	cis	rs71520386	0.607	rs11767419	ENSG00000179428.2	AC073072.5	3.39	0.000736	0.0339	0.12	0.1	Fibrinogen levels;	chr7:22839364	chr7:22725395~22727620:-
BRCA	cis	rs77106637	1	rs11602858	ENSG00000256633.1	RP11-169D4.2	3.39	0.000737	0.0339	0.15	0.1	Type 2 diabetes;	chr11:72904024	chr11:72584572~72587979:+
BRCA	cis	rs6496932	0.774	rs12901648	ENSG00000176700.18	SCAND2P	-3.39	0.000737	0.0339	-0.14	-0.1	Central corneal thickness;Corneal structure;	chr15:85408487	chr15:84631451~84647478:+
BRCA	cis	rs875971	1	rs11974219	ENSG00000271064.1	RP11-792A8.3	3.39	0.000737	0.0339	0.12	0.1	Aortic root size;	chr7:66182423	chr7:66748838~66749077:-
BRCA	cis	rs11673344	0.503	rs10414520	ENSG00000276846.1	CTD-3220F14.3	3.39	0.000737	0.0339	0.12	0.1	Obesity-related traits;	chr19:37057279	chr19:37314868~37315620:-
BRCA	cis	rs17711722	0.701	rs781143	ENSG00000272831.1	RP11-792A8.4	3.39	0.000737	0.0339	0.09	0.1	Calcium levels;	chr7:65974892	chr7:66739829~66740385:-
BRCA	cis	rs1389724	0.632	rs4839566	ENSG00000231346.4	LINC01160	-3.39	0.000737	0.0339	-0.13	-0.1	Schizophrenia;	chr1:110788378	chr1:111599655~111608723:-
BRCA	cis	rs987724	0.519	rs1875622	ENSG00000240875.4	LINC00886	-3.39	0.000737	0.0339	-0.12	-0.1	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156901217	chr3:156747346~156817062:-
BRCA	cis	rs6545883	0.831	rs1186704	ENSG00000270820.4	RP11-355B11.2	3.39	0.000737	0.0339	0.12	0.1	Tuberculosis;	chr2:61445856	chr2:61471188~61484130:+
BRCA	cis	rs8062405	0.755	rs4788073	ENSG00000261766.1	RP11-22P6.2	-3.39	0.000737	0.0339	-0.1	-0.1	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28583228	chr16:28862166~28863340:-
BRCA	cis	rs1018697	1	rs10786710	ENSG00000236937.2	PTGES3P4	3.39	0.000737	0.0339	0.13	0.1	Colorectal adenoma (advanced);	chr10:102788982	chr10:102845595~102845950:+
BRCA	cis	rs1616122	0.606	rs1193239	ENSG00000229519.2	RP11-58A11.2	3.39	0.000737	0.0339	0.11	0.1	Periodontal microbiota;	chr1:7466127	chr1:6547905~6548619:+
BRCA	cis	rs1005277	0.522	rs200943	ENSG00000273019.1	RP11-508N22.13	-3.39	0.000737	0.0339	-0.12	-0.1	Extrinsic epigenetic age acceleration;	chr10:37859802	chr10:38149968~38150293:+
BRCA	cis	rs11723261	0.621	rs6599306	ENSG00000198155.5	ZNF876P	3.39	0.000737	0.0339	0.18	0.1	Immune response to smallpox vaccine (IL-6);	chr4:149655	chr4:212610~255985:+
BRCA	cis	rs324126	0.78	rs34425941	ENSG00000277977.1	CTD-3018O17.5	3.39	0.000737	0.0339	0.13	0.1	Colonoscopy-negative controls vs population controls;	chr19:52377359	chr19:52392659~52392755:+
BRCA	cis	rs7267979	1	rs448396	ENSG00000276952.1	RP5-965G21.6	3.39	0.000737	0.0339	0.13	0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25459633	chr20:25284915~25285588:-
BRCA	cis	rs10761482	0.906	rs2219534	ENSG00000254271.1	RP11-131N11.4	3.39	0.000737	0.0339	0.14	0.1	Schizophrenia;	chr10:60335167	chr10:60734342~60741828:+
BRCA	cis	rs7520050	0.966	rs61102033	ENSG00000226957.1	RP4-533D7.4	3.39	0.000737	0.0339	0.11	0.1	Reticulocyte count;Red blood cell count;	chr1:45916769	chr1:46046818~46048368:+
BRCA	cis	rs9470794	0.92	rs77640477	ENSG00000204110.6	RP1-153P14.8	-3.39	0.000737	0.0339	-0.21	-0.1	Type 2 diabetes;	chr6:38086241	chr6:37507348~37535616:+
BRCA	cis	rs9470794	0.92	rs73419971	ENSG00000204110.6	RP1-153P14.8	-3.39	0.000737	0.0339	-0.21	-0.1	Type 2 diabetes;	chr6:38086437	chr6:37507348~37535616:+
BRCA	cis	rs4886920	0.536	rs11857840	ENSG00000260776.4	RP11-114H24.2	-3.39	0.000737	0.0339	-0.13	-0.1	Neuroticism;	chr15:77864411	chr15:77914217~77926846:-
BRCA	cis	rs240764	0.755	rs12206564	ENSG00000220695.1	RP1-121G13.3	-3.39	0.000737	0.0339	-0.11	-0.1	Neuroticism;	chr6:100539133	chr6:100530276~100531052:+
BRCA	cis	rs60843830	1	rs3791220	ENSG00000223751.1	AC116609.2	3.39	0.000737	0.0339	0.13	0.1	Spherical equivalent (joint analysis main effects and education interaction);	chr2:227066	chr2:742488~747767:+
BRCA	cis	rs6545883	0.655	rs11893880	ENSG00000270820.4	RP11-355B11.2	3.39	0.000738	0.0339	0.12	0.1	Tuberculosis;	chr2:61194884	chr2:61471188~61484130:+
BRCA	cis	rs17270561	0.636	rs1185977	ENSG00000272462.2	U91328.19	-3.39	0.000738	0.0339	-0.12	-0.1	Iron status biomarkers;	chr6:25828826	chr6:25992662~26001775:+
BRCA	cis	rs7104764	0.957	rs6598064	ENSG00000254910.1	RP11-326C3.7	-3.39	0.000738	0.0339	-0.12	-0.1	Menarche (age at onset);	chr11:243557	chr11:310139~311141:-
BRCA	cis	rs8180040	1	rs11714294	ENSG00000260236.1	RP11-708J19.1	-3.39	0.000738	0.0339	-0.09	-0.1	Colorectal cancer;	chr3:47298233	chr3:47379089~47380999:-
BRCA	cis	rs11148252	0.74	rs3803264	ENSG00000198384.8	TPTE2P3	-3.39	0.000738	0.0339	-0.12	-0.1	Lewy body disease;	chr13:52397758	chr13:52522632~52586906:+
BRCA	cis	rs10792665	0.611	rs12277804	ENSG00000254965.1	RP11-113K21.2	-3.39	0.000738	0.0339	-0.1	-0.1	Obesity-related traits;	chr11:82910507	chr11:83111060~83111442:-
BRCA	cis	rs2832191	0.679	rs2705659	ENSG00000236056.1	GAPDHP14	-3.39	0.000738	0.0339	-0.12	-0.1	Dental caries;	chr21:28991587	chr21:29222321~29223257:+
BRCA	cis	rs2599510	0.783	rs13399071	ENSG00000276517.1	AL133243.2	-3.39	0.000738	0.0339	-0.13	-0.1	Interleukin-18 levels;	chr2:32568716	chr2:32526504~32529507:+
BRCA	cis	rs7267979	1	rs6050555	ENSG00000231081.1	RP4-760C5.3	3.39	0.000738	0.034	0.14	0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25347907	chr20:26008791~26010531:-
BRCA	cis	rs10792665	0.512	rs11233361	ENSG00000254965.1	RP11-113K21.2	-3.39	0.000738	0.034	-0.1	-0.1	Obesity-related traits;	chr11:82886203	chr11:83111060~83111442:-
BRCA	cis	rs13393800	0.956	rs1190453	ENSG00000237126.7	AC073254.1	3.39	0.000738	0.034	0.14	0.1	Height;	chr2:232552602	chr2:232580948~232611971:-
BRCA	cis	rs2153535	0.585	rs58117210	ENSG00000251164.1	HULC	-3.38	0.000738	0.034	-0.12	-0.1	Motion sickness;	chr6:8603881	chr6:8652137~8653846:+
BRCA	cis	rs7954584	0.567	rs1169071	ENSG00000272849.1	RP11-347I19.8	-3.38	0.000738	0.034	-0.08	-0.1	Mean corpuscular volume;	chr12:121952178	chr12:121797511~121801972:+
BRCA	cis	rs7577696	0.962	rs2280967	ENSG00000276334.1	AL133243.1	-3.38	0.000738	0.034	-0.13	-0.1	Inflammatory biomarkers;	chr2:32064677	chr2:32521927~32523547:+
BRCA	cis	rs7520050	0.966	rs4660321	ENSG00000226957.1	RP4-533D7.4	3.38	0.000738	0.034	0.11	0.1	Reticulocyte count;Red blood cell count;	chr1:45901088	chr1:46046818~46048368:+
BRCA	cis	rs7520050	0.931	rs6698247	ENSG00000226957.1	RP4-533D7.4	3.38	0.000738	0.034	0.11	0.1	Reticulocyte count;Red blood cell count;	chr1:45905814	chr1:46046818~46048368:+
BRCA	cis	rs7520050	0.966	rs6675946	ENSG00000226957.1	RP4-533D7.4	3.38	0.000738	0.034	0.11	0.1	Reticulocyte count;Red blood cell count;	chr1:45906102	chr1:46046818~46048368:+
BRCA	cis	rs7520050	0.931	rs7526678	ENSG00000226957.1	RP4-533D7.4	3.38	0.000738	0.034	0.11	0.1	Reticulocyte count;Red blood cell count;	chr1:45908487	chr1:46046818~46048368:+
BRCA	cis	rs6545883	0.862	rs778141	ENSG00000273302.1	RP11-493E12.2	3.38	0.000738	0.034	0.1	0.1	Tuberculosis;	chr2:61455043	chr2:61199979~61200769:+
BRCA	cis	rs9926296	0.744	rs164749	ENSG00000275734.1	RP11-368I7.6	-3.38	0.000739	0.034	-0.11	-0.1	Vitiligo;	chr16:89641816	chr16:89684642~89685304:+
BRCA	cis	rs26949	0.504	rs10054744	ENSG00000251279.1	CTC-436P18.1	3.38	0.000739	0.034	0.13	0.1	Intelligence (multi-trait analysis);	chr5:60744220	chr5:61162070~61232040:+
BRCA	cis	rs61160187	0.51	rs4577661	ENSG00000251279.1	CTC-436P18.1	3.38	0.000739	0.034	0.13	0.1	Educational attainment (years of education);Educational attainment (college completion);	chr5:60744640	chr5:61162070~61232040:+
BRCA	cis	rs2882667	0.69	rs6596456	ENSG00000242683.1	CTB-46B19.1	-3.38	0.000739	0.034	-0.12	-0.1	Age-related hearing impairment (SNP x SNP interaction);	chr5:138831808	chr5:139035148~139035987:-
BRCA	cis	rs2346177	0.875	rs2881327	ENSG00000279254.1	RP11-536C12.1	-3.38	0.000739	0.034	-0.12	-0.1	HDL cholesterol;	chr2:46414816	chr2:46668870~46670778:+
BRCA	cis	rs10864907	0.691	rs4848306	ENSG00000231747.1	AC079922.2	3.38	0.000739	0.034	0.1	0.1	Pulmonary function;	chr2:112840530	chr2:112621809~112622167:-
BRCA	cis	rs6456156	0.773	rs6456159	ENSG00000272549.1	RP11-351J23.2	3.38	0.000739	0.034	0.1	0.1	Primary biliary cholangitis;	chr6:167115784	chr6:167666840~167679270:-
BRCA	cis	rs2262909	0.962	rs439574	ENSG00000279377.1	AC003973.3	3.38	0.000739	0.034	0.14	0.1	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;	chr19:22049222	chr19:21965708~21968529:-
BRCA	cis	rs1912124	1	rs68193205	ENSG00000259343.4	TMC3-AS1	3.38	0.000739	0.034	0.24	0.1	Peripheral arterial disease (traffic-related air pollution interaction);	chr15:81225114	chr15:81324377~81362037:+
BRCA	cis	rs35146811	0.735	rs2272345	ENSG00000221487.1	AC069294.1	3.38	0.000739	0.034	0.13	0.1	Coronary artery disease;	chr7:100199408	chr7:99713037~99713152:+
BRCA	cis	rs1838105	0.674	rs10514915	ENSG00000263142.4	LRRC37A17P	3.38	0.000739	0.034	0.08	0.1	Nonsyndromic cleft lip with cleft palate;	chr17:47088760	chr17:46978481~47054569:+
BRCA	cis	rs1032833	0.66	rs77975658	ENSG00000271401.1	RP11-171I2.3	-3.38	0.000739	0.034	-0.25	-0.1	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);	chr2:179108627	chr2:178644717~178645179:+
BRCA	cis	rs1032833	0.732	rs1048026	ENSG00000271401.1	RP11-171I2.3	-3.38	0.000739	0.034	-0.25	-0.1	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);	chr2:179108740	chr2:178644717~178645179:+
BRCA	cis	rs818427	0.964	rs151978	ENSG00000279522.1	CTC-487M23.6	3.38	0.000739	0.034	0.12	0.1	Total body bone mineral density;	chr5:112898801	chr5:112894933~112896531:+
BRCA	cis	rs9813712	0.818	rs16845853	ENSG00000228252.7	COL6A4P2	3.38	0.000739	0.034	0.14	0.1	Response to amphetamines;	chr3:130229587	chr3:130212823~130273806:+
BRCA	cis	rs10792665	0.512	rs7928466	ENSG00000254965.1	RP11-113K21.2	-3.38	0.000739	0.034	-0.1	-0.1	Obesity-related traits;	chr11:82885691	chr11:83111060~83111442:-
BRCA	cis	rs2242116	0.592	rs2290545	ENSG00000273682.1	RP11-427P5.3	3.38	0.000739	0.034	0.13	0.1	Birth weight;	chr3:46925550	chr3:46918807~46918935:-
BRCA	cis	rs61542988	0.57	rs62448267	ENSG00000228649.7	AC005682.5	3.38	0.000739	0.034	0.11	0.1	Fibrinogen levels;	chr7:22782882	chr7:22854178~22861579:+
BRCA	cis	rs61869271	0.688	rs2420070	ENSG00000236799.1	RP11-383C6.2	3.38	0.000739	0.034	0.12	0.1	Tonsillectomy;	chr10:114921569	chr10:114994657~114996593:+
BRCA	cis	rs863345	0.604	rs6663277	ENSG00000176320.2	RP11-404O13.5	-3.38	0.000739	0.034	-0.11	-0.1	Pneumococcal bacteremia;	chr1:158525211	chr1:158197922~158203877:-
BRCA	cis	rs2811415	0.597	rs2033445	ENSG00000242551.2	POU5F1P6	3.38	0.000739	0.034	0.14	0.1	Lung function (FEV1/FVC);	chr3:128011664	chr3:128674735~128677005:-
BRCA	cis	rs948562	0.744	rs73485972	ENSG00000255299.4	RP11-655C2.3	-3.38	0.000739	0.034	-0.12	-0.1	Lymphoma;	chr11:58452991	chr11:58497888~58505758:-
BRCA	cis	rs300890	0.651	rs300917	ENSG00000250326.1	RP11-284M14.1	3.38	0.000739	0.034	0.12	0.1	Nasopharyngeal carcinoma;	chr4:143348696	chr4:142933195~143184861:-
BRCA	cis	rs7200543	1	rs6498541	ENSG00000270580.4	PKD1P6	3.38	0.000739	0.034	0.11	0.1	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15046800	chr16:15104723~15131601:-
BRCA	cis	rs4664293	0.867	rs6720304	ENSG00000230783.1	AC009961.2	-3.38	0.000739	0.034	-0.14	-0.1	Monocyte percentage of white cells;	chr2:159787321	chr2:159689217~159690291:-
BRCA	cis	rs4834770	0.668	rs10007409	ENSG00000249244.1	RP11-548H18.2	-3.38	0.000739	0.034	-0.12	-0.1	Blood protein levels;	chr4:119221151	chr4:119391831~119395335:-
BRCA	cis	rs2518049	1	rs4478887	ENSG00000224034.1	RP11-445P17.8	3.38	0.000739	0.034	0.18	0.1	Metabolic traits;	chr10:5100605	chr10:5266033~5271236:-
BRCA	cis	rs80226907	1	rs117376143	ENSG00000258413.1	RP11-665C16.6	-3.38	0.00074	0.034	-0.28	-0.1	Mean platelet volume;	chr14:55356604	chr14:55262767~55272075:-
BRCA	cis	rs12893668	0.572	rs11846404	ENSG00000258914.1	CTD-2134A5.3	3.38	0.00074	0.034	0.14	0.1	Reticulocyte count;	chr14:103689771	chr14:103875055~103877478:+
BRCA	cis	rs875971	0.964	rs6945019	ENSG00000272831.1	RP11-792A8.4	3.38	0.00074	0.034	0.09	0.1	Aortic root size;	chr7:66457471	chr7:66739829~66740385:-
BRCA	cis	rs4869313	0.594	rs2549782	ENSG00000248734.2	CTD-2260A17.1	-3.38	0.00074	0.034	-0.1	-0.1	Pediatric autoimmune diseases;	chr5:96895296	chr5:96784777~96785999:+
BRCA	cis	rs4869313	0.593	rs2549784	ENSG00000248734.2	CTD-2260A17.1	-3.38	0.00074	0.034	-0.1	-0.1	Pediatric autoimmune diseases;	chr5:96895816	chr5:96784777~96785999:+
BRCA	cis	rs4869313	0.642	rs2548538	ENSG00000248734.2	CTD-2260A17.1	-3.38	0.00074	0.034	-0.1	-0.1	Pediatric autoimmune diseases;	chr5:96896438	chr5:96784777~96785999:+
BRCA	cis	rs4869313	0.617	rs2548537	ENSG00000248734.2	CTD-2260A17.1	-3.38	0.00074	0.034	-0.1	-0.1	Pediatric autoimmune diseases;	chr5:96896518	chr5:96784777~96785999:+
BRCA	cis	rs4869313	0.617	rs2549785	ENSG00000248734.2	CTD-2260A17.1	-3.38	0.00074	0.034	-0.1	-0.1	Pediatric autoimmune diseases;	chr5:96896582	chr5:96784777~96785999:+
BRCA	cis	rs4869313	0.703	rs2548535	ENSG00000248734.2	CTD-2260A17.1	-3.38	0.00074	0.034	-0.1	-0.1	Pediatric autoimmune diseases;	chr5:96896995	chr5:96784777~96785999:+
BRCA	cis	rs4869313	0.618	rs2548534	ENSG00000248734.2	CTD-2260A17.1	-3.38	0.00074	0.034	-0.1	-0.1	Pediatric autoimmune diseases;	chr5:96897904	chr5:96784777~96785999:+
BRCA	cis	rs4869313	0.595	rs3096167	ENSG00000248734.2	CTD-2260A17.1	-3.38	0.00074	0.034	-0.1	-0.1	Pediatric autoimmune diseases;	chr5:96898510	chr5:96784777~96785999:+
BRCA	cis	rs4869313	0.668	rs2042383	ENSG00000248734.2	CTD-2260A17.1	-3.38	0.00074	0.034	-0.1	-0.1	Pediatric autoimmune diseases;	chr5:96898917	chr5:96784777~96785999:+
BRCA	cis	rs4869313	0.668	rs193993	ENSG00000248734.2	CTD-2260A17.1	-3.38	0.00074	0.034	-0.1	-0.1	Pediatric autoimmune diseases;	chr5:96899168	chr5:96784777~96785999:+
BRCA	cis	rs4869313	0.668	rs2248374	ENSG00000248734.2	CTD-2260A17.1	-3.38	0.00074	0.034	-0.1	-0.1	Pediatric autoimmune diseases;	chr5:96900192	chr5:96784777~96785999:+
BRCA	cis	rs4869313	0.642	rs2113190	ENSG00000248734.2	CTD-2260A17.1	-3.38	0.00074	0.034	-0.1	-0.1	Pediatric autoimmune diseases;	chr5:96900614	chr5:96784777~96785999:+
BRCA	cis	rs4869313	0.642	rs2287988	ENSG00000248734.2	CTD-2260A17.1	-3.38	0.00074	0.034	-0.1	-0.1	Pediatric autoimmune diseases;	chr5:96901622	chr5:96784777~96785999:+
BRCA	cis	rs4869313	0.668	rs171647	ENSG00000248734.2	CTD-2260A17.1	-3.38	0.00074	0.034	-0.1	-0.1	Pediatric autoimmune diseases;	chr5:96901709	chr5:96784777~96785999:+
BRCA	cis	rs6964587	0.839	rs12536702	ENSG00000188693.7	CYP51A1-AS1	-3.38	0.00074	0.034	-0.11	-0.1	Breast cancer;	chr7:91842262	chr7:92134604~92180725:+
BRCA	cis	rs11239930	0.517	rs942689	ENSG00000227242.3	NBPF13P	-3.38	0.00074	0.034	-0.13	-0.1	AIDS progression;	chr1:147079231	chr1:147021320~147124525:-
BRCA	cis	rs10883723	0.81	rs10748823	ENSG00000213061.2	PFN1P11	-3.38	0.00074	0.034	-0.14	-0.1	Allergic disease (asthma, hay fever or eczema);	chr10:102514708	chr10:102838011~102845473:-
BRCA	cis	rs17221829	0.59	rs10830300	ENSG00000280385.1	AP000648.5	-3.38	0.00074	0.034	-0.12	-0.1	Anxiety in major depressive disorder;	chr11:89629898	chr11:90193614~90198120:+
BRCA	cis	rs10211296	0.585	rs729869	ENSG00000223318.1	RNA5SP111	-3.38	0.00074	0.034	-0.13	-0.1	Risky sexual behaviors in alcohol dependence;	chr2:165629846	chr2:164895677~164895777:-
BRCA	cis	rs2640806	0.645	rs62514609	ENSG00000253105.4	KB-1448A5.1	3.38	0.00074	0.034	0.12	0.1	Obesity-related traits;	chr8:96321597	chr8:96371865~96387438:-
BRCA	cis	rs997295	0.592	rs7162320	ENSG00000259673.4	IQCH-AS1	3.38	0.00074	0.034	0.12	0.1	Motion sickness;	chr15:67473700	chr15:67403619~67521844:-
BRCA	cis	rs3760982	0.967	rs3760984	ENSG00000278917.1	RP11-15A1.4	-3.38	0.00074	0.034	-0.12	-0.1	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43782610	chr19:43891233~43895411:+
BRCA	cis	rs4578769	0.765	rs10502430	ENSG00000273232.1	RP11-370A5.2	-3.38	0.00074	0.034	-0.15	-0.1	Eosinophil percentage of white cells;	chr18:22916946	chr18:22882825~22883357:-
BRCA	cis	rs9341808	0.69	rs2322634	ENSG00000279022.1	RP11-250B2.4	3.38	0.00074	0.034	0.12	0.1	Sitting height ratio;	chr6:80164297	chr6:80440730~80441172:+
BRCA	cis	rs2882667	0.69	rs7446631	ENSG00000242683.1	CTB-46B19.1	3.38	0.00074	0.034	0.12	0.1	Age-related hearing impairment (SNP x SNP interaction);	chr5:138891376	chr5:139035148~139035987:-
BRCA	cis	rs13113518	0.51	rs3749473	ENSG00000239040.1	Y_RNA	-3.38	0.00074	0.034	-0.11	-0.1	Height;	chr4:55428461	chr4:55412636~55412738:+
BRCA	cis	rs4267450	0.697	rs11667683	ENSG00000261770.1	CTC-459F4.1	3.38	0.00074	0.034	0.21	0.1	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);	chr19:28381856	chr19:27757184~27760849:-
BRCA	cis	rs11969893	0.85	rs3734351	ENSG00000260000.2	RP3-467N11.1	-3.38	0.00074	0.034	-0.22	-0.1	Economic and political preferences (immigration/crime);	chr6:100859255	chr6:100881471~100882987:+
BRCA	cis	rs10876993	0.89	rs2640630	ENSG00000269903.1	RP11-571M6.18	3.38	0.00074	0.034	0.13	0.1	Celiac disease or Rheumatoid arthritis;	chr12:57673484	chr12:57814494~57814926:+
BRCA	cis	rs11902236	0.545	rs3791749	ENSG00000188525.3	AC010969.1	-3.38	0.00074	0.034	-0.12	-0.1	Prostate cancer;	chr2:9999636	chr2:10003158~10006030:-
BRCA	cis	rs8058578	0.887	rs28421305	ENSG00000260082.1	RP11-2C24.5	3.38	0.00074	0.034	0.12	0.1	Multiple myeloma;	chr16:30826807	chr16:30821068~30822110:-
BRCA	cis	rs11098499	0.863	rs3822192	ENSG00000260091.1	RP11-33B1.4	-3.38	0.000741	0.034	-0.1	-0.1	Corneal astigmatism;	chr4:119524565	chr4:119409333~119410233:+
BRCA	cis	rs4388249	1	rs13172735	ENSG00000249068.1	CTC-287O8.1	-3.38	0.000741	0.034	-0.15	-0.1	Schizophrenia;	chr5:109724132	chr5:109840128~109840692:-
BRCA	cis	rs12477602	0.938	rs13027711	ENSG00000272966.1	RP11-686O6.1	3.38	0.000741	0.034	0.17	0.1	Intelligence (multi-trait analysis);	chr2:202420974	chr2:202336739~202337200:+
BRCA	cis	rs10256972	0.758	rs7799391	ENSG00000199023.2	MIR339	-3.38	0.000741	0.034	-0.13	-0.1	Endometriosis;Longevity;	chr7:1042930	chr7:1022935~1023045:-
BRCA	cis	rs13315871	0.929	rs7635697	ENSG00000272182.1	RP11-802O23.3	3.38	0.000741	0.034	0.21	0.1	Cholesterol, total;	chr3:58327979	chr3:58428255~58428815:+
BRCA	cis	rs721917	0.646	rs2819096	ENSG00000244733.5	RP11-506M13.3	-3.38	0.000741	0.034	-0.12	-0.1	Chronic obstructive pulmonary disease;	chr10:79947857	chr10:79660891~79677996:+
BRCA	cis	rs490234	0.812	rs4838286	ENSG00000232630.1	PRPS1P2	-3.38	0.000741	0.034	-0.11	-0.1	Mean arterial pressure;	chr9:125697778	chr9:125150653~125151589:+
BRCA	cis	rs494453	0.744	rs2182016	ENSG00000227811.2	FAM212B-AS1	3.38	0.000741	0.034	0.15	0.1	Osteoporosis-related phenotypes;	chr1:111641877	chr1:111739841~111747798:+
BRCA	cis	rs9527	0.615	rs7096452	ENSG00000236937.2	PTGES3P4	3.38	0.000741	0.0341	0.14	0.1	Arsenic metabolism;	chr10:102976806	chr10:102845595~102845950:+
BRCA	cis	rs9527	0.615	rs7080462	ENSG00000236937.2	PTGES3P4	3.38	0.000741	0.0341	0.14	0.1	Arsenic metabolism;	chr10:102976942	chr10:102845595~102845950:+
BRCA	cis	rs67180937	0.504	rs3008625	ENSG00000225265.1	TAF1A-AS1	-3.38	0.000741	0.0341	-0.13	-0.1	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222646680	chr1:222589825~222593032:+
BRCA	cis	rs1334894	0.892	rs11545925	ENSG00000187762.5	HSPE1P11	3.38	0.000741	0.0341	0.25	0.1	Coronary artery disease;	chr6:35574749	chr6:35023522~35023831:+
BRCA	cis	rs4388249	1	rs2284990	ENSG00000271849.1	CTC-332L22.1	-3.38	0.000741	0.0341	-0.17	-0.1	Schizophrenia;	chr5:109743666	chr5:109687802~109688329:-
BRCA	cis	rs4388249	1	rs2300997	ENSG00000271849.1	CTC-332L22.1	-3.38	0.000741	0.0341	-0.17	-0.1	Schizophrenia;	chr5:109746893	chr5:109687802~109688329:-
BRCA	cis	rs6840360	0.837	rs4696294	ENSG00000251611.1	RP11-610P16.1	3.38	0.000741	0.0341	0.09	0.1	Intelligence (multi-trait analysis);	chr4:151791937	chr4:151407551~151408835:-
BRCA	cis	rs875971	0.964	rs778723	ENSG00000229886.1	RP5-1132H15.3	3.38	0.000741	0.0341	0.11	0.1	Aortic root size;	chr7:66364510	chr7:66025126~66031544:-
BRCA	cis	rs8114671	0.562	rs725521	ENSG00000261582.1	RP4-614O4.11	-3.38	0.000741	0.0341	-0.1	-0.1	Height;	chr20:34928268	chr20:35267885~35280043:-
BRCA	cis	rs4835473	0.897	rs7656786	ENSG00000246448.2	RP13-578N3.3	-3.38	0.000741	0.0341	-0.12	-0.1	Immature fraction of reticulocytes;	chr4:143759455	chr4:143700257~143865072:+
BRCA	cis	rs17756712	0.57	rs1122256	ENSG00000271727.1	RP11-532F6.4	3.38	0.000741	0.0341	0.15	0.1	Vertical cup-disc ratio;	chr6:611969	chr6:711533~750729:+
BRCA	cis	rs8062405	0.755	rs7193402	ENSG00000261766.1	RP11-22P6.2	-3.38	0.000741	0.0341	-0.1	-0.1	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28574806	chr16:28862166~28863340:-
BRCA	cis	rs72772090	0.539	rs11749811	ENSG00000272109.1	CTD-2260A17.3	3.38	0.000741	0.0341	0.2	0.1	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96780221	chr5:96804353~96806105:+
BRCA	cis	rs9311676	0.594	rs55954186	ENSG00000244161.1	FLNB-AS1	-3.38	0.000741	0.0341	-0.09	-0.1	Systemic lupus erythematosus;	chr3:58450749	chr3:58162547~58170636:-
BRCA	cis	rs2836950	0.501	rs4818018	ENSG00000235701.1	PCBP2P1	-3.38	0.000741	0.0341	-0.12	-0.1	Menarche (age at onset);	chr21:39322146	chr21:39171130~39172106:-
BRCA	cis	rs2836950	0.501	rs4818019	ENSG00000235701.1	PCBP2P1	-3.38	0.000741	0.0341	-0.12	-0.1	Menarche (age at onset);	chr21:39322530	chr21:39171130~39172106:-
BRCA	cis	rs13401620	0.587	rs12476921	ENSG00000236878.1	AC012363.7	3.38	0.000741	0.0341	0.13	0.1	Breast size;	chr2:120097877	chr2:120211054~120211715:+
BRCA	cis	rs748802	0.704	rs10814296	ENSG00000231518.1	RP11-327L3.3	-3.38	0.000741	0.0341	-0.13	-0.1	Resting heart rate;	chr9:35910804	chr9:35930012~35937151:+
BRCA	cis	rs8127691	0.967	rs762422	ENSG00000225331.1	AP001055.6	-3.38	0.000741	0.0341	-0.12	-0.1	Inflammatory bowel disease;	chr21:44195755	chr21:44158740~44160076:-
BRCA	cis	rs1870634	0.518	rs4948811	ENSG00000273008.1	RP11-351D16.3	-3.38	0.000741	0.0341	-0.12	-0.1	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;	chr10:44004491	chr10:43136824~43138334:-
BRCA	cis	rs7020830	0.898	rs997318	ENSG00000230188.1	RP11-405L18.4	-3.38	0.000742	0.0341	-0.13	-0.1	Schizophrenia;	chr9:37364097	chr9:37490421~37490893:-
BRCA	cis	rs9650657	0.504	rs10109167	ENSG00000254866.2	DEFB109P3	3.38	0.000742	0.0341	0.13	0.1	Neuroticism;	chr8:11176016	chr8:12150895~12151134:-
BRCA	cis	rs8062405	0.755	rs7186573	ENSG00000261766.1	RP11-22P6.2	-3.38	0.000742	0.0341	-0.1	-0.1	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576068	chr16:28862166~28863340:-
BRCA	cis	rs66887589	0.777	rs2017058	ENSG00000249244.1	RP11-548H18.2	3.38	0.000742	0.0341	0.11	0.1	Diastolic blood pressure;	chr4:119336584	chr4:119391831~119395335:-
BRCA	cis	rs11209261	0.572	rs4926352	ENSG00000232284.6	GNG12-AS1	3.38	0.000742	0.0341	0.11	0.1	Airflow obstruction;	chr1:68337872	chr1:67832303~68202987:+
BRCA	cis	rs11039100	0.85	rs34161300	ENSG00000224295.2	AC087380.14	3.38	0.000742	0.0341	0.2	0.1	Peripheral arterial disease (traffic-related air pollution interaction);	chr11:5809510	chr11:5518441~5524955:-
BRCA	cis	rs8056446	0.71	rs8059793	ENSG00000280274.1	RP11-556H2.1	-3.38	0.000742	0.0341	-0.12	-0.1	Pulmonary function (smoking interaction);	chr16:78155401	chr16:79016136~79017429:+
BRCA	cis	rs16917546	0.935	rs10822050	ENSG00000238280.1	RP11-436D10.3	3.38	0.000742	0.0341	0.14	0.1	Basal cell carcinoma;	chr10:62679011	chr10:62793562~62805887:-
BRCA	cis	rs6678639	0.522	rs2221324	ENSG00000225154.2	RP11-184J23.2	-3.38	0.000742	0.0341	-0.16	-0.1	Blood metabolite ratios;	chr1:47038545	chr1:47074778~47075979:-
BRCA	cis	rs62458065	0.513	rs10265319	ENSG00000273014.1	RP11-225B17.2	-3.38	0.000742	0.0341	-0.16	-0.1	Metabolite levels (HVA/MHPG ratio);	chr7:32531952	chr7:32758882~32759353:+
BRCA	cis	rs910873	0.803	rs1885120	ENSG00000250917.1	RP4-785G19.5	-3.38	0.000742	0.0341	-0.29	-0.1	Melanoma;	chr20:34989186	chr20:34234840~34281173:-
BRCA	cis	rs7940866	0.74	rs2162060	ENSG00000254842.5	RP11-890B15.2	3.38	0.000742	0.0341	0.12	0.1	Schizophrenia;	chr11:130960868	chr11:130844191~130865561:-
BRCA	cis	rs10191559	0.552	rs6717590	ENSG00000234663.4	AC104820.2	3.38	0.000742	0.0341	0.09	0.1	Red blood cell count;	chr2:181219100	chr2:181101932~181399559:+
BRCA	cis	rs10191559	0.552	rs4511685	ENSG00000234663.4	AC104820.2	3.38	0.000742	0.0341	0.09	0.1	Red blood cell count;	chr2:181219937	chr2:181101932~181399559:+
BRCA	cis	rs10191559	0.508	rs4233795	ENSG00000234663.4	AC104820.2	3.38	0.000742	0.0341	0.09	0.1	Red blood cell count;	chr2:181222524	chr2:181101932~181399559:+
BRCA	cis	rs4308124	1	rs4308124	ENSG00000271590.1	RP11-181E10.3	3.38	0.000742	0.0341	0.1	0.1	Vitiligo;	chr2:111252909	chr2:111210995~111212476:-
BRCA	cis	rs6496932	0.802	rs2063442	ENSG00000259630.2	CTD-2262B20.1	3.38	0.000742	0.0341	0.13	0.1	Central corneal thickness;Corneal structure;	chr15:85314813	chr15:85415228~85415633:+
BRCA	cis	rs78587638	0.79	rs76588671	ENSG00000226856.4	AC093901.1	-3.38	0.000742	0.0341	-0.19	-0.1	Mosquito bite size;	chr2:118406151	chr2:118132128~118186386:-
BRCA	cis	rs4665809	1	rs11678157	ENSG00000231655.1	AC011742.3	3.38	0.000742	0.0341	0.15	0.1	Gut microbiome composition (summer);	chr2:26098657	chr2:26140263~26141264:-
BRCA	cis	rs9394169	0.875	rs1547669	ENSG00000249346.5	LINC01016	-3.38	0.000742	0.0341	-0.1	-0.1	Essential tremor;	chr6:33807864	chr6:33867506~33896914:-
BRCA	cis	rs959695	1	rs2442756	ENSG00000253948.1	RP11-410L14.2	3.38	0.000742	0.0341	0.12	0.1	Hippocampal atrophy;	chr8:99816910	chr8:98996763~99013044:-
BRCA	cis	rs7165170	0.529	rs4454949	ENSG00000245479.2	LINC01585	3.38	0.000742	0.0341	0.13	0.1	Crohn's disease;Inflammatory bowel disease;	chr15:90603950	chr15:90660234~90664967:+
BRCA	cis	rs2216824	1	rs12328359	ENSG00000278908.1	RP11-523J2.1	3.38	0.000742	0.0341	0.18	0.1	Oropharynx cancer;	chr2:30883379	chr2:30677762~30679895:+
BRCA	cis	rs11887277	0.557	rs12473482	ENSG00000272148.1	RP11-195B17.1	-3.38	0.000743	0.0341	-0.12	-0.1	Obesity-related traits;	chr2:26752300	chr2:27062428~27062907:-
BRCA	cis	rs11887277	0.557	rs2384412	ENSG00000272148.1	RP11-195B17.1	-3.38	0.000743	0.0341	-0.12	-0.1	Obesity-related traits;	chr2:26753843	chr2:27062428~27062907:-
BRCA	cis	rs4767841	0.904	rs278110	ENSG00000248636.5	RP11-768F21.1	-3.38	0.000743	0.0341	-0.13	-0.1	Urgency urinary incontinence;	chr12:119734722	chr12:119387987~119668079:-
BRCA	cis	rs7703051	1	rs10045497	ENSG00000271815.1	CTD-2235C13.3	-3.38	0.000743	0.0341	-0.14	-0.1	Age-related diseases, mortality and associated endophenotypes;LDL cholesterol;Age-related disease endophenotypes;	chr5:75340659	chr5:75363760~75364242:+
BRCA	cis	rs1005277	0.579	rs1780122	ENSG00000276805.1	RP11-291L22.6	3.38	0.000743	0.0341	0.11	0.1	Extrinsic epigenetic age acceleration;	chr10:38240581	chr10:38451030~38451785:+
BRCA	cis	rs2243480	0.901	rs57126451	ENSG00000234585.5	CCT6P3	-3.38	0.000743	0.0341	-0.15	-0.1	Diabetic kidney disease;	chr7:65951319	chr7:65038354~65074713:+
BRCA	cis	rs2694917	0.68	rs2657880	ENSG00000257576.1	RP11-153M3.1	3.38	0.000743	0.0341	0.19	0.1	Blood metabolite ratios;	chr12:56469986	chr12:56511002~56512703:+
BRCA	cis	rs11098499	0.955	rs4145951	ENSG00000260404.2	RP11-384K6.6	3.38	0.000743	0.0341	0.1	0.1	Corneal astigmatism;	chr4:119234662	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.955	rs35916640	ENSG00000260404.2	RP11-384K6.6	3.38	0.000743	0.0341	0.1	0.1	Corneal astigmatism;	chr4:119234697	chr4:118591773~118633729:+
BRCA	cis	rs4243971	0.516	rs56930149	ENSG00000275576.1	RP5-836N17.4	-3.38	0.000743	0.0341	-0.12	-0.1	Inflammatory bowel disease;Crohn's disease;	chr20:32288383	chr20:32116171~32116629:+
BRCA	cis	rs1124769	0.619	rs4598846	ENSG00000274528.1	CTD-2650P22.2	3.38	0.000743	0.0341	0.12	0.1	Cognitive performance;	chr15:51095918	chr15:52017167~52018032:-
BRCA	cis	rs1005277	0.579	rs1780145	ENSG00000276805.1	RP11-291L22.6	3.38	0.000743	0.0341	0.11	0.1	Extrinsic epigenetic age acceleration;	chr10:38248142	chr10:38451030~38451785:+
BRCA	cis	rs4950322	0.57	rs79810882	ENSG00000277406.1	CH17-385C13.2	-3.38	0.000743	0.0341	-0.14	-0.1	Protein quantitative trait loci;	chr1:147235575	chr1:146321842~146328211:-
BRCA	cis	rs2562456	0.917	rs6511256	ENSG00000268705.1	BNIP3P26	-3.38	0.000743	0.0341	-0.12	-0.1	Pain;	chr19:21510513	chr19:21521343~21521896:-
BRCA	cis	rs10792665	0.541	rs7106519	ENSG00000254965.1	RP11-113K21.2	3.38	0.000743	0.0341	0.1	0.1	Obesity-related traits;	chr11:82916988	chr11:83111060~83111442:-
BRCA	cis	rs9990333	0.562	rs56038600	ENSG00000273009.1	RP11-352G9.1	-3.38	0.000743	0.0341	-0.13	-0.1	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196090109	chr3:195913078~195913683:-
BRCA	cis	rs13393800	0.697	rs10206657	ENSG00000237126.7	AC073254.1	3.38	0.000743	0.0341	0.15	0.1	Height;	chr2:232597385	chr2:232580948~232611971:-
BRCA	cis	rs6840360	0.571	rs7664663	ENSG00000278978.1	RP11-164P12.5	-3.38	0.000743	0.0341	-0.12	-0.1	Intelligence (multi-trait analysis);	chr4:151586862	chr4:151669786~151670503:+
BRCA	cis	rs826838	0.559	rs4882276	ENSG00000257718.1	RP11-396F22.1	3.38	0.000743	0.0341	0.1	0.1	Heart rate;	chr12:38218192	chr12:38906451~38909592:+
BRCA	cis	rs2153535	0.526	rs9505487	ENSG00000251164.1	HULC	-3.38	0.000743	0.0341	-0.12	-0.1	Motion sickness;	chr6:8593521	chr6:8652137~8653846:+
BRCA	cis	rs6714710	0.535	rs13033383	ENSG00000228486.8	LINC01125	-3.38	0.000743	0.0341	-0.1	-0.1	Posterior cortical atrophy and Alzheimer's disease;	chr2:97723050	chr2:97664217~97703064:+
BRCA	cis	rs5762752	0.555	rs695388	ENSG00000235954.5	TTC28-AS1	-3.38	0.000743	0.0341	-0.11	-0.1	Optic disc area;	chr22:28437514	chr22:27919376~28008581:+
BRCA	cis	rs2555155	0.935	rs61151131	ENSG00000254595.1	CTD-2010I16.1	3.38	0.000743	0.0341	0.12	0.1	DNA methylation (variation);	chr11:6500161	chr11:6488186~6489377:-
BRCA	cis	rs2832077	0.883	rs11702413	ENSG00000215533.7	LINC00189	3.38	0.000743	0.0341	0.15	0.1	Cognitive test performance;	chr21:28816072	chr21:29193480~29288205:+
BRCA	cis	rs2625529	0.529	rs1552133	ENSG00000261187.1	RP11-1007O24.2	3.38	0.000743	0.0341	0.11	0.1	Red blood cell count;	chr15:71940556	chr15:72465128~72466262:-
BRCA	cis	rs2625529	0.556	rs1552134	ENSG00000261187.1	RP11-1007O24.2	3.38	0.000743	0.0341	0.11	0.1	Red blood cell count;	chr15:71940557	chr15:72465128~72466262:-
BRCA	cis	rs7647973	0.56	rs77473999	ENSG00000228008.1	CTD-2330K9.3	3.38	0.000743	0.0342	0.14	0.1	Menarche (age at onset);	chr3:49740227	chr3:49903845~49916937:+
BRCA	cis	rs2832077	0.527	rs9981922	ENSG00000176054.6	RPL23P2	-3.38	0.000744	0.0342	-0.12	-0.1	Cognitive test performance;	chr21:28840396	chr21:28997613~28998033:-
BRCA	cis	rs17685	0.725	rs4728548	ENSG00000205485.12	AC004980.7	3.38	0.000744	0.0342	0.12	0.1	Coffee consumption (cups per day);Coffee consumption;	chr7:76025314	chr7:76549360~76627982:+
BRCA	cis	rs73206853	0.62	rs17682644	ENSG00000277299.1	RP11-837J7.4	-3.38	0.000744	0.0342	-0.2	-0.1	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr12:110718203	chr12:109948389~109949029:+
BRCA	cis	rs3015497	0.637	rs12587877	ENSG00000259113.1	RP11-406H23.2	3.38	0.000744	0.0342	0.12	0.1	Mean platelet volume;	chr14:50710284	chr14:50448807~50456742:+
BRCA	cis	rs4921164	1	rs55874544	ENSG00000245812.2	RP11-175K6.1	-3.38	0.000744	0.0342	-0.13	-0.1	Gut microbiome composition (winter);	chr5:159117454	chr5:159100483~159117478:+
BRCA	cis	rs6432860	0.545	rs1841550	ENSG00000232411.1	AC009495.3	-3.38	0.000744	0.0342	-0.12	-0.1	Febrile seizures (MMR vaccine-unrelated);Febrile seizures;	chr2:166057723	chr2:165833048~165839098:-
BRCA	cis	rs3011225	0.738	rs783303	ENSG00000237950.1	RP11-7O11.3	3.38	0.000744	0.0342	0.16	0.1	Amyotrophic lateral sclerosis (age of onset);	chr1:43899857	chr1:43944370~43946551:-
BRCA	cis	rs495337	0.736	rs483508	ENSG00000229222.1	KRT18P4	-3.38	0.000744	0.0342	-0.13	-0.1	Psoriasis;	chr20:49883072	chr20:49956745~49958032:+
BRCA	cis	rs4462272	0.557	rs17885645	ENSG00000230224.1	PHBP9	3.38	0.000744	0.0342	0.09	0.1	Age-related hearing impairment (SNP x SNP interaction);	chr10:100227710	chr10:100248271~100249095:+
BRCA	cis	rs12778749	0.596	rs11819232	ENSG00000234134.1	RP11-383C5.5	3.38	0.000744	0.0342	0.15	0.1	Endometrial cancer;	chr10:126135969	chr10:125718771~125719365:-
BRCA	cis	rs7267979	0.873	rs6083853	ENSG00000231081.1	RP4-760C5.3	3.38	0.000744	0.0342	0.14	0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25423905	chr20:26008791~26010531:-
BRCA	cis	rs7267979	0.934	rs2482913	ENSG00000231081.1	RP4-760C5.3	3.38	0.000744	0.0342	0.14	0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25424450	chr20:26008791~26010531:-
BRCA	cis	rs6714710	0.603	rs11680321	ENSG00000228486.8	LINC01125	-3.38	0.000744	0.0342	-0.09	-0.1	Posterior cortical atrophy and Alzheimer's disease;	chr2:97762804	chr2:97664217~97703064:+
BRCA	cis	rs6714710	0.58	rs6711101	ENSG00000228486.8	LINC01125	-3.38	0.000744	0.0342	-0.09	-0.1	Posterior cortical atrophy and Alzheimer's disease;	chr2:97763350	chr2:97664217~97703064:+
BRCA	cis	rs8114671	0.562	rs2076667	ENSG00000261582.1	RP4-614O4.11	-3.38	0.000744	0.0342	-0.1	-0.1	Height;	chr20:34919161	chr20:35267885~35280043:-
BRCA	cis	rs7252981	0.632	rs11878202	ENSG00000267419.1	CTC-559E9.6	3.38	0.000744	0.0342	0.12	0.1	Perceived unattractiveness to mosquitoes;	chr19:19633270	chr19:19776602~19834927:+
BRCA	cis	rs4835473	0.897	rs55635947	ENSG00000246448.2	RP13-578N3.3	-3.38	0.000744	0.0342	-0.12	-0.1	Immature fraction of reticulocytes;	chr4:143736218	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.897	rs56334914	ENSG00000246448.2	RP13-578N3.3	-3.38	0.000744	0.0342	-0.12	-0.1	Immature fraction of reticulocytes;	chr4:143736291	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.897	rs56324738	ENSG00000246448.2	RP13-578N3.3	-3.38	0.000744	0.0342	-0.12	-0.1	Immature fraction of reticulocytes;	chr4:143736297	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.932	rs55862664	ENSG00000246448.2	RP13-578N3.3	-3.38	0.000744	0.0342	-0.12	-0.1	Immature fraction of reticulocytes;	chr4:143736311	chr4:143700257~143865072:+
BRCA	cis	rs12368653	0.525	rs1564374	ENSG00000257159.1	RP11-58A17.3	-3.38	0.000744	0.0342	-0.12	-0.1	Multiple sclerosis;	chr12:57616380	chr12:57967058~57968399:+
BRCA	cis	rs4819052	0.851	rs2838848	ENSG00000223768.1	LINC00205	-3.38	0.000744	0.0342	-0.14	-0.1	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251102	chr21:45293285~45297354:+
BRCA	cis	rs4819052	0.851	rs2838849	ENSG00000223768.1	LINC00205	-3.38	0.000744	0.0342	-0.14	-0.1	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251112	chr21:45293285~45297354:+
BRCA	cis	rs4713118	0.786	rs200503	ENSG00000219392.1	RP1-265C24.5	-3.38	0.000745	0.0342	-0.15	-0.1	Parkinson's disease;	chr6:27818104	chr6:28115628~28116551:+
BRCA	cis	rs4713118	0.786	rs200502	ENSG00000219392.1	RP1-265C24.5	-3.38	0.000745	0.0342	-0.15	-0.1	Parkinson's disease;	chr6:27820284	chr6:28115628~28116551:+
BRCA	cis	rs16944613	0.541	rs7183319	ENSG00000259212.1	CTD-3065B20.2	3.38	0.000745	0.0342	0.15	0.1	Colorectal cancer;	chr15:90551800	chr15:90595840~90596447:-
BRCA	cis	rs375066	0.935	rs399098	ENSG00000278917.1	RP11-15A1.4	-3.38	0.000745	0.0342	-0.12	-0.1	Breast cancer;	chr19:43914672	chr19:43891233~43895411:+
BRCA	cis	rs2411233	1	rs2411235	ENSG00000259278.1	RP11-62C7.2	-3.38	0.000745	0.0342	-0.12	-0.1	Platelet count;	chr15:38983120	chr15:39019233~39024918:+
BRCA	cis	rs875971	0.867	rs1002053	ENSG00000272831.1	RP11-792A8.4	-3.38	0.000745	0.0342	-0.09	-0.1	Aortic root size;	chr7:66333558	chr7:66739829~66740385:-
BRCA	cis	rs17221829	0.673	rs10741307	ENSG00000280385.1	AP000648.5	-3.38	0.000745	0.0342	-0.12	-0.1	Anxiety in major depressive disorder;	chr11:89634103	chr11:90193614~90198120:+
BRCA	cis	rs897984	0.609	rs1108431	ENSG00000275263.1	RP11-1072A3.4	-3.38	0.000745	0.0342	-0.12	-0.1	Dementia with Lewy bodies;	chr16:31043286	chr16:30956872~30957199:-
BRCA	cis	rs2921073	0.605	rs2976933	ENSG00000248538.5	RP11-10A14.5	-3.38	0.000745	0.0342	-0.11	-0.1	Parkinson's disease;	chr8:8397365	chr8:9189011~9202854:+
BRCA	cis	rs2835345	0.511	rs2835356	ENSG00000233818.1	AP000695.4	3.38	0.000745	0.0342	0.12	0.1	Pulmonary function;	chr21:36444900	chr21:36445731~36532408:+
BRCA	cis	rs470089	1	rs138102	ENSG00000261251.1	RP3-388M5.9	3.38	0.000745	0.0342	0.14	0.1	Type 2 diabetes (dietary heme iron intake interaction);	chr22:43857209	chr22:43812456~43817394:+
BRCA	cis	rs7795541	0.739	rs10251002	ENSG00000230658.1	KLHL7-AS1	3.38	0.000745	0.0342	0.14	0.1	Morning vs. evening chronotype;	chr7:24045891	chr7:23101228~23105703:-
BRCA	cis	rs58521262	0.592	rs62123860	ENSG00000268105.1	RP11-369G6.2	-3.38	0.000745	0.0342	-0.17	-0.1	Testicular germ cell tumor;	chr19:22839042	chr19:23125665~23128543:+
BRCA	cis	rs6964587	0.692	rs10227225	ENSG00000188693.7	CYP51A1-AS1	3.38	0.000745	0.0342	0.11	0.1	Breast cancer;	chr7:91941760	chr7:92134604~92180725:+
BRCA	cis	rs4356203	0.905	rs7930058	ENSG00000184669.7	OR7E14P	-3.38	0.000745	0.0342	-0.13	-0.1	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17045071	chr11:17013998~17053024:+
BRCA	cis	rs8114671	0.562	rs6088647	ENSG00000126005.14	MMP24-AS1	-3.38	0.000745	0.0342	-0.13	-0.1	Height;	chr20:34918194	chr20:35216462~35278131:-
BRCA	cis	rs8114671	0.562	rs2223881	ENSG00000126005.14	MMP24-AS1	-3.38	0.000745	0.0342	-0.13	-0.1	Height;	chr20:34918660	chr20:35216462~35278131:-
BRCA	cis	rs72775230	0.733	rs72775238	ENSG00000233990.1	RP11-401E9.3	-3.38	0.000745	0.0342	-0.18	-0.1	Conotruncal heart defects (inherited effects);	chr10:8518712	chr10:7833618~7833957:-
BRCA	cis	rs17221829	0.733	rs2388105	ENSG00000280385.1	AP000648.5	3.38	0.000745	0.0342	0.12	0.1	Anxiety in major depressive disorder;	chr11:89622149	chr11:90193614~90198120:+
BRCA	cis	rs9535495	0.931	rs9535499	ENSG00000231856.2	RP11-327P2.5	3.38	0.000746	0.0342	0.12	0.1	High light scatter reticulocyte count;Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;	chr13:50821881	chr13:51803838~51813832:+
BRCA	cis	rs8114671	0.562	rs3818273	ENSG00000261582.1	RP4-614O4.11	-3.38	0.000746	0.0342	-0.1	-0.1	Height;	chr20:34921472	chr20:35267885~35280043:-
BRCA	cis	rs7620503	1	rs1875096	ENSG00000228561.2	RP11-114M1.1	3.38	0.000746	0.0342	0.12	0.1	Corneal structure;	chr3:177586076	chr3:177683627~177691250:+
BRCA	cis	rs7620503	1	rs1875097	ENSG00000228561.2	RP11-114M1.1	3.38	0.000746	0.0342	0.12	0.1	Corneal structure;	chr3:177586244	chr3:177683627~177691250:+
BRCA	cis	rs7620503	1	rs7620503	ENSG00000228561.2	RP11-114M1.1	3.38	0.000746	0.0342	0.12	0.1	Corneal structure;	chr3:177586510	chr3:177683627~177691250:+
BRCA	cis	rs2835872	0.793	rs976894	ENSG00000230366.8	DSCR9	-3.38	0.000746	0.0342	-0.13	-0.1	Electroencephalographic traits in alcoholism;	chr21:37614181	chr21:37208503~37221736:+
BRCA	cis	rs7267979	1	rs398036	ENSG00000276952.1	RP5-965G21.6	3.38	0.000746	0.0342	0.13	0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25459214	chr20:25284915~25285588:-
BRCA	cis	rs7267979	1	rs397119	ENSG00000276952.1	RP5-965G21.6	3.38	0.000746	0.0342	0.13	0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25459551	chr20:25284915~25285588:-
BRCA	cis	rs7647973	1	rs9862534	ENSG00000225399.4	RP11-3B7.1	3.38	0.000746	0.0342	0.11	0.1	Menarche (age at onset);	chr3:49560631	chr3:49260085~49261316:+
BRCA	cis	rs2688608	0.672	rs2688621	ENSG00000271816.1	BMS1P4	3.38	0.000746	0.0342	0.1	0.1	Inflammatory bowel disease;	chr10:73928091	chr10:73699151~73730487:-
BRCA	cis	rs6696239	0.956	rs12131114	ENSG00000215812.5	ZNF847P	3.38	0.000746	0.0342	0.14	0.1	Height;	chr1:227590926	chr1:227696892~227706699:-
BRCA	cis	rs2832077	0.883	rs35672956	ENSG00000215533.7	LINC00189	3.38	0.000746	0.0342	0.15	0.1	Cognitive test performance;	chr21:28816719	chr21:29193480~29288205:+
BRCA	cis	rs2832077	0.943	rs11700746	ENSG00000215533.7	LINC00189	3.38	0.000746	0.0342	0.15	0.1	Cognitive test performance;	chr21:28816884	chr21:29193480~29288205:+
BRCA	cis	rs2832077	0.943	rs2272701	ENSG00000215533.7	LINC00189	3.38	0.000746	0.0342	0.15	0.1	Cognitive test performance;	chr21:28818585	chr21:29193480~29288205:+
BRCA	cis	rs875971	0.52	rs160645	ENSG00000226767.1	RP11-328P23.3	-3.38	0.000746	0.0342	-0.13	-0.1	Aortic root size;	chr7:66091320	chr7:65508773~65508944:-
BRCA	cis	rs4356203	0.905	rs9919600	ENSG00000184669.7	OR7E14P	-3.38	0.000746	0.0342	-0.14	-0.1	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17058198	chr11:17013998~17053024:+
BRCA	cis	rs4356203	0.905	rs7939750	ENSG00000184669.7	OR7E14P	-3.38	0.000746	0.0342	-0.14	-0.1	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17058208	chr11:17013998~17053024:+
BRCA	cis	rs6088580	0.524	rs2378251	ENSG00000279253.1	RP4-614O4.13	3.38	0.000746	0.0342	0.12	0.1	Glomerular filtration rate (creatinine);	chr20:34688946	chr20:35262727~35264187:-
BRCA	cis	rs804280	0.525	rs17153755	ENSG00000255046.1	RP11-297N6.4	-3.38	0.000746	0.0342	-0.12	-0.1	Myopia (pathological);	chr8:11753991	chr8:11797928~11802568:-
BRCA	cis	rs952623	0.611	rs10435033	ENSG00000227191.5	TRGC2	3.38	0.000746	0.0343	0.1	0.1	Intelligence (multi-trait analysis);	chr7:39015237	chr7:38239580~38368091:-
BRCA	cis	rs7712401	0.791	rs154507	ENSG00000249996.1	RP11-359P5.1	-3.38	0.000746	0.0343	-0.12	-0.1	Mean platelet volume;	chr5:122865212	chr5:123036271~123054667:+
BRCA	cis	rs931127	0.719	rs7949980	ENSG00000245532.5	NEAT1	-3.38	0.000746	0.0343	-0.09	-0.1	Systemic lupus erythematosus;	chr11:65678479	chr11:65422774~65445540:+
BRCA	cis	rs13256369	1	rs12545771	ENSG00000254153.1	CTA-398F10.2	3.38	0.000746	0.0343	0.14	0.1	Obesity-related traits;	chr8:8710467	chr8:8456909~8461337:-
BRCA	cis	rs7179228	0.613	rs7179347	ENSG00000260657.2	RP11-315D16.4	3.38	0.000747	0.0343	0.18	0.1	Systolic blood pressure;	chr15:68338532	chr15:68267792~68277994:-
BRCA	cis	rs8058578	0.832	rs35969813	ENSG00000260082.1	RP11-2C24.5	3.38	0.000747	0.0343	0.13	0.1	Multiple myeloma;	chr16:30703096	chr16:30821068~30822110:-
BRCA	cis	rs6068583	0.86	rs6068588	ENSG00000197670.6	RP4-724E16.2	-3.38	0.000747	0.0343	-0.14	-0.1	Colorectal adenoma (advanced);	chr20:53580827	chr20:53552770~53575863:+
BRCA	cis	rs1730008	0.865	rs827124	ENSG00000279311.1	RP11-170K4.2	-3.38	0.000747	0.0343	-0.11	-0.1	Lobe attachment (rater-scored or self-reported);	chr3:158236129	chr3:158869898~158871821:+
BRCA	cis	rs10266483	0.881	rs665452	ENSG00000227986.1	TRIM60P18	-3.38	0.000747	0.0343	-0.11	-0.1	Response to statin therapy;	chr7:64289077	chr7:64355078~64356199:+
BRCA	cis	rs1710990	1	rs11628126	ENSG00000259165.1	DDX18P1	3.38	0.000747	0.0343	0.12	0.1	Intelligence (multi-trait analysis);	chr14:69098476	chr14:69083398~69085389:+
BRCA	cis	rs7037266	0.892	rs7861518	ENSG00000178654.11	PPIAP33	3.38	0.000747	0.0343	0.12	0.1	Menarche (age at onset);	chr9:6936862	chr9:7597823~7598377:+
BRCA	cis	rs10995356	0.844	rs10822103	ENSG00000238280.1	RP11-436D10.3	-3.38	0.000747	0.0343	-0.14	-0.1	Temperament;	chr10:62989476	chr10:62793562~62805887:-
BRCA	cis	rs6840360	0.532	rs4235221	ENSG00000278978.1	RP11-164P12.5	-3.38	0.000747	0.0343	-0.12	-0.1	Intelligence (multi-trait analysis);	chr4:151590041	chr4:151669786~151670503:+
BRCA	cis	rs6840360	0.571	rs62327268	ENSG00000278978.1	RP11-164P12.5	-3.38	0.000747	0.0343	-0.12	-0.1	Intelligence (multi-trait analysis);	chr4:151601174	chr4:151669786~151670503:+
BRCA	cis	rs35306767	0.903	rs34270014	ENSG00000229869.1	RP11-363N22.2	-3.38	0.000747	0.0343	-0.16	-0.1	Eosinophil percentage of granulocytes;	chr10:858726	chr10:933026~942743:+
BRCA	cis	rs875971	0.964	rs778708	ENSG00000273024.4	INTS4P2	-3.38	0.000747	0.0343	-0.11	-0.1	Aortic root size;	chr7:66391332	chr7:65647864~65715661:+
BRCA	cis	rs7412746	0.611	rs2864873	ENSG00000224800.1	RP11-235D19.2	-3.38	0.000747	0.0343	-0.13	-0.1	Melanoma;	chr1:150841698	chr1:150881236~150881683:-
BRCA	cis	rs1865760	0.566	rs9366634	ENSG00000272462.2	U91328.19	-3.38	0.000747	0.0343	-0.12	-0.1	Height;	chr6:26072168	chr6:25992662~26001775:+
BRCA	cis	rs889122	0.765	rs62105756	ENSG00000267289.1	CTD-2623N2.11	3.38	0.000747	0.0343	0.14	0.1	Menarche (age at onset);	chr19:9863257	chr19:9834079~9835013:-
BRCA	cis	rs9377188	0.556	rs2500521	ENSG00000219433.2	RP11-350J20.4	-3.38	0.000747	0.0343	-0.14	-0.1	Cancer;	chr6:148980772	chr6:149794763~149795746:+
BRCA	cis	rs6840360	0.615	rs6858483	ENSG00000270265.1	RP11-731D1.4	-3.38	0.000747	0.0343	-0.13	-0.1	Intelligence (multi-trait analysis);	chr4:151544357	chr4:151333775~151353224:-
BRCA	cis	rs4713118	0.868	rs35069907	ENSG00000219392.1	RP1-265C24.5	-3.38	0.000747	0.0343	-0.16	-0.1	Parkinson's disease;	chr6:27778913	chr6:28115628~28116551:+
BRCA	cis	rs2276314	1	rs2298715	ENSG00000267627.4	RP11-905K4.1	-3.38	0.000747	0.0343	-0.14	-0.1	Endometriosis;Drug-induced torsades de pointes;	chr18:35972462	chr18:35951803~35966118:-
BRCA	cis	rs2276314	1	rs4573997	ENSG00000267627.4	RP11-905K4.1	-3.38	0.000747	0.0343	-0.14	-0.1	Endometriosis;Drug-induced torsades de pointes;	chr18:35972605	chr18:35951803~35966118:-
BRCA	cis	rs875971	1	rs6957199	ENSG00000273448.1	RP11-166O4.6	3.38	0.000747	0.0343	0.09	0.1	Aortic root size;	chr7:66513532	chr7:67333047~67334383:+
BRCA	cis	rs7267979	1	rs11100	ENSG00000274414.1	RP5-965G21.4	-3.38	0.000747	0.0343	-0.12	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25300548	chr20:25239007~25245229:-
BRCA	cis	rs7267979	1	rs1046073	ENSG00000274414.1	RP5-965G21.4	-3.38	0.000747	0.0343	-0.12	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25300697	chr20:25239007~25245229:-
BRCA	cis	rs7267979	1	rs2259926	ENSG00000274414.1	RP5-965G21.4	-3.38	0.000747	0.0343	-0.12	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25301097	chr20:25239007~25245229:-
BRCA	cis	rs7267979	1	rs2259928	ENSG00000274414.1	RP5-965G21.4	-3.38	0.000747	0.0343	-0.12	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25301198	chr20:25239007~25245229:-
BRCA	cis	rs7267979	1	rs2259956	ENSG00000274414.1	RP5-965G21.4	-3.38	0.000747	0.0343	-0.12	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25301797	chr20:25239007~25245229:-
BRCA	cis	rs7412746	0.658	rs6657388	ENSG00000224800.1	RP11-235D19.2	-3.38	0.000747	0.0343	-0.13	-0.1	Melanoma;	chr1:150776310	chr1:150881236~150881683:-
BRCA	cis	rs8114671	0.804	rs6088666	ENSG00000261582.1	RP4-614O4.11	-3.38	0.000747	0.0343	-0.1	-0.1	Height;	chr20:34976767	chr20:35267885~35280043:-
BRCA	cis	rs73198271	0.96	rs11778970	ENSG00000248538.5	RP11-10A14.5	3.38	0.000747	0.0343	0.13	0.1	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8751824	chr8:9189011~9202854:+
BRCA	cis	rs9393777	1	rs9393777	ENSG00000241549.7	GUSBP2	3.38	0.000747	0.0343	0.17	0.1	Intelligence (multi-trait analysis);	chr6:26974248	chr6:26871484~26956554:-
BRCA	cis	rs748404	0.666	rs7181634	ENSG00000166763.7	STRCP1	3.38	0.000747	0.0343	0.15	0.1	Lung cancer;	chr15:43351703	chr15:43699488~43718184:-
BRCA	cis	rs4272720	0.901	rs17011799	ENSG00000228754.1	RP11-534L6.3	3.38	0.000747	0.0343	0.15	0.1	Platelet count;Plateletcrit;	chr10:49090146	chr10:48745545~48746128:-
BRCA	cis	rs170183	1	rs170183	ENSG00000231324.1	AP000696.2	3.38	0.000748	0.0343	0.13	0.1	Bone mineral density;	chr21:36476036	chr21:36632681~36637033:-
BRCA	cis	rs6929812	0.577	rs2294308	ENSG00000271755.1	RP1-153G14.4	3.38	0.000748	0.0343	0.12	0.1	Neuroticism (multi-trait analysis);	chr6:27515481	chr6:27404010~27406964:-
BRCA	cis	rs8105895	0.935	rs988211	ENSG00000269345.1	VN1R85P	3.38	0.000748	0.0343	0.17	0.1	Body mass index (change over time);	chr19:22119734	chr19:22174766~22175191:-
BRCA	cis	rs9402743	0.632	rs2104133	ENSG00000231028.7	LINC00271	-3.38	0.000748	0.0343	-0.11	-0.1	Systemic lupus erythematosus;	chr6:135781149	chr6:135497801~135716055:+
BRCA	cis	rs3764021	0.527	rs10844427	ENSG00000260423.1	RP13-735L24.1	-3.38	0.000748	0.0343	-0.12	-0.1	Type 1 diabetes;	chr12:9681798	chr12:9367464~9397617:+
BRCA	cis	rs10504130	0.597	rs4598243	ENSG00000272076.1	RP11-11C20.3	3.38	0.000748	0.0343	0.15	0.1	Venous thromboembolism (SNP x SNP interaction);	chr8:51797158	chr8:51810110~51810681:-
BRCA	cis	rs7577696	0.889	rs212731	ENSG00000276334.1	AL133243.1	3.38	0.000748	0.0343	0.13	0.1	Inflammatory biomarkers;	chr2:32247081	chr2:32521927~32523547:+
BRCA	cis	rs897984	0.806	rs8050588	ENSG00000279196.1	RP11-1072A3.3	3.38	0.000748	0.0343	0.11	0.1	Dementia with Lewy bodies;	chr16:30926478	chr16:30984630~30988270:-
BRCA	cis	rs1005277	0.579	rs1780146	ENSG00000276805.1	RP11-291L22.6	3.38	0.000748	0.0343	0.11	0.1	Extrinsic epigenetic age acceleration;	chr10:38228946	chr10:38451030~38451785:+
BRCA	cis	rs6854137	0.553	rs7688994	ENSG00000214676.4	RPL9P16	-3.38	0.000748	0.0343	-0.12	-0.1	Vein graft stenosis in coronary artery bypass grafting;	chr4:168782011	chr4:168755816~168756382:+
BRCA	cis	rs9402743	0.597	rs9483880	ENSG00000231028.7	LINC00271	-3.38	0.000748	0.0343	-0.11	-0.1	Systemic lupus erythematosus;	chr6:135781474	chr6:135497801~135716055:+
BRCA	cis	rs875971	0.929	rs10950041	ENSG00000271064.1	RP11-792A8.3	-3.38	0.000748	0.0343	-0.12	-0.1	Aortic root size;	chr7:66508888	chr7:66748838~66749077:-
BRCA	cis	rs10129255	0.53	rs11624912	ENSG00000211976.2	IGHV3-73	-3.38	0.000748	0.0343	-0.08	-0.1	Kawasaki disease;	chr14:106673891	chr14:106802694~106803233:-
BRCA	cis	rs11259403	0.506	rs11259272	ENSG00000228951.1	RP11-336A10.4	3.38	0.000748	0.0343	0.12	0.1	Body mass index in asthmatics;	chr10:6504109	chr10:5616862~5618161:-
BRCA	cis	rs62244186	0.659	rs12108134	ENSG00000214820.3	MPRIPP1	-3.38	0.000748	0.0343	-0.12	-0.1	Depressive symptoms;	chr3:44501538	chr3:44579938~44581026:-
BRCA	cis	rs7142881	0.844	rs9972191	ENSG00000258648.1	UBE2CP1	3.38	0.000748	0.0343	0.12	0.1	Response to iloperidone treatment (QT prolongation);	chr14:31560274	chr14:30683045~30683598:-
BRCA	cis	rs6801044	0.789	rs823525	ENSG00000229178.1	AC069513.4	3.38	0.000748	0.0343	0.15	0.1	Creatinine levels in ischemic stroke;	chr3:195552301	chr3:195655565~195657927:-
BRCA	cis	rs7577696	0.889	rs212726	ENSG00000276334.1	AL133243.1	3.38	0.000749	0.0343	0.13	0.1	Inflammatory biomarkers;	chr2:32244316	chr2:32521927~32523547:+
BRCA	cis	rs7577696	0.889	rs212727	ENSG00000276334.1	AL133243.1	3.38	0.000749	0.0343	0.13	0.1	Inflammatory biomarkers;	chr2:32244659	chr2:32521927~32523547:+
BRCA	cis	rs7246760	0.867	rs8112764	ENSG00000267106.4	ZNF561-AS1	3.38	0.000749	0.0343	0.2	0.1	Pursuit maintenance gain;	chr19:9638231	chr19:9621291~9645896:+
BRCA	cis	rs4873772	0.834	rs4873546	ENSG00000253330.1	RP11-697N18.3	-3.38	0.000749	0.0343	-0.14	-0.1	Lobe attachment (rater-scored or self-reported);	chr8:47664103	chr8:47511034~47512141:-
BRCA	cis	rs4767841	1	rs2996029	ENSG00000248636.5	RP11-768F21.1	-3.38	0.000749	0.0343	-0.13	-0.1	Urgency urinary incontinence;	chr12:119727377	chr12:119387987~119668079:-
BRCA	cis	rs6142618	0.562	rs2235900	ENSG00000275576.1	RP5-836N17.4	-3.38	0.000749	0.0343	-0.12	-0.1	Inflammatory bowel disease;	chr20:32131775	chr20:32116171~32116629:+
BRCA	cis	rs76382185	0.622	rs11586136	ENSG00000235795.1	RP11-421L21.2	-3.38	0.000749	0.0343	-0.19	-0.1	Lymphocyte counts;	chr1:100770581	chr1:100995473~100996260:+
BRCA	cis	rs67478160	0.572	rs8015603	ENSG00000269910.1	RP11-73M18.10	3.38	0.000749	0.0343	0.1	0.1	Schizophrenia;	chr14:103827341	chr14:103694516~103695050:-
BRCA	cis	rs740363	0.818	rs1614092	ENSG00000281599.1	AC023283.1	3.38	0.000749	0.0343	0.11	0.1	Heart failure;	chr10:116829668	chr10:116827489~116827564:-
BRCA	cis	rs6963495	0.745	rs68153235	ENSG00000223886.3	RP11-251G23.2	3.38	0.000749	0.0343	0.14	0.1	Bipolar disorder (body mass index interaction);	chr7:105544385	chr7:105530209~105530671:+
BRCA	cis	rs6496932	0.635	rs67659163	ENSG00000218052.5	ADAMTS7P4	-3.38	0.000749	0.0343	-0.12	-0.1	Central corneal thickness;Corneal structure;	chr15:85387673	chr15:85255369~85330334:-
BRCA	cis	rs72899227	0.74	rs10168943	ENSG00000226131.1	AC073465.3	3.38	0.000749	0.0343	0.15	0.1	Lung cancer;	chr2:173359627	chr2:173485865~173486362:-
BRCA	cis	rs762407	0.925	rs4594536	ENSG00000237864.1	LINC00322	3.38	0.000749	0.0343	0.14	0.1	Systolic blood pressure change trajectories;	chr21:43744973	chr21:43322417~43332039:-
BRCA	cis	rs7017914	0.967	rs62530792	ENSG00000246366.5	RP11-382J12.1	3.38	0.000749	0.0344	0.11	0.1	Bone mineral density;	chr8:70706532	chr8:70608577~70663279:+
BRCA	cis	rs7017914	0.902	rs35893260	ENSG00000246366.5	RP11-382J12.1	3.38	0.000749	0.0344	0.11	0.1	Bone mineral density;	chr8:70707838	chr8:70608577~70663279:+
BRCA	cis	rs6542838	0.646	rs17756034	ENSG00000231822.1	AC019097.7	-3.38	0.000749	0.0344	-0.13	-0.1	Fear of minor pain;	chr2:98766347	chr2:99102018~99102752:+
BRCA	cis	rs801193	0.773	rs801207	ENSG00000271064.1	RP11-792A8.3	3.38	0.000749	0.0344	0.12	0.1	Aortic root size;	chr7:66555603	chr7:66748838~66749077:-
BRCA	cis	rs875971	0.895	rs12698520	ENSG00000273448.1	RP11-166O4.6	3.38	0.000749	0.0344	0.09	0.1	Aortic root size;	chr7:66453720	chr7:67333047~67334383:+
BRCA	cis	rs12282928	0.743	rs10769322	ENSG00000255197.4	RP11-750H9.5	3.38	0.000749	0.0344	0.09	0.1	Migraine - clinic-based;	chr11:48191894	chr11:47383148~47409190:-
BRCA	cis	rs12282928	0.743	rs10769323	ENSG00000255197.4	RP11-750H9.5	3.38	0.000749	0.0344	0.09	0.1	Migraine - clinic-based;	chr11:48191901	chr11:47383148~47409190:-
BRCA	cis	rs12282928	0.743	rs10769324	ENSG00000255197.4	RP11-750H9.5	3.38	0.000749	0.0344	0.09	0.1	Migraine - clinic-based;	chr11:48191963	chr11:47383148~47409190:-
BRCA	cis	rs7267979	0.873	rs6115093	ENSG00000231081.1	RP4-760C5.3	-3.38	0.000749	0.0344	-0.14	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25230094	chr20:26008791~26010531:-
BRCA	cis	rs1816752	0.721	rs7399656	ENSG00000273628.1	RP11-756A22.7	3.38	0.000749	0.0344	0.13	0.1	Obesity-related traits;	chr13:24415708	chr13:24933006~24936796:+
BRCA	cis	rs875971	0.651	rs313829	ENSG00000226767.1	RP11-328P23.3	-3.38	0.000749	0.0344	-0.13	-0.1	Aortic root size;	chr7:66087510	chr7:65508773~65508944:-
BRCA	cis	rs321358	0.731	rs516177	ENSG00000271390.1	RP11-89C3.3	3.38	0.000749	0.0344	0.16	0.1	Body mass index;	chr11:111138173	chr11:111089870~111090368:-
BRCA	cis	rs13256369	1	rs4840352	ENSG00000233609.3	RP11-62H7.2	3.38	0.000749	0.0344	0.11	0.1	Obesity-related traits;	chr8:8715998	chr8:8961200~8979025:+
BRCA	cis	rs73198271	0.813	rs17697237	ENSG00000173295.6	FAM86B3P	3.38	0.000749	0.0344	0.11	0.1	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8758364	chr8:8228595~8244865:+
BRCA	cis	rs619865	1	rs619865	ENSG00000250917.1	RP4-785G19.5	3.38	0.000749	0.0344	0.26	0.1	Freckling;	chr20:35279894	chr20:34234840~34281173:-
BRCA	cis	rs62458065	0.513	rs7805536	ENSG00000273014.1	RP11-225B17.2	-3.38	0.000749	0.0344	-0.16	-0.1	Metabolite levels (HVA/MHPG ratio);	chr7:32533958	chr7:32758882~32759353:+
BRCA	cis	rs62458065	0.513	rs10268149	ENSG00000273014.1	RP11-225B17.2	-3.38	0.000749	0.0344	-0.16	-0.1	Metabolite levels (HVA/MHPG ratio);	chr7:32535887	chr7:32758882~32759353:+
BRCA	cis	rs66530629	0.958	rs4543739	ENSG00000225315.2	RP11-293P20.2	3.38	0.000749	0.0344	0.14	0.1	Plateletcrit;	chr1:24723189	chr1:24040835~24086799:+
BRCA	cis	rs11877825	0.826	rs9676146	ENSG00000265728.1	RP11-883A18.3	-3.38	0.000749	0.0344	-0.14	-0.1	Gut microbiota (bacterial taxa);	chr18:10571492	chr18:10594590~10604798:+
BRCA	cis	rs2638953	0.962	rs10843158	ENSG00000273989.1	RP11-425D17.2	3.38	0.000749	0.0344	0.16	0.1	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28354259	chr12:28236227~28236828:+
BRCA	cis	rs1979679	0.608	rs4931084	ENSG00000244712.1	RP11-874G11.1	3.38	0.000749	0.0344	0.16	0.1	Ossification of the posterior longitudinal ligament of the spine;	chr12:28569378	chr12:28564678~28565141:-
BRCA	cis	rs783540	0.967	rs1864699	ENSG00000274376.3	ADAMTS7P1	3.38	0.000749	0.0344	0.11	0.1	Schizophrenia;	chr15:82654567	chr15:82298553~82334609:+
BRCA	cis	rs4356203	0.905	rs7946165	ENSG00000184669.7	OR7E14P	-3.38	0.00075	0.0344	-0.13	-0.1	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17057080	chr11:17013998~17053024:+
BRCA	cis	rs7520050	0.966	rs6429582	ENSG00000226957.1	RP4-533D7.4	-3.38	0.00075	0.0344	-0.11	-0.1	Reticulocyte count;Red blood cell count;	chr1:45856171	chr1:46046818~46048368:+
BRCA	cis	rs7267979	0.966	rs2151144	ENSG00000204556.4	CTD-2514C3.1	3.38	0.00075	0.0344	0.14	0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25434288	chr20:26018832~26020684:+
BRCA	cis	rs6964587	0.626	rs68009402	ENSG00000188693.7	CYP51A1-AS1	3.38	0.00075	0.0344	0.11	0.1	Breast cancer;	chr7:91886912	chr7:92134604~92180725:+
BRCA	cis	rs6964587	0.626	rs10234074	ENSG00000188693.7	CYP51A1-AS1	3.38	0.00075	0.0344	0.11	0.1	Breast cancer;	chr7:91890805	chr7:92134604~92180725:+
BRCA	cis	rs2227564	0.672	rs2459449	ENSG00000272140.2	RP11-574K11.29	3.38	0.00075	0.0344	0.11	0.1	Crohn's disease;Inflammatory bowel disease;	chr10:73909255	chr10:73703735~73713581:-
BRCA	cis	rs1030420	0.848	rs11784186	ENSG00000200714.1	Y_RNA	-3.38	0.00075	0.0344	-0.18	-0.1	Blood metabolite levels;	chr8:66384856	chr8:65592731~65592820:+
BRCA	cis	rs10819861	0.679	rs4623574	ENSG00000175611.10	LINC00476	3.38	0.00075	0.0344	0.11	0.1	Electrocardiographic traits;	chr9:96087342	chr9:95759231~95875977:-
BRCA	cis	rs7267979	1	rs2258719	ENSG00000231081.1	RP4-760C5.3	-3.38	0.00075	0.0344	-0.14	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25295207	chr20:26008791~26010531:-
BRCA	cis	rs9866825	0.902	rs3912614	ENSG00000227110.5	LMCD1-AS1	3.38	0.00075	0.0344	0.13	0.1	QT interval;	chr3:8222358	chr3:7952805~8611924:-
BRCA	cis	rs7020830	0.894	rs13300951	ENSG00000230188.1	RP11-405L18.4	-3.38	0.00075	0.0344	-0.13	-0.1	Schizophrenia;	chr9:37146630	chr9:37490421~37490893:-
BRCA	cis	rs7274811	0.681	rs291705	ENSG00000228265.4	RALY-AS1	3.38	0.00075	0.0344	0.11	0.1	Height;	chr20:33381852	chr20:33983052~33994357:-
BRCA	cis	rs934734	0.736	rs10186240	ENSG00000204929.10	AC074391.1	3.38	0.00075	0.0344	0.13	0.1	Rheumatoid arthritis;	chr2:65350517	chr2:65436711~66084639:+
BRCA	cis	rs6943931	1	rs73685441	ENSG00000230658.1	KLHL7-AS1	-3.38	0.00075	0.0344	-0.14	-0.1	Diabetic kidney disease;	chr7:22380739	chr7:23101228~23105703:-
BRCA	cis	rs4981053	0.644	rs1958712	ENSG00000259001.3	RPPH1	3.38	0.00075	0.0344	0.12	0.1	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr14:20057226	chr14:20343048~20343685:-
BRCA	cis	rs12915845	0.584	rs17196732	ENSG00000271997.1	RP11-97O12.6	3.38	0.00075	0.0344	0.08	0.1	Menarche (age at onset);	chr15:88526068	chr15:88501944~88505787:-
BRCA	cis	rs67478160	0.643	rs8005594	ENSG00000269940.1	RP11-73M18.7	3.38	0.00075	0.0344	0.1	0.1	Schizophrenia;	chr14:103813552	chr14:103694560~103695170:+
BRCA	cis	rs11035577	0.632	rs2089475	ENSG00000279675.1	RP11-454H19.2	-3.38	0.00075	0.0344	-0.16	-0.1	Temperament (bipolar disorder);	chr11:39754406	chr11:40107244~40112599:-
BRCA	cis	rs11035577	0.632	rs2100844	ENSG00000279675.1	RP11-454H19.2	-3.38	0.00075	0.0344	-0.16	-0.1	Temperament (bipolar disorder);	chr11:39754913	chr11:40107244~40112599:-
BRCA	cis	rs17767294	0.522	rs41270589	ENSG00000219392.1	RP1-265C24.5	-3.38	0.00075	0.0344	-0.29	-0.1	Parkinson's disease;	chr6:28435663	chr6:28115628~28116551:+
BRCA	cis	rs7578361	0.918	rs2377262	ENSG00000231969.1	AC144449.1	-3.38	0.00075	0.0344	-0.16	-0.1	Acute lymphoblastic leukemia (childhood);	chr2:149498297	chr2:149587196~149848233:+
BRCA	cis	rs7578361	0.918	rs1918250	ENSG00000231969.1	AC144449.1	-3.38	0.00075	0.0344	-0.16	-0.1	Acute lymphoblastic leukemia (childhood);	chr2:149507501	chr2:149587196~149848233:+
BRCA	cis	rs10197140	0.925	rs28769005	ENSG00000235721.1	AC013268.3	-3.38	0.00075	0.0344	-0.14	-0.1	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110898376	chr2:110007675~110010783:+
BRCA	cis	rs861318	0.941	rs1772414	ENSG00000236257.1	EI24P2	3.38	0.000751	0.0344	0.15	0.1	Obesity-related traits;	chr1:159033117	chr1:158454198~158455273:+
BRCA	cis	rs6496932	0.663	rs4843051	ENSG00000259630.2	CTD-2262B20.1	-3.38	0.000751	0.0344	-0.13	-0.1	Central corneal thickness;Corneal structure;	chr15:85360907	chr15:85415228~85415633:+
BRCA	cis	rs3753275	0.519	rs6658881	ENSG00000270282.1	RP5-1115A15.2	3.38	0.000751	0.0344	0.14	0.1	Educational attainment;	chr1:8691209	chr1:8512653~8513021:+
BRCA	cis	rs739496	0.615	rs56884502	ENSG00000257624.1	RP1-128M12.3	3.38	0.000751	0.0344	0.15	0.1	Platelet count;	chr12:111769496	chr12:112000739~112000985:-
BRCA	cis	rs739496	0.642	rs74849450	ENSG00000257624.1	RP1-128M12.3	3.38	0.000751	0.0344	0.15	0.1	Platelet count;	chr12:111771034	chr12:112000739~112000985:-
BRCA	cis	rs10838687	0.673	rs59567949	ENSG00000243802.2	RP11-390K5.1	3.38	0.000751	0.0344	0.15	0.1	Proinsulin levels;	chr11:47278604	chr11:47191181~47191542:-
BRCA	cis	rs2342406	0.825	rs1026062	ENSG00000259439.2	RP11-89K21.1	3.38	0.000751	0.0344	0.17	0.1	Myopia;	chr2:44914939	chr2:44921077~44939199:-
BRCA	cis	rs2274273	1	rs2075603	ENSG00000233924.1	AL160471.6	-3.38	0.000751	0.0344	-0.12	-0.1	Protein biomarker;	chr14:55143237	chr14:55004813~55005687:-
BRCA	cis	rs7103648	0.695	rs11039290	ENSG00000255520.1	RP11-390K5.3	3.38	0.000751	0.0344	0.14	0.1	Systolic blood pressure;Diastolic blood pressure;	chr11:47550727	chr11:47123104~47130801:-
BRCA	cis	rs11048434	0.518	rs11048496	ENSG00000111788.10	RP11-22B23.1	3.38	0.000751	0.0344	0.1	0.1	Sjögren's syndrome;	chr12:9019825	chr12:9277235~9313241:+
BRCA	cis	rs7412746	0.658	rs4970982	ENSG00000224800.1	RP11-235D19.2	-3.38	0.000751	0.0344	-0.13	-0.1	Melanoma;	chr1:150892608	chr1:150881236~150881683:-
BRCA	cis	rs993804	0.528	rs9809401	ENSG00000264219.1	MIR4442	3.38	0.000751	0.0344	0.11	0.1	Bipolar disorder and schizophrenia;	chr3:25040525	chr3:25664873~25664939:-
BRCA	cis	rs561341	0.941	rs8081016	ENSG00000277511.1	CTD-2095E4.5	3.38	0.000752	0.0345	0.16	0.1	Hip circumference adjusted for BMI;	chr17:32004732	chr17:32127595~32128454:+
BRCA	cis	rs7258465	0.931	rs875396	ENSG00000273654.1	CTB-52I2.4	-3.38	0.000752	0.0345	-0.13	-0.1	Breast cancer;	chr19:18500337	chr19:18022403~18032099:+
BRCA	cis	rs8180040	0.967	rs17411375	ENSG00000260236.1	RP11-708J19.1	-3.38	0.000752	0.0345	-0.09	-0.1	Colorectal cancer;	chr3:47353645	chr3:47379089~47380999:-
BRCA	cis	rs17092148	0.887	rs4911431	ENSG00000269202.1	RP4-614O4.12	3.38	0.000752	0.0345	0.14	0.1	Neuroticism;	chr20:34570514	chr20:35201747~35203288:-
BRCA	cis	rs818427	0.697	rs1661036	ENSG00000279522.1	CTC-487M23.6	-3.38	0.000752	0.0345	-0.12	-0.1	Total body bone mineral density;	chr5:112709890	chr5:112894933~112896531:+
BRCA	cis	rs10501293	0.912	rs4755694	ENSG00000252652.1	Y_RNA	3.38	0.000752	0.0345	0.13	0.1	Cognitive performance;	chr11:43067032	chr11:43331261~43331356:+
BRCA	cis	rs4927850	1	rs10881564	ENSG00000185485.13	SDHAP1	3.38	0.000752	0.0345	0.11	0.1	Pancreatic cancer;	chr3:196023455	chr3:195959748~195990318:-
BRCA	cis	rs6012953	0.874	rs2426159	ENSG00000231715.1	COX6CP2	-3.38	0.000752	0.0345	-0.11	-0.1	Vitiligo;	chr20:50556642	chr20:50479767~50479991:+
BRCA	cis	rs2811415	0.597	rs13059751	ENSG00000242551.2	POU5F1P6	3.38	0.000752	0.0345	0.14	0.1	Lung function (FEV1/FVC);	chr3:128063819	chr3:128674735~128677005:-
BRCA	cis	rs2811415	0.597	rs1044843	ENSG00000242551.2	POU5F1P6	3.38	0.000752	0.0345	0.14	0.1	Lung function (FEV1/FVC);	chr3:128064855	chr3:128674735~128677005:-
BRCA	cis	rs2811415	0.597	rs13070488	ENSG00000242551.2	POU5F1P6	3.38	0.000752	0.0345	0.14	0.1	Lung function (FEV1/FVC);	chr3:128065275	chr3:128674735~128677005:-
BRCA	cis	rs2811415	0.597	rs9819960	ENSG00000242551.2	POU5F1P6	3.38	0.000752	0.0345	0.14	0.1	Lung function (FEV1/FVC);	chr3:128065670	chr3:128674735~128677005:-
BRCA	cis	rs2811415	0.597	rs9858267	ENSG00000242551.2	POU5F1P6	3.38	0.000752	0.0345	0.14	0.1	Lung function (FEV1/FVC);	chr3:128067708	chr3:128674735~128677005:-
BRCA	cis	rs2811415	0.597	rs2276867	ENSG00000242551.2	POU5F1P6	3.38	0.000752	0.0345	0.14	0.1	Lung function (FEV1/FVC);	chr3:128067832	chr3:128674735~128677005:-
BRCA	cis	rs2811415	0.597	rs3733158	ENSG00000242551.2	POU5F1P6	3.38	0.000752	0.0345	0.14	0.1	Lung function (FEV1/FVC);	chr3:128068314	chr3:128674735~128677005:-
BRCA	cis	rs2811415	0.569	rs9829877	ENSG00000242551.2	POU5F1P6	3.38	0.000752	0.0345	0.14	0.1	Lung function (FEV1/FVC);	chr3:128069126	chr3:128674735~128677005:-
BRCA	cis	rs2811415	0.597	rs1042912	ENSG00000242551.2	POU5F1P6	3.38	0.000752	0.0345	0.14	0.1	Lung function (FEV1/FVC);	chr3:128070852	chr3:128674735~128677005:-
BRCA	cis	rs7577696	0.888	rs494569	ENSG00000276334.1	AL133243.1	3.38	0.000752	0.0345	0.13	0.1	Inflammatory biomarkers;	chr2:32244553	chr2:32521927~32523547:+
BRCA	cis	rs3960554	0.808	rs79864016	ENSG00000205485.12	AC004980.7	-3.38	0.000752	0.0345	-0.14	-0.1	Eotaxin levels;	chr7:76026520	chr7:76549360~76627982:+
BRCA	cis	rs977987	0.806	rs1109342	ENSG00000261476.1	RP11-77K12.3	3.38	0.000752	0.0345	0.12	0.1	Dupuytren's disease;	chr16:75411777	chr16:75458252~75460017:-
BRCA	cis	rs2562456	0.516	rs56072098	ENSG00000268555.1	RP11-678G14.3	-3.38	0.000752	0.0345	-0.13	-0.1	Pain;	chr19:21469158	chr19:21570822~21587322:-
BRCA	cis	rs13401620	0.554	rs34639700	ENSG00000223549.1	MTND5P28	3.38	0.000752	0.0345	0.13	0.1	Breast size;	chr2:120211264	chr2:120215181~120217279:+
BRCA	cis	rs875971	0.825	rs1000464	ENSG00000106610.13	STAG3L4	3.38	0.000752	0.0345	0.14	0.1	Aortic root size;	chr7:66312922	chr7:67302621~67321526:+
BRCA	cis	rs2836974	0.583	rs9981884	ENSG00000235701.1	PCBP2P1	3.38	0.000752	0.0345	0.12	0.1	Cognitive function;	chr21:39213707	chr21:39171130~39172106:-
BRCA	cis	rs72899227	0.74	rs12693024	ENSG00000226131.1	AC073465.3	3.38	0.000752	0.0345	0.15	0.1	Lung cancer;	chr2:173361872	chr2:173485865~173486362:-
BRCA	cis	rs13126694	0.744	rs6821252	ENSG00000251073.1	NUDT19P5	3.38	0.000752	0.0345	0.1	0.1	Blood osmolality (transformed sodium);	chr4:158076296	chr4:158182825~158183393:+
BRCA	cis	rs875971	0.825	rs66981195	ENSG00000265600.1	AC006480.1	3.38	0.000752	0.0345	0.13	0.1	Aortic root size;	chr7:66614048	chr7:67356680~67356779:+
BRCA	cis	rs875971	0.862	rs3926380	ENSG00000265600.1	AC006480.1	3.38	0.000752	0.0345	0.13	0.1	Aortic root size;	chr7:66615658	chr7:67356680~67356779:+
BRCA	cis	rs875971	0.825	rs1860472	ENSG00000265600.1	AC006480.1	3.38	0.000752	0.0345	0.13	0.1	Aortic root size;	chr7:66617736	chr7:67356680~67356779:+
BRCA	cis	rs7311936	1	rs7303735	ENSG00000269980.1	RP11-282O18.7	-3.38	0.000752	0.0345	-0.13	-0.1	Vertical cup-disc ratio;	chr12:124151757	chr12:123262060~123262402:+
BRCA	cis	rs2638953	0.925	rs7967281	ENSG00000273989.1	RP11-425D17.2	-3.38	0.000752	0.0345	-0.16	-0.1	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28397843	chr12:28236227~28236828:+
BRCA	cis	rs13153459	0.649	rs6870835	ENSG00000249203.1	RP11-473L15.3	-3.38	0.000752	0.0345	-0.15	-0.1	Parkinson's disease;	chr5:44514546	chr5:44495618~44510282:-
BRCA	cis	rs1156327	0.51	rs1023441	ENSG00000188477.11	AC003003.5	-3.38	0.000752	0.0345	-0.23	-0.1	Periodontal disease-related phenotypes;	chr16:19320136	chr16:19285783~19310947:+
BRCA	cis	rs6728642	1	rs116171118	ENSG00000275655.1	Metazoa_SRP	-3.38	0.000753	0.0345	-0.24	-0.1	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:97029299	chr2:97100587~97100874:+
BRCA	cis	rs1865760	0.566	rs9358902	ENSG00000272462.2	U91328.19	-3.38	0.000753	0.0345	-0.12	-0.1	Height;	chr6:26058342	chr6:25992662~26001775:+
BRCA	cis	rs9329221	0.698	rs35388602	ENSG00000154316.13	TDH	-3.38	0.000753	0.0345	-0.14	-0.1	Neuroticism;	chr8:10401678	chr8:11339637~11368452:+
BRCA	cis	rs8180040	0.654	rs1466740	ENSG00000280667.1	Y_RNA	-3.38	0.000753	0.0345	-0.12	-0.1	Colorectal cancer;	chr3:47204393	chr3:47501083~47501182:+
BRCA	cis	rs7487075	0.637	rs4438106	ENSG00000274723.1	RP11-618L22.1	3.38	0.000753	0.0345	0.12	0.1	Itch intensity from mosquito bite;	chr12:46321745	chr12:46970504~46972155:+
BRCA	cis	rs7487075	0.786	rs11183441	ENSG00000274723.1	RP11-618L22.1	3.38	0.000753	0.0345	0.12	0.1	Itch intensity from mosquito bite;	chr12:46322137	chr12:46970504~46972155:+
BRCA	cis	rs7914558	0.505	rs12260436	ENSG00000213277.3	MARCKSL1P1	3.38	0.000753	0.0345	0.13	0.1	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102981357	chr10:103175554~103176094:+
BRCA	cis	rs34014631	1	rs34014631	ENSG00000226009.1	KCNIP2-AS1	3.38	0.000753	0.0345	0.26	0.1	Coronary artery calcification;	chr10:101938948	chr10:101819078~101828779:+
BRCA	cis	rs4907240	0.735	rs1122238	ENSG00000230606.9	AC159540.1	3.38	0.000753	0.0345	0.13	0.1	Event-related brain oscillations;	chr2:96521180	chr2:97416165~97433527:-
BRCA	cis	rs660899	0.894	rs3791035	ENSG00000229431.1	RP1-92O14.6	-3.38	0.000753	0.0345	-0.11	-0.1	Hypertension risk in short sleep duration;	chr1:43688808	chr1:43385113~43389155:+
BRCA	cis	rs2307449	0.861	rs7496308	ENSG00000260123.1	RP11-326A19.4	3.38	0.000753	0.0345	0.12	0.1	Menopause (age at onset);	chr15:89268312	chr15:89041223~89082819:+
BRCA	cis	rs301901	1	rs300051	ENSG00000272103.1	CTD-2653M23.3	3.38	0.000753	0.0345	0.13	0.1	Height;	chr5:37088525	chr5:36861736~36862217:-
BRCA	cis	rs74233809	0.901	rs1004467	ENSG00000213061.2	PFN1P11	3.38	0.000754	0.0345	0.2	0.1	Birth weight;	chr10:102834750	chr10:102838011~102845473:-
BRCA	cis	rs2832191	0.74	rs2832177	ENSG00000236056.1	GAPDHP14	3.38	0.000754	0.0345	0.12	0.1	Dental caries;	chr21:29106032	chr21:29222321~29223257:+
BRCA	cis	rs3018712	0.532	rs2513289	ENSG00000251637.5	RP11-119D9.1	3.38	0.000754	0.0345	0.17	0.1	Total body bone mineral density;	chr11:68652187	chr11:67886477~67906350:+
BRCA	cis	rs9437689	0.508	rs1887094	ENSG00000235501.4	RP4-639F20.1	-3.38	0.000754	0.0345	-0.13	-0.1	Phospholipid levels (plasma);	chr1:94953146	chr1:94927566~94963270:+
BRCA	cis	rs3770752	0.791	rs11683872	ENSG00000272054.1	RP11-423P10.2	-3.38	0.000754	0.0345	-0.09	-0.1	Schizophrenia;	chr2:37292936	chr2:37208875~37212677:+
BRCA	cis	rs1075265	0.87	rs7569370	ENSG00000272156.1	RP11-477N3.1	-3.38	0.000754	0.0345	-0.11	-0.1	Chronotype;Morning vs. evening chronotype;	chr2:53989212	chr2:54082554~54085066:+
BRCA	cis	rs1400816	0.85	rs10196521	ENSG00000228389.1	AC068039.4	3.38	0.000754	0.0345	0.19	0.1	Amyotrophic lateral sclerosis (sporadic);	chr2:171861735	chr2:171773482~171775844:+
BRCA	cis	rs16846053	0.605	rs62188792	ENSG00000227403.1	AC009299.3	3.38	0.000754	0.0345	0.26	0.1	Blood osmolality (transformed sodium);	chr2:161881430	chr2:161244739~161249050:+
BRCA	cis	rs16846053	0.605	rs41267443	ENSG00000227403.1	AC009299.3	3.38	0.000754	0.0345	0.26	0.1	Blood osmolality (transformed sodium);	chr2:161882271	chr2:161244739~161249050:+
BRCA	cis	rs660899	0.894	rs4660257	ENSG00000229431.1	RP1-92O14.6	-3.38	0.000754	0.0345	-0.11	-0.1	Hypertension risk in short sleep duration;	chr1:43682497	chr1:43385113~43389155:+
BRCA	cis	rs11018874	0.597	rs4268468	ENSG00000280367.1	RP11-121L10.2	3.38	0.000754	0.0345	0.15	0.1	White blood cell types;	chr11:90153116	chr11:90223153~90226538:+
BRCA	cis	rs656900	0.669	rs7178799	ENSG00000261229.4	MTHFS	-3.38	0.000754	0.0345	-0.1	-0.1	Cerebrospinal P-tau181p levels;	chr15:79826981	chr15:79843547~79897285:-
BRCA	cis	rs17473412	0.677	rs11749673	ENSG00000263432.2	RN7SL689P	3.38	0.000754	0.0345	0.15	0.1	Total body bone mineral density;	chr5:123498545	chr5:123022487~123022783:-
BRCA	cis	rs10943724	0.556	rs10943727	ENSG00000272129.1	RP11-250B2.6	3.38	0.000754	0.0345	0.14	0.1	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr6:80595527	chr6:80355424~80356859:+
BRCA	cis	rs10876993	0.728	rs1082503	ENSG00000269903.1	RP11-571M6.18	3.38	0.000754	0.0345	0.13	0.1	Celiac disease or Rheumatoid arthritis;	chr12:57642934	chr12:57814494~57814926:+
BRCA	cis	rs7520050	0.966	rs12564541	ENSG00000226957.1	RP4-533D7.4	3.38	0.000754	0.0345	0.11	0.1	Reticulocyte count;Red blood cell count;	chr1:45914565	chr1:46046818~46048368:+
BRCA	cis	rs6964587	0.839	rs13246743	ENSG00000188693.7	CYP51A1-AS1	-3.38	0.000754	0.0345	-0.11	-0.1	Breast cancer;	chr7:91824631	chr7:92134604~92180725:+
BRCA	cis	rs875971	0.862	rs4236208	ENSG00000223473.2	GS1-124K5.3	-3.38	0.000754	0.0346	-0.08	-0.1	Aortic root size;	chr7:66284091	chr7:66491049~66493566:-
BRCA	cis	rs10844706	1	rs10844706	ENSG00000256594.6	RP11-705C15.2	3.38	0.000754	0.0346	0.13	0.1	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9757536	chr12:9633419~9658412:+
BRCA	cis	rs7712401	0.791	rs6887101	ENSG00000249996.1	RP11-359P5.1	-3.38	0.000754	0.0346	-0.12	-0.1	Mean platelet volume;	chr5:122773512	chr5:123036271~123054667:+
BRCA	cis	rs1865760	0.865	rs1115920	ENSG00000272810.1	U91328.22	-3.38	0.000755	0.0346	-0.12	-0.1	Height;	chr6:25953799	chr6:26013241~26013757:+
BRCA	cis	rs12530	0.54	rs737779	ENSG00000241954.1	RP1-149A16.17	-3.38	0.000755	0.0346	-0.12	-0.1	IgG glycosylation;	chr22:32400260	chr22:32383786~32385631:+
BRCA	cis	rs412658	0.704	rs8105767	ENSG00000269345.1	VN1R85P	3.38	0.000755	0.0346	0.13	0.1	Telomere length;	chr19:22032639	chr19:22174766~22175191:-
BRCA	cis	rs4809760	0.935	rs6020084	ENSG00000224397.4	LINC01272	3.38	0.000755	0.0346	0.1	0.1	Gut microbiota (beta diversity);	chr20:49845827	chr20:50267486~50279795:+
BRCA	cis	rs17756712	0.725	rs4335022	ENSG00000272463.1	RP11-532F6.3	3.38	0.000755	0.0346	0.18	0.1	Vertical cup-disc ratio;	chr6:596417	chr6:708592~711405:-
BRCA	cis	rs17756712	0.725	rs72835956	ENSG00000272463.1	RP11-532F6.3	3.38	0.000755	0.0346	0.18	0.1	Vertical cup-disc ratio;	chr6:597164	chr6:708592~711405:-
BRCA	cis	rs7734985	0.634	rs10062171	ENSG00000236882.6	LINC01554	-3.38	0.000755	0.0346	-0.12	-0.1	IgG glycosylation;	chr5:96173996	chr5:95852232~95860133:+
BRCA	cis	rs7017914	0.967	rs34677078	ENSG00000246366.5	RP11-382J12.1	3.38	0.000755	0.0346	0.11	0.1	Bone mineral density;	chr8:70705480	chr8:70608577~70663279:+
BRCA	cis	rs11673344	0.734	rs320887	ENSG00000267422.1	CTD-2554C21.1	-3.38	0.000755	0.0346	-0.14	-0.1	Obesity-related traits;	chr19:37202536	chr19:37779686~37792865:+
BRCA	cis	rs875971	0.502	rs2946580	ENSG00000226767.1	RP11-328P23.3	-3.38	0.000755	0.0346	-0.13	-0.1	Aortic root size;	chr7:66066855	chr7:65508773~65508944:-
BRCA	cis	rs4819052	0.851	rs7275870	ENSG00000223768.1	LINC00205	-3.38	0.000755	0.0346	-0.14	-0.1	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251299	chr21:45293285~45297354:+
BRCA	cis	rs4819052	0.851	rs7275874	ENSG00000223768.1	LINC00205	-3.38	0.000755	0.0346	-0.14	-0.1	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251308	chr21:45293285~45297354:+
BRCA	cis	rs202072	0.872	rs375661	ENSG00000215022.6	RP1-257A7.4	-3.38	0.000755	0.0346	-0.14	-0.1	HIV-1 viral setpoint;	chr6:13279199	chr6:13264861~13295586:-
BRCA	cis	rs34792	0.76	rs153808	ENSG00000258354.1	MIR3180-1	3.38	0.000755	0.0346	0.13	0.1	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15464485	chr16:14909887~14911345:-
BRCA	cis	rs7918232	0.941	rs7096505	ENSG00000262412.1	RP11-85G18.6	3.38	0.000755	0.0346	0.17	0.1	Breast cancer;	chr10:27038070	chr10:27243130~27250804:+
BRCA	cis	rs6012953	0.874	rs1885177	ENSG00000231715.1	COX6CP2	-3.38	0.000755	0.0346	-0.11	-0.1	Vitiligo;	chr20:50574691	chr20:50479767~50479991:+
BRCA	cis	rs36051895	0.664	rs10115172	ENSG00000237711.1	RP11-39K24.13	-3.38	0.000755	0.0346	-0.13	-0.1	Pediatric autoimmune diseases;	chr9:5098549	chr9:5100236~5101009:+
BRCA	cis	rs11892454	0.565	rs34721056	ENSG00000217643.1	PTGES3P2	-3.38	0.000755	0.0346	-0.12	-0.1	Heschl's gyrus morphology;	chr2:25798387	chr2:25822469~25822950:+
BRCA	cis	rs911119	0.913	rs2405392	ENSG00000270001.1	RP11-218C14.8	-3.38	0.000755	0.0346	-0.13	-0.1	Chronic kidney disease;	chr20:23588549	chr20:23631826~23632316:-
BRCA	cis	rs10792665	0.686	rs1904428	ENSG00000254965.1	RP11-113K21.2	3.38	0.000756	0.0346	0.1	0.1	Obesity-related traits;	chr11:83007210	chr11:83111060~83111442:-
BRCA	cis	rs9578106	0.777	rs9579399	ENSG00000122043.9	LINC00544	3.38	0.000756	0.0346	0.17	0.1	Breast cancer;	chr13:29547223	chr13:29935905~29950488:+
BRCA	cis	rs3735485	0.738	rs3735493	ENSG00000201772.1	SNORA5C	3.38	0.000756	0.0346	0.14	0.1	White blood cell count;Sum basophil neutrophil counts;Neutrophil count;Granulocyte percentage of myeloid white cells;Monocyte percentage of white cells;Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Lymphocyte counts;	chr7:45082725	chr7:45104906~45105042:-
BRCA	cis	rs1865760	0.865	rs2164485	ENSG00000272810.1	U91328.22	-3.38	0.000756	0.0346	-0.12	-0.1	Height;	chr6:25951878	chr6:26013241~26013757:+
BRCA	cis	rs930395	0.514	rs6880275	ENSG00000248779.1	RP11-53O19.2	-3.38	0.000756	0.0346	-0.1	-0.1	Breast cancer;	chr5:44908833	chr5:44752949~44765744:+
BRCA	cis	rs930395	0.514	rs6870136	ENSG00000248779.1	RP11-53O19.2	-3.38	0.000756	0.0346	-0.1	-0.1	Breast cancer;	chr5:44910560	chr5:44752949~44765744:+
BRCA	cis	rs930395	0.514	rs6881563	ENSG00000248779.1	RP11-53O19.2	-3.38	0.000756	0.0346	-0.1	-0.1	Breast cancer;	chr5:44912751	chr5:44752949~44765744:+
BRCA	cis	rs863345	0.604	rs7555174	ENSG00000176320.2	RP11-404O13.5	-3.38	0.000756	0.0346	-0.11	-0.1	Pneumococcal bacteremia;	chr1:158517636	chr1:158197922~158203877:-
BRCA	cis	rs10905065	0.717	rs11254266	ENSG00000215267.7	AKR1C7P	3.38	0.000756	0.0346	0.14	0.1	Menopause (age at onset);	chr10:5708115	chr10:5275173~5288470:-
BRCA	cis	rs258892	0.895	rs34066594	ENSG00000272525.1	RP11-79P5.9	-3.38	0.000756	0.0346	-0.13	-0.1	Small cell lung carcinoma;	chr5:72734800	chr5:73497550~73498293:-
BRCA	cis	rs258892	0.895	rs4254881	ENSG00000272525.1	RP11-79P5.9	-3.38	0.000756	0.0346	-0.13	-0.1	Small cell lung carcinoma;	chr5:72735533	chr5:73497550~73498293:-
BRCA	cis	rs258892	0.895	rs4254882	ENSG00000272525.1	RP11-79P5.9	-3.38	0.000756	0.0346	-0.13	-0.1	Small cell lung carcinoma;	chr5:72735822	chr5:73497550~73498293:-
BRCA	cis	rs258892	0.843	rs11950068	ENSG00000272525.1	RP11-79P5.9	-3.38	0.000756	0.0346	-0.13	-0.1	Small cell lung carcinoma;	chr5:72737171	chr5:73497550~73498293:-
BRCA	cis	rs7649443	0.758	rs34305944	ENSG00000243339.3	RN7SL738P	-3.38	0.000756	0.0346	-0.15	-0.1	Nonsyndromic cleft lip with cleft palate;	chr3:197288547	chr3:196399911~196400207:+
BRCA	cis	rs9467711	0.659	rs66757203	ENSG00000241549.7	GUSBP2	3.38	0.000756	0.0346	0.22	0.1	Autism spectrum disorder or schizophrenia;	chr6:26454728	chr6:26871484~26956554:-
BRCA	cis	rs74233809	1	rs77787671	ENSG00000213061.2	PFN1P11	3.38	0.000756	0.0346	0.23	0.1	Birth weight;	chr10:103016448	chr10:102838011~102845473:-
BRCA	cis	rs6088580	0.524	rs6087612	ENSG00000126005.14	MMP24-AS1	3.38	0.000756	0.0346	0.12	0.1	Glomerular filtration rate (creatinine);	chr20:34643018	chr20:35216462~35278131:-
BRCA	cis	rs10799445	0.569	rs2999745	ENSG00000227711.2	RP11-275O4.5	-3.38	0.000756	0.0346	-0.12	-0.1	Height;	chr1:227604838	chr1:227509028~227520477:-
BRCA	cis	rs6696239	0.513	rs2999746	ENSG00000227711.2	RP11-275O4.5	-3.38	0.000756	0.0346	-0.12	-0.1	Height;	chr1:227605784	chr1:227509028~227520477:-
BRCA	cis	rs6672530	0.518	rs3010196	ENSG00000227711.2	RP11-275O4.5	-3.38	0.000756	0.0346	-0.12	-0.1	Hip circumference adjusted for BMI;	chr1:227606207	chr1:227509028~227520477:-
BRCA	cis	rs6696239	0.531	rs3010195	ENSG00000227711.2	RP11-275O4.5	-3.38	0.000756	0.0346	-0.12	-0.1	Height;	chr1:227607008	chr1:227509028~227520477:-
BRCA	cis	rs62458065	1	rs10246687	ENSG00000273014.1	RP11-225B17.2	-3.38	0.000756	0.0346	-0.15	-0.1	Metabolite levels (HVA/MHPG ratio);	chr7:32425571	chr7:32758882~32759353:+
BRCA	cis	rs3096299	0.933	rs2965823	ENSG00000261546.1	CTD-2555A7.3	-3.38	0.000756	0.0346	-0.11	-0.1	Multiple myeloma (IgH translocation);	chr16:89388516	chr16:89113175~89115279:-
BRCA	cis	rs71520386	0.898	rs12536091	ENSG00000179428.2	AC073072.5	3.38	0.000756	0.0346	0.15	0.1	Fibrinogen levels;	chr7:22788581	chr7:22725395~22727620:-
BRCA	cis	rs6142102	0.923	rs3787230	ENSG00000206582.1	Y_RNA	-3.38	0.000756	0.0346	-0.12	-0.1	Skin pigmentation;	chr20:34052466	chr20:34526510~34526606:-
BRCA	cis	rs7267979	1	rs2258879	ENSG00000274414.1	RP5-965G21.4	-3.38	0.000756	0.0346	-0.12	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25298577	chr20:25239007~25245229:-
BRCA	cis	rs7267979	1	rs2257496	ENSG00000274414.1	RP5-965G21.4	-3.38	0.000756	0.0346	-0.12	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25298679	chr20:25239007~25245229:-
BRCA	cis	rs7267979	1	rs2258884	ENSG00000274414.1	RP5-965G21.4	-3.38	0.000756	0.0346	-0.12	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25298903	chr20:25239007~25245229:-
BRCA	cis	rs7267979	1	rs2259837	ENSG00000274414.1	RP5-965G21.4	-3.38	0.000756	0.0346	-0.12	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25299569	chr20:25239007~25245229:-
BRCA	cis	rs7267979	1	rs2259873	ENSG00000274414.1	RP5-965G21.4	-3.38	0.000756	0.0346	-0.12	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25300145	chr20:25239007~25245229:-
BRCA	cis	rs875971	1	rs10244498	ENSG00000230189.5	GS1-124K5.2	3.38	0.000756	0.0346	0.08	0.1	Aortic root size;	chr7:66651069	chr7:66409143~66490059:-
BRCA	cis	rs10771431	0.967	rs7137443	ENSG00000214776.8	RP11-726G1.1	-3.38	0.000756	0.0346	-0.11	-0.1	Breast size;	chr12:9219433	chr12:9467552~9576275:+
BRCA	cis	rs1424638	0.655	rs2195491	ENSG00000233251.6	AC007743.1	-3.38	0.000756	0.0346	-0.12	-0.1	Intelligence (multi-trait analysis);	chr2:57027499	chr2:56173534~56185770:-
BRCA	cis	rs4664293	0.867	rs13432	ENSG00000230783.1	AC009961.2	-3.38	0.000756	0.0346	-0.14	-0.1	Monocyte percentage of white cells;	chr2:159769216	chr2:159689217~159690291:-
BRCA	cis	rs6556937	1	rs6556937	ENSG00000272109.1	CTD-2260A17.3	-3.38	0.000756	0.0346	-0.17	-0.1	Blood protein levels;	chr5:96649578	chr5:96804353~96806105:+
BRCA	cis	rs80226907	0.831	rs72717751	ENSG00000258413.1	RP11-665C16.6	-3.38	0.000756	0.0346	-0.26	-0.1	Mean platelet volume;	chr14:55396480	chr14:55262767~55272075:-
BRCA	cis	rs6142618	0.562	rs6142617	ENSG00000275576.1	RP5-836N17.4	-3.38	0.000756	0.0346	-0.12	-0.1	Inflammatory bowel disease;	chr20:32127959	chr20:32116171~32116629:+
BRCA	cis	rs1376877	0.87	rs11690927	ENSG00000273456.1	RP11-686O6.2	3.38	0.000757	0.0346	0.1	0.1	Subclinical atherosclerosis traits (other);	chr2:203079305	chr2:202374932~202375604:-
BRCA	cis	rs12760731	0.565	rs11583144	ENSG00000213057.5	C1orf220	3.38	0.000757	0.0346	0.16	0.1	Obesity-related traits;	chr1:178252935	chr1:178542752~178548889:+
BRCA	cis	rs889122	0.765	rs16996255	ENSG00000267289.1	CTD-2623N2.11	3.38	0.000757	0.0346	0.15	0.1	Menarche (age at onset);	chr19:9872134	chr19:9834079~9835013:-
BRCA	cis	rs10819083	0.654	rs7848507	ENSG00000232630.1	PRPS1P2	-3.38	0.000757	0.0346	-0.1	-0.1	Squamous cell lung carcinoma;	chr9:125830853	chr9:125150653~125151589:+
BRCA	cis	rs17221829	0.644	rs7943100	ENSG00000280385.1	AP000648.5	-3.38	0.000757	0.0346	-0.12	-0.1	Anxiety in major depressive disorder;	chr11:89648869	chr11:90193614~90198120:+
BRCA	cis	rs2489715	0.7	rs2489697	ENSG00000185904.10	LINC00839	-3.38	0.000757	0.0346	-0.13	-0.1	Helix rolling;	chr10:42392724	chr10:42475543~42495336:+
BRCA	cis	rs2262909	0.924	rs11085509	ENSG00000279377.1	AC003973.3	3.38	0.000757	0.0346	0.15	0.1	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;	chr19:22021771	chr19:21965708~21968529:-
BRCA	cis	rs7781266	0.79	rs11982966	ENSG00000226205.1	AC007790.4	-3.38	0.000757	0.0346	-0.16	-0.1	Educational attainment (college completion);	chr7:133468370	chr7:133732493~133733595:-
BRCA	cis	rs11098499	0.863	rs6534139	ENSG00000260091.1	RP11-33B1.4	3.38	0.000757	0.0346	0.1	0.1	Corneal astigmatism;	chr4:119528301	chr4:119409333~119410233:+
BRCA	cis	rs9847710	0.967	rs2564934	ENSG00000242849.2	ALDOAP1	3.38	0.000757	0.0346	0.12	0.1	Ulcerative colitis;	chr3:52990564	chr3:52193170~52194785:+
BRCA	cis	rs863345	0.604	rs7544134	ENSG00000229914.1	RP11-404O13.4	-3.38	0.000757	0.0346	-0.11	-0.1	Pneumococcal bacteremia;	chr1:158505631	chr1:158195633~158196131:-
BRCA	cis	rs9341808	0.754	rs9341810	ENSG00000279022.1	RP11-250B2.4	3.38	0.000757	0.0346	0.12	0.1	Sitting height ratio;	chr6:80265121	chr6:80440730~80441172:+
BRCA	cis	rs9341808	0.7	rs12215236	ENSG00000279022.1	RP11-250B2.4	3.38	0.000757	0.0346	0.12	0.1	Sitting height ratio;	chr6:80265341	chr6:80440730~80441172:+
BRCA	cis	rs1730008	0.585	rs12634907	ENSG00000279311.1	RP11-170K4.2	3.38	0.000757	0.0346	0.12	0.1	Lobe attachment (rater-scored or self-reported);	chr3:158509097	chr3:158869898~158871821:+
BRCA	cis	rs875971	0.522	rs2008188	ENSG00000227113.2	RP11-460N20.4	3.38	0.000757	0.0346	0.11	0.1	Aortic root size;	chr7:65964026	chr7:65075023~65078780:+
BRCA	cis	rs17221829	0.733	rs1873083	ENSG00000280385.1	AP000648.5	-3.38	0.000757	0.0346	-0.12	-0.1	Anxiety in major depressive disorder;	chr11:89663642	chr11:90193614~90198120:+
BRCA	cis	rs7520050	0.931	rs35743647	ENSG00000226957.1	RP4-533D7.4	3.38	0.000757	0.0346	0.11	0.1	Reticulocyte count;Red blood cell count;	chr1:45941580	chr1:46046818~46048368:+
BRCA	cis	rs11098499	0.863	rs3822192	ENSG00000225892.3	RP11-384K6.2	3.38	0.000757	0.0346	0.11	0.1	Corneal astigmatism;	chr4:119524565	chr4:118632274~118634759:+
BRCA	cis	rs7260598	0.539	rs10418377	ENSG00000268442.1	CTD-2027I19.2	3.38	0.000757	0.0347	0.18	0.1	Response to taxane treatment (placlitaxel);	chr19:23898542	chr19:24162370~24163425:-
BRCA	cis	rs3177980	0.673	rs10489172	ENSG00000239494.2	RN7SL333P	-3.38	0.000757	0.0347	-0.1	-0.1	Amyotrophic lateral sclerosis;	chr1:169855238	chr1:169859756~169860052:+
BRCA	cis	rs7968440	0.554	rs861204	ENSG00000272368.2	RP4-605O3.4	-3.38	0.000757	0.0347	-0.11	-0.1	Fibrinogen;	chr12:50844033	chr12:50112197~50165618:+
BRCA	cis	rs10191559	0.507	rs4233796	ENSG00000234663.4	AC104820.2	3.38	0.000757	0.0347	0.09	0.1	Red blood cell count;	chr2:181223622	chr2:181101932~181399559:+
BRCA	cis	rs9402743	0.632	rs7773035	ENSG00000231028.7	LINC00271	-3.38	0.000757	0.0347	-0.11	-0.1	Systemic lupus erythematosus;	chr6:135784743	chr6:135497801~135716055:+
BRCA	cis	rs7395581	0.959	rs2167079	ENSG00000280615.1	Y_RNA	3.38	0.000757	0.0347	0.13	0.1	HDL cholesterol;	chr11:47248704	chr11:47614898~47614994:-
BRCA	cis	rs12042938	1	rs11122319	ENSG00000223393.1	RP5-858B6.3	-3.38	0.000757	0.0347	-0.11	-0.1	Neuranatomic and neurocognitive phenotypes;	chr1:231672536	chr1:230874846~230879015:+
BRCA	cis	rs1730008	0.585	rs11718554	ENSG00000279311.1	RP11-170K4.2	3.38	0.000757	0.0347	0.12	0.1	Lobe attachment (rater-scored or self-reported);	chr3:158518423	chr3:158869898~158871821:+
BRCA	cis	rs8054556	1	rs11150579	ENSG00000214725.6	CDIPT-AS1	-3.38	0.000757	0.0347	-0.13	-0.1	Autism spectrum disorder or schizophrenia;	chr16:29989009	chr16:29863593~29868053:+
BRCA	cis	rs6545883	0.86	rs13023037	ENSG00000273302.1	RP11-493E12.2	-3.38	0.000757	0.0347	-0.1	-0.1	Tuberculosis;	chr2:61393854	chr2:61199979~61200769:+
BRCA	cis	rs7569084	1	rs13385171	ENSG00000281920.1	RP11-418H16.1	-3.38	0.000757	0.0347	-0.12	-0.1	Sum eosinophil basophil counts;	chr2:65434709	chr2:65623272~65628424:+
BRCA	cis	rs7487637	0.529	rs11168244	ENSG00000274902.1	RP1-197B17.4	3.38	0.000757	0.0347	0.17	0.1	Mononucleosis;	chr12:47809158	chr12:47731908~47732351:+
BRCA	cis	rs4819052	0.851	rs13052312	ENSG00000223768.1	LINC00205	-3.38	0.000757	0.0347	-0.14	-0.1	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45242444	chr21:45293285~45297354:+
BRCA	cis	rs12468226	0.938	rs76658848	ENSG00000272966.1	RP11-686O6.1	3.38	0.000757	0.0347	0.17	0.1	Urate levels;	chr2:202275548	chr2:202336739~202337200:+
BRCA	cis	rs736408	0.812	rs2270197	ENSG00000239557.1	RP11-168J18.6	3.38	0.000758	0.0347	0.14	0.1	Bipolar disorder;	chr3:52790079	chr3:52373652~52374882:+
BRCA	cis	rs3808502	0.605	rs11784572	ENSG00000254866.2	DEFB109P3	3.38	0.000758	0.0347	0.14	0.1	Neuroticism;	chr8:11316975	chr8:12150895~12151134:-
BRCA	cis	rs4763879	0.778	rs11052497	ENSG00000256582.1	RP11-75L1.1	-3.38	0.000758	0.0347	-0.11	-0.1	Type 1 diabetes;	chr12:9696679	chr12:9704077~9709350:+
BRCA	cis	rs2288884	0.579	rs6509603	ENSG00000268849.4	SIGLEC22P	-3.38	0.000758	0.0347	-0.14	-0.1	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:51960977	chr19:51211080~51212088:+
BRCA	cis	rs62025270	0.522	rs338519	ENSG00000259416.2	RP11-158M2.5	-3.38	0.000758	0.0347	-0.13	-0.1	Idiopathic pulmonary fibrosis;	chr15:85671648	chr15:85754941~85756237:-
BRCA	cis	rs9393813	0.516	rs4713099	ENSG00000241549.7	GUSBP2	-3.38	0.000758	0.0347	-0.11	-0.1	Bipolar disorder;	chr6:27437423	chr6:26871484~26956554:-
BRCA	cis	rs35520189	0.845	rs12479173	ENSG00000231747.1	AC079922.2	-3.38	0.000758	0.0347	-0.11	-0.1	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:112891633	chr2:112621809~112622167:-
BRCA	cis	rs9467773	0.62	rs9461276	ENSG00000261353.1	CTA-14H9.5	-3.38	0.000758	0.0347	-0.1	-0.1	Intelligence (multi-trait analysis);	chr6:26594940	chr6:26527063~26527404:+
BRCA	cis	rs6840360	0.904	rs73862064	ENSG00000251611.1	RP11-610P16.1	-3.38	0.000758	0.0347	-0.09	-0.1	Intelligence (multi-trait analysis);	chr4:151581948	chr4:151407551~151408835:-
BRCA	cis	rs73222236	0.825	rs7622833	ENSG00000239213.4	NCK1-AS1	3.38	0.000758	0.0347	0.11	0.1	Coronary artery disease;	chr3:136323079	chr3:136841726~136862054:-
BRCA	cis	rs7578361	0.918	rs10439269	ENSG00000231969.1	AC144449.1	3.38	0.000758	0.0347	0.16	0.1	Acute lymphoblastic leukemia (childhood);	chr2:149520267	chr2:149587196~149848233:+
BRCA	cis	rs2148307	0.787	rs10734036	ENSG00000228339.1	AMD1P1	-3.38	0.000758	0.0347	-0.13	-0.1	Photic sneeze reflex;	chr10:20801226	chr10:20350049~20351100:+
BRCA	cis	rs13256369	1	rs7820159	ENSG00000254153.1	CTA-398F10.2	3.38	0.000758	0.0347	0.14	0.1	Obesity-related traits;	chr8:8718705	chr8:8456909~8461337:-
BRCA	cis	rs71520386	0.53	rs10256628	ENSG00000179428.2	AC073072.5	3.38	0.000758	0.0347	0.12	0.1	Fibrinogen levels;	chr7:22843640	chr7:22725395~22727620:-
BRCA	cis	rs2154319	0.79	rs11209376	ENSG00000230638.4	RP11-486B10.4	3.38	0.000758	0.0347	0.18	0.1	Height;	chr1:41032676	chr1:41542069~41544310:+
BRCA	cis	rs2836950	0.545	rs11700449	ENSG00000235701.1	PCBP2P1	-3.38	0.000758	0.0347	-0.12	-0.1	Menarche (age at onset);	chr21:39150493	chr21:39171130~39172106:-
BRCA	cis	rs875971	0.862	rs6971059	ENSG00000271064.1	RP11-792A8.3	3.38	0.000758	0.0347	0.12	0.1	Aortic root size;	chr7:66602045	chr7:66748838~66749077:-
BRCA	cis	rs9973361	0.531	rs62176288	ENSG00000232411.1	AC009495.3	-3.38	0.000758	0.0347	-0.13	-0.1	Total body bone mineral density;	chr2:165838327	chr2:165833048~165839098:-
BRCA	cis	rs860295	0.702	rs12081067	ENSG00000236675.1	MTX1P1	-3.38	0.000758	0.0347	-0.13	-0.1	Body mass index;	chr1:155389191	chr1:155230975~155234325:+
BRCA	cis	rs2455799	1	rs1348983	ENSG00000224728.1	AC090945.1	-3.38	0.000758	0.0347	-0.11	-0.1	Mean platelet volume;	chr3:15858922	chr3:15878047~15879571:+
BRCA	cis	rs2880765	0.835	rs4842884	ENSG00000230373.7	GOLGA6L5P	3.38	0.000759	0.0347	0.11	0.1	Coronary artery disease;	chr15:85491943	chr15:84507885~84516814:-
BRCA	cis	rs1665650	0.874	rs73385592	ENSG00000232767.1	RP11-498B4.5	3.38	0.000759	0.0347	0.11	0.1	Colorectal cancer;	chr10:116732787	chr10:116670103~116672739:+
BRCA	cis	rs1665650	0.874	rs66688522	ENSG00000232767.1	RP11-498B4.5	3.38	0.000759	0.0347	0.11	0.1	Colorectal cancer;	chr10:116733882	chr10:116670103~116672739:+
BRCA	cis	rs17711722	0.701	rs781145	ENSG00000272831.1	RP11-792A8.4	3.38	0.000759	0.0347	0.09	0.1	Calcium levels;	chr7:65975383	chr7:66739829~66740385:-
BRCA	cis	rs4665809	1	rs7599132	ENSG00000231655.1	AC011742.3	-3.38	0.000759	0.0347	-0.15	-0.1	Gut microbiome composition (summer);	chr2:26056941	chr2:26140263~26141264:-
BRCA	cis	rs258892	0.895	rs13181060	ENSG00000272525.1	RP11-79P5.9	-3.38	0.000759	0.0347	-0.13	-0.1	Small cell lung carcinoma;	chr5:72775942	chr5:73497550~73498293:-
BRCA	cis	rs6968419	0.537	rs10953809	ENSG00000279086.1	RP11-667F14.1	-3.38	0.000759	0.0347	-0.11	-0.1	Intraocular pressure;	chr7:116127110	chr7:116209234~116211511:-
BRCA	cis	rs6968419	0.504	rs56038916	ENSG00000279086.1	RP11-667F14.1	-3.38	0.000759	0.0347	-0.11	-0.1	Intraocular pressure;	chr7:116127662	chr7:116209234~116211511:-
BRCA	cis	rs2439831	0.85	rs2228368	ENSG00000206991.1	RNU6-610P	-3.38	0.000759	0.0347	-0.17	-0.1	Lung cancer in ever smokers;	chr15:43809812	chr15:43637632~43637738:-
BRCA	cis	rs9341808	0.718	rs9343971	ENSG00000279022.1	RP11-250B2.4	3.38	0.000759	0.0347	0.12	0.1	Sitting height ratio;	chr6:80172339	chr6:80440730~80441172:+
BRCA	cis	rs11877825	0.826	rs3911954	ENSG00000265728.1	RP11-883A18.3	-3.38	0.000759	0.0347	-0.14	-0.1	Gut microbiota (bacterial taxa);	chr18:10569115	chr18:10594590~10604798:+
BRCA	cis	rs11877825	0.865	rs8098008	ENSG00000265728.1	RP11-883A18.3	-3.38	0.000759	0.0347	-0.14	-0.1	Gut microbiota (bacterial taxa);	chr18:10569446	chr18:10594590~10604798:+
BRCA	cis	rs9959145	0.706	rs117416781	ENSG00000267199.1	RP11-861E21.2	3.38	0.000759	0.0347	0.18	0.1	Immune response to smallpox vaccine (IL-6);	chr18:12684925	chr18:12438890~12448205:+
BRCA	cis	rs9959145	1	rs78421903	ENSG00000267199.1	RP11-861E21.2	3.38	0.000759	0.0347	0.18	0.1	Immune response to smallpox vaccine (IL-6);	chr18:12688701	chr18:12438890~12448205:+
BRCA	cis	rs10875746	0.859	rs4760695	ENSG00000273765.1	RP11-370I10.11	-3.38	0.000759	0.0347	-0.14	-0.1	Longevity (90 years and older);	chr12:48198065	chr12:48360920~48361377:+
BRCA	cis	rs9527	0.615	rs12248123	ENSG00000236937.2	PTGES3P4	3.38	0.000759	0.0347	0.14	0.1	Arsenic metabolism;	chr10:102975609	chr10:102845595~102845950:+
BRCA	cis	rs1348850	0.526	rs10803912	ENSG00000271825.1	RP11-337N6.2	-3.38	0.000759	0.0347	-0.17	-0.1	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177542448	chr2:177300600~177302006:+
BRCA	cis	rs67766926	0.953	rs6545836	ENSG00000237522.1	NONOP2	3.38	0.000759	0.0347	0.11	0.1	Inflammatory skin disease;	chr2:60895838	chr2:60936819~60938049:-
BRCA	cis	rs68170813	0.652	rs6957186	ENSG00000241764.3	AC002467.7	3.38	0.000759	0.0347	0.18	0.1	Coronary artery disease;	chr7:107560147	chr7:107742817~107744581:-
BRCA	cis	rs1443512	0.812	rs4759058	ENSG00000228630.4	HOTAIR	-3.38	0.000759	0.0347	-0.13	-0.1	Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-hip ratio;Waist-to-hip ratio adjusted for body mass index;	chr12:53945268	chr12:53962308~53974956:-
BRCA	cis	rs6696239	0.956	rs12131114	ENSG00000227711.2	RP11-275O4.5	-3.38	0.000759	0.0347	-0.14	-0.1	Height;	chr1:227590926	chr1:227509028~227520477:-
BRCA	cis	rs9297216	0.602	rs1390129	ENSG00000272338.2	RP11-722E23.2	-3.38	0.000759	0.0347	-0.13	-0.1	Asthma (childhood onset);	chr8:34189331	chr8:33360839~33361415:-
BRCA	cis	rs722599	0.715	rs11851433	ENSG00000279594.1	RP11-950C14.10	3.38	0.000759	0.0347	0.12	0.1	IgG glycosylation;	chr14:74872747	chr14:75011269~75012851:-
BRCA	cis	rs7267979	1	rs6083844	ENSG00000231081.1	RP4-760C5.3	3.38	0.000759	0.0347	0.13	0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25406196	chr20:26008791~26010531:-
BRCA	cis	rs7020830	0.931	rs13297576	ENSG00000230188.1	RP11-405L18.4	-3.38	0.000759	0.0347	-0.13	-0.1	Schizophrenia;	chr9:37142192	chr9:37490421~37490893:-
BRCA	cis	rs879500	0.653	rs4800881	ENSG00000266296.1	ARIH2P1	-3.38	0.000759	0.0347	-0.15	-0.1	Lung function (FVC);	chr18:28495567	chr18:28651732~28653208:+
BRCA	cis	rs879500	0.653	rs4800882	ENSG00000266296.1	ARIH2P1	-3.38	0.000759	0.0347	-0.15	-0.1	Lung function (FVC);	chr18:28495623	chr18:28651732~28653208:+
BRCA	cis	rs72772090	0.539	rs3333	ENSG00000272109.1	CTD-2260A17.3	3.38	0.000759	0.0347	0.2	0.1	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96779407	chr5:96804353~96806105:+
BRCA	cis	rs67766926	0.953	rs6545835	ENSG00000237522.1	NONOP2	-3.38	0.000759	0.0347	-0.11	-0.1	Inflammatory skin disease;	chr2:60885417	chr2:60936819~60938049:-
BRCA	cis	rs2692947	0.794	rs2692893	ENSG00000168992.4	OR7E102P	3.38	0.00076	0.0347	0.15	0.1	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96090799	chr2:95546531~95547545:+
BRCA	cis	rs6012564	0.927	rs6019553	ENSG00000227431.4	CSE1L-AS1	-3.38	0.00076	0.0347	-0.13	-0.1	Anger;	chr20:48955014	chr20:49040463~49046044:-
BRCA	cis	rs8028182	0.525	rs9920028	ENSG00000260269.4	CTD-2323K18.1	-3.38	0.00076	0.0347	-0.16	-0.1	Sudden cardiac arrest;	chr15:75635376	chr15:75527150~75601205:-
BRCA	cis	rs2154319	0.636	rs213762	ENSG00000230638.4	RP11-486B10.4	3.38	0.00076	0.0347	0.17	0.1	Height;	chr1:41117938	chr1:41542069~41544310:+
BRCA	cis	rs10819861	0.598	rs7041954	ENSG00000175611.10	LINC00476	3.38	0.00076	0.0348	0.11	0.1	Electrocardiographic traits;	chr9:96094119	chr9:95759231~95875977:-
BRCA	cis	rs11673344	0.523	rs36096221	ENSG00000276846.1	CTD-3220F14.3	3.38	0.00076	0.0348	0.12	0.1	Obesity-related traits;	chr19:37060838	chr19:37314868~37315620:-
BRCA	cis	rs7705502	0.89	rs72810976	ENSG00000251144.1	CTD-2532K18.2	-3.38	0.00076	0.0348	-0.13	-0.1	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for body mass index;	chr5:173882054	chr5:174820027~174826324:+
BRCA	cis	rs875971	0.54	rs1723268	ENSG00000229180.5	GS1-124K5.11	3.38	0.00076	0.0348	0.09	0.1	Aortic root size;	chr7:66008093	chr7:66526088~66542624:-
BRCA	cis	rs1865760	0.593	rs3903852	ENSG00000272462.2	U91328.19	-3.38	0.00076	0.0348	-0.12	-0.1	Height;	chr6:25914919	chr6:25992662~26001775:+
BRCA	cis	rs4819052	0.765	rs2838827	ENSG00000215447.6	BX322557.10	-3.38	0.00076	0.0348	-0.11	-0.1	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45236231	chr21:45288052~45291738:+
BRCA	cis	rs9633740	1	rs7922621	ENSG00000226659.1	RP11-137H2.4	-3.38	0.00076	0.0348	-0.17	-0.1	Post bronchodilator FEV1;	chr10:80491788	chr10:80529597~80535942:-
BRCA	cis	rs6964587	0.839	rs62466809	ENSG00000188693.7	CYP51A1-AS1	-3.38	0.00076	0.0348	-0.11	-0.1	Breast cancer;	chr7:91843487	chr7:92134604~92180725:+
BRCA	cis	rs7426380	0.525	rs1367226	ENSG00000272606.1	RP11-554J4.1	-3.38	0.00076	0.0348	-0.12	-0.1	Intraocular pressure;	chr2:55862405	chr2:55617909~55618373:+
BRCA	cis	rs597539	0.689	rs596874	ENSG00000255741.1	RP11-757G1.5	3.38	0.00076	0.0348	0.14	0.1	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68863406	chr11:68941503~68942852:-
BRCA	cis	rs6600671	0.692	rs11249430	ENSG00000275131.1	CH17-472G23.4	-3.38	0.00076	0.0348	-0.1	-0.1	Hip geometry;	chr1:121547115	chr1:120489625~120579190:-
BRCA	cis	rs34779708	0.966	rs4934725	ENSG00000269952.1	RP11-324I22.3	-3.38	0.00076	0.0348	-0.14	-0.1	Inflammatory bowel disease;Crohn's disease;	chr10:35109308	chr10:35210416~35210750:+
BRCA	cis	rs34779708	0.966	rs12774834	ENSG00000269952.1	RP11-324I22.3	-3.38	0.00076	0.0348	-0.14	-0.1	Inflammatory bowel disease;Crohn's disease;	chr10:35111142	chr10:35210416~35210750:+
BRCA	cis	rs34779708	0.966	rs12775759	ENSG00000269952.1	RP11-324I22.3	-3.38	0.00076	0.0348	-0.14	-0.1	Inflammatory bowel disease;Crohn's disease;	chr10:35111255	chr10:35210416~35210750:+
BRCA	cis	rs34779708	0.966	rs35777088	ENSG00000269952.1	RP11-324I22.3	-3.38	0.00076	0.0348	-0.14	-0.1	Inflammatory bowel disease;Crohn's disease;	chr10:35120120	chr10:35210416~35210750:+
BRCA	cis	rs34779708	0.966	rs11592567	ENSG00000269952.1	RP11-324I22.3	-3.38	0.00076	0.0348	-0.14	-0.1	Inflammatory bowel disease;Crohn's disease;	chr10:35120441	chr10:35210416~35210750:+
BRCA	cis	rs8114671	0.562	rs8117491	ENSG00000279253.1	RP4-614O4.13	-3.38	0.00076	0.0348	-0.12	-0.1	Height;	chr20:34922317	chr20:35262727~35264187:-
BRCA	cis	rs6964587	0.692	rs4729021	ENSG00000188693.7	CYP51A1-AS1	-3.38	0.00076	0.0348	-0.11	-0.1	Breast cancer;	chr7:92129108	chr7:92134604~92180725:+
BRCA	cis	rs465969	1	rs4509157	ENSG00000271789.1	RP5-1112D6.7	3.38	0.00076	0.0348	0.22	0.1	Psoriasis;	chr6:111513875	chr6:111297126~111298510:+
BRCA	cis	rs4841134	0.625	rs12235038	ENSG00000233609.3	RP11-62H7.2	-3.38	0.00076	0.0348	-0.1	-0.1	Age-related disease endophenotypes;	chr8:9379893	chr8:8961200~8979025:+
BRCA	cis	rs9341808	0.718	rs10943699	ENSG00000279022.1	RP11-250B2.4	3.38	0.00076	0.0348	0.12	0.1	Sitting height ratio;	chr6:80230824	chr6:80440730~80441172:+
BRCA	cis	rs459571	1	rs456207	ENSG00000235106.7	LINC00094	3.38	0.00076	0.0348	0.11	0.1	Platelet distribution width;	chr9:134046018	chr9:134025439~134034666:+
BRCA	cis	rs7020830	0.867	rs7852593	ENSG00000230188.1	RP11-405L18.4	-3.38	0.00076	0.0348	-0.13	-0.1	Schizophrenia;	chr9:37332383	chr9:37490421~37490893:-
BRCA	cis	rs970548	0.739	rs34563674	ENSG00000237840.5	FAM21FP	3.38	0.00076	0.0348	0.12	0.1	Total cholesterol levels;HDL cholesterol;HDL cholesterol levels;Cholesterol, total;	chr10:45526704	chr10:45706431~45727231:-
BRCA	cis	rs4805834	0.777	rs12151320	ENSG00000201388.1	SNORA68	3.38	0.000761	0.0348	0.18	0.1	Creatinine levels;	chr19:32892999	chr19:32608337~32608469:-
BRCA	cis	rs4805834	0.843	rs12151322	ENSG00000201388.1	SNORA68	3.38	0.000761	0.0348	0.18	0.1	Creatinine levels;	chr19:32893057	chr19:32608337~32608469:-
BRCA	cis	rs4589258	0.788	rs1573549	ENSG00000280367.1	RP11-121L10.2	3.38	0.000761	0.0348	0.12	0.1	Intelligence (multi-trait analysis);	chr11:90731347	chr11:90223153~90226538:+
BRCA	cis	rs11671005	0.735	rs45617039	ENSG00000265272.2	RN7SL693P	3.38	0.000761	0.0348	0.15	0.1	Mean platelet volume;	chr19:58439729	chr19:58490797~58491075:+
BRCA	cis	rs7165170	0.678	rs13379889	ENSG00000245479.2	LINC01585	-3.38	0.000761	0.0348	-0.13	-0.1	Crohn's disease;Inflammatory bowel disease;	chr15:90651808	chr15:90660234~90664967:+
BRCA	cis	rs7917772	0.536	rs4919667	ENSG00000213061.2	PFN1P11	3.38	0.000761	0.0348	0.15	0.1	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;	chr10:102666254	chr10:102838011~102845473:-
BRCA	cis	rs10876993	0.89	rs4760165	ENSG00000270039.1	RP11-571M6.17	3.38	0.000761	0.0348	0.14	0.1	Celiac disease or Rheumatoid arthritis;	chr12:57670018	chr12:57803838~57804415:+
BRCA	cis	rs6693567	0.565	rs834242	ENSG00000237976.1	RP11-126K1.6	3.38	0.000761	0.0348	0.11	0.1	Migraine;	chr1:150407382	chr1:151346967~151348027:+
BRCA	cis	rs6582630	0.539	rs12308081	ENSG00000257718.1	RP11-396F22.1	-3.38	0.000761	0.0348	-0.11	-0.1	Drug-induced liver injury (flucloxacillin);	chr12:37949079	chr12:38906451~38909592:+
BRCA	cis	rs6840360	0.615	rs3828546	ENSG00000270265.1	RP11-731D1.4	-3.38	0.000761	0.0348	-0.12	-0.1	Intelligence (multi-trait analysis);	chr4:151758664	chr4:151333775~151353224:-
BRCA	cis	rs4921164	1	rs34314314	ENSG00000245812.2	RP11-175K6.1	-3.38	0.000761	0.0348	-0.13	-0.1	Gut microbiome composition (winter);	chr5:159117671	chr5:159100483~159117478:+
BRCA	cis	rs8114671	0.562	rs7266550	ENSG00000261582.1	RP4-614O4.11	-3.38	0.000761	0.0348	-0.1	-0.1	Height;	chr20:34907707	chr20:35267885~35280043:-
BRCA	cis	rs7017914	0.967	rs6472539	ENSG00000246366.5	RP11-382J12.1	3.38	0.000761	0.0348	0.11	0.1	Bone mineral density;	chr8:70717575	chr8:70608577~70663279:+
BRCA	cis	rs7017914	0.935	rs6981435	ENSG00000246366.5	RP11-382J12.1	3.38	0.000761	0.0348	0.11	0.1	Bone mineral density;	chr8:70724913	chr8:70608577~70663279:+
BRCA	cis	rs7017914	0.967	rs7013657	ENSG00000246366.5	RP11-382J12.1	3.38	0.000761	0.0348	0.11	0.1	Bone mineral density;	chr8:70725324	chr8:70608577~70663279:+
BRCA	cis	rs7017914	0.934	rs7006615	ENSG00000246366.5	RP11-382J12.1	3.38	0.000761	0.0348	0.11	0.1	Bone mineral density;	chr8:70727572	chr8:70608577~70663279:+
BRCA	cis	rs7017914	1	rs7007450	ENSG00000246366.5	RP11-382J12.1	3.38	0.000761	0.0348	0.11	0.1	Bone mineral density;	chr8:70728034	chr8:70608577~70663279:+
BRCA	cis	rs7017914	0.967	rs11989553	ENSG00000246366.5	RP11-382J12.1	3.38	0.000761	0.0348	0.11	0.1	Bone mineral density;	chr8:70728664	chr8:70608577~70663279:+
BRCA	cis	rs7017914	0.934	rs62530826	ENSG00000246366.5	RP11-382J12.1	3.38	0.000761	0.0348	0.11	0.1	Bone mineral density;	chr8:70729408	chr8:70608577~70663279:+
BRCA	cis	rs7017914	0.967	rs35295900	ENSG00000246366.5	RP11-382J12.1	3.38	0.000761	0.0348	0.11	0.1	Bone mineral density;	chr8:70729826	chr8:70608577~70663279:+
BRCA	cis	rs7017914	0.967	rs35115527	ENSG00000246366.5	RP11-382J12.1	3.38	0.000761	0.0348	0.11	0.1	Bone mineral density;	chr8:70730774	chr8:70608577~70663279:+
BRCA	cis	rs7017914	0.902	rs11991273	ENSG00000246366.5	RP11-382J12.1	3.38	0.000761	0.0348	0.11	0.1	Bone mineral density;	chr8:70733625	chr8:70608577~70663279:+
BRCA	cis	rs7017914	0.869	rs11987511	ENSG00000246366.5	RP11-382J12.1	3.38	0.000761	0.0348	0.11	0.1	Bone mineral density;	chr8:70733636	chr8:70608577~70663279:+
BRCA	cis	rs7267979	0.932	rs433352	ENSG00000231081.1	RP4-760C5.3	3.38	0.000761	0.0348	0.13	0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25487356	chr20:26008791~26010531:-
BRCA	cis	rs9297216	0.571	rs1580707	ENSG00000272338.2	RP11-722E23.2	-3.38	0.000761	0.0348	-0.12	-0.1	Asthma (childhood onset);	chr8:34202373	chr8:33360839~33361415:-
BRCA	cis	rs12612619	0.579	rs827884	ENSG00000229122.1	AGBL5-IT1	-3.38	0.000761	0.0348	-0.11	-0.1	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:26871974	chr2:27061038~27061815:+
BRCA	cis	rs1865760	0.865	rs9467645	ENSG00000272810.1	U91328.22	-3.38	0.000761	0.0348	-0.12	-0.1	Height;	chr6:25954948	chr6:26013241~26013757:+
BRCA	cis	rs7432375	0.641	rs835649	ENSG00000273486.1	RP11-731C17.2	3.38	0.000761	0.0348	0.11	0.1	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136953048	chr3:136837338~136839021:-
BRCA	cis	rs654950	0.875	rs881719	ENSG00000230881.1	RP11-486B10.3	3.38	0.000761	0.0348	0.11	0.1	Airway imaging phenotypes;	chr1:41525756	chr1:41535443~41535868:+
BRCA	cis	rs12210905	0.925	rs72838228	ENSG00000272462.2	U91328.19	-3.38	0.000761	0.0348	-0.19	-0.1	Hip circumference adjusted for BMI;	chr6:26978141	chr6:25992662~26001775:+
BRCA	cis	rs7713317	1	rs17085593	ENSG00000236882.6	LINC01554	3.38	0.000761	0.0348	0.13	0.1	Body mass index;	chr5:96295001	chr5:95852232~95860133:+
BRCA	cis	rs3735485	0.843	rs6463256	ENSG00000201772.1	SNORA5C	-3.38	0.000761	0.0348	-0.14	-0.1	White blood cell count;Sum basophil neutrophil counts;Neutrophil count;Granulocyte percentage of myeloid white cells;Monocyte percentage of white cells;Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Lymphocyte counts;	chr7:44985277	chr7:45104906~45105042:-
BRCA	cis	rs3735485	0.843	rs3213658	ENSG00000201772.1	SNORA5C	-3.38	0.000761	0.0348	-0.14	-0.1	White blood cell count;Sum basophil neutrophil counts;Neutrophil count;Granulocyte percentage of myeloid white cells;Monocyte percentage of white cells;Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Lymphocyte counts;	chr7:44986121	chr7:45104906~45105042:-
BRCA	cis	rs4478858	0.735	rs7523438	ENSG00000229447.2	RP11-490K7.4	3.38	0.000761	0.0348	0.1	0.1	Alcohol dependence;	chr1:31315466	chr1:31263245~31263681:-
BRCA	cis	rs10504130	0.867	rs11786167	ENSG00000272076.1	RP11-11C20.3	3.38	0.000761	0.0348	0.18	0.1	Venous thromboembolism (SNP x SNP interaction);	chr8:51763097	chr8:51810110~51810681:-
BRCA	cis	rs36051895	0.664	rs3780371	ENSG00000237711.1	RP11-39K24.13	-3.38	0.000761	0.0348	-0.13	-0.1	Pediatric autoimmune diseases;	chr9:5095191	chr9:5100236~5101009:+
BRCA	cis	rs863345	0.604	rs1894038	ENSG00000176320.2	RP11-404O13.5	-3.38	0.000761	0.0348	-0.11	-0.1	Pneumococcal bacteremia;	chr1:158486157	chr1:158197922~158203877:-
BRCA	cis	rs4462272	0.557	rs3904036	ENSG00000230224.1	PHBP9	3.38	0.000762	0.0348	0.09	0.1	Age-related hearing impairment (SNP x SNP interaction);	chr10:100238657	chr10:100248271~100249095:+
BRCA	cis	rs4462272	0.557	rs17729876	ENSG00000230224.1	PHBP9	3.38	0.000762	0.0348	0.09	0.1	Age-related hearing impairment (SNP x SNP interaction);	chr10:100239989	chr10:100248271~100249095:+
BRCA	cis	rs4462272	0.557	rs17668255	ENSG00000230224.1	PHBP9	3.38	0.000762	0.0348	0.09	0.1	Age-related hearing impairment (SNP x SNP interaction);	chr10:100240944	chr10:100248271~100249095:+
BRCA	cis	rs4462272	0.557	rs17668357	ENSG00000230224.1	PHBP9	3.38	0.000762	0.0348	0.09	0.1	Age-related hearing impairment (SNP x SNP interaction);	chr10:100244149	chr10:100248271~100249095:+
BRCA	cis	rs9900280	1	rs35763383	ENSG00000264808.1	RP11-802D6.1	-3.38	0.000762	0.0348	-0.13	-0.1	Mean platelet volume;	chr17:29526267	chr17:29369717~29390777:-
BRCA	cis	rs9900280	1	rs592862	ENSG00000264808.1	RP11-802D6.1	-3.38	0.000762	0.0348	-0.13	-0.1	Mean platelet volume;	chr17:29527984	chr17:29369717~29390777:-
BRCA	cis	rs9900280	1	rs605898	ENSG00000264808.1	RP11-802D6.1	-3.38	0.000762	0.0348	-0.13	-0.1	Mean platelet volume;	chr17:29529478	chr17:29369717~29390777:-
BRCA	cis	rs9868809	0.772	rs2286651	ENSG00000225399.4	RP11-3B7.1	-3.38	0.000762	0.0348	-0.16	-0.1	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48656714	chr3:49260085~49261316:+
BRCA	cis	rs3136202	0.684	rs11860979	ENSG00000242307.1	RPS26P52	3.38	0.000762	0.0348	0.13	0.1	Conduct disorder (symptom count);	chr16:13977396	chr16:13922332~13922679:-
BRCA	cis	rs4687718	0.528	rs77413676	ENSG00000274967.1	Y_RNA	3.38	0.000762	0.0348	0.15	0.1	QRS duration;	chr3:53324090	chr3:53290640~53290751:+
BRCA	cis	rs6946131	0.593	rs1534737	ENSG00000235207.1	TUBBP6	-3.38	0.000762	0.0348	-0.13	-0.1	Systemic lupus erythematosus;	chr7:54773808	chr7:55645620~55646951:+
BRCA	cis	rs6772849	0.93	rs9813197	ENSG00000207088.1	SNORA7B	-3.38	0.000762	0.0348	-0.13	-0.1	Monocyte percentage of white cells;Monocyte count;	chr3:128650261	chr3:129397210~129397348:-
BRCA	cis	rs2832191	0.716	rs1888439	ENSG00000236056.1	GAPDHP14	-3.38	0.000762	0.0348	-0.12	-0.1	Dental caries;	chr21:29082136	chr21:29222321~29223257:+
BRCA	cis	rs911119	0.657	rs2104005	ENSG00000270001.1	RP11-218C14.8	-3.38	0.000762	0.0348	-0.15	-0.1	Chronic kidney disease;	chr20:23650124	chr20:23631826~23632316:-
BRCA	cis	rs11673344	0.67	rs35011739	ENSG00000267422.1	CTD-2554C21.1	3.38	0.000762	0.0348	0.13	0.1	Obesity-related traits;	chr19:36943328	chr19:37779686~37792865:+
BRCA	cis	rs11673344	0.704	rs540451	ENSG00000267422.1	CTD-2554C21.1	3.38	0.000762	0.0348	0.13	0.1	Obesity-related traits;	chr19:36944619	chr19:37779686~37792865:+
BRCA	cis	rs11096990	0.656	rs7693837	ENSG00000249685.1	RP11-360F5.3	3.38	0.000762	0.0348	0.13	0.1	Cognitive function;	chr4:39301481	chr4:39133913~39135608:+
BRCA	cis	rs1348850	0.567	rs3770012	ENSG00000280374.1	RP11-337N6.3	-3.38	0.000762	0.0348	-0.14	-0.1	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177673295	chr2:177317715~177318471:-
BRCA	cis	rs13219787	0.915	rs13214703	ENSG00000220721.1	OR1F12	-3.38	0.000762	0.0348	-0.25	-0.1	Mean corpuscular hemoglobin;Mean corpuscular volume;Hemoglobin levels;	chr6:27973609	chr6:28073316~28074233:+
BRCA	cis	rs6456156	0.742	rs6456157	ENSG00000272549.1	RP11-351J23.2	3.38	0.000762	0.0348	0.1	0.1	Primary biliary cholangitis;	chr6:167114330	chr6:167666840~167679270:-
BRCA	cis	rs6914598	0.876	rs9465978	ENSG00000240869.3	RN7SL128P	-3.38	0.000762	0.0348	-0.15	-0.1	Cutaneous malignant melanoma;Melanoma;	chr6:21161294	chr6:20421583~20421887:-
BRCA	cis	rs17382723	0.887	rs1062748	ENSG00000225521.1	AC005237.4	-3.38	0.000762	0.0348	-0.16	-0.1	Height;	chr2:241089326	chr2:241015599~241064116:-
BRCA	cis	rs5758511	0.773	rs10154700	ENSG00000233903.2	Z83851.4	3.38	0.000762	0.0348	0.16	0.1	Birth weight;	chr22:41969069	chr22:42276355~42277052:+
BRCA	cis	rs4218	0.619	rs10851643	ENSG00000259732.1	RP11-59H7.3	-3.38	0.000762	0.0348	-0.12	-0.1	Social communication problems;	chr15:59102985	chr15:59121034~59133250:+
BRCA	cis	rs6058526	1	rs67028492	ENSG00000275576.1	RP5-836N17.4	3.38	0.000762	0.0348	0.17	0.1	Chronic obstructive pulmonary disease;	chr20:32104134	chr20:32116171~32116629:+
BRCA	cis	rs8114671	0.527	rs6060068	ENSG00000126005.14	MMP24-AS1	-3.38	0.000762	0.0348	-0.12	-0.1	Height;	chr20:34828017	chr20:35216462~35278131:-
BRCA	cis	rs1421334	0.679	rs2160935	ENSG00000271869.1	RP11-51J9.5	-3.38	0.000762	0.0348	-0.11	-0.1	Intelligence (multi-trait analysis);	chr8:30983135	chr8:30155830~30156232:-
BRCA	cis	rs7267979	0.528	rs6076366	ENSG00000274973.1	RP13-401N8.7	3.38	0.000762	0.0348	0.12	0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25583990	chr20:25845497~25845862:+
BRCA	cis	rs752010	0.695	rs10890156	ENSG00000230638.4	RP11-486B10.4	-3.38	0.000762	0.0348	-0.13	-0.1	Lupus nephritis in systemic lupus erythematosus;	chr1:41642419	chr1:41542069~41544310:+
BRCA	cis	rs9333290	0.93	rs7575516	ENSG00000259915.2	RP11-410E4.1	3.38	0.000762	0.0348	0.15	0.1	Urinary albumin-to-creatinine ratio in non-diabetics;Urinary albumin-to-creatinine ratio;	chr2:186648554	chr2:186354570~186356773:-
BRCA	cis	rs2664588	0.613	rs6125187	ENSG00000276923.1	RP11-321P16.1	-3.38	0.000762	0.0348	-0.14	-0.1	Cerebrospinal fluid AB1-42 levels;	chr20:47953827	chr20:48073869~48074188:+
BRCA	cis	rs875971	0.522	rs4718285	ENSG00000227113.2	RP11-460N20.4	3.38	0.000762	0.0348	0.11	0.1	Aortic root size;	chr7:65827018	chr7:65075023~65078780:+
BRCA	cis	rs9863	0.931	rs6488914	ENSG00000270028.1	RP11-380L11.4	-3.38	0.000762	0.0348	-0.13	-0.1	White blood cell count;	chr12:123963294	chr12:123925461~123926083:-
BRCA	cis	rs925946	0.518	rs12419462	ENSG00000245573.6	BDNF-AS	-3.38	0.000762	0.0349	-0.13	-0.1	Weight;Body mass index;	chr11:27601762	chr11:27506838~27698174:+
BRCA	cis	rs6487679	1	rs6487679	ENSG00000256069.6	A2MP1	3.38	0.000762	0.0349	0.13	0.1	Non-alcoholic fatty liver disease histology (AST);	chr12:9218736	chr12:9228533~9275817:-
BRCA	cis	rs71520386	0.632	rs12532922	ENSG00000179428.2	AC073072.5	3.38	0.000762	0.0349	0.12	0.1	Fibrinogen levels;	chr7:22820796	chr7:22725395~22727620:-
BRCA	cis	rs10090774	0.965	rs7824374	ENSG00000280303.2	ERICD	3.38	0.000762	0.0349	0.12	0.1	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:141006810	chr8:140636281~140638283:+
BRCA	cis	rs944990	0.793	rs1556416	ENSG00000227603.1	RP11-165J3.6	-3.38	0.000762	0.0349	-0.12	-0.1	Body mass index;	chr9:93494301	chr9:93435332~93437121:-
BRCA	cis	rs10971721	0.822	rs117703548	ENSG00000279489.1	RP11-392A14.8	3.38	0.000762	0.0349	0.22	0.1	Body mass index;	chr9:34041199	chr9:35001913~35003663:+
BRCA	cis	rs11700980	0.636	rs17797032	ENSG00000232855.5	AF131217.1	3.38	0.000763	0.0349	0.18	0.1	QRS complex (12-leadsum);	chr21:28893263	chr21:28439346~28674848:-
BRCA	cis	rs5758659	0.652	rs6519301	ENSG00000270083.1	RP1-257I20.14	3.38	0.000763	0.0349	0.12	0.1	Cognitive function;	chr22:41989963	chr22:42089630~42090028:-
BRCA	cis	rs6028335	0.61	rs67743908	ENSG00000274825.1	RP4-616B8.5	-3.38	0.000763	0.0349	-0.13	-0.1	Alcohol and nicotine co-dependence;	chr20:38944000	chr20:38955910~38956547:+
BRCA	cis	rs6028335	0.61	rs12624839	ENSG00000274825.1	RP4-616B8.5	-3.38	0.000763	0.0349	-0.13	-0.1	Alcohol and nicotine co-dependence;	chr20:38945173	chr20:38955910~38956547:+
BRCA	cis	rs1497266	0.556	rs6789560	ENSG00000214280.3	RP11-553K23.2	-3.38	0.000763	0.0349	-0.13	-0.1	Gut microbiota (functional units);	chr3:139585541	chr3:139582928~139583593:-
BRCA	cis	rs17092148	0.887	rs6059915	ENSG00000202150.1	RNU6-407P	3.38	0.000763	0.0349	0.15	0.1	Neuroticism;	chr20:34559933	chr20:35030317~35030420:-
BRCA	cis	rs889312	0.5	rs832580	ENSG00000271828.1	CTD-2310F14.1	-3.38	0.000763	0.0349	-0.13	-0.1	Breast cancer (early onset);Breast cancer;	chr5:56876819	chr5:56927874~56929573:+
BRCA	cis	rs35740288	0.787	rs11637768	ENSG00000259295.5	CSPG4P12	3.38	0.000763	0.0349	0.15	0.1	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85680179	chr15:85191438~85213905:+
BRCA	cis	rs71520386	0.561	rs10274260	ENSG00000226329.2	AC005682.6	-3.38	0.000763	0.0349	-0.11	-0.1	Fibrinogen levels;	chr7:22805227	chr7:22863874~22881350:-
BRCA	cis	rs112184198	0.833	rs7072737	ENSG00000236308.1	RP11-316M21.7	3.38	0.000763	0.0349	0.2	0.1	Systolic blood pressure;	chr10:100796418	chr10:100190036~100190747:+
BRCA	cis	rs8105895	0.935	rs7252547	ENSG00000269345.1	VN1R85P	3.38	0.000763	0.0349	0.16	0.1	Body mass index (change over time);	chr19:22122679	chr19:22174766~22175191:-
BRCA	cis	rs6678639	0.522	rs74073885	ENSG00000225154.2	RP11-184J23.2	-3.38	0.000763	0.0349	-0.16	-0.1	Blood metabolite ratios;	chr1:47034805	chr1:47074778~47075979:-
BRCA	cis	rs6432852	0.702	rs2195143	ENSG00000232411.1	AC009495.3	-3.38	0.000763	0.0349	-0.12	-0.1	Diabetic kidney disease;	chr2:166057400	chr2:165833048~165839098:-
BRCA	cis	rs7569084	0.566	rs7584295	ENSG00000237979.1	AC007389.1	3.38	0.000763	0.0349	0.12	0.1	Sum eosinophil basophil counts;	chr2:65353940	chr2:65500993~65502138:-
BRCA	cis	rs934734	0.563	rs11695373	ENSG00000237979.1	AC007389.1	3.38	0.000763	0.0349	0.12	0.1	Rheumatoid arthritis;	chr2:65354066	chr2:65500993~65502138:-
BRCA	cis	rs6142102	0.961	rs2268089	ENSG00000206582.1	Y_RNA	-3.38	0.000763	0.0349	-0.12	-0.1	Skin pigmentation;	chr20:34079492	chr20:34526510~34526606:-
BRCA	cis	rs7649443	0.796	rs2340433	ENSG00000243339.3	RN7SL738P	-3.38	0.000763	0.0349	-0.14	-0.1	Nonsyndromic cleft lip with cleft palate;	chr3:197250008	chr3:196399911~196400207:+
BRCA	cis	rs9402743	0.632	rs4895458	ENSG00000231028.7	LINC00271	-3.38	0.000763	0.0349	-0.11	-0.1	Systemic lupus erythematosus;	chr6:135783235	chr6:135497801~135716055:+
BRCA	cis	rs7618501	0.699	rs1317154	ENSG00000281433.1	Metazoa_SRP	-3.38	0.000763	0.0349	-0.1	-0.1	Intelligence (multi-trait analysis);	chr3:49872651	chr3:49320296~49320564:+
BRCA	cis	rs7412746	0.611	rs11204748	ENSG00000224800.1	RP11-235D19.2	-3.38	0.000763	0.0349	-0.13	-0.1	Melanoma;	chr1:150954893	chr1:150881236~150881683:-
BRCA	cis	rs9393777	0.778	rs35526527	ENSG00000220721.1	OR1F12	3.38	0.000763	0.0349	0.19	0.1	Intelligence (multi-trait analysis);	chr6:27074508	chr6:28073316~28074233:+
BRCA	cis	rs7618501	0.699	rs2681780	ENSG00000281433.1	Metazoa_SRP	-3.38	0.000763	0.0349	-0.1	-0.1	Intelligence (multi-trait analysis);	chr3:49860397	chr3:49320296~49320564:+
BRCA	cis	rs36051895	0.659	rs67006981	ENSG00000237711.1	RP11-39K24.13	-3.38	0.000763	0.0349	-0.13	-0.1	Pediatric autoimmune diseases;	chr9:5070401	chr9:5100236~5101009:+
BRCA	cis	rs910316	0.967	rs4903292	ENSG00000259138.1	RP11-950C14.7	3.38	0.000763	0.0349	0.11	0.1	Height;	chr14:75189542	chr14:75127153~75136930:+
BRCA	cis	rs2638953	0.853	rs10843179	ENSG00000273989.1	RP11-425D17.2	3.38	0.000763	0.0349	0.15	0.1	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28462125	chr12:28236227~28236828:+
BRCA	cis	rs11997175	0.545	rs7388496	ENSG00000272338.2	RP11-722E23.2	3.38	0.000763	0.0349	0.12	0.1	Body mass index;	chr8:33810380	chr8:33360839~33361415:-
BRCA	cis	rs7221109	0.601	rs7209404	ENSG00000224244.1	AC090283.3	3.38	0.000763	0.0349	0.12	0.1	Type 1 diabetes;	chr17:40668150	chr17:40687038~40689360:-
BRCA	cis	rs7221109	0.645	rs7223332	ENSG00000224244.1	AC090283.3	3.38	0.000763	0.0349	0.12	0.1	Type 1 diabetes;	chr17:40668384	chr17:40687038~40689360:-
BRCA	cis	rs427943	0.75	rs2838803	ENSG00000184274.3	LINC00315	3.38	0.000764	0.0349	0.14	0.1	Body mass index;	chr21:45180211	chr21:45300245~45305257:-
BRCA	cis	rs853679	0.546	rs34295134	ENSG00000216676.2	RP1-15D7.1	-3.38	0.000764	0.0349	-0.18	-0.1	Depression;	chr6:27860373	chr6:27652602~27652825:-
BRCA	cis	rs7267979	0.966	rs6083818	ENSG00000231081.1	RP4-760C5.3	3.38	0.000764	0.0349	0.13	0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25365446	chr20:26008791~26010531:-
BRCA	cis	rs7267979	1	rs4815409	ENSG00000231081.1	RP4-760C5.3	3.38	0.000764	0.0349	0.13	0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25366061	chr20:26008791~26010531:-
BRCA	cis	rs62289301	0.531	rs3822296	ENSG00000249234.1	RP11-452J21.2	3.38	0.000764	0.0349	0.12	0.1	Joint mobility (Beighton score);	chr4:15415200	chr4:16178939~16183120:+
BRCA	cis	rs7649443	0.959	rs61394945	ENSG00000243339.3	RN7SL738P	-3.38	0.000764	0.0349	-0.14	-0.1	Nonsyndromic cleft lip with cleft palate;	chr3:197247731	chr3:196399911~196400207:+
BRCA	cis	rs66887589	0.616	rs7659403	ENSG00000260091.1	RP11-33B1.4	-3.38	0.000764	0.0349	-0.09	-0.1	Diastolic blood pressure;	chr4:119286099	chr4:119409333~119410233:+
BRCA	cis	rs2562456	0.833	rs4321312	ENSG00000240522.1	RPL7AP10	-3.38	0.000764	0.0349	-0.12	-0.1	Pain;	chr19:21336614	chr19:21149648~21150438:-
BRCA	cis	rs10792665	0.512	rs4280021	ENSG00000254965.1	RP11-113K21.2	-3.38	0.000764	0.0349	-0.1	-0.1	Obesity-related traits;	chr11:82871521	chr11:83111060~83111442:-
BRCA	cis	rs10792665	0.512	rs4280022	ENSG00000254965.1	RP11-113K21.2	-3.38	0.000764	0.0349	-0.1	-0.1	Obesity-related traits;	chr11:82871573	chr11:83111060~83111442:-
BRCA	cis	rs7927592	0.956	rs11228269	ENSG00000254610.1	RP5-903G2.2	-3.38	0.000764	0.0349	-0.14	-0.1	Total body bone mineral density;	chr11:68522328	chr11:67934563~67939774:-
BRCA	cis	rs2380205	0.689	rs11255602	ENSG00000232807.2	RP11-536K7.3	3.38	0.000764	0.0349	0.11	0.1	Breast cancer;	chr10:5861754	chr10:5934270~5945900:-
BRCA	cis	rs1865760	0.541	rs1436309	ENSG00000272462.2	U91328.19	-3.38	0.000764	0.0349	-0.12	-0.1	Height;	chr6:25969881	chr6:25992662~26001775:+
BRCA	cis	rs1348850	0.918	rs4893966	ENSG00000280374.1	RP11-337N6.3	3.38	0.000764	0.0349	0.14	0.1	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177605410	chr2:177317715~177318471:-
BRCA	cis	rs6001482	0.702	rs5757586	ENSG00000253818.1	IGLV1-41	-3.38	0.000764	0.0349	-0.1	-0.1	Diastolic blood pressure;	chr22:22234458	chr22:22404207~22404721:+
BRCA	cis	rs8180040	0.522	rs749512	ENSG00000271161.1	BOLA2P2	-3.38	0.000764	0.0349	-0.11	-0.1	Colorectal cancer;	chr3:46994410	chr3:47499841~47500407:+
BRCA	cis	rs3770081	1	rs12617717	ENSG00000232504.4	ST3GAL5-AS1	3.38	0.000764	0.0349	0.26	0.1	Facial emotion recognition (sad faces);	chr2:86115180	chr2:85889280~85890980:+
BRCA	cis	rs9868809	0.764	rs2633958	ENSG00000270441.1	RP11-694I15.7	-3.38	0.000764	0.0349	-0.24	-0.1	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48597999	chr3:49140086~49160851:-
BRCA	cis	rs7103648	0.695	rs6485758	ENSG00000255520.1	RP11-390K5.3	3.38	0.000764	0.0349	0.14	0.1	Systolic blood pressure;Diastolic blood pressure;	chr11:47508472	chr11:47123104~47130801:-
BRCA	cis	rs72772090	0.539	rs111237997	ENSG00000272109.1	CTD-2260A17.3	3.38	0.000764	0.0349	0.2	0.1	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96779249	chr5:96804353~96806105:+
BRCA	cis	rs4356203	0.87	rs10832751	ENSG00000184669.7	OR7E14P	-3.38	0.000764	0.0349	-0.13	-0.1	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17252469	chr11:17013998~17053024:+
BRCA	cis	rs736408	0.812	rs2071506	ENSG00000239557.1	RP11-168J18.6	3.38	0.000764	0.0349	0.14	0.1	Bipolar disorder;	chr3:52792260	chr3:52373652~52374882:+
BRCA	cis	rs875971	0.522	rs2008188	ENSG00000232546.1	RP11-458F8.1	-3.38	0.000764	0.0349	-0.09	-0.1	Aortic root size;	chr7:65964026	chr7:66848496~66858136:+
BRCA	cis	rs4578769	0.765	rs67551099	ENSG00000273232.1	RP11-370A5.2	-3.38	0.000764	0.0349	-0.15	-0.1	Eosinophil percentage of white cells;	chr18:22831167	chr18:22882825~22883357:-
BRCA	cis	rs11671005	0.735	rs3826682	ENSG00000265272.2	RN7SL693P	3.38	0.000764	0.0349	0.15	0.1	Mean platelet volume;	chr19:58407381	chr19:58490797~58491075:+
BRCA	cis	rs7037266	0.824	rs10975916	ENSG00000178654.11	PPIAP33	3.38	0.000764	0.0349	0.12	0.1	Menarche (age at onset);	chr9:6937200	chr9:7597823~7598377:+
BRCA	cis	rs7620503	1	rs2173608	ENSG00000228561.2	RP11-114M1.1	3.38	0.000765	0.0349	0.12	0.1	Corneal structure;	chr3:177584550	chr3:177683627~177691250:+
BRCA	cis	rs10129255	0.789	rs61997796	ENSG00000211974.3	IGHV2-70	3.38	0.000765	0.0349	0.11	0.1	Kawasaki disease;	chr14:106813798	chr14:106723574~106724093:-
BRCA	cis	rs61931739	0.534	rs7138522	ENSG00000258794.3	DUX4L27	3.38	0.000765	0.0349	0.15	0.1	Morning vs. evening chronotype;	chr12:33886827	chr12:34208415~34209675:-
BRCA	cis	rs61931739	0.534	rs4931770	ENSG00000258794.3	DUX4L27	3.38	0.000765	0.0349	0.15	0.1	Morning vs. evening chronotype;	chr12:33891544	chr12:34208415~34209675:-
BRCA	cis	rs61931739	0.517	rs4931771	ENSG00000258794.3	DUX4L27	3.38	0.000765	0.0349	0.15	0.1	Morning vs. evening chronotype;	chr12:33891622	chr12:34208415~34209675:-
BRCA	cis	rs7264396	0.563	rs2425146	ENSG00000088340.14	FER1L4	-3.38	0.000765	0.0349	-0.15	-0.1	Total cholesterol levels;	chr20:35767346	chr20:35558737~35607562:-
BRCA	cis	rs7017914	0.967	rs6472543	ENSG00000246366.5	RP11-382J12.1	3.38	0.000765	0.0349	0.11	0.1	Bone mineral density;	chr8:70752173	chr8:70608577~70663279:+
BRCA	cis	rs7017914	0.967	rs7819332	ENSG00000246366.5	RP11-382J12.1	3.38	0.000765	0.0349	0.11	0.1	Bone mineral density;	chr8:70756030	chr8:70608577~70663279:+
BRCA	cis	rs7017914	0.967	rs7012404	ENSG00000246366.5	RP11-382J12.1	3.38	0.000765	0.0349	0.11	0.1	Bone mineral density;	chr8:70756463	chr8:70608577~70663279:+
BRCA	cis	rs7017914	0.967	rs7018381	ENSG00000246366.5	RP11-382J12.1	3.38	0.000765	0.0349	0.11	0.1	Bone mineral density;	chr8:70757882	chr8:70608577~70663279:+
BRCA	cis	rs7017914	0.967	rs13258584	ENSG00000246366.5	RP11-382J12.1	3.38	0.000765	0.0349	0.11	0.1	Bone mineral density;	chr8:70759344	chr8:70608577~70663279:+
BRCA	cis	rs7017914	0.934	rs7009297	ENSG00000246366.5	RP11-382J12.1	3.38	0.000765	0.0349	0.11	0.1	Bone mineral density;	chr8:70760131	chr8:70608577~70663279:+
BRCA	cis	rs7017914	0.967	rs7014012	ENSG00000246366.5	RP11-382J12.1	3.38	0.000765	0.0349	0.11	0.1	Bone mineral density;	chr8:70760508	chr8:70608577~70663279:+
BRCA	cis	rs34773007	0.542	rs7075749	ENSG00000232709.1	MARK2P9	-3.38	0.000765	0.0349	-0.14	-0.1	Type 2 diabetes;	chr10:92958511	chr10:92418667~92420875:+
BRCA	cis	rs8114671	0.562	rs6088655	ENSG00000261582.1	RP4-614O4.11	-3.38	0.000765	0.0349	-0.1	-0.1	Height;	chr20:34940035	chr20:35267885~35280043:-
BRCA	cis	rs4805834	0.777	rs3813152	ENSG00000201388.1	SNORA68	-3.38	0.000765	0.0349	-0.18	-0.1	Creatinine levels;	chr19:32926407	chr19:32608337~32608469:-
BRCA	cis	rs7474896	0.943	rs2799496	ENSG00000120555.12	SEPT7P9	-3.38	0.000765	0.0349	-0.18	-0.1	Obesity (extreme);	chr10:37954871	chr10:38383069~38402916:-
BRCA	cis	rs7474896	1	rs2103936	ENSG00000120555.12	SEPT7P9	-3.38	0.000765	0.0349	-0.18	-0.1	Obesity (extreme);	chr10:37964405	chr10:38383069~38402916:-
BRCA	cis	rs7474896	0.945	rs2092995	ENSG00000120555.12	SEPT7P9	-3.38	0.000765	0.0349	-0.18	-0.1	Obesity (extreme);	chr10:37964646	chr10:38383069~38402916:-
BRCA	cis	rs7474896	0.945	rs2749593	ENSG00000120555.12	SEPT7P9	-3.38	0.000765	0.0349	-0.18	-0.1	Obesity (extreme);	chr10:37965179	chr10:38383069~38402916:-
BRCA	cis	rs7474896	1	rs2738186	ENSG00000120555.12	SEPT7P9	-3.38	0.000765	0.0349	-0.18	-0.1	Obesity (extreme);	chr10:37967061	chr10:38383069~38402916:-
BRCA	cis	rs9311676	0.609	rs12634722	ENSG00000273493.1	RP11-80H18.4	-3.38	0.000765	0.0349	-0.12	-0.1	Systemic lupus erythematosus;	chr3:58362430	chr3:58329965~58330118:+
BRCA	cis	rs748404	1	rs12911132	ENSG00000166763.7	STRCP1	3.38	0.000765	0.0349	0.15	0.1	Lung cancer;	chr15:43268238	chr15:43699488~43718184:-
BRCA	cis	rs4805834	0.92	rs4635450	ENSG00000201388.1	SNORA68	-3.38	0.000765	0.0349	-0.18	-0.1	Creatinine levels;	chr19:32942843	chr19:32608337~32608469:-
BRCA	cis	rs6142618	0.523	rs6141636	ENSG00000224452.1	RSL24D1P6	3.38	0.000765	0.0349	0.14	0.1	Inflammatory bowel disease;	chr20:32210865	chr20:32170390~32170790:-
BRCA	cis	rs6429422	0.769	rs3904683	ENSG00000224727.1	FCF1P7	-3.38	0.000765	0.035	-0.12	-0.1	Cognitive ability (multi-trait analysis);	chr1:243253223	chr1:243267257~243268119:-
BRCA	cis	rs11671005	0.735	rs1122955	ENSG00000265272.2	RN7SL693P	3.38	0.000765	0.035	0.15	0.1	Mean platelet volume;	chr19:58434836	chr19:58490797~58491075:+
BRCA	cis	rs4218	0.689	rs12900369	ENSG00000259732.1	RP11-59H7.3	-3.38	0.000765	0.035	-0.13	-0.1	Social communication problems;	chr15:59099254	chr15:59121034~59133250:+
BRCA	cis	rs4218	0.689	rs28514475	ENSG00000259732.1	RP11-59H7.3	-3.38	0.000765	0.035	-0.13	-0.1	Social communication problems;	chr15:59099896	chr15:59121034~59133250:+
BRCA	cis	rs4218	0.689	rs28610479	ENSG00000259732.1	RP11-59H7.3	-3.38	0.000765	0.035	-0.13	-0.1	Social communication problems;	chr15:59099906	chr15:59121034~59133250:+
BRCA	cis	rs4388249	1	rs12654396	ENSG00000249068.1	CTC-287O8.1	3.38	0.000765	0.035	0.15	0.1	Schizophrenia;	chr5:109700097	chr5:109840128~109840692:-
BRCA	cis	rs5167	0.534	rs56803710	ENSG00000214855.8	APOC1P1	3.38	0.000765	0.035	0.14	0.1	Blood protein levels;	chr19:44978627	chr19:44926804~44931386:+
BRCA	cis	rs5167	0.566	rs7253458	ENSG00000214855.8	APOC1P1	3.38	0.000765	0.035	0.14	0.1	Blood protein levels;	chr19:44979313	chr19:44926804~44931386:+
BRCA	cis	rs5167	0.533	rs55778858	ENSG00000214855.8	APOC1P1	3.38	0.000765	0.035	0.14	0.1	Blood protein levels;	chr19:44982208	chr19:44926804~44931386:+
BRCA	cis	rs5167	0.533	rs11083755	ENSG00000214855.8	APOC1P1	3.38	0.000765	0.035	0.14	0.1	Blood protein levels;	chr19:44986807	chr19:44926804~44931386:+
BRCA	cis	rs7267979	0.932	rs6115214	ENSG00000274973.1	RP13-401N8.7	3.38	0.000765	0.035	0.12	0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25576790	chr20:25845497~25845862:+
BRCA	cis	rs10820912	1	rs7848094	ENSG00000225460.1	RP13-93L13.1	-3.37	0.000765	0.035	-0.1	-0.1	Left atrial antero-posterior diameter;	chr9:90113778	chr9:89472237~89472692:+
BRCA	cis	rs709400	0.633	rs3783395	ENSG00000260285.1	RP11-600F24.7	3.37	0.000765	0.035	0.1	0.1	Body mass index;	chr14:103428683	chr14:103525010~103529072:-
BRCA	cis	rs8040855	0.694	rs12908400	ENSG00000229212.6	RP11-561C5.4	-3.37	0.000765	0.035	-0.13	-0.1	Bulimia nervosa;	chr15:85029945	chr15:85205440~85234795:-
BRCA	cis	rs7162943	0.887	rs11858077	ENSG00000261407.1	RP11-326A19.3	-3.37	0.000765	0.035	-0.12	-0.1	Mean platelet volume;	chr15:89068326	chr15:89087078~89088267:-
BRCA	cis	rs7000551	0.663	rs11778831	ENSG00000254272.1	RP11-382J24.2	-3.37	0.000766	0.035	-0.12	-0.1	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr8:22477575	chr8:22492631~22493044:+
BRCA	cis	rs7267979	1	rs2257991	ENSG00000276952.1	RP5-965G21.6	-3.37	0.000766	0.035	-0.13	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25289703	chr20:25284915~25285588:-
BRCA	cis	rs6495122	0.501	rs7163636	ENSG00000260269.4	CTD-2323K18.1	-3.37	0.000766	0.035	-0.13	-0.1	Diastolic blood pressure;Coffee consumption;Caffeine consumption;	chr15:75054419	chr15:75527150~75601205:-
BRCA	cis	rs17767294	0.708	rs61744109	ENSG00000272009.1	RP1-313I6.12	-3.37	0.000766	0.035	-0.27	-0.1	Parkinson's disease;	chr6:28107741	chr6:28078792~28081130:-
BRCA	cis	rs17767294	0.708	rs72851168	ENSG00000272009.1	RP1-313I6.12	-3.37	0.000766	0.035	-0.27	-0.1	Parkinson's disease;	chr6:28112230	chr6:28078792~28081130:-
BRCA	cis	rs17767294	0.708	rs77450054	ENSG00000272009.1	RP1-313I6.12	-3.37	0.000766	0.035	-0.27	-0.1	Parkinson's disease;	chr6:28116171	chr6:28078792~28081130:-
BRCA	cis	rs2243480	1	rs1638734	ENSG00000229180.5	GS1-124K5.11	3.37	0.000766	0.035	0.14	0.1	Diabetic kidney disease;	chr7:66632552	chr7:66526088~66542624:-
BRCA	cis	rs965469	0.895	rs6051841	ENSG00000215063.3	RPL21P2	3.37	0.000766	0.035	0.14	0.1	IFN-related cytopenia;	chr20:3412224	chr20:4059633~4060113:-
BRCA	cis	rs8180040	0.62	rs2305635	ENSG00000280667.1	Y_RNA	-3.37	0.000766	0.035	-0.12	-0.1	Colorectal cancer;	chr3:47002132	chr3:47501083~47501182:+
BRCA	cis	rs9816784	0.566	rs11720913	ENSG00000273009.1	RP11-352G9.1	-3.37	0.000766	0.035	-0.13	-0.1	Mean corpuscular hemoglobin;	chr3:196105689	chr3:195913078~195913683:-
BRCA	cis	rs7520050	0.833	rs1085242	ENSG00000226957.1	RP4-533D7.4	3.37	0.000766	0.035	0.11	0.1	Reticulocyte count;Red blood cell count;	chr1:46078552	chr1:46046818~46048368:+
BRCA	cis	rs275856	0.51	rs2408	ENSG00000264924.1	RP11-799B12.2	-3.37	0.000766	0.035	-0.17	-0.1	Type 2 diabetes;	chr18:24249659	chr18:24113637~24121003:-
BRCA	cis	rs4919694	1	rs12261040	ENSG00000236937.2	PTGES3P4	3.37	0.000766	0.035	0.21	0.1	Arsenic metabolism;	chr10:102905640	chr10:102845595~102845950:+
BRCA	cis	rs4356203	0.875	rs680205	ENSG00000184669.7	OR7E14P	-3.37	0.000766	0.035	-0.13	-0.1	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17186210	chr11:17013998~17053024:+
BRCA	cis	rs7686660	0.517	rs4690767	ENSG00000250326.1	RP11-284M14.1	3.37	0.000766	0.035	0.11	0.1	Asthma;	chr4:143109041	chr4:142933195~143184861:-
BRCA	cis	rs2070488	0.965	rs3762791	ENSG00000232439.1	RPL18AP7	-3.37	0.000766	0.035	-0.12	-0.1	Electrocardiographic conduction measures;	chr3:38527337	chr3:38526802~38527325:-
BRCA	cis	rs6452790	0.529	rs1534605	ENSG00000247828.6	TMEM161B-AS1	-3.37	0.000766	0.035	-0.14	-0.1	Cognitive function;	chr5:87961868	chr5:88268895~88436685:+
BRCA	cis	rs8097070	0.661	rs9966711	ENSG00000188985.6	DHFRP1	3.37	0.000766	0.035	0.24	0.1	Systemic juvenile idiopathic arthritis;	chr18:25591449	chr18:26170726~26171284:-
BRCA	cis	rs952623	0.649	rs7801660	ENSG00000227191.5	TRGC2	3.37	0.000766	0.035	0.09	0.1	Intelligence (multi-trait analysis);	chr7:39032873	chr7:38239580~38368091:-
BRCA	cis	rs7017914	0.967	rs1471114	ENSG00000246366.5	RP11-382J12.1	3.37	0.000766	0.035	0.11	0.1	Bone mineral density;	chr8:70763312	chr8:70608577~70663279:+
BRCA	cis	rs11098499	0.78	rs7692994	ENSG00000249244.1	RP11-548H18.2	3.37	0.000766	0.035	0.12	0.1	Corneal astigmatism;	chr4:119506334	chr4:119391831~119395335:-
BRCA	cis	rs875971	0.767	rs12668005	ENSG00000106610.13	STAG3L4	-3.37	0.000766	0.035	-0.14	-0.1	Aortic root size;	chr7:66444034	chr7:67302621~67321526:+
BRCA	cis	rs1823874	0.605	rs1840300	ENSG00000259590.1	RP11-20G13.3	-3.37	0.000766	0.035	-0.12	-0.1	IgG glycosylation;	chr15:99826739	chr15:99395179~99396593:-
BRCA	cis	rs7267979	0.966	rs6050611	ENSG00000204556.4	CTD-2514C3.1	-3.37	0.000766	0.035	-0.14	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25433783	chr20:26018832~26020684:+
BRCA	cis	rs801193	1	rs2659915	ENSG00000273142.1	RP11-458F8.4	-3.37	0.000766	0.035	-0.09	-0.1	Aortic root size;	chr7:66688114	chr7:66902857~66906297:+
BRCA	cis	rs13401620	0.843	rs2968773	ENSG00000223549.1	MTND5P28	-3.37	0.000766	0.035	-0.13	-0.1	Breast size;	chr2:119848575	chr2:120215181~120217279:+
BRCA	cis	rs875971	1	rs6961717	ENSG00000230189.5	GS1-124K5.2	-3.37	0.000766	0.035	-0.08	-0.1	Aortic root size;	chr7:66122550	chr7:66409143~66490059:-
BRCA	cis	rs321358	0.731	rs494921	ENSG00000271390.1	RP11-89C3.3	-3.37	0.000766	0.035	-0.15	-0.1	Body mass index;	chr11:111140385	chr11:111089870~111090368:-
BRCA	cis	rs6671200	0.51	rs35556400	ENSG00000235501.4	RP4-639F20.1	-3.37	0.000766	0.035	-0.28	-0.1	Stearic acid (18:0) levels;	chr1:95451329	chr1:94927566~94963270:+
BRCA	cis	rs4363385	0.747	rs6670614	ENSG00000272654.1	RP11-422P24.11	3.37	0.000766	0.035	0.11	0.1	Inflammatory skin disease;	chr1:152991862	chr1:153977743~153979160:+
BRCA	cis	rs7429990	0.932	rs7620736	ENSG00000199476.1	Y_RNA	3.37	0.000766	0.035	0.13	0.1	Educational attainment (years of education);	chr3:48068479	chr3:48288587~48288694:+
BRCA	cis	rs7677281	1	rs6851181	ENSG00000271676.1	RP11-1E1.2	3.37	0.000766	0.035	0.14	0.1	Lung function (FEV1/FVC);	chr4:77420322	chr4:77112495~77113458:-
BRCA	cis	rs933360	0.557	rs7794299	ENSG00000228204.2	RP4-724E13.2	3.37	0.000766	0.035	0.17	0.1	Ratio of the area under the curve for insulin and the area under the curve for glucose;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Area under the curve of insulin levels;Incremental insulin;Corrected insulin response;	chr7:50715494	chr7:50866747~51022990:+
BRCA	cis	rs270545	1	rs430409	ENSG00000249911.1	LINC01265	3.37	0.000767	0.035	0.13	0.1	Major depressive disorder;	chr5:38047121	chr5:38710367~38720273:-
BRCA	cis	rs8105895	0.735	rs17554694	ENSG00000269345.1	VN1R85P	-3.37	0.000767	0.035	-0.15	-0.1	Body mass index (change over time);	chr19:22134346	chr19:22174766~22175191:-
BRCA	cis	rs17767294	0.708	rs72851138	ENSG00000272009.1	RP1-313I6.12	-3.37	0.000767	0.035	-0.27	-0.1	Parkinson's disease;	chr6:28074876	chr6:28078792~28081130:-
BRCA	cis	rs17767294	0.708	rs72851139	ENSG00000272009.1	RP1-313I6.12	-3.37	0.000767	0.035	-0.27	-0.1	Parkinson's disease;	chr6:28074920	chr6:28078792~28081130:-
BRCA	cis	rs17767294	0.708	rs72851156	ENSG00000272009.1	RP1-313I6.12	-3.37	0.000767	0.035	-0.27	-0.1	Parkinson's disease;	chr6:28092308	chr6:28078792~28081130:-
BRCA	cis	rs17767294	0.708	rs72851158	ENSG00000272009.1	RP1-313I6.12	-3.37	0.000767	0.035	-0.27	-0.1	Parkinson's disease;	chr6:28092707	chr6:28078792~28081130:-
BRCA	cis	rs17767294	0.708	rs72851160	ENSG00000272009.1	RP1-313I6.12	-3.37	0.000767	0.035	-0.27	-0.1	Parkinson's disease;	chr6:28100063	chr6:28078792~28081130:-
BRCA	cis	rs9468199	0.51	rs72851161	ENSG00000272009.1	RP1-313I6.12	-3.37	0.000767	0.035	-0.27	-0.1	Parkinson's disease;	chr6:28103345	chr6:28078792~28081130:-
BRCA	cis	rs17767294	0.708	rs77689085	ENSG00000272009.1	RP1-313I6.12	-3.37	0.000767	0.035	-0.27	-0.1	Parkinson's disease;	chr6:28104758	chr6:28078792~28081130:-
BRCA	cis	rs2835872	0.759	rs4816567	ENSG00000230366.8	DSCR9	-3.37	0.000767	0.035	-0.13	-0.1	Electroencephalographic traits in alcoholism;	chr21:37615853	chr21:37208503~37221736:+
BRCA	cis	rs4218	0.689	rs35555888	ENSG00000259732.1	RP11-59H7.3	-3.37	0.000767	0.035	-0.13	-0.1	Social communication problems;	chr15:59093935	chr15:59121034~59133250:+
BRCA	cis	rs11673344	0.74	rs113752815	ENSG00000267682.1	CTD-3220F14.2	-3.37	0.000767	0.035	-0.1	-0.1	Obesity-related traits;	chr19:37043829	chr19:37337236~37337743:+
BRCA	cis	rs881375	0.935	rs7034390	ENSG00000238181.2	AHCYP2	-3.37	0.000767	0.035	-0.13	-0.1	Rheumatoid arthritis;	chr9:120884210	chr9:120720673~120721972:+
BRCA	cis	rs739496	0.615	rs4646778	ENSG00000234608.6	MAPKAPK5-AS1	3.37	0.000767	0.035	0.13	0.1	Platelet count;	chr12:111797979	chr12:111839764~111842902:-
BRCA	cis	rs12681366	0.708	rs2445699	ENSG00000253704.1	RP11-267M23.4	-3.37	0.000767	0.035	-0.11	-0.1	Nonsyndromic cleft lip with cleft palate;	chr8:94334289	chr8:94553722~94569745:+
BRCA	cis	rs300890	0.651	rs300915	ENSG00000250326.1	RP11-284M14.1	-3.37	0.000767	0.035	-0.12	-0.1	Nasopharyngeal carcinoma;	chr4:143353003	chr4:142933195~143184861:-
BRCA	cis	rs4981053	0.644	rs1959634	ENSG00000259001.3	RPPH1	3.37	0.000767	0.035	0.12	0.1	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr14:20056449	chr14:20343048~20343685:-
BRCA	cis	rs881375	0.933	rs7028641	ENSG00000238181.2	AHCYP2	-3.37	0.000767	0.035	-0.13	-0.1	Rheumatoid arthritis;	chr9:120928863	chr9:120720673~120721972:+
BRCA	cis	rs7523050	0.73	rs12729728	ENSG00000203897.3	SPATA42	-3.37	0.000767	0.035	-0.21	-0.1	Fat distribution (HIV);	chr1:108888488	chr1:108857217~108858524:+
BRCA	cis	rs987724	0.574	rs9856725	ENSG00000240875.4	LINC00886	-3.37	0.000767	0.035	-0.12	-0.1	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156954781	chr3:156747346~156817062:-
BRCA	cis	rs6490294	0.571	rs7965087	ENSG00000257624.1	RP1-128M12.3	3.37	0.000767	0.035	0.17	0.1	Mean platelet volume;	chr12:112110758	chr12:112000739~112000985:-
BRCA	cis	rs7955516	0.967	rs10770643	ENSG00000255910.1	RP11-405A12.2	-3.37	0.000767	0.035	-0.11	-0.1	Adiponectin levels;	chr12:20340900	chr12:19775451~20009937:+
BRCA	cis	rs875971	0.862	rs2088653	ENSG00000106610.13	STAG3L4	3.37	0.000767	0.035	0.14	0.1	Aortic root size;	chr7:66343621	chr7:67302621~67321526:+
BRCA	cis	rs875971	0.862	rs6460293	ENSG00000106610.13	STAG3L4	3.37	0.000767	0.035	0.14	0.1	Aortic root size;	chr7:66345205	chr7:67302621~67321526:+
BRCA	cis	rs934734	0.532	rs2028151	ENSG00000237979.1	AC007389.1	-3.37	0.000767	0.035	-0.12	-0.1	Rheumatoid arthritis;	chr2:65428479	chr2:65500993~65502138:-
BRCA	cis	rs17507216	0.667	rs13379724	ENSG00000255769.6	GOLGA2P10	-3.37	0.000767	0.035	-0.14	-0.1	Excessive daytime sleepiness;	chr15:82619892	chr15:82472993~82513950:-
BRCA	cis	rs2416257	0.673	rs72784252	ENSG00000249619.1	HMGN1P13	3.37	0.000767	0.035	0.17	0.1	Eosinophil counts;	chr5:111131634	chr5:111572102~111572239:-
BRCA	cis	rs372883	0.901	rs407463	ENSG00000176054.6	RPL23P2	-3.37	0.000767	0.035	-0.11	-0.1	Pancreatic cancer;	chr21:29350119	chr21:28997613~28998033:-
BRCA	cis	rs202072	0.585	rs1512414	ENSG00000215022.6	RP1-257A7.4	-3.37	0.000767	0.035	-0.13	-0.1	HIV-1 viral setpoint;	chr6:13276183	chr6:13264861~13295586:-
BRCA	cis	rs10792320	0.565	rs77709427	ENSG00000244176.1	RP11-810P12.1	-3.37	0.000768	0.035	-0.17	-0.1	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr11:61968663	chr11:62011751~62012602:-
BRCA	cis	rs11098499	0.955	rs56386062	ENSG00000260404.2	RP11-384K6.6	3.37	0.000768	0.035	0.1	0.1	Corneal astigmatism;	chr4:119233980	chr4:118591773~118633729:+
BRCA	cis	rs10792665	0.649	rs11233432	ENSG00000254965.1	RP11-113K21.2	-3.37	0.000768	0.035	-0.1	-0.1	Obesity-related traits;	chr11:83028711	chr11:83111060~83111442:-
BRCA	cis	rs4853525	0.923	rs7578618	ENSG00000235852.1	AC005540.3	3.37	0.000768	0.035	0.12	0.1	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190868631	chr2:190880797~190882059:-
BRCA	cis	rs11711311	0.712	rs6795099	ENSG00000241529.3	RN7SL767P	-3.37	0.000768	0.035	-0.12	-0.1	IgG glycosylation;	chr3:113619935	chr3:113632704~113632998:+
BRCA	cis	rs11035577	0.538	rs10837239	ENSG00000279675.1	RP11-454H19.2	-3.37	0.000768	0.035	-0.16	-0.1	Temperament (bipolar disorder);	chr11:39740919	chr11:40107244~40112599:-
BRCA	cis	rs875971	0.862	rs7809814	ENSG00000223473.2	GS1-124K5.3	-3.37	0.000768	0.0351	-0.08	-0.1	Aortic root size;	chr7:66150410	chr7:66491049~66493566:-
BRCA	cis	rs2289681	0.524	rs12150327	ENSG00000233175.2	CTD-2020K17.3	3.37	0.000768	0.0351	0.19	0.1	Cognitive function;	chr17:44956911	chr17:45238028~45241734:-
BRCA	cis	rs7649443	0.917	rs3843374	ENSG00000243339.3	RN7SL738P	-3.37	0.000768	0.0351	-0.15	-0.1	Nonsyndromic cleft lip with cleft palate;	chr3:197070329	chr3:196399911~196400207:+
BRCA	cis	rs7649443	0.959	rs35260201	ENSG00000243339.3	RN7SL738P	-3.37	0.000768	0.0351	-0.15	-0.1	Nonsyndromic cleft lip with cleft palate;	chr3:197071830	chr3:196399911~196400207:+
BRCA	cis	rs7781266	0.79	rs4731951	ENSG00000226205.1	AC007790.4	-3.37	0.000768	0.0351	-0.15	-0.1	Educational attainment (college completion);	chr7:133417528	chr7:133732493~133733595:-
BRCA	cis	rs4835473	0.932	rs17762299	ENSG00000246448.2	RP13-578N3.3	-3.37	0.000768	0.0351	-0.12	-0.1	Immature fraction of reticulocytes;	chr4:143777196	chr4:143700257~143865072:+
BRCA	cis	rs12234571	1	rs78146324	ENSG00000214293.7	APTR	3.37	0.000768	0.0351	0.22	0.1	Obesity-related traits;	chr7:77956639	chr7:77657660~77696265:-
BRCA	cis	rs2692947	0.77	rs2579552	ENSG00000168992.4	OR7E102P	3.37	0.000768	0.0351	0.15	0.1	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96071335	chr2:95546531~95547545:+
BRCA	cis	rs739525	0.518	rs178268	ENSG00000183506.15	PI4KAP2	3.37	0.000768	0.0351	0.12	0.1	Testicular germ cell tumor;	chr22:20975977	chr22:21473000~21517533:-
BRCA	cis	rs11877825	0.826	rs9676161	ENSG00000265728.1	RP11-883A18.3	-3.37	0.000768	0.0351	-0.14	-0.1	Gut microbiota (bacterial taxa);	chr18:10571442	chr18:10594590~10604798:+
BRCA	cis	rs11877825	0.762	rs9676152	ENSG00000265728.1	RP11-883A18.3	-3.37	0.000768	0.0351	-0.14	-0.1	Gut microbiota (bacterial taxa);	chr18:10571443	chr18:10594590~10604798:+
BRCA	cis	rs2613964	0.513	rs2204789	ENSG00000240057.4	RP11-572M11.4	-3.37	0.000769	0.0351	-0.13	-0.1	Pediatric bone mineral content (spine);Pediatric bone mineral density (spine);	chr3:113132437	chr3:113019532~113183301:+
BRCA	cis	rs1348850	0.519	rs1527407	ENSG00000238082.1	AC009948.7	-3.37	0.000769	0.0351	-0.14	-0.1	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177660902	chr2:178454716~178455428:+
BRCA	cis	rs1348850	0.519	rs1527406	ENSG00000238082.1	AC009948.7	-3.37	0.000769	0.0351	-0.14	-0.1	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177660927	chr2:178454716~178455428:+
BRCA	cis	rs9467773	0.62	rs6925087	ENSG00000261353.1	CTA-14H9.5	-3.37	0.000769	0.0351	-0.1	-0.1	Intelligence (multi-trait analysis);	chr6:26592625	chr6:26527063~26527404:+
BRCA	cis	rs9467773	0.62	rs4368798	ENSG00000261353.1	CTA-14H9.5	-3.37	0.000769	0.0351	-0.1	-0.1	Intelligence (multi-trait analysis);	chr6:26593243	chr6:26527063~26527404:+
BRCA	cis	rs258892	0.793	rs10062154	ENSG00000272525.1	RP11-79P5.9	-3.37	0.000769	0.0351	-0.13	-0.1	Small cell lung carcinoma;	chr5:72725707	chr5:73497550~73498293:-
BRCA	cis	rs258892	0.895	rs3846643	ENSG00000272525.1	RP11-79P5.9	-3.37	0.000769	0.0351	-0.13	-0.1	Small cell lung carcinoma;	chr5:72727211	chr5:73497550~73498293:-
BRCA	cis	rs6512645	1	rs6512645	ENSG00000228663.1	PSMD10P1	-3.37	0.000769	0.0351	-0.1	-0.1	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr20:50470475	chr20:50913731~50914411:+
BRCA	cis	rs3816183	0.585	rs2037884	ENSG00000226491.1	FTOP1	-3.37	0.000769	0.0351	-0.13	-0.1	Hypospadias;	chr2:42651032	chr2:42797225~42798712:-
BRCA	cis	rs7246967	0.866	rs12984122	ENSG00000198153.8	ZNF849P	-3.37	0.000769	0.0351	-0.15	-0.1	Bronchopulmonary dysplasia;	chr19:22847872	chr19:22685167~22686732:+
BRCA	cis	rs11098499	0.863	rs58452170	ENSG00000225892.3	RP11-384K6.2	3.37	0.000769	0.0351	0.11	0.1	Corneal astigmatism;	chr4:119538519	chr4:118632274~118634759:+
BRCA	cis	rs8181477	1	rs8181477	ENSG00000240291.1	RP11-499P20.2	3.37	0.000769	0.0351	0.1	0.1	Obesity-related traits;	chr10:18493951	chr10:18513115~18545651:-
BRCA	cis	rs2842992	0.692	rs9347342	ENSG00000207392.1	SNORA20	-3.37	0.000769	0.0351	-0.13	-0.1	Age-related macular degeneration (geographic atrophy);	chr6:159772097	chr6:159780250~159780381:-
BRCA	cis	rs3809060	0.549	rs10835924	ENSG00000183242.10	WT1-AS	3.37	0.000769	0.0351	0.14	0.1	Inguinal hernia;	chr11:32479673	chr11:32435518~32458769:+
BRCA	cis	rs6942407	0.546	rs2190424	ENSG00000224046.1	AC005076.5	-3.37	0.000769	0.0351	-0.15	-0.1	Food allergy;	chr7:87212655	chr7:87151423~87152420:-
BRCA	cis	rs13136331	0.641	rs2732174	ENSG00000249001.4	RP11-742B18.1	3.37	0.000769	0.0351	0.14	0.1	Sitting height ratio;	chr4:87761758	chr4:87568035~87733956:-
BRCA	cis	rs10819083	0.666	rs10819079	ENSG00000232630.1	PRPS1P2	-3.37	0.000769	0.0351	-0.1	-0.1	Squamous cell lung carcinoma;	chr9:125821620	chr9:125150653~125151589:+
BRCA	cis	rs10771431	0.967	rs7137443	ENSG00000256673.1	RP11-599J14.2	3.37	0.000769	0.0351	0.12	0.1	Breast size;	chr12:9219433	chr12:9398355~9414851:-
BRCA	cis	rs12479064	0.694	rs4341989	ENSG00000231822.1	AC019097.7	-3.37	0.000769	0.0351	-0.12	-0.1	Chronic sinus infection;	chr2:99430321	chr2:99102018~99102752:+
BRCA	cis	rs9329221	0.736	rs2001338	ENSG00000154316.13	TDH	-3.37	0.000769	0.0351	-0.14	-0.1	Neuroticism;	chr8:10393707	chr8:11339637~11368452:+
BRCA	cis	rs55883249	1	rs56372340	ENSG00000217258.2	AC007249.3	3.37	0.000769	0.0351	0.16	0.1	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:9601407	chr2:10452319~10455552:+
BRCA	cis	rs8127691	0.967	rs4380337	ENSG00000225331.1	AP001055.6	3.37	0.000769	0.0351	0.12	0.1	Inflammatory bowel disease;	chr21:44196166	chr21:44158740~44160076:-
BRCA	cis	rs2832077	0.506	rs2832093	ENSG00000232855.5	AF131217.1	3.37	0.00077	0.0351	0.14	0.1	Cognitive test performance;	chr21:28792533	chr21:28439346~28674848:-
BRCA	cis	rs453301	0.606	rs6601279	ENSG00000173295.6	FAM86B3P	-3.37	0.00077	0.0351	-0.11	-0.1	Joint mobility (Beighton score);	chr8:9050721	chr8:8228595~8244865:+
BRCA	cis	rs453301	0.606	rs6981060	ENSG00000173295.6	FAM86B3P	-3.37	0.00077	0.0351	-0.11	-0.1	Joint mobility (Beighton score);	chr8:9050725	chr8:8228595~8244865:+
BRCA	cis	rs997295	0.57	rs737226	ENSG00000260657.2	RP11-315D16.4	3.37	0.00077	0.0351	0.13	0.1	Motion sickness;	chr15:67548435	chr15:68267792~68277994:-
BRCA	cis	rs11874712	0.965	rs12954944	ENSG00000251939.1	RNU6-1278P	-3.37	0.00077	0.0351	-0.11	-0.1	Migraine - clinic-based;	chr18:46084149	chr18:46121615~46121721:-
BRCA	cis	rs11874712	1	rs8088881	ENSG00000251939.1	RNU6-1278P	-3.37	0.00077	0.0351	-0.11	-0.1	Migraine - clinic-based;	chr18:46085004	chr18:46121615~46121721:-
BRCA	cis	rs11874712	0.965	rs28694780	ENSG00000251939.1	RNU6-1278P	-3.37	0.00077	0.0351	-0.11	-0.1	Migraine - clinic-based;	chr18:46085372	chr18:46121615~46121721:-
BRCA	cis	rs11874712	1	rs28504655	ENSG00000251939.1	RNU6-1278P	-3.37	0.00077	0.0351	-0.11	-0.1	Migraine - clinic-based;	chr18:46085382	chr18:46121615~46121721:-
BRCA	cis	rs11874712	0.932	rs8092674	ENSG00000251939.1	RNU6-1278P	-3.37	0.00077	0.0351	-0.11	-0.1	Migraine - clinic-based;	chr18:46086016	chr18:46121615~46121721:-
BRCA	cis	rs11874712	0.931	rs8095031	ENSG00000251939.1	RNU6-1278P	-3.37	0.00077	0.0351	-0.11	-0.1	Migraine - clinic-based;	chr18:46086895	chr18:46121615~46121721:-
BRCA	cis	rs11874712	0.933	rs8097521	ENSG00000251939.1	RNU6-1278P	-3.37	0.00077	0.0351	-0.11	-0.1	Migraine - clinic-based;	chr18:46086986	chr18:46121615~46121721:-
BRCA	cis	rs11874712	1	rs7244921	ENSG00000251939.1	RNU6-1278P	-3.37	0.00077	0.0351	-0.11	-0.1	Migraine - clinic-based;	chr18:46087562	chr18:46121615~46121721:-
BRCA	cis	rs2811415	0.597	rs10934847	ENSG00000242551.2	POU5F1P6	3.37	0.00077	0.0351	0.14	0.1	Lung function (FEV1/FVC);	chr3:128070112	chr3:128674735~128677005:-
BRCA	cis	rs2070488	0.965	rs1065800	ENSG00000232439.1	RPL18AP7	-3.37	0.00077	0.0351	-0.12	-0.1	Electrocardiographic conduction measures;	chr3:38524989	chr3:38526802~38527325:-
BRCA	cis	rs1116357	0.512	rs1878280	ENSG00000233251.6	AC007743.1	-3.37	0.00077	0.0351	-0.13	-0.1	Type 2 diabetes;	chr2:57004189	chr2:56173534~56185770:-
BRCA	cis	rs8180040	0.967	rs17411375	ENSG00000280667.1	Y_RNA	-3.37	0.00077	0.0351	-0.12	-0.1	Colorectal cancer;	chr3:47353645	chr3:47501083~47501182:+
BRCA	cis	rs258892	0.843	rs13190547	ENSG00000272525.1	RP11-79P5.9	-3.37	0.00077	0.0351	-0.13	-0.1	Small cell lung carcinoma;	chr5:72739926	chr5:73497550~73498293:-
BRCA	cis	rs258892	0.895	rs13157632	ENSG00000272525.1	RP11-79P5.9	-3.37	0.00077	0.0351	-0.13	-0.1	Small cell lung carcinoma;	chr5:72740672	chr5:73497550~73498293:-
BRCA	cis	rs258892	0.895	rs10473898	ENSG00000272525.1	RP11-79P5.9	-3.37	0.00077	0.0351	-0.13	-0.1	Small cell lung carcinoma;	chr5:72741986	chr5:73497550~73498293:-
BRCA	cis	rs258892	0.895	rs4540158	ENSG00000272525.1	RP11-79P5.9	-3.37	0.00077	0.0351	-0.13	-0.1	Small cell lung carcinoma;	chr5:72742397	chr5:73497550~73498293:-
BRCA	cis	rs258892	0.895	rs2338789	ENSG00000272525.1	RP11-79P5.9	-3.37	0.00077	0.0351	-0.13	-0.1	Small cell lung carcinoma;	chr5:72742654	chr5:73497550~73498293:-
BRCA	cis	rs258892	0.895	rs13166571	ENSG00000272525.1	RP11-79P5.9	-3.37	0.00077	0.0351	-0.13	-0.1	Small cell lung carcinoma;	chr5:72744031	chr5:73497550~73498293:-
BRCA	cis	rs258892	0.895	rs11948547	ENSG00000272525.1	RP11-79P5.9	-3.37	0.00077	0.0351	-0.13	-0.1	Small cell lung carcinoma;	chr5:72745195	chr5:73497550~73498293:-
BRCA	cis	rs258892	0.843	rs10053857	ENSG00000272525.1	RP11-79P5.9	-3.37	0.00077	0.0351	-0.13	-0.1	Small cell lung carcinoma;	chr5:72746192	chr5:73497550~73498293:-
BRCA	cis	rs10246939	0.505	rs892354	ENSG00000270923.1	TAS2R6P	-3.37	0.00077	0.0351	-0.11	-0.1	Bitter taste perception;	chr7:141844934	chr7:141787815~141788640:+
BRCA	cis	rs993804	0.571	rs994267	ENSG00000264219.1	MIR4442	-3.37	0.00077	0.0351	-0.12	-0.1	Bipolar disorder and schizophrenia;	chr3:25073703	chr3:25664873~25664939:-
BRCA	cis	rs7709909	0.755	rs2035256	ENSG00000249655.1	CTC-325J23.2	3.37	0.00077	0.0351	0.11	0.1	HDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;	chr5:80700813	chr5:80630313~80631590:-
BRCA	cis	rs67478160	0.643	rs2295145	ENSG00000269910.1	RP11-73M18.10	3.37	0.00077	0.0351	0.1	0.1	Schizophrenia;	chr14:103735967	chr14:103694516~103695050:-
BRCA	cis	rs359466	0.938	rs17076705	ENSG00000254164.1	CTB-33O18.2	-3.37	0.00077	0.0351	-0.17	-0.1	QRS complex (Sokolow-Lyon);	chr5:173925800	chr5:173574938~173576275:+
BRCA	cis	rs10487112	0.833	rs12704544	ENSG00000235436.9	DPY19L2P4	-3.37	0.00077	0.0351	-0.11	-0.1	Perceived unattractiveness to mosquitoes;	chr7:90501736	chr7:90119400~90125600:+
BRCA	cis	rs417065	0.516	rs6687168	ENSG00000238290.1	RP11-431K24.1	-3.37	0.00077	0.0351	-0.13	-0.1	Psoriasis;	chr1:8208853	chr1:8026738~8122702:+
BRCA	cis	rs6545883	0.929	rs2264100	ENSG00000273302.1	RP11-493E12.2	3.37	0.00077	0.0351	0.1	0.1	Tuberculosis;	chr2:61443694	chr2:61199979~61200769:+
BRCA	cis	rs13118159	0.573	rs4974618	ENSG00000273179.1	RP11-20I20.4	3.37	0.00077	0.0351	0.11	0.1	Longevity;	chr4:1379875	chr4:1167778~1168174:+
BRCA	cis	rs3011225	0.697	rs72678691	ENSG00000237950.1	RP11-7O11.3	-3.37	0.00077	0.0351	-0.15	-0.1	Amyotrophic lateral sclerosis (age of onset);	chr1:43790258	chr1:43944370~43946551:-
BRCA	cis	rs853679	0.505	rs200992	ENSG00000241549.7	GUSBP2	3.37	0.00077	0.0351	0.19	0.1	Depression;	chr6:27846899	chr6:26871484~26956554:-
BRCA	cis	rs964611	0.935	rs8029972	ENSG00000259488.2	RP11-154J22.1	-3.37	0.00077	0.0351	-0.16	-0.1	Metabolite levels (Pyroglutamine);	chr15:48285970	chr15:48312353~48331856:-
BRCA	cis	rs9467773	0.967	rs6456732	ENSG00000261353.1	CTA-14H9.5	-3.37	0.00077	0.0351	-0.1	-0.1	Intelligence (multi-trait analysis);	chr6:26514217	chr6:26527063~26527404:+
BRCA	cis	rs944990	0.538	rs10821165	ENSG00000227603.1	RP11-165J3.6	3.37	0.00077	0.0351	0.11	0.1	Body mass index;	chr9:93589352	chr9:93435332~93437121:-
BRCA	cis	rs6142102	1	rs6059673	ENSG00000206582.1	Y_RNA	-3.37	0.00077	0.0351	-0.13	-0.1	Skin pigmentation;	chr20:34117755	chr20:34526510~34526606:-
BRCA	cis	rs6600671	1	rs4844616	ENSG00000223345.3	HIST2H2BA	3.37	0.000771	0.0351	0.12	0.1	Hip geometry;	chr1:121429348	chr1:121108210~121117257:-
BRCA	cis	rs7637701	0.901	rs13071598	ENSG00000240875.4	LINC00886	-3.37	0.000771	0.0351	-0.12	-0.1	Breast cancer;	chr3:156854426	chr3:156747346~156817062:-
BRCA	cis	rs6499755	0.712	rs31111	ENSG00000260135.5	RP11-212I21.2	-3.37	0.000771	0.0352	-0.12	-0.1	Hypospadias;	chr16:55344774	chr16:55426797~55462297:-
BRCA	cis	rs898097	0.625	rs2125479	ENSG00000265458.1	RP13-20L14.6	-3.37	0.000771	0.0352	-0.12	-0.1	Breast cancer;	chr17:82932386	chr17:82454273~82458521:-
BRCA	cis	rs66887589	0.777	rs1814815	ENSG00000249244.1	RP11-548H18.2	3.37	0.000771	0.0352	0.11	0.1	Diastolic blood pressure;	chr4:119336936	chr4:119391831~119395335:-
BRCA	cis	rs613391	0.522	rs491563	ENSG00000265194.1	RP11-70L8.4	-3.37	0.000771	0.0352	-0.11	-0.1	Quantitative traits;	chr9:22730788	chr9:21858910~21861926:-
BRCA	cis	rs924712	0.645	rs2816811	ENSG00000224984.1	RP11-524H19.2	-3.37	0.000771	0.0352	-0.13	-0.1	Breast cancer;	chr6:54892993	chr6:54840118~54840855:-
BRCA	cis	rs77106637	1	rs76793820	ENSG00000256633.1	RP11-169D4.2	3.37	0.000771	0.0352	0.14	0.1	Type 2 diabetes;	chr11:72908815	chr11:72584572~72587979:+
BRCA	cis	rs8040855	0.599	rs6496791	ENSG00000259570.1	RP11-671M22.4	-3.37	0.000771	0.0352	-0.11	-0.1	Bulimia nervosa;	chr15:85182428	chr15:84394512~84395514:+
BRCA	cis	rs721917	0.506	rs2758543	ENSG00000280355.1	RP11-119F19.5	-3.37	0.000771	0.0352	-0.11	-0.1	Chronic obstructive pulmonary disease;	chr10:79902710	chr10:79681973~79684094:-
BRCA	cis	rs721917	0.525	rs2250473	ENSG00000280355.1	RP11-119F19.5	-3.37	0.000771	0.0352	-0.11	-0.1	Chronic obstructive pulmonary disease;	chr10:79904639	chr10:79681973~79684094:-
BRCA	cis	rs6121246	0.559	rs1484994	ENSG00000230613.1	HM13-AS1	3.37	0.000771	0.0352	0.14	0.1	Mean corpuscular hemoglobin;	chr20:31718172	chr20:31567707~31573263:-
BRCA	cis	rs6840360	0.554	rs4643789	ENSG00000270265.1	RP11-731D1.4	-3.37	0.000771	0.0352	-0.12	-0.1	Intelligence (multi-trait analysis);	chr4:151805539	chr4:151333775~151353224:-
BRCA	cis	rs13126694	0.65	rs13103614	ENSG00000248429.4	RP11-597D13.9	3.37	0.000771	0.0352	0.09	0.1	Blood osmolality (transformed sodium);	chr4:157938359	chr4:158170752~158202877:+
BRCA	cis	rs12496230	0.794	rs7629637	ENSG00000272610.1	MAGI1-IT1	-3.37	0.000771	0.0352	-0.13	-0.1	Type 2 diabetes;	chr3:66812641	chr3:65872815~65954558:-
BRCA	cis	rs13118159	0.55	rs4974612	ENSG00000273179.1	RP11-20I20.4	3.37	0.000771	0.0352	0.11	0.1	Longevity;	chr4:1370755	chr4:1167778~1168174:+
BRCA	cis	rs2412980	0.744	rs11549795	ENSG00000232530.1	RP1-102K2.6	3.37	0.000771	0.0352	0.21	0.1	Dialysis-related mortality;	chr22:29825131	chr22:30239194~30240538:+
BRCA	cis	rs1015213	0.619	rs7814773	ENSG00000253475.1	RP11-110G21.2	3.37	0.000771	0.0352	0.19	0.1	Glaucoma (primary angle closure);	chr8:51980506	chr8:51895957~51896374:-
BRCA	cis	rs4650943	0.503	rs17354120	ENSG00000227740.1	RP11-318C24.2	3.37	0.000771	0.0352	0.11	0.1	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in inactive individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr1:176117412	chr1:175904762~175920513:-
BRCA	cis	rs17807624	0.78	rs11250152	ENSG00000255046.1	RP11-297N6.4	3.37	0.000771	0.0352	0.13	0.1	Systemic lupus erythematosus;	chr8:11596691	chr8:11797928~11802568:-
BRCA	cis	rs12477602	0.938	rs35223496	ENSG00000272966.1	RP11-686O6.1	3.37	0.000771	0.0352	0.18	0.1	Intelligence (multi-trait analysis);	chr2:202468770	chr2:202336739~202337200:+
BRCA	cis	rs875971	0.666	rs13242072	ENSG00000232559.3	GS1-124K5.12	-3.37	0.000771	0.0352	-0.12	-0.1	Aortic root size;	chr7:66301001	chr7:66554588~66576923:-
BRCA	cis	rs6088590	0.965	rs6088620	ENSG00000276073.1	RP5-1125A11.7	-3.37	0.000772	0.0352	-0.12	-0.1	Coronary artery disease;	chr20:34824219	chr20:33985617~33988989:-
BRCA	cis	rs17209837	0.915	rs12538707	ENSG00000224046.1	AC005076.5	3.37	0.000772	0.0352	0.16	0.1	Gallbladder cancer;	chr7:87494952	chr7:87151423~87152420:-
BRCA	cis	rs35740288	0.58	rs34526042	ENSG00000259407.1	RP11-158M2.3	-3.37	0.000772	0.0352	-0.14	-0.1	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85796725	chr15:85744109~85750281:-
BRCA	cis	rs1119582	1	rs463656	ENSG00000279118.1	RP11-517I3.2	-3.37	0.000772	0.0352	-0.12	-0.1	Select biomarker traits;	chr5:125940161	chr5:126496279~126498604:+
BRCA	cis	rs9287719	0.699	rs4669602	ENSG00000224177.5	LINC00570	3.37	0.000772	0.0352	0.12	0.1	Prostate cancer;	chr2:10647841	chr2:11393981~11403077:+
BRCA	cis	rs1510510	0.742	rs1027927	ENSG00000229915.1	AC016999.2	-3.37	0.000772	0.0352	-0.17	-0.1	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr2:238615957	chr2:238427077~238427729:-
BRCA	cis	rs863345	0.625	rs12075903	ENSG00000176320.2	RP11-404O13.5	-3.37	0.000772	0.0352	-0.11	-0.1	Pneumococcal bacteremia;	chr1:158489142	chr1:158197922~158203877:-
BRCA	cis	rs863345	0.604	rs2023632	ENSG00000176320.2	RP11-404O13.5	-3.37	0.000772	0.0352	-0.11	-0.1	Pneumococcal bacteremia;	chr1:158489244	chr1:158197922~158203877:-
BRCA	cis	rs12760731	0.565	rs2095133	ENSG00000213057.5	C1orf220	3.37	0.000772	0.0352	0.15	0.1	Obesity-related traits;	chr1:178229477	chr1:178542752~178548889:+
BRCA	cis	rs12760731	0.565	rs7541122	ENSG00000213057.5	C1orf220	3.37	0.000772	0.0352	0.15	0.1	Obesity-related traits;	chr1:178230079	chr1:178542752~178548889:+
BRCA	cis	rs12760731	0.565	rs10913520	ENSG00000213057.5	C1orf220	3.37	0.000772	0.0352	0.15	0.1	Obesity-related traits;	chr1:178231625	chr1:178542752~178548889:+
BRCA	cis	rs2562456	0.917	rs2650825	ENSG00000268117.1	VN1R84P	3.37	0.000772	0.0352	0.16	0.1	Pain;	chr19:21516423	chr19:21719801~21720035:-
BRCA	cis	rs7188861	0.681	rs8050084	ENSG00000262636.1	CTD-3088G3.4	-3.37	0.000772	0.0352	-0.19	-0.1	HDL cholesterol;	chr16:11313423	chr16:11380859~11381118:-
BRCA	cis	rs6840360	0.509	rs62327273	ENSG00000278978.1	RP11-164P12.5	-3.37	0.000772	0.0352	-0.13	-0.1	Intelligence (multi-trait analysis);	chr4:151626442	chr4:151669786~151670503:+
BRCA	cis	rs13118159	0.55	rs10016557	ENSG00000211482.1	AC092574.1	-3.37	0.000772	0.0352	-0.14	-0.1	Longevity;	chr4:1369840	chr4:409809~409915:+
BRCA	cis	rs240764	0.614	rs12210312	ENSG00000220695.1	RP1-121G13.3	-3.37	0.000772	0.0352	-0.12	-0.1	Neuroticism;	chr6:100722973	chr6:100530276~100531052:+
BRCA	cis	rs6142618	0.562	rs6061197	ENSG00000277692.1	RP11-358N2.2	-3.37	0.000772	0.0352	-0.11	-0.1	Inflammatory bowel disease;	chr20:32162543	chr20:32355053~32355734:+
BRCA	cis	rs6142618	0.562	rs6061198	ENSG00000277692.1	RP11-358N2.2	-3.37	0.000772	0.0352	-0.11	-0.1	Inflammatory bowel disease;	chr20:32162661	chr20:32355053~32355734:+
BRCA	cis	rs6964587	0.773	rs38793	ENSG00000188693.7	CYP51A1-AS1	3.37	0.000772	0.0352	0.12	0.1	Breast cancer;	chr7:92397873	chr7:92134604~92180725:+
BRCA	cis	rs7615952	0.609	rs13088451	ENSG00000241288.6	RP11-379B18.5	-3.37	0.000772	0.0352	-0.14	-0.1	Blood pressure (smoking interaction);	chr3:125834656	chr3:125827238~125916384:-
BRCA	cis	rs943466	0.826	rs3828783	ENSG00000223837.2	BRD2-IT1	3.37	0.000772	0.0352	0.15	0.1	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;	chr6:33799950	chr6:32970232~32970886:+
BRCA	cis	rs6545883	0.791	rs4672445	ENSG00000270820.4	RP11-355B11.2	-3.37	0.000772	0.0352	-0.12	-0.1	Tuberculosis;	chr2:61427873	chr2:61471188~61484130:+
BRCA	cis	rs1862618	0.671	rs28397234	ENSG00000271828.1	CTD-2310F14.1	-3.37	0.000772	0.0352	-0.13	-0.1	Initial pursuit acceleration;	chr5:56952601	chr5:56927874~56929573:+
BRCA	cis	rs62025270	0.632	rs6496109	ENSG00000259367.1	RP11-815J21.4	3.37	0.000772	0.0352	0.1	0.1	Idiopathic pulmonary fibrosis;	chr15:85588777	chr15:85619623~85670948:-
BRCA	cis	rs13153459	0.594	rs1552184	ENSG00000279557.1	CTD-2210P15.3	-3.37	0.000772	0.0352	-0.19	-0.1	Parkinson's disease;	chr5:44537012	chr5:43586367~43587543:-
BRCA	cis	rs2235642	0.75	rs1894649	ENSG00000260260.1	SNHG19	-3.37	0.000772	0.0352	-0.1	-0.1	Coronary artery disease;	chr16:1607283	chr16:2154797~2155358:-
BRCA	cis	rs12216545	0.765	rs3946494	ENSG00000244151.1	RP11-148K1.12	-3.37	0.000772	0.0352	-0.09	-0.1	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150556230	chr7:151074742~151076530:-
BRCA	cis	rs12479064	0.703	rs28382977	ENSG00000231822.1	AC019097.7	-3.37	0.000773	0.0352	-0.12	-0.1	Chronic sinus infection;	chr2:99401841	chr2:99102018~99102752:+
BRCA	cis	rs4388249	0.95	rs34097054	ENSG00000271849.1	CTC-332L22.1	-3.37	0.000773	0.0352	-0.17	-0.1	Schizophrenia;	chr5:109759753	chr5:109687802~109688329:-
BRCA	cis	rs12760731	0.582	rs4607830	ENSG00000213057.5	C1orf220	3.37	0.000773	0.0352	0.13	0.1	Obesity-related traits;	chr1:178566017	chr1:178542752~178548889:+
BRCA	cis	rs2921036	0.529	rs2979192	ENSG00000254153.1	CTA-398F10.2	3.37	0.000773	0.0352	0.13	0.1	Neuroticism;	chr8:8480637	chr8:8456909~8461337:-
BRCA	cis	rs4388249	0.95	rs34837720	ENSG00000271849.1	CTC-332L22.1	-3.37	0.000773	0.0352	-0.17	-0.1	Schizophrenia;	chr5:109759863	chr5:109687802~109688329:-
BRCA	cis	rs62458065	1	rs10275978	ENSG00000273014.1	RP11-225B17.2	-3.37	0.000773	0.0352	-0.15	-0.1	Metabolite levels (HVA/MHPG ratio);	chr7:32427107	chr7:32758882~32759353:+
BRCA	cis	rs1250259	0.542	rs17456939	ENSG00000225166.1	AC012462.2	-3.37	0.000773	0.0352	-0.13	-0.1	Coronary artery disease;Pulse pressure;	chr2:215406921	chr2:215453707~215463871:+
BRCA	cis	rs73222236	0.817	rs7629905	ENSG00000239213.4	NCK1-AS1	3.37	0.000773	0.0352	0.12	0.1	Coronary artery disease;	chr3:136620847	chr3:136841726~136862054:-
BRCA	cis	rs73222236	0.817	rs9828068	ENSG00000239213.4	NCK1-AS1	3.37	0.000773	0.0352	0.12	0.1	Coronary artery disease;	chr3:136623860	chr3:136841726~136862054:-
BRCA	cis	rs11170631	0.504	rs10128880	ENSG00000270175.1	RP11-793H13.11	-3.37	0.000773	0.0352	-0.09	-0.1	Height;	chr12:53533999	chr12:53500162~53500936:-
BRCA	cis	rs13126694	0.75	rs2346782	ENSG00000251073.1	NUDT19P5	3.37	0.000773	0.0352	0.1	0.1	Blood osmolality (transformed sodium);	chr4:158147143	chr4:158182825~158183393:+
BRCA	cis	rs8114671	0.562	rs6087653	ENSG00000261582.1	RP4-614O4.11	-3.37	0.000773	0.0352	-0.1	-0.1	Height;	chr20:34934251	chr20:35267885~35280043:-
BRCA	cis	rs9437689	0.53	rs12137644	ENSG00000235501.4	RP4-639F20.1	-3.37	0.000773	0.0352	-0.12	-0.1	Phospholipid levels (plasma);	chr1:94953523	chr1:94927566~94963270:+
BRCA	cis	rs1208	0.932	rs1908586	ENSG00000253671.1	RP11-806O11.1	-3.37	0.000773	0.0352	-0.12	-0.1	Insulin resistance/response;	chr8:18403987	chr8:17808941~17820868:+
BRCA	cis	rs1003719	0.788	rs2156076	ENSG00000242553.1	AP001432.14	-3.37	0.000773	0.0352	-0.12	-0.1	Eye color traits;	chr21:37080334	chr21:37221419~37237744:+
BRCA	cis	rs198846	0.542	rs198839	ENSG00000241549.7	GUSBP2	3.37	0.000773	0.0352	0.12	0.1	Mean corpuscular volume;Mean corpuscular hemoglobin concentration;Hemoglobin levels;Hemoglobin;Glycated hemoglobin levels;Blood pressure;	chr6:26112392	chr6:26871484~26956554:-
BRCA	cis	rs10129255	0.833	rs7156689	ENSG00000253132.1	IGHV3-62	-3.37	0.000773	0.0352	-0.08	-0.1	Kawasaki disease;	chr14:106816039	chr14:106643142~106643585:-
BRCA	cis	rs6828577	0.817	rs298996	ENSG00000225892.3	RP11-384K6.2	-3.37	0.000774	0.0353	-0.11	-0.1	Perioperative myocardial infarction in coronary artery bypass surgery;	chr4:118703590	chr4:118632274~118634759:+
BRCA	cis	rs2681735	0.574	rs2222311	ENSG00000274991.1	AC004846.1	-3.37	0.000774	0.0353	-0.12	-0.1	Antibody status in Tripanosoma cruzi seropositivity;	chr14:72330079	chr14:73208378~73208463:-
BRCA	cis	rs9394169	0.875	rs1547670	ENSG00000249346.5	LINC01016	-3.37	0.000774	0.0353	-0.1	-0.1	Essential tremor;	chr6:33808091	chr6:33867506~33896914:-
BRCA	cis	rs1401543	0.891	rs61790391	ENSG00000273486.1	RP11-731C17.2	-3.37	0.000774	0.0353	-0.13	-0.1	Anticoagulant levels;	chr3:135841546	chr3:136837338~136839021:-
BRCA	cis	rs1401543	1	rs57527075	ENSG00000273486.1	RP11-731C17.2	-3.37	0.000774	0.0353	-0.13	-0.1	Anticoagulant levels;	chr3:135844256	chr3:136837338~136839021:-
BRCA	cis	rs3796352	0.527	rs11715498	ENSG00000243224.1	RP5-1157M23.2	-3.37	0.000774	0.0353	-0.17	-0.1	Immune reponse to smallpox (secreted IL-2);	chr3:52909535	chr3:52239258~52241097:+
BRCA	cis	rs2998286	0.862	rs1416817	ENSG00000237128.1	RP11-351M16.3	3.37	0.000774	0.0353	0.13	0.1	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28503548	chr10:28433008~28495813:-
BRCA	cis	rs8114671	0.562	rs6088640	ENSG00000261582.1	RP4-614O4.11	-3.37	0.000774	0.0353	-0.1	-0.1	Height;	chr20:34884706	chr20:35267885~35280043:-
BRCA	cis	rs12915845	0.545	rs12907930	ENSG00000271997.1	RP11-97O12.6	3.37	0.000774	0.0353	0.08	0.1	Menarche (age at onset);	chr15:88540083	chr15:88501944~88505787:-
BRCA	cis	rs61931739	0.5	rs11615231	ENSG00000258794.3	DUX4L27	3.37	0.000774	0.0353	0.15	0.1	Morning vs. evening chronotype;	chr12:34260395	chr12:34208415~34209675:-
BRCA	cis	rs7520050	0.966	rs4134386	ENSG00000281133.1	AL355480.3	3.37	0.000774	0.0353	0.12	0.1	Reticulocyte count;Red blood cell count;	chr1:45929417	chr1:45580892~45580996:-
BRCA	cis	rs7520050	0.966	rs12561806	ENSG00000281133.1	AL355480.3	3.37	0.000774	0.0353	0.12	0.1	Reticulocyte count;Red blood cell count;	chr1:45931104	chr1:45580892~45580996:-
BRCA	cis	rs3748656	1	rs2306940	ENSG00000273483.1	RP4-671G15.2	3.37	0.000774	0.0353	0.14	0.1	Hip circumference adjusted for BMI;	chr1:112698430	chr1:112517799~112518441:-
BRCA	cis	rs8114671	0.527	rs2253484	ENSG00000279253.1	RP4-614O4.13	3.37	0.000774	0.0353	0.12	0.1	Height;	chr20:34817460	chr20:35262727~35264187:-
BRCA	cis	rs752010	0.806	rs4641303	ENSG00000230638.4	RP11-486B10.4	-3.37	0.000774	0.0353	-0.13	-0.1	Lupus nephritis in systemic lupus erythematosus;	chr1:41625639	chr1:41542069~41544310:+
BRCA	cis	rs752010	0.806	rs4457567	ENSG00000230638.4	RP11-486B10.4	-3.37	0.000774	0.0353	-0.13	-0.1	Lupus nephritis in systemic lupus erythematosus;	chr1:41625736	chr1:41542069~41544310:+
BRCA	cis	rs752010	0.806	rs10890148	ENSG00000230638.4	RP11-486B10.4	-3.37	0.000774	0.0353	-0.13	-0.1	Lupus nephritis in systemic lupus erythematosus;	chr1:41625846	chr1:41542069~41544310:+
BRCA	cis	rs6840360	0.837	rs4696294	ENSG00000278978.1	RP11-164P12.5	3.37	0.000774	0.0353	0.12	0.1	Intelligence (multi-trait analysis);	chr4:151791937	chr4:151669786~151670503:+
BRCA	cis	rs4713118	0.866	rs9468217	ENSG00000280107.1	AL022393.9	-3.37	0.000774	0.0353	-0.15	-0.1	Parkinson's disease;	chr6:27758688	chr6:28170845~28172521:+
BRCA	cis	rs4713118	0.911	rs9295746	ENSG00000280107.1	AL022393.9	-3.37	0.000774	0.0353	-0.15	-0.1	Parkinson's disease;	chr6:27762285	chr6:28170845~28172521:+
BRCA	cis	rs16846053	0.605	rs55949502	ENSG00000227403.1	AC009299.3	3.37	0.000774	0.0353	0.26	0.1	Blood osmolality (transformed sodium);	chr2:161915604	chr2:161244739~161249050:+
BRCA	cis	rs7246967	0.673	rs56209802	ENSG00000241282.1	RPL34P33	3.37	0.000774	0.0353	0.2	0.1	Bronchopulmonary dysplasia;	chr19:22842750	chr19:22699352~22699685:+
BRCA	cis	rs2333021	1	rs4899453	ENSG00000258408.1	NT5CP2	-3.37	0.000774	0.0353	-0.11	-0.1	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:73021883	chr14:73539221~73539781:-
BRCA	cis	rs6453278	0.559	rs13168613	ENSG00000250802.5	ZBED3-AS1	-3.37	0.000774	0.0353	-0.16	-0.1	Autism;	chr5:77098757	chr5:77086740~77166909:+
BRCA	cis	rs1912124	1	rs59415196	ENSG00000259343.4	TMC3-AS1	3.37	0.000774	0.0353	0.24	0.1	Peripheral arterial disease (traffic-related air pollution interaction);	chr15:81214642	chr15:81324377~81362037:+
BRCA	cis	rs10504130	0.569	rs34319820	ENSG00000272076.1	RP11-11C20.3	3.37	0.000774	0.0353	0.15	0.1	Venous thromboembolism (SNP x SNP interaction);	chr8:51777314	chr8:51810110~51810681:-
BRCA	cis	rs4374383	0.591	rs7571447	ENSG00000243389.1	AC012442.5	3.37	0.000774	0.0353	0.13	0.1	Hepatitis C induced liver fibrosis;	chr2:111918551	chr2:112589040~112614431:+
BRCA	cis	rs6893300	0.961	rs11741570	ENSG00000225051.5	HMGB3P22	3.37	0.000774	0.0353	0.14	0.1	Resting heart rate;	chr5:179781909	chr5:179679032~179694768:+
BRCA	cis	rs7474896	1	rs12571820	ENSG00000120555.12	SEPT7P9	3.37	0.000774	0.0353	0.19	0.1	Obesity (extreme);	chr10:37720426	chr10:38383069~38402916:-
BRCA	cis	rs11662721	0.683	rs60354581	ENSG00000264188.1	RP11-13N13.5	3.37	0.000774	0.0353	0.14	0.1	Phospholipid levels (plasma);	chr18:21634972	chr18:21661787~21662395:-
BRCA	cis	rs7017914	0.967	rs3954897	ENSG00000246366.5	RP11-382J12.1	3.37	0.000775	0.0353	0.11	0.1	Bone mineral density;	chr8:70723720	chr8:70608577~70663279:+
BRCA	cis	rs4713118	0.738	rs200465	ENSG00000280107.1	AL022393.9	-3.37	0.000775	0.0353	-0.15	-0.1	Parkinson's disease;	chr6:27789875	chr6:28170845~28172521:+
BRCA	cis	rs488400	0.571	rs518213	ENSG00000278978.1	RP11-164P12.5	-3.37	0.000775	0.0353	-0.12	-0.1	Trans fatty acid levels;	chr4:151892080	chr4:151669786~151670503:+
BRCA	cis	rs7824557	0.547	rs2409745	ENSG00000255020.1	AF131216.5	-3.37	0.000775	0.0353	-0.13	-0.1	Retinal vascular caliber;	chr8:11219126	chr8:11345748~11347502:-
BRCA	cis	rs7824557	0.652	rs12677504	ENSG00000255046.1	RP11-297N6.4	3.37	0.000775	0.0353	0.13	0.1	Retinal vascular caliber;	chr8:11275666	chr8:11797928~11802568:-
BRCA	cis	rs990171	0.538	rs2072508	ENSG00000234389.1	AC007278.3	3.37	0.000775	0.0353	0.11	0.1	Lymphocyte counts;	chr2:102501883	chr2:102438713~102440475:+
BRCA	cis	rs860295	0.702	rs2025669	ENSG00000236675.1	MTX1P1	-3.37	0.000775	0.0353	-0.13	-0.1	Body mass index;	chr1:155387818	chr1:155230975~155234325:+
BRCA	cis	rs12681366	0.734	rs2291439	ENSG00000253175.1	RP11-267M23.6	3.37	0.000775	0.0353	0.12	0.1	Nonsyndromic cleft lip with cleft palate;	chr8:94407470	chr8:94565036~94565715:+
BRCA	cis	rs9929218	0.52	rs1078621	ENSG00000260459.2	FTLP14	3.37	0.000775	0.0353	0.13	0.1	Colorectal cancer;	chr16:68745093	chr16:68822587~68823070:+
BRCA	cis	rs10411262	0.527	rs314672	ENSG00000245598.5	DACT3-AS1	-3.37	0.000775	0.0353	-0.15	-0.1	Tonsillectomy;	chr19:46690997	chr19:46660364~46677447:+
BRCA	cis	rs875971	0.862	rs4368860	ENSG00000223473.2	GS1-124K5.3	-3.37	0.000775	0.0353	-0.08	-0.1	Aortic root size;	chr7:66143495	chr7:66491049~66493566:-
BRCA	cis	rs943466	0.793	rs59137082	ENSG00000223837.2	BRD2-IT1	3.37	0.000775	0.0353	0.13	0.1	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;	chr6:33764588	chr6:32970232~32970886:+
BRCA	cis	rs812925	0.502	rs13028833	ENSG00000273302.1	RP11-493E12.2	-3.37	0.000775	0.0353	-0.09	-0.1	Immature fraction of reticulocytes;	chr2:61417194	chr2:61199979~61200769:+
BRCA	cis	rs4415084	0.768	rs9292915	ENSG00000248779.1	RP11-53O19.2	-3.37	0.000775	0.0353	-0.1	-0.1	Breast cancer;	chr5:44871555	chr5:44752949~44765744:+
BRCA	cis	rs1005277	0.505	rs10827835	ENSG00000099251.13	HSD17B7P2	-3.37	0.000775	0.0353	-0.11	-0.1	Extrinsic epigenetic age acceleration;	chr10:37861781	chr10:38356380~38378505:+
BRCA	cis	rs2795502	1	rs2795503	ENSG00000185904.10	LINC00839	-3.37	0.000775	0.0353	-0.15	-0.1	Blood protein levels;	chr10:42851776	chr10:42475543~42495336:+
BRCA	cis	rs2795502	1	rs1581702	ENSG00000185904.10	LINC00839	3.37	0.000775	0.0353	0.15	0.1	Blood protein levels;	chr10:42848798	chr10:42475543~42495336:+
BRCA	cis	rs6490294	0.571	rs35662477	ENSG00000257624.1	RP1-128M12.3	3.37	0.000775	0.0353	0.18	0.1	Mean platelet volume;	chr12:111875404	chr12:112000739~112000985:-
BRCA	cis	rs17159640	0.677	rs7810149	ENSG00000214194.7	LINC00998	-3.37	0.000775	0.0353	-0.27	-0.1	Mortality in heart failure;	chr7:112259309	chr7:113116718~113118613:-
BRCA	cis	rs924712	0.844	rs7765721	ENSG00000261116.1	RP3-523K23.2	3.37	0.000775	0.0353	0.13	0.1	Breast cancer;	chr6:54870143	chr6:54943167~54945099:+
BRCA	cis	rs4660456	0.913	rs2780953	ENSG00000272145.1	NFYC-AS1	-3.37	0.000775	0.0353	-0.11	-0.1	Platelet count;	chr1:40694105	chr1:40690380~40692066:-
BRCA	cis	rs17166082	0.826	rs17166083	ENSG00000236281.1	AC093106.5	3.37	0.000775	0.0353	0.18	0.1	Self-employment;	chr7:132028659	chr7:131753746~131754252:-
BRCA	cis	rs4714291	0.963	rs940352	ENSG00000180211.5	RP1-278E11.3	-3.37	0.000775	0.0353	-0.11	-0.1	Strep throat;	chr6:40145875	chr6:39958414~39958833:-
BRCA	cis	rs8133974	0.816	rs73205380	ENSG00000225555.1	AP000320.6	-3.37	0.000776	0.0353	-0.21	-0.1	Sum eosinophil basophil counts;Eosinophil counts;Eosinophil percentage of granulocytes;	chr21:35118750	chr21:34370802~34375348:-
BRCA	cis	rs36051895	0.623	rs7023639	ENSG00000237711.1	RP11-39K24.13	-3.37	0.000776	0.0353	-0.12	-0.1	Pediatric autoimmune diseases;	chr9:5244058	chr9:5100236~5101009:+
BRCA	cis	rs9287719	0.837	rs4233883	ENSG00000224177.5	LINC00570	3.37	0.000776	0.0353	0.12	0.1	Prostate cancer;	chr2:10615470	chr2:11393981~11403077:+
BRCA	cis	rs7508	0.619	rs483159	ENSG00000253671.1	RP11-806O11.1	-3.37	0.000776	0.0353	-0.17	-0.1	Atrial fibrillation;	chr8:18054329	chr8:17808941~17820868:+
BRCA	cis	rs875971	0.545	rs313828	ENSG00000226767.1	RP11-328P23.3	-3.37	0.000776	0.0353	-0.13	-0.1	Aortic root size;	chr7:66087627	chr7:65508773~65508944:-
BRCA	cis	rs8114671	0.562	rs6087651	ENSG00000261582.1	RP4-614O4.11	-3.37	0.000776	0.0353	-0.1	-0.1	Height;	chr20:34930550	chr20:35267885~35280043:-
BRCA	cis	rs8114671	0.562	rs6119545	ENSG00000261582.1	RP4-614O4.11	-3.37	0.000776	0.0353	-0.1	-0.1	Height;	chr20:34935066	chr20:35267885~35280043:-
BRCA	cis	rs875971	0.929	rs6970860	ENSG00000271064.1	RP11-792A8.3	-3.37	0.000776	0.0353	-0.12	-0.1	Aortic root size;	chr7:66511647	chr7:66748838~66749077:-
BRCA	cis	rs6545883	0.894	rs6545867	ENSG00000273302.1	RP11-493E12.2	-3.37	0.000776	0.0353	-0.1	-0.1	Tuberculosis;	chr2:61423892	chr2:61199979~61200769:+
BRCA	cis	rs73206853	0.62	rs55845219	ENSG00000277299.1	RP11-837J7.4	-3.37	0.000776	0.0353	-0.19	-0.1	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr12:110727070	chr12:109948389~109949029:+
BRCA	cis	rs2386661	0.637	rs7099771	ENSG00000242147.1	RP13-463N16.6	3.37	0.000776	0.0353	0.13	0.1	Breast cancer;	chr10:5612779	chr10:5594991~5596118:-
BRCA	cis	rs4699052	0.507	rs10005997	ENSG00000246560.2	RP11-10L12.4	3.37	0.000776	0.0353	0.12	0.1	Testicular germ cell tumor;	chr4:103380554	chr4:102828055~102844075:+
BRCA	cis	rs8114671	0.562	rs6058137	ENSG00000279253.1	RP4-614O4.13	-3.37	0.000776	0.0354	-0.12	-0.1	Height;	chr20:34887271	chr20:35262727~35264187:-
BRCA	cis	rs11700980	1	rs2831990	ENSG00000232855.5	AF131217.1	3.37	0.000776	0.0354	0.21	0.1	QRS complex (12-leadsum);	chr21:28726128	chr21:28439346~28674848:-
BRCA	cis	rs911555	0.755	rs7148567	ENSG00000269940.1	RP11-73M18.7	3.37	0.000776	0.0354	0.11	0.1	Intelligence (multi-trait analysis);	chr14:103415897	chr14:103694560~103695170:+
BRCA	cis	rs911555	0.755	rs10144051	ENSG00000269940.1	RP11-73M18.7	3.37	0.000776	0.0354	0.11	0.1	Intelligence (multi-trait analysis);	chr14:103419594	chr14:103694560~103695170:+
BRCA	cis	rs2189234	0.507	rs10010325	ENSG00000250522.1	AC004066.3	3.37	0.000776	0.0354	0.09	0.1	Inflammatory bowel disease;Ulcerative colitis;	chr4:105185196	chr4:105540190~105552355:-
BRCA	cis	rs9309473	0.607	rs6546826	ENSG00000230002.2	ALMS1-IT1	-3.37	0.000776	0.0354	-0.12	-0.1	Metabolite levels;	chr2:73372680	chr2:73456764~73459484:+
BRCA	cis	rs11035577	0.632	rs6485143	ENSG00000279675.1	RP11-454H19.2	-3.37	0.000776	0.0354	-0.16	-0.1	Temperament (bipolar disorder);	chr11:39768934	chr11:40107244~40112599:-
BRCA	cis	rs11035577	0.632	rs10837256	ENSG00000279675.1	RP11-454H19.2	-3.37	0.000776	0.0354	-0.16	-0.1	Temperament (bipolar disorder);	chr11:39769076	chr11:40107244~40112599:-
BRCA	cis	rs11035577	0.632	rs4756531	ENSG00000279675.1	RP11-454H19.2	-3.37	0.000776	0.0354	-0.16	-0.1	Temperament (bipolar disorder);	chr11:39769282	chr11:40107244~40112599:-
BRCA	cis	rs11035577	0.632	rs4756533	ENSG00000279675.1	RP11-454H19.2	-3.37	0.000776	0.0354	-0.16	-0.1	Temperament (bipolar disorder);	chr11:39769588	chr11:40107244~40112599:-
BRCA	cis	rs10256972	0.758	rs9801444	ENSG00000199023.2	MIR339	3.37	0.000777	0.0354	0.13	0.1	Endometriosis;Longevity;	chr7:1040808	chr7:1022935~1023045:-
BRCA	cis	rs934734	0.736	rs7559283	ENSG00000204929.10	AC074391.1	3.37	0.000777	0.0354	0.13	0.1	Rheumatoid arthritis;	chr2:65351234	chr2:65436711~66084639:+
BRCA	cis	rs863345	0.604	rs4584390	ENSG00000176320.2	RP11-404O13.5	-3.37	0.000777	0.0354	-0.11	-0.1	Pneumococcal bacteremia;	chr1:158536185	chr1:158197922~158203877:-
BRCA	cis	rs1144333	1	rs2202019	ENSG00000181227.3	RP4-682C21.2	-3.37	0.000777	0.0354	-0.15	-0.1	Attention function in attention deficit hyperactive disorder;	chr1:75833496	chr1:75743423~75744776:-
BRCA	cis	rs1401999	0.836	rs34571027	ENSG00000223882.1	ABCC5-AS1	-3.37	0.000777	0.0354	-0.12	-0.1	Anterior chamber depth;	chr3:184008856	chr3:184006338~184011419:+
BRCA	cis	rs863345	0.604	rs1157524	ENSG00000176320.2	RP11-404O13.5	-3.37	0.000777	0.0354	-0.11	-0.1	Pneumococcal bacteremia;	chr1:158487508	chr1:158197922~158203877:-
BRCA	cis	rs4718428	1	rs1830070	ENSG00000106610.13	STAG3L4	3.37	0.000777	0.0354	0.14	0.1	Corneal structure;	chr7:66884684	chr7:67302621~67321526:+
BRCA	cis	rs2243480	1	rs313814	ENSG00000229180.5	GS1-124K5.11	3.37	0.000777	0.0354	0.15	0.1	Diabetic kidney disease;	chr7:66038306	chr7:66526088~66542624:-
BRCA	cis	rs6840360	0.567	rs6844259	ENSG00000278978.1	RP11-164P12.5	-3.37	0.000777	0.0354	-0.12	-0.1	Intelligence (multi-trait analysis);	chr4:151370032	chr4:151669786~151670503:+
BRCA	cis	rs875971	0.964	rs778708	ENSG00000229886.1	RP5-1132H15.3	3.37	0.000777	0.0354	0.11	0.1	Aortic root size;	chr7:66391332	chr7:66025126~66031544:-
BRCA	cis	rs10819861	0.645	rs12686105	ENSG00000175611.10	LINC00476	3.37	0.000777	0.0354	0.11	0.1	Electrocardiographic traits;	chr9:96090021	chr9:95759231~95875977:-
BRCA	cis	rs6918586	0.658	rs198844	ENSG00000272462.2	U91328.19	-3.37	0.000777	0.0354	-0.12	-0.1	Schizophrenia;	chr6:26108054	chr6:25992662~26001775:+
BRCA	cis	rs7487075	0.554	rs7960819	ENSG00000274723.1	RP11-618L22.1	3.37	0.000777	0.0354	0.12	0.1	Itch intensity from mosquito bite;	chr12:46234999	chr12:46970504~46972155:+
BRCA	cis	rs7487075	0.554	rs7957777	ENSG00000274723.1	RP11-618L22.1	3.37	0.000777	0.0354	0.12	0.1	Itch intensity from mosquito bite;	chr12:46235006	chr12:46970504~46972155:+
BRCA	cis	rs6001482	0.686	rs9623125	ENSG00000253818.1	IGLV1-41	-3.37	0.000777	0.0354	-0.1	-0.1	Diastolic blood pressure;	chr22:22234600	chr22:22404207~22404721:+
BRCA	cis	rs6001482	0.702	rs9623126	ENSG00000253818.1	IGLV1-41	-3.37	0.000777	0.0354	-0.1	-0.1	Diastolic blood pressure;	chr22:22234624	chr22:22404207~22404721:+
BRCA	cis	rs9323205	0.577	rs9672038	ENSG00000277050.1	RP11-102G14.1	3.37	0.000777	0.0354	0.1	0.1	Cancer;	chr14:51258138	chr14:51637348~51637947:-
BRCA	cis	rs13434995	0.513	rs550144	ENSG00000273257.1	RP11-177J6.1	3.37	0.000777	0.0354	0.15	0.1	Adiponectin levels;	chr4:55415317	chr4:55387949~55388271:+
BRCA	cis	rs3099143	1	rs3102712	ENSG00000196274.5	Metazoa_SRP	3.37	0.000777	0.0354	0.15	0.1	Recalcitrant atopic dermatitis;	chr15:76766585	chr15:76230048~76230390:-
BRCA	cis	rs2832191	0.692	rs2245517	ENSG00000236056.1	GAPDHP14	-3.37	0.000778	0.0354	-0.12	-0.1	Dental caries;	chr21:28985647	chr21:29222321~29223257:+
BRCA	cis	rs7944584	1	rs7944584	ENSG00000200376.1	RNU5E-10P	3.37	0.000778	0.0354	0.14	0.1	Fasting blood glucose;Fasting blood glucose (BMI interaction);	chr11:47314769	chr11:47576471~47576588:-
BRCA	cis	rs9341808	0.718	rs910266	ENSG00000279022.1	RP11-250B2.4	3.37	0.000778	0.0354	0.12	0.1	Sitting height ratio;	chr6:80211453	chr6:80440730~80441172:+
BRCA	cis	rs2075671	0.903	rs11983334	ENSG00000208036.1	MIR106B	3.37	0.000778	0.0354	0.14	0.1	Other erythrocyte phenotypes;	chr7:100704811	chr7:100093993~100094074:-
BRCA	cis	rs8098244	1	rs1941521	ENSG00000273321.1	RP11-621L6.3	-3.37	0.000778	0.0354	-0.12	-0.1	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23824370	chr18:24402153~24402714:+
BRCA	cis	rs1401543	0.947	rs7646013	ENSG00000273486.1	RP11-731C17.2	-3.37	0.000778	0.0354	-0.13	-0.1	Anticoagulant levels;	chr3:135842873	chr3:136837338~136839021:-
BRCA	cis	rs2416257	0.673	rs72784253	ENSG00000249619.1	HMGN1P13	3.37	0.000778	0.0354	0.17	0.1	Eosinophil counts;	chr5:111131699	chr5:111572102~111572239:-
BRCA	cis	rs4660214	0.666	rs7554206	ENSG00000243970.1	PPIEL	-3.37	0.000778	0.0354	-0.13	-0.1	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39463568	chr1:39531838~39558707:-
BRCA	cis	rs17822114	0.609	rs4785115	ENSG00000224631.4	RP11-51O6.1	-3.37	0.000778	0.0354	-0.15	-0.1	Myopia (pathological);	chr16:60501034	chr16:61055399~61055964:-
BRCA	cis	rs3735485	0.678	rs113572217	ENSG00000201772.1	SNORA5C	3.37	0.000778	0.0354	0.13	0.1	White blood cell count;Sum basophil neutrophil counts;Neutrophil count;Granulocyte percentage of myeloid white cells;Monocyte percentage of white cells;Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Lymphocyte counts;	chr7:45059177	chr7:45104906~45105042:-
BRCA	cis	rs11175492	1	rs11175500	ENSG00000243024.5	RPS11P6	-3.37	0.000778	0.0354	-0.22	-0.1	Platelet count;	chr12:64648050	chr12:64222337~64397065:+
BRCA	cis	rs11888559	0.655	rs2247094	ENSG00000232479.2	AC010900.2	-3.37	0.000778	0.0354	-0.24	-0.1	Height;	chr2:203442443	chr2:202924609~202925904:+
BRCA	cis	rs8058578	1	rs2289442	ENSG00000275263.1	RP11-1072A3.4	-3.37	0.000778	0.0354	-0.13	-0.1	Multiple myeloma;	chr16:30728598	chr16:30956872~30957199:-
BRCA	cis	rs7615952	0.543	rs4645102	ENSG00000171084.14	FAM86JP	3.37	0.000778	0.0354	0.16	0.1	Blood pressure (smoking interaction);	chr3:125705597	chr3:125916620~125930024:+
BRCA	cis	rs7688540	0.8	rs6857106	ENSG00000250892.1	RP11-1365D11.1	3.37	0.000778	0.0354	0.14	0.1	Facial morphology (factor 6, height of vermillion lower lip);	chr4:255641	chr4:201409~205009:-
BRCA	cis	rs4950322	0.58	rs4950371	ENSG00000237188.3	RP11-337C18.8	3.37	0.000778	0.0354	0.13	0.1	Protein quantitative trait loci;	chr1:147114243	chr1:147172771~147211568:+
BRCA	cis	rs4363385	0.53	rs10888529	ENSG00000231416.1	RP11-422P24.9	3.37	0.000778	0.0354	0.11	0.1	Inflammatory skin disease;	chr1:153078178	chr1:153995632~153995960:+
BRCA	cis	rs5167	0.566	rs2075618	ENSG00000214855.8	APOC1P1	3.37	0.000778	0.0354	0.14	0.1	Blood protein levels;	chr19:44992410	chr19:44926804~44931386:+
BRCA	cis	rs6088580	0.634	rs6059851	ENSG00000269202.1	RP4-614O4.12	-3.37	0.000778	0.0354	-0.1	-0.1	Glomerular filtration rate (creatinine);	chr20:34460140	chr20:35201747~35203288:-
BRCA	cis	rs7045881	0.576	rs7857669	ENSG00000254396.1	RP11-56F10.3	-3.37	0.000778	0.0354	-0.13	-0.1	Schizophrenia;	chr9:27032387	chr9:27102630~27104728:+
BRCA	cis	rs10876993	0.89	rs812304	ENSG00000270039.1	RP11-571M6.17	3.37	0.000778	0.0354	0.14	0.1	Celiac disease or Rheumatoid arthritis;	chr12:57681070	chr12:57803838~57804415:+
BRCA	cis	rs10876993	0.89	rs810204	ENSG00000270039.1	RP11-571M6.17	3.37	0.000778	0.0354	0.14	0.1	Celiac disease or Rheumatoid arthritis;	chr12:57681950	chr12:57803838~57804415:+
BRCA	cis	rs10129255	0.957	rs10132367	ENSG00000253936.1	IGHV3-63	3.37	0.000779	0.0354	0.09	0.1	Kawasaki disease;	chr14:106690981	chr14:106652237~106652681:-
BRCA	cis	rs17711722	0.701	rs781145	ENSG00000229180.5	GS1-124K5.11	3.37	0.000779	0.0354	0.09	0.1	Calcium levels;	chr7:65975383	chr7:66526088~66542624:-
BRCA	cis	rs875971	0.522	rs1701760	ENSG00000273142.1	RP11-458F8.4	-3.37	0.000779	0.0354	-0.09	-0.1	Aortic root size;	chr7:66008701	chr7:66902857~66906297:+
BRCA	cis	rs9467773	1	rs9467783	ENSG00000224843.5	LINC00240	-3.37	0.000779	0.0354	-0.11	-0.1	Intelligence (multi-trait analysis);	chr6:26542666	chr6:26956992~27023924:+
BRCA	cis	rs1424638	0.655	rs6740263	ENSG00000233251.6	AC007743.1	-3.37	0.000779	0.0354	-0.12	-0.1	Intelligence (multi-trait analysis);	chr2:57023977	chr2:56173534~56185770:-
BRCA	cis	rs9388451	0.626	rs1935983	ENSG00000237742.5	RP11-624M8.1	-3.37	0.000779	0.0354	-0.13	-0.1	Brugada syndrome;	chr6:125747768	chr6:125578558~125749190:-
BRCA	cis	rs3096490	0.513	rs1648012	ENSG00000225094.3	SETP20	-3.37	0.000779	0.0354	-0.12	-0.1	Body mass index;	chr4:109006877	chr4:109553243~109554094:-
BRCA	cis	rs6695567	0.528	rs12140961	ENSG00000226754.1	RP5-1024G6.5	-3.37	0.000779	0.0355	-0.12	-0.1	Systemic lupus erythematosus;	chr1:53165357	chr1:53238610~53242783:+
BRCA	cis	rs343496	0.877	rs340921	ENSG00000254017.1	IGHEP2	3.37	0.000779	0.0355	0.15	0.1	Asthma and hay fever;	chr9:6090160	chr9:5113549~5114804:+
BRCA	cis	rs977987	0.806	rs11865004	ENSG00000280152.1	RP11-331F4.5	-3.37	0.000779	0.0355	-0.11	-0.1	Dupuytren's disease;	chr16:75361879	chr16:75245994~75250077:-
BRCA	cis	rs77926410	0.613	rs35318826	ENSG00000256667.5	KLRAP1	-3.37	0.000779	0.0355	-0.13	-0.1	Mean corpuscular volume;	chr12:10458982	chr12:10588063~10599669:-
BRCA	cis	rs1555133	0.694	rs6141707	ENSG00000275576.1	RP5-836N17.4	-3.37	0.000779	0.0355	-0.12	-0.1	Monocyte count;	chr20:32407315	chr20:32116171~32116629:+
BRCA	cis	rs739401	0.611	rs7109088	ENSG00000247473.2	CARS-AS1	3.37	0.000779	0.0355	0.12	0.1	Longevity;	chr11:3006255	chr11:3029009~3041260:+
BRCA	cis	rs853679	0.517	rs1340004	ENSG00000272009.1	RP1-313I6.12	-3.37	0.000779	0.0355	-0.15	-0.1	Depression;	chr6:28135913	chr6:28078792~28081130:-
BRCA	cis	rs345013	1	rs11716508	ENSG00000240032.1	RP11-274H2.3	3.37	0.000779	0.0355	0.18	0.1	Prostate cancer;	chr3:145349913	chr3:146066344~146069185:-
BRCA	cis	rs9646944	0.501	rs12991737	ENSG00000234389.1	AC007278.3	3.37	0.000779	0.0355	0.12	0.1	Blood protein levels;	chr2:102401668	chr2:102438713~102440475:+
BRCA	cis	rs950169	0.58	rs17598114	ENSG00000230373.7	GOLGA6L5P	-3.37	0.000779	0.0355	-0.13	-0.1	Schizophrenia;	chr15:84628086	chr15:84507885~84516814:-
BRCA	cis	rs4578769	0.729	rs12456875	ENSG00000273232.1	RP11-370A5.2	-3.37	0.000779	0.0355	-0.15	-0.1	Eosinophil percentage of white cells;	chr18:22830208	chr18:22882825~22883357:-
BRCA	cis	rs28374715	0.662	rs28827035	ENSG00000247556.5	OIP5-AS1	3.37	0.000779	0.0355	0.12	0.1	Ulcerative colitis;	chr15:41200092	chr15:41283990~41309737:+
BRCA	cis	rs1437396	0.632	rs2589103	ENSG00000203327.2	AC012358.7	3.37	0.000779	0.0355	0.1	0.1	Alcohol dependence;	chr2:55356261	chr2:55214387~55216126:-
BRCA	cis	rs3755021	1	rs79965377	ENSG00000260742.1	RP11-366L5.1	3.37	0.000779	0.0355	0.15	0.1	Monocyte-lymphocyte ratio;	chr2:181486445	chr2:181887851~181891663:-
BRCA	cis	rs321358	0.731	rs580656	ENSG00000271390.1	RP11-89C3.3	3.37	0.000779	0.0355	0.16	0.1	Body mass index;	chr11:111141436	chr11:111089870~111090368:-
BRCA	cis	rs9535495	0.833	rs7320482	ENSG00000237152.3	DLEU7-AS1	-3.37	0.000779	0.0355	-0.13	-0.1	High light scatter reticulocyte count;Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;	chr13:50793353	chr13:50807856~50849905:+
BRCA	cis	rs2921073	0.605	rs2976933	ENSG00000254153.1	CTA-398F10.2	3.37	0.000779	0.0355	0.13	0.1	Parkinson's disease;	chr8:8397365	chr8:8456909~8461337:-
BRCA	cis	rs2243480	1	rs1723269	ENSG00000237026.1	RP11-328P23.2	3.37	0.000779	0.0355	0.19	0.1	Diabetic kidney disease;	chr7:66007799	chr7:65235790~65236723:-
BRCA	cis	rs875971	1	rs2087647	ENSG00000230189.5	GS1-124K5.2	-3.37	0.000779	0.0355	-0.08	-0.1	Aortic root size;	chr7:66128201	chr7:66409143~66490059:-
BRCA	cis	rs2617170	0.725	rs2734436	ENSG00000256039.1	RP11-291B21.2	-3.37	0.00078	0.0355	-0.09	-0.1	Behcet's disease;	chr12:10454521	chr12:10553363~10558049:+
BRCA	cis	rs2904967	0.778	rs77130160	ENSG00000254501.1	AP003068.9	3.37	0.00078	0.0355	0.25	0.1	Mean corpuscular volume;	chr11:65355223	chr11:65110714~65111695:-
BRCA	cis	rs8040855	1	rs6496768	ENSG00000230373.7	GOLGA6L5P	-3.37	0.00078	0.0355	-0.11	-0.1	Bulimia nervosa;	chr15:85159701	chr15:84507885~84516814:-
BRCA	cis	rs1348850	0.914	rs9789582	ENSG00000271825.1	RP11-337N6.2	3.37	0.00078	0.0355	0.13	0.1	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177465445	chr2:177300600~177302006:+
BRCA	cis	rs13126694	0.75	rs6833295	ENSG00000251073.1	NUDT19P5	3.37	0.00078	0.0355	0.1	0.1	Blood osmolality (transformed sodium);	chr4:158143520	chr4:158182825~158183393:+
BRCA	cis	rs962856	0.537	rs623457	ENSG00000236780.4	AC078941.1	-3.37	0.00078	0.0355	-0.13	-0.1	Pancreatic cancer;	chr2:67454959	chr2:67123357~67215319:-
BRCA	cis	rs1424638	0.655	rs2865289	ENSG00000233251.6	AC007743.1	-3.37	0.00078	0.0355	-0.12	-0.1	Intelligence (multi-trait analysis);	chr2:57016137	chr2:56173534~56185770:-
BRCA	cis	rs511515	1	rs511515	ENSG00000237398.1	HLA-DPA3	-3.37	0.00078	0.0355	-0.12	-0.1	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr6:33573730	chr6:33131216~33143325:-
BRCA	cis	rs875971	0.862	rs10261398	ENSG00000223473.2	GS1-124K5.3	-3.37	0.00078	0.0355	-0.08	-0.1	Aortic root size;	chr7:66285177	chr7:66491049~66493566:-
BRCA	cis	rs875971	0.862	rs10224872	ENSG00000223473.2	GS1-124K5.3	-3.37	0.00078	0.0355	-0.08	-0.1	Aortic root size;	chr7:66294786	chr7:66491049~66493566:-
BRCA	cis	rs224278	0.531	rs7905229	ENSG00000238280.1	RP11-436D10.3	-3.37	0.00078	0.0355	-0.15	-0.1	Ewing sarcoma;	chr10:62883743	chr10:62793562~62805887:-
BRCA	cis	rs783540	0.869	rs783521	ENSG00000255769.6	GOLGA2P10	3.37	0.00078	0.0355	0.11	0.1	Schizophrenia;	chr15:82611694	chr15:82472993~82513950:-
BRCA	cis	rs783540	0.835	rs783522	ENSG00000255769.6	GOLGA2P10	3.37	0.00078	0.0355	0.11	0.1	Schizophrenia;	chr15:82611862	chr15:82472993~82513950:-
BRCA	cis	rs686320	0.666	rs11605125	ENSG00000245532.5	NEAT1	3.37	0.00078	0.0355	0.13	0.1	Hip circumference adjusted for BMI;	chr11:65443548	chr11:65422774~65445540:+
BRCA	cis	rs7713065	0.765	rs10062371	ENSG00000202533.1	Y_RNA	-3.37	0.00078	0.0355	-0.11	-0.1	Lung function (FEV1/FVC);	chr5:132442721	chr5:132468147~132468257:+
BRCA	cis	rs2834655	0.773	rs2252175	ENSG00000237945.6	LINC00649	3.37	0.00078	0.0355	0.14	0.1	Immune response to smallpox vaccine (IL-6);	chr21:34865902	chr21:33915534~33977691:+
BRCA	cis	rs12681366	0.734	rs16916802	ENSG00000253175.1	RP11-267M23.6	3.37	0.00078	0.0355	0.12	0.1	Nonsyndromic cleft lip with cleft palate;	chr8:94397280	chr8:94565036~94565715:+
BRCA	cis	rs258892	0.842	rs34956	ENSG00000272525.1	RP11-79P5.9	3.37	0.00078	0.0355	0.13	0.1	Small cell lung carcinoma;	chr5:72907869	chr5:73497550~73498293:-
BRCA	cis	rs9341808	0.754	rs3805925	ENSG00000279022.1	RP11-250B2.4	3.37	0.00078	0.0355	0.12	0.1	Sitting height ratio;	chr6:80174116	chr6:80440730~80441172:+
BRCA	cis	rs9863	0.861	rs11057396	ENSG00000270028.1	RP11-380L11.4	3.37	0.00078	0.0355	0.14	0.1	White blood cell count;	chr12:123934515	chr12:123925461~123926083:-
BRCA	cis	rs10967586	0.622	rs17756299	ENSG00000254396.1	RP11-56F10.3	3.37	0.00078	0.0355	0.21	0.1	Schizophrenia;	chr9:27009740	chr9:27102630~27104728:+
BRCA	cis	rs8114671	0.562	rs6088647	ENSG00000279253.1	RP4-614O4.13	-3.37	0.00078	0.0355	-0.12	-0.1	Height;	chr20:34918194	chr20:35262727~35264187:-
BRCA	cis	rs8114671	0.562	rs2223881	ENSG00000279253.1	RP4-614O4.13	-3.37	0.00078	0.0355	-0.12	-0.1	Height;	chr20:34918660	chr20:35262727~35264187:-
BRCA	cis	rs4578769	0.959	rs9945114	ENSG00000273232.1	RP11-370A5.2	3.37	0.00078	0.0355	0.14	0.1	Eosinophil percentage of white cells;	chr18:22884044	chr18:22882825~22883357:-
BRCA	cis	rs10191559	0.552	rs4667162	ENSG00000234663.4	AC104820.2	3.37	0.00078	0.0355	0.09	0.1	Red blood cell count;	chr2:181231032	chr2:181101932~181399559:+
BRCA	cis	rs10191559	0.552	rs13008615	ENSG00000234663.4	AC104820.2	3.37	0.00078	0.0355	0.09	0.1	Red blood cell count;	chr2:181231453	chr2:181101932~181399559:+
BRCA	cis	rs10208649	0.831	rs75123794	ENSG00000272156.1	RP11-477N3.1	3.37	0.00078	0.0355	0.23	0.1	Body mass index;	chr2:53684845	chr2:54082554~54085066:+
BRCA	cis	rs7267979	1	rs6050598	ENSG00000204556.4	CTD-2514C3.1	-3.37	0.00078	0.0355	-0.14	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25416621	chr20:26018832~26020684:+
BRCA	cis	rs28374715	0.662	rs8038983	ENSG00000247556.5	OIP5-AS1	3.37	0.00078	0.0355	0.12	0.1	Ulcerative colitis;	chr15:41181118	chr15:41283990~41309737:+
BRCA	cis	rs911555	0.713	rs10162425	ENSG00000269958.1	RP11-73M18.8	3.37	0.00078	0.0355	0.11	0.1	Intelligence (multi-trait analysis);	chr14:103465284	chr14:103696353~103697163:+
BRCA	cis	rs875971	1	rs6958271	ENSG00000273024.4	INTS4P2	-3.37	0.00078	0.0355	-0.11	-0.1	Aortic root size;	chr7:66514344	chr7:65647864~65715661:+
BRCA	cis	rs875971	1	rs6958277	ENSG00000273024.4	INTS4P2	-3.37	0.00078	0.0355	-0.11	-0.1	Aortic root size;	chr7:66514362	chr7:65647864~65715661:+
BRCA	cis	rs6771316	1	rs12631016	ENSG00000241163.6	LINC00877	-3.37	0.000781	0.0355	-0.15	-0.1	Venous thromboembolism (SNP x SNP interaction);	chr3:72081051	chr3:72035300~72279503:-
BRCA	cis	rs61931739	0.5	rs11524949	ENSG00000258794.3	DUX4L27	3.37	0.000781	0.0355	0.15	0.1	Morning vs. evening chronotype;	chr12:34282616	chr12:34208415~34209675:-
BRCA	cis	rs863345	0.604	rs11264991	ENSG00000176320.2	RP11-404O13.5	-3.37	0.000781	0.0355	-0.11	-0.1	Pneumococcal bacteremia;	chr1:158503071	chr1:158197922~158203877:-
BRCA	cis	rs10129255	0.957	rs2007467	ENSG00000211958.2	IGHV3-38	-3.37	0.000781	0.0355	-0.08	-0.1	Kawasaki disease;	chr14:106771605	chr14:106410493~106411021:-
BRCA	cis	rs848490	0.851	rs62462686	ENSG00000214293.7	APTR	3.37	0.000781	0.0355	0.14	0.1	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77879330	chr7:77657660~77696265:-
BRCA	cis	rs7044106	0.664	rs7861679	ENSG00000270917.1	RP11-27I1.6	3.37	0.000781	0.0355	0.14	0.1	Hip circumference adjusted for BMI;	chr9:120613311	chr9:120812475~120812845:-
BRCA	cis	rs13287066	0.967	rs7870079	ENSG00000203364.2	RP11-370F5.4	3.37	0.000781	0.0355	0.11	0.1	Intelligence (multi-trait analysis);	chr9:93399018	chr9:93147040~93148556:+
BRCA	cis	rs56046484	0.913	rs17611290	ENSG00000259630.2	CTD-2262B20.1	-3.37	0.000781	0.0355	-0.18	-0.1	Testicular germ cell tumor;	chr15:85031188	chr15:85415228~85415633:+
BRCA	cis	rs56046484	0.913	rs12906544	ENSG00000259630.2	CTD-2262B20.1	-3.37	0.000781	0.0355	-0.18	-0.1	Testicular germ cell tumor;	chr15:85032832	chr15:85415228~85415633:+
BRCA	cis	rs12477438	0.501	rs9941561	ENSG00000231822.1	AC019097.7	3.37	0.000781	0.0355	0.11	0.1	Chronic sinus infection;	chr2:99137366	chr2:99102018~99102752:+
BRCA	cis	rs66887589	0.66	rs4833613	ENSG00000260091.1	RP11-33B1.4	3.37	0.000781	0.0355	0.08	0.1	Diastolic blood pressure;	chr4:119229001	chr4:119409333~119410233:+
BRCA	cis	rs943466	1	rs747692	ENSG00000223837.2	BRD2-IT1	3.37	0.000781	0.0355	0.13	0.1	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;	chr6:33769659	chr6:32970232~32970886:+
BRCA	cis	rs654950	0.776	rs2759254	ENSG00000230638.4	RP11-486B10.4	3.37	0.000781	0.0355	0.14	0.1	Airway imaging phenotypes;	chr1:41570012	chr1:41542069~41544310:+
BRCA	cis	rs2262909	0.849	rs10420483	ENSG00000279377.1	AC003973.3	3.37	0.000781	0.0355	0.15	0.1	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;	chr19:22007576	chr19:21965708~21968529:-
BRCA	cis	rs875971	0.862	rs6971059	ENSG00000265600.1	AC006480.1	3.37	0.000781	0.0355	0.13	0.1	Aortic root size;	chr7:66602045	chr7:67356680~67356779:+
BRCA	cis	rs3820068	0.58	rs7512308	ENSG00000237301.1	RP4-680D5.2	-3.37	0.000781	0.0355	-0.14	-0.1	Systolic blood pressure;	chr1:15680109	chr1:15586136~15603626:-
BRCA	cis	rs60843830	1	rs6709534	ENSG00000223751.1	AC116609.2	3.37	0.000781	0.0355	0.14	0.1	Spherical equivalent (joint analysis main effects and education interaction);	chr2:217334	chr2:742488~747767:+
BRCA	cis	rs1023500	0.505	rs134874	ENSG00000273366.1	CTA-989H11.1	-3.37	0.000781	0.0355	-0.12	-0.1	Schizophrenia;	chr22:42265138	chr22:42278188~42278846:+
BRCA	cis	rs56046484	0.956	rs34889576	ENSG00000259630.2	CTD-2262B20.1	-3.37	0.000781	0.0355	-0.17	-0.1	Testicular germ cell tumor;	chr15:85121445	chr15:85415228~85415633:+
BRCA	cis	rs56046484	0.956	rs34076898	ENSG00000259630.2	CTD-2262B20.1	-3.37	0.000781	0.0355	-0.17	-0.1	Testicular germ cell tumor;	chr15:85121569	chr15:85415228~85415633:+
BRCA	cis	rs56046484	0.956	rs35533990	ENSG00000259630.2	CTD-2262B20.1	-3.37	0.000781	0.0355	-0.17	-0.1	Testicular germ cell tumor;	chr15:85121590	chr15:85415228~85415633:+
BRCA	cis	rs10504130	0.696	rs76522329	ENSG00000272076.1	RP11-11C20.3	3.37	0.000781	0.0355	0.16	0.1	Venous thromboembolism (SNP x SNP interaction);	chr8:51928822	chr8:51810110~51810681:-
BRCA	cis	rs1510510	0.69	rs2089758	ENSG00000186235.9	AC016757.3	-3.37	0.000781	0.0355	-0.17	-0.1	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr2:238621515	chr2:238224552~238231677:-
BRCA	cis	rs1348850	0.914	rs1348849	ENSG00000271825.1	RP11-337N6.2	3.37	0.000781	0.0355	0.13	0.1	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177493344	chr2:177300600~177302006:+
BRCA	cis	rs1348850	0.567	rs7605609	ENSG00000280374.1	RP11-337N6.3	3.37	0.000781	0.0355	0.14	0.1	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177670214	chr2:177317715~177318471:-
BRCA	cis	rs3764021	0.527	rs10844503	ENSG00000256594.6	RP11-705C15.2	3.37	0.000781	0.0355	0.14	0.1	Type 1 diabetes;	chr12:9701660	chr12:9633419~9658412:+
BRCA	cis	rs35520189	0.591	rs6723582	ENSG00000231747.1	AC079922.2	-3.37	0.000781	0.0355	-0.1	-0.1	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:112950525	chr2:112621809~112622167:-
BRCA	cis	rs875971	0.545	rs313830	ENSG00000226767.1	RP11-328P23.3	-3.37	0.000781	0.0355	-0.13	-0.1	Aortic root size;	chr7:66086944	chr7:65508773~65508944:-
BRCA	cis	rs7615952	0.575	rs35949599	ENSG00000248787.1	RP11-666A20.4	-3.37	0.000781	0.0355	-0.16	-0.1	Blood pressure (smoking interaction);	chr3:125825359	chr3:125908005~125910272:-
BRCA	cis	rs10992471	0.566	rs5003738	ENSG00000275318.1	RP11-526D8.11	-3.37	0.000781	0.0355	-0.09	-0.1	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr9:92875646	chr9:92840955~92841688:-
BRCA	cis	rs962856	0.619	rs6739471	ENSG00000236605.1	AC023115.4	3.37	0.000781	0.0355	0.14	0.1	Pancreatic cancer;	chr2:67358461	chr2:67324627~67325304:+
BRCA	cis	rs4478147	0.636	rs4640633	ENSG00000251411.1	RP11-397E7.4	-3.37	0.000781	0.0355	-0.11	-0.1	Migraine - clinic-based;	chr4:86503186	chr4:86913266~86914817:-
BRCA	cis	rs2149954	0.53	rs2988320	ENSG00000245812.2	RP11-175K6.1	3.37	0.000781	0.0355	0.1	0.1	Longevity (90 years and older);Longevity (85 years and older);	chr5:158314753	chr5:159100483~159117478:+
BRCA	cis	rs76963786	0.685	rs2800000	ENSG00000276148.1	RP11-278C7.4	-3.37	0.000781	0.0355	-0.13	-0.1	Interleukin-9 levels;	chr12:31883189	chr12:32725248~32725660:-
BRCA	cis	rs4781563	0.544	rs1646333	ENSG00000242307.1	RPS26P52	3.37	0.000781	0.0355	0.15	0.1	Bilirubin levels;	chr16:13978089	chr16:13922332~13922679:-
BRCA	cis	rs875971	0.543	rs801191	ENSG00000271064.1	RP11-792A8.3	3.37	0.000781	0.0355	0.12	0.1	Aortic root size;	chr7:66567968	chr7:66748838~66749077:-
BRCA	cis	rs10246939	0.505	rs9640203	ENSG00000270923.1	TAS2R6P	-3.37	0.000781	0.0355	-0.11	-0.1	Bitter taste perception;	chr7:141844295	chr7:141787815~141788640:+
BRCA	cis	rs7520050	0.966	rs6669522	ENSG00000226957.1	RP4-533D7.4	3.37	0.000781	0.0355	0.11	0.1	Reticulocyte count;Red blood cell count;	chr1:45932269	chr1:46046818~46048368:+
BRCA	cis	rs7781266	0.79	rs62469963	ENSG00000226205.1	AC007790.4	3.37	0.000782	0.0356	0.15	0.1	Educational attainment (college completion);	chr7:133491665	chr7:133732493~133733595:-
BRCA	cis	rs13326165	0.76	rs11714402	ENSG00000275956.1	RP5-966M1.7	3.37	0.000782	0.0356	0.15	0.1	HDL cholesterol levels;HDL cholesterol;	chr3:52357719	chr3:52732547~52733867:+
BRCA	cis	rs71520386	0.632	rs12532938	ENSG00000179428.2	AC073072.5	3.37	0.000782	0.0356	0.12	0.1	Fibrinogen levels;	chr7:22820876	chr7:22725395~22727620:-
BRCA	cis	rs8180040	0.62	rs17784127	ENSG00000260236.1	RP11-708J19.1	-3.37	0.000782	0.0356	-0.09	-0.1	Colorectal cancer;	chr3:47020210	chr3:47379089~47380999:-
BRCA	cis	rs9951698	0.728	rs35790309	ENSG00000266969.1	RP11-773H22.4	3.37	0.000782	0.0356	0.14	0.1	Intelligence (multi-trait analysis);	chr18:13026121	chr18:12984694~12991173:-
BRCA	cis	rs875971	0.862	rs1981799	ENSG00000273448.1	RP11-166O4.6	3.37	0.000782	0.0356	0.09	0.1	Aortic root size;	chr7:66490572	chr7:67333047~67334383:+
BRCA	cis	rs2744375	0.6	rs2008748	ENSG00000261189.1	RP3-512B11.3	3.37	0.000782	0.0356	0.13	0.1	Resting heart rate;	chr6:7551445	chr6:7540451~7541338:-
BRCA	cis	rs7141336	0.896	rs8009816	ENSG00000260810.1	CTD-2547L24.4	3.37	0.000782	0.0356	0.12	0.1	Anxiety disorder;	chr14:90820661	chr14:91258299~91259003:+
BRCA	cis	rs313426	0.5	rs11225866	ENSG00000260966.1	RP11-690D19.3	3.37	0.000782	0.0356	0.12	0.1	Toenail selenium levels;	chr11:103541012	chr11:103050687~103055799:-
BRCA	cis	rs875971	0.522	rs10807697	ENSG00000272831.1	RP11-792A8.4	3.37	0.000782	0.0356	0.09	0.1	Aortic root size;	chr7:65951183	chr7:66739829~66740385:-
BRCA	cis	rs7520050	0.966	rs785495	ENSG00000226957.1	RP4-533D7.4	3.37	0.000782	0.0356	0.11	0.1	Reticulocyte count;Red blood cell count;	chr1:46122215	chr1:46046818~46048368:+
BRCA	cis	rs2839186	0.9	rs2839196	ENSG00000215424.8	MCM3AP-AS1	3.37	0.000782	0.0356	0.09	0.1	Testicular germ cell tumor;	chr21:46288123	chr21:46229217~46259390:+
BRCA	cis	rs10992471	0.56	rs12685086	ENSG00000275318.1	RP11-526D8.11	3.37	0.000782	0.0356	0.1	0.1	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr9:92884838	chr9:92840955~92841688:-
BRCA	cis	rs7701440	0.512	rs7443733	ENSG00000272308.1	RP11-231G3.1	-3.37	0.000782	0.0356	-0.11	-0.1	Educational attainment;	chr5:61238155	chr5:60866457~60866935:-
BRCA	cis	rs10420951	0.617	rs79888481	ENSG00000243455.3	RPS18P13	-3.37	0.000782	0.0356	-0.16	-0.1	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr19:18459147	chr19:18048637~18049090:+
BRCA	cis	rs10986311	0.708	rs34011920	ENSG00000227200.1	RP11-121A14.3	-3.37	0.000783	0.0356	-0.14	-0.1	Vitiligo;	chr9:124265133	chr9:124262876~124265809:+
BRCA	cis	rs1075265	0.584	rs10164409	ENSG00000272156.1	RP11-477N3.1	-3.37	0.000783	0.0356	-0.11	-0.1	Chronotype;Morning vs. evening chronotype;	chr2:53940867	chr2:54082554~54085066:+
BRCA	cis	rs2280018	0.963	rs4985147	ENSG00000258354.1	MIR3180-1	-3.37	0.000783	0.0356	-0.13	-0.1	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15074903	chr16:14909887~14911345:-
BRCA	cis	rs897984	0.511	rs7196726	ENSG00000232748.3	RP11-196G11.6	-3.37	0.000783	0.0356	-0.12	-0.1	Dementia with Lewy bodies;	chr16:31080754	chr16:31056460~31062803:+
BRCA	cis	rs55863869	0.748	rs2291312	ENSG00000271401.1	RP11-171I2.3	3.37	0.000783	0.0356	0.2	0.1	QT interval;	chr2:178766487	chr2:178644717~178645179:+
BRCA	cis	rs80028505	0.908	rs7761118	ENSG00000271304.1	DPRXP2	3.37	0.000783	0.0356	0.18	0.1	Foot ulcer in diabetes and neuropathy;	chr6:36100526	chr6:35989515~35990436:-
BRCA	cis	rs6728642	1	rs113934577	ENSG00000279791.1	RP11-499E14.1	-3.37	0.000783	0.0356	-0.22	-0.1	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:97222310	chr2:97094935~97097433:+
BRCA	cis	rs67180937	0.553	rs2936023	ENSG00000225265.1	TAF1A-AS1	-3.37	0.000783	0.0356	-0.13	-0.1	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222656989	chr1:222589825~222593032:+
BRCA	cis	rs11723261	0.621	rs6599306	ENSG00000250892.1	RP11-1365D11.1	3.37	0.000783	0.0356	0.18	0.1	Immune response to smallpox vaccine (IL-6);	chr4:149655	chr4:201409~205009:-
BRCA	cis	rs3790268	0.527	rs6112466	ENSG00000275142.1	RP5-999L4.2	3.37	0.000783	0.0356	0.18	0.1	Matrix metalloproteinase levels;	chr20:19574059	chr20:19871891~19872284:+
BRCA	cis	rs867529	0.924	rs1913671	ENSG00000234028.3	AC062029.1	3.37	0.000783	0.0356	0.11	0.1	Height;	chr2:88600365	chr2:88627539~88631821:+
BRCA	cis	rs3764021	0.527	rs10844380	ENSG00000260423.1	RP13-735L24.1	-3.37	0.000783	0.0356	-0.12	-0.1	Type 1 diabetes;	chr12:9670678	chr12:9367464~9397617:+
BRCA	cis	rs36051895	0.664	rs11788834	ENSG00000237711.1	RP11-39K24.13	-3.37	0.000783	0.0356	-0.13	-0.1	Pediatric autoimmune diseases;	chr9:5092466	chr9:5100236~5101009:+
BRCA	cis	rs5742933	1	rs7557519	ENSG00000253559.1	OSGEPL1-AS1	-3.37	0.000783	0.0356	-0.14	-0.1	Ferritin levels;	chr2:189718461	chr2:189762704~189765556:+
BRCA	cis	rs754133	0.964	rs4759318	ENSG00000248265.1	FLJ12825	3.37	0.000783	0.0356	0.13	0.1	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);	chr12:54026314	chr12:54058254~54122234:+
BRCA	cis	rs12468226	0.938	rs57571703	ENSG00000272966.1	RP11-686O6.1	3.37	0.000783	0.0356	0.17	0.1	Urate levels;	chr2:202281997	chr2:202336739~202337200:+
BRCA	cis	rs12468226	0.938	rs77062060	ENSG00000272966.1	RP11-686O6.1	3.37	0.000783	0.0356	0.17	0.1	Urate levels;	chr2:202285639	chr2:202336739~202337200:+
BRCA	cis	rs4950322	0.57	rs11800580	ENSG00000237188.3	RP11-337C18.8	-3.37	0.000783	0.0356	-0.13	-0.1	Protein quantitative trait loci;	chr1:147261053	chr1:147172771~147211568:+
BRCA	cis	rs853679	0.517	rs6922063	ENSG00000272009.1	RP1-313I6.12	-3.37	0.000783	0.0356	-0.15	-0.1	Depression;	chr6:28126588	chr6:28078792~28081130:-
BRCA	cis	rs853679	0.517	rs2275508	ENSG00000272009.1	RP1-313I6.12	-3.37	0.000783	0.0356	-0.15	-0.1	Depression;	chr6:28126953	chr6:28078792~28081130:-
BRCA	cis	rs7267979	0.816	rs6115094	ENSG00000125804.12	FAM182A	-3.37	0.000783	0.0356	-0.14	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25230191	chr20:26054655~26086917:+
BRCA	cis	rs801193	0.569	rs10950050	ENSG00000271064.1	RP11-792A8.3	-3.37	0.000784	0.0356	-0.12	-0.1	Aortic root size;	chr7:66774601	chr7:66748838~66749077:-
BRCA	cis	rs7620503	0.921	rs7620560	ENSG00000228561.2	RP11-114M1.1	3.37	0.000784	0.0356	0.12	0.1	Corneal structure;	chr3:177586388	chr3:177683627~177691250:+
BRCA	cis	rs7824557	0.564	rs13260727	ENSG00000248896.2	CTD-2135J3.3	3.37	0.000784	0.0356	0.13	0.1	Retinal vascular caliber;	chr8:11375351	chr8:10729314~10771392:+
BRCA	cis	rs17197037	0.545	rs8009616	ENSG00000277734.3	TRAC	-3.37	0.000784	0.0356	-0.07	-0.1	Bipolar disorder;	chr14:21318241	chr14:22281105~22552155:+
BRCA	cis	rs6142618	0.562	rs6061206	ENSG00000275576.1	RP5-836N17.4	-3.37	0.000784	0.0356	-0.12	-0.1	Inflammatory bowel disease;	chr20:32174169	chr20:32116171~32116629:+
BRCA	cis	rs7586085	0.868	rs1968293	ENSG00000229195.1	AC009495.4	-3.37	0.000784	0.0356	-0.12	-0.1	Total body bone mineral density;	chr2:165761147	chr2:165794857~165846091:-
BRCA	cis	rs17345786	1	rs58907984	ENSG00000256628.3	ZBTB11-AS1	3.37	0.000784	0.0356	0.14	0.1	Colonoscopy-negative controls vs population controls;	chr3:101586326	chr3:101676475~101679217:+
BRCA	cis	rs10754283	0.557	rs1215511	ENSG00000231613.1	RP5-943J3.1	3.37	0.000784	0.0356	0.12	0.1	Amyotrophic lateral sclerosis (sporadic);	chr1:89621984	chr1:89788914~89790492:+
BRCA	cis	rs9402743	0.632	rs4896178	ENSG00000231028.7	LINC00271	-3.37	0.000784	0.0356	-0.11	-0.1	Systemic lupus erythematosus;	chr6:135783957	chr6:135497801~135716055:+
BRCA	cis	rs932316	0.825	rs56034365	ENSG00000272402.1	RP1-30M3.6	-3.37	0.000784	0.0356	-0.15	-0.1	Iron status biomarkers;	chr6:25658352	chr6:24706747~24707151:+
BRCA	cis	rs3018066	0.867	rs6843331	ENSG00000249635.1	RP11-710F7.3	3.37	0.000784	0.0356	0.12	0.1	Cancer;	chr4:106037147	chr4:106003317~106022478:-
BRCA	cis	rs77457752	0.73	rs17191861	ENSG00000270547.4	LINC01235	3.37	0.000784	0.0356	0.18	0.1	Breast cancer;	chr9:13925425	chr9:13406380~13433053:-
BRCA	cis	rs10198628	1	rs7572835	ENSG00000264370.1	MIR3125	-3.37	0.000784	0.0356	-0.12	-0.1	Pericardial fat;Pericardial adipose tissue adjusted for height and weight;	chr2:12826380	chr2:12737367~12737444:+
BRCA	cis	rs7405404	0.672	rs8046122	ENSG00000276564.1	CTA-276F8.1	3.37	0.000784	0.0356	0.12	0.1	Bipolar disorder lithium response (categorical) or schizophrenia;Schizophrenia;	chr16:13645789	chr16:14150833~14153235:+
BRCA	cis	rs2337406	1	rs17113257	ENSG00000211970.3	IGHV4-61	3.37	0.000784	0.0356	0.09	0.1	Alzheimer's disease (late onset);	chr14:106679574	chr14:106639119~106639657:-
BRCA	cis	rs6088590	0.61	rs6120663	ENSG00000275784.1	RP5-1125A11.6	3.37	0.000784	0.0356	0.12	0.1	Coronary artery disease;	chr20:34494101	chr20:33989480~33991818:-
BRCA	cis	rs7729723	0.562	rs1046576	ENSG00000253404.1	AC034243.1	3.37	0.000784	0.0356	0.13	0.1	Amyotrophic lateral sclerosis (C9orf72 mutation interaction);	chr5:138446646	chr5:138744434~138753309:-
BRCA	cis	rs7020830	0.931	rs13293916	ENSG00000230188.1	RP11-405L18.4	-3.37	0.000784	0.0356	-0.13	-0.1	Schizophrenia;	chr9:37136362	chr9:37490421~37490893:-
BRCA	cis	rs60515486	0.527	rs2254240	ENSG00000243802.2	RP11-390K5.1	3.37	0.000784	0.0356	0.14	0.1	Lymphocyte counts;	chr11:47335619	chr11:47191181~47191542:-
BRCA	cis	rs67478160	0.654	rs4906365	ENSG00000269910.1	RP11-73M18.10	3.37	0.000784	0.0356	0.1	0.1	Schizophrenia;	chr14:103762893	chr14:103694516~103695050:-
BRCA	cis	rs890448	0.796	rs4478190	ENSG00000254531.1	FLJ20021	3.37	0.000784	0.0356	0.12	0.1	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101417304	chr4:101347780~101348883:+
BRCA	cis	rs10838634	1	rs12273360	ENSG00000280615.1	Y_RNA	-3.37	0.000784	0.0357	-0.18	-0.1	Schizophrenia;	chr11:46868168	chr11:47614898~47614994:-
BRCA	cis	rs34421088	0.506	rs10091637	ENSG00000154316.13	TDH	-3.37	0.000784	0.0357	-0.14	-0.1	Neuroticism;	chr8:11286805	chr8:11339637~11368452:+
BRCA	cis	rs3748682	0.861	rs28625842	ENSG00000212541.1	RNU6-510P	-3.37	0.000784	0.0357	-0.15	-0.1	Hypothyroidism;	chr1:37845114	chr1:37991462~37991569:+
BRCA	cis	rs12282928	0.959	rs11039637	ENSG00000255197.4	RP11-750H9.5	-3.37	0.000784	0.0357	-0.1	-0.1	Migraine - clinic-based;	chr11:48285428	chr11:47383148~47409190:-
BRCA	cis	rs6964587	0.967	rs41371748	ENSG00000188693.7	CYP51A1-AS1	-3.37	0.000784	0.0357	-0.12	-0.1	Breast cancer;	chr7:92078905	chr7:92134604~92180725:+
BRCA	cis	rs10035650	0.617	rs7705424	ENSG00000243806.1	RPL7P18	-3.37	0.000784	0.0357	-0.13	-0.1	Cancer;	chr5:94666594	chr5:94825961~94826694:-
BRCA	cis	rs6813195	0.642	rs11931711	ENSG00000245954.5	RP11-18H21.1	3.37	0.000784	0.0357	0.09	0.1	Type 2 diabetes;	chr4:152370361	chr4:152100754~152104720:+
BRCA	cis	rs4835473	0.932	rs4835279	ENSG00000246448.2	RP13-578N3.3	-3.37	0.000784	0.0357	-0.12	-0.1	Immature fraction of reticulocytes;	chr4:143788917	chr4:143700257~143865072:+
BRCA	cis	rs2380205	0.666	rs11819695	ENSG00000232807.2	RP11-536K7.3	3.37	0.000784	0.0357	0.11	0.1	Breast cancer;	chr10:5845316	chr10:5934270~5945900:-
BRCA	cis	rs17767294	0.708	rs61744109	ENSG00000219392.1	RP1-265C24.5	-3.37	0.000785	0.0357	-0.28	-0.1	Parkinson's disease;	chr6:28107741	chr6:28115628~28116551:+
BRCA	cis	rs17767294	0.708	rs72851168	ENSG00000219392.1	RP1-265C24.5	-3.37	0.000785	0.0357	-0.28	-0.1	Parkinson's disease;	chr6:28112230	chr6:28115628~28116551:+
BRCA	cis	rs17767294	0.708	rs77450054	ENSG00000219392.1	RP1-265C24.5	-3.37	0.000785	0.0357	-0.28	-0.1	Parkinson's disease;	chr6:28116171	chr6:28115628~28116551:+
BRCA	cis	rs7620503	1	rs6783033	ENSG00000228561.2	RP11-114M1.1	3.37	0.000785	0.0357	0.12	0.1	Corneal structure;	chr3:177584963	chr3:177683627~177691250:+
BRCA	cis	rs7620503	0.959	rs6770216	ENSG00000228561.2	RP11-114M1.1	3.37	0.000785	0.0357	0.12	0.1	Corneal structure;	chr3:177585139	chr3:177683627~177691250:+
BRCA	cis	rs7620503	0.959	rs2863016	ENSG00000228561.2	RP11-114M1.1	3.37	0.000785	0.0357	0.12	0.1	Corneal structure;	chr3:177585192	chr3:177683627~177691250:+
BRCA	cis	rs698833	0.501	rs35347977	ENSG00000259439.2	RP11-89K21.1	3.37	0.000785	0.0357	0.12	0.1	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr2:44279782	chr2:44921077~44939199:-
BRCA	cis	rs2243480	1	rs160633	ENSG00000237026.1	RP11-328P23.2	3.37	0.000785	0.0357	0.2	0.1	Diabetic kidney disease;	chr7:66063241	chr7:65235790~65236723:-
BRCA	cis	rs7172689	0.908	rs11634869	ENSG00000271725.1	RP11-761I4.4	3.37	0.000785	0.0357	0.14	0.1	Inattentive symptoms;	chr15:81274272	chr15:81303215~81309391:-
BRCA	cis	rs3771570	1	rs1984598	ENSG00000271153.1	ABC7-43041300I9.1	-3.37	0.000785	0.0357	-0.18	-0.1	Prostate cancer;	chr2:241345409	chr2:242175181~242175634:+
BRCA	cis	rs1119582	0.568	rs435225	ENSG00000279118.1	RP11-517I3.2	3.37	0.000785	0.0357	0.15	0.1	Select biomarker traits;	chr5:125867814	chr5:126496279~126498604:+
BRCA	cis	rs1119582	0.636	rs420713	ENSG00000279118.1	RP11-517I3.2	3.37	0.000785	0.0357	0.15	0.1	Select biomarker traits;	chr5:125867845	chr5:126496279~126498604:+
BRCA	cis	rs1119582	0.568	rs421219	ENSG00000279118.1	RP11-517I3.2	3.37	0.000785	0.0357	0.15	0.1	Select biomarker traits;	chr5:125867847	chr5:126496279~126498604:+
BRCA	cis	rs8007846	0.588	rs1075566	ENSG00000276116.2	FUT8-AS1	-3.37	0.000785	0.0357	-0.11	-0.1	Multiple sclerosis--Brain Glutamate Levels;	chr14:65772739	chr14:65411170~65412690:-
BRCA	cis	rs13434995	0.589	rs62306207	ENSG00000273257.1	RP11-177J6.1	-3.37	0.000785	0.0357	-0.16	-0.1	Adiponectin levels;	chr4:55384548	chr4:55387949~55388271:+
BRCA	cis	rs6430585	0.646	rs1057031	ENSG00000226806.1	AC011893.3	3.37	0.000785	0.0357	0.14	0.1	Corneal structure;	chr2:135876392	chr2:135820191~135823087:+
BRCA	cis	rs17197037	0.545	rs3748357	ENSG00000277734.3	TRAC	3.37	0.000785	0.0357	0.07	0.1	Bipolar disorder;	chr14:21317631	chr14:22281105~22552155:+
BRCA	cis	rs36051895	0.626	rs10283564	ENSG00000237711.1	RP11-39K24.13	-3.37	0.000785	0.0357	-0.13	-0.1	Pediatric autoimmune diseases;	chr9:5075628	chr9:5100236~5101009:+
BRCA	cis	rs752010	0.63	rs11210507	ENSG00000230638.4	RP11-486B10.4	-3.37	0.000785	0.0357	-0.13	-0.1	Lupus nephritis in systemic lupus erythematosus;	chr1:41639817	chr1:41542069~41544310:+
BRCA	cis	rs6963495	0.769	rs11556986	ENSG00000223886.3	RP11-251G23.2	3.37	0.000785	0.0357	0.15	0.1	Bipolar disorder (body mass index interaction);	chr7:105536594	chr7:105530209~105530671:+
BRCA	cis	rs6901004	0.935	rs1150078	ENSG00000231889.6	TRAF3IP2-AS1	-3.37	0.000785	0.0357	-0.11	-0.1	Blood metabolite levels;	chr6:111239098	chr6:111483511~111598302:+
BRCA	cis	rs2274273	0.554	rs3742564	ENSG00000233924.1	AL160471.6	3.37	0.000785	0.0357	0.12	0.1	Protein biomarker;	chr14:55063402	chr14:55004813~55005687:-
BRCA	cis	rs1865760	0.929	rs12195653	ENSG00000272810.1	U91328.22	-3.37	0.000785	0.0357	-0.12	-0.1	Height;	chr6:25958393	chr6:26013241~26013757:+
BRCA	cis	rs11955398	0.502	rs10471502	ENSG00000272308.1	RP11-231G3.1	-3.37	0.000785	0.0357	-0.12	-0.1	Intelligence (multi-trait analysis);	chr5:61073256	chr5:60866457~60866935:-
BRCA	cis	rs34467563	0.5	rs7821730	ENSG00000253105.4	KB-1448A5.1	3.37	0.000785	0.0357	0.12	0.1	Lobe attachment (rater-scored or self-reported);	chr8:96322622	chr8:96371865~96387438:-
BRCA	cis	rs9377188	0.556	rs1116527	ENSG00000219433.2	RP11-350J20.4	-3.37	0.000785	0.0357	-0.13	-0.1	Cancer;	chr6:148980917	chr6:149794763~149795746:+
BRCA	cis	rs11887277	0.586	rs828261	ENSG00000272148.1	RP11-195B17.1	-3.37	0.000786	0.0357	-0.12	-0.1	Obesity-related traits;	chr2:26769503	chr2:27062428~27062907:-
BRCA	cis	rs4714291	0.963	rs847743	ENSG00000180211.5	RP1-278E11.3	3.37	0.000786	0.0357	0.11	0.1	Strep throat;	chr6:40119415	chr6:39958414~39958833:-
BRCA	cis	rs17301013	0.861	rs34819375	ENSG00000200674.1	RN7SKP160	3.37	0.000786	0.0357	0.14	0.1	Systemic lupus erythematosus;	chr1:174654958	chr1:173791548~173791887:+
BRCA	cis	rs4819052	0.851	rs10470258	ENSG00000223768.1	LINC00205	-3.37	0.000786	0.0357	-0.14	-0.1	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239074	chr21:45293285~45297354:+
BRCA	cis	rs4819052	0.851	rs4819038	ENSG00000223768.1	LINC00205	-3.37	0.000786	0.0357	-0.14	-0.1	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239478	chr21:45293285~45297354:+
BRCA	cis	rs4819052	0.851	rs4819039	ENSG00000223768.1	LINC00205	-3.37	0.000786	0.0357	-0.14	-0.1	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239543	chr21:45293285~45297354:+
BRCA	cis	rs4819052	0.851	rs4818768	ENSG00000223768.1	LINC00205	-3.37	0.000786	0.0357	-0.14	-0.1	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239903	chr21:45293285~45297354:+
BRCA	cis	rs4819052	0.851	rs4819042	ENSG00000223768.1	LINC00205	-3.37	0.000786	0.0357	-0.14	-0.1	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240157	chr21:45293285~45297354:+
BRCA	cis	rs4819052	0.8	rs4819045	ENSG00000223768.1	LINC00205	-3.37	0.000786	0.0357	-0.14	-0.1	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240223	chr21:45293285~45297354:+
BRCA	cis	rs4819052	0.851	rs13047598	ENSG00000223768.1	LINC00205	-3.37	0.000786	0.0357	-0.14	-0.1	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240862	chr21:45293285~45297354:+
BRCA	cis	rs4819052	0.724	rs9753962	ENSG00000223768.1	LINC00205	-3.37	0.000786	0.0357	-0.14	-0.1	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45241469	chr21:45293285~45297354:+
BRCA	cis	rs4819052	0.724	rs9753987	ENSG00000223768.1	LINC00205	-3.37	0.000786	0.0357	-0.14	-0.1	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45241474	chr21:45293285~45297354:+
BRCA	cis	rs4819052	0.851	rs9753963	ENSG00000223768.1	LINC00205	-3.37	0.000786	0.0357	-0.14	-0.1	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45241522	chr21:45293285~45297354:+
BRCA	cis	rs220519	0.681	rs220505	ENSG00000235408.4	SNORA71B	-3.37	0.000786	0.0357	-0.1	-0.1	Schizophrenia;	chr20:38664488	chr20:38425083~38425354:-
BRCA	cis	rs853679	0.517	rs2281588	ENSG00000272009.1	RP1-313I6.12	-3.37	0.000786	0.0357	-0.15	-0.1	Depression;	chr6:28104824	chr6:28078792~28081130:-
BRCA	cis	rs8127691	0.967	rs2838521	ENSG00000225331.1	AP001055.6	-3.37	0.000786	0.0357	-0.12	-0.1	Inflammatory bowel disease;	chr21:44196034	chr21:44158740~44160076:-
BRCA	cis	rs10852151	0.901	rs6496825	ENSG00000259704.1	CTD-3094K11.1	3.37	0.000786	0.0357	0.11	0.1	Gastroesophageal reflux disease;	chr15:91545988	chr15:90839724~90841378:+
BRCA	cis	rs4381241	0.569	rs17382596	ENSG00000236434.2	RP11-296A18.6	-3.37	0.000786	0.0357	-0.13	-0.1	Renal cell carcinoma;	chr1:50472787	chr1:51264916~51266074:-
BRCA	cis	rs7647973	1	rs9862534	ENSG00000272434.1	RP13-131K19.6	-3.37	0.000786	0.0357	-0.14	-0.1	Menarche (age at onset);	chr3:49560631	chr3:49029316~49029706:+
BRCA	cis	rs849141	1	rs849141	ENSG00000234336.5	JAZF1-AS1	3.37	0.000786	0.0357	0.15	0.1	Height;Hip circumference adjusted for BMI;	chr7:28145472	chr7:28180322~28243917:+
BRCA	cis	rs801193	0.636	rs2659895	ENSG00000230189.5	GS1-124K5.2	3.37	0.000786	0.0357	0.08	0.1	Aortic root size;	chr7:66731484	chr7:66409143~66490059:-
BRCA	cis	rs11673344	0.667	rs504549	ENSG00000267005.1	AC002984.2	3.37	0.000786	0.0357	0.13	0.1	Obesity-related traits;	chr19:36946299	chr19:36173406~36173853:-
BRCA	cis	rs6460942	0.597	rs6944517	ENSG00000226690.5	AC005281.1	3.37	0.000786	0.0357	0.2	0.1	Coronary artery disease;	chr7:12475657	chr7:12496429~12541910:+
BRCA	cis	rs6460942	0.597	rs6968664	ENSG00000226690.5	AC005281.1	3.37	0.000786	0.0357	0.2	0.1	Coronary artery disease;	chr7:12475867	chr7:12496429~12541910:+
BRCA	cis	rs11098499	0.604	rs2389886	ENSG00000250412.1	KLHL2P1	3.37	0.000786	0.0357	0.13	0.1	Corneal astigmatism;	chr4:119649267	chr4:119334329~119378233:+
BRCA	cis	rs754133	0.964	rs894737	ENSG00000248265.1	FLJ12825	3.37	0.000786	0.0357	0.14	0.1	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);	chr12:54024359	chr12:54058254~54122234:+
BRCA	cis	rs7914558	0.933	rs2066323	ENSG00000213277.3	MARCKSL1P1	3.37	0.000786	0.0357	0.12	0.1	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103111604	chr10:103175554~103176094:+
BRCA	cis	rs13256369	0.708	rs10903310	ENSG00000254153.1	CTA-398F10.2	-3.37	0.000786	0.0357	-0.15	-0.1	Obesity-related traits;	chr8:8732177	chr8:8456909~8461337:-
BRCA	cis	rs853679	0.567	rs7740429	ENSG00000273712.1	RP5-874C20.7	3.37	0.000786	0.0357	0.15	0.1	Depression;	chr6:28431469	chr6:28315613~28315883:-
BRCA	cis	rs11239930	0.538	rs9663073	ENSG00000227242.3	NBPF13P	-3.37	0.000787	0.0357	-0.13	-0.1	AIDS progression;	chr1:147083022	chr1:147021320~147124525:-
BRCA	cis	rs4948102	0.731	rs7800001	ENSG00000226278.1	PSPHP1	-3.37	0.000787	0.0357	-0.12	-0.1	Plasma homocysteine levels (post-methionine load test);	chr7:56004317	chr7:55764797~55773288:+
BRCA	cis	rs62289301	0.531	rs10212844	ENSG00000249234.1	RP11-452J21.2	-3.37	0.000787	0.0357	-0.12	-0.1	Joint mobility (Beighton score);	chr4:15415744	chr4:16178939~16183120:+
BRCA	cis	rs62289301	0.531	rs10213628	ENSG00000249234.1	RP11-452J21.2	-3.37	0.000787	0.0357	-0.12	-0.1	Joint mobility (Beighton score);	chr4:15415813	chr4:16178939~16183120:+
BRCA	cis	rs12428035	1	rs12428035	ENSG00000247400.3	DNAJC3-AS1	3.37	0.000787	0.0357	0.17	0.1	Glomerular filtration rate (cystatin C);Response to statins (LDL cholesterol change);	chr13:95648618	chr13:95648733~95676925:-
BRCA	cis	rs80226907	0.634	rs75295884	ENSG00000186615.9	KTN1-AS1	-3.37	0.000787	0.0357	-0.23	-0.1	Mean platelet volume;	chr14:55429098	chr14:55499278~55580110:-
BRCA	cis	rs6964587	0.839	rs9656002	ENSG00000188693.7	CYP51A1-AS1	3.37	0.000787	0.0357	0.12	0.1	Breast cancer;	chr7:91845693	chr7:92134604~92180725:+
BRCA	cis	rs7695732	0.619	rs72877642	ENSG00000270720.1	RP11-84C13.2	3.37	0.000787	0.0357	0.14	0.1	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr4:89119536	chr4:89119284~89119871:+
BRCA	cis	rs7695732	0.619	rs62306391	ENSG00000270720.1	RP11-84C13.2	3.37	0.000787	0.0357	0.14	0.1	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr4:89119605	chr4:89119284~89119871:+
BRCA	cis	rs4648045	0.861	rs230520	ENSG00000251288.2	RP11-10L12.2	3.37	0.000787	0.0358	0.13	0.1	Lymphocyte percentage of white cells;	chr4:102544455	chr4:102751401~102752641:+
BRCA	cis	rs3916	0.91	rs7306541	ENSG00000277423.1	RP11-173P15.9	-3.37	0.000787	0.0358	-0.14	-0.1	Urinary metabolites (H-NMR features);	chr12:120692243	chr12:120703867~120704282:+
BRCA	cis	rs8094794	0.697	rs9652999	ENSG00000278986.1	RP11-723J4.3	3.37	0.000787	0.0358	0.15	0.1	Periodontal disease-related phenotypes;	chr18:36715544	chr18:35972151~35973916:+
BRCA	cis	rs71520386	0.583	rs28799344	ENSG00000179428.2	AC073072.5	3.37	0.000787	0.0358	0.12	0.1	Fibrinogen levels;	chr7:22805647	chr7:22725395~22727620:-
BRCA	cis	rs875971	1	rs6958484	ENSG00000230189.5	GS1-124K5.2	-3.37	0.000787	0.0358	-0.08	-0.1	Aortic root size;	chr7:66134459	chr7:66409143~66490059:-
BRCA	cis	rs74233809	1	rs11191555	ENSG00000213061.2	PFN1P11	3.37	0.000787	0.0358	0.23	0.1	Birth weight;	chr10:103097766	chr10:102838011~102845473:-
BRCA	cis	rs74233809	1	rs11191557	ENSG00000213061.2	PFN1P11	3.37	0.000787	0.0358	0.23	0.1	Birth weight;	chr10:103104857	chr10:102838011~102845473:-
BRCA	cis	rs74233809	1	rs11191558	ENSG00000213061.2	PFN1P11	3.37	0.000787	0.0358	0.23	0.1	Birth weight;	chr10:103104921	chr10:102838011~102845473:-
BRCA	cis	rs6918152	0.646	rs2473488	ENSG00000218027.2	RP11-157J24.1	-3.37	0.000787	0.0358	-0.13	-0.1	Black vs. red hair color;Black vs. blond hair color;	chr6:544239	chr6:1513698~1515289:-
BRCA	cis	rs17123764	0.71	rs58278271	ENSG00000257464.1	RP11-161H23.8	-3.37	0.000787	0.0358	-0.18	-0.1	Intelligence (multi-trait analysis);	chr12:49624192	chr12:49442424~49442652:-
BRCA	cis	rs6840360	0.573	rs2407171	ENSG00000278978.1	RP11-164P12.5	-3.37	0.000787	0.0358	-0.11	-0.1	Intelligence (multi-trait analysis);	chr4:151335630	chr4:151669786~151670503:+
BRCA	cis	rs863345	0.604	rs1157525	ENSG00000176320.2	RP11-404O13.5	-3.37	0.000787	0.0358	-0.11	-0.1	Pneumococcal bacteremia;	chr1:158487463	chr1:158197922~158203877:-
BRCA	cis	rs4665809	0.887	rs28699126	ENSG00000231655.1	AC011742.3	3.37	0.000787	0.0358	0.15	0.1	Gut microbiome composition (summer);	chr2:26134425	chr2:26140263~26141264:-
BRCA	cis	rs7104764	1	rs6598063	ENSG00000254910.1	RP11-326C3.7	-3.37	0.000787	0.0358	-0.12	-0.1	Menarche (age at onset);	chr11:243672	chr11:310139~311141:-
BRCA	cis	rs7104764	1	rs6598062	ENSG00000254910.1	RP11-326C3.7	-3.37	0.000787	0.0358	-0.12	-0.1	Menarche (age at onset);	chr11:243712	chr11:310139~311141:-
BRCA	cis	rs4919687	0.55	rs7904396	ENSG00000236937.2	PTGES3P4	3.37	0.000787	0.0358	0.14	0.1	Colorectal cancer;	chr10:102697081	chr10:102845595~102845950:+
BRCA	cis	rs1730008	0.865	rs13072413	ENSG00000279311.1	RP11-170K4.2	-3.37	0.000788	0.0358	-0.11	-0.1	Lobe attachment (rater-scored or self-reported);	chr3:158170016	chr3:158869898~158871821:+
BRCA	cis	rs7618501	0.699	rs6446187	ENSG00000281433.1	Metazoa_SRP	-3.37	0.000788	0.0358	-0.1	-0.1	Intelligence (multi-trait analysis);	chr3:49869678	chr3:49320296~49320564:+
BRCA	cis	rs477895	0.629	rs7130030	ENSG00000256940.1	RP11-783K16.5	3.37	0.000788	0.0358	0.15	0.1	Mean platelet volume;	chr11:64166261	chr11:64245964~64248217:+
BRCA	cis	rs6840360	0.615	rs1561917	ENSG00000270265.1	RP11-731D1.4	-3.37	0.000788	0.0358	-0.12	-0.1	Intelligence (multi-trait analysis);	chr4:151558081	chr4:151333775~151353224:-
BRCA	cis	rs6840360	0.615	rs1561916	ENSG00000270265.1	RP11-731D1.4	-3.37	0.000788	0.0358	-0.12	-0.1	Intelligence (multi-trait analysis);	chr4:151558082	chr4:151333775~151353224:-
BRCA	cis	rs35123781	1	rs585101	ENSG00000250635.1	CTD-3224K15.2	-3.37	0.000788	0.0358	-0.11	-0.1	Schizophrenia;	chr5:139678869	chr5:139648999~139649728:-
BRCA	cis	rs783540	1	rs698500	ENSG00000274376.3	ADAMTS7P1	-3.37	0.000788	0.0358	-0.11	-0.1	Schizophrenia;	chr15:82569019	chr15:82298553~82334609:+
BRCA	cis	rs801193	0.844	rs2244022	ENSG00000265600.1	AC006480.1	-3.37	0.000788	0.0358	-0.12	-0.1	Aortic root size;	chr7:66737443	chr7:67356680~67356779:+
BRCA	cis	rs10876993	0.89	rs774887	ENSG00000270039.1	RP11-571M6.17	3.37	0.000788	0.0358	0.14	0.1	Celiac disease or Rheumatoid arthritis;	chr12:57641052	chr12:57803838~57804415:+
BRCA	cis	rs34779708	0.966	rs12257770	ENSG00000269952.1	RP11-324I22.3	-3.37	0.000788	0.0358	-0.13	-0.1	Inflammatory bowel disease;Crohn's disease;	chr10:35228306	chr10:35210416~35210750:+
BRCA	cis	rs6120141	1	rs6059134	ENSG00000198547.7	C20orf203	3.37	0.000788	0.0358	0.22	0.1	Smooth-surface caries;	chr20:33166430	chr20:32631652~32673941:-
BRCA	cis	rs117533700	0.661	rs10415363	ENSG00000267582.1	CTD-3252C9.2	3.37	0.000788	0.0358	0.24	0.1	Monocyte count;	chr19:13000821	chr19:13796574~13796933:-
BRCA	cis	rs1165668	0.959	rs2576954	ENSG00000257681.1	RP11-341G23.4	-3.37	0.000788	0.0358	-0.13	-0.1	Coronary heart disease (SNP X SNP interaction);	chr12:103918476	chr12:103746315~103768858:-
BRCA	cis	rs2227564	0.574	rs3849969	ENSG00000242288.9	RP11-464F9.1	-3.37	0.000788	0.0358	-0.13	-0.1	Crohn's disease;Inflammatory bowel disease;	chr10:73766241	chr10:73674295~73730466:-
BRCA	cis	rs8023401	0.872	rs11854943	ENSG00000274654.1	CTD-3247H4.2	-3.37	0.000788	0.0358	-0.16	-0.1	Spherical equivalent (joint analysis main effects and education interaction);	chr15:48569090	chr15:48528980~48529728:-
BRCA	cis	rs10986311	0.832	rs10119911	ENSG00000214593.3	RP11-65N13.6	-3.37	0.000788	0.0358	-0.11	-0.1	Vitiligo;	chr9:124364893	chr9:125263845~125264090:-
BRCA	cis	rs2574985	0.813	rs76883711	ENSG00000226200.5	SGMS1-AS1	-3.37	0.000788	0.0358	-0.11	-0.1	Subjective well-being;	chr10:50476017	chr10:50624951~50641451:+
BRCA	cis	rs6893300	0.961	rs11744616	ENSG00000225051.5	HMGB3P22	3.37	0.000788	0.0358	0.14	0.1	Resting heart rate;	chr5:179782112	chr5:179679032~179694768:+
BRCA	cis	rs7620503	0.659	rs11707350	ENSG00000228561.2	RP11-114M1.1	3.37	0.000788	0.0358	0.14	0.1	Corneal structure;	chr3:177570055	chr3:177683627~177691250:+
BRCA	cis	rs9844666	0.512	rs6779603	ENSG00000239213.4	NCK1-AS1	3.37	0.000788	0.0358	0.12	0.1	Height;	chr3:135921113	chr3:136841726~136862054:-
BRCA	cis	rs10883723	0.81	rs3740406	ENSG00000213061.2	PFN1P11	-3.37	0.000788	0.0358	-0.14	-0.1	Allergic disease (asthma, hay fever or eczema);	chr10:102513032	chr10:102838011~102845473:-
BRCA	cis	rs10883723	0.81	rs10748824	ENSG00000213061.2	PFN1P11	-3.37	0.000788	0.0358	-0.14	-0.1	Allergic disease (asthma, hay fever or eczema);	chr10:102514709	chr10:102838011~102845473:-
BRCA	cis	rs1577917	0.518	rs6454482	ENSG00000220563.1	PKMP3	3.37	0.000788	0.0358	0.1	0.1	Response to antipsychotic treatment;	chr6:85708470	chr6:85659892~85660606:-
BRCA	cis	rs687432	0.924	rs2089747	ENSG00000213592.4	AP000662.9	-3.37	0.000788	0.0358	-0.15	-0.1	Parkinson's disease;	chr11:57977570	chr11:57718044~57718530:-
BRCA	cis	rs16858210	0.657	rs73177515	ENSG00000234371.6	RPSAP31	3.37	0.000788	0.0358	0.15	0.1	Menopause (age at onset);	chr3:183849037	chr3:183884924~183888449:+
BRCA	cis	rs875971	0.895	rs12698520	ENSG00000272831.1	RP11-792A8.4	3.37	0.000788	0.0358	0.09	0.1	Aortic root size;	chr7:66453720	chr7:66739829~66740385:-
BRCA	cis	rs1018697	1	rs6584525	ENSG00000236937.2	PTGES3P4	3.37	0.000788	0.0358	0.13	0.1	Colorectal adenoma (advanced);	chr10:102792224	chr10:102845595~102845950:+
BRCA	cis	rs10876993	0.89	rs1082502	ENSG00000269903.1	RP11-571M6.18	3.37	0.000788	0.0358	0.13	0.1	Celiac disease or Rheumatoid arthritis;	chr12:57641923	chr12:57814494~57814926:+
BRCA	cis	rs10761482	0.861	rs7096426	ENSG00000254271.1	RP11-131N11.4	-3.37	0.000788	0.0358	-0.15	-0.1	Schizophrenia;	chr10:60346787	chr10:60734342~60741828:+
BRCA	cis	rs10792665	0.51	rs7116170	ENSG00000254965.1	RP11-113K21.2	-3.37	0.000788	0.0358	-0.1	-0.1	Obesity-related traits;	chr11:82919660	chr11:83111060~83111442:-
BRCA	cis	rs687432	0.924	rs11608016	ENSG00000213592.4	AP000662.9	-3.37	0.000788	0.0358	-0.15	-0.1	Parkinson's disease;	chr11:58007013	chr11:57718044~57718530:-
BRCA	cis	rs2380205	0.538	rs11255774	ENSG00000238266.1	LINC00707	-3.37	0.000788	0.0358	-0.11	-0.1	Breast cancer;	chr10:5897096	chr10:6779598~6842906:+
BRCA	cis	rs2254135	0.505	rs2244444	ENSG00000238142.1	RP11-108M9.4	-3.37	0.000788	0.0358	-0.12	-0.1	Response to hepatitis C treatment;	chr1:17520426	chr1:16888538~16889649:-
BRCA	cis	rs13418717	1	rs10496658	ENSG00000272789.1	RP11-286H15.1	-3.37	0.000789	0.0358	-0.19	-0.1	Heart failure;	chr2:126905921	chr2:127625997~127626848:-
BRCA	cis	rs7131987	0.65	rs6487808	ENSG00000273680.1	RP11-996F15.6	-3.37	0.000789	0.0358	-0.13	-0.1	QT interval;	chr12:29310426	chr12:29332733~29333383:-
BRCA	cis	rs11239930	0.517	rs556976	ENSG00000237188.3	RP11-337C18.8	3.37	0.000789	0.0358	0.12	0.1	AIDS progression;	chr1:147073643	chr1:147172771~147211568:+
BRCA	cis	rs1555322	0.53	rs2425044	ENSG00000278035.1	RP11-234K24.6	3.37	0.000789	0.0358	0.15	0.1	Attention deficit hyperactivity disorder;	chr20:35281932	chr20:36233851~36234297:+
BRCA	cis	rs77688320	0.553	rs6722889	ENSG00000230799.1	AC007279.2	3.37	0.000789	0.0358	0.13	0.1	Breast cancer;	chr2:201439359	chr2:201762737~201763573:+
BRCA	cis	rs875971	1	rs778726	ENSG00000273024.4	INTS4P2	-3.37	0.000789	0.0358	-0.11	-0.1	Aortic root size;	chr7:66363744	chr7:65647864~65715661:+
BRCA	cis	rs875971	0.767	rs1695815	ENSG00000273024.4	INTS4P2	-3.37	0.000789	0.0358	-0.11	-0.1	Aortic root size;	chr7:66366357	chr7:65647864~65715661:+
BRCA	cis	rs875971	1	rs778685	ENSG00000273024.4	INTS4P2	-3.37	0.000789	0.0358	-0.11	-0.1	Aortic root size;	chr7:66371189	chr7:65647864~65715661:+
BRCA	cis	rs875971	0.929	rs778682	ENSG00000273024.4	INTS4P2	-3.37	0.000789	0.0358	-0.11	-0.1	Aortic root size;	chr7:66372947	chr7:65647864~65715661:+
BRCA	cis	rs875971	0.964	rs11765965	ENSG00000273024.4	INTS4P2	-3.37	0.000789	0.0358	-0.11	-0.1	Aortic root size;	chr7:66377234	chr7:65647864~65715661:+
BRCA	cis	rs466639	0.929	rs79627842	ENSG00000236364.3	RP11-525G13.2	3.37	0.000789	0.0358	0.13	0.1	Menarche (age at onset);	chr1:165436950	chr1:165890795~165900683:-
BRCA	cis	rs466639	0.929	rs77182452	ENSG00000236364.3	RP11-525G13.2	3.37	0.000789	0.0358	0.13	0.1	Menarche (age at onset);	chr1:165437006	chr1:165890795~165900683:-
BRCA	cis	rs4835473	0.801	rs35839125	ENSG00000246448.2	RP13-578N3.3	-3.37	0.000789	0.0358	-0.12	-0.1	Immature fraction of reticulocytes;	chr4:143792351	chr4:143700257~143865072:+
BRCA	cis	rs6694270	0.529	rs4076925	ENSG00000230424.1	RP1-43E13.2	3.37	0.000789	0.0358	0.14	0.1	Drug-induced liver injury (nitrofurantoin);	chr1:18786532	chr1:19210501~19240704:+
BRCA	cis	rs9467773	1	rs1321479	ENSG00000224843.5	LINC00240	3.37	0.000789	0.0358	0.11	0.1	Intelligence (multi-trait analysis);	chr6:26501669	chr6:26956992~27023924:+
BRCA	cis	rs4568518	0.502	rs4544985	ENSG00000279048.1	RP11-511H23.2	3.37	0.000789	0.0358	0.1	0.1	Measles;	chr7:17944184	chr7:17940503~17942922:+
BRCA	cis	rs354225	0.539	rs13428703	ENSG00000240401.7	AC012358.8	-3.37	0.000789	0.0358	-0.16	-0.1	Schizophrenia;	chr2:54733543	chr2:55282350~55346049:+
BRCA	cis	rs687432	0.688	rs12804808	ENSG00000265566.2	RN7SL605P	-3.37	0.000789	0.0358	-0.14	-0.1	Parkinson's disease;	chr11:58124840	chr11:57528085~57528365:-
BRCA	cis	rs7578199	0.889	rs7600666	ENSG00000228989.1	AC133528.2	3.37	0.000789	0.0358	0.12	0.1	Chronic lymphocytic leukemia;	chr2:241231889	chr2:241690414~241694289:+
BRCA	cis	rs417065	0.516	rs6701941	ENSG00000238290.1	RP11-431K24.1	-3.37	0.00079	0.0358	-0.13	-0.1	Psoriasis;	chr1:8208655	chr1:8026738~8122702:+
BRCA	cis	rs10124101	1	rs10124101	ENSG00000215283.3	HMGB3P24	3.37	0.00079	0.0358	0.12	0.1	Schizophrenia;	chr9:36308830	chr9:36303499~36304924:-
BRCA	cis	rs2018683	0.707	rs4722875	ENSG00000228421.2	AC005013.5	3.37	0.00079	0.0358	0.13	0.1	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28930015	chr7:28957667~28959345:+
BRCA	cis	rs11642862	1	rs11642862	ENSG00000261487.1	AC135048.13	3.37	0.00079	0.0359	0.19	0.1	Tonsillectomy;	chr16:30774503	chr16:30948386~30956511:+
BRCA	cis	rs6964587	0.839	rs62466159	ENSG00000188693.7	CYP51A1-AS1	-3.37	0.00079	0.0359	-0.11	-0.1	Breast cancer;	chr7:91821193	chr7:92134604~92180725:+
BRCA	cis	rs6087685	1	rs6088764	ENSG00000202150.1	RNU6-407P	-3.37	0.00079	0.0359	-0.12	-0.1	Venous thromboembolism;	chr20:35205356	chr20:35030317~35030420:-
BRCA	cis	rs885150	0.688	rs10985349	ENSG00000238181.2	AHCYP2	-3.37	0.00079	0.0359	-0.16	-0.1	Coronary artery disease;	chr9:121662964	chr9:120720673~120721972:+
BRCA	cis	rs1039766	1	rs1039766	ENSG00000227791.3	AC007365.4	3.37	0.00079	0.0359	0.16	0.1	Lung adenocarcinoma;Lung cancer;	chr2:65293011	chr2:64665607~64666064:+
BRCA	cis	rs11700980	0.636	rs11702742	ENSG00000232855.5	AF131217.1	3.37	0.00079	0.0359	0.18	0.1	QRS complex (12-leadsum);	chr21:28881700	chr21:28439346~28674848:-
BRCA	cis	rs11700980	0.636	rs61735765	ENSG00000232855.5	AF131217.1	3.37	0.00079	0.0359	0.18	0.1	QRS complex (12-leadsum);	chr21:28883025	chr21:28439346~28674848:-
BRCA	cis	rs11700980	0.636	rs115245768	ENSG00000232855.5	AF131217.1	3.37	0.00079	0.0359	0.18	0.1	QRS complex (12-leadsum);	chr21:28883796	chr21:28439346~28674848:-
BRCA	cis	rs4760636	0.954	rs9859	ENSG00000276691.1	RP5-1057I20.5	3.37	0.00079	0.0359	0.12	0.1	Urate levels;	chr12:47783117	chr12:47788426~47788971:+
BRCA	cis	rs2795502	0.882	rs2744095	ENSG00000185904.10	LINC00839	-3.37	0.00079	0.0359	-0.15	-0.1	Blood protein levels;	chr10:42842501	chr10:42475543~42495336:+
BRCA	cis	rs875971	1	rs2036264	ENSG00000273448.1	RP11-166O4.6	-3.37	0.00079	0.0359	-0.09	-0.1	Aortic root size;	chr7:66334917	chr7:67333047~67334383:+
BRCA	cis	rs875971	1	rs7783613	ENSG00000273448.1	RP11-166O4.6	-3.37	0.00079	0.0359	-0.09	-0.1	Aortic root size;	chr7:66340274	chr7:67333047~67334383:+
BRCA	cis	rs890448	0.796	rs2433298	ENSG00000254531.1	FLJ20021	3.37	0.00079	0.0359	0.12	0.1	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101421169	chr4:101347780~101348883:+
BRCA	cis	rs76963786	0.901	rs1797779	ENSG00000276148.1	RP11-278C7.4	-3.37	0.00079	0.0359	-0.14	-0.1	Interleukin-9 levels;	chr12:31886553	chr12:32725248~32725660:-
BRCA	cis	rs4499344	0.556	rs259230	ENSG00000267475.1	CTD-2538C1.2	3.37	0.00079	0.0359	0.14	0.1	Mean platelet volume;	chr19:32642959	chr19:32687089~32691750:-
BRCA	cis	rs875971	0.862	rs1968126	ENSG00000223473.2	GS1-124K5.3	-3.37	0.00079	0.0359	-0.08	-0.1	Aortic root size;	chr7:66592017	chr7:66491049~66493566:-
BRCA	cis	rs36051895	0.559	rs7850228	ENSG00000237711.1	RP11-39K24.13	3.37	0.00079	0.0359	0.12	0.1	Pediatric autoimmune diseases;	chr9:5210671	chr9:5100236~5101009:+
BRCA	cis	rs4243971	0.516	rs6141716	ENSG00000275576.1	RP5-836N17.4	-3.37	0.00079	0.0359	-0.12	-0.1	Inflammatory bowel disease;Crohn's disease;	chr20:32424558	chr20:32116171~32116629:+
BRCA	cis	rs35520189	0.591	rs12995439	ENSG00000231747.1	AC079922.2	-3.37	0.00079	0.0359	-0.11	-0.1	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:112946069	chr2:112621809~112622167:-
BRCA	cis	rs9341808	0.718	rs10080237	ENSG00000279022.1	RP11-250B2.4	3.37	0.00079	0.0359	0.12	0.1	Sitting height ratio;	chr6:80144753	chr6:80440730~80441172:+
BRCA	cis	rs2562456	0.792	rs2562398	ENSG00000268705.1	BNIP3P26	-3.37	0.00079	0.0359	-0.11	-0.1	Pain;	chr19:21540147	chr19:21521343~21521896:-
BRCA	cis	rs17135159	0.917	rs2209500	ENSG00000273001.1	RP11-118K6.3	3.37	0.00079	0.0359	0.13	0.1	Reading and spelling;	chr10:3360142	chr10:3065424~3066001:-
BRCA	cis	rs17135159	0.917	rs10508252	ENSG00000273001.1	RP11-118K6.3	3.37	0.00079	0.0359	0.13	0.1	Reading and spelling;	chr10:3360399	chr10:3065424~3066001:-
BRCA	cis	rs375066	0.935	rs371875	ENSG00000278917.1	RP11-15A1.4	-3.37	0.000791	0.0359	-0.12	-0.1	Breast cancer;	chr19:43889105	chr19:43891233~43895411:+
BRCA	cis	rs3789045	0.56	rs3747634	ENSG00000176754.11	LINC00303	3.37	0.000791	0.0359	0.17	0.1	Educational attainment (college completion);	chr1:204441935	chr1:204032447~204041265:-
BRCA	cis	rs9513675	0.588	rs1028710	ENSG00000260992.1	DOCK9-AS2	3.37	0.000791	0.0359	0.11	0.1	Obesity-related traits;	chr13:99830366	chr13:99087819~99088625:+
BRCA	cis	rs11209261	0.549	rs6660213	ENSG00000232284.6	GNG12-AS1	3.37	0.000791	0.0359	0.11	0.1	Airflow obstruction;	chr1:68335126	chr1:67832303~68202987:+
BRCA	cis	rs6088580	0.524	rs1853056	ENSG00000126005.14	MMP24-AS1	3.37	0.000791	0.0359	0.12	0.1	Glomerular filtration rate (creatinine);	chr20:34674254	chr20:35216462~35278131:-
BRCA	cis	rs867371	0.896	rs8033831	ENSG00000276710.3	CSPG4P8	-3.37	0.000791	0.0359	-0.11	-0.1	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82220953	chr15:82459472~82477258:+
BRCA	cis	rs13256369	0.95	rs12548792	ENSG00000254153.1	CTA-398F10.2	3.37	0.000791	0.0359	0.14	0.1	Obesity-related traits;	chr8:8710521	chr8:8456909~8461337:-
BRCA	cis	rs113835537	0.529	rs11227499	ENSG00000253024.1	RNU6-1238P	-3.37	0.000791	0.0359	-0.12	-0.1	Airway imaging phenotypes;	chr11:66505353	chr11:67395210~67395311:-
BRCA	cis	rs6494488	0.5	rs72742930	ENSG00000248415.1	GAPDHP61	-3.37	0.000791	0.0359	-0.23	-0.1	Coronary artery disease;	chr15:64578145	chr15:64528667~64529671:-
BRCA	cis	rs3916	0.955	rs12828810	ENSG00000277423.1	RP11-173P15.9	-3.37	0.000791	0.0359	-0.14	-0.1	Urinary metabolites (H-NMR features);	chr12:120714214	chr12:120703867~120704282:+
BRCA	cis	rs7429990	0.965	rs35689209	ENSG00000199476.1	Y_RNA	3.37	0.000791	0.0359	0.13	0.1	Educational attainment (years of education);	chr3:48078273	chr3:48288587~48288694:+
BRCA	cis	rs7020830	0.858	rs1492714	ENSG00000230188.1	RP11-405L18.4	-3.37	0.000791	0.0359	-0.13	-0.1	Schizophrenia;	chr9:37141262	chr9:37490421~37490893:-
BRCA	cis	rs17801127	0.818	rs12233116	ENSG00000231969.1	AC144449.1	3.37	0.000791	0.0359	0.18	0.1	Liver enzyme levels (alanine transaminase);	chr2:149690652	chr2:149587196~149848233:+
BRCA	cis	rs17801127	0.818	rs12992502	ENSG00000231969.1	AC144449.1	3.37	0.000791	0.0359	0.18	0.1	Liver enzyme levels (alanine transaminase);	chr2:149691124	chr2:149587196~149848233:+
BRCA	cis	rs7267979	0.932	rs13040655	ENSG00000274973.1	RP13-401N8.7	-3.37	0.000791	0.0359	-0.12	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25601561	chr20:25845497~25845862:+
BRCA	cis	rs9992667	0.563	rs17500878	ENSG00000231160.8	KLF3-AS1	3.37	0.000791	0.0359	0.11	0.1	Eosinophil percentage of granulocytes;	chr4:38701308	chr4:38612701~38664883:-
BRCA	cis	rs886774	0.707	rs10232049	ENSG00000273055.1	CTB-13F3.1	-3.37	0.000791	0.0359	-0.11	-0.1	Ulcerative colitis;	chr7:107926043	chr7:107942116~107942740:+
BRCA	cis	rs17192198	0.613	rs17465265	ENSG00000258302.2	RP11-981P6.1	3.37	0.000791	0.0359	0.12	0.1	Diastolic blood pressure;	chr12:89570491	chr12:89561129~89594878:+
BRCA	cis	rs6429422	0.769	rs12744216	ENSG00000224727.1	FCF1P7	-3.37	0.000791	0.0359	-0.12	-0.1	Cognitive ability (multi-trait analysis);	chr1:243239991	chr1:243267257~243268119:-
BRCA	cis	rs863345	0.584	rs6427438	ENSG00000176320.2	RP11-404O13.5	-3.37	0.000791	0.0359	-0.11	-0.1	Pneumococcal bacteremia;	chr1:158484940	chr1:158197922~158203877:-
BRCA	cis	rs863345	0.604	rs10908653	ENSG00000176320.2	RP11-404O13.5	-3.37	0.000791	0.0359	-0.11	-0.1	Pneumococcal bacteremia;	chr1:158485563	chr1:158197922~158203877:-
BRCA	cis	rs2281603	0.951	rs60908674	ENSG00000259116.1	RP11-973N13.4	-3.37	0.000791	0.0359	-0.1	-0.1	Lymphocyte counts;	chr14:64514181	chr14:64514154~64540368:-
BRCA	cis	rs2281603	0.904	rs59440409	ENSG00000259116.1	RP11-973N13.4	-3.37	0.000791	0.0359	-0.1	-0.1	Lymphocyte counts;	chr14:64514249	chr14:64514154~64540368:-
BRCA	cis	rs7819412	0.505	rs17782554	ENSG00000255046.1	RP11-297N6.4	3.37	0.000792	0.0359	0.13	0.1	Triglycerides;	chr8:11164596	chr8:11797928~11802568:-
BRCA	cis	rs849141	0.961	rs506154	ENSG00000234336.5	JAZF1-AS1	-3.37	0.000792	0.0359	-0.15	-0.1	Height;Hip circumference adjusted for BMI;	chr7:28162460	chr7:28180322~28243917:+
BRCA	cis	rs832540	0.864	rs832576	ENSG00000237705.1	AC008937.2	3.37	0.000792	0.0359	0.1	0.1	Coronary artery disease;	chr5:56867428	chr5:56842016~56862164:-
BRCA	cis	rs77106637	0.932	rs2886599	ENSG00000256633.1	RP11-169D4.2	3.37	0.000792	0.0359	0.15	0.1	Type 2 diabetes;	chr11:73010226	chr11:72584572~72587979:+
BRCA	cis	rs7809799	0.85	rs6962075	ENSG00000242798.1	RP11-506M12.1	3.37	0.000792	0.0359	0.2	0.1	Ulcerative colitis;	chr7:99160317	chr7:100115214~100127139:-
BRCA	cis	rs8114671	0.967	rs12481169	ENSG00000261582.1	RP4-614O4.11	3.37	0.000792	0.0359	0.1	0.1	Height;	chr20:35206707	chr20:35267885~35280043:-
BRCA	cis	rs324126	0.78	rs3170100	ENSG00000277977.1	CTD-3018O17.5	3.37	0.000792	0.0359	0.12	0.1	Colonoscopy-negative controls vs population controls;	chr19:52385367	chr19:52392659~52392755:+
BRCA	cis	rs10129255	0.913	rs10140943	ENSG00000211959.2	IGHV4-39	3.37	0.000792	0.0359	0.08	0.1	Kawasaki disease;	chr14:106767441	chr14:106421711~106422218:-
BRCA	cis	rs8023401	0.938	rs12907671	ENSG00000274654.1	CTD-3247H4.2	3.37	0.000792	0.0359	0.15	0.1	Spherical equivalent (joint analysis main effects and education interaction);	chr15:48486941	chr15:48528980~48529728:-
BRCA	cis	rs9467773	1	rs6456734	ENSG00000261353.1	CTA-14H9.5	-3.37	0.000792	0.0359	-0.11	-0.1	Intelligence (multi-trait analysis);	chr6:26566737	chr6:26527063~26527404:+
BRCA	cis	rs713477	0.505	rs1953740	ENSG00000186615.9	KTN1-AS1	-3.37	0.000792	0.0359	-0.13	-0.1	Pediatric bone mineral content (femoral neck);	chr14:55419999	chr14:55499278~55580110:-
BRCA	cis	rs1468333	0.567	rs6889491	ENSG00000206989.1	SNORD63	3.37	0.000792	0.0359	0.12	0.1	Resting heart rate;	chr5:138336462	chr5:138561043~138561110:-
BRCA	cis	rs6560517	0.581	rs2501935	ENSG00000234618.1	RPSAP9	3.37	0.000792	0.0359	0.11	0.1	Dialysis-related mortality;	chr9:76374913	chr9:76398699~76399586:+
BRCA	cis	rs8099594	0.64	rs9949963	ENSG00000266696.1	RP11-30L3.2	3.37	0.000792	0.0359	0.12	0.1	Height;	chr18:49410356	chr18:49205912~49208781:+
BRCA	cis	rs8040855	0.658	rs11634877	ENSG00000229212.6	RP11-561C5.4	-3.37	0.000792	0.0359	-0.14	-0.1	Bulimia nervosa;	chr15:85068246	chr15:85205440~85234795:-
BRCA	cis	rs8040855	0.627	rs11632175	ENSG00000229212.6	RP11-561C5.4	-3.37	0.000792	0.0359	-0.14	-0.1	Bulimia nervosa;	chr15:85068449	chr15:85205440~85234795:-
BRCA	cis	rs17270561	0.609	rs9348694	ENSG00000272462.2	U91328.19	-3.37	0.000792	0.0359	-0.13	-0.1	Iron status biomarkers;	chr6:25753412	chr6:25992662~26001775:+
BRCA	cis	rs12887734	0.569	rs66953418	ENSG00000269940.1	RP11-73M18.7	3.37	0.000792	0.0359	0.11	0.1	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103805133	chr14:103694560~103695170:+
BRCA	cis	rs2832077	0.943	rs2832084	ENSG00000236056.1	GAPDHP14	3.37	0.000792	0.0359	0.15	0.1	Cognitive test performance;	chr21:28782476	chr21:29222321~29223257:+
BRCA	cis	rs1124769	0.719	rs12911168	ENSG00000274528.1	CTD-2650P22.2	3.37	0.000792	0.0359	0.13	0.1	Cognitive performance;	chr15:51088391	chr15:52017167~52018032:-
BRCA	cis	rs875971	1	rs7789554	ENSG00000273448.1	RP11-166O4.6	3.37	0.000792	0.0359	0.09	0.1	Aortic root size;	chr7:66481051	chr7:67333047~67334383:+
BRCA	cis	rs875971	1	rs4717300	ENSG00000273448.1	RP11-166O4.6	3.37	0.000792	0.0359	0.09	0.1	Aortic root size;	chr7:66482393	chr7:67333047~67334383:+
BRCA	cis	rs875971	0.895	rs1974769	ENSG00000273448.1	RP11-166O4.6	3.37	0.000792	0.0359	0.09	0.1	Aortic root size;	chr7:66485627	chr7:67333047~67334383:+
BRCA	cis	rs875971	0.895	rs6460300	ENSG00000273448.1	RP11-166O4.6	3.37	0.000792	0.0359	0.09	0.1	Aortic root size;	chr7:66487937	chr7:67333047~67334383:+
BRCA	cis	rs875971	0.862	rs7803416	ENSG00000273448.1	RP11-166O4.6	3.37	0.000792	0.0359	0.09	0.1	Aortic root size;	chr7:66489212	chr7:67333047~67334383:+
BRCA	cis	rs875971	0.964	rs2277911	ENSG00000273448.1	RP11-166O4.6	3.37	0.000792	0.0359	0.09	0.1	Aortic root size;	chr7:66493638	chr7:67333047~67334383:+
BRCA	cis	rs4654783	0.627	rs1046310	ENSG00000271428.1	RP1-224A6.8	3.37	0.000792	0.0359	0.11	0.1	Endometriosis;	chr1:22117394	chr1:22068340~22068827:-
BRCA	cis	rs57709857	0.915	rs12681196	ENSG00000272092.1	RP11-350N15.5	-3.37	0.000792	0.0359	-0.13	-0.1	Autism spectrum disorder or schizophrenia;	chr8:38379076	chr8:38382364~38383461:+
BRCA	cis	rs11971186	1	rs10954138	ENSG00000279265.1	AC000123.3	-3.37	0.000792	0.0359	-0.13	-0.1	Chemerin levels;	chr7:126785691	chr7:127349833~127350293:-
BRCA	cis	rs4713118	0.662	rs149970	ENSG00000226314.6	ZNF192P1	-3.37	0.000792	0.036	-0.15	-0.1	Parkinson's disease;	chr6:28012442	chr6:28161781~28169594:+
BRCA	cis	rs4714291	0.963	rs761801	ENSG00000180211.5	RP1-278E11.3	3.37	0.000792	0.036	0.11	0.1	Strep throat;	chr6:40029437	chr6:39958414~39958833:-
BRCA	cis	rs6545883	0.965	rs778752	ENSG00000212978.6	AC016747.3	3.37	0.000792	0.036	0.14	0.1	Tuberculosis;	chr2:61549767	chr2:61141592~61144969:-
BRCA	cis	rs2832077	0.506	rs10222093	ENSG00000232855.5	AF131217.1	3.37	0.000793	0.036	0.14	0.1	Cognitive test performance;	chr21:28791196	chr21:28439346~28674848:-
BRCA	cis	rs2277027	1	rs4579242	ENSG00000251405.2	CTB-109A12.1	3.37	0.000793	0.036	0.13	0.1	Pulmonary function;Pulmonary function (smoking interaction);	chr5:157512490	chr5:157362615~157460078:-
BRCA	cis	rs4356203	0.87	rs7925692	ENSG00000184669.7	OR7E14P	3.37	0.000793	0.036	0.13	0.1	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17249575	chr11:17013998~17053024:+
BRCA	cis	rs76963786	0.901	rs1666212	ENSG00000201563.1	Y_RNA	3.37	0.000793	0.036	0.15	0.1	Interleukin-9 levels;	chr12:31884720	chr12:32705403~32705506:-
BRCA	cis	rs11887277	0.557	rs12465368	ENSG00000272148.1	RP11-195B17.1	-3.37	0.000793	0.036	-0.12	-0.1	Obesity-related traits;	chr2:26744241	chr2:27062428~27062907:-
BRCA	cis	rs3858526	0.883	rs10769326	ENSG00000224295.2	AC087380.14	3.37	0.000793	0.036	0.15	0.1	DNA methylation (variation);	chr11:5913128	chr11:5518441~5524955:-
BRCA	cis	rs875971	0.522	rs4718285	ENSG00000229180.5	GS1-124K5.11	3.37	0.000793	0.036	0.09	0.1	Aortic root size;	chr7:65827018	chr7:66526088~66542624:-
BRCA	cis	rs3781264	0.595	rs11187901	ENSG00000268894.5	PLCE1-AS1	-3.37	0.000793	0.036	-0.14	-0.1	Esophageal cancer and gastric cancer;	chr10:94355251	chr10:94279277~94287478:-
BRCA	cis	rs6964587	0.655	rs6965864	ENSG00000188693.7	CYP51A1-AS1	-3.37	0.000793	0.036	-0.11	-0.1	Breast cancer;	chr7:91966282	chr7:92134604~92180725:+
BRCA	cis	rs6964587	0.62	rs7808587	ENSG00000188693.7	CYP51A1-AS1	-3.37	0.000793	0.036	-0.11	-0.1	Breast cancer;	chr7:91990782	chr7:92134604~92180725:+
BRCA	cis	rs2832077	0.943	rs2832106	ENSG00000215533.7	LINC00189	3.37	0.000793	0.036	0.15	0.1	Cognitive test performance;	chr21:28819445	chr21:29193480~29288205:+
BRCA	cis	rs12893668	0.703	rs8017993	ENSG00000258914.1	CTD-2134A5.3	3.37	0.000793	0.036	0.14	0.1	Reticulocyte count;	chr14:103581397	chr14:103875055~103877478:+
BRCA	cis	rs4869313	0.643	rs6556943	ENSG00000248734.2	CTD-2260A17.1	-3.37	0.000793	0.036	-0.1	-0.1	Pediatric autoimmune diseases;	chr5:96894699	chr5:96784777~96785999:+
BRCA	cis	rs7620503	1	rs7630147	ENSG00000228561.2	RP11-114M1.1	3.36	0.000793	0.036	0.12	0.1	Corneal structure;	chr3:177582603	chr3:177683627~177691250:+
BRCA	cis	rs7620503	0.959	rs4857709	ENSG00000228561.2	RP11-114M1.1	3.36	0.000793	0.036	0.12	0.1	Corneal structure;	chr3:177583167	chr3:177683627~177691250:+
BRCA	cis	rs7620503	1	rs4857710	ENSG00000228561.2	RP11-114M1.1	3.36	0.000793	0.036	0.12	0.1	Corneal structure;	chr3:177583177	chr3:177683627~177691250:+
BRCA	cis	rs7620503	1	rs6763782	ENSG00000228561.2	RP11-114M1.1	3.36	0.000793	0.036	0.12	0.1	Corneal structure;	chr3:177583492	chr3:177683627~177691250:+
BRCA	cis	rs7620503	0.729	rs2863018	ENSG00000228561.2	RP11-114M1.1	3.36	0.000793	0.036	0.12	0.1	Corneal structure;	chr3:177584123	chr3:177683627~177691250:+
BRCA	cis	rs2133593	1	rs2133593	ENSG00000228561.2	RP11-114M1.1	3.36	0.000793	0.036	0.12	0.1	Chin dimples;	chr3:177584204	chr3:177683627~177691250:+
BRCA	cis	rs6840360	0.615	rs12647616	ENSG00000270265.1	RP11-731D1.4	-3.36	0.000793	0.036	-0.12	-0.1	Intelligence (multi-trait analysis);	chr4:151686510	chr4:151333775~151353224:-
BRCA	cis	rs56046484	0.871	rs34978449	ENSG00000259630.2	CTD-2262B20.1	-3.36	0.000793	0.036	-0.17	-0.1	Testicular germ cell tumor;	chr15:85036917	chr15:85415228~85415633:+
BRCA	cis	rs9990333	0.521	rs3862281	ENSG00000273009.1	RP11-352G9.1	-3.36	0.000793	0.036	-0.13	-0.1	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196092985	chr3:195913078~195913683:-
BRCA	cis	rs8105895	1	rs11881224	ENSG00000269345.1	VN1R85P	3.36	0.000794	0.036	0.16	0.1	Body mass index (change over time);	chr19:22037538	chr19:22174766~22175191:-
BRCA	cis	rs6813195	0.602	rs4146039	ENSG00000245954.5	RP11-18H21.1	3.36	0.000794	0.036	0.09	0.1	Type 2 diabetes;	chr4:152449955	chr4:152100754~152104720:+
BRCA	cis	rs17767294	0.708	rs72851138	ENSG00000219392.1	RP1-265C24.5	-3.36	0.000794	0.036	-0.28	-0.1	Parkinson's disease;	chr6:28074876	chr6:28115628~28116551:+
BRCA	cis	rs17767294	0.708	rs72851139	ENSG00000219392.1	RP1-265C24.5	-3.36	0.000794	0.036	-0.28	-0.1	Parkinson's disease;	chr6:28074920	chr6:28115628~28116551:+
BRCA	cis	rs17767294	0.708	rs72851156	ENSG00000219392.1	RP1-265C24.5	-3.36	0.000794	0.036	-0.28	-0.1	Parkinson's disease;	chr6:28092308	chr6:28115628~28116551:+
BRCA	cis	rs17767294	0.708	rs72851158	ENSG00000219392.1	RP1-265C24.5	-3.36	0.000794	0.036	-0.28	-0.1	Parkinson's disease;	chr6:28092707	chr6:28115628~28116551:+
BRCA	cis	rs17767294	0.708	rs72851160	ENSG00000219392.1	RP1-265C24.5	-3.36	0.000794	0.036	-0.28	-0.1	Parkinson's disease;	chr6:28100063	chr6:28115628~28116551:+
BRCA	cis	rs9468199	0.51	rs72851161	ENSG00000219392.1	RP1-265C24.5	-3.36	0.000794	0.036	-0.28	-0.1	Parkinson's disease;	chr6:28103345	chr6:28115628~28116551:+
BRCA	cis	rs17767294	0.708	rs77689085	ENSG00000219392.1	RP1-265C24.5	-3.36	0.000794	0.036	-0.28	-0.1	Parkinson's disease;	chr6:28104758	chr6:28115628~28116551:+
BRCA	cis	rs2899832	0.5	rs77131173	ENSG00000258704.4	SRP54-AS1	3.36	0.000794	0.036	0.24	0.1	Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:35272378	chr14:34920858~34982532:-
BRCA	cis	rs17192198	0.544	rs1554391	ENSG00000270344.2	RP11-734K2.4	3.36	0.000794	0.036	0.11	0.1	Diastolic blood pressure;	chr12:89744235	chr12:89525654~89548005:+
BRCA	cis	rs3808502	0.549	rs7831039	ENSG00000248896.2	CTD-2135J3.3	-3.36	0.000794	0.036	-0.13	-0.1	Neuroticism;	chr8:11570128	chr8:10729314~10771392:+
BRCA	cis	rs748404	0.55	rs12912505	ENSG00000201136.1	RNU6-353P	3.36	0.000794	0.036	0.15	0.1	Lung cancer;	chr15:43525206	chr15:43702363~43702470:+
BRCA	cis	rs830124	0.925	rs2230681	ENSG00000272849.1	RP11-347I19.8	-3.36	0.000794	0.036	-0.11	-0.1	Urinary metabolites;	chr12:121888906	chr12:121797511~121801972:+
BRCA	cis	rs755249	0.51	rs599892	ENSG00000243970.1	PPIEL	3.36	0.000794	0.036	0.13	0.1	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39457212	chr1:39531838~39558707:-
BRCA	cis	rs687432	0.887	rs11601202	ENSG00000213592.4	AP000662.9	-3.36	0.000794	0.036	-0.15	-0.1	Parkinson's disease;	chr11:58005688	chr11:57718044~57718530:-
BRCA	cis	rs7712401	0.791	rs10071135	ENSG00000249996.1	RP11-359P5.1	3.36	0.000794	0.036	0.12	0.1	Mean platelet volume;	chr5:122811283	chr5:123036271~123054667:+
BRCA	cis	rs3096299	0.685	rs3803682	ENSG00000259877.2	RP11-46C24.7	-3.36	0.000794	0.036	-0.1	-0.1	Multiple myeloma (IgH translocation);	chr16:89478228	chr16:89215211~89217653:-
BRCA	cis	rs854765	0.52	rs9899355	ENSG00000197815.4	RP1-253P7.4	-3.36	0.000794	0.036	-0.08	-0.1	Total body bone mineral density;	chr17:17994929	chr17:17858227~17860041:+
BRCA	cis	rs12477438	0.501	rs12995473	ENSG00000231822.1	AC019097.7	3.36	0.000794	0.036	0.11	0.1	Chronic sinus infection;	chr2:99148421	chr2:99102018~99102752:+
BRCA	cis	rs12477438	0.501	rs11685756	ENSG00000231822.1	AC019097.7	3.36	0.000794	0.036	0.11	0.1	Chronic sinus infection;	chr2:99149752	chr2:99102018~99102752:+
BRCA	cis	rs9807841	0.643	rs3843751	ENSG00000267100.1	ILF3-AS1	3.36	0.000794	0.036	0.11	0.1	Inflammatory skin disease;	chr19:10637445	chr19:10651862~10653844:-
BRCA	cis	rs6671200	1	rs62625008	ENSG00000228852.5	RP11-57H12.5	3.36	0.000794	0.036	0.19	0.1	Stearic acid (18:0) levels;	chr1:95237026	chr1:95243167~95278940:-
BRCA	cis	rs6671200	0.92	rs35403759	ENSG00000228852.5	RP11-57H12.5	3.36	0.000794	0.036	0.19	0.1	Stearic acid (18:0) levels;	chr1:95237334	chr1:95243167~95278940:-
BRCA	cis	rs2708977	0.842	rs10209780	ENSG00000271569.1	IGKV1OR2-6	-3.36	0.000794	0.036	-0.07	-0.1	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96474405	chr2:97355059~97355335:+
BRCA	cis	rs12439619	0.693	rs4778989	ENSG00000259429.4	UBE2Q2P2	-3.36	0.000794	0.036	-0.12	-0.1	Intelligence (multi-trait analysis);	chr15:82276963	chr15:82355142~82420075:+
BRCA	cis	rs1208	0.899	rs7011792	ENSG00000253671.1	RP11-806O11.1	3.36	0.000794	0.036	0.12	0.1	Insulin resistance/response;	chr8:18394559	chr8:17808941~17820868:+
BRCA	cis	rs2235642	0.717	rs2236269	ENSG00000260260.1	SNHG19	-3.36	0.000794	0.036	-0.1	-0.1	Coronary artery disease;	chr16:1602613	chr16:2154797~2155358:-
BRCA	cis	rs4657482	0.607	rs3790671	ENSG00000203307.2	RP11-375H19.2	-3.36	0.000794	0.036	-0.14	-0.1	Testicular germ cell tumor;	chr1:165904085	chr1:166081183~166087483:+
BRCA	cis	rs4665809	0.838	rs6546780	ENSG00000231655.1	AC011742.3	3.36	0.000794	0.036	0.15	0.1	Gut microbiome composition (summer);	chr2:26129988	chr2:26140263~26141264:-
BRCA	cis	rs875971	0.545	rs221986	ENSG00000226767.1	RP11-328P23.3	-3.36	0.000795	0.036	-0.13	-0.1	Aortic root size;	chr7:66105323	chr7:65508773~65508944:-
BRCA	cis	rs10761482	0.859	rs2219533	ENSG00000254271.1	RP11-131N11.4	3.36	0.000795	0.036	0.14	0.1	Schizophrenia;	chr10:60335156	chr10:60734342~60741828:+
BRCA	cis	rs9527	0.615	rs7899622	ENSG00000236937.2	PTGES3P4	3.36	0.000795	0.036	0.14	0.1	Arsenic metabolism;	chr10:102967576	chr10:102845595~102845950:+
BRCA	cis	rs6556937	0.627	rs6860934	ENSG00000247121.5	CTD-2260A17.2	3.36	0.000795	0.036	0.12	0.1	Blood protein levels;	chr5:96666138	chr5:96814028~96935809:-
BRCA	cis	rs76096589	0.557	rs3783409	ENSG00000270062.1	RP11-248J18.3	-3.36	0.000795	0.036	-0.25	-0.1	Diisocyanate-induced asthma;	chr14:50523682	chr14:50723777~50724272:-
BRCA	cis	rs7577696	0.962	rs34856365	ENSG00000276334.1	AL133243.1	-3.36	0.000795	0.036	-0.13	-0.1	Inflammatory biomarkers;	chr2:32079931	chr2:32521927~32523547:+
BRCA	cis	rs7577696	0.962	rs6760105	ENSG00000276334.1	AL133243.1	-3.36	0.000795	0.036	-0.13	-0.1	Inflammatory biomarkers;	chr2:32082317	chr2:32521927~32523547:+
BRCA	cis	rs7577696	0.924	rs6747488	ENSG00000276334.1	AL133243.1	-3.36	0.000795	0.036	-0.13	-0.1	Inflammatory biomarkers;	chr2:32086215	chr2:32521927~32523547:+
BRCA	cis	rs7577696	0.924	rs7561519	ENSG00000276334.1	AL133243.1	-3.36	0.000795	0.036	-0.13	-0.1	Inflammatory biomarkers;	chr2:32087631	chr2:32521927~32523547:+
BRCA	cis	rs2625529	0.627	rs12902661	ENSG00000260037.4	CTD-2524L6.3	-3.36	0.000795	0.036	-0.15	-0.1	Red blood cell count;	chr15:72187817	chr15:71818396~71823384:+
BRCA	cis	rs2054399	0.521	rs2054397	ENSG00000260743.1	RP11-255C15.3	3.36	0.000795	0.036	0.13	0.1	Bipolar disorder and schizophrenia;	chr3:178544652	chr3:179340322~179341887:+
BRCA	cis	rs2688608	0.836	rs2675668	ENSG00000213731.2	RAB5CP1	-3.36	0.000795	0.0361	-0.12	-0.1	Inflammatory bowel disease;	chr10:73876390	chr10:74423435~74424014:-
BRCA	cis	rs8050907	0.744	rs8044698	ENSG00000280063.1	RP11-295D4.3	3.36	0.000795	0.0361	0.14	0.1	Obesity-related traits;	chr16:4527068	chr16:4346694~4348648:-
BRCA	cis	rs754133	0.891	rs12426399	ENSG00000248265.1	FLJ12825	3.36	0.000795	0.0361	0.13	0.1	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);	chr12:54026126	chr12:54058254~54122234:+
BRCA	cis	rs1005277	0.522	rs9418276	ENSG00000099251.13	HSD17B7P2	3.36	0.000795	0.0361	0.11	0.1	Extrinsic epigenetic age acceleration;	chr10:37651188	chr10:38356380~38378505:+
BRCA	cis	rs1005277	0.522	rs7072977	ENSG00000099251.13	HSD17B7P2	3.36	0.000795	0.0361	0.11	0.1	Extrinsic epigenetic age acceleration;	chr10:37651512	chr10:38356380~38378505:+
BRCA	cis	rs911555	0.755	rs35233301	ENSG00000259775.1	RP11-45P15.4	3.36	0.000795	0.0361	0.12	0.1	Intelligence (multi-trait analysis);	chr14:103418954	chr14:103331674~103332367:-
BRCA	cis	rs4381241	0.5	rs6664846	ENSG00000236434.2	RP11-296A18.6	-3.36	0.000795	0.0361	-0.13	-0.1	Renal cell carcinoma;	chr1:50412430	chr1:51264916~51266074:-
BRCA	cis	rs2834288	0.613	rs2040113	ENSG00000237945.6	LINC00649	3.36	0.000795	0.0361	0.12	0.1	Gut microbiota (bacterial taxa);	chr21:33908879	chr21:33915534~33977691:+
BRCA	cis	rs7209700	0.662	rs8074094	ENSG00000228782.6	CTD-2026D20.3	-3.36	0.000795	0.0361	-0.13	-0.1	IgG glycosylation;	chr17:47270655	chr17:47450568~47492492:-
BRCA	cis	rs7577696	0.889	rs455060	ENSG00000276334.1	AL133243.1	3.36	0.000795	0.0361	0.13	0.1	Inflammatory biomarkers;	chr2:32250040	chr2:32521927~32523547:+
BRCA	cis	rs10844706	0.699	rs2401390	ENSG00000256594.6	RP11-705C15.2	3.36	0.000795	0.0361	0.14	0.1	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9719218	chr12:9633419~9658412:+
BRCA	cis	rs12714314	0.756	rs10175420	ENSG00000228613.1	AC144450.1	3.36	0.000795	0.0361	0.11	0.1	Type 2 diabetes (age of onset);	chr2:1934366	chr2:1546665~1620113:-
BRCA	cis	rs4919694	1	rs12253284	ENSG00000236937.2	PTGES3P4	3.36	0.000795	0.0361	0.21	0.1	Arsenic metabolism;	chr10:102905388	chr10:102845595~102845950:+
BRCA	cis	rs2195987	1	rs2195987	ENSG00000268442.1	CTD-2027I19.2	-3.36	0.000795	0.0361	-0.16	-0.1	Testicular germ cell tumor;	chr19:23966743	chr19:24162370~24163425:-
BRCA	cis	rs7000551	0.725	rs2443496	ENSG00000253125.1	RP11-459E5.1	3.36	0.000795	0.0361	0.1	0.1	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr8:22508275	chr8:22690150~22798616:+
BRCA	cis	rs984222	0.838	rs7553422	ENSG00000231365.4	RP11-418J17.1	-3.36	0.000795	0.0361	-0.12	-0.1	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:118998096	chr1:119140396~119275973:+
BRCA	cis	rs2562456	1	rs2359155	ENSG00000240522.1	RPL7AP10	3.36	0.000795	0.0361	0.11	0.1	Pain;	chr19:21489067	chr19:21149648~21150438:-
BRCA	cis	rs6517329	0.564	rs881712	ENSG00000230212.5	AP000688.14	3.36	0.000796	0.0361	0.13	0.1	Schizophrenia;	chr21:36135471	chr21:36069642~36126640:-
BRCA	cis	rs4699052	1	rs4699055	ENSG00000230069.3	LRRC37A15P	-3.36	0.000796	0.0361	-0.1	-0.1	Testicular germ cell tumor;	chr4:103233343	chr4:102727274~102730721:-
BRCA	cis	rs1549733	0.523	rs7571683	ENSG00000229754.1	CXCR2P1	-3.36	0.000796	0.0361	-0.1	-0.1	Optic disc area;	chr2:217556790	chr2:218059155~218065729:-
BRCA	cis	rs11877825	0.826	rs8082984	ENSG00000265728.1	RP11-883A18.3	-3.36	0.000796	0.0361	-0.14	-0.1	Gut microbiota (bacterial taxa);	chr18:10571907	chr18:10594590~10604798:+
BRCA	cis	rs10816359	0.894	rs10816364	ENSG00000234323.4	RP11-308N19.1	-3.36	0.000796	0.0361	-0.15	-0.1	Menarche (age at onset);	chr9:106013485	chr9:106278392~106604795:+
BRCA	cis	rs8114671	0.527	rs6060112	ENSG00000261582.1	RP4-614O4.11	-3.36	0.000796	0.0361	-0.1	-0.1	Height;	chr20:34901473	chr20:35267885~35280043:-
BRCA	cis	rs7222240	1	rs12568	ENSG00000233483.2	CTD-2020K17.4	-3.36	0.000796	0.0361	-0.13	-0.1	Craniofacial microsomia;	chr17:45023463	chr17:45245186~45248836:-
BRCA	cis	rs12893668	0.572	rs12590968	ENSG00000258914.1	CTD-2134A5.3	3.36	0.000796	0.0361	0.14	0.1	Reticulocyte count;	chr14:103670296	chr14:103875055~103877478:+
BRCA	cis	rs61869271	0.692	rs61869274	ENSG00000236799.1	RP11-383C6.2	-3.36	0.000796	0.0361	-0.13	-0.1	Tonsillectomy;	chr10:114982570	chr10:114994657~114996593:+
BRCA	cis	rs7572644	0.537	rs10198041	ENSG00000223522.1	AC093690.1	-3.36	0.000796	0.0361	-0.12	-0.1	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:28169595	chr2:28307691~28310459:-
BRCA	cis	rs7267979	0.586	rs1007708	ENSG00000276952.1	RP5-965G21.6	3.36	0.000796	0.0361	0.12	0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25210323	chr20:25284915~25285588:-
BRCA	cis	rs11874712	1	rs11082509	ENSG00000251939.1	RNU6-1278P	-3.36	0.000796	0.0361	-0.11	-0.1	Migraine - clinic-based;	chr18:46075044	chr18:46121615~46121721:-
BRCA	cis	rs11874712	1	rs11082510	ENSG00000251939.1	RNU6-1278P	-3.36	0.000796	0.0361	-0.11	-0.1	Migraine - clinic-based;	chr18:46076654	chr18:46121615~46121721:-
BRCA	cis	rs7572733	0.765	rs2164068	ENSG00000231621.1	AC013264.2	-3.36	0.000796	0.0361	-0.1	-0.1	Dermatomyositis;	chr2:198079128	chr2:197197991~197199273:+
BRCA	cis	rs12438356	1	rs7165082	ENSG00000259222.2	RP11-809H16.5	3.36	0.000796	0.0361	0.14	0.1	CTACK levels;	chr15:69288451	chr15:69080879~69099987:+
BRCA	cis	rs8062405	0.824	rs240702	ENSG00000261766.1	RP11-22P6.2	-3.36	0.000796	0.0361	-0.1	-0.1	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28520032	chr16:28862166~28863340:-
BRCA	cis	rs2288884	0.537	rs4145658	ENSG00000267927.1	CTD-2525I3.2	3.36	0.000796	0.0361	0.13	0.1	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52085465	chr19:52171158~52177002:+
BRCA	cis	rs863345	0.604	rs1112915	ENSG00000229914.1	RP11-404O13.4	-3.36	0.000796	0.0361	-0.11	-0.1	Pneumococcal bacteremia;	chr1:158474657	chr1:158195633~158196131:-
BRCA	cis	rs35306767	0.855	rs2050944	ENSG00000229869.1	RP11-363N22.2	-3.36	0.000796	0.0361	-0.16	-0.1	Eosinophil percentage of granulocytes;	chr10:872970	chr10:933026~942743:+
BRCA	cis	rs7267979	0.528	rs2387976	ENSG00000274973.1	RP13-401N8.7	3.36	0.000796	0.0361	0.12	0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25618924	chr20:25845497~25845862:+
BRCA	cis	rs7953704	1	rs61952922	ENSG00000212694.7	LINC01089	-3.36	0.000796	0.0361	-0.08	-0.1	Urate levels;	chr12:122082669	chr12:121795267~121803906:-
BRCA	cis	rs11877825	0.737	rs6505572	ENSG00000265728.1	RP11-883A18.3	-3.36	0.000796	0.0361	-0.14	-0.1	Gut microbiota (bacterial taxa);	chr18:10579369	chr18:10594590~10604798:+
BRCA	cis	rs459571	0.959	rs461462	ENSG00000235106.7	LINC00094	3.36	0.000796	0.0361	0.11	0.1	Platelet distribution width;	chr9:134046150	chr9:134025439~134034666:+
BRCA	cis	rs35493131	0.557	rs7251466	ENSG00000213904.7	LIPE-AS1	-3.36	0.000796	0.0361	-0.18	-0.1	Monocyte count;	chr19:42072800	chr19:42397128~42652355:+
BRCA	cis	rs6942407	0.546	rs4140847	ENSG00000224046.1	AC005076.5	-3.36	0.000796	0.0361	-0.15	-0.1	Food allergy;	chr7:87153947	chr7:87151423~87152420:-
BRCA	cis	rs6942407	0.546	rs3789251	ENSG00000224046.1	AC005076.5	-3.36	0.000796	0.0361	-0.15	-0.1	Food allergy;	chr7:87163987	chr7:87151423~87152420:-
BRCA	cis	rs6942407	0.546	rs3789252	ENSG00000224046.1	AC005076.5	-3.36	0.000796	0.0361	-0.15	-0.1	Food allergy;	chr7:87164046	chr7:87151423~87152420:-
BRCA	cis	rs6942407	0.546	rs765968	ENSG00000224046.1	AC005076.5	-3.36	0.000796	0.0361	-0.15	-0.1	Food allergy;	chr7:87165408	chr7:87151423~87152420:-
BRCA	cis	rs11790994	0.915	rs114106234	ENSG00000175611.10	LINC00476	3.36	0.000797	0.0361	0.18	0.1	Inattentive symptoms;	chr9:95665886	chr9:95759231~95875977:-
BRCA	cis	rs4805834	0.764	rs57910615	ENSG00000201388.1	SNORA68	3.36	0.000797	0.0361	0.18	0.1	Creatinine levels;	chr19:32869436	chr19:32608337~32608469:-
BRCA	cis	rs1795240	0.818	rs4916390	ENSG00000231424.2	RP1-45C12.1	3.36	0.000797	0.0361	0.11	0.1	Lentiform nucleus volume;	chr1:171128422	chr1:171247580~171251794:-
BRCA	cis	rs962856	0.575	rs3770657	ENSG00000236780.4	AC078941.1	3.36	0.000797	0.0361	0.14	0.1	Pancreatic cancer;	chr2:67403848	chr2:67123357~67215319:-
BRCA	cis	rs875971	0.522	rs2949690	ENSG00000232546.1	RP11-458F8.1	3.36	0.000797	0.0361	0.09	0.1	Aortic root size;	chr7:66018255	chr7:66848496~66858136:+
BRCA	cis	rs1466788	0.932	rs2274568	ENSG00000224965.1	KCNC4-AS1	3.36	0.000797	0.0361	0.12	0.1	Blood metabolite levels;	chr1:110070303	chr1:110208834~110209987:-
BRCA	cis	rs2692947	0.794	rs2140938	ENSG00000168992.4	OR7E102P	3.36	0.000797	0.0361	0.15	0.1	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96085647	chr2:95546531~95547545:+
BRCA	cis	rs952623	0.622	rs12667652	ENSG00000227191.5	TRGC2	3.36	0.000797	0.0361	0.09	0.1	Intelligence (multi-trait analysis);	chr7:39034972	chr7:38239580~38368091:-
BRCA	cis	rs11098499	0.863	rs3822195	ENSG00000260404.2	RP11-384K6.6	3.36	0.000797	0.0361	0.1	0.1	Corneal astigmatism;	chr4:119550505	chr4:118591773~118633729:+
BRCA	cis	rs2411233	1	rs8026182	ENSG00000259278.1	RP11-62C7.2	3.36	0.000797	0.0361	0.12	0.1	Platelet count;	chr15:38981743	chr15:39019233~39024918:+
BRCA	cis	rs7927592	0.956	rs12365160	ENSG00000254610.1	RP5-903G2.2	-3.36	0.000797	0.0361	-0.14	-0.1	Total body bone mineral density;	chr11:68482951	chr11:67934563~67939774:-
BRCA	cis	rs7927592	0.956	rs11228256	ENSG00000254610.1	RP5-903G2.2	-3.36	0.000797	0.0361	-0.14	-0.1	Total body bone mineral density;	chr11:68483992	chr11:67934563~67939774:-
BRCA	cis	rs853679	0.666	rs200956	ENSG00000280107.1	AL022393.9	-3.36	0.000797	0.0361	-0.17	-0.1	Depression;	chr6:27871968	chr6:28170845~28172521:+
BRCA	cis	rs1434538	0.967	rs989383	ENSG00000271474.1	RP11-710C12.1	-3.36	0.000797	0.0361	-0.13	-0.1	Coronary artery disease;	chr4:95153901	chr4:95549129~95552457:+
BRCA	cis	rs1434538	0.967	rs1434536	ENSG00000271474.1	RP11-710C12.1	-3.36	0.000797	0.0361	-0.13	-0.1	Coronary artery disease;	chr4:95154814	chr4:95549129~95552457:+
BRCA	cis	rs4848143	0.64	rs4848676	ENSG00000236859.5	NIFK-AS1	-3.36	0.000797	0.0361	-0.12	-0.1	Capecitabine sensitivity;	chr2:121044064	chr2:121649650~121728208:+
BRCA	cis	rs72775230	0.733	rs72775239	ENSG00000233990.1	RP11-401E9.3	-3.36	0.000798	0.0361	-0.18	-0.1	Conotruncal heart defects (inherited effects);	chr10:8519244	chr10:7833618~7833957:-
BRCA	cis	rs4955793	0.579	rs7615259	ENSG00000260743.1	RP11-255C15.3	3.36	0.000798	0.0361	0.22	0.1	Post-traumatic stress disorder (asjusted for relatedness);	chr3:179146095	chr3:179340322~179341887:+
BRCA	cis	rs1075265	0.87	rs1421617	ENSG00000272156.1	RP11-477N3.1	-3.36	0.000798	0.0361	-0.11	-0.1	Chronotype;Morning vs. evening chronotype;	chr2:54032995	chr2:54082554~54085066:+
BRCA	cis	rs7267979	0.586	rs6050439	ENSG00000274414.1	RP5-965G21.4	-3.36	0.000798	0.0361	-0.12	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25211695	chr20:25239007~25245229:-
BRCA	cis	rs7520050	0.751	rs2991975	ENSG00000281133.1	AL355480.3	3.36	0.000798	0.0361	0.12	0.1	Reticulocyte count;Red blood cell count;	chr1:45558854	chr1:45580892~45580996:-
BRCA	cis	rs375066	0.935	rs4803662	ENSG00000278917.1	RP11-15A1.4	-3.36	0.000798	0.0361	-0.12	-0.1	Breast cancer;	chr19:43855412	chr19:43891233~43895411:+
BRCA	cis	rs13136331	0.532	rs2615492	ENSG00000249001.4	RP11-742B18.1	3.36	0.000798	0.0361	0.14	0.1	Sitting height ratio;	chr4:87648339	chr4:87568035~87733956:-
BRCA	cis	rs6840360	0.615	rs55932132	ENSG00000270265.1	RP11-731D1.4	-3.36	0.000798	0.0361	-0.12	-0.1	Intelligence (multi-trait analysis);	chr4:151542745	chr4:151333775~151353224:-
BRCA	cis	rs465969	1	rs9387010	ENSG00000271789.1	RP5-1112D6.7	-3.36	0.000798	0.0362	-0.23	-0.1	Psoriasis;	chr6:111384741	chr6:111297126~111298510:+
BRCA	cis	rs11035577	0.704	rs4756532	ENSG00000279675.1	RP11-454H19.2	-3.36	0.000798	0.0362	-0.16	-0.1	Temperament (bipolar disorder);	chr11:39769548	chr11:40107244~40112599:-
BRCA	cis	rs6012953	0.692	rs941798	ENSG00000231715.1	COX6CP2	-3.36	0.000798	0.0362	-0.11	-0.1	Vitiligo;	chr20:50546698	chr20:50479767~50479991:+
BRCA	cis	rs4835473	0.932	rs12512649	ENSG00000246448.2	RP13-578N3.3	-3.36	0.000798	0.0362	-0.12	-0.1	Immature fraction of reticulocytes;	chr4:143736745	chr4:143700257~143865072:+
BRCA	cis	rs4648045	0.964	rs1801	ENSG00000246560.2	RP11-10L12.4	-3.36	0.000798	0.0362	-0.12	-0.1	Lymphocyte percentage of white cells;	chr4:102579897	chr4:102828055~102844075:+
BRCA	cis	rs11874712	0.966	rs8094902	ENSG00000251939.1	RNU6-1278P	-3.36	0.000798	0.0362	-0.11	-0.1	Migraine - clinic-based;	chr18:46086808	chr18:46121615~46121721:-
BRCA	cis	rs11874712	0.966	rs8093880	ENSG00000251939.1	RNU6-1278P	-3.36	0.000798	0.0362	-0.11	-0.1	Migraine - clinic-based;	chr18:46086820	chr18:46121615~46121721:-
BRCA	cis	rs863345	0.604	rs11264981	ENSG00000176320.2	RP11-404O13.5	-3.36	0.000798	0.0362	-0.11	-0.1	Pneumococcal bacteremia;	chr1:158486100	chr1:158197922~158203877:-
BRCA	cis	rs983392	0.678	rs7108663	ENSG00000275344.1	MIR6503	3.36	0.000798	0.0362	0.1	0.1	Alzheimer's disease (late onset);	chr11:60260669	chr11:60209071~60209156:-
BRCA	cis	rs6012564	0.826	rs2869715	ENSG00000230758.1	SNAP23P	3.36	0.000798	0.0362	0.12	0.1	Anger;	chr20:49143463	chr20:49038357~49038602:-
BRCA	cis	rs6012564	0.793	rs6066979	ENSG00000230758.1	SNAP23P	3.36	0.000798	0.0362	0.12	0.1	Anger;	chr20:49144319	chr20:49038357~49038602:-
BRCA	cis	rs6012564	0.762	rs6066980	ENSG00000230758.1	SNAP23P	3.36	0.000798	0.0362	0.12	0.1	Anger;	chr20:49144320	chr20:49038357~49038602:-
BRCA	cis	rs4981053	0.644	rs2150326	ENSG00000259001.3	RPPH1	3.36	0.000798	0.0362	0.12	0.1	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr14:20059200	chr14:20343048~20343685:-
BRCA	cis	rs1799955	0.554	rs9567578	ENSG00000212293.1	SNORA16	3.36	0.000798	0.0362	0.12	0.1	LDL cholesterol levels;	chr13:32347807	chr13:32420390~32420516:-
BRCA	cis	rs4805834	0.719	rs11673502	ENSG00000201388.1	SNORA68	3.36	0.000798	0.0362	0.18	0.1	Creatinine levels;	chr19:32802701	chr19:32608337~32608469:-
BRCA	cis	rs7487075	0.808	rs10880961	ENSG00000274723.1	RP11-618L22.1	3.36	0.000798	0.0362	0.13	0.1	Itch intensity from mosquito bite;	chr12:46371445	chr12:46970504~46972155:+
BRCA	cis	rs7829975	0.572	rs28730413	ENSG00000254153.1	CTA-398F10.2	-3.36	0.000798	0.0362	-0.12	-0.1	Mood instability;	chr8:8937937	chr8:8456909~8461337:-
BRCA	cis	rs7712401	0.755	rs3213794	ENSG00000249996.1	RP11-359P5.1	3.36	0.000798	0.0362	0.12	0.1	Mean platelet volume;	chr5:122825943	chr5:123036271~123054667:+
BRCA	cis	rs80226907	0.901	rs77895518	ENSG00000258413.1	RP11-665C16.6	-3.36	0.000798	0.0362	-0.27	-0.1	Mean platelet volume;	chr14:55356181	chr14:55262767~55272075:-
BRCA	cis	rs80226907	1	rs112349258	ENSG00000258413.1	RP11-665C16.6	-3.36	0.000798	0.0362	-0.27	-0.1	Mean platelet volume;	chr14:55358958	chr14:55262767~55272075:-
BRCA	cis	rs80226907	1	rs76605795	ENSG00000258413.1	RP11-665C16.6	-3.36	0.000798	0.0362	-0.27	-0.1	Mean platelet volume;	chr14:55361909	chr14:55262767~55272075:-
BRCA	cis	rs853679	0.517	rs36078605	ENSG00000272009.1	RP1-313I6.12	-3.36	0.000799	0.0362	-0.15	-0.1	Depression;	chr6:28110254	chr6:28078792~28081130:-
BRCA	cis	rs4718428	0.705	rs10267335	ENSG00000229886.1	RP5-1132H15.3	3.36	0.000799	0.0362	0.13	0.1	Corneal structure;	chr7:66938233	chr7:66025126~66031544:-
BRCA	cis	rs2836974	0.644	rs11088471	ENSG00000238141.2	BRWD1-AS1	-3.36	0.000799	0.0362	-0.12	-0.1	Cognitive function;	chr21:39327387	chr21:39315707~39323218:+
BRCA	cis	rs7697932	0.521	rs4507366	ENSG00000245322.5	RP11-15B17.1	3.36	0.000799	0.0362	0.13	0.1	Renal cell carcinoma;	chr4:100152515	chr4:99950006~100195099:+
BRCA	cis	rs1670533	1	rs2014318	ENSG00000251639.2	RP11-20I20.1	-3.36	0.000799	0.0362	-0.16	-0.1	Recombination rate (females);	chr4:1074990	chr4:1100016~1101558:-
BRCA	cis	rs7705502	0.78	rs111991836	ENSG00000251144.1	CTD-2532K18.2	-3.36	0.000799	0.0362	-0.13	-0.1	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for body mass index;	chr5:173872574	chr5:174820027~174826324:+
BRCA	cis	rs7705502	0.78	rs56285306	ENSG00000251144.1	CTD-2532K18.2	-3.36	0.000799	0.0362	-0.13	-0.1	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for body mass index;	chr5:173872897	chr5:174820027~174826324:+
BRCA	cis	rs7267979	1	rs6050573	ENSG00000276952.1	RP5-965G21.6	3.36	0.000799	0.0362	0.13	0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25385429	chr20:25284915~25285588:-
BRCA	cis	rs10895275	0.961	rs10895278	ENSG00000277459.1	RP11-732A21.3	-3.36	0.000799	0.0362	-0.11	-0.1	Migraine;	chr11:102224604	chr11:102109827~102110457:-
BRCA	cis	rs9990333	0.544	rs73208092	ENSG00000273009.1	RP11-352G9.1	-3.36	0.000799	0.0362	-0.13	-0.1	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196091703	chr3:195913078~195913683:-
BRCA	cis	rs10501293	0.746	rs7952412	ENSG00000252652.1	Y_RNA	-3.36	0.000799	0.0362	-0.12	-0.1	Cognitive performance;	chr11:42996222	chr11:43331261~43331356:+
BRCA	cis	rs12282928	0.657	rs10838826	ENSG00000255197.4	RP11-750H9.5	3.36	0.000799	0.0362	0.09	0.1	Migraine - clinic-based;	chr11:48198260	chr11:47383148~47409190:-
BRCA	cis	rs2236293	0.789	rs10758323	ENSG00000178723.7	GLULP4	3.36	0.000799	0.0362	0.13	0.1	Blood protein levels;	chr9:35786452	chr9:34917175~34918296:+
BRCA	cis	rs9875589	0.509	rs1386932	ENSG00000228242.5	AC093495.4	3.36	0.000799	0.0362	0.08	0.1	Ovarian reserve;	chr3:14019869	chr3:14144637~14165978:+
BRCA	cis	rs7112925	0.687	rs5006007	ENSG00000255038.1	RP11-1167A19.2	3.36	0.000799	0.0362	0.14	0.1	Height;	chr11:67063091	chr11:66067277~66069619:-
BRCA	cis	rs937213	0.573	rs3816900	ENSG00000275636.1	RP11-521C20.5	-3.36	0.000799	0.0362	-0.12	-0.1	Endometrial cancer;Endometrial endometrioid carcinoma;	chr15:40010042	chr15:40078892~40079347:+
BRCA	cis	rs937213	0.573	rs12592831	ENSG00000275636.1	RP11-521C20.5	-3.36	0.000799	0.0362	-0.12	-0.1	Endometrial cancer;Endometrial endometrioid carcinoma;	chr15:40010240	chr15:40078892~40079347:+
BRCA	cis	rs2414856	0.504	rs72742986	ENSG00000248415.1	GAPDHP61	-3.36	0.000799	0.0362	-0.24	-0.1	Pulse pressure;Systolic blood pressure;	chr15:64695030	chr15:64528667~64529671:-
BRCA	cis	rs74233809	1	rs1060240	ENSG00000236937.2	PTGES3P4	3.36	0.000799	0.0362	0.22	0.1	Birth weight;	chr10:103123580	chr10:102845595~102845950:+
BRCA	cis	rs74233809	1	rs10883835	ENSG00000236937.2	PTGES3P4	3.36	0.000799	0.0362	0.22	0.1	Birth weight;	chr10:103124451	chr10:102845595~102845950:+
BRCA	cis	rs7267979	1	rs6050573	ENSG00000231081.1	RP4-760C5.3	-3.36	0.000799	0.0362	-0.13	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25385429	chr20:26008791~26010531:-
BRCA	cis	rs4950322	0.563	rs6686480	ENSG00000230832.3	RP11-325P15.2	-3.36	0.000799	0.0362	-0.16	-0.1	Protein quantitative trait loci;	chr1:147111986	chr1:147082338~147083578:-
BRCA	cis	rs5751168	0.704	rs4239896	ENSG00000211670.2	IGLV3-9	3.36	8e-04	0.0362	0.13	0.1	Prostate cancer (SNP x SNP interaction);	chr22:22497821	chr22:22819010~22819756:+
BRCA	cis	rs2486012	0.737	rs541487	ENSG00000237950.1	RP11-7O11.3	3.36	8e-04	0.0362	0.16	0.1	Intelligence (multi-trait analysis);	chr1:43818237	chr1:43944370~43946551:-
BRCA	cis	rs2486012	0.649	rs37464	ENSG00000237950.1	RP11-7O11.3	3.36	8e-04	0.0362	0.16	0.1	Intelligence (multi-trait analysis);	chr1:43818489	chr1:43944370~43946551:-
BRCA	cis	rs6429082	0.806	rs2382570	ENSG00000230026.2	RP11-382D8.5	3.36	8e-04	0.0362	0.11	0.1	Adiposity;	chr1:235407208	chr1:235361153~235362540:+
BRCA	cis	rs897984	0.542	rs59061704	ENSG00000262766.1	RP11-196G11.4	3.36	8e-04	0.0362	0.08	0.1	Dementia with Lewy bodies;	chr16:31051383	chr16:31118078~31118747:+
BRCA	cis	rs11671005	0.735	rs11084544	ENSG00000265272.2	RN7SL693P	3.36	8e-04	0.0362	0.15	0.1	Mean platelet volume;	chr19:58428760	chr19:58490797~58491075:+
BRCA	cis	rs10139154	0.889	rs7147530	ENSG00000258640.3	RPL21P5	3.36	8e-04	0.0362	0.13	0.1	Amyotrophic lateral sclerosis;	chr14:30725416	chr14:31111569~31112239:-
BRCA	cis	rs875971	0.825	rs7384021	ENSG00000265600.1	AC006480.1	3.36	8e-04	0.0362	0.13	0.1	Aortic root size;	chr7:66612917	chr7:67356680~67356779:+
BRCA	cis	rs4653663	0.598	rs11587971	ENSG00000226349.1	RP11-145A3.2	-3.36	8e-04	0.0362	-0.14	-0.1	Neuroticism;	chr1:225749916	chr1:225710968~225736274:-
BRCA	cis	rs863345	0.604	rs1342945	ENSG00000176320.2	RP11-404O13.5	-3.36	8e-04	0.0362	-0.11	-0.1	Pneumococcal bacteremia;	chr1:158543122	chr1:158197922~158203877:-
BRCA	cis	rs10129255	0.536	rs10139058	ENSG00000253359.1	IGHV3-37	3.36	8e-04	0.0362	0.09	0.1	Kawasaki disease;	chr14:106685899	chr14:106396676~106397114:-
BRCA	cis	rs6452790	0.543	rs35348748	ENSG00000247828.6	TMEM161B-AS1	-3.36	8e-04	0.0362	-0.14	-0.1	Cognitive function;	chr5:87979045	chr5:88268895~88436685:+
BRCA	cis	rs7608910	0.578	rs2564114	ENSG00000237522.1	NONOP2	-3.36	8e-04	0.0362	-0.1	-0.1	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;	chr2:61003512	chr2:60936819~60938049:-
BRCA	cis	rs72775230	0.733	rs72775247	ENSG00000233990.1	RP11-401E9.3	-3.36	8e-04	0.0362	-0.18	-0.1	Conotruncal heart defects (inherited effects);	chr10:8520898	chr10:7833618~7833957:-
BRCA	cis	rs2041840	1	rs6544065	ENSG00000272054.1	RP11-423P10.2	-3.36	0.000801	0.0363	-0.1	-0.1	Chronic lymphocytic leukemia;	chr2:37270274	chr2:37208875~37212677:+
BRCA	cis	rs6840360	0.615	rs10001603	ENSG00000270265.1	RP11-731D1.4	-3.36	0.000801	0.0363	-0.12	-0.1	Intelligence (multi-trait analysis);	chr4:151726425	chr4:151333775~151353224:-
BRCA	cis	rs7591351	0.539	rs4952781	ENSG00000239332.4	LINC01119	3.36	0.000801	0.0363	0.11	0.1	Pathological gambling;	chr2:45846858	chr2:46816697~46859007:+
BRCA	cis	rs6750047	0.516	rs458704	ENSG00000235848.3	RMDN2-AS1	-3.36	0.000801	0.0363	-0.13	-0.1	Cutaneous malignant melanoma;Melanoma;	chr2:38090992	chr2:37949911~38067041:-
BRCA	cis	rs79387448	0.745	rs7583683	ENSG00000234389.1	AC007278.3	-3.36	0.000801	0.0363	-0.14	-0.1	Gut microbiota (bacterial taxa);	chr2:102497304	chr2:102438713~102440475:+
BRCA	cis	rs656900	0.647	rs1615963	ENSG00000261229.4	MTHFS	3.36	0.000801	0.0363	0.1	0.1	Cerebrospinal P-tau181p levels;	chr15:79823484	chr15:79843547~79897285:-
BRCA	cis	rs1400816	0.85	rs16859721	ENSG00000228389.1	AC068039.4	-3.36	0.000801	0.0363	-0.19	-0.1	Amyotrophic lateral sclerosis (sporadic);	chr2:171679662	chr2:171773482~171775844:+
BRCA	cis	rs897984	0.609	rs732173	ENSG00000275263.1	RP11-1072A3.4	-3.36	0.000801	0.0363	-0.12	-0.1	Dementia with Lewy bodies;	chr16:31038702	chr16:30956872~30957199:-
BRCA	cis	rs7165170	0.554	rs4244882	ENSG00000245479.2	LINC01585	-3.36	0.000801	0.0363	-0.13	-0.1	Crohn's disease;Inflammatory bowel disease;	chr15:90605945	chr15:90660234~90664967:+
BRCA	cis	rs7165170	0.554	rs4932175	ENSG00000245479.2	LINC01585	-3.36	0.000801	0.0363	-0.13	-0.1	Crohn's disease;Inflammatory bowel disease;	chr15:90605958	chr15:90660234~90664967:+
BRCA	cis	rs10782582	0.593	rs6704444	ENSG00000181227.3	RP4-682C21.2	3.36	0.000801	0.0363	0.11	0.1	Daytime sleep phenotypes;	chr1:75739423	chr1:75743423~75744776:-
BRCA	cis	rs2813490	0.956	rs2747643	ENSG00000227627.1	RP1-101K10.6	3.36	0.000801	0.0363	0.14	0.1	Number of pregnancies;	chr6:152153840	chr6:152983750~152989223:+
BRCA	cis	rs860295	0.702	rs12041534	ENSG00000236675.1	MTX1P1	3.36	0.000801	0.0363	0.12	0.1	Body mass index;	chr1:155437305	chr1:155230975~155234325:+
BRCA	cis	rs6028335	0.61	rs67882716	ENSG00000274825.1	RP4-616B8.5	-3.36	0.000801	0.0363	-0.13	-0.1	Alcohol and nicotine co-dependence;	chr20:38944596	chr20:38955910~38956547:+
BRCA	cis	rs72928364	1	rs13080859	ENSG00000244119.1	PDCL3P4	3.36	0.000801	0.0363	0.13	0.1	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100959216	chr3:101712472~101713191:+
BRCA	cis	rs1870634	0.541	rs4948808	ENSG00000273008.1	RP11-351D16.3	-3.36	0.000801	0.0363	-0.12	-0.1	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;	chr10:43995406	chr10:43136824~43138334:-
BRCA	cis	rs11098499	0.691	rs12502524	ENSG00000249244.1	RP11-548H18.2	3.36	0.000801	0.0363	0.12	0.1	Corneal astigmatism;	chr4:119350259	chr4:119391831~119395335:-
BRCA	cis	rs3771570	0.901	rs4675964	ENSG00000271153.1	ABC7-43041300I9.1	-3.36	0.000801	0.0363	-0.18	-0.1	Prostate cancer;	chr2:241385345	chr2:242175181~242175634:+
BRCA	cis	rs3771570	0.901	rs4675963	ENSG00000271153.1	ABC7-43041300I9.1	-3.36	0.000801	0.0363	-0.18	-0.1	Prostate cancer;	chr2:241385348	chr2:242175181~242175634:+
BRCA	cis	rs7412746	0.552	rs4970980	ENSG00000224800.1	RP11-235D19.2	-3.36	0.000801	0.0363	-0.13	-0.1	Melanoma;	chr1:150892516	chr1:150881236~150881683:-
BRCA	cis	rs6582630	0.563	rs923281	ENSG00000257718.1	RP11-396F22.1	-3.36	0.000801	0.0363	-0.11	-0.1	Drug-induced liver injury (flucloxacillin);	chr12:38196439	chr12:38906451~38909592:+
BRCA	cis	rs62458065	0.64	rs6950077	ENSG00000273014.1	RP11-225B17.2	3.36	0.000801	0.0363	0.16	0.1	Metabolite levels (HVA/MHPG ratio);	chr7:32463283	chr7:32758882~32759353:+
BRCA	cis	rs6743068	0.541	rs6714736	ENSG00000230799.1	AC007279.2	3.36	0.000802	0.0363	0.12	0.1	Lymphocyte percentage of white cells;	chr2:201349425	chr2:201762737~201763573:+
BRCA	cis	rs7487637	0.566	rs875023	ENSG00000257433.4	RP1-197B17.3	-3.36	0.000802	0.0363	-0.15	-0.1	Mononucleosis;	chr12:47800652	chr12:47706085~47742294:+
BRCA	cis	rs4820539	1	rs885963	ENSG00000211647.1	IGLV5-48	-3.36	0.000802	0.0363	-0.08	-0.1	Bone mineral density;	chr22:23118752	chr22:22352940~22353433:+
BRCA	cis	rs2288884	0.559	rs12611043	ENSG00000268282.1	CTD-2620I22.2	-3.36	0.000802	0.0363	-0.13	-0.1	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52084372	chr19:53004040~53005150:+
BRCA	cis	rs4374383	0.631	rs10175316	ENSG00000236307.2	EEF1E1P1	3.36	0.000802	0.0363	0.11	0.1	Hepatitis C induced liver fibrosis;	chr2:111912297	chr2:111887914~111888741:+
BRCA	cis	rs11098499	0.588	rs6534149	ENSG00000249244.1	RP11-548H18.2	-3.36	0.000802	0.0363	-0.12	-0.1	Corneal astigmatism;	chr4:119638137	chr4:119391831~119395335:-
BRCA	cis	rs754133	0.964	rs894738	ENSG00000248265.1	FLJ12825	3.36	0.000802	0.0363	0.13	0.1	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);	chr12:54023741	chr12:54058254~54122234:+
BRCA	cis	rs11877825	0.826	rs4121956	ENSG00000265728.1	RP11-883A18.3	-3.36	0.000802	0.0363	-0.14	-0.1	Gut microbiota (bacterial taxa);	chr18:10569933	chr18:10594590~10604798:+
BRCA	cis	rs4699052	0.662	rs1996346	ENSG00000230069.3	LRRC37A15P	-3.36	0.000802	0.0363	-0.1	-0.1	Testicular germ cell tumor;	chr4:103329167	chr4:102727274~102730721:-
BRCA	cis	rs8023401	0.872	rs2018854	ENSG00000274654.1	CTD-3247H4.2	-3.36	0.000802	0.0363	-0.16	-0.1	Spherical equivalent (joint analysis main effects and education interaction);	chr15:48618394	chr15:48528980~48529728:-
BRCA	cis	rs13401620	0.523	rs4849813	ENSG00000236878.1	AC012363.7	3.36	0.000802	0.0363	0.13	0.1	Breast size;	chr2:120016082	chr2:120211054~120211715:+
BRCA	cis	rs9341808	0.718	rs9448893	ENSG00000279022.1	RP11-250B2.4	3.36	0.000802	0.0363	0.12	0.1	Sitting height ratio;	chr6:80127522	chr6:80440730~80441172:+
BRCA	cis	rs9947662	0.917	rs11873243	ENSG00000267800.1	RP11-49K24.5	3.36	0.000802	0.0363	0.13	0.1	Migraine;	chr18:47335799	chr18:47137018~47137290:+
BRCA	cis	rs9527	0.615	rs11191489	ENSG00000236937.2	PTGES3P4	3.36	0.000802	0.0363	0.14	0.1	Arsenic metabolism;	chr10:102980811	chr10:102845595~102845950:+
BRCA	cis	rs6600671	1	rs1856572	ENSG00000223345.3	HIST2H2BA	3.36	0.000802	0.0363	0.12	0.1	Hip geometry;	chr1:121427719	chr1:121108210~121117257:-
BRCA	cis	rs2638953	0.924	rs11049619	ENSG00000273989.1	RP11-425D17.2	-3.36	0.000802	0.0363	-0.16	-0.1	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28453495	chr12:28236227~28236828:+
BRCA	cis	rs2638953	0.924	rs60703205	ENSG00000273989.1	RP11-425D17.2	-3.36	0.000802	0.0363	-0.16	-0.1	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28454371	chr12:28236227~28236828:+
BRCA	cis	rs10777288	0.561	rs2408419	ENSG00000258100.1	RP11-121E16.1	-3.36	0.000802	0.0363	-0.14	-0.1	Pulmonary function (smoking interaction);	chr12:90992545	chr12:91362196~91368606:+
BRCA	cis	rs4835473	0.932	rs34618381	ENSG00000246448.2	RP13-578N3.3	-3.36	0.000803	0.0363	-0.12	-0.1	Immature fraction of reticulocytes;	chr4:143762612	chr4:143700257~143865072:+
BRCA	cis	rs801193	1	rs2420824	ENSG00000265600.1	AC006480.1	3.36	0.000803	0.0363	0.12	0.1	Aortic root size;	chr7:66666129	chr7:67356680~67356779:+
BRCA	cis	rs240993	0.812	rs9398272	ENSG00000219773.1	RP11-506B6.3	-3.36	0.000803	0.0363	-0.14	-0.1	Inflammatory skin disease;Psoriasis;	chr6:111522345	chr6:112355841~112356714:-
BRCA	cis	rs13147122	0.881	rs13117608	ENSG00000270265.1	RP11-731D1.4	-3.36	0.000803	0.0363	-0.22	-0.1	Peripheral arterial disease (traffic-related air pollution interaction);	chr4:150900933	chr4:151333775~151353224:-
BRCA	cis	rs1865760	0.865	rs4478388	ENSG00000272810.1	U91328.22	-3.36	0.000803	0.0363	-0.12	-0.1	Height;	chr6:25953405	chr6:26013241~26013757:+
BRCA	cis	rs6088580	0.543	rs13042351	ENSG00000126005.14	MMP24-AS1	3.36	0.000803	0.0363	0.12	0.1	Glomerular filtration rate (creatinine);	chr20:34650769	chr20:35216462~35278131:-
BRCA	cis	rs10986311	0.851	rs35956754	ENSG00000227200.1	RP11-121A14.3	-3.36	0.000803	0.0363	-0.13	-0.1	Vitiligo;	chr9:124272079	chr9:124262876~124265809:+
BRCA	cis	rs1414896	0.646	rs12728422	ENSG00000226835.1	RP11-148B18.3	3.36	0.000803	0.0363	0.11	0.1	Non-alcoholic fatty liver disease histology (AST);	chr1:95200431	chr1:94333267~94334848:+
BRCA	cis	rs13136331	0.532	rs1462366	ENSG00000249001.4	RP11-742B18.1	3.36	0.000803	0.0363	0.14	0.1	Sitting height ratio;	chr4:87649340	chr4:87568035~87733956:-
BRCA	cis	rs35146811	0.735	rs7811662	ENSG00000214313.7	AZGP1P1	3.36	0.000803	0.0363	0.11	0.1	Coronary artery disease;	chr7:100194985	chr7:99980762~99987535:+
BRCA	cis	rs61931739	0.517	rs11052977	ENSG00000258794.3	DUX4L27	3.36	0.000803	0.0364	0.15	0.1	Morning vs. evening chronotype;	chr12:33882095	chr12:34208415~34209675:-
BRCA	cis	rs2288884	0.559	rs12611043	ENSG00000267927.1	CTD-2525I3.2	3.36	0.000803	0.0364	0.13	0.1	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52084372	chr19:52171158~52177002:+
BRCA	cis	rs6964587	0.692	rs7807490	ENSG00000188693.7	CYP51A1-AS1	-3.36	0.000803	0.0364	-0.11	-0.1	Breast cancer;	chr7:92144045	chr7:92134604~92180725:+
BRCA	cis	rs1075265	0.655	rs13432632	ENSG00000272156.1	RP11-477N3.1	-3.36	0.000803	0.0364	-0.11	-0.1	Chronotype;Morning vs. evening chronotype;	chr2:53713586	chr2:54082554~54085066:+
BRCA	cis	rs4950322	0.58	rs4950371	ENSG00000230832.3	RP11-325P15.2	-3.36	0.000803	0.0364	-0.17	-0.1	Protein quantitative trait loci;	chr1:147114243	chr1:147082338~147083578:-
BRCA	cis	rs11035577	0.632	rs1472854	ENSG00000279675.1	RP11-454H19.2	-3.36	0.000803	0.0364	-0.16	-0.1	Temperament (bipolar disorder);	chr11:39751697	chr11:40107244~40112599:-
BRCA	cis	rs11035577	0.57	rs1472853	ENSG00000279675.1	RP11-454H19.2	-3.36	0.000803	0.0364	-0.16	-0.1	Temperament (bipolar disorder);	chr11:39751782	chr11:40107244~40112599:-
BRCA	cis	rs9967417	0.562	rs484892	ENSG00000266696.1	RP11-30L3.2	3.36	0.000803	0.0364	0.12	0.1	Height;	chr18:49298147	chr18:49205912~49208781:+
BRCA	cis	rs7267979	0.966	rs2151144	ENSG00000277938.1	RP5-965G21.3	-3.36	0.000803	0.0364	-0.12	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25434288	chr20:25229150~25231933:+
BRCA	cis	rs9501744	1	rs9501744	ENSG00000250903.7	GMDS-AS1	3.36	0.000803	0.0364	0.14	0.1	Coronary artery disease;	chr6:1616908	chr6:2245748~2482022:+
BRCA	cis	rs7267979	0.903	rs6107015	ENSG00000231081.1	RP4-760C5.3	-3.36	0.000803	0.0364	-0.14	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25236128	chr20:26008791~26010531:-
BRCA	cis	rs295490	0.748	rs79361389	ENSG00000178631.7	ACTG1P1	-3.36	0.000804	0.0364	-0.22	-0.1	PR interval in Tripanosoma cruzi seropositivity;	chr3:139458517	chr3:139493809~139494937:+
BRCA	cis	rs10483282	1	rs12897758	ENSG00000258657.4	RP11-104E19.1	-3.36	0.000804	0.0364	-0.13	-0.1	Alcohol dependence;	chr14:23777144	chr14:24595723~24657774:+
BRCA	cis	rs10838634	1	rs7112060	ENSG00000280615.1	Y_RNA	-3.36	0.000804	0.0364	-0.17	-0.1	Schizophrenia;	chr11:46870350	chr11:47614898~47614994:-
BRCA	cis	rs12282928	0.714	rs1354295	ENSG00000255197.4	RP11-750H9.5	3.36	0.000804	0.0364	0.09	0.1	Migraine - clinic-based;	chr11:48210995	chr11:47383148~47409190:-
BRCA	cis	rs34779708	0.966	rs4934536	ENSG00000269952.1	RP11-324I22.3	-3.36	0.000804	0.0364	-0.14	-0.1	Inflammatory bowel disease;Crohn's disease;	chr10:35152241	chr10:35210416~35210750:+
BRCA	cis	rs78472555	0.661	rs2862871	ENSG00000259363.4	CTD-2054N24.2	-3.36	0.000804	0.0364	-0.14	-0.1	Post bronchodilator FEV1/FVC ratio in COPD;	chr15:99603013	chr15:99807023~99877148:+
BRCA	cis	rs72765298	0.79	rs72767017	ENSG00000232630.1	PRPS1P2	3.36	0.000804	0.0364	0.14	0.1	Pulse pressure;	chr9:125188076	chr9:125150653~125151589:+
BRCA	cis	rs4664293	0.867	rs3764968	ENSG00000230783.1	AC009961.2	-3.36	0.000804	0.0364	-0.13	-0.1	Monocyte percentage of white cells;	chr2:159790579	chr2:159689217~159690291:-
BRCA	cis	rs311392	1	rs2666871	ENSG00000270980.1	RP11-626A5.2	3.36	0.000804	0.0364	0.12	0.1	Pelvic organ prolapse (moderate/severe);	chr8:54176624	chr8:54191582~54192035:-
BRCA	cis	rs11676348	0.791	rs4133195	ENSG00000272555.1	RP11-459I19.1	3.36	0.000804	0.0364	0.12	0.1	Ulcerative colitis;	chr2:218086522	chr2:218818690~218819144:+
BRCA	cis	rs4981053	0.622	rs2792158	ENSG00000259001.3	RPPH1	3.36	0.000804	0.0364	0.12	0.1	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr14:20058745	chr14:20343048~20343685:-
BRCA	cis	rs4981053	0.6	rs7145013	ENSG00000259001.3	RPPH1	3.36	0.000804	0.0364	0.12	0.1	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr14:20058753	chr14:20343048~20343685:-
BRCA	cis	rs911119	0.913	rs6036461	ENSG00000270001.1	RP11-218C14.8	-3.36	0.000804	0.0364	-0.13	-0.1	Chronic kidney disease;	chr20:23596117	chr20:23631826~23632316:-
BRCA	cis	rs3816183	0.585	rs10208367	ENSG00000226491.1	FTOP1	-3.36	0.000804	0.0364	-0.13	-0.1	Hypospadias;	chr2:42654352	chr2:42797225~42798712:-
BRCA	cis	rs848490	0.889	rs62462688	ENSG00000214293.7	APTR	3.36	0.000804	0.0364	0.13	0.1	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77886105	chr7:77657660~77696265:-
BRCA	cis	rs2148307	0.55	rs11012349	ENSG00000228339.1	AMD1P1	-3.36	0.000804	0.0364	-0.14	-0.1	Photic sneeze reflex;	chr10:20803484	chr10:20350049~20351100:+
BRCA	cis	rs301901	0.965	rs13158310	ENSG00000244073.1	RPS4XP6	3.36	0.000804	0.0364	0.11	0.1	Height;	chr5:36789552	chr5:37085056~37085852:+
BRCA	cis	rs13401620	0.61	rs11123547	ENSG00000229326.3	AC069154.4	3.36	0.000804	0.0364	0.13	0.1	Breast size;	chr2:120159454	chr2:119698623~119700151:+
BRCA	cis	rs6840360	0.571	rs1978955	ENSG00000278978.1	RP11-164P12.5	-3.36	0.000805	0.0364	-0.12	-0.1	Intelligence (multi-trait analysis);	chr4:151588357	chr4:151669786~151670503:+
BRCA	cis	rs7771547	0.589	rs6941918	ENSG00000224666.3	RP1-50J22.4	3.36	0.000805	0.0364	0.12	0.1	Platelet distribution width;	chr6:36546944	chr6:36386831~36393462:+
BRCA	cis	rs990171	0.538	rs4851015	ENSG00000234389.1	AC007278.3	3.36	0.000805	0.0364	0.11	0.1	Lymphocyte counts;	chr2:102503897	chr2:102438713~102440475:+
BRCA	cis	rs6828577	1	rs6854328	ENSG00000281731.1	RP11-384K6.8	-3.36	0.000805	0.0364	-0.12	-0.1	Perioperative myocardial infarction in coronary artery bypass surgery;	chr4:118762337	chr4:118664087~118685341:-
BRCA	cis	rs59551326	0.764	rs67156369	ENSG00000234883.3	MIR155HG	3.36	0.000805	0.0364	0.15	0.1	Alcohol dependence;	chr21:25327843	chr21:25561909~25575168:+
BRCA	cis	rs9486719	0.947	rs12208556	ENSG00000233797.1	UFL1-AS1	3.36	0.000805	0.0364	0.15	0.1	Coronary artery disease;Migraine;	chr6:96455610	chr6:96358374~96521669:-
BRCA	cis	rs1075265	0.756	rs3821081	ENSG00000272156.1	RP11-477N3.1	3.36	0.000805	0.0364	0.11	0.1	Chronotype;Morning vs. evening chronotype;	chr2:53738252	chr2:54082554~54085066:+
BRCA	cis	rs13108904	0.875	rs10024013	ENSG00000211482.1	AC092574.1	-3.36	0.000805	0.0364	-0.12	-0.1	Obesity-related traits;	chr4:1287004	chr4:409809~409915:+
BRCA	cis	rs4950322	0.57	rs7554833	ENSG00000230832.3	RP11-325P15.2	3.36	0.000805	0.0364	0.17	0.1	Protein quantitative trait loci;	chr1:147289362	chr1:147082338~147083578:-
BRCA	cis	rs359466	0.938	rs359417	ENSG00000254164.1	CTB-33O18.2	-3.36	0.000805	0.0364	-0.17	-0.1	QRS complex (Sokolow-Lyon);	chr5:173919575	chr5:173574938~173576275:+
BRCA	cis	rs359466	0.938	rs359418	ENSG00000254164.1	CTB-33O18.2	-3.36	0.000805	0.0364	-0.17	-0.1	QRS complex (Sokolow-Lyon);	chr5:173919582	chr5:173574938~173576275:+
BRCA	cis	rs6601327	0.641	rs11780399	ENSG00000233609.3	RP11-62H7.2	-3.36	0.000805	0.0364	-0.1	-0.1	Multiple myeloma (hyperdiploidy);	chr8:9731657	chr8:8961200~8979025:+
BRCA	cis	rs2692947	0.696	rs2969490	ENSG00000232931.4	LINC00342	3.36	0.000805	0.0364	0.11	0.1	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96138165	chr2:95807118~95816215:-
BRCA	cis	rs875971	0.54	rs1723268	ENSG00000232559.3	GS1-124K5.12	3.36	0.000805	0.0364	0.12	0.1	Aortic root size;	chr7:66008093	chr7:66554588~66576923:-
BRCA	cis	rs11671005	0.735	rs56292587	ENSG00000265272.2	RN7SL693P	3.36	0.000805	0.0364	0.15	0.1	Mean platelet volume;	chr19:58407699	chr19:58490797~58491075:+
BRCA	cis	rs11671005	0.735	rs56290606	ENSG00000265272.2	RN7SL693P	3.36	0.000805	0.0364	0.15	0.1	Mean platelet volume;	chr19:58407953	chr19:58490797~58491075:+
BRCA	cis	rs11671005	0.735	rs11878198	ENSG00000265272.2	RN7SL693P	3.36	0.000805	0.0364	0.15	0.1	Mean platelet volume;	chr19:58408935	chr19:58490797~58491075:+
BRCA	cis	rs11671005	0.735	rs11666716	ENSG00000265272.2	RN7SL693P	3.36	0.000805	0.0364	0.15	0.1	Mean platelet volume;	chr19:58409585	chr19:58490797~58491075:+
BRCA	cis	rs11671005	0.735	rs34511020	ENSG00000265272.2	RN7SL693P	3.36	0.000805	0.0364	0.15	0.1	Mean platelet volume;	chr19:58409929	chr19:58490797~58491075:+
BRCA	cis	rs11671005	0.735	rs11666303	ENSG00000265272.2	RN7SL693P	3.36	0.000805	0.0364	0.15	0.1	Mean platelet volume;	chr19:58411135	chr19:58490797~58491075:+
BRCA	cis	rs2041840	0.538	rs10196818	ENSG00000272054.1	RP11-423P10.2	-3.36	0.000805	0.0364	-0.09	-0.1	Chronic lymphocytic leukemia;	chr2:37349709	chr2:37208875~37212677:+
BRCA	cis	rs9341808	0.718	rs9343978	ENSG00000279022.1	RP11-250B2.4	3.36	0.000805	0.0364	0.12	0.1	Sitting height ratio;	chr6:80262261	chr6:80440730~80441172:+
BRCA	cis	rs1974653	0.781	rs9606241	ENSG00000236540.6	AC006547.13	-3.36	0.000805	0.0364	-0.12	-0.1	Schizophrenia;	chr22:20088335	chr22:20058030~20070569:-
BRCA	cis	rs4835473	0.9	rs13119630	ENSG00000246448.2	RP13-578N3.3	-3.36	0.000805	0.0364	-0.12	-0.1	Immature fraction of reticulocytes;	chr4:143773901	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.932	rs1450233	ENSG00000246448.2	RP13-578N3.3	-3.36	0.000805	0.0364	-0.12	-0.1	Immature fraction of reticulocytes;	chr4:143774710	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.932	rs4308330	ENSG00000246448.2	RP13-578N3.3	-3.36	0.000805	0.0364	-0.12	-0.1	Immature fraction of reticulocytes;	chr4:143774761	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.932	rs11725708	ENSG00000246448.2	RP13-578N3.3	-3.36	0.000805	0.0364	-0.12	-0.1	Immature fraction of reticulocytes;	chr4:143775683	chr4:143700257~143865072:+
BRCA	cis	rs7267979	1	rs1077889	ENSG00000204556.4	CTD-2514C3.1	-3.36	0.000805	0.0364	-0.14	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25287257	chr20:26018832~26020684:+
BRCA	cis	rs73198271	0.96	rs10503392	ENSG00000248538.5	RP11-10A14.5	3.36	0.000805	0.0364	0.13	0.1	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8752045	chr8:9189011~9202854:+
BRCA	cis	rs1843834	0.505	rs7585047	ENSG00000274629.1	RP11-92F20.1	-3.36	0.000805	0.0364	-0.13	-0.1	IgE levels in asthmatics (D.p. specific);	chr2:224509180	chr2:224464682~224474500:+
BRCA	cis	rs2625529	0.652	rs2415128	ENSG00000261187.1	RP11-1007O24.2	3.36	0.000805	0.0364	0.11	0.1	Red blood cell count;	chr15:71898732	chr15:72465128~72466262:-
BRCA	cis	rs10958369	0.613	rs7829521	ENSG00000274295.1	RP11-1081M5.3	3.36	0.000805	0.0364	0.13	0.1	Response to antineoplastic agents;	chr8:53521328	chr8:53394215~53394795:+
BRCA	cis	rs9959145	0.85	rs76780647	ENSG00000267199.1	RP11-861E21.2	3.36	0.000805	0.0364	0.18	0.1	Immune response to smallpox vaccine (IL-6);	chr18:12710821	chr18:12438890~12448205:+
BRCA	cis	rs3808502	0.516	rs6983727	ENSG00000254866.2	DEFB109P3	-3.36	0.000806	0.0364	-0.14	-0.1	Neuroticism;	chr8:11558303	chr8:12150895~12151134:-
BRCA	cis	rs10129255	0.957	rs8005468	ENSG00000211958.2	IGHV3-38	3.36	0.000806	0.0364	0.08	0.1	Kawasaki disease;	chr14:106686431	chr14:106410493~106411021:-
BRCA	cis	rs875971	0.929	rs34406470	ENSG00000273448.1	RP11-166O4.6	3.36	0.000806	0.0364	0.09	0.1	Aortic root size;	chr7:66464969	chr7:67333047~67334383:+
BRCA	cis	rs6088590	1	rs910870	ENSG00000276073.1	RP5-1125A11.7	-3.36	0.000806	0.0365	-0.12	-0.1	Coronary artery disease;	chr20:34705089	chr20:33985617~33988989:-
BRCA	cis	rs34198350	0.683	rs78888036	ENSG00000277396.1	Metazoa_SRP	-3.36	0.000806	0.0365	-0.2	-0.1	QT interval in Tripanosoma cruzi seropositivity;	chr2:47808684	chr2:47383160~47383421:+
BRCA	cis	rs13287066	0.598	rs10739947	ENSG00000203364.2	RP11-370F5.4	-3.36	0.000806	0.0365	-0.11	-0.1	Intelligence (multi-trait analysis);	chr9:93379863	chr9:93147040~93148556:+
BRCA	cis	rs206936	0.706	rs2237098	ENSG00000276404.1	MIR6835	-3.36	0.000806	0.0365	-0.13	-0.1	Body mass index;	chr6:34338120	chr6:34240673~34240736:+
BRCA	cis	rs10129255	0.957	rs10141052	ENSG00000231475.3	IGHV4-31	-3.36	0.000806	0.0365	-0.08	-0.1	Kawasaki disease;	chr14:106776528	chr14:106349283~106349792:-
BRCA	cis	rs4909189	0.957	rs71547528	ENSG00000225365.1	AC078942.1	-3.36	0.000806	0.0365	-0.15	-0.1	Response to amphetamines;	chr7:158342739	chr7:158537495~158539879:+
BRCA	cis	rs4909189	0.957	rs11766348	ENSG00000225365.1	AC078942.1	-3.36	0.000806	0.0365	-0.15	-0.1	Response to amphetamines;	chr7:158343165	chr7:158537495~158539879:+
BRCA	cis	rs9810890	1	rs73198827	ENSG00000239483.1	RPS15AP16	3.36	0.000807	0.0365	0.27	0.1	Dental caries;	chr3:128770678	chr3:128798841~128799201:-
BRCA	cis	rs9810890	0.85	rs73198858	ENSG00000239483.1	RPS15AP16	3.36	0.000807	0.0365	0.27	0.1	Dental caries;	chr3:128795218	chr3:128798841~128799201:-
BRCA	cis	rs7474896	1	rs3824585	ENSG00000120555.12	SEPT7P9	3.36	0.000807	0.0365	0.18	0.1	Obesity (extreme);	chr10:37820493	chr10:38383069~38402916:-
BRCA	cis	rs6088590	0.542	rs6059956	ENSG00000269202.1	RP4-614O4.12	-3.36	0.000807	0.0365	-0.1	-0.1	Coronary artery disease;	chr20:34632266	chr20:35201747~35203288:-
BRCA	cis	rs2742417	0.603	rs2742395	ENSG00000244357.3	RN7SL145P	3.36	0.000807	0.0365	0.11	0.1	Response to anti-depressant treatment in major depressive disorder;	chr3:45717103	chr3:45742675~45742970:+
BRCA	cis	rs9329221	0.502	rs11777364	ENSG00000272505.1	RP11-981G7.6	3.36	0.000807	0.0365	0.1	0.1	Neuroticism;	chr8:10431036	chr8:10486807~10489666:+
BRCA	cis	rs4352251	0.673	rs4851418	ENSG00000212283.1	SNORD89	-3.36	0.000807	0.0365	-0.18	-0.1	Adiponectin levels (BMI-adjusted);Adiponectin levels;	chr2:101322666	chr2:101272936~101273049:-
BRCA	cis	rs672059	1	rs1760621	ENSG00000224468.3	RP11-181K3.4	-3.36	0.000807	0.0365	-0.11	-0.1	Hypertriglyceridemia;	chr1:183186871	chr1:183138402~183141282:-
BRCA	cis	rs2839186	0.869	rs17176513	ENSG00000215424.8	MCM3AP-AS1	3.36	0.000807	0.0365	0.09	0.1	Testicular germ cell tumor;	chr21:46262514	chr21:46229217~46259390:+
BRCA	cis	rs5751614	0.537	rs3788358	ENSG00000273000.4	KB-1572G7.2	3.36	0.000807	0.0365	0.11	0.1	Height;	chr22:23274168	chr22:23652860~23717347:-
BRCA	cis	rs559928	0.576	rs750832	ENSG00000231680.1	AP003774.6	3.36	0.000807	0.0365	0.14	0.1	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64395830	chr11:64394342~64395831:-
BRCA	cis	rs10911902	0.643	rs76469621	ENSG00000229739.2	RP11-295K2.3	-3.36	0.000807	0.0365	-0.14	-0.1	Schizophrenia;	chr1:186363848	chr1:186435161~186470291:+
BRCA	cis	rs10911902	0.643	rs79081972	ENSG00000229739.2	RP11-295K2.3	-3.36	0.000807	0.0365	-0.14	-0.1	Schizophrenia;	chr1:186364669	chr1:186435161~186470291:+
BRCA	cis	rs2153535	0.536	rs1328876	ENSG00000251164.1	HULC	-3.36	0.000807	0.0365	-0.12	-0.1	Motion sickness;	chr6:8620940	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.585	rs1328875	ENSG00000251164.1	HULC	-3.36	0.000807	0.0365	-0.12	-0.1	Motion sickness;	chr6:8620946	chr6:8652137~8653846:+
BRCA	cis	rs7264396	0.836	rs6120995	ENSG00000088340.14	FER1L4	-3.36	0.000807	0.0365	-0.12	-0.1	Total cholesterol levels;	chr20:35597804	chr20:35558737~35607562:-
BRCA	cis	rs7578361	0.918	rs1405574	ENSG00000231969.1	AC144449.1	-3.36	0.000807	0.0365	-0.16	-0.1	Acute lymphoblastic leukemia (childhood);	chr2:149511234	chr2:149587196~149848233:+
BRCA	cis	rs11795343	0.527	rs657454	ENSG00000232303.2	DFFBP1	-3.36	0.000807	0.0365	-0.12	-0.1	Psoriasis;Psoriasis vulgaris;Inflammatory skin disease;	chr9:32534853	chr9:32566148~32567126:-
BRCA	cis	rs1200821	0.535	rs1208784	ENSG00000099251.13	HSD17B7P2	3.36	0.000807	0.0365	0.12	0.1	Hemostatic factors and hematological phenotypes;	chr10:37479505	chr10:38356380~38378505:+
BRCA	cis	rs9341808	0.718	rs2874829	ENSG00000279022.1	RP11-250B2.4	3.36	0.000807	0.0365	0.12	0.1	Sitting height ratio;	chr6:80146380	chr6:80440730~80441172:+
BRCA	cis	rs11098499	0.739	rs2203039	ENSG00000260091.1	RP11-33B1.4	3.36	0.000807	0.0365	0.09	0.1	Corneal astigmatism;	chr4:119211192	chr4:119409333~119410233:+
BRCA	cis	rs10975870	0.847	rs4742276	ENSG00000232946.1	RP11-390F4.2	-3.36	0.000807	0.0365	-0.13	-0.1	Body mass index;	chr9:6960544	chr9:6675284~6675614:+
BRCA	cis	rs7914558	0.966	rs10748837	ENSG00000213277.3	MARCKSL1P1	3.36	0.000807	0.0365	0.12	0.1	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103120479	chr10:103175554~103176094:+
BRCA	cis	rs564309	0.764	rs61825312	ENSG00000212237.1	RNA5SP18	3.36	0.000807	0.0365	0.2	0.1	Hip circumference (psychosocial stress interaction);	chr1:228343047	chr1:228647912~228648032:-
BRCA	cis	rs564309	0.867	rs34673199	ENSG00000212237.1	RNA5SP18	3.36	0.000807	0.0365	0.2	0.1	Hip circumference (psychosocial stress interaction);	chr1:228343373	chr1:228647912~228648032:-
BRCA	cis	rs564309	0.764	rs12065660	ENSG00000212237.1	RNA5SP18	3.36	0.000807	0.0365	0.2	0.1	Hip circumference (psychosocial stress interaction);	chr1:228346366	chr1:228647912~228648032:-
BRCA	cis	rs2904524	1	rs58612372	ENSG00000257613.1	LINC01481	-3.36	0.000807	0.0365	-0.18	-0.1	Amyotrophic lateral sclerosis (age of onset);	chr12:70276566	chr12:70219132~70221862:-
BRCA	cis	rs6496932	0.663	rs12915663	ENSG00000259630.2	CTD-2262B20.1	-3.36	0.000807	0.0365	-0.13	-0.1	Central corneal thickness;Corneal structure;	chr15:85362249	chr15:85415228~85415633:+
BRCA	cis	rs2120991	1	rs2120991	ENSG00000250742.1	RP11-834C11.4	-3.36	0.000807	0.0365	-0.13	-0.1	Biliary atresia;	chr12:53876444	chr12:54126098~54132843:+
BRCA	cis	rs7520050	0.931	rs35743647	ENSG00000281133.1	AL355480.3	3.36	0.000807	0.0365	0.12	0.1	Reticulocyte count;Red blood cell count;	chr1:45941580	chr1:45580892~45580996:-
BRCA	cis	rs11035577	0.516	rs10768529	ENSG00000279675.1	RP11-454H19.2	-3.36	0.000807	0.0365	-0.16	-0.1	Temperament (bipolar disorder);	chr11:39740851	chr11:40107244~40112599:-
BRCA	cis	rs7274811	0.711	rs291697	ENSG00000228265.4	RALY-AS1	-3.36	0.000807	0.0365	-0.11	-0.1	Height;	chr20:33397442	chr20:33983052~33994357:-
BRCA	cis	rs6494488	0.5	rs1133357	ENSG00000248415.1	GAPDHP61	-3.36	0.000808	0.0365	-0.24	-0.1	Coronary artery disease;	chr15:64695371	chr15:64528667~64529671:-
BRCA	cis	rs6942407	0.545	rs6465101	ENSG00000224046.1	AC005076.5	-3.36	0.000808	0.0365	-0.16	-0.1	Food allergy;	chr7:87229749	chr7:87151423~87152420:-
BRCA	cis	rs13387221	0.569	rs6746182	ENSG00000231848.1	AC012354.8	-3.36	0.000808	0.0365	-0.14	-0.1	Intelligence (childhood);	chr2:44001259	chr2:44996413~44996873:+
BRCA	cis	rs2289328	0.825	rs35777573	ENSG00000259330.1	INAFM2	3.36	0.000808	0.0365	0.17	0.1	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr15:40352045	chr15:40325216~40326715:+
BRCA	cis	rs6931421	0.8	rs12662365	ENSG00000279022.1	RP11-250B2.4	3.36	0.000808	0.0365	0.13	0.1	Sitting height ratio;	chr6:80195672	chr6:80440730~80441172:+
BRCA	cis	rs1424638	0.614	rs6717495	ENSG00000233251.6	AC007743.1	-3.36	0.000808	0.0365	-0.12	-0.1	Intelligence (multi-trait analysis);	chr2:56992150	chr2:56173534~56185770:-
BRCA	cis	rs7911264	0.739	rs7071905	ENSG00000232709.1	MARK2P9	-3.36	0.000808	0.0365	-0.13	-0.1	Inflammatory bowel disease;	chr10:92626365	chr10:92418667~92420875:+
BRCA	cis	rs7911264	0.739	rs10882094	ENSG00000232709.1	MARK2P9	-3.36	0.000808	0.0365	-0.13	-0.1	Inflammatory bowel disease;	chr10:92627919	chr10:92418667~92420875:+
BRCA	cis	rs80093141	0.706	rs2145607	ENSG00000271424.1	RP11-647O20.1	3.36	0.000808	0.0365	0.15	0.1	Common carotid intima-media thickness in HIV infection;	chr14:38901092	chr14:39370279~39370756:-
BRCA	cis	rs1424638	0.522	rs6545638	ENSG00000233251.6	AC007743.1	3.36	0.000808	0.0365	0.14	0.1	Intelligence (multi-trait analysis);	chr2:57175857	chr2:56173534~56185770:-
BRCA	cis	rs2277027	1	rs11134779	ENSG00000251405.2	CTB-109A12.1	-3.36	0.000808	0.0365	-0.13	-0.1	Pulmonary function;Pulmonary function (smoking interaction);	chr5:157509758	chr5:157362615~157460078:-
BRCA	cis	rs72634258	0.554	rs12092614	ENSG00000269925.1	RP3-467L1.6	3.36	0.000808	0.0365	0.17	0.1	Inflammatory bowel disease;	chr1:7805650	chr1:7776383~7776775:+
BRCA	cis	rs10129255	0.833	rs61997797	ENSG00000211974.3	IGHV2-70	3.36	0.000808	0.0365	0.11	0.1	Kawasaki disease;	chr14:106815190	chr14:106723574~106724093:-
BRCA	cis	rs10486003	1	rs10486003	ENSG00000213455.3	AC091654.7	3.36	0.000808	0.0365	0.17	0.1	Response to platinum-based agents;	chr7:97600466	chr7:98454119~98454617:-
BRCA	cis	rs4703129	1	rs12521683	ENSG00000246763.5	RGMB-AS1	-3.36	0.000808	0.0365	-0.12	-0.1	Asperger disorder;	chr5:98525287	chr5:98769618~98773469:-
BRCA	cis	rs2400749	0.712	rs8016105	ENSG00000258521.1	RP11-638I2.9	3.36	0.000808	0.0365	0.1	0.1	Alzheimer's disease (survival time);	chr14:99564198	chr14:100339832~100340554:+
BRCA	cis	rs8114671	0.904	rs6060197	ENSG00000261582.1	RP4-614O4.11	3.36	0.000808	0.0365	0.1	0.1	Height;	chr20:35066512	chr20:35267885~35280043:-
BRCA	cis	rs8114671	0.839	rs6142290	ENSG00000261582.1	RP4-614O4.11	3.36	0.000808	0.0365	0.1	0.1	Height;	chr20:35066869	chr20:35267885~35280043:-
BRCA	cis	rs8114671	0.869	rs6060199	ENSG00000261582.1	RP4-614O4.11	3.36	0.000808	0.0365	0.1	0.1	Height;	chr20:35066970	chr20:35267885~35280043:-
BRCA	cis	rs7098100	0.601	rs2807985	ENSG00000231920.1	NEBL-AS1	3.36	0.000808	0.0365	0.12	0.1	Breast cancer;	chr10:21941545	chr10:21174014~21175048:+
BRCA	cis	rs2731006	0.64	rs2731000	ENSG00000257114.2	RP11-25I15.3	-3.36	0.000808	0.0365	-0.17	-0.1	Panic disorder;	chr12:42787472	chr12:42692216~42717119:+
BRCA	cis	rs17027750	0.67	rs3762760	ENSG00000271870.1	RP11-97C16.1	-3.36	0.000808	0.0365	-0.12	-0.1	Basophil percentage of granulocytes;Basophil percentage of white cells;	chr3:3146332	chr3:3152942~3153435:+
BRCA	cis	rs16852403	0.548	rs10798600	ENSG00000224687.1	RASAL2-AS1	3.36	0.000808	0.0365	0.13	0.1	Childhood ear infection;	chr1:178211584	chr1:178091508~178093984:-
BRCA	cis	rs867529	0.813	rs4972221	ENSG00000234028.3	AC062029.1	-3.36	0.000808	0.0365	-0.11	-0.1	Height;	chr2:88571114	chr2:88627539~88631821:+
BRCA	cis	rs7520050	0.931	rs11211224	ENSG00000281133.1	AL355480.3	3.36	0.000808	0.0365	0.12	0.1	Reticulocyte count;Red blood cell count;	chr1:45918716	chr1:45580892~45580996:-
BRCA	cis	rs250518	0.926	rs6875670	ENSG00000271926.1	CTD-2376I4.1	3.36	0.000808	0.0365	0.14	0.1	Mean corpuscular hemoglobin concentration;	chr5:72785943	chr5:72953635~72954274:-
BRCA	cis	rs2262909	0.962	rs73021832	ENSG00000279377.1	AC003973.3	-3.36	0.000808	0.0365	-0.15	-0.1	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;	chr19:22133342	chr19:21965708~21968529:-
BRCA	cis	rs10504130	0.569	rs4418329	ENSG00000272076.1	RP11-11C20.3	3.36	0.000808	0.0365	0.15	0.1	Venous thromboembolism (SNP x SNP interaction);	chr8:51758554	chr8:51810110~51810681:-
BRCA	cis	rs10504130	0.569	rs4442134	ENSG00000272076.1	RP11-11C20.3	3.36	0.000808	0.0365	0.15	0.1	Venous thromboembolism (SNP x SNP interaction);	chr8:51758584	chr8:51810110~51810681:-
BRCA	cis	rs2011503	0.782	rs8113006	ENSG00000267419.1	CTC-559E9.6	3.36	0.000809	0.0365	0.14	0.1	Bipolar disorder;	chr19:19558632	chr19:19776602~19834927:+
BRCA	cis	rs2625529	0.689	rs12898868	ENSG00000261187.1	RP11-1007O24.2	3.36	0.000809	0.0365	0.11	0.1	Red blood cell count;	chr15:71820577	chr15:72465128~72466262:-
BRCA	cis	rs8098244	0.964	rs8086359	ENSG00000265752.2	RP11-403A21.1	3.36	0.000809	0.0365	0.13	0.1	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23849607	chr18:23957754~23982556:-
BRCA	cis	rs359466	0.938	rs35447628	ENSG00000253768.1	CTB-33O18.1	-3.36	0.000809	0.0365	-0.16	-0.1	QRS complex (Sokolow-Lyon);	chr5:173958905	chr5:173562478~173573199:+
BRCA	cis	rs2803122	0.905	rs10757053	ENSG00000272842.1	RP11-513M16.7	-3.36	0.000809	0.0366	-0.11	-0.1	Pulse pressure;	chr9:19314156	chr9:19371386~19371945:-
BRCA	cis	rs2839186	0.656	rs8128380	ENSG00000215424.8	MCM3AP-AS1	3.36	0.000809	0.0366	0.1	0.1	Testicular germ cell tumor;	chr21:46245779	chr21:46229217~46259390:+
BRCA	cis	rs11992162	1	rs7460395	ENSG00000255310.2	AF131215.2	3.36	0.000809	0.0366	0.12	0.1	Monocyte count;	chr8:11977866	chr8:11107788~11109726:-
BRCA	cis	rs58521262	0.729	rs62120834	ENSG00000268105.1	RP11-369G6.2	-3.36	0.000809	0.0366	-0.18	-0.1	Testicular germ cell tumor;	chr19:22891313	chr19:23125665~23128543:+
BRCA	cis	rs4947019	0.686	rs3757229	ENSG00000260273.1	RP11-425D10.10	3.36	0.000809	0.0366	0.27	0.1	Hematological parameters;	chr6:109382935	chr6:109382795~109383666:+
BRCA	cis	rs4947019	0.686	rs17070554	ENSG00000260273.1	RP11-425D10.10	3.36	0.000809	0.0366	0.27	0.1	Hematological parameters;	chr6:109383183	chr6:109382795~109383666:+
BRCA	cis	rs9614461	0.609	rs9614666	ENSG00000273145.1	CITF22-92A6.1	3.36	0.000809	0.0366	0.14	0.1	Tonsillectomy;	chr22:45433680	chr22:46013606~46015498:+
BRCA	cis	rs216345	0.966	rs3843935	ENSG00000260947.1	RP11-384P7.7	-3.36	0.000809	0.0366	-0.11	-0.1	Bipolar disorder;	chr9:33787873	chr9:33697459~33700986:+
BRCA	cis	rs3760982	1	rs3760982	ENSG00000278917.1	RP11-15A1.4	-3.36	0.000809	0.0366	-0.12	-0.1	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43782361	chr19:43891233~43895411:+
BRCA	cis	rs12681366	0.734	rs13281619	ENSG00000253175.1	RP11-267M23.6	3.36	0.000809	0.0366	0.12	0.1	Nonsyndromic cleft lip with cleft palate;	chr8:94384658	chr8:94565036~94565715:+
BRCA	cis	rs12681366	0.708	rs13280849	ENSG00000253175.1	RP11-267M23.6	3.36	0.000809	0.0366	0.12	0.1	Nonsyndromic cleft lip with cleft palate;	chr8:94384731	chr8:94565036~94565715:+
BRCA	cis	rs867186	1	rs17092215	ENSG00000126005.14	MMP24-AS1	-3.36	0.000809	0.0366	-0.17	-0.1	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35008110	chr20:35216462~35278131:-
BRCA	cis	rs7045881	0.66	rs16910888	ENSG00000254396.1	RP11-56F10.3	3.36	0.000809	0.0366	0.15	0.1	Schizophrenia;	chr9:26919668	chr9:27102630~27104728:+
BRCA	cis	rs3924048	0.559	rs6541037	ENSG00000221340.1	RNU6ATAC18P	3.36	0.000809	0.0366	0.13	0.1	Optic cup area;	chr1:12566126	chr1:12569972~12570072:-
BRCA	cis	rs6840360	0.593	rs1877186	ENSG00000270265.1	RP11-731D1.4	-3.36	0.000809	0.0366	-0.12	-0.1	Intelligence (multi-trait analysis);	chr4:151771266	chr4:151333775~151353224:-
BRCA	cis	rs3770752	0.897	rs7584565	ENSG00000272054.1	RP11-423P10.2	-3.36	0.000809	0.0366	-0.09	-0.1	Schizophrenia;	chr2:37323760	chr2:37208875~37212677:+
BRCA	cis	rs718433	0.677	rs4982494	ENSG00000211778.2	TRAV4	-3.36	0.000809	0.0366	-0.08	-0.1	Intraocular pressure;	chr14:21751141	chr14:21736152~21736982:+
BRCA	cis	rs873549	0.959	rs6604701	ENSG00000238042.4	RP11-815M8.1	3.36	0.000809	0.0366	0.12	0.1	Keloid;	chr1:222094158	chr1:221880981~221978523:-
BRCA	cis	rs873549	1	rs6604702	ENSG00000238042.4	RP11-815M8.1	3.36	0.000809	0.0366	0.12	0.1	Keloid;	chr1:222094181	chr1:221880981~221978523:-
BRCA	cis	rs873549	1	rs3910712	ENSG00000238042.4	RP11-815M8.1	3.36	0.000809	0.0366	0.12	0.1	Keloid;	chr1:222094609	chr1:221880981~221978523:-
BRCA	cis	rs873549	1	rs3910711	ENSG00000238042.4	RP11-815M8.1	3.36	0.000809	0.0366	0.12	0.1	Keloid;	chr1:222094622	chr1:221880981~221978523:-
BRCA	cis	rs13256369	1	rs7843488	ENSG00000254153.1	CTA-398F10.2	3.36	0.000809	0.0366	0.14	0.1	Obesity-related traits;	chr8:8718707	chr8:8456909~8461337:-
BRCA	cis	rs2288884	0.537	rs16983434	ENSG00000268282.1	CTD-2620I22.2	-3.36	0.00081	0.0366	-0.13	-0.1	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52088180	chr19:53004040~53005150:+
BRCA	cis	rs7037266	0.853	rs2185464	ENSG00000178654.11	PPIAP33	3.36	0.00081	0.0366	0.12	0.1	Menarche (age at onset);	chr9:6924843	chr9:7597823~7598377:+
BRCA	cis	rs10211296	0.622	rs17252066	ENSG00000223318.1	RNA5SP111	-3.36	0.00081	0.0366	-0.13	-0.1	Risky sexual behaviors in alcohol dependence;	chr2:165629572	chr2:164895677~164895777:-
BRCA	cis	rs8012947	0.565	rs4901852	ENSG00000180189.10	HMGB1P14	3.36	0.00081	0.0366	0.11	0.1	Alcohol consumption in current drinkers;	chr14:58355211	chr14:58284773~58285363:+
BRCA	cis	rs875971	0.862	rs4368860	ENSG00000229886.1	RP5-1132H15.3	-3.36	0.00081	0.0366	-0.12	-0.1	Aortic root size;	chr7:66143495	chr7:66025126~66031544:-
BRCA	cis	rs7274811	0.744	rs34489266	ENSG00000228265.4	RALY-AS1	3.36	0.00081	0.0366	0.12	0.1	Height;	chr20:33635234	chr20:33983052~33994357:-
BRCA	cis	rs34792	0.554	rs4597346	ENSG00000275910.1	RP11-680G24.6	-3.36	0.00081	0.0366	-0.12	-0.1	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15529889	chr16:15015828~15016390:-
BRCA	cis	rs7523050	0.908	rs12036331	ENSG00000203897.3	SPATA42	-3.36	0.00081	0.0366	-0.17	-0.1	Fat distribution (HIV);	chr1:108856085	chr1:108857217~108858524:+
BRCA	cis	rs7577696	0.889	rs212759	ENSG00000276334.1	AL133243.1	3.36	0.00081	0.0366	0.13	0.1	Inflammatory biomarkers;	chr2:32201753	chr2:32521927~32523547:+
BRCA	cis	rs4805834	0.697	rs58026555	ENSG00000201388.1	SNORA68	3.36	0.00081	0.0366	0.18	0.1	Creatinine levels;	chr19:32774107	chr19:32608337~32608469:-
BRCA	cis	rs7917772	0.636	rs7897384	ENSG00000236937.2	PTGES3P4	3.36	0.00081	0.0366	0.14	0.1	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;	chr10:102769285	chr10:102845595~102845950:+
BRCA	cis	rs56046484	0.956	rs17540501	ENSG00000259630.2	CTD-2262B20.1	-3.36	0.00081	0.0366	-0.17	-0.1	Testicular germ cell tumor;	chr15:85094870	chr15:85415228~85415633:+
BRCA	cis	rs67478160	0.643	rs4900600	ENSG00000269910.1	RP11-73M18.10	3.36	0.00081	0.0366	0.1	0.1	Schizophrenia;	chr14:103825502	chr14:103694516~103695050:-
BRCA	cis	rs7267979	1	rs6076339	ENSG00000274414.1	RP5-965G21.4	3.36	0.00081	0.0366	0.12	0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25368076	chr20:25239007~25245229:-
BRCA	cis	rs16846053	0.605	rs115071626	ENSG00000227403.1	AC009299.3	3.36	0.00081	0.0366	0.26	0.1	Blood osmolality (transformed sodium);	chr2:161896092	chr2:161244739~161249050:+
BRCA	cis	rs13401620	0.655	rs1446306	ENSG00000236878.1	AC012363.7	3.36	0.00081	0.0366	0.12	0.1	Breast size;	chr2:120041296	chr2:120211054~120211715:+
BRCA	cis	rs13401620	0.503	rs7596327	ENSG00000223549.1	MTND5P28	3.36	0.00081	0.0366	0.14	0.1	Breast size;	chr2:120194551	chr2:120215181~120217279:+
BRCA	cis	rs4499344	0.623	rs11670818	ENSG00000201388.1	SNORA68	3.36	0.00081	0.0366	0.14	0.1	Mean platelet volume;	chr19:32608948	chr19:32608337~32608469:-
BRCA	cis	rs36051895	0.623	rs10118267	ENSG00000237711.1	RP11-39K24.13	-3.36	0.00081	0.0366	-0.12	-0.1	Pediatric autoimmune diseases;	chr9:5243736	chr9:5100236~5101009:+
BRCA	cis	rs7674212	0.531	rs10006474	ENSG00000248740.4	RP11-328K4.1	3.36	0.00081	0.0366	0.12	0.1	Type 2 diabetes;	chr4:103006890	chr4:103256159~103453658:+
BRCA	cis	rs970548	0.955	rs61854156	ENSG00000237840.5	FAM21FP	3.36	0.00081	0.0366	0.14	0.1	Total cholesterol levels;HDL cholesterol;HDL cholesterol levels;Cholesterol, total;	chr10:45643216	chr10:45706431~45727231:-
BRCA	cis	rs983392	0.617	rs617135	ENSG00000275344.1	MIR6503	-3.36	0.00081	0.0366	-0.11	-0.1	Alzheimer's disease (late onset);	chr11:60169284	chr11:60209071~60209156:-
BRCA	cis	rs875971	0.508	rs10242423	ENSG00000265600.1	AC006480.1	3.36	0.00081	0.0366	0.12	0.1	Aortic root size;	chr7:66594188	chr7:67356680~67356779:+
BRCA	cis	rs875971	0.508	rs10253883	ENSG00000265600.1	AC006480.1	3.36	0.00081	0.0366	0.12	0.1	Aortic root size;	chr7:66596151	chr7:67356680~67356779:+
BRCA	cis	rs6582630	0.555	rs61932279	ENSG00000257718.1	RP11-396F22.1	-3.36	0.000811	0.0366	-0.11	-0.1	Drug-induced liver injury (flucloxacillin);	chr12:37955294	chr12:38906451~38909592:+
BRCA	cis	rs10792665	0.541	rs10898050	ENSG00000254965.1	RP11-113K21.2	-3.36	0.000811	0.0366	-0.1	-0.1	Obesity-related traits;	chr11:82882483	chr11:83111060~83111442:-
BRCA	cis	rs4803480	0.872	rs10420470	ENSG00000268355.1	AC006129.1	-3.36	0.000811	0.0366	-0.15	-0.1	Schizophrenia;	chr19:41567075	chr19:41531206~41532174:+
BRCA	cis	rs6964587	0.934	rs6465344	ENSG00000188693.7	CYP51A1-AS1	-3.36	0.000811	0.0366	-0.11	-0.1	Breast cancer;	chr7:92010959	chr7:92134604~92180725:+
BRCA	cis	rs9813712	0.818	rs11718381	ENSG00000228252.7	COL6A4P2	3.36	0.000811	0.0366	0.14	0.1	Response to amphetamines;	chr3:130222660	chr3:130212823~130273806:+
BRCA	cis	rs58521262	1	rs58521262	ENSG00000268105.1	RP11-369G6.2	-3.36	0.000811	0.0366	-0.17	-0.1	Testicular germ cell tumor;	chr19:23022382	chr19:23125665~23128543:+
BRCA	cis	rs7914558	1	rs11191577	ENSG00000213277.3	MARCKSL1P1	3.36	0.000811	0.0366	0.12	0.1	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103142408	chr10:103175554~103176094:+
BRCA	cis	rs6565180	0.962	rs11642676	ENSG00000261332.1	RP11-297C4.1	-3.36	0.000811	0.0366	-0.14	-0.1	Tonsillectomy;	chr16:30360334	chr16:30498766~30499554:-
BRCA	cis	rs16940212	0.618	rs76679589	ENSG00000259771.1	RP11-429D19.1	-3.36	0.000811	0.0366	-0.18	-0.1	HDL cholesterol;HDL cholesterol levels;	chr15:58394492	chr15:59266720~59271162:-
BRCA	cis	rs8049367	0.684	rs2283487	ENSG00000279031.1	LA16c-360H6.1	3.36	0.000811	0.0366	0.12	0.1	Nonsyndromic cleft lip with or without cleft palate;	chr16:3919885	chr16:3292879~3293403:+
BRCA	cis	rs7789940	1	rs758944	ENSG00000231087.2	FDPSP7	-3.36	0.000811	0.0366	-0.13	-0.1	Multiple sclerosis;	chr7:76323980	chr7:76968197~76969250:-
BRCA	cis	rs1424638	0.587	rs1366797	ENSG00000233251.6	AC007743.1	-3.36	0.000811	0.0366	-0.13	-0.1	Intelligence (multi-trait analysis);	chr2:56991601	chr2:56173534~56185770:-
BRCA	cis	rs10851411	0.657	rs1048571	ENSG00000260490.2	RP11-265N6.3	-3.36	0.000811	0.0366	-0.19	-0.1	Glucose homeostasis traits;	chr15:42569826	chr15:42571927~42572433:+
BRCA	cis	rs10851411	0.697	rs62019315	ENSG00000260490.2	RP11-265N6.3	-3.36	0.000811	0.0366	-0.19	-0.1	Glucose homeostasis traits;	chr15:42571344	chr15:42571927~42572433:+
BRCA	cis	rs10420951	0.617	rs2303694	ENSG00000243455.3	RPS18P13	-3.36	0.000811	0.0366	-0.16	-0.1	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr19:18451628	chr19:18048637~18049090:+
BRCA	cis	rs10420951	0.617	rs79257623	ENSG00000243455.3	RPS18P13	-3.36	0.000811	0.0366	-0.16	-0.1	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr19:18452904	chr19:18048637~18049090:+
BRCA	cis	rs10420951	0.617	rs8103520	ENSG00000243455.3	RPS18P13	-3.36	0.000811	0.0366	-0.16	-0.1	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr19:18453160	chr19:18048637~18049090:+
BRCA	cis	rs1998359	0.715	rs11849126	ENSG00000259087.4	RP11-356O9.2	3.36	0.000811	0.0366	0.11	0.1	Self-reported allergy;	chr14:37675387	chr14:37556158~37567095:-
BRCA	cis	rs875971	0.964	rs778723	ENSG00000273024.4	INTS4P2	-3.36	0.000811	0.0366	-0.11	-0.1	Aortic root size;	chr7:66364510	chr7:65647864~65715661:+
BRCA	cis	rs2412980	0.744	rs249403	ENSG00000232530.1	RP1-102K2.6	3.36	0.000811	0.0366	0.2	0.1	Dialysis-related mortality;	chr22:29823556	chr22:30239194~30240538:+
BRCA	cis	rs28374715	0.662	rs513280	ENSG00000247556.5	OIP5-AS1	-3.36	0.000811	0.0366	-0.11	-0.1	Ulcerative colitis;	chr15:41190602	chr15:41283990~41309737:+
BRCA	cis	rs2304003	0.583	rs1056341	ENSG00000229195.1	AC009495.4	3.36	0.000811	0.0366	0.13	0.1	Social communication problems;	chr2:165867464	chr2:165794857~165846091:-
BRCA	cis	rs1355223	0.867	rs1377495	ENSG00000271369.1	RP11-350D17.3	3.36	0.000811	0.0366	0.12	0.1	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34661415	chr11:34709600~34710161:+
BRCA	cis	rs965469	0.947	rs6051692	ENSG00000215063.3	RPL21P2	3.36	0.000811	0.0366	0.14	0.1	IFN-related cytopenia;	chr20:3263452	chr20:4059633~4060113:-
BRCA	cis	rs12893668	0.703	rs7148456	ENSG00000269940.1	RP11-73M18.7	-3.36	0.000811	0.0366	-0.12	-0.1	Reticulocyte count;	chr14:103561933	chr14:103694560~103695170:+
BRCA	cis	rs1823874	0.71	rs2085086	ENSG00000259363.4	CTD-2054N24.2	3.36	0.000811	0.0366	0.12	0.1	IgG glycosylation;	chr15:99819887	chr15:99807023~99877148:+
BRCA	cis	rs10838687	0.8	rs10838686	ENSG00000243802.2	RP11-390K5.1	3.36	0.000812	0.0367	0.15	0.1	Proinsulin levels;	chr11:47289816	chr11:47191181~47191542:-
BRCA	cis	rs4919694	1	rs11191439	ENSG00000213061.2	PFN1P11	-3.36	0.000812	0.0367	-0.21	-0.1	Arsenic metabolism;	chr10:102878966	chr10:102838011~102845473:-
BRCA	cis	rs12887734	0.546	rs12885509	ENSG00000269910.1	RP11-73M18.10	3.36	0.000812	0.0367	0.11	0.1	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103806988	chr14:103694516~103695050:-
BRCA	cis	rs804280	0.509	rs12719915	ENSG00000227888.4	FAM66A	-3.36	0.000812	0.0367	-0.13	-0.1	Myopia (pathological);	chr8:11928746	chr8:12362019~12388296:+
BRCA	cis	rs564309	0.681	rs1188482	ENSG00000183929.7	DUSP5P1	-3.36	0.000812	0.0367	-0.19	-0.1	Hip circumference (psychosocial stress interaction);	chr1:228429792	chr1:228650241~228651379:+
BRCA	cis	rs2462686	0.798	rs13241830	ENSG00000229628.1	AC073115.7	3.36	0.000812	0.0367	0.13	0.1	Major depressive disorder;	chr7:45921459	chr7:45990905~46000898:+
BRCA	cis	rs7426380	0.505	rs6733730	ENSG00000272606.1	RP11-554J4.1	3.36	0.000812	0.0367	0.12	0.1	Intraocular pressure;	chr2:55827081	chr2:55617909~55618373:+
BRCA	cis	rs1580019	0.961	rs1868777	ENSG00000281332.1	LINC00997	3.36	0.000812	0.0367	0.12	0.1	Cognitive ability;	chr7:32454464	chr7:32760279~32762924:+
BRCA	cis	rs11673344	0.523	rs2082010	ENSG00000276846.1	CTD-3220F14.3	3.36	0.000812	0.0367	0.12	0.1	Obesity-related traits;	chr19:37039874	chr19:37314868~37315620:-
BRCA	cis	rs993804	0.528	rs9866836	ENSG00000264219.1	MIR4442	3.36	0.000812	0.0367	0.1	0.1	Bipolar disorder and schizophrenia;	chr3:25040390	chr3:25664873~25664939:-
BRCA	cis	rs11773103	1	rs11971131	ENSG00000224046.1	AC005076.5	3.36	0.000812	0.0367	0.21	0.1	Bipolar disorder or major depressive disorder (combined);	chr7:87194303	chr7:87151423~87152420:-
BRCA	cis	rs6963495	0.818	rs818619	ENSG00000223886.3	RP11-251G23.2	3.36	0.000812	0.0367	0.14	0.1	Bipolar disorder (body mass index interaction);	chr7:105532058	chr7:105530209~105530671:+
BRCA	cis	rs4618572	1	rs4618572	ENSG00000230433.1	RP1-20B11.2	3.36	0.000812	0.0367	0.18	0.1	Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin;	chr6:1492427	chr6:524171~525581:+
BRCA	cis	rs12324805	0.532	rs6495638	ENSG00000276710.3	CSPG4P8	-3.36	0.000812	0.0367	-0.12	-0.1	Body mass index;	chr15:82030912	chr15:82459472~82477258:+
BRCA	cis	rs2276314	0.857	rs4799408	ENSG00000267627.4	RP11-905K4.1	3.36	0.000812	0.0367	0.13	0.1	Endometriosis;Drug-induced torsades de pointes;	chr18:36009019	chr18:35951803~35966118:-
BRCA	cis	rs1670533	1	rs10084888	ENSG00000251639.2	RP11-20I20.1	3.36	0.000812	0.0367	0.16	0.1	Recombination rate (females);	chr4:1060026	chr4:1100016~1101558:-
BRCA	cis	rs1670533	1	rs10084889	ENSG00000251639.2	RP11-20I20.1	3.36	0.000812	0.0367	0.16	0.1	Recombination rate (females);	chr4:1060027	chr4:1100016~1101558:-
BRCA	cis	rs11992162	0.967	rs10088415	ENSG00000154316.13	TDH	3.36	0.000812	0.0367	0.13	0.1	Monocyte count;	chr8:11973316	chr8:11339637~11368452:+
BRCA	cis	rs10992471	0.513	rs710163	ENSG00000275318.1	RP11-526D8.11	3.36	0.000812	0.0367	0.1	0.1	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr9:92297522	chr9:92840955~92841688:-
BRCA	cis	rs9472719	0.891	rs11752318	ENSG00000231769.2	RP1-8B1.4	3.36	0.000812	0.0367	0.14	0.1	Total cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;	chr6:46184602	chr6:46097093~46129706:-
BRCA	cis	rs2836974	0.644	rs2836986	ENSG00000238141.2	BRWD1-AS1	-3.36	0.000812	0.0367	-0.12	-0.1	Cognitive function;	chr21:39330210	chr21:39315707~39323218:+
BRCA	cis	rs1712517	0.526	rs113528138	ENSG00000234699.1	RP11-225H22.4	3.36	0.000812	0.0367	0.13	0.1	Migraine;	chr10:103365694	chr10:103452846~103462695:+
BRCA	cis	rs1712517	0.525	rs11191667	ENSG00000234699.1	RP11-225H22.4	3.36	0.000812	0.0367	0.13	0.1	Migraine;	chr10:103369141	chr10:103452846~103462695:+
BRCA	cis	rs12135191	0.523	rs7518118	ENSG00000229795.2	RPS21P1	3.36	0.000812	0.0367	0.13	0.1	Urate levels (BMI interaction);	chr1:236325929	chr1:235432985~235433231:+
BRCA	cis	rs10943724	0.556	rs1840334	ENSG00000272129.1	RP11-250B2.6	3.36	0.000812	0.0367	0.14	0.1	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr6:80596778	chr6:80355424~80356859:+
BRCA	cis	rs4879656	0.602	rs13301356	ENSG00000236184.1	TCEA1P4	-3.36	0.000812	0.0367	-0.14	-0.1	Menopause (age at onset);	chr9:33085497	chr9:32979560~32980403:-
BRCA	cis	rs2625529	0.73	rs2929528	ENSG00000261187.1	RP11-1007O24.2	3.36	0.000812	0.0367	0.11	0.1	Red blood cell count;	chr15:71976996	chr15:72465128~72466262:-
BRCA	cis	rs67340775	0.541	rs200975	ENSG00000241549.7	GUSBP2	3.36	0.000812	0.0367	0.15	0.1	Lung cancer in ever smokers;	chr6:27887847	chr6:26871484~26956554:-
BRCA	cis	rs67340775	0.541	rs200974	ENSG00000241549.7	GUSBP2	3.36	0.000812	0.0367	0.15	0.1	Lung cancer in ever smokers;	chr6:27888067	chr6:26871484~26956554:-
BRCA	cis	rs889122	0.684	rs1978453	ENSG00000267289.1	CTD-2623N2.11	3.36	0.000812	0.0367	0.14	0.1	Menarche (age at onset);	chr19:9872769	chr19:9834079~9835013:-
BRCA	cis	rs889122	0.729	rs10413248	ENSG00000267289.1	CTD-2623N2.11	3.36	0.000812	0.0367	0.14	0.1	Menarche (age at onset);	chr19:9873420	chr19:9834079~9835013:-
BRCA	cis	rs10771431	0.597	rs7976807	ENSG00000214776.8	RP11-726G1.1	-3.36	0.000812	0.0367	-0.11	-0.1	Breast size;	chr12:9199863	chr12:9467552~9576275:+
BRCA	cis	rs2412819	0.571	rs11070411	ENSG00000201136.1	RNU6-353P	-3.36	0.000812	0.0367	-0.15	-0.1	Lung cancer;	chr15:43766436	chr15:43702363~43702470:+
BRCA	cis	rs1510510	0.757	rs12993655	ENSG00000229915.1	AC016999.2	3.36	0.000813	0.0367	0.17	0.1	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr2:238623411	chr2:238427077~238427729:-
BRCA	cis	rs258892	0.947	rs266446	ENSG00000272525.1	RP11-79P5.9	3.36	0.000813	0.0367	0.13	0.1	Small cell lung carcinoma;	chr5:72886203	chr5:73497550~73498293:-
BRCA	cis	rs11148252	0.74	rs7981050	ENSG00000281106.1	LINC00282	3.36	0.000813	0.0367	0.12	0.1	Lewy body disease;	chr13:52181014	chr13:51813347~51845175:-
BRCA	cis	rs8030605	0.778	rs72740578	ENSG00000277245.1	RP11-48G14.3	3.36	0.000813	0.0367	0.22	0.1	Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;	chr15:56345898	chr15:56447120~56447697:+
BRCA	cis	rs853679	0.825	rs8180562	ENSG00000219392.1	RP1-265C24.5	-3.36	0.000813	0.0367	-0.22	-0.1	Depression;	chr6:28173682	chr6:28115628~28116551:+
BRCA	cis	rs853679	0.882	rs9380064	ENSG00000219392.1	RP1-265C24.5	-3.36	0.000813	0.0367	-0.22	-0.1	Depression;	chr6:28175340	chr6:28115628~28116551:+
BRCA	cis	rs863345	0.625	rs10752626	ENSG00000176320.2	RP11-404O13.5	-3.36	0.000813	0.0367	-0.11	-0.1	Pneumococcal bacteremia;	chr1:158558328	chr1:158197922~158203877:-
BRCA	cis	rs4927850	1	rs7630875	ENSG00000273009.1	RP11-352G9.1	-3.36	0.000813	0.0367	-0.13	-0.1	Pancreatic cancer;	chr3:196026895	chr3:195913078~195913683:-
BRCA	cis	rs2638953	0.64	rs1511549	ENSG00000273989.1	RP11-425D17.2	-3.36	0.000813	0.0367	-0.14	-0.1	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28578968	chr12:28236227~28236828:+
BRCA	cis	rs6496932	0.676	rs7183651	ENSG00000259630.2	CTD-2262B20.1	-3.36	0.000813	0.0367	-0.13	-0.1	Central corneal thickness;Corneal structure;	chr15:85352490	chr15:85415228~85415633:+
BRCA	cis	rs9388451	0.626	rs3799712	ENSG00000237742.5	RP11-624M8.1	-3.36	0.000813	0.0367	-0.13	-0.1	Brugada syndrome;	chr6:125753957	chr6:125578558~125749190:-
BRCA	cis	rs10129255	1	rs10141557	ENSG00000211959.2	IGHV4-39	3.36	0.000813	0.0367	0.08	0.1	Kawasaki disease;	chr14:106767990	chr14:106421711~106422218:-
BRCA	cis	rs853679	0.55	rs1225598	ENSG00000261839.1	RP1-265C24.8	3.36	0.000813	0.0367	0.14	0.1	Depression;	chr6:28193021	chr6:28136849~28139678:+
BRCA	cis	rs10851411	0.697	rs12439377	ENSG00000260490.2	RP11-265N6.3	-3.36	0.000813	0.0367	-0.19	-0.1	Glucose homeostasis traits;	chr15:42569164	chr15:42571927~42572433:+
BRCA	cis	rs2882667	0.659	rs12719515	ENSG00000242683.1	CTB-46B19.1	3.36	0.000813	0.0367	0.12	0.1	Age-related hearing impairment (SNP x SNP interaction);	chr5:138905629	chr5:139035148~139035987:-
BRCA	cis	rs1383484	0.798	rs7179241	ENSG00000230373.7	GOLGA6L5P	-3.36	0.000813	0.0367	-0.13	-0.1	Height;	chr15:83882959	chr15:84507885~84516814:-
BRCA	cis	rs7746082	0.627	rs12216416	ENSG00000219902.1	RPL35P3	3.36	0.000813	0.0367	0.14	0.1	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr6:106025395	chr6:105302453~105302823:-
BRCA	cis	rs1334894	0.901	rs56353810	ENSG00000187762.5	HSPE1P11	3.36	0.000813	0.0367	0.24	0.1	Coronary artery disease;	chr6:35553309	chr6:35023522~35023831:+
BRCA	cis	rs1334894	0.901	rs56062505	ENSG00000187762.5	HSPE1P11	3.36	0.000813	0.0367	0.24	0.1	Coronary artery disease;	chr6:35553405	chr6:35023522~35023831:+
BRCA	cis	rs890448	0.796	rs2433307	ENSG00000254531.1	FLJ20021	3.36	0.000814	0.0367	0.12	0.1	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101426059	chr4:101347780~101348883:+
BRCA	cis	rs9650657	0.631	rs1124010	ENSG00000154316.13	TDH	3.36	0.000814	0.0367	0.13	0.1	Neuroticism;	chr8:10737992	chr8:11339637~11368452:+
BRCA	cis	rs2615061	0.872	rs10915871	ENSG00000229965.1	RP11-118H4.1	3.36	0.000814	0.0367	0.19	0.1	Monocyte count;	chr1:225756172	chr1:226438564~226439344:+
BRCA	cis	rs4869313	0.583	rs2548540	ENSG00000248734.2	CTD-2260A17.1	-3.36	0.000814	0.0367	-0.1	-0.1	Pediatric autoimmune diseases;	chr5:96894474	chr5:96784777~96785999:+
BRCA	cis	rs6840360	0.615	rs4696266	ENSG00000270265.1	RP11-731D1.4	-3.36	0.000814	0.0367	-0.12	-0.1	Intelligence (multi-trait analysis);	chr4:151542269	chr4:151333775~151353224:-
BRCA	cis	rs6840360	0.615	rs6836249	ENSG00000270265.1	RP11-731D1.4	-3.36	0.000814	0.0367	-0.12	-0.1	Intelligence (multi-trait analysis);	chr4:151544677	chr4:151333775~151353224:-
BRCA	cis	rs6840360	0.615	rs72728179	ENSG00000270265.1	RP11-731D1.4	-3.36	0.000814	0.0367	-0.12	-0.1	Intelligence (multi-trait analysis);	chr4:151556725	chr4:151333775~151353224:-
BRCA	cis	rs6964587	0.626	rs6951795	ENSG00000188693.7	CYP51A1-AS1	3.36	0.000814	0.0367	0.11	0.1	Breast cancer;	chr7:91914450	chr7:92134604~92180725:+
BRCA	cis	rs886774	0.809	rs7561	ENSG00000273055.1	CTB-13F3.1	-3.36	0.000814	0.0367	-0.11	-0.1	Ulcerative colitis;	chr7:107923921	chr7:107942116~107942740:+
BRCA	cis	rs1979679	1	rs11049506	ENSG00000244712.1	RP11-874G11.1	3.36	0.000814	0.0367	0.15	0.1	Ossification of the posterior longitudinal ligament of the spine;	chr12:28289141	chr12:28564678~28565141:-
BRCA	cis	rs13256369	1	rs873063	ENSG00000233609.3	RP11-62H7.2	3.36	0.000814	0.0367	0.11	0.1	Obesity-related traits;	chr8:8714937	chr8:8961200~8979025:+
BRCA	cis	rs62458065	1	rs10231294	ENSG00000273014.1	RP11-225B17.2	-3.36	0.000814	0.0367	-0.15	-0.1	Metabolite levels (HVA/MHPG ratio);	chr7:32425745	chr7:32758882~32759353:+
BRCA	cis	rs2924679	1	rs3019587	ENSG00000265539.1	MIR3164	3.36	0.000814	0.0367	0.23	0.1	Obesity-related traits;	chr11:68802174	chr11:69083176~69083258:+
BRCA	cis	rs60871478	0.636	rs12534606	ENSG00000237181.1	AC147651.4	3.36	0.000814	0.0367	0.12	0.1	Cerebrospinal P-tau181p levels;	chr7:856291	chr7:603185~608482:+
BRCA	cis	rs56046484	0.956	rs35885781	ENSG00000230373.7	GOLGA6L5P	3.36	0.000814	0.0367	0.16	0.1	Testicular germ cell tumor;	chr15:85047852	chr15:84507885~84516814:-
BRCA	cis	rs35660623	0.867	rs6983180	ENSG00000246477.3	AF131216.6	3.36	0.000814	0.0367	0.17	0.1	3-hydroxypropylmercapturic acid levels in smokers;	chr8:10802607	chr8:11315859~11325429:-
BRCA	cis	rs2288327	0.818	rs2288325	ENSG00000271011.1	RP11-171I2.5	3.36	0.000814	0.0367	0.19	0.1	Atrial fibrillation;	chr2:178540059	chr2:178577103~178577622:+
BRCA	cis	rs603446	0.61	rs1263058	ENSG00000254851.1	RP11-109L13.1	-3.36	0.000814	0.0367	-0.13	-0.1	Triglycerides;	chr11:116704839	chr11:117135528~117138582:+
BRCA	cis	rs12612435	0.736	rs867563	ENSG00000226806.1	AC011893.3	3.36	0.000814	0.0367	0.13	0.1	Takotsubo syndrome;	chr2:136384930	chr2:135820191~135823087:+
BRCA	cis	rs62458065	1	rs10250808	ENSG00000273014.1	RP11-225B17.2	-3.36	0.000814	0.0368	-0.15	-0.1	Metabolite levels (HVA/MHPG ratio);	chr7:32426541	chr7:32758882~32759353:+
BRCA	cis	rs8058578	1	rs2289442	ENSG00000260082.1	RP11-2C24.5	3.36	0.000814	0.0368	0.12	0.1	Multiple myeloma;	chr16:30728598	chr16:30821068~30822110:-
BRCA	cis	rs2692947	0.537	rs12478605	ENSG00000232931.4	LINC00342	3.36	0.000814	0.0368	0.11	0.1	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95711330	chr2:95807118~95816215:-
BRCA	cis	rs4427176	0.714	rs12335065	ENSG00000233609.3	RP11-62H7.2	3.36	0.000814	0.0368	0.13	0.1	Mosquito bite size;	chr8:9612874	chr8:8961200~8979025:+
BRCA	cis	rs928391	1	rs10157555	ENSG00000223356.1	RP11-66D17.5	3.36	0.000814	0.0368	0.13	0.1	Platelet count;	chr1:156802060	chr1:156712212~156713174:-
BRCA	cis	rs29784	0.633	rs7701353	ENSG00000253683.1	CTB-79E8.3	3.36	0.000814	0.0368	0.13	0.1	Infantile hypertrophic pyloric stenosis;	chr5:173197479	chr5:172656522~172656713:-
BRCA	cis	rs4538475	0.527	rs3815466	ENSG00000214846.4	RP11-115L11.1	-3.36	0.000815	0.0368	-0.17	-0.1	Parkinson's disease;	chr4:15738669	chr4:15730962~15731627:-
BRCA	cis	rs910873	1	rs62212343	ENSG00000250917.1	RP4-785G19.5	-3.36	0.000815	0.0368	-0.29	-0.1	Melanoma;	chr20:34609133	chr20:34234840~34281173:-
BRCA	cis	rs2835345	0.563	rs60727080	ENSG00000214914.3	RPL23AP3	-3.36	0.000815	0.0368	-0.14	-0.1	Pulmonary function;	chr21:36454876	chr21:36016079~36016546:-
BRCA	cis	rs3018066	0.831	rs6842919	ENSG00000251175.4	RP11-45L9.1	3.36	0.000815	0.0368	0.13	0.1	Cancer;	chr4:106037013	chr4:105746245~105827172:-
BRCA	cis	rs76917914	1	rs76917914	ENSG00000236896.1	RP11-535C21.3	3.36	0.000815	0.0368	0.13	0.1	Immature fraction of reticulocytes;	chr9:98009158	chr9:97986551~97987656:-
BRCA	cis	rs13401620	0.587	rs13012932	ENSG00000236878.1	AC012363.7	3.36	0.000815	0.0368	0.13	0.1	Breast size;	chr2:120070143	chr2:120211054~120211715:+
BRCA	cis	rs4589258	0.933	rs1783788	ENSG00000280367.1	RP11-121L10.2	3.36	0.000815	0.0368	0.12	0.1	Intelligence (multi-trait analysis);	chr11:90701023	chr11:90223153~90226538:+
BRCA	cis	rs875971	0.929	rs778692	ENSG00000229886.1	RP5-1132H15.3	3.36	0.000815	0.0368	0.11	0.1	Aortic root size;	chr7:66407462	chr7:66025126~66031544:-
BRCA	cis	rs875971	1	rs4718343	ENSG00000229886.1	RP5-1132H15.3	3.36	0.000815	0.0368	0.11	0.1	Aortic root size;	chr7:66409301	chr7:66025126~66031544:-
BRCA	cis	rs875971	1	rs1968225	ENSG00000229886.1	RP5-1132H15.3	3.36	0.000815	0.0368	0.11	0.1	Aortic root size;	chr7:66409786	chr7:66025126~66031544:-
BRCA	cis	rs875971	1	rs6460295	ENSG00000229886.1	RP5-1132H15.3	3.36	0.000815	0.0368	0.11	0.1	Aortic root size;	chr7:66417741	chr7:66025126~66031544:-
BRCA	cis	rs875971	0.964	rs6978721	ENSG00000229886.1	RP5-1132H15.3	3.36	0.000815	0.0368	0.11	0.1	Aortic root size;	chr7:66418217	chr7:66025126~66031544:-
BRCA	cis	rs6600671	1	rs10794671	ENSG00000270231.3	NBPF8P	3.36	0.000815	0.0368	0.11	0.1	Hip geometry;	chr1:121426382	chr1:120436353~120467739:+
BRCA	cis	rs12477602	0.938	rs12472248	ENSG00000272966.1	RP11-686O6.1	3.36	0.000815	0.0368	0.18	0.1	Intelligence (multi-trait analysis);	chr2:202523530	chr2:202336739~202337200:+
BRCA	cis	rs7264396	0.836	rs1886695	ENSG00000088340.14	FER1L4	3.36	0.000815	0.0368	0.12	0.1	Total cholesterol levels;	chr20:35592613	chr20:35558737~35607562:-
BRCA	cis	rs9843304	0.616	rs4131174	ENSG00000244503.1	RP11-278L15.6	3.36	0.000815	0.0368	0.13	0.1	Gallstone disease;	chr3:149486123	chr3:149494660~149495995:+
BRCA	cis	rs4499344	0.73	rs7247597	ENSG00000201388.1	SNORA68	3.36	0.000815	0.0368	0.12	0.1	Mean platelet volume;	chr19:32611351	chr19:32608337~32608469:-
BRCA	cis	rs8180040	0.764	rs11716539	ENSG00000260236.1	RP11-708J19.1	3.36	0.000815	0.0368	0.09	0.1	Colorectal cancer;	chr3:47145013	chr3:47379089~47380999:-
BRCA	cis	rs2688608	0.592	rs12253429	ENSG00000242288.9	RP11-464F9.1	3.36	0.000815	0.0368	0.13	0.1	Inflammatory bowel disease;	chr10:73736403	chr10:73674295~73730466:-
BRCA	cis	rs6142102	1	rs6142102	ENSG00000206582.1	Y_RNA	-3.36	0.000815	0.0368	-0.12	-0.1	Skin pigmentation;	chr20:34116821	chr20:34526510~34526606:-
BRCA	cis	rs673253	0.686	rs17371903	ENSG00000229431.1	RP1-92O14.6	-3.36	0.000815	0.0368	-0.11	-0.1	Intelligence (multi-trait analysis);	chr1:43605020	chr1:43385113~43389155:+
BRCA	cis	rs8058578	0.943	rs35629860	ENSG00000275263.1	RP11-1072A3.4	-3.36	0.000815	0.0368	-0.14	-0.1	Multiple myeloma;	chr16:30660211	chr16:30956872~30957199:-
BRCA	cis	rs4873772	0.558	rs7825148	ENSG00000253330.1	RP11-697N18.3	-3.36	0.000815	0.0368	-0.15	-0.1	Lobe attachment (rater-scored or self-reported);	chr8:47465991	chr8:47511034~47512141:-
BRCA	cis	rs1334894	1	rs2294807	ENSG00000187762.5	HSPE1P11	3.36	0.000816	0.0368	0.24	0.1	Coronary artery disease;	chr6:35587333	chr6:35023522~35023831:+
BRCA	cis	rs11098499	0.954	rs3733520	ENSG00000225892.3	RP11-384K6.2	3.36	0.000816	0.0368	0.1	0.1	Corneal astigmatism;	chr4:119502325	chr4:118632274~118634759:+
BRCA	cis	rs801193	0.613	rs2016325	ENSG00000223473.2	GS1-124K5.3	-3.36	0.000816	0.0368	-0.08	-0.1	Aortic root size;	chr7:66858513	chr7:66491049~66493566:-
BRCA	cis	rs8058578	0.832	rs35969813	ENSG00000275263.1	RP11-1072A3.4	-3.36	0.000816	0.0368	-0.13	-0.1	Multiple myeloma;	chr16:30703096	chr16:30956872~30957199:-
BRCA	cis	rs832540	0.83	rs252907	ENSG00000237705.1	AC008937.2	3.36	0.000816	0.0368	0.11	0.1	Coronary artery disease;	chr5:56824819	chr5:56842016~56862164:-
BRCA	cis	rs3808502	0.525	rs9650661	ENSG00000248896.2	CTD-2135J3.3	-3.36	0.000816	0.0368	-0.13	-0.1	Neuroticism;	chr8:11569624	chr8:10729314~10771392:+
BRCA	cis	rs35306767	0.903	rs11253475	ENSG00000229869.1	RP11-363N22.2	-3.36	0.000816	0.0368	-0.16	-0.1	Eosinophil percentage of granulocytes;	chr10:861322	chr10:933026~942743:+
BRCA	cis	rs873549	1	rs10863688	ENSG00000238042.4	RP11-815M8.1	3.36	0.000816	0.0368	0.12	0.1	Keloid;	chr1:222093432	chr1:221880981~221978523:-
BRCA	cis	rs258892	0.895	rs10041942	ENSG00000272525.1	RP11-79P5.9	-3.36	0.000816	0.0368	-0.13	-0.1	Small cell lung carcinoma;	chr5:72754137	chr5:73497550~73498293:-
BRCA	cis	rs524281	0.861	rs918299	ENSG00000255038.1	RP11-1167A19.2	-3.36	0.000816	0.0368	-0.15	-0.1	Electroencephalogram traits;	chr11:66160136	chr11:66067277~66069619:-
BRCA	cis	rs77320796	1	rs61781290	ENSG00000236546.1	RP1-118J21.5	3.36	0.000816	0.0368	0.14	0.1	Platelet count;	chr1:39927488	chr1:39897745~39899098:+
BRCA	cis	rs10863681	0.846	rs12125086	ENSG00000232679.1	RP11-400N13.3	3.36	0.000816	0.0368	0.11	0.1	Metabolite levels (HVA-5-HIAA Factor score);	chr1:222095514	chr1:222041705~222064763:-
BRCA	cis	rs35740288	0.58	rs34635893	ENSG00000259407.1	RP11-158M2.3	-3.36	0.000816	0.0368	-0.14	-0.1	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85797017	chr15:85744109~85750281:-
BRCA	cis	rs11587682	0.714	rs74127616	ENSG00000228126.1	FALEC	3.36	0.000816	0.0368	0.14	0.1	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr1:150486848	chr1:150515757~150518032:+
BRCA	cis	rs4713118	0.621	rs9295755	ENSG00000226314.6	ZNF192P1	3.36	0.000816	0.0368	0.16	0.1	Parkinson's disease;	chr6:28065396	chr6:28161781~28169594:+
BRCA	cis	rs9531006	0.571	rs12583025	ENSG00000227676.3	LINC01068	3.36	0.000816	0.0368	0.15	0.1	Sleep duration;	chr13:79930017	chr13:79566727~79571436:+
BRCA	cis	rs6964587	0.967	rs7788092	ENSG00000188693.7	CYP51A1-AS1	-3.36	0.000816	0.0368	-0.11	-0.1	Breast cancer;	chr7:92016884	chr7:92134604~92180725:+
BRCA	cis	rs12282928	1	rs12288484	ENSG00000255197.4	RP11-750H9.5	-3.36	0.000816	0.0368	-0.09	-0.1	Migraine - clinic-based;	chr11:48305924	chr11:47383148~47409190:-
BRCA	cis	rs4981053	0.644	rs1958711	ENSG00000259001.3	RPPH1	3.36	0.000816	0.0368	0.12	0.1	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr14:20057161	chr14:20343048~20343685:-
BRCA	cis	rs13256369	1	rs10095733	ENSG00000233609.3	RP11-62H7.2	3.36	0.000816	0.0368	0.11	0.1	Obesity-related traits;	chr8:8717136	chr8:8961200~8979025:+
BRCA	cis	rs12477438	0.52	rs34766932	ENSG00000231822.1	AC019097.7	3.36	0.000816	0.0368	0.11	0.1	Chronic sinus infection;	chr2:99120810	chr2:99102018~99102752:+
BRCA	cis	rs875971	0.651	rs2420596	ENSG00000265600.1	AC006480.1	-3.36	0.000816	0.0368	-0.12	-0.1	Aortic root size;	chr7:66450996	chr7:67356680~67356779:+
BRCA	cis	rs875971	0.52	rs2420597	ENSG00000265600.1	AC006480.1	-3.36	0.000816	0.0368	-0.12	-0.1	Aortic root size;	chr7:66450999	chr7:67356680~67356779:+
BRCA	cis	rs11902236	0.545	rs744033	ENSG00000188525.3	AC010969.1	-3.36	0.000816	0.0368	-0.12	-0.1	Prostate cancer;	chr2:9984331	chr2:10003158~10006030:-
BRCA	cis	rs3739034	0.941	rs4953927	ENSG00000224043.6	CCNT2-AS1	-3.36	0.000816	0.0368	-0.16	-0.1	Gut microbiome composition (winter);	chr2:134724055	chr2:134735464~134918710:-
BRCA	cis	rs72928364	1	rs62275825	ENSG00000256628.3	ZBTB11-AS1	3.36	0.000816	0.0368	0.2	0.1	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:101039866	chr3:101676475~101679217:+
BRCA	cis	rs7283707	0.681	rs74774121	ENSG00000270071.1	AP001172.2	-3.36	0.000817	0.0368	-0.17	-0.1	QRS complex (12-leadsum);	chr21:15802579	chr21:16291791~16308133:-
BRCA	cis	rs6828577	0.955	rs13127508	ENSG00000281731.1	RP11-384K6.8	3.36	0.000817	0.0368	0.12	0.1	Perioperative myocardial infarction in coronary artery bypass surgery;	chr4:118760088	chr4:118664087~118685341:-
BRCA	cis	rs6831352	0.842	rs1230156	ENSG00000260641.1	RP11-1299A16.3	3.36	0.000817	0.0368	0.15	0.1	Alcohol dependence;	chr4:99068475	chr4:98658904~98664550:+
BRCA	cis	rs728616	0.681	rs12769764	ENSG00000272447.1	RP11-182L21.6	-3.36	0.000817	0.0368	-0.13	-0.1	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80157357	chr10:79825902~79827602:+
BRCA	cis	rs4805834	1	rs4805834	ENSG00000201388.1	SNORA68	-3.36	0.000817	0.0369	-0.18	-0.1	Creatinine levels;	chr19:32962753	chr19:32608337~32608469:-
BRCA	cis	rs875971	0.798	rs6460304	ENSG00000106610.13	STAG3L4	-3.36	0.000817	0.0369	-0.14	-0.1	Aortic root size;	chr7:66499741	chr7:67302621~67321526:+
BRCA	cis	rs875971	0.862	rs6945775	ENSG00000106610.13	STAG3L4	-3.36	0.000817	0.0369	-0.14	-0.1	Aortic root size;	chr7:66503987	chr7:67302621~67321526:+
BRCA	cis	rs524281	0.861	rs10896090	ENSG00000255038.1	RP11-1167A19.2	-3.36	0.000817	0.0369	-0.16	-0.1	Electroencephalogram traits;	chr11:66177715	chr11:66067277~66069619:-
BRCA	cis	rs2882667	0.659	rs10056014	ENSG00000242683.1	CTB-46B19.1	3.36	0.000817	0.0369	0.12	0.1	Age-related hearing impairment (SNP x SNP interaction);	chr5:138920329	chr5:139035148~139035987:-
BRCA	cis	rs6452790	0.543	rs10070939	ENSG00000247828.6	TMEM161B-AS1	-3.36	0.000817	0.0369	-0.15	-0.1	Cognitive function;	chr5:88058403	chr5:88268895~88436685:+
BRCA	cis	rs2985684	0.841	rs12894785	ENSG00000278009.1	RP11-649E7.8	3.36	0.000817	0.0369	0.15	0.1	Carotid intima media thickness;	chr14:49583037	chr14:49601011~49601124:-
BRCA	cis	rs2617170	0.961	rs1841957	ENSG00000245648.1	RP11-277P12.20	3.36	0.000817	0.0369	0.13	0.1	Behcet's disease;	chr12:10409426	chr12:10363769~10398506:+
BRCA	cis	rs4388249	0.95	rs34097054	ENSG00000249068.1	CTC-287O8.1	3.36	0.000817	0.0369	0.15	0.1	Schizophrenia;	chr5:109759753	chr5:109840128~109840692:-
BRCA	cis	rs2882667	0.69	rs288022	ENSG00000242683.1	CTB-46B19.1	3.36	0.000817	0.0369	0.12	0.1	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888586	chr5:139035148~139035987:-
BRCA	cis	rs2882667	0.598	rs288020	ENSG00000242683.1	CTB-46B19.1	3.36	0.000817	0.0369	0.12	0.1	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888609	chr5:139035148~139035987:-
BRCA	cis	rs2337406	0.925	rs11851094	ENSG00000211976.2	IGHV3-73	-3.36	0.000817	0.0369	-0.11	-0.1	Alzheimer's disease (late onset);	chr14:106688967	chr14:106802694~106803233:-
BRCA	cis	rs4415084	0.662	rs12109710	ENSG00000248779.1	RP11-53O19.2	-3.36	0.000817	0.0369	-0.1	-0.1	Breast cancer;	chr5:44929826	chr5:44752949~44765744:+
BRCA	cis	rs875971	0.862	rs778734	ENSG00000223473.2	GS1-124K5.3	3.36	0.000817	0.0369	0.08	0.1	Aortic root size;	chr7:66349862	chr7:66491049~66493566:-
BRCA	cis	rs7260598	0.539	rs11670289	ENSG00000268442.1	CTD-2027I19.2	3.36	0.000818	0.0369	0.18	0.1	Response to taxane treatment (placlitaxel);	chr19:23884154	chr19:24162370~24163425:-
BRCA	cis	rs1325195	0.881	rs3813642	ENSG00000232750.2	RP11-177A2.5	-3.36	0.000818	0.0369	-0.11	-0.1	IgE grass sensitization;	chr1:179100985	chr1:179035309~179035652:-
BRCA	cis	rs4650943	0.503	rs10218714	ENSG00000227740.1	RP11-318C24.2	3.36	0.000818	0.0369	0.11	0.1	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in inactive individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr1:176073953	chr1:175904762~175920513:-
BRCA	cis	rs7829975	0.742	rs1533059	ENSG00000173295.6	FAM86B3P	-3.36	0.000818	0.0369	-0.11	-0.1	Mood instability;	chr8:8827443	chr8:8228595~8244865:+
BRCA	cis	rs7267979	1	rs6076339	ENSG00000277938.1	RP5-965G21.3	-3.36	0.000818	0.0369	-0.12	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25368076	chr20:25229150~25231933:+
BRCA	cis	rs7647973	1	rs6805609	ENSG00000272434.1	RP13-131K19.6	3.36	0.000818	0.0369	0.14	0.1	Menarche (age at onset);	chr3:49434089	chr3:49029316~49029706:+
BRCA	cis	rs7267979	0.932	rs2387891	ENSG00000276952.1	RP5-965G21.6	3.36	0.000818	0.0369	0.12	0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25489692	chr20:25284915~25285588:-
BRCA	cis	rs7520050	0.966	rs4134386	ENSG00000226957.1	RP4-533D7.4	3.36	0.000818	0.0369	0.11	0.1	Reticulocyte count;Red blood cell count;	chr1:45929417	chr1:46046818~46048368:+
BRCA	cis	rs7520050	0.966	rs12561806	ENSG00000226957.1	RP4-533D7.4	3.36	0.000818	0.0369	0.11	0.1	Reticulocyte count;Red blood cell count;	chr1:45931104	chr1:46046818~46048368:+
BRCA	cis	rs804280	0.509	rs12719915	ENSG00000255046.1	RP11-297N6.4	3.36	0.000818	0.0369	0.12	0.1	Myopia (pathological);	chr8:11928746	chr8:11797928~11802568:-
BRCA	cis	rs16893526	1	rs13192697	ENSG00000224995.1	LINC01526	3.36	0.000818	0.0369	0.18	0.1	Coronary heart disease;	chr6:81781387	chr6:81813286~81814157:-
BRCA	cis	rs7594648	0.782	rs2691768	ENSG00000226383.4	AC093375.1	3.36	0.000818	0.0369	0.15	0.1	Age-related hearing impairment;	chr2:155640655	chr2:156011617~156024613:-
BRCA	cis	rs7781266	0.79	rs1364503	ENSG00000226205.1	AC007790.4	-3.36	0.000818	0.0369	-0.15	-0.1	Educational attainment (college completion);	chr7:133398750	chr7:133732493~133733595:-
BRCA	cis	rs6600671	0.691	rs6600662	ENSG00000275131.1	CH17-472G23.4	-3.36	0.000818	0.0369	-0.1	-0.1	Hip geometry;	chr1:121488992	chr1:120489625~120579190:-
BRCA	cis	rs13416342	0.8	rs1503241	ENSG00000236259.1	AC017083.2	3.36	0.000818	0.0369	0.11	0.1	Breast cancer;	chr2:67873569	chr2:68125265~68125747:+
BRCA	cis	rs721917	0.629	rs1304463	ENSG00000242600.5	MBL1P	3.36	0.000818	0.0369	0.12	0.1	Chronic obstructive pulmonary disease;	chr10:79969516	chr10:79904898~79950336:+
BRCA	cis	rs10816359	0.947	rs10816366	ENSG00000234323.4	RP11-308N19.1	-3.36	0.000818	0.0369	-0.16	-0.1	Menarche (age at onset);	chr9:106015282	chr9:106278392~106604795:+
BRCA	cis	rs1555322	0.53	rs2425047	ENSG00000278035.1	RP11-234K24.6	-3.36	0.000818	0.0369	-0.14	-0.1	Attention deficit hyperactivity disorder;	chr20:35283872	chr20:36233851~36234297:+
BRCA	cis	rs863345	0.604	rs4313395	ENSG00000229914.1	RP11-404O13.4	-3.36	0.000818	0.0369	-0.11	-0.1	Pneumococcal bacteremia;	chr1:158535345	chr1:158195633~158196131:-
BRCA	cis	rs2640806	0.645	rs7824505	ENSG00000253105.4	KB-1448A5.1	3.36	0.000818	0.0369	0.12	0.1	Obesity-related traits;	chr8:96318463	chr8:96371865~96387438:-
BRCA	cis	rs12282928	0.918	rs1503174	ENSG00000255197.4	RP11-750H9.5	3.36	0.000818	0.0369	0.1	0.1	Migraine - clinic-based;	chr11:48224784	chr11:47383148~47409190:-
BRCA	cis	rs1552244	0.572	rs7645759	ENSG00000269894.1	RP11-1020A11.1	-3.36	0.000818	0.0369	-0.14	-0.1	Alzheimer's disease;	chr3:10115684	chr3:9935706~9936258:+
BRCA	cis	rs4950322	0.58	rs2083720	ENSG00000227242.3	NBPF13P	-3.36	0.000819	0.0369	-0.15	-0.1	Protein quantitative trait loci;	chr1:147122296	chr1:147021320~147124525:-
BRCA	cis	rs12234571	1	rs59056139	ENSG00000214293.7	APTR	3.36	0.000819	0.0369	0.22	0.1	Obesity-related traits;	chr7:77819354	chr7:77657660~77696265:-
BRCA	cis	rs2496589	0.963	rs9484744	ENSG00000218896.1	TUBB8P2	3.36	0.000819	0.0369	0.13	0.1	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);	chr6:143423127	chr6:143436216~143436710:+
BRCA	cis	rs13236243	0.569	rs62444550	ENSG00000237773.4	AC003075.4	-3.36	0.000819	0.0369	-0.13	-0.1	Sensory disturbances after bilateral sagittal split ramus osteotomy;	chr7:17290494	chr7:17279834~17299357:-
BRCA	cis	rs5762752	0.509	rs5752746	ENSG00000272858.1	CTA-292E10.8	-3.36	0.000819	0.0369	-0.12	-0.1	Optic disc area;	chr22:28450592	chr22:28814914~28815662:+
BRCA	cis	rs3177980	0.673	rs17603022	ENSG00000239494.2	RN7SL333P	-3.36	0.000819	0.0369	-0.1	-0.1	Amyotrophic lateral sclerosis;	chr1:169869137	chr1:169859756~169860052:+
BRCA	cis	rs4835473	0.75	rs12498381	ENSG00000246448.2	RP13-578N3.3	-3.36	0.000819	0.0369	-0.12	-0.1	Immature fraction of reticulocytes;	chr4:143793928	chr4:143700257~143865072:+
BRCA	cis	rs875971	0.862	rs7786892	ENSG00000229886.1	RP5-1132H15.3	-3.36	0.000819	0.0369	-0.12	-0.1	Aortic root size;	chr7:66163889	chr7:66025126~66031544:-
BRCA	cis	rs2574985	0.813	rs1203409	ENSG00000226200.5	SGMS1-AS1	-3.36	0.000819	0.0369	-0.11	-0.1	Subjective well-being;	chr10:50437435	chr10:50624951~50641451:+
BRCA	cis	rs67478160	0.643	rs12878868	ENSG00000269910.1	RP11-73M18.10	3.36	0.000819	0.0369	0.1	0.1	Schizophrenia;	chr14:103767388	chr14:103694516~103695050:-
BRCA	cis	rs896655	0.582	rs2891165	ENSG00000265194.1	RP11-70L8.4	-3.36	0.000819	0.0369	-0.1	-0.1	Coronary artery disease;	chr9:21711802	chr9:21858910~21861926:-
BRCA	cis	rs896655	0.601	rs1335501	ENSG00000265194.1	RP11-70L8.4	-3.36	0.000819	0.0369	-0.1	-0.1	Coronary artery disease;	chr9:21711816	chr9:21858910~21861926:-
BRCA	cis	rs6089829	0.962	rs4809456	ENSG00000233017.2	RP5-908M14.5	3.36	0.000819	0.0369	0.13	0.1	Prostate cancer (SNP x SNP interaction);	chr20:63029497	chr20:62427827~62447621:+
BRCA	cis	rs1008953	0.95	rs1548227	ENSG00000273555.1	MIR6812	3.36	0.000819	0.0369	0.13	0.1	Psoriasis;	chr20:45354870	chr20:45425510~45425573:+
BRCA	cis	rs2638953	0.924	rs11049613	ENSG00000273989.1	RP11-425D17.2	-3.36	0.000819	0.0369	-0.16	-0.1	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28449859	chr12:28236227~28236828:+
BRCA	cis	rs4631830	0.863	rs4486572	ENSG00000204177.9	BMS1P1	-3.36	0.000819	0.0369	-0.1	-0.1	Prostate-specific antigen levels;	chr10:46064017	chr10:46786674~46811989:+
BRCA	cis	rs7429990	0.965	rs319689	ENSG00000199476.1	Y_RNA	-3.36	0.000819	0.0369	-0.13	-0.1	Educational attainment (years of education);	chr3:47886677	chr3:48288587~48288694:+
BRCA	cis	rs1865760	1	rs2071297	ENSG00000272810.1	U91328.22	3.36	0.000819	0.0369	0.12	0.1	Height;	chr6:25924285	chr6:26013241~26013757:+
BRCA	cis	rs8114671	0.562	rs1013677	ENSG00000279253.1	RP4-614O4.13	-3.36	0.000819	0.0369	-0.12	-0.1	Height;	chr20:34880990	chr20:35262727~35264187:-
BRCA	cis	rs301901	0.581	rs10941343	ENSG00000272103.1	CTD-2653M23.3	-3.36	0.000819	0.0369	-0.12	-0.1	Height;	chr5:37543239	chr5:36861736~36862217:-
BRCA	cis	rs301901	0.573	rs12652433	ENSG00000272103.1	CTD-2653M23.3	-3.36	0.000819	0.0369	-0.12	-0.1	Height;	chr5:37543358	chr5:36861736~36862217:-
BRCA	cis	rs11098499	0.526	rs10026625	ENSG00000225892.3	RP11-384K6.2	3.36	0.000819	0.0369	0.1	0.1	Corneal astigmatism;	chr4:119358981	chr4:118632274~118634759:+
BRCA	cis	rs993804	0.571	rs1574901	ENSG00000264219.1	MIR4442	-3.36	0.000819	0.0369	-0.12	-0.1	Bipolar disorder and schizophrenia;	chr3:25073922	chr3:25664873~25664939:-
BRCA	cis	rs4363385	0.51	rs7531076	ENSG00000231416.1	RP11-422P24.9	3.36	0.000819	0.0369	0.11	0.1	Inflammatory skin disease;	chr1:153066691	chr1:153995632~153995960:+
BRCA	cis	rs2050392	0.517	rs160018	ENSG00000224473.1	CCND3P1	3.36	0.000819	0.0369	0.14	0.1	Inflammatory bowel disease;	chr10:30483774	chr10:30403197~30403776:-
BRCA	cis	rs1030420	0.659	rs55878528	ENSG00000200714.1	Y_RNA	-3.36	0.00082	0.0369	-0.13	-0.1	Blood metabolite levels;	chr8:66453346	chr8:65592731~65592820:+
BRCA	cis	rs2832191	0.716	rs7509628	ENSG00000236056.1	GAPDHP14	-3.36	0.00082	0.0369	-0.11	-0.1	Dental caries;	chr21:29081931	chr21:29222321~29223257:+
BRCA	cis	rs13136331	0.641	rs2627682	ENSG00000249001.4	RP11-742B18.1	3.36	0.00082	0.0369	0.14	0.1	Sitting height ratio;	chr4:87741338	chr4:87568035~87733956:-
BRCA	cis	rs12468226	1	rs13389798	ENSG00000272966.1	RP11-686O6.1	3.36	0.00082	0.0369	0.17	0.1	Urate levels;	chr2:202348370	chr2:202336739~202337200:+
BRCA	cis	rs801193	0.839	rs12534943	ENSG00000271064.1	RP11-792A8.3	3.36	0.00082	0.037	0.12	0.1	Aortic root size;	chr7:66605533	chr7:66748838~66749077:-
BRCA	cis	rs9990333	0.562	rs56224853	ENSG00000207650.1	MIR570	3.36	0.00082	0.037	0.13	0.1	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196102005	chr3:195699401~195699497:+
BRCA	cis	rs9990333	0.544	rs73210008	ENSG00000207650.1	MIR570	3.36	0.00082	0.037	0.13	0.1	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196102260	chr3:195699401~195699497:+
BRCA	cis	rs11148252	0.669	rs61958050	ENSG00000198384.8	TPTE2P3	3.36	0.00082	0.037	0.13	0.1	Lewy body disease;	chr13:52420292	chr13:52522632~52586906:+
BRCA	cis	rs2154319	0.887	rs213743	ENSG00000230638.4	RP11-486B10.4	3.36	0.00082	0.037	0.17	0.1	Height;	chr1:41154715	chr1:41542069~41544310:+
BRCA	cis	rs34779708	0.966	rs4934537	ENSG00000269952.1	RP11-324I22.3	-3.36	0.00082	0.037	-0.14	-0.1	Inflammatory bowel disease;Crohn's disease;	chr10:35152584	chr10:35210416~35210750:+
BRCA	cis	rs34779708	0.966	rs12784482	ENSG00000269952.1	RP11-324I22.3	-3.36	0.00082	0.037	-0.14	-0.1	Inflammatory bowel disease;Crohn's disease;	chr10:35157937	chr10:35210416~35210750:+
BRCA	cis	rs7267979	1	rs2424704	ENSG00000204556.4	CTD-2514C3.1	-3.36	0.00082	0.037	-0.14	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25293293	chr20:26018832~26020684:+
BRCA	cis	rs6019512	0.625	rs6066908	ENSG00000227431.4	CSE1L-AS1	-3.36	0.00082	0.037	-0.12	-0.1	Intelligence (multi-trait analysis);	chr20:48912414	chr20:49040463~49046044:-
BRCA	cis	rs11892454	0.565	rs34946160	ENSG00000217643.1	PTGES3P2	-3.36	0.00082	0.037	-0.11	-0.1	Heschl's gyrus morphology;	chr2:25799885	chr2:25822469~25822950:+
BRCA	cis	rs10760158	0.865	rs4836843	ENSG00000235865.2	GSN-AS1	3.36	0.00082	0.037	0.09	0.1	Pulse pressure;	chr9:121279393	chr9:121280768~121285530:-
BRCA	cis	rs944990	0.793	rs10761235	ENSG00000227603.1	RP11-165J3.6	3.36	0.00082	0.037	0.12	0.1	Body mass index;	chr9:93546384	chr9:93435332~93437121:-
BRCA	cis	rs7037266	0.889	rs2185463	ENSG00000178654.11	PPIAP33	3.36	0.00082	0.037	0.12	0.1	Menarche (age at onset);	chr9:6924416	chr9:7597823~7598377:+
BRCA	cis	rs2281603	0.951	rs12589947	ENSG00000259116.1	RP11-973N13.4	-3.36	0.00082	0.037	-0.1	-0.1	Lymphocyte counts;	chr14:64515453	chr14:64514154~64540368:-
BRCA	cis	rs2281603	0.951	rs10142835	ENSG00000259116.1	RP11-973N13.4	-3.36	0.00082	0.037	-0.1	-0.1	Lymphocyte counts;	chr14:64526733	chr14:64514154~64540368:-
BRCA	cis	rs561341	1	rs72823785	ENSG00000277511.1	CTD-2095E4.5	3.36	0.00082	0.037	0.16	0.1	Hip circumference adjusted for BMI;	chr17:31946765	chr17:32127595~32128454:+
BRCA	cis	rs6429082	0.905	rs12405889	ENSG00000230026.2	RP11-382D8.5	3.36	0.00082	0.037	0.11	0.1	Adiposity;	chr1:235433937	chr1:235361153~235362540:+
BRCA	cis	rs7267979	0.745	rs6132845	ENSG00000204556.4	CTD-2514C3.1	-3.36	0.00082	0.037	-0.14	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25567131	chr20:26018832~26020684:+
BRCA	cis	rs4415084	0.804	rs7705343	ENSG00000272335.1	RP11-53O19.3	3.36	0.000821	0.037	0.09	0.1	Breast cancer;	chr5:44879475	chr5:44826076~44828592:+
BRCA	cis	rs9733	0.744	rs3754211	ENSG00000231073.1	RP11-316M1.3	3.36	0.000821	0.037	0.11	0.1	Tonsillectomy;	chr1:150979381	chr1:150973123~150975534:+
BRCA	cis	rs6088580	0.505	rs6058106	ENSG00000279253.1	RP4-614O4.13	3.36	0.000821	0.037	0.12	0.1	Glomerular filtration rate (creatinine);	chr20:34690451	chr20:35262727~35264187:-
BRCA	cis	rs17597773	0.674	rs1494371	ENSG00000257551.1	HLX-AS1	-3.36	0.000821	0.037	-0.12	-0.1	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220841256	chr1:220832763~220880140:-
BRCA	cis	rs7267979	0.586	rs11087505	ENSG00000276952.1	RP5-965G21.6	3.36	0.000821	0.037	0.13	0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25215884	chr20:25284915~25285588:-
BRCA	cis	rs2337406	1	rs4774172	ENSG00000211970.3	IGHV4-61	3.36	0.000821	0.037	0.09	0.1	Alzheimer's disease (late onset);	chr14:106681320	chr14:106639119~106639657:-
BRCA	cis	rs7188697	0.809	rs4784956	ENSG00000276259.1	RP11-481J2.4	3.36	0.000821	0.037	0.12	0.1	QT interval;	chr16:58562387	chr16:58522970~58523842:+
BRCA	cis	rs8058578	0.943	rs35629860	ENSG00000260082.1	RP11-2C24.5	3.36	0.000821	0.037	0.13	0.1	Multiple myeloma;	chr16:30660211	chr16:30821068~30822110:-
BRCA	cis	rs7647973	1	rs974495	ENSG00000225399.4	RP11-3B7.1	3.36	0.000821	0.037	0.11	0.1	Menarche (age at onset);	chr3:49363049	chr3:49260085~49261316:+
BRCA	cis	rs7647973	1	rs11719762	ENSG00000225399.4	RP11-3B7.1	3.36	0.000821	0.037	0.11	0.1	Menarche (age at onset);	chr3:49371569	chr3:49260085~49261316:+
BRCA	cis	rs801193	0.569	rs3846973	ENSG00000271064.1	RP11-792A8.3	3.36	0.000821	0.037	0.12	0.1	Aortic root size;	chr7:66655048	chr7:66748838~66749077:-
BRCA	cis	rs2274273	1	rs57970196	ENSG00000233924.1	AL160471.6	-3.36	0.000821	0.037	-0.12	-0.1	Protein biomarker;	chr14:55133687	chr14:55004813~55005687:-
BRCA	cis	rs2307449	0.929	rs16942918	ENSG00000260123.1	RP11-326A19.4	3.36	0.000821	0.037	0.12	0.1	Menopause (age at onset);	chr15:89260880	chr15:89041223~89082819:+
BRCA	cis	rs2333021	0.833	rs10141389	ENSG00000258408.1	NT5CP2	3.36	0.000821	0.037	0.11	0.1	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:73000413	chr14:73539221~73539781:-
BRCA	cis	rs7656342	0.686	rs6822889	ENSG00000250342.1	SNRPCP16	-3.36	0.000821	0.037	-0.11	-0.1	Gut microbiota (bacterial taxa);	chr4:9825133	chr4:9051842~9052051:-
BRCA	cis	rs7260598	0.636	rs62114769	ENSG00000268442.1	CTD-2027I19.2	3.36	0.000821	0.037	0.16	0.1	Response to taxane treatment (placlitaxel);	chr19:24052658	chr19:24162370~24163425:-
BRCA	cis	rs7954584	0.567	rs1720033	ENSG00000272849.1	RP11-347I19.8	3.36	0.000821	0.037	0.08	0.1	Mean corpuscular volume;	chr12:121946438	chr12:121797511~121801972:+
BRCA	cis	rs9494145	0.68	rs9376092	ENSG00000236703.1	MYB-AS1	3.36	0.000821	0.037	0.1	0.1	Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count;	chr6:135106006	chr6:135195083~135195995:-
BRCA	cis	rs74233809	1	rs17115213	ENSG00000236937.2	PTGES3P4	3.36	0.000821	0.037	0.23	0.1	Birth weight;	chr10:102921386	chr10:102845595~102845950:+
BRCA	cis	rs7953704	0.967	rs28530689	ENSG00000212694.7	LINC01089	3.36	0.000821	0.037	0.08	0.1	Urate levels;	chr12:122062842	chr12:121795267~121803906:-
BRCA	cis	rs12303914	0.762	rs11611333	ENSG00000256682.2	TAS2R12	3.36	0.000821	0.037	0.12	0.1	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr12:10314468	chr12:10894943~10896952:-
BRCA	cis	rs4848143	0.64	rs4848679	ENSG00000236859.5	NIFK-AS1	-3.36	0.000821	0.037	-0.12	-0.1	Capecitabine sensitivity;	chr2:121046354	chr2:121649650~121728208:+
BRCA	cis	rs2118674	1	rs2118674	ENSG00000128692.8	EIF2S2P4	-3.36	0.000821	0.037	-0.21	-0.1	Palmitoleic acid (16:1n-7) levels;	chr2:170462384	chr2:170751805~170752788:+
BRCA	cis	rs4356203	0.87	rs10766381	ENSG00000184669.7	OR7E14P	-3.36	0.000822	0.037	-0.13	-0.1	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17235498	chr11:17013998~17053024:+
BRCA	cis	rs3114020	0.746	rs2622621	ENSG00000249001.4	RP11-742B18.1	-3.36	0.000822	0.037	-0.12	-0.1	Gout;	chr4:88109768	chr4:87568035~87733956:-
BRCA	cis	rs7781557	1	rs17474893	ENSG00000239969.4	RP11-163E9.2	-3.36	0.000822	0.037	-0.17	-0.1	Colorectal adenoma (advanced);	chr7:102840310	chr7:102364162~102380633:+
BRCA	cis	rs2836974	0.602	rs2836987	ENSG00000238141.2	BRWD1-AS1	-3.36	0.000822	0.037	-0.12	-0.1	Cognitive function;	chr21:39334668	chr21:39315707~39323218:+
BRCA	cis	rs8180040	0.647	rs57756484	ENSG00000280667.1	Y_RNA	-3.36	0.000822	0.037	-0.12	-0.1	Colorectal cancer;	chr3:47197843	chr3:47501083~47501182:+
BRCA	cis	rs7308116	1	rs7303317	ENSG00000274395.1	RP11-554D14.8	-3.36	0.000822	0.037	-0.11	-0.1	Pelvic organ prolapse (moderate/severe);	chr12:107805621	chr12:107835541~107836555:-
BRCA	cis	rs6517329	0.6	rs2835279	ENSG00000231106.2	LINC01436	3.36	0.000822	0.037	0.12	0.1	Schizophrenia;	chr21:36112905	chr21:36005338~36007838:+
BRCA	cis	rs7246657	0.508	rs10419845	ENSG00000180458.2	CTD-3064H18.4	3.36	0.000822	0.037	0.18	0.1	Coronary artery calcification;	chr19:37000290	chr19:37545470~37549171:-
BRCA	cis	rs7429990	0.965	rs6791834	ENSG00000199476.1	Y_RNA	3.36	0.000822	0.037	0.13	0.1	Educational attainment (years of education);	chr3:48073598	chr3:48288587~48288694:+
BRCA	cis	rs4243971	0.516	rs4911231	ENSG00000275576.1	RP5-836N17.4	-3.36	0.000822	0.037	-0.12	-0.1	Inflammatory bowel disease;Crohn's disease;	chr20:32436471	chr20:32116171~32116629:+
BRCA	cis	rs9860340	0.656	rs67189590	ENSG00000239572.1	RP11-451B8.1	-3.36	0.000822	0.037	-0.15	-0.1	Electroencephalographic traits in alcoholism;	chr3:87655137	chr3:87731402~87793629:-
BRCA	cis	rs2562456	0.793	rs627522	ENSG00000268555.1	RP11-678G14.3	3.36	0.000822	0.037	0.13	0.1	Pain;	chr19:21313002	chr19:21570822~21587322:-
BRCA	cis	rs7914558	1	rs7899084	ENSG00000213277.3	MARCKSL1P1	3.36	0.000822	0.037	0.12	0.1	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103112790	chr10:103175554~103176094:+
BRCA	cis	rs10198628	1	rs10186351	ENSG00000264370.1	MIR3125	3.36	0.000822	0.037	0.12	0.1	Pericardial fat;Pericardial adipose tissue adjusted for height and weight;	chr2:12824302	chr2:12737367~12737444:+
BRCA	cis	rs2070488	0.861	rs2067082	ENSG00000232439.1	RPL18AP7	3.36	0.000822	0.037	0.12	0.1	Electrocardiographic conduction measures;	chr3:38396691	chr3:38526802~38527325:-
BRCA	cis	rs2638953	0.924	rs11049608	ENSG00000273989.1	RP11-425D17.2	-3.36	0.000822	0.037	-0.16	-0.1	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28445528	chr12:28236227~28236828:+
BRCA	cis	rs2638953	0.924	rs11049609	ENSG00000273989.1	RP11-425D17.2	-3.36	0.000822	0.037	-0.16	-0.1	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28445732	chr12:28236227~28236828:+
BRCA	cis	rs2638953	0.924	rs11049612	ENSG00000273989.1	RP11-425D17.2	-3.36	0.000822	0.037	-0.16	-0.1	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28449160	chr12:28236227~28236828:+
BRCA	cis	rs294588	0.586	rs991508	ENSG00000250061.4	RP11-541P9.3	3.35	0.000822	0.037	0.13	0.1	Aging;	chr5:163569850	chr5:163012265~163437326:-
BRCA	cis	rs1056107	0.737	rs7041381	ENSG00000266315.1	MIR4668	3.35	0.000822	0.037	0.11	0.1	Colorectal cancer;	chr9:112309799	chr9:111932100~111932169:+
BRCA	cis	rs863345	0.564	rs11265014	ENSG00000176320.2	RP11-404O13.5	-3.35	0.000822	0.037	-0.11	-0.1	Pneumococcal bacteremia;	chr1:158533431	chr1:158197922~158203877:-
BRCA	cis	rs863345	0.604	rs11265015	ENSG00000176320.2	RP11-404O13.5	-3.35	0.000822	0.037	-0.11	-0.1	Pneumococcal bacteremia;	chr1:158533462	chr1:158197922~158203877:-
BRCA	cis	rs17228212	1	rs17227883	ENSG00000270964.1	RP11-502I4.3	-3.35	0.000823	0.0371	-0.14	-0.1	Coronary heart disease;	chr15:67150740	chr15:67541072~67542604:-
BRCA	cis	rs9311676	0.632	rs6785572	ENSG00000244161.1	FLNB-AS1	3.35	0.000823	0.0371	0.09	0.1	Systemic lupus erythematosus;	chr3:58375790	chr3:58162547~58170636:-
BRCA	cis	rs7989332	1	rs7320606	ENSG00000180172.6	RPS12P23	-3.35	0.000823	0.0371	-0.12	-0.1	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);	chr13:20478382	chr13:21094318~21094714:-
BRCA	cis	rs10043228	1	rs79889615	ENSG00000271918.1	CTD-2287O16.5	-3.35	0.000823	0.0371	-0.15	-0.1	Asthma or chronic obstructive pulmonary disease;	chr5:116255595	chr5:116083807~116085416:-
BRCA	cis	rs2018683	0.707	rs917219	ENSG00000233517.1	AC005162.5	-3.35	0.000823	0.0371	-0.13	-0.1	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28935726	chr7:28987028~28988899:+
BRCA	cis	rs9863	0.931	rs11831913	ENSG00000270028.1	RP11-380L11.4	3.35	0.000823	0.0371	0.13	0.1	White blood cell count;	chr12:123962351	chr12:123925461~123926083:-
BRCA	cis	rs2762353	0.505	rs2096386	ENSG00000272462.2	U91328.19	3.35	0.000823	0.0371	0.12	0.1	Blood metabolite levels;	chr6:25787589	chr6:25992662~26001775:+
BRCA	cis	rs687432	0.885	rs1113334	ENSG00000213592.4	AP000662.9	-3.35	0.000823	0.0371	-0.15	-0.1	Parkinson's disease;	chr11:57975861	chr11:57718044~57718530:-
BRCA	cis	rs687432	0.924	rs1113335	ENSG00000213592.4	AP000662.9	-3.35	0.000823	0.0371	-0.15	-0.1	Parkinson's disease;	chr11:57975977	chr11:57718044~57718530:-
BRCA	cis	rs7914558	1	rs7077291	ENSG00000213277.3	MARCKSL1P1	3.35	0.000823	0.0371	0.12	0.1	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103185994	chr10:103175554~103176094:+
BRCA	cis	rs2274273	1	rs67098772	ENSG00000233924.1	AL160471.6	-3.35	0.000823	0.0371	-0.12	-0.1	Protein biomarker;	chr14:55128524	chr14:55004813~55005687:-
BRCA	cis	rs2274273	1	rs2147972	ENSG00000233924.1	AL160471.6	-3.35	0.000823	0.0371	-0.12	-0.1	Protein biomarker;	chr14:55131312	chr14:55004813~55005687:-
BRCA	cis	rs7577696	0.962	rs11681731	ENSG00000276334.1	AL133243.1	-3.35	0.000823	0.0371	-0.13	-0.1	Inflammatory biomarkers;	chr2:32120256	chr2:32521927~32523547:+
BRCA	cis	rs6120849	0.754	rs6088678	ENSG00000202150.1	RNU6-407P	-3.35	0.000823	0.0371	-0.15	-0.1	Protein C levels;	chr20:35019748	chr20:35030317~35030420:-
BRCA	cis	rs10851411	0.542	rs10454692	ENSG00000260490.2	RP11-265N6.3	-3.35	0.000823	0.0371	-0.19	-0.1	Glucose homeostasis traits;	chr15:42564857	chr15:42571927~42572433:+
BRCA	cis	rs4921164	1	rs34440003	ENSG00000245812.2	RP11-175K6.1	-3.35	0.000823	0.0371	-0.13	-0.1	Gut microbiome composition (winter);	chr5:159117788	chr5:159100483~159117478:+
BRCA	cis	rs8114671	0.804	rs3803936	ENSG00000261582.1	RP4-614O4.11	3.35	0.000823	0.0371	0.1	0.1	Height;	chr20:35044972	chr20:35267885~35280043:-
BRCA	cis	rs8114671	0.836	rs13042358	ENSG00000261582.1	RP4-614O4.11	3.35	0.000823	0.0371	0.1	0.1	Height;	chr20:35046676	chr20:35267885~35280043:-
BRCA	cis	rs7812879	0.543	rs6993775	ENSG00000255020.1	AF131216.5	-3.35	0.000823	0.0371	-0.14	-0.1	Systemic lupus erythematosus;	chr8:11512480	chr8:11345748~11347502:-
BRCA	cis	rs8040855	0.599	rs1964724	ENSG00000259570.1	RP11-671M22.4	-3.35	0.000823	0.0371	-0.11	-0.1	Bulimia nervosa;	chr15:85183269	chr15:84394512~84395514:+
BRCA	cis	rs7712401	0.755	rs10071705	ENSG00000263432.2	RN7SL689P	3.35	0.000824	0.0371	0.12	0.1	Mean platelet volume;	chr5:122797030	chr5:123022487~123022783:-
BRCA	cis	rs2952768	1	rs2709379	ENSG00000224137.1	AC079767.4	-3.35	0.000824	0.0371	-0.09	-0.1	Opioid sensitivity;	chr2:207631458	chr2:207662375~207667024:+
BRCA	cis	rs9976876	0.9	rs2242924	ENSG00000231106.2	LINC01436	-3.35	0.000824	0.0371	-0.12	-0.1	Total body bone mineral density;	chr21:35572483	chr21:36005338~36007838:+
BRCA	cis	rs8098244	0.628	rs8083184	ENSG00000264745.1	TTC39C-AS1	3.35	0.000824	0.0371	0.12	0.1	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23683708	chr18:23994213~24015339:-
BRCA	cis	rs10501293	0.789	rs4755690	ENSG00000252652.1	Y_RNA	-3.35	0.000824	0.0371	-0.13	-0.1	Cognitive performance;	chr11:43033130	chr11:43331261~43331356:+
BRCA	cis	rs10501293	0.746	rs4755691	ENSG00000252652.1	Y_RNA	-3.35	0.000824	0.0371	-0.13	-0.1	Cognitive performance;	chr11:43033315	chr11:43331261~43331356:+
BRCA	cis	rs12477438	0.52	rs13035311	ENSG00000231822.1	AC019097.7	3.35	0.000824	0.0371	0.11	0.1	Chronic sinus infection;	chr2:99100859	chr2:99102018~99102752:+
BRCA	cis	rs965469	0.895	rs6051840	ENSG00000215063.3	RPL21P2	-3.35	0.000824	0.0371	-0.14	-0.1	IFN-related cytopenia;	chr20:3410836	chr20:4059633~4060113:-
BRCA	cis	rs737008	0.96	rs34764020	ENSG00000262703.1	RP11-485G7.6	-3.35	0.000824	0.0371	-0.11	-0.1	Obesity-related traits;	chr16:11284502	chr16:11348143~11349321:-
BRCA	cis	rs897984	0.542	rs35713203	ENSG00000275263.1	RP11-1072A3.4	-3.35	0.000824	0.0371	-0.12	-0.1	Dementia with Lewy bodies;	chr16:31079086	chr16:30956872~30957199:-
BRCA	cis	rs1056107	0.83	rs10739340	ENSG00000266315.1	MIR4668	3.35	0.000824	0.0371	0.11	0.1	Colorectal cancer;	chr9:112295272	chr9:111932100~111932169:+
BRCA	cis	rs2243480	0.522	rs1638736	ENSG00000222364.1	RNU6-96P	-3.35	0.000824	0.0371	-0.23	-0.1	Diabetic kidney disease;	chr7:66627321	chr7:66395191~66395286:+
BRCA	cis	rs3862030	0.503	rs10786673	ENSG00000213061.2	PFN1P11	-3.35	0.000824	0.0371	-0.14	-0.1	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr10:102520780	chr10:102838011~102845473:-
BRCA	cis	rs10883723	0.81	rs7090276	ENSG00000213061.2	PFN1P11	-3.35	0.000824	0.0371	-0.14	-0.1	Allergic disease (asthma, hay fever or eczema);	chr10:102521482	chr10:102838011~102845473:-
BRCA	cis	rs7917772	0.503	rs1409310	ENSG00000213061.2	PFN1P11	-3.35	0.000824	0.0371	-0.14	-0.1	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;	chr10:102522508	chr10:102838011~102845473:-
BRCA	cis	rs7917772	0.503	rs7087665	ENSG00000213061.2	PFN1P11	-3.35	0.000824	0.0371	-0.14	-0.1	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;	chr10:102522661	chr10:102838011~102845473:-
BRCA	cis	rs10883723	0.81	rs7074343	ENSG00000213061.2	PFN1P11	-3.35	0.000824	0.0371	-0.14	-0.1	Allergic disease (asthma, hay fever or eczema);	chr10:102523408	chr10:102838011~102845473:-
BRCA	cis	rs113835537	0.529	rs7950790	ENSG00000258297.1	RP11-658F2.8	-3.35	0.000824	0.0371	-0.14	-0.1	Airway imaging phenotypes;	chr11:66490582	chr11:66666036~66668374:+
BRCA	cis	rs6964587	1	rs6967256	ENSG00000188693.7	CYP51A1-AS1	-3.35	0.000824	0.0371	-0.11	-0.1	Breast cancer;	chr7:92013905	chr7:92134604~92180725:+
BRCA	cis	rs6964587	0.967	rs28594877	ENSG00000188693.7	CYP51A1-AS1	-3.35	0.000824	0.0371	-0.11	-0.1	Breast cancer;	chr7:92014756	chr7:92134604~92180725:+
BRCA	cis	rs13272568	0.614	rs10095221	ENSG00000254352.1	RP11-578O24.2	-3.35	0.000824	0.0371	-0.13	-0.1	Bone mineral density;	chr8:78134257	chr8:78723796~78724136:-
BRCA	cis	rs4664293	0.51	rs3903306	ENSG00000230783.1	AC009961.2	3.35	0.000824	0.0371	0.13	0.1	Monocyte percentage of white cells;	chr2:159592171	chr2:159689217~159690291:-
BRCA	cis	rs372883	0.624	rs1153286	ENSG00000176054.6	RPL23P2	-3.35	0.000824	0.0371	-0.11	-0.1	Pancreatic cancer;	chr21:29312062	chr21:28997613~28998033:-
BRCA	cis	rs2908197	0.765	rs2098205	ENSG00000205485.12	AC004980.7	3.35	0.000824	0.0371	0.11	0.1	3-hydroxypropylmercapturic acid levels in smokers;	chr7:76309571	chr7:76549360~76627982:+
BRCA	cis	rs1982963	0.95	rs1566132	ENSG00000277050.1	RP11-102G14.1	-3.35	0.000824	0.0371	-0.12	-0.1	Waist-to-hip ratio adjusted for body mass index;	chr14:52045118	chr14:51637348~51637947:-
BRCA	cis	rs10771431	0.597	rs3759275	ENSG00000214776.8	RP11-726G1.1	-3.35	0.000824	0.0371	-0.11	-0.1	Breast size;	chr12:9201232	chr12:9467552~9576275:+
BRCA	cis	rs10771431	0.597	rs3759274	ENSG00000214776.8	RP11-726G1.1	-3.35	0.000824	0.0371	-0.11	-0.1	Breast size;	chr12:9201279	chr12:9467552~9576275:+
BRCA	cis	rs10771431	0.597	rs10771412	ENSG00000214776.8	RP11-726G1.1	-3.35	0.000824	0.0371	-0.11	-0.1	Breast size;	chr12:9201757	chr12:9467552~9576275:+
BRCA	cis	rs10771431	0.597	rs10771413	ENSG00000214776.8	RP11-726G1.1	-3.35	0.000824	0.0371	-0.11	-0.1	Breast size;	chr12:9201817	chr12:9467552~9576275:+
BRCA	cis	rs6496932	0.802	rs12442399	ENSG00000259630.2	CTD-2262B20.1	3.35	0.000824	0.0371	0.13	0.1	Central corneal thickness;Corneal structure;	chr15:85311619	chr15:85415228~85415633:+
BRCA	cis	rs897984	0.52	rs4889534	ENSG00000280211.1	RP11-2C24.3	-3.35	0.000824	0.0371	-0.11	-0.1	Dementia with Lewy bodies;	chr16:30854119	chr16:30773532~30776033:-
BRCA	cis	rs863345	0.565	rs2220633	ENSG00000176320.2	RP11-404O13.5	-3.35	0.000825	0.0371	-0.11	-0.1	Pneumococcal bacteremia;	chr1:158475482	chr1:158197922~158203877:-
BRCA	cis	rs13063635	0.79	rs35951367	ENSG00000223552.1	RP11-24F11.2	-3.35	0.000825	0.0371	-0.15	-0.1	Eosinophil percentage of granulocytes;	chr3:46076947	chr3:46364955~46407059:-
BRCA	cis	rs2235642	0.75	rs2859310	ENSG00000260260.1	SNHG19	3.35	0.000825	0.0371	0.1	0.1	Coronary artery disease;	chr16:1606764	chr16:2154797~2155358:-
BRCA	cis	rs9467773	0.62	rs1027203	ENSG00000224843.5	LINC00240	-3.35	0.000825	0.0371	-0.12	-0.1	Intelligence (multi-trait analysis);	chr6:26639104	chr6:26956992~27023924:+
BRCA	cis	rs9467773	0.595	rs2172007	ENSG00000224843.5	LINC00240	-3.35	0.000825	0.0371	-0.12	-0.1	Intelligence (multi-trait analysis);	chr6:26639549	chr6:26956992~27023924:+
BRCA	cis	rs67478160	0.643	rs2223937	ENSG00000269910.1	RP11-73M18.10	3.35	0.000825	0.0371	0.1	0.1	Schizophrenia;	chr14:103820043	chr14:103694516~103695050:-
BRCA	cis	rs7646881	0.504	rs67305172	ENSG00000271778.1	RP11-379F4.8	-3.35	0.000825	0.0371	-0.14	-0.1	Tetralogy of Fallot;	chr3:158746485	chr3:158782547~158783124:+
BRCA	cis	rs9783347	0.6	rs2403254	ENSG00000256361.1	RP11-613F22.6	3.35	0.000825	0.0371	0.12	0.1	Pancreatic cancer;	chr11:18303599	chr11:18511043~18511475:-
BRCA	cis	rs2692947	0.537	rs11685849	ENSG00000237510.6	AC008268.2	3.35	0.000825	0.0371	0.15	0.1	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95578056	chr2:95789654~95800166:+
BRCA	cis	rs2692947	0.537	rs11688045	ENSG00000237510.6	AC008268.2	3.35	0.000825	0.0371	0.15	0.1	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95578057	chr2:95789654~95800166:+
BRCA	cis	rs316341	0.723	rs316339	ENSG00000266750.1	MIR4645	3.35	0.000825	0.0371	0.13	0.1	Cerebrospinal fluid AB1-42 levels;	chr6:2837812	chr6:2854031~2854107:-
BRCA	cis	rs36051895	0.623	rs17426903	ENSG00000237711.1	RP11-39K24.13	-3.35	0.000825	0.0371	-0.13	-0.1	Pediatric autoimmune diseases;	chr9:5203292	chr9:5100236~5101009:+
BRCA	cis	rs1005277	0.505	rs719569	ENSG00000273019.1	RP11-508N22.13	3.35	0.000825	0.0371	0.12	0.1	Extrinsic epigenetic age acceleration;	chr10:37865487	chr10:38149968~38150293:+
BRCA	cis	rs854765	0.647	rs854790	ENSG00000223979.2	SMCR2	-3.35	0.000825	0.0371	-0.12	-0.1	Total body bone mineral density;	chr17:18125004	chr17:17674026~17677688:-
BRCA	cis	rs1250259	0.955	rs1250247	ENSG00000225166.1	AC012462.2	3.35	0.000825	0.0371	0.15	0.1	Coronary artery disease;Pulse pressure;	chr2:215434906	chr2:215453707~215463871:+
BRCA	cis	rs1730008	0.835	rs698988	ENSG00000279311.1	RP11-170K4.2	-3.35	0.000825	0.0371	-0.11	-0.1	Lobe attachment (rater-scored or self-reported);	chr3:158225071	chr3:158869898~158871821:+
BRCA	cis	rs10129255	1	rs10129319	ENSG00000253763.1	IGHV3-6	3.35	0.000825	0.0371	0.09	0.1	Kawasaki disease;	chr14:106767996	chr14:106055549~106055998:-
BRCA	cis	rs7847231	0.504	rs10120836	ENSG00000234692.1	RP11-445L6.3	3.35	0.000825	0.0372	0.12	0.1	Educational attainment;	chr9:115414293	chr9:115252538~115254251:-
BRCA	cis	rs17597773	0.674	rs2279638	ENSG00000257551.1	HLX-AS1	-3.35	0.000825	0.0372	-0.12	-0.1	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220828445	chr1:220832763~220880140:-
BRCA	cis	rs4713118	0.581	rs200504	ENSG00000216676.2	RP1-15D7.1	-3.35	0.000825	0.0372	-0.14	-0.1	Parkinson's disease;	chr6:27818042	chr6:27652602~27652825:-
BRCA	cis	rs853679	0.517	rs4713146	ENSG00000226314.6	ZNF192P1	-3.35	0.000825	0.0372	-0.16	-0.1	Depression;	chr6:28143758	chr6:28161781~28169594:+
BRCA	cis	rs853679	0.517	rs9393894	ENSG00000226314.6	ZNF192P1	-3.35	0.000825	0.0372	-0.16	-0.1	Depression;	chr6:28144784	chr6:28161781~28169594:+
BRCA	cis	rs10792665	0.844	rs7130899	ENSG00000246067.6	RAB30-AS1	-3.35	0.000825	0.0372	-0.11	-0.1	Obesity-related traits;	chr11:82933862	chr11:83072066~83106719:+
BRCA	cis	rs2274273	0.588	rs17128145	ENSG00000259318.1	RP11-454L9.2	-3.35	0.000825	0.0372	-0.09	-0.1	Protein biomarker;	chr14:55069688	chr14:55394940~55395233:-
BRCA	cis	rs59721556	0.918	rs17752262	ENSG00000240233.3	RN7SL587P	-3.35	0.000826	0.0372	-0.15	-0.1	Response to paliperidone in schizophrenia (Multivariate);Response to paliperidone in schizophrenia (CGI-S score);Response to paliperidone in schizophrenia (PANSS score);Red cell distribution width;Response to paliperidone in schizophrenia (positive Marder score);	chr14:77653026	chr14:77547566~77547846:-
BRCA	cis	rs875971	1	rs3735148	ENSG00000273448.1	RP11-166O4.6	3.35	0.000826	0.0372	0.09	0.1	Aortic root size;	chr7:66506022	chr7:67333047~67334383:+
BRCA	cis	rs6088590	0.735	rs6088618	ENSG00000276073.1	RP5-1125A11.7	-3.35	0.000826	0.0372	-0.11	-0.1	Coronary artery disease;	chr20:34821547	chr20:33985617~33988989:-
BRCA	cis	rs2333021	0.801	rs4903086	ENSG00000258408.1	NT5CP2	3.35	0.000826	0.0372	0.11	0.1	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:72995605	chr14:73539221~73539781:-
BRCA	cis	rs7487075	0.578	rs4072304	ENSG00000257261.4	RP11-96H19.1	3.35	0.000826	0.0372	0.12	0.1	Itch intensity from mosquito bite;	chr12:46432404	chr12:46383679~46876159:+
BRCA	cis	rs6593122	1	rs6960827	ENSG00000235454.1	HAUS6P3	-3.35	0.000826	0.0372	-0.16	-0.1	Vaccine-related adverse events;	chr7:54134612	chr7:53862233~53863339:+
BRCA	cis	rs6593122	0.583	rs2140612	ENSG00000235454.1	HAUS6P3	-3.35	0.000826	0.0372	-0.14	-0.1	Vaccine-related adverse events;	chr7:54116143	chr7:53862233~53863339:+
BRCA	cis	rs6593122	0.583	rs28544390	ENSG00000235454.1	HAUS6P3	-3.35	0.000826	0.0372	-0.14	-0.1	Vaccine-related adverse events;	chr7:54116662	chr7:53862233~53863339:+
BRCA	cis	rs7020830	0.898	rs7846747	ENSG00000230188.1	RP11-405L18.4	-3.35	0.000826	0.0372	-0.13	-0.1	Schizophrenia;	chr9:37167542	chr9:37490421~37490893:-
BRCA	cis	rs934734	0.736	rs1396210	ENSG00000204929.10	AC074391.1	3.35	0.000826	0.0372	0.13	0.1	Rheumatoid arthritis;	chr2:65357140	chr2:65436711~66084639:+
BRCA	cis	rs10129255	0.957	rs8009948	ENSG00000232216.1	IGHV3-43	3.35	0.000826	0.0372	0.09	0.1	Kawasaki disease;	chr14:106805607	chr14:106470264~106470800:-
BRCA	cis	rs8113308	0.752	rs113374423	ENSG00000269235.1	ZNF350-AS1	3.35	0.000826	0.0372	0.2	0.1	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51987699	chr19:51949134~51981367:+
BRCA	cis	rs17209837	0.915	rs12672720	ENSG00000224046.1	AC005076.5	3.35	0.000826	0.0372	0.16	0.1	Gallbladder cancer;	chr7:87497122	chr7:87151423~87152420:-
BRCA	cis	rs10129255	0.957	rs6576233	ENSG00000253763.1	IGHV3-6	3.35	0.000826	0.0372	0.09	0.1	Kawasaki disease;	chr14:106787239	chr14:106055549~106055998:-
BRCA	cis	rs60871478	0.541	rs56964970	ENSG00000237181.1	AC147651.4	3.35	0.000826	0.0372	0.12	0.1	Cerebrospinal P-tau181p levels;	chr7:871154	chr7:603185~608482:+
BRCA	cis	rs11239930	0.538	rs719969	ENSG00000227242.3	NBPF13P	-3.35	0.000826	0.0372	-0.13	-0.1	AIDS progression;	chr1:147084111	chr1:147021320~147124525:-
BRCA	cis	rs10954779	0.524	rs7016874	ENSG00000253961.1	RP11-363L24.3	-3.35	0.000826	0.0372	-0.12	-0.1	Intelligence (multi-trait analysis);	chr8:31058111	chr8:31167078~31177167:-
BRCA	cis	rs2205299	0.516	rs2824059	ENSG00000215386.9	MIR99AHG	3.35	0.000826	0.0372	0.1	0.1	Schizophrenia;	chr21:16805852	chr21:16070522~16627397:+
BRCA	cis	rs1376877	0.934	rs62183910	ENSG00000273456.1	RP11-686O6.2	3.35	0.000826	0.0372	0.1	0.1	Subclinical atherosclerosis traits (other);	chr2:203287412	chr2:202374932~202375604:-
BRCA	cis	rs1436904	0.9	rs1154205	ENSG00000260372.5	AQP4-AS1	-3.35	0.000826	0.0372	-0.12	-0.1	Breast cancer;	chr18:27006988	chr18:26655742~27190698:+
BRCA	cis	rs17092148	1	rs7265992	ENSG00000206582.1	Y_RNA	3.35	0.000826	0.0372	0.15	0.1	Neuroticism;	chr20:34937604	chr20:34526510~34526606:-
BRCA	cis	rs7871395	1	rs7871395	ENSG00000225460.1	RP13-93L13.1	3.35	0.000826	0.0372	0.11	0.1	Nonsyndromic cleft lip with cleft palate;	chr9:89594672	chr9:89472237~89472692:+
BRCA	cis	rs4478858	0.602	rs6425723	ENSG00000229447.2	RP11-490K7.4	-3.35	0.000826	0.0372	-0.1	-0.1	Alcohol dependence;	chr1:31242357	chr1:31263245~31263681:-
BRCA	cis	rs295490	0.748	rs78490940	ENSG00000178631.7	ACTG1P1	-3.35	0.000826	0.0372	-0.21	-0.1	PR interval in Tripanosoma cruzi seropositivity;	chr3:139370333	chr3:139493809~139494937:+
BRCA	cis	rs2235649	0.561	rs12599786	ENSG00000279520.1	RP11-20I23.2	-3.35	0.000826	0.0372	-0.11	-0.1	Blood metabolite levels;	chr16:1915256	chr16:2516658~2517999:+
BRCA	cis	rs7071275	0.891	rs725982	ENSG00000276742.1	RP11-500G22.4	-3.35	0.000826	0.0372	-0.16	-0.1	Dupuytren's disease;	chr10:121674435	chr10:121956782~121957098:+
BRCA	cis	rs372883	0.935	rs1153294	ENSG00000176054.6	RPL23P2	-3.35	0.000826	0.0372	-0.11	-0.1	Pancreatic cancer;	chr21:29328775	chr21:28997613~28998033:-
BRCA	cis	rs301801	0.513	rs2708629	ENSG00000238290.1	RP11-431K24.1	-3.35	0.000826	0.0372	-0.12	-0.1	Optic cup area;Vertical cup-disc ratio;	chr1:8394732	chr1:8026738~8122702:+
BRCA	cis	rs2337406	1	rs17113276	ENSG00000211970.3	IGHV4-61	-3.35	0.000827	0.0372	-0.09	-0.1	Alzheimer's disease (late onset);	chr14:106683485	chr14:106639119~106639657:-
BRCA	cis	rs1333657	0.966	rs9356749	ENSG00000216368.2	RP3-486D24.1	-3.35	0.000827	0.0372	-0.12	-0.1	Orofacial clefts;	chr6:10301172	chr6:10118452~10119253:+
BRCA	cis	rs7267979	1	rs6083862	ENSG00000276952.1	RP5-965G21.6	-3.35	0.000827	0.0372	-0.12	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25430450	chr20:25284915~25285588:-
BRCA	cis	rs157554	0.596	rs425101	ENSG00000249149.2	RP11-79P5.3	3.35	0.000827	0.0372	0.14	0.1	Breast cancer;	chr5:73978535	chr5:73382384~73410509:+
BRCA	cis	rs8058578	1	rs67128646	ENSG00000280211.1	RP11-2C24.3	3.35	0.000827	0.0372	0.11	0.1	Multiple myeloma;	chr16:30660776	chr16:30773532~30776033:-
BRCA	cis	rs354225	0.539	rs6740110	ENSG00000235937.1	AC008280.1	3.35	0.000827	0.0372	0.14	0.1	Schizophrenia;	chr2:54731955	chr2:54029552~54030682:-
BRCA	cis	rs950776	0.72	rs11633223	ENSG00000279373.1	RP11-650L12.4	3.35	0.000827	0.0372	0.13	0.1	Sudden cardiac arrest;	chr15:78643134	chr15:78537681~78538946:+
BRCA	cis	rs6600671	1	rs10794671	ENSG00000223345.3	HIST2H2BA	3.35	0.000827	0.0372	0.12	0.1	Hip geometry;	chr1:121426382	chr1:121108210~121117257:-
BRCA	cis	rs28573326	0.692	rs4481204	ENSG00000248771.4	LINC01207	-3.35	0.000827	0.0372	-0.12	-0.1	Pelvic organ prolapse (moderate/severe);	chr4:165438269	chr4:164754064~164803795:+
BRCA	cis	rs8058578	0.832	rs35969813	ENSG00000280211.1	RP11-2C24.3	3.35	0.000827	0.0372	0.11	0.1	Multiple myeloma;	chr16:30703096	chr16:30773532~30776033:-
BRCA	cis	rs7520050	0.831	rs61783170	ENSG00000281133.1	AL355480.3	3.35	0.000827	0.0372	0.12	0.1	Reticulocyte count;Red blood cell count;	chr1:45790657	chr1:45580892~45580996:-
BRCA	cis	rs6840360	0.593	rs6857073	ENSG00000270265.1	RP11-731D1.4	3.35	0.000827	0.0372	0.12	0.1	Intelligence (multi-trait analysis);	chr4:151768122	chr4:151333775~151353224:-
BRCA	cis	rs875971	0.516	rs6945322	ENSG00000229180.5	GS1-124K5.11	3.35	0.000827	0.0372	0.09	0.1	Aortic root size;	chr7:65871069	chr7:66526088~66542624:-
BRCA	cis	rs11088226	0.75	rs2833885	ENSG00000186842.4	LINC00846	-3.35	0.000827	0.0372	-0.16	-0.1	Gastritis;	chr21:32550851	chr21:32572238~32575881:-
BRCA	cis	rs11955398	0.502	rs295573	ENSG00000272308.1	RP11-231G3.1	-3.35	0.000827	0.0372	-0.12	-0.1	Intelligence (multi-trait analysis);	chr5:61130433	chr5:60866457~60866935:-
BRCA	cis	rs8101881	0.965	rs7252778	ENSG00000267567.1	CTD-2538C1.3	3.35	0.000827	0.0372	0.13	0.1	Blood metabolite levels;Urinary metabolites (H-NMR features);Urinary metabolites;	chr19:32869463	chr19:32718298~32719595:-
BRCA	cis	rs4835473	0.838	rs4271960	ENSG00000246448.2	RP13-578N3.3	-3.35	0.000827	0.0372	-0.12	-0.1	Immature fraction of reticulocytes;	chr4:143763591	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.808	rs2323198	ENSG00000246448.2	RP13-578N3.3	-3.35	0.000827	0.0372	-0.12	-0.1	Immature fraction of reticulocytes;	chr4:143763595	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.9	rs2323199	ENSG00000246448.2	RP13-578N3.3	-3.35	0.000827	0.0372	-0.12	-0.1	Immature fraction of reticulocytes;	chr4:143763606	chr4:143700257~143865072:+
BRCA	cis	rs6012564	0.893	rs6012579	ENSG00000230758.1	SNAP23P	-3.35	0.000828	0.0372	-0.12	-0.1	Anger;	chr20:49006883	chr20:49038357~49038602:-
BRCA	cis	rs4908768	0.657	rs3938719	ENSG00000270282.1	RP5-1115A15.2	-3.35	0.000828	0.0372	-0.13	-0.1	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8744938	chr1:8512653~8513021:+
BRCA	cis	rs7943953	0.865	rs11229958	ENSG00000254717.2	GLYATL1P2	-3.35	0.000828	0.0372	-0.14	-0.1	Odorant perception (&beta-ionone);	chr11:59453511	chr11:58878302~58893460:+
BRCA	cis	rs7267979	0.932	rs2260997	ENSG00000231081.1	RP4-760C5.3	3.35	0.000828	0.0372	0.13	0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25275630	chr20:26008791~26010531:-
BRCA	cis	rs67311347	0.544	rs2123998	ENSG00000199906.1	RNU5B-2P	3.35	0.000828	0.0372	0.1	0.1	Renal cell carcinoma;	chr3:40317514	chr3:40498891~40499003:-
BRCA	cis	rs2191566	0.576	rs448692	ENSG00000266921.1	RP11-15A1.7	-3.35	0.000828	0.0372	-0.13	-0.1	Acute lymphoblastic leukemia (childhood);	chr19:43990578	chr19:43996896~44002836:-
BRCA	cis	rs938554	0.571	rs12509955	ENSG00000250413.1	RP11-448G15.1	3.35	0.000828	0.0372	0.15	0.1	Blood metabolite levels;	chr4:10022679	chr4:10006482~10009725:+
BRCA	cis	rs2281603	0.951	rs12586212	ENSG00000259116.1	RP11-973N13.4	-3.35	0.000828	0.0373	-0.1	-0.1	Lymphocyte counts;	chr14:64513329	chr14:64514154~64540368:-
BRCA	cis	rs2281603	0.951	rs61615397	ENSG00000259116.1	RP11-973N13.4	-3.35	0.000828	0.0373	-0.1	-0.1	Lymphocyte counts;	chr14:64514346	chr14:64514154~64540368:-
BRCA	cis	rs2281603	0.951	rs10133243	ENSG00000259116.1	RP11-973N13.4	-3.35	0.000828	0.0373	-0.1	-0.1	Lymphocyte counts;	chr14:64514807	chr14:64514154~64540368:-
BRCA	cis	rs2281603	0.951	rs3783724	ENSG00000259116.1	RP11-973N13.4	-3.35	0.000828	0.0373	-0.1	-0.1	Lymphocyte counts;	chr14:64516759	chr14:64514154~64540368:-
BRCA	cis	rs2281603	0.951	rs3783723	ENSG00000259116.1	RP11-973N13.4	-3.35	0.000828	0.0373	-0.1	-0.1	Lymphocyte counts;	chr14:64516821	chr14:64514154~64540368:-
BRCA	cis	rs2281603	0.951	rs12587136	ENSG00000259116.1	RP11-973N13.4	-3.35	0.000828	0.0373	-0.1	-0.1	Lymphocyte counts;	chr14:64518570	chr14:64514154~64540368:-
BRCA	cis	rs2281603	0.951	rs58893738	ENSG00000259116.1	RP11-973N13.4	-3.35	0.000828	0.0373	-0.1	-0.1	Lymphocyte counts;	chr14:64519093	chr14:64514154~64540368:-
BRCA	cis	rs2281603	0.951	rs28626711	ENSG00000259116.1	RP11-973N13.4	-3.35	0.000828	0.0373	-0.1	-0.1	Lymphocyte counts;	chr14:64521561	chr14:64514154~64540368:-
BRCA	cis	rs2281603	0.951	rs10133411	ENSG00000259116.1	RP11-973N13.4	-3.35	0.000828	0.0373	-0.1	-0.1	Lymphocyte counts;	chr14:64522206	chr14:64514154~64540368:-
BRCA	cis	rs2281603	0.951	rs17101896	ENSG00000259116.1	RP11-973N13.4	-3.35	0.000828	0.0373	-0.1	-0.1	Lymphocyte counts;	chr14:64526205	chr14:64514154~64540368:-
BRCA	cis	rs2281603	0.951	rs59512674	ENSG00000259116.1	RP11-973N13.4	-3.35	0.000828	0.0373	-0.1	-0.1	Lymphocyte counts;	chr14:64526295	chr14:64514154~64540368:-
BRCA	cis	rs2281603	0.951	rs61985711	ENSG00000259116.1	RP11-973N13.4	-3.35	0.000828	0.0373	-0.1	-0.1	Lymphocyte counts;	chr14:64526540	chr14:64514154~64540368:-
BRCA	cis	rs2281603	0.951	rs10143170	ENSG00000259116.1	RP11-973N13.4	-3.35	0.000828	0.0373	-0.1	-0.1	Lymphocyte counts;	chr14:64527045	chr14:64514154~64540368:-
BRCA	cis	rs7474896	0.515	rs2505233	ENSG00000226086.5	EIF3LP3	-3.35	0.000828	0.0373	-0.15	-0.1	Obesity (extreme);	chr10:38051337	chr10:38080056~38080877:-
BRCA	cis	rs74233809	1	rs12412038	ENSG00000213061.2	PFN1P11	3.35	0.000828	0.0373	0.23	0.1	Birth weight;	chr10:103096405	chr10:102838011~102845473:-
BRCA	cis	rs3796352	0.527	rs11716506	ENSG00000243224.1	RP5-1157M23.2	-3.35	0.000828	0.0373	-0.17	-0.1	Immune reponse to smallpox (secreted IL-2);	chr3:52910312	chr3:52239258~52241097:+
BRCA	cis	rs6088580	0.634	rs6059866	ENSG00000269202.1	RP4-614O4.12	-3.35	0.000828	0.0373	-0.1	-0.1	Glomerular filtration rate (creatinine);	chr20:34488005	chr20:35201747~35203288:-
BRCA	cis	rs4443100	0.77	rs876101	ENSG00000230701.2	FBXW4P1	3.35	0.000828	0.0373	0.13	0.1	Serum parathyroid hormone levels;	chr22:23022202	chr22:23262767~23265005:+
BRCA	cis	rs3781913	0.874	rs12363065	ENSG00000255843.1	AP000593.7	3.35	0.000828	0.0373	0.13	0.1	Rheumatoid arthritis;	chr11:72659855	chr11:72302139~72302965:+
BRCA	cis	rs13098911	0.54	rs34381952	ENSG00000223552.1	RP11-24F11.2	-3.35	0.000828	0.0373	-0.17	-0.1	Celiac disease;	chr3:45954256	chr3:46364955~46407059:-
BRCA	cis	rs4415084	0.716	rs6868232	ENSG00000248779.1	RP11-53O19.2	3.35	0.000828	0.0373	0.1	0.1	Breast cancer;	chr5:44827578	chr5:44752949~44765744:+
BRCA	cis	rs7246760	0.867	rs55846005	ENSG00000267106.4	ZNF561-AS1	3.35	0.000828	0.0373	0.2	0.1	Pursuit maintenance gain;	chr19:9686033	chr19:9621291~9645896:+
BRCA	cis	rs2216824	1	rs17010429	ENSG00000278908.1	RP11-523J2.1	3.35	0.000828	0.0373	0.17	0.1	Oropharynx cancer;	chr2:30883108	chr2:30677762~30679895:+
BRCA	cis	rs11098499	0.71	rs6851130	ENSG00000260091.1	RP11-33B1.4	3.35	0.000828	0.0373	0.09	0.1	Corneal astigmatism;	chr4:119212557	chr4:119409333~119410233:+
BRCA	cis	rs11098403	0.753	rs28767227	ENSG00000225892.3	RP11-384K6.2	3.35	0.000829	0.0373	0.1	0.1	Schizophrenia;	chr4:117858309	chr4:118632274~118634759:+
BRCA	cis	rs875971	0.964	rs12668936	ENSG00000273448.1	RP11-166O4.6	3.35	0.000829	0.0373	0.09	0.1	Aortic root size;	chr7:66449417	chr7:67333047~67334383:+
BRCA	cis	rs11227306	0.902	rs625652	ENSG00000254510.1	RP11-867G23.10	-3.35	0.000829	0.0373	-0.11	-0.1	DNA methylation (variation);	chr11:65874460	chr11:66409158~66417137:+
BRCA	cis	rs74233809	1	rs11191607	ENSG00000213061.2	PFN1P11	3.35	0.000829	0.0373	0.23	0.1	Birth weight;	chr10:103199431	chr10:102838011~102845473:-
BRCA	cis	rs10782582	0.593	rs6675212	ENSG00000181227.3	RP4-682C21.2	3.35	0.000829	0.0373	0.11	0.1	Daytime sleep phenotypes;	chr1:75765144	chr1:75743423~75744776:-
BRCA	cis	rs801193	0.636	rs2659895	ENSG00000229886.1	RP5-1132H15.3	3.35	0.000829	0.0373	0.12	0.1	Aortic root size;	chr7:66731484	chr7:66025126~66031544:-
BRCA	cis	rs3936840	0.548	rs1190545	ENSG00000258512.1	LINC00239	3.35	0.000829	0.0373	0.12	0.1	Plateletcrit;	chr14:102437842	chr14:101730437~101732522:+
BRCA	cis	rs897984	0.568	rs4889653	ENSG00000280211.1	RP11-2C24.3	-3.35	0.000829	0.0373	-0.11	-0.1	Dementia with Lewy bodies;	chr16:30884392	chr16:30773532~30776033:-
BRCA	cis	rs1510510	0.69	rs4663934	ENSG00000229915.1	AC016999.2	3.35	0.000829	0.0373	0.17	0.1	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr2:238622165	chr2:238427077~238427729:-
BRCA	cis	rs17270561	0.609	rs4712963	ENSG00000272462.2	U91328.19	-3.35	0.000829	0.0373	-0.13	-0.1	Iron status biomarkers;	chr6:25740274	chr6:25992662~26001775:+
BRCA	cis	rs72775230	0.733	rs17389770	ENSG00000233990.1	RP11-401E9.3	-3.35	0.000829	0.0373	-0.18	-0.1	Conotruncal heart defects (inherited effects);	chr10:8523747	chr10:7833618~7833957:-
BRCA	cis	rs11098499	0.722	rs17595727	ENSG00000225892.3	RP11-384K6.2	-3.35	0.000829	0.0373	-0.1	-0.1	Corneal astigmatism;	chr4:119340919	chr4:118632274~118634759:+
BRCA	cis	rs10504130	0.569	rs34073804	ENSG00000272076.1	RP11-11C20.3	3.35	0.000829	0.0373	0.15	0.1	Venous thromboembolism (SNP x SNP interaction);	chr8:51776808	chr8:51810110~51810681:-
BRCA	cis	rs55675132	0.548	rs12126634	ENSG00000226167.1	AP4B1-AS1	3.35	0.000829	0.0373	0.1	0.1	Schizophrenia;	chr1:114801264	chr1:113856635~113901237:+
BRCA	cis	rs3924048	0.559	rs4075304	ENSG00000221340.1	RNU6ATAC18P	3.35	0.000829	0.0373	0.13	0.1	Optic cup area;	chr1:12566774	chr1:12569972~12570072:-
BRCA	cis	rs7239883	0.5	rs442250	ENSG00000267652.1	RP11-188I24.1	-3.35	0.000829	0.0373	-0.15	-0.1	Waist circumference;Body mass index;	chr18:42490280	chr18:41789162~41789395:-
BRCA	cis	rs931127	0.719	rs2170082	ENSG00000255557.1	RP11-770G2.2	3.35	0.000829	0.0373	0.12	0.1	Systemic lupus erythematosus;	chr11:65687324	chr11:65745729~65771585:+
BRCA	cis	rs9341808	0.527	rs7453746	ENSG00000279022.1	RP11-250B2.4	3.35	0.000829	0.0373	0.12	0.1	Sitting height ratio;	chr6:80100296	chr6:80440730~80441172:+
BRCA	cis	rs4835473	0.932	rs17018500	ENSG00000249741.2	RP11-673E1.3	3.35	0.000829	0.0373	0.11	0.1	Immature fraction of reticulocytes;	chr4:143824849	chr4:143911514~143912053:-
BRCA	cis	rs2243480	1	rs1723269	ENSG00000226767.1	RP11-328P23.3	-3.35	0.000829	0.0373	-0.18	-0.1	Diabetic kidney disease;	chr7:66007799	chr7:65508773~65508944:-
BRCA	cis	rs4927850	1	rs7625570	ENSG00000185485.13	SDHAP1	3.35	0.000829	0.0373	0.11	0.1	Pancreatic cancer;	chr3:196020527	chr3:195959748~195990318:-
BRCA	cis	rs6540556	0.723	rs6679099	ENSG00000236136.1	ADORA2BP1	-3.35	0.00083	0.0373	-0.13	-0.1	Red blood cell count;	chr1:209722507	chr1:209744373~209745214:+
BRCA	cis	rs321358	0.731	rs536679	ENSG00000271390.1	RP11-89C3.3	3.35	0.00083	0.0373	0.16	0.1	Body mass index;	chr11:111142497	chr11:111089870~111090368:-
BRCA	cis	rs321358	0.731	rs502584	ENSG00000271390.1	RP11-89C3.3	3.35	0.00083	0.0373	0.16	0.1	Body mass index;	chr11:111142620	chr11:111089870~111090368:-
BRCA	cis	rs13434995	0.513	rs62303681	ENSG00000239040.1	Y_RNA	3.35	0.00083	0.0373	0.13	0.1	Adiponectin levels;	chr4:55403812	chr4:55412636~55412738:+
BRCA	cis	rs4578769	0.918	rs6507457	ENSG00000265939.1	UBE2CP2	-3.35	0.00083	0.0373	-0.13	-0.1	Eosinophil percentage of white cells;	chr18:23046473	chr18:22900486~22900995:-
BRCA	cis	rs925946	0.518	rs12577586	ENSG00000245573.6	BDNF-AS	-3.35	0.00083	0.0373	-0.12	-0.1	Weight;Body mass index;	chr11:27578888	chr11:27506838~27698174:+
BRCA	cis	rs2486012	1	rs2231283	ENSG00000237950.1	RP11-7O11.3	-3.35	0.00083	0.0373	-0.2	-0.1	Intelligence (multi-trait analysis);	chr1:43985065	chr1:43944370~43946551:-
BRCA	cis	rs7474896	1	rs12763409	ENSG00000120555.12	SEPT7P9	3.35	0.00083	0.0373	0.19	0.1	Obesity (extreme);	chr10:37803762	chr10:38383069~38402916:-
BRCA	cis	rs736408	0.812	rs2270197	ENSG00000243224.1	RP5-1157M23.2	-3.35	0.00083	0.0373	-0.12	-0.1	Bipolar disorder;	chr3:52790079	chr3:52239258~52241097:+
BRCA	cis	rs9341808	0.618	rs6916507	ENSG00000279022.1	RP11-250B2.4	3.35	0.00083	0.0373	0.12	0.1	Sitting height ratio;	chr6:80152548	chr6:80440730~80441172:+
BRCA	cis	rs8054556	0.633	rs12928610	ENSG00000214725.6	CDIPT-AS1	-3.35	0.00083	0.0373	-0.12	-0.1	Autism spectrum disorder or schizophrenia;	chr16:30004701	chr16:29863593~29868053:+
BRCA	cis	rs189798	0.592	rs10111263	ENSG00000254153.1	CTA-398F10.2	-3.35	0.00083	0.0373	-0.13	-0.1	Myopia (pathological);	chr8:9111923	chr8:8456909~8461337:-
BRCA	cis	rs7208859	0.673	rs73263776	ENSG00000264538.5	SUZ12P1	-3.35	0.00083	0.0373	-0.16	-0.1	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30884313	chr17:30709299~30790908:+
BRCA	cis	rs7208859	0.623	rs11650271	ENSG00000264538.5	SUZ12P1	-3.35	0.00083	0.0373	-0.16	-0.1	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30886925	chr17:30709299~30790908:+
BRCA	cis	rs9392556	0.829	rs584585	ENSG00000272248.1	RP3-406P24.4	3.35	0.00083	0.0373	0.13	0.1	Blood metabolite levels;	chr6:4118555	chr6:4018713~4019202:+
BRCA	cis	rs7429990	1	rs1665982	ENSG00000228638.1	FCF1P2	3.35	0.00083	0.0373	0.12	0.1	Educational attainment (years of education);	chr3:47863589	chr3:48290793~48291375:-
BRCA	cis	rs1510510	0.69	rs4663934	ENSG00000186235.9	AC016757.3	-3.35	0.00083	0.0373	-0.17	-0.1	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr2:238622165	chr2:238224552~238231677:-
BRCA	cis	rs962856	0.592	rs6546296	ENSG00000236605.1	AC023115.4	3.35	0.00083	0.0373	0.14	0.1	Pancreatic cancer;	chr2:67351290	chr2:67324627~67325304:+
BRCA	cis	rs11671005	0.735	rs34873624	ENSG00000265272.2	RN7SL693P	3.35	0.00083	0.0373	0.15	0.1	Mean platelet volume;	chr19:58432035	chr19:58490797~58491075:+
BRCA	cis	rs11671005	0.735	rs3764529	ENSG00000265272.2	RN7SL693P	3.35	0.00083	0.0373	0.15	0.1	Mean platelet volume;	chr19:58433722	chr19:58490797~58491075:+
BRCA	cis	rs7893279	0.543	rs7093454	ENSG00000240291.1	RP11-499P20.2	-3.35	0.00083	0.0373	-0.12	-0.1	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr10:18597751	chr10:18513115~18545651:-
BRCA	cis	rs801193	0.569	rs6978178	ENSG00000223473.2	GS1-124K5.3	-3.35	0.00083	0.0373	-0.08	-0.1	Aortic root size;	chr7:66658097	chr7:66491049~66493566:-
BRCA	cis	rs12068986	1	rs12068986	ENSG00000236257.1	EI24P2	-3.35	0.00083	0.0373	-0.15	-0.1	Electroencephalogram traits;	chr1:158121627	chr1:158454198~158455273:+
BRCA	cis	rs9866825	0.967	rs9846352	ENSG00000227110.5	LMCD1-AS1	3.35	0.00083	0.0373	0.12	0.1	QT interval;	chr3:8208328	chr3:7952805~8611924:-
BRCA	cis	rs9866825	0.934	rs9846387	ENSG00000227110.5	LMCD1-AS1	3.35	0.00083	0.0373	0.12	0.1	QT interval;	chr3:8208396	chr3:7952805~8611924:-
BRCA	cis	rs9866825	0.967	rs9883008	ENSG00000227110.5	LMCD1-AS1	3.35	0.00083	0.0373	0.12	0.1	QT interval;	chr3:8208499	chr3:7952805~8611924:-
BRCA	cis	rs875971	0.964	rs60193905	ENSG00000229886.1	RP5-1132H15.3	3.35	0.00083	0.0373	0.11	0.1	Aortic root size;	chr7:66506273	chr7:66025126~66031544:-
BRCA	cis	rs2976388	0.609	rs2717605	ENSG00000253196.1	RP11-706C16.7	3.35	0.00083	0.0373	0.1	0.1	Urinary tract infection frequency;	chr8:142719597	chr8:142763116~142766427:+
BRCA	cis	rs2032366	1	rs1840047	ENSG00000267279.1	RP11-879F14.2	-3.35	0.00083	0.0373	-0.13	-0.1	Obesity-related traits;	chr18:61591312	chr18:61585746~61606916:-
BRCA	cis	rs4713118	0.868	rs742047	ENSG00000280107.1	AL022393.9	-3.35	0.00083	0.0373	-0.15	-0.1	Parkinson's disease;	chr6:27771601	chr6:28170845~28172521:+
BRCA	cis	rs2562456	0.837	rs62110205	ENSG00000268555.1	RP11-678G14.3	3.35	0.00083	0.0373	0.14	0.1	Pain;	chr19:21577269	chr19:21570822~21587322:-
BRCA	cis	rs4374383	0.631	rs1516640	ENSG00000243389.1	AC012442.5	3.35	0.00083	0.0373	0.13	0.1	Hepatitis C induced liver fibrosis;	chr2:111917281	chr2:112589040~112614431:+
BRCA	cis	rs875971	0.789	rs7808013	ENSG00000265600.1	AC006480.1	3.35	0.000831	0.0373	0.13	0.1	Aortic root size;	chr7:66606209	chr7:67356680~67356779:+
BRCA	cis	rs9868809	0.881	rs2286652	ENSG00000225399.4	RP11-3B7.1	-3.35	0.000831	0.0373	-0.16	-0.1	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr3:48651759	chr3:49260085~49261316:+
BRCA	cis	rs77633900	0.772	rs284904	ENSG00000196274.5	Metazoa_SRP	-3.35	0.000831	0.0373	-0.19	-0.1	Glioma;Non-glioblastoma glioma;	chr15:76451961	chr15:76230048~76230390:-
BRCA	cis	rs11098403	0.753	rs28881193	ENSG00000225892.3	RP11-384K6.2	3.35	0.000831	0.0373	0.1	0.1	Schizophrenia;	chr4:117853839	chr4:118632274~118634759:+
BRCA	cis	rs72928364	0.86	rs13085636	ENSG00000244119.1	PDCL3P4	3.35	0.000831	0.0373	0.13	0.1	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:101078260	chr3:101712472~101713191:+
BRCA	cis	rs8006682	0.827	rs12435141	ENSG00000259165.1	DDX18P1	3.35	0.000831	0.0373	0.12	0.1	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr14:68642664	chr14:69083398~69085389:+
BRCA	cis	rs6012953	0.934	rs2904269	ENSG00000231715.1	COX6CP2	3.35	0.000831	0.0373	0.11	0.1	Vitiligo;	chr20:50539794	chr20:50479767~50479991:+
BRCA	cis	rs4819052	0.851	rs2838829	ENSG00000223768.1	LINC00205	-3.35	0.000831	0.0373	-0.14	-0.1	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244125	chr21:45293285~45297354:+
BRCA	cis	rs4499344	0.696	rs10402929	ENSG00000201388.1	SNORA68	3.35	0.000831	0.0373	0.12	0.1	Mean platelet volume;	chr19:32609339	chr19:32608337~32608469:-
BRCA	cis	rs4499344	0.73	rs7250272	ENSG00000201388.1	SNORA68	3.35	0.000831	0.0373	0.12	0.1	Mean platelet volume;	chr19:32609432	chr19:32608337~32608469:-
BRCA	cis	rs4499344	0.664	rs4286210	ENSG00000201388.1	SNORA68	3.35	0.000831	0.0373	0.12	0.1	Mean platelet volume;	chr19:32610315	chr19:32608337~32608469:-
BRCA	cis	rs4713118	0.662	rs175954	ENSG00000226314.6	ZNF192P1	-3.35	0.000831	0.0374	-0.16	-0.1	Parkinson's disease;	chr6:28043807	chr6:28161781~28169594:+
BRCA	cis	rs10992471	0.526	rs10992518	ENSG00000187984.11	ANKRD19P	-3.35	0.000831	0.0374	-0.1	-0.1	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr9:92900079	chr9:92809388~92888693:+
BRCA	cis	rs9863	0.896	rs76283024	ENSG00000269938.1	RP11-214K3.20	-3.35	0.000831	0.0374	-0.11	-0.1	White blood cell count;	chr12:123982232	chr12:123968023~123968579:-
BRCA	cis	rs2243480	1	rs781157	ENSG00000226767.1	RP11-328P23.3	-3.35	0.000831	0.0374	-0.18	-0.1	Diabetic kidney disease;	chr7:66013324	chr7:65508773~65508944:-
BRCA	cis	rs17556665	0.808	rs7131289	ENSG00000254418.1	RP11-21L19.1	3.35	0.000831	0.0374	0.19	0.1	Inflammatory biomarkers;	chr11:14056324	chr11:14262846~14273691:-
BRCA	cis	rs957448	1	rs56716157	ENSG00000254315.1	RP11-267M23.3	3.35	0.000831	0.0374	0.15	0.1	Nonsyndromic cleft lip with cleft palate;	chr8:94530644	chr8:94533628~94534391:+
BRCA	cis	rs801193	0.66	rs2659914	ENSG00000229886.1	RP5-1132H15.3	3.35	0.000831	0.0374	0.11	0.1	Aortic root size;	chr7:66691927	chr7:66025126~66031544:-
BRCA	cis	rs801193	0.591	rs2707839	ENSG00000229886.1	RP5-1132H15.3	3.35	0.000831	0.0374	0.11	0.1	Aortic root size;	chr7:66728097	chr7:66025126~66031544:-
BRCA	cis	rs2243480	0.706	rs34466769	ENSG00000223473.2	GS1-124K5.3	3.35	0.000831	0.0374	0.11	0.1	Diabetic kidney disease;	chr7:65988305	chr7:66491049~66493566:-
BRCA	cis	rs10958369	0.613	rs1477957	ENSG00000274295.1	RP11-1081M5.3	3.35	0.000831	0.0374	0.13	0.1	Response to antineoplastic agents;	chr8:53522873	chr8:53394215~53394795:+
BRCA	cis	rs17228212	1	rs35738694	ENSG00000270964.1	RP11-502I4.3	-3.35	0.000831	0.0374	-0.14	-0.1	Coronary heart disease;	chr15:67161897	chr15:67541072~67542604:-
BRCA	cis	rs2199351	0.687	rs60004394	ENSG00000250129.4	RP11-265F19.1	-3.35	0.000832	0.0374	-0.18	-0.1	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr3:131897375	chr3:131053317~131072339:-
BRCA	cis	rs12986413	0.651	rs2238612	ENSG00000248015.5	AC005329.7	3.35	0.000832	0.0374	0.12	0.1	Height;	chr19:2149695	chr19:1392170~1396467:-
BRCA	cis	rs2055729	0.528	rs11987861	ENSG00000233609.3	RP11-62H7.2	-3.35	0.000832	0.0374	-0.11	-0.1	Multiple myeloma (hyperdiploidy);	chr8:9884696	chr8:8961200~8979025:+
BRCA	cis	rs12413361	0.967	rs1538951	ENSG00000272914.1	RP11-330O11.3	-3.35	0.000832	0.0374	-0.13	-0.1	Height;	chr10:30840556	chr10:30831828~30833387:-
BRCA	cis	rs8180040	1	rs7613282	ENSG00000280667.1	Y_RNA	-3.35	0.000832	0.0374	-0.12	-0.1	Colorectal cancer;	chr3:47347919	chr3:47501083~47501182:+
BRCA	cis	rs11098499	0.863	rs10004484	ENSG00000260404.2	RP11-384K6.6	3.35	0.000832	0.0374	0.1	0.1	Corneal astigmatism;	chr4:119521273	chr4:118591773~118633729:+
BRCA	cis	rs9311474	0.629	rs7636227	ENSG00000222345.1	SNORD19	3.35	0.000832	0.0374	0.1	0.1	Electroencephalogram traits;	chr3:52532666	chr3:52691378~52691453:+
BRCA	cis	rs613391	0.702	rs584680	ENSG00000279670.1	RP11-70L8.5	-3.35	0.000832	0.0374	-0.13	-0.1	Quantitative traits;	chr9:22706598	chr9:21892188~21893857:+
BRCA	cis	rs467650	0.509	rs2545678	ENSG00000246763.5	RGMB-AS1	-3.35	0.000832	0.0374	-0.11	-0.1	Venous thromboembolism (SNP x SNP interaction);	chr5:98664664	chr5:98769618~98773469:-
BRCA	cis	rs6582630	0.5	rs35251810	ENSG00000257718.1	RP11-396F22.1	-3.35	0.000832	0.0374	-0.11	-0.1	Drug-induced liver injury (flucloxacillin);	chr12:38183864	chr12:38906451~38909592:+
BRCA	cis	rs11098499	0.863	rs10030660	ENSG00000225892.3	RP11-384K6.2	3.35	0.000832	0.0374	0.11	0.1	Corneal astigmatism;	chr4:119515549	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.863	rs13149407	ENSG00000225892.3	RP11-384K6.2	3.35	0.000832	0.0374	0.11	0.1	Corneal astigmatism;	chr4:119516670	chr4:118632274~118634759:+
BRCA	cis	rs17407555	0.909	rs9999470	ENSG00000251087.3	ALG1L3P	-3.35	0.000832	0.0374	-0.14	-0.1	Schizophrenia (age at onset);	chr4:10315399	chr4:9703754~9710812:-
BRCA	cis	rs2041840	0.961	rs2372888	ENSG00000272054.1	RP11-423P10.2	3.35	0.000832	0.0374	0.09	0.1	Chronic lymphocytic leukemia;	chr2:37233091	chr2:37208875~37212677:+
BRCA	cis	rs9400467	0.506	rs12203741	ENSG00000231889.6	TRAF3IP2-AS1	-3.35	0.000832	0.0374	-0.16	-0.1	Amino acid levels;Blood metabolite levels;	chr6:111356341	chr6:111483511~111598302:+
BRCA	cis	rs80226907	1	rs117109421	ENSG00000258413.1	RP11-665C16.6	-3.35	0.000832	0.0374	-0.26	-0.1	Mean platelet volume;	chr14:55290915	chr14:55262767~55272075:-
BRCA	cis	rs7943953	0.865	rs1901856	ENSG00000254717.2	GLYATL1P2	-3.35	0.000832	0.0374	-0.14	-0.1	Odorant perception (&beta-ionone);	chr11:59452220	chr11:58878302~58893460:+
BRCA	cis	rs7577696	0.924	rs7601267	ENSG00000276334.1	AL133243.1	-3.35	0.000832	0.0374	-0.13	-0.1	Inflammatory biomarkers;	chr2:32047330	chr2:32521927~32523547:+
BRCA	cis	rs860295	0.702	rs5005770	ENSG00000203761.5	MSTO2P	3.35	0.000833	0.0374	0.09	0.1	Body mass index;	chr1:155375252	chr1:155745829~155750137:+
BRCA	cis	rs10139154	0.889	rs229243	ENSG00000258640.3	RPL21P5	3.35	0.000833	0.0374	0.12	0.1	Amyotrophic lateral sclerosis;	chr14:30614542	chr14:31111569~31112239:-
BRCA	cis	rs6545883	0.718	rs2694624	ENSG00000237522.1	NONOP2	-3.35	0.000833	0.0374	-0.1	-0.1	Tuberculosis;	chr2:61445178	chr2:60936819~60938049:-
BRCA	cis	rs301901	0.664	rs4504403	ENSG00000272103.1	CTD-2653M23.3	-3.35	0.000833	0.0374	-0.13	-0.1	Height;	chr5:37481330	chr5:36861736~36862217:-
BRCA	cis	rs7487075	0.82	rs12310125	ENSG00000257261.4	RP11-96H19.1	3.35	0.000833	0.0374	0.11	0.1	Itch intensity from mosquito bite;	chr12:46299371	chr12:46383679~46876159:+
BRCA	cis	rs6929812	0.639	rs726830	ENSG00000220721.1	OR1F12	-3.35	0.000833	0.0374	-0.12	-0.1	Neuroticism (multi-trait analysis);	chr6:27455411	chr6:28073316~28074233:+
BRCA	cis	rs10876993	0.89	rs7963927	ENSG00000270039.1	RP11-571M6.17	3.35	0.000833	0.0374	0.14	0.1	Celiac disease or Rheumatoid arthritis;	chr12:57652489	chr12:57803838~57804415:+
BRCA	cis	rs2243480	1	rs316332	ENSG00000229180.5	GS1-124K5.11	3.35	0.000833	0.0374	0.14	0.1	Diabetic kidney disease;	chr7:66139312	chr7:66526088~66542624:-
BRCA	cis	rs526231	0.819	rs26233	ENSG00000175749.11	EIF3KP1	3.35	0.000833	0.0374	0.15	0.1	Primary biliary cholangitis;	chr5:103261115	chr5:103032376~103033031:+
BRCA	cis	rs17301013	0.932	rs4233195	ENSG00000234741.6	GAS5	-3.35	0.000833	0.0374	-0.1	-0.1	Systemic lupus erythematosus;	chr1:174806736	chr1:173863900~173868882:-
BRCA	cis	rs11992162	0.636	rs11250182	ENSG00000250794.2	ALG1L12P	3.35	0.000833	0.0374	0.12	0.1	Monocyte count;	chr8:11950067	chr8:12421032~12425000:+
BRCA	cis	rs7487075	0.619	rs11183478	ENSG00000257261.4	RP11-96H19.1	3.35	0.000833	0.0374	0.12	0.1	Itch intensity from mosquito bite;	chr12:46430283	chr12:46383679~46876159:+
BRCA	cis	rs16858210	0.52	rs34190894	ENSG00000233885.6	YEATS2-AS1	-3.35	0.000833	0.0374	-0.14	-0.1	Menopause (age at onset);	chr3:183832624	chr3:183806457~183810783:-
BRCA	cis	rs9393777	0.778	rs13219354	ENSG00000216901.1	AL022393.7	3.35	0.000833	0.0374	0.21	0.1	Intelligence (multi-trait analysis);	chr6:27217885	chr6:28176188~28176674:+
BRCA	cis	rs4869313	0.668	rs2042385	ENSG00000248734.2	CTD-2260A17.1	-3.35	0.000833	0.0374	-0.1	-0.1	Pediatric autoimmune diseases;	chr5:96912289	chr5:96784777~96785999:+
BRCA	cis	rs4374383	0.884	rs908518	ENSG00000236307.2	EEF1E1P1	3.35	0.000833	0.0374	0.12	0.1	Hepatitis C induced liver fibrosis;	chr2:111920049	chr2:111887914~111888741:+
BRCA	cis	rs67478160	0.643	rs2887282	ENSG00000269958.1	RP11-73M18.8	3.35	0.000833	0.0375	0.11	0.1	Schizophrenia;	chr14:103814397	chr14:103696353~103697163:+
BRCA	cis	rs875971	0.862	rs7809814	ENSG00000229886.1	RP5-1132H15.3	-3.35	0.000833	0.0375	-0.12	-0.1	Aortic root size;	chr7:66150410	chr7:66025126~66031544:-
BRCA	cis	rs863345	0.625	rs11265006	ENSG00000176320.2	RP11-404O13.5	-3.35	0.000833	0.0375	-0.11	-0.1	Pneumococcal bacteremia;	chr1:158528695	chr1:158197922~158203877:-
BRCA	cis	rs757081	0.648	rs10832750	ENSG00000272034.1	SNORD14A	3.35	0.000833	0.0375	0.11	0.1	Systolic blood pressure;	chr11:17239371	chr11:17074654~17074744:-
BRCA	cis	rs6943931	1	rs10950901	ENSG00000230658.1	KLHL7-AS1	-3.35	0.000833	0.0375	-0.14	-0.1	Diabetic kidney disease;	chr7:22380490	chr7:23101228~23105703:-
BRCA	cis	rs55780018	0.645	rs7595131	ENSG00000224137.1	AC079767.4	3.35	0.000833	0.0375	0.08	0.1	Systolic blood pressure;	chr2:207641672	chr2:207662375~207667024:+
BRCA	cis	rs6095357	1	rs6095357	ENSG00000230758.1	SNAP23P	-3.35	0.000833	0.0375	-0.13	-0.1	Schizophrenia;	chr20:48907328	chr20:49038357~49038602:-
BRCA	cis	rs6012564	0.859	rs1997851	ENSG00000230758.1	SNAP23P	-3.35	0.000833	0.0375	-0.13	-0.1	Anger;	chr20:48909956	chr20:49038357~49038602:-
BRCA	cis	rs72775230	0.733	rs72775252	ENSG00000233990.1	RP11-401E9.3	-3.35	0.000833	0.0375	-0.18	-0.1	Conotruncal heart defects (inherited effects);	chr10:8521933	chr10:7833618~7833957:-
BRCA	cis	rs6456156	0.774	rs6908364	ENSG00000272549.1	RP11-351J23.2	3.35	0.000834	0.0375	0.1	0.1	Primary biliary cholangitis;	chr6:167113808	chr6:167666840~167679270:-
BRCA	cis	rs4561483	0.815	rs7198817	ENSG00000261216.1	RP11-166B2.5	3.35	0.000834	0.0375	0.12	0.1	Testicular germ cell tumor;	chr16:11851921	chr16:11908208~11908916:+
BRCA	cis	rs2811415	0.597	rs9820563	ENSG00000242551.2	POU5F1P6	3.35	0.000834	0.0375	0.14	0.1	Lung function (FEV1/FVC);	chr3:128062028	chr3:128674735~128677005:-
BRCA	cis	rs2274273	0.967	rs11622740	ENSG00000233924.1	AL160471.6	-3.35	0.000834	0.0375	-0.12	-0.1	Protein biomarker;	chr14:55151126	chr14:55004813~55005687:-
BRCA	cis	rs9818758	0.607	rs5030795	ENSG00000225399.4	RP11-3B7.1	-3.35	0.000834	0.0375	-0.17	-0.1	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;	chr3:49103683	chr3:49260085~49261316:+
BRCA	cis	rs910316	1	rs175426	ENSG00000259138.1	RP11-950C14.7	-3.35	0.000834	0.0375	-0.11	-0.1	Height;	chr14:75157431	chr14:75127153~75136930:+
BRCA	cis	rs4869313	0.642	rs2549796	ENSG00000248734.2	CTD-2260A17.1	-3.35	0.000834	0.0375	-0.1	-0.1	Pediatric autoimmune diseases;	chr5:96909639	chr5:96784777~96785999:+
BRCA	cis	rs11039100	0.85	rs12363853	ENSG00000224295.2	AC087380.14	3.35	0.000834	0.0375	0.2	0.1	Peripheral arterial disease (traffic-related air pollution interaction);	chr11:5808933	chr11:5518441~5524955:-
BRCA	cis	rs11039100	0.85	rs12363855	ENSG00000224295.2	AC087380.14	3.35	0.000834	0.0375	0.2	0.1	Peripheral arterial disease (traffic-related air pollution interaction);	chr11:5808956	chr11:5518441~5524955:-
BRCA	cis	rs11673344	0.583	rs10421436	ENSG00000233527.7	ZNF529-AS1	-3.35	0.000834	0.0375	-0.11	-0.1	Obesity-related traits;	chr19:37394601	chr19:36573070~36594708:+
BRCA	cis	rs8114671	0.562	rs6087644	ENSG00000279253.1	RP4-614O4.13	-3.35	0.000834	0.0375	-0.12	-0.1	Height;	chr20:34893114	chr20:35262727~35264187:-
BRCA	cis	rs11874712	1	rs2298787	ENSG00000251939.1	RNU6-1278P	-3.35	0.000834	0.0375	-0.11	-0.1	Migraine - clinic-based;	chr18:46090014	chr18:46121615~46121721:-
BRCA	cis	rs11874712	1	rs1800637	ENSG00000251939.1	RNU6-1278P	-3.35	0.000834	0.0375	-0.11	-0.1	Migraine - clinic-based;	chr18:46090224	chr18:46121615~46121721:-
BRCA	cis	rs11874712	1	rs1800636	ENSG00000251939.1	RNU6-1278P	-3.35	0.000834	0.0375	-0.11	-0.1	Migraine - clinic-based;	chr18:46090454	chr18:46121615~46121721:-
BRCA	cis	rs11874712	1	rs13381709	ENSG00000251939.1	RNU6-1278P	-3.35	0.000834	0.0375	-0.11	-0.1	Migraine - clinic-based;	chr18:46091022	chr18:46121615~46121721:-
BRCA	cis	rs2991971	0.729	rs10890328	ENSG00000281133.1	AL355480.3	-3.35	0.000834	0.0375	-0.12	-0.1	High light scatter reticulocyte count;	chr1:45439711	chr1:45580892~45580996:-
BRCA	cis	rs360932	0.674	rs360953	ENSG00000270265.1	RP11-731D1.4	3.35	0.000834	0.0375	0.12	0.1	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr4:151960534	chr4:151333775~151353224:-
BRCA	cis	rs6545883	0.895	rs796597	ENSG00000237522.1	NONOP2	-3.35	0.000834	0.0375	-0.1	-0.1	Tuberculosis;	chr2:61453925	chr2:60936819~60938049:-
BRCA	cis	rs7429990	0.901	rs7431567	ENSG00000199476.1	Y_RNA	3.35	0.000834	0.0375	0.14	0.1	Educational attainment (years of education);	chr3:47986342	chr3:48288587~48288694:+
BRCA	cis	rs4927850	1	rs10881564	ENSG00000273009.1	RP11-352G9.1	-3.35	0.000834	0.0375	-0.12	-0.1	Pancreatic cancer;	chr3:196023455	chr3:195913078~195913683:-
BRCA	cis	rs4374383	0.631	rs1516639	ENSG00000243389.1	AC012442.5	3.35	0.000834	0.0375	0.13	0.1	Hepatitis C induced liver fibrosis;	chr2:111917508	chr2:112589040~112614431:+
BRCA	cis	rs68170813	0.652	rs7807154	ENSG00000241764.3	AC002467.7	3.35	0.000834	0.0375	0.18	0.1	Coronary artery disease;	chr7:107520946	chr7:107742817~107744581:-
BRCA	cis	rs61008539	0.815	rs6960062	ENSG00000273151.1	RP11-449P15.2	-3.35	0.000834	0.0375	-0.09	-0.1	Perceived unattractiveness to mosquitoes;	chr7:845028	chr7:879790~886547:-
BRCA	cis	rs911555	0.755	rs7147664	ENSG00000269940.1	RP11-73M18.7	3.35	0.000834	0.0375	0.11	0.1	Intelligence (multi-trait analysis);	chr14:103497083	chr14:103694560~103695170:+
BRCA	cis	rs897984	0.609	rs4889609	ENSG00000260267.1	RP11-452L6.5	3.35	0.000834	0.0375	0.1	0.1	Dementia with Lewy bodies;	chr16:31015106	chr16:31456711~31459736:-
BRCA	cis	rs561341	1	rs510264	ENSG00000277511.1	CTD-2095E4.5	3.35	0.000834	0.0375	0.16	0.1	Hip circumference adjusted for BMI;	chr17:31996395	chr17:32127595~32128454:+
BRCA	cis	rs7267979	0.966	rs4815425	ENSG00000231081.1	RP4-760C5.3	3.35	0.000835	0.0375	0.13	0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25418240	chr20:26008791~26010531:-
BRCA	cis	rs6840360	0.593	rs11723227	ENSG00000270265.1	RP11-731D1.4	-3.35	0.000835	0.0375	-0.12	-0.1	Intelligence (multi-trait analysis);	chr4:151768565	chr4:151333775~151353224:-
BRCA	cis	rs4907240	0.77	rs4907236	ENSG00000230606.9	AC159540.1	3.35	0.000835	0.0375	0.12	0.1	Event-related brain oscillations;	chr2:96521868	chr2:97416165~97433527:-
BRCA	cis	rs8031584	0.723	rs11632229	ENSG00000260128.5	ULK4P2	3.35	0.000835	0.0375	0.13	0.1	Huntington's disease progression;	chr15:30887331	chr15:30572738~30600647:+
BRCA	cis	rs10005067	0.967	rs12511124	ENSG00000249001.4	RP11-742B18.1	-3.35	0.000835	0.0375	-0.12	-0.1	Total body bone mineral density (age 30-45);	chr4:87898416	chr4:87568035~87733956:-
BRCA	cis	rs1555322	0.872	rs2425033	ENSG00000261582.1	RP4-614O4.11	-3.35	0.000835	0.0375	-0.13	-0.1	Attention deficit hyperactivity disorder;	chr20:35267823	chr20:35267885~35280043:-
BRCA	cis	rs1437396	0.609	rs2920971	ENSG00000203327.2	AC012358.7	-3.35	0.000835	0.0375	-0.11	-0.1	Alcohol dependence;	chr2:55357024	chr2:55214387~55216126:-
BRCA	cis	rs7267979	0.932	rs6115200	ENSG00000274973.1	RP13-401N8.7	-3.35	0.000835	0.0375	-0.12	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25506741	chr20:25845497~25845862:+
BRCA	cis	rs4414128	0.832	rs2386649	ENSG00000231483.1	RP11-336A10.5	3.35	0.000835	0.0375	0.16	0.1	Breast cancer;	chr10:5638879	chr10:5608475~5610793:-
BRCA	cis	rs7781557	1	rs727175	ENSG00000170409.7	CTA-313A17.2	3.35	0.000835	0.0375	0.18	0.1	Colorectal adenoma (advanced);	chr7:102831333	chr7:102327256~102329530:-
BRCA	cis	rs36051895	0.589	rs2224571	ENSG00000237711.1	RP11-39K24.13	-3.35	0.000835	0.0375	-0.12	-0.1	Pediatric autoimmune diseases;	chr9:5196253	chr9:5100236~5101009:+
BRCA	cis	rs12505749	0.542	rs56099714	ENSG00000270147.1	RP11-646I6.6	-3.35	0.000835	0.0375	-0.12	-0.1	Airflow obstruction;	chr4:56496995	chr4:56396312~56396871:+
BRCA	cis	rs2312236	0.714	rs704838	ENSG00000225171.2	DUTP6	3.35	0.000835	0.0375	0.15	0.1	Post-traumatic stress disorder;	chr1:166768977	chr1:166868748~166869209:+
BRCA	cis	rs2638953	0.815	rs11049709	ENSG00000273989.1	RP11-425D17.2	-3.35	0.000835	0.0375	-0.15	-0.1	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28545099	chr12:28236227~28236828:+
BRCA	cis	rs2638953	0.782	rs11049710	ENSG00000273989.1	RP11-425D17.2	-3.35	0.000835	0.0375	-0.15	-0.1	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28546231	chr12:28236227~28236828:+
BRCA	cis	rs36051895	0.603	rs10974972	ENSG00000236254.1	MTND4P14	-3.35	0.000835	0.0375	-0.12	-0.1	Pediatric autoimmune diseases;	chr9:5130146	chr9:5107937~5109290:+
BRCA	cis	rs9341808	0.754	rs9361591	ENSG00000279022.1	RP11-250B2.4	3.35	0.000835	0.0375	0.12	0.1	Sitting height ratio;	chr6:80243538	chr6:80440730~80441172:+
BRCA	cis	rs9321659	0.614	rs11155028	ENSG00000219755.1	RP1-199J3.5	-3.35	0.000835	0.0375	-0.21	-0.1	Menarche (age at onset);	chr6:99733434	chr6:99575712~99576456:+
BRCA	cis	rs7812879	0.81	rs2618479	ENSG00000270154.1	RP11-419I17.1	3.35	0.000835	0.0375	0.15	0.1	Systemic lupus erythematosus;	chr8:11498312	chr8:12476462~12477122:+
BRCA	cis	rs9467773	0.62	rs2451732	ENSG00000261353.1	CTA-14H9.5	3.35	0.000835	0.0375	0.1	0.1	Intelligence (multi-trait analysis);	chr6:26622676	chr6:26527063~26527404:+
BRCA	cis	rs7246967	0.866	rs111292710	ENSG00000241282.1	RPL34P33	3.35	0.000836	0.0375	0.2	0.1	Bronchopulmonary dysplasia;	chr19:22884678	chr19:22699352~22699685:+
BRCA	cis	rs10129255	0.536	rs10139058	ENSG00000211964.3	IGHV3-48	-3.35	0.000836	0.0375	-0.07	-0.1	Kawasaki disease;	chr14:106685899	chr14:106537810~106538344:-
BRCA	cis	rs11158026	0.526	rs11626210	ENSG00000233924.1	AL160471.6	-3.35	0.000836	0.0375	-0.15	-0.1	Parkinson's disease;	chr14:54882831	chr14:55004813~55005687:-
BRCA	cis	rs863345	0.564	rs12145401	ENSG00000176320.2	RP11-404O13.5	-3.35	0.000836	0.0375	-0.11	-0.1	Pneumococcal bacteremia;	chr1:158524903	chr1:158197922~158203877:-
BRCA	cis	rs2638953	0.853	rs3911810	ENSG00000273989.1	RP11-425D17.2	-3.35	0.000836	0.0375	-0.15	-0.1	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28461669	chr12:28236227~28236828:+
BRCA	cis	rs7789940	0.904	rs12531348	ENSG00000231087.2	FDPSP7	-3.35	0.000836	0.0375	-0.14	-0.1	Multiple sclerosis;	chr7:76307874	chr7:76968197~76969250:-
BRCA	cis	rs7789940	0.904	rs61294900	ENSG00000231087.2	FDPSP7	-3.35	0.000836	0.0375	-0.14	-0.1	Multiple sclerosis;	chr7:76307895	chr7:76968197~76969250:-
BRCA	cis	rs72772090	0.539	rs35898772	ENSG00000272109.1	CTD-2260A17.3	3.35	0.000836	0.0375	0.2	0.1	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96843982	chr5:96804353~96806105:+
BRCA	cis	rs10411161	0.702	rs11878583	ENSG00000269483.1	AC006272.1	-3.35	0.000836	0.0375	-0.17	-0.1	Breast cancer;	chr19:51885293	chr19:51839924~51843324:-
BRCA	cis	rs488400	0.558	rs361163	ENSG00000251611.1	RP11-610P16.1	3.35	0.000836	0.0375	0.1	0.1	Trans fatty acid levels;	chr4:151878731	chr4:151407551~151408835:-
BRCA	cis	rs11671005	0.695	rs11673069	ENSG00000269473.1	CTD-2619J13.19	3.35	0.000836	0.0375	0.16	0.1	Mean platelet volume;	chr19:58423551	chr19:58440448~58445849:+
BRCA	cis	rs9847710	1	rs2564956	ENSG00000242849.2	ALDOAP1	3.35	0.000836	0.0376	0.12	0.1	Ulcerative colitis;	chr3:53036446	chr3:52193170~52194785:+
BRCA	cis	rs1075265	0.73	rs11893270	ENSG00000272156.1	RP11-477N3.1	-3.35	0.000836	0.0376	-0.11	-0.1	Chronotype;Morning vs. evening chronotype;	chr2:54019828	chr2:54082554~54085066:+
BRCA	cis	rs75804782	0.521	rs55657931	ENSG00000186235.9	AC016757.3	3.35	0.000836	0.0376	0.2	0.1	Chronotype;Morning vs. evening chronotype;	chr2:238513431	chr2:238224552~238231677:-
BRCA	cis	rs739401	0.572	rs739400	ENSG00000247473.2	CARS-AS1	3.35	0.000836	0.0376	0.12	0.1	Longevity;	chr11:2995290	chr11:3029009~3041260:+
BRCA	cis	rs721917	0.506	rs2758561	ENSG00000280355.1	RP11-119F19.5	-3.35	0.000836	0.0376	-0.11	-0.1	Chronic obstructive pulmonary disease;	chr10:79909718	chr10:79681973~79684094:-
BRCA	cis	rs4435363	0.51	rs6509286	ENSG00000268423.3	AC011551.3	-3.35	0.000836	0.0376	-0.15	-0.1	Immature fraction of reticulocytes;P wave terminal force;	chr19:46573021	chr19:46547056~46600861:-
BRCA	cis	rs7267979	1	rs404394	ENSG00000276952.1	RP5-965G21.6	3.35	0.000836	0.0376	0.13	0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25467260	chr20:25284915~25285588:-
BRCA	cis	rs970548	0.954	rs12243153	ENSG00000237840.5	FAM21FP	3.35	0.000836	0.0376	0.14	0.1	Total cholesterol levels;HDL cholesterol;HDL cholesterol levels;Cholesterol, total;	chr10:45506612	chr10:45706431~45727231:-
BRCA	cis	rs4141153	0.528	rs67793024	ENSG00000213721.3	HMGN2P30	3.35	0.000836	0.0376	0.17	0.1	Menarche (age at onset);	chr7:41456116	chr7:42113365~42113620:+
BRCA	cis	rs4141153	0.528	rs55925433	ENSG00000213721.3	HMGN2P30	3.35	0.000836	0.0376	0.17	0.1	Menarche (age at onset);	chr7:41456151	chr7:42113365~42113620:+
BRCA	cis	rs9494145	0.638	rs6934903	ENSG00000232876.1	CTA-212D2.2	3.35	0.000836	0.0376	0.17	0.1	Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count;	chr6:135130426	chr6:135055033~135060550:+
BRCA	cis	rs13256369	1	rs4841016	ENSG00000233609.3	RP11-62H7.2	3.35	0.000837	0.0376	0.11	0.1	Obesity-related traits;	chr8:8715051	chr8:8961200~8979025:+
BRCA	cis	rs4699052	0.963	rs2085978	ENSG00000251288.2	RP11-10L12.2	-3.35	0.000837	0.0376	-0.12	-0.1	Testicular germ cell tumor;	chr4:103272457	chr4:102751401~102752641:+
BRCA	cis	rs1448792	0.729	rs566679	ENSG00000265194.1	RP11-70L8.4	-3.35	0.000837	0.0376	-0.12	-0.1	Endometriosis;	chr9:22634894	chr9:21858910~21861926:-
BRCA	cis	rs987724	0.593	rs13316183	ENSG00000240875.4	LINC00886	-3.35	0.000837	0.0376	-0.12	-0.1	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156942983	chr3:156747346~156817062:-
BRCA	cis	rs7104764	1	rs1128322	ENSG00000254910.1	RP11-326C3.7	3.35	0.000837	0.0376	0.12	0.1	Menarche (age at onset);	chr11:244197	chr11:310139~311141:-
BRCA	cis	rs11673344	0.583	rs7247090	ENSG00000233527.7	ZNF529-AS1	3.35	0.000837	0.0376	0.12	0.1	Obesity-related traits;	chr19:37522509	chr19:36573070~36594708:+
BRCA	cis	rs1144333	0.85	rs1144341	ENSG00000181227.3	RP4-682C21.2	3.35	0.000837	0.0376	0.14	0.1	Attention function in attention deficit hyperactive disorder;	chr1:75816974	chr1:75743423~75744776:-
BRCA	cis	rs1144333	0.85	rs1144342	ENSG00000181227.3	RP4-682C21.2	3.35	0.000837	0.0376	0.14	0.1	Attention function in attention deficit hyperactive disorder;	chr1:75818679	chr1:75743423~75744776:-
BRCA	cis	rs11642862	1	rs11645367	ENSG00000260082.1	RP11-2C24.5	-3.35	0.000837	0.0376	-0.19	-0.1	Tonsillectomy;	chr16:30758753	chr16:30821068~30822110:-
BRCA	cis	rs35520189	0.591	rs12465526	ENSG00000231747.1	AC079922.2	-3.35	0.000837	0.0376	-0.11	-0.1	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:112942404	chr2:112621809~112622167:-
BRCA	cis	rs35520189	0.591	rs67995749	ENSG00000231747.1	AC079922.2	-3.35	0.000837	0.0376	-0.11	-0.1	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:112943315	chr2:112621809~112622167:-
BRCA	cis	rs35520189	0.591	rs12466653	ENSG00000231747.1	AC079922.2	-3.35	0.000837	0.0376	-0.11	-0.1	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:112943411	chr2:112621809~112622167:-
BRCA	cis	rs35520189	0.591	rs6722962	ENSG00000231747.1	AC079922.2	-3.35	0.000837	0.0376	-0.11	-0.1	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:112943806	chr2:112621809~112622167:-
BRCA	cis	rs35520189	0.591	rs6733001	ENSG00000231747.1	AC079922.2	-3.35	0.000837	0.0376	-0.11	-0.1	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:112943870	chr2:112621809~112622167:-
BRCA	cis	rs35520189	0.591	rs6733003	ENSG00000231747.1	AC079922.2	-3.35	0.000837	0.0376	-0.11	-0.1	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:112943875	chr2:112621809~112622167:-
BRCA	cis	rs35520189	0.591	rs6723197	ENSG00000231747.1	AC079922.2	-3.35	0.000837	0.0376	-0.11	-0.1	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:112944021	chr2:112621809~112622167:-
BRCA	cis	rs35520189	0.591	rs6705432	ENSG00000231747.1	AC079922.2	-3.35	0.000837	0.0376	-0.11	-0.1	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:112944247	chr2:112621809~112622167:-
BRCA	cis	rs35520189	0.591	rs12614988	ENSG00000231747.1	AC079922.2	-3.35	0.000837	0.0376	-0.11	-0.1	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:112944601	chr2:112621809~112622167:-
BRCA	cis	rs35520189	0.591	rs12466604	ENSG00000231747.1	AC079922.2	-3.35	0.000837	0.0376	-0.11	-0.1	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:112945487	chr2:112621809~112622167:-
BRCA	cis	rs35520189	0.591	rs12464758	ENSG00000231747.1	AC079922.2	-3.35	0.000837	0.0376	-0.11	-0.1	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:112945704	chr2:112621809~112622167:-
BRCA	cis	rs634534	0.563	rs470192	ENSG00000255320.1	RP11-755F10.1	-3.35	0.000837	0.0376	-0.13	-0.1	Sum eosinophil basophil counts;Eosinophil counts;	chr11:65956820	chr11:66244840~66246239:-
BRCA	cis	rs17684571	0.872	rs16888135	ENSG00000231441.1	RP11-472M19.2	3.35	0.000837	0.0376	0.15	0.1	Schizophrenia;	chr6:56734969	chr6:56844002~56864078:+
BRCA	cis	rs13256369	1	rs885000	ENSG00000254153.1	CTA-398F10.2	3.35	0.000837	0.0376	0.14	0.1	Obesity-related traits;	chr8:8711365	chr8:8456909~8461337:-
BRCA	cis	rs2337406	1	rs1961901	ENSG00000211970.3	IGHV4-61	3.35	0.000837	0.0376	0.09	0.1	Alzheimer's disease (late onset);	chr14:106680856	chr14:106639119~106639657:-
BRCA	cis	rs7674212	0.531	rs2866416	ENSG00000248740.4	RP11-328K4.1	3.35	0.000837	0.0376	0.12	0.1	Type 2 diabetes;	chr4:102959554	chr4:103256159~103453658:+
BRCA	cis	rs4648045	0.796	rs4648050	ENSG00000251288.2	RP11-10L12.2	-3.35	0.000837	0.0376	-0.13	-0.1	Lymphocyte percentage of white cells;	chr4:102593584	chr4:102751401~102752641:+
BRCA	cis	rs1334894	0.901	rs12528458	ENSG00000187762.5	HSPE1P11	3.35	0.000838	0.0376	0.24	0.1	Coronary artery disease;	chr6:35537534	chr6:35023522~35023831:+
BRCA	cis	rs9788682	0.747	rs28480606	ENSG00000261143.1	ADAMTS7P3	-3.35	0.000838	0.0376	-0.14	-0.1	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78469971	chr15:77976042~77993057:+
BRCA	cis	rs9788682	0.747	rs7174190	ENSG00000261143.1	ADAMTS7P3	-3.35	0.000838	0.0376	-0.14	-0.1	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78471275	chr15:77976042~77993057:+
BRCA	cis	rs9788682	0.747	rs11072766	ENSG00000261143.1	ADAMTS7P3	-3.35	0.000838	0.0376	-0.14	-0.1	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78479204	chr15:77976042~77993057:+
BRCA	cis	rs7713065	0.765	rs4371745	ENSG00000202533.1	Y_RNA	-3.35	0.000838	0.0376	-0.11	-0.1	Lung function (FEV1/FVC);	chr5:132444263	chr5:132468147~132468257:+
BRCA	cis	rs1865760	0.865	rs9467641	ENSG00000272810.1	U91328.22	-3.35	0.000838	0.0376	-0.12	-0.1	Height;	chr6:25947008	chr6:26013241~26013757:+
BRCA	cis	rs7893279	0.822	rs10764483	ENSG00000240291.1	RP11-499P20.2	-3.35	0.000838	0.0376	-0.15	-0.1	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr10:18427417	chr10:18513115~18545651:-
BRCA	cis	rs2642442	1	rs867772	ENSG00000238078.1	LINC01352	3.35	0.000838	0.0376	0.12	0.1	Cholesterol, total;LDL cholesterol;	chr1:220799001	chr1:220829255~220832429:+
BRCA	cis	rs11098499	0.739	rs10031033	ENSG00000225892.3	RP11-384K6.2	3.35	0.000838	0.0376	0.1	0.1	Corneal astigmatism;	chr4:119230297	chr4:118632274~118634759:+
BRCA	cis	rs1865760	0.865	rs9393677	ENSG00000272810.1	U91328.22	-3.35	0.000838	0.0376	-0.12	-0.1	Height;	chr6:25945587	chr6:26013241~26013757:+
BRCA	cis	rs1865760	0.865	rs9393678	ENSG00000272810.1	U91328.22	-3.35	0.000838	0.0376	-0.12	-0.1	Height;	chr6:25945591	chr6:26013241~26013757:+
BRCA	cis	rs76076331	0.887	rs10184911	ENSG00000271952.1	RP11-245G13.2	-3.35	0.000838	0.0376	-0.17	-0.1	Educational attainment (college completion);Educational attainment (years of education);	chr2:10848391	chr2:10878269~10885118:+
BRCA	cis	rs76076331	0.887	rs9287724	ENSG00000271952.1	RP11-245G13.2	-3.35	0.000838	0.0376	-0.17	-0.1	Educational attainment (college completion);Educational attainment (years of education);	chr2:10848462	chr2:10878269~10885118:+
BRCA	cis	rs911119	0.913	rs6036463	ENSG00000270001.1	RP11-218C14.8	3.35	0.000838	0.0376	0.13	0.1	Chronic kidney disease;	chr20:23598303	chr20:23631826~23632316:-
BRCA	cis	rs875971	0.838	rs2173570	ENSG00000230189.5	GS1-124K5.2	-3.35	0.000838	0.0376	-0.08	-0.1	Aortic root size;	chr7:66297976	chr7:66409143~66490059:-
BRCA	cis	rs3198697	0.663	rs12928099	ENSG00000260872.1	RP11-680G24.5	3.35	0.000838	0.0376	0.13	0.1	Triglycerides;	chr16:15056648	chr16:15018106~15020488:-
BRCA	cis	rs964611	0.938	rs7163887	ENSG00000259488.2	RP11-154J22.1	3.35	0.000839	0.0376	0.13	0.1	Metabolite levels (Pyroglutamine);	chr15:48367357	chr15:48312353~48331856:-
BRCA	cis	rs6496044	0.568	rs1982743	ENSG00000259630.2	CTD-2262B20.1	-3.35	0.000839	0.0376	-0.12	-0.1	Interstitial lung disease;	chr15:85525528	chr15:85415228~85415633:+
BRCA	cis	rs13358904	0.868	rs10478074	ENSG00000278921.2	EPB41L4A-AS2	3.35	0.000839	0.0376	0.12	0.1	Suicide ideation score in major depressive disorder;	chr5:112267986	chr5:112419583~112420978:+
BRCA	cis	rs1113500	0.787	rs4571989	ENSG00000230489.1	VAV3-AS1	-3.35	0.000839	0.0376	-0.12	-0.1	Growth-regulated protein alpha levels;	chr1:108088722	chr1:107964443~107994607:+
BRCA	cis	rs964611	0.882	rs4630496	ENSG00000259488.2	RP11-154J22.1	-3.35	0.000839	0.0376	-0.13	-0.1	Metabolite levels (Pyroglutamine);	chr15:48366466	chr15:48312353~48331856:-
BRCA	cis	rs8023401	0.872	rs11858610	ENSG00000274654.1	CTD-3247H4.2	3.35	0.000839	0.0377	0.16	0.1	Spherical equivalent (joint analysis main effects and education interaction);	chr15:48602413	chr15:48528980~48529728:-
BRCA	cis	rs2692947	0.832	rs2579550	ENSG00000168992.4	OR7E102P	3.35	0.000839	0.0377	0.15	0.1	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96076196	chr2:95546531~95547545:+
BRCA	cis	rs2692947	0.8	rs2692936	ENSG00000168992.4	OR7E102P	3.35	0.000839	0.0377	0.15	0.1	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96079981	chr2:95546531~95547545:+
BRCA	cis	rs853679	0.723	rs9366718	ENSG00000261839.1	RP1-265C24.8	3.35	0.000839	0.0377	0.15	0.1	Depression;	chr6:28237724	chr6:28136849~28139678:+
BRCA	cis	rs4950322	0.857	rs55790545	ENSG00000237188.3	RP11-337C18.8	3.35	0.000839	0.0377	0.13	0.1	Protein quantitative trait loci;	chr1:147366649	chr1:147172771~147211568:+
BRCA	cis	rs4950322	0.857	rs7522219	ENSG00000237188.3	RP11-337C18.8	3.35	0.000839	0.0377	0.13	0.1	Protein quantitative trait loci;	chr1:147366904	chr1:147172771~147211568:+
BRCA	cis	rs11779988	0.545	rs448882	ENSG00000254054.2	RP11-156K13.3	-3.35	0.000839	0.0377	-0.16	-0.1	Breast cancer;	chr8:17936530	chr8:17905756~17907887:+
BRCA	cis	rs7954584	0.56	rs745327	ENSG00000274292.1	RP11-347I19.7	3.35	0.000839	0.0377	0.09	0.1	Mean corpuscular volume;	chr12:122018618	chr12:121800797~121803403:+
BRCA	cis	rs36051895	0.664	rs10117459	ENSG00000237711.1	RP11-39K24.13	-3.35	0.000839	0.0377	-0.13	-0.1	Pediatric autoimmune diseases;	chr9:5094034	chr9:5100236~5101009:+
BRCA	cis	rs9388451	0.626	rs1343116	ENSG00000237742.5	RP11-624M8.1	-3.35	0.000839	0.0377	-0.13	-0.1	Brugada syndrome;	chr6:125748556	chr6:125578558~125749190:-
BRCA	cis	rs9388451	0.626	rs1343115	ENSG00000237742.5	RP11-624M8.1	-3.35	0.000839	0.0377	-0.13	-0.1	Brugada syndrome;	chr6:125748671	chr6:125578558~125749190:-
BRCA	cis	rs72799341	0.706	rs1060506	ENSG00000274678.1	RP11-2C24.7	3.35	0.000839	0.0377	0.12	0.1	Diastolic blood pressure;	chr16:31122128	chr16:30821338~30821884:+
BRCA	cis	rs7229439	0.667	rs11873896	ENSG00000267414.1	RP11-456K23.1	-3.35	0.000839	0.0377	-0.12	-0.1	Antipsychotic drug-induced QTc interval change in schizophrenia;	chr18:45353898	chr18:44676927~44679717:-
BRCA	cis	rs4953911	1	rs7573104	ENSG00000224043.6	CCNT2-AS1	3.35	0.000839	0.0377	0.14	0.1	Multiple sclerosis (severity);	chr2:134308372	chr2:134735464~134918710:-
BRCA	cis	rs2444043	1	rs12910930	ENSG00000279145.1	RP11-547D13.1	-3.35	0.000839	0.0377	-0.1	-0.1	Fractional exhaled nitric oxide levels;	chr15:55253508	chr15:55171972~55178175:-
BRCA	cis	rs2795502	0.938	rs3121324	ENSG00000185904.10	LINC00839	3.35	0.000839	0.0377	0.14	0.1	Blood protein levels;	chr10:42884067	chr10:42475543~42495336:+
BRCA	cis	rs67478160	0.679	rs8011109	ENSG00000269940.1	RP11-73M18.7	3.35	0.000839	0.0377	0.1	0.1	Schizophrenia;	chr14:103813637	chr14:103694560~103695170:+
BRCA	cis	rs316020	0.764	rs595853	ENSG00000251988.1	RNU4ATAC18P	-3.35	0.000839	0.0377	-0.21	-0.1	Blood metabolite ratios;	chr6:160216453	chr6:159720415~159720540:-
BRCA	cis	rs4374383	0.631	rs12992449	ENSG00000243389.1	AC012442.5	3.35	0.000839	0.0377	0.13	0.1	Hepatitis C induced liver fibrosis;	chr2:111915111	chr2:112589040~112614431:+
BRCA	cis	rs4374383	0.631	rs13397063	ENSG00000243389.1	AC012442.5	3.35	0.000839	0.0377	0.13	0.1	Hepatitis C induced liver fibrosis;	chr2:111915280	chr2:112589040~112614431:+
BRCA	cis	rs4374383	0.631	rs13391947	ENSG00000243389.1	AC012442.5	3.35	0.000839	0.0377	0.13	0.1	Hepatitis C induced liver fibrosis;	chr2:111916386	chr2:112589040~112614431:+
BRCA	cis	rs3816183	0.585	rs1534758	ENSG00000226491.1	FTOP1	-3.35	0.00084	0.0377	-0.12	-0.1	Hypospadias;	chr2:42611661	chr2:42797225~42798712:-
BRCA	cis	rs3816183	0.585	rs4953499	ENSG00000226491.1	FTOP1	-3.35	0.00084	0.0377	-0.12	-0.1	Hypospadias;	chr2:42611692	chr2:42797225~42798712:-
BRCA	cis	rs10043228	0.826	rs11241356	ENSG00000250015.1	CTC-339F2.2	3.35	0.00084	0.0377	0.14	0.1	Asthma or chronic obstructive pulmonary disease;	chr5:116110826	chr5:116302354~116304134:-
BRCA	cis	rs9333290	0.893	rs12998294	ENSG00000259915.2	RP11-410E4.1	3.35	0.00084	0.0377	0.14	0.1	Urinary albumin-to-creatinine ratio in non-diabetics;Urinary albumin-to-creatinine ratio;	chr2:186690852	chr2:186354570~186356773:-
BRCA	cis	rs10844706	0.699	rs1008610	ENSG00000278635.1	CTD-2318O12.1	-3.35	0.00084	0.0377	-0.11	-0.1	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9731264	chr12:9415641~9416718:+
BRCA	cis	rs4763879	0.729	rs10844472	ENSG00000256582.1	RP11-75L1.1	-3.35	0.00084	0.0377	-0.11	-0.1	Type 1 diabetes;	chr12:9691137	chr12:9704077~9709350:+
BRCA	cis	rs1122401	0.881	rs2564982	ENSG00000280159.1	CTD-2591A1.1	3.35	0.00084	0.0377	0.14	0.1	Smoking initiation;	chr5:54575251	chr5:54643557~54645987:+
BRCA	cis	rs2243480	1	rs313802	ENSG00000226002.1	RP11-460N20.5	-3.35	0.00084	0.0377	-0.18	-0.1	Diabetic kidney disease;	chr7:66051386	chr7:65084103~65100232:+
BRCA	cis	rs2243480	0.803	rs403089	ENSG00000226002.1	RP11-460N20.5	-3.35	0.00084	0.0377	-0.18	-0.1	Diabetic kidney disease;	chr7:66052736	chr7:65084103~65100232:+
BRCA	cis	rs2243480	1	rs458291	ENSG00000226002.1	RP11-460N20.5	-3.35	0.00084	0.0377	-0.18	-0.1	Diabetic kidney disease;	chr7:66055492	chr7:65084103~65100232:+
BRCA	cis	rs6494488	0.5	rs72742916	ENSG00000248415.1	GAPDHP61	-3.35	0.00084	0.0377	-0.23	-0.1	Coronary artery disease;	chr15:64558476	chr15:64528667~64529671:-
BRCA	cis	rs6494488	0.5	rs55990268	ENSG00000248415.1	GAPDHP61	-3.35	0.00084	0.0377	-0.23	-0.1	Coronary artery disease;	chr15:64562105	chr15:64528667~64529671:-
BRCA	cis	rs6494488	0.5	rs72742921	ENSG00000248415.1	GAPDHP61	-3.35	0.00084	0.0377	-0.23	-0.1	Coronary artery disease;	chr15:64563357	chr15:64528667~64529671:-
BRCA	cis	rs6494488	0.5	rs72742923	ENSG00000248415.1	GAPDHP61	-3.35	0.00084	0.0377	-0.23	-0.1	Coronary artery disease;	chr15:64563497	chr15:64528667~64529671:-
BRCA	cis	rs17742757	0.522	rs899364	ENSG00000269899.1	RP11-589N15.2	3.35	0.00084	0.0377	0.13	0.1	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:11472035	chr8:11846154~11846391:-
BRCA	cis	rs2882667	0.658	rs10076442	ENSG00000242683.1	CTB-46B19.1	3.35	0.00084	0.0377	0.12	0.1	Age-related hearing impairment (SNP x SNP interaction);	chr5:138941090	chr5:139035148~139035987:-
BRCA	cis	rs875971	1	rs4717292	ENSG00000273448.1	RP11-166O4.6	3.35	0.00084	0.0377	0.09	0.1	Aortic root size;	chr7:66430611	chr7:67333047~67334383:+
BRCA	cis	rs875971	1	rs35149210	ENSG00000273448.1	RP11-166O4.6	3.35	0.00084	0.0377	0.09	0.1	Aortic root size;	chr7:66464938	chr7:67333047~67334383:+
BRCA	cis	rs7520050	0.966	rs2486447	ENSG00000226957.1	RP4-533D7.4	3.35	0.00084	0.0377	0.11	0.1	Reticulocyte count;Red blood cell count;	chr1:46080052	chr1:46046818~46048368:+
BRCA	cis	rs72928364	0.872	rs13064121	ENSG00000244119.1	PDCL3P4	3.35	0.00084	0.0377	0.13	0.1	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100991869	chr3:101712472~101713191:+
BRCA	cis	rs10129255	0.518	rs7143784	ENSG00000211976.2	IGHV3-73	-3.35	0.00084	0.0377	-0.08	-0.1	Kawasaki disease;	chr14:106687277	chr14:106802694~106803233:-
BRCA	cis	rs10843647	0.904	rs2101306	ENSG00000245614.3	DDX11-AS1	-3.35	0.00084	0.0377	-0.11	-0.1	Glucose homeostasis traits;	chr12:30182468	chr12:31020763~31073847:-
BRCA	cis	rs4805834	0.719	rs73035337	ENSG00000201388.1	SNORA68	3.35	0.00084	0.0377	0.18	0.1	Creatinine levels;	chr19:32799527	chr19:32608337~32608469:-
BRCA	cis	rs4805834	0.719	rs73035338	ENSG00000201388.1	SNORA68	3.35	0.00084	0.0377	0.18	0.1	Creatinine levels;	chr19:32801106	chr19:32608337~32608469:-
BRCA	cis	rs2243480	1	rs160633	ENSG00000226767.1	RP11-328P23.3	-3.35	0.00084	0.0377	-0.19	-0.1	Diabetic kidney disease;	chr7:66063241	chr7:65508773~65508944:-
BRCA	cis	rs761926	1	rs761926	ENSG00000272716.1	RP11-563N4.1	-3.35	0.00084	0.0377	-0.13	-0.1	Obesity-related traits;	chr2:31367919	chr2:32165046~32165757:-
BRCA	cis	rs8114671	0.967	rs3746427	ENSG00000126005.14	MMP24-AS1	-3.35	0.00084	0.0377	-0.12	-0.1	Height;	chr20:35142661	chr20:35216462~35278131:-
BRCA	cis	rs36051895	0.589	rs10491650	ENSG00000237711.1	RP11-39K24.13	3.35	0.00084	0.0377	0.12	0.1	Pediatric autoimmune diseases;	chr9:5203054	chr9:5100236~5101009:+
BRCA	cis	rs27434	0.66	rs42398	ENSG00000248734.2	CTD-2260A17.1	3.35	0.00084	0.0377	0.14	0.1	Ankylosing spondylitis;	chr5:96784751	chr5:96784777~96785999:+
BRCA	cis	rs748404	1	rs66651343	ENSG00000166763.7	STRCP1	3.35	0.00084	0.0377	0.15	0.1	Lung cancer;	chr15:43265806	chr15:43699488~43718184:-
BRCA	cis	rs875971	0.862	rs1983372	ENSG00000229886.1	RP5-1132H15.3	-3.35	0.00084	0.0377	-0.11	-0.1	Aortic root size;	chr7:66146364	chr7:66025126~66031544:-
BRCA	cis	rs4849845	0.653	rs3925970	ENSG00000236878.1	AC012363.7	3.35	0.00084	0.0377	0.12	0.1	Mean platelet volume;	chr2:120260577	chr2:120211054~120211715:+
BRCA	cis	rs10005067	0.967	rs713539	ENSG00000249001.4	RP11-742B18.1	-3.35	0.00084	0.0377	-0.12	-0.1	Total body bone mineral density (age 30-45);	chr4:87902296	chr4:87568035~87733956:-
BRCA	cis	rs2333021	0.624	rs9888617	ENSG00000259015.1	RP11-109N23.6	3.35	0.00084	0.0377	0.11	0.1	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:72996154	chr14:72960595~72961993:+
BRCA	cis	rs11098499	0.863	rs3775854	ENSG00000260404.2	RP11-384K6.6	3.35	0.00084	0.0377	0.1	0.1	Corneal astigmatism;	chr4:119550816	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.863	rs6853998	ENSG00000260404.2	RP11-384K6.6	3.35	0.00084	0.0377	0.1	0.1	Corneal astigmatism;	chr4:119554705	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.863	rs6858777	ENSG00000260404.2	RP11-384K6.6	3.35	0.00084	0.0377	0.1	0.1	Corneal astigmatism;	chr4:119554811	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.863	rs11731756	ENSG00000260404.2	RP11-384K6.6	3.35	0.00084	0.0377	0.1	0.1	Corneal astigmatism;	chr4:119557541	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.863	rs34308924	ENSG00000260404.2	RP11-384K6.6	3.35	0.00084	0.0377	0.1	0.1	Corneal astigmatism;	chr4:119560276	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.863	rs2170276	ENSG00000260404.2	RP11-384K6.6	3.35	0.00084	0.0377	0.1	0.1	Corneal astigmatism;	chr4:119564669	chr4:118591773~118633729:+
BRCA	cis	rs801193	1	rs62466794	ENSG00000275400.1	RP4-756H11.5	-3.35	0.00084	0.0377	-0.12	-0.1	Aortic root size;	chr7:66726592	chr7:66553805~66554199:-
BRCA	cis	rs7680126	0.672	rs4697957	ENSG00000250413.1	RP11-448G15.1	3.35	0.00084	0.0377	0.17	0.1	Urate levels in obese individuals;Urate levels in lean individuals;Urate levels in overweight individuals;	chr4:10180630	chr4:10006482~10009725:+
BRCA	cis	rs1156327	0.51	rs1023439	ENSG00000188477.11	AC003003.5	-3.35	0.000841	0.0377	-0.23	-0.1	Periodontal disease-related phenotypes;	chr16:19319921	chr16:19285783~19310947:+
BRCA	cis	rs4934494	0.681	rs12572928	ENSG00000232229.4	LINC00865	-3.35	0.000841	0.0377	-0.16	-0.1	Red blood cell count;	chr10:89793792	chr10:89829510~89840861:+
BRCA	cis	rs9341808	0.69	rs3805926	ENSG00000279022.1	RP11-250B2.4	3.35	0.000841	0.0377	0.12	0.1	Sitting height ratio;	chr6:80169563	chr6:80440730~80441172:+
BRCA	cis	rs62025270	0.632	rs17636096	ENSG00000259416.2	RP11-158M2.5	-3.35	0.000841	0.0377	-0.16	-0.1	Idiopathic pulmonary fibrosis;	chr15:85675503	chr15:85754941~85756237:-
BRCA	cis	rs2229238	0.774	rs4240872	ENSG00000272030.1	RP1-178F15.4	-3.35	0.000841	0.0377	-0.13	-0.1	Coronary heart disease;	chr1:154463719	chr1:153631438~153634397:-
BRCA	cis	rs873549	1	rs873549	ENSG00000227925.1	RP11-191N8.2	3.35	0.000841	0.0377	0.12	0.1	Keloid;	chr1:222098425	chr1:221827666~221840666:-
BRCA	cis	rs10129255	0.956	rs10137268	ENSG00000211958.2	IGHV3-38	3.35	0.000841	0.0377	0.08	0.1	Kawasaki disease;	chr14:106697402	chr14:106410493~106411021:-
BRCA	cis	rs7098100	0.601	rs12571634	ENSG00000231920.1	NEBL-AS1	3.35	0.000841	0.0377	0.12	0.1	Breast cancer;	chr10:21998793	chr10:21174014~21175048:+
BRCA	cis	rs76527535	0.804	rs114675033	ENSG00000228989.1	AC133528.2	3.35	0.000841	0.0377	0.14	0.1	Crohn's disease;Inflammatory bowel disease;	chr2:241532730	chr2:241690414~241694289:+
BRCA	cis	rs5771225	0.544	rs1555048	ENSG00000273137.1	RP3-402G11.28	3.35	0.000841	0.0377	0.09	0.1	Late-onset Alzheimer's disease;	chr22:50249919	chr22:50208461~50209542:-
BRCA	cis	rs1912124	1	rs67601221	ENSG00000259343.4	TMC3-AS1	3.35	0.000841	0.0377	0.22	0.1	Peripheral arterial disease (traffic-related air pollution interaction);	chr15:81186610	chr15:81324377~81362037:+
BRCA	cis	rs977987	0.806	rs7185640	ENSG00000280152.1	RP11-331F4.5	-3.35	0.000841	0.0377	-0.11	-0.1	Dupuytren's disease;	chr16:75360501	chr16:75245994~75250077:-
BRCA	cis	rs977987	0.806	rs11640674	ENSG00000280152.1	RP11-331F4.5	-3.35	0.000841	0.0377	-0.11	-0.1	Dupuytren's disease;	chr16:75361046	chr16:75245994~75250077:-
BRCA	cis	rs8023401	0.808	rs4774520	ENSG00000274654.1	CTD-3247H4.2	3.35	0.000841	0.0377	0.16	0.1	Spherical equivalent (joint analysis main effects and education interaction);	chr15:48586023	chr15:48528980~48529728:-
BRCA	cis	rs11108495	0.752	rs7132619	ENSG00000258177.1	RP11-394J1.2	3.35	0.000841	0.0377	0.13	0.1	Weight;	chr12:96416146	chr12:96222797~96223973:-
BRCA	cis	rs6452790	0.529	rs10473911	ENSG00000247828.6	TMEM161B-AS1	-3.35	0.000841	0.0377	-0.14	-0.1	Cognitive function;	chr5:87964842	chr5:88268895~88436685:+
BRCA	cis	rs7914558	0.966	rs3902934	ENSG00000272912.1	RP11-724N1.1	-3.35	0.000841	0.0377	-0.12	-0.1	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102986892	chr10:102914585~102915404:+
BRCA	cis	rs1914816	0.941	rs2957037	ENSG00000259422.1	RP11-593F23.1	3.35	0.000841	0.0377	0.15	0.1	Response to tocilizumab in rheumatoid arthritis;	chr15:76193195	chr15:76174891~76181486:-
BRCA	cis	rs7811142	0.83	rs7792525	ENSG00000214313.7	AZGP1P1	-3.35	0.000841	0.0377	-0.13	-0.1	Platelet count;	chr7:100374499	chr7:99980762~99987535:+
BRCA	cis	rs8062405	0.755	rs17640009	ENSG00000261766.1	RP11-22P6.2	-3.35	0.000841	0.0377	-0.1	-0.1	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28584379	chr16:28862166~28863340:-
BRCA	cis	rs4665809	0.878	rs4143538	ENSG00000231655.1	AC011742.3	3.35	0.000841	0.0377	0.16	0.1	Gut microbiome composition (summer);	chr2:26067309	chr2:26140263~26141264:-
BRCA	cis	rs495337	0.677	rs6012750	ENSG00000224397.4	LINC01272	3.35	0.000841	0.0377	0.1	0.1	Psoriasis;	chr20:49814143	chr20:50267486~50279795:+
BRCA	cis	rs10129255	0.912	rs6576227	ENSG00000253132.1	IGHV3-62	-3.35	0.000842	0.0377	-0.08	-0.1	Kawasaki disease;	chr14:106778202	chr14:106643142~106643585:-
BRCA	cis	rs10129255	0.957	rs6576228	ENSG00000253132.1	IGHV3-62	-3.35	0.000842	0.0377	-0.08	-0.1	Kawasaki disease;	chr14:106778401	chr14:106643142~106643585:-
BRCA	cis	rs9825823	0.617	rs2083264	ENSG00000226360.5	RPL10AP6	-3.35	0.000842	0.0377	-0.08	-0.1	Depressive symptom measurement or major depressive disorder;	chr3:61088556	chr3:61742455~61743106:-
BRCA	cis	rs34779708	0.966	rs12775799	ENSG00000269952.1	RP11-324I22.3	-3.35	0.000842	0.0378	-0.14	-0.1	Inflammatory bowel disease;Crohn's disease;	chr10:35199336	chr10:35210416~35210750:+
BRCA	cis	rs34779708	0.966	rs11010122	ENSG00000269952.1	RP11-324I22.3	-3.35	0.000842	0.0378	-0.14	-0.1	Inflammatory bowel disease;Crohn's disease;	chr10:35204590	chr10:35210416~35210750:+
BRCA	cis	rs34779708	0.9	rs73262807	ENSG00000269952.1	RP11-324I22.3	-3.35	0.000842	0.0378	-0.14	-0.1	Inflammatory bowel disease;Crohn's disease;	chr10:35207458	chr10:35210416~35210750:+
BRCA	cis	rs34779708	0.966	rs4934736	ENSG00000269952.1	RP11-324I22.3	-3.35	0.000842	0.0378	-0.14	-0.1	Inflammatory bowel disease;Crohn's disease;	chr10:35207940	chr10:35210416~35210750:+
BRCA	cis	rs3845817	0.868	rs702890	ENSG00000273763.1	RP11-420C9.1	-3.35	0.000842	0.0378	-0.13	-0.1	Bipolar disorder;	chr2:65530517	chr2:65203571~65203813:-
BRCA	cis	rs2880765	0.835	rs4843063	ENSG00000259630.2	CTD-2262B20.1	-3.35	0.000842	0.0378	-0.12	-0.1	Coronary artery disease;	chr15:85505517	chr15:85415228~85415633:+
BRCA	cis	rs10139154	0.807	rs2378781	ENSG00000258640.3	RPL21P5	3.35	0.000842	0.0378	0.13	0.1	Amyotrophic lateral sclerosis;	chr14:30725743	chr14:31111569~31112239:-
BRCA	cis	rs10139154	0.889	rs2378782	ENSG00000258640.3	RPL21P5	3.35	0.000842	0.0378	0.13	0.1	Amyotrophic lateral sclerosis;	chr14:30725785	chr14:31111569~31112239:-
BRCA	cis	rs9900280	1	rs576426	ENSG00000264808.1	RP11-802D6.1	-3.35	0.000842	0.0378	-0.13	-0.1	Mean platelet volume;	chr17:29523184	chr17:29369717~29390777:-
BRCA	cis	rs2836974	0.623	rs7280326	ENSG00000238141.2	BRWD1-AS1	-3.35	0.000842	0.0378	-0.12	-0.1	Cognitive function;	chr21:39328482	chr21:39315707~39323218:+
BRCA	cis	rs1979679	0.608	rs1581075	ENSG00000244712.1	RP11-874G11.1	3.35	0.000842	0.0378	0.17	0.1	Ossification of the posterior longitudinal ligament of the spine;	chr12:28570992	chr12:28564678~28565141:-
BRCA	cis	rs5758511	0.689	rs11913578	ENSG00000231261.1	HMGN2P10	-3.35	0.000842	0.0378	-0.14	-0.1	Birth weight;	chr22:41951387	chr22:41709225~41709489:-
BRCA	cis	rs7572733	0.875	rs7587043	ENSG00000231621.1	AC013264.2	-3.35	0.000842	0.0378	-0.1	-0.1	Dermatomyositis;	chr2:197977005	chr2:197197991~197199273:+
BRCA	cis	rs7572733	0.935	rs7587598	ENSG00000231621.1	AC013264.2	-3.35	0.000842	0.0378	-0.1	-0.1	Dermatomyositis;	chr2:197977520	chr2:197197991~197199273:+
BRCA	cis	rs8023401	0.938	rs8030753	ENSG00000274654.1	CTD-3247H4.2	3.35	0.000842	0.0378	0.15	0.1	Spherical equivalent (joint analysis main effects and education interaction);	chr15:48509738	chr15:48528980~48529728:-
BRCA	cis	rs7246760	0.867	rs66927855	ENSG00000267106.4	ZNF561-AS1	3.35	0.000842	0.0378	0.19	0.1	Pursuit maintenance gain;	chr19:9701052	chr19:9621291~9645896:+
BRCA	cis	rs67073037	0.955	rs3924271	ENSG00000230730.1	AC074011.2	-3.35	0.000842	0.0378	-0.14	-0.1	Breast cancer;Breast cancer (estrogen-receptor negative);	chr2:28944826	chr2:28633282~28664540:-
BRCA	cis	rs875971	0.545	rs2420612	ENSG00000273448.1	RP11-166O4.6	3.35	0.000842	0.0378	0.11	0.1	Aortic root size;	chr7:66536825	chr7:67333047~67334383:+
BRCA	cis	rs13420028	0.606	rs6721950	ENSG00000230992.3	FAM201B	-3.35	0.000842	0.0378	-0.12	-0.1	Hypertension (SNP x SNP interaction);	chr2:132426423	chr2:132352722~132353318:+
BRCA	cis	rs7239883	0.5	rs7240250	ENSG00000267652.1	RP11-188I24.1	3.35	0.000842	0.0378	0.15	0.1	Waist circumference;Body mass index;	chr18:42518602	chr18:41789162~41789395:-
BRCA	cis	rs7239883	0.5	rs7239826	ENSG00000267652.1	RP11-188I24.1	3.35	0.000842	0.0378	0.15	0.1	Waist circumference;Body mass index;	chr18:42518609	chr18:41789162~41789395:-
BRCA	cis	rs2192161	0.748	rs62228746	ENSG00000226751.2	AF127936.5	-3.35	0.000842	0.0378	-0.19	-0.1	Non-word repetition;	chr21:14332876	chr21:14761710~14763090:-
BRCA	cis	rs12760731	0.843	rs12023718	ENSG00000213057.5	C1orf220	-3.35	0.000842	0.0378	-0.13	-0.1	Obesity-related traits;	chr1:178522744	chr1:178542752~178548889:+
BRCA	cis	rs8054556	0.647	rs11649149	ENSG00000183604.13	SMG1P5	-3.35	0.000842	0.0378	-0.1	-0.1	Autism spectrum disorder or schizophrenia;	chr16:29997323	chr16:30267553~30335374:-
BRCA	cis	rs2281603	0.808	rs10132424	ENSG00000259116.1	RP11-973N13.4	-3.35	0.000842	0.0378	-0.1	-0.1	Lymphocyte counts;	chr14:64527157	chr14:64514154~64540368:-
BRCA	cis	rs7705502	0.89	rs3860770	ENSG00000251144.1	CTD-2532K18.2	-3.35	0.000842	0.0378	-0.13	-0.1	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for body mass index;	chr5:173874424	chr5:174820027~174826324:+
BRCA	cis	rs11892454	0.565	rs878223	ENSG00000217643.1	PTGES3P2	-3.35	0.000843	0.0378	-0.11	-0.1	Heschl's gyrus morphology;	chr2:25815796	chr2:25822469~25822950:+
BRCA	cis	rs7917772	0.636	rs1475644	ENSG00000236937.2	PTGES3P4	-3.35	0.000843	0.0378	-0.14	-0.1	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;	chr10:102731407	chr10:102845595~102845950:+
BRCA	cis	rs3756407	1	rs267952	ENSG00000259802.1	CTD-2256P15.2	-3.35	0.000843	0.0378	-0.19	-0.1	Metabolite levels (Pyroglutamine);	chr5:10743023	chr5:10352701~10353601:-
BRCA	cis	rs467650	0.549	rs2547958	ENSG00000246763.5	RGMB-AS1	-3.35	0.000843	0.0378	-0.11	-0.1	Venous thromboembolism (SNP x SNP interaction);	chr5:98658249	chr5:98769618~98773469:-
BRCA	cis	rs634534	0.562	rs661335	ENSG00000255320.1	RP11-755F10.1	-3.35	0.000843	0.0378	-0.13	-0.1	Sum eosinophil basophil counts;Eosinophil counts;	chr11:65986590	chr11:66244840~66246239:-
BRCA	cis	rs637571	0.522	rs566590	ENSG00000255320.1	RP11-755F10.1	-3.35	0.000843	0.0378	-0.13	-0.1	Eosinophil percentage of white cells;	chr11:65986591	chr11:66244840~66246239:-
BRCA	cis	rs2638953	0.853	rs10843178	ENSG00000273989.1	RP11-425D17.2	-3.35	0.000843	0.0378	-0.15	-0.1	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28460501	chr12:28236227~28236828:+
BRCA	cis	rs1424638	0.655	rs4290696	ENSG00000233251.6	AC007743.1	-3.35	0.000843	0.0378	-0.12	-0.1	Intelligence (multi-trait analysis);	chr2:57019395	chr2:56173534~56185770:-
BRCA	cis	rs3820068	0.58	rs12746773	ENSG00000237301.1	RP4-680D5.2	-3.35	0.000843	0.0378	-0.14	-0.1	Systolic blood pressure;	chr1:15675093	chr1:15586136~15603626:-
BRCA	cis	rs964611	0.935	rs74011994	ENSG00000259488.2	RP11-154J22.1	-3.35	0.000843	0.0378	-0.15	-0.1	Metabolite levels (Pyroglutamine);	chr15:48283226	chr15:48312353~48331856:-
BRCA	cis	rs7660883	1	rs3775220	ENSG00000251411.1	RP11-397E7.4	-3.35	0.000843	0.0378	-0.12	-0.1	HDL cholesterol levels;	chr4:87093601	chr4:86913266~86914817:-
BRCA	cis	rs10888690	0.582	rs17363827	ENSG00000236434.2	RP11-296A18.6	-3.35	0.000843	0.0378	-0.13	-0.1	Male-pattern baldness;	chr1:50416002	chr1:51264916~51266074:-
BRCA	cis	rs875971	1	rs2077593	ENSG00000229886.1	RP5-1132H15.3	3.35	0.000843	0.0378	0.11	0.1	Aortic root size;	chr7:66427543	chr7:66025126~66031544:-
BRCA	cis	rs34017685	0.609	rs7558220	ENSG00000228384.4	AC007040.6	-3.35	0.000843	0.0378	-0.21	-0.1	Stem cell growth factor beta levels;	chr2:71103201	chr2:70994510~71002754:+
BRCA	cis	rs11613189	0.546	rs1027569	ENSG00000279071.1	RP11-83B20.3	-3.35	0.000843	0.0378	-0.11	-0.1	Optic cup area;	chr12:124158845	chr12:124537844~124539677:+
BRCA	cis	rs34773007	0.559	rs17465590	ENSG00000232709.1	MARK2P9	-3.35	0.000843	0.0378	-0.18	-0.1	Type 2 diabetes;	chr10:93080319	chr10:92418667~92420875:+
BRCA	cis	rs6672530	0.518	rs10916182	ENSG00000227711.2	RP11-275O4.5	-3.35	0.000843	0.0378	-0.12	-0.1	Hip circumference adjusted for BMI;	chr1:227634239	chr1:227509028~227520477:-
BRCA	cis	rs11098499	0.866	rs7665125	ENSG00000225892.3	RP11-384K6.2	3.35	0.000843	0.0378	0.1	0.1	Corneal astigmatism;	chr4:119480924	chr4:118632274~118634759:+
BRCA	cis	rs524281	0.861	rs7120326	ENSG00000255557.1	RP11-770G2.2	3.35	0.000843	0.0378	0.14	0.1	Electroencephalogram traits;	chr11:66081785	chr11:65745729~65771585:+
BRCA	cis	rs6708331	1	rs62151174	ENSG00000231024.1	AC092431.3	-3.35	0.000843	0.0378	-0.14	-0.1	Obesity-related traits;	chr2:70136836	chr2:69700192~69713847:-
BRCA	cis	rs8054556	0.647	rs11863174	ENSG00000183604.13	SMG1P5	-3.35	0.000843	0.0378	-0.1	-0.1	Autism spectrum disorder or schizophrenia;	chr16:30008054	chr16:30267553~30335374:-
BRCA	cis	rs3816183	0.597	rs4953569	ENSG00000226491.1	FTOP1	-3.35	0.000843	0.0378	-0.13	-0.1	Hypospadias;	chr2:42691160	chr2:42797225~42798712:-
BRCA	cis	rs74233809	1	rs11191575	ENSG00000236937.2	PTGES3P4	3.35	0.000843	0.0378	0.22	0.1	Birth weight;	chr10:103138580	chr10:102845595~102845950:+
BRCA	cis	rs7226408	0.842	rs72885229	ENSG00000274849.1	RP11-49I11.4	3.35	0.000843	0.0378	0.19	0.1	Obesity-related traits;	chr18:36826389	chr18:36189824~36190272:+
BRCA	cis	rs7226408	0.948	rs11660471	ENSG00000274849.1	RP11-49I11.4	3.35	0.000843	0.0378	0.19	0.1	Obesity-related traits;	chr18:36826873	chr18:36189824~36190272:+
BRCA	cis	rs7226408	0.948	rs11662148	ENSG00000274849.1	RP11-49I11.4	3.35	0.000843	0.0378	0.19	0.1	Obesity-related traits;	chr18:36828460	chr18:36189824~36190272:+
BRCA	cis	rs17092148	0.887	rs6058077	ENSG00000202150.1	RNU6-407P	3.35	0.000843	0.0378	0.15	0.1	Neuroticism;	chr20:34553195	chr20:35030317~35030420:-
BRCA	cis	rs801193	0.66	rs2659914	ENSG00000230189.5	GS1-124K5.2	3.35	0.000844	0.0378	0.08	0.1	Aortic root size;	chr7:66691927	chr7:66409143~66490059:-
BRCA	cis	rs801193	0.591	rs2707839	ENSG00000230189.5	GS1-124K5.2	3.35	0.000844	0.0378	0.08	0.1	Aortic root size;	chr7:66728097	chr7:66409143~66490059:-
BRCA	cis	rs2554380	0.628	rs963690	ENSG00000176700.18	SCAND2P	-3.35	0.000844	0.0378	-0.11	-0.1	Height;	chr15:83771068	chr15:84631451~84647478:+
BRCA	cis	rs7520050	0.966	rs6677007	ENSG00000281133.1	AL355480.3	3.35	0.000844	0.0378	0.12	0.1	Reticulocyte count;Red blood cell count;	chr1:45934918	chr1:45580892~45580996:-
BRCA	cis	rs7520050	0.966	rs4660898	ENSG00000281133.1	AL355480.3	3.35	0.000844	0.0378	0.12	0.1	Reticulocyte count;Red blood cell count;	chr1:45936499	chr1:45580892~45580996:-
BRCA	cis	rs76963786	0.901	rs2128625	ENSG00000276148.1	RP11-278C7.4	-3.35	0.000844	0.0378	-0.13	-0.1	Interleukin-9 levels;	chr12:31888293	chr12:32725248~32725660:-
BRCA	cis	rs76963786	0.901	rs2388968	ENSG00000276148.1	RP11-278C7.4	-3.35	0.000844	0.0378	-0.13	-0.1	Interleukin-9 levels;	chr12:31889970	chr12:32725248~32725660:-
BRCA	cis	rs36051895	0.659	rs67006981	ENSG00000236254.1	MTND4P14	-3.35	0.000844	0.0378	-0.13	-0.1	Pediatric autoimmune diseases;	chr9:5070401	chr9:5107937~5109290:+
BRCA	cis	rs875971	1	rs709597	ENSG00000273024.4	INTS4P2	3.35	0.000844	0.0378	0.11	0.1	Aortic root size;	chr7:66360996	chr7:65647864~65715661:+
BRCA	cis	rs72627123	0.53	rs79371463	ENSG00000259065.1	RP5-1021I20.1	-3.35	0.000844	0.0378	-0.23	-0.1	Morning vs. evening chronotype;	chr14:74008153	chr14:73787360~73803270:+
BRCA	cis	rs72627123	0.867	rs73303107	ENSG00000259065.1	RP5-1021I20.1	-3.35	0.000844	0.0378	-0.23	-0.1	Morning vs. evening chronotype;	chr14:74010581	chr14:73787360~73803270:+
BRCA	cis	rs2836950	0.501	rs11088470	ENSG00000235701.1	PCBP2P1	-3.35	0.000844	0.0378	-0.12	-0.1	Menarche (age at onset);	chr21:39317236	chr21:39171130~39172106:-
BRCA	cis	rs2836950	0.501	rs2836983	ENSG00000235701.1	PCBP2P1	-3.35	0.000844	0.0378	-0.12	-0.1	Menarche (age at onset);	chr21:39317410	chr21:39171130~39172106:-
BRCA	cis	rs2836950	0.52	rs8133927	ENSG00000235701.1	PCBP2P1	-3.35	0.000844	0.0378	-0.12	-0.1	Menarche (age at onset);	chr21:39318035	chr21:39171130~39172106:-
BRCA	cis	rs2836950	0.52	rs8133928	ENSG00000235701.1	PCBP2P1	-3.35	0.000844	0.0378	-0.12	-0.1	Menarche (age at onset);	chr21:39318037	chr21:39171130~39172106:-
BRCA	cis	rs34779708	0.966	rs34605125	ENSG00000269952.1	RP11-324I22.3	-3.35	0.000844	0.0378	-0.14	-0.1	Inflammatory bowel disease;Crohn's disease;	chr10:35122318	chr10:35210416~35210750:+
BRCA	cis	rs11098499	0.739	rs7441137	ENSG00000225892.3	RP11-384K6.2	-3.35	0.000844	0.0378	-0.1	-0.1	Corneal astigmatism;	chr4:119212066	chr4:118632274~118634759:+
BRCA	cis	rs6545883	0.895	rs2442029	ENSG00000273302.1	RP11-493E12.2	3.35	0.000844	0.0378	0.1	0.1	Tuberculosis;	chr2:61452417	chr2:61199979~61200769:+
BRCA	cis	rs6545883	0.929	rs2256615	ENSG00000273302.1	RP11-493E12.2	3.35	0.000844	0.0378	0.1	0.1	Tuberculosis;	chr2:61452759	chr2:61199979~61200769:+
BRCA	cis	rs11338569	1	rs11338569	ENSG00000236896.1	RP11-535C21.3	3.35	0.000844	0.0378	0.13	0.1	Mean corpuscular hemoglobin;Red blood cell count;	chr9:98001175	chr9:97986551~97987656:-
BRCA	cis	rs4243971	0.516	rs2151437	ENSG00000277692.1	RP11-358N2.2	-3.35	0.000844	0.0378	-0.11	-0.1	Inflammatory bowel disease;Crohn's disease;	chr20:32333144	chr20:32355053~32355734:+
BRCA	cis	rs8094794	0.744	rs9652998	ENSG00000278986.1	RP11-723J4.3	3.35	0.000844	0.0378	0.15	0.1	Periodontal disease-related phenotypes;	chr18:36715525	chr18:35972151~35973916:+
BRCA	cis	rs8094794	0.744	rs8097414	ENSG00000278986.1	RP11-723J4.3	3.35	0.000844	0.0378	0.15	0.1	Periodontal disease-related phenotypes;	chr18:36715637	chr18:35972151~35973916:+
BRCA	cis	rs8094794	0.744	rs8097541	ENSG00000278986.1	RP11-723J4.3	3.35	0.000844	0.0378	0.15	0.1	Periodontal disease-related phenotypes;	chr18:36715664	chr18:35972151~35973916:+
BRCA	cis	rs897984	0.574	rs11647284	ENSG00000275263.1	RP11-1072A3.4	-3.35	0.000844	0.0378	-0.13	-0.1	Dementia with Lewy bodies;	chr16:31066014	chr16:30956872~30957199:-
BRCA	cis	rs7631605	0.576	rs6806158	ENSG00000230067.3	HSPD1P6	3.35	0.000844	0.0378	0.13	0.1	Cerebrospinal P-tau181p levels;	chr3:36924576	chr3:36767117~36784167:-
BRCA	cis	rs10129255	0.957	rs12590735	ENSG00000231475.3	IGHV4-31	-3.35	0.000844	0.0378	-0.08	-0.1	Kawasaki disease;	chr14:106779660	chr14:106349283~106349792:-
BRCA	cis	rs60871478	0.636	rs55663559	ENSG00000237181.1	AC147651.4	3.35	0.000844	0.0378	0.12	0.1	Cerebrospinal P-tau181p levels;	chr7:844420	chr7:603185~608482:+
BRCA	cis	rs11175492	0.92	rs11175514	ENSG00000255693.1	RP11-766N7.3	-3.35	0.000844	0.0378	-0.25	-0.1	Platelet count;	chr12:64685608	chr12:64883394~64977522:+
BRCA	cis	rs7221109	0.533	rs7210983	ENSG00000229028.2	KRT223P	3.35	0.000844	0.0378	0.12	0.1	Type 1 diabetes;	chr17:40660862	chr17:40717235~40721932:-
BRCA	cis	rs10129255	0.957	rs2007467	ENSG00000211959.2	IGHV4-39	-3.35	0.000844	0.0379	-0.08	-0.1	Kawasaki disease;	chr14:106771605	chr14:106421711~106422218:-
BRCA	cis	rs6490294	0.528	rs12578195	ENSG00000257624.1	RP1-128M12.3	3.35	0.000844	0.0379	0.19	0.1	Mean platelet volume;	chr12:111956130	chr12:112000739~112000985:-
BRCA	cis	rs8030605	0.704	rs76730249	ENSG00000277245.1	RP11-48G14.3	3.35	0.000844	0.0379	0.22	0.1	Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;	chr15:56336865	chr15:56447120~56447697:+
BRCA	cis	rs10091374	0.762	rs10087358	ENSG00000241204.1	RP11-333A23.1	3.35	0.000844	0.0379	0.12	0.1	Cardiac Troponin-T levels;	chr8:70475410	chr8:70424125~70424576:-
BRCA	cis	rs10911902	0.643	rs6689129	ENSG00000229739.2	RP11-295K2.3	-3.35	0.000845	0.0379	-0.14	-0.1	Schizophrenia;	chr1:186357078	chr1:186435161~186470291:+
BRCA	cis	rs1119582	1	rs463569	ENSG00000279118.1	RP11-517I3.2	-3.35	0.000845	0.0379	-0.12	-0.1	Select biomarker traits;	chr5:125938242	chr5:126496279~126498604:+
BRCA	cis	rs1119582	1	rs462715	ENSG00000279118.1	RP11-517I3.2	-3.35	0.000845	0.0379	-0.12	-0.1	Select biomarker traits;	chr5:125939395	chr5:126496279~126498604:+
BRCA	cis	rs1119582	1	rs463706	ENSG00000279118.1	RP11-517I3.2	-3.35	0.000845	0.0379	-0.12	-0.1	Select biomarker traits;	chr5:125940024	chr5:126496279~126498604:+
BRCA	cis	rs1119582	1	rs467210	ENSG00000279118.1	RP11-517I3.2	-3.35	0.000845	0.0379	-0.12	-0.1	Select biomarker traits;	chr5:125940802	chr5:126496279~126498604:+
BRCA	cis	rs1119582	1	rs460940	ENSG00000279118.1	RP11-517I3.2	-3.35	0.000845	0.0379	-0.12	-0.1	Select biomarker traits;	chr5:125941151	chr5:126496279~126498604:+
BRCA	cis	rs1119582	1	rs456845	ENSG00000279118.1	RP11-517I3.2	-3.35	0.000845	0.0379	-0.12	-0.1	Select biomarker traits;	chr5:125941478	chr5:126496279~126498604:+
BRCA	cis	rs752590	0.614	rs7585510	ENSG00000189223.12	PAX8-AS1	3.35	0.000845	0.0379	0.2	0.1	Mucinous ovarian carcinoma;	chr2:113263334	chr2:113211522~113276581:+
BRCA	cis	rs11723261	0.582	rs7679573	ENSG00000198155.5	ZNF876P	-3.35	0.000845	0.0379	-0.16	-0.1	Immune response to smallpox vaccine (IL-6);	chr4:157810	chr4:212610~255985:+
BRCA	cis	rs4141404	0.561	rs5994376	ENSG00000213888.3	LINC01521	-3.35	0.000845	0.0379	-0.09	-0.1	Paclitaxel-induced neuropathy;	chr22:31167569	chr22:31346777~31348719:+
BRCA	cis	rs58521262	0.729	rs12608610	ENSG00000268105.1	RP11-369G6.2	-3.35	0.000845	0.0379	-0.17	-0.1	Testicular germ cell tumor;	chr19:22884113	chr19:23125665~23128543:+
BRCA	cis	rs801193	1	rs10252765	ENSG00000275400.1	RP4-756H11.5	-3.35	0.000845	0.0379	-0.12	-0.1	Aortic root size;	chr7:66763745	chr7:66553805~66554199:-
BRCA	cis	rs73108077	1	rs73108027	ENSG00000277112.2	RP11-755J8.1	-3.35	0.000845	0.0379	-0.21	-0.1	Red blood cell density in sickle cell anemia;	chr20:31398778	chr20:30681825~30723932:-
BRCA	cis	rs11048434	0.518	rs2377678	ENSG00000256069.6	A2MP1	-3.35	0.000845	0.0379	-0.11	-0.1	Sjögren's syndrome;	chr12:9021562	chr12:9228533~9275817:-
BRCA	cis	rs4499344	0.73	rs421607	ENSG00000201388.1	SNORA68	3.35	0.000845	0.0379	0.12	0.1	Mean platelet volume;	chr19:32614045	chr19:32608337~32608469:-
BRCA	cis	rs516805	0.667	rs225080	ENSG00000279114.1	RP3-425C14.5	-3.35	0.000845	0.0379	-0.13	-0.1	Lymphocyte counts;	chr6:122295949	chr6:122471923~122484161:+
BRCA	cis	rs9325144	0.581	rs6582564	ENSG00000257718.1	RP11-396F22.1	-3.35	0.000845	0.0379	-0.1	-0.1	Morning vs. evening chronotype;	chr12:38277480	chr12:38906451~38909592:+
BRCA	cis	rs17270561	0.583	rs6926425	ENSG00000272462.2	U91328.19	-3.35	0.000845	0.0379	-0.12	-0.1	Iron status biomarkers;	chr6:25785076	chr6:25992662~26001775:+
BRCA	cis	rs12282928	0.918	rs1503173	ENSG00000255197.4	RP11-750H9.5	3.35	0.000845	0.0379	0.1	0.1	Migraine - clinic-based;	chr11:48224745	chr11:47383148~47409190:-
BRCA	cis	rs1912124	1	rs68188101	ENSG00000259343.4	TMC3-AS1	3.35	0.000845	0.0379	0.23	0.1	Peripheral arterial disease (traffic-related air pollution interaction);	chr15:81215591	chr15:81324377~81362037:+
BRCA	cis	rs12477438	0.52	rs11695751	ENSG00000231822.1	AC019097.7	3.35	0.000845	0.0379	0.11	0.1	Chronic sinus infection;	chr2:99091784	chr2:99102018~99102752:+
BRCA	cis	rs875971	0.862	rs6962717	ENSG00000106610.13	STAG3L4	-3.35	0.000845	0.0379	-0.14	-0.1	Aortic root size;	chr7:66418748	chr7:67302621~67321526:+
BRCA	cis	rs8037137	0.915	rs2290202	ENSG00000275345.1	RP11-697E2.11	-3.35	0.000845	0.0379	-0.18	-0.1	Platelet count;Invasive epithelial ovarian cancer;Serous invasive ovarian cancer;High-grade serous ovarian cancer;	chr15:90969037	chr15:90281858~90282270:+
BRCA	cis	rs2512987	1	rs2512986	ENSG00000254731.1	CTD-2005H7.1	-3.35	0.000846	0.0379	-0.12	-0.1	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr11:86703286	chr11:86703099~86714092:+
BRCA	cis	rs113835537	0.529	rs11227499	ENSG00000255468.5	RP11-867G23.8	-3.35	0.000846	0.0379	-0.13	-0.1	Airway imaging phenotypes;	chr11:66505353	chr11:66347950~66364804:+
BRCA	cis	rs4691139	0.549	rs10001548	ENSG00000248632.1	RP11-366M4.11	3.35	0.000846	0.0379	0.12	0.1	Ovarian cancer in BRCA1 mutation carriers;	chr4:164958229	chr4:164968587~164970002:-
BRCA	cis	rs11634944	1	rs11634690	ENSG00000270246.3	RP11-701H24.8	-3.35	0.000846	0.0379	-0.11	-0.1	Interleukin-8 levels;	chr15:24952988	chr15:25041918~25042428:+
BRCA	cis	rs12541491	0.506	rs11250007	ENSG00000154316.13	TDH	3.35	0.000846	0.0379	0.14	0.1	Schizophrenia;	chr8:10427576	chr8:11339637~11368452:+
BRCA	cis	rs1479090	0.762	rs4443236	ENSG00000250027.1	RP11-563E2.2	-3.35	0.000846	0.0379	-0.13	-0.1	Lung cancer;	chr4:163089984	chr4:163108785~163119965:+
BRCA	cis	rs4805834	0.843	rs1865038	ENSG00000201388.1	SNORA68	-3.35	0.000846	0.0379	-0.18	-0.1	Creatinine levels;	chr19:32930580	chr19:32608337~32608469:-
BRCA	cis	rs11157436	0.56	rs11623957	ENSG00000211813.2	TRAV34	3.35	0.000846	0.0379	0.1	0.1	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22224735	chr14:22207522~22208129:+
BRCA	cis	rs1443512	0.812	rs1975470	ENSG00000274817.1	HOTAIR_4	-3.35	0.000846	0.0379	-0.12	-0.1	Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-hip ratio;Waist-to-hip ratio adjusted for body mass index;	chr12:53943057	chr12:53968002~53968178:+
BRCA	cis	rs9796	0.621	rs11858678	ENSG00000223313.1	RNU6-516P	3.35	0.000846	0.0379	0.12	0.1	Menopause (age at onset);	chr15:41175734	chr15:40529570~40529673:+
BRCA	cis	rs6571943	0.857	rs17624620	ENSG00000258526.4	RP11-111A21.1	3.35	0.000846	0.0379	0.17	0.1	Verbal memory performance (residualized delayed recall level);	chr14:39581993	chr14:39474840~39513780:+
BRCA	cis	rs4499344	0.73	rs2903755	ENSG00000201388.1	SNORA68	3.35	0.000846	0.0379	0.12	0.1	Mean platelet volume;	chr19:32607964	chr19:32608337~32608469:-
BRCA	cis	rs4499344	0.73	rs2868150	ENSG00000201388.1	SNORA68	3.35	0.000846	0.0379	0.12	0.1	Mean platelet volume;	chr19:32607969	chr19:32608337~32608469:-
BRCA	cis	rs4499344	0.73	rs28402742	ENSG00000201388.1	SNORA68	3.35	0.000846	0.0379	0.12	0.1	Mean platelet volume;	chr19:32608828	chr19:32608337~32608469:-
BRCA	cis	rs4499344	0.73	rs28416849	ENSG00000201388.1	SNORA68	3.35	0.000846	0.0379	0.12	0.1	Mean platelet volume;	chr19:32608852	chr19:32608337~32608469:-
BRCA	cis	rs10883723	0.81	rs10786671	ENSG00000213061.2	PFN1P11	-3.35	0.000846	0.0379	-0.14	-0.1	Allergic disease (asthma, hay fever or eczema);	chr10:102511546	chr10:102838011~102845473:-
BRCA	cis	rs1443512	0.796	rs1822437	ENSG00000228630.4	HOTAIR	3.35	0.000846	0.0379	0.13	0.1	Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-hip ratio;Waist-to-hip ratio adjusted for body mass index;	chr12:53946293	chr12:53962308~53974956:-
BRCA	cis	rs6142618	0.562	rs6061185	ENSG00000275576.1	RP5-836N17.4	3.35	0.000846	0.0379	0.11	0.1	Inflammatory bowel disease;	chr20:32143669	chr20:32116171~32116629:+
BRCA	cis	rs4130344	0.874	rs17286116	ENSG00000271817.2	U3	-3.35	0.000846	0.0379	-0.11	-0.1	Intelligence (multi-trait analysis);	chr4:158871478	chr4:158700691~158700909:+
BRCA	cis	rs7017914	0.967	rs2732091	ENSG00000246366.5	RP11-382J12.1	-3.35	0.000846	0.0379	-0.11	-0.1	Bone mineral density;	chr8:71006188	chr8:70608577~70663279:+
BRCA	cis	rs875971	0.502	rs6460311	ENSG00000273448.1	RP11-166O4.6	-3.35	0.000846	0.0379	-0.11	-0.1	Aortic root size;	chr7:66646886	chr7:67333047~67334383:+
BRCA	cis	rs193541	0.509	rs7720862	ENSG00000260686.1	CTB-36H16.2	-3.35	0.000846	0.0379	-0.09	-0.1	Glucose homeostasis traits;	chr5:122832420	chr5:122832356~122834533:+
BRCA	cis	rs11098499	0.615	rs59867181	ENSG00000249244.1	RP11-548H18.2	-3.35	0.000846	0.0379	-0.12	-0.1	Corneal astigmatism;	chr4:119635312	chr4:119391831~119395335:-
BRCA	cis	rs8023401	0.882	rs11855862	ENSG00000274654.1	CTD-3247H4.2	3.35	0.000846	0.0379	0.15	0.1	Spherical equivalent (joint analysis main effects and education interaction);	chr15:48546868	chr15:48528980~48529728:-
BRCA	cis	rs7426380	0.525	rs934278	ENSG00000272606.1	RP11-554J4.1	3.35	0.000846	0.0379	0.12	0.1	Intraocular pressure;	chr2:55843217	chr2:55617909~55618373:+
BRCA	cis	rs7267979	0.932	rs6138588	ENSG00000274973.1	RP13-401N8.7	-3.35	0.000846	0.0379	-0.12	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25506887	chr20:25845497~25845862:+
BRCA	cis	rs62025270	0.632	rs62023935	ENSG00000259367.1	RP11-815J21.4	3.35	0.000846	0.0379	0.1	0.1	Idiopathic pulmonary fibrosis;	chr15:85605604	chr15:85619623~85670948:-
BRCA	cis	rs8049367	0.647	rs2075136	ENSG00000279031.1	LA16c-360H6.1	3.35	0.000846	0.0379	0.12	0.1	Nonsyndromic cleft lip with or without cleft palate;	chr16:3921279	chr16:3292879~3293403:+
BRCA	cis	rs736408	0.5	rs2878762	ENSG00000280422.1	RP11-155D18.13	-3.35	0.000846	0.0379	-0.14	-0.1	Bipolar disorder;	chr3:52884986	chr3:51951849~51953902:-
BRCA	cis	rs6088580	0.634	rs6059897	ENSG00000269202.1	RP4-614O4.12	-3.35	0.000846	0.0379	-0.1	-0.1	Glomerular filtration rate (creatinine);	chr20:34525419	chr20:35201747~35203288:-
BRCA	cis	rs10644111	1	rs10644111	ENSG00000188693.7	CYP51A1-AS1	-3.35	0.000847	0.0379	-0.11	-0.1	Breast cancer;	chr7:92022864	chr7:92134604~92180725:+
BRCA	cis	rs1998359	0.953	rs17179288	ENSG00000259087.4	RP11-356O9.2	3.35	0.000847	0.0379	0.12	0.1	Self-reported allergy;	chr14:37619154	chr14:37556158~37567095:-
BRCA	cis	rs6964833	0.872	rs4717903	ENSG00000277072.3	STAG3L2	3.35	0.000847	0.0379	0.11	0.1	Menarche (age at onset);	chr7:74653827	chr7:74882163~74890610:-
BRCA	cis	rs1667284	0.967	rs1667281	ENSG00000259985.1	RP11-549B18.1	-3.35	0.000847	0.0379	-0.12	-0.1	Problematic alcohol use in trauma-exposed individuals;	chr18:31640793	chr18:31685655~31686823:+
BRCA	cis	rs1667284	1	rs1612691	ENSG00000259985.1	RP11-549B18.1	-3.35	0.000847	0.0379	-0.12	-0.1	Problematic alcohol use in trauma-exposed individuals;	chr18:31640955	chr18:31685655~31686823:+
BRCA	cis	rs4763879	0.778	rs7977940	ENSG00000256582.1	RP11-75L1.1	-3.35	0.000847	0.0379	-0.11	-0.1	Type 1 diabetes;	chr12:9686320	chr12:9704077~9709350:+
BRCA	cis	rs962856	0.575	rs644032	ENSG00000236605.1	AC023115.4	3.35	0.000847	0.0379	0.13	0.1	Pancreatic cancer;	chr2:67432524	chr2:67324627~67325304:+
BRCA	cis	rs8180040	0.62	rs9845728	ENSG00000280667.1	Y_RNA	3.35	0.000847	0.0379	0.12	0.1	Colorectal cancer;	chr3:47061886	chr3:47501083~47501182:+
BRCA	cis	rs8180040	0.62	rs9844122	ENSG00000280667.1	Y_RNA	3.35	0.000847	0.0379	0.12	0.1	Colorectal cancer;	chr3:47066840	chr3:47501083~47501182:+
BRCA	cis	rs6453278	0.768	rs4703726	ENSG00000250802.5	ZBED3-AS1	3.35	0.000847	0.0379	0.16	0.1	Autism;	chr5:77108413	chr5:77086740~77166909:+
BRCA	cis	rs1178127	0.765	rs1178150	ENSG00000232821.1	AC003986.6	3.35	0.000847	0.0379	0.14	0.1	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);	chr7:18740107	chr7:19112474~19114271:+
BRCA	cis	rs7620503	0.613	rs11715814	ENSG00000228561.2	RP11-114M1.1	3.35	0.000847	0.0379	0.13	0.1	Corneal structure;	chr3:177562207	chr3:177683627~177691250:+
BRCA	cis	rs886774	0.74	rs2283046	ENSG00000273055.1	CTB-13F3.1	-3.35	0.000847	0.0379	-0.11	-0.1	Ulcerative colitis;	chr7:107928218	chr7:107942116~107942740:+
BRCA	cis	rs17767294	0.708	rs72851105	ENSG00000219392.1	RP1-265C24.5	-3.35	0.000847	0.0379	-0.29	-0.1	Parkinson's disease;	chr6:28068630	chr6:28115628~28116551:+
BRCA	cis	rs12681366	0.734	rs10102233	ENSG00000253175.1	RP11-267M23.6	3.35	0.000847	0.038	0.12	0.1	Nonsyndromic cleft lip with cleft palate;	chr8:94389429	chr8:94565036~94565715:+
BRCA	cis	rs886774	0.774	rs7806946	ENSG00000273055.1	CTB-13F3.1	-3.35	0.000847	0.038	-0.11	-0.1	Ulcerative colitis;	chr7:107925985	chr7:107942116~107942740:+
BRCA	cis	rs9866825	0.935	rs7635372	ENSG00000227110.5	LMCD1-AS1	3.35	0.000847	0.038	0.12	0.1	QT interval;	chr3:8206852	chr3:7952805~8611924:-
BRCA	cis	rs12477438	0.52	rs4340581	ENSG00000231822.1	AC019097.7	3.35	0.000847	0.038	0.11	0.1	Chronic sinus infection;	chr2:99108562	chr2:99102018~99102752:+
BRCA	cis	rs6723226	0.842	rs1901355	ENSG00000276517.1	AL133243.2	3.35	0.000847	0.038	0.13	0.1	Intelligence (multi-trait analysis);	chr2:32610597	chr2:32526504~32529507:+
BRCA	cis	rs11098499	0.722	rs10025925	ENSG00000249244.1	RP11-548H18.2	3.35	0.000847	0.038	0.12	0.1	Corneal astigmatism;	chr4:119350589	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.731	rs10015579	ENSG00000249244.1	RP11-548H18.2	3.35	0.000847	0.038	0.12	0.1	Corneal astigmatism;	chr4:119350647	chr4:119391831~119395335:-
BRCA	cis	rs35520189	0.557	rs12617864	ENSG00000189223.12	PAX8-AS1	3.35	0.000847	0.038	0.15	0.1	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:112957399	chr2:113211522~113276581:+
BRCA	cis	rs1354774	0.505	rs8105985	ENSG00000197588.8	KLKP1	-3.35	0.000847	0.038	-0.11	-0.1	Prostate-specific antigen levels;	chr19:50894815	chr19:50882096~50896398:-
BRCA	cis	rs6696239	0.911	rs12138198	ENSG00000215812.5	ZNF847P	3.35	0.000847	0.038	0.14	0.1	Height;	chr1:227712349	chr1:227696892~227706699:-
BRCA	cis	rs7985	0.725	rs1007476	ENSG00000244625.4	MIATNB	-3.35	0.000848	0.038	-0.11	-0.1	Electroencephalogram traits;	chr22:26660685	chr22:26672767~26780207:+
BRCA	cis	rs2262909	0.962	rs12610034	ENSG00000279377.1	AC003973.3	-3.35	0.000848	0.038	-0.14	-0.1	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;	chr19:22131726	chr19:21965708~21968529:-
BRCA	cis	rs73108077	1	rs73105976	ENSG00000277112.2	RP11-755J8.1	-3.35	0.000848	0.038	-0.22	-0.1	Red blood cell density in sickle cell anemia;	chr20:31378130	chr20:30681825~30723932:-
BRCA	cis	rs1119582	0.706	rs2568403	ENSG00000279118.1	RP11-517I3.2	3.35	0.000848	0.038	0.14	0.1	Select biomarker traits;	chr5:125842065	chr5:126496279~126498604:+
BRCA	cis	rs1119582	0.636	rs2568402	ENSG00000279118.1	RP11-517I3.2	3.35	0.000848	0.038	0.14	0.1	Select biomarker traits;	chr5:125842141	chr5:126496279~126498604:+
BRCA	cis	rs1119582	0.636	rs437547	ENSG00000279118.1	RP11-517I3.2	3.35	0.000848	0.038	0.14	0.1	Select biomarker traits;	chr5:125845412	chr5:126496279~126498604:+
BRCA	cis	rs1119582	0.636	rs397587	ENSG00000279118.1	RP11-517I3.2	3.35	0.000848	0.038	0.14	0.1	Select biomarker traits;	chr5:125846114	chr5:126496279~126498604:+
BRCA	cis	rs1119582	0.561	rs383096	ENSG00000279118.1	RP11-517I3.2	3.35	0.000848	0.038	0.14	0.1	Select biomarker traits;	chr5:125847126	chr5:126496279~126498604:+
BRCA	cis	rs1119582	0.636	rs1428291	ENSG00000279118.1	RP11-517I3.2	3.35	0.000848	0.038	0.14	0.1	Select biomarker traits;	chr5:125847391	chr5:126496279~126498604:+
BRCA	cis	rs3770081	1	rs78032828	ENSG00000232504.4	ST3GAL5-AS1	3.35	0.000848	0.038	0.24	0.1	Facial emotion recognition (sad faces);	chr2:86081909	chr2:85889280~85890980:+
BRCA	cis	rs7781266	0.79	rs2113565	ENSG00000226205.1	AC007790.4	-3.35	0.000848	0.038	-0.15	-0.1	Educational attainment (college completion);	chr7:133500457	chr7:133732493~133733595:-
BRCA	cis	rs2617170	0.961	rs11053802	ENSG00000245648.1	RP11-277P12.20	3.35	0.000848	0.038	0.13	0.1	Behcet's disease;	chr12:10444608	chr12:10363769~10398506:+
BRCA	cis	rs72772787	0.826	rs6690724	ENSG00000235749.2	RP11-634B7.4	3.35	0.000848	0.038	0.23	0.1	Response to serotonin reuptake inhibitors in major depressive disorder;	chr1:247845366	chr1:247639749~247747062:+
BRCA	cis	rs13113518	0.51	rs6858749	ENSG00000239040.1	Y_RNA	-3.35	0.000848	0.038	-0.11	-0.1	Height;	chr4:55424270	chr4:55412636~55412738:+
BRCA	cis	rs27434	0.605	rs39840	ENSG00000248734.2	CTD-2260A17.1	3.35	0.000848	0.038	0.14	0.1	Ankylosing spondylitis;	chr5:96784350	chr5:96784777~96785999:+
BRCA	cis	rs2842483	0.849	rs2260499	ENSG00000234618.1	RPSAP9	3.35	0.000848	0.038	0.14	0.1	Multiple sclerosis (age of onset);	chr9:76290137	chr9:76398699~76399586:+
BRCA	cis	rs2842483	0.89	rs2260500	ENSG00000234618.1	RPSAP9	3.35	0.000848	0.038	0.14	0.1	Multiple sclerosis (age of onset);	chr9:76290138	chr9:76398699~76399586:+
BRCA	cis	rs7103648	0.966	rs1534576	ENSG00000280615.1	Y_RNA	-3.35	0.000848	0.038	-0.12	-0.1	Systolic blood pressure;Diastolic blood pressure;	chr11:47398112	chr11:47614898~47614994:-
BRCA	cis	rs12413816	0.784	rs11258560	ENSG00000199407.1	RNA5SP301	-3.35	0.000848	0.038	-0.13	-0.1	Red cell distribution width;	chr10:13728137	chr10:13727796~13727916:+
BRCA	cis	rs7677281	1	rs6847193	ENSG00000271676.1	RP11-1E1.2	3.35	0.000848	0.038	0.14	0.1	Lung function (FEV1/FVC);	chr4:77420032	chr4:77112495~77113458:-
BRCA	cis	rs4787491	0.729	rs11150584	ENSG00000275371.1	RP11-455F5.6	-3.35	0.000848	0.038	-0.1	-0.1	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30028357	chr16:30110895~30111955:+
BRCA	cis	rs10843647	0.538	rs1485398	ENSG00000245614.3	DDX11-AS1	3.35	0.000848	0.038	0.11	0.1	Glucose homeostasis traits;	chr12:30096384	chr12:31020763~31073847:-
BRCA	cis	rs198426	0.81	rs198436	ENSG00000243742.4	RPLP0P2	-3.35	0.000848	0.038	-0.13	-0.1	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr11:61714574	chr11:61615036~61639449:+
BRCA	cis	rs7089973	0.966	rs55711292	ENSG00000236799.1	RP11-383C6.2	-3.35	0.000848	0.038	-0.13	-0.1	Bipolar disorder or attention deficit hyperactivity disorder;	chr10:114845111	chr10:114994657~114996593:+
BRCA	cis	rs80028505	0.908	rs6910685	ENSG00000271304.1	DPRXP2	3.35	0.000848	0.038	0.19	0.1	Foot ulcer in diabetes and neuropathy;	chr6:36080640	chr6:35989515~35990436:-
BRCA	cis	rs13326165	0.76	rs2016575	ENSG00000275956.1	RP5-966M1.7	3.35	0.000849	0.038	0.15	0.1	HDL cholesterol levels;HDL cholesterol;	chr3:52443064	chr3:52732547~52733867:+
BRCA	cis	rs2274273	0.682	rs7141975	ENSG00000259318.1	RP11-454L9.2	3.35	0.000849	0.038	0.09	0.1	Protein biomarker;	chr14:55075498	chr14:55394940~55395233:-
BRCA	cis	rs7020830	0.83	rs17487601	ENSG00000260100.1	RP11-220I1.5	-3.35	0.000849	0.038	-0.13	-0.1	Schizophrenia;	chr9:37213644	chr9:37078813~37079776:-
BRCA	cis	rs4711350	0.906	rs943463	ENSG00000224557.6	HLA-DPB2	-3.35	0.000849	0.038	-0.14	-0.1	Schizophrenia;	chr6:33752100	chr6:33112451~33129084:+
BRCA	cis	rs66887589	0.616	rs11098497	ENSG00000260091.1	RP11-33B1.4	-3.35	0.000849	0.038	-0.08	-0.1	Diastolic blood pressure;	chr4:119265913	chr4:119409333~119410233:+
BRCA	cis	rs300890	0.729	rs11100786	ENSG00000250326.1	RP11-284M14.1	3.35	0.000849	0.038	0.12	0.1	Nasopharyngeal carcinoma;	chr4:143379901	chr4:142933195~143184861:-
BRCA	cis	rs9527	0.59	rs3781282	ENSG00000269609.4	RPARP-AS1	3.35	0.000849	0.038	0.1	0.1	Arsenic metabolism;	chr10:103092662	chr10:102449817~102461106:+
BRCA	cis	rs8040855	0.576	rs62022527	ENSG00000259774.1	RP11-182J1.13	3.35	0.000849	0.038	0.15	0.1	Bulimia nervosa;	chr15:84988022	chr15:84422618~84425882:+
BRCA	cis	rs2243480	1	rs160643	ENSG00000229180.5	GS1-124K5.11	3.35	0.000849	0.038	0.13	0.1	Diabetic kidney disease;	chr7:66093235	chr7:66526088~66542624:-
BRCA	cis	rs7824557	0.815	rs958648	ENSG00000254948.1	OR7E158P	3.35	0.000849	0.038	0.12	0.1	Retinal vascular caliber;	chr8:11246386	chr8:11919900~11920809:-
BRCA	cis	rs4356203	0.905	rs10832743	ENSG00000184669.7	OR7E14P	-3.35	0.000849	0.038	-0.13	-0.1	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17194933	chr11:17013998~17053024:+
BRCA	cis	rs6005807	0.719	rs6005809	ENSG00000272858.1	CTA-292E10.8	3.35	0.000849	0.038	0.17	0.1	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28546239	chr22:28814914~28815662:+
BRCA	cis	rs35306767	0.807	rs1013505	ENSG00000229869.1	RP11-363N22.2	-3.35	0.000849	0.038	-0.16	-0.1	Eosinophil percentage of granulocytes;	chr10:907333	chr10:933026~942743:+
BRCA	cis	rs10129255	0.5	rs988134	ENSG00000211976.2	IGHV3-73	-3.35	0.000849	0.038	-0.08	-0.1	Kawasaki disease;	chr14:106776698	chr14:106802694~106803233:-
BRCA	cis	rs10129255	0.5	rs988133	ENSG00000211976.2	IGHV3-73	-3.35	0.000849	0.038	-0.08	-0.1	Kawasaki disease;	chr14:106776724	chr14:106802694~106803233:-
BRCA	cis	rs2066819	1	rs59811639	ENSG00000257740.1	RP11-977G19.12	3.35	0.000849	0.038	0.25	0.1	Psoriasis vulgaris;	chr12:56302170	chr12:56308868~56309449:+
BRCA	cis	rs2066819	1	rs57279772	ENSG00000257740.1	RP11-977G19.12	3.35	0.000849	0.038	0.25	0.1	Psoriasis vulgaris;	chr12:56305176	chr12:56308868~56309449:+
BRCA	cis	rs2066819	1	rs76430365	ENSG00000257740.1	RP11-977G19.12	3.35	0.000849	0.038	0.25	0.1	Psoriasis vulgaris;	chr12:56306209	chr12:56308868~56309449:+
BRCA	cis	rs2066819	1	rs79750959	ENSG00000257740.1	RP11-977G19.12	3.35	0.000849	0.038	0.25	0.1	Psoriasis vulgaris;	chr12:56308228	chr12:56308868~56309449:+
BRCA	cis	rs2066819	1	rs58852079	ENSG00000257740.1	RP11-977G19.12	3.35	0.000849	0.038	0.25	0.1	Psoriasis vulgaris;	chr12:56313138	chr12:56308868~56309449:+
BRCA	cis	rs2066819	1	rs59295315	ENSG00000257740.1	RP11-977G19.12	3.35	0.000849	0.038	0.25	0.1	Psoriasis vulgaris;	chr12:56314792	chr12:56308868~56309449:+
BRCA	cis	rs2066819	1	rs2291361	ENSG00000257740.1	RP11-977G19.12	3.35	0.000849	0.038	0.25	0.1	Psoriasis vulgaris;	chr12:56324021	chr12:56308868~56309449:+
BRCA	cis	rs2066819	1	rs76466034	ENSG00000257740.1	RP11-977G19.12	3.35	0.000849	0.038	0.25	0.1	Psoriasis vulgaris;	chr12:56325666	chr12:56308868~56309449:+
BRCA	cis	rs2066819	1	rs77768890	ENSG00000257740.1	RP11-977G19.12	3.35	0.000849	0.038	0.25	0.1	Psoriasis vulgaris;	chr12:56331337	chr12:56308868~56309449:+
BRCA	cis	rs2066819	1	rs75754909	ENSG00000257740.1	RP11-977G19.12	3.35	0.000849	0.038	0.25	0.1	Psoriasis vulgaris;	chr12:56332565	chr12:56308868~56309449:+
BRCA	cis	rs860295	0.702	rs11264375	ENSG00000203761.5	MSTO2P	3.35	0.000849	0.038	0.09	0.1	Body mass index;	chr1:155454274	chr1:155745829~155750137:+
BRCA	cis	rs4820539	0.966	rs2157709	ENSG00000211647.1	IGLV5-48	-3.35	0.000849	0.038	-0.08	-0.1	Bone mineral density;	chr22:23115233	chr22:22352940~22353433:+
BRCA	cis	rs360932	0.963	rs360913	ENSG00000270265.1	RP11-731D1.4	3.35	0.000849	0.038	0.12	0.1	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr4:151964203	chr4:151333775~151353224:-
BRCA	cis	rs873549	1	rs3910710	ENSG00000238042.4	RP11-815M8.1	3.35	0.000849	0.038	0.12	0.1	Keloid;	chr1:222094781	chr1:221880981~221978523:-
BRCA	cis	rs6918586	1	rs6918586	ENSG00000272462.2	U91328.19	3.35	0.00085	0.038	0.12	0.1	Schizophrenia;	chr6:26097156	chr6:25992662~26001775:+
BRCA	cis	rs10514758	0.744	rs72947718	ENSG00000242880.1	RP11-190P13.2	3.35	0.00085	0.038	0.25	0.1	Urate levels in obese individuals;	chr3:115162112	chr3:115251196~115285347:+
BRCA	cis	rs2502731	0.539	rs3003615	ENSG00000228510.2	RP11-339B21.8	3.35	0.00085	0.038	0.14	0.1	Attention deficit hyperactivity disorder;	chr9:128235613	chr9:128444587~128446628:+
BRCA	cis	rs4687718	0.528	rs79550721	ENSG00000274967.1	Y_RNA	3.35	0.00085	0.038	0.15	0.1	QRS duration;	chr3:53315335	chr3:53290640~53290751:+
BRCA	cis	rs986417	0.748	rs4400969	ENSG00000258670.1	RP11-1042B17.3	-3.35	0.00085	0.0381	-0.19	-0.1	Gut microbiota (bacterial taxa);	chr14:60546580	chr14:60515119~60554916:+
BRCA	cis	rs986417	0.901	rs4901989	ENSG00000258670.1	RP11-1042B17.3	-3.35	0.00085	0.0381	-0.19	-0.1	Gut microbiota (bacterial taxa);	chr14:60548025	chr14:60515119~60554916:+
BRCA	cis	rs986417	0.818	rs12883272	ENSG00000258670.1	RP11-1042B17.3	-3.35	0.00085	0.0381	-0.19	-0.1	Gut microbiota (bacterial taxa);	chr14:60548435	chr14:60515119~60554916:+
BRCA	cis	rs13068223	0.819	rs8792	ENSG00000241770.1	RP11-555M1.3	3.35	0.00085	0.0381	0.12	0.1	Age-related hearing impairment (SNP x SNP interaction);	chr3:156747639	chr3:157163452~157169133:+
BRCA	cis	rs4648045	0.828	rs230492	ENSG00000246560.2	RP11-10L12.4	-3.35	0.00085	0.0381	-0.12	-0.1	Lymphocyte percentage of white cells;	chr4:102564623	chr4:102828055~102844075:+
BRCA	cis	rs5751614	0.537	rs9608100	ENSG00000273000.4	KB-1572G7.2	3.35	0.00085	0.0381	0.11	0.1	Height;	chr22:23290070	chr22:23652860~23717347:-
BRCA	cis	rs7267979	1	rs2482927	ENSG00000274973.1	RP13-401N8.7	3.35	0.00085	0.0381	0.12	0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25346515	chr20:25845497~25845862:+
BRCA	cis	rs250518	0.926	rs13157511	ENSG00000271926.1	CTD-2376I4.1	-3.35	0.00085	0.0381	-0.14	-0.1	Mean corpuscular hemoglobin concentration;	chr5:72775976	chr5:72953635~72954274:-
BRCA	cis	rs7267979	0.866	rs2424698	ENSG00000231081.1	RP4-760C5.3	-3.35	0.00085	0.0381	-0.13	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25275470	chr20:26008791~26010531:-
BRCA	cis	rs762407	1	rs762407	ENSG00000237864.1	LINC00322	3.35	0.00085	0.0381	0.14	0.1	Systolic blood pressure change trajectories;	chr21:43761565	chr21:43322417~43332039:-
BRCA	cis	rs224278	0.509	rs7100204	ENSG00000238280.1	RP11-436D10.3	-3.35	0.00085	0.0381	-0.16	-0.1	Ewing sarcoma;	chr10:62880783	chr10:62793562~62805887:-
BRCA	cis	rs7917772	0.636	rs2486757	ENSG00000236937.2	PTGES3P4	-3.35	0.00085	0.0381	-0.14	-0.1	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;	chr10:102775388	chr10:102845595~102845950:+
BRCA	cis	rs17197037	0.505	rs3748358	ENSG00000277734.3	TRAC	-3.35	0.00085	0.0381	-0.07	-0.1	Bipolar disorder;	chr14:21321635	chr14:22281105~22552155:+
BRCA	cis	rs2839186	0.872	rs2250213	ENSG00000215424.8	MCM3AP-AS1	3.35	0.00085	0.0381	0.09	0.1	Testicular germ cell tumor;	chr21:46254361	chr21:46229217~46259390:+
BRCA	cis	rs1129187	0.837	rs3763236	ENSG00000220614.1	RP11-480N24.4	-3.35	0.000851	0.0381	-0.11	-0.1	Alzheimer's disease in APOE e4+ carriers;	chr6:42934770	chr6:43328134~43328476:+
BRCA	cis	rs965469	1	rs6139103	ENSG00000215063.3	RPL21P2	3.35	0.000851	0.0381	0.14	0.1	IFN-related cytopenia;	chr20:3380493	chr20:4059633~4060113:-
BRCA	cis	rs73215715	0.517	rs73215754	ENSG00000238358.2	RP5-1121E10.2	3.35	0.000851	0.0381	0.15	0.1	Heschl's gyrus morphology;	chr7:90015387	chr7:90119299~90122890:-
BRCA	cis	rs3105593	1	rs17645523	ENSG00000259298.1	RP11-562A8.4	3.35	0.000851	0.0381	0.09	0.1	QT interval;	chr15:50590448	chr15:50497195~50498744:-
BRCA	cis	rs17092148	1	rs6060017	ENSG00000206582.1	Y_RNA	-3.35	0.000851	0.0381	-0.15	-0.1	Neuroticism;	chr20:34725238	chr20:34526510~34526606:-
BRCA	cis	rs875971	0.895	rs10755833	ENSG00000273448.1	RP11-166O4.6	3.35	0.000851	0.0381	0.09	0.1	Aortic root size;	chr7:66448930	chr7:67333047~67334383:+
BRCA	cis	rs875971	0.895	rs1833495	ENSG00000273448.1	RP11-166O4.6	3.35	0.000851	0.0381	0.09	0.1	Aortic root size;	chr7:66456608	chr7:67333047~67334383:+
BRCA	cis	rs875971	0.964	rs6945032	ENSG00000273448.1	RP11-166O4.6	3.35	0.000851	0.0381	0.09	0.1	Aortic root size;	chr7:66457499	chr7:67333047~67334383:+
BRCA	cis	rs875971	0.929	rs12673810	ENSG00000273448.1	RP11-166O4.6	3.35	0.000851	0.0381	0.09	0.1	Aortic root size;	chr7:66458866	chr7:67333047~67334383:+
BRCA	cis	rs875971	1	rs6961155	ENSG00000273448.1	RP11-166O4.6	3.35	0.000851	0.0381	0.09	0.1	Aortic root size;	chr7:66468308	chr7:67333047~67334383:+
BRCA	cis	rs875971	1	rs7789768	ENSG00000273448.1	RP11-166O4.6	3.35	0.000851	0.0381	0.09	0.1	Aortic root size;	chr7:66473993	chr7:67333047~67334383:+
BRCA	cis	rs875971	1	rs1363055	ENSG00000273448.1	RP11-166O4.6	3.35	0.000851	0.0381	0.09	0.1	Aortic root size;	chr7:66478288	chr7:67333047~67334383:+
BRCA	cis	rs875971	0.964	rs9691480	ENSG00000273448.1	RP11-166O4.6	3.35	0.000851	0.0381	0.09	0.1	Aortic root size;	chr7:66479319	chr7:67333047~67334383:+
BRCA	cis	rs2204008	0.606	rs6582502	ENSG00000257718.1	RP11-396F22.1	-3.35	0.000851	0.0381	-0.1	-0.1	Bladder cancer;	chr12:38149550	chr12:38906451~38909592:+
BRCA	cis	rs7811142	0.83	rs7341507	ENSG00000214313.7	AZGP1P1	-3.35	0.000851	0.0381	-0.13	-0.1	Platelet count;	chr7:100353692	chr7:99980762~99987535:+
BRCA	cis	rs721917	0.506	rs2758558	ENSG00000280355.1	RP11-119F19.5	-3.35	0.000851	0.0381	-0.11	-0.1	Chronic obstructive pulmonary disease;	chr10:79923822	chr10:79681973~79684094:-
BRCA	cis	rs7943953	0.833	rs17584022	ENSG00000254717.2	GLYATL1P2	3.35	0.000851	0.0381	0.13	0.1	Odorant perception (&beta-ionone);	chr11:59423177	chr11:58878302~58893460:+
BRCA	cis	rs6493487	0.512	rs28566562	ENSG00000259298.1	RP11-562A8.4	-3.35	0.000851	0.0381	-0.12	-0.1	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr15:50821847	chr15:50497195~50498744:-
BRCA	cis	rs721917	0.525	rs1054053	ENSG00000280355.1	RP11-119F19.5	-3.35	0.000851	0.0381	-0.11	-0.1	Chronic obstructive pulmonary disease;	chr10:79922889	chr10:79681973~79684094:-
BRCA	cis	rs4886920	0.672	rs11638053	ENSG00000259792.1	RP11-114H24.6	3.35	0.000851	0.0381	0.13	0.1	Neuroticism;	chr15:77858106	chr15:77993405~77995289:+
BRCA	cis	rs4631830	0.863	rs2611489	ENSG00000204177.9	BMS1P1	-3.35	0.000851	0.0381	-0.1	-0.1	Prostate-specific antigen levels;	chr10:46070933	chr10:46786674~46811989:+
BRCA	cis	rs1555322	0.53	rs932562	ENSG00000278035.1	RP11-234K24.6	3.35	0.000851	0.0381	0.14	0.1	Attention deficit hyperactivity disorder;	chr20:35283507	chr20:36233851~36234297:+
BRCA	cis	rs964611	0.882	rs4775748	ENSG00000259488.2	RP11-154J22.1	3.35	0.000851	0.0381	0.13	0.1	Metabolite levels (Pyroglutamine);	chr15:48346598	chr15:48312353~48331856:-
BRCA	cis	rs964611	0.882	rs12917438	ENSG00000259488.2	RP11-154J22.1	3.35	0.000851	0.0381	0.13	0.1	Metabolite levels (Pyroglutamine);	chr15:48347540	chr15:48312353~48331856:-
BRCA	cis	rs7089973	0.61	rs17721905	ENSG00000236799.1	RP11-383C6.2	-3.35	0.000852	0.0381	-0.13	-0.1	Bipolar disorder or attention deficit hyperactivity disorder;	chr10:114971837	chr10:114994657~114996593:+
BRCA	cis	rs10937405	0.857	rs9812901	ENSG00000236182.1	RP11-297K7.1	-3.35	0.000852	0.0381	-0.12	-0.1	Lung adenocarcinoma;	chr3:189614015	chr3:188989382~188990135:-
BRCA	cis	rs6601327	0.606	rs4841203	ENSG00000233609.3	RP11-62H7.2	-3.35	0.000852	0.0381	-0.1	-0.1	Multiple myeloma (hyperdiploidy);	chr8:9725220	chr8:8961200~8979025:+
BRCA	cis	rs11098499	0.691	rs28396837	ENSG00000249244.1	RP11-548H18.2	3.35	0.000852	0.0381	0.12	0.1	Corneal astigmatism;	chr4:119350386	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.629	rs28369518	ENSG00000249244.1	RP11-548H18.2	3.35	0.000852	0.0381	0.12	0.1	Corneal astigmatism;	chr4:119350475	chr4:119391831~119395335:-
BRCA	cis	rs11673344	0.864	rs7260386	ENSG00000267005.1	AC002984.2	3.35	0.000852	0.0381	0.13	0.1	Obesity-related traits;	chr19:37158656	chr19:36173406~36173853:-
BRCA	cis	rs16831128	0.597	rs11894434	ENSG00000230992.3	FAM201B	-3.35	0.000852	0.0381	-0.12	-0.1	Conduct disorder;Conduct disorder (symptom count);	chr2:132321799	chr2:132352722~132353318:+
BRCA	cis	rs13260300	0.533	rs4385449	ENSG00000254349.4	FLJ39080	3.35	0.000852	0.0381	0.13	0.1	Breast cancer-free interval (treatment with aromatase inhibitor);	chr8:74582027	chr8:74599775~74823313:+
BRCA	cis	rs7121756	0.515	rs1510418	ENSG00000265566.2	RN7SL605P	3.35	0.000852	0.0381	0.13	0.1	Fractures (vertebral);	chr11:57984627	chr11:57528085~57528365:-
BRCA	cis	rs2412819	0.571	rs7174260	ENSG00000201136.1	RNU6-353P	3.35	0.000852	0.0381	0.16	0.1	Lung cancer;	chr15:43751988	chr15:43702363~43702470:+
BRCA	cis	rs4835473	0.932	rs1375986	ENSG00000246448.2	RP13-578N3.3	-3.35	0.000852	0.0381	-0.12	-0.1	Immature fraction of reticulocytes;	chr4:143746048	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.868	rs35420625	ENSG00000246448.2	RP13-578N3.3	-3.35	0.000852	0.0381	-0.12	-0.1	Immature fraction of reticulocytes;	chr4:143746089	chr4:143700257~143865072:+
BRCA	cis	rs11170468	0.621	rs10876548	ENSG00000257718.1	RP11-396F22.1	-3.35	0.000852	0.0381	-0.14	-0.1	Body mass index;	chr12:39143802	chr12:38906451~38909592:+
BRCA	cis	rs6545883	0.718	rs2694624	ENSG00000270820.4	RP11-355B11.2	3.35	0.000852	0.0381	0.12	0.1	Tuberculosis;	chr2:61445178	chr2:61471188~61484130:+
BRCA	cis	rs6671200	0.541	rs3738170	ENSG00000226026.4	RP11-57H12.3	-3.35	0.000852	0.0381	-0.16	-0.1	Stearic acid (18:0) levels;	chr1:95234048	chr1:95163219~95233982:-
BRCA	cis	rs938554	0.571	rs7696092	ENSG00000250413.1	RP11-448G15.1	-3.35	0.000852	0.0381	-0.15	-0.1	Blood metabolite levels;	chr4:10023696	chr4:10006482~10009725:+
BRCA	cis	rs6545883	0.772	rs1186709	ENSG00000270820.4	RP11-355B11.2	3.35	0.000852	0.0381	0.12	0.1	Tuberculosis;	chr2:61462245	chr2:61471188~61484130:+
BRCA	cis	rs946836	0.793	rs10890505	ENSG00000224805.2	LINC00853	-3.35	0.000852	0.0381	-0.12	-0.1	White matter integrity;	chr1:47829335	chr1:47179250~47180339:+
BRCA	cis	rs1912124	0.925	rs66933405	ENSG00000259343.4	TMC3-AS1	3.35	0.000852	0.0381	0.22	0.1	Peripheral arterial disease (traffic-related air pollution interaction);	chr15:81186444	chr15:81324377~81362037:+
BRCA	cis	rs7200543	1	rs35574015	ENSG00000270580.4	PKD1P6	3.35	0.000852	0.0381	0.12	0.1	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15052204	chr16:15104723~15131601:-
BRCA	cis	rs4950322	0.57	rs80270233	ENSG00000227242.3	NBPF13P	-3.35	0.000852	0.0381	-0.15	-0.1	Protein quantitative trait loci;	chr1:147263320	chr1:147021320~147124525:-
BRCA	cis	rs1823874	0.71	rs8042933	ENSG00000259363.4	CTD-2054N24.2	-3.34	0.000852	0.0381	-0.12	-0.1	IgG glycosylation;	chr15:99824641	chr15:99807023~99877148:+
BRCA	cis	rs2277027	1	rs3734030	ENSG00000251405.2	CTB-109A12.1	3.34	0.000852	0.0381	0.13	0.1	Pulmonary function;Pulmonary function (smoking interaction);	chr5:157512872	chr5:157362615~157460078:-
BRCA	cis	rs863345	0.604	rs1342948	ENSG00000229914.1	RP11-404O13.4	-3.34	0.000852	0.0381	-0.11	-0.1	Pneumococcal bacteremia;	chr1:158493504	chr1:158195633~158196131:-
BRCA	cis	rs6601327	0.585	rs1394	ENSG00000233609.3	RP11-62H7.2	-3.34	0.000852	0.0381	-0.1	-0.1	Multiple myeloma (hyperdiploidy);	chr8:9654144	chr8:8961200~8979025:+
BRCA	cis	rs4650994	0.593	rs10753180	ENSG00000213057.5	C1orf220	-3.34	0.000852	0.0381	-0.1	-0.1	HDL cholesterol;HDL cholesterol levels;	chr1:178551518	chr1:178542752~178548889:+
BRCA	cis	rs1046491	0.901	rs12454908	ENSG00000264964.1	RP11-888D10.3	3.34	0.000852	0.0381	0.21	0.1	Scarlet fever;	chr18:9134356	chr18:9315194~9334441:-
BRCA	cis	rs7914558	1	rs10509757	ENSG00000272912.1	RP11-724N1.1	-3.34	0.000853	0.0381	-0.11	-0.1	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102993203	chr10:102914585~102915404:+
BRCA	cis	rs2625529	0.503	rs7162299	ENSG00000261187.1	RP11-1007O24.2	3.34	0.000853	0.0381	0.11	0.1	Red blood cell count;	chr15:72121724	chr15:72465128~72466262:-
BRCA	cis	rs875971	0.893	rs62465470	ENSG00000229886.1	RP5-1132H15.3	-3.34	0.000853	0.0381	-0.12	-0.1	Aortic root size;	chr7:66136231	chr7:66025126~66031544:-
BRCA	cis	rs34779708	0.966	rs1057108	ENSG00000269952.1	RP11-324I22.3	-3.34	0.000853	0.0381	-0.14	-0.1	Inflammatory bowel disease;Crohn's disease;	chr10:35196021	chr10:35210416~35210750:+
BRCA	cis	rs4819852	1	rs2073743	ENSG00000272829.1	XXbac-B135H6.18	3.34	0.000853	0.0381	0.11	0.1	Pulse pressure;	chr22:20002089	chr22:20981361~20981755:-
BRCA	cis	rs931127	0.719	rs11227259	ENSG00000255557.1	RP11-770G2.2	3.34	0.000853	0.0382	0.12	0.1	Systemic lupus erythematosus;	chr11:65691933	chr11:65745729~65771585:+
BRCA	cis	rs8177876	0.597	rs1048194	ENSG00000261141.1	RP11-303E16.5	-3.34	0.000853	0.0382	-0.2	-0.1	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81031097	chr16:81055301~81056426:+
BRCA	cis	rs9783347	0.714	rs4757638	ENSG00000279837.1	RP11-504G3.2	-3.34	0.000853	0.0382	-0.1	-0.1	Pancreatic cancer;	chr11:18291406	chr11:18601882~18602649:+
BRCA	cis	rs6696239	0.869	rs12129704	ENSG00000227711.2	RP11-275O4.5	-3.34	0.000853	0.0382	-0.15	-0.1	Height;	chr1:227635447	chr1:227509028~227520477:-
BRCA	cis	rs1005277	0.691	rs2474558	ENSG00000272983.1	RP11-508N22.12	-3.34	0.000853	0.0382	-0.11	-0.1	Extrinsic epigenetic age acceleration;	chr10:38197213	chr10:38137337~38144399:+
BRCA	cis	rs7960483	0.627	rs4277176	ENSG00000258096.1	RP11-474P2.2	-3.34	0.000853	0.0382	-0.12	-0.1	Hypertension (SNP x SNP interaction);	chr12:45548328	chr12:46371463~46373778:+
BRCA	cis	rs8113308	0.752	rs73068868	ENSG00000269235.1	ZNF350-AS1	3.34	0.000853	0.0382	0.2	0.1	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51987748	chr19:51949134~51981367:+
BRCA	cis	rs4415084	0.652	rs10473376	ENSG00000272335.1	RP11-53O19.3	-3.34	0.000853	0.0382	-0.1	-0.1	Breast cancer;	chr5:44931126	chr5:44826076~44828592:+
BRCA	cis	rs930395	0.514	rs10473377	ENSG00000272335.1	RP11-53O19.3	-3.34	0.000853	0.0382	-0.1	-0.1	Breast cancer;	chr5:44931144	chr5:44826076~44828592:+
BRCA	cis	rs6460942	0.659	rs13247370	ENSG00000226690.5	AC005281.1	3.34	0.000853	0.0382	0.2	0.1	Coronary artery disease;	chr7:12475006	chr7:12496429~12541910:+
BRCA	cis	rs16846053	0.685	rs62188773	ENSG00000227403.1	AC009299.3	3.34	0.000853	0.0382	0.26	0.1	Blood osmolality (transformed sodium);	chr2:161879765	chr2:161244739~161249050:+
BRCA	cis	rs12344583	0.673	rs2073928	ENSG00000221676.1	RNU6ATAC	-3.34	0.000853	0.0382	-0.18	-0.1	vWF and FVIII levels;	chr9:133855308	chr9:134164439~134164564:-
BRCA	cis	rs3820068	0.581	rs58567918	ENSG00000237301.1	RP4-680D5.2	-3.34	0.000853	0.0382	-0.13	-0.1	Systolic blood pressure;	chr1:15599328	chr1:15586136~15603626:-
BRCA	cis	rs3820068	0.581	rs72645871	ENSG00000237301.1	RP4-680D5.2	-3.34	0.000853	0.0382	-0.13	-0.1	Systolic blood pressure;	chr1:15599647	chr1:15586136~15603626:-
BRCA	cis	rs3820068	0.581	rs74054797	ENSG00000237301.1	RP4-680D5.2	-3.34	0.000853	0.0382	-0.13	-0.1	Systolic blood pressure;	chr1:15599722	chr1:15586136~15603626:-
BRCA	cis	rs3820068	0.581	rs72645874	ENSG00000237301.1	RP4-680D5.2	-3.34	0.000853	0.0382	-0.13	-0.1	Systolic blood pressure;	chr1:15599743	chr1:15586136~15603626:-
BRCA	cis	rs2880765	0.835	rs4514633	ENSG00000259630.2	CTD-2262B20.1	-3.34	0.000854	0.0382	-0.12	-0.1	Coronary artery disease;	chr15:85497786	chr15:85415228~85415633:+
BRCA	cis	rs4869313	0.668	rs1230382	ENSG00000248734.2	CTD-2260A17.1	3.34	0.000854	0.0382	0.1	0.1	Pediatric autoimmune diseases;	chr5:96918650	chr5:96784777~96785999:+
BRCA	cis	rs4869313	0.642	rs1019503	ENSG00000248734.2	CTD-2260A17.1	3.34	0.000854	0.0382	0.1	0.1	Pediatric autoimmune diseases;	chr5:96919113	chr5:96784777~96785999:+
BRCA	cis	rs2625529	0.617	rs2128112	ENSG00000261187.1	RP11-1007O24.2	3.34	0.000854	0.0382	0.11	0.1	Red blood cell count;	chr15:71893945	chr15:72465128~72466262:-
BRCA	cis	rs875971	0.862	rs778680	ENSG00000106610.13	STAG3L4	-3.34	0.000854	0.0382	-0.14	-0.1	Aortic root size;	chr7:66375427	chr7:67302621~67321526:+
BRCA	cis	rs875971	0.862	rs11769079	ENSG00000106610.13	STAG3L4	-3.34	0.000854	0.0382	-0.14	-0.1	Aortic root size;	chr7:66377141	chr7:67302621~67321526:+
BRCA	cis	rs875971	0.862	rs1695820	ENSG00000106610.13	STAG3L4	-3.34	0.000854	0.0382	-0.14	-0.1	Aortic root size;	chr7:66379576	chr7:67302621~67321526:+
BRCA	cis	rs6494488	0.5	rs16948182	ENSG00000248415.1	GAPDHP61	-3.34	0.000854	0.0382	-0.2	-0.1	Coronary artery disease;	chr15:64687183	chr15:64528667~64529671:-
BRCA	cis	rs7481311	0.917	rs11030067	ENSG00000245573.6	BDNF-AS	-3.34	0.000854	0.0382	-0.12	-0.1	Weight;Body mass index;	chr11:27599385	chr11:27506838~27698174:+
BRCA	cis	rs4835473	0.932	rs6827971	ENSG00000246448.2	RP13-578N3.3	-3.34	0.000854	0.0382	-0.12	-0.1	Immature fraction of reticulocytes;	chr4:143822126	chr4:143700257~143865072:+
BRCA	cis	rs2832191	0.716	rs2297252	ENSG00000236056.1	GAPDHP14	-3.34	0.000854	0.0382	-0.11	-0.1	Dental caries;	chr21:29004783	chr21:29222321~29223257:+
BRCA	cis	rs6734238	0.739	rs7575402	ENSG00000189223.12	PAX8-AS1	3.34	0.000854	0.0382	0.14	0.1	Fibrinogen levels;C-reactive protein levels or total cholesterol levels (pleiotropy);Fibrinogen;C-reactive protein;White blood cell count;C-reactive protein levels;	chr2:113086533	chr2:113211522~113276581:+
BRCA	cis	rs962856	0.619	rs6721534	ENSG00000236605.1	AC023115.4	3.34	0.000854	0.0382	0.14	0.1	Pancreatic cancer;	chr2:67347530	chr2:67324627~67325304:+
BRCA	cis	rs77320796	1	rs11207138	ENSG00000236546.1	RP1-118J21.5	3.34	0.000854	0.0382	0.14	0.1	Platelet count;	chr1:39926485	chr1:39897745~39899098:+
BRCA	cis	rs1979679	0.842	rs7138497	ENSG00000247934.4	RP11-967K21.1	-3.34	0.000854	0.0382	-0.13	-0.1	Ossification of the posterior longitudinal ligament of the spine;	chr12:28242918	chr12:28163298~28190738:-
BRCA	cis	rs853679	0.55	rs1233701	ENSG00000226314.6	ZNF192P1	3.34	0.000854	0.0382	0.15	0.1	Depression;	chr6:28200948	chr6:28161781~28169594:+
BRCA	cis	rs6121246	0.559	rs6121172	ENSG00000230613.1	HM13-AS1	3.34	0.000854	0.0382	0.14	0.1	Mean corpuscular hemoglobin;	chr20:31708292	chr20:31567707~31573263:-
BRCA	cis	rs72627123	0.867	rs73303113	ENSG00000259065.1	RP5-1021I20.1	-3.34	0.000854	0.0382	-0.23	-0.1	Morning vs. evening chronotype;	chr14:74014365	chr14:73787360~73803270:+
BRCA	cis	rs12310956	0.532	rs7979535	ENSG00000258794.3	DUX4L27	-3.34	0.000854	0.0382	-0.15	-0.1	Morning vs. evening chronotype;	chr12:33794515	chr12:34208415~34209675:-
BRCA	cis	rs1969253	0.583	rs843370	ENSG00000272721.4	RP11-778D9.12	-3.34	0.000854	0.0382	-0.12	-0.1	Major depressive disorder;	chr3:184158034	chr3:184134019~184135238:-
BRCA	cis	rs4243971	0.516	rs6141700	ENSG00000277692.1	RP11-358N2.2	-3.34	0.000854	0.0382	-0.12	-0.1	Inflammatory bowel disease;Crohn's disease;	chr20:32394763	chr20:32355053~32355734:+
BRCA	cis	rs1555133	0.543	rs13043838	ENSG00000277692.1	RP11-358N2.2	-3.34	0.000854	0.0382	-0.12	-0.1	Monocyte count;	chr20:32396999	chr20:32355053~32355734:+
BRCA	cis	rs11098499	0.739	rs2203039	ENSG00000249244.1	RP11-548H18.2	-3.34	0.000854	0.0382	-0.12	-0.1	Corneal astigmatism;	chr4:119211192	chr4:119391831~119395335:-
BRCA	cis	rs4809760	1	rs4809760	ENSG00000224397.4	LINC01272	-3.34	0.000854	0.0382	-0.1	-0.1	Gut microbiota (beta diversity);	chr20:49838134	chr20:50267486~50279795:+
BRCA	cis	rs344364	0.511	rs2982449	ENSG00000219027.2	RPS3AP2	3.34	0.000854	0.0382	0.16	0.1	Glomerular filtration rate in chronic kidney disease;	chr16:1897877	chr16:1477830~1478583:+
BRCA	cis	rs344364	0.511	rs62040569	ENSG00000219027.2	RPS3AP2	3.34	0.000854	0.0382	0.16	0.1	Glomerular filtration rate in chronic kidney disease;	chr16:1898136	chr16:1477830~1478583:+
BRCA	cis	rs344364	0.511	rs62040571	ENSG00000219027.2	RPS3AP2	3.34	0.000854	0.0382	0.16	0.1	Glomerular filtration rate in chronic kidney disease;	chr16:1898513	chr16:1477830~1478583:+
BRCA	cis	rs344364	0.511	rs56077812	ENSG00000219027.2	RPS3AP2	3.34	0.000854	0.0382	0.16	0.1	Glomerular filtration rate in chronic kidney disease;	chr16:1898869	chr16:1477830~1478583:+
BRCA	cis	rs344364	0.511	rs12596510	ENSG00000219027.2	RPS3AP2	3.34	0.000854	0.0382	0.16	0.1	Glomerular filtration rate in chronic kidney disease;	chr16:1899479	chr16:1477830~1478583:+
BRCA	cis	rs344364	0.511	rs2982452	ENSG00000219027.2	RPS3AP2	3.34	0.000854	0.0382	0.16	0.1	Glomerular filtration rate in chronic kidney disease;	chr16:1899510	chr16:1477830~1478583:+
BRCA	cis	rs344364	0.511	rs2982453	ENSG00000219027.2	RPS3AP2	3.34	0.000854	0.0382	0.16	0.1	Glomerular filtration rate in chronic kidney disease;	chr16:1899519	chr16:1477830~1478583:+
BRCA	cis	rs344364	0.511	rs1657132	ENSG00000219027.2	RPS3AP2	3.34	0.000854	0.0382	0.16	0.1	Glomerular filtration rate in chronic kidney disease;	chr16:1899923	chr16:1477830~1478583:+
BRCA	cis	rs656900	0.765	rs599842	ENSG00000261229.4	MTHFS	-3.34	0.000854	0.0382	-0.1	-0.1	Cerebrospinal P-tau181p levels;	chr15:79819549	chr15:79843547~79897285:-
BRCA	cis	rs10186876	0.965	rs11684833	ENSG00000223658.6	AC011242.6	-3.34	0.000855	0.0382	-0.13	-0.1	Hand grip strength;	chr2:44022988	chr2:43675380~43676322:-
BRCA	cis	rs6088580	0.609	rs6059845	ENSG00000269202.1	RP4-614O4.12	-3.34	0.000855	0.0382	-0.1	-0.1	Glomerular filtration rate (creatinine);	chr20:34448695	chr20:35201747~35203288:-
BRCA	cis	rs11902236	0.544	rs5018439	ENSG00000188525.3	AC010969.1	-3.34	0.000855	0.0382	-0.12	-0.1	Prostate cancer;	chr2:9998424	chr2:10003158~10006030:-
BRCA	cis	rs224278	0.531	rs10822079	ENSG00000238280.1	RP11-436D10.3	-3.34	0.000855	0.0382	-0.14	-0.1	Ewing sarcoma;	chr10:62884407	chr10:62793562~62805887:-
BRCA	cis	rs34773007	0.514	rs2488084	ENSG00000232709.1	MARK2P9	-3.34	0.000855	0.0382	-0.16	-0.1	Type 2 diabetes;	chr10:92776096	chr10:92418667~92420875:+
BRCA	cis	rs2185341	1	rs10799748	ENSG00000218510.5	LINC00339	3.34	0.000855	0.0382	0.13	0.1	Amyotrophic lateral sclerosis;	chr1:22404018	chr1:22025188~22031223:+
BRCA	cis	rs934734	0.736	rs6738087	ENSG00000204929.10	AC074391.1	3.34	0.000855	0.0382	0.13	0.1	Rheumatoid arthritis;	chr2:65365191	chr2:65436711~66084639:+
BRCA	cis	rs6593122	0.959	rs2049411	ENSG00000235454.1	HAUS6P3	-3.34	0.000855	0.0382	-0.16	-0.1	Vaccine-related adverse events;	chr7:54139022	chr7:53862233~53863339:+
BRCA	cis	rs7662987	0.517	rs3018047	ENSG00000260641.1	RP11-1299A16.3	-3.34	0.000855	0.0382	-0.15	-0.1	Smoking initiation;	chr4:99093359	chr4:98658904~98664550:+
BRCA	cis	rs11673344	0.523	rs7245520	ENSG00000276846.1	CTD-3220F14.3	3.34	0.000855	0.0382	0.12	0.1	Obesity-related traits;	chr19:37036416	chr19:37314868~37315620:-
BRCA	cis	rs7598759	0.712	rs6740474	ENSG00000223198.1	RNU2-22P	-3.34	0.000855	0.0382	-0.12	-0.1	Noise-induced hearing loss;	chr2:231467120	chr2:231501990~231502201:-
BRCA	cis	rs7598759	0.712	rs6727510	ENSG00000223198.1	RNU2-22P	-3.34	0.000855	0.0382	-0.12	-0.1	Noise-induced hearing loss;	chr2:231467305	chr2:231501990~231502201:-
BRCA	cis	rs7598759	0.675	rs6727530	ENSG00000223198.1	RNU2-22P	-3.34	0.000855	0.0382	-0.12	-0.1	Noise-induced hearing loss;	chr2:231467347	chr2:231501990~231502201:-
BRCA	cis	rs7598759	0.712	rs10933372	ENSG00000223198.1	RNU2-22P	-3.34	0.000855	0.0382	-0.12	-0.1	Noise-induced hearing loss;	chr2:231467614	chr2:231501990~231502201:-
BRCA	cis	rs7598759	0.712	rs997400	ENSG00000223198.1	RNU2-22P	-3.34	0.000855	0.0382	-0.12	-0.1	Noise-induced hearing loss;	chr2:231468136	chr2:231501990~231502201:-
BRCA	cis	rs863345	0.604	rs6697656	ENSG00000229914.1	RP11-404O13.4	-3.34	0.000855	0.0382	-0.11	-0.1	Pneumococcal bacteremia;	chr1:158550947	chr1:158195633~158196131:-
BRCA	cis	rs224278	0.531	rs7071512	ENSG00000238280.1	RP11-436D10.3	-3.34	0.000855	0.0382	-0.15	-0.1	Ewing sarcoma;	chr10:62916880	chr10:62793562~62805887:-
BRCA	cis	rs9467773	1	rs28558133	ENSG00000224843.5	LINC00240	-3.34	0.000855	0.0382	-0.11	-0.1	Intelligence (multi-trait analysis);	chr6:26531205	chr6:26956992~27023924:+
BRCA	cis	rs2281603	0.951	rs61985707	ENSG00000259116.1	RP11-973N13.4	-3.34	0.000855	0.0382	-0.1	-0.1	Lymphocyte counts;	chr14:64512846	chr14:64514154~64540368:-
BRCA	cis	rs6517329	0.513	rs2835289	ENSG00000231106.2	LINC01436	3.34	0.000855	0.0382	0.11	0.1	Schizophrenia;	chr21:36163599	chr21:36005338~36007838:+
BRCA	cis	rs875971	0.83	rs12673450	ENSG00000271064.1	RP11-792A8.3	-3.34	0.000855	0.0382	-0.12	-0.1	Aortic root size;	chr7:66544233	chr7:66748838~66749077:-
BRCA	cis	rs687432	0.774	rs921445	ENSG00000213592.4	AP000662.9	-3.34	0.000855	0.0382	-0.15	-0.1	Parkinson's disease;	chr11:58128101	chr11:57718044~57718530:-
BRCA	cis	rs4805834	0.843	rs10418340	ENSG00000201388.1	SNORA68	-3.34	0.000855	0.0382	-0.18	-0.1	Creatinine levels;	chr19:32899890	chr19:32608337~32608469:-
BRCA	cis	rs11035577	0.632	rs4756525	ENSG00000279675.1	RP11-454H19.2	-3.34	0.000855	0.0382	-0.16	-0.1	Temperament (bipolar disorder);	chr11:39761440	chr11:40107244~40112599:-
BRCA	cis	rs6087771	0.89	rs6089056	ENSG00000230613.1	HM13-AS1	3.34	0.000855	0.0382	0.14	0.1	Putamen volume;Subcortical brain region volumes;	chr20:31737970	chr20:31567707~31573263:-
BRCA	cis	rs6121246	0.559	rs6060919	ENSG00000230613.1	HM13-AS1	3.34	0.000855	0.0382	0.14	0.1	Mean corpuscular hemoglobin;	chr20:31744119	chr20:31567707~31573263:-
BRCA	cis	rs6121246	0.559	rs6060922	ENSG00000230613.1	HM13-AS1	3.34	0.000855	0.0382	0.14	0.1	Mean corpuscular hemoglobin;	chr20:31746106	chr20:31567707~31573263:-
BRCA	cis	rs57502260	0.573	rs11228294	ENSG00000251637.5	RP11-119D9.1	-3.34	0.000855	0.0382	-0.15	-0.1	Total body bone mineral density (age 45-60);	chr11:68621099	chr11:67886477~67906350:+
BRCA	cis	rs875971	0.862	rs778686	ENSG00000106610.13	STAG3L4	-3.34	0.000855	0.0382	-0.14	-0.1	Aortic root size;	chr7:66370923	chr7:67302621~67321526:+
BRCA	cis	rs6496044	0.568	rs11632326	ENSG00000259630.2	CTD-2262B20.1	-3.34	0.000855	0.0382	-0.12	-0.1	Interstitial lung disease;	chr15:85536603	chr15:85415228~85415633:+
BRCA	cis	rs7520050	0.966	rs12405451	ENSG00000281133.1	AL355480.3	3.34	0.000855	0.0382	0.12	0.1	Reticulocyte count;Red blood cell count;	chr1:45918654	chr1:45580892~45580996:-
BRCA	cis	rs875971	1	rs12532998	ENSG00000273448.1	RP11-166O4.6	3.34	0.000855	0.0382	0.09	0.1	Aortic root size;	chr7:66502472	chr7:67333047~67334383:+
BRCA	cis	rs6058526	1	rs17266770	ENSG00000275576.1	RP5-836N17.4	3.34	0.000855	0.0382	0.16	0.1	Chronic obstructive pulmonary disease;	chr20:32135121	chr20:32116171~32116629:+
BRCA	cis	rs1730008	0.691	rs56123505	ENSG00000279311.1	RP11-170K4.2	3.34	0.000856	0.0383	0.13	0.1	Lobe attachment (rater-scored or self-reported);	chr3:158387464	chr3:158869898~158871821:+
BRCA	cis	rs1730008	0.691	rs7641036	ENSG00000279311.1	RP11-170K4.2	3.34	0.000856	0.0383	0.13	0.1	Lobe attachment (rater-scored or self-reported);	chr3:158388042	chr3:158869898~158871821:+
BRCA	cis	rs1730008	0.691	rs4680432	ENSG00000279311.1	RP11-170K4.2	3.34	0.000856	0.0383	0.13	0.1	Lobe attachment (rater-scored or self-reported);	chr3:158388724	chr3:158869898~158871821:+
BRCA	cis	rs1730008	0.691	rs73170373	ENSG00000279311.1	RP11-170K4.2	3.34	0.000856	0.0383	0.13	0.1	Lobe attachment (rater-scored or self-reported);	chr3:158393579	chr3:158869898~158871821:+
BRCA	cis	rs1730008	0.691	rs11716327	ENSG00000279311.1	RP11-170K4.2	3.34	0.000856	0.0383	0.13	0.1	Lobe attachment (rater-scored or self-reported);	chr3:158398126	chr3:158869898~158871821:+
BRCA	cis	rs12122100	0.651	rs6665411	ENSG00000206585.1	RNVU1-7	-3.34	0.000856	0.0383	-0.14	-0.1	HIV-1 control;	chr1:147075547	chr1:148038753~148038916:-
BRCA	cis	rs7694379	0.641	rs7688657	ENSG00000251411.1	RP11-397E7.4	3.34	0.000856	0.0383	0.11	0.1	Platelet count;	chr4:87241942	chr4:86913266~86914817:-
BRCA	cis	rs1056107	0.933	rs6477912	ENSG00000266315.1	MIR4668	3.34	0.000856	0.0383	0.11	0.1	Colorectal cancer;	chr9:112308937	chr9:111932100~111932169:+
BRCA	cis	rs748404	0.736	rs542036	ENSG00000166763.7	STRCP1	-3.34	0.000856	0.0383	-0.13	-0.1	Lung cancer;	chr15:43248941	chr15:43699488~43718184:-
BRCA	cis	rs7267979	0.932	rs1541061	ENSG00000277938.1	RP5-965G21.3	3.34	0.000856	0.0383	0.12	0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25540421	chr20:25229150~25231933:+
BRCA	cis	rs7474896	1	rs12358108	ENSG00000120555.12	SEPT7P9	3.34	0.000856	0.0383	0.19	0.1	Obesity (extreme);	chr10:37726679	chr10:38383069~38402916:-
BRCA	cis	rs4879656	0.564	rs1888869	ENSG00000232303.2	DFFBP1	3.34	0.000856	0.0383	0.11	0.1	Menopause (age at onset);	chr9:32998239	chr9:32566148~32567126:-
BRCA	cis	rs12714314	0.756	rs11687068	ENSG00000228613.1	AC144450.1	3.34	0.000856	0.0383	0.11	0.1	Type 2 diabetes (age of onset);	chr2:1945177	chr2:1546665~1620113:-
BRCA	cis	rs6964587	1	rs2299240	ENSG00000188693.7	CYP51A1-AS1	-3.34	0.000856	0.0383	-0.11	-0.1	Breast cancer;	chr7:92025304	chr7:92134604~92180725:+
BRCA	cis	rs6918586	0.658	rs1572982	ENSG00000272462.2	U91328.19	3.34	0.000856	0.0383	0.11	0.1	Schizophrenia;	chr6:26094139	chr6:25992662~26001775:+
BRCA	cis	rs4835473	0.932	rs28796049	ENSG00000246448.2	RP13-578N3.3	3.34	0.000856	0.0383	0.12	0.1	Immature fraction of reticulocytes;	chr4:143733990	chr4:143700257~143865072:+
BRCA	cis	rs698833	0.819	rs1372078	ENSG00000259439.2	RP11-89K21.1	-3.34	0.000856	0.0383	-0.13	-0.1	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr2:44316250	chr2:44921077~44939199:-
BRCA	cis	rs561341	1	rs564714	ENSG00000277511.1	CTD-2095E4.5	3.34	0.000856	0.0383	0.16	0.1	Hip circumference adjusted for BMI;	chr17:31991385	chr17:32127595~32128454:+
BRCA	cis	rs6456156	0.742	rs2022000	ENSG00000272549.1	RP11-351J23.2	3.34	0.000856	0.0383	0.1	0.1	Primary biliary cholangitis;	chr6:167116123	chr6:167666840~167679270:-
BRCA	cis	rs4819052	0.851	rs2236444	ENSG00000223768.1	LINC00205	-3.34	0.000856	0.0383	-0.14	-0.1	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258311	chr21:45293285~45297354:+
BRCA	cis	rs1843834	0.505	rs3820763	ENSG00000274629.1	RP11-92F20.1	3.34	0.000856	0.0383	0.13	0.1	IgE levels in asthmatics (D.p. specific);	chr2:224482553	chr2:224464682~224474500:+
BRCA	cis	rs4578769	0.802	rs66816194	ENSG00000273232.1	RP11-370A5.2	-3.34	0.000856	0.0383	-0.15	-0.1	Eosinophil percentage of white cells;	chr18:22895554	chr18:22882825~22883357:-
BRCA	cis	rs2075671	0.903	rs4727459	ENSG00000208036.1	MIR106B	3.34	0.000856	0.0383	0.14	0.1	Other erythrocyte phenotypes;	chr7:100679198	chr7:100093993~100094074:-
BRCA	cis	rs11858159	0.535	rs7497405	ENSG00000207279.1	SNORD116-24	-3.34	0.000856	0.0383	-0.11	-0.1	Platelet thrombus formation;	chr15:24571284	chr15:25094037~25094128:+
BRCA	cis	rs6430585	1	rs6732236	ENSG00000231890.6	DARS-AS1	-3.34	0.000856	0.0383	-0.15	-0.1	Corneal structure;	chr2:135743939	chr2:135985176~136022593:+
BRCA	cis	rs721917	0.506	rs4320898	ENSG00000280355.1	RP11-119F19.5	-3.34	0.000856	0.0383	-0.11	-0.1	Chronic obstructive pulmonary disease;	chr10:79891322	chr10:79681973~79684094:-
BRCA	cis	rs721917	0.506	rs4322333	ENSG00000280355.1	RP11-119F19.5	-3.34	0.000856	0.0383	-0.11	-0.1	Chronic obstructive pulmonary disease;	chr10:79891340	chr10:79681973~79684094:-
BRCA	cis	rs6943931	0.824	rs73685438	ENSG00000230658.1	KLHL7-AS1	-3.34	0.000856	0.0383	-0.14	-0.1	Diabetic kidney disease;	chr7:22380723	chr7:23101228~23105703:-
BRCA	cis	rs6943931	0.824	rs73685439	ENSG00000230658.1	KLHL7-AS1	-3.34	0.000856	0.0383	-0.14	-0.1	Diabetic kidney disease;	chr7:22380724	chr7:23101228~23105703:-
BRCA	cis	rs6943931	0.892	rs73685440	ENSG00000230658.1	KLHL7-AS1	-3.34	0.000856	0.0383	-0.14	-0.1	Diabetic kidney disease;	chr7:22380733	chr7:23101228~23105703:-
BRCA	cis	rs6929812	0.577	rs2294309	ENSG00000237154.2	MCFD2P1	3.34	0.000856	0.0383	0.12	0.1	Neuroticism (multi-trait analysis);	chr6:27516037	chr6:27407697~27407996:+
BRCA	cis	rs1144713	0.531	rs1716941	ENSG00000274964.1	RP11-817I4.1	-3.34	0.000856	0.0383	-0.14	-0.1	Obesity-related traits;	chr12:32102160	chr12:32339368~32340724:+
BRCA	cis	rs4927850	0.881	rs7624638	ENSG00000185485.13	SDHAP1	3.34	0.000856	0.0383	0.11	0.1	Pancreatic cancer;	chr3:196021858	chr3:195959748~195990318:-
BRCA	cis	rs12893668	0.572	rs1606	ENSG00000258914.1	CTD-2134A5.3	3.34	0.000856	0.0383	0.14	0.1	Reticulocyte count;	chr14:103694944	chr14:103875055~103877478:+
BRCA	cis	rs17723470	1	rs3758723	ENSG00000254427.1	RP11-430H10.1	-3.34	0.000857	0.0383	-0.14	-0.1	Thyroid hormone levels;	chr11:45221961	chr11:45355371~45366121:+
BRCA	cis	rs7267979	0.932	rs367666	ENSG00000276952.1	RP5-965G21.6	3.34	0.000857	0.0383	0.13	0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25469182	chr20:25284915~25285588:-
BRCA	cis	rs6500602	0.623	rs9929311	ENSG00000280063.1	RP11-295D4.3	3.34	0.000857	0.0383	0.08	0.1	Schizophrenia;	chr16:4460425	chr16:4346694~4348648:-
BRCA	cis	rs6929812	0.639	rs7754724	ENSG00000271755.1	RP1-153G14.4	3.34	0.000857	0.0383	0.12	0.1	Neuroticism (multi-trait analysis);	chr6:27483018	chr6:27404010~27406964:-
BRCA	cis	rs4848143	0.64	rs13426461	ENSG00000236859.5	NIFK-AS1	-3.34	0.000857	0.0383	-0.12	-0.1	Capecitabine sensitivity;	chr2:121035703	chr2:121649650~121728208:+
BRCA	cis	rs13126694	0.744	rs10005901	ENSG00000251073.1	NUDT19P5	3.34	0.000857	0.0383	0.1	0.1	Blood osmolality (transformed sodium);	chr4:158041750	chr4:158182825~158183393:+
BRCA	cis	rs149313	1	rs149313	ENSG00000272109.1	CTD-2260A17.3	3.34	0.000857	0.0383	0.12	0.1	Blood protein levels;	chr5:96734501	chr5:96804353~96806105:+
BRCA	cis	rs6028335	0.61	rs67621213	ENSG00000274825.1	RP4-616B8.5	-3.34	0.000857	0.0383	-0.13	-0.1	Alcohol and nicotine co-dependence;	chr20:38953910	chr20:38955910~38956547:+
BRCA	cis	rs74233809	0.901	rs12416331	ENSG00000213061.2	PFN1P11	3.34	0.000857	0.0383	0.23	0.1	Birth weight;	chr10:103169157	chr10:102838011~102845473:-
BRCA	cis	rs1178127	0.765	rs1178128	ENSG00000232821.1	AC003986.6	-3.34	0.000857	0.0383	-0.14	-0.1	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);	chr7:18728091	chr7:19112474~19114271:+
BRCA	cis	rs7188861	0.681	rs1345880	ENSG00000262636.1	CTD-3088G3.4	3.34	0.000857	0.0383	0.2	0.1	HDL cholesterol;	chr16:11311000	chr16:11380859~11381118:-
BRCA	cis	rs875971	0.508	rs10950045	ENSG00000271064.1	RP11-792A8.3	3.34	0.000857	0.0383	0.12	0.1	Aortic root size;	chr7:66601386	chr7:66748838~66749077:-
BRCA	cis	rs801193	0.839	rs6968619	ENSG00000271064.1	RP11-792A8.3	3.34	0.000857	0.0383	0.12	0.1	Aortic root size;	chr7:66603880	chr7:66748838~66749077:-
BRCA	cis	rs801193	0.805	rs12532355	ENSG00000271064.1	RP11-792A8.3	3.34	0.000857	0.0383	0.12	0.1	Aortic root size;	chr7:66605597	chr7:66748838~66749077:-
BRCA	cis	rs952623	0.501	rs12670003	ENSG00000233306.2	TRGV2	3.34	0.000857	0.0383	0.09	0.1	Intelligence (multi-trait analysis);	chr7:39044053	chr7:38362864~38363518:-
BRCA	cis	rs11877825	0.826	rs4121954	ENSG00000265728.1	RP11-883A18.3	-3.34	0.000857	0.0383	-0.14	-0.1	Gut microbiota (bacterial taxa);	chr18:10569716	chr18:10594590~10604798:+
BRCA	cis	rs7598759	0.712	rs6727372	ENSG00000223198.1	RNU2-22P	-3.34	0.000857	0.0383	-0.12	-0.1	Noise-induced hearing loss;	chr2:231467195	chr2:231501990~231502201:-
BRCA	cis	rs16975963	0.644	rs12151280	ENSG00000276846.1	CTD-3220F14.3	-3.34	0.000857	0.0383	-0.15	-0.1	Longevity;	chr19:37576988	chr19:37314868~37315620:-
BRCA	cis	rs889956	0.714	rs10496062	ENSG00000233251.6	AC007743.1	-3.34	0.000857	0.0383	-0.12	-0.1	Educational attainment;	chr2:57073254	chr2:56173534~56185770:-
BRCA	cis	rs2243480	1	rs427044	ENSG00000226767.1	RP11-328P23.3	-3.34	0.000857	0.0383	-0.18	-0.1	Diabetic kidney disease;	chr7:66043558	chr7:65508773~65508944:-
BRCA	cis	rs8081187	0.71	rs17803815	ENSG00000263531.1	RP13-753N3.1	-3.34	0.000857	0.0383	-0.24	-0.1	Breast cancer;	chr17:30376863	chr17:30863921~30864940:-
BRCA	cis	rs1056107	0.933	rs12376681	ENSG00000266315.1	MIR4668	3.34	0.000857	0.0383	0.11	0.1	Colorectal cancer;	chr9:112297115	chr9:111932100~111932169:+
BRCA	cis	rs72772090	0.539	rs67140788	ENSG00000272109.1	CTD-2260A17.3	3.34	0.000857	0.0383	0.2	0.1	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96780582	chr5:96804353~96806105:+
BRCA	cis	rs72772090	0.539	rs72773922	ENSG00000272109.1	CTD-2260A17.3	3.34	0.000857	0.0383	0.2	0.1	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96780956	chr5:96804353~96806105:+
BRCA	cis	rs875971	0.825	rs7384021	ENSG00000223473.2	GS1-124K5.3	-3.34	0.000857	0.0383	-0.08	-0.1	Aortic root size;	chr7:66612917	chr7:66491049~66493566:-
BRCA	cis	rs7636293	0.592	rs6801264	ENSG00000270773.1	RP13-685P2.7	3.34	0.000857	0.0383	0.14	0.1	Height;	chr3:129326435	chr3:129345411~129346164:+
BRCA	cis	rs721917	0.607	rs4319455	ENSG00000242600.5	MBL1P	3.34	0.000857	0.0383	0.12	0.1	Chronic obstructive pulmonary disease;	chr10:79979389	chr10:79904898~79950336:+
BRCA	cis	rs6088580	0.543	rs4911158	ENSG00000126005.14	MMP24-AS1	3.34	0.000857	0.0383	0.12	0.1	Glomerular filtration rate (creatinine);	chr20:34651708	chr20:35216462~35278131:-
BRCA	cis	rs1389724	0.606	rs11102163	ENSG00000231346.4	LINC01160	-3.34	0.000857	0.0383	-0.13	-0.1	Schizophrenia;	chr1:110792058	chr1:111599655~111608723:-
BRCA	cis	rs3739034	0.941	rs3886740	ENSG00000224043.6	CCNT2-AS1	-3.34	0.000858	0.0383	-0.16	-0.1	Gut microbiome composition (winter);	chr2:134726390	chr2:134735464~134918710:-
BRCA	cis	rs3809060	0.549	rs4963209	ENSG00000183242.10	WT1-AS	3.34	0.000858	0.0383	0.14	0.1	Inguinal hernia;	chr11:32483026	chr11:32435518~32458769:+
BRCA	cis	rs36051895	0.559	rs1590268	ENSG00000237711.1	RP11-39K24.13	-3.34	0.000858	0.0383	-0.12	-0.1	Pediatric autoimmune diseases;	chr9:5209433	chr9:5100236~5101009:+
BRCA	cis	rs4499344	0.73	rs10413061	ENSG00000201388.1	SNORA68	3.34	0.000858	0.0383	0.12	0.1	Mean platelet volume;	chr19:32612372	chr19:32608337~32608469:-
BRCA	cis	rs4499344	0.73	rs10410888	ENSG00000201388.1	SNORA68	3.34	0.000858	0.0383	0.12	0.1	Mean platelet volume;	chr19:32612422	chr19:32608337~32608469:-
BRCA	cis	rs4499344	0.73	rs35098593	ENSG00000201388.1	SNORA68	3.34	0.000858	0.0383	0.12	0.1	Mean platelet volume;	chr19:32613033	chr19:32608337~32608469:-
BRCA	cis	rs4499344	0.73	rs34270210	ENSG00000201388.1	SNORA68	3.34	0.000858	0.0383	0.12	0.1	Mean platelet volume;	chr19:32613039	chr19:32608337~32608469:-
BRCA	cis	rs10129255	0.913	rs28861466	ENSG00000211967.3	IGHV3-53	-3.34	0.000858	0.0383	-0.08	-0.1	Kawasaki disease;	chr14:106718572	chr14:106592676~106593347:-
BRCA	cis	rs709400	0.628	rs7155014	ENSG00000260285.1	RP11-600F24.7	3.34	0.000858	0.0383	0.1	0.1	Body mass index;	chr14:103397633	chr14:103525010~103529072:-
BRCA	cis	rs889122	0.68	rs1077220	ENSG00000267289.1	CTD-2623N2.11	-3.34	0.000858	0.0383	-0.14	-0.1	Menarche (age at onset);	chr19:9836241	chr19:9834079~9835013:-
BRCA	cis	rs875971	0.862	rs1643375	ENSG00000106610.13	STAG3L4	-3.34	0.000858	0.0383	-0.14	-0.1	Aortic root size;	chr7:66407690	chr7:67302621~67321526:+
BRCA	cis	rs6088590	0.687	rs6088582	ENSG00000276073.1	RP5-1125A11.7	-3.34	0.000858	0.0383	-0.11	-0.1	Coronary artery disease;	chr20:34698994	chr20:33985617~33988989:-
BRCA	cis	rs7918232	0.627	rs6482588	ENSG00000236983.1	LINC00614	3.34	0.000858	0.0383	0.13	0.1	Breast cancer;	chr10:27019378	chr10:26943323~26944418:-
BRCA	cis	rs9325144	0.555	rs1843867	ENSG00000257718.1	RP11-396F22.1	-3.34	0.000858	0.0383	-0.1	-0.1	Morning vs. evening chronotype;	chr12:38310053	chr12:38906451~38909592:+
BRCA	cis	rs6918586	0.658	rs198837	ENSG00000272462.2	U91328.19	3.34	0.000858	0.0383	0.11	0.1	Schizophrenia;	chr6:26113170	chr6:25992662~26001775:+
BRCA	cis	rs2692947	0.683	rs62153700	ENSG00000237510.6	AC008268.2	3.34	0.000858	0.0383	0.16	0.1	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95915590	chr2:95789654~95800166:+
BRCA	cis	rs10876993	0.928	rs10877001	ENSG00000270039.1	RP11-571M6.17	-3.34	0.000858	0.0383	-0.14	-0.1	Celiac disease or Rheumatoid arthritis;	chr12:57689294	chr12:57803838~57804415:+
BRCA	cis	rs35740288	0.539	rs11634553	ENSG00000259407.1	RP11-158M2.3	-3.34	0.000858	0.0383	-0.14	-0.1	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85793380	chr15:85744109~85750281:-
BRCA	cis	rs10934853	0.561	rs760383	ENSG00000250796.1	RP11-723O4.3	3.34	0.000858	0.0383	0.14	0.1	Prostate cancer;Prostate cancer (SNP x SNP interaction);	chr3:128400722	chr3:128869624~128870026:+
BRCA	cis	rs9907295	0.688	rs2526327	ENSG00000270871.1	AC015849.19	3.34	0.000858	0.0383	0.11	0.1	Fibroblast growth factor basic levels;	chr17:35929902	chr17:35816717~35830293:-
BRCA	cis	rs6672530	0.5	rs10916185	ENSG00000227711.2	RP11-275O4.5	-3.34	0.000858	0.0384	-0.12	-0.1	Hip circumference adjusted for BMI;	chr1:227634997	chr1:227509028~227520477:-
BRCA	cis	rs4356203	0.875	rs7939614	ENSG00000184669.7	OR7E14P	-3.34	0.000858	0.0384	-0.13	-0.1	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17058073	chr11:17013998~17053024:+
BRCA	cis	rs4356203	0.905	rs9919540	ENSG00000184669.7	OR7E14P	-3.34	0.000858	0.0384	-0.13	-0.1	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17058786	chr11:17013998~17053024:+
BRCA	cis	rs1387259	0.619	rs2130095	ENSG00000226413.2	OR8T1P	-3.34	0.000858	0.0384	-0.13	-0.1	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48244972	chr12:48442030~48442947:-
BRCA	cis	rs7598759	0.588	rs6737291	ENSG00000223198.1	RNU2-22P	-3.34	0.000858	0.0384	-0.12	-0.1	Noise-induced hearing loss;	chr2:231464848	chr2:231501990~231502201:-
BRCA	cis	rs11098499	0.913	rs35271032	ENSG00000225892.3	RP11-384K6.2	3.34	0.000859	0.0384	0.11	0.1	Corneal astigmatism;	chr4:119235504	chr4:118632274~118634759:+
BRCA	cis	rs60871478	0.636	rs4721834	ENSG00000237181.1	AC147651.4	3.34	0.000859	0.0384	0.11	0.1	Cerebrospinal P-tau181p levels;	chr7:856505	chr7:603185~608482:+
BRCA	cis	rs10129255	0.872	rs1858683	ENSG00000211958.2	IGHV3-38	3.34	0.000859	0.0384	0.08	0.1	Kawasaki disease;	chr14:106670217	chr14:106410493~106411021:-
BRCA	cis	rs17684571	0.872	rs3002009	ENSG00000231441.1	RP11-472M19.2	3.34	0.000859	0.0384	0.15	0.1	Schizophrenia;	chr6:56757983	chr6:56844002~56864078:+
BRCA	cis	rs987724	0.515	rs4315647	ENSG00000243926.1	TIPARP-AS1	3.34	0.000859	0.0384	0.14	0.1	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156941199	chr3:156671862~156674378:-
BRCA	cis	rs6792584	0.638	rs6789939	ENSG00000241316.5	SUCLG2-AS1	3.34	0.000859	0.0384	0.1	0.1	Corneal astigmatism;	chr3:67457114	chr3:67654697~67947713:+
BRCA	cis	rs6792584	0.638	rs6805028	ENSG00000241316.5	SUCLG2-AS1	3.34	0.000859	0.0384	0.1	0.1	Corneal astigmatism;	chr3:67457351	chr3:67654697~67947713:+
BRCA	cis	rs6792584	0.638	rs6802566	ENSG00000241316.5	SUCLG2-AS1	3.34	0.000859	0.0384	0.1	0.1	Corneal astigmatism;	chr3:67457369	chr3:67654697~67947713:+
BRCA	cis	rs1730008	0.623	rs62287861	ENSG00000279311.1	RP11-170K4.2	3.34	0.000859	0.0384	0.12	0.1	Lobe attachment (rater-scored or self-reported);	chr3:158483669	chr3:158869898~158871821:+
BRCA	cis	rs7208859	0.623	rs9914242	ENSG00000264538.5	SUZ12P1	-3.34	0.000859	0.0384	-0.15	-0.1	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30889227	chr17:30709299~30790908:+
BRCA	cis	rs11088226	0.681	rs2833897	ENSG00000186842.4	LINC00846	-3.34	0.000859	0.0384	-0.17	-0.1	Gastritis;	chr21:32559482	chr21:32572238~32575881:-
BRCA	cis	rs111914382	1	rs111914382	ENSG00000259087.4	RP11-356O9.2	3.34	0.000859	0.0384	0.12	0.1	Allergic disease (asthma, hay fever or eczema);	chr14:37627796	chr14:37556158~37567095:-
BRCA	cis	rs2148307	0.893	rs2038915	ENSG00000228339.1	AMD1P1	-3.34	0.000859	0.0384	-0.12	-0.1	Photic sneeze reflex;	chr10:20789138	chr10:20350049~20351100:+
BRCA	cis	rs28374715	0.662	rs28587487	ENSG00000247556.5	OIP5-AS1	3.34	0.000859	0.0384	0.12	0.1	Ulcerative colitis;	chr15:41203262	chr15:41283990~41309737:+
BRCA	cis	rs2486012	0.85	rs42962	ENSG00000237950.1	RP11-7O11.3	3.34	0.000859	0.0384	0.16	0.1	Intelligence (multi-trait analysis);	chr1:43832892	chr1:43944370~43946551:-
BRCA	cis	rs7259376	0.936	rs4932759	ENSG00000269345.1	VN1R85P	3.34	0.000859	0.0384	0.12	0.1	Menopause (age at onset);	chr19:22357303	chr19:22174766~22175191:-
BRCA	cis	rs9847710	1	rs2581817	ENSG00000242849.2	ALDOAP1	3.34	0.000859	0.0384	0.12	0.1	Ulcerative colitis;	chr3:53037781	chr3:52193170~52194785:+
BRCA	cis	rs10129255	1	rs10129255	ENSG00000211959.2	IGHV4-39	-3.34	0.000859	0.0384	-0.08	-0.1	Kawasaki disease;	chr14:106767970	chr14:106421711~106422218:-
BRCA	cis	rs1434538	0.967	rs3857227	ENSG00000271474.1	RP11-710C12.1	-3.34	0.000859	0.0384	-0.13	-0.1	Coronary artery disease;	chr4:95161842	chr4:95549129~95552457:+
BRCA	cis	rs7709909	0.72	rs6864512	ENSG00000249655.1	CTC-325J23.2	3.34	0.000859	0.0384	0.11	0.1	HDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;	chr5:80690128	chr5:80630313~80631590:-
BRCA	cis	rs7709909	0.72	rs6868774	ENSG00000249655.1	CTC-325J23.2	3.34	0.000859	0.0384	0.11	0.1	HDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;	chr5:80690144	chr5:80630313~80631590:-
BRCA	cis	rs4356203	0.875	rs527810	ENSG00000184669.7	OR7E14P	-3.34	0.000859	0.0384	-0.13	-0.1	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17179519	chr11:17013998~17053024:+
BRCA	cis	rs9467773	1	rs9467779	ENSG00000261353.1	CTA-14H9.5	3.34	0.000859	0.0384	0.1	0.1	Intelligence (multi-trait analysis);	chr6:26536459	chr6:26527063~26527404:+
BRCA	cis	rs7000551	0.715	rs34649162	ENSG00000254272.1	RP11-382J24.2	-3.34	0.000859	0.0384	-0.13	-0.1	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr8:22457217	chr8:22492631~22493044:+
BRCA	cis	rs9866825	0.967	rs7645587	ENSG00000227110.5	LMCD1-AS1	3.34	0.000859	0.0384	0.12	0.1	QT interval;	chr3:8206967	chr3:7952805~8611924:-
BRCA	cis	rs8114671	0.967	rs6088734	ENSG00000126005.14	MMP24-AS1	-3.34	0.000859	0.0384	-0.12	-0.1	Height;	chr20:35157243	chr20:35216462~35278131:-
BRCA	cis	rs853679	0.598	rs9380054	ENSG00000272009.1	RP1-313I6.12	-3.34	0.000859	0.0384	-0.15	-0.1	Depression;	chr6:28099759	chr6:28078792~28081130:-
BRCA	cis	rs4713118	0.547	rs2116981	ENSG00000272009.1	RP1-313I6.12	-3.34	0.000859	0.0384	-0.15	-0.1	Parkinson's disease;	chr6:28100173	chr6:28078792~28081130:-
BRCA	cis	rs853679	0.517	rs9368552	ENSG00000272009.1	RP1-313I6.12	-3.34	0.000859	0.0384	-0.15	-0.1	Depression;	chr6:28100648	chr6:28078792~28081130:-
BRCA	cis	rs853679	0.542	rs34131763	ENSG00000272009.1	RP1-313I6.12	-3.34	0.000859	0.0384	-0.15	-0.1	Depression;	chr6:28107222	chr6:28078792~28081130:-
BRCA	cis	rs930395	0.514	rs10070037	ENSG00000251141.4	RP11-53O19.1	-3.34	0.00086	0.0384	-0.1	-0.1	Breast cancer;	chr5:44870135	chr5:44744900~44808777:-
BRCA	cis	rs3820928	0.874	rs6706802	ENSG00000261379.1	RP11-395N3.1	3.34	0.00086	0.0384	0.1	0.1	Pulmonary function;	chr2:226986060	chr2:226804036~226805061:+
BRCA	cis	rs534126	0.778	rs6464540	ENSG00000170356.8	OR2A20P	3.34	0.00086	0.0384	0.15	0.1	Cancer;	chr7:143257810	chr7:144250045~144252957:-
BRCA	cis	rs11955398	0.502	rs34623	ENSG00000272308.1	RP11-231G3.1	-3.34	0.00086	0.0384	-0.12	-0.1	Intelligence (multi-trait analysis);	chr5:61166012	chr5:60866457~60866935:-
BRCA	cis	rs1008375	0.868	rs6816286	ENSG00000249502.1	AC006160.5	-3.34	0.00086	0.0384	-0.12	-0.1	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17696465	chr4:17587467~17614571:-
BRCA	cis	rs8054556	1	rs9924686	ENSG00000214725.6	CDIPT-AS1	-3.34	0.00086	0.0384	-0.13	-0.1	Autism spectrum disorder or schizophrenia;	chr16:29991755	chr16:29863593~29868053:+
BRCA	cis	rs2154319	0.887	rs213741	ENSG00000230638.4	RP11-486B10.4	3.34	0.00086	0.0384	0.17	0.1	Height;	chr1:41155713	chr1:41542069~41544310:+
BRCA	cis	rs875971	0.558	rs4433015	ENSG00000230189.5	GS1-124K5.2	-3.34	0.00086	0.0384	-0.08	-0.1	Aortic root size;	chr7:66174736	chr7:66409143~66490059:-
BRCA	cis	rs7577696	0.889	rs2365558	ENSG00000276334.1	AL133243.1	-3.34	0.00086	0.0384	-0.13	-0.1	Inflammatory biomarkers;	chr2:32111588	chr2:32521927~32523547:+
BRCA	cis	rs4703129	0.967	rs11241845	ENSG00000246763.5	RGMB-AS1	-3.34	0.00086	0.0384	-0.12	-0.1	Asperger disorder;	chr5:98526206	chr5:98769618~98773469:-
BRCA	cis	rs6593122	0.628	rs1404208	ENSG00000235454.1	HAUS6P3	-3.34	0.00086	0.0384	-0.14	-0.1	Vaccine-related adverse events;	chr7:54114910	chr7:53862233~53863339:+
BRCA	cis	rs7561149	0.768	rs17362581	ENSG00000270574.1	RP11-171I2.2	3.34	0.00086	0.0384	0.15	0.1	QT interval;	chr2:178852404	chr2:178578790~178580906:+
BRCA	cis	rs853679	0.517	rs9393890	ENSG00000272009.1	RP1-313I6.12	-3.34	0.00086	0.0384	-0.15	-0.1	Depression;	chr6:28096077	chr6:28078792~28081130:-
BRCA	cis	rs853679	0.517	rs9366715	ENSG00000272009.1	RP1-313I6.12	-3.34	0.00086	0.0384	-0.15	-0.1	Depression;	chr6:28096855	chr6:28078792~28081130:-
BRCA	cis	rs2235649	0.552	rs7203361	ENSG00000279520.1	RP11-20I23.2	-3.34	0.00086	0.0384	-0.11	-0.1	Blood metabolite levels;	chr16:1913084	chr16:2516658~2517999:+
BRCA	cis	rs2243480	1	rs313802	ENSG00000226767.1	RP11-328P23.3	-3.34	0.00086	0.0384	-0.18	-0.1	Diabetic kidney disease;	chr7:66051386	chr7:65508773~65508944:-
BRCA	cis	rs2243480	0.803	rs403089	ENSG00000226767.1	RP11-328P23.3	-3.34	0.00086	0.0384	-0.18	-0.1	Diabetic kidney disease;	chr7:66052736	chr7:65508773~65508944:-
BRCA	cis	rs2243480	1	rs458291	ENSG00000226767.1	RP11-328P23.3	-3.34	0.00086	0.0384	-0.18	-0.1	Diabetic kidney disease;	chr7:66055492	chr7:65508773~65508944:-
BRCA	cis	rs890448	0.796	rs293217	ENSG00000254531.1	FLJ20021	3.34	0.00086	0.0384	0.12	0.1	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101391036	chr4:101347780~101348883:+
BRCA	cis	rs890448	0.796	rs293216	ENSG00000254531.1	FLJ20021	3.34	0.00086	0.0384	0.12	0.1	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101391116	chr4:101347780~101348883:+
BRCA	cis	rs890448	0.796	rs833949	ENSG00000254531.1	FLJ20021	3.34	0.00086	0.0384	0.12	0.1	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101391363	chr4:101347780~101348883:+
BRCA	cis	rs1795240	0.837	rs7054564	ENSG00000231424.2	RP1-45C12.1	-3.34	0.00086	0.0384	-0.11	-0.1	Lentiform nucleus volume;	chr1:171077741	chr1:171247580~171251794:-
BRCA	cis	rs863345	0.604	rs10908654	ENSG00000176320.2	RP11-404O13.5	-3.34	0.00086	0.0384	-0.11	-0.1	Pneumococcal bacteremia;	chr1:158486000	chr1:158197922~158203877:-
BRCA	cis	rs78487399	0.808	rs72865267	ENSG00000234936.1	AC010883.5	3.34	0.00086	0.0384	0.15	0.1	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43499189	chr2:43229573~43233394:+
BRCA	cis	rs801193	0.66	rs974239	ENSG00000229886.1	RP5-1132H15.3	3.34	0.00086	0.0384	0.12	0.1	Aortic root size;	chr7:66748504	chr7:66025126~66031544:-
BRCA	cis	rs9368481	0.729	rs9379950	ENSG00000124549.13	BTN2A3P	-3.34	0.00086	0.0384	-0.11	-0.1	Autism spectrum disorder or schizophrenia;	chr6:26993769	chr6:26421391~26432383:+
BRCA	cis	rs910316	0.737	rs28687415	ENSG00000259138.1	RP11-950C14.7	3.34	0.000861	0.0384	0.11	0.1	Height;	chr14:75028779	chr14:75127153~75136930:+
BRCA	cis	rs4356203	0.905	rs7107283	ENSG00000184669.7	OR7E14P	3.34	0.000861	0.0384	0.13	0.1	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17067856	chr11:17013998~17053024:+
BRCA	cis	rs952623	0.501	rs1000869	ENSG00000233306.2	TRGV2	3.34	0.000861	0.0384	0.09	0.1	Intelligence (multi-trait analysis);	chr7:39042627	chr7:38362864~38363518:-
BRCA	cis	rs77688320	0.535	rs10186894	ENSG00000230799.1	AC007279.2	-3.34	0.000861	0.0384	-0.12	-0.1	Breast cancer;	chr2:201440909	chr2:201762737~201763573:+
BRCA	cis	rs10995356	0.844	rs10822099	ENSG00000238280.1	RP11-436D10.3	-3.34	0.000861	0.0384	-0.14	-0.1	Temperament;	chr10:62962272	chr10:62793562~62805887:-
BRCA	cis	rs10995356	0.844	rs10822100	ENSG00000238280.1	RP11-436D10.3	-3.34	0.000861	0.0384	-0.14	-0.1	Temperament;	chr10:62962646	chr10:62793562~62805887:-
BRCA	cis	rs7070797	0.518	rs1992625	ENSG00000237233.2	TMEM26-AS1	3.34	0.000861	0.0384	0.14	0.1	Takotsubo syndrome;	chr10:61760940	chr10:61452639~61481956:+
BRCA	cis	rs17221829	0.965	rs10830363	ENSG00000280385.1	AP000648.5	-3.34	0.000861	0.0385	-0.11	-0.1	Anxiety in major depressive disorder;	chr11:89725300	chr11:90193614~90198120:+
BRCA	cis	rs9914544	0.689	rs11078421	ENSG00000273018.4	CTD-2303H24.2	-3.34	0.000861	0.0385	-0.13	-0.1	Educational attainment (years of education);	chr17:18901072	chr17:18511221~18551705:-
BRCA	cis	rs9393813	0.529	rs4711155	ENSG00000241549.7	GUSBP2	-3.34	0.000861	0.0385	-0.11	-0.1	Bipolar disorder;	chr6:27478667	chr6:26871484~26956554:-
BRCA	cis	rs6445975	0.666	rs4390943	ENSG00000272360.1	RP11-359I18.5	-3.34	0.000861	0.0385	-0.13	-0.1	Systemic lupus erythematosus;	chr3:58390912	chr3:58490830~58491291:-
BRCA	cis	rs9399135	0.967	rs7741515	ENSG00000234084.1	RP3-388E23.2	3.34	0.000861	0.0385	0.1	0.1	Red blood cell count;	chr6:135053230	chr6:135301568~135307158:+
BRCA	cis	rs12612435	0.869	rs7573339	ENSG00000226806.1	AC011893.3	-3.34	0.000861	0.0385	-0.13	-0.1	Takotsubo syndrome;	chr2:136348050	chr2:135820191~135823087:+
BRCA	cis	rs72899227	0.74	rs3210728	ENSG00000226131.1	AC073465.3	3.34	0.000861	0.0385	0.15	0.1	Lung cancer;	chr2:173367894	chr2:173485865~173486362:-
BRCA	cis	rs3924048	0.559	rs6541038	ENSG00000221340.1	RNU6ATAC18P	3.34	0.000861	0.0385	0.13	0.1	Optic cup area;	chr1:12566181	chr1:12569972~12570072:-
BRCA	cis	rs9325144	0.56	rs1843910	ENSG00000257718.1	RP11-396F22.1	-3.34	0.000861	0.0385	-0.1	-0.1	Morning vs. evening chronotype;	chr12:38283606	chr12:38906451~38909592:+
BRCA	cis	rs1362602	0.844	rs11056101	ENSG00000214772.2	RP11-174G6.1	-3.34	0.000861	0.0385	-0.19	-0.1	Pediatric bone mineral content (radius);	chr12:14693253	chr12:14665655~14757963:+
BRCA	cis	rs2908197	0.713	rs2961037	ENSG00000205485.12	AC004980.7	3.34	0.000861	0.0385	0.11	0.1	3-hydroxypropylmercapturic acid levels in smokers;	chr7:76322895	chr7:76549360~76627982:+
BRCA	cis	rs17192198	1	rs17192198	ENSG00000258302.2	RP11-981P6.1	-3.34	0.000861	0.0385	-0.14	-0.1	Diastolic blood pressure;	chr12:89830058	chr12:89561129~89594878:+
BRCA	cis	rs17092148	1	rs6088579	ENSG00000206582.1	Y_RNA	-3.34	0.000862	0.0385	-0.15	-0.1	Neuroticism;	chr20:34696820	chr20:34526510~34526606:-
BRCA	cis	rs10464366	0.879	rs1527952	ENSG00000233306.2	TRGV2	3.34	0.000862	0.0385	0.1	0.1	IgG glycosylation;	chr7:39079720	chr7:38362864~38363518:-
BRCA	cis	rs11877825	0.826	rs4121955	ENSG00000265728.1	RP11-883A18.3	-3.34	0.000862	0.0385	-0.14	-0.1	Gut microbiota (bacterial taxa);	chr18:10569882	chr18:10594590~10604798:+
BRCA	cis	rs8180040	0.62	rs1811652	ENSG00000260236.1	RP11-708J19.1	-3.34	0.000862	0.0385	-0.09	-0.1	Colorectal cancer;	chr3:47167208	chr3:47379089~47380999:-
BRCA	cis	rs6840360	0.533	rs13147021	ENSG00000278978.1	RP11-164P12.5	3.34	0.000862	0.0385	0.12	0.1	Intelligence (multi-trait analysis);	chr4:151801536	chr4:151669786~151670503:+
BRCA	cis	rs74233809	0.892	rs11191447	ENSG00000213061.2	PFN1P11	3.34	0.000862	0.0385	0.23	0.1	Birth weight;	chr10:102892566	chr10:102838011~102845473:-
BRCA	cis	rs74233809	1	rs74233296	ENSG00000213061.2	PFN1P11	3.34	0.000862	0.0385	0.23	0.1	Birth weight;	chr10:102895593	chr10:102838011~102845473:-
BRCA	cis	rs6893300	0.542	rs3797774	ENSG00000250999.1	RP11-1379J22.5	-3.34	0.000862	0.0385	-0.12	-0.1	Resting heart rate;	chr5:179766969	chr5:179657762~179664432:+
BRCA	cis	rs6088580	0.634	rs6088483	ENSG00000269202.1	RP4-614O4.12	3.34	0.000862	0.0385	0.1	0.1	Glomerular filtration rate (creatinine);	chr20:34396908	chr20:35201747~35203288:-
BRCA	cis	rs72700829	0.593	rs4418603	ENSG00000237976.1	RP11-126K1.6	3.34	0.000862	0.0385	0.2	0.1	Schizophrenia;	chr1:151016798	chr1:151346967~151348027:+
BRCA	cis	rs748404	0.666	rs12900259	ENSG00000166763.7	STRCP1	3.34	0.000862	0.0385	0.15	0.1	Lung cancer;	chr15:43427369	chr15:43699488~43718184:-
BRCA	cis	rs748404	0.666	rs34921640	ENSG00000166763.7	STRCP1	3.34	0.000862	0.0385	0.15	0.1	Lung cancer;	chr15:43429187	chr15:43699488~43718184:-
BRCA	cis	rs748404	0.666	rs62020574	ENSG00000166763.7	STRCP1	3.34	0.000862	0.0385	0.15	0.1	Lung cancer;	chr15:43429380	chr15:43699488~43718184:-
BRCA	cis	rs6568686	0.786	rs4458728	ENSG00000255389.1	C6orf3	3.34	0.000862	0.0385	0.15	0.1	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr6:111519359	chr6:111599875~111602295:+
BRCA	cis	rs7444	0.882	rs5754387	ENSG00000234252.1	AC007308.6	-3.34	0.000862	0.0385	-0.11	-0.1	Systemic lupus erythematosus;	chr22:21620414	chr22:20723047~20725920:+
BRCA	cis	rs1670533	1	rs11247971	ENSG00000251639.2	RP11-20I20.1	3.34	0.000862	0.0385	0.16	0.1	Recombination rate (females);	chr4:1059792	chr4:1100016~1101558:-
BRCA	cis	rs1670533	1	rs10084849	ENSG00000251639.2	RP11-20I20.1	3.34	0.000862	0.0385	0.16	0.1	Recombination rate (females);	chr4:1059798	chr4:1100016~1101558:-
BRCA	cis	rs7017914	0.967	rs13274381	ENSG00000246366.5	RP11-382J12.1	3.34	0.000862	0.0385	0.11	0.1	Bone mineral density;	chr8:70852859	chr8:70608577~70663279:+
BRCA	cis	rs2486012	1	rs2486014	ENSG00000237950.1	RP11-7O11.3	-3.34	0.000862	0.0385	-0.19	-0.1	Intelligence (multi-trait analysis);	chr1:43953874	chr1:43944370~43946551:-
BRCA	cis	rs6545883	0.895	rs796597	ENSG00000273302.1	RP11-493E12.2	3.34	0.000862	0.0385	0.1	0.1	Tuberculosis;	chr2:61453925	chr2:61199979~61200769:+
BRCA	cis	rs9863	0.896	rs12311114	ENSG00000269938.1	RP11-214K3.20	3.34	0.000862	0.0385	0.11	0.1	White blood cell count;	chr12:123976156	chr12:123968023~123968579:-
BRCA	cis	rs17767294	0.708	rs72848791	ENSG00000219392.1	RP1-265C24.5	-3.34	0.000862	0.0385	-0.28	-0.1	Parkinson's disease;	chr6:28018421	chr6:28115628~28116551:+
BRCA	cis	rs4879656	0.576	rs10813945	ENSG00000236184.1	TCEA1P4	-3.34	0.000863	0.0385	-0.14	-0.1	Menopause (age at onset);	chr9:33096840	chr9:32979560~32980403:-
BRCA	cis	rs4363385	0.51	rs6587724	ENSG00000231416.1	RP11-422P24.9	3.34	0.000863	0.0385	0.11	0.1	Inflammatory skin disease;	chr1:153062025	chr1:153995632~153995960:+
BRCA	cis	rs875971	0.789	rs7808013	ENSG00000223473.2	GS1-124K5.3	-3.34	0.000863	0.0385	-0.08	-0.1	Aortic root size;	chr7:66606209	chr7:66491049~66493566:-
BRCA	cis	rs6496932	0.802	rs4843047	ENSG00000259630.2	CTD-2262B20.1	3.34	0.000863	0.0385	0.13	0.1	Central corneal thickness;Corneal structure;	chr15:85316545	chr15:85415228~85415633:+
BRCA	cis	rs6943931	1	rs9648284	ENSG00000230658.1	KLHL7-AS1	-3.34	0.000863	0.0385	-0.14	-0.1	Diabetic kidney disease;	chr7:22377595	chr7:23101228~23105703:-
BRCA	cis	rs6088580	0.634	rs6120669	ENSG00000269202.1	RP4-614O4.12	-3.34	0.000863	0.0385	-0.1	-0.1	Glomerular filtration rate (creatinine);	chr20:34517223	chr20:35201747~35203288:-
BRCA	cis	rs7520050	0.931	rs11211224	ENSG00000226957.1	RP4-533D7.4	3.34	0.000863	0.0385	0.11	0.1	Reticulocyte count;Red blood cell count;	chr1:45918716	chr1:46046818~46048368:+
BRCA	cis	rs11098499	0.644	rs17517414	ENSG00000225892.3	RP11-384K6.2	3.34	0.000863	0.0385	0.1	0.1	Corneal astigmatism;	chr4:119340946	chr4:118632274~118634759:+
BRCA	cis	rs2880765	0.835	rs56406982	ENSG00000259630.2	CTD-2262B20.1	-3.34	0.000863	0.0385	-0.12	-0.1	Coronary artery disease;	chr15:85493148	chr15:85415228~85415633:+
BRCA	cis	rs7474896	0.832	rs11011401	ENSG00000120555.12	SEPT7P9	3.34	0.000863	0.0385	0.2	0.1	Obesity (extreme);	chr10:37918490	chr10:38383069~38402916:-
BRCA	cis	rs4650994	0.593	rs7552110	ENSG00000273384.1	RP5-1098D14.1	-3.34	0.000863	0.0385	-0.14	-0.1	HDL cholesterol;HDL cholesterol levels;	chr1:178573019	chr1:178651706~178652282:+
BRCA	cis	rs4650994	0.509	rs7519794	ENSG00000273384.1	RP5-1098D14.1	-3.34	0.000863	0.0385	-0.14	-0.1	HDL cholesterol;HDL cholesterol levels;	chr1:178573255	chr1:178651706~178652282:+
BRCA	cis	rs4650994	0.55	rs12047530	ENSG00000273384.1	RP5-1098D14.1	-3.34	0.000863	0.0385	-0.14	-0.1	HDL cholesterol;HDL cholesterol levels;	chr1:178574272	chr1:178651706~178652282:+
BRCA	cis	rs875971	1	rs6460292	ENSG00000272831.1	RP11-792A8.4	-3.34	0.000863	0.0385	-0.09	-0.1	Aortic root size;	chr7:66345088	chr7:66739829~66740385:-
BRCA	cis	rs7020830	0.861	rs13295981	ENSG00000230188.1	RP11-405L18.4	-3.34	0.000863	0.0385	-0.13	-0.1	Schizophrenia;	chr9:37330070	chr9:37490421~37490893:-
BRCA	cis	rs4962416	0.916	rs12769019	ENSG00000234134.1	RP11-383C5.5	-3.34	0.000863	0.0385	-0.14	-0.1	Prostate cancer (SNP x SNP interaction);Prostate cancer;	chr10:125008758	chr10:125718771~125719365:-
BRCA	cis	rs4849845	0.678	rs3896632	ENSG00000236878.1	AC012363.7	3.34	0.000863	0.0385	0.12	0.1	Mean platelet volume;	chr2:120265920	chr2:120211054~120211715:+
BRCA	cis	rs748404	0.666	rs12911569	ENSG00000205771.5	CATSPER2P1	-3.34	0.000863	0.0385	-0.16	-0.1	Lung cancer;	chr15:43305099	chr15:43726918~43747094:-
BRCA	cis	rs1376303	0.558	rs41479949	ENSG00000205763.12	RP9P	-3.34	0.000863	0.0385	-0.18	-0.1	Intelligence (multi-trait analysis);	chr7:32906751	chr7:32916815~32943176:-
BRCA	cis	rs3816183	0.53	rs10199169	ENSG00000226491.1	FTOP1	-3.34	0.000863	0.0385	-0.12	-0.1	Hypospadias;	chr2:42616093	chr2:42797225~42798712:-
BRCA	cis	rs3096299	0.754	rs2965816	ENSG00000261118.1	RP11-104N10.1	-3.34	0.000863	0.0385	-0.11	-0.1	Multiple myeloma (IgH translocation);	chr16:89447775	chr16:89492017~89504460:-
BRCA	cis	rs71520386	0.632	rs1474349	ENSG00000179428.2	AC073072.5	3.34	0.000863	0.0385	0.12	0.1	Fibrinogen levels;	chr7:22814146	chr7:22725395~22727620:-
BRCA	cis	rs4819052	1	rs2297286	ENSG00000223768.1	LINC00205	-3.34	0.000863	0.0385	-0.15	-0.1	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45287982	chr21:45293285~45297354:+
BRCA	cis	rs6696239	1	rs7549475	ENSG00000215812.5	ZNF847P	-3.34	0.000863	0.0385	-0.14	-0.1	Height;	chr1:227586999	chr1:227696892~227706699:-
BRCA	cis	rs6466055	0.72	rs13239067	ENSG00000242154.1	RP4-778K6.3	-3.34	0.000863	0.0385	-0.14	-0.1	Schizophrenia;	chr7:105371182	chr7:105304277~105306642:+
BRCA	cis	rs911555	0.755	rs11620897	ENSG00000269940.1	RP11-73M18.7	3.34	0.000864	0.0385	0.11	0.1	Intelligence (multi-trait analysis);	chr14:103478524	chr14:103694560~103695170:+
BRCA	cis	rs12480328	1	rs7274624	ENSG00000228663.1	PSMD10P1	3.34	0.000864	0.0385	0.19	0.1	Prostate cancer;	chr20:50946563	chr20:50913731~50914411:+
BRCA	cis	rs17711722	0.74	rs7809991	ENSG00000229180.5	GS1-124K5.11	3.34	0.000864	0.0385	0.09	0.1	Calcium levels;	chr7:65941231	chr7:66526088~66542624:-
BRCA	cis	rs7735319	0.774	rs13168871	ENSG00000249572.1	CTD-2203K17.1	3.34	0.000864	0.0385	0.15	0.1	Systolic blood pressure;	chr5:33066773	chr5:33424025~33440619:-
BRCA	cis	rs12778749	0.596	rs11819232	ENSG00000224023.9	FLJ37035	3.34	0.000864	0.0385	0.14	0.1	Endometrial cancer;	chr10:126135969	chr10:125700436~125719566:-
BRCA	cis	rs11098499	0.863	rs2291185	ENSG00000225892.3	RP11-384K6.2	3.34	0.000864	0.0385	0.11	0.1	Corneal astigmatism;	chr4:119513678	chr4:118632274~118634759:+
BRCA	cis	rs75920871	0.502	rs10790166	ENSG00000254851.1	RP11-109L13.1	3.34	0.000864	0.0385	0.13	0.1	Subjective well-being;	chr11:116908783	chr11:117135528~117138582:+
BRCA	cis	rs10043228	1	rs77849630	ENSG00000271918.1	CTD-2287O16.5	-3.34	0.000864	0.0385	-0.15	-0.1	Asthma or chronic obstructive pulmonary disease;	chr5:116221203	chr5:116083807~116085416:-
BRCA	cis	rs12479064	0.724	rs11885942	ENSG00000231822.1	AC019097.7	-3.34	0.000864	0.0385	-0.12	-0.1	Chronic sinus infection;	chr2:99387702	chr2:99102018~99102752:+
BRCA	cis	rs4849845	0.653	rs34874174	ENSG00000236878.1	AC012363.7	3.34	0.000864	0.0386	0.12	0.1	Mean platelet volume;	chr2:120254404	chr2:120211054~120211715:+
BRCA	cis	rs853679	0.517	rs9393891	ENSG00000272009.1	RP1-313I6.12	-3.34	0.000864	0.0386	-0.15	-0.1	Depression;	chr6:28111382	chr6:28078792~28081130:-
BRCA	cis	rs853679	0.517	rs9468286	ENSG00000272009.1	RP1-313I6.12	-3.34	0.000864	0.0386	-0.15	-0.1	Depression;	chr6:28111650	chr6:28078792~28081130:-
BRCA	cis	rs853679	0.517	rs9380055	ENSG00000272009.1	RP1-313I6.12	-3.34	0.000864	0.0386	-0.15	-0.1	Depression;	chr6:28113851	chr6:28078792~28081130:-
BRCA	cis	rs853679	0.517	rs9368553	ENSG00000272009.1	RP1-313I6.12	-3.34	0.000864	0.0386	-0.15	-0.1	Depression;	chr6:28114487	chr6:28078792~28081130:-
BRCA	cis	rs853679	0.517	rs9368554	ENSG00000272009.1	RP1-313I6.12	-3.34	0.000864	0.0386	-0.15	-0.1	Depression;	chr6:28114933	chr6:28078792~28081130:-
BRCA	cis	rs853679	0.517	rs4713137	ENSG00000272009.1	RP1-313I6.12	-3.34	0.000864	0.0386	-0.15	-0.1	Depression;	chr6:28115743	chr6:28078792~28081130:-
BRCA	cis	rs853679	0.517	rs9348793	ENSG00000272009.1	RP1-313I6.12	-3.34	0.000864	0.0386	-0.15	-0.1	Depression;	chr6:28116411	chr6:28078792~28081130:-
BRCA	cis	rs4713118	0.586	rs6905516	ENSG00000272009.1	RP1-313I6.12	-3.34	0.000864	0.0386	-0.15	-0.1	Parkinson's disease;	chr6:28118700	chr6:28078792~28081130:-
BRCA	cis	rs4713118	0.586	rs6905522	ENSG00000272009.1	RP1-313I6.12	-3.34	0.000864	0.0386	-0.15	-0.1	Parkinson's disease;	chr6:28118701	chr6:28078792~28081130:-
BRCA	cis	rs4713118	0.586	rs9468290	ENSG00000272009.1	RP1-313I6.12	-3.34	0.000864	0.0386	-0.15	-0.1	Parkinson's disease;	chr6:28119896	chr6:28078792~28081130:-
BRCA	cis	rs8180040	0.62	rs9875235	ENSG00000280667.1	Y_RNA	3.34	0.000864	0.0386	0.12	0.1	Colorectal cancer;	chr3:47042131	chr3:47501083~47501182:+
BRCA	cis	rs7267979	0.509	rs6115218	ENSG00000276952.1	RP5-965G21.6	3.34	0.000864	0.0386	0.13	0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25585849	chr20:25284915~25285588:-
BRCA	cis	rs7226408	0.948	rs1426755	ENSG00000274849.1	RP11-49I11.4	3.34	0.000864	0.0386	0.19	0.1	Obesity-related traits;	chr18:36830868	chr18:36189824~36190272:+
BRCA	cis	rs12468226	1	rs16839149	ENSG00000272966.1	RP11-686O6.1	3.34	0.000864	0.0386	0.17	0.1	Urate levels;	chr2:202427621	chr2:202336739~202337200:+
BRCA	cis	rs8114671	0.562	rs1801310	ENSG00000279253.1	RP4-614O4.13	-3.34	0.000864	0.0386	-0.12	-0.1	Height;	chr20:34929211	chr20:35262727~35264187:-
BRCA	cis	rs258892	0.841	rs1598010	ENSG00000272525.1	RP11-79P5.9	-3.34	0.000864	0.0386	-0.13	-0.1	Small cell lung carcinoma;	chr5:72779547	chr5:73497550~73498293:-
BRCA	cis	rs9341808	0.718	rs9352801	ENSG00000233967.5	RP11-250B2.3	3.34	0.000864	0.0386	0.11	0.1	Sitting height ratio;	chr6:80107751	chr6:80443344~80465927:+
BRCA	cis	rs686320	0.748	rs673753	ENSG00000245532.5	NEAT1	-3.34	0.000864	0.0386	-0.14	-0.1	Hip circumference adjusted for BMI;	chr11:65438546	chr11:65422774~65445540:+
BRCA	cis	rs10246939	0.505	rs13236432	ENSG00000270923.1	TAS2R6P	-3.34	0.000864	0.0386	-0.11	-0.1	Bitter taste perception;	chr7:141850980	chr7:141787815~141788640:+
BRCA	cis	rs10197140	0.885	rs7355443	ENSG00000235721.1	AC013268.3	-3.34	0.000864	0.0386	-0.13	-0.1	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110880279	chr2:110007675~110010783:+
BRCA	cis	rs924712	0.844	rs973205	ENSG00000261116.1	RP3-523K23.2	3.34	0.000864	0.0386	0.12	0.1	Breast cancer;	chr6:54865151	chr6:54943167~54945099:+
BRCA	cis	rs73222236	0.782	rs9820513	ENSG00000239213.4	NCK1-AS1	3.34	0.000864	0.0386	0.11	0.1	Coronary artery disease;	chr3:136627450	chr3:136841726~136862054:-
BRCA	cis	rs7620503	1	rs2133595	ENSG00000228561.2	RP11-114M1.1	3.34	0.000864	0.0386	0.12	0.1	Corneal structure;	chr3:177585822	chr3:177683627~177691250:+
BRCA	cis	rs171748	0.649	rs12516321	ENSG00000272308.1	RP11-231G3.1	3.34	0.000864	0.0386	0.13	0.1	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:61253283	chr5:60866457~60866935:-
BRCA	cis	rs7017914	0.967	rs6982406	ENSG00000246366.5	RP11-382J12.1	3.34	0.000865	0.0386	0.11	0.1	Bone mineral density;	chr8:70742373	chr8:70608577~70663279:+
BRCA	cis	rs17407555	0.697	rs73212821	ENSG00000250413.1	RP11-448G15.1	3.34	0.000865	0.0386	0.17	0.1	Schizophrenia (age at onset);	chr4:10067827	chr4:10006482~10009725:+
BRCA	cis	rs7811142	0.83	rs6948685	ENSG00000214313.7	AZGP1P1	-3.34	0.000865	0.0386	-0.13	-0.1	Platelet count;	chr7:100372565	chr7:99980762~99987535:+
BRCA	cis	rs889956	0.747	rs2902969	ENSG00000233251.6	AC007743.1	-3.34	0.000865	0.0386	-0.12	-0.1	Educational attainment;	chr2:57016078	chr2:56173534~56185770:-
BRCA	cis	rs4805834	0.843	rs73036834	ENSG00000201388.1	SNORA68	3.34	0.000865	0.0386	0.18	0.1	Creatinine levels;	chr19:32856497	chr19:32608337~32608469:-
BRCA	cis	rs2749592	0.531	rs10764134	ENSG00000263064.2	RP11-291L22.7	-3.34	0.000865	0.0386	-0.13	-0.1	Age-related hearing impairment (SNP x SNP interaction);	chr10:37567732	chr10:38448689~38448949:+
BRCA	cis	rs35306767	0.903	rs12250937	ENSG00000229869.1	RP11-363N22.2	-3.34	0.000865	0.0386	-0.16	-0.1	Eosinophil percentage of granulocytes;	chr10:854269	chr10:933026~942743:+
BRCA	cis	rs3781264	0.848	rs6583934	ENSG00000268894.5	PLCE1-AS1	-3.34	0.000865	0.0386	-0.14	-0.1	Esophageal cancer and gastric cancer;	chr10:94309648	chr10:94279277~94287478:-
BRCA	cis	rs2243480	0.711	rs1626926	ENSG00000234585.5	CCT6P3	-3.34	0.000865	0.0386	-0.15	-0.1	Diabetic kidney disease;	chr7:65970805	chr7:65038354~65074713:+
BRCA	cis	rs67478160	0.595	rs67768834	ENSG00000269910.1	RP11-73M18.10	3.34	0.000865	0.0386	0.1	0.1	Schizophrenia;	chr14:103754748	chr14:103694516~103695050:-
BRCA	cis	rs860295	0.702	rs10796943	ENSG00000236675.1	MTX1P1	-3.34	0.000865	0.0386	-0.13	-0.1	Body mass index;	chr1:155444938	chr1:155230975~155234325:+
BRCA	cis	rs7412746	0.611	rs4509581	ENSG00000224800.1	RP11-235D19.2	-3.34	0.000865	0.0386	-0.13	-0.1	Melanoma;	chr1:150801989	chr1:150881236~150881683:-
BRCA	cis	rs7474896	1	rs7086833	ENSG00000120555.12	SEPT7P9	-3.34	0.000865	0.0386	-0.18	-0.1	Obesity (extreme);	chr10:37988097	chr10:38383069~38402916:-
BRCA	cis	rs801193	0.569	rs6951302	ENSG00000271064.1	RP11-792A8.3	3.34	0.000865	0.0386	0.12	0.1	Aortic root size;	chr7:66667525	chr7:66748838~66749077:-
BRCA	cis	rs1424638	0.655	rs2195489	ENSG00000233251.6	AC007743.1	-3.34	0.000865	0.0386	-0.12	-0.1	Intelligence (multi-trait analysis);	chr2:57027623	chr2:56173534~56185770:-
BRCA	cis	rs6142102	0.961	rs2056990	ENSG00000206582.1	Y_RNA	-3.34	0.000865	0.0386	-0.13	-0.1	Skin pigmentation;	chr20:34035658	chr20:34526510~34526606:-
BRCA	cis	rs2066819	1	rs80317430	ENSG00000257740.1	RP11-977G19.12	3.34	0.000865	0.0386	0.25	0.1	Psoriasis vulgaris;	chr12:56333921	chr12:56308868~56309449:+
BRCA	cis	rs2066819	1	rs79824801	ENSG00000257740.1	RP11-977G19.12	3.34	0.000865	0.0386	0.25	0.1	Psoriasis vulgaris;	chr12:56334353	chr12:56308868~56309449:+
BRCA	cis	rs2066819	1	rs79101914	ENSG00000257740.1	RP11-977G19.12	3.34	0.000865	0.0386	0.25	0.1	Psoriasis vulgaris;	chr12:56335955	chr12:56308868~56309449:+
BRCA	cis	rs35146811	0.735	rs2272345	ENSG00000214313.7	AZGP1P1	3.34	0.000865	0.0386	0.11	0.1	Coronary artery disease;	chr7:100199408	chr7:99980762~99987535:+
BRCA	cis	rs2704588	0.955	rs2704591	ENSG00000270720.1	RP11-84C13.2	-3.34	0.000865	0.0386	-0.15	-0.1	Longevity;	chr4:88912813	chr4:89119284~89119871:+
BRCA	cis	rs11098499	0.71	rs6851130	ENSG00000249244.1	RP11-548H18.2	-3.34	0.000866	0.0386	-0.12	-0.1	Corneal astigmatism;	chr4:119212557	chr4:119391831~119395335:-
BRCA	cis	rs6005807	0.841	rs9625492	ENSG00000272858.1	CTA-292E10.8	-3.34	0.000866	0.0386	-0.21	-0.1	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28527017	chr22:28814914~28815662:+
BRCA	cis	rs4363385	0.835	rs431242	ENSG00000272654.1	RP11-422P24.11	3.34	0.000866	0.0386	0.11	0.1	Inflammatory skin disease;	chr1:153077938	chr1:153977743~153979160:+
BRCA	cis	rs62247992	0.698	rs737351	ENSG00000227245.1	RP11-136C24.2	3.34	0.000866	0.0386	0.15	0.1	Facial morphology (factor 15, philtrum width);	chr3:43087845	chr3:43087479~43088068:+
BRCA	cis	rs6724465	0.673	rs2293081	ENSG00000272644.1	RP11-33O4.1	3.34	0.000866	0.0386	0.16	0.1	Height;	chr2:219146370	chr2:219069354~219069809:-
BRCA	cis	rs7714670	0.736	rs1565005	ENSG00000184084.7	CTD-2372A4.1	-3.34	0.000866	0.0386	-0.12	-0.1	Venous thromboembolism (SNP x SNP interaction);	chr5:73799810	chr5:73803296~73803599:-
BRCA	cis	rs71520386	0.632	rs2286509	ENSG00000179428.2	AC073072.5	3.34	0.000866	0.0386	0.12	0.1	Fibrinogen levels;	chr7:22814832	chr7:22725395~22727620:-
BRCA	cis	rs8180040	0.62	rs6414435	ENSG00000280667.1	Y_RNA	3.34	0.000866	0.0386	0.12	0.1	Colorectal cancer;	chr3:47079650	chr3:47501083~47501182:+
BRCA	cis	rs10005067	0.967	rs2869721	ENSG00000249001.4	RP11-742B18.1	-3.34	0.000866	0.0386	-0.12	-0.1	Total body bone mineral density (age 30-45);	chr4:87903344	chr4:87568035~87733956:-
BRCA	cis	rs12681366	0.683	rs56285115	ENSG00000253175.1	RP11-267M23.6	3.34	0.000866	0.0386	0.12	0.1	Nonsyndromic cleft lip with cleft palate;	chr8:94389244	chr8:94565036~94565715:+
BRCA	cis	rs2283831	0.89	rs4820685	ENSG00000224003.1	YES1P1	3.34	0.000866	0.0386	0.12	0.1	Anti-saccade response;	chr22:26555623	chr22:25647261~25649232:+
BRCA	cis	rs2274273	1	rs72718804	ENSG00000233924.1	AL160471.6	-3.34	0.000866	0.0386	-0.12	-0.1	Protein biomarker;	chr14:55163892	chr14:55004813~55005687:-
BRCA	cis	rs6089829	0.962	rs4809455	ENSG00000233017.2	RP5-908M14.5	3.34	0.000866	0.0386	0.13	0.1	Prostate cancer (SNP x SNP interaction);	chr20:63029429	chr20:62427827~62447621:+
BRCA	cis	rs6089829	0.855	rs4809459	ENSG00000233017.2	RP5-908M14.5	3.34	0.000866	0.0386	0.13	0.1	Prostate cancer (SNP x SNP interaction);	chr20:63029993	chr20:62427827~62447621:+
BRCA	cis	rs6089829	0.851	rs4809460	ENSG00000233017.2	RP5-908M14.5	3.34	0.000866	0.0386	0.13	0.1	Prostate cancer (SNP x SNP interaction);	chr20:63030003	chr20:62427827~62447621:+
BRCA	cis	rs2991971	0.967	rs512026	ENSG00000281133.1	AL355480.3	3.34	0.000866	0.0386	0.12	0.1	High light scatter reticulocyte count;	chr1:45544274	chr1:45580892~45580996:-
BRCA	cis	rs17711722	0.727	rs1880555	ENSG00000273142.1	RP11-458F8.4	-3.34	0.000866	0.0386	-0.09	-0.1	Calcium levels;	chr7:65967580	chr7:66902857~66906297:+
BRCA	cis	rs80226907	0.634	rs17743484	ENSG00000186615.9	KTN1-AS1	-3.34	0.000866	0.0386	-0.21	-0.1	Mean platelet volume;	chr14:55430780	chr14:55499278~55580110:-
BRCA	cis	rs7267979	1	rs13038834	ENSG00000231081.1	RP4-760C5.3	-3.34	0.000866	0.0386	-0.13	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25460797	chr20:26008791~26010531:-
BRCA	cis	rs875971	1	rs7781698	ENSG00000272831.1	RP11-792A8.4	3.34	0.000867	0.0386	0.09	0.1	Aortic root size;	chr7:66431325	chr7:66739829~66740385:-
BRCA	cis	rs4665809	0.887	rs2384324	ENSG00000231655.1	AC011742.3	3.34	0.000867	0.0387	0.16	0.1	Gut microbiome composition (summer);	chr2:26131370	chr2:26140263~26141264:-
BRCA	cis	rs8127691	0.967	rs4317019	ENSG00000225331.1	AP001055.6	3.34	0.000867	0.0387	0.12	0.1	Inflammatory bowel disease;	chr21:44196392	chr21:44158740~44160076:-
BRCA	cis	rs6696239	1	rs12140848	ENSG00000227711.2	RP11-275O4.5	-3.34	0.000867	0.0387	-0.14	-0.1	Height;	chr1:227589241	chr1:227509028~227520477:-
BRCA	cis	rs6696239	0.955	rs12129894	ENSG00000227711.2	RP11-275O4.5	-3.34	0.000867	0.0387	-0.14	-0.1	Height;	chr1:227589287	chr1:227509028~227520477:-
BRCA	cis	rs9990174	0.515	rs1919075	ENSG00000186162.9	CIDECP	3.34	0.000867	0.0387	0.13	0.1	Conduct disorder (maternal expressed emotions interaction);	chr3:11001333	chr3:10014238~10026365:-
BRCA	cis	rs6599077	0.756	rs4676460	ENSG00000223797.4	ENTPD3-AS1	3.34	0.000867	0.0387	0.11	0.1	Sleep-related phenotypes;	chr3:40049322	chr3:40313802~40453329:-
BRCA	cis	rs4699052	0.507	rs6533085	ENSG00000230069.3	LRRC37A15P	-3.34	0.000867	0.0387	-0.11	-0.1	Testicular germ cell tumor;	chr4:103360429	chr4:102727274~102730721:-
BRCA	cis	rs3743266	0.634	rs7165874	ENSG00000245534.5	RORA-AS1	-3.34	0.000867	0.0387	-0.11	-0.1	Menarche (age at onset);	chr15:60492410	chr15:60479178~60630637:+
BRCA	cis	rs10504130	0.569	rs2069119	ENSG00000272076.1	RP11-11C20.3	3.34	0.000867	0.0387	0.15	0.1	Venous thromboembolism (SNP x SNP interaction);	chr8:51773876	chr8:51810110~51810681:-
BRCA	cis	rs10504130	0.569	rs35603537	ENSG00000272076.1	RP11-11C20.3	3.34	0.000867	0.0387	0.15	0.1	Venous thromboembolism (SNP x SNP interaction);	chr8:51773899	chr8:51810110~51810681:-
BRCA	cis	rs10504130	0.502	rs71513552	ENSG00000272076.1	RP11-11C20.3	3.34	0.000867	0.0387	0.15	0.1	Venous thromboembolism (SNP x SNP interaction);	chr8:51776662	chr8:51810110~51810681:-
BRCA	cis	rs7620503	1	rs1463859	ENSG00000228561.2	RP11-114M1.1	3.34	0.000867	0.0387	0.12	0.1	Corneal structure;	chr3:177580283	chr3:177683627~177691250:+
BRCA	cis	rs6678639	0.522	rs12406683	ENSG00000225154.2	RP11-184J23.2	-3.34	0.000867	0.0387	-0.16	-0.1	Blood metabolite ratios;	chr1:47037042	chr1:47074778~47075979:-
BRCA	cis	rs12282928	0.743	rs1354294	ENSG00000255197.4	RP11-750H9.5	3.34	0.000867	0.0387	0.09	0.1	Migraine - clinic-based;	chr11:48210996	chr11:47383148~47409190:-
BRCA	cis	rs7017914	0.934	rs7015035	ENSG00000246366.5	RP11-382J12.1	3.34	0.000867	0.0387	0.11	0.1	Bone mineral density;	chr8:70741366	chr8:70608577~70663279:+
BRCA	cis	rs10132760	0.774	rs8003447	ENSG00000255569.1	TRAV1-1	3.34	0.000867	0.0387	0.11	0.1	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;	chr14:21721018	chr14:21621838~21622567:+
BRCA	cis	rs4449834	0.851	rs4738827	ENSG00000254432.1	RP11-33I11.2	-3.34	0.000867	0.0387	-0.14	-0.1	Sum eosinophil basophil counts;	chr8:60806961	chr8:60808735~60809606:-
BRCA	cis	rs7989336	0.663	rs8000148	ENSG00000247400.3	DNAJC3-AS1	-3.34	0.000867	0.0387	-0.11	-0.1	Obesity;	chr13:96323314	chr13:95648733~95676925:-
BRCA	cis	rs910316	0.789	rs175444	ENSG00000259138.1	RP11-950C14.7	-3.34	0.000867	0.0387	-0.11	-0.1	Height;	chr14:75135079	chr14:75127153~75136930:+
BRCA	cis	rs115769866	0.609	rs974334	ENSG00000220721.1	OR1F12	3.34	0.000867	0.0387	0.13	0.1	Bipolar disorder;	chr6:28506441	chr6:28073316~28074233:+
BRCA	cis	rs2531992	1	rs2531992	ENSG00000263072.4	ZNF213-AS1	3.34	0.000867	0.0387	0.12	0.1	Waist circumference;	chr16:3971733	chr16:3116042~3134882:-
BRCA	cis	rs6108958	0.833	rs2103761	ENSG00000235036.4	RP5-1099D15.1	-3.34	0.000867	0.0387	-0.11	-0.1	Gut microbiome composition (summer);	chr20:11416214	chr20:10612861~10614229:-
BRCA	cis	rs6432860	0.545	rs13398150	ENSG00000232411.1	AC009495.3	-3.34	0.000867	0.0387	-0.12	-0.1	Febrile seizures (MMR vaccine-unrelated);Febrile seizures;	chr2:166060447	chr2:165833048~165839098:-
BRCA	cis	rs372883	0.967	rs1153287	ENSG00000176054.6	RPL23P2	-3.34	0.000867	0.0387	-0.11	-0.1	Pancreatic cancer;	chr21:29313290	chr21:28997613~28998033:-
BRCA	cis	rs77688320	0.553	rs10804114	ENSG00000242696.3	RN7SL40P	-3.34	0.000868	0.0387	-0.11	-0.1	Breast cancer;	chr2:201402139	chr2:202357076~202357417:-
BRCA	cis	rs2832191	0.74	rs13048618	ENSG00000236056.1	GAPDHP14	-3.34	0.000868	0.0387	-0.11	-0.1	Dental caries;	chr21:29086363	chr21:29222321~29223257:+
BRCA	cis	rs6946131	0.593	rs2699240	ENSG00000235207.1	TUBBP6	-3.34	0.000868	0.0387	-0.13	-0.1	Systemic lupus erythematosus;	chr7:54775430	chr7:55645620~55646951:+
BRCA	cis	rs6121246	0.559	rs1062794	ENSG00000230613.1	HM13-AS1	3.34	0.000868	0.0387	0.14	0.1	Mean corpuscular hemoglobin;	chr20:31793955	chr20:31567707~31573263:-
BRCA	cis	rs6430585	1	rs6430585	ENSG00000231890.6	DARS-AS1	3.34	0.000868	0.0387	0.14	0.1	Corneal structure;	chr2:135749357	chr2:135985176~136022593:+
BRCA	cis	rs11587682	0.714	rs41264059	ENSG00000228126.1	FALEC	3.34	0.000868	0.0387	0.14	0.1	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr1:150488366	chr1:150515757~150518032:+
BRCA	cis	rs11587682	0.714	rs41264139	ENSG00000228126.1	FALEC	3.34	0.000868	0.0387	0.14	0.1	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr1:150488374	chr1:150515757~150518032:+
BRCA	cis	rs11098499	0.739	rs6534130	ENSG00000249244.1	RP11-548H18.2	-3.34	0.000868	0.0387	-0.12	-0.1	Corneal astigmatism;	chr4:119210184	chr4:119391831~119395335:-
BRCA	cis	rs3822625	1	rs16886448	ENSG00000271828.1	CTD-2310F14.1	3.34	0.000868	0.0387	0.22	0.1	Breast cancer (early onset);	chr5:56874986	chr5:56927874~56929573:+
BRCA	cis	rs6736093	0.871	rs35471545	ENSG00000243389.1	AC012442.5	-3.34	0.000868	0.0387	-0.14	-0.1	Coronary artery disease;	chr2:111999134	chr2:112589040~112614431:+
BRCA	cis	rs11098499	0.955	rs13129661	ENSG00000260404.2	RP11-384K6.6	3.34	0.000868	0.0387	0.1	0.1	Corneal astigmatism;	chr4:119231754	chr4:118591773~118633729:+
BRCA	cis	rs863345	0.604	rs4313395	ENSG00000176320.2	RP11-404O13.5	-3.34	0.000868	0.0387	-0.11	-0.1	Pneumococcal bacteremia;	chr1:158535345	chr1:158197922~158203877:-
BRCA	cis	rs3018066	0.867	rs60538413	ENSG00000249635.1	RP11-710F7.3	3.34	0.000868	0.0387	0.12	0.1	Cancer;	chr4:106031078	chr4:106003317~106022478:-
BRCA	cis	rs875971	0.862	rs778702	ENSG00000106610.13	STAG3L4	-3.34	0.000868	0.0387	-0.14	-0.1	Aortic root size;	chr7:66399848	chr7:67302621~67321526:+
BRCA	cis	rs4356203	0.87	rs7342262	ENSG00000184669.7	OR7E14P	-3.34	0.000868	0.0387	-0.13	-0.1	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17264260	chr11:17013998~17053024:+
BRCA	cis	rs9341808	0.718	rs35447745	ENSG00000233967.5	RP11-250B2.3	3.34	0.000868	0.0387	0.11	0.1	Sitting height ratio;	chr6:80107031	chr6:80443344~80465927:+
BRCA	cis	rs7017914	0.967	rs34905858	ENSG00000246366.5	RP11-382J12.1	3.34	0.000868	0.0387	0.11	0.1	Bone mineral density;	chr8:70747215	chr8:70608577~70663279:+
BRCA	cis	rs7017914	0.934	rs6998024	ENSG00000246366.5	RP11-382J12.1	3.34	0.000868	0.0387	0.11	0.1	Bone mineral density;	chr8:70748605	chr8:70608577~70663279:+
BRCA	cis	rs2985684	0.948	rs2883437	ENSG00000258568.1	RHOQP1	3.34	0.000868	0.0387	0.13	0.1	Carotid intima media thickness;	chr14:49564948	chr14:49599994~49600572:+
BRCA	cis	rs2692947	0.566	rs11676901	ENSG00000232931.4	LINC00342	3.34	0.000868	0.0387	0.11	0.1	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95704823	chr2:95807118~95816215:-
BRCA	cis	rs490234	0.783	rs10986848	ENSG00000232630.1	PRPS1P2	-3.34	0.000868	0.0387	-0.1	-0.1	Mean arterial pressure;	chr9:125699610	chr9:125150653~125151589:+
BRCA	cis	rs984222	0.967	rs10923713	ENSG00000231365.4	RP11-418J17.1	-3.34	0.000868	0.0387	-0.12	-0.1	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:118967864	chr1:119140396~119275973:+
BRCA	cis	rs12449964	0.524	rs4925094	ENSG00000223979.2	SMCR2	3.34	0.000869	0.0387	0.12	0.1	Coronary artery disease or ischemic stroke;	chr17:17665698	chr17:17674026~17677688:-
BRCA	cis	rs2518049	0.852	rs7071638	ENSG00000224034.1	RP11-445P17.8	3.34	0.000869	0.0387	0.19	0.1	Metabolic traits;	chr10:5076650	chr10:5266033~5271236:-
BRCA	cis	rs2301573	0.504	rs16864090	ENSG00000271270.4	TMCC1-AS1	-3.34	0.000869	0.0387	-0.23	-0.1	Hip circumference;	chr3:129912163	chr3:129893871~129918575:+
BRCA	cis	rs13136331	0.532	rs2615478	ENSG00000249001.4	RP11-742B18.1	3.34	0.000869	0.0387	0.14	0.1	Sitting height ratio;	chr4:87657920	chr4:87568035~87733956:-
BRCA	cis	rs13136331	0.532	rs2615477	ENSG00000249001.4	RP11-742B18.1	3.34	0.000869	0.0387	0.14	0.1	Sitting height ratio;	chr4:87658651	chr4:87568035~87733956:-
BRCA	cis	rs860818	1	rs858277	ENSG00000230658.1	KLHL7-AS1	3.34	0.000869	0.0387	0.29	0.1	Initial pursuit acceleration;	chr7:23212642	chr7:23101228~23105703:-
BRCA	cis	rs6142102	0.961	rs2300204	ENSG00000206582.1	Y_RNA	-3.34	0.000869	0.0387	-0.12	-0.1	Skin pigmentation;	chr20:34000967	chr20:34526510~34526606:-
BRCA	cis	rs4947019	1	rs12192279	ENSG00000232311.1	RP1-249I4.2	3.34	0.000869	0.0387	0.21	0.1	Hematological parameters;	chr6:109734110	chr6:109826522~109828785:+
BRCA	cis	rs879500	0.653	rs4545899	ENSG00000266296.1	ARIH2P1	-3.34	0.000869	0.0387	-0.15	-0.1	Lung function (FVC);	chr18:28488659	chr18:28651732~28653208:+
BRCA	cis	rs879500	0.653	rs4619479	ENSG00000266296.1	ARIH2P1	-3.34	0.000869	0.0387	-0.15	-0.1	Lung function (FVC);	chr18:28488785	chr18:28651732~28653208:+
BRCA	cis	rs6582630	0.593	rs11182590	ENSG00000257718.1	RP11-396F22.1	3.34	0.000869	0.0387	0.11	0.1	Drug-induced liver injury (flucloxacillin);	chr12:38180472	chr12:38906451~38909592:+
BRCA	cis	rs17221829	0.673	rs10830330	ENSG00000280385.1	AP000648.5	-3.34	0.000869	0.0387	-0.12	-0.1	Anxiety in major depressive disorder;	chr11:89659631	chr11:90193614~90198120:+
BRCA	cis	rs9584850	0.834	rs745639	ENSG00000231194.1	FARP1-AS1	3.34	0.000869	0.0387	0.13	0.1	Neuroticism;	chr13:98467025	chr13:98435405~98435840:-
BRCA	cis	rs3743102	1	rs8023873	ENSG00000278603.1	RP13-608F4.5	-3.34	0.000869	0.0387	-0.17	-0.1	Colorectal adenoma (advanced);	chr15:82758932	chr15:82472203~82472426:+
BRCA	cis	rs9840812	0.906	rs61791757	ENSG00000239213.4	NCK1-AS1	-3.34	0.000869	0.0387	-0.13	-0.1	Fibrinogen levels;	chr3:136186483	chr3:136841726~136862054:-
BRCA	cis	rs12530	0.54	rs737779	ENSG00000230736.2	RP1-149A16.3	-3.34	0.000869	0.0387	-0.11	-0.1	IgG glycosylation;	chr22:32400260	chr22:32376664~32384343:+
BRCA	cis	rs6452790	0.543	rs10061518	ENSG00000247828.6	TMEM161B-AS1	-3.34	0.000869	0.0387	-0.15	-0.1	Cognitive function;	chr5:88066292	chr5:88268895~88436685:+
BRCA	cis	rs10419113	0.641	rs61333077	ENSG00000268379.1	CTC-360J11.4	3.34	0.000869	0.0388	0.12	0.1	Pediatric bone mineral density (spine);	chr19:57766589	chr19:57175233~57177921:+
BRCA	cis	rs10792665	0.844	rs10751084	ENSG00000246067.6	RAB30-AS1	-3.34	0.00087	0.0388	-0.11	-0.1	Obesity-related traits;	chr11:82971876	chr11:83072066~83106719:+
BRCA	cis	rs12413361	0.967	rs10826875	ENSG00000272914.1	RP11-330O11.3	-3.34	0.00087	0.0388	-0.13	-0.1	Height;	chr10:30830785	chr10:30831828~30833387:-
BRCA	cis	rs4819052	0.851	rs35064782	ENSG00000223768.1	LINC00205	-3.34	0.00087	0.0388	-0.14	-0.1	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45254445	chr21:45293285~45297354:+
BRCA	cis	rs752010	0.695	rs10890155	ENSG00000230638.4	RP11-486B10.4	-3.34	0.00087	0.0388	-0.12	-0.1	Lupus nephritis in systemic lupus erythematosus;	chr1:41642172	chr1:41542069~41544310:+
BRCA	cis	rs10783487	0.749	rs3817606	ENSG00000257542.4	OR7E47P	-3.34	0.00087	0.0388	-0.13	-0.1	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr12:52091857	chr12:52079696~52108261:+
BRCA	cis	rs6142618	0.543	rs6142632	ENSG00000275576.1	RP5-836N17.4	-3.34	0.00087	0.0388	-0.12	-0.1	Inflammatory bowel disease;	chr20:32182645	chr20:32116171~32116629:+
BRCA	cis	rs739496	0.615	rs11609628	ENSG00000257624.1	RP1-128M12.3	3.34	0.00087	0.0388	0.15	0.1	Platelet count;	chr12:111779404	chr12:112000739~112000985:-
BRCA	cis	rs72775230	0.733	rs72775244	ENSG00000233990.1	RP11-401E9.3	-3.34	0.00087	0.0388	-0.18	-0.1	Conotruncal heart defects (inherited effects);	chr10:8520453	chr10:7833618~7833957:-
BRCA	cis	rs6568686	0.732	rs6932122	ENSG00000255389.1	C6orf3	3.34	0.00087	0.0388	0.13	0.1	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr6:111524367	chr6:111599875~111602295:+
BRCA	cis	rs2154490	0.853	rs2186305	ENSG00000176054.6	RPL23P2	-3.34	0.00087	0.0388	-0.11	-0.1	Glucocorticoid-induced osteonecrosis;	chr21:29543953	chr21:28997613~28998033:-
BRCA	cis	rs8062405	0.558	rs231976	ENSG00000275441.1	RP11-666O2.2	3.34	0.00087	0.0388	0.09	0.1	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28534266	chr16:28553709~28554140:-
BRCA	cis	rs28489187	0.643	rs1884139	ENSG00000223653.4	RP11-131L23.1	3.34	0.00087	0.0388	0.12	0.1	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85380315	chr1:85276715~85448124:+
BRCA	cis	rs4304977	0.763	rs2387689	ENSG00000258741.3	RP11-386M24.4	3.34	0.00087	0.0388	0.12	0.1	DNA methylation (variation);	chr15:92231568	chr15:92715710~92734195:-
BRCA	cis	rs875971	0.522	rs2008188	ENSG00000232559.3	GS1-124K5.12	3.34	0.00087	0.0388	0.12	0.1	Aortic root size;	chr7:65964026	chr7:66554588~66576923:-
BRCA	cis	rs6691170	0.861	rs7544478	ENSG00000238042.4	RP11-815M8.1	-3.34	0.00087	0.0388	-0.11	-0.1	Colorectal cancer;	chr1:221866373	chr1:221880981~221978523:-
BRCA	cis	rs4927850	0.958	rs1975582	ENSG00000273009.1	RP11-352G9.1	-3.34	0.00087	0.0388	-0.12	-0.1	Pancreatic cancer;	chr3:196024568	chr3:195913078~195913683:-
BRCA	cis	rs10782582	0.593	rs12129523	ENSG00000181227.3	RP4-682C21.2	3.34	0.00087	0.0388	0.11	0.1	Daytime sleep phenotypes;	chr1:75663538	chr1:75743423~75744776:-
BRCA	cis	rs853679	0.567	rs13209596	ENSG00000273712.1	RP5-874C20.7	3.34	0.00087	0.0388	0.15	0.1	Depression;	chr6:28428413	chr6:28315613~28315883:-
BRCA	cis	rs13108904	0.901	rs4974594	ENSG00000211482.1	AC092574.1	-3.34	0.00087	0.0388	-0.12	-0.1	Obesity-related traits;	chr4:1306692	chr4:409809~409915:+
BRCA	cis	rs7017914	0.967	rs1902614	ENSG00000246366.5	RP11-382J12.1	3.34	0.00087	0.0388	0.11	0.1	Bone mineral density;	chr8:70743932	chr8:70608577~70663279:+
BRCA	cis	rs3015497	0.575	rs8023035	ENSG00000259113.1	RP11-406H23.2	-3.34	0.000871	0.0388	-0.12	-0.1	Mean platelet volume;	chr14:50695701	chr14:50448807~50456742:+
BRCA	cis	rs10129255	0.83	rs61997609	ENSG00000253936.1	IGHV3-63	3.34	0.000871	0.0388	0.09	0.1	Kawasaki disease;	chr14:106692376	chr14:106652237~106652681:-
BRCA	cis	rs2638953	0.924	rs11049607	ENSG00000273989.1	RP11-425D17.2	-3.34	0.000871	0.0388	-0.15	-0.1	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28444574	chr12:28236227~28236828:+
BRCA	cis	rs17581137	0.591	rs4321146	ENSG00000259542.4	RP11-522B15.4	-3.34	0.000871	0.0388	-0.11	-0.1	Coronary artery disease;	chr15:95635587	chr15:96393146~96405189:-
BRCA	cis	rs1167827	0.68	rs1167796	ENSG00000123965.13	PMS2P5	-3.34	0.000871	0.0388	-0.15	-0.1	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75543861	chr7:74894116~74897835:+
BRCA	cis	rs9307239	0.533	rs12502290	ENSG00000246090.5	RP11-696N14.1	3.34	0.000871	0.0388	0.1	0.1	Alcohol dependence;	chr4:99395509	chr4:99088857~99301356:+
BRCA	cis	rs765787	0.53	rs12905246	ENSG00000259539.1	CTD-2651B20.1	-3.34	0.000871	0.0388	-0.13	-0.1	Uric acid levels;	chr15:45208643	chr15:45152664~45167526:-
BRCA	cis	rs6142102	1	rs6059672	ENSG00000206582.1	Y_RNA	-3.34	0.000871	0.0388	-0.13	-0.1	Skin pigmentation;	chr20:34117662	chr20:34526510~34526606:-
BRCA	cis	rs1555133	0.92	rs6058714	ENSG00000277692.1	RP11-358N2.2	-3.34	0.000871	0.0388	-0.11	-0.1	Monocyte count;	chr20:32481080	chr20:32355053~32355734:+
BRCA	cis	rs7017914	0.967	rs7814648	ENSG00000246366.5	RP11-382J12.1	3.34	0.000871	0.0388	0.11	0.1	Bone mineral density;	chr8:70691749	chr8:70608577~70663279:+
BRCA	cis	rs10911902	0.643	rs1406294	ENSG00000229739.2	RP11-295K2.3	-3.34	0.000871	0.0388	-0.14	-0.1	Schizophrenia;	chr1:186314293	chr1:186435161~186470291:+
BRCA	cis	rs10911902	0.643	rs76559138	ENSG00000229739.2	RP11-295K2.3	-3.34	0.000871	0.0388	-0.14	-0.1	Schizophrenia;	chr1:186314891	chr1:186435161~186470291:+
BRCA	cis	rs1005277	0.579	rs2008449	ENSG00000276805.1	RP11-291L22.6	-3.34	0.000871	0.0388	-0.11	-0.1	Extrinsic epigenetic age acceleration;	chr10:38125276	chr10:38451030~38451785:+
BRCA	cis	rs2882667	0.722	rs2011462	ENSG00000242683.1	CTB-46B19.1	-3.34	0.000871	0.0388	-0.12	-0.1	Age-related hearing impairment (SNP x SNP interaction);	chr5:138827083	chr5:139035148~139035987:-
BRCA	cis	rs7577696	0.962	rs6738349	ENSG00000276334.1	AL133243.1	-3.34	0.000871	0.0388	-0.13	-0.1	Inflammatory biomarkers;	chr2:32089062	chr2:32521927~32523547:+
BRCA	cis	rs1193	0.837	rs9309636	ENSG00000266931.1	RP11-1252D15.1	-3.34	0.000871	0.0388	-0.12	-0.1	High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;High light scatter reticulocyte count;	chr2:86748847	chr2:87055658~87055800:-
BRCA	cis	rs1193	0.837	rs9309637	ENSG00000266931.1	RP11-1252D15.1	-3.34	0.000871	0.0388	-0.12	-0.1	High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;High light scatter reticulocyte count;	chr2:86749116	chr2:87055658~87055800:-
BRCA	cis	rs1193	0.837	rs9309638	ENSG00000266931.1	RP11-1252D15.1	-3.34	0.000871	0.0388	-0.12	-0.1	High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;High light scatter reticulocyte count;	chr2:86749225	chr2:87055658~87055800:-
BRCA	cis	rs4927850	0.957	rs4927851	ENSG00000273009.1	RP11-352G9.1	-3.34	0.000871	0.0388	-0.12	-0.1	Pancreatic cancer;	chr3:196024982	chr3:195913078~195913683:-
BRCA	cis	rs867186	1	rs80277764	ENSG00000279253.1	RP4-614O4.13	-3.34	0.000871	0.0388	-0.2	-0.1	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35151653	chr20:35262727~35264187:-
BRCA	cis	rs7558911	0.677	rs12620010	ENSG00000230408.3	AC007163.6	-3.34	0.000871	0.0388	-0.11	-0.1	Chronic lymphocytic leukemia;	chr2:201234533	chr2:200780495~200812170:-
BRCA	cis	rs9325144	0.56	rs2013804	ENSG00000257718.1	RP11-396F22.1	-3.34	0.000871	0.0388	-0.1	-0.1	Morning vs. evening chronotype;	chr12:38237277	chr12:38906451~38909592:+
BRCA	cis	rs68170813	0.652	rs77056542	ENSG00000241764.3	AC002467.7	3.34	0.000871	0.0388	0.18	0.1	Coronary artery disease;	chr7:107449306	chr7:107742817~107744581:-
BRCA	cis	rs9470794	1	rs55731063	ENSG00000204110.6	RP1-153P14.8	-3.34	0.000871	0.0388	-0.19	-0.1	Type 2 diabetes;	chr6:38161399	chr6:37507348~37535616:+
BRCA	cis	rs35123781	0.696	rs356433	ENSG00000249526.1	CTB-35F21.1	3.34	0.000871	0.0388	0.14	0.1	Schizophrenia;	chr5:139691608	chr5:139684645~139745010:+
BRCA	cis	rs9325144	0.6	rs61931871	ENSG00000257718.1	RP11-396F22.1	-3.34	0.000871	0.0388	-0.11	-0.1	Morning vs. evening chronotype;	chr12:38436087	chr12:38906451~38909592:+
BRCA	cis	rs10851411	0.697	rs56069741	ENSG00000260490.2	RP11-265N6.3	-3.34	0.000871	0.0388	-0.19	-0.1	Glucose homeostasis traits;	chr15:42562859	chr15:42571927~42572433:+
BRCA	cis	rs9437689	0.541	rs1246351	ENSG00000235501.4	RP4-639F20.1	-3.34	0.000872	0.0388	-0.12	-0.1	Phospholipid levels (plasma);	chr1:94951185	chr1:94927566~94963270:+
BRCA	cis	rs343604	1	rs1953099	ENSG00000232811.1	RP11-96K19.2	-3.34	0.000872	0.0388	-0.21	-0.1	Acute lymphoblastic leukemia (childhood);	chr1:110747920	chr1:110943467~110952848:+
BRCA	cis	rs1830951	0.611	rs12416202	ENSG00000243350.1	RP11-379F12.3	-3.34	0.000872	0.0388	-0.1	-0.1	Eosinophil counts;	chr10:8525926	chr10:8052242~8053449:-
BRCA	cis	rs1005277	0.522	rs289650	ENSG00000099251.13	HSD17B7P2	3.34	0.000872	0.0388	0.11	0.1	Extrinsic epigenetic age acceleration;	chr10:37686577	chr10:38356380~38378505:+
BRCA	cis	rs4787491	0.729	rs11544328	ENSG00000275371.1	RP11-455F5.6	-3.34	0.000872	0.0388	-0.1	-0.1	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30025807	chr16:30110895~30111955:+
BRCA	cis	rs11671005	0.735	rs11670871	ENSG00000265272.2	RN7SL693P	-3.34	0.000872	0.0388	-0.15	-0.1	Mean platelet volume;	chr19:58429147	chr19:58490797~58491075:+
BRCA	cis	rs8054556	1	rs8054556	ENSG00000183604.13	SMG1P5	-3.34	0.000872	0.0388	-0.1	-0.1	Autism spectrum disorder or schizophrenia;	chr16:29946895	chr16:30267553~30335374:-
BRCA	cis	rs56281245	0.793	rs10515552	ENSG00000249363.1	CTB-78O21.1	3.34	0.000872	0.0388	0.22	0.1	Hepcidin levels;	chr5:145659268	chr5:145728360~145729349:-
BRCA	cis	rs2835872	0.869	rs73203821	ENSG00000230366.8	DSCR9	-3.34	0.000872	0.0388	-0.13	-0.1	Electroencephalographic traits in alcoholism;	chr21:37674442	chr21:37208503~37221736:+
BRCA	cis	rs6671200	0.607	rs1927043	ENSG00000228852.5	RP11-57H12.5	-3.34	0.000872	0.0388	-0.13	-0.1	Stearic acid (18:0) levels;	chr1:95201695	chr1:95243167~95278940:-
BRCA	cis	rs863345	0.604	rs12025831	ENSG00000176320.2	RP11-404O13.5	-3.34	0.000872	0.0388	-0.11	-0.1	Pneumococcal bacteremia;	chr1:158526492	chr1:158197922~158203877:-
BRCA	cis	rs3889199	0.779	rs6678642	ENSG00000272226.1	RP11-63G10.3	3.34	0.000872	0.0388	0.14	0.1	Pulse pressure;	chr1:59214574	chr1:58812808~58813342:-
BRCA	cis	rs9567406	0.588	rs7325084	ENSG00000227258.4	SMIM2-AS1	3.34	0.000872	0.0389	0.16	0.1	Peripheral arterial disease (traffic-related air pollution interaction);	chr13:44269455	chr13:44110451~44240517:+
BRCA	cis	rs4450131	1	rs10901799	ENSG00000229455.2	RPS10P18	-3.34	0.000872	0.0389	-0.12	-0.1	White blood cell count (basophil);	chr10:124659705	chr10:124489823~124490578:-
BRCA	cis	rs6102185	0.55	rs6124287	ENSG00000229771.2	RP4-644L1.2	-3.34	0.000872	0.0389	-0.13	-0.1	IgG glycosylation;	chr20:40888129	chr20:40696499~40698616:-
BRCA	cis	rs61542988	0.57	rs62448268	ENSG00000226329.2	AC005682.6	3.34	0.000872	0.0389	0.11	0.1	Fibrinogen levels;	chr7:22789845	chr7:22863874~22881350:-
BRCA	cis	rs6460942	1	rs2033871	ENSG00000226690.5	AC005281.1	3.34	0.000872	0.0389	0.19	0.1	Coronary artery disease;	chr7:12365472	chr7:12496429~12541910:+
BRCA	cis	rs748404	0.666	rs35158584	ENSG00000166763.7	STRCP1	3.34	0.000872	0.0389	0.15	0.1	Lung cancer;	chr15:43392876	chr15:43699488~43718184:-
BRCA	cis	rs11098499	0.863	rs7678400	ENSG00000225892.3	RP11-384K6.2	3.34	0.000872	0.0389	0.11	0.1	Corneal astigmatism;	chr4:119540802	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.863	rs1480936	ENSG00000225892.3	RP11-384K6.2	3.34	0.000872	0.0389	0.11	0.1	Corneal astigmatism;	chr4:119541706	chr4:118632274~118634759:+
BRCA	cis	rs1538970	0.924	rs11211111	ENSG00000281133.1	AL355480.3	-3.34	0.000872	0.0389	-0.14	-0.1	Platelet count;	chr1:45443110	chr1:45580892~45580996:-
BRCA	cis	rs1538970	0.924	rs1006216	ENSG00000281133.1	AL355480.3	-3.34	0.000872	0.0389	-0.14	-0.1	Platelet count;	chr1:45444322	chr1:45580892~45580996:-
BRCA	cis	rs4665809	1	rs4665298	ENSG00000231655.1	AC011742.3	3.34	0.000872	0.0389	0.14	0.1	Gut microbiome composition (summer);	chr2:26033509	chr2:26140263~26141264:-
BRCA	cis	rs11101442	0.965	rs10857632	ENSG00000270025.2	BMS1P7	3.34	0.000873	0.0389	0.12	0.1	Systemic lupus erythematosus;	chr10:48748800	chr10:48050282~48060016:-
BRCA	cis	rs11101442	0.965	rs10857633	ENSG00000270025.2	BMS1P7	3.34	0.000873	0.0389	0.12	0.1	Systemic lupus erythematosus;	chr10:48749363	chr10:48050282~48060016:-
BRCA	cis	rs2562456	0.876	rs2650844	ENSG00000268555.1	RP11-678G14.3	3.34	0.000873	0.0389	0.14	0.1	Pain;	chr19:21419288	chr19:21570822~21587322:-
BRCA	cis	rs7647973	1	rs10155014	ENSG00000225399.4	RP11-3B7.1	3.34	0.000873	0.0389	0.11	0.1	Menarche (age at onset);	chr3:49394888	chr3:49260085~49261316:+
BRCA	cis	rs13401620	0.587	rs1034489	ENSG00000236878.1	AC012363.7	-3.34	0.000873	0.0389	-0.13	-0.1	Breast size;	chr2:120127734	chr2:120211054~120211715:+
BRCA	cis	rs2880765	0.835	rs4843062	ENSG00000259630.2	CTD-2262B20.1	-3.34	0.000873	0.0389	-0.12	-0.1	Coronary artery disease;	chr15:85496906	chr15:85415228~85415633:+
BRCA	cis	rs7712401	0.818	rs13166350	ENSG00000249996.1	RP11-359P5.1	3.34	0.000873	0.0389	0.12	0.1	Mean platelet volume;	chr5:122817874	chr5:123036271~123054667:+
BRCA	cis	rs74233809	0.901	rs1004467	ENSG00000236937.2	PTGES3P4	3.34	0.000873	0.0389	0.2	0.1	Birth weight;	chr10:102834750	chr10:102845595~102845950:+
BRCA	cis	rs875971	0.651	rs313829	ENSG00000273142.1	RP11-458F8.4	-3.34	0.000873	0.0389	-0.1	-0.1	Aortic root size;	chr7:66087510	chr7:66902857~66906297:+
BRCA	cis	rs62025270	0.688	rs62022941	ENSG00000259367.1	RP11-815J21.4	3.34	0.000873	0.0389	0.1	0.1	Idiopathic pulmonary fibrosis;	chr15:85712824	chr15:85619623~85670948:-
BRCA	cis	rs1941023	0.967	rs10501386	ENSG00000254477.1	AP000640.10	3.34	0.000873	0.0389	0.13	0.1	Congenital heart disease (maternal effect);	chr11:60543650	chr11:59753015~59754975:-
BRCA	cis	rs10744816	0.875	rs7973374	ENSG00000257817.1	RP4-601P9.2	-3.34	0.000873	0.0389	-0.13	-0.1	Obesity-related traits;	chr12:114272877	chr12:114713811~114767957:+
BRCA	cis	rs13113518	0.51	rs10049561	ENSG00000249700.7	SRD5A3-AS1	3.34	0.000873	0.0389	0.13	0.1	Height;	chr4:55426623	chr4:55363971~55395847:-
BRCA	cis	rs6696239	0.78	rs10799424	ENSG00000215812.5	ZNF847P	3.34	0.000873	0.0389	0.14	0.1	Height;	chr1:227567774	chr1:227696892~227706699:-
BRCA	cis	rs200880	0.853	rs11697660	ENSG00000234684.5	SDCBP2-AS1	3.34	0.000873	0.0389	0.16	0.1	Mean platelet volume;	chr20:1786640	chr20:1325405~1378734:+
BRCA	cis	rs34421088	0.603	rs10086064	ENSG00000246477.3	AF131216.6	-3.34	0.000873	0.0389	-0.1	-0.1	Neuroticism;	chr8:11726332	chr8:11315859~11325429:-
BRCA	cis	rs2985684	0.846	rs11157693	ENSG00000258568.1	RHOQP1	3.34	0.000873	0.0389	0.13	0.1	Carotid intima media thickness;	chr14:49581708	chr14:49599994~49600572:+
BRCA	cis	rs2985684	0.846	rs10150624	ENSG00000258568.1	RHOQP1	3.34	0.000873	0.0389	0.13	0.1	Carotid intima media thickness;	chr14:49584847	chr14:49599994~49600572:+
BRCA	cis	rs2985684	0.802	rs10150823	ENSG00000258568.1	RHOQP1	3.34	0.000873	0.0389	0.13	0.1	Carotid intima media thickness;	chr14:49585033	chr14:49599994~49600572:+
BRCA	cis	rs61931739	0.534	rs10844732	ENSG00000258794.3	DUX4L27	3.34	0.000873	0.0389	0.15	0.1	Morning vs. evening chronotype;	chr12:33884169	chr12:34208415~34209675:-
BRCA	cis	rs4820539	1	rs885965	ENSG00000236794.5	BCRP8	-3.34	0.000873	0.0389	-0.12	-0.1	Bone mineral density;	chr22:23119238	chr22:23179918~23180172:-
BRCA	cis	rs372883	0.901	rs13048365	ENSG00000176054.6	RPL23P2	3.34	0.000873	0.0389	0.11	0.1	Pancreatic cancer;	chr21:29368073	chr21:28997613~28998033:-
BRCA	cis	rs2562456	0.876	rs11085468	ENSG00000268119.4	CTD-2561J22.5	3.34	0.000873	0.0389	0.15	0.1	Pain;	chr19:21569087	chr19:21444241~21463908:-
BRCA	cis	rs2736340	0.539	rs11250138	ENSG00000227888.4	FAM66A	-3.34	0.000873	0.0389	-0.13	-0.1	Systemic lupus erythematosus;Systemic lupus erythematosus or rheumatoid arthritis;Kawasaki disease;Systemic lupus erythematosus and Systemic sclerosis;Rheumatoid arthritis;	chr8:11465803	chr8:12362019~12388296:+
BRCA	cis	rs6088580	0.634	rs4911418	ENSG00000269202.1	RP4-614O4.12	3.34	0.000873	0.0389	0.1	0.1	Glomerular filtration rate (creatinine);	chr20:34406451	chr20:35201747~35203288:-
BRCA	cis	rs6088580	0.634	rs6579165	ENSG00000269202.1	RP4-614O4.12	3.34	0.000873	0.0389	0.1	0.1	Glomerular filtration rate (creatinine);	chr20:34406909	chr20:35201747~35203288:-
BRCA	cis	rs6088580	0.634	rs4911419	ENSG00000269202.1	RP4-614O4.12	3.34	0.000873	0.0389	0.1	0.1	Glomerular filtration rate (creatinine);	chr20:34408067	chr20:35201747~35203288:-
BRCA	cis	rs6088580	0.634	rs4911421	ENSG00000269202.1	RP4-614O4.12	3.34	0.000873	0.0389	0.1	0.1	Glomerular filtration rate (creatinine);	chr20:34411142	chr20:35201747~35203288:-
BRCA	cis	rs6088580	0.634	rs4911422	ENSG00000269202.1	RP4-614O4.12	3.34	0.000873	0.0389	0.1	0.1	Glomerular filtration rate (creatinine);	chr20:34411539	chr20:35201747~35203288:-
BRCA	cis	rs6088580	0.634	rs2225837	ENSG00000269202.1	RP4-614O4.12	3.34	0.000873	0.0389	0.1	0.1	Glomerular filtration rate (creatinine);	chr20:34417828	chr20:35201747~35203288:-
BRCA	cis	rs10836699	0.635	rs1381152	ENSG00000280331.1	RP11-545D22.1	3.34	0.000873	0.0389	0.13	0.1	Low high density lipoprotein cholesterol levels;	chr11:37143020	chr11:36510361~36510537:+
BRCA	cis	rs12368653	0.591	rs1552842	ENSG00000257159.1	RP11-58A17.3	3.34	0.000874	0.0389	0.12	0.1	Multiple sclerosis;	chr12:57618380	chr12:57967058~57968399:+
BRCA	cis	rs7267979	0.932	rs6138600	ENSG00000277938.1	RP5-965G21.3	3.34	0.000874	0.0389	0.12	0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25540710	chr20:25229150~25231933:+
BRCA	cis	rs9324022	0.929	rs72698718	ENSG00000271198.1	VDAC3P1	-3.34	0.000874	0.0389	-0.17	-0.1	Plateletcrit;	chr14:100712218	chr14:99964529~99965378:+
BRCA	cis	rs1334894	0.584	rs2067997	ENSG00000187762.5	HSPE1P11	-3.34	0.000874	0.0389	-0.17	-0.1	Coronary artery disease;	chr6:35503469	chr6:35023522~35023831:+
BRCA	cis	rs1320333	0.772	rs17786120	ENSG00000272342.1	RP13-539J13.1	-3.34	0.000874	0.0389	-0.18	-0.1	Obesity-related traits;	chr2:700580	chr2:739588~740164:-
BRCA	cis	rs75804782	0.521	rs55915157	ENSG00000186235.9	AC016757.3	3.34	0.000874	0.0389	0.2	0.1	Chronotype;Morning vs. evening chronotype;	chr2:238515632	chr2:238224552~238231677:-
BRCA	cis	rs7515577	1	rs4970712	ENSG00000207523.1	SNORA66	-3.34	0.000874	0.0389	-0.14	-0.1	Cholesterol, total;	chr1:92527990	chr1:92840719~92840851:+
BRCA	cis	rs1730008	0.865	rs4679823	ENSG00000279311.1	RP11-170K4.2	-3.34	0.000874	0.0389	-0.11	-0.1	Lobe attachment (rater-scored or self-reported);	chr3:158173627	chr3:158869898~158871821:+
BRCA	cis	rs1730008	0.865	rs1581412	ENSG00000279311.1	RP11-170K4.2	-3.34	0.000874	0.0389	-0.11	-0.1	Lobe attachment (rater-scored or self-reported);	chr3:158174398	chr3:158869898~158871821:+
BRCA	cis	rs1730008	0.865	rs1589528	ENSG00000279311.1	RP11-170K4.2	-3.34	0.000874	0.0389	-0.11	-0.1	Lobe attachment (rater-scored or self-reported);	chr3:158174589	chr3:158869898~158871821:+
BRCA	cis	rs962856	0.575	rs18122	ENSG00000236605.1	AC023115.4	3.34	0.000874	0.0389	0.13	0.1	Pancreatic cancer;	chr2:67427302	chr2:67324627~67325304:+
BRCA	cis	rs1424638	0.655	rs6709818	ENSG00000233251.6	AC007743.1	-3.34	0.000874	0.0389	-0.12	-0.1	Intelligence (multi-trait analysis);	chr2:57020611	chr2:56173534~56185770:-
BRCA	cis	rs4879656	0.966	rs3780475	ENSG00000225693.1	LAGE3P1	3.34	0.000874	0.0389	0.12	0.1	Menopause (age at onset);	chr9:32984393	chr9:33019682~33020165:-
BRCA	cis	rs890448	0.796	rs10433984	ENSG00000254531.1	FLJ20021	3.34	0.000874	0.0389	0.12	0.1	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101419152	chr4:101347780~101348883:+
BRCA	cis	rs863345	0.564	rs34701257	ENSG00000229914.1	RP11-404O13.4	-3.34	0.000874	0.0389	-0.11	-0.1	Pneumococcal bacteremia;	chr1:158511165	chr1:158195633~158196131:-
BRCA	cis	rs6142618	0.562	rs6141277	ENSG00000224452.1	RSL24D1P6	3.34	0.000874	0.0389	0.14	0.1	Inflammatory bowel disease;	chr20:32243354	chr20:32170390~32170790:-
BRCA	cis	rs801193	0.569	rs4717315	ENSG00000106610.13	STAG3L4	-3.34	0.000874	0.0389	-0.14	-0.1	Aortic root size;	chr7:66713338	chr7:67302621~67321526:+
BRCA	cis	rs6142618	0.562	rs3746604	ENSG00000224452.1	RSL24D1P6	3.34	0.000874	0.0389	0.14	0.1	Inflammatory bowel disease;	chr20:32191327	chr20:32170390~32170790:-
BRCA	cis	rs4243971	0.516	rs11699120	ENSG00000277692.1	RP11-358N2.2	-3.34	0.000874	0.0389	-0.12	-0.1	Inflammatory bowel disease;Crohn's disease;	chr20:32361172	chr20:32355053~32355734:+
BRCA	cis	rs16831128	1	rs41334446	ENSG00000230992.3	FAM201B	3.34	0.000874	0.0389	0.14	0.1	Conduct disorder;Conduct disorder (symptom count);	chr2:132391161	chr2:132352722~132353318:+
BRCA	cis	rs6088580	0.524	rs6088570	ENSG00000126005.14	MMP24-AS1	3.34	0.000875	0.0389	0.12	0.1	Glomerular filtration rate (creatinine);	chr20:34680491	chr20:35216462~35278131:-
BRCA	cis	rs11088226	1	rs11701627	ENSG00000186842.4	LINC00846	-3.34	0.000875	0.0389	-0.16	-0.1	Gastritis;	chr21:32555484	chr21:32572238~32575881:-
BRCA	cis	rs10501293	0.666	rs7118471	ENSG00000252652.1	Y_RNA	-3.34	0.000875	0.0389	-0.12	-0.1	Cognitive performance;	chr11:42983962	chr11:43331261~43331356:+
BRCA	cis	rs10501293	0.746	rs7943869	ENSG00000252652.1	Y_RNA	-3.34	0.000875	0.0389	-0.12	-0.1	Cognitive performance;	chr11:42984688	chr11:43331261~43331356:+
BRCA	cis	rs10501293	0.709	rs7943878	ENSG00000252652.1	Y_RNA	-3.34	0.000875	0.0389	-0.12	-0.1	Cognitive performance;	chr11:42984719	chr11:43331261~43331356:+
BRCA	cis	rs10501293	0.746	rs7944392	ENSG00000252652.1	Y_RNA	-3.34	0.000875	0.0389	-0.12	-0.1	Cognitive performance;	chr11:42985122	chr11:43331261~43331356:+
BRCA	cis	rs10501293	0.746	rs7929831	ENSG00000252652.1	Y_RNA	-3.34	0.000875	0.0389	-0.12	-0.1	Cognitive performance;	chr11:42985275	chr11:43331261~43331356:+
BRCA	cis	rs875971	0.83	rs809025	ENSG00000106610.13	STAG3L4	-3.34	0.000875	0.0389	-0.14	-0.1	Aortic root size;	chr7:66384832	chr7:67302621~67321526:+
BRCA	cis	rs4819052	0.851	rs2255766	ENSG00000223768.1	LINC00205	-3.34	0.000875	0.0389	-0.14	-0.1	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45263862	chr21:45293285~45297354:+
BRCA	cis	rs6545883	0.929	rs2593626	ENSG00000273302.1	RP11-493E12.2	3.34	0.000875	0.0389	0.1	0.1	Tuberculosis;	chr2:61438049	chr2:61199979~61200769:+
BRCA	cis	rs6545883	0.929	rs2592352	ENSG00000273302.1	RP11-493E12.2	3.34	0.000875	0.0389	0.1	0.1	Tuberculosis;	chr2:61438201	chr2:61199979~61200769:+
BRCA	cis	rs7586085	0.845	rs3791848	ENSG00000229195.1	AC009495.4	3.34	0.000875	0.0389	0.12	0.1	Total body bone mineral density;	chr2:165756733	chr2:165794857~165846091:-
BRCA	cis	rs9467773	1	rs28558133	ENSG00000261353.1	CTA-14H9.5	-3.34	0.000875	0.0389	-0.1	-0.1	Intelligence (multi-trait analysis);	chr6:26531205	chr6:26527063~26527404:+
BRCA	cis	rs4865762	0.514	rs2547526	ENSG00000247796.2	CTD-2366F13.1	-3.34	0.000875	0.039	-0.11	-0.1	Intraocular pressure;	chr5:53141038	chr5:53109842~53115126:+
BRCA	cis	rs17489649	0.785	rs10040716	ENSG00000271849.1	CTC-332L22.1	3.34	0.000875	0.039	0.13	0.1	Intelligence (multi-trait analysis);	chr5:109864333	chr5:109687802~109688329:-
BRCA	cis	rs10782582	0.593	rs6675076	ENSG00000181227.3	RP4-682C21.2	3.34	0.000875	0.039	0.11	0.1	Daytime sleep phenotypes;	chr1:75652818	chr1:75743423~75744776:-
BRCA	cis	rs28489187	0.617	rs233118	ENSG00000223653.4	RP11-131L23.1	-3.34	0.000875	0.039	-0.11	-0.1	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85322284	chr1:85276715~85448124:+
BRCA	cis	rs13393800	0.956	rs2293338	ENSG00000237126.7	AC073254.1	-3.34	0.000875	0.039	-0.14	-0.1	Height;	chr2:232574076	chr2:232580948~232611971:-
BRCA	cis	rs6696239	0.956	rs12138229	ENSG00000215812.5	ZNF847P	3.34	0.000875	0.039	0.14	0.1	Height;	chr1:227712437	chr1:227696892~227706699:-
BRCA	cis	rs6696239	0.956	rs11576992	ENSG00000215812.5	ZNF847P	3.34	0.000875	0.039	0.14	0.1	Height;	chr1:227714105	chr1:227696892~227706699:-
BRCA	cis	rs6426833	0.715	rs7553638	ENSG00000117242.7	PINK1-AS	-3.34	0.000875	0.039	-0.12	-0.1	Ulcerative colitis;Inflammatory bowel disease;	chr1:19872444	chr1:20642657~20652193:-
BRCA	cis	rs4713118	0.868	rs760587	ENSG00000219392.1	RP1-265C24.5	-3.34	0.000875	0.039	-0.15	-0.1	Parkinson's disease;	chr6:27772521	chr6:28115628~28116551:+
BRCA	cis	rs752010	0.684	rs10789402	ENSG00000230638.4	RP11-486B10.4	-3.34	0.000875	0.039	-0.13	-0.1	Lupus nephritis in systemic lupus erythematosus;	chr1:41618978	chr1:41542069~41544310:+
BRCA	cis	rs2050392	0.517	rs160017	ENSG00000224473.1	CCND3P1	3.34	0.000875	0.039	0.13	0.1	Inflammatory bowel disease;	chr10:30483965	chr10:30403197~30403776:-
BRCA	cis	rs2803122	0.745	rs6475325	ENSG00000272842.1	RP11-513M16.7	3.34	0.000876	0.039	0.1	0.1	Pulse pressure;	chr9:19386375	chr9:19371386~19371945:-
BRCA	cis	rs860295	0.702	rs12239100	ENSG00000236675.1	MTX1P1	-3.34	0.000876	0.039	-0.13	-0.1	Body mass index;	chr1:155458685	chr1:155230975~155234325:+
BRCA	cis	rs10995356	0.772	rs10822093	ENSG00000238280.1	RP11-436D10.3	-3.34	0.000876	0.039	-0.14	-0.1	Temperament;	chr10:62945379	chr10:62793562~62805887:-
BRCA	cis	rs875971	1	rs6957199	ENSG00000273024.4	INTS4P2	-3.34	0.000876	0.039	-0.11	-0.1	Aortic root size;	chr7:66513532	chr7:65647864~65715661:+
BRCA	cis	rs372883	0.563	rs1153293	ENSG00000232855.5	AF131217.1	-3.34	0.000876	0.039	-0.13	-0.1	Pancreatic cancer;	chr21:29319004	chr21:28439346~28674848:-
BRCA	cis	rs526231	0.853	rs376286	ENSG00000175749.11	EIF3KP1	3.34	0.000876	0.039	0.15	0.1	Primary biliary cholangitis;	chr5:103263689	chr5:103032376~103033031:+
BRCA	cis	rs7429990	0.965	rs4858887	ENSG00000280173.1	RP11-447D11.3	-3.34	0.000876	0.039	-0.09	-0.1	Educational attainment (years of education);	chr3:48050527	chr3:47346950~47349073:+
BRCA	cis	rs7267979	0.933	rs2424708	ENSG00000274414.1	RP5-965G21.4	-3.34	0.000876	0.039	-0.12	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25300762	chr20:25239007~25245229:-
BRCA	cis	rs34779708	0.966	rs34296409	ENSG00000269952.1	RP11-324I22.3	-3.34	0.000876	0.039	-0.14	-0.1	Inflammatory bowel disease;Crohn's disease;	chr10:35115685	chr10:35210416~35210750:+
BRCA	cis	rs10246939	0.543	rs9640357	ENSG00000270157.1	RP5-894A10.6	3.34	0.000876	0.039	0.11	0.1	Bitter taste perception;	chr7:141843298	chr7:141662922~141663846:-
BRCA	cis	rs4589258	0.788	rs2226920	ENSG00000280367.1	RP11-121L10.2	3.34	0.000876	0.039	0.12	0.1	Intelligence (multi-trait analysis);	chr11:90731220	chr11:90223153~90226538:+
BRCA	cis	rs7824557	0.767	rs6985146	ENSG00000254936.4	AF131215.3	3.34	0.000876	0.039	0.12	0.1	Retinal vascular caliber;	chr8:11313212	chr8:11123381~11126064:-
BRCA	cis	rs78857879	0.541	rs17278665	ENSG00000272606.1	RP11-554J4.1	3.34	0.000876	0.039	0.15	0.1	White matter hyperintensity burden;	chr2:55868859	chr2:55617909~55618373:+
BRCA	cis	rs4865762	0.514	rs254614	ENSG00000247796.2	CTD-2366F13.1	3.34	0.000876	0.039	0.11	0.1	Intraocular pressure;	chr5:53150185	chr5:53109842~53115126:+
BRCA	cis	rs6460942	0.915	rs62447642	ENSG00000226690.5	AC005281.1	3.34	0.000876	0.039	0.2	0.1	Coronary artery disease;	chr7:12449521	chr7:12496429~12541910:+
BRCA	cis	rs11098499	1	rs6837898	ENSG00000225892.3	RP11-384K6.2	3.34	0.000876	0.039	0.1	0.1	Corneal astigmatism;	chr4:119257999	chr4:118632274~118634759:+
BRCA	cis	rs4805834	0.719	rs10853922	ENSG00000201388.1	SNORA68	-3.34	0.000877	0.039	-0.17	-0.1	Creatinine levels;	chr19:32777519	chr19:32608337~32608469:-
BRCA	cis	rs8121203	1	rs56330183	ENSG00000213950.2	RPS10P2	-3.34	0.000877	0.039	-0.25	-0.1	Peripheral arterial disease (traffic-related air pollution interaction);	chr20:15061455	chr20:14757563~14758056:+
BRCA	cis	rs2360027	0.599	rs11590559	ENSG00000231365.4	RP11-418J17.1	-3.34	0.000877	0.039	-0.12	-0.1	Tonsillectomy;	chr1:118557358	chr1:119140396~119275973:+
BRCA	cis	rs12477438	0.52	rs13030961	ENSG00000231822.1	AC019097.7	3.34	0.000877	0.039	0.11	0.1	Chronic sinus infection;	chr2:99183057	chr2:99102018~99102752:+
BRCA	cis	rs258892	0.947	rs62360681	ENSG00000272525.1	RP11-79P5.9	3.34	0.000877	0.039	0.13	0.1	Small cell lung carcinoma;	chr5:72891186	chr5:73497550~73498293:-
BRCA	cis	rs1008375	0.646	rs13103430	ENSG00000249502.1	AC006160.5	3.34	0.000877	0.039	0.12	0.1	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17565732	chr4:17587467~17614571:-
BRCA	cis	rs7017914	0.967	rs59992214	ENSG00000246366.5	RP11-382J12.1	3.34	0.000877	0.039	0.11	0.1	Bone mineral density;	chr8:70687310	chr8:70608577~70663279:+
BRCA	cis	rs7017914	0.935	rs35564237	ENSG00000246366.5	RP11-382J12.1	3.34	0.000877	0.039	0.11	0.1	Bone mineral density;	chr8:70688239	chr8:70608577~70663279:+
BRCA	cis	rs7017914	0.934	rs62530772	ENSG00000246366.5	RP11-382J12.1	3.34	0.000877	0.039	0.11	0.1	Bone mineral density;	chr8:70689306	chr8:70608577~70663279:+
BRCA	cis	rs4950322	0.547	rs61838945	ENSG00000230832.3	RP11-325P15.2	-3.34	0.000877	0.039	-0.16	-0.1	Protein quantitative trait loci;	chr1:147111477	chr1:147082338~147083578:-
BRCA	cis	rs2310173	0.575	rs11123902	ENSG00000281162.1	LINC01127	-3.34	0.000877	0.039	-0.11	-0.1	Ulcerative colitis;Ankylosing spondylitis;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr2:101994180	chr2:101962056~101987167:+
BRCA	cis	rs75757892	0.621	rs76345703	ENSG00000236512.1	RP3-336K20__B.2	3.34	0.000877	0.039	0.17	0.1	Hematocrit;Red blood cell count;	chr6:7282141	chr6:7620422~7620878:+
BRCA	cis	rs6456156	0.774	rs2021999	ENSG00000272549.1	RP11-351J23.2	3.34	0.000878	0.039	0.1	0.1	Primary biliary cholangitis;	chr6:167116278	chr6:167666840~167679270:-
BRCA	cis	rs35740288	0.577	rs10163090	ENSG00000202081.1	RNU6-1280P	3.34	0.000878	0.0391	0.12	0.1	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85650525	chr15:85651522~85651628:-
BRCA	cis	rs11098499	0.754	rs10518300	ENSG00000250412.1	KLHL2P1	-3.34	0.000878	0.0391	-0.12	-0.1	Corneal astigmatism;	chr4:119328344	chr4:119334329~119378233:+
BRCA	cis	rs72634258	0.554	rs1012477	ENSG00000269925.1	RP3-467L1.6	-3.34	0.000878	0.0391	-0.16	-0.1	Inflammatory bowel disease;	chr1:7798075	chr1:7776383~7776775:+
BRCA	cis	rs6128907	0.898	rs62202466	ENSG00000196756.10	SNHG17	3.34	0.000878	0.0391	0.14	0.1	Liver fibrosis in pediatric non-alcoholic fatty acid liver disease;	chr20:38753004	chr20:38420588~38435353:-
BRCA	cis	rs6128907	1	rs62202467	ENSG00000196756.10	SNHG17	3.34	0.000878	0.0391	0.14	0.1	Liver fibrosis in pediatric non-alcoholic fatty acid liver disease;	chr20:38753138	chr20:38420588~38435353:-
BRCA	cis	rs7481311	0.956	rs6484311	ENSG00000245573.6	BDNF-AS	3.34	0.000878	0.0391	0.13	0.1	Weight;Body mass index;	chr11:27510217	chr11:27506838~27698174:+
BRCA	cis	rs4356203	0.87	rs214916	ENSG00000184669.7	OR7E14P	-3.34	0.000878	0.0391	-0.13	-0.1	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17220102	chr11:17013998~17053024:+
BRCA	cis	rs76076331	0.887	rs13387062	ENSG00000271952.1	RP11-245G13.2	-3.34	0.000878	0.0391	-0.17	-0.1	Educational attainment (college completion);Educational attainment (years of education);	chr2:10846989	chr2:10878269~10885118:+
BRCA	cis	rs9796	0.621	rs537244	ENSG00000223313.1	RNU6-516P	-3.34	0.000878	0.0391	-0.12	-0.1	Menopause (age at onset);	chr15:41177115	chr15:40529570~40529673:+
BRCA	cis	rs9796	0.621	rs2928142	ENSG00000223313.1	RNU6-516P	-3.34	0.000878	0.0391	-0.12	-0.1	Menopause (age at onset);	chr15:41178251	chr15:40529570~40529673:+
BRCA	cis	rs830124	0.866	rs2707056	ENSG00000272849.1	RP11-347I19.8	-3.34	0.000878	0.0391	-0.11	-0.1	Urinary metabolites;	chr12:121849384	chr12:121797511~121801972:+
BRCA	cis	rs10411161	0.63	rs76234335	ENSG00000275055.1	CTC-471J1.11	-3.34	0.000878	0.0391	-0.24	-0.1	Breast cancer;	chr19:51954215	chr19:52049007~52049754:+
BRCA	cis	rs613391	0.536	rs682022	ENSG00000265194.1	RP11-70L8.4	-3.34	0.000878	0.0391	-0.11	-0.1	Quantitative traits;	chr9:22722160	chr9:21858910~21861926:-
BRCA	cis	rs6963495	0.745	rs818620	ENSG00000223886.3	RP11-251G23.2	3.34	0.000878	0.0391	0.14	0.1	Bipolar disorder (body mass index interaction);	chr7:105532238	chr7:105530209~105530671:+
BRCA	cis	rs6963495	0.818	rs818621	ENSG00000223886.3	RP11-251G23.2	3.34	0.000878	0.0391	0.14	0.1	Bipolar disorder (body mass index interaction);	chr7:105532582	chr7:105530209~105530671:+
BRCA	cis	rs6893300	0.542	rs7736300	ENSG00000250999.1	RP11-1379J22.5	-3.34	0.000878	0.0391	-0.12	-0.1	Resting heart rate;	chr5:179769897	chr5:179657762~179664432:+
BRCA	cis	rs11098499	0.866	rs10518329	ENSG00000250950.1	RP11-33B1.3	-3.34	0.000878	0.0391	-0.12	-0.1	Corneal astigmatism;	chr4:119480680	chr4:119456350~119457277:+
BRCA	cis	rs703842	0.616	rs871871	ENSG00000257159.1	RP11-58A17.3	3.34	0.000878	0.0391	0.13	0.1	Multiple sclerosis;	chr12:57825898	chr12:57967058~57968399:+
BRCA	cis	rs7781266	0.79	rs1017945	ENSG00000226205.1	AC007790.4	-3.34	0.000878	0.0391	-0.14	-0.1	Educational attainment (college completion);	chr7:133463329	chr7:133732493~133733595:-
BRCA	cis	rs9500256	0.967	rs4928431	ENSG00000239650.4	GUSBP4	-3.34	0.000878	0.0391	-0.11	-0.1	Eosinophilic esophagitis (pediatric);	chr6:57979980	chr6:57919784~57930291:-
BRCA	cis	rs6432860	0.545	rs10192608	ENSG00000232411.1	AC009495.3	-3.34	0.000878	0.0391	-0.12	-0.1	Febrile seizures (MMR vaccine-unrelated);Febrile seizures;	chr2:166057168	chr2:165833048~165839098:-
BRCA	cis	rs2562456	0.754	rs11673234	ENSG00000268357.1	VN1R81P	-3.34	0.000878	0.0391	-0.15	-0.1	Pain;	chr19:21324800	chr19:21123817~21124188:+
BRCA	cis	rs2562456	0.754	rs11673320	ENSG00000268357.1	VN1R81P	-3.34	0.000878	0.0391	-0.15	-0.1	Pain;	chr19:21324801	chr19:21123817~21124188:+
BRCA	cis	rs78487399	0.614	rs77389971	ENSG00000234936.1	AC010883.5	3.34	0.000879	0.0391	0.16	0.1	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43490945	chr2:43229573~43233394:+
BRCA	cis	rs74233809	1	rs34747231	ENSG00000236937.2	PTGES3P4	3.34	0.000879	0.0391	0.23	0.1	Birth weight;	chr10:103182487	chr10:102845595~102845950:+
BRCA	cis	rs7474896	0.945	rs2749575	ENSG00000120555.12	SEPT7P9	-3.34	0.000879	0.0391	-0.18	-0.1	Obesity (extreme);	chr10:37993647	chr10:38383069~38402916:-
BRCA	cis	rs7474896	1	rs2474550	ENSG00000120555.12	SEPT7P9	-3.34	0.000879	0.0391	-0.18	-0.1	Obesity (extreme);	chr10:38001842	chr10:38383069~38402916:-
BRCA	cis	rs7474896	1	rs2474549	ENSG00000120555.12	SEPT7P9	-3.34	0.000879	0.0391	-0.18	-0.1	Obesity (extreme);	chr10:38001844	chr10:38383069~38402916:-
BRCA	cis	rs11686241	0.935	rs55671904	ENSG00000232485.2	AC098820.3	3.34	0.000879	0.0391	0.15	0.1	Cancer;	chr2:216448732	chr2:216479030~216498761:-
BRCA	cis	rs904092	0.592	rs1229969	ENSG00000246090.5	RP11-696N14.1	-3.34	0.000879	0.0391	-0.12	-0.1	Alcohol dependence;	chr4:99285561	chr4:99088857~99301356:+
BRCA	cis	rs7954584	0.567	rs1720037	ENSG00000272849.1	RP11-347I19.8	3.34	0.000879	0.0391	0.08	0.1	Mean corpuscular volume;	chr12:121944323	chr12:121797511~121801972:+
BRCA	cis	rs283610	0.527	rs416286	ENSG00000249149.2	RP11-79P5.3	-3.34	0.000879	0.0391	-0.15	-0.1	Obesity-related traits;	chr5:73966288	chr5:73382384~73410509:+
BRCA	cis	rs7712401	0.791	rs10063253	ENSG00000263432.2	RN7SL689P	3.34	0.000879	0.0391	0.12	0.1	Mean platelet volume;	chr5:122793016	chr5:123022487~123022783:-
BRCA	cis	rs11838267	0.527	rs7311672	ENSG00000213942.3	RP1-102E24.1	-3.34	0.000879	0.0391	-0.13	-0.1	Coronary artery disease;	chr12:7057810	chr12:6409637~6410013:-
BRCA	cis	rs9860340	0.547	rs111654912	ENSG00000239572.1	RP11-451B8.1	-3.34	0.000879	0.0391	-0.15	-0.1	Electroencephalographic traits in alcoholism;	chr3:87597658	chr3:87731402~87793629:-
BRCA	cis	rs7520050	0.966	rs785471	ENSG00000226957.1	RP4-533D7.4	3.34	0.000879	0.0391	0.11	0.1	Reticulocyte count;Red blood cell count;	chr1:46053005	chr1:46046818~46048368:+
BRCA	cis	rs9788682	1	rs9788682	ENSG00000261143.1	ADAMTS7P3	3.34	0.000879	0.0391	0.14	0.1	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78510244	chr15:77976042~77993057:+
BRCA	cis	rs6539247	0.775	rs736788	ENSG00000257890.1	RP11-114F10.2	-3.34	0.000879	0.0391	-0.13	-0.1	Attention function in attention deficit hyperactive disorder;	chr12:106077893	chr12:106050961~106058254:-
BRCA	cis	rs6802315	0.604	rs2364927	ENSG00000272440.1	RP11-379F4.6	3.34	0.000879	0.0391	0.13	0.1	Periodontitis (CDC/AAP);	chr3:158760066	chr3:158695367~158695581:+
BRCA	cis	rs6102185	0.572	rs6102201	ENSG00000226648.1	PLCG1-AS1	-3.34	0.000879	0.0391	-0.11	-0.1	IgG glycosylation;	chr20:40891166	chr20:41098329~41138003:-
BRCA	cis	rs873549	1	rs873548	ENSG00000227925.1	RP11-191N8.2	3.34	0.00088	0.0391	0.12	0.1	Keloid;	chr1:222098598	chr1:221827666~221840666:-
BRCA	cis	rs7811142	0.83	rs11769057	ENSG00000214313.7	AZGP1P1	-3.34	0.00088	0.0391	-0.13	-0.1	Platelet count;	chr7:100367038	chr7:99980762~99987535:+
BRCA	cis	rs943466	1	rs943462	ENSG00000223837.2	BRD2-IT1	3.34	0.00088	0.0391	0.13	0.1	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;	chr6:33801801	chr6:32970232~32970886:+
BRCA	cis	rs6964833	0.935	rs35735900	ENSG00000277072.3	STAG3L2	3.34	0.00088	0.0391	0.11	0.1	Menarche (age at onset);	chr7:74651887	chr7:74882163~74890610:-
BRCA	cis	rs2613964	0.583	rs2700229	ENSG00000240057.4	RP11-572M11.4	-3.34	0.00088	0.0391	-0.13	-0.1	Pediatric bone mineral content (spine);Pediatric bone mineral density (spine);	chr3:113135061	chr3:113019532~113183301:+
BRCA	cis	rs4538475	0.559	rs73224656	ENSG00000214846.4	RP11-115L11.1	3.34	0.00088	0.0391	0.19	0.1	Parkinson's disease;	chr4:15698170	chr4:15730962~15731627:-
BRCA	cis	rs930395	0.514	rs6871820	ENSG00000248779.1	RP11-53O19.2	-3.34	0.00088	0.0391	-0.1	-0.1	Breast cancer;	chr5:44919455	chr5:44752949~44765744:+
BRCA	cis	rs2400362	0.793	rs1438227	ENSG00000254162.1	RP11-48B3.3	-3.34	0.00088	0.0391	-0.12	-0.1	Glucocorticoid-induced osteonecrosis (age 10 years and older);	chr8:80957358	chr8:80535006~80539135:-
BRCA	cis	rs739401	0.572	rs389128	ENSG00000183562.3	CTC-343N3.1	-3.34	0.00088	0.0391	-0.11	-0.1	Longevity;	chr11:3062643	chr11:2989863~2991344:+
BRCA	cis	rs656900	0.647	rs898436	ENSG00000259548.1	RP11-38G5.2	3.34	0.00088	0.0391	0.12	0.1	Cerebrospinal P-tau181p levels;	chr15:79824790	chr15:79832466~79833554:-
BRCA	cis	rs4356203	0.905	rs589319	ENSG00000184669.7	OR7E14P	-3.34	0.00088	0.0391	-0.13	-0.1	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17181050	chr11:17013998~17053024:+
BRCA	cis	rs7267979	0.744	rs6050463	ENSG00000125804.12	FAM182A	-3.34	0.00088	0.0391	-0.13	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25228354	chr20:26054655~26086917:+
BRCA	cis	rs35146811	0.696	rs1727124	ENSG00000214313.7	AZGP1P1	-3.34	0.00088	0.0391	-0.11	-0.1	Coronary artery disease;	chr7:100206481	chr7:99980762~99987535:+
BRCA	cis	rs10777288	0.561	rs10859092	ENSG00000258100.1	RP11-121E16.1	-3.34	0.00088	0.0391	-0.13	-0.1	Pulmonary function (smoking interaction);	chr12:91009231	chr12:91362196~91368606:+
BRCA	cis	rs258892	0.895	rs67011705	ENSG00000272525.1	RP11-79P5.9	-3.34	0.00088	0.0392	-0.13	-0.1	Small cell lung carcinoma;	chr5:72780711	chr5:73497550~73498293:-
BRCA	cis	rs6088590	0.735	rs6060003	ENSG00000206582.1	Y_RNA	-3.34	0.00088	0.0392	-0.11	-0.1	Coronary artery disease;	chr20:34707141	chr20:34526510~34526606:-
BRCA	cis	rs2400362	0.712	rs2166305	ENSG00000260317.1	RP11-48B3.4	-3.34	0.00088	0.0392	-0.13	-0.1	Glucocorticoid-induced osteonecrosis (age 10 years and older);	chr8:80957974	chr8:80541300~80543104:+
BRCA	cis	rs11098499	0.955	rs13114751	ENSG00000225892.3	RP11-384K6.2	3.34	0.00088	0.0392	0.1	0.1	Corneal astigmatism;	chr4:119235462	chr4:118632274~118634759:+
BRCA	cis	rs56313388	0.505	rs11076146	ENSG00000260549.1	MT1L	-3.34	0.000881	0.0392	-0.11	-0.1	Pulse pressure;	chr16:56227517	chr16:56617476~56618818:+
BRCA	cis	rs7226408	0.948	rs4368229	ENSG00000267707.2	RP11-95O2.5	-3.34	0.000881	0.0392	-0.16	-0.1	Obesity-related traits;	chr18:36815280	chr18:37243776~37247506:+
BRCA	cis	rs7208859	0.623	rs3794796	ENSG00000276250.1	CTD-2349P21.12	-3.34	0.000881	0.0392	-0.17	-0.1	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30803862	chr17:30803654~30804077:+
BRCA	cis	rs9967417	0.543	rs523373	ENSG00000266696.1	RP11-30L3.2	3.34	0.000881	0.0392	0.11	0.1	Height;	chr18:49291327	chr18:49205912~49208781:+
BRCA	cis	rs2985334	0.89	rs2930842	ENSG00000237934.1	RP11-467D18.2	-3.34	0.000881	0.0392	-0.13	-0.1	Amyotrophic lateral sclerosis (sporadic);	chr1:28977927	chr1:29223933~29224816:+
BRCA	cis	rs1119582	0.568	rs418962	ENSG00000279118.1	RP11-517I3.2	-3.34	0.000881	0.0392	-0.13	-0.1	Select biomarker traits;	chr5:125866307	chr5:126496279~126498604:+
BRCA	cis	rs67766926	0.953	rs12713428	ENSG00000237522.1	NONOP2	-3.34	0.000881	0.0392	-0.11	-0.1	Inflammatory skin disease;	chr2:60890978	chr2:60936819~60938049:-
BRCA	cis	rs2574985	0.813	rs2983368	ENSG00000226200.5	SGMS1-AS1	-3.34	0.000881	0.0392	-0.11	-0.1	Subjective well-being;	chr10:50478621	chr10:50624951~50641451:+
BRCA	cis	rs9346455	0.614	rs2273888	ENSG00000233237.5	LINC00472	-3.34	0.000881	0.0392	-0.16	-0.1	Antipsychotic drug-induced weight gain;Antipsychotic drug-induced weight gain (time interaction);	chr6:71296809	chr6:71344344~71420769:-
BRCA	cis	rs4805834	0.843	rs75195087	ENSG00000201388.1	SNORA68	3.34	0.000881	0.0392	0.18	0.1	Creatinine levels;	chr19:32891204	chr19:32608337~32608469:-
BRCA	cis	rs7267979	0.833	rs6138556	ENSG00000277938.1	RP5-965G21.3	3.34	0.000881	0.0392	0.13	0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25262674	chr20:25229150~25231933:+
BRCA	cis	rs4965598	0.958	rs4965593	ENSG00000259381.2	RP11-192M23.1	-3.34	0.000881	0.0392	-0.1	-0.1	Height;	chr15:100218180	chr15:100645434~100646655:-
BRCA	cis	rs11035577	0.632	rs10768534	ENSG00000279675.1	RP11-454H19.2	-3.34	0.000881	0.0392	-0.16	-0.1	Temperament (bipolar disorder);	chr11:39753346	chr11:40107244~40112599:-
BRCA	cis	rs79478560	0.552	rs7314335	ENSG00000270028.1	RP11-380L11.4	3.34	0.000881	0.0392	0.12	0.1	Lymphocyte counts;	chr12:123858894	chr12:123925461~123926083:-
BRCA	cis	rs854765	0.547	rs4072739	ENSG00000197815.4	RP1-253P7.4	-3.34	0.000881	0.0392	-0.08	-0.1	Total body bone mineral density;	chr17:17981346	chr17:17858227~17860041:+
BRCA	cis	rs2795502	0.882	rs3123754	ENSG00000185904.10	LINC00839	-3.34	0.000881	0.0392	-0.15	-0.1	Blood protein levels;	chr10:42843563	chr10:42475543~42495336:+
BRCA	cis	rs2795502	0.882	rs2744093	ENSG00000185904.10	LINC00839	-3.34	0.000881	0.0392	-0.15	-0.1	Blood protein levels;	chr10:42843795	chr10:42475543~42495336:+
BRCA	cis	rs2795502	1	rs2744092	ENSG00000185904.10	LINC00839	-3.34	0.000881	0.0392	-0.15	-0.1	Blood protein levels;	chr10:42843895	chr10:42475543~42495336:+
BRCA	cis	rs2795502	1	rs2795497	ENSG00000185904.10	LINC00839	-3.34	0.000881	0.0392	-0.15	-0.1	Blood protein levels;	chr10:42844027	chr10:42475543~42495336:+
BRCA	cis	rs2795502	1	rs2744090	ENSG00000185904.10	LINC00839	-3.34	0.000881	0.0392	-0.15	-0.1	Blood protein levels;	chr10:42844166	chr10:42475543~42495336:+
BRCA	cis	rs2795502	0.882	rs2744087	ENSG00000185904.10	LINC00839	-3.34	0.000881	0.0392	-0.15	-0.1	Blood protein levels;	chr10:42844822	chr10:42475543~42495336:+
BRCA	cis	rs875971	0.862	rs13226170	ENSG00000223473.2	GS1-124K5.3	3.34	0.000882	0.0392	0.08	0.1	Aortic root size;	chr7:66534311	chr7:66491049~66493566:-
BRCA	cis	rs875971	0.862	rs2420611	ENSG00000223473.2	GS1-124K5.3	3.34	0.000882	0.0392	0.08	0.1	Aortic root size;	chr7:66534333	chr7:66491049~66493566:-
BRCA	cis	rs3740909	1	rs3740911	ENSG00000255062.1	RP11-712L6.5	-3.34	0.000882	0.0392	-0.16	-0.1	Blood protein levels;	chr11:126019860	chr11:126294298~126304318:-
BRCA	cis	rs875971	0.862	rs778686	ENSG00000223473.2	GS1-124K5.3	3.34	0.000882	0.0392	0.08	0.1	Aortic root size;	chr7:66370923	chr7:66491049~66493566:-
BRCA	cis	rs62246343	0.564	rs17050383	ENSG00000214041.4	PGAM1P4	3.34	0.000882	0.0392	0.14	0.1	Fibrinogen levels;	chr3:9472896	chr3:9348443~9349192:+
BRCA	cis	rs1032466	0.783	rs6572681	ENSG00000270062.1	RP11-248J18.3	-3.34	0.000882	0.0392	-0.13	-0.1	Dupuytren's disease;	chr14:50650341	chr14:50723777~50724272:-
BRCA	cis	rs1710990	0.819	rs1275407	ENSG00000258957.1	RP11-363J20.1	-3.34	0.000882	0.0392	-0.13	-0.1	Intelligence (multi-trait analysis);	chr14:69126735	chr14:69183020~69214092:-
BRCA	cis	rs3087591	0.922	rs2953013	ENSG00000263531.1	RP13-753N3.1	3.34	0.000882	0.0392	0.14	0.1	Hip circumference;	chr17:31169325	chr17:30863921~30864940:-
BRCA	cis	rs7800418	0.578	rs2286183	ENSG00000280255.1	RP5-1007F24.1	3.34	0.000882	0.0392	0.12	0.1	Cognitive function;	chr7:26585246	chr7:26538378~26541048:+
BRCA	cis	rs7577696	0.889	rs212735	ENSG00000276334.1	AL133243.1	3.34	0.000882	0.0392	0.13	0.1	Inflammatory biomarkers;	chr2:32248019	chr2:32521927~32523547:+
BRCA	cis	rs9967417	0.523	rs4939867	ENSG00000266696.1	RP11-30L3.2	3.34	0.000882	0.0392	0.11	0.1	Height;	chr18:49391203	chr18:49205912~49208781:+
BRCA	cis	rs6943931	0.895	rs2686504	ENSG00000230658.1	KLHL7-AS1	3.34	0.000882	0.0392	0.13	0.1	Diabetic kidney disease;	chr7:22387556	chr7:23101228~23105703:-
BRCA	cis	rs1730008	0.654	rs60745172	ENSG00000279311.1	RP11-170K4.2	3.34	0.000882	0.0392	0.12	0.1	Lobe attachment (rater-scored or self-reported);	chr3:158482578	chr3:158869898~158871821:+
BRCA	cis	rs7267979	0.903	rs6115101	ENSG00000274414.1	RP5-965G21.4	-3.34	0.000882	0.0392	-0.12	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25248928	chr20:25239007~25245229:-
BRCA	cis	rs6460942	1	rs6460938	ENSG00000226690.5	AC005281.1	3.34	0.000882	0.0392	0.2	0.1	Coronary artery disease;	chr7:12367182	chr7:12496429~12541910:+
BRCA	cis	rs2617170	1	rs2617170	ENSG00000256039.1	RP11-291B21.2	3.34	0.000882	0.0392	0.09	0.1	Behcet's disease;	chr12:10408358	chr12:10553363~10558049:+
BRCA	cis	rs9467773	1	rs1321479	ENSG00000261353.1	CTA-14H9.5	3.34	0.000882	0.0392	0.1	0.1	Intelligence (multi-trait analysis);	chr6:26501669	chr6:26527063~26527404:+
BRCA	cis	rs875971	0.756	rs2901210	ENSG00000223473.2	GS1-124K5.3	-3.34	0.000882	0.0392	-0.08	-0.1	Aortic root size;	chr7:66552518	chr7:66491049~66493566:-
BRCA	cis	rs7960483	0.652	rs11183106	ENSG00000258096.1	RP11-474P2.2	-3.34	0.000882	0.0392	-0.12	-0.1	Hypertension (SNP x SNP interaction);	chr12:45548561	chr12:46371463~46373778:+
BRCA	cis	rs2625529	0.627	rs12898585	ENSG00000260037.4	CTD-2524L6.3	-3.34	0.000882	0.0392	-0.14	-0.1	Red blood cell count;	chr15:72181587	chr15:71818396~71823384:+
BRCA	cis	rs1730008	0.865	rs6768496	ENSG00000279311.1	RP11-170K4.2	-3.34	0.000882	0.0392	-0.11	-0.1	Lobe attachment (rater-scored or self-reported);	chr3:158155162	chr3:158869898~158871821:+
BRCA	cis	rs12664873	0.566	rs3799545	ENSG00000279453.1	RP3-425C14.4	-3.34	0.000882	0.0392	-0.14	-0.1	Atrial fibrillation;	chr6:122414473	chr6:122436789~122439223:-
BRCA	cis	rs1876905	0.68	rs193281	ENSG00000271789.1	RP5-1112D6.7	3.34	0.000882	0.0392	0.15	0.1	Mean corpuscular hemoglobin;	chr6:111166487	chr6:111297126~111298510:+
BRCA	cis	rs13113518	0.51	rs11732723	ENSG00000249700.7	SRD5A3-AS1	-3.34	0.000882	0.0392	-0.13	-0.1	Height;	chr4:55424391	chr4:55363971~55395847:-
BRCA	cis	rs13434995	0.589	rs62305201	ENSG00000273257.1	RP11-177J6.1	-3.34	0.000883	0.0392	-0.15	-0.1	Adiponectin levels;	chr4:55386778	chr4:55387949~55388271:+
BRCA	cis	rs13434995	0.589	rs62305202	ENSG00000273257.1	RP11-177J6.1	-3.34	0.000883	0.0392	-0.15	-0.1	Adiponectin levels;	chr4:55386861	chr4:55387949~55388271:+
BRCA	cis	rs10958369	0.575	rs11776806	ENSG00000260484.1	RP11-1081M5.2	-3.34	0.000883	0.0392	-0.12	-0.1	Response to antineoplastic agents;	chr8:53514135	chr8:53388701~53390872:-
BRCA	cis	rs6772849	1	rs66910450	ENSG00000242551.2	POU5F1P6	-3.34	0.000883	0.0392	-0.13	-0.1	Monocyte percentage of white cells;Monocyte count;	chr3:128585050	chr3:128674735~128677005:-
BRCA	cis	rs943466	1	rs943461	ENSG00000223837.2	BRD2-IT1	3.34	0.000883	0.0392	0.13	0.1	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;	chr6:33801632	chr6:32970232~32970886:+
BRCA	cis	rs853679	0.517	rs35193936	ENSG00000272009.1	RP1-313I6.12	-3.34	0.000883	0.0392	-0.15	-0.1	Depression;	chr6:28108492	chr6:28078792~28081130:-
BRCA	cis	rs13113518	0.51	rs11732723	ENSG00000239040.1	Y_RNA	3.34	0.000883	0.0392	0.11	0.1	Height;	chr4:55424391	chr4:55412636~55412738:+
BRCA	cis	rs6545883	0.929	rs1186711	ENSG00000237522.1	NONOP2	-3.34	0.000883	0.0392	-0.1	-0.1	Tuberculosis;	chr2:61461370	chr2:60936819~60938049:-
BRCA	cis	rs875971	0.798	rs6460304	ENSG00000223473.2	GS1-124K5.3	3.34	0.000883	0.0392	0.08	0.1	Aortic root size;	chr7:66499741	chr7:66491049~66493566:-
BRCA	cis	rs875971	0.862	rs6945775	ENSG00000223473.2	GS1-124K5.3	3.34	0.000883	0.0392	0.08	0.1	Aortic root size;	chr7:66503987	chr7:66491049~66493566:-
BRCA	cis	rs7200543	1	rs4500751	ENSG00000270580.4	PKD1P6	3.34	0.000883	0.0392	0.11	0.1	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15046354	chr16:15104723~15131601:-
BRCA	cis	rs7729723	0.591	rs4835681	ENSG00000253404.1	AC034243.1	-3.33	0.000883	0.0393	-0.13	-0.1	Amyotrophic lateral sclerosis (C9orf72 mutation interaction);	chr5:138448001	chr5:138744434~138753309:-
BRCA	cis	rs8113308	0.81	rs17695737	ENSG00000268225.1	CTD-2331H12.5	3.33	0.000883	0.0393	0.17	0.1	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51942283	chr19:52861807~52862866:-
BRCA	cis	rs2908197	0.653	rs2961034	ENSG00000205485.12	AC004980.7	3.33	0.000883	0.0393	0.11	0.1	3-hydroxypropylmercapturic acid levels in smokers;	chr7:76332233	chr7:76549360~76627982:+
BRCA	cis	rs180730	0.752	rs343167	ENSG00000251609.2	SETP12	-3.33	0.000883	0.0393	-0.17	-0.1	Fasting plasma glucose;	chr4:120897351	chr4:120895494~120897083:-
BRCA	cis	rs962856	0.619	rs4671795	ENSG00000236605.1	AC023115.4	3.33	0.000883	0.0393	0.14	0.1	Pancreatic cancer;	chr2:67339936	chr2:67324627~67325304:+
BRCA	cis	rs2842992	0.83	rs2842974	ENSG00000207392.1	SNORA20	-3.33	0.000883	0.0393	-0.14	-0.1	Age-related macular degeneration (geographic atrophy);	chr6:159738002	chr6:159780250~159780381:-
BRCA	cis	rs990171	0.538	rs1523201	ENSG00000234389.1	AC007278.3	3.33	0.000884	0.0393	0.11	0.1	Lymphocyte counts;	chr2:102490605	chr2:102438713~102440475:+
BRCA	cis	rs13418410	0.668	rs4670206	ENSG00000187999.4	HNRNPA1P61	3.33	0.000884	0.0393	0.12	0.1	Non-response to antidepressants and depression;	chr2:33571267	chr2:33636502~33637425:+
BRCA	cis	rs16852403	0.658	rs10157702	ENSG00000224687.1	RASAL2-AS1	3.33	0.000884	0.0393	0.13	0.1	Childhood ear infection;	chr1:178139910	chr1:178091508~178093984:-
BRCA	cis	rs2411233	1	rs11637063	ENSG00000259278.1	RP11-62C7.2	3.33	0.000884	0.0393	0.12	0.1	Platelet count;	chr15:38974107	chr15:39019233~39024918:+
BRCA	cis	rs2576037	0.583	rs8096263	ENSG00000267156.1	TPMTP1	3.33	0.000884	0.0393	0.13	0.1	Personality dimensions;	chr18:46935253	chr18:47630112~47630848:+
BRCA	cis	rs10821973	0.527	rs2393869	ENSG00000238280.1	RP11-436D10.3	-3.33	0.000884	0.0393	-0.15	-0.1	Hypothyroidism;	chr10:62239504	chr10:62793562~62805887:-
BRCA	cis	rs9467773	1	rs9467783	ENSG00000261353.1	CTA-14H9.5	-3.33	0.000884	0.0393	-0.1	-0.1	Intelligence (multi-trait analysis);	chr6:26542666	chr6:26527063~26527404:+
BRCA	cis	rs74233809	0.901	rs17115100	ENSG00000213061.2	PFN1P11	3.33	0.000884	0.0393	0.21	0.1	Birth weight;	chr10:102831636	chr10:102838011~102845473:-
BRCA	cis	rs4835473	0.932	rs6843671	ENSG00000246448.2	RP13-578N3.3	-3.33	0.000884	0.0393	-0.12	-0.1	Immature fraction of reticulocytes;	chr4:143772041	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.9	rs35395070	ENSG00000246448.2	RP13-578N3.3	-3.33	0.000884	0.0393	-0.12	-0.1	Immature fraction of reticulocytes;	chr4:143772283	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.9	rs34614750	ENSG00000246448.2	RP13-578N3.3	-3.33	0.000884	0.0393	-0.12	-0.1	Immature fraction of reticulocytes;	chr4:143772369	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.932	rs35002497	ENSG00000246448.2	RP13-578N3.3	-3.33	0.000884	0.0393	-0.12	-0.1	Immature fraction of reticulocytes;	chr4:143772952	chr4:143700257~143865072:+
BRCA	cis	rs2282300	0.956	rs654710	ENSG00000242353.1	RP4-710M3.1	3.33	0.000884	0.0393	0.14	0.1	Morning vs. evening chronotype;	chr11:30372756	chr11:30368148~30368646:+
BRCA	cis	rs911555	0.511	rs8007489	ENSG00000258851.1	RP11-894P9.2	3.33	0.000884	0.0393	0.12	0.1	Intelligence (multi-trait analysis);	chr14:103588235	chr14:103553421~103561877:+
BRCA	cis	rs324126	0.78	rs1993530	ENSG00000277977.1	CTD-3018O17.5	-3.33	0.000884	0.0393	-0.12	-0.1	Colonoscopy-negative controls vs population controls;	chr19:52381756	chr19:52392659~52392755:+
BRCA	cis	rs2439831	0.85	rs28413704	ENSG00000206991.1	RNU6-610P	-3.33	0.000884	0.0393	-0.17	-0.1	Lung cancer in ever smokers;	chr15:43856229	chr15:43637632~43637738:-
BRCA	cis	rs4849845	0.637	rs62168279	ENSG00000236878.1	AC012363.7	3.33	0.000884	0.0393	0.12	0.1	Mean platelet volume;	chr2:120269195	chr2:120211054~120211715:+
BRCA	cis	rs397969	0.646	rs1638527	ENSG00000261033.1	RP11-209D14.2	3.33	0.000884	0.0393	0.15	0.1	Platelet count;	chr17:19942080	chr17:20008051~20009234:-
BRCA	cis	rs2243480	0.901	rs313808	ENSG00000226767.1	RP11-328P23.3	-3.33	0.000884	0.0393	-0.18	-0.1	Diabetic kidney disease;	chr7:66034886	chr7:65508773~65508944:-
BRCA	cis	rs375066	0.901	rs1050054	ENSG00000278917.1	RP11-15A1.4	-3.33	0.000884	0.0393	-0.12	-0.1	Breast cancer;	chr19:43872529	chr19:43891233~43895411:+
BRCA	cis	rs1865760	0.613	rs9295674	ENSG00000272462.2	U91328.19	-3.33	0.000884	0.0393	-0.12	-0.1	Height;	chr6:25912114	chr6:25992662~26001775:+
BRCA	cis	rs7412746	0.658	rs2272214	ENSG00000224800.1	RP11-235D19.2	-3.33	0.000884	0.0393	-0.13	-0.1	Melanoma;	chr1:150958986	chr1:150881236~150881683:-
BRCA	cis	rs737008	0.821	rs28671554	ENSG00000262703.1	RP11-485G7.6	3.33	0.000884	0.0393	0.11	0.1	Obesity-related traits;	chr16:11309896	chr16:11348143~11349321:-
BRCA	cis	rs13136331	0.68	rs2732208	ENSG00000249001.4	RP11-742B18.1	3.33	0.000884	0.0393	0.14	0.1	Sitting height ratio;	chr4:87729378	chr4:87568035~87733956:-
BRCA	cis	rs4664293	0.867	rs6740910	ENSG00000230783.1	AC009961.2	-3.33	0.000884	0.0393	-0.13	-0.1	Monocyte percentage of white cells;	chr2:159792709	chr2:159689217~159690291:-
BRCA	cis	rs875971	1	rs55962648	ENSG00000230189.5	GS1-124K5.2	-3.33	0.000884	0.0393	-0.08	-0.1	Aortic root size;	chr7:66160764	chr7:66409143~66490059:-
BRCA	cis	rs2692947	0.8	rs4332959	ENSG00000237510.6	AC008268.2	3.33	0.000884	0.0393	0.14	0.1	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95883373	chr2:95789654~95800166:+
BRCA	cis	rs13034020	0.641	rs12996153	ENSG00000271889.1	RP11-493E12.1	3.33	0.000884	0.0393	0.18	0.1	Hodgkin's lymphoma;	chr2:60995601	chr2:61151433~61162105:-
BRCA	cis	rs6088580	0.542	rs6059882	ENSG00000269202.1	RP4-614O4.12	-3.33	0.000884	0.0393	-0.1	-0.1	Glomerular filtration rate (creatinine);	chr20:34502362	chr20:35201747~35203288:-
BRCA	cis	rs1208	0.777	rs67629306	ENSG00000253671.1	RP11-806O11.1	-3.33	0.000885	0.0393	-0.12	-0.1	Insulin resistance/response;	chr8:18406848	chr8:17808941~17820868:+
BRCA	cis	rs10908521	0.611	rs7516736	ENSG00000223356.1	RP11-66D17.5	3.33	0.000885	0.0393	0.12	0.1	Uric acid clearance;	chr1:156825994	chr1:156712212~156713174:-
BRCA	cis	rs67478160	0.654	rs1997913	ENSG00000269910.1	RP11-73M18.10	3.33	0.000885	0.0393	0.1	0.1	Schizophrenia;	chr14:103747623	chr14:103694516~103695050:-
BRCA	cis	rs7578199	0.779	rs7585107	ENSG00000228989.1	AC133528.2	3.33	0.000885	0.0393	0.13	0.1	Chronic lymphocytic leukemia;	chr2:241460103	chr2:241690414~241694289:+
BRCA	cis	rs4883201	0.656	rs1805248	ENSG00000237248.4	LINC00987	3.33	0.000885	0.0393	0.13	0.1	Total cholesterol levels;Cholesterol, total;	chr12:8948541	chr12:9240003~9243052:+
BRCA	cis	rs2991971	0.81	rs12738318	ENSG00000281133.1	AL355480.3	-3.33	0.000885	0.0393	-0.12	-0.1	High light scatter reticulocyte count;	chr1:45463917	chr1:45580892~45580996:-
BRCA	cis	rs7837791	0.619	rs11777176	ENSG00000167912.5	RP11-25K19.1	-3.33	0.000885	0.0393	-0.09	-0.1	Refractive error;	chr8:59263770	chr8:59119040~59121346:+
BRCA	cis	rs4805834	0.843	rs77856651	ENSG00000201388.1	SNORA68	3.33	0.000885	0.0393	0.18	0.1	Creatinine levels;	chr19:32893757	chr19:32608337~32608469:-
BRCA	cis	rs735860	0.712	rs2294864	ENSG00000271367.1	RP3-483K16.4	3.33	0.000885	0.0393	0.11	0.1	Glaucoma;	chr6:53276130	chr6:53350158~53350705:+
BRCA	cis	rs4950322	0.512	rs2353981	ENSG00000237188.3	RP11-337C18.8	-3.33	0.000885	0.0393	-0.11	-0.1	Protein quantitative trait loci;	chr1:147368365	chr1:147172771~147211568:+
BRCA	cis	rs13401620	0.871	rs2289581	ENSG00000229326.3	AC069154.4	3.33	0.000885	0.0393	0.14	0.1	Breast size;	chr2:119946266	chr2:119698623~119700151:+
BRCA	cis	rs8038465	0.662	rs7497012	ENSG00000260898.4	ADPGK-AS1	3.33	0.000885	0.0393	0.11	0.1	Liver enzyme levels (gamma-glutamyl transferase);	chr15:73676378	chr15:72782835~72798199:+
BRCA	cis	rs801193	0.569	rs2013908	ENSG00000271064.1	RP11-792A8.3	3.33	0.000885	0.0393	0.12	0.1	Aortic root size;	chr7:66656082	chr7:66748838~66749077:-
BRCA	cis	rs9987353	0.566	rs13260067	ENSG00000233609.3	RP11-62H7.2	-3.33	0.000885	0.0393	-0.1	-0.1	Recombination measurement;	chr8:9213523	chr8:8961200~8979025:+
BRCA	cis	rs1348850	0.914	rs10170546	ENSG00000271825.1	RP11-337N6.2	3.33	0.000885	0.0393	0.13	0.1	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177384062	chr2:177300600~177302006:+
BRCA	cis	rs3750552	0.898	rs10867357	ENSG00000278910.2	BANCR	-3.33	0.000886	0.0393	-0.13	-0.1	Bipolar disorder;	chr9:69324515	chr9:69296682~69306977:-
BRCA	cis	rs17092148	0.887	rs2068474	ENSG00000250917.1	RP4-785G19.5	3.33	0.000886	0.0393	0.17	0.1	Neuroticism;	chr20:34643275	chr20:34234840~34281173:-
BRCA	cis	rs4302906	0.964	rs10121856	ENSG00000187984.11	ANKRD19P	-3.33	0.000886	0.0393	-0.09	-0.1	Lobe attachment (rater-scored or self-reported);	chr9:92973982	chr9:92809388~92888693:+
BRCA	cis	rs12893668	0.572	rs7148857	ENSG00000258914.1	CTD-2134A5.3	3.33	0.000886	0.0393	0.14	0.1	Reticulocyte count;	chr14:103676900	chr14:103875055~103877478:+
BRCA	cis	rs7914558	0.966	rs4917997	ENSG00000213277.3	MARCKSL1P1	3.33	0.000886	0.0393	0.12	0.1	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103185456	chr10:103175554~103176094:+
BRCA	cis	rs74233809	1	rs11191514	ENSG00000213061.2	PFN1P11	3.33	0.000886	0.0393	0.22	0.1	Birth weight;	chr10:103013607	chr10:102838011~102845473:-
BRCA	cis	rs7259811	0.859	rs4801368	ENSG00000268266.1	AC003005.2	3.33	0.000886	0.0394	0.13	0.1	Western dietary pattern;	chr19:56718357	chr19:57477649~57482996:+
BRCA	cis	rs9783347	0.6	rs10766467	ENSG00000279837.1	RP11-504G3.2	-3.33	0.000886	0.0394	-0.1	-0.1	Pancreatic cancer;	chr11:18288902	chr11:18601882~18602649:+
BRCA	cis	rs9346455	1	rs9342829	ENSG00000279289.1	RP3-331H24.6	3.33	0.000886	0.0394	0.17	0.1	Antipsychotic drug-induced weight gain;Antipsychotic drug-induced weight gain (time interaction);	chr6:71311060	chr6:71386852~71390829:-
BRCA	cis	rs193541	0.507	rs7727137	ENSG00000260686.1	CTB-36H16.2	3.33	0.000886	0.0394	0.09	0.1	Glucose homeostasis traits;	chr5:122746145	chr5:122832356~122834533:+
BRCA	cis	rs3102460	1	rs3102460	ENSG00000225401.2	TGIF2P1	-3.33	0.000886	0.0394	-0.13	-0.1	Obesity-related traits;	chr1:244413415	chr1:244394976~244395660:-
BRCA	cis	rs7520050	0.966	rs4073846	ENSG00000226957.1	RP4-533D7.4	-3.33	0.000886	0.0394	-0.11	-0.1	Reticulocyte count;Red blood cell count;	chr1:45997209	chr1:46046818~46048368:+
BRCA	cis	rs2777491	0.574	rs316611	ENSG00000247556.5	OIP5-AS1	-3.33	0.000886	0.0394	-0.12	-0.1	Ulcerative colitis;	chr15:41459480	chr15:41283990~41309737:+
BRCA	cis	rs13401620	0.917	rs10189247	ENSG00000229326.3	AC069154.4	3.33	0.000886	0.0394	0.13	0.1	Breast size;	chr2:119794134	chr2:119698623~119700151:+
BRCA	cis	rs739496	0.615	rs77684561	ENSG00000257624.1	RP1-128M12.3	3.33	0.000886	0.0394	0.15	0.1	Platelet count;	chr12:111623919	chr12:112000739~112000985:-
BRCA	cis	rs2904524	1	rs17107933	ENSG00000257613.1	LINC01481	3.33	0.000886	0.0394	0.17	0.1	Amyotrophic lateral sclerosis (age of onset);	chr12:70283707	chr12:70219132~70221862:-
BRCA	cis	rs6893300	0.524	rs12522926	ENSG00000250999.1	RP11-1379J22.5	-3.33	0.000886	0.0394	-0.12	-0.1	Resting heart rate;	chr5:179787817	chr5:179657762~179664432:+
BRCA	cis	rs860295	0.702	rs56675301	ENSG00000203761.5	MSTO2P	-3.33	0.000886	0.0394	-0.09	-0.1	Body mass index;	chr1:155394536	chr1:155745829~155750137:+
BRCA	cis	rs2832191	0.791	rs9983651	ENSG00000232855.5	AF131217.1	3.33	0.000886	0.0394	0.12	0.1	Dental caries;	chr21:29118906	chr21:28439346~28674848:-
BRCA	cis	rs2832191	0.755	rs55671430	ENSG00000232855.5	AF131217.1	3.33	0.000886	0.0394	0.12	0.1	Dental caries;	chr21:29120100	chr21:28439346~28674848:-
BRCA	cis	rs2832191	0.72	rs2832194	ENSG00000232855.5	AF131217.1	3.33	0.000886	0.0394	0.12	0.1	Dental caries;	chr21:29121929	chr21:28439346~28674848:-
BRCA	cis	rs10129255	0.5	rs34326748	ENSG00000211976.2	IGHV3-73	-3.33	0.000886	0.0394	-0.08	-0.1	Kawasaki disease;	chr14:106782523	chr14:106802694~106803233:-
BRCA	cis	rs10129255	0.5	rs10143385	ENSG00000211976.2	IGHV3-73	-3.33	0.000886	0.0394	-0.08	-0.1	Kawasaki disease;	chr14:106782559	chr14:106802694~106803233:-
BRCA	cis	rs6088580	0.634	rs2424992	ENSG00000269202.1	RP4-614O4.12	-3.33	0.000886	0.0394	-0.1	-0.1	Glomerular filtration rate (creatinine);	chr20:34424254	chr20:35201747~35203288:-
BRCA	cis	rs6088580	0.634	rs6119497	ENSG00000269202.1	RP4-614O4.12	-3.33	0.000886	0.0394	-0.1	-0.1	Glomerular filtration rate (creatinine);	chr20:34424723	chr20:35201747~35203288:-
BRCA	cis	rs889312	0.5	rs252903	ENSG00000237705.1	AC008937.2	3.33	0.000886	0.0394	0.1	0.1	Breast cancer (early onset);Breast cancer;	chr5:56822125	chr5:56842016~56862164:-
BRCA	cis	rs35306767	0.903	rs12249828	ENSG00000229869.1	RP11-363N22.2	-3.33	0.000886	0.0394	-0.16	-0.1	Eosinophil percentage of granulocytes;	chr10:848898	chr10:933026~942743:+
BRCA	cis	rs11039100	1	rs11039100	ENSG00000224295.2	AC087380.14	-3.33	0.000887	0.0394	-0.18	-0.1	Peripheral arterial disease (traffic-related air pollution interaction);	chr11:5805773	chr11:5518441~5524955:-
BRCA	cis	rs6943931	0.895	rs2686488	ENSG00000230658.1	KLHL7-AS1	3.33	0.000887	0.0394	0.13	0.1	Diabetic kidney disease;	chr7:22384705	chr7:23101228~23105703:-
BRCA	cis	rs77688320	0.535	rs12468504	ENSG00000242696.3	RN7SL40P	3.33	0.000887	0.0394	0.11	0.1	Breast cancer;	chr2:201393746	chr2:202357076~202357417:-
BRCA	cis	rs4218	0.689	rs28391430	ENSG00000259732.1	RP11-59H7.3	-3.33	0.000887	0.0394	-0.13	-0.1	Social communication problems;	chr15:59100318	chr15:59121034~59133250:+
BRCA	cis	rs10129255	0.789	rs61997796	ENSG00000231475.3	IGHV4-31	-3.33	0.000887	0.0394	-0.09	-0.1	Kawasaki disease;	chr14:106813798	chr14:106349283~106349792:-
BRCA	cis	rs11241621	0.579	rs1422723	ENSG00000248489.1	CTD-2007H13.3	3.33	0.000887	0.0394	0.13	0.1	Plantar warts;	chr5:98510171	chr5:98929171~98995013:+
BRCA	cis	rs860295	0.702	rs11264380	ENSG00000203761.5	MSTO2P	-3.33	0.000887	0.0394	-0.09	-0.1	Body mass index;	chr1:155550353	chr1:155745829~155750137:+
BRCA	cis	rs7818688	0.697	rs35032356	ENSG00000245080.5	RP11-320N21.1	-3.33	0.000887	0.0394	-0.17	-0.1	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94965256	chr8:95066808~95073182:-
BRCA	cis	rs1865760	0.613	rs9379801	ENSG00000272462.2	U91328.19	-3.33	0.000887	0.0394	-0.12	-0.1	Height;	chr6:25901483	chr6:25992662~26001775:+
BRCA	cis	rs2262909	0.893	rs4244912	ENSG00000279377.1	AC003973.3	3.33	0.000887	0.0394	0.15	0.1	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;	chr19:22020435	chr19:21965708~21968529:-
BRCA	cis	rs7071275	0.891	rs725983	ENSG00000276742.1	RP11-500G22.4	-3.33	0.000887	0.0394	-0.16	-0.1	Dupuytren's disease;	chr10:121674436	chr10:121956782~121957098:+
BRCA	cis	rs7172677	0.737	rs8027604	ENSG00000260269.4	CTD-2323K18.1	-3.33	0.000887	0.0394	-0.14	-0.1	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75155432	chr15:75527150~75601205:-
BRCA	cis	rs7172677	0.737	rs4886668	ENSG00000260269.4	CTD-2323K18.1	-3.33	0.000887	0.0394	-0.14	-0.1	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75155693	chr15:75527150~75601205:-
BRCA	cis	rs494453	0.6	rs530173	ENSG00000227811.2	FAM212B-AS1	-3.33	0.000887	0.0394	-0.13	-0.1	Osteoporosis-related phenotypes;	chr1:111654908	chr1:111739841~111747798:+
BRCA	cis	rs494453	0.6	rs561309	ENSG00000227811.2	FAM212B-AS1	-3.33	0.000887	0.0394	-0.13	-0.1	Osteoporosis-related phenotypes;	chr1:111655994	chr1:111739841~111747798:+
BRCA	cis	rs4363385	0.747	rs1577964	ENSG00000272654.1	RP11-422P24.11	3.33	0.000887	0.0394	0.11	0.1	Inflammatory skin disease;	chr1:152989308	chr1:153977743~153979160:+
BRCA	cis	rs28489187	0.66	rs2207368	ENSG00000223653.4	RP11-131L23.1	3.33	0.000887	0.0394	0.11	0.1	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85382000	chr1:85276715~85448124:+
BRCA	cis	rs78487399	0.71	rs6544665	ENSG00000234936.1	AC010883.5	3.33	0.000887	0.0394	0.15	0.1	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43502073	chr2:43229573~43233394:+
BRCA	cis	rs8105895	0.935	rs62110990	ENSG00000269345.1	VN1R85P	3.33	0.000887	0.0394	0.15	0.1	Body mass index (change over time);	chr19:22077639	chr19:22174766~22175191:-
BRCA	cis	rs873549	0.785	rs7549980	ENSG00000238042.4	RP11-815M8.1	3.33	0.000888	0.0394	0.12	0.1	Keloid;	chr1:222095156	chr1:221880981~221978523:-
BRCA	cis	rs873549	1	rs7552392	ENSG00000238042.4	RP11-815M8.1	3.33	0.000888	0.0394	0.12	0.1	Keloid;	chr1:222095349	chr1:221880981~221978523:-
BRCA	cis	rs873549	1	rs6703147	ENSG00000238042.4	RP11-815M8.1	3.33	0.000888	0.0394	0.12	0.1	Keloid;	chr1:222095423	chr1:221880981~221978523:-
BRCA	cis	rs873549	1	rs6703389	ENSG00000238042.4	RP11-815M8.1	3.33	0.000888	0.0394	0.12	0.1	Keloid;	chr1:222095609	chr1:221880981~221978523:-
BRCA	cis	rs3087591	1	rs2905877	ENSG00000263531.1	RP13-753N3.1	3.33	0.000888	0.0394	0.13	0.1	Hip circumference;	chr17:31216251	chr17:30863921~30864940:-
BRCA	cis	rs7172809	0.615	rs907371	ENSG00000260139.5	CSPG4P13	3.33	0.000888	0.0394	0.12	0.1	Glucose homeostasis traits;	chr15:77552033	chr15:77894684~77904674:+
BRCA	cis	rs7141336	0.864	rs7148903	ENSG00000260810.1	CTD-2547L24.4	3.33	0.000888	0.0394	0.12	0.1	Anxiety disorder;	chr14:90821483	chr14:91258299~91259003:+
BRCA	cis	rs74233809	1	rs9633712	ENSG00000236937.2	PTGES3P4	3.33	0.000888	0.0394	0.22	0.1	Birth weight;	chr10:103114004	chr10:102845595~102845950:+
BRCA	cis	rs74233809	0.786	rs11191564	ENSG00000236937.2	PTGES3P4	3.33	0.000888	0.0394	0.22	0.1	Birth weight;	chr10:103118786	chr10:102845595~102845950:+
BRCA	cis	rs26949	1	rs26949	ENSG00000272308.1	RP11-231G3.1	3.33	0.000888	0.0394	0.12	0.1	Intelligence (multi-trait analysis);	chr5:60529473	chr5:60866457~60866935:-
BRCA	cis	rs9467773	0.595	rs7767847	ENSG00000261353.1	CTA-14H9.5	-3.33	0.000888	0.0394	-0.1	-0.1	Intelligence (multi-trait analysis);	chr6:26597665	chr6:26527063~26527404:+
BRCA	cis	rs6710503	0.632	rs62140560	ENSG00000224165.4	DNAJC27-AS1	3.33	0.000888	0.0394	0.14	0.1	Lung cancer in ever smokers;Breast cancer;	chr2:24785409	chr2:24971390~25039694:+
BRCA	cis	rs997295	0.57	rs60066681	ENSG00000260657.2	RP11-315D16.4	3.33	0.000888	0.0394	0.13	0.1	Motion sickness;	chr15:67515738	chr15:68267792~68277994:-
BRCA	cis	rs2617583	0.53	rs12652860	ENSG00000185986.11	SDHAP3	3.33	0.000888	0.0394	0.1	0.1	Breast cancer;	chr5:1453657	chr5:1572222~1594620:-
BRCA	cis	rs6088580	0.634	rs6059829	ENSG00000269202.1	RP4-614O4.12	-3.33	0.000888	0.0394	-0.1	-0.1	Glomerular filtration rate (creatinine);	chr20:34429268	chr20:35201747~35203288:-
BRCA	cis	rs6840360	0.558	rs2709821	ENSG00000251603.1	RP11-164P12.4	-3.33	0.000888	0.0394	-0.1	-0.1	Intelligence (multi-trait analysis);	chr4:151421038	chr4:151667224~151670502:+
BRCA	cis	rs4141153	0.528	rs56101331	ENSG00000213721.3	HMGN2P30	3.33	0.000888	0.0394	0.17	0.1	Menarche (age at onset);	chr7:41456754	chr7:42113365~42113620:+
BRCA	cis	rs258892	0.895	rs7702660	ENSG00000272525.1	RP11-79P5.9	-3.33	0.000888	0.0394	-0.13	-0.1	Small cell lung carcinoma;	chr5:72748860	chr5:73497550~73498293:-
BRCA	cis	rs417065	1	rs417065	ENSG00000270171.1	RP11-338N10.1	-3.33	0.000888	0.0394	-0.14	-0.1	Psoriasis;	chr1:8204052	chr1:7693124~7694844:-
BRCA	cis	rs11662721	0.938	rs11660389	ENSG00000264188.1	RP11-13N13.5	3.33	0.000888	0.0394	0.14	0.1	Phospholipid levels (plasma);	chr18:21648213	chr18:21661787~21662395:-
BRCA	cis	rs3816183	0.598	rs6749160	ENSG00000226491.1	FTOP1	-3.33	0.000888	0.0394	-0.13	-0.1	Hypospadias;	chr2:42665450	chr2:42797225~42798712:-
BRCA	cis	rs13434995	0.562	rs73236140	ENSG00000273257.1	RP11-177J6.1	-3.33	0.000888	0.0394	-0.16	-0.1	Adiponectin levels;	chr4:55440049	chr4:55387949~55388271:+
BRCA	cis	rs683250	0.661	rs2510475	ENSG00000254551.1	RP11-727A23.7	3.33	0.000888	0.0394	0.13	0.1	Subcortical brain region volumes;	chr11:83412261	chr11:83209431~83213379:-
BRCA	cis	rs7403037	0.617	rs7172269	ENSG00000207279.1	SNORD116-24	-3.33	0.000888	0.0394	-0.13	-0.1	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24598940	chr15:25094037~25094128:+
BRCA	cis	rs9393777	0.528	rs34843552	ENSG00000216901.1	AL022393.7	3.33	0.000888	0.0394	0.15	0.1	Intelligence (multi-trait analysis);	chr6:27274136	chr6:28176188~28176674:+
BRCA	cis	rs8040855	0.599	rs6496800	ENSG00000230373.7	GOLGA6L5P	-3.33	0.000888	0.0394	-0.11	-0.1	Bulimia nervosa;	chr15:85185055	chr15:84507885~84516814:-
BRCA	cis	rs2113818	0.574	rs10179809	ENSG00000264370.1	MIR3125	-3.33	0.000888	0.0394	-0.12	-0.1	Optic cup area;	chr2:12822459	chr2:12737367~12737444:+
BRCA	cis	rs12210905	0.565	rs2393805	ENSG00000272462.2	U91328.19	-3.33	0.000889	0.0395	-0.19	-0.1	Hip circumference adjusted for BMI;	chr6:26860885	chr6:25992662~26001775:+
BRCA	cis	rs1912124	1	rs67895155	ENSG00000259343.4	TMC3-AS1	3.33	0.000889	0.0395	0.23	0.1	Peripheral arterial disease (traffic-related air pollution interaction);	chr15:81215978	chr15:81324377~81362037:+
BRCA	cis	rs1912124	1	rs66484136	ENSG00000259343.4	TMC3-AS1	3.33	0.000889	0.0395	0.23	0.1	Peripheral arterial disease (traffic-related air pollution interaction);	chr15:81216042	chr15:81324377~81362037:+
BRCA	cis	rs10197140	0.925	rs4849203	ENSG00000235721.1	AC013268.3	3.33	0.000889	0.0395	0.13	0.1	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110900433	chr2:110007675~110010783:+
BRCA	cis	rs8058578	0.943	rs35629860	ENSG00000280211.1	RP11-2C24.3	3.33	0.000889	0.0395	0.11	0.1	Multiple myeloma;	chr16:30660211	chr16:30773532~30776033:-
BRCA	cis	rs12474201	0.963	rs11676737	ENSG00000279254.1	RP11-536C12.1	-3.33	0.000889	0.0395	-0.13	-0.1	Height;	chr2:46702734	chr2:46668870~46670778:+
BRCA	cis	rs6429637	0.541	rs3791101	ENSG00000237950.1	RP11-7O11.3	-3.33	0.000889	0.0395	-0.13	-0.1	Intelligence (multi-trait analysis);	chr1:43900578	chr1:43944370~43946551:-
BRCA	cis	rs886774	0.774	rs6466208	ENSG00000273055.1	CTB-13F3.1	-3.33	0.000889	0.0395	-0.11	-0.1	Ulcerative colitis;	chr7:107922512	chr7:107942116~107942740:+
BRCA	cis	rs17209837	1	rs6465116	ENSG00000224046.1	AC005076.5	3.33	0.000889	0.0395	0.15	0.1	Gallbladder cancer;	chr7:87483685	chr7:87151423~87152420:-
BRCA	cis	rs3750082	0.817	rs2060731	ENSG00000231952.3	DPY19L1P2	-3.33	0.000889	0.0395	-0.12	-0.1	Glomerular filtration rate (creatinine);	chr7:32928734	chr7:32812757~32838570:+
BRCA	cis	rs7314811	0.52	rs7311667	ENSG00000198134.3	RP11-267J23.4	-3.33	0.000889	0.0395	-0.13	-0.1	IgG glycosylation;	chr12:11809789	chr12:12111163~12111489:+
BRCA	cis	rs2836974	0.644	rs7281853	ENSG00000238141.2	BRWD1-AS1	-3.33	0.000889	0.0395	-0.12	-0.1	Cognitive function;	chr21:39321564	chr21:39315707~39323218:+
BRCA	cis	rs6001482	0.679	rs5750786	ENSG00000253818.1	IGLV1-41	-3.33	0.000889	0.0395	-0.1	-0.1	Diastolic blood pressure;	chr22:22235358	chr22:22404207~22404721:+
BRCA	cis	rs1730008	0.865	rs699922	ENSG00000279311.1	RP11-170K4.2	-3.33	0.000889	0.0395	-0.11	-0.1	Lobe attachment (rater-scored or self-reported);	chr3:158223985	chr3:158869898~158871821:+
BRCA	cis	rs8023401	0.938	rs16960982	ENSG00000274654.1	CTD-3247H4.2	3.33	0.000889	0.0395	0.14	0.1	Spherical equivalent (joint analysis main effects and education interaction);	chr15:48477421	chr15:48528980~48529728:-
BRCA	cis	rs12612435	0.736	rs13032229	ENSG00000226806.1	AC011893.3	-3.33	0.000889	0.0395	-0.13	-0.1	Takotsubo syndrome;	chr2:136391684	chr2:135820191~135823087:+
BRCA	cis	rs1843834	0.539	rs2047135	ENSG00000274629.1	RP11-92F20.1	-3.33	0.000889	0.0395	-0.13	-0.1	IgE levels in asthmatics (D.p. specific);	chr2:224562585	chr2:224464682~224474500:+
BRCA	cis	rs7577696	0.708	rs610758	ENSG00000276334.1	AL133243.1	3.33	0.000889	0.0395	0.12	0.1	Inflammatory biomarkers;	chr2:31608492	chr2:32521927~32523547:+
BRCA	cis	rs7590268	0.697	rs11124938	ENSG00000279873.2	LINC01126	3.33	0.000889	0.0395	0.12	0.1	Orofacial clefts;	chr2:43470836	chr2:43227210~43228855:+
BRCA	cis	rs2518049	0.852	rs10752001	ENSG00000224034.1	RP11-445P17.8	3.33	0.000889	0.0395	0.19	0.1	Metabolic traits;	chr10:5076653	chr10:5266033~5271236:-
BRCA	cis	rs875971	0.929	rs778712	ENSG00000067601.7	PMS2P4	-3.33	0.000889	0.0395	-0.12	-0.1	Aortic root size;	chr7:66384991	chr7:67295608~67302907:-
BRCA	cis	rs10248619	0.505	rs2329492	ENSG00000228204.2	RP4-724E13.2	3.33	0.000889	0.0395	0.19	0.1	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr7:50735884	chr7:50866747~51022990:+
BRCA	cis	rs62025270	0.688	rs17575870	ENSG00000259367.1	RP11-815J21.4	3.33	0.000889	0.0395	0.1	0.1	Idiopathic pulmonary fibrosis;	chr15:85713926	chr15:85619623~85670948:-
BRCA	cis	rs1003719	0.788	rs2835582	ENSG00000273210.1	AP001437.1	3.33	0.00089	0.0395	0.11	0.1	Eye color traits;	chr21:37086473	chr21:37365477~37365932:-
BRCA	cis	rs240764	0.725	rs11155477	ENSG00000220695.1	RP1-121G13.3	-3.33	0.00089	0.0395	-0.11	-0.1	Neuroticism;	chr6:100487629	chr6:100530276~100531052:+
BRCA	cis	rs9847710	0.901	rs2564937	ENSG00000242849.2	ALDOAP1	3.33	0.00089	0.0395	0.12	0.1	Ulcerative colitis;	chr3:52991843	chr3:52193170~52194785:+
BRCA	cis	rs3739034	0.818	rs17883869	ENSG00000224043.6	CCNT2-AS1	-3.33	0.00089	0.0395	-0.17	-0.1	Gut microbiome composition (winter);	chr2:134731609	chr2:134735464~134918710:-
BRCA	cis	rs7697932	0.502	rs6848273	ENSG00000245322.5	RP11-15B17.1	3.33	0.00089	0.0395	0.12	0.1	Renal cell carcinoma;	chr4:100156038	chr4:99950006~100195099:+
BRCA	cis	rs979233	0.935	rs11741390	ENSG00000188850.9	RP11-159F24.2	3.33	0.00089	0.0395	0.12	0.1	Systemic lupus erythematosus;	chr5:42525250	chr5:43336164~43348716:+
BRCA	cis	rs6710503	0.632	rs13401689	ENSG00000224165.4	DNAJC27-AS1	3.33	0.00089	0.0395	0.13	0.1	Lung cancer in ever smokers;Breast cancer;	chr2:24748469	chr2:24971390~25039694:+
BRCA	cis	rs17192198	0.904	rs73200994	ENSG00000270344.2	RP11-734K2.4	-3.33	0.00089	0.0395	-0.15	-0.1	Diastolic blood pressure;	chr12:89767689	chr12:89525654~89548005:+
BRCA	cis	rs11030122	0.702	rs10835406	ENSG00000166492.9	FAM86GP	-3.33	0.00089	0.0395	-0.15	-0.1	Mean platelet volume;Platelet distribution width;	chr11:3971724	chr11:3410352~3422496:-
BRCA	cis	rs7412746	0.611	rs66847267	ENSG00000224800.1	RP11-235D19.2	-3.33	0.00089	0.0395	-0.13	-0.1	Melanoma;	chr1:150902697	chr1:150881236~150881683:-
BRCA	cis	rs1878931	0.582	rs10048083	ENSG00000279568.1	RP11-20I23.5	3.33	0.00089	0.0395	0.11	0.1	Body mass index (adult);	chr16:3367465	chr16:2575628~2577373:-
BRCA	cis	rs258892	0.843	rs4288100	ENSG00000272525.1	RP11-79P5.9	-3.33	0.00089	0.0395	-0.13	-0.1	Small cell lung carcinoma;	chr5:72735933	chr5:73497550~73498293:-
BRCA	cis	rs258892	0.843	rs4560525	ENSG00000272525.1	RP11-79P5.9	-3.33	0.00089	0.0395	-0.13	-0.1	Small cell lung carcinoma;	chr5:72735941	chr5:73497550~73498293:-
BRCA	cis	rs258892	0.895	rs11950735	ENSG00000272525.1	RP11-79P5.9	-3.33	0.00089	0.0395	-0.13	-0.1	Small cell lung carcinoma;	chr5:72735986	chr5:73497550~73498293:-
BRCA	cis	rs7045881	0.735	rs16910895	ENSG00000254396.1	RP11-56F10.3	3.33	0.00089	0.0395	0.15	0.1	Schizophrenia;	chr9:26925658	chr9:27102630~27104728:+
BRCA	cis	rs495337	0.76	rs6125813	ENSG00000224397.4	LINC01272	-3.33	0.00089	0.0395	-0.1	-0.1	Psoriasis;	chr20:49924646	chr20:50267486~50279795:+
BRCA	cis	rs863345	0.526	rs2051067	ENSG00000176320.2	RP11-404O13.5	-3.33	0.00089	0.0395	-0.11	-0.1	Pneumococcal bacteremia;	chr1:158537608	chr1:158197922~158203877:-
BRCA	cis	rs4481887	0.604	rs10888330	ENSG00000202079.1	Y_RNA	-3.33	0.00089	0.0395	-0.12	-0.1	Common traits (Other);	chr1:248247204	chr1:247294835~247294941:+
BRCA	cis	rs67478160	0.655	rs4900598	ENSG00000269910.1	RP11-73M18.10	3.33	0.00089	0.0395	0.1	0.1	Schizophrenia;	chr14:103815204	chr14:103694516~103695050:-
BRCA	cis	rs6586163	0.509	rs2031610	ENSG00000261438.1	RP11-399O19.9	-3.33	0.00089	0.0395	-0.1	-0.1	Chronic lymphocytic leukemia;	chr10:88994730	chr10:89015836~89017059:+
BRCA	cis	rs3916	1	rs1799958	ENSG00000277423.1	RP11-173P15.9	-3.33	0.000891	0.0395	-0.14	-0.1	Urinary metabolites (H-NMR features);	chr12:120738280	chr12:120703867~120704282:+
BRCA	cis	rs9783347	0.6	rs10766468	ENSG00000256361.1	RP11-613F22.6	-3.33	0.000891	0.0395	-0.12	-0.1	Pancreatic cancer;	chr11:18300396	chr11:18511043~18511475:-
BRCA	cis	rs2281558	0.583	rs7260957	ENSG00000226465.1	RP13-401N8.1	-3.33	0.000891	0.0395	-0.19	-0.1	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25741826	chr20:25751218~25752761:+
BRCA	cis	rs2832077	0.943	rs4816332	ENSG00000215533.7	LINC00189	3.33	0.000891	0.0395	0.15	0.1	Cognitive test performance;	chr21:28829384	chr21:29193480~29288205:+
BRCA	cis	rs2832077	0.824	rs4816333	ENSG00000215533.7	LINC00189	3.33	0.000891	0.0395	0.15	0.1	Cognitive test performance;	chr21:28829455	chr21:29193480~29288205:+
BRCA	cis	rs13113518	0.51	rs3749473	ENSG00000249700.7	SRD5A3-AS1	3.33	0.000891	0.0395	0.13	0.1	Height;	chr4:55428461	chr4:55363971~55395847:-
BRCA	cis	rs1144333	0.85	rs1251273	ENSG00000181227.3	RP4-682C21.2	3.33	0.000891	0.0395	0.14	0.1	Attention function in attention deficit hyperactive disorder;	chr1:75822932	chr1:75743423~75744776:-
BRCA	cis	rs372883	0.58	rs2254038	ENSG00000176054.6	RPL23P2	3.33	0.000891	0.0395	0.11	0.1	Pancreatic cancer;	chr21:29373402	chr21:28997613~28998033:-
BRCA	cis	rs1450679	1	rs1450679	ENSG00000270332.1	SMC2-AS1	3.33	0.000891	0.0395	0.16	0.1	Response to cytadine analogues (cytosine arabinoside);	chr9:104264531	chr9:104080024~104093073:-
BRCA	cis	rs703108	0.956	rs12766604	ENSG00000272516.1	RP11-573G6.9	-3.33	0.000891	0.0395	-0.16	-0.1	Monocyte percentage of white cells;	chr10:22122342	chr10:22332404~22332987:+
BRCA	cis	rs1250229	0.516	rs1250255	ENSG00000225166.1	AC012462.2	3.33	0.000891	0.0395	0.15	0.1	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);LDL cholesterol;Cholesterol, total;LDL cholesterol levels;Coronary artery disease;	chr2:215451764	chr2:215453707~215463871:+
BRCA	cis	rs7714670	0.586	rs1009200	ENSG00000184084.7	CTD-2372A4.1	-3.33	0.000891	0.0395	-0.13	-0.1	Venous thromboembolism (SNP x SNP interaction);	chr5:73809450	chr5:73803296~73803599:-
BRCA	cis	rs8098244	0.77	rs62094786	ENSG00000265752.2	RP11-403A21.1	3.33	0.000891	0.0395	0.13	0.1	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23795719	chr18:23957754~23982556:-
BRCA	cis	rs4243971	0.516	rs6141666	ENSG00000277692.1	RP11-358N2.2	-3.33	0.000891	0.0395	-0.12	-0.1	Inflammatory bowel disease;Crohn's disease;	chr20:32307959	chr20:32355053~32355734:+
BRCA	cis	rs2692947	0.759	rs1917890	ENSG00000168992.4	OR7E102P	3.33	0.000891	0.0395	0.14	0.1	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96006253	chr2:95546531~95547545:+
BRCA	cis	rs875971	0.651	rs2420596	ENSG00000106610.13	STAG3L4	-3.33	0.000891	0.0395	-0.14	-0.1	Aortic root size;	chr7:66450996	chr7:67302621~67321526:+
BRCA	cis	rs875971	0.52	rs2420597	ENSG00000106610.13	STAG3L4	-3.33	0.000891	0.0395	-0.14	-0.1	Aortic root size;	chr7:66450999	chr7:67302621~67321526:+
BRCA	cis	rs11700980	0.551	rs16983159	ENSG00000232855.5	AF131217.1	3.33	0.000891	0.0395	0.15	0.1	QRS complex (12-leadsum);	chr21:28746004	chr21:28439346~28674848:-
BRCA	cis	rs1113500	0.787	rs12047429	ENSG00000230489.1	VAV3-AS1	-3.33	0.000891	0.0395	-0.12	-0.1	Growth-regulated protein alpha levels;	chr1:108090617	chr1:107964443~107994607:+
BRCA	cis	rs7818688	0.697	rs11784212	ENSG00000245080.5	RP11-320N21.1	-3.33	0.000891	0.0395	-0.17	-0.1	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94964767	chr8:95066808~95073182:-
BRCA	cis	rs4718428	0.705	rs68168107	ENSG00000229886.1	RP5-1132H15.3	3.33	0.000891	0.0395	0.13	0.1	Corneal structure;	chr7:66790251	chr7:66025126~66031544:-
BRCA	cis	rs1912124	1	rs950070	ENSG00000259343.4	TMC3-AS1	3.33	0.000891	0.0396	0.24	0.1	Peripheral arterial disease (traffic-related air pollution interaction);	chr15:81226465	chr15:81324377~81362037:+
BRCA	cis	rs60678552	0.642	rs9488903	ENSG00000233558.1	RP3-486I3.4	3.33	0.000891	0.0396	0.18	0.1	Heschl's gyrus morphology;	chr6:116321749	chr6:116258493~116259115:-
BRCA	cis	rs6453278	0.52	rs13182877	ENSG00000250802.5	ZBED3-AS1	-3.33	0.000891	0.0396	-0.16	-0.1	Autism;	chr5:77098755	chr5:77086740~77166909:+
BRCA	cis	rs3750082	1	rs3750082	ENSG00000231952.3	DPY19L1P2	3.33	0.000891	0.0396	0.12	0.1	Glomerular filtration rate (creatinine);	chr7:32880315	chr7:32812757~32838570:+
BRCA	cis	rs2281603	0.857	rs3783722	ENSG00000259116.1	RP11-973N13.4	-3.33	0.000891	0.0396	-0.1	-0.1	Lymphocyte counts;	chr14:64531248	chr14:64514154~64540368:-
BRCA	cis	rs2642442	0.962	rs2807834	ENSG00000238078.1	LINC01352	3.33	0.000892	0.0396	0.11	0.1	Cholesterol, total;LDL cholesterol;	chr1:220797251	chr1:220829255~220832429:+
BRCA	cis	rs36093844	0.8	rs17817326	ENSG00000279742.1	RP11-700A24.1	-3.33	0.000892	0.0396	-0.16	-0.1	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85884170	chr11:85852557~85854943:-
BRCA	cis	rs375066	0.935	rs367283	ENSG00000278917.1	RP11-15A1.4	-3.33	0.000892	0.0396	-0.12	-0.1	Breast cancer;	chr19:43901975	chr19:43891233~43895411:+
BRCA	cis	rs11673344	0.704	rs510757	ENSG00000267682.1	CTD-3220F14.2	3.33	0.000892	0.0396	0.09	0.1	Obesity-related traits;	chr19:36931900	chr19:37337236~37337743:+
BRCA	cis	rs75757892	0.621	rs77690503	ENSG00000236512.1	RP3-336K20__B.2	3.33	0.000892	0.0396	0.17	0.1	Hematocrit;Red blood cell count;	chr6:7285312	chr6:7620422~7620878:+
BRCA	cis	rs75757892	0.621	rs1050681	ENSG00000236512.1	RP3-336K20__B.2	3.33	0.000892	0.0396	0.17	0.1	Hematocrit;Red blood cell count;	chr6:7289549	chr6:7620422~7620878:+
BRCA	cis	rs863345	0.604	rs7514968	ENSG00000176320.2	RP11-404O13.5	-3.33	0.000892	0.0396	-0.11	-0.1	Pneumococcal bacteremia;	chr1:158524062	chr1:158197922~158203877:-
BRCA	cis	rs863345	0.604	rs7525362	ENSG00000176320.2	RP11-404O13.5	-3.33	0.000892	0.0396	-0.11	-0.1	Pneumococcal bacteremia;	chr1:158524100	chr1:158197922~158203877:-
BRCA	cis	rs875971	0.895	rs6460278	ENSG00000223473.2	GS1-124K5.3	-3.33	0.000892	0.0396	-0.08	-0.1	Aortic root size;	chr7:66197749	chr7:66491049~66493566:-
BRCA	cis	rs875971	0.862	rs6460279	ENSG00000223473.2	GS1-124K5.3	-3.33	0.000892	0.0396	-0.08	-0.1	Aortic root size;	chr7:66197774	chr7:66491049~66493566:-
BRCA	cis	rs875971	0.862	rs28491091	ENSG00000223473.2	GS1-124K5.3	-3.33	0.000892	0.0396	-0.08	-0.1	Aortic root size;	chr7:66204077	chr7:66491049~66493566:-
BRCA	cis	rs1664789	0.715	rs697111	ENSG00000272416.1	CTD-2081C10.7	3.33	0.000892	0.0396	0.11	0.1	Waist circumference adjusted for body mass index;	chr5:53965500	chr5:53880293~53881051:-
BRCA	cis	rs950169	0.544	rs62021193	ENSG00000230373.7	GOLGA6L5P	-3.33	0.000892	0.0396	-0.12	-0.1	Schizophrenia;	chr15:84627352	chr15:84507885~84516814:-
BRCA	cis	rs875971	1	rs778726	ENSG00000229886.1	RP5-1132H15.3	3.33	0.000892	0.0396	0.11	0.1	Aortic root size;	chr7:66363744	chr7:66025126~66031544:-
BRCA	cis	rs875971	0.767	rs1695815	ENSG00000229886.1	RP5-1132H15.3	3.33	0.000892	0.0396	0.11	0.1	Aortic root size;	chr7:66366357	chr7:66025126~66031544:-
BRCA	cis	rs875971	1	rs778685	ENSG00000229886.1	RP5-1132H15.3	3.33	0.000892	0.0396	0.11	0.1	Aortic root size;	chr7:66371189	chr7:66025126~66031544:-
BRCA	cis	rs875971	0.929	rs778682	ENSG00000229886.1	RP5-1132H15.3	3.33	0.000892	0.0396	0.11	0.1	Aortic root size;	chr7:66372947	chr7:66025126~66031544:-
BRCA	cis	rs875971	0.964	rs11765965	ENSG00000229886.1	RP5-1132H15.3	3.33	0.000892	0.0396	0.11	0.1	Aortic root size;	chr7:66377234	chr7:66025126~66031544:-
BRCA	cis	rs8060686	0.545	rs8056649	ENSG00000260459.2	FTLP14	3.33	0.000892	0.0396	0.17	0.1	HDL cholesterol;Metabolic syndrome;	chr16:68226180	chr16:68822587~68823070:+
BRCA	cis	rs10992471	0.526	rs10761181	ENSG00000187984.11	ANKRD19P	-3.33	0.000892	0.0396	-0.09	-0.1	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr9:92895995	chr9:92809388~92888693:+
BRCA	cis	rs7267979	1	rs2258201	ENSG00000204556.4	CTD-2514C3.1	-3.33	0.000892	0.0396	-0.14	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25291854	chr20:26018832~26020684:+
BRCA	cis	rs10883723	0.81	rs7912901	ENSG00000213061.2	PFN1P11	-3.33	0.000892	0.0396	-0.14	-0.1	Allergic disease (asthma, hay fever or eczema);	chr10:102517683	chr10:102838011~102845473:-
BRCA	cis	rs9375946	0.512	rs12191555	ENSG00000228439.4	TSTD3	3.33	0.000892	0.0396	0.15	0.1	Depressive symptoms;	chr6:99089840	chr6:99520693~99531918:+
BRCA	cis	rs7267979	1	rs6107033	ENSG00000274414.1	RP5-965G21.4	3.33	0.000892	0.0396	0.12	0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25382955	chr20:25239007~25245229:-
BRCA	cis	rs7647973	1	rs940045	ENSG00000225399.4	RP11-3B7.1	3.33	0.000892	0.0396	0.11	0.1	Menarche (age at onset);	chr3:49412205	chr3:49260085~49261316:+
BRCA	cis	rs12477438	0.7	rs12467679	ENSG00000226791.5	AC109826.1	3.33	0.000892	0.0396	0.14	0.1	Chronic sinus infection;	chr2:99037986	chr2:98761938~98772920:-
BRCA	cis	rs875971	0.522	rs10807697	ENSG00000229180.5	GS1-124K5.11	3.33	0.000892	0.0396	0.09	0.1	Aortic root size;	chr7:65951183	chr7:66526088~66542624:-
BRCA	cis	rs875971	0.929	rs10950041	ENSG00000273448.1	RP11-166O4.6	3.33	0.000892	0.0396	0.09	0.1	Aortic root size;	chr7:66508888	chr7:67333047~67334383:+
BRCA	cis	rs7226835	0.818	rs11659814	ENSG00000267374.1	RP11-244M2.1	3.33	0.000893	0.0396	0.23	0.1	Obesity-related traits;	chr18:39589197	chr18:39206924~39800318:-
BRCA	cis	rs1555322	1	rs1555322	ENSG00000269202.1	RP4-614O4.12	-3.33	0.000893	0.0396	-0.15	-0.1	Attention deficit hyperactivity disorder;	chr20:35261376	chr20:35201747~35203288:-
BRCA	cis	rs72820985	1	rs16954075	ENSG00000260643.1	RP11-303E16.8	-3.33	0.000893	0.0396	-0.14	-0.1	Breast cancer;	chr16:80813665	chr16:81053665~81087651:-
BRCA	cis	rs4921164	1	rs11959798	ENSG00000245812.2	RP11-175K6.1	-3.33	0.000893	0.0396	-0.13	-0.1	Gut microbiome composition (winter);	chr5:159115504	chr5:159100483~159117478:+
BRCA	cis	rs2625529	0.652	rs8027164	ENSG00000261187.1	RP11-1007O24.2	3.33	0.000893	0.0396	0.11	0.1	Red blood cell count;	chr15:72115392	chr15:72465128~72466262:-
BRCA	cis	rs8114671	0.57	rs3761144	ENSG00000261582.1	RP4-614O4.11	-3.33	0.000893	0.0396	-0.1	-0.1	Height;	chr20:34956272	chr20:35267885~35280043:-
BRCA	cis	rs654950	0.841	rs2759247	ENSG00000230881.1	RP11-486B10.3	3.33	0.000893	0.0396	0.1	0.1	Airway imaging phenotypes;	chr1:41526085	chr1:41535443~41535868:+
BRCA	cis	rs654950	0.841	rs2810549	ENSG00000230881.1	RP11-486B10.3	3.33	0.000893	0.0396	0.1	0.1	Airway imaging phenotypes;	chr1:41526090	chr1:41535443~41535868:+
BRCA	cis	rs9346455	1	rs9346455	ENSG00000279289.1	RP3-331H24.6	3.33	0.000893	0.0396	0.17	0.1	Antipsychotic drug-induced weight gain;Antipsychotic drug-induced weight gain (time interaction);	chr6:71282113	chr6:71386852~71390829:-
BRCA	cis	rs7487075	0.82	rs7134855	ENSG00000274723.1	RP11-618L22.1	3.33	0.000893	0.0396	0.12	0.1	Itch intensity from mosquito bite;	chr12:46317527	chr12:46970504~46972155:+
BRCA	cis	rs6088580	0.602	rs6059834	ENSG00000269202.1	RP4-614O4.12	-3.33	0.000893	0.0396	-0.1	-0.1	Glomerular filtration rate (creatinine);	chr20:34431493	chr20:35201747~35203288:-
BRCA	cis	rs6088580	0.634	rs6059835	ENSG00000269202.1	RP4-614O4.12	-3.33	0.000893	0.0396	-0.1	-0.1	Glomerular filtration rate (creatinine);	chr20:34432335	chr20:35201747~35203288:-
BRCA	cis	rs4664293	0.546	rs12469866	ENSG00000230783.1	AC009961.2	3.33	0.000893	0.0396	0.13	0.1	Monocyte percentage of white cells;	chr2:159766119	chr2:159689217~159690291:-
BRCA	cis	rs1542829	0.539	rs55919113	ENSG00000249846.5	RP11-77P16.4	-3.33	0.000893	0.0396	-0.19	-0.1	Body mass index;	chr3:130516404	chr3:130112550~130120579:+
BRCA	cis	rs6504622	0.537	rs1662594	ENSG00000263142.4	LRRC37A17P	3.33	0.000893	0.0396	0.08	0.1	Orofacial clefts;	chr17:46915371	chr17:46978481~47054569:+
BRCA	cis	rs67478160	0.608	rs11160760	ENSG00000269910.1	RP11-73M18.10	3.33	0.000893	0.0396	0.1	0.1	Schizophrenia;	chr14:103782601	chr14:103694516~103695050:-
BRCA	cis	rs6710503	0.715	rs79682290	ENSG00000224165.4	DNAJC27-AS1	3.33	0.000893	0.0396	0.12	0.1	Lung cancer in ever smokers;Breast cancer;	chr2:24818697	chr2:24971390~25039694:+
BRCA	cis	rs13434995	0.513	rs62303722	ENSG00000273257.1	RP11-177J6.1	-3.33	0.000893	0.0396	-0.16	-0.1	Adiponectin levels;	chr4:55482076	chr4:55387949~55388271:+
BRCA	cis	rs1119582	1	rs327819	ENSG00000279118.1	RP11-517I3.2	3.33	0.000893	0.0396	0.12	0.1	Select biomarker traits;	chr5:125943836	chr5:126496279~126498604:+
BRCA	cis	rs7617480	0.648	rs6801211	ENSG00000244380.1	RP11-24C3.2	3.33	0.000893	0.0396	0.13	0.1	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48736987	chr3:48440352~48446656:-
BRCA	cis	rs867371	0.614	rs1814739	ENSG00000276710.3	CSPG4P8	-3.33	0.000893	0.0396	-0.12	-0.1	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82234283	chr15:82459472~82477258:+
BRCA	cis	rs950169	0.614	rs765524	ENSG00000176700.18	SCAND2P	-3.33	0.000893	0.0396	-0.11	-0.1	Schizophrenia;	chr15:84013030	chr15:84631451~84647478:+
BRCA	cis	rs6546886	0.625	rs12991192	ENSG00000257800.1	FNBP1P1	-3.33	0.000894	0.0396	-0.11	-0.1	Dialysis-related mortality;	chr2:74082539	chr2:74120680~74123218:+
BRCA	cis	rs6012564	0.963	rs2075679	ENSG00000227431.4	CSE1L-AS1	3.33	0.000894	0.0396	0.12	0.1	Anger;	chr20:49085052	chr20:49040463~49046044:-
BRCA	cis	rs4664293	0.802	rs7563417	ENSG00000230783.1	AC009961.2	-3.33	0.000894	0.0396	-0.14	-0.1	Monocyte percentage of white cells;	chr2:159727762	chr2:159689217~159690291:-
BRCA	cis	rs853679	0.517	rs4713150	ENSG00000226314.6	ZNF192P1	-3.33	0.000894	0.0396	-0.16	-0.1	Depression;	chr6:28168434	chr6:28161781~28169594:+
BRCA	cis	rs4713118	0.527	rs4713151	ENSG00000226314.6	ZNF192P1	-3.33	0.000894	0.0396	-0.16	-0.1	Parkinson's disease;	chr6:28168578	chr6:28161781~28169594:+
BRCA	cis	rs853679	0.517	rs9393901	ENSG00000226314.6	ZNF192P1	-3.33	0.000894	0.0396	-0.16	-0.1	Depression;	chr6:28169019	chr6:28161781~28169594:+
BRCA	cis	rs853679	0.517	rs3173443	ENSG00000226314.6	ZNF192P1	-3.33	0.000894	0.0396	-0.16	-0.1	Depression;	chr6:28169249	chr6:28161781~28169594:+
BRCA	cis	rs853679	0.517	rs4713152	ENSG00000226314.6	ZNF192P1	-3.33	0.000894	0.0396	-0.16	-0.1	Depression;	chr6:28169676	chr6:28161781~28169594:+
BRCA	cis	rs853679	0.517	rs9348797	ENSG00000226314.6	ZNF192P1	-3.33	0.000894	0.0396	-0.16	-0.1	Depression;	chr6:28169755	chr6:28161781~28169594:+
BRCA	cis	rs853679	0.517	rs9380062	ENSG00000226314.6	ZNF192P1	-3.33	0.000894	0.0396	-0.16	-0.1	Depression;	chr6:28169791	chr6:28161781~28169594:+
BRCA	cis	rs853679	0.542	rs9380063	ENSG00000226314.6	ZNF192P1	-3.33	0.000894	0.0396	-0.16	-0.1	Depression;	chr6:28170075	chr6:28161781~28169594:+
BRCA	cis	rs74233809	1	rs12217501	ENSG00000213061.2	PFN1P11	3.33	0.000894	0.0396	0.23	0.1	Birth weight;	chr10:103092132	chr10:102838011~102845473:-
BRCA	cis	rs6696239	0.956	rs10916189	ENSG00000227711.2	RP11-275O4.5	-3.33	0.000894	0.0396	-0.14	-0.1	Height;	chr1:227639425	chr1:227509028~227520477:-
BRCA	cis	rs8180040	0.676	rs11130114	ENSG00000260236.1	RP11-708J19.1	3.33	0.000894	0.0396	0.09	0.1	Colorectal cancer;	chr3:47113161	chr3:47379089~47380999:-
BRCA	cis	rs853679	0.607	rs71559070	ENSG00000216901.1	AL022393.7	3.33	0.000894	0.0396	0.27	0.1	Depression;	chr6:28071151	chr6:28176188~28176674:+
BRCA	cis	rs853679	0.607	rs35902873	ENSG00000216901.1	AL022393.7	3.33	0.000894	0.0396	0.27	0.1	Depression;	chr6:28091171	chr6:28176188~28176674:+
BRCA	cis	rs853679	0.607	rs13197574	ENSG00000216901.1	AL022393.7	3.33	0.000894	0.0396	0.27	0.1	Depression;	chr6:28092461	chr6:28176188~28176674:+
BRCA	cis	rs6764184	1	rs12715519	ENSG00000244161.1	FLNB-AS1	3.33	0.000894	0.0396	0.09	0.1	Optic cup area;Vertical cup-disc ratio;	chr3:58016379	chr3:58162547~58170636:-
BRCA	cis	rs12949688	0.87	rs9906591	ENSG00000262623.1	RP5-1107A17.2	-3.33	0.000894	0.0396	-0.11	-0.1	Schizophrenia;	chr17:57739471	chr17:56951664~56952404:+
BRCA	cis	rs10484434	0.818	rs61289224	ENSG00000272810.1	U91328.22	3.33	0.000894	0.0396	0.15	0.1	HIV-1 viral setpoint;	chr6:26049068	chr6:26013241~26013757:+
BRCA	cis	rs863345	0.604	rs10908666	ENSG00000176320.2	RP11-404O13.5	-3.33	0.000894	0.0397	-0.11	-0.1	Pneumococcal bacteremia;	chr1:158530308	chr1:158197922~158203877:-
BRCA	cis	rs863345	0.564	rs10908667	ENSG00000176320.2	RP11-404O13.5	-3.33	0.000894	0.0397	-0.11	-0.1	Pneumococcal bacteremia;	chr1:158530331	chr1:158197922~158203877:-
BRCA	cis	rs13326165	0.76	rs17052061	ENSG00000243224.1	RP5-1157M23.2	-3.33	0.000894	0.0397	-0.15	-0.1	HDL cholesterol levels;HDL cholesterol;	chr3:52312224	chr3:52239258~52241097:+
BRCA	cis	rs62025270	0.632	rs62022942	ENSG00000259367.1	RP11-815J21.4	3.33	0.000895	0.0397	0.1	0.1	Idiopathic pulmonary fibrosis;	chr15:85715337	chr15:85619623~85670948:-
BRCA	cis	rs7713317	1	rs12186664	ENSG00000236882.6	LINC01554	3.33	0.000895	0.0397	0.12	0.1	Body mass index;	chr5:96294521	chr5:95852232~95860133:+
BRCA	cis	rs877819	0.697	rs7094742	ENSG00000228403.1	RP11-563N6.6	-3.33	0.000895	0.0397	-0.11	-0.1	Systemic lupus erythematosus;	chr10:48849280	chr10:48878022~48878649:+
BRCA	cis	rs11671005	0.57	rs73062110	ENSG00000269473.1	CTD-2619J13.19	3.33	0.000895	0.0397	0.16	0.1	Mean platelet volume;	chr19:58425275	chr19:58440448~58445849:+
BRCA	cis	rs74233809	1	rs79082900	ENSG00000213061.2	PFN1P11	3.33	0.000895	0.0397	0.23	0.1	Birth weight;	chr10:103117545	chr10:102838011~102845473:-
BRCA	cis	rs8073060	0.963	rs4795082	ENSG00000270871.1	AC015849.19	3.33	0.000895	0.0397	0.1	0.1	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35546482	chr17:35816717~35830293:-
BRCA	cis	rs1424638	0.609	rs11685013	ENSG00000233251.6	AC007743.1	-3.33	0.000895	0.0397	-0.12	-0.1	Intelligence (multi-trait analysis);	chr2:57014623	chr2:56173534~56185770:-
BRCA	cis	rs6089829	0.962	rs6062777	ENSG00000233017.2	RP5-908M14.5	3.33	0.000895	0.0397	0.13	0.1	Prostate cancer (SNP x SNP interaction);	chr20:63032396	chr20:62427827~62447621:+
BRCA	cis	rs4714291	0.963	rs1721411	ENSG00000180211.5	RP1-278E11.3	3.33	0.000895	0.0397	0.11	0.1	Strep throat;	chr6:40134651	chr6:39958414~39958833:-
BRCA	cis	rs2400749	0.83	rs4905858	ENSG00000258521.1	RP11-638I2.9	-3.33	0.000895	0.0397	-0.1	-0.1	Alzheimer's disease (survival time);	chr14:99566071	chr14:100339832~100340554:+
BRCA	cis	rs1949733	0.701	rs2688222	ENSG00000251615.3	RP11-774O3.3	-3.33	0.000895	0.0397	-0.11	-0.1	Response to antineoplastic agents;	chr4:8472008	chr4:8355090~8358338:-
BRCA	cis	rs9457247	0.624	rs9457260	ENSG00000272549.1	RP11-351J23.2	-3.33	0.000895	0.0397	-0.11	-0.1	Crohn's disease;	chr6:167053177	chr6:167666840~167679270:-
BRCA	cis	rs9866825	0.967	rs9830988	ENSG00000227110.5	LMCD1-AS1	3.33	0.000895	0.0397	0.12	0.1	QT interval;	chr3:8207798	chr3:7952805~8611924:-
BRCA	cis	rs867529	0.924	rs6731022	ENSG00000234028.3	AC062029.1	3.33	0.000895	0.0397	0.11	0.1	Height;	chr2:88617517	chr2:88627539~88631821:+
BRCA	cis	rs977987	0.788	rs7184525	ENSG00000261476.1	RP11-77K12.3	-3.33	0.000895	0.0397	-0.11	-0.1	Dupuytren's disease;	chr16:75403288	chr16:75458252~75460017:-
BRCA	cis	rs7914558	1	rs10748838	ENSG00000213277.3	MARCKSL1P1	3.33	0.000895	0.0397	0.12	0.1	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103184229	chr10:103175554~103176094:+
BRCA	cis	rs7914558	0.966	rs3758543	ENSG00000213277.3	MARCKSL1P1	3.33	0.000895	0.0397	0.12	0.1	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103184987	chr10:103175554~103176094:+
BRCA	cis	rs713477	0.654	rs12886848	ENSG00000186615.9	KTN1-AS1	-3.33	0.000895	0.0397	-0.12	-0.1	Pediatric bone mineral content (femoral neck);	chr14:55444420	chr14:55499278~55580110:-
BRCA	cis	rs988913	0.723	rs7761568	ENSG00000261116.1	RP3-523K23.2	3.33	0.000895	0.0397	0.12	0.1	Menarche (age at onset);	chr6:55140628	chr6:54943167~54945099:+
BRCA	cis	rs3843482	1	rs3843482	ENSG00000271815.1	CTD-2235C13.3	-3.33	0.000895	0.0397	-0.14	-0.1	LDL cholesterol;	chr5:75343434	chr5:75363760~75364242:+
BRCA	cis	rs7267979	1	rs2257982	ENSG00000204556.4	CTD-2514C3.1	-3.33	0.000895	0.0397	-0.14	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25288994	chr20:26018832~26020684:+
BRCA	cis	rs7267979	1	rs2257985	ENSG00000204556.4	CTD-2514C3.1	-3.33	0.000895	0.0397	-0.14	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25289107	chr20:26018832~26020684:+
BRCA	cis	rs7267979	1	rs2257988	ENSG00000204556.4	CTD-2514C3.1	-3.33	0.000895	0.0397	-0.14	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25289367	chr20:26018832~26020684:+
BRCA	cis	rs2882667	0.69	rs288014	ENSG00000242683.1	CTB-46B19.1	-3.33	0.000895	0.0397	-0.12	-0.1	Age-related hearing impairment (SNP x SNP interaction);	chr5:138860104	chr5:139035148~139035987:-
BRCA	cis	rs4660456	0.913	rs552147	ENSG00000272145.1	NFYC-AS1	3.33	0.000895	0.0397	0.12	0.1	Platelet count;	chr1:40689141	chr1:40690380~40692066:-
BRCA	cis	rs58521262	0.556	rs290582	ENSG00000267920.1	SNX6P1	3.33	0.000895	0.0397	0.14	0.1	Testicular germ cell tumor;	chr19:23015301	chr19:23126569~23127792:-
BRCA	cis	rs7474896	1	rs2738209	ENSG00000120555.12	SEPT7P9	-3.33	0.000895	0.0397	-0.18	-0.1	Obesity (extreme);	chr10:38018286	chr10:38383069~38402916:-
BRCA	cis	rs1150668	0.83	rs2859365	ENSG00000273712.1	RP5-874C20.7	-3.33	0.000895	0.0397	-0.12	-0.1	Pubertal anthropometrics;	chr6:28423688	chr6:28315613~28315883:-
BRCA	cis	rs10905065	0.898	rs2892078	ENSG00000215267.7	AKR1C7P	-3.33	0.000895	0.0397	-0.13	-0.1	Menopause (age at onset);	chr10:5789175	chr10:5275173~5288470:-
BRCA	cis	rs7264396	0.563	rs17093093	ENSG00000088340.14	FER1L4	-3.33	0.000895	0.0397	-0.15	-0.1	Total cholesterol levels;	chr20:35793003	chr20:35558737~35607562:-
BRCA	cis	rs62025270	0.632	rs10520594	ENSG00000259367.1	RP11-815J21.4	-3.33	0.000895	0.0397	-0.1	-0.1	Idiopathic pulmonary fibrosis;	chr15:85585410	chr15:85619623~85670948:-
BRCA	cis	rs752010	0.644	rs7541348	ENSG00000230638.4	RP11-486B10.4	-3.33	0.000895	0.0397	-0.13	-0.1	Lupus nephritis in systemic lupus erythematosus;	chr1:41647544	chr1:41542069~41544310:+
BRCA	cis	rs2559856	1	rs10778139	ENSG00000199933.1	RNY1P16	-3.33	0.000895	0.0397	-0.11	-0.1	Blood protein levels;	chr12:101689424	chr12:101719808~101719918:+
BRCA	cis	rs35520189	0.845	rs34899562	ENSG00000274877.1	RP11-65I12.1	-3.33	0.000895	0.0397	-0.15	-0.1	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:112883895	chr2:113237595~113240825:+
BRCA	cis	rs35520189	0.845	rs13021862	ENSG00000274877.1	RP11-65I12.1	-3.33	0.000895	0.0397	-0.15	-0.1	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:112884367	chr2:113237595~113240825:+
BRCA	cis	rs72928364	1	rs17398684	ENSG00000244119.1	PDCL3P4	3.33	0.000896	0.0397	0.13	0.1	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100976498	chr3:101712472~101713191:+
BRCA	cis	rs72928364	1	rs62275199	ENSG00000244119.1	PDCL3P4	3.33	0.000896	0.0397	0.13	0.1	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100976569	chr3:101712472~101713191:+
BRCA	cis	rs72928364	1	rs62275200	ENSG00000244119.1	PDCL3P4	3.33	0.000896	0.0397	0.13	0.1	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100977787	chr3:101712472~101713191:+
BRCA	cis	rs72928364	1	rs35517882	ENSG00000244119.1	PDCL3P4	3.33	0.000896	0.0397	0.13	0.1	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100978330	chr3:101712472~101713191:+
BRCA	cis	rs8114671	0.562	rs8116657	ENSG00000279253.1	RP4-614O4.13	-3.33	0.000896	0.0397	-0.12	-0.1	Height;	chr20:34888671	chr20:35262727~35264187:-
BRCA	cis	rs10807026	1	rs10807026	ENSG00000219392.1	RP1-265C24.5	3.33	0.000896	0.0397	0.14	0.1	Lung adenocarcinoma;	chr6:27587740	chr6:28115628~28116551:+
BRCA	cis	rs11212260	0.522	rs1789163	ENSG00000240652.1	RP11-832N8.1	3.33	0.000896	0.0397	0.13	0.1	IgG glycosylation;	chr11:107506284	chr11:107908420~107908764:+
BRCA	cis	rs1974653	0.781	rs4476436	ENSG00000236540.6	AC006547.13	-3.33	0.000896	0.0397	-0.12	-0.1	Schizophrenia;	chr22:20095438	chr22:20058030~20070569:-
BRCA	cis	rs35306767	0.903	rs34847097	ENSG00000229869.1	RP11-363N22.2	-3.33	0.000896	0.0397	-0.16	-0.1	Eosinophil percentage of granulocytes;	chr10:856312	chr10:933026~942743:+
BRCA	cis	rs8114671	0.527	rs2253484	ENSG00000261582.1	RP4-614O4.11	3.33	0.000896	0.0397	0.1	0.1	Height;	chr20:34817460	chr20:35267885~35280043:-
BRCA	cis	rs7267979	1	rs2257432	ENSG00000204556.4	CTD-2514C3.1	-3.33	0.000896	0.0397	-0.14	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25290450	chr20:26018832~26020684:+
BRCA	cis	rs7267979	1	rs2258066	ENSG00000204556.4	CTD-2514C3.1	-3.33	0.000896	0.0397	-0.14	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25290690	chr20:26018832~26020684:+
BRCA	cis	rs7267979	1	rs2258135	ENSG00000204556.4	CTD-2514C3.1	-3.33	0.000896	0.0397	-0.14	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25291687	chr20:26018832~26020684:+
BRCA	cis	rs78587638	0.654	rs7589626	ENSG00000226856.4	AC093901.1	-3.33	0.000896	0.0397	-0.13	-0.1	Mosquito bite size;	chr2:118416730	chr2:118132128~118186386:-
BRCA	cis	rs6088590	0.561	rs764597	ENSG00000269202.1	RP4-614O4.12	-3.33	0.000896	0.0397	-0.1	-0.1	Coronary artery disease;	chr20:34573421	chr20:35201747~35203288:-
BRCA	cis	rs17209837	1	rs60541816	ENSG00000224046.1	AC005076.5	3.33	0.000896	0.0397	0.16	0.1	Gallbladder cancer;	chr7:87498545	chr7:87151423~87152420:-
BRCA	cis	rs10129255	0.957	rs11846893	ENSG00000253132.1	IGHV3-62	-3.33	0.000896	0.0397	-0.08	-0.1	Kawasaki disease;	chr14:106779068	chr14:106643142~106643585:-
BRCA	cis	rs72772090	0.539	rs116360011	ENSG00000272109.1	CTD-2260A17.3	3.33	0.000896	0.0397	0.2	0.1	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96782093	chr5:96804353~96806105:+
BRCA	cis	rs1178127	0.719	rs1178179	ENSG00000232821.1	AC003986.6	-3.33	0.000896	0.0397	-0.13	-0.1	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);	chr7:18760159	chr7:19112474~19114271:+
BRCA	cis	rs2638953	0.676	rs11049727	ENSG00000273989.1	RP11-425D17.2	-3.33	0.000896	0.0397	-0.16	-0.1	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28584864	chr12:28236227~28236828:+
BRCA	cis	rs10995356	0.872	rs2065449	ENSG00000238280.1	RP11-436D10.3	-3.33	0.000897	0.0397	-0.13	-0.1	Temperament;	chr10:62949281	chr10:62793562~62805887:-
BRCA	cis	rs875971	0.755	rs76288834	ENSG00000223473.2	GS1-124K5.3	-3.33	0.000897	0.0397	-0.08	-0.1	Aortic root size;	chr7:66604815	chr7:66491049~66493566:-
BRCA	cis	rs2692947	0.759	rs2692937	ENSG00000168992.4	OR7E102P	3.33	0.000897	0.0397	0.15	0.1	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96086123	chr2:95546531~95547545:+
BRCA	cis	rs962856	0.575	rs6740919	ENSG00000236605.1	AC023115.4	-3.33	0.000897	0.0397	-0.13	-0.1	Pancreatic cancer;	chr2:67392923	chr2:67324627~67325304:+
BRCA	cis	rs964611	0.935	rs3784618	ENSG00000259488.2	RP11-154J22.1	-3.33	0.000897	0.0397	-0.15	-0.1	Metabolite levels (Pyroglutamine);	chr15:48284184	chr15:48312353~48331856:-
BRCA	cis	rs60871478	0.898	rs62432897	ENSG00000237181.1	AC147651.4	-3.33	0.000897	0.0397	-0.11	-0.1	Cerebrospinal P-tau181p levels;	chr7:785792	chr7:603185~608482:+
BRCA	cis	rs6141600	0.627	rs6141601	ENSG00000126005.14	MMP24-AS1	-3.33	0.000897	0.0397	-0.14	-0.1	Height;Hip circumference;	chr20:36128126	chr20:35216462~35278131:-
BRCA	cis	rs6496044	0.568	rs6496039	ENSG00000259630.2	CTD-2262B20.1	-3.33	0.000897	0.0397	-0.12	-0.1	Interstitial lung disease;	chr15:85518732	chr15:85415228~85415633:+
BRCA	cis	rs7097397	0.591	rs12768835	ENSG00000270025.2	BMS1P7	-3.33	0.000897	0.0397	-0.12	-0.1	Systemic lupus erythematosus;	chr10:48768924	chr10:48050282~48060016:-
BRCA	cis	rs11587682	0.76	rs12145967	ENSG00000228126.1	FALEC	3.33	0.000897	0.0397	0.14	0.1	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr1:150431812	chr1:150515757~150518032:+
BRCA	cis	rs11587682	0.806	rs36038795	ENSG00000228126.1	FALEC	3.33	0.000897	0.0397	0.14	0.1	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr1:150432998	chr1:150515757~150518032:+
BRCA	cis	rs10865541	0.869	rs4971505	ENSG00000234171.2	RNASEH1-AS1	3.33	0.000897	0.0397	0.12	0.1	Obesity-related traits;	chr2:3428779	chr2:3558492~3561745:+
BRCA	cis	rs3770752	0.866	rs9309004	ENSG00000272054.1	RP11-423P10.2	-3.33	0.000897	0.0397	-0.09	-0.1	Schizophrenia;	chr2:37291304	chr2:37208875~37212677:+
BRCA	cis	rs897984	0.52	rs4889536	ENSG00000280211.1	RP11-2C24.3	-3.33	0.000897	0.0397	-0.11	-0.1	Dementia with Lewy bodies;	chr16:30860434	chr16:30773532~30776033:-
BRCA	cis	rs660899	0.894	rs11805774	ENSG00000229431.1	RP1-92O14.6	-3.33	0.000897	0.0397	-0.11	-0.1	Hypertension risk in short sleep duration;	chr1:43687044	chr1:43385113~43389155:+
BRCA	cis	rs660899	0.894	rs17401357	ENSG00000229431.1	RP1-92O14.6	-3.33	0.000897	0.0397	-0.11	-0.1	Hypertension risk in short sleep duration;	chr1:43687948	chr1:43385113~43389155:+
BRCA	cis	rs1354774	0.505	rs61044983	ENSG00000228674.4	CTB-147C22.3	-3.33	0.000897	0.0397	-0.14	-0.1	Prostate-specific antigen levels;	chr19:50893666	chr19:50927079~50927571:-
BRCA	cis	rs10198628	1	rs7559029	ENSG00000264370.1	MIR3125	3.33	0.000897	0.0397	0.12	0.1	Pericardial fat;Pericardial adipose tissue adjusted for height and weight;	chr2:12830029	chr2:12737367~12737444:+
BRCA	cis	rs12505328	0.966	rs10023094	ENSG00000213370.3	RANP6	3.33	0.000897	0.0397	0.12	0.1	Chin dimples;	chr4:173435513	chr4:173633728~173634371:-
BRCA	cis	rs1436904	0.933	rs1175745	ENSG00000260372.5	AQP4-AS1	-3.33	0.000897	0.0397	-0.12	-0.1	Breast cancer;	chr18:27007085	chr18:26655742~27190698:+
BRCA	cis	rs4650943	0.732	rs10913154	ENSG00000227740.1	RP11-318C24.2	-3.33	0.000897	0.0397	-0.1	-0.1	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in inactive individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr1:176299142	chr1:175904762~175920513:-
BRCA	cis	rs9457247	0.544	rs6920858	ENSG00000272549.1	RP11-351J23.2	-3.33	0.000897	0.0397	-0.11	-0.1	Crohn's disease;	chr6:167051142	chr6:167666840~167679270:-
BRCA	cis	rs3737883	1	rs3737883	ENSG00000233791.4	LINC01136	3.33	0.000897	0.0398	0.13	0.1	Early onset atrial fibrillation;	chr1:203065778	chr1:203298758~203305309:-
BRCA	cis	rs752010	0.808	rs7529858	ENSG00000230638.4	RP11-486B10.4	-3.33	0.000897	0.0398	-0.13	-0.1	Lupus nephritis in systemic lupus erythematosus;	chr1:41620935	chr1:41542069~41544310:+
BRCA	cis	rs752010	0.714	rs7552928	ENSG00000230638.4	RP11-486B10.4	-3.33	0.000897	0.0398	-0.13	-0.1	Lupus nephritis in systemic lupus erythematosus;	chr1:41620993	chr1:41542069~41544310:+
BRCA	cis	rs7412746	0.634	rs12409208	ENSG00000224800.1	RP11-235D19.2	-3.33	0.000897	0.0398	-0.13	-0.1	Melanoma;	chr1:150887579	chr1:150881236~150881683:-
BRCA	cis	rs7412746	0.658	rs12410394	ENSG00000224800.1	RP11-235D19.2	-3.33	0.000897	0.0398	-0.13	-0.1	Melanoma;	chr1:150887710	chr1:150881236~150881683:-
BRCA	cis	rs3820068	0.553	rs7545782	ENSG00000237301.1	RP4-680D5.2	-3.33	0.000897	0.0398	-0.13	-0.1	Systolic blood pressure;	chr1:15628732	chr1:15586136~15603626:-
BRCA	cis	rs4713118	0.662	rs149961	ENSG00000226314.6	ZNF192P1	-3.33	0.000897	0.0398	-0.15	-0.1	Parkinson's disease;	chr6:28047791	chr6:28161781~28169594:+
BRCA	cis	rs13153459	0.602	rs73752037	ENSG00000249203.1	RP11-473L15.3	-3.33	0.000897	0.0398	-0.14	-0.1	Parkinson's disease;	chr5:44501378	chr5:44495618~44510282:-
BRCA	cis	rs35306767	0.855	rs11253459	ENSG00000229869.1	RP11-363N22.2	-3.33	0.000897	0.0398	-0.15	-0.1	Eosinophil percentage of granulocytes;	chr10:840462	chr10:933026~942743:+
BRCA	cis	rs11035577	0.57	rs1158735	ENSG00000279675.1	RP11-454H19.2	-3.33	0.000898	0.0398	-0.16	-0.1	Temperament (bipolar disorder);	chr11:39745665	chr11:40107244~40112599:-
BRCA	cis	rs62247992	0.698	rs11719573	ENSG00000227245.1	RP11-136C24.2	-3.33	0.000898	0.0398	-0.14	-0.1	Facial morphology (factor 15, philtrum width);	chr3:43083698	chr3:43087479~43088068:+
BRCA	cis	rs56046484	1	rs12911330	ENSG00000259630.2	CTD-2262B20.1	-3.33	0.000898	0.0398	-0.17	-0.1	Testicular germ cell tumor;	chr15:85087103	chr15:85415228~85415633:+
BRCA	cis	rs56046484	0.956	rs34919315	ENSG00000259630.2	CTD-2262B20.1	-3.33	0.000898	0.0398	-0.17	-0.1	Testicular germ cell tumor;	chr15:85088675	chr15:85415228~85415633:+
BRCA	cis	rs9368481	1	rs9368481	ENSG00000124549.13	BTN2A3P	-3.33	0.000898	0.0398	-0.11	-0.1	Autism spectrum disorder or schizophrenia;	chr6:26993982	chr6:26421391~26432383:+
BRCA	cis	rs8099996	0.597	rs3786722	ENSG00000238364.1	RNU7-140P	3.33	0.000898	0.0398	0.16	0.1	Inflammatory skin disease;	chr19:11050861	chr19:10551033~10551092:-
BRCA	cis	rs7932354	0.583	rs6485695	ENSG00000243802.2	RP11-390K5.1	-3.33	0.000898	0.0398	-0.13	-0.1	Bone mineral density (hip);Bone mineral density;	chr11:46814615	chr11:47191181~47191542:-
BRCA	cis	rs8181477	1	rs8181477	ENSG00000225527.1	RP11-383B4.4	-3.33	0.000898	0.0398	-0.12	-0.1	Obesity-related traits;	chr10:18493951	chr10:18531849~18533336:-
BRCA	cis	rs7176093	1	rs72757332	ENSG00000259407.1	RP11-158M2.3	-3.33	0.000898	0.0398	-0.13	-0.1	Aging traits;	chr15:85825819	chr15:85744109~85750281:-
BRCA	cis	rs7829975	0.539	rs940031	ENSG00000254153.1	CTA-398F10.2	-3.33	0.000898	0.0398	-0.13	-0.1	Mood instability;	chr8:8689338	chr8:8456909~8461337:-
BRCA	cis	rs2204008	0.521	rs7311188	ENSG00000257718.1	RP11-396F22.1	-3.33	0.000898	0.0398	-0.1	-0.1	Bladder cancer;	chr12:38149011	chr12:38906451~38909592:+
BRCA	cis	rs3816183	0.72	rs2119020	ENSG00000226491.1	FTOP1	-3.33	0.000898	0.0398	-0.13	-0.1	Hypospadias;	chr2:42837194	chr2:42797225~42798712:-
BRCA	cis	rs240764	0.764	rs12208241	ENSG00000220695.1	RP1-121G13.3	-3.33	0.000898	0.0398	-0.11	-0.1	Neuroticism;	chr6:100485596	chr6:100530276~100531052:+
BRCA	cis	rs10129255	0.828	rs10140989	ENSG00000253763.1	IGHV3-6	3.33	0.000898	0.0398	0.1	0.1	Kawasaki disease;	chr14:106668657	chr14:106055549~106055998:-
BRCA	cis	rs6028335	0.622	rs73621984	ENSG00000274825.1	RP4-616B8.5	-3.33	0.000898	0.0398	-0.13	-0.1	Alcohol and nicotine co-dependence;	chr20:39010566	chr20:38955910~38956547:+
BRCA	cis	rs2562456	0.876	rs11085467	ENSG00000268705.1	BNIP3P26	3.33	0.000899	0.0398	0.11	0.1	Pain;	chr19:21569041	chr19:21521343~21521896:-
BRCA	cis	rs6901004	0.716	rs35312643	ENSG00000231889.6	TRAF3IP2-AS1	-3.33	0.000899	0.0398	-0.11	-0.1	Blood metabolite levels;	chr6:111253333	chr6:111483511~111598302:+
BRCA	cis	rs6901004	0.688	rs34151782	ENSG00000231889.6	TRAF3IP2-AS1	-3.33	0.000899	0.0398	-0.11	-0.1	Blood metabolite levels;	chr6:111253334	chr6:111483511~111598302:+
BRCA	cis	rs7130284	1	rs11018629	ENSG00000134612.10	FOLH1B	-3.33	0.000899	0.0398	-0.23	-0.1	Homocysteine levels;	chr11:89473796	chr11:89639227~89698718:+
BRCA	cis	rs10792665	0.512	rs7106981	ENSG00000254965.1	RP11-113K21.2	-3.33	0.000899	0.0398	-0.1	-0.1	Obesity-related traits;	chr11:82889834	chr11:83111060~83111442:-
BRCA	cis	rs7246657	0.508	rs1628959	ENSG00000267470.4	ZNF571-AS1	3.33	0.000899	0.0398	0.16	0.1	Coronary artery calcification;	chr19:36999474	chr19:37548914~37587348:+
BRCA	cis	rs17270561	0.609	rs1165181	ENSG00000272462.2	U91328.19	-3.33	0.000899	0.0398	-0.12	-0.1	Iron status biomarkers;	chr6:25825162	chr6:25992662~26001775:+
BRCA	cis	rs9816784	0.576	rs12631246	ENSG00000273009.1	RP11-352G9.1	-3.33	0.000899	0.0398	-0.13	-0.1	Mean corpuscular hemoglobin;	chr3:196094713	chr3:195913078~195913683:-
BRCA	cis	rs4130344	0.845	rs34680567	ENSG00000271817.2	U3	-3.33	0.000899	0.0398	-0.11	-0.1	Intelligence (multi-trait analysis);	chr4:158874579	chr4:158700691~158700909:+
BRCA	cis	rs4805834	0.843	rs35158384	ENSG00000201388.1	SNORA68	3.33	0.000899	0.0398	0.18	0.1	Creatinine levels;	chr19:32888337	chr19:32608337~32608469:-
BRCA	cis	rs4805834	0.843	rs4550589	ENSG00000201388.1	SNORA68	3.33	0.000899	0.0398	0.18	0.1	Creatinine levels;	chr19:32889591	chr19:32608337~32608469:-
BRCA	cis	rs11700980	0.636	rs114711857	ENSG00000232855.5	AF131217.1	3.33	0.000899	0.0398	0.18	0.1	QRS complex (12-leadsum);	chr21:28887877	chr21:28439346~28674848:-
BRCA	cis	rs7487075	0.786	rs4768110	ENSG00000274723.1	RP11-618L22.1	3.33	0.000899	0.0398	0.12	0.1	Itch intensity from mosquito bite;	chr12:46283678	chr12:46970504~46972155:+
BRCA	cis	rs7487075	0.786	rs4768694	ENSG00000274723.1	RP11-618L22.1	3.33	0.000899	0.0398	0.12	0.1	Itch intensity from mosquito bite;	chr12:46283875	chr12:46970504~46972155:+
BRCA	cis	rs2842992	0.724	rs4709368	ENSG00000207392.1	SNORA20	3.33	0.000899	0.0398	0.13	0.1	Age-related macular degeneration (geographic atrophy);	chr6:159783095	chr6:159780250~159780381:-
BRCA	cis	rs1030420	0.796	rs77801947	ENSG00000272010.1	CTD-3025N20.3	-3.33	0.000899	0.0398	-0.17	-0.1	Blood metabolite levels;	chr8:66406026	chr8:65591850~65592472:-
BRCA	cis	rs1348850	0.914	rs7573763	ENSG00000271825.1	RP11-337N6.2	3.33	0.000899	0.0398	0.13	0.1	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177385080	chr2:177300600~177302006:+
BRCA	cis	rs17767294	0.614	rs41269291	ENSG00000272009.1	RP1-313I6.12	-3.33	0.000899	0.0398	-0.27	-0.1	Parkinson's disease;	chr6:28283762	chr6:28078792~28081130:-
BRCA	cis	rs17767294	0.614	rs72854506	ENSG00000272009.1	RP1-313I6.12	-3.33	0.000899	0.0398	-0.27	-0.1	Parkinson's disease;	chr6:28284720	chr6:28078792~28081130:-
BRCA	cis	rs7520050	0.902	rs9429088	ENSG00000226957.1	RP4-533D7.4	3.33	0.000899	0.0398	0.11	0.1	Reticulocyte count;Red blood cell count;	chr1:46031828	chr1:46046818~46048368:+
BRCA	cis	rs7620503	0.625	rs7620805	ENSG00000277241.1	RP11-114M1.3	3.33	9e-04	0.0398	0.13	0.1	Corneal structure;	chr3:177586637	chr3:177700346~177701072:-
BRCA	cis	rs4835473	0.9	rs4835009	ENSG00000246448.2	RP13-578N3.3	-3.33	9e-04	0.0398	-0.12	-0.1	Immature fraction of reticulocytes;	chr4:143746130	chr4:143700257~143865072:+
BRCA	cis	rs849141	0.961	rs702815	ENSG00000234336.5	JAZF1-AS1	-3.33	9e-04	0.0398	-0.14	-0.1	Height;Hip circumference adjusted for BMI;	chr7:28133903	chr7:28180322~28243917:+
BRCA	cis	rs849141	0.961	rs849136	ENSG00000234336.5	JAZF1-AS1	-3.33	9e-04	0.0398	-0.14	-0.1	Height;Hip circumference adjusted for BMI;	chr7:28135338	chr7:28180322~28243917:+
BRCA	cis	rs849141	0.961	rs849137	ENSG00000234336.5	JAZF1-AS1	-3.33	9e-04	0.0398	-0.14	-0.1	Height;Hip circumference adjusted for BMI;	chr7:28135671	chr7:28180322~28243917:+
BRCA	cis	rs61776290	0.843	rs190775	ENSG00000271989.1	RP4-736L20.3	-3.33	9e-04	0.0398	-0.16	-0.1	Alcohol dependence (age at onset);	chr1:10623626	chr1:10429881~10430677:-
BRCA	cis	rs1969253	0.712	rs843368	ENSG00000205955.4	HSP90AA5P	-3.33	9e-04	0.0398	-0.13	-0.1	Major depressive disorder;	chr3:184179837	chr3:184115352~184117898:+
BRCA	cis	rs17711722	0.74	rs7809991	ENSG00000232559.3	GS1-124K5.12	3.33	9e-04	0.0398	0.12	0.1	Calcium levels;	chr7:65941231	chr7:66554588~66576923:-
BRCA	cis	rs7773456	0.74	rs6917179	ENSG00000217379.2	RP11-254A17.1	3.33	9e-04	0.0398	0.12	0.1	Lupus nephritis in systemic lupus erythematosus;	chr6:19817570	chr6:19143695~19144160:+
BRCA	cis	rs7680126	0.671	rs7663044	ENSG00000250413.1	RP11-448G15.1	-3.33	9e-04	0.0399	-0.19	-0.1	Urate levels in obese individuals;Urate levels in lean individuals;Urate levels in overweight individuals;	chr4:10022315	chr4:10006482~10009725:+
BRCA	cis	rs4352251	0.543	rs17025374	ENSG00000212283.1	SNORD89	3.33	9e-04	0.0399	0.19	0.1	Adiponectin levels (BMI-adjusted);Adiponectin levels;	chr2:101299765	chr2:101272936~101273049:-
BRCA	cis	rs10198628	1	rs12999821	ENSG00000264370.1	MIR3125	-3.33	9e-04	0.0399	-0.12	-0.1	Pericardial fat;Pericardial adipose tissue adjusted for height and weight;	chr2:12833414	chr2:12737367~12737444:+
BRCA	cis	rs875971	0.545	rs73150604	ENSG00000273448.1	RP11-166O4.6	3.33	9e-04	0.0399	0.11	0.1	Aortic root size;	chr7:66480545	chr7:67333047~67334383:+
BRCA	cis	rs7656342	0.866	rs11731100	ENSG00000250342.1	SNRPCP16	3.33	9e-04	0.0399	0.12	0.1	Gut microbiota (bacterial taxa);	chr4:9765556	chr4:9051842~9052051:-
BRCA	cis	rs72765298	0.848	rs10986626	ENSG00000232630.1	PRPS1P2	-3.33	9e-04	0.0399	-0.14	-0.1	Pulse pressure;	chr9:125186042	chr9:125150653~125151589:+
BRCA	cis	rs72819225	0.616	rs1411120	ENSG00000228701.1	TNKS2-AS1	3.33	9e-04	0.0399	0.13	0.1	Yeast infection;	chr10:91565355	chr10:91782839~91798291:-
BRCA	cis	rs4664293	0.51	rs72961735	ENSG00000230783.1	AC009961.2	3.33	9e-04	0.0399	0.13	0.1	Monocyte percentage of white cells;	chr2:159708009	chr2:159689217~159690291:-
BRCA	cis	rs7712401	1	rs7712401	ENSG00000263432.2	RN7SL689P	3.33	9e-04	0.0399	0.12	0.1	Mean platelet volume;	chr5:123038764	chr5:123022487~123022783:-
BRCA	cis	rs848087	0.967	rs2774035	ENSG00000200385.1	SNORA42	3.33	9e-04	0.0399	0.09	0.1	Breast cancer;	chr14:36809942	chr14:37720425~37720561:+
BRCA	cis	rs7682317	0.664	rs2013701	ENSG00000270720.1	RP11-84C13.2	3.33	9e-04	0.0399	0.11	0.1	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr4:88963935	chr4:89119284~89119871:+
BRCA	cis	rs7000551	0.751	rs2449341	ENSG00000253125.1	RP11-459E5.1	3.33	0.000901	0.0399	0.1	0.1	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr8:22533424	chr8:22690150~22798616:+
BRCA	cis	rs711830	1	rs1549334	ENSG00000272729.1	RP11-387A1.5	-3.33	0.000901	0.0399	-0.13	-0.1	Serous invasive ovarian cancer;Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;High-grade serous ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;	chr2:176174469	chr2:176164164~176165716:-
BRCA	cis	rs10865541	0.935	rs4971502	ENSG00000234171.2	RNASEH1-AS1	3.33	0.000901	0.0399	0.11	0.1	Obesity-related traits;	chr2:3410258	chr2:3558492~3561745:+
BRCA	cis	rs9810890	1	rs73196974	ENSG00000239483.1	RPS15AP16	3.33	0.000901	0.0399	0.27	0.1	Dental caries;	chr3:128730163	chr3:128798841~128799201:-
BRCA	cis	rs9810890	1	rs73196983	ENSG00000239483.1	RPS15AP16	3.33	0.000901	0.0399	0.27	0.1	Dental caries;	chr3:128733657	chr3:128798841~128799201:-
BRCA	cis	rs9810890	1	rs73196988	ENSG00000239483.1	RPS15AP16	3.33	0.000901	0.0399	0.27	0.1	Dental caries;	chr3:128734624	chr3:128798841~128799201:-
BRCA	cis	rs9810890	1	rs73196989	ENSG00000239483.1	RPS15AP16	3.33	0.000901	0.0399	0.27	0.1	Dental caries;	chr3:128735795	chr3:128798841~128799201:-
BRCA	cis	rs9810890	1	rs77303548	ENSG00000239483.1	RPS15AP16	3.33	0.000901	0.0399	0.27	0.1	Dental caries;	chr3:128735923	chr3:128798841~128799201:-
BRCA	cis	rs9810890	0.85	rs73196995	ENSG00000239483.1	RPS15AP16	3.33	0.000901	0.0399	0.27	0.1	Dental caries;	chr3:128739227	chr3:128798841~128799201:-
BRCA	cis	rs9810890	1	rs73196996	ENSG00000239483.1	RPS15AP16	3.33	0.000901	0.0399	0.27	0.1	Dental caries;	chr3:128739573	chr3:128798841~128799201:-
BRCA	cis	rs9810890	1	rs73196999	ENSG00000239483.1	RPS15AP16	3.33	0.000901	0.0399	0.27	0.1	Dental caries;	chr3:128741738	chr3:128798841~128799201:-
BRCA	cis	rs9810890	1	rs114261227	ENSG00000239483.1	RPS15AP16	3.33	0.000901	0.0399	0.27	0.1	Dental caries;	chr3:128750917	chr3:128798841~128799201:-
BRCA	cis	rs36093844	0.752	rs17817308	ENSG00000279742.1	RP11-700A24.1	-3.33	0.000901	0.0399	-0.16	-0.1	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85882486	chr11:85852557~85854943:-
BRCA	cis	rs11642862	1	rs11645367	ENSG00000274678.1	RP11-2C24.7	-3.33	0.000901	0.0399	-0.2	-0.1	Tonsillectomy;	chr16:30758753	chr16:30821338~30821884:+
BRCA	cis	rs13401620	0.554	rs12052328	ENSG00000223549.1	MTND5P28	3.33	0.000901	0.0399	0.13	0.1	Breast size;	chr2:120206730	chr2:120215181~120217279:+
BRCA	cis	rs752010	0.695	rs12123834	ENSG00000230638.4	RP11-486B10.4	-3.33	0.000901	0.0399	-0.12	-0.1	Lupus nephritis in systemic lupus erythematosus;	chr1:41640056	chr1:41542069~41544310:+
BRCA	cis	rs13434995	0.513	rs62303691	ENSG00000273257.1	RP11-177J6.1	-3.33	0.000901	0.0399	-0.16	-0.1	Adiponectin levels;	chr4:55442085	chr4:55387949~55388271:+
BRCA	cis	rs2153535	0.585	rs9502734	ENSG00000251164.1	HULC	-3.33	0.000901	0.0399	-0.12	-0.1	Motion sickness;	chr6:8631618	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.56	rs7750064	ENSG00000251164.1	HULC	-3.33	0.000901	0.0399	-0.12	-0.1	Motion sickness;	chr6:8632012	chr6:8652137~8653846:+
BRCA	cis	rs11992162	0.591	rs35657308	ENSG00000270154.1	RP11-419I17.1	-3.33	0.000901	0.0399	-0.12	-0.1	Monocyte count;	chr8:11946893	chr8:12476462~12477122:+
BRCA	cis	rs6790105	1	rs6790105	ENSG00000225399.4	RP11-3B7.1	3.33	0.000901	0.0399	0.11	0.1	Childhood ear infection;	chr3:49355976	chr3:49260085~49261316:+
BRCA	cis	rs2795502	1	rs3121279	ENSG00000185904.10	LINC00839	3.33	0.000901	0.0399	0.14	0.1	Blood protein levels;	chr10:42883001	chr10:42475543~42495336:+
BRCA	cis	rs13126694	0.744	rs13121497	ENSG00000251073.1	NUDT19P5	3.33	0.000901	0.0399	0.1	0.1	Blood osmolality (transformed sodium);	chr4:158076724	chr4:158182825~158183393:+
BRCA	cis	rs13108904	0.967	rs62293658	ENSG00000211482.1	AC092574.1	-3.33	0.000901	0.0399	-0.12	-0.1	Obesity-related traits;	chr4:1282628	chr4:409809~409915:+
BRCA	cis	rs6012564	0.963	rs6125551	ENSG00000230758.1	SNAP23P	-3.33	0.000901	0.0399	-0.12	-0.1	Anger;	chr20:49103849	chr20:49038357~49038602:-
BRCA	cis	rs58521262	0.729	rs12460438	ENSG00000268105.1	RP11-369G6.2	-3.33	0.000901	0.0399	-0.17	-0.1	Testicular germ cell tumor;	chr19:22892977	chr19:23125665~23128543:+
BRCA	cis	rs10419113	0.668	rs2360533	ENSG00000268379.1	CTC-360J11.4	3.33	0.000901	0.0399	0.12	0.1	Pediatric bone mineral density (spine);	chr19:57668907	chr19:57175233~57177921:+
BRCA	cis	rs10129255	0.833	rs7156689	ENSG00000211974.3	IGHV2-70	3.33	0.000902	0.0399	0.11	0.1	Kawasaki disease;	chr14:106816039	chr14:106723574~106724093:-
BRCA	cis	rs2573652	1	rs2581358	ENSG00000254744.3	CTD-3076O17.1	-3.33	0.000902	0.0399	-0.12	-0.1	Height;	chr15:99973520	chr15:99970215~99974010:+
BRCA	cis	rs11035577	0.632	rs11035453	ENSG00000279675.1	RP11-454H19.2	3.33	0.000902	0.0399	0.16	0.1	Temperament (bipolar disorder);	chr11:39761844	chr11:40107244~40112599:-
BRCA	cis	rs6494488	0.5	rs61117068	ENSG00000248415.1	GAPDHP61	-3.33	0.000902	0.0399	-0.2	-0.1	Coronary artery disease;	chr15:64667435	chr15:64528667~64529671:-
BRCA	cis	rs5167	0.566	rs35080293	ENSG00000214855.8	APOC1P1	3.33	0.000902	0.0399	0.14	0.1	Blood protein levels;	chr19:44993366	chr19:44926804~44931386:+
BRCA	cis	rs61352607	0.96	rs540730	ENSG00000208028.1	MIR616	3.33	0.000902	0.0399	0.13	0.1	Triglycerides;	chr12:57413331	chr12:57519163~57519259:-
BRCA	cis	rs875971	0.964	rs6978429	ENSG00000273448.1	RP11-166O4.6	3.33	0.000902	0.0399	0.09	0.1	Aortic root size;	chr7:66494889	chr7:67333047~67334383:+
BRCA	cis	rs875971	1	rs4718357	ENSG00000273448.1	RP11-166O4.6	3.33	0.000902	0.0399	0.09	0.1	Aortic root size;	chr7:66495891	chr7:67333047~67334383:+
BRCA	cis	rs12216545	0.765	rs7792574	ENSG00000244151.1	RP11-148K1.12	-3.33	0.000902	0.0399	-0.09	-0.1	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150527118	chr7:151074742~151076530:-
BRCA	cis	rs687432	0.847	rs11601223	ENSG00000213592.4	AP000662.9	-3.33	0.000902	0.0399	-0.14	-0.1	Parkinson's disease;	chr11:57984531	chr11:57718044~57718530:-
BRCA	cis	rs60843830	1	rs10193373	ENSG00000272342.1	RP13-539J13.1	-3.33	0.000902	0.0399	-0.12	-0.1	Spherical equivalent (joint analysis main effects and education interaction);	chr2:281886	chr2:739588~740164:-
BRCA	cis	rs4538475	0.559	rs73224656	ENSG00000273133.1	RP11-799M12.2	-3.33	0.000902	0.0399	-0.19	-0.1	Parkinson's disease;	chr4:15698170	chr4:15563698~15564253:-
BRCA	cis	rs4415084	0.87	rs10447145	ENSG00000272335.1	RP11-53O19.3	3.33	0.000902	0.0399	0.1	0.1	Breast cancer;	chr5:44689694	chr5:44826076~44828592:+
BRCA	cis	rs9951698	0.678	rs490853	ENSG00000266969.1	RP11-773H22.4	3.33	0.000902	0.0399	0.14	0.1	Intelligence (multi-trait analysis);	chr18:13106338	chr18:12984694~12991173:-
BRCA	cis	rs6142102	1	rs4911409	ENSG00000206582.1	Y_RNA	-3.33	0.000902	0.0399	-0.12	-0.1	Skin pigmentation;	chr20:34122904	chr20:34526510~34526606:-
BRCA	cis	rs2638953	0.924	rs2272361	ENSG00000273989.1	RP11-425D17.2	-3.33	0.000902	0.0399	-0.14	-0.1	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28450037	chr12:28236227~28236828:+
BRCA	cis	rs11758351	1	rs80095925	ENSG00000216331.1	HIST1H1PS1	3.33	0.000902	0.0399	0.2	0.1	Renal underexcretion gout;Gout;	chr6:26184714	chr6:26195566~26195771:+
BRCA	cis	rs11758351	1	rs77961951	ENSG00000216331.1	HIST1H1PS1	3.33	0.000902	0.0399	0.2	0.1	Renal underexcretion gout;Gout;	chr6:26185847	chr6:26195566~26195771:+
BRCA	cis	rs1463132	0.636	rs10500373	ENSG00000229917.2	RPL7P46	-3.33	0.000902	0.0399	-0.14	-0.1	HIV-1 control;	chr16:10031619	chr16:11027024~11027763:+
BRCA	cis	rs7267979	1	rs11087520	ENSG00000276952.1	RP5-965G21.6	3.33	0.000902	0.0399	0.12	0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25456191	chr20:25284915~25285588:-
BRCA	cis	rs8115445	0.515	rs13039059	ENSG00000214535.3	RPS15AP1	3.33	0.000903	0.0399	0.15	0.1	Pediatric bone mineral content (radius);	chr20:21426222	chr20:21166206~21166596:-
BRCA	cis	rs258892	0.843	rs16901045	ENSG00000272525.1	RP11-79P5.9	-3.33	0.000903	0.0399	-0.13	-0.1	Small cell lung carcinoma;	chr5:72738159	chr5:73497550~73498293:-
BRCA	cis	rs258892	0.895	rs13171293	ENSG00000272525.1	RP11-79P5.9	-3.33	0.000903	0.0399	-0.13	-0.1	Small cell lung carcinoma;	chr5:72738480	chr5:73497550~73498293:-
BRCA	cis	rs10129255	0.957	rs12590799	ENSG00000231475.3	IGHV4-31	-3.33	0.000903	0.04	-0.08	-0.1	Kawasaki disease;	chr14:106779713	chr14:106349283~106349792:-
BRCA	cis	rs7819412	0.745	rs4841498	ENSG00000154316.13	TDH	3.33	0.000903	0.04	0.13	0.1	Triglycerides;	chr8:11127922	chr8:11339637~11368452:+
BRCA	cis	rs67311347	1	rs7628796	ENSG00000199906.1	RNU5B-2P	3.33	0.000903	0.04	0.11	0.1	Renal cell carcinoma;	chr3:40465841	chr3:40498891~40499003:-
BRCA	cis	rs427943	0.778	rs8134789	ENSG00000261706.1	LINC00165	-3.33	0.000903	0.04	-0.12	-0.1	Body mass index;	chr21:45199643	chr21:44994362~44995185:-
BRCA	cis	rs9467773	1	rs6925895	ENSG00000261353.1	CTA-14H9.5	-3.33	0.000903	0.04	-0.1	-0.1	Intelligence (multi-trait analysis);	chr6:26571937	chr6:26527063~26527404:+
BRCA	cis	rs875971	0.862	rs7783779	ENSG00000106610.13	STAG3L4	3.33	0.000903	0.04	0.14	0.1	Aortic root size;	chr7:66331639	chr7:67302621~67321526:+
BRCA	cis	rs853679	0.607	rs34166054	ENSG00000216901.1	AL022393.7	3.33	0.000903	0.04	0.27	0.1	Depression;	chr6:28098023	chr6:28176188~28176674:+
BRCA	cis	rs853679	0.607	rs13203816	ENSG00000216901.1	AL022393.7	3.33	0.000903	0.04	0.27	0.1	Depression;	chr6:28111820	chr6:28176188~28176674:+
BRCA	cis	rs853679	0.556	rs34588114	ENSG00000216901.1	AL022393.7	3.33	0.000903	0.04	0.27	0.1	Depression;	chr6:28112850	chr6:28176188~28176674:+
BRCA	cis	rs853679	0.607	rs68188794	ENSG00000216901.1	AL022393.7	3.33	0.000903	0.04	0.27	0.1	Depression;	chr6:28112999	chr6:28176188~28176674:+
BRCA	cis	rs853679	0.546	rs34371502	ENSG00000216901.1	AL022393.7	3.33	0.000903	0.04	0.27	0.1	Depression;	chr6:28113980	chr6:28176188~28176674:+
BRCA	cis	rs853679	0.607	rs66886492	ENSG00000216901.1	AL022393.7	3.33	0.000903	0.04	0.27	0.1	Depression;	chr6:28121953	chr6:28176188~28176674:+
BRCA	cis	rs853679	0.607	rs35345226	ENSG00000216901.1	AL022393.7	3.33	0.000903	0.04	0.27	0.1	Depression;	chr6:28123802	chr6:28176188~28176674:+
BRCA	cis	rs9951698	0.687	rs478399	ENSG00000279275.1	RP11-756J15.2	3.33	0.000903	0.04	0.13	0.1	Intelligence (multi-trait analysis);	chr18:13093797	chr18:13279415~13280110:-
BRCA	cis	rs4654783	0.627	rs2092322	ENSG00000230068.2	CDC42-IT1	-3.33	0.000903	0.04	-0.12	-0.1	Endometriosis;	chr1:22109230	chr1:22059197~22064199:+
BRCA	cis	rs2153535	0.585	rs9379226	ENSG00000251164.1	HULC	-3.33	0.000903	0.04	-0.12	-0.1	Motion sickness;	chr6:8584232	chr6:8652137~8653846:+
BRCA	cis	rs2243480	1	rs781142	ENSG00000234585.5	CCT6P3	-3.33	0.000903	0.04	-0.15	-0.1	Diabetic kidney disease;	chr7:65973791	chr7:65038354~65074713:+
BRCA	cis	rs2243480	1	rs781150	ENSG00000237026.1	RP11-328P23.2	3.33	0.000903	0.04	0.19	0.1	Diabetic kidney disease;	chr7:66015986	chr7:65235790~65236723:-
BRCA	cis	rs2243480	1	rs313798	ENSG00000237026.1	RP11-328P23.2	3.33	0.000903	0.04	0.19	0.1	Diabetic kidney disease;	chr7:66028044	chr7:65235790~65236723:-
BRCA	cis	rs9467773	1	rs1535277	ENSG00000261353.1	CTA-14H9.5	-3.33	0.000903	0.04	-0.1	-0.1	Intelligence (multi-trait analysis);	chr6:26567574	chr6:26527063~26527404:+
BRCA	cis	rs9467773	1	rs1884948	ENSG00000261353.1	CTA-14H9.5	-3.33	0.000903	0.04	-0.1	-0.1	Intelligence (multi-trait analysis);	chr6:26567760	chr6:26527063~26527404:+
BRCA	cis	rs9467773	1	rs1884949	ENSG00000261353.1	CTA-14H9.5	-3.33	0.000903	0.04	-0.1	-0.1	Intelligence (multi-trait analysis);	chr6:26567839	chr6:26527063~26527404:+
BRCA	cis	rs9467773	1	rs9467796	ENSG00000261353.1	CTA-14H9.5	-3.33	0.000903	0.04	-0.1	-0.1	Intelligence (multi-trait analysis);	chr6:26568183	chr6:26527063~26527404:+
BRCA	cis	rs9467773	1	rs9467797	ENSG00000261353.1	CTA-14H9.5	-3.33	0.000903	0.04	-0.1	-0.1	Intelligence (multi-trait analysis);	chr6:26568245	chr6:26527063~26527404:+
BRCA	cis	rs9467773	1	rs1078679	ENSG00000261353.1	CTA-14H9.5	-3.33	0.000903	0.04	-0.1	-0.1	Intelligence (multi-trait analysis);	chr6:26568513	chr6:26527063~26527404:+
BRCA	cis	rs7104764	1	rs10902113	ENSG00000254910.1	RP11-326C3.7	-3.33	0.000903	0.04	-0.12	-0.1	Menarche (age at onset);	chr11:245523	chr11:310139~311141:-
BRCA	cis	rs7104764	1	rs7482591	ENSG00000254910.1	RP11-326C3.7	-3.33	0.000903	0.04	-0.12	-0.1	Menarche (age at onset);	chr11:245861	chr11:310139~311141:-
BRCA	cis	rs9976876	0.829	rs1883061	ENSG00000231106.2	LINC01436	-3.33	0.000903	0.04	-0.12	-0.1	Total body bone mineral density;	chr21:35571072	chr21:36005338~36007838:+
BRCA	cis	rs9976876	0.9	rs4817726	ENSG00000231106.2	LINC01436	-3.33	0.000903	0.04	-0.12	-0.1	Total body bone mineral density;	chr21:35571266	chr21:36005338~36007838:+
BRCA	cis	rs7264396	0.563	rs11906854	ENSG00000088340.14	FER1L4	-3.33	0.000903	0.04	-0.15	-0.1	Total cholesterol levels;	chr20:35795712	chr20:35558737~35607562:-
BRCA	cis	rs11098499	0.604	rs10022185	ENSG00000250412.1	KLHL2P1	3.33	0.000903	0.04	0.13	0.1	Corneal astigmatism;	chr4:119650610	chr4:119334329~119378233:+
BRCA	cis	rs748404	0.666	rs7176923	ENSG00000201136.1	RNU6-353P	3.33	0.000903	0.04	0.15	0.1	Lung cancer;	chr15:43317679	chr15:43702363~43702470:+
BRCA	cis	rs9467773	1	rs6932156	ENSG00000261353.1	CTA-14H9.5	-3.33	0.000904	0.04	-0.1	-0.1	Intelligence (multi-trait analysis);	chr6:26571278	chr6:26527063~26527404:+
BRCA	cis	rs9467773	1	rs6924838	ENSG00000261353.1	CTA-14H9.5	-3.33	0.000904	0.04	-0.1	-0.1	Intelligence (multi-trait analysis);	chr6:26571528	chr6:26527063~26527404:+
BRCA	cis	rs7637230	1	rs4683948	ENSG00000244119.1	PDCL3P4	-3.33	0.000904	0.04	-0.1	-0.1	Psoriasis vulgaris;Psoriasis;	chr3:101931344	chr3:101712472~101713191:+
BRCA	cis	rs11887277	0.557	rs35277048	ENSG00000272148.1	RP11-195B17.1	-3.33	0.000904	0.04	-0.12	-0.1	Obesity-related traits;	chr2:26764943	chr2:27062428~27062907:-
BRCA	cis	rs9792269	0.735	rs12542862	ENSG00000207110.1	RNU1-106P	-3.33	0.000904	0.04	-0.15	-0.1	Celiac disease;	chr8:128233141	chr8:127999131~127999294:+
BRCA	cis	rs67478160	0.643	rs11626377	ENSG00000269910.1	RP11-73M18.10	3.33	0.000904	0.04	0.1	0.1	Schizophrenia;	chr14:103768020	chr14:103694516~103695050:-
BRCA	cis	rs67478160	0.643	rs876002	ENSG00000269910.1	RP11-73M18.10	3.33	0.000904	0.04	0.1	0.1	Schizophrenia;	chr14:103773360	chr14:103694516~103695050:-
BRCA	cis	rs6540556	0.723	rs10863785	ENSG00000236136.1	ADORA2BP1	3.33	0.000904	0.04	0.13	0.1	Red blood cell count;	chr1:209735531	chr1:209744373~209745214:+
BRCA	cis	rs17123764	0.71	rs60121503	ENSG00000257464.1	RP11-161H23.8	-3.33	0.000904	0.04	-0.18	-0.1	Intelligence (multi-trait analysis);	chr12:49694964	chr12:49442424~49442652:-
BRCA	cis	rs2243480	1	rs778729	ENSG00000229180.5	GS1-124K5.11	3.33	0.000904	0.04	0.14	0.1	Diabetic kidney disease;	chr7:66359432	chr7:66526088~66542624:-
BRCA	cis	rs4805834	0.668	rs17272190	ENSG00000201388.1	SNORA68	3.33	0.000904	0.04	0.17	0.1	Creatinine levels;	chr19:32830869	chr19:32608337~32608469:-
BRCA	cis	rs10843647	1	rs1318326	ENSG00000245614.3	DDX11-AS1	3.33	0.000904	0.04	0.11	0.1	Glucose homeostasis traits;	chr12:30182282	chr12:31020763~31073847:-
BRCA	cis	rs36051895	0.664	rs10116560	ENSG00000237711.1	RP11-39K24.13	-3.33	0.000904	0.04	-0.13	-0.1	Pediatric autoimmune diseases;	chr9:5096433	chr9:5100236~5101009:+
BRCA	cis	rs10129255	0.5	rs8014529	ENSG00000211976.2	IGHV3-73	-3.33	0.000904	0.04	-0.08	-0.1	Kawasaki disease;	chr14:106784065	chr14:106802694~106803233:-
BRCA	cis	rs67478160	0.625	rs7141473	ENSG00000269910.1	RP11-73M18.10	-3.33	0.000904	0.04	-0.1	-0.1	Schizophrenia;	chr14:103849718	chr14:103694516~103695050:-
BRCA	cis	rs7259376	0.936	rs4932760	ENSG00000269345.1	VN1R85P	3.33	0.000904	0.04	0.12	0.1	Menopause (age at onset);	chr19:22357653	chr19:22174766~22175191:-
BRCA	cis	rs2562456	0.839	rs2562411	ENSG00000240522.1	RPL7AP10	-3.33	0.000905	0.04	-0.12	-0.1	Pain;	chr19:21419181	chr19:21149648~21150438:-
BRCA	cis	rs2562456	0.876	rs2562413	ENSG00000240522.1	RPL7AP10	-3.33	0.000905	0.04	-0.12	-0.1	Pain;	chr19:21420084	chr19:21149648~21150438:-
BRCA	cis	rs2562456	0.916	rs1967182	ENSG00000240522.1	RPL7AP10	-3.33	0.000905	0.04	-0.12	-0.1	Pain;	chr19:21420337	chr19:21149648~21150438:-
BRCA	cis	rs1039766	1	rs268864	ENSG00000227791.3	AC007365.4	3.33	0.000905	0.04	0.16	0.1	Lung adenocarcinoma;Lung cancer;	chr2:65262608	chr2:64665607~64666064:+
BRCA	cis	rs9467773	0.62	rs2504571	ENSG00000261353.1	CTA-14H9.5	-3.33	0.000905	0.04	-0.1	-0.1	Intelligence (multi-trait analysis);	chr6:26643207	chr6:26527063~26527404:+
BRCA	cis	rs1730008	0.691	rs11707386	ENSG00000279311.1	RP11-170K4.2	3.33	0.000905	0.04	0.13	0.1	Lobe attachment (rater-scored or self-reported);	chr3:158434284	chr3:158869898~158871821:+
BRCA	cis	rs7200543	0.583	rs4985149	ENSG00000207425.1	Y_RNA	-3.33	0.000905	0.04	-0.12	-0.1	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15053481	chr16:14915457~14915556:-
BRCA	cis	rs12627687	0.544	rs12627001	ENSG00000237945.6	LINC00649	3.33	0.000905	0.04	0.18	0.1	Colorectal cancer;	chr21:34180132	chr21:33915534~33977691:+
BRCA	cis	rs7781266	0.739	rs62469985	ENSG00000226205.1	AC007790.4	3.33	0.000905	0.04	0.15	0.1	Educational attainment (college completion);	chr7:133533330	chr7:133732493~133733595:-
BRCA	cis	rs7515577	1	rs2391159	ENSG00000207523.1	SNORA66	3.33	0.000905	0.04	0.15	0.1	Cholesterol, total;	chr1:92506394	chr1:92840719~92840851:+
BRCA	cis	rs17507216	0.56	rs28493687	ENSG00000276710.3	CSPG4P8	-3.33	0.000905	0.04	-0.1	-0.1	Excessive daytime sleepiness;	chr15:82560062	chr15:82459472~82477258:+
BRCA	cis	rs11098499	0.955	rs4145951	ENSG00000225892.3	RP11-384K6.2	3.33	0.000905	0.04	0.1	0.1	Corneal astigmatism;	chr4:119234662	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.955	rs35916640	ENSG00000225892.3	RP11-384K6.2	3.33	0.000905	0.04	0.1	0.1	Corneal astigmatism;	chr4:119234697	chr4:118632274~118634759:+
BRCA	cis	rs1400816	0.85	rs10177679	ENSG00000228389.1	AC068039.4	-3.33	0.000905	0.04	-0.19	-0.1	Amyotrophic lateral sclerosis (sporadic);	chr2:171963728	chr2:171773482~171775844:+
BRCA	cis	rs375066	0.901	rs438517	ENSG00000278917.1	RP11-15A1.4	-3.33	0.000905	0.04	-0.12	-0.1	Breast cancer;	chr19:43915506	chr19:43891233~43895411:+
BRCA	cis	rs375066	0.935	rs446674	ENSG00000278917.1	RP11-15A1.4	-3.33	0.000905	0.04	-0.12	-0.1	Breast cancer;	chr19:43916855	chr19:43891233~43895411:+
BRCA	cis	rs7312933	0.898	rs10880221	ENSG00000257225.1	RP11-328C8.4	-3.33	0.000905	0.04	-0.13	-0.1	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:41990787	chr12:42459366~42466128:+
BRCA	cis	rs863345	0.625	rs10908655	ENSG00000176320.2	RP11-404O13.5	-3.33	0.000905	0.04	-0.11	-0.1	Pneumococcal bacteremia;	chr1:158491109	chr1:158197922~158203877:-
BRCA	cis	rs4930103	1	rs4930103	ENSG00000230080.2	AC139143.2	3.33	0.000905	0.04	0.12	0.1	DNA methylation (variation);DNA methylation (parent-of-origin);	chr11:2003314	chr11:1802889~1804095:-
BRCA	cis	rs4919694	1	rs78893207	ENSG00000236937.2	PTGES3P4	3.33	0.000906	0.04	0.21	0.1	Arsenic metabolism;	chr10:103036381	chr10:102845595~102845950:+
BRCA	cis	rs6517329	0.576	rs7283730	ENSG00000231106.2	LINC01436	3.33	0.000906	0.04	0.12	0.1	Schizophrenia;	chr21:36123076	chr21:36005338~36007838:+
BRCA	cis	rs1119582	0.562	rs450515	ENSG00000279118.1	RP11-517I3.2	3.33	0.000906	0.04	0.14	0.1	Select biomarker traits;	chr5:125866432	chr5:126496279~126498604:+
BRCA	cis	rs1119582	0.568	rs373011	ENSG00000279118.1	RP11-517I3.2	3.33	0.000906	0.04	0.14	0.1	Select biomarker traits;	chr5:125866560	chr5:126496279~126498604:+
BRCA	cis	rs1119582	0.568	rs428784	ENSG00000279118.1	RP11-517I3.2	3.33	0.000906	0.04	0.14	0.1	Select biomarker traits;	chr5:125866621	chr5:126496279~126498604:+
BRCA	cis	rs1119582	0.568	rs411383	ENSG00000279118.1	RP11-517I3.2	3.33	0.000906	0.04	0.14	0.1	Select biomarker traits;	chr5:125866847	chr5:126496279~126498604:+
BRCA	cis	rs1119582	0.636	rs393314	ENSG00000279118.1	RP11-517I3.2	3.33	0.000906	0.04	0.14	0.1	Select biomarker traits;	chr5:125867016	chr5:126496279~126498604:+
BRCA	cis	rs4950322	0.547	rs17355509	ENSG00000227242.3	NBPF13P	-3.33	0.000906	0.0401	-0.14	-0.1	Protein quantitative trait loci;	chr1:147123139	chr1:147021320~147124525:-
BRCA	cis	rs10263639	1	rs10263639	ENSG00000225573.4	RPL35P5	-3.33	0.000906	0.0401	-0.16	-0.1	Breast cancer;	chr7:67594280	chr7:66606738~66607107:-
BRCA	cis	rs10129255	0.536	rs8004835	ENSG00000253359.1	IGHV3-37	3.33	0.000906	0.0401	0.09	0.1	Kawasaki disease;	chr14:106686361	chr14:106396676~106397114:-
BRCA	cis	rs12149862	1	rs9930728	ENSG00000261556.7	SMG1P7	3.33	0.000906	0.0401	0.11	0.1	Blood pressure (smoking interaction);	chr16:69432372	chr16:70219574~70245616:-
BRCA	cis	rs7620503	1	rs1463859	ENSG00000231574.4	RP11-91K9.1	3.33	0.000906	0.0401	0.11	0.1	Corneal structure;	chr3:177580283	chr3:177816865~177899224:+
BRCA	cis	rs6493487	0.512	rs71471523	ENSG00000259378.1	DCAF13P3	-3.33	0.000906	0.0401	-0.17	-0.1	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr15:50905127	chr15:50944663~50945996:+
BRCA	cis	rs4819052	1	rs9306123	ENSG00000215447.6	BX322557.10	-3.33	0.000906	0.0401	-0.11	-0.1	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45290007	chr21:45288052~45291738:+
BRCA	cis	rs2227564	0.729	rs2675675	ENSG00000279689.1	RP11-574K11.32	3.33	0.000906	0.0401	0.12	0.1	Crohn's disease;Inflammatory bowel disease;	chr10:73889290	chr10:73769264~73772862:-
BRCA	cis	rs979233	0.935	rs13189275	ENSG00000188850.9	RP11-159F24.2	-3.33	0.000906	0.0401	-0.12	-0.1	Systemic lupus erythematosus;	chr5:42521225	chr5:43336164~43348716:+
BRCA	cis	rs9372498	0.536	rs25422	ENSG00000216809.1	RP11-57K17.1	3.33	0.000906	0.0401	0.13	0.1	Diastolic blood pressure;	chr6:118486684	chr6:118452469~118454992:-
BRCA	cis	rs12973672	0.812	rs13345192	ENSG00000268947.1	AD000684.2	3.33	0.000906	0.0401	0.12	0.1	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr19:35265252	chr19:35262846~35264804:+
BRCA	cis	rs1552244	1	rs7628448	ENSG00000240288.6	GHRLOS	3.33	0.000906	0.0401	0.15	0.1	Alzheimer's disease;	chr3:10105144	chr3:10285754~10293449:+
BRCA	cis	rs11887277	0.585	rs13018103	ENSG00000272148.1	RP11-195B17.1	-3.33	0.000906	0.0401	-0.12	-0.1	Obesity-related traits;	chr2:26763035	chr2:27062428~27062907:-
BRCA	cis	rs10905065	0.965	rs2797488	ENSG00000215267.7	AKR1C7P	3.33	0.000906	0.0401	0.13	0.1	Menopause (age at onset);	chr10:5742546	chr10:5275173~5288470:-
BRCA	cis	rs7735319	0.834	rs7707864	ENSG00000249572.1	CTD-2203K17.1	3.33	0.000906	0.0401	0.15	0.1	Systolic blood pressure;	chr5:33067611	chr5:33424025~33440619:-
BRCA	cis	rs7914558	0.966	rs10883817	ENSG00000213277.3	MARCKSL1P1	3.33	0.000906	0.0401	0.11	0.1	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102995674	chr10:103175554~103176094:+
BRCA	cis	rs875971	0.929	rs12535036	ENSG00000273448.1	RP11-166O4.6	3.33	0.000906	0.0401	0.09	0.1	Aortic root size;	chr7:66499076	chr7:67333047~67334383:+
BRCA	cis	rs875971	1	rs6970030	ENSG00000273448.1	RP11-166O4.6	3.33	0.000906	0.0401	0.09	0.1	Aortic root size;	chr7:66503692	chr7:67333047~67334383:+
BRCA	cis	rs875971	0.928	rs6970357	ENSG00000273448.1	RP11-166O4.6	3.33	0.000906	0.0401	0.09	0.1	Aortic root size;	chr7:66503891	chr7:67333047~67334383:+
BRCA	cis	rs2011503	0.941	rs6511027	ENSG00000271283.1	CTC-412M14.6	3.33	0.000907	0.0401	0.15	0.1	Bipolar disorder;	chr19:19281042	chr19:19699203~19699409:-
BRCA	cis	rs10844706	0.699	rs10844627	ENSG00000278635.1	CTD-2318O12.1	-3.33	0.000907	0.0401	-0.11	-0.1	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9733781	chr12:9415641~9416718:+
BRCA	cis	rs4660214	0.756	rs11205823	ENSG00000243970.1	PPIEL	-3.33	0.000907	0.0401	-0.13	-0.1	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39248566	chr1:39531838~39558707:-
BRCA	cis	rs10197140	0.925	rs10188079	ENSG00000235721.1	AC013268.3	3.33	0.000907	0.0401	0.13	0.1	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110886898	chr2:110007675~110010783:+
BRCA	cis	rs35740288	0.571	rs11629608	ENSG00000259407.1	RP11-158M2.3	-3.33	0.000907	0.0401	-0.14	-0.1	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85786893	chr15:85744109~85750281:-
BRCA	cis	rs34929064	0.718	rs17302823	ENSG00000179428.2	AC073072.5	-3.33	0.000907	0.0401	-0.15	-0.1	Major depression and alcohol dependence;	chr7:22679790	chr7:22725395~22727620:-
BRCA	cis	rs7246657	0.943	rs7255952	ENSG00000267470.4	ZNF571-AS1	3.33	0.000907	0.0401	0.14	0.1	Coronary artery calcification;	chr19:37497895	chr19:37548914~37587348:+
BRCA	cis	rs2832191	0.74	rs2832168	ENSG00000236056.1	GAPDHP14	-3.33	0.000907	0.0401	-0.11	-0.1	Dental caries;	chr21:29091374	chr21:29222321~29223257:+
BRCA	cis	rs2333021	0.689	rs12878701	ENSG00000259015.1	RP11-109N23.6	3.33	0.000907	0.0401	0.11	0.1	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:72976068	chr14:72960595~72961993:+
BRCA	cis	rs1178968	1	rs12539763	ENSG00000225648.4	SBDSP1	3.33	0.000907	0.0401	0.18	0.1	Triglyceride levels;	chr7:73348420	chr7:72829425~72836701:+
BRCA	cis	rs1730008	0.691	rs73170384	ENSG00000279311.1	RP11-170K4.2	3.33	0.000907	0.0401	0.13	0.1	Lobe attachment (rater-scored or self-reported);	chr3:158401141	chr3:158869898~158871821:+
BRCA	cis	rs7647973	0.769	rs11130181	ENSG00000244380.1	RP11-24C3.2	3.33	0.000907	0.0401	0.13	0.1	Menarche (age at onset);	chr3:49072486	chr3:48440352~48446656:-
BRCA	cis	rs8062405	0.895	rs62036658	ENSG00000261766.1	RP11-22P6.2	-3.33	0.000907	0.0401	-0.11	-0.1	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28839050	chr16:28862166~28863340:-
BRCA	cis	rs2839186	0.605	rs2839170	ENSG00000223901.2	AP001469.5	3.33	0.000907	0.0401	0.1	0.1	Testicular germ cell tumor;	chr21:46251391	chr21:46220269~46225364:+
BRCA	cis	rs2337406	1	rs3858878	ENSG00000211968.3	IGHV1-58	-3.33	0.000907	0.0401	-0.11	-0.1	Alzheimer's disease (late onset);	chr14:106688061	chr14:106622357~106622855:-
BRCA	cis	rs372883	0.583	rs117214	ENSG00000176054.6	RPL23P2	3.33	0.000907	0.0401	0.11	0.1	Pancreatic cancer;	chr21:29348513	chr21:28997613~28998033:-
BRCA	cis	rs3916	0.955	rs35771722	ENSG00000277423.1	RP11-173P15.9	-3.33	0.000907	0.0401	-0.14	-0.1	Urinary metabolites (H-NMR features);	chr12:120716197	chr12:120703867~120704282:+
BRCA	cis	rs10504130	0.569	rs10958305	ENSG00000272076.1	RP11-11C20.3	3.33	0.000908	0.0401	0.15	0.1	Venous thromboembolism (SNP x SNP interaction);	chr8:51906464	chr8:51810110~51810681:-
BRCA	cis	rs344364	0.511	rs1742467	ENSG00000219027.2	RPS3AP2	3.33	0.000908	0.0401	0.16	0.1	Glomerular filtration rate in chronic kidney disease;	chr16:1900186	chr16:1477830~1478583:+
BRCA	cis	rs344364	0.511	rs1742468	ENSG00000219027.2	RPS3AP2	3.33	0.000908	0.0401	0.16	0.1	Glomerular filtration rate in chronic kidney disease;	chr16:1900242	chr16:1477830~1478583:+
BRCA	cis	rs344364	0.511	rs1742469	ENSG00000219027.2	RPS3AP2	3.33	0.000908	0.0401	0.16	0.1	Glomerular filtration rate in chronic kidney disease;	chr16:1900243	chr16:1477830~1478583:+
BRCA	cis	rs344364	0.511	rs1657133	ENSG00000219027.2	RPS3AP2	3.33	0.000908	0.0401	0.16	0.1	Glomerular filtration rate in chronic kidney disease;	chr16:1900299	chr16:1477830~1478583:+
BRCA	cis	rs2400749	0.83	rs12434962	ENSG00000258521.1	RP11-638I2.9	-3.33	0.000908	0.0401	-0.1	-0.1	Alzheimer's disease (survival time);	chr14:99565649	chr14:100339832~100340554:+
BRCA	cis	rs875971	1	rs778706	ENSG00000229886.1	RP5-1132H15.3	3.33	0.000908	0.0401	0.11	0.1	Aortic root size;	chr7:66395437	chr7:66025126~66031544:-
BRCA	cis	rs12637928	0.507	rs13097144	ENSG00000206532.2	RP11-553A10.1	-3.33	0.000908	0.0401	-0.13	-0.1	Neuroticism;	chr3:110600855	chr3:110888384~110893476:-
BRCA	cis	rs375066	0.935	rs448823	ENSG00000278917.1	RP11-15A1.4	-3.33	0.000908	0.0401	-0.12	-0.1	Breast cancer;	chr19:43902139	chr19:43891233~43895411:+
BRCA	cis	rs375066	0.868	rs448829	ENSG00000278917.1	RP11-15A1.4	-3.33	0.000908	0.0401	-0.12	-0.1	Breast cancer;	chr19:43902169	chr19:43891233~43895411:+
BRCA	cis	rs4699052	1	rs4699055	ENSG00000246560.2	RP11-10L12.4	3.33	0.000908	0.0401	0.11	0.1	Testicular germ cell tumor;	chr4:103233343	chr4:102828055~102844075:+
BRCA	cis	rs6545883	0.558	rs7587389	ENSG00000273302.1	RP11-493E12.2	-3.33	0.000908	0.0401	-0.09	-0.1	Tuberculosis;	chr2:61422656	chr2:61199979~61200769:+
BRCA	cis	rs8180040	0.62	rs17784127	ENSG00000280667.1	Y_RNA	-3.33	0.000908	0.0401	-0.12	-0.1	Colorectal cancer;	chr3:47020210	chr3:47501083~47501182:+
BRCA	cis	rs60871478	1	rs62432253	ENSG00000237181.1	AC147651.4	-3.33	0.000908	0.0401	-0.11	-0.1	Cerebrospinal P-tau181p levels;	chr7:763291	chr7:603185~608482:+
BRCA	cis	rs7649443	0.917	rs13077565	ENSG00000243339.3	RN7SL738P	-3.33	0.000908	0.0401	-0.14	-0.1	Nonsyndromic cleft lip with cleft palate;	chr3:197239949	chr3:196399911~196400207:+
BRCA	cis	rs11170468	0.621	rs11170823	ENSG00000257718.1	RP11-396F22.1	-3.33	0.000908	0.0401	-0.13	-0.1	Body mass index;	chr12:39129637	chr12:38906451~38909592:+
BRCA	cis	rs8040855	0.627	rs4843019	ENSG00000229212.6	RP11-561C5.4	3.33	0.000908	0.0401	0.14	0.1	Bulimia nervosa;	chr15:85101228	chr15:85205440~85234795:-
BRCA	cis	rs881375	0.934	rs1468671	ENSG00000238181.2	AHCYP2	-3.33	0.000908	0.0401	-0.14	-0.1	Rheumatoid arthritis;	chr9:120895224	chr9:120720673~120721972:+
BRCA	cis	rs7520050	0.966	rs785481	ENSG00000234329.1	RP11-767N6.2	-3.33	0.000908	0.0401	-0.1	-0.1	Reticulocyte count;Red blood cell count;	chr1:46088846	chr1:45651039~45651826:-
BRCA	cis	rs875971	0.798	rs12698522	ENSG00000223473.2	GS1-124K5.3	3.33	0.000908	0.0401	0.08	0.1	Aortic root size;	chr7:66502354	chr7:66491049~66493566:-
BRCA	cis	rs875971	0.83	rs28714531	ENSG00000223473.2	GS1-124K5.3	3.33	0.000908	0.0401	0.08	0.1	Aortic root size;	chr7:66503250	chr7:66491049~66493566:-
BRCA	cis	rs875971	0.862	rs12698526	ENSG00000223473.2	GS1-124K5.3	3.33	0.000908	0.0401	0.08	0.1	Aortic root size;	chr7:66504118	chr7:66491049~66493566:-
BRCA	cis	rs4697263	0.671	rs34927464	ENSG00000237350.1	CDC42P6	3.33	0.000908	0.0402	0.13	0.1	Age-related hearing impairment (SNP x SNP interaction);	chr4:22044157	chr4:22727375~22727950:-
BRCA	cis	rs4697263	0.671	rs13132801	ENSG00000237350.1	CDC42P6	3.33	0.000908	0.0402	0.13	0.1	Age-related hearing impairment (SNP x SNP interaction);	chr4:22044313	chr4:22727375~22727950:-
BRCA	cis	rs1555133	0.694	rs6141289	ENSG00000277692.1	RP11-358N2.2	-3.33	0.000908	0.0402	-0.11	-0.1	Monocyte count;	chr20:32324757	chr20:32355053~32355734:+
BRCA	cis	rs258892	0.843	rs34455289	ENSG00000272525.1	RP11-79P5.9	-3.33	0.000908	0.0402	-0.13	-0.1	Small cell lung carcinoma;	chr5:72757455	chr5:73497550~73498293:-
BRCA	cis	rs78487399	0.808	rs6544664	ENSG00000234936.1	AC010883.5	3.33	0.000908	0.0402	0.15	0.1	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43501969	chr2:43229573~43233394:+
BRCA	cis	rs78487399	0.808	rs6708735	ENSG00000234936.1	AC010883.5	3.33	0.000908	0.0402	0.15	0.1	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43504215	chr2:43229573~43233394:+
BRCA	cis	rs78487399	0.808	rs6737882	ENSG00000234936.1	AC010883.5	3.33	0.000908	0.0402	0.15	0.1	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43504769	chr2:43229573~43233394:+
BRCA	cis	rs78487399	0.808	rs6544666	ENSG00000234936.1	AC010883.5	3.33	0.000908	0.0402	0.15	0.1	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43505095	chr2:43229573~43233394:+
BRCA	cis	rs2811403	0.765	rs9857323	ENSG00000270773.1	RP13-685P2.7	3.33	0.000908	0.0402	0.12	0.1	Basophil percentage of white cells;	chr3:128433188	chr3:129345411~129346164:+
BRCA	cis	rs78487399	0.808	rs10180005	ENSG00000234936.1	AC010883.5	3.33	0.000909	0.0402	0.15	0.1	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43510326	chr2:43229573~43233394:+
BRCA	cis	rs78487399	0.808	rs13405776	ENSG00000234936.1	AC010883.5	3.33	0.000909	0.0402	0.15	0.1	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43511982	chr2:43229573~43233394:+
BRCA	cis	rs78487399	0.808	rs13419380	ENSG00000234936.1	AC010883.5	3.33	0.000909	0.0402	0.15	0.1	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43512045	chr2:43229573~43233394:+
BRCA	cis	rs6496044	0.634	rs4843066	ENSG00000259630.2	CTD-2262B20.1	-3.33	0.000909	0.0402	-0.12	-0.1	Interstitial lung disease;	chr15:85519680	chr15:85415228~85415633:+
BRCA	cis	rs2277027	0.955	rs7728609	ENSG00000251405.2	CTB-109A12.1	3.33	0.000909	0.0402	0.13	0.1	Pulmonary function;Pulmonary function (smoking interaction);	chr5:157508516	chr5:157362615~157460078:-
BRCA	cis	rs1468333	0.537	rs10479184	ENSG00000206989.1	SNORD63	3.33	0.000909	0.0402	0.12	0.1	Resting heart rate;	chr5:138418228	chr5:138561043~138561110:-
BRCA	cis	rs4713118	0.662	rs149900	ENSG00000226314.6	ZNF192P1	-3.33	0.000909	0.0402	-0.15	-0.1	Parkinson's disease;	chr6:28046819	chr6:28161781~28169594:+
BRCA	cis	rs7017914	0.934	rs2732092	ENSG00000246366.5	RP11-382J12.1	3.33	0.000909	0.0402	0.11	0.1	Bone mineral density;	chr8:71006364	chr8:70608577~70663279:+
BRCA	cis	rs9399135	0.636	rs4646871	ENSG00000234084.1	RP3-388E23.2	3.33	0.000909	0.0402	0.1	0.1	Red blood cell count;	chr6:134944479	chr6:135301568~135307158:+
BRCA	cis	rs4588572	0.601	rs10942855	ENSG00000245556.2	SCAMP1-AS1	-3.33	0.000909	0.0402	-0.13	-0.1	Triglycerides;	chr5:78441705	chr5:78342365~78360507:-
BRCA	cis	rs687432	0.924	rs938011	ENSG00000265566.2	RN7SL605P	3.33	0.000909	0.0402	0.14	0.1	Parkinson's disease;	chr11:57942525	chr11:57528085~57528365:-
BRCA	cis	rs6912958	0.967	rs6914299	ENSG00000272008.1	RP11-393I2.4	3.33	0.000909	0.0402	0.11	0.1	Monocyte percentage of white cells;	chr6:87439458	chr6:87151159~87155285:-
BRCA	cis	rs10937405	0.86	rs10937396	ENSG00000236182.1	RP11-297K7.1	3.33	0.000909	0.0402	0.12	0.1	Lung adenocarcinoma;	chr3:189623508	chr3:188989382~188990135:-
BRCA	cis	rs3864261	0.515	rs12186995	ENSG00000251467.1	CTC-250P20.2	3.33	0.000909	0.0402	0.13	0.1	Discordance in emotional problems in monozygotic twins;	chr5:73039500	chr5:72996920~72997642:+
BRCA	cis	rs61160187	0.51	rs4400080	ENSG00000251279.1	CTC-436P18.1	3.33	0.000909	0.0402	0.13	0.1	Educational attainment (years of education);Educational attainment (college completion);	chr5:60744809	chr5:61162070~61232040:+
BRCA	cis	rs13401620	0.626	rs2860928	ENSG00000229326.3	AC069154.4	3.33	0.000909	0.0402	0.13	0.1	Breast size;	chr2:120109017	chr2:119698623~119700151:+
BRCA	cis	rs2835872	0.965	rs73222314	ENSG00000230366.8	DSCR9	-3.33	0.000909	0.0402	-0.14	-0.1	Electroencephalographic traits in alcoholism;	chr21:37642500	chr21:37208503~37221736:+
BRCA	cis	rs2835872	0.965	rs2835853	ENSG00000230366.8	DSCR9	-3.33	0.000909	0.0402	-0.14	-0.1	Electroencephalographic traits in alcoholism;	chr21:37642590	chr21:37208503~37221736:+
BRCA	cis	rs13014235	0.592	rs55860809	ENSG00000242696.3	RN7SL40P	-3.33	0.000909	0.0402	-0.11	-0.1	Basal cell carcinoma;	chr2:201394347	chr2:202357076~202357417:-
BRCA	cis	rs3743266	0.507	rs10162677	ENSG00000245534.5	RORA-AS1	-3.33	0.000909	0.0402	-0.15	-0.1	Menarche (age at onset);	chr15:60456369	chr15:60479178~60630637:+
BRCA	cis	rs801193	1	rs13239306	ENSG00000265600.1	AC006480.1	3.33	0.000909	0.0402	0.12	0.1	Aortic root size;	chr7:66671030	chr7:67356680~67356779:+
BRCA	cis	rs1007738	0.507	rs61897857	ENSG00000200376.1	RNU5E-10P	-3.33	0.000909	0.0402	-0.14	-0.1	Bone mineral density (hip);	chr11:47211907	chr11:47576471~47576588:-
BRCA	cis	rs8054556	0.669	rs9972866	ENSG00000275371.1	RP11-455F5.6	-3.33	0.00091	0.0402	-0.1	-0.1	Autism spectrum disorder or schizophrenia;	chr16:30007661	chr16:30110895~30111955:+
BRCA	cis	rs13118159	0.55	rs28614045	ENSG00000273179.1	RP11-20I20.4	3.33	0.00091	0.0402	0.11	0.1	Longevity;	chr4:1380907	chr4:1167778~1168174:+
BRCA	cis	rs4243971	0.516	rs4911223	ENSG00000277692.1	RP11-358N2.2	-3.33	0.00091	0.0402	-0.11	-0.1	Inflammatory bowel disease;Crohn's disease;	chr20:32373538	chr20:32355053~32355734:+
BRCA	cis	rs1466788	0.895	rs1077581	ENSG00000224965.1	KCNC4-AS1	-3.33	0.00091	0.0402	-0.12	-0.1	Blood metabolite levels;	chr1:110064324	chr1:110208834~110209987:-
BRCA	cis	rs72928364	0.86	rs62274066	ENSG00000244119.1	PDCL3P4	3.33	0.00091	0.0402	0.13	0.1	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:101082335	chr3:101712472~101713191:+
BRCA	cis	rs6439153	0.933	rs2630262	ENSG00000242551.2	POU5F1P6	3.33	0.00091	0.0402	0.13	0.1	Pneumococcal bacteremia;	chr3:128958255	chr3:128674735~128677005:-
BRCA	cis	rs2204008	0.618	rs8186932	ENSG00000257718.1	RP11-396F22.1	-3.33	0.00091	0.0402	-0.1	-0.1	Bladder cancer;	chr12:37944584	chr12:38906451~38909592:+
BRCA	cis	rs687432	0.885	rs7123727	ENSG00000213592.4	AP000662.9	-3.33	0.00091	0.0402	-0.15	-0.1	Parkinson's disease;	chr11:58031711	chr11:57718044~57718530:-
BRCA	cis	rs801193	0.591	rs4506088	ENSG00000271064.1	RP11-792A8.3	3.33	0.00091	0.0402	0.12	0.1	Aortic root size;	chr7:66670470	chr7:66748838~66749077:-
BRCA	cis	rs10484434	0.818	rs66536062	ENSG00000272810.1	U91328.22	3.33	0.00091	0.0402	0.15	0.1	HIV-1 viral setpoint;	chr6:26012479	chr6:26013241~26013757:+
BRCA	cis	rs1414896	0.624	rs4949999	ENSG00000226835.1	RP11-148B18.3	-3.33	0.00091	0.0402	-0.11	-0.1	Non-alcoholic fatty liver disease histology (AST);	chr1:95186227	chr1:94333267~94334848:+
BRCA	cis	rs4835473	0.932	rs10016223	ENSG00000246448.2	RP13-578N3.3	3.33	0.00091	0.0402	0.12	0.1	Immature fraction of reticulocytes;	chr4:143777429	chr4:143700257~143865072:+
BRCA	cis	rs10197140	0.925	rs750225	ENSG00000235721.1	AC013268.3	-3.33	0.00091	0.0402	-0.13	-0.1	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110876290	chr2:110007675~110010783:+
BRCA	cis	rs7637230	0.891	rs4683946	ENSG00000244119.1	PDCL3P4	-3.33	0.00091	0.0402	-0.1	-0.1	Psoriasis vulgaris;Psoriasis;	chr3:101896982	chr3:101712472~101713191:+
BRCA	cis	rs3820068	0.581	rs78175477	ENSG00000237301.1	RP4-680D5.2	-3.33	0.00091	0.0402	-0.13	-0.1	Systolic blood pressure;	chr1:15621596	chr1:15586136~15603626:-
BRCA	cis	rs4981053	0.644	rs2775246	ENSG00000259001.3	RPPH1	3.33	0.00091	0.0402	0.12	0.1	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr14:20058376	chr14:20343048~20343685:-
BRCA	cis	rs7246657	0.722	rs2972438	ENSG00000267470.4	ZNF571-AS1	3.33	0.00091	0.0402	0.14	0.1	Coronary artery calcification;	chr19:37719946	chr19:37548914~37587348:+
BRCA	cis	rs9400180	1	rs1913	ENSG00000228834.1	RP11-249L21.4	3.33	0.00091	0.0402	0.13	0.1	Major depressive disorder;	chr6:108030793	chr6:108907615~108907873:-
BRCA	cis	rs1862618	0.671	rs2591965	ENSG00000271828.1	CTD-2310F14.1	-3.33	0.00091	0.0402	-0.13	-0.1	Initial pursuit acceleration;	chr5:56940349	chr5:56927874~56929573:+
BRCA	cis	rs875971	0.508	rs10258739	ENSG00000229886.1	RP5-1132H15.3	-3.33	0.00091	0.0402	-0.11	-0.1	Aortic root size;	chr7:66597948	chr7:66025126~66031544:-
BRCA	cis	rs6500602	0.592	rs7206782	ENSG00000280063.1	RP11-295D4.3	3.33	0.00091	0.0402	0.08	0.1	Schizophrenia;	chr16:4465144	chr16:4346694~4348648:-
BRCA	cis	rs10197140	0.925	rs62159474	ENSG00000235721.1	AC013268.3	-3.33	0.00091	0.0402	-0.13	-0.1	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110877502	chr2:110007675~110010783:+
BRCA	cis	rs1437396	0.609	rs2589066	ENSG00000203327.2	AC012358.7	3.33	0.00091	0.0402	0.1	0.1	Alcohol dependence;	chr2:55331423	chr2:55214387~55216126:-
BRCA	cis	rs9393813	0.528	rs4713108	ENSG00000271755.1	RP1-153G14.4	3.33	0.00091	0.0402	0.12	0.1	Bipolar disorder;	chr6:27490234	chr6:27404010~27406964:-
BRCA	cis	rs6121246	0.559	rs6060933	ENSG00000230613.1	HM13-AS1	3.33	0.00091	0.0402	0.14	0.1	Mean corpuscular hemoglobin;	chr20:31764100	chr20:31567707~31573263:-
BRCA	cis	rs4759375	1	rs7312145	ENSG00000256092.2	RP13-942N8.1	3.33	0.00091	0.0402	0.16	0.1	HDL cholesterol;	chr12:123340792	chr12:123363868~123366113:+
BRCA	cis	rs4759375	1	rs7315453	ENSG00000256092.2	RP13-942N8.1	3.33	0.00091	0.0402	0.16	0.1	HDL cholesterol;	chr12:123340842	chr12:123363868~123366113:+
BRCA	cis	rs4759375	0.92	rs7298909	ENSG00000256092.2	RP13-942N8.1	3.33	0.00091	0.0402	0.16	0.1	HDL cholesterol;	chr12:123346392	chr12:123363868~123366113:+
BRCA	cis	rs4759375	0.79	rs9739171	ENSG00000256092.2	RP13-942N8.1	3.33	0.00091	0.0402	0.16	0.1	HDL cholesterol;	chr12:123356447	chr12:123363868~123366113:+
BRCA	cis	rs977987	0.806	rs4993970	ENSG00000280152.1	RP11-331F4.5	-3.33	0.00091	0.0402	-0.1	-0.1	Dupuytren's disease;	chr16:75377721	chr16:75245994~75250077:-
BRCA	cis	rs977987	0.736	rs4888392	ENSG00000280152.1	RP11-331F4.5	-3.33	0.00091	0.0402	-0.1	-0.1	Dupuytren's disease;	chr16:75378364	chr16:75245994~75250077:-
BRCA	cis	rs875971	1	rs709597	ENSG00000230189.5	GS1-124K5.2	-3.33	0.00091	0.0402	-0.08	-0.1	Aortic root size;	chr7:66360996	chr7:66409143~66490059:-
BRCA	cis	rs11887277	0.557	rs3845684	ENSG00000272148.1	RP11-195B17.1	-3.33	0.00091	0.0402	-0.12	-0.1	Obesity-related traits;	chr2:26756803	chr2:27062428~27062907:-
BRCA	cis	rs9296095	0.747	rs12206050	ENSG00000224796.1	RPL32P1	3.33	0.000911	0.0402	0.12	0.1	Platelet count;	chr6:33596519	chr6:33079451~33079860:+
BRCA	cis	rs2554380	0.628	rs2081541	ENSG00000176700.18	SCAND2P	-3.33	0.000911	0.0402	-0.11	-0.1	Height;	chr15:83774934	chr15:84631451~84647478:+
BRCA	cis	rs9650657	0.623	rs10094497	ENSG00000255020.1	AF131216.5	-3.33	0.000911	0.0402	-0.11	-0.1	Neuroticism;	chr8:10745319	chr8:11345748~11347502:-
BRCA	cis	rs897984	0.568	rs8050107	ENSG00000280211.1	RP11-2C24.3	-3.33	0.000911	0.0402	-0.11	-0.1	Dementia with Lewy bodies;	chr16:30882130	chr16:30773532~30776033:-
BRCA	cis	rs240764	0.578	rs12215909	ENSG00000220695.1	RP1-121G13.3	-3.33	0.000911	0.0402	-0.11	-0.1	Neuroticism;	chr6:100779722	chr6:100530276~100531052:+
BRCA	cis	rs3735485	0.843	rs10235175	ENSG00000201772.1	SNORA5C	3.33	0.000911	0.0402	0.14	0.1	White blood cell count;Sum basophil neutrophil counts;Neutrophil count;Granulocyte percentage of myeloid white cells;Monocyte percentage of white cells;Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Lymphocyte counts;	chr7:44993067	chr7:45104906~45105042:-
BRCA	cis	rs7267979	0.903	rs6050482	ENSG00000231081.1	RP4-760C5.3	-3.33	0.000911	0.0402	-0.13	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25245691	chr20:26008791~26010531:-
BRCA	cis	rs11241621	0.615	rs1345571	ENSG00000248489.1	CTD-2007H13.3	3.33	0.000911	0.0402	0.12	0.1	Plantar warts;	chr5:98537448	chr5:98929171~98995013:+
BRCA	cis	rs1436904	0.967	rs1786623	ENSG00000260372.5	AQP4-AS1	-3.33	0.000911	0.0402	-0.11	-0.1	Breast cancer;	chr18:26969695	chr18:26655742~27190698:+
BRCA	cis	rs5758659	0.714	rs5758589	ENSG00000182057.4	OGFRP1	-3.33	0.000911	0.0402	-0.12	-0.1	Cognitive function;	chr22:42122378	chr22:42269753~42275196:+
BRCA	cis	rs11229030	0.893	rs2584859	ENSG00000265566.2	RN7SL605P	3.33	0.000911	0.0402	0.13	0.1	Crohn's disease;	chr11:57439974	chr11:57528085~57528365:-
BRCA	cis	rs73222236	0.825	rs9812513	ENSG00000239213.4	NCK1-AS1	3.33	0.000911	0.0402	0.11	0.1	Coronary artery disease;	chr3:136335316	chr3:136841726~136862054:-
BRCA	cis	rs853679	0.517	rs4713145	ENSG00000272009.1	RP1-313I6.12	-3.33	0.000911	0.0402	-0.15	-0.1	Depression;	chr6:28139049	chr6:28078792~28081130:-
BRCA	cis	rs6988985	0.728	rs7003319	ENSG00000253741.1	CTD-2292P10.4	-3.33	0.000911	0.0402	-0.12	-0.1	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;	chr8:142873331	chr8:142702252~142726973:-
BRCA	cis	rs6988985	0.728	rs5017238	ENSG00000253741.1	CTD-2292P10.4	-3.33	0.000911	0.0402	-0.12	-0.1	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;	chr8:142873353	chr8:142702252~142726973:-
BRCA	cis	rs6487679	1	rs1017302	ENSG00000256069.6	A2MP1	3.33	0.000911	0.0402	0.13	0.1	Non-alcoholic fatty liver disease histology (AST);	chr12:9214806	chr12:9228533~9275817:-
BRCA	cis	rs9844666	0.512	rs9829329	ENSG00000239213.4	NCK1-AS1	3.33	0.000911	0.0403	0.11	0.1	Height;	chr3:135921818	chr3:136841726~136862054:-
BRCA	cis	rs9844666	0.512	rs9829476	ENSG00000239213.4	NCK1-AS1	3.33	0.000911	0.0403	0.11	0.1	Height;	chr3:135921914	chr3:136841726~136862054:-
BRCA	cis	rs3198697	0.663	rs12928099	ENSG00000275910.1	RP11-680G24.6	3.33	0.000911	0.0403	0.14	0.1	Triglycerides;	chr16:15056648	chr16:15015828~15016390:-
BRCA	cis	rs12477438	0.798	rs10202452	ENSG00000226791.5	AC109826.1	3.33	0.000911	0.0403	0.13	0.1	Chronic sinus infection;	chr2:98952946	chr2:98761938~98772920:-
BRCA	cis	rs853679	0.545	rs35949109	ENSG00000216676.2	RP1-15D7.1	-3.33	0.000911	0.0403	-0.18	-0.1	Depression;	chr6:28058148	chr6:27652602~27652825:-
BRCA	cis	rs4691139	0.588	rs6818620	ENSG00000248632.1	RP11-366M4.11	3.33	0.000911	0.0403	0.12	0.1	Ovarian cancer in BRCA1 mutation carriers;	chr4:164992407	chr4:164968587~164970002:-
BRCA	cis	rs2898279	0.815	rs9792397	ENSG00000255354.1	RP11-148O21.2	-3.33	0.000912	0.0403	-0.09	-0.1	Small cell lung carcinoma;	chr8:11445212	chr8:11558466~11560020:-
BRCA	cis	rs1049564	0.932	rs1049562	ENSG00000258451.1	RP11-903H12.3	-3.33	0.000912	0.0403	-0.16	-0.1	Interferon alpha levels in systemic lupus erythematosus;	chr14:20472356	chr14:20693480~20707120:-
BRCA	cis	rs4499344	0.73	rs259286	ENSG00000267475.1	CTD-2538C1.2	3.33	0.000912	0.0403	0.13	0.1	Mean platelet volume;	chr19:32673853	chr19:32687089~32691750:-
BRCA	cis	rs600626	0.636	rs11236516	ENSG00000255507.4	RP11-535A19.2	3.33	0.000912	0.0403	0.19	0.1	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr11:75740623	chr11:75803431~75815406:-
BRCA	cis	rs4869313	0.668	rs2548529	ENSG00000248734.2	CTD-2260A17.1	-3.33	0.000912	0.0403	-0.1	-0.1	Pediatric autoimmune diseases;	chr5:96904516	chr5:96784777~96785999:+
BRCA	cis	rs10191559	0.519	rs4233792	ENSG00000234663.4	AC104820.2	-3.33	0.000912	0.0403	-0.09	-0.1	Red blood cell count;	chr2:181197586	chr2:181101932~181399559:+
BRCA	cis	rs988913	0.723	rs4490666	ENSG00000261116.1	RP3-523K23.2	3.33	0.000912	0.0403	0.12	0.1	Menarche (age at onset);	chr6:55135853	chr6:54943167~54945099:+
BRCA	cis	rs988913	0.723	rs7761785	ENSG00000261116.1	RP3-523K23.2	3.33	0.000912	0.0403	0.12	0.1	Menarche (age at onset);	chr6:55137239	chr6:54943167~54945099:+
BRCA	cis	rs2832077	0.943	rs11702320	ENSG00000215533.7	LINC00189	3.33	0.000912	0.0403	0.15	0.1	Cognitive test performance;	chr21:28822929	chr21:29193480~29288205:+
BRCA	cis	rs116095464	0.558	rs56081398	ENSG00000250848.1	CTD-2083E4.5	-3.33	0.000912	0.0403	-0.16	-0.1	Breast cancer;	chr5:247203	chr5:288833~290321:-
BRCA	cis	rs4671400	0.543	rs2290324	ENSG00000212978.6	AC016747.3	-3.33	0.000912	0.0403	-0.16	-0.1	3-hydroxypropylmercapturic acid levels in smokers;	chr2:61221641	chr2:61141592~61144969:-
BRCA	cis	rs2243480	1	rs73150014	ENSG00000226767.1	RP11-328P23.3	-3.33	0.000912	0.0403	-0.18	-0.1	Diabetic kidney disease;	chr7:65985932	chr7:65508773~65508944:-
BRCA	cis	rs924712	0.844	rs12211168	ENSG00000261116.1	RP3-523K23.2	3.33	0.000912	0.0403	0.13	0.1	Breast cancer;	chr6:54876808	chr6:54943167~54945099:+
BRCA	cis	rs2692947	0.509	rs4907303	ENSG00000232931.4	LINC00342	3.33	0.000912	0.0403	0.11	0.1	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95551486	chr2:95807118~95816215:-
BRCA	cis	rs1005277	0.505	rs7099777	ENSG00000099251.13	HSD17B7P2	-3.33	0.000912	0.0403	-0.11	-0.1	Extrinsic epigenetic age acceleration;	chr10:37894641	chr10:38356380~38378505:+
BRCA	cis	rs718433	0.616	rs10438000	ENSG00000211778.2	TRAV4	-3.33	0.000912	0.0403	-0.08	-0.1	Intraocular pressure;	chr14:21741707	chr14:21736152~21736982:+
BRCA	cis	rs7701440	0.508	rs476099	ENSG00000272308.1	RP11-231G3.1	-3.33	0.000912	0.0403	-0.11	-0.1	Educational attainment;	chr5:61237147	chr5:60866457~60866935:-
BRCA	cis	rs2400749	0.685	rs10147748	ENSG00000258521.1	RP11-638I2.9	-3.33	0.000912	0.0403	-0.1	-0.1	Alzheimer's disease (survival time);	chr14:99555297	chr14:100339832~100340554:+
BRCA	cis	rs6704644	0.584	rs56336977	ENSG00000224287.2	MSL3P1	3.33	0.000912	0.0403	0.19	0.1	Bilirubin levels;	chr2:233448850	chr2:233865437~233868444:-
BRCA	cis	rs12479064	0.724	rs2305352	ENSG00000231822.1	AC019097.7	-3.33	0.000912	0.0403	-0.12	-0.1	Chronic sinus infection;	chr2:99398661	chr2:99102018~99102752:+
BRCA	cis	rs2836950	0.501	rs62223052	ENSG00000235701.1	PCBP2P1	-3.33	0.000912	0.0403	-0.12	-0.1	Menarche (age at onset);	chr21:39336776	chr21:39171130~39172106:-
BRCA	cis	rs7647973	0.626	rs11709734	ENSG00000281433.1	Metazoa_SRP	3.33	0.000912	0.0403	0.13	0.1	Menarche (age at onset);	chr3:49707802	chr3:49320296~49320564:+
BRCA	cis	rs7647973	0.626	rs9870858	ENSG00000281433.1	Metazoa_SRP	3.33	0.000912	0.0403	0.13	0.1	Menarche (age at onset);	chr3:49731638	chr3:49320296~49320564:+
BRCA	cis	rs7020830	0.571	rs7031314	ENSG00000230188.1	RP11-405L18.4	3.33	0.000912	0.0403	0.14	0.1	Schizophrenia;	chr9:37376125	chr9:37490421~37490893:-
BRCA	cis	rs1984450	1	rs1984450	ENSG00000269349.1	CTD-3099C6.5	3.33	0.000912	0.0403	0.19	0.1	Longitudinal alcohol consumption;	chr19:52510546	chr19:52511282~52512342:-
BRCA	cis	rs6477918	0.598	rs9650733	ENSG00000230185.4	C9orf147	3.33	0.000912	0.0403	0.14	0.1	Obstetric antiphospholipid syndrome;	chr9:112439722	chr9:112433816~112487204:-
BRCA	cis	rs10129255	0.833	rs61997797	ENSG00000231475.3	IGHV4-31	-3.33	0.000913	0.0403	-0.08	-0.1	Kawasaki disease;	chr14:106815190	chr14:106349283~106349792:-
BRCA	cis	rs2832191	0.791	rs8134407	ENSG00000232855.5	AF131217.1	-3.33	0.000913	0.0403	-0.12	-0.1	Dental caries;	chr21:29104265	chr21:28439346~28674848:-
BRCA	cis	rs2338971	0.571	rs367202	ENSG00000260940.1	RP4-575N6.5	3.33	0.000913	0.0403	0.14	0.1	Parkinson's disease;	chr1:101502464	chr1:101243158~101243749:+
BRCA	cis	rs2836950	0.805	rs2836961	ENSG00000235701.1	PCBP2P1	-3.33	0.000913	0.0403	-0.12	-0.1	Menarche (age at onset);	chr21:39255094	chr21:39171130~39172106:-
BRCA	cis	rs337100	0.522	rs419201	ENSG00000263432.2	RN7SL689P	-3.33	0.000913	0.0403	-0.12	-0.1	Pulse pressure;	chr5:123137984	chr5:123022487~123022783:-
BRCA	cis	rs13401620	0.917	rs11689531	ENSG00000229326.3	AC069154.4	-3.33	0.000913	0.0403	-0.14	-0.1	Breast size;	chr2:119793253	chr2:119698623~119700151:+
BRCA	cis	rs6575836	0.539	rs963924	ENSG00000258512.1	LINC00239	3.33	0.000913	0.0403	0.12	0.1	Tuberculosis;	chr14:101185411	chr14:101730437~101732522:+
BRCA	cis	rs875971	0.522	rs4502988	ENSG00000232559.3	GS1-124K5.12	3.33	0.000913	0.0403	0.12	0.1	Aortic root size;	chr7:65832759	chr7:66554588~66576923:-
BRCA	cis	rs17711722	0.701	rs4467826	ENSG00000227113.2	RP11-460N20.4	3.33	0.000913	0.0403	0.11	0.1	Calcium levels;	chr7:65903721	chr7:65075023~65078780:+
BRCA	cis	rs13315871	0.929	rs76226186	ENSG00000272182.1	RP11-802O23.3	3.33	0.000913	0.0403	0.21	0.1	Cholesterol, total;	chr3:58332772	chr3:58428255~58428815:+
BRCA	cis	rs13315871	0.858	rs78946071	ENSG00000272182.1	RP11-802O23.3	3.33	0.000913	0.0403	0.21	0.1	Cholesterol, total;	chr3:58332796	chr3:58428255~58428815:+
BRCA	cis	rs889956	0.776	rs11694571	ENSG00000233251.6	AC007743.1	-3.33	0.000913	0.0403	-0.12	-0.1	Educational attainment;	chr2:57140303	chr2:56173534~56185770:-
BRCA	cis	rs7705502	0.855	rs72810972	ENSG00000251144.1	CTD-2532K18.2	-3.33	0.000913	0.0403	-0.13	-0.1	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for body mass index;	chr5:173880325	chr5:174820027~174826324:+
BRCA	cis	rs7705502	0.89	rs72810974	ENSG00000251144.1	CTD-2532K18.2	-3.33	0.000913	0.0403	-0.13	-0.1	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for body mass index;	chr5:173880502	chr5:174820027~174826324:+
BRCA	cis	rs2832077	0.943	rs4816336	ENSG00000215533.7	LINC00189	3.33	0.000913	0.0403	0.15	0.1	Cognitive test performance;	chr21:28821197	chr21:29193480~29288205:+
BRCA	cis	rs7701440	0.512	rs34631	ENSG00000272308.1	RP11-231G3.1	-3.33	0.000913	0.0403	-0.11	-0.1	Educational attainment;	chr5:61230499	chr5:60866457~60866935:-
BRCA	cis	rs7914558	1	rs7077097	ENSG00000213277.3	MARCKSL1P1	3.33	0.000913	0.0403	0.12	0.1	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103185706	chr10:103175554~103176094:+
BRCA	cis	rs11673344	0.966	rs111927298	ENSG00000267682.1	CTD-3220F14.2	-3.33	0.000913	0.0403	-0.09	-0.1	Obesity-related traits;	chr19:37193034	chr19:37337236~37337743:+
BRCA	cis	rs4819052	0.851	rs8131143	ENSG00000223768.1	LINC00205	3.33	0.000913	0.0403	0.14	0.1	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251731	chr21:45293285~45297354:+
BRCA	cis	rs7786877	0.723	rs62482239	ENSG00000208036.1	MIR106B	3.33	0.000913	0.0403	0.15	0.1	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr7:100620187	chr7:100093993~100094074:-
BRCA	cis	rs8121203	1	rs73897247	ENSG00000213950.2	RPS10P2	-3.33	0.000913	0.0403	-0.25	-0.1	Peripheral arterial disease (traffic-related air pollution interaction);	chr20:15071017	chr20:14757563~14758056:+
BRCA	cis	rs258892	0.947	rs266443	ENSG00000272525.1	RP11-79P5.9	3.33	0.000913	0.0403	0.13	0.1	Small cell lung carcinoma;	chr5:72884550	chr5:73497550~73498293:-
BRCA	cis	rs2243480	1	rs316326	ENSG00000229180.5	GS1-124K5.11	3.33	0.000913	0.0403	0.14	0.1	Diabetic kidney disease;	chr7:66144466	chr7:66526088~66542624:-
BRCA	cis	rs2243480	1	rs316325	ENSG00000229180.5	GS1-124K5.11	3.33	0.000913	0.0403	0.14	0.1	Diabetic kidney disease;	chr7:66144531	chr7:66526088~66542624:-
BRCA	cis	rs62490346	0.528	rs7842443	ENSG00000154316.13	TDH	3.33	0.000913	0.0403	0.16	0.1	Chickenpox;	chr8:10372534	chr8:11339637~11368452:+
BRCA	cis	rs1155750	1	rs1503137	ENSG00000224984.1	RP11-524H19.2	-3.33	0.000913	0.0403	-0.16	-0.1	Colorectal cancer;	chr6:54866013	chr6:54840118~54840855:-
BRCA	cis	rs6517329	0.564	rs879892	ENSG00000230212.5	AP000688.14	3.33	0.000914	0.0403	0.13	0.1	Schizophrenia;	chr21:36136580	chr21:36069642~36126640:-
BRCA	cis	rs3960554	0.808	rs2286829	ENSG00000205485.12	AC004980.7	-3.33	0.000914	0.0403	-0.14	-0.1	Eotaxin levels;	chr7:76048421	chr7:76549360~76627982:+
BRCA	cis	rs4803480	0.63	rs16975338	ENSG00000270164.1	LINC01480	3.33	0.000914	0.0403	0.19	0.1	Schizophrenia;	chr19:41551655	chr19:41535183~41536904:+
BRCA	cis	rs4294134	0.529	rs62479497	ENSG00000223718.3	AC093107.7	3.33	0.000914	0.0403	0.14	0.1	Paget's disease;	chr7:135562322	chr7:135660039~135660647:+
BRCA	cis	rs2688608	0.53	rs71507081	ENSG00000242288.9	RP11-464F9.1	3.33	0.000914	0.0403	0.13	0.1	Inflammatory bowel disease;	chr10:73733378	chr10:73674295~73730466:-
BRCA	cis	rs465969	0.546	rs77990243	ENSG00000271789.1	RP5-1112D6.7	3.33	0.000914	0.0403	0.21	0.1	Psoriasis;	chr6:111513183	chr6:111297126~111298510:+
BRCA	cis	rs36051895	0.626	rs3780368	ENSG00000237711.1	RP11-39K24.13	-3.33	0.000914	0.0403	-0.13	-0.1	Pediatric autoimmune diseases;	chr9:5093188	chr9:5100236~5101009:+
BRCA	cis	rs1126510	0.823	rs4803986	ENSG00000268423.3	AC011551.3	-3.33	0.000914	0.0403	-0.13	-0.1	Ulcerative colitis;	chr19:46628624	chr19:46547056~46600861:-
BRCA	cis	rs6490294	0.528	rs57502306	ENSG00000257624.1	RP1-128M12.3	3.33	0.000914	0.0403	0.18	0.1	Mean platelet volume;	chr12:111852639	chr12:112000739~112000985:-
BRCA	cis	rs848490	0.889	rs55708205	ENSG00000214293.7	APTR	3.33	0.000914	0.0403	0.13	0.1	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77560753	chr7:77657660~77696265:-
BRCA	cis	rs7000551	0.751	rs1116085	ENSG00000253125.1	RP11-459E5.1	3.33	0.000914	0.0403	0.1	0.1	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr8:22537407	chr8:22690150~22798616:+
BRCA	cis	rs11170468	0.614	rs11170521	ENSG00000257718.1	RP11-396F22.1	3.33	0.000914	0.0404	0.13	0.1	Body mass index;	chr12:39054870	chr12:38906451~38909592:+
BRCA	cis	rs74233809	1	rs79993475	ENSG00000236937.2	PTGES3P4	3.33	0.000914	0.0404	0.22	0.1	Birth weight;	chr10:103141274	chr10:102845595~102845950:+
BRCA	cis	rs7487075	0.751	rs7310869	ENSG00000274723.1	RP11-618L22.1	3.33	0.000914	0.0404	0.12	0.1	Itch intensity from mosquito bite;	chr12:46271603	chr12:46970504~46972155:+
BRCA	cis	rs801193	0.569	rs13242290	ENSG00000223473.2	GS1-124K5.3	-3.33	0.000914	0.0404	-0.08	-0.1	Aortic root size;	chr7:66656898	chr7:66491049~66493566:-
BRCA	cis	rs7577696	0.744	rs2268797	ENSG00000276334.1	AL133243.1	3.33	0.000914	0.0404	0.13	0.1	Inflammatory biomarkers;	chr2:31558682	chr2:32521927~32523547:+
BRCA	cis	rs11473501	1	rs11473501	ENSG00000189223.12	PAX8-AS1	3.33	0.000914	0.0404	0.14	0.1	Lymphocyte percentage of white cells;	chr2:113106901	chr2:113211522~113276581:+
BRCA	cis	rs34620785	0.825	rs13249798	ENSG00000266289.1	RP11-1C8.6	3.33	0.000914	0.0404	0.18	0.1	Type 2 diabetes (age of onset);	chr8:102446513	chr8:103383078~103383854:-
BRCA	cis	rs2214681	0.872	rs2707582	ENSG00000273314.1	RP5-1136G13.2	3.33	0.000914	0.0404	0.12	0.1	Bone mineral density;	chr7:148037473	chr7:148696467~148698664:-
BRCA	cis	rs55675132	0.548	rs17274753	ENSG00000226167.1	AP4B1-AS1	3.33	0.000914	0.0404	0.11	0.1	Schizophrenia;	chr1:114836925	chr1:113856635~113901237:+
BRCA	cis	rs74233809	1	rs11191575	ENSG00000213061.2	PFN1P11	3.33	0.000914	0.0404	0.22	0.1	Birth weight;	chr10:103138580	chr10:102838011~102845473:-
BRCA	cis	rs35146811	0.735	rs1637001	ENSG00000221487.1	AC069294.1	-3.33	0.000914	0.0404	-0.13	-0.1	Coronary artery disease;	chr7:100210528	chr7:99713037~99713152:+
BRCA	cis	rs10458771	0.667	rs17106692	ENSG00000223482.6	NUTM2A-AS1	3.33	0.000914	0.0404	0.22	0.1	Amyotrophic lateral sclerosis (sporadic);	chr10:86394006	chr10:87203875~87342612:-
BRCA	cis	rs765787	0.53	rs1648285	ENSG00000259539.1	CTD-2651B20.1	3.33	0.000914	0.0404	0.12	0.1	Uric acid levels;	chr15:45225307	chr15:45152664~45167526:-
BRCA	cis	rs7914558	1	rs4917994	ENSG00000213277.3	MARCKSL1P1	3.33	0.000914	0.0404	0.11	0.1	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103051942	chr10:103175554~103176094:+
BRCA	cis	rs7914558	1	rs2275271	ENSG00000213277.3	MARCKSL1P1	3.33	0.000914	0.0404	0.11	0.1	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103054405	chr10:103175554~103176094:+
BRCA	cis	rs7914558	1	rs11191539	ENSG00000213277.3	MARCKSL1P1	3.33	0.000914	0.0404	0.11	0.1	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103060013	chr10:103175554~103176094:+
BRCA	cis	rs7267979	0.903	rs6115118	ENSG00000204556.4	CTD-2514C3.1	-3.33	0.000915	0.0404	-0.14	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25266098	chr20:26018832~26020684:+
BRCA	cis	rs7267979	0.903	rs1118963	ENSG00000204556.4	CTD-2514C3.1	-3.33	0.000915	0.0404	-0.14	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25266813	chr20:26018832~26020684:+
BRCA	cis	rs2811415	0.597	rs13092555	ENSG00000242551.2	POU5F1P6	3.33	0.000915	0.0404	0.14	0.1	Lung function (FEV1/FVC);	chr3:128019795	chr3:128674735~128677005:-
BRCA	cis	rs4660456	0.619	rs753753	ENSG00000272145.1	NFYC-AS1	3.33	0.000915	0.0404	0.1	0.1	Platelet count;	chr1:40771716	chr1:40690380~40692066:-
BRCA	cis	rs3789045	0.56	rs1002779	ENSG00000176754.11	LINC00303	-3.33	0.000915	0.0404	-0.17	-0.1	Educational attainment (college completion);	chr1:204435970	chr1:204032447~204041265:-
BRCA	cis	rs7927592	0.956	rs10896334	ENSG00000254610.1	RP5-903G2.2	-3.33	0.000915	0.0404	-0.14	-0.1	Total body bone mineral density;	chr11:68514026	chr11:67934563~67939774:-
BRCA	cis	rs4372836	0.504	rs7597048	ENSG00000226833.4	AC097724.3	-3.32	0.000915	0.0404	-0.12	-0.1	Body mass index;	chr2:28843890	chr2:28708953~28736205:-
BRCA	cis	rs9346455	1	rs9364153	ENSG00000279289.1	RP3-331H24.6	3.32	0.000915	0.0404	0.16	0.1	Antipsychotic drug-induced weight gain;Antipsychotic drug-induced weight gain (time interaction);	chr6:71302361	chr6:71386852~71390829:-
BRCA	cis	rs4578769	0.722	rs1010801	ENSG00000273232.1	RP11-370A5.2	3.32	0.000915	0.0404	0.15	0.1	Eosinophil percentage of white cells;	chr18:23027435	chr18:22882825~22883357:-
BRCA	cis	rs36051895	0.559	rs72701682	ENSG00000237711.1	RP11-39K24.13	-3.32	0.000915	0.0404	-0.13	-0.1	Pediatric autoimmune diseases;	chr9:5208025	chr9:5100236~5101009:+
BRCA	cis	rs7267979	0.903	rs2474766	ENSG00000231081.1	RP4-760C5.3	-3.32	0.000915	0.0404	-0.13	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25265517	chr20:26008791~26010531:-
BRCA	cis	rs7267979	0.903	rs2474769	ENSG00000231081.1	RP4-760C5.3	-3.32	0.000915	0.0404	-0.13	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25268089	chr20:26008791~26010531:-
BRCA	cis	rs9951698	0.703	rs7233600	ENSG00000266969.1	RP11-773H22.4	3.32	0.000916	0.0404	0.13	0.1	Intelligence (multi-trait analysis);	chr18:12986001	chr18:12984694~12991173:-
BRCA	cis	rs28573326	0.682	rs6536913	ENSG00000248771.4	LINC01207	-3.32	0.000916	0.0404	-0.12	-0.1	Pelvic organ prolapse (moderate/severe);	chr4:165442649	chr4:164754064~164803795:+
BRCA	cis	rs427943	0.75	rs8133307	ENSG00000261706.1	LINC00165	3.32	0.000916	0.0404	0.12	0.1	Body mass index;	chr21:45179799	chr21:44994362~44995185:-
BRCA	cis	rs1075265	0.692	rs805358	ENSG00000272156.1	RP11-477N3.1	-3.32	0.000916	0.0404	-0.11	-0.1	Chronotype;Morning vs. evening chronotype;	chr2:53934885	chr2:54082554~54085066:+
BRCA	cis	rs6565189	1	rs6565189	ENSG00000261332.1	RP11-297C4.1	3.32	0.000916	0.0404	0.13	0.1	Tonsillectomy;	chr16:30495944	chr16:30498766~30499554:-
BRCA	cis	rs6001482	0.679	rs5750786	ENSG00000223350.2	IGLV9-49	-3.32	0.000916	0.0404	-0.09	-0.1	Diastolic blood pressure;	chr22:22235358	chr22:22343187~22343732:+
BRCA	cis	rs1982963	0.95	rs61973203	ENSG00000277050.1	RP11-102G14.1	3.32	0.000916	0.0404	0.13	0.1	Waist-to-hip ratio adjusted for body mass index;	chr14:52043849	chr14:51637348~51637947:-
BRCA	cis	rs6890684	0.569	rs34627	ENSG00000272308.1	RP11-231G3.1	-3.32	0.000916	0.0404	-0.11	-0.1	Intelligence (multi-trait analysis);	chr5:61232979	chr5:60866457~60866935:-
BRCA	cis	rs6890684	0.569	rs159360	ENSG00000272308.1	RP11-231G3.1	-3.32	0.000916	0.0404	-0.11	-0.1	Intelligence (multi-trait analysis);	chr5:61233623	chr5:60866457~60866935:-
BRCA	cis	rs2675662	0.525	rs12264025	ENSG00000242288.9	RP11-464F9.1	3.32	0.000916	0.0404	0.13	0.1	Psoriasis vulgaris;Psoriasis;	chr10:73734692	chr10:73674295~73730466:-
BRCA	cis	rs8179	0.645	rs2282979	ENSG00000230927.2	TMBIM7P	3.32	0.000916	0.0404	0.14	0.1	White blood cell count (basophil);Sum neutrophil eosinophil counts;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Granulocyte count;	chr7:92635679	chr7:92412976~92439562:-
BRCA	cis	rs4074961	0.527	rs10908355	ENSG00000232273.1	FTH1P1	3.32	0.000916	0.0404	0.12	0.1	Axial length;	chr1:37569685	chr1:37544763~37545294:+
BRCA	cis	rs7819412	0.505	rs17782536	ENSG00000255046.1	RP11-297N6.4	3.32	0.000916	0.0404	0.13	0.1	Triglycerides;	chr8:11164172	chr8:11797928~11802568:-
BRCA	cis	rs249954	0.512	rs171617	ENSG00000260136.4	CTD-2270L9.4	3.32	0.000916	0.0404	0.11	0.1	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr16:23683453	chr16:23452758~23457606:+
BRCA	cis	rs62458065	0.64	rs28587905	ENSG00000273014.1	RP11-225B17.2	-3.32	0.000916	0.0404	-0.16	-0.1	Metabolite levels (HVA/MHPG ratio);	chr7:32493442	chr7:32758882~32759353:+
BRCA	cis	rs10129255	0.912	rs8009135	ENSG00000253132.1	IGHV3-62	-3.32	0.000916	0.0404	-0.08	-0.1	Kawasaki disease;	chr14:106777528	chr14:106643142~106643585:-
BRCA	cis	rs8098244	0.565	rs2850205	ENSG00000265752.2	RP11-403A21.1	3.32	0.000917	0.0404	0.11	0.1	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23677531	chr18:23957754~23982556:-
BRCA	cis	rs72772090	0.539	rs17481856	ENSG00000272109.1	CTD-2260A17.3	3.32	0.000917	0.0404	0.2	0.1	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96781104	chr5:96804353~96806105:+
BRCA	cis	rs72772090	0.539	rs72773923	ENSG00000272109.1	CTD-2260A17.3	3.32	0.000917	0.0404	0.2	0.1	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96781875	chr5:96804353~96806105:+
BRCA	cis	rs9807841	0.67	rs2738039	ENSG00000267100.1	ILF3-AS1	3.32	0.000917	0.0404	0.1	0.1	Inflammatory skin disease;	chr19:10683073	chr19:10651862~10653844:-
BRCA	cis	rs4237845	0.844	rs4630335	ENSG00000270039.1	RP11-571M6.17	-3.32	0.000917	0.0404	-0.14	-0.1	Intelligence (multi-trait analysis);	chr12:57908475	chr12:57803838~57804415:+
BRCA	cis	rs826838	0.616	rs2200605	ENSG00000257718.1	RP11-396F22.1	3.32	0.000917	0.0404	0.1	0.1	Heart rate;	chr12:38230286	chr12:38906451~38909592:+
BRCA	cis	rs8114671	0.562	rs2273683	ENSG00000261582.1	RP4-614O4.11	-3.32	0.000917	0.0404	-0.1	-0.1	Height;	chr20:34921720	chr20:35267885~35280043:-
BRCA	cis	rs9527	0.59	rs2148198	ENSG00000269609.4	RPARP-AS1	3.32	0.000917	0.0405	0.1	0.1	Arsenic metabolism;	chr10:103155553	chr10:102449817~102461106:+
BRCA	cis	rs80130819	0.636	rs2634690	ENSG00000273765.1	RP11-370I10.11	3.32	0.000917	0.0405	0.15	0.1	Prostate cancer;	chr12:48318855	chr12:48360920~48361377:+
BRCA	cis	rs11031096	0.738	rs2284452	ENSG00000224513.2	AC109309.4	-3.32	0.000917	0.0405	-0.13	-0.1	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr11:4134876	chr11:3226061~3232838:+
BRCA	cis	rs56046484	0.956	rs35204319	ENSG00000259630.2	CTD-2262B20.1	-3.32	0.000917	0.0405	-0.17	-0.1	Testicular germ cell tumor;	chr15:85107246	chr15:85415228~85415633:+
BRCA	cis	rs2839186	0.807	rs2032226	ENSG00000215424.8	MCM3AP-AS1	3.32	0.000917	0.0405	0.09	0.1	Testicular germ cell tumor;	chr21:46260438	chr21:46229217~46259390:+
BRCA	cis	rs10838687	0.736	rs2306353	ENSG00000243802.2	RP11-390K5.1	3.32	0.000917	0.0405	0.15	0.1	Proinsulin levels;	chr11:47235157	chr11:47191181~47191542:-
BRCA	cis	rs875971	0.862	rs11765791	ENSG00000265600.1	AC006480.1	-3.32	0.000917	0.0405	-0.12	-0.1	Aortic root size;	chr7:66471587	chr7:67356680~67356779:+
BRCA	cis	rs742004	0.891	rs738158	ENSG00000235271.4	RP1-90L6.3	3.32	0.000917	0.0405	0.13	0.1	Metabolite levels (HVA/MHPG ratio);	chr22:27040327	chr22:26903292~26920611:+
BRCA	cis	rs4835473	0.932	rs62339580	ENSG00000246448.2	RP13-578N3.3	-3.32	0.000917	0.0405	-0.11	-0.1	Immature fraction of reticulocytes;	chr4:143785090	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.932	rs62339581	ENSG00000246448.2	RP13-578N3.3	-3.32	0.000917	0.0405	-0.11	-0.1	Immature fraction of reticulocytes;	chr4:143785172	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.932	rs7666368	ENSG00000246448.2	RP13-578N3.3	-3.32	0.000917	0.0405	-0.11	-0.1	Immature fraction of reticulocytes;	chr4:143785372	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.932	rs7690428	ENSG00000246448.2	RP13-578N3.3	-3.32	0.000917	0.0405	-0.11	-0.1	Immature fraction of reticulocytes;	chr4:143785400	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.932	rs34781605	ENSG00000246448.2	RP13-578N3.3	-3.32	0.000917	0.0405	-0.11	-0.1	Immature fraction of reticulocytes;	chr4:143785486	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.9	rs11100810	ENSG00000246448.2	RP13-578N3.3	-3.32	0.000917	0.0405	-0.11	-0.1	Immature fraction of reticulocytes;	chr4:143787518	chr4:143700257~143865072:+
BRCA	cis	rs10844706	0.699	rs10844632	ENSG00000278635.1	CTD-2318O12.1	-3.32	0.000917	0.0405	-0.11	-0.1	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9734309	chr12:9415641~9416718:+
BRCA	cis	rs10191559	0.552	rs6747566	ENSG00000234663.4	AC104820.2	3.32	0.000917	0.0405	0.09	0.1	Red blood cell count;	chr2:181207192	chr2:181101932~181399559:+
BRCA	cis	rs2243480	1	rs465359	ENSG00000226767.1	RP11-328P23.3	-3.32	0.000917	0.0405	-0.18	-0.1	Diabetic kidney disease;	chr7:66093177	chr7:65508773~65508944:-
BRCA	cis	rs2243480	1	rs462853	ENSG00000226767.1	RP11-328P23.3	-3.32	0.000917	0.0405	-0.18	-0.1	Diabetic kidney disease;	chr7:66093180	chr7:65508773~65508944:-
BRCA	cis	rs2243480	1	rs160644	ENSG00000226767.1	RP11-328P23.3	-3.32	0.000917	0.0405	-0.18	-0.1	Diabetic kidney disease;	chr7:66093199	chr7:65508773~65508944:-
BRCA	cis	rs2243480	1	rs160642	ENSG00000226767.1	RP11-328P23.3	-3.32	0.000917	0.0405	-0.18	-0.1	Diabetic kidney disease;	chr7:66093386	chr7:65508773~65508944:-
BRCA	cis	rs2243480	0.614	rs34032527	ENSG00000226767.1	RP11-328P23.3	-3.32	0.000917	0.0405	-0.18	-0.1	Diabetic kidney disease;	chr7:66100154	chr7:65508773~65508944:-
BRCA	cis	rs4702718	0.616	rs7733385	ENSG00000272324.4	CTD-2154B17.4	3.32	0.000917	0.0405	0.12	0.1	Obesity-related traits;	chr5:10712087	chr5:10761065~10770294:+
BRCA	cis	rs7512898	0.9	rs6427847	ENSG00000260088.1	RP11-92G12.3	-3.32	0.000917	0.0405	-0.13	-0.1	Electrocardiographic conduction measures;	chr1:200700052	chr1:200669507~200694250:+
BRCA	cis	rs875971	1	rs6979382	ENSG00000229886.1	RP5-1132H15.3	3.32	0.000917	0.0405	0.11	0.1	Aortic root size;	chr7:66421388	chr7:66025126~66031544:-
BRCA	cis	rs875971	1	rs6961990	ENSG00000229886.1	RP5-1132H15.3	3.32	0.000917	0.0405	0.11	0.1	Aortic root size;	chr7:66423583	chr7:66025126~66031544:-
BRCA	cis	rs7267979	0.868	rs6107019	ENSG00000274414.1	RP5-965G21.4	-3.32	0.000917	0.0405	-0.12	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25253349	chr20:25239007~25245229:-
BRCA	cis	rs1007738	0.542	rs7937410	ENSG00000200376.1	RNU5E-10P	-3.32	0.000918	0.0405	-0.13	-0.1	Bone mineral density (hip);	chr11:47184531	chr11:47576471~47576588:-
BRCA	cis	rs597539	0.652	rs627731	ENSG00000255741.1	RP11-757G1.5	-3.32	0.000918	0.0405	-0.15	-0.1	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68931195	chr11:68941503~68942852:-
BRCA	cis	rs4927850	0.918	rs4361313	ENSG00000273009.1	RP11-352G9.1	-3.32	0.000918	0.0405	-0.12	-0.1	Pancreatic cancer;	chr3:196025389	chr3:195913078~195913683:-
BRCA	cis	rs962856	0.729	rs1483350	ENSG00000236605.1	AC023115.4	3.32	0.000918	0.0405	0.12	0.1	Pancreatic cancer;	chr2:67292771	chr2:67324627~67325304:+
BRCA	cis	rs7020830	0.898	rs308495	ENSG00000230188.1	RP11-405L18.4	-3.32	0.000918	0.0405	-0.12	-0.1	Schizophrenia;	chr9:37277606	chr9:37490421~37490893:-
BRCA	cis	rs4332037	0.851	rs1403175	ENSG00000273230.1	RP11-1246C19.1	-3.32	0.000918	0.0405	-0.15	-0.1	Bipolar disorder;	chr7:1924721	chr7:1464497~1467522:-
BRCA	cis	rs4805834	0.668	rs17272183	ENSG00000201388.1	SNORA68	3.32	0.000918	0.0405	0.17	0.1	Creatinine levels;	chr19:32830307	chr19:32608337~32608469:-
BRCA	cis	rs11098499	0.863	rs2306457	ENSG00000260404.2	RP11-384K6.6	3.32	0.000918	0.0405	0.1	0.1	Corneal astigmatism;	chr4:119551684	chr4:118591773~118633729:+
BRCA	cis	rs9890032	1	rs9890032	ENSG00000264538.5	SUZ12P1	3.32	0.000918	0.0405	0.1	0.1	Hip circumference adjusted for BMI;	chr17:30838916	chr17:30709299~30790908:+
BRCA	cis	rs7701440	0.512	rs10939886	ENSG00000272308.1	RP11-231G3.1	-3.32	0.000918	0.0405	-0.11	-0.1	Educational attainment;	chr5:61235738	chr5:60866457~60866935:-
BRCA	cis	rs801193	0.569	rs6951302	ENSG00000223473.2	GS1-124K5.3	-3.32	0.000918	0.0405	-0.08	-0.1	Aortic root size;	chr7:66667525	chr7:66491049~66493566:-
BRCA	cis	rs17836934	0.565	rs4240746	ENSG00000270344.2	RP11-734K2.4	-3.32	0.000918	0.0405	-0.1	-0.1	Total body bone mineral density;	chr12:90005097	chr12:89525654~89548005:+
BRCA	cis	rs17756712	0.527	rs1193742	ENSG00000271727.1	RP11-532F6.4	-3.32	0.000918	0.0405	-0.13	-0.1	Vertical cup-disc ratio;	chr6:635629	chr6:711533~750729:+
BRCA	cis	rs11887277	0.557	rs828270	ENSG00000272148.1	RP11-195B17.1	3.32	0.000918	0.0405	0.12	0.1	Obesity-related traits;	chr2:26747241	chr2:27062428~27062907:-
BRCA	cis	rs13421350	0.579	rs77167534	ENSG00000225205.4	AC093818.1	-3.32	0.000919	0.0405	-0.2	-0.1	Diabetic kidney disease;	chr2:172455202	chr2:172480840~172556596:-
BRCA	cis	rs258892	0.843	rs34329209	ENSG00000272525.1	RP11-79P5.9	-3.32	0.000919	0.0405	-0.13	-0.1	Small cell lung carcinoma;	chr5:72749690	chr5:73497550~73498293:-
BRCA	cis	rs258892	0.895	rs13177678	ENSG00000272525.1	RP11-79P5.9	-3.32	0.000919	0.0405	-0.13	-0.1	Small cell lung carcinoma;	chr5:72749819	chr5:73497550~73498293:-
BRCA	cis	rs258892	0.895	rs10070210	ENSG00000272525.1	RP11-79P5.9	-3.32	0.000919	0.0405	-0.13	-0.1	Small cell lung carcinoma;	chr5:72750215	chr5:73497550~73498293:-
BRCA	cis	rs258892	0.895	rs57787613	ENSG00000272525.1	RP11-79P5.9	-3.32	0.000919	0.0405	-0.13	-0.1	Small cell lung carcinoma;	chr5:72751451	chr5:73497550~73498293:-
BRCA	cis	rs2704588	1	rs2704588	ENSG00000270720.1	RP11-84C13.2	3.32	0.000919	0.0405	0.15	0.1	Longevity;	chr4:88928621	chr4:89119284~89119871:+
BRCA	cis	rs6142102	1	rs6059681	ENSG00000206582.1	Y_RNA	-3.32	0.000919	0.0405	-0.13	-0.1	Skin pigmentation;	chr20:34135535	chr20:34526510~34526606:-
BRCA	cis	rs4631830	0.965	rs7070301	ENSG00000204177.9	BMS1P1	-3.32	0.000919	0.0405	-0.1	-0.1	Prostate-specific antigen levels;	chr10:46052752	chr10:46786674~46811989:+
BRCA	cis	rs6599077	0.618	rs73067622	ENSG00000223797.4	ENTPD3-AS1	3.32	0.000919	0.0405	0.14	0.1	Sleep-related phenotypes;	chr3:40149413	chr3:40313802~40453329:-
BRCA	cis	rs7647973	1	rs8897	ENSG00000244380.1	RP11-24C3.2	3.32	0.000919	0.0405	0.13	0.1	Menarche (age at onset);	chr3:49422974	chr3:48440352~48446656:-
BRCA	cis	rs4950322	0.58	rs4950308	ENSG00000230832.3	RP11-325P15.2	-3.32	0.000919	0.0405	-0.16	-0.1	Protein quantitative trait loci;	chr1:147120092	chr1:147082338~147083578:-
BRCA	cis	rs12477438	0.52	rs11123764	ENSG00000231822.1	AC019097.7	3.32	0.000919	0.0405	0.11	0.1	Chronic sinus infection;	chr2:99134214	chr2:99102018~99102752:+
BRCA	cis	rs12477438	0.52	rs8179690	ENSG00000231822.1	AC019097.7	-3.32	0.000919	0.0405	-0.11	-0.1	Chronic sinus infection;	chr2:99178837	chr2:99102018~99102752:+
BRCA	cis	rs1865760	0.82	rs9348697	ENSG00000272810.1	U91328.22	-3.32	0.00092	0.0406	-0.12	-0.1	Height;	chr6:25890606	chr6:26013241~26013757:+
BRCA	cis	rs1005277	0.505	rs7917943	ENSG00000099251.13	HSD17B7P2	-3.32	0.00092	0.0406	-0.11	-0.1	Extrinsic epigenetic age acceleration;	chr10:37906883	chr10:38356380~38378505:+
BRCA	cis	rs7508	0.595	rs383091	ENSG00000253671.1	RP11-806O11.1	-3.32	0.00092	0.0406	-0.12	-0.1	Atrial fibrillation;	chr8:18027097	chr8:17808941~17820868:+
BRCA	cis	rs9400180	0.959	rs2157501	ENSG00000271734.1	RP1-111B22.3	-3.32	0.00092	0.0406	-0.13	-0.1	Major depressive disorder;	chr6:108047265	chr6:108030249~108030718:-
BRCA	cis	rs1437396	0.609	rs2589055	ENSG00000203327.2	AC012358.7	3.32	0.00092	0.0406	0.1	0.1	Alcohol dependence;	chr2:55325260	chr2:55214387~55216126:-
BRCA	cis	rs853679	0.882	rs9393908	ENSG00000216676.2	RP1-15D7.1	-3.32	0.00092	0.0406	-0.19	-0.1	Depression;	chr6:28223052	chr6:27652602~27652825:-
BRCA	cis	rs853679	0.882	rs9366717	ENSG00000216676.2	RP1-15D7.1	-3.32	0.00092	0.0406	-0.19	-0.1	Depression;	chr6:28223279	chr6:27652602~27652825:-
BRCA	cis	rs17092148	1	rs6060017	ENSG00000202150.1	RNU6-407P	3.32	0.00092	0.0406	0.15	0.1	Neuroticism;	chr20:34725238	chr20:35030317~35030420:-
BRCA	cis	rs7537765	1	rs7537765	ENSG00000242349.4	NPPA-AS1	3.32	0.00092	0.0406	0.15	0.1	QRS complex (12-leadsum);	chr1:11827246	chr1:11841017~11848079:+
BRCA	cis	rs4657175	0.611	rs10918859	ENSG00000272574.1	RP11-359K18.4	-3.32	0.00092	0.0406	-0.12	-0.1	QT interval;	chr1:162199478	chr1:162593103~162593754:+
BRCA	cis	rs7412746	0.611	rs1889741	ENSG00000224800.1	RP11-235D19.2	-3.32	0.00092	0.0406	-0.13	-0.1	Melanoma;	chr1:150896569	chr1:150881236~150881683:-
BRCA	cis	rs9549328	0.731	rs7983602	ENSG00000235280.2	MCF2L-AS1	3.32	0.00092	0.0406	0.15	0.1	Systolic blood pressure;	chr13:112966168	chr13:112967484~112968824:-
BRCA	cis	rs2041840	1	rs10178975	ENSG00000272054.1	RP11-423P10.2	-3.32	0.00092	0.0406	-0.09	-0.1	Chronic lymphocytic leukemia;	chr2:37287421	chr2:37208875~37212677:+
BRCA	cis	rs34779708	0.931	rs4934535	ENSG00000269952.1	RP11-324I22.3	-3.32	0.00092	0.0406	-0.14	-0.1	Inflammatory bowel disease;Crohn's disease;	chr10:35143793	chr10:35210416~35210750:+
BRCA	cis	rs34779708	0.966	rs4934734	ENSG00000269952.1	RP11-324I22.3	-3.32	0.00092	0.0406	-0.14	-0.1	Inflammatory bowel disease;Crohn's disease;	chr10:35145445	chr10:35210416~35210750:+
BRCA	cis	rs34779708	0.966	rs12769575	ENSG00000269952.1	RP11-324I22.3	-3.32	0.00092	0.0406	-0.14	-0.1	Inflammatory bowel disease;Crohn's disease;	chr10:35146999	chr10:35210416~35210750:+
BRCA	cis	rs950880	0.56	rs12712141	ENSG00000281162.1	LINC01127	-3.32	0.00092	0.0406	-0.1	-0.1	Serum protein levels (sST2);	chr2:102336607	chr2:101962056~101987167:+
BRCA	cis	rs4811117	1	rs4811117	ENSG00000237595.3	RP11-112L6.3	-3.32	0.00092	0.0406	-0.18	-0.1	Molar-incisor hypomineralization;	chr20:51054898	chr20:50162765~50166102:-
BRCA	cis	rs11955398	0.585	rs10063407	ENSG00000251279.1	CTC-436P18.1	3.32	0.00092	0.0406	0.13	0.1	Intelligence (multi-trait analysis);	chr5:60713236	chr5:61162070~61232040:+
BRCA	cis	rs3770752	0.836	rs11679617	ENSG00000272054.1	RP11-423P10.2	-3.32	0.00092	0.0406	-0.09	-0.1	Schizophrenia;	chr2:37250100	chr2:37208875~37212677:+
BRCA	cis	rs7011507	1	rs76393713	ENSG00000279881.1	RP11-513O13.1	-3.32	0.000921	0.0406	-0.15	-0.1	Inflammatory bowel disease;Ulcerative colitis;	chr8:48254988	chr8:48428143~48431041:-
BRCA	cis	rs2370759	1	rs16933225	ENSG00000227253.3	RP11-166N17.1	-3.32	0.000921	0.0406	-0.15	-0.1	Sexual dysfunction (female);	chr10:32310536	chr10:32266289~32269474:+
BRCA	cis	rs4481887	0.676	rs946764	ENSG00000235749.2	RP11-634B7.4	-3.32	0.000921	0.0406	-0.12	-0.1	Common traits (Other);	chr1:248358731	chr1:247639749~247747062:+
BRCA	cis	rs648163	0.59	rs675500	ENSG00000229989.3	MIR181A1HG	3.32	0.000921	0.0406	0.13	0.1	Educational attainment (years of education);	chr1:199388750	chr1:198807493~198937429:-
BRCA	cis	rs648163	0.614	rs473646	ENSG00000229989.3	MIR181A1HG	3.32	0.000921	0.0406	0.13	0.1	Educational attainment (years of education);	chr1:199388853	chr1:198807493~198937429:-
BRCA	cis	rs10129255	0.957	rs4387509	ENSG00000211958.2	IGHV3-38	3.32	0.000921	0.0406	0.08	0.1	Kawasaki disease;	chr14:106704386	chr14:106410493~106411021:-
BRCA	cis	rs737008	0.96	rs949429	ENSG00000262703.1	RP11-485G7.6	-3.32	0.000921	0.0406	-0.11	-0.1	Obesity-related traits;	chr16:11282172	chr16:11348143~11349321:-
BRCA	cis	rs9368481	0.554	rs2754603	ENSG00000124549.13	BTN2A3P	-3.32	0.000921	0.0406	-0.11	-0.1	Autism spectrum disorder or schizophrenia;	chr6:26997360	chr6:26421391~26432383:+
BRCA	cis	rs2243480	1	rs313803	ENSG00000226767.1	RP11-328P23.3	-3.32	0.000921	0.0406	-0.18	-0.1	Diabetic kidney disease;	chr7:66049744	chr7:65508773~65508944:-
BRCA	cis	rs6088580	0.634	rs1205344	ENSG00000275784.1	RP5-1125A11.6	3.32	0.000921	0.0406	0.11	0.1	Glomerular filtration rate (creatinine);	chr20:34330492	chr20:33989480~33991818:-
BRCA	cis	rs6494488	0.5	rs72744764	ENSG00000259635.1	AC100830.3	-3.32	0.000921	0.0406	-0.23	-0.1	Coronary artery disease;	chr15:64784688	chr15:64701248~64719602:+
BRCA	cis	rs1982963	1	rs3742536	ENSG00000277050.1	RP11-102G14.1	3.32	0.000921	0.0406	0.12	0.1	Waist-to-hip ratio adjusted for body mass index;	chr14:52040711	chr14:51637348~51637947:-
BRCA	cis	rs2832191	0.791	rs2065270	ENSG00000232855.5	AF131217.1	3.32	0.000921	0.0406	0.12	0.1	Dental caries;	chr21:29113099	chr21:28439346~28674848:-
BRCA	cis	rs4415084	0.662	rs12109710	ENSG00000272335.1	RP11-53O19.3	-3.32	0.000921	0.0406	-0.1	-0.1	Breast cancer;	chr5:44929826	chr5:44826076~44828592:+
BRCA	cis	rs73201462	1	rs2955096	ENSG00000242551.2	POU5F1P6	3.32	0.000921	0.0406	0.17	0.1	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128259023	chr3:128674735~128677005:-
BRCA	cis	rs1843834	0.539	rs12694643	ENSG00000274629.1	RP11-92F20.1	-3.32	0.000921	0.0406	-0.13	-0.1	IgE levels in asthmatics (D.p. specific);	chr2:224581886	chr2:224464682~224474500:+
BRCA	cis	rs67478160	0.643	rs11847468	ENSG00000269910.1	RP11-73M18.10	3.32	0.000921	0.0406	0.1	0.1	Schizophrenia;	chr14:103753958	chr14:103694516~103695050:-
BRCA	cis	rs34779708	0.931	rs34087268	ENSG00000269952.1	RP11-324I22.3	-3.32	0.000921	0.0406	-0.14	-0.1	Inflammatory bowel disease;Crohn's disease;	chr10:35057796	chr10:35210416~35210750:+
BRCA	cis	rs34779708	0.931	rs58159560	ENSG00000269952.1	RP11-324I22.3	-3.32	0.000921	0.0406	-0.14	-0.1	Inflammatory bowel disease;Crohn's disease;	chr10:35062321	chr10:35210416~35210750:+
BRCA	cis	rs6681460	0.966	rs10749765	ENSG00000248458.2	RP4-598P13.1	3.32	0.000921	0.0406	0.11	0.1	Presence of antiphospholipid antibodies;	chr1:66684597	chr1:66665864~66677027:-
BRCA	cis	rs1030420	0.848	rs1473817	ENSG00000200714.1	Y_RNA	-3.32	0.000921	0.0406	-0.17	-0.1	Blood metabolite levels;	chr8:66384164	chr8:65592731~65592820:+
BRCA	cis	rs1005277	0.522	rs289649	ENSG00000099251.13	HSD17B7P2	3.32	0.000921	0.0406	0.11	0.1	Extrinsic epigenetic age acceleration;	chr10:37686456	chr10:38356380~38378505:+
BRCA	cis	rs1424638	0.655	rs6750630	ENSG00000233251.6	AC007743.1	-3.32	0.000921	0.0406	-0.12	-0.1	Intelligence (multi-trait analysis);	chr2:57023862	chr2:56173534~56185770:-
BRCA	cis	rs3816183	0.571	rs11679371	ENSG00000226491.1	FTOP1	-3.32	0.000922	0.0406	-0.12	-0.1	Hypospadias;	chr2:42683779	chr2:42797225~42798712:-
BRCA	cis	rs2924679	1	rs3019587	ENSG00000259799.1	RP11-554A11.9	3.32	0.000922	0.0406	0.23	0.1	Obesity-related traits;	chr11:68802174	chr11:69155910~69159752:+
BRCA	cis	rs6599077	0.901	rs9854779	ENSG00000223797.4	ENTPD3-AS1	3.32	0.000922	0.0406	0.12	0.1	Sleep-related phenotypes;	chr3:40051383	chr3:40313802~40453329:-
BRCA	cis	rs10816359	0.793	rs7866703	ENSG00000234323.4	RP11-308N19.1	-3.32	0.000922	0.0406	-0.15	-0.1	Menarche (age at onset);	chr9:106027938	chr9:106278392~106604795:+
BRCA	cis	rs879500	0.653	rs4800308	ENSG00000266296.1	ARIH2P1	-3.32	0.000922	0.0406	-0.15	-0.1	Lung function (FVC);	chr18:28500513	chr18:28651732~28653208:+
BRCA	cis	rs2281603	0.951	rs73267743	ENSG00000259116.1	RP11-973N13.4	-3.32	0.000922	0.0406	-0.1	-0.1	Lymphocyte counts;	chr14:64511424	chr14:64514154~64540368:-
BRCA	cis	rs4819052	0.808	rs11909411	ENSG00000223768.1	LINC00205	-3.32	0.000922	0.0406	-0.14	-0.1	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45256641	chr21:45293285~45297354:+
BRCA	cis	rs4819052	0.851	rs28676615	ENSG00000223768.1	LINC00205	-3.32	0.000922	0.0406	-0.14	-0.1	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45256661	chr21:45293285~45297354:+
BRCA	cis	rs13108904	0.65	rs3796618	ENSG00000196810.4	CTBP1-AS2	3.32	0.000922	0.0406	0.11	0.1	Obesity-related traits;	chr4:1355814	chr4:1249300~1288291:+
BRCA	cis	rs924712	0.844	rs12208341	ENSG00000261116.1	RP3-523K23.2	3.32	0.000922	0.0406	0.13	0.1	Breast cancer;	chr6:54880148	chr6:54943167~54945099:+
BRCA	cis	rs7412746	0.621	rs11204749	ENSG00000224800.1	RP11-235D19.2	-3.32	0.000922	0.0406	-0.13	-0.1	Melanoma;	chr1:150957087	chr1:150881236~150881683:-
BRCA	cis	rs8040855	0.557	rs9744503	ENSG00000259416.2	RP11-158M2.5	-3.32	0.000922	0.0406	-0.12	-0.1	Bulimia nervosa;	chr15:85180986	chr15:85754941~85756237:-
BRCA	cis	rs4923705	0.706	rs11638994	ENSG00000259336.1	RP11-323I15.5	3.32	0.000922	0.0406	0.16	0.1	Attention deficit hyperactivity disorder;	chr15:35988773	chr15:35099022~35169698:-
BRCA	cis	rs72928364	1	rs35530876	ENSG00000244119.1	PDCL3P4	3.32	0.000922	0.0406	0.13	0.1	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100961648	chr3:101712472~101713191:+
BRCA	cis	rs12282928	0.876	rs7937826	ENSG00000255197.4	RP11-750H9.5	3.32	0.000922	0.0406	0.1	0.1	Migraine - clinic-based;	chr11:48277796	chr11:47383148~47409190:-
BRCA	cis	rs1665650	0.874	rs7093835	ENSG00000232767.1	RP11-498B4.5	3.32	0.000922	0.0406	0.11	0.1	Colorectal cancer;	chr10:116733101	chr10:116670103~116672739:+
BRCA	cis	rs793108	0.506	rs793094	ENSG00000237135.1	DDX10P1	-3.32	0.000922	0.0406	-0.13	-0.1	Multiple sclerosis;Rheumatoid arthritis;	chr10:31097893	chr10:30919012~30921235:-
BRCA	cis	rs7259811	0.787	rs56300648	ENSG00000268266.1	AC003005.2	3.32	0.000922	0.0407	0.14	0.1	Western dietary pattern;	chr19:56710464	chr19:57477649~57482996:+
BRCA	cis	rs9473147	0.551	rs10948375	ENSG00000270761.1	RP11-385F7.1	-3.32	0.000922	0.0407	-0.11	-0.1	Platelet distribution width;Mean platelet volume;	chr6:47685893	chr6:47477243~47477572:-
BRCA	cis	rs4906332	0.966	rs12894275	ENSG00000259775.1	RP11-45P15.4	3.32	0.000923	0.0407	0.12	0.1	Coronary artery disease;	chr14:103435087	chr14:103331674~103332367:-
BRCA	cis	rs6600671	0.934	rs11249348	ENSG00000223345.3	HIST2H2BA	3.32	0.000923	0.0407	0.12	0.1	Hip geometry;	chr1:121446444	chr1:121108210~121117257:-
BRCA	cis	rs613391	0.561	rs589423	ENSG00000265194.1	RP11-70L8.4	-3.32	0.000923	0.0407	-0.1	-0.1	Quantitative traits;	chr9:22721049	chr9:21858910~21861926:-
BRCA	cis	rs6728642	0.708	rs115507803	ENSG00000279791.1	RP11-499E14.1	-3.32	0.000923	0.0407	-0.22	-0.1	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:97086317	chr2:97094935~97097433:+
BRCA	cis	rs6108958	0.838	rs973970	ENSG00000235036.4	RP5-1099D15.1	3.32	0.000923	0.0407	0.11	0.1	Gut microbiome composition (summer);	chr20:11496994	chr20:10612861~10614229:-
BRCA	cis	rs2562456	0.833	rs2650776	ENSG00000268705.1	BNIP3P26	3.32	0.000923	0.0407	0.12	0.1	Pain;	chr19:21430595	chr19:21521343~21521896:-
BRCA	cis	rs80033912	0.64	rs6785832	ENSG00000244380.1	RP11-24C3.2	3.32	0.000923	0.0407	0.13	0.1	Intelligence (multi-trait analysis);	chr3:49186883	chr3:48440352~48446656:-
BRCA	cis	rs1730008	0.691	rs4516653	ENSG00000279311.1	RP11-170K4.2	3.32	0.000923	0.0407	0.13	0.1	Lobe attachment (rater-scored or self-reported);	chr3:158400667	chr3:158869898~158871821:+
BRCA	cis	rs1730008	0.654	rs7652970	ENSG00000279311.1	RP11-170K4.2	3.32	0.000923	0.0407	0.13	0.1	Lobe attachment (rater-scored or self-reported);	chr3:158406102	chr3:158869898~158871821:+
BRCA	cis	rs1730008	0.691	rs11716969	ENSG00000279311.1	RP11-170K4.2	3.32	0.000923	0.0407	0.13	0.1	Lobe attachment (rater-scored or self-reported);	chr3:158411162	chr3:158869898~158871821:+
BRCA	cis	rs9863	0.828	rs11057408	ENSG00000269938.1	RP11-214K3.20	-3.32	0.000923	0.0407	-0.11	-0.1	White blood cell count;	chr12:123980289	chr12:123968023~123968579:-
BRCA	cis	rs8105895	0.799	rs62110863	ENSG00000269345.1	VN1R85P	3.32	0.000923	0.0407	0.17	0.1	Body mass index (change over time);	chr19:21917706	chr19:22174766~22175191:-
BRCA	cis	rs925946	0.518	rs7481311	ENSG00000245573.6	BDNF-AS	3.32	0.000923	0.0407	0.12	0.1	Weight;Body mass index;	chr11:27561582	chr11:27506838~27698174:+
BRCA	cis	rs11098499	0.955	rs56386062	ENSG00000225892.3	RP11-384K6.2	3.32	0.000923	0.0407	0.1	0.1	Corneal astigmatism;	chr4:119233980	chr4:118632274~118634759:+
BRCA	cis	rs5762752	0.555	rs695629	ENSG00000272858.1	CTA-292E10.8	-3.32	0.000923	0.0407	-0.12	-0.1	Optic disc area;	chr22:28438781	chr22:28814914~28815662:+
BRCA	cis	rs55675132	0.51	rs12120851	ENSG00000226167.1	AP4B1-AS1	3.32	0.000923	0.0407	0.11	0.1	Schizophrenia;	chr1:114720224	chr1:113856635~113901237:+
BRCA	cis	rs7937127	0.557	rs113179541	ENSG00000254907.1	RP11-484D2.2	3.32	0.000923	0.0407	0.19	0.1	Fibrinogen levels;	chr11:43510640	chr11:43328748~43359296:-
BRCA	cis	rs2277027	1	rs9313617	ENSG00000251405.2	CTB-109A12.1	3.32	0.000923	0.0407	0.13	0.1	Pulmonary function;Pulmonary function (smoking interaction);	chr5:157506450	chr5:157362615~157460078:-
BRCA	cis	rs2555155	0.87	rs10839575	ENSG00000254595.1	CTD-2010I16.1	-3.32	0.000924	0.0407	-0.12	-0.1	DNA methylation (variation);	chr11:6530405	chr11:6488186~6489377:-
BRCA	cis	rs2243480	1	rs73150014	ENSG00000237026.1	RP11-328P23.2	3.32	0.000924	0.0407	0.19	0.1	Diabetic kidney disease;	chr7:65985932	chr7:65235790~65236723:-
BRCA	cis	rs17741049	0.881	rs60087251	ENSG00000260493.1	RP11-219B4.7	-3.32	0.000924	0.0407	-0.24	-0.1	Blood protein levels;	chr8:85290294	chr8:85172077~85177062:-
BRCA	cis	rs2075671	0.855	rs62483567	ENSG00000208036.1	MIR106B	3.32	0.000924	0.0407	0.14	0.1	Other erythrocyte phenotypes;	chr7:100688812	chr7:100093993~100094074:-
BRCA	cis	rs12893668	0.572	rs35011804	ENSG00000258914.1	CTD-2134A5.3	3.32	0.000924	0.0407	0.14	0.1	Reticulocyte count;	chr14:103685063	chr14:103875055~103877478:+
BRCA	cis	rs11887277	0.557	rs13026040	ENSG00000272148.1	RP11-195B17.1	-3.32	0.000924	0.0407	-0.12	-0.1	Obesity-related traits;	chr2:26748550	chr2:27062428~27062907:-
BRCA	cis	rs875971	1	rs12698523	ENSG00000273448.1	RP11-166O4.6	3.32	0.000924	0.0407	0.09	0.1	Aortic root size;	chr7:66503126	chr7:67333047~67334383:+
BRCA	cis	rs17653722	0.562	rs10444538	ENSG00000272724.1	OR7E47P	-3.32	0.000924	0.0407	-0.17	-0.1	Telomere length;	chr12:52183701	chr12:52084744~52092285:+
BRCA	cis	rs5750830	0.546	rs4821891	ENSG00000280216.1	RP3-333H23.9	-3.32	0.000924	0.0407	-0.12	-0.1	Intelligence (multi-trait analysis);	chr22:39389376	chr22:39379610~39380015:+
BRCA	cis	rs1334894	1	rs16878812	ENSG00000273870.1	RP11-174N3.4	3.32	0.000924	0.0407	0.18	0.1	Coronary artery disease;	chr6:35601785	chr6:35070871~35071049:-
BRCA	cis	rs911555	0.723	rs6575986	ENSG00000269910.1	RP11-73M18.10	3.32	0.000924	0.0407	0.11	0.1	Intelligence (multi-trait analysis);	chr14:103420334	chr14:103694516~103695050:-
BRCA	cis	rs35146811	0.735	rs6465766	ENSG00000214313.7	AZGP1P1	3.32	0.000924	0.0407	0.11	0.1	Coronary artery disease;	chr7:100188048	chr7:99980762~99987535:+
BRCA	cis	rs935111	0.901	rs10460960	ENSG00000232354.6	VIPR1-AS1	3.32	0.000924	0.0407	0.13	0.1	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);	chr3:42267243	chr3:42506465~42533258:-
BRCA	cis	rs7103648	0.695	rs12577643	ENSG00000255520.1	RP11-390K5.3	3.32	0.000925	0.0407	0.13	0.1	Systolic blood pressure;Diastolic blood pressure;	chr11:47445620	chr11:47123104~47130801:-
BRCA	cis	rs12477602	0.938	rs13033003	ENSG00000272966.1	RP11-686O6.1	3.32	0.000925	0.0407	0.17	0.1	Intelligence (multi-trait analysis);	chr2:202395108	chr2:202336739~202337200:+
BRCA	cis	rs6940638	0.688	rs7764984	ENSG00000124549.13	BTN2A3P	-3.32	0.000925	0.0407	-0.11	-0.1	Intelligence (multi-trait analysis);	chr6:27066402	chr6:26421391~26432383:+
BRCA	cis	rs2813490	0.956	rs718528	ENSG00000227627.1	RP1-101K10.6	3.32	0.000925	0.0407	0.14	0.1	Number of pregnancies;	chr6:152148739	chr6:152983750~152989223:+
BRCA	cis	rs7818688	0.697	rs3802191	ENSG00000245080.5	RP11-320N21.1	3.32	0.000925	0.0407	0.17	0.1	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94975356	chr8:95066808~95073182:-
BRCA	cis	rs11700980	0.636	rs116954706	ENSG00000232855.5	AF131217.1	3.32	0.000925	0.0407	0.19	0.1	QRS complex (12-leadsum);	chr21:28847082	chr21:28439346~28674848:-
BRCA	cis	rs13108904	0.935	rs1680072	ENSG00000211482.1	AC092574.1	-3.32	0.000925	0.0408	-0.12	-0.1	Obesity-related traits;	chr4:1287907	chr4:409809~409915:+
BRCA	cis	rs1635	0.826	rs115041649	ENSG00000220721.1	OR1F12	3.32	0.000925	0.0408	0.23	0.1	Schizophrenia;	chr6:28306876	chr6:28073316~28074233:+
BRCA	cis	rs853679	0.55	rs1233699	ENSG00000261839.1	RP1-265C24.8	3.32	0.000925	0.0408	0.13	0.1	Depression;	chr6:28201380	chr6:28136849~28139678:+
BRCA	cis	rs6582630	0.679	rs10785514	ENSG00000257718.1	RP11-396F22.1	3.32	0.000925	0.0408	0.1	0.1	Drug-induced liver injury (flucloxacillin);	chr12:38179887	chr12:38906451~38909592:+
BRCA	cis	rs2276314	0.857	rs3737474	ENSG00000267627.4	RP11-905K4.1	-3.32	0.000925	0.0408	-0.14	-0.1	Endometriosis;Drug-induced torsades de pointes;	chr18:36033632	chr18:35951803~35966118:-
BRCA	cis	rs7598759	0.679	rs6740843	ENSG00000223198.1	RNU2-22P	-3.32	0.000925	0.0408	-0.12	-0.1	Noise-induced hearing loss;	chr2:231467428	chr2:231501990~231502201:-
BRCA	cis	rs875971	0.965	rs28682868	ENSG00000271064.1	RP11-792A8.3	3.32	0.000925	0.0408	0.12	0.1	Aortic root size;	chr7:66224822	chr7:66748838~66749077:-
BRCA	cis	rs849141	0.857	rs1708299	ENSG00000234336.5	JAZF1-AS1	-3.32	0.000926	0.0408	-0.15	-0.1	Height;Hip circumference adjusted for BMI;	chr7:28150327	chr7:28180322~28243917:+
BRCA	cis	rs72775230	0.733	rs72775257	ENSG00000233990.1	RP11-401E9.3	-3.32	0.000926	0.0408	-0.18	-0.1	Conotruncal heart defects (inherited effects);	chr10:8523989	chr10:7833618~7833957:-
BRCA	cis	rs16852403	0.619	rs6685876	ENSG00000224687.1	RASAL2-AS1	3.32	0.000926	0.0408	0.13	0.1	Childhood ear infection;	chr1:178165984	chr1:178091508~178093984:-
BRCA	cis	rs1400816	1	rs1400816	ENSG00000228389.1	AC068039.4	3.32	0.000926	0.0408	0.19	0.1	Amyotrophic lateral sclerosis (sporadic);	chr2:171824168	chr2:171773482~171775844:+
BRCA	cis	rs6088590	1	rs6119524	ENSG00000276073.1	RP5-1125A11.7	-3.32	0.000926	0.0408	-0.12	-0.1	Coronary artery disease;	chr20:34786010	chr20:33985617~33988989:-
BRCA	cis	rs9467773	0.869	rs742090	ENSG00000224843.5	LINC00240	3.32	0.000926	0.0408	0.12	0.1	Intelligence (multi-trait analysis);	chr6:26415409	chr6:26956992~27023924:+
BRCA	cis	rs7173064	1	rs7173064	ENSG00000272888.4	LINC01578	3.32	0.000926	0.0408	0.11	0.1	White matter hyperintensity burden;	chr15:93727999	chr15:92882707~92899701:+
BRCA	cis	rs7586085	0.845	rs3791848	ENSG00000232411.1	AC009495.3	3.32	0.000926	0.0408	0.12	0.1	Total body bone mineral density;	chr2:165756733	chr2:165833048~165839098:-
BRCA	cis	rs2638953	0.64	rs10843211	ENSG00000273989.1	RP11-425D17.2	-3.32	0.000926	0.0408	-0.15	-0.1	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28577717	chr12:28236227~28236828:+
BRCA	cis	rs9863	0.827	rs4930724	ENSG00000256596.1	RP11-522N14.2	3.32	0.000926	0.0408	0.13	0.1	White blood cell count;	chr12:123939270	chr12:124206228~124209018:+
BRCA	cis	rs8114671	0.552	rs2024635	ENSG00000126005.14	MMP24-AS1	-3.32	0.000926	0.0408	-0.12	-0.1	Height;	chr20:34834811	chr20:35216462~35278131:-
BRCA	cis	rs867529	1	rs11681299	ENSG00000253497.1	IGKV1-13	-3.32	0.000926	0.0408	-0.1	-0.1	Height;	chr2:88602214	chr2:89045995~89046466:-
BRCA	cis	rs6952809	0.532	rs6953297	ENSG00000230487.6	PSMG3-AS1	-3.32	0.000926	0.0408	-0.17	-0.1	Multiple sclerosis;	chr7:2401239	chr7:1570073~1589626:+
BRCA	cis	rs875971	0.862	rs35378740	ENSG00000223473.2	GS1-124K5.3	3.32	0.000926	0.0408	0.08	0.1	Aortic root size;	chr7:66522725	chr7:66491049~66493566:-
BRCA	cis	rs2306786	0.558	rs78473832	ENSG00000259732.1	RP11-59H7.3	-3.32	0.000926	0.0408	-0.25	-0.1	Metabolite levels;	chr15:59204066	chr15:59121034~59133250:+
BRCA	cis	rs853679	0.599	rs202906	ENSG00000216901.1	AL022393.7	-3.32	0.000926	0.0408	-0.19	-0.1	Depression;	chr6:28043874	chr6:28176188~28176674:+
BRCA	cis	rs1005277	0.54	rs2145487	ENSG00000099251.13	HSD17B7P2	3.32	0.000926	0.0408	0.11	0.1	Extrinsic epigenetic age acceleration;	chr10:37721149	chr10:38356380~38378505:+
BRCA	cis	rs1005277	0.54	rs4934907	ENSG00000099251.13	HSD17B7P2	3.32	0.000927	0.0408	0.11	0.1	Extrinsic epigenetic age acceleration;	chr10:37726302	chr10:38356380~38378505:+
BRCA	cis	rs1005277	0.54	rs11011351	ENSG00000099251.13	HSD17B7P2	3.32	0.000927	0.0408	0.11	0.1	Extrinsic epigenetic age acceleration;	chr10:37741597	chr10:38356380~38378505:+
BRCA	cis	rs7959452	0.64	rs4761154	ENSG00000274979.1	RP11-1143G9.5	3.32	0.000927	0.0408	0.11	0.1	Blood protein levels;	chr12:69311582	chr12:69326574~69331882:-
BRCA	cis	rs10129255	0.833	rs61997797	ENSG00000232216.1	IGHV3-43	3.32	0.000927	0.0408	0.09	0.1	Kawasaki disease;	chr14:106815190	chr14:106470264~106470800:-
BRCA	cis	rs1008953	1	rs2743402	ENSG00000273555.1	MIR6812	-3.32	0.000927	0.0408	-0.13	-0.1	Psoriasis;	chr20:45356564	chr20:45425510~45425573:+
BRCA	cis	rs12282928	0.918	rs11039656	ENSG00000255197.4	RP11-750H9.5	-3.32	0.000927	0.0408	-0.1	-0.1	Migraine - clinic-based;	chr11:48299153	chr11:47383148~47409190:-
BRCA	cis	rs1710990	0.819	rs11158786	ENSG00000259165.1	DDX18P1	3.32	0.000927	0.0408	0.12	0.1	Intelligence (multi-trait analysis);	chr14:69086721	chr14:69083398~69085389:+
BRCA	cis	rs6840360	0.571	rs10007653	ENSG00000270265.1	RP11-731D1.4	-3.32	0.000927	0.0408	-0.12	-0.1	Intelligence (multi-trait analysis);	chr4:151602903	chr4:151333775~151353224:-
BRCA	cis	rs6866721	0.608	rs712609	ENSG00000249167.1	CTB-118N6.2	3.32	0.000927	0.0408	0.12	0.1	Body mass index;	chr5:116885417	chr5:116574482~116591398:+
BRCA	cis	rs10129255	0.957	rs8009464	ENSG00000211958.2	IGHV3-38	3.32	0.000927	0.0408	0.08	0.1	Kawasaki disease;	chr14:106777611	chr14:106410493~106411021:-
BRCA	cis	rs1971762	0.527	rs4759211	ENSG00000270175.1	RP11-793H13.11	-3.32	0.000927	0.0408	-0.09	-0.1	Height;	chr12:53537161	chr12:53500162~53500936:-
BRCA	cis	rs1032833	0.732	rs17454024	ENSG00000271401.1	RP11-171I2.3	-3.32	0.000927	0.0408	-0.25	-0.1	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);	chr2:179108106	chr2:178644717~178645179:+
BRCA	cis	rs7735319	0.565	rs6885648	ENSG00000249572.1	CTD-2203K17.1	3.32	0.000927	0.0408	0.13	0.1	Systolic blood pressure;	chr5:33116038	chr5:33424025~33440619:-
BRCA	cis	rs9341808	0.727	rs10943697	ENSG00000279022.1	RP11-250B2.4	3.32	0.000927	0.0408	0.12	0.1	Sitting height ratio;	chr6:80221789	chr6:80440730~80441172:+
BRCA	cis	rs9341808	0.718	rs1324123	ENSG00000279022.1	RP11-250B2.4	3.32	0.000927	0.0408	0.12	0.1	Sitting height ratio;	chr6:80223177	chr6:80440730~80441172:+
BRCA	cis	rs11887277	0.586	rs3769126	ENSG00000272148.1	RP11-195B17.1	-3.32	0.000927	0.0408	-0.12	-0.1	Obesity-related traits;	chr2:26769202	chr2:27062428~27062907:-
BRCA	cis	rs300890	0.544	rs13136521	ENSG00000250326.1	RP11-284M14.1	3.32	0.000927	0.0408	0.12	0.1	Nasopharyngeal carcinoma;	chr4:143284411	chr4:142933195~143184861:-
BRCA	cis	rs2688608	0.592	rs11814282	ENSG00000242288.9	RP11-464F9.1	3.32	0.000927	0.0408	0.13	0.1	Inflammatory bowel disease;	chr10:73730459	chr10:73674295~73730466:-
BRCA	cis	rs11098403	0.879	rs7685680	ENSG00000225892.3	RP11-384K6.2	3.32	0.000927	0.0408	0.1	0.1	Schizophrenia;	chr4:117743667	chr4:118632274~118634759:+
BRCA	cis	rs875971	0.862	rs1860469	ENSG00000272831.1	RP11-792A8.4	-3.32	0.000927	0.0408	-0.09	-0.1	Aortic root size;	chr7:66641888	chr7:66739829~66740385:-
BRCA	cis	rs295490	0.748	rs74340696	ENSG00000178631.7	ACTG1P1	-3.32	0.000927	0.0408	-0.22	-0.1	PR interval in Tripanosoma cruzi seropositivity;	chr3:139341859	chr3:139493809~139494937:+
BRCA	cis	rs1018697	1	rs7073114	ENSG00000236937.2	PTGES3P4	3.32	0.000928	0.0408	0.13	0.1	Colorectal adenoma (advanced);	chr10:102795894	chr10:102845595~102845950:+
BRCA	cis	rs62344088	1	rs62344088	ENSG00000277812.1	AC021087.1	3.32	0.000928	0.0408	0.29	0.1	Asthma (childhood onset);	chr5:95949	chr5:262769~262881:+
BRCA	cis	rs78487399	0.808	rs77791126	ENSG00000234936.1	AC010883.5	3.32	0.000928	0.0408	0.16	0.1	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43516911	chr2:43229573~43233394:+
BRCA	cis	rs6991838	0.831	rs11992528	ENSG00000272155.1	RP11-707M3.3	-3.32	0.000928	0.0408	-0.09	-0.1	Intelligence (multi-trait analysis);	chr8:65561644	chr8:65714334~65714778:-
BRCA	cis	rs12282928	1	rs10160559	ENSG00000255197.4	RP11-750H9.5	3.32	0.000928	0.0408	0.1	0.1	Migraine - clinic-based;	chr11:48259132	chr11:47383148~47409190:-
BRCA	cis	rs477895	0.713	rs12575642	ENSG00000256940.1	RP11-783K16.5	3.32	0.000928	0.0408	0.14	0.1	Mean platelet volume;	chr11:64212171	chr11:64245964~64248217:+
BRCA	cis	rs2066819	1	rs116849218	ENSG00000257740.1	RP11-977G19.12	3.32	0.000928	0.0408	0.25	0.1	Psoriasis vulgaris;	chr12:56290191	chr12:56308868~56309449:+
BRCA	cis	rs2066819	1	rs79436528	ENSG00000257740.1	RP11-977G19.12	3.32	0.000928	0.0408	0.25	0.1	Psoriasis vulgaris;	chr12:56293213	chr12:56308868~56309449:+
BRCA	cis	rs2066819	1	rs77853814	ENSG00000257740.1	RP11-977G19.12	3.32	0.000928	0.0408	0.25	0.1	Psoriasis vulgaris;	chr12:56293788	chr12:56308868~56309449:+
BRCA	cis	rs6771316	0.504	rs6796822	ENSG00000241163.6	LINC00877	-3.32	0.000928	0.0408	-0.12	-0.1	Venous thromboembolism (SNP x SNP interaction);	chr3:72091558	chr3:72035300~72279503:-
BRCA	cis	rs4835473	0.932	rs6537183	ENSG00000246448.2	RP13-578N3.3	-3.32	0.000928	0.0408	-0.12	-0.1	Immature fraction of reticulocytes;	chr4:143770441	chr4:143700257~143865072:+
BRCA	cis	rs3764021	0.527	rs12227655	ENSG00000256594.6	RP11-705C15.2	3.32	0.000928	0.0408	0.14	0.1	Type 1 diabetes;	chr12:9715652	chr12:9633419~9658412:+
BRCA	cis	rs3764021	0.506	rs12228641	ENSG00000256594.6	RP11-705C15.2	3.32	0.000928	0.0408	0.14	0.1	Type 1 diabetes;	chr12:9715680	chr12:9633419~9658412:+
BRCA	cis	rs1819043	1	rs705747	ENSG00000236439.4	RP11-175B9.3	3.32	0.000928	0.0409	0.1	0.1	Sex ratio;	chr1:202536155	chr1:202471864~202472117:-
BRCA	cis	rs2043112	0.691	rs10214103	ENSG00000249911.1	LINC01265	3.32	0.000928	0.0409	0.12	0.1	Obesity-related traits;	chr5:39077358	chr5:38710367~38720273:-
BRCA	cis	rs2952768	1	rs2551938	ENSG00000224137.1	AC079767.4	-3.32	0.000928	0.0409	-0.09	-0.1	Opioid sensitivity;	chr2:207631666	chr2:207662375~207667024:+
BRCA	cis	rs2952768	1	rs2709380	ENSG00000224137.1	AC079767.4	-3.32	0.000928	0.0409	-0.09	-0.1	Opioid sensitivity;	chr2:207631686	chr2:207662375~207667024:+
BRCA	cis	rs7707921	0.881	rs12108833	ENSG00000251374.1	RPS23P5	3.32	0.000928	0.0409	0.14	0.1	Breast cancer;	chr5:82075936	chr5:82265157~82265259:-
BRCA	cis	rs34779708	0.931	rs4934711	ENSG00000269952.1	RP11-324I22.3	-3.32	0.000928	0.0409	-0.13	-0.1	Inflammatory bowel disease;Crohn's disease;	chr10:35071382	chr10:35210416~35210750:+
BRCA	cis	rs4805834	0.719	rs73035335	ENSG00000201388.1	SNORA68	3.32	0.000928	0.0409	0.17	0.1	Creatinine levels;	chr19:32798649	chr19:32608337~32608469:-
BRCA	cis	rs17767294	0.708	rs72846802	ENSG00000272009.1	RP1-313I6.12	-3.32	0.000928	0.0409	-0.27	-0.1	Parkinson's disease;	chr6:28197064	chr6:28078792~28081130:-
BRCA	cis	rs4631830	0.832	rs1585378	ENSG00000204177.9	BMS1P1	-3.32	0.000928	0.0409	-0.1	-0.1	Prostate-specific antigen levels;	chr10:46072609	chr10:46786674~46811989:+
BRCA	cis	rs3820928	0.874	rs13419455	ENSG00000261379.1	RP11-395N3.1	3.32	0.000928	0.0409	0.1	0.1	Pulmonary function;	chr2:226985749	chr2:226804036~226805061:+
BRCA	cis	rs4631830	0.863	rs10826127	ENSG00000204177.9	BMS1P1	-3.32	0.000928	0.0409	-0.1	-0.1	Prostate-specific antigen levels;	chr10:46065065	chr10:46786674~46811989:+
BRCA	cis	rs1178127	0.765	rs1178152	ENSG00000232821.1	AC003986.6	3.32	0.000928	0.0409	0.14	0.1	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);	chr7:18741374	chr7:19112474~19114271:+
BRCA	cis	rs9388451	0.626	rs2875881	ENSG00000237742.5	RP11-624M8.1	-3.32	0.000928	0.0409	-0.13	-0.1	Brugada syndrome;	chr6:125751707	chr6:125578558~125749190:-
BRCA	cis	rs11673344	0.77	rs34729406	ENSG00000267309.1	CTD-2630F21.1	-3.32	0.000928	0.0409	-0.13	-0.1	Obesity-related traits;	chr19:37012764	chr19:36489649~36491040:+
BRCA	cis	rs783540	1	rs1267657	ENSG00000274376.3	ADAMTS7P1	-3.32	0.000928	0.0409	-0.11	-0.1	Schizophrenia;	chr15:82546501	chr15:82298553~82334609:+
BRCA	cis	rs783540	1	rs803688	ENSG00000274376.3	ADAMTS7P1	-3.32	0.000928	0.0409	-0.11	-0.1	Schizophrenia;	chr15:82548043	chr15:82298553~82334609:+
BRCA	cis	rs9393813	0.528	rs6899950	ENSG00000271755.1	RP1-153G14.4	3.32	0.000928	0.0409	0.12	0.1	Bipolar disorder;	chr6:27466216	chr6:27404010~27406964:-
BRCA	cis	rs804280	0.509	rs12719915	ENSG00000251402.3	FAM90A25P	-3.32	0.000929	0.0409	-0.12	-0.1	Myopia (pathological);	chr8:11928746	chr8:12415080~12418090:-
BRCA	cis	rs3750082	0.754	rs35110377	ENSG00000231952.3	DPY19L1P2	-3.32	0.000929	0.0409	-0.12	-0.1	Glomerular filtration rate (creatinine);	chr7:32932158	chr7:32812757~32838570:+
BRCA	cis	rs6708331	0.816	rs10196979	ENSG00000231024.1	AC092431.3	-3.32	0.000929	0.0409	-0.14	-0.1	Obesity-related traits;	chr2:70140265	chr2:69700192~69713847:-
BRCA	cis	rs10888690	0.582	rs12071347	ENSG00000236434.2	RP11-296A18.6	-3.32	0.000929	0.0409	-0.12	-0.1	Male-pattern baldness;	chr1:50373486	chr1:51264916~51266074:-
BRCA	cis	rs7735319	0.565	rs4346781	ENSG00000249572.1	CTD-2203K17.1	3.32	0.000929	0.0409	0.13	0.1	Systolic blood pressure;	chr5:33093488	chr5:33424025~33440619:-
BRCA	cis	rs1005277	0.522	rs1208767	ENSG00000099251.13	HSD17B7P2	3.32	0.000929	0.0409	0.11	0.1	Extrinsic epigenetic age acceleration;	chr10:37753367	chr10:38356380~38378505:+
BRCA	cis	rs7267979	1	rs2258563	ENSG00000204556.4	CTD-2514C3.1	-3.32	0.000929	0.0409	-0.14	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25292799	chr20:26018832~26020684:+
BRCA	cis	rs6545883	0.895	rs6545871	ENSG00000270820.4	RP11-355B11.2	3.32	0.000929	0.0409	0.12	0.1	Tuberculosis;	chr2:61465068	chr2:61471188~61484130:+
BRCA	cis	rs10181042	0.565	rs1177233	ENSG00000273302.1	RP11-493E12.2	-3.32	0.000929	0.0409	-0.09	-0.1	Crohn's disease;	chr2:61034999	chr2:61199979~61200769:+
BRCA	cis	rs6120849	0.95	rs6088732	ENSG00000232406.5	RP11-234K24.3	3.32	0.000929	0.0409	0.13	0.1	Protein C levels;	chr20:35156331	chr20:36148726~36155760:-
BRCA	cis	rs2337406	1	rs3858878	ENSG00000211976.2	IGHV3-73	-3.32	0.000929	0.0409	-0.1	-0.1	Alzheimer's disease (late onset);	chr14:106688061	chr14:106802694~106803233:-
BRCA	cis	rs7590368	0.779	rs3856465	ENSG00000272275.1	RP11-791G15.2	3.32	0.000929	0.0409	0.14	0.1	Educational attainment (years of education);	chr2:10776544	chr2:10767875~10770058:-
BRCA	cis	rs7568498	1	rs13004784	ENSG00000227403.1	AC009299.3	-3.32	0.000929	0.0409	-0.18	-0.1	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);	chr2:161022320	chr2:161244739~161249050:+
BRCA	cis	rs7200786	0.715	rs8050144	ENSG00000263033.2	RP11-396B14.2	-3.32	0.000929	0.0409	-0.12	-0.1	Systemic lupus erythematosus;Multiple sclerosis;	chr16:10996230	chr16:11196177~11224969:+
BRCA	cis	rs3750965	0.959	rs11228490	ENSG00000265539.1	MIR3164	3.32	0.000929	0.0409	0.12	0.1	Hair color;	chr11:69093404	chr11:69083176~69083258:+
BRCA	cis	rs10198628	1	rs6432340	ENSG00000264370.1	MIR3125	-3.32	0.00093	0.0409	-0.12	-0.1	Pericardial fat;Pericardial adipose tissue adjusted for height and weight;	chr2:12822991	chr2:12737367~12737444:+
BRCA	cis	rs34286592	0.929	rs1057451	ENSG00000238045.8	AC009133.12	3.32	0.00093	0.0409	0.13	0.1	Multiple sclerosis;	chr16:29822167	chr16:29808636~29821252:-
BRCA	cis	rs783540	0.967	rs7494860	ENSG00000274376.3	ADAMTS7P1	3.32	0.00093	0.0409	0.11	0.1	Schizophrenia;	chr15:82665667	chr15:82298553~82334609:+
BRCA	cis	rs2411233	0.967	rs11070164	ENSG00000259278.1	RP11-62C7.2	3.32	0.00093	0.0409	0.12	0.1	Platelet count;	chr15:38985178	chr15:39019233~39024918:+
BRCA	cis	rs2411233	0.967	rs11070165	ENSG00000259278.1	RP11-62C7.2	3.32	0.00093	0.0409	0.12	0.1	Platelet count;	chr15:38985187	chr15:39019233~39024918:+
BRCA	cis	rs1843834	0.505	rs4674911	ENSG00000274629.1	RP11-92F20.1	-3.32	0.00093	0.0409	-0.13	-0.1	IgE levels in asthmatics (D.p. specific);	chr2:224480537	chr2:224464682~224474500:+
BRCA	cis	rs875971	1	rs2420591	ENSG00000273448.1	RP11-166O4.6	3.32	0.00093	0.0409	0.09	0.1	Aortic root size;	chr7:66447394	chr7:67333047~67334383:+
BRCA	cis	rs793571	0.866	rs11071401	ENSG00000259250.1	RP11-50C13.1	-3.32	0.00093	0.0409	-0.16	-0.1	Schizophrenia;	chr15:58918736	chr15:58587507~58591676:+
BRCA	cis	rs11035577	0.632	rs6485141	ENSG00000279675.1	RP11-454H19.2	3.32	0.00093	0.0409	0.16	0.1	Temperament (bipolar disorder);	chr11:39768601	chr11:40107244~40112599:-
BRCA	cis	rs860295	0.812	rs2297775	ENSG00000246203.2	RP11-29H23.5	3.32	0.00093	0.0409	0.12	0.1	Body mass index;	chr1:155765221	chr1:155614726~155660245:-
BRCA	cis	rs35123781	0.955	rs34530707	ENSG00000250635.1	CTD-3224K15.2	-3.32	0.00093	0.0409	-0.11	-0.1	Schizophrenia;	chr5:139679431	chr5:139648999~139649728:-
BRCA	cis	rs986417	0.901	rs2351172	ENSG00000258670.1	RP11-1042B17.3	-3.32	0.00093	0.0409	-0.18	-0.1	Gut microbiota (bacterial taxa);	chr14:60541969	chr14:60515119~60554916:+
BRCA	cis	rs986417	0.901	rs7159628	ENSG00000258670.1	RP11-1042B17.3	-3.32	0.00093	0.0409	-0.18	-0.1	Gut microbiota (bacterial taxa);	chr14:60543970	chr14:60515119~60554916:+
BRCA	cis	rs12612619	0.542	rs6710065	ENSG00000229122.1	AGBL5-IT1	-3.32	0.00093	0.0409	-0.11	-0.1	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:26853689	chr2:27061038~27061815:+
BRCA	cis	rs2403083	0.535	rs2896454	ENSG00000253283.1	RP11-146E23.2	-3.32	0.00093	0.0409	-0.12	-0.1	Plasma amyloid beta peptide concentrations (ABx-40);	chr8:85147837	chr8:85086615~85087186:+
BRCA	cis	rs2403083	0.578	rs7004765	ENSG00000253283.1	RP11-146E23.2	-3.32	0.00093	0.0409	-0.12	-0.1	Plasma amyloid beta peptide concentrations (ABx-40);	chr8:85150260	chr8:85086615~85087186:+
BRCA	cis	rs6714710	0.603	rs11690687	ENSG00000228486.8	LINC01125	-3.32	0.00093	0.0409	-0.09	-0.1	Posterior cortical atrophy and Alzheimer's disease;	chr2:97845358	chr2:97664217~97703064:+
BRCA	cis	rs4415084	0.716	rs6451775	ENSG00000272335.1	RP11-53O19.3	-3.32	0.00093	0.0409	-0.1	-0.1	Breast cancer;	chr5:44836686	chr5:44826076~44828592:+
BRCA	cis	rs2307449	0.929	rs2013628	ENSG00000260123.1	RP11-326A19.4	3.32	0.00093	0.0409	0.12	0.1	Menopause (age at onset);	chr15:89272721	chr15:89041223~89082819:+
BRCA	cis	rs889122	0.68	rs4804459	ENSG00000267289.1	CTD-2623N2.11	-3.32	0.00093	0.0409	-0.15	-0.1	Menarche (age at onset);	chr19:9834111	chr19:9834079~9835013:-
BRCA	cis	rs860295	0.702	rs11264381	ENSG00000203761.5	MSTO2P	3.32	0.00093	0.0409	0.09	0.1	Body mass index;	chr1:155552781	chr1:155745829~155750137:+
BRCA	cis	rs965469	1	rs6037579	ENSG00000215063.3	RPL21P2	3.32	0.00093	0.0409	0.14	0.1	IFN-related cytopenia;	chr20:3367333	chr20:4059633~4060113:-
BRCA	cis	rs748404	0.666	rs34178146	ENSG00000166763.7	STRCP1	3.32	0.00093	0.0409	0.15	0.1	Lung cancer;	chr15:43384406	chr15:43699488~43718184:-
BRCA	cis	rs6433921	1	rs11687348	ENSG00000260742.1	RP11-366L5.1	3.32	0.00093	0.0409	0.13	0.1	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;	chr2:181578664	chr2:181887851~181891663:-
BRCA	cis	rs866743	1	rs1831558	ENSG00000229720.1	RP3-495K2.2	3.32	0.00093	0.0409	0.11	0.1	Post bronchodilator FEV1/FVC ratio;	chr6:169028041	chr6:169034197~169035642:-
BRCA	cis	rs9393813	0.529	rs7761966	ENSG00000241549.7	GUSBP2	-3.32	0.000931	0.0409	-0.11	-0.1	Bipolar disorder;	chr6:27477924	chr6:26871484~26956554:-
BRCA	cis	rs6991838	0.806	rs17302392	ENSG00000272155.1	RP11-707M3.3	-3.32	0.000931	0.0409	-0.09	-0.1	Intelligence (multi-trait analysis);	chr8:65551073	chr8:65714334~65714778:-
BRCA	cis	rs2011013	0.957	rs61378395	ENSG00000225151.9	GOLGA2P7	3.32	0.000931	0.0409	0.13	0.1	Sitting height ratio;	chr15:83939182	chr15:84199311~84230136:-
BRCA	cis	rs867371	0.929	rs7173852	ENSG00000276710.3	CSPG4P8	-3.32	0.000931	0.0409	-0.11	-0.1	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82169512	chr15:82459472~82477258:+
BRCA	cis	rs4648045	0.861	rs230520	ENSG00000246560.2	RP11-10L12.4	-3.32	0.000931	0.041	-0.12	-0.1	Lymphocyte percentage of white cells;	chr4:102544455	chr4:102828055~102844075:+
BRCA	cis	rs28489187	0.629	rs2012683	ENSG00000223653.4	RP11-131L23.1	3.32	0.000931	0.041	0.11	0.1	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85375802	chr1:85276715~85448124:+
BRCA	cis	rs9381040	0.701	rs4711658	ENSG00000161912.16	ADCY10P1	-3.32	0.000931	0.041	-0.12	-0.1	Alzheimer's disease (late onset);	chr6:41195153	chr6:41101022~41140835:+
BRCA	cis	rs2832191	0.74	rs2012645	ENSG00000236056.1	GAPDHP14	-3.32	0.000931	0.041	-0.11	-0.1	Dental caries;	chr21:29073640	chr21:29222321~29223257:+
BRCA	cis	rs2832191	0.716	rs2692625	ENSG00000236056.1	GAPDHP14	-3.32	0.000931	0.041	-0.11	-0.1	Dental caries;	chr21:29074039	chr21:29222321~29223257:+
BRCA	cis	rs2281603	0.951	rs73267744	ENSG00000259116.1	RP11-973N13.4	-3.32	0.000931	0.041	-0.1	-0.1	Lymphocyte counts;	chr14:64511461	chr14:64514154~64540368:-
BRCA	cis	rs11098499	0.955	rs6815725	ENSG00000260404.2	RP11-384K6.6	3.32	0.000931	0.041	0.1	0.1	Corneal astigmatism;	chr4:119237255	chr4:118591773~118633729:+
BRCA	cis	rs34779708	0.966	rs7077242	ENSG00000269952.1	RP11-324I22.3	3.32	0.000931	0.041	0.14	0.1	Inflammatory bowel disease;Crohn's disease;	chr10:35193037	chr10:35210416~35210750:+
BRCA	cis	rs6429422	0.706	rs4658552	ENSG00000224727.1	FCF1P7	-3.32	0.000931	0.041	-0.12	-0.1	Cognitive ability (multi-trait analysis);	chr1:243249634	chr1:243267257~243268119:-
BRCA	cis	rs7267979	0.932	rs13040655	ENSG00000274414.1	RP5-965G21.4	-3.32	0.000931	0.041	-0.12	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25601561	chr20:25239007~25245229:-
BRCA	cis	rs8114671	0.562	rs1801310	ENSG00000126005.14	MMP24-AS1	-3.32	0.000931	0.041	-0.12	-0.1	Height;	chr20:34929211	chr20:35216462~35278131:-
BRCA	cis	rs4849845	0.598	rs3889223	ENSG00000223549.1	MTND5P28	3.32	0.000931	0.041	0.12	0.1	Mean platelet volume;	chr2:120266856	chr2:120215181~120217279:+
BRCA	cis	rs4849845	0.573	rs33971369	ENSG00000223549.1	MTND5P28	3.32	0.000931	0.041	0.12	0.1	Mean platelet volume;	chr2:120267411	chr2:120215181~120217279:+
BRCA	cis	rs801193	1	rs62466793	ENSG00000275400.1	RP4-756H11.5	-3.32	0.000931	0.041	-0.12	-0.1	Aortic root size;	chr7:66726530	chr7:66553805~66554199:-
BRCA	cis	rs11098499	0.863	rs1155576	ENSG00000260404.2	RP11-384K6.6	3.32	0.000931	0.041	0.1	0.1	Corneal astigmatism;	chr4:119529004	chr4:118591773~118633729:+
BRCA	cis	rs12900413	0.562	rs28450767	ENSG00000259212.1	CTD-3065B20.2	3.32	0.000932	0.041	0.12	0.1	Coronary artery aneurysm in Kawasaki disease;	chr15:89754997	chr15:90595840~90596447:-
BRCA	cis	rs11098499	0.909	rs10017335	ENSG00000250950.1	RP11-33B1.3	3.32	0.000932	0.041	0.13	0.1	Corneal astigmatism;	chr4:119460368	chr4:119456350~119457277:+
BRCA	cis	rs8073060	0.614	rs72829932	ENSG00000267554.1	RP11-686D22.10	3.32	0.000932	0.041	0.11	0.1	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35728916	chr17:35470069~35470628:-
BRCA	cis	rs6088580	0.634	rs6059880	ENSG00000269202.1	RP4-614O4.12	-3.32	0.000932	0.041	-0.1	-0.1	Glomerular filtration rate (creatinine);	chr20:34500864	chr20:35201747~35203288:-
BRCA	cis	rs74233809	1	rs35125602	ENSG00000213061.2	PFN1P11	3.32	0.000932	0.041	0.22	0.1	Birth weight;	chr10:102896282	chr10:102838011~102845473:-
BRCA	cis	rs73173548	1	rs979364	ENSG00000247828.6	TMEM161B-AS1	3.32	0.000932	0.041	0.19	0.1	Macular telangiectasia type 2;	chr5:88501331	chr5:88268895~88436685:+
BRCA	cis	rs13387221	0.569	rs6746170	ENSG00000231848.1	AC012354.8	3.32	0.000932	0.041	0.14	0.1	Intelligence (childhood);	chr2:44001242	chr2:44996413~44996873:+
BRCA	cis	rs4820539	1	rs4822361	ENSG00000211647.1	IGLV5-48	3.32	0.000932	0.041	0.08	0.1	Bone mineral density;	chr22:23140531	chr22:22352940~22353433:+
BRCA	cis	rs62090893	0.656	rs2581655	ENSG00000264247.1	LINC00909	-3.32	0.000932	0.041	-0.16	-0.1	Anorexia nervosa;	chr18:75311188	chr18:74591774~74598508:-
BRCA	cis	rs7713065	0.765	rs4643947	ENSG00000202533.1	Y_RNA	-3.32	0.000932	0.041	-0.11	-0.1	Lung function (FEV1/FVC);	chr5:132445089	chr5:132468147~132468257:+
BRCA	cis	rs7713065	0.765	rs1012794	ENSG00000202533.1	Y_RNA	-3.32	0.000932	0.041	-0.11	-0.1	Lung function (FEV1/FVC);	chr5:132445989	chr5:132468147~132468257:+
BRCA	cis	rs7713065	0.765	rs4235801	ENSG00000202533.1	Y_RNA	-3.32	0.000932	0.041	-0.11	-0.1	Lung function (FEV1/FVC);	chr5:132446752	chr5:132468147~132468257:+
BRCA	cis	rs7246967	0.673	rs7258098	ENSG00000198153.8	ZNF849P	-3.32	0.000932	0.041	-0.18	-0.1	Bronchopulmonary dysplasia;	chr19:22873927	chr19:22685167~22686732:+
BRCA	cis	rs10877839	1	rs1390854	ENSG00000257354.2	RP11-631N16.2	-3.32	0.000932	0.041	-0.1	-0.1	IgG glycosylation;	chr12:62402247	chr12:62602752~62622213:+
BRCA	cis	rs6490294	0.571	rs11066119	ENSG00000257595.2	RP3-473L9.4	3.32	0.000932	0.041	0.17	0.1	Mean platelet volume;	chr12:111996700	chr12:111369282~111403310:+
BRCA	cis	rs911555	0.755	rs11627446	ENSG00000269940.1	RP11-73M18.7	3.32	0.000932	0.041	0.11	0.1	Intelligence (multi-trait analysis);	chr14:103480113	chr14:103694560~103695170:+
BRCA	cis	rs7267979	1	rs6050631	ENSG00000204556.4	CTD-2514C3.1	-3.32	0.000932	0.041	-0.14	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25451113	chr20:26018832~26020684:+
BRCA	cis	rs113835537	0.529	rs11824771	ENSG00000258297.1	RP11-658F2.8	-3.32	0.000932	0.041	-0.14	-0.1	Airway imaging phenotypes;	chr11:66495079	chr11:66666036~66668374:+
BRCA	cis	rs7071275	0.6	rs11200052	ENSG00000276742.1	RP11-500G22.4	3.32	0.000932	0.041	0.18	0.1	Dupuytren's disease;	chr10:121642723	chr10:121956782~121957098:+
BRCA	cis	rs1371614	0.552	rs35538505	ENSG00000229122.1	AGBL5-IT1	-3.32	0.000932	0.041	-0.11	-0.1	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26903159	chr2:27061038~27061815:+
BRCA	cis	rs3864261	0.515	rs57149385	ENSG00000251467.1	CTC-250P20.2	3.32	0.000932	0.041	0.13	0.1	Discordance in emotional problems in monozygotic twins;	chr5:73060354	chr5:72996920~72997642:+
BRCA	cis	rs3864261	0.515	rs10942539	ENSG00000251467.1	CTC-250P20.2	3.32	0.000932	0.041	0.13	0.1	Discordance in emotional problems in monozygotic twins;	chr5:73061259	chr5:72996920~72997642:+
BRCA	cis	rs10819083	0.691	rs10156445	ENSG00000232630.1	PRPS1P2	-3.32	0.000932	0.041	-0.11	-0.1	Squamous cell lung carcinoma;	chr9:125854965	chr9:125150653~125151589:+
BRCA	cis	rs9388451	0.839	rs10457469	ENSG00000237742.5	RP11-624M8.1	-3.32	0.000932	0.041	-0.13	-0.1	Brugada syndrome;	chr6:125762512	chr6:125578558~125749190:-
BRCA	cis	rs375066	0.901	rs12977303	ENSG00000278917.1	RP11-15A1.4	-3.32	0.000932	0.041	-0.12	-0.1	Breast cancer;	chr19:43873517	chr19:43891233~43895411:+
BRCA	cis	rs2832077	0.883	rs11702413	ENSG00000236056.1	GAPDHP14	3.32	0.000933	0.041	0.15	0.1	Cognitive test performance;	chr21:28816072	chr21:29222321~29223257:+
BRCA	cis	rs2795502	1	rs2795496	ENSG00000185904.10	LINC00839	-3.32	0.000933	0.041	-0.15	-0.1	Blood protein levels;	chr10:42842394	chr10:42475543~42495336:+
BRCA	cis	rs7267979	1	rs2258769	ENSG00000204556.4	CTD-2514C3.1	-3.32	0.000933	0.041	-0.14	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25296044	chr20:26018832~26020684:+
BRCA	cis	rs13108904	0.875	rs73069950	ENSG00000196810.4	CTBP1-AS2	-3.32	0.000933	0.041	-0.11	-0.1	Obesity-related traits;	chr4:1282257	chr4:1249300~1288291:+
BRCA	cis	rs28489187	0.617	rs233109	ENSG00000223653.4	RP11-131L23.1	3.32	0.000933	0.041	0.11	0.1	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85317418	chr1:85276715~85448124:+
BRCA	cis	rs7267979	1	rs2387881	ENSG00000274414.1	RP5-965G21.4	3.32	0.000933	0.041	0.12	0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25397536	chr20:25239007~25245229:-
BRCA	cis	rs80226907	0.634	rs41299189	ENSG00000186615.9	KTN1-AS1	-3.32	0.000933	0.041	-0.2	-0.1	Mean platelet volume;	chr14:55440286	chr14:55499278~55580110:-
BRCA	cis	rs12659622	1	rs79060911	ENSG00000250415.1	CTC-461F20.1	3.32	0.000933	0.041	0.18	0.1	Obesity-related traits;	chr5:15632015	chr5:16617225~16621276:+
BRCA	cis	rs10771431	0.935	rs1117735	ENSG00000256673.1	RP11-599J14.2	3.32	0.000933	0.041	0.11	0.1	Breast size;	chr12:9220132	chr12:9398355~9414851:-
BRCA	cis	rs36051895	0.664	rs3780369	ENSG00000237711.1	RP11-39K24.13	-3.32	0.000933	0.041	-0.13	-0.1	Pediatric autoimmune diseases;	chr9:5095095	chr9:5100236~5101009:+
BRCA	cis	rs6545883	0.929	rs10200055	ENSG00000273302.1	RP11-493E12.2	-3.32	0.000933	0.041	-0.1	-0.1	Tuberculosis;	chr2:61400882	chr2:61199979~61200769:+
BRCA	cis	rs875971	0.545	rs7810213	ENSG00000273448.1	RP11-166O4.6	3.32	0.000933	0.041	0.11	0.1	Aortic root size;	chr7:66481592	chr7:67333047~67334383:+
BRCA	cis	rs4542783	0.546	rs4804313	ENSG00000267986.1	AC130469.2	-3.32	0.000933	0.041	-0.13	-0.1	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr19:8575502	chr19:8581160~8582715:+
BRCA	cis	rs1065852	0.526	rs8138080	ENSG00000226450.2	CYP2D8P	-3.32	0.000933	0.041	-0.1	-0.1	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42000367	chr22:42149886~42155001:-
BRCA	cis	rs4819052	0.851	rs2877018	ENSG00000223768.1	LINC00205	-3.32	0.000933	0.041	-0.14	-0.1	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238391	chr21:45293285~45297354:+
BRCA	cis	rs4819052	0.851	rs2330012	ENSG00000223768.1	LINC00205	-3.32	0.000933	0.041	-0.14	-0.1	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238677	chr21:45293285~45297354:+
BRCA	cis	rs4819052	0.851	rs2877019	ENSG00000223768.1	LINC00205	-3.32	0.000933	0.041	-0.14	-0.1	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238732	chr21:45293285~45297354:+
BRCA	cis	rs4819052	0.851	rs2877020	ENSG00000223768.1	LINC00205	-3.32	0.000933	0.041	-0.14	-0.1	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238827	chr21:45293285~45297354:+
BRCA	cis	rs4819052	0.851	rs10470245	ENSG00000223768.1	LINC00205	-3.32	0.000933	0.041	-0.14	-0.1	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238997	chr21:45293285~45297354:+
BRCA	cis	rs863345	0.604	rs12133794	ENSG00000176320.2	RP11-404O13.5	-3.32	0.000933	0.041	-0.11	-0.1	Pneumococcal bacteremia;	chr1:158536907	chr1:158197922~158203877:-
BRCA	cis	rs4848143	0.64	rs1992792	ENSG00000236859.5	NIFK-AS1	-3.32	0.000933	0.041	-0.11	-0.1	Capecitabine sensitivity;	chr2:121044766	chr2:121649650~121728208:+
BRCA	cis	rs17092148	0.887	rs6059919	ENSG00000269202.1	RP4-614O4.12	3.32	0.000933	0.041	0.14	0.1	Neuroticism;	chr20:34563741	chr20:35201747~35203288:-
BRCA	cis	rs5751614	0.537	rs3788358	ENSG00000234630.1	LL22NC03-2H8.4	3.32	0.000933	0.041	0.09	0.1	Height;	chr22:23274168	chr22:22293733~22294794:+
BRCA	cis	rs1519814	1	rs10104973	ENSG00000279347.1	RP11-85I17.2	-3.32	0.000933	0.041	-0.11	-0.1	Breast cancer;	chr8:120092146	chr8:119838736~119840385:-
BRCA	cis	rs8098244	0.571	rs72876000	ENSG00000265752.2	RP11-403A21.1	-3.32	0.000933	0.041	-0.15	-0.1	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23989446	chr18:23957754~23982556:-
BRCA	cis	rs12887734	0.546	rs12886637	ENSG00000269910.1	RP11-73M18.10	-3.32	0.000934	0.0411	-0.11	-0.1	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103756555	chr14:103694516~103695050:-
BRCA	cis	rs67478160	0.643	rs2024667	ENSG00000269910.1	RP11-73M18.10	3.32	0.000934	0.0411	0.1	0.1	Schizophrenia;	chr14:103745192	chr14:103694516~103695050:-
BRCA	cis	rs9796	0.689	rs8032195	ENSG00000223313.1	RNU6-516P	3.32	0.000934	0.0411	0.12	0.1	Menopause (age at onset);	chr15:41156592	chr15:40529570~40529673:+
BRCA	cis	rs2277027	1	rs2277027	ENSG00000251405.2	CTB-109A12.1	3.32	0.000934	0.0411	0.13	0.1	Pulmonary function;Pulmonary function (smoking interaction);	chr5:157505368	chr5:157362615~157460078:-
BRCA	cis	rs2277027	0.956	rs10078178	ENSG00000251405.2	CTB-109A12.1	3.32	0.000934	0.0411	0.13	0.1	Pulmonary function;Pulmonary function (smoking interaction);	chr5:157505976	chr5:157362615~157460078:-
BRCA	cis	rs7267979	1	rs6107033	ENSG00000277938.1	RP5-965G21.3	-3.32	0.000934	0.0411	-0.12	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25382955	chr20:25229150~25231933:+
BRCA	cis	rs7520050	0.966	rs1707304	ENSG00000226957.1	RP4-533D7.4	3.32	0.000934	0.0411	0.11	0.1	Reticulocyte count;Red blood cell count;	chr1:46132597	chr1:46046818~46048368:+
BRCA	cis	rs9467773	0.596	rs62396201	ENSG00000224843.5	LINC00240	-3.32	0.000934	0.0411	-0.11	-0.1	Intelligence (multi-trait analysis);	chr6:26667988	chr6:26956992~27023924:+
BRCA	cis	rs2154319	0.887	rs213767	ENSG00000230638.4	RP11-486B10.4	3.32	0.000934	0.0411	0.17	0.1	Height;	chr1:41115640	chr1:41542069~41544310:+
BRCA	cis	rs2154319	0.887	rs213766	ENSG00000230638.4	RP11-486B10.4	3.32	0.000934	0.0411	0.17	0.1	Height;	chr1:41116291	chr1:41542069~41544310:+
BRCA	cis	rs4835473	0.932	rs1597442	ENSG00000246448.2	RP13-578N3.3	-3.32	0.000934	0.0411	-0.12	-0.1	Immature fraction of reticulocytes;	chr4:143764359	chr4:143700257~143865072:+
BRCA	cis	rs721917	0.526	rs2256574	ENSG00000225484.5	NUTM2B-AS1	-3.32	0.000934	0.0411	-0.14	-0.1	Chronic obstructive pulmonary disease;	chr10:79925283	chr10:79663088~79826594:-
BRCA	cis	rs1953600	0.54	rs2784773	ENSG00000226659.1	RP11-137H2.4	-3.32	0.000934	0.0411	-0.13	-0.1	Sarcoidosis;	chr10:80160044	chr10:80529597~80535942:-
BRCA	cis	rs6802315	0.575	rs57932243	ENSG00000272440.1	RP11-379F4.6	3.32	0.000934	0.0411	0.13	0.1	Periodontitis (CDC/AAP);	chr3:158754187	chr3:158695367~158695581:+
BRCA	cis	rs12714314	0.718	rs10167552	ENSG00000228613.1	AC144450.1	3.32	0.000934	0.0411	0.11	0.1	Type 2 diabetes (age of onset);	chr2:1949023	chr2:1546665~1620113:-
BRCA	cis	rs4449834	0.851	rs7834977	ENSG00000254432.1	RP11-33I11.2	-3.32	0.000934	0.0411	-0.14	-0.1	Sum eosinophil basophil counts;	chr8:60813227	chr8:60808735~60809606:-
BRCA	cis	rs1730008	0.691	rs4402974	ENSG00000279311.1	RP11-170K4.2	-3.32	0.000934	0.0411	-0.13	-0.1	Lobe attachment (rater-scored or self-reported);	chr3:158400879	chr3:158869898~158871821:+
BRCA	cis	rs4660214	0.666	rs7554206	ENSG00000182109.6	RP11-69E11.4	-3.32	0.000934	0.0411	-0.12	-0.1	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39463568	chr1:39522280~39546187:-
BRCA	cis	rs2243480	1	rs4718269	ENSG00000275400.1	RP4-756H11.5	-3.32	0.000934	0.0411	-0.18	-0.1	Diabetic kidney disease;	chr7:65735810	chr7:66553805~66554199:-
BRCA	cis	rs34779708	0.966	rs1545757	ENSG00000269952.1	RP11-324I22.3	-3.32	0.000934	0.0411	-0.14	-0.1	Inflammatory bowel disease;Crohn's disease;	chr10:35156660	chr10:35210416~35210750:+
BRCA	cis	rs10129255	0.912	rs61997792	ENSG00000231475.3	IGHV4-31	-3.32	0.000934	0.0411	-0.08	-0.1	Kawasaki disease;	chr14:106799304	chr14:106349283~106349792:-
BRCA	cis	rs13153459	0.649	rs1482695	ENSG00000279557.1	CTD-2210P15.3	-3.32	0.000934	0.0411	-0.19	-0.1	Parkinson's disease;	chr5:44533021	chr5:43586367~43587543:-
BRCA	cis	rs2148307	0.928	rs2296612	ENSG00000228339.1	AMD1P1	-3.32	0.000934	0.0411	-0.12	-0.1	Photic sneeze reflex;	chr10:20785415	chr10:20350049~20351100:+
BRCA	cis	rs28374715	0.662	rs28493087	ENSG00000247556.5	OIP5-AS1	3.32	0.000934	0.0411	0.11	0.1	Ulcerative colitis;	chr15:41194306	chr15:41283990~41309737:+
BRCA	cis	rs597539	0.652	rs513615	ENSG00000255741.1	RP11-757G1.5	-3.32	0.000935	0.0411	-0.15	-0.1	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68938036	chr11:68941503~68942852:-
BRCA	cis	rs477895	0.653	rs72918475	ENSG00000256940.1	RP11-783K16.5	3.32	0.000935	0.0411	0.15	0.1	Mean platelet volume;	chr11:64111172	chr11:64245964~64248217:+
BRCA	cis	rs2835872	0.76	rs73220491	ENSG00000230366.8	DSCR9	-3.32	0.000935	0.0411	-0.13	-0.1	Electroencephalographic traits in alcoholism;	chr21:37616021	chr21:37208503~37221736:+
BRCA	cis	rs2835872	0.793	rs4817877	ENSG00000230366.8	DSCR9	-3.32	0.000935	0.0411	-0.13	-0.1	Electroencephalographic traits in alcoholism;	chr21:37616091	chr21:37208503~37221736:+
BRCA	cis	rs9863	0.896	rs4930722	ENSG00000270028.1	RP11-380L11.4	3.32	0.000935	0.0411	0.13	0.1	White blood cell count;	chr12:123938728	chr12:123925461~123926083:-
BRCA	cis	rs2153535	0.561	rs9405407	ENSG00000251164.1	HULC	-3.32	0.000935	0.0411	-0.12	-0.1	Motion sickness;	chr6:8665199	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.585	rs9378566	ENSG00000251164.1	HULC	-3.32	0.000935	0.0411	-0.12	-0.1	Motion sickness;	chr6:8665203	chr6:8652137~8653846:+
BRCA	cis	rs6601327	0.641	rs11782886	ENSG00000233609.3	RP11-62H7.2	-3.32	0.000935	0.0411	-0.1	-0.1	Multiple myeloma (hyperdiploidy);	chr8:9730381	chr8:8961200~8979025:+
BRCA	cis	rs10844706	0.699	rs10844620	ENSG00000278635.1	CTD-2318O12.1	-3.32	0.000935	0.0411	-0.11	-0.1	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9729910	chr12:9415641~9416718:+
BRCA	cis	rs354225	0.544	rs4455200	ENSG00000240401.7	AC012358.8	-3.32	0.000935	0.0411	-0.14	-0.1	Schizophrenia;	chr2:54574454	chr2:55282350~55346049:+
BRCA	cis	rs35306767	0.855	rs35825568	ENSG00000229869.1	RP11-363N22.2	-3.32	0.000935	0.0411	-0.16	-0.1	Eosinophil percentage of granulocytes;	chr10:904820	chr10:933026~942743:+
BRCA	cis	rs6750047	0.771	rs1056836	ENSG00000235848.3	RMDN2-AS1	3.32	0.000935	0.0411	0.13	0.1	Cutaneous malignant melanoma;Melanoma;	chr2:38071060	chr2:37949911~38067041:-
BRCA	cis	rs9368481	0.729	rs9379948	ENSG00000224843.5	LINC00240	-3.32	0.000935	0.0411	-0.12	-0.1	Autism spectrum disorder or schizophrenia;	chr6:26977004	chr6:26956992~27023924:+
BRCA	cis	rs997295	0.554	rs7180312	ENSG00000259673.4	IQCH-AS1	-3.32	0.000935	0.0411	-0.11	-0.1	Motion sickness;	chr15:67812918	chr15:67403619~67521844:-
BRCA	cis	rs10129255	0.957	rs10136781	ENSG00000231475.3	IGHV4-31	-3.32	0.000935	0.0411	-0.08	-0.1	Kawasaki disease;	chr14:106780451	chr14:106349283~106349792:-
BRCA	cis	rs687432	0.885	rs7121128	ENSG00000213592.4	AP000662.9	-3.32	0.000935	0.0411	-0.14	-0.1	Parkinson's disease;	chr11:57976459	chr11:57718044~57718530:-
BRCA	cis	rs7395581	0.959	rs2279239	ENSG00000280615.1	Y_RNA	3.32	0.000935	0.0411	0.13	0.1	HDL cholesterol;	chr11:47260229	chr11:47614898~47614994:-
BRCA	cis	rs1466921	0.705	rs2654224	ENSG00000278603.1	RP13-608F4.5	-3.32	0.000935	0.0411	-0.13	-0.1	Left superior temporal gyrus thickness (schizophrenia interaction);	chr15:82079763	chr15:82472203~82472426:+
BRCA	cis	rs6517329	0.564	rs67013231	ENSG00000230212.5	AP000688.14	3.32	0.000935	0.0411	0.13	0.1	Schizophrenia;	chr21:36133804	chr21:36069642~36126640:-
BRCA	cis	rs660899	0.588	rs37470	ENSG00000229431.1	RP1-92O14.6	-3.32	0.000935	0.0411	-0.11	-0.1	Hypertension risk in short sleep duration;	chr1:43812276	chr1:43385113~43389155:+
BRCA	cis	rs13256369	0.802	rs11249887	ENSG00000254153.1	CTA-398F10.2	3.32	0.000936	0.0411	0.14	0.1	Obesity-related traits;	chr8:8704674	chr8:8456909~8461337:-
BRCA	cis	rs751728	0.664	rs943475	ENSG00000224557.6	HLA-DPB2	3.32	0.000936	0.0411	0.12	0.1	Crohn's disease;	chr6:33782201	chr6:33112451~33129084:+
BRCA	cis	rs2455826	0.521	rs1447649	ENSG00000224728.1	AC090945.1	3.32	0.000936	0.0411	0.11	0.1	Inflammatory skin disease;	chr3:15796277	chr3:15878047~15879571:+
BRCA	cis	rs4848143	0.612	rs13420895	ENSG00000236859.5	NIFK-AS1	-3.32	0.000936	0.0411	-0.11	-0.1	Capecitabine sensitivity;	chr2:121038259	chr2:121649650~121728208:+
BRCA	cis	rs990171	0.538	rs7591878	ENSG00000234389.1	AC007278.3	3.32	0.000936	0.0411	0.1	0.1	Lymphocyte counts;	chr2:102496199	chr2:102438713~102440475:+
BRCA	cis	rs12682352	0.579	rs7006589	ENSG00000254153.1	CTA-398F10.2	3.32	0.000936	0.0411	0.13	0.1	Neuroticism;	chr8:8810976	chr8:8456909~8461337:-
BRCA	cis	rs477895	0.653	rs11231701	ENSG00000256940.1	RP11-783K16.5	3.32	0.000936	0.0411	0.14	0.1	Mean platelet volume;	chr11:64126230	chr11:64245964~64248217:+
BRCA	cis	rs4665809	0.941	rs7602922	ENSG00000231655.1	AC011742.3	3.32	0.000936	0.0411	0.16	0.1	Gut microbiome composition (summer);	chr2:26042913	chr2:26140263~26141264:-
BRCA	cis	rs4834770	0.668	rs11737086	ENSG00000245958.5	RP11-33B1.1	3.32	0.000936	0.0411	0.1	0.1	Blood protein levels;	chr4:119205962	chr4:119454791~119552025:+
BRCA	cis	rs2834256	0.552	rs7276923	ENSG00000231355.1	AP000302.58	3.32	0.000936	0.0411	0.12	0.1	Red cell distribution width;	chr21:33496454	chr21:33482499~33484258:-
BRCA	cis	rs2018683	0.677	rs55718000	ENSG00000228421.2	AC005013.5	3.32	0.000936	0.0411	0.13	0.1	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28936008	chr7:28957667~28959345:+
BRCA	cis	rs8180040	1	rs295442	ENSG00000260236.1	RP11-708J19.1	3.32	0.000936	0.0411	0.09	0.1	Colorectal cancer;	chr3:47294391	chr3:47379089~47380999:-
BRCA	cis	rs1510510	0.643	rs1606007	ENSG00000186235.9	AC016757.3	-3.32	0.000936	0.0411	-0.16	-0.1	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr2:238624123	chr2:238224552~238231677:-
BRCA	cis	rs13153459	0.602	rs72748082	ENSG00000249203.1	RP11-473L15.3	-3.32	0.000936	0.0411	-0.14	-0.1	Parkinson's disease;	chr5:44505704	chr5:44495618~44510282:-
BRCA	cis	rs13153459	0.602	rs957739	ENSG00000249203.1	RP11-473L15.3	-3.32	0.000936	0.0411	-0.14	-0.1	Parkinson's disease;	chr5:44506312	chr5:44495618~44510282:-
BRCA	cis	rs2638953	0.925	rs11049604	ENSG00000273989.1	RP11-425D17.2	-3.32	0.000936	0.0411	-0.15	-0.1	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28443092	chr12:28236227~28236828:+
BRCA	cis	rs12723316	0.932	rs10437027	ENSG00000233008.4	RP11-475O6.1	-3.32	0.000936	0.0411	-0.2	-0.1	Schizophrenia;	chr1:83812182	chr1:83575776~83861023:-
BRCA	cis	rs1434538	0.967	rs12506402	ENSG00000271474.1	RP11-710C12.1	-3.32	0.000936	0.0411	-0.13	-0.1	Coronary artery disease;	chr4:95153615	chr4:95549129~95552457:+
BRCA	cis	rs10971721	0.822	rs10971850	ENSG00000279489.1	RP11-392A14.8	3.32	0.000937	0.0412	0.21	0.1	Body mass index;	chr9:34013910	chr9:35001913~35003663:+
BRCA	cis	rs10971721	0.731	rs10814061	ENSG00000279489.1	RP11-392A14.8	3.32	0.000937	0.0412	0.21	0.1	Body mass index;	chr9:34014032	chr9:35001913~35003663:+
BRCA	cis	rs62458065	1	rs1450868	ENSG00000273014.1	RP11-225B17.2	-3.32	0.000937	0.0412	-0.15	-0.1	Metabolite levels (HVA/MHPG ratio);	chr7:32424054	chr7:32758882~32759353:+
BRCA	cis	rs2243480	1	rs313803	ENSG00000226002.1	RP11-460N20.5	-3.32	0.000937	0.0412	-0.18	-0.1	Diabetic kidney disease;	chr7:66049744	chr7:65084103~65100232:+
BRCA	cis	rs9973361	1	rs9677856	ENSG00000232411.1	AC009495.3	-3.32	0.000937	0.0412	-0.14	-0.1	Total body bone mineral density;	chr2:165859347	chr2:165833048~165839098:-
BRCA	cis	rs987724	0.593	rs7652112	ENSG00000240875.4	LINC00886	-3.32	0.000937	0.0412	-0.12	-0.1	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156854774	chr3:156747346~156817062:-
BRCA	cis	rs987724	0.593	rs2060015	ENSG00000240875.4	LINC00886	-3.32	0.000937	0.0412	-0.12	-0.1	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156856141	chr3:156747346~156817062:-
BRCA	cis	rs6599077	0.951	rs9860463	ENSG00000223797.4	ENTPD3-AS1	3.32	0.000937	0.0412	0.12	0.1	Sleep-related phenotypes;	chr3:40052571	chr3:40313802~40453329:-
BRCA	cis	rs6494488	0.5	rs72744751	ENSG00000259635.1	AC100830.3	-3.32	0.000937	0.0412	-0.23	-0.1	Coronary artery disease;	chr15:64772458	chr15:64701248~64719602:+
BRCA	cis	rs6494488	0.5	rs77463022	ENSG00000259635.1	AC100830.3	-3.32	0.000937	0.0412	-0.23	-0.1	Coronary artery disease;	chr15:64772642	chr15:64701248~64719602:+
BRCA	cis	rs12949688	1	rs4793566	ENSG00000262623.1	RP5-1107A17.2	-3.32	0.000937	0.0412	-0.11	-0.1	Schizophrenia;	chr17:57738108	chr17:56951664~56952404:+
BRCA	cis	rs12949688	1	rs7211686	ENSG00000262623.1	RP5-1107A17.2	-3.32	0.000937	0.0412	-0.11	-0.1	Schizophrenia;	chr17:57738939	chr17:56951664~56952404:+
BRCA	cis	rs11168618	0.967	rs1895996	ENSG00000273765.1	RP11-370I10.11	3.32	0.000937	0.0412	0.12	0.1	Adiponectin levels;	chr12:48561788	chr12:48360920~48361377:+
BRCA	cis	rs962856	0.619	rs1027000	ENSG00000236605.1	AC023115.4	3.32	0.000937	0.0412	0.14	0.1	Pancreatic cancer;	chr2:67373657	chr2:67324627~67325304:+
BRCA	cis	rs962856	0.619	rs1032158	ENSG00000236605.1	AC023115.4	3.32	0.000937	0.0412	0.14	0.1	Pancreatic cancer;	chr2:67373896	chr2:67324627~67325304:+
BRCA	cis	rs4835473	0.932	rs12512202	ENSG00000246448.2	RP13-578N3.3	-3.32	0.000937	0.0412	-0.12	-0.1	Immature fraction of reticulocytes;	chr4:143771248	chr4:143700257~143865072:+
BRCA	cis	rs4664293	0.867	rs13022404	ENSG00000230783.1	AC009961.2	-3.32	0.000937	0.0412	-0.13	-0.1	Monocyte percentage of white cells;	chr2:159732981	chr2:159689217~159690291:-
BRCA	cis	rs2692947	0.683	rs1813381	ENSG00000237510.6	AC008268.2	-3.32	0.000937	0.0412	-0.15	-0.1	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95757191	chr2:95789654~95800166:+
BRCA	cis	rs711244	0.783	rs2252032	ENSG00000279519.1	RP11-288C18.1	3.32	0.000937	0.0412	0.09	0.1	Mean platelet volume;	chr2:36872196	chr2:36839922~36842539:-
BRCA	cis	rs2277027	1	rs7729274	ENSG00000251405.2	CTB-109A12.1	3.32	0.000937	0.0412	0.13	0.1	Pulmonary function;Pulmonary function (smoking interaction);	chr5:157508900	chr5:157362615~157460078:-
BRCA	cis	rs71520386	0.632	rs9691076	ENSG00000179428.2	AC073072.5	3.32	0.000937	0.0412	0.12	0.1	Fibrinogen levels;	chr7:22829742	chr7:22725395~22727620:-
BRCA	cis	rs2688608	0.62	rs12253408	ENSG00000242288.9	RP11-464F9.1	3.32	0.000937	0.0412	0.13	0.1	Inflammatory bowel disease;	chr10:73736198	chr10:73674295~73730466:-
BRCA	cis	rs3748656	1	rs3795819	ENSG00000273483.1	RP4-671G15.2	-3.32	0.000937	0.0412	-0.14	-0.1	Hip circumference adjusted for BMI;	chr1:112691557	chr1:112517799~112518441:-
BRCA	cis	rs8054556	1	rs4788209	ENSG00000214725.6	CDIPT-AS1	-3.32	0.000937	0.0412	-0.13	-0.1	Autism spectrum disorder or schizophrenia;	chr16:30001945	chr16:29863593~29868053:+
BRCA	cis	rs8054556	1	rs4788210	ENSG00000214725.6	CDIPT-AS1	-3.32	0.000937	0.0412	-0.13	-0.1	Autism spectrum disorder or schizophrenia;	chr16:30002353	chr16:29863593~29868053:+
BRCA	cis	rs2243480	1	rs4548056	ENSG00000226767.1	RP11-328P23.3	-3.32	0.000937	0.0412	-0.18	-0.1	Diabetic kidney disease;	chr7:65833886	chr7:65508773~65508944:-
BRCA	cis	rs8094794	0.744	rs9652997	ENSG00000278986.1	RP11-723J4.3	3.32	0.000937	0.0412	0.15	0.1	Periodontal disease-related phenotypes;	chr18:36715227	chr18:35972151~35973916:+
BRCA	cis	rs12216545	0.765	rs2140140	ENSG00000244151.1	RP11-148K1.12	-3.32	0.000937	0.0412	-0.09	-0.1	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150552266	chr7:151074742~151076530:-
BRCA	cis	rs12216545	0.765	rs2373807	ENSG00000244151.1	RP11-148K1.12	-3.32	0.000937	0.0412	-0.09	-0.1	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150552282	chr7:151074742~151076530:-
BRCA	cis	rs12216545	0.765	rs2373808	ENSG00000244151.1	RP11-148K1.12	-3.32	0.000937	0.0412	-0.09	-0.1	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150552303	chr7:151074742~151076530:-
BRCA	cis	rs26949	0.526	rs3899221	ENSG00000251279.1	CTC-436P18.1	3.32	0.000937	0.0412	0.13	0.1	Intelligence (multi-trait analysis);	chr5:60740550	chr5:61162070~61232040:+
BRCA	cis	rs26949	0.526	rs10058456	ENSG00000251279.1	CTC-436P18.1	3.32	0.000937	0.0412	0.13	0.1	Intelligence (multi-trait analysis);	chr5:60742114	chr5:61162070~61232040:+
BRCA	cis	rs863345	0.604	rs1342953	ENSG00000176320.2	RP11-404O13.5	-3.32	0.000937	0.0412	-0.11	-0.1	Pneumococcal bacteremia;	chr1:158494709	chr1:158197922~158203877:-
BRCA	cis	rs2320614	1	rs2320614	ENSG00000250027.1	RP11-563E2.2	-3.32	0.000938	0.0412	-0.11	-0.1	Lung adenocarcinoma;	chr4:163148970	chr4:163108785~163119965:+
BRCA	cis	rs1348850	0.526	rs2178017	ENSG00000271825.1	RP11-337N6.2	3.32	0.000938	0.0412	0.18	0.1	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177510060	chr2:177300600~177302006:+
BRCA	cis	rs875971	0.83	rs809025	ENSG00000223473.2	GS1-124K5.3	3.32	0.000938	0.0412	0.08	0.1	Aortic root size;	chr7:66384832	chr7:66491049~66493566:-
BRCA	cis	rs58521262	0.79	rs56103105	ENSG00000268105.1	RP11-369G6.2	-3.32	0.000938	0.0412	-0.17	-0.1	Testicular germ cell tumor;	chr19:22938025	chr19:23125665~23128543:+
BRCA	cis	rs4805834	0.841	rs8101313	ENSG00000201388.1	SNORA68	-3.32	0.000938	0.0412	-0.18	-0.1	Creatinine levels;	chr19:32911260	chr19:32608337~32608469:-
BRCA	cis	rs4805834	0.686	rs8101546	ENSG00000201388.1	SNORA68	-3.32	0.000938	0.0412	-0.18	-0.1	Creatinine levels;	chr19:32911394	chr19:32608337~32608469:-
BRCA	cis	rs4805834	0.764	rs6510305	ENSG00000201388.1	SNORA68	-3.32	0.000938	0.0412	-0.18	-0.1	Creatinine levels;	chr19:32911794	chr19:32608337~32608469:-
BRCA	cis	rs10479542	0.549	rs4376229	ENSG00000273549.1	Metazoa_SRP	-3.32	0.000938	0.0412	-0.13	-0.1	Lung cancer;	chr5:179615970	chr5:179629151~179629410:+
BRCA	cis	rs2562456	0.55	rs4809143	ENSG00000268119.4	CTD-2561J22.5	3.32	0.000938	0.0412	0.17	0.1	Pain;	chr19:21589926	chr19:21444241~21463908:-
BRCA	cis	rs2562456	0.583	rs4809144	ENSG00000268119.4	CTD-2561J22.5	3.32	0.000938	0.0412	0.17	0.1	Pain;	chr19:21589928	chr19:21444241~21463908:-
BRCA	cis	rs74233809	1	rs11191499	ENSG00000236937.2	PTGES3P4	3.32	0.000938	0.0412	0.21	0.1	Birth weight;	chr10:103004514	chr10:102845595~102845950:+
BRCA	cis	rs1429524	0.813	rs1346666	ENSG00000243144.5	RP11-115N4.1	-3.32	0.000938	0.0412	-0.14	-0.1	Ejection fraction in Tripanosoma cruzi seropositivity;	chr7:91296897	chr7:91311368~91515409:+
BRCA	cis	rs524281	0.861	rs3953856	ENSG00000255038.1	RP11-1167A19.2	-3.32	0.000938	0.0412	-0.15	-0.1	Electroencephalogram traits;	chr11:66198437	chr11:66067277~66069619:-
BRCA	cis	rs524281	0.861	rs2889313	ENSG00000255038.1	RP11-1167A19.2	-3.32	0.000938	0.0412	-0.15	-0.1	Electroencephalogram traits;	chr11:66198595	chr11:66067277~66069619:-
BRCA	cis	rs6964587	0.839	rs6949700	ENSG00000188693.7	CYP51A1-AS1	-3.32	0.000938	0.0412	-0.11	-0.1	Breast cancer;	chr7:91838121	chr7:92134604~92180725:+
BRCA	cis	rs763121	0.524	rs760645	ENSG00000273076.1	RP3-508I15.22	3.32	0.000938	0.0412	0.11	0.1	Menopause (age at onset);	chr22:38636265	chr22:38743495~38743910:+
BRCA	cis	rs875971	0.964	rs1643388	ENSG00000273024.4	INTS4P2	-3.32	0.000938	0.0412	-0.11	-0.1	Aortic root size;	chr7:66379575	chr7:65647864~65715661:+
BRCA	cis	rs875971	1	rs778722	ENSG00000273024.4	INTS4P2	-3.32	0.000938	0.0412	-0.11	-0.1	Aortic root size;	chr7:66379841	chr7:65647864~65715661:+
BRCA	cis	rs13153459	0.649	rs28561538	ENSG00000279557.1	CTD-2210P15.3	-3.32	0.000938	0.0412	-0.19	-0.1	Parkinson's disease;	chr5:44575702	chr5:43586367~43587543:-
BRCA	cis	rs4950322	0.58	rs1813002	ENSG00000237188.3	RP11-337C18.8	3.32	0.000938	0.0412	0.12	0.1	Protein quantitative trait loci;	chr1:147112579	chr1:147172771~147211568:+
BRCA	cis	rs4787491	0.765	rs8054507	ENSG00000275371.1	RP11-455F5.6	-3.32	0.000938	0.0412	-0.1	-0.1	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30034721	chr16:30110895~30111955:+
BRCA	cis	rs6599077	0.642	rs2257066	ENSG00000223797.4	ENTPD3-AS1	3.32	0.000938	0.0412	0.11	0.1	Sleep-related phenotypes;	chr3:40046490	chr3:40313802~40453329:-
BRCA	cis	rs3750082	0.926	rs11762628	ENSG00000231952.3	DPY19L1P2	3.32	0.000938	0.0412	0.12	0.1	Glomerular filtration rate (creatinine);	chr7:32886959	chr7:32812757~32838570:+
BRCA	cis	rs7429990	0.965	rs6772396	ENSG00000228638.1	FCF1P2	-3.32	0.000939	0.0412	-0.1	-0.1	Educational attainment (years of education);	chr3:47918280	chr3:48290793~48291375:-
BRCA	cis	rs3816183	0.585	rs6730799	ENSG00000226491.1	FTOP1	-3.32	0.000939	0.0412	-0.12	-0.1	Hypospadias;	chr2:42616959	chr2:42797225~42798712:-
BRCA	cis	rs2847281	0.761	rs592390	ENSG00000260302.1	RP11-973H7.1	-3.32	0.000939	0.0412	-0.13	-0.1	C-reactive protein levels;Esophageal cancer (squamous cell);	chr18:12822315	chr18:12774651~12775923:-
BRCA	cis	rs7660883	0.897	rs236996	ENSG00000251411.1	RP11-397E7.4	-3.32	0.000939	0.0412	-0.11	-0.1	HDL cholesterol levels;	chr4:87084051	chr4:86913266~86914817:-
BRCA	cis	rs3764021	0.506	rs10844468	ENSG00000260423.1	RP13-735L24.1	-3.32	0.000939	0.0412	-0.12	-0.1	Type 1 diabetes;	chr12:9690799	chr12:9367464~9397617:+
BRCA	cis	rs9844666	0.512	rs9864656	ENSG00000273486.1	RP11-731C17.2	-3.32	0.000939	0.0412	-0.12	-0.1	Height;	chr3:135924696	chr3:136837338~136839021:-
BRCA	cis	rs4819052	1	rs2297286	ENSG00000215447.6	BX322557.10	-3.32	0.000939	0.0412	-0.11	-0.1	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45287982	chr21:45288052~45291738:+
BRCA	cis	rs1156327	0.655	rs179235	ENSG00000188477.11	AC003003.5	3.32	0.000939	0.0412	0.24	0.1	Periodontal disease-related phenotypes;	chr16:19313411	chr16:19285783~19310947:+
BRCA	cis	rs10043228	1	rs13362043	ENSG00000250015.1	CTC-339F2.2	3.32	0.000939	0.0412	0.13	0.1	Asthma or chronic obstructive pulmonary disease;	chr5:116260565	chr5:116302354~116304134:-
BRCA	cis	rs2288327	0.75	rs12693166	ENSG00000271011.1	RP11-171I2.5	-3.32	0.000939	0.0412	-0.18	-0.1	Atrial fibrillation;	chr2:178722403	chr2:178577103~178577622:+
BRCA	cis	rs9467773	0.62	rs2504565	ENSG00000261353.1	CTA-14H9.5	-3.32	0.000939	0.0412	-0.1	-0.1	Intelligence (multi-trait analysis);	chr6:26656662	chr6:26527063~26527404:+
BRCA	cis	rs6964587	0.626	rs12704631	ENSG00000188693.7	CYP51A1-AS1	3.32	0.000939	0.0412	0.11	0.1	Breast cancer;	chr7:91894211	chr7:92134604~92180725:+
BRCA	cis	rs6964587	0.626	rs10280301	ENSG00000188693.7	CYP51A1-AS1	3.32	0.000939	0.0412	0.11	0.1	Breast cancer;	chr7:91894944	chr7:92134604~92180725:+
BRCA	cis	rs8015152	0.583	rs8012628	ENSG00000258670.1	RP11-1042B17.3	-3.32	0.000939	0.0412	-0.15	-0.1	Vertical cup-disc ratio;	chr14:60466475	chr14:60515119~60554916:+
BRCA	cis	rs910873	0.505	rs67260051	ENSG00000206582.1	Y_RNA	3.32	0.000939	0.0412	0.15	0.1	Melanoma;	chr20:34860614	chr20:34526510~34526606:-
BRCA	cis	rs7474896	0.848	rs2738193	ENSG00000120555.12	SEPT7P9	-3.32	0.000939	0.0412	-0.18	-0.1	Obesity (extreme);	chr10:37978834	chr10:38383069~38402916:-
BRCA	cis	rs7474896	0.895	rs2749587	ENSG00000120555.12	SEPT7P9	-3.32	0.000939	0.0412	-0.18	-0.1	Obesity (extreme);	chr10:37980609	chr10:38383069~38402916:-
BRCA	cis	rs7474896	0.731	rs2749577	ENSG00000120555.12	SEPT7P9	-3.32	0.000939	0.0412	-0.18	-0.1	Obesity (extreme);	chr10:37991957	chr10:38383069~38402916:-
BRCA	cis	rs8040855	0.603	rs10520585	ENSG00000189136.7	UBE2Q2P1	-3.32	0.000939	0.0412	-0.11	-0.1	Bulimia nervosa;	chr15:85118275	chr15:84526781~84571216:-
BRCA	cis	rs2991971	0.967	rs12133294	ENSG00000281133.1	AL355480.3	3.32	0.000939	0.0412	0.12	0.1	High light scatter reticulocyte count;	chr1:45523092	chr1:45580892~45580996:-
BRCA	cis	rs6914598	0.876	rs72838025	ENSG00000240869.3	RN7SL128P	-3.32	0.000939	0.0412	-0.14	-0.1	Cutaneous malignant melanoma;Melanoma;	chr6:21154181	chr6:20421583~20421887:-
BRCA	cis	rs4835473	0.932	rs11100808	ENSG00000246448.2	RP13-578N3.3	-3.32	0.000939	0.0413	-0.12	-0.1	Immature fraction of reticulocytes;	chr4:143762728	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.932	rs7661407	ENSG00000246448.2	RP13-578N3.3	-3.32	0.000939	0.0413	-0.12	-0.1	Immature fraction of reticulocytes;	chr4:143762982	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.932	rs1562777	ENSG00000246448.2	RP13-578N3.3	-3.32	0.000939	0.0413	-0.12	-0.1	Immature fraction of reticulocytes;	chr4:143763676	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.932	rs1562778	ENSG00000246448.2	RP13-578N3.3	-3.32	0.000939	0.0413	-0.12	-0.1	Immature fraction of reticulocytes;	chr4:143763816	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.932	rs1562779	ENSG00000246448.2	RP13-578N3.3	-3.32	0.000939	0.0413	-0.12	-0.1	Immature fraction of reticulocytes;	chr4:143763999	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.932	rs1597441	ENSG00000246448.2	RP13-578N3.3	-3.32	0.000939	0.0413	-0.12	-0.1	Immature fraction of reticulocytes;	chr4:143764158	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.932	rs1597443	ENSG00000246448.2	RP13-578N3.3	-3.32	0.000939	0.0413	-0.12	-0.1	Immature fraction of reticulocytes;	chr4:143764406	chr4:143700257~143865072:+
BRCA	cis	rs1003719	0.715	rs9974494	ENSG00000242553.1	AP001432.14	3.32	0.000939	0.0413	0.12	0.1	Eye color traits;	chr21:37194265	chr21:37221419~37237744:+
BRCA	cis	rs36051895	0.664	rs3780370	ENSG00000236254.1	MTND4P14	-3.32	0.00094	0.0413	-0.12	-0.1	Pediatric autoimmune diseases;	chr9:5095167	chr9:5107937~5109290:+
BRCA	cis	rs950881	0.932	rs10173081	ENSG00000234389.1	AC007278.3	3.32	0.00094	0.0413	0.13	0.1	Allergy;	chr2:102340888	chr2:102438713~102440475:+
BRCA	cis	rs4919694	1	rs4917986	ENSG00000236937.2	PTGES3P4	3.32	0.00094	0.0413	0.2	0.1	Arsenic metabolism;	chr10:102870424	chr10:102845595~102845950:+
BRCA	cis	rs11633886	0.546	rs1033167	ENSG00000273972.1	CTD-2306A12.1	-3.32	0.00094	0.0413	-0.12	-0.1	Diisocyanate-induced asthma;	chr15:45747340	chr15:45702640~45703183:+
BRCA	cis	rs3796352	1	rs11707780	ENSG00000275956.1	RP5-966M1.7	3.32	0.00094	0.0413	0.17	0.1	Immune reponse to smallpox (secreted IL-2);	chr3:53050310	chr3:52732547~52733867:+
BRCA	cis	rs6487679	1	rs10734765	ENSG00000256069.6	A2MP1	3.32	0.00094	0.0413	0.13	0.1	Non-alcoholic fatty liver disease histology (AST);	chr12:9216789	chr12:9228533~9275817:-
BRCA	cis	rs301901	1	rs292182	ENSG00000272103.1	CTD-2653M23.3	3.32	0.00094	0.0413	0.12	0.1	Height;	chr5:36954710	chr5:36861736~36862217:-
BRCA	cis	rs1969253	0.712	rs843345	ENSG00000205955.4	HSP90AA5P	-3.32	0.00094	0.0413	-0.12	-0.1	Major depressive disorder;	chr3:184188727	chr3:184115352~184117898:+
BRCA	cis	rs6426833	0.687	rs10916664	ENSG00000117242.7	PINK1-AS	-3.32	0.00094	0.0413	-0.12	-0.1	Ulcerative colitis;Inflammatory bowel disease;	chr1:19887472	chr1:20642657~20652193:-
BRCA	cis	rs10464366	0.843	rs12701691	ENSG00000233306.2	TRGV2	3.32	0.00094	0.0413	0.1	0.1	IgG glycosylation;	chr7:39050577	chr7:38362864~38363518:-
BRCA	cis	rs910873	0.505	rs6058089	ENSG00000250917.1	RP4-785G19.5	-3.32	0.00094	0.0413	-0.17	-0.1	Melanoma;	chr20:34606453	chr20:34234840~34281173:-
BRCA	cis	rs6493487	0.512	rs16963912	ENSG00000259298.1	RP11-562A8.4	-3.32	0.00094	0.0413	-0.12	-0.1	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr15:50821975	chr15:50497195~50498744:-
BRCA	cis	rs7914558	1	rs10509757	ENSG00000213277.3	MARCKSL1P1	3.32	0.00094	0.0413	0.11	0.1	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102993203	chr10:103175554~103176094:+
BRCA	cis	rs10129255	0.957	rs4387509	ENSG00000232216.1	IGHV3-43	3.32	0.00094	0.0413	0.09	0.1	Kawasaki disease;	chr14:106704386	chr14:106470264~106470800:-
BRCA	cis	rs73242632	0.5	rs1718834	ENSG00000269949.1	RP11-738E22.3	-3.32	0.00094	0.0413	-0.16	-0.1	Congenital heart disease (maternal effect);	chr4:57052738	chr4:56960927~56961373:-
BRCA	cis	rs17301013	0.612	rs56199565	ENSG00000200674.1	RN7SKP160	3.32	0.000941	0.0413	0.13	0.1	Systemic lupus erythematosus;	chr1:174640992	chr1:173791548~173791887:+
BRCA	cis	rs4820539	1	rs4822357	ENSG00000236794.5	BCRP8	-3.32	0.000941	0.0413	-0.12	-0.1	Bone mineral density;	chr22:23131044	chr22:23179918~23180172:-
BRCA	cis	rs2070488	0.804	rs1870914	ENSG00000229589.1	ACVR2B-AS1	3.32	0.000941	0.0413	0.11	0.1	Electrocardiographic conduction measures;	chr3:38452729	chr3:38451027~38454820:-
BRCA	cis	rs953492	0.51	rs10926958	ENSG00000224727.1	FCF1P7	-3.32	0.000941	0.0413	-0.12	-0.1	Diastolic blood pressure;	chr1:243174914	chr1:243267257~243268119:-
BRCA	cis	rs7520050	0.966	rs1085244	ENSG00000226957.1	RP4-533D7.4	3.32	0.000941	0.0413	0.11	0.1	Reticulocyte count;Red blood cell count;	chr1:46098008	chr1:46046818~46048368:+
BRCA	cis	rs7520050	0.966	rs6662641	ENSG00000226957.1	RP4-533D7.4	3.32	0.000941	0.0413	0.11	0.1	Reticulocyte count;Red blood cell count;	chr1:46105837	chr1:46046818~46048368:+
BRCA	cis	rs7520050	0.966	rs1707335	ENSG00000226957.1	RP4-533D7.4	3.32	0.000941	0.0413	0.11	0.1	Reticulocyte count;Red blood cell count;	chr1:46106249	chr1:46046818~46048368:+
BRCA	cis	rs2227564	0.761	rs2227552	ENSG00000272140.2	RP11-574K11.29	3.32	0.000941	0.0413	0.11	0.1	Crohn's disease;Inflammatory bowel disease;	chr10:73909561	chr10:73703735~73713581:-
BRCA	cis	rs2908197	0.737	rs6465096	ENSG00000205485.12	AC004980.7	3.32	0.000941	0.0413	0.11	0.1	3-hydroxypropylmercapturic acid levels in smokers;	chr7:76343555	chr7:76549360~76627982:+
BRCA	cis	rs7786896	1	rs7786896	ENSG00000188185.10	LINC00265	3.32	0.000941	0.0413	0.1	0.1	Schizophrenia;	chr7:39054328	chr7:39733632~39793092:+
BRCA	cis	rs12135191	0.523	rs6428951	ENSG00000229795.2	RPS21P1	3.32	0.000941	0.0413	0.13	0.1	Urate levels (BMI interaction);	chr1:236322668	chr1:235432985~235433231:+
BRCA	cis	rs6931421	1	rs6931421	ENSG00000279022.1	RP11-250B2.4	3.32	0.000941	0.0413	0.13	0.1	Sitting height ratio;	chr6:80170421	chr6:80440730~80441172:+
BRCA	cis	rs10484434	0.901	rs62396160	ENSG00000216331.1	HIST1H1PS1	3.32	0.000941	0.0413	0.18	0.1	HIV-1 viral setpoint;	chr6:26075165	chr6:26195566~26195771:+
BRCA	cis	rs9393777	0.778	rs67457459	ENSG00000216901.1	AL022393.7	3.32	0.000941	0.0413	0.2	0.1	Intelligence (multi-trait analysis);	chr6:27230564	chr6:28176188~28176674:+
BRCA	cis	rs67478160	0.595	rs1475007	ENSG00000269910.1	RP11-73M18.10	3.32	0.000941	0.0413	0.1	0.1	Schizophrenia;	chr14:103830810	chr14:103694516~103695050:-
BRCA	cis	rs57545798	0.963	rs8042860	ENSG00000259381.2	RP11-192M23.1	-3.32	0.000941	0.0413	-0.1	-0.1	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr15:100099837	chr15:100645434~100646655:-
BRCA	cis	rs2274273	0.84	rs11547116	ENSG00000259318.1	RP11-454L9.2	3.32	0.000941	0.0413	0.09	0.1	Protein biomarker;	chr14:55271447	chr14:55394940~55395233:-
BRCA	cis	rs10829156	0.898	rs4748504	ENSG00000225527.1	RP11-383B4.4	-3.32	0.000941	0.0413	-0.14	-0.1	Sudden cardiac arrest;	chr10:18651868	chr10:18531849~18533336:-
BRCA	cis	rs76843715	0.666	rs17830968	ENSG00000276092.1	RP11-734B5.2	3.32	0.000941	0.0413	0.21	0.1	Chickenpox;	chr18:69354476	chr18:68721082~68721560:+
BRCA	cis	rs1119582	0.925	rs17153642	ENSG00000279118.1	RP11-517I3.2	-3.32	0.000941	0.0413	-0.13	-0.1	Select biomarker traits;	chr5:125900894	chr5:126496279~126498604:+
BRCA	cis	rs2836950	0.501	rs2836984	ENSG00000235701.1	PCBP2P1	-3.32	0.000941	0.0413	-0.12	-0.1	Menarche (age at onset);	chr21:39329023	chr21:39171130~39172106:-
BRCA	cis	rs7264396	0.563	rs7264869	ENSG00000088340.14	FER1L4	-3.32	0.000941	0.0413	-0.14	-0.1	Total cholesterol levels;	chr20:35758580	chr20:35558737~35607562:-
BRCA	cis	rs944990	0.538	rs10821167	ENSG00000227603.1	RP11-165J3.6	3.32	0.000941	0.0413	0.11	0.1	Body mass index;	chr9:93593722	chr9:93435332~93437121:-
BRCA	cis	rs6517329	0.564	rs12626189	ENSG00000230212.5	AP000688.14	3.32	0.000941	0.0413	0.13	0.1	Schizophrenia;	chr21:36137654	chr21:36069642~36126640:-
BRCA	cis	rs10876993	0.784	rs7314152	ENSG00000270039.1	RP11-571M6.17	-3.32	0.000941	0.0413	-0.14	-0.1	Celiac disease or Rheumatoid arthritis;	chr12:57623918	chr12:57803838~57804415:+
BRCA	cis	rs7520050	0.933	rs12045165	ENSG00000281133.1	AL355480.3	3.32	0.000941	0.0413	0.12	0.1	Reticulocyte count;Red blood cell count;	chr1:45790350	chr1:45580892~45580996:-
BRCA	cis	rs2712184	0.756	rs2541393	ENSG00000237930.1	AC007563.4	3.32	0.000941	0.0413	0.11	0.1	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);	chr2:216786507	chr2:216785774~216786144:-
BRCA	cis	rs4713118	0.621	rs9295756	ENSG00000226314.6	ZNF192P1	-3.32	0.000942	0.0413	-0.16	-0.1	Parkinson's disease;	chr6:28065618	chr6:28161781~28169594:+
BRCA	cis	rs10792665	0.512	rs7112902	ENSG00000254965.1	RP11-113K21.2	-3.32	0.000942	0.0413	-0.1	-0.1	Obesity-related traits;	chr11:82878719	chr11:83111060~83111442:-
BRCA	cis	rs10792665	0.512	rs4551795	ENSG00000254965.1	RP11-113K21.2	-3.32	0.000942	0.0413	-0.1	-0.1	Obesity-related traits;	chr11:82878928	chr11:83111060~83111442:-
BRCA	cis	rs17092148	0.887	rs2068474	ENSG00000202150.1	RNU6-407P	3.32	0.000942	0.0413	0.15	0.1	Neuroticism;	chr20:34643275	chr20:35030317~35030420:-
BRCA	cis	rs301901	0.581	rs6881383	ENSG00000272103.1	CTD-2653M23.3	-3.32	0.000942	0.0413	-0.12	-0.1	Height;	chr5:37545897	chr5:36861736~36862217:-
BRCA	cis	rs10129255	0.957	rs10140904	ENSG00000253132.1	IGHV3-62	-3.32	0.000942	0.0413	-0.08	-0.1	Kawasaki disease;	chr14:106776558	chr14:106643142~106643585:-
BRCA	cis	rs875971	0.862	rs6460307	ENSG00000265600.1	AC006480.1	-3.32	0.000942	0.0413	-0.12	-0.1	Aortic root size;	chr7:66595884	chr7:67356680~67356779:+
BRCA	cis	rs6840360	0.571	rs11940881	ENSG00000270265.1	RP11-731D1.4	-3.32	0.000942	0.0413	-0.12	-0.1	Intelligence (multi-trait analysis);	chr4:151579898	chr4:151333775~151353224:-
BRCA	cis	rs10198628	0.967	rs10204312	ENSG00000264370.1	MIR3125	-3.32	0.000942	0.0413	-0.12	-0.1	Pericardial fat;Pericardial adipose tissue adjusted for height and weight;	chr2:12825287	chr2:12737367~12737444:+
BRCA	cis	rs12282928	0.959	rs11500496	ENSG00000255197.4	RP11-750H9.5	-3.32	0.000942	0.0413	-0.1	-0.1	Migraine - clinic-based;	chr11:48282884	chr11:47383148~47409190:-
BRCA	cis	rs12282928	0.959	rs11039640	ENSG00000255197.4	RP11-750H9.5	-3.32	0.000942	0.0413	-0.1	-0.1	Migraine - clinic-based;	chr11:48285684	chr11:47383148~47409190:-
BRCA	cis	rs7267979	0.586	rs1007707	ENSG00000276952.1	RP5-965G21.6	3.32	0.000942	0.0413	0.12	0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25209962	chr20:25284915~25285588:-
BRCA	cis	rs12477438	0.52	rs11123761	ENSG00000231822.1	AC019097.7	3.32	0.000942	0.0413	0.11	0.1	Chronic sinus infection;	chr2:99089440	chr2:99102018~99102752:+
BRCA	cis	rs7551222	0.892	rs7539399	ENSG00000240219.1	RP11-430C7.5	-3.32	0.000942	0.0413	-0.12	-0.1	Schizophrenia;	chr1:204620916	chr1:204626775~204629712:+
BRCA	cis	rs2191566	0.691	rs55676341	ENSG00000266921.1	RP11-15A1.7	-3.32	0.000942	0.0414	-0.13	-0.1	Acute lymphoblastic leukemia (childhood);	chr19:44083536	chr19:43996896~44002836:-
BRCA	cis	rs61931739	0.5	rs6488211	ENSG00000258794.3	DUX4L27	-3.32	0.000942	0.0414	-0.14	-0.1	Morning vs. evening chronotype;	chr12:34222685	chr12:34208415~34209675:-
BRCA	cis	rs6517329	0.649	rs4817776	ENSG00000231106.2	LINC01436	3.32	0.000942	0.0414	0.12	0.1	Schizophrenia;	chr21:36121124	chr21:36005338~36007838:+
BRCA	cis	rs1865760	0.566	rs10807006	ENSG00000272462.2	U91328.19	-3.32	0.000942	0.0414	-0.12	-0.1	Height;	chr6:26048524	chr6:25992662~26001775:+
BRCA	cis	rs2559856	0.903	rs10128996	ENSG00000199933.1	RNY1P16	3.32	0.000942	0.0414	0.11	0.1	Blood protein levels;	chr12:101687720	chr12:101719808~101719918:+
BRCA	cis	rs748404	1	rs12909095	ENSG00000166763.7	STRCP1	3.32	0.000942	0.0414	0.14	0.1	Lung cancer;	chr15:43265944	chr15:43699488~43718184:-
BRCA	cis	rs73397619	0.576	rs12213891	ENSG00000272345.1	RP1-30M3.5	3.32	0.000942	0.0414	0.11	0.1	Intrinsic epigenetic age acceleration;	chr6:25664813	chr6:24700907~24701793:-
BRCA	cis	rs9816784	0.901	rs56253832	ENSG00000231443.2	AC024937.6	3.32	0.000942	0.0414	0.11	0.1	Mean corpuscular hemoglobin;	chr3:196090304	chr3:195937243~195938739:+
BRCA	cis	rs987724	0.502	rs4680320	ENSG00000240875.4	LINC00886	-3.32	0.000942	0.0414	-0.12	-0.1	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156955813	chr3:156747346~156817062:-
BRCA	cis	rs977987	0.806	rs11643410	ENSG00000280152.1	RP11-331F4.5	-3.32	0.000942	0.0414	-0.11	-0.1	Dupuytren's disease;	chr16:75394408	chr16:75245994~75250077:-
BRCA	cis	rs875971	0.895	rs778700	ENSG00000229886.1	RP5-1132H15.3	3.32	0.000943	0.0414	0.11	0.1	Aortic root size;	chr7:66401463	chr7:66025126~66031544:-
BRCA	cis	rs875971	1	rs778699	ENSG00000229886.1	RP5-1132H15.3	3.32	0.000943	0.0414	0.11	0.1	Aortic root size;	chr7:66403303	chr7:66025126~66031544:-
BRCA	cis	rs7618915	0.57	rs11130319	ENSG00000279144.1	RP11-894J14.2	3.32	0.000943	0.0414	0.13	0.1	Bipolar disorder;	chr3:52721576	chr3:52848085~52848553:-
BRCA	cis	rs4921164	1	rs13187731	ENSG00000245812.2	RP11-175K6.1	-3.32	0.000943	0.0414	-0.13	-0.1	Gut microbiome composition (winter);	chr5:159114259	chr5:159100483~159117478:+
BRCA	cis	rs6918586	0.615	rs198841	ENSG00000272462.2	U91328.19	-3.32	0.000943	0.0414	-0.11	-0.1	Schizophrenia;	chr6:26111443	chr6:25992662~26001775:+
BRCA	cis	rs60843830	1	rs3828165	ENSG00000223751.1	AC116609.2	3.32	0.000943	0.0414	0.14	0.1	Spherical equivalent (joint analysis main effects and education interaction);	chr2:220889	chr2:742488~747767:+
BRCA	cis	rs2277339	0.558	rs747906	ENSG00000258199.1	RP11-977G19.5	3.32	0.000943	0.0414	0.16	0.1	Plateletcrit;Menopause (age at onset);Mean corpuscular volume;	chr12:56839566	chr12:56162359~56190284:-
BRCA	cis	rs911119	0.866	rs6048925	ENSG00000270001.1	RP11-218C14.8	-3.32	0.000943	0.0414	-0.13	-0.1	Chronic kidney disease;	chr20:23598419	chr20:23631826~23632316:-
BRCA	cis	rs12477438	0.52	rs4851187	ENSG00000231822.1	AC019097.7	-3.32	0.000943	0.0414	-0.11	-0.1	Chronic sinus infection;	chr2:99129397	chr2:99102018~99102752:+
BRCA	cis	rs875971	0.862	rs2909688	ENSG00000223473.2	GS1-124K5.3	3.32	0.000943	0.0414	0.08	0.1	Aortic root size;	chr7:66376625	chr7:66491049~66493566:-
BRCA	cis	rs9650657	0.645	rs4841409	ENSG00000255020.1	AF131216.5	-3.32	0.000943	0.0414	-0.12	-0.1	Neuroticism;	chr8:10658864	chr8:11345748~11347502:-
BRCA	cis	rs7649443	0.959	rs59171696	ENSG00000243339.3	RN7SL738P	-3.32	0.000943	0.0414	-0.14	-0.1	Nonsyndromic cleft lip with cleft palate;	chr3:197072503	chr3:196399911~196400207:+
BRCA	cis	rs1165668	0.958	rs1165674	ENSG00000257681.1	RP11-341G23.4	3.32	0.000943	0.0414	0.12	0.1	Coronary heart disease (SNP X SNP interaction);	chr12:103926819	chr12:103746315~103768858:-
BRCA	cis	rs10895987	1	rs10895987	ENSG00000254501.1	AP003068.9	3.32	0.000943	0.0414	0.15	0.1	Blood protein levels;	chr11:65137437	chr11:65110714~65111695:-
BRCA	cis	rs754466	0.58	rs1054608	ENSG00000213514.2	RP11-428P16.2	3.32	0.000944	0.0414	0.14	0.1	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77783550	chr10:77730766~77734769:+
BRCA	cis	rs2153535	0.585	rs6900539	ENSG00000251164.1	HULC	-3.32	0.000944	0.0414	-0.12	-0.1	Motion sickness;	chr6:8592054	chr6:8652137~8653846:+
BRCA	cis	rs11098499	0.739	rs9884728	ENSG00000249244.1	RP11-548H18.2	-3.32	0.000944	0.0414	-0.12	-0.1	Corneal astigmatism;	chr4:119205924	chr4:119391831~119395335:-
BRCA	cis	rs10782582	0.593	rs12131493	ENSG00000181227.3	RP4-682C21.2	3.32	0.000944	0.0414	0.11	0.1	Daytime sleep phenotypes;	chr1:75673487	chr1:75743423~75744776:-
BRCA	cis	rs7264396	0.563	rs6060560	ENSG00000088340.14	FER1L4	-3.32	0.000944	0.0414	-0.15	-0.1	Total cholesterol levels;	chr20:35690968	chr20:35558737~35607562:-
BRCA	cis	rs5017598	1	rs5017598	ENSG00000229214.1	LINC00242	3.32	0.000944	0.0414	0.13	0.1	Pediatric bone mineral density (femoral neck);Pediatric bone mineral density (hip);	chr6:168811399	chr6:169788790~169798825:-
BRCA	cis	rs11241621	0.615	rs6870691	ENSG00000248489.1	CTD-2007H13.3	3.32	0.000944	0.0414	0.13	0.1	Plantar warts;	chr5:98513362	chr5:98929171~98995013:+
BRCA	cis	rs1355223	0.902	rs1453387	ENSG00000271369.1	RP11-350D17.3	-3.32	0.000944	0.0414	-0.12	-0.1	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34686351	chr11:34709600~34710161:+
BRCA	cis	rs9368481	0.761	rs9357028	ENSG00000124549.13	BTN2A3P	-3.32	0.000944	0.0414	-0.11	-0.1	Autism spectrum disorder or schizophrenia;	chr6:26999445	chr6:26421391~26432383:+
BRCA	cis	rs1971762	0.527	rs6580950	ENSG00000270175.1	RP11-793H13.11	-3.32	0.000944	0.0414	-0.09	-0.1	Height;	chr12:53532872	chr12:53500162~53500936:-
BRCA	cis	rs885518	0.636	rs10811612	ENSG00000266446.1	RP11-149I2.4	3.32	0.000944	0.0414	0.23	0.1	Lung adenocarcinoma;	chr9:21774168	chr9:21995482~21996013:+
BRCA	cis	rs875971	0.862	rs778680	ENSG00000223473.2	GS1-124K5.3	3.32	0.000944	0.0414	0.08	0.1	Aortic root size;	chr7:66375427	chr7:66491049~66493566:-
BRCA	cis	rs875971	0.862	rs11769079	ENSG00000223473.2	GS1-124K5.3	3.32	0.000944	0.0414	0.08	0.1	Aortic root size;	chr7:66377141	chr7:66491049~66493566:-
BRCA	cis	rs875971	0.862	rs1695820	ENSG00000223473.2	GS1-124K5.3	3.32	0.000944	0.0414	0.08	0.1	Aortic root size;	chr7:66379576	chr7:66491049~66493566:-
BRCA	cis	rs10266483	0.774	rs10253630	ENSG00000228653.2	HNRNPCP7	3.32	0.000944	0.0414	0.12	0.1	Response to statin therapy;	chr7:64366962	chr7:64500825~64501729:+
BRCA	cis	rs875971	0.862	rs4718383	ENSG00000272831.1	RP11-792A8.4	-3.32	0.000944	0.0414	-0.09	-0.1	Aortic root size;	chr7:66643422	chr7:66739829~66740385:-
BRCA	cis	rs7267979	1	rs2258879	ENSG00000204556.4	CTD-2514C3.1	-3.32	0.000944	0.0414	-0.14	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25298577	chr20:26018832~26020684:+
BRCA	cis	rs7267979	1	rs2257496	ENSG00000204556.4	CTD-2514C3.1	-3.32	0.000944	0.0414	-0.14	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25298679	chr20:26018832~26020684:+
BRCA	cis	rs7267979	1	rs2258884	ENSG00000204556.4	CTD-2514C3.1	-3.32	0.000944	0.0414	-0.14	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25298903	chr20:26018832~26020684:+
BRCA	cis	rs7267979	1	rs2259837	ENSG00000204556.4	CTD-2514C3.1	-3.32	0.000944	0.0414	-0.14	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25299569	chr20:26018832~26020684:+
BRCA	cis	rs7267979	1	rs2259873	ENSG00000204556.4	CTD-2514C3.1	-3.32	0.000944	0.0414	-0.14	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25300145	chr20:26018832~26020684:+
BRCA	cis	rs34467563	0.67	rs6468501	ENSG00000253105.4	KB-1448A5.1	3.32	0.000944	0.0414	0.12	0.1	Lobe attachment (rater-scored or self-reported);	chr8:96342723	chr8:96371865~96387438:-
BRCA	cis	rs1376877	0.901	rs57235969	ENSG00000273456.1	RP11-686O6.2	3.32	0.000944	0.0414	0.1	0.1	Subclinical atherosclerosis traits (other);	chr2:203240680	chr2:202374932~202375604:-
BRCA	cis	rs6672530	0.518	rs2093610	ENSG00000227711.2	RP11-275O4.5	-3.32	0.000944	0.0414	-0.12	-0.1	Hip circumference adjusted for BMI;	chr1:227633345	chr1:227509028~227520477:-
BRCA	cis	rs10411161	0.752	rs10404812	ENSG00000268095.1	ZNF649-AS1	3.32	0.000944	0.0414	0.18	0.1	Breast cancer;	chr19:51897438	chr19:51888025~51900463:+
BRCA	cis	rs612683	0.894	rs10875290	ENSG00000223656.1	HMGB3P10	-3.32	0.000944	0.0414	-0.13	-0.1	Breast cancer;	chr1:100388199	chr1:99698242~99699178:+
BRCA	cis	rs6024905	0.587	rs1579101	ENSG00000275401.1	RP4-564F22.7	3.32	0.000944	0.0414	0.12	0.1	Bipolar disorder and schizophrenia;	chr20:38337932	chr20:38418483~38419202:-
BRCA	cis	rs4697263	0.706	rs7695992	ENSG00000237350.1	CDC42P6	-3.32	0.000944	0.0414	-0.12	-0.1	Age-related hearing impairment (SNP x SNP interaction);	chr4:22047014	chr4:22727375~22727950:-
BRCA	cis	rs2985684	0.894	rs4900927	ENSG00000278009.1	RP11-649E7.8	3.32	0.000944	0.0414	0.14	0.1	Carotid intima media thickness;	chr14:49552023	chr14:49601011~49601124:-
BRCA	cis	rs11773103	0.786	rs73202985	ENSG00000224046.1	AC005076.5	3.32	0.000944	0.0414	0.18	0.1	Bipolar disorder or major depressive disorder (combined);	chr7:87126604	chr7:87151423~87152420:-
BRCA	cis	rs2836974	0.568	rs2142111	ENSG00000238141.2	BRWD1-AS1	3.32	0.000945	0.0414	0.12	0.1	Cognitive function;	chr21:39177363	chr21:39315707~39323218:+
BRCA	cis	rs8049367	0.612	rs8062591	ENSG00000279031.1	LA16c-360H6.1	3.32	0.000945	0.0414	0.12	0.1	Nonsyndromic cleft lip with or without cleft palate;	chr16:3920585	chr16:3292879~3293403:+
BRCA	cis	rs2638953	0.815	rs10843193	ENSG00000273989.1	RP11-425D17.2	-3.32	0.000945	0.0414	-0.15	-0.1	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28509763	chr12:28236227~28236828:+
BRCA	cis	rs2638953	0.853	rs7485676	ENSG00000273989.1	RP11-425D17.2	-3.32	0.000945	0.0414	-0.15	-0.1	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28510734	chr12:28236227~28236828:+
BRCA	cis	rs253959	0.739	rs168826	ENSG00000272265.1	CTD-2287O16.4	-3.32	0.000945	0.0414	-0.12	-0.1	Bipolar disorder and schizophrenia;	chr5:116299083	chr5:116078110~116078570:-
BRCA	cis	rs4660214	0.756	rs11205823	ENSG00000182109.6	RP11-69E11.4	-3.32	0.000945	0.0414	-0.12	-0.1	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39248566	chr1:39522280~39546187:-
BRCA	cis	rs10888690	0.502	rs74080008	ENSG00000236434.2	RP11-296A18.6	-3.32	0.000945	0.0414	-0.13	-0.1	Male-pattern baldness;	chr1:50582045	chr1:51264916~51266074:-
BRCA	cis	rs8094794	0.744	rs9652998	ENSG00000267707.2	RP11-95O2.5	3.32	0.000945	0.0414	0.14	0.1	Periodontal disease-related phenotypes;	chr18:36715525	chr18:37243776~37247506:+
BRCA	cis	rs8094794	0.744	rs8097414	ENSG00000267707.2	RP11-95O2.5	3.32	0.000945	0.0414	0.14	0.1	Periodontal disease-related phenotypes;	chr18:36715637	chr18:37243776~37247506:+
BRCA	cis	rs8094794	0.744	rs8097541	ENSG00000267707.2	RP11-95O2.5	3.32	0.000945	0.0414	0.14	0.1	Periodontal disease-related phenotypes;	chr18:36715664	chr18:37243776~37247506:+
BRCA	cis	rs2262909	0.962	rs401424	ENSG00000279377.1	AC003973.3	3.32	0.000945	0.0415	0.13	0.1	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;	chr19:22049221	chr19:21965708~21968529:-
BRCA	cis	rs6088590	0.93	rs6120723	ENSG00000276073.1	RP5-1125A11.7	-3.32	0.000945	0.0415	-0.12	-0.1	Coronary artery disease;	chr20:34776852	chr20:33985617~33988989:-
BRCA	cis	rs4578769	0.722	rs12458865	ENSG00000273232.1	RP11-370A5.2	-3.32	0.000945	0.0415	-0.15	-0.1	Eosinophil percentage of white cells;	chr18:22954677	chr18:22882825~22883357:-
BRCA	cis	rs1119582	1	rs189016	ENSG00000279118.1	RP11-517I3.2	-3.32	0.000945	0.0415	-0.12	-0.1	Select biomarker traits;	chr5:125944740	chr5:126496279~126498604:+
BRCA	cis	rs36051895	0.632	rs7871515	ENSG00000237711.1	RP11-39K24.13	3.32	0.000945	0.0415	0.12	0.1	Pediatric autoimmune diseases;	chr9:5175288	chr9:5100236~5101009:+
BRCA	cis	rs7141336	0.8	rs1570114	ENSG00000260810.1	CTD-2547L24.4	3.32	0.000945	0.0415	0.12	0.1	Anxiety disorder;	chr14:90821190	chr14:91258299~91259003:+
BRCA	cis	rs6012564	0.89	rs6125591	ENSG00000222365.1	SNORD12B	3.32	0.000945	0.0415	0.11	0.1	Anger;	chr20:49204130	chr20:49280319~49280409:+
BRCA	cis	rs10844706	0.699	rs2058560	ENSG00000256594.6	RP11-705C15.2	3.32	0.000945	0.0415	0.14	0.1	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9721093	chr12:9633419~9658412:+
BRCA	cis	rs2274273	1	rs11621351	ENSG00000233924.1	AL160471.6	-3.32	0.000945	0.0415	-0.12	-0.1	Protein biomarker;	chr14:55150022	chr14:55004813~55005687:-
BRCA	cis	rs875971	0.577	rs34888281	ENSG00000230189.5	GS1-124K5.2	-3.32	0.000945	0.0415	-0.08	-0.1	Aortic root size;	chr7:66120784	chr7:66409143~66490059:-
BRCA	cis	rs13326165	0.76	rs17052058	ENSG00000243224.1	RP5-1157M23.2	-3.32	0.000945	0.0415	-0.15	-0.1	HDL cholesterol levels;HDL cholesterol;	chr3:52310664	chr3:52239258~52241097:+
BRCA	cis	rs7520050	0.931	rs1707333	ENSG00000234329.1	RP11-767N6.2	-3.32	0.000945	0.0415	-0.1	-0.1	Reticulocyte count;Red blood cell count;	chr1:46081363	chr1:45651039~45651826:-
BRCA	cis	rs9837347	0.624	rs6778301	ENSG00000228956.7	SATB1-AS1	3.32	0.000945	0.0415	0.12	0.1	Itch intensity from mosquito bite adjusted by bite size;	chr3:18723537	chr3:18445024~18920401:+
BRCA	cis	rs12893668	0.603	rs12896171	ENSG00000258914.1	CTD-2134A5.3	3.32	0.000946	0.0415	0.14	0.1	Reticulocyte count;	chr14:103669629	chr14:103875055~103877478:+
BRCA	cis	rs948562	0.744	rs11229475	ENSG00000255299.4	RP11-655C2.3	-3.32	0.000946	0.0415	-0.12	-0.1	Lymphoma;	chr11:58459910	chr11:58497888~58505758:-
BRCA	cis	rs10246939	0.529	rs60165685	ENSG00000270923.1	TAS2R6P	-3.32	0.000946	0.0415	-0.11	-0.1	Bitter taste perception;	chr7:141861190	chr7:141787815~141788640:+
BRCA	cis	rs10838687	0.736	rs16938581	ENSG00000243802.2	RP11-390K5.1	3.32	0.000946	0.0415	0.15	0.1	Proinsulin levels;	chr11:47249488	chr11:47191181~47191542:-
BRCA	cis	rs6463739	0.785	rs6463734	ENSG00000219545.8	UMAD1	3.32	0.000946	0.0415	0.1	0.1	Small cell lung carcinoma;	chr7:7866157	chr7:7640711~8004059:+
BRCA	cis	rs6463739	0.785	rs6463735	ENSG00000219545.8	UMAD1	3.32	0.000946	0.0415	0.1	0.1	Small cell lung carcinoma;	chr7:7866204	chr7:7640711~8004059:+
BRCA	cis	rs2638953	0.671	rs10843099	ENSG00000247934.4	RP11-967K21.1	-3.32	0.000946	0.0415	-0.15	-0.1	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28116901	chr12:28163298~28190738:-
BRCA	cis	rs11098499	0.863	rs1383533	ENSG00000225892.3	RP11-384K6.2	3.32	0.000946	0.0415	0.1	0.1	Corneal astigmatism;	chr4:119513421	chr4:118632274~118634759:+
BRCA	cis	rs11673344	0.864	rs2562587	ENSG00000267422.1	CTD-2554C21.1	3.32	0.000946	0.0415	0.13	0.1	Obesity-related traits;	chr19:37019357	chr19:37779686~37792865:+
BRCA	cis	rs494453	0.6	rs575208	ENSG00000227811.2	FAM212B-AS1	-3.32	0.000946	0.0415	-0.13	-0.1	Osteoporosis-related phenotypes;	chr1:111663769	chr1:111739841~111747798:+
BRCA	cis	rs739401	0.611	rs2239900	ENSG00000247473.2	CARS-AS1	3.32	0.000946	0.0415	0.12	0.1	Longevity;	chr11:3009762	chr11:3029009~3041260:+
BRCA	cis	rs2638953	0.962	rs11049558	ENSG00000273989.1	RP11-425D17.2	-3.32	0.000946	0.0415	-0.16	-0.1	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28371438	chr12:28236227~28236828:+
BRCA	cis	rs1144333	0.85	rs1251274	ENSG00000181227.3	RP4-682C21.2	3.32	0.000946	0.0415	0.14	0.1	Attention function in attention deficit hyperactive disorder;	chr1:75822902	chr1:75743423~75744776:-
BRCA	cis	rs7578361	0.918	rs6716959	ENSG00000231969.1	AC144449.1	-3.32	0.000946	0.0415	-0.16	-0.1	Acute lymphoblastic leukemia (childhood);	chr2:149494021	chr2:149587196~149848233:+
BRCA	cis	rs10851478	0.817	rs692309	ENSG00000259531.2	RP11-295H24.3	-3.32	0.000946	0.0415	-0.13	-0.1	Oral cavity cancer;	chr15:49706485	chr15:49365124~49366685:-
BRCA	cis	rs683250	0.825	rs3815988	ENSG00000254551.1	RP11-727A23.7	3.32	0.000946	0.0415	0.12	0.1	Subcortical brain region volumes;	chr11:83532989	chr11:83209431~83213379:-
BRCA	cis	rs863345	0.604	rs60104403	ENSG00000176320.2	RP11-404O13.5	-3.32	0.000946	0.0415	-0.11	-0.1	Pneumococcal bacteremia;	chr1:158531057	chr1:158197922~158203877:-
BRCA	cis	rs17027633	1	rs10489791	ENSG00000234020.1	CHIAP3	-3.32	0.000946	0.0415	-0.2	-0.1	Cerebrospinal fluid t-tau:AB1-42 ratio;	chr1:111416263	chr1:111353275~111367409:-
BRCA	cis	rs687432	0.774	rs11604473	ENSG00000213592.4	AP000662.9	-3.32	0.000946	0.0415	-0.14	-0.1	Parkinson's disease;	chr11:58129055	chr11:57718044~57718530:-
BRCA	cis	rs944990	0.824	rs10992749	ENSG00000227603.1	RP11-165J3.6	-3.32	0.000946	0.0415	-0.12	-0.1	Body mass index;	chr9:93470592	chr9:93435332~93437121:-
BRCA	cis	rs36051895	0.559	rs12342390	ENSG00000237711.1	RP11-39K24.13	-3.32	0.000946	0.0415	-0.12	-0.1	Pediatric autoimmune diseases;	chr9:5211297	chr9:5100236~5101009:+
BRCA	cis	rs763121	0.889	rs6001209	ENSG00000273096.1	RP3-508I15.20	3.32	0.000946	0.0415	0.1	0.1	Menopause (age at onset);	chr22:38725247	chr22:38736610~38736792:-
BRCA	cis	rs2017387	0.572	rs157546	ENSG00000161643.11	SIGLEC16	-3.32	0.000946	0.0415	-0.2	-0.1	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50021869	chr19:49969673~49975814:+
BRCA	cis	rs896655	0.582	rs1335500	ENSG00000265194.1	RP11-70L8.4	-3.32	0.000946	0.0415	-0.1	-0.1	Coronary artery disease;	chr9:21711676	chr9:21858910~21861926:-
BRCA	cis	rs875971	0.964	rs778721	ENSG00000273024.4	INTS4P2	-3.32	0.000946	0.0415	-0.11	-0.1	Aortic root size;	chr7:66380410	chr7:65647864~65715661:+
BRCA	cis	rs687432	0.924	rs61905309	ENSG00000213592.4	AP000662.9	-3.32	0.000946	0.0415	-0.14	-0.1	Parkinson's disease;	chr11:57979102	chr11:57718044~57718530:-
BRCA	cis	rs6088580	0.634	rs6120642	ENSG00000269202.1	RP4-614O4.12	-3.32	0.000946	0.0415	-0.1	-0.1	Glomerular filtration rate (creatinine);	chr20:34424725	chr20:35201747~35203288:-
BRCA	cis	rs13118159	0.509	rs4974556	ENSG00000273179.1	RP11-20I20.4	3.32	0.000947	0.0415	0.11	0.1	Longevity;	chr4:1364353	chr4:1167778~1168174:+
BRCA	cis	rs2657888	0.598	rs2657909	ENSG00000257576.1	RP11-153M3.1	3.32	0.000947	0.0415	0.13	0.1	Adiponectin levels;	chr12:56501719	chr12:56511002~56512703:+
BRCA	cis	rs13260300	0.533	rs12548780	ENSG00000254349.4	FLJ39080	3.32	0.000947	0.0415	0.13	0.1	Breast cancer-free interval (treatment with aromatase inhibitor);	chr8:74582379	chr8:74599775~74823313:+
BRCA	cis	rs11673344	0.668	rs7248693	ENSG00000267309.1	CTD-2630F21.1	-3.32	0.000947	0.0415	-0.13	-0.1	Obesity-related traits;	chr19:36991864	chr19:36489649~36491040:+
BRCA	cis	rs2638953	0.853	rs2141203	ENSG00000273989.1	RP11-425D17.2	-3.32	0.000947	0.0415	-0.15	-0.1	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28461928	chr12:28236227~28236828:+
BRCA	cis	rs115320831	0.623	rs9790344	ENSG00000271817.2	U3	-3.32	0.000947	0.0415	-0.11	-0.1	Excessive daytime sleepiness;	chr4:158257212	chr4:158700691~158700909:+
BRCA	cis	rs9325144	0.555	rs61929925	ENSG00000257718.1	RP11-396F22.1	-3.32	0.000947	0.0415	-0.1	-0.1	Morning vs. evening chronotype;	chr12:38305026	chr12:38906451~38909592:+
BRCA	cis	rs780676	1	rs780674	ENSG00000279406.1	RP11-327E2.5	3.32	0.000947	0.0415	0.13	0.1	Gestational age at birth (child effect);	chr10:71353740	chr10:71364243~71366374:+
BRCA	cis	rs2337406	1	rs4774173	ENSG00000211970.3	IGHV4-61	3.32	0.000947	0.0415	0.09	0.1	Alzheimer's disease (late onset);	chr14:106682029	chr14:106639119~106639657:-
BRCA	cis	rs875971	0.928	rs2036263	ENSG00000223473.2	GS1-124K5.3	-3.32	0.000947	0.0415	-0.08	-0.1	Aortic root size;	chr7:66335210	chr7:66491049~66493566:-
BRCA	cis	rs875971	0.862	rs10240949	ENSG00000223473.2	GS1-124K5.3	-3.32	0.000947	0.0415	-0.08	-0.1	Aortic root size;	chr7:66339430	chr7:66491049~66493566:-
BRCA	cis	rs875971	0.862	rs7782704	ENSG00000223473.2	GS1-124K5.3	-3.32	0.000947	0.0415	-0.08	-0.1	Aortic root size;	chr7:66340379	chr7:66491049~66493566:-
BRCA	cis	rs3820068	0.581	rs59991988	ENSG00000237301.1	RP4-680D5.2	-3.32	0.000947	0.0415	-0.13	-0.1	Systolic blood pressure;	chr1:15624057	chr1:15586136~15603626:-
BRCA	cis	rs1884752	0.641	rs2208179	ENSG00000278816.1	RP5-1116H23.4	-3.32	0.000947	0.0415	-0.12	-0.1	Anti-saccade response;	chr20:5408813	chr20:5061037~5061340:-
BRCA	cis	rs6067053	0.558	rs79274472	ENSG00000222365.1	SNORD12B	3.32	0.000947	0.0415	0.11	0.1	Intelligence (multi-trait analysis);	chr20:49297643	chr20:49280319~49280409:+
BRCA	cis	rs7267979	0.932	rs1541061	ENSG00000274973.1	RP13-401N8.7	-3.32	0.000947	0.0415	-0.12	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25540421	chr20:25845497~25845862:+
BRCA	cis	rs7267979	0.966	rs2482918	ENSG00000231081.1	RP4-760C5.3	3.32	0.000947	0.0415	0.13	0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25431499	chr20:26008791~26010531:-
BRCA	cis	rs8105895	0.866	rs17701834	ENSG00000269345.1	VN1R85P	-3.32	0.000948	0.0415	-0.16	-0.1	Body mass index (change over time);	chr19:21938656	chr19:22174766~22175191:-
BRCA	cis	rs2333021	0.649	rs12884588	ENSG00000259015.1	RP11-109N23.6	3.32	0.000948	0.0415	0.12	0.1	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:73007111	chr14:72960595~72961993:+
BRCA	cis	rs344364	0.511	rs337284	ENSG00000219027.2	RPS3AP2	3.32	0.000948	0.0415	0.15	0.1	Glomerular filtration rate in chronic kidney disease;	chr16:1904798	chr16:1477830~1478583:+
BRCA	cis	rs7709909	0.532	rs73132417	ENSG00000248569.1	CTC-512J14.5	-3.32	0.000948	0.0415	-0.15	-0.1	HDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;	chr5:80661219	chr5:80351021~80351956:-
BRCA	cis	rs801193	0.613	rs2659900	ENSG00000229886.1	RP5-1132H15.3	3.32	0.000948	0.0415	0.11	0.1	Aortic root size;	chr7:66719456	chr7:66025126~66031544:-
BRCA	cis	rs2599510	0.811	rs2710615	ENSG00000276517.1	AL133243.2	-3.32	0.000948	0.0416	-0.12	-0.1	Interleukin-18 levels;	chr2:32566155	chr2:32526504~32529507:+
BRCA	cis	rs2072510	0.683	rs2246972	ENSG00000237774.3	RP11-129B9.1	3.32	0.000948	0.0416	0.12	0.1	Metabolite levels (small molecules and protein measures);	chr12:96034111	chr12:95125760~95126389:+
BRCA	cis	rs1476587	0.92	rs2106954	ENSG00000224046.1	AC005076.5	3.32	0.000948	0.0416	0.16	0.1	Brachial circumference;	chr7:87111018	chr7:87151423~87152420:-
BRCA	cis	rs17473412	0.677	rs17475188	ENSG00000263432.2	RN7SL689P	-3.32	0.000948	0.0416	-0.14	-0.1	Total body bone mineral density;	chr5:123547057	chr5:123022487~123022783:-
BRCA	cis	rs17092148	0.597	rs57495888	ENSG00000206582.1	Y_RNA	3.32	0.000948	0.0416	0.15	0.1	Neuroticism;	chr20:34504919	chr20:34526510~34526606:-
BRCA	cis	rs345013	0.92	rs9813934	ENSG00000240032.1	RP11-274H2.3	-3.31	0.000948	0.0416	-0.18	-0.1	Prostate cancer;	chr3:145284964	chr3:146066344~146069185:-
BRCA	cis	rs345013	0.92	rs66652960	ENSG00000240032.1	RP11-274H2.3	-3.31	0.000948	0.0416	-0.18	-0.1	Prostate cancer;	chr3:145285339	chr3:146066344~146069185:-
BRCA	cis	rs2985684	0.802	rs8015368	ENSG00000258568.1	RHOQP1	3.31	0.000948	0.0416	0.12	0.1	Carotid intima media thickness;	chr14:49553792	chr14:49599994~49600572:+
BRCA	cis	rs3750965	0.575	rs3892895	ENSG00000265539.1	MIR3164	3.31	0.000948	0.0416	0.11	0.1	Hair color;	chr11:69117287	chr11:69083176~69083258:+
BRCA	cis	rs7267979	1	rs2258617	ENSG00000204556.4	CTD-2514C3.1	-3.31	0.000948	0.0416	-0.14	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25293682	chr20:26018832~26020684:+
BRCA	cis	rs4427176	0.66	rs59004915	ENSG00000233609.3	RP11-62H7.2	3.31	0.000948	0.0416	0.13	0.1	Mosquito bite size;	chr8:9722986	chr8:8961200~8979025:+
BRCA	cis	rs76917914	0.821	rs112500293	ENSG00000236896.1	RP11-535C21.3	3.31	0.000948	0.0416	0.13	0.1	Immature fraction of reticulocytes;	chr9:98001173	chr9:97986551~97987656:-
BRCA	cis	rs115320831	0.556	rs62335904	ENSG00000271817.2	U3	-3.31	0.000949	0.0416	-0.11	-0.1	Excessive daytime sleepiness;	chr4:158256892	chr4:158700691~158700909:+
BRCA	cis	rs16917546	0.933	rs10995238	ENSG00000238280.1	RP11-436D10.3	-3.31	0.000949	0.0416	-0.14	-0.1	Basal cell carcinoma;	chr10:62627348	chr10:62793562~62805887:-
BRCA	cis	rs6121246	0.559	rs6060932	ENSG00000230613.1	HM13-AS1	3.31	0.000949	0.0416	0.14	0.1	Mean corpuscular hemoglobin;	chr20:31762742	chr20:31567707~31573263:-
BRCA	cis	rs6121246	0.583	rs28815498	ENSG00000230613.1	HM13-AS1	3.31	0.000949	0.0416	0.14	0.1	Mean corpuscular hemoglobin;	chr20:31763757	chr20:31567707~31573263:-
BRCA	cis	rs6121246	0.512	rs6060938	ENSG00000230613.1	HM13-AS1	3.31	0.000949	0.0416	0.14	0.1	Mean corpuscular hemoglobin;	chr20:31775842	chr20:31567707~31573263:-
BRCA	cis	rs6121246	0.512	rs6060941	ENSG00000230613.1	HM13-AS1	3.31	0.000949	0.0416	0.14	0.1	Mean corpuscular hemoglobin;	chr20:31779580	chr20:31567707~31573263:-
BRCA	cis	rs6121246	0.559	rs6087779	ENSG00000230613.1	HM13-AS1	3.31	0.000949	0.0416	0.14	0.1	Mean corpuscular hemoglobin;	chr20:31782763	chr20:31567707~31573263:-
BRCA	cis	rs6121246	0.559	rs6060944	ENSG00000230613.1	HM13-AS1	3.31	0.000949	0.0416	0.14	0.1	Mean corpuscular hemoglobin;	chr20:31784311	chr20:31567707~31573263:-
BRCA	cis	rs2998286	0.723	rs332151	ENSG00000237128.1	RP11-351M16.3	3.31	0.000949	0.0416	0.13	0.1	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28585331	chr10:28433008~28495813:-
BRCA	cis	rs7829975	0.714	rs11784052	ENSG00000173295.6	FAM86B3P	3.31	0.000949	0.0416	0.1	0.1	Mood instability;	chr8:8814452	chr8:8228595~8244865:+
BRCA	cis	rs4415084	1	rs1438825	ENSG00000248779.1	RP11-53O19.2	3.31	0.000949	0.0416	0.09	0.1	Breast cancer;	chr5:44706829	chr5:44752949~44765744:+
BRCA	cis	rs3781264	0.761	rs7081265	ENSG00000268894.5	PLCE1-AS1	3.31	0.000949	0.0416	0.14	0.1	Esophageal cancer and gastric cancer;	chr10:94365892	chr10:94279277~94287478:-
BRCA	cis	rs2018683	0.707	rs917218	ENSG00000228421.2	AC005013.5	3.31	0.000949	0.0416	0.13	0.1	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28935505	chr7:28957667~28959345:+
BRCA	cis	rs1348850	0.872	rs13004955	ENSG00000271825.1	RP11-337N6.2	-3.31	0.000949	0.0416	-0.13	-0.1	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177534195	chr2:177300600~177302006:+
BRCA	cis	rs6545883	0.868	rs778755	ENSG00000212978.6	AC016747.3	-3.31	0.000949	0.0416	-0.14	-0.1	Tuberculosis;	chr2:61553902	chr2:61141592~61144969:-
BRCA	cis	rs997295	0.57	rs72747464	ENSG00000259673.4	IQCH-AS1	3.31	0.000949	0.0416	0.12	0.1	Motion sickness;	chr15:67526202	chr15:67403619~67521844:-
BRCA	cis	rs875971	0.862	rs4718377	ENSG00000265600.1	AC006480.1	3.31	0.000949	0.0416	0.12	0.1	Aortic root size;	chr7:66584691	chr7:67356680~67356779:+
BRCA	cis	rs875971	0.862	rs10278014	ENSG00000265600.1	AC006480.1	3.31	0.000949	0.0416	0.12	0.1	Aortic root size;	chr7:66586277	chr7:67356680~67356779:+
BRCA	cis	rs2736337	0.532	rs6998387	ENSG00000251402.3	FAM90A25P	3.31	0.000949	0.0416	0.12	0.1	Rheumatoid arthritis;	chr8:11435949	chr8:12415080~12418090:-
BRCA	cis	rs17213965	0.561	rs9929522	ENSG00000275910.1	RP11-680G24.6	-3.31	0.000949	0.0416	-0.13	-0.1	Waist-hip ratio;	chr16:15785903	chr16:15015828~15016390:-
BRCA	cis	rs4930561	0.765	rs1894204	ENSG00000255306.1	RP5-901A4.1	-3.31	0.000949	0.0416	-0.1	-0.1	Breast cancer in childhood cancer survivors;IgG glycosylation;	chr11:68162204	chr11:68024809~68030461:-
BRCA	cis	rs12413361	0.967	rs947100	ENSG00000272914.1	RP11-330O11.3	-3.31	0.000949	0.0416	-0.13	-0.1	Height;	chr10:30840980	chr10:30831828~30833387:-
BRCA	cis	rs4650994	0.593	rs12735140	ENSG00000273384.1	RP5-1098D14.1	-3.31	0.000949	0.0416	-0.13	-0.1	HDL cholesterol;HDL cholesterol levels;	chr1:178575083	chr1:178651706~178652282:+
BRCA	cis	rs13188386	0.585	rs7721461	ENSG00000249779.1	RP11-447H19.3	3.31	0.000949	0.0416	0.16	0.1	Iron status biomarkers;	chr5:42419770	chr5:43206709~43207811:+
BRCA	cis	rs2704588	1	rs1458555	ENSG00000270720.1	RP11-84C13.2	-3.31	0.000949	0.0416	-0.15	-0.1	Longevity;	chr4:88913866	chr4:89119284~89119871:+
BRCA	cis	rs875971	0.502	rs1796227	ENSG00000273448.1	RP11-166O4.6	-3.31	0.000949	0.0416	-0.11	-0.1	Aortic root size;	chr7:66622032	chr7:67333047~67334383:+
BRCA	cis	rs2823962	0.727	rs2211991	ENSG00000270093.1	AP000473.8	-3.31	0.000949	0.0416	-0.1	-0.1	Amyotrophic lateral sclerosis;	chr21:16652303	chr21:16643529~16645065:+
BRCA	cis	rs2638953	0.925	rs11049597	ENSG00000273989.1	RP11-425D17.2	-3.31	0.000949	0.0416	-0.15	-0.1	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28433584	chr12:28236227~28236828:+
BRCA	cis	rs2638953	0.962	rs11049599	ENSG00000273989.1	RP11-425D17.2	-3.31	0.000949	0.0416	-0.15	-0.1	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28437218	chr12:28236227~28236828:+
BRCA	cis	rs12517906	0.725	rs17702375	ENSG00000250900.5	CTC-338M12.6	3.31	0.000949	0.0416	0.17	0.1	Weight;Body mass index;	chr5:180738435	chr5:181195496~181203103:+
BRCA	cis	rs4372836	0.729	rs4132617	ENSG00000226833.4	AC097724.3	3.31	0.000949	0.0416	0.12	0.1	Body mass index;	chr2:28808446	chr2:28708953~28736205:-
BRCA	cis	rs10844706	0.699	rs10772087	ENSG00000278635.1	CTD-2318O12.1	-3.31	0.00095	0.0416	-0.11	-0.1	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9730515	chr12:9415641~9416718:+
BRCA	cis	rs4718428	0.672	rs12530806	ENSG00000229886.1	RP5-1132H15.3	3.31	0.00095	0.0416	0.12	0.1	Corneal structure;	chr7:66925737	chr7:66025126~66031544:-
BRCA	cis	rs12310956	0.532	rs11052933	ENSG00000258794.3	DUX4L27	3.31	0.00095	0.0416	0.15	0.1	Morning vs. evening chronotype;	chr12:33816946	chr12:34208415~34209675:-
BRCA	cis	rs4499344	0.73	rs434020	ENSG00000201388.1	SNORA68	3.31	0.00095	0.0416	0.12	0.1	Mean platelet volume;	chr19:32613164	chr19:32608337~32608469:-
BRCA	cis	rs4499344	0.696	rs398990	ENSG00000201388.1	SNORA68	3.31	0.00095	0.0416	0.12	0.1	Mean platelet volume;	chr19:32613338	chr19:32608337~32608469:-
BRCA	cis	rs4499344	0.73	rs369859	ENSG00000201388.1	SNORA68	3.31	0.00095	0.0416	0.12	0.1	Mean platelet volume;	chr19:32613399	chr19:32608337~32608469:-
BRCA	cis	rs9392556	0.829	rs629362	ENSG00000272248.1	RP3-406P24.4	3.31	0.00095	0.0416	0.13	0.1	Blood metabolite levels;	chr6:4121597	chr6:4018713~4019202:+
BRCA	cis	rs17684571	0.872	rs59085778	ENSG00000231441.1	RP11-472M19.2	3.31	0.00095	0.0416	0.15	0.1	Schizophrenia;	chr6:56723357	chr6:56844002~56864078:+
BRCA	cis	rs4803480	0.63	rs16975338	ENSG00000239868.3	RN7SL34P	-3.31	0.00095	0.0416	-0.23	-0.1	Schizophrenia;	chr19:41551655	chr19:41286424~41286693:-
BRCA	cis	rs17548007	0.597	rs4764928	ENSG00000257681.1	RP11-341G23.4	-3.31	0.00095	0.0416	-0.16	-0.1	Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin;	chr12:102970160	chr12:103746315~103768858:-
BRCA	cis	rs7017914	0.967	rs6472538	ENSG00000246366.5	RP11-382J12.1	3.31	0.00095	0.0416	0.11	0.1	Bone mineral density;	chr8:70674736	chr8:70608577~70663279:+
BRCA	cis	rs7267979	0.899	rs6115213	ENSG00000274973.1	RP13-401N8.7	-3.31	0.00095	0.0416	-0.12	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25569736	chr20:25845497~25845862:+
BRCA	cis	rs17221829	0.965	rs10830364	ENSG00000280385.1	AP000648.5	-3.31	0.00095	0.0416	-0.12	-0.1	Anxiety in major depressive disorder;	chr11:89725464	chr11:90193614~90198120:+
BRCA	cis	rs987724	0.593	rs9844054	ENSG00000240875.4	LINC00886	3.31	0.00095	0.0416	0.12	0.1	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156957527	chr3:156747346~156817062:-
BRCA	cis	rs603446	0.967	rs180340	ENSG00000246100.3	LINC00900	-3.31	0.00095	0.0416	-0.11	-0.1	Triglycerides;	chr11:116745686	chr11:115754248~115760627:-
BRCA	cis	rs9325144	0.647	rs7316392	ENSG00000257718.1	RP11-396F22.1	-3.31	0.00095	0.0416	-0.11	-0.1	Morning vs. evening chronotype;	chr12:38670579	chr12:38906451~38909592:+
BRCA	cis	rs6951643	0.782	rs35351503	ENSG00000224138.1	AC000123.4	-3.31	0.000951	0.0416	-0.12	-0.1	Creutzfeldt-Jakob disease (sporadic);	chr7:126873067	chr7:127350128~127351523:+
BRCA	cis	rs8073060	0.504	rs225271	ENSG00000267554.1	RP11-686D22.10	-3.31	0.000951	0.0416	-0.11	-0.1	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35642817	chr17:35470069~35470628:-
BRCA	cis	rs7927592	0.913	rs10896330	ENSG00000254610.1	RP5-903G2.2	-3.31	0.000951	0.0416	-0.14	-0.1	Total body bone mineral density;	chr11:68487530	chr11:67934563~67939774:-
BRCA	cis	rs146671954	1	rs146671954	ENSG00000235106.7	LINC00094	3.31	0.000951	0.0416	0.14	0.1	Red cell distribution width;	chr9:134069081	chr9:134025439~134034666:+
BRCA	cis	rs10005067	0.935	rs36060267	ENSG00000249001.4	RP11-742B18.1	-3.31	0.000951	0.0417	-0.12	-0.1	Total body bone mineral density (age 30-45);	chr4:87903860	chr4:87568035~87733956:-
BRCA	cis	rs4578769	0.918	rs8085287	ENSG00000273232.1	RP11-370A5.2	3.31	0.000951	0.0417	0.14	0.1	Eosinophil percentage of white cells;	chr18:22884208	chr18:22882825~22883357:-
BRCA	cis	rs9311676	0.632	rs56033718	ENSG00000244161.1	FLNB-AS1	-3.31	0.000951	0.0417	-0.09	-0.1	Systemic lupus erythematosus;	chr3:58460671	chr3:58162547~58170636:-
BRCA	cis	rs2252865	0.517	rs2587513	ENSG00000238290.1	RP11-431K24.1	-3.31	0.000951	0.0417	-0.12	-0.1	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Optic cup area;Total body bone mineral density;Schizophrenia;	chr1:8387177	chr1:8026738~8122702:+
BRCA	cis	rs74024059	0.661	rs1503955	ENSG00000260269.4	CTD-2323K18.1	-3.31	0.000951	0.0417	-0.29	-0.1	Red blood cell count;Hematocrit;	chr15:75950277	chr15:75527150~75601205:-
BRCA	cis	rs61931739	0.5	rs11053167	ENSG00000258794.3	DUX4L27	3.31	0.000951	0.0417	0.15	0.1	Morning vs. evening chronotype;	chr12:34234157	chr12:34208415~34209675:-
BRCA	cis	rs10504130	0.696	rs17212214	ENSG00000272076.1	RP11-11C20.3	-3.31	0.000951	0.0417	-0.15	-0.1	Venous thromboembolism (SNP x SNP interaction);	chr8:51918582	chr8:51810110~51810681:-
BRCA	cis	rs12681366	0.734	rs1872889	ENSG00000253175.1	RP11-267M23.6	3.31	0.000951	0.0417	0.11	0.1	Nonsyndromic cleft lip with cleft palate;	chr8:94406193	chr8:94565036~94565715:+
BRCA	cis	rs4809760	1	rs4810988	ENSG00000224397.4	LINC01272	3.31	0.000951	0.0417	0.1	0.1	Gut microbiota (beta diversity);	chr20:49849432	chr20:50267486~50279795:+
BRCA	cis	rs2692947	0.77	rs2315417	ENSG00000232931.4	LINC00342	3.31	0.000951	0.0417	0.11	0.1	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95834541	chr2:95807118~95816215:-
BRCA	cis	rs3820068	0.58	rs12747696	ENSG00000237301.1	RP4-680D5.2	-3.31	0.000951	0.0417	-0.14	-0.1	Systolic blood pressure;	chr1:15676483	chr1:15586136~15603626:-
BRCA	cis	rs3808502	0.527	rs2736374	ENSG00000269918.1	AF131215.9	-3.31	0.000951	0.0417	-0.12	-0.1	Neuroticism;	chr8:11256319	chr8:11104691~11106704:-
BRCA	cis	rs62244186	0.711	rs6778410	ENSG00000233509.2	ZNF197-AS1	3.31	0.000951	0.0417	0.13	0.1	Depressive symptoms;	chr3:44702501	chr3:44617128~44624797:-
BRCA	cis	rs9394169	0.514	rs1886355	ENSG00000249346.5	LINC01016	-3.31	0.000951	0.0417	-0.1	-0.1	Essential tremor;	chr6:33809100	chr6:33867506~33896914:-
BRCA	cis	rs1156327	0.51	rs978463	ENSG00000188477.11	AC003003.5	-3.31	0.000951	0.0417	-0.22	-0.1	Periodontal disease-related phenotypes;	chr16:19319630	chr16:19285783~19310947:+
BRCA	cis	rs62025270	0.632	rs3169119	ENSG00000259416.2	RP11-158M2.5	-3.31	0.000952	0.0417	-0.16	-0.1	Idiopathic pulmonary fibrosis;	chr15:85748038	chr15:85754941~85756237:-
BRCA	cis	rs6084875	0.686	rs11697426	ENSG00000274949.1	RP5-1009E24.9	-3.31	0.000952	0.0417	-0.14	-0.1	Systemic lupus erythematosus;	chr20:4766638	chr20:3811384~3823882:+
BRCA	cis	rs13434995	0.513	rs2101476	ENSG00000273257.1	RP11-177J6.1	-3.31	0.000952	0.0417	-0.16	-0.1	Adiponectin levels;	chr4:55578961	chr4:55387949~55388271:+
BRCA	cis	rs28489187	0.597	rs6576765	ENSG00000223653.4	RP11-131L23.1	-3.31	0.000952	0.0417	-0.11	-0.1	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85405329	chr1:85276715~85448124:+
BRCA	cis	rs61352607	0.84	rs11614506	ENSG00000259125.1	RP11-545N8.3	-3.31	0.000952	0.0417	-0.15	-0.1	Triglycerides;	chr12:57421892	chr12:57144620~57147619:-
BRCA	cis	rs879500	0.653	rs4366789	ENSG00000266296.1	ARIH2P1	-3.31	0.000952	0.0417	-0.15	-0.1	Lung function (FVC);	chr18:28509067	chr18:28651732~28653208:+
BRCA	cis	rs449789	1	rs389546	ENSG00000233682.3	RP11-13P5.2	3.31	0.000952	0.0417	0.15	0.1	Pulse pressure;	chr6:159270625	chr6:159165899~159170007:-
BRCA	cis	rs3748656	1	rs34848593	ENSG00000273483.1	RP4-671G15.2	3.31	0.000952	0.0417	0.14	0.1	Hip circumference adjusted for BMI;	chr1:112697484	chr1:112517799~112518441:-
BRCA	cis	rs7267979	0.966	rs7270835	ENSG00000204556.4	CTD-2514C3.1	-3.31	0.000952	0.0417	-0.14	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25454431	chr20:26018832~26020684:+
BRCA	cis	rs7267979	1	rs6115191	ENSG00000204556.4	CTD-2514C3.1	-3.31	0.000952	0.0417	-0.14	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25459842	chr20:26018832~26020684:+
BRCA	cis	rs7267979	1	rs6107045	ENSG00000204556.4	CTD-2514C3.1	-3.31	0.000952	0.0417	-0.14	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25461300	chr20:26018832~26020684:+
BRCA	cis	rs7267979	1	rs6107046	ENSG00000204556.4	CTD-2514C3.1	-3.31	0.000952	0.0417	-0.14	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25461413	chr20:26018832~26020684:+
BRCA	cis	rs7267979	1	rs6107047	ENSG00000204556.4	CTD-2514C3.1	-3.31	0.000952	0.0417	-0.14	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25461461	chr20:26018832~26020684:+
BRCA	cis	rs1334894	0.901	rs76489311	ENSG00000187762.5	HSPE1P11	3.31	0.000952	0.0417	0.24	0.1	Coronary artery disease;	chr6:35539641	chr6:35023522~35023831:+
BRCA	cis	rs2274273	0.967	rs17832359	ENSG00000233924.1	AL160471.6	-3.31	0.000952	0.0417	-0.12	-0.1	Protein biomarker;	chr14:55149223	chr14:55004813~55005687:-
BRCA	cis	rs35306767	0.855	rs11253465	ENSG00000229869.1	RP11-363N22.2	-3.31	0.000952	0.0417	-0.15	-0.1	Eosinophil percentage of granulocytes;	chr10:851268	chr10:933026~942743:+
BRCA	cis	rs35306767	0.903	rs11253467	ENSG00000229869.1	RP11-363N22.2	-3.31	0.000952	0.0417	-0.15	-0.1	Eosinophil percentage of granulocytes;	chr10:855304	chr10:933026~942743:+
BRCA	cis	rs17059400	0.822	rs17053610	ENSG00000219755.1	RP1-199J3.5	-3.31	0.000952	0.0417	-0.23	-0.1	Illicit drug use;	chr6:99317908	chr6:99575712~99576456:+
BRCA	cis	rs2832077	0.943	rs11702320	ENSG00000236056.1	GAPDHP14	3.31	0.000952	0.0417	0.15	0.1	Cognitive test performance;	chr21:28822929	chr21:29222321~29223257:+
BRCA	cis	rs829880	1	rs829880	ENSG00000245017.2	RP11-181C3.1	3.31	0.000952	0.0417	0.13	0.1	Colonoscopy-negative controls vs population controls;	chr12:98451553	chr12:98485544~98503855:-
BRCA	cis	rs6456156	0.774	rs2022001	ENSG00000272549.1	RP11-351J23.2	3.31	0.000952	0.0417	0.1	0.1	Primary biliary cholangitis;	chr6:167116021	chr6:167666840~167679270:-
BRCA	cis	rs6728642	0.614	rs113485946	ENSG00000279791.1	RP11-499E14.1	-3.31	0.000952	0.0417	-0.22	-0.1	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:97200705	chr2:97094935~97097433:+
BRCA	cis	rs2985684	0.894	rs4581611	ENSG00000258568.1	RHOQP1	3.31	0.000952	0.0417	0.13	0.1	Carotid intima media thickness;	chr14:49576802	chr14:49599994~49600572:+
BRCA	cis	rs818427	0.927	rs461424	ENSG00000279522.1	CTC-487M23.6	3.31	0.000952	0.0417	0.12	0.1	Total body bone mineral density;	chr5:112894206	chr5:112894933~112896531:+
BRCA	cis	rs8105895	0.935	rs7253053	ENSG00000269345.1	VN1R85P	3.31	0.000953	0.0417	0.14	0.1	Body mass index (change over time);	chr19:22062883	chr19:22174766~22175191:-
BRCA	cis	rs8105895	0.935	rs7247041	ENSG00000269345.1	VN1R85P	3.31	0.000953	0.0417	0.14	0.1	Body mass index (change over time);	chr19:22066988	chr19:22174766~22175191:-
BRCA	cis	rs8105895	0.935	rs10420042	ENSG00000269345.1	VN1R85P	3.31	0.000953	0.0417	0.14	0.1	Body mass index (change over time);	chr19:22069124	chr19:22174766~22175191:-
BRCA	cis	rs8105895	0.935	rs2043315	ENSG00000269345.1	VN1R85P	3.31	0.000953	0.0417	0.14	0.1	Body mass index (change over time);	chr19:22070021	chr19:22174766~22175191:-
BRCA	cis	rs8105895	0.935	rs10411275	ENSG00000269345.1	VN1R85P	3.31	0.000953	0.0417	0.14	0.1	Body mass index (change over time);	chr19:22076667	chr19:22174766~22175191:-
BRCA	cis	rs8105895	0.935	rs10411943	ENSG00000269345.1	VN1R85P	3.31	0.000953	0.0417	0.14	0.1	Body mass index (change over time);	chr19:22076980	chr19:22174766~22175191:-
BRCA	cis	rs848490	0.889	rs56265941	ENSG00000214293.7	APTR	3.31	0.000953	0.0417	0.12	0.1	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77593621	chr7:77657660~77696265:-
BRCA	cis	rs13034020	0.522	rs13017457	ENSG00000237522.1	NONOP2	3.31	0.000953	0.0417	0.13	0.1	Hodgkin's lymphoma;	chr2:61021510	chr2:60936819~60938049:-
BRCA	cis	rs6141600	0.57	rs1046383	ENSG00000278035.1	RP11-234K24.6	3.31	0.000953	0.0417	0.14	0.1	Height;Hip circumference;	chr20:36232725	chr20:36233851~36234297:+
BRCA	cis	rs752590	0.614	rs7558326	ENSG00000189223.12	PAX8-AS1	3.31	0.000953	0.0417	0.19	0.1	Mucinous ovarian carcinoma;	chr2:113263541	chr2:113211522~113276581:+
BRCA	cis	rs397969	0.646	rs850622	ENSG00000261033.1	RP11-209D14.2	-3.31	0.000953	0.0417	-0.15	-0.1	Platelet count;	chr17:19934223	chr17:20008051~20009234:-
BRCA	cis	rs77688320	0.553	rs2540449	ENSG00000230799.1	AC007279.2	3.31	0.000953	0.0417	0.12	0.1	Breast cancer;	chr2:201451036	chr2:201762737~201763573:+
BRCA	cis	rs4819052	1	rs13047688	ENSG00000223768.1	LINC00205	-3.31	0.000953	0.0417	-0.14	-0.1	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45249375	chr21:45293285~45297354:+
BRCA	cis	rs67073037	1	rs7580240	ENSG00000226833.4	AC097724.3	-3.31	0.000953	0.0417	-0.14	-0.1	Breast cancer;Breast cancer (estrogen-receptor negative);	chr2:28891506	chr2:28708953~28736205:-
BRCA	cis	rs7695732	0.621	rs1708668	ENSG00000270720.1	RP11-84C13.2	-3.31	0.000953	0.0417	-0.14	-0.1	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr4:89030410	chr4:89119284~89119871:+
BRCA	cis	rs875971	0.83	rs778715	ENSG00000223473.2	GS1-124K5.3	3.31	0.000953	0.0417	0.08	0.1	Aortic root size;	chr7:66384222	chr7:66491049~66493566:-
BRCA	cis	rs3748656	1	rs12133583	ENSG00000273483.1	RP4-671G15.2	3.31	0.000953	0.0417	0.14	0.1	Hip circumference adjusted for BMI;	chr1:112698168	chr1:112517799~112518441:-
BRCA	cis	rs6088590	0.561	rs6059926	ENSG00000269202.1	RP4-614O4.12	-3.31	0.000953	0.0417	-0.1	-0.1	Coronary artery disease;	chr20:34577000	chr20:35201747~35203288:-
BRCA	cis	rs2400749	0.685	rs12888131	ENSG00000258521.1	RP11-638I2.9	-3.31	0.000953	0.0417	-0.1	-0.1	Alzheimer's disease (survival time);	chr14:99552931	chr14:100339832~100340554:+
BRCA	cis	rs736801	0.808	rs72797303	ENSG00000233006.5	AC034220.3	3.31	0.000953	0.0417	0.08	0.1	Mosquito bite size;Breast cancer;	chr5:132460471	chr5:132311285~132369916:-
BRCA	cis	rs853679	0.76	rs9393910	ENSG00000219392.1	RP1-265C24.5	-3.31	0.000953	0.0417	-0.17	-0.1	Depression;	chr6:28240414	chr6:28115628~28116551:+
BRCA	cis	rs10044254	0.95	rs2964268	ENSG00000246214.1	RP11-260E18.1	3.31	0.000953	0.0417	0.13	0.1	Asthma (corticosteroid response);	chr5:15764601	chr5:16615926~16629969:+
BRCA	cis	rs6088580	0.609	rs945674	ENSG00000269202.1	RP4-614O4.12	3.31	0.000953	0.0417	0.1	0.1	Glomerular filtration rate (creatinine);	chr20:34376441	chr20:35201747~35203288:-
BRCA	cis	rs7487075	0.619	rs10880971	ENSG00000257261.4	RP11-96H19.1	3.31	0.000953	0.0417	0.12	0.1	Itch intensity from mosquito bite;	chr12:46445715	chr12:46383679~46876159:+
BRCA	cis	rs7487075	0.619	rs10467214	ENSG00000257261.4	RP11-96H19.1	3.31	0.000953	0.0417	0.12	0.1	Itch intensity from mosquito bite;	chr12:46447427	chr12:46383679~46876159:+
BRCA	cis	rs11887277	0.586	rs12478975	ENSG00000272148.1	RP11-195B17.1	-3.31	0.000953	0.0417	-0.12	-0.1	Obesity-related traits;	chr2:26767561	chr2:27062428~27062907:-
BRCA	cis	rs12303914	0.559	rs10845086	ENSG00000256682.2	TAS2R12	-3.31	0.000953	0.0417	-0.14	-0.1	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr12:10247756	chr12:10894943~10896952:-
BRCA	cis	rs12303914	0.603	rs10845087	ENSG00000256682.2	TAS2R12	-3.31	0.000953	0.0417	-0.14	-0.1	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr12:10247837	chr12:10894943~10896952:-
BRCA	cis	rs12303914	0.603	rs10772251	ENSG00000256682.2	TAS2R12	-3.31	0.000953	0.0417	-0.14	-0.1	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr12:10248255	chr12:10894943~10896952:-
BRCA	cis	rs1119582	0.636	rs2568404	ENSG00000279118.1	RP11-517I3.2	3.31	0.000953	0.0417	0.14	0.1	Select biomarker traits;	chr5:125843128	chr5:126496279~126498604:+
BRCA	cis	rs12760731	0.72	rs10913545	ENSG00000213057.5	C1orf220	3.31	0.000953	0.0417	0.14	0.1	Obesity-related traits;	chr1:178391066	chr1:178542752~178548889:+
BRCA	cis	rs4927850	0.918	rs4361313	ENSG00000278820.1	AC024937.1	3.31	0.000954	0.0417	0.12	0.1	Pancreatic cancer;	chr3:196025389	chr3:195960500~195960612:-
BRCA	cis	rs8180040	0.593	rs10433549	ENSG00000280667.1	Y_RNA	-3.31	0.000954	0.0417	-0.11	-0.1	Colorectal cancer;	chr3:46989943	chr3:47501083~47501182:+
BRCA	cis	rs7260598	1	rs8110727	ENSG00000268442.1	CTD-2027I19.2	3.31	0.000954	0.0418	0.17	0.1	Response to taxane treatment (placlitaxel);	chr19:24048114	chr19:24162370~24163425:-
BRCA	cis	rs9828082	0.961	rs996000	ENSG00000228956.7	SATB1-AS1	3.31	0.000954	0.0418	0.11	0.1	Neuroticism;	chr3:18576135	chr3:18445024~18920401:+
BRCA	cis	rs1355223	0.902	rs7129089	ENSG00000271369.1	RP11-350D17.3	-3.31	0.000954	0.0418	-0.12	-0.1	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34678152	chr11:34709600~34710161:+
BRCA	cis	rs6593122	0.628	rs1524410	ENSG00000235454.1	HAUS6P3	-3.31	0.000954	0.0418	-0.13	-0.1	Vaccine-related adverse events;	chr7:54119160	chr7:53862233~53863339:+
BRCA	cis	rs347685	0.626	rs12636926	ENSG00000233597.3	RP11-343B5.1	-3.31	0.000954	0.0418	-0.13	-0.1	Glomerular filtration rate in non diabetics (creatinine);Chronic kidney disease;	chr3:141941900	chr3:142043623~142044198:-
BRCA	cis	rs1003719	0.788	rs4817843	ENSG00000242553.1	AP001432.14	-3.31	0.000954	0.0418	-0.11	-0.1	Eye color traits;	chr21:37074740	chr21:37221419~37237744:+
BRCA	cis	rs1003719	0.788	rs4817845	ENSG00000242553.1	AP001432.14	-3.31	0.000954	0.0418	-0.11	-0.1	Eye color traits;	chr21:37074832	chr21:37221419~37237744:+
BRCA	cis	rs1008375	0.966	rs12503540	ENSG00000249502.1	AC006160.5	3.31	0.000954	0.0418	0.12	0.1	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17697158	chr4:17587467~17614571:-
BRCA	cis	rs7520050	0.966	rs1085243	ENSG00000234329.1	RP11-767N6.2	-3.31	0.000954	0.0418	-0.1	-0.1	Reticulocyte count;Red blood cell count;	chr1:46079096	chr1:45651039~45651826:-
BRCA	cis	rs8056446	0.71	rs8059793	ENSG00000260816.2	RP11-319G9.3	-3.31	0.000954	0.0418	-0.12	-0.1	Pulmonary function (smoking interaction);	chr16:78155401	chr16:78895361~78899644:+
BRCA	cis	rs72928364	0.929	rs62275197	ENSG00000244119.1	PDCL3P4	3.31	0.000954	0.0418	0.13	0.1	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100964303	chr3:101712472~101713191:+
BRCA	cis	rs4713118	0.621	rs9368548	ENSG00000226314.6	ZNF192P1	-3.31	0.000954	0.0418	-0.16	-0.1	Parkinson's disease;	chr6:28066959	chr6:28161781~28169594:+
BRCA	cis	rs1790761	0.52	rs12805884	ENSG00000273819.1	ENPP7P7	-3.31	0.000954	0.0418	-0.13	-0.1	Mean corpuscular volume;	chr11:67620506	chr11:67812557~67873367:-
BRCA	cis	rs2868985	1	rs7564878	ENSG00000203327.2	AC012358.7	-3.31	0.000954	0.0418	-0.13	-0.1	Schizophrenia;	chr2:55970141	chr2:55214387~55216126:-
BRCA	cis	rs7487075	0.619	rs2408498	ENSG00000257261.4	RP11-96H19.1	3.31	0.000954	0.0418	0.11	0.1	Itch intensity from mosquito bite;	chr12:46403117	chr12:46383679~46876159:+
BRCA	cis	rs6487679	0.526	rs7305336	ENSG00000256427.1	RP11-118B22.4	3.31	0.000955	0.0418	0.11	0.1	Non-alcoholic fatty liver disease histology (AST);	chr12:9222493	chr12:9246497~9257960:+
BRCA	cis	rs4499344	0.696	rs2868153	ENSG00000201388.1	SNORA68	3.31	0.000955	0.0418	0.12	0.1	Mean platelet volume;	chr19:32608371	chr19:32608337~32608469:-
BRCA	cis	rs7267979	0.966	rs2261790	ENSG00000204556.4	CTD-2514C3.1	-3.31	0.000955	0.0418	-0.14	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25282153	chr20:26018832~26020684:+
BRCA	cis	rs7267979	0.966	rs2261794	ENSG00000204556.4	CTD-2514C3.1	-3.31	0.000955	0.0418	-0.14	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25282426	chr20:26018832~26020684:+
BRCA	cis	rs7267979	0.966	rs2145126	ENSG00000204556.4	CTD-2514C3.1	-3.31	0.000955	0.0418	-0.14	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25283012	chr20:26018832~26020684:+
BRCA	cis	rs7267979	0.966	rs2257705	ENSG00000204556.4	CTD-2514C3.1	-3.31	0.000955	0.0418	-0.14	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25284028	chr20:26018832~26020684:+
BRCA	cis	rs7267979	0.966	rs2227892	ENSG00000204556.4	CTD-2514C3.1	-3.31	0.000955	0.0418	-0.14	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25284178	chr20:26018832~26020684:+
BRCA	cis	rs7267979	0.966	rs2257712	ENSG00000204556.4	CTD-2514C3.1	-3.31	0.000955	0.0418	-0.14	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25284274	chr20:26018832~26020684:+
BRCA	cis	rs7267979	0.966	rs2257461	ENSG00000204556.4	CTD-2514C3.1	-3.31	0.000955	0.0418	-0.14	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25284918	chr20:26018832~26020684:+
BRCA	cis	rs77686669	1	rs77686669	ENSG00000235713.1	RP4-604G5.3	-3.31	0.000955	0.0418	-0.12	-0.1	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr7:100146949	chr7:99992397~99993050:+
BRCA	cis	rs7781266	0.847	rs2971970	ENSG00000226205.1	AC007790.4	-3.31	0.000955	0.0418	-0.15	-0.1	Educational attainment (college completion);	chr7:133959025	chr7:133732493~133733595:-
BRCA	cis	rs12949688	1	rs7212186	ENSG00000262623.1	RP5-1107A17.2	-3.31	0.000955	0.0418	-0.11	-0.1	Schizophrenia;	chr17:57741093	chr17:56951664~56952404:+
BRCA	cis	rs7914558	1	rs10883837	ENSG00000213277.3	MARCKSL1P1	3.31	0.000955	0.0418	0.11	0.1	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103136729	chr10:103175554~103176094:+
BRCA	cis	rs7914558	0.966	rs746293	ENSG00000213277.3	MARCKSL1P1	3.31	0.000955	0.0418	0.11	0.1	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103137497	chr10:103175554~103176094:+
BRCA	cis	rs930395	0.514	rs9791056	ENSG00000272335.1	RP11-53O19.3	-3.31	0.000955	0.0418	-0.1	-0.1	Breast cancer;	chr5:44903789	chr5:44826076~44828592:+
BRCA	cis	rs7598759	0.679	rs6437018	ENSG00000223198.1	RNU2-22P	-3.31	0.000955	0.0418	-0.12	-0.1	Noise-induced hearing loss;	chr2:231462980	chr2:231501990~231502201:-
BRCA	cis	rs7598759	0.679	rs6437019	ENSG00000223198.1	RNU2-22P	-3.31	0.000955	0.0418	-0.12	-0.1	Noise-induced hearing loss;	chr2:231462996	chr2:231501990~231502201:-
BRCA	cis	rs2898279	0.614	rs7007712	ENSG00000255354.1	RP11-148O21.2	3.31	0.000955	0.0418	0.09	0.1	Small cell lung carcinoma;	chr8:11433293	chr8:11558466~11560020:-
BRCA	cis	rs7800418	0.612	rs17286397	ENSG00000280255.1	RP5-1007F24.1	-3.31	0.000955	0.0418	-0.13	-0.1	Cognitive function;	chr7:26586594	chr7:26538378~26541048:+
BRCA	cis	rs28489187	0.73	rs12140103	ENSG00000223653.4	RP11-131L23.1	3.31	0.000955	0.0418	0.11	0.1	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85383806	chr1:85276715~85448124:+
BRCA	cis	rs7520050	0.966	rs6669522	ENSG00000281133.1	AL355480.3	3.31	0.000955	0.0418	0.12	0.1	Reticulocyte count;Red blood cell count;	chr1:45932269	chr1:45580892~45580996:-
BRCA	cis	rs7259376	0.837	rs1368476	ENSG00000269345.1	VN1R85P	-3.31	0.000955	0.0418	-0.12	-0.1	Menopause (age at onset);	chr19:22403390	chr19:22174766~22175191:-
BRCA	cis	rs801193	0.636	rs10233806	ENSG00000229886.1	RP5-1132H15.3	-3.31	0.000955	0.0418	-0.11	-0.1	Aortic root size;	chr7:66653261	chr7:66025126~66031544:-
BRCA	cis	rs8054556	1	rs11150580	ENSG00000214725.6	CDIPT-AS1	-3.31	0.000955	0.0418	-0.13	-0.1	Autism spectrum disorder or schizophrenia;	chr16:30003243	chr16:29863593~29868053:+
BRCA	cis	rs4415084	1	rs10805686	ENSG00000248464.1	FGF10-AS1	3.31	0.000955	0.0418	0.12	0.1	Breast cancer;	chr5:44662026	chr5:44388732~44413989:+
BRCA	cis	rs4718428	0.96	rs6460317	ENSG00000106610.13	STAG3L4	3.31	0.000955	0.0418	0.14	0.1	Corneal structure;	chr7:66925268	chr7:67302621~67321526:+
BRCA	cis	rs875971	0.767	rs12668005	ENSG00000265600.1	AC006480.1	-3.31	0.000956	0.0418	-0.12	-0.1	Aortic root size;	chr7:66444034	chr7:67356680~67356779:+
BRCA	cis	rs7037266	0.892	rs4740863	ENSG00000232946.1	RP11-390F4.2	-3.31	0.000956	0.0418	-0.13	-0.1	Menarche (age at onset);	chr9:6944404	chr9:6675284~6675614:+
BRCA	cis	rs4713118	0.619	rs200486	ENSG00000216676.2	RP1-15D7.1	-3.31	0.000956	0.0418	-0.14	-0.1	Parkinson's disease;	chr6:27811728	chr6:27652602~27652825:-
BRCA	cis	rs8073060	0.586	rs2523116	ENSG00000267554.1	RP11-686D22.10	-3.31	0.000956	0.0418	-0.11	-0.1	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35698441	chr17:35470069~35470628:-
BRCA	cis	rs9457247	0.765	rs10484531	ENSG00000272549.1	RP11-351J23.2	-3.31	0.000956	0.0418	-0.1	-0.1	Crohn's disease;	chr6:167040946	chr6:167666840~167679270:-
BRCA	cis	rs12234571	1	rs4729710	ENSG00000214293.7	APTR	3.31	0.000956	0.0418	0.21	0.1	Obesity-related traits;	chr7:77764422	chr7:77657660~77696265:-
BRCA	cis	rs860295	0.702	rs10908465	ENSG00000203761.5	MSTO2P	-3.31	0.000956	0.0418	-0.09	-0.1	Body mass index;	chr1:155419897	chr1:155745829~155750137:+
BRCA	cis	rs2842483	0.89	rs2260502	ENSG00000234618.1	RPSAP9	3.31	0.000956	0.0418	0.14	0.1	Multiple sclerosis (age of onset);	chr9:76290283	chr9:76398699~76399586:+
BRCA	cis	rs3735485	0.738	rs10266586	ENSG00000201772.1	SNORA5C	3.31	0.000956	0.0418	0.13	0.1	White blood cell count;Sum basophil neutrophil counts;Neutrophil count;Granulocyte percentage of myeloid white cells;Monocyte percentage of white cells;Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Lymphocyte counts;	chr7:45058726	chr7:45104906~45105042:-
BRCA	cis	rs9388451	0.839	rs3799709	ENSG00000237742.5	RP11-624M8.1	-3.31	0.000956	0.0418	-0.13	-0.1	Brugada syndrome;	chr6:125757215	chr6:125578558~125749190:-
BRCA	cis	rs4141153	0.528	rs62450316	ENSG00000213721.3	HMGN2P30	3.31	0.000956	0.0418	0.17	0.1	Menarche (age at onset);	chr7:41453208	chr7:42113365~42113620:+
BRCA	cis	rs9547692	1	rs493248	ENSG00000236711.2	SMAD9-IT1	-3.31	0.000956	0.0418	-0.12	-0.1	Coronary artery disease;	chr13:36899249	chr13:36849366~36850046:-
BRCA	cis	rs4374383	0.884	rs11683409	ENSG00000243389.1	AC012442.5	-3.31	0.000956	0.0418	-0.13	-0.1	Hepatitis C induced liver fibrosis;	chr2:112012557	chr2:112589040~112614431:+
BRCA	cis	rs911555	0.755	rs7148567	ENSG00000269910.1	RP11-73M18.10	3.31	0.000956	0.0418	0.1	0.1	Intelligence (multi-trait analysis);	chr14:103415897	chr14:103694516~103695050:-
BRCA	cis	rs911555	0.755	rs10144051	ENSG00000269910.1	RP11-73M18.10	3.31	0.000956	0.0418	0.1	0.1	Intelligence (multi-trait analysis);	chr14:103419594	chr14:103694516~103695050:-
BRCA	cis	rs2646428	0.883	rs2646434	ENSG00000233990.1	RP11-401E9.3	-3.31	0.000956	0.0418	-0.13	-0.1	Tuberculosis;	chr10:8525710	chr10:7833618~7833957:-
BRCA	cis	rs34421088	0.532	rs1545073	ENSG00000248896.2	CTD-2135J3.3	3.31	0.000956	0.0418	0.13	0.1	Neuroticism;	chr8:11310191	chr8:10729314~10771392:+
BRCA	cis	rs11229030	0.893	rs2581925	ENSG00000265566.2	RN7SL605P	-3.31	0.000956	0.0418	-0.13	-0.1	Crohn's disease;	chr11:57439941	chr11:57528085~57528365:-
BRCA	cis	rs875971	0.862	rs2024192	ENSG00000223473.2	GS1-124K5.3	-3.31	0.000956	0.0418	-0.08	-0.1	Aortic root size;	chr7:66576460	chr7:66491049~66493566:-
BRCA	cis	rs7957470	0.517	rs7957463	ENSG00000275409.1	RP11-131L12.4	3.31	0.000956	0.0418	0.11	0.1	Obesity-related traits;	chr12:118080501	chr12:118430147~118430699:+
BRCA	cis	rs7182946	1	rs4779820	ENSG00000259772.5	RP11-16E12.2	-3.31	0.000956	0.0418	-0.09	-0.1	Advanced age-related macular degeneration;	chr15:31102607	chr15:31221999~31230838:-
BRCA	cis	rs875971	0.522	rs1617484	ENSG00000227113.2	RP11-460N20.4	3.31	0.000956	0.0418	0.11	0.1	Aortic root size;	chr7:65998108	chr7:65075023~65078780:+
BRCA	cis	rs944990	0.765	rs10821160	ENSG00000227603.1	RP11-165J3.6	3.31	0.000956	0.0419	0.12	0.1	Body mass index;	chr9:93563845	chr9:93435332~93437121:-
BRCA	cis	rs6121246	0.559	rs12479491	ENSG00000230613.1	HM13-AS1	3.31	0.000956	0.0419	0.14	0.1	Mean corpuscular hemoglobin;	chr20:31677647	chr20:31567707~31573263:-
BRCA	cis	rs2832077	0.943	rs4816332	ENSG00000236056.1	GAPDHP14	3.31	0.000956	0.0419	0.15	0.1	Cognitive test performance;	chr21:28829384	chr21:29222321~29223257:+
BRCA	cis	rs2832077	0.824	rs4816333	ENSG00000236056.1	GAPDHP14	3.31	0.000956	0.0419	0.15	0.1	Cognitive test performance;	chr21:28829455	chr21:29222321~29223257:+
BRCA	cis	rs2120991	0.818	rs7139337	ENSG00000250742.1	RP11-834C11.4	3.31	0.000957	0.0419	0.12	0.1	Biliary atresia;	chr12:53900811	chr12:54126098~54132843:+
BRCA	cis	rs13315871	0.929	rs1554124	ENSG00000272182.1	RP11-802O23.3	3.31	0.000957	0.0419	0.18	0.1	Cholesterol, total;	chr3:58283241	chr3:58428255~58428815:+
BRCA	cis	rs13126694	0.744	rs11100148	ENSG00000251073.1	NUDT19P5	3.31	0.000957	0.0419	0.1	0.1	Blood osmolality (transformed sodium);	chr4:158074688	chr4:158182825~158183393:+
BRCA	cis	rs17837474	0.656	rs17273	ENSG00000211746.3	TRBV19	3.31	0.000957	0.0419	0.1	0.1	Cancer;	chr7:142407435	chr7:142618849~142619532:+
BRCA	cis	rs2899832	0.568	rs118127067	ENSG00000258704.4	SRP54-AS1	3.31	0.000957	0.0419	0.25	0.1	Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:35303911	chr14:34920858~34982532:-
BRCA	cis	rs561341	1	rs542132	ENSG00000277511.1	CTD-2095E4.5	3.31	0.000957	0.0419	0.15	0.1	Hip circumference adjusted for BMI;	chr17:31980174	chr17:32127595~32128454:+
BRCA	cis	rs1510510	0.867	rs7576590	ENSG00000229915.1	AC016999.2	3.31	0.000957	0.0419	0.17	0.1	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr2:238602145	chr2:238427077~238427729:-
BRCA	cis	rs6088580	0.608	rs8114616	ENSG00000269202.1	RP4-614O4.12	3.31	0.000957	0.0419	0.1	0.1	Glomerular filtration rate (creatinine);	chr20:34381286	chr20:35201747~35203288:-
BRCA	cis	rs2985684	0.894	rs8005990	ENSG00000278009.1	RP11-649E7.8	3.31	0.000957	0.0419	0.14	0.1	Carotid intima media thickness;	chr14:49555530	chr14:49601011~49601124:-
BRCA	cis	rs6763768	0.606	rs6798771	ENSG00000274967.1	Y_RNA	-3.31	0.000957	0.0419	-0.12	-0.1	Bacterial meningitis;	chr3:53278899	chr3:53290640~53290751:+
BRCA	cis	rs13118159	0.934	rs4974608	ENSG00000254094.1	AC078852.1	-3.31	0.000957	0.0419	-0.11	-0.1	Longevity;	chr4:1362992	chr4:1356581~1358075:+
BRCA	cis	rs5758511	0.773	rs12167978	ENSG00000231261.1	HMGN2P10	-3.31	0.000957	0.0419	-0.14	-0.1	Birth weight;	chr22:41950471	chr22:41709225~41709489:-
BRCA	cis	rs7037266	0.853	rs3818893	ENSG00000232946.1	RP11-390F4.2	-3.31	0.000957	0.0419	-0.13	-0.1	Menarche (age at onset);	chr9:6942089	chr9:6675284~6675614:+
BRCA	cis	rs7781266	0.79	rs11772553	ENSG00000226205.1	AC007790.4	3.31	0.000957	0.0419	0.15	0.1	Educational attainment (college completion);	chr7:133438450	chr7:133732493~133733595:-
BRCA	cis	rs2360027	0.599	rs1575616	ENSG00000231365.4	RP11-418J17.1	-3.31	0.000957	0.0419	-0.13	-0.1	Tonsillectomy;	chr1:118542689	chr1:119140396~119275973:+
BRCA	cis	rs2360027	0.599	rs2102337	ENSG00000231365.4	RP11-418J17.1	-3.31	0.000957	0.0419	-0.13	-0.1	Tonsillectomy;	chr1:118543266	chr1:119140396~119275973:+
BRCA	cis	rs1348850	0.872	rs2084233	ENSG00000271825.1	RP11-337N6.2	3.31	0.000957	0.0419	0.13	0.1	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177466478	chr2:177300600~177302006:+
BRCA	cis	rs1549733	0.559	rs4674193	ENSG00000229754.1	CXCR2P1	-3.31	0.000957	0.0419	-0.13	-0.1	Optic disc area;	chr2:217579638	chr2:218059155~218065729:-
BRCA	cis	rs11700980	0.636	rs118001912	ENSG00000232855.5	AF131217.1	3.31	0.000957	0.0419	0.19	0.1	QRS complex (12-leadsum);	chr21:28838637	chr21:28439346~28674848:-
BRCA	cis	rs12893668	0.572	rs4906350	ENSG00000258914.1	CTD-2134A5.3	3.31	0.000957	0.0419	0.14	0.1	Reticulocyte count;	chr14:103645457	chr14:103875055~103877478:+
BRCA	cis	rs17221829	0.965	rs1967075	ENSG00000280385.1	AP000648.5	-3.31	0.000957	0.0419	-0.11	-0.1	Anxiety in major depressive disorder;	chr11:89714088	chr11:90193614~90198120:+
BRCA	cis	rs875971	0.862	rs6962717	ENSG00000223473.2	GS1-124K5.3	3.31	0.000957	0.0419	0.08	0.1	Aortic root size;	chr7:66418748	chr7:66491049~66493566:-
BRCA	cis	rs4635383	0.571	rs4794381	ENSG00000262902.1	RP11-750B16.1	3.31	0.000957	0.0419	0.11	0.1	Body fat mass;	chr17:52730321	chr17:53105734~53106358:+
BRCA	cis	rs3751972	0.668	rs4796228	ENSG00000267644.1	CTD-2008P7.10	3.31	0.000957	0.0419	0.13	0.1	Fractional exhaled nitric oxide (childhood);	chr17:27895784	chr17:28219285~28220005:+
BRCA	cis	rs7267979	1	rs2257420	ENSG00000204556.4	CTD-2514C3.1	-3.31	0.000957	0.0419	-0.14	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25295254	chr20:26018832~26020684:+
BRCA	cis	rs4481887	0.676	rs1538704	ENSG00000235749.2	RP11-634B7.4	-3.31	0.000958	0.0419	-0.11	-0.1	Common traits (Other);	chr1:248360252	chr1:247639749~247747062:+
BRCA	cis	rs2638953	0.853	rs11049668	ENSG00000273989.1	RP11-425D17.2	-3.31	0.000958	0.0419	-0.15	-0.1	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28497680	chr12:28236227~28236828:+
BRCA	cis	rs35520189	0.591	rs34027384	ENSG00000231747.1	AC079922.2	-3.31	0.000958	0.0419	-0.11	-0.1	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:112940517	chr2:112621809~112622167:-
BRCA	cis	rs11158345	0.929	rs11621346	ENSG00000258670.1	RP11-1042B17.3	3.31	0.000958	0.0419	0.13	0.1	Word reading;	chr14:61426473	chr14:60515119~60554916:+
BRCA	cis	rs2688608	0.592	rs11000757	ENSG00000242288.9	RP11-464F9.1	3.31	0.000958	0.0419	0.13	0.1	Inflammatory bowel disease;	chr10:73727057	chr10:73674295~73730466:-
BRCA	cis	rs6142618	0.562	rs6141646	ENSG00000224452.1	RSL24D1P6	3.31	0.000958	0.0419	0.14	0.1	Inflammatory bowel disease;	chr20:32244052	chr20:32170390~32170790:-
BRCA	cis	rs8023401	0.938	rs16961046	ENSG00000274654.1	CTD-3247H4.2	3.31	0.000958	0.0419	0.15	0.1	Spherical equivalent (joint analysis main effects and education interaction);	chr15:48506511	chr15:48528980~48529728:-
BRCA	cis	rs6445967	1	rs7622074	ENSG00000272360.1	RP11-359I18.5	3.31	0.000958	0.0419	0.11	0.1	Platelet count;	chr3:58326570	chr3:58490830~58491291:-
BRCA	cis	rs6684709	0.638	rs2038027	ENSG00000271420.1	RP5-1057J7.7	-3.31	0.000958	0.0419	-0.1	-0.1	White blood cell count;	chr1:23521550	chr1:23378380~23379029:-
BRCA	cis	rs875971	1	rs2420168	ENSG00000230189.5	GS1-124K5.2	-3.31	0.000958	0.0419	-0.08	-0.1	Aortic root size;	chr7:66165644	chr7:66409143~66490059:-
BRCA	cis	rs2731664	0.792	rs335434	ENSG00000248996.1	RP11-1334A24.6	3.31	0.000958	0.0419	0.1	0.1	Intelligence (multi-trait analysis);	chr5:177440275	chr5:177494995~177503647:+
BRCA	cis	rs9847710	1	rs12488768	ENSG00000242849.2	ALDOAP1	-3.31	0.000958	0.0419	-0.12	-0.1	Ulcerative colitis;	chr3:53052218	chr3:52193170~52194785:+
BRCA	cis	rs3739034	0.938	rs10164986	ENSG00000224043.6	CCNT2-AS1	-3.31	0.000958	0.0419	-0.16	-0.1	Gut microbiome composition (winter);	chr2:134710815	chr2:134735464~134918710:-
BRCA	cis	rs2306786	0.558	rs79136389	ENSG00000259732.1	RP11-59H7.3	-3.31	0.000958	0.0419	-0.25	-0.1	Metabolite levels;	chr15:59202952	chr15:59121034~59133250:+
BRCA	cis	rs17796831	0.965	rs10498586	ENSG00000205562.2	RP11-497E19.1	3.31	0.000958	0.0419	0.12	0.1	Lobe attachment (rater-scored or self-reported);	chr14:85343269	chr14:85524432~85529988:-
BRCA	cis	rs77741769	0.571	rs3897746	ENSG00000277423.1	RP11-173P15.9	-3.31	0.000958	0.0419	-0.12	-0.1	Mean corpuscular volume;	chr12:120886924	chr12:120703867~120704282:+
BRCA	cis	rs12216545	0.765	rs12538773	ENSG00000244151.1	RP11-148K1.12	-3.31	0.000958	0.0419	-0.09	-0.1	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150552967	chr7:151074742~151076530:-
BRCA	cis	rs4934494	0.727	rs12572012	ENSG00000232229.4	LINC00865	-3.31	0.000958	0.0419	-0.16	-0.1	Red blood cell count;	chr10:89727892	chr10:89829510~89840861:+
BRCA	cis	rs4934494	0.727	rs3758388	ENSG00000232229.4	LINC00865	-3.31	0.000958	0.0419	-0.16	-0.1	Red blood cell count;	chr10:89729222	chr10:89829510~89840861:+
BRCA	cis	rs4934494	0.727	rs12783582	ENSG00000232229.4	LINC00865	-3.31	0.000958	0.0419	-0.16	-0.1	Red blood cell count;	chr10:89735210	chr10:89829510~89840861:+
BRCA	cis	rs1878931	0.501	rs17136359	ENSG00000279568.1	RP11-20I23.5	-3.31	0.000958	0.0419	-0.1	-0.1	Body mass index (adult);	chr16:3370814	chr16:2575628~2577373:-
BRCA	cis	rs2254135	0.79	rs2243430	ENSG00000280222.1	RP11-174G17.3	-3.31	0.000958	0.0419	-0.12	-0.1	Response to hepatitis C treatment;	chr1:17516673	chr1:18109389~18115861:+
BRCA	cis	rs55882075	0.723	rs56227602	ENSG00000250999.1	RP11-1379J22.5	-3.31	0.000958	0.0419	-0.12	-0.1	Monocyte percentage of white cells;	chr5:179752471	chr5:179657762~179664432:+
BRCA	cis	rs375066	0.868	rs368079	ENSG00000278917.1	RP11-15A1.4	-3.31	0.000958	0.0419	-0.12	-0.1	Breast cancer;	chr19:43889204	chr19:43891233~43895411:+
BRCA	cis	rs6772849	0.93	rs6768344	ENSG00000207088.1	SNORA7B	-3.31	0.000959	0.0419	-0.13	-0.1	Monocyte percentage of white cells;Monocyte count;	chr3:128654713	chr3:129397210~129397348:-
BRCA	cis	rs860295	0.58	rs66466805	ENSG00000225855.5	RUSC1-AS1	3.31	0.000959	0.0419	0.09	0.1	Body mass index;	chr1:155918875	chr1:155316863~155324176:-
BRCA	cis	rs10129255	0.957	rs10132367	ENSG00000211959.2	IGHV4-39	3.31	0.000959	0.0419	0.08	0.1	Kawasaki disease;	chr14:106690981	chr14:106421711~106422218:-
BRCA	cis	rs2904967	0.929	rs482842	ENSG00000254501.1	AP003068.9	3.31	0.000959	0.0419	0.18	0.1	Mean corpuscular volume;	chr11:65277807	chr11:65110714~65111695:-
BRCA	cis	rs1003719	0.715	rs2835659	ENSG00000242553.1	AP001432.14	3.31	0.000959	0.0419	0.12	0.1	Eye color traits;	chr21:37195601	chr21:37221419~37237744:+
BRCA	cis	rs1003719	0.715	rs7280251	ENSG00000242553.1	AP001432.14	3.31	0.000959	0.0419	0.12	0.1	Eye color traits;	chr21:37195610	chr21:37221419~37237744:+
BRCA	cis	rs1003719	0.715	rs6579	ENSG00000242553.1	AP001432.14	3.31	0.000959	0.0419	0.12	0.1	Eye color traits;	chr21:37196007	chr21:37221419~37237744:+
BRCA	cis	rs12344583	0.673	rs3819500	ENSG00000221676.1	RNU6ATAC	3.31	0.000959	0.0419	0.17	0.1	vWF and FVIII levels;	chr9:133855677	chr9:134164439~134164564:-
BRCA	cis	rs7017914	0.967	rs34042354	ENSG00000246366.5	RP11-382J12.1	3.31	0.000959	0.0419	0.11	0.1	Bone mineral density;	chr8:70818726	chr8:70608577~70663279:+
BRCA	cis	rs7017914	0.967	rs13261712	ENSG00000246366.5	RP11-382J12.1	3.31	0.000959	0.0419	0.11	0.1	Bone mineral density;	chr8:70820029	chr8:70608577~70663279:+
BRCA	cis	rs7017914	0.934	rs13274062	ENSG00000246366.5	RP11-382J12.1	3.31	0.000959	0.0419	0.11	0.1	Bone mineral density;	chr8:70824852	chr8:70608577~70663279:+
BRCA	cis	rs2243480	1	rs35432774	ENSG00000234585.5	CCT6P3	-3.31	0.000959	0.0419	-0.15	-0.1	Diabetic kidney disease;	chr7:65928032	chr7:65038354~65074713:+
BRCA	cis	rs10057188	0.545	rs10069173	ENSG00000245556.2	SCAMP1-AS1	3.31	0.000959	0.0419	0.11	0.1	Pulse pressure;	chr5:78633200	chr5:78342365~78360507:-
BRCA	cis	rs875971	0.964	rs6945019	ENSG00000273024.4	INTS4P2	-3.31	0.000959	0.0419	-0.11	-0.1	Aortic root size;	chr7:66457471	chr7:65647864~65715661:+
BRCA	cis	rs2908197	0.737	rs59755579	ENSG00000205485.12	AC004980.7	3.31	0.000959	0.0419	0.11	0.1	3-hydroxypropylmercapturic acid levels in smokers;	chr7:76363127	chr7:76549360~76627982:+
BRCA	cis	rs2400362	0.838	rs4739609	ENSG00000254162.1	RP11-48B3.3	-3.31	0.000959	0.0419	-0.12	-0.1	Glucocorticoid-induced osteonecrosis (age 10 years and older);	chr8:80958987	chr8:80535006~80539135:-
BRCA	cis	rs4074961	0.527	rs10908355	ENSG00000233621.1	LINC01137	-3.31	0.000959	0.0419	-0.11	-0.1	Axial length;	chr1:37569685	chr1:37454879~37474411:-
BRCA	cis	rs962856	0.521	rs6749629	ENSG00000236780.4	AC078941.1	3.31	0.000959	0.0419	0.15	0.1	Pancreatic cancer;	chr2:67412414	chr2:67123357~67215319:-
BRCA	cis	rs12893668	0.572	rs34000399	ENSG00000258914.1	CTD-2134A5.3	3.31	0.000959	0.0419	0.14	0.1	Reticulocyte count;	chr14:103635080	chr14:103875055~103877478:+
BRCA	cis	rs13393800	1	rs7571716	ENSG00000237126.7	AC073254.1	3.31	0.000959	0.0419	0.14	0.1	Height;	chr2:232576710	chr2:232580948~232611971:-
BRCA	cis	rs17486696	0.51	rs17678924	ENSG00000121089.4	NACA3P	-3.31	0.000959	0.0419	-0.25	-0.1	Positive affect;	chr4:164770667	chr4:164943290~164943937:+
BRCA	cis	rs564309	0.764	rs12096217	ENSG00000212237.1	RNA5SP18	3.31	0.000959	0.0419	0.22	0.1	Hip circumference (psychosocial stress interaction);	chr1:228346751	chr1:228647912~228648032:-
BRCA	cis	rs875971	0.862	rs13232191	ENSG00000223473.2	GS1-124K5.3	3.31	0.000959	0.0419	0.08	0.1	Aortic root size;	chr7:66521661	chr7:66491049~66493566:-
BRCA	cis	rs875971	0.862	rs10950043	ENSG00000223473.2	GS1-124K5.3	3.31	0.000959	0.0419	0.08	0.1	Aortic root size;	chr7:66523623	chr7:66491049~66493566:-
BRCA	cis	rs875971	0.862	rs17747530	ENSG00000223473.2	GS1-124K5.3	3.31	0.000959	0.0419	0.08	0.1	Aortic root size;	chr7:66529742	chr7:66491049~66493566:-
BRCA	cis	rs875971	0.862	rs13536	ENSG00000223473.2	GS1-124K5.3	-3.31	0.000959	0.0419	-0.08	-0.1	Aortic root size;	chr7:66554203	chr7:66491049~66493566:-
BRCA	cis	rs875971	0.862	rs801209	ENSG00000223473.2	GS1-124K5.3	-3.31	0.000959	0.0419	-0.08	-0.1	Aortic root size;	chr7:66554403	chr7:66491049~66493566:-
BRCA	cis	rs875971	0.862	rs801206	ENSG00000223473.2	GS1-124K5.3	-3.31	0.000959	0.0419	-0.08	-0.1	Aortic root size;	chr7:66556979	chr7:66491049~66493566:-
BRCA	cis	rs875971	0.862	rs801204	ENSG00000223473.2	GS1-124K5.3	-3.31	0.000959	0.0419	-0.08	-0.1	Aortic root size;	chr7:66557934	chr7:66491049~66493566:-
BRCA	cis	rs875971	0.862	rs801203	ENSG00000223473.2	GS1-124K5.3	-3.31	0.000959	0.0419	-0.08	-0.1	Aortic root size;	chr7:66558025	chr7:66491049~66493566:-
BRCA	cis	rs6728642	0.808	rs114192053	ENSG00000279791.1	RP11-499E14.1	-3.31	0.000959	0.0419	-0.22	-0.1	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:97206169	chr2:97094935~97097433:+
BRCA	cis	rs9990333	1	rs9990333	ENSG00000252620.1	RNU6ATAC24P	-3.31	0.000959	0.0419	-0.1	-0.1	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196100334	chr3:195523087~195523221:-
BRCA	cis	rs6044112	0.607	rs6044083	ENSG00000273998.1	RP4-777L9.2	3.31	0.000959	0.0419	0.16	0.1	Response to taxane treatment (docetaxel);	chr20:16534666	chr20:16576068~16579615:+
BRCA	cis	rs6946131	0.593	rs2709307	ENSG00000235207.1	TUBBP6	-3.31	0.000959	0.042	-0.12	-0.1	Systemic lupus erythematosus;	chr7:54779631	chr7:55645620~55646951:+
BRCA	cis	rs7267979	1	rs11100	ENSG00000204556.4	CTD-2514C3.1	-3.31	0.00096	0.042	-0.14	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25300548	chr20:26018832~26020684:+
BRCA	cis	rs7267979	1	rs1046073	ENSG00000204556.4	CTD-2514C3.1	-3.31	0.00096	0.042	-0.14	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25300697	chr20:26018832~26020684:+
BRCA	cis	rs7267979	1	rs2259926	ENSG00000204556.4	CTD-2514C3.1	-3.31	0.00096	0.042	-0.14	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25301097	chr20:26018832~26020684:+
BRCA	cis	rs7267979	1	rs2259928	ENSG00000204556.4	CTD-2514C3.1	-3.31	0.00096	0.042	-0.14	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25301198	chr20:26018832~26020684:+
BRCA	cis	rs7267979	1	rs2259956	ENSG00000204556.4	CTD-2514C3.1	-3.31	0.00096	0.042	-0.14	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25301797	chr20:26018832~26020684:+
BRCA	cis	rs997295	0.57	rs72747462	ENSG00000260657.2	RP11-315D16.4	3.31	0.00096	0.042	0.13	0.1	Motion sickness;	chr15:67526200	chr15:68267792~68277994:-
BRCA	cis	rs1411478	1	rs12744212	ENSG00000243155.1	RP11-46A10.5	3.31	0.00096	0.042	0.11	0.1	Menopause (age at onset);Progressive supranuclear palsy;	chr1:180983380	chr1:180944042~180976482:-
BRCA	cis	rs6142618	0.523	rs2377473	ENSG00000224452.1	RSL24D1P6	3.31	0.00096	0.042	0.14	0.1	Inflammatory bowel disease;	chr20:32262445	chr20:32170390~32170790:-
BRCA	cis	rs6517329	0.649	rs7282480	ENSG00000231106.2	LINC01436	3.31	0.00096	0.042	0.12	0.1	Schizophrenia;	chr21:36119262	chr21:36005338~36007838:+
BRCA	cis	rs8114671	0.562	rs2064454	ENSG00000261582.1	RP4-614O4.11	-3.31	0.00096	0.042	-0.1	-0.1	Height;	chr20:34908366	chr20:35267885~35280043:-
BRCA	cis	rs10129255	0.556	rs9324093	ENSG00000211964.3	IGHV3-48	-3.31	0.00096	0.042	-0.07	-0.1	Kawasaki disease;	chr14:106683893	chr14:106537810~106538344:-
BRCA	cis	rs7590720	1	rs7592663	ENSG00000230838.1	AC093850.2	-3.31	0.00096	0.042	-0.09	-0.1	Alcohol dependence;	chr2:216030255	chr2:215718043~215719424:+
BRCA	cis	rs6912958	0.703	rs12207825	ENSG00000272008.1	RP11-393I2.4	-3.31	0.00096	0.042	-0.11	-0.1	Monocyte percentage of white cells;	chr6:87388574	chr6:87151159~87155285:-
BRCA	cis	rs9400180	0.879	rs9386693	ENSG00000271734.1	RP1-111B22.3	3.31	0.00096	0.042	0.13	0.1	Major depressive disorder;	chr6:108022869	chr6:108030249~108030718:-
BRCA	cis	rs1113500	0.636	rs3853493	ENSG00000230489.1	VAV3-AS1	-3.31	0.00096	0.042	-0.12	-0.1	Growth-regulated protein alpha levels;	chr1:108094571	chr1:107964443~107994607:+
BRCA	cis	rs4848143	0.605	rs731004	ENSG00000236859.5	NIFK-AS1	-3.31	0.00096	0.042	-0.11	-0.1	Capecitabine sensitivity;	chr2:121045873	chr2:121649650~121728208:+
BRCA	cis	rs8062405	0.723	rs4788079	ENSG00000261766.1	RP11-22P6.2	-3.31	0.00096	0.042	-0.1	-0.1	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548042	chr16:28862166~28863340:-
BRCA	cis	rs910873	0.505	rs6059961	ENSG00000202150.1	RNU6-407P	3.31	0.000961	0.042	0.15	0.1	Melanoma;	chr20:34643686	chr20:35030317~35030420:-
BRCA	cis	rs1510510	0.809	rs12692233	ENSG00000229915.1	AC016999.2	3.31	0.000961	0.042	0.17	0.1	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr2:238600713	chr2:238427077~238427729:-
BRCA	cis	rs12726943	0.518	rs57540216	ENSG00000229989.3	MIR181A1HG	3.31	0.000961	0.042	0.18	0.1	Perceived unattractiveness to mosquitoes;	chr1:199397999	chr1:198807493~198937429:-
BRCA	cis	rs6449502	0.764	rs12696975	ENSG00000251279.1	CTC-436P18.1	3.31	0.000961	0.042	0.18	0.1	Mean platelet volume;	chr5:60772528	chr5:61162070~61232040:+
BRCA	cis	rs1003719	1	rs2835607	ENSG00000273210.1	AP001437.1	3.31	0.000961	0.042	0.11	0.1	Eye color traits;	chr21:37119673	chr21:37365477~37365932:-
BRCA	cis	rs7781557	1	rs10487281	ENSG00000170409.7	CTA-313A17.2	3.31	0.000961	0.042	0.18	0.1	Colorectal adenoma (advanced);	chr7:102837134	chr7:102327256~102329530:-
BRCA	cis	rs1664789	0.904	rs1694061	ENSG00000272416.1	CTD-2081C10.7	3.31	0.000961	0.042	0.11	0.1	Waist circumference adjusted for body mass index;	chr5:53982342	chr5:53880293~53881051:-
BRCA	cis	rs13420028	0.651	rs4414734	ENSG00000230992.3	FAM201B	-3.31	0.000961	0.042	-0.12	-0.1	Hypertension (SNP x SNP interaction);	chr2:132420408	chr2:132352722~132353318:+
BRCA	cis	rs6866721	0.634	rs1972623	ENSG00000249167.1	CTB-118N6.2	3.31	0.000961	0.042	0.12	0.1	Body mass index;	chr5:116886523	chr5:116574482~116591398:+
BRCA	cis	rs6866721	0.634	rs2545406	ENSG00000249167.1	CTB-118N6.2	3.31	0.000961	0.042	0.12	0.1	Body mass index;	chr5:116886611	chr5:116574482~116591398:+
BRCA	cis	rs6866721	0.634	rs1643883	ENSG00000249167.1	CTB-118N6.2	3.31	0.000961	0.042	0.12	0.1	Body mass index;	chr5:116886660	chr5:116574482~116591398:+
BRCA	cis	rs7781266	0.741	rs62469960	ENSG00000226205.1	AC007790.4	3.31	0.000961	0.042	0.15	0.1	Educational attainment (college completion);	chr7:133456941	chr7:133732493~133733595:-
BRCA	cis	rs2483374	0.557	rs735372	ENSG00000253771.4	TPTE2P1	-3.31	0.000961	0.042	-0.13	-0.1	Obesity-related traits;	chr13:24890500	chr13:24924677~24968487:-
BRCA	cis	rs2638953	0.64	rs11049723	ENSG00000273989.1	RP11-425D17.2	3.31	0.000961	0.042	0.15	0.1	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28575903	chr12:28236227~28236828:+
BRCA	cis	rs2289328	0.825	rs35777573	ENSG00000259390.2	RP11-27M9.1	3.31	0.000961	0.042	0.15	0.1	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr15:40352045	chr15:39512404~39519854:-
BRCA	cis	rs494526	0.641	rs7906373	ENSG00000229272.1	RP11-498J9.2	3.31	0.000962	0.042	0.12	0.1	Alcoholic chronic pancreatitis;	chr10:119114555	chr10:119003536~119003884:-
BRCA	cis	rs7520050	0.966	rs10890361	ENSG00000234329.1	RP11-767N6.2	-3.31	0.000962	0.042	-0.09	-0.1	Reticulocyte count;Red blood cell count;	chr1:45880562	chr1:45651039~45651826:-
BRCA	cis	rs10266483	0.515	rs6948710	ENSG00000271550.1	BNIP3P11	-3.31	0.000962	0.042	-0.15	-0.1	Response to statin therapy;	chr7:64405625	chr7:64678954~64687393:-
BRCA	cis	rs67478160	0.643	rs8004408	ENSG00000269910.1	RP11-73M18.10	3.31	0.000962	0.042	0.1	0.1	Schizophrenia;	chr14:103737601	chr14:103694516~103695050:-
BRCA	cis	rs7914558	0.966	rs12571568	ENSG00000213277.3	MARCKSL1P1	3.31	0.000962	0.042	0.11	0.1	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103131639	chr10:103175554~103176094:+
BRCA	cis	rs7914558	0.966	rs12766205	ENSG00000213277.3	MARCKSL1P1	3.31	0.000962	0.042	0.11	0.1	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103133811	chr10:103175554~103176094:+
BRCA	cis	rs4722585	0.533	rs6964215	ENSG00000273237.1	CTB-119C2.1	-3.31	0.000962	0.042	-0.13	-0.1	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);	chr7:26157199	chr7:26173533~26174945:-
BRCA	cis	rs2204008	0.694	rs10880262	ENSG00000257718.1	RP11-396F22.1	3.31	0.000962	0.042	0.11	0.1	Bladder cancer;	chr12:37934894	chr12:38906451~38909592:+
BRCA	cis	rs11673344	0.583	rs10425719	ENSG00000233527.7	ZNF529-AS1	-3.31	0.000962	0.042	-0.11	-0.1	Obesity-related traits;	chr19:37459896	chr19:36573070~36594708:+
BRCA	cis	rs9783347	1	rs1520884	ENSG00000279837.1	RP11-504G3.2	3.31	0.000962	0.042	0.1	0.1	Pancreatic cancer;	chr11:18288153	chr11:18601882~18602649:+
BRCA	cis	rs3755605	0.664	rs12493997	ENSG00000242578.1	RP11-469J4.3	3.31	0.000962	0.042	0.12	0.1	Testicular germ cell tumor;	chr3:170192077	chr3:170410512~170418615:+
BRCA	cis	rs6918586	0.594	rs198842	ENSG00000272462.2	U91328.19	-3.31	0.000962	0.042	-0.11	-0.1	Schizophrenia;	chr6:26111220	chr6:25992662~26001775:+
BRCA	cis	rs6918586	0.658	rs198840	ENSG00000272462.2	U91328.19	-3.31	0.000962	0.042	-0.11	-0.1	Schizophrenia;	chr6:26111936	chr6:25992662~26001775:+
BRCA	cis	rs1424638	0.559	rs1429323	ENSG00000233251.6	AC007743.1	-3.31	0.000962	0.042	-0.12	-0.1	Intelligence (multi-trait analysis);	chr2:57003975	chr2:56173534~56185770:-
BRCA	cis	rs3105593	1	rs3101852	ENSG00000259618.1	RP11-562A8.5	-3.31	0.000962	0.042	-0.11	-0.1	QT interval;	chr15:50556173	chr15:50494018~50497080:-
BRCA	cis	rs853679	0.517	rs9295761	ENSG00000226314.6	ZNF192P1	-3.31	0.000962	0.042	-0.16	-0.1	Depression;	chr6:28180209	chr6:28161781~28169594:+
BRCA	cis	rs11764590	0.694	rs4721321	ENSG00000230914.2	AC004840.8	3.31	0.000962	0.0421	0.12	0.1	Neuroticism;	chr7:2028835	chr7:2384121~2388597:+
BRCA	cis	rs9788682	0.747	rs2938674	ENSG00000261143.1	ADAMTS7P3	-3.31	0.000962	0.0421	-0.14	-0.1	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78465571	chr15:77976042~77993057:+
BRCA	cis	rs9341808	0.718	rs2322631	ENSG00000279022.1	RP11-250B2.4	3.31	0.000962	0.0421	0.12	0.1	Sitting height ratio;	chr6:80134239	chr6:80440730~80441172:+
BRCA	cis	rs801193	0.569	rs2659893	ENSG00000106610.13	STAG3L4	-3.31	0.000962	0.0421	-0.14	-0.1	Aortic root size;	chr7:66735006	chr7:67302621~67321526:+
BRCA	cis	rs801193	0.569	rs2659892	ENSG00000106610.13	STAG3L4	-3.31	0.000962	0.0421	-0.14	-0.1	Aortic root size;	chr7:66735318	chr7:67302621~67321526:+
BRCA	cis	rs801193	0.569	rs2707847	ENSG00000106610.13	STAG3L4	-3.31	0.000962	0.0421	-0.14	-0.1	Aortic root size;	chr7:66737884	chr7:67302621~67321526:+
BRCA	cis	rs8133974	1	rs73203086	ENSG00000225555.1	AP000320.6	-3.31	0.000962	0.0421	-0.2	-0.1	Sum eosinophil basophil counts;Eosinophil counts;Eosinophil percentage of granulocytes;	chr21:35079926	chr21:34370802~34375348:-
BRCA	cis	rs7914558	1	rs12780843	ENSG00000272912.1	RP11-724N1.1	-3.31	0.000962	0.0421	-0.11	-0.1	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103009578	chr10:102914585~102915404:+
BRCA	cis	rs11887277	0.586	rs35628191	ENSG00000272148.1	RP11-195B17.1	-3.31	0.000962	0.0421	-0.12	-0.1	Obesity-related traits;	chr2:26781386	chr2:27062428~27062907:-
BRCA	cis	rs11098499	0.739	rs6534130	ENSG00000225892.3	RP11-384K6.2	-3.31	0.000962	0.0421	-0.1	-0.1	Corneal astigmatism;	chr4:119210184	chr4:118632274~118634759:+
BRCA	cis	rs9990333	0.562	rs55970879	ENSG00000273009.1	RP11-352G9.1	-3.31	0.000963	0.0421	-0.13	-0.1	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196095095	chr3:195913078~195913683:-
BRCA	cis	rs957448	1	rs2381882	ENSG00000261437.1	RP11-22C11.2	3.31	0.000963	0.0421	0.11	0.1	Nonsyndromic cleft lip with cleft palate;	chr8:94535496	chr8:94637285~94639467:-
BRCA	cis	rs564309	0.867	rs12093491	ENSG00000183929.7	DUSP5P1	3.31	0.000963	0.0421	0.21	0.1	Hip circumference (psychosocial stress interaction);	chr1:228381797	chr1:228650241~228651379:+
BRCA	cis	rs4665809	1	rs6546766	ENSG00000231655.1	AC011742.3	3.31	0.000963	0.0421	0.15	0.1	Gut microbiome composition (summer);	chr2:26105811	chr2:26140263~26141264:-
BRCA	cis	rs4665809	1	rs6546767	ENSG00000231655.1	AC011742.3	3.31	0.000963	0.0421	0.15	0.1	Gut microbiome composition (summer);	chr2:26105877	chr2:26140263~26141264:-
BRCA	cis	rs4665809	1	rs6546768	ENSG00000231655.1	AC011742.3	3.31	0.000963	0.0421	0.15	0.1	Gut microbiome composition (summer);	chr2:26105931	chr2:26140263~26141264:-
BRCA	cis	rs7267979	0.966	rs2257233	ENSG00000204556.4	CTD-2514C3.1	3.31	0.000963	0.0421	0.14	0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25285348	chr20:26018832~26020684:+
BRCA	cis	rs11108495	0.789	rs10745761	ENSG00000258177.1	RP11-394J1.2	3.31	0.000963	0.0421	0.13	0.1	Weight;	chr12:96417587	chr12:96222797~96223973:-
BRCA	cis	rs948562	0.711	rs12361623	ENSG00000255299.4	RP11-655C2.3	-3.31	0.000963	0.0421	-0.12	-0.1	Lymphoma;	chr11:58454953	chr11:58497888~58505758:-
BRCA	cis	rs948562	0.744	rs12362108	ENSG00000255299.4	RP11-655C2.3	-3.31	0.000963	0.0421	-0.12	-0.1	Lymphoma;	chr11:58456879	chr11:58497888~58505758:-
BRCA	cis	rs948562	0.744	rs11229472	ENSG00000255299.4	RP11-655C2.3	-3.31	0.000963	0.0421	-0.12	-0.1	Lymphoma;	chr11:58458778	chr11:58497888~58505758:-
BRCA	cis	rs948562	0.744	rs12362953	ENSG00000255299.4	RP11-655C2.3	-3.31	0.000963	0.0421	-0.12	-0.1	Lymphoma;	chr11:58459432	chr11:58497888~58505758:-
BRCA	cis	rs1178127	0.729	rs1178123	ENSG00000232821.1	AC003986.6	3.31	0.000963	0.0421	0.14	0.1	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);	chr7:18724221	chr7:19112474~19114271:+
BRCA	cis	rs6601327	0.607	rs13276086	ENSG00000233609.3	RP11-62H7.2	-3.31	0.000963	0.0421	-0.1	-0.1	Multiple myeloma (hyperdiploidy);	chr8:9721472	chr8:8961200~8979025:+
BRCA	cis	rs1816752	1	rs7988810	ENSG00000273628.1	RP11-756A22.7	3.31	0.000963	0.0421	0.13	0.1	Obesity-related traits;	chr13:24444958	chr13:24933006~24936796:+
BRCA	cis	rs4714291	0.963	rs1743969	ENSG00000180211.5	RP1-278E11.3	3.31	0.000963	0.0421	0.11	0.1	Strep throat;	chr6:40129179	chr6:39958414~39958833:-
BRCA	cis	rs28595532	0.92	rs17258830	ENSG00000248213.3	CICP16	3.31	0.000963	0.0421	0.19	0.1	Cannabis dependence symptom count;	chr4:118804388	chr4:118635970~118638782:-
BRCA	cis	rs80226907	1	rs74550269	ENSG00000258413.1	RP11-665C16.6	-3.31	0.000963	0.0421	-0.27	-0.1	Mean platelet volume;	chr14:55341254	chr14:55262767~55272075:-
BRCA	cis	rs80226907	1	rs79759423	ENSG00000258413.1	RP11-665C16.6	-3.31	0.000963	0.0421	-0.27	-0.1	Mean platelet volume;	chr14:55341885	chr14:55262767~55272075:-
BRCA	cis	rs818427	1	rs151977	ENSG00000279522.1	CTC-487M23.6	3.31	0.000963	0.0421	0.11	0.1	Total body bone mineral density;	chr5:112898852	chr5:112894933~112896531:+
BRCA	cis	rs12447180	0.527	rs4782365	ENSG00000260671.2	RP11-278A23.2	-3.31	0.000963	0.0421	-0.12	-0.1	Basophil percentage of white cells;Basophil percentage of granulocytes;White blood cell count (basophil);	chr16:88449763	chr16:87739771~87747706:-
BRCA	cis	rs875971	0.862	rs6460306	ENSG00000223473.2	GS1-124K5.3	-3.31	0.000964	0.0421	-0.08	-0.1	Aortic root size;	chr7:66595806	chr7:66491049~66493566:-
BRCA	cis	rs4272720	0.851	rs55872223	ENSG00000228754.1	RP11-534L6.3	-3.31	0.000964	0.0421	-0.14	-0.1	Platelet count;Plateletcrit;	chr10:49090014	chr10:48745545~48746128:-
BRCA	cis	rs6708331	0.878	rs12994100	ENSG00000231024.1	AC092431.3	-3.31	0.000964	0.0421	-0.14	-0.1	Obesity-related traits;	chr2:70133785	chr2:69700192~69713847:-
BRCA	cis	rs10129255	0.957	rs1024349	ENSG00000253936.1	IGHV3-63	3.31	0.000964	0.0421	0.08	0.1	Kawasaki disease;	chr14:106689997	chr14:106652237~106652681:-
BRCA	cis	rs11250098	0.567	rs4326350	ENSG00000255046.1	RP11-297N6.4	-3.31	0.000964	0.0421	-0.12	-0.1	Morning vs. evening chronotype;	chr8:10906145	chr8:11797928~11802568:-
BRCA	cis	rs1865760	0.622	rs9295685	ENSG00000272462.2	U91328.19	-3.31	0.000964	0.0421	-0.12	-0.1	Height;	chr6:26071497	chr6:25992662~26001775:+
BRCA	cis	rs897984	0.572	rs4889526	ENSG00000260267.1	RP11-452L6.5	3.31	0.000964	0.0421	0.1	0.1	Dementia with Lewy bodies;	chr16:31019023	chr16:31456711~31459736:-
BRCA	cis	rs13136331	0.721	rs2732186	ENSG00000249001.4	RP11-742B18.1	3.31	0.000964	0.0421	0.14	0.1	Sitting height ratio;	chr4:87752835	chr4:87568035~87733956:-
BRCA	cis	rs1003719	0.68	rs767998	ENSG00000242553.1	AP001432.14	3.31	0.000964	0.0421	0.12	0.1	Eye color traits;	chr21:37153352	chr21:37221419~37237744:+
BRCA	cis	rs896655	0.541	rs1335499	ENSG00000265194.1	RP11-70L8.4	-3.31	0.000964	0.0421	-0.1	-0.1	Coronary artery disease;	chr9:21711648	chr9:21858910~21861926:-
BRCA	cis	rs9311474	0.597	rs13303	ENSG00000222345.1	SNORD19	3.31	0.000964	0.0421	0.1	0.1	Electroencephalogram traits;	chr3:52523992	chr3:52691378~52691453:+
BRCA	cis	rs2346160	0.867	rs2076005	ENSG00000272980.3	RP11-517H2.6	-3.31	0.000964	0.0421	-0.09	-0.1	Parental extreme longevity (95 years and older);	chr6:167291456	chr6:166999405~167139141:+
BRCA	cis	rs67478160	0.583	rs12879612	ENSG00000269940.1	RP11-73M18.7	3.31	0.000964	0.0421	0.1	0.1	Schizophrenia;	chr14:103767281	chr14:103694560~103695170:+
BRCA	cis	rs4363385	0.747	rs9919276	ENSG00000272654.1	RP11-422P24.11	3.31	0.000964	0.0421	0.11	0.1	Inflammatory skin disease;	chr1:152996178	chr1:153977743~153979160:+
BRCA	cis	rs11064837	0.523	rs1978107	ENSG00000248636.5	RP11-768F21.1	3.31	0.000964	0.0421	0.14	0.1	Schizophrenia;	chr12:119663909	chr12:119387987~119668079:-
BRCA	cis	rs561341	0.783	rs512698	ENSG00000277511.1	CTD-2095E4.5	3.31	0.000964	0.0421	0.15	0.1	Hip circumference adjusted for BMI;	chr17:31965488	chr17:32127595~32128454:+
BRCA	cis	rs10995356	0.844	rs1949064	ENSG00000238280.1	RP11-436D10.3	-3.31	0.000964	0.0421	-0.14	-0.1	Temperament;	chr10:62975717	chr10:62793562~62805887:-
BRCA	cis	rs11239930	0.538	rs59064267	ENSG00000227242.3	NBPF13P	-3.31	0.000964	0.0421	-0.13	-0.1	AIDS progression;	chr1:147089146	chr1:147021320~147124525:-
BRCA	cis	rs13034020	0.522	rs4564760	ENSG00000237522.1	NONOP2	3.31	0.000964	0.0421	0.11	0.1	Hodgkin's lymphoma;	chr2:61021440	chr2:60936819~60938049:-
BRCA	cis	rs7267979	1	rs2500432	ENSG00000276952.1	RP5-965G21.6	3.31	0.000964	0.0421	0.12	0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25309876	chr20:25284915~25285588:-
BRCA	cis	rs67478160	0.595	rs8022783	ENSG00000269910.1	RP11-73M18.10	3.31	0.000964	0.0421	0.1	0.1	Schizophrenia;	chr14:103779236	chr14:103694516~103695050:-
BRCA	cis	rs3742264	0.615	rs4941536	ENSG00000235903.6	CPB2-AS1	-3.31	0.000964	0.0421	-0.12	-0.1	Blood protein levels;	chr13:45949309	chr13:46052806~46113332:+
BRCA	cis	rs4415084	1	rs12515012	ENSG00000248779.1	RP11-53O19.2	3.31	0.000964	0.0421	0.1	0.1	Breast cancer;	chr5:44694433	chr5:44752949~44765744:+
BRCA	cis	rs1124769	0.719	rs56036336	ENSG00000274528.1	CTD-2650P22.2	3.31	0.000964	0.0421	0.13	0.1	Cognitive performance;	chr15:51097090	chr15:52017167~52018032:-
BRCA	cis	rs7927592	0.956	rs60212556	ENSG00000254610.1	RP5-903G2.2	-3.31	0.000964	0.0421	-0.14	-0.1	Total body bone mineral density;	chr11:68538026	chr11:67934563~67939774:-
BRCA	cis	rs71520386	0.898	rs12536144	ENSG00000179428.2	AC073072.5	3.31	0.000964	0.0421	0.14	0.1	Fibrinogen levels;	chr7:22782890	chr7:22725395~22727620:-
BRCA	cis	rs67696533	0.62	rs911529	ENSG00000277692.1	RP11-358N2.2	-3.31	0.000965	0.0421	-0.12	-0.1	White blood cell count (basophil);Basophil percentage of granulocytes;Basophil percentage of white cells;	chr20:32559137	chr20:32355053~32355734:+
BRCA	cis	rs12893668	0.644	rs12890820	ENSG00000269910.1	RP11-73M18.10	3.31	0.000965	0.0421	0.11	0.1	Reticulocyte count;	chr14:103568512	chr14:103694516~103695050:-
BRCA	cis	rs7818688	0.697	rs11781757	ENSG00000245080.5	RP11-320N21.1	-3.31	0.000965	0.0421	-0.17	-0.1	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94975663	chr8:95066808~95073182:-
BRCA	cis	rs6840360	0.718	rs2136960	ENSG00000251603.1	RP11-164P12.4	3.31	0.000965	0.0421	0.09	0.1	Intelligence (multi-trait analysis);	chr4:151825037	chr4:151667224~151670502:+
BRCA	cis	rs6463739	0.812	rs36060210	ENSG00000219545.8	UMAD1	3.31	0.000965	0.0421	0.1	0.1	Small cell lung carcinoma;	chr7:7864952	chr7:7640711~8004059:+
BRCA	cis	rs8127691	0.904	rs7282490	ENSG00000232124.1	AP001057.1	-3.31	0.000965	0.0421	-0.13	-0.1	Inflammatory bowel disease;	chr21:44195858	chr21:44201290~44202696:+
BRCA	cis	rs1003719	0.68	rs2835629	ENSG00000242553.1	AP001432.14	3.31	0.000965	0.0421	0.12	0.1	Eye color traits;	chr21:37149360	chr21:37221419~37237744:+
BRCA	cis	rs6714710	0.603	rs1470483	ENSG00000201806.1	RNU4-8P	-3.31	0.000965	0.0421	-0.12	-0.1	Posterior cortical atrophy and Alzheimer's disease;	chr2:97777431	chr2:97664591~97664731:-
BRCA	cis	rs6671200	0.92	rs11165339	ENSG00000226026.4	RP11-57H12.3	-3.31	0.000965	0.0421	-0.18	-0.1	Stearic acid (18:0) levels;	chr1:95208508	chr1:95163219~95233982:-
BRCA	cis	rs12216545	0.737	rs4339548	ENSG00000244151.1	RP11-148K1.12	-3.31	0.000965	0.0421	-0.09	-0.1	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150532227	chr7:151074742~151076530:-
BRCA	cis	rs12216545	0.765	rs4607525	ENSG00000244151.1	RP11-148K1.12	-3.31	0.000965	0.0421	-0.09	-0.1	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150532262	chr7:151074742~151076530:-
BRCA	cis	rs6433921	1	rs56095368	ENSG00000260742.1	RP11-366L5.1	3.31	0.000965	0.0421	0.13	0.1	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;	chr2:181527416	chr2:181887851~181891663:-
BRCA	cis	rs4950322	0.58	rs72706441	ENSG00000227242.3	NBPF13P	-3.31	0.000965	0.0421	-0.14	-0.1	Protein quantitative trait loci;	chr1:147122601	chr1:147021320~147124525:-
BRCA	cis	rs875971	0.522	rs10807697	ENSG00000232559.3	GS1-124K5.12	3.31	0.000965	0.0421	0.12	0.1	Aortic root size;	chr7:65951183	chr7:66554588~66576923:-
BRCA	cis	rs490234	0.783	rs2416967	ENSG00000232630.1	PRPS1P2	-3.31	0.000965	0.0421	-0.1	-0.1	Mean arterial pressure;	chr9:125677735	chr9:125150653~125151589:+
BRCA	cis	rs73222236	0.75	rs9832572	ENSG00000239213.4	NCK1-AS1	3.31	0.000965	0.0421	0.11	0.1	Coronary artery disease;	chr3:136615386	chr3:136841726~136862054:-
BRCA	cis	rs4950322	0.58	rs7541393	ENSG00000237188.3	RP11-337C18.8	3.31	0.000965	0.0422	0.12	0.1	Protein quantitative trait loci;	chr1:147117186	chr1:147172771~147211568:+
BRCA	cis	rs11088226	0.645	rs7281844	ENSG00000186842.4	LINC00846	-3.31	0.000965	0.0422	-0.16	-0.1	Gastritis;	chr21:32560125	chr21:32572238~32575881:-
BRCA	cis	rs13113518	0.51	rs10049561	ENSG00000239040.1	Y_RNA	-3.31	0.000965	0.0422	-0.11	-0.1	Height;	chr4:55426623	chr4:55412636~55412738:+
BRCA	cis	rs4787491	0.729	rs4788212	ENSG00000275371.1	RP11-455F5.6	3.31	0.000965	0.0422	0.1	0.1	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30023148	chr16:30110895~30111955:+
BRCA	cis	rs881375	0.967	rs7034653	ENSG00000238181.2	AHCYP2	-3.31	0.000965	0.0422	-0.13	-0.1	Rheumatoid arthritis;	chr9:120925094	chr9:120720673~120721972:+
BRCA	cis	rs638893	0.578	rs582200	ENSG00000255435.5	RP11-770J1.3	-3.31	0.000965	0.0422	-0.16	-0.1	Vitiligo;	chr11:118798199	chr11:118511911~118531094:-
BRCA	cis	rs7246657	0.507	rs8107654	ENSG00000267470.4	ZNF571-AS1	3.31	0.000965	0.0422	0.16	0.1	Coronary artery calcification;	chr19:36962632	chr19:37548914~37587348:+
BRCA	cis	rs7264396	0.836	rs2010565	ENSG00000088340.14	FER1L4	-3.31	0.000966	0.0422	-0.12	-0.1	Total cholesterol levels;	chr20:35594595	chr20:35558737~35607562:-
BRCA	cis	rs7789940	1	rs2072435	ENSG00000231087.2	FDPSP7	-3.31	0.000966	0.0422	-0.13	-0.1	Multiple sclerosis;	chr7:76329871	chr7:76968197~76969250:-
BRCA	cis	rs765787	0.53	rs4774542	ENSG00000259539.1	CTD-2651B20.1	-3.31	0.000966	0.0422	-0.12	-0.1	Uric acid levels;	chr15:45233828	chr15:45152664~45167526:-
BRCA	cis	rs6964833	0.786	rs35633336	ENSG00000277072.3	STAG3L2	3.31	0.000966	0.0422	0.11	0.1	Menarche (age at onset);	chr7:74643961	chr7:74882163~74890610:-
BRCA	cis	rs4819052	0.851	rs13052344	ENSG00000223768.1	LINC00205	-3.31	0.000966	0.0422	-0.14	-0.1	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45256186	chr21:45293285~45297354:+
BRCA	cis	rs4819052	0.851	rs28501512	ENSG00000223768.1	LINC00205	-3.31	0.000966	0.0422	-0.14	-0.1	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45256787	chr21:45293285~45297354:+
BRCA	cis	rs9457247	0.582	rs9459855	ENSG00000272549.1	RP11-351J23.2	-3.31	0.000966	0.0422	-0.11	-0.1	Crohn's disease;	chr6:167052662	chr6:167666840~167679270:-
BRCA	cis	rs13083990	1	rs13083990	ENSG00000272758.4	RP11-299J3.8	3.31	0.000966	0.0422	0.11	0.1	Cardiac Troponin-T levels;	chr3:122295719	chr3:122416207~122443180:+
BRCA	cis	rs12216545	0.765	rs9986804	ENSG00000244151.1	RP11-148K1.12	-3.31	0.000966	0.0422	-0.09	-0.1	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150559323	chr7:151074742~151076530:-
BRCA	cis	rs10487112	0.721	rs12154771	ENSG00000235436.9	DPY19L2P4	-3.31	0.000966	0.0422	-0.11	-0.1	Perceived unattractiveness to mosquitoes;	chr7:90531994	chr7:90119400~90125600:+
BRCA	cis	rs71520386	0.607	rs28617621	ENSG00000179428.2	AC073072.5	3.31	0.000966	0.0422	0.12	0.1	Fibrinogen levels;	chr7:22818063	chr7:22725395~22727620:-
BRCA	cis	rs6493487	0.512	rs7162631	ENSG00000259298.1	RP11-562A8.4	-3.31	0.000966	0.0422	-0.12	-0.1	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr15:50820930	chr15:50497195~50498744:-
BRCA	cis	rs6493487	0.512	rs16963910	ENSG00000259298.1	RP11-562A8.4	-3.31	0.000966	0.0422	-0.12	-0.1	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr15:50821706	chr15:50497195~50498744:-
BRCA	cis	rs6493487	0.512	rs34297767	ENSG00000259298.1	RP11-562A8.4	-3.31	0.000966	0.0422	-0.12	-0.1	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr15:50821781	chr15:50497195~50498744:-
BRCA	cis	rs6493487	0.512	rs34581168	ENSG00000259298.1	RP11-562A8.4	-3.31	0.000966	0.0422	-0.12	-0.1	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr15:50821934	chr15:50497195~50498744:-
BRCA	cis	rs6493487	0.512	rs3896066	ENSG00000259298.1	RP11-562A8.4	-3.31	0.000966	0.0422	-0.12	-0.1	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr15:50822120	chr15:50497195~50498744:-
BRCA	cis	rs6493487	0.512	rs3848135	ENSG00000259298.1	RP11-562A8.4	-3.31	0.000966	0.0422	-0.12	-0.1	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr15:50822453	chr15:50497195~50498744:-
BRCA	cis	rs881375	0.967	rs7034492	ENSG00000238181.2	AHCYP2	-3.31	0.000966	0.0422	-0.13	-0.1	Rheumatoid arthritis;	chr9:120924933	chr9:120720673~120721972:+
BRCA	cis	rs2243480	1	rs67728539	ENSG00000234585.5	CCT6P3	-3.31	0.000966	0.0422	-0.15	-0.1	Diabetic kidney disease;	chr7:65913137	chr7:65038354~65074713:+
BRCA	cis	rs6696239	0.911	rs12129213	ENSG00000227711.2	RP11-275O4.5	-3.31	0.000966	0.0422	-0.14	-0.1	Height;	chr1:227698506	chr1:227509028~227520477:-
BRCA	cis	rs6142102	0.961	rs4911392	ENSG00000206582.1	Y_RNA	-3.31	0.000966	0.0422	-0.12	-0.1	Skin pigmentation;	chr20:33982712	chr20:34526510~34526606:-
BRCA	cis	rs6142102	0.961	rs4911393	ENSG00000206582.1	Y_RNA	-3.31	0.000966	0.0422	-0.12	-0.1	Skin pigmentation;	chr20:33983120	chr20:34526510~34526606:-
BRCA	cis	rs13034020	0.522	rs62150978	ENSG00000237522.1	NONOP2	3.31	0.000966	0.0422	0.12	0.1	Hodgkin's lymphoma;	chr2:61029087	chr2:60936819~60938049:-
BRCA	cis	rs7594648	0.847	rs1548191	ENSG00000226383.4	AC093375.1	-3.31	0.000966	0.0422	-0.15	-0.1	Age-related hearing impairment;	chr2:155646913	chr2:156011617~156024613:-
BRCA	cis	rs801193	0.569	rs2013908	ENSG00000223473.2	GS1-124K5.3	-3.31	0.000966	0.0422	-0.08	-0.1	Aortic root size;	chr7:66656082	chr7:66491049~66493566:-
BRCA	cis	rs12893668	0.572	rs11540512	ENSG00000258914.1	CTD-2134A5.3	3.31	0.000967	0.0422	0.14	0.1	Reticulocyte count;	chr14:103681040	chr14:103875055~103877478:+
BRCA	cis	rs17270561	0.583	rs12662869	ENSG00000272462.2	U91328.19	3.31	0.000967	0.0422	0.12	0.1	Iron status biomarkers;	chr6:25784253	chr6:25992662~26001775:+
BRCA	cis	rs7474896	1	rs34496143	ENSG00000120555.12	SEPT7P9	3.31	0.000967	0.0422	0.19	0.1	Obesity (extreme);	chr10:37703730	chr10:38383069~38402916:-
BRCA	cis	rs7474896	1	rs12357418	ENSG00000120555.12	SEPT7P9	3.31	0.000967	0.0422	0.19	0.1	Obesity (extreme);	chr10:37704932	chr10:38383069~38402916:-
BRCA	cis	rs7474896	1	rs72639533	ENSG00000120555.12	SEPT7P9	3.31	0.000967	0.0422	0.19	0.1	Obesity (extreme);	chr10:37708882	chr10:38383069~38402916:-
BRCA	cis	rs1003719	0.582	rs2835634	ENSG00000242553.1	AP001432.14	3.31	0.000967	0.0422	0.12	0.1	Eye color traits;	chr21:37155969	chr21:37221419~37237744:+
BRCA	cis	rs875971	0.755	rs76288834	ENSG00000265600.1	AC006480.1	3.31	0.000967	0.0422	0.12	0.1	Aortic root size;	chr7:66604815	chr7:67356680~67356779:+
BRCA	cis	rs9650657	0.504	rs10108347	ENSG00000254866.2	DEFB109P3	3.31	0.000967	0.0422	0.13	0.1	Neuroticism;	chr8:11176008	chr8:12150895~12151134:-
BRCA	cis	rs801193	0.569	rs7782587	ENSG00000106610.13	STAG3L4	-3.31	0.000967	0.0422	-0.14	-0.1	Aortic root size;	chr7:66701485	chr7:67302621~67321526:+
BRCA	cis	rs2908197	0.737	rs2109857	ENSG00000205485.12	AC004980.7	3.31	0.000967	0.0422	0.11	0.1	3-hydroxypropylmercapturic acid levels in smokers;	chr7:76333852	chr7:76549360~76627982:+
BRCA	cis	rs4372836	0.729	rs11127190	ENSG00000226833.4	AC097724.3	-3.31	0.000967	0.0422	-0.12	-0.1	Body mass index;	chr2:28820346	chr2:28708953~28736205:-
BRCA	cis	rs12477438	0.501	rs2632284	ENSG00000231822.1	AC019097.7	3.31	0.000967	0.0422	0.11	0.1	Chronic sinus infection;	chr2:99159402	chr2:99102018~99102752:+
BRCA	cis	rs12477438	0.52	rs2969379	ENSG00000231822.1	AC019097.7	3.31	0.000967	0.0422	0.11	0.1	Chronic sinus infection;	chr2:99160223	chr2:99102018~99102752:+
BRCA	cis	rs12477438	0.52	rs12621007	ENSG00000231822.1	AC019097.7	3.31	0.000967	0.0422	0.11	0.1	Chronic sinus infection;	chr2:99175483	chr2:99102018~99102752:+
BRCA	cis	rs189798	0.738	rs330908	ENSG00000233609.3	RP11-62H7.2	3.31	0.000967	0.0422	0.1	0.1	Myopia (pathological);	chr8:9137656	chr8:8961200~8979025:+
BRCA	cis	rs6772849	0.805	rs13325747	ENSG00000207088.1	SNORA7B	-3.31	0.000967	0.0422	-0.12	-0.1	Monocyte percentage of white cells;Monocyte count;	chr3:128617180	chr3:129397210~129397348:-
BRCA	cis	rs9457247	0.638	rs239933	ENSG00000227598.1	RP1-167A14.2	-3.31	0.000967	0.0422	-0.11	-0.1	Crohn's disease;	chr6:166999742	chr6:166969626~166999065:-
BRCA	cis	rs924712	0.816	rs971526	ENSG00000261116.1	RP3-523K23.2	3.31	0.000967	0.0422	0.12	0.1	Breast cancer;	chr6:54863331	chr6:54943167~54945099:+
BRCA	cis	rs9467773	0.869	rs1796520	ENSG00000224843.5	LINC00240	3.31	0.000967	0.0422	0.12	0.1	Intelligence (multi-trait analysis);	chr6:26410572	chr6:26956992~27023924:+
BRCA	cis	rs2839186	0.619	rs2187118	ENSG00000228137.1	AP001469.7	3.31	0.000967	0.0422	0.1	0.1	Testicular germ cell tumor;	chr21:46191396	chr21:46246890~46247682:+
BRCA	cis	rs17092148	0.887	rs2378199	ENSG00000250917.1	RP4-785G19.5	3.31	0.000967	0.0422	0.17	0.1	Neuroticism;	chr20:34598676	chr20:34234840~34281173:-
BRCA	cis	rs1376877	0.934	rs4625888	ENSG00000273456.1	RP11-686O6.2	3.31	0.000967	0.0422	0.1	0.1	Subclinical atherosclerosis traits (other);	chr2:203236434	chr2:202374932~202375604:-
BRCA	cis	rs4834770	0.668	rs1397610	ENSG00000245958.5	RP11-33B1.1	3.31	0.000967	0.0422	0.1	0.1	Blood protein levels;	chr4:119206606	chr4:119454791~119552025:+
BRCA	cis	rs7395581	0.959	rs901746	ENSG00000280615.1	Y_RNA	3.31	0.000967	0.0422	0.12	0.1	HDL cholesterol;	chr11:47238768	chr11:47614898~47614994:-
BRCA	cis	rs3739034	1	rs3739036	ENSG00000224043.6	CCNT2-AS1	3.31	0.000968	0.0422	0.17	0.1	Gut microbiome composition (winter);	chr2:134725964	chr2:134735464~134918710:-
BRCA	cis	rs9844666	0.512	rs9833799	ENSG00000239213.4	NCK1-AS1	3.31	0.000968	0.0422	0.11	0.1	Height;	chr3:135922325	chr3:136841726~136862054:-
BRCA	cis	rs988913	0.723	rs9464197	ENSG00000261116.1	RP3-523K23.2	-3.31	0.000968	0.0422	-0.12	-0.1	Menarche (age at onset);	chr6:55133940	chr6:54943167~54945099:+
BRCA	cis	rs36051895	0.664	rs12340866	ENSG00000237711.1	RP11-39K24.13	-3.31	0.000968	0.0422	-0.13	-0.1	Pediatric autoimmune diseases;	chr9:5094185	chr9:5100236~5101009:+
BRCA	cis	rs863345	0.584	rs11265018	ENSG00000176320.2	RP11-404O13.5	-3.31	0.000968	0.0422	-0.11	-0.1	Pneumococcal bacteremia;	chr1:158536619	chr1:158197922~158203877:-
BRCA	cis	rs863345	0.604	rs12133791	ENSG00000176320.2	RP11-404O13.5	-3.31	0.000968	0.0422	-0.11	-0.1	Pneumococcal bacteremia;	chr1:158536892	chr1:158197922~158203877:-
BRCA	cis	rs863345	0.604	rs12122663	ENSG00000176320.2	RP11-404O13.5	-3.31	0.000968	0.0422	-0.11	-0.1	Pneumococcal bacteremia;	chr1:158536934	chr1:158197922~158203877:-
BRCA	cis	rs62025270	0.632	rs62022924	ENSG00000259416.2	RP11-158M2.5	-3.31	0.000968	0.0422	-0.15	-0.1	Idiopathic pulmonary fibrosis;	chr15:85692276	chr15:85754941~85756237:-
BRCA	cis	rs62025270	0.576	rs62022925	ENSG00000259416.2	RP11-158M2.5	-3.31	0.000968	0.0422	-0.15	-0.1	Idiopathic pulmonary fibrosis;	chr15:85692835	chr15:85754941~85756237:-
BRCA	cis	rs72928364	1	rs62275198	ENSG00000244119.1	PDCL3P4	3.31	0.000968	0.0422	0.13	0.1	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100969129	chr3:101712472~101713191:+
BRCA	cis	rs72928364	1	rs13088524	ENSG00000244119.1	PDCL3P4	3.31	0.000968	0.0422	0.13	0.1	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100969238	chr3:101712472~101713191:+
BRCA	cis	rs72928364	1	rs67946790	ENSG00000244119.1	PDCL3P4	3.31	0.000968	0.0422	0.13	0.1	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100969838	chr3:101712472~101713191:+
BRCA	cis	rs10771431	0.597	rs10843144	ENSG00000214776.8	RP11-726G1.1	-3.31	0.000968	0.0422	-0.11	-0.1	Breast size;	chr12:9204981	chr12:9467552~9576275:+
BRCA	cis	rs699371	0.525	rs10138386	ENSG00000270000.1	RP3-449M8.9	3.31	0.000968	0.0423	0.12	0.1	Height;	chr14:74434183	chr14:74471930~74472360:-
BRCA	cis	rs3136441	1	rs4752946	ENSG00000200376.1	RNU5E-10P	-3.31	0.000968	0.0423	-0.16	-0.1	HDL cholesterol;	chr11:46875357	chr11:47576471~47576588:-
BRCA	cis	rs10501293	0.675	rs7103629	ENSG00000252652.1	Y_RNA	-3.31	0.000968	0.0423	-0.12	-0.1	Cognitive performance;	chr11:43022877	chr11:43331261~43331356:+
BRCA	cis	rs11031096	0.966	rs232044	ENSG00000224513.2	AC109309.4	-3.31	0.000968	0.0423	-0.12	-0.1	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr11:4116976	chr11:3226061~3232838:+
BRCA	cis	rs9341808	0.718	rs2143887	ENSG00000279022.1	RP11-250B2.4	3.31	0.000968	0.0423	0.12	0.1	Sitting height ratio;	chr6:80207570	chr6:80440730~80441172:+
BRCA	cis	rs427943	0.778	rs2838797	ENSG00000261706.1	LINC00165	3.31	0.000968	0.0423	0.12	0.1	Body mass index;	chr21:45173333	chr21:44994362~44995185:-
BRCA	cis	rs2839186	0.708	rs6518285	ENSG00000215424.8	MCM3AP-AS1	3.31	0.000968	0.0423	0.09	0.1	Testicular germ cell tumor;	chr21:46224753	chr21:46229217~46259390:+
BRCA	cis	rs7254232	0.96	rs10414789	ENSG00000211513.4	MIR320E	-3.31	0.000969	0.0423	-0.13	-0.1	Chronic periodontitis;	chr19:47290306	chr19:46709271~46709382:-
BRCA	cis	rs4693089	0.604	rs13124479	ENSG00000213608.5	SLC25A14P1	3.31	0.000969	0.0423	0.12	0.1	Menopause (age at onset);	chr4:83483243	chr4:83477524~83478424:+
BRCA	cis	rs36051895	0.664	rs11793659	ENSG00000237711.1	RP11-39K24.13	-3.31	0.000969	0.0423	-0.12	-0.1	Pediatric autoimmune diseases;	chr9:5109707	chr9:5100236~5101009:+
BRCA	cis	rs4130344	0.874	rs13148521	ENSG00000271817.2	U3	-3.31	0.000969	0.0423	-0.11	-0.1	Intelligence (multi-trait analysis);	chr4:158880959	chr4:158700691~158700909:+
BRCA	cis	rs890448	0.796	rs2433306	ENSG00000254531.1	FLJ20021	3.31	0.000969	0.0423	0.12	0.1	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101425843	chr4:101347780~101348883:+
BRCA	cis	rs1730008	1	rs698977	ENSG00000279311.1	RP11-170K4.2	-3.31	0.000969	0.0423	-0.12	-0.1	Lobe attachment (rater-scored or self-reported);	chr3:158221409	chr3:158869898~158871821:+
BRCA	cis	rs1730008	1	rs698976	ENSG00000279311.1	RP11-170K4.2	-3.31	0.000969	0.0423	-0.12	-0.1	Lobe attachment (rater-scored or self-reported);	chr3:158221420	chr3:158869898~158871821:+
BRCA	cis	rs2307449	0.929	rs7497351	ENSG00000260123.1	RP11-326A19.4	3.31	0.000969	0.0423	0.12	0.1	Menopause (age at onset);	chr15:89268251	chr15:89041223~89082819:+
BRCA	cis	rs7520050	0.966	rs10789481	ENSG00000281133.1	AL355480.3	3.31	0.000969	0.0423	0.12	0.1	Reticulocyte count;Red blood cell count;	chr1:45917911	chr1:45580892~45580996:-
BRCA	cis	rs703108	0.572	rs2245272	ENSG00000279623.1	RP11-399C16.3	3.31	0.000969	0.0423	0.13	0.1	Monocyte percentage of white cells;	chr10:22245261	chr10:21865335~21865921:-
BRCA	cis	rs889312	0.5	rs185219	ENSG00000271828.1	CTD-2310F14.1	-3.31	0.000969	0.0423	-0.12	-0.1	Breast cancer (early onset);Breast cancer;	chr5:56840665	chr5:56927874~56929573:+
BRCA	cis	rs6500602	0.701	rs1362626	ENSG00000280063.1	RP11-295D4.3	3.31	0.000969	0.0423	0.08	0.1	Schizophrenia;	chr16:4499225	chr16:4346694~4348648:-
BRCA	cis	rs749052	0.831	rs2679178	ENSG00000261829.1	RP11-223I10.1	-3.31	0.000969	0.0423	-0.22	-0.1	Height;	chr2:231933151	chr2:231052040~231052637:+
BRCA	cis	rs516805	0.706	rs1339533	ENSG00000279114.1	RP3-425C14.5	-3.31	0.000969	0.0423	-0.12	-0.1	Lymphocyte counts;	chr6:122348687	chr6:122471923~122484161:+
BRCA	cis	rs4848143	0.64	rs7562893	ENSG00000236859.5	NIFK-AS1	-3.31	0.000969	0.0423	-0.11	-0.1	Capecitabine sensitivity;	chr2:121043498	chr2:121649650~121728208:+
BRCA	cis	rs2276314	1	rs4799835	ENSG00000267627.4	RP11-905K4.1	-3.31	0.000969	0.0423	-0.14	-0.1	Endometriosis;Drug-induced torsades de pointes;	chr18:35991305	chr18:35951803~35966118:-
BRCA	cis	rs10420951	0.617	rs7251067	ENSG00000243455.3	RPS18P13	-3.31	0.000969	0.0423	-0.16	-0.1	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr19:18489246	chr19:18048637~18049090:+
BRCA	cis	rs10876993	0.89	rs1689584	ENSG00000269903.1	RP11-571M6.18	3.31	0.000969	0.0423	0.13	0.1	Celiac disease or Rheumatoid arthritis;	chr12:57687695	chr12:57814494~57814926:+
BRCA	cis	rs17767294	0.614	rs41269291	ENSG00000219392.1	RP1-265C24.5	-3.31	0.000969	0.0423	-0.28	-0.1	Parkinson's disease;	chr6:28283762	chr6:28115628~28116551:+
BRCA	cis	rs17767294	0.614	rs72854506	ENSG00000219392.1	RP1-265C24.5	-3.31	0.000969	0.0423	-0.28	-0.1	Parkinson's disease;	chr6:28284720	chr6:28115628~28116551:+
BRCA	cis	rs12760731	0.565	rs11585355	ENSG00000213057.5	C1orf220	3.31	0.000969	0.0423	0.16	0.1	Obesity-related traits;	chr1:178212084	chr1:178542752~178548889:+
BRCA	cis	rs295490	0.748	rs75634125	ENSG00000178631.7	ACTG1P1	-3.31	0.00097	0.0423	-0.22	-0.1	PR interval in Tripanosoma cruzi seropositivity;	chr3:139371639	chr3:139493809~139494937:+
BRCA	cis	rs295490	0.748	rs80249265	ENSG00000178631.7	ACTG1P1	-3.31	0.00097	0.0423	-0.22	-0.1	PR interval in Tripanosoma cruzi seropositivity;	chr3:139371856	chr3:139493809~139494937:+
BRCA	cis	rs4835473	0.808	rs62339607	ENSG00000246448.2	RP13-578N3.3	-3.31	0.00097	0.0423	-0.11	-0.1	Immature fraction of reticulocytes;	chr4:143791474	chr4:143700257~143865072:+
BRCA	cis	rs4665809	1	rs4233710	ENSG00000231655.1	AC011742.3	3.31	0.00097	0.0423	0.16	0.1	Gut microbiome composition (summer);	chr2:26068696	chr2:26140263~26141264:-
BRCA	cis	rs2070488	1	rs1002676	ENSG00000229589.1	ACVR2B-AS1	-3.31	0.00097	0.0423	-0.11	-0.1	Electrocardiographic conduction measures;	chr3:38403441	chr3:38451027~38454820:-
BRCA	cis	rs3770752	0.828	rs12618410	ENSG00000272054.1	RP11-423P10.2	-3.31	0.00097	0.0423	-0.09	-0.1	Schizophrenia;	chr2:37294707	chr2:37208875~37212677:+
BRCA	cis	rs7795541	0.691	rs272695	ENSG00000230658.1	KLHL7-AS1	3.31	0.00097	0.0423	0.14	0.1	Morning vs. evening chronotype;	chr7:24052553	chr7:23101228~23105703:-
BRCA	cis	rs115320831	0.643	rs1410789	ENSG00000271817.2	U3	-3.31	0.00097	0.0423	-0.11	-0.1	Excessive daytime sleepiness;	chr4:158258710	chr4:158700691~158700909:+
BRCA	cis	rs7089973	0.966	rs12775180	ENSG00000236799.1	RP11-383C6.2	-3.31	0.00097	0.0423	-0.13	-0.1	Bipolar disorder or attention deficit hyperactivity disorder;	chr10:114879995	chr10:114994657~114996593:+
BRCA	cis	rs1178127	0.729	rs1178148	ENSG00000232821.1	AC003986.6	-3.31	0.00097	0.0423	-0.14	-0.1	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);	chr7:18738490	chr7:19112474~19114271:+
BRCA	cis	rs911555	0.755	rs6575988	ENSG00000269910.1	RP11-73M18.10	-3.31	0.00097	0.0423	-0.1	-0.1	Intelligence (multi-trait analysis);	chr14:103434490	chr14:103694516~103695050:-
BRCA	cis	rs11048434	0.518	rs7311509	ENSG00000256937.1	KRT17P8	-3.31	0.00097	0.0423	-0.11	-0.1	Sjögren's syndrome;	chr12:9026438	chr12:9127783~9128645:+
BRCA	cis	rs4819052	0.851	rs1056101	ENSG00000215447.6	BX322557.10	-3.31	0.00097	0.0423	-0.1	-0.1	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258787	chr21:45288052~45291738:+
BRCA	cis	rs931127	0.747	rs11820062	ENSG00000255557.1	RP11-770G2.2	3.31	0.00097	0.0423	0.12	0.1	Systemic lupus erythematosus;	chr11:65662465	chr11:65745729~65771585:+
BRCA	cis	rs7656342	0.686	rs10031303	ENSG00000250342.1	SNRPCP16	-3.31	0.00097	0.0423	-0.11	-0.1	Gut microbiota (bacterial taxa);	chr4:9840066	chr4:9051842~9052051:-
BRCA	cis	rs7914558	0.966	rs11191518	ENSG00000213277.3	MARCKSL1P1	3.31	0.00097	0.0423	0.11	0.1	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103023096	chr10:103175554~103176094:+
BRCA	cis	rs10792665	0.649	rs10792671	ENSG00000254965.1	RP11-113K21.2	-3.31	0.00097	0.0423	-0.1	-0.1	Obesity-related traits;	chr11:83017167	chr11:83111060~83111442:-
BRCA	cis	rs896655	0.541	rs7039487	ENSG00000265194.1	RP11-70L8.4	-3.31	0.00097	0.0423	-0.1	-0.1	Coronary artery disease;	chr9:21709998	chr9:21858910~21861926:-
BRCA	cis	rs896655	0.541	rs2383202	ENSG00000265194.1	RP11-70L8.4	-3.31	0.00097	0.0423	-0.1	-0.1	Coronary artery disease;	chr9:21710216	chr9:21858910~21861926:-
BRCA	cis	rs896655	0.582	rs1414232	ENSG00000265194.1	RP11-70L8.4	-3.31	0.00097	0.0423	-0.1	-0.1	Coronary artery disease;	chr9:21711063	chr9:21858910~21861926:-
BRCA	cis	rs896655	0.582	rs1414233	ENSG00000265194.1	RP11-70L8.4	-3.31	0.00097	0.0423	-0.1	-0.1	Coronary artery disease;	chr9:21711126	chr9:21858910~21861926:-
BRCA	cis	rs6840360	0.593	rs3805356	ENSG00000270265.1	RP11-731D1.4	3.31	0.000971	0.0423	0.12	0.1	Intelligence (multi-trait analysis);	chr4:151759549	chr4:151333775~151353224:-
BRCA	cis	rs10851411	0.697	rs72711767	ENSG00000260490.2	RP11-265N6.3	-3.31	0.000971	0.0423	-0.19	-0.1	Glucose homeostasis traits;	chr15:42551772	chr15:42571927~42572433:+
BRCA	cis	rs9393813	0.529	rs12526864	ENSG00000241549.7	GUSBP2	3.31	0.000971	0.0423	0.11	0.1	Bipolar disorder;	chr6:27488463	chr6:26871484~26956554:-
BRCA	cis	rs4819052	0.851	rs13048789	ENSG00000223768.1	LINC00205	-3.31	0.000971	0.0423	-0.14	-0.1	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240799	chr21:45293285~45297354:+
BRCA	cis	rs6918586	0.658	rs198843	ENSG00000272462.2	U91328.19	-3.31	0.000971	0.0423	-0.11	-0.1	Schizophrenia;	chr6:26110086	chr6:25992662~26001775:+
BRCA	cis	rs2908197	0.713	rs2961038	ENSG00000205485.12	AC004980.7	3.31	0.000971	0.0424	0.11	0.1	3-hydroxypropylmercapturic acid levels in smokers;	chr7:76322753	chr7:76549360~76627982:+
BRCA	cis	rs3748656	1	rs1110042	ENSG00000273483.1	RP4-671G15.2	3.31	0.000971	0.0424	0.14	0.1	Hip circumference adjusted for BMI;	chr1:112693912	chr1:112517799~112518441:-
BRCA	cis	rs3748656	1	rs3748656	ENSG00000273483.1	RP4-671G15.2	3.31	0.000971	0.0424	0.14	0.1	Hip circumference adjusted for BMI;	chr1:112694059	chr1:112517799~112518441:-
BRCA	cis	rs3748656	0.832	rs883593	ENSG00000273483.1	RP4-671G15.2	3.31	0.000971	0.0424	0.14	0.1	Hip circumference adjusted for BMI;	chr1:112694549	chr1:112517799~112518441:-
BRCA	cis	rs9472719	0.836	rs13216050	ENSG00000231769.2	RP1-8B1.4	3.31	0.000971	0.0424	0.18	0.1	Total cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;	chr6:46190316	chr6:46097093~46129706:-
BRCA	cis	rs11035577	0.632	rs7941163	ENSG00000279675.1	RP11-454H19.2	-3.31	0.000971	0.0424	-0.16	-0.1	Temperament (bipolar disorder);	chr11:39764440	chr11:40107244~40112599:-
BRCA	cis	rs1075265	0.756	rs2542576	ENSG00000272156.1	RP11-477N3.1	-3.31	0.000971	0.0424	-0.1	-0.1	Chronotype;Morning vs. evening chronotype;	chr2:53821659	chr2:54082554~54085066:+
BRCA	cis	rs3749237	0.964	rs2352967	ENSG00000225399.4	RP11-3B7.1	3.31	0.000971	0.0424	0.1	0.1	Resting heart rate;	chr3:49834208	chr3:49260085~49261316:+
BRCA	cis	rs2018683	0.649	rs221193	ENSG00000272568.4	CTB-113D17.1	3.31	0.000971	0.0424	0.14	0.1	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28976168	chr7:28979967~29013367:+
BRCA	cis	rs170020	1	rs170020	ENSG00000253921.1	CTB-113P19.3	3.31	0.000971	0.0424	0.11	0.1	Interstitial lung disease;	chr5:151964997	chr5:151753992~151767247:+
BRCA	cis	rs3816183	0.716	rs4952943	ENSG00000226491.1	FTOP1	-3.31	0.000971	0.0424	-0.13	-0.1	Hypospadias;	chr2:42854922	chr2:42797225~42798712:-
BRCA	cis	rs7395581	0.959	rs35879051	ENSG00000280615.1	Y_RNA	3.31	0.000971	0.0424	0.12	0.1	HDL cholesterol;	chr11:47254331	chr11:47614898~47614994:-
BRCA	cis	rs7395581	0.959	rs59663860	ENSG00000280615.1	Y_RNA	3.31	0.000971	0.0424	0.12	0.1	HDL cholesterol;	chr11:47254799	chr11:47614898~47614994:-
BRCA	cis	rs7395581	0.879	rs3758673	ENSG00000280615.1	Y_RNA	3.31	0.000971	0.0424	0.12	0.1	HDL cholesterol;	chr11:47257366	chr11:47614898~47614994:-
BRCA	cis	rs7267979	0.903	rs2500400	ENSG00000231081.1	RP4-760C5.3	3.31	0.000971	0.0424	0.13	0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25374069	chr20:26008791~26010531:-
BRCA	cis	rs2043112	0.691	rs13154561	ENSG00000249911.1	LINC01265	3.31	0.000972	0.0424	0.12	0.1	Obesity-related traits;	chr5:39078189	chr5:38710367~38720273:-
BRCA	cis	rs300890	0.52	rs713140	ENSG00000250326.1	RP11-284M14.1	3.31	0.000972	0.0424	0.12	0.1	Nasopharyngeal carcinoma;	chr4:143396714	chr4:142933195~143184861:-
BRCA	cis	rs80226907	1	rs77247150	ENSG00000258413.1	RP11-665C16.6	-3.31	0.000972	0.0424	-0.27	-0.1	Mean platelet volume;	chr14:55393496	chr14:55262767~55272075:-
BRCA	cis	rs80226907	1	rs79907117	ENSG00000258413.1	RP11-665C16.6	-3.31	0.000972	0.0424	-0.27	-0.1	Mean platelet volume;	chr14:55394485	chr14:55262767~55272075:-
BRCA	cis	rs80226907	1	rs76977612	ENSG00000258413.1	RP11-665C16.6	-3.31	0.000972	0.0424	-0.27	-0.1	Mean platelet volume;	chr14:55395357	chr14:55262767~55272075:-
BRCA	cis	rs80226907	0.708	rs112798848	ENSG00000258413.1	RP11-665C16.6	-3.31	0.000972	0.0424	-0.27	-0.1	Mean platelet volume;	chr14:55395414	chr14:55262767~55272075:-
BRCA	cis	rs80226907	1	rs77604075	ENSG00000258413.1	RP11-665C16.6	-3.31	0.000972	0.0424	-0.27	-0.1	Mean platelet volume;	chr14:55395686	chr14:55262767~55272075:-
BRCA	cis	rs80226907	1	rs76264591	ENSG00000258413.1	RP11-665C16.6	-3.31	0.000972	0.0424	-0.27	-0.1	Mean platelet volume;	chr14:55395805	chr14:55262767~55272075:-
BRCA	cis	rs4650994	0.593	rs2761459	ENSG00000273384.1	RP5-1098D14.1	-3.31	0.000972	0.0424	-0.13	-0.1	HDL cholesterol;HDL cholesterol levels;	chr1:178582441	chr1:178651706~178652282:+
BRCA	cis	rs300890	0.698	rs3828512	ENSG00000250326.1	RP11-284M14.1	3.31	0.000972	0.0424	0.12	0.1	Nasopharyngeal carcinoma;	chr4:143395607	chr4:142933195~143184861:-
BRCA	cis	rs853679	0.542	rs9393892	ENSG00000272009.1	RP1-313I6.12	-3.31	0.000972	0.0424	-0.15	-0.1	Depression;	chr6:28113616	chr6:28078792~28081130:-
BRCA	cis	rs7487075	0.619	rs4768719	ENSG00000257261.4	RP11-96H19.1	3.31	0.000972	0.0424	0.12	0.1	Itch intensity from mosquito bite;	chr12:46447055	chr12:46383679~46876159:+
BRCA	cis	rs1712517	0.503	rs72846198	ENSG00000234699.1	RP11-225H22.4	3.31	0.000972	0.0424	0.13	0.1	Migraine;	chr10:103338267	chr10:103452846~103462695:+
BRCA	cis	rs561341	0.714	rs111760509	ENSG00000265798.5	RP11-271K11.5	3.31	0.000972	0.0424	0.17	0.1	Hip circumference adjusted for BMI;	chr17:31977301	chr17:31038575~31059121:-
BRCA	cis	rs6429082	0.871	rs9662392	ENSG00000230026.2	RP11-382D8.5	3.31	0.000972	0.0424	0.11	0.1	Adiposity;	chr1:235413634	chr1:235361153~235362540:+
BRCA	cis	rs17169635	0.836	rs3800735	ENSG00000272941.1	RP11-134L10.1	-3.31	0.000972	0.0424	-0.11	-0.1	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);	chr7:134852218	chr7:135168403~135169547:+
BRCA	cis	rs3764021	0.527	rs10844380	ENSG00000278635.1	CTD-2318O12.1	-3.31	0.000972	0.0424	-0.11	-0.1	Type 1 diabetes;	chr12:9670678	chr12:9415641~9416718:+
BRCA	cis	rs1334894	0.901	rs6906096	ENSG00000187762.5	HSPE1P11	3.31	0.000972	0.0424	0.24	0.1	Coronary artery disease;	chr6:35532877	chr6:35023522~35023831:+
BRCA	cis	rs2638953	0.925	rs11049567	ENSG00000273989.1	RP11-425D17.2	3.31	0.000972	0.0424	0.15	0.1	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28385502	chr12:28236227~28236828:+
BRCA	cis	rs6723226	0.557	rs62136260	ENSG00000276517.1	AL133243.2	3.31	0.000972	0.0424	0.12	0.1	Intelligence (multi-trait analysis);	chr2:32350379	chr2:32526504~32529507:+
BRCA	cis	rs60871478	0.636	rs12532761	ENSG00000237181.1	AC147651.4	3.31	0.000972	0.0424	0.12	0.1	Cerebrospinal P-tau181p levels;	chr7:865592	chr7:603185~608482:+
BRCA	cis	rs8127691	0.967	rs762423	ENSG00000225331.1	AP001055.6	3.31	0.000972	0.0424	0.12	0.1	Inflammatory bowel disease;	chr21:44195803	chr21:44158740~44160076:-
BRCA	cis	rs7917772	0.503	rs11191330	ENSG00000213061.2	PFN1P11	-3.31	0.000972	0.0424	-0.14	-0.1	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;	chr10:102546403	chr10:102838011~102845473:-
BRCA	cis	rs783540	1	rs11631963	ENSG00000274376.3	ADAMTS7P1	3.31	0.000972	0.0424	0.11	0.1	Schizophrenia;	chr15:82649451	chr15:82298553~82334609:+
BRCA	cis	rs10905065	0.93	rs10795485	ENSG00000215267.7	AKR1C7P	3.31	0.000972	0.0424	0.13	0.1	Menopause (age at onset);	chr10:5713084	chr10:5275173~5288470:-
BRCA	cis	rs8038465	0.638	rs8036954	ENSG00000260898.4	ADPGK-AS1	3.31	0.000972	0.0424	0.11	0.1	Liver enzyme levels (gamma-glutamyl transferase);	chr15:73681941	chr15:72782835~72798199:+
BRCA	cis	rs4699052	0.963	rs56144793	ENSG00000246560.2	RP11-10L12.4	3.31	0.000972	0.0424	0.1	0.1	Testicular germ cell tumor;	chr4:103229496	chr4:102828055~102844075:+
BRCA	cis	rs10782582	0.617	rs1846233	ENSG00000181227.3	RP4-682C21.2	3.31	0.000973	0.0424	0.11	0.1	Daytime sleep phenotypes;	chr1:75693669	chr1:75743423~75744776:-
BRCA	cis	rs673253	0.686	rs2819336	ENSG00000229431.1	RP1-92O14.6	3.31	0.000973	0.0424	0.11	0.1	Intelligence (multi-trait analysis);	chr1:43550138	chr1:43385113~43389155:+
BRCA	cis	rs564309	0.764	rs12089997	ENSG00000212237.1	RNA5SP18	3.31	0.000973	0.0424	0.2	0.1	Hip circumference (psychosocial stress interaction);	chr1:228339485	chr1:228647912~228648032:-
BRCA	cis	rs1325195	0.92	rs2793799	ENSG00000261060.1	RP11-545A16.4	3.31	0.000973	0.0424	0.14	0.1	IgE grass sensitization;	chr1:179233074	chr1:179590372~179591305:+
BRCA	cis	rs2562456	0.876	rs2359144	ENSG00000268555.1	RP11-678G14.3	3.31	0.000973	0.0424	0.14	0.1	Pain;	chr19:21407834	chr19:21570822~21587322:-
BRCA	cis	rs2562456	0.876	rs4638726	ENSG00000268555.1	RP11-678G14.3	3.31	0.000973	0.0424	0.14	0.1	Pain;	chr19:21409710	chr19:21570822~21587322:-
BRCA	cis	rs1995809	1	rs1467039	ENSG00000251298.1	RP11-425A23.1	3.31	0.000973	0.0424	0.21	0.1	Plasma amyloid beta peptide concentrations (ABx-40);	chr4:146894953	chr4:147609552~147617245:-
BRCA	cis	rs1995809	1	rs78181888	ENSG00000251298.1	RP11-425A23.1	3.31	0.000973	0.0424	0.21	0.1	Plasma amyloid beta peptide concentrations (ABx-40);	chr4:146902213	chr4:147609552~147617245:-
BRCA	cis	rs8114671	0.562	rs4911164	ENSG00000279253.1	RP4-614O4.13	-3.31	0.000973	0.0424	-0.12	-0.1	Height;	chr20:34891685	chr20:35262727~35264187:-
BRCA	cis	rs12681366	0.708	rs2470728	ENSG00000253175.1	RP11-267M23.6	-3.31	0.000973	0.0424	-0.11	-0.1	Nonsyndromic cleft lip with cleft palate;	chr8:94354142	chr8:94565036~94565715:+
BRCA	cis	rs2625529	0.652	rs2930069	ENSG00000261187.1	RP11-1007O24.2	3.31	0.000973	0.0424	0.11	0.1	Red blood cell count;	chr15:71934636	chr15:72465128~72466262:-
BRCA	cis	rs2191566	0.576	rs436790	ENSG00000266921.1	RP11-15A1.7	-3.31	0.000973	0.0424	-0.13	-0.1	Acute lymphoblastic leukemia (childhood);	chr19:43987775	chr19:43996896~44002836:-
BRCA	cis	rs66887589	0.616	rs1052633	ENSG00000260091.1	RP11-33B1.4	-3.31	0.000973	0.0424	-0.08	-0.1	Diastolic blood pressure;	chr4:119294159	chr4:119409333~119410233:+
BRCA	cis	rs9467773	1	rs6456733	ENSG00000261353.1	CTA-14H9.5	-3.31	0.000973	0.0424	-0.1	-0.1	Intelligence (multi-trait analysis);	chr6:26566576	chr6:26527063~26527404:+
BRCA	cis	rs10782582	0.593	rs4638068	ENSG00000181227.3	RP4-682C21.2	3.31	0.000973	0.0424	0.11	0.1	Daytime sleep phenotypes;	chr1:75695978	chr1:75743423~75744776:-
BRCA	cis	rs9467773	0.967	rs6924865	ENSG00000261353.1	CTA-14H9.5	-3.31	0.000973	0.0424	-0.1	-0.1	Intelligence (multi-trait analysis);	chr6:26521125	chr6:26527063~26527404:+
BRCA	cis	rs73195822	0.614	rs17190144	ENSG00000277299.1	RP11-837J7.4	-3.31	0.000973	0.0424	-0.17	-0.1	Itch intensity from mosquito bite;	chr12:110776962	chr12:109948389~109949029:+
BRCA	cis	rs73195822	0.614	rs55946973	ENSG00000277299.1	RP11-837J7.4	-3.31	0.000973	0.0424	-0.17	-0.1	Itch intensity from mosquito bite;	chr12:110777131	chr12:109948389~109949029:+
BRCA	cis	rs73195822	0.614	rs73194056	ENSG00000277299.1	RP11-837J7.4	-3.31	0.000973	0.0424	-0.17	-0.1	Itch intensity from mosquito bite;	chr12:110778520	chr12:109948389~109949029:+
BRCA	cis	rs1129187	0.967	rs6941212	ENSG00000261068.2	RP11-7K24.3	3.31	0.000973	0.0424	0.13	0.1	Alzheimer's disease in APOE e4+ carriers;	chr6:42948182	chr6:42092233~42094259:-
BRCA	cis	rs7781266	0.697	rs4731952	ENSG00000226205.1	AC007790.4	-3.31	0.000973	0.0424	-0.14	-0.1	Educational attainment (college completion);	chr7:133417574	chr7:133732493~133733595:-
BRCA	cis	rs16893526	1	rs6454240	ENSG00000224995.1	LINC01526	-3.31	0.000973	0.0424	-0.18	-0.1	Coronary heart disease;	chr6:81789040	chr6:81813286~81814157:-
BRCA	cis	rs2018683	0.87	rs13232487	ENSG00000233517.1	AC005162.5	-3.31	0.000973	0.0424	-0.12	-0.1	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28945502	chr7:28987028~28988899:+
BRCA	cis	rs17767294	0.708	rs72848773	ENSG00000219392.1	RP1-265C24.5	-3.31	0.000973	0.0424	-0.28	-0.1	Parkinson's disease;	chr6:27958742	chr6:28115628~28116551:+
BRCA	cis	rs17767294	0.708	rs76223516	ENSG00000219392.1	RP1-265C24.5	-3.31	0.000973	0.0424	-0.28	-0.1	Parkinson's disease;	chr6:27971697	chr6:28115628~28116551:+
BRCA	cis	rs17767294	0.708	rs72848776	ENSG00000219392.1	RP1-265C24.5	-3.31	0.000973	0.0424	-0.28	-0.1	Parkinson's disease;	chr6:27987048	chr6:28115628~28116551:+
BRCA	cis	rs990171	0.538	rs6543154	ENSG00000234389.1	AC007278.3	3.31	0.000973	0.0424	0.1	0.1	Lymphocyte counts;	chr2:102497875	chr2:102438713~102440475:+
BRCA	cis	rs6601327	0.54	rs6982148	ENSG00000233609.3	RP11-62H7.2	-3.31	0.000973	0.0424	-0.1	-0.1	Multiple myeloma (hyperdiploidy);	chr8:9723560	chr8:8961200~8979025:+
BRCA	cis	rs7759001	0.744	rs13217162	ENSG00000204789.4	ZNF204P	3.31	0.000974	0.0424	0.13	0.1	Glomerular filtration rate (creatinine);	chr6:27509320	chr6:27357825~27360221:-
BRCA	cis	rs2148307	0.55	rs3781488	ENSG00000228339.1	AMD1P1	-3.31	0.000974	0.0424	-0.13	-0.1	Photic sneeze reflex;	chr10:20797575	chr10:20350049~20351100:+
BRCA	cis	rs2337406	1	rs3858878	ENSG00000231475.3	IGHV4-31	3.31	0.000974	0.0424	0.1	0.1	Alzheimer's disease (late onset);	chr14:106688061	chr14:106349283~106349792:-
BRCA	cis	rs896655	0.738	rs4615669	ENSG00000229298.1	TUBB8P1	-3.31	0.000974	0.0424	-0.11	-0.1	Coronary artery disease;	chr9:21818675	chr9:21811621~21812347:-
BRCA	cis	rs2120461	0.517	rs754346	ENSG00000238290.1	RP11-431K24.1	-3.31	0.000974	0.0425	-0.12	-0.1	Bone mineral density;	chr1:8373687	chr1:8026738~8122702:+
BRCA	cis	rs4372836	0.58	rs6718662	ENSG00000226833.4	AC097724.3	3.31	0.000974	0.0425	0.12	0.1	Body mass index;	chr2:28825892	chr2:28708953~28736205:-
BRCA	cis	rs11673344	0.864	rs826322	ENSG00000267422.1	CTD-2554C21.1	3.31	0.000974	0.0425	0.13	0.1	Obesity-related traits;	chr19:37013694	chr19:37779686~37792865:+
BRCA	cis	rs74233809	1	rs79237883	ENSG00000236937.2	PTGES3P4	3.31	0.000974	0.0425	0.23	0.1	Birth weight;	chr10:103181189	chr10:102845595~102845950:+
BRCA	cis	rs1376877	0.776	rs7575778	ENSG00000273456.1	RP11-686O6.2	3.31	0.000974	0.0425	0.1	0.1	Subclinical atherosclerosis traits (other);	chr2:203008566	chr2:202374932~202375604:-
BRCA	cis	rs17767294	0.615	rs72845058	ENSG00000272009.1	RP1-313I6.12	-3.31	0.000974	0.0425	-0.26	-0.1	Parkinson's disease;	chr6:27679641	chr6:28078792~28081130:-
BRCA	cis	rs9468199	0.51	rs72845064	ENSG00000272009.1	RP1-313I6.12	-3.31	0.000974	0.0425	-0.26	-0.1	Parkinson's disease;	chr6:27687191	chr6:28078792~28081130:-
BRCA	cis	rs17767294	0.614	rs72845068	ENSG00000272009.1	RP1-313I6.12	-3.31	0.000974	0.0425	-0.26	-0.1	Parkinson's disease;	chr6:27700368	chr6:28078792~28081130:-
BRCA	cis	rs2562456	0.754	rs55771551	ENSG00000268119.4	CTD-2561J22.5	3.31	0.000974	0.0425	0.16	0.1	Pain;	chr19:21563578	chr19:21444241~21463908:-
BRCA	cis	rs10266483	1	rs1960321	ENSG00000271550.1	BNIP3P11	3.31	0.000974	0.0425	0.13	0.1	Response to statin therapy;	chr7:64270906	chr7:64678954~64687393:-
BRCA	cis	rs17361889	0.517	rs62440455	ENSG00000229108.1	MEOX2-AS1	3.31	0.000974	0.0425	0.13	0.1	Pediatric bone mineral content (hip);	chr7:16285646	chr7:15688378~15695491:+
BRCA	cis	rs8014204	0.816	rs28426374	ENSG00000279594.1	RP11-950C14.10	-3.31	0.000974	0.0425	-0.11	-0.1	Caffeine consumption;	chr14:74880037	chr14:75011269~75012851:-
BRCA	cis	rs300703	0.719	rs389621	ENSG00000228643.1	AC079779.4	-3.31	0.000974	0.0425	-0.17	-0.1	Blood protein levels;	chr2:206636	chr2:286419~301515:+
BRCA	cis	rs875971	0.862	rs778724	ENSG00000223473.2	GS1-124K5.3	3.31	0.000974	0.0425	0.08	0.1	Aortic root size;	chr7:66364304	chr7:66491049~66493566:-
BRCA	cis	rs7893279	0.822	rs10828679	ENSG00000240291.1	RP11-499P20.2	-3.31	0.000974	0.0425	-0.14	-0.1	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr10:18422359	chr10:18513115~18545651:-
BRCA	cis	rs2562456	0.833	rs2562487	ENSG00000240522.1	RPL7AP10	-3.31	0.000974	0.0425	-0.12	-0.1	Pain;	chr19:21468580	chr19:21149648~21150438:-
BRCA	cis	rs4650994	0.593	rs12568310	ENSG00000273384.1	RP5-1098D14.1	-3.31	0.000974	0.0425	-0.14	-0.1	HDL cholesterol;HDL cholesterol levels;	chr1:178545487	chr1:178651706~178652282:+
BRCA	cis	rs2267137	0.903	rs5752903	ENSG00000279159.1	RP3-394A18.1	3.31	0.000974	0.0425	0.08	0.1	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr22:29373317	chr22:29978950~30028236:-
BRCA	cis	rs66887589	0.616	rs11732621	ENSG00000260091.1	RP11-33B1.4	-3.31	0.000974	0.0425	-0.08	-0.1	Diastolic blood pressure;	chr4:119291728	chr4:119409333~119410233:+
BRCA	cis	rs990171	0.538	rs1403548	ENSG00000234389.1	AC007278.3	3.31	0.000974	0.0425	0.1	0.1	Lymphocyte counts;	chr2:102493916	chr2:102438713~102440475:+
BRCA	cis	rs2562456	0.876	rs10424079	ENSG00000268555.1	RP11-678G14.3	3.31	0.000975	0.0425	0.14	0.1	Pain;	chr19:21406377	chr19:21570822~21587322:-
BRCA	cis	rs4648045	0.796	rs7683854	ENSG00000251288.2	RP11-10L12.2	-3.31	0.000975	0.0425	-0.13	-0.1	Lymphocyte percentage of white cells;	chr4:102608899	chr4:102751401~102752641:+
BRCA	cis	rs6142102	1	rs4911410	ENSG00000206582.1	Y_RNA	-3.31	0.000975	0.0425	-0.12	-0.1	Skin pigmentation;	chr20:34123168	chr20:34526510~34526606:-
BRCA	cis	rs17192198	0.66	rs12813149	ENSG00000258302.2	RP11-981P6.1	-3.31	0.000975	0.0425	-0.12	-0.1	Diastolic blood pressure;	chr12:89748860	chr12:89561129~89594878:+
BRCA	cis	rs7618501	0.699	rs2777888	ENSG00000281433.1	Metazoa_SRP	-3.31	0.000975	0.0425	-0.1	-0.1	Intelligence (multi-trait analysis);	chr3:49860567	chr3:49320296~49320564:+
BRCA	cis	rs6840360	0.571	rs10007653	ENSG00000278978.1	RP11-164P12.5	-3.31	0.000975	0.0425	-0.12	-0.1	Intelligence (multi-trait analysis);	chr4:151602903	chr4:151669786~151670503:+
BRCA	cis	rs4665809	1	rs6709595	ENSG00000231655.1	AC011742.3	3.31	0.000975	0.0425	0.14	0.1	Gut microbiome composition (summer);	chr2:26037016	chr2:26140263~26141264:-
BRCA	cis	rs7267979	0.932	rs6138600	ENSG00000274973.1	RP13-401N8.7	-3.31	0.000975	0.0425	-0.12	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25540710	chr20:25845497~25845862:+
BRCA	cis	rs12479064	0.724	rs3792143	ENSG00000231822.1	AC019097.7	-3.31	0.000975	0.0425	-0.12	-0.1	Chronic sinus infection;	chr2:99440558	chr2:99102018~99102752:+
BRCA	cis	rs16852403	0.583	rs6670912	ENSG00000224687.1	RASAL2-AS1	3.31	0.000975	0.0425	0.13	0.1	Childhood ear infection;	chr1:178113275	chr1:178091508~178093984:-
BRCA	cis	rs56146007	0.55	rs2133627	ENSG00000277855.1	RP11-154H23.4	-3.31	0.000975	0.0425	-0.16	-0.1	Selective IgA deficiency;	chr3:71502719	chr3:71581721~71628558:+
BRCA	cis	rs9510795	0.55	rs9510796	ENSG00000205861.10	C1QTNF9B-AS1	-3.31	0.000975	0.0425	-0.15	-0.1	Diabetic kidney disease;	chr13:23648631	chr13:23888889~23897263:+
BRCA	cis	rs875971	0.571	rs78668714	ENSG00000273448.1	RP11-166O4.6	3.31	0.000975	0.0425	0.11	0.1	Aortic root size;	chr7:66474464	chr7:67333047~67334383:+
BRCA	cis	rs4415084	0.8	rs2330572	ENSG00000272335.1	RP11-53O19.3	-3.31	0.000975	0.0425	-0.09	-0.1	Breast cancer;	chr5:44740887	chr5:44826076~44828592:+
BRCA	cis	rs4982731	1	rs4982731	ENSG00000279656.1	RP11-298I3.6	3.31	0.000975	0.0425	0.13	0.1	Basophil percentage of granulocytes;Acute lymphoblastic leukemia (childhood);Basophil percentage of white cells;	chr14:23116124	chr14:23023083~23024217:-
BRCA	cis	rs4819052	0.851	rs58644915	ENSG00000223768.1	LINC00205	-3.31	0.000975	0.0425	-0.14	-0.1	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45249997	chr21:45293285~45297354:+
BRCA	cis	rs7098100	0.641	rs2807987	ENSG00000231920.1	NEBL-AS1	3.31	0.000975	0.0425	0.12	0.1	Breast cancer;	chr10:21951023	chr10:21174014~21175048:+
BRCA	cis	rs7560272	0.501	rs2421676	ENSG00000204872.3	NAT8B	3.31	0.000975	0.0425	0.14	0.1	Schizophrenia;	chr2:73738960	chr2:73700576~73701340:-
BRCA	cis	rs9341808	0.754	rs9343973	ENSG00000279022.1	RP11-250B2.4	3.31	0.000976	0.0425	0.12	0.1	Sitting height ratio;	chr6:80203499	chr6:80440730~80441172:+
BRCA	cis	rs1165668	1	rs1866071	ENSG00000257681.1	RP11-341G23.4	-3.31	0.000976	0.0425	-0.12	-0.1	Coronary heart disease (SNP X SNP interaction);	chr12:103916860	chr12:103746315~103768858:-
BRCA	cis	rs9329221	0.725	rs11250001	ENSG00000154316.13	TDH	3.31	0.000976	0.0425	0.14	0.1	Neuroticism;	chr8:10398391	chr8:11339637~11368452:+
BRCA	cis	rs5167	0.566	rs60876330	ENSG00000214855.8	APOC1P1	3.31	0.000976	0.0425	0.13	0.1	Blood protein levels;	chr19:44984875	chr19:44926804~44931386:+
BRCA	cis	rs7762018	0.77	rs3823466	ENSG00000266896.1	RP1-266L20.9	3.31	0.000976	0.0425	0.12	0.1	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr6:169789830	chr6:169770413~169772042:+
BRCA	cis	rs2351088	0.764	rs17653487	ENSG00000231010.1	RP6-109B7.2	-3.31	0.000976	0.0425	-0.18	-0.1	Tonsillectomy;	chr22:45803452	chr22:46055740~46058160:-
BRCA	cis	rs9467773	0.838	rs3734540	ENSG00000241549.7	GUSBP2	3.31	0.000976	0.0425	0.11	0.1	Intelligence (multi-trait analysis);	chr6:26463093	chr6:26871484~26956554:-
BRCA	cis	rs986417	0.901	rs1955692	ENSG00000258670.1	RP11-1042B17.3	-3.31	0.000976	0.0425	-0.18	-0.1	Gut microbiota (bacterial taxa);	chr14:60541690	chr14:60515119~60554916:+
BRCA	cis	rs9481169	0.85	rs13210247	ENSG00000271789.1	RP5-1112D6.7	3.31	0.000976	0.0425	0.2	0.1	Inflammatory skin disease;	chr6:111601517	chr6:111297126~111298510:+
BRCA	cis	rs7818688	0.674	rs74632106	ENSG00000245080.5	RP11-320N21.1	-3.31	0.000976	0.0425	-0.17	-0.1	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94965804	chr8:95066808~95073182:-
BRCA	cis	rs7818688	0.697	rs112076731	ENSG00000245080.5	RP11-320N21.1	-3.31	0.000976	0.0425	-0.17	-0.1	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94965893	chr8:95066808~95073182:-
BRCA	cis	rs7267979	1	rs6132835	ENSG00000276952.1	RP5-965G21.6	3.31	0.000976	0.0425	0.12	0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25454031	chr20:25284915~25285588:-
BRCA	cis	rs7267979	0.933	rs11699203	ENSG00000276952.1	RP5-965G21.6	3.31	0.000976	0.0425	0.12	0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25454533	chr20:25284915~25285588:-
BRCA	cis	rs7267979	0.933	rs6138571	ENSG00000276952.1	RP5-965G21.6	3.31	0.000976	0.0425	0.12	0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25454752	chr20:25284915~25285588:-
BRCA	cis	rs7267979	0.966	rs416745	ENSG00000276952.1	RP5-965G21.6	3.31	0.000976	0.0425	0.12	0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25458232	chr20:25284915~25285588:-
BRCA	cis	rs7267979	1	rs447722	ENSG00000276952.1	RP5-965G21.6	3.31	0.000976	0.0425	0.12	0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25462874	chr20:25284915~25285588:-
BRCA	cis	rs7267979	1	rs422424	ENSG00000276952.1	RP5-965G21.6	3.31	0.000976	0.0425	0.12	0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25464810	chr20:25284915~25285588:-
BRCA	cis	rs7267979	1	rs422844	ENSG00000276952.1	RP5-965G21.6	3.31	0.000976	0.0425	0.12	0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25464955	chr20:25284915~25285588:-
BRCA	cis	rs7267979	1	rs401166	ENSG00000276952.1	RP5-965G21.6	3.31	0.000976	0.0425	0.12	0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25465672	chr20:25284915~25285588:-
BRCA	cis	rs875971	0.83	rs12673450	ENSG00000273024.4	INTS4P2	-3.31	0.000976	0.0425	-0.12	-0.1	Aortic root size;	chr7:66544233	chr7:65647864~65715661:+
BRCA	cis	rs17756712	0.725	rs57111852	ENSG00000272463.1	RP11-532F6.3	3.31	0.000976	0.0425	0.17	0.1	Vertical cup-disc ratio;	chr6:606263	chr6:708592~711405:-
BRCA	cis	rs924712	0.844	rs10456176	ENSG00000261116.1	RP3-523K23.2	3.31	0.000976	0.0425	0.13	0.1	Breast cancer;	chr6:54865382	chr6:54943167~54945099:+
BRCA	cis	rs4742903	1	rs3780535	ENSG00000270332.1	SMC2-AS1	3.31	0.000976	0.0425	0.11	0.1	Breast cancer;High-grade serous ovarian cancer;	chr9:104131930	chr9:104080024~104093073:-
BRCA	cis	rs1008375	1	rs917665	ENSG00000249502.1	AC006160.5	3.31	0.000976	0.0425	0.12	0.1	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17666881	chr4:17587467~17614571:-
BRCA	cis	rs10129255	0.957	rs8005468	ENSG00000253132.1	IGHV3-62	-3.31	0.000976	0.0425	-0.08	-0.1	Kawasaki disease;	chr14:106686431	chr14:106643142~106643585:-
BRCA	cis	rs4665809	1	rs4665299	ENSG00000231655.1	AC011742.3	3.31	0.000976	0.0425	0.16	0.1	Gut microbiome composition (summer);	chr2:26033971	chr2:26140263~26141264:-
BRCA	cis	rs2070488	0.965	rs13079145	ENSG00000232439.1	RPL18AP7	3.31	0.000976	0.0425	0.12	0.1	Electrocardiographic conduction measures;	chr3:38476501	chr3:38526802~38527325:-
BRCA	cis	rs2692947	0.74	rs59076415	ENSG00000237510.6	AC008268.2	3.31	0.000977	0.0425	0.15	0.1	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95728196	chr2:95789654~95800166:+
BRCA	cis	rs848490	0.889	rs6955503	ENSG00000214293.7	APTR	3.31	0.000977	0.0425	0.13	0.1	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77597924	chr7:77657660~77696265:-
BRCA	cis	rs17301013	0.932	rs444678	ENSG00000200674.1	RN7SKP160	3.31	0.000977	0.0426	0.13	0.1	Systemic lupus erythematosus;	chr1:174706080	chr1:173791548~173791887:+
BRCA	cis	rs7818688	0.697	rs75349998	ENSG00000245080.5	RP11-320N21.1	-3.31	0.000977	0.0426	-0.17	-0.1	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94978690	chr8:95066808~95073182:-
BRCA	cis	rs4706831	0.647	rs627240	ENSG00000279022.1	RP11-250B2.4	-3.31	0.000977	0.0426	-0.11	-0.1	Joint mobility (Beighton score);	chr6:80276168	chr6:80440730~80441172:+
BRCA	cis	rs504458	0.618	rs569450	ENSG00000241975.1	TCEB1P19	-3.31	0.000977	0.0426	-0.12	-0.1	Childhood ear infection;	chr1:88285748	chr1:88829102~88829419:+
BRCA	cis	rs67478160	0.619	rs8018062	ENSG00000269910.1	RP11-73M18.10	3.31	0.000977	0.0426	0.1	0.1	Schizophrenia;	chr14:103815617	chr14:103694516~103695050:-
BRCA	cis	rs494459	0.838	rs555649	ENSG00000254873.1	RP11-770J1.5	3.31	0.000977	0.0426	0.12	0.1	Height;	chr11:118781100	chr11:118397095~118401895:-
BRCA	cis	rs10129255	0.785	rs10150044	ENSG00000253132.1	IGHV3-62	-3.31	0.000977	0.0426	-0.08	-0.1	Kawasaki disease;	chr14:106775695	chr14:106643142~106643585:-
BRCA	cis	rs12282928	0.959	rs873043	ENSG00000255197.4	RP11-750H9.5	3.31	0.000977	0.0426	0.1	0.1	Migraine - clinic-based;	chr11:48257413	chr11:47383148~47409190:-
BRCA	cis	rs13256369	1	rs10103769	ENSG00000233609.3	RP11-62H7.2	3.31	0.000977	0.0426	0.11	0.1	Obesity-related traits;	chr8:8715526	chr8:8961200~8979025:+
BRCA	cis	rs77688320	0.535	rs11680694	ENSG00000242696.3	RN7SL40P	-3.31	0.000977	0.0426	-0.11	-0.1	Breast cancer;	chr2:201393498	chr2:202357076~202357417:-
BRCA	cis	rs6142102	0.961	rs6059651	ENSG00000206582.1	Y_RNA	-3.31	0.000977	0.0426	-0.13	-0.1	Skin pigmentation;	chr20:34057246	chr20:34526510~34526606:-
BRCA	cis	rs6964587	0.692	rs6953256	ENSG00000188693.7	CYP51A1-AS1	3.31	0.000977	0.0426	0.11	0.1	Breast cancer;	chr7:91946103	chr7:92134604~92180725:+
BRCA	cis	rs7849420	0.537	rs1360526	ENSG00000240498.5	CDKN2B-AS1	-3.31	0.000977	0.0426	-0.12	-0.1	Lipid traits;	chr9:21532566	chr9:21994778~22121097:+
BRCA	cis	rs6540556	0.723	rs1000283	ENSG00000236136.1	ADORA2BP1	3.31	0.000978	0.0426	0.13	0.1	Red blood cell count;	chr1:209721316	chr1:209744373~209745214:+
BRCA	cis	rs4699052	0.963	rs7657390	ENSG00000230069.3	LRRC37A15P	-3.31	0.000978	0.0426	-0.1	-0.1	Testicular germ cell tumor;	chr4:103291957	chr4:102727274~102730721:-
BRCA	cis	rs1008375	1	rs2872959	ENSG00000249502.1	AC006160.5	3.31	0.000978	0.0426	0.12	0.1	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17675540	chr4:17587467~17614571:-
BRCA	cis	rs11887277	0.557	rs4665904	ENSG00000272148.1	RP11-195B17.1	-3.31	0.000978	0.0426	-0.12	-0.1	Obesity-related traits;	chr2:26759732	chr2:27062428~27062907:-
BRCA	cis	rs71520386	0.583	rs28799344	ENSG00000226329.2	AC005682.6	-3.31	0.000978	0.0426	-0.1	-0.1	Fibrinogen levels;	chr7:22805647	chr7:22863874~22881350:-
BRCA	cis	rs3750552	0.615	rs10780308	ENSG00000278910.2	BANCR	3.31	0.000978	0.0426	0.13	0.1	Bipolar disorder;	chr9:69339698	chr9:69296682~69306977:-
BRCA	cis	rs7474896	1	rs12358094	ENSG00000120555.12	SEPT7P9	3.31	0.000978	0.0426	0.19	0.1	Obesity (extreme);	chr10:37726578	chr10:38383069~38402916:-
BRCA	cis	rs12760731	0.545	rs34112873	ENSG00000213057.5	C1orf220	3.31	0.000978	0.0426	0.13	0.1	Obesity-related traits;	chr1:178550808	chr1:178542752~178548889:+
BRCA	cis	rs4481887	0.604	rs6694598	ENSG00000202079.1	Y_RNA	-3.31	0.000978	0.0426	-0.12	-0.1	Common traits (Other);	chr1:248246188	chr1:247294835~247294941:+
BRCA	cis	rs7578361	0.918	rs12476540	ENSG00000231969.1	AC144449.1	-3.31	0.000978	0.0426	-0.16	-0.1	Acute lymphoblastic leukemia (childhood);	chr2:149513242	chr2:149587196~149848233:+
BRCA	cis	rs7578361	0.918	rs12473350	ENSG00000231969.1	AC144449.1	-3.31	0.000978	0.0426	-0.16	-0.1	Acute lymphoblastic leukemia (childhood);	chr2:149513302	chr2:149587196~149848233:+
BRCA	cis	rs7020830	0.522	rs10814509	ENSG00000230188.1	RP11-405L18.4	-3.31	0.000978	0.0426	-0.12	-0.1	Schizophrenia;	chr9:37111060	chr9:37490421~37490893:-
BRCA	cis	rs6792584	0.962	rs4423787	ENSG00000241316.5	SUCLG2-AS1	3.31	0.000978	0.0426	0.12	0.1	Corneal astigmatism;	chr3:67461690	chr3:67654697~67947713:+
BRCA	cis	rs6672530	0.518	rs12025815	ENSG00000227711.2	RP11-275O4.5	3.31	0.000978	0.0426	0.12	0.1	Hip circumference adjusted for BMI;	chr1:227570371	chr1:227509028~227520477:-
BRCA	cis	rs2638953	0.853	rs10506038	ENSG00000273989.1	RP11-425D17.2	3.31	0.000978	0.0426	0.15	0.1	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28506239	chr12:28236227~28236828:+
BRCA	cis	rs13401620	0.626	rs2860928	ENSG00000236878.1	AC012363.7	3.31	0.000978	0.0426	0.12	0.1	Breast size;	chr2:120109017	chr2:120211054~120211715:+
BRCA	cis	rs2625529	0.652	rs2957728	ENSG00000261187.1	RP11-1007O24.2	3.31	0.000978	0.0426	0.11	0.1	Red blood cell count;	chr15:71944091	chr15:72465128~72466262:-
BRCA	cis	rs3820068	0.581	rs1122386	ENSG00000237301.1	RP4-680D5.2	-3.31	0.000978	0.0426	-0.13	-0.1	Systolic blood pressure;	chr1:15620382	chr1:15586136~15603626:-
BRCA	cis	rs3820068	0.603	rs1122387	ENSG00000237301.1	RP4-680D5.2	-3.31	0.000978	0.0426	-0.13	-0.1	Systolic blood pressure;	chr1:15620787	chr1:15586136~15603626:-
BRCA	cis	rs6921919	0.583	rs16894108	ENSG00000219891.2	ZSCAN12P1	3.31	0.000978	0.0426	0.13	0.1	Autism spectrum disorder or schizophrenia;	chr6:28434013	chr6:28091154~28093664:+
BRCA	cis	rs495337	0.965	rs2056991	ENSG00000224397.4	LINC01272	-3.31	0.000978	0.0426	-0.1	-0.1	Psoriasis;	chr20:49944743	chr20:50267486~50279795:+
BRCA	cis	rs1443512	0.812	rs1975472	ENSG00000274817.1	HOTAIR_4	-3.31	0.000978	0.0426	-0.12	-0.1	Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-hip ratio;Waist-to-hip ratio adjusted for body mass index;	chr12:53943299	chr12:53968002~53968178:+
BRCA	cis	rs687432	0.774	rs17152376	ENSG00000213592.4	AP000662.9	-3.31	0.000978	0.0426	-0.14	-0.1	Parkinson's disease;	chr11:58117457	chr11:57718044~57718530:-
BRCA	cis	rs4388249	0.948	rs34364676	ENSG00000249068.1	CTC-287O8.1	3.31	0.000979	0.0426	0.15	0.1	Schizophrenia;	chr5:109760822	chr5:109840128~109840692:-
BRCA	cis	rs4388249	1	rs34961375	ENSG00000249068.1	CTC-287O8.1	3.31	0.000979	0.0426	0.15	0.1	Schizophrenia;	chr5:109761009	chr5:109840128~109840692:-
BRCA	cis	rs9921338	1	rs9921338	ENSG00000263080.1	RP11-485G7.5	-3.31	0.000979	0.0426	-0.15	-0.1	Vein graft stenosis in coronary artery bypass grafting;	chr16:11322982	chr16:11341809~11345211:-
BRCA	cis	rs7188861	0.681	rs34947566	ENSG00000262636.1	CTD-3088G3.4	3.31	0.000979	0.0426	0.2	0.1	HDL cholesterol;	chr16:11319069	chr16:11380859~11381118:-
BRCA	cis	rs34975555	0.803	rs2299599	ENSG00000254054.2	RP11-156K13.3	-3.31	0.000979	0.0426	-0.15	-0.1	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:17978999	chr8:17905756~17907887:+
BRCA	cis	rs4714291	1	rs9380924	ENSG00000180211.5	RP1-278E11.3	3.31	0.000979	0.0426	0.11	0.1	Strep throat;	chr6:40026436	chr6:39958414~39958833:-
BRCA	cis	rs863345	0.604	rs12041348	ENSG00000229914.1	RP11-404O13.4	-3.31	0.000979	0.0426	-0.11	-0.1	Pneumococcal bacteremia;	chr1:158512252	chr1:158195633~158196131:-
BRCA	cis	rs863345	0.604	rs12041350	ENSG00000229914.1	RP11-404O13.4	-3.31	0.000979	0.0426	-0.11	-0.1	Pneumococcal bacteremia;	chr1:158512258	chr1:158195633~158196131:-
BRCA	cis	rs7487075	0.859	rs7968283	ENSG00000257261.4	RP11-96H19.1	3.31	0.000979	0.0426	0.12	0.1	Itch intensity from mosquito bite;	chr12:46365353	chr12:46383679~46876159:+
BRCA	cis	rs7944735	0.817	rs7101582	ENSG00000252874.2	Y_RNA	3.31	0.000979	0.0426	0.13	0.1	Intraocular pressure;	chr11:47693058	chr11:47820200~47820289:-
BRCA	cis	rs1466788	0.932	rs3754442	ENSG00000224965.1	KCNC4-AS1	3.31	0.000979	0.0426	0.12	0.1	Blood metabolite levels;	chr1:110069264	chr1:110208834~110209987:-
BRCA	cis	rs739496	0.843	rs583140	ENSG00000257624.1	RP1-128M12.3	3.31	0.000979	0.0426	0.14	0.1	Platelet count;	chr12:111548150	chr12:112000739~112000985:-
BRCA	cis	rs10905065	1	rs10795488	ENSG00000215267.7	AKR1C7P	3.31	0.000979	0.0426	0.13	0.1	Menopause (age at onset);	chr10:5713244	chr10:5275173~5288470:-
BRCA	cis	rs10812641	0.837	rs7049072	ENSG00000236404.7	VLDLR-AS1	3.31	0.000979	0.0426	0.12	0.1	Blood trace element (Se levels);	chr9:2787594	chr9:2422702~2643359:-
BRCA	cis	rs4714291	0.963	rs847777	ENSG00000180211.5	RP1-278E11.3	3.31	0.000979	0.0426	0.11	0.1	Strep throat;	chr6:40088015	chr6:39958414~39958833:-
BRCA	cis	rs4697263	0.606	rs34512134	ENSG00000237350.1	CDC42P6	3.31	0.000979	0.0427	0.13	0.1	Age-related hearing impairment (SNP x SNP interaction);	chr4:22021301	chr4:22727375~22727950:-
BRCA	cis	rs4834770	0.668	rs6833072	ENSG00000249244.1	RP11-548H18.2	-3.31	0.00098	0.0427	-0.12	-0.1	Blood protein levels;	chr4:119212737	chr4:119391831~119395335:-
BRCA	cis	rs765787	0.53	rs3759895	ENSG00000259539.1	CTD-2651B20.1	3.31	0.00098	0.0427	0.12	0.1	Uric acid levels;	chr15:45251672	chr15:45152664~45167526:-
BRCA	cis	rs8180040	1	rs7613282	ENSG00000260236.1	RP11-708J19.1	-3.31	0.00098	0.0427	-0.09	-0.1	Colorectal cancer;	chr3:47347919	chr3:47379089~47380999:-
BRCA	cis	rs4631830	0.863	rs2249986	ENSG00000204177.9	BMS1P1	-3.31	0.00098	0.0427	-0.1	-0.1	Prostate-specific antigen levels;	chr10:46074138	chr10:46786674~46811989:+
BRCA	cis	rs2113818	0.765	rs4669869	ENSG00000225649.4	AC064875.2	3.31	0.00098	0.0427	0.12	0.1	Optic cup area;	chr2:12758334	chr2:12966784~13007013:-
BRCA	cis	rs930395	0.514	rs6874167	ENSG00000248779.1	RP11-53O19.2	-3.31	0.00098	0.0427	-0.1	-0.1	Breast cancer;	chr5:44916572	chr5:44752949~44765744:+
BRCA	cis	rs930395	0.514	rs4866921	ENSG00000248779.1	RP11-53O19.2	-3.31	0.00098	0.0427	-0.1	-0.1	Breast cancer;	chr5:44917035	chr5:44752949~44765744:+
BRCA	cis	rs930395	0.514	rs6451783	ENSG00000248779.1	RP11-53O19.2	-3.31	0.00098	0.0427	-0.1	-0.1	Breast cancer;	chr5:44918191	chr5:44752949~44765744:+
BRCA	cis	rs930395	0.514	rs7736092	ENSG00000248779.1	RP11-53O19.2	-3.31	0.00098	0.0427	-0.1	-0.1	Breast cancer;	chr5:44920893	chr5:44752949~44765744:+
BRCA	cis	rs930395	0.514	rs10941687	ENSG00000248779.1	RP11-53O19.2	-3.31	0.00098	0.0427	-0.1	-0.1	Breast cancer;	chr5:44921081	chr5:44752949~44765744:+
BRCA	cis	rs930395	0.514	rs7708506	ENSG00000248779.1	RP11-53O19.2	-3.31	0.00098	0.0427	-0.1	-0.1	Breast cancer;	chr5:44922602	chr5:44752949~44765744:+
BRCA	cis	rs930395	0.514	rs7708686	ENSG00000248779.1	RP11-53O19.2	-3.31	0.00098	0.0427	-0.1	-0.1	Breast cancer;	chr5:44922736	chr5:44752949~44765744:+
BRCA	cis	rs4415084	0.68	rs10042455	ENSG00000248779.1	RP11-53O19.2	-3.31	0.00098	0.0427	-0.1	-0.1	Breast cancer;	chr5:44924916	chr5:44752949~44765744:+
BRCA	cis	rs930395	0.514	rs10039866	ENSG00000248779.1	RP11-53O19.2	-3.31	0.00098	0.0427	-0.1	-0.1	Breast cancer;	chr5:44924959	chr5:44752949~44765744:+
BRCA	cis	rs8007846	0.588	rs11625362	ENSG00000276116.2	FUT8-AS1	-3.31	0.00098	0.0427	-0.11	-0.1	Multiple sclerosis--Brain Glutamate Levels;	chr14:65766151	chr14:65411170~65412690:-
BRCA	cis	rs2562456	0.652	rs62110214	ENSG00000268119.4	CTD-2561J22.5	3.31	0.00098	0.0427	0.17	0.1	Pain;	chr19:21592406	chr19:21444241~21463908:-
BRCA	cis	rs11673344	0.864	rs703537	ENSG00000267422.1	CTD-2554C21.1	3.31	0.00098	0.0427	0.13	0.1	Obesity-related traits;	chr19:37016827	chr19:37779686~37792865:+
BRCA	cis	rs7716600	0.501	rs1438827	ENSG00000248779.1	RP11-53O19.2	3.31	0.00098	0.0427	0.1	0.1	Breast cancer;	chr5:44751854	chr5:44752949~44765744:+
BRCA	cis	rs2839186	0.585	rs2839154	ENSG00000215424.8	MCM3AP-AS1	-3.31	0.00098	0.0427	-0.09	-0.1	Testicular germ cell tumor;	chr21:46217846	chr21:46229217~46259390:+
BRCA	cis	rs7267979	1	rs6050559	ENSG00000204556.4	CTD-2514C3.1	-3.31	0.00098	0.0427	-0.14	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25349279	chr20:26018832~26020684:+
BRCA	cis	rs853679	0.517	rs1947863	ENSG00000272009.1	RP1-313I6.12	-3.31	0.00098	0.0427	-0.15	-0.1	Depression;	chr6:28131566	chr6:28078792~28081130:-
BRCA	cis	rs12468226	1	rs7565875	ENSG00000233579.1	KRT8P15	-3.31	0.00098	0.0427	-0.17	-0.1	Urate levels;	chr2:202516412	chr2:202840331~202841781:-
BRCA	cis	rs7520050	0.966	rs1707304	ENSG00000234329.1	RP11-767N6.2	-3.31	0.00098	0.0427	-0.1	-0.1	Reticulocyte count;Red blood cell count;	chr1:46132597	chr1:45651039~45651826:-
BRCA	cis	rs2562456	0.876	rs2650844	ENSG00000240522.1	RPL7AP10	-3.31	0.00098	0.0427	-0.12	-0.1	Pain;	chr19:21419288	chr19:21149648~21150438:-
BRCA	cis	rs11239930	0.517	rs632861	ENSG00000227242.3	NBPF13P	-3.31	0.00098	0.0427	-0.13	-0.1	AIDS progression;	chr1:147079826	chr1:147021320~147124525:-
BRCA	cis	rs4499344	0.556	rs259228	ENSG00000267475.1	CTD-2538C1.2	3.31	0.00098	0.0427	0.14	0.1	Mean platelet volume;	chr19:32643729	chr19:32687089~32691750:-
BRCA	cis	rs1949733	1	rs3103067	ENSG00000251615.3	RP11-774O3.3	-3.31	0.00098	0.0427	-0.11	-0.1	Response to antineoplastic agents;	chr4:8509496	chr4:8355090~8358338:-
BRCA	cis	rs13260300	0.533	rs890217	ENSG00000254349.4	FLJ39080	3.31	0.00098	0.0427	0.13	0.1	Breast cancer-free interval (treatment with aromatase inhibitor);	chr8:74581782	chr8:74599775~74823313:+
BRCA	cis	rs13260300	0.533	rs890216	ENSG00000254349.4	FLJ39080	3.31	0.00098	0.0427	0.13	0.1	Breast cancer-free interval (treatment with aromatase inhibitor);	chr8:74581948	chr8:74599775~74823313:+
BRCA	cis	rs13260300	0.533	rs4557676	ENSG00000254349.4	FLJ39080	3.31	0.00098	0.0427	0.13	0.1	Breast cancer-free interval (treatment with aromatase inhibitor);	chr8:74582120	chr8:74599775~74823313:+
BRCA	cis	rs13260300	0.533	rs4557677	ENSG00000254349.4	FLJ39080	3.31	0.00098	0.0427	0.13	0.1	Breast cancer-free interval (treatment with aromatase inhibitor);	chr8:74582171	chr8:74599775~74823313:+
BRCA	cis	rs67073037	0.955	rs6734079	ENSG00000230730.1	AC074011.2	-3.31	0.00098	0.0427	-0.14	-0.1	Breast cancer;Breast cancer (estrogen-receptor negative);	chr2:28937555	chr2:28633282~28664540:-
BRCA	cis	rs2277027	0.956	rs13361953	ENSG00000251405.2	CTB-109A12.1	3.31	0.00098	0.0427	0.13	0.1	Pulmonary function;Pulmonary function (smoking interaction);	chr5:157499434	chr5:157362615~157460078:-
BRCA	cis	rs11098499	0.739	rs951570	ENSG00000225892.3	RP11-384K6.2	-3.31	0.00098	0.0427	-0.1	-0.1	Corneal astigmatism;	chr4:119229312	chr4:118632274~118634759:+
BRCA	cis	rs4869313	0.721	rs7713127	ENSG00000248734.2	CTD-2260A17.1	3.31	0.00098	0.0427	0.1	0.1	Pediatric autoimmune diseases;	chr5:96952434	chr5:96784777~96785999:+
BRCA	cis	rs9875589	0.509	rs4685058	ENSG00000228242.5	AC093495.4	3.31	0.00098	0.0427	0.07	0.1	Ovarian reserve;	chr3:13988884	chr3:14144637~14165978:+
BRCA	cis	rs6088619	1	rs6088619	ENSG00000202150.1	RNU6-407P	-3.31	0.00098	0.0427	-0.2	-0.1	Hip circumference adjusted for BMI;	chr20:34824068	chr20:35030317~35030420:-
BRCA	cis	rs924135	0.577	rs12445600	ENSG00000263065.1	AF001548.6	3.31	0.00098	0.0427	0.14	0.1	White blood cell count (basophil);Blood metabolite levels;	chr16:16051890	chr16:15741151~15741791:+
BRCA	cis	rs6601327	0.606	rs13268319	ENSG00000233609.3	RP11-62H7.2	-3.31	0.00098	0.0427	-0.1	-0.1	Multiple myeloma (hyperdiploidy);	chr8:9721739	chr8:8961200~8979025:+
BRCA	cis	rs970548	1	rs58865519	ENSG00000230869.1	CTGLF10P	3.31	0.000981	0.0427	0.13	0.1	Total cholesterol levels;HDL cholesterol;HDL cholesterol levels;Cholesterol, total;	chr10:45515443	chr10:45678692~45700532:+
BRCA	cis	rs12477438	0.52	rs6741772	ENSG00000231822.1	AC019097.7	3.31	0.000981	0.0427	0.11	0.1	Chronic sinus infection;	chr2:99122498	chr2:99102018~99102752:+
BRCA	cis	rs12477438	0.52	rs6741773	ENSG00000231822.1	AC019097.7	3.31	0.000981	0.0427	0.11	0.1	Chronic sinus infection;	chr2:99122499	chr2:99102018~99102752:+
BRCA	cis	rs12477438	0.677	rs12475034	ENSG00000231822.1	AC019097.7	-3.31	0.000981	0.0427	-0.13	-0.1	Chronic sinus infection;	chr2:99083001	chr2:99102018~99102752:+
BRCA	cis	rs4865762	0.512	rs7724504	ENSG00000247796.2	CTD-2366F13.1	-3.31	0.000981	0.0427	-0.12	-0.1	Intraocular pressure;	chr5:53221668	chr5:53109842~53115126:+
BRCA	cis	rs74233809	0.901	rs3824755	ENSG00000213061.2	PFN1P11	3.31	0.000981	0.0427	0.2	0.1	Birth weight;	chr10:102836092	chr10:102838011~102845473:-
BRCA	cis	rs6456156	0.792	rs10946215	ENSG00000272549.1	RP11-351J23.2	3.31	0.000981	0.0427	0.11	0.1	Primary biliary cholangitis;	chr6:167102693	chr6:167666840~167679270:-
BRCA	cis	rs4699052	0.928	rs2126473	ENSG00000246560.2	RP11-10L12.4	3.31	0.000981	0.0427	0.1	0.1	Testicular germ cell tumor;	chr4:103220376	chr4:102828055~102844075:+
BRCA	cis	rs4699052	0.963	rs6816055	ENSG00000246560.2	RP11-10L12.4	3.31	0.000981	0.0427	0.1	0.1	Testicular germ cell tumor;	chr4:103222003	chr4:102828055~102844075:+
BRCA	cis	rs1005277	0.505	rs7917943	ENSG00000273019.1	RP11-508N22.13	3.31	0.000981	0.0427	0.12	0.1	Extrinsic epigenetic age acceleration;	chr10:37906883	chr10:38149968~38150293:+
BRCA	cis	rs7781266	0.842	rs6967240	ENSG00000226205.1	AC007790.4	3.31	0.000981	0.0427	0.14	0.1	Educational attainment (college completion);	chr7:133549199	chr7:133732493~133733595:-
BRCA	cis	rs7267979	0.873	rs6083853	ENSG00000274414.1	RP5-965G21.4	3.31	0.000981	0.0427	0.12	0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25423905	chr20:25239007~25245229:-
BRCA	cis	rs7267979	0.934	rs2482913	ENSG00000274414.1	RP5-965G21.4	3.31	0.000981	0.0427	0.12	0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25424450	chr20:25239007~25245229:-
BRCA	cis	rs7429990	0.965	rs319682	ENSG00000199476.1	Y_RNA	-3.31	0.000981	0.0427	-0.13	-0.1	Educational attainment (years of education);	chr3:47873628	chr3:48288587~48288694:+
BRCA	cis	rs7781557	1	rs12113073	ENSG00000170409.7	CTA-313A17.2	3.31	0.000981	0.0427	0.18	0.1	Colorectal adenoma (advanced);	chr7:102842080	chr7:102327256~102329530:-
BRCA	cis	rs6088590	1	rs1998028	ENSG00000276073.1	RP5-1125A11.7	-3.31	0.000981	0.0427	-0.12	-0.1	Coronary artery disease;	chr20:34756792	chr20:33985617~33988989:-
BRCA	cis	rs2625529	0.526	rs62022789	ENSG00000260037.4	CTD-2524L6.3	3.31	0.000981	0.0427	0.13	0.1	Red blood cell count;	chr15:72272151	chr15:71818396~71823384:+
BRCA	cis	rs1555133	0.584	rs13038256	ENSG00000224452.1	RSL24D1P6	3.31	0.000981	0.0427	0.14	0.1	Monocyte count;	chr20:32440206	chr20:32170390~32170790:-
BRCA	cis	rs1555133	0.625	rs13043144	ENSG00000224452.1	RSL24D1P6	3.31	0.000981	0.0427	0.14	0.1	Monocyte count;	chr20:32440207	chr20:32170390~32170790:-
BRCA	cis	rs687432	0.774	rs1814059	ENSG00000213592.4	AP000662.9	-3.31	0.000981	0.0427	-0.14	-0.1	Parkinson's disease;	chr11:58127298	chr11:57718044~57718530:-
BRCA	cis	rs2333021	0.649	rs34158414	ENSG00000259015.1	RP11-109N23.6	3.31	0.000982	0.0427	0.11	0.1	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:72995629	chr14:72960595~72961993:+
BRCA	cis	rs2333021	0.649	rs9888613	ENSG00000259015.1	RP11-109N23.6	3.31	0.000982	0.0427	0.11	0.1	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:72995635	chr14:72960595~72961993:+
BRCA	cis	rs687432	0.774	rs11601841	ENSG00000213592.4	AP000662.9	-3.31	0.000982	0.0427	-0.14	-0.1	Parkinson's disease;	chr11:58122094	chr11:57718044~57718530:-
BRCA	cis	rs3753275	0.624	rs7517436	ENSG00000232912.4	RP5-1115A15.1	-3.31	0.000982	0.0427	-0.13	-0.1	Educational attainment;	chr1:8810817	chr1:8424645~8434838:+
BRCA	cis	rs4819052	0.851	rs1056100	ENSG00000215447.6	BX322557.10	-3.31	0.000982	0.0427	-0.1	-0.1	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258796	chr21:45288052~45291738:+
BRCA	cis	rs7818688	0.697	rs11781397	ENSG00000245080.5	RP11-320N21.1	-3.31	0.000982	0.0427	-0.17	-0.1	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94962278	chr8:95066808~95073182:-
BRCA	cis	rs7097397	0.661	rs7904251	ENSG00000270025.2	BMS1P7	-3.31	0.000982	0.0427	-0.12	-0.1	Systemic lupus erythematosus;	chr10:48768290	chr10:48050282~48060016:-
BRCA	cis	rs7824557	0.767	rs6985146	ENSG00000255310.2	AF131215.2	3.31	0.000982	0.0427	0.12	0.1	Retinal vascular caliber;	chr8:11313212	chr8:11107788~11109726:-
BRCA	cis	rs7639513	0.767	rs2348201	ENSG00000274514.1	Metazoa_SRP	3.31	0.000982	0.0427	0.12	0.1	Itch intensity from mosquito bite;	chr3:12670197	chr3:12576961~12577237:-
BRCA	cis	rs1414896	0.572	rs10782999	ENSG00000226835.1	RP11-148B18.3	-3.31	0.000982	0.0427	-0.11	-0.1	Non-alcoholic fatty liver disease histology (AST);	chr1:95169046	chr1:94333267~94334848:+
BRCA	cis	rs7551222	0.784	rs2045624	ENSG00000240219.1	RP11-430C7.5	-3.31	0.000982	0.0427	-0.11	-0.1	Schizophrenia;	chr1:204615257	chr1:204626775~204629712:+
BRCA	cis	rs6546537	0.503	rs13433043	ENSG00000231024.1	AC092431.3	3.31	0.000982	0.0427	0.15	0.1	Serum thyroid-stimulating hormone levels;	chr2:69679526	chr2:69700192~69713847:-
BRCA	cis	rs721917	0.506	rs927452	ENSG00000280355.1	RP11-119F19.5	-3.31	0.000982	0.0427	-0.11	-0.1	Chronic obstructive pulmonary disease;	chr10:79892510	chr10:79681973~79684094:-
BRCA	cis	rs6445967	0.53	rs12490706	ENSG00000244161.1	FLNB-AS1	-3.31	0.000982	0.0427	-0.09	-0.1	Platelet count;	chr3:58422520	chr3:58162547~58170636:-
BRCA	cis	rs739496	0.615	rs4646777	ENSG00000234608.6	MAPKAPK5-AS1	3.31	0.000982	0.0427	0.13	0.1	Platelet count;	chr12:111792232	chr12:111839764~111842902:-
BRCA	cis	rs4819052	0.851	rs8133045	ENSG00000223768.1	LINC00205	-3.3	0.000982	0.0427	-0.14	-0.1	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238222	chr21:45293285~45297354:+
BRCA	cis	rs4363385	0.667	rs78426057	ENSG00000272654.1	RP11-422P24.11	3.3	0.000982	0.0427	0.11	0.1	Inflammatory skin disease;	chr1:152992052	chr1:153977743~153979160:+
BRCA	cis	rs7688540	0.723	rs7687112	ENSG00000250892.1	RP11-1365D11.1	-3.3	0.000982	0.0427	-0.16	-0.1	Facial morphology (factor 6, height of vermillion lower lip);	chr4:249767	chr4:201409~205009:-
BRCA	cis	rs875971	1	rs1981798	ENSG00000230189.5	GS1-124K5.2	3.3	0.000982	0.0427	0.08	0.1	Aortic root size;	chr7:66489916	chr7:66409143~66490059:-
BRCA	cis	rs875971	0.862	rs6959268	ENSG00000223473.2	GS1-124K5.3	-3.3	0.000983	0.0428	-0.08	-0.1	Aortic root size;	chr7:66347979	chr7:66491049~66493566:-
BRCA	cis	rs35520189	0.556	rs12470439	ENSG00000231747.1	AC079922.2	-3.3	0.000983	0.0428	-0.11	-0.1	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:112943587	chr2:112621809~112622167:-
BRCA	cis	rs7339483	0.541	rs1433128	ENSG00000268442.1	CTD-2027I19.2	3.3	0.000983	0.0428	0.19	0.1	Discordance in emotional problems in monozygotic twins;	chr19:24157827	chr19:24162370~24163425:-
BRCA	cis	rs752010	0.695	rs12134166	ENSG00000230638.4	RP11-486B10.4	-3.3	0.000983	0.0428	-0.12	-0.1	Lupus nephritis in systemic lupus erythematosus;	chr1:41640196	chr1:41542069~41544310:+
BRCA	cis	rs752010	0.695	rs10789407	ENSG00000230638.4	RP11-486B10.4	-3.3	0.000983	0.0428	-0.12	-0.1	Lupus nephritis in systemic lupus erythematosus;	chr1:41640867	chr1:41542069~41544310:+
BRCA	cis	rs752010	0.695	rs10789408	ENSG00000230638.4	RP11-486B10.4	-3.3	0.000983	0.0428	-0.12	-0.1	Lupus nephritis in systemic lupus erythematosus;	chr1:41640908	chr1:41542069~41544310:+
BRCA	cis	rs10129255	0.83	rs61997609	ENSG00000231475.3	IGHV4-31	-3.3	0.000983	0.0428	-0.08	-0.1	Kawasaki disease;	chr14:106692376	chr14:106349283~106349792:-
BRCA	cis	rs2638953	0.541	rs10843209	ENSG00000273989.1	RP11-425D17.2	-3.3	0.000983	0.0428	-0.14	-0.1	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28573702	chr12:28236227~28236828:+
BRCA	cis	rs10129255	0.833	rs7156689	ENSG00000232216.1	IGHV3-43	3.3	0.000983	0.0428	0.09	0.1	Kawasaki disease;	chr14:106816039	chr14:106470264~106470800:-
BRCA	cis	rs11035577	0.516	rs10837241	ENSG00000279675.1	RP11-454H19.2	-3.3	0.000983	0.0428	-0.15	-0.1	Temperament (bipolar disorder);	chr11:39741055	chr11:40107244~40112599:-
BRCA	cis	rs259282	0.524	rs4805006	ENSG00000267475.1	CTD-2538C1.2	3.3	0.000983	0.0428	0.12	0.1	Schizophrenia;	chr19:32633230	chr19:32687089~32691750:-
BRCA	cis	rs7773456	0.576	rs12206194	ENSG00000217379.2	RP11-254A17.1	-3.3	0.000983	0.0428	-0.12	-0.1	Lupus nephritis in systemic lupus erythematosus;	chr6:19819677	chr6:19143695~19144160:+
BRCA	cis	rs7267979	1	rs6107033	ENSG00000231081.1	RP4-760C5.3	3.3	0.000983	0.0428	0.13	0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25382955	chr20:26008791~26010531:-
BRCA	cis	rs35306767	0.903	rs11253485	ENSG00000229869.1	RP11-363N22.2	-3.3	0.000983	0.0428	-0.15	-0.1	Eosinophil percentage of granulocytes;	chr10:873422	chr10:933026~942743:+
BRCA	cis	rs7572733	0.755	rs6716898	ENSG00000231621.1	AC013264.2	-3.3	0.000983	0.0428	-0.09	-0.1	Dermatomyositis;	chr2:198079547	chr2:197197991~197199273:+
BRCA	cis	rs7572733	0.792	rs1440089	ENSG00000231621.1	AC013264.2	-3.3	0.000983	0.0428	-0.09	-0.1	Dermatomyositis;	chr2:198080223	chr2:197197991~197199273:+
BRCA	cis	rs4449834	0.816	rs7823484	ENSG00000254432.1	RP11-33I11.2	-3.3	0.000983	0.0428	-0.13	-0.1	Sum eosinophil basophil counts;	chr8:60762902	chr8:60808735~60809606:-
BRCA	cis	rs2625529	0.652	rs2957735	ENSG00000261187.1	RP11-1007O24.2	3.3	0.000983	0.0428	0.11	0.1	Red blood cell count;	chr15:71972832	chr15:72465128~72466262:-
BRCA	cis	rs866743	1	rs866743	ENSG00000229720.1	RP3-495K2.2	-3.3	0.000983	0.0428	-0.11	-0.1	Post bronchodilator FEV1/FVC ratio;	chr6:169028357	chr6:169034197~169035642:-
BRCA	cis	rs13034020	0.522	rs12996059	ENSG00000237522.1	NONOP2	3.3	0.000983	0.0428	0.13	0.1	Hodgkin's lymphoma;	chr2:61018416	chr2:60936819~60938049:-
BRCA	cis	rs13034020	0.522	rs35217978	ENSG00000237522.1	NONOP2	3.3	0.000983	0.0428	0.13	0.1	Hodgkin's lymphoma;	chr2:61019413	chr2:60936819~60938049:-
BRCA	cis	rs1998359	0.953	rs61987976	ENSG00000259087.4	RP11-356O9.2	3.3	0.000983	0.0428	0.12	0.1	Self-reported allergy;	chr14:37619149	chr14:37556158~37567095:-
BRCA	cis	rs11098499	1	rs12506395	ENSG00000260404.2	RP11-384K6.6	3.3	0.000983	0.0428	0.1	0.1	Corneal astigmatism;	chr4:119263939	chr4:118591773~118633729:+
BRCA	cis	rs739496	0.579	rs2238152	ENSG00000234608.6	MAPKAPK5-AS1	3.3	0.000983	0.0428	0.13	0.1	Platelet count;	chr12:111776655	chr12:111839764~111842902:-
BRCA	cis	rs481331	0.866	rs499558	ENSG00000273008.1	RP11-351D16.3	-3.3	0.000983	0.0428	-0.15	-0.1	Systemic juvenile idiopathic arthritis;	chr10:42716583	chr10:43136824~43138334:-
BRCA	cis	rs11992162	0.613	rs56094399	ENSG00000255020.1	AF131216.5	3.3	0.000984	0.0428	0.12	0.1	Monocyte count;	chr8:11939961	chr8:11345748~11347502:-
BRCA	cis	rs7746199	0.736	rs6904596	ENSG00000241549.7	GUSBP2	3.3	0.000984	0.0428	0.19	0.1	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27523520	chr6:26871484~26956554:-
BRCA	cis	rs59551326	0.563	rs2829675	ENSG00000234883.3	MIR155HG	-3.3	0.000984	0.0428	-0.11	-0.1	Alcohol dependence;	chr21:25263753	chr21:25561909~25575168:+
BRCA	cis	rs72928364	1	rs10511181	ENSG00000244119.1	PDCL3P4	3.3	0.000984	0.0428	0.13	0.1	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100971018	chr3:101712472~101713191:+
BRCA	cis	rs3960554	0.808	rs61303167	ENSG00000205485.12	AC004980.7	-3.3	0.000984	0.0428	-0.13	-0.1	Eotaxin levels;	chr7:76041857	chr7:76549360~76627982:+
BRCA	cis	rs3960554	0.808	rs78340819	ENSG00000205485.12	AC004980.7	-3.3	0.000984	0.0428	-0.13	-0.1	Eotaxin levels;	chr7:76044515	chr7:76549360~76627982:+
BRCA	cis	rs745109	0.938	rs72932358	ENSG00000273080.1	RP11-301O19.1	3.3	0.000984	0.0428	0.15	0.1	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86521734	chr2:86195590~86196049:+
BRCA	cis	rs524281	0.861	rs7937281	ENSG00000255557.1	RP11-770G2.2	3.3	0.000984	0.0428	0.14	0.1	Electroencephalogram traits;	chr11:66182603	chr11:65745729~65771585:+
BRCA	cis	rs7567687	0.591	rs1251172	ENSG00000227632.2	AC018804.6	3.3	0.000984	0.0428	0.13	0.1	Periodontitis (PAL4Q3);	chr2:129241617	chr2:130202312~130212628:+
BRCA	cis	rs61008539	0.893	rs11765528	ENSG00000237181.1	AC147651.4	3.3	0.000984	0.0428	0.09	0.1	Perceived unattractiveness to mosquitoes;	chr7:822315	chr7:603185~608482:+
BRCA	cis	rs754133	0.964	rs894737	ENSG00000257534.1	RP11-834C11.10	3.3	0.000984	0.0428	0.12	0.1	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);	chr12:54024359	chr12:54162065~54164452:-
BRCA	cis	rs1005277	0.522	rs289648	ENSG00000273019.1	RP11-508N22.13	-3.3	0.000984	0.0428	-0.12	-0.1	Extrinsic epigenetic age acceleration;	chr10:37682909	chr10:38149968~38150293:+
BRCA	cis	rs2638953	0.962	rs9300176	ENSG00000273989.1	RP11-425D17.2	3.3	0.000984	0.0428	0.14	0.1	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28368584	chr12:28236227~28236828:+
BRCA	cis	rs12887734	0.546	rs12885509	ENSG00000269940.1	RP11-73M18.7	3.3	0.000984	0.0428	0.11	0.1	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103806988	chr14:103694560~103695170:+
BRCA	cis	rs10266483	0.921	rs683510	ENSG00000227986.1	TRIM60P18	-3.3	0.000984	0.0428	-0.11	-0.1	Response to statin therapy;	chr7:64288983	chr7:64355078~64356199:+
BRCA	cis	rs11671005	0.695	rs8106061	ENSG00000252334.1	RNU6-1337P	-3.3	0.000984	0.0428	-0.13	-0.1	Mean platelet volume;	chr19:58406623	chr19:58483749~58483843:-
BRCA	cis	rs9649465	1	rs3807635	ENSG00000272686.1	RP11-390E23.6	3.3	0.000984	0.0428	0.1	0.1	Migraine;	chr7:123742098	chr7:123749068~123751166:+
BRCA	cis	rs6496044	0.568	rs12899946	ENSG00000259630.2	CTD-2262B20.1	-3.3	0.000984	0.0428	-0.12	-0.1	Interstitial lung disease;	chr15:85522851	chr15:85415228~85415633:+
BRCA	cis	rs6496044	0.568	rs12898783	ENSG00000259630.2	CTD-2262B20.1	-3.3	0.000984	0.0428	-0.12	-0.1	Interstitial lung disease;	chr15:85522869	chr15:85415228~85415633:+
BRCA	cis	rs6496044	0.568	rs11855789	ENSG00000259630.2	CTD-2262B20.1	-3.3	0.000984	0.0428	-0.12	-0.1	Interstitial lung disease;	chr15:85523172	chr15:85415228~85415633:+
BRCA	cis	rs7005380	0.965	rs9918815	ENSG00000279347.1	RP11-85I17.2	3.3	0.000984	0.0428	0.11	0.1	Interstitial lung disease;	chr8:119939370	chr8:119838736~119840385:-
BRCA	cis	rs648163	0.59	rs580529	ENSG00000229989.3	MIR181A1HG	3.3	0.000985	0.0428	0.13	0.1	Educational attainment (years of education);	chr1:199389203	chr1:198807493~198937429:-
BRCA	cis	rs648163	0.59	rs580472	ENSG00000229989.3	MIR181A1HG	3.3	0.000985	0.0428	0.13	0.1	Educational attainment (years of education);	chr1:199389222	chr1:198807493~198937429:-
BRCA	cis	rs317865	0.737	rs73234651	ENSG00000263327.5	TAPT1-AS1	-3.3	0.000985	0.0428	-0.18	-0.1	Kidney disease (early stage) in type 1 diabetes;	chr4:16195028	chr4:16226685~16320140:+
BRCA	cis	rs2562456	0.724	rs58001930	ENSG00000268119.4	CTD-2561J22.5	3.3	0.000985	0.0428	0.16	0.1	Pain;	chr19:21560061	chr19:21444241~21463908:-
BRCA	cis	rs10943724	0.556	rs6926124	ENSG00000272129.1	RP11-250B2.6	3.3	0.000985	0.0428	0.14	0.1	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr6:80599963	chr6:80355424~80356859:+
BRCA	cis	rs17711722	0.727	rs2658585	ENSG00000272831.1	RP11-792A8.4	3.3	0.000985	0.0428	0.09	0.1	Calcium levels;	chr7:65996954	chr7:66739829~66740385:-
BRCA	cis	rs10986311	0.832	rs10123514	ENSG00000214593.3	RP11-65N13.6	3.3	0.000985	0.0428	0.11	0.1	Vitiligo;	chr9:124380599	chr9:125263845~125264090:-
BRCA	cis	rs9325144	0.647	rs61937754	ENSG00000257718.1	RP11-396F22.1	-3.3	0.000985	0.0428	-0.11	-0.1	Morning vs. evening chronotype;	chr12:38666741	chr12:38906451~38909592:+
BRCA	cis	rs11955398	0.501	rs10057004	ENSG00000251279.1	CTC-436P18.1	3.3	0.000985	0.0428	0.13	0.1	Intelligence (multi-trait analysis);	chr5:60745207	chr5:61162070~61232040:+
BRCA	cis	rs239339	0.92	rs2926483	ENSG00000238260.1	RP11-46F15.2	3.3	0.000985	0.0428	0.09	0.1	Obesity-related traits;	chr1:4376225	chr1:3623190~3624743:-
BRCA	cis	rs10911902	0.643	rs7525634	ENSG00000229739.2	RP11-295K2.3	-3.3	0.000985	0.0428	-0.14	-0.1	Schizophrenia;	chr1:186411333	chr1:186435161~186470291:+
BRCA	cis	rs4374383	0.962	rs11887259	ENSG00000243389.1	AC012442.5	-3.3	0.000985	0.0428	-0.13	-0.1	Hepatitis C induced liver fibrosis;	chr2:112016617	chr2:112589040~112614431:+
BRCA	cis	rs721917	0.506	rs2265961	ENSG00000280355.1	RP11-119F19.5	-3.3	0.000985	0.0428	-0.11	-0.1	Chronic obstructive pulmonary disease;	chr10:79886101	chr10:79681973~79684094:-
BRCA	cis	rs721917	0.506	rs7088752	ENSG00000280355.1	RP11-119F19.5	-3.3	0.000985	0.0428	-0.11	-0.1	Chronic obstructive pulmonary disease;	chr10:79886704	chr10:79681973~79684094:-
BRCA	cis	rs721917	0.506	rs7078242	ENSG00000280355.1	RP11-119F19.5	-3.3	0.000985	0.0428	-0.11	-0.1	Chronic obstructive pulmonary disease;	chr10:79886885	chr10:79681973~79684094:-
BRCA	cis	rs721917	0.525	rs2244001	ENSG00000280355.1	RP11-119F19.5	-3.3	0.000985	0.0428	-0.11	-0.1	Chronic obstructive pulmonary disease;	chr10:79888813	chr10:79681973~79684094:-
BRCA	cis	rs721917	0.506	rs1811886	ENSG00000280355.1	RP11-119F19.5	-3.3	0.000985	0.0428	-0.11	-0.1	Chronic obstructive pulmonary disease;	chr10:79889812	chr10:79681973~79684094:-
BRCA	cis	rs1436904	0.901	rs1185795	ENSG00000260372.5	AQP4-AS1	-3.3	0.000985	0.0428	-0.11	-0.1	Breast cancer;	chr18:27011283	chr18:26655742~27190698:+
BRCA	cis	rs5758659	0.714	rs5758574	ENSG00000182057.4	OGFRP1	-3.3	0.000985	0.0428	-0.11	-0.1	Cognitive function;	chr22:42085396	chr22:42269753~42275196:+
BRCA	cis	rs7833986	0.534	rs72653924	ENSG00000253603.1	CTA-397H3.3	-3.3	0.000985	0.0429	-0.15	-0.1	Height;	chr8:55993529	chr8:56074592~56075274:+
BRCA	cis	rs7833986	0.534	rs2667972	ENSG00000253603.1	CTA-397H3.3	-3.3	0.000985	0.0429	-0.15	-0.1	Height;	chr8:55994102	chr8:56074592~56075274:+
BRCA	cis	rs10501293	0.828	rs17497596	ENSG00000252652.1	Y_RNA	-3.3	0.000985	0.0429	-0.12	-0.1	Cognitive performance;	chr11:43081348	chr11:43331261~43331356:+
BRCA	cis	rs10908521	1	rs10908521	ENSG00000223356.1	RP11-66D17.5	-3.3	0.000986	0.0429	-0.12	-0.1	Uric acid clearance;	chr1:156843858	chr1:156712212~156713174:-
BRCA	cis	rs12317459	1	rs7296227	ENSG00000213270.5	RPL6P25	-3.3	0.000986	0.0429	-0.14	-0.1	Prostate cancer (SNP x SNP interaction);	chr12:82768285	chr12:83151331~83152190:+
BRCA	cis	rs4919694	1	rs12242000	ENSG00000236937.2	PTGES3P4	3.3	0.000986	0.0429	0.21	0.1	Arsenic metabolism;	chr10:102942656	chr10:102845595~102845950:+
BRCA	cis	rs4919694	1	rs11191473	ENSG00000236937.2	PTGES3P4	3.3	0.000986	0.0429	0.21	0.1	Arsenic metabolism;	chr10:102950953	chr10:102845595~102845950:+
BRCA	cis	rs4919694	0.901	rs113541728	ENSG00000236937.2	PTGES3P4	3.3	0.000986	0.0429	0.21	0.1	Arsenic metabolism;	chr10:102957014	chr10:102845595~102845950:+
BRCA	cis	rs11587682	0.714	rs12739019	ENSG00000228126.1	FALEC	3.3	0.000986	0.0429	0.13	0.1	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr1:150458485	chr1:150515757~150518032:+
BRCA	cis	rs10420951	0.579	rs75445489	ENSG00000243455.3	RPS18P13	-3.3	0.000986	0.0429	-0.16	-0.1	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr19:18460340	chr19:18048637~18049090:+
BRCA	cis	rs4478858	0.684	rs10753245	ENSG00000229447.2	RP11-490K7.4	-3.3	0.000986	0.0429	-0.1	-0.1	Alcohol dependence;	chr1:31258361	chr1:31263245~31263681:-
BRCA	cis	rs35146811	0.695	rs1623264	ENSG00000221487.1	AC069294.1	-3.3	0.000986	0.0429	-0.13	-0.1	Coronary artery disease;	chr7:100213581	chr7:99713037~99713152:+
BRCA	cis	rs6600671	1	rs2319969	ENSG00000234998.1	RP11-439A17.10	3.3	0.000986	0.0429	0.12	0.1	Hip geometry;	chr1:121465481	chr1:121087528~121116676:-
BRCA	cis	rs3096299	0.933	rs28608022	ENSG00000275734.1	RP11-368I7.6	-3.3	0.000986	0.0429	-0.11	-0.1	Multiple myeloma (IgH translocation);	chr16:89387884	chr16:89684642~89685304:+
BRCA	cis	rs7937127	0.696	rs72902746	ENSG00000254907.1	RP11-484D2.2	3.3	0.000986	0.0429	0.19	0.1	Fibrinogen levels;	chr11:43509423	chr11:43328748~43359296:-
BRCA	cis	rs12477438	0.52	rs36071868	ENSG00000231822.1	AC019097.7	3.3	0.000986	0.0429	0.11	0.1	Chronic sinus infection;	chr2:99120657	chr2:99102018~99102752:+
BRCA	cis	rs12477438	0.52	rs34252185	ENSG00000231822.1	AC019097.7	3.3	0.000986	0.0429	0.11	0.1	Chronic sinus infection;	chr2:99121183	chr2:99102018~99102752:+
BRCA	cis	rs12477438	0.52	rs13023744	ENSG00000231822.1	AC019097.7	3.3	0.000986	0.0429	0.11	0.1	Chronic sinus infection;	chr2:99121761	chr2:99102018~99102752:+
BRCA	cis	rs12477438	0.501	rs6751927	ENSG00000231822.1	AC019097.7	3.3	0.000986	0.0429	0.11	0.1	Chronic sinus infection;	chr2:99123712	chr2:99102018~99102752:+
BRCA	cis	rs6088580	0.602	rs6059840	ENSG00000269202.1	RP4-614O4.12	-3.3	0.000986	0.0429	-0.1	-0.1	Glomerular filtration rate (creatinine);	chr20:34442600	chr20:35201747~35203288:-
BRCA	cis	rs6028335	0.61	rs1130247	ENSG00000274825.1	RP4-616B8.5	-3.3	0.000986	0.0429	-0.13	-0.1	Alcohol and nicotine co-dependence;	chr20:38952794	chr20:38955910~38956547:+
BRCA	cis	rs2835872	0.965	rs2835855	ENSG00000230366.8	DSCR9	-3.3	0.000986	0.0429	-0.14	-0.1	Electroencephalographic traits in alcoholism;	chr21:37643452	chr21:37208503~37221736:+
BRCA	cis	rs7577696	0.853	rs56740303	ENSG00000276334.1	AL133243.1	-3.3	0.000986	0.0429	-0.13	-0.1	Inflammatory biomarkers;	chr2:32079587	chr2:32521927~32523547:+
BRCA	cis	rs801193	0.591	rs4506088	ENSG00000223473.2	GS1-124K5.3	-3.3	0.000986	0.0429	-0.08	-0.1	Aortic root size;	chr7:66670470	chr7:66491049~66493566:-
BRCA	cis	rs4665809	1	rs6739061	ENSG00000231655.1	AC011742.3	3.3	0.000986	0.0429	0.14	0.1	Gut microbiome composition (summer);	chr2:26033278	chr2:26140263~26141264:-
BRCA	cis	rs56176327	0.532	rs9849038	ENSG00000281433.1	Metazoa_SRP	3.3	0.000986	0.0429	0.13	0.1	Intelligence (multi-trait analysis);	chr3:49734557	chr3:49320296~49320564:+
BRCA	cis	rs7048146	0.509	rs55796394	ENSG00000213539.4	YBX1P6	3.3	0.000986	0.0429	0.13	0.1	Vascular brain injury;	chr9:109538348	chr9:109532830~109534332:-
BRCA	cis	rs4927850	0.957	rs4927851	ENSG00000278820.1	AC024937.1	3.3	0.000986	0.0429	0.12	0.1	Pancreatic cancer;	chr3:196024982	chr3:195960500~195960612:-
BRCA	cis	rs7097397	0.686	rs10776643	ENSG00000270025.2	BMS1P7	3.3	0.000986	0.0429	0.12	0.1	Systemic lupus erythematosus;	chr10:48770745	chr10:48050282~48060016:-
BRCA	cis	rs8180040	0.62	rs7373821	ENSG00000280667.1	Y_RNA	3.3	0.000987	0.0429	0.11	0.1	Colorectal cancer;	chr3:47038637	chr3:47501083~47501182:+
BRCA	cis	rs8026198	0.929	rs1359003	ENSG00000260571.1	BNIP3P5	-3.3	0.000987	0.0429	-0.17	-0.1	Fibrinogen levels;	chr15:42364741	chr15:42313687~42314386:+
BRCA	cis	rs17361889	0.517	rs62440456	ENSG00000229108.1	MEOX2-AS1	3.3	0.000987	0.0429	0.13	0.1	Pediatric bone mineral content (hip);	chr7:16285655	chr7:15688378~15695491:+
BRCA	cis	rs721917	0.506	rs2819113	ENSG00000280355.1	RP11-119F19.5	-3.3	0.000987	0.0429	-0.11	-0.1	Chronic obstructive pulmonary disease;	chr10:79890987	chr10:79681973~79684094:-
BRCA	cis	rs4713118	0.629	rs203890	ENSG00000226314.6	ZNF192P1	-3.3	0.000987	0.0429	-0.15	-0.1	Parkinson's disease;	chr6:28054470	chr6:28161781~28169594:+
BRCA	cis	rs1029738	0.5	rs10264441	ENSG00000228649.7	AC005682.5	-3.3	0.000987	0.0429	-0.09	-0.1	Fibrinogen levels;	chr7:22845395	chr7:22854178~22861579:+
BRCA	cis	rs713477	0.524	rs4901560	ENSG00000186615.9	KTN1-AS1	3.3	0.000987	0.0429	0.12	0.1	Pediatric bone mineral content (femoral neck);	chr14:55421815	chr14:55499278~55580110:-
BRCA	cis	rs875971	1	rs11974219	ENSG00000230189.5	GS1-124K5.2	-3.3	0.000987	0.0429	-0.08	-0.1	Aortic root size;	chr7:66182423	chr7:66409143~66490059:-
BRCA	cis	rs10971721	0.822	rs12380173	ENSG00000279489.1	RP11-392A14.8	3.3	0.000987	0.0429	0.21	0.1	Body mass index;	chr9:34018500	chr9:35001913~35003663:+
BRCA	cis	rs10971721	0.822	rs12377970	ENSG00000279489.1	RP11-392A14.8	3.3	0.000987	0.0429	0.21	0.1	Body mass index;	chr9:34021269	chr9:35001913~35003663:+
BRCA	cis	rs10838687	0.8	rs4752977	ENSG00000243802.2	RP11-390K5.1	3.3	0.000987	0.0429	0.14	0.1	Proinsulin levels;	chr11:47278878	chr11:47191181~47191542:-
BRCA	cis	rs1003719	0.715	rs2835658	ENSG00000242553.1	AP001432.14	3.3	0.000987	0.0429	0.12	0.1	Eye color traits;	chr21:37192900	chr21:37221419~37237744:+
BRCA	cis	rs875971	1	rs3981131	ENSG00000273024.4	INTS4P2	-3.3	0.000987	0.0429	-0.11	-0.1	Aortic root size;	chr7:66486690	chr7:65647864~65715661:+
BRCA	cis	rs7246657	0.653	rs4805208	ENSG00000267470.4	ZNF571-AS1	3.3	0.000987	0.0429	0.15	0.1	Coronary artery calcification;	chr19:37183357	chr19:37548914~37587348:+
BRCA	cis	rs875971	0.862	rs6947339	ENSG00000223473.2	GS1-124K5.3	3.3	0.000987	0.0429	0.08	0.1	Aortic root size;	chr7:66423483	chr7:66491049~66493566:-
BRCA	cis	rs4352251	0.841	rs4280474	ENSG00000212283.1	SNORD89	3.3	0.000987	0.0429	0.18	0.1	Adiponectin levels (BMI-adjusted);Adiponectin levels;	chr2:101365332	chr2:101272936~101273049:-
BRCA	cis	rs4648045	0.828	rs62328542	ENSG00000246560.2	RP11-10L12.4	3.3	0.000987	0.0429	0.12	0.1	Lymphocyte percentage of white cells;	chr4:102516430	chr4:102828055~102844075:+
BRCA	cis	rs4648045	0.861	rs4235404	ENSG00000246560.2	RP11-10L12.4	3.3	0.000987	0.0429	0.12	0.1	Lymphocyte percentage of white cells;	chr4:102518908	chr4:102828055~102844075:+
BRCA	cis	rs4648045	0.828	rs4647980	ENSG00000246560.2	RP11-10L12.4	3.3	0.000987	0.0429	0.12	0.1	Lymphocyte percentage of white cells;	chr4:102518936	chr4:102828055~102844075:+
BRCA	cis	rs6582630	0.594	rs7308707	ENSG00000257718.1	RP11-396F22.1	-3.3	0.000987	0.0429	-0.1	-0.1	Drug-induced liver injury (flucloxacillin);	chr12:38056626	chr12:38906451~38909592:+
BRCA	cis	rs524281	0.814	rs10896093	ENSG00000255038.1	RP11-1167A19.2	-3.3	0.000987	0.0429	-0.15	-0.1	Electroencephalogram traits;	chr11:66190940	chr11:66067277~66069619:-
BRCA	cis	rs495337	0.735	rs636987	ENSG00000224397.4	LINC01272	-3.3	0.000987	0.0429	-0.1	-0.1	Psoriasis;	chr20:49907751	chr20:50267486~50279795:+
BRCA	cis	rs11191419	1	rs11191419	ENSG00000213277.3	MARCKSL1P1	3.3	0.000987	0.0429	0.11	0.1	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr10:102852578	chr10:103175554~103176094:+
BRCA	cis	rs1437396	0.609	rs2589056	ENSG00000203327.2	AC012358.7	3.3	0.000987	0.0429	0.1	0.1	Alcohol dependence;	chr2:55327168	chr2:55214387~55216126:-
BRCA	cis	rs2712184	0.687	rs62180470	ENSG00000237930.1	AC007563.4	-3.3	0.000987	0.0429	-0.11	-0.1	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);	chr2:216780728	chr2:216785774~216786144:-
BRCA	cis	rs7017914	0.902	rs10504481	ENSG00000246366.5	RP11-382J12.1	3.3	0.000987	0.0429	0.11	0.1	Bone mineral density;	chr8:70787282	chr8:70608577~70663279:+
BRCA	cis	rs4713118	0.629	rs149899	ENSG00000226314.6	ZNF192P1	-3.3	0.000987	0.0429	-0.15	-0.1	Parkinson's disease;	chr6:28052201	chr6:28161781~28169594:+
BRCA	cis	rs4713118	0.629	rs172165	ENSG00000226314.6	ZNF192P1	-3.3	0.000987	0.0429	-0.15	-0.1	Parkinson's disease;	chr6:28053036	chr6:28161781~28169594:+
BRCA	cis	rs11711311	0.712	rs2271498	ENSG00000241529.3	RN7SL767P	-3.3	0.000988	0.0429	-0.12	-0.1	IgG glycosylation;	chr3:113615905	chr3:113632704~113632998:+
BRCA	cis	rs7267979	0.966	rs2261698	ENSG00000204556.4	CTD-2514C3.1	-3.3	0.000988	0.0429	-0.14	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25279274	chr20:26018832~26020684:+
BRCA	cis	rs6741148	1	rs17021872	ENSG00000232973.10	CYP1B1-AS1	-3.3	0.000988	0.0429	-0.21	-0.1	Erectile dysfunction and prostate cancer treatment;	chr2:38033887	chr2:38073447~38231651:+
BRCA	cis	rs2638953	0.853	rs11049656	ENSG00000273989.1	RP11-425D17.2	-3.3	0.000988	0.0429	-0.14	-0.1	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28481705	chr12:28236227~28236828:+
BRCA	cis	rs295490	0.748	rs2291555	ENSG00000178631.7	ACTG1P1	-3.3	0.000988	0.0429	-0.2	-0.1	PR interval in Tripanosoma cruzi seropositivity;	chr3:139355352	chr3:139493809~139494937:+
BRCA	cis	rs673253	0.686	rs2842185	ENSG00000229431.1	RP1-92O14.6	3.3	0.000988	0.0429	0.11	0.1	Intelligence (multi-trait analysis);	chr1:43554060	chr1:43385113~43389155:+
BRCA	cis	rs7773456	0.576	rs4140624	ENSG00000217379.2	RP11-254A17.1	3.3	0.000988	0.0429	0.12	0.1	Lupus nephritis in systemic lupus erythematosus;	chr6:19818329	chr6:19143695~19144160:+
BRCA	cis	rs7487075	0.619	rs12314541	ENSG00000257261.4	RP11-96H19.1	3.3	0.000988	0.043	0.11	0.1	Itch intensity from mosquito bite;	chr12:46400983	chr12:46383679~46876159:+
BRCA	cis	rs13136331	0.68	rs2732178	ENSG00000249001.4	RP11-742B18.1	3.3	0.000988	0.043	0.14	0.1	Sitting height ratio;	chr4:87733437	chr4:87568035~87733956:-
BRCA	cis	rs10191559	0.552	rs7355504	ENSG00000234663.4	AC104820.2	3.3	0.000988	0.043	0.09	0.1	Red blood cell count;	chr2:181228214	chr2:181101932~181399559:+
BRCA	cis	rs10191559	0.552	rs10177832	ENSG00000234663.4	AC104820.2	3.3	0.000988	0.043	0.09	0.1	Red blood cell count;	chr2:181228605	chr2:181101932~181399559:+
BRCA	cis	rs6545883	0.929	rs10193666	ENSG00000273302.1	RP11-493E12.2	-3.3	0.000988	0.043	-0.1	-0.1	Tuberculosis;	chr2:61402273	chr2:61199979~61200769:+
BRCA	cis	rs4415084	0.652	rs11747159	ENSG00000272335.1	RP11-53O19.3	3.3	0.000988	0.043	0.1	0.1	Breast cancer;	chr5:44737608	chr5:44826076~44828592:+
BRCA	cis	rs7168365	0.815	rs473664	ENSG00000214896.4	RPSAP55	-3.3	0.000988	0.043	-0.11	-0.1	Longevity;	chr15:53518798	chr15:52885595~52886470:+
BRCA	cis	rs10197140	0.925	rs6542189	ENSG00000235721.1	AC013268.3	-3.3	0.000988	0.043	-0.13	-0.1	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110880350	chr2:110007675~110010783:+
BRCA	cis	rs198846	0.542	rs198839	ENSG00000272462.2	U91328.19	-3.3	0.000988	0.043	-0.13	-0.1	Mean corpuscular volume;Mean corpuscular hemoglobin concentration;Hemoglobin levels;Hemoglobin;Glycated hemoglobin levels;Blood pressure;	chr6:26112392	chr6:25992662~26001775:+
BRCA	cis	rs4713118	0.516	rs7739216	ENSG00000272009.1	RP1-313I6.12	-3.3	0.000989	0.043	-0.15	-0.1	Parkinson's disease;	chr6:28112168	chr6:28078792~28081130:-
BRCA	cis	rs853679	0.517	rs35512245	ENSG00000272009.1	RP1-313I6.12	-3.3	0.000989	0.043	-0.15	-0.1	Depression;	chr6:28112175	chr6:28078792~28081130:-
BRCA	cis	rs4886920	0.537	rs6495247	ENSG00000259322.1	RP11-762H8.1	3.3	0.000989	0.043	0.1	0.1	Neuroticism;	chr15:77777089	chr15:78293286~78296049:+
BRCA	cis	rs12612435	0.736	rs13015181	ENSG00000226806.1	AC011893.3	3.3	0.000989	0.043	0.13	0.1	Takotsubo syndrome;	chr2:136393250	chr2:135820191~135823087:+
BRCA	cis	rs1371614	0.589	rs935018	ENSG00000229122.1	AGBL5-IT1	-3.3	0.000989	0.043	-0.11	-0.1	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr2:26883757	chr2:27061038~27061815:+
BRCA	cis	rs71520386	0.561	rs10274260	ENSG00000179428.2	AC073072.5	3.3	0.000989	0.043	0.12	0.1	Fibrinogen levels;	chr7:22805227	chr7:22725395~22727620:-
BRCA	cis	rs2281603	0.57	rs1470851	ENSG00000259116.1	RP11-973N13.4	-3.3	0.000989	0.043	-0.09	-0.1	Lymphocyte counts;	chr14:64509402	chr14:64514154~64540368:-
BRCA	cis	rs2150410	0.915	rs2272576	ENSG00000238141.2	BRWD1-AS1	-3.3	0.000989	0.043	-0.23	-0.1	Temperament (bipolar disorder);	chr21:39312463	chr21:39315707~39323218:+
BRCA	cis	rs3760982	0.813	rs8104447	ENSG00000267191.1	RP11-15A1.2	3.3	0.000989	0.043	0.13	0.1	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43789126	chr19:43902001~43926545:+
BRCA	cis	rs4499344	0.556	rs259220	ENSG00000267475.1	CTD-2538C1.2	3.3	0.000989	0.043	0.14	0.1	Mean platelet volume;	chr19:32646723	chr19:32687089~32691750:-
BRCA	cis	rs2108225	0.872	rs6980029	ENSG00000231006.1	RPL7P32	-3.3	0.000989	0.043	-0.1	-0.1	Ulcerative colitis;	chr7:107805682	chr7:108510233~108510976:+
BRCA	cis	rs1923626	0.93	rs10913418	ENSG00000242193.8	RP11-568K15.1	3.3	0.000989	0.043	0.11	0.1	Amyotrophic lateral sclerosis (C9orf72 mutation interaction);	chr1:177786164	chr1:178006136~178037950:-
BRCA	cis	rs11098499	0.739	rs9884728	ENSG00000260091.1	RP11-33B1.4	3.3	0.000989	0.043	0.09	0.1	Corneal astigmatism;	chr4:119205924	chr4:119409333~119410233:+
BRCA	cis	rs11877825	0.826	rs9961960	ENSG00000265728.1	RP11-883A18.3	3.3	0.000989	0.043	0.14	0.1	Gut microbiota (bacterial taxa);	chr18:10570306	chr18:10594590~10604798:+
BRCA	cis	rs466639	0.929	rs75965843	ENSG00000236364.3	RP11-525G13.2	3.3	0.000989	0.043	0.13	0.1	Menarche (age at onset);	chr1:165438355	chr1:165890795~165900683:-
BRCA	cis	rs9650657	0.623	rs6601514	ENSG00000248896.2	CTD-2135J3.3	-3.3	0.000989	0.043	-0.12	-0.1	Neuroticism;	chr8:10743771	chr8:10729314~10771392:+
BRCA	cis	rs708547	0.511	rs1713998	ENSG00000269949.1	RP11-738E22.3	-3.3	0.000989	0.043	-0.13	-0.1	Response to bleomycin (chromatid breaks);	chr4:56978736	chr4:56960927~56961373:-
BRCA	cis	rs2153535	0.585	rs1983603	ENSG00000251164.1	HULC	-3.3	0.00099	0.043	-0.12	-0.1	Motion sickness;	chr6:8580747	chr6:8652137~8653846:+
BRCA	cis	rs6499640	0.664	rs8048396	ENSG00000279344.1	RP11-44F14.7	3.3	0.00099	0.043	0.11	0.1	Body mass index;Weight;	chr16:53736837	chr16:53478957~53481550:-
BRCA	cis	rs2518049	0.852	rs10752002	ENSG00000224034.1	RP11-445P17.8	3.3	0.00099	0.043	0.19	0.1	Metabolic traits;	chr10:5076726	chr10:5266033~5271236:-
BRCA	cis	rs8054556	0.647	rs4077410	ENSG00000183604.13	SMG1P5	-3.3	0.00099	0.043	-0.1	-0.1	Autism spectrum disorder or schizophrenia;	chr16:29986879	chr16:30267553~30335374:-
BRCA	cis	rs1865760	0.566	rs9379821	ENSG00000272462.2	U91328.19	-3.3	0.00099	0.043	-0.12	-0.1	Height;	chr6:26054040	chr6:25992662~26001775:+
BRCA	cis	rs10792665	0.512	rs7118894	ENSG00000254965.1	RP11-113K21.2	-3.3	0.00099	0.043	-0.1	-0.1	Obesity-related traits;	chr11:82895343	chr11:83111060~83111442:-
BRCA	cis	rs1005277	0.505	rs7099777	ENSG00000273019.1	RP11-508N22.13	3.3	0.00099	0.043	0.12	0.1	Extrinsic epigenetic age acceleration;	chr10:37894641	chr10:38149968~38150293:+
BRCA	cis	rs7944584	0.511	rs10838731	ENSG00000255520.1	RP11-390K5.3	3.3	0.00099	0.043	0.13	0.1	Fasting blood glucose;Fasting blood glucose (BMI interaction);	chr11:47585583	chr11:47123104~47130801:-
BRCA	cis	rs3743102	0.591	rs8040152	ENSG00000259429.4	UBE2Q2P2	3.3	0.00099	0.043	0.14	0.1	Colorectal adenoma (advanced);	chr15:82687976	chr15:82355142~82420075:+
BRCA	cis	rs1129187	0.902	rs6907751	ENSG00000261068.2	RP11-7K24.3	3.3	0.00099	0.043	0.13	0.1	Alzheimer's disease in APOE e4+ carriers;	chr6:42977112	chr6:42092233~42094259:-
BRCA	cis	rs6460942	1	rs118083671	ENSG00000226690.5	AC005281.1	3.3	0.00099	0.043	0.2	0.1	Coronary artery disease;	chr7:12426410	chr7:12496429~12541910:+
BRCA	cis	rs6840360	0.593	rs2175409	ENSG00000270265.1	RP11-731D1.4	-3.3	0.00099	0.043	-0.12	-0.1	Intelligence (multi-trait analysis);	chr4:151780504	chr4:151333775~151353224:-
BRCA	cis	rs4795519	0.614	rs11654504	ENSG00000265646.2	TUFMP1	-3.3	0.00099	0.043	-0.14	-0.1	Chronic myeloid leukemia;	chr17:27168769	chr17:27082690~27084036:-
BRCA	cis	rs2832077	0.883	rs35672956	ENSG00000236056.1	GAPDHP14	3.3	0.000991	0.043	0.15	0.1	Cognitive test performance;	chr21:28816719	chr21:29222321~29223257:+
BRCA	cis	rs2832077	0.943	rs11700746	ENSG00000236056.1	GAPDHP14	3.3	0.000991	0.043	0.15	0.1	Cognitive test performance;	chr21:28816884	chr21:29222321~29223257:+
BRCA	cis	rs2832077	0.943	rs2272701	ENSG00000236056.1	GAPDHP14	3.3	0.000991	0.043	0.15	0.1	Cognitive test performance;	chr21:28818585	chr21:29222321~29223257:+
BRCA	cis	rs7618501	0.699	rs2681781	ENSG00000281433.1	Metazoa_SRP	-3.3	0.000991	0.043	-0.1	-0.1	Intelligence (multi-trait analysis);	chr3:49860840	chr3:49320296~49320564:+
BRCA	cis	rs9693857	0.518	rs7001721	ENSG00000233609.3	RP11-62H7.2	-3.3	0.000991	0.043	-0.11	-0.1	Systolic blood pressure;	chr8:9413900	chr8:8961200~8979025:+
BRCA	cis	rs2243480	1	rs437889	ENSG00000226767.1	RP11-328P23.3	-3.3	0.000991	0.043	-0.18	-0.1	Diabetic kidney disease;	chr7:66044247	chr7:65508773~65508944:-
BRCA	cis	rs875971	0.798	rs6460304	ENSG00000265600.1	AC006480.1	-3.3	0.000991	0.0431	-0.12	-0.1	Aortic root size;	chr7:66499741	chr7:67356680~67356779:+
BRCA	cis	rs875971	0.862	rs6945775	ENSG00000265600.1	AC006480.1	-3.3	0.000991	0.0431	-0.12	-0.1	Aortic root size;	chr7:66503987	chr7:67356680~67356779:+
BRCA	cis	rs656319	0.559	rs17689037	ENSG00000272267.2	RP11-375N15.2	3.3	0.000991	0.0431	0.12	0.1	Myopia (pathological);	chr8:10117348	chr8:9555144~9556520:-
BRCA	cis	rs9875589	0.509	rs28865280	ENSG00000228242.5	AC093495.4	3.3	0.000991	0.0431	0.07	0.1	Ovarian reserve;	chr3:14023458	chr3:14144637~14165978:+
BRCA	cis	rs801193	0.569	rs2659907	ENSG00000106610.13	STAG3L4	-3.3	0.000991	0.0431	-0.14	-0.1	Aortic root size;	chr7:66699045	chr7:67302621~67321526:+
BRCA	cis	rs910316	0.763	rs175490	ENSG00000259138.1	RP11-950C14.7	3.3	0.000991	0.0431	0.11	0.1	Height;	chr14:75078982	chr14:75127153~75136930:+
BRCA	cis	rs477895	0.653	rs2015226	ENSG00000256940.1	RP11-783K16.5	3.3	0.000991	0.0431	0.14	0.1	Mean platelet volume;	chr11:64135062	chr11:64245964~64248217:+
BRCA	cis	rs477895	0.653	rs2875749	ENSG00000256940.1	RP11-783K16.5	3.3	0.000991	0.0431	0.14	0.1	Mean platelet volume;	chr11:64136406	chr11:64245964~64248217:+
BRCA	cis	rs477895	0.653	rs7939784	ENSG00000256940.1	RP11-783K16.5	3.3	0.000991	0.0431	0.14	0.1	Mean platelet volume;	chr11:64142681	chr11:64245964~64248217:+
BRCA	cis	rs6700559	0.647	rs11801159	ENSG00000260088.1	RP11-92G12.3	3.3	0.000991	0.0431	0.13	0.1	Coronary artery disease;	chr1:200623974	chr1:200669507~200694250:+
BRCA	cis	rs6700559	0.605	rs11802836	ENSG00000260088.1	RP11-92G12.3	3.3	0.000991	0.0431	0.13	0.1	Coronary artery disease;	chr1:200624027	chr1:200669507~200694250:+
BRCA	cis	rs6700559	0.692	rs12744809	ENSG00000260088.1	RP11-92G12.3	3.3	0.000991	0.0431	0.13	0.1	Coronary artery disease;	chr1:200624197	chr1:200669507~200694250:+
BRCA	cis	rs13427836	1	rs13386088	ENSG00000272667.1	RP11-395A13.2	3.3	0.000991	0.0431	0.16	0.1	Urinary albumin-to-creatinine ratio in diabetes;	chr2:128271317	chr2:127886556~127887185:+
BRCA	cis	rs7487075	0.786	rs2172398	ENSG00000274723.1	RP11-618L22.1	3.3	0.000991	0.0431	0.12	0.1	Itch intensity from mosquito bite;	chr12:46278788	chr12:46970504~46972155:+
BRCA	cis	rs6964587	0.626	rs404	ENSG00000188693.7	CYP51A1-AS1	3.3	0.000991	0.0431	0.11	0.1	Breast cancer;	chr7:91915002	chr7:92134604~92180725:+
BRCA	cis	rs7104764	1	rs6598065	ENSG00000254910.1	RP11-326C3.7	-3.3	0.000992	0.0431	-0.12	-0.1	Menarche (age at onset);	chr11:243211	chr11:310139~311141:-
BRCA	cis	rs6432860	0.527	rs7609055	ENSG00000232411.1	AC009495.3	-3.3	0.000992	0.0431	-0.12	-0.1	Febrile seizures (MMR vaccine-unrelated);Febrile seizures;	chr2:166059743	chr2:165833048~165839098:-
BRCA	cis	rs4415084	0.804	rs4329028	ENSG00000248779.1	RP11-53O19.2	3.3	0.000992	0.0431	0.09	0.1	Breast cancer;	chr5:44872251	chr5:44752949~44765744:+
BRCA	cis	rs11098499	0.863	rs6858592	ENSG00000260404.2	RP11-384K6.6	3.3	0.000992	0.0431	0.1	0.1	Corneal astigmatism;	chr4:119537537	chr4:118591773~118633729:+
BRCA	cis	rs2688482	0.512	rs3103953	ENSG00000242086.7	LINC00969	-3.3	0.000992	0.0431	-0.15	-0.1	Lung disease severity in cystic fibrosis;	chr3:195793726	chr3:195658062~195739964:+
BRCA	cis	rs10888690	0.502	rs79521580	ENSG00000236434.2	RP11-296A18.6	-3.3	0.000992	0.0431	-0.13	-0.1	Male-pattern baldness;	chr1:50578053	chr1:51264916~51266074:-
BRCA	cis	rs4934494	0.681	rs1129777	ENSG00000232229.4	LINC00865	-3.3	0.000992	0.0431	-0.16	-0.1	Red blood cell count;	chr10:89709168	chr10:89829510~89840861:+
BRCA	cis	rs4934494	0.727	rs3824607	ENSG00000232229.4	LINC00865	-3.3	0.000992	0.0431	-0.16	-0.1	Red blood cell count;	chr10:89711258	chr10:89829510~89840861:+
BRCA	cis	rs4934494	0.681	rs3740035	ENSG00000232229.4	LINC00865	-3.3	0.000992	0.0431	-0.16	-0.1	Red blood cell count;	chr10:89716708	chr10:89829510~89840861:+
BRCA	cis	rs6089829	0.962	rs1060490	ENSG00000233017.2	RP5-908M14.5	3.3	0.000992	0.0431	0.12	0.1	Prostate cancer (SNP x SNP interaction);	chr20:63034519	chr20:62427827~62447621:+
BRCA	cis	rs5758511	0.68	rs5758692	ENSG00000231261.1	HMGN2P10	-3.3	0.000992	0.0431	-0.14	-0.1	Birth weight;	chr22:42273023	chr22:41709225~41709489:-
BRCA	cis	rs68170813	0.617	rs17481842	ENSG00000241764.3	AC002467.7	3.3	0.000992	0.0431	0.18	0.1	Coronary artery disease;	chr7:107481417	chr7:107742817~107744581:-
BRCA	cis	rs1376303	0.643	rs4723222	ENSG00000205763.12	RP9P	-3.3	0.000992	0.0431	-0.17	-0.1	Intelligence (multi-trait analysis);	chr7:32918049	chr7:32916815~32943176:-
BRCA	cis	rs359466	0.938	rs17076706	ENSG00000253768.1	CTB-33O18.1	-3.3	0.000992	0.0431	-0.14	-0.1	QRS complex (Sokolow-Lyon);	chr5:173927283	chr5:173562478~173573199:+
BRCA	cis	rs7188697	0.922	rs9923491	ENSG00000276259.1	RP11-481J2.4	3.3	0.000992	0.0431	0.12	0.1	QT interval;	chr16:58569272	chr16:58522970~58523842:+
BRCA	cis	rs467650	0.509	rs2591443	ENSG00000246763.5	RGMB-AS1	-3.3	0.000992	0.0431	-0.12	-0.1	Venous thromboembolism (SNP x SNP interaction);	chr5:98661785	chr5:98769618~98773469:-
BRCA	cis	rs72899227	0.696	rs10184558	ENSG00000226131.1	AC073465.3	3.3	0.000992	0.0431	0.15	0.1	Lung cancer;	chr2:173369493	chr2:173485865~173486362:-
BRCA	cis	rs10871290	0.551	rs3863435	ENSG00000262904.1	TMPOP2	3.3	0.000992	0.0431	0.1	0.1	Breast cancer;	chr16:74431498	chr16:74667506~74668706:+
BRCA	cis	rs2692947	0.727	rs893173	ENSG00000232931.4	LINC00342	3.3	0.000993	0.0431	0.11	0.1	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96124048	chr2:95807118~95816215:-
BRCA	cis	rs783540	1	rs783540	ENSG00000274376.3	ADAMTS7P1	3.3	0.000993	0.0431	0.11	0.1	Schizophrenia;	chr15:82585958	chr15:82298553~82334609:+
BRCA	cis	rs9377188	0.556	rs2500515	ENSG00000219433.2	RP11-350J20.4	-3.3	0.000993	0.0431	-0.13	-0.1	Cancer;	chr6:148976109	chr6:149794763~149795746:+
BRCA	cis	rs249954	0.559	rs35586	ENSG00000260136.4	CTD-2270L9.4	3.3	0.000993	0.0431	0.11	0.1	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr16:23665685	chr16:23452758~23457606:+
BRCA	cis	rs3820068	0.603	rs7531396	ENSG00000237301.1	RP4-680D5.2	-3.3	0.000993	0.0431	-0.13	-0.1	Systolic blood pressure;	chr1:15643375	chr1:15586136~15603626:-
BRCA	cis	rs11662721	0.938	rs11661119	ENSG00000264188.1	RP11-13N13.5	3.3	0.000993	0.0431	0.14	0.1	Phospholipid levels (plasma);	chr18:21655100	chr18:21661787~21662395:-
BRCA	cis	rs4664293	0.546	rs72956113	ENSG00000230783.1	AC009961.2	3.3	0.000993	0.0431	0.13	0.1	Monocyte percentage of white cells;	chr2:159631132	chr2:159689217~159690291:-
BRCA	cis	rs3735485	0.738	rs10280402	ENSG00000201772.1	SNORA5C	3.3	0.000993	0.0431	0.13	0.1	White blood cell count;Sum basophil neutrophil counts;Neutrophil count;Granulocyte percentage of myeloid white cells;Monocyte percentage of white cells;Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Lymphocyte counts;	chr7:45049419	chr7:45104906~45105042:-
BRCA	cis	rs76963786	0.901	rs2128625	ENSG00000201563.1	Y_RNA	3.3	0.000993	0.0431	0.15	0.1	Interleukin-9 levels;	chr12:31888293	chr12:32705403~32705506:-
BRCA	cis	rs76963786	0.901	rs2388968	ENSG00000201563.1	Y_RNA	3.3	0.000993	0.0431	0.15	0.1	Interleukin-9 levels;	chr12:31889970	chr12:32705403~32705506:-
BRCA	cis	rs9860340	0.621	rs4484212	ENSG00000239572.1	RP11-451B8.1	-3.3	0.000993	0.0431	-0.16	-0.1	Electroencephalographic traits in alcoholism;	chr3:87583965	chr3:87731402~87793629:-
BRCA	cis	rs11773103	0.786	rs73202988	ENSG00000224046.1	AC005076.5	3.3	0.000993	0.0431	0.17	0.1	Bipolar disorder or major depressive disorder (combined);	chr7:87127087	chr7:87151423~87152420:-
BRCA	cis	rs11773103	0.786	rs73202994	ENSG00000224046.1	AC005076.5	3.3	0.000993	0.0431	0.17	0.1	Bipolar disorder or major depressive disorder (combined);	chr7:87127312	chr7:87151423~87152420:-
BRCA	cis	rs11773103	0.786	rs73202997	ENSG00000224046.1	AC005076.5	3.3	0.000993	0.0431	0.17	0.1	Bipolar disorder or major depressive disorder (combined);	chr7:87127363	chr7:87151423~87152420:-
BRCA	cis	rs4374383	0.631	rs28637361	ENSG00000243389.1	AC012442.5	-3.3	0.000993	0.0431	-0.13	-0.1	Hepatitis C induced liver fibrosis;	chr2:111921728	chr2:112589040~112614431:+
BRCA	cis	rs2638953	0.64	rs11049721	ENSG00000273989.1	RP11-425D17.2	-3.3	0.000993	0.0431	-0.15	-0.1	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28573743	chr12:28236227~28236828:+
BRCA	cis	rs1466788	1	rs7531202	ENSG00000224965.1	KCNC4-AS1	3.3	0.000993	0.0431	0.12	0.1	Blood metabolite levels;	chr1:110073852	chr1:110208834~110209987:-
BRCA	cis	rs10070219	0.505	rs62380385	ENSG00000248445.4	SEMA6A-AS1	-3.3	0.000993	0.0431	-0.13	-0.1	3-hydroxypropylmercapturic acid levels in smokers;	chr5:117357608	chr5:116447547~116508276:+
BRCA	cis	rs10070219	0.505	rs13354532	ENSG00000248445.4	SEMA6A-AS1	-3.3	0.000993	0.0431	-0.13	-0.1	3-hydroxypropylmercapturic acid levels in smokers;	chr5:117358115	chr5:116447547~116508276:+
BRCA	cis	rs4699052	0.963	rs11097801	ENSG00000246560.2	RP11-10L12.4	3.3	0.000993	0.0431	0.1	0.1	Testicular germ cell tumor;	chr4:103229166	chr4:102828055~102844075:+
BRCA	cis	rs10129255	1	rs8010605	ENSG00000211958.2	IGHV3-38	3.3	0.000993	0.0431	0.08	0.1	Kawasaki disease;	chr14:106678742	chr14:106410493~106411021:-
BRCA	cis	rs4699052	0.507	rs7662107	ENSG00000246560.2	RP11-10L12.4	3.3	0.000993	0.0431	0.12	0.1	Testicular germ cell tumor;	chr4:103337239	chr4:102828055~102844075:+
BRCA	cis	rs821367	0.871	rs17308266	ENSG00000280042.1	RP11-71H17.8	3.3	0.000993	0.0431	0.14	0.1	Platelet distribution width;	chr3:124687251	chr3:124791119~124793104:-
BRCA	cis	rs12282928	0.959	rs1503192	ENSG00000255197.4	RP11-750H9.5	3.3	0.000993	0.0431	0.1	0.1	Migraine - clinic-based;	chr11:48267803	chr11:47383148~47409190:-
BRCA	cis	rs875971	0.862	rs6978028	ENSG00000223473.2	GS1-124K5.3	3.3	0.000993	0.0431	0.08	0.1	Aortic root size;	chr7:66421313	chr7:66491049~66493566:-
BRCA	cis	rs2840044	1	rs11653310	ENSG00000270871.1	AC015849.19	-3.3	0.000993	0.0431	-0.08	-0.1	Response to radiotherapy in cancer (late toxicity);	chr17:35566359	chr17:35816717~35830293:-
BRCA	cis	rs11668609	0.81	rs9305015	ENSG00000268058.1	BNIP3P40	3.3	0.000993	0.0431	0.13	0.1	Response to taxane treatment (docetaxel);	chr19:24157700	chr19:24098425~24098980:-
BRCA	cis	rs1878931	0.535	rs10852706	ENSG00000263280.1	LA16c-325D7.2	3.3	0.000994	0.0431	0.11	0.1	Body mass index (adult);	chr16:3362582	chr16:2866348~2867618:-
BRCA	cis	rs762407	0.925	rs2010795	ENSG00000237864.1	LINC00322	3.3	0.000994	0.0431	0.14	0.1	Systolic blood pressure change trajectories;	chr21:43752747	chr21:43322417~43332039:-
BRCA	cis	rs17092148	0.887	rs6058077	ENSG00000250917.1	RP4-785G19.5	3.3	0.000994	0.0432	0.17	0.1	Neuroticism;	chr20:34553195	chr20:34234840~34281173:-
BRCA	cis	rs7259376	0.902	rs8112041	ENSG00000269345.1	VN1R85P	-3.3	0.000994	0.0432	-0.12	-0.1	Menopause (age at onset);	chr19:22421763	chr19:22174766~22175191:-
BRCA	cis	rs7412746	0.611	rs4970985	ENSG00000224800.1	RP11-235D19.2	3.3	0.000994	0.0432	0.13	0.1	Melanoma;	chr1:150914966	chr1:150881236~150881683:-
BRCA	cis	rs13401620	0.554	rs7563035	ENSG00000236878.1	AC012363.7	3.3	0.000994	0.0432	0.12	0.1	Breast size;	chr2:120054688	chr2:120211054~120211715:+
BRCA	cis	rs12505749	0.66	rs7690100	ENSG00000270147.1	RP11-646I6.6	-3.3	0.000994	0.0432	-0.12	-0.1	Airflow obstruction;	chr4:56478154	chr4:56396312~56396871:+
BRCA	cis	rs2333021	0.624	rs12050080	ENSG00000259015.1	RP11-109N23.6	3.3	0.000994	0.0432	0.11	0.1	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:73012645	chr14:72960595~72961993:+
BRCA	cis	rs7474896	1	rs2799505	ENSG00000120555.12	SEPT7P9	-3.3	0.000994	0.0432	-0.18	-0.1	Obesity (extreme);	chr10:37934086	chr10:38383069~38402916:-
BRCA	cis	rs7474896	1	rs1007133	ENSG00000120555.12	SEPT7P9	-3.3	0.000994	0.0432	-0.18	-0.1	Obesity (extreme);	chr10:37936365	chr10:38383069~38402916:-
BRCA	cis	rs7474896	0.945	rs2799506	ENSG00000120555.12	SEPT7P9	-3.3	0.000994	0.0432	-0.18	-0.1	Obesity (extreme);	chr10:37936431	chr10:38383069~38402916:-
BRCA	cis	rs7474896	1	rs2799507	ENSG00000120555.12	SEPT7P9	-3.3	0.000994	0.0432	-0.18	-0.1	Obesity (extreme);	chr10:37938136	chr10:38383069~38402916:-
BRCA	cis	rs7474896	0.945	rs2092993	ENSG00000120555.12	SEPT7P9	-3.3	0.000994	0.0432	-0.18	-0.1	Obesity (extreme);	chr10:37939207	chr10:38383069~38402916:-
BRCA	cis	rs9650657	0.547	rs11250099	ENSG00000154316.13	TDH	-3.3	0.000994	0.0432	-0.13	-0.1	Neuroticism;	chr8:10961147	chr8:11339637~11368452:+
BRCA	cis	rs7695732	1	rs7687539	ENSG00000270720.1	RP11-84C13.2	3.3	0.000994	0.0432	0.12	0.1	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr4:88885633	chr4:89119284~89119871:+
BRCA	cis	rs4713118	0.911	rs9461406	ENSG00000280107.1	AL022393.9	3.3	0.000994	0.0432	0.15	0.1	Parkinson's disease;	chr6:27751985	chr6:28170845~28172521:+
BRCA	cis	rs875971	0.54	rs4717275	ENSG00000232559.3	GS1-124K5.12	-3.3	0.000994	0.0432	-0.12	-0.1	Aortic root size;	chr7:65800193	chr7:66554588~66576923:-
BRCA	cis	rs6676180	0.555	rs947430	ENSG00000236804.1	RPS3AP12	-3.3	0.000994	0.0432	-0.11	-0.1	Monobrow;	chr1:119236111	chr1:119126539~119127291:-
BRCA	cis	rs36051895	0.664	rs62543877	ENSG00000237711.1	RP11-39K24.13	-3.3	0.000994	0.0432	-0.13	-0.1	Pediatric autoimmune diseases;	chr9:5093465	chr9:5100236~5101009:+
BRCA	cis	rs72634258	0.554	rs4908699	ENSG00000269925.1	RP3-467L1.6	3.3	0.000994	0.0432	0.17	0.1	Inflammatory bowel disease;	chr1:7845214	chr1:7776383~7776775:+
BRCA	cis	rs2657888	0.593	rs2638318	ENSG00000257576.1	RP11-153M3.1	3.3	0.000995	0.0432	0.13	0.1	Adiponectin levels;	chr12:56463638	chr12:56511002~56512703:+
BRCA	cis	rs67766926	0.953	rs13406503	ENSG00000237522.1	NONOP2	-3.3	0.000995	0.0432	-0.11	-0.1	Inflammatory skin disease;	chr2:60897331	chr2:60936819~60938049:-
BRCA	cis	rs10129255	0.956	rs10137268	ENSG00000232216.1	IGHV3-43	3.3	0.000995	0.0432	0.09	0.1	Kawasaki disease;	chr14:106697402	chr14:106470264~106470800:-
BRCA	cis	rs2562456	0.958	rs2562508	ENSG00000268705.1	BNIP3P26	-3.3	0.000995	0.0432	-0.11	-0.1	Pain;	chr19:21543479	chr19:21521343~21521896:-
BRCA	cis	rs7474896	0.836	rs584630	ENSG00000120555.12	SEPT7P9	3.3	0.000995	0.0432	0.17	0.1	Obesity (extreme);	chr10:38049771	chr10:38383069~38402916:-
BRCA	cis	rs7283707	0.681	rs76592107	ENSG00000270071.1	AP001172.2	-3.3	0.000995	0.0432	-0.17	-0.1	QRS complex (12-leadsum);	chr21:15782082	chr21:16291791~16308133:-
BRCA	cis	rs7819412	0.505	rs17726209	ENSG00000248896.2	CTD-2135J3.3	3.3	0.000995	0.0432	0.13	0.1	Triglycerides;	chr8:11164675	chr8:10729314~10771392:+
BRCA	cis	rs6012564	0.819	rs1467417	ENSG00000230758.1	SNAP23P	-3.3	0.000995	0.0432	-0.12	-0.1	Anger;	chr20:48917118	chr20:49038357~49038602:-
BRCA	cis	rs7267979	1	rs2297497	ENSG00000204556.4	CTD-2514C3.1	3.3	0.000995	0.0432	0.14	0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25317273	chr20:26018832~26020684:+
BRCA	cis	rs10844706	0.699	rs10844630	ENSG00000278635.1	CTD-2318O12.1	-3.3	0.000995	0.0432	-0.11	-0.1	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9734268	chr12:9415641~9416718:+
BRCA	cis	rs1790761	0.501	rs4930210	ENSG00000255318.1	RP11-655M14.13	-3.3	0.000995	0.0432	-0.12	-0.1	Mean corpuscular volume;	chr11:67637255	chr11:67618279~67627304:-
BRCA	cis	rs2692947	0.644	rs1724125	ENSG00000168992.4	OR7E102P	3.3	0.000995	0.0432	0.15	0.1	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96165617	chr2:95546531~95547545:+
BRCA	cis	rs987724	0.593	rs13322318	ENSG00000240875.4	LINC00886	-3.3	0.000995	0.0432	-0.12	-0.1	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156906481	chr3:156747346~156817062:-
BRCA	cis	rs854765	0.565	rs4072738	ENSG00000197815.4	RP1-253P7.4	-3.3	0.000995	0.0432	-0.07	-0.1	Total body bone mineral density;	chr17:17981233	chr17:17858227~17860041:+
BRCA	cis	rs6968419	0.537	rs61487707	ENSG00000279086.1	RP11-667F14.1	-3.3	0.000995	0.0432	-0.11	-0.1	Intraocular pressure;	chr7:116141002	chr7:116209234~116211511:-
BRCA	cis	rs12439619	0.883	rs62012045	ENSG00000274376.3	ADAMTS7P1	3.3	0.000996	0.0432	0.13	0.1	Intelligence (multi-trait analysis);	chr15:82229366	chr15:82298553~82334609:+
BRCA	cis	rs4388249	0.95	rs34837720	ENSG00000249068.1	CTC-287O8.1	3.3	0.000996	0.0432	0.15	0.1	Schizophrenia;	chr5:109759863	chr5:109840128~109840692:-
BRCA	cis	rs1424638	0.629	rs718350	ENSG00000233251.6	AC007743.1	-3.3	0.000996	0.0432	-0.12	-0.1	Intelligence (multi-trait analysis);	chr2:57078505	chr2:56173534~56185770:-
BRCA	cis	rs67478160	0.643	rs2295141	ENSG00000269910.1	RP11-73M18.10	3.3	0.000996	0.0432	0.1	0.1	Schizophrenia;	chr14:103746612	chr14:103694516~103695050:-
BRCA	cis	rs67478160	0.643	rs3818085	ENSG00000269910.1	RP11-73M18.10	3.3	0.000996	0.0432	0.1	0.1	Schizophrenia;	chr14:103749648	chr14:103694516~103695050:-
BRCA	cis	rs67478160	0.643	rs1535098	ENSG00000269910.1	RP11-73M18.10	3.3	0.000996	0.0432	0.1	0.1	Schizophrenia;	chr14:103750176	chr14:103694516~103695050:-
BRCA	cis	rs9635324	0.964	rs11638033	ENSG00000223313.1	RNU6-516P	3.3	0.000996	0.0432	0.12	0.1	Blood metabolite ratios;Blood metabolite levels;	chr15:40417909	chr15:40529570~40529673:+
BRCA	cis	rs10771431	0.935	rs1988852	ENSG00000214776.8	RP11-726G1.1	-3.3	0.000996	0.0432	-0.11	-0.1	Breast size;	chr12:9220266	chr12:9467552~9576275:+
BRCA	cis	rs656319	0.559	rs17689289	ENSG00000255310.2	AF131215.2	3.3	0.000996	0.0432	0.11	0.1	Myopia (pathological);	chr8:10120470	chr8:11107788~11109726:-
BRCA	cis	rs5758659	0.714	rs133373	ENSG00000205702.9	CYP2D7	3.3	0.000996	0.0432	0.09	0.1	Cognitive function;	chr22:42069784	chr22:42140203~42144577:-
BRCA	cis	rs6142618	0.583	rs2235904	ENSG00000224452.1	RSL24D1P6	3.3	0.000996	0.0432	0.14	0.1	Inflammatory bowel disease;	chr20:32133909	chr20:32170390~32170790:-
BRCA	cis	rs11098499	0.863	rs13134665	ENSG00000225892.3	RP11-384K6.2	3.3	0.000996	0.0432	0.1	0.1	Corneal astigmatism;	chr4:119505275	chr4:118632274~118634759:+
BRCA	cis	rs1376877	0.837	rs11691351	ENSG00000273456.1	RP11-686O6.2	3.3	0.000996	0.0432	0.1	0.1	Subclinical atherosclerosis traits (other);	chr2:203009189	chr2:202374932~202375604:-
BRCA	cis	rs6071166	0.683	rs6071101	ENSG00000275401.1	RP4-564F22.7	-3.3	0.000996	0.0432	-0.12	-0.1	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38689335	chr20:38418483~38419202:-
BRCA	cis	rs6071166	0.683	rs6015637	ENSG00000275401.1	RP4-564F22.7	-3.3	0.000996	0.0432	-0.12	-0.1	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38689862	chr20:38418483~38419202:-
BRCA	cis	rs6792584	0.888	rs6548593	ENSG00000241316.5	SUCLG2-AS1	3.3	0.000996	0.0432	0.12	0.1	Corneal astigmatism;	chr3:67486264	chr3:67654697~67947713:+
BRCA	cis	rs875971	1	rs10215948	ENSG00000230189.5	GS1-124K5.2	-3.3	0.000996	0.0432	-0.08	-0.1	Aortic root size;	chr7:66282799	chr7:66409143~66490059:-
BRCA	cis	rs711244	0.935	rs2110942	ENSG00000279519.1	RP11-288C18.1	3.3	0.000997	0.0432	0.09	0.1	Mean platelet volume;	chr2:36869866	chr2:36839922~36842539:-
BRCA	cis	rs17836934	0.565	rs4842504	ENSG00000270344.2	RP11-734K2.4	-3.3	0.000997	0.0432	-0.09	-0.1	Total body bone mineral density;	chr12:90008924	chr12:89525654~89548005:+
BRCA	cis	rs6964587	0.655	rs6465351	ENSG00000188693.7	CYP51A1-AS1	-3.3	0.000997	0.0433	-0.11	-0.1	Breast cancer;	chr7:92143899	chr7:92134604~92180725:+
BRCA	cis	rs7980687	0.628	rs1609520	ENSG00000280389.1	RP11-512M8.11	3.3	0.000997	0.0433	0.14	0.1	Head circumference (infant);Educational attainment;Height;	chr12:123251390	chr12:122255119~122260274:-
BRCA	cis	rs10266483	1	rs10266483	ENSG00000271550.1	BNIP3P11	3.3	0.000997	0.0433	0.13	0.1	Response to statin therapy;	chr7:64272953	chr7:64678954~64687393:-
BRCA	cis	rs4947019	0.609	rs2275649	ENSG00000260273.1	RP11-425D10.10	3.3	0.000997	0.0433	0.27	0.1	Hematological parameters;	chr6:109370125	chr6:109382795~109383666:+
BRCA	cis	rs12505328	0.569	rs6832610	ENSG00000213370.3	RANP6	3.3	0.000997	0.0433	0.13	0.1	Chin dimples;	chr4:173438194	chr4:173633728~173634371:-
BRCA	cis	rs9437689	0.899	rs6683112	ENSG00000235501.4	RP4-639F20.1	3.3	0.000997	0.0433	0.13	0.1	Phospholipid levels (plasma);	chr1:95069890	chr1:94927566~94963270:+
BRCA	cis	rs4130344	0.874	rs4619844	ENSG00000271817.2	U3	-3.3	0.000997	0.0433	-0.11	-0.1	Intelligence (multi-trait analysis);	chr4:158877386	chr4:158700691~158700909:+
BRCA	cis	rs12479064	0.724	rs112900993	ENSG00000273306.1	RP11-527J8.1	3.3	0.000997	0.0433	0.12	0.1	Chronic sinus infection;	chr2:99332342	chr2:99405218~99405843:+
BRCA	cis	rs12479064	0.724	rs2309618	ENSG00000273306.1	RP11-527J8.1	3.3	0.000997	0.0433	0.12	0.1	Chronic sinus infection;	chr2:99358010	chr2:99405218~99405843:+
BRCA	cis	rs2835872	0.965	rs2835849	ENSG00000230366.8	DSCR9	-3.3	0.000997	0.0433	-0.14	-0.1	Electroencephalographic traits in alcoholism;	chr21:37639222	chr21:37208503~37221736:+
BRCA	cis	rs74233809	1	rs12220375	ENSG00000213061.2	PFN1P11	3.3	0.000997	0.0433	0.23	0.1	Birth weight;	chr10:103141734	chr10:102838011~102845473:-
BRCA	cis	rs990171	0.538	rs11123934	ENSG00000234389.1	AC007278.3	3.3	0.000997	0.0433	0.1	0.1	Lymphocyte counts;	chr2:102499109	chr2:102438713~102440475:+
BRCA	cis	rs7636293	1	rs7636293	ENSG00000270773.1	RP13-685P2.7	-3.3	0.000997	0.0433	-0.11	-0.1	Height;	chr3:129327063	chr3:129345411~129346164:+
BRCA	cis	rs17836934	0.565	rs4406875	ENSG00000270344.2	RP11-734K2.4	-3.3	0.000997	0.0433	-0.09	-0.1	Total body bone mineral density;	chr12:90000940	chr12:89525654~89548005:+
BRCA	cis	rs752010	0.967	rs2038978	ENSG00000230638.4	RP11-486B10.4	-3.3	0.000997	0.0433	-0.12	-0.1	Lupus nephritis in systemic lupus erythematosus;	chr1:41629048	chr1:41542069~41544310:+
BRCA	cis	rs4927850	1	rs4927850	ENSG00000273009.1	RP11-352G9.1	3.3	0.000997	0.0433	0.12	0.1	Pancreatic cancer;	chr3:196024759	chr3:195913078~195913683:-
BRCA	cis	rs76917914	1	rs4742711	ENSG00000236896.1	RP11-535C21.3	3.3	0.000997	0.0433	0.13	0.1	Immature fraction of reticulocytes;	chr9:98018508	chr9:97986551~97987656:-
BRCA	cis	rs7637230	1	rs10511191	ENSG00000244119.1	PDCL3P4	-3.3	0.000997	0.0433	-0.1	-0.1	Psoriasis vulgaris;Psoriasis;	chr3:101927008	chr3:101712472~101713191:+
BRCA	cis	rs2638953	0.777	rs10843181	ENSG00000273989.1	RP11-425D17.2	-3.3	0.000997	0.0433	-0.15	-0.1	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28462824	chr12:28236227~28236828:+
BRCA	cis	rs36051895	0.589	rs12682672	ENSG00000236254.1	MTND4P14	-3.3	0.000997	0.0433	-0.12	-0.1	Pediatric autoimmune diseases;	chr9:5187941	chr9:5107937~5109290:+
BRCA	cis	rs8049367	0.866	rs2892141	ENSG00000267077.1	RP11-127I20.5	3.3	0.000997	0.0433	0.1	0.1	Nonsyndromic cleft lip with or without cleft palate;	chr16:3924032	chr16:4795265~4796532:-
BRCA	cis	rs7577696	0.962	rs67157050	ENSG00000276334.1	AL133243.1	-3.3	0.000997	0.0433	-0.13	-0.1	Inflammatory biomarkers;	chr2:32046295	chr2:32521927~32523547:+
BRCA	cis	rs27434	0.583	rs34761	ENSG00000272109.1	CTD-2260A17.3	-3.3	0.000998	0.0433	-0.14	-0.1	Ankylosing spondylitis;	chr5:96817921	chr5:96804353~96806105:+
BRCA	cis	rs11088226	0.681	rs2833895	ENSG00000186842.4	LINC00846	-3.3	0.000998	0.0433	-0.16	-0.1	Gastritis;	chr21:32557492	chr21:32572238~32575881:-
BRCA	cis	rs11088226	0.645	rs2409457	ENSG00000186842.4	LINC00846	-3.3	0.000998	0.0433	-0.16	-0.1	Gastritis;	chr21:32557585	chr21:32572238~32575881:-
BRCA	cis	rs7586085	0.874	rs2303393	ENSG00000229195.1	AC009495.4	-3.3	0.000998	0.0433	-0.12	-0.1	Total body bone mineral density;	chr2:165749290	chr2:165794857~165846091:-
BRCA	cis	rs7586085	0.837	rs2303394	ENSG00000229195.1	AC009495.4	-3.3	0.000998	0.0433	-0.12	-0.1	Total body bone mineral density;	chr2:165749417	chr2:165794857~165846091:-
BRCA	cis	rs7487075	0.786	rs12302984	ENSG00000274723.1	RP11-618L22.1	3.3	0.000998	0.0433	0.12	0.1	Itch intensity from mosquito bite;	chr12:46290287	chr12:46970504~46972155:+
BRCA	cis	rs2072510	0.722	rs2247330	ENSG00000237774.3	RP11-129B9.1	-3.3	0.000998	0.0433	-0.11	-0.1	Metabolite levels (small molecules and protein measures);	chr12:96030344	chr12:95125760~95126389:+
BRCA	cis	rs67478160	0.571	rs1155751	ENSG00000269940.1	RP11-73M18.7	3.3	0.000998	0.0433	0.1	0.1	Schizophrenia;	chr14:103820210	chr14:103694560~103695170:+
BRCA	cis	rs4713118	0.868	rs742047	ENSG00000219392.1	RP1-265C24.5	-3.3	0.000998	0.0433	-0.15	-0.1	Parkinson's disease;	chr6:27771601	chr6:28115628~28116551:+
BRCA	cis	rs9467773	0.967	rs1056347	ENSG00000224843.5	LINC00240	-3.3	0.000998	0.0433	-0.11	-0.1	Intelligence (multi-trait analysis);	chr6:26527296	chr6:26956992~27023924:+
BRCA	cis	rs561341	1	rs530209	ENSG00000277511.1	CTD-2095E4.5	3.3	0.000998	0.0433	0.15	0.1	Hip circumference adjusted for BMI;	chr17:31988268	chr17:32127595~32128454:+
BRCA	cis	rs561341	1	rs561341	ENSG00000277511.1	CTD-2095E4.5	3.3	0.000998	0.0433	0.15	0.1	Hip circumference adjusted for BMI;	chr17:31989366	chr17:32127595~32128454:+
BRCA	cis	rs11098499	0.863	rs11098531	ENSG00000225892.3	RP11-384K6.2	3.3	0.000998	0.0433	0.1	0.1	Corneal astigmatism;	chr4:119543846	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.863	rs28718422	ENSG00000225892.3	RP11-384K6.2	3.3	0.000998	0.0433	0.1	0.1	Corneal astigmatism;	chr4:119545149	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.818	rs12498599	ENSG00000225892.3	RP11-384K6.2	3.3	0.000998	0.0433	0.1	0.1	Corneal astigmatism;	chr4:119547348	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.863	rs10009626	ENSG00000225892.3	RP11-384K6.2	3.3	0.000998	0.0433	0.1	0.1	Corneal astigmatism;	chr4:119548850	chr4:118632274~118634759:+
BRCA	cis	rs930395	0.514	rs6874167	ENSG00000272335.1	RP11-53O19.3	-3.3	0.000998	0.0433	-0.1	-0.1	Breast cancer;	chr5:44916572	chr5:44826076~44828592:+
BRCA	cis	rs930395	0.514	rs4866921	ENSG00000272335.1	RP11-53O19.3	-3.3	0.000998	0.0433	-0.1	-0.1	Breast cancer;	chr5:44917035	chr5:44826076~44828592:+
BRCA	cis	rs930395	0.514	rs6451783	ENSG00000272335.1	RP11-53O19.3	-3.3	0.000998	0.0433	-0.1	-0.1	Breast cancer;	chr5:44918191	chr5:44826076~44828592:+
BRCA	cis	rs930395	0.514	rs7736092	ENSG00000272335.1	RP11-53O19.3	-3.3	0.000998	0.0433	-0.1	-0.1	Breast cancer;	chr5:44920893	chr5:44826076~44828592:+
BRCA	cis	rs930395	0.514	rs10941687	ENSG00000272335.1	RP11-53O19.3	-3.3	0.000998	0.0433	-0.1	-0.1	Breast cancer;	chr5:44921081	chr5:44826076~44828592:+
BRCA	cis	rs930395	0.514	rs7708506	ENSG00000272335.1	RP11-53O19.3	-3.3	0.000998	0.0433	-0.1	-0.1	Breast cancer;	chr5:44922602	chr5:44826076~44828592:+
BRCA	cis	rs930395	0.514	rs7708686	ENSG00000272335.1	RP11-53O19.3	-3.3	0.000998	0.0433	-0.1	-0.1	Breast cancer;	chr5:44922736	chr5:44826076~44828592:+
BRCA	cis	rs4415084	0.68	rs10042455	ENSG00000272335.1	RP11-53O19.3	-3.3	0.000998	0.0433	-0.1	-0.1	Breast cancer;	chr5:44924916	chr5:44826076~44828592:+
BRCA	cis	rs930395	0.514	rs10039866	ENSG00000272335.1	RP11-53O19.3	-3.3	0.000998	0.0433	-0.1	-0.1	Breast cancer;	chr5:44924959	chr5:44826076~44828592:+
BRCA	cis	rs897984	0.513	rs17839568	ENSG00000279196.1	RP11-1072A3.3	3.3	0.000998	0.0433	0.1	0.1	Dementia with Lewy bodies;	chr16:31088462	chr16:30984630~30988270:-
BRCA	cis	rs2835872	0.965	rs73222309	ENSG00000230366.8	DSCR9	-3.3	0.000998	0.0433	-0.14	-0.1	Electroencephalographic traits in alcoholism;	chr21:37641384	chr21:37208503~37221736:+
BRCA	cis	rs2154319	0.836	rs804660	ENSG00000230638.4	RP11-486B10.4	3.3	0.000998	0.0433	0.17	0.1	Height;	chr1:41106492	chr1:41542069~41544310:+
BRCA	cis	rs2154319	0.79	rs710248	ENSG00000230638.4	RP11-486B10.4	3.3	0.000998	0.0433	0.17	0.1	Height;	chr1:41108950	chr1:41542069~41544310:+
BRCA	cis	rs2124910	0.815	rs2864102	ENSG00000255441.1	CTD-2616J11.2	-3.3	0.000998	0.0433	-0.12	-0.1	Blood protein levels;	chr19:51526838	chr19:51415724~51417425:+
BRCA	cis	rs1124769	0.5	rs79722088	ENSG00000259298.1	RP11-562A8.4	-3.3	0.000998	0.0433	-0.1	-0.1	Cognitive performance;	chr15:50853702	chr15:50497195~50498744:-
BRCA	cis	rs7267979	0.816	rs6115094	ENSG00000204556.4	CTD-2514C3.1	-3.3	0.000998	0.0433	-0.14	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25230191	chr20:26018832~26020684:+
BRCA	cis	rs62244186	0.632	rs1402751	ENSG00000214820.3	MPRIPP1	3.3	0.000998	0.0433	0.12	0.1	Depressive symptoms;	chr3:44552538	chr3:44579938~44581026:-
BRCA	cis	rs6445967	1	rs6791748	ENSG00000272182.1	RP11-802O23.3	3.3	0.000998	0.0433	0.11	0.1	Platelet count;	chr3:58322792	chr3:58428255~58428815:+
BRCA	cis	rs7944735	0.508	rs1872167	ENSG00000243802.2	RP11-390K5.1	3.3	0.000999	0.0433	0.15	0.1	Intraocular pressure;	chr11:47879717	chr11:47191181~47191542:-
BRCA	cis	rs2904524	1	rs17107926	ENSG00000257613.1	LINC01481	-3.3	0.000999	0.0433	-0.17	-0.1	Amyotrophic lateral sclerosis (age of onset);	chr12:70282250	chr12:70219132~70221862:-
BRCA	cis	rs2298948	1	rs2298948	ENSG00000270696.1	RP11-342K6.1	-3.3	0.000999	0.0433	-0.12	-0.1	Hippocampal atrophy;	chr2:75699439	chr2:75660462~75662208:+
BRCA	cis	rs2964802	0.505	rs7737359	ENSG00000259802.1	CTD-2256P15.2	3.3	0.000999	0.0433	0.1	0.1	Major depressive disorder;Recurrent major depressive disorder;	chr5:10831992	chr5:10352701~10353601:-
BRCA	cis	rs9308731	0.505	rs10169613	ENSG00000230499.1	AC108463.1	-3.3	0.000999	0.0433	-0.12	-0.1	Chronic lymphocytic leukemia;	chr2:111177400	chr2:111195963~111206494:+
BRCA	cis	rs6736093	0.736	rs10195619	ENSG00000236307.2	EEF1E1P1	-3.3	0.000999	0.0433	-0.11	-0.1	Coronary artery disease;	chr2:112007985	chr2:111887914~111888741:+
BRCA	cis	rs8016982	0.662	rs7148100	ENSG00000258999.1	RP11-114N19.3	3.3	0.000999	0.0433	0.14	0.1	Schizophrenia;	chr14:81211752	chr14:81107033~81170414:-
BRCA	cis	rs5758511	0.773	rs12167978	ENSG00000233903.2	Z83851.4	3.3	0.000999	0.0433	0.15	0.1	Birth weight;	chr22:41950471	chr22:42276355~42277052:+
BRCA	cis	rs2645424	0.666	rs2272767	ENSG00000255046.1	RP11-297N6.4	3.3	0.000999	0.0433	0.12	0.1	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);	chr8:11853550	chr8:11797928~11802568:-
BRCA	cis	rs12699921	0.935	rs6461363	ENSG00000279048.1	RP11-511H23.2	3.3	0.000999	0.0433	0.1	0.1	Fibrinogen levels;	chr7:17952527	chr7:17940503~17942922:+
BRCA	cis	rs6964587	0.626	rs7785941	ENSG00000188693.7	CYP51A1-AS1	3.3	0.000999	0.0433	0.11	0.1	Breast cancer;	chr7:91901710	chr7:92134604~92180725:+
BRCA	cis	rs324126	0.78	rs10445586	ENSG00000277977.1	CTD-3018O17.5	3.3	0.000999	0.0433	0.12	0.1	Colonoscopy-negative controls vs population controls;	chr19:52379870	chr19:52392659~52392755:+
BRCA	cis	rs13034020	0.522	rs12464096	ENSG00000237522.1	NONOP2	3.3	0.000999	0.0433	0.13	0.1	Hodgkin's lymphoma;	chr2:61012197	chr2:60936819~60938049:-
BRCA	cis	rs13034020	0.522	rs13005116	ENSG00000237522.1	NONOP2	3.3	0.000999	0.0433	0.13	0.1	Hodgkin's lymphoma;	chr2:61014432	chr2:60936819~60938049:-
BRCA	cis	rs8023401	0.938	rs11853943	ENSG00000274654.1	CTD-3247H4.2	3.3	0.000999	0.0433	0.15	0.1	Spherical equivalent (joint analysis main effects and education interaction);	chr15:48487205	chr15:48528980~48529728:-
BRCA	cis	rs931127	0.547	rs3886859	ENSG00000255557.1	RP11-770G2.2	3.3	0.000999	0.0433	0.12	0.1	Systemic lupus erythematosus;	chr11:65690839	chr11:65745729~65771585:+
BRCA	cis	rs739401	1	rs739401	ENSG00000247473.2	CARS-AS1	-3.3	0.000999	0.0433	-0.11	-0.1	Longevity;	chr11:3015094	chr11:3029009~3041260:+
BRCA	cis	rs2289328	1	rs2289328	ENSG00000259330.1	INAFM2	3.3	0.000999	0.0433	0.17	0.1	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr15:40413218	chr15:40325216~40326715:+
BRCA	cis	rs7692995	1	rs16896128	ENSG00000235413.3	KRT18P63	3.3	0.000999	0.0433	0.16	0.1	Height;	chr4:17951967	chr4:17911674~17912976:+
BRCA	cis	rs10876993	0.928	rs2640636	ENSG00000269903.1	RP11-571M6.18	3.3	0.000999	0.0434	0.13	0.1	Celiac disease or Rheumatoid arthritis;	chr12:57683761	chr12:57814494~57814926:+
BRCA	cis	rs10876993	0.928	rs2640637	ENSG00000269903.1	RP11-571M6.18	3.3	0.000999	0.0434	0.13	0.1	Celiac disease or Rheumatoid arthritis;	chr12:57683803	chr12:57814494~57814926:+
BRCA	cis	rs4869313	0.642	rs2548539	ENSG00000248734.2	CTD-2260A17.1	-3.3	0.001	0.0434	-0.1	-0.1	Pediatric autoimmune diseases;	chr5:96895800	chr5:96784777~96785999:+
BRCA	cis	rs11681884	0.892	rs11123159	ENSG00000189223.12	PAX8-AS1	3.3	0.001	0.0434	0.21	0.1	Stroke;	chr2:113076453	chr2:113211522~113276581:+
BRCA	cis	rs875971	0.789	rs28815324	ENSG00000226767.1	RP11-328P23.3	-3.3	0.001	0.0434	-0.13	-0.1	Aortic root size;	chr7:66100789	chr7:65508773~65508944:-
BRCA	cis	rs977987	0.806	rs4888405	ENSG00000280152.1	RP11-331F4.5	-3.3	0.001	0.0434	-0.1	-0.1	Dupuytren's disease;	chr16:75394298	chr16:75245994~75250077:-
BRCA	cis	rs875971	1	rs875971	ENSG00000271064.1	RP11-792A8.3	3.3	0.001	0.0434	0.12	0.1	Aortic root size;	chr7:66152608	chr7:66748838~66749077:-
BRCA	cis	rs71520386	0.634	rs13240023	ENSG00000179428.2	AC073072.5	3.3	0.001	0.0434	0.12	0.1	Fibrinogen levels;	chr7:22827874	chr7:22725395~22727620:-
BRCA	cis	rs13256369	1	rs12547721	ENSG00000254153.1	CTA-398F10.2	3.3	0.001	0.0434	0.14	0.1	Obesity-related traits;	chr8:8713161	chr8:8456909~8461337:-
BRCA	cis	rs9947662	0.778	rs1019990	ENSG00000267800.1	RP11-49K24.5	3.3	0.001	0.0434	0.12	0.1	Migraine;	chr18:47340365	chr18:47137018~47137290:+
BRCA	cis	rs10761256	0.806	rs10761251	ENSG00000227603.1	RP11-165J3.6	3.3	0.001	0.0434	0.11	0.1	Itch intensity from mosquito bite adjusted by bite size;	chr9:93659264	chr9:93435332~93437121:-
BRCA	cis	rs875971	0.862	rs778702	ENSG00000223473.2	GS1-124K5.3	3.3	0.001	0.0434	0.08	0.1	Aortic root size;	chr7:66399848	chr7:66491049~66493566:-
BRCA	cis	rs10129255	0.784	rs7147210	ENSG00000232216.1	IGHV3-43	3.3	0.001	0.0434	0.09	0.1	Kawasaki disease;	chr14:106705271	chr14:106470264~106470800:-
BRCA	cis	rs4908769	0.624	rs2120461	ENSG00000232912.4	RP5-1115A15.1	-3.3	0.001	0.0434	-0.11	-0.1	Allergy;	chr1:8387662	chr1:8424645~8434838:+
BRCA	cis	rs4819052	0.807	rs1075788	ENSG00000215447.6	BX322557.10	-3.3	0.001	0.0434	-0.1	-0.1	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45246649	chr21:45288052~45291738:+
BRCA	cis	rs987724	0.593	rs3910072	ENSG00000240875.4	LINC00886	-3.3	0.001	0.0434	-0.12	-0.1	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156843137	chr3:156747346~156817062:-
BRCA	cis	rs987724	0.551	rs9876010	ENSG00000240875.4	LINC00886	-3.3	0.001	0.0434	-0.12	-0.1	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156845715	chr3:156747346~156817062:-
BRCA	cis	rs6142618	0.523	rs6141636	ENSG00000275576.1	RP5-836N17.4	-3.3	0.001	0.0434	-0.11	-0.1	Inflammatory bowel disease;	chr20:32210865	chr20:32116171~32116629:+
BRCA	cis	rs9420907	0.579	rs11598840	ENSG00000280693.1	SH3PXD2A-AS1	3.3	0.001	0.0434	0.18	0.1	Telomere length;	chr10:103885423	chr10:103745966~103755423:+
BRCA	cis	rs6142618	0.583	rs2281364	ENSG00000277692.1	RP11-358N2.2	-3.3	0.001	0.0434	-0.11	-0.1	Inflammatory bowel disease;	chr20:32164349	chr20:32355053~32355734:+
BRCA	cis	rs6142618	0.562	rs6061203	ENSG00000277692.1	RP11-358N2.2	-3.3	0.001	0.0434	-0.11	-0.1	Inflammatory bowel disease;	chr20:32165167	chr20:32355053~32355734:+
BRCA	cis	rs6142618	0.562	rs2377416	ENSG00000277692.1	RP11-358N2.2	-3.3	0.001	0.0434	-0.11	-0.1	Inflammatory bowel disease;	chr20:32169571	chr20:32355053~32355734:+
BRCA	cis	rs12637928	0.539	rs6776980	ENSG00000206532.2	RP11-553A10.1	-3.3	0.001	0.0434	-0.13	-0.1	Neuroticism;	chr3:110602857	chr3:110888384~110893476:-
BRCA	cis	rs253959	0.545	rs712588	ENSG00000272265.1	CTD-2287O16.4	-3.3	0.001	0.0434	-0.12	-0.1	Bipolar disorder and schizophrenia;	chr5:116318908	chr5:116078110~116078570:-
BRCA	cis	rs12216545	0.765	rs1403222	ENSG00000244151.1	RP11-148K1.12	3.3	0.001	0.0434	0.09	0.1	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150556825	chr7:151074742~151076530:-
BRCA	cis	rs4481887	0.676	rs7520659	ENSG00000235749.2	RP11-634B7.4	-3.3	0.001	0.0434	-0.11	-0.1	Common traits (Other);	chr1:248364284	chr1:247639749~247747062:+
BRCA	cis	rs4481887	0.617	rs7511986	ENSG00000235749.2	RP11-634B7.4	-3.3	0.001	0.0434	-0.11	-0.1	Common traits (Other);	chr1:248364508	chr1:247639749~247747062:+
BRCA	cis	rs8098244	1	rs1941521	ENSG00000265752.2	RP11-403A21.1	3.3	0.001	0.0434	0.12	0.1	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23824370	chr18:23957754~23982556:-
BRCA	cis	rs801193	0.569	rs3846973	ENSG00000223473.2	GS1-124K5.3	-3.3	0.001	0.0434	-0.08	-0.1	Aortic root size;	chr7:66655048	chr7:66491049~66493566:-
BRCA	cis	rs2710103	0.748	rs2538963	ENSG00000264918.1	AC005229.1	-3.3	0.001	0.0434	-0.14	-0.1	Facial morphology (factor 11, projection of the nose);	chr7:147902354	chr7:148730829~148730928:-
BRCA	cis	rs4869313	0.668	rs2617434	ENSG00000248734.2	CTD-2260A17.1	3.3	0.001	0.0434	0.1	0.1	Pediatric autoimmune diseases;	chr5:96935934	chr5:96784777~96785999:+
BRCA	cis	rs2274273	0.686	rs57033289	ENSG00000259318.1	RP11-454L9.2	3.3	0.001	0.0434	0.09	0.1	Protein biomarker;	chr14:55156599	chr14:55394940~55395233:-
BRCA	cis	rs2274273	0.686	rs11624679	ENSG00000259318.1	RP11-454L9.2	3.3	0.001	0.0434	0.09	0.1	Protein biomarker;	chr14:55157526	chr14:55394940~55395233:-
BRCA	cis	rs1046491	0.901	rs10853373	ENSG00000264964.1	RP11-888D10.3	3.3	0.001	0.0434	0.21	0.1	Scarlet fever;	chr18:9149417	chr18:9315194~9334441:-
BRCA	cis	rs10045413	0.598	rs17168730	ENSG00000250167.1	CTC-321K16.1	-3.3	0.001	0.0434	-0.12	-0.1	Age at smoking initiation in chronic obstructive pulmonary disease;	chr5:135607754	chr5:135559577~135634874:+
BRCA	cis	rs757110	0.834	rs1002226	ENSG00000197149.5	RP11-452G18.2	-3.3	0.001	0.0434	-0.13	-0.1	Type 2 diabetes;	chr11:17384070	chr11:17228279~17229151:+
BRCA	cis	rs9341808	0.718	rs7740627	ENSG00000279022.1	RP11-250B2.4	3.3	0.001	0.0434	0.12	0.1	Sitting height ratio;	chr6:80206630	chr6:80440730~80441172:+
BRCA	cis	rs372883	0.53	rs2832305	ENSG00000232855.5	AF131217.1	-3.3	0.001	0.0434	-0.13	-0.1	Pancreatic cancer;	chr21:29380644	chr21:28439346~28674848:-
BRCA	cis	rs34779708	0.966	rs12782948	ENSG00000269952.1	RP11-324I22.3	-3.3	0.001	0.0434	-0.14	-0.1	Inflammatory bowel disease;Crohn's disease;	chr10:35161679	chr10:35210416~35210750:+
BRCA	cis	rs718433	0.584	rs10438076	ENSG00000211805.1	TRAV24	-3.3	0.001	0.0434	-0.08	-0.1	Intraocular pressure;	chr14:21741785	chr14:22105343~22105846:+
BRCA	cis	rs875971	0.825	rs1129531	ENSG00000229886.1	RP5-1132H15.3	-3.3	0.001	0.0434	-0.11	-0.1	Aortic root size;	chr7:66154117	chr7:66025126~66031544:-
BRCA	cis	rs4660214	0.666	rs1180376	ENSG00000182109.6	RP11-69E11.4	3.3	0.001	0.0434	0.12	0.1	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39418761	chr1:39522280~39546187:-
BRCA	cis	rs6582630	0.512	rs11182667	ENSG00000257718.1	RP11-396F22.1	-3.3	0.001	0.0434	-0.1	-0.1	Drug-induced liver injury (flucloxacillin);	chr12:38194590	chr12:38906451~38909592:+
BRCA	cis	rs9341808	0.718	rs9443735	ENSG00000233967.5	RP11-250B2.3	3.3	0.001	0.0434	0.11	0.1	Sitting height ratio;	chr6:80110757	chr6:80443344~80465927:+
BRCA	cis	rs3096299	0.632	rs4399533	ENSG00000259877.2	RP11-46C24.7	-3.3	0.001	0.0434	-0.09	-0.1	Multiple myeloma (IgH translocation);	chr16:89472974	chr16:89215211~89217653:-
BRCA	cis	rs7149337	0.78	rs4369569	ENSG00000258955.1	LINC00519	3.3	0.001	0.0434	0.11	0.1	Cancer;	chr14:51222463	chr14:51304416~51328386:-
BRCA	cis	rs481331	0.866	rs6593349	ENSG00000273008.1	RP11-351D16.3	-3.3	0.001	0.0434	-0.13	-0.1	Systemic juvenile idiopathic arthritis;	chr10:42489844	chr10:43136824~43138334:-
BRCA	cis	rs600550	0.557	rs1899572	ENSG00000275344.1	MIR6503	3.3	0.001	0.0434	0.11	0.1	Lipoprotein-associated phospholipase A2 activity and mass;	chr11:60318551	chr11:60209071~60209156:-
BRCA	cis	rs78472555	0.661	rs11636728	ENSG00000259363.4	CTD-2054N24.2	-3.3	0.001	0.0434	-0.14	-0.1	Post bronchodilator FEV1/FVC ratio in COPD;	chr15:99581527	chr15:99807023~99877148:+
BRCA	cis	rs6583331	0.818	rs7614184	ENSG00000225578.1	NCBP2-AS1	-3.3	0.001	0.0434	-0.1	-0.1	Vitiligo;	chr3:196619326	chr3:196939877~196942534:+
BRCA	cis	rs4388249	0.687	rs3797672	ENSG00000271849.1	CTC-332L22.1	3.3	0.001	0.0434	0.14	0.1	Schizophrenia;	chr5:109866122	chr5:109687802~109688329:-
BRCA	cis	rs360932	0.674	rs361149	ENSG00000270265.1	RP11-731D1.4	3.3	0.001	0.0434	0.12	0.1	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr4:151970796	chr4:151333775~151353224:-
BRCA	cis	rs13136331	0.532	rs2615480	ENSG00000249001.4	RP11-742B18.1	3.3	0.001	0.0434	0.14	0.1	Sitting height ratio;	chr4:87656421	chr4:87568035~87733956:-
BRCA	cis	rs11239930	0.517	rs2477569	ENSG00000227242.3	NBPF13P	3.3	0.001	0.0434	0.13	0.1	AIDS progression;	chr1:147076261	chr1:147021320~147124525:-
BRCA	cis	rs6088580	0.634	rs6120644	ENSG00000269202.1	RP4-614O4.12	-3.3	0.001	0.0434	-0.1	-0.1	Glomerular filtration rate (creatinine);	chr20:34436005	chr20:35201747~35203288:-
BRCA	cis	rs9788682	1	rs9788682	ENSG00000261762.1	RP11-650L12.2	3.3	0.001	0.0434	0.13	0.1	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78510244	chr15:78589123~78591276:-
BRCA	cis	rs13401620	0.917	rs7561560	ENSG00000229326.3	AC069154.4	-3.3	0.001	0.0434	-0.14	-0.1	Breast size;	chr2:119773031	chr2:119698623~119700151:+
BRCA	cis	rs7577894	0.967	rs13404193	ENSG00000272606.1	RP11-554J4.1	3.3	0.001	0.0434	0.11	0.1	Amyotrophic lateral sclerosis;	chr2:55770511	chr2:55617909~55618373:+
BRCA	cis	rs17406451	0.655	rs6708660	ENSG00000234936.1	AC010883.5	3.3	0.001	0.0434	0.1	0.1	Mitochondrial DNA levels;	chr2:43525243	chr2:43229573~43233394:+
BRCA	cis	rs2803122	0.777	rs6475326	ENSG00000272842.1	RP11-513M16.7	3.3	0.001	0.0434	0.1	0.1	Pulse pressure;	chr9:19386567	chr9:19371386~19371945:-
BRCA	cis	rs10043228	1	rs10073364	ENSG00000250015.1	CTC-339F2.2	3.3	0.001	0.0434	0.13	0.1	Asthma or chronic obstructive pulmonary disease;	chr5:116256885	chr5:116302354~116304134:-
BRCA	cis	rs10043228	1	rs10036292	ENSG00000250015.1	CTC-339F2.2	3.3	0.001	0.0434	0.13	0.1	Asthma or chronic obstructive pulmonary disease;	chr5:116260174	chr5:116302354~116304134:-
BRCA	cis	rs6802315	0.74	rs9822005	ENSG00000272440.1	RP11-379F4.6	3.3	0.001	0.0434	0.13	0.1	Periodontitis (CDC/AAP);	chr3:158794592	chr3:158695367~158695581:+
BRCA	cis	rs12122100	0.651	rs12127461	ENSG00000278811.3	LINC00624	-3.3	0.001	0.0435	-0.12	-0.1	HIV-1 control;	chr1:147080339	chr1:147258885~147517875:-
BRCA	cis	rs10876993	0.68	rs2277322	ENSG00000270039.1	RP11-571M6.17	-3.3	0.001	0.0435	-0.14	-0.1	Celiac disease or Rheumatoid arthritis;	chr12:57615419	chr12:57803838~57804415:+
BRCA	cis	rs11603023	0.772	rs540800	ENSG00000278376.1	RP11-158I9.8	-3.3	0.001	0.0435	-0.1	-0.1	Cholesterol, total;	chr11:118694942	chr11:118791254~118793137:+
BRCA	cis	rs11969893	0.737	rs6930051	ENSG00000270987.1	RP3-467N11.2	3.3	0.001	0.0435	0.23	0.1	Economic and political preferences (immigration/crime);	chr6:100958232	chr6:100889603~100890338:+
BRCA	cis	rs58950470	0.521	rs7950197	ENSG00000254510.1	RP11-867G23.10	-3.3	0.001	0.0435	-0.1	-0.1	Schizophrenia;	chr11:65678655	chr11:66409158~66417137:+
BRCA	cis	rs9611565	0.694	rs202631	ENSG00000281538.1	RP4-669P10.20	-3.3	0.001	0.0435	-0.12	-0.1	Vitiligo;	chr22:41467419	chr22:42138060~42139726:+
BRCA	cis	rs16917546	0.935	rs10995271	ENSG00000238280.1	RP11-436D10.3	3.3	0.001	0.0435	0.14	0.1	Basal cell carcinoma;	chr10:62678726	chr10:62793562~62805887:-
BRCA	cis	rs7829975	0.509	rs7838674	ENSG00000173295.6	FAM86B3P	-3.3	0.001	0.0435	-0.1	-0.1	Mood instability;	chr8:8939563	chr8:8228595~8244865:+
BRCA	cis	rs7097397	0.661	rs2683610	ENSG00000265018.5	CTGLF12P	-3.3	0.001	0.0435	-0.14	-0.1	Systemic lupus erythematosus;	chr10:48769674	chr10:48009873~48031640:-
BRCA	cis	rs9467773	1	rs12526680	ENSG00000224843.5	LINC00240	-3.3	0.001	0.0435	-0.11	-0.1	Intelligence (multi-trait analysis);	chr6:26550726	chr6:26956992~27023924:+
BRCA	cis	rs68130068	0.808	rs56031019	ENSG00000228389.1	AC068039.4	3.3	0.001	0.0435	0.19	0.1	HER2 status in breast cancer;	chr2:172308739	chr2:171773482~171775844:+
BRCA	cis	rs7686384	0.522	rs11947850	ENSG00000242169.2	RP11-219G10.1	-3.3	0.001	0.0435	-0.13	-0.1	Obesity-related traits;	chr4:188715133	chr4:188349376~188350024:-
BRCA	cis	rs6445967	1	rs1913715	ENSG00000272182.1	RP11-802O23.3	3.3	0.001	0.0435	0.11	0.1	Platelet count;	chr3:58322487	chr3:58428255~58428815:+
BRCA	cis	rs4481887	0.741	rs6587471	ENSG00000235749.2	RP11-634B7.4	-3.3	0.001	0.0435	-0.12	-0.1	Common traits (Other);	chr1:248397440	chr1:247639749~247747062:+
BRCA	cis	rs875971	0.862	rs1643375	ENSG00000223473.2	GS1-124K5.3	3.3	0.001	0.0435	0.08	0.1	Aortic root size;	chr7:66407690	chr7:66491049~66493566:-
BRCA	cis	rs17684571	1	rs16888133	ENSG00000231441.1	RP11-472M19.2	3.3	0.001	0.0435	0.14	0.1	Schizophrenia;	chr6:56709593	chr6:56844002~56864078:+
BRCA	cis	rs1816752	1	rs7326932	ENSG00000273628.1	RP11-756A22.7	3.3	0.001	0.0435	0.12	0.1	Obesity-related traits;	chr13:24430355	chr13:24933006~24936796:+
BRCA	cis	rs9834970	0.611	rs925135	ENSG00000235482.1	RPL21P135	3.3	0.001	0.0435	0.12	0.1	Bipolar disorder with mood-incongruent psychosis;Bipolar disorder;Schizophrenia or bipolar disorder;Subjective response to lithium treatment;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr3:36812762	chr3:37748110~37748900:+
BRCA	cis	rs7526034	1	rs12031051	ENSG00000224209.5	LINC00466	3.3	0.001	0.0435	0.18	0.1	Brain imaging;	chr1:63123747	chr1:63189989~63317231:-
BRCA	cis	rs58521262	0.556	rs290584	ENSG00000267920.1	SNX6P1	-3.3	0.001	0.0435	-0.14	-0.1	Testicular germ cell tumor;	chr19:23015674	chr19:23126569~23127792:-
BRCA	cis	rs7104764	1	rs10902114	ENSG00000254910.1	RP11-326C3.7	-3.3	0.001	0.0435	-0.12	-0.1	Menarche (age at onset);	chr11:246234	chr11:310139~311141:-
BRCA	cis	rs6142102	0.961	rs1007090	ENSG00000206582.1	Y_RNA	-3.3	0.001	0.0435	-0.12	-0.1	Skin pigmentation;	chr20:33995065	chr20:34526510~34526606:-
BRCA	cis	rs6142102	0.923	rs2284377	ENSG00000206582.1	Y_RNA	-3.3	0.001	0.0435	-0.12	-0.1	Skin pigmentation;	chr20:33998876	chr20:34526510~34526606:-
BRCA	cis	rs6142102	0.961	rs2284378	ENSG00000206582.1	Y_RNA	-3.3	0.001	0.0435	-0.12	-0.1	Skin pigmentation;	chr20:34000289	chr20:34526510~34526606:-
BRCA	cis	rs6142102	0.961	rs2268080	ENSG00000206582.1	Y_RNA	-3.3	0.001	0.0435	-0.12	-0.1	Skin pigmentation;	chr20:34009910	chr20:34526510~34526606:-
BRCA	cis	rs7914558	1	rs7067970	ENSG00000213277.3	MARCKSL1P1	3.3	0.001	0.0435	0.11	0.1	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103154113	chr10:103175554~103176094:+
BRCA	cis	rs7520050	0.966	rs10789481	ENSG00000226957.1	RP4-533D7.4	3.3	0.001	0.0435	0.11	0.1	Reticulocyte count;Red blood cell count;	chr1:45917911	chr1:46046818~46048368:+
BRCA	cis	rs2243480	0.908	rs313822	ENSG00000226767.1	RP11-328P23.3	-3.3	0.001	0.0435	-0.18	-0.1	Diabetic kidney disease;	chr7:66108952	chr7:65508773~65508944:-
BRCA	cis	rs11773103	0.581	rs73202987	ENSG00000224046.1	AC005076.5	3.3	0.001	0.0435	0.18	0.1	Bipolar disorder or major depressive disorder (combined);	chr7:87126637	chr7:87151423~87152420:-
BRCA	cis	rs4691139	0.588	rs72697954	ENSG00000248632.1	RP11-366M4.11	3.3	0.001	0.0435	0.11	0.1	Ovarian cancer in BRCA1 mutation carriers;	chr4:164982890	chr4:164968587~164970002:-
BRCA	cis	rs4415084	0.716	rs727305	ENSG00000272335.1	RP11-53O19.3	3.3	0.001	0.0435	0.09	0.1	Breast cancer;	chr5:44795940	chr5:44826076~44828592:+
BRCA	cis	rs10129255	0.957	rs10141009	ENSG00000231475.3	IGHV4-31	-3.3	0.001	0.0435	-0.08	-0.1	Kawasaki disease;	chr14:106776695	chr14:106349283~106349792:-
BRCA	cis	rs7487075	0.619	rs11183488	ENSG00000257261.4	RP11-96H19.1	3.3	0.001	0.0435	0.12	0.1	Itch intensity from mosquito bite;	chr12:46448053	chr12:46383679~46876159:+
BRCA	cis	rs721399	0.752	rs35570672	ENSG00000253671.1	RP11-806O11.1	-3.3	0.001	0.0435	-0.13	-0.1	Blood metabolite levels;	chr8:18415125	chr8:17808941~17820868:+
BRCA	cis	rs1383484	1	rs4357909	ENSG00000259728.4	LINC00933	3.3	0.001	0.0435	0.12	0.1	Height;	chr15:83846823	chr15:84570649~84580175:+
BRCA	cis	rs10735946	1	rs2870957	ENSG00000255733.4	IFNG-AS1	-3.3	0.001	0.0435	-0.09	-0.1	Anti-saccade response;	chr12:68092655	chr12:67989445~68234686:+
BRCA	cis	rs453301	0.658	rs6986044	ENSG00000233609.3	RP11-62H7.2	-3.3	0.001	0.0435	-0.1	-0.1	Joint mobility (Beighton score);	chr8:9017276	chr8:8961200~8979025:+
BRCA	cis	rs853679	0.517	rs4713141	ENSG00000272009.1	RP1-313I6.12	-3.3	0.001	0.0435	-0.15	-0.1	Depression;	chr6:28133900	chr6:28078792~28081130:-
BRCA	cis	rs10876993	0.928	rs1689586	ENSG00000269903.1	RP11-571M6.18	3.3	0.001	0.0435	0.13	0.1	Celiac disease or Rheumatoid arthritis;	chr12:57685803	chr12:57814494~57814926:+
BRCA	cis	rs2839186	0.587	rs35679325	ENSG00000215424.8	MCM3AP-AS1	-3.3	0.001	0.0435	-0.1	-0.1	Testicular germ cell tumor;	chr21:46221066	chr21:46229217~46259390:+
BRCA	cis	rs10816359	0.894	rs10521075	ENSG00000234323.4	RP11-308N19.1	3.3	0.00101	0.0435	0.14	0.1	Menarche (age at onset);	chr9:106015361	chr9:106278392~106604795:+
BRCA	cis	rs6840360	0.571	rs10026670	ENSG00000278978.1	RP11-164P12.5	-3.3	0.00101	0.0435	-0.12	-0.1	Intelligence (multi-trait analysis);	chr4:151618060	chr4:151669786~151670503:+
BRCA	cis	rs2574985	0.813	rs3011771	ENSG00000226200.5	SGMS1-AS1	-3.3	0.00101	0.0435	-0.11	-0.1	Subjective well-being;	chr10:50477528	chr10:50624951~50641451:+
BRCA	cis	rs930395	0.514	rs4360054	ENSG00000272335.1	RP11-53O19.3	-3.3	0.00101	0.0435	-0.1	-0.1	Breast cancer;	chr5:44928902	chr5:44826076~44828592:+
BRCA	cis	rs4578769	0.959	rs3911557	ENSG00000273232.1	RP11-370A5.2	-3.3	0.00101	0.0435	-0.13	-0.1	Eosinophil percentage of white cells;	chr18:22892600	chr18:22882825~22883357:-
BRCA	cis	rs12701220	0.655	rs9638973	ENSG00000224079.1	AC091729.7	3.3	0.00101	0.0436	0.15	0.1	Bronchopulmonary dysplasia;	chr7:1094042	chr7:1074450~1078036:+
BRCA	cis	rs3805389	0.504	rs17725163	ENSG00000273257.1	RP11-177J6.1	3.3	0.00101	0.0436	0.17	0.1	Waist-to-hip ratio adjusted for body mass index;	chr4:55609280	chr4:55387949~55388271:+
BRCA	cis	rs17711722	0.701	rs781143	ENSG00000229180.5	GS1-124K5.11	3.3	0.00101	0.0436	0.09	0.1	Calcium levels;	chr7:65974892	chr7:66526088~66542624:-
BRCA	cis	rs6494488	0.5	rs72744738	ENSG00000259635.1	AC100830.3	-3.3	0.00101	0.0436	-0.25	-0.1	Coronary artery disease;	chr15:64756135	chr15:64701248~64719602:+
BRCA	cis	rs8038465	0.662	rs57771618	ENSG00000260898.4	ADPGK-AS1	3.3	0.00101	0.0436	0.11	0.1	Liver enzyme levels (gamma-glutamyl transferase);	chr15:73675237	chr15:72782835~72798199:+
BRCA	cis	rs216345	0.7	rs307652	ENSG00000260947.1	RP11-384P7.7	3.3	0.00101	0.0436	0.11	0.1	Bipolar disorder;	chr9:33935738	chr9:33697459~33700986:+
BRCA	cis	rs6568686	1	rs6568686	ENSG00000231889.6	TRAF3IP2-AS1	3.3	0.00101	0.0436	0.13	0.1	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr6:111551279	chr6:111483511~111598302:+
BRCA	cis	rs613391	0.702	rs1667087	ENSG00000279670.1	RP11-70L8.5	3.3	0.00101	0.0436	0.13	0.1	Quantitative traits;	chr9:22696346	chr9:21892188~21893857:+
BRCA	cis	rs2191566	0.576	rs419839	ENSG00000266921.1	RP11-15A1.7	3.3	0.00101	0.0436	0.13	0.1	Acute lymphoblastic leukemia (childhood);	chr19:43991446	chr19:43996896~44002836:-
BRCA	cis	rs8121203	1	rs73897243	ENSG00000213950.2	RPS10P2	-3.3	0.00101	0.0436	-0.24	-0.1	Peripheral arterial disease (traffic-related air pollution interaction);	chr20:15060848	chr20:14757563~14758056:+
BRCA	cis	rs4243971	0.516	rs4911229	ENSG00000277692.1	RP11-358N2.2	3.3	0.00101	0.0436	0.11	0.1	Inflammatory bowel disease;Crohn's disease;	chr20:32426173	chr20:32355053~32355734:+
BRCA	cis	rs4835937	0.587	rs10213776	ENSG00000245937.6	LINC01184	3.3	0.00101	0.0436	0.13	0.1	Cancer;	chr5:127979217	chr5:127940426~128083172:-
BRCA	cis	rs7229439	0.737	rs10853532	ENSG00000267414.1	RP11-456K23.1	-3.3	0.00101	0.0436	-0.11	-0.1	Antipsychotic drug-induced QTc interval change in schizophrenia;	chr18:45351467	chr18:44676927~44679717:-
BRCA	cis	rs3617	0.573	rs13072537	ENSG00000242142.1	SERBP1P3	3.3	0.00101	0.0436	0.11	0.1	Red blood cell count;Autism spectrum disorder or schizophrenia;	chr3:52862016	chr3:53064283~53065091:-
BRCA	cis	rs2360027	0.599	rs1575615	ENSG00000231365.4	RP11-418J17.1	-3.3	0.00101	0.0436	-0.13	-0.1	Tonsillectomy;	chr1:118542661	chr1:119140396~119275973:+
BRCA	cis	rs1009077	0.709	rs10004865	ENSG00000250412.1	KLHL2P1	-3.3	0.00101	0.0436	-0.14	-0.1	Endometriosis;	chr4:119745118	chr4:119334329~119378233:+
BRCA	cis	rs8099594	0.897	rs4939870	ENSG00000266696.1	RP11-30L3.2	3.3	0.00101	0.0436	0.11	0.1	Height;	chr18:49394962	chr18:49205912~49208781:+
BRCA	cis	rs4950322	0.6	rs11240014	ENSG00000237188.3	RP11-337C18.8	3.3	0.00101	0.0436	0.11	0.1	Protein quantitative trait loci;	chr1:147380674	chr1:147172771~147211568:+
BRCA	cis	rs4950322	0.576	rs11240015	ENSG00000237188.3	RP11-337C18.8	3.3	0.00101	0.0436	0.11	0.1	Protein quantitative trait loci;	chr1:147380813	chr1:147172771~147211568:+
BRCA	cis	rs4950322	0.553	rs12093870	ENSG00000237188.3	RP11-337C18.8	3.3	0.00101	0.0436	0.11	0.1	Protein quantitative trait loci;	chr1:147380815	chr1:147172771~147211568:+
BRCA	cis	rs9646944	0.501	rs10174323	ENSG00000234389.1	AC007278.3	3.3	0.00101	0.0436	0.12	0.1	Blood protein levels;	chr2:102396321	chr2:102438713~102440475:+
BRCA	cis	rs9646944	0.501	rs3732127	ENSG00000234389.1	AC007278.3	3.3	0.00101	0.0436	0.12	0.1	Blood protein levels;	chr2:102397290	chr2:102438713~102440475:+
BRCA	cis	rs17228212	1	rs17228212	ENSG00000270964.1	RP11-502I4.3	-3.3	0.00101	0.0436	-0.13	-0.1	Coronary heart disease;	chr15:67166301	chr15:67541072~67542604:-
BRCA	cis	rs1200821	0.584	rs1200819	ENSG00000151963.4	RP11-775A3.1	3.3	0.00101	0.0436	0.12	0.1	Hemostatic factors and hematological phenotypes;	chr10:37270422	chr10:37883594~37884109:+
BRCA	cis	rs2692947	0.74	rs60452119	ENSG00000237510.6	AC008268.2	3.3	0.00101	0.0436	0.14	0.1	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95754302	chr2:95789654~95800166:+
BRCA	cis	rs73222236	0.825	rs55797013	ENSG00000239213.4	NCK1-AS1	3.3	0.00101	0.0436	0.11	0.1	Coronary artery disease;	chr3:136300362	chr3:136841726~136862054:-
BRCA	cis	rs1979679	0.608	rs4931082	ENSG00000244712.1	RP11-874G11.1	3.3	0.00101	0.0436	0.16	0.1	Ossification of the posterior longitudinal ligament of the spine;	chr12:28567087	chr12:28564678~28565141:-
BRCA	cis	rs9527	0.59	rs7067663	ENSG00000236937.2	PTGES3P4	3.3	0.00101	0.0436	0.13	0.1	Arsenic metabolism;	chr10:103123893	chr10:102845595~102845950:+
BRCA	cis	rs8113308	0.689	rs8112515	ENSG00000269235.1	ZNF350-AS1	3.3	0.00101	0.0436	0.18	0.1	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51987997	chr19:51949134~51981367:+
BRCA	cis	rs10198628	1	rs12621238	ENSG00000264370.1	MIR3125	-3.3	0.00101	0.0436	-0.12	-0.1	Pericardial fat;Pericardial adipose tissue adjusted for height and weight;	chr2:12823940	chr2:12737367~12737444:+
BRCA	cis	rs539096	0.789	rs10890253	ENSG00000236200.4	KDM4A-AS1	-3.3	0.00101	0.0436	-0.12	-0.1	Intelligence (multi-trait analysis);	chr1:43555785	chr1:43699765~43708138:-
BRCA	cis	rs7172809	0.643	rs75334741	ENSG00000260139.5	CSPG4P13	-3.3	0.00101	0.0436	-0.12	-0.1	Glucose homeostasis traits;	chr15:77549150	chr15:77894684~77904674:+
BRCA	cis	rs4243971	0.516	rs14353	ENSG00000277692.1	RP11-358N2.2	-3.3	0.00101	0.0436	-0.11	-0.1	Inflammatory bowel disease;Crohn's disease;	chr20:32334595	chr20:32355053~32355734:+
BRCA	cis	rs7017914	0.967	rs13256250	ENSG00000246366.5	RP11-382J12.1	3.3	0.00101	0.0436	0.11	0.1	Bone mineral density;	chr8:70683958	chr8:70608577~70663279:+
BRCA	cis	rs6929812	0.605	rs12526495	ENSG00000241549.7	GUSBP2	-3.3	0.00101	0.0436	-0.11	-0.1	Neuroticism (multi-trait analysis);	chr6:27426092	chr6:26871484~26956554:-
BRCA	cis	rs4499344	0.556	rs259219	ENSG00000267475.1	CTD-2538C1.2	3.3	0.00101	0.0436	0.14	0.1	Mean platelet volume;	chr19:32647161	chr19:32687089~32691750:-
BRCA	cis	rs13401620	0.622	rs6734822	ENSG00000236878.1	AC012363.7	3.3	0.00101	0.0436	0.12	0.1	Breast size;	chr2:120058500	chr2:120211054~120211715:+
BRCA	cis	rs13401620	0.622	rs2166434	ENSG00000236878.1	AC012363.7	3.3	0.00101	0.0436	0.12	0.1	Breast size;	chr2:120058790	chr2:120211054~120211715:+
BRCA	cis	rs1974653	0.781	rs175166	ENSG00000236540.6	AC006547.13	3.3	0.00101	0.0436	0.12	0.1	Schizophrenia;	chr22:20128659	chr22:20058030~20070569:-
BRCA	cis	rs7166081	0.704	rs2414952	ENSG00000270964.1	RP11-502I4.3	-3.3	0.00101	0.0436	-0.13	-0.1	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);	chr15:67432054	chr15:67541072~67542604:-
BRCA	cis	rs4742903	0.967	rs2417485	ENSG00000270332.1	SMC2-AS1	3.3	0.00101	0.0436	0.11	0.1	Breast cancer;High-grade serous ovarian cancer;	chr9:104104825	chr9:104080024~104093073:-
BRCA	cis	rs7239883	0.5	rs4588064	ENSG00000267652.1	RP11-188I24.1	3.3	0.00101	0.0436	0.15	0.1	Waist circumference;Body mass index;	chr18:42522111	chr18:41789162~41789395:-
BRCA	cis	rs1870634	0.518	rs4145118	ENSG00000273008.1	RP11-351D16.3	-3.3	0.00101	0.0436	-0.12	-0.1	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;	chr10:43988280	chr10:43136824~43138334:-
BRCA	cis	rs2832077	0.506	rs2832088	ENSG00000232855.5	AF131217.1	3.3	0.00101	0.0436	0.13	0.1	Cognitive test performance;	chr21:28786298	chr21:28439346~28674848:-
BRCA	cis	rs9650657	0.596	rs2409675	ENSG00000248896.2	CTD-2135J3.3	-3.3	0.00101	0.0436	-0.12	-0.1	Neuroticism;	chr8:10737749	chr8:10729314~10771392:+
BRCA	cis	rs3743102	0.591	rs78104714	ENSG00000278603.1	RP13-608F4.5	-3.3	0.00101	0.0436	-0.19	-0.1	Colorectal adenoma (advanced);	chr15:82712447	chr15:82472203~82472426:+
BRCA	cis	rs12949688	1	rs886925	ENSG00000262623.1	RP5-1107A17.2	-3.3	0.00101	0.0436	-0.11	-0.1	Schizophrenia;	chr17:57740288	chr17:56951664~56952404:+
BRCA	cis	rs2625529	0.652	rs2899776	ENSG00000261187.1	RP11-1007O24.2	3.3	0.00101	0.0436	0.11	0.1	Red blood cell count;	chr15:71976024	chr15:72465128~72466262:-
BRCA	cis	rs45509595	0.841	rs200501	ENSG00000241549.7	GUSBP2	3.3	0.00101	0.0436	0.18	0.1	Breast cancer;	chr6:27821164	chr6:26871484~26956554:-
BRCA	cis	rs2559856	0.935	rs2695287	ENSG00000274560.1	RP11-285E23.2	3.3	0.00101	0.0436	0.11	0.1	Blood protein levels;	chr12:101694583	chr12:101696002~101696450:-
BRCA	cis	rs220519	0.783	rs220512	ENSG00000235408.4	SNORA71B	-3.3	0.00101	0.0436	-0.1	-0.1	Schizophrenia;	chr20:38657478	chr20:38425083~38425354:-
BRCA	cis	rs67073037	0.915	rs12613887	ENSG00000230730.1	AC074011.2	-3.3	0.00101	0.0436	-0.13	-0.1	Breast cancer;Breast cancer (estrogen-receptor negative);	chr2:28888233	chr2:28633282~28664540:-
BRCA	cis	rs8180040	0.701	rs1079276	ENSG00000280667.1	Y_RNA	3.3	0.00101	0.0436	0.11	0.1	Colorectal cancer;	chr3:47004249	chr3:47501083~47501182:+
BRCA	cis	rs10129255	0.957	rs2007467	ENSG00000211967.3	IGHV3-53	3.3	0.00101	0.0436	0.08	0.1	Kawasaki disease;	chr14:106771605	chr14:106592676~106593347:-
BRCA	cis	rs17189298	0.874	rs4849749	ENSG00000226856.4	AC093901.1	3.3	0.00101	0.0436	0.12	0.1	Cerebrospinal T-tau levels;	chr2:119074730	chr2:118132128~118186386:-
BRCA	cis	rs77741769	0.651	rs3999421	ENSG00000277423.1	RP11-173P15.9	-3.3	0.00101	0.0436	-0.12	-0.1	Mean corpuscular volume;	chr12:120930715	chr12:120703867~120704282:+
BRCA	cis	rs3820068	0.603	rs72647118	ENSG00000237301.1	RP4-680D5.2	-3.3	0.00101	0.0436	-0.13	-0.1	Systolic blood pressure;	chr1:15630040	chr1:15586136~15603626:-
BRCA	cis	rs7475343	0.501	rs74827952	ENSG00000224034.1	RP11-445P17.8	-3.3	0.00101	0.0436	-0.18	-0.1	Intelligence;	chr10:5203233	chr10:5266033~5271236:-
BRCA	cis	rs4761470	0.649	rs8553	ENSG00000258365.1	RP11-1105G2.3	-3.3	0.00101	0.0437	-0.14	-0.1	Estradiol plasma levels (breast cancer);	chr12:94307542	chr12:94277758~94282844:-
BRCA	cis	rs1979679	0.918	rs1257741	ENSG00000244712.1	RP11-874G11.1	-3.3	0.00101	0.0437	-0.15	-0.1	Ossification of the posterior longitudinal ligament of the spine;	chr12:28381636	chr12:28564678~28565141:-
BRCA	cis	rs6487679	0.526	rs7305336	ENSG00000256069.6	A2MP1	3.3	0.00101	0.0437	0.11	0.1	Non-alcoholic fatty liver disease histology (AST);	chr12:9222493	chr12:9228533~9275817:-
BRCA	cis	rs6445975	1	rs6445975	ENSG00000272360.1	RP11-359I18.5	3.3	0.00101	0.0437	0.11	0.1	Systemic lupus erythematosus;	chr3:58384450	chr3:58490830~58491291:-
BRCA	cis	rs9527	0.59	rs7089680	ENSG00000269609.4	RPARP-AS1	3.3	0.00101	0.0437	0.1	0.1	Arsenic metabolism;	chr10:103042314	chr10:102449817~102461106:+
BRCA	cis	rs36051895	0.632	rs7030853	ENSG00000237711.1	RP11-39K24.13	-3.3	0.00101	0.0437	-0.12	-0.1	Pediatric autoimmune diseases;	chr9:5179002	chr9:5100236~5101009:+
BRCA	cis	rs4499344	0.524	rs259242	ENSG00000267475.1	CTD-2538C1.2	3.3	0.00101	0.0437	0.13	0.1	Mean platelet volume;	chr19:32653342	chr19:32687089~32691750:-
BRCA	cis	rs2274273	0.648	rs58553156	ENSG00000259318.1	RP11-454L9.2	3.3	0.00101	0.0437	0.09	0.1	Protein biomarker;	chr14:55115976	chr14:55394940~55395233:-
BRCA	cis	rs4950322	0.547	rs6660507	ENSG00000198658.4	ABHD17AP1	3.3	0.00101	0.0437	0.14	0.1	Protein quantitative trait loci;	chr1:147148574	chr1:148146395~148149566:+
BRCA	cis	rs11622475	1	rs10149651	ENSG00000259775.1	RP11-45P15.4	-3.3	0.00101	0.0437	-0.12	-0.1	Bipolar disorder;	chr14:103928103	chr14:103331674~103332367:-
BRCA	cis	rs76798021	0.935	rs6804675	ENSG00000271976.1	RP11-884K10.7	3.3	0.00101	0.0437	0.13	0.1	Lung function (FEV1/FVC);	chr3:53667110	chr3:53858994~53861576:-
BRCA	cis	rs35130793	0.583	rs6025457	ENSG00000226308.1	RP4-813D12.3	3.3	0.00101	0.0437	0.12	0.1	Nose size;	chr20:57238489	chr20:57266797~57282998:+
BRCA	cis	rs853679	0.882	rs9468287	ENSG00000219392.1	RP1-265C24.5	-3.3	0.00101	0.0437	-0.21	-0.1	Depression;	chr6:28111963	chr6:28115628~28116551:+
BRCA	cis	rs6005807	0.686	rs9620768	ENSG00000272858.1	CTA-292E10.8	-3.3	0.00101	0.0437	-0.2	-0.1	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28091743	chr22:28814914~28815662:+
BRCA	cis	rs2380205	0.689	rs12359234	ENSG00000232807.2	RP11-536K7.3	-3.3	0.00101	0.0437	-0.1	-0.1	Breast cancer;	chr10:5860748	chr10:5934270~5945900:-
BRCA	cis	rs7267979	0.966	rs2387885	ENSG00000204556.4	CTD-2514C3.1	3.3	0.00101	0.0437	0.14	0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25434588	chr20:26018832~26020684:+
BRCA	cis	rs7267979	1	rs2424713	ENSG00000204556.4	CTD-2514C3.1	-3.3	0.00101	0.0437	-0.14	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25437846	chr20:26018832~26020684:+
BRCA	cis	rs12477438	0.52	rs11678456	ENSG00000231822.1	AC019097.7	3.3	0.00101	0.0437	0.11	0.1	Chronic sinus infection;	chr2:99091774	chr2:99102018~99102752:+
BRCA	cis	rs7927592	0.913	rs11228268	ENSG00000254610.1	RP5-903G2.2	-3.3	0.00101	0.0437	-0.14	-0.1	Total body bone mineral density;	chr11:68519979	chr11:67934563~67939774:-
BRCA	cis	rs12282928	0.959	rs1503168	ENSG00000255197.4	RP11-750H9.5	3.3	0.00101	0.0437	0.09	0.1	Migraine - clinic-based;	chr11:48251144	chr11:47383148~47409190:-
BRCA	cis	rs34779708	0.966	rs113170867	ENSG00000269952.1	RP11-324I22.3	-3.3	0.00101	0.0437	-0.14	-0.1	Inflammatory bowel disease;Crohn's disease;	chr10:35161219	chr10:35210416~35210750:+
BRCA	cis	rs2055375	0.643	rs173946	ENSG00000272308.1	RP11-231G3.1	-3.3	0.00101	0.0437	-0.12	-0.1	Intelligence (multi-trait analysis);	chr5:61192470	chr5:60866457~60866935:-
BRCA	cis	rs2615061	0.935	rs61849047	ENSG00000229965.1	RP11-118H4.1	3.3	0.00101	0.0437	0.19	0.1	Monocyte count;	chr1:225748764	chr1:226438564~226439344:+
BRCA	cis	rs1046491	0.667	rs6506641	ENSG00000264964.1	RP11-888D10.3	3.3	0.00101	0.0437	0.21	0.1	Scarlet fever;	chr18:9111440	chr18:9315194~9334441:-
BRCA	cis	rs1046491	0.901	rs10502390	ENSG00000264964.1	RP11-888D10.3	3.3	0.00101	0.0437	0.21	0.1	Scarlet fever;	chr18:9113232	chr18:9315194~9334441:-
BRCA	cis	rs10132760	0.774	rs58030148	ENSG00000255569.1	TRAV1-1	3.3	0.00101	0.0437	0.11	0.1	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;	chr14:21718449	chr14:21621838~21622567:+
BRCA	cis	rs58521262	1	rs2132818	ENSG00000268105.1	RP11-369G6.2	3.3	0.00101	0.0437	0.17	0.1	Testicular germ cell tumor;	chr19:22999578	chr19:23125665~23128543:+
BRCA	cis	rs76963786	0.901	rs1666212	ENSG00000276148.1	RP11-278C7.4	-3.3	0.00101	0.0437	-0.12	-0.1	Interleukin-9 levels;	chr12:31884720	chr12:32725248~32725660:-
BRCA	cis	rs6494488	0.5	rs72741357	ENSG00000248415.1	GAPDHP61	-3.3	0.00101	0.0437	-0.23	-0.1	Coronary artery disease;	chr15:64491253	chr15:64528667~64529671:-
BRCA	cis	rs6494488	0.5	rs116857608	ENSG00000248415.1	GAPDHP61	-3.3	0.00101	0.0437	-0.23	-0.1	Coronary artery disease;	chr15:64505969	chr15:64528667~64529671:-
BRCA	cis	rs6494488	0.5	rs72741373	ENSG00000248415.1	GAPDHP61	-3.3	0.00101	0.0437	-0.23	-0.1	Coronary artery disease;	chr15:64508662	chr15:64528667~64529671:-
BRCA	cis	rs6494488	0.5	rs72741379	ENSG00000248415.1	GAPDHP61	-3.3	0.00101	0.0437	-0.23	-0.1	Coronary artery disease;	chr15:64512564	chr15:64528667~64529671:-
BRCA	cis	rs6494488	0.5	rs72741381	ENSG00000248415.1	GAPDHP61	-3.3	0.00101	0.0437	-0.23	-0.1	Coronary artery disease;	chr15:64514362	chr15:64528667~64529671:-
BRCA	cis	rs6494488	0.5	rs72741385	ENSG00000248415.1	GAPDHP61	-3.3	0.00101	0.0437	-0.23	-0.1	Coronary artery disease;	chr15:64517112	chr15:64528667~64529671:-
BRCA	cis	rs874460	1	rs874460	ENSG00000211513.4	MIR320E	3.3	0.00101	0.0437	0.18	0.1	Chronic lymphocytic leukemia;	chr19:46673495	chr19:46709271~46709382:-
BRCA	cis	rs8180040	0.654	rs6791062	ENSG00000280667.1	Y_RNA	3.3	0.00101	0.0437	0.11	0.1	Colorectal cancer;	chr3:47132853	chr3:47501083~47501182:+
BRCA	cis	rs9341808	0.718	rs4437429	ENSG00000233967.5	RP11-250B2.3	3.3	0.00101	0.0437	0.1	0.1	Sitting height ratio;	chr6:80118875	chr6:80443344~80465927:+
BRCA	cis	rs7267979	0.565	rs3752273	ENSG00000274973.1	RP13-401N8.7	3.3	0.00101	0.0437	0.12	0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25614147	chr20:25845497~25845862:+
BRCA	cis	rs11098499	0.863	rs17050695	ENSG00000260404.2	RP11-384K6.6	3.3	0.00101	0.0437	0.09	0.1	Corneal astigmatism;	chr4:119568372	chr4:118591773~118633729:+
BRCA	cis	rs6964587	0.61	rs6942852	ENSG00000188693.7	CYP51A1-AS1	-3.3	0.00101	0.0437	-0.11	-0.1	Breast cancer;	chr7:91808569	chr7:92134604~92180725:+
BRCA	cis	rs77106637	1	rs11600585	ENSG00000256633.1	RP11-169D4.2	3.3	0.00101	0.0437	0.14	0.1	Type 2 diabetes;	chr11:73016795	chr11:72584572~72587979:+
BRCA	cis	rs9866825	0.967	rs9846822	ENSG00000227110.5	LMCD1-AS1	3.3	0.00101	0.0437	0.12	0.1	QT interval;	chr3:8208628	chr3:7952805~8611924:-
BRCA	cis	rs801193	0.66	rs974239	ENSG00000230189.5	GS1-124K5.2	3.3	0.00101	0.0437	0.08	0.1	Aortic root size;	chr7:66748504	chr7:66409143~66490059:-
BRCA	cis	rs310501	0.921	rs485996	ENSG00000281327.1	LINC01338	-3.3	0.00101	0.0437	-0.13	-0.1	Major depressive disorder;	chr5:83591691	chr5:82850864~82859836:-
BRCA	cis	rs728616	0.717	rs17098169	ENSG00000225484.5	NUTM2B-AS1	3.3	0.00101	0.0437	0.23	0.1	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80056378	chr10:79663088~79826594:-
BRCA	cis	rs4664293	0.51	rs66571608	ENSG00000230783.1	AC009961.2	3.3	0.00101	0.0437	0.13	0.1	Monocyte percentage of white cells;	chr2:159635851	chr2:159689217~159690291:-
BRCA	cis	rs7071275	0.891	rs10510099	ENSG00000276742.1	RP11-500G22.4	3.3	0.00101	0.0437	0.15	0.1	Dupuytren's disease;	chr10:121672332	chr10:121956782~121957098:+
BRCA	cis	rs1144333	1	rs12082448	ENSG00000181227.3	RP4-682C21.2	-3.3	0.00101	0.0437	-0.14	-0.1	Attention function in attention deficit hyperactive disorder;	chr1:75887540	chr1:75743423~75744776:-
BRCA	cis	rs7188697	0.769	rs9932944	ENSG00000276259.1	RP11-481J2.4	3.3	0.00101	0.0437	0.12	0.1	QT interval;	chr16:58582261	chr16:58522970~58523842:+
BRCA	cis	rs2070488	0.965	rs1058945	ENSG00000232439.1	RPL18AP7	-3.3	0.00101	0.0437	-0.12	-0.1	Electrocardiographic conduction measures;	chr3:38491020	chr3:38526802~38527325:-
BRCA	cis	rs6545883	0.929	rs2593635	ENSG00000273302.1	RP11-493E12.2	-3.3	0.00101	0.0437	-0.1	-0.1	Tuberculosis;	chr2:61407571	chr2:61199979~61200769:+
BRCA	cis	rs4820539	0.966	rs2267000	ENSG00000211650.2	IGLV5-45	-3.3	0.00101	0.0437	-0.08	-0.1	Bone mineral density;	chr22:23113179	chr22:22375986~22376505:+
BRCA	cis	rs10819861	0.621	rs4743536	ENSG00000175611.10	LINC00476	3.3	0.00101	0.0437	0.11	0.1	Electrocardiographic traits;	chr9:96095704	chr9:95759231~95875977:-
BRCA	cis	rs354225	0.544	rs10184128	ENSG00000240401.7	AC012358.8	-3.3	0.00101	0.0437	-0.14	-0.1	Schizophrenia;	chr2:54576679	chr2:55282350~55346049:+
BRCA	cis	rs7017914	0.902	rs7831792	ENSG00000246366.5	RP11-382J12.1	3.3	0.00101	0.0437	0.11	0.1	Bone mineral density;	chr8:70653121	chr8:70608577~70663279:+
BRCA	cis	rs2524276	1	rs2524276	ENSG00000256166.1	XXbac-BPG248L24.13	-3.3	0.00101	0.0437	-0.23	-0.1	Capecitabine sensitivity;	chr6:31440488	chr6:31293908~31301642:-
BRCA	cis	rs2276314	0.947	rs16967319	ENSG00000267627.4	RP11-905K4.1	-3.3	0.00101	0.0437	-0.14	-0.1	Endometriosis;Drug-induced torsades de pointes;	chr18:35993562	chr18:35951803~35966118:-
BRCA	cis	rs8181166	0.613	rs7852505	ENSG00000234424.2	RP11-213G2.1	3.3	0.00101	0.0437	0.13	0.1	Height;	chr9:86531731	chr9:85753306~85786575:+
BRCA	cis	rs17192198	0.661	rs73198557	ENSG00000258302.2	RP11-981P6.1	-3.3	0.00101	0.0437	-0.12	-0.1	Diastolic blood pressure;	chr12:89682516	chr12:89561129~89594878:+
BRCA	cis	rs36051895	0.559	rs72701680	ENSG00000237711.1	RP11-39K24.13	-3.3	0.00101	0.0437	-0.12	-0.1	Pediatric autoimmune diseases;	chr9:5207294	chr9:5100236~5101009:+
BRCA	cis	rs6019512	0.846	rs2024596	ENSG00000222365.1	SNORD12B	3.3	0.00101	0.0437	0.11	0.1	Intelligence (multi-trait analysis);	chr20:48901515	chr20:49280319~49280409:+
BRCA	cis	rs6545883	0.862	rs778141	ENSG00000237522.1	NONOP2	-3.3	0.00101	0.0437	-0.1	-0.1	Tuberculosis;	chr2:61455043	chr2:60936819~60938049:-
BRCA	cis	rs2281603	0.951	rs11158544	ENSG00000259116.1	RP11-973N13.4	-3.3	0.00101	0.0437	-0.1	-0.1	Lymphocyte counts;	chr14:64529769	chr14:64514154~64540368:-
BRCA	cis	rs2281603	0.951	rs12588886	ENSG00000259116.1	RP11-973N13.4	-3.3	0.00101	0.0437	-0.1	-0.1	Lymphocyte counts;	chr14:64530226	chr14:64514154~64540368:-
BRCA	cis	rs17221829	0.521	rs10741306	ENSG00000280385.1	AP000648.5	-3.3	0.00101	0.0437	-0.11	-0.1	Anxiety in major depressive disorder;	chr11:89580461	chr11:90193614~90198120:+
BRCA	cis	rs10971721	0.822	rs10971866	ENSG00000279489.1	RP11-392A14.8	3.3	0.00101	0.0437	0.21	0.1	Body mass index;	chr9:34043163	chr9:35001913~35003663:+
BRCA	cis	rs4908769	0.66	rs13596	ENSG00000232912.4	RP5-1115A15.1	-3.3	0.00101	0.0437	-0.11	-0.1	Allergy;	chr1:8361143	chr1:8424645~8434838:+
BRCA	cis	rs10876993	0.89	rs1678539	ENSG00000270039.1	RP11-571M6.17	3.3	0.00101	0.0437	0.13	0.1	Celiac disease or Rheumatoid arthritis;	chr12:57666576	chr12:57803838~57804415:+
BRCA	cis	rs1348850	0.626	rs1901825	ENSG00000227098.1	AC073636.1	3.3	0.00101	0.0437	0.12	0.1	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177360603	chr2:176845993~176849428:-
BRCA	cis	rs2288061	0.638	rs13337655	ENSG00000276408.1	RP11-490B18.5	3.3	0.00101	0.0437	0.13	0.1	Delta-5 desaturase activity;	chr16:76099950	chr16:75556392~75557059:+
BRCA	cis	rs360929	0.935	rs578765	ENSG00000245954.5	RP11-18H21.1	3.3	0.00101	0.0437	0.12	0.1	Volumetric brain MRI;	chr4:151958041	chr4:152100754~152104720:+
BRCA	cis	rs12900463	0.752	rs12904777	ENSG00000275120.1	RP11-182J1.17	3.3	0.00101	0.0437	0.13	0.1	Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine);	chr15:84872514	chr15:84599434~84606463:-
BRCA	cis	rs4308124	0.708	rs6747657	ENSG00000271590.1	RP11-181E10.3	3.3	0.00101	0.0437	0.11	0.1	Vitiligo;	chr2:111245586	chr2:111210995~111212476:-
BRCA	cis	rs11610206	1	rs11610206	ENSG00000275481.1	RP11-474P2.6	3.3	0.00101	0.0437	0.19	0.1	Alzheimer's disease;	chr12:47245743	chr12:46388856~46392126:+
BRCA	cis	rs6964587	0.626	rs7807765	ENSG00000188693.7	CYP51A1-AS1	3.3	0.00101	0.0437	0.11	0.1	Breast cancer;	chr7:91902660	chr7:92134604~92180725:+
BRCA	cis	rs9863	0.896	rs12824567	ENSG00000269938.1	RP11-214K3.20	-3.3	0.00101	0.0438	-0.11	-0.1	White blood cell count;	chr12:124010656	chr12:123968023~123968579:-
BRCA	cis	rs35520189	0.806	rs11123151	ENSG00000274877.1	RP11-65I12.1	-3.3	0.00101	0.0438	-0.15	-0.1	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:112910428	chr2:113237595~113240825:+
BRCA	cis	rs74233809	1	rs11191582	ENSG00000213061.2	PFN1P11	3.3	0.00101	0.0438	0.25	0.1	Birth weight;	chr10:103153896	chr10:102838011~102845473:-
BRCA	cis	rs9811423	0.625	rs12695286	ENSG00000243795.1	RP11-572M11.3	3.3	0.00101	0.0438	0.11	0.1	Psychosis and Alzheimer's disease;	chr3:113097899	chr3:113142350~113167819:-
BRCA	cis	rs8016982	0.662	rs8014406	ENSG00000258999.1	RP11-114N19.3	3.3	0.00101	0.0438	0.14	0.1	Schizophrenia;	chr14:81191416	chr14:81107033~81170414:-
BRCA	cis	rs8114671	0.562	rs2378292	ENSG00000279253.1	RP4-614O4.13	-3.3	0.00101	0.0438	-0.12	-0.1	Height;	chr20:34897375	chr20:35262727~35264187:-
BRCA	cis	rs1156327	0.51	rs2157034	ENSG00000188477.11	AC003003.5	-3.3	0.00101	0.0438	-0.27	-0.1	Periodontal disease-related phenotypes;	chr16:19319506	chr16:19285783~19310947:+
BRCA	cis	rs2072510	0.722	rs2247323	ENSG00000237774.3	RP11-129B9.1	3.3	0.00101	0.0438	0.11	0.1	Metabolite levels (small molecules and protein measures);	chr12:96030478	chr12:95125760~95126389:+
BRCA	cis	rs2072510	0.722	rs2247313	ENSG00000237774.3	RP11-129B9.1	3.3	0.00101	0.0438	0.11	0.1	Metabolite levels (small molecules and protein measures);	chr12:96030669	chr12:95125760~95126389:+
BRCA	cis	rs2072510	0.722	rs2247309	ENSG00000237774.3	RP11-129B9.1	3.3	0.00101	0.0438	0.11	0.1	Metabolite levels (small molecules and protein measures);	chr12:96030764	chr12:95125760~95126389:+
BRCA	cis	rs934734	0.532	rs7569113	ENSG00000237979.1	AC007389.1	3.3	0.00101	0.0438	0.12	0.1	Rheumatoid arthritis;	chr2:65429907	chr2:65500993~65502138:-
BRCA	cis	rs863345	0.604	rs923664	ENSG00000176320.2	RP11-404O13.5	-3.3	0.00101	0.0438	-0.11	-0.1	Pneumococcal bacteremia;	chr1:158537901	chr1:158197922~158203877:-
BRCA	cis	rs12723316	0.932	rs12744687	ENSG00000233008.4	RP11-475O6.1	-3.3	0.00101	0.0438	-0.19	-0.1	Schizophrenia;	chr1:83845213	chr1:83575776~83861023:-
BRCA	cis	rs8141529	0.748	rs1318026	ENSG00000226471.5	CTA-292E10.6	-3.3	0.00101	0.0438	-0.12	-0.1	Lymphocyte counts;	chr22:28887530	chr22:28800683~28848559:+
BRCA	cis	rs2941484	0.509	rs2977966	ENSG00000254023.1	PKMP4	3.3	0.00101	0.0438	0.11	0.1	Urate levels;	chr8:75583806	chr8:75376709~75377014:+
BRCA	cis	rs72928364	1	rs62275825	ENSG00000244119.1	PDCL3P4	3.3	0.00101	0.0438	0.12	0.1	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:101039866	chr3:101712472~101713191:+
BRCA	cis	rs4148883	0.689	rs2851275	ENSG00000272777.1	RP11-571L19.8	-3.3	0.00101	0.0438	-0.1	-0.1	Alcohol dependence;	chr4:99103732	chr4:99067256~99068125:-
BRCA	cis	rs10266483	0.515	rs17689514	ENSG00000228014.1	ZNF680P1	3.3	0.00101	0.0438	0.15	0.1	Response to statin therapy;	chr7:64279269	chr7:64469185~64470653:+
BRCA	cis	rs72928364	1	rs62275204	ENSG00000244119.1	PDCL3P4	3.3	0.00101	0.0438	0.12	0.1	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100995762	chr3:101712472~101713191:+
BRCA	cis	rs7239883	0.516	rs382962	ENSG00000267586.5	LINC00907	3.3	0.00101	0.0438	0.11	0.1	Waist circumference;Body mass index;	chr18:42351169	chr18:42159283~42691422:+
BRCA	cis	rs3176789	0.624	rs3176787	ENSG00000256673.1	RP11-599J14.2	3.3	0.00101	0.0438	0.11	0.1	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9760538	chr12:9398355~9414851:-
BRCA	cis	rs17197037	0.505	rs3748358	ENSG00000211778.2	TRAV4	-3.3	0.00101	0.0438	-0.07	-0.1	Bipolar disorder;	chr14:21321635	chr14:21736152~21736982:+
BRCA	cis	rs34779708	0.801	rs12246600	ENSG00000269952.1	RP11-324I22.3	-3.3	0.00101	0.0438	-0.13	-0.1	Inflammatory bowel disease;Crohn's disease;	chr10:35249193	chr10:35210416~35210750:+
BRCA	cis	rs7172689	0.908	rs8026245	ENSG00000271725.1	RP11-761I4.4	3.3	0.00101	0.0438	0.13	0.1	Inattentive symptoms;	chr15:81268660	chr15:81303215~81309391:-
BRCA	cis	rs9467773	0.869	rs1796521	ENSG00000241549.7	GUSBP2	-3.3	0.00101	0.0438	-0.12	-0.1	Intelligence (multi-trait analysis);	chr6:26421164	chr6:26871484~26956554:-
BRCA	cis	rs9325144	0.56	rs1601745	ENSG00000257718.1	RP11-396F22.1	-3.3	0.00101	0.0438	-0.1	-0.1	Morning vs. evening chronotype;	chr12:38254026	chr12:38906451~38909592:+
BRCA	cis	rs8058578	1	rs67128646	ENSG00000260082.1	RP11-2C24.5	3.3	0.00101	0.0438	0.12	0.1	Multiple myeloma;	chr16:30660776	chr16:30821068~30822110:-
BRCA	cis	rs2361701	0.929	rs1467979	ENSG00000275479.1	RP11-334C17.6	-3.3	0.00101	0.0438	-0.12	-0.1	IgG glycosylation;	chr17:80086944	chr17:80149627~80149798:+
BRCA	cis	rs4849845	0.637	rs11688038	ENSG00000223549.1	MTND5P28	3.3	0.00101	0.0438	0.12	0.1	Mean platelet volume;	chr2:120269006	chr2:120215181~120217279:+
BRCA	cis	rs7651446	0.85	rs2292336	ENSG00000240875.4	LINC00886	-3.3	0.00101	0.0438	-0.2	-0.1	Ovarian cancer;Epithelial ovarian cancer;	chr3:156630633	chr3:156747346~156817062:-
BRCA	cis	rs495337	0.76	rs1056200	ENSG00000224397.4	LINC01272	-3.3	0.00101	0.0438	-0.1	-0.1	Psoriasis;	chr20:49939711	chr20:50267486~50279795:+
BRCA	cis	rs8040855	0.627	rs4842863	ENSG00000229212.6	RP11-561C5.4	-3.3	0.00101	0.0438	-0.14	-0.1	Bulimia nervosa;	chr15:85098974	chr15:85205440~85234795:-
BRCA	cis	rs9557207	1	rs9585032	ENSG00000231194.1	FARP1-AS1	-3.3	0.00101	0.0438	-0.15	-0.1	Inflammatory bowel disease;Peripheral arterial disease (traffic-related air pollution interaction);	chr13:99282927	chr13:98435405~98435840:-
BRCA	cis	rs7953704	0.967	rs35676267	ENSG00000212694.7	LINC01089	-3.3	0.00101	0.0438	-0.08	-0.1	Urate levels;	chr12:122076568	chr12:121795267~121803906:-
BRCA	cis	rs7697932	0.573	rs4699389	ENSG00000246090.5	RP11-696N14.1	3.3	0.00101	0.0438	0.1	0.1	Renal cell carcinoma;	chr4:100062565	chr4:99088857~99301356:+
BRCA	cis	rs66887589	0.592	rs2175383	ENSG00000260091.1	RP11-33B1.4	-3.3	0.00101	0.0438	-0.08	-0.1	Diastolic blood pressure;	chr4:119294681	chr4:119409333~119410233:+
BRCA	cis	rs6142102	0.961	rs6059649	ENSG00000206582.1	Y_RNA	-3.3	0.00101	0.0438	-0.12	-0.1	Skin pigmentation;	chr20:34056071	chr20:34526510~34526606:-
BRCA	cis	rs2952768	1	rs2248062	ENSG00000224137.1	AC079767.4	-3.3	0.00101	0.0438	-0.09	-0.1	Opioid sensitivity;	chr2:207630327	chr2:207662375~207667024:+
BRCA	cis	rs2952768	1	rs2248061	ENSG00000224137.1	AC079767.4	-3.3	0.00101	0.0438	-0.09	-0.1	Opioid sensitivity;	chr2:207630335	chr2:207662375~207667024:+
BRCA	cis	rs35123781	0.696	rs10067965	ENSG00000249526.1	CTB-35F21.1	3.3	0.00101	0.0438	0.13	0.1	Schizophrenia;	chr5:139691768	chr5:139684645~139745010:+
BRCA	cis	rs6432860	0.527	rs7564306	ENSG00000232411.1	AC009495.3	-3.3	0.00101	0.0438	-0.12	-0.1	Febrile seizures (MMR vaccine-unrelated);Febrile seizures;	chr2:166058385	chr2:165833048~165839098:-
BRCA	cis	rs6691170	0.897	rs7550628	ENSG00000238042.4	RP11-815M8.1	-3.3	0.00101	0.0438	-0.11	-0.1	Colorectal cancer;	chr1:221865973	chr1:221880981~221978523:-
BRCA	cis	rs6142102	0.961	rs8119937	ENSG00000206582.1	Y_RNA	-3.3	0.00101	0.0438	-0.12	-0.1	Skin pigmentation;	chr20:34057745	chr20:34526510~34526606:-
BRCA	cis	rs16849225	0.57	rs7574118	ENSG00000206869.1	SNORA70F	-3.3	0.00101	0.0438	-0.12	-0.1	Systolic blood pressure;Blood pressure;	chr2:163931111	chr2:164687643~164687777:-
BRCA	cis	rs10876993	0.928	rs1689594	ENSG00000270039.1	RP11-571M6.17	3.3	0.00101	0.0438	0.13	0.1	Celiac disease or Rheumatoid arthritis;	chr12:57663373	chr12:57803838~57804415:+
BRCA	cis	rs7812879	0.852	rs1478895	ENSG00000255354.1	RP11-148O21.2	-3.3	0.00101	0.0438	-0.12	-0.1	Systemic lupus erythematosus;	chr8:11495826	chr8:11558466~11560020:-
BRCA	cis	rs1008375	0.932	rs6857678	ENSG00000249502.1	AC006160.5	-3.3	0.00101	0.0438	-0.11	-0.1	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17695341	chr4:17587467~17614571:-
BRCA	cis	rs2310173	0.575	rs4851527	ENSG00000281162.1	LINC01127	3.3	0.00101	0.0438	0.1	0.1	Ulcerative colitis;Ankylosing spondylitis;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr2:102005914	chr2:101962056~101987167:+
BRCA	cis	rs12468226	0.938	rs116601501	ENSG00000272966.1	RP11-686O6.1	3.3	0.00101	0.0438	0.17	0.1	Urate levels;	chr2:202274567	chr2:202336739~202337200:+
BRCA	cis	rs12468226	0.938	rs78928733	ENSG00000272966.1	RP11-686O6.1	3.3	0.00101	0.0438	0.17	0.1	Urate levels;	chr2:202283787	chr2:202336739~202337200:+
BRCA	cis	rs1348850	0.519	rs4144275	ENSG00000280374.1	RP11-337N6.3	3.3	0.00101	0.0438	0.14	0.1	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177658640	chr2:177317715~177318471:-
BRCA	cis	rs1722141	0.633	rs2132570	ENSG00000237471.1	AC073115.6	3.3	0.00101	0.0438	0.14	0.1	Sitting height ratio;	chr7:45922864	chr7:45969657~45980191:+
BRCA	cis	rs1499614	1	rs1267817	ENSG00000229180.5	GS1-124K5.11	3.3	0.00101	0.0438	0.14	0.1	Gout;	chr7:66645053	chr7:66526088~66542624:-
BRCA	cis	rs561341	1	rs113115092	ENSG00000277511.1	CTD-2095E4.5	3.3	0.00101	0.0438	0.15	0.1	Hip circumference adjusted for BMI;	chr17:31957145	chr17:32127595~32128454:+
BRCA	cis	rs561341	1	rs555629	ENSG00000277511.1	CTD-2095E4.5	3.3	0.00101	0.0438	0.15	0.1	Hip circumference adjusted for BMI;	chr17:31967117	chr17:32127595~32128454:+
BRCA	cis	rs561341	0.769	rs559228	ENSG00000277511.1	CTD-2095E4.5	3.3	0.00101	0.0438	0.15	0.1	Hip circumference adjusted for BMI;	chr17:31967508	chr17:32127595~32128454:+
BRCA	cis	rs561341	1	rs1681718	ENSG00000277511.1	CTD-2095E4.5	3.3	0.00101	0.0438	0.15	0.1	Hip circumference adjusted for BMI;	chr17:31969426	chr17:32127595~32128454:+
BRCA	cis	rs9341808	0.718	rs9359408	ENSG00000233967.5	RP11-250B2.3	3.3	0.00101	0.0438	0.11	0.1	Sitting height ratio;	chr6:80110415	chr6:80443344~80465927:+
BRCA	cis	rs6750047	0.541	rs162330	ENSG00000235848.3	RMDN2-AS1	-3.3	0.00101	0.0438	-0.13	-0.1	Cutaneous malignant melanoma;Melanoma;	chr2:38092354	chr2:37949911~38067041:-
BRCA	cis	rs36051895	0.664	rs884132	ENSG00000237711.1	RP11-39K24.13	-3.3	0.00101	0.0438	-0.12	-0.1	Pediatric autoimmune diseases;	chr9:5114522	chr9:5100236~5101009:+
BRCA	cis	rs4923705	0.706	rs11073137	ENSG00000259336.1	RP11-323I15.5	-3.3	0.00101	0.0439	-0.17	-0.1	Attention deficit hyperactivity disorder;	chr15:35996504	chr15:35099022~35169698:-
BRCA	cis	rs2416257	0.673	rs17624563	ENSG00000249619.1	HMGN1P13	-3.3	0.00101	0.0439	-0.16	-0.1	Eosinophil counts;	chr5:111120565	chr5:111572102~111572239:-
BRCA	cis	rs2074518	0.701	rs3926358	ENSG00000207297.1	SNORD7	3.3	0.00101	0.0439	0.11	0.1	QT interval;	chr17:35026313	chr17:35573657~35573753:+
BRCA	cis	rs911555	0.706	rs10129426	ENSG00000269910.1	RP11-73M18.10	3.3	0.00101	0.0439	0.1	0.1	Intelligence (multi-trait analysis);	chr14:103552118	chr14:103694516~103695050:-
BRCA	cis	rs1949733	0.877	rs940133	ENSG00000205959.3	RP11-689P11.2	-3.3	0.00101	0.0439	-0.11	-0.1	Response to antineoplastic agents;	chr4:8471887	chr4:8482270~8512610:+
BRCA	cis	rs965469	0.947	rs965468	ENSG00000215063.3	RPL21P2	3.3	0.00101	0.0439	0.14	0.1	IFN-related cytopenia;	chr20:3400796	chr20:4059633~4060113:-
BRCA	cis	rs34779708	0.966	rs17499811	ENSG00000269952.1	RP11-324I22.3	-3.3	0.00101	0.0439	-0.14	-0.1	Inflammatory bowel disease;Crohn's disease;	chr10:35167287	chr10:35210416~35210750:+
BRCA	cis	rs1971762	0.545	rs6580949	ENSG00000270175.1	RP11-793H13.11	-3.3	0.00101	0.0439	-0.09	-0.1	Height;	chr12:53530509	chr12:53500162~53500936:-
BRCA	cis	rs1348850	0.519	rs13034781	ENSG00000238082.1	AC009948.7	-3.3	0.00101	0.0439	-0.13	-0.1	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177658822	chr2:178454716~178455428:+
BRCA	cis	rs4761470	1	rs4761470	ENSG00000258365.1	RP11-1105G2.3	-3.3	0.00101	0.0439	-0.15	-0.1	Estradiol plasma levels (breast cancer);	chr12:94289428	chr12:94277758~94282844:-
BRCA	cis	rs4865762	0.512	rs12521034	ENSG00000247796.2	CTD-2366F13.1	3.3	0.00101	0.0439	0.12	0.1	Intraocular pressure;	chr5:53218777	chr5:53109842~53115126:+
BRCA	cis	rs4865762	0.512	rs6897187	ENSG00000247796.2	CTD-2366F13.1	3.3	0.00101	0.0439	0.12	0.1	Intraocular pressure;	chr5:53218847	chr5:53109842~53115126:+
BRCA	cis	rs38055	0.581	rs6897912	ENSG00000247796.2	CTD-2366F13.1	3.3	0.00101	0.0439	0.12	0.1	Acne (severe);	chr5:53219317	chr5:53109842~53115126:+
BRCA	cis	rs60843830	1	rs60484953	ENSG00000223751.1	AC116609.2	3.3	0.00101	0.0439	0.13	0.1	Spherical equivalent (joint analysis main effects and education interaction);	chr2:221560	chr2:742488~747767:+
BRCA	cis	rs7590268	0.697	rs6738365	ENSG00000279873.2	LINC01126	3.3	0.00101	0.0439	0.12	0.1	Orofacial clefts;	chr2:43458598	chr2:43227210~43228855:+
BRCA	cis	rs12681366	0.734	rs3019146	ENSG00000253175.1	RP11-267M23.6	3.3	0.00101	0.0439	0.11	0.1	Nonsyndromic cleft lip with cleft palate;	chr8:94401878	chr8:94565036~94565715:+
BRCA	cis	rs6929812	0.967	rs35394453	ENSG00000220721.1	OR1F12	-3.3	0.00101	0.0439	-0.11	-0.1	Neuroticism (multi-trait analysis);	chr6:27446052	chr6:28073316~28074233:+
BRCA	cis	rs7200543	1	rs16966953	ENSG00000270580.4	PKD1P6	3.3	0.00101	0.0439	0.11	0.1	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15041997	chr16:15104723~15131601:-
BRCA	cis	rs9527	0.668	rs7092815	ENSG00000236937.2	PTGES3P4	3.3	0.00101	0.0439	0.14	0.1	Arsenic metabolism;	chr10:102976588	chr10:102845595~102845950:+
BRCA	cis	rs2153535	0.585	rs9378565	ENSG00000251164.1	HULC	-3.3	0.00101	0.0439	-0.12	-0.1	Motion sickness;	chr6:8664580	chr6:8652137~8653846:+
BRCA	cis	rs930395	0.514	rs13153556	ENSG00000272335.1	RP11-53O19.3	-3.3	0.00101	0.0439	-0.1	-0.1	Breast cancer;	chr5:44927999	chr5:44826076~44828592:+
BRCA	cis	rs59551326	0.85	rs68006537	ENSG00000234883.3	MIR155HG	3.3	0.00101	0.0439	0.14	0.1	Alcohol dependence;	chr21:25334495	chr21:25561909~25575168:+
BRCA	cis	rs7267979	0.903	rs6132819	ENSG00000231081.1	RP4-760C5.3	-3.3	0.00101	0.0439	-0.13	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25237982	chr20:26008791~26010531:-
BRCA	cis	rs2882667	0.728	rs13181830	ENSG00000242683.1	CTB-46B19.1	-3.3	0.00101	0.0439	-0.12	-0.1	Age-related hearing impairment (SNP x SNP interaction);	chr5:138944727	chr5:139035148~139035987:-
BRCA	cis	rs6785206	0.527	rs9844706	ENSG00000242551.2	POU5F1P6	-3.3	0.00101	0.0439	-0.18	-0.1	Lymphocyte percentage of white cells;	chr3:128661938	chr3:128674735~128677005:-
BRCA	cis	rs428445	1	rs6069758	ENSG00000280387.1	RP5-1153D9.5	-3.3	0.00101	0.0439	-0.11	-0.1	Refractive astigmatism;	chr20:56471679	chr20:56522252~56523499:+
BRCA	cis	rs62458065	0.713	rs1597560	ENSG00000273014.1	RP11-225B17.2	-3.3	0.00102	0.0439	-0.15	-0.1	Metabolite levels (HVA/MHPG ratio);	chr7:32454274	chr7:32758882~32759353:+
BRCA	cis	rs77688320	0.535	rs3815515	ENSG00000242696.3	RN7SL40P	-3.3	0.00102	0.0439	-0.11	-0.1	Breast cancer;	chr2:201393207	chr2:202357076~202357417:-
BRCA	cis	rs13401620	0.587	rs2861027	ENSG00000236878.1	AC012363.7	3.3	0.00102	0.0439	0.12	0.1	Breast size;	chr2:120016460	chr2:120211054~120211715:+
BRCA	cis	rs11711311	0.747	rs11928494	ENSG00000241529.3	RN7SL767P	-3.3	0.00102	0.0439	-0.12	-0.1	IgG glycosylation;	chr3:113624372	chr3:113632704~113632998:+
BRCA	cis	rs6686842	0.542	rs11209779	ENSG00000230638.4	RP11-486B10.4	-3.3	0.00102	0.0439	-0.13	-0.1	Height;	chr1:41271817	chr1:41542069~41544310:+
BRCA	cis	rs860295	0.58	rs867549	ENSG00000225855.5	RUSC1-AS1	3.3	0.00102	0.0439	0.09	0.1	Body mass index;	chr1:155910368	chr1:155316863~155324176:-
BRCA	cis	rs7243790	0.846	rs56053948	ENSG00000264296.1	RP11-116K4.1	-3.3	0.00102	0.0439	-0.11	-0.1	Diastolic blood pressure;	chr18:54434295	chr18:54142133~54142577:+
BRCA	cis	rs8179	0.514	rs2282978	ENSG00000230927.2	TMBIM7P	3.3	0.00102	0.0439	0.12	0.1	White blood cell count (basophil);Sum neutrophil eosinophil counts;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Granulocyte count;	chr7:92635096	chr7:92412976~92439562:-
BRCA	cis	rs875971	1	rs10257427	ENSG00000230189.5	GS1-124K5.2	-3.3	0.00102	0.0439	-0.08	-0.1	Aortic root size;	chr7:66278221	chr7:66409143~66490059:-
BRCA	cis	rs4927850	1	rs10881563	ENSG00000278820.1	AC024937.1	3.3	0.00102	0.0439	0.12	0.1	Pancreatic cancer;	chr3:196023354	chr3:195960500~195960612:-
BRCA	cis	rs13434995	0.513	rs62303730	ENSG00000273257.1	RP11-177J6.1	-3.3	0.00102	0.0439	-0.15	-0.1	Adiponectin levels;	chr4:55498948	chr4:55387949~55388271:+
BRCA	cis	rs17507216	0.518	rs1877240	ENSG00000259429.4	UBE2Q2P2	-3.3	0.00102	0.0439	-0.13	-0.1	Excessive daytime sleepiness;	chr15:82770126	chr15:82355142~82420075:+
BRCA	cis	rs853679	0.546	rs200949	ENSG00000216676.2	RP1-15D7.1	-3.3	0.00102	0.0439	-0.17	-0.1	Depression;	chr6:27867657	chr6:27652602~27652825:-
BRCA	cis	rs13068223	0.663	rs12107178	ENSG00000240875.4	LINC00886	-3.3	0.00102	0.0439	-0.12	-0.1	Age-related hearing impairment (SNP x SNP interaction);	chr3:156756735	chr3:156747346~156817062:-
BRCA	cis	rs28489187	0.706	rs18582	ENSG00000223653.4	RP11-131L23.1	3.3	0.00102	0.0439	0.12	0.1	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85329136	chr1:85276715~85448124:+
BRCA	cis	rs2281603	0.517	rs10134770	ENSG00000259116.1	RP11-973N13.4	-3.3	0.00102	0.0439	-0.09	-0.1	Lymphocyte counts;	chr14:64596597	chr14:64514154~64540368:-
BRCA	cis	rs13434995	0.513	rs62310862	ENSG00000273257.1	RP11-177J6.1	-3.3	0.00102	0.0439	-0.15	-0.1	Adiponectin levels;	chr4:55572594	chr4:55387949~55388271:+
BRCA	cis	rs17345786	0.798	rs4257518	ENSG00000244119.1	PDCL3P4	-3.3	0.00102	0.0439	-0.08	-0.1	Colonoscopy-negative controls vs population controls;	chr3:101562865	chr3:101712472~101713191:+
BRCA	cis	rs7695732	0.7	rs2869986	ENSG00000270720.1	RP11-84C13.2	3.3	0.00102	0.0439	0.14	0.1	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr4:89063505	chr4:89119284~89119871:+
BRCA	cis	rs4363385	0.51	rs12083211	ENSG00000231416.1	RP11-422P24.9	-3.3	0.00102	0.0439	-0.11	-0.1	Inflammatory skin disease;	chr1:153059655	chr1:153995632~153995960:+
BRCA	cis	rs8127691	0.967	rs2838520	ENSG00000225331.1	AP001055.6	3.3	0.00102	0.0439	0.12	0.1	Inflammatory bowel disease;	chr21:44196013	chr21:44158740~44160076:-
BRCA	cis	rs10744816	0.875	rs11067021	ENSG00000257817.1	RP4-601P9.2	-3.3	0.00102	0.0439	-0.13	-0.1	Obesity-related traits;	chr12:114271909	chr12:114713811~114767957:+
BRCA	cis	rs66887589	0.777	rs10015883	ENSG00000260404.2	RP11-384K6.6	3.3	0.00102	0.0439	0.09	0.1	Diastolic blood pressure;	chr4:119346991	chr4:118591773~118633729:+
BRCA	cis	rs890448	0.796	rs4235418	ENSG00000254531.1	FLJ20021	3.3	0.00102	0.0439	0.12	0.1	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101420762	chr4:101347780~101348883:+
BRCA	cis	rs4699052	0.963	rs7679365	ENSG00000230069.3	LRRC37A15P	-3.3	0.00102	0.0439	-0.1	-0.1	Testicular germ cell tumor;	chr4:103291823	chr4:102727274~102730721:-
BRCA	cis	rs4267450	0.842	rs11666652	ENSG00000261770.1	CTC-459F4.1	3.3	0.00102	0.0439	0.21	0.1	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);	chr19:28397433	chr19:27757184~27760849:-
BRCA	cis	rs1555133	0.518	rs6141714	ENSG00000277692.1	RP11-358N2.2	-3.3	0.00102	0.0439	-0.11	-0.1	Monocyte count;	chr20:32414549	chr20:32355053~32355734:+
BRCA	cis	rs9341808	0.718	rs9448898	ENSG00000279022.1	RP11-250B2.4	3.3	0.00102	0.0439	0.12	0.1	Sitting height ratio;	chr6:80135624	chr6:80440730~80441172:+
BRCA	cis	rs6545883	0.965	rs1562308	ENSG00000273302.1	RP11-493E12.2	3.3	0.00102	0.0439	0.1	0.1	Tuberculosis;	chr2:61541286	chr2:61199979~61200769:+
BRCA	cis	rs1816752	0.905	rs9511249	ENSG00000273628.1	RP11-756A22.7	3.3	0.00102	0.044	0.12	0.1	Obesity-related traits;	chr13:24425457	chr13:24933006~24936796:+
BRCA	cis	rs13418410	0.715	rs7571269	ENSG00000187999.4	HNRNPA1P61	3.3	0.00102	0.044	0.12	0.1	Non-response to antidepressants and depression;	chr2:33572204	chr2:33636502~33637425:+
BRCA	cis	rs2904524	1	rs75796761	ENSG00000257613.1	LINC01481	-3.3	0.00102	0.044	-0.17	-0.1	Amyotrophic lateral sclerosis (age of onset);	chr12:70298071	chr12:70219132~70221862:-
BRCA	cis	rs2904524	1	rs74809484	ENSG00000257613.1	LINC01481	-3.3	0.00102	0.044	-0.17	-0.1	Amyotrophic lateral sclerosis (age of onset);	chr12:70299136	chr12:70219132~70221862:-
BRCA	cis	rs2904524	1	rs75846246	ENSG00000257613.1	LINC01481	-3.3	0.00102	0.044	-0.17	-0.1	Amyotrophic lateral sclerosis (age of onset);	chr12:70305146	chr12:70219132~70221862:-
BRCA	cis	rs2904524	1	rs79903423	ENSG00000257613.1	LINC01481	-3.3	0.00102	0.044	-0.17	-0.1	Amyotrophic lateral sclerosis (age of onset);	chr12:70308032	chr12:70219132~70221862:-
BRCA	cis	rs7927592	0.913	rs67605986	ENSG00000254610.1	RP5-903G2.2	-3.3	0.00102	0.044	-0.14	-0.1	Total body bone mineral density;	chr11:68533487	chr11:67934563~67939774:-
BRCA	cis	rs1998359	0.954	rs464306	ENSG00000259087.4	RP11-356O9.2	3.3	0.00102	0.044	0.12	0.1	Self-reported allergy;	chr14:37623209	chr14:37556158~37567095:-
BRCA	cis	rs1998359	1	rs177831	ENSG00000259087.4	RP11-356O9.2	3.3	0.00102	0.044	0.12	0.1	Self-reported allergy;	chr14:37624299	chr14:37556158~37567095:-
BRCA	cis	rs7267979	0.844	rs8184820	ENSG00000274414.1	RP5-965G21.4	3.3	0.00102	0.044	0.12	0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25269941	chr20:25239007~25245229:-
BRCA	cis	rs4718428	0.705	rs4717331	ENSG00000229886.1	RP5-1132H15.3	3.3	0.00102	0.044	0.12	0.1	Corneal structure;	chr7:66913899	chr7:66025126~66031544:-
BRCA	cis	rs2243480	1	rs958550	ENSG00000226767.1	RP11-328P23.3	3.3	0.00102	0.044	0.17	0.1	Diabetic kidney disease;	chr7:66170692	chr7:65508773~65508944:-
BRCA	cis	rs9527	0.59	rs7067663	ENSG00000269609.4	RPARP-AS1	-3.3	0.00102	0.044	-0.1	-0.1	Arsenic metabolism;	chr10:103123893	chr10:102449817~102461106:+
BRCA	cis	rs6466055	0.72	rs1204077	ENSG00000242154.1	RP4-778K6.3	3.3	0.00102	0.044	0.14	0.1	Schizophrenia;	chr7:105343572	chr7:105304277~105306642:+
BRCA	cis	rs860295	0.812	rs2297775	ENSG00000203761.5	MSTO2P	3.29	0.00102	0.044	0.09	0.1	Body mass index;	chr1:155765221	chr1:155745829~155750137:+
BRCA	cis	rs7578199	0.744	rs33961871	ENSG00000228989.1	AC133528.2	3.29	0.00102	0.044	0.13	0.1	Chronic lymphocytic leukemia;	chr2:241497813	chr2:241690414~241694289:+
BRCA	cis	rs6772849	1	rs6772849	ENSG00000242551.2	POU5F1P6	-3.29	0.00102	0.044	-0.13	-0.1	Monocyte percentage of white cells;Monocyte count;	chr3:128587575	chr3:128674735~128677005:-
BRCA	cis	rs12410462	0.551	rs12095502	ENSG00000215812.5	ZNF847P	-3.29	0.00102	0.044	-0.14	-0.1	Major depressive disorder;	chr1:227668821	chr1:227696892~227706699:-
BRCA	cis	rs1998359	0.953	rs61988002	ENSG00000259087.4	RP11-356O9.2	3.29	0.00102	0.044	0.12	0.1	Self-reported allergy;	chr14:37635582	chr14:37556158~37567095:-
BRCA	cis	rs2411233	0.935	rs11855986	ENSG00000259278.1	RP11-62C7.2	-3.29	0.00102	0.044	-0.12	-0.1	Platelet count;	chr15:38977639	chr15:39019233~39024918:+
BRCA	cis	rs9393813	0.529	rs73395360	ENSG00000241549.7	GUSBP2	-3.29	0.00102	0.044	-0.11	-0.1	Bipolar disorder;	chr6:27489538	chr6:26871484~26956554:-
BRCA	cis	rs13118159	0.55	rs28522910	ENSG00000273179.1	RP11-20I20.4	3.29	0.00102	0.044	0.11	0.1	Longevity;	chr4:1380986	chr4:1167778~1168174:+
BRCA	cis	rs4849845	0.612	rs3806491	ENSG00000236878.1	AC012363.7	3.29	0.00102	0.044	0.12	0.1	Mean platelet volume;	chr2:120251099	chr2:120211054~120211715:+
BRCA	cis	rs925946	0.541	rs4923454	ENSG00000245573.6	BDNF-AS	-3.29	0.00102	0.044	-0.12	-0.1	Weight;Body mass index;	chr11:27572582	chr11:27506838~27698174:+
BRCA	cis	rs9437689	0.966	rs11585462	ENSG00000235501.4	RP4-639F20.1	3.29	0.00102	0.044	0.13	0.1	Phospholipid levels (plasma);	chr1:95072236	chr1:94927566~94963270:+
BRCA	cis	rs9437689	1	rs35678413	ENSG00000235501.4	RP4-639F20.1	3.29	0.00102	0.044	0.13	0.1	Phospholipid levels (plasma);	chr1:95073327	chr1:94927566~94963270:+
BRCA	cis	rs2842483	0.89	rs903547	ENSG00000234618.1	RPSAP9	3.29	0.00102	0.044	0.14	0.1	Multiple sclerosis (age of onset);	chr9:76289592	chr9:76398699~76399586:+
BRCA	cis	rs6019512	0.625	rs4810893	ENSG00000227431.4	CSE1L-AS1	-3.29	0.00102	0.044	-0.12	-0.1	Intelligence (multi-trait analysis);	chr20:48912974	chr20:49040463~49046044:-
BRCA	cis	rs561341	1	rs548957	ENSG00000277511.1	CTD-2095E4.5	3.29	0.00102	0.044	0.15	0.1	Hip circumference adjusted for BMI;	chr17:31975392	chr17:32127595~32128454:+
BRCA	cis	rs561341	1	rs484175	ENSG00000277511.1	CTD-2095E4.5	3.29	0.00102	0.044	0.15	0.1	Hip circumference adjusted for BMI;	chr17:31982022	chr17:32127595~32128454:+
BRCA	cis	rs561341	0.941	rs4525554	ENSG00000277511.1	CTD-2095E4.5	3.29	0.00102	0.044	0.15	0.1	Hip circumference adjusted for BMI;	chr17:31985800	chr17:32127595~32128454:+
BRCA	cis	rs879500	0.653	rs4239458	ENSG00000266296.1	ARIH2P1	-3.29	0.00102	0.044	-0.15	-0.1	Lung function (FVC);	chr18:28500347	chr18:28651732~28653208:+
BRCA	cis	rs9397240	0.789	rs9384308	ENSG00000235381.1	RP11-477D19.2	3.29	0.00102	0.044	0.16	0.1	Life satisfaction;	chr6:155294814	chr6:155253139~155256724:-
BRCA	cis	rs4953911	1	rs2321678	ENSG00000224043.6	CCNT2-AS1	3.29	0.00102	0.044	0.14	0.1	Multiple sclerosis (severity);	chr2:134310182	chr2:134735464~134918710:-
BRCA	cis	rs4934494	0.911	rs34486602	ENSG00000235100.3	RP11-80H5.9	-3.29	0.00102	0.044	-0.13	-0.1	Red blood cell count;	chr10:89655895	chr10:89667181~89699671:-
BRCA	cis	rs6142618	0.562	rs6058541	ENSG00000277692.1	RP11-358N2.2	-3.29	0.00102	0.044	-0.11	-0.1	Inflammatory bowel disease;	chr20:32170845	chr20:32355053~32355734:+
BRCA	cis	rs2638953	0.671	rs7969830	ENSG00000247934.4	RP11-967K21.1	-3.29	0.00102	0.044	-0.15	-0.1	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28111770	chr12:28163298~28190738:-
BRCA	cis	rs11671005	0.735	rs3826684	ENSG00000265272.2	RN7SL693P	3.29	0.00102	0.044	0.15	0.1	Mean platelet volume;	chr19:58407338	chr19:58490797~58491075:+
BRCA	cis	rs11671005	0.735	rs3826683	ENSG00000265272.2	RN7SL693P	3.29	0.00102	0.044	0.15	0.1	Mean platelet volume;	chr19:58407366	chr19:58490797~58491075:+
BRCA	cis	rs11671005	0.735	rs3826681	ENSG00000265272.2	RN7SL693P	3.29	0.00102	0.044	0.15	0.1	Mean platelet volume;	chr19:58407397	chr19:58490797~58491075:+
BRCA	cis	rs4775041	1	rs4775041	ENSG00000259771.1	RP11-429D19.1	3.29	0.00102	0.044	0.14	0.1	HDL cholesterol;Metabolite levels;Triglycerides;	chr15:58382496	chr15:59266720~59271162:-
BRCA	cis	rs10843247	0.649	rs309018	ENSG00000275476.1	RP11-996F15.4	-3.29	0.00102	0.044	-0.12	-0.1	Essential tremor;	chr12:28819685	chr12:29277397~29277882:-
BRCA	cis	rs13006863	0.527	rs12196	ENSG00000257800.1	FNBP1P1	-3.29	0.00102	0.044	-0.09	-0.1	Immune reponse to smallpox (secreted TNF-alpha);Post-traumatic stress disorder (asjusted for relatedness);	chr2:74214672	chr2:74120680~74123218:+
BRCA	cis	rs2342406	0.825	rs7340480	ENSG00000259439.2	RP11-89K21.1	3.29	0.00102	0.044	0.16	0.1	Myopia;	chr2:44924418	chr2:44921077~44939199:-
BRCA	cis	rs7578361	0.918	rs12468484	ENSG00000231969.1	AC144449.1	3.29	0.00102	0.044	0.15	0.1	Acute lymphoblastic leukemia (childhood);	chr2:149514430	chr2:149587196~149848233:+
BRCA	cis	rs2615061	0.872	rs12048908	ENSG00000229965.1	RP11-118H4.1	3.29	0.00102	0.044	0.19	0.1	Monocyte count;	chr1:225760118	chr1:226438564~226439344:+
BRCA	cis	rs4805834	0.843	rs77577471	ENSG00000201388.1	SNORA68	3.29	0.00102	0.044	0.18	0.1	Creatinine levels;	chr19:32892282	chr19:32608337~32608469:-
BRCA	cis	rs11955398	0.502	rs6868884	ENSG00000272308.1	RP11-231G3.1	-3.29	0.00102	0.044	-0.12	-0.1	Intelligence (multi-trait analysis);	chr5:61087133	chr5:60866457~60866935:-
BRCA	cis	rs13118159	0.509	rs10023473	ENSG00000211482.1	AC092574.1	3.29	0.00102	0.044	0.13	0.1	Longevity;	chr4:1381497	chr4:409809~409915:+
BRCA	cis	rs806321	0.51	rs1149866	ENSG00000237152.3	DLEU7-AS1	3.29	0.00102	0.044	0.13	0.1	Multiple sclerosis;	chr13:50326295	chr13:50807856~50849905:+
BRCA	cis	rs62025270	0.632	rs55981798	ENSG00000259416.2	RP11-158M2.5	-3.29	0.00102	0.044	-0.15	-0.1	Idiopathic pulmonary fibrosis;	chr15:85600869	chr15:85754941~85756237:-
BRCA	cis	rs62025270	0.576	rs17633959	ENSG00000259416.2	RP11-158M2.5	-3.29	0.00102	0.044	-0.15	-0.1	Idiopathic pulmonary fibrosis;	chr15:85600950	chr15:85754941~85756237:-
BRCA	cis	rs4332037	0.851	rs10268609	ENSG00000273230.1	RP11-1246C19.1	3.29	0.00102	0.044	0.15	0.1	Bipolar disorder;	chr7:1922527	chr7:1464497~1467522:-
BRCA	cis	rs860295	0.702	rs12041534	ENSG00000246203.2	RP11-29H23.5	3.29	0.00102	0.044	0.11	0.1	Body mass index;	chr1:155437305	chr1:155614726~155660245:-
BRCA	cis	rs6840360	0.615	rs4696094	ENSG00000270265.1	RP11-731D1.4	-3.29	0.00102	0.044	-0.13	-0.1	Intelligence (multi-trait analysis);	chr4:151544349	chr4:151333775~151353224:-
BRCA	cis	rs180730	0.752	rs3115316	ENSG00000251609.2	SETP12	-3.29	0.00102	0.044	-0.17	-0.1	Fasting plasma glucose;	chr4:120891306	chr4:120895494~120897083:-
BRCA	cis	rs718433	0.584	rs10133988	ENSG00000211805.1	TRAV24	-3.29	0.00102	0.044	-0.08	-0.1	Intraocular pressure;	chr14:21746376	chr14:22105343~22105846:+
BRCA	cis	rs9325144	0.555	rs7968322	ENSG00000257718.1	RP11-396F22.1	-3.29	0.00102	0.044	-0.1	-0.1	Morning vs. evening chronotype;	chr12:38398546	chr12:38906451~38909592:+
BRCA	cis	rs8062405	0.824	rs153106	ENSG00000261766.1	RP11-22P6.2	-3.29	0.00102	0.044	-0.1	-0.1	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28515576	chr16:28862166~28863340:-
BRCA	cis	rs10198628	1	rs2098823	ENSG00000264370.1	MIR3125	-3.29	0.00102	0.044	-0.12	-0.1	Pericardial fat;Pericardial adipose tissue adjusted for height and weight;	chr2:12827899	chr2:12737367~12737444:+
BRCA	cis	rs948562	0.725	rs11229476	ENSG00000255299.4	RP11-655C2.3	-3.29	0.00102	0.044	-0.12	-0.1	Lymphoma;	chr11:58461120	chr11:58497888~58505758:-
BRCA	cis	rs10456847	0.844	rs9358186	ENSG00000229700.1	RP1-130G2.1	3.29	0.00102	0.044	0.12	0.1	Chronic periodontitis (mean interproximal clinical attachment level);	chr6:19101557	chr6:20042455~20042940:-
BRCA	cis	rs1056107	0.933	rs10739341	ENSG00000266315.1	MIR4668	3.29	0.00102	0.044	0.1	0.1	Colorectal cancer;	chr9:112310497	chr9:111932100~111932169:+
BRCA	cis	rs67478160	0.619	rs11628481	ENSG00000269910.1	RP11-73M18.10	3.29	0.00102	0.044	0.1	0.1	Schizophrenia;	chr14:103775162	chr14:103694516~103695050:-
BRCA	cis	rs56775891	0.537	rs7236339	ENSG00000267270.4	PARD6G-AS1	-3.29	0.00102	0.044	-0.15	-0.1	Schizophrenia;	chr18:79819773	chr18:80147924~80178432:+
BRCA	cis	rs10043228	1	rs10043228	ENSG00000250015.1	CTC-339F2.2	3.29	0.00102	0.044	0.13	0.1	Asthma or chronic obstructive pulmonary disease;	chr5:116261351	chr5:116302354~116304134:-
BRCA	cis	rs694739	0.796	rs479777	ENSG00000237410.1	AP001092.4	-3.29	0.00102	0.0441	-0.13	-0.1	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64340005	chr11:64646399~64659681:+
BRCA	cis	rs7111546	0.565	rs4565895	ENSG00000246225.5	RP11-17A1.3	3.29	0.00102	0.0441	0.17	0.1	Dialysis-related mortality;	chr11:22936935	chr11:22829380~22945393:+
BRCA	cis	rs755249	0.517	rs66880209	ENSG00000243970.1	PPIEL	3.29	0.00102	0.0441	0.17	0.1	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39254140	chr1:39531838~39558707:-
BRCA	cis	rs2018683	0.835	rs7782264	ENSG00000233517.1	AC005162.5	3.29	0.00102	0.0441	0.12	0.1	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28939369	chr7:28987028~28988899:+
BRCA	cis	rs9309473	0.687	rs7576824	ENSG00000230002.2	ALMS1-IT1	-3.29	0.00102	0.0441	-0.12	-0.1	Metabolite levels;	chr2:73384153	chr2:73456764~73459484:+
BRCA	cis	rs875971	0.767	rs1643394	ENSG00000106610.13	STAG3L4	-3.29	0.00102	0.0441	-0.14	-0.1	Aortic root size;	chr7:66371107	chr7:67302621~67321526:+
BRCA	cis	rs76798021	0.745	rs11707976	ENSG00000271976.1	RP11-884K10.7	3.29	0.00102	0.0441	0.12	0.1	Lung function (FEV1/FVC);	chr3:53634681	chr3:53858994~53861576:-
BRCA	cis	rs17507216	0.518	rs1877240	ENSG00000276710.3	CSPG4P8	-3.29	0.00102	0.0441	-0.15	-0.1	Excessive daytime sleepiness;	chr15:82770126	chr15:82459472~82477258:+
BRCA	cis	rs9309473	0.948	rs10183818	ENSG00000230002.2	ALMS1-IT1	3.29	0.00102	0.0441	0.13	0.1	Metabolite levels;	chr2:73487429	chr2:73456764~73459484:+
BRCA	cis	rs2041840	1	rs6730503	ENSG00000272054.1	RP11-423P10.2	3.29	0.00102	0.0441	0.09	0.1	Chronic lymphocytic leukemia;	chr2:37301335	chr2:37208875~37212677:+
BRCA	cis	rs910316	0.934	rs4903278	ENSG00000259138.1	RP11-950C14.7	3.29	0.00102	0.0441	0.11	0.1	Height;	chr14:75068316	chr14:75127153~75136930:+
BRCA	cis	rs61931739	0.5	rs11053210	ENSG00000258794.3	DUX4L27	-3.29	0.00102	0.0441	-0.15	-0.1	Morning vs. evening chronotype;	chr12:34308836	chr12:34208415~34209675:-
BRCA	cis	rs6088590	1	rs2076668	ENSG00000269202.1	RP4-614O4.12	-3.29	0.00102	0.0441	-0.11	-0.1	Coronary artery disease;	chr20:34849818	chr20:35201747~35203288:-
BRCA	cis	rs67073037	0.955	rs4666144	ENSG00000230730.1	AC074011.2	-3.29	0.00102	0.0441	-0.14	-0.1	Breast cancer;Breast cancer (estrogen-receptor negative);	chr2:28951239	chr2:28633282~28664540:-
BRCA	cis	rs12282928	0.788	rs753095	ENSG00000255197.4	RP11-750H9.5	-3.29	0.00102	0.0441	-0.09	-0.1	Migraine - clinic-based;	chr11:48307092	chr11:47383148~47409190:-
BRCA	cis	rs1119582	0.561	rs591068	ENSG00000279118.1	RP11-517I3.2	3.29	0.00102	0.0441	0.14	0.1	Select biomarker traits;	chr5:125848129	chr5:126496279~126498604:+
BRCA	cis	rs4478858	0.735	rs10914344	ENSG00000229447.2	RP11-490K7.4	-3.29	0.00102	0.0441	-0.1	-0.1	Alcohol dependence;	chr1:31296178	chr1:31263245~31263681:-
BRCA	cis	rs12500824	0.564	rs62303261	ENSG00000214062.5	RPL7P17	-3.29	0.00102	0.0441	-0.13	-0.1	Coronary artery disease;	chr4:76365776	chr4:77082403~77083126:-
BRCA	cis	rs1555322	1	rs2425032	ENSG00000269202.1	RP4-614O4.12	-3.29	0.00102	0.0441	-0.15	-0.1	Attention deficit hyperactivity disorder;	chr20:35267651	chr20:35201747~35203288:-
BRCA	cis	rs6772849	1	rs6798431	ENSG00000207088.1	SNORA7B	-3.29	0.00102	0.0441	-0.13	-0.1	Monocyte percentage of white cells;Monocyte count;	chr3:128584530	chr3:129397210~129397348:-
BRCA	cis	rs6772849	1	rs9836257	ENSG00000207088.1	SNORA7B	-3.29	0.00102	0.0441	-0.13	-0.1	Monocyte percentage of white cells;Monocyte count;	chr3:128584640	chr3:129397210~129397348:-
BRCA	cis	rs4927850	1	rs7625570	ENSG00000278820.1	AC024937.1	3.29	0.00102	0.0441	0.12	0.1	Pancreatic cancer;	chr3:196020527	chr3:195960500~195960612:-
BRCA	cis	rs7647973	0.925	rs4955439	ENSG00000272434.1	RP13-131K19.6	3.29	0.00102	0.0441	0.13	0.1	Menarche (age at onset);	chr3:49208212	chr3:49029316~49029706:+
BRCA	cis	rs2438150	1	rs2438150	ENSG00000263432.2	RN7SL689P	3.29	0.00102	0.0441	0.12	0.1	Plateletcrit;	chr5:122863501	chr5:123022487~123022783:-
BRCA	cis	rs116095464	0.558	rs10065584	ENSG00000250848.1	CTD-2083E4.5	-3.29	0.00102	0.0441	-0.16	-0.1	Breast cancer;	chr5:253882	chr5:288833~290321:-
BRCA	cis	rs2400362	0.752	rs4739774	ENSG00000260317.1	RP11-48B3.4	-3.29	0.00102	0.0441	-0.13	-0.1	Glucocorticoid-induced osteonecrosis (age 10 years and older);	chr8:80935179	chr8:80541300~80543104:+
BRCA	cis	rs10782582	0.593	rs11576534	ENSG00000181227.3	RP4-682C21.2	3.29	0.00102	0.0441	0.11	0.1	Daytime sleep phenotypes;	chr1:75647066	chr1:75743423~75744776:-
BRCA	cis	rs654950	0.776	rs2759254	ENSG00000230881.1	RP11-486B10.3	3.29	0.00102	0.0441	0.11	0.1	Airway imaging phenotypes;	chr1:41570012	chr1:41535443~41535868:+
BRCA	cis	rs8099594	0.64	rs498929	ENSG00000266696.1	RP11-30L3.2	3.29	0.00102	0.0441	0.12	0.1	Height;	chr18:49333154	chr18:49205912~49208781:+
BRCA	cis	rs61935443	0.778	rs78522691	ENSG00000271382.1	RP11-1060G2.2	-3.29	0.00102	0.0441	-0.14	-0.1	Schizophrenia;	chr12:94873564	chr12:93945041~93947813:+
BRCA	cis	rs61935443	0.832	rs10859778	ENSG00000271382.1	RP11-1060G2.2	-3.29	0.00102	0.0441	-0.14	-0.1	Schizophrenia;	chr12:94874234	chr12:93945041~93947813:+
BRCA	cis	rs6560517	0.56	rs2490573	ENSG00000234618.1	RPSAP9	-3.29	0.00102	0.0441	-0.11	-0.1	Dialysis-related mortality;	chr9:76374612	chr9:76398699~76399586:+
BRCA	cis	rs34779708	0.966	rs1213392	ENSG00000269952.1	RP11-324I22.3	-3.29	0.00102	0.0441	-0.13	-0.1	Inflammatory bowel disease;Crohn's disease;	chr10:35141357	chr10:35210416~35210750:+
BRCA	cis	rs13118159	0.767	rs2141656	ENSG00000254094.1	AC078852.1	-3.29	0.00102	0.0441	-0.11	-0.1	Longevity;	chr4:1323404	chr4:1356581~1358075:+
BRCA	cis	rs4805834	0.843	rs17206254	ENSG00000201388.1	SNORA68	3.29	0.00102	0.0441	0.17	0.1	Creatinine levels;	chr19:32866056	chr19:32608337~32608469:-
BRCA	cis	rs7674212	0.556	rs34475639	ENSG00000248740.4	RP11-328K4.1	3.29	0.00102	0.0441	0.12	0.1	Type 2 diabetes;	chr4:103033694	chr4:103256159~103453658:+
BRCA	cis	rs7412746	0.646	rs10399947	ENSG00000224800.1	RP11-235D19.2	-3.29	0.00102	0.0441	-0.13	-0.1	Melanoma;	chr1:150889484	chr1:150881236~150881683:-
BRCA	cis	rs7911264	0.739	rs7914814	ENSG00000232709.1	MARK2P9	-3.29	0.00102	0.0441	-0.13	-0.1	Inflammatory bowel disease;	chr10:92623193	chr10:92418667~92420875:+
BRCA	cis	rs495337	1	rs6125829	ENSG00000224397.4	LINC01272	3.29	0.00102	0.0441	0.1	0.1	Psoriasis;	chr20:49952392	chr20:50267486~50279795:+
BRCA	cis	rs2625529	0.557	rs1000281	ENSG00000260037.4	CTD-2524L6.3	3.29	0.00102	0.0441	0.12	0.1	Red blood cell count;	chr15:72261081	chr15:71818396~71823384:+
BRCA	cis	rs875971	1	rs709595	ENSG00000229886.1	RP5-1132H15.3	3.29	0.00102	0.0441	0.11	0.1	Aortic root size;	chr7:66352346	chr7:66025126~66031544:-
BRCA	cis	rs875971	1	rs811880	ENSG00000229886.1	RP5-1132H15.3	3.29	0.00102	0.0441	0.11	0.1	Aortic root size;	chr7:66353659	chr7:66025126~66031544:-
BRCA	cis	rs713477	0.505	rs10131672	ENSG00000186615.9	KTN1-AS1	-3.29	0.00102	0.0441	-0.12	-0.1	Pediatric bone mineral content (femoral neck);	chr14:55438373	chr14:55499278~55580110:-
BRCA	cis	rs36096196	0.891	rs74046969	ENSG00000272106.1	RP11-345P4.9	3.29	0.00102	0.0441	0.11	0.1	Coronary artery disease;	chr1:2319909	chr1:1613758~1615795:-
BRCA	cis	rs2559856	1	rs2695286	ENSG00000274560.1	RP11-285E23.2	3.29	0.00102	0.0441	0.11	0.1	Blood protein levels;	chr12:101694729	chr12:101696002~101696450:-
BRCA	cis	rs2836950	0.501	rs11702505	ENSG00000235701.1	PCBP2P1	-3.29	0.00102	0.0441	-0.12	-0.1	Menarche (age at onset);	chr21:39328688	chr21:39171130~39172106:-
BRCA	cis	rs2836950	0.501	rs2836985	ENSG00000235701.1	PCBP2P1	-3.29	0.00102	0.0441	-0.12	-0.1	Menarche (age at onset);	chr21:39329243	chr21:39171130~39172106:-
BRCA	cis	rs4665809	1	rs750451	ENSG00000231655.1	AC011742.3	3.29	0.00102	0.0441	0.14	0.1	Gut microbiome composition (summer);	chr2:26101372	chr2:26140263~26141264:-
BRCA	cis	rs875971	1	rs6460296	ENSG00000273448.1	RP11-166O4.6	3.29	0.00102	0.0441	0.09	0.1	Aortic root size;	chr7:66430152	chr7:67333047~67334383:+
BRCA	cis	rs801193	1	rs10234018	ENSG00000223473.2	GS1-124K5.3	-3.29	0.00102	0.0441	-0.08	-0.1	Aortic root size;	chr7:66681297	chr7:66491049~66493566:-
BRCA	cis	rs6088590	0.561	rs2295444	ENSG00000269202.1	RP4-614O4.12	-3.29	0.00102	0.0441	-0.1	-0.1	Coronary artery disease;	chr20:34586079	chr20:35201747~35203288:-
BRCA	cis	rs7188861	0.681	rs34294744	ENSG00000262636.1	CTD-3088G3.4	3.29	0.00102	0.0441	0.2	0.1	HDL cholesterol;	chr16:11313766	chr16:11380859~11381118:-
BRCA	cis	rs7188861	0.681	rs55752638	ENSG00000262636.1	CTD-3088G3.4	3.29	0.00102	0.0441	0.2	0.1	HDL cholesterol;	chr16:11315636	chr16:11380859~11381118:-
BRCA	cis	rs35520189	0.591	rs12618418	ENSG00000189223.12	PAX8-AS1	-3.29	0.00102	0.0442	-0.16	-0.1	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:112950068	chr2:113211522~113276581:+
BRCA	cis	rs6582630	0.502	rs1589390	ENSG00000257718.1	RP11-396F22.1	-3.29	0.00102	0.0442	-0.1	-0.1	Drug-induced liver injury (flucloxacillin);	chr12:38022337	chr12:38906451~38909592:+
BRCA	cis	rs36093844	0.615	rs77258124	ENSG00000279742.1	RP11-700A24.1	-3.29	0.00102	0.0442	-0.16	-0.1	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85867038	chr11:85852557~85854943:-
BRCA	cis	rs1050288	0.525	rs10743608	ENSG00000256377.4	RP11-1060J15.4	-3.29	0.00102	0.0442	-0.14	-0.1	Pulse pressure;Resting heart rate;	chr12:27786422	chr12:27696388~27710770:-
BRCA	cis	rs7112925	0.966	rs11602157	ENSG00000255038.1	RP11-1167A19.2	3.29	0.00102	0.0442	0.13	0.1	Height;	chr11:67059848	chr11:66067277~66069619:-
BRCA	cis	rs4879656	0.602	rs12554192	ENSG00000236184.1	TCEA1P4	-3.29	0.00102	0.0442	-0.13	-0.1	Menopause (age at onset);	chr9:33084734	chr9:32979560~32980403:-
BRCA	cis	rs12216545	0.737	rs7788962	ENSG00000244151.1	RP11-148K1.12	-3.29	0.00102	0.0442	-0.09	-0.1	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150530139	chr7:151074742~151076530:-
BRCA	cis	rs3820068	0.603	rs56032936	ENSG00000237301.1	RP4-680D5.2	-3.29	0.00102	0.0442	-0.13	-0.1	Systolic blood pressure;	chr1:15644458	chr1:15586136~15603626:-
BRCA	cis	rs3820068	0.603	rs59558854	ENSG00000237301.1	RP4-680D5.2	-3.29	0.00102	0.0442	-0.13	-0.1	Systolic blood pressure;	chr1:15644904	chr1:15586136~15603626:-
BRCA	cis	rs4664293	0.51	rs66537229	ENSG00000230783.1	AC009961.2	3.29	0.00102	0.0442	0.13	0.1	Monocyte percentage of white cells;	chr2:159624095	chr2:159689217~159690291:-
BRCA	cis	rs6453278	0.559	rs13183218	ENSG00000250802.5	ZBED3-AS1	-3.29	0.00102	0.0442	-0.16	-0.1	Autism;	chr5:77098982	chr5:77086740~77166909:+
BRCA	cis	rs10129255	0.957	rs10136560	ENSG00000253132.1	IGHV3-62	-3.29	0.00102	0.0442	-0.08	-0.1	Kawasaki disease;	chr14:106787630	chr14:106643142~106643585:-
BRCA	cis	rs36051895	0.559	rs10815172	ENSG00000237711.1	RP11-39K24.13	-3.29	0.00102	0.0442	-0.12	-0.1	Pediatric autoimmune diseases;	chr9:5212254	chr9:5100236~5101009:+
BRCA	cis	rs7011507	1	rs4347021	ENSG00000279881.1	RP11-513O13.1	3.29	0.00102	0.0442	0.15	0.1	Inflammatory bowel disease;Ulcerative colitis;	chr8:48258584	chr8:48428143~48431041:-
BRCA	cis	rs10129255	0.912	rs6576227	ENSG00000231475.3	IGHV4-31	-3.29	0.00102	0.0442	-0.08	-0.1	Kawasaki disease;	chr14:106778202	chr14:106349283~106349792:-
BRCA	cis	rs10129255	0.957	rs6576228	ENSG00000231475.3	IGHV4-31	-3.29	0.00102	0.0442	-0.08	-0.1	Kawasaki disease;	chr14:106778401	chr14:106349283~106349792:-
BRCA	cis	rs11035577	0.632	rs4755519	ENSG00000279675.1	RP11-454H19.2	-3.29	0.00102	0.0442	-0.16	-0.1	Temperament (bipolar disorder);	chr11:39750244	chr11:40107244~40112599:-
BRCA	cis	rs11035577	0.632	rs7127016	ENSG00000279675.1	RP11-454H19.2	-3.29	0.00102	0.0442	-0.16	-0.1	Temperament (bipolar disorder);	chr11:39750768	chr11:40107244~40112599:-
BRCA	cis	rs11035577	0.632	rs7127150	ENSG00000279675.1	RP11-454H19.2	-3.29	0.00102	0.0442	-0.16	-0.1	Temperament (bipolar disorder);	chr11:39750833	chr11:40107244~40112599:-
BRCA	cis	rs6687758	1	rs12135286	ENSG00000232679.1	RP11-400N13.3	3.29	0.00102	0.0442	0.14	0.1	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:222045419	chr1:222041705~222064763:-
BRCA	cis	rs6142618	0.562	rs4589835	ENSG00000277692.1	RP11-358N2.2	-3.29	0.00102	0.0442	-0.11	-0.1	Inflammatory bowel disease;	chr20:32168811	chr20:32355053~32355734:+
BRCA	cis	rs10971721	0.908	rs72729329	ENSG00000279489.1	RP11-392A14.8	3.29	0.00102	0.0442	0.21	0.1	Body mass index;	chr9:34022884	chr9:35001913~35003663:+
BRCA	cis	rs10971721	0.908	rs10971858	ENSG00000279489.1	RP11-392A14.8	3.29	0.00102	0.0442	0.21	0.1	Body mass index;	chr9:34023693	chr9:35001913~35003663:+
BRCA	cis	rs10971721	0.822	rs72729341	ENSG00000279489.1	RP11-392A14.8	3.29	0.00102	0.0442	0.21	0.1	Body mass index;	chr9:34031693	chr9:35001913~35003663:+
BRCA	cis	rs10971721	0.822	rs72729344	ENSG00000279489.1	RP11-392A14.8	3.29	0.00102	0.0442	0.21	0.1	Body mass index;	chr9:34034032	chr9:35001913~35003663:+
BRCA	cis	rs2227564	0.672	rs2461864	ENSG00000279689.1	RP11-574K11.32	3.29	0.00102	0.0442	0.11	0.1	Crohn's disease;Inflammatory bowel disease;	chr10:73900114	chr10:73769264~73772862:-
BRCA	cis	rs4930103	0.904	rs4929984	ENSG00000230080.2	AC139143.2	-3.29	0.00102	0.0442	-0.11	-0.1	DNA methylation (variation);DNA methylation (parent-of-origin);	chr11:2003453	chr11:1802889~1804095:-
BRCA	cis	rs2303149	0.577	rs4808452	ENSG00000269243.1	CTD-2231E14.8	-3.29	0.00102	0.0442	-0.1	-0.1	Mean platelet volume;	chr19:16094866	chr19:16123661~16139892:-
BRCA	cis	rs7520050	0.966	rs785520	ENSG00000234329.1	RP11-767N6.2	-3.29	0.00102	0.0442	-0.1	-0.1	Reticulocyte count;Red blood cell count;	chr1:46103164	chr1:45651039~45651826:-
BRCA	cis	rs16950303	0.661	rs12456845	ENSG00000264269.1	RP11-15F12.1	3.29	0.00102	0.0442	0.22	0.1	Height;	chr18:49049688	chr18:49023703~49048474:+
BRCA	cis	rs8127691	1	rs8127691	ENSG00000225331.1	AP001055.6	3.29	0.00102	0.0442	0.12	0.1	Inflammatory bowel disease;	chr21:44194977	chr21:44158740~44160076:-
BRCA	cis	rs7260538	0.803	rs4802102	ENSG00000268034.1	AC005795.1	3.29	0.00102	0.0442	0.11	0.1	DDT metabolite (p,p'-DDE levels);	chr19:40997334	chr19:41506152~41506898:+
BRCA	cis	rs13136331	0.684	rs12505482	ENSG00000249001.4	RP11-742B18.1	-3.29	0.00102	0.0442	-0.14	-0.1	Sitting height ratio;	chr4:87809058	chr4:87568035~87733956:-
BRCA	cis	rs9388451	0.626	rs7748729	ENSG00000237742.5	RP11-624M8.1	-3.29	0.00102	0.0442	-0.12	-0.1	Brugada syndrome;	chr6:125756235	chr6:125578558~125749190:-
BRCA	cis	rs7515577	1	rs10782922	ENSG00000207523.1	SNORA66	3.29	0.00102	0.0442	0.14	0.1	Cholesterol, total;	chr1:92509038	chr1:92840719~92840851:+
BRCA	cis	rs11239930	0.517	rs3011809	ENSG00000227242.3	NBPF13P	-3.29	0.00102	0.0442	-0.13	-0.1	AIDS progression;	chr1:147077593	chr1:147021320~147124525:-
BRCA	cis	rs7264396	0.563	rs6060558	ENSG00000088340.14	FER1L4	-3.29	0.00102	0.0442	-0.15	-0.1	Total cholesterol levels;	chr20:35683170	chr20:35558737~35607562:-
BRCA	cis	rs10883723	0.773	rs2296578	ENSG00000213061.2	PFN1P11	-3.29	0.00102	0.0442	-0.14	-0.1	Allergic disease (asthma, hay fever or eczema);	chr10:102481217	chr10:102838011~102845473:-
BRCA	cis	rs10883723	0.775	rs2296579	ENSG00000213061.2	PFN1P11	-3.29	0.00102	0.0442	-0.14	-0.1	Allergic disease (asthma, hay fever or eczema);	chr10:102481618	chr10:102838011~102845473:-
BRCA	cis	rs1056107	0.572	rs10817334	ENSG00000230185.4	C9orf147	3.29	0.00102	0.0442	0.12	0.1	Colorectal cancer;	chr9:112401777	chr9:112433816~112487204:-
BRCA	cis	rs2075671	0.857	rs11772849	ENSG00000208036.1	MIR106B	3.29	0.00102	0.0442	0.14	0.1	Other erythrocyte phenotypes;	chr7:100710789	chr7:100093993~100094074:-
BRCA	cis	rs12612435	0.91	rs60201100	ENSG00000226806.1	AC011893.3	-3.29	0.00102	0.0442	-0.13	-0.1	Takotsubo syndrome;	chr2:136345491	chr2:135820191~135823087:+
BRCA	cis	rs911555	0.755	rs2273702	ENSG00000269940.1	RP11-73M18.7	-3.29	0.00102	0.0442	-0.11	-0.1	Intelligence (multi-trait analysis);	chr14:103451845	chr14:103694560~103695170:+
BRCA	cis	rs6840360	0.55	rs7683134	ENSG00000278978.1	RP11-164P12.5	-3.29	0.00102	0.0442	-0.12	-0.1	Intelligence (multi-trait analysis);	chr4:151582210	chr4:151669786~151670503:+
BRCA	cis	rs8177876	0.915	rs8059692	ENSG00000261061.1	RP11-303E16.2	-3.29	0.00102	0.0442	-0.13	-0.1	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81096889	chr16:81030770~81031485:+
BRCA	cis	rs4919694	1	rs77969925	ENSG00000236937.2	PTGES3P4	3.29	0.00102	0.0442	0.2	0.1	Arsenic metabolism;	chr10:102889600	chr10:102845595~102845950:+
BRCA	cis	rs4919694	1	rs76255497	ENSG00000236937.2	PTGES3P4	3.29	0.00102	0.0442	0.2	0.1	Arsenic metabolism;	chr10:102892198	chr10:102845595~102845950:+
BRCA	cis	rs4919694	1	rs75691516	ENSG00000236937.2	PTGES3P4	3.29	0.00102	0.0442	0.2	0.1	Arsenic metabolism;	chr10:102892288	chr10:102845595~102845950:+
BRCA	cis	rs4848143	0.67	rs7565883	ENSG00000236859.5	NIFK-AS1	-3.29	0.00102	0.0442	-0.11	-0.1	Capecitabine sensitivity;	chr2:121043873	chr2:121649650~121728208:+
BRCA	cis	rs9921338	0.924	rs7193645	ENSG00000263080.1	RP11-485G7.5	3.29	0.00102	0.0442	0.15	0.1	Vein graft stenosis in coronary artery bypass grafting;	chr16:11287179	chr16:11341809~11345211:-
BRCA	cis	rs8114671	0.967	rs6088747	ENSG00000126005.14	MMP24-AS1	-3.29	0.00102	0.0442	-0.12	-0.1	Height;	chr20:35166801	chr20:35216462~35278131:-
BRCA	cis	rs6439153	0.967	rs12695512	ENSG00000242551.2	POU5F1P6	-3.29	0.00102	0.0442	-0.13	-0.1	Pneumococcal bacteremia;	chr3:129003239	chr3:128674735~128677005:-
BRCA	cis	rs11098499	0.691	rs10010355	ENSG00000249244.1	RP11-548H18.2	3.29	0.00102	0.0442	0.11	0.1	Corneal astigmatism;	chr4:119339888	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.691	rs9307471	ENSG00000249244.1	RP11-548H18.2	3.29	0.00102	0.0442	0.11	0.1	Corneal astigmatism;	chr4:119340107	chr4:119391831~119395335:-
BRCA	cis	rs6545883	0.562	rs777588	ENSG00000270820.4	RP11-355B11.2	3.29	0.00103	0.0442	0.11	0.1	Tuberculosis;	chr2:61199685	chr2:61471188~61484130:+
BRCA	cis	rs6463739	0.708	rs10228869	ENSG00000219545.8	UMAD1	3.29	0.00103	0.0442	0.1	0.1	Small cell lung carcinoma;	chr7:7852000	chr7:7640711~8004059:+
BRCA	cis	rs7763441	1	rs9501843	ENSG00000272465.1	RP1-136B1.1	3.29	0.00103	0.0442	0.12	0.1	Monobrow;	chr6:2449638	chr6:2437549~2438249:+
BRCA	cis	rs7260538	0.9	rs4803417	ENSG00000268034.1	AC005795.1	3.29	0.00103	0.0442	0.11	0.1	DDT metabolite (p,p'-DDE levels);	chr19:41002115	chr19:41506152~41506898:+
BRCA	cis	rs12956045	0.742	rs12968854	ENSG00000267529.3	RP11-53B2.1	3.29	0.00103	0.0442	0.11	0.1	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr18:13849365	chr18:13471012~13472709:-
BRCA	cis	rs7239883	0.5	rs16976266	ENSG00000267652.1	RP11-188I24.1	3.29	0.00103	0.0442	0.15	0.1	Waist circumference;Body mass index;	chr18:42511704	chr18:41789162~41789395:-
BRCA	cis	rs1056107	0.933	rs4979095	ENSG00000266315.1	MIR4668	3.29	0.00103	0.0442	0.1	0.1	Colorectal cancer;	chr9:112286527	chr9:111932100~111932169:+
BRCA	cis	rs2625529	0.59	rs7183196	ENSG00000260037.4	CTD-2524L6.3	-3.29	0.00103	0.0443	-0.13	-0.1	Red blood cell count;	chr15:72252060	chr15:71818396~71823384:+
BRCA	cis	rs7944735	0.702	rs60515486	ENSG00000252874.2	Y_RNA	3.29	0.00103	0.0443	0.13	0.1	Intraocular pressure;	chr11:47661173	chr11:47820200~47820289:-
BRCA	cis	rs73195822	0.527	rs73194059	ENSG00000277299.1	RP11-837J7.4	-3.29	0.00103	0.0443	-0.17	-0.1	Itch intensity from mosquito bite;	chr12:110783935	chr12:109948389~109949029:+
BRCA	cis	rs73195822	0.614	rs73194061	ENSG00000277299.1	RP11-837J7.4	-3.29	0.00103	0.0443	-0.17	-0.1	Itch intensity from mosquito bite;	chr12:110784136	chr12:109948389~109949029:+
BRCA	cis	rs17684571	0.748	rs13192478	ENSG00000231441.1	RP11-472M19.2	3.29	0.00103	0.0443	0.15	0.1	Schizophrenia;	chr6:56719979	chr6:56844002~56864078:+
BRCA	cis	rs3824435	0.783	rs1322220	ENSG00000272866.1	RP11-12D24.10	-3.29	0.00103	0.0443	-0.11	-0.1	Risky sexual behaviors in alcohol dependence;	chr9:5340596	chr9:5351796~5352410:-
BRCA	cis	rs12712133	0.552	rs11123915	ENSG00000234389.1	AC007278.3	-3.29	0.00103	0.0443	-0.1	-0.1	Primary biliary cholangitis;	chr2:102264363	chr2:102438713~102440475:+
BRCA	cis	rs853679	0.517	rs9283884	ENSG00000226314.6	ZNF192P1	3.29	0.00103	0.0443	0.15	0.1	Depression;	chr6:28167882	chr6:28161781~28169594:+
BRCA	cis	rs875971	0.545	rs4441996	ENSG00000226767.1	RP11-328P23.3	-3.29	0.00103	0.0443	-0.12	-0.1	Aortic root size;	chr7:66123233	chr7:65508773~65508944:-
BRCA	cis	rs4388249	0.706	rs2301010	ENSG00000249068.1	CTC-287O8.1	-3.29	0.00103	0.0443	-0.16	-0.1	Schizophrenia;	chr5:109796760	chr5:109840128~109840692:-
BRCA	cis	rs7023329	0.562	rs4620362	ENSG00000265194.1	RP11-70L8.4	-3.29	0.00103	0.0443	-0.1	-0.1	Melanoma;	chr9:21711789	chr9:21858910~21861926:-
BRCA	cis	rs7927592	0.913	rs6591340	ENSG00000254610.1	RP5-903G2.2	-3.29	0.00103	0.0443	-0.14	-0.1	Total body bone mineral density;	chr11:68530168	chr11:67934563~67939774:-
BRCA	cis	rs4415084	0.716	rs727304	ENSG00000272335.1	RP11-53O19.3	3.29	0.00103	0.0443	0.09	0.1	Breast cancer;	chr5:44796188	chr5:44826076~44828592:+
BRCA	cis	rs7267979	1	rs910997	ENSG00000204556.4	CTD-2514C3.1	-3.29	0.00103	0.0443	-0.14	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25286665	chr20:26018832~26020684:+
BRCA	cis	rs4308124	0.708	rs6716091	ENSG00000271590.1	RP11-181E10.3	3.29	0.00103	0.0443	0.11	0.1	Vitiligo;	chr2:111233556	chr2:111210995~111212476:-
BRCA	cis	rs7615952	0.558	rs7641353	ENSG00000171084.14	FAM86JP	3.29	0.00103	0.0443	0.15	0.1	Blood pressure (smoking interaction);	chr3:125621035	chr3:125916620~125930024:+
BRCA	cis	rs10005067	0.967	rs12513086	ENSG00000249001.4	RP11-742B18.1	-3.29	0.00103	0.0443	-0.12	-0.1	Total body bone mineral density (age 30-45);	chr4:87896824	chr4:87568035~87733956:-
BRCA	cis	rs1325195	0.92	rs2816206	ENSG00000261060.1	RP11-545A16.4	-3.29	0.00103	0.0443	-0.14	-0.1	IgE grass sensitization;	chr1:179199670	chr1:179590372~179591305:+
BRCA	cis	rs253959	0.545	rs712597	ENSG00000248445.4	SEMA6A-AS1	-3.29	0.00103	0.0443	-0.1	-0.1	Bipolar disorder and schizophrenia;	chr5:116322485	chr5:116447547~116508276:+
BRCA	cis	rs7694379	0.641	rs62305669	ENSG00000251411.1	RP11-397E7.4	-3.29	0.00103	0.0443	-0.11	-0.1	Platelet count;	chr4:87248150	chr4:86913266~86914817:-
BRCA	cis	rs2899832	0.5	rs76654590	ENSG00000258704.4	SRP54-AS1	3.29	0.00103	0.0443	0.23	0.1	Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:35209554	chr14:34920858~34982532:-
BRCA	cis	rs2899832	0.5	rs111233262	ENSG00000258704.4	SRP54-AS1	3.29	0.00103	0.0443	0.23	0.1	Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:35209833	chr14:34920858~34982532:-
BRCA	cis	rs9341808	0.718	rs9443734	ENSG00000233967.5	RP11-250B2.3	3.29	0.00103	0.0443	0.11	0.1	Sitting height ratio;	chr6:80110576	chr6:80443344~80465927:+
BRCA	cis	rs12439619	0.921	rs4778672	ENSG00000274376.3	ADAMTS7P1	-3.29	0.00103	0.0443	-0.13	-0.1	Intelligence (multi-trait analysis);	chr15:82245013	chr15:82298553~82334609:+
BRCA	cis	rs9325144	0.647	rs12227834	ENSG00000257718.1	RP11-396F22.1	-3.29	0.00103	0.0443	-0.1	-0.1	Morning vs. evening chronotype;	chr12:38455444	chr12:38906451~38909592:+
BRCA	cis	rs10129255	0.957	rs10142918	ENSG00000253132.1	IGHV3-62	-3.29	0.00103	0.0443	-0.08	-0.1	Kawasaki disease;	chr14:106782206	chr14:106643142~106643585:-
BRCA	cis	rs564309	0.764	rs35553922	ENSG00000183929.7	DUSP5P1	3.29	0.00103	0.0443	0.24	0.1	Hip circumference (psychosocial stress interaction);	chr1:228343392	chr1:228650241~228651379:+
BRCA	cis	rs11098499	0.562	rs2389879	ENSG00000249244.1	RP11-548H18.2	-3.29	0.00103	0.0443	-0.11	-0.1	Corneal astigmatism;	chr4:119636529	chr4:119391831~119395335:-
BRCA	cis	rs7308116	0.967	rs11838238	ENSG00000274395.1	RP11-554D14.8	-3.29	0.00103	0.0443	-0.11	-0.1	Pelvic organ prolapse (moderate/severe);	chr12:107799446	chr12:107835541~107836555:-
BRCA	cis	rs930395	0.514	rs6871820	ENSG00000272335.1	RP11-53O19.3	-3.29	0.00103	0.0443	-0.1	-0.1	Breast cancer;	chr5:44919455	chr5:44826076~44828592:+
BRCA	cis	rs1355223	0.872	rs913204	ENSG00000271369.1	RP11-350D17.3	3.29	0.00103	0.0443	0.12	0.1	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34684677	chr11:34709600~34710161:+
BRCA	cis	rs9990333	0.862	rs6806599	ENSG00000224769.1	AC069213.1	-3.29	0.00103	0.0443	-0.14	-0.1	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196089280	chr3:195614947~195620233:+
BRCA	cis	rs4718428	0.705	rs12698547	ENSG00000229886.1	RP5-1132H15.3	3.29	0.00103	0.0443	0.12	0.1	Corneal structure;	chr7:66813271	chr7:66025126~66031544:-
BRCA	cis	rs709400	0.567	rs28496120	ENSG00000260285.1	RP11-600F24.7	3.29	0.00103	0.0443	0.1	0.1	Body mass index;	chr14:103431562	chr14:103525010~103529072:-
BRCA	cis	rs6912958	0.525	rs242262	ENSG00000272008.1	RP11-393I2.4	-3.29	0.00103	0.0443	-0.11	-0.1	Monocyte percentage of white cells;	chr6:87308339	chr6:87151159~87155285:-
BRCA	cis	rs11035577	0.516	rs4756513	ENSG00000279675.1	RP11-454H19.2	-3.29	0.00103	0.0443	-0.15	-0.1	Temperament (bipolar disorder);	chr11:39742398	chr11:40107244~40112599:-
BRCA	cis	rs6496044	0.568	rs7176291	ENSG00000259630.2	CTD-2262B20.1	-3.29	0.00103	0.0443	-0.12	-0.1	Interstitial lung disease;	chr15:85524167	chr15:85415228~85415633:+
BRCA	cis	rs889312	0.5	rs3099460	ENSG00000271828.1	CTD-2310F14.1	-3.29	0.00103	0.0443	-0.12	-0.1	Breast cancer (early onset);Breast cancer;	chr5:56837921	chr5:56927874~56929573:+
BRCA	cis	rs1355223	0.902	rs7121272	ENSG00000271369.1	RP11-350D17.3	-3.29	0.00103	0.0443	-0.12	-0.1	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34731015	chr11:34709600~34710161:+
BRCA	cis	rs10744816	0.875	rs10850302	ENSG00000257817.1	RP4-601P9.2	-3.29	0.00103	0.0443	-0.13	-0.1	Obesity-related traits;	chr12:114274290	chr12:114713811~114767957:+
BRCA	cis	rs6102185	0.549	rs6029415	ENSG00000226648.1	PLCG1-AS1	-3.29	0.00103	0.0443	-0.11	-0.1	IgG glycosylation;	chr20:40889551	chr20:41098329~41138003:-
BRCA	cis	rs2638953	0.671	rs10843101	ENSG00000247934.4	RP11-967K21.1	-3.29	0.00103	0.0443	-0.15	-0.1	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28117129	chr12:28163298~28190738:-
BRCA	cis	rs4981053	0.644	rs2775245	ENSG00000259001.3	RPPH1	3.29	0.00103	0.0443	0.12	0.1	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr14:20058352	chr14:20343048~20343685:-
BRCA	cis	rs711830	1	rs1318778	ENSG00000272729.1	RP11-387A1.5	-3.29	0.00103	0.0443	-0.13	-0.1	Serous invasive ovarian cancer;Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;High-grade serous ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;	chr2:176173103	chr2:176164164~176165716:-
BRCA	cis	rs3748682	0.861	rs28411034	ENSG00000212541.1	RNU6-510P	-3.29	0.00103	0.0443	-0.14	-0.1	Hypothyroidism;	chr1:37811325	chr1:37991462~37991569:+
BRCA	cis	rs7267979	1	rs2500448	ENSG00000274414.1	RP5-965G21.4	3.29	0.00103	0.0443	0.12	0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25423391	chr20:25239007~25245229:-
BRCA	cis	rs9863	0.896	rs2130382	ENSG00000270028.1	RP11-380L11.4	3.29	0.00103	0.0443	0.13	0.1	White blood cell count;	chr12:124000096	chr12:123925461~123926083:-
BRCA	cis	rs4879656	0.966	rs7869475	ENSG00000225693.1	LAGE3P1	-3.29	0.00103	0.0443	-0.11	-0.1	Menopause (age at onset);	chr9:32986250	chr9:33019682~33020165:-
BRCA	cis	rs7172689	1	rs4128768	ENSG00000271725.1	RP11-761I4.4	3.29	0.00103	0.0443	0.15	0.1	Inattentive symptoms;	chr15:81250926	chr15:81303215~81309391:-
BRCA	cis	rs7172689	1	rs66628172	ENSG00000271725.1	RP11-761I4.4	3.29	0.00103	0.0443	0.15	0.1	Inattentive symptoms;	chr15:81251482	chr15:81303215~81309391:-
BRCA	cis	rs62025270	0.632	rs62022943	ENSG00000259367.1	RP11-815J21.4	3.29	0.00103	0.0443	0.1	0.1	Idiopathic pulmonary fibrosis;	chr15:85716239	chr15:85619623~85670948:-
BRCA	cis	rs2692947	0.696	rs2969490	ENSG00000168992.4	OR7E102P	3.29	0.00103	0.0443	0.14	0.1	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96138165	chr2:95546531~95547545:+
BRCA	cis	rs875971	0.964	rs55748098	ENSG00000230189.5	GS1-124K5.2	-3.29	0.00103	0.0443	-0.08	-0.1	Aortic root size;	chr7:66298631	chr7:66409143~66490059:-
BRCA	cis	rs1348850	0.519	rs13034781	ENSG00000280374.1	RP11-337N6.3	3.29	0.00103	0.0443	0.14	0.1	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177658822	chr2:177317715~177318471:-
BRCA	cis	rs28489187	0.597	rs1001604	ENSG00000223653.4	RP11-131L23.1	-3.29	0.00103	0.0443	-0.11	-0.1	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85413841	chr1:85276715~85448124:+
BRCA	cis	rs4819052	1	rs9306123	ENSG00000223768.1	LINC00205	-3.29	0.00103	0.0443	-0.15	-0.1	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45290007	chr21:45293285~45297354:+
BRCA	cis	rs11209261	0.572	rs4622101	ENSG00000232284.6	GNG12-AS1	3.29	0.00103	0.0443	0.11	0.1	Airflow obstruction;	chr1:68334733	chr1:67832303~68202987:+
BRCA	cis	rs1730008	0.731	rs6800218	ENSG00000279311.1	RP11-170K4.2	3.29	0.00103	0.0443	0.12	0.1	Lobe attachment (rater-scored or self-reported);	chr3:158157432	chr3:158869898~158871821:+
BRCA	cis	rs2625529	0.73	rs1481861	ENSG00000261187.1	RP11-1007O24.2	3.29	0.00103	0.0443	0.11	0.1	Red blood cell count;	chr15:71947788	chr15:72465128~72466262:-
BRCA	cis	rs9900280	0.935	rs2559629	ENSG00000264808.1	RP11-802D6.1	-3.29	0.00103	0.0443	-0.12	-0.1	Mean platelet volume;	chr17:29519548	chr17:29369717~29390777:-
BRCA	cis	rs7620503	0.659	rs11707350	ENSG00000228221.4	LINC00578	3.29	0.00103	0.0444	0.14	0.1	Corneal structure;	chr3:177570055	chr3:177441921~177752305:+
BRCA	cis	rs10816359	0.846	rs12336906	ENSG00000234323.4	RP11-308N19.1	-3.29	0.00103	0.0444	-0.15	-0.1	Menarche (age at onset);	chr9:106001585	chr9:106278392~106604795:+
BRCA	cis	rs58106596	0.517	rs56272010	ENSG00000237641.1	RP11-690I21.1	-3.29	0.00103	0.0444	-0.1	-0.1	Lymphocyte counts;White blood cell count;	chr2:231800253	chr2:231789481~231789887:-
BRCA	cis	rs977987	0.806	rs17696696	ENSG00000280152.1	RP11-331F4.5	3.29	0.00103	0.0444	0.1	0.1	Dupuytren's disease;	chr16:75359454	chr16:75245994~75250077:-
BRCA	cis	rs4561483	0.864	rs190461	ENSG00000261216.1	RP11-166B2.5	-3.29	0.00103	0.0444	-0.13	-0.1	Testicular germ cell tumor;	chr16:11911888	chr16:11908208~11908916:+
BRCA	cis	rs875971	0.545	rs73148639	ENSG00000226767.1	RP11-328P23.3	3.29	0.00103	0.0444	0.13	0.1	Aortic root size;	chr7:66390342	chr7:65508773~65508944:-
BRCA	cis	rs6696239	0.956	rs1390401	ENSG00000215812.5	ZNF847P	3.29	0.00103	0.0444	0.14	0.1	Height;	chr1:227610249	chr1:227696892~227706699:-
BRCA	cis	rs2502399	0.689	rs2502372	ENSG00000228624.6	RP3-399L15.3	-3.29	0.00103	0.0444	-0.1	-0.1	Plasma clusterin levels;	chr6:113183352	chr6:113969701~114471705:+
BRCA	cis	rs7914558	1	rs11191541	ENSG00000213277.3	MARCKSL1P1	3.29	0.00103	0.0444	0.11	0.1	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103064442	chr10:103175554~103176094:+
BRCA	cis	rs12477438	0.871	rs13396584	ENSG00000231822.1	AC019097.7	3.29	0.00103	0.0444	0.12	0.1	Chronic sinus infection;	chr2:98995305	chr2:99102018~99102752:+
BRCA	cis	rs853679	0.824	rs34712084	ENSG00000204709.4	LINC01556	3.29	0.00103	0.0444	0.21	0.1	Depression;	chr6:28076050	chr6:28943877~28944537:+
BRCA	cis	rs853679	0.824	rs1321505	ENSG00000204709.4	LINC01556	3.29	0.00103	0.0444	0.21	0.1	Depression;	chr6:28085045	chr6:28943877~28944537:+
BRCA	cis	rs68130068	0.808	rs72882674	ENSG00000228389.1	AC068039.4	3.29	0.00103	0.0444	0.19	0.1	HER2 status in breast cancer;	chr2:172303896	chr2:171773482~171775844:+
BRCA	cis	rs9785234	1	rs10989532	ENSG00000175611.10	LINC00476	-3.29	0.00103	0.0444	-0.14	-0.1	Glomerular filtration rate in chronic kidney disease;	chr9:96167621	chr9:95759231~95875977:-
BRCA	cis	rs12887734	0.524	rs12588797	ENSG00000269910.1	RP11-73M18.10	-3.29	0.00103	0.0444	-0.11	-0.1	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103833683	chr14:103694516~103695050:-
BRCA	cis	rs10129255	1	rs10134517	ENSG00000231475.3	IGHV4-31	-3.29	0.00103	0.0444	-0.08	-0.1	Kawasaki disease;	chr14:106718498	chr14:106349283~106349792:-
BRCA	cis	rs1468333	0.667	rs113322698	ENSG00000206989.1	SNORD63	3.29	0.00103	0.0444	0.12	0.1	Resting heart rate;	chr5:138433887	chr5:138561043~138561110:-
BRCA	cis	rs930395	0.514	rs13153556	ENSG00000248779.1	RP11-53O19.2	-3.29	0.00103	0.0444	-0.1	-0.1	Breast cancer;	chr5:44927999	chr5:44752949~44765744:+
BRCA	cis	rs9368481	0.761	rs4713062	ENSG00000224843.5	LINC00240	3.29	0.00103	0.0444	0.12	0.1	Autism spectrum disorder or schizophrenia;	chr6:26980416	chr6:26956992~27023924:+
BRCA	cis	rs55788414	0.505	rs7190949	ENSG00000260495.1	RP11-55K13.1	3.29	0.00103	0.0444	0.11	0.1	Left ventricular obstructive tract defect (maternal effect);	chr16:81155978	chr16:81310731~81313423:-
BRCA	cis	rs7789940	0.951	rs73140055	ENSG00000231087.2	FDPSP7	-3.29	0.00103	0.0444	-0.13	-0.1	Multiple sclerosis;	chr7:76346460	chr7:76968197~76969250:-
BRCA	cis	rs7819412	0.521	rs2409720	ENSG00000154316.13	TDH	3.29	0.00103	0.0444	0.13	0.1	Triglycerides;	chr8:11180394	chr8:11339637~11368452:+
BRCA	cis	rs6479901	0.548	rs10995441	ENSG00000232075.1	MRPL35P2	-3.29	0.00103	0.0444	-0.15	-0.1	Intelligence (multi-trait analysis);	chr10:63109479	chr10:63634317~63634827:-
BRCA	cis	rs1401999	0.898	rs6443928	ENSG00000223882.1	ABCC5-AS1	-3.29	0.00103	0.0444	-0.12	-0.1	Anterior chamber depth;	chr3:184011699	chr3:184006338~184011419:+
BRCA	cis	rs11673344	0.67	rs73039188	ENSG00000267682.1	CTD-3220F14.2	-3.29	0.00103	0.0444	-0.1	-0.1	Obesity-related traits;	chr19:36922449	chr19:37337236~37337743:+
BRCA	cis	rs10924970	0.967	rs2382616	ENSG00000230026.2	RP11-382D8.5	-3.29	0.00103	0.0444	-0.11	-0.1	Asthma;	chr1:235290922	chr1:235361153~235362540:+
BRCA	cis	rs1862618	0.802	rs7733041	ENSG00000235635.1	AC016644.1	3.29	0.00103	0.0444	0.12	0.1	Initial pursuit acceleration;	chr5:56811550	chr5:56941307~56947152:+
BRCA	cis	rs2456568	0.548	rs10501809	ENSG00000250519.5	RP11-680H20.2	3.29	0.00103	0.0444	0.12	0.1	Response to serotonin reuptake inhibitors in major depressive disorder;	chr11:93933097	chr11:94238150~94279206:+
BRCA	cis	rs962856	0.619	rs1842958	ENSG00000236605.1	AC023115.4	3.29	0.00103	0.0444	0.13	0.1	Pancreatic cancer;	chr2:67349427	chr2:67324627~67325304:+
BRCA	cis	rs1510510	0.69	rs2089758	ENSG00000229915.1	AC016999.2	3.29	0.00103	0.0444	0.17	0.1	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr2:238621515	chr2:238427077~238427729:-
BRCA	cis	rs4516970	1	rs7752664	ENSG00000251988.1	RNU4ATAC18P	3.29	0.00103	0.0444	0.24	0.1	Iron status biomarkers;	chr6:159798003	chr6:159720415~159720540:-
BRCA	cis	rs2835872	0.694	rs4816568	ENSG00000230366.8	DSCR9	-3.29	0.00103	0.0444	-0.13	-0.1	Electroencephalographic traits in alcoholism;	chr21:37616044	chr21:37208503~37221736:+
BRCA	cis	rs2243480	1	rs160655	ENSG00000226002.1	RP11-460N20.5	-3.29	0.00103	0.0444	-0.17	-0.1	Diabetic kidney disease;	chr7:66068227	chr7:65084103~65100232:+
BRCA	cis	rs875971	0.862	rs11763189	ENSG00000223473.2	GS1-124K5.3	3.29	0.00103	0.0444	0.08	0.1	Aortic root size;	chr7:66518542	chr7:66491049~66493566:-
BRCA	cis	rs875971	0.964	rs1643388	ENSG00000229886.1	RP5-1132H15.3	3.29	0.00103	0.0444	0.11	0.1	Aortic root size;	chr7:66379575	chr7:66025126~66031544:-
BRCA	cis	rs875971	1	rs778722	ENSG00000229886.1	RP5-1132H15.3	3.29	0.00103	0.0444	0.11	0.1	Aortic root size;	chr7:66379841	chr7:66025126~66031544:-
BRCA	cis	rs4664293	0.51	rs66589863	ENSG00000230783.1	AC009961.2	3.29	0.00103	0.0444	0.13	0.1	Monocyte percentage of white cells;	chr2:159649684	chr2:159689217~159690291:-
BRCA	cis	rs9990333	0.562	rs75681503	ENSG00000273009.1	RP11-352G9.1	-3.29	0.00103	0.0444	-0.13	-0.1	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196095414	chr3:195913078~195913683:-
BRCA	cis	rs4835473	0.9	rs10032963	ENSG00000246448.2	RP13-578N3.3	3.29	0.00103	0.0444	0.11	0.1	Immature fraction of reticulocytes;	chr4:143733068	chr4:143700257~143865072:+
BRCA	cis	rs962856	0.619	rs7564335	ENSG00000236605.1	AC023115.4	3.29	0.00103	0.0444	0.13	0.1	Pancreatic cancer;	chr2:67352835	chr2:67324627~67325304:+
BRCA	cis	rs34779708	0.801	rs12098720	ENSG00000269952.1	RP11-324I22.3	-3.29	0.00103	0.0444	-0.13	-0.1	Inflammatory bowel disease;Crohn's disease;	chr10:35249755	chr10:35210416~35210750:+
BRCA	cis	rs34779708	0.801	rs34592588	ENSG00000269952.1	RP11-324I22.3	-3.29	0.00103	0.0444	-0.13	-0.1	Inflammatory bowel disease;Crohn's disease;	chr10:35251206	chr10:35210416~35210750:+
BRCA	cis	rs6088580	0.624	rs6120645	ENSG00000269202.1	RP4-614O4.12	-3.29	0.00103	0.0444	-0.1	-0.1	Glomerular filtration rate (creatinine);	chr20:34437366	chr20:35201747~35203288:-
BRCA	cis	rs7824557	0.767	rs6985146	ENSG00000248896.2	CTD-2135J3.3	3.29	0.00103	0.0444	0.13	0.1	Retinal vascular caliber;	chr8:11313212	chr8:10729314~10771392:+
BRCA	cis	rs4374383	0.962	rs4524124	ENSG00000243389.1	AC012442.5	-3.29	0.00103	0.0444	-0.13	-0.1	Hepatitis C induced liver fibrosis;	chr2:112014626	chr2:112589040~112614431:+
BRCA	cis	rs863345	0.625	rs6663286	ENSG00000176320.2	RP11-404O13.5	-3.29	0.00103	0.0444	-0.11	-0.1	Pneumococcal bacteremia;	chr1:158503935	chr1:158197922~158203877:-
BRCA	cis	rs2274273	1	rs10140857	ENSG00000259318.1	RP11-454L9.2	3.29	0.00103	0.0444	0.09	0.1	Protein biomarker;	chr14:55152893	chr14:55394940~55395233:-
BRCA	cis	rs740363	0.818	rs1681723	ENSG00000281599.1	AC023283.1	3.29	0.00103	0.0444	0.1	0.1	Heart failure;	chr10:116832104	chr10:116827489~116827564:-
BRCA	cis	rs7142881	0.815	rs12888673	ENSG00000258648.1	UBE2CP1	-3.29	0.00103	0.0444	-0.11	-0.1	Response to iloperidone treatment (QT prolongation);	chr14:31682089	chr14:30683045~30683598:-
BRCA	cis	rs6728642	0.708	rs115507803	ENSG00000275655.1	Metazoa_SRP	-3.29	0.00103	0.0444	-0.24	-0.1	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:97086317	chr2:97100587~97100874:+
BRCA	cis	rs965469	0.947	rs1854834	ENSG00000215063.3	RPL21P2	3.29	0.00103	0.0444	0.14	0.1	IFN-related cytopenia;	chr20:3395972	chr20:4059633~4060113:-
BRCA	cis	rs7246967	0.932	rs35968517	ENSG00000241282.1	RPL34P33	3.29	0.00103	0.0445	0.16	0.1	Bronchopulmonary dysplasia;	chr19:22844238	chr19:22699352~22699685:+
BRCA	cis	rs73215715	0.517	rs74723210	ENSG00000238358.2	RP5-1121E10.2	3.29	0.00103	0.0445	0.14	0.1	Heschl's gyrus morphology;	chr7:90015649	chr7:90119299~90122890:-
BRCA	cis	rs73215715	0.517	rs10452942	ENSG00000238358.2	RP5-1121E10.2	3.29	0.00103	0.0445	0.14	0.1	Heschl's gyrus morphology;	chr7:90015831	chr7:90119299~90122890:-
BRCA	cis	rs73215715	0.517	rs10452946	ENSG00000238358.2	RP5-1121E10.2	3.29	0.00103	0.0445	0.14	0.1	Heschl's gyrus morphology;	chr7:90016421	chr7:90119299~90122890:-
BRCA	cis	rs10819861	0.645	rs10739800	ENSG00000175611.10	LINC00476	3.29	0.00103	0.0445	0.11	0.1	Electrocardiographic traits;	chr9:96090888	chr9:95759231~95875977:-
BRCA	cis	rs6736093	0.736	rs10864895	ENSG00000236307.2	EEF1E1P1	-3.29	0.00103	0.0445	-0.11	-0.1	Coronary artery disease;	chr2:112006817	chr2:111887914~111888741:+
BRCA	cis	rs258892	0.842	rs11952089	ENSG00000272525.1	RP11-79P5.9	-3.29	0.00103	0.0445	-0.13	-0.1	Small cell lung carcinoma;	chr5:72724681	chr5:73497550~73498293:-
BRCA	cis	rs258892	0.793	rs16900954	ENSG00000272525.1	RP11-79P5.9	-3.29	0.00103	0.0445	-0.13	-0.1	Small cell lung carcinoma;	chr5:72725364	chr5:73497550~73498293:-
BRCA	cis	rs258892	0.793	rs13168325	ENSG00000272525.1	RP11-79P5.9	-3.29	0.00103	0.0445	-0.13	-0.1	Small cell lung carcinoma;	chr5:72725693	chr5:73497550~73498293:-
BRCA	cis	rs258892	0.895	rs6452657	ENSG00000272525.1	RP11-79P5.9	-3.29	0.00103	0.0445	-0.13	-0.1	Small cell lung carcinoma;	chr5:72727091	chr5:73497550~73498293:-
BRCA	cis	rs13008689	0.875	rs17443836	ENSG00000236790.4	LINC00299	-3.29	0.00103	0.0445	-0.12	-0.1	Longevity;	chr2:8389213	chr2:8007771~8383621:-
BRCA	cis	rs6600671	0.719	rs9728991	ENSG00000275538.1	RNVU1-19	3.29	0.00103	0.0445	0.12	0.1	Hip geometry;	chr1:121522281	chr1:120850819~120850985:-
BRCA	cis	rs886427	0.838	rs4149782	ENSG00000260565.5	CTD-2270P14.1	-3.29	0.00103	0.0445	-0.08	-0.1	Metabolic syndrome;	chr16:2977295	chr16:2660349~2673444:-
BRCA	cis	rs962856	0.575	rs7597266	ENSG00000236780.4	AC078941.1	3.29	0.00103	0.0445	0.15	0.1	Pancreatic cancer;	chr2:67394509	chr2:67123357~67215319:-
BRCA	cis	rs7258465	0.931	rs8107347	ENSG00000273654.1	CTB-52I2.4	-3.29	0.00103	0.0445	-0.13	-0.1	Breast cancer;	chr19:18501938	chr19:18022403~18032099:+
BRCA	cis	rs7258465	0.931	rs8107351	ENSG00000273654.1	CTB-52I2.4	-3.29	0.00103	0.0445	-0.13	-0.1	Breast cancer;	chr19:18501948	chr19:18022403~18032099:+
BRCA	cis	rs1389724	0.632	rs11102160	ENSG00000231346.4	LINC01160	-3.29	0.00103	0.0445	-0.13	-0.1	Schizophrenia;	chr1:110788802	chr1:111599655~111608723:-
BRCA	cis	rs987724	0.515	rs4680309	ENSG00000243926.1	TIPARP-AS1	3.29	0.00103	0.0445	0.14	0.1	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156865807	chr3:156671862~156674378:-
BRCA	cis	rs987724	0.515	rs2874488	ENSG00000243926.1	TIPARP-AS1	3.29	0.00103	0.0445	0.14	0.1	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156868027	chr3:156671862~156674378:-
BRCA	cis	rs987724	0.515	rs6765353	ENSG00000243926.1	TIPARP-AS1	3.29	0.00103	0.0445	0.14	0.1	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156868755	chr3:156671862~156674378:-
BRCA	cis	rs987724	0.515	rs7638330	ENSG00000243926.1	TIPARP-AS1	3.29	0.00103	0.0445	0.14	0.1	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156869976	chr3:156671862~156674378:-
BRCA	cis	rs875971	0.964	rs778721	ENSG00000229886.1	RP5-1132H15.3	3.29	0.00103	0.0445	0.11	0.1	Aortic root size;	chr7:66380410	chr7:66025126~66031544:-
BRCA	cis	rs4308124	0.708	rs6749633	ENSG00000271590.1	RP11-181E10.3	-3.29	0.00103	0.0445	-0.11	-0.1	Vitiligo;	chr2:111230439	chr2:111210995~111212476:-
BRCA	cis	rs875971	0.862	rs801195	ENSG00000223473.2	GS1-124K5.3	-3.29	0.00103	0.0445	-0.08	-0.1	Aortic root size;	chr7:66561128	chr7:66491049~66493566:-
BRCA	cis	rs713477	0.692	rs56280202	ENSG00000186615.9	KTN1-AS1	-3.29	0.00103	0.0445	-0.11	-0.1	Pediatric bone mineral content (femoral neck);	chr14:55444483	chr14:55499278~55580110:-
BRCA	cis	rs11733284	0.962	rs4694879	ENSG00000259959.1	RP11-121C2.2	3.29	0.00103	0.0445	0.1	0.1	Gout;Renal underexcretion gout;	chr4:48030339	chr4:47840122~47844339:-
BRCA	cis	rs8062405	1	rs72793812	ENSG00000261766.1	RP11-22P6.2	-3.29	0.00103	0.0445	-0.11	-0.1	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28829060	chr16:28862166~28863340:-
BRCA	cis	rs6946131	0.593	rs2699232	ENSG00000235207.1	TUBBP6	-3.29	0.00103	0.0445	-0.12	-0.1	Systemic lupus erythematosus;	chr7:54766516	chr7:55645620~55646951:+
BRCA	cis	rs78487399	0.808	rs6544668	ENSG00000234936.1	AC010883.5	3.29	0.00103	0.0445	0.15	0.1	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43505349	chr2:43229573~43233394:+
BRCA	cis	rs78487399	0.808	rs7578597	ENSG00000234936.1	AC010883.5	3.29	0.00103	0.0445	0.15	0.1	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43505684	chr2:43229573~43233394:+
BRCA	cis	rs78487399	0.808	rs6544669	ENSG00000234936.1	AC010883.5	3.29	0.00103	0.0445	0.15	0.1	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43509032	chr2:43229573~43233394:+
BRCA	cis	rs7176527	0.579	rs366717	ENSG00000176700.18	SCAND2P	3.29	0.00103	0.0445	0.11	0.1	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84544848	chr15:84631451~84647478:+
BRCA	cis	rs28530618	0.87	rs6058790	ENSG00000175730.8	BAK1P1	3.29	0.00103	0.0445	0.12	0.1	Birth weight;	chr20:32659515	chr20:32690180~32690815:-
BRCA	cis	rs7781266	0.79	rs11766325	ENSG00000226205.1	AC007790.4	3.29	0.00103	0.0445	0.15	0.1	Educational attainment (college completion);	chr7:133438862	chr7:133732493~133733595:-
BRCA	cis	rs11686241	0.748	rs11892361	ENSG00000241520.1	AC098820.4	-3.29	0.00103	0.0445	-0.17	-0.1	Cancer;	chr2:216424232	chr2:216483032~216487196:-
BRCA	cis	rs6723162	0.868	rs2192403	ENSG00000277764.1	Vax2os1_3	-3.29	0.00103	0.0445	-0.12	-0.1	Neurocognitive impairment in HIV-1 infection (dichotomous);	chr2:70886008	chr2:70900155~70900351:+
BRCA	cis	rs34421088	0.585	rs1390950	ENSG00000254507.2	RP11-481A20.10	3.29	0.00103	0.0445	0.13	0.1	Neuroticism;	chr8:11738320	chr8:12003400~12004082:-
BRCA	cis	rs59551326	0.85	rs66841913	ENSG00000234883.3	MIR155HG	3.29	0.00103	0.0445	0.14	0.1	Alcohol dependence;	chr21:25337662	chr21:25561909~25575168:+
BRCA	cis	rs7000551	0.715	rs2469745	ENSG00000254272.1	RP11-382J24.2	-3.29	0.00103	0.0445	-0.12	-0.1	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr8:22485951	chr8:22492631~22493044:+
BRCA	cis	rs877819	0.5	rs11101517	ENSG00000228403.1	RP11-563N6.6	-3.29	0.00103	0.0445	-0.12	-0.1	Systemic lupus erythematosus;	chr10:48823456	chr10:48878022~48878649:+
BRCA	cis	rs2017387	0.572	rs283518	ENSG00000161643.11	SIGLEC16	-3.29	0.00103	0.0445	-0.2	-0.1	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:49989307	chr19:49969673~49975814:+
BRCA	cis	rs2113818	0.597	rs2059428	ENSG00000264370.1	MIR3125	-3.29	0.00103	0.0445	-0.12	-0.1	Optic cup area;	chr2:12752803	chr2:12737367~12737444:+
BRCA	cis	rs7226408	0.857	rs11081983	ENSG00000267707.2	RP11-95O2.5	3.29	0.00103	0.0445	0.14	0.1	Obesity-related traits;	chr18:37086716	chr18:37243776~37247506:+
BRCA	cis	rs6951245	0.744	rs10265758	ENSG00000224079.1	AC091729.7	-3.29	0.00103	0.0445	-0.16	-0.1	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1132882	chr7:1074450~1078036:+
BRCA	cis	rs7097397	0.591	rs17836440	ENSG00000270025.2	BMS1P7	3.29	0.00103	0.0445	0.12	0.1	Systemic lupus erythematosus;	chr10:48768184	chr10:48050282~48060016:-
BRCA	cis	rs60843830	1	rs3791221	ENSG00000223751.1	AC116609.2	3.29	0.00103	0.0445	0.13	0.1	Spherical equivalent (joint analysis main effects and education interaction);	chr2:226933	chr2:742488~747767:+
BRCA	cis	rs4578769	0.765	rs998184	ENSG00000265939.1	UBE2CP2	-3.29	0.00103	0.0445	-0.13	-0.1	Eosinophil percentage of white cells;	chr18:22925006	chr18:22900486~22900995:-
BRCA	cis	rs4578769	0.765	rs4800440	ENSG00000265939.1	UBE2CP2	-3.29	0.00103	0.0445	-0.13	-0.1	Eosinophil percentage of white cells;	chr18:22928158	chr18:22900486~22900995:-
BRCA	cis	rs783540	0.967	rs783529	ENSG00000274376.3	ADAMTS7P1	-3.29	0.00103	0.0445	-0.11	-0.1	Schizophrenia;	chr15:82599231	chr15:82298553~82334609:+
BRCA	cis	rs6089829	0.962	rs2277768	ENSG00000233017.2	RP5-908M14.5	3.29	0.00103	0.0445	0.12	0.1	Prostate cancer (SNP x SNP interaction);	chr20:63035471	chr20:62427827~62447621:+
BRCA	cis	rs6840360	0.571	rs17275536	ENSG00000270265.1	RP11-731D1.4	-3.29	0.00103	0.0445	-0.12	-0.1	Intelligence (multi-trait analysis);	chr4:151577473	chr4:151333775~151353224:-
BRCA	cis	rs55883249	1	rs62119428	ENSG00000217258.2	AC007249.3	3.29	0.00103	0.0445	0.16	0.1	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:9603203	chr2:10452319~10455552:+
BRCA	cis	rs55883249	1	rs62119429	ENSG00000217258.2	AC007249.3	3.29	0.00103	0.0445	0.16	0.1	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:9603456	chr2:10452319~10455552:+
BRCA	cis	rs11587682	0.714	rs12121133	ENSG00000228126.1	FALEC	3.29	0.00103	0.0445	0.13	0.1	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr1:150446621	chr1:150515757~150518032:+
BRCA	cis	rs1436904	0.805	rs1175743	ENSG00000260372.5	AQP4-AS1	-3.29	0.00103	0.0445	-0.11	-0.1	Breast cancer;	chr18:27011236	chr18:26655742~27190698:+
BRCA	cis	rs4356203	0.905	rs17472886	ENSG00000184669.7	OR7E14P	-3.29	0.00103	0.0445	-0.13	-0.1	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17064620	chr11:17013998~17053024:+
BRCA	cis	rs7017914	0.967	rs2100908	ENSG00000246366.5	RP11-382J12.1	3.29	0.00103	0.0445	0.11	0.1	Bone mineral density;	chr8:70671075	chr8:70608577~70663279:+
BRCA	cis	rs4723738	1	rs4723733	ENSG00000233306.2	TRGV2	3.29	0.00103	0.0445	0.09	0.1	Treatment response for severe sepsis;	chr7:38184011	chr7:38362864~38363518:-
BRCA	cis	rs9341808	0.754	rs1015158	ENSG00000279022.1	RP11-250B2.4	3.29	0.00103	0.0445	0.12	0.1	Sitting height ratio;	chr6:80236028	chr6:80440730~80441172:+
BRCA	cis	rs9341808	0.791	rs1324122	ENSG00000279022.1	RP11-250B2.4	3.29	0.00103	0.0445	0.12	0.1	Sitting height ratio;	chr6:80236344	chr6:80440730~80441172:+
BRCA	cis	rs6540556	0.723	rs6752	ENSG00000236136.1	ADORA2BP1	-3.29	0.00103	0.0445	-0.13	-0.1	Red blood cell count;	chr1:209734755	chr1:209744373~209745214:+
BRCA	cis	rs12317459	1	rs10082955	ENSG00000213270.5	RPL6P25	3.29	0.00103	0.0445	0.14	0.1	Prostate cancer (SNP x SNP interaction);	chr12:82775518	chr12:83151331~83152190:+
BRCA	cis	rs11673344	0.504	rs4239587	ENSG00000267672.1	CTD-2293H3.1	3.29	0.00103	0.0445	0.12	0.1	Obesity-related traits;	chr19:37136211	chr19:37091341~37092564:+
BRCA	cis	rs11098499	0.863	rs3775845	ENSG00000225892.3	RP11-384K6.2	3.29	0.00103	0.0445	0.1	0.1	Corneal astigmatism;	chr4:119511292	chr4:118632274~118634759:+
BRCA	cis	rs4848143	0.64	rs13405954	ENSG00000236859.5	NIFK-AS1	-3.29	0.00103	0.0445	-0.11	-0.1	Capecitabine sensitivity;	chr2:121041228	chr2:121649650~121728208:+
BRCA	cis	rs4848143	0.64	rs13406192	ENSG00000236859.5	NIFK-AS1	-3.29	0.00103	0.0445	-0.11	-0.1	Capecitabine sensitivity;	chr2:121041450	chr2:121649650~121728208:+
BRCA	cis	rs11009175	0.547	rs12256126	ENSG00000273038.2	RP11-479G22.8	3.29	0.00103	0.0445	0.15	0.1	Depression (quantitative trait);	chr10:33106704	chr10:32887255~32889311:-
BRCA	cis	rs68170813	0.617	rs2283041	ENSG00000241764.3	AC002467.7	3.29	0.00103	0.0445	0.18	0.1	Coronary artery disease;	chr7:107549970	chr7:107742817~107744581:-
BRCA	cis	rs55962025	0.557	rs2298969	ENSG00000249047.2	COX6B1P5	-3.29	0.00103	0.0445	-0.11	-0.1	Parental longevity (mother's age at death);	chr4:3184517	chr4:2234251~2234499:+
BRCA	cis	rs7613875	0.62	rs2526747	ENSG00000226913.1	BSN-AS2	-3.29	0.00103	0.0446	-0.1	-0.1	Body mass index;	chr3:50045481	chr3:49549306~49554366:-
BRCA	cis	rs13136331	0.684	rs13123354	ENSG00000249001.4	RP11-742B18.1	-3.29	0.00103	0.0446	-0.14	-0.1	Sitting height ratio;	chr4:87808760	chr4:87568035~87733956:-
BRCA	cis	rs6005807	0.777	rs9620809	ENSG00000272858.1	CTA-292E10.8	-3.29	0.00103	0.0446	-0.19	-0.1	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28628703	chr22:28814914~28815662:+
BRCA	cis	rs6005807	0.843	rs9625516	ENSG00000272858.1	CTA-292E10.8	-3.29	0.00103	0.0446	-0.19	-0.1	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28628742	chr22:28814914~28815662:+
BRCA	cis	rs477895	0.653	rs34089806	ENSG00000256940.1	RP11-783K16.5	3.29	0.00103	0.0446	0.14	0.1	Mean platelet volume;	chr11:64120515	chr11:64245964~64248217:+
BRCA	cis	rs8062405	0.755	rs62034325	ENSG00000261766.1	RP11-22P6.2	-3.29	0.00103	0.0446	-0.1	-0.1	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28527319	chr16:28862166~28863340:-
BRCA	cis	rs7200543	1	rs55727637	ENSG00000207425.1	Y_RNA	-3.29	0.00103	0.0446	-0.12	-0.1	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15051395	chr16:14915457~14915556:-
BRCA	cis	rs10501293	1	rs2114087	ENSG00000252652.1	Y_RNA	3.29	0.00103	0.0446	0.12	0.1	Cognitive performance;	chr11:43111452	chr11:43331261~43331356:+
BRCA	cis	rs886774	0.932	rs2007417	ENSG00000273055.1	CTB-13F3.1	-3.29	0.00103	0.0446	-0.11	-0.1	Ulcerative colitis;	chr7:107859802	chr7:107942116~107942740:+
BRCA	cis	rs2411233	1	rs964144	ENSG00000259278.1	RP11-62C7.2	3.29	0.00103	0.0446	0.12	0.1	Platelet count;	chr15:38984117	chr15:39019233~39024918:+
BRCA	cis	rs2613964	0.626	rs4528911	ENSG00000240057.4	RP11-572M11.4	-3.29	0.00103	0.0446	-0.13	-0.1	Pediatric bone mineral content (spine);Pediatric bone mineral density (spine);	chr3:113132234	chr3:113019532~113183301:+
BRCA	cis	rs202072	1	rs202053	ENSG00000215022.6	RP1-257A7.4	-3.29	0.00103	0.0446	-0.14	-0.1	HIV-1 viral setpoint;	chr6:13273411	chr6:13264861~13295586:-
BRCA	cis	rs2832077	0.943	rs11701445	ENSG00000215533.7	LINC00189	3.29	0.00103	0.0446	0.14	0.1	Cognitive test performance;	chr21:28788485	chr21:29193480~29288205:+
BRCA	cis	rs7586085	0.837	rs13429321	ENSG00000229195.1	AC009495.4	-3.29	0.00103	0.0446	-0.12	-0.1	Total body bone mineral density;	chr2:165748500	chr2:165794857~165846091:-
BRCA	cis	rs9796	0.621	rs557864	ENSG00000223313.1	RNU6-516P	-3.29	0.00103	0.0446	-0.12	-0.1	Menopause (age at onset);	chr15:41179160	chr15:40529570~40529673:+
BRCA	cis	rs111342015	1	rs111342015	ENSG00000272170.1	RP11-387M24.5	3.29	0.00103	0.0446	0.22	0.1	Breast cancer;	chr6:43259403	chr6:43074331~43074739:-
BRCA	cis	rs2835872	0.965	rs2835848	ENSG00000230366.8	DSCR9	-3.29	0.00103	0.0446	-0.14	-0.1	Electroencephalographic traits in alcoholism;	chr21:37638771	chr21:37208503~37221736:+
BRCA	cis	rs2835872	0.965	rs73222307	ENSG00000230366.8	DSCR9	-3.29	0.00103	0.0446	-0.14	-0.1	Electroencephalographic traits in alcoholism;	chr21:37639923	chr21:37208503~37221736:+
BRCA	cis	rs875971	0.895	rs4718349	ENSG00000273448.1	RP11-166O4.6	3.29	0.00103	0.0446	0.09	0.1	Aortic root size;	chr7:66444024	chr7:67333047~67334383:+
BRCA	cis	rs875971	1	rs2042133	ENSG00000273448.1	RP11-166O4.6	3.29	0.00103	0.0446	0.09	0.1	Aortic root size;	chr7:66466935	chr7:67333047~67334383:+
BRCA	cis	rs875971	0.964	rs2161065	ENSG00000273448.1	RP11-166O4.6	3.29	0.00103	0.0446	0.09	0.1	Aortic root size;	chr7:66467918	chr7:67333047~67334383:+
BRCA	cis	rs875971	0.862	rs12698521	ENSG00000273448.1	RP11-166O4.6	3.29	0.00103	0.0446	0.09	0.1	Aortic root size;	chr7:66474502	chr7:67333047~67334383:+
BRCA	cis	rs1998359	0.715	rs61977077	ENSG00000259087.4	RP11-356O9.2	3.29	0.00104	0.0446	0.11	0.1	Self-reported allergy;	chr14:37706340	chr14:37556158~37567095:-
BRCA	cis	rs1005277	0.579	rs1780137	ENSG00000276805.1	RP11-291L22.6	3.29	0.00104	0.0446	0.11	0.1	Extrinsic epigenetic age acceleration;	chr10:38212547	chr10:38451030~38451785:+
BRCA	cis	rs10876993	0.928	rs1689587	ENSG00000269903.1	RP11-571M6.18	3.29	0.00104	0.0446	0.13	0.1	Celiac disease or Rheumatoid arthritis;	chr12:57681615	chr12:57814494~57814926:+
BRCA	cis	rs7017914	0.87	rs34282253	ENSG00000246366.5	RP11-382J12.1	3.29	0.00104	0.0446	0.11	0.1	Bone mineral density;	chr8:70670131	chr8:70608577~70663279:+
BRCA	cis	rs6582630	0.554	rs7299735	ENSG00000257718.1	RP11-396F22.1	-3.29	0.00104	0.0446	-0.1	-0.1	Drug-induced liver injury (flucloxacillin);	chr12:38057088	chr12:38906451~38909592:+
BRCA	cis	rs459482	0.508	rs467558	ENSG00000227702.1	LINC00111	3.29	0.00104	0.0446	0.12	0.1	IgG glycosylation;	chr21:41439468	chr21:41679181~41697336:+
BRCA	cis	rs4934494	0.911	rs6586213	ENSG00000235100.3	RP11-80H5.9	-3.29	0.00104	0.0446	-0.13	-0.1	Red blood cell count;	chr10:89656327	chr10:89667181~89699671:-
BRCA	cis	rs4834272	0.662	rs2106993	ENSG00000249509.1	RP11-402J6.1	-3.29	0.00104	0.0446	-0.11	-0.1	Body mass index;	chr4:112383186	chr4:112515385~112546881:+
BRCA	cis	rs6460942	0.778	rs17444259	ENSG00000226690.5	AC005281.1	3.29	0.00104	0.0446	0.17	0.1	Coronary artery disease;	chr7:12422802	chr7:12496429~12541910:+
BRCA	cis	rs526231	0.747	rs434830	ENSG00000175749.11	EIF3KP1	3.29	0.00104	0.0446	0.14	0.1	Primary biliary cholangitis;	chr5:103263605	chr5:103032376~103033031:+
BRCA	cis	rs80226907	1	rs76647998	ENSG00000258413.1	RP11-665C16.6	-3.29	0.00104	0.0446	-0.26	-0.1	Mean platelet volume;	chr14:55310874	chr14:55262767~55272075:-
BRCA	cis	rs80226907	0.634	rs77941566	ENSG00000186615.9	KTN1-AS1	-3.29	0.00104	0.0446	-0.2	-0.1	Mean platelet volume;	chr14:55439459	chr14:55499278~55580110:-
BRCA	cis	rs7927592	0.956	rs10896337	ENSG00000254610.1	RP5-903G2.2	-3.29	0.00104	0.0446	-0.14	-0.1	Total body bone mineral density;	chr11:68516768	chr11:67934563~67939774:-
BRCA	cis	rs7089973	0.966	rs17721283	ENSG00000236799.1	RP11-383C6.2	-3.29	0.00104	0.0446	-0.13	-0.1	Bipolar disorder or attention deficit hyperactivity disorder;	chr10:114884382	chr10:114994657~114996593:+
BRCA	cis	rs2638953	0.604	rs10843100	ENSG00000247934.4	RP11-967K21.1	-3.29	0.00104	0.0446	-0.15	-0.1	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28117101	chr12:28163298~28190738:-
BRCA	cis	rs10090774	0.965	rs12548549	ENSG00000280303.2	ERICD	3.29	0.00104	0.0446	0.12	0.1	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140957173	chr8:140636281~140638283:+
BRCA	cis	rs7584330	0.868	rs2325839	ENSG00000222022.1	AC112721.1	3.29	0.00104	0.0446	0.13	0.1	Prostate cancer;	chr2:237477643	chr2:237421420~237425276:-
BRCA	cis	rs7927592	0.913	rs7116994	ENSG00000254610.1	RP5-903G2.2	-3.29	0.00104	0.0446	-0.14	-0.1	Total body bone mineral density;	chr11:68487159	chr11:67934563~67939774:-
BRCA	cis	rs6493487	0.556	rs8034718	ENSG00000259298.1	RP11-562A8.4	-3.29	0.00104	0.0446	-0.12	-0.1	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr15:50815656	chr15:50497195~50498744:-
BRCA	cis	rs35520189	0.591	rs11696039	ENSG00000231747.1	AC079922.2	-3.29	0.00104	0.0446	-0.11	-0.1	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:112940501	chr2:112621809~112622167:-
BRCA	cis	rs3739034	1	rs3739034	ENSG00000224043.6	CCNT2-AS1	3.29	0.00104	0.0446	0.17	0.1	Gut microbiome composition (winter);	chr2:134725811	chr2:134735464~134918710:-
BRCA	cis	rs7017914	1	rs7017914	ENSG00000246366.5	RP11-382J12.1	3.29	0.00104	0.0446	0.11	0.1	Bone mineral density;	chr8:70678968	chr8:70608577~70663279:+
BRCA	cis	rs4728142	0.604	rs2272347	ENSG00000229413.2	RP11-274B21.12	3.29	0.00104	0.0446	0.09	0.1	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128979361	chr7:128653690~128654019:-
BRCA	cis	rs8024058	0.568	rs11559060	ENSG00000261549.2	RP11-320A16.1	-3.29	0.00104	0.0446	-0.18	-0.1	Night sleep phenotypes;	chr15:88631278	chr15:88989519~88990245:-
BRCA	cis	rs3822411	0.565	rs2930055	ENSG00000272324.4	CTD-2154B17.4	-3.29	0.00104	0.0446	-0.14	-0.1	Sum eosinophil basophil counts;	chr5:10710035	chr5:10761065~10770294:+
BRCA	cis	rs2904524	1	rs17107935	ENSG00000257613.1	LINC01481	-3.29	0.00104	0.0446	-0.17	-0.1	Amyotrophic lateral sclerosis (age of onset);	chr12:70286084	chr12:70219132~70221862:-
BRCA	cis	rs8098244	0.964	rs948435	ENSG00000265752.2	RP11-403A21.1	3.29	0.00104	0.0446	0.13	0.1	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23803808	chr18:23957754~23982556:-
BRCA	cis	rs7474896	1	rs2799495	ENSG00000120555.12	SEPT7P9	-3.29	0.00104	0.0446	-0.18	-0.1	Obesity (extreme);	chr10:37949056	chr10:38383069~38402916:-
BRCA	cis	rs7586085	1	rs6710388	ENSG00000229195.1	AC009495.4	-3.29	0.00104	0.0446	-0.12	-0.1	Total body bone mineral density;	chr2:165726631	chr2:165794857~165846091:-
BRCA	cis	rs1436904	0.967	rs1154215	ENSG00000260372.5	AQP4-AS1	-3.29	0.00104	0.0446	-0.11	-0.1	Breast cancer;	chr18:26964338	chr18:26655742~27190698:+
BRCA	cis	rs6571943	0.963	rs1950326	ENSG00000258526.4	RP11-111A21.1	-3.29	0.00104	0.0446	-0.15	-0.1	Verbal memory performance (residualized delayed recall level);	chr14:39570112	chr14:39474840~39513780:+
BRCA	cis	rs2243480	1	rs402418	ENSG00000226002.1	RP11-460N20.5	-3.29	0.00104	0.0446	-0.17	-0.1	Diabetic kidney disease;	chr7:66044482	chr7:65084103~65100232:+
BRCA	cis	rs67133203	0.851	rs4768964	ENSG00000257246.1	RP11-416A17.6	3.29	0.00104	0.0446	0.15	0.1	Urinary tract infection frequency;	chr12:51114290	chr12:51124628~51125381:-
BRCA	cis	rs9436747	0.626	rs7513047	ENSG00000237852.1	RP4-630A11.3	3.29	0.00104	0.0446	0.13	0.1	Myeloid white cell count;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;White blood cell count;Sum neutrophil eosinophil counts;	chr1:65484657	chr1:65486406~65494188:+
BRCA	cis	rs4860223	0.951	rs9991979	ENSG00000270292.1	RP11-453E17.4	-3.29	0.00104	0.0446	-0.14	-0.1	Response to platinum-based chemotherapy (cisplatin);	chr4:66755001	chr4:67725183~67726395:-
BRCA	cis	rs495337	1	rs4809769	ENSG00000224397.4	LINC01272	-3.29	0.00104	0.0446	-0.1	-0.1	Psoriasis;	chr20:49962627	chr20:50267486~50279795:+
BRCA	cis	rs10971721	0.822	rs10971867	ENSG00000279489.1	RP11-392A14.8	3.29	0.00104	0.0446	0.21	0.1	Body mass index;	chr9:34046758	chr9:35001913~35003663:+
BRCA	cis	rs10971721	0.822	rs72729361	ENSG00000279489.1	RP11-392A14.8	3.29	0.00104	0.0446	0.21	0.1	Body mass index;	chr9:34047525	chr9:35001913~35003663:+
BRCA	cis	rs801193	0.66	rs10950049	ENSG00000229886.1	RP5-1132H15.3	3.29	0.00104	0.0446	0.11	0.1	Aortic root size;	chr7:66765873	chr7:66025126~66031544:-
BRCA	cis	rs1178127	0.765	rs1178133	ENSG00000232821.1	AC003986.6	3.29	0.00104	0.0446	0.14	0.1	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);	chr7:18732408	chr7:19112474~19114271:+
BRCA	cis	rs1030420	0.799	rs10112574	ENSG00000200714.1	Y_RNA	-3.29	0.00104	0.0446	-0.14	-0.1	Blood metabolite levels;	chr8:66469033	chr8:65592731~65592820:+
BRCA	cis	rs2905347	0.757	rs1006509	ENSG00000230658.1	KLHL7-AS1	3.29	0.00104	0.0447	0.13	0.1	Major depression and alcohol dependence;	chr7:22658847	chr7:23101228~23105703:-
BRCA	cis	rs17711722	0.727	rs2658585	ENSG00000229180.5	GS1-124K5.11	3.29	0.00104	0.0447	0.09	0.1	Calcium levels;	chr7:65996954	chr7:66526088~66542624:-
BRCA	cis	rs853679	0.517	rs12332979	ENSG00000226314.6	ZNF192P1	-3.29	0.00104	0.0447	-0.15	-0.1	Depression;	chr6:28173770	chr6:28161781~28169594:+
BRCA	cis	rs853679	0.517	rs67878650	ENSG00000226314.6	ZNF192P1	-3.29	0.00104	0.0447	-0.15	-0.1	Depression;	chr6:28174809	chr6:28161781~28169594:+
BRCA	cis	rs853679	0.569	rs9348798	ENSG00000226314.6	ZNF192P1	-3.29	0.00104	0.0447	-0.15	-0.1	Depression;	chr6:28175233	chr6:28161781~28169594:+
BRCA	cis	rs853679	0.517	rs9380065	ENSG00000226314.6	ZNF192P1	-3.29	0.00104	0.0447	-0.15	-0.1	Depression;	chr6:28176973	chr6:28161781~28169594:+
BRCA	cis	rs1510510	0.867	rs9287633	ENSG00000229915.1	AC016999.2	3.29	0.00104	0.0447	0.17	0.1	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;	chr2:238602892	chr2:238427077~238427729:-
BRCA	cis	rs8056446	0.837	rs4888748	ENSG00000261837.1	RP11-264L1.3	-3.29	0.00104	0.0447	-0.11	-0.1	Pulmonary function (smoking interaction);	chr16:78139257	chr16:78534374~78535648:+
BRCA	cis	rs7520050	0.966	rs785492	ENSG00000226957.1	RP4-533D7.4	3.29	0.00104	0.0447	0.11	0.1	Reticulocyte count;Red blood cell count;	chr1:46117935	chr1:46046818~46048368:+
BRCA	cis	rs6557876	1	rs1008974	ENSG00000228451.3	SDAD1P1	3.29	0.00104	0.0447	0.14	0.1	Systolic blood pressure;	chr8:26046972	chr8:26379259~26382953:-
BRCA	cis	rs7795541	0.683	rs104987	ENSG00000230658.1	KLHL7-AS1	-3.29	0.00104	0.0447	-0.14	-0.1	Morning vs. evening chronotype;	chr7:24058110	chr7:23101228~23105703:-
BRCA	cis	rs7267979	1	rs2500424	ENSG00000274414.1	RP5-965G21.4	3.29	0.00104	0.0447	0.12	0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25411333	chr20:25239007~25245229:-
BRCA	cis	rs848490	0.889	rs11767942	ENSG00000214293.7	APTR	3.29	0.00104	0.0447	0.12	0.1	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77589922	chr7:77657660~77696265:-
BRCA	cis	rs3735485	0.738	rs10247593	ENSG00000201772.1	SNORA5C	3.29	0.00104	0.0447	0.13	0.1	White blood cell count;Sum basophil neutrophil counts;Neutrophil count;Granulocyte percentage of myeloid white cells;Monocyte percentage of white cells;Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Lymphocyte counts;	chr7:45056119	chr7:45104906~45105042:-
BRCA	cis	rs3735485	0.598	rs10251344	ENSG00000201772.1	SNORA5C	3.29	0.00104	0.0447	0.13	0.1	White blood cell count;Sum basophil neutrophil counts;Neutrophil count;Granulocyte percentage of myeloid white cells;Monocyte percentage of white cells;Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Lymphocyte counts;	chr7:45056837	chr7:45104906~45105042:-
BRCA	cis	rs1843834	0.505	rs940317	ENSG00000274629.1	RP11-92F20.1	-3.29	0.00104	0.0447	-0.13	-0.1	IgE levels in asthmatics (D.p. specific);	chr2:224493401	chr2:224464682~224474500:+
BRCA	cis	rs59551326	0.85	rs66592092	ENSG00000234883.3	MIR155HG	3.29	0.00104	0.0447	0.14	0.1	Alcohol dependence;	chr21:25336346	chr21:25561909~25575168:+
BRCA	cis	rs59551326	0.85	rs2155958	ENSG00000234883.3	MIR155HG	3.29	0.00104	0.0447	0.14	0.1	Alcohol dependence;	chr21:25336943	chr21:25561909~25575168:+
BRCA	cis	rs875971	0.54	rs4717275	ENSG00000230189.5	GS1-124K5.2	-3.29	0.00104	0.0447	-0.08	-0.1	Aortic root size;	chr7:65800193	chr7:66409143~66490059:-
BRCA	cis	rs3770752	0.823	rs10190959	ENSG00000224891.1	AC007899.3	-3.29	0.00104	0.0447	-0.12	-0.1	Schizophrenia;	chr2:37312433	chr2:37148530~37149304:+
BRCA	cis	rs2043112	0.73	rs2303808	ENSG00000249911.1	LINC01265	3.29	0.00104	0.0447	0.12	0.1	Obesity-related traits;	chr5:39074194	chr5:38710367~38720273:-
BRCA	cis	rs13434995	0.513	rs62303728	ENSG00000273257.1	RP11-177J6.1	-3.29	0.00104	0.0447	-0.15	-0.1	Adiponectin levels;	chr4:55495762	chr4:55387949~55388271:+
BRCA	cis	rs2455799	0.613	rs7617039	ENSG00000224728.1	AC090945.1	3.29	0.00104	0.0447	0.1	0.1	Mean platelet volume;	chr3:15759233	chr3:15878047~15879571:+
BRCA	cis	rs9921338	0.961	rs4390613	ENSG00000263080.1	RP11-485G7.5	-3.29	0.00104	0.0447	-0.15	-0.1	Vein graft stenosis in coronary artery bypass grafting;	chr16:11328979	chr16:11341809~11345211:-
BRCA	cis	rs8180040	0.587	rs62246398	ENSG00000280667.1	Y_RNA	-3.29	0.00104	0.0447	-0.11	-0.1	Colorectal cancer;	chr3:47024713	chr3:47501083~47501182:+
BRCA	cis	rs2204008	0.527	rs8189480	ENSG00000257718.1	RP11-396F22.1	-3.29	0.00104	0.0447	-0.1	-0.1	Bladder cancer;	chr12:37951846	chr12:38906451~38909592:+
BRCA	cis	rs889122	0.765	rs62105756	ENSG00000270614.1	CTC-325H20.7	-3.29	0.00104	0.0447	-0.12	-0.1	Menarche (age at onset);	chr19:9863257	chr19:9348106~9348703:-
BRCA	cis	rs1325195	0.92	rs2816209	ENSG00000261060.1	RP11-545A16.4	-3.29	0.00104	0.0447	-0.14	-0.1	IgE grass sensitization;	chr1:179202359	chr1:179590372~179591305:+
BRCA	cis	rs4865762	0.514	rs251329	ENSG00000247796.2	CTD-2366F13.1	-3.29	0.00104	0.0447	-0.11	-0.1	Intraocular pressure;	chr5:53140394	chr5:53109842~53115126:+
BRCA	cis	rs2692947	0.537	rs11679899	ENSG00000168992.4	OR7E102P	3.29	0.00104	0.0447	0.14	0.1	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95712414	chr2:95546531~95547545:+
BRCA	cis	rs2436153	0.676	rs7924348	ENSG00000254551.1	RP11-727A23.7	3.29	0.00104	0.0447	0.12	0.1	Facial morphology (factor 16);	chr11:83538945	chr11:83209431~83213379:-
BRCA	cis	rs1023500	0.505	rs134874	ENSG00000233903.2	Z83851.4	3.29	0.00104	0.0447	0.12	0.1	Schizophrenia;	chr22:42265138	chr22:42276355~42277052:+
BRCA	cis	rs1075265	0.749	rs2692518	ENSG00000272156.1	RP11-477N3.1	-3.29	0.00104	0.0447	-0.1	-0.1	Chronotype;Morning vs. evening chronotype;	chr2:53804746	chr2:54082554~54085066:+
BRCA	cis	rs11451044	1	rs11451044	ENSG00000248265.1	FLJ12825	3.29	0.00104	0.0447	0.13	0.1	Red blood cell count;	chr12:54322000	chr12:54058254~54122234:+
BRCA	cis	rs36051895	0.623	rs11790680	ENSG00000237711.1	RP11-39K24.13	-3.29	0.00104	0.0447	-0.13	-0.1	Pediatric autoimmune diseases;	chr9:5248768	chr9:5100236~5101009:+
BRCA	cis	rs1116357	0.512	rs1878279	ENSG00000233251.6	AC007743.1	-3.29	0.00104	0.0447	-0.12	-0.1	Type 2 diabetes;	chr2:57004178	chr2:56173534~56185770:-
BRCA	cis	rs1466788	1	rs7533623	ENSG00000224965.1	KCNC4-AS1	3.29	0.00104	0.0447	0.12	0.1	Blood metabolite levels;	chr1:110073853	chr1:110208834~110209987:-
BRCA	cis	rs11638815	0.668	rs1877242	ENSG00000279758.1	RP11-752G15.10	-3.29	0.00104	0.0447	-0.11	-0.1	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82728706	chr15:82738386~82739122:+
BRCA	cis	rs1468333	0.567	rs10072318	ENSG00000206989.1	SNORD63	3.29	0.00104	0.0447	0.11	0.1	Resting heart rate;	chr5:138310532	chr5:138561043~138561110:-
BRCA	cis	rs1468333	0.507	rs13361619	ENSG00000206989.1	SNORD63	3.29	0.00104	0.0447	0.11	0.1	Resting heart rate;	chr5:138312990	chr5:138561043~138561110:-
BRCA	cis	rs2562456	0.52	rs250001	ENSG00000268658.4	LINC00664	3.29	0.00104	0.0447	0.18	0.1	Pain;	chr19:21225387	chr19:21483374~21503238:+
BRCA	cis	rs2276314	1	rs2298716	ENSG00000267627.4	RP11-905K4.1	-3.29	0.00104	0.0447	-0.14	-0.1	Endometriosis;Drug-induced torsades de pointes;	chr18:35972635	chr18:35951803~35966118:-
BRCA	cis	rs10504130	0.569	rs13275967	ENSG00000272076.1	RP11-11C20.3	3.29	0.00104	0.0447	0.15	0.1	Venous thromboembolism (SNP x SNP interaction);	chr8:51761316	chr8:51810110~51810681:-
BRCA	cis	rs10504130	0.569	rs13274159	ENSG00000272076.1	RP11-11C20.3	3.29	0.00104	0.0447	0.15	0.1	Venous thromboembolism (SNP x SNP interaction);	chr8:51761450	chr8:51810110~51810681:-
BRCA	cis	rs10504130	0.569	rs4436115	ENSG00000272076.1	RP11-11C20.3	3.29	0.00104	0.0447	0.15	0.1	Venous thromboembolism (SNP x SNP interaction);	chr8:51761932	chr8:51810110~51810681:-
BRCA	cis	rs10504130	0.569	rs4573262	ENSG00000272076.1	RP11-11C20.3	3.29	0.00104	0.0447	0.15	0.1	Venous thromboembolism (SNP x SNP interaction);	chr8:51762249	chr8:51810110~51810681:-
BRCA	cis	rs6540556	0.637	rs12060922	ENSG00000236136.1	ADORA2BP1	-3.29	0.00104	0.0447	-0.13	-0.1	Red blood cell count;	chr1:209731088	chr1:209744373~209745214:+
BRCA	cis	rs360932	0.963	rs360916	ENSG00000270265.1	RP11-731D1.4	3.29	0.00104	0.0447	0.12	0.1	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr4:151966971	chr4:151333775~151353224:-
BRCA	cis	rs3750965	0.575	rs3892895	ENSG00000259799.1	RP11-554A11.9	-3.29	0.00104	0.0447	-0.12	-0.1	Hair color;	chr11:69117287	chr11:69155910~69159752:+
BRCA	cis	rs17102884	0.506	rs11845397	ENSG00000279594.1	RP11-950C14.10	-3.29	0.00104	0.0447	-0.11	-0.1	Neuroticism;	chr14:74937884	chr14:75011269~75012851:-
BRCA	cis	rs7781266	0.842	rs6968089	ENSG00000226205.1	AC007790.4	3.29	0.00104	0.0447	0.14	0.1	Educational attainment (college completion);	chr7:133558691	chr7:133732493~133733595:-
BRCA	cis	rs4805834	0.764	rs12150992	ENSG00000201388.1	SNORA68	3.29	0.00104	0.0447	0.18	0.1	Creatinine levels;	chr19:32892498	chr19:32608337~32608469:-
BRCA	cis	rs6141600	0.627	rs66697630	ENSG00000278035.1	RP11-234K24.6	3.29	0.00104	0.0447	0.14	0.1	Height;Hip circumference;	chr20:36114513	chr20:36233851~36234297:+
BRCA	cis	rs7781266	0.741	rs1149555	ENSG00000226205.1	AC007790.4	-3.29	0.00104	0.0447	-0.15	-0.1	Educational attainment (college completion);	chr7:133377911	chr7:133732493~133733595:-
BRCA	cis	rs4763879	0.634	rs917913	ENSG00000256582.1	RP11-75L1.1	-3.29	0.00104	0.0447	-0.1	-0.1	Type 1 diabetes;	chr12:9707040	chr12:9704077~9709350:+
BRCA	cis	rs7412746	0.611	rs4319334	ENSG00000224800.1	RP11-235D19.2	-3.29	0.00104	0.0447	-0.13	-0.1	Melanoma;	chr1:150794346	chr1:150881236~150881683:-
BRCA	cis	rs890448	0.796	rs1365381	ENSG00000254531.1	FLJ20021	-3.29	0.00104	0.0447	-0.12	-0.1	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101422718	chr4:101347780~101348883:+
BRCA	cis	rs4878639	0.695	rs10972726	ENSG00000235387.1	LINC00961	-3.29	0.00104	0.0447	-0.12	-0.1	IgG glycosylation;	chr9:36109950	chr9:35909483~35911686:+
BRCA	cis	rs6142618	0.562	rs4911546	ENSG00000275576.1	RP5-836N17.4	-3.29	0.00104	0.0447	-0.11	-0.1	Inflammatory bowel disease;	chr20:32130530	chr20:32116171~32116629:+
BRCA	cis	rs2692947	0.832	rs4907212	ENSG00000232931.4	LINC00342	3.29	0.00104	0.0447	0.11	0.1	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95744300	chr2:95807118~95816215:-
BRCA	cis	rs11673344	0.573	rs73039109	ENSG00000267682.1	CTD-3220F14.2	-3.29	0.00104	0.0447	-0.1	-0.1	Obesity-related traits;	chr19:36891073	chr19:37337236~37337743:+
BRCA	cis	rs2154319	0.887	rs6696524	ENSG00000230638.4	RP11-486B10.4	3.29	0.00104	0.0447	0.17	0.1	Height;	chr1:41073822	chr1:41542069~41544310:+
BRCA	cis	rs61776290	0.764	rs284301	ENSG00000271989.1	RP4-736L20.3	3.29	0.00104	0.0447	0.15	0.1	Alcohol dependence (age at onset);	chr1:10634068	chr1:10429881~10430677:-
BRCA	cis	rs2400362	0.54	rs895274	ENSG00000272518.1	RP11-26J3.3	-3.29	0.00104	0.0447	-0.11	-0.1	Glucocorticoid-induced osteonecrosis (age 10 years and older);	chr8:80950314	chr8:79956465~79957381:-
BRCA	cis	rs801193	0.773	rs801207	ENSG00000229886.1	RP5-1132H15.3	-3.29	0.00104	0.0447	-0.11	-0.1	Aortic root size;	chr7:66555603	chr7:66025126~66031544:-
BRCA	cis	rs4699052	0.507	rs6533085	ENSG00000246560.2	RP11-10L12.4	3.29	0.00104	0.0447	0.11	0.1	Testicular germ cell tumor;	chr4:103360429	chr4:102828055~102844075:+
BRCA	cis	rs113835537	0.597	rs3737525	ENSG00000214659.4	KRT8P26	3.29	0.00104	0.0447	0.15	0.1	Airway imaging phenotypes;	chr11:66538884	chr11:65726939~65728214:+
BRCA	cis	rs12216545	0.765	rs2204129	ENSG00000244151.1	RP11-148K1.12	-3.29	0.00104	0.0447	-0.09	-0.1	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150554351	chr7:151074742~151076530:-
BRCA	cis	rs7098100	0.601	rs2666776	ENSG00000279623.1	RP11-399C16.3	3.29	0.00104	0.0447	0.14	0.1	Breast cancer;	chr10:21953059	chr10:21865335~21865921:-
BRCA	cis	rs4934494	0.911	rs7081788	ENSG00000235100.3	RP11-80H5.9	-3.29	0.00104	0.0447	-0.13	-0.1	Red blood cell count;	chr10:89648999	chr10:89667181~89699671:-
BRCA	cis	rs8105895	1	rs1849004	ENSG00000269345.1	VN1R85P	3.29	0.00104	0.0447	0.16	0.1	Body mass index (change over time);	chr19:21959653	chr19:22174766~22175191:-
BRCA	cis	rs6504622	0.677	rs12949446	ENSG00000263142.4	LRRC37A17P	-3.29	0.00104	0.0447	-0.08	-0.1	Orofacial clefts;	chr17:46994311	chr17:46978481~47054569:+
BRCA	cis	rs2191566	0.576	rs381759	ENSG00000266921.1	RP11-15A1.7	-3.29	0.00104	0.0447	-0.13	-0.1	Acute lymphoblastic leukemia (childhood);	chr19:43990993	chr19:43996896~44002836:-
BRCA	cis	rs1570854	1	rs1570854	ENSG00000233321.1	RP11-482E14.1	3.29	0.00104	0.0448	0.11	0.1	Economic and political preferences (environmentalism);	chr10:3375932	chr10:3486894~3502838:-
BRCA	cis	rs2386661	0.543	rs61832673	ENSG00000242147.1	RP13-463N16.6	3.29	0.00104	0.0448	0.12	0.1	Breast cancer;	chr10:5601855	chr10:5594991~5596118:-
BRCA	cis	rs2625529	0.652	rs7497104	ENSG00000261187.1	RP11-1007O24.2	-3.29	0.00104	0.0448	-0.11	-0.1	Red blood cell count;	chr15:71861659	chr15:72465128~72466262:-
BRCA	cis	rs8062405	1	rs72793811	ENSG00000261766.1	RP11-22P6.2	-3.29	0.00104	0.0448	-0.11	-0.1	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828071	chr16:28862166~28863340:-
BRCA	cis	rs7578199	0.779	rs35743491	ENSG00000228989.1	AC133528.2	3.29	0.00104	0.0448	0.13	0.1	Chronic lymphocytic leukemia;	chr2:241489657	chr2:241690414~241694289:+
BRCA	cis	rs11690462	0.528	rs1344734	ENSG00000205500.7	AC013472.3	-3.29	0.00104	0.0448	-0.14	-0.1	Coronary artery disease;	chr2:26414200	chr2:26984776~27014612:-
BRCA	cis	rs4665809	1	rs6704930	ENSG00000231655.1	AC011742.3	3.29	0.00104	0.0448	0.14	0.1	Gut microbiome composition (summer);	chr2:26102836	chr2:26140263~26141264:-
BRCA	cis	rs4665809	1	rs4665308	ENSG00000231655.1	AC011742.3	3.29	0.00104	0.0448	0.14	0.1	Gut microbiome composition (summer);	chr2:26107645	chr2:26140263~26141264:-
BRCA	cis	rs4665809	0.887	rs4665825	ENSG00000231655.1	AC011742.3	3.29	0.00104	0.0448	0.14	0.1	Gut microbiome composition (summer);	chr2:26110231	chr2:26140263~26141264:-
BRCA	cis	rs4665809	1	rs4665309	ENSG00000231655.1	AC011742.3	3.29	0.00104	0.0448	0.14	0.1	Gut microbiome composition (summer);	chr2:26112633	chr2:26140263~26141264:-
BRCA	cis	rs4665809	1	rs10182857	ENSG00000231655.1	AC011742.3	3.29	0.00104	0.0448	0.14	0.1	Gut microbiome composition (summer);	chr2:26121542	chr2:26140263~26141264:-
BRCA	cis	rs4665809	1	rs11126375	ENSG00000231655.1	AC011742.3	3.29	0.00104	0.0448	0.14	0.1	Gut microbiome composition (summer);	chr2:26121918	chr2:26140263~26141264:-
BRCA	cis	rs4665809	1	rs2289022	ENSG00000231655.1	AC011742.3	3.29	0.00104	0.0448	0.14	0.1	Gut microbiome composition (summer);	chr2:26127267	chr2:26140263~26141264:-
BRCA	cis	rs4665809	0.941	rs41285975	ENSG00000231655.1	AC011742.3	3.29	0.00104	0.0448	0.14	0.1	Gut microbiome composition (summer);	chr2:26128275	chr2:26140263~26141264:-
BRCA	cis	rs4665809	1	rs17040322	ENSG00000231655.1	AC011742.3	3.29	0.00104	0.0448	0.14	0.1	Gut microbiome composition (summer);	chr2:26128405	chr2:26140263~26141264:-
BRCA	cis	rs12438356	0.686	rs12443208	ENSG00000259222.2	RP11-809H16.5	3.29	0.00104	0.0448	0.15	0.1	CTACK levels;	chr15:69277040	chr15:69080879~69099987:+
BRCA	cis	rs7577696	0.512	rs212691	ENSG00000276334.1	AL133243.1	3.29	0.00104	0.0448	0.14	0.1	Inflammatory biomarkers;	chr2:32213006	chr2:32521927~32523547:+
BRCA	cis	rs10843647	1	rs11050711	ENSG00000245614.3	DDX11-AS1	-3.29	0.00104	0.0448	-0.11	-0.1	Glucose homeostasis traits;	chr12:30179880	chr12:31020763~31073847:-
BRCA	cis	rs7308116	0.967	rs7307409	ENSG00000274395.1	RP11-554D14.8	-3.29	0.00104	0.0448	-0.11	-0.1	Pelvic organ prolapse (moderate/severe);	chr12:107797267	chr12:107835541~107836555:-
BRCA	cis	rs8049367	0.684	rs759276	ENSG00000279031.1	LA16c-360H6.1	3.29	0.00104	0.0448	0.11	0.1	Nonsyndromic cleft lip with or without cleft palate;	chr16:3917543	chr16:3292879~3293403:+
BRCA	cis	rs8101881	1	rs8101881	ENSG00000267567.1	CTD-2538C1.3	3.29	0.00104	0.0448	0.12	0.1	Blood metabolite levels;Urinary metabolites (H-NMR features);Urinary metabolites;	chr19:32873722	chr19:32718298~32719595:-
BRCA	cis	rs4664293	0.625	rs6745448	ENSG00000224152.1	AC009506.1	-3.29	0.00104	0.0448	-0.11	-0.1	Monocyte percentage of white cells;	chr2:159699087	chr2:159615296~159617082:+
BRCA	cis	rs10971721	0.822	rs10971845	ENSG00000279489.1	RP11-392A14.8	3.29	0.00104	0.0448	0.21	0.1	Body mass index;	chr9:34009879	chr9:35001913~35003663:+
BRCA	cis	rs10971721	0.822	rs10971847	ENSG00000279489.1	RP11-392A14.8	3.29	0.00104	0.0448	0.21	0.1	Body mass index;	chr9:34011460	chr9:35001913~35003663:+
BRCA	cis	rs10971721	0.822	rs10971848	ENSG00000279489.1	RP11-392A14.8	3.29	0.00104	0.0448	0.21	0.1	Body mass index;	chr9:34012504	chr9:35001913~35003663:+
BRCA	cis	rs962856	0.619	rs1601530	ENSG00000236605.1	AC023115.4	3.29	0.00104	0.0448	0.13	0.1	Pancreatic cancer;	chr2:67367784	chr2:67324627~67325304:+
BRCA	cis	rs3735485	0.843	rs1476617	ENSG00000201772.1	SNORA5C	-3.29	0.00104	0.0448	-0.14	-0.1	White blood cell count;Sum basophil neutrophil counts;Neutrophil count;Granulocyte percentage of myeloid white cells;Monocyte percentage of white cells;Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Lymphocyte counts;	chr7:44998135	chr7:45104906~45105042:-
BRCA	cis	rs6545883	0.895	rs2442029	ENSG00000237522.1	NONOP2	-3.29	0.00104	0.0448	-0.1	-0.1	Tuberculosis;	chr2:61452417	chr2:60936819~60938049:-
BRCA	cis	rs6545883	0.929	rs2256615	ENSG00000237522.1	NONOP2	-3.29	0.00104	0.0448	-0.1	-0.1	Tuberculosis;	chr2:61452759	chr2:60936819~60938049:-
BRCA	cis	rs12220238	0.915	rs11001020	ENSG00000213731.2	RAB5CP1	-3.29	0.00104	0.0448	-0.15	-0.1	Soluble interleukin-2 receptor subunit alpha;	chr10:74379459	chr10:74423435~74424014:-
BRCA	cis	rs561341	0.556	rs542244	ENSG00000265798.5	RP11-271K11.5	3.29	0.00104	0.0448	0.17	0.1	Hip circumference adjusted for BMI;	chr17:31980223	chr17:31038575~31059121:-
BRCA	cis	rs2072510	0.722	rs2540490	ENSG00000237774.3	RP11-129B9.1	3.29	0.00104	0.0448	0.11	0.1	Metabolite levels (small molecules and protein measures);	chr12:96032494	chr12:95125760~95126389:+
BRCA	cis	rs2072510	0.722	rs2540489	ENSG00000237774.3	RP11-129B9.1	3.29	0.00104	0.0448	0.11	0.1	Metabolite levels (small molecules and protein measures);	chr12:96032724	chr12:95125760~95126389:+
BRCA	cis	rs7267979	0.527	rs6083891	ENSG00000274414.1	RP5-965G21.4	3.29	0.00104	0.0448	0.12	0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25593636	chr20:25239007~25245229:-
BRCA	cis	rs7786877	0.723	rs73407376	ENSG00000208036.1	MIR106B	3.29	0.00104	0.0448	0.15	0.1	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr7:100617577	chr7:100093993~100094074:-
BRCA	cis	rs3789045	0.56	rs4553256	ENSG00000176754.11	LINC00303	-3.29	0.00104	0.0448	-0.17	-0.1	Educational attainment (college completion);	chr1:204442016	chr1:204032447~204041265:-
BRCA	cis	rs12317459	1	rs12311396	ENSG00000213270.5	RPL6P25	-3.29	0.00104	0.0448	-0.14	-0.1	Prostate cancer (SNP x SNP interaction);	chr12:82767178	chr12:83151331~83152190:+
BRCA	cis	rs10739695	0.935	rs10739696	ENSG00000225032.4	RP11-228B15.4	-3.29	0.00104	0.0448	-0.09	-0.1	Monocyte percentage of white cells;	chr9:127765507	chr9:127816066~127822520:+
BRCA	cis	rs2337406	1	rs3858878	ENSG00000211970.3	IGHV4-61	3.29	0.00104	0.0448	0.09	0.1	Alzheimer's disease (late onset);	chr14:106688061	chr14:106639119~106639657:-
BRCA	cis	rs12282928	1	rs11039675	ENSG00000255197.4	RP11-750H9.5	-3.29	0.00104	0.0448	-0.1	-0.1	Migraine - clinic-based;	chr11:48314749	chr11:47383148~47409190:-
BRCA	cis	rs1119582	1	rs464947	ENSG00000279118.1	RP11-517I3.2	-3.29	0.00104	0.0448	-0.12	-0.1	Select biomarker traits;	chr5:125941119	chr5:126496279~126498604:+
BRCA	cis	rs2307449	0.929	rs6496570	ENSG00000260123.1	RP11-326A19.4	3.29	0.00104	0.0448	0.12	0.1	Menopause (age at onset);	chr15:89262340	chr15:89041223~89082819:+
BRCA	cis	rs1730008	0.865	rs1609523	ENSG00000279311.1	RP11-170K4.2	-3.29	0.00104	0.0448	-0.11	-0.1	Lobe attachment (rater-scored or self-reported);	chr3:158142293	chr3:158869898~158871821:+
BRCA	cis	rs6557876	0.511	rs7815775	ENSG00000228451.3	SDAD1P1	-3.29	0.00104	0.0448	-0.13	-0.1	Systolic blood pressure;	chr8:26067465	chr8:26379259~26382953:-
BRCA	cis	rs7246967	0.866	rs115497901	ENSG00000198153.8	ZNF849P	-3.29	0.00104	0.0448	-0.15	-0.1	Bronchopulmonary dysplasia;	chr19:22859959	chr19:22685167~22686732:+
BRCA	cis	rs4718428	0.705	rs4718422	ENSG00000275400.1	RP4-756H11.5	-3.29	0.00104	0.0448	-0.13	-0.1	Corneal structure;	chr7:66894282	chr7:66553805~66554199:-
BRCA	cis	rs6120849	0.663	rs6088662	ENSG00000276073.1	RP5-1125A11.7	-3.29	0.00104	0.0448	-0.14	-0.1	Protein C levels;	chr20:34959830	chr20:33985617~33988989:-
BRCA	cis	rs228614	0.502	rs4648004	ENSG00000246560.2	RP11-10L12.4	-3.29	0.00104	0.0448	-0.12	-0.1	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102539950	chr4:102828055~102844075:+
BRCA	cis	rs1185460	1	rs1185460	ENSG00000272186.1	RP11-110I1.13	3.29	0.00104	0.0448	0.13	0.1	Coronary artery disease;	chr11:119072723	chr11:119067374~119067698:-
BRCA	cis	rs36051895	0.664	rs3780371	ENSG00000236254.1	MTND4P14	-3.29	0.00104	0.0448	-0.12	-0.1	Pediatric autoimmune diseases;	chr9:5095191	chr9:5107937~5109290:+
BRCA	cis	rs875971	0.895	rs4718349	ENSG00000272831.1	RP11-792A8.4	3.29	0.00104	0.0448	0.09	0.1	Aortic root size;	chr7:66444024	chr7:66739829~66740385:-
BRCA	cis	rs875971	1	rs2042133	ENSG00000272831.1	RP11-792A8.4	3.29	0.00104	0.0448	0.09	0.1	Aortic root size;	chr7:66466935	chr7:66739829~66740385:-
BRCA	cis	rs875971	0.964	rs2161065	ENSG00000272831.1	RP11-792A8.4	3.29	0.00104	0.0448	0.09	0.1	Aortic root size;	chr7:66467918	chr7:66739829~66740385:-
BRCA	cis	rs875971	0.862	rs12698521	ENSG00000272831.1	RP11-792A8.4	3.29	0.00104	0.0448	0.09	0.1	Aortic root size;	chr7:66474502	chr7:66739829~66740385:-
BRCA	cis	rs2029362	0.846	rs1140711	ENSG00000245573.6	BDNF-AS	3.29	0.00104	0.0448	0.1	0.1	Total body bone mineral density;	chr11:27495862	chr11:27506838~27698174:+
BRCA	cis	rs1200821	0.535	rs1208789	ENSG00000099251.13	HSD17B7P2	3.29	0.00104	0.0448	0.11	0.1	Hemostatic factors and hematological phenotypes;	chr10:37433544	chr10:38356380~38378505:+
BRCA	cis	rs2502399	0.652	rs1321021	ENSG00000228624.6	RP3-399L15.3	-3.29	0.00104	0.0448	-0.1	-0.1	Plasma clusterin levels;	chr6:113184584	chr6:113969701~114471705:+
BRCA	cis	rs853679	0.567	rs16894091	ENSG00000273712.1	RP5-874C20.7	-3.29	0.00104	0.0448	-0.14	-0.1	Depression;	chr6:28422360	chr6:28315613~28315883:-
BRCA	cis	rs9393777	0.778	rs4452638	ENSG00000220721.1	OR1F12	-3.29	0.00104	0.0448	-0.19	-0.1	Intelligence (multi-trait analysis);	chr6:27261486	chr6:28073316~28074233:+
BRCA	cis	rs739496	0.615	rs609230	ENSG00000234608.6	MAPKAPK5-AS1	-3.29	0.00104	0.0448	-0.13	-0.1	Platelet count;	chr12:111709107	chr12:111839764~111842902:-
BRCA	cis	rs875971	0.965	rs10267430	ENSG00000230189.5	GS1-124K5.2	-3.29	0.00104	0.0448	-0.08	-0.1	Aortic root size;	chr7:66278036	chr7:66409143~66490059:-
BRCA	cis	rs8023401	0.938	rs12914007	ENSG00000274654.1	CTD-3247H4.2	3.29	0.00104	0.0448	0.17	0.1	Spherical equivalent (joint analysis main effects and education interaction);	chr15:48502241	chr15:48528980~48529728:-
BRCA	cis	rs61677309	0.638	rs57461652	ENSG00000280032.1	RP11-832A4.7	3.29	0.00104	0.0448	0.09	0.1	Lung cancer in ever smokers;	chr11:118275482	chr11:118264593~118266817:+
BRCA	cis	rs61677309	0.638	rs58162302	ENSG00000280032.1	RP11-832A4.7	3.29	0.00104	0.0448	0.09	0.1	Lung cancer in ever smokers;	chr11:118275484	chr11:118264593~118266817:+
BRCA	cis	rs61677309	0.638	rs58507982	ENSG00000280032.1	RP11-832A4.7	3.29	0.00104	0.0448	0.09	0.1	Lung cancer in ever smokers;	chr11:118275795	chr11:118264593~118266817:+
BRCA	cis	rs259282	0.524	rs1559180	ENSG00000267475.1	CTD-2538C1.2	3.29	0.00104	0.0448	0.12	0.1	Schizophrenia;	chr19:32636537	chr19:32687089~32691750:-
BRCA	cis	rs7712401	0.72	rs12109791	ENSG00000249996.1	RP11-359P5.1	3.29	0.00104	0.0449	0.12	0.1	Mean platelet volume;	chr5:122811136	chr5:123036271~123054667:+
BRCA	cis	rs6430585	1	rs73958618	ENSG00000231890.6	DARS-AS1	-3.29	0.00104	0.0449	-0.15	-0.1	Corneal structure;	chr2:135742905	chr2:135985176~136022593:+
BRCA	cis	rs10876993	0.928	rs1689596	ENSG00000270039.1	RP11-571M6.17	3.29	0.00104	0.0449	0.13	0.1	Celiac disease or Rheumatoid arthritis;	chr12:57659246	chr12:57803838~57804415:+
BRCA	cis	rs564309	0.867	rs12094956	ENSG00000212237.1	RNA5SP18	-3.29	0.00104	0.0449	-0.19	-0.1	Hip circumference (psychosocial stress interaction);	chr1:228382881	chr1:228647912~228648032:-
BRCA	cis	rs7412746	0.611	rs111905669	ENSG00000224800.1	RP11-235D19.2	-3.29	0.00104	0.0449	-0.13	-0.1	Melanoma;	chr1:150805089	chr1:150881236~150881683:-
BRCA	cis	rs12714314	0.756	rs7355512	ENSG00000228613.1	AC144450.1	3.29	0.00104	0.0449	0.11	0.1	Type 2 diabetes (age of onset);	chr2:1944394	chr2:1546665~1620113:-
BRCA	cis	rs6918586	1	rs198806	ENSG00000272462.2	U91328.19	-3.29	0.00104	0.0449	-0.11	-0.1	Schizophrenia;	chr6:26133388	chr6:25992662~26001775:+
BRCA	cis	rs7975161	0.64	rs10735394	ENSG00000257681.1	RP11-341G23.4	-3.29	0.00104	0.0449	-0.15	-0.1	Toenail selenium levels;	chr12:104293364	chr12:103746315~103768858:-
BRCA	cis	rs7308116	0.935	rs7342299	ENSG00000274395.1	RP11-554D14.8	-3.29	0.00104	0.0449	-0.11	-0.1	Pelvic organ prolapse (moderate/severe);	chr12:107800392	chr12:107835541~107836555:-
BRCA	cis	rs7308116	0.967	rs61938588	ENSG00000274395.1	RP11-554D14.8	-3.29	0.00104	0.0449	-0.11	-0.1	Pelvic organ prolapse (moderate/severe);	chr12:107801018	chr12:107835541~107836555:-
BRCA	cis	rs7308116	0.935	rs61938589	ENSG00000274395.1	RP11-554D14.8	-3.29	0.00104	0.0449	-0.11	-0.1	Pelvic organ prolapse (moderate/severe);	chr12:107801065	chr12:107835541~107836555:-
BRCA	cis	rs7308116	0.935	rs61938591	ENSG00000274395.1	RP11-554D14.8	-3.29	0.00104	0.0449	-0.11	-0.1	Pelvic organ prolapse (moderate/severe);	chr12:107801227	chr12:107835541~107836555:-
BRCA	cis	rs7308116	0.967	rs11113495	ENSG00000274395.1	RP11-554D14.8	-3.29	0.00104	0.0449	-0.11	-0.1	Pelvic organ prolapse (moderate/severe);	chr12:107801737	chr12:107835541~107836555:-
BRCA	cis	rs7308116	0.967	rs11113496	ENSG00000274395.1	RP11-554D14.8	-3.29	0.00104	0.0449	-0.11	-0.1	Pelvic organ prolapse (moderate/severe);	chr12:107801826	chr12:107835541~107836555:-
BRCA	cis	rs7308116	0.935	rs7313108	ENSG00000274395.1	RP11-554D14.8	-3.29	0.00104	0.0449	-0.11	-0.1	Pelvic organ prolapse (moderate/severe);	chr12:107802399	chr12:107835541~107836555:-
BRCA	cis	rs4950322	0.512	rs4625342	ENSG00000237188.3	RP11-337C18.8	-3.29	0.00104	0.0449	-0.11	-0.1	Protein quantitative trait loci;	chr1:147369887	chr1:147172771~147211568:+
BRCA	cis	rs16858210	0.52	rs10460892	ENSG00000276325.1	AC131160.2	-3.29	0.00104	0.0449	-0.16	-0.1	Menopause (age at onset);	chr3:183828336	chr3:183806156~183806204:+
BRCA	cis	rs2148307	0.752	rs3781487	ENSG00000228339.1	AMD1P1	-3.29	0.00104	0.0449	-0.12	-0.1	Photic sneeze reflex;	chr10:20797603	chr10:20350049~20351100:+
BRCA	cis	rs7639513	0.767	rs3806661	ENSG00000274514.1	Metazoa_SRP	3.29	0.00104	0.0449	0.12	0.1	Itch intensity from mosquito bite;	chr3:12664356	chr3:12576961~12577237:-
BRCA	cis	rs7918232	0.698	rs6482586	ENSG00000236983.1	LINC00614	3.29	0.00104	0.0449	0.13	0.1	Breast cancer;	chr10:27008900	chr10:26943323~26944418:-
BRCA	cis	rs7072574	1	rs4918188	ENSG00000273450.1	RP11-76P2.4	3.29	0.00104	0.0449	0.13	0.1	Vertical cup-disc ratio;	chr10:94274009	chr10:94314907~94315327:-
BRCA	cis	rs979233	0.902	rs11739243	ENSG00000188850.9	RP11-159F24.2	3.29	0.00104	0.0449	0.12	0.1	Systemic lupus erythematosus;	chr5:42527836	chr5:43336164~43348716:+
BRCA	cis	rs4718428	0.705	rs4717328	ENSG00000275400.1	RP4-756H11.5	-3.29	0.00104	0.0449	-0.13	-0.1	Corneal structure;	chr7:66887678	chr7:66553805~66554199:-
BRCA	cis	rs2562456	0.917	rs6511253	ENSG00000213976.4	CTD-2561J22.2	3.29	0.00104	0.0449	0.12	0.1	Pain;	chr19:21495996	chr19:21382865~21387177:+
BRCA	cis	rs4835473	0.864	rs13145791	ENSG00000246448.2	RP13-578N3.3	-3.29	0.00104	0.0449	-0.12	-0.1	Immature fraction of reticulocytes;	chr4:143735688	chr4:143700257~143865072:+
BRCA	cis	rs13008689	1	rs7419273	ENSG00000236790.4	LINC00299	3.29	0.00104	0.0449	0.12	0.1	Longevity;	chr2:8381150	chr2:8007771~8383621:-
BRCA	cis	rs7590720	0.819	rs6435931	ENSG00000230838.1	AC093850.2	-3.29	0.00104	0.0449	-0.09	-0.1	Alcohol dependence;	chr2:216028031	chr2:215718043~215719424:+
BRCA	cis	rs2075671	0.903	rs11983334	ENSG00000242798.1	RP11-506M12.1	-3.29	0.00104	0.0449	-0.1	-0.1	Other erythrocyte phenotypes;	chr7:100704811	chr7:100115214~100127139:-
BRCA	cis	rs3739034	0.941	rs7565713	ENSG00000224043.6	CCNT2-AS1	-3.29	0.00104	0.0449	-0.16	-0.1	Gut microbiome composition (winter);	chr2:134720069	chr2:134735464~134918710:-
BRCA	cis	rs2664588	1	rs2664588	ENSG00000276923.1	RP11-321P16.1	-3.29	0.00104	0.0449	-0.13	-0.1	Cerebrospinal fluid AB1-42 levels;	chr20:47951890	chr20:48073869~48074188:+
BRCA	cis	rs10197140	0.925	rs1872062	ENSG00000235721.1	AC013268.3	-3.29	0.00104	0.0449	-0.13	-0.1	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110872912	chr2:110007675~110010783:+
BRCA	cis	rs13136331	0.5	rs1462371	ENSG00000249001.4	RP11-742B18.1	3.29	0.00104	0.0449	0.14	0.1	Sitting height ratio;	chr4:87655503	chr4:87568035~87733956:-
BRCA	cis	rs11170468	0.722	rs7302407	ENSG00000257718.1	RP11-396F22.1	-3.29	0.00104	0.0449	-0.12	-0.1	Body mass index;	chr12:39090816	chr12:38906451~38909592:+
BRCA	cis	rs6993270	0.557	rs10505375	ENSG00000245330.4	KB-1471A8.1	-3.29	0.00104	0.0449	-0.21	-0.1	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr8:119934228	chr8:119867419~119874488:-
BRCA	cis	rs1499614	1	rs2707832	ENSG00000229180.5	GS1-124K5.11	3.29	0.00104	0.0449	0.14	0.1	Gout;	chr7:66671562	chr7:66526088~66542624:-
BRCA	cis	rs7893279	0.505	rs11815228	ENSG00000240291.1	RP11-499P20.2	-3.29	0.00104	0.0449	-0.12	-0.1	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr10:18590899	chr10:18513115~18545651:-
BRCA	cis	rs12413361	0.967	rs4749617	ENSG00000237135.1	DDX10P1	-3.29	0.00104	0.0449	-0.12	-0.1	Height;	chr10:30824794	chr10:30919012~30921235:-
BRCA	cis	rs2836950	0.501	rs2836980	ENSG00000235701.1	PCBP2P1	-3.29	0.00104	0.0449	-0.12	-0.1	Menarche (age at onset);	chr21:39315692	chr21:39171130~39172106:-
BRCA	cis	rs1005277	0.54	rs1987431	ENSG00000099251.13	HSD17B7P2	3.29	0.00104	0.0449	0.11	0.1	Extrinsic epigenetic age acceleration;	chr10:37699959	chr10:38356380~38378505:+
BRCA	cis	rs7542375	0.594	rs1577545	ENSG00000272823.1	RP11-295M18.6	3.29	0.00104	0.0449	0.11	0.1	Obesity-related traits;	chr1:220847404	chr1:220828676~220829211:-
BRCA	cis	rs56046484	0.871	rs35000527	ENSG00000259630.2	CTD-2262B20.1	-3.29	0.00104	0.0449	-0.17	-0.1	Testicular germ cell tumor;	chr15:85010550	chr15:85415228~85415633:+
BRCA	cis	rs28374715	0.662	rs28382348	ENSG00000247556.5	OIP5-AS1	3.29	0.00104	0.0449	0.11	0.1	Ulcerative colitis;	chr15:41195736	chr15:41283990~41309737:+
BRCA	cis	rs6433205	0.602	rs6753558	ENSG00000229827.1	AC093899.3	-3.29	0.00104	0.0449	-0.11	-0.1	Lobe attachment (rater scored);	chr2:170497042	chr2:169577371~169577746:-
BRCA	cis	rs4631830	0.869	rs7896437	ENSG00000204177.9	BMS1P1	-3.29	0.00105	0.0449	-0.1	-0.1	Prostate-specific antigen levels;	chr10:46066229	chr10:46786674~46811989:+
BRCA	cis	rs250585	1	rs7202661	ENSG00000280039.1	CTD-2270L9.3	3.29	0.00105	0.0449	0.11	0.1	Egg allergy;	chr16:23492720	chr16:23412380~23416680:+
BRCA	cis	rs9368481	0.546	rs12664610	ENSG00000272462.2	U91328.19	-3.29	0.00105	0.0449	-0.12	-0.1	Autism spectrum disorder or schizophrenia;	chr6:26917252	chr6:25992662~26001775:+
BRCA	cis	rs59551326	0.833	rs56987153	ENSG00000234883.3	MIR155HG	3.29	0.00105	0.0449	0.14	0.1	Alcohol dependence;	chr21:25343731	chr21:25561909~25575168:+
BRCA	cis	rs4665809	1	rs1560868	ENSG00000231655.1	AC011742.3	-3.29	0.00105	0.0449	-0.15	-0.1	Gut microbiome composition (summer);	chr2:26058590	chr2:26140263~26141264:-
BRCA	cis	rs189798	0.807	rs9949	ENSG00000254153.1	CTA-398F10.2	3.29	0.00105	0.0449	0.14	0.1	Myopia (pathological);	chr8:9137002	chr8:8456909~8461337:-
BRCA	cis	rs4332037	0.851	rs28728306	ENSG00000273230.1	RP11-1246C19.1	3.29	0.00105	0.0449	0.16	0.1	Bipolar disorder;	chr7:1922178	chr7:1464497~1467522:-
BRCA	cis	rs4919694	1	rs10509760	ENSG00000236937.2	PTGES3P4	3.29	0.00105	0.0449	0.2	0.1	Arsenic metabolism;	chr10:102874350	chr10:102845595~102845950:+
BRCA	cis	rs962856	0.575	rs673005	ENSG00000236780.4	AC078941.1	3.29	0.00105	0.0449	0.14	0.1	Pancreatic cancer;	chr2:67427249	chr2:67123357~67215319:-
BRCA	cis	rs453301	0.658	rs13271797	ENSG00000254153.1	CTA-398F10.2	-3.29	0.00105	0.0449	-0.12	-0.1	Joint mobility (Beighton score);	chr8:9028444	chr8:8456909~8461337:-
BRCA	cis	rs11157436	0.56	rs11623957	ENSG00000259092.1	TRAV30	-3.29	0.00105	0.0449	-0.1	-0.1	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22224735	chr14:22168429~22168988:+
BRCA	cis	rs10129255	0.957	rs10141009	ENSG00000253132.1	IGHV3-62	-3.29	0.00105	0.0449	-0.08	-0.1	Kawasaki disease;	chr14:106776695	chr14:106643142~106643585:-
BRCA	cis	rs12659622	1	rs12656824	ENSG00000250415.1	CTC-461F20.1	3.29	0.00105	0.0449	0.18	0.1	Obesity-related traits;	chr5:15632446	chr5:16617225~16621276:+
BRCA	cis	rs7429990	0.965	rs4858871	ENSG00000228638.1	FCF1P2	-3.29	0.00105	0.0449	-0.1	-0.1	Educational attainment (years of education);	chr3:47911915	chr3:48290793~48291375:-
BRCA	cis	rs258892	0.842	rs11951999	ENSG00000272525.1	RP11-79P5.9	-3.29	0.00105	0.0449	-0.13	-0.1	Small cell lung carcinoma;	chr5:72724317	chr5:73497550~73498293:-
BRCA	cis	rs258892	0.739	rs11952024	ENSG00000272525.1	RP11-79P5.9	-3.29	0.00105	0.0449	-0.13	-0.1	Small cell lung carcinoma;	chr5:72724368	chr5:73497550~73498293:-
BRCA	cis	rs258892	0.842	rs11956081	ENSG00000272525.1	RP11-79P5.9	-3.29	0.00105	0.0449	-0.13	-0.1	Small cell lung carcinoma;	chr5:72724460	chr5:73497550~73498293:-
BRCA	cis	rs3018712	0.532	rs2510397	ENSG00000251637.5	RP11-119D9.1	3.29	0.00105	0.0449	0.17	0.1	Total body bone mineral density;	chr11:68652091	chr11:67886477~67906350:+
BRCA	cis	rs13393800	0.956	rs10185980	ENSG00000237126.7	AC073254.1	-3.29	0.00105	0.0449	-0.14	-0.1	Height;	chr2:232575141	chr2:232580948~232611971:-
BRCA	cis	rs11888559	0.655	rs2247097	ENSG00000232479.2	AC010900.2	3.29	0.00105	0.0449	0.24	0.1	Height;	chr2:203442280	chr2:202924609~202925904:+
BRCA	cis	rs2288327	0.818	rs13029629	ENSG00000271011.1	RP11-171I2.5	3.29	0.00105	0.045	0.19	0.1	Atrial fibrillation;	chr2:178515438	chr2:178577103~178577622:+
BRCA	cis	rs1979679	0.918	rs11049529	ENSG00000244712.1	RP11-874G11.1	-3.29	0.00105	0.045	-0.15	-0.1	Ossification of the posterior longitudinal ligament of the spine;	chr12:28318571	chr12:28564678~28565141:-
BRCA	cis	rs2823962	0.927	rs11911892	ENSG00000270093.1	AP000473.8	-3.29	0.00105	0.045	-0.1	-0.1	Amyotrophic lateral sclerosis;	chr21:16652861	chr21:16643529~16645065:+
BRCA	cis	rs17361889	0.517	rs12699776	ENSG00000229108.1	MEOX2-AS1	3.29	0.00105	0.045	0.13	0.1	Pediatric bone mineral content (hip);	chr7:16286676	chr7:15688378~15695491:+
BRCA	cis	rs1949733	0.656	rs6845969	ENSG00000250471.2	GMPSP1	3.29	0.00105	0.045	0.1	0.1	Response to antineoplastic agents;	chr4:8400738	chr4:8174421~8174999:+
BRCA	cis	rs709400	0.633	rs1951391	ENSG00000260285.1	RP11-600F24.7	3.29	0.00105	0.045	0.1	0.1	Body mass index;	chr14:103431976	chr14:103525010~103529072:-
BRCA	cis	rs524281	0.692	rs10791845	ENSG00000255038.1	RP11-1167A19.2	3.29	0.00105	0.045	0.14	0.1	Electroencephalogram traits;	chr11:66066869	chr11:66067277~66069619:-
BRCA	cis	rs17756712	0.666	rs1099773	ENSG00000272485.1	RP11-284J1.1	-3.29	0.00105	0.045	-0.12	-0.1	Vertical cup-disc ratio;	chr6:646076	chr6:774747~780214:-
BRCA	cis	rs7098100	0.601	rs2666772	ENSG00000279623.1	RP11-399C16.3	3.29	0.00105	0.045	0.14	0.1	Breast cancer;	chr10:21944158	chr10:21865335~21865921:-
BRCA	cis	rs829880	0.858	rs733180	ENSG00000245017.2	RP11-181C3.1	3.29	0.00105	0.045	0.12	0.1	Colonoscopy-negative controls vs population controls;	chr12:98448810	chr12:98485544~98503855:-
BRCA	cis	rs970548	0.721	rs11239541	ENSG00000237840.5	FAM21FP	3.29	0.00105	0.045	0.12	0.1	Total cholesterol levels;HDL cholesterol;HDL cholesterol levels;Cholesterol, total;	chr10:45506418	chr10:45706431~45727231:-
BRCA	cis	rs970548	0.69	rs964686	ENSG00000237840.5	FAM21FP	3.29	0.00105	0.045	0.12	0.1	Total cholesterol levels;HDL cholesterol;HDL cholesterol levels;Cholesterol, total;	chr10:45508364	chr10:45706431~45727231:-
BRCA	cis	rs6088813	0.961	rs3795159	ENSG00000261582.1	RP4-614O4.11	-3.29	0.00105	0.045	-0.1	-0.1	Height;	chr20:35308459	chr20:35267885~35280043:-
BRCA	cis	rs4415084	0.716	rs6451774	ENSG00000272335.1	RP11-53O19.3	3.29	0.00105	0.045	0.09	0.1	Breast cancer;	chr5:44793882	chr5:44826076~44828592:+
BRCA	cis	rs4415084	0.716	rs2330619	ENSG00000272335.1	RP11-53O19.3	3.29	0.00105	0.045	0.09	0.1	Breast cancer;	chr5:44795960	chr5:44826076~44828592:+
BRCA	cis	rs4415084	0.716	rs1438819	ENSG00000272335.1	RP11-53O19.3	3.29	0.00105	0.045	0.09	0.1	Breast cancer;	chr5:44797744	chr5:44826076~44828592:+
BRCA	cis	rs9313772	0.505	rs2964329	ENSG00000245812.2	RP11-175K6.1	3.29	0.00105	0.045	0.1	0.1	Blood pressure;	chr5:158308725	chr5:159100483~159117478:+
BRCA	cis	rs6788497	0.708	rs72977381	ENSG00000242551.2	POU5F1P6	3.29	0.00105	0.045	0.18	0.1	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr3:128397055	chr3:128674735~128677005:-
BRCA	cis	rs8098244	0.964	rs8091948	ENSG00000265752.2	RP11-403A21.1	3.29	0.00105	0.045	0.13	0.1	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23793331	chr18:23957754~23982556:-
BRCA	cis	rs4934494	0.727	rs12783845	ENSG00000232229.4	LINC00865	-3.29	0.00105	0.045	-0.16	-0.1	Red blood cell count;	chr10:89722872	chr10:89829510~89840861:+
BRCA	cis	rs875971	0.83	rs778711	ENSG00000223473.2	GS1-124K5.3	3.29	0.00105	0.045	0.08	0.1	Aortic root size;	chr7:66386670	chr7:66491049~66493566:-
BRCA	cis	rs875971	0.862	rs1083554	ENSG00000223473.2	GS1-124K5.3	3.29	0.00105	0.045	0.08	0.1	Aortic root size;	chr7:66387354	chr7:66491049~66493566:-
BRCA	cis	rs875971	0.862	rs778707	ENSG00000223473.2	GS1-124K5.3	3.29	0.00105	0.045	0.08	0.1	Aortic root size;	chr7:66392040	chr7:66491049~66493566:-
BRCA	cis	rs875971	0.862	rs778705	ENSG00000223473.2	GS1-124K5.3	3.29	0.00105	0.045	0.08	0.1	Aortic root size;	chr7:66396128	chr7:66491049~66493566:-
BRCA	cis	rs875971	0.862	rs778697	ENSG00000223473.2	GS1-124K5.3	3.29	0.00105	0.045	0.08	0.1	Aortic root size;	chr7:66405439	chr7:66491049~66493566:-
BRCA	cis	rs875971	0.798	rs7789615	ENSG00000223473.2	GS1-124K5.3	3.29	0.00105	0.045	0.08	0.1	Aortic root size;	chr7:66413674	chr7:66491049~66493566:-
BRCA	cis	rs2638953	0.962	rs12366617	ENSG00000273989.1	RP11-425D17.2	-3.29	0.00105	0.045	-0.15	-0.1	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28395726	chr12:28236227~28236828:+
BRCA	cis	rs2638953	0.815	rs1534340	ENSG00000273989.1	RP11-425D17.2	-3.29	0.00105	0.045	-0.15	-0.1	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28515550	chr12:28236227~28236828:+
BRCA	cis	rs259282	0.602	rs194589	ENSG00000267475.1	CTD-2538C1.2	3.29	0.00105	0.045	0.13	0.1	Schizophrenia;	chr19:32653715	chr19:32687089~32691750:-
BRCA	cis	rs875971	0.522	rs7784623	ENSG00000229180.5	GS1-124K5.11	3.29	0.00105	0.045	0.09	0.1	Aortic root size;	chr7:65930047	chr7:66526088~66542624:-
BRCA	cis	rs9768139	0.658	rs28425474	ENSG00000225365.1	AC078942.1	-3.29	0.00105	0.045	-0.12	-0.1	Calcium levels;	chr7:158323668	chr7:158537495~158539879:+
BRCA	cis	rs3764021	0.527	rs11052423	ENSG00000260423.1	RP13-735L24.1	3.29	0.00105	0.045	0.12	0.1	Type 1 diabetes;	chr12:9687442	chr12:9367464~9397617:+
BRCA	cis	rs2139634	1	rs11706090	ENSG00000227398.3	KIF9-AS1	-3.29	0.00105	0.045	-0.12	-0.1	Cerebrospinal fluid biomarker levels;	chr3:46477855	chr3:47164497~47246601:+
BRCA	cis	rs17214007	0.597	rs4781677	ENSG00000261819.1	RP11-680G24.4	3.29	0.00105	0.045	0.18	0.1	Cognitive function;	chr16:15636388	chr16:14988259~14990160:-
BRCA	cis	rs7636839	0.504	rs6794898	ENSG00000236182.1	RP11-297K7.1	-3.29	0.00105	0.045	-0.12	-0.1	EGFR mutation-positive lung adenocarcinoma;	chr3:189672911	chr3:188989382~188990135:-
BRCA	cis	rs7429990	0.864	rs883662	ENSG00000199476.1	Y_RNA	-3.29	0.00105	0.045	-0.14	-0.1	Educational attainment (years of education);	chr3:47619342	chr3:48288587~48288694:+
BRCA	cis	rs10129255	1	rs10134517	ENSG00000232216.1	IGHV3-43	3.29	0.00105	0.045	0.08	0.1	Kawasaki disease;	chr14:106718498	chr14:106470264~106470800:-
BRCA	cis	rs2018683	0.649	rs12536605	ENSG00000228421.2	AC005013.5	3.29	0.00105	0.045	0.13	0.1	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28930883	chr7:28957667~28959345:+
BRCA	cis	rs9527	0.59	rs1926037	ENSG00000269609.4	RPARP-AS1	-3.29	0.00105	0.045	-0.1	-0.1	Arsenic metabolism;	chr10:103118253	chr10:102449817~102461106:+
BRCA	cis	rs9527	0.567	rs6584539	ENSG00000269609.4	RPARP-AS1	-3.29	0.00105	0.045	-0.1	-0.1	Arsenic metabolism;	chr10:103119645	chr10:102449817~102461106:+
BRCA	cis	rs9527	0.59	rs2148200	ENSG00000269609.4	RPARP-AS1	-3.29	0.00105	0.045	-0.1	-0.1	Arsenic metabolism;	chr10:103120090	chr10:102449817~102461106:+
BRCA	cis	rs9527	0.614	rs2153774	ENSG00000269609.4	RPARP-AS1	-3.29	0.00105	0.045	-0.1	-0.1	Arsenic metabolism;	chr10:103121278	chr10:102449817~102461106:+
BRCA	cis	rs9527	0.59	rs10883834	ENSG00000269609.4	RPARP-AS1	-3.29	0.00105	0.045	-0.1	-0.1	Arsenic metabolism;	chr10:103121645	chr10:102449817~102461106:+
BRCA	cis	rs9527	0.545	rs7915816	ENSG00000269609.4	RPARP-AS1	-3.29	0.00105	0.045	-0.1	-0.1	Arsenic metabolism;	chr10:103121993	chr10:102449817~102461106:+
BRCA	cis	rs9527	0.568	rs1926036	ENSG00000269609.4	RPARP-AS1	-3.29	0.00105	0.045	-0.1	-0.1	Arsenic metabolism;	chr10:103124055	chr10:102449817~102461106:+
BRCA	cis	rs600550	0.551	rs12792791	ENSG00000275344.1	MIR6503	3.29	0.00105	0.045	0.11	0.1	Lipoprotein-associated phospholipase A2 activity and mass;	chr11:60315024	chr11:60209071~60209156:-
BRCA	cis	rs1325195	0.92	rs12130276	ENSG00000232750.2	RP11-177A2.5	-3.29	0.00105	0.045	-0.11	-0.1	IgE grass sensitization;	chr1:179113390	chr1:179035309~179035652:-
BRCA	cis	rs2205299	0.913	rs8127348	ENSG00000215386.9	MIR99AHG	3.29	0.00105	0.045	0.1	0.1	Schizophrenia;	chr21:16826614	chr21:16070522~16627397:+
BRCA	cis	rs12477438	0.765	rs6749059	ENSG00000231822.1	AC019097.7	-3.29	0.00105	0.045	-0.12	-0.1	Chronic sinus infection;	chr2:98974558	chr2:99102018~99102752:+
BRCA	cis	rs3796619	1	rs4974601	ENSG00000272588.1	RP11-440L14.4	-3.29	0.00105	0.045	-0.11	-0.1	Recombination rate (males);	chr4:1101622	chr4:757022~757740:-
BRCA	cis	rs6460942	0.915	rs62447638	ENSG00000226690.5	AC005281.1	3.29	0.00105	0.045	0.2	0.1	Coronary artery disease;	chr7:12445041	chr7:12496429~12541910:+
BRCA	cis	rs1424638	0.502	rs1025335	ENSG00000233251.6	AC007743.1	-3.29	0.00105	0.045	-0.12	-0.1	Intelligence (multi-trait analysis);	chr2:57005077	chr2:56173534~56185770:-
BRCA	cis	rs7487075	0.647	rs12580583	ENSG00000274723.1	RP11-618L22.1	3.29	0.00105	0.045	0.12	0.1	Itch intensity from mosquito bite;	chr12:46313218	chr12:46970504~46972155:+
BRCA	cis	rs7017914	0.967	rs34558600	ENSG00000246366.5	RP11-382J12.1	3.29	0.00105	0.045	0.11	0.1	Bone mineral density;	chr8:70673917	chr8:70608577~70663279:+
BRCA	cis	rs7017914	0.967	rs7001162	ENSG00000246366.5	RP11-382J12.1	3.29	0.00105	0.045	0.11	0.1	Bone mineral density;	chr8:70675235	chr8:70608577~70663279:+
BRCA	cis	rs7017914	0.967	rs56112621	ENSG00000246366.5	RP11-382J12.1	3.29	0.00105	0.045	0.11	0.1	Bone mineral density;	chr8:70676159	chr8:70608577~70663279:+
BRCA	cis	rs17331151	0.573	rs2276818	ENSG00000270941.1	RP5-966M1.5	-3.29	0.00105	0.045	-0.16	-0.1	Immune reponse to smallpox (secreted IL-2);	chr3:52830619	chr3:52734735~52735013:+
BRCA	cis	rs17331151	0.573	rs28552648	ENSG00000270941.1	RP5-966M1.5	-3.29	0.00105	0.045	-0.16	-0.1	Immune reponse to smallpox (secreted IL-2);	chr3:52831577	chr3:52734735~52735013:+
BRCA	cis	rs962856	0.619	rs1027000	ENSG00000236780.4	AC078941.1	3.29	0.00105	0.045	0.14	0.1	Pancreatic cancer;	chr2:67373657	chr2:67123357~67215319:-
BRCA	cis	rs962856	0.619	rs1032158	ENSG00000236780.4	AC078941.1	3.29	0.00105	0.045	0.14	0.1	Pancreatic cancer;	chr2:67373896	chr2:67123357~67215319:-
BRCA	cis	rs12282928	1	rs11039671	ENSG00000255197.4	RP11-750H9.5	-3.29	0.00105	0.045	-0.1	-0.1	Migraine - clinic-based;	chr11:48311433	chr11:47383148~47409190:-
BRCA	cis	rs12282928	0.959	rs7124318	ENSG00000255197.4	RP11-750H9.5	-3.29	0.00105	0.045	-0.1	-0.1	Migraine - clinic-based;	chr11:48316478	chr11:47383148~47409190:-
BRCA	cis	rs12282928	0.917	rs9651621	ENSG00000255197.4	RP11-750H9.5	-3.29	0.00105	0.045	-0.1	-0.1	Migraine - clinic-based;	chr11:48318496	chr11:47383148~47409190:-
BRCA	cis	rs12282928	0.592	rs7119161	ENSG00000255197.4	RP11-750H9.5	-3.29	0.00105	0.045	-0.1	-0.1	Migraine - clinic-based;	chr11:48322013	chr11:47383148~47409190:-
BRCA	cis	rs12282928	0.694	rs1872023	ENSG00000255197.4	RP11-750H9.5	-3.29	0.00105	0.045	-0.1	-0.1	Migraine - clinic-based;	chr11:48322107	chr11:47383148~47409190:-
BRCA	cis	rs6743226	0.934	rs6705421	ENSG00000266621.1	AC104841.1	3.29	0.00105	0.045	0.12	0.1	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in non-smokers;	chr2:241273257	chr2:241245202~241245299:-
BRCA	cis	rs36051895	0.664	rs10117565	ENSG00000237711.1	RP11-39K24.13	-3.29	0.00105	0.045	-0.12	-0.1	Pediatric autoimmune diseases;	chr9:5094461	chr9:5100236~5101009:+
BRCA	cis	rs36051895	0.664	rs10115518	ENSG00000237711.1	RP11-39K24.13	-3.29	0.00105	0.045	-0.12	-0.1	Pediatric autoimmune diseases;	chr9:5094559	chr9:5100236~5101009:+
BRCA	cis	rs2070488	0.965	rs6796845	ENSG00000232439.1	RPL18AP7	-3.29	0.00105	0.045	-0.12	-0.1	Electrocardiographic conduction measures;	chr3:38526280	chr3:38526802~38527325:-
BRCA	cis	rs2070488	0.965	rs9829192	ENSG00000232439.1	RPL18AP7	-3.29	0.00105	0.045	-0.12	-0.1	Electrocardiographic conduction measures;	chr3:38527972	chr3:38526802~38527325:-
BRCA	cis	rs7432375	0.61	rs60574021	ENSG00000273486.1	RP11-731C17.2	3.29	0.00105	0.045	0.11	0.1	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136801439	chr3:136837338~136839021:-
BRCA	cis	rs694419	0.6	rs620068	ENSG00000278017.1	RP11-120K19.4	-3.29	0.00105	0.045	-0.12	-0.1	Serum albumin level;	chr18:62473343	chr18:62525919~62526325:-
BRCA	cis	rs875971	0.895	rs3857684	ENSG00000273448.1	RP11-166O4.6	3.29	0.00105	0.045	0.09	0.1	Aortic root size;	chr7:66473171	chr7:67333047~67334383:+
BRCA	cis	rs259282	0.652	rs2161458	ENSG00000267475.1	CTD-2538C1.2	3.29	0.00105	0.045	0.12	0.1	Schizophrenia;	chr19:32638132	chr19:32687089~32691750:-
BRCA	cis	rs829883	0.659	rs11109524	ENSG00000227825.4	SLC9A7P1	-3.29	0.00105	0.045	-0.14	-0.1	Colorectal adenoma (advanced);	chr12:98545394	chr12:98453835~98457145:-
BRCA	cis	rs12282928	0.959	rs2101185	ENSG00000255197.4	RP11-750H9.5	-3.29	0.00105	0.045	-0.1	-0.1	Migraine - clinic-based;	chr11:48298021	chr11:47383148~47409190:-
BRCA	cis	rs12282928	1	rs2128677	ENSG00000255197.4	RP11-750H9.5	-3.29	0.00105	0.045	-0.1	-0.1	Migraine - clinic-based;	chr11:48298422	chr11:47383148~47409190:-
BRCA	cis	rs2708977	0.643	rs35071802	ENSG00000230606.9	AC159540.1	-3.29	0.00105	0.045	-0.13	-0.1	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96736327	chr2:97416165~97433527:-
BRCA	cis	rs9959145	1	rs76195993	ENSG00000267199.1	RP11-861E21.2	3.29	0.00105	0.045	0.17	0.1	Immune response to smallpox vaccine (IL-6);	chr18:12651888	chr18:12438890~12448205:+
BRCA	cis	rs9959145	1	rs74732619	ENSG00000267199.1	RP11-861E21.2	3.29	0.00105	0.045	0.17	0.1	Immune response to smallpox vaccine (IL-6);	chr18:12652017	chr18:12438890~12448205:+
BRCA	cis	rs901683	1	rs9422650	ENSG00000230869.1	CTGLF10P	-3.29	0.00105	0.045	-0.23	-0.1	Mean corpuscular volume;Red blood cell traits;	chr10:45550313	chr10:45678692~45700532:+
BRCA	cis	rs972578	1	rs5751410	ENSG00000230319.1	AL022476.2	3.29	0.00105	0.045	0.11	0.1	Mean platelet volume;	chr22:42997979	chr22:43038585~43052366:+
BRCA	cis	rs863345	0.604	rs879637	ENSG00000176320.2	RP11-404O13.5	-3.29	0.00105	0.045	-0.11	-0.1	Pneumococcal bacteremia;	chr1:158492907	chr1:158197922~158203877:-
BRCA	cis	rs863345	0.604	rs879635	ENSG00000176320.2	RP11-404O13.5	-3.29	0.00105	0.045	-0.11	-0.1	Pneumococcal bacteremia;	chr1:158493118	chr1:158197922~158203877:-
BRCA	cis	rs4078252	0.85	rs4705783	ENSG00000279522.1	CTC-487M23.6	3.29	0.00105	0.045	0.11	0.1	Response to cytadine analogues (cytosine arabinoside);	chr5:113126752	chr5:112894933~112896531:+
BRCA	cis	rs17597773	0.674	rs12089958	ENSG00000257551.1	HLX-AS1	-3.29	0.00105	0.045	-0.12	-0.1	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220828021	chr1:220832763~220880140:-
BRCA	cis	rs1178968	1	rs757938	ENSG00000225648.4	SBDSP1	3.29	0.00105	0.045	0.17	0.1	Triglyceride levels;	chr7:73364564	chr7:72829425~72836701:+
BRCA	cis	rs7578361	0.918	rs1818997	ENSG00000231969.1	AC144449.1	-3.29	0.00105	0.0451	-0.15	-0.1	Acute lymphoblastic leukemia (childhood);	chr2:149493417	chr2:149587196~149848233:+
BRCA	cis	rs853679	0.517	rs1947862	ENSG00000272009.1	RP1-313I6.12	-3.29	0.00105	0.0451	-0.15	-0.1	Depression;	chr6:28137418	chr6:28078792~28081130:-
BRCA	cis	rs2274273	1	rs74617736	ENSG00000259318.1	RP11-454L9.2	3.29	0.00105	0.0451	0.09	0.1	Protein biomarker;	chr14:55154201	chr14:55394940~55395233:-
BRCA	cis	rs7953704	0.775	rs12812519	ENSG00000256546.1	AC156455.1	-3.29	0.00105	0.0451	-0.12	-0.1	Urate levels;	chr12:122049374	chr12:122063306~122068616:+
BRCA	cis	rs687432	0.924	rs7119218	ENSG00000265566.2	RN7SL605P	-3.29	0.00105	0.0451	-0.13	-0.1	Parkinson's disease;	chr11:57949957	chr11:57528085~57528365:-
BRCA	cis	rs6429422	0.8	rs12091558	ENSG00000224727.1	FCF1P7	3.29	0.00105	0.0451	0.12	0.1	Cognitive ability (multi-trait analysis);	chr1:243290608	chr1:243267257~243268119:-
BRCA	cis	rs10865541	0.935	rs7579868	ENSG00000234171.2	RNASEH1-AS1	3.29	0.00105	0.0451	0.11	0.1	Obesity-related traits;	chr2:3427386	chr2:3558492~3561745:+
BRCA	cis	rs2832191	0.72	rs7277028	ENSG00000232855.5	AF131217.1	3.29	0.00105	0.0451	0.12	0.1	Dental caries;	chr21:29122283	chr21:28439346~28674848:-
BRCA	cis	rs375066	0.935	rs10406290	ENSG00000278917.1	RP11-15A1.4	-3.29	0.00105	0.0451	-0.12	-0.1	Breast cancer;	chr19:43874725	chr19:43891233~43895411:+
BRCA	cis	rs7429990	0.864	rs3772399	ENSG00000228638.1	FCF1P2	3.29	0.00105	0.0451	0.1	0.1	Educational attainment (years of education);	chr3:47826237	chr3:48290793~48291375:-
BRCA	cis	rs10971721	0.822	rs72729357	ENSG00000279489.1	RP11-392A14.8	3.29	0.00105	0.0451	0.21	0.1	Body mass index;	chr9:34041170	chr9:35001913~35003663:+
BRCA	cis	rs9341808	0.718	rs11962614	ENSG00000233967.5	RP11-250B2.3	3.29	0.00105	0.0451	0.1	0.1	Sitting height ratio;	chr6:80113589	chr6:80443344~80465927:+
BRCA	cis	rs9341808	0.718	rs12208016	ENSG00000233967.5	RP11-250B2.3	3.29	0.00105	0.0451	0.1	0.1	Sitting height ratio;	chr6:80113846	chr6:80443344~80465927:+
BRCA	cis	rs9341808	0.718	rs9448886	ENSG00000233967.5	RP11-250B2.3	3.29	0.00105	0.0451	0.1	0.1	Sitting height ratio;	chr6:80116184	chr6:80443344~80465927:+
BRCA	cis	rs9341808	0.683	rs9359409	ENSG00000233967.5	RP11-250B2.3	3.29	0.00105	0.0451	0.1	0.1	Sitting height ratio;	chr6:80117180	chr6:80443344~80465927:+
BRCA	cis	rs8114671	0.562	rs6087643	ENSG00000261582.1	RP4-614O4.11	-3.29	0.00105	0.0451	-0.1	-0.1	Height;	chr20:34886659	chr20:35267885~35280043:-
BRCA	cis	rs7028939	1	rs7862614	ENSG00000239908.3	RN7SL75P	3.29	0.00105	0.0451	0.17	0.1	Preeclampsia;	chr9:100162418	chr9:100102559~100102839:+
BRCA	cis	rs8114671	0.562	rs7263157	ENSG00000126005.14	MMP24-AS1	-3.29	0.00105	0.0451	-0.12	-0.1	Height;	chr20:34871324	chr20:35216462~35278131:-
BRCA	cis	rs12922040	0.651	rs35288467	ENSG00000275910.1	RP11-680G24.6	3.29	0.00105	0.0451	0.11	0.1	Serum uric acid levels in response to allopurinol in gout;	chr16:15773097	chr16:15015828~15016390:-
BRCA	cis	rs2337406	1	rs17113257	ENSG00000231475.3	IGHV4-31	3.29	0.00105	0.0451	0.1	0.1	Alzheimer's disease (late onset);	chr14:106679574	chr14:106349283~106349792:-
BRCA	cis	rs3015497	0.646	rs3015492	ENSG00000269906.1	RP11-248J18.2	-3.29	0.00105	0.0451	-0.14	-0.1	Mean platelet volume;	chr14:50658025	chr14:50662511~50663178:-
BRCA	cis	rs561341	1	rs501957	ENSG00000277511.1	CTD-2095E4.5	3.29	0.00105	0.0451	0.15	0.1	Hip circumference adjusted for BMI;	chr17:31987485	chr17:32127595~32128454:+
BRCA	cis	rs875971	0.545	rs10261710	ENSG00000226767.1	RP11-328P23.3	3.29	0.00105	0.0451	0.13	0.1	Aortic root size;	chr7:66249202	chr7:65508773~65508944:-
BRCA	cis	rs28374715	0.662	rs10851403	ENSG00000247556.5	OIP5-AS1	3.29	0.00105	0.0451	0.11	0.1	Ulcerative colitis;	chr15:41173889	chr15:41283990~41309737:+
BRCA	cis	rs71520386	0.632	rs9692432	ENSG00000179428.2	AC073072.5	3.29	0.00105	0.0451	0.12	0.1	Fibrinogen levels;	chr7:22829244	chr7:22725395~22727620:-
BRCA	cis	rs71520386	0.632	rs71520387	ENSG00000179428.2	AC073072.5	3.29	0.00105	0.0451	0.12	0.1	Fibrinogen levels;	chr7:22830057	chr7:22725395~22727620:-
BRCA	cis	rs71520386	0.632	rs10224244	ENSG00000179428.2	AC073072.5	3.29	0.00105	0.0451	0.12	0.1	Fibrinogen levels;	chr7:22830455	chr7:22725395~22727620:-
BRCA	cis	rs10043228	1	rs12515466	ENSG00000250015.1	CTC-339F2.2	3.29	0.00105	0.0451	0.13	0.1	Asthma or chronic obstructive pulmonary disease;	chr5:116256180	chr5:116302354~116304134:-
BRCA	cis	rs2904967	0.852	rs1858783	ENSG00000254501.1	AP003068.9	3.29	0.00105	0.0451	0.17	0.1	Mean corpuscular volume;	chr11:65275470	chr11:65110714~65111695:-
BRCA	cis	rs7918232	0.662	rs10764662	ENSG00000236983.1	LINC00614	3.29	0.00105	0.0451	0.13	0.1	Breast cancer;	chr10:27011714	chr10:26943323~26944418:-
BRCA	cis	rs4388249	0.904	rs71575306	ENSG00000249068.1	CTC-287O8.1	3.29	0.00105	0.0451	0.15	0.1	Schizophrenia;	chr5:109710509	chr5:109840128~109840692:-
BRCA	cis	rs10421328	0.717	rs2288865	ENSG00000267419.1	CTC-559E9.6	-3.29	0.00105	0.0451	-0.12	-0.1	Parental longevity (combined parental age at death);	chr19:19652826	chr19:19776602~19834927:+
BRCA	cis	rs3816183	0.626	rs13023683	ENSG00000226491.1	FTOP1	-3.29	0.00105	0.0451	-0.13	-0.1	Hypospadias;	chr2:42681811	chr2:42797225~42798712:-
BRCA	cis	rs8049367	0.684	rs2283485	ENSG00000279031.1	LA16c-360H6.1	3.29	0.00105	0.0451	0.11	0.1	Nonsyndromic cleft lip with or without cleft palate;	chr16:3919555	chr16:3292879~3293403:+
BRCA	cis	rs875971	1	rs6958271	ENSG00000230189.5	GS1-124K5.2	3.29	0.00105	0.0451	0.08	0.1	Aortic root size;	chr7:66514344	chr7:66409143~66490059:-
BRCA	cis	rs875971	1	rs6958277	ENSG00000230189.5	GS1-124K5.2	3.29	0.00105	0.0451	0.08	0.1	Aortic root size;	chr7:66514362	chr7:66409143~66490059:-
BRCA	cis	rs10971721	0.731	rs10971857	ENSG00000279489.1	RP11-392A14.8	3.29	0.00105	0.0451	0.21	0.1	Body mass index;	chr9:34021621	chr9:35001913~35003663:+
BRCA	cis	rs948562	0.947	rs73470778	ENSG00000255299.4	RP11-655C2.3	-3.29	0.00105	0.0451	-0.13	-0.1	Lymphoma;	chr11:58650594	chr11:58497888~58505758:-
BRCA	cis	rs4718428	0.705	rs2901311	ENSG00000275400.1	RP4-756H11.5	-3.29	0.00105	0.0451	-0.13	-0.1	Corneal structure;	chr7:66950082	chr7:66553805~66554199:-
BRCA	cis	rs2185341	1	rs4655058	ENSG00000218510.5	LINC00339	3.29	0.00105	0.0451	0.13	0.1	Amyotrophic lateral sclerosis;	chr1:22402068	chr1:22025188~22031223:+
BRCA	cis	rs6439153	0.933	rs6769662	ENSG00000242551.2	POU5F1P6	-3.29	0.00105	0.0451	-0.13	-0.1	Pneumococcal bacteremia;	chr3:129002467	chr3:128674735~128677005:-
BRCA	cis	rs8127691	0.967	rs2070551	ENSG00000225331.1	AP001055.6	3.29	0.00105	0.0451	0.12	0.1	Inflammatory bowel disease;	chr21:44196789	chr21:44158740~44160076:-
BRCA	cis	rs6142102	0.961	rs4911408	ENSG00000206582.1	Y_RNA	-3.29	0.00105	0.0451	-0.13	-0.1	Skin pigmentation;	chr20:34112760	chr20:34526510~34526606:-
BRCA	cis	rs10819083	0.688	rs2111365	ENSG00000232630.1	PRPS1P2	-3.29	0.00105	0.0451	-0.1	-0.1	Squamous cell lung carcinoma;	chr9:125977323	chr9:125150653~125151589:+
BRCA	cis	rs477895	0.653	rs66648159	ENSG00000256940.1	RP11-783K16.5	3.29	0.00105	0.0451	0.14	0.1	Mean platelet volume;	chr11:64131957	chr11:64245964~64248217:+
BRCA	cis	rs1178127	0.719	rs1178164	ENSG00000232821.1	AC003986.6	3.29	0.00105	0.0451	0.13	0.1	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);	chr7:18748966	chr7:19112474~19114271:+
BRCA	cis	rs4819052	0.851	rs9974628	ENSG00000223768.1	LINC00205	-3.29	0.00105	0.0451	-0.14	-0.1	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45252732	chr21:45293285~45297354:+
BRCA	cis	rs1048886	0.872	rs9455182	ENSG00000271967.1	RP11-134K13.4	-3.29	0.00105	0.0451	-0.14	-0.1	Type 2 diabetes;	chr6:70593212	chr6:70596438~70596980:+
BRCA	cis	rs9392556	0.829	rs7744628	ENSG00000230648.1	RP3-406P24.3	-3.29	0.00105	0.0451	-0.13	-0.1	Blood metabolite levels;	chr6:4119762	chr6:4018843~4021215:-
BRCA	cis	rs875971	0.825	rs10281499	ENSG00000265600.1	AC006480.1	3.29	0.00105	0.0451	0.12	0.1	Aortic root size;	chr7:66583979	chr7:67356680~67356779:+
BRCA	cis	rs7520050	0.966	rs1768803	ENSG00000234329.1	RP11-767N6.2	-3.29	0.00105	0.0451	-0.1	-0.1	Reticulocyte count;Red blood cell count;	chr1:46080536	chr1:45651039~45651826:-
BRCA	cis	rs2712184	0.655	rs1003622	ENSG00000237930.1	AC007563.4	3.29	0.00105	0.0451	0.11	0.1	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);	chr2:216788885	chr2:216785774~216786144:-
BRCA	cis	rs321358	0.731	rs534858	ENSG00000271390.1	RP11-89C3.3	3.29	0.00105	0.0451	0.15	0.1	Body mass index;	chr11:111145583	chr11:111089870~111090368:-
BRCA	cis	rs35520189	0.845	rs12479173	ENSG00000274877.1	RP11-65I12.1	-3.29	0.00105	0.0451	-0.15	-0.1	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:112891633	chr2:113237595~113240825:+
BRCA	cis	rs9527	0.518	rs7899608	ENSG00000236937.2	PTGES3P4	3.29	0.00105	0.0451	0.19	0.1	Arsenic metabolism;	chr10:102967547	chr10:102845595~102845950:+
BRCA	cis	rs17345786	0.817	rs11720560	ENSG00000256628.3	ZBTB11-AS1	3.29	0.00105	0.0451	0.14	0.1	Colonoscopy-negative controls vs population controls;	chr3:101609640	chr3:101676475~101679217:+
BRCA	cis	rs12303914	0.762	rs1600130	ENSG00000256682.2	TAS2R12	-3.29	0.00105	0.0451	-0.12	-0.1	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr12:10301897	chr12:10894943~10896952:-
BRCA	cis	rs6672530	0.518	rs10916169	ENSG00000227711.2	RP11-275O4.5	3.29	0.00105	0.0451	0.12	0.1	Hip circumference adjusted for BMI;	chr1:227577156	chr1:227509028~227520477:-
BRCA	cis	rs6696239	0.513	rs903697	ENSG00000227711.2	RP11-275O4.5	3.29	0.00105	0.0451	0.12	0.1	Height;	chr1:227579144	chr1:227509028~227520477:-
BRCA	cis	rs2638953	0.925	rs7312201	ENSG00000273989.1	RP11-425D17.2	-3.29	0.00105	0.0451	-0.15	-0.1	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28417885	chr12:28236227~28236828:+
BRCA	cis	rs2638953	0.962	rs12372172	ENSG00000273989.1	RP11-425D17.2	-3.29	0.00105	0.0451	-0.15	-0.1	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28419945	chr12:28236227~28236828:+
BRCA	cis	rs860295	0.702	rs2025669	ENSG00000203761.5	MSTO2P	-3.29	0.00105	0.0451	-0.09	-0.1	Body mass index;	chr1:155387818	chr1:155745829~155750137:+
BRCA	cis	rs11098499	0.754	rs10518300	ENSG00000260091.1	RP11-33B1.4	3.29	0.00105	0.0451	0.09	0.1	Corneal astigmatism;	chr4:119328344	chr4:119409333~119410233:+
BRCA	cis	rs38055	0.558	rs62357442	ENSG00000247796.2	CTD-2366F13.1	3.29	0.00105	0.0451	0.13	0.1	Acne (severe);	chr5:53231042	chr5:53109842~53115126:+
BRCA	cis	rs11098499	0.754	rs1849457	ENSG00000250412.1	KLHL2P1	3.29	0.00105	0.0451	0.12	0.1	Corneal astigmatism;	chr4:119333200	chr4:119334329~119378233:+
BRCA	cis	rs4809760	0.967	rs2235620	ENSG00000224397.4	LINC01272	3.29	0.00105	0.0451	0.1	0.1	Gut microbiota (beta diversity);	chr20:49857663	chr20:50267486~50279795:+
BRCA	cis	rs7647973	0.626	rs4855882	ENSG00000228008.1	CTD-2330K9.3	-3.29	0.00105	0.0451	-0.14	-0.1	Menarche (age at onset);	chr3:49677921	chr3:49903845~49916937:+
BRCA	cis	rs1334894	0.892	rs9689799	ENSG00000187762.5	HSPE1P11	3.29	0.00105	0.0451	0.24	0.1	Coronary artery disease;	chr6:35505280	chr6:35023522~35023831:+
BRCA	cis	rs10246939	0.544	rs6955562	ENSG00000270923.1	TAS2R6P	-3.29	0.00105	0.0451	-0.11	-0.1	Bitter taste perception;	chr7:141886641	chr7:141787815~141788640:+
BRCA	cis	rs7586085	0.868	rs3762552	ENSG00000229195.1	AC009495.4	-3.29	0.00105	0.0451	-0.12	-0.1	Total body bone mineral density;	chr2:165758269	chr2:165794857~165846091:-
BRCA	cis	rs2638953	0.853	rs10843195	ENSG00000273989.1	RP11-425D17.2	-3.29	0.00105	0.0451	-0.15	-0.1	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28513633	chr12:28236227~28236828:+
BRCA	cis	rs2638953	0.853	rs10843196	ENSG00000273989.1	RP11-425D17.2	-3.29	0.00105	0.0451	-0.15	-0.1	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28513660	chr12:28236227~28236828:+
BRCA	cis	rs2243480	1	rs431318	ENSG00000226002.1	RP11-460N20.5	-3.29	0.00105	0.0452	-0.17	-0.1	Diabetic kidney disease;	chr7:66046610	chr7:65084103~65100232:+
BRCA	cis	rs4848143	0.64	rs2312440	ENSG00000236859.5	NIFK-AS1	-3.29	0.00105	0.0452	-0.11	-0.1	Capecitabine sensitivity;	chr2:121041881	chr2:121649650~121728208:+
BRCA	cis	rs4848143	0.64	rs2312441	ENSG00000236859.5	NIFK-AS1	-3.29	0.00105	0.0452	-0.11	-0.1	Capecitabine sensitivity;	chr2:121041944	chr2:121649650~121728208:+
BRCA	cis	rs4848143	0.605	rs2312442	ENSG00000236859.5	NIFK-AS1	-3.29	0.00105	0.0452	-0.11	-0.1	Capecitabine sensitivity;	chr2:121041954	chr2:121649650~121728208:+
BRCA	cis	rs4848143	0.571	rs2312443	ENSG00000236859.5	NIFK-AS1	-3.29	0.00105	0.0452	-0.11	-0.1	Capecitabine sensitivity;	chr2:121042101	chr2:121649650~121728208:+
BRCA	cis	rs4848143	0.64	rs2312444	ENSG00000236859.5	NIFK-AS1	-3.29	0.00105	0.0452	-0.11	-0.1	Capecitabine sensitivity;	chr2:121042139	chr2:121649650~121728208:+
BRCA	cis	rs4848143	0.571	rs2872036	ENSG00000236859.5	NIFK-AS1	-3.29	0.00105	0.0452	-0.11	-0.1	Capecitabine sensitivity;	chr2:121042291	chr2:121649650~121728208:+
BRCA	cis	rs4848143	0.64	rs6707099	ENSG00000236859.5	NIFK-AS1	-3.29	0.00105	0.0452	-0.11	-0.1	Capecitabine sensitivity;	chr2:121042375	chr2:121649650~121728208:+
BRCA	cis	rs4848143	0.64	rs2176426	ENSG00000236859.5	NIFK-AS1	-3.29	0.00105	0.0452	-0.11	-0.1	Capecitabine sensitivity;	chr2:121042411	chr2:121649650~121728208:+
BRCA	cis	rs4848143	0.64	rs2138819	ENSG00000236859.5	NIFK-AS1	-3.29	0.00105	0.0452	-0.11	-0.1	Capecitabine sensitivity;	chr2:121042532	chr2:121649650~121728208:+
BRCA	cis	rs4848143	0.64	rs2138818	ENSG00000236859.5	NIFK-AS1	-3.29	0.00105	0.0452	-0.11	-0.1	Capecitabine sensitivity;	chr2:121042685	chr2:121649650~121728208:+
BRCA	cis	rs4848143	0.64	rs2176425	ENSG00000236859.5	NIFK-AS1	-3.29	0.00105	0.0452	-0.11	-0.1	Capecitabine sensitivity;	chr2:121042842	chr2:121649650~121728208:+
BRCA	cis	rs4848143	0.64	rs4848141	ENSG00000236859.5	NIFK-AS1	-3.29	0.00105	0.0452	-0.11	-0.1	Capecitabine sensitivity;	chr2:121043026	chr2:121649650~121728208:+
BRCA	cis	rs4848143	0.64	rs12619184	ENSG00000236859.5	NIFK-AS1	-3.29	0.00105	0.0452	-0.11	-0.1	Capecitabine sensitivity;	chr2:121043253	chr2:121649650~121728208:+
BRCA	cis	rs4848143	0.64	rs12616252	ENSG00000236859.5	NIFK-AS1	-3.29	0.00105	0.0452	-0.11	-0.1	Capecitabine sensitivity;	chr2:121043265	chr2:121649650~121728208:+
BRCA	cis	rs4848143	0.64	rs7562900	ENSG00000236859.5	NIFK-AS1	-3.29	0.00105	0.0452	-0.11	-0.1	Capecitabine sensitivity;	chr2:121043515	chr2:121649650~121728208:+
BRCA	cis	rs194045	0.609	rs252344	ENSG00000279106.1	RP11-426C22.1	-3.29	0.00105	0.0452	-0.14	-0.1	Yu-Zhi constitution type in type 2 diabetes;	chr16:29173561	chr16:29204633~29205855:+
BRCA	cis	rs6540556	0.723	rs12060420	ENSG00000236136.1	ADORA2BP1	-3.29	0.00105	0.0452	-0.13	-0.1	Red blood cell count;	chr1:209733474	chr1:209744373~209745214:+
BRCA	cis	rs654950	0.875	rs2759248	ENSG00000230881.1	RP11-486B10.3	3.29	0.00105	0.0452	0.1	0.1	Airway imaging phenotypes;	chr1:41525124	chr1:41535443~41535868:+
BRCA	cis	rs6088580	0.561	rs3761147	ENSG00000269202.1	RP4-614O4.12	3.29	0.00105	0.0452	0.1	0.1	Glomerular filtration rate (creatinine);	chr20:34408883	chr20:35201747~35203288:-
BRCA	cis	rs1923539	0.545	rs10159532	ENSG00000272447.1	RP11-182L21.6	3.29	0.00105	0.0452	0.12	0.1	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79982301	chr10:79825902~79827602:+
BRCA	cis	rs10771431	0.967	rs7137443	ENSG00000256069.6	A2MP1	3.29	0.00105	0.0452	0.1	0.1	Breast size;	chr12:9219433	chr12:9228533~9275817:-
BRCA	cis	rs7914558	1	rs67908413	ENSG00000272912.1	RP11-724N1.1	-3.29	0.00105	0.0452	-0.11	-0.1	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103005232	chr10:102914585~102915404:+
BRCA	cis	rs6445967	1	rs1913716	ENSG00000272182.1	RP11-802O23.3	3.29	0.00105	0.0452	0.11	0.1	Platelet count;	chr3:58322604	chr3:58428255~58428815:+
BRCA	cis	rs11673344	0.832	rs77772684	ENSG00000267682.1	CTD-3220F14.2	-3.29	0.00105	0.0452	-0.09	-0.1	Obesity-related traits;	chr19:37055838	chr19:37337236~37337743:+
BRCA	cis	rs1003719	0.688	rs2835660	ENSG00000242553.1	AP001432.14	3.29	0.00105	0.0452	0.12	0.1	Eye color traits;	chr21:37196581	chr21:37221419~37237744:+
BRCA	cis	rs1003719	0.688	rs2835662	ENSG00000242553.1	AP001432.14	3.29	0.00105	0.0452	0.12	0.1	Eye color traits;	chr21:37196666	chr21:37221419~37237744:+
BRCA	cis	rs7789940	1	rs17149161	ENSG00000231087.2	FDPSP7	-3.29	0.00105	0.0452	-0.13	-0.1	Multiple sclerosis;	chr7:76348912	chr7:76968197~76969250:-
BRCA	cis	rs4699052	0.626	rs10017383	ENSG00000230069.3	LRRC37A15P	-3.29	0.00105	0.0452	-0.1	-0.1	Testicular germ cell tumor;	chr4:103328800	chr4:102727274~102730721:-
BRCA	cis	rs12234571	1	rs73374135	ENSG00000214293.7	APTR	3.29	0.00105	0.0452	0.21	0.1	Obesity-related traits;	chr7:77753938	chr7:77657660~77696265:-
BRCA	cis	rs7149337	1	rs35567150	ENSG00000258955.1	LINC00519	-3.29	0.00105	0.0452	-0.11	-0.1	Cancer;	chr14:51259226	chr14:51304416~51328386:-
BRCA	cis	rs1730008	0.865	rs1624094	ENSG00000279311.1	RP11-170K4.2	-3.29	0.00105	0.0452	-0.11	-0.1	Lobe attachment (rater-scored or self-reported);	chr3:158204321	chr3:158869898~158871821:+
BRCA	cis	rs4919694	0.908	rs11191523	ENSG00000236937.2	PTGES3P4	3.29	0.00105	0.0452	0.21	0.1	Arsenic metabolism;	chr10:103032643	chr10:102845595~102845950:+
BRCA	cis	rs4919694	1	rs11191525	ENSG00000236937.2	PTGES3P4	3.29	0.00105	0.0452	0.21	0.1	Arsenic metabolism;	chr10:103033678	chr10:102845595~102845950:+
BRCA	cis	rs4919694	1	rs12252500	ENSG00000236937.2	PTGES3P4	3.29	0.00105	0.0452	0.21	0.1	Arsenic metabolism;	chr10:103035227	chr10:102845595~102845950:+
BRCA	cis	rs9400467	0.568	rs9320364	ENSG00000255389.1	C6orf3	3.29	0.00105	0.0452	0.12	0.1	Amino acid levels;Blood metabolite levels;	chr6:111490719	chr6:111599875~111602295:+
BRCA	cis	rs2842992	0.724	rs9347340	ENSG00000251988.1	RNU4ATAC18P	-3.29	0.00105	0.0452	-0.13	-0.1	Age-related macular degeneration (geographic atrophy);	chr6:159767859	chr6:159720415~159720540:-
BRCA	cis	rs1048886	0.872	rs9455177	ENSG00000271967.1	RP11-134K13.4	-3.29	0.00105	0.0452	-0.14	-0.1	Type 2 diabetes;	chr6:70591822	chr6:70596438~70596980:+
BRCA	cis	rs10129255	0.957	rs2007467	ENSG00000253132.1	IGHV3-62	3.29	0.00105	0.0452	0.08	0.1	Kawasaki disease;	chr14:106771605	chr14:106643142~106643585:-
BRCA	cis	rs4948102	0.731	rs4948099	ENSG00000226278.1	PSPHP1	3.29	0.00105	0.0452	0.11	0.1	Plasma homocysteine levels (post-methionine load test);	chr7:56004557	chr7:55764797~55773288:+
BRCA	cis	rs12468226	1	rs6739198	ENSG00000233579.1	KRT8P15	-3.29	0.00105	0.0452	-0.17	-0.1	Urate levels;	chr2:202492273	chr2:202840331~202841781:-
BRCA	cis	rs7274811	0.744	rs6119395	ENSG00000228265.4	RALY-AS1	3.29	0.00105	0.0452	0.12	0.1	Height;	chr20:33656905	chr20:33983052~33994357:-
BRCA	cis	rs4374383	0.631	rs1400322	ENSG00000236307.2	EEF1E1P1	-3.29	0.00105	0.0452	-0.11	-0.1	Hepatitis C induced liver fibrosis;	chr2:111912608	chr2:111887914~111888741:+
BRCA	cis	rs564309	0.764	rs12089997	ENSG00000183929.7	DUSP5P1	3.29	0.00105	0.0452	0.21	0.1	Hip circumference (psychosocial stress interaction);	chr1:228339485	chr1:228650241~228651379:+
BRCA	cis	rs10070219	0.505	rs10477562	ENSG00000248445.4	SEMA6A-AS1	-3.28	0.00105	0.0452	-0.13	-0.1	3-hydroxypropylmercapturic acid levels in smokers;	chr5:117355804	chr5:116447547~116508276:+
BRCA	cis	rs55962025	0.737	rs2237006	ENSG00000249047.2	COX6B1P5	3.28	0.00105	0.0452	0.12	0.1	Parental longevity (mother's age at death);	chr4:3226765	chr4:2234251~2234499:+
BRCA	cis	rs801193	0.66	rs10950049	ENSG00000230189.5	GS1-124K5.2	3.28	0.00105	0.0452	0.08	0.1	Aortic root size;	chr7:66765873	chr7:66409143~66490059:-
BRCA	cis	rs875971	1	rs1565531	ENSG00000230189.5	GS1-124K5.2	-3.28	0.00105	0.0452	-0.08	-0.1	Aortic root size;	chr7:66198126	chr7:66409143~66490059:-
BRCA	cis	rs2811415	0.597	rs9827668	ENSG00000242551.2	POU5F1P6	3.28	0.00105	0.0452	0.14	0.1	Lung function (FEV1/FVC);	chr3:128056637	chr3:128674735~128677005:-
BRCA	cis	rs2811415	0.597	rs9827421	ENSG00000242551.2	POU5F1P6	3.28	0.00105	0.0452	0.14	0.1	Lung function (FEV1/FVC);	chr3:128056656	chr3:128674735~128677005:-
BRCA	cis	rs7849420	0.52	rs10811560	ENSG00000240498.5	CDKN2B-AS1	-3.28	0.00105	0.0452	-0.12	-0.1	Lipid traits;	chr9:21530542	chr9:21994778~22121097:+
BRCA	cis	rs72772090	0.71	rs11750400	ENSG00000272109.1	CTD-2260A17.3	3.28	0.00105	0.0452	0.19	0.1	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96742264	chr5:96804353~96806105:+
BRCA	cis	rs72772090	0.71	rs10515244	ENSG00000272109.1	CTD-2260A17.3	3.28	0.00105	0.0452	0.19	0.1	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96742633	chr5:96804353~96806105:+
BRCA	cis	rs72772090	0.71	rs1559085	ENSG00000272109.1	CTD-2260A17.3	3.28	0.00105	0.0452	0.19	0.1	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96742998	chr5:96804353~96806105:+
BRCA	cis	rs6120849	0.663	rs11698868	ENSG00000276073.1	RP5-1125A11.7	-3.28	0.00105	0.0452	-0.14	-0.1	Protein C levels;	chr20:34962143	chr20:33985617~33988989:-
BRCA	cis	rs6120849	0.663	rs6119548	ENSG00000276073.1	RP5-1125A11.7	-3.28	0.00105	0.0452	-0.14	-0.1	Protein C levels;	chr20:34964809	chr20:33985617~33988989:-
BRCA	cis	rs4718428	0.705	rs12536410	ENSG00000229886.1	RP5-1132H15.3	3.28	0.00105	0.0452	0.13	0.1	Corneal structure;	chr7:66789303	chr7:66025126~66031544:-
BRCA	cis	rs875971	0.862	rs778684	ENSG00000106610.13	STAG3L4	-3.28	0.00105	0.0452	-0.14	-0.1	Aortic root size;	chr7:66371416	chr7:67302621~67321526:+
BRCA	cis	rs2842992	0.789	rs4709376	ENSG00000207392.1	SNORA20	-3.28	0.00105	0.0452	-0.14	-0.1	Age-related macular degeneration (geographic atrophy);	chr6:159805305	chr6:159780250~159780381:-
BRCA	cis	rs977987	0.778	rs4888400	ENSG00000280152.1	RP11-331F4.5	-3.28	0.00105	0.0452	-0.1	-0.1	Dupuytren's disease;	chr16:75391698	chr16:75245994~75250077:-
BRCA	cis	rs1003719	0.68	rs1034357	ENSG00000242553.1	AP001432.14	3.28	0.00105	0.0452	0.12	0.1	Eye color traits;	chr21:37199181	chr21:37221419~37237744:+
BRCA	cis	rs1003719	0.68	rs2835664	ENSG00000242553.1	AP001432.14	3.28	0.00105	0.0452	0.12	0.1	Eye color traits;	chr21:37201128	chr21:37221419~37237744:+
BRCA	cis	rs1003719	0.553	rs1063948	ENSG00000242553.1	AP001432.14	3.28	0.00105	0.0452	0.12	0.1	Eye color traits;	chr21:37202373	chr21:37221419~37237744:+
BRCA	cis	rs1003719	0.646	rs2032063	ENSG00000242553.1	AP001432.14	3.28	0.00105	0.0452	0.12	0.1	Eye color traits;	chr21:37204356	chr21:37221419~37237744:+
BRCA	cis	rs1003719	0.646	rs7276711	ENSG00000242553.1	AP001432.14	3.28	0.00105	0.0452	0.12	0.1	Eye color traits;	chr21:37205888	chr21:37221419~37237744:+
BRCA	cis	rs1003719	0.68	rs7276569	ENSG00000242553.1	AP001432.14	3.28	0.00105	0.0452	0.12	0.1	Eye color traits;	chr21:37205906	chr21:37221419~37237744:+
BRCA	cis	rs1003719	0.715	rs2212742	ENSG00000242553.1	AP001432.14	3.28	0.00105	0.0452	0.12	0.1	Eye color traits;	chr21:37206384	chr21:37221419~37237744:+
BRCA	cis	rs9341808	0.718	rs9361584	ENSG00000233967.5	RP11-250B2.3	3.28	0.00105	0.0452	0.1	0.1	Sitting height ratio;	chr6:80110229	chr6:80443344~80465927:+
BRCA	cis	rs875971	0.577	rs35072105	ENSG00000272831.1	RP11-792A8.4	-3.28	0.00105	0.0452	-0.09	-0.1	Aortic root size;	chr7:66144830	chr7:66739829~66740385:-
BRCA	cis	rs6504622	0.693	rs12952596	ENSG00000263142.4	LRRC37A17P	-3.28	0.00105	0.0452	-0.08	-0.1	Orofacial clefts;	chr17:46994319	chr17:46978481~47054569:+
BRCA	cis	rs6840360	0.615	rs1877188	ENSG00000270265.1	RP11-731D1.4	-3.28	0.00105	0.0452	-0.12	-0.1	Intelligence (multi-trait analysis);	chr4:151686779	chr4:151333775~151353224:-
BRCA	cis	rs7005380	0.965	rs9918814	ENSG00000279347.1	RP11-85I17.2	3.28	0.00105	0.0452	0.11	0.1	Interstitial lung disease;	chr8:119939362	chr8:119838736~119840385:-
BRCA	cis	rs1005277	0.505	rs7069702	ENSG00000099251.13	HSD17B7P2	-3.28	0.00105	0.0452	-0.11	-0.1	Extrinsic epigenetic age acceleration;	chr10:37958431	chr10:38356380~38378505:+
BRCA	cis	rs863345	0.604	rs10908651	ENSG00000229914.1	RP11-404O13.4	3.28	0.00105	0.0452	0.1	0.1	Pneumococcal bacteremia;	chr1:158481482	chr1:158195633~158196131:-
BRCA	cis	rs3096299	0.719	rs2965817	ENSG00000261118.1	RP11-104N10.1	3.28	0.00105	0.0452	0.1	0.1	Multiple myeloma (IgH translocation);	chr16:89446826	chr16:89492017~89504460:-
BRCA	cis	rs198426	0.506	rs198465	ENSG00000243742.4	RPLP0P2	3.28	0.00105	0.0453	0.12	0.1	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr11:61753846	chr11:61615036~61639449:+
BRCA	cis	rs11907546	1	rs11907546	ENSG00000206582.1	Y_RNA	-3.28	0.00106	0.0453	-0.12	-0.1	Cancer (pleiotropy);Cancer;	chr20:34131991	chr20:34526510~34526606:-
BRCA	cis	rs7017914	0.902	rs34882924	ENSG00000246366.5	RP11-382J12.1	3.28	0.00106	0.0453	0.11	0.1	Bone mineral density;	chr8:70654073	chr8:70608577~70663279:+
BRCA	cis	rs3096299	0.658	rs34590044	ENSG00000259877.2	RP11-46C24.7	-3.28	0.00106	0.0453	-0.09	-0.1	Multiple myeloma (IgH translocation);	chr16:89476749	chr16:89215211~89217653:-
BRCA	cis	rs34792	0.626	rs153788	ENSG00000260872.1	RP11-680G24.5	-3.28	0.00106	0.0453	-0.11	-0.1	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15500346	chr16:15018106~15020488:-
BRCA	cis	rs4849845	0.637	rs2028147	ENSG00000236878.1	AC012363.7	-3.28	0.00106	0.0453	-0.12	-0.1	Mean platelet volume;	chr2:120300836	chr2:120211054~120211715:+
BRCA	cis	rs11858159	1	rs11858159	ENSG00000207279.1	SNORD116-24	-3.28	0.00106	0.0453	-0.1	-0.1	Platelet thrombus formation;	chr15:24579041	chr15:25094037~25094128:+
BRCA	cis	rs7800418	0.775	rs3948698	ENSG00000280255.1	RP5-1007F24.1	3.28	0.00106	0.0453	0.12	0.1	Cognitive function;	chr7:26561044	chr7:26538378~26541048:+
BRCA	cis	rs6439153	0.967	rs12695513	ENSG00000242551.2	POU5F1P6	-3.28	0.00106	0.0453	-0.13	-0.1	Pneumococcal bacteremia;	chr3:129003469	chr3:128674735~128677005:-
BRCA	cis	rs970548	0.955	rs10900232	ENSG00000237840.5	FAM21FP	3.28	0.00106	0.0453	0.13	0.1	Total cholesterol levels;HDL cholesterol;HDL cholesterol levels;Cholesterol, total;	chr10:45662444	chr10:45706431~45727231:-
BRCA	cis	rs359466	0.938	rs17076705	ENSG00000253768.1	CTB-33O18.1	-3.28	0.00106	0.0453	-0.16	-0.1	QRS complex (Sokolow-Lyon);	chr5:173925800	chr5:173562478~173573199:+
BRCA	cis	rs7520050	0.966	rs4660910	ENSG00000234329.1	RP11-767N6.2	-3.28	0.00106	0.0453	-0.1	-0.1	Reticulocyte count;Red blood cell count;	chr1:46082730	chr1:45651039~45651826:-
BRCA	cis	rs2999083	0.524	rs9827325	ENSG00000242551.2	POU5F1P6	3.28	0.00106	0.0453	0.14	0.1	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr3:128017331	chr3:128674735~128677005:-
BRCA	cis	rs7636293	0.897	rs7623428	ENSG00000270773.1	RP13-685P2.7	3.28	0.00106	0.0453	0.11	0.1	Height;	chr3:129330050	chr3:129345411~129346164:+
BRCA	cis	rs4718428	0.705	rs13231140	ENSG00000275400.1	RP4-756H11.5	-3.28	0.00106	0.0453	-0.13	-0.1	Corneal structure;	chr7:66896631	chr7:66553805~66554199:-
BRCA	cis	rs7624327	1	rs77927407	ENSG00000244515.1	KRT18P34	-3.28	0.00106	0.0453	-0.21	-0.1	Eating disorders;	chr3:157119941	chr3:157162663~157163932:-
BRCA	cis	rs11955398	0.502	rs295531	ENSG00000272308.1	RP11-231G3.1	-3.28	0.00106	0.0453	-0.12	-0.1	Intelligence (multi-trait analysis);	chr5:61099916	chr5:60866457~60866935:-
BRCA	cis	rs11227306	0.934	rs2303385	ENSG00000254510.1	RP11-867G23.10	-3.28	0.00106	0.0453	-0.11	-0.1	DNA methylation (variation);	chr11:65873091	chr11:66409158~66417137:+
BRCA	cis	rs7267979	0.903	rs6132819	ENSG00000204556.4	CTD-2514C3.1	-3.28	0.00106	0.0453	-0.14	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25237982	chr20:26018832~26020684:+
BRCA	cis	rs77741769	0.571	rs3809313	ENSG00000277423.1	RP11-173P15.9	-3.28	0.00106	0.0453	-0.12	-0.1	Mean corpuscular volume;	chr12:120892164	chr12:120703867~120704282:+
BRCA	cis	rs2227564	0.729	rs2688617	ENSG00000279689.1	RP11-574K11.32	3.28	0.00106	0.0453	0.11	0.1	Crohn's disease;Inflammatory bowel disease;	chr10:73886389	chr10:73769264~73772862:-
BRCA	cis	rs1816752	1	rs9511265	ENSG00000273628.1	RP11-756A22.7	3.28	0.00106	0.0453	0.12	0.1	Obesity-related traits;	chr13:24438221	chr13:24933006~24936796:+
BRCA	cis	rs1005277	0.505	rs13503	ENSG00000099251.13	HSD17B7P2	-3.28	0.00106	0.0453	-0.11	-0.1	Extrinsic epigenetic age acceleration;	chr10:37950915	chr10:38356380~38378505:+
BRCA	cis	rs6546886	0.625	rs76483403	ENSG00000257800.1	FNBP1P1	-3.28	0.00106	0.0453	-0.11	-0.1	Dialysis-related mortality;	chr2:74026281	chr2:74120680~74123218:+
BRCA	cis	rs7943953	0.714	rs1453551	ENSG00000254717.2	GLYATL1P2	3.28	0.00106	0.0453	0.14	0.1	Odorant perception (&beta-ionone);	chr11:59426074	chr11:58878302~58893460:+
BRCA	cis	rs875971	0.545	rs75840613	ENSG00000226767.1	RP11-328P23.3	3.28	0.00106	0.0453	0.13	0.1	Aortic root size;	chr7:66376399	chr7:65508773~65508944:-
BRCA	cis	rs12477438	0.52	rs6542864	ENSG00000231822.1	AC019097.7	3.28	0.00106	0.0453	0.11	0.1	Chronic sinus infection;	chr2:99108760	chr2:99102018~99102752:+
BRCA	cis	rs258892	0.895	rs10072874	ENSG00000272525.1	RP11-79P5.9	-3.28	0.00106	0.0453	-0.13	-0.1	Small cell lung carcinoma;	chr5:72748456	chr5:73497550~73498293:-
BRCA	cis	rs7474896	1	rs2738187	ENSG00000120555.12	SEPT7P9	-3.28	0.00106	0.0453	-0.18	-0.1	Obesity (extreme);	chr10:37971377	chr10:38383069~38402916:-
BRCA	cis	rs7474896	0.895	rs2245081	ENSG00000120555.12	SEPT7P9	-3.28	0.00106	0.0453	-0.18	-0.1	Obesity (extreme);	chr10:37971479	chr10:38383069~38402916:-
BRCA	cis	rs1542829	0.614	rs6792960	ENSG00000249846.5	RP11-77P16.4	-3.28	0.00106	0.0453	-0.19	-0.1	Body mass index;	chr3:130510365	chr3:130112550~130120579:+
BRCA	cis	rs28735056	0.904	rs11520415	ENSG00000267270.4	PARD6G-AS1	-3.28	0.00106	0.0453	-0.12	-0.1	Schizophrenia;	chr18:79860620	chr18:80147924~80178432:+
BRCA	cis	rs12468226	0.689	rs73989733	ENSG00000272966.1	RP11-686O6.1	3.28	0.00106	0.0453	0.16	0.1	Urate levels;	chr2:202115241	chr2:202336739~202337200:+
BRCA	cis	rs12760731	0.565	rs12040475	ENSG00000213057.5	C1orf220	3.28	0.00106	0.0453	0.15	0.1	Obesity-related traits;	chr1:178216516	chr1:178542752~178548889:+
BRCA	cis	rs4865762	0.595	rs27323	ENSG00000247796.2	CTD-2366F13.1	-3.28	0.00106	0.0453	-0.11	-0.1	Intraocular pressure;	chr5:53256409	chr5:53109842~53115126:+
BRCA	cis	rs17382723	0.775	rs2302042	ENSG00000225521.1	AC005237.4	-3.28	0.00106	0.0453	-0.16	-0.1	Height;	chr2:241081108	chr2:241015599~241064116:-
BRCA	cis	rs494453	0.583	rs559981	ENSG00000227811.2	FAM212B-AS1	-3.28	0.00106	0.0453	-0.15	-0.1	Osteoporosis-related phenotypes;	chr1:111676716	chr1:111739841~111747798:+
BRCA	cis	rs9467773	0.873	rs9295698	ENSG00000261353.1	CTA-14H9.5	-3.28	0.00106	0.0453	-0.1	-0.1	Intelligence (multi-trait analysis);	chr6:26565871	chr6:26527063~26527404:+
BRCA	cis	rs1914816	0.653	rs157763	ENSG00000196274.5	Metazoa_SRP	3.28	0.00106	0.0453	0.14	0.1	Response to tocilizumab in rheumatoid arthritis;	chr15:76500498	chr15:76230048~76230390:-
BRCA	cis	rs9457247	0.624	rs17524252	ENSG00000272549.1	RP11-351J23.2	-3.28	0.00106	0.0453	-0.11	-0.1	Crohn's disease;	chr6:167053490	chr6:167666840~167679270:-
BRCA	cis	rs4704187	0.687	rs6896474	ENSG00000271815.1	CTD-2235C13.3	3.28	0.00106	0.0453	0.13	0.1	Response to amphetamines;	chr5:75157993	chr5:75363760~75364242:+
BRCA	cis	rs10129255	0.957	rs6576233	ENSG00000231475.3	IGHV4-31	-3.28	0.00106	0.0453	-0.08	-0.1	Kawasaki disease;	chr14:106787239	chr14:106349283~106349792:-
BRCA	cis	rs801193	0.591	rs721717	ENSG00000223473.2	GS1-124K5.3	-3.28	0.00106	0.0453	-0.08	-0.1	Aortic root size;	chr7:66665305	chr7:66491049~66493566:-
BRCA	cis	rs3820928	0.874	rs2177593	ENSG00000261379.1	RP11-395N3.1	3.28	0.00106	0.0453	0.1	0.1	Pulmonary function;	chr2:226969153	chr2:226804036~226805061:+
BRCA	cis	rs11673344	0.832	rs11540540	ENSG00000267422.1	CTD-2554C21.1	3.28	0.00106	0.0453	0.14	0.1	Obesity-related traits;	chr19:37129629	chr19:37779686~37792865:+
BRCA	cis	rs837841	0.535	rs13020865	ENSG00000227632.2	AC018804.6	3.28	0.00106	0.0453	0.13	0.1	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);	chr2:129241079	chr2:130202312~130212628:+
BRCA	cis	rs875971	0.706	rs1643374	ENSG00000232559.3	GS1-124K5.12	3.28	0.00106	0.0453	0.12	0.1	Aortic root size;	chr7:66407695	chr7:66554588~66576923:-
BRCA	cis	rs6142618	0.562	rs6142620	ENSG00000275576.1	RP5-836N17.4	-3.28	0.00106	0.0453	-0.11	-0.1	Inflammatory bowel disease;	chr20:32147191	chr20:32116171~32116629:+
BRCA	cis	rs2880765	0.835	rs7169429	ENSG00000230373.7	GOLGA6L5P	3.28	0.00106	0.0453	0.11	0.1	Coronary artery disease;	chr15:85493417	chr15:84507885~84516814:-
BRCA	cis	rs7188861	0.681	rs9932855	ENSG00000262636.1	CTD-3088G3.4	3.28	0.00106	0.0453	0.2	0.1	HDL cholesterol;	chr16:11312687	chr16:11380859~11381118:-
BRCA	cis	rs910316	0.763	rs175042	ENSG00000259138.1	RP11-950C14.7	-3.28	0.00106	0.0453	-0.11	-0.1	Height;	chr14:75004130	chr14:75127153~75136930:+
BRCA	cis	rs2243480	1	rs78803505	ENSG00000234585.5	CCT6P3	-3.28	0.00106	0.0453	-0.15	-0.1	Diabetic kidney disease;	chr7:65917585	chr7:65038354~65074713:+
BRCA	cis	rs2243480	1	rs34577383	ENSG00000234585.5	CCT6P3	-3.28	0.00106	0.0453	-0.15	-0.1	Diabetic kidney disease;	chr7:65920739	chr7:65038354~65074713:+
BRCA	cis	rs2243480	1	rs55895244	ENSG00000234585.5	CCT6P3	-3.28	0.00106	0.0453	-0.15	-0.1	Diabetic kidney disease;	chr7:65922691	chr7:65038354~65074713:+
BRCA	cis	rs2243480	1	rs7795242	ENSG00000234585.5	CCT6P3	-3.28	0.00106	0.0453	-0.15	-0.1	Diabetic kidney disease;	chr7:65925107	chr7:65038354~65074713:+
BRCA	cis	rs2243480	1	rs2177703	ENSG00000234585.5	CCT6P3	-3.28	0.00106	0.0453	-0.15	-0.1	Diabetic kidney disease;	chr7:65926730	chr7:65038354~65074713:+
BRCA	cis	rs2243480	1	rs56985706	ENSG00000234585.5	CCT6P3	-3.28	0.00106	0.0453	-0.15	-0.1	Diabetic kidney disease;	chr7:65929575	chr7:65038354~65074713:+
BRCA	cis	rs2243480	1	rs60683927	ENSG00000234585.5	CCT6P3	-3.28	0.00106	0.0453	-0.15	-0.1	Diabetic kidney disease;	chr7:65929781	chr7:65038354~65074713:+
BRCA	cis	rs2243480	1	rs58062456	ENSG00000234585.5	CCT6P3	-3.28	0.00106	0.0453	-0.15	-0.1	Diabetic kidney disease;	chr7:65929865	chr7:65038354~65074713:+
BRCA	cis	rs1468333	0.567	rs11567983	ENSG00000206989.1	SNORD63	3.28	0.00106	0.0453	0.11	0.1	Resting heart rate;	chr5:138312258	chr5:138561043~138561110:-
BRCA	cis	rs9330316	0.667	rs7568492	ENSG00000204588.5	LINC01123	3.28	0.00106	0.0454	0.17	0.1	Schizophrenia;	chr2:109610992	chr2:109987063~109996140:+
BRCA	cis	rs6494488	0.5	rs66500186	ENSG00000248415.1	GAPDHP61	-3.28	0.00106	0.0454	-0.21	-0.1	Coronary artery disease;	chr15:64710395	chr15:64528667~64529671:-
BRCA	cis	rs1008375	0.966	rs7666888	ENSG00000249502.1	AC006160.5	-3.28	0.00106	0.0454	-0.11	-0.1	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17694099	chr4:17587467~17614571:-
BRCA	cis	rs7943953	0.765	rs12787182	ENSG00000245571.5	AP001258.4	-3.28	0.00106	0.0454	-0.13	-0.1	Odorant perception (&beta-ionone);	chr11:59423338	chr11:59130133~59143015:-
BRCA	cis	rs6813195	0.642	rs17028954	ENSG00000245954.5	RP11-18H21.1	-3.28	0.00106	0.0454	-0.09	-0.1	Type 2 diabetes;	chr4:152517181	chr4:152100754~152104720:+
BRCA	cis	rs36051895	0.632	rs12349918	ENSG00000237711.1	RP11-39K24.13	-3.28	0.00106	0.0454	-0.12	-0.1	Pediatric autoimmune diseases;	chr9:5125250	chr9:5100236~5101009:+
BRCA	cis	rs7577696	0.597	rs212689	ENSG00000276334.1	AL133243.1	3.28	0.00106	0.0454	0.14	0.1	Inflammatory biomarkers;	chr2:32212269	chr2:32521927~32523547:+
BRCA	cis	rs7577696	0.568	rs462878	ENSG00000276334.1	AL133243.1	3.28	0.00106	0.0454	0.14	0.1	Inflammatory biomarkers;	chr2:32213586	chr2:32521927~32523547:+
BRCA	cis	rs2496589	0.926	rs9496627	ENSG00000218896.1	TUBB8P2	3.28	0.00106	0.0454	0.12	0.1	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);	chr6:143430645	chr6:143436216~143436710:+
BRCA	cis	rs6772849	0.708	rs12491942	ENSG00000242551.2	POU5F1P6	-3.28	0.00106	0.0454	-0.13	-0.1	Monocyte percentage of white cells;Monocyte count;	chr3:128702626	chr3:128674735~128677005:-
BRCA	cis	rs11718502	0.66	rs6798660	ENSG00000230084.4	RP4-613B23.1	3.28	0.00106	0.0454	0.14	0.1	Magnesium levels;	chr3:42458086	chr3:42601963~42654388:-
BRCA	cis	rs11098499	0.739	rs951570	ENSG00000249244.1	RP11-548H18.2	-3.28	0.00106	0.0454	-0.12	-0.1	Corneal astigmatism;	chr4:119229312	chr4:119391831~119395335:-
BRCA	cis	rs641862	1	rs641862	ENSG00000275830.1	RP11-403A3.3	3.28	0.00106	0.0454	0.2	0.1	Obesity-related traits;	chr13:110137885	chr13:109988097~110057331:-
BRCA	cis	rs6490294	0.8	rs78783055	ENSG00000234608.6	MAPKAPK5-AS1	3.28	0.00106	0.0454	0.13	0.1	Mean platelet volume;	chr12:111795691	chr12:111839764~111842902:-
BRCA	cis	rs7339483	0.702	rs4986347	ENSG00000268442.1	CTD-2027I19.2	3.28	0.00106	0.0454	0.21	0.1	Discordance in emotional problems in monozygotic twins;	chr19:24177736	chr19:24162370~24163425:-
BRCA	cis	rs3767633	0.925	rs2499855	ENSG00000229808.1	RP11-456P18.2	-3.28	0.00106	0.0454	-0.19	-0.1	IgG glycosylation;	chr1:161959971	chr1:161890833~161892196:+
BRCA	cis	rs7833790	0.66	rs67666182	ENSG00000254689.1	RP11-354A14.1	-3.28	0.00106	0.0454	-0.12	-0.1	Diastolic blood pressure;	chr8:81859802	chr8:81885377~81923193:+
BRCA	cis	rs6545883	0.965	rs3771258	ENSG00000273302.1	RP11-493E12.2	3.28	0.00106	0.0454	0.09	0.1	Tuberculosis;	chr2:61537005	chr2:61199979~61200769:+
BRCA	cis	rs7020830	0.505	rs12553878	ENSG00000230188.1	RP11-405L18.4	-3.28	0.00106	0.0454	-0.12	-0.1	Schizophrenia;	chr9:37095708	chr9:37490421~37490893:-
BRCA	cis	rs1008375	0.966	rs6832414	ENSG00000249502.1	AC006160.5	-3.28	0.00106	0.0454	-0.11	-0.1	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17695243	chr4:17587467~17614571:-
BRCA	cis	rs1008375	0.966	rs11722132	ENSG00000249502.1	AC006160.5	-3.28	0.00106	0.0454	-0.11	-0.1	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17695594	chr4:17587467~17614571:-
BRCA	cis	rs6840360	0.615	rs4696290	ENSG00000270265.1	RP11-731D1.4	-3.28	0.00106	0.0454	-0.11	-0.1	Intelligence (multi-trait analysis);	chr4:151710320	chr4:151333775~151353224:-
BRCA	cis	rs1334894	1	rs10498734	ENSG00000187762.5	HSPE1P11	3.28	0.00106	0.0454	0.24	0.1	Coronary artery disease;	chr6:35591996	chr6:35023522~35023831:+
BRCA	cis	rs7258465	1	rs4808136	ENSG00000273654.1	CTB-52I2.4	3.28	0.00106	0.0454	0.12	0.1	Breast cancer;	chr19:18508057	chr19:18022403~18032099:+
BRCA	cis	rs7818688	0.654	rs75680386	ENSG00000245080.5	RP11-320N21.1	-3.28	0.00106	0.0454	-0.17	-0.1	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94973920	chr8:95066808~95073182:-
BRCA	cis	rs2749592	0.55	rs4934881	ENSG00000226578.1	RP11-258F22.1	3.28	0.00106	0.0454	0.11	0.1	Age-related hearing impairment (SNP x SNP interaction);	chr10:37625418	chr10:37775371~37784131:-
BRCA	cis	rs9457247	0.602	rs9459854	ENSG00000272549.1	RP11-351J23.2	-3.28	0.00106	0.0454	-0.11	-0.1	Crohn's disease;	chr6:167052394	chr6:167666840~167679270:-
BRCA	cis	rs6893300	0.961	rs3797776	ENSG00000225051.5	HMGB3P22	3.28	0.00106	0.0454	0.14	0.1	Resting heart rate;	chr5:179766597	chr5:179679032~179694768:+
BRCA	cis	rs2227564	0.672	rs10824042	ENSG00000279689.1	RP11-574K11.32	3.28	0.00106	0.0454	0.11	0.1	Crohn's disease;Inflammatory bowel disease;	chr10:73885870	chr10:73769264~73772862:-
BRCA	cis	rs4919694	1	rs12241091	ENSG00000236937.2	PTGES3P4	3.28	0.00106	0.0454	0.21	0.1	Arsenic metabolism;	chr10:103049240	chr10:102845595~102845950:+
BRCA	cis	rs987724	0.927	rs7616633	ENSG00000240875.4	LINC00886	-3.28	0.00106	0.0454	-0.13	-0.1	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156863245	chr3:156747346~156817062:-
BRCA	cis	rs4665809	0.941	rs11126336	ENSG00000231655.1	AC011742.3	3.28	0.00106	0.0454	0.15	0.1	Gut microbiome composition (summer);	chr2:26023062	chr2:26140263~26141264:-
BRCA	cis	rs4148883	0.645	rs2851287	ENSG00000272777.1	RP11-571L19.8	-3.28	0.00106	0.0454	-0.11	-0.1	Alcohol dependence;	chr4:99093397	chr4:99067256~99068125:-
BRCA	cis	rs10256972	0.721	rs2030959	ENSG00000199023.2	MIR339	-3.28	0.00106	0.0454	-0.13	-0.1	Endometriosis;Longevity;	chr7:1036270	chr7:1022935~1023045:-
BRCA	cis	rs6840360	0.571	rs7685697	ENSG00000278978.1	RP11-164P12.5	-3.28	0.00106	0.0454	-0.12	-0.1	Intelligence (multi-trait analysis);	chr4:151637697	chr4:151669786~151670503:+
BRCA	cis	rs6840360	0.593	rs10022023	ENSG00000278978.1	RP11-164P12.5	-3.28	0.00106	0.0454	-0.12	-0.1	Intelligence (multi-trait analysis);	chr4:151639579	chr4:151669786~151670503:+
BRCA	cis	rs9788682	0.747	rs2036533	ENSG00000261143.1	ADAMTS7P3	-3.28	0.00106	0.0454	-0.14	-0.1	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78489345	chr15:77976042~77993057:+
BRCA	cis	rs7174348	1	rs7174348	ENSG00000261143.1	ADAMTS7P3	-3.28	0.00106	0.0454	-0.14	-0.1	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78500097	chr15:77976042~77993057:+
BRCA	cis	rs73201462	1	rs6784159	ENSG00000242551.2	POU5F1P6	3.28	0.00106	0.0454	0.17	0.1	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128124535	chr3:128674735~128677005:-
BRCA	cis	rs4927850	0.881	rs7624638	ENSG00000278820.1	AC024937.1	3.28	0.00106	0.0454	0.12	0.1	Pancreatic cancer;	chr3:196021858	chr3:195960500~195960612:-
BRCA	cis	rs10876993	0.784	rs1871417	ENSG00000270039.1	RP11-571M6.17	-3.28	0.00106	0.0454	-0.13	-0.1	Celiac disease or Rheumatoid arthritis;	chr12:57625196	chr12:57803838~57804415:+
BRCA	cis	rs6912958	0.703	rs9353483	ENSG00000272008.1	RP11-393I2.4	-3.28	0.00106	0.0454	-0.11	-0.1	Monocyte percentage of white cells;	chr6:87387462	chr6:87151159~87155285:-
BRCA	cis	rs10435719	0.902	rs4840599	ENSG00000254948.1	OR7E158P	3.28	0.00106	0.0454	0.12	0.1	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11947871	chr8:11919900~11920809:-
BRCA	cis	rs13118159	0.509	rs4974556	ENSG00000211482.1	AC092574.1	3.28	0.00106	0.0454	0.13	0.1	Longevity;	chr4:1364353	chr4:409809~409915:+
BRCA	cis	rs9309473	0.5	rs12996463	ENSG00000230002.2	ALMS1-IT1	-3.28	0.00106	0.0454	-0.12	-0.1	Metabolite levels;	chr2:73428368	chr2:73456764~73459484:+
BRCA	cis	rs911555	0.723	rs11160751	ENSG00000269940.1	RP11-73M18.7	3.28	0.00106	0.0454	0.11	0.1	Intelligence (multi-trait analysis);	chr14:103459403	chr14:103694560~103695170:+
BRCA	cis	rs73195822	0.614	rs56259130	ENSG00000277299.1	RP11-837J7.4	-3.28	0.00106	0.0454	-0.17	-0.1	Itch intensity from mosquito bite;	chr12:110787845	chr12:109948389~109949029:+
BRCA	cis	rs6466055	0.777	rs2299319	ENSG00000242154.1	RP4-778K6.3	-3.28	0.00106	0.0454	-0.13	-0.1	Schizophrenia;	chr7:105237469	chr7:105304277~105306642:+
BRCA	cis	rs2227564	0.649	rs2948689	ENSG00000279689.1	RP11-574K11.32	3.28	0.00106	0.0454	0.11	0.1	Crohn's disease;Inflammatory bowel disease;	chr10:73898102	chr10:73769264~73772862:-
BRCA	cis	rs2638953	0.962	rs11049482	ENSG00000273989.1	RP11-425D17.2	-3.28	0.00106	0.0454	-0.16	-0.1	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28252088	chr12:28236227~28236828:+
BRCA	cis	rs2638953	0.962	rs11049484	ENSG00000273989.1	RP11-425D17.2	-3.28	0.00106	0.0454	-0.16	-0.1	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28252254	chr12:28236227~28236828:+
BRCA	cis	rs2638953	0.962	rs11049485	ENSG00000273989.1	RP11-425D17.2	-3.28	0.00106	0.0454	-0.16	-0.1	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28252522	chr12:28236227~28236828:+
BRCA	cis	rs7578361	0.877	rs7597580	ENSG00000231969.1	AC144449.1	-3.28	0.00106	0.0454	-0.15	-0.1	Acute lymphoblastic leukemia (childhood);	chr2:149510891	chr2:149587196~149848233:+
BRCA	cis	rs12893668	0.703	rs729438	ENSG00000244691.1	RPL10AP1	3.28	0.00106	0.0454	0.13	0.1	Reticulocyte count;	chr14:103626452	chr14:103412119~103412761:-
BRCA	cis	rs4713118	0.597	rs172166	ENSG00000226314.6	ZNF192P1	-3.28	0.00106	0.0454	-0.15	-0.1	Parkinson's disease;	chr6:28053042	chr6:28161781~28169594:+
BRCA	cis	rs964611	0.882	rs73406442	ENSG00000259488.2	RP11-154J22.1	-3.28	0.00106	0.0454	-0.13	-0.1	Metabolite levels (Pyroglutamine);	chr15:48354146	chr15:48312353~48331856:-
BRCA	cis	rs35974940	1	rs7119590	ENSG00000255455.2	RP11-890B15.3	-3.28	0.00106	0.0454	-0.19	-0.1	Aggressiveness in attention deficit hyperactivity disorder;	chr11:131369909	chr11:130866254~130870247:-
BRCA	cis	rs6088590	0.561	rs11167239	ENSG00000269202.1	RP4-614O4.12	-3.28	0.00106	0.0454	-0.1	-0.1	Coronary artery disease;	chr20:34552668	chr20:35201747~35203288:-
BRCA	cis	rs758324	0.947	rs7708140	ENSG00000233006.5	AC034220.3	3.28	0.00106	0.0454	0.08	0.1	Alzheimer's disease in APOE e4- carriers;	chr5:131916703	chr5:132311285~132369916:-
BRCA	cis	rs28489187	0.756	rs233047	ENSG00000223653.4	RP11-131L23.1	3.28	0.00106	0.0455	0.12	0.1	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85364887	chr1:85276715~85448124:+
BRCA	cis	rs2243480	1	rs313814	ENSG00000226767.1	RP11-328P23.3	-3.28	0.00106	0.0455	-0.18	-0.1	Diabetic kidney disease;	chr7:66038306	chr7:65508773~65508944:-
BRCA	cis	rs1859596	0.625	rs6946634	ENSG00000234456.6	MAGI2-AS3	3.28	0.00106	0.0455	0.06	0.1	Reading or mathematical ability;	chr7:79463780	chr7:79452877~79471208:+
BRCA	cis	rs1859596	0.646	rs6964015	ENSG00000234456.6	MAGI2-AS3	3.28	0.00106	0.0455	0.06	0.1	Reading or mathematical ability;	chr7:79463836	chr7:79452877~79471208:+
BRCA	cis	rs2842992	0.513	rs7759086	ENSG00000207392.1	SNORA20	-3.28	0.00106	0.0455	-0.13	-0.1	Age-related macular degeneration (geographic atrophy);	chr6:159772821	chr6:159780250~159780381:-
BRCA	cis	rs17684571	0.872	rs34566275	ENSG00000231441.1	RP11-472M19.2	3.28	0.00106	0.0455	0.17	0.1	Schizophrenia;	chr6:56740130	chr6:56844002~56864078:+
BRCA	cis	rs427943	0.722	rs2150439	ENSG00000184274.3	LINC00315	-3.28	0.00106	0.0455	-0.14	-0.1	Body mass index;	chr21:45215051	chr21:45300245~45305257:-
BRCA	cis	rs1982963	1	rs3818187	ENSG00000277050.1	RP11-102G14.1	3.28	0.00106	0.0455	0.13	0.1	Waist-to-hip ratio adjusted for body mass index;	chr14:52043070	chr14:51637348~51637947:-
BRCA	cis	rs3820068	0.581	rs2861387	ENSG00000237301.1	RP4-680D5.2	-3.28	0.00106	0.0455	-0.13	-0.1	Systolic blood pressure;	chr1:15624801	chr1:15586136~15603626:-
BRCA	cis	rs9527	0.59	rs10786738	ENSG00000269609.4	RPARP-AS1	-3.28	0.00106	0.0455	-0.1	-0.1	Arsenic metabolism;	chr10:103109694	chr10:102449817~102461106:+
BRCA	cis	rs9527	0.59	rs1807298	ENSG00000269609.4	RPARP-AS1	-3.28	0.00106	0.0455	-0.1	-0.1	Arsenic metabolism;	chr10:103110461	chr10:102449817~102461106:+
BRCA	cis	rs9527	0.59	rs2182348	ENSG00000269609.4	RPARP-AS1	-3.28	0.00106	0.0455	-0.1	-0.1	Arsenic metabolism;	chr10:103112927	chr10:102449817~102461106:+
BRCA	cis	rs11858159	1	rs12905994	ENSG00000207279.1	SNORD116-24	-3.28	0.00106	0.0455	-0.1	-0.1	Platelet thrombus formation;	chr15:24577169	chr15:25094037~25094128:+
BRCA	cis	rs76206723	1	rs17171694	ENSG00000233225.3	AC004987.9	3.28	0.00106	0.0455	0.19	0.1	Pulse pressure;	chr7:40355388	chr7:39833571~39834718:+
BRCA	cis	rs12726943	0.671	rs1359748	ENSG00000229989.3	MIR181A1HG	3.28	0.00106	0.0455	0.16	0.1	Perceived unattractiveness to mosquitoes;	chr1:199458968	chr1:198807493~198937429:-
BRCA	cis	rs1816752	0.87	rs9318529	ENSG00000273628.1	RP11-756A22.7	3.28	0.00106	0.0455	0.12	0.1	Obesity-related traits;	chr13:24424190	chr13:24933006~24936796:+
BRCA	cis	rs6948772	0.884	rs6948778	ENSG00000216895.7	AC009403.2	-3.28	0.00106	0.0455	-0.12	-0.1	Colorectal cancer;	chr7:155608207	chr7:155611231~155645205:-
BRCA	cis	rs72799341	1	rs35675346	ENSG00000275263.1	RP11-1072A3.4	-3.28	0.00106	0.0455	-0.14	-0.1	Diastolic blood pressure;	chr16:30924760	chr16:30956872~30957199:-
BRCA	cis	rs1008375	1	rs13106338	ENSG00000249502.1	AC006160.5	3.28	0.00106	0.0455	0.11	0.1	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17675248	chr4:17587467~17614571:-
BRCA	cis	rs2518049	0.852	rs10795242	ENSG00000224034.1	RP11-445P17.8	3.28	0.00106	0.0455	0.19	0.1	Metabolic traits;	chr10:5076835	chr10:5266033~5271236:-
BRCA	cis	rs4865762	0.687	rs166129	ENSG00000247796.2	CTD-2366F13.1	3.28	0.00106	0.0455	0.11	0.1	Intraocular pressure;	chr5:53202943	chr5:53109842~53115126:+
BRCA	cis	rs2554380	0.628	rs4843158	ENSG00000176700.18	SCAND2P	-3.28	0.00106	0.0455	-0.1	-0.1	Height;	chr15:83802884	chr15:84631451~84647478:+
BRCA	cis	rs7267979	1	rs398036	ENSG00000231081.1	RP4-760C5.3	-3.28	0.00106	0.0455	-0.13	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25459214	chr20:26008791~26010531:-
BRCA	cis	rs7267979	1	rs397119	ENSG00000231081.1	RP4-760C5.3	-3.28	0.00106	0.0455	-0.13	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25459551	chr20:26008791~26010531:-
BRCA	cis	rs875971	1	rs6460292	ENSG00000230189.5	GS1-124K5.2	-3.28	0.00106	0.0455	-0.08	-0.1	Aortic root size;	chr7:66345088	chr7:66409143~66490059:-
BRCA	cis	rs1878931	0.501	rs28735976	ENSG00000279568.1	RP11-20I23.5	3.28	0.00106	0.0455	0.1	0.1	Body mass index (adult);	chr16:3368419	chr16:2575628~2577373:-
BRCA	cis	rs12439619	0.693	rs8034801	ENSG00000259429.4	UBE2Q2P2	-3.28	0.00106	0.0455	-0.12	-0.1	Intelligence (multi-trait analysis);	chr15:82183996	chr15:82355142~82420075:+
BRCA	cis	rs1348850	0.914	rs10170667	ENSG00000271825.1	RP11-337N6.2	3.28	0.00106	0.0455	0.13	0.1	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177472150	chr2:177300600~177302006:+
BRCA	cis	rs7162943	0.708	rs293365	ENSG00000261407.1	RP11-326A19.3	-3.28	0.00106	0.0455	-0.12	-0.1	Mean platelet volume;	chr15:89070777	chr15:89087078~89088267:-
BRCA	cis	rs4851551	0.619	rs34722443	ENSG00000234389.1	AC007278.3	3.28	0.00106	0.0455	0.2	0.1	Blood protein levels;	chr2:102223859	chr2:102438713~102440475:+
BRCA	cis	rs1005277	0.505	rs200935	ENSG00000273019.1	RP11-508N22.13	-3.28	0.00106	0.0455	-0.12	-0.1	Extrinsic epigenetic age acceleration;	chr10:37843882	chr10:38149968~38150293:+
BRCA	cis	rs71520386	0.607	rs4308627	ENSG00000179428.2	AC073072.5	3.28	0.00106	0.0455	0.12	0.1	Fibrinogen levels;	chr7:22840285	chr7:22725395~22727620:-
BRCA	cis	rs6088590	0.965	rs6120727	ENSG00000276073.1	RP5-1125A11.7	-3.28	0.00106	0.0455	-0.12	-0.1	Coronary artery disease;	chr20:34786299	chr20:33985617~33988989:-
BRCA	cis	rs7944735	0.508	rs4752877	ENSG00000243802.2	RP11-390K5.1	3.28	0.00106	0.0455	0.15	0.1	Intraocular pressure;	chr11:47864613	chr11:47191181~47191542:-
BRCA	cis	rs7267979	0.932	rs6037125	ENSG00000204556.4	CTD-2514C3.1	-3.28	0.00106	0.0455	-0.13	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25482746	chr20:26018832~26020684:+
BRCA	cis	rs10464366	0.798	rs885352	ENSG00000227191.5	TRGC2	3.28	0.00106	0.0455	0.1	0.1	IgG glycosylation;	chr7:39076568	chr7:38239580~38368091:-
BRCA	cis	rs1008375	0.931	rs2109519	ENSG00000249502.1	AC006160.5	-3.28	0.00106	0.0455	-0.11	-0.1	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17693830	chr4:17587467~17614571:-
BRCA	cis	rs11679640	0.671	rs13395650	ENSG00000234362.4	AC104654.2	-3.28	0.00106	0.0455	-0.13	-0.1	White matter hyperintensity burden;	chr2:42849131	chr2:41931599~41933723:-
BRCA	cis	rs860295	0.702	rs12081067	ENSG00000203761.5	MSTO2P	-3.28	0.00106	0.0455	-0.09	-0.1	Body mass index;	chr1:155389191	chr1:155745829~155750137:+
BRCA	cis	rs10819861	0.645	rs4443780	ENSG00000175611.10	LINC00476	3.28	0.00106	0.0455	0.11	0.1	Electrocardiographic traits;	chr9:96089485	chr9:95759231~95875977:-
BRCA	cis	rs2288327	0.818	rs3829748	ENSG00000271011.1	RP11-171I2.5	3.28	0.00106	0.0455	0.19	0.1	Atrial fibrillation;	chr2:178531627	chr2:178577103~178577622:+
BRCA	cis	rs2288327	0.818	rs2857265	ENSG00000271011.1	RP11-171I2.5	3.28	0.00106	0.0455	0.19	0.1	Atrial fibrillation;	chr2:178534096	chr2:178577103~178577622:+
BRCA	cis	rs1048886	0.872	rs10945235	ENSG00000271967.1	RP11-134K13.4	-3.28	0.00106	0.0455	-0.14	-0.1	Type 2 diabetes;	chr6:70595342	chr6:70596438~70596980:+
BRCA	cis	rs12999542	1	rs1946131	ENSG00000234389.1	AC007278.3	3.28	0.00106	0.0455	0.14	0.1	Serum protein levels (sST2);	chr2:102345469	chr2:102438713~102440475:+
BRCA	cis	rs783540	0.542	rs62009945	ENSG00000279758.1	RP11-752G15.10	3.28	0.00106	0.0455	0.12	0.1	Schizophrenia;	chr15:82631205	chr15:82738386~82739122:+
BRCA	cis	rs12893668	0.572	rs4900591	ENSG00000258914.1	CTD-2134A5.3	3.28	0.00106	0.0455	0.14	0.1	Reticulocyte count;	chr14:103688541	chr14:103875055~103877478:+
BRCA	cis	rs2832191	0.791	rs2832182	ENSG00000232855.5	AF131217.1	3.28	0.00106	0.0455	0.12	0.1	Dental caries;	chr21:29109291	chr21:28439346~28674848:-
BRCA	cis	rs1129187	0.902	rs10948059	ENSG00000220614.1	RP11-480N24.4	3.28	0.00106	0.0455	0.11	0.1	Alzheimer's disease in APOE e4+ carriers;	chr6:42960723	chr6:43328134~43328476:+
BRCA	cis	rs1555133	0.652	rs6141304	ENSG00000277692.1	RP11-358N2.2	-3.28	0.00106	0.0455	-0.11	-0.1	Monocyte count;	chr20:32401407	chr20:32355053~32355734:+
BRCA	cis	rs7647973	0.667	rs9869256	ENSG00000228008.1	CTD-2330K9.3	-3.28	0.00106	0.0455	-0.14	-0.1	Menarche (age at onset);	chr3:49586662	chr3:49903845~49916937:+
BRCA	cis	rs7647973	0.71	rs6446285	ENSG00000228008.1	CTD-2330K9.3	-3.28	0.00106	0.0455	-0.14	-0.1	Menarche (age at onset);	chr3:49588873	chr3:49903845~49916937:+
BRCA	cis	rs972578	0.967	rs7291153	ENSG00000230319.1	AL022476.2	3.28	0.00106	0.0455	0.11	0.1	Mean platelet volume;	chr22:42960493	chr22:43038585~43052366:+
BRCA	cis	rs4713118	0.516	rs6931858	ENSG00000216901.1	AL022393.7	3.28	0.00106	0.0455	0.14	0.1	Parkinson's disease;	chr6:28110633	chr6:28176188~28176674:+
BRCA	cis	rs10129255	0.957	rs28887506	ENSG00000231475.3	IGHV4-31	-3.28	0.00106	0.0455	-0.08	-0.1	Kawasaki disease;	chr14:106785589	chr14:106349283~106349792:-
BRCA	cis	rs2832077	0.943	rs11701445	ENSG00000236056.1	GAPDHP14	3.28	0.00106	0.0455	0.14	0.1	Cognitive test performance;	chr21:28788485	chr21:29222321~29223257:+
BRCA	cis	rs8180040	1	rs11130127	ENSG00000280667.1	Y_RNA	-3.28	0.00106	0.0456	-0.11	-0.1	Colorectal cancer;	chr3:47357303	chr3:47501083~47501182:+
BRCA	cis	rs7173064	0.935	rs7171616	ENSG00000272888.4	LINC01578	3.28	0.00106	0.0456	0.11	0.1	White matter hyperintensity burden;	chr15:93730964	chr15:92882707~92899701:+
BRCA	cis	rs9951698	0.703	rs475139	ENSG00000266969.1	RP11-773H22.4	3.28	0.00106	0.0456	0.13	0.1	Intelligence (multi-trait analysis);	chr18:13141397	chr18:12984694~12991173:-
BRCA	cis	rs11098499	0.739	rs9996382	ENSG00000249244.1	RP11-548H18.2	3.28	0.00106	0.0456	0.12	0.1	Corneal astigmatism;	chr4:119229857	chr4:119391831~119395335:-
BRCA	cis	rs6964587	0.626	rs9008	ENSG00000188693.7	CYP51A1-AS1	3.28	0.00106	0.0456	0.11	0.1	Breast cancer;	chr7:91873093	chr7:92134604~92180725:+
BRCA	cis	rs8073060	0.559	rs17550632	ENSG00000267554.1	RP11-686D22.10	3.28	0.00106	0.0456	0.11	0.1	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35563864	chr17:35470069~35470628:-
BRCA	cis	rs2277027	1	rs4579242	ENSG00000253653.1	CTC-248O19.1	3.28	0.00106	0.0456	0.12	0.1	Pulmonary function;Pulmonary function (smoking interaction);	chr5:157512490	chr5:157260122~157266625:-
BRCA	cis	rs2576037	0.526	rs10853545	ENSG00000267156.1	TPMTP1	3.28	0.00106	0.0456	0.13	0.1	Personality dimensions;	chr18:46895257	chr18:47630112~47630848:+
BRCA	cis	rs11098499	0.691	rs10028773	ENSG00000250950.1	RP11-33B1.3	3.28	0.00106	0.0456	0.11	0.1	Corneal astigmatism;	chr4:119344104	chr4:119456350~119457277:+
BRCA	cis	rs10489896	0.568	rs2273875	ENSG00000227962.1	RP11-382D8.3	3.28	0.00106	0.0456	0.1	0.1	Cognitive test performance;	chr1:234437611	chr1:235336806~235337087:+
BRCA	cis	rs6544311	0.965	rs765555	ENSG00000273035.1	RP11-449G16.1	-3.28	0.00106	0.0456	-0.13	-0.1	QT interval;	chr2:40131214	chr2:39323328~39323804:-
BRCA	cis	rs9325144	0.56	rs11183090	ENSG00000257718.1	RP11-396F22.1	-3.28	0.00106	0.0456	-0.1	-0.1	Morning vs. evening chronotype;	chr12:38268491	chr12:38906451~38909592:+
BRCA	cis	rs9325144	0.56	rs2387923	ENSG00000257718.1	RP11-396F22.1	-3.28	0.00106	0.0456	-0.1	-0.1	Morning vs. evening chronotype;	chr12:38268875	chr12:38906451~38909592:+
BRCA	cis	rs9325144	0.56	rs2387924	ENSG00000257718.1	RP11-396F22.1	-3.28	0.00106	0.0456	-0.1	-0.1	Morning vs. evening chronotype;	chr12:38269081	chr12:38906451~38909592:+
BRCA	cis	rs6466055	0.72	rs2030776	ENSG00000242154.1	RP4-778K6.3	-3.28	0.00106	0.0456	-0.13	-0.1	Schizophrenia;	chr7:105368011	chr7:105304277~105306642:+
BRCA	cis	rs6088580	0.634	rs4911423	ENSG00000269202.1	RP4-614O4.12	3.28	0.00106	0.0456	0.1	0.1	Glomerular filtration rate (creatinine);	chr20:34411580	chr20:35201747~35203288:-
BRCA	cis	rs6088580	0.634	rs6141471	ENSG00000269202.1	RP4-614O4.12	3.28	0.00106	0.0456	0.1	0.1	Glomerular filtration rate (creatinine);	chr20:34418924	chr20:35201747~35203288:-
BRCA	cis	rs77741769	0.7	rs7969196	ENSG00000272849.1	RP11-347I19.8	-3.28	0.00106	0.0456	-0.08	-0.1	Mean corpuscular volume;	chr12:120939853	chr12:121797511~121801972:+
BRCA	cis	rs17221829	0.932	rs4753236	ENSG00000280385.1	AP000648.5	-3.28	0.00106	0.0456	-0.11	-0.1	Anxiety in major depressive disorder;	chr11:89714979	chr11:90193614~90198120:+
BRCA	cis	rs2274273	1	rs74617736	ENSG00000233924.1	AL160471.6	-3.28	0.00106	0.0456	-0.11	-0.1	Protein biomarker;	chr14:55154201	chr14:55004813~55005687:-
BRCA	cis	rs2599510	0.783	rs2038534	ENSG00000276517.1	AL133243.2	-3.28	0.00106	0.0456	-0.13	-0.1	Interleukin-18 levels;	chr2:32434421	chr2:32526504~32529507:+
BRCA	cis	rs853679	0.824	rs34712084	ENSG00000219392.1	RP1-265C24.5	-3.28	0.00106	0.0456	-0.22	-0.1	Depression;	chr6:28076050	chr6:28115628~28116551:+
BRCA	cis	rs853679	0.824	rs1321505	ENSG00000219392.1	RP1-265C24.5	-3.28	0.00106	0.0456	-0.22	-0.1	Depression;	chr6:28085045	chr6:28115628~28116551:+
BRCA	cis	rs1466788	0.931	rs7514385	ENSG00000224965.1	KCNC4-AS1	3.28	0.00106	0.0456	0.12	0.1	Blood metabolite levels;	chr1:110084718	chr1:110208834~110209987:-
BRCA	cis	rs801193	1	rs10252765	ENSG00000232546.1	RP11-458F8.1	-3.28	0.00106	0.0456	-0.08	-0.1	Aortic root size;	chr7:66763745	chr7:66848496~66858136:+
BRCA	cis	rs35520189	0.556	rs11893071	ENSG00000231747.1	AC079922.2	-3.28	0.00106	0.0456	-0.1	-0.1	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:112951213	chr2:112621809~112622167:-
BRCA	cis	rs6772849	1	rs6772849	ENSG00000207088.1	SNORA7B	-3.28	0.00106	0.0456	-0.13	-0.1	Monocyte percentage of white cells;Monocyte count;	chr3:128587575	chr3:129397210~129397348:-
BRCA	cis	rs6866721	0.634	rs1672494	ENSG00000249167.1	CTB-118N6.2	3.28	0.00106	0.0456	0.12	0.1	Body mass index;	chr5:116886912	chr5:116574482~116591398:+
BRCA	cis	rs383182	1	rs4474087	ENSG00000225434.2	LINC01504	3.28	0.00106	0.0456	0.19	0.1	Urate levels in obese individuals;	chr9:73291906	chr9:72305430~72343210:+
BRCA	cis	rs60678552	0.642	rs9488903	ENSG00000237021.2	RP3-486I3.7	3.28	0.00106	0.0456	0.17	0.1	Heschl's gyrus morphology;	chr6:116321749	chr6:116254207~116256743:+
BRCA	cis	rs10816359	0.894	rs10816365	ENSG00000234323.4	RP11-308N19.1	-3.28	0.00106	0.0456	-0.15	-0.1	Menarche (age at onset);	chr9:106014851	chr9:106278392~106604795:+
BRCA	cis	rs654950	0.934	rs654220	ENSG00000230881.1	RP11-486B10.3	3.28	0.00106	0.0456	0.1	0.1	Airway imaging phenotypes;	chr1:41536885	chr1:41535443~41535868:+
BRCA	cis	rs11673344	0.668	rs7248693	ENSG00000267260.1	CTD-2162K18.4	-3.28	0.00107	0.0456	-0.15	-0.1	Obesity-related traits;	chr19:36991864	chr19:36773153~36777078:+
BRCA	cis	rs10838687	0.736	rs4647741	ENSG00000243802.2	RP11-390K5.1	3.28	0.00107	0.0456	0.15	0.1	Proinsulin levels;	chr11:47232459	chr11:47191181~47191542:-
BRCA	cis	rs829883	0.659	rs11109521	ENSG00000227825.4	SLC9A7P1	-3.28	0.00107	0.0456	-0.14	-0.1	Colorectal adenoma (advanced);	chr12:98537031	chr12:98453835~98457145:-
BRCA	cis	rs829883	0.659	rs11109522	ENSG00000227825.4	SLC9A7P1	-3.28	0.00107	0.0456	-0.14	-0.1	Colorectal adenoma (advanced);	chr12:98537186	chr12:98453835~98457145:-
BRCA	cis	rs829883	0.646	rs4762494	ENSG00000227825.4	SLC9A7P1	-3.28	0.00107	0.0456	-0.14	-0.1	Colorectal adenoma (advanced);	chr12:98540056	chr12:98453835~98457145:-
BRCA	cis	rs829883	0.659	rs4762495	ENSG00000227825.4	SLC9A7P1	-3.28	0.00107	0.0456	-0.14	-0.1	Colorectal adenoma (advanced);	chr12:98540327	chr12:98453835~98457145:-
BRCA	cis	rs3767633	0.925	rs10733044	ENSG00000229808.1	RP11-456P18.2	3.28	0.00107	0.0456	0.19	0.1	IgG glycosylation;	chr1:161933744	chr1:161890833~161892196:+
BRCA	cis	rs4703129	1	rs4703104	ENSG00000246763.5	RGMB-AS1	-3.28	0.00107	0.0456	-0.11	-0.1	Asperger disorder;	chr5:98515003	chr5:98769618~98773469:-
BRCA	cis	rs879500	0.653	rs4309478	ENSG00000266296.1	ARIH2P1	-3.28	0.00107	0.0456	-0.15	-0.1	Lung function (FVC);	chr18:28507843	chr18:28651732~28653208:+
BRCA	cis	rs2638953	0.853	rs12370338	ENSG00000273989.1	RP11-425D17.2	-3.28	0.00107	0.0456	-0.15	-0.1	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28486787	chr12:28236227~28236828:+
BRCA	cis	rs7412746	0.658	rs12097963	ENSG00000224800.1	RP11-235D19.2	-3.28	0.00107	0.0456	-0.13	-0.1	Melanoma;	chr1:150897974	chr1:150881236~150881683:-
BRCA	cis	rs7267979	1	rs4815412	ENSG00000231081.1	RP4-760C5.3	-3.28	0.00107	0.0456	-0.13	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25369689	chr20:26008791~26010531:-
BRCA	cis	rs9392556	0.829	rs693953	ENSG00000272248.1	RP3-406P24.4	3.28	0.00107	0.0456	0.13	0.1	Blood metabolite levels;	chr6:4120331	chr6:4018713~4019202:+
BRCA	cis	rs9392556	0.829	rs613260	ENSG00000272248.1	RP3-406P24.4	3.28	0.00107	0.0456	0.13	0.1	Blood metabolite levels;	chr6:4120333	chr6:4018713~4019202:+
BRCA	cis	rs10463316	0.817	rs2112419	ENSG00000260581.1	CTB-113P19.4	3.28	0.00107	0.0456	0.12	0.1	Metabolite levels (Pyroglutamine);	chr5:151418243	chr5:151652275~151655449:+
BRCA	cis	rs10836699	0.635	rs1381155	ENSG00000280331.1	RP11-545D22.1	3.28	0.00107	0.0456	0.13	0.1	Low high density lipoprotein cholesterol levels;	chr11:37143217	chr11:36510361~36510537:+
BRCA	cis	rs6964587	0.869	rs6979024	ENSG00000188693.7	CYP51A1-AS1	3.28	0.00107	0.0456	0.11	0.1	Breast cancer;	chr7:91852198	chr7:92134604~92180725:+
BRCA	cis	rs6500602	0.627	rs9938228	ENSG00000262312.2	LA16c-390H2.4	3.28	0.00107	0.0456	0.09	0.1	Schizophrenia;	chr16:4480596	chr16:3542739~3545785:+
BRCA	cis	rs7569084	1	rs7569084	ENSG00000281920.1	RP11-418H16.1	-3.28	0.00107	0.0456	-0.12	-0.1	Sum eosinophil basophil counts;	chr2:65429835	chr2:65623272~65628424:+
BRCA	cis	rs9393813	0.529	rs2064093	ENSG00000241549.7	GUSBP2	3.28	0.00107	0.0456	0.11	0.1	Bipolar disorder;	chr6:27474468	chr6:26871484~26956554:-
BRCA	cis	rs12141041	0.653	rs7540738	ENSG00000274642.1	CH17-472G23.1	3.28	0.00107	0.0456	0.12	0.1	Blood metabolite levels;	chr1:119435080	chr1:120197085~120319680:+
BRCA	cis	rs11763147	1	rs11763147	ENSG00000232546.1	RP11-458F8.1	3.28	0.00107	0.0456	0.08	0.1	Corneal structure;	chr7:65861834	chr7:66848496~66858136:+
BRCA	cis	rs1979679	0.572	rs6487692	ENSG00000244712.1	RP11-874G11.1	3.28	0.00107	0.0456	0.16	0.1	Ossification of the posterior longitudinal ligament of the spine;	chr12:28573109	chr12:28564678~28565141:-
BRCA	cis	rs1155750	0.72	rs239833	ENSG00000224984.1	RP11-524H19.2	-3.28	0.00107	0.0456	-0.15	-0.1	Colorectal cancer;	chr6:54904555	chr6:54840118~54840855:-
BRCA	cis	rs1155750	0.72	rs406149	ENSG00000224984.1	RP11-524H19.2	-3.28	0.00107	0.0456	-0.15	-0.1	Colorectal cancer;	chr6:54914721	chr6:54840118~54840855:-
BRCA	cis	rs1155750	0.656	rs1028423	ENSG00000224984.1	RP11-524H19.2	-3.28	0.00107	0.0456	-0.15	-0.1	Colorectal cancer;	chr6:54914905	chr6:54840118~54840855:-
BRCA	cis	rs1155750	0.72	rs183011	ENSG00000224984.1	RP11-524H19.2	-3.28	0.00107	0.0456	-0.15	-0.1	Colorectal cancer;	chr6:54915982	chr6:54840118~54840855:-
BRCA	cis	rs6582630	0.598	rs10880645	ENSG00000257718.1	RP11-396F22.1	-3.28	0.00107	0.0456	-0.1	-0.1	Drug-induced liver injury (flucloxacillin);	chr12:38162370	chr12:38906451~38909592:+
BRCA	cis	rs7474896	0.778	rs11011384	ENSG00000120555.12	SEPT7P9	3.28	0.00107	0.0456	0.19	0.1	Obesity (extreme);	chr10:37862034	chr10:38383069~38402916:-
BRCA	cis	rs12122100	0.651	rs12129691	ENSG00000229828.2	PDE4DIP1	-3.28	0.00107	0.0456	-0.14	-0.1	HIV-1 control;	chr1:147082598	chr1:148080598~148093883:+
BRCA	cis	rs9783347	0.621	rs2305564	ENSG00000256361.1	RP11-613F22.6	-3.28	0.00107	0.0456	-0.11	-0.1	Pancreatic cancer;	chr11:18295911	chr11:18511043~18511475:-
BRCA	cis	rs17684571	0.81	rs41267675	ENSG00000231441.1	RP11-472M19.2	3.28	0.00107	0.0456	0.17	0.1	Schizophrenia;	chr6:56735323	chr6:56844002~56864078:+
BRCA	cis	rs17092148	0.616	rs1122174	ENSG00000206582.1	Y_RNA	-3.28	0.00107	0.0456	-0.14	-0.1	Neuroticism;	chr20:34523041	chr20:34526510~34526606:-
BRCA	cis	rs6088590	1	rs6088595	ENSG00000269202.1	RP4-614O4.12	-3.28	0.00107	0.0456	-0.11	-0.1	Coronary artery disease;	chr20:34770696	chr20:35201747~35203288:-
BRCA	cis	rs35520189	0.806	rs11123151	ENSG00000231747.1	AC079922.2	-3.28	0.00107	0.0456	-0.11	-0.1	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:112910428	chr2:112621809~112622167:-
BRCA	cis	rs74233809	1	rs11191587	ENSG00000213061.2	PFN1P11	3.28	0.00107	0.0456	0.22	0.1	Birth weight;	chr10:103169959	chr10:102838011~102845473:-
BRCA	cis	rs4665809	1	rs6749855	ENSG00000231655.1	AC011742.3	3.28	0.00107	0.0456	0.15	0.1	Gut microbiome composition (summer);	chr2:26032394	chr2:26140263~26141264:-
BRCA	cis	rs2018683	0.683	rs12538606	ENSG00000228421.2	AC005013.5	3.28	0.00107	0.0456	0.13	0.1	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28929791	chr7:28957667~28959345:+
BRCA	cis	rs9368481	0.524	rs12530345	ENSG00000272462.2	U91328.19	-3.28	0.00107	0.0456	-0.12	-0.1	Autism spectrum disorder or schizophrenia;	chr6:26916464	chr6:25992662~26001775:+
BRCA	cis	rs4372836	0.677	rs4632298	ENSG00000226833.4	AC097724.3	-3.28	0.00107	0.0456	-0.12	-0.1	Body mass index;	chr2:28853416	chr2:28708953~28736205:-
BRCA	cis	rs853679	0.55	rs1150689	ENSG00000261839.1	RP1-265C24.8	3.28	0.00107	0.0456	0.13	0.1	Depression;	chr6:28197321	chr6:28136849~28139678:+
BRCA	cis	rs853679	0.55	rs1225599	ENSG00000261839.1	RP1-265C24.8	3.28	0.00107	0.0456	0.13	0.1	Depression;	chr6:28197412	chr6:28136849~28139678:+
BRCA	cis	rs853679	0.574	rs1233705	ENSG00000261839.1	RP1-265C24.8	3.28	0.00107	0.0456	0.13	0.1	Depression;	chr6:28198669	chr6:28136849~28139678:+
BRCA	cis	rs7429990	0.965	rs184388	ENSG00000228638.1	FCF1P2	-3.28	0.00107	0.0456	-0.1	-0.1	Educational attainment (years of education);	chr3:47898136	chr3:48290793~48291375:-
BRCA	cis	rs9423406	0.752	rs9423408	ENSG00000272764.1	RP11-318E3.9	3.28	0.00107	0.0457	0.17	0.1	Intelligence;	chr10:5317047	chr10:5813985~5814441:+
BRCA	cis	rs2154490	0.853	rs2832392	ENSG00000176054.6	RPL23P2	3.28	0.00107	0.0457	0.11	0.1	Glucocorticoid-induced osteonecrosis;	chr21:29545896	chr21:28997613~28998033:-
BRCA	cis	rs7267979	0.899	rs2104734	ENSG00000277938.1	RP5-965G21.3	3.28	0.00107	0.0457	0.12	0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25546032	chr20:25229150~25231933:+
BRCA	cis	rs66887589	0.748	rs28439855	ENSG00000249244.1	RP11-548H18.2	3.28	0.00107	0.0457	0.11	0.1	Diastolic blood pressure;	chr4:119341101	chr4:119391831~119395335:-
BRCA	cis	rs600231	0.706	rs1111934	ENSG00000254614.2	AP003068.23	3.28	0.00107	0.0457	0.14	0.1	Bone mineral density;	chr11:65561921	chr11:65177606~65181834:-
BRCA	cis	rs74233809	1	rs1060240	ENSG00000213061.2	PFN1P11	3.28	0.00107	0.0457	0.22	0.1	Birth weight;	chr10:103123580	chr10:102838011~102845473:-
BRCA	cis	rs74233809	1	rs10883835	ENSG00000213061.2	PFN1P11	3.28	0.00107	0.0457	0.22	0.1	Birth weight;	chr10:103124451	chr10:102838011~102845473:-
BRCA	cis	rs9392556	0.829	rs634698	ENSG00000272248.1	RP3-406P24.4	3.28	0.00107	0.0457	0.13	0.1	Blood metabolite levels;	chr6:4114013	chr6:4018713~4019202:+
BRCA	cis	rs7914558	0.966	rs1890185	ENSG00000272912.1	RP11-724N1.1	-3.28	0.00107	0.0457	-0.11	-0.1	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102988961	chr10:102914585~102915404:+
BRCA	cis	rs67478160	0.619	rs11160759	ENSG00000269910.1	RP11-73M18.10	3.28	0.00107	0.0457	0.1	0.1	Schizophrenia;	chr14:103765205	chr14:103694516~103695050:-
BRCA	cis	rs7103648	0.695	rs7933019	ENSG00000255520.1	RP11-390K5.3	3.28	0.00107	0.0457	0.13	0.1	Systolic blood pressure;Diastolic blood pressure;	chr11:47487585	chr11:47123104~47130801:-
BRCA	cis	rs12413816	0.824	rs1571008	ENSG00000234175.1	RP11-730A19.9	-3.28	0.00107	0.0457	-0.12	-0.1	Red cell distribution width;	chr10:13718776	chr10:13139196~13139533:-
BRCA	cis	rs757081	0.671	rs214091	ENSG00000184669.7	OR7E14P	-3.28	0.00107	0.0457	-0.16	-0.1	Systolic blood pressure;	chr11:17274916	chr11:17013998~17053024:+
BRCA	cis	rs13434995	0.589	rs499110	ENSG00000249700.7	SRD5A3-AS1	-3.28	0.00107	0.0457	-0.15	-0.1	Adiponectin levels;	chr4:55381628	chr4:55363971~55395847:-
BRCA	cis	rs7020830	0.898	rs308492	ENSG00000260100.1	RP11-220I1.5	-3.28	0.00107	0.0457	-0.12	-0.1	Schizophrenia;	chr9:37298023	chr9:37078813~37079776:-
BRCA	cis	rs1348850	0.918	rs4893966	ENSG00000271825.1	RP11-337N6.2	3.28	0.00107	0.0457	0.13	0.1	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177605410	chr2:177300600~177302006:+
BRCA	cis	rs863345	0.584	rs10908676	ENSG00000176320.2	RP11-404O13.5	-3.28	0.00107	0.0457	-0.11	-0.1	Pneumococcal bacteremia;	chr1:158536373	chr1:158197922~158203877:-
BRCA	cis	rs12701220	0.655	rs7799656	ENSG00000224079.1	AC091729.7	3.28	0.00107	0.0457	0.14	0.1	Bronchopulmonary dysplasia;	chr7:1100879	chr7:1074450~1078036:+
BRCA	cis	rs4356203	0.87	rs7937176	ENSG00000184669.7	OR7E14P	-3.28	0.00107	0.0457	-0.13	-0.1	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17258198	chr11:17013998~17053024:+
BRCA	cis	rs17023223	0.581	rs10923750	ENSG00000227056.2	RPL6P2	-3.28	0.00107	0.0457	-0.13	-0.1	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119108172	chr1:119219314~119220096:-
BRCA	cis	rs2638953	0.924	rs11049478	ENSG00000273989.1	RP11-425D17.2	-3.28	0.00107	0.0457	-0.16	-0.1	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28244827	chr12:28236227~28236828:+
BRCA	cis	rs10129255	0.957	rs10142859	ENSG00000253132.1	IGHV3-62	-3.28	0.00107	0.0457	-0.08	-0.1	Kawasaki disease;	chr14:106782238	chr14:106643142~106643585:-
BRCA	cis	rs1208	0.965	rs4646258	ENSG00000253671.1	RP11-806O11.1	-3.28	0.00107	0.0457	-0.12	-0.1	Insulin resistance/response;	chr8:18405169	chr8:17808941~17820868:+
BRCA	cis	rs10129255	0.957	rs8005468	ENSG00000231475.3	IGHV4-31	-3.28	0.00107	0.0457	-0.08	-0.1	Kawasaki disease;	chr14:106686431	chr14:106349283~106349792:-
BRCA	cis	rs4713118	0.826	rs2893929	ENSG00000219392.1	RP1-265C24.5	-3.28	0.00107	0.0457	-0.15	-0.1	Parkinson's disease;	chr6:27770953	chr6:28115628~28116551:+
BRCA	cis	rs4713118	0.666	rs4140646	ENSG00000219392.1	RP1-265C24.5	-3.28	0.00107	0.0457	-0.15	-0.1	Parkinson's disease;	chr6:27771022	chr6:28115628~28116551:+
BRCA	cis	rs4713118	0.666	rs2893930	ENSG00000219392.1	RP1-265C24.5	-3.28	0.00107	0.0457	-0.15	-0.1	Parkinson's disease;	chr6:27771027	chr6:28115628~28116551:+
BRCA	cis	rs13008689	1	rs12692353	ENSG00000236790.4	LINC00299	3.28	0.00107	0.0457	0.12	0.1	Longevity;	chr2:8390074	chr2:8007771~8383621:-
BRCA	cis	rs7789940	0.904	rs6948661	ENSG00000231087.2	FDPSP7	-3.28	0.00107	0.0457	-0.13	-0.1	Multiple sclerosis;	chr7:76332330	chr7:76968197~76969250:-
BRCA	cis	rs2836974	0.526	rs1888488	ENSG00000238141.2	BRWD1-AS1	-3.28	0.00107	0.0457	-0.12	-0.1	Cognitive function;	chr21:39314595	chr21:39315707~39323218:+
BRCA	cis	rs10798959	1	rs10798959	ENSG00000266239.2	AL513327.1	3.28	0.00107	0.0457	0.12	0.1	Metabolite levels (HVA/MHPG ratio);	chr1:33517419	chr1:33332431~33332541:-
BRCA	cis	rs853679	0.546	rs175597	ENSG00000241549.7	GUSBP2	3.28	0.00107	0.0457	0.18	0.1	Depression;	chr6:27842848	chr6:26871484~26956554:-
BRCA	cis	rs987724	0.515	rs453219	ENSG00000243926.1	TIPARP-AS1	3.28	0.00107	0.0457	0.14	0.1	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156856463	chr3:156671862~156674378:-
BRCA	cis	rs12141041	0.967	rs12735092	ENSG00000274642.1	CH17-472G23.1	-3.28	0.00107	0.0457	-0.12	-0.1	Blood metabolite levels;	chr1:119412851	chr1:120197085~120319680:+
BRCA	cis	rs7017914	0.934	rs13255886	ENSG00000246366.5	RP11-382J12.1	3.28	0.00107	0.0457	0.11	0.1	Bone mineral density;	chr8:70653719	chr8:70608577~70663279:+
BRCA	cis	rs2153535	0.585	rs1328873	ENSG00000251164.1	HULC	-3.28	0.00107	0.0457	-0.12	-0.1	Motion sickness;	chr6:8621171	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.585	rs9393047	ENSG00000251164.1	HULC	-3.28	0.00107	0.0457	-0.12	-0.1	Motion sickness;	chr6:8622373	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.585	rs9505495	ENSG00000251164.1	HULC	-3.28	0.00107	0.0457	-0.12	-0.1	Motion sickness;	chr6:8622963	chr6:8652137~8653846:+
BRCA	cis	rs2153535	0.585	rs9328499	ENSG00000251164.1	HULC	-3.28	0.00107	0.0457	-0.12	-0.1	Motion sickness;	chr6:8623546	chr6:8652137~8653846:+
BRCA	cis	rs2839186	0.504	rs4347941	ENSG00000228137.1	AP001469.7	-3.28	0.00107	0.0457	-0.1	-0.1	Testicular germ cell tumor;	chr21:46518326	chr21:46246890~46247682:+
BRCA	cis	rs8094794	0.744	rs9652997	ENSG00000267707.2	RP11-95O2.5	3.28	0.00107	0.0457	0.14	0.1	Periodontal disease-related phenotypes;	chr18:36715227	chr18:37243776~37247506:+
BRCA	cis	rs1005277	0.579	rs2505241	ENSG00000276805.1	RP11-291L22.6	3.28	0.00107	0.0457	0.11	0.1	Extrinsic epigenetic age acceleration;	chr10:38153493	chr10:38451030~38451785:+
BRCA	cis	rs2043112	0.965	rs6864478	ENSG00000249911.1	LINC01265	3.28	0.00107	0.0457	0.12	0.1	Obesity-related traits;	chr5:38922724	chr5:38710367~38720273:-
BRCA	cis	rs1376877	0.905	rs60905637	ENSG00000273456.1	RP11-686O6.2	3.28	0.00107	0.0457	0.1	0.1	Subclinical atherosclerosis traits (other);	chr2:203336342	chr2:202374932~202375604:-
BRCA	cis	rs4356203	0.87	rs214919	ENSG00000184669.7	OR7E14P	-3.28	0.00107	0.0457	-0.13	-0.1	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17217157	chr11:17013998~17053024:+
BRCA	cis	rs6893300	0.961	rs11738269	ENSG00000225051.5	HMGB3P22	-3.28	0.00107	0.0457	-0.13	-0.1	Resting heart rate;	chr5:179782058	chr5:179679032~179694768:+
BRCA	cis	rs77688320	0.553	rs6761777	ENSG00000242696.3	RN7SL40P	-3.28	0.00107	0.0457	-0.11	-0.1	Breast cancer;	chr2:201399879	chr2:202357076~202357417:-
BRCA	cis	rs1144333	1	rs5745327	ENSG00000181227.3	RP4-682C21.2	3.28	0.00107	0.0457	0.13	0.1	Attention function in attention deficit hyperactive disorder;	chr1:75804355	chr1:75743423~75744776:-
BRCA	cis	rs875971	0.571	rs160641	ENSG00000226767.1	RP11-328P23.3	-3.28	0.00107	0.0457	-0.12	-0.1	Aortic root size;	chr7:66112359	chr7:65508773~65508944:-
BRCA	cis	rs2286492	0.655	rs117841439	ENSG00000226329.2	AC005682.6	-3.28	0.00107	0.0457	-0.17	-0.1	Bipolar disorder;	chr7:22870922	chr7:22863874~22881350:-
BRCA	cis	rs2638953	0.741	rs10843194	ENSG00000273989.1	RP11-425D17.2	-3.28	0.00107	0.0457	-0.15	-0.1	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28510237	chr12:28236227~28236828:+
BRCA	cis	rs2832191	0.632	rs1984011	ENSG00000236056.1	GAPDHP14	3.28	0.00107	0.0457	0.11	0.1	Dental caries;	chr21:28965509	chr21:29222321~29223257:+
BRCA	cis	rs9976876	0.9	rs1888454	ENSG00000231106.2	LINC01436	-3.28	0.00107	0.0458	-0.11	-0.1	Total body bone mineral density;	chr21:35566328	chr21:36005338~36007838:+
BRCA	cis	rs7712401	0.755	rs10071705	ENSG00000249996.1	RP11-359P5.1	3.28	0.00107	0.0458	0.12	0.1	Mean platelet volume;	chr5:122797030	chr5:123036271~123054667:+
BRCA	cis	rs35146811	0.735	rs7811662	ENSG00000221487.1	AC069294.1	3.28	0.00107	0.0458	0.13	0.1	Coronary artery disease;	chr7:100194985	chr7:99713037~99713152:+
BRCA	cis	rs12477438	0.798	rs4851179	ENSG00000226791.5	AC109826.1	3.28	0.00107	0.0458	0.13	0.1	Chronic sinus infection;	chr2:98952311	chr2:98761938~98772920:-
BRCA	cis	rs1730008	0.865	rs7645383	ENSG00000279311.1	RP11-170K4.2	-3.28	0.00107	0.0458	-0.11	-0.1	Lobe attachment (rater-scored or self-reported);	chr3:158175654	chr3:158869898~158871821:+
BRCA	cis	rs6545883	0.929	rs778154	ENSG00000273302.1	RP11-493E12.2	-3.28	0.00107	0.0458	-0.1	-0.1	Tuberculosis;	chr2:61419496	chr2:61199979~61200769:+
BRCA	cis	rs17767294	0.708	rs72849204	ENSG00000272009.1	RP1-313I6.12	-3.28	0.00107	0.0458	-0.26	-0.1	Parkinson's disease;	chr6:28203165	chr6:28078792~28081130:-
BRCA	cis	rs17767294	0.708	rs72849205	ENSG00000272009.1	RP1-313I6.12	-3.28	0.00107	0.0458	-0.26	-0.1	Parkinson's disease;	chr6:28203751	chr6:28078792~28081130:-
BRCA	cis	rs17767294	0.708	rs72849206	ENSG00000272009.1	RP1-313I6.12	-3.28	0.00107	0.0458	-0.26	-0.1	Parkinson's disease;	chr6:28204926	chr6:28078792~28081130:-
BRCA	cis	rs1488902	0.785	rs1948188	ENSG00000280385.1	AP000648.5	-3.28	0.00107	0.0458	-0.1	-0.1	Amyotrophic lateral sclerosis;	chr11:89600217	chr11:90193614~90198120:+
BRCA	cis	rs9308433	0.529	rs4655336	ENSG00000213036.3	RP11-365D23.4	-3.28	0.00107	0.0458	-0.14	-0.1	IgG glycosylation;	chr1:214326324	chr1:214482813~214483387:-
BRCA	cis	rs6490294	0.571	rs57168159	ENSG00000257624.1	RP1-128M12.3	3.28	0.00107	0.0458	0.16	0.1	Mean platelet volume;	chr12:112189041	chr12:112000739~112000985:-
BRCA	cis	rs1789	0.872	rs4333182	ENSG00000214846.4	RP11-115L11.1	3.28	0.00107	0.0458	0.13	0.1	Blood protein levels;	chr4:15683089	chr4:15730962~15731627:-
BRCA	cis	rs300890	0.729	rs7680959	ENSG00000250326.1	RP11-284M14.1	3.28	0.00107	0.0458	0.11	0.1	Nasopharyngeal carcinoma;	chr4:143391367	chr4:142933195~143184861:-
BRCA	cis	rs7917772	0.636	rs4919674	ENSG00000236937.2	PTGES3P4	3.28	0.00107	0.0458	0.14	0.1	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;	chr10:102762469	chr10:102845595~102845950:+
BRCA	cis	rs7917772	0.629	rs1475646	ENSG00000236937.2	PTGES3P4	3.28	0.00107	0.0458	0.14	0.1	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;	chr10:102762807	chr10:102845595~102845950:+
BRCA	cis	rs6445975	0.666	rs4681680	ENSG00000272360.1	RP11-359I18.5	-3.28	0.00107	0.0458	-0.12	-0.1	Systemic lupus erythematosus;	chr3:58346490	chr3:58490830~58491291:-
BRCA	cis	rs34779708	0.733	rs11597184	ENSG00000269952.1	RP11-324I22.3	-3.28	0.00107	0.0458	-0.14	-0.1	Inflammatory bowel disease;Crohn's disease;	chr10:35108468	chr10:35210416~35210750:+
BRCA	cis	rs853679	0.546	rs200490	ENSG00000241549.7	GUSBP2	3.28	0.00107	0.0458	0.18	0.1	Depression;	chr6:27829157	chr6:26871484~26956554:-
BRCA	cis	rs3213958	0.574	rs6440159	ENSG00000239445.4	ST3GAL6-AS1	-3.28	0.00107	0.0458	-0.15	-0.1	Blood protein levels;	chr3:98823350	chr3:98714330~98732651:-
BRCA	cis	rs12149695	0.872	rs12934078	ENSG00000259940.2	CTD-3203P2.1	-3.28	0.00107	0.0458	-0.13	-0.1	Gut microbiota (bacterial taxa);	chr16:27236340	chr16:27213308~27214993:-
BRCA	cis	rs7267979	0.932	rs6132848	ENSG00000274973.1	RP13-401N8.7	-3.28	0.00107	0.0458	-0.11	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25581009	chr20:25845497~25845862:+
BRCA	cis	rs561341	0.556	rs542244	ENSG00000277511.1	CTD-2095E4.5	3.28	0.00107	0.0458	0.15	0.1	Hip circumference adjusted for BMI;	chr17:31980223	chr17:32127595~32128454:+
BRCA	cis	rs2280018	1	rs2280017	ENSG00000258354.1	MIR3180-1	3.28	0.00107	0.0458	0.12	0.1	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15057504	chr16:14909887~14911345:-
BRCA	cis	rs7267979	0.706	rs6138542	ENSG00000274973.1	RP13-401N8.7	-3.28	0.00107	0.0458	-0.12	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25227137	chr20:25845497~25845862:+
BRCA	cis	rs7829975	0.593	rs2921061	ENSG00000253981.4	ALG1L13P	3.28	0.00107	0.0458	0.12	0.1	Mood instability;	chr8:8460105	chr8:8236003~8244667:-
BRCA	cis	rs8180040	0.577	rs12493425	ENSG00000260236.1	RP11-708J19.1	3.28	0.00107	0.0458	0.09	0.1	Colorectal cancer;	chr3:47135456	chr3:47379089~47380999:-
BRCA	cis	rs10838798	0.504	rs11039627	ENSG00000280615.1	Y_RNA	-3.28	0.00107	0.0458	-0.12	-0.1	Height;	chr11:48272379	chr11:47614898~47614994:-
BRCA	cis	rs58521262	0.585	rs11669602	ENSG00000241282.1	RPL34P33	3.28	0.00107	0.0458	0.17	0.1	Testicular germ cell tumor;	chr19:22769447	chr19:22699352~22699685:+
BRCA	cis	rs11642862	1	rs112234000	ENSG00000274678.1	RP11-2C24.7	-3.28	0.00107	0.0458	-0.19	-0.1	Tonsillectomy;	chr16:30767487	chr16:30821338~30821884:+
BRCA	cis	rs11642862	1	rs75500538	ENSG00000274678.1	RP11-2C24.7	-3.28	0.00107	0.0458	-0.19	-0.1	Tonsillectomy;	chr16:30771128	chr16:30821338~30821884:+
BRCA	cis	rs1914816	0.653	rs403656	ENSG00000196274.5	Metazoa_SRP	3.28	0.00107	0.0458	0.14	0.1	Response to tocilizumab in rheumatoid arthritis;	chr15:76463165	chr15:76230048~76230390:-
BRCA	cis	rs1914816	0.653	rs157776	ENSG00000196274.5	Metazoa_SRP	3.28	0.00107	0.0458	0.14	0.1	Response to tocilizumab in rheumatoid arthritis;	chr15:76464362	chr15:76230048~76230390:-
BRCA	cis	rs11671005	0.735	rs34152946	ENSG00000269600.1	AC016629.3	-3.28	0.00107	0.0458	-0.15	-0.1	Mean platelet volume;	chr19:58411896	chr19:58593896~58599355:-
BRCA	cis	rs11673344	0.764	rs474017	ENSG00000267682.1	CTD-3220F14.2	-3.28	0.00107	0.0458	-0.09	-0.1	Obesity-related traits;	chr19:36963217	chr19:37337236~37337743:+
BRCA	cis	rs3743102	0.591	rs17841171	ENSG00000278603.1	RP13-608F4.5	3.28	0.00107	0.0458	0.2	0.1	Colorectal adenoma (advanced);	chr15:82689636	chr15:82472203~82472426:+
BRCA	cis	rs812925	0.537	rs10208769	ENSG00000212978.6	AC016747.3	-3.28	0.00107	0.0458	-0.13	-0.1	Immature fraction of reticulocytes;	chr2:61378479	chr2:61141592~61144969:-
BRCA	cis	rs2842992	0.83	rs2025190	ENSG00000207392.1	SNORA20	-3.28	0.00107	0.0458	-0.14	-0.1	Age-related macular degeneration (geographic atrophy);	chr6:159717209	chr6:159780250~159780381:-
BRCA	cis	rs28472312	0.894	rs7498491	ENSG00000259982.1	CDC37P1	3.28	0.00107	0.0458	0.13	0.1	Intelligence (multi-trait analysis);	chr16:28832747	chr16:28700294~28701540:-
BRCA	cis	rs6893300	0.961	rs113829727	ENSG00000225051.5	HMGB3P22	3.28	0.00107	0.0458	0.14	0.1	Resting heart rate;	chr5:179764895	chr5:179679032~179694768:+
BRCA	cis	rs863345	0.625	rs7534112	ENSG00000176320.2	RP11-404O13.5	-3.28	0.00107	0.0458	-0.11	-0.1	Pneumococcal bacteremia;	chr1:158562275	chr1:158197922~158203877:-
BRCA	cis	rs2795502	1	rs2473119	ENSG00000185904.10	LINC00839	-3.28	0.00107	0.0458	-0.15	-0.1	Blood protein levels;	chr10:42843590	chr10:42475543~42495336:+
BRCA	cis	rs9467711	0.659	rs35680819	ENSG00000241549.7	GUSBP2	3.28	0.00107	0.0458	0.22	0.1	Autism spectrum disorder or schizophrenia;	chr6:26455586	chr6:26871484~26956554:-
BRCA	cis	rs10129255	0.518	rs2006284	ENSG00000211976.2	IGHV3-73	-3.28	0.00107	0.0458	-0.08	-0.1	Kawasaki disease;	chr14:106676185	chr14:106802694~106803233:-
BRCA	cis	rs910316	0.663	rs175034	ENSG00000259138.1	RP11-950C14.7	-3.28	0.00107	0.0458	-0.11	-0.1	Height;	chr14:74996984	chr14:75127153~75136930:+
BRCA	cis	rs7520050	0.902	rs9429088	ENSG00000234329.1	RP11-767N6.2	-3.28	0.00107	0.0458	-0.1	-0.1	Reticulocyte count;Red blood cell count;	chr1:46031828	chr1:45651039~45651826:-
BRCA	cis	rs2076295	0.503	rs34533690	ENSG00000261189.1	RP3-512B11.3	-3.28	0.00107	0.0458	-0.12	-0.1	Idiopathic pulmonary fibrosis;Interstitial lung disease;Chronic obstructive pulmonary disease;	chr6:7564652	chr6:7540451~7541338:-
BRCA	cis	rs10876993	0.89	rs12302350	ENSG00000270039.1	RP11-571M6.17	3.28	0.00107	0.0458	0.13	0.1	Celiac disease or Rheumatoid arthritis;	chr12:57668806	chr12:57803838~57804415:+
BRCA	cis	rs10876993	0.89	rs12302351	ENSG00000270039.1	RP11-571M6.17	3.28	0.00107	0.0458	0.13	0.1	Celiac disease or Rheumatoid arthritis;	chr12:57668807	chr12:57803838~57804415:+
BRCA	cis	rs1155750	0.72	rs171226	ENSG00000224984.1	RP11-524H19.2	-3.28	0.00107	0.0458	-0.15	-0.1	Colorectal cancer;	chr6:54908276	chr6:54840118~54840855:-
BRCA	cis	rs2638953	1	rs2638953	ENSG00000273989.1	RP11-425D17.2	3.28	0.00107	0.0458	0.14	0.1	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28381482	chr12:28236227~28236828:+
BRCA	cis	rs73198271	0.74	rs10092720	ENSG00000233609.3	RP11-62H7.2	-3.28	0.00107	0.0458	-0.1	-0.1	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8791607	chr8:8961200~8979025:+
BRCA	cis	rs4449834	0.781	rs11995234	ENSG00000254432.1	RP11-33I11.2	-3.28	0.00107	0.0458	-0.14	-0.1	Sum eosinophil basophil counts;	chr8:60721585	chr8:60808735~60809606:-
BRCA	cis	rs740698	0.522	rs1024653	ENSG00000279713.1	CTD-3035K23.3	3.28	0.00107	0.0458	0.1	0.1	Pulse pressure;	chr17:62714457	chr17:62679403~62681354:-
BRCA	cis	rs12369179	0.737	rs116896792	ENSG00000256028.2	RP11-197N18.2	3.28	0.00107	0.0458	0.17	0.1	Age-related diseases, mortality and associated endophenotypes;Age-related disease endophenotypes;	chr12:122464360	chr12:122975320~122982907:+
BRCA	cis	rs11098499	0.955	rs1397608	ENSG00000260404.2	RP11-384K6.6	3.28	0.00107	0.0458	0.1	0.1	Corneal astigmatism;	chr4:119240589	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.955	rs7685268	ENSG00000260404.2	RP11-384K6.6	3.28	0.00107	0.0458	0.1	0.1	Corneal astigmatism;	chr4:119241033	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.955	rs7684942	ENSG00000260404.2	RP11-384K6.6	3.28	0.00107	0.0458	0.1	0.1	Corneal astigmatism;	chr4:119241046	chr4:118591773~118633729:+
BRCA	cis	rs935334	1	rs2289836	ENSG00000258454.1	RP11-361H10.3	-3.28	0.00107	0.0458	-0.17	-0.1	Blood pressure;	chr14:76173782	chr14:76235817~76263474:+
BRCA	cis	rs915286	0.967	rs9532498	ENSG00000275149.1	RP11-427J23.1	3.28	0.00107	0.0458	0.11	0.1	Crohn's disease;Inflammatory bowel disease;	chr13:40104306	chr13:40079106~40273509:-
BRCA	cis	rs1910358	0.919	rs2331690	ENSG00000248874.4	C5orf17	3.28	0.00107	0.0459	0.15	0.1	Venous thromboembolism (SNP x SNP interaction);	chr5:23865627	chr5:23951348~24178263:+
BRCA	cis	rs91731	0.79	rs412407	ENSG00000249572.1	CTD-2203K17.1	-3.28	0.00107	0.0459	-0.19	-0.1	Lung function (FVC);	chr5:33276628	chr5:33424025~33440619:-
BRCA	cis	rs4699052	0.662	rs6848593	ENSG00000230069.3	LRRC37A15P	-3.28	0.00107	0.0459	-0.1	-0.1	Testicular germ cell tumor;	chr4:103328956	chr4:102727274~102730721:-
BRCA	cis	rs7474896	0.778	rs11011440	ENSG00000120555.12	SEPT7P9	3.28	0.00107	0.0459	0.18	0.1	Obesity (extreme);	chr10:38075213	chr10:38383069~38402916:-
BRCA	cis	rs10864907	0.806	rs879711	ENSG00000231747.1	AC079922.2	-3.28	0.00107	0.0459	-0.09	-0.1	Pulmonary function;	chr2:112958677	chr2:112621809~112622167:-
BRCA	cis	rs6929812	0.967	rs7509	ENSG00000220721.1	OR1F12	-3.28	0.00107	0.0459	-0.11	-0.1	Neuroticism (multi-trait analysis);	chr6:27451068	chr6:28073316~28074233:+
BRCA	cis	rs2227564	0.729	rs2633303	ENSG00000279689.1	RP11-574K11.32	3.28	0.00107	0.0459	0.11	0.1	Crohn's disease;Inflammatory bowel disease;	chr10:73886124	chr10:73769264~73772862:-
BRCA	cis	rs7904321	1	rs7904321	ENSG00000232075.1	MRPL35P2	-3.28	0.00107	0.0459	-0.13	-0.1	Intelligence (multi-trait analysis);	chr10:63080905	chr10:63634317~63634827:-
BRCA	cis	rs17756712	0.725	rs3823130	ENSG00000272463.1	RP11-532F6.3	3.28	0.00107	0.0459	0.18	0.1	Vertical cup-disc ratio;	chr6:594012	chr6:708592~711405:-
BRCA	cis	rs7781266	0.79	rs10260563	ENSG00000226205.1	AC007790.4	-3.28	0.00107	0.0459	-0.15	-0.1	Educational attainment (college completion);	chr7:133493917	chr7:133732493~133733595:-
BRCA	cis	rs7781266	0.656	rs6979546	ENSG00000226205.1	AC007790.4	-3.28	0.00107	0.0459	-0.15	-0.1	Educational attainment (college completion);	chr7:133494856	chr7:133732493~133733595:-
BRCA	cis	rs3018066	0.867	rs6843331	ENSG00000251175.4	RP11-45L9.1	3.28	0.00107	0.0459	0.13	0.1	Cancer;	chr4:106037147	chr4:105746245~105827172:-
BRCA	cis	rs9527	0.551	rs28606370	ENSG00000213277.3	MARCKSL1P1	3.28	0.00107	0.0459	0.12	0.1	Arsenic metabolism;	chr10:102911075	chr10:103175554~103176094:+
BRCA	cis	rs2243480	1	rs34529418	ENSG00000234585.5	CCT6P3	-3.28	0.00107	0.0459	-0.15	-0.1	Diabetic kidney disease;	chr7:65938222	chr7:65038354~65074713:+
BRCA	cis	rs687432	0.774	rs7934149	ENSG00000213592.4	AP000662.9	-3.28	0.00107	0.0459	-0.14	-0.1	Parkinson's disease;	chr11:58121094	chr11:57718044~57718530:-
BRCA	cis	rs9400467	0.6	rs4521634	ENSG00000231889.6	TRAF3IP2-AS1	-3.28	0.00107	0.0459	-0.12	-0.1	Amino acid levels;Blood metabolite levels;	chr6:111523908	chr6:111483511~111598302:+
BRCA	cis	rs12144610	1	rs12133982	ENSG00000236804.1	RPS3AP12	3.28	0.00107	0.0459	0.16	0.1	Lobe attachment (rater-scored or self-reported);	chr1:118921379	chr1:119126539~119127291:-
BRCA	cis	rs6912958	0.512	rs910563	ENSG00000272008.1	RP11-393I2.4	-3.28	0.00107	0.0459	-0.11	-0.1	Monocyte percentage of white cells;	chr6:87349167	chr6:87151159~87155285:-
BRCA	cis	rs6912958	0.559	rs6921504	ENSG00000272008.1	RP11-393I2.4	-3.28	0.00107	0.0459	-0.11	-0.1	Monocyte percentage of white cells;	chr6:87349254	chr6:87151159~87155285:-
BRCA	cis	rs1032833	0.557	rs74550225	ENSG00000271401.1	RP11-171I2.3	-3.28	0.00107	0.0459	-0.25	-0.1	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);	chr2:179103619	chr2:178644717~178645179:+
BRCA	cis	rs10211296	0.622	rs10198146	ENSG00000229195.1	AC009495.4	-3.28	0.00107	0.0459	-0.13	-0.1	Risky sexual behaviors in alcohol dependence;	chr2:165648306	chr2:165794857~165846091:-
BRCA	cis	rs3617	0.625	rs2240915	ENSG00000243224.1	RP5-1157M23.2	-3.28	0.00107	0.0459	-0.11	-0.1	Red blood cell count;Autism spectrum disorder or schizophrenia;	chr3:52825510	chr3:52239258~52241097:+
BRCA	cis	rs3617	0.625	rs2245647	ENSG00000243224.1	RP5-1157M23.2	-3.28	0.00107	0.0459	-0.11	-0.1	Red blood cell count;Autism spectrum disorder or schizophrenia;	chr3:52828737	chr3:52239258~52241097:+
BRCA	cis	rs2737273	0.884	rs7873822	ENSG00000281205.1	LINC00950	-3.28	0.00107	0.0459	-0.12	-0.1	Platelet distribution width;	chr9:35726824	chr9:35858738~35865518:+
BRCA	cis	rs1998359	0.953	rs61987973	ENSG00000259087.4	RP11-356O9.2	3.28	0.00107	0.0459	0.12	0.1	Self-reported allergy;	chr14:37615743	chr14:37556158~37567095:-
BRCA	cis	rs6728642	1	rs80303184	ENSG00000279791.1	RP11-499E14.1	-3.28	0.00107	0.0459	-0.22	-0.1	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:97349066	chr2:97094935~97097433:+
BRCA	cis	rs2638953	0.889	rs11049481	ENSG00000273989.1	RP11-425D17.2	-3.28	0.00107	0.0459	-0.16	-0.1	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28252087	chr12:28236227~28236828:+
BRCA	cis	rs2625529	0.761	rs3743224	ENSG00000260037.4	CTD-2524L6.3	-3.28	0.00107	0.0459	-0.14	-0.1	Red blood cell count;	chr15:72174458	chr15:71818396~71823384:+
BRCA	cis	rs754466	0.58	rs2579177	ENSG00000213514.2	RP11-428P16.2	3.28	0.00107	0.0459	0.14	0.1	Liver enzyme levels (gamma-glutamyl transferase);	chr10:77769487	chr10:77730766~77734769:+
BRCA	cis	rs1941184	0.526	rs2022525	ENSG00000266521.1	RP11-650P15.1	-3.28	0.00107	0.0459	-0.13	-0.1	Parkinson's disease (age of onset);	chr18:31438151	chr18:31496645~31497195:-
BRCA	cis	rs2712184	0.66	rs10164732	ENSG00000237930.1	AC007563.4	-3.28	0.00107	0.0459	-0.11	-0.1	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);	chr2:216780946	chr2:216785774~216786144:-
BRCA	cis	rs3770752	0.897	rs2041836	ENSG00000224891.1	AC007899.3	-3.28	0.00107	0.0459	-0.12	-0.1	Schizophrenia;	chr2:37281990	chr2:37148530~37149304:+
BRCA	cis	rs736408	0.736	rs4687550	ENSG00000239557.1	RP11-168J18.6	3.28	0.00107	0.0459	0.13	0.1	Bipolar disorder;	chr3:52789414	chr3:52373652~52374882:+
BRCA	cis	rs11098499	0.866	rs10518329	ENSG00000225892.3	RP11-384K6.2	3.28	0.00107	0.0459	0.1	0.1	Corneal astigmatism;	chr4:119480680	chr4:118632274~118634759:+
BRCA	cis	rs2908197	0.762	rs2908192	ENSG00000186704.9	DTX2P1	3.28	0.00107	0.0459	0.12	0.1	3-hydroxypropylmercapturic acid levels in smokers;	chr7:76320300	chr7:76978617~77004308:+
BRCA	cis	rs10458771	0.599	rs10788500	ENSG00000223482.6	NUTM2A-AS1	-3.28	0.00107	0.0459	-0.18	-0.1	Amyotrophic lateral sclerosis (sporadic);	chr10:86397082	chr10:87203875~87342612:-
BRCA	cis	rs1056107	0.931	rs7847972	ENSG00000266315.1	MIR4668	-3.28	0.00107	0.0459	-0.11	-0.1	Colorectal cancer;	chr9:112214590	chr9:111932100~111932169:+
BRCA	cis	rs9393777	0.502	rs3823427	ENSG00000220721.1	OR1F12	3.28	0.00107	0.0459	0.15	0.1	Intelligence (multi-trait analysis);	chr6:27288567	chr6:28073316~28074233:+
BRCA	cis	rs4363385	1	rs310124	ENSG00000272654.1	RP11-422P24.11	3.28	0.00107	0.0459	0.11	0.1	Inflammatory skin disease;	chr1:153047799	chr1:153977743~153979160:+
BRCA	cis	rs7759001	0.744	rs7771590	ENSG00000204789.4	ZNF204P	3.28	0.00107	0.0459	0.13	0.1	Glomerular filtration rate (creatinine);	chr6:27500117	chr6:27357825~27360221:-
BRCA	cis	rs7267979	0.899	rs2104734	ENSG00000274973.1	RP13-401N8.7	-3.28	0.00107	0.0459	-0.11	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25546032	chr20:25845497~25845862:+
BRCA	cis	rs7701440	0.512	rs40506	ENSG00000272308.1	RP11-231G3.1	-3.28	0.00107	0.0459	-0.11	-0.1	Educational attainment;	chr5:61229383	chr5:60866457~60866935:-
BRCA	cis	rs4653425	0.564	rs4653659	ENSG00000226349.1	RP11-145A3.2	-3.28	0.00107	0.0459	-0.21	-0.1	Neuroticism;	chr1:225724918	chr1:225710968~225736274:-
BRCA	cis	rs6772849	0.805	rs61159406	ENSG00000207088.1	SNORA7B	-3.28	0.00107	0.0459	-0.12	-0.1	Monocyte percentage of white cells;Monocyte count;	chr3:128617166	chr3:129397210~129397348:-
BRCA	cis	rs10875746	0.951	rs2228500	ENSG00000273765.1	RP11-370I10.11	3.28	0.00107	0.0459	0.14	0.1	Longevity (90 years and older);	chr12:48132929	chr12:48360920~48361377:+
BRCA	cis	rs1555133	0.518	rs6141714	ENSG00000275576.1	RP5-836N17.4	-3.28	0.00107	0.0459	-0.11	-0.1	Monocyte count;	chr20:32414549	chr20:32116171~32116629:+
BRCA	cis	rs11098499	0.82	rs13128602	ENSG00000225892.3	RP11-384K6.2	-3.28	0.00108	0.0459	-0.1	-0.1	Corneal astigmatism;	chr4:119538211	chr4:118632274~118634759:+
BRCA	cis	rs2274459	0.556	rs35250767	ENSG00000249346.5	LINC01016	3.28	0.00108	0.0459	0.12	0.1	Obesity (extreme);	chr6:33718063	chr6:33867506~33896914:-
BRCA	cis	rs2333021	0.78	rs2243596	ENSG00000259015.1	RP11-109N23.6	-3.28	0.00108	0.0459	-0.1	-0.1	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:72961952	chr14:72960595~72961993:+
BRCA	cis	rs4906332	1	rs3783398	ENSG00000259775.1	RP11-45P15.4	3.28	0.00108	0.0459	0.11	0.1	Coronary artery disease;	chr14:103483041	chr14:103331674~103332367:-
BRCA	cis	rs801193	0.569	rs13242290	ENSG00000271064.1	RP11-792A8.3	3.28	0.00108	0.0459	0.12	0.1	Aortic root size;	chr7:66656898	chr7:66748838~66749077:-
BRCA	cis	rs72928364	0.929	rs62275826	ENSG00000256628.3	ZBTB11-AS1	3.28	0.00108	0.0459	0.2	0.1	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:101043800	chr3:101676475~101679217:+
BRCA	cis	rs12317459	0.591	rs11115409	ENSG00000213270.5	RPL6P25	-3.28	0.00108	0.0459	-0.16	-0.1	Prostate cancer (SNP x SNP interaction);	chr12:82774334	chr12:83151331~83152190:+
BRCA	cis	rs3764021	0.87	rs10743819	ENSG00000256594.6	RP11-705C15.2	3.28	0.00108	0.0459	0.12	0.1	Type 1 diabetes;	chr12:9724172	chr12:9633419~9658412:+
BRCA	cis	rs2337406	1	rs17113276	ENSG00000280411.1	IGHV1-69-2	3.28	0.00108	0.0459	0.09	0.1	Alzheimer's disease (late onset);	chr14:106683485	chr14:106762092~106762588:-
BRCA	cis	rs7098100	0.737	rs1243182	ENSG00000228753.1	EIF4BP2	-3.28	0.00108	0.0459	-0.13	-0.1	Breast cancer;	chr10:21627799	chr10:21028999~21030792:+
BRCA	cis	rs7612463	1	rs7627380	ENSG00000231395.1	AC124914.3	-3.28	0.00108	0.0459	-0.13	-0.1	Type 2 diabetes;	chr3:23305304	chr3:23878981~23879498:-
BRCA	cis	rs10786436	0.588	rs57455933	ENSG00000224934.2	RP11-441O15.3	-3.28	0.00108	0.0459	-0.09	-0.1	Type 1 diabetes;	chr10:98576795	chr10:99431191~99438117:+
BRCA	cis	rs9392556	0.829	rs617790	ENSG00000272248.1	RP3-406P24.4	3.28	0.00108	0.0459	0.13	0.1	Blood metabolite levels;	chr6:4115524	chr6:4018713~4019202:+
BRCA	cis	rs8098244	0.516	rs1711451	ENSG00000265752.2	RP11-403A21.1	3.28	0.00108	0.0459	0.11	0.1	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23690470	chr18:23957754~23982556:-
BRCA	cis	rs4835473	0.932	rs6858195	ENSG00000246448.2	RP13-578N3.3	-3.28	0.00108	0.046	-0.11	-0.1	Immature fraction of reticulocytes;	chr4:143768444	chr4:143700257~143865072:+
BRCA	cis	rs875971	1	rs937495	ENSG00000230189.5	GS1-124K5.2	-3.28	0.00108	0.046	-0.08	-0.1	Aortic root size;	chr7:66314811	chr7:66409143~66490059:-
BRCA	cis	rs875971	1	rs2036264	ENSG00000230189.5	GS1-124K5.2	-3.28	0.00108	0.046	-0.08	-0.1	Aortic root size;	chr7:66334917	chr7:66409143~66490059:-
BRCA	cis	rs875971	1	rs7783613	ENSG00000230189.5	GS1-124K5.2	-3.28	0.00108	0.046	-0.08	-0.1	Aortic root size;	chr7:66340274	chr7:66409143~66490059:-
BRCA	cis	rs875971	0.964	rs697969	ENSG00000273024.4	INTS4P2	3.28	0.00108	0.046	0.11	0.1	Aortic root size;	chr7:66093491	chr7:65647864~65715661:+
BRCA	cis	rs875971	1	rs1182882	ENSG00000273024.4	INTS4P2	3.28	0.00108	0.046	0.11	0.1	Aortic root size;	chr7:66097076	chr7:65647864~65715661:+
BRCA	cis	rs490234	0.966	rs545900	ENSG00000232630.1	PRPS1P2	3.28	0.00108	0.046	0.1	0.1	Mean arterial pressure;	chr9:125578999	chr9:125150653~125151589:+
BRCA	cis	rs1355223	0.902	rs286858	ENSG00000271369.1	RP11-350D17.3	3.28	0.00108	0.046	0.12	0.1	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34695810	chr11:34709600~34710161:+
BRCA	cis	rs875971	1	rs6460292	ENSG00000271064.1	RP11-792A8.3	3.28	0.00108	0.046	0.12	0.1	Aortic root size;	chr7:66345088	chr7:66748838~66749077:-
BRCA	cis	rs2692947	0.537	rs11164049	ENSG00000237510.6	AC008268.2	3.28	0.00108	0.046	0.14	0.1	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95679770	chr2:95789654~95800166:+
BRCA	cis	rs875971	0.862	rs3893216	ENSG00000223473.2	GS1-124K5.3	-3.28	0.00108	0.046	-0.08	-0.1	Aortic root size;	chr7:66325720	chr7:66491049~66493566:-
BRCA	cis	rs875971	0.862	rs6958294	ENSG00000223473.2	GS1-124K5.3	-3.28	0.00108	0.046	-0.08	-0.1	Aortic root size;	chr7:66329809	chr7:66491049~66493566:-
BRCA	cis	rs875971	0.862	rs2088655	ENSG00000223473.2	GS1-124K5.3	-3.28	0.00108	0.046	-0.08	-0.1	Aortic root size;	chr7:66330724	chr7:66491049~66493566:-
BRCA	cis	rs875971	0.895	rs10447522	ENSG00000223473.2	GS1-124K5.3	-3.28	0.00108	0.046	-0.08	-0.1	Aortic root size;	chr7:66331087	chr7:66491049~66493566:-
BRCA	cis	rs55883249	1	rs76964971	ENSG00000217258.2	AC007249.3	3.28	0.00108	0.046	0.16	0.1	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:9623775	chr2:10452319~10455552:+
BRCA	cis	rs11209261	0.602	rs4926359	ENSG00000232284.6	GNG12-AS1	3.28	0.00108	0.046	0.11	0.1	Airflow obstruction;	chr1:68338819	chr1:67832303~68202987:+
BRCA	cis	rs896655	0.521	rs2891164	ENSG00000265194.1	RP11-70L8.4	-3.28	0.00108	0.046	-0.1	-0.1	Coronary artery disease;	chr9:21711736	chr9:21858910~21861926:-
BRCA	cis	rs853679	0.599	rs149990	ENSG00000216676.2	RP1-15D7.1	-3.28	0.00108	0.046	-0.18	-0.1	Depression;	chr6:28030480	chr6:27652602~27652825:-
BRCA	cis	rs875971	0.522	rs4502988	ENSG00000272831.1	RP11-792A8.4	3.28	0.00108	0.046	0.09	0.1	Aortic root size;	chr7:65832759	chr7:66739829~66740385:-
BRCA	cis	rs2832191	0.74	rs6516890	ENSG00000232855.5	AF131217.1	-3.28	0.00108	0.046	-0.12	-0.1	Dental caries;	chr21:29104491	chr21:28439346~28674848:-
BRCA	cis	rs6840360	0.533	rs4696295	ENSG00000278978.1	RP11-164P12.5	3.28	0.00108	0.046	0.12	0.1	Intelligence (multi-trait analysis);	chr4:151796278	chr4:151669786~151670503:+
BRCA	cis	rs2274273	1	rs10140857	ENSG00000233924.1	AL160471.6	-3.28	0.00108	0.046	-0.11	-0.1	Protein biomarker;	chr14:55152893	chr14:55004813~55005687:-
BRCA	cis	rs7819412	0.594	rs17724226	ENSG00000255020.1	AF131216.5	3.28	0.00108	0.046	0.12	0.1	Triglycerides;	chr8:11111416	chr8:11345748~11347502:-
BRCA	cis	rs748404	0.666	rs12911569	ENSG00000201136.1	RNU6-353P	3.28	0.00108	0.046	0.15	0.1	Lung cancer;	chr15:43305099	chr15:43702363~43702470:+
BRCA	cis	rs73198271	0.74	rs10105690	ENSG00000233609.3	RP11-62H7.2	-3.28	0.00108	0.046	-0.1	-0.1	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8791722	chr8:8961200~8979025:+
BRCA	cis	rs1414896	0.646	rs10158681	ENSG00000226835.1	RP11-148B18.3	3.28	0.00108	0.046	0.11	0.1	Non-alcoholic fatty liver disease histology (AST);	chr1:95201223	chr1:94333267~94334848:+
BRCA	cis	rs9889262	0.663	rs8081878	ENSG00000242067.1	RPL9P28	3.28	0.00108	0.046	0.1	0.1	Eosinophil percentage of granulocytes;Allergic disease (asthma, hay fever or eczema);Eosinophil counts;	chr17:49359450	chr17:48691116~48691694:-
BRCA	cis	rs10043228	1	rs12516100	ENSG00000250015.1	CTC-339F2.2	3.28	0.00108	0.046	0.14	0.1	Asthma or chronic obstructive pulmonary disease;	chr5:116116053	chr5:116302354~116304134:-
BRCA	cis	rs4449834	0.701	rs7845701	ENSG00000254432.1	RP11-33I11.2	-3.28	0.00108	0.046	-0.13	-0.1	Sum eosinophil basophil counts;	chr8:60711732	chr8:60808735~60809606:-
BRCA	cis	rs875971	0.545	rs11767262	ENSG00000226767.1	RP11-328P23.3	3.28	0.00108	0.046	0.13	0.1	Aortic root size;	chr7:66302237	chr7:65508773~65508944:-
BRCA	cis	rs2803122	0.905	rs2772401	ENSG00000272842.1	RP11-513M16.7	3.28	0.00108	0.046	0.1	0.1	Pulse pressure;	chr9:19322933	chr9:19371386~19371945:-
BRCA	cis	rs8062405	0.755	rs4788080	ENSG00000261766.1	RP11-22P6.2	-3.28	0.00108	0.046	-0.1	-0.1	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28546760	chr16:28862166~28863340:-
BRCA	cis	rs8062405	0.755	rs4787456	ENSG00000261766.1	RP11-22P6.2	-3.28	0.00108	0.046	-0.1	-0.1	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548252	chr16:28862166~28863340:-
BRCA	cis	rs8062405	0.755	rs4788078	ENSG00000261766.1	RP11-22P6.2	-3.28	0.00108	0.046	-0.1	-0.1	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548660	chr16:28862166~28863340:-
BRCA	cis	rs6952809	0.59	rs1468337	ENSG00000230487.6	PSMG3-AS1	-3.28	0.00108	0.046	-0.16	-0.1	Multiple sclerosis;	chr7:2392576	chr7:1570073~1589626:+
BRCA	cis	rs4819852	1	rs2073743	ENSG00000236540.6	AC006547.13	3.28	0.00108	0.046	0.13	0.1	Pulse pressure;	chr22:20002089	chr22:20058030~20070569:-
BRCA	cis	rs4873772	0.932	rs7462209	ENSG00000253330.1	RP11-697N18.3	-3.28	0.00108	0.046	-0.13	-0.1	Lobe attachment (rater-scored or self-reported);	chr8:47697536	chr8:47511034~47512141:-
BRCA	cis	rs2243480	1	rs466983	ENSG00000226767.1	RP11-328P23.3	-3.28	0.00108	0.046	-0.18	-0.1	Diabetic kidney disease;	chr7:66055509	chr7:65508773~65508944:-
BRCA	cis	rs4873772	0.834	rs6986054	ENSG00000253330.1	RP11-697N18.3	-3.28	0.00108	0.046	-0.13	-0.1	Lobe attachment (rater-scored or self-reported);	chr8:47661576	chr8:47511034~47512141:-
BRCA	cis	rs9468199	0.51	rs77576207	ENSG00000219392.1	RP1-265C24.5	-3.28	0.00108	0.046	-0.27	-0.1	Parkinson's disease;	chr6:27874377	chr6:28115628~28116551:+
BRCA	cis	rs875971	0.66	rs2013222	ENSG00000271064.1	RP11-792A8.3	3.28	0.00108	0.046	0.11	0.1	Aortic root size;	chr7:66570949	chr7:66748838~66749077:-
BRCA	cis	rs300703	0.515	rs424292	ENSG00000228643.1	AC079779.4	-3.28	0.00108	0.046	-0.16	-0.1	Blood protein levels;	chr2:191931	chr2:286419~301515:+
BRCA	cis	rs848490	0.851	rs62473661	ENSG00000214293.7	APTR	3.28	0.00108	0.046	0.13	0.1	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77576197	chr7:77657660~77696265:-
BRCA	cis	rs4665809	1	rs750452	ENSG00000231655.1	AC011742.3	3.28	0.00108	0.046	0.14	0.1	Gut microbiome composition (summer);	chr2:26102126	chr2:26140263~26141264:-
BRCA	cis	rs7918232	0.567	rs4749215	ENSG00000236983.1	LINC00614	3.28	0.00108	0.046	0.12	0.1	Breast cancer;	chr10:27023076	chr10:26943323~26944418:-
BRCA	cis	rs2836974	0.563	rs997147	ENSG00000238141.2	BRWD1-AS1	-3.28	0.00108	0.046	-0.12	-0.1	Cognitive function;	chr21:39323399	chr21:39315707~39323218:+
BRCA	cis	rs790006	0.874	rs35086651	ENSG00000243024.5	RPS11P6	-3.28	0.00108	0.046	-0.18	-0.1	Response to cytidine analogues (gemcitabine);	chr12:64227995	chr12:64222337~64397065:+
BRCA	cis	rs10508774	0.852	rs76752110	ENSG00000273038.2	RP11-479G22.8	3.28	0.00108	0.046	0.23	0.1	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32907389	chr10:32887255~32889311:-
BRCA	cis	rs4697263	0.608	rs17584884	ENSG00000237350.1	CDC42P6	3.28	0.00108	0.046	0.13	0.1	Age-related hearing impairment (SNP x SNP interaction);	chr4:22007526	chr4:22727375~22727950:-
BRCA	cis	rs3760982	0.585	rs8109812	ENSG00000266921.1	RP11-15A1.7	-3.28	0.00108	0.046	-0.13	-0.1	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43794342	chr19:43996896~44002836:-
BRCA	cis	rs425277	0.958	rs626479	ENSG00000269737.1	RP11-345P4.7	-3.28	0.00108	0.046	-0.1	-0.1	Height;	chr1:2178821	chr1:1671990~1673411:+
BRCA	cis	rs6840360	0.555	rs4554052	ENSG00000278978.1	RP11-164P12.5	3.28	0.00108	0.046	0.12	0.1	Intelligence (multi-trait analysis);	chr4:151805458	chr4:151669786~151670503:+
BRCA	cis	rs2310173	0.575	rs4850993	ENSG00000281162.1	LINC01127	-3.28	0.00108	0.046	-0.1	-0.1	Ulcerative colitis;Ankylosing spondylitis;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr2:102006004	chr2:101962056~101987167:+
BRCA	cis	rs8030136	0.645	rs11852400	ENSG00000275529.1	SNORD116-4	3.28	0.00108	0.046	0.14	0.1	Periodontitis (DPAL);	chr15:24746267	chr15:25059538~25059633:+
BRCA	cis	rs17092148	1	rs60789653	ENSG00000206582.1	Y_RNA	3.28	0.00108	0.046	0.15	0.1	Neuroticism;	chr20:34859359	chr20:34526510~34526606:-
BRCA	cis	rs1003719	0.788	rs4817844	ENSG00000242553.1	AP001432.14	3.28	0.00108	0.046	0.11	0.1	Eye color traits;	chr21:37074764	chr21:37221419~37237744:+
BRCA	cis	rs2898857	0.898	rs12185257	ENSG00000250948.1	RP11-1079K10.2	-3.28	0.00108	0.046	-0.15	-0.1	Cancer;	chr17:49330400	chr17:49375380~49380094:+
BRCA	cis	rs4718428	1	rs4718428	ENSG00000106610.13	STAG3L4	3.28	0.00108	0.046	0.14	0.1	Corneal structure;	chr7:66956459	chr7:67302621~67321526:+
BRCA	cis	rs4718428	0.705	rs4718424	ENSG00000229886.1	RP5-1132H15.3	3.28	0.00108	0.046	0.12	0.1	Corneal structure;	chr7:66911108	chr7:66025126~66031544:-
BRCA	cis	rs8180040	0.62	rs11715121	ENSG00000280667.1	Y_RNA	-3.28	0.00108	0.046	-0.11	-0.1	Colorectal cancer;	chr3:47031131	chr3:47501083~47501182:+
BRCA	cis	rs8180040	0.62	rs11709660	ENSG00000280667.1	Y_RNA	-3.28	0.00108	0.046	-0.11	-0.1	Colorectal cancer;	chr3:47033437	chr3:47501083~47501182:+
BRCA	cis	rs8180040	0.62	rs6768722	ENSG00000280667.1	Y_RNA	3.28	0.00108	0.046	0.11	0.1	Colorectal cancer;	chr3:47037622	chr3:47501083~47501182:+
BRCA	cis	rs4415084	0.774	rs4571481	ENSG00000272335.1	RP11-53O19.3	3.28	0.00108	0.046	0.1	0.1	Breast cancer;	chr5:44687331	chr5:44826076~44828592:+
BRCA	cis	rs7833790	0.724	rs6473310	ENSG00000254689.1	RP11-354A14.1	3.28	0.00108	0.046	0.12	0.1	Diastolic blood pressure;	chr8:81795746	chr8:81885377~81923193:+
BRCA	cis	rs739496	0.615	rs59905228	ENSG00000234608.6	MAPKAPK5-AS1	3.28	0.00108	0.0461	0.13	0.1	Platelet count;	chr12:111743422	chr12:111839764~111842902:-
BRCA	cis	rs2598592	0.531	rs2598593	ENSG00000271868.1	RP11-1293J14.1	3.28	0.00108	0.0461	0.16	0.1	White matter integrity;	chr2:2586687	chr2:3496956~3497428:+
BRCA	cis	rs10501293	0.917	rs7951266	ENSG00000252652.1	Y_RNA	-3.28	0.00108	0.0461	-0.12	-0.1	Cognitive performance;	chr11:43089178	chr11:43331261~43331356:+
BRCA	cis	rs6439699	0.7	rs16844621	ENSG00000273486.1	RP11-731C17.2	-3.28	0.00108	0.0461	-0.13	-0.1	Intelligence (multi-trait analysis);	chr3:137227085	chr3:136837338~136839021:-
BRCA	cis	rs2692947	0.673	rs4907279	ENSG00000237510.6	AC008268.2	3.28	0.00108	0.0461	0.15	0.1	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95734220	chr2:95789654~95800166:+
BRCA	cis	rs875971	1	rs6460296	ENSG00000272831.1	RP11-792A8.4	3.28	0.00108	0.0461	0.09	0.1	Aortic root size;	chr7:66430152	chr7:66739829~66740385:-
BRCA	cis	rs952623	0.501	rs11972294	ENSG00000233306.2	TRGV2	3.28	0.00108	0.0461	0.09	0.1	Intelligence (multi-trait analysis);	chr7:39046143	chr7:38362864~38363518:-
BRCA	cis	rs7919656	0.626	rs2671694	ENSG00000278561.1	PTPN20CP	-3.28	0.00108	0.0461	-0.13	-0.1	Clinically amyopathic dermatomyositis;	chr10:48908030	chr10:48064308~48119455:-
BRCA	cis	rs12612435	0.696	rs2222016	ENSG00000226806.1	AC011893.3	3.28	0.00108	0.0461	0.12	0.1	Takotsubo syndrome;	chr2:136385737	chr2:135820191~135823087:+
BRCA	cis	rs613391	0.612	rs618109	ENSG00000279670.1	RP11-70L8.5	-3.28	0.00108	0.0461	-0.13	-0.1	Quantitative traits;	chr9:22698066	chr9:21892188~21893857:+
BRCA	cis	rs8031584	0.678	rs3122	ENSG00000260128.5	ULK4P2	3.28	0.00108	0.0461	0.13	0.1	Huntington's disease progression;	chr15:30878087	chr15:30572738~30600647:+
BRCA	cis	rs1577917	0.682	rs1173419	ENSG00000220563.1	PKMP3	-3.28	0.00108	0.0461	-0.1	-0.1	Response to antipsychotic treatment;	chr6:85692445	chr6:85659892~85660606:-
BRCA	cis	rs2838568	0.967	rs2838569	ENSG00000228709.1	AP001065.15	3.28	0.00108	0.0461	0.13	0.1	Amyotrophic lateral sclerosis in C9orf72 mutation negative individuals;	chr21:44478340	chr21:44485577~44490288:+
BRCA	cis	rs7914558	1	rs943038	ENSG00000213277.3	MARCKSL1P1	3.28	0.00108	0.0461	0.11	0.1	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103066504	chr10:103175554~103176094:+
BRCA	cis	rs2880765	0.835	rs12708553	ENSG00000259630.2	CTD-2262B20.1	3.28	0.00108	0.0461	0.12	0.1	Coronary artery disease;	chr15:85503602	chr15:85415228~85415633:+
BRCA	cis	rs4665809	1	rs10048648	ENSG00000231655.1	AC011742.3	3.28	0.00108	0.0461	0.14	0.1	Gut microbiome composition (summer);	chr2:26097446	chr2:26140263~26141264:-
BRCA	cis	rs36051895	0.664	rs884132	ENSG00000236254.1	MTND4P14	-3.28	0.00108	0.0461	-0.12	-0.1	Pediatric autoimmune diseases;	chr9:5114522	chr9:5107937~5109290:+
BRCA	cis	rs11673344	0.832	rs11084871	ENSG00000267005.1	AC002984.2	3.28	0.00108	0.0461	0.13	0.1	Obesity-related traits;	chr19:37042023	chr19:36173406~36173853:-
BRCA	cis	rs7487075	0.619	rs10785628	ENSG00000257261.4	RP11-96H19.1	3.28	0.00108	0.0461	0.12	0.1	Itch intensity from mosquito bite;	chr12:46460893	chr12:46383679~46876159:+
BRCA	cis	rs673253	0.608	rs605709	ENSG00000229431.1	RP1-92O14.6	-3.28	0.00108	0.0461	-0.11	-0.1	Intelligence (multi-trait analysis);	chr1:43592796	chr1:43385113~43389155:+
BRCA	cis	rs673253	0.686	rs72673082	ENSG00000229431.1	RP1-92O14.6	-3.28	0.00108	0.0461	-0.11	-0.1	Intelligence (multi-trait analysis);	chr1:43593571	chr1:43385113~43389155:+
BRCA	cis	rs673253	0.71	rs583040	ENSG00000229431.1	RP1-92O14.6	-3.28	0.00108	0.0461	-0.11	-0.1	Intelligence (multi-trait analysis);	chr1:43594812	chr1:43385113~43389155:+
BRCA	cis	rs853679	0.666	rs200956	ENSG00000216676.2	RP1-15D7.1	-3.28	0.00108	0.0461	-0.14	-0.1	Depression;	chr6:27871968	chr6:27652602~27652825:-
BRCA	cis	rs7267979	1	rs6076336	ENSG00000204556.4	CTD-2514C3.1	3.28	0.00108	0.0461	0.14	0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25338576	chr20:26018832~26020684:+
BRCA	cis	rs1050631	1	rs1785914	ENSG00000274849.1	RP11-49I11.4	-3.28	0.00108	0.0461	-0.13	-0.1	Esophageal squamous cell cancer (length of survival);	chr18:36120833	chr18:36189824~36190272:+
BRCA	cis	rs860295	0.812	rs12081192	ENSG00000203761.5	MSTO2P	-3.28	0.00108	0.0461	-0.09	-0.1	Body mass index;	chr1:155768253	chr1:155745829~155750137:+
BRCA	cis	rs2278170	1	rs55940502	ENSG00000225101.4	OR52K3P	-3.28	0.00108	0.0461	-0.13	-0.1	Amyotrophic lateral sclerosis;	chr11:4463507	chr11:4474813~4475755:+
BRCA	cis	rs4722166	0.532	rs1404008	ENSG00000225541.1	AC002480.5	-3.28	0.00108	0.0461	-0.1	-0.1	Lung cancer;	chr7:22716381	chr7:22571607~22661792:-
BRCA	cis	rs13401620	0.554	rs12992469	ENSG00000223549.1	MTND5P28	3.28	0.00108	0.0461	0.13	0.1	Breast size;	chr2:120209474	chr2:120215181~120217279:+
BRCA	cis	rs2823962	0.892	rs2211993	ENSG00000270093.1	AP000473.8	-3.28	0.00108	0.0461	-0.1	-0.1	Amyotrophic lateral sclerosis;	chr21:16652447	chr21:16643529~16645065:+
BRCA	cis	rs10733682	1	rs10733682	ENSG00000224842.2	RP11-123K19.1	3.28	0.00108	0.0461	0.1	0.1	Body mass index;Body mass index (joint analysis main effects and smoking interaction);BMI (adjusted for smoking behaviour);	chr9:126698635	chr9:126589594~126613700:-
BRCA	cis	rs36051895	0.623	rs10118434	ENSG00000237711.1	RP11-39K24.13	-3.28	0.00108	0.0461	-0.12	-0.1	Pediatric autoimmune diseases;	chr9:5238460	chr9:5100236~5101009:+
BRCA	cis	rs310501	0.773	rs12657869	ENSG00000242858.1	CTC-484M2.1	3.28	0.00108	0.0461	0.11	0.1	Major depressive disorder;	chr5:83633860	chr5:83746388~83746989:-
BRCA	cis	rs6787172	0.811	rs939117	ENSG00000272087.1	RP11-379F4.7	-3.28	0.00108	0.0461	-0.12	-0.1	Subjective well-being;	chr3:158483080	chr3:158693120~158693768:-
BRCA	cis	rs736408	0.812	rs6778329	ENSG00000239557.1	RP11-168J18.6	3.28	0.00108	0.0461	0.13	0.1	Bipolar disorder;	chr3:52790594	chr3:52373652~52374882:+
BRCA	cis	rs687432	0.924	rs7121139	ENSG00000213592.4	AP000662.9	-3.28	0.00108	0.0461	-0.15	-0.1	Parkinson's disease;	chr11:58015348	chr11:57718044~57718530:-
BRCA	cis	rs453301	0.658	rs13271797	ENSG00000233609.3	RP11-62H7.2	-3.28	0.00108	0.0461	-0.1	-0.1	Joint mobility (Beighton score);	chr8:9028444	chr8:8961200~8979025:+
BRCA	cis	rs4363385	0.626	rs11205179	ENSG00000231416.1	RP11-422P24.9	3.28	0.00108	0.0461	0.11	0.1	Inflammatory skin disease;	chr1:153048923	chr1:153995632~153995960:+
BRCA	cis	rs3858145	0.546	rs7912806	ENSG00000233590.1	RP11-153K11.3	3.28	0.00108	0.0461	0.13	0.1	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68296578	chr10:68233251~68242379:-
BRCA	cis	rs7927592	0.956	rs7124078	ENSG00000254610.1	RP5-903G2.2	-3.28	0.00108	0.0461	-0.14	-0.1	Total body bone mineral density;	chr11:68531165	chr11:67934563~67939774:-
BRCA	cis	rs875971	1	rs6957199	ENSG00000230189.5	GS1-124K5.2	3.28	0.00108	0.0461	0.08	0.1	Aortic root size;	chr7:66513532	chr7:66409143~66490059:-
BRCA	cis	rs4835473	0.932	rs1597444	ENSG00000246448.2	RP13-578N3.3	-3.28	0.00108	0.0461	-0.11	-0.1	Immature fraction of reticulocytes;	chr4:143764547	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.9	rs60038202	ENSG00000246448.2	RP13-578N3.3	-3.28	0.00108	0.0461	-0.11	-0.1	Immature fraction of reticulocytes;	chr4:143764662	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.932	rs1450230	ENSG00000246448.2	RP13-578N3.3	-3.28	0.00108	0.0461	-0.11	-0.1	Immature fraction of reticulocytes;	chr4:143765118	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.932	rs34683160	ENSG00000246448.2	RP13-578N3.3	-3.28	0.00108	0.0461	-0.11	-0.1	Immature fraction of reticulocytes;	chr4:143765227	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.9	rs72946226	ENSG00000246448.2	RP13-578N3.3	-3.28	0.00108	0.0461	-0.11	-0.1	Immature fraction of reticulocytes;	chr4:143765238	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.932	rs34230433	ENSG00000246448.2	RP13-578N3.3	-3.28	0.00108	0.0461	-0.11	-0.1	Immature fraction of reticulocytes;	chr4:143765253	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.932	rs7696869	ENSG00000246448.2	RP13-578N3.3	-3.28	0.00108	0.0461	-0.11	-0.1	Immature fraction of reticulocytes;	chr4:143765855	chr4:143700257~143865072:+
BRCA	cis	rs4835473	0.932	rs7698287	ENSG00000246448.2	RP13-578N3.3	-3.28	0.00108	0.0461	-0.11	-0.1	Immature fraction of reticulocytes;	chr4:143765859	chr4:143700257~143865072:+
BRCA	cis	rs7267979	0.528	rs6076366	ENSG00000274414.1	RP5-965G21.4	3.28	0.00108	0.0461	0.12	0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25583990	chr20:25239007~25245229:-
BRCA	cis	rs7142881	0.815	rs8015282	ENSG00000258648.1	UBE2CP1	3.28	0.00108	0.0461	0.11	0.1	Response to iloperidone treatment (QT prolongation);	chr14:31572771	chr14:30683045~30683598:-
BRCA	cis	rs9783347	0.961	rs2061163	ENSG00000279837.1	RP11-504G3.2	-3.28	0.00108	0.0461	-0.1	-0.1	Pancreatic cancer;	chr11:18301377	chr11:18601882~18602649:+
BRCA	cis	rs703108	0.673	rs10764333	ENSG00000279623.1	RP11-399C16.3	3.28	0.00108	0.0461	0.14	0.1	Monocyte percentage of white cells;	chr10:22031264	chr10:21865335~21865921:-
BRCA	cis	rs17407555	0.909	rs76748344	ENSG00000251087.3	ALG1L3P	-3.28	0.00108	0.0461	-0.16	-0.1	Schizophrenia (age at onset);	chr4:10310361	chr4:9703754~9710812:-
BRCA	cis	rs13185784	0.667	rs4454029	ENSG00000278970.1	HEIH	-3.28	0.00108	0.0461	-0.12	-0.1	TRAIL levels;	chr5:180218325	chr5:180829954~180831605:-
BRCA	cis	rs1816752	0.719	rs11841989	ENSG00000273628.1	RP11-756A22.7	3.28	0.00108	0.0461	0.12	0.1	Obesity-related traits;	chr13:24423560	chr13:24933006~24936796:+
BRCA	cis	rs2333021	0.649	rs997667	ENSG00000258376.2	RP4-647C14.2	-3.28	0.00108	0.0461	-0.12	-0.1	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:72998295	chr14:73242651~73245979:-
BRCA	cis	rs10876993	0.928	rs1689592	ENSG00000270039.1	RP11-571M6.17	3.28	0.00108	0.0461	0.13	0.1	Celiac disease or Rheumatoid arthritis;	chr12:57663990	chr12:57803838~57804415:+
BRCA	cis	rs7617480	0.648	rs6796790	ENSG00000244380.1	RP11-24C3.2	3.28	0.00108	0.0461	0.13	0.1	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48742884	chr3:48440352~48446656:-
BRCA	cis	rs4949454	0.542	rs10914457	ENSG00000220785.6	MTMR9LP	-3.28	0.00108	0.0461	-0.11	-0.1	Intelligence (multi-trait analysis);	chr1:31628660	chr1:32231658~32241620:-
BRCA	cis	rs970548	0.954	rs11239571	ENSG00000230869.1	CTGLF10P	-3.28	0.00108	0.0461	-0.13	-0.1	Total cholesterol levels;HDL cholesterol;HDL cholesterol levels;Cholesterol, total;	chr10:45592444	chr10:45678692~45700532:+
BRCA	cis	rs2835872	0.931	rs10483038	ENSG00000228677.1	TTC3-AS1	-3.28	0.00108	0.0461	-0.13	-0.1	Electroencephalographic traits in alcoholism;	chr21:37652469	chr21:37187666~37193926:-
BRCA	cis	rs875971	0.965	rs7794930	ENSG00000067601.7	PMS2P4	3.28	0.00108	0.0461	0.12	0.1	Aortic root size;	chr7:66313559	chr7:67295608~67302907:-
BRCA	cis	rs2555155	0.806	rs10839574	ENSG00000254595.1	CTD-2010I16.1	-3.28	0.00108	0.0461	-0.11	-0.1	DNA methylation (variation);	chr11:6530240	chr11:6488186~6489377:-
BRCA	cis	rs7927592	0.956	rs12274114	ENSG00000254610.1	RP5-903G2.2	-3.28	0.00108	0.0462	-0.14	-0.1	Total body bone mineral density;	chr11:68488109	chr11:67934563~67939774:-
BRCA	cis	rs7927592	0.913	rs12294029	ENSG00000254610.1	RP5-903G2.2	-3.28	0.00108	0.0462	-0.14	-0.1	Total body bone mineral density;	chr11:68489591	chr11:67934563~67939774:-
BRCA	cis	rs12468226	0.702	rs114634431	ENSG00000272966.1	RP11-686O6.1	3.28	0.00108	0.0462	0.18	0.1	Urate levels;	chr2:202142530	chr2:202336739~202337200:+
BRCA	cis	rs2191566	0.576	rs381888	ENSG00000266921.1	RP11-15A1.7	3.28	0.00108	0.0462	0.13	0.1	Acute lymphoblastic leukemia (childhood);	chr19:43988853	chr19:43996896~44002836:-
BRCA	cis	rs74233809	1	rs9633712	ENSG00000213061.2	PFN1P11	3.28	0.00108	0.0462	0.22	0.1	Birth weight;	chr10:103114004	chr10:102838011~102845473:-
BRCA	cis	rs74233809	0.786	rs11191564	ENSG00000213061.2	PFN1P11	3.28	0.00108	0.0462	0.22	0.1	Birth weight;	chr10:103118786	chr10:102838011~102845473:-
BRCA	cis	rs9844666	0.512	rs13434196	ENSG00000239213.4	NCK1-AS1	3.28	0.00108	0.0462	0.11	0.1	Height;	chr3:135924461	chr3:136841726~136862054:-
BRCA	cis	rs7621331	0.714	rs9844478	ENSG00000239213.4	NCK1-AS1	3.28	0.00108	0.0462	0.11	0.1	Waist circumference adjusted for body mass index;	chr3:135924473	chr3:136841726~136862054:-
BRCA	cis	rs6582630	0.504	rs4882367	ENSG00000257718.1	RP11-396F22.1	-3.28	0.00108	0.0462	-0.1	-0.1	Drug-induced liver injury (flucloxacillin);	chr12:37937076	chr12:38906451~38909592:+
BRCA	cis	rs11679640	0.671	rs62140177	ENSG00000234362.4	AC104654.2	-3.28	0.00108	0.0462	-0.13	-0.1	White matter hyperintensity burden;	chr2:42848423	chr2:41931599~41933723:-
BRCA	cis	rs2262909	0.745	rs1989120	ENSG00000279377.1	AC003973.3	3.28	0.00108	0.0462	0.13	0.1	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;	chr19:22022726	chr19:21965708~21968529:-
BRCA	cis	rs4878639	0.606	rs11788747	ENSG00000281649.1	EBLN3	3.28	0.00108	0.0462	0.1	0.1	IgG glycosylation;	chr9:36105267	chr9:37079857~37090507:+
BRCA	cis	rs687432	0.812	rs4509781	ENSG00000213592.4	AP000662.9	-3.28	0.00108	0.0462	-0.14	-0.1	Parkinson's disease;	chr11:58075086	chr11:57718044~57718530:-
BRCA	cis	rs1008375	0.966	rs11737844	ENSG00000249502.1	AC006160.5	-3.28	0.00108	0.0462	-0.11	-0.1	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17695798	chr4:17587467~17614571:-
BRCA	cis	rs10266483	0.739	rs12665990	ENSG00000271550.1	BNIP3P11	-3.28	0.00108	0.0462	-0.15	-0.1	Response to statin therapy;	chr7:64404622	chr7:64678954~64687393:-
BRCA	cis	rs6671200	1	rs12755552	ENSG00000228852.5	RP11-57H12.5	3.28	0.00108	0.0462	0.18	0.1	Stearic acid (18:0) levels;	chr1:95219470	chr1:95243167~95278940:-
BRCA	cis	rs17556665	0.741	rs10500789	ENSG00000254418.1	RP11-21L19.1	3.28	0.00108	0.0462	0.2	0.1	Inflammatory biomarkers;	chr11:14010166	chr11:14262846~14273691:-
BRCA	cis	rs8030136	0.617	rs11161133	ENSG00000275529.1	SNORD116-4	3.28	0.00108	0.0462	0.14	0.1	Periodontitis (DPAL);	chr15:24746476	chr15:25059538~25059633:+
BRCA	cis	rs972578	0.651	rs5759002	ENSG00000274717.1	RP1-47A17.1	3.28	0.00108	0.0462	0.11	0.1	Mean platelet volume;	chr22:42867426	chr22:42791814~42794313:-
BRCA	cis	rs948562	0.744	rs12362087	ENSG00000255299.4	RP11-655C2.3	-3.28	0.00108	0.0462	-0.12	-0.1	Lymphoma;	chr11:58456447	chr11:58497888~58505758:-
BRCA	cis	rs7429990	0.965	rs319696	ENSG00000228638.1	FCF1P2	-3.28	0.00108	0.0462	-0.1	-0.1	Educational attainment (years of education);	chr3:47902371	chr3:48290793~48291375:-
BRCA	cis	rs6540556	0.769	rs2272867	ENSG00000236136.1	ADORA2BP1	-3.28	0.00108	0.0462	-0.13	-0.1	Red blood cell count;	chr1:209756234	chr1:209744373~209745214:+
BRCA	cis	rs427943	0.798	rs1537122	ENSG00000261706.1	LINC00165	3.28	0.00108	0.0462	0.11	0.1	Body mass index;	chr21:45178591	chr21:44994362~44995185:-
BRCA	cis	rs2613964	0.548	rs9870733	ENSG00000272844.1	RP11-484K9.4	-3.28	0.00108	0.0462	-0.11	-0.1	Pediatric bone mineral content (spine);Pediatric bone mineral density (spine);	chr3:113130407	chr3:112990447~112991153:-
BRCA	cis	rs7188697	0.922	rs9924805	ENSG00000276259.1	RP11-481J2.4	3.28	0.00108	0.0462	0.12	0.1	QT interval;	chr16:58581755	chr16:58522970~58523842:+
BRCA	cis	rs1878931	0.535	rs7188903	ENSG00000263280.1	LA16c-325D7.2	3.28	0.00108	0.0462	0.11	0.1	Body mass index (adult);	chr16:3362861	chr16:2866348~2867618:-
BRCA	cis	rs17092148	1	rs62211617	ENSG00000206582.1	Y_RNA	3.28	0.00108	0.0462	0.15	0.1	Neuroticism;	chr20:34812552	chr20:34526510~34526606:-
BRCA	cis	rs17092148	1	rs11699062	ENSG00000206582.1	Y_RNA	3.28	0.00108	0.0462	0.15	0.1	Neuroticism;	chr20:34812576	chr20:34526510~34526606:-
BRCA	cis	rs1344694	0.566	rs4672790	ENSG00000230838.1	AC093850.2	-3.28	0.00108	0.0462	-0.09	-0.1	Alcohol dependence;	chr2:216027723	chr2:215718043~215719424:+
BRCA	cis	rs1468333	0.538	rs13153017	ENSG00000206989.1	SNORD63	3.28	0.00108	0.0462	0.11	0.1	Resting heart rate;	chr5:138414980	chr5:138561043~138561110:-
BRCA	cis	rs13434995	0.562	rs10529258	ENSG00000273257.1	RP11-177J6.1	-3.28	0.00108	0.0462	-0.15	-0.1	Adiponectin levels;	chr4:55546702	chr4:55387949~55388271:+
BRCA	cis	rs13434995	0.512	rs115635692	ENSG00000273257.1	RP11-177J6.1	-3.28	0.00108	0.0462	-0.15	-0.1	Adiponectin levels;	chr4:55546706	chr4:55387949~55388271:+
BRCA	cis	rs13434995	0.626	rs116135676	ENSG00000273257.1	RP11-177J6.1	-3.28	0.00108	0.0462	-0.15	-0.1	Adiponectin levels;	chr4:55546707	chr4:55387949~55388271:+
BRCA	cis	rs4965272	0.83	rs11637820	ENSG00000254744.3	CTD-3076O17.1	3.28	0.00108	0.0462	0.13	0.1	Gastroesophageal reflux disease;	chr15:100020034	chr15:99970215~99974010:+
BRCA	cis	rs1348850	0.914	rs4893957	ENSG00000271825.1	RP11-337N6.2	3.28	0.00108	0.0462	0.13	0.1	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177515681	chr2:177300600~177302006:+
BRCA	cis	rs1730008	1	rs827801	ENSG00000279311.1	RP11-170K4.2	-3.28	0.00108	0.0462	-0.12	-0.1	Lobe attachment (rater-scored or self-reported);	chr3:158203603	chr3:158869898~158871821:+
BRCA	cis	rs7552393	0.636	rs11163849	ENSG00000233008.4	RP11-475O6.1	3.28	0.00108	0.0462	0.15	0.1	Select biomarker traits;	chr1:83815514	chr1:83575776~83861023:-
BRCA	cis	rs4714291	0.963	rs1743973	ENSG00000180211.5	RP1-278E11.3	3.28	0.00108	0.0462	0.11	0.1	Strep throat;	chr6:40126810	chr6:39958414~39958833:-
BRCA	cis	rs12216545	0.765	rs6949018	ENSG00000244151.1	RP11-148K1.12	-3.28	0.00108	0.0462	-0.09	-0.1	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150558495	chr7:151074742~151076530:-
BRCA	cis	rs9651367	0.559	rs1326234	ENSG00000238246.1	RP11-575A19.2	3.28	0.00108	0.0462	0.15	0.1	Blood protein levels;	chr10:19950008	chr10:20070805~20091784:-
BRCA	cis	rs76096589	0.557	rs59230713	ENSG00000270062.1	RP11-248J18.3	-3.28	0.00108	0.0462	-0.25	-0.1	Diisocyanate-induced asthma;	chr14:50529011	chr14:50723777~50724272:-
BRCA	cis	rs1843834	0.539	rs3912999	ENSG00000274629.1	RP11-92F20.1	-3.28	0.00108	0.0462	-0.13	-0.1	IgE levels in asthmatics (D.p. specific);	chr2:224525372	chr2:224464682~224474500:+
BRCA	cis	rs600550	0.588	rs2304934	ENSG00000275344.1	MIR6503	3.28	0.00108	0.0462	0.11	0.1	Lipoprotein-associated phospholipase A2 activity and mass;	chr11:60334923	chr11:60209071~60209156:-
BRCA	cis	rs600550	0.588	rs2304933	ENSG00000275344.1	MIR6503	3.28	0.00108	0.0462	0.11	0.1	Lipoprotein-associated phospholipase A2 activity and mass;	chr11:60335034	chr11:60209071~60209156:-
BRCA	cis	rs600550	0.588	rs10792268	ENSG00000275344.1	MIR6503	3.28	0.00108	0.0462	0.11	0.1	Lipoprotein-associated phospholipase A2 activity and mass;	chr11:60335158	chr11:60209071~60209156:-
BRCA	cis	rs34975555	0.803	rs62498194	ENSG00000245281.5	CTD-2547L16.1	3.28	0.00108	0.0462	0.16	0.1	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:17992718	chr8:18084868~18096394:+
BRCA	cis	rs12413816	0.818	rs35567671	ENSG00000199407.1	RNA5SP301	-3.28	0.00108	0.0462	-0.13	-0.1	Red cell distribution width;	chr10:13727722	chr10:13727796~13727916:+
BRCA	cis	rs9308433	0.529	rs9430133	ENSG00000213036.3	RP11-365D23.4	-3.28	0.00108	0.0462	-0.14	-0.1	IgG glycosylation;	chr1:214322970	chr1:214482813~214483387:-
BRCA	cis	rs875971	1	rs1981798	ENSG00000273024.4	INTS4P2	-3.28	0.00108	0.0462	-0.11	-0.1	Aortic root size;	chr7:66489916	chr7:65647864~65715661:+
BRCA	cis	rs4835937	0.67	rs10064559	ENSG00000245937.6	LINC01184	3.28	0.00108	0.0462	0.14	0.1	Cancer;	chr5:127993991	chr5:127940426~128083172:-
BRCA	cis	rs8105895	0.733	rs62110861	ENSG00000269345.1	VN1R85P	3.28	0.00108	0.0462	0.17	0.1	Body mass index (change over time);	chr19:21912962	chr19:22174766~22175191:-
BRCA	cis	rs2638953	0.962	rs11049539	ENSG00000273989.1	RP11-425D17.2	-3.28	0.00108	0.0462	-0.16	-0.1	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28335953	chr12:28236227~28236828:+
BRCA	cis	rs4374383	0.886	rs6711146	ENSG00000243389.1	AC012442.5	-3.28	0.00108	0.0463	-0.13	-0.1	Hepatitis C induced liver fibrosis;	chr2:112016257	chr2:112589040~112614431:+
BRCA	cis	rs911555	0.723	rs11160751	ENSG00000269958.1	RP11-73M18.8	3.28	0.00108	0.0463	0.11	0.1	Intelligence (multi-trait analysis);	chr14:103459403	chr14:103696353~103697163:+
BRCA	cis	rs13401620	0.763	rs3106241	ENSG00000223549.1	MTND5P28	-3.28	0.00108	0.0463	-0.12	-0.1	Breast size;	chr2:119900567	chr2:120215181~120217279:+
BRCA	cis	rs490234	0.812	rs4329365	ENSG00000232630.1	PRPS1P2	-3.28	0.00108	0.0463	-0.1	-0.1	Mean arterial pressure;	chr9:125683479	chr9:125150653~125151589:+
BRCA	cis	rs2139634	0.864	rs885485	ENSG00000227398.3	KIF9-AS1	-3.28	0.00108	0.0463	-0.11	-0.1	Cerebrospinal fluid biomarker levels;	chr3:46469678	chr3:47164497~47246601:+
BRCA	cis	rs2139634	0.896	rs885486	ENSG00000227398.3	KIF9-AS1	-3.28	0.00108	0.0463	-0.11	-0.1	Cerebrospinal fluid biomarker levels;	chr3:46469736	chr3:47164497~47246601:+
BRCA	cis	rs4130344	0.845	rs11726096	ENSG00000271817.2	U3	-3.28	0.00108	0.0463	-0.11	-0.1	Intelligence (multi-trait analysis);	chr4:158867848	chr4:158700691~158700909:+
BRCA	cis	rs6678639	0.522	rs74073884	ENSG00000225154.2	RP11-184J23.2	-3.28	0.00108	0.0463	-0.16	-0.1	Blood metabolite ratios;	chr1:47034799	chr1:47074778~47075979:-
BRCA	cis	rs2692947	0.727	rs749457	ENSG00000232931.4	LINC00342	3.28	0.00108	0.0463	0.1	0.1	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96130205	chr2:95807118~95816215:-
BRCA	cis	rs3213958	0.574	rs56075614	ENSG00000239445.4	ST3GAL6-AS1	-3.28	0.00108	0.0463	-0.15	-0.1	Blood protein levels;	chr3:98819973	chr3:98714330~98732651:-
BRCA	cis	rs2562456	0.917	rs2650805	ENSG00000268705.1	BNIP3P26	-3.28	0.00108	0.0463	-0.11	-0.1	Pain;	chr19:21505137	chr19:21521343~21521896:-
BRCA	cis	rs4650943	0.6	rs2938156	ENSG00000227740.1	RP11-318C24.2	-3.28	0.00108	0.0463	-0.1	-0.1	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in inactive individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr1:176306393	chr1:175904762~175920513:-
BRCA	cis	rs7267979	0.932	rs6115215	ENSG00000274973.1	RP13-401N8.7	-3.28	0.00108	0.0463	-0.11	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25581864	chr20:25845497~25845862:+
BRCA	cis	rs4950322	0.57	rs17356240	ENSG00000227242.3	NBPF13P	-3.28	0.00108	0.0463	-0.14	-0.1	Protein quantitative trait loci;	chr1:147269877	chr1:147021320~147124525:-
BRCA	cis	rs4950322	0.57	rs1999820	ENSG00000227242.3	NBPF13P	-3.28	0.00108	0.0463	-0.14	-0.1	Protein quantitative trait loci;	chr1:147270329	chr1:147021320~147124525:-
BRCA	cis	rs4950322	0.57	rs4950316	ENSG00000227242.3	NBPF13P	-3.28	0.00108	0.0463	-0.14	-0.1	Protein quantitative trait loci;	chr1:147273712	chr1:147021320~147124525:-
BRCA	cis	rs4130344	0.874	rs35747642	ENSG00000271817.2	U3	-3.28	0.00109	0.0463	-0.11	-0.1	Intelligence (multi-trait analysis);	chr4:158884218	chr4:158700691~158700909:+
BRCA	cis	rs6540556	0.723	rs3766619	ENSG00000236136.1	ADORA2BP1	-3.28	0.00109	0.0463	-0.13	-0.1	Red blood cell count;	chr1:209721953	chr1:209744373~209745214:+
BRCA	cis	rs4835473	0.932	rs11721495	ENSG00000246448.2	RP13-578N3.3	-3.28	0.00109	0.0463	-0.11	-0.1	Immature fraction of reticulocytes;	chr4:143767216	chr4:143700257~143865072:+
BRCA	cis	rs10005067	0.935	rs62318300	ENSG00000249001.4	RP11-742B18.1	-3.28	0.00109	0.0463	-0.12	-0.1	Total body bone mineral density (age 30-45);	chr4:87890022	chr4:87568035~87733956:-
BRCA	cis	rs321358	0.731	rs511835	ENSG00000271390.1	RP11-89C3.3	3.28	0.00109	0.0463	0.15	0.1	Body mass index;	chr11:111145338	chr11:111089870~111090368:-
BRCA	cis	rs12468226	1	rs74766638	ENSG00000272966.1	RP11-686O6.1	3.28	0.00109	0.0463	0.17	0.1	Urate levels;	chr2:202445168	chr2:202336739~202337200:+
BRCA	cis	rs1449587	0.749	rs9535094	ENSG00000276968.1	RP11-90M2.5	3.28	0.00109	0.0463	0.12	0.1	Verbal memory performance (immediate recall level);	chr13:48850012	chr13:48041751~48042184:-
BRCA	cis	rs1878931	0.507	rs11648783	ENSG00000263280.1	LA16c-325D7.2	3.28	0.00109	0.0463	0.11	0.1	Body mass index (adult);	chr16:3356626	chr16:2866348~2867618:-
BRCA	cis	rs4835473	0.9	rs7689374	ENSG00000246448.2	RP13-578N3.3	-3.28	0.00109	0.0463	-0.11	-0.1	Immature fraction of reticulocytes;	chr4:143769567	chr4:143700257~143865072:+
BRCA	cis	rs10043228	0.826	rs77863323	ENSG00000250015.1	CTC-339F2.2	3.28	0.00109	0.0463	0.14	0.1	Asthma or chronic obstructive pulmonary disease;	chr5:116113415	chr5:116302354~116304134:-
BRCA	cis	rs10043228	1	rs79404901	ENSG00000250015.1	CTC-339F2.2	3.28	0.00109	0.0463	0.14	0.1	Asthma or chronic obstructive pulmonary disease;	chr5:116113635	chr5:116302354~116304134:-
BRCA	cis	rs28735056	0.967	rs56328473	ENSG00000261126.6	RP11-795F19.1	-3.28	0.00109	0.0463	-0.1	-0.1	Schizophrenia;	chr18:79876101	chr18:80046900~80095482:+
BRCA	cis	rs34779708	0.931	rs34954932	ENSG00000269952.1	RP11-324I22.3	-3.28	0.00109	0.0463	-0.13	-0.1	Inflammatory bowel disease;Crohn's disease;	chr10:35121879	chr10:35210416~35210750:+
BRCA	cis	rs1790761	0.52	rs4930461	ENSG00000273819.1	ENPP7P7	3.28	0.00109	0.0463	0.13	0.1	Mean corpuscular volume;	chr11:67627424	chr11:67812557~67873367:-
BRCA	cis	rs36051895	0.664	rs7852755	ENSG00000237711.1	RP11-39K24.13	-3.28	0.00109	0.0463	-0.12	-0.1	Pediatric autoimmune diseases;	chr9:5100862	chr9:5100236~5101009:+
BRCA	cis	rs13028485	0.541	rs578058	ENSG00000236449.1	AC018890.6	3.28	0.00109	0.0463	0.18	0.1	Multiple myeloma (IgH translocation);	chr2:173646442	chr2:174547141~174774827:+
BRCA	cis	rs904092	0.72	rs1229976	ENSG00000246090.5	RP11-696N14.1	-3.28	0.00109	0.0463	-0.12	-0.1	Alcohol dependence;	chr4:99280921	chr4:99088857~99301356:+
BRCA	cis	rs10851411	0.697	rs41315252	ENSG00000260490.2	RP11-265N6.3	-3.28	0.00109	0.0463	-0.19	-0.1	Glucose homeostasis traits;	chr15:42545299	chr15:42571927~42572433:+
BRCA	cis	rs2998286	0.723	rs2807729	ENSG00000237128.1	RP11-351M16.3	-3.28	0.00109	0.0463	-0.15	-0.1	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28526427	chr10:28433008~28495813:-
BRCA	cis	rs875971	1	rs6963646	ENSG00000271064.1	RP11-792A8.3	3.28	0.00109	0.0463	0.12	0.1	Aortic root size;	chr7:66220780	chr7:66748838~66749077:-
BRCA	cis	rs13401620	0.655	rs1446306	ENSG00000223549.1	MTND5P28	3.28	0.00109	0.0463	0.12	0.1	Breast size;	chr2:120041296	chr2:120215181~120217279:+
BRCA	cis	rs600550	0.588	rs11230248	ENSG00000275344.1	MIR6503	3.28	0.00109	0.0463	0.11	0.1	Lipoprotein-associated phospholipase A2 activity and mass;	chr11:60318420	chr11:60209071~60209156:-
BRCA	cis	rs2638953	0.962	rs79708115	ENSG00000273989.1	RP11-425D17.2	-3.28	0.00109	0.0463	-0.15	-0.1	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28440784	chr12:28236227~28236828:+
BRCA	cis	rs2880765	0.805	rs34598679	ENSG00000259630.2	CTD-2262B20.1	-3.28	0.00109	0.0463	-0.12	-0.1	Coronary artery disease;	chr15:85498974	chr15:85415228~85415633:+
BRCA	cis	rs2880765	0.835	rs4344688	ENSG00000259630.2	CTD-2262B20.1	-3.28	0.00109	0.0463	-0.12	-0.1	Coronary artery disease;	chr15:85499776	chr15:85415228~85415633:+
BRCA	cis	rs950881	0.932	rs3771175	ENSG00000234389.1	AC007278.3	-3.28	0.00109	0.0463	-0.13	-0.1	Allergy;	chr2:102343750	chr2:102438713~102440475:+
BRCA	cis	rs66887589	0.616	rs6843509	ENSG00000260091.1	RP11-33B1.4	-3.28	0.00109	0.0463	-0.08	-0.1	Diastolic blood pressure;	chr4:119299041	chr4:119409333~119410233:+
BRCA	cis	rs7515577	1	rs962221	ENSG00000207523.1	SNORA66	3.28	0.00109	0.0463	0.14	0.1	Cholesterol, total;	chr1:92505213	chr1:92840719~92840851:+
BRCA	cis	rs7515577	1	rs962222	ENSG00000207523.1	SNORA66	3.28	0.00109	0.0463	0.14	0.1	Cholesterol, total;	chr1:92505396	chr1:92840719~92840851:+
BRCA	cis	rs7515577	1	rs1570836	ENSG00000207523.1	SNORA66	3.28	0.00109	0.0463	0.14	0.1	Cholesterol, total;	chr1:92506900	chr1:92840719~92840851:+
BRCA	cis	rs7515577	0.947	rs4970706	ENSG00000207523.1	SNORA66	3.28	0.00109	0.0463	0.14	0.1	Cholesterol, total;	chr1:92507518	chr1:92840719~92840851:+
BRCA	cis	rs6918152	0.605	rs2493034	ENSG00000218027.2	RP11-157J24.1	-3.28	0.00109	0.0463	-0.13	-0.1	Black vs. red hair color;Black vs. blond hair color;	chr6:528736	chr6:1513698~1515289:-
BRCA	cis	rs34779708	0.966	rs35146199	ENSG00000269952.1	RP11-324I22.3	-3.28	0.00109	0.0463	-0.14	-0.1	Inflammatory bowel disease;Crohn's disease;	chr10:35172011	chr10:35210416~35210750:+
BRCA	cis	rs6691170	0.897	rs4384245	ENSG00000238042.4	RP11-815M8.1	-3.28	0.00109	0.0463	-0.11	-0.1	Colorectal cancer;	chr1:221868373	chr1:221880981~221978523:-
BRCA	cis	rs6691170	0.865	rs6604677	ENSG00000238042.4	RP11-815M8.1	-3.28	0.00109	0.0463	-0.11	-0.1	Colorectal cancer;	chr1:221868875	chr1:221880981~221978523:-
BRCA	cis	rs17684571	0.751	rs7758867	ENSG00000231441.1	RP11-472M19.2	3.28	0.00109	0.0463	0.14	0.1	Schizophrenia;	chr6:56836000	chr6:56844002~56864078:+
BRCA	cis	rs11673344	0.683	rs11668615	ENSG00000267260.1	CTD-2162K18.4	-3.28	0.00109	0.0463	-0.15	-0.1	Obesity-related traits;	chr19:37063632	chr19:36773153~36777078:+
BRCA	cis	rs8141529	0.748	rs5762881	ENSG00000226471.5	CTA-292E10.6	-3.28	0.00109	0.0463	-0.12	-0.1	Lymphocyte counts;	chr22:28893358	chr22:28800683~28848559:+
BRCA	cis	rs7829975	0.606	rs891570	ENSG00000253981.4	ALG1L13P	-3.28	0.00109	0.0463	-0.11	-0.1	Mood instability;	chr8:8936944	chr8:8236003~8244667:-
BRCA	cis	rs7474896	1	rs2144845	ENSG00000120555.12	SEPT7P9	-3.28	0.00109	0.0463	-0.18	-0.1	Obesity (extreme);	chr10:37932591	chr10:38383069~38402916:-
BRCA	cis	rs55904328	1	rs61894546	ENSG00000255135.3	RP11-111M22.3	-3.28	0.00109	0.0463	-0.11	-0.1	3-hydroxypropylmercapturic acid levels in smokers;	chr11:76527220	chr11:76441338~76444656:-
BRCA	cis	rs8058578	1	rs8051050	ENSG00000280211.1	RP11-2C24.3	3.28	0.00109	0.0463	0.1	0.1	Multiple myeloma;	chr16:30676588	chr16:30773532~30776033:-
BRCA	cis	rs6456156	0.806	rs11967165	ENSG00000272549.1	RP11-351J23.2	3.28	0.00109	0.0463	0.1	0.1	Primary biliary cholangitis;	chr6:167116448	chr6:167666840~167679270:-
BRCA	cis	rs7239883	0.547	rs449775	ENSG00000267586.5	LINC00907	3.28	0.00109	0.0463	0.11	0.1	Waist circumference;Body mass index;	chr18:42348924	chr18:42159283~42691422:+
BRCA	cis	rs10489896	1	rs10489895	ENSG00000231768.1	LINC01354	-3.28	0.00109	0.0463	-0.1	-0.1	Cognitive test performance;	chr1:234445657	chr1:234527891~234531779:-
BRCA	cis	rs6997458	0.785	rs1389247	ENSG00000254231.1	CTD-2284J15.1	3.28	0.00109	0.0464	0.09	0.1	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;	chr8:85410354	chr8:86333274~86343314:-
BRCA	cis	rs1552244	0.882	rs34706481	ENSG00000269894.1	RP11-1020A11.1	-3.28	0.00109	0.0464	-0.13	-0.1	Alzheimer's disease;	chr3:9962439	chr3:9935706~9936258:+
BRCA	cis	rs7832552	1	rs7832552	ENSG00000253796.1	RP11-1084E5.1	-3.28	0.00109	0.0464	-0.11	-0.1	Body mass (lean);	chr8:109103447	chr8:108895029~109063417:-
BRCA	cis	rs7017914	0.967	rs35207116	ENSG00000246366.5	RP11-382J12.1	3.28	0.00109	0.0464	0.11	0.1	Bone mineral density;	chr8:70796736	chr8:70608577~70663279:+
BRCA	cis	rs11673344	0.864	rs55921822	ENSG00000267422.1	CTD-2554C21.1	3.28	0.00109	0.0464	0.13	0.1	Obesity-related traits;	chr19:37005910	chr19:37779686~37792865:+
BRCA	cis	rs8038465	0.615	rs11637315	ENSG00000260898.4	ADPGK-AS1	3.28	0.00109	0.0464	0.11	0.1	Liver enzyme levels (gamma-glutamyl transferase);	chr15:73651727	chr15:72782835~72798199:+
BRCA	cis	rs7735319	0.932	rs1479644	ENSG00000249572.1	CTD-2203K17.1	3.28	0.00109	0.0464	0.14	0.1	Systolic blood pressure;	chr5:33170717	chr5:33424025~33440619:-
BRCA	cis	rs7686660	0.614	rs1105832	ENSG00000250326.1	RP11-284M14.1	-3.28	0.00109	0.0464	-0.11	-0.1	Asthma;	chr4:143020705	chr4:142933195~143184861:-
BRCA	cis	rs1155750	0.72	rs2746440	ENSG00000224984.1	RP11-524H19.2	-3.28	0.00109	0.0464	-0.15	-0.1	Colorectal cancer;	chr6:54927438	chr6:54840118~54840855:-
BRCA	cis	rs10464366	0.912	rs7785889	ENSG00000233306.2	TRGV2	3.28	0.00109	0.0464	0.1	0.1	IgG glycosylation;	chr7:39066768	chr7:38362864~38363518:-
BRCA	cis	rs2307449	0.929	rs7163655	ENSG00000260123.1	RP11-326A19.4	3.28	0.00109	0.0464	0.12	0.1	Menopause (age at onset);	chr15:89284191	chr15:89041223~89082819:+
BRCA	cis	rs1816752	0.87	rs9581029	ENSG00000273628.1	RP11-756A22.7	3.28	0.00109	0.0464	0.12	0.1	Obesity-related traits;	chr13:24425147	chr13:24933006~24936796:+
BRCA	cis	rs1005277	0.579	rs2505248	ENSG00000276805.1	RP11-291L22.6	3.28	0.00109	0.0464	0.11	0.1	Extrinsic epigenetic age acceleration;	chr10:38170169	chr10:38451030~38451785:+
BRCA	cis	rs2562456	0.917	rs11085463	ENSG00000279377.1	AC003973.3	3.28	0.00109	0.0464	0.13	0.1	Pain;	chr19:21568500	chr19:21965708~21968529:-
BRCA	cis	rs7200543	0.961	rs3803573	ENSG00000207425.1	Y_RNA	-3.28	0.00109	0.0464	-0.12	-0.1	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15044556	chr16:14915457~14915556:-
BRCA	cis	rs11047510	0.73	rs7978604	ENSG00000164845.15	FAM86FP	-3.28	0.00109	0.0464	-0.15	-0.1	Exploratory eye movement dysfunction in schizophrenia (responsive search score);	chr12:8849121	chr12:8232512~8242948:-
BRCA	cis	rs6545883	0.895	rs4430924	ENSG00000273302.1	RP11-493E12.2	3.28	0.00109	0.0464	0.1	0.1	Tuberculosis;	chr2:61476721	chr2:61199979~61200769:+
BRCA	cis	rs2562456	0.917	rs2681376	ENSG00000268705.1	BNIP3P26	-3.28	0.00109	0.0464	-0.11	-0.1	Pain;	chr19:21532723	chr19:21521343~21521896:-
BRCA	cis	rs10504130	0.569	rs11785467	ENSG00000272076.1	RP11-11C20.3	3.28	0.00109	0.0464	0.15	0.1	Venous thromboembolism (SNP x SNP interaction);	chr8:51763108	chr8:51810110~51810681:-
BRCA	cis	rs6532023	1	rs1471401	ENSG00000249001.4	RP11-742B18.1	-3.28	0.00109	0.0464	-0.12	-0.1	Bone mineral density (paediatric, total body less head);Bone mineral density;	chr4:87853188	chr4:87568035~87733956:-
BRCA	cis	rs310291	0.585	rs182565	ENSG00000253930.1	RP11-1149O23.2	3.28	0.00109	0.0464	0.12	0.1	Breast cancer;	chr8:23835918	chr8:23189279~23190675:+
BRCA	cis	rs12282928	1	rs1905285	ENSG00000255197.4	RP11-750H9.5	-3.28	0.00109	0.0464	-0.1	-0.1	Migraine - clinic-based;	chr11:48304472	chr11:47383148~47409190:-
BRCA	cis	rs875971	0.862	rs1968126	ENSG00000265600.1	AC006480.1	3.28	0.00109	0.0464	0.12	0.1	Aortic root size;	chr7:66592017	chr7:67356680~67356779:+
BRCA	cis	rs10843647	1	rs2086941	ENSG00000245614.3	DDX11-AS1	-3.28	0.00109	0.0464	-0.11	-0.1	Glucose homeostasis traits;	chr12:30182517	chr12:31020763~31073847:-
BRCA	cis	rs7943953	0.58	rs34387009	ENSG00000254717.2	GLYATL1P2	-3.28	0.00109	0.0464	-0.14	-0.1	Odorant perception (&beta-ionone);	chr11:59351708	chr11:58878302~58893460:+
BRCA	cis	rs7943953	0.58	rs61904597	ENSG00000254717.2	GLYATL1P2	-3.28	0.00109	0.0464	-0.14	-0.1	Odorant perception (&beta-ionone);	chr11:59353803	chr11:58878302~58893460:+
BRCA	cis	rs739496	0.579	rs2238152	ENSG00000257624.1	RP1-128M12.3	3.28	0.00109	0.0464	0.14	0.1	Platelet count;	chr12:111776655	chr12:112000739~112000985:-
BRCA	cis	rs6088580	0.634	rs6087579	ENSG00000269202.1	RP4-614O4.12	3.28	0.00109	0.0464	0.1	0.1	Glomerular filtration rate (creatinine);	chr20:34397349	chr20:35201747~35203288:-
BRCA	cis	rs12664873	0.537	rs3823188	ENSG00000279453.1	RP3-425C14.4	-3.28	0.00109	0.0464	-0.14	-0.1	Atrial fibrillation;	chr6:122422541	chr6:122436789~122439223:-
BRCA	cis	rs11858159	1	rs3901472	ENSG00000207279.1	SNORD116-24	-3.28	0.00109	0.0464	-0.1	-0.1	Platelet thrombus formation;	chr15:24569435	chr15:25094037~25094128:+
BRCA	cis	rs1552244	1	rs17032414	ENSG00000269894.1	RP11-1020A11.1	-3.28	0.00109	0.0464	-0.12	-0.1	Alzheimer's disease;	chr3:10116618	chr3:9935706~9936258:+
BRCA	cis	rs67478160	0.644	rs7159810	ENSG00000269940.1	RP11-73M18.7	3.28	0.00109	0.0464	0.1	0.1	Schizophrenia;	chr14:103827780	chr14:103694560~103695170:+
BRCA	cis	rs6840360	0.571	rs7678080	ENSG00000278978.1	RP11-164P12.5	-3.28	0.00109	0.0464	-0.12	-0.1	Intelligence (multi-trait analysis);	chr4:151636198	chr4:151669786~151670503:+
BRCA	cis	rs875971	1	rs6979382	ENSG00000230189.5	GS1-124K5.2	3.28	0.00109	0.0464	0.08	0.1	Aortic root size;	chr7:66421388	chr7:66409143~66490059:-
BRCA	cis	rs875971	1	rs6961990	ENSG00000230189.5	GS1-124K5.2	3.28	0.00109	0.0464	0.08	0.1	Aortic root size;	chr7:66423583	chr7:66409143~66490059:-
BRCA	cis	rs2835872	0.793	rs2835833	ENSG00000230366.8	DSCR9	3.28	0.00109	0.0464	0.13	0.1	Electroencephalographic traits in alcoholism;	chr21:37615595	chr21:37208503~37221736:+
BRCA	cis	rs12760731	0.565	rs34303391	ENSG00000213057.5	C1orf220	3.28	0.00109	0.0464	0.15	0.1	Obesity-related traits;	chr1:178208991	chr1:178542752~178548889:+
BRCA	cis	rs55962025	0.883	rs362275	ENSG00000261643.1	RP11-529E10.6	3.28	0.00109	0.0464	0.13	0.1	Parental longevity (mother's age at death);	chr4:3222875	chr4:3503597~3504457:-
BRCA	cis	rs7404928	0.557	rs8051700	ENSG00000260136.4	CTD-2270L9.4	3.28	0.00109	0.0464	0.09	0.1	Rheumatoid arthritis;Primary biliary cholangitis;	chr16:23933391	chr16:23452758~23457606:+
BRCA	cis	rs1555322	0.53	rs2275275	ENSG00000278035.1	RP11-234K24.6	3.28	0.00109	0.0464	0.14	0.1	Attention deficit hyperactivity disorder;	chr20:35284508	chr20:36233851~36234297:+
BRCA	cis	rs848490	0.851	rs56052251	ENSG00000214293.7	APTR	3.28	0.00109	0.0464	0.13	0.1	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77626547	chr7:77657660~77696265:-
BRCA	cis	rs848490	0.817	rs17467232	ENSG00000214293.7	APTR	3.28	0.00109	0.0464	0.13	0.1	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77626624	chr7:77657660~77696265:-
BRCA	cis	rs879568	0.874	rs12605417	ENSG00000278986.1	RP11-723J4.3	-3.28	0.00109	0.0464	-0.12	-0.1	QRS duration;	chr18:36714933	chr18:35972151~35973916:+
BRCA	cis	rs2048656	0.6	rs1976671	ENSG00000233609.3	RP11-62H7.2	3.28	0.00109	0.0464	0.1	0.1	Schizophrenia;	chr8:9822124	chr8:8961200~8979025:+
BRCA	cis	rs7267979	1	rs2387881	ENSG00000204556.4	CTD-2514C3.1	3.28	0.00109	0.0464	0.14	0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25397536	chr20:26018832~26020684:+
BRCA	cis	rs7618501	1	rs2271961	ENSG00000228008.1	CTD-2330K9.3	-3.28	0.00109	0.0464	-0.1	-0.1	Intelligence (multi-trait analysis);	chr3:49840680	chr3:49903845~49916937:+
BRCA	cis	rs4805834	0.719	rs12151363	ENSG00000201388.1	SNORA68	3.28	0.00109	0.0464	0.17	0.1	Creatinine levels;	chr19:32818124	chr19:32608337~32608469:-
BRCA	cis	rs4805834	0.623	rs58018786	ENSG00000201388.1	SNORA68	3.28	0.00109	0.0464	0.17	0.1	Creatinine levels;	chr19:32819242	chr19:32608337~32608469:-
BRCA	cis	rs10097669	0.679	rs2617068	ENSG00000254244.1	PAICSP4	-3.28	0.00109	0.0464	-0.11	-0.1	Trans fatty acid levels;	chr8:4580726	chr8:4787332~4788584:+
BRCA	cis	rs4388249	0.948	rs961663	ENSG00000249068.1	CTC-287O8.1	3.28	0.00109	0.0464	0.15	0.1	Schizophrenia;	chr5:109788177	chr5:109840128~109840692:-
BRCA	cis	rs2191566	0.576	rs431509	ENSG00000266921.1	RP11-15A1.7	3.28	0.00109	0.0464	0.13	0.1	Acute lymphoblastic leukemia (childhood);	chr19:43991918	chr19:43996896~44002836:-
BRCA	cis	rs71520386	0.632	rs10224533	ENSG00000179428.2	AC073072.5	3.28	0.00109	0.0464	0.12	0.1	Fibrinogen levels;	chr7:22821522	chr7:22725395~22727620:-
BRCA	cis	rs13136331	0.759	rs6855426	ENSG00000249001.4	RP11-742B18.1	3.28	0.00109	0.0464	0.13	0.1	Sitting height ratio;	chr4:87725183	chr4:87568035~87733956:-
BRCA	cis	rs1008375	0.932	rs4235390	ENSG00000249502.1	AC006160.5	-3.28	0.00109	0.0464	-0.11	-0.1	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17694755	chr4:17587467~17614571:-
BRCA	cis	rs1008375	0.966	rs4235391	ENSG00000249502.1	AC006160.5	-3.28	0.00109	0.0464	-0.11	-0.1	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17694786	chr4:17587467~17614571:-
BRCA	cis	rs7226408	0.857	rs8098708	ENSG00000274849.1	RP11-49I11.4	3.28	0.00109	0.0464	0.17	0.1	Obesity-related traits;	chr18:36983410	chr18:36189824~36190272:+
BRCA	cis	rs67478160	0.643	rs4906369	ENSG00000269910.1	RP11-73M18.10	3.28	0.00109	0.0464	0.1	0.1	Schizophrenia;	chr14:103776121	chr14:103694516~103695050:-
BRCA	cis	rs4819052	0.851	rs2838840	ENSG00000223768.1	LINC00205	-3.28	0.00109	0.0464	-0.13	-0.1	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45248579	chr21:45293285~45297354:+
BRCA	cis	rs6840360	1	rs10007167	ENSG00000278978.1	RP11-164P12.5	-3.28	0.00109	0.0464	-0.12	-0.1	Intelligence (multi-trait analysis);	chr4:151682503	chr4:151669786~151670503:+
BRCA	cis	rs2811415	0.597	rs11721281	ENSG00000242551.2	POU5F1P6	3.28	0.00109	0.0464	0.14	0.1	Lung function (FEV1/FVC);	chr3:128072092	chr3:128674735~128677005:-
BRCA	cis	rs74233809	1	rs12217501	ENSG00000236937.2	PTGES3P4	3.28	0.00109	0.0464	0.22	0.1	Birth weight;	chr10:103092132	chr10:102845595~102845950:+
BRCA	cis	rs11867129	1	rs11859337	ENSG00000261613.2	RP11-20I23.13	-3.28	0.00109	0.0464	-0.21	-0.1	RR interval (tricyclic/tetracyclic antidepressant use interaction);	chr16:2315703	chr16:2554060~2556060:-
BRCA	cis	rs3890324	0.524	rs6102895	ENSG00000237555.1	RP5-862K6.4	3.28	0.00109	0.0464	0.15	0.1	Age-related nuclear cataracts;	chr20:42540129	chr20:43388642~43389041:-
BRCA	cis	rs3864261	0.887	rs2602632	ENSG00000272081.1	CTD-2376I4.2	3.28	0.00109	0.0464	0.18	0.1	Discordance in emotional problems in monozygotic twins;	chr5:72921504	chr5:72955206~72955699:-
BRCA	cis	rs853679	0.76	rs9368563	ENSG00000219392.1	RP1-265C24.5	-3.28	0.00109	0.0464	-0.16	-0.1	Depression;	chr6:28240780	chr6:28115628~28116551:+
BRCA	cis	rs853679	0.76	rs9295768	ENSG00000219392.1	RP1-265C24.5	-3.28	0.00109	0.0464	-0.16	-0.1	Depression;	chr6:28241324	chr6:28115628~28116551:+
BRCA	cis	rs4650994	0.571	rs11588907	ENSG00000213057.5	C1orf220	-3.28	0.00109	0.0464	-0.1	-0.1	HDL cholesterol;HDL cholesterol levels;	chr1:178540327	chr1:178542752~178548889:+
BRCA	cis	rs9341808	0.718	rs12203867	ENSG00000233967.5	RP11-250B2.3	3.28	0.00109	0.0464	0.1	0.1	Sitting height ratio;	chr6:80111116	chr6:80443344~80465927:+
BRCA	cis	rs904092	0.678	rs1230020	ENSG00000246090.5	RP11-696N14.1	3.28	0.00109	0.0464	0.12	0.1	Alcohol dependence;	chr4:99254250	chr4:99088857~99301356:+
BRCA	cis	rs12479064	0.724	rs62153852	ENSG00000273306.1	RP11-527J8.1	3.28	0.00109	0.0464	0.12	0.1	Chronic sinus infection;	chr2:99318250	chr2:99405218~99405843:+
BRCA	cis	rs1075265	0.73	rs7601692	ENSG00000272156.1	RP11-477N3.1	-3.28	0.00109	0.0464	-0.11	-0.1	Chronotype;Morning vs. evening chronotype;	chr2:53705532	chr2:54082554~54085066:+
BRCA	cis	rs2408955	0.515	rs10875742	ENSG00000276814.1	RP1-228P16.8	3.28	0.00109	0.0465	0.12	0.1	Glycated hemoglobin levels;	chr12:48099591	chr12:48039784~48040761:-
BRCA	cis	rs4788196	1	rs4788196	ENSG00000183604.13	SMG1P5	-3.28	0.00109	0.0465	-0.1	-0.1	Pubertal anthropometrics;	chr16:29956113	chr16:30267553~30335374:-
BRCA	cis	rs7781266	0.739	rs6971417	ENSG00000226205.1	AC007790.4	-3.28	0.00109	0.0465	-0.15	-0.1	Educational attainment (college completion);	chr7:133481415	chr7:133732493~133733595:-
BRCA	cis	rs11031096	0.933	rs725519	ENSG00000224513.2	AC109309.4	-3.28	0.00109	0.0465	-0.12	-0.1	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr11:4107256	chr11:3226061~3232838:+
BRCA	cis	rs6005807	0.764	rs75235539	ENSG00000272858.1	CTA-292E10.8	-3.28	0.00109	0.0465	-0.21	-0.1	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28415227	chr22:28814914~28815662:+
BRCA	cis	rs863345	0.604	rs1342945	ENSG00000229914.1	RP11-404O13.4	-3.28	0.00109	0.0465	-0.11	-0.1	Pneumococcal bacteremia;	chr1:158543122	chr1:158195633~158196131:-
BRCA	cis	rs3099143	1	rs2046415	ENSG00000196274.5	Metazoa_SRP	3.28	0.00109	0.0465	0.15	0.1	Recalcitrant atopic dermatitis;	chr15:76792912	chr15:76230048~76230390:-
BRCA	cis	rs889956	0.776	rs35068051	ENSG00000233251.6	AC007743.1	-3.28	0.00109	0.0465	-0.12	-0.1	Educational attainment;	chr2:57140509	chr2:56173534~56185770:-
BRCA	cis	rs1900005	0.519	rs2894061	ENSG00000226493.1	RP11-524O24.2	3.28	0.00109	0.0465	0.14	0.1	Vertical cup-disc ratio;	chr10:68191152	chr10:68499532~68499968:+
BRCA	cis	rs375066	0.935	rs388685	ENSG00000278917.1	RP11-15A1.4	-3.28	0.00109	0.0465	-0.12	-0.1	Breast cancer;	chr19:43914528	chr19:43891233~43895411:+
BRCA	cis	rs4869313	0.668	rs251342	ENSG00000248734.2	CTD-2260A17.1	-3.28	0.00109	0.0465	-0.1	-0.1	Pediatric autoimmune diseases;	chr5:96901139	chr5:96784777~96785999:+
BRCA	cis	rs6828577	0.862	rs299005	ENSG00000225892.3	RP11-384K6.2	-3.28	0.00109	0.0465	-0.1	-0.1	Perioperative myocardial infarction in coronary artery bypass surgery;	chr4:118674209	chr4:118632274~118634759:+
BRCA	cis	rs7267979	1	rs6083804	ENSG00000204556.4	CTD-2514C3.1	3.28	0.00109	0.0465	0.14	0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25336424	chr20:26018832~26020684:+
BRCA	cis	rs7267979	1	rs4815405	ENSG00000204556.4	CTD-2514C3.1	3.28	0.00109	0.0465	0.14	0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25336856	chr20:26018832~26020684:+
BRCA	cis	rs7267979	1	rs6050542	ENSG00000204556.4	CTD-2514C3.1	3.28	0.00109	0.0465	0.14	0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25338243	chr20:26018832~26020684:+
BRCA	cis	rs1348850	0.519	rs4144275	ENSG00000238082.1	AC009948.7	-3.28	0.00109	0.0465	-0.13	-0.1	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177658640	chr2:178454716~178455428:+
BRCA	cis	rs9472155	1	rs9462939	ENSG00000220614.1	RP11-480N24.4	3.28	0.00109	0.0465	0.14	0.1	Vascular endothelial growth factor levels;	chr6:43931909	chr6:43328134~43328476:+
BRCA	cis	rs4657178	1	rs6427665	ENSG00000272574.1	RP11-359K18.4	-3.28	0.00109	0.0465	-0.1	-0.1	QT interval;	chr1:162244972	chr1:162593103~162593754:+
BRCA	cis	rs4356203	0.905	rs651513	ENSG00000184669.7	OR7E14P	-3.28	0.00109	0.0465	-0.13	-0.1	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17177781	chr11:17013998~17053024:+
BRCA	cis	rs7260538	0.867	rs10412702	ENSG00000268034.1	AC005795.1	3.28	0.00109	0.0465	0.11	0.1	DDT metabolite (p,p'-DDE levels);	chr19:41001048	chr19:41506152~41506898:+
BRCA	cis	rs4243971	0.516	rs6141721	ENSG00000224452.1	RSL24D1P6	-3.28	0.00109	0.0465	-0.14	-0.1	Inflammatory bowel disease;Crohn's disease;	chr20:32440324	chr20:32170390~32170790:-
BRCA	cis	rs3816183	0.585	rs6544577	ENSG00000226491.1	FTOP1	-3.28	0.00109	0.0465	-0.12	-0.1	Hypospadias;	chr2:42627625	chr2:42797225~42798712:-
BRCA	cis	rs7713065	0.765	rs4235802	ENSG00000202533.1	Y_RNA	-3.28	0.00109	0.0465	-0.11	-0.1	Lung function (FEV1/FVC);	chr5:132447145	chr5:132468147~132468257:+
BRCA	cis	rs2438150	1	rs2438150	ENSG00000249996.1	RP11-359P5.1	3.28	0.00109	0.0465	0.12	0.1	Plateletcrit;	chr5:122863501	chr5:123036271~123054667:+
BRCA	cis	rs2303790	1	rs2303790	ENSG00000261114.1	RP11-325K4.2	-3.28	0.00109	0.0465	-0.24	-0.1	Exudative age-related macular degeneration;	chr16:56983380	chr16:56941028~56941726:+
BRCA	cis	rs8016982	0.662	rs1951616	ENSG00000258999.1	RP11-114N19.3	3.28	0.00109	0.0465	0.14	0.1	Schizophrenia;	chr14:81205408	chr14:81107033~81170414:-
BRCA	cis	rs12887734	0.524	rs4906363	ENSG00000269958.1	RP11-73M18.8	3.28	0.00109	0.0465	0.12	0.1	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103743902	chr14:103696353~103697163:+
BRCA	cis	rs2235649	0.561	rs12599786	ENSG00000206630.1	SNORD60	-3.28	0.00109	0.0465	-0.12	-0.1	Blood metabolite levels;	chr16:1915256	chr16:2155023~2155105:-
BRCA	cis	rs903552	0.8	rs6598479	ENSG00000259205.2	PRKXP1	-3.28	0.00109	0.0465	-0.16	-0.1	Diabetic kidney disease;	chr15:101465708	chr15:100553529~100558954:-
BRCA	cis	rs62025270	0.632	rs17637411	ENSG00000259416.2	RP11-158M2.5	-3.27	0.00109	0.0465	-0.15	-0.1	Idiopathic pulmonary fibrosis;	chr15:85703216	chr15:85754941~85756237:-
BRCA	cis	rs62025270	0.58	rs62022938	ENSG00000259416.2	RP11-158M2.5	-3.27	0.00109	0.0465	-0.15	-0.1	Idiopathic pulmonary fibrosis;	chr15:85704764	chr15:85754941~85756237:-
BRCA	cis	rs3770752	0.866	rs62133261	ENSG00000272054.1	RP11-423P10.2	-3.27	0.00109	0.0465	-0.09	-0.1	Schizophrenia;	chr2:37299020	chr2:37208875~37212677:+
BRCA	cis	rs4953911	1	rs7587559	ENSG00000224043.6	CCNT2-AS1	3.27	0.00109	0.0465	0.14	0.1	Multiple sclerosis (severity);	chr2:134311901	chr2:134735464~134918710:-
BRCA	cis	rs10198628	1	rs10198628	ENSG00000264370.1	MIR3125	-3.27	0.00109	0.0465	-0.12	-0.1	Pericardial fat;Pericardial adipose tissue adjusted for height and weight;	chr2:12824371	chr2:12737367~12737444:+
BRCA	cis	rs16940212	0.542	rs28495863	ENSG00000259771.1	RP11-429D19.1	-3.27	0.00109	0.0465	-0.17	-0.1	HDL cholesterol;HDL cholesterol levels;	chr15:58392182	chr15:59266720~59271162:-
BRCA	cis	rs1178968	0.901	rs4717753	ENSG00000225648.4	SBDSP1	3.27	0.00109	0.0465	0.16	0.1	Triglyceride levels;	chr7:73340352	chr7:72829425~72836701:+
BRCA	cis	rs6433921	1	rs1375488	ENSG00000260742.1	RP11-366L5.1	3.27	0.00109	0.0465	0.13	0.1	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;	chr2:181563167	chr2:181887851~181891663:-
BRCA	cis	rs875971	0.522	rs9530	ENSG00000272831.1	RP11-792A8.4	3.27	0.00109	0.0465	0.09	0.1	Aortic root size;	chr7:65960907	chr7:66739829~66740385:-
BRCA	cis	rs4787491	0.729	rs4238960	ENSG00000275371.1	RP11-455F5.6	-3.27	0.00109	0.0465	-0.1	-0.1	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30027327	chr16:30110895~30111955:+
BRCA	cis	rs934734	0.789	rs11689314	ENSG00000281920.1	RP11-418H16.1	-3.27	0.00109	0.0465	-0.12	-0.1	Rheumatoid arthritis;	chr2:65378274	chr2:65623272~65628424:+
BRCA	cis	rs73222236	0.825	rs59931907	ENSG00000239213.4	NCK1-AS1	3.27	0.00109	0.0465	0.11	0.1	Coronary artery disease;	chr3:136646255	chr3:136841726~136862054:-
BRCA	cis	rs6964587	0.61	rs6465338	ENSG00000188693.7	CYP51A1-AS1	-3.27	0.00109	0.0465	-0.11	-0.1	Breast cancer;	chr7:91821310	chr7:92134604~92180725:+
BRCA	cis	rs6964587	0.541	rs6947170	ENSG00000188693.7	CYP51A1-AS1	-3.27	0.00109	0.0465	-0.11	-0.1	Breast cancer;	chr7:91822157	chr7:92134604~92180725:+
BRCA	cis	rs10504130	0.569	rs11784869	ENSG00000272076.1	RP11-11C20.3	3.27	0.00109	0.0465	0.15	0.1	Venous thromboembolism (SNP x SNP interaction);	chr8:51906951	chr8:51810110~51810681:-
BRCA	cis	rs875971	0.577	rs35072105	ENSG00000230189.5	GS1-124K5.2	-3.27	0.00109	0.0465	-0.08	-0.1	Aortic root size;	chr7:66144830	chr7:66409143~66490059:-
BRCA	cis	rs8127691	0.904	rs2070552	ENSG00000225331.1	AP001055.6	3.27	0.00109	0.0465	0.12	0.1	Inflammatory bowel disease;	chr21:44197186	chr21:44158740~44160076:-
BRCA	cis	rs6678639	0.522	rs2202221	ENSG00000225154.2	RP11-184J23.2	-3.27	0.00109	0.0465	-0.16	-0.1	Blood metabolite ratios;	chr1:47042020	chr1:47074778~47075979:-
BRCA	cis	rs1126510	0.86	rs3760757	ENSG00000268423.3	AC011551.3	-3.27	0.00109	0.0465	-0.13	-0.1	Ulcerative colitis;	chr19:46626313	chr19:46547056~46600861:-
BRCA	cis	rs832540	0.898	rs331498	ENSG00000237705.1	AC008937.2	-3.27	0.00109	0.0465	-0.1	-0.1	Coronary artery disease;	chr5:56954015	chr5:56842016~56862164:-
BRCA	cis	rs13420028	0.628	rs4260295	ENSG00000230992.3	FAM201B	-3.27	0.00109	0.0465	-0.12	-0.1	Hypertension (SNP x SNP interaction);	chr2:132436262	chr2:132352722~132353318:+
BRCA	cis	rs12049351	0.943	rs6687883	ENSG00000213028.3	RP11-108F13.2	3.27	0.00109	0.0465	0.16	0.1	Circulating myeloperoxidase levels (plasma);	chr1:229582109	chr1:229688999~229689904:-
BRCA	cis	rs11098499	0.82	rs6829903	ENSG00000260404.2	RP11-384K6.6	3.27	0.00109	0.0465	0.1	0.1	Corneal astigmatism;	chr4:119585729	chr4:118591773~118633729:+
BRCA	cis	rs9325144	0.513	rs12313652	ENSG00000257718.1	RP11-396F22.1	-3.27	0.00109	0.0465	-0.1	-0.1	Morning vs. evening chronotype;	chr12:38271610	chr12:38906451~38909592:+
BRCA	cis	rs7258177	0.597	rs10409148	ENSG00000267783.1	CTB-55O6.10	-3.27	0.00109	0.0465	-0.12	-0.1	Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid);	chr19:13659916	chr19:14119106~14119537:+
BRCA	cis	rs6840360	0.571	rs1822346	ENSG00000278978.1	RP11-164P12.5	-3.27	0.00109	0.0465	-0.12	-0.1	Intelligence (multi-trait analysis);	chr4:151604151	chr4:151669786~151670503:+
BRCA	cis	rs6840360	0.571	rs1822347	ENSG00000278978.1	RP11-164P12.5	-3.27	0.00109	0.0465	-0.12	-0.1	Intelligence (multi-trait analysis);	chr4:151604167	chr4:151669786~151670503:+
BRCA	cis	rs6840360	0.571	rs4696272	ENSG00000278978.1	RP11-164P12.5	-3.27	0.00109	0.0465	-0.12	-0.1	Intelligence (multi-trait analysis);	chr4:151607077	chr4:151669786~151670503:+
BRCA	cis	rs9308433	0.529	rs4655243	ENSG00000213036.3	RP11-365D23.4	-3.27	0.00109	0.0465	-0.14	-0.1	IgG glycosylation;	chr1:214323948	chr1:214482813~214483387:-
BRCA	cis	rs9308433	0.529	rs4655244	ENSG00000213036.3	RP11-365D23.4	-3.27	0.00109	0.0465	-0.14	-0.1	IgG glycosylation;	chr1:214324237	chr1:214482813~214483387:-
BRCA	cis	rs9308433	0.529	rs3767842	ENSG00000213036.3	RP11-365D23.4	-3.27	0.00109	0.0465	-0.14	-0.1	IgG glycosylation;	chr1:214324963	chr1:214482813~214483387:-
BRCA	cis	rs4714291	0.855	rs1743971	ENSG00000180211.5	RP1-278E11.3	3.27	0.00109	0.0466	0.11	0.1	Strep throat;	chr6:40128188	chr6:39958414~39958833:-
BRCA	cis	rs8040855	0.599	rs8037195	ENSG00000259416.2	RP11-158M2.5	-3.27	0.00109	0.0466	-0.12	-0.1	Bulimia nervosa;	chr15:85181455	chr15:85754941~85756237:-
BRCA	cis	rs7781266	0.842	rs17656452	ENSG00000226205.1	AC007790.4	3.27	0.00109	0.0466	0.15	0.1	Educational attainment (college completion);	chr7:133508671	chr7:133732493~133733595:-
BRCA	cis	rs9951698	0.678	rs576963	ENSG00000266969.1	RP11-773H22.4	-3.27	0.00109	0.0466	-0.13	-0.1	Intelligence (multi-trait analysis);	chr18:13145265	chr18:12984694~12991173:-
BRCA	cis	rs4803480	0.872	rs2058149	ENSG00000268355.1	AC006129.1	-3.27	0.00109	0.0466	-0.14	-0.1	Schizophrenia;	chr19:41580312	chr19:41531206~41532174:+
BRCA	cis	rs3785888	0.548	rs197922	ENSG00000261886.1	RP11-63A1.1	3.27	0.00109	0.0466	0.12	0.1	Cleft lip with or without cleft palate;	chr17:46931204	chr17:46916770~46923034:-
BRCA	cis	rs683250	0.599	rs1943742	ENSG00000255234.4	RP11-727A23.10	3.27	0.00109	0.0466	0.13	0.1	Subcortical brain region volumes;	chr11:83369540	chr11:83286128~83423516:+
BRCA	cis	rs4415084	0.716	rs10462081	ENSG00000272335.1	RP11-53O19.3	3.27	0.00109	0.0466	0.09	0.1	Breast cancer;	chr5:44800563	chr5:44826076~44828592:+
BRCA	cis	rs11098499	0.863	rs2306456	ENSG00000225892.3	RP11-384K6.2	3.27	0.00109	0.0466	0.1	0.1	Corneal astigmatism;	chr4:119551267	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.863	rs11947234	ENSG00000225892.3	RP11-384K6.2	3.27	0.00109	0.0466	0.1	0.1	Corneal astigmatism;	chr4:119553704	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.863	rs11933966	ENSG00000225892.3	RP11-384K6.2	3.27	0.00109	0.0466	0.1	0.1	Corneal astigmatism;	chr4:119555560	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.863	rs36040693	ENSG00000225892.3	RP11-384K6.2	3.27	0.00109	0.0466	0.1	0.1	Corneal astigmatism;	chr4:119556461	chr4:118632274~118634759:+
BRCA	cis	rs6946131	0.593	rs2709314	ENSG00000235207.1	TUBBP6	-3.27	0.00109	0.0466	-0.13	-0.1	Systemic lupus erythematosus;	chr7:54782184	chr7:55645620~55646951:+
BRCA	cis	rs4953911	1	rs4953911	ENSG00000224043.6	CCNT2-AS1	3.27	0.00109	0.0466	0.14	0.1	Multiple sclerosis (severity);	chr2:134311223	chr2:134735464~134918710:-
BRCA	cis	rs6121246	0.909	rs7354225	ENSG00000230613.1	HM13-AS1	3.27	0.00109	0.0466	0.16	0.1	Mean corpuscular hemoglobin;	chr20:31709078	chr20:31567707~31573263:-
BRCA	cis	rs2638953	0.85	rs59879751	ENSG00000273989.1	RP11-425D17.2	-3.27	0.00109	0.0466	-0.15	-0.1	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28454490	chr12:28236227~28236828:+
BRCA	cis	rs2638953	0.924	rs59193275	ENSG00000273989.1	RP11-425D17.2	-3.27	0.00109	0.0466	-0.15	-0.1	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28454560	chr12:28236227~28236828:+
BRCA	cis	rs9733	0.744	rs12125650	ENSG00000203804.4	ADAMTSL4-AS1	-3.27	0.00109	0.0466	-0.11	-0.1	Tonsillectomy;	chr1:150787698	chr1:150560202~150574552:-
BRCA	cis	rs9733	0.688	rs12725667	ENSG00000203804.4	ADAMTSL4-AS1	-3.27	0.00109	0.0466	-0.11	-0.1	Tonsillectomy;	chr1:150793594	chr1:150560202~150574552:-
BRCA	cis	rs6942756	0.713	rs691807	ENSG00000244218.3	RN7SL81P	3.27	0.00109	0.0466	0.11	0.1	White matter hyperintensity burden;	chr7:129436362	chr7:128761338~128761598:+
BRCA	cis	rs4761470	0.524	rs73218261	ENSG00000213250.5	RBMS2P1	-3.27	0.00109	0.0466	-0.17	-0.1	Estradiol plasma levels (breast cancer);	chr12:94416593	chr12:94423744~94424969:-
BRCA	cis	rs8105895	1	rs11882234	ENSG00000269345.1	VN1R85P	3.27	0.00109	0.0466	0.15	0.1	Body mass index (change over time);	chr19:21962925	chr19:22174766~22175191:-
BRCA	cis	rs6772849	0.93	rs7639400	ENSG00000207088.1	SNORA7B	-3.27	0.00109	0.0466	-0.13	-0.1	Monocyte percentage of white cells;Monocyte count;	chr3:128604513	chr3:129397210~129397348:-
BRCA	cis	rs2692947	0.673	rs1168965	ENSG00000168992.4	OR7E102P	-3.27	0.00109	0.0466	-0.14	-0.1	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96122160	chr2:95546531~95547545:+
BRCA	cis	rs654950	0.807	rs941970	ENSG00000230881.1	RP11-486B10.3	3.27	0.00109	0.0466	0.1	0.1	Airway imaging phenotypes;	chr1:41525196	chr1:41535443~41535868:+
BRCA	cis	rs2708977	0.637	rs675239	ENSG00000271569.1	IGKV1OR2-6	-3.27	0.00109	0.0466	-0.07	-0.1	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96410819	chr2:97355059~97355335:+
BRCA	cis	rs4787491	0.729	rs8043883	ENSG00000275371.1	RP11-455F5.6	-3.27	0.00109	0.0466	-0.1	-0.1	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30033260	chr16:30110895~30111955:+
BRCA	cis	rs13401620	0.555	rs1437421	ENSG00000234065.2	MTND4P26	-3.27	0.00109	0.0466	-0.11	-0.1	Breast size;	chr2:120218255	chr2:120213631~120214989:+
BRCA	cis	rs2562456	0.834	rs2173727	ENSG00000268555.1	RP11-678G14.3	-3.27	0.00109	0.0466	-0.13	-0.1	Pain;	chr19:21491155	chr19:21570822~21587322:-
BRCA	cis	rs7188697	0.775	rs8056620	ENSG00000276259.1	RP11-481J2.4	3.27	0.00109	0.0466	0.12	0.1	QT interval;	chr16:58570483	chr16:58522970~58523842:+
BRCA	cis	rs7594648	0.847	rs2048932	ENSG00000226383.4	AC093375.1	-3.27	0.00109	0.0466	-0.15	-0.1	Age-related hearing impairment;	chr2:155652077	chr2:156011617~156024613:-
BRCA	cis	rs2811415	0.597	rs11719889	ENSG00000242551.2	POU5F1P6	3.27	0.00109	0.0466	0.14	0.1	Lung function (FEV1/FVC);	chr3:128086937	chr3:128674735~128677005:-
BRCA	cis	rs801193	0.66	rs10950049	ENSG00000271064.1	RP11-792A8.3	-3.27	0.00109	0.0466	-0.12	-0.1	Aortic root size;	chr7:66765873	chr7:66748838~66749077:-
BRCA	cis	rs10246939	0.579	rs58093678	ENSG00000270923.1	TAS2R6P	-3.27	0.00109	0.0466	-0.11	-0.1	Bitter taste perception;	chr7:141856719	chr7:141787815~141788640:+
BRCA	cis	rs36051895	0.623	rs1555476	ENSG00000237711.1	RP11-39K24.13	-3.27	0.00109	0.0466	-0.13	-0.1	Pediatric autoimmune diseases;	chr9:5233054	chr9:5100236~5101009:+
BRCA	cis	rs7085104	0.66	rs7902804	ENSG00000213277.3	MARCKSL1P1	3.27	0.00109	0.0466	0.11	0.1	Immature fraction of reticulocytes;Schizophrenia;	chr10:102825648	chr10:103175554~103176094:+
BRCA	cis	rs10129255	1	rs4612959	ENSG00000253763.1	IGHV3-6	3.27	0.00109	0.0466	0.09	0.1	Kawasaki disease;	chr14:106767055	chr14:106055549~106055998:-
BRCA	cis	rs703108	0.913	rs12773841	ENSG00000279623.1	RP11-399C16.3	-3.27	0.00109	0.0466	-0.15	-0.1	Monocyte percentage of white cells;	chr10:22132692	chr10:21865335~21865921:-
BRCA	cis	rs7651446	0.85	rs344008	ENSG00000240875.4	LINC00886	3.27	0.00109	0.0466	0.18	0.1	Ovarian cancer;Epithelial ovarian cancer;	chr3:156688610	chr3:156747346~156817062:-
BRCA	cis	rs11098499	1	rs6849889	ENSG00000225892.3	RP11-384K6.2	3.27	0.00109	0.0466	0.1	0.1	Corneal astigmatism;	chr4:119265193	chr4:118632274~118634759:+
BRCA	cis	rs17192198	0.571	rs10777191	ENSG00000270344.2	RP11-734K2.4	3.27	0.00109	0.0466	0.1	0.1	Diastolic blood pressure;	chr12:89741920	chr12:89525654~89548005:+
BRCA	cis	rs17192198	0.571	rs10858924	ENSG00000270344.2	RP11-734K2.4	3.27	0.00109	0.0466	0.1	0.1	Diastolic blood pressure;	chr12:89742148	chr12:89525654~89548005:+
BRCA	cis	rs11764932	0.79	rs56217404	ENSG00000229108.1	MEOX2-AS1	-3.27	0.00109	0.0466	-0.11	-0.1	Kidney function decline traits;	chr7:15704498	chr7:15688378~15695491:+
BRCA	cis	rs1129187	0.934	rs9471974	ENSG00000261068.2	RP11-7K24.3	3.27	0.00109	0.0466	0.13	0.1	Alzheimer's disease in APOE e4+ carriers;	chr6:42951246	chr6:42092233~42094259:-
BRCA	cis	rs6866721	0.634	rs1672493	ENSG00000249167.1	CTB-118N6.2	3.27	0.00109	0.0466	0.12	0.1	Body mass index;	chr5:116886983	chr5:116574482~116591398:+
BRCA	cis	rs6866721	0.634	rs1643884	ENSG00000249167.1	CTB-118N6.2	3.27	0.00109	0.0466	0.12	0.1	Body mass index;	chr5:116887051	chr5:116574482~116591398:+
BRCA	cis	rs6866721	0.634	rs1643885	ENSG00000249167.1	CTB-118N6.2	3.27	0.00109	0.0466	0.12	0.1	Body mass index;	chr5:116887078	chr5:116574482~116591398:+
BRCA	cis	rs7487075	0.619	rs7486532	ENSG00000257261.4	RP11-96H19.1	3.27	0.00109	0.0466	0.12	0.1	Itch intensity from mosquito bite;	chr12:46449472	chr12:46383679~46876159:+
BRCA	cis	rs4921164	0.891	rs13184662	ENSG00000245812.2	RP11-175K6.1	-3.27	0.00109	0.0466	-0.13	-0.1	Gut microbiome composition (winter);	chr5:159108033	chr5:159100483~159117478:+
BRCA	cis	rs4713118	0.662	rs149969	ENSG00000226314.6	ZNF192P1	-3.27	0.00109	0.0466	-0.15	-0.1	Parkinson's disease;	chr6:28009959	chr6:28161781~28169594:+
BRCA	cis	rs7048146	0.531	rs12554939	ENSG00000213539.4	YBX1P6	3.27	0.00109	0.0466	0.13	0.1	Vascular brain injury;	chr9:109529001	chr9:109532830~109534332:-
BRCA	cis	rs2562456	0.793	rs3853837	ENSG00000268705.1	BNIP3P26	3.27	0.00109	0.0466	0.12	0.1	Pain;	chr19:21419172	chr19:21521343~21521896:-
BRCA	cis	rs2562456	0.793	rs3853838	ENSG00000268705.1	BNIP3P26	3.27	0.00109	0.0466	0.12	0.1	Pain;	chr19:21419192	chr19:21521343~21521896:-
BRCA	cis	rs2562456	0.833	rs62110426	ENSG00000268705.1	BNIP3P26	3.27	0.00109	0.0466	0.12	0.1	Pain;	chr19:21420124	chr19:21521343~21521896:-
BRCA	cis	rs950893	0.557	rs2942194	ENSG00000253200.1	RP11-582J16.5	3.27	0.0011	0.0466	0.1	0.1	Mean corpuscular hemoglobin;	chr8:23566156	chr8:22613908~22616657:-
BRCA	cis	rs904092	0.72	rs1229970	ENSG00000246090.5	RP11-696N14.1	-3.27	0.0011	0.0466	-0.12	-0.1	Alcohol dependence;	chr4:99283223	chr4:99088857~99301356:+
BRCA	cis	rs35520189	0.845	rs34899562	ENSG00000231747.1	AC079922.2	-3.27	0.0011	0.0466	-0.11	-0.1	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:112883895	chr2:112621809~112622167:-
BRCA	cis	rs35520189	0.845	rs13021862	ENSG00000231747.1	AC079922.2	-3.27	0.0011	0.0466	-0.11	-0.1	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:112884367	chr2:112621809~112622167:-
BRCA	cis	rs853679	0.542	rs6934769	ENSG00000272009.1	RP1-313I6.12	-3.27	0.0011	0.0466	-0.15	-0.1	Depression;	chr6:28123153	chr6:28078792~28081130:-
BRCA	cis	rs853679	0.517	rs17711801	ENSG00000272009.1	RP1-313I6.12	-3.27	0.0011	0.0466	-0.15	-0.1	Depression;	chr6:28124529	chr6:28078792~28081130:-
BRCA	cis	rs4713118	0.527	rs9461433	ENSG00000272009.1	RP1-313I6.12	-3.27	0.0011	0.0466	-0.15	-0.1	Parkinson's disease;	chr6:28127394	chr6:28078792~28081130:-
BRCA	cis	rs853679	0.517	rs9468292	ENSG00000272009.1	RP1-313I6.12	-3.27	0.0011	0.0466	-0.15	-0.1	Depression;	chr6:28127577	chr6:28078792~28081130:-
BRCA	cis	rs3796619	0.503	rs13147452	ENSG00000227189.2	AC092535.3	3.27	0.0011	0.0466	0.13	0.1	Recombination rate (males);	chr4:1084336	chr4:1151372~1153701:+
BRCA	cis	rs10876993	0.89	rs2619441	ENSG00000269903.1	RP11-571M6.18	3.27	0.0011	0.0466	0.13	0.1	Celiac disease or Rheumatoid arthritis;	chr12:57689232	chr12:57814494~57814926:+
BRCA	cis	rs10771431	0.817	rs10843149	ENSG00000256673.1	RP11-599J14.2	3.27	0.0011	0.0466	0.11	0.1	Breast size;	chr12:9209471	chr12:9398355~9414851:-
BRCA	cis	rs2555155	0.935	rs2723645	ENSG00000254595.1	CTD-2010I16.1	3.27	0.0011	0.0466	0.11	0.1	DNA methylation (variation);	chr11:6498133	chr11:6488186~6489377:-
BRCA	cis	rs9437689	1	rs4950058	ENSG00000235501.4	RP4-639F20.1	3.27	0.0011	0.0466	0.13	0.1	Phospholipid levels (plasma);	chr1:95082595	chr1:94927566~94963270:+
BRCA	cis	rs11587682	0.714	rs35699789	ENSG00000228126.1	FALEC	3.27	0.0011	0.0466	0.13	0.1	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr1:150469624	chr1:150515757~150518032:+
BRCA	cis	rs56046484	0.871	rs62021230	ENSG00000230373.7	GOLGA6L5P	3.27	0.0011	0.0466	0.16	0.1	Testicular germ cell tumor;	chr15:85040721	chr15:84507885~84516814:-
BRCA	cis	rs7795541	0.739	rs272696	ENSG00000230658.1	KLHL7-AS1	3.27	0.0011	0.0466	0.13	0.1	Morning vs. evening chronotype;	chr7:24052659	chr7:23101228~23105703:-
BRCA	cis	rs875971	0.522	rs1917563	ENSG00000232559.3	GS1-124K5.12	-3.27	0.0011	0.0466	-0.12	-0.1	Aortic root size;	chr7:65950660	chr7:66554588~66576923:-
BRCA	cis	rs17406451	0.759	rs11124936	ENSG00000234936.1	AC010883.5	3.27	0.0011	0.0466	0.1	0.1	Mitochondrial DNA levels;	chr2:43425861	chr2:43229573~43233394:+
BRCA	cis	rs863345	0.604	rs2054993	ENSG00000176320.2	RP11-404O13.5	-3.27	0.0011	0.0466	-0.1	-0.1	Pneumococcal bacteremia;	chr1:158536178	chr1:158197922~158203877:-
BRCA	cis	rs863345	0.604	rs2054992	ENSG00000176320.2	RP11-404O13.5	-3.27	0.0011	0.0466	-0.1	-0.1	Pneumococcal bacteremia;	chr1:158536225	chr1:158197922~158203877:-
BRCA	cis	rs2625529	0.59	rs2856929	ENSG00000260037.4	CTD-2524L6.3	-3.27	0.0011	0.0466	-0.14	-0.1	Red blood cell count;	chr15:72204421	chr15:71818396~71823384:+
BRCA	cis	rs881375	0.933	rs1548784	ENSG00000238181.2	AHCYP2	-3.27	0.0011	0.0466	-0.13	-0.1	Rheumatoid arthritis;	chr9:120923002	chr9:120720673~120721972:+
BRCA	cis	rs9400317	0.901	rs78941670	ENSG00000260273.1	RP11-425D10.10	-3.27	0.0011	0.0466	-0.19	-0.1	Response to hepatitis C treatment;	chr6:109634646	chr6:109382795~109383666:+
BRCA	cis	rs12701220	0.696	rs12112029	ENSG00000224079.1	AC091729.7	3.27	0.0011	0.0467	0.15	0.1	Bronchopulmonary dysplasia;	chr7:1098253	chr7:1074450~1078036:+
BRCA	cis	rs10129255	0.5	rs59939897	ENSG00000211976.2	IGHV3-73	-3.27	0.0011	0.0467	-0.08	-0.1	Kawasaki disease;	chr14:106783414	chr14:106802694~106803233:-
BRCA	cis	rs930395	0.514	rs4391175	ENSG00000248779.1	RP11-53O19.2	-3.27	0.0011	0.0467	-0.1	-0.1	Breast cancer;	chr5:44889954	chr5:44752949~44765744:+
BRCA	cis	rs7656342	0.599	rs6812007	ENSG00000250342.1	SNRPCP16	-3.27	0.0011	0.0467	-0.11	-0.1	Gut microbiota (bacterial taxa);	chr4:9848596	chr4:9051842~9052051:-
BRCA	cis	rs2694917	0.632	rs2638315	ENSG00000257576.1	RP11-153M3.1	3.27	0.0011	0.0467	0.16	0.1	Blood metabolite ratios;	chr12:56471272	chr12:56511002~56512703:+
BRCA	cis	rs6433921	0.964	rs1551033	ENSG00000260742.1	RP11-366L5.1	-3.27	0.0011	0.0467	-0.12	-0.1	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;	chr2:181504449	chr2:181887851~181891663:-
BRCA	cis	rs7618501	0.933	rs1128535	ENSG00000228008.1	CTD-2330K9.3	3.27	0.0011	0.0467	0.1	0.1	Intelligence (multi-trait analysis);	chr3:49828959	chr3:49903845~49916937:+
BRCA	cis	rs7618501	1	rs695238	ENSG00000228008.1	CTD-2330K9.3	3.27	0.0011	0.0467	0.1	0.1	Intelligence (multi-trait analysis);	chr3:49831725	chr3:49903845~49916937:+
BRCA	cis	rs881375	0.933	rs4837804	ENSG00000238181.2	AHCYP2	-3.27	0.0011	0.0467	-0.12	-0.1	Rheumatoid arthritis;	chr9:120943026	chr9:120720673~120721972:+
BRCA	cis	rs881375	0.967	rs7039505	ENSG00000238181.2	AHCYP2	-3.27	0.0011	0.0467	-0.12	-0.1	Rheumatoid arthritis;	chr9:120943667	chr9:120720673~120721972:+
BRCA	cis	rs711830	1	rs2249131	ENSG00000272729.1	RP11-387A1.5	-3.27	0.0011	0.0467	-0.13	-0.1	Serous invasive ovarian cancer;Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;High-grade serous ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;	chr2:176167367	chr2:176164164~176165716:-
BRCA	cis	rs11227306	0.934	rs2303384	ENSG00000254510.1	RP11-867G23.10	-3.27	0.0011	0.0467	-0.11	-0.1	DNA methylation (variation);	chr11:65872733	chr11:66409158~66417137:+
BRCA	cis	rs9309473	1	rs10187192	ENSG00000230002.2	ALMS1-IT1	3.27	0.0011	0.0467	0.13	0.1	Metabolite levels;	chr2:73486373	chr2:73456764~73459484:+
BRCA	cis	rs4835473	0.932	rs34886773	ENSG00000246448.2	RP13-578N3.3	-3.27	0.0011	0.0467	-0.11	-0.1	Immature fraction of reticulocytes;	chr4:143764678	chr4:143700257~143865072:+
BRCA	cis	rs2802372	0.616	rs1250545	ENSG00000280355.1	RP11-119F19.5	3.27	0.0011	0.0467	0.1	0.1	Granulocyte count;	chr10:79273060	chr10:79681973~79684094:-
BRCA	cis	rs72766638	0.806	rs56303154	ENSG00000235106.7	LINC00094	3.27	0.0011	0.0467	0.13	0.1	Mosquito bite size;	chr9:134071254	chr9:134025439~134034666:+
BRCA	cis	rs4819052	1	rs2297284	ENSG00000215447.6	BX322557.10	-3.27	0.0011	0.0467	-0.11	-0.1	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45285430	chr21:45288052~45291738:+
BRCA	cis	rs1005277	0.505	rs10827836	ENSG00000273019.1	RP11-508N22.13	3.27	0.0011	0.0467	0.12	0.1	Extrinsic epigenetic age acceleration;	chr10:37926513	chr10:38149968~38150293:+
BRCA	cis	rs7188697	0.882	rs9921370	ENSG00000276259.1	RP11-481J2.4	3.27	0.0011	0.0467	0.12	0.1	QT interval;	chr16:58578031	chr16:58522970~58523842:+
BRCA	cis	rs6496044	0.611	rs8026938	ENSG00000259630.2	CTD-2262B20.1	3.27	0.0011	0.0467	0.12	0.1	Interstitial lung disease;	chr15:85525887	chr15:85415228~85415633:+
BRCA	cis	rs7267979	0.866	rs6138609	ENSG00000274973.1	RP13-401N8.7	-3.27	0.0011	0.0467	-0.11	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25590349	chr20:25845497~25845862:+
BRCA	cis	rs7023329	0.846	rs7023680	ENSG00000265194.1	RP11-70L8.4	-3.27	0.0011	0.0467	-0.11	-0.1	Melanoma;	chr9:21816574	chr9:21858910~21861926:-
BRCA	cis	rs7023329	0.776	rs7023474	ENSG00000265194.1	RP11-70L8.4	-3.27	0.0011	0.0467	-0.11	-0.1	Melanoma;	chr9:21816647	chr9:21858910~21861926:-
BRCA	cis	rs4848143	0.64	rs4848675	ENSG00000236859.5	NIFK-AS1	-3.27	0.0011	0.0467	-0.11	-0.1	Capecitabine sensitivity;	chr2:121040073	chr2:121649650~121728208:+
BRCA	cis	rs4848143	0.64	rs6718048	ENSG00000236859.5	NIFK-AS1	-3.27	0.0011	0.0467	-0.11	-0.1	Capecitabine sensitivity;	chr2:121041082	chr2:121649650~121728208:+
BRCA	cis	rs4848143	0.64	rs6731464	ENSG00000236859.5	NIFK-AS1	-3.27	0.0011	0.0467	-0.11	-0.1	Capecitabine sensitivity;	chr2:121041116	chr2:121649650~121728208:+
BRCA	cis	rs4848143	0.64	rs13431377	ENSG00000236859.5	NIFK-AS1	-3.27	0.0011	0.0467	-0.11	-0.1	Capecitabine sensitivity;	chr2:121041166	chr2:121649650~121728208:+
BRCA	cis	rs58950470	0.887	rs1787034	ENSG00000255557.1	RP11-770G2.2	-3.27	0.0011	0.0467	-0.12	-0.1	Schizophrenia;	chr11:65615093	chr11:65745729~65771585:+
BRCA	cis	rs4130344	0.874	rs4690916	ENSG00000271817.2	U3	3.27	0.0011	0.0467	0.1	0.1	Intelligence (multi-trait analysis);	chr4:158919325	chr4:158700691~158700909:+
BRCA	cis	rs6120849	0.901	rs6088735	ENSG00000202150.1	RNU6-407P	3.27	0.0011	0.0467	0.14	0.1	Protein C levels;	chr20:35157873	chr20:35030317~35030420:-
BRCA	cis	rs6120849	0.901	rs6088737	ENSG00000202150.1	RNU6-407P	3.27	0.0011	0.0467	0.14	0.1	Protein C levels;	chr20:35158135	chr20:35030317~35030420:-
BRCA	cis	rs7217780	0.684	rs10852830	ENSG00000234324.1	RPL9P2	3.27	0.0011	0.0467	0.11	0.1	Preterm birth (maternal effect);	chr17:15278209	chr17:15443639~15444191:+
BRCA	cis	rs853679	0.882	rs9468287	ENSG00000204709.4	LINC01556	3.27	0.0011	0.0467	0.21	0.1	Depression;	chr6:28111963	chr6:28943877~28944537:+
BRCA	cis	rs10129255	0.536	rs8004835	ENSG00000211964.3	IGHV3-48	-3.27	0.0011	0.0467	-0.07	-0.1	Kawasaki disease;	chr14:106686361	chr14:106537810~106538344:-
BRCA	cis	rs11098499	0.691	rs12510133	ENSG00000249244.1	RP11-548H18.2	3.27	0.0011	0.0467	0.11	0.1	Corneal astigmatism;	chr4:119350189	chr4:119391831~119395335:-
BRCA	cis	rs11098499	0.754	rs12506487	ENSG00000249244.1	RP11-548H18.2	3.27	0.0011	0.0467	0.11	0.1	Corneal astigmatism;	chr4:119350206	chr4:119391831~119395335:-
BRCA	cis	rs17473412	0.677	rs6887967	ENSG00000263432.2	RN7SL689P	-3.27	0.0011	0.0467	-0.14	-0.1	Total body bone mineral density;	chr5:123548720	chr5:123022487~123022783:-
BRCA	cis	rs12477438	0.798	rs2084987	ENSG00000226791.5	AC109826.1	3.27	0.0011	0.0467	0.13	0.1	Chronic sinus infection;	chr2:98971422	chr2:98761938~98772920:-
BRCA	cis	rs12144610	1	rs12134163	ENSG00000236804.1	RPS3AP12	3.27	0.0011	0.0467	0.16	0.1	Lobe attachment (rater-scored or self-reported);	chr1:118924370	chr1:119126539~119127291:-
BRCA	cis	rs7165170	0.58	rs7176303	ENSG00000259685.2	CTD-2315E11.1	3.27	0.0011	0.0467	0.14	0.1	Crohn's disease;Inflammatory bowel disease;	chr15:90606879	chr15:90102649~90133445:+
BRCA	cis	rs7546	0.505	rs760118	ENSG00000267077.1	RP11-127I20.5	-3.27	0.0011	0.0467	-0.1	-0.1	Cancer;	chr16:4890993	chr16:4795265~4796532:-
BRCA	cis	rs890448	0.76	rs293215	ENSG00000254531.1	FLJ20021	3.27	0.0011	0.0467	0.12	0.1	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101392717	chr4:101347780~101348883:+
BRCA	cis	rs71520386	0.632	rs12535331	ENSG00000179428.2	AC073072.5	-3.27	0.0011	0.0467	-0.12	-0.1	Fibrinogen levels;	chr7:22838485	chr7:22725395~22727620:-
BRCA	cis	rs1144333	1	rs1586936	ENSG00000181227.3	RP4-682C21.2	-3.27	0.0011	0.0467	-0.14	-0.1	Attention function in attention deficit hyperactive disorder;	chr1:75901192	chr1:75743423~75744776:-
BRCA	cis	rs926326	0.643	rs1980448	ENSG00000272462.2	U91328.19	3.27	0.0011	0.0467	0.13	0.1	Platelet count;	chr6:25626411	chr6:25992662~26001775:+
BRCA	cis	rs2692947	0.8	rs61409777	ENSG00000237510.6	AC008268.2	3.27	0.0011	0.0467	0.14	0.1	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95915625	chr2:95789654~95800166:+
BRCA	cis	rs8028182	0.636	rs11637068	ENSG00000260274.1	RP11-817O13.8	3.27	0.0011	0.0467	0.11	0.1	Sudden cardiac arrest;	chr15:75450661	chr15:75368155~75369584:+
BRCA	cis	rs1119582	1	rs456317	ENSG00000279118.1	RP11-517I3.2	-3.27	0.0011	0.0467	-0.12	-0.1	Select biomarker traits;	chr5:125941286	chr5:126496279~126498604:+
BRCA	cis	rs6964587	0.61	rs6950682	ENSG00000188693.7	CYP51A1-AS1	-3.27	0.0011	0.0467	-0.11	-0.1	Breast cancer;	chr7:91834904	chr7:92134604~92180725:+
BRCA	cis	rs7808935	0.958	rs17156041	ENSG00000234336.5	JAZF1-AS1	-3.27	0.0011	0.0467	-0.16	-0.1	Prostate cancer;	chr7:27936126	chr7:28180322~28243917:+
BRCA	cis	rs12893668	0.645	rs12889403	ENSG00000269910.1	RP11-73M18.10	3.27	0.0011	0.0467	0.11	0.1	Reticulocyte count;	chr14:103568409	chr14:103694516~103695050:-
BRCA	cis	rs12893668	0.703	rs12894729	ENSG00000269910.1	RP11-73M18.10	3.27	0.0011	0.0467	0.11	0.1	Reticulocyte count;	chr14:103568955	chr14:103694516~103695050:-
BRCA	cis	rs7636839	0.522	rs1920248	ENSG00000236182.1	RP11-297K7.1	-3.27	0.0011	0.0467	-0.12	-0.1	EGFR mutation-positive lung adenocarcinoma;	chr3:189656202	chr3:188989382~188990135:-
BRCA	cis	rs1200821	0.535	rs1208789	ENSG00000236313.1	VN1R53P	-3.27	0.0011	0.0467	-0.09	-0.1	Hemostatic factors and hematological phenotypes;	chr10:37433544	chr10:37348616~37349572:+
BRCA	cis	rs10905065	0.648	rs4237365	ENSG00000215267.7	AKR1C7P	-3.27	0.0011	0.0467	-0.13	-0.1	Menopause (age at onset);	chr10:5779521	chr10:5275173~5288470:-
BRCA	cis	rs12612619	0.689	rs1124649	ENSG00000272148.1	RP11-195B17.1	-3.27	0.0011	0.0467	-0.12	-0.1	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr2:27037601	chr2:27062428~27062907:-
BRCA	cis	rs1436904	0.901	rs1786636	ENSG00000260372.5	AQP4-AS1	-3.27	0.0011	0.0467	-0.11	-0.1	Breast cancer;	chr18:27011391	chr18:26655742~27190698:+
BRCA	cis	rs875971	0.964	rs60193905	ENSG00000272831.1	RP11-792A8.4	3.27	0.0011	0.0467	0.09	0.1	Aortic root size;	chr7:66506273	chr7:66739829~66740385:-
BRCA	cis	rs7927592	0.913	rs12285993	ENSG00000254610.1	RP5-903G2.2	-3.27	0.0011	0.0467	-0.14	-0.1	Total body bone mineral density;	chr11:68535070	chr11:67934563~67939774:-
BRCA	cis	rs34467563	0.872	rs16894512	ENSG00000253105.4	KB-1448A5.1	3.27	0.0011	0.0467	0.13	0.1	Lobe attachment (rater-scored or self-reported);	chr8:96353508	chr8:96371865~96387438:-
BRCA	cis	rs1730008	0.865	rs827806	ENSG00000279311.1	RP11-170K4.2	-3.27	0.0011	0.0467	-0.11	-0.1	Lobe attachment (rater-scored or self-reported);	chr3:158222606	chr3:158869898~158871821:+
BRCA	cis	rs7975161	0.63	rs6539131	ENSG00000257681.1	RP11-341G23.4	-3.27	0.0011	0.0467	-0.21	-0.1	Toenail selenium levels;	chr12:104250919	chr12:103746315~103768858:-
BRCA	cis	rs13108904	0.557	rs1680030	ENSG00000273179.1	RP11-20I20.4	-3.27	0.0011	0.0467	-0.11	-0.1	Obesity-related traits;	chr4:1251712	chr4:1167778~1168174:+
BRCA	cis	rs78487399	0.808	rs6757251	ENSG00000234936.1	AC010883.5	3.27	0.0011	0.0467	0.15	0.1	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43507708	chr2:43229573~43233394:+
BRCA	cis	rs736408	0.812	rs1075653	ENSG00000239557.1	RP11-168J18.6	3.27	0.0011	0.0468	0.13	0.1	Bipolar disorder;	chr3:52791512	chr3:52373652~52374882:+
BRCA	cis	rs72772090	0.539	rs72775807	ENSG00000272109.1	CTD-2260A17.3	3.27	0.0011	0.0468	0.2	0.1	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96844058	chr5:96804353~96806105:+
BRCA	cis	rs2150410	0.915	rs6517540	ENSG00000238141.2	BRWD1-AS1	-3.27	0.0011	0.0468	-0.22	-0.1	Temperament (bipolar disorder);	chr21:39307877	chr21:39315707~39323218:+
BRCA	cis	rs718433	0.616	rs2222916	ENSG00000211805.1	TRAV24	-3.27	0.0011	0.0468	-0.08	-0.1	Intraocular pressure;	chr14:21744319	chr14:22105343~22105846:+
BRCA	cis	rs613391	0.671	rs2784854	ENSG00000279670.1	RP11-70L8.5	-3.27	0.0011	0.0468	-0.13	-0.1	Quantitative traits;	chr9:22713834	chr9:21892188~21893857:+
BRCA	cis	rs7893279	0.505	rs12766105	ENSG00000240291.1	RP11-499P20.2	-3.27	0.0011	0.0468	-0.12	-0.1	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr10:18584296	chr10:18513115~18545651:-
BRCA	cis	rs10991814	0.557	rs76379507	ENSG00000235641.4	LINC00484	3.27	0.0011	0.0468	0.15	0.1	Neutrophil percentage of granulocytes;	chr9:91232926	chr9:91159573~91165658:+
BRCA	cis	rs3816183	0.626	rs4411758	ENSG00000226491.1	FTOP1	-3.27	0.0011	0.0468	-0.13	-0.1	Hypospadias;	chr2:42698025	chr2:42797225~42798712:-
BRCA	cis	rs2411233	1	rs9920185	ENSG00000259278.1	RP11-62C7.2	3.27	0.0011	0.0468	0.12	0.1	Platelet count;	chr15:38981374	chr15:39019233~39024918:+
BRCA	cis	rs7097397	0.661	rs7904251	ENSG00000265018.5	CTGLF12P	-3.27	0.0011	0.0468	-0.13	-0.1	Systemic lupus erythematosus;	chr10:48768290	chr10:48009873~48031640:-
BRCA	cis	rs4631830	0.9	rs4630241	ENSG00000204177.9	BMS1P1	-3.27	0.0011	0.0468	-0.1	-0.1	Prostate-specific antigen levels;	chr10:46063071	chr10:46786674~46811989:+
BRCA	cis	rs2880765	0.835	rs4360874	ENSG00000259630.2	CTD-2262B20.1	-3.27	0.0011	0.0468	-0.12	-0.1	Coronary artery disease;	chr15:85497589	chr15:85415228~85415633:+
BRCA	cis	rs7412746	0.611	rs12410869	ENSG00000224800.1	RP11-235D19.2	-3.27	0.0011	0.0468	-0.13	-0.1	Melanoma;	chr1:150883677	chr1:150881236~150881683:-
BRCA	cis	rs7412746	0.611	rs36008098	ENSG00000224800.1	RP11-235D19.2	-3.27	0.0011	0.0468	-0.13	-0.1	Melanoma;	chr1:150884330	chr1:150881236~150881683:-
BRCA	cis	rs10129255	0.5	rs8022547	ENSG00000211976.2	IGHV3-73	-3.27	0.0011	0.0468	-0.08	-0.1	Kawasaki disease;	chr14:106781985	chr14:106802694~106803233:-
BRCA	cis	rs4243971	0.516	rs1467479	ENSG00000275576.1	RP5-836N17.4	-3.27	0.0011	0.0468	-0.11	-0.1	Inflammatory bowel disease;Crohn's disease;	chr20:32442766	chr20:32116171~32116629:+
BRCA	cis	rs11239930	0.934	rs10900313	ENSG00000244371.2	PFN1P8	-3.27	0.0011	0.0468	-0.11	-0.1	AIDS progression;	chr1:147089200	chr1:146957117~146957659:-
BRCA	cis	rs875971	1	rs12533997	ENSG00000273448.1	RP11-166O4.6	3.27	0.0011	0.0468	0.09	0.1	Aortic root size;	chr7:66500390	chr7:67333047~67334383:+
BRCA	cis	rs7937682	0.883	rs566647	ENSG00000230911.1	PPIHP1	3.27	0.0011	0.0468	0.15	0.1	Primary sclerosing cholangitis;	chr11:111595883	chr11:112029858~112030367:-
BRCA	cis	rs1003719	0.641	rs13046844	ENSG00000242553.1	AP001432.14	3.27	0.0011	0.0468	0.11	0.1	Eye color traits;	chr21:37145303	chr21:37221419~37237744:+
BRCA	cis	rs7246657	0.943	rs13343502	ENSG00000267470.4	ZNF571-AS1	3.27	0.0011	0.0468	0.14	0.1	Coronary artery calcification;	chr19:37471390	chr19:37548914~37587348:+
BRCA	cis	rs17209837	1	rs17209662	ENSG00000224046.1	AC005076.5	3.27	0.0011	0.0468	0.15	0.1	Gallbladder cancer;	chr7:87492652	chr7:87151423~87152420:-
BRCA	cis	rs17209837	1	rs17275514	ENSG00000224046.1	AC005076.5	3.27	0.0011	0.0468	0.15	0.1	Gallbladder cancer;	chr7:87492714	chr7:87151423~87152420:-
BRCA	cis	rs11866328	0.525	rs1362319	ENSG00000260350.1	RP11-152P23.2	3.27	0.0011	0.0468	0.13	0.1	Hepatitis B;	chr16:9776229	chr16:8847650~8848724:-
BRCA	cis	rs7162943	0.887	rs12438271	ENSG00000261407.1	RP11-326A19.3	-3.27	0.0011	0.0468	-0.12	-0.1	Mean platelet volume;	chr15:89069996	chr15:89087078~89088267:-
BRCA	cis	rs6545883	0.868	rs6748003	ENSG00000273302.1	RP11-493E12.2	3.27	0.0011	0.0468	0.09	0.1	Tuberculosis;	chr2:61579565	chr2:61199979~61200769:+
BRCA	cis	rs10484434	0.818	rs6935470	ENSG00000216331.1	HIST1H1PS1	3.27	0.0011	0.0468	0.17	0.1	HIV-1 viral setpoint;	chr6:25990590	chr6:26195566~26195771:+
BRCA	cis	rs10484434	0.818	rs2051538	ENSG00000216331.1	HIST1H1PS1	3.27	0.0011	0.0468	0.17	0.1	HIV-1 viral setpoint;	chr6:25991392	chr6:26195566~26195771:+
BRCA	cis	rs6968419	0.537	rs9641558	ENSG00000279086.1	RP11-667F14.1	-3.27	0.0011	0.0468	-0.1	-0.1	Intraocular pressure;	chr7:116129257	chr7:116209234~116211511:-
BRCA	cis	rs76798021	0.935	rs11719110	ENSG00000271976.1	RP11-884K10.7	3.27	0.0011	0.0468	0.14	0.1	Lung function (FEV1/FVC);	chr3:53648148	chr3:53858994~53861576:-
BRCA	cis	rs3020264	0.579	rs2454517	ENSG00000249898.6	CTD-2541M15.1	-3.27	0.0011	0.0468	-0.14	-0.1	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 24 weeks);	chr8:6616237	chr8:6618475~6708209:-
BRCA	cis	rs7412746	0.658	rs6669855	ENSG00000224800.1	RP11-235D19.2	-3.27	0.0011	0.0468	-0.13	-0.1	Melanoma;	chr1:150888753	chr1:150881236~150881683:-
BRCA	cis	rs875971	0.862	rs801194	ENSG00000223473.2	GS1-124K5.3	-3.27	0.0011	0.0468	-0.08	-0.1	Aortic root size;	chr7:66563508	chr7:66491049~66493566:-
BRCA	cis	rs10043228	1	rs10051240	ENSG00000250015.1	CTC-339F2.2	3.27	0.0011	0.0468	0.13	0.1	Asthma or chronic obstructive pulmonary disease;	chr5:116234234	chr5:116302354~116304134:-
BRCA	cis	rs10043228	1	rs12523347	ENSG00000250015.1	CTC-339F2.2	3.27	0.0011	0.0468	0.13	0.1	Asthma or chronic obstructive pulmonary disease;	chr5:116236698	chr5:116302354~116304134:-
BRCA	cis	rs459571	0.959	rs2520099	ENSG00000235106.7	LINC00094	3.27	0.0011	0.0468	0.1	0.1	Platelet distribution width;	chr9:134053017	chr9:134025439~134034666:+
BRCA	cis	rs16858210	0.874	rs10937153	ENSG00000234371.6	RPSAP31	-3.27	0.0011	0.0468	-0.13	-0.1	Menopause (age at onset);	chr3:183845137	chr3:183884924~183888449:+
BRCA	cis	rs7098100	0.564	rs2666754	ENSG00000231920.1	NEBL-AS1	3.27	0.0011	0.0468	0.11	0.1	Breast cancer;	chr10:21954143	chr10:21174014~21175048:+
BRCA	cis	rs875971	0.964	rs12668936	ENSG00000230189.5	GS1-124K5.2	3.27	0.0011	0.0468	0.08	0.1	Aortic root size;	chr7:66449417	chr7:66409143~66490059:-
BRCA	cis	rs11239930	1	rs11239930	ENSG00000244371.2	PFN1P8	-3.27	0.0011	0.0468	-0.11	-0.1	AIDS progression;	chr1:147089017	chr1:146957117~146957659:-
BRCA	cis	rs9650657	0.571	rs2409672	ENSG00000248896.2	CTD-2135J3.3	-3.27	0.0011	0.0468	-0.12	-0.1	Neuroticism;	chr8:10741270	chr8:10729314~10771392:+
BRCA	cis	rs9921338	0.632	rs80945	ENSG00000263080.1	RP11-485G7.5	3.27	0.0011	0.0468	0.16	0.1	Vein graft stenosis in coronary artery bypass grafting;	chr16:11249263	chr16:11341809~11345211:-
BRCA	cis	rs77741769	0.549	rs57697145	ENSG00000277423.1	RP11-173P15.9	-3.27	0.0011	0.0468	-0.12	-0.1	Mean corpuscular volume;	chr12:120895749	chr12:120703867~120704282:+
BRCA	cis	rs4725065	0.509	rs37970	ENSG00000234718.6	AC007161.5	-3.27	0.0011	0.0468	-0.12	-0.1	Intelligence (multi-trait analysis);	chr7:7967443	chr7:7738524~7742574:-
BRCA	cis	rs7649443	0.513	rs7641	ENSG00000243339.3	RN7SL738P	-3.27	0.0011	0.0468	-0.13	-0.1	Nonsyndromic cleft lip with cleft palate;	chr3:197043111	chr3:196399911~196400207:+
BRCA	cis	rs12760731	0.72	rs10913557	ENSG00000213057.5	C1orf220	3.27	0.0011	0.0468	0.14	0.1	Obesity-related traits;	chr1:178473055	chr1:178542752~178548889:+
BRCA	cis	rs6964587	0.626	rs10225241	ENSG00000188693.7	CYP51A1-AS1	3.27	0.0011	0.0468	0.11	0.1	Breast cancer;	chr7:91895626	chr7:92134604~92180725:+
BRCA	cis	rs9324022	0.929	rs1004574	ENSG00000271198.1	VDAC3P1	-3.27	0.0011	0.0468	-0.17	-0.1	Plateletcrit;	chr14:100711730	chr14:99964529~99965378:+
BRCA	cis	rs879500	0.653	rs4324211	ENSG00000266296.1	ARIH2P1	-3.27	0.0011	0.0468	-0.15	-0.1	Lung function (FVC);	chr18:28499393	chr18:28651732~28653208:+
BRCA	cis	rs2284219	0.565	rs2284217	ENSG00000226874.1	AC005154.8	-3.27	0.0011	0.0468	-0.12	-0.1	Type 2 diabetes;	chr7:30673992	chr7:30544053~30544431:+
BRCA	cis	rs6710503	0.547	rs62142311	ENSG00000224165.4	DNAJC27-AS1	3.27	0.0011	0.0468	0.13	0.1	Lung cancer in ever smokers;Breast cancer;	chr2:24641817	chr2:24971390~25039694:+
BRCA	cis	rs13256369	0.708	rs11249886	ENSG00000254153.1	CTA-398F10.2	3.27	0.0011	0.0468	0.14	0.1	Obesity-related traits;	chr8:8704511	chr8:8456909~8461337:-
BRCA	cis	rs7267979	0.527	rs6076369	ENSG00000274414.1	RP5-965G21.4	3.27	0.0011	0.0468	0.12	0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25596147	chr20:25239007~25245229:-
BRCA	cis	rs600231	0.719	rs7114809	ENSG00000254614.2	AP003068.23	3.27	0.0011	0.0468	0.13	0.1	Bone mineral density;	chr11:65483973	chr11:65177606~65181834:-
BRCA	cis	rs6088580	0.524	rs6088570	ENSG00000261582.1	RP4-614O4.11	3.27	0.0011	0.0468	0.1	0.1	Glomerular filtration rate (creatinine);	chr20:34680491	chr20:35267885~35280043:-
BRCA	cis	rs12500824	0.564	rs72657826	ENSG00000214062.5	RPL7P17	-3.27	0.0011	0.0468	-0.12	-0.1	Coronary artery disease;	chr4:76372421	chr4:77082403~77083126:-
BRCA	cis	rs343496	0.877	rs821164	ENSG00000254017.1	IGHEP2	-3.27	0.0011	0.0468	-0.14	-0.1	Asthma and hay fever;	chr9:6090989	chr9:5113549~5114804:+
BRCA	cis	rs7020830	0.898	rs13290794	ENSG00000260100.1	RP11-220I1.5	-3.27	0.0011	0.0468	-0.12	-0.1	Schizophrenia;	chr9:37183631	chr9:37078813~37079776:-
BRCA	cis	rs10129255	0.518	rs10136903	ENSG00000211976.2	IGHV3-73	-3.27	0.0011	0.0468	-0.08	-0.1	Kawasaki disease;	chr14:106778866	chr14:106802694~106803233:-
BRCA	cis	rs7989336	0.625	rs9513122	ENSG00000247400.3	DNAJC3-AS1	-3.27	0.0011	0.0468	-0.12	-0.1	Obesity;	chr13:96348280	chr13:95648733~95676925:-
BRCA	cis	rs4805834	0.719	rs111484921	ENSG00000201388.1	SNORA68	3.27	0.0011	0.0468	0.18	0.1	Creatinine levels;	chr19:32786742	chr19:32608337~32608469:-
BRCA	cis	rs77633900	0.614	rs280029	ENSG00000196274.5	Metazoa_SRP	3.27	0.0011	0.0468	0.15	0.1	Glioma;Non-glioblastoma glioma;	chr15:76738894	chr15:76230048~76230390:-
BRCA	cis	rs1387259	0.619	rs7134565	ENSG00000257763.1	OR5BK1P	-3.27	0.0011	0.0468	-0.1	-0.1	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48236241	chr12:48355792~48356614:-
BRCA	cis	rs2985684	0.74	rs2883438	ENSG00000278009.1	RP11-649E7.8	3.27	0.0011	0.0468	0.14	0.1	Carotid intima media thickness;	chr14:49577674	chr14:49601011~49601124:-
BRCA	cis	rs1005277	0.522	rs9417256	ENSG00000099251.13	HSD17B7P2	3.27	0.0011	0.0468	0.11	0.1	Extrinsic epigenetic age acceleration;	chr10:37688062	chr10:38356380~38378505:+
BRCA	cis	rs6921919	0.945	rs7765989	ENSG00000281706.1	LINC01012	3.27	0.0011	0.0468	0.16	0.1	Autism spectrum disorder or schizophrenia;	chr6:28432518	chr6:27694035~27710222:+
BRCA	cis	rs801193	0.569	rs2707824	ENSG00000106610.13	STAG3L4	-3.27	0.0011	0.0468	-0.13	-0.1	Aortic root size;	chr7:66724256	chr7:67302621~67321526:+
BRCA	cis	rs7173064	0.607	rs4290432	ENSG00000272888.4	LINC01578	3.27	0.0011	0.0468	0.11	0.1	White matter hyperintensity burden;	chr15:93691378	chr15:92882707~92899701:+
BRCA	cis	rs28374715	0.662	rs113913466	ENSG00000247556.5	OIP5-AS1	3.27	0.0011	0.0468	0.11	0.1	Ulcerative colitis;	chr15:41190902	chr15:41283990~41309737:+
BRCA	cis	rs875971	0.798	rs12698522	ENSG00000265600.1	AC006480.1	-3.27	0.0011	0.0468	-0.12	-0.1	Aortic root size;	chr7:66502354	chr7:67356680~67356779:+
BRCA	cis	rs875971	0.83	rs28714531	ENSG00000265600.1	AC006480.1	-3.27	0.0011	0.0468	-0.12	-0.1	Aortic root size;	chr7:66503250	chr7:67356680~67356779:+
BRCA	cis	rs875971	0.862	rs12698526	ENSG00000265600.1	AC006480.1	-3.27	0.0011	0.0468	-0.12	-0.1	Aortic root size;	chr7:66504118	chr7:67356680~67356779:+
BRCA	cis	rs2462686	1	rs2471553	ENSG00000229628.1	AC073115.7	-3.27	0.0011	0.0468	-0.12	-0.1	Major depressive disorder;	chr7:45938524	chr7:45990905~46000898:+
BRCA	cis	rs2002030	0.915	rs11775511	ENSG00000269899.1	RP11-589N15.2	-3.27	0.0011	0.0469	-0.2	-0.1	Cognitive performance;	chr8:11414570	chr8:11846154~11846391:-
BRCA	cis	rs897984	0.542	rs11865038	ENSG00000279196.1	RP11-1072A3.3	3.27	0.0011	0.0469	0.1	0.1	Dementia with Lewy bodies;	chr16:31083850	chr16:30984630~30988270:-
BRCA	cis	rs897984	0.542	rs11864806	ENSG00000279196.1	RP11-1072A3.3	3.27	0.0011	0.0469	0.1	0.1	Dementia with Lewy bodies;	chr16:31083883	chr16:30984630~30988270:-
BRCA	cis	rs897984	0.542	rs7199949	ENSG00000279196.1	RP11-1072A3.3	3.27	0.0011	0.0469	0.1	0.1	Dementia with Lewy bodies;	chr16:31084843	chr16:30984630~30988270:-
BRCA	cis	rs4363385	0.747	rs6668696	ENSG00000272654.1	RP11-422P24.11	3.27	0.0011	0.0469	0.11	0.1	Inflammatory skin disease;	chr1:152992434	chr1:153977743~153979160:+
BRCA	cis	rs2115630	0.645	rs1107179	ENSG00000230373.7	GOLGA6L5P	3.27	0.0011	0.0469	0.11	0.1	P wave terminal force;	chr15:84655131	chr15:84507885~84516814:-
BRCA	cis	rs6466055	0.777	rs66599006	ENSG00000242154.1	RP4-778K6.3	3.27	0.0011	0.0469	0.14	0.1	Schizophrenia;	chr7:105293824	chr7:105304277~105306642:+
BRCA	cis	rs7819412	0.595	rs10503416	ENSG00000254507.2	RP11-481A20.10	-3.27	0.0011	0.0469	-0.12	-0.1	Triglycerides;	chr8:11130043	chr8:12003400~12004082:-
BRCA	cis	rs27434	0.605	rs2351012	ENSG00000248734.2	CTD-2260A17.1	3.27	0.0011	0.0469	0.13	0.1	Ankylosing spondylitis;	chr5:96856044	chr5:96784777~96785999:+
BRCA	cis	rs301901	1	rs300058	ENSG00000272103.1	CTD-2653M23.3	3.27	0.0011	0.0469	0.12	0.1	Height;	chr5:37053874	chr5:36861736~36862217:-
BRCA	cis	rs12282928	0.959	rs960640	ENSG00000255197.4	RP11-750H9.5	3.27	0.0011	0.0469	0.1	0.1	Migraine - clinic-based;	chr11:48268768	chr11:47383148~47409190:-
BRCA	cis	rs12282928	1	rs7107408	ENSG00000255197.4	RP11-750H9.5	3.27	0.0011	0.0469	0.1	0.1	Migraine - clinic-based;	chr11:48270006	chr11:47383148~47409190:-
BRCA	cis	rs7267979	1	rs2424700	ENSG00000204556.4	CTD-2514C3.1	-3.27	0.0011	0.0469	-0.14	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25285877	chr20:26018832~26020684:+
BRCA	cis	rs11858159	1	rs8036695	ENSG00000207279.1	SNORD116-24	-3.27	0.0011	0.0469	-0.1	-0.1	Platelet thrombus formation;	chr15:24574711	chr15:25094037~25094128:+
BRCA	cis	rs4934494	0.681	rs34591435	ENSG00000232229.4	LINC00865	-3.27	0.0011	0.0469	-0.15	-0.1	Red blood cell count;	chr10:89721691	chr10:89829510~89840861:+
BRCA	cis	rs7953704	1	rs34974633	ENSG00000212694.7	LINC01089	-3.27	0.0011	0.0469	-0.08	-0.1	Urate levels;	chr12:122065538	chr12:121795267~121803906:-
BRCA	cis	rs10420951	0.617	rs3746176	ENSG00000243455.3	RPS18P13	-3.27	0.0011	0.0469	-0.16	-0.1	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr19:18458141	chr19:18048637~18049090:+
BRCA	cis	rs6490294	0.571	rs7959011	ENSG00000257624.1	RP1-128M12.3	3.27	0.0011	0.0469	0.17	0.1	Mean platelet volume;	chr12:112063433	chr12:112000739~112000985:-
BRCA	cis	rs6740462	0.58	rs268120	ENSG00000237979.1	AC007389.1	3.27	0.0011	0.0469	0.13	0.1	Inflammatory bowel disease;Crohn's disease;	chr2:65377780	chr2:65500993~65502138:-
BRCA	cis	rs9816784	0.901	rs12490036	ENSG00000231443.2	AC024937.6	-3.27	0.0011	0.0469	-0.11	-0.1	Mean corpuscular hemoglobin;	chr3:196089324	chr3:195937243~195938739:+
BRCA	cis	rs3764021	0.527	rs10844537	ENSG00000256594.6	RP11-705C15.2	3.27	0.0011	0.0469	0.14	0.1	Type 1 diabetes;	chr12:9709528	chr12:9633419~9658412:+
BRCA	cis	rs17169807	1	rs73319407	ENSG00000252821.1	RNU6-388P	-3.27	0.0011	0.0469	-0.21	-0.1	Smooth-surface caries;	chr7:33189195	chr7:33001950~33002054:-
BRCA	cis	rs6095360	1	rs6095360	ENSG00000227431.4	CSE1L-AS1	-3.27	0.0011	0.0469	-0.13	-0.1	Intelligence (multi-trait analysis);	chr20:48915999	chr20:49040463~49046044:-
BRCA	cis	rs6763768	0.606	rs7649323	ENSG00000274967.1	Y_RNA	-3.27	0.0011	0.0469	-0.11	-0.1	Bacterial meningitis;	chr3:53298676	chr3:53290640~53290751:+
BRCA	cis	rs2692947	0.644	rs1168968	ENSG00000168992.4	OR7E102P	3.27	0.0011	0.0469	0.14	0.1	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96159625	chr2:95546531~95547545:+
BRCA	cis	rs801193	0.66	rs1962050	ENSG00000229180.5	GS1-124K5.11	-3.27	0.0011	0.0469	-0.09	-0.1	Aortic root size;	chr7:66775021	chr7:66526088~66542624:-
BRCA	cis	rs7267979	0.903	rs6115101	ENSG00000231081.1	RP4-760C5.3	-3.27	0.0011	0.0469	-0.13	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25248928	chr20:26008791~26010531:-
BRCA	cis	rs875971	0.929	rs4122249	ENSG00000273448.1	RP11-166O4.6	3.27	0.0011	0.0469	0.09	0.1	Aortic root size;	chr7:66455949	chr7:67333047~67334383:+
BRCA	cis	rs2154319	0.887	rs7531344	ENSG00000230638.4	RP11-486B10.4	3.27	0.0011	0.0469	0.17	0.1	Height;	chr1:41041759	chr1:41542069~41544310:+
BRCA	cis	rs4374383	0.962	rs10187041	ENSG00000243389.1	AC012442.5	-3.27	0.0011	0.0469	-0.13	-0.1	Hepatitis C induced liver fibrosis;	chr2:112018075	chr2:112589040~112614431:+
BRCA	cis	rs17684571	0.872	rs13210876	ENSG00000231441.1	RP11-472M19.2	-3.27	0.0011	0.0469	-0.15	-0.1	Schizophrenia;	chr6:56739425	chr6:56844002~56864078:+
BRCA	cis	rs7555006	0.527	rs17384731	ENSG00000236434.2	RP11-296A18.6	-3.27	0.0011	0.0469	-0.12	-0.1	Headache;	chr1:50775948	chr1:51264916~51266074:-
BRCA	cis	rs3018066	0.748	rs6823347	ENSG00000249635.1	RP11-710F7.3	3.27	0.0011	0.0469	0.12	0.1	Cancer;	chr4:106041568	chr4:106003317~106022478:-
BRCA	cis	rs6517329	0.513	rs2187300	ENSG00000231106.2	LINC01436	3.27	0.0011	0.0469	0.11	0.1	Schizophrenia;	chr21:36165173	chr21:36005338~36007838:+
BRCA	cis	rs699371	0.564	rs56992115	ENSG00000270000.1	RP3-449M8.9	3.27	0.0011	0.0469	0.12	0.1	Height;	chr14:74442708	chr14:74471930~74472360:-
BRCA	cis	rs17684571	0.872	rs36068365	ENSG00000231441.1	RP11-472M19.2	3.27	0.0011	0.0469	0.15	0.1	Schizophrenia;	chr6:56716358	chr6:56844002~56864078:+
BRCA	cis	rs10992471	0.56	rs2281715	ENSG00000275318.1	RP11-526D8.11	-3.27	0.0011	0.0469	-0.09	-0.1	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr9:92885692	chr9:92840955~92841688:-
BRCA	cis	rs9325144	0.624	rs10783329	ENSG00000257718.1	RP11-396F22.1	-3.27	0.0011	0.0469	-0.1	-0.1	Morning vs. evening chronotype;	chr12:38720149	chr12:38906451~38909592:+
BRCA	cis	rs613391	0.631	rs518020	ENSG00000279670.1	RP11-70L8.5	-3.27	0.0011	0.0469	-0.13	-0.1	Quantitative traits;	chr9:22698209	chr9:21892188~21893857:+
BRCA	cis	rs3105593	1	rs3848129	ENSG00000259618.1	RP11-562A8.5	3.27	0.0011	0.0469	0.11	0.1	QT interval;	chr15:50599867	chr15:50494018~50497080:-
BRCA	cis	rs911119	0.837	rs2208289	ENSG00000270001.1	RP11-218C14.8	3.27	0.0011	0.0469	0.12	0.1	Chronic kidney disease;	chr20:23598889	chr20:23631826~23632316:-
BRCA	cis	rs875971	0.767	rs61348003	ENSG00000223473.2	GS1-124K5.3	3.27	0.0011	0.0469	0.08	0.1	Aortic root size;	chr7:66540947	chr7:66491049~66493566:-
BRCA	cis	rs875971	0.825	rs801202	ENSG00000223473.2	GS1-124K5.3	-3.27	0.0011	0.0469	-0.08	-0.1	Aortic root size;	chr7:66558942	chr7:66491049~66493566:-
BRCA	cis	rs875971	0.545	rs75577046	ENSG00000226767.1	RP11-328P23.3	3.27	0.0011	0.0469	0.13	0.1	Aortic root size;	chr7:66493729	chr7:65508773~65508944:-
BRCA	cis	rs1119582	0.537	rs327877	ENSG00000279118.1	RP11-517I3.2	3.27	0.0011	0.0469	0.14	0.1	Select biomarker traits;	chr5:125874403	chr5:126496279~126498604:+
BRCA	cis	rs6479874	0.831	rs2660216	ENSG00000223502.1	RP11-96B5.3	-3.27	0.0011	0.0469	-0.19	-0.1	Migraine;	chr10:50992191	chr10:51062579~51068553:-
BRCA	cis	rs2835345	0.561	rs5026478	ENSG00000214914.3	RPL23AP3	-3.27	0.0011	0.0469	-0.13	-0.1	Pulmonary function;	chr21:36453531	chr21:36016079~36016546:-
BRCA	cis	rs7412746	0.658	rs11204739	ENSG00000224800.1	RP11-235D19.2	-3.27	0.0011	0.0469	-0.13	-0.1	Melanoma;	chr1:150893284	chr1:150881236~150881683:-
BRCA	cis	rs6724465	0.673	rs6751232	ENSG00000272644.1	RP11-33O4.1	3.27	0.0011	0.0469	0.16	0.1	Height;	chr2:219151208	chr2:219069354~219069809:-
BRCA	cis	rs9863	0.896	rs12311114	ENSG00000270028.1	RP11-380L11.4	-3.27	0.0011	0.0469	-0.13	-0.1	White blood cell count;	chr12:123976156	chr12:123925461~123926083:-
BRCA	cis	rs12936587	0.535	rs7215833	ENSG00000223979.2	SMCR2	3.27	0.0011	0.0469	0.11	0.1	Coronary heart disease;Coronary artery disease or large artery stroke;Coronary artery disease;Hip circumference;	chr17:17603994	chr17:17674026~17677688:-
BRCA	cis	rs10782582	0.593	rs11164042	ENSG00000181227.3	RP4-682C21.2	3.27	0.0011	0.0469	0.11	0.1	Daytime sleep phenotypes;	chr1:75712755	chr1:75743423~75744776:-
BRCA	cis	rs1193	1	rs1049457	ENSG00000266931.1	RP11-1252D15.1	3.27	0.0011	0.0469	0.12	0.1	High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;High light scatter reticulocyte count;	chr2:86775905	chr2:87055658~87055800:-
BRCA	cis	rs10266483	0.545	rs1812912	ENSG00000228014.1	ZNF680P1	3.27	0.0011	0.047	0.15	0.1	Response to statin therapy;	chr7:64282891	chr7:64469185~64470653:+
BRCA	cis	rs4415084	0.745	rs12188871	ENSG00000272335.1	RP11-53O19.3	3.27	0.0011	0.047	0.09	0.1	Breast cancer;	chr5:44813902	chr5:44826076~44828592:+
BRCA	cis	rs12893668	0.703	rs7148456	ENSG00000269910.1	RP11-73M18.10	-3.27	0.0011	0.047	-0.11	-0.1	Reticulocyte count;	chr14:103561933	chr14:103694516~103695050:-
BRCA	cis	rs1326116	0.955	rs11842112	ENSG00000260509.2	RP11-271M24.2	-3.27	0.0011	0.047	-0.14	-0.1	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;	chr13:25793934	chr13:25300124~25301438:-
BRCA	cis	rs12216545	0.737	rs10238055	ENSG00000244151.1	RP11-148K1.12	-3.27	0.0011	0.047	-0.09	-0.1	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150552641	chr7:151074742~151076530:-
BRCA	cis	rs1466788	0.965	rs3768470	ENSG00000224965.1	KCNC4-AS1	3.27	0.0011	0.047	0.12	0.1	Blood metabolite levels;	chr1:110070040	chr1:110208834~110209987:-
BRCA	cis	rs3018712	0.547	rs4930237	ENSG00000251637.5	RP11-119D9.1	3.27	0.0011	0.047	0.17	0.1	Total body bone mineral density;	chr11:68646570	chr11:67886477~67906350:+
BRCA	cis	rs2228638	0.516	rs28538497	ENSG00000273038.2	RP11-479G22.8	3.27	0.0011	0.047	0.13	0.1	Tetralogy of Fallot;	chr10:33203519	chr10:32887255~32889311:-
BRCA	cis	rs2228638	0.574	rs28417729	ENSG00000273038.2	RP11-479G22.8	3.27	0.0011	0.047	0.13	0.1	Tetralogy of Fallot;	chr10:33203520	chr10:32887255~32889311:-
BRCA	cis	rs2228638	0.516	rs28398335	ENSG00000273038.2	RP11-479G22.8	3.27	0.0011	0.047	0.13	0.1	Tetralogy of Fallot;	chr10:33203529	chr10:32887255~32889311:-
BRCA	cis	rs9952980	0.671	rs16978343	ENSG00000267414.1	RP11-456K23.1	3.27	0.00111	0.047	0.11	0.1	Breast cancer;	chr18:45336230	chr18:44676927~44679717:-
BRCA	cis	rs1354774	0.505	rs8105985	ENSG00000228674.4	CTB-147C22.3	-3.27	0.00111	0.047	-0.14	-0.1	Prostate-specific antigen levels;	chr19:50894815	chr19:50927079~50927571:-
BRCA	cis	rs12282928	1	rs1503169	ENSG00000255197.4	RP11-750H9.5	3.27	0.00111	0.047	0.1	0.1	Migraine - clinic-based;	chr11:48249735	chr11:47383148~47409190:-
BRCA	cis	rs7520050	0.902	rs1355642	ENSG00000234329.1	RP11-767N6.2	-3.27	0.00111	0.047	-0.1	-0.1	Reticulocyte count;Red blood cell count;	chr1:46133231	chr1:45651039~45651826:-
BRCA	cis	rs6546043	0.71	rs13384707	ENSG00000234488.1	AC096664.1	-3.27	0.00111	0.047	-0.12	-0.1	Clozapine-induced agranulocytosis;	chr2:63714922	chr2:63684305~63684710:+
BRCA	cis	rs7267979	0.932	rs446649	ENSG00000276952.1	RP5-965G21.6	3.27	0.00111	0.047	0.12	0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25486723	chr20:25284915~25285588:-
BRCA	cis	rs58688157	0.705	rs36060383	ENSG00000255158.1	RP11-754B17.1	-3.27	0.00111	0.047	-0.14	-0.1	Systemic lupus erythematosus;	chr11:598723	chr11:665910~678391:+
BRCA	cis	rs1730008	0.865	rs699929	ENSG00000279311.1	RP11-170K4.2	-3.27	0.00111	0.047	-0.11	-0.1	Lobe attachment (rater-scored or self-reported);	chr3:158214048	chr3:158869898~158871821:+
BRCA	cis	rs6918586	0.565	rs198855	ENSG00000241549.7	GUSBP2	3.27	0.00111	0.047	0.12	0.1	Schizophrenia;	chr6:26103170	chr6:26871484~26956554:-
BRCA	cis	rs2243480	1	rs316307	ENSG00000226767.1	RP11-328P23.3	-3.27	0.00111	0.047	-0.18	-0.1	Diabetic kidney disease;	chr7:66105184	chr7:65508773~65508944:-
BRCA	cis	rs1499614	0.901	rs2178742	ENSG00000229180.5	GS1-124K5.11	3.27	0.00111	0.047	0.14	0.1	Gout;	chr7:66732812	chr7:66526088~66542624:-
BRCA	cis	rs4926298	1	rs931068	ENSG00000213290.4	PGK1P2	3.27	0.00111	0.047	0.13	0.1	Bipolar disorder;	chr19:13047864	chr19:12559571~12561105:+
BRCA	cis	rs3748682	0.731	rs3891572	ENSG00000212541.1	RNU6-510P	-3.27	0.00111	0.047	-0.14	-0.1	Hypothyroidism;	chr1:37833204	chr1:37991462~37991569:+
BRCA	cis	rs6840360	0.615	rs2406973	ENSG00000201264.1	SNORD73	3.27	0.00111	0.047	0.11	0.1	Intelligence (multi-trait analysis);	chr4:151687187	chr4:151102057~151102128:+
BRCA	cis	rs6921919	0.583	rs740622	ENSG00000219891.2	ZSCAN12P1	3.27	0.00111	0.047	0.13	0.1	Autism spectrum disorder or schizophrenia;	chr6:28430514	chr6:28091154~28093664:+
BRCA	cis	rs11098499	0.863	rs1552092	ENSG00000225892.3	RP11-384K6.2	3.27	0.00111	0.047	0.1	0.1	Corneal astigmatism;	chr4:119567341	chr4:118632274~118634759:+
BRCA	cis	rs220519	0.736	rs220511	ENSG00000235408.4	SNORA71B	-3.27	0.00111	0.047	-0.1	-0.1	Schizophrenia;	chr20:38661095	chr20:38425083~38425354:-
BRCA	cis	rs6120849	0.901	rs6060273	ENSG00000202150.1	RNU6-407P	3.27	0.00111	0.047	0.13	0.1	Protein C levels;	chr20:35156520	chr20:35030317~35030420:-
BRCA	cis	rs3176789	0.914	rs12582052	ENSG00000214776.8	RP11-726G1.1	3.27	0.00111	0.047	0.13	0.1	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9774974	chr12:9467552~9576275:+
BRCA	cis	rs962856	0.619	rs6546298	ENSG00000236605.1	AC023115.4	3.27	0.00111	0.047	0.13	0.1	Pancreatic cancer;	chr2:67354721	chr2:67324627~67325304:+
BRCA	cis	rs6599077	0.573	rs12494283	ENSG00000223797.4	ENTPD3-AS1	3.27	0.00111	0.047	0.13	0.1	Sleep-related phenotypes;	chr3:40166959	chr3:40313802~40453329:-
BRCA	cis	rs7953704	0.967	rs28530689	ENSG00000274292.1	RP11-347I19.7	3.27	0.00111	0.047	0.08	0.1	Urate levels;	chr12:122062842	chr12:121800797~121803403:+
BRCA	cis	rs57502260	0.573	rs11228295	ENSG00000251637.5	RP11-119D9.1	-3.27	0.00111	0.047	-0.15	-0.1	Total body bone mineral density (age 45-60);	chr11:68621120	chr11:67886477~67906350:+
BRCA	cis	rs751728	0.687	rs943479	ENSG00000224557.6	HLA-DPB2	-3.27	0.00111	0.047	-0.12	-0.1	Crohn's disease;	chr6:33784236	chr6:33112451~33129084:+
BRCA	cis	rs751728	0.664	rs9394167	ENSG00000224557.6	HLA-DPB2	-3.27	0.00111	0.047	-0.12	-0.1	Crohn's disease;	chr6:33786619	chr6:33112451~33129084:+
BRCA	cis	rs751728	0.626	rs6457741	ENSG00000224557.6	HLA-DPB2	-3.27	0.00111	0.047	-0.12	-0.1	Crohn's disease;	chr6:33788249	chr6:33112451~33129084:+
BRCA	cis	rs4657482	0.639	rs12045367	ENSG00000236364.3	RP11-525G13.2	-3.27	0.00111	0.047	-0.1	-0.1	Testicular germ cell tumor;	chr1:165906735	chr1:165890795~165900683:-
BRCA	cis	rs12714314	0.756	rs4481014	ENSG00000228613.1	AC144450.1	3.27	0.00111	0.047	0.11	0.1	Type 2 diabetes (age of onset);	chr2:1945120	chr2:1546665~1620113:-
BRCA	cis	rs673253	0.662	rs11210869	ENSG00000229431.1	RP1-92O14.6	-3.27	0.00111	0.047	-0.11	-0.1	Intelligence (multi-trait analysis);	chr1:43560369	chr1:43385113~43389155:+
BRCA	cis	rs860295	0.812	rs3820594	ENSG00000246203.2	RP11-29H23.5	-3.27	0.00111	0.047	-0.12	-0.1	Body mass index;	chr1:155859720	chr1:155614726~155660245:-
BRCA	cis	rs4665809	0.793	rs6546715	ENSG00000231655.1	AC011742.3	3.27	0.00111	0.047	0.14	0.1	Gut microbiome composition (summer);	chr2:26038651	chr2:26140263~26141264:-
BRCA	cis	rs2337406	0.538	rs10141701	ENSG00000211972.2	IGHV3-66	3.27	0.00111	0.047	0.09	0.1	Alzheimer's disease (late onset);	chr14:106633467	chr14:106675017~106675544:-
BRCA	cis	rs7267979	0.966	rs2261795	ENSG00000231081.1	RP4-760C5.3	-3.27	0.00111	0.047	-0.13	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25282500	chr20:26008791~26010531:-
BRCA	cis	rs5758511	0.68	rs5758682	ENSG00000231261.1	HMGN2P10	-3.27	0.00111	0.047	-0.14	-0.1	Birth weight;	chr22:42249196	chr22:41709225~41709489:-
BRCA	cis	rs56046484	0.797	rs907260	ENSG00000259630.2	CTD-2262B20.1	3.27	0.00111	0.047	0.16	0.1	Testicular germ cell tumor;	chr15:85133526	chr15:85415228~85415633:+
BRCA	cis	rs7927592	0.913	rs4084149	ENSG00000254610.1	RP5-903G2.2	-3.27	0.00111	0.047	-0.14	-0.1	Total body bone mineral density;	chr11:68521099	chr11:67934563~67939774:-
BRCA	cis	rs58521262	0.519	rs10500220	ENSG00000241282.1	RPL34P33	-3.27	0.00111	0.047	-0.17	-0.1	Testicular germ cell tumor;	chr19:22825300	chr19:22699352~22699685:+
BRCA	cis	rs1466788	1	rs3754440	ENSG00000224965.1	KCNC4-AS1	3.27	0.00111	0.047	0.12	0.1	Blood metabolite levels;	chr1:110071052	chr1:110208834~110209987:-
BRCA	cis	rs7267979	1	rs6083856	ENSG00000231081.1	RP4-760C5.3	3.27	0.00111	0.047	0.13	0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25426949	chr20:26008791~26010531:-
BRCA	cis	rs11587682	0.76	rs10788874	ENSG00000228126.1	FALEC	3.27	0.00111	0.047	0.13	0.1	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr1:150456449	chr1:150515757~150518032:+
BRCA	cis	rs11587682	0.76	rs6686809	ENSG00000228126.1	FALEC	3.27	0.00111	0.047	0.13	0.1	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr1:150459240	chr1:150515757~150518032:+
BRCA	cis	rs11587682	0.76	rs12131083	ENSG00000228126.1	FALEC	3.27	0.00111	0.047	0.13	0.1	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr1:150461347	chr1:150515757~150518032:+
BRCA	cis	rs11587682	0.76	rs66513313	ENSG00000228126.1	FALEC	3.27	0.00111	0.047	0.13	0.1	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr1:150464739	chr1:150515757~150518032:+
BRCA	cis	rs11587682	0.76	rs12130082	ENSG00000228126.1	FALEC	3.27	0.00111	0.047	0.13	0.1	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr1:150465580	chr1:150515757~150518032:+
BRCA	cis	rs11587682	0.76	rs12129491	ENSG00000228126.1	FALEC	3.27	0.00111	0.047	0.13	0.1	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr1:150467298	chr1:150515757~150518032:+
BRCA	cis	rs11587682	0.714	rs72698829	ENSG00000228126.1	FALEC	3.27	0.00111	0.047	0.13	0.1	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr1:150467965	chr1:150515757~150518032:+
BRCA	cis	rs67073037	0.955	rs4666141	ENSG00000230730.1	AC074011.2	-3.27	0.00111	0.047	-0.14	-0.1	Breast cancer;Breast cancer (estrogen-receptor negative);	chr2:28941156	chr2:28633282~28664540:-
BRCA	cis	rs3749237	1	rs11130214	ENSG00000225399.4	RP11-3B7.1	-3.27	0.00111	0.047	-0.1	-0.1	Resting heart rate;	chr3:49698313	chr3:49260085~49261316:+
BRCA	cis	rs721917	0.506	rs7073842	ENSG00000280355.1	RP11-119F19.5	-3.27	0.00111	0.047	-0.11	-0.1	Chronic obstructive pulmonary disease;	chr10:79896644	chr10:79681973~79684094:-
BRCA	cis	rs4611433	0.904	rs4932529	ENSG00000260661.1	RP11-152L20.3	-3.27	0.00111	0.047	-0.11	-0.1	Response to metformin (IC50);	chr15:91393208	chr15:92148752~92331037:-
BRCA	cis	rs889312	0.5	rs832585	ENSG00000271828.1	CTD-2310F14.1	-3.27	0.00111	0.047	-0.12	-0.1	Breast cancer (early onset);Breast cancer;	chr5:56830077	chr5:56927874~56929573:+
BRCA	cis	rs3809060	0.503	rs6484577	ENSG00000183242.10	WT1-AS	3.27	0.00111	0.047	0.14	0.1	Inguinal hernia;	chr11:32403058	chr11:32435518~32458769:+
BRCA	cis	rs703108	0.956	rs11591377	ENSG00000279623.1	RP11-399C16.3	-3.27	0.00111	0.047	-0.15	-0.1	Monocyte percentage of white cells;	chr10:22134373	chr10:21865335~21865921:-
BRCA	cis	rs9341808	0.754	rs10733162	ENSG00000279022.1	RP11-250B2.4	3.27	0.00111	0.0471	0.11	0.1	Sitting height ratio;	chr6:80313672	chr6:80440730~80441172:+
BRCA	cis	rs34734847	0.965	rs2005455	ENSG00000274029.1	RP11-340F14.6	-3.27	0.00111	0.0471	-0.12	-0.1	Mean corpuscular volume;	chr12:120690896	chr12:121190868~121191518:+
BRCA	cis	rs873549	1	rs1348270	ENSG00000238042.4	RP11-815M8.1	3.27	0.00111	0.0471	0.12	0.1	Keloid;	chr1:222096919	chr1:221880981~221978523:-
BRCA	cis	rs2277027	0.956	rs12522418	ENSG00000251405.2	CTB-109A12.1	3.27	0.00111	0.0471	0.13	0.1	Pulmonary function;Pulmonary function (smoking interaction);	chr5:157499769	chr5:157362615~157460078:-
BRCA	cis	rs765787	0.53	rs2554454	ENSG00000259539.1	CTD-2651B20.1	3.27	0.00111	0.0471	0.12	0.1	Uric acid levels;	chr15:45229338	chr15:45152664~45167526:-
BRCA	cis	rs2243480	1	rs316327	ENSG00000229180.5	GS1-124K5.11	-3.27	0.00111	0.0471	-0.13	-0.1	Diabetic kidney disease;	chr7:66144214	chr7:66526088~66542624:-
BRCA	cis	rs11696845	0.666	rs6103849	ENSG00000276223.1	RP4-781B1.5	3.27	0.00111	0.0471	0.1	0.1	Obesity-related traits;	chr20:44737046	chr20:44746642~44747201:+
BRCA	cis	rs56804039	1	rs34154295	ENSG00000233609.3	RP11-62H7.2	-3.27	0.00111	0.0471	-0.11	-0.1	Cervical cancer;	chr8:8525967	chr8:8961200~8979025:+
BRCA	cis	rs4835473	0.932	rs1597445	ENSG00000246448.2	RP13-578N3.3	-3.27	0.00111	0.0471	-0.11	-0.1	Immature fraction of reticulocytes;	chr4:143768543	chr4:143700257~143865072:+
BRCA	cis	rs10411161	0.671	rs10412377	ENSG00000269349.1	CTD-3099C6.5	-3.27	0.00111	0.0471	-0.15	-0.1	Breast cancer;	chr19:51847419	chr19:52511282~52512342:-
BRCA	cis	rs7259376	0.777	rs7247735	ENSG00000269345.1	VN1R85P	-3.27	0.00111	0.0471	-0.12	-0.1	Menopause (age at onset);	chr19:22392686	chr19:22174766~22175191:-
BRCA	cis	rs490234	0.729	rs10819050	ENSG00000232630.1	PRPS1P2	-3.27	0.00111	0.0471	-0.1	-0.1	Mean arterial pressure;	chr9:125474899	chr9:125150653~125151589:+
BRCA	cis	rs308403	0.6	rs13135445	ENSG00000224786.1	CETN4P	3.27	0.00111	0.0471	0.15	0.1	Blood protein levels;	chr4:122743302	chr4:122730548~122732193:-
BRCA	cis	rs7819412	0.749	rs11991118	ENSG00000254948.1	OR7E158P	-3.27	0.00111	0.0471	-0.12	-0.1	Triglycerides;	chr8:11081763	chr8:11919900~11920809:-
BRCA	cis	rs12481680	1	rs4811928	ENSG00000278709.1	RP5-1059L7.1	3.27	0.00111	0.0471	0.17	0.1	Response to fenofibrate (adiponectin levels);	chr20:57837400	chr20:57710183~57712780:+
BRCA	cis	rs853679	0.882	rs4713140	ENSG00000216676.2	RP1-15D7.1	-3.27	0.00111	0.0471	-0.17	-0.1	Depression;	chr6:28129415	chr6:27652602~27652825:-
BRCA	cis	rs7429990	0.965	rs2631721	ENSG00000199476.1	Y_RNA	-3.27	0.00111	0.0471	-0.13	-0.1	Educational attainment (years of education);	chr3:47881807	chr3:48288587~48288694:+
BRCA	cis	rs853679	0.882	rs4713139	ENSG00000216676.2	RP1-15D7.1	-3.27	0.00111	0.0471	-0.18	-0.1	Depression;	chr6:28124907	chr6:27652602~27652825:-
BRCA	cis	rs72928364	1	rs34509910	ENSG00000244119.1	PDCL3P4	3.27	0.00111	0.0471	0.12	0.1	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:100998623	chr3:101712472~101713191:+
BRCA	cis	rs72928364	0.858	rs66512629	ENSG00000244119.1	PDCL3P4	3.27	0.00111	0.0471	0.12	0.1	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:101000713	chr3:101712472~101713191:+
BRCA	cis	rs2574985	0.703	rs2983357	ENSG00000226200.5	SGMS1-AS1	3.27	0.00111	0.0471	0.11	0.1	Subjective well-being;	chr10:50541662	chr10:50624951~50641451:+
BRCA	cis	rs6813195	0.781	rs1545904	ENSG00000245954.5	RP11-18H21.1	3.27	0.00111	0.0471	0.09	0.1	Type 2 diabetes;	chr4:152575021	chr4:152100754~152104720:+
BRCA	cis	rs7917772	0.636	rs7088981	ENSG00000236937.2	PTGES3P4	3.27	0.00111	0.0471	0.14	0.1	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;	chr10:102760666	chr10:102845595~102845950:+
BRCA	cis	rs7104764	1	rs6598060	ENSG00000254910.1	RP11-326C3.7	-3.27	0.00111	0.0471	-0.12	-0.1	Menarche (age at onset);	chr11:243987	chr11:310139~311141:-
BRCA	cis	rs11603691	1	rs11228925	ENSG00000254662.1	RP11-872D17.4	-3.27	0.00111	0.0471	-0.22	-0.1	Low high density lipoprotein cholesterol levels;	chr11:57155887	chr11:57325603~57327958:+
BRCA	cis	rs9796	0.558	rs7166205	ENSG00000223313.1	RNU6-516P	3.27	0.00111	0.0471	0.12	0.1	Menopause (age at onset);	chr15:41222535	chr15:40529570~40529673:+
BRCA	cis	rs687432	0.924	rs34563263	ENSG00000265566.2	RN7SL605P	-3.27	0.00111	0.0471	-0.14	-0.1	Parkinson's disease;	chr11:57931130	chr11:57528085~57528365:-
BRCA	cis	rs875971	0.558	rs4433015	ENSG00000232546.1	RP11-458F8.1	3.27	0.00111	0.0471	0.08	0.1	Aortic root size;	chr7:66174736	chr7:66848496~66858136:+
BRCA	cis	rs12517906	0.943	rs11739406	ENSG00000250900.5	CTC-338M12.6	3.27	0.00111	0.0471	0.16	0.1	Weight;Body mass index;	chr5:180751738	chr5:181195496~181203103:+
BRCA	cis	rs965469	1	rs2236089	ENSG00000215063.3	RPL21P2	3.27	0.00111	0.0471	0.14	0.1	IFN-related cytopenia;	chr20:3276548	chr20:4059633~4060113:-
BRCA	cis	rs564309	0.618	rs12061733	ENSG00000212237.1	RNA5SP18	3.27	0.00111	0.0471	0.19	0.1	Hip circumference (psychosocial stress interaction);	chr1:228335711	chr1:228647912~228648032:-
BRCA	cis	rs6907629	0.776	rs1999375	ENSG00000261420.1	RP1-168L15.5	-3.27	0.00111	0.0471	-0.11	-0.1	Asthma (childhood onset);	chr6:167163210	chr6:166383189~166384824:+
BRCA	cis	rs875971	0.862	rs6955837	ENSG00000265600.1	AC006480.1	3.27	0.00111	0.0471	0.12	0.1	Aortic root size;	chr7:66578155	chr7:67356680~67356779:+
BRCA	cis	rs1424638	0.655	rs6745210	ENSG00000233251.6	AC007743.1	-3.27	0.00111	0.0471	-0.12	-0.1	Intelligence (multi-trait analysis);	chr2:57025744	chr2:56173534~56185770:-
BRCA	cis	rs2274273	0.686	rs2296489	ENSG00000259318.1	RP11-454L9.2	3.27	0.00111	0.0471	0.09	0.1	Protein biomarker;	chr14:55158259	chr14:55394940~55395233:-
BRCA	cis	rs5030062	0.531	rs1469859	ENSG00000223803.1	RPS20P14	-3.27	0.00111	0.0471	-0.11	-0.1	Blood protein levels;Plasma renin activity levels;Blood metabolite levels;	chr3:186722454	chr3:186900198~186900557:+
BRCA	cis	rs2403083	0.578	rs6605627	ENSG00000253283.1	RP11-146E23.2	-3.27	0.00111	0.0471	-0.12	-0.1	Plasma amyloid beta peptide concentrations (ABx-40);	chr8:85157680	chr8:85086615~85087186:+
BRCA	cis	rs4499344	0.556	rs259217	ENSG00000267475.1	CTD-2538C1.2	3.27	0.00111	0.0471	0.14	0.1	Mean platelet volume;	chr19:32647462	chr19:32687089~32691750:-
BRCA	cis	rs4499344	0.556	rs865659	ENSG00000267475.1	CTD-2538C1.2	3.27	0.00111	0.0471	0.14	0.1	Mean platelet volume;	chr19:32649061	chr19:32687089~32691750:-
BRCA	cis	rs6689306	0.837	rs11265612	ENSG00000201129.1	SNORA58	3.27	0.00111	0.0471	0.12	0.1	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:154444568	chr1:154259727~154259862:+
BRCA	cis	rs7824557	0.778	rs6601572	ENSG00000255046.1	RP11-297N6.4	3.27	0.00111	0.0471	0.12	0.1	Retinal vascular caliber;	chr8:11235828	chr8:11797928~11802568:-
BRCA	cis	rs7618501	0.815	rs3819325	ENSG00000228008.1	CTD-2330K9.3	3.27	0.00111	0.0471	0.1	0.1	Intelligence (multi-trait analysis);	chr3:49806290	chr3:49903845~49916937:+
BRCA	cis	rs1144333	1	rs5745354	ENSG00000181227.3	RP4-682C21.2	3.27	0.00111	0.0471	0.13	0.1	Attention function in attention deficit hyperactive disorder;	chr1:75809493	chr1:75743423~75744776:-
BRCA	cis	rs6142102	0.961	rs2284386	ENSG00000206582.1	Y_RNA	-3.27	0.00111	0.0471	-0.12	-0.1	Skin pigmentation;	chr20:34056590	chr20:34526510~34526606:-
BRCA	cis	rs1730008	0.865	rs827143	ENSG00000279311.1	RP11-170K4.2	-3.27	0.00111	0.0471	-0.11	-0.1	Lobe attachment (rater-scored or self-reported);	chr3:158206532	chr3:158869898~158871821:+
BRCA	cis	rs1730008	0.835	rs852110	ENSG00000279311.1	RP11-170K4.2	-3.27	0.00111	0.0471	-0.11	-0.1	Lobe attachment (rater-scored or self-reported);	chr3:158206584	chr3:158869898~158871821:+
BRCA	cis	rs13256369	1	rs873064	ENSG00000233609.3	RP11-62H7.2	3.27	0.00111	0.0471	0.11	0.1	Obesity-related traits;	chr8:8714870	chr8:8961200~8979025:+
BRCA	cis	rs321358	0.731	rs7926634	ENSG00000271390.1	RP11-89C3.3	-3.27	0.00111	0.0471	-0.15	-0.1	Body mass index;	chr11:111149618	chr11:111089870~111090368:-
BRCA	cis	rs10129255	0.957	rs10137980	ENSG00000231475.3	IGHV4-31	-3.27	0.00111	0.0471	-0.08	-0.1	Kawasaki disease;	chr14:106775735	chr14:106349283~106349792:-
BRCA	cis	rs12141041	0.653	rs6702900	ENSG00000274642.1	CH17-472G23.1	-3.27	0.00111	0.0471	-0.12	-0.1	Blood metabolite levels;	chr1:119429552	chr1:120197085~120319680:+
BRCA	cis	rs7824557	0.591	rs2572452	ENSG00000255046.1	RP11-297N6.4	3.27	0.00111	0.0471	0.12	0.1	Retinal vascular caliber;	chr8:11370745	chr8:11797928~11802568:-
BRCA	cis	rs6089829	0.962	rs6122344	ENSG00000233017.2	RP5-908M14.5	3.27	0.00111	0.0471	0.12	0.1	Prostate cancer (SNP x SNP interaction);	chr20:63030386	chr20:62427827~62447621:+
BRCA	cis	rs6089829	0.851	rs6122346	ENSG00000233017.2	RP5-908M14.5	3.27	0.00111	0.0471	0.12	0.1	Prostate cancer (SNP x SNP interaction);	chr20:63030470	chr20:62427827~62447621:+
BRCA	cis	rs6089829	0.962	rs6122347	ENSG00000233017.2	RP5-908M14.5	3.27	0.00111	0.0471	0.12	0.1	Prostate cancer (SNP x SNP interaction);	chr20:63030514	chr20:62427827~62447621:+
BRCA	cis	rs6089829	0.962	rs4997812	ENSG00000233017.2	RP5-908M14.5	3.27	0.00111	0.0471	0.12	0.1	Prostate cancer (SNP x SNP interaction);	chr20:63031801	chr20:62427827~62447621:+
BRCA	cis	rs6089829	0.962	rs6062393	ENSG00000233017.2	RP5-908M14.5	3.27	0.00111	0.0471	0.12	0.1	Prostate cancer (SNP x SNP interaction);	chr20:63031878	chr20:62427827~62447621:+
BRCA	cis	rs6089829	0.855	rs6090203	ENSG00000233017.2	RP5-908M14.5	3.27	0.00111	0.0471	0.12	0.1	Prostate cancer (SNP x SNP interaction);	chr20:63032280	chr20:62427827~62447621:+
BRCA	cis	rs6089829	0.89	rs6062775	ENSG00000233017.2	RP5-908M14.5	3.27	0.00111	0.0471	0.12	0.1	Prostate cancer (SNP x SNP interaction);	chr20:63032298	chr20:62427827~62447621:+
BRCA	cis	rs6089829	0.962	rs6062776	ENSG00000233017.2	RP5-908M14.5	3.27	0.00111	0.0471	0.12	0.1	Prostate cancer (SNP x SNP interaction);	chr20:63032384	chr20:62427827~62447621:+
BRCA	cis	rs6089829	0.889	rs6122348	ENSG00000233017.2	RP5-908M14.5	3.27	0.00111	0.0471	0.12	0.1	Prostate cancer (SNP x SNP interaction);	chr20:63032569	chr20:62427827~62447621:+
BRCA	cis	rs6089829	0.962	rs6062778	ENSG00000233017.2	RP5-908M14.5	3.27	0.00111	0.0471	0.12	0.1	Prostate cancer (SNP x SNP interaction);	chr20:63032607	chr20:62427827~62447621:+
BRCA	cis	rs6089829	0.925	rs6122087	ENSG00000233017.2	RP5-908M14.5	3.27	0.00111	0.0471	0.12	0.1	Prostate cancer (SNP x SNP interaction);	chr20:63033201	chr20:62427827~62447621:+
BRCA	cis	rs6089829	0.962	rs6122350	ENSG00000233017.2	RP5-908M14.5	3.27	0.00111	0.0471	0.12	0.1	Prostate cancer (SNP x SNP interaction);	chr20:63033265	chr20:62427827~62447621:+
BRCA	cis	rs6089829	0.962	rs11086151	ENSG00000233017.2	RP5-908M14.5	3.27	0.00111	0.0471	0.12	0.1	Prostate cancer (SNP x SNP interaction);	chr20:63033292	chr20:62427827~62447621:+
BRCA	cis	rs754133	0.963	rs12319419	ENSG00000248265.1	FLJ12825	3.27	0.00111	0.0471	0.13	0.1	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);	chr12:54026992	chr12:54058254~54122234:+
BRCA	cis	rs2108225	0.934	rs2190392	ENSG00000231006.1	RPL7P32	-3.27	0.00111	0.0471	-0.1	-0.1	Ulcerative colitis;	chr7:107812240	chr7:108510233~108510976:+
BRCA	cis	rs7735319	0.727	rs35860535	ENSG00000249572.1	CTD-2203K17.1	3.27	0.00111	0.0472	0.15	0.1	Systolic blood pressure;	chr5:33167069	chr5:33424025~33440619:-
BRCA	cis	rs17270561	0.636	rs1575535	ENSG00000272462.2	U91328.19	-3.27	0.00111	0.0472	-0.12	-0.1	Iron status biomarkers;	chr6:25809681	chr6:25992662~26001775:+
BRCA	cis	rs7017914	0.967	rs13272523	ENSG00000246366.5	RP11-382J12.1	3.27	0.00111	0.0472	0.11	0.1	Bone mineral density;	chr8:70729237	chr8:70608577~70663279:+
BRCA	cis	rs2099613	0.86	rs35499543	ENSG00000271889.1	RP11-493E12.1	-3.27	0.00111	0.0472	-0.14	-0.1	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr2:60749402	chr2:61151433~61162105:-
BRCA	cis	rs73222236	0.825	rs9843801	ENSG00000239213.4	NCK1-AS1	3.27	0.00111	0.0472	0.11	0.1	Coronary artery disease;	chr3:136281904	chr3:136841726~136862054:-
BRCA	cis	rs62158800	0.778	rs72823033	ENSG00000237223.5	SULT1C2P1	3.27	0.00111	0.0472	0.22	0.1	Facial morphology (factor 22);	chr2:107570342	chr2:108322238~108353799:+
BRCA	cis	rs2243480	1	rs437889	ENSG00000226002.1	RP11-460N20.5	-3.27	0.00111	0.0472	-0.17	-0.1	Diabetic kidney disease;	chr7:66044247	chr7:65084103~65100232:+
BRCA	cis	rs7637701	0.78	rs9858158	ENSG00000240875.4	LINC00886	-3.27	0.00111	0.0472	-0.12	-0.1	Breast cancer;	chr3:156845538	chr3:156747346~156817062:-
BRCA	cis	rs9372498	0.536	rs9320656	ENSG00000216809.1	RP11-57K17.1	3.27	0.00111	0.0472	0.13	0.1	Diastolic blood pressure;	chr6:118573305	chr6:118452469~118454992:-
BRCA	cis	rs875971	0.545	rs12670811	ENSG00000106610.13	STAG3L4	-3.27	0.00111	0.0472	-0.15	-0.1	Aortic root size;	chr7:66358032	chr7:67302621~67321526:+
BRCA	cis	rs2991971	0.934	rs11580609	ENSG00000281133.1	AL355480.3	3.27	0.00111	0.0472	0.12	0.1	High light scatter reticulocyte count;	chr1:45510184	chr1:45580892~45580996:-
BRCA	cis	rs1552244	0.572	rs67227131	ENSG00000269894.1	RP11-1020A11.1	-3.27	0.00111	0.0472	-0.15	-0.1	Alzheimer's disease;	chr3:10131060	chr3:9935706~9936258:+
BRCA	cis	rs9991779	0.563	rs6844246	ENSG00000234801.3	MORF4	-3.27	0.00111	0.0472	-0.14	-0.1	Pediatric bone mineral content (hip);	chr4:173982198	chr4:173615936~173616906:-
BRCA	cis	rs2243480	1	rs427044	ENSG00000226002.1	RP11-460N20.5	-3.27	0.00111	0.0472	-0.17	-0.1	Diabetic kidney disease;	chr7:66043558	chr7:65084103~65100232:+
BRCA	cis	rs7927592	0.913	rs10896338	ENSG00000254610.1	RP5-903G2.2	-3.27	0.00111	0.0472	-0.14	-0.1	Total body bone mineral density;	chr11:68531892	chr11:67934563~67939774:-
BRCA	cis	rs7927592	0.913	rs7115374	ENSG00000254610.1	RP5-903G2.2	-3.27	0.00111	0.0472	-0.14	-0.1	Total body bone mineral density;	chr11:68532608	chr11:67934563~67939774:-
BRCA	cis	rs8030136	0.645	rs11161134	ENSG00000275529.1	SNORD116-4	3.27	0.00111	0.0472	0.14	0.1	Periodontitis (DPAL);	chr15:24746667	chr15:25059538~25059633:+
BRCA	cis	rs7116495	1	rs659513	ENSG00000248671.6	ALG1L9P	3.27	0.00111	0.0472	0.19	0.1	Severe influenza A (H1N1) infection;	chr11:72101365	chr11:71794363~71818238:-
BRCA	cis	rs11451044	1	rs11451044	ENSG00000249388.1	RP11-834C11.6	-3.27	0.00111	0.0472	-0.13	-0.1	Red blood cell count;	chr12:54322000	chr12:54082118~54102693:+
BRCA	cis	rs4713118	0.869	rs7776351	ENSG00000219392.1	RP1-265C24.5	3.27	0.00111	0.0472	0.14	0.1	Parkinson's disease;	chr6:27758952	chr6:28115628~28116551:+
BRCA	cis	rs6582630	0.538	rs8189550	ENSG00000257718.1	RP11-396F22.1	-3.27	0.00111	0.0472	-0.1	-0.1	Drug-induced liver injury (flucloxacillin);	chr12:37939256	chr12:38906451~38909592:+
BRCA	cis	rs7267979	0.966	rs6050611	ENSG00000231081.1	RP4-760C5.3	-3.27	0.00111	0.0472	-0.13	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25433783	chr20:26008791~26010531:-
BRCA	cis	rs16958445	1	rs16958445	ENSG00000260103.2	RP11-10O17.1	3.27	0.00111	0.0472	0.21	0.1	Exfoliation glaucoma or exfoliation syndrome;	chr15:73884216	chr15:74478070~74490286:-
BRCA	cis	rs300890	0.597	rs3805249	ENSG00000250326.1	RP11-284M14.1	3.27	0.00111	0.0472	0.12	0.1	Nasopharyngeal carcinoma;	chr4:143377417	chr4:142933195~143184861:-
BRCA	cis	rs10129255	0.826	rs7150693	ENSG00000232216.1	IGHV3-43	3.27	0.00111	0.0472	0.09	0.1	Kawasaki disease;	chr14:106705382	chr14:106470264~106470800:-
BRCA	cis	rs10129255	0.869	rs7150549	ENSG00000232216.1	IGHV3-43	3.27	0.00111	0.0472	0.09	0.1	Kawasaki disease;	chr14:106705441	chr14:106470264~106470800:-
BRCA	cis	rs7020830	0.931	rs7851239	ENSG00000230188.1	RP11-405L18.4	3.27	0.00111	0.0472	0.12	0.1	Schizophrenia;	chr9:37138675	chr9:37490421~37490893:-
BRCA	cis	rs6429422	0.84	rs3943093	ENSG00000230199.1	RP11-331N16.1	3.27	0.00111	0.0472	0.1	0.1	Cognitive ability (multi-trait analysis);	chr1:243295200	chr1:242975005~242975084:+
BRCA	cis	rs2243480	1	rs35820085	ENSG00000237026.1	RP11-328P23.2	3.27	0.00111	0.0472	0.19	0.1	Diabetic kidney disease;	chr7:65977771	chr7:65235790~65236723:-
BRCA	cis	rs11170468	0.667	rs11170656	ENSG00000257718.1	RP11-396F22.1	3.27	0.00111	0.0472	0.13	0.1	Body mass index;	chr12:39088081	chr12:38906451~38909592:+
BRCA	cis	rs863345	0.604	rs7555174	ENSG00000229914.1	RP11-404O13.4	-3.27	0.00111	0.0472	-0.11	-0.1	Pneumococcal bacteremia;	chr1:158517636	chr1:158195633~158196131:-
BRCA	cis	rs6801044	0.954	rs862063	ENSG00000272792.1	RP11-141C7.4	-3.27	0.00111	0.0472	-0.15	-0.1	Creatinine levels in ischemic stroke;	chr3:195557541	chr3:195639990~195640460:+
BRCA	cis	rs9341808	0.718	rs10080237	ENSG00000233967.5	RP11-250B2.3	3.27	0.00111	0.0472	0.1	0.1	Sitting height ratio;	chr6:80144753	chr6:80443344~80465927:+
BRCA	cis	rs202072	0.585	rs3817735	ENSG00000215022.6	RP1-257A7.4	-3.27	0.00111	0.0472	-0.12	-0.1	HIV-1 viral setpoint;	chr6:13278416	chr6:13264861~13295586:-
BRCA	cis	rs930395	0.514	rs6880275	ENSG00000272335.1	RP11-53O19.3	-3.27	0.00111	0.0472	-0.1	-0.1	Breast cancer;	chr5:44908833	chr5:44826076~44828592:+
BRCA	cis	rs930395	0.514	rs6870136	ENSG00000272335.1	RP11-53O19.3	-3.27	0.00111	0.0472	-0.1	-0.1	Breast cancer;	chr5:44910560	chr5:44826076~44828592:+
BRCA	cis	rs930395	0.514	rs6881563	ENSG00000272335.1	RP11-53O19.3	-3.27	0.00111	0.0472	-0.1	-0.1	Breast cancer;	chr5:44912751	chr5:44826076~44828592:+
BRCA	cis	rs11098499	0.863	rs3775841	ENSG00000225892.3	RP11-384K6.2	3.27	0.00111	0.0472	0.1	0.1	Corneal astigmatism;	chr4:119504622	chr4:118632274~118634759:+
BRCA	cis	rs875971	0.545	rs10950025	ENSG00000226767.1	RP11-328P23.3	3.27	0.00111	0.0472	0.12	0.1	Aortic root size;	chr7:66158946	chr7:65508773~65508944:-
BRCA	cis	rs875971	0.52	rs12666485	ENSG00000226767.1	RP11-328P23.3	3.27	0.00111	0.0472	0.12	0.1	Aortic root size;	chr7:66160135	chr7:65508773~65508944:-
BRCA	cis	rs875971	0.545	rs67688847	ENSG00000226767.1	RP11-328P23.3	3.27	0.00111	0.0472	0.12	0.1	Aortic root size;	chr7:66161064	chr7:65508773~65508944:-
BRCA	cis	rs965469	1	rs6051753	ENSG00000215063.3	RPL21P2	3.27	0.00111	0.0472	0.14	0.1	IFN-related cytopenia;	chr20:3334866	chr20:4059633~4060113:-
BRCA	cis	rs6490294	0.571	rs7970397	ENSG00000257624.1	RP1-128M12.3	3.27	0.00111	0.0472	0.16	0.1	Mean platelet volume;	chr12:112142267	chr12:112000739~112000985:-
BRCA	cis	rs1436904	0.967	rs1182168	ENSG00000260372.5	AQP4-AS1	-3.27	0.00111	0.0472	-0.11	-0.1	Breast cancer;	chr18:26967279	chr18:26655742~27190698:+
BRCA	cis	rs7267979	0.899	rs6115213	ENSG00000277938.1	RP5-965G21.3	3.27	0.00111	0.0472	0.12	0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25569736	chr20:25229150~25231933:+
BRCA	cis	rs9503598	0.644	rs10498663	ENSG00000266750.1	MIR4645	3.27	0.00111	0.0472	0.11	0.1	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr6:3430205	chr6:2854031~2854107:-
BRCA	cis	rs910316	0.699	rs175039	ENSG00000259138.1	RP11-950C14.7	-3.27	0.00111	0.0472	-0.11	-0.1	Height;	chr14:75002247	chr14:75127153~75136930:+
BRCA	cis	rs7267979	1	rs1888999	ENSG00000231081.1	RP4-760C5.3	-3.27	0.00111	0.0472	-0.13	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25311212	chr20:26008791~26010531:-
BRCA	cis	rs60515486	0.702	rs11828339	ENSG00000243802.2	RP11-390K5.1	3.27	0.00111	0.0472	0.15	0.1	Lymphocyte counts;	chr11:47382763	chr11:47191181~47191542:-
BRCA	cis	rs1167827	1	rs1167827	ENSG00000123965.13	PMS2P5	3.27	0.00111	0.0472	0.14	0.1	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75533848	chr7:74894116~74897835:+
BRCA	cis	rs875971	0.83	rs6976714	ENSG00000223473.2	GS1-124K5.3	3.27	0.00111	0.0472	0.08	0.1	Aortic root size;	chr7:66426474	chr7:66491049~66493566:-
BRCA	cis	rs7246967	0.932	rs7256599	ENSG00000241282.1	RPL34P33	3.27	0.00111	0.0472	0.16	0.1	Bronchopulmonary dysplasia;	chr19:22863119	chr19:22699352~22699685:+
BRCA	cis	rs7188697	0.922	rs37034	ENSG00000276259.1	RP11-481J2.4	-3.27	0.00111	0.0472	-0.12	-0.1	QT interval;	chr16:58517456	chr16:58522970~58523842:+
BRCA	cis	rs1075265	0.783	rs6545376	ENSG00000272156.1	RP11-477N3.1	-3.27	0.00111	0.0472	-0.1	-0.1	Chronotype;Morning vs. evening chronotype;	chr2:53987685	chr2:54082554~54085066:+
BRCA	cis	rs79387448	0.745	rs72993720	ENSG00000234389.1	AC007278.3	3.27	0.00111	0.0472	0.14	0.1	Gut microbiota (bacterial taxa);	chr2:102504810	chr2:102438713~102440475:+
BRCA	cis	rs801193	0.844	rs2244022	ENSG00000229886.1	RP5-1132H15.3	3.27	0.00111	0.0472	0.11	0.1	Aortic root size;	chr7:66737443	chr7:66025126~66031544:-
BRCA	cis	rs3816183	0.53	rs2374437	ENSG00000226491.1	FTOP1	-3.27	0.00111	0.0472	-0.12	-0.1	Hypospadias;	chr2:42637830	chr2:42797225~42798712:-
BRCA	cis	rs687432	0.737	rs61902767	ENSG00000213592.4	AP000662.9	-3.27	0.00111	0.0472	-0.14	-0.1	Parkinson's disease;	chr11:58122259	chr11:57718044~57718530:-
BRCA	cis	rs10248619	0.505	rs2190503	ENSG00000228204.2	RP4-724E13.2	-3.27	0.00111	0.0472	-0.17	-0.1	Fasting blood glucose (BMI interaction);Fasting blood glucose;	chr7:50674920	chr7:50866747~51022990:+
BRCA	cis	rs253959	0.545	rs712596	ENSG00000272265.1	CTD-2287O16.4	-3.27	0.00111	0.0472	-0.12	-0.1	Bipolar disorder and schizophrenia;	chr5:116322214	chr5:116078110~116078570:-
BRCA	cis	rs9527	0.615	rs1556960	ENSG00000236937.2	PTGES3P4	3.27	0.00111	0.0473	0.13	0.1	Arsenic metabolism;	chr10:102966916	chr10:102845595~102845950:+
BRCA	cis	rs7267979	0.933	rs2261109	ENSG00000204556.4	CTD-2514C3.1	-3.27	0.00111	0.0473	-0.14	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25278564	chr20:26018832~26020684:+
BRCA	cis	rs7267979	0.966	rs2261720	ENSG00000204556.4	CTD-2514C3.1	-3.27	0.00111	0.0473	-0.14	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25280005	chr20:26018832~26020684:+
BRCA	cis	rs1555133	0.694	rs6141680	ENSG00000277692.1	RP11-358N2.2	-3.27	0.00111	0.0473	-0.11	-0.1	Monocyte count;	chr20:32341389	chr20:32355053~32355734:+
BRCA	cis	rs6088580	0.524	rs2378251	ENSG00000275784.1	RP5-1125A11.6	3.27	0.00111	0.0473	0.11	0.1	Glomerular filtration rate (creatinine);	chr20:34688946	chr20:33989480~33991818:-
BRCA	cis	rs2139634	1	rs12638228	ENSG00000227398.3	KIF9-AS1	-3.27	0.00111	0.0473	-0.11	-0.1	Cerebrospinal fluid biomarker levels;	chr3:46475232	chr3:47164497~47246601:+
BRCA	cis	rs6121246	0.559	rs6060857	ENSG00000230613.1	HM13-AS1	3.27	0.00111	0.0473	0.14	0.1	Mean corpuscular hemoglobin;	chr20:31712419	chr20:31567707~31573263:-
BRCA	cis	rs7649443	0.959	rs7624764	ENSG00000243339.3	RN7SL738P	-3.27	0.00111	0.0473	-0.14	-0.1	Nonsyndromic cleft lip with cleft palate;	chr3:197244326	chr3:196399911~196400207:+
BRCA	cis	rs8042680	0.554	rs7180016	ENSG00000258384.1	AC068831.6	-3.27	0.00111	0.0473	-0.12	-0.1	Type 2 diabetes;	chr15:90983045	chr15:90952239~90955225:-
BRCA	cis	rs80226907	0.901	rs78572718	ENSG00000258413.1	RP11-665C16.6	-3.27	0.00111	0.0473	-0.27	-0.1	Mean platelet volume;	chr14:55355200	chr14:55262767~55272075:-
BRCA	cis	rs7812879	0.516	rs12543308	ENSG00000255052.4	FAM66D	3.27	0.00111	0.0473	0.15	0.1	Systemic lupus erythematosus;	chr8:11451284	chr8:12115782~12177550:+
BRCA	cis	rs12762955	0.507	rs7070724	ENSG00000205740.2	RP11-363N22.3	-3.27	0.00111	0.0473	-0.1	-0.1	Response to angiotensin II receptor blocker therapy;	chr10:994198	chr10:971146~988341:-
BRCA	cis	rs7474896	0.832	rs12357256	ENSG00000120555.12	SEPT7P9	3.27	0.00111	0.0473	0.18	0.1	Obesity (extreme);	chr10:38070573	chr10:38383069~38402916:-
BRCA	cis	rs12477438	0.798	rs12473029	ENSG00000226791.5	AC109826.1	3.27	0.00111	0.0473	0.13	0.1	Chronic sinus infection;	chr2:99021498	chr2:98761938~98772920:-
BRCA	cis	rs12477438	0.798	rs1349779	ENSG00000226791.5	AC109826.1	3.27	0.00111	0.0473	0.13	0.1	Chronic sinus infection;	chr2:99028592	chr2:98761938~98772920:-
BRCA	cis	rs301901	1	rs388098	ENSG00000272103.1	CTD-2653M23.3	3.27	0.00111	0.0473	0.12	0.1	Height;	chr5:37068442	chr5:36861736~36862217:-
BRCA	cis	rs4869313	0.687	rs11135485	ENSG00000248734.2	CTD-2260A17.1	3.27	0.00111	0.0473	0.1	0.1	Pediatric autoimmune diseases;	chr5:96951265	chr5:96784777~96785999:+
BRCA	cis	rs4869313	0.694	rs7700332	ENSG00000248734.2	CTD-2260A17.1	3.27	0.00111	0.0473	0.1	0.1	Pediatric autoimmune diseases;	chr5:96971908	chr5:96784777~96785999:+
BRCA	cis	rs3176789	0.914	rs10772132	ENSG00000214776.8	RP11-726G1.1	3.27	0.00111	0.0473	0.12	0.1	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr12:9772316	chr12:9467552~9576275:+
BRCA	cis	rs301901	1	rs188541	ENSG00000272103.1	CTD-2653M23.3	3.27	0.00111	0.0473	0.12	0.1	Height;	chr5:37061159	chr5:36861736~36862217:-
BRCA	cis	rs8062405	0.789	rs2106480	ENSG00000261766.1	RP11-22P6.2	-3.27	0.00111	0.0473	-0.1	-0.1	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28526650	chr16:28862166~28863340:-
BRCA	cis	rs853679	0.546	rs71537572	ENSG00000216901.1	AL022393.7	3.27	0.00111	0.0473	0.26	0.1	Depression;	chr6:28002937	chr6:28176188~28176674:+
BRCA	cis	rs10170310	1	rs10803568	ENSG00000241772.2	AC092620.2	-3.27	0.00111	0.0473	-0.14	-0.1	Response to antipsychotic treatment;	chr2:138533344	chr2:138569090~138574458:+
BRCA	cis	rs1119582	1	rs461816	ENSG00000279118.1	RP11-517I3.2	-3.27	0.00111	0.0473	-0.12	-0.1	Select biomarker traits;	chr5:125939541	chr5:126496279~126498604:+
BRCA	cis	rs11098499	0.863	rs7664986	ENSG00000225892.3	RP11-384K6.2	3.27	0.00111	0.0473	0.1	0.1	Corneal astigmatism;	chr4:119508797	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.818	rs10008791	ENSG00000225892.3	RP11-384K6.2	3.27	0.00111	0.0473	0.1	0.1	Corneal astigmatism;	chr4:119510314	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.863	rs11736416	ENSG00000225892.3	RP11-384K6.2	3.27	0.00111	0.0473	0.1	0.1	Corneal astigmatism;	chr4:119510506	chr4:118632274~118634759:+
BRCA	cis	rs885389	1	rs885389	ENSG00000250208.5	FZD10-AS1	-3.27	0.00111	0.0473	-0.12	-0.1	RR interval (heart rate);	chr12:131137217	chr12:130144315~130162256:-
BRCA	cis	rs11587682	0.76	rs55816515	ENSG00000228126.1	FALEC	3.27	0.00111	0.0473	0.13	0.1	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr1:150467803	chr1:150515757~150518032:+
BRCA	cis	rs9813712	0.78	rs7625942	ENSG00000228252.7	COL6A4P2	3.27	0.00111	0.0473	0.13	0.1	Response to amphetamines;	chr3:130232611	chr3:130212823~130273806:+
BRCA	cis	rs4243971	0.516	rs6057567	ENSG00000277692.1	RP11-358N2.2	-3.27	0.00111	0.0473	-0.11	-0.1	Inflammatory bowel disease;Crohn's disease;	chr20:32378588	chr20:32355053~32355734:+
BRCA	cis	rs7786877	0.508	rs11765509	ENSG00000208036.1	MIR106B	3.27	0.00112	0.0473	0.14	0.1	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr7:100713367	chr7:100093993~100094074:-
BRCA	cis	rs4691139	0.549	rs28728214	ENSG00000248632.1	RP11-366M4.11	3.27	0.00112	0.0473	0.11	0.1	Ovarian cancer in BRCA1 mutation carriers;	chr4:164993866	chr4:164968587~164970002:-
BRCA	cis	rs10995356	0.565	rs7096063	ENSG00000238280.1	RP11-436D10.3	-3.27	0.00112	0.0473	-0.13	-0.1	Temperament;	chr10:62971134	chr10:62793562~62805887:-
BRCA	cis	rs8030379	0.811	rs7162542	ENSG00000176700.18	SCAND2P	-3.27	0.00112	0.0473	-0.09	-0.1	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83845538	chr15:84631451~84647478:+
BRCA	cis	rs875971	0.545	rs7787063	ENSG00000226767.1	RP11-328P23.3	3.27	0.00112	0.0473	0.12	0.1	Aortic root size;	chr7:66164012	chr7:65508773~65508944:-
BRCA	cis	rs875971	0.545	rs12673308	ENSG00000226767.1	RP11-328P23.3	3.27	0.00112	0.0473	0.12	0.1	Aortic root size;	chr7:66166374	chr7:65508773~65508944:-
BRCA	cis	rs6832769	0.643	rs11735910	ENSG00000272969.1	RP11-528I4.2	-3.27	0.00112	0.0473	-0.12	-0.1	Personality dimensions;	chr4:55652579	chr4:55547112~55547889:+
BRCA	cis	rs2813490	0.956	rs2813493	ENSG00000227627.1	RP1-101K10.6	3.27	0.00112	0.0473	0.14	0.1	Number of pregnancies;	chr6:152150068	chr6:152983750~152989223:+
BRCA	cis	rs56156301	1	rs72671376	ENSG00000246263.2	KB-431C1.4	-3.27	0.00112	0.0473	-0.17	-0.1	Pelvic organ prolapse;	chr8:103157353	chr8:102239394~102253333:+
BRCA	cis	rs36051895	0.632	rs7040806	ENSG00000237711.1	RP11-39K24.13	-3.27	0.00112	0.0473	-0.12	-0.1	Pediatric autoimmune diseases;	chr9:5174782	chr9:5100236~5101009:+
BRCA	cis	rs7709909	0.782	rs3958547	ENSG00000249655.1	CTC-325J23.2	3.27	0.00112	0.0473	0.11	0.1	HDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;	chr5:80699751	chr5:80630313~80631590:-
BRCA	cis	rs7359257	0.536	rs11629568	ENSG00000270964.1	RP11-502I4.3	-3.27	0.00112	0.0473	-0.12	-0.1	Menarche (age at onset);	chr15:67190030	chr15:67541072~67542604:-
BRCA	cis	rs9987353	0.566	rs13260067	ENSG00000248538.5	RP11-10A14.5	3.27	0.00112	0.0473	0.11	0.1	Recombination measurement;	chr8:9213523	chr8:9189011~9202854:+
BRCA	cis	rs3770081	1	rs17584578	ENSG00000232504.4	ST3GAL5-AS1	-3.27	0.00112	0.0473	-0.23	-0.1	Facial emotion recognition (sad faces);	chr2:86080501	chr2:85889280~85890980:+
BRCA	cis	rs13401620	0.626	rs2860989	ENSG00000229326.3	AC069154.4	3.27	0.00112	0.0473	0.13	0.1	Breast size;	chr2:120172258	chr2:119698623~119700151:+
BRCA	cis	rs4950322	0.57	rs72691054	ENSG00000227242.3	NBPF13P	-3.27	0.00112	0.0473	-0.14	-0.1	Protein quantitative trait loci;	chr1:147277942	chr1:147021320~147124525:-
BRCA	cis	rs2531992	0.686	rs2041247	ENSG00000262888.1	RP11-462G12.2	-3.27	0.00112	0.0473	-0.14	-0.1	Waist circumference;	chr16:3982580	chr16:3931217~3946305:-
BRCA	cis	rs6582630	0.638	rs12425531	ENSG00000257718.1	RP11-396F22.1	-3.27	0.00112	0.0473	-0.1	-0.1	Drug-induced liver injury (flucloxacillin);	chr12:38156585	chr12:38906451~38909592:+
BRCA	cis	rs6088590	0.561	rs6059934	ENSG00000269202.1	RP4-614O4.12	-3.27	0.00112	0.0473	-0.1	-0.1	Coronary artery disease;	chr20:34590520	chr20:35201747~35203288:-
BRCA	cis	rs2411233	1	rs11856921	ENSG00000259278.1	RP11-62C7.2	-3.27	0.00112	0.0473	-0.12	-0.1	Platelet count;	chr15:38985906	chr15:39019233~39024918:+
BRCA	cis	rs875971	1	rs2087647	ENSG00000273024.4	INTS4P2	3.27	0.00112	0.0473	0.11	0.1	Aortic root size;	chr7:66128201	chr7:65647864~65715661:+
BRCA	cis	rs1730008	0.865	rs699921	ENSG00000279311.1	RP11-170K4.2	-3.27	0.00112	0.0473	-0.11	-0.1	Lobe attachment (rater-scored or self-reported);	chr3:158224087	chr3:158869898~158871821:+
BRCA	cis	rs1730008	0.865	rs827807	ENSG00000279311.1	RP11-170K4.2	-3.27	0.00112	0.0473	-0.11	-0.1	Lobe attachment (rater-scored or self-reported);	chr3:158224120	chr3:158869898~158871821:+
BRCA	cis	rs558971	0.636	rs513575	ENSG00000227630.2	LINC01132	-3.27	0.00112	0.0473	-0.12	-0.1	Total cholesterol levels;	chr1:234729407	chr1:234724042~234731643:+
BRCA	cis	rs36051895	0.622	rs12686652	ENSG00000237711.1	RP11-39K24.13	-3.27	0.00112	0.0473	-0.13	-0.1	Pediatric autoimmune diseases;	chr9:5071942	chr9:5100236~5101009:+
BRCA	cis	rs9951698	0.678	rs482360	ENSG00000266969.1	RP11-773H22.4	3.27	0.00112	0.0473	0.13	0.1	Intelligence (multi-trait analysis);	chr18:13137993	chr18:12984694~12991173:-
BRCA	cis	rs6496044	0.568	rs6496040	ENSG00000259630.2	CTD-2262B20.1	-3.27	0.00112	0.0473	-0.12	-0.1	Interstitial lung disease;	chr15:85520898	chr15:85415228~85415633:+
BRCA	cis	rs359466	0.938	rs359420	ENSG00000254164.1	CTB-33O18.2	-3.27	0.00112	0.0474	-0.17	-0.1	QRS complex (Sokolow-Lyon);	chr5:173919805	chr5:173574938~173576275:+
BRCA	cis	rs116988415	0.786	rs118028978	ENSG00000258809.1	CTD-2555O16.1	3.27	0.00112	0.0474	0.23	0.1	Daytime sleep phenotypes;	chr14:64835394	chr14:64358768~64379318:-
BRCA	cis	rs13108904	0.905	rs1732108	ENSG00000196810.4	CTBP1-AS2	-3.27	0.00112	0.0474	-0.11	-0.1	Obesity-related traits;	chr4:1282762	chr4:1249300~1288291:+
BRCA	cis	rs11763147	1	rs11763147	ENSG00000228409.4	CCT6P1	3.27	0.00112	0.0474	0.09	0.1	Corneal structure;	chr7:65861834	chr7:65751142~65763354:+
BRCA	cis	rs962856	0.575	rs598108	ENSG00000236780.4	AC078941.1	3.27	0.00112	0.0474	0.14	0.1	Pancreatic cancer;	chr2:67429100	chr2:67123357~67215319:-
BRCA	cis	rs12477438	0.52	rs6739579	ENSG00000231822.1	AC019097.7	3.27	0.00112	0.0474	0.11	0.1	Chronic sinus infection;	chr2:99115089	chr2:99102018~99102752:+
BRCA	cis	rs2811415	0.597	rs11715883	ENSG00000242551.2	POU5F1P6	3.27	0.00112	0.0474	0.14	0.1	Lung function (FEV1/FVC);	chr3:128007622	chr3:128674735~128677005:-
BRCA	cis	rs8180040	0.62	rs6767907	ENSG00000280667.1	Y_RNA	-3.27	0.00112	0.0474	-0.11	-0.1	Colorectal cancer;	chr3:47121171	chr3:47501083~47501182:+
BRCA	cis	rs718433	0.584	rs2204935	ENSG00000211805.1	TRAV24	-3.27	0.00112	0.0474	-0.08	-0.1	Intraocular pressure;	chr14:21744180	chr14:22105343~22105846:+
BRCA	cis	rs718433	0.584	rs4982492	ENSG00000211805.1	TRAV24	-3.27	0.00112	0.0474	-0.08	-0.1	Intraocular pressure;	chr14:21744535	chr14:22105343~22105846:+
BRCA	cis	rs10208649	1	rs17045242	ENSG00000233266.1	HMGB1P31	3.27	0.00112	0.0474	0.24	0.1	Body mass index;	chr2:53806326	chr2:54051334~54051760:+
BRCA	cis	rs7404928	0.557	rs12932420	ENSG00000260136.4	CTD-2270L9.4	-3.27	0.00112	0.0474	-0.09	-0.1	Rheumatoid arthritis;Primary biliary cholangitis;	chr16:23928117	chr16:23452758~23457606:+
BRCA	cis	rs1466788	0.895	rs1077580	ENSG00000224965.1	KCNC4-AS1	-3.27	0.00112	0.0474	-0.12	-0.1	Blood metabolite levels;	chr1:110064397	chr1:110208834~110209987:-
BRCA	cis	rs7618501	1	rs2271960	ENSG00000281433.1	Metazoa_SRP	-3.27	0.00112	0.0474	-0.1	-0.1	Intelligence (multi-trait analysis);	chr3:49840645	chr3:49320296~49320564:+
BRCA	cis	rs950169	0.579	rs11633088	ENSG00000176700.18	SCAND2P	3.27	0.00112	0.0474	0.11	0.1	Schizophrenia;	chr15:84003429	chr15:84631451~84647478:+
BRCA	cis	rs898097	0.607	rs2199111	ENSG00000263063.1	RP11-388C12.1	-3.27	0.00112	0.0474	-0.1	-0.1	Breast cancer;	chr17:82865327	chr17:82713908~82716255:-
BRCA	cis	rs258892	0.793	rs56762233	ENSG00000272525.1	RP11-79P5.9	-3.27	0.00112	0.0474	-0.13	-0.1	Small cell lung carcinoma;	chr5:72761055	chr5:73497550~73498293:-
BRCA	cis	rs2692947	0.673	rs2692894	ENSG00000232931.4	LINC00342	-3.27	0.00112	0.0474	-0.11	-0.1	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96119195	chr2:95807118~95816215:-
BRCA	cis	rs1519814	1	rs7826920	ENSG00000279347.1	RP11-85I17.2	-3.27	0.00112	0.0474	-0.11	-0.1	Breast cancer;	chr8:120108771	chr8:119838736~119840385:-
BRCA	cis	rs13118159	0.55	rs4974611	ENSG00000211482.1	AC092574.1	3.27	0.00112	0.0474	0.13	0.1	Longevity;	chr4:1364661	chr4:409809~409915:+
BRCA	cis	rs2243480	1	rs160652	ENSG00000226767.1	RP11-328P23.3	-3.27	0.00112	0.0474	-0.18	-0.1	Diabetic kidney disease;	chr7:66073444	chr7:65508773~65508944:-
BRCA	cis	rs7308116	0.967	rs11113483	ENSG00000274395.1	RP11-554D14.8	-3.27	0.00112	0.0474	-0.11	-0.1	Pelvic organ prolapse (moderate/severe);	chr12:107796576	chr12:107835541~107836555:-
BRCA	cis	rs7178572	0.625	rs12904553	ENSG00000259362.2	RP11-307C19.1	-3.27	0.00112	0.0474	-0.13	-0.1	Type 2 diabetes;	chr15:77553617	chr15:77525540~77534110:+
BRCA	cis	rs16944613	0.541	rs4288973	ENSG00000259212.1	CTD-3065B20.2	3.27	0.00112	0.0474	0.15	0.1	Colorectal cancer;	chr15:90550444	chr15:90595840~90596447:-
BRCA	cis	rs930395	0.514	rs4360054	ENSG00000248779.1	RP11-53O19.2	-3.27	0.00112	0.0474	-0.1	-0.1	Breast cancer;	chr5:44928902	chr5:44752949~44765744:+
BRCA	cis	rs987724	0.515	rs9876148	ENSG00000243926.1	TIPARP-AS1	3.27	0.00112	0.0474	0.13	0.1	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156894349	chr3:156671862~156674378:-
BRCA	cis	rs875971	1	rs6979382	ENSG00000273024.4	INTS4P2	-3.27	0.00112	0.0474	-0.11	-0.1	Aortic root size;	chr7:66421388	chr7:65647864~65715661:+
BRCA	cis	rs875971	1	rs6961990	ENSG00000273024.4	INTS4P2	-3.27	0.00112	0.0474	-0.11	-0.1	Aortic root size;	chr7:66423583	chr7:65647864~65715661:+
BRCA	cis	rs1499614	1	rs2707840	ENSG00000229180.5	GS1-124K5.11	3.27	0.00112	0.0474	0.14	0.1	Gout;	chr7:66693028	chr7:66526088~66542624:-
BRCA	cis	rs10819861	0.645	rs10819815	ENSG00000175611.10	LINC00476	3.27	0.00112	0.0474	0.11	0.1	Electrocardiographic traits;	chr9:96092440	chr9:95759231~95875977:-
BRCA	cis	rs875971	1	rs6958484	ENSG00000273024.4	INTS4P2	3.27	0.00112	0.0474	0.11	0.1	Aortic root size;	chr7:66134459	chr7:65647864~65715661:+
BRCA	cis	rs2163813	0.788	rs247774	ENSG00000270325.1	BNIP3P9	3.27	0.00112	0.0474	0.13	0.1	Toenail selenium levels;	chr19:19732742	chr19:19856975~19857527:+
BRCA	cis	rs8114671	0.562	rs6120739	ENSG00000279253.1	RP4-614O4.13	-3.27	0.00112	0.0474	-0.11	-0.1	Height;	chr20:34817424	chr20:35262727~35264187:-
BRCA	cis	rs10484434	0.818	rs66536062	ENSG00000216331.1	HIST1H1PS1	3.27	0.00112	0.0474	0.17	0.1	HIV-1 viral setpoint;	chr6:26012479	chr6:26195566~26195771:+
BRCA	cis	rs875971	0.545	rs1796219	ENSG00000273448.1	RP11-166O4.6	-3.27	0.00112	0.0474	-0.11	-0.1	Aortic root size;	chr7:66645977	chr7:67333047~67334383:+
BRCA	cis	rs34779708	0.966	rs1478463	ENSG00000269952.1	RP11-324I22.3	-3.27	0.00112	0.0474	-0.13	-0.1	Inflammatory bowel disease;Crohn's disease;	chr10:35184107	chr10:35210416~35210750:+
BRCA	cis	rs4363385	0.51	rs7531076	ENSG00000272654.1	RP11-422P24.11	3.27	0.00112	0.0474	0.11	0.1	Inflammatory skin disease;	chr1:153066691	chr1:153977743~153979160:+
BRCA	cis	rs10761256	0.835	rs10821196	ENSG00000227603.1	RP11-165J3.6	3.27	0.00112	0.0474	0.11	0.1	Itch intensity from mosquito bite adjusted by bite size;	chr9:93671114	chr9:93435332~93437121:-
BRCA	cis	rs8114671	0.836	rs6060165	ENSG00000261582.1	RP4-614O4.11	3.27	0.00112	0.0474	0.1	0.1	Height;	chr20:35031677	chr20:35267885~35280043:-
BRCA	cis	rs9457247	0.602	rs10484530	ENSG00000272549.1	RP11-351J23.2	-3.27	0.00112	0.0474	-0.1	-0.1	Crohn's disease;	chr6:167048074	chr6:167666840~167679270:-
BRCA	cis	rs7324021	0.867	rs7321929	ENSG00000238286.1	SLC35E1P1	-3.27	0.00112	0.0474	-0.19	-0.1	Gut microbiome composition (winter);	chr13:20067872	chr13:20607268~20608131:+
BRCA	cis	rs8105895	0.935	rs7252380	ENSG00000269345.1	VN1R85P	3.27	0.00112	0.0474	0.16	0.1	Body mass index (change over time);	chr19:22062913	chr19:22174766~22175191:-
BRCA	cis	rs11098499	0.865	rs4001305	ENSG00000250950.1	RP11-33B1.3	-3.27	0.00112	0.0474	-0.12	-0.1	Corneal astigmatism;	chr4:119438081	chr4:119456350~119457277:+
BRCA	cis	rs17123764	0.786	rs60613973	ENSG00000257464.1	RP11-161H23.8	-3.27	0.00112	0.0474	-0.19	-0.1	Intelligence (multi-trait analysis);	chr12:49664478	chr12:49442424~49442652:-
BRCA	cis	rs8040855	0.599	rs4643289	ENSG00000259416.2	RP11-158M2.5	-3.27	0.00112	0.0474	-0.12	-0.1	Bulimia nervosa;	chr15:85183483	chr15:85754941~85756237:-
BRCA	cis	rs10971721	0.822	rs72729316	ENSG00000279489.1	RP11-392A14.8	3.27	0.00112	0.0474	0.21	0.1	Body mass index;	chr9:34008175	chr9:35001913~35003663:+
BRCA	cis	rs8114671	0.562	rs6120739	ENSG00000126005.14	MMP24-AS1	-3.27	0.00112	0.0474	-0.11	-0.1	Height;	chr20:34817424	chr20:35216462~35278131:-
BRCA	cis	rs8180040	0.701	rs13066214	ENSG00000260236.1	RP11-708J19.1	3.27	0.00112	0.0474	0.09	0.1	Colorectal cancer;	chr3:46992447	chr3:47379089~47380999:-
BRCA	cis	rs873549	1	rs11118946	ENSG00000238042.4	RP11-815M8.1	3.27	0.00112	0.0474	0.12	0.1	Keloid;	chr1:222096451	chr1:221880981~221978523:-
BRCA	cis	rs873549	1	rs11118947	ENSG00000238042.4	RP11-815M8.1	3.27	0.00112	0.0474	0.12	0.1	Keloid;	chr1:222096463	chr1:221880981~221978523:-
BRCA	cis	rs13068223	0.74	rs344028	ENSG00000241770.1	RP11-555M1.3	-3.27	0.00112	0.0474	-0.13	-0.1	Age-related hearing impairment (SNP x SNP interaction);	chr3:156747980	chr3:157163452~157169133:+
BRCA	cis	rs55883249	0.957	rs62119431	ENSG00000217258.2	AC007249.3	3.27	0.00112	0.0474	0.16	0.1	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:9610332	chr2:10452319~10455552:+
BRCA	cis	rs116988415	0.584	rs4899145	ENSG00000258809.1	CTD-2555O16.1	3.27	0.00112	0.0474	0.23	0.1	Daytime sleep phenotypes;	chr14:64775149	chr14:64358768~64379318:-
BRCA	cis	rs116988415	0.584	rs4902310	ENSG00000258809.1	CTD-2555O16.1	3.27	0.00112	0.0474	0.23	0.1	Daytime sleep phenotypes;	chr14:64775188	chr14:64358768~64379318:-
BRCA	cis	rs10760158	0.832	rs4837832	ENSG00000235865.2	GSN-AS1	-3.27	0.00112	0.0474	-0.09	-0.1	Pulse pressure;	chr9:121294150	chr9:121280768~121285530:-
BRCA	cis	rs2243480	1	rs465359	ENSG00000229180.5	GS1-124K5.11	3.27	0.00112	0.0474	0.14	0.1	Diabetic kidney disease;	chr7:66093177	chr7:66526088~66542624:-
BRCA	cis	rs2243480	1	rs462853	ENSG00000229180.5	GS1-124K5.11	3.27	0.00112	0.0474	0.14	0.1	Diabetic kidney disease;	chr7:66093180	chr7:66526088~66542624:-
BRCA	cis	rs2243480	1	rs160644	ENSG00000229180.5	GS1-124K5.11	3.27	0.00112	0.0474	0.14	0.1	Diabetic kidney disease;	chr7:66093199	chr7:66526088~66542624:-
BRCA	cis	rs2243480	1	rs160642	ENSG00000229180.5	GS1-124K5.11	3.27	0.00112	0.0474	0.14	0.1	Diabetic kidney disease;	chr7:66093386	chr7:66526088~66542624:-
BRCA	cis	rs2243480	0.614	rs34032527	ENSG00000229180.5	GS1-124K5.11	3.27	0.00112	0.0474	0.14	0.1	Diabetic kidney disease;	chr7:66100154	chr7:66526088~66542624:-
BRCA	cis	rs1549733	0.609	rs11674239	ENSG00000229754.1	CXCR2P1	-3.27	0.00112	0.0474	-0.1	-0.1	Optic disc area;	chr2:217559851	chr2:218059155~218065729:-
BRCA	cis	rs4718428	0.705	rs4717328	ENSG00000229886.1	RP5-1132H15.3	3.27	0.00112	0.0475	0.12	0.1	Corneal structure;	chr7:66887678	chr7:66025126~66031544:-
BRCA	cis	rs1661178	0.826	rs1623156	ENSG00000186019.10	AC084219.4	3.27	0.00112	0.0475	0.22	0.1	Exploratory eye movement dysfunction in schizophrenia (responsive search score);	chr19:44540600	chr19:44105463~44113145:-
BRCA	cis	rs17684571	0.938	rs4262190	ENSG00000231441.1	RP11-472M19.2	3.27	0.00112	0.0475	0.14	0.1	Schizophrenia;	chr6:56702404	chr6:56844002~56864078:+
BRCA	cis	rs11098499	0.863	rs3775843	ENSG00000225892.3	RP11-384K6.2	3.27	0.00112	0.0475	0.1	0.1	Corneal astigmatism;	chr4:119506689	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.863	rs3775844	ENSG00000225892.3	RP11-384K6.2	3.27	0.00112	0.0475	0.1	0.1	Corneal astigmatism;	chr4:119506878	chr4:118632274~118634759:+
BRCA	cis	rs9646944	0.501	rs10197310	ENSG00000234389.1	AC007278.3	-3.27	0.00112	0.0475	-0.11	-0.1	Blood protein levels;	chr2:102403570	chr2:102438713~102440475:+
BRCA	cis	rs11758351	0.866	rs75091077	ENSG00000216331.1	HIST1H1PS1	3.27	0.00112	0.0475	0.17	0.1	Renal underexcretion gout;Gout;	chr6:26207318	chr6:26195566~26195771:+
BRCA	cis	rs4919087	0.962	rs3814164	ENSG00000225850.3	RP11-452K12.4	-3.27	0.00112	0.0475	-0.12	-0.1	Monocyte count;	chr10:97222992	chr10:97334564~97343203:+
BRCA	cis	rs4578769	0.765	rs12455548	ENSG00000273232.1	RP11-370A5.2	-3.27	0.00112	0.0475	-0.14	-0.1	Eosinophil percentage of white cells;	chr18:22831514	chr18:22882825~22883357:-
BRCA	cis	rs7639513	0.767	rs9878151	ENSG00000274514.1	Metazoa_SRP	3.27	0.00112	0.0475	0.12	0.1	Itch intensity from mosquito bite;	chr3:12662215	chr3:12576961~12577237:-
BRCA	cis	rs55883249	0.957	rs10495572	ENSG00000217258.2	AC007249.3	-3.27	0.00112	0.0475	-0.16	-0.1	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:9594730	chr2:10452319~10455552:+
BRCA	cis	rs9635324	0.964	rs11638033	ENSG00000259330.1	INAFM2	3.27	0.00112	0.0475	0.12	0.1	Blood metabolite ratios;Blood metabolite levels;	chr15:40417909	chr15:40325216~40326715:+
BRCA	cis	rs10198628	1	rs2081407	ENSG00000264370.1	MIR3125	-3.27	0.00112	0.0475	-0.12	-0.1	Pericardial fat;Pericardial adipose tissue adjusted for height and weight;	chr2:12827758	chr2:12737367~12737444:+
BRCA	cis	rs2638953	0.924	rs10843169	ENSG00000273989.1	RP11-425D17.2	3.27	0.00112	0.0475	0.15	0.1	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28430051	chr12:28236227~28236828:+
BRCA	cis	rs673253	0.571	rs55684236	ENSG00000229431.1	RP1-92O14.6	-3.27	0.00112	0.0475	-0.11	-0.1	Intelligence (multi-trait analysis);	chr1:43614338	chr1:43385113~43389155:+
BRCA	cis	rs801193	0.569	rs6978178	ENSG00000271064.1	RP11-792A8.3	3.27	0.00112	0.0475	0.12	0.1	Aortic root size;	chr7:66658097	chr7:66748838~66749077:-
BRCA	cis	rs4650994	0.593	rs10798618	ENSG00000273384.1	RP5-1098D14.1	-3.27	0.00112	0.0475	-0.13	-0.1	HDL cholesterol;HDL cholesterol levels;	chr1:178549989	chr1:178651706~178652282:+
BRCA	cis	rs10129255	0.957	rs10140904	ENSG00000211958.2	IGHV3-38	3.27	0.00112	0.0475	0.08	0.1	Kawasaki disease;	chr14:106776558	chr14:106410493~106411021:-
BRCA	cis	rs7804356	0.501	rs212852	ENSG00000199085.2	MIR148A	3.27	0.00112	0.0475	0.12	0.1	Type 1 diabetes;	chr7:26686365	chr7:25949903~25950013:-
BRCA	cis	rs2638953	0.853	rs11049632	ENSG00000273989.1	RP11-425D17.2	-3.27	0.00112	0.0475	-0.15	-0.1	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28461130	chr12:28236227~28236828:+
BRCA	cis	rs13126694	0.682	rs9991381	ENSG00000251073.1	NUDT19P5	3.27	0.00112	0.0475	0.1	0.1	Blood osmolality (transformed sodium);	chr4:157982239	chr4:158182825~158183393:+
BRCA	cis	rs2562456	0.833	rs2562507	ENSG00000268705.1	BNIP3P26	-3.27	0.00112	0.0475	-0.11	-0.1	Pain;	chr19:21543535	chr19:21521343~21521896:-
BRCA	cis	rs2288884	0.806	rs17779439	ENSG00000269959.1	SPACA6P-AS	-3.27	0.00112	0.0475	-0.14	-0.1	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52080738	chr19:51685363~51693456:-
BRCA	cis	rs34548439	0.779	rs71621887	ENSG00000249911.1	LINC01265	3.27	0.00112	0.0475	0.15	0.1	Colorectal adenoma (advanced);	chr5:38865814	chr5:38710367~38720273:-
BRCA	cis	rs4237845	0.513	rs7134797	ENSG00000270039.1	RP11-571M6.17	-3.27	0.00112	0.0475	-0.14	-0.1	Intelligence (multi-trait analysis);	chr12:57870069	chr12:57803838~57804415:+
BRCA	cis	rs7812879	0.929	rs2618480	ENSG00000255354.1	RP11-148O21.2	-3.27	0.00112	0.0475	-0.12	-0.1	Systemic lupus erythematosus;	chr8:11496598	chr8:11558466~11560020:-
BRCA	cis	rs1878931	0.501	rs4785934	ENSG00000279568.1	RP11-20I23.5	3.27	0.00112	0.0475	0.1	0.1	Body mass index (adult);	chr16:3369934	chr16:2575628~2577373:-
BRCA	cis	rs739496	0.793	rs655107	ENSG00000226469.1	ADAM1B	3.27	0.00112	0.0475	0.13	0.1	Platelet count;	chr12:111558753	chr12:111927018~111929017:+
BRCA	cis	rs739496	0.843	rs642536	ENSG00000226469.1	ADAM1B	3.27	0.00112	0.0475	0.13	0.1	Platelet count;	chr12:111559219	chr12:111927018~111929017:+
BRCA	cis	rs739496	0.843	rs848129	ENSG00000226469.1	ADAM1B	3.27	0.00112	0.0475	0.13	0.1	Platelet count;	chr12:111559698	chr12:111927018~111929017:+
BRCA	cis	rs9341808	0.69	rs9343970	ENSG00000279022.1	RP11-250B2.4	3.27	0.00112	0.0475	0.12	0.1	Sitting height ratio;	chr6:80171572	chr6:80440730~80441172:+
BRCA	cis	rs2835872	0.965	rs1787331	ENSG00000230366.8	DSCR9	3.27	0.00112	0.0475	0.13	0.1	Electroencephalographic traits in alcoholism;	chr21:37631223	chr21:37208503~37221736:+
BRCA	cis	rs793278	0.887	rs75264737	ENSG00000256006.1	AC084117.3	-3.27	0.00112	0.0475	-0.18	-0.1	Antipsychotic drug-induced QTc interval change in schizophrenia;	chr11:19201602	chr11:18405609~18406731:+
BRCA	cis	rs4657482	0.606	rs3790665	ENSG00000203307.2	RP11-375H19.2	-3.27	0.00112	0.0475	-0.13	-0.1	Testicular germ cell tumor;	chr1:165900834	chr1:166081183~166087483:+
BRCA	cis	rs10129255	0.5	rs12101190	ENSG00000211976.2	IGHV3-73	-3.27	0.00112	0.0475	-0.08	-0.1	Kawasaki disease;	chr14:106784149	chr14:106802694~106803233:-
BRCA	cis	rs10129255	0.518	rs8004895	ENSG00000211976.2	IGHV3-73	-3.27	0.00112	0.0475	-0.08	-0.1	Kawasaki disease;	chr14:106785139	chr14:106802694~106803233:-
BRCA	cis	rs7308116	0.935	rs7965919	ENSG00000274395.1	RP11-554D14.8	-3.27	0.00112	0.0475	-0.11	-0.1	Pelvic organ prolapse (moderate/severe);	chr12:107800015	chr12:107835541~107836555:-
BRCA	cis	rs7308116	0.935	rs7342364	ENSG00000274395.1	RP11-554D14.8	-3.27	0.00112	0.0475	-0.11	-0.1	Pelvic organ prolapse (moderate/severe);	chr12:107800291	chr12:107835541~107836555:-
BRCA	cis	rs17201317	0.609	rs1587275	ENSG00000207399.1	RNU6-1011P	3.27	0.00112	0.0475	0.14	0.1	Small vessel stroke;	chr8:103107950	chr8:103384961~103385067:+
BRCA	cis	rs40067	1	rs288171	ENSG00000272523.1	LINC01023	3.27	0.00112	0.0475	0.11	0.1	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr5:108018436	chr5:108727825~108728260:-
BRCA	cis	rs7712401	0.791	rs10063253	ENSG00000249996.1	RP11-359P5.1	3.27	0.00112	0.0475	0.12	0.1	Mean platelet volume;	chr5:122793016	chr5:123036271~123054667:+
BRCA	cis	rs7763441	1	rs7763441	ENSG00000272465.1	RP1-136B1.1	-3.27	0.00112	0.0475	-0.12	-0.1	Monobrow;	chr6:2452463	chr6:2437549~2438249:+
BRCA	cis	rs1730008	0.806	rs698989	ENSG00000279311.1	RP11-170K4.2	-3.27	0.00112	0.0475	-0.11	-0.1	Lobe attachment (rater-scored or self-reported);	chr3:158226866	chr3:158869898~158871821:+
BRCA	cis	rs6019512	0.549	rs6019515	ENSG00000227431.4	CSE1L-AS1	-3.27	0.00112	0.0475	-0.12	-0.1	Intelligence (multi-trait analysis);	chr20:48911800	chr20:49040463~49046044:-
BRCA	cis	rs13108904	0.935	rs1732100	ENSG00000211482.1	AC092574.1	-3.27	0.00112	0.0475	-0.11	-0.1	Obesity-related traits;	chr4:1287973	chr4:409809~409915:+
BRCA	cis	rs875971	0.862	rs778736	ENSG00000223473.2	GS1-124K5.3	3.27	0.00112	0.0475	0.08	0.1	Aortic root size;	chr7:66348861	chr7:66491049~66493566:-
BRCA	cis	rs34779708	0.966	rs4934538	ENSG00000269952.1	RP11-324I22.3	-3.27	0.00112	0.0475	-0.14	-0.1	Inflammatory bowel disease;Crohn's disease;	chr10:35183222	chr10:35210416~35210750:+
BRCA	cis	rs2066819	1	rs41392645	ENSG00000257740.1	RP11-977G19.12	3.27	0.00112	0.0475	0.24	0.1	Psoriasis vulgaris;	chr12:56302958	chr12:56308868~56309449:+
BRCA	cis	rs36051895	0.559	rs7858422	ENSG00000237711.1	RP11-39K24.13	-3.27	0.00112	0.0476	-0.12	-0.1	Pediatric autoimmune diseases;	chr9:5209797	chr9:5100236~5101009:+
BRCA	cis	rs6493487	0.556	rs8033351	ENSG00000259298.1	RP11-562A8.4	-3.27	0.00112	0.0476	-0.11	-0.1	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr15:50819123	chr15:50497195~50498744:-
BRCA	cis	rs524281	0.692	rs2302884	ENSG00000255038.1	RP11-1167A19.2	-3.27	0.00112	0.0476	-0.14	-0.1	Electroencephalogram traits;	chr11:66056613	chr11:66067277~66069619:-
BRCA	cis	rs7662987	0.517	rs1154410	ENSG00000260641.1	RP11-1299A16.3	3.27	0.00112	0.0476	0.15	0.1	Smoking initiation;	chr4:99085494	chr4:98658904~98664550:+
BRCA	cis	rs970548	0.954	rs12249012	ENSG00000230869.1	CTGLF10P	3.27	0.00112	0.0476	0.13	0.1	Total cholesterol levels;HDL cholesterol;HDL cholesterol levels;Cholesterol, total;	chr10:45497022	chr10:45678692~45700532:+
BRCA	cis	rs35740288	0.77	rs62022867	ENSG00000259407.1	RP11-158M2.3	-3.27	0.00112	0.0476	-0.13	-0.1	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85630050	chr15:85744109~85750281:-
BRCA	cis	rs35740288	0.703	rs10520598	ENSG00000259407.1	RP11-158M2.3	-3.27	0.00112	0.0476	-0.13	-0.1	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85630150	chr15:85744109~85750281:-
BRCA	cis	rs35740288	0.77	rs11635587	ENSG00000259407.1	RP11-158M2.3	-3.27	0.00112	0.0476	-0.13	-0.1	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85630402	chr15:85744109~85750281:-
BRCA	cis	rs875971	0.798	rs57739047	ENSG00000106610.13	STAG3L4	-3.27	0.00112	0.0476	-0.13	-0.1	Aortic root size;	chr7:66507579	chr7:67302621~67321526:+
BRCA	cis	rs8016982	0.632	rs7142641	ENSG00000258999.1	RP11-114N19.3	3.27	0.00112	0.0476	0.14	0.1	Schizophrenia;	chr14:81211110	chr14:81107033~81170414:-
BRCA	cis	rs9650657	0.524	rs2163379	ENSG00000255046.1	RP11-297N6.4	-3.27	0.00112	0.0476	-0.12	-0.1	Neuroticism;	chr8:10874540	chr8:11797928~11802568:-
BRCA	cis	rs1730008	0.865	rs862351	ENSG00000279311.1	RP11-170K4.2	-3.27	0.00112	0.0476	-0.11	-0.1	Lobe attachment (rater-scored or self-reported);	chr3:158209003	chr3:158869898~158871821:+
BRCA	cis	rs1730008	0.865	rs1730100	ENSG00000279311.1	RP11-170K4.2	-3.27	0.00112	0.0476	-0.11	-0.1	Lobe attachment (rater-scored or self-reported);	chr3:158209861	chr3:158869898~158871821:+
BRCA	cis	rs1730008	0.865	rs1729997	ENSG00000279311.1	RP11-170K4.2	-3.27	0.00112	0.0476	-0.11	-0.1	Lobe attachment (rater-scored or self-reported);	chr3:158210110	chr3:158869898~158871821:+
BRCA	cis	rs1730008	0.865	rs1729999	ENSG00000279311.1	RP11-170K4.2	-3.27	0.00112	0.0476	-0.11	-0.1	Lobe attachment (rater-scored or self-reported);	chr3:158210912	chr3:158869898~158871821:+
BRCA	cis	rs11673344	0.523	rs7256380	ENSG00000276846.1	CTD-3220F14.3	3.27	0.00112	0.0476	0.12	0.1	Obesity-related traits;	chr19:37041178	chr19:37314868~37315620:-
BRCA	cis	rs7200543	1	rs6498541	ENSG00000207425.1	Y_RNA	-3.27	0.00112	0.0476	-0.12	-0.1	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15046800	chr16:14915457~14915556:-
BRCA	cis	rs72634258	0.554	rs12061787	ENSG00000269925.1	RP3-467L1.6	3.27	0.00112	0.0476	0.17	0.1	Inflammatory bowel disease;	chr1:7828670	chr1:7776383~7776775:+
BRCA	cis	rs9341808	0.754	rs9341811	ENSG00000233967.5	RP11-250B2.3	3.27	0.00112	0.0476	0.1	0.1	Sitting height ratio;	chr6:80272984	chr6:80443344~80465927:+
BRCA	cis	rs300890	0.597	rs3805246	ENSG00000250326.1	RP11-284M14.1	3.27	0.00112	0.0476	0.12	0.1	Nasopharyngeal carcinoma;	chr4:143382955	chr4:142933195~143184861:-
BRCA	cis	rs4787491	0.658	rs11647753	ENSG00000260114.2	CTD-2574D22.4	3.27	0.00112	0.0476	0.09	0.1	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:29916794	chr16:29919634~29921905:-
BRCA	cis	rs2235544	1	rs2235544	ENSG00000225183.1	RP4-758J24.4	-3.27	0.00112	0.0476	-0.12	-0.1	Thyroid hormone levels;Multiple myeloma (hyperdiploidy);	chr1:53909897	chr1:54089856~54090093:+
BRCA	cis	rs1119582	0.706	rs373175	ENSG00000279118.1	RP11-517I3.2	3.27	0.00112	0.0476	0.14	0.1	Select biomarker traits;	chr5:125845898	chr5:126496279~126498604:+
BRCA	cis	rs9951698	0.678	rs547084	ENSG00000279275.1	RP11-756J15.2	3.27	0.00112	0.0476	0.13	0.1	Intelligence (multi-trait analysis);	chr18:13123646	chr18:13279415~13280110:-
BRCA	cis	rs55801554	0.951	rs7718670	ENSG00000279204.1	RP11-175K6.2	-3.27	0.00112	0.0476	-0.11	-0.1	Mean platelet volume;	chr5:159166365	chr5:159106380~159108617:+
BRCA	cis	rs4934494	0.911	rs7098233	ENSG00000232229.4	LINC00865	3.27	0.00112	0.0476	0.15	0.1	Red blood cell count;	chr10:89663111	chr10:89829510~89840861:+
BRCA	cis	rs2835872	0.828	rs2835840	ENSG00000230366.8	DSCR9	-3.27	0.00112	0.0476	-0.13	-0.1	Electroencephalographic traits in alcoholism;	chr21:37619019	chr21:37208503~37221736:+
BRCA	cis	rs12531458	1	rs12531458	ENSG00000227191.5	TRGC2	-3.27	0.00112	0.0476	-0.09	-0.1	Educational attainment (years of education);	chr7:39051098	chr7:38239580~38368091:-
BRCA	cis	rs863345	0.608	rs11265013	ENSG00000176320.2	RP11-404O13.5	-3.27	0.00112	0.0476	-0.1	-0.1	Pneumococcal bacteremia;	chr1:158529835	chr1:158197922~158203877:-
BRCA	cis	rs863345	0.535	rs12064570	ENSG00000176320.2	RP11-404O13.5	-3.27	0.00112	0.0476	-0.1	-0.1	Pneumococcal bacteremia;	chr1:158529841	chr1:158197922~158203877:-
BRCA	cis	rs863345	0.535	rs12068285	ENSG00000176320.2	RP11-404O13.5	-3.27	0.00112	0.0476	-0.1	-0.1	Pneumococcal bacteremia;	chr1:158529842	chr1:158197922~158203877:-
BRCA	cis	rs600231	0.665	rs2105608	ENSG00000254614.2	AP003068.23	3.27	0.00112	0.0476	0.13	0.1	Bone mineral density;	chr11:65461147	chr11:65177606~65181834:-
BRCA	cis	rs4787491	0.729	rs4788215	ENSG00000275371.1	RP11-455F5.6	-3.27	0.00112	0.0476	-0.1	-0.1	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30036609	chr16:30110895~30111955:+
BRCA	cis	rs9649465	0.967	rs10269196	ENSG00000272686.1	RP11-390E23.6	3.27	0.00112	0.0476	0.1	0.1	Migraine;	chr7:123681019	chr7:123749068~123751166:+
BRCA	cis	rs1923539	0.713	rs2758544	ENSG00000272447.1	RP11-182L21.6	3.27	0.00112	0.0476	0.13	0.1	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79970366	chr10:79825902~79827602:+
BRCA	cis	rs1862618	0.641	rs170733	ENSG00000271828.1	CTD-2310F14.1	-3.27	0.00113	0.0476	-0.12	-0.1	Initial pursuit acceleration;	chr5:56953424	chr5:56927874~56929573:+
BRCA	cis	rs1219515	0.614	rs1696819	ENSG00000226864.1	ATE1-AS1	-3.27	0.00113	0.0476	-0.22	-0.1	Magnesium levels;	chr10:121702937	chr10:121928312~121951965:+
BRCA	cis	rs873549	1	rs7517086	ENSG00000238042.4	RP11-815M8.1	3.27	0.00113	0.0476	0.12	0.1	Keloid;	chr1:222097983	chr1:221880981~221978523:-
BRCA	cis	rs12714314	0.756	rs10439522	ENSG00000228613.1	AC144450.1	3.27	0.00113	0.0476	0.11	0.1	Type 2 diabetes (age of onset);	chr2:1941588	chr2:1546665~1620113:-
BRCA	cis	rs2333021	0.649	rs9888558	ENSG00000259015.1	RP11-109N23.6	3.27	0.00113	0.0476	0.11	0.1	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:72997435	chr14:72960595~72961993:+
BRCA	cis	rs10266483	0.739	rs12538943	ENSG00000271550.1	BNIP3P11	-3.27	0.00113	0.0476	-0.15	-0.1	Response to statin therapy;	chr7:64395990	chr7:64678954~64687393:-
BRCA	cis	rs2455799	0.896	rs2470533	ENSG00000224728.1	AC090945.1	-3.27	0.00113	0.0476	-0.1	-0.1	Mean platelet volume;	chr3:15656586	chr3:15878047~15879571:+
BRCA	cis	rs6582630	0.623	rs12299293	ENSG00000257718.1	RP11-396F22.1	-3.27	0.00113	0.0476	-0.1	-0.1	Drug-induced liver injury (flucloxacillin);	chr12:38042486	chr12:38906451~38909592:+
BRCA	cis	rs6813195	0.781	rs10011174	ENSG00000245954.5	RP11-18H21.1	-3.27	0.00113	0.0476	-0.09	-0.1	Type 2 diabetes;	chr4:152574363	chr4:152100754~152104720:+
BRCA	cis	rs61856137	0.642	rs4881390	ENSG00000151631.8	AKR1C6P	3.27	0.00113	0.0476	0.12	0.1	Longevity;	chr10:5066629	chr10:4871901~4891975:-
BRCA	cis	rs300890	0.597	rs11730569	ENSG00000250326.1	RP11-284M14.1	3.27	0.00113	0.0476	0.12	0.1	Nasopharyngeal carcinoma;	chr4:143375687	chr4:142933195~143184861:-
BRCA	cis	rs6432852	1	rs12692787	ENSG00000232411.1	AC009495.3	3.27	0.00113	0.0477	0.11	0.1	Diabetic kidney disease;	chr2:165897642	chr2:165833048~165839098:-
BRCA	cis	rs8114671	0.562	rs6120757	ENSG00000261582.1	RP4-614O4.11	-3.27	0.00113	0.0477	-0.1	-0.1	Height;	chr20:34900968	chr20:35267885~35280043:-
BRCA	cis	rs6743226	0.934	rs6704615	ENSG00000266621.1	AC104841.1	-3.27	0.00113	0.0477	-0.12	-0.1	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in non-smokers;	chr2:241289318	chr2:241245202~241245299:-
BRCA	cis	rs495337	1	rs2235617	ENSG00000224397.4	LINC01272	-3.27	0.00113	0.0477	-0.1	-0.1	Psoriasis;	chr20:49938440	chr20:50267486~50279795:+
BRCA	cis	rs9329221	0.736	rs12548025	ENSG00000154316.13	TDH	-3.27	0.00113	0.0477	-0.14	-0.1	Neuroticism;	chr8:10403411	chr8:11339637~11368452:+
BRCA	cis	rs372883	0.935	rs379592	ENSG00000176054.6	RPL23P2	-3.27	0.00113	0.0477	-0.1	-0.1	Pancreatic cancer;	chr21:29334149	chr21:28997613~28998033:-
BRCA	cis	rs881375	0.967	rs7046108	ENSG00000238181.2	AHCYP2	3.27	0.00113	0.0477	0.13	0.1	Rheumatoid arthritis;	chr9:120898061	chr9:120720673~120721972:+
BRCA	cis	rs7176093	1	rs112154559	ENSG00000259407.1	RP11-158M2.3	-3.27	0.00113	0.0477	-0.13	-0.1	Aging traits;	chr15:85824968	chr15:85744109~85750281:-
BRCA	cis	rs1424638	0.655	rs2195490	ENSG00000233251.6	AC007743.1	-3.27	0.00113	0.0477	-0.12	-0.1	Intelligence (multi-trait analysis);	chr2:57027593	chr2:56173534~56185770:-
BRCA	cis	rs931127	0.658	rs4244812	ENSG00000255557.1	RP11-770G2.2	3.27	0.00113	0.0477	0.11	0.1	Systemic lupus erythematosus;	chr11:65713297	chr11:65745729~65771585:+
BRCA	cis	rs8114671	0.869	rs2145559	ENSG00000261582.1	RP4-614O4.11	3.27	0.00113	0.0477	0.1	0.1	Height;	chr20:35063922	chr20:35267885~35280043:-
BRCA	cis	rs72928364	0.858	rs66598219	ENSG00000244119.1	PDCL3P4	3.27	0.00113	0.0477	0.13	0.1	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:101060591	chr3:101712472~101713191:+
BRCA	cis	rs11955398	0.502	rs159357	ENSG00000272308.1	RP11-231G3.1	-3.27	0.00113	0.0477	-0.12	-0.1	Intelligence (multi-trait analysis);	chr5:61174363	chr5:60866457~60866935:-
BRCA	cis	rs417065	0.516	rs11121129	ENSG00000238290.1	RP11-431K24.1	3.27	0.00113	0.0477	0.13	0.1	Psoriasis;	chr1:8208035	chr1:8026738~8122702:+
BRCA	cis	rs2154490	0.821	rs9305398	ENSG00000176054.6	RPL23P2	-3.27	0.00113	0.0477	-0.11	-0.1	Glucocorticoid-induced osteonecrosis;	chr21:29543288	chr21:28997613~28998033:-
BRCA	cis	rs1552244	0.572	rs41464050	ENSG00000269894.1	RP11-1020A11.1	-3.27	0.00113	0.0477	-0.13	-0.1	Alzheimer's disease;	chr3:10116709	chr3:9935706~9936258:+
BRCA	cis	rs7833986	0.501	rs9650314	ENSG00000253603.1	CTA-397H3.3	-3.27	0.00113	0.0477	-0.15	-0.1	Height;	chr8:55991051	chr8:56074592~56075274:+
BRCA	cis	rs9951698	0.667	rs7234094	ENSG00000266969.1	RP11-773H22.4	3.27	0.00113	0.0477	0.13	0.1	Intelligence (multi-trait analysis);	chr18:13007481	chr18:12984694~12991173:-
BRCA	cis	rs10501293	0.675	rs7949021	ENSG00000252652.1	Y_RNA	-3.27	0.00113	0.0477	-0.12	-0.1	Cognitive performance;	chr11:42982584	chr11:43331261~43331356:+
BRCA	cis	rs10501293	0.746	rs7936295	ENSG00000252652.1	Y_RNA	-3.27	0.00113	0.0477	-0.12	-0.1	Cognitive performance;	chr11:42983122	chr11:43331261~43331356:+
BRCA	cis	rs2148307	0.523	rs3781486	ENSG00000228339.1	AMD1P1	3.27	0.00113	0.0477	0.13	0.1	Photic sneeze reflex;	chr10:20798556	chr10:20350049~20351100:+
BRCA	cis	rs7662987	0.517	rs2851260	ENSG00000260641.1	RP11-1299A16.3	3.27	0.00113	0.0477	0.15	0.1	Smoking initiation;	chr4:99112423	chr4:98658904~98664550:+
BRCA	cis	rs7662987	0.517	rs2602865	ENSG00000260641.1	RP11-1299A16.3	3.27	0.00113	0.0477	0.15	0.1	Smoking initiation;	chr4:99113690	chr4:98658904~98664550:+
BRCA	cis	rs7662987	0.517	rs2602866	ENSG00000260641.1	RP11-1299A16.3	3.27	0.00113	0.0477	0.15	0.1	Smoking initiation;	chr4:99113846	chr4:98658904~98664550:+
BRCA	cis	rs7662987	0.517	rs2602873	ENSG00000260641.1	RP11-1299A16.3	3.27	0.00113	0.0477	0.15	0.1	Smoking initiation;	chr4:99117881	chr4:98658904~98664550:+
BRCA	cis	rs7662987	0.517	rs2851256	ENSG00000260641.1	RP11-1299A16.3	3.27	0.00113	0.0477	0.15	0.1	Smoking initiation;	chr4:99118398	chr4:98658904~98664550:+
BRCA	cis	rs7662987	0.517	rs4235436	ENSG00000260641.1	RP11-1299A16.3	3.27	0.00113	0.0477	0.15	0.1	Smoking initiation;	chr4:99118469	chr4:98658904~98664550:+
BRCA	cis	rs6831352	0.879	rs2602879	ENSG00000260641.1	RP11-1299A16.3	3.27	0.00113	0.0477	0.15	0.1	Alcohol dependence;	chr4:99119501	chr4:98658904~98664550:+
BRCA	cis	rs7662987	0.517	rs2602880	ENSG00000260641.1	RP11-1299A16.3	3.27	0.00113	0.0477	0.15	0.1	Smoking initiation;	chr4:99119502	chr4:98658904~98664550:+
BRCA	cis	rs1436904	0.967	rs1154208	ENSG00000260372.5	AQP4-AS1	-3.27	0.00113	0.0477	-0.11	-0.1	Breast cancer;	chr18:26999892	chr18:26655742~27190698:+
BRCA	cis	rs35740288	0.77	rs35447727	ENSG00000259407.1	RP11-158M2.3	-3.27	0.00113	0.0477	-0.13	-0.1	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85631168	chr15:85744109~85750281:-
BRCA	cis	rs35740288	0.77	rs34058174	ENSG00000259407.1	RP11-158M2.3	-3.27	0.00113	0.0477	-0.13	-0.1	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85631231	chr15:85744109~85750281:-
BRCA	cis	rs35740288	0.587	rs4843089	ENSG00000259407.1	RP11-158M2.3	-3.27	0.00113	0.0477	-0.13	-0.1	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85632905	chr15:85744109~85750281:-
BRCA	cis	rs6433205	0.777	rs934861	ENSG00000229827.1	AC093899.3	-3.27	0.00113	0.0477	-0.11	-0.1	Lobe attachment (rater scored);	chr2:170484178	chr2:169577371~169577746:-
BRCA	cis	rs58521262	0.585	rs2548887	ENSG00000267920.1	SNX6P1	-3.27	0.00113	0.0477	-0.13	-0.1	Testicular germ cell tumor;	chr19:23028515	chr19:23126569~23127792:-
BRCA	cis	rs10876993	0.855	rs1689585	ENSG00000269903.1	RP11-571M6.18	-3.27	0.00113	0.0477	-0.13	-0.1	Celiac disease or Rheumatoid arthritis;	chr12:57686357	chr12:57814494~57814926:+
BRCA	cis	rs6142102	0.961	rs4911144	ENSG00000206582.1	Y_RNA	-3.27	0.00113	0.0477	-0.12	-0.1	Skin pigmentation;	chr20:34026565	chr20:34526510~34526606:-
BRCA	cis	rs11098499	0.863	rs13140391	ENSG00000225892.3	RP11-384K6.2	3.27	0.00113	0.0477	0.1	0.1	Corneal astigmatism;	chr4:119582282	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.863	rs13140409	ENSG00000225892.3	RP11-384K6.2	3.27	0.00113	0.0477	0.1	0.1	Corneal astigmatism;	chr4:119582305	chr4:118632274~118634759:+
BRCA	cis	rs1865760	1	rs2071301	ENSG00000272810.1	U91328.22	-3.27	0.00113	0.0477	-0.12	-0.1	Height;	chr6:25914035	chr6:26013241~26013757:+
BRCA	cis	rs687432	0.924	rs7123570	ENSG00000265566.2	RN7SL605P	-3.27	0.00113	0.0478	-0.13	-0.1	Parkinson's disease;	chr11:57938476	chr11:57528085~57528365:-
BRCA	cis	rs3816183	0.626	rs7578494	ENSG00000226491.1	FTOP1	-3.27	0.00113	0.0478	-0.12	-0.1	Hypospadias;	chr2:42669115	chr2:42797225~42798712:-
BRCA	cis	rs763121	0.889	rs4820335	ENSG00000228274.3	RP3-508I15.9	3.27	0.00113	0.0478	0.11	0.1	Menopause (age at onset);	chr22:38539922	chr22:38667585~38681820:-
BRCA	cis	rs875971	0.965	rs7794930	ENSG00000229886.1	RP5-1132H15.3	-3.27	0.00113	0.0478	-0.11	-0.1	Aortic root size;	chr7:66313559	chr7:66025126~66031544:-
BRCA	cis	rs11158026	0.526	rs3783639	ENSG00000233924.1	AL160471.6	-3.27	0.00113	0.0478	-0.14	-0.1	Parkinson's disease;	chr14:54881948	chr14:55004813~55005687:-
BRCA	cis	rs6493487	0.512	rs34874493	ENSG00000259378.1	DCAF13P3	-3.27	0.00113	0.0478	-0.17	-0.1	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr15:51020554	chr15:50944663~50945996:+
BRCA	cis	rs1664789	0.904	rs1694058	ENSG00000272416.1	CTD-2081C10.7	3.27	0.00113	0.0478	0.11	0.1	Waist circumference adjusted for body mass index;	chr5:53981585	chr5:53880293~53881051:-
BRCA	cis	rs12959333	0.527	rs12709679	ENSG00000274918.1	RP11-54G14.1	-3.27	0.00113	0.0478	-0.16	-0.1	Post bronchodilator FEV1;	chr18:35689830	chr18:35317396~35317848:+
BRCA	cis	rs12723316	0.932	rs78491820	ENSG00000233008.4	RP11-475O6.1	-3.27	0.00113	0.0478	-0.19	-0.1	Schizophrenia;	chr1:83846633	chr1:83575776~83861023:-
BRCA	cis	rs8114671	0.562	rs959829	ENSG00000261582.1	RP4-614O4.11	3.27	0.00113	0.0478	0.1	0.1	Height;	chr20:34758244	chr20:35267885~35280043:-
BRCA	cis	rs10905065	0.931	rs10795510	ENSG00000215267.7	AKR1C7P	3.27	0.00113	0.0478	0.13	0.1	Menopause (age at onset);	chr10:5716864	chr10:5275173~5288470:-
BRCA	cis	rs11673344	0.864	rs703530	ENSG00000267422.1	CTD-2554C21.1	3.27	0.00113	0.0478	0.13	0.1	Obesity-related traits;	chr19:37010016	chr19:37779686~37792865:+
BRCA	cis	rs1478897	0.575	rs12679960	ENSG00000251402.3	FAM90A25P	3.27	0.00113	0.0478	0.13	0.1	Systemic lupus erythematosus;	chr8:11573481	chr8:12415080~12418090:-
BRCA	cis	rs6430585	0.528	rs309152	ENSG00000224043.6	CCNT2-AS1	3.27	0.00113	0.0478	0.16	0.1	Corneal structure;	chr2:135899682	chr2:134735464~134918710:-
BRCA	cis	rs3748682	0.821	rs12751325	ENSG00000212541.1	RNU6-510P	-3.27	0.00113	0.0478	-0.14	-0.1	Hypothyroidism;	chr1:37823711	chr1:37991462~37991569:+
BRCA	cis	rs875971	0.83	rs6950137	ENSG00000106610.13	STAG3L4	-3.27	0.00113	0.0478	-0.13	-0.1	Aortic root size;	chr7:66511623	chr7:67302621~67321526:+
BRCA	cis	rs240764	0.764	rs6910391	ENSG00000220695.1	RP1-121G13.3	-3.27	0.00113	0.0478	-0.11	-0.1	Neuroticism;	chr6:100477898	chr6:100530276~100531052:+
BRCA	cis	rs259282	0.605	rs28615461	ENSG00000267475.1	CTD-2538C1.2	3.27	0.00113	0.0478	0.12	0.1	Schizophrenia;	chr19:32619243	chr19:32687089~32691750:-
BRCA	cis	rs6089829	0.855	rs6090205	ENSG00000233017.2	RP5-908M14.5	3.27	0.00113	0.0478	0.12	0.1	Prostate cancer (SNP x SNP interaction);	chr20:63033917	chr20:62427827~62447621:+
BRCA	cis	rs4589258	0.737	rs2226919	ENSG00000280367.1	RP11-121L10.2	3.27	0.00113	0.0478	0.11	0.1	Intelligence (multi-trait analysis);	chr11:90731273	chr11:90223153~90226538:+
BRCA	cis	rs875971	0.522	rs1617484	ENSG00000272831.1	RP11-792A8.4	3.27	0.00113	0.0478	0.09	0.1	Aortic root size;	chr7:65998108	chr7:66739829~66740385:-
BRCA	cis	rs6948772	0.923	rs6948795	ENSG00000216895.7	AC009403.2	-3.27	0.00113	0.0478	-0.12	-0.1	Colorectal cancer;	chr7:155608255	chr7:155611231~155645205:-
BRCA	cis	rs9467773	0.933	rs35355150	ENSG00000224843.5	LINC00240	-3.27	0.00113	0.0478	-0.11	-0.1	Intelligence (multi-trait analysis);	chr6:26525811	chr6:26956992~27023924:+
BRCA	cis	rs875971	0.895	rs12698520	ENSG00000230189.5	GS1-124K5.2	3.27	0.00113	0.0478	0.08	0.1	Aortic root size;	chr7:66453720	chr7:66409143~66490059:-
BRCA	cis	rs35306767	0.715	rs1871622	ENSG00000229869.1	RP11-363N22.2	-3.27	0.00113	0.0478	-0.17	-0.1	Eosinophil percentage of granulocytes;	chr10:1003369	chr10:933026~942743:+
BRCA	cis	rs35306767	0.761	rs1871621	ENSG00000229869.1	RP11-363N22.2	-3.27	0.00113	0.0478	-0.17	-0.1	Eosinophil percentage of granulocytes;	chr10:1003656	chr10:933026~942743:+
BRCA	cis	rs35306767	0.761	rs12770910	ENSG00000229869.1	RP11-363N22.2	-3.27	0.00113	0.0478	-0.17	-0.1	Eosinophil percentage of granulocytes;	chr10:1004378	chr10:933026~942743:+
BRCA	cis	rs35306767	0.761	rs12771539	ENSG00000229869.1	RP11-363N22.2	-3.27	0.00113	0.0478	-0.17	-0.1	Eosinophil percentage of granulocytes;	chr10:1004713	chr10:933026~942743:+
BRCA	cis	rs17102884	0.506	rs4899540	ENSG00000279594.1	RP11-950C14.10	-3.27	0.00113	0.0478	-0.11	-0.1	Neuroticism;	chr14:74936705	chr14:75011269~75012851:-
BRCA	cis	rs4805834	0.64	rs11671862	ENSG00000201388.1	SNORA68	3.27	0.00113	0.0478	0.17	0.1	Creatinine levels;	chr19:32813392	chr19:32608337~32608469:-
BRCA	cis	rs854765	0.547	rs9896837	ENSG00000223979.2	SMCR2	-3.26	0.00113	0.0478	-0.12	-0.1	Total body bone mineral density;	chr17:18021554	chr17:17674026~17677688:-
BRCA	cis	rs72615157	0.634	rs74742883	ENSG00000214313.7	AZGP1P1	-3.26	0.00113	0.0478	-0.12	-0.1	Lung function (FEV1/FVC);	chr7:100188142	chr7:99980762~99987535:+
BRCA	cis	rs597539	0.652	rs559032	ENSG00000255741.1	RP11-757G1.5	-3.26	0.00113	0.0478	-0.14	-0.1	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68943379	chr11:68941503~68942852:-
BRCA	cis	rs56114371	0.53	rs9348774	ENSG00000168126.3	OR2W6P	3.26	0.00113	0.0478	0.14	0.1	Breast cancer;	chr6:27721151	chr6:27937465~27938403:+
BRCA	cis	rs2287838	1	rs12609594	ENSG00000267289.1	CTD-2623N2.11	3.26	0.00113	0.0478	0.12	0.1	Sleep duration;	chr19:9861741	chr19:9834079~9835013:-
BRCA	cis	rs4824093	0.61	rs4141437	ENSG00000213683.4	AC002056.3	-3.26	0.00113	0.0478	-0.2	-0.1	Amyotrophic lateral sclerosis (sporadic);	chr22:49850071	chr22:50754675~50755434:-
BRCA	cis	rs7824557	0.767	rs6985460	ENSG00000255495.1	AC145124.2	3.26	0.00113	0.0478	0.12	0.1	Retinal vascular caliber;	chr8:11313578	chr8:12194467~12196280:+
BRCA	cis	rs2380205	0.689	rs12779398	ENSG00000232807.2	RP11-536K7.3	3.26	0.00113	0.0478	0.11	0.1	Breast cancer;	chr10:5854662	chr10:5934270~5945900:-
BRCA	cis	rs801193	0.527	rs2707837	ENSG00000106610.13	STAG3L4	-3.26	0.00113	0.0478	-0.13	-0.1	Aortic root size;	chr7:66716086	chr7:67302621~67321526:+
BRCA	cis	rs9813712	0.585	rs9855392	ENSG00000228252.7	COL6A4P2	-3.26	0.00113	0.0478	-0.14	-0.1	Response to amphetamines;	chr3:130214403	chr3:130212823~130273806:+
BRCA	cis	rs2436153	0.706	rs3793945	ENSG00000254551.1	RP11-727A23.7	3.26	0.00113	0.0478	0.12	0.1	Facial morphology (factor 16);	chr11:83536534	chr11:83209431~83213379:-
BRCA	cis	rs62229266	0.771	rs7280136	ENSG00000214914.3	RPL23AP3	-3.26	0.00113	0.0478	-0.12	-0.1	Mitral valve prolapse;	chr21:36060612	chr21:36016079~36016546:-
BRCA	cis	rs67478160	0.529	rs12880413	ENSG00000269940.1	RP11-73M18.7	3.26	0.00113	0.0478	0.1	0.1	Schizophrenia;	chr14:103801070	chr14:103694560~103695170:+
BRCA	cis	rs67478160	0.619	rs11623546	ENSG00000269940.1	RP11-73M18.7	3.26	0.00113	0.0478	0.1	0.1	Schizophrenia;	chr14:103802761	chr14:103694560~103695170:+
BRCA	cis	rs67478160	0.619	rs55824307	ENSG00000269940.1	RP11-73M18.7	3.26	0.00113	0.0478	0.1	0.1	Schizophrenia;	chr14:103804870	chr14:103694560~103695170:+
BRCA	cis	rs7701440	0.512	rs7444594	ENSG00000272308.1	RP11-231G3.1	-3.26	0.00113	0.0478	-0.11	-0.1	Educational attainment;	chr5:61238832	chr5:60866457~60866935:-
BRCA	cis	rs7927592	0.913	rs7106339	ENSG00000254610.1	RP5-903G2.2	-3.26	0.00113	0.0478	-0.14	-0.1	Total body bone mineral density;	chr11:68472773	chr11:67934563~67939774:-
BRCA	cis	rs7590368	0.961	rs12474895	ENSG00000272275.1	RP11-791G15.2	3.26	0.00113	0.0478	0.14	0.1	Educational attainment (years of education);	chr2:10817722	chr2:10767875~10770058:-
BRCA	cis	rs889956	0.747	rs35180076	ENSG00000233251.6	AC007743.1	-3.26	0.00113	0.0478	-0.12	-0.1	Educational attainment;	chr2:57140663	chr2:56173534~56185770:-
BRCA	cis	rs9341808	0.718	rs9448899	ENSG00000279022.1	RP11-250B2.4	3.26	0.00113	0.0478	0.12	0.1	Sitting height ratio;	chr6:80136147	chr6:80440730~80441172:+
BRCA	cis	rs801193	0.66	rs1016265	ENSG00000229886.1	RP5-1132H15.3	3.26	0.00113	0.0478	0.11	0.1	Aortic root size;	chr7:66749580	chr7:66025126~66031544:-
BRCA	cis	rs801193	0.66	rs4610622	ENSG00000229886.1	RP5-1132H15.3	3.26	0.00113	0.0478	0.11	0.1	Aortic root size;	chr7:66759510	chr7:66025126~66031544:-
BRCA	cis	rs17548007	0.542	rs7301337	ENSG00000257681.1	RP11-341G23.4	-3.26	0.00113	0.0478	-0.17	-0.1	Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin;	chr12:102969445	chr12:103746315~103768858:-
BRCA	cis	rs17548007	0.542	rs1498700	ENSG00000257681.1	RP11-341G23.4	-3.26	0.00113	0.0478	-0.17	-0.1	Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin;	chr12:102969491	chr12:103746315~103768858:-
BRCA	cis	rs6494488	0.5	rs111858590	ENSG00000259635.1	AC100830.3	-3.26	0.00113	0.0478	-0.23	-0.1	Coronary artery disease;	chr15:64771423	chr15:64701248~64719602:+
BRCA	cis	rs875971	0.545	rs6460298	ENSG00000226767.1	RP11-328P23.3	3.26	0.00113	0.0478	0.13	0.1	Aortic root size;	chr7:66442783	chr7:65508773~65508944:-
BRCA	cis	rs2904967	0.81	rs507005	ENSG00000254501.1	AP003068.9	3.26	0.00113	0.0478	0.16	0.1	Mean corpuscular volume;	chr11:65278144	chr11:65110714~65111695:-
BRCA	cis	rs2904967	0.852	rs668735	ENSG00000254501.1	AP003068.9	3.26	0.00113	0.0478	0.16	0.1	Mean corpuscular volume;	chr11:65278254	chr11:65110714~65111695:-
BRCA	cis	rs4965598	0.957	rs12901204	ENSG00000259381.2	RP11-192M23.1	-3.26	0.00113	0.0479	-0.1	-0.1	Height;	chr15:100216202	chr15:100645434~100646655:-
BRCA	cis	rs7590268	0.577	rs7604544	ENSG00000279873.2	LINC01126	3.26	0.00113	0.0479	0.11	0.1	Orofacial clefts;	chr2:43396347	chr2:43227210~43228855:+
BRCA	cis	rs10129255	0.833	rs61997797	ENSG00000274576.2	IGHV2-70	3.26	0.00113	0.0479	0.09	0.1	Kawasaki disease;	chr14:106815190	chr14:106770577~106771020:-
BRCA	cis	rs7395581	0.918	rs7124955	ENSG00000280615.1	Y_RNA	3.26	0.00113	0.0479	0.12	0.1	HDL cholesterol;	chr11:47293723	chr11:47614898~47614994:-
BRCA	cis	rs3739034	0.941	rs7592128	ENSG00000224043.6	CCNT2-AS1	-3.26	0.00113	0.0479	-0.17	-0.1	Gut microbiome composition (winter);	chr2:134725300	chr2:134735464~134918710:-
BRCA	cis	rs7116495	1	rs6592455	ENSG00000254682.1	RP11-660L16.2	-3.26	0.00113	0.0479	-0.21	-0.1	Severe influenza A (H1N1) infection;	chr11:71978495	chr11:71448674~71452157:+
BRCA	cis	rs12505328	0.966	rs13108546	ENSG00000213370.3	RANP6	-3.26	0.00113	0.0479	-0.12	-0.1	Chin dimples;	chr4:173438676	chr4:173633728~173634371:-
BRCA	cis	rs6430585	0.583	rs58116536	ENSG00000226806.1	AC011893.3	3.26	0.00113	0.0479	0.14	0.1	Corneal structure;	chr2:135827753	chr2:135820191~135823087:+
BRCA	cis	rs7149337	1	rs4261445	ENSG00000258955.1	LINC00519	-3.26	0.00113	0.0479	-0.11	-0.1	Cancer;	chr14:51256822	chr14:51304416~51328386:-
BRCA	cis	rs4704187	0.506	rs3935470	ENSG00000272040.1	CTC-366B18.4	-3.26	0.00113	0.0479	-0.1	-0.1	Response to amphetamines;	chr5:75056355	chr5:75608817~75609983:+
BRCA	cis	rs10129255	0.556	rs6576222	ENSG00000211976.2	IGHV3-73	-3.26	0.00113	0.0479	-0.08	-0.1	Kawasaki disease;	chr14:106776442	chr14:106802694~106803233:-
BRCA	cis	rs3771570	0.792	rs4675970	ENSG00000271153.1	ABC7-43041300I9.1	-3.26	0.00113	0.0479	-0.17	-0.1	Prostate cancer;	chr2:241260991	chr2:242175181~242175634:+
BRCA	cis	rs6088590	0.687	rs13044899	ENSG00000276073.1	RP5-1125A11.7	-3.26	0.00113	0.0479	-0.11	-0.1	Coronary artery disease;	chr20:34699274	chr20:33985617~33988989:-
BRCA	cis	rs1336900	0.637	rs35967040	ENSG00000203804.4	ADAMTSL4-AS1	-3.26	0.00113	0.0479	-0.11	-0.1	Blood protein levels;	chr1:150583112	chr1:150560202~150574552:-
BRCA	cis	rs7508	0.538	rs374024	ENSG00000253384.1	CTD-2547L16.3	-3.26	0.00113	0.0479	-0.11	-0.1	Atrial fibrillation;	chr8:18054448	chr8:18088569~18089687:-
BRCA	cis	rs793571	0.822	rs28529423	ENSG00000259250.1	RP11-50C13.1	-3.26	0.00113	0.0479	-0.15	-0.1	Schizophrenia;	chr15:58881183	chr15:58587507~58591676:+
BRCA	cis	rs793571	0.822	rs28709922	ENSG00000259250.1	RP11-50C13.1	-3.26	0.00113	0.0479	-0.15	-0.1	Schizophrenia;	chr15:58881282	chr15:58587507~58591676:+
BRCA	cis	rs7800418	0.695	rs11766071	ENSG00000214870.7	AC004540.5	3.26	0.00113	0.0479	0.12	0.1	Cognitive function;	chr7:26552727	chr7:26398593~26494256:+
BRCA	cis	rs9400180	0.959	rs4946894	ENSG00000271734.1	RP1-111B22.3	-3.26	0.00113	0.0479	-0.13	-0.1	Major depressive disorder;	chr6:108039473	chr6:108030249~108030718:-
BRCA	cis	rs11585357	0.895	rs4625336	ENSG00000226526.1	RP1-37C10.3	-3.26	0.00113	0.0479	-0.17	-0.1	Hair shape;	chr1:17304469	chr1:16978926~17005091:+
BRCA	cis	rs6860806	1	rs6860806	ENSG00000233006.5	AC034220.3	-3.26	0.00113	0.0479	-0.07	-0.1	Breast cancer;	chr5:132304843	chr5:132311285~132369916:-
BRCA	cis	rs875971	1	rs6460292	ENSG00000273448.1	RP11-166O4.6	-3.26	0.00113	0.0479	-0.09	-0.1	Aortic root size;	chr7:66345088	chr7:67333047~67334383:+
BRCA	cis	rs867529	0.924	rs11684404	ENSG00000234028.3	AC062029.1	-3.26	0.00113	0.0479	-0.11	-0.1	Height;	chr2:88625104	chr2:88627539~88631821:+
BRCA	cis	rs10191559	0.552	rs4666723	ENSG00000234663.4	AC104820.2	3.26	0.00113	0.0479	0.09	0.1	Red blood cell count;	chr2:181209775	chr2:181101932~181399559:+
BRCA	cis	rs925228	0.504	rs6729231	ENSG00000232642.1	AC008073.7	-3.26	0.00113	0.0479	-0.19	-0.1	Reticulocyte count;Reticulocyte fraction of red cells;	chr2:24069727	chr2:24165884~24175005:-
BRCA	cis	rs12512126	0.559	rs3887856	ENSG00000280219.1	RP11-752L20.3	-3.26	0.00113	0.0479	-0.13	-0.1	Facial morphology (factor 8, orbital inclination due to vertical and horizontal position of exocanthion);	chr4:148248906	chr4:147487971~147496062:+
BRCA	cis	rs648163	0.59	rs590258	ENSG00000236468.1	RP11-104D3.2	-3.26	0.00113	0.0479	-0.1	-0.1	Educational attainment (years of education);	chr1:199351657	chr1:199387141~199388475:+
BRCA	cis	rs4691139	0.524	rs28548593	ENSG00000248632.1	RP11-366M4.11	3.26	0.00113	0.0479	0.12	0.1	Ovarian cancer in BRCA1 mutation carriers;	chr4:164965160	chr4:164968587~164970002:-
BRCA	cis	rs904092	0.72	rs1229967	ENSG00000246090.5	RP11-696N14.1	-3.26	0.00113	0.0479	-0.12	-0.1	Alcohol dependence;	chr4:99286421	chr4:99088857~99301356:+
BRCA	cis	rs6840360	0.904	rs73862064	ENSG00000251603.1	RP11-164P12.4	-3.26	0.00113	0.0479	-0.09	-0.1	Intelligence (multi-trait analysis);	chr4:151581948	chr4:151667224~151670502:+
BRCA	cis	rs832540	0.669	rs832539	ENSG00000237705.1	AC008937.2	3.26	0.00113	0.0479	0.1	0.1	Coronary artery disease;	chr5:56903559	chr5:56842016~56862164:-
BRCA	cis	rs9333290	0.897	rs13016261	ENSG00000259915.2	RP11-410E4.1	3.26	0.00113	0.0479	0.14	0.1	Urinary albumin-to-creatinine ratio in non-diabetics;Urinary albumin-to-creatinine ratio;	chr2:186684566	chr2:186354570~186356773:-
BRCA	cis	rs9333290	0.93	rs12615659	ENSG00000259915.2	RP11-410E4.1	3.26	0.00113	0.0479	0.14	0.1	Urinary albumin-to-creatinine ratio in non-diabetics;Urinary albumin-to-creatinine ratio;	chr2:186686580	chr2:186354570~186356773:-
BRCA	cis	rs877819	0.697	rs7915340	ENSG00000228403.1	RP11-563N6.6	-3.26	0.00113	0.0479	-0.11	-0.1	Systemic lupus erythematosus;	chr10:48840495	chr10:48878022~48878649:+
BRCA	cis	rs8180040	0.739	rs11719306	ENSG00000280667.1	Y_RNA	3.26	0.00113	0.0479	0.11	0.1	Colorectal cancer;	chr3:47142692	chr3:47501083~47501182:+
BRCA	cis	rs7927592	0.913	rs11228276	ENSG00000254610.1	RP5-903G2.2	-3.26	0.00113	0.0479	-0.14	-0.1	Total body bone mineral density;	chr11:68540057	chr11:67934563~67939774:-
BRCA	cis	rs6466055	0.72	rs7800928	ENSG00000242154.1	RP4-778K6.3	-3.26	0.00113	0.0479	-0.13	-0.1	Schizophrenia;	chr7:105367023	chr7:105304277~105306642:+
BRCA	cis	rs2243480	1	rs1723270	ENSG00000237026.1	RP11-328P23.2	3.26	0.00113	0.0479	0.19	0.1	Diabetic kidney disease;	chr7:66004843	chr7:65235790~65236723:-
BRCA	cis	rs10266483	0.883	rs683689	ENSG00000271550.1	BNIP3P11	3.26	0.00113	0.0479	0.13	0.1	Response to statin therapy;	chr7:64282165	chr7:64678954~64687393:-
BRCA	cis	rs853679	0.607	rs67662114	ENSG00000216901.1	AL022393.7	3.26	0.00113	0.0479	0.26	0.1	Depression;	chr6:27964523	chr6:28176188~28176674:+
BRCA	cis	rs853679	0.607	rs13216117	ENSG00000216901.1	AL022393.7	3.26	0.00113	0.0479	0.26	0.1	Depression;	chr6:27970706	chr6:28176188~28176674:+
BRCA	cis	rs853679	0.607	rs36101351	ENSG00000216901.1	AL022393.7	3.26	0.00113	0.0479	0.26	0.1	Depression;	chr6:27975591	chr6:28176188~28176674:+
BRCA	cis	rs853679	0.607	rs28360499	ENSG00000216901.1	AL022393.7	3.26	0.00113	0.0479	0.26	0.1	Depression;	chr6:27977618	chr6:28176188~28176674:+
BRCA	cis	rs3105593	1	rs17645523	ENSG00000259618.1	RP11-562A8.5	3.26	0.00113	0.0479	0.11	0.1	QT interval;	chr15:50590448	chr15:50494018~50497080:-
BRCA	cis	rs2191566	0.576	rs405763	ENSG00000266921.1	RP11-15A1.7	3.26	0.00113	0.0479	0.13	0.1	Acute lymphoblastic leukemia (childhood);	chr19:43989395	chr19:43996896~44002836:-
BRCA	cis	rs2191566	0.576	rs370809	ENSG00000266921.1	RP11-15A1.7	3.26	0.00113	0.0479	0.13	0.1	Acute lymphoblastic leukemia (childhood);	chr19:43989678	chr19:43996896~44002836:-
BRCA	cis	rs2191566	0.576	rs382255	ENSG00000266921.1	RP11-15A1.7	3.26	0.00113	0.0479	0.13	0.1	Acute lymphoblastic leukemia (childhood);	chr19:43990004	chr19:43996896~44002836:-
BRCA	cis	rs7267979	0.966	rs2261784	ENSG00000204556.4	CTD-2514C3.1	-3.26	0.00113	0.0479	-0.14	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25281760	chr20:26018832~26020684:+
BRCA	cis	rs7267979	0.966	rs2261785	ENSG00000204556.4	CTD-2514C3.1	-3.26	0.00113	0.0479	-0.14	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25281767	chr20:26018832~26020684:+
BRCA	cis	rs10129255	0.536	rs6576223	ENSG00000211976.2	IGHV3-73	-3.26	0.00113	0.0479	-0.08	-0.1	Kawasaki disease;	chr14:106776448	chr14:106802694~106803233:-
BRCA	cis	rs1766786	1	rs1766786	ENSG00000231365.4	RP11-418J17.1	-3.26	0.00113	0.0479	-0.19	-0.1	Chin dimples;	chr1:118909877	chr1:119140396~119275973:+
BRCA	cis	rs1766786	0.925	rs1766787	ENSG00000231365.4	RP11-418J17.1	-3.26	0.00113	0.0479	-0.19	-0.1	Chin dimples;	chr1:118910135	chr1:119140396~119275973:+
BRCA	cis	rs7712401	0.791	rs10071135	ENSG00000263432.2	RN7SL689P	3.26	0.00113	0.048	0.11	0.1	Mean platelet volume;	chr5:122811283	chr5:123022487~123022783:-
BRCA	cis	rs4919669	0.668	rs17114808	ENSG00000213277.3	MARCKSL1P1	3.26	0.00113	0.048	0.16	0.1	Mean arterial pressure (long-term average);Systolic blood pressure (long-term average);	chr10:102631528	chr10:103175554~103176094:+
BRCA	cis	rs4671400	0.571	rs4672429	ENSG00000270820.4	RP11-355B11.2	-3.26	0.00113	0.048	-0.13	-0.1	3-hydroxypropylmercapturic acid levels in smokers;	chr2:61268334	chr2:61471188~61484130:+
BRCA	cis	rs2712381	0.517	rs62273237	ENSG00000261159.1	RP11-723O4.9	-3.26	0.00113	0.048	-0.1	-0.1	Monocyte count;	chr3:128591264	chr3:128859716~128860526:-
BRCA	cis	rs10070219	0.505	rs72814413	ENSG00000248445.4	SEMA6A-AS1	-3.26	0.00113	0.048	-0.13	-0.1	3-hydroxypropylmercapturic acid levels in smokers;	chr5:117356639	chr5:116447547~116508276:+
BRCA	cis	rs10070219	0.505	rs62380382	ENSG00000248445.4	SEMA6A-AS1	-3.26	0.00113	0.048	-0.13	-0.1	3-hydroxypropylmercapturic acid levels in smokers;	chr5:117357181	chr5:116447547~116508276:+
BRCA	cis	rs10070219	0.505	rs62380383	ENSG00000248445.4	SEMA6A-AS1	-3.26	0.00113	0.048	-0.13	-0.1	3-hydroxypropylmercapturic acid levels in smokers;	chr5:117357365	chr5:116447547~116508276:+
BRCA	cis	rs4631830	0.863	rs2843550	ENSG00000204177.9	BMS1P1	-3.26	0.00113	0.048	-0.1	-0.1	Prostate-specific antigen levels;	chr10:46074370	chr10:46786674~46811989:+
BRCA	cis	rs2307121	0.7	rs10940034	ENSG00000250081.1	CTD-2116N20.1	-3.26	0.00113	0.048	-0.12	-0.1	Corneal structure;	chr5:65433248	chr5:65486444~65487048:-
BRCA	cis	rs40363	0.645	rs4786421	ENSG00000240311.1	LA16c-306E5.1	3.26	0.00113	0.048	0.12	0.1	Tuberculosis;	chr16:3472303	chr16:3496201~3496768:+
BRCA	cis	rs4869313	0.694	rs6870825	ENSG00000248734.2	CTD-2260A17.1	3.26	0.00113	0.048	0.1	0.1	Pediatric autoimmune diseases;	chr5:96945765	chr5:96784777~96785999:+
BRCA	cis	rs4869313	0.687	rs10061936	ENSG00000248734.2	CTD-2260A17.1	3.26	0.00113	0.048	0.1	0.1	Pediatric autoimmune diseases;	chr5:96948117	chr5:96784777~96785999:+
BRCA	cis	rs4869313	0.694	rs10069361	ENSG00000248734.2	CTD-2260A17.1	3.26	0.00113	0.048	0.1	0.1	Pediatric autoimmune diseases;	chr5:96949099	chr5:96784777~96785999:+
BRCA	cis	rs6581612	0.836	rs7307410	ENSG00000255693.1	RP11-766N7.3	-3.26	0.00113	0.048	-0.15	-0.1	Hippocampal volume;	chr12:65148798	chr12:64883394~64977522:+
BRCA	cis	rs67478160	0.643	rs12891175	ENSG00000269940.1	RP11-73M18.7	3.26	0.00113	0.048	0.1	0.1	Schizophrenia;	chr14:103807829	chr14:103694560~103695170:+
BRCA	cis	rs67478160	0.595	rs12889993	ENSG00000269940.1	RP11-73M18.7	3.26	0.00113	0.048	0.1	0.1	Schizophrenia;	chr14:103807957	chr14:103694560~103695170:+
BRCA	cis	rs698833	0.518	rs7562945	ENSG00000259439.2	RP11-89K21.1	3.26	0.00113	0.048	0.14	0.1	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr2:44325633	chr2:44921077~44939199:-
BRCA	cis	rs10836699	0.635	rs2662204	ENSG00000280331.1	RP11-545D22.1	3.26	0.00113	0.048	0.12	0.1	Low high density lipoprotein cholesterol levels;	chr11:37143397	chr11:36510361~36510537:+
BRCA	cis	rs977987	0.778	rs11858992	ENSG00000280152.1	RP11-331F4.5	-3.26	0.00113	0.048	-0.1	-0.1	Dupuytren's disease;	chr16:75377547	chr16:75245994~75250077:-
BRCA	cis	rs224278	0.531	rs6479852	ENSG00000238280.1	RP11-436D10.3	-3.26	0.00114	0.048	-0.15	-0.1	Ewing sarcoma;	chr10:62903547	chr10:62793562~62805887:-
BRCA	cis	rs13434995	0.513	rs6802	ENSG00000273257.1	RP11-177J6.1	-3.26	0.00114	0.048	-0.15	-0.1	Adiponectin levels;	chr4:55425934	chr4:55387949~55388271:+
BRCA	cis	rs11758351	0.866	rs2069018	ENSG00000216331.1	HIST1H1PS1	3.26	0.00114	0.048	0.17	0.1	Renal underexcretion gout;Gout;	chr6:26205490	chr6:26195566~26195771:+
BRCA	cis	rs11758351	0.866	rs11757394	ENSG00000216331.1	HIST1H1PS1	3.26	0.00114	0.048	0.17	0.1	Renal underexcretion gout;Gout;	chr6:26206466	chr6:26195566~26195771:+
BRCA	cis	rs6005807	0.688	rs16986077	ENSG00000272858.1	CTA-292E10.8	3.26	0.00114	0.048	0.22	0.1	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28152979	chr22:28814914~28815662:+
BRCA	cis	rs9341808	0.69	rs2322634	ENSG00000233967.5	RP11-250B2.3	3.26	0.00114	0.048	0.1	0.1	Sitting height ratio;	chr6:80164297	chr6:80443344~80465927:+
BRCA	cis	rs7742824	1	rs57576544	ENSG00000219222.1	RP11-480N24.3	3.26	0.00114	0.048	0.12	0.1	Major depressive disorder;	chr6:44104989	chr6:43310231~43310357:+
BRCA	cis	rs986417	0.901	rs1955693	ENSG00000258670.1	RP11-1042B17.3	-3.26	0.00114	0.048	-0.18	-0.1	Gut microbiota (bacterial taxa);	chr14:60545613	chr14:60515119~60554916:+
BRCA	cis	rs1003719	0.762	rs6517402	ENSG00000242553.1	AP001432.14	-3.26	0.00114	0.048	-0.11	-0.1	Eye color traits;	chr21:37075123	chr21:37221419~37237744:+
BRCA	cis	rs1003719	0.788	rs8133549	ENSG00000242553.1	AP001432.14	-3.26	0.00114	0.048	-0.11	-0.1	Eye color traits;	chr21:37075189	chr21:37221419~37237744:+
BRCA	cis	rs875971	0.66	rs1860468	ENSG00000271064.1	RP11-792A8.3	3.26	0.00114	0.048	0.12	0.1	Aortic root size;	chr7:66642265	chr7:66748838~66749077:-
BRCA	cis	rs1005277	0.522	rs200943	ENSG00000099251.13	HSD17B7P2	3.26	0.00114	0.048	0.11	0.1	Extrinsic epigenetic age acceleration;	chr10:37859802	chr10:38356380~38378505:+
BRCA	cis	rs748404	0.666	rs36078097	ENSG00000201136.1	RNU6-353P	3.26	0.00114	0.048	0.14	0.1	Lung cancer;	chr15:43466209	chr15:43702363~43702470:+
BRCA	cis	rs748404	0.666	rs7181783	ENSG00000201136.1	RNU6-353P	3.26	0.00114	0.048	0.14	0.1	Lung cancer;	chr15:43469723	chr15:43702363~43702470:+
BRCA	cis	rs748404	0.666	rs35903301	ENSG00000201136.1	RNU6-353P	3.26	0.00114	0.048	0.14	0.1	Lung cancer;	chr15:43472332	chr15:43702363~43702470:+
BRCA	cis	rs748404	0.666	rs34002293	ENSG00000201136.1	RNU6-353P	3.26	0.00114	0.048	0.14	0.1	Lung cancer;	chr15:43472401	chr15:43702363~43702470:+
BRCA	cis	rs748404	0.666	rs34181131	ENSG00000201136.1	RNU6-353P	3.26	0.00114	0.048	0.14	0.1	Lung cancer;	chr15:43478527	chr15:43702363~43702470:+
BRCA	cis	rs748404	0.666	rs7173383	ENSG00000201136.1	RNU6-353P	3.26	0.00114	0.048	0.14	0.1	Lung cancer;	chr15:43480838	chr15:43702363~43702470:+
BRCA	cis	rs748404	0.666	rs55801120	ENSG00000201136.1	RNU6-353P	3.26	0.00114	0.048	0.14	0.1	Lung cancer;	chr15:43495042	chr15:43702363~43702470:+
BRCA	cis	rs748404	0.666	rs12911740	ENSG00000201136.1	RNU6-353P	3.26	0.00114	0.048	0.14	0.1	Lung cancer;	chr15:43498254	chr15:43702363~43702470:+
BRCA	cis	rs875971	0.755	rs76288834	ENSG00000271064.1	RP11-792A8.3	3.26	0.00114	0.048	0.12	0.1	Aortic root size;	chr7:66604815	chr7:66748838~66749077:-
BRCA	cis	rs4372836	0.729	rs10865508	ENSG00000226833.4	AC097724.3	-3.26	0.00114	0.048	-0.12	-0.1	Body mass index;	chr2:28830838	chr2:28708953~28736205:-
BRCA	cis	rs13401620	0.843	rs34265631	ENSG00000223549.1	MTND5P28	3.26	0.00114	0.048	0.13	0.1	Breast size;	chr2:119760017	chr2:120215181~120217279:+
BRCA	cis	rs9650657	0.631	rs1124010	ENSG00000248896.2	CTD-2135J3.3	-3.26	0.00114	0.048	-0.12	-0.1	Neuroticism;	chr8:10737992	chr8:10729314~10771392:+
BRCA	cis	rs2904967	0.929	rs655433	ENSG00000254501.1	AP003068.9	3.26	0.00114	0.048	0.18	0.1	Mean corpuscular volume;	chr11:65301804	chr11:65110714~65111695:-
BRCA	cis	rs116988415	0.584	rs4902311	ENSG00000258809.1	CTD-2555O16.1	3.26	0.00114	0.048	0.23	0.1	Daytime sleep phenotypes;	chr14:64775215	chr14:64358768~64379318:-
BRCA	cis	rs80226907	1	rs76072059	ENSG00000258413.1	RP11-665C16.6	-3.26	0.00114	0.048	-0.27	-0.1	Mean platelet volume;	chr14:55388534	chr14:55262767~55272075:-
BRCA	cis	rs80226907	1	rs76413332	ENSG00000258413.1	RP11-665C16.6	-3.26	0.00114	0.048	-0.27	-0.1	Mean platelet volume;	chr14:55388876	chr14:55262767~55272075:-
BRCA	cis	rs80226907	1	rs17675052	ENSG00000258413.1	RP11-665C16.6	-3.26	0.00114	0.048	-0.27	-0.1	Mean platelet volume;	chr14:55388986	chr14:55262767~55272075:-
BRCA	cis	rs80226907	1	rs75285274	ENSG00000258413.1	RP11-665C16.6	-3.26	0.00114	0.048	-0.27	-0.1	Mean platelet volume;	chr14:55389686	chr14:55262767~55272075:-
BRCA	cis	rs12368653	0.557	rs903067	ENSG00000257159.1	RP11-58A17.3	3.26	0.00114	0.048	0.12	0.1	Multiple sclerosis;	chr12:57618074	chr12:57967058~57968399:+
BRCA	cis	rs6681460	0.546	rs10889648	ENSG00000248458.2	RP4-598P13.1	3.26	0.00114	0.048	0.1	0.1	Presence of antiphospholipid antibodies;	chr1:66702499	chr1:66665864~66677027:-
BRCA	cis	rs1501138	0.547	rs317856	ENSG00000263327.5	TAPT1-AS1	3.26	0.00114	0.048	0.14	0.1	Systemic juvenile idiopathic arthritis;	chr4:16159942	chr4:16226685~16320140:+
BRCA	cis	rs7474896	0.945	rs615718	ENSG00000120555.12	SEPT7P9	-3.26	0.00114	0.048	-0.18	-0.1	Obesity (extreme);	chr10:38022937	chr10:38383069~38402916:-
BRCA	cis	rs7474896	0.895	rs650873	ENSG00000120555.12	SEPT7P9	-3.26	0.00114	0.048	-0.18	-0.1	Obesity (extreme);	chr10:38035537	chr10:38383069~38402916:-
BRCA	cis	rs11673344	0.504	rs35579954	ENSG00000267672.1	CTD-2293H3.1	3.26	0.00114	0.048	0.12	0.1	Obesity-related traits;	chr19:37139308	chr19:37091341~37092564:+
BRCA	cis	rs34779708	0.966	rs4934540	ENSG00000269952.1	RP11-324I22.3	-3.26	0.00114	0.048	-0.13	-0.1	Inflammatory bowel disease;Crohn's disease;	chr10:35185771	chr10:35210416~35210750:+
BRCA	cis	rs4218	0.573	rs4775115	ENSG00000259732.1	RP11-59H7.3	-3.26	0.00114	0.048	-0.12	-0.1	Social communication problems;	chr15:59076311	chr15:59121034~59133250:+
BRCA	cis	rs3816183	0.626	rs4952908	ENSG00000226491.1	FTOP1	-3.26	0.00114	0.048	-0.12	-0.1	Hypospadias;	chr2:42685125	chr2:42797225~42798712:-
BRCA	cis	rs10504130	0.569	rs34004633	ENSG00000272076.1	RP11-11C20.3	3.26	0.00114	0.048	0.15	0.1	Venous thromboembolism (SNP x SNP interaction);	chr8:51764279	chr8:51810110~51810681:-
BRCA	cis	rs295490	0.748	rs75866638	ENSG00000178631.7	ACTG1P1	-3.26	0.00114	0.048	-0.21	-0.1	PR interval in Tripanosoma cruzi seropositivity;	chr3:139338830	chr3:139493809~139494937:+
BRCA	cis	rs2833693	1	rs2833696	ENSG00000261610.1	AP000265.1	-3.26	0.00114	0.048	-0.13	-0.1	Temperament;	chr21:32182271	chr21:32259804~32261585:-
BRCA	cis	rs4272720	0.639	rs2264846	ENSG00000228754.1	RP11-534L6.3	3.26	0.00114	0.048	0.12	0.1	Platelet count;Plateletcrit;	chr10:49045142	chr10:48745545~48746128:-
BRCA	cis	rs4835473	0.932	rs13130345	ENSG00000246448.2	RP13-578N3.3	3.26	0.00114	0.048	0.12	0.1	Immature fraction of reticulocytes;	chr4:143920939	chr4:143700257~143865072:+
BRCA	cis	rs6088590	0.648	rs6059991	ENSG00000269202.1	RP4-614O4.12	-3.26	0.00114	0.048	-0.1	-0.1	Coronary artery disease;	chr20:34693032	chr20:35201747~35203288:-
BRCA	cis	rs1008375	0.966	rs6832387	ENSG00000249502.1	AC006160.5	-3.26	0.00114	0.048	-0.11	-0.1	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17695923	chr4:17587467~17614571:-
BRCA	cis	rs484621	0.967	rs547738	ENSG00000216977.1	RPL21P65	3.26	0.00114	0.048	0.12	0.1	Glucose homeostasis traits;	chr6:106290848	chr6:106642463~106642928:+
BRCA	cis	rs4650994	0.571	rs6700047	ENSG00000213057.5	C1orf220	-3.26	0.00114	0.048	-0.1	-0.1	HDL cholesterol;HDL cholesterol levels;	chr1:178539607	chr1:178542752~178548889:+
BRCA	cis	rs4650994	0.571	rs6676507	ENSG00000213057.5	C1orf220	-3.26	0.00114	0.048	-0.1	-0.1	HDL cholesterol;HDL cholesterol levels;	chr1:178539608	chr1:178542752~178548889:+
BRCA	cis	rs10924970	0.934	rs4288584	ENSG00000230026.2	RP11-382D8.5	-3.26	0.00114	0.048	-0.11	-0.1	Asthma;	chr1:235273316	chr1:235361153~235362540:+
BRCA	cis	rs11773103	0.786	rs73203002	ENSG00000224046.1	AC005076.5	3.26	0.00114	0.048	0.17	0.1	Bipolar disorder or major depressive disorder (combined);	chr7:87129584	chr7:87151423~87152420:-
BRCA	cis	rs6142102	0.923	rs4911394	ENSG00000206582.1	Y_RNA	-3.26	0.00114	0.0481	-0.12	-0.1	Skin pigmentation;	chr20:33989521	chr20:34526510~34526606:-
BRCA	cis	rs4849845	0.584	rs3896630	ENSG00000236878.1	AC012363.7	3.26	0.00114	0.0481	0.12	0.1	Mean platelet volume;	chr2:120279442	chr2:120211054~120211715:+
BRCA	cis	rs4849845	0.637	rs13022486	ENSG00000236878.1	AC012363.7	3.26	0.00114	0.0481	0.12	0.1	Mean platelet volume;	chr2:120281035	chr2:120211054~120211715:+
BRCA	cis	rs1843834	0.611	rs1058360	ENSG00000274629.1	RP11-92F20.1	-3.26	0.00114	0.0481	-0.13	-0.1	IgE levels in asthmatics (D.p. specific);	chr2:224584525	chr2:224464682~224474500:+
BRCA	cis	rs757110	0.933	rs7124355	ENSG00000184669.7	OR7E14P	-3.26	0.00114	0.0481	-0.14	-0.1	Type 2 diabetes;	chr11:17391413	chr11:17013998~17053024:+
BRCA	cis	rs3781264	0.595	rs3818432	ENSG00000268894.5	PLCE1-AS1	-3.26	0.00114	0.0481	-0.14	-0.1	Esophageal cancer and gastric cancer;	chr10:94304411	chr10:94279277~94287478:-
BRCA	cis	rs561341	1	rs554078	ENSG00000277511.1	CTD-2095E4.5	3.26	0.00114	0.0481	0.16	0.1	Hip circumference adjusted for BMI;	chr17:32003090	chr17:32127595~32128454:+
BRCA	cis	rs11250097	0.549	rs11778177	ENSG00000270074.1	RP11-351I21.11	3.26	0.00114	0.0481	0.13	0.1	Neuroticism;	chr8:11452853	chr8:12412827~12414373:+
BRCA	cis	rs10843647	1	rs2101305	ENSG00000245614.3	DDX11-AS1	-3.26	0.00114	0.0481	-0.11	-0.1	Glucose homeostasis traits;	chr12:30182481	chr12:31020763~31073847:-
BRCA	cis	rs10043228	1	rs1876673	ENSG00000250015.1	CTC-339F2.2	3.26	0.00114	0.0481	0.15	0.1	Asthma or chronic obstructive pulmonary disease;	chr5:116115076	chr5:116302354~116304134:-
BRCA	cis	rs72928364	0.725	rs13099753	ENSG00000256628.3	ZBTB11-AS1	3.26	0.00114	0.0481	0.15	0.1	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:101050480	chr3:101676475~101679217:+
BRCA	cis	rs55904328	0.961	rs72930511	ENSG00000255135.3	RP11-111M22.3	-3.26	0.00114	0.0481	-0.11	-0.1	3-hydroxypropylmercapturic acid levels in smokers;	chr11:76496665	chr11:76441338~76444656:-
BRCA	cis	rs11638815	0.668	rs11635460	ENSG00000279758.1	RP11-752G15.10	3.26	0.00114	0.0481	0.11	0.1	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82725801	chr15:82738386~82739122:+
BRCA	cis	rs10816359	0.947	rs10978370	ENSG00000234323.4	RP11-308N19.1	3.26	0.00114	0.0481	0.15	0.1	Menarche (age at onset);	chr9:105999346	chr9:106278392~106604795:+
BRCA	cis	rs12477602	0.938	rs6706495	ENSG00000272966.1	RP11-686O6.1	3.26	0.00114	0.0481	0.17	0.1	Intelligence (multi-trait analysis);	chr2:202403732	chr2:202336739~202337200:+
BRCA	cis	rs853679	0.882	rs9468287	ENSG00000216676.2	RP1-15D7.1	-3.26	0.00114	0.0481	-0.18	-0.1	Depression;	chr6:28111963	chr6:27652602~27652825:-
BRCA	cis	rs896655	0.631	rs1335511	ENSG00000279670.1	RP11-70L8.5	3.26	0.00114	0.0481	0.12	0.1	Coronary artery disease;	chr9:21757917	chr9:21892188~21893857:+
BRCA	cis	rs10266483	0.545	rs7777148	ENSG00000227986.1	TRIM60P18	3.26	0.00114	0.0481	0.13	0.1	Response to statin therapy;	chr7:64285795	chr7:64355078~64356199:+
BRCA	cis	rs1113500	0.787	rs11185266	ENSG00000230489.1	VAV3-AS1	-3.26	0.00114	0.0481	-0.12	-0.1	Growth-regulated protein alpha levels;	chr1:108100042	chr1:107964443~107994607:+
BRCA	cis	rs62247992	0.698	rs60879744	ENSG00000227245.1	RP11-136C24.2	3.26	0.00114	0.0481	0.14	0.1	Facial morphology (factor 15, philtrum width);	chr3:43110995	chr3:43087479~43088068:+
BRCA	cis	rs10792665	0.512	rs6592087	ENSG00000254965.1	RP11-113K21.2	-3.26	0.00114	0.0481	-0.1	-0.1	Obesity-related traits;	chr11:82884933	chr11:83111060~83111442:-
BRCA	cis	rs4622329	0.552	rs4764669	ENSG00000257202.1	RP11-512N21.3	3.26	0.00114	0.0481	0.12	0.1	Systemic lupus erythematosus;	chr12:101894472	chr12:101923410~101924719:-
BRCA	cis	rs2904967	1	rs487989	ENSG00000254501.1	AP003068.9	3.26	0.00114	0.0481	0.18	0.1	Mean corpuscular volume;	chr11:65297219	chr11:65110714~65111695:-
BRCA	cis	rs7537765	1	rs56190030	ENSG00000242349.4	NPPA-AS1	-3.26	0.00114	0.0481	-0.15	-0.1	QRS complex (12-leadsum);	chr1:11827325	chr1:11841017~11848079:+
BRCA	cis	rs2043112	0.867	rs1239344	ENSG00000249911.1	LINC01265	3.26	0.00114	0.0481	0.12	0.1	Obesity-related traits;	chr5:38933647	chr5:38710367~38720273:-
BRCA	cis	rs4671400	0.571	rs28480287	ENSG00000212978.6	AC016747.3	-3.26	0.00114	0.0481	-0.16	-0.1	3-hydroxypropylmercapturic acid levels in smokers;	chr2:61262154	chr2:61141592~61144969:-
BRCA	cis	rs2307022	0.671	rs9889191	ENSG00000263276.1	RP11-96D1.10	-3.26	0.00114	0.0481	-0.1	-0.1	Body mass index;	chr16:68343945	chr16:68224713~68227734:+
BRCA	cis	rs10463316	0.779	rs6861968	ENSG00000260581.1	CTB-113P19.4	3.26	0.00114	0.0481	0.12	0.1	Metabolite levels (Pyroglutamine);	chr5:151438164	chr5:151652275~151655449:+
BRCA	cis	rs2274273	0.624	rs7150234	ENSG00000259318.1	RP11-454L9.2	3.26	0.00114	0.0481	0.09	0.1	Protein biomarker;	chr14:55335463	chr14:55394940~55395233:-
BRCA	cis	rs8073060	0.586	rs2523114	ENSG00000267554.1	RP11-686D22.10	-3.26	0.00114	0.0481	-0.11	-0.1	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35696743	chr17:35470069~35470628:-
BRCA	cis	rs9876781	0.559	rs7630053	ENSG00000199476.1	Y_RNA	-3.26	0.00114	0.0481	-0.13	-0.1	Longevity;	chr3:48357096	chr3:48288587~48288694:+
BRCA	cis	rs6490294	0.571	rs58886972	ENSG00000257624.1	RP1-128M12.3	3.26	0.00114	0.0481	0.18	0.1	Mean platelet volume;	chr12:112071477	chr12:112000739~112000985:-
BRCA	cis	rs12200782	0.53	rs9379892	ENSG00000124549.13	BTN2A3P	3.26	0.00114	0.0481	0.13	0.1	Small cell lung carcinoma;	chr6:26582186	chr6:26421391~26432383:+
BRCA	cis	rs6532023	1	rs7683315	ENSG00000249001.4	RP11-742B18.1	3.26	0.00114	0.0481	0.12	0.1	Bone mineral density (paediatric, total body less head);Bone mineral density;	chr4:87851943	chr4:87568035~87733956:-
BRCA	cis	rs6088590	0.561	rs6088527	ENSG00000269202.1	RP4-614O4.12	-3.26	0.00114	0.0481	-0.1	-0.1	Coronary artery disease;	chr20:34568037	chr20:35201747~35203288:-
BRCA	cis	rs2559856	1	rs2251187	ENSG00000199933.1	RNY1P16	3.26	0.00114	0.0481	0.11	0.1	Blood protein levels;	chr12:101688111	chr12:101719808~101719918:+
BRCA	cis	rs8113308	0.515	rs113082012	ENSG00000269235.1	ZNF350-AS1	3.26	0.00114	0.0481	0.25	0.1	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51960980	chr19:51949134~51981367:+
BRCA	cis	rs1113500	0.787	rs473704	ENSG00000230489.1	VAV3-AS1	3.26	0.00114	0.0481	0.12	0.1	Growth-regulated protein alpha levels;	chr1:108094688	chr1:107964443~107994607:+
BRCA	cis	rs10937405	0.603	rs2378503	ENSG00000236182.1	RP11-297K7.1	-3.26	0.00114	0.0481	-0.11	-0.1	Lung adenocarcinoma;	chr3:189597725	chr3:188989382~188990135:-
BRCA	cis	rs911555	0.673	rs7144271	ENSG00000269940.1	RP11-73M18.7	3.26	0.00114	0.0481	0.11	0.1	Intelligence (multi-trait analysis);	chr14:103424337	chr14:103694560~103695170:+
BRCA	cis	rs7011507	1	rs76247795	ENSG00000279881.1	RP11-513O13.1	-3.26	0.00114	0.0481	-0.15	-0.1	Inflammatory bowel disease;Ulcerative colitis;	chr8:48220901	chr8:48428143~48431041:-
BRCA	cis	rs7267979	0.903	rs6115109	ENSG00000204556.4	CTD-2514C3.1	-3.26	0.00114	0.0481	-0.14	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25259031	chr20:26018832~26020684:+
BRCA	cis	rs7267979	0.833	rs4619688	ENSG00000204556.4	CTD-2514C3.1	-3.26	0.00114	0.0481	-0.14	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25263465	chr20:26018832~26020684:+
BRCA	cis	rs6696239	0.513	rs2935155	ENSG00000227711.2	RP11-275O4.5	3.26	0.00114	0.0481	0.12	0.1	Height;	chr1:227585305	chr1:227509028~227520477:-
BRCA	cis	rs2496589	0.963	rs9496640	ENSG00000217648.1	RP1-95L4.4	3.26	0.00114	0.0481	0.15	0.1	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);	chr6:143447994	chr6:143342246~143343383:+
BRCA	cis	rs3816183	0.626	rs4444592	ENSG00000226491.1	FTOP1	-3.26	0.00114	0.0481	-0.13	-0.1	Hypospadias;	chr2:42672619	chr2:42797225~42798712:-
BRCA	cis	rs8015152	0.552	rs8008796	ENSG00000258670.1	RP11-1042B17.3	3.26	0.00114	0.0481	0.14	0.1	Vertical cup-disc ratio;	chr14:60460530	chr14:60515119~60554916:+
BRCA	cis	rs1499614	1	rs2659913	ENSG00000229180.5	GS1-124K5.11	3.26	0.00114	0.0481	0.14	0.1	Gout;	chr7:66692349	chr7:66526088~66542624:-
BRCA	cis	rs1499614	1	rs2659911	ENSG00000229180.5	GS1-124K5.11	3.26	0.00114	0.0481	0.14	0.1	Gout;	chr7:66693433	chr7:66526088~66542624:-
BRCA	cis	rs1499614	1	rs2707838	ENSG00000229180.5	GS1-124K5.11	3.26	0.00114	0.0481	0.14	0.1	Gout;	chr7:66694214	chr7:66526088~66542624:-
BRCA	cis	rs1499614	1	rs60326618	ENSG00000229180.5	GS1-124K5.11	3.26	0.00114	0.0481	0.14	0.1	Gout;	chr7:66701371	chr7:66526088~66542624:-
BRCA	cis	rs1499614	1	rs2707830	ENSG00000229180.5	GS1-124K5.11	3.26	0.00114	0.0481	0.14	0.1	Gout;	chr7:66702658	chr7:66526088~66542624:-
BRCA	cis	rs1499614	1	rs2707828	ENSG00000229180.5	GS1-124K5.11	3.26	0.00114	0.0481	0.14	0.1	Gout;	chr7:66706390	chr7:66526088~66542624:-
BRCA	cis	rs1499614	0.803	rs1922723	ENSG00000229180.5	GS1-124K5.11	3.26	0.00114	0.0481	0.14	0.1	Gout;	chr7:66710076	chr7:66526088~66542624:-
BRCA	cis	rs11673344	0.801	rs112263309	ENSG00000267005.1	AC002984.2	3.26	0.00114	0.0481	0.12	0.1	Obesity-related traits;	chr19:37160333	chr19:36173406~36173853:-
BRCA	cis	rs2041840	0.62	rs6710046	ENSG00000272054.1	RP11-423P10.2	-3.26	0.00114	0.0481	-0.1	-0.1	Chronic lymphocytic leukemia;	chr2:37178512	chr2:37208875~37212677:+
BRCA	cis	rs27434	0.583	rs34756	ENSG00000248734.2	CTD-2260A17.1	-3.26	0.00114	0.0481	-0.11	-0.1	Ankylosing spondylitis;	chr5:96816680	chr5:96784777~96785999:+
BRCA	cis	rs112184198	0.764	rs4548562	ENSG00000236308.1	RP11-316M21.7	3.26	0.00114	0.0481	0.2	0.1	Systolic blood pressure;	chr10:100796500	chr10:100190036~100190747:+
BRCA	cis	rs7869969	0.527	rs10761239	ENSG00000227603.1	RP11-165J3.6	3.26	0.00114	0.0481	0.11	0.1	Childhood body mass index;	chr9:93597602	chr9:93435332~93437121:-
BRCA	cis	rs6687821	0.531	rs7534656	ENSG00000261737.1	RP4-612B15.3	3.26	0.00114	0.0481	0.14	0.1	Yeast infection;	chr1:87045715	chr1:86703502~86704462:-
BRCA	cis	rs7695597	0.965	rs6825138	ENSG00000249173.4	LINC01093	-3.26	0.00114	0.0481	-0.11	-0.1	Night sleep phenotypes;	chr4:184252808	chr4:184893871~184899454:-
BRCA	cis	rs11239930	0.517	rs556976	ENSG00000277406.1	CH17-385C13.2	-3.26	0.00114	0.0481	-0.12	-0.1	AIDS progression;	chr1:147073643	chr1:146321842~146328211:-
BRCA	cis	rs58521262	0.519	rs12461496	ENSG00000241282.1	RPL34P33	3.26	0.00114	0.0481	0.17	0.1	Testicular germ cell tumor;	chr19:22742983	chr19:22699352~22699685:+
BRCA	cis	rs2011503	0.739	rs8108659	ENSG00000267419.1	CTC-559E9.6	3.26	0.00114	0.0481	0.14	0.1	Bipolar disorder;	chr19:19569929	chr19:19776602~19834927:+
BRCA	cis	rs7914558	0.966	rs3977751	ENSG00000213277.3	MARCKSL1P1	3.26	0.00114	0.0481	0.11	0.1	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103160475	chr10:103175554~103176094:+
BRCA	cis	rs6452790	0.543	rs34712971	ENSG00000247828.6	TMEM161B-AS1	-3.26	0.00114	0.0481	-0.14	-0.1	Cognitive function;	chr5:88006139	chr5:88268895~88436685:+
BRCA	cis	rs478607	1	rs478607	ENSG00000237410.1	AP001092.4	3.26	0.00114	0.0481	0.14	0.1	Urate levels;	chr11:64710591	chr11:64646399~64659681:+
BRCA	cis	rs4742903	0.967	rs7871759	ENSG00000270332.1	SMC2-AS1	3.26	0.00114	0.0481	0.11	0.1	Breast cancer;High-grade serous ovarian cancer;	chr9:104103157	chr9:104080024~104093073:-
BRCA	cis	rs1009077	0.61	rs2389866	ENSG00000250412.1	KLHL2P1	3.26	0.00114	0.0481	0.13	0.1	Endometriosis;	chr4:119594108	chr4:119334329~119378233:+
BRCA	cis	rs1009077	0.579	rs10032993	ENSG00000250412.1	KLHL2P1	3.26	0.00114	0.0481	0.13	0.1	Endometriosis;	chr4:119595462	chr4:119334329~119378233:+
BRCA	cis	rs1009077	0.504	rs9998919	ENSG00000250412.1	KLHL2P1	3.26	0.00114	0.0481	0.13	0.1	Endometriosis;	chr4:119595538	chr4:119334329~119378233:+
BRCA	cis	rs73186030	0.844	rs73186015	ENSG00000272758.4	RP11-299J3.8	3.26	0.00114	0.0481	0.16	0.1	Serum parathyroid hormone levels;	chr3:122272236	chr3:122416207~122443180:+
BRCA	cis	rs73186030	0.764	rs17251221	ENSG00000272758.4	RP11-299J3.8	3.26	0.00114	0.0481	0.16	0.1	Serum parathyroid hormone levels;	chr3:122274400	chr3:122416207~122443180:+
BRCA	cis	rs72772090	0.71	rs11750399	ENSG00000272109.1	CTD-2260A17.3	3.26	0.00114	0.0482	0.19	0.1	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96742236	chr5:96804353~96806105:+
BRCA	cis	rs17767294	0.708	rs72848790	ENSG00000219392.1	RP1-265C24.5	-3.26	0.00114	0.0482	-0.28	-0.1	Parkinson's disease;	chr6:28018074	chr6:28115628~28116551:+
BRCA	cis	rs3753275	0.684	rs3866804	ENSG00000232912.4	RP5-1115A15.1	3.26	0.00114	0.0482	0.14	0.1	Educational attainment;	chr1:8838916	chr1:8424645~8434838:+
BRCA	cis	rs11250097	0.549	rs11784897	ENSG00000270074.1	RP11-351I21.11	3.26	0.00114	0.0482	0.13	0.1	Neuroticism;	chr8:11452933	chr8:12412827~12414373:+
BRCA	cis	rs11673344	0.704	rs1667384	ENSG00000267005.1	AC002984.2	3.26	0.00114	0.0482	0.12	0.1	Obesity-related traits;	chr19:36925852	chr19:36173406~36173853:-
BRCA	cis	rs8114671	0.869	rs1407202	ENSG00000261582.1	RP4-614O4.11	3.26	0.00114	0.0482	0.1	0.1	Height;	chr20:35064164	chr20:35267885~35280043:-
BRCA	cis	rs35520189	0.961	rs58788639	ENSG00000231747.1	AC079922.2	-3.26	0.00114	0.0482	-0.11	-0.1	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:112869012	chr2:112621809~112622167:-
BRCA	cis	rs4819052	0.851	rs4819041	ENSG00000215447.6	BX322557.10	-3.26	0.00114	0.0482	-0.1	-0.1	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240040	chr21:45288052~45291738:+
BRCA	cis	rs7142881	0.844	rs7152067	ENSG00000258648.1	UBE2CP1	3.26	0.00114	0.0482	0.11	0.1	Response to iloperidone treatment (QT prolongation);	chr14:31563847	chr14:30683045~30683598:-
BRCA	cis	rs7142881	0.844	rs7152506	ENSG00000258648.1	UBE2CP1	3.26	0.00114	0.0482	0.11	0.1	Response to iloperidone treatment (QT prolongation);	chr14:31563887	chr14:30683045~30683598:-
BRCA	cis	rs11098499	0.863	rs11098532	ENSG00000225892.3	RP11-384K6.2	3.26	0.00114	0.0482	0.1	0.1	Corneal astigmatism;	chr4:119569571	chr4:118632274~118634759:+
BRCA	cis	rs2535633	0.631	rs6799185	ENSG00000279144.1	RP11-894J14.2	3.26	0.00114	0.0482	0.12	0.1	Body mass index;	chr3:53067564	chr3:52848085~52848553:-
BRCA	cis	rs964184	1	rs964184	ENSG00000254851.1	RP11-109L13.1	-3.26	0.00114	0.0482	-0.15	-0.1	Very long-chain saturated fatty acid levels (fatty acid 20:0);Response to Vitamin E supplementation;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Metabolite levels (lipoprotein measures);LDL cholesterol levels;Vitamin E levels;Platelet distribution width;Mean corpuscular hemoglobin concentration;Metabolic syndrome;HDL cholesterol;Coronary artery disease;Hypertriglyceridemia;LDL cholesterol;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Metabolite levels;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;Reticulocyte fraction of red cells;Blood metabolite levels;Red cell distribution width;Lipoprotein-associated phospholipase A2 activity and mass;Reticulocyte count;Triglyceride levels;Circulating phylloquinone levels;Coronary heart disease;Triglycerides;Postprandial triglyceride response to high fat diet meal;Coronary artery disease or large artery stroke;Phospholipid levels (plasma);Total cholesterol levels;Very low density lipoprotein cholesterol levels;Mean platelet volume;Cholesterol, total;	chr11:116778201	chr11:117135528~117138582:+
BRCA	cis	rs4805834	0.719	rs55977451	ENSG00000201388.1	SNORA68	3.26	0.00114	0.0482	0.18	0.1	Creatinine levels;	chr19:32807216	chr19:32608337~32608469:-
BRCA	cis	rs13153459	0.602	rs72748082	ENSG00000279557.1	CTD-2210P15.3	-3.26	0.00114	0.0482	-0.19	-0.1	Parkinson's disease;	chr5:44505704	chr5:43586367~43587543:-
BRCA	cis	rs13153459	0.602	rs957739	ENSG00000279557.1	CTD-2210P15.3	-3.26	0.00114	0.0482	-0.19	-0.1	Parkinson's disease;	chr5:44506312	chr5:43586367~43587543:-
BRCA	cis	rs58521262	0.519	rs11669364	ENSG00000241282.1	RPL34P33	3.26	0.00114	0.0482	0.17	0.1	Testicular germ cell tumor;	chr19:22774514	chr19:22699352~22699685:+
BRCA	cis	rs11702148	0.552	rs3787708	ENSG00000231355.1	AP000302.58	3.26	0.00114	0.0482	0.12	0.1	Mean corpuscular hemoglobin;	chr21:33533733	chr21:33482499~33484258:-
BRCA	cis	rs76866386	0.786	rs4507142	ENSG00000231826.4	AC016735.2	-3.26	0.00114	0.0482	-0.19	-0.1	Cholesterol, total;	chr2:43859452	chr2:43027853~43039547:-
BRCA	cis	rs924712	0.57	rs2134536	ENSG00000224984.1	RP11-524H19.2	3.26	0.00114	0.0482	0.13	0.1	Breast cancer;	chr6:54992882	chr6:54840118~54840855:-
BRCA	cis	rs2899832	0.5	rs77298387	ENSG00000258704.4	SRP54-AS1	3.26	0.00114	0.0482	0.24	0.1	Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:35321371	chr14:34920858~34982532:-
BRCA	cis	rs2204008	0.528	rs11503820	ENSG00000257718.1	RP11-396F22.1	-3.26	0.00114	0.0482	-0.1	-0.1	Bladder cancer;	chr12:38001577	chr12:38906451~38909592:+
BRCA	cis	rs2999052	0.509	rs1735537	ENSG00000250796.1	RP11-723O4.3	3.26	0.00114	0.0482	0.14	0.1	Hypospadias;	chr3:128403977	chr3:128869624~128870026:+
BRCA	cis	rs863345	0.564	rs11264988	ENSG00000229914.1	RP11-404O13.4	-3.26	0.00114	0.0482	-0.11	-0.1	Pneumococcal bacteremia;	chr1:158497122	chr1:158195633~158196131:-
BRCA	cis	rs4834770	0.668	rs1397610	ENSG00000249244.1	RP11-548H18.2	-3.26	0.00114	0.0482	-0.12	-0.1	Blood protein levels;	chr4:119206606	chr4:119391831~119395335:-
BRCA	cis	rs2395128	0.667	rs10490991	ENSG00000213731.2	RAB5CP1	-3.26	0.00114	0.0482	-0.21	-0.1	Ulcerative colitis;Inflammatory bowel disease;	chr10:74923142	chr10:74423435~74424014:-
BRCA	cis	rs6840360	0.615	rs62329085	ENSG00000270265.1	RP11-731D1.4	-3.26	0.00114	0.0482	-0.12	-0.1	Intelligence (multi-trait analysis);	chr4:151549085	chr4:151333775~151353224:-
BRCA	cis	rs6012564	1	rs4810909	ENSG00000222365.1	SNORD12B	-3.26	0.00114	0.0482	-0.11	-0.1	Anger;	chr20:49004835	chr20:49280319~49280409:+
BRCA	cis	rs7591351	0.551	rs2002949	ENSG00000239332.4	LINC01119	3.26	0.00114	0.0482	0.11	0.1	Pathological gambling;	chr2:45837290	chr2:46816697~46859007:+
BRCA	cis	rs2638953	0.925	rs11049563	ENSG00000273989.1	RP11-425D17.2	-3.26	0.00114	0.0482	-0.15	-0.1	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28376041	chr12:28236227~28236828:+
BRCA	cis	rs240993	0.812	rs6937734	ENSG00000255389.1	C6orf3	3.26	0.00114	0.0482	0.11	0.1	Inflammatory skin disease;Psoriasis;	chr6:111415439	chr6:111599875~111602295:+
BRCA	cis	rs1528472	0.836	rs11631095	ENSG00000276533.1	RP11-139H15.5	3.26	0.00114	0.0482	0.12	0.1	Urinary albumin-to-creatinine ratio;Urinary albumin-to-creatinine ratio in non-diabetics;	chr15:55022064	chr15:55288849~55289346:-
BRCA	cis	rs1528472	0.868	rs35507766	ENSG00000276533.1	RP11-139H15.5	3.26	0.00114	0.0482	0.12	0.1	Urinary albumin-to-creatinine ratio;Urinary albumin-to-creatinine ratio in non-diabetics;	chr15:55022093	chr15:55288849~55289346:-
BRCA	cis	rs4725617	0.686	rs7780371	ENSG00000229153.4	EPHA1-AS1	-3.26	0.00114	0.0482	-0.21	-0.1	Blood protein levels;	chr7:143395825	chr7:143407813~143523449:+
BRCA	cis	rs17684571	0.938	rs16888130	ENSG00000231441.1	RP11-472M19.2	3.26	0.00114	0.0482	0.14	0.1	Schizophrenia;	chr6:56709382	chr6:56844002~56864078:+
BRCA	cis	rs7812879	0.571	rs4841540	ENSG00000255046.1	RP11-297N6.4	3.26	0.00114	0.0482	0.17	0.1	Systemic lupus erythematosus;	chr8:11451998	chr8:11797928~11802568:-
BRCA	cis	rs12893668	0.603	rs61637848	ENSG00000258534.1	CTD-2134A5.4	3.26	0.00114	0.0482	0.13	0.1	Reticulocyte count;	chr14:103629694	chr14:103854366~103880111:-
BRCA	cis	rs8040855	0.599	rs6496791	ENSG00000259416.2	RP11-158M2.5	-3.26	0.00114	0.0482	-0.12	-0.1	Bulimia nervosa;	chr15:85182428	chr15:85754941~85756237:-
BRCA	cis	rs1476679	0.962	rs34995835	ENSG00000214313.7	AZGP1P1	-3.26	0.00114	0.0482	-0.11	-0.1	Alzheimer's disease (late onset);	chr7:100392741	chr7:99980762~99987535:+
BRCA	cis	rs11662721	0.872	rs11659715	ENSG00000264188.1	RP11-13N13.5	3.26	0.00114	0.0482	0.14	0.1	Phospholipid levels (plasma);	chr18:21671445	chr18:21661787~21662395:-
BRCA	cis	rs13108904	0.967	rs12502916	ENSG00000196810.4	CTBP1-AS2	-3.26	0.00114	0.0482	-0.11	-0.1	Obesity-related traits;	chr4:1282561	chr4:1249300~1288291:+
BRCA	cis	rs7943953	0.516	rs11229925	ENSG00000254717.2	GLYATL1P2	-3.26	0.00114	0.0482	-0.14	-0.1	Odorant perception (&beta-ionone);	chr11:59341025	chr11:58878302~58893460:+
BRCA	cis	rs875971	1	rs1544549	ENSG00000273024.4	INTS4P2	3.26	0.00114	0.0482	0.11	0.1	Aortic root size;	chr7:66625676	chr7:65647864~65715661:+
BRCA	cis	rs6583331	1	rs6799977	ENSG00000225578.1	NCBP2-AS1	-3.26	0.00114	0.0482	-0.1	-0.1	Vitiligo;	chr3:196623970	chr3:196939877~196942534:+
BRCA	cis	rs10877839	1	rs10784293	ENSG00000257354.2	RP11-631N16.2	-3.26	0.00114	0.0482	-0.1	-0.1	IgG glycosylation;	chr12:62417548	chr12:62602752~62622213:+
BRCA	cis	rs12216545	0.765	rs10254007	ENSG00000244151.1	RP11-148K1.12	-3.26	0.00114	0.0482	-0.09	-0.1	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150556293	chr7:151074742~151076530:-
BRCA	cis	rs4415084	0.716	rs9637796	ENSG00000272335.1	RP11-53O19.3	3.26	0.00114	0.0482	0.09	0.1	Breast cancer;	chr5:44817817	chr5:44826076~44828592:+
BRCA	cis	rs4374383	0.962	rs3811638	ENSG00000243389.1	AC012442.5	-3.26	0.00114	0.0482	-0.13	-0.1	Hepatitis C induced liver fibrosis;	chr2:112019149	chr2:112589040~112614431:+
BRCA	cis	rs8054556	0.669	rs12931955	ENSG00000214725.6	CDIPT-AS1	-3.26	0.00114	0.0482	-0.12	-0.1	Autism spectrum disorder or schizophrenia;	chr16:30001745	chr16:29863593~29868053:+
BRCA	cis	rs1046491	0.901	rs11081463	ENSG00000264964.1	RP11-888D10.3	3.26	0.00114	0.0482	0.2	0.1	Scarlet fever;	chr18:9152877	chr18:9315194~9334441:-
BRCA	cis	rs7520050	0.966	rs7556436	ENSG00000226957.1	RP4-533D7.4	-3.26	0.00114	0.0482	-0.11	-0.1	Reticulocyte count;Red blood cell count;	chr1:45898208	chr1:46046818~46048368:+
BRCA	cis	rs12612435	0.696	rs11683736	ENSG00000226806.1	AC011893.3	3.26	0.00114	0.0482	0.12	0.1	Takotsubo syndrome;	chr2:136393559	chr2:135820191~135823087:+
BRCA	cis	rs10876993	0.672	rs2640611	ENSG00000270039.1	RP11-571M6.17	3.26	0.00114	0.0482	0.13	0.1	Celiac disease or Rheumatoid arthritis;	chr12:57643974	chr12:57803838~57804415:+
BRCA	cis	rs2274273	0.686	rs66531545	ENSG00000259318.1	RP11-454L9.2	3.26	0.00114	0.0482	0.09	0.1	Protein biomarker;	chr14:55120742	chr14:55394940~55395233:-
BRCA	cis	rs233721	0.553	rs2891403	ENSG00000234608.6	MAPKAPK5-AS1	3.26	0.00114	0.0482	0.13	0.1	Tonsillectomy;	chr12:112699767	chr12:111839764~111842902:-
BRCA	cis	rs78905543	1	rs4872049	ENSG00000253616.4	RP11-875O11.3	-3.26	0.00114	0.0482	-0.12	-0.1	Mean corpuscular volume;	chr8:23074266	chr8:23071377~23074488:-
BRCA	cis	rs56046484	0.956	rs34105012	ENSG00000259630.2	CTD-2262B20.1	-3.26	0.00114	0.0482	-0.17	-0.1	Testicular germ cell tumor;	chr15:85048455	chr15:85415228~85415633:+
BRCA	cis	rs7239883	0.5	rs1431841	ENSG00000267652.1	RP11-188I24.1	3.26	0.00114	0.0482	0.15	0.1	Waist circumference;Body mass index;	chr18:42507133	chr18:41789162~41789395:-
BRCA	cis	rs7239883	0.5	rs1431838	ENSG00000267652.1	RP11-188I24.1	3.26	0.00114	0.0482	0.15	0.1	Waist circumference;Body mass index;	chr18:42507572	chr18:41789162~41789395:-
BRCA	cis	rs10129255	0.957	rs4387509	ENSG00000211967.3	IGHV3-53	-3.26	0.00114	0.0483	-0.08	-0.1	Kawasaki disease;	chr14:106704386	chr14:106592676~106593347:-
BRCA	cis	rs2704588	1	rs2125410	ENSG00000270720.1	RP11-84C13.2	-3.26	0.00114	0.0483	-0.14	-0.1	Longevity;	chr4:88928164	chr4:89119284~89119871:+
BRCA	cis	rs2243480	1	rs402418	ENSG00000226767.1	RP11-328P23.3	-3.26	0.00114	0.0483	-0.18	-0.1	Diabetic kidney disease;	chr7:66044482	chr7:65508773~65508944:-
BRCA	cis	rs7209700	0.662	rs8080254	ENSG00000228782.6	CTD-2026D20.3	3.26	0.00114	0.0483	0.12	0.1	IgG glycosylation;	chr17:47270526	chr17:47450568~47492492:-
BRCA	cis	rs2638953	0.815	rs11049677	ENSG00000273989.1	RP11-425D17.2	3.26	0.00114	0.0483	0.15	0.1	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28505106	chr12:28236227~28236828:+
BRCA	cis	rs977987	0.806	rs4146809	ENSG00000261476.1	RP11-77K12.3	3.26	0.00114	0.0483	0.11	0.1	Dupuytren's disease;	chr16:75381877	chr16:75458252~75460017:-
BRCA	cis	rs1003719	0.679	rs1133001	ENSG00000242553.1	AP001432.14	3.26	0.00114	0.0483	0.11	0.1	Eye color traits;	chr21:37140656	chr21:37221419~37237744:+
BRCA	cis	rs1003719	0.654	rs764175	ENSG00000242553.1	AP001432.14	3.26	0.00114	0.0483	0.11	0.1	Eye color traits;	chr21:37144758	chr21:37221419~37237744:+
BRCA	cis	rs11587682	0.714	rs115578438	ENSG00000228126.1	FALEC	3.26	0.00114	0.0483	0.13	0.1	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr1:150465876	chr1:150515757~150518032:+
BRCA	cis	rs11587682	0.76	rs74335909	ENSG00000228126.1	FALEC	3.26	0.00114	0.0483	0.13	0.1	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr1:150465886	chr1:150515757~150518032:+
BRCA	cis	rs10129255	0.5	rs8006888	ENSG00000211976.2	IGHV3-73	-3.26	0.00114	0.0483	-0.08	-0.1	Kawasaki disease;	chr14:106782219	chr14:106802694~106803233:-
BRCA	cis	rs853679	0.517	rs9380056	ENSG00000272009.1	RP1-313I6.12	-3.26	0.00114	0.0483	-0.15	-0.1	Depression;	chr6:28136698	chr6:28078792~28081130:-
BRCA	cis	rs853679	0.517	rs9380057	ENSG00000272009.1	RP1-313I6.12	-3.26	0.00114	0.0483	-0.15	-0.1	Depression;	chr6:28136856	chr6:28078792~28081130:-
BRCA	cis	rs853679	0.517	rs6941992	ENSG00000272009.1	RP1-313I6.12	-3.26	0.00114	0.0483	-0.15	-0.1	Depression;	chr6:28138363	chr6:28078792~28081130:-
BRCA	cis	rs4713118	0.516	rs4713142	ENSG00000272009.1	RP1-313I6.12	-3.26	0.00114	0.0483	-0.15	-0.1	Parkinson's disease;	chr6:28138569	chr6:28078792~28081130:-
BRCA	cis	rs853679	0.517	rs4713143	ENSG00000272009.1	RP1-313I6.12	-3.26	0.00114	0.0483	-0.15	-0.1	Depression;	chr6:28138981	chr6:28078792~28081130:-
BRCA	cis	rs853679	0.517	rs4713144	ENSG00000272009.1	RP1-313I6.12	-3.26	0.00114	0.0483	-0.15	-0.1	Depression;	chr6:28139012	chr6:28078792~28081130:-
BRCA	cis	rs7020830	0.516	rs36047049	ENSG00000230188.1	RP11-405L18.4	-3.26	0.00114	0.0483	-0.14	-0.1	Schizophrenia;	chr9:37375475	chr9:37490421~37490893:-
BRCA	cis	rs1984450	0.92	rs2115371	ENSG00000269349.1	CTD-3099C6.5	3.26	0.00114	0.0483	0.19	0.1	Longitudinal alcohol consumption;	chr19:52506861	chr19:52511282~52512342:-
BRCA	cis	rs4927850	1	rs7614767	ENSG00000185485.13	SDHAP1	3.26	0.00114	0.0483	0.1	0.1	Pancreatic cancer;	chr3:196026580	chr3:195959748~195990318:-
BRCA	cis	rs853679	0.517	rs9295761	ENSG00000219891.2	ZSCAN12P1	3.26	0.00114	0.0483	0.14	0.1	Depression;	chr6:28180209	chr6:28091154~28093664:+
BRCA	cis	rs7267979	0.833	rs6138556	ENSG00000231081.1	RP4-760C5.3	-3.26	0.00114	0.0483	-0.13	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25262674	chr20:26008791~26010531:-
BRCA	cis	rs7520050	0.966	rs785485	ENSG00000234329.1	RP11-767N6.2	-3.26	0.00114	0.0483	-0.09	-0.1	Reticulocyte count;Red blood cell count;	chr1:46108752	chr1:45651039~45651826:-
BRCA	cis	rs11098499	0.644	rs17517414	ENSG00000249244.1	RP11-548H18.2	3.26	0.00114	0.0483	0.11	0.1	Corneal astigmatism;	chr4:119340946	chr4:119391831~119395335:-
BRCA	cis	rs7520050	0.966	rs6675726	ENSG00000234329.1	RP11-767N6.2	-3.26	0.00114	0.0483	-0.09	-0.1	Reticulocyte count;Red blood cell count;	chr1:46094971	chr1:45651039~45651826:-
BRCA	cis	rs11673344	0.832	rs56210764	ENSG00000267682.1	CTD-3220F14.2	-3.26	0.00114	0.0483	-0.1	-0.1	Obesity-related traits;	chr19:37125970	chr19:37337236~37337743:+
BRCA	cis	rs6964587	0.61	rs4729008	ENSG00000188693.7	CYP51A1-AS1	-3.26	0.00114	0.0483	-0.11	-0.1	Breast cancer;	chr7:91827740	chr7:92134604~92180725:+
BRCA	cis	rs2075671	0.855	rs11974395	ENSG00000208036.1	MIR106B	3.26	0.00114	0.0483	0.14	0.1	Other erythrocyte phenotypes;	chr7:100684915	chr7:100093993~100094074:-
BRCA	cis	rs7403037	0.617	rs4073701	ENSG00000207279.1	SNORD116-24	-3.26	0.00114	0.0483	-0.13	-0.1	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24599765	chr15:25094037~25094128:+
BRCA	cis	rs4834770	0.668	rs11737086	ENSG00000249244.1	RP11-548H18.2	-3.26	0.00114	0.0483	-0.12	-0.1	Blood protein levels;	chr4:119205962	chr4:119391831~119395335:-
BRCA	cis	rs8048589	0.515	rs4780412	ENSG00000175604.2	RP11-276H1.3	-3.26	0.00114	0.0483	-0.15	-0.1	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);	chr16:12138552	chr16:12086746~12090302:-
BRCA	cis	rs35520189	0.591	rs12105482	ENSG00000231747.1	AC079922.2	-3.26	0.00114	0.0483	-0.11	-0.1	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:112939658	chr2:112621809~112622167:-
BRCA	cis	rs6772849	0.93	rs9873888	ENSG00000207088.1	SNORA7B	-3.26	0.00114	0.0483	-0.13	-0.1	Monocyte percentage of white cells;Monocyte count;	chr3:128642144	chr3:129397210~129397348:-
BRCA	cis	rs258892	0.843	rs16901116	ENSG00000272525.1	RP11-79P5.9	-3.26	0.00114	0.0483	-0.13	-0.1	Small cell lung carcinoma;	chr5:72757555	chr5:73497550~73498293:-
BRCA	cis	rs258892	0.895	rs34252662	ENSG00000272525.1	RP11-79P5.9	-3.26	0.00114	0.0483	-0.13	-0.1	Small cell lung carcinoma;	chr5:72758481	chr5:73497550~73498293:-
BRCA	cis	rs258892	0.895	rs16901131	ENSG00000272525.1	RP11-79P5.9	-3.26	0.00114	0.0483	-0.13	-0.1	Small cell lung carcinoma;	chr5:72759009	chr5:73497550~73498293:-
BRCA	cis	rs258892	0.895	rs2338790	ENSG00000272525.1	RP11-79P5.9	-3.26	0.00114	0.0483	-0.13	-0.1	Small cell lung carcinoma;	chr5:72759357	chr5:73497550~73498293:-
BRCA	cis	rs258892	0.895	rs9293442	ENSG00000272525.1	RP11-79P5.9	-3.26	0.00114	0.0483	-0.13	-0.1	Small cell lung carcinoma;	chr5:72759768	chr5:73497550~73498293:-
BRCA	cis	rs258892	0.895	rs9293443	ENSG00000272525.1	RP11-79P5.9	-3.26	0.00114	0.0483	-0.13	-0.1	Small cell lung carcinoma;	chr5:72759795	chr5:73497550~73498293:-
BRCA	cis	rs6433921	0.557	rs10490692	ENSG00000260742.1	RP11-366L5.1	-3.26	0.00114	0.0483	-0.11	-0.1	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;	chr2:181515978	chr2:181887851~181891663:-
BRCA	cis	rs56046484	0.62	rs34585903	ENSG00000259630.2	CTD-2262B20.1	-3.26	0.00114	0.0483	-0.18	-0.1	Testicular germ cell tumor;	chr15:84984893	chr15:85415228~85415633:+
BRCA	cis	rs10043228	1	rs17138917	ENSG00000250015.1	CTC-339F2.2	3.26	0.00114	0.0483	0.13	0.1	Asthma or chronic obstructive pulmonary disease;	chr5:116133619	chr5:116302354~116304134:-
BRCA	cis	rs11673344	0.796	rs16971886	ENSG00000267309.1	CTD-2630F21.1	-3.26	0.00114	0.0483	-0.12	-0.1	Obesity-related traits;	chr19:36997073	chr19:36489649~36491040:+
BRCA	cis	rs6560517	0.581	rs2501933	ENSG00000234618.1	RPSAP9	-3.26	0.00114	0.0483	-0.11	-0.1	Dialysis-related mortality;	chr9:76375259	chr9:76398699~76399586:+
BRCA	cis	rs4478858	0.684	rs7519766	ENSG00000229447.2	RP11-490K7.4	-3.26	0.00114	0.0483	-0.1	-0.1	Alcohol dependence;	chr1:31262665	chr1:31263245~31263681:-
BRCA	cis	rs9847710	0.933	rs1529544	ENSG00000275956.1	RP5-966M1.7	3.26	0.00114	0.0483	0.11	0.1	Ulcerative colitis;	chr3:53005439	chr3:52732547~52733867:+
BRCA	cis	rs7028939	1	rs7020780	ENSG00000239908.3	RN7SL75P	-3.26	0.00114	0.0483	-0.17	-0.1	Preeclampsia;	chr9:100196454	chr9:100102559~100102839:+
BRCA	cis	rs875971	1	rs778710	ENSG00000067601.7	PMS2P4	-3.26	0.00114	0.0483	-0.12	-0.1	Aortic root size;	chr7:66389847	chr7:67295608~67302907:-
BRCA	cis	rs7833787	1	rs6586778	ENSG00000254054.2	RP11-156K13.3	3.26	0.00115	0.0483	0.12	0.1	Obesity-related traits;	chr8:18848660	chr8:17905756~17907887:+
BRCA	cis	rs6429422	0.613	rs12749004	ENSG00000224727.1	FCF1P7	-3.26	0.00115	0.0483	-0.12	-0.1	Cognitive ability (multi-trait analysis);	chr1:243245850	chr1:243267257~243268119:-
BRCA	cis	rs890448	0.796	rs2471679	ENSG00000254531.1	FLJ20021	3.26	0.00115	0.0483	0.11	0.1	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);	chr4:101426354	chr4:101347780~101348883:+
BRCA	cis	rs1005277	0.54	rs2224248	ENSG00000276805.1	RP11-291L22.6	3.26	0.00115	0.0483	0.11	0.1	Extrinsic epigenetic age acceleration;	chr10:38162958	chr10:38451030~38451785:+
BRCA	cis	rs13160562	0.623	rs26509	ENSG00000248734.2	CTD-2260A17.1	-3.26	0.00115	0.0483	-0.11	-0.1	Alcohol dependence;	chr5:96746976	chr5:96784777~96785999:+
BRCA	cis	rs4964805	0.632	rs11111782	ENSG00000214198.6	RP11-642P15.1	3.26	0.00115	0.0483	0.11	0.1	Attention deficit hyperactivity disorder;	chr12:103794698	chr12:103843749~103930211:-
BRCA	cis	rs313462	0.592	rs313439	ENSG00000231298.5	LINC00704	-3.26	0.00115	0.0483	-0.14	-0.1	Major depressive disorder;	chr10:4641023	chr10:4650185~4678154:-
BRCA	cis	rs748404	0.666	rs34515241	ENSG00000166763.7	STRCP1	3.26	0.00115	0.0483	0.15	0.1	Lung cancer;	chr15:43342011	chr15:43699488~43718184:-
BRCA	cis	rs13401620	0.626	rs4849826	ENSG00000236878.1	AC012363.7	3.26	0.00115	0.0483	0.12	0.1	Breast size;	chr2:120130628	chr2:120211054~120211715:+
BRCA	cis	rs987724	0.501	rs2321293	ENSG00000243926.1	TIPARP-AS1	3.26	0.00115	0.0483	0.13	0.1	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156931311	chr3:156671862~156674378:-
BRCA	cis	rs4078252	0.671	rs13179421	ENSG00000279522.1	CTC-487M23.6	-3.26	0.00115	0.0483	-0.11	-0.1	Response to cytadine analogues (cytosine arabinoside);	chr5:113114149	chr5:112894933~112896531:+
BRCA	cis	rs6743226	0.87	rs4675966	ENSG00000266621.1	AC104841.1	3.26	0.00115	0.0483	0.12	0.1	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in non-smokers;	chr2:241304927	chr2:241245202~241245299:-
BRCA	cis	rs4819052	1	rs2838847	ENSG00000223768.1	LINC00205	-3.26	0.00115	0.0483	-0.14	-0.1	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251043	chr21:45293285~45297354:+
BRCA	cis	rs10129255	0.826	rs7150693	ENSG00000211967.3	IGHV3-53	-3.26	0.00115	0.0483	-0.08	-0.1	Kawasaki disease;	chr14:106705382	chr14:106592676~106593347:-
BRCA	cis	rs10129255	0.869	rs7150549	ENSG00000211967.3	IGHV3-53	-3.26	0.00115	0.0483	-0.08	-0.1	Kawasaki disease;	chr14:106705441	chr14:106592676~106593347:-
BRCA	cis	rs4948102	0.731	rs10229446	ENSG00000226278.1	PSPHP1	3.26	0.00115	0.0483	0.12	0.1	Plasma homocysteine levels (post-methionine load test);	chr7:55996569	chr7:55764797~55773288:+
BRCA	cis	rs683250	0.661	rs2510476	ENSG00000254551.1	RP11-727A23.7	-3.26	0.00115	0.0483	-0.13	-0.1	Subcortical brain region volumes;	chr11:83411630	chr11:83209431~83213379:-
BRCA	cis	rs6601327	0.613	rs4612345	ENSG00000233609.3	RP11-62H7.2	-3.26	0.00115	0.0483	-0.09	-0.1	Multiple myeloma (hyperdiploidy);	chr8:9722491	chr8:8961200~8979025:+
BRCA	cis	rs6893300	0.826	rs7709723	ENSG00000250999.1	RP11-1379J22.5	3.26	0.00115	0.0483	0.13	0.1	Resting heart rate;	chr5:179717262	chr5:179657762~179664432:+
BRCA	cis	rs403814	0.81	rs59596655	ENSG00000264707.1	L3MBTL4-AS1	3.26	0.00115	0.0483	0.16	0.1	Hypertension;	chr18:6348257	chr18:6256747~6260934:+
BRCA	cis	rs6545883	0.708	rs2518936	ENSG00000212978.6	AC016747.3	3.26	0.00115	0.0484	0.14	0.1	Tuberculosis;	chr2:61565207	chr2:61141592~61144969:-
BRCA	cis	rs812925	0.511	rs11886950	ENSG00000270820.4	RP11-355B11.2	3.26	0.00115	0.0484	0.11	0.1	Immature fraction of reticulocytes;	chr2:61172182	chr2:61471188~61484130:+
BRCA	cis	rs6725041	0.547	rs61696052	ENSG00000196096.3	AC079610.2	-3.26	0.00115	0.0484	-0.13	-0.1	QT interval (ambient particulate matter interaction);	chr2:212336571	chr2:213276552~213284205:-
BRCA	cis	rs4622329	0.636	rs4764665	ENSG00000257202.1	RP11-512N21.3	3.26	0.00115	0.0484	0.12	0.1	Systemic lupus erythematosus;	chr12:101894151	chr12:101923410~101924719:-
BRCA	cis	rs8081187	0.71	rs17803815	ENSG00000264943.1	SH3GL1P2	-3.26	0.00115	0.0484	-0.21	-0.1	Breast cancer;	chr17:30376863	chr17:30624413~30625494:+
BRCA	cis	rs2562456	0.754	rs112195516	ENSG00000268705.1	BNIP3P26	3.26	0.00115	0.0484	0.12	0.1	Pain;	chr19:21410849	chr19:21521343~21521896:-
BRCA	cis	rs2307449	0.929	rs7162771	ENSG00000260123.1	RP11-326A19.4	3.26	0.00115	0.0484	0.12	0.1	Menopause (age at onset);	chr15:89310237	chr15:89041223~89082819:+
BRCA	cis	rs2559856	0.967	rs2695297	ENSG00000199933.1	RNY1P16	3.26	0.00115	0.0484	0.11	0.1	Blood protein levels;	chr12:101688440	chr12:101719808~101719918:+
BRCA	cis	rs2559856	1	rs2695298	ENSG00000199933.1	RNY1P16	3.26	0.00115	0.0484	0.11	0.1	Blood protein levels;	chr12:101688811	chr12:101719808~101719918:+
BRCA	cis	rs6893213	0.513	rs6892259	ENSG00000249619.1	HMGN1P13	-3.26	0.00115	0.0484	-0.16	-0.1	Asthma;	chr5:110750042	chr5:111572102~111572239:-
BRCA	cis	rs62244186	0.632	rs1402751	ENSG00000233509.2	ZNF197-AS1	3.26	0.00115	0.0484	0.12	0.1	Depressive symptoms;	chr3:44552538	chr3:44617128~44624797:-
BRCA	cis	rs7949030	0.626	rs11231141	ENSG00000254964.1	RP11-831H9.3	-3.26	0.00115	0.0484	-0.12	-0.1	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62558793	chr11:62606161~62606405:+
BRCA	cis	rs991427	0.908	rs7978438	ENSG00000258100.1	RP11-121E16.1	-3.26	0.00115	0.0484	-0.13	-0.1	Systolic blood pressure (alcohol consumption interaction);	chr12:91069126	chr12:91362196~91368606:+
BRCA	cis	rs12893668	0.572	rs4906356	ENSG00000258914.1	CTD-2134A5.3	3.26	0.00115	0.0484	0.14	0.1	Reticulocyte count;	chr14:103672364	chr14:103875055~103877478:+
BRCA	cis	rs8073060	0.821	rs11080355	ENSG00000255987.1	TOMM20P2	3.26	0.00115	0.0484	0.09	0.1	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35545675	chr17:35514766~35515186:-
BRCA	cis	rs10208649	1	rs6545367	ENSG00000233266.1	HMGB1P31	3.26	0.00115	0.0484	0.23	0.1	Body mass index;	chr2:53810148	chr2:54051334~54051760:+
BRCA	cis	rs9467773	1	rs6940188	ENSG00000261353.1	CTA-14H9.5	-3.26	0.00115	0.0484	-0.1	-0.1	Intelligence (multi-trait analysis);	chr6:26561801	chr6:26527063~26527404:+
BRCA	cis	rs7188697	0.882	rs37054	ENSG00000276259.1	RP11-481J2.4	-3.26	0.00115	0.0484	-0.11	-0.1	QT interval;	chr16:58525085	chr16:58522970~58523842:+
BRCA	cis	rs703108	0.956	rs1555922	ENSG00000279623.1	RP11-399C16.3	-3.26	0.00115	0.0484	-0.14	-0.1	Monocyte percentage of white cells;	chr10:22212400	chr10:21865335~21865921:-
BRCA	cis	rs6517329	0.544	rs9305578	ENSG00000230212.5	AP000688.14	3.26	0.00115	0.0484	0.12	0.1	Schizophrenia;	chr21:36141857	chr21:36069642~36126640:-
BRCA	cis	rs711830	0.931	rs717852	ENSG00000272729.1	RP11-387A1.5	-3.26	0.00115	0.0484	-0.13	-0.1	Serous invasive ovarian cancer;Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;High-grade serous ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;	chr2:176166895	chr2:176164164~176165716:-
BRCA	cis	rs12216545	0.711	rs939957	ENSG00000244151.1	RP11-148K1.12	-3.26	0.00115	0.0484	-0.09	-0.1	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150560517	chr7:151074742~151076530:-
BRCA	cis	rs12216545	0.765	rs939958	ENSG00000244151.1	RP11-148K1.12	-3.26	0.00115	0.0484	-0.09	-0.1	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150560680	chr7:151074742~151076530:-
BRCA	cis	rs12216545	0.64	rs1879867	ENSG00000244151.1	RP11-148K1.12	-3.26	0.00115	0.0484	-0.09	-0.1	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150561018	chr7:151074742~151076530:-
BRCA	cis	rs4713118	0.824	rs2179095	ENSG00000280107.1	AL022393.9	3.26	0.00115	0.0484	0.14	0.1	Parkinson's disease;	chr6:27783079	chr6:28170845~28172521:+
BRCA	cis	rs875971	1	rs6961717	ENSG00000273024.4	INTS4P2	3.26	0.00115	0.0484	0.11	0.1	Aortic root size;	chr7:66122550	chr7:65647864~65715661:+
BRCA	cis	rs73072330	1	rs17729010	ENSG00000236409.1	NRADDP	3.26	0.00115	0.0484	0.2	0.1	Stem cell growth factor beta levels;	chr3:47871213	chr3:47011542~47013146:+
BRCA	cis	rs9467773	1	rs6940053	ENSG00000261353.1	CTA-14H9.5	-3.26	0.00115	0.0484	-0.1	-0.1	Intelligence (multi-trait analysis);	chr6:26561894	chr6:26527063~26527404:+
BRCA	cis	rs7122539	0.684	rs10896139	ENSG00000255038.1	RP11-1167A19.2	-3.26	0.00115	0.0484	-0.13	-0.1	HIV-1 susceptibility;	chr11:66882589	chr11:66067277~66069619:-
BRCA	cis	rs495337	0.965	rs4809768	ENSG00000229222.1	KRT18P4	-3.26	0.00115	0.0484	-0.13	-0.1	Psoriasis;	chr20:49959775	chr20:49956745~49958032:+
BRCA	cis	rs1549733	0.66	rs16857995	ENSG00000229754.1	CXCR2P1	3.26	0.00115	0.0484	0.12	0.1	Optic disc area;	chr2:217596683	chr2:218059155~218065729:-
BRCA	cis	rs72772090	0.539	rs10515250	ENSG00000272109.1	CTD-2260A17.3	3.26	0.00115	0.0484	0.2	0.1	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96814490	chr5:96804353~96806105:+
BRCA	cis	rs2400749	0.685	rs4445835	ENSG00000232573.1	RPL3P4	-3.26	0.00115	0.0484	-0.08	-0.1	Alzheimer's disease (survival time);	chr14:99557059	chr14:98972879~98973301:-
BRCA	cis	rs45509595	0.841	rs200485	ENSG00000241549.7	GUSBP2	3.26	0.00115	0.0484	0.17	0.1	Breast cancer;	chr6:27807919	chr6:26871484~26956554:-
BRCA	cis	rs6840360	0.726	rs6816292	ENSG00000251603.1	RP11-164P12.4	3.26	0.00115	0.0484	0.09	0.1	Intelligence (multi-trait analysis);	chr4:151809391	chr4:151667224~151670502:+
BRCA	cis	rs7258177	0.597	rs10409510	ENSG00000267783.1	CTB-55O6.10	-3.26	0.00115	0.0484	-0.12	-0.1	Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid);	chr19:13669212	chr19:14119106~14119537:+
BRCA	cis	rs6453278	0.559	rs3934501	ENSG00000250802.5	ZBED3-AS1	-3.26	0.00115	0.0484	-0.15	-0.1	Autism;	chr5:77097859	chr5:77086740~77166909:+
BRCA	cis	rs6088580	0.608	rs1205342	ENSG00000269202.1	RP4-614O4.12	3.26	0.00115	0.0484	0.1	0.1	Glomerular filtration rate (creatinine);	chr20:34334036	chr20:35201747~35203288:-
BRCA	cis	rs10044254	0.901	rs1394654	ENSG00000246214.1	RP11-260E18.1	3.26	0.00115	0.0484	0.13	0.1	Asthma (corticosteroid response);	chr5:15768873	chr5:16615926~16629969:+
BRCA	cis	rs7267979	0.934	rs2257464	ENSG00000204556.4	CTD-2514C3.1	-3.26	0.00115	0.0484	-0.14	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25285236	chr20:26018832~26020684:+
BRCA	cis	rs7267979	0.966	rs6050532	ENSG00000204556.4	CTD-2514C3.1	3.26	0.00115	0.0484	0.14	0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25328157	chr20:26018832~26020684:+
BRCA	cis	rs792448	0.743	rs351393	ENSG00000229983.1	RP11-15I11.2	-3.26	0.00115	0.0484	-0.12	-0.1	White blood cell count (basophil);	chr1:212303177	chr1:212168207~212190259:+
BRCA	cis	rs12760731	0.582	rs34016755	ENSG00000213057.5	C1orf220	3.26	0.00115	0.0484	0.14	0.1	Obesity-related traits;	chr1:178547870	chr1:178542752~178548889:+
BRCA	cis	rs7759001	0.744	rs7771590	ENSG00000237154.2	MCFD2P1	3.26	0.00115	0.0484	0.12	0.1	Glomerular filtration rate (creatinine);	chr6:27500117	chr6:27407697~27407996:+
BRCA	cis	rs721917	0.629	rs1304463	ENSG00000244733.5	RP11-506M13.3	-3.26	0.00115	0.0484	-0.12	-0.1	Chronic obstructive pulmonary disease;	chr10:79969516	chr10:79660891~79677996:+
BRCA	cis	rs4697263	0.706	rs1513567	ENSG00000237350.1	CDC42P6	3.26	0.00115	0.0484	0.13	0.1	Age-related hearing impairment (SNP x SNP interaction);	chr4:22020098	chr4:22727375~22727950:-
BRCA	cis	rs58235267	0.591	rs2162014	ENSG00000242412.1	DBIL5P2	-3.26	0.00115	0.0484	-0.12	-0.1	Prostate-specific antigen levels (conditioned on lead SNPs);	chr2:63118372	chr2:63117851~63119542:-
BRCA	cis	rs7953704	1	rs11609875	ENSG00000212694.7	LINC01089	-3.26	0.00115	0.0484	-0.08	-0.1	Urate levels;	chr12:122123955	chr12:121795267~121803906:-
BRCA	cis	rs875971	0.895	rs10755833	ENSG00000230189.5	GS1-124K5.2	3.26	0.00115	0.0484	0.08	0.1	Aortic root size;	chr7:66448930	chr7:66409143~66490059:-
BRCA	cis	rs875971	0.895	rs1833495	ENSG00000230189.5	GS1-124K5.2	3.26	0.00115	0.0484	0.08	0.1	Aortic root size;	chr7:66456608	chr7:66409143~66490059:-
BRCA	cis	rs875971	0.964	rs6945032	ENSG00000230189.5	GS1-124K5.2	3.26	0.00115	0.0484	0.08	0.1	Aortic root size;	chr7:66457499	chr7:66409143~66490059:-
BRCA	cis	rs875971	0.929	rs12673810	ENSG00000230189.5	GS1-124K5.2	3.26	0.00115	0.0484	0.08	0.1	Aortic root size;	chr7:66458866	chr7:66409143~66490059:-
BRCA	cis	rs875971	1	rs6961155	ENSG00000230189.5	GS1-124K5.2	3.26	0.00115	0.0484	0.08	0.1	Aortic root size;	chr7:66468308	chr7:66409143~66490059:-
BRCA	cis	rs875971	1	rs7789768	ENSG00000230189.5	GS1-124K5.2	3.26	0.00115	0.0484	0.08	0.1	Aortic root size;	chr7:66473993	chr7:66409143~66490059:-
BRCA	cis	rs875971	1	rs1363055	ENSG00000230189.5	GS1-124K5.2	3.26	0.00115	0.0484	0.08	0.1	Aortic root size;	chr7:66478288	chr7:66409143~66490059:-
BRCA	cis	rs875971	0.964	rs9691480	ENSG00000230189.5	GS1-124K5.2	3.26	0.00115	0.0484	0.08	0.1	Aortic root size;	chr7:66479319	chr7:66409143~66490059:-
BRCA	cis	rs10129255	0.5	rs6576231	ENSG00000211976.2	IGHV3-73	-3.26	0.00115	0.0484	-0.08	-0.1	Kawasaki disease;	chr14:106783693	chr14:106802694~106803233:-
BRCA	cis	rs7590268	0.666	rs9677398	ENSG00000279873.2	LINC01126	3.26	0.00115	0.0484	0.11	0.1	Orofacial clefts;	chr2:43406996	chr2:43227210~43228855:+
BRCA	cis	rs12477438	0.798	rs1530996	ENSG00000231822.1	AC019097.7	-3.26	0.00115	0.0484	-0.11	-0.1	Chronic sinus infection;	chr2:98967616	chr2:99102018~99102752:+
BRCA	cis	rs12477438	0.765	rs62154861	ENSG00000231822.1	AC019097.7	-3.26	0.00115	0.0484	-0.11	-0.1	Chronic sinus infection;	chr2:98973772	chr2:99102018~99102752:+
BRCA	cis	rs9785234	0.793	rs10989550	ENSG00000175611.10	LINC00476	3.26	0.00115	0.0484	0.12	0.1	Glomerular filtration rate in chronic kidney disease;	chr9:96171470	chr9:95759231~95875977:-
BRCA	cis	rs80226907	1	rs118044538	ENSG00000258413.1	RP11-665C16.6	-3.26	0.00115	0.0484	-0.27	-0.1	Mean platelet volume;	chr14:55390392	chr14:55262767~55272075:-
BRCA	cis	rs67696533	0.6	rs910890	ENSG00000275576.1	RP5-836N17.4	-3.26	0.00115	0.0484	-0.12	-0.1	White blood cell count (basophil);Basophil percentage of granulocytes;Basophil percentage of white cells;	chr20:32521129	chr20:32116171~32116629:+
BRCA	cis	rs9527	0.501	rs12244388	ENSG00000213277.3	MARCKSL1P1	3.26	0.00115	0.0484	0.11	0.1	Arsenic metabolism;	chr10:102880295	chr10:103175554~103176094:+
BRCA	cis	rs12439619	0.693	rs28689861	ENSG00000259429.4	UBE2Q2P2	-3.26	0.00115	0.0484	-0.11	-0.1	Intelligence (multi-trait analysis);	chr15:82206369	chr15:82355142~82420075:+
BRCA	cis	rs860295	0.812	rs12407800	ENSG00000225855.5	RUSC1-AS1	3.26	0.00115	0.0484	0.08	0.1	Body mass index;	chr1:155790951	chr1:155316863~155324176:-
BRCA	cis	rs67478160	0.643	rs12880167	ENSG00000269910.1	RP11-73M18.10	3.26	0.00115	0.0484	0.1	0.1	Schizophrenia;	chr14:103834492	chr14:103694516~103695050:-
BRCA	cis	rs10777288	0.636	rs1920716	ENSG00000258100.1	RP11-121E16.1	3.26	0.00115	0.0484	0.13	0.1	Pulmonary function (smoking interaction);	chr12:91112772	chr12:91362196~91368606:+
BRCA	cis	rs6432860	0.545	rs10185885	ENSG00000232411.1	AC009495.3	-3.26	0.00115	0.0484	-0.11	-0.1	Febrile seizures (MMR vaccine-unrelated);Febrile seizures;	chr2:166055152	chr2:165833048~165839098:-
BRCA	cis	rs6432860	0.545	rs10209560	ENSG00000232411.1	AC009495.3	-3.26	0.00115	0.0484	-0.11	-0.1	Febrile seizures (MMR vaccine-unrelated);Febrile seizures;	chr2:166055175	chr2:165833048~165839098:-
BRCA	cis	rs7620503	0.613	rs11720644	ENSG00000228561.2	RP11-114M1.1	-3.26	0.00115	0.0484	-0.13	-0.1	Corneal structure;	chr3:177559917	chr3:177683627~177691250:+
BRCA	cis	rs2425143	1	rs11696369	ENSG00000088340.14	FER1L4	-3.26	0.00115	0.0484	-0.16	-0.1	Blood protein levels;	chr20:35790707	chr20:35558737~35607562:-
BRCA	cis	rs11733284	1	rs6832503	ENSG00000259959.1	RP11-121C2.2	-3.26	0.00115	0.0484	-0.1	-0.1	Gout;Renal underexcretion gout;	chr4:48026425	chr4:47840122~47844339:-
BRCA	cis	rs7598759	0.712	rs12991636	ENSG00000223198.1	RNU2-22P	-3.26	0.00115	0.0484	-0.12	-0.1	Noise-induced hearing loss;	chr2:231468955	chr2:231501990~231502201:-
BRCA	cis	rs7923837	0.634	rs1544210	ENSG00000232709.1	MARK2P9	3.26	0.00115	0.0484	0.13	0.1	Multiple sclerosis;Body mass index;	chr10:92728044	chr10:92418667~92420875:+
BRCA	cis	rs56046484	0.826	rs35816571	ENSG00000259630.2	CTD-2262B20.1	-3.26	0.00115	0.0484	-0.17	-0.1	Testicular germ cell tumor;	chr15:85010891	chr15:85415228~85415633:+
BRCA	cis	rs61542988	0.606	rs4722185	ENSG00000226329.2	AC005682.6	3.26	0.00115	0.0484	0.11	0.1	Fibrinogen levels;	chr7:22793092	chr7:22863874~22881350:-
BRCA	cis	rs7870753	0.578	rs10990558	ENSG00000224848.1	RP11-535M15.1	3.26	0.00115	0.0485	0.16	0.1	Height;	chr9:96331663	chr9:96687056~96721121:+
BRCA	cis	rs4835473	0.932	rs4835278	ENSG00000246448.2	RP13-578N3.3	-3.26	0.00115	0.0485	-0.11	-0.1	Immature fraction of reticulocytes;	chr4:143788433	chr4:143700257~143865072:+
BRCA	cis	rs2084597	0.51	rs7602366	ENSG00000235847.2	LDHAP7	-3.26	0.00115	0.0485	-0.15	-0.1	Gut microbiota (functional units);	chr2:83808603	chr2:84777259~84778223:-
BRCA	cis	rs8054556	1	rs10871451	ENSG00000183604.13	SMG1P5	-3.26	0.00115	0.0485	-0.09	-0.1	Autism spectrum disorder or schizophrenia;	chr16:29974884	chr16:30267553~30335374:-
BRCA	cis	rs7649443	0.959	rs56309312	ENSG00000243339.3	RN7SL738P	-3.26	0.00115	0.0485	-0.14	-0.1	Nonsyndromic cleft lip with cleft palate;	chr3:197103636	chr3:196399911~196400207:+
BRCA	cis	rs4846217	1	rs6670157	ENSG00000271895.2	RP4-635E18.8	3.26	0.00115	0.0485	0.1	0.1	Platelet count;	chr1:10398382	chr1:11029659~11030528:+
BRCA	cis	rs3748682	0.731	rs9729719	ENSG00000212541.1	RNU6-510P	-3.26	0.00115	0.0485	-0.14	-0.1	Hypothyroidism;	chr1:37832535	chr1:37991462~37991569:+
BRCA	cis	rs4356203	0.905	rs621246	ENSG00000184669.7	OR7E14P	-3.26	0.00115	0.0485	-0.13	-0.1	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17182218	chr11:17013998~17053024:+
BRCA	cis	rs860295	0.702	rs5005770	ENSG00000236675.1	MTX1P1	3.26	0.00115	0.0485	0.12	0.1	Body mass index;	chr1:155375252	chr1:155230975~155234325:+
BRCA	cis	rs950169	0.614	rs12911536	ENSG00000176700.18	SCAND2P	-3.26	0.00115	0.0485	-0.11	-0.1	Schizophrenia;	chr15:84004278	chr15:84631451~84647478:+
BRCA	cis	rs2562456	0.833	rs55790393	ENSG00000268357.1	VN1R81P	-3.26	0.00115	0.0485	-0.15	-0.1	Pain;	chr19:21323382	chr19:21123817~21124188:+
BRCA	cis	rs2562456	0.793	rs11672341	ENSG00000268357.1	VN1R81P	-3.26	0.00115	0.0485	-0.15	-0.1	Pain;	chr19:21324502	chr19:21123817~21124188:+
BRCA	cis	rs3743102	0.591	rs12148608	ENSG00000278603.1	RP13-608F4.5	3.26	0.00115	0.0485	0.19	0.1	Colorectal adenoma (advanced);	chr15:82713350	chr15:82472203~82472426:+
BRCA	cis	rs1730008	0.865	rs827118	ENSG00000279311.1	RP11-170K4.2	-3.26	0.00115	0.0485	-0.11	-0.1	Lobe attachment (rater-scored or self-reported);	chr3:158320653	chr3:158869898~158871821:+
BRCA	cis	rs2235642	0.75	rs2755185	ENSG00000260260.1	SNHG19	-3.26	0.00115	0.0485	-0.1	-0.1	Coronary artery disease;	chr16:1595826	chr16:2154797~2155358:-
BRCA	cis	rs7914558	1	rs7911789	ENSG00000213277.3	MARCKSL1P1	3.26	0.00115	0.0485	0.11	0.1	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102996617	chr10:103175554~103176094:+
BRCA	cis	rs2403083	0.522	rs7841142	ENSG00000258256.1	RP11-219B4.5	-3.26	0.00115	0.0485	-0.14	-0.1	Plasma amyloid beta peptide concentrations (ABx-40);	chr8:85122399	chr8:85222446~85245717:-
BRCA	cis	rs7089973	0.61	rs61869271	ENSG00000236799.1	RP11-383C6.2	-3.26	0.00115	0.0485	-0.13	-0.1	Bipolar disorder or attention deficit hyperactivity disorder;	chr10:114971570	chr10:114994657~114996593:+
BRCA	cis	rs7429990	0.965	rs11707679	ENSG00000228638.1	FCF1P2	-3.26	0.00115	0.0485	-0.11	-0.1	Educational attainment (years of education);	chr3:47915016	chr3:48290793~48291375:-
BRCA	cis	rs4702718	0.616	rs267973	ENSG00000272324.4	CTD-2154B17.4	3.26	0.00115	0.0485	0.12	0.1	Obesity-related traits;	chr5:10726169	chr5:10761065~10770294:+
BRCA	cis	rs7229439	0.707	rs8085852	ENSG00000279319.1	RP11-693M3.1	-3.26	0.00115	0.0485	-0.11	-0.1	Antipsychotic drug-induced QTc interval change in schizophrenia;	chr18:45352100	chr18:44986109~44989203:+
BRCA	cis	rs1044573	0.514	rs2268879	ENSG00000274973.1	RP13-401N8.7	3.26	0.00115	0.0485	0.11	0.1	Allergic rhinitis;	chr20:25197169	chr20:25845497~25845862:+
BRCA	cis	rs13418410	0.715	rs10201046	ENSG00000187999.4	HNRNPA1P61	3.26	0.00115	0.0485	0.12	0.1	Non-response to antidepressants and depression;	chr2:33569371	chr2:33636502~33637425:+
BRCA	cis	rs911555	0.519	rs8014069	ENSG00000269940.1	RP11-73M18.7	3.26	0.00115	0.0485	0.11	0.1	Intelligence (multi-trait analysis);	chr14:103537974	chr14:103694560~103695170:+
BRCA	cis	rs12477438	0.52	rs13009147	ENSG00000231822.1	AC019097.7	3.26	0.00115	0.0485	0.11	0.1	Chronic sinus infection;	chr2:99187535	chr2:99102018~99102752:+
BRCA	cis	rs7188697	0.922	rs4471670	ENSG00000276259.1	RP11-481J2.4	3.26	0.00115	0.0485	0.12	0.1	QT interval;	chr16:58567461	chr16:58522970~58523842:+
BRCA	cis	rs7188697	0.743	rs11859781	ENSG00000276259.1	RP11-481J2.4	3.26	0.00115	0.0485	0.12	0.1	QT interval;	chr16:58568685	chr16:58522970~58523842:+
BRCA	cis	rs7188697	0.922	rs7186997	ENSG00000276259.1	RP11-481J2.4	3.26	0.00115	0.0485	0.12	0.1	QT interval;	chr16:58569444	chr16:58522970~58523842:+
BRCA	cis	rs7188697	0.922	rs2090727	ENSG00000276259.1	RP11-481J2.4	3.26	0.00115	0.0485	0.12	0.1	QT interval;	chr16:58570257	chr16:58522970~58523842:+
BRCA	cis	rs564309	1	rs564309	ENSG00000212237.1	RNA5SP18	-3.26	0.00115	0.0485	-0.17	-0.1	Hip circumference (psychosocial stress interaction);	chr1:228397861	chr1:228647912~228648032:-
BRCA	cis	rs6456156	0.586	rs12525855	ENSG00000272549.1	RP11-351J23.2	-3.26	0.00115	0.0485	-0.1	-0.1	Primary biliary cholangitis;	chr6:167066525	chr6:167666840~167679270:-
BRCA	cis	rs3750552	0.615	rs4744566	ENSG00000278910.2	BANCR	-3.26	0.00115	0.0485	-0.13	-0.1	Bipolar disorder;	chr9:69340259	chr9:69296682~69306977:-
BRCA	cis	rs2688482	0.557	rs2550236	ENSG00000235897.1	TM4SF19-AS1	3.26	0.00115	0.0485	0.16	0.1	Lung disease severity in cystic fibrosis;	chr3:195795450	chr3:196318330~196325570:+
BRCA	cis	rs12497850	0.931	rs6442130	ENSG00000271973.1	RP11-572O6.1	3.26	0.00115	0.0485	0.13	0.1	Parkinson's disease;	chr3:48740594	chr3:48672455~48672733:+
BRCA	cis	rs600550	0.588	rs2304935	ENSG00000275344.1	MIR6503	-3.26	0.00115	0.0485	-0.11	-0.1	Lipoprotein-associated phospholipase A2 activity and mass;	chr11:60334911	chr11:60209071~60209156:-
BRCA	cis	rs6973609	0.626	rs34206766	ENSG00000271122.1	RP11-379H18.1	3.26	0.00115	0.0485	0.12	0.1	Obesity-related traits;	chr7:35569083	chr7:35695214~35699413:+
BRCA	cis	rs3858526	0.523	rs10742818	ENSG00000224295.2	AC087380.14	3.26	0.00115	0.0485	0.13	0.1	DNA methylation (variation);	chr11:5861305	chr11:5518441~5524955:-
BRCA	cis	rs4970966	1	rs4970966	ENSG00000224800.1	RP11-235D19.2	-3.26	0.00115	0.0485	-0.15	-0.1	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:150611627	chr1:150881236~150881683:-
BRCA	cis	rs3816183	0.626	rs6724638	ENSG00000226491.1	FTOP1	-3.26	0.00115	0.0485	-0.12	-0.1	Hypospadias;	chr2:42668347	chr2:42797225~42798712:-
BRCA	cis	rs1949733	0.675	rs2688235	ENSG00000250471.2	GMPSP1	3.26	0.00115	0.0485	0.1	0.1	Response to antineoplastic agents;	chr4:8448819	chr4:8174421~8174999:+
BRCA	cis	rs2638953	0.962	rs10506032	ENSG00000273989.1	RP11-425D17.2	-3.26	0.00115	0.0485	-0.15	-0.1	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28384177	chr12:28236227~28236828:+
BRCA	cis	rs1056107	0.541	rs2150258	ENSG00000230185.4	C9orf147	3.26	0.00115	0.0485	0.12	0.1	Colorectal cancer;	chr9:112412328	chr9:112433816~112487204:-
BRCA	cis	rs875971	0.862	rs10274883	ENSG00000223473.2	GS1-124K5.3	-3.26	0.00115	0.0485	-0.08	-0.1	Aortic root size;	chr7:66651104	chr7:66491049~66493566:-
BRCA	cis	rs7520050	0.966	rs7550746	ENSG00000226957.1	RP4-533D7.4	3.26	0.00115	0.0485	0.11	0.1	Reticulocyte count;Red blood cell count;	chr1:45886047	chr1:46046818~46048368:+
BRCA	cis	rs67478160	0.619	rs2368560	ENSG00000269940.1	RP11-73M18.7	3.26	0.00115	0.0485	0.1	0.1	Schizophrenia;	chr14:103806974	chr14:103694560~103695170:+
BRCA	cis	rs2638953	0.815	rs11049683	ENSG00000273989.1	RP11-425D17.2	-3.26	0.00115	0.0485	-0.15	-0.1	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28509597	chr12:28236227~28236828:+
BRCA	cis	rs4718428	1	rs4718428	ENSG00000229886.1	RP5-1132H15.3	3.26	0.00115	0.0485	0.11	0.1	Corneal structure;	chr7:66956459	chr7:66025126~66031544:-
BRCA	cis	rs7017914	0.934	rs3110239	ENSG00000246366.5	RP11-382J12.1	3.26	0.00115	0.0485	0.11	0.1	Bone mineral density;	chr8:71004510	chr8:70608577~70663279:+
BRCA	cis	rs3822625	1	rs56822906	ENSG00000271828.1	CTD-2310F14.1	3.26	0.00115	0.0485	0.22	0.1	Breast cancer (early onset);	chr5:56870087	chr5:56927874~56929573:+
BRCA	cis	rs6772849	1	rs2712379	ENSG00000242551.2	POU5F1P6	-3.26	0.00115	0.0485	-0.13	-0.1	Monocyte percentage of white cells;Monocyte count;	chr3:128590217	chr3:128674735~128677005:-
BRCA	cis	rs875971	0.522	rs6960048	ENSG00000229180.5	GS1-124K5.11	3.26	0.00115	0.0486	0.09	0.1	Aortic root size;	chr7:65943052	chr7:66526088~66542624:-
BRCA	cis	rs10463316	0.817	rs13355052	ENSG00000260581.1	CTB-113P19.4	3.26	0.00115	0.0486	0.11	0.1	Metabolite levels (Pyroglutamine);	chr5:151422442	chr5:151652275~151655449:+
BRCA	cis	rs10463316	0.817	rs13359941	ENSG00000260581.1	CTB-113P19.4	3.26	0.00115	0.0486	0.11	0.1	Metabolite levels (Pyroglutamine);	chr5:151422557	chr5:151652275~151655449:+
BRCA	cis	rs2108225	0.837	rs6466186	ENSG00000231006.1	RPL7P32	-3.26	0.00115	0.0486	-0.1	-0.1	Ulcerative colitis;	chr7:107806521	chr7:108510233~108510976:+
BRCA	cis	rs801193	0.967	rs3800823	ENSG00000232559.3	GS1-124K5.12	-3.26	0.00115	0.0486	-0.12	-0.1	Aortic root size;	chr7:66682123	chr7:66554588~66576923:-
BRCA	cis	rs9325144	0.957	rs1995419	ENSG00000257718.1	RP11-396F22.1	3.26	0.00115	0.0486	0.12	0.1	Morning vs. evening chronotype;	chr12:38556924	chr12:38906451~38909592:+
BRCA	cis	rs4787951	0.568	rs12933581	ENSG00000259940.2	CTD-3203P2.1	-3.26	0.00115	0.0486	-0.13	-0.1	Eosinophil percentage of white cells;	chr16:27293527	chr16:27213308~27214993:-
BRCA	cis	rs13401620	0.626	rs4849826	ENSG00000229326.3	AC069154.4	3.26	0.00115	0.0486	0.13	0.1	Breast size;	chr2:120130628	chr2:119698623~119700151:+
BRCA	cis	rs311392	0.903	rs6993362	ENSG00000270980.1	RP11-626A5.2	3.26	0.00115	0.0486	0.12	0.1	Pelvic organ prolapse (moderate/severe);	chr8:54176660	chr8:54191582~54192035:-
BRCA	cis	rs13153459	0.649	rs10061166	ENSG00000279557.1	CTD-2210P15.3	-3.26	0.00115	0.0486	-0.18	-0.1	Parkinson's disease;	chr5:44562881	chr5:43586367~43587543:-
BRCA	cis	rs9646944	0.501	rs9807934	ENSG00000234389.1	AC007278.3	3.26	0.00115	0.0486	0.11	0.1	Blood protein levels;	chr2:102423722	chr2:102438713~102440475:+
BRCA	cis	rs2638953	0.79	rs11049653	ENSG00000273989.1	RP11-425D17.2	-3.26	0.00115	0.0486	-0.15	-0.1	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28479882	chr12:28236227~28236828:+
BRCA	cis	rs11098499	0.863	rs9884402	ENSG00000260404.2	RP11-384K6.6	3.26	0.00115	0.0486	0.1	0.1	Corneal astigmatism;	chr4:119568827	chr4:118591773~118633729:+
BRCA	cis	rs11098499	0.731	rs9995026	ENSG00000260404.2	RP11-384K6.6	3.26	0.00115	0.0486	0.1	0.1	Corneal astigmatism;	chr4:119569344	chr4:118591773~118633729:+
BRCA	cis	rs7267979	0.586	rs6083776	ENSG00000276952.1	RP5-965G21.6	3.26	0.00115	0.0486	0.12	0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25205480	chr20:25284915~25285588:-
BRCA	cis	rs7267979	0.586	rs1473695	ENSG00000276952.1	RP5-965G21.6	3.26	0.00115	0.0486	0.12	0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25206329	chr20:25284915~25285588:-
BRCA	cis	rs1005277	0.505	rs719569	ENSG00000099251.13	HSD17B7P2	-3.26	0.00115	0.0486	-0.11	-0.1	Extrinsic epigenetic age acceleration;	chr10:37865487	chr10:38356380~38378505:+
BRCA	cis	rs7487075	0.859	rs2307061	ENSG00000274723.1	RP11-618L22.1	3.26	0.00115	0.0486	0.13	0.1	Itch intensity from mosquito bite;	chr12:46364711	chr12:46970504~46972155:+
BRCA	cis	rs4848143	0.64	rs6752619	ENSG00000236859.5	NIFK-AS1	-3.26	0.00115	0.0486	-0.11	-0.1	Capecitabine sensitivity;	chr2:121039550	chr2:121649650~121728208:+
BRCA	cis	rs10986311	0.802	rs6478659	ENSG00000227200.1	RP11-121A14.3	-3.26	0.00115	0.0486	-0.11	-0.1	Vitiligo;	chr9:124365995	chr9:124262876~124265809:+
BRCA	cis	rs2277027	1	rs4331881	ENSG00000251405.2	CTB-109A12.1	3.26	0.00115	0.0486	0.13	0.1	Pulmonary function;Pulmonary function (smoking interaction);	chr5:157517467	chr5:157362615~157460078:-
BRCA	cis	rs11122895	0.791	rs10864876	ENSG00000227992.1	AC108463.2	3.26	0.00115	0.0486	0.11	0.1	Allergic sensitization;	chr2:111712414	chr2:111203964~111206215:-
BRCA	cis	rs3764021	0.527	rs11052423	ENSG00000278635.1	CTD-2318O12.1	3.26	0.00115	0.0486	0.11	0.1	Type 1 diabetes;	chr12:9687442	chr12:9415641~9416718:+
BRCA	cis	rs2692947	0.763	rs7570074	ENSG00000237510.6	AC008268.2	3.26	0.00115	0.0486	0.14	0.1	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95741289	chr2:95789654~95800166:+
BRCA	cis	rs2512987	0.76	rs2512988	ENSG00000255250.1	CTD-2005H7.2	-3.26	0.00115	0.0486	-0.11	-0.1	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr11:86702985	chr11:86727355~86765265:+
BRCA	cis	rs731174	0.592	rs6699887	ENSG00000212541.1	RNU6-510P	3.26	0.00115	0.0486	0.15	0.1	Prostate cancer (SNP x SNP interaction);	chr1:37726932	chr1:37991462~37991569:+
BRCA	cis	rs4144743	0.759	rs16969966	ENSG00000228782.6	CTD-2026D20.3	-3.26	0.00115	0.0486	-0.14	-0.1	Body mass index;	chr17:47241086	chr17:47450568~47492492:-
BRCA	cis	rs13136331	0.606	rs7686829	ENSG00000249001.4	RP11-742B18.1	3.26	0.00115	0.0486	0.13	0.1	Sitting height ratio;	chr4:87718558	chr4:87568035~87733956:-
BRCA	cis	rs4356203	0.87	rs2171615	ENSG00000184669.7	OR7E14P	-3.26	0.00115	0.0486	-0.13	-0.1	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17231094	chr11:17013998~17053024:+
BRCA	cis	rs875971	1	rs6945843	ENSG00000272831.1	RP11-792A8.4	-3.26	0.00115	0.0486	-0.09	-0.1	Aortic root size;	chr7:66269796	chr7:66739829~66740385:-
BRCA	cis	rs4805834	0.843	rs76316637	ENSG00000201388.1	SNORA68	3.26	0.00115	0.0486	0.18	0.1	Creatinine levels;	chr19:32858845	chr19:32608337~32608469:-
BRCA	cis	rs4356203	0.905	rs214939	ENSG00000184669.7	OR7E14P	3.26	0.00115	0.0486	0.13	0.1	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17165992	chr11:17013998~17053024:+
BRCA	cis	rs9467773	1	rs10214634	ENSG00000261353.1	CTA-14H9.5	-3.26	0.00115	0.0486	-0.1	-0.1	Intelligence (multi-trait analysis);	chr6:26564354	chr6:26527063~26527404:+
BRCA	cis	rs9467711	0.606	rs34273322	ENSG00000241549.7	GUSBP2	3.26	0.00115	0.0486	0.2	0.1	Autism spectrum disorder or schizophrenia;	chr6:26415181	chr6:26871484~26956554:-
BRCA	cis	rs9467711	0.606	rs9358939	ENSG00000241549.7	GUSBP2	3.26	0.00115	0.0486	0.2	0.1	Autism spectrum disorder or schizophrenia;	chr6:26416559	chr6:26871484~26956554:-
BRCA	cis	rs10129255	0.509	rs756583	ENSG00000253359.1	IGHV3-37	3.26	0.00115	0.0486	0.08	0.1	Kawasaki disease;	chr14:106680002	chr14:106396676~106397114:-
BRCA	cis	rs13256369	1	rs7820159	ENSG00000233609.3	RP11-62H7.2	3.26	0.00115	0.0486	0.11	0.1	Obesity-related traits;	chr8:8718705	chr8:8961200~8979025:+
BRCA	cis	rs67478160	0.619	rs12885018	ENSG00000269940.1	RP11-73M18.7	3.26	0.00115	0.0486	0.1	0.1	Schizophrenia;	chr14:103807475	chr14:103694560~103695170:+
BRCA	cis	rs7681440	0.746	rs6812192	ENSG00000270720.1	RP11-84C13.2	-3.26	0.00115	0.0486	-0.11	-0.1	Dementia with Lewy bodies;	chr4:89896697	chr4:89119284~89119871:+
BRCA	cis	rs9646944	1	rs9646944	ENSG00000234389.1	AC007278.3	3.26	0.00115	0.0486	0.12	0.1	Blood protein levels;	chr2:102249415	chr2:102438713~102440475:+
BRCA	cis	rs3770752	0.866	rs74177070	ENSG00000224891.1	AC007899.3	-3.26	0.00115	0.0486	-0.12	-0.1	Schizophrenia;	chr2:37299694	chr2:37148530~37149304:+
BRCA	cis	rs2642442	0.962	rs2642439	ENSG00000238078.1	LINC01352	-3.26	0.00115	0.0486	-0.12	-0.1	Cholesterol, total;LDL cholesterol;	chr1:220797157	chr1:220829255~220832429:+
BRCA	cis	rs4081724	0.565	rs118046236	ENSG00000263960.1	AC007773.1	3.26	0.00115	0.0486	0.19	0.1	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for body mass index;	chr19:33316199	chr19:32377282~32377367:-
BRCA	cis	rs1119582	1	rs463196	ENSG00000279118.1	RP11-517I3.2	-3.26	0.00115	0.0486	-0.12	-0.1	Select biomarker traits;	chr5:125938625	chr5:126496279~126498604:+
BRCA	cis	rs17092148	0.616	rs6059908	ENSG00000206582.1	Y_RNA	-3.26	0.00115	0.0486	-0.14	-0.1	Neuroticism;	chr20:34544355	chr20:34526510~34526606:-
BRCA	cis	rs2823962	0.892	rs2823940	ENSG00000270093.1	AP000473.8	-3.26	0.00115	0.0486	-0.1	-0.1	Amyotrophic lateral sclerosis;	chr21:16654319	chr21:16643529~16645065:+
BRCA	cis	rs2832077	0.943	rs4816336	ENSG00000236056.1	GAPDHP14	3.26	0.00116	0.0486	0.14	0.1	Cognitive test performance;	chr21:28821197	chr21:29222321~29223257:+
BRCA	cis	rs7951870	1	rs61884295	ENSG00000265559.2	RN7SL652P	3.26	0.00116	0.0486	0.15	0.1	Schizophrenia;	chr11:46671619	chr11:47557534~47557833:-
BRCA	cis	rs10508774	0.852	rs3780873	ENSG00000273038.2	RP11-479G22.8	3.26	0.00116	0.0486	0.23	0.1	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32924752	chr10:32887255~32889311:-
BRCA	cis	rs2562456	0.837	rs62110205	ENSG00000268119.4	CTD-2561J22.5	3.26	0.00116	0.0486	0.15	0.1	Pain;	chr19:21577269	chr19:21444241~21463908:-
BRCA	cis	rs8073060	0.586	rs6505486	ENSG00000267554.1	RP11-686D22.10	-3.26	0.00116	0.0487	-0.1	-0.1	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35669757	chr17:35470069~35470628:-
BRCA	cis	rs12477602	0.938	rs12469580	ENSG00000272966.1	RP11-686O6.1	3.26	0.00116	0.0487	0.17	0.1	Intelligence (multi-trait analysis);	chr2:202408838	chr2:202336739~202337200:+
BRCA	cis	rs7259376	0.905	rs2082479	ENSG00000269345.1	VN1R85P	3.26	0.00116	0.0487	0.11	0.1	Menopause (age at onset);	chr19:22357045	chr19:22174766~22175191:-
BRCA	cis	rs10876993	0.784	rs10083154	ENSG00000270039.1	RP11-571M6.17	-3.26	0.00116	0.0487	-0.14	-0.1	Celiac disease or Rheumatoid arthritis;	chr12:57627150	chr12:57803838~57804415:+
BRCA	cis	rs7590268	0.666	rs17406472	ENSG00000279873.2	LINC01126	3.26	0.00116	0.0487	0.11	0.1	Orofacial clefts;	chr2:43406707	chr2:43227210~43228855:+
BRCA	cis	rs1466788	1	rs1466788	ENSG00000224965.1	KCNC4-AS1	3.26	0.00116	0.0487	0.12	0.1	Blood metabolite levels;	chr1:110076108	chr1:110208834~110209987:-
BRCA	cis	rs875971	1	rs6945843	ENSG00000230189.5	GS1-124K5.2	-3.26	0.00116	0.0487	-0.08	-0.1	Aortic root size;	chr7:66269796	chr7:66409143~66490059:-
BRCA	cis	rs4718428	0.705	rs13220977	ENSG00000275400.1	RP4-756H11.5	3.26	0.00116	0.0487	0.12	0.1	Corneal structure;	chr7:66872661	chr7:66553805~66554199:-
BRCA	cis	rs7071275	0.843	rs10886963	ENSG00000276742.1	RP11-500G22.4	-3.26	0.00116	0.0487	-0.15	-0.1	Dupuytren's disease;	chr10:121670615	chr10:121956782~121957098:+
BRCA	cis	rs7071275	0.891	rs10886964	ENSG00000276742.1	RP11-500G22.4	-3.26	0.00116	0.0487	-0.15	-0.1	Dupuytren's disease;	chr10:121670650	chr10:121956782~121957098:+
BRCA	cis	rs7694379	0.641	rs4583723	ENSG00000251411.1	RP11-397E7.4	3.26	0.00116	0.0487	0.11	0.1	Platelet count;	chr4:87240160	chr4:86913266~86914817:-
BRCA	cis	rs1160351	0.599	rs6572432	ENSG00000244053.1	RPL13AP2	-3.26	0.00116	0.0487	-0.1	-0.1	Sexual dysfunction (SSRI/SNRI-related);	chr14:47497651	chr14:47200575~47201104:-
BRCA	cis	rs3758086	0.594	rs1347548	ENSG00000246582.2	RP11-1149O23.3	3.26	0.00116	0.0487	0.13	0.1	Glomerular filtration rate (creatinine);	chr8:23849388	chr8:23224471~23230926:+
BRCA	cis	rs7577696	0.568	rs177082	ENSG00000276334.1	AL133243.1	3.26	0.00116	0.0487	0.14	0.1	Inflammatory biomarkers;	chr2:32213281	chr2:32521927~32523547:+
BRCA	cis	rs4691139	0.588	rs6827270	ENSG00000248632.1	RP11-366M4.11	3.26	0.00116	0.0487	0.12	0.1	Ovarian cancer in BRCA1 mutation carriers;	chr4:164967275	chr4:164968587~164970002:-
BRCA	cis	rs863345	0.604	rs2054993	ENSG00000229914.1	RP11-404O13.4	-3.26	0.00116	0.0487	-0.11	-0.1	Pneumococcal bacteremia;	chr1:158536178	chr1:158195633~158196131:-
BRCA	cis	rs863345	0.604	rs2054992	ENSG00000229914.1	RP11-404O13.4	-3.26	0.00116	0.0487	-0.11	-0.1	Pneumococcal bacteremia;	chr1:158536225	chr1:158195633~158196131:-
BRCA	cis	rs9733	0.791	rs11204693	ENSG00000276103.1	U4	-3.26	0.00116	0.0487	-0.11	-0.1	Tonsillectomy;	chr1:150675511	chr1:150608507~150608623:-
BRCA	cis	rs10129255	0.957	rs12590799	ENSG00000253132.1	IGHV3-62	-3.26	0.00116	0.0487	-0.08	-0.1	Kawasaki disease;	chr14:106779713	chr14:106643142~106643585:-
BRCA	cis	rs79478560	0.518	rs12306328	ENSG00000270028.1	RP11-380L11.4	3.26	0.00116	0.0487	0.13	0.1	Lymphocyte counts;	chr12:123898497	chr12:123925461~123926083:-
BRCA	cis	rs983392	0.679	rs6591559	ENSG00000275344.1	MIR6503	-3.26	0.00116	0.0487	-0.11	-0.1	Alzheimer's disease (late onset);	chr11:60258092	chr11:60209071~60209156:-
BRCA	cis	rs1468333	0.567	rs10080108	ENSG00000206989.1	SNORD63	3.26	0.00116	0.0487	0.11	0.1	Resting heart rate;	chr5:138319553	chr5:138561043~138561110:-
BRCA	cis	rs7011507	0.947	rs77746636	ENSG00000279881.1	RP11-513O13.1	-3.26	0.00116	0.0487	-0.15	-0.1	Inflammatory bowel disease;Ulcerative colitis;	chr8:48271861	chr8:48428143~48431041:-
BRCA	cis	rs1005277	0.579	rs1780136	ENSG00000273019.1	RP11-508N22.13	-3.26	0.00116	0.0487	-0.12	-0.1	Extrinsic epigenetic age acceleration;	chr10:38212525	chr10:38149968~38150293:+
BRCA	cis	rs1005277	0.579	rs1780138	ENSG00000273019.1	RP11-508N22.13	-3.26	0.00116	0.0487	-0.12	-0.1	Extrinsic epigenetic age acceleration;	chr10:38212726	chr10:38149968~38150293:+
BRCA	cis	rs1005277	0.579	rs1780139	ENSG00000273019.1	RP11-508N22.13	-3.26	0.00116	0.0487	-0.12	-0.1	Extrinsic epigenetic age acceleration;	chr10:38214090	chr10:38149968~38150293:+
BRCA	cis	rs1005277	0.602	rs1780141	ENSG00000273019.1	RP11-508N22.13	-3.26	0.00116	0.0487	-0.12	-0.1	Extrinsic epigenetic age acceleration;	chr10:38215371	chr10:38149968~38150293:+
BRCA	cis	rs6963495	0.745	rs2392749	ENSG00000223886.3	RP11-251G23.2	3.26	0.00116	0.0487	0.14	0.1	Bipolar disorder (body mass index interaction);	chr7:105542158	chr7:105530209~105530671:+
BRCA	cis	rs7662987	0.517	rs2602881	ENSG00000260641.1	RP11-1299A16.3	3.26	0.00116	0.0487	0.15	0.1	Smoking initiation;	chr4:99119544	chr4:98658904~98664550:+
BRCA	cis	rs889312	0.5	rs3099460	ENSG00000237705.1	AC008937.2	3.26	0.00116	0.0487	0.1	0.1	Breast cancer (early onset);Breast cancer;	chr5:56837921	chr5:56842016~56862164:-
BRCA	cis	rs4819052	0.851	rs2838839	ENSG00000223768.1	LINC00205	3.26	0.00116	0.0487	0.14	0.1	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45247943	chr21:45293285~45297354:+
BRCA	cis	rs875971	0.545	rs4718335	ENSG00000273448.1	RP11-166O4.6	3.26	0.00116	0.0487	0.11	0.1	Aortic root size;	chr7:66339619	chr7:67333047~67334383:+
BRCA	cis	rs3735485	0.843	rs12533346	ENSG00000201772.1	SNORA5C	-3.26	0.00116	0.0487	-0.13	-0.1	White blood cell count;Sum basophil neutrophil counts;Neutrophil count;Granulocyte percentage of myeloid white cells;Monocyte percentage of white cells;Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Lymphocyte counts;	chr7:44981290	chr7:45104906~45105042:-
BRCA	cis	rs8112211	0.599	rs2887262	ENSG00000268510.1	IFNL3P1	-3.26	0.00116	0.0487	-0.15	-0.1	Blood protein levels;	chr19:38340671	chr19:39236433~39237293:-
BRCA	cis	rs4374383	0.631	rs1400323	ENSG00000236307.2	EEF1E1P1	3.26	0.00116	0.0487	0.11	0.1	Hepatitis C induced liver fibrosis;	chr2:111912884	chr2:111887914~111888741:+
BRCA	cis	rs7915131	0.507	rs7071642	ENSG00000238280.1	RP11-436D10.3	3.26	0.00116	0.0487	0.16	0.1	Schizophrenia;	chr10:62654300	chr10:62793562~62805887:-
BRCA	cis	rs28489187	0.638	rs233055	ENSG00000223653.4	RP11-131L23.1	3.26	0.00116	0.0487	0.11	0.1	Serum dimethylarginine levels (asymmetric/symetric ratio);Asymmetrical dimethylarginine levels;	chr1:85332803	chr1:85276715~85448124:+
BRCA	cis	rs4478858	0.684	rs10798837	ENSG00000229447.2	RP11-490K7.4	-3.26	0.00116	0.0487	-0.09	-0.1	Alcohol dependence;	chr1:31246493	chr1:31263245~31263681:-
BRCA	cis	rs4478858	0.684	rs10798838	ENSG00000229447.2	RP11-490K7.4	-3.26	0.00116	0.0487	-0.09	-0.1	Alcohol dependence;	chr1:31246603	chr1:31263245~31263681:-
BRCA	cis	rs16849225	0.526	rs6710706	ENSG00000206869.1	SNORA70F	-3.26	0.00116	0.0487	-0.12	-0.1	Systolic blood pressure;Blood pressure;	chr2:163957531	chr2:164687643~164687777:-
BRCA	cis	rs866743	1	rs10945359	ENSG00000229720.1	RP3-495K2.2	3.26	0.00116	0.0487	0.11	0.1	Post bronchodilator FEV1/FVC ratio;	chr6:169028217	chr6:169034197~169035642:-
BRCA	cis	rs13153459	0.602	rs73752037	ENSG00000279557.1	CTD-2210P15.3	-3.26	0.00116	0.0487	-0.19	-0.1	Parkinson's disease;	chr5:44501378	chr5:43586367~43587543:-
BRCA	cis	rs9990333	0.562	rs56224853	ENSG00000273009.1	RP11-352G9.1	-3.26	0.00116	0.0487	-0.12	-0.1	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196102005	chr3:195913078~195913683:-
BRCA	cis	rs9990333	0.544	rs73210008	ENSG00000273009.1	RP11-352G9.1	-3.26	0.00116	0.0487	-0.12	-0.1	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196102260	chr3:195913078~195913683:-
BRCA	cis	rs490234	0.691	rs1472467	ENSG00000232630.1	PRPS1P2	-3.26	0.00116	0.0487	-0.1	-0.1	Mean arterial pressure;	chr9:125410842	chr9:125150653~125151589:+
BRCA	cis	rs7590368	1	rs2884289	ENSG00000272275.1	RP11-791G15.2	3.26	0.00116	0.0487	0.13	0.1	Educational attainment (years of education);	chr2:10819598	chr2:10767875~10770058:-
BRCA	cis	rs7590368	0.961	rs2357815	ENSG00000272275.1	RP11-791G15.2	3.26	0.00116	0.0487	0.13	0.1	Educational attainment (years of education);	chr2:10819643	chr2:10767875~10770058:-
BRCA	cis	rs7590368	0.962	rs13431633	ENSG00000272275.1	RP11-791G15.2	3.26	0.00116	0.0487	0.13	0.1	Educational attainment (years of education);	chr2:10820099	chr2:10767875~10770058:-
BRCA	cis	rs7590368	0.961	rs13431852	ENSG00000272275.1	RP11-791G15.2	3.26	0.00116	0.0487	0.13	0.1	Educational attainment (years of education);	chr2:10820284	chr2:10767875~10770058:-
BRCA	cis	rs7590368	1	rs13429247	ENSG00000272275.1	RP11-791G15.2	3.26	0.00116	0.0487	0.13	0.1	Educational attainment (years of education);	chr2:10820403	chr2:10767875~10770058:-
BRCA	cis	rs7590368	0.961	rs13432104	ENSG00000272275.1	RP11-791G15.2	3.26	0.00116	0.0487	0.13	0.1	Educational attainment (years of education);	chr2:10820535	chr2:10767875~10770058:-
BRCA	cis	rs1116357	0.502	rs1594149	ENSG00000233251.6	AC007743.1	-3.26	0.00116	0.0487	-0.12	-0.1	Type 2 diabetes;	chr2:57009293	chr2:56173534~56185770:-
BRCA	cis	rs9372498	0.536	rs62421536	ENSG00000216809.1	RP11-57K17.1	-3.26	0.00116	0.0487	-0.14	-0.1	Diastolic blood pressure;	chr6:118406809	chr6:118452469~118454992:-
BRCA	cis	rs11098499	0.955	rs35197422	ENSG00000260404.2	RP11-384K6.6	3.26	0.00116	0.0487	0.1	0.1	Corneal astigmatism;	chr4:119248159	chr4:118591773~118633729:+
BRCA	cis	rs4714291	1	rs1100103	ENSG00000180211.5	RP1-278E11.3	3.26	0.00116	0.0487	0.11	0.1	Strep throat;	chr6:40072685	chr6:39958414~39958833:-
BRCA	cis	rs5758511	0.68	rs1107553	ENSG00000270083.1	RP1-257I20.14	-3.26	0.00116	0.0487	-0.14	-0.1	Birth weight;	chr22:42271467	chr22:42089630~42090028:-
BRCA	cis	rs8179	0.645	rs66939011	ENSG00000230927.2	TMBIM7P	3.26	0.00116	0.0487	0.13	0.1	White blood cell count (basophil);Sum neutrophil eosinophil counts;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Granulocyte count;	chr7:92636484	chr7:92412976~92439562:-
BRCA	cis	rs2904804	0.522	rs10904378	ENSG00000224251.5	RP11-499O7.7	3.26	0.00116	0.0487	0.11	0.1	Economic and political preferences (immigration/crime);	chr10:4945047	chr10:4995488~4997380:+
BRCA	cis	rs6456156	0.586	rs10946209	ENSG00000272549.1	RP11-351J23.2	-3.26	0.00116	0.0487	-0.1	-0.1	Primary biliary cholangitis;	chr6:167067503	chr6:167666840~167679270:-
BRCA	cis	rs36563	0.631	rs1859915	ENSG00000269927.1	RP6-91H8.3	3.26	0.00116	0.0487	0.18	0.1	Alcohol dependence;	chr14:71018861	chr14:71141125~71143253:-
BRCA	cis	rs6088590	1	rs6120705	ENSG00000276073.1	RP5-1125A11.7	-3.26	0.00116	0.0487	-0.11	-0.1	Coronary artery disease;	chr20:34725936	chr20:33985617~33988989:-
BRCA	cis	rs2496589	0.963	rs2473453	ENSG00000217648.1	RP1-95L4.4	3.26	0.00116	0.0487	0.15	0.1	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);	chr6:143417433	chr6:143342246~143343383:+
BRCA	cis	rs13126694	0.839	rs66490968	ENSG00000251073.1	NUDT19P5	3.26	0.00116	0.0487	0.09	0.1	Blood osmolality (transformed sodium);	chr4:157994770	chr4:158182825~158183393:+
BRCA	cis	rs17767294	0.708	rs6908688	ENSG00000272312.1	RP11-239L20.6	3.26	0.00116	0.0487	0.22	0.1	Parkinson's disease;	chr6:27918273	chr6:27001208~27001648:-
BRCA	cis	rs7308116	0.967	rs11113486	ENSG00000274395.1	RP11-554D14.8	-3.26	0.00116	0.0487	-0.11	-0.1	Pelvic organ prolapse (moderate/severe);	chr12:107798312	chr12:107835541~107836555:-
BRCA	cis	rs7308116	0.935	rs11113487	ENSG00000274395.1	RP11-554D14.8	-3.26	0.00116	0.0487	-0.11	-0.1	Pelvic organ prolapse (moderate/severe);	chr12:107798331	chr12:107835541~107836555:-
BRCA	cis	rs7308116	0.967	rs11113488	ENSG00000274395.1	RP11-554D14.8	-3.26	0.00116	0.0487	-0.11	-0.1	Pelvic organ prolapse (moderate/severe);	chr12:107798344	chr12:107835541~107836555:-
BRCA	cis	rs3816183	0.598	rs2374438	ENSG00000226491.1	FTOP1	-3.26	0.00116	0.0487	-0.13	-0.1	Hypospadias;	chr2:42681870	chr2:42797225~42798712:-
BRCA	cis	rs359466	0.938	rs62378660	ENSG00000254164.1	CTB-33O18.2	-3.26	0.00116	0.0487	-0.17	-0.1	QRS complex (Sokolow-Lyon);	chr5:173955774	chr5:173574938~173576275:+
BRCA	cis	rs17213965	0.852	rs4781692	ENSG00000258354.1	MIR3180-1	3.26	0.00116	0.0487	0.18	0.1	Waist-hip ratio;	chr16:15784296	chr16:14909887~14911345:-
BRCA	cis	rs9333290	0.93	rs12151442	ENSG00000259915.2	RP11-410E4.1	3.26	0.00116	0.0487	0.14	0.1	Urinary albumin-to-creatinine ratio in non-diabetics;Urinary albumin-to-creatinine ratio;	chr2:186673120	chr2:186354570~186356773:-
BRCA	cis	rs2360027	0.599	rs2211476	ENSG00000231365.4	RP11-418J17.1	-3.26	0.00116	0.0487	-0.12	-0.1	Tonsillectomy;	chr1:118544858	chr1:119140396~119275973:+
BRCA	cis	rs7429990	0.965	rs7619882	ENSG00000228638.1	FCF1P2	-3.26	0.00116	0.0487	-0.1	-0.1	Educational attainment (years of education);	chr3:47943334	chr3:48290793~48291375:-
BRCA	cis	rs17192198	0.66	rs67524827	ENSG00000258302.2	RP11-981P6.1	-3.26	0.00116	0.0487	-0.12	-0.1	Diastolic blood pressure;	chr12:89743135	chr12:89561129~89594878:+
BRCA	cis	rs12586478	0.538	rs28396120	ENSG00000205562.2	RP11-497E19.1	-3.26	0.00116	0.0488	-0.09	-0.1	Post bronchodilator FEV1;	chr14:86335186	chr14:85524432~85529988:-
BRCA	cis	rs1923539	0.713	rs2265960	ENSG00000272447.1	RP11-182L21.6	3.26	0.00116	0.0488	0.13	0.1	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79969830	chr10:79825902~79827602:+
BRCA	cis	rs7818688	0.697	rs76631135	ENSG00000245080.5	RP11-320N21.1	-3.26	0.00116	0.0488	-0.17	-0.1	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94968760	chr8:95066808~95073182:-
BRCA	cis	rs7818688	0.697	rs57890591	ENSG00000245080.5	RP11-320N21.1	-3.26	0.00116	0.0488	-0.17	-0.1	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94970902	chr8:95066808~95073182:-
BRCA	cis	rs67478160	0.619	rs11160761	ENSG00000269910.1	RP11-73M18.10	3.26	0.00116	0.0488	0.1	0.1	Schizophrenia;	chr14:103788519	chr14:103694516~103695050:-
BRCA	cis	rs6840360	0.615	rs6831810	ENSG00000270265.1	RP11-731D1.4	-3.26	0.00116	0.0488	-0.12	-0.1	Intelligence (multi-trait analysis);	chr4:151540843	chr4:151333775~151353224:-
BRCA	cis	rs6840360	0.615	rs56319216	ENSG00000270265.1	RP11-731D1.4	-3.26	0.00116	0.0488	-0.12	-0.1	Intelligence (multi-trait analysis);	chr4:151542564	chr4:151333775~151353224:-
BRCA	cis	rs6840360	0.615	rs4696095	ENSG00000270265.1	RP11-731D1.4	-3.26	0.00116	0.0488	-0.12	-0.1	Intelligence (multi-trait analysis);	chr4:151546091	chr4:151333775~151353224:-
BRCA	cis	rs6840360	0.615	rs72728171	ENSG00000270265.1	RP11-731D1.4	-3.26	0.00116	0.0488	-0.12	-0.1	Intelligence (multi-trait analysis);	chr4:151548220	chr4:151333775~151353224:-
BRCA	cis	rs6840360	0.615	rs72728173	ENSG00000270265.1	RP11-731D1.4	-3.26	0.00116	0.0488	-0.12	-0.1	Intelligence (multi-trait analysis);	chr4:151548221	chr4:151333775~151353224:-
BRCA	cis	rs11573156	0.507	rs10799598	ENSG00000270728.1	RP4-657E11.10	3.26	0.00116	0.0488	0.12	0.1	Blood protein levels;	chr1:19961873	chr1:19297080~19297903:+
BRCA	cis	rs7914558	1	rs12780843	ENSG00000213277.3	MARCKSL1P1	3.26	0.00116	0.0488	0.11	0.1	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:103009578	chr10:103175554~103176094:+
BRCA	cis	rs11633886	0.585	rs2460628	ENSG00000273972.1	CTD-2306A12.1	3.26	0.00116	0.0488	0.12	0.1	Diisocyanate-induced asthma;	chr15:45795754	chr15:45702640~45703183:+
BRCA	cis	rs687432	0.737	rs11600060	ENSG00000213592.4	AP000662.9	-3.26	0.00116	0.0488	-0.14	-0.1	Parkinson's disease;	chr11:58131395	chr11:57718044~57718530:-
BRCA	cis	rs1912124	1	rs1912124	ENSG00000259343.4	TMC3-AS1	3.26	0.00116	0.0488	0.22	0.1	Peripheral arterial disease (traffic-related air pollution interaction);	chr15:81206630	chr15:81324377~81362037:+
BRCA	cis	rs6545883	0.868	rs2518933	ENSG00000273302.1	RP11-493E12.2	3.26	0.00116	0.0488	0.09	0.1	Tuberculosis;	chr2:61569895	chr2:61199979~61200769:+
BRCA	cis	rs11671005	0.735	rs12986387	ENSG00000269473.1	CTD-2619J13.19	3.26	0.00116	0.0488	0.15	0.1	Mean platelet volume;	chr19:58415848	chr19:58440448~58445849:+
BRCA	cis	rs11671005	0.735	rs11667723	ENSG00000269473.1	CTD-2619J13.19	3.26	0.00116	0.0488	0.15	0.1	Mean platelet volume;	chr19:58416122	chr19:58440448~58445849:+
BRCA	cis	rs11671005	0.735	rs11668789	ENSG00000269473.1	CTD-2619J13.19	3.26	0.00116	0.0488	0.15	0.1	Mean platelet volume;	chr19:58416942	chr19:58440448~58445849:+
BRCA	cis	rs4578769	0.797	rs4800447	ENSG00000265939.1	UBE2CP2	-3.26	0.00116	0.0488	-0.13	-0.1	Eosinophil percentage of white cells;	chr18:23045939	chr18:22900486~22900995:-
BRCA	cis	rs12277962	1	rs740320	ENSG00000256282.1	RP11-504G3.4	3.26	0.00116	0.0488	0.11	0.1	Night sleep phenotypes;	chr11:17636973	chr11:18595459~18599683:-
BRCA	cis	rs7615952	0.558	rs7641353	ENSG00000241288.6	RP11-379B18.5	-3.26	0.00116	0.0488	-0.13	-0.1	Blood pressure (smoking interaction);	chr3:125621035	chr3:125827238~125916384:-
BRCA	cis	rs6460942	0.908	rs112897715	ENSG00000226690.5	AC005281.1	3.26	0.00116	0.0488	0.18	0.1	Coronary artery disease;	chr7:12201915	chr7:12496429~12541910:+
BRCA	cis	rs2880765	0.835	rs2170735	ENSG00000259630.2	CTD-2262B20.1	-3.26	0.00116	0.0488	-0.12	-0.1	Coronary artery disease;	chr15:85500254	chr15:85415228~85415633:+
BRCA	cis	rs6725041	0.532	rs12623803	ENSG00000196096.3	AC079610.2	-3.26	0.00116	0.0488	-0.13	-0.1	QT interval (ambient particulate matter interaction);	chr2:212336918	chr2:213276552~213284205:-
BRCA	cis	rs8073060	0.544	rs8071584	ENSG00000267554.1	RP11-686D22.10	-3.26	0.00116	0.0488	-0.1	-0.1	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35672416	chr17:35470069~35470628:-
BRCA	cis	rs672059	0.565	rs525410	ENSG00000224468.3	RP11-181K3.4	3.26	0.00116	0.0488	0.1	0.1	Hypertriglyceridemia;	chr1:183207295	chr1:183138402~183141282:-
BRCA	cis	rs7594648	0.847	rs11692209	ENSG00000226383.4	AC093375.1	-3.26	0.00116	0.0488	-0.15	-0.1	Age-related hearing impairment;	chr2:155649246	chr2:156011617~156024613:-
BRCA	cis	rs8133974	1	rs17227266	ENSG00000225555.1	AP000320.6	3.26	0.00116	0.0488	0.2	0.1	Sum eosinophil basophil counts;Eosinophil counts;Eosinophil percentage of granulocytes;	chr21:35072927	chr21:34370802~34375348:-
BRCA	cis	rs337100	0.546	rs480764	ENSG00000263432.2	RN7SL689P	-3.26	0.00116	0.0488	-0.12	-0.1	Pulse pressure;	chr5:123144581	chr5:123022487~123022783:-
BRCA	cis	rs10876993	0.89	rs1092472	ENSG00000270039.1	RP11-571M6.17	3.26	0.00116	0.0488	0.13	0.1	Celiac disease or Rheumatoid arthritis;	chr12:57642905	chr12:57803838~57804415:+
BRCA	cis	rs7072574	0.964	rs55753709	ENSG00000273450.1	RP11-76P2.4	3.26	0.00116	0.0488	0.13	0.1	Vertical cup-disc ratio;	chr10:94269413	chr10:94314907~94315327:-
BRCA	cis	rs3753275	0.624	rs10864364	ENSG00000270282.1	RP5-1115A15.2	-3.26	0.00116	0.0488	-0.14	-0.1	Educational attainment;	chr1:8707721	chr1:8512653~8513021:+
BRCA	cis	rs1325195	0.843	rs390018	ENSG00000261060.1	RP11-545A16.4	-3.26	0.00116	0.0488	-0.14	-0.1	IgE grass sensitization;	chr1:179246612	chr1:179590372~179591305:+
BRCA	cis	rs7781266	0.646	rs4728287	ENSG00000226205.1	AC007790.4	-3.26	0.00116	0.0488	-0.13	-0.1	Educational attainment (college completion);	chr7:133429503	chr7:133732493~133733595:-
BRCA	cis	rs7712401	0.818	rs13166350	ENSG00000263432.2	RN7SL689P	3.26	0.00116	0.0488	0.12	0.1	Mean platelet volume;	chr5:122817874	chr5:123022487~123022783:-
BRCA	cis	rs17092148	0.887	rs4911430	ENSG00000269202.1	RP4-614O4.12	3.26	0.00116	0.0488	0.13	0.1	Neuroticism;	chr20:34557600	chr20:35201747~35203288:-
BRCA	cis	rs6840360	0.571	rs28608620	ENSG00000278978.1	RP11-164P12.5	-3.26	0.00116	0.0488	-0.12	-0.1	Intelligence (multi-trait analysis);	chr4:151583639	chr4:151669786~151670503:+
BRCA	cis	rs739496	1	rs739496	ENSG00000257624.1	RP1-128M12.3	3.26	0.00116	0.0488	0.13	0.1	Platelet count;	chr12:111449855	chr12:112000739~112000985:-
BRCA	cis	rs801193	0.548	rs2659904	ENSG00000229886.1	RP5-1132H15.3	3.26	0.00116	0.0488	0.11	0.1	Aortic root size;	chr7:66713615	chr7:66025126~66031544:-
BRCA	cis	rs1865760	0.928	rs9295673	ENSG00000272810.1	U91328.22	-3.26	0.00116	0.0488	-0.12	-0.1	Height;	chr6:25911866	chr6:26013241~26013757:+
BRCA	cis	rs12364620	1	rs12364620	ENSG00000254610.1	RP5-903G2.2	-3.26	0.00116	0.0488	-0.14	-0.1	Total body bone mineral density (age 0-15);	chr11:68484655	chr11:67934563~67939774:-
BRCA	cis	rs7800418	0.695	rs11766071	ENSG00000253552.6	HOXA-AS2	-3.26	0.00116	0.0488	-0.09	-0.1	Cognitive function;	chr7:26552727	chr7:27107777~27134302:+
BRCA	cis	rs10197140	0.925	rs7563488	ENSG00000235721.1	AC013268.3	-3.26	0.00116	0.0488	-0.13	-0.1	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110875340	chr2:110007675~110010783:+
BRCA	cis	rs301901	1	rs300055	ENSG00000272103.1	CTD-2653M23.3	3.26	0.00116	0.0488	0.12	0.1	Height;	chr5:37072722	chr5:36861736~36862217:-
BRCA	cis	rs4820539	0.966	rs5759600	ENSG00000211647.1	IGLV5-48	-3.26	0.00116	0.0488	-0.08	-0.1	Bone mineral density;	chr22:23141582	chr22:22352940~22353433:+
BRCA	cis	rs2436153	0.676	rs1432057	ENSG00000254551.1	RP11-727A23.7	3.26	0.00116	0.0488	0.12	0.1	Facial morphology (factor 16);	chr11:83541234	chr11:83209431~83213379:-
BRCA	cis	rs2839186	0.504	rs11702278	ENSG00000228137.1	AP001469.7	-3.26	0.00116	0.0488	-0.1	-0.1	Testicular germ cell tumor;	chr21:46516382	chr21:46246890~46247682:+
BRCA	cis	rs875971	0.964	rs55748098	ENSG00000272831.1	RP11-792A8.4	-3.26	0.00116	0.0488	-0.09	-0.1	Aortic root size;	chr7:66298631	chr7:66739829~66740385:-
BRCA	cis	rs7267979	1	rs2500436	ENSG00000231081.1	RP4-760C5.3	3.26	0.00116	0.0488	0.13	0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25425730	chr20:26008791~26010531:-
BRCA	cis	rs11673344	0.764	rs13345491	ENSG00000267682.1	CTD-3220F14.2	-3.26	0.00116	0.0488	-0.09	-0.1	Obesity-related traits;	chr19:36982197	chr19:37337236~37337743:+
BRCA	cis	rs2880765	0.743	rs4551990	ENSG00000259244.1	RP11-182J1.12	3.26	0.00116	0.0488	0.1	0.1	Coronary artery disease;	chr15:85472056	chr15:84513241~84526949:-
BRCA	cis	rs6088580	0.634	rs6088484	ENSG00000269202.1	RP4-614O4.12	3.26	0.00116	0.0488	0.1	0.1	Glomerular filtration rate (creatinine);	chr20:34398155	chr20:35201747~35203288:-
BRCA	cis	rs7572733	1	rs9973400	ENSG00000231621.1	AC013264.2	-3.26	0.00116	0.0488	-0.09	-0.1	Dermatomyositis;	chr2:198076854	chr2:197197991~197199273:+
BRCA	cis	rs10129255	0.833	rs7156689	ENSG00000274576.2	IGHV2-70	3.26	0.00116	0.0488	0.09	0.1	Kawasaki disease;	chr14:106816039	chr14:106770577~106771020:-
BRCA	cis	rs4664293	0.585	rs13019325	ENSG00000230783.1	AC009961.2	3.26	0.00116	0.0488	0.12	0.1	Monocyte percentage of white cells;	chr2:159772479	chr2:159689217~159690291:-
BRCA	cis	rs11673344	0.864	rs1533736	ENSG00000267422.1	CTD-2554C21.1	3.26	0.00116	0.0488	0.14	0.1	Obesity-related traits;	chr19:37164074	chr19:37779686~37792865:+
BRCA	cis	rs6582630	0.679	rs7301806	ENSG00000257718.1	RP11-396F22.1	3.26	0.00116	0.0488	0.1	0.1	Drug-induced liver injury (flucloxacillin);	chr12:38202865	chr12:38906451~38909592:+
BRCA	cis	rs7188861	0.681	rs12928822	ENSG00000262636.1	CTD-3088G3.4	3.26	0.00116	0.0488	0.19	0.1	HDL cholesterol;	chr16:11310036	chr16:11380859~11381118:-
BRCA	cis	rs7943953	0.714	rs59295759	ENSG00000254717.2	GLYATL1P2	-3.26	0.00116	0.0488	-0.14	-0.1	Odorant perception (&beta-ionone);	chr11:59446795	chr11:58878302~58893460:+
BRCA	cis	rs7943953	0.714	rs1013736	ENSG00000254717.2	GLYATL1P2	-3.26	0.00116	0.0488	-0.14	-0.1	Odorant perception (&beta-ionone);	chr11:59449571	chr11:58878302~58893460:+
BRCA	cis	rs7943953	0.714	rs17500063	ENSG00000254717.2	GLYATL1P2	-3.26	0.00116	0.0488	-0.14	-0.1	Odorant perception (&beta-ionone);	chr11:59451504	chr11:58878302~58893460:+
BRCA	cis	rs7943953	0.714	rs12803202	ENSG00000254717.2	GLYATL1P2	-3.26	0.00116	0.0488	-0.14	-0.1	Odorant perception (&beta-ionone);	chr11:59451800	chr11:58878302~58893460:+
BRCA	cis	rs7943953	0.714	rs34927910	ENSG00000254717.2	GLYATL1P2	-3.26	0.00116	0.0488	-0.14	-0.1	Odorant perception (&beta-ionone);	chr11:59451865	chr11:58878302~58893460:+
BRCA	cis	rs4664293	0.967	rs12611922	ENSG00000230783.1	AC009961.2	-3.26	0.00116	0.0488	-0.12	-0.1	Monocyte percentage of white cells;	chr2:159606238	chr2:159689217~159690291:-
BRCA	cis	rs4950322	0.518	rs61838938	ENSG00000230832.3	RP11-325P15.2	-3.26	0.00116	0.0488	-0.15	-0.1	Protein quantitative trait loci;	chr1:147105943	chr1:147082338~147083578:-
BRCA	cis	rs4950322	0.529	rs11809327	ENSG00000230832.3	RP11-325P15.2	-3.26	0.00116	0.0488	-0.15	-0.1	Protein quantitative trait loci;	chr1:147106679	chr1:147082338~147083578:-
BRCA	cis	rs4950322	0.563	rs11809328	ENSG00000230832.3	RP11-325P15.2	-3.26	0.00116	0.0488	-0.15	-0.1	Protein quantitative trait loci;	chr1:147106681	chr1:147082338~147083578:-
BRCA	cis	rs875971	0.861	rs801215	ENSG00000223473.2	GS1-124K5.3	-3.26	0.00116	0.0488	-0.08	-0.1	Aortic root size;	chr7:66546951	chr7:66491049~66493566:-
BRCA	cis	rs34779708	0.966	rs10827493	ENSG00000269952.1	RP11-324I22.3	-3.26	0.00116	0.0488	-0.13	-0.1	Inflammatory bowel disease;Crohn's disease;	chr10:35166048	chr10:35210416~35210750:+
BRCA	cis	rs2991971	0.933	rs12568144	ENSG00000281133.1	AL355480.3	3.26	0.00116	0.0488	0.12	0.1	High light scatter reticulocyte count;	chr1:45499635	chr1:45580892~45580996:-
BRCA	cis	rs4657178	0.887	rs6427664	ENSG00000272574.1	RP11-359K18.4	-3.26	0.00116	0.0489	-0.1	-0.1	QT interval;	chr1:162244683	chr1:162593103~162593754:+
BRCA	cis	rs875971	1	rs10257427	ENSG00000272831.1	RP11-792A8.4	-3.26	0.00116	0.0489	-0.09	-0.1	Aortic root size;	chr7:66278221	chr7:66739829~66740385:-
BRCA	cis	rs1367226	0.761	rs13401519	ENSG00000272606.1	RP11-554J4.1	3.26	0.00116	0.0489	0.11	0.1	Height;	chr2:55847275	chr2:55617909~55618373:+
BRCA	cis	rs1355223	0.872	rs7112608	ENSG00000271369.1	RP11-350D17.3	-3.26	0.00116	0.0489	-0.12	-0.1	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34677722	chr11:34709600~34710161:+
BRCA	cis	rs7259376	0.936	rs2099354	ENSG00000269345.1	VN1R85P	3.26	0.00116	0.0489	0.11	0.1	Menopause (age at onset);	chr19:22356730	chr19:22174766~22175191:-
BRCA	cis	rs7707921	0.752	rs6882565	ENSG00000251374.1	RPS23P5	3.26	0.00116	0.0489	0.13	0.1	Breast cancer;	chr5:82060602	chr5:82265157~82265259:-
BRCA	cis	rs7267979	1	rs2297496	ENSG00000204556.4	CTD-2514C3.1	3.26	0.00116	0.0489	0.14	0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25315151	chr20:26018832~26020684:+
BRCA	cis	rs2832077	0.943	rs2832094	ENSG00000236056.1	GAPDHP14	3.26	0.00116	0.0489	0.14	0.1	Cognitive test performance;	chr21:28793588	chr21:29222321~29223257:+
BRCA	cis	rs11673344	0.864	rs7260386	ENSG00000267422.1	CTD-2554C21.1	3.26	0.00116	0.0489	0.13	0.1	Obesity-related traits;	chr19:37158656	chr19:37779686~37792865:+
BRCA	cis	rs7267979	1	rs6050602	ENSG00000231081.1	RP4-760C5.3	3.26	0.00116	0.0489	0.13	0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25420567	chr20:26008791~26010531:-
BRCA	cis	rs9472155	0.951	rs1326141	ENSG00000220614.1	RP11-480N24.4	3.26	0.00116	0.0489	0.14	0.1	Vascular endothelial growth factor levels;	chr6:43935540	chr6:43328134~43328476:+
BRCA	cis	rs13153459	0.649	rs922855	ENSG00000249203.1	RP11-473L15.3	-3.26	0.00116	0.0489	-0.14	-0.1	Parkinson's disease;	chr5:44517290	chr5:44495618~44510282:-
BRCA	cis	rs9828082	0.961	rs965699	ENSG00000228956.7	SATB1-AS1	3.26	0.00116	0.0489	0.11	0.1	Neuroticism;	chr3:18581413	chr3:18445024~18920401:+
BRCA	cis	rs9828082	0.961	rs996556	ENSG00000228956.7	SATB1-AS1	3.26	0.00116	0.0489	0.11	0.1	Neuroticism;	chr3:18582766	chr3:18445024~18920401:+
BRCA	cis	rs4578769	0.685	rs973482	ENSG00000265939.1	UBE2CP2	-3.26	0.00116	0.0489	-0.13	-0.1	Eosinophil percentage of white cells;	chr18:22951923	chr18:22900486~22900995:-
BRCA	cis	rs4578769	0.722	rs55758053	ENSG00000265939.1	UBE2CP2	-3.26	0.00116	0.0489	-0.13	-0.1	Eosinophil percentage of white cells;	chr18:22958405	chr18:22900486~22900995:-
BRCA	cis	rs12534093	0.921	rs11762335	ENSG00000234286.1	AC006026.13	-3.26	0.00116	0.0489	-0.16	-0.1	Infant length;Height;	chr7:23455577	chr7:23680195~23680786:-
BRCA	cis	rs12534093	0.921	rs12700441	ENSG00000234286.1	AC006026.13	-3.26	0.00116	0.0489	-0.16	-0.1	Infant length;Height;	chr7:23456292	chr7:23680195~23680786:-
BRCA	cis	rs6142102	0.812	rs761238	ENSG00000228265.4	RALY-AS1	3.26	0.00116	0.0489	0.11	0.1	Skin pigmentation;	chr20:33932182	chr20:33983052~33994357:-
BRCA	cis	rs875971	0.545	rs10950027	ENSG00000226767.1	RP11-328P23.3	3.26	0.00116	0.0489	0.12	0.1	Aortic root size;	chr7:66169164	chr7:65508773~65508944:-
BRCA	cis	rs4578769	0.765	rs16972427	ENSG00000273232.1	RP11-370A5.2	-3.26	0.00116	0.0489	-0.14	-0.1	Eosinophil percentage of white cells;	chr18:22833393	chr18:22882825~22883357:-
BRCA	cis	rs9368481	0.569	rs10946868	ENSG00000272462.2	U91328.19	-3.26	0.00116	0.0489	-0.12	-0.1	Autism spectrum disorder or schizophrenia;	chr6:26920151	chr6:25992662~26001775:+
BRCA	cis	rs11955398	0.585	rs1456743	ENSG00000251279.1	CTC-436P18.1	3.26	0.00116	0.0489	0.12	0.1	Intelligence (multi-trait analysis);	chr5:60711594	chr5:61162070~61232040:+
BRCA	cis	rs11955398	0.585	rs10063166	ENSG00000251279.1	CTC-436P18.1	3.26	0.00116	0.0489	0.12	0.1	Intelligence (multi-trait analysis);	chr5:60713017	chr5:61162070~61232040:+
BRCA	cis	rs11955398	0.585	rs10041431	ENSG00000251279.1	CTC-436P18.1	3.26	0.00116	0.0489	0.12	0.1	Intelligence (multi-trait analysis);	chr5:60715090	chr5:61162070~61232040:+
BRCA	cis	rs4803480	0.572	rs8111065	ENSG00000270164.1	LINC01480	-3.26	0.00116	0.0489	-0.2	-0.1	Schizophrenia;	chr19:41606201	chr19:41535183~41536904:+
BRCA	cis	rs12413361	0.967	rs10826875	ENSG00000237135.1	DDX10P1	-3.26	0.00116	0.0489	-0.12	-0.1	Height;	chr10:30830785	chr10:30919012~30921235:-
BRCA	cis	rs13153459	0.649	rs6870835	ENSG00000279557.1	CTD-2210P15.3	-3.26	0.00116	0.0489	-0.19	-0.1	Parkinson's disease;	chr5:44514546	chr5:43586367~43587543:-
BRCA	cis	rs35275482	0.541	rs11635283	ENSG00000259238.1	RP11-361D15.2	-3.26	0.00116	0.0489	-0.13	-0.1	Gut microbiota (bacterial taxa);	chr15:59811002	chr15:59688517~59689418:+
BRCA	cis	rs7695732	1	rs12648534	ENSG00000270720.1	RP11-84C13.2	3.26	0.00116	0.0489	0.12	0.1	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr4:88878055	chr4:89119284~89119871:+
BRCA	cis	rs58521262	0.585	rs2645877	ENSG00000267920.1	SNX6P1	-3.26	0.00116	0.0489	-0.13	-0.1	Testicular germ cell tumor;	chr19:23028009	chr19:23126569~23127792:-
BRCA	cis	rs58521262	0.585	rs2548888	ENSG00000267920.1	SNX6P1	-3.26	0.00116	0.0489	-0.13	-0.1	Testicular germ cell tumor;	chr19:23028226	chr19:23126569~23127792:-
BRCA	cis	rs2638953	0.886	rs11049572	ENSG00000273989.1	RP11-425D17.2	-3.26	0.00116	0.0489	-0.15	-0.1	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28397268	chr12:28236227~28236828:+
BRCA	cis	rs4950322	0.57	rs17160051	ENSG00000227242.3	NBPF13P	-3.26	0.00116	0.0489	-0.14	-0.1	Protein quantitative trait loci;	chr1:147255733	chr1:147021320~147124525:-
BRCA	cis	rs7655841	0.947	rs337263	ENSG00000251432.5	RP11-420A23.1	3.26	0.00116	0.0489	0.12	0.1	Chronic obstructive pulmonary disease (moderate to severe);	chr4:129112510	chr4:128292751~128519394:+
BRCA	cis	rs13393800	0.536	rs2697804	ENSG00000237126.7	AC073254.1	3.26	0.00116	0.0489	0.13	0.1	Height;	chr2:232515310	chr2:232580948~232611971:-
BRCA	cis	rs6496932	0.802	rs56306166	ENSG00000259630.2	CTD-2262B20.1	3.26	0.00116	0.0489	0.13	0.1	Central corneal thickness;Corneal structure;	chr15:85326848	chr15:85415228~85415633:+
BRCA	cis	rs10844706	0.699	rs10844626	ENSG00000278635.1	CTD-2318O12.1	-3.26	0.00116	0.0489	-0.11	-0.1	Lymphocyte counts;Lymphocyte percentage of white cells;	chr12:9733757	chr12:9415641~9416718:+
BRCA	cis	rs875971	0.929	rs6970860	ENSG00000230189.5	GS1-124K5.2	3.26	0.00116	0.0489	0.08	0.1	Aortic root size;	chr7:66511647	chr7:66409143~66490059:-
BRCA	cis	rs2277027	1	rs4331881	ENSG00000253653.1	CTC-248O19.1	3.26	0.00116	0.0489	0.12	0.1	Pulmonary function;Pulmonary function (smoking interaction);	chr5:157517467	chr5:157260122~157266625:-
BRCA	cis	rs7647973	0.626	rs7649428	ENSG00000281433.1	Metazoa_SRP	-3.26	0.00116	0.0489	-0.13	-0.1	Menarche (age at onset);	chr3:49831443	chr3:49320296~49320564:+
BRCA	cis	rs2276314	0.857	rs28431958	ENSG00000267627.4	RP11-905K4.1	-3.26	0.00116	0.0489	-0.14	-0.1	Endometriosis;Drug-induced torsades de pointes;	chr18:35998438	chr18:35951803~35966118:-
BRCA	cis	rs6426833	0.74	rs10737482	ENSG00000227066.1	RP3-340N1.2	3.26	0.00116	0.0489	0.13	0.1	Ulcerative colitis;Inflammatory bowel disease;	chr1:19847365	chr1:20154338~20160568:+
BRCA	cis	rs2348418	0.715	rs1912782	ENSG00000244712.1	RP11-874G11.1	3.26	0.00116	0.0489	0.13	0.1	Lung function (FEV1);Lung function (FVC);	chr12:28568774	chr12:28564678~28565141:-
BRCA	cis	rs2496589	1	rs9496639	ENSG00000218896.1	TUBB8P2	-3.26	0.00116	0.0489	-0.14	-0.1	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);	chr6:143447371	chr6:143436216~143436710:+
BRCA	cis	rs72482608	0.636	rs10753830	ENSG00000271811.1	RP1-79C4.4	3.26	0.00116	0.0489	0.11	0.1	Emphysema imaging phenotypes;	chr1:170886924	chr1:170667381~170669425:+
BRCA	cis	rs1005277	0.579	rs1985707	ENSG00000276805.1	RP11-291L22.6	3.26	0.00116	0.0489	0.11	0.1	Extrinsic epigenetic age acceleration;	chr10:38145170	chr10:38451030~38451785:+
BRCA	cis	rs7308116	0.967	rs7136671	ENSG00000274395.1	RP11-554D14.8	-3.26	0.00116	0.0489	-0.11	-0.1	Pelvic organ prolapse (moderate/severe);	chr12:107797378	chr12:107835541~107836555:-
BRCA	cis	rs7308116	0.967	rs10861790	ENSG00000274395.1	RP11-554D14.8	-3.26	0.00116	0.0489	-0.11	-0.1	Pelvic organ prolapse (moderate/severe);	chr12:107797979	chr12:107835541~107836555:-
BRCA	cis	rs7308116	0.967	rs11113485	ENSG00000274395.1	RP11-554D14.8	-3.26	0.00116	0.0489	-0.11	-0.1	Pelvic organ prolapse (moderate/severe);	chr12:107798044	chr12:107835541~107836555:-
BRCA	cis	rs7308116	0.967	rs11113489	ENSG00000274395.1	RP11-554D14.8	-3.26	0.00116	0.0489	-0.11	-0.1	Pelvic organ prolapse (moderate/severe);	chr12:107798394	chr12:107835541~107836555:-
BRCA	cis	rs116988415	1	rs11622962	ENSG00000258809.1	CTD-2555O16.1	3.26	0.00116	0.0489	0.23	0.1	Daytime sleep phenotypes;	chr14:64832427	chr14:64358768~64379318:-
BRCA	cis	rs17756712	0.697	rs2294669	ENSG00000271727.1	RP11-532F6.4	-3.26	0.00116	0.0489	-0.13	-0.1	Vertical cup-disc ratio;	chr6:625673	chr6:711533~750729:+
BRCA	cis	rs8192917	1	rs8192917	ENSG00000258744.1	RP11-80A15.1	-3.26	0.00116	0.0489	-0.13	-0.1	Vitiligo;	chr14:24632954	chr14:24501594~24508688:+
BRCA	cis	rs7927592	0.956	rs7126340	ENSG00000254610.1	RP5-903G2.2	-3.26	0.00116	0.0489	-0.14	-0.1	Total body bone mineral density;	chr11:68489825	chr11:67934563~67939774:-
BRCA	cis	rs13434995	0.513	rs73236153	ENSG00000273257.1	RP11-177J6.1	-3.26	0.00116	0.0489	-0.15	-0.1	Adiponectin levels;	chr4:55585600	chr4:55387949~55388271:+
BRCA	cis	rs848087	0.967	rs712330	ENSG00000200385.1	SNORA42	3.26	0.00116	0.0489	0.09	0.1	Breast cancer;	chr14:36787717	chr14:37720425~37720561:+
BRCA	cis	rs7578361	0.918	rs4309548	ENSG00000231969.1	AC144449.1	3.26	0.00116	0.0489	0.15	0.1	Acute lymphoblastic leukemia (childhood);	chr2:149520913	chr2:149587196~149848233:+
BRCA	cis	rs7578361	0.918	rs4494703	ENSG00000231969.1	AC144449.1	3.26	0.00116	0.0489	0.15	0.1	Acute lymphoblastic leukemia (childhood);	chr2:149520961	chr2:149587196~149848233:+
BRCA	cis	rs7578361	0.918	rs4592816	ENSG00000231969.1	AC144449.1	3.26	0.00116	0.0489	0.15	0.1	Acute lymphoblastic leukemia (childhood);	chr2:149521110	chr2:149587196~149848233:+
BRCA	cis	rs7487075	0.619	rs1472178	ENSG00000257261.4	RP11-96H19.1	3.26	0.00116	0.0489	0.12	0.1	Itch intensity from mosquito bite;	chr12:46410392	chr12:46383679~46876159:+
BRCA	cis	rs1979679	0.879	rs55996833	ENSG00000244712.1	RP11-874G11.1	-3.26	0.00116	0.0489	-0.15	-0.1	Ossification of the posterior longitudinal ligament of the spine;	chr12:28313303	chr12:28564678~28565141:-
BRCA	cis	rs11673344	0.523	rs7245453	ENSG00000276846.1	CTD-3220F14.3	3.26	0.00116	0.049	0.12	0.1	Obesity-related traits;	chr19:37043447	chr19:37314868~37315620:-
BRCA	cis	rs250585	0.736	rs2040574	ENSG00000280039.1	CTD-2270L9.3	3.26	0.00116	0.049	0.11	0.1	Egg allergy;	chr16:23499005	chr16:23412380~23416680:+
BRCA	cis	rs7520050	0.966	rs785491	ENSG00000234329.1	RP11-767N6.2	-3.26	0.00116	0.049	-0.09	-0.1	Reticulocyte count;Red blood cell count;	chr1:46117746	chr1:45651039~45651826:-
BRCA	cis	rs6921919	0.945	rs61289879	ENSG00000281706.1	LINC01012	3.26	0.00117	0.049	0.16	0.1	Autism spectrum disorder or schizophrenia;	chr6:28451385	chr6:27694035~27710222:+
BRCA	cis	rs4713118	0.868	rs7756968	ENSG00000280107.1	AL022393.9	-3.26	0.00117	0.049	-0.15	-0.1	Parkinson's disease;	chr6:27767175	chr6:28170845~28172521:+
BRCA	cis	rs4699052	0.662	rs6848091	ENSG00000230069.3	LRRC37A15P	-3.26	0.00117	0.049	-0.09	-0.1	Testicular germ cell tumor;	chr4:103328944	chr4:102727274~102730721:-
BRCA	cis	rs7896471	0.546	rs77807035	ENSG00000227695.4	DNMBP-AS1	-3.26	0.00117	0.049	-0.24	-0.1	Blood protein levels;	chr10:99959159	chr10:99927010~99958381:+
BRCA	cis	rs11700980	0.636	rs2832138	ENSG00000232855.5	AF131217.1	3.26	0.00117	0.049	0.18	0.1	QRS complex (12-leadsum);	chr21:28911801	chr21:28439346~28674848:-
BRCA	cis	rs10129255	0.536	rs6576201	ENSG00000253359.1	IGHV3-37	-3.26	0.00117	0.049	-0.08	-0.1	Kawasaki disease;	chr14:106683696	chr14:106396676~106397114:-
BRCA	cis	rs12681366	0.647	rs12545262	ENSG00000253175.1	RP11-267M23.6	3.26	0.00117	0.049	0.11	0.1	Nonsyndromic cleft lip with cleft palate;	chr8:94392813	chr8:94565036~94565715:+
BRCA	cis	rs758324	0.797	rs82125	ENSG00000244192.1	RP11-114H7.1	-3.26	0.00117	0.049	-0.12	-0.1	Alzheimer's disease in APOE e4- carriers;	chr5:131986548	chr5:130989897~130990428:+
BRCA	cis	rs4834770	0.718	rs4833618	ENSG00000250412.1	KLHL2P1	-3.26	0.00117	0.049	-0.11	-0.1	Blood protein levels;	chr4:119388345	chr4:119334329~119378233:+
BRCA	cis	rs295490	0.748	rs56993164	ENSG00000178631.7	ACTG1P1	-3.26	0.00117	0.049	-0.2	-0.1	PR interval in Tripanosoma cruzi seropositivity;	chr3:139388391	chr3:139493809~139494937:+
BRCA	cis	rs911555	0.673	rs7144271	ENSG00000269910.1	RP11-73M18.10	3.26	0.00117	0.049	0.1	0.1	Intelligence (multi-trait analysis);	chr14:103424337	chr14:103694516~103695050:-
BRCA	cis	rs7267979	1	rs11087520	ENSG00000231081.1	RP4-760C5.3	-3.26	0.00117	0.049	-0.13	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25456191	chr20:26008791~26010531:-
BRCA	cis	rs6914079	1	rs9370760	ENSG00000235488.1	JARID2-AS1	3.26	0.00117	0.049	0.15	0.1	Cognitive test performance;	chr6:14572267	chr6:15247815~15248634:-
BRCA	cis	rs6914079	0.95	rs10949248	ENSG00000235488.1	JARID2-AS1	3.26	0.00117	0.049	0.15	0.1	Cognitive test performance;	chr6:14572358	chr6:15247815~15248634:-
BRCA	cis	rs10958369	0.871	rs10958370	ENSG00000270980.1	RP11-626A5.2	3.26	0.00117	0.049	0.11	0.1	Response to antineoplastic agents;	chr8:53505150	chr8:54191582~54192035:-
BRCA	cis	rs9921338	0.961	rs7198849	ENSG00000263080.1	RP11-485G7.5	3.26	0.00117	0.049	0.15	0.1	Vein graft stenosis in coronary artery bypass grafting;	chr16:11279444	chr16:11341809~11345211:-
BRCA	cis	rs11150038	0.536	rs2464764	ENSG00000276007.1	RP11-358L22.3	-3.26	0.00117	0.049	-0.16	-0.1	Colorectal or endometrial cancer;	chr16:78012157	chr16:78123243~78124332:+
BRCA	cis	rs6545883	0.929	rs778140	ENSG00000237522.1	NONOP2	-3.26	0.00117	0.049	-0.1	-0.1	Tuberculosis;	chr2:61455841	chr2:60936819~60938049:-
BRCA	cis	rs72647484	0.554	rs2807340	ENSG00000228397.1	RP1-224A6.3	-3.26	0.00117	0.049	-0.27	-0.1	Colorectal cancer;	chr1:22253980	chr1:22023994~22024968:-
BRCA	cis	rs67478160	0.595	rs12879501	ENSG00000269940.1	RP11-73M18.7	3.26	0.00117	0.049	0.1	0.1	Schizophrenia;	chr14:103806297	chr14:103694560~103695170:+
BRCA	cis	rs7267979	0.745	rs6132845	ENSG00000276952.1	RP5-965G21.6	3.26	0.00117	0.049	0.12	0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25567131	chr20:25284915~25285588:-
BRCA	cis	rs6921919	0.609	rs67211468	ENSG00000219891.2	ZSCAN12P1	3.26	0.00117	0.049	0.13	0.1	Autism spectrum disorder or schizophrenia;	chr6:28424210	chr6:28091154~28093664:+
BRCA	cis	rs2070488	0.965	rs7433277	ENSG00000232439.1	RPL18AP7	3.26	0.00117	0.049	0.12	0.1	Electrocardiographic conduction measures;	chr3:38488327	chr3:38526802~38527325:-
BRCA	cis	rs9810888	0.691	rs3796345	ENSG00000270941.1	RP5-966M1.5	3.26	0.00117	0.049	0.11	0.1	Hypertension;Diastolic blood pressure;Systolic blood pressure;	chr3:53619125	chr3:52734735~52735013:+
BRCA	cis	rs11587682	0.76	rs11205383	ENSG00000228126.1	FALEC	3.26	0.00117	0.049	0.13	0.1	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr1:150483337	chr1:150515757~150518032:+
BRCA	cis	rs4665809	1	rs6546728	ENSG00000231655.1	AC011742.3	3.26	0.00117	0.049	0.16	0.1	Gut microbiome composition (summer);	chr2:26053662	chr2:26140263~26141264:-
BRCA	cis	rs6678639	0.522	rs11584372	ENSG00000225154.2	RP11-184J23.2	-3.26	0.00117	0.049	-0.16	-0.1	Blood metabolite ratios;	chr1:47042825	chr1:47074778~47075979:-
BRCA	cis	rs6678639	0.522	rs9700422	ENSG00000225154.2	RP11-184J23.2	-3.26	0.00117	0.049	-0.16	-0.1	Blood metabolite ratios;	chr1:47043684	chr1:47074778~47075979:-
BRCA	cis	rs6678639	0.522	rs11211424	ENSG00000225154.2	RP11-184J23.2	-3.26	0.00117	0.049	-0.16	-0.1	Blood metabolite ratios;	chr1:47047914	chr1:47074778~47075979:-
BRCA	cis	rs7267979	0.586	rs6037057	ENSG00000274414.1	RP5-965G21.4	-3.26	0.00117	0.049	-0.12	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25201453	chr20:25239007~25245229:-
BRCA	cis	rs524281	0.647	rs2302883	ENSG00000255038.1	RP11-1167A19.2	-3.26	0.00117	0.049	-0.14	-0.1	Electroencephalogram traits;	chr11:66057523	chr11:66067277~66069619:-
BRCA	cis	rs12704294	0.711	rs7807203	ENSG00000233073.1	AC005009.2	3.26	0.00117	0.049	0.12	0.1	Peripheral arterial disease (traffic-related air pollution interaction);	chr7:86903260	chr7:86784226~86786670:-
BRCA	cis	rs10782582	0.532	rs12132503	ENSG00000181227.3	RP4-682C21.2	3.26	0.00117	0.049	0.11	0.1	Daytime sleep phenotypes;	chr1:75672077	chr1:75743423~75744776:-
BRCA	cis	rs2976388	0.609	rs2572907	ENSG00000253196.1	RP11-706C16.7	3.26	0.00117	0.049	0.1	0.1	Urinary tract infection frequency;	chr8:142720520	chr8:142763116~142766427:+
BRCA	cis	rs2976388	0.609	rs2572908	ENSG00000253196.1	RP11-706C16.7	3.26	0.00117	0.049	0.1	0.1	Urinary tract infection frequency;	chr8:142721218	chr8:142763116~142766427:+
BRCA	cis	rs6490294	0.571	rs73421065	ENSG00000234608.6	MAPKAPK5-AS1	3.26	0.00117	0.049	0.15	0.1	Mean platelet volume;	chr12:112121575	chr12:111839764~111842902:-
BRCA	cis	rs6490294	0.528	rs58047810	ENSG00000234608.6	MAPKAPK5-AS1	3.26	0.00117	0.049	0.15	0.1	Mean platelet volume;	chr12:112124682	chr12:111839764~111842902:-
BRCA	cis	rs6714710	0.603	rs11692010	ENSG00000228486.8	LINC01125	-3.26	0.00117	0.049	-0.09	-0.1	Posterior cortical atrophy and Alzheimer's disease;	chr2:97780838	chr2:97664217~97703064:+
BRCA	cis	rs875971	0.543	rs801191	ENSG00000229886.1	RP5-1132H15.3	-3.26	0.00117	0.049	-0.11	-0.1	Aortic root size;	chr7:66567968	chr7:66025126~66031544:-
BRCA	cis	rs3770752	0.741	rs2268990	ENSG00000272054.1	RP11-423P10.2	-3.26	0.00117	0.049	-0.09	-0.1	Schizophrenia;	chr2:37220801	chr2:37208875~37212677:+
BRCA	cis	rs853679	0.55	rs1233699	ENSG00000226314.6	ZNF192P1	-3.26	0.00117	0.049	-0.14	-0.1	Depression;	chr6:28201380	chr6:28161781~28169594:+
BRCA	cis	rs2638953	0.962	rs10843159	ENSG00000273989.1	RP11-425D17.2	-3.26	0.00117	0.049	-0.15	-0.1	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28354597	chr12:28236227~28236828:+
BRCA	cis	rs4834770	0.668	rs11737086	ENSG00000248280.1	RP11-33B1.2	-3.26	0.00117	0.049	-0.1	-0.1	Blood protein levels;	chr4:119205962	chr4:119440561~119450157:-
BRCA	cis	rs7048146	0.531	rs34302146	ENSG00000213539.4	YBX1P6	3.26	0.00117	0.049	0.13	0.1	Vascular brain injury;	chr9:109521469	chr9:109532830~109534332:-
BRCA	cis	rs11955398	0.563	rs1816864	ENSG00000251279.1	CTC-436P18.1	3.26	0.00117	0.049	0.12	0.1	Intelligence (multi-trait analysis);	chr5:60715446	chr5:61162070~61232040:+
BRCA	cis	rs11955398	0.585	rs1816861	ENSG00000251279.1	CTC-436P18.1	3.26	0.00117	0.049	0.12	0.1	Intelligence (multi-trait analysis);	chr5:60715849	chr5:61162070~61232040:+
BRCA	cis	rs2518049	1	rs7091485	ENSG00000224034.1	RP11-445P17.8	3.26	0.00117	0.049	0.18	0.1	Metabolic traits;	chr10:5103257	chr10:5266033~5271236:-
BRCA	cis	rs875971	0.862	rs6955837	ENSG00000106610.13	STAG3L4	3.26	0.00117	0.0491	0.14	0.1	Aortic root size;	chr7:66578155	chr7:67302621~67321526:+
BRCA	cis	rs4934494	0.911	rs6586213	ENSG00000232229.4	LINC00865	-3.26	0.00117	0.0491	-0.15	-0.1	Red blood cell count;	chr10:89656327	chr10:89829510~89840861:+
BRCA	cis	rs4512344	0.509	rs2409784	ENSG00000254866.2	DEFB109P3	3.26	0.00117	0.0491	0.13	0.1	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:11539347	chr8:12150895~12151134:-
BRCA	cis	rs4578769	0.765	rs11662489	ENSG00000273232.1	RP11-370A5.2	-3.26	0.00117	0.0491	-0.14	-0.1	Eosinophil percentage of white cells;	chr18:22816959	chr18:22882825~22883357:-
BRCA	cis	rs1148737	0.806	rs2742158	ENSG00000243064.7	ABCC13	-3.26	0.00117	0.0491	-0.11	-0.1	Colonoscopy-negative controls vs population controls;	chr21:13266595	chr21:14236206~14362754:+
BRCA	cis	rs1348850	0.914	rs10497503	ENSG00000280374.1	RP11-337N6.3	3.26	0.00117	0.0491	0.14	0.1	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177507011	chr2:177317715~177318471:-
BRCA	cis	rs2153535	0.585	rs6934905	ENSG00000251164.1	HULC	-3.26	0.00117	0.0491	-0.12	-0.1	Motion sickness;	chr6:8661326	chr6:8652137~8653846:+
BRCA	cis	rs72772090	0.71	rs11739280	ENSG00000272109.1	CTD-2260A17.3	-3.26	0.00117	0.0491	-0.18	-0.1	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96738443	chr5:96804353~96806105:+
BRCA	cis	rs687432	0.885	rs7949741	ENSG00000213592.4	AP000662.9	-3.26	0.00117	0.0491	-0.14	-0.1	Parkinson's disease;	chr11:57992295	chr11:57718044~57718530:-
BRCA	cis	rs687432	0.924	rs12802044	ENSG00000213592.4	AP000662.9	-3.26	0.00117	0.0491	-0.14	-0.1	Parkinson's disease;	chr11:57993211	chr11:57718044~57718530:-
BRCA	cis	rs2839186	0.526	rs2839297	ENSG00000228137.1	AP001469.7	3.26	0.00117	0.0491	0.1	0.1	Testicular germ cell tumor;	chr21:46501926	chr21:46246890~46247682:+
BRCA	cis	rs17221829	0.836	rs3931233	ENSG00000280385.1	AP000648.5	-3.26	0.00117	0.0491	-0.11	-0.1	Anxiety in major depressive disorder;	chr11:89718420	chr11:90193614~90198120:+
BRCA	cis	rs2243480	1	rs313814	ENSG00000226002.1	RP11-460N20.5	-3.26	0.00117	0.0491	-0.17	-0.1	Diabetic kidney disease;	chr7:66038306	chr7:65084103~65100232:+
BRCA	cis	rs6102185	0.572	rs6016464	ENSG00000229771.2	RP4-644L1.2	-3.26	0.00117	0.0491	-0.13	-0.1	IgG glycosylation;	chr20:40892147	chr20:40696499~40698616:-
BRCA	cis	rs886144	0.814	rs57102165	ENSG00000259212.1	CTD-3065B20.2	-3.26	0.00117	0.0491	-0.12	-0.1	Metabolite levels;	chr15:91169190	chr15:90595840~90596447:-
BRCA	cis	rs4665809	1	rs12475854	ENSG00000231655.1	AC011742.3	3.26	0.00117	0.0491	0.14	0.1	Gut microbiome composition (summer);	chr2:26044506	chr2:26140263~26141264:-
BRCA	cis	rs345013	0.92	rs9873432	ENSG00000240032.1	RP11-274H2.3	-3.26	0.00117	0.0491	-0.17	-0.1	Prostate cancer;	chr3:145276158	chr3:146066344~146069185:-
BRCA	cis	rs345013	0.92	rs9856022	ENSG00000240032.1	RP11-274H2.3	-3.26	0.00117	0.0491	-0.17	-0.1	Prostate cancer;	chr3:145276189	chr3:146066344~146069185:-
BRCA	cis	rs7695732	1	rs62308746	ENSG00000270720.1	RP11-84C13.2	3.26	0.00117	0.0491	0.12	0.1	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr4:88884818	chr4:89119284~89119871:+
BRCA	cis	rs2124910	0.815	rs3976745	ENSG00000255441.1	CTD-2616J11.2	-3.26	0.00117	0.0491	-0.12	-0.1	Blood protein levels;	chr19:51529710	chr19:51415724~51417425:+
BRCA	cis	rs12760731	0.582	rs6700741	ENSG00000213057.5	C1orf220	3.26	0.00117	0.0491	0.12	0.1	Obesity-related traits;	chr1:178597251	chr1:178542752~178548889:+
BRCA	cis	rs395892	1	rs418664	ENSG00000226025.8	LGALS17A	-3.26	0.00117	0.0491	-0.11	-0.1	Eosinophil counts;Eosinophil percentage of white cells;	chr19:39729248	chr19:39679374~39686373:+
BRCA	cis	rs863345	0.584	rs1342949	ENSG00000176320.2	RP11-404O13.5	-3.26	0.00117	0.0491	-0.1	-0.1	Pneumococcal bacteremia;	chr1:158493505	chr1:158197922~158203877:-
BRCA	cis	rs7520050	0.966	rs6695809	ENSG00000226957.1	RP4-533D7.4	3.26	0.00117	0.0491	0.11	0.1	Reticulocyte count;Red blood cell count;	chr1:45819789	chr1:46046818~46048368:+
BRCA	cis	rs4449834	1	rs11986059	ENSG00000254432.1	RP11-33I11.2	-3.26	0.00117	0.0491	-0.13	-0.1	Sum eosinophil basophil counts;	chr8:60837443	chr8:60808735~60809606:-
BRCA	cis	rs4449834	1	rs7844902	ENSG00000254432.1	RP11-33I11.2	-3.26	0.00117	0.0491	-0.13	-0.1	Sum eosinophil basophil counts;	chr8:60838301	chr8:60808735~60809606:-
BRCA	cis	rs4449834	1	rs4387010	ENSG00000254432.1	RP11-33I11.2	-3.26	0.00117	0.0491	-0.13	-0.1	Sum eosinophil basophil counts;	chr8:60839321	chr8:60808735~60809606:-
BRCA	cis	rs10771431	0.935	rs1988852	ENSG00000256673.1	RP11-599J14.2	3.26	0.00117	0.0491	0.11	0.1	Breast size;	chr12:9220266	chr12:9398355~9414851:-
BRCA	cis	rs6545883	0.525	rs1729658	ENSG00000273302.1	RP11-493E12.2	3.26	0.00117	0.0491	0.09	0.1	Tuberculosis;	chr2:61146385	chr2:61199979~61200769:+
BRCA	cis	rs202072	0.872	rs377704	ENSG00000215022.6	RP1-257A7.4	-3.26	0.00117	0.0491	-0.13	-0.1	HIV-1 viral setpoint;	chr6:13279787	chr6:13264861~13295586:-
BRCA	cis	rs3760982	0.585	rs4803659	ENSG00000266921.1	RP11-15A1.7	-3.26	0.00117	0.0491	-0.13	-0.1	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43786083	chr19:43996896~44002836:-
BRCA	cis	rs2899832	0.5	rs17537213	ENSG00000258704.4	SRP54-AS1	3.26	0.00117	0.0491	0.24	0.1	Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:35295832	chr14:34920858~34982532:-
BRCA	cis	rs2899832	0.5	rs17537248	ENSG00000258704.4	SRP54-AS1	3.26	0.00117	0.0491	0.24	0.1	Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:35296707	chr14:34920858~34982532:-
BRCA	cis	rs2899832	0.5	rs17458715	ENSG00000258704.4	SRP54-AS1	3.26	0.00117	0.0491	0.24	0.1	Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:35297052	chr14:34920858~34982532:-
BRCA	cis	rs2899832	0.5	rs111587294	ENSG00000258704.4	SRP54-AS1	3.26	0.00117	0.0491	0.24	0.1	Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:35299300	chr14:34920858~34982532:-
BRCA	cis	rs2899832	0.5	rs78512404	ENSG00000258704.4	SRP54-AS1	3.26	0.00117	0.0491	0.24	0.1	Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:35303399	chr14:34920858~34982532:-
BRCA	cis	rs2899832	0.5	rs117098068	ENSG00000258704.4	SRP54-AS1	3.26	0.00117	0.0491	0.24	0.1	Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:35304496	chr14:34920858~34982532:-
BRCA	cis	rs2899832	0.5	rs79049475	ENSG00000258704.4	SRP54-AS1	3.26	0.00117	0.0491	0.24	0.1	Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:35306382	chr14:34920858~34982532:-
BRCA	cis	rs2899832	0.568	rs7156874	ENSG00000258704.4	SRP54-AS1	3.26	0.00117	0.0491	0.24	0.1	Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:35309263	chr14:34920858~34982532:-
BRCA	cis	rs2832191	0.791	rs2832179	ENSG00000232855.5	AF131217.1	3.26	0.00117	0.0491	0.12	0.1	Dental caries;	chr21:29108045	chr21:28439346~28674848:-
BRCA	cis	rs2832191	0.791	rs4817270	ENSG00000232855.5	AF131217.1	3.26	0.00117	0.0491	0.12	0.1	Dental caries;	chr21:29108047	chr21:28439346~28674848:-
BRCA	cis	rs658191	0.661	rs10888807	ENSG00000237624.1	OXCT2P1	-3.26	0.00117	0.0491	-0.24	-0.1	Colorectal cancer;	chr1:39505033	chr1:39514956~39516490:+
BRCA	cis	rs873549	1	rs873548	ENSG00000238042.4	RP11-815M8.1	3.26	0.00117	0.0491	0.12	0.1	Keloid;	chr1:222098598	chr1:221880981~221978523:-
BRCA	cis	rs7226835	1	rs10853465	ENSG00000267374.1	RP11-244M2.1	3.26	0.00117	0.0491	0.24	0.1	Obesity-related traits;	chr18:39561237	chr18:39206924~39800318:-
BRCA	cis	rs4713118	0.955	rs9393848	ENSG00000219392.1	RP1-265C24.5	-3.26	0.00117	0.0491	-0.14	-0.1	Parkinson's disease;	chr6:27720590	chr6:28115628~28116551:+
BRCA	cis	rs875971	0.929	rs34406470	ENSG00000067601.7	PMS2P4	-3.26	0.00117	0.0491	-0.12	-0.1	Aortic root size;	chr7:66464969	chr7:67295608~67302907:-
BRCA	cis	rs10791097	0.694	rs4436551	ENSG00000255155.1	RP11-535N6.2	-3.26	0.00117	0.0491	-0.1	-0.1	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:130885844	chr11:130544643~130544856:-
BRCA	cis	rs2835872	0.793	rs80000115	ENSG00000230366.8	DSCR9	-3.26	0.00117	0.0491	-0.14	-0.1	Electroencephalographic traits in alcoholism;	chr21:37613534	chr21:37208503~37221736:+
BRCA	cis	rs10819861	0.62	rs10819834	ENSG00000175611.10	LINC00476	3.26	0.00117	0.0491	0.11	0.1	Electrocardiographic traits;	chr9:96095191	chr9:95759231~95875977:-
BRCA	cis	rs6121246	0.512	rs45443696	ENSG00000230613.1	HM13-AS1	3.26	0.00117	0.0491	0.14	0.1	Mean corpuscular hemoglobin;	chr20:31723593	chr20:31567707~31573263:-
BRCA	cis	rs6822297	0.841	rs9998368	ENSG00000240005.4	RP11-293A21.1	-3.26	0.00117	0.0491	-0.12	-0.1	Obesity-related traits;	chr4:26887432	chr4:26859806~26860599:-
BRCA	cis	rs2704588	1	rs2609281	ENSG00000270720.1	RP11-84C13.2	-3.26	0.00117	0.0491	-0.14	-0.1	Longevity;	chr4:88930924	chr4:89119284~89119871:+
BRCA	cis	rs10129255	0.536	rs10142951	ENSG00000211976.2	IGHV3-73	-3.26	0.00117	0.0491	-0.08	-0.1	Kawasaki disease;	chr14:106782337	chr14:106802694~106803233:-
BRCA	cis	rs77633900	0.614	rs280013	ENSG00000196274.5	Metazoa_SRP	-3.26	0.00117	0.0491	-0.15	-0.1	Glioma;Non-glioblastoma glioma;	chr15:76685798	chr15:76230048~76230390:-
BRCA	cis	rs2243480	0.901	rs73148097	ENSG00000237026.1	RP11-328P23.2	3.26	0.00117	0.0491	0.19	0.1	Diabetic kidney disease;	chr7:65966800	chr7:65235790~65236723:-
BRCA	cis	rs2243480	1	rs906134	ENSG00000237026.1	RP11-328P23.2	3.26	0.00117	0.0491	0.19	0.1	Diabetic kidney disease;	chr7:65979301	chr7:65235790~65236723:-
BRCA	cis	rs886774	0.803	rs7790757	ENSG00000273055.1	CTB-13F3.1	-3.26	0.00117	0.0491	-0.1	-0.1	Ulcerative colitis;	chr7:107898058	chr7:107942116~107942740:+
BRCA	cis	rs8127691	0.904	rs2070552	ENSG00000232124.1	AP001057.1	-3.26	0.00117	0.0491	-0.13	-0.1	Inflammatory bowel disease;	chr21:44197186	chr21:44201290~44202696:+
BRCA	cis	rs16958440	0.581	rs11082564	ENSG00000280212.1	RP11-49K24.3	3.26	0.00117	0.0491	0.18	0.1	Sitting height ratio;	chr18:47132778	chr18:47076117~47076594:+
BRCA	cis	rs16958440	0.708	rs62096477	ENSG00000280212.1	RP11-49K24.3	3.26	0.00117	0.0491	0.18	0.1	Sitting height ratio;	chr18:47135939	chr18:47076117~47076594:+
BRCA	cis	rs3764021	0.509	rs10844569	ENSG00000256594.6	RP11-705C15.2	3.26	0.00117	0.0491	0.14	0.1	Type 1 diabetes;	chr12:9717756	chr12:9633419~9658412:+
BRCA	cis	rs4950322	0.57	rs3737855	ENSG00000227242.3	NBPF13P	-3.26	0.00117	0.0491	-0.14	-0.1	Protein quantitative trait loci;	chr1:147271257	chr1:147021320~147124525:-
BRCA	cis	rs2832191	0.729	rs2832201	ENSG00000236056.1	GAPDHP14	3.26	0.00117	0.0491	0.11	0.1	Dental caries;	chr21:29127520	chr21:29222321~29223257:+
BRCA	cis	rs4965593	0.526	rs10902566	ENSG00000270127.2	RP11-526I2.5	-3.26	0.00117	0.0491	-0.13	-0.1	Height;	chr15:100264277	chr15:100547765~100550153:-
BRCA	cis	rs867371	0.929	rs1501371	ENSG00000280753.1	AC044907.1	-3.26	0.00117	0.0491	-0.09	-0.1	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82168099	chr15:82847870~82847998:-
BRCA	cis	rs860295	0.557	rs12035524	ENSG00000203761.5	MSTO2P	-3.26	0.00117	0.0491	-0.09	-0.1	Body mass index;	chr1:155697311	chr1:155745829~155750137:+
BRCA	cis	rs4714291	1	rs9369156	ENSG00000180211.5	RP1-278E11.3	3.26	0.00117	0.0491	0.11	0.1	Strep throat;	chr6:40025986	chr6:39958414~39958833:-
BRCA	cis	rs718433	0.616	rs7142911	ENSG00000211778.2	TRAV4	-3.26	0.00117	0.0491	-0.07	-0.1	Intraocular pressure;	chr14:21745252	chr14:21736152~21736982:+
BRCA	cis	rs66887589	0.967	rs1155577	ENSG00000260404.2	RP11-384K6.6	-3.26	0.00117	0.0491	-0.09	-0.1	Diastolic blood pressure;	chr4:119528655	chr4:118591773~118633729:+
BRCA	cis	rs6088580	0.634	rs6059896	ENSG00000269202.1	RP4-614O4.12	-3.26	0.00117	0.0491	-0.1	-0.1	Glomerular filtration rate (creatinine);	chr20:34523978	chr20:35201747~35203288:-
BRCA	cis	rs36051895	0.659	rs62543863	ENSG00000236254.1	MTND4P14	-3.26	0.00117	0.0491	-0.12	-0.1	Pediatric autoimmune diseases;	chr9:5085417	chr9:5107937~5109290:+
BRCA	cis	rs2066819	0.786	rs116934693	ENSG00000257740.1	RP11-977G19.12	3.26	0.00117	0.0491	0.25	0.1	Psoriasis vulgaris;	chr12:56302761	chr12:56308868~56309449:+
BRCA	cis	rs11098403	0.753	rs4834640	ENSG00000225892.3	RP11-384K6.2	3.26	0.00117	0.0491	0.1	0.1	Schizophrenia;	chr4:117852204	chr4:118632274~118634759:+
BRCA	cis	rs5167	0.677	rs12709889	ENSG00000214855.8	APOC1P1	-3.26	0.00117	0.0491	-0.13	-0.1	Blood protein levels;	chr19:44949982	chr19:44926804~44931386:+
BRCA	cis	rs8012947	0.565	rs12891852	ENSG00000257621.6	PSMA3-AS1	-3.26	0.00117	0.0491	-0.09	-0.1	Alcohol consumption in current drinkers;	chr14:58330922	chr14:58265365~58298134:-
BRCA	cis	rs2880765	0.835	rs4340287	ENSG00000259630.2	CTD-2262B20.1	-3.26	0.00117	0.0491	-0.12	-0.1	Coronary artery disease;	chr15:85500506	chr15:85415228~85415633:+
BRCA	cis	rs3105593	1	rs3105591	ENSG00000242737.1	RP11-562A8.1	3.26	0.00117	0.0491	0.12	0.1	QT interval;	chr15:50576845	chr15:50466738~50467096:+
BRCA	cis	rs4767841	0.874	rs6490269	ENSG00000248636.5	RP11-768F21.1	-3.26	0.00117	0.0491	-0.13	-0.1	Urgency urinary incontinence;	chr12:119769371	chr12:119387987~119668079:-
BRCA	cis	rs830124	0.929	rs2596144	ENSG00000272849.1	RP11-347I19.8	-3.26	0.00117	0.0491	-0.11	-0.1	Urinary metabolites;	chr12:121859832	chr12:121797511~121801972:+
BRCA	cis	rs853679	0.699	rs9468318	ENSG00000219392.1	RP1-265C24.5	-3.26	0.00117	0.0491	-0.16	-0.1	Depression;	chr6:28241753	chr6:28115628~28116551:+
BRCA	cis	rs1710990	0.819	rs1892297	ENSG00000258957.1	RP11-363J20.1	-3.25	0.00117	0.0491	-0.12	-0.1	Intelligence (multi-trait analysis);	chr14:69121880	chr14:69183020~69214092:-
BRCA	cis	rs115344852	0.585	rs1016069	ENSG00000204709.4	LINC01556	3.25	0.00117	0.0492	0.14	0.1	Epithelial ovarian cancer;	chr6:28472641	chr6:28943877~28944537:+
BRCA	cis	rs7637230	1	rs78913826	ENSG00000244119.1	PDCL3P4	-3.25	0.00117	0.0492	-0.1	-0.1	Psoriasis vulgaris;Psoriasis;	chr3:101913794	chr3:101712472~101713191:+
BRCA	cis	rs7229439	0.737	rs10853532	ENSG00000279319.1	RP11-693M3.1	-3.25	0.00117	0.0492	-0.11	-0.1	Antipsychotic drug-induced QTc interval change in schizophrenia;	chr18:45351467	chr18:44986109~44989203:+
BRCA	cis	rs1376877	0.901	rs2351774	ENSG00000273456.1	RP11-686O6.2	3.25	0.00117	0.0492	0.1	0.1	Subclinical atherosclerosis traits (other);	chr2:203234499	chr2:202374932~202375604:-
BRCA	cis	rs4699052	0.662	rs1400363	ENSG00000230069.3	LRRC37A15P	-3.25	0.00117	0.0492	-0.09	-0.1	Testicular germ cell tumor;	chr4:103329565	chr4:102727274~102730721:-
BRCA	cis	rs6030	0.871	rs6662593	ENSG00000224286.4	LINC01142	-3.25	0.00117	0.0492	-0.12	-0.1	Uric acid levels;	chr1:169543356	chr1:170271603~170284208:-
BRCA	cis	rs11035577	0.632	rs7108109	ENSG00000279675.1	RP11-454H19.2	-3.25	0.00117	0.0492	-0.15	-0.1	Temperament (bipolar disorder);	chr11:39765737	chr11:40107244~40112599:-
BRCA	cis	rs11035577	0.57	rs4756528	ENSG00000279675.1	RP11-454H19.2	-3.25	0.00117	0.0492	-0.15	-0.1	Temperament (bipolar disorder);	chr11:39765882	chr11:40107244~40112599:-
BRCA	cis	rs11035577	0.632	rs4755523	ENSG00000279675.1	RP11-454H19.2	-3.25	0.00117	0.0492	-0.15	-0.1	Temperament (bipolar disorder);	chr11:39766182	chr11:40107244~40112599:-
BRCA	cis	rs6001482	0.679	rs5995706	ENSG00000253818.1	IGLV1-41	-3.25	0.00117	0.0492	-0.09	-0.1	Diastolic blood pressure;	chr22:22236371	chr22:22404207~22404721:+
BRCA	cis	rs80226907	1	rs77021467	ENSG00000258413.1	RP11-665C16.6	-3.25	0.00117	0.0492	-0.26	-0.1	Mean platelet volume;	chr14:55320941	chr14:55262767~55272075:-
BRCA	cis	rs77688320	0.573	rs2080327	ENSG00000230799.1	AC007279.2	3.25	0.00117	0.0492	0.12	0.1	Breast cancer;	chr2:201461495	chr2:201762737~201763573:+
BRCA	cis	rs495337	1	rs1056198	ENSG00000224397.4	LINC01272	-3.25	0.00117	0.0492	-0.1	-0.1	Psoriasis;	chr20:49939692	chr20:50267486~50279795:+
BRCA	cis	rs757081	0.671	rs214090	ENSG00000184669.7	OR7E14P	-3.25	0.00117	0.0492	-0.16	-0.1	Systolic blood pressure;	chr11:17275614	chr11:17013998~17053024:+
BRCA	cis	rs6496932	0.755	rs56909106	ENSG00000259630.2	CTD-2262B20.1	3.25	0.00117	0.0492	0.13	0.1	Central corneal thickness;Corneal structure;	chr15:85320817	chr15:85415228~85415633:+
BRCA	cis	rs3820928	0.874	rs2177594	ENSG00000261379.1	RP11-395N3.1	3.25	0.00117	0.0492	0.1	0.1	Pulmonary function;	chr2:226971523	chr2:226804036~226805061:+
BRCA	cis	rs4427176	0.825	rs62491551	ENSG00000233609.3	RP11-62H7.2	3.25	0.00117	0.0492	0.13	0.1	Mosquito bite size;	chr8:9707366	chr8:8961200~8979025:+
BRCA	cis	rs875971	0.545	rs67397473	ENSG00000226767.1	RP11-328P23.3	3.25	0.00117	0.0492	0.12	0.1	Aortic root size;	chr7:66168318	chr7:65508773~65508944:-
BRCA	cis	rs924712	0.844	rs7752349	ENSG00000261116.1	RP3-523K23.2	3.25	0.00117	0.0492	0.12	0.1	Breast cancer;	chr6:54862933	chr6:54943167~54945099:+
BRCA	cis	rs2744375	0.544	rs2744365	ENSG00000261189.1	RP3-512B11.3	3.25	0.00117	0.0492	0.13	0.1	Resting heart rate;	chr6:7551787	chr6:7540451~7541338:-
BRCA	cis	rs970548	0.865	rs12246131	ENSG00000230869.1	CTGLF10P	3.25	0.00117	0.0492	0.13	0.1	Total cholesterol levels;HDL cholesterol;HDL cholesterol levels;Cholesterol, total;	chr10:45498334	chr10:45678692~45700532:+
BRCA	cis	rs970548	0.908	rs11239538	ENSG00000230869.1	CTGLF10P	3.25	0.00117	0.0492	0.13	0.1	Total cholesterol levels;HDL cholesterol;HDL cholesterol levels;Cholesterol, total;	chr10:45499148	chr10:45678692~45700532:+
BRCA	cis	rs970548	0.954	rs7076198	ENSG00000230869.1	CTGLF10P	3.25	0.00117	0.0492	0.13	0.1	Total cholesterol levels;HDL cholesterol;HDL cholesterol levels;Cholesterol, total;	chr10:45500861	chr10:45678692~45700532:+
BRCA	cis	rs986417	1	rs1955699	ENSG00000258670.1	RP11-1042B17.3	-3.25	0.00117	0.0492	-0.18	-0.1	Gut microbiota (bacterial taxa);	chr14:60579271	chr14:60515119~60554916:+
BRCA	cis	rs4848143	0.64	rs11693648	ENSG00000236859.5	NIFK-AS1	-3.25	0.00117	0.0492	-0.11	-0.1	Capecitabine sensitivity;	chr2:121039743	chr2:121649650~121728208:+
BRCA	cis	rs2836974	0.666	rs1888487	ENSG00000238141.2	BRWD1-AS1	-3.25	0.00117	0.0492	-0.12	-0.1	Cognitive function;	chr21:39311333	chr21:39315707~39323218:+
BRCA	cis	rs17192198	0.661	rs73198545	ENSG00000258302.2	RP11-981P6.1	-3.25	0.00117	0.0492	-0.12	-0.1	Diastolic blood pressure;	chr12:89656878	chr12:89561129~89594878:+
BRCA	cis	rs10129255	0.509	rs756583	ENSG00000211964.3	IGHV3-48	-3.25	0.00117	0.0492	-0.07	-0.1	Kawasaki disease;	chr14:106680002	chr14:106537810~106538344:-
BRCA	cis	rs34467563	0.967	rs17709854	ENSG00000253105.4	KB-1448A5.1	3.25	0.00117	0.0492	0.13	0.1	Lobe attachment (rater-scored or self-reported);	chr8:96387344	chr8:96371865~96387438:-
BRCA	cis	rs2436153	0.706	rs3793946	ENSG00000254551.1	RP11-727A23.7	3.25	0.00117	0.0492	0.12	0.1	Facial morphology (factor 16);	chr11:83536744	chr11:83209431~83213379:-
BRCA	cis	rs3816183	0.626	rs11690432	ENSG00000226491.1	FTOP1	-3.25	0.00117	0.0492	-0.13	-0.1	Hypospadias;	chr2:42683843	chr2:42797225~42798712:-
BRCA	cis	rs8141529	0.748	rs9620841	ENSG00000226471.5	CTA-292E10.6	-3.25	0.00117	0.0492	-0.12	-0.1	Lymphocyte counts;	chr22:28894993	chr22:28800683~28848559:+
BRCA	cis	rs1005277	0.579	rs2474587	ENSG00000276805.1	RP11-291L22.6	3.25	0.00117	0.0492	0.11	0.1	Extrinsic epigenetic age acceleration;	chr10:38131738	chr10:38451030~38451785:+
BRCA	cis	rs1005277	0.579	rs2474588	ENSG00000276805.1	RP11-291L22.6	3.25	0.00117	0.0492	0.11	0.1	Extrinsic epigenetic age acceleration;	chr10:38131942	chr10:38451030~38451785:+
BRCA	cis	rs397969	0.646	rs17604987	ENSG00000261033.1	RP11-209D14.2	3.25	0.00117	0.0492	0.14	0.1	Platelet count;	chr17:19964018	chr17:20008051~20009234:-
BRCA	cis	rs2638953	0.886	rs11049594	ENSG00000273989.1	RP11-425D17.2	3.25	0.00117	0.0492	0.15	0.1	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28430368	chr12:28236227~28236828:+
BRCA	cis	rs4950322	0.57	rs4301678	ENSG00000227242.3	NBPF13P	-3.25	0.00117	0.0492	-0.14	-0.1	Protein quantitative trait loci;	chr1:147261907	chr1:147021320~147124525:-
BRCA	cis	rs10777332	0.649	rs10859214	ENSG00000277851.1	RP11-756G20.1	3.25	0.00117	0.0492	0.14	0.1	Biochemical measures;	chr12:91825268	chr12:92247756~92363832:-
BRCA	cis	rs2243480	1	rs11538349	ENSG00000234585.5	CCT6P3	-3.25	0.00117	0.0492	-0.15	-0.1	Diabetic kidney disease;	chr7:65956884	chr7:65038354~65074713:+
BRCA	cis	rs3816183	0.585	rs12996750	ENSG00000226491.1	FTOP1	-3.25	0.00117	0.0492	-0.12	-0.1	Hypospadias;	chr2:42653631	chr2:42797225~42798712:-
BRCA	cis	rs7403037	0.617	rs13329120	ENSG00000207279.1	SNORD116-24	-3.25	0.00117	0.0492	-0.13	-0.1	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24597526	chr15:25094037~25094128:+
BRCA	cis	rs2899832	0.5	rs6571711	ENSG00000258704.4	SRP54-AS1	3.25	0.00117	0.0492	0.24	0.1	Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:35311275	chr14:34920858~34982532:-
BRCA	cis	rs2899832	0.5	rs17597246	ENSG00000258704.4	SRP54-AS1	3.25	0.00117	0.0492	0.24	0.1	Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:35312675	chr14:34920858~34982532:-
BRCA	cis	rs2899832	0.5	rs80315070	ENSG00000258704.4	SRP54-AS1	3.25	0.00117	0.0492	0.24	0.1	Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:35312732	chr14:34920858~34982532:-
BRCA	cis	rs911555	0.723	rs6575986	ENSG00000269958.1	RP11-73M18.8	3.25	0.00117	0.0492	0.11	0.1	Intelligence (multi-trait analysis);	chr14:103420334	chr14:103696353~103697163:+
BRCA	cis	rs6672530	0.518	rs6683151	ENSG00000227711.2	RP11-275O4.5	-3.25	0.00117	0.0492	-0.12	-0.1	Hip circumference adjusted for BMI;	chr1:227623813	chr1:227509028~227520477:-
BRCA	cis	rs73222236	0.825	rs9826146	ENSG00000239213.4	NCK1-AS1	3.25	0.00117	0.0492	0.11	0.1	Coronary artery disease;	chr3:136264247	chr3:136841726~136862054:-
BRCA	cis	rs258892	0.895	rs3846645	ENSG00000272525.1	RP11-79P5.9	-3.25	0.00117	0.0492	-0.13	-0.1	Small cell lung carcinoma;	chr5:72727333	chr5:73497550~73498293:-
BRCA	cis	rs258892	0.895	rs7722344	ENSG00000272525.1	RP11-79P5.9	-3.25	0.00117	0.0492	-0.13	-0.1	Small cell lung carcinoma;	chr5:72727781	chr5:73497550~73498293:-
BRCA	cis	rs258892	0.895	rs6452660	ENSG00000272525.1	RP11-79P5.9	-3.25	0.00117	0.0492	-0.13	-0.1	Small cell lung carcinoma;	chr5:72728162	chr5:73497550~73498293:-
BRCA	cis	rs258892	0.895	rs13187277	ENSG00000272525.1	RP11-79P5.9	-3.25	0.00117	0.0492	-0.13	-0.1	Small cell lung carcinoma;	chr5:72734159	chr5:73497550~73498293:-
BRCA	cis	rs258892	0.895	rs34811011	ENSG00000272525.1	RP11-79P5.9	-3.25	0.00117	0.0492	-0.13	-0.1	Small cell lung carcinoma;	chr5:72734416	chr5:73497550~73498293:-
BRCA	cis	rs258892	0.843	rs4260644	ENSG00000272525.1	RP11-79P5.9	-3.25	0.00117	0.0492	-0.13	-0.1	Small cell lung carcinoma;	chr5:72735548	chr5:73497550~73498293:-
BRCA	cis	rs258892	0.895	rs13156244	ENSG00000272525.1	RP11-79P5.9	-3.25	0.00117	0.0492	-0.13	-0.1	Small cell lung carcinoma;	chr5:72736339	chr5:73497550~73498293:-
BRCA	cis	rs4908768	0.657	rs12144099	ENSG00000270282.1	RP5-1115A15.2	-3.25	0.00117	0.0492	-0.13	-0.1	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8756116	chr1:8512653~8513021:+
BRCA	cis	rs4128725	0.925	rs4656237	ENSG00000224261.2	RP11-179G5.1	-3.25	0.00117	0.0492	-0.17	-0.1	Select biomarker traits;	chr1:159444034	chr1:160266340~160267225:-
BRCA	cis	rs4128725	0.925	rs4656826	ENSG00000224261.2	RP11-179G5.1	-3.25	0.00117	0.0492	-0.17	-0.1	Select biomarker traits;	chr1:159444136	chr1:160266340~160267225:-
BRCA	cis	rs4128725	0.925	rs75431404	ENSG00000224261.2	RP11-179G5.1	-3.25	0.00117	0.0492	-0.17	-0.1	Select biomarker traits;	chr1:159444895	chr1:160266340~160267225:-
BRCA	cis	rs4660214	0.614	rs6688708	ENSG00000182109.6	RP11-69E11.4	-3.25	0.00117	0.0492	-0.12	-0.1	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39293321	chr1:39522280~39546187:-
BRCA	cis	rs561341	0.882	rs2521594	ENSG00000277511.1	CTD-2095E4.5	3.25	0.00117	0.0492	0.15	0.1	Hip circumference adjusted for BMI;	chr17:31975068	chr17:32127595~32128454:+
BRCA	cis	rs7577696	0.889	rs212730	ENSG00000276334.1	AL133243.1	3.25	0.00117	0.0493	0.13	0.1	Inflammatory biomarkers;	chr2:32246604	chr2:32521927~32523547:+
BRCA	cis	rs7474896	0.836	rs633029	ENSG00000120555.12	SEPT7P9	-3.25	0.00117	0.0493	-0.18	-0.1	Obesity (extreme);	chr10:38029325	chr10:38383069~38402916:-
BRCA	cis	rs930395	0.514	rs4323241	ENSG00000248779.1	RP11-53O19.2	-3.25	0.00117	0.0493	-0.1	-0.1	Breast cancer;	chr5:44929054	chr5:44752949~44765744:+
BRCA	cis	rs711830	1	rs1051929	ENSG00000272729.1	RP11-387A1.5	-3.25	0.00117	0.0493	-0.13	-0.1	Serous invasive ovarian cancer;Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;High-grade serous ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;	chr2:176172026	chr2:176164164~176165716:-
BRCA	cis	rs7636839	0.504	rs2378507	ENSG00000236182.1	RP11-297K7.1	-3.25	0.00117	0.0493	-0.12	-0.1	EGFR mutation-positive lung adenocarcinoma;	chr3:189665749	chr3:188989382~188990135:-
BRCA	cis	rs78487399	0.665	rs17030980	ENSG00000234936.1	AC010883.5	3.25	0.00117	0.0493	0.15	0.1	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43524341	chr2:43229573~43233394:+
BRCA	cis	rs13421350	0.579	rs16860426	ENSG00000225205.4	AC093818.1	-3.25	0.00117	0.0493	-0.19	-0.1	Diabetic kidney disease;	chr2:172454384	chr2:172480840~172556596:-
BRCA	cis	rs67696533	0.6	rs3746614	ENSG00000275576.1	RP5-836N17.4	-3.25	0.00117	0.0493	-0.12	-0.1	White blood cell count (basophil);Basophil percentage of granulocytes;Basophil percentage of white cells;	chr20:32520674	chr20:32116171~32116629:+
BRCA	cis	rs2638953	0.853	rs17433981	ENSG00000273989.1	RP11-425D17.2	-3.25	0.00117	0.0493	-0.15	-0.1	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28393634	chr12:28236227~28236828:+
BRCA	cis	rs360932	0.588	rs360947	ENSG00000270265.1	RP11-731D1.4	3.25	0.00117	0.0493	0.12	0.1	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr4:151947375	chr4:151333775~151353224:-
BRCA	cis	rs7520050	0.966	rs785494	ENSG00000234329.1	RP11-767N6.2	-3.25	0.00117	0.0493	-0.09	-0.1	Reticulocyte count;Red blood cell count;	chr1:46120954	chr1:45651039~45651826:-
BRCA	cis	rs16944613	0.51	rs8026218	ENSG00000273691.1	RP11-617F23.2	3.25	0.00117	0.0493	0.13	0.1	Colorectal cancer;	chr15:90602033	chr15:90024955~90026003:+
BRCA	cis	rs10760158	0.832	rs4836848	ENSG00000235865.2	GSN-AS1	3.25	0.00117	0.0493	0.09	0.1	Pulse pressure;	chr9:121301074	chr9:121280768~121285530:-
BRCA	cis	rs6088580	0.634	rs6059875	ENSG00000269202.1	RP4-614O4.12	-3.25	0.00117	0.0493	-0.1	-0.1	Glomerular filtration rate (creatinine);	chr20:34498285	chr20:35201747~35203288:-
BRCA	cis	rs6088580	0.634	rs6088512	ENSG00000269202.1	RP4-614O4.12	-3.25	0.00117	0.0493	-0.1	-0.1	Glomerular filtration rate (creatinine);	chr20:34508086	chr20:35201747~35203288:-
BRCA	cis	rs6088580	0.634	rs6058070	ENSG00000269202.1	RP4-614O4.12	-3.25	0.00117	0.0493	-0.1	-0.1	Glomerular filtration rate (creatinine);	chr20:34515716	chr20:35201747~35203288:-
BRCA	cis	rs1678542	0.651	rs2888334	ENSG00000270039.1	RP11-571M6.17	3.25	0.00117	0.0493	0.14	0.1	Rheumatoid arthritis;	chr12:57582864	chr12:57803838~57804415:+
BRCA	cis	rs5760092	0.572	rs738806	ENSG00000228039.3	KB-1125A3.10	3.25	0.00117	0.0493	0.13	0.1	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23891985	chr22:23963780~23964374:+
BRCA	cis	rs1005277	0.522	rs1208684	ENSG00000099251.13	HSD17B7P2	3.25	0.00117	0.0493	0.11	0.1	Extrinsic epigenetic age acceleration;	chr10:37805008	chr10:38356380~38378505:+
BRCA	cis	rs2880765	0.835	rs2170736	ENSG00000259630.2	CTD-2262B20.1	-3.25	0.00117	0.0493	-0.12	-0.1	Coronary artery disease;	chr15:85500167	chr15:85415228~85415633:+
BRCA	cis	rs2991971	0.934	rs7903	ENSG00000281133.1	AL355480.3	3.25	0.00117	0.0493	0.12	0.1	High light scatter reticulocyte count;	chr1:45510800	chr1:45580892~45580996:-
BRCA	cis	rs8062405	0.723	rs35175818	ENSG00000261766.1	RP11-22P6.2	-3.25	0.00117	0.0493	-0.1	-0.1	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28597425	chr16:28862166~28863340:-
BRCA	cis	rs1979679	0.608	rs1355472	ENSG00000244712.1	RP11-874G11.1	-3.25	0.00117	0.0493	-0.16	-0.1	Ossification of the posterior longitudinal ligament of the spine;	chr12:28568481	chr12:28564678~28565141:-
BRCA	cis	rs853679	0.882	rs3757188	ENSG00000226314.6	ZNF192P1	-3.25	0.00117	0.0493	-0.21	-0.1	Depression;	chr6:28139579	chr6:28161781~28169594:+
BRCA	cis	rs11681930	0.908	rs6758662	ENSG00000207047.2	SNORD51	-3.25	0.00117	0.0493	-0.13	-0.1	Attention deficit hyperactivity disorder (combined symptoms);	chr2:205222623	chr2:206161878~206161957:+
BRCA	cis	rs4148883	0.689	rs2602861	ENSG00000272777.1	RP11-571L19.8	-3.25	0.00117	0.0493	-0.1	-0.1	Alcohol dependence;	chr4:99109745	chr4:99067256~99068125:-
BRCA	cis	rs197770	0.542	rs197721	ENSG00000272334.1	RP11-129K12.1	-3.25	0.00117	0.0493	-0.2	-0.1	Phospholipid levels (plasma);	chr3:37468545	chr3:36973117~36973672:-
BRCA	cis	rs10816359	0.947	rs10759163	ENSG00000234323.4	RP11-308N19.1	-3.25	0.00117	0.0493	-0.15	-0.1	Menarche (age at onset);	chr9:106000648	chr9:106278392~106604795:+
BRCA	cis	rs7927592	0.913	rs66752716	ENSG00000254610.1	RP5-903G2.2	-3.25	0.00118	0.0493	-0.14	-0.1	Total body bone mineral density;	chr11:68506158	chr11:67934563~67939774:-
BRCA	cis	rs7927592	0.913	rs11228262	ENSG00000254610.1	RP5-903G2.2	-3.25	0.00118	0.0493	-0.14	-0.1	Total body bone mineral density;	chr11:68507439	chr11:67934563~67939774:-
BRCA	cis	rs7927592	0.913	rs55883802	ENSG00000254610.1	RP5-903G2.2	-3.25	0.00118	0.0493	-0.14	-0.1	Total body bone mineral density;	chr11:68511361	chr11:67934563~67939774:-
BRCA	cis	rs324126	0.78	rs10445583	ENSG00000277977.1	CTD-3018O17.5	3.25	0.00118	0.0493	0.12	0.1	Colonoscopy-negative controls vs population controls;	chr19:52379480	chr19:52392659~52392755:+
BRCA	cis	rs324126	0.752	rs10445584	ENSG00000277977.1	CTD-3018O17.5	3.25	0.00118	0.0493	0.12	0.1	Colonoscopy-negative controls vs population controls;	chr19:52379552	chr19:52392659~52392755:+
BRCA	cis	rs324126	0.78	rs10445585	ENSG00000277977.1	CTD-3018O17.5	3.25	0.00118	0.0493	0.12	0.1	Colonoscopy-negative controls vs population controls;	chr19:52379571	chr19:52392659~52392755:+
BRCA	cis	rs4631830	0.832	rs2843554	ENSG00000204177.9	BMS1P1	-3.25	0.00118	0.0493	-0.09	-0.1	Prostate-specific antigen levels;	chr10:46071961	chr10:46786674~46811989:+
BRCA	cis	rs11673344	0.796	rs16971886	ENSG00000267682.1	CTD-3220F14.2	-3.25	0.00118	0.0493	-0.09	-0.1	Obesity-related traits;	chr19:36997073	chr19:37337236~37337743:+
BRCA	cis	rs875971	0.862	rs10276077	ENSG00000223473.2	GS1-124K5.3	-3.25	0.00118	0.0493	-0.08	-0.1	Aortic root size;	chr7:66263424	chr7:66491049~66493566:-
BRCA	cis	rs6840360	0.593	rs6857073	ENSG00000201264.1	SNORD73	3.25	0.00118	0.0493	0.12	0.1	Intelligence (multi-trait analysis);	chr4:151768122	chr4:151102057~151102128:+
BRCA	cis	rs73186030	0.764	rs34408666	ENSG00000272758.4	RP11-299J3.8	3.25	0.00118	0.0493	0.16	0.1	Serum parathyroid hormone levels;	chr3:122262762	chr3:122416207~122443180:+
BRCA	cis	rs9467773	0.967	rs7753565	ENSG00000261353.1	CTA-14H9.5	-3.25	0.00118	0.0493	-0.1	-0.1	Intelligence (multi-trait analysis);	chr6:26559784	chr6:26527063~26527404:+
BRCA	cis	rs930395	0.514	rs10060878	ENSG00000248779.1	RP11-53O19.2	-3.25	0.00118	0.0493	-0.09	-0.1	Breast cancer;	chr5:44899322	chr5:44752949~44765744:+
BRCA	cis	rs1119582	0.568	rs395517	ENSG00000279118.1	RP11-517I3.2	3.25	0.00118	0.0493	0.14	0.1	Select biomarker traits;	chr5:125866130	chr5:126496279~126498604:+
BRCA	cis	rs1119582	0.568	rs391874	ENSG00000279118.1	RP11-517I3.2	3.25	0.00118	0.0493	0.14	0.1	Select biomarker traits;	chr5:125866140	chr5:126496279~126498604:+
BRCA	cis	rs1119582	0.636	rs437077	ENSG00000279118.1	RP11-517I3.2	3.25	0.00118	0.0493	0.14	0.1	Select biomarker traits;	chr5:125866189	chr5:126496279~126498604:+
BRCA	cis	rs9467773	0.62	rs2504540	ENSG00000261353.1	CTA-14H9.5	-3.25	0.00118	0.0493	-0.1	-0.1	Intelligence (multi-trait analysis);	chr6:26641398	chr6:26527063~26527404:+
BRCA	cis	rs748404	0.666	rs34591748	ENSG00000166763.7	STRCP1	3.25	0.00118	0.0493	0.15	0.1	Lung cancer;	chr15:43334917	chr15:43699488~43718184:-
BRCA	cis	rs7781557	1	rs2041094	ENSG00000170409.7	CTA-313A17.2	3.25	0.00118	0.0493	0.17	0.1	Colorectal adenoma (advanced);	chr7:102854987	chr7:102327256~102329530:-
BRCA	cis	rs7221109	0.56	rs758630	ENSG00000229028.2	KRT223P	-3.25	0.00118	0.0493	-0.11	-0.1	Type 1 diabetes;	chr17:40713053	chr17:40717235~40721932:-
BRCA	cis	rs67072384	0.818	rs12287481	ENSG00000245148.2	ARAP1-AS2	-3.25	0.00118	0.0493	-0.14	-0.1	Alloimmunization response to red blood cell transfusion in sickle cell anemia;	chr11:72761291	chr11:72700474~72705607:+
BRCA	cis	rs4618572	1	rs4618572	ENSG00000272485.1	RP11-284J1.1	3.25	0.00118	0.0493	0.16	0.1	Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin;	chr6:1492427	chr6:774747~780214:-
BRCA	cis	rs4950322	0.547	rs56864370	ENSG00000237188.3	RP11-337C18.8	3.25	0.00118	0.0493	0.12	0.1	Protein quantitative trait loci;	chr1:147111847	chr1:147172771~147211568:+
BRCA	cis	rs7811142	0.83	rs11765869	ENSG00000214313.7	AZGP1P1	-3.25	0.00118	0.0493	-0.14	-0.1	Platelet count;	chr7:100367166	chr7:99980762~99987535:+
BRCA	cis	rs12893668	0.572	rs4900590	ENSG00000258914.1	CTD-2134A5.3	3.25	0.00118	0.0493	0.14	0.1	Reticulocyte count;	chr14:103680084	chr14:103875055~103877478:+
BRCA	cis	rs9840812	0.953	rs34330586	ENSG00000273486.1	RP11-731C17.2	-3.25	0.00118	0.0493	-0.12	-0.1	Fibrinogen levels;	chr3:136081567	chr3:136837338~136839021:-
BRCA	cis	rs6452790	0.627	rs10079980	ENSG00000247828.6	TMEM161B-AS1	-3.25	0.00118	0.0493	-0.13	-0.1	Cognitive function;	chr5:88103185	chr5:88268895~88436685:+
BRCA	cis	rs9341808	0.621	rs2322627	ENSG00000279022.1	RP11-250B2.4	3.25	0.00118	0.0493	0.11	0.1	Sitting height ratio;	chr6:80096624	chr6:80440730~80441172:+
BRCA	cis	rs7812879	0.81	rs2618479	ENSG00000251402.3	FAM90A25P	3.25	0.00118	0.0493	0.15	0.1	Systemic lupus erythematosus;	chr8:11498312	chr8:12415080~12418090:-
BRCA	cis	rs4578769	0.765	rs55762801	ENSG00000273232.1	RP11-370A5.2	-3.25	0.00118	0.0493	-0.14	-0.1	Eosinophil percentage of white cells;	chr18:22807096	chr18:22882825~22883357:-
BRCA	cis	rs910316	0.687	rs175059	ENSG00000259138.1	RP11-950C14.7	-3.25	0.00118	0.0493	-0.11	-0.1	Height;	chr14:75023964	chr14:75127153~75136930:+
BRCA	cis	rs10905065	0.965	rs12571639	ENSG00000215267.7	AKR1C7P	3.25	0.00118	0.0493	0.13	0.1	Menopause (age at onset);	chr10:5706089	chr10:5275173~5288470:-
BRCA	cis	rs13401620	0.778	rs3111726	ENSG00000223549.1	MTND5P28	-3.25	0.00118	0.0493	-0.12	-0.1	Breast size;	chr2:119908079	chr2:120215181~120217279:+
BRCA	cis	rs76206723	1	rs17171710	ENSG00000233225.3	AC004987.9	3.25	0.00118	0.0493	0.18	0.1	Pulse pressure;	chr7:40400634	chr7:39833571~39834718:+
BRCA	cis	rs295490	0.748	rs74846775	ENSG00000178631.7	ACTG1P1	-3.25	0.00118	0.0493	-0.22	-0.1	PR interval in Tripanosoma cruzi seropositivity;	chr3:139354736	chr3:139493809~139494937:+
BRCA	cis	rs3820068	0.581	rs59684759	ENSG00000237301.1	RP4-680D5.2	-3.25	0.00118	0.0493	-0.13	-0.1	Systolic blood pressure;	chr1:15593398	chr1:15586136~15603626:-
BRCA	cis	rs2380205	0.689	rs867053	ENSG00000232807.2	RP11-536K7.3	3.25	0.00118	0.0493	0.11	0.1	Breast cancer;	chr10:5845207	chr10:5934270~5945900:-
BRCA	cis	rs55883249	0.958	rs17362734	ENSG00000217258.2	AC007249.3	3.25	0.00118	0.0494	0.16	0.1	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:9590079	chr2:10452319~10455552:+
BRCA	cis	rs964611	0.882	rs8027003	ENSG00000259488.2	RP11-154J22.1	-3.25	0.00118	0.0494	-0.12	-0.1	Metabolite levels (Pyroglutamine);	chr15:48355229	chr15:48312353~48331856:-
BRCA	cis	rs2286492	0.655	rs117841439	ENSG00000230658.1	KLHL7-AS1	3.25	0.00118	0.0494	0.24	0.1	Bipolar disorder;	chr7:22870922	chr7:23101228~23105703:-
BRCA	cis	rs6493487	0.512	rs35416047	ENSG00000259378.1	DCAF13P3	-3.25	0.00118	0.0494	-0.17	-0.1	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr15:50896348	chr15:50944663~50945996:+
BRCA	cis	rs62458065	0.513	rs9655340	ENSG00000273014.1	RP11-225B17.2	3.25	0.00118	0.0494	0.15	0.1	Metabolite levels (HVA/MHPG ratio);	chr7:32496308	chr7:32758882~32759353:+
BRCA	cis	rs77688320	0.535	rs13001194	ENSG00000242696.3	RN7SL40P	-3.25	0.00118	0.0494	-0.11	-0.1	Breast cancer;	chr2:201396452	chr2:202357076~202357417:-
BRCA	cis	rs77688320	0.535	rs7597850	ENSG00000242696.3	RN7SL40P	-3.25	0.00118	0.0494	-0.11	-0.1	Breast cancer;	chr2:201396679	chr2:202357076~202357417:-
BRCA	cis	rs77688320	0.535	rs7571761	ENSG00000242696.3	RN7SL40P	-3.25	0.00118	0.0494	-0.11	-0.1	Breast cancer;	chr2:201396837	chr2:202357076~202357417:-
BRCA	cis	rs77688320	0.535	rs10931944	ENSG00000242696.3	RN7SL40P	-3.25	0.00118	0.0494	-0.11	-0.1	Breast cancer;	chr2:201398875	chr2:202357076~202357417:-
BRCA	cis	rs77688320	0.553	rs11681526	ENSG00000242696.3	RN7SL40P	-3.25	0.00118	0.0494	-0.11	-0.1	Breast cancer;	chr2:201399037	chr2:202357076~202357417:-
BRCA	cis	rs77688320	0.535	rs13022344	ENSG00000242696.3	RN7SL40P	-3.25	0.00118	0.0494	-0.11	-0.1	Breast cancer;	chr2:201399433	chr2:202357076~202357417:-
BRCA	cis	rs77688320	0.535	rs6732993	ENSG00000242696.3	RN7SL40P	-3.25	0.00118	0.0494	-0.11	-0.1	Breast cancer;	chr2:201399593	chr2:202357076~202357417:-
BRCA	cis	rs2333021	0.649	rs12888375	ENSG00000259015.1	RP11-109N23.6	3.25	0.00118	0.0494	0.11	0.1	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:73003877	chr14:72960595~72961993:+
BRCA	cis	rs10771431	0.935	rs1988852	ENSG00000256069.6	A2MP1	3.25	0.00118	0.0494	0.1	0.1	Breast size;	chr12:9220266	chr12:9228533~9275817:-
BRCA	cis	rs6545883	0.801	rs778142	ENSG00000237522.1	NONOP2	-3.25	0.00118	0.0494	-0.1	-0.1	Tuberculosis;	chr2:61454293	chr2:60936819~60938049:-
BRCA	cis	rs2904524	1	rs2091131	ENSG00000257613.1	LINC01481	-3.25	0.00118	0.0494	-0.17	-0.1	Amyotrophic lateral sclerosis (age of onset);	chr12:70294834	chr12:70219132~70221862:-
BRCA	cis	rs2904524	1	rs17107947	ENSG00000257613.1	LINC01481	-3.25	0.00118	0.0494	-0.17	-0.1	Amyotrophic lateral sclerosis (age of onset);	chr12:70295689	chr12:70219132~70221862:-
BRCA	cis	rs372883	0.638	rs371432	ENSG00000232855.5	AF131217.1	3.25	0.00118	0.0494	0.13	0.1	Pancreatic cancer;	chr21:29338555	chr21:28439346~28674848:-
BRCA	cis	rs6743226	0.934	rs4303713	ENSG00000266621.1	AC104841.1	3.25	0.00118	0.0494	0.11	0.1	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in non-smokers;	chr2:241318444	chr2:241245202~241245299:-
BRCA	cis	rs11587682	0.76	rs12123103	ENSG00000228126.1	FALEC	3.25	0.00118	0.0494	0.13	0.1	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr1:150448810	chr1:150515757~150518032:+
BRCA	cis	rs11587682	0.76	rs11205378	ENSG00000228126.1	FALEC	3.25	0.00118	0.0494	0.13	0.1	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr1:150448981	chr1:150515757~150518032:+
BRCA	cis	rs10208649	1	rs10188834	ENSG00000272156.1	RP11-477N3.1	3.25	0.00118	0.0494	0.2	0.1	Body mass index;	chr2:53937236	chr2:54082554~54085066:+
BRCA	cis	rs12723316	0.932	rs12728368	ENSG00000233008.4	RP11-475O6.1	-3.25	0.00118	0.0494	-0.19	-0.1	Schizophrenia;	chr1:83824605	chr1:83575776~83861023:-
BRCA	cis	rs9368481	0.672	rs3931463	ENSG00000224843.5	LINC00240	-3.25	0.00118	0.0494	-0.12	-0.1	Autism spectrum disorder or schizophrenia;	chr6:26972018	chr6:26956992~27023924:+
BRCA	cis	rs7037266	0.817	rs1018587	ENSG00000232946.1	RP11-390F4.2	-3.25	0.00118	0.0494	-0.12	-0.1	Menarche (age at onset);	chr9:6969572	chr9:6675284~6675614:+
BRCA	cis	rs4932480	0.713	rs7168186	ENSG00000261441.1	RP11-217B1.2	3.25	0.00118	0.0494	0.13	0.1	Age-related macular degeneration (SNP x mitochondrial G12771A interaction);Advanced age-related macular degeneration;	chr15:89207729	chr15:89335053~89336161:+
BRCA	cis	rs2562456	0.833	rs56179986	ENSG00000268705.1	BNIP3P26	3.25	0.00118	0.0494	0.12	0.1	Pain;	chr19:21337882	chr19:21521343~21521896:-
BRCA	cis	rs10043228	1	rs12515308	ENSG00000250015.1	CTC-339F2.2	3.25	0.00118	0.0494	0.13	0.1	Asthma or chronic obstructive pulmonary disease;	chr5:116114744	chr5:116302354~116304134:-
BRCA	cis	rs2414856	0.51	rs10400921	ENSG00000259635.1	AC100830.3	-3.25	0.00118	0.0494	-0.22	-0.1	Pulse pressure;Systolic blood pressure;	chr15:64369738	chr15:64701248~64719602:+
BRCA	cis	rs6565180	1	rs11646130	ENSG00000261332.1	RP11-297C4.1	-3.25	0.00118	0.0494	-0.14	-0.1	Tonsillectomy;	chr16:30365638	chr16:30498766~30499554:-
BRCA	cis	rs1348850	0.914	rs12104588	ENSG00000280374.1	RP11-337N6.3	3.25	0.00118	0.0494	0.13	0.1	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177388947	chr2:177317715~177318471:-
BRCA	cis	rs7917772	0.503	rs7902306	ENSG00000213061.2	PFN1P11	-3.25	0.00118	0.0494	-0.14	-0.1	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;	chr10:102530705	chr10:102838011~102845473:-
BRCA	cis	rs710446	0.603	rs5030060	ENSG00000223803.1	RPS20P14	-3.25	0.00118	0.0494	-0.12	-0.1	Activated partial thromboplastin time;Thrombosis;Factor XI;	chr3:186735128	chr3:186900198~186900557:+
BRCA	cis	rs757978	1	rs757978	ENSG00000223374.1	AC005104.3	3.25	0.00118	0.0494	0.13	0.1	Chronic lymphocytic leukemia;	chr2:241431686	chr2:241351340~241353104:-
BRCA	cis	rs1528472	0.836	rs1690375	ENSG00000276533.1	RP11-139H15.5	3.25	0.00118	0.0494	0.12	0.1	Urinary albumin-to-creatinine ratio;Urinary albumin-to-creatinine ratio in non-diabetics;	chr15:55024897	chr15:55288849~55289346:-
BRCA	cis	rs6782228	1	rs12635488	ENSG00000239608.1	RUVBL1-AS1	-3.25	0.00118	0.0494	-0.15	-0.1	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128633535	chr3:128075810~128079056:+
BRCA	cis	rs2227564	0.761	rs2227552	ENSG00000242288.9	RP11-464F9.1	3.25	0.00118	0.0494	0.14	0.1	Crohn's disease;Inflammatory bowel disease;	chr10:73909561	chr10:73674295~73730466:-
BRCA	cis	rs2243480	0.803	rs35480979	ENSG00000226767.1	RP11-328P23.3	-3.25	0.00118	0.0494	-0.17	-0.1	Diabetic kidney disease;	chr7:65892097	chr7:65508773~65508944:-
BRCA	cis	rs2243480	1	rs35391607	ENSG00000226767.1	RP11-328P23.3	-3.25	0.00118	0.0494	-0.17	-0.1	Diabetic kidney disease;	chr7:65895842	chr7:65508773~65508944:-
BRCA	cis	rs2243480	1	rs13220979	ENSG00000226767.1	RP11-328P23.3	-3.25	0.00118	0.0494	-0.17	-0.1	Diabetic kidney disease;	chr7:65898217	chr7:65508773~65508944:-
BRCA	cis	rs2243480	1	rs34974928	ENSG00000226767.1	RP11-328P23.3	-3.25	0.00118	0.0494	-0.17	-0.1	Diabetic kidney disease;	chr7:65899019	chr7:65508773~65508944:-
BRCA	cis	rs745109	0.938	rs11548929	ENSG00000273080.1	RP11-301O19.1	3.25	0.00118	0.0494	0.15	0.1	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86529258	chr2:86195590~86196049:+
BRCA	cis	rs11997175	0.679	rs10954935	ENSG00000272338.2	RP11-722E23.2	3.25	0.00118	0.0494	0.11	0.1	Body mass index;	chr8:33812861	chr8:33360839~33361415:-
BRCA	cis	rs12900413	0.562	rs28557101	ENSG00000259212.1	CTD-3065B20.2	3.25	0.00118	0.0494	0.12	0.1	Coronary artery aneurysm in Kawasaki disease;	chr15:89754918	chr15:90595840~90596447:-
BRCA	cis	rs2609255	1	rs2125409	ENSG00000270720.1	RP11-84C13.2	-3.25	0.00118	0.0494	-0.15	-0.1	Interstitial lung disease;	chr4:88929391	chr4:89119284~89119871:+
BRCA	cis	rs7487075	0.619	rs4768123	ENSG00000257261.4	RP11-96H19.1	3.25	0.00118	0.0494	0.12	0.1	Itch intensity from mosquito bite;	chr12:46458310	chr12:46383679~46876159:+
BRCA	cis	rs7712401	0.755	rs13172043	ENSG00000263432.2	RN7SL689P	3.25	0.00118	0.0494	0.12	0.1	Mean platelet volume;	chr5:122849064	chr5:123022487~123022783:-
BRCA	cis	rs6496044	0.568	rs1982742	ENSG00000259630.2	CTD-2262B20.1	-3.25	0.00118	0.0494	-0.12	-0.1	Interstitial lung disease;	chr15:85525519	chr15:85415228~85415633:+
BRCA	cis	rs6496044	0.568	rs6496049	ENSG00000259630.2	CTD-2262B20.1	-3.25	0.00118	0.0494	-0.12	-0.1	Interstitial lung disease;	chr15:85525974	chr15:85415228~85415633:+
BRCA	cis	rs7188697	0.885	rs1646010	ENSG00000276259.1	RP11-481J2.4	-3.25	0.00118	0.0494	-0.11	-0.1	QT interval;	chr16:58515300	chr16:58522970~58523842:+
BRCA	cis	rs8114671	0.935	rs6058198	ENSG00000279253.1	RP4-614O4.13	-3.25	0.00118	0.0494	-0.12	-0.1	Height;	chr20:35160450	chr20:35262727~35264187:-
BRCA	cis	rs8062405	0.824	rs4788085	ENSG00000261766.1	RP11-22P6.2	-3.25	0.00118	0.0494	-0.1	-0.1	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28523682	chr16:28862166~28863340:-
BRCA	cis	rs8062405	0.824	rs28772958	ENSG00000261766.1	RP11-22P6.2	-3.25	0.00118	0.0494	-0.1	-0.1	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28523984	chr16:28862166~28863340:-
BRCA	cis	rs12681366	0.708	rs12680029	ENSG00000253175.1	RP11-267M23.6	3.25	0.00118	0.0494	0.11	0.1	Nonsyndromic cleft lip with cleft palate;	chr8:94392418	chr8:94565036~94565715:+
BRCA	cis	rs1865760	0.566	rs7772312	ENSG00000272462.2	U91328.19	-3.25	0.00118	0.0494	-0.12	-0.1	Height;	chr6:26049388	chr6:25992662~26001775:+
BRCA	cis	rs1865760	0.508	rs9379820	ENSG00000272462.2	U91328.19	-3.25	0.00118	0.0494	-0.12	-0.1	Height;	chr6:26049696	chr6:25992662~26001775:+
BRCA	cis	rs7520050	0.898	rs785502	ENSG00000234329.1	RP11-767N6.2	-3.25	0.00118	0.0494	-0.09	-0.1	Reticulocyte count;Red blood cell count;	chr1:46115772	chr1:45651039~45651826:-
BRCA	cis	rs253959	0.545	rs712592	ENSG00000248445.4	SEMA6A-AS1	-3.25	0.00118	0.0494	-0.09	-0.1	Bipolar disorder and schizophrenia;	chr5:116321684	chr5:116447547~116508276:+
BRCA	cis	rs253959	0.545	rs712593	ENSG00000248445.4	SEMA6A-AS1	-3.25	0.00118	0.0494	-0.09	-0.1	Bipolar disorder and schizophrenia;	chr5:116321700	chr5:116447547~116508276:+
BRCA	cis	rs253959	0.545	rs712594	ENSG00000248445.4	SEMA6A-AS1	-3.25	0.00118	0.0494	-0.09	-0.1	Bipolar disorder and schizophrenia;	chr5:116321762	chr5:116447547~116508276:+
BRCA	cis	rs253959	0.545	rs712595	ENSG00000248445.4	SEMA6A-AS1	-3.25	0.00118	0.0494	-0.09	-0.1	Bipolar disorder and schizophrenia;	chr5:116321801	chr5:116447547~116508276:+
BRCA	cis	rs2688608	0.592	rs11000760	ENSG00000242288.9	RP11-464F9.1	3.25	0.00118	0.0494	0.12	0.1	Inflammatory bowel disease;	chr10:73733976	chr10:73674295~73730466:-
BRCA	cis	rs504458	0.608	rs12403601	ENSG00000241975.1	TCEB1P19	-3.25	0.00118	0.0494	-0.11	-0.1	Childhood ear infection;	chr1:88208862	chr1:88829102~88829419:+
BRCA	cis	rs38055	0.558	rs2406615	ENSG00000247796.2	CTD-2366F13.1	3.25	0.00118	0.0494	0.13	0.1	Acne (severe);	chr5:53217705	chr5:53109842~53115126:+
BRCA	cis	rs7267979	0.873	rs6115093	ENSG00000274973.1	RP13-401N8.7	-3.25	0.00118	0.0494	-0.12	-0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25230094	chr20:25845497~25845862:+
BRCA	cis	rs13113518	0.51	rs6828454	ENSG00000239040.1	Y_RNA	-3.25	0.00118	0.0494	-0.1	-0.1	Height;	chr4:55424329	chr4:55412636~55412738:+
BRCA	cis	rs7639513	0.767	rs9861472	ENSG00000274514.1	Metazoa_SRP	-3.25	0.00118	0.0494	-0.12	-0.1	Itch intensity from mosquito bite;	chr3:12666277	chr3:12576961~12577237:-
BRCA	cis	rs875971	0.862	rs6460306	ENSG00000265600.1	AC006480.1	3.25	0.00118	0.0494	0.12	0.1	Aortic root size;	chr7:66595806	chr7:67356680~67356779:+
BRCA	cis	rs11673344	0.931	rs73622783	ENSG00000267422.1	CTD-2554C21.1	3.25	0.00118	0.0494	0.13	0.1	Obesity-related traits;	chr19:37165155	chr19:37779686~37792865:+
BRCA	cis	rs9844666	0.512	rs9849088	ENSG00000239213.4	NCK1-AS1	3.25	0.00118	0.0494	0.11	0.1	Height;	chr3:135925060	chr3:136841726~136862054:-
BRCA	cis	rs9844666	0.512	rs56807950	ENSG00000239213.4	NCK1-AS1	3.25	0.00118	0.0494	0.11	0.1	Height;	chr3:135925531	chr3:136841726~136862054:-
BRCA	cis	rs9844666	0.512	rs59063369	ENSG00000239213.4	NCK1-AS1	3.25	0.00118	0.0494	0.11	0.1	Height;	chr3:135925636	chr3:136841726~136862054:-
BRCA	cis	rs951005	0.572	rs59417728	ENSG00000228352.2	RP11-537H15.3	-3.25	0.00118	0.0494	-0.16	-0.1	Rheumatoid arthritis;	chr9:34716191	chr9:34084332~34096225:+
BRCA	cis	rs6017291	0.793	rs12624924	ENSG00000223891.4	OSER1-AS1	3.25	0.00118	0.0495	0.21	0.1	Cognitive performance;	chr20:44216629	chr20:44210960~44226027:+
BRCA	cis	rs4243971	0.557	rs1040752	ENSG00000275576.1	RP5-836N17.4	-3.25	0.00118	0.0495	-0.11	-0.1	Inflammatory bowel disease;Crohn's disease;	chr20:32441221	chr20:32116171~32116629:+
BRCA	cis	rs10876993	0.928	rs1678530	ENSG00000270039.1	RP11-571M6.17	3.25	0.00118	0.0495	0.13	0.1	Celiac disease or Rheumatoid arthritis;	chr12:57660293	chr12:57803838~57804415:+
BRCA	cis	rs10876993	0.928	rs1678532	ENSG00000270039.1	RP11-571M6.17	3.25	0.00118	0.0495	0.13	0.1	Celiac disease or Rheumatoid arthritis;	chr12:57661414	chr12:57803838~57804415:+
BRCA	cis	rs7094310	1	rs7094310	ENSG00000213994.3	RP11-414H17.5	-3.25	0.00118	0.0495	-0.27	-0.1	Hip circumference (psychosocial stress interaction);	chr10:6749072	chr10:6197612~6202693:-
BRCA	cis	rs35000415	0.938	rs12706861	ENSG00000275106.1	RP11-309L24.10	-3.25	0.00118	0.0495	-0.22	-0.1	Systemic lupus erythematosus;	chr7:128976528	chr7:128952527~128953316:-
BRCA	cis	rs7258465	1	rs7252848	ENSG00000273654.1	CTB-52I2.4	-3.25	0.00118	0.0495	-0.12	-0.1	Breast cancer;	chr19:18501541	chr19:18022403~18032099:+
BRCA	cis	rs889956	0.776	rs11688471	ENSG00000233251.6	AC007743.1	-3.25	0.00118	0.0495	-0.12	-0.1	Educational attainment;	chr2:57127835	chr2:56173534~56185770:-
BRCA	cis	rs35520189	1	rs35520189	ENSG00000231747.1	AC079922.2	-3.25	0.00118	0.0495	-0.11	-0.1	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:112861653	chr2:112621809~112622167:-
BRCA	cis	rs35520189	0.961	rs12477661	ENSG00000231747.1	AC079922.2	-3.25	0.00118	0.0495	-0.11	-0.1	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:112863188	chr2:112621809~112622167:-
BRCA	cis	rs4557020	0.904	rs4671942	ENSG00000203327.2	AC012358.7	-3.25	0.00118	0.0495	-0.1	-0.1	Myopia (pathological);	chr2:54486929	chr2:55214387~55216126:-
BRCA	cis	rs8062405	0.755	rs56272201	ENSG00000261766.1	RP11-22P6.2	-3.25	0.00118	0.0495	-0.11	-0.1	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28569364	chr16:28862166~28863340:-
BRCA	cis	rs8062405	0.755	rs62034355	ENSG00000261766.1	RP11-22P6.2	-3.25	0.00118	0.0495	-0.11	-0.1	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28569717	chr16:28862166~28863340:-
BRCA	cis	rs561341	1	rs72823785	ENSG00000265798.5	RP11-271K11.5	3.25	0.00118	0.0495	0.18	0.1	Hip circumference adjusted for BMI;	chr17:31946765	chr17:31038575~31059121:-
BRCA	cis	rs1003719	0.788	rs1155785	ENSG00000242553.1	AP001432.14	-3.25	0.00118	0.0495	-0.11	-0.1	Eye color traits;	chr21:37075639	chr21:37221419~37237744:+
BRCA	cis	rs1003719	0.788	rs1155787	ENSG00000242553.1	AP001432.14	-3.25	0.00118	0.0495	-0.11	-0.1	Eye color traits;	chr21:37075769	chr21:37221419~37237744:+
BRCA	cis	rs1003719	0.788	rs60447195	ENSG00000242553.1	AP001432.14	-3.25	0.00118	0.0495	-0.11	-0.1	Eye color traits;	chr21:37076300	chr21:37221419~37237744:+
BRCA	cis	rs1003719	0.699	rs1015549	ENSG00000242553.1	AP001432.14	-3.25	0.00118	0.0495	-0.11	-0.1	Eye color traits;	chr21:37076580	chr21:37221419~37237744:+
BRCA	cis	rs4787951	0.505	rs3024575	ENSG00000259940.2	CTD-3203P2.1	-3.25	0.00118	0.0495	-0.12	-0.1	Eosinophil percentage of white cells;	chr16:27346811	chr16:27213308~27214993:-
BRCA	cis	rs867529	0.924	rs6547787	ENSG00000234028.3	AC062029.1	3.25	0.00118	0.0495	0.11	0.1	Height;	chr2:88630218	chr2:88627539~88631821:+
BRCA	cis	rs10876993	0.928	rs2640629	ENSG00000270039.1	RP11-571M6.17	3.25	0.00118	0.0495	0.13	0.1	Celiac disease or Rheumatoid arthritis;	chr12:57671665	chr12:57803838~57804415:+
BRCA	cis	rs55728055	0.661	rs7293143	ENSG00000230736.2	RP1-149A16.3	-3.25	0.00118	0.0495	-0.22	-0.1	Age-related hearing impairment;	chr22:31617379	chr22:32376664~32384343:+
BRCA	cis	rs4714291	0.925	rs847747	ENSG00000180211.5	RP1-278E11.3	3.25	0.00118	0.0495	0.11	0.1	Strep throat;	chr6:40112330	chr6:39958414~39958833:-
BRCA	cis	rs1348850	0.567	rs4893838	ENSG00000280374.1	RP11-337N6.3	3.25	0.00118	0.0495	0.14	0.1	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177666708	chr2:177317715~177318471:-
BRCA	cis	rs490234	0.756	rs10986849	ENSG00000232630.1	PRPS1P2	-3.25	0.00118	0.0495	-0.1	-0.1	Mean arterial pressure;	chr9:125707404	chr9:125150653~125151589:+
BRCA	cis	rs11098499	0.754	rs2036857	ENSG00000250412.1	KLHL2P1	3.25	0.00118	0.0495	0.11	0.1	Corneal astigmatism;	chr4:119328085	chr4:119334329~119378233:+
BRCA	cis	rs11098499	0.754	rs2036856	ENSG00000250412.1	KLHL2P1	3.25	0.00118	0.0495	0.11	0.1	Corneal astigmatism;	chr4:119328133	chr4:119334329~119378233:+
BRCA	cis	rs11098499	0.754	rs4443261	ENSG00000250412.1	KLHL2P1	3.25	0.00118	0.0495	0.11	0.1	Corneal astigmatism;	chr4:119328146	chr4:119334329~119378233:+
BRCA	cis	rs7824557	0.707	rs3808518	ENSG00000248896.2	CTD-2135J3.3	-3.25	0.00118	0.0495	-0.13	-0.1	Retinal vascular caliber;	chr8:11285763	chr8:10729314~10771392:+
BRCA	cis	rs170557	0.573	rs11590161	ENSG00000203706.7	SERTAD4-AS1	-3.25	0.00118	0.0495	-0.12	-0.1	Alopecia areata;	chr1:209992583	chr1:210231456~210234047:-
BRCA	cis	rs3760982	0.585	rs61013802	ENSG00000266921.1	RP11-15A1.7	-3.25	0.00118	0.0495	-0.13	-0.1	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43787990	chr19:43996896~44002836:-
BRCA	cis	rs7660883	1	rs4693156	ENSG00000251411.1	RP11-397E7.4	3.25	0.00118	0.0495	0.11	0.1	HDL cholesterol levels;	chr4:87086075	chr4:86913266~86914817:-
BRCA	cis	rs2638953	0.853	rs1918418	ENSG00000273989.1	RP11-425D17.2	-3.25	0.00118	0.0495	-0.15	-0.1	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28483789	chr12:28236227~28236828:+
BRCA	cis	rs2638953	0.853	rs1511550	ENSG00000273989.1	RP11-425D17.2	-3.25	0.00118	0.0495	-0.15	-0.1	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28484182	chr12:28236227~28236828:+
BRCA	cis	rs10043228	0.826	rs4532392	ENSG00000250015.1	CTC-339F2.2	3.25	0.00118	0.0495	0.13	0.1	Asthma or chronic obstructive pulmonary disease;	chr5:116119808	chr5:116302354~116304134:-
BRCA	cis	rs2625529	0.529	rs7183055	ENSG00000261187.1	RP11-1007O24.2	3.25	0.00118	0.0495	0.11	0.1	Red blood cell count;	chr15:72084707	chr15:72465128~72466262:-
BRCA	cis	rs2899832	0.568	rs17458562	ENSG00000258704.4	SRP54-AS1	3.25	0.00118	0.0495	0.24	0.1	Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:35292761	chr14:34920858~34982532:-
BRCA	cis	rs3820068	0.581	rs16851876	ENSG00000237301.1	RP4-680D5.2	3.25	0.00118	0.0495	0.13	0.1	Systolic blood pressure;	chr1:15624133	chr1:15586136~15603626:-
BRCA	cis	rs2276314	0.802	rs9963714	ENSG00000267627.4	RP11-905K4.1	-3.25	0.00118	0.0495	-0.14	-0.1	Endometriosis;Drug-induced torsades de pointes;	chr18:36012093	chr18:35951803~35966118:-
BRCA	cis	rs2276314	0.802	rs4799838	ENSG00000267627.4	RP11-905K4.1	-3.25	0.00118	0.0495	-0.14	-0.1	Endometriosis;Drug-induced torsades de pointes;	chr18:36017567	chr18:35951803~35966118:-
BRCA	cis	rs2276314	0.748	rs4799839	ENSG00000267627.4	RP11-905K4.1	-3.25	0.00118	0.0495	-0.14	-0.1	Endometriosis;Drug-induced torsades de pointes;	chr18:36017568	chr18:35951803~35966118:-
BRCA	cis	rs2276314	0.857	rs28375959	ENSG00000267627.4	RP11-905K4.1	-3.25	0.00118	0.0495	-0.14	-0.1	Endometriosis;Drug-induced torsades de pointes;	chr18:36021571	chr18:35951803~35966118:-
BRCA	cis	rs11603023	0.967	rs7936556	ENSG00000278376.1	RP11-158I9.8	3.25	0.00118	0.0495	0.1	0.1	Cholesterol, total;	chr11:118630582	chr11:118791254~118793137:+
BRCA	cis	rs2562456	0.876	rs11085468	ENSG00000268705.1	BNIP3P26	3.25	0.00118	0.0495	0.11	0.1	Pain;	chr19:21569087	chr19:21521343~21521896:-
BRCA	cis	rs2357982	0.828	rs6750514	ENSG00000227403.1	AC009299.3	-3.25	0.00118	0.0495	-0.14	-0.1	Presence of antiphospholipid antibodies;	chr2:161092788	chr2:161244739~161249050:+
BRCA	cis	rs1816752	0.875	rs1050110	ENSG00000273628.1	RP11-756A22.7	3.25	0.00118	0.0495	0.12	0.1	Obesity-related traits;	chr13:24435347	chr13:24933006~24936796:+
BRCA	cis	rs1003719	0.762	rs1015551	ENSG00000242553.1	AP001432.14	-3.25	0.00118	0.0495	-0.11	-0.1	Eye color traits;	chr21:37077210	chr21:37221419~37237744:+
BRCA	cis	rs539096	0.872	rs3791138	ENSG00000228452.1	RP5-994D16.9	-3.25	0.00118	0.0495	-0.13	-0.1	Intelligence (multi-trait analysis);	chr1:43584356	chr1:42775813~42776790:-
BRCA	cis	rs193541	0.507	rs7726207	ENSG00000251538.4	RP11-166A12.1	3.25	0.00118	0.0495	0.11	0.1	Glucose homeostasis traits;	chr5:122745582	chr5:122628952~122730685:-
BRCA	cis	rs11047510	0.668	rs17729753	ENSG00000164845.15	FAM86FP	3.25	0.00118	0.0495	0.16	0.1	Exploratory eye movement dysfunction in schizophrenia (responsive search score);	chr12:8866881	chr12:8232512~8242948:-
BRCA	cis	rs2554380	0.628	rs4843158	ENSG00000259570.1	RP11-671M22.4	3.25	0.00118	0.0495	0.13	0.1	Height;	chr15:83802884	chr15:84394512~84395514:+
BRCA	cis	rs8062405	0.824	rs4788085	ENSG00000275441.1	RP11-666O2.2	3.25	0.00118	0.0495	0.09	0.1	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28523682	chr16:28553709~28554140:-
BRCA	cis	rs8062405	0.824	rs28772958	ENSG00000275441.1	RP11-666O2.2	3.25	0.00118	0.0495	0.09	0.1	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28523984	chr16:28553709~28554140:-
BRCA	cis	rs10238623	0.859	rs66539057	ENSG00000228421.2	AC005013.5	-3.25	0.00118	0.0495	-0.13	-0.1	Anxiety in major depressive disorder;	chr7:28782075	chr7:28957667~28959345:+
BRCA	cis	rs67478160	0.643	rs8003653	ENSG00000269910.1	RP11-73M18.10	3.25	0.00118	0.0495	0.1	0.1	Schizophrenia;	chr14:103832499	chr14:103694516~103695050:-
BRCA	cis	rs7760535	0.656	rs1883136	ENSG00000231889.6	TRAF3IP2-AS1	3.25	0.00118	0.0495	0.1	0.1	Metabolic traits;	chr6:111585820	chr6:111483511~111598302:+
BRCA	cis	rs11098499	0.955	rs13129661	ENSG00000225892.3	RP11-384K6.2	3.25	0.00118	0.0495	0.1	0.1	Corneal astigmatism;	chr4:119231754	chr4:118632274~118634759:+
BRCA	cis	rs7520050	0.966	rs785503	ENSG00000234329.1	RP11-767N6.2	-3.25	0.00118	0.0495	-0.09	-0.1	Reticulocyte count;Red blood cell count;	chr1:46130196	chr1:45651039~45651826:-
BRCA	cis	rs2277027	1	rs3734030	ENSG00000253653.1	CTC-248O19.1	3.25	0.00118	0.0495	0.12	0.1	Pulmonary function;Pulmonary function (smoking interaction);	chr5:157512872	chr5:157260122~157266625:-
BRCA	cis	rs886774	0.773	rs7799327	ENSG00000273055.1	CTB-13F3.1	-3.25	0.00118	0.0495	-0.1	-0.1	Ulcerative colitis;	chr7:107912240	chr7:107942116~107942740:+
BRCA	cis	rs3735485	0.722	rs10271709	ENSG00000201772.1	SNORA5C	3.25	0.00118	0.0495	0.13	0.1	White blood cell count;Sum basophil neutrophil counts;Neutrophil count;Granulocyte percentage of myeloid white cells;Monocyte percentage of white cells;Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Lymphocyte counts;	chr7:45054481	chr7:45104906~45105042:-
BRCA	cis	rs17092148	0.836	rs6059910	ENSG00000250917.1	RP4-785G19.5	3.25	0.00118	0.0495	0.16	0.1	Neuroticism;	chr20:34554303	chr20:34234840~34281173:-
BRCA	cis	rs10492096	0.947	rs10849482	ENSG00000276718.1	RP1-102E24.10	-3.25	0.00118	0.0496	-0.13	-0.1	Hip geometry;	chr12:6526108	chr12:6466537~6467135:+
BRCA	cis	rs10492096	0.947	rs10849483	ENSG00000276718.1	RP1-102E24.10	-3.25	0.00118	0.0496	-0.13	-0.1	Hip geometry;	chr12:6526208	chr12:6466537~6467135:+
BRCA	cis	rs7267979	0.966	rs2482918	ENSG00000204556.4	CTD-2514C3.1	3.25	0.00118	0.0496	0.14	0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25431499	chr20:26018832~26020684:+
BRCA	cis	rs5742933	1	rs5743061	ENSG00000273240.1	RP11-455J20.3	3.25	0.00118	0.0496	0.14	0.1	Ferritin levels;	chr2:189829540	chr2:189763859~189764456:-
BRCA	cis	rs863345	0.604	rs1894040	ENSG00000176320.2	RP11-404O13.5	3.25	0.00118	0.0496	0.1	0.1	Pneumococcal bacteremia;	chr1:158486546	chr1:158197922~158203877:-
BRCA	cis	rs7894407	0.856	rs7093667	ENSG00000213061.2	PFN1P11	3.25	0.00118	0.0496	0.14	0.1	White matter hyperintensity burden;	chr10:103320818	chr10:102838011~102845473:-
BRCA	cis	rs35520189	0.885	rs6720230	ENSG00000231747.1	AC079922.2	-3.25	0.00118	0.0496	-0.11	-0.1	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:112872887	chr2:112621809~112622167:-
BRCA	cis	rs12900413	0.603	rs12906832	ENSG00000259212.1	CTD-3065B20.2	3.25	0.00118	0.0496	0.12	0.1	Coronary artery aneurysm in Kawasaki disease;	chr15:89758083	chr15:90595840~90596447:-
BRCA	cis	rs9287719	0.639	rs2357650	ENSG00000234818.1	AC092687.5	3.25	0.00118	0.0496	0.12	0.1	Prostate cancer;	chr2:10556751	chr2:10589166~10604830:+
BRCA	cis	rs4648045	0.861	rs3774937	ENSG00000246560.2	RP11-10L12.4	3.25	0.00118	0.0496	0.12	0.1	Lymphocyte percentage of white cells;	chr4:102513096	chr4:102828055~102844075:+
BRCA	cis	rs561341	0.882	rs2428337	ENSG00000277511.1	CTD-2095E4.5	3.25	0.00118	0.0496	0.15	0.1	Hip circumference adjusted for BMI;	chr17:31972448	chr17:32127595~32128454:+
BRCA	cis	rs3816183	0.585	rs10172447	ENSG00000226491.1	FTOP1	-3.25	0.00118	0.0496	-0.13	-0.1	Hypospadias;	chr2:42654585	chr2:42797225~42798712:-
BRCA	cis	rs6496932	1	rs12917495	ENSG00000218052.5	ADAMTS7P4	3.25	0.00118	0.0496	0.11	0.1	Central corneal thickness;Corneal structure;	chr15:85286330	chr15:85255369~85330334:-
BRCA	cis	rs10836699	0.635	rs1381154	ENSG00000280331.1	RP11-545D22.1	3.25	0.00118	0.0496	0.12	0.1	Low high density lipoprotein cholesterol levels;	chr11:37143107	chr11:36510361~36510537:+
BRCA	cis	rs2711721	0.535	rs1989911	ENSG00000274723.1	RP11-618L22.1	3.25	0.00118	0.0496	0.12	0.1	Prostate cancer (SNP x SNP interaction);	chr12:47008126	chr12:46970504~46972155:+
BRCA	cis	rs9325144	0.602	rs11169100	ENSG00000257718.1	RP11-396F22.1	-3.25	0.00118	0.0496	-0.11	-0.1	Morning vs. evening chronotype;	chr12:38684059	chr12:38906451~38909592:+
BRCA	cis	rs28530618	0.87	rs6058790	ENSG00000198547.7	C20orf203	-3.25	0.00118	0.0496	-0.11	-0.1	Birth weight;	chr20:32659515	chr20:32631652~32673941:-
BRCA	cis	rs721399	0.752	rs4921915	ENSG00000253671.1	RP11-806O11.1	-3.25	0.00118	0.0496	-0.13	-0.1	Blood metabolite levels;	chr8:18414956	chr8:17808941~17820868:+
BRCA	cis	rs7017914	0.934	rs35214141	ENSG00000246366.5	RP11-382J12.1	3.25	0.00118	0.0496	0.11	0.1	Bone mineral density;	chr8:70662329	chr8:70608577~70663279:+
BRCA	cis	rs7017914	0.934	rs10504479	ENSG00000246366.5	RP11-382J12.1	3.25	0.00118	0.0496	0.11	0.1	Bone mineral density;	chr8:70665280	chr8:70608577~70663279:+
BRCA	cis	rs7017914	0.934	rs35109143	ENSG00000246366.5	RP11-382J12.1	3.25	0.00118	0.0496	0.11	0.1	Bone mineral density;	chr8:70665665	chr8:70608577~70663279:+
BRCA	cis	rs7017914	0.902	rs13269513	ENSG00000246366.5	RP11-382J12.1	3.25	0.00118	0.0496	0.11	0.1	Bone mineral density;	chr8:70665844	chr8:70608577~70663279:+
BRCA	cis	rs6689306	0.87	rs4845371	ENSG00000201129.1	SNORA58	3.25	0.00118	0.0496	0.11	0.1	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:154435864	chr1:154259727~154259862:+
BRCA	cis	rs6689306	0.905	rs6667434	ENSG00000201129.1	SNORA58	3.25	0.00118	0.0496	0.11	0.1	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:154436624	chr1:154259727~154259862:+
BRCA	cis	rs80226907	0.901	rs79196946	ENSG00000258413.1	RP11-665C16.6	-3.25	0.00118	0.0496	-0.26	-0.1	Mean platelet volume;	chr14:55287844	chr14:55262767~55272075:-
BRCA	cis	rs3018712	0.532	rs4930587	ENSG00000251637.5	RP11-119D9.1	3.25	0.00118	0.0496	0.17	0.1	Total body bone mineral density;	chr11:68647667	chr11:67886477~67906350:+
BRCA	cis	rs6840360	0.571	rs2406976	ENSG00000278978.1	RP11-164P12.5	-3.25	0.00118	0.0496	-0.12	-0.1	Intelligence (multi-trait analysis);	chr4:151619904	chr4:151669786~151670503:+
BRCA	cis	rs6571943	0.818	rs11845726	ENSG00000258526.4	RP11-111A21.1	-3.25	0.00118	0.0496	-0.16	-0.1	Verbal memory performance (residualized delayed recall level);	chr14:39566690	chr14:39474840~39513780:+
BRCA	cis	rs11035577	0.57	rs4756526	ENSG00000279675.1	RP11-454H19.2	-3.25	0.00118	0.0496	-0.15	-0.1	Temperament (bipolar disorder);	chr11:39763086	chr11:40107244~40112599:-
BRCA	cis	rs11035577	0.57	rs7937923	ENSG00000279675.1	RP11-454H19.2	-3.25	0.00118	0.0496	-0.15	-0.1	Temperament (bipolar disorder);	chr11:39764096	chr11:40107244~40112599:-
BRCA	cis	rs11035577	0.632	rs7937930	ENSG00000279675.1	RP11-454H19.2	-3.25	0.00118	0.0496	-0.15	-0.1	Temperament (bipolar disorder);	chr11:39764113	chr11:40107244~40112599:-
BRCA	cis	rs11035577	0.632	rs7951186	ENSG00000279675.1	RP11-454H19.2	-3.25	0.00118	0.0496	-0.15	-0.1	Temperament (bipolar disorder);	chr11:39764120	chr11:40107244~40112599:-
BRCA	cis	rs11035577	0.632	rs7951603	ENSG00000279675.1	RP11-454H19.2	-3.25	0.00118	0.0496	-0.15	-0.1	Temperament (bipolar disorder);	chr11:39764158	chr11:40107244~40112599:-
BRCA	cis	rs11035577	0.632	rs7104293	ENSG00000279675.1	RP11-454H19.2	-3.25	0.00118	0.0496	-0.15	-0.1	Temperament (bipolar disorder);	chr11:39765108	chr11:40107244~40112599:-
BRCA	cis	rs11035577	0.516	rs7104076	ENSG00000279675.1	RP11-454H19.2	-3.25	0.00118	0.0496	-0.15	-0.1	Temperament (bipolar disorder);	chr11:39765158	chr11:40107244~40112599:-
BRCA	cis	rs11035577	0.57	rs7104559	ENSG00000279675.1	RP11-454H19.2	-3.25	0.00118	0.0496	-0.15	-0.1	Temperament (bipolar disorder);	chr11:39765302	chr11:40107244~40112599:-
BRCA	cis	rs17092148	0.887	rs4911430	ENSG00000250917.1	RP4-785G19.5	3.25	0.00118	0.0496	0.16	0.1	Neuroticism;	chr20:34557600	chr20:34234840~34281173:-
BRCA	cis	rs9372498	0.536	rs72954806	ENSG00000216809.1	RP11-57K17.1	-3.25	0.00118	0.0496	-0.14	-0.1	Diastolic blood pressure;	chr6:118578802	chr6:118452469~118454992:-
BRCA	cis	rs9372498	0.536	rs62663261	ENSG00000216809.1	RP11-57K17.1	-3.25	0.00118	0.0496	-0.14	-0.1	Diastolic blood pressure;	chr6:118579390	chr6:118452469~118454992:-
BRCA	cis	rs6142618	0.523	rs4911087	ENSG00000224452.1	RSL24D1P6	3.25	0.00118	0.0496	0.14	0.1	Inflammatory bowel disease;	chr20:32256733	chr20:32170390~32170790:-
BRCA	cis	rs9796	0.689	rs13329537	ENSG00000223313.1	RNU6-516P	-3.25	0.00118	0.0496	-0.11	-0.1	Menopause (age at onset);	chr15:41157013	chr15:40529570~40529673:+
BRCA	cis	rs8040855	0.599	rs4577058	ENSG00000230373.7	GOLGA6L5P	-3.25	0.00118	0.0496	-0.11	-0.1	Bulimia nervosa;	chr15:85183227	chr15:84507885~84516814:-
BRCA	cis	rs3755021	1	rs17224699	ENSG00000260742.1	RP11-366L5.1	3.25	0.00118	0.0496	0.14	0.1	Monocyte-lymphocyte ratio;	chr2:181483827	chr2:181887851~181891663:-
BRCA	cis	rs8040855	0.599	rs6496792	ENSG00000230373.7	GOLGA6L5P	-3.25	0.00118	0.0496	-0.11	-0.1	Bulimia nervosa;	chr15:85182514	chr15:84507885~84516814:-
BRCA	cis	rs8040855	0.599	rs6496793	ENSG00000230373.7	GOLGA6L5P	-3.25	0.00118	0.0496	-0.11	-0.1	Bulimia nervosa;	chr15:85182515	chr15:84507885~84516814:-
BRCA	cis	rs8040855	0.599	rs6496795	ENSG00000230373.7	GOLGA6L5P	-3.25	0.00118	0.0496	-0.11	-0.1	Bulimia nervosa;	chr15:85182622	chr15:84507885~84516814:-
BRCA	cis	rs9863	0.896	rs7307053	ENSG00000269938.1	RP11-214K3.20	3.25	0.00118	0.0496	0.11	0.1	White blood cell count;	chr12:124009993	chr12:123968023~123968579:-
BRCA	cis	rs4665809	0.838	rs2243834	ENSG00000231655.1	AC011742.3	-3.25	0.00118	0.0496	-0.14	-0.1	Gut microbiome composition (summer);	chr2:26134879	chr2:26140263~26141264:-
BRCA	cis	rs739496	0.501	rs441	ENSG00000234608.6	MAPKAPK5-AS1	3.25	0.00118	0.0496	0.13	0.1	Platelet count;	chr12:111791045	chr12:111839764~111842902:-
BRCA	cis	rs7264396	0.836	rs41293080	ENSG00000088340.14	FER1L4	-3.25	0.00118	0.0496	-0.12	-0.1	Total cholesterol levels;	chr20:35599775	chr20:35558737~35607562:-
BRCA	cis	rs801193	0.569	rs881285	ENSG00000223473.2	GS1-124K5.3	-3.25	0.00118	0.0496	-0.08	-0.1	Aortic root size;	chr7:66654433	chr7:66491049~66493566:-
BRCA	cis	rs7953704	1	rs28414202	ENSG00000212694.7	LINC01089	-3.25	0.00118	0.0496	-0.08	-0.1	Urate levels;	chr12:122106016	chr12:121795267~121803906:-
BRCA	cis	rs10988449	0.657	rs12335819	ENSG00000224988.1	RP11-409K20.7	3.25	0.00118	0.0496	0.14	0.1	Response to anti-depressant treatment in major depressive disorder;	chr9:129633037	chr9:129883693~129884170:-
BRCA	cis	rs79387448	0.745	rs17027341	ENSG00000234389.1	AC007278.3	3.25	0.00118	0.0496	0.13	0.1	Gut microbiota (bacterial taxa);	chr2:102520100	chr2:102438713~102440475:+
BRCA	cis	rs11679640	1	rs11682091	ENSG00000234362.4	AC104654.2	-3.25	0.00118	0.0496	-0.14	-0.1	White matter hyperintensity burden;	chr2:42917816	chr2:41931599~41933723:-
BRCA	cis	rs875971	1	rs778706	ENSG00000273448.1	RP11-166O4.6	3.25	0.00118	0.0496	0.09	0.1	Aortic root size;	chr7:66395437	chr7:67333047~67334383:+
BRCA	cis	rs7587205	0.823	rs2716712	ENSG00000231312.5	AC007246.3	-3.25	0.00118	0.0496	-0.11	-0.1	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);	chr2:39631393	chr2:39436637~39665343:+
BRCA	cis	rs1003719	0.751	rs7280371	ENSG00000242553.1	AP001432.14	-3.25	0.00118	0.0496	-0.11	-0.1	Eye color traits;	chr21:37077708	chr21:37221419~37237744:+
BRCA	cis	rs8028182	0.636	rs7495610	ENSG00000246877.1	DNM1P35	3.25	0.00118	0.0496	0.13	0.1	Sudden cardiac arrest;	chr15:75492100	chr15:75727670~75738623:-
BRCA	cis	rs965469	1	rs6037526	ENSG00000215063.3	RPL21P2	3.25	0.00118	0.0496	0.13	0.1	IFN-related cytopenia;	chr20:3270602	chr20:4059633~4060113:-
BRCA	cis	rs965469	1	rs6051702	ENSG00000215063.3	RPL21P2	3.25	0.00118	0.0496	0.13	0.1	IFN-related cytopenia;	chr20:3271278	chr20:4059633~4060113:-
BRCA	cis	rs2235682	0.816	rs713641	ENSG00000237668.1	RPS15AP38	-3.25	0.00118	0.0496	-0.11	-0.1	Airway responsiveness in chronic obstructive pulmonary disease;	chr22:36587914	chr22:36421273~36421644:-
BRCA	cis	rs74233809	1	rs12412038	ENSG00000236937.2	PTGES3P4	3.25	0.00119	0.0496	0.22	0.1	Birth weight;	chr10:103096405	chr10:102845595~102845950:+
BRCA	cis	rs947583	0.588	rs2208574	ENSG00000234084.1	RP3-388E23.2	-3.25	0.00119	0.0496	-0.1	-0.1	Phosphorus levels;	chr6:135754479	chr6:135301568~135307158:+
BRCA	cis	rs453301	0.686	rs1045527	ENSG00000254153.1	CTA-398F10.2	-3.25	0.00119	0.0496	-0.12	-0.1	Joint mobility (Beighton score);	chr8:9032531	chr8:8456909~8461337:-
BRCA	cis	rs4699052	1	rs4699052	ENSG00000246560.2	RP11-10L12.4	3.25	0.00119	0.0496	0.1	0.1	Testicular germ cell tumor;	chr4:103216633	chr4:102828055~102844075:+
BRCA	cis	rs6121246	0.559	rs6087782	ENSG00000230613.1	HM13-AS1	3.25	0.00119	0.0496	0.14	0.1	Mean corpuscular hemoglobin;	chr20:31803777	chr20:31567707~31573263:-
BRCA	cis	rs11673344	0.764	rs16971873	ENSG00000267682.1	CTD-3220F14.2	-3.25	0.00119	0.0496	-0.09	-0.1	Obesity-related traits;	chr19:36978521	chr19:37337236~37337743:+
BRCA	cis	rs997295	0.592	rs8026627	ENSG00000259673.4	IQCH-AS1	-3.25	0.00119	0.0496	-0.11	-0.1	Motion sickness;	chr15:67477968	chr15:67403619~67521844:-
BRCA	cis	rs3760982	0.585	rs8109478	ENSG00000266921.1	RP11-15A1.7	-3.25	0.00119	0.0496	-0.13	-0.1	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43794104	chr19:43996896~44002836:-
BRCA	cis	rs875971	0.862	rs28470208	ENSG00000164669.11	INTS4P1	3.25	0.00119	0.0496	0.13	0.1	Aortic root size;	chr7:66119713	chr7:65141225~65234216:+
BRCA	cis	rs962856	0.756	rs13016812	ENSG00000236605.1	AC023115.4	-3.25	0.00119	0.0496	-0.13	-0.1	Pancreatic cancer;	chr2:67397170	chr2:67324627~67325304:+
BRCA	cis	rs62458065	0.85	rs28693551	ENSG00000281332.1	LINC00997	-3.25	0.00119	0.0496	-0.15	-0.1	Metabolite levels (HVA/MHPG ratio);	chr7:32429775	chr7:32760279~32762924:+
BRCA	cis	rs7017914	0.934	rs17760050	ENSG00000246366.5	RP11-382J12.1	3.25	0.00119	0.0496	0.11	0.1	Bone mineral density;	chr8:70662016	chr8:70608577~70663279:+
BRCA	cis	rs4759375	1	rs9669295	ENSG00000235423.7	RP11-282O18.3	-3.25	0.00119	0.0496	-0.18	-0.1	HDL cholesterol;	chr12:123358123	chr12:123252030~123261483:-
BRCA	cis	rs1075232	1	rs16956838	ENSG00000254912.2	RP11-632K20.2	-3.25	0.00119	0.0496	-0.23	-0.1	Survival in colorectal cancer (non-distant metastatic);	chr15:31527492	chr15:32494003~32500346:-
BRCA	cis	rs2832191	0.791	rs2832199	ENSG00000232855.5	AF131217.1	3.25	0.00119	0.0497	0.12	0.1	Dental caries;	chr21:29126180	chr21:28439346~28674848:-
BRCA	cis	rs9325144	0.555	rs28738714	ENSG00000257718.1	RP11-396F22.1	-3.25	0.00119	0.0497	-0.1	-0.1	Morning vs. evening chronotype;	chr12:38313110	chr12:38906451~38909592:+
BRCA	cis	rs12701220	0.5	rs6463224	ENSG00000224079.1	AC091729.7	3.25	0.00119	0.0497	0.14	0.1	Bronchopulmonary dysplasia;	chr7:1100782	chr7:1074450~1078036:+
BRCA	cis	rs2795502	1	rs2795502	ENSG00000185904.10	LINC00839	-3.25	0.00119	0.0497	-0.15	-0.1	Blood protein levels;	chr10:42845214	chr10:42475543~42495336:+
BRCA	cis	rs2795502	1	rs2142991	ENSG00000185904.10	LINC00839	-3.25	0.00119	0.0497	-0.15	-0.1	Blood protein levels;	chr10:42845657	chr10:42475543~42495336:+
BRCA	cis	rs698833	0.509	rs12987415	ENSG00000223658.6	AC011242.6	3.25	0.00119	0.0497	0.13	0.1	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr2:44303284	chr2:43675380~43676322:-
BRCA	cis	rs73198271	0.595	rs11780672	ENSG00000233609.3	RP11-62H7.2	-3.25	0.00119	0.0497	-0.13	-0.1	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8726643	chr8:8961200~8979025:+
BRCA	cis	rs7520050	0.966	rs785488	ENSG00000234329.1	RP11-767N6.2	-3.25	0.00119	0.0497	-0.09	-0.1	Reticulocyte count;Red blood cell count;	chr1:46110423	chr1:45651039~45651826:-
BRCA	cis	rs7520050	0.966	rs785489	ENSG00000234329.1	RP11-767N6.2	-3.25	0.00119	0.0497	-0.09	-0.1	Reticulocyte count;Red blood cell count;	chr1:46110718	chr1:45651039~45651826:-
BRCA	cis	rs2235649	0.592	rs7197113	ENSG00000279520.1	RP11-20I23.2	-3.25	0.00119	0.0497	-0.11	-0.1	Blood metabolite levels;	chr16:1919482	chr16:2516658~2517999:+
BRCA	cis	rs6787172	0.811	rs6441204	ENSG00000272087.1	RP11-379F4.7	3.25	0.00119	0.0497	0.12	0.1	Subjective well-being;	chr3:158482424	chr3:158693120~158693768:-
BRCA	cis	rs6787172	0.755	rs6778202	ENSG00000272087.1	RP11-379F4.7	3.25	0.00119	0.0497	0.12	0.1	Subjective well-being;	chr3:158482786	chr3:158693120~158693768:-
BRCA	cis	rs1003719	0.788	rs9981226	ENSG00000242553.1	AP001432.14	-3.25	0.00119	0.0497	-0.11	-0.1	Eye color traits;	chr21:37079827	chr21:37221419~37237744:+
BRCA	cis	rs2688608	0.869	rs2250140	ENSG00000213731.2	RAB5CP1	-3.25	0.00119	0.0497	-0.11	-0.1	Inflammatory bowel disease;	chr10:73853123	chr10:74423435~74424014:-
BRCA	cis	rs11098499	0.909	rs79026312	ENSG00000225892.3	RP11-384K6.2	3.25	0.00119	0.0497	0.1	0.1	Corneal astigmatism;	chr4:119519522	chr4:118632274~118634759:+
BRCA	cis	rs11098499	0.909	rs35111518	ENSG00000225892.3	RP11-384K6.2	3.25	0.00119	0.0497	0.1	0.1	Corneal astigmatism;	chr4:119519527	chr4:118632274~118634759:+
BRCA	cis	rs2880765	0.835	rs900573	ENSG00000259630.2	CTD-2262B20.1	3.25	0.00119	0.0497	0.12	0.1	Coronary artery disease;	chr15:85494762	chr15:85415228~85415633:+
BRCA	cis	rs2562456	0.834	rs2173727	ENSG00000268705.1	BNIP3P26	-3.25	0.00119	0.0497	-0.11	-0.1	Pain;	chr19:21491155	chr19:21521343~21521896:-
BRCA	cis	rs8114671	0.628	rs6060130	ENSG00000261582.1	RP4-614O4.11	-3.25	0.00119	0.0497	-0.1	-0.1	Height;	chr20:34961516	chr20:35267885~35280043:-
BRCA	cis	rs8016982	0.662	rs9806020	ENSG00000258999.1	RP11-114N19.3	3.25	0.00119	0.0497	0.14	0.1	Schizophrenia;	chr14:81202211	chr14:81107033~81170414:-
BRCA	cis	rs875971	0.83	rs4718358	ENSG00000273024.4	INTS4P2	-3.25	0.00119	0.0497	-0.11	-0.1	Aortic root size;	chr7:66508681	chr7:65647864~65715661:+
BRCA	cis	rs4415084	0.688	rs11741772	ENSG00000272335.1	RP11-53O19.3	3.25	0.00119	0.0497	0.09	0.1	Breast cancer;	chr5:44814495	chr5:44826076~44828592:+
BRCA	cis	rs7188697	0.922	rs37055	ENSG00000276259.1	RP11-481J2.4	-3.25	0.00119	0.0497	-0.11	-0.1	QT interval;	chr16:58526871	chr16:58522970~58523842:+
BRCA	cis	rs4718428	0.705	rs4718422	ENSG00000229886.1	RP5-1132H15.3	3.25	0.00119	0.0497	0.12	0.1	Corneal structure;	chr7:66894282	chr7:66025126~66031544:-
BRCA	cis	rs17767294	0.614	rs116420641	ENSG00000272009.1	RP1-313I6.12	-3.25	0.00119	0.0497	-0.27	-0.1	Parkinson's disease;	chr6:28307681	chr6:28078792~28081130:-
BRCA	cis	rs17767294	0.614	rs78521938	ENSG00000272009.1	RP1-313I6.12	-3.25	0.00119	0.0497	-0.27	-0.1	Parkinson's disease;	chr6:28312046	chr6:28078792~28081130:-
BRCA	cis	rs17767294	0.614	rs72854521	ENSG00000272009.1	RP1-313I6.12	-3.25	0.00119	0.0497	-0.27	-0.1	Parkinson's disease;	chr6:28317021	chr6:28078792~28081130:-
BRCA	cis	rs6687758	0.687	rs12137323	ENSG00000227925.1	RP11-191N8.2	-3.25	0.00119	0.0497	-0.14	-0.1	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:221952186	chr1:221827666~221840666:-
BRCA	cis	rs7713317	0.925	rs13162665	ENSG00000236882.6	LINC01554	3.25	0.00119	0.0497	0.12	0.1	Body mass index;	chr5:96306815	chr5:95852232~95860133:+
BRCA	cis	rs801193	0.569	rs2659908	ENSG00000106610.13	STAG3L4	-3.25	0.00119	0.0497	-0.13	-0.1	Aortic root size;	chr7:66695835	chr7:67302621~67321526:+
BRCA	cis	rs10266483	0.843	rs667644	ENSG00000271550.1	BNIP3P11	3.25	0.00119	0.0497	0.13	0.1	Response to statin therapy;	chr7:64290180	chr7:64678954~64687393:-
BRCA	cis	rs2041840	0.813	rs4670690	ENSG00000272054.1	RP11-423P10.2	-3.25	0.00119	0.0497	-0.1	-0.1	Chronic lymphocytic leukemia;	chr2:37328425	chr2:37208875~37212677:+
BRCA	cis	rs7020830	0.861	rs13289001	ENSG00000260100.1	RP11-220I1.5	-3.25	0.00119	0.0497	-0.12	-0.1	Schizophrenia;	chr9:37311595	chr9:37078813~37079776:-
BRCA	cis	rs3739034	0.941	rs13399881	ENSG00000224043.6	CCNT2-AS1	-3.25	0.00119	0.0497	-0.16	-0.1	Gut microbiome composition (winter);	chr2:134727106	chr2:134735464~134918710:-
BRCA	cis	rs6792584	0.627	rs11920877	ENSG00000241316.5	SUCLG2-AS1	3.25	0.00119	0.0497	0.1	0.1	Corneal astigmatism;	chr3:67460154	chr3:67654697~67947713:+
BRCA	cis	rs6792584	0.627	rs11923553	ENSG00000241316.5	SUCLG2-AS1	3.25	0.00119	0.0497	0.1	0.1	Corneal astigmatism;	chr3:67460209	chr3:67654697~67947713:+
BRCA	cis	rs11115322	1	rs12580500	ENSG00000213270.5	RPL6P25	-3.25	0.00119	0.0497	-0.22	-0.1	Immune response to smallpox vaccine (IL-6);	chr12:82595978	chr12:83151331~83152190:+
BRCA	cis	rs1424638	0.614	rs10865298	ENSG00000233251.6	AC007743.1	-3.25	0.00119	0.0497	-0.12	-0.1	Intelligence (multi-trait analysis);	chr2:56992442	chr2:56173534~56185770:-
BRCA	cis	rs1056107	0.933	rs7866603	ENSG00000228623.3	ZNF883	-3.25	0.00119	0.0497	-0.12	-0.1	Colorectal cancer;	chr9:112202052	chr9:112997120~113050043:-
BRCA	cis	rs2625529	0.775	rs4777466	ENSG00000261187.1	RP11-1007O24.2	-3.25	0.00119	0.0497	-0.11	-0.1	Red blood cell count;	chr15:71844531	chr15:72465128~72466262:-
BRCA	cis	rs10501293	0.703	rs7937503	ENSG00000252652.1	Y_RNA	-3.25	0.00119	0.0497	-0.12	-0.1	Cognitive performance;	chr11:42987052	chr11:43331261~43331356:+
BRCA	cis	rs16940212	0.618	rs7497636	ENSG00000259771.1	RP11-429D19.1	-3.25	0.00119	0.0497	-0.17	-0.1	HDL cholesterol;HDL cholesterol levels;	chr15:58393432	chr15:59266720~59271162:-
BRCA	cis	rs1436904	0.901	rs1184360	ENSG00000260372.5	AQP4-AS1	-3.25	0.00119	0.0497	-0.11	-0.1	Breast cancer;	chr18:27010286	chr18:26655742~27190698:+
BRCA	cis	rs12545912	0.569	rs688245	ENSG00000253695.1	RP11-177H2.2	3.25	0.00119	0.0497	0.15	0.1	Multiple myeloma (hyperdiploidy);	chr8:9936136	chr8:10840576~10846501:+
BRCA	cis	rs35520189	0.591	rs11690185	ENSG00000274877.1	RP11-65I12.1	-3.25	0.00119	0.0497	-0.15	-0.1	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:112940559	chr2:113237595~113240825:+
BRCA	cis	rs1005277	0.557	rs1854563	ENSG00000276805.1	RP11-291L22.6	3.25	0.00119	0.0497	0.11	0.1	Extrinsic epigenetic age acceleration;	chr10:38146033	chr10:38451030~38451785:+
BRCA	cis	rs1005277	0.579	rs2505240	ENSG00000276805.1	RP11-291L22.6	3.25	0.00119	0.0497	0.11	0.1	Extrinsic epigenetic age acceleration;	chr10:38153491	chr10:38451030~38451785:+
BRCA	cis	rs7590268	0.666	rs6544655	ENSG00000279873.2	LINC01126	3.25	0.00119	0.0497	0.11	0.1	Orofacial clefts;	chr2:43407937	chr2:43227210~43228855:+
BRCA	cis	rs10411161	0.81	rs77082285	ENSG00000275055.1	CTC-471J1.11	-3.25	0.00119	0.0497	-0.19	-0.1	Breast cancer;	chr19:51884330	chr19:52049007~52049754:+
BRCA	cis	rs10129255	0.957	rs28887506	ENSG00000253132.1	IGHV3-62	-3.25	0.00119	0.0497	-0.08	-0.1	Kawasaki disease;	chr14:106785589	chr14:106643142~106643585:-
BRCA	cis	rs2832077	0.527	rs1048546	ENSG00000215533.7	LINC00189	3.25	0.00119	0.0497	0.12	0.1	Cognitive test performance;	chr21:28872555	chr21:29193480~29288205:+
BRCA	cis	rs4415084	1	rs12187196	ENSG00000248464.1	FGF10-AS1	3.25	0.00119	0.0497	0.11	0.1	Breast cancer;	chr5:44683717	chr5:44388732~44413989:+
BRCA	cis	rs2243480	1	rs57057549	ENSG00000237026.1	RP11-328P23.2	3.25	0.00119	0.0497	0.18	0.1	Diabetic kidney disease;	chr7:65940751	chr7:65235790~65236723:-
BRCA	cis	rs4557020	0.805	rs4640425	ENSG00000203327.2	AC012358.7	-3.25	0.00119	0.0497	-0.1	-0.1	Myopia (pathological);	chr2:54471221	chr2:55214387~55216126:-
BRCA	cis	rs2195987	0.668	rs4533408	ENSG00000268442.1	CTD-2027I19.2	3.25	0.00119	0.0497	0.15	0.1	Testicular germ cell tumor;	chr19:23971002	chr19:24162370~24163425:-
BRCA	cis	rs901683	1	rs71499567	ENSG00000230869.1	CTGLF10P	-3.25	0.00119	0.0497	-0.25	-0.1	Mean corpuscular volume;Red blood cell traits;	chr10:45588508	chr10:45678692~45700532:+
BRCA	cis	rs2150410	0.833	rs7283439	ENSG00000232608.1	TIMM9P2	-3.25	0.00119	0.0497	-0.21	-0.1	Temperament (bipolar disorder);	chr21:39273811	chr21:39216624~39217506:+
BRCA	cis	rs2638953	0.853	rs1355473	ENSG00000273989.1	RP11-425D17.2	-3.25	0.00119	0.0497	-0.15	-0.1	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28463632	chr12:28236227~28236828:+
BRCA	cis	rs2836974	0.644	rs9978775	ENSG00000238141.2	BRWD1-AS1	-3.25	0.00119	0.0497	-0.12	-0.1	Cognitive function;	chr21:39322600	chr21:39315707~39323218:+
BRCA	cis	rs495337	1	rs4287819	ENSG00000229222.1	KRT18P4	-3.25	0.00119	0.0497	-0.13	-0.1	Psoriasis;	chr20:49935419	chr20:49956745~49958032:+
BRCA	cis	rs4869313	0.846	rs2278019	ENSG00000248734.2	CTD-2260A17.1	3.25	0.00119	0.0497	0.1	0.1	Pediatric autoimmune diseases;	chr5:96889548	chr5:96784777~96785999:+
BRCA	cis	rs7617773	0.746	rs4371540	ENSG00000228350.1	CELSR3-AS1	3.25	0.00119	0.0497	0.14	0.1	Coronary artery disease;	chr3:48312053	chr3:48663776~48669174:+
BRCA	cis	rs61931739	0.5	rs7312938	ENSG00000258794.3	DUX4L27	3.25	0.00119	0.0497	0.14	0.1	Morning vs. evening chronotype;	chr12:34225773	chr12:34208415~34209675:-
BRCA	cis	rs13118159	0.55	rs1137789	ENSG00000211482.1	AC092574.1	3.25	0.00119	0.0497	0.13	0.1	Longevity;	chr4:1388010	chr4:409809~409915:+
BRCA	cis	rs848087	0.967	rs2764956	ENSG00000200385.1	SNORA42	3.25	0.00119	0.0497	0.09	0.1	Breast cancer;	chr14:36780671	chr14:37720425~37720561:+
BRCA	cis	rs9368481	0.678	rs62402024	ENSG00000224843.5	LINC00240	-3.25	0.00119	0.0497	-0.12	-0.1	Autism spectrum disorder or schizophrenia;	chr6:26956197	chr6:26956992~27023924:+
BRCA	cis	rs35000415	0.938	rs17338998	ENSG00000275106.1	RP11-309L24.10	-3.25	0.00119	0.0497	-0.22	-0.1	Systemic lupus erythematosus;	chr7:128978505	chr7:128952527~128953316:-
BRCA	cis	rs853679	0.824	rs34712084	ENSG00000216676.2	RP1-15D7.1	-3.25	0.00119	0.0498	-0.18	-0.1	Depression;	chr6:28076050	chr6:27652602~27652825:-
BRCA	cis	rs853679	0.824	rs1321505	ENSG00000216676.2	RP1-15D7.1	-3.25	0.00119	0.0498	-0.18	-0.1	Depression;	chr6:28085045	chr6:27652602~27652825:-
BRCA	cis	rs7267979	0.899	rs2179459	ENSG00000277938.1	RP5-965G21.3	3.25	0.00119	0.0498	0.12	0.1	Liver enzyme levels (alkaline phosphatase);	chr20:25475505	chr20:25229150~25231933:+
BRCA	cis	rs763121	0.853	rs138716	ENSG00000228274.3	RP3-508I15.9	-3.25	0.00119	0.0498	-0.12	-0.1	Menopause (age at onset);	chr22:38750522	chr22:38667585~38681820:-
BRCA	cis	rs4820539	1	rs756631	ENSG00000211647.1	IGLV5-48	-3.25	0.00119	0.0498	-0.08	-0.1	Bone mineral density;	chr22:23120996	chr22:22352940~22353433:+
BRCA	cis	rs3745567	1	rs11569521	ENSG00000276980.1	CTD-3128G10.7	3.25	0.00119	0.0498	0.17	0.1	Complement C3 and C4 levels;	chr19:6689476	chr19:6716386~6717742:-
BRCA	cis	rs3745567	1	rs11569520	ENSG00000276980.1	CTD-3128G10.7	3.25	0.00119	0.0498	0.17	0.1	Complement C3 and C4 levels;	chr19:6689496	chr19:6716386~6717742:-
BRCA	cis	rs3745567	1	rs11569519	ENSG00000276980.1	CTD-3128G10.7	3.25	0.00119	0.0498	0.17	0.1	Complement C3 and C4 levels;	chr19:6689843	chr19:6716386~6717742:-
BRCA	cis	rs9951698	0.618	rs472992	ENSG00000266969.1	RP11-773H22.4	3.25	0.00119	0.0498	0.13	0.1	Intelligence (multi-trait analysis);	chr18:13087790	chr18:12984694~12991173:-
BRCA	cis	rs1443512	0.812	rs2044210	ENSG00000274817.1	HOTAIR_4	-3.25	0.00119	0.0498	-0.11	-0.1	Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-hip ratio;Waist-to-hip ratio adjusted for body mass index;	chr12:53941749	chr12:53968002~53968178:+
BRCA	cis	rs7927592	0.871	rs113020558	ENSG00000254610.1	RP5-903G2.2	-3.25	0.00119	0.0498	-0.14	-0.1	Total body bone mineral density;	chr11:68529364	chr11:67934563~67939774:-
BRCA	cis	rs2638953	0.924	rs10843170	ENSG00000273989.1	RP11-425D17.2	-3.25	0.00119	0.0498	-0.15	-0.1	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28430118	chr12:28236227~28236828:+
BRCA	cis	rs2400749	0.66	rs12889313	ENSG00000258521.1	RP11-638I2.9	-3.25	0.00119	0.0498	-0.1	-0.1	Alzheimer's disease (survival time);	chr14:99554734	chr14:100339832~100340554:+
BRCA	cis	rs875971	1	rs4718307	ENSG00000230189.5	GS1-124K5.2	-3.25	0.00119	0.0498	-0.08	-0.1	Aortic root size;	chr7:66146001	chr7:66409143~66490059:-
BRCA	cis	rs875971	1	rs7801282	ENSG00000230189.5	GS1-124K5.2	-3.25	0.00119	0.0498	-0.08	-0.1	Aortic root size;	chr7:66148700	chr7:66409143~66490059:-
BRCA	cis	rs1730008	0.865	rs698986	ENSG00000279311.1	RP11-170K4.2	-3.25	0.00119	0.0498	-0.11	-0.1	Lobe attachment (rater-scored or self-reported);	chr3:158216066	chr3:158869898~158871821:+
BRCA	cis	rs1730008	0.865	rs699924	ENSG00000279311.1	RP11-170K4.2	-3.25	0.00119	0.0498	-0.11	-0.1	Lobe attachment (rater-scored or self-reported);	chr3:158218439	chr3:158869898~158871821:+
BRCA	cis	rs1730008	0.865	rs698980	ENSG00000279311.1	RP11-170K4.2	-3.25	0.00119	0.0498	-0.11	-0.1	Lobe attachment (rater-scored or self-reported);	chr3:158219583	chr3:158869898~158871821:+
BRCA	cis	rs11858159	1	rs12900285	ENSG00000207279.1	SNORD116-24	-3.25	0.00119	0.0498	-0.1	-0.1	Platelet thrombus formation;	chr15:24572506	chr15:25094037~25094128:+
BRCA	cis	rs7403037	0.509	rs7402599	ENSG00000207279.1	SNORD116-24	-3.25	0.00119	0.0498	-0.1	-0.1	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr15:24572787	chr15:25094037~25094128:+
BRCA	cis	rs11858159	1	rs7402269	ENSG00000207279.1	SNORD116-24	-3.25	0.00119	0.0498	-0.1	-0.1	Platelet thrombus formation;	chr15:24573014	chr15:25094037~25094128:+
BRCA	cis	rs11858159	1	rs7402480	ENSG00000207279.1	SNORD116-24	-3.25	0.00119	0.0498	-0.1	-0.1	Platelet thrombus formation;	chr15:24573269	chr15:25094037~25094128:+
BRCA	cis	rs11858159	1	rs7402588	ENSG00000207279.1	SNORD116-24	-3.25	0.00119	0.0498	-0.1	-0.1	Platelet thrombus formation;	chr15:24573298	chr15:25094037~25094128:+
BRCA	cis	rs6120849	0.95	rs6088732	ENSG00000202150.1	RNU6-407P	-3.25	0.00119	0.0498	-0.13	-0.1	Protein C levels;	chr20:35156331	chr20:35030317~35030420:-
BRCA	cis	rs3816183	0.585	rs12712856	ENSG00000226491.1	FTOP1	-3.25	0.00119	0.0498	-0.12	-0.1	Hypospadias;	chr2:42641533	chr2:42797225~42798712:-
BRCA	cis	rs10043775	0.831	rs4705252	ENSG00000251330.3	CTD-2283N19.1	-3.25	0.00119	0.0498	-0.12	-0.1	Periodontal microbiota;	chr5:148381722	chr5:148430159~148430807:-
BRCA	cis	rs9467773	0.62	rs2494716	ENSG00000261353.1	CTA-14H9.5	-3.25	0.00119	0.0498	-0.1	-0.1	Intelligence (multi-trait analysis);	chr6:26662508	chr6:26527063~26527404:+
BRCA	cis	rs4578769	0.722	rs5013130	ENSG00000265939.1	UBE2CP2	-3.25	0.00119	0.0498	-0.13	-0.1	Eosinophil percentage of white cells;	chr18:22945388	chr18:22900486~22900995:-
BRCA	cis	rs13136331	0.84	rs13113106	ENSG00000249001.4	RP11-742B18.1	-3.25	0.00119	0.0498	-0.14	-0.1	Sitting height ratio;	chr4:87782857	chr4:87568035~87733956:-
BRCA	cis	rs736408	0.774	rs4687551	ENSG00000242142.1	SERBP1P3	-3.25	0.00119	0.0498	-0.12	-0.1	Bipolar disorder;	chr3:52789432	chr3:53064283~53065091:-
BRCA	cis	rs7617773	0.925	rs7374376	ENSG00000228350.1	CELSR3-AS1	-3.25	0.00119	0.0498	-0.12	-0.1	Coronary artery disease;	chr3:48131197	chr3:48663776~48669174:+
BRCA	cis	rs897984	0.542	rs8061047	ENSG00000262766.1	RP11-196G11.4	3.25	0.00119	0.0498	0.08	0.1	Dementia with Lewy bodies;	chr16:31057639	chr16:31118078~31118747:+
BRCA	cis	rs9527	0.59	rs1541213	ENSG00000269609.4	RPARP-AS1	-3.25	0.00119	0.0498	-0.1	-0.1	Arsenic metabolism;	chr10:103125573	chr10:102449817~102461106:+
BRCA	cis	rs9527	0.59	rs10883836	ENSG00000269609.4	RPARP-AS1	-3.25	0.00119	0.0498	-0.1	-0.1	Arsenic metabolism;	chr10:103131441	chr10:102449817~102461106:+
BRCA	cis	rs9527	0.59	rs11191572	ENSG00000269609.4	RPARP-AS1	-3.25	0.00119	0.0498	-0.1	-0.1	Arsenic metabolism;	chr10:103133380	chr10:102449817~102461106:+
BRCA	cis	rs9527	0.59	rs12415199	ENSG00000269609.4	RPARP-AS1	-3.25	0.00119	0.0498	-0.1	-0.1	Arsenic metabolism;	chr10:103135779	chr10:102449817~102461106:+
BRCA	cis	rs9527	0.59	rs34104646	ENSG00000269609.4	RPARP-AS1	-3.25	0.00119	0.0498	-0.1	-0.1	Arsenic metabolism;	chr10:103136321	chr10:102449817~102461106:+
BRCA	cis	rs9527	0.567	rs11191573	ENSG00000269609.4	RPARP-AS1	-3.25	0.00119	0.0498	-0.1	-0.1	Arsenic metabolism;	chr10:103137059	chr10:102449817~102461106:+
BRCA	cis	rs10484434	0.818	rs11756400	ENSG00000272810.1	U91328.22	3.25	0.00119	0.0498	0.14	0.1	HIV-1 viral setpoint;	chr6:26040625	chr6:26013241~26013757:+
BRCA	cis	rs7917772	0.636	rs10786708	ENSG00000236937.2	PTGES3P4	-3.25	0.00119	0.0498	-0.14	-0.1	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;	chr10:102766488	chr10:102845595~102845950:+
BRCA	cis	rs586688	0.625	rs602668	ENSG00000243323.4	PTPRVP	3.25	0.00119	0.0498	0.11	0.1	Obesity-related traits;	chr1:201688581	chr1:202168051~202189455:+
BRCA	cis	rs10905065	0.965	rs2244755	ENSG00000215267.7	AKR1C7P	3.25	0.00119	0.0498	0.13	0.1	Menopause (age at onset);	chr10:5712648	chr10:5275173~5288470:-
BRCA	cis	rs11159086	0.938	rs11623040	ENSG00000258524.1	NT5CP1	-3.25	0.00119	0.0498	-0.17	-0.1	Advanced glycation end-product levels;	chr14:74496743	chr14:73571159~73571667:-
BRCA	cis	rs613391	0.671	rs594958	ENSG00000265194.1	RP11-70L8.4	-3.25	0.00119	0.0498	-0.1	-0.1	Quantitative traits;	chr9:22714080	chr9:21858910~21861926:-
BRCA	cis	rs9527	0.59	rs2281877	ENSG00000269609.4	RPARP-AS1	-3.25	0.00119	0.0498	-0.1	-0.1	Arsenic metabolism;	chr10:103106305	chr10:102449817~102461106:+
BRCA	cis	rs11673344	0.808	rs57916401	ENSG00000267422.1	CTD-2554C21.1	3.25	0.00119	0.0498	0.13	0.1	Obesity-related traits;	chr19:37153149	chr19:37779686~37792865:+
BRCA	cis	rs72627509	0.638	rs1608165	ENSG00000245067.5	IGFBP7-AS1	-3.25	0.00119	0.0498	-0.17	-0.1	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:57028551	chr4:57109762~57205510:+
BRCA	cis	rs6912958	0.703	rs6903219	ENSG00000272008.1	RP11-393I2.4	-3.25	0.00119	0.0498	-0.11	-0.1	Monocyte percentage of white cells;	chr6:87386780	chr6:87151159~87155285:-
BRCA	cis	rs2880765	0.835	rs7163958	ENSG00000259630.2	CTD-2262B20.1	-3.25	0.00119	0.0498	-0.12	-0.1	Coronary artery disease;	chr15:85501984	chr15:85415228~85415633:+
BRCA	cis	rs2832077	0.527	rs11088095	ENSG00000215533.7	LINC00189	3.25	0.00119	0.0498	0.12	0.1	Cognitive test performance;	chr21:28850866	chr21:29193480~29288205:+
BRCA	cis	rs2832077	0.527	rs2142375	ENSG00000215533.7	LINC00189	3.25	0.00119	0.0498	0.12	0.1	Cognitive test performance;	chr21:28851420	chr21:29193480~29288205:+
BRCA	cis	rs7474896	1	rs61858625	ENSG00000120555.12	SEPT7P9	3.25	0.00119	0.0498	0.19	0.1	Obesity (extreme);	chr10:37713114	chr10:38383069~38402916:-
BRCA	cis	rs9422860	0.562	rs12782166	ENSG00000199466.1	Y_RNA	-3.25	0.00119	0.0498	-0.17	-0.1	3-hydroxypropylmercapturic acid levels in smokers;	chr10:125365014	chr10:124766196~124766297:+
BRCA	cis	rs9856151	1	rs9816797	ENSG00000261167.1	RP11-517B11.7	3.25	0.00119	0.0498	0.12	0.1	Body mass index;	chr3:131895751	chr3:131455126~131458598:-
BRCA	cis	rs3816183	0.626	rs4952910	ENSG00000226491.1	FTOP1	-3.25	0.00119	0.0498	-0.12	-0.1	Hypospadias;	chr2:42685377	chr2:42797225~42798712:-
BRCA	cis	rs6785206	0.73	rs9861429	ENSG00000242551.2	POU5F1P6	-3.25	0.00119	0.0498	-0.19	-0.1	Lymphocyte percentage of white cells;	chr3:128706906	chr3:128674735~128677005:-
BRCA	cis	rs889956	0.747	rs1594144	ENSG00000233251.6	AC007743.1	-3.25	0.00119	0.0498	-0.12	-0.1	Educational attainment;	chr2:57027246	chr2:56173534~56185770:-
BRCA	cis	rs1538970	0.924	rs7528573	ENSG00000281133.1	AL355480.3	-3.25	0.00119	0.0498	-0.14	-0.1	Platelet count;	chr1:45448188	chr1:45580892~45580996:-
BRCA	cis	rs1555133	0.625	rs6141671	ENSG00000277692.1	RP11-358N2.2	-3.25	0.00119	0.0498	-0.11	-0.1	Monocyte count;	chr20:32317768	chr20:32355053~32355734:+
BRCA	cis	rs4243971	0.516	rs4911216	ENSG00000277692.1	RP11-358N2.2	-3.25	0.00119	0.0498	-0.11	-0.1	Inflammatory bowel disease;Crohn's disease;	chr20:32322107	chr20:32355053~32355734:+
BRCA	cis	rs4243971	0.516	rs4911217	ENSG00000277692.1	RP11-358N2.2	-3.25	0.00119	0.0498	-0.11	-0.1	Inflammatory bowel disease;Crohn's disease;	chr20:32322148	chr20:32355053~32355734:+
BRCA	cis	rs4243971	0.516	rs56012551	ENSG00000277692.1	RP11-358N2.2	-3.25	0.00119	0.0498	-0.11	-0.1	Inflammatory bowel disease;Crohn's disease;	chr20:32323312	chr20:32355053~32355734:+
BRCA	cis	rs4243971	0.516	rs56366536	ENSG00000277692.1	RP11-358N2.2	-3.25	0.00119	0.0498	-0.11	-0.1	Inflammatory bowel disease;Crohn's disease;	chr20:32323462	chr20:32355053~32355734:+
BRCA	cis	rs1555133	0.624	rs55647947	ENSG00000277692.1	RP11-358N2.2	-3.25	0.00119	0.0498	-0.11	-0.1	Monocyte count;	chr20:32323583	chr20:32355053~32355734:+
BRCA	cis	rs4243971	0.516	rs13043343	ENSG00000277692.1	RP11-358N2.2	-3.25	0.00119	0.0498	-0.11	-0.1	Inflammatory bowel disease;Crohn's disease;	chr20:32324404	chr20:32355053~32355734:+
BRCA	cis	rs4243971	0.516	rs2024952	ENSG00000277692.1	RP11-358N2.2	-3.25	0.00119	0.0498	-0.11	-0.1	Inflammatory bowel disease;Crohn's disease;	chr20:32326149	chr20:32355053~32355734:+
BRCA	cis	rs4243971	0.516	rs3746606	ENSG00000277692.1	RP11-358N2.2	-3.25	0.00119	0.0498	-0.11	-0.1	Inflammatory bowel disease;Crohn's disease;	chr20:32326903	chr20:32355053~32355734:+
BRCA	cis	rs2357982	0.507	rs59174355	ENSG00000227403.1	AC009299.3	-3.25	0.00119	0.0498	-0.17	-0.1	Presence of antiphospholipid antibodies;	chr2:161023627	chr2:161244739~161249050:+
BRCA	cis	rs1555133	0.625	rs6141297	ENSG00000277692.1	RP11-358N2.2	-3.25	0.00119	0.0498	-0.11	-0.1	Monocyte count;	chr20:32375694	chr20:32355053~32355734:+
BRCA	cis	rs7246967	0.673	rs56209802	ENSG00000198153.8	ZNF849P	-3.25	0.00119	0.0498	-0.17	-0.1	Bronchopulmonary dysplasia;	chr19:22842750	chr19:22685167~22686732:+
BRCA	cis	rs3770752	0.897	rs2041836	ENSG00000272054.1	RP11-423P10.2	-3.25	0.00119	0.0498	-0.09	-0.1	Schizophrenia;	chr2:37281990	chr2:37208875~37212677:+
BRCA	cis	rs7917772	0.636	rs4919676	ENSG00000236937.2	PTGES3P4	3.25	0.00119	0.0499	0.14	0.1	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;	chr10:102764595	chr10:102845595~102845950:+
BRCA	cis	rs7917772	0.636	rs7894154	ENSG00000236937.2	PTGES3P4	3.25	0.00119	0.0499	0.14	0.1	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;	chr10:102764890	chr10:102845595~102845950:+
BRCA	cis	rs7917772	0.636	rs4418737	ENSG00000236937.2	PTGES3P4	3.25	0.00119	0.0499	0.14	0.1	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;	chr10:102765366	chr10:102845595~102845950:+
BRCA	cis	rs1454934	0.915	rs35826324	ENSG00000276115.1	RP11-817I4.2	-3.25	0.00119	0.0499	-0.16	-0.1	Prevalent atrial fibrillation;	chr12:32799977	chr12:32352349~32354144:+
BRCA	cis	rs1133146	0.532	rs12460704	ENSG00000269001.1	ZNF818P	3.25	0.00119	0.0499	0.13	0.1	Yu-Zhi constitution type in type 2 diabetes;	chr19:53172468	chr19:53212988~53213396:+
BRCA	cis	rs2191566	0.54	rs391267	ENSG00000266921.1	RP11-15A1.7	3.25	0.00119	0.0499	0.13	0.1	Acute lymphoblastic leukemia (childhood);	chr19:43988335	chr19:43996896~44002836:-
BRCA	cis	rs2031532	0.544	rs2407691	ENSG00000236577.1	SNRPGP14	3.25	0.00119	0.0499	0.12	0.1	Cardiac hypertrophy;	chr13:49463820	chr13:49488970~49489364:+
BRCA	cis	rs2400749	0.634	rs12888297	ENSG00000258521.1	RP11-638I2.9	-3.25	0.00119	0.0499	-0.1	-0.1	Alzheimer's disease (survival time);	chr14:99552970	chr14:100339832~100340554:+
BRCA	cis	rs6881634	0.501	rs11950060	ENSG00000253558.1	CTD-2179L22.1	3.25	0.00119	0.0499	0.12	0.1	Hippocampal atrophy;	chr5:78423392	chr5:78041879~78044138:-
BRCA	cis	rs13126694	0.744	rs10027000	ENSG00000251073.1	NUDT19P5	3.25	0.00119	0.0499	0.09	0.1	Blood osmolality (transformed sodium);	chr4:158053401	chr4:158182825~158183393:+
BRCA	cis	rs2638953	0.853	rs11614463	ENSG00000273989.1	RP11-425D17.2	-3.25	0.00119	0.0499	-0.15	-0.1	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28467278	chr12:28236227~28236828:+
BRCA	cis	rs2638953	0.853	rs10843183	ENSG00000273989.1	RP11-425D17.2	-3.25	0.00119	0.0499	-0.15	-0.1	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28467775	chr12:28236227~28236828:+
BRCA	cis	rs2638953	0.853	rs11494781	ENSG00000273989.1	RP11-425D17.2	-3.25	0.00119	0.0499	-0.15	-0.1	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28469166	chr12:28236227~28236828:+
BRCA	cis	rs2638953	0.853	rs11049638	ENSG00000273989.1	RP11-425D17.2	-3.25	0.00119	0.0499	-0.15	-0.1	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28469687	chr12:28236227~28236828:+
BRCA	cis	rs2638953	0.853	rs11049639	ENSG00000273989.1	RP11-425D17.2	-3.25	0.00119	0.0499	-0.15	-0.1	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28469868	chr12:28236227~28236828:+
BRCA	cis	rs4819052	1	rs733738	ENSG00000223768.1	LINC00205	3.25	0.00119	0.0499	0.14	0.1	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45246481	chr21:45293285~45297354:+
BRCA	cis	rs3820068	0.581	rs6666373	ENSG00000237301.1	RP4-680D5.2	-3.25	0.00119	0.0499	-0.13	-0.1	Systolic blood pressure;	chr1:15613389	chr1:15586136~15603626:-
BRCA	cis	rs1275411	0.511	rs4902683	ENSG00000259062.2	ACTN1-AS1	3.25	0.00119	0.0499	0.11	0.1	Neuroticism;	chr14:68976131	chr14:68979682~68987463:+
BRCA	cis	rs7426380	0.505	rs1346781	ENSG00000272606.1	RP11-554J4.1	3.25	0.00119	0.0499	0.11	0.1	Intraocular pressure;	chr2:55809941	chr2:55617909~55618373:+
BRCA	cis	rs863345	0.625	rs11264978	ENSG00000229914.1	RP11-404O13.4	-3.25	0.00119	0.0499	-0.11	-0.1	Pneumococcal bacteremia;	chr1:158478131	chr1:158195633~158196131:-
BRCA	cis	rs7781557	0.938	rs73192015	ENSG00000239969.4	RP11-163E9.2	-3.25	0.00119	0.0499	-0.15	-0.1	Colorectal adenoma (advanced);	chr7:102871285	chr7:102364162~102380633:+
BRCA	cis	rs10198628	0.967	rs10192149	ENSG00000264370.1	MIR3125	-3.25	0.00119	0.0499	-0.11	-0.1	Pericardial fat;Pericardial adipose tissue adjusted for height and weight;	chr2:12822552	chr2:12737367~12737444:+
BRCA	cis	rs111342015	0.772	rs77818628	ENSG00000272170.1	RP11-387M24.5	3.25	0.00119	0.0499	0.23	0.1	Breast cancer;	chr6:43193395	chr6:43074331~43074739:-
BRCA	cis	rs12282928	0.959	rs11039631	ENSG00000255197.4	RP11-750H9.5	3.25	0.00119	0.0499	0.09	0.1	Migraine - clinic-based;	chr11:48275510	chr11:47383148~47409190:-
BRCA	cis	rs6754311	0.861	rs12475139	ENSG00000231890.6	DARS-AS1	-3.25	0.00119	0.0499	-0.13	-0.1	Mosquito bite size;	chr2:136029081	chr2:135985176~136022593:+
BRCA	cis	rs962856	0.575	rs3770655	ENSG00000236780.4	AC078941.1	3.25	0.00119	0.0499	0.14	0.1	Pancreatic cancer;	chr2:67404993	chr2:67123357~67215319:-
BRCA	cis	rs2338971	0.571	rs263913	ENSG00000260940.1	RP4-575N6.5	3.25	0.00119	0.0499	0.14	0.1	Parkinson's disease;	chr1:101510772	chr1:101243158~101243749:+
BRCA	cis	rs7260598	0.502	rs6511585	ENSG00000269662.1	BNIP3P39	-3.25	0.00119	0.0499	-0.16	-0.1	Response to taxane treatment (placlitaxel);	chr19:23820470	chr19:23798924~23799477:-
BRCA	cis	rs4665809	1	rs10202478	ENSG00000231655.1	AC011742.3	3.25	0.00119	0.0499	0.15	0.1	Gut microbiome composition (summer);	chr2:26053180	chr2:26140263~26141264:-
BRCA	cis	rs4665809	1	rs7588802	ENSG00000231655.1	AC011742.3	3.25	0.00119	0.0499	0.15	0.1	Gut microbiome composition (summer);	chr2:26054920	chr2:26140263~26141264:-
BRCA	cis	rs9372498	0.536	rs72952793	ENSG00000216809.1	RP11-57K17.1	-3.25	0.00119	0.0499	-0.14	-0.1	Diastolic blood pressure;	chr6:118571816	chr6:118452469~118454992:-
BRCA	cis	rs703108	0.871	rs3011644	ENSG00000279623.1	RP11-399C16.3	-3.25	0.00119	0.0499	-0.15	-0.1	Monocyte percentage of white cells;	chr10:22109066	chr10:21865335~21865921:-
BRCA	cis	rs7789940	0.951	rs7779014	ENSG00000231087.2	FDPSP7	-3.25	0.00119	0.0499	-0.13	-0.1	Multiple sclerosis;	chr7:76346269	chr7:76968197~76969250:-
BRCA	cis	rs7944735	0.508	rs2869531	ENSG00000243802.2	RP11-390K5.1	3.25	0.00119	0.0499	0.15	0.1	Intraocular pressure;	chr11:47775850	chr11:47191181~47191542:-
BRCA	cis	rs801193	0.844	rs732465	ENSG00000229886.1	RP5-1132H15.3	3.25	0.00119	0.0499	0.11	0.1	Aortic root size;	chr7:66533463	chr7:66025126~66031544:-
BRCA	cis	rs12141041	0.653	rs7540738	ENSG00000261662.1	RP5-1042I8.7	3.25	0.00119	0.0499	0.12	0.1	Blood metabolite levels;	chr1:119435080	chr1:119909255~119910613:-
BRCA	cis	rs6445975	0.666	rs6773099	ENSG00000272182.1	RP11-802O23.3	3.25	0.00119	0.0499	0.12	0.1	Systemic lupus erythematosus;	chr3:58417725	chr3:58428255~58428815:+
BRCA	cis	rs6445975	0.578	rs6772652	ENSG00000272182.1	RP11-802O23.3	3.25	0.00119	0.0499	0.12	0.1	Systemic lupus erythematosus;	chr3:58420966	chr3:58428255~58428815:+
BRCA	cis	rs6445975	0.578	rs6782218	ENSG00000272182.1	RP11-802O23.3	3.25	0.00119	0.0499	0.12	0.1	Systemic lupus erythematosus;	chr3:58423038	chr3:58428255~58428815:+
BRCA	cis	rs6445975	0.572	rs12485999	ENSG00000272182.1	RP11-802O23.3	3.25	0.00119	0.0499	0.12	0.1	Systemic lupus erythematosus;	chr3:58424036	chr3:58428255~58428815:+
BRCA	cis	rs13118159	0.55	rs2878607	ENSG00000211482.1	AC092574.1	3.25	0.00119	0.0499	0.13	0.1	Longevity;	chr4:1359522	chr4:409809~409915:+
BRCA	cis	rs7837791	0.647	rs4571722	ENSG00000242970.2	AC068522.4	-3.25	0.00119	0.0499	-0.13	-0.1	Refractive error;	chr8:59251621	chr8:58588420~58588764:-
BRCA	cis	rs1003719	0.762	rs9975361	ENSG00000242553.1	AP001432.14	-3.25	0.00119	0.0499	-0.11	-0.1	Eye color traits;	chr21:37077725	chr21:37221419~37237744:+
BRCA	cis	rs17684571	0.872	rs13198938	ENSG00000231441.1	RP11-472M19.2	3.25	0.00119	0.0499	0.16	0.1	Schizophrenia;	chr6:56733628	chr6:56844002~56864078:+
BRCA	cis	rs7172809	0.643	rs4243046	ENSG00000260139.5	CSPG4P13	-3.25	0.00119	0.0499	-0.11	-0.1	Glucose homeostasis traits;	chr15:77542404	chr15:77894684~77904674:+
BRCA	cis	rs2153535	0.518	rs9328485	ENSG00000251164.1	HULC	-3.25	0.00119	0.0499	-0.12	-0.1	Motion sickness;	chr6:8524831	chr6:8652137~8653846:+
BRCA	cis	rs12999542	0.5	rs13001301	ENSG00000234389.1	AC007278.3	3.25	0.00119	0.0499	0.16	0.1	Serum protein levels (sST2);	chr2:102322538	chr2:102438713~102440475:+
BRCA	cis	rs12999542	0.5	rs17695648	ENSG00000234389.1	AC007278.3	3.25	0.00119	0.0499	0.16	0.1	Serum protein levels (sST2);	chr2:102331721	chr2:102438713~102440475:+
BRCA	cis	rs818427	0.737	rs1661035	ENSG00000279522.1	CTC-487M23.6	-3.25	0.00119	0.0499	-0.11	-0.1	Total body bone mineral density;	chr5:112716131	chr5:112894933~112896531:+
BRCA	cis	rs1949733	0.656	rs2688224	ENSG00000250471.2	GMPSP1	3.25	0.00119	0.0499	0.1	0.1	Response to antineoplastic agents;	chr4:8402973	chr4:8174421~8174999:+
BRCA	cis	rs11686241	0.935	rs909330	ENSG00000232485.2	AC098820.3	3.25	0.00119	0.0499	0.14	0.1	Cancer;	chr2:216480367	chr2:216479030~216498761:-
BRCA	cis	rs6452790	0.627	rs6452772	ENSG00000247828.6	TMEM161B-AS1	-3.25	0.00119	0.0499	-0.13	-0.1	Cognitive function;	chr5:88105536	chr5:88268895~88436685:+
BRCA	cis	rs1730008	0.731	rs11715599	ENSG00000279311.1	RP11-170K4.2	3.25	0.00119	0.0499	0.13	0.1	Lobe attachment (rater-scored or self-reported);	chr3:158181769	chr3:158869898~158871821:+
BRCA	cis	rs9324022	0.858	rs1004572	ENSG00000271198.1	VDAC3P1	-3.25	0.00119	0.0499	-0.17	-0.1	Plateletcrit;	chr14:100711993	chr14:99964529~99965378:+
BRCA	cis	rs897984	0.568	rs8063565	ENSG00000280211.1	RP11-2C24.3	-3.25	0.00119	0.0499	-0.11	-0.1	Dementia with Lewy bodies;	chr16:30872644	chr16:30773532~30776033:-
BRCA	cis	rs897984	0.52	rs12928081	ENSG00000280211.1	RP11-2C24.3	-3.25	0.00119	0.0499	-0.11	-0.1	Dementia with Lewy bodies;	chr16:30873838	chr16:30773532~30776033:-
BRCA	cis	rs2163813	1	rs2013561	ENSG00000275540.1	CTC-559E9.12	-3.25	0.00119	0.0499	-0.14	-0.1	Toenail selenium levels;	chr19:19715368	chr19:19740884~19750127:+
BRCA	cis	rs2163813	1	rs36006965	ENSG00000275540.1	CTC-559E9.12	-3.25	0.00119	0.0499	-0.14	-0.1	Toenail selenium levels;	chr19:19719242	chr19:19740884~19750127:+
BRCA	cis	rs2163813	1	rs12982273	ENSG00000275540.1	CTC-559E9.12	-3.25	0.00119	0.0499	-0.14	-0.1	Toenail selenium levels;	chr19:19719335	chr19:19740884~19750127:+
BRCA	cis	rs4415084	0.716	rs13154781	ENSG00000272335.1	RP11-53O19.3	3.25	0.00119	0.0499	0.1	0.1	Breast cancer;	chr5:44774925	chr5:44826076~44828592:+
BRCA	cis	rs17221829	0.521	rs2118022	ENSG00000280385.1	AP000648.5	-3.25	0.00119	0.0499	-0.11	-0.1	Anxiety in major depressive disorder;	chr11:89582965	chr11:90193614~90198120:+
BRCA	cis	rs848490	0.889	rs55641721	ENSG00000214293.7	APTR	3.25	0.00119	0.0499	0.13	0.1	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77559584	chr7:77657660~77696265:-
BRCA	cis	rs2243480	0.908	rs313822	ENSG00000229180.5	GS1-124K5.11	3.25	0.00119	0.0499	0.14	0.1	Diabetic kidney disease;	chr7:66108952	chr7:66526088~66542624:-
BRCA	cis	rs9880772	0.747	rs9817112	ENSG00000272282.1	RP11-222K16.2	-3.25	0.00119	0.0499	-0.08	-0.1	Chronic lymphocytic leukemia;B-cell malignancies (chronic lymphocytic leukemia, Hodgkin lymphoma or multiple myeloma) (pleiotropy);	chr3:27786242	chr3:27712910~27714005:+
BRCA	cis	rs17192198	0.661	rs17191974	ENSG00000258302.2	RP11-981P6.1	-3.25	0.00119	0.05	-0.12	-0.1	Diastolic blood pressure;	chr12:89655590	chr12:89561129~89594878:+
BRCA	cis	rs7200543	1	rs16966947	ENSG00000270580.4	PKD1P6	3.25	0.00119	0.05	0.11	0.1	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15047188	chr16:15104723~15131601:-
BRCA	cis	rs12435908	1	rs10083488	ENSG00000276116.2	FUT8-AS1	-3.25	0.0012	0.05	-0.15	-0.1	Ischemic stroke;	chr14:65386628	chr14:65411170~65412690:-
BRCA	cis	rs4326844	0.903	rs10876550	ENSG00000249388.1	RP11-834C11.6	-3.25	0.0012	0.05	-0.13	-0.1	Platelet count;	chr12:54318524	chr12:54082118~54102693:+
BRCA	cis	rs7923452	0.507	rs215494	ENSG00000224473.1	CCND3P1	3.25	0.0012	0.05	0.13	0.1	Itch intensity from mosquito bite;	chr10:30487660	chr10:30403197~30403776:-
BRCA	cis	rs17767294	0.708	rs72847332	ENSG00000219392.1	RP1-265C24.5	-3.25	0.0012	0.05	-0.27	-0.1	Parkinson's disease;	chr6:27805998	chr6:28115628~28116551:+
BRCA	cis	rs17767294	0.708	rs72847355	ENSG00000219392.1	RP1-265C24.5	-3.25	0.0012	0.05	-0.27	-0.1	Parkinson's disease;	chr6:27857398	chr6:28115628~28116551:+
BRCA	cis	rs17767294	0.708	rs72847356	ENSG00000219392.1	RP1-265C24.5	-3.25	0.0012	0.05	-0.27	-0.1	Parkinson's disease;	chr6:27857816	chr6:28115628~28116551:+
BRCA	cis	rs2688608	0.592	rs10762560	ENSG00000242288.9	RP11-464F9.1	3.25	0.0012	0.05	0.12	0.1	Inflammatory bowel disease;	chr10:73735647	chr10:73674295~73730466:-
BRCA	cis	rs875971	0.895	rs7788984	ENSG00000273024.4	INTS4P2	-3.25	0.0012	0.05	-0.11	-0.1	Aortic root size;	chr7:66450629	chr7:65647864~65715661:+
BRCA	cis	rs354225	0.554	rs10166844	ENSG00000240401.7	AC012358.8	-3.25	0.0012	0.05	-0.14	-0.1	Schizophrenia;	chr2:54571135	chr2:55282350~55346049:+
BRCA	cis	rs7953704	1	rs10744335	ENSG00000212694.7	LINC01089	3.25	0.0012	0.05	0.08	0.1	Urate levels;	chr12:122127599	chr12:121795267~121803906:-
BRCA	cis	rs17550532	1	rs17550532	ENSG00000260310.1	RP11-27M24.2	3.25	0.0012	0.05	0.14	0.1	Sudden cardiac arrest;	chr16:9650238	chr16:10576499~10578183:-
BRCA	cis	rs2736345	0.788	rs2618476	ENSG00000154316.13	TDH	-3.25	0.0012	0.05	-0.14	-0.1	Systemic lupus erythematosus;Sjögren's syndrome;	chr8:11495032	chr8:11339637~11368452:+
BRCA	cis	rs10760158	0.865	rs10760165	ENSG00000235865.2	GSN-AS1	3.25	0.0012	0.05	0.09	0.1	Pulse pressure;	chr9:121258976	chr9:121280768~121285530:-
BRCA	cis	rs1979679	0.65	rs3963302	ENSG00000256056.1	RP11-709A23.2	3.25	0.0012	0.05	0.16	0.1	Ossification of the posterior longitudinal ligament of the spine;	chr12:28367813	chr12:27592461~27594039:-
BRCA	cis	rs6121246	0.512	rs6058384	ENSG00000230613.1	HM13-AS1	3.25	0.0012	0.05	0.14	0.1	Mean corpuscular hemoglobin;	chr20:31688606	chr20:31567707~31573263:-
BRCA	cis	rs4713118	0.629	rs203888	ENSG00000226314.6	ZNF192P1	-3.25	0.0012	0.05	-0.15	-0.1	Parkinson's disease;	chr6:28053811	chr6:28161781~28169594:+
BRCA	cis	rs8026198	0.929	rs2289295	ENSG00000246740.2	PLA2G4E-AS1	3.25	0.0012	0.05	0.16	0.1	Fibrinogen levels;	chr15:42345577	chr15:41972763~41999094:+
BRCA	cis	rs6696239	0.513	rs3010191	ENSG00000227711.2	RP11-275O4.5	3.25	0.0012	0.05	0.12	0.1	Height;	chr1:227615460	chr1:227509028~227520477:-
BRCA	cis	rs2638953	0.853	rs1355474	ENSG00000273989.1	RP11-425D17.2	-3.25	0.0012	0.05	-0.15	-0.1	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28463599	chr12:28236227~28236828:+
BRCA	cis	rs6545883	0.868	rs2427885	ENSG00000273302.1	RP11-493E12.2	3.25	0.0012	0.05	0.09	0.1	Tuberculosis;	chr2:61589642	chr2:61199979~61200769:+
BRCA	cis	rs10876993	0.928	rs1689595	ENSG00000270039.1	RP11-571M6.17	3.25	0.0012	0.05	0.13	0.1	Celiac disease or Rheumatoid arthritis;	chr12:57662980	chr12:57803838~57804415:+
BRCA	cis	rs76206723	1	rs17171703	ENSG00000233225.3	AC004987.9	-3.25	0.0012	0.05	-0.18	-0.1	Pulse pressure;	chr7:40376718	chr7:39833571~39834718:+
BRCA	cis	rs7712401	0.791	rs3822367	ENSG00000263432.2	RN7SL689P	-3.25	0.0012	0.05	-0.12	-0.1	Mean platelet volume;	chr5:122810577	chr5:123022487~123022783:-
BRCA	cis	rs7927592	0.913	rs10896329	ENSG00000254610.1	RP5-903G2.2	-3.25	0.0012	0.05	-0.14	-0.1	Total body bone mineral density;	chr11:68482561	chr11:67934563~67939774:-
BRCA	cis	rs875971	1	rs2077593	ENSG00000273448.1	RP11-166O4.6	3.25	0.0012	0.05	0.09	0.1	Aortic root size;	chr7:66427543	chr7:67333047~67334383:+
BRCA	cis	rs10129255	0.784	rs7147210	ENSG00000211967.3	IGHV3-53	-3.25	0.0012	0.05	-0.08	-0.1	Kawasaki disease;	chr14:106705271	chr14:106592676~106593347:-
BRCA	cis	rs7695732	0.913	rs7668636	ENSG00000270720.1	RP11-84C13.2	3.25	0.0012	0.05	0.12	0.1	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr4:88898156	chr4:89119284~89119871:+
BRCA	cis	rs4650994	0.593	rs16853043	ENSG00000273384.1	RP5-1098D14.1	-3.25	0.0012	0.05	-0.13	-0.1	HDL cholesterol;HDL cholesterol levels;	chr1:178576791	chr1:178651706~178652282:+
BRCA	cis	rs7811142	0.83	rs3087502	ENSG00000214313.7	AZGP1P1	-3.25	0.0012	0.05	-0.13	-0.1	Platelet count;	chr7:100357741	chr7:99980762~99987535:+
BRCA	cis	rs7811142	0.83	rs61735533	ENSG00000214313.7	AZGP1P1	-3.25	0.0012	0.05	-0.13	-0.1	Platelet count;	chr7:100358243	chr7:99980762~99987535:+
BRCA	trans	rs7949030	0.626	rs1061093	ENSG00000186676.3	EEF1GP1	48.39	9.1e-269	2.09e-260	1.14	0.83	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62567436	chr7:125033453~125035301:+
BRCA	trans	rs7949030	0.626	rs11231144	ENSG00000186676.3	EEF1GP1	47.95	6.78e-266	1.53e-257	1.12	0.83	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62560566	chr7:125033453~125035301:+
BRCA	trans	rs1816752	0.905	rs9511264	ENSG00000237917.1	PARP4P1	-47.52	4.35e-263	9.76e-255	-1.01	-0.83	Obesity-related traits;	chr13:24438079	chrY:26594851~26634652:-
BRCA	trans	rs7949030	0.626	rs11231141	ENSG00000186676.3	EEF1GP1	47.51	4.64e-263	1.03e-254	1.12	0.83	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62558793	chr7:125033453~125035301:+
BRCA	trans	rs7949030	0.626	rs7943191	ENSG00000186676.3	EEF1GP1	47.44	1.49e-262	3.3e-254	1.12	0.83	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62561079	chr7:125033453~125035301:+
BRCA	trans	rs6477998	0.58	rs9299214	ENSG00000238072.1	RP11-305M3.2	47.03	6.43e-260	1.41e-251	1.12	0.82	Hematology traits;	chr9:113273416	chr7:129410113~129410370:-
BRCA	trans	rs1816752	0.817	rs7985394	ENSG00000237917.1	PARP4P1	46.42	6.61e-256	1.42e-247	1.02	0.82	Obesity-related traits;	chr13:24438714	chrY:26594851~26634652:-
BRCA	trans	rs1816752	0.789	rs7986037	ENSG00000237917.1	PARP4P1	46.42	6.61e-256	1.42e-247	1.02	0.82	Obesity-related traits;	chr13:24438715	chrY:26594851~26634652:-
BRCA	trans	rs1816752	0.87	rs7320102	ENSG00000237917.1	PARP4P1	46.15	4.28e-254	9.07e-246	1.01	0.82	Obesity-related traits;	chr13:24437435	chrY:26594851~26634652:-
BRCA	trans	rs1816752	0.905	rs9511266	ENSG00000237917.1	PARP4P1	46.15	4.29e-254	9.07e-246	1.02	0.82	Obesity-related traits;	chr13:24438366	chrY:26594851~26634652:-
BRCA	trans	rs1816752	0.87	rs3825449	ENSG00000237917.1	PARP4P1	46.14	5.02e-254	1.01e-245	1.02	0.82	Obesity-related traits;	chr13:24440303	chrY:26594851~26634652:-
BRCA	trans	rs1816752	0.87	rs7998797	ENSG00000237917.1	PARP4P1	46.14	5.02e-254	1.01e-245	1.02	0.82	Obesity-related traits;	chr13:24440850	chrY:26594851~26634652:-
BRCA	trans	rs1816752	0.87	rs7981337	ENSG00000237917.1	PARP4P1	46.14	5.02e-254	1.01e-245	1.02	0.82	Obesity-related traits;	chr13:24440915	chrY:26594851~26634652:-
BRCA	trans	rs1816752	0.87	rs7981480	ENSG00000237917.1	PARP4P1	46.14	5.02e-254	1.01e-245	1.02	0.82	Obesity-related traits;	chr13:24440966	chrY:26594851~26634652:-
BRCA	trans	rs1816752	0.837	rs4769355	ENSG00000237917.1	PARP4P1	46.14	5.02e-254	1.01e-245	1.02	0.82	Obesity-related traits;	chr13:24441059	chrY:26594851~26634652:-
BRCA	trans	rs1816752	0.905	rs4770680	ENSG00000237917.1	PARP4P1	46.14	5.02e-254	1.01e-245	1.02	0.82	Obesity-related traits;	chr13:24441110	chrY:26594851~26634652:-
BRCA	trans	rs1816752	0.905	rs7995909	ENSG00000237917.1	PARP4P1	46.13	5.52e-254	1.07e-245	1.02	0.82	Obesity-related traits;	chr13:24439159	chrY:26594851~26634652:-
BRCA	trans	rs1816752	0.905	rs6490927	ENSG00000237917.1	PARP4P1	46.13	5.52e-254	1.07e-245	1.02	0.82	Obesity-related traits;	chr13:24439802	chrY:26594851~26634652:-
BRCA	trans	rs1816752	0.905	rs6490928	ENSG00000237917.1	PARP4P1	46.13	5.52e-254	1.07e-245	1.02	0.82	Obesity-related traits;	chr13:24439921	chrY:26594851~26634652:-
BRCA	trans	rs1816752	0.905	rs6490929	ENSG00000237917.1	PARP4P1	46.13	5.52e-254	1.07e-245	1.02	0.82	Obesity-related traits;	chr13:24440114	chrY:26594851~26634652:-
BRCA	trans	rs1816752	0.905	rs7339140	ENSG00000237917.1	PARP4P1	46.12	6.08e-254	1.17e-245	1.01	0.82	Obesity-related traits;	chr13:24437764	chrY:26594851~26634652:-
BRCA	trans	rs928391	0.681	rs12145743	ENSG00000227183.3	HDGFP1	46.08	1.2e-253	2.27e-245	1.1	0.82	Platelet count;	chr1:156730859	chrX:131646639~131646890:+
BRCA	trans	rs1816752	0.87	rs9511261	ENSG00000237917.1	PARP4P1	45.93	1.15e-252	2.17e-244	1.01	0.82	Obesity-related traits;	chr13:24437880	chrY:26594851~26634652:-
BRCA	trans	rs1816752	0.905	rs9511262	ENSG00000237917.1	PARP4P1	45.93	1.15e-252	2.17e-244	1.01	0.82	Obesity-related traits;	chr13:24437885	chrY:26594851~26634652:-
BRCA	trans	rs1816752	0.774	rs55888616	ENSG00000237917.1	PARP4P1	45.82	5.8e-252	1.08e-243	1.02	0.82	Obesity-related traits;	chr13:24441954	chrY:26594851~26634652:-
BRCA	trans	rs1816752	0.905	rs11839006	ENSG00000237917.1	PARP4P1	45.78	1.16e-251	2.14e-243	1.03	0.82	Obesity-related traits;	chr13:24435893	chrY:26594851~26634652:-
BRCA	trans	rs1816752	0.805	rs61614647	ENSG00000237917.1	PARP4P1	45.77	1.29e-251	2.38e-243	1.02	0.82	Obesity-related traits;	chr13:24441829	chrY:26594851~26634652:-
BRCA	trans	rs7949030	0.626	rs11231145	ENSG00000186676.3	EEF1GP1	45.64	9.91e-251	1.81e-242	1.12	0.82	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62561382	chr7:125033453~125035301:+
BRCA	trans	rs7949030	0.626	rs7930896	ENSG00000186676.3	EEF1GP1	45.59	1.96e-250	3.54e-242	1.1	0.82	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62557800	chr7:125033453~125035301:+
BRCA	trans	rs1816752	0.905	rs9511260	ENSG00000237917.1	PARP4P1	45.58	2.19e-250	3.94e-242	1.02	0.82	Obesity-related traits;	chr13:24437038	chrY:26594851~26634652:-
BRCA	trans	rs1816752	0.87	rs2033955	ENSG00000237917.1	PARP4P1	45.53	5.18e-250	9.22e-242	1.02	0.82	Obesity-related traits;	chr13:24436406	chrY:26594851~26634652:-
BRCA	trans	rs7949030	0.626	rs72927213	ENSG00000186676.3	EEF1GP1	45.5	8.02e-250	1.41e-241	1.13	0.82	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62583726	chr7:125033453~125035301:+
BRCA	trans	rs1816752	0.87	rs2033954	ENSG00000237917.1	PARP4P1	45.43	2.14e-249	3.73e-241	1.02	0.82	Obesity-related traits;	chr13:24436429	chrY:26594851~26634652:-
BRCA	trans	rs7949030	0.626	rs71490390	ENSG00000186676.3	EEF1GP1	45.41	3.07e-249	5.31e-241	1.12	0.82	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62561713	chr7:125033453~125035301:+
BRCA	trans	rs7949030	0.626	rs7124057	ENSG00000186676.3	EEF1GP1	45.3	1.66e-248	2.84e-240	1.13	0.81	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62566624	chr7:125033453~125035301:+
BRCA	trans	rs7949030	0.626	rs11231154	ENSG00000186676.3	EEF1GP1	45.14	2e-247	3.4e-239	1.13	0.81	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62594821	chr7:125033453~125035301:+
BRCA	trans	rs1816752	0.713	rs7336357	ENSG00000237917.1	PARP4P1	45.13	2.25e-247	3.8e-239	1.02	0.81	Obesity-related traits;	chr13:24443452	chrY:26594851~26634652:-
BRCA	trans	rs1816752	0.683	rs7330532	ENSG00000237917.1	PARP4P1	45.13	2.25e-247	3.8e-239	1.02	0.81	Obesity-related traits;	chr13:24443453	chrY:26594851~26634652:-
BRCA	trans	rs6477998	0.603	rs10117451	ENSG00000238072.1	RP11-305M3.2	45.09	4.21e-247	7.07e-239	1.11	0.81	Hematology traits;	chr9:113273610	chr7:129410113~129410370:-
BRCA	trans	rs1816752	0.712	rs6490932	ENSG00000237917.1	PARP4P1	45.08	4.93e-247	8.25e-239	1.02	0.81	Obesity-related traits;	chr13:24443313	chrY:26594851~26634652:-
BRCA	trans	rs1816752	0.87	rs8000215	ENSG00000237917.1	PARP4P1	45.04	8.54e-247	1.42e-238	1.03	0.81	Obesity-related traits;	chr13:24435648	chrY:26594851~26634652:-
BRCA	trans	rs1816752	0.776	rs7998843	ENSG00000237917.1	PARP4P1	44.91	6.98e-246	1.15e-237	1.02	0.81	Obesity-related traits;	chr13:24443147	chrY:26594851~26634652:-
BRCA	trans	rs1816752	0.905	rs1050112	ENSG00000237917.1	PARP4P1	44.89	8.69e-246	1.43e-237	1.02	0.81	Obesity-related traits;	chr13:24435159	chrY:26594851~26634652:-
BRCA	trans	rs1816752	0.746	rs9511270	ENSG00000237917.1	PARP4P1	44.88	1.01e-245	1.65e-237	1.03	0.81	Obesity-related traits;	chr13:24444542	chrY:26594851~26634652:-
BRCA	trans	rs1816752	0.806	rs3816218	ENSG00000237917.1	PARP4P1	44.87	1.2e-245	1.92e-237	1.02	0.81	Obesity-related traits;	chr13:24443033	chrY:26594851~26634652:-
BRCA	trans	rs1816752	0.666	rs7994022	ENSG00000237917.1	PARP4P1	44.87	1.2e-245	1.92e-237	1.02	0.81	Obesity-related traits;	chr13:24443092	chrY:26594851~26634652:-
BRCA	trans	rs1816752	0.59	rs61947036	ENSG00000237917.1	PARP4P1	44.87	1.2e-245	1.92e-237	1.02	0.81	Obesity-related traits;	chr13:24443544	chrY:26594851~26634652:-
BRCA	trans	rs1816752	0.905	rs13428	ENSG00000237917.1	PARP4P1	44.87	1.21e-245	1.93e-237	1.02	0.81	Obesity-related traits;	chr13:24435303	chrY:26594851~26634652:-
BRCA	trans	rs1816752	0.905	rs7995492	ENSG00000237917.1	PARP4P1	44.51	3.22e-243	5.13e-235	1.01	0.81	Obesity-related traits;	chr13:24438885	chrY:26594851~26634652:-
BRCA	trans	rs13177918	0.629	rs13161261	ENSG00000213058.3	RP4-765C7.2	44.46	6.05e-243	9.6e-235	1.17	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442844	chr1:178411616~178411972:+
BRCA	trans	rs13177918	0.677	rs3857421	ENSG00000213058.3	RP4-765C7.2	-44.46	6.89e-243	1.09e-234	-1.17	-0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443584	chr1:178411616~178411972:+
BRCA	trans	rs13177918	0.677	rs4541646	ENSG00000213058.3	RP4-765C7.2	44.44	8.32e-243	1.3e-234	1.17	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443355	chr1:178411616~178411972:+
BRCA	trans	rs13177918	0.677	rs3900644	ENSG00000213058.3	RP4-765C7.2	44.44	8.32e-243	1.3e-234	1.17	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443359	chr1:178411616~178411972:+
BRCA	trans	rs13177918	0.677	rs13161099	ENSG00000213058.3	RP4-765C7.2	44.4	1.63e-242	2.44e-234	1.17	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442799	chr1:178411616~178411972:+
BRCA	trans	rs13177918	0.677	rs13161417	ENSG00000213058.3	RP4-765C7.2	44.4	1.63e-242	2.44e-234	1.17	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442937	chr1:178411616~178411972:+
BRCA	trans	rs13177918	0.677	rs13161156	ENSG00000213058.3	RP4-765C7.2	44.4	1.63e-242	2.44e-234	1.17	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443023	chr1:178411616~178411972:+
BRCA	trans	rs13177918	0.677	rs13181401	ENSG00000213058.3	RP4-765C7.2	44.4	1.63e-242	2.44e-234	1.17	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443033	chr1:178411616~178411972:+
BRCA	trans	rs13177918	0.677	rs2070844	ENSG00000213058.3	RP4-765C7.2	44.4	1.63e-242	2.44e-234	1.17	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444222	chr1:178411616~178411972:+
BRCA	trans	rs13177918	0.629	rs2070842	ENSG00000213058.3	RP4-765C7.2	44.4	1.63e-242	2.44e-234	1.17	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444660	chr1:178411616~178411972:+
BRCA	trans	rs7949030	0.591	rs35156678	ENSG00000186676.3	EEF1GP1	44.27	1.28e-241	1.91e-233	1.13	0.81	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62602409	chr7:125033453~125035301:+
BRCA	trans	rs7949030	0.591	rs11231156	ENSG00000186676.3	EEF1GP1	44.22	2.64e-241	3.91e-233	1.13	0.81	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62598982	chr7:125033453~125035301:+
BRCA	trans	rs7949030	0.591	rs12049914	ENSG00000186676.3	EEF1GP1	44.15	7.18e-241	1.05e-232	1.13	0.81	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62601964	chr7:125033453~125035301:+
BRCA	trans	rs7949030	0.596	rs71490394	ENSG00000186676.3	EEF1GP1	44.15	7.18e-241	1.05e-232	1.13	0.81	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62602683	chr7:125033453~125035301:+
BRCA	trans	rs1816752	0.875	rs1050110	ENSG00000237917.1	PARP4P1	44.02	5.6e-240	8.16e-232	1.02	0.81	Obesity-related traits;	chr13:24435347	chrY:26594851~26634652:-
BRCA	trans	rs7949030	0.688	rs11231155	ENSG00000186676.3	EEF1GP1	43.41	6.49e-236	9.38e-228	1.1	0.8	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62598147	chr7:125033453~125035301:+
BRCA	trans	rs941207	0.724	rs4788	ENSG00000121089.4	NACA3P	42.99	4.33e-233	6.17e-225	1.04	0.8	Platelet count;	chr12:56712876	chr4:164943290~164943937:+
BRCA	trans	rs7949030	0.59	rs12225213	ENSG00000186676.3	EEF1GP1	42.82	6.64e-232	9.37e-224	1.13	0.8	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62582776	chr7:125033453~125035301:+
BRCA	trans	rs1816752	0.905	rs7400631	ENSG00000237917.1	PARP4P1	42.7	4.35e-231	6.12e-223	1	0.8	Obesity-related traits;	chr13:24415927	chrY:26594851~26634652:-
BRCA	trans	rs1816752	0.905	rs8002215	ENSG00000237917.1	PARP4P1	42.68	5.75e-231	8.06e-223	1	0.8	Obesity-related traits;	chr13:24416229	chrY:26594851~26634652:-
BRCA	trans	rs1816752	0.905	rs4770666	ENSG00000237917.1	PARP4P1	42.53	5.64e-230	7.88e-222	1	0.8	Obesity-related traits;	chr13:24414891	chrY:26594851~26634652:-
BRCA	trans	rs7949030	0.591	rs35880596	ENSG00000186676.3	EEF1GP1	42.42	3.04e-229	4.19e-221	1.13	0.8	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62602412	chr7:125033453~125035301:+
BRCA	trans	rs13177918	0.677	rs3857421	ENSG00000224114.1	RP11-343H5.4	-42.11	4.19e-227	5.71e-219	-1.17	-0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443584	chr1:206695837~206696269:-
BRCA	trans	rs6477998	0.58	rs7027833	ENSG00000238072.1	RP11-305M3.2	42.03	1.3e-226	1.77e-218	1.07	0.79	Hematology traits;	chr9:113301377	chr7:129410113~129410370:-
BRCA	trans	rs6477998	0.58	rs11552582	ENSG00000238072.1	RP11-305M3.2	41.94	6.13e-226	8.27e-218	1.08	0.79	Hematology traits;	chr9:113282718	chr7:129410113~129410370:-
BRCA	trans	rs1816752	0.905	rs7317850	ENSG00000237917.1	PARP4P1	41.82	3.66e-225	4.92e-217	1	0.79	Obesity-related traits;	chr13:24419899	chrY:26594851~26634652:-
BRCA	trans	rs13177918	0.557	rs12520101	ENSG00000213058.3	RP4-765C7.2	41.72	1.9e-224	2.54e-216	1.17	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150431360	chr1:178411616~178411972:+
BRCA	trans	rs6477998	0.58	rs2296073	ENSG00000238072.1	RP11-305M3.2	41.68	3.31e-224	4.4e-216	1.05	0.79	Hematology traits;	chr9:113299348	chr7:129410113~129410370:-
BRCA	trans	rs1816752	0.905	rs9511242	ENSG00000237917.1	PARP4P1	41.63	7.48e-224	9.9e-216	0.99	0.79	Obesity-related traits;	chr13:24419261	chrY:26594851~26634652:-
BRCA	trans	rs13177918	0.677	rs4541646	ENSG00000224114.1	RP11-343H5.4	41.61	9.74e-224	1.28e-215	1.17	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443355	chr1:206695837~206696269:-
BRCA	trans	rs13177918	0.677	rs3900644	ENSG00000224114.1	RP11-343H5.4	41.61	9.74e-224	1.28e-215	1.17	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443359	chr1:206695837~206696269:-
BRCA	trans	rs13177918	0.677	rs13161099	ENSG00000224114.1	RP11-343H5.4	41.59	1.34e-223	1.69e-215	1.17	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442799	chr1:206695837~206696269:-
BRCA	trans	rs13177918	0.677	rs13161417	ENSG00000224114.1	RP11-343H5.4	41.59	1.34e-223	1.69e-215	1.17	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442937	chr1:206695837~206696269:-
BRCA	trans	rs13177918	0.677	rs13161156	ENSG00000224114.1	RP11-343H5.4	41.59	1.34e-223	1.69e-215	1.17	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443023	chr1:206695837~206696269:-
BRCA	trans	rs13177918	0.677	rs13181401	ENSG00000224114.1	RP11-343H5.4	41.59	1.34e-223	1.69e-215	1.17	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443033	chr1:206695837~206696269:-
BRCA	trans	rs13177918	0.677	rs2070844	ENSG00000224114.1	RP11-343H5.4	41.59	1.34e-223	1.69e-215	1.17	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444222	chr1:206695837~206696269:-
BRCA	trans	rs13177918	0.629	rs2070842	ENSG00000224114.1	RP11-343H5.4	41.59	1.34e-223	1.69e-215	1.17	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444660	chr1:206695837~206696269:-
BRCA	trans	rs1816752	1	rs9511265	ENSG00000237917.1	PARP4P1	41.55	2.68e-223	3.38e-215	0.99	0.79	Obesity-related traits;	chr13:24438221	chrY:26594851~26634652:-
BRCA	trans	rs13177918	0.629	rs13161261	ENSG00000224114.1	RP11-343H5.4	41.54	2.91e-223	3.65e-215	1.17	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442844	chr1:206695837~206696269:-
BRCA	trans	rs6477998	0.58	rs10759638	ENSG00000238072.1	RP11-305M3.2	-41.43	1.79e-222	2.22e-214	-1.06	-0.79	Hematology traits;	chr9:113280212	chr7:129410113~129410370:-
BRCA	trans	rs1816752	1	rs7988810	ENSG00000237917.1	PARP4P1	41.42	1.85e-222	2.29e-214	1	0.79	Obesity-related traits;	chr13:24444958	chrY:26594851~26634652:-
BRCA	trans	rs1816752	0.905	rs9581026	ENSG00000237917.1	PARP4P1	41.26	2.28e-221	2.82e-213	0.99	0.79	Obesity-related traits;	chr13:24423788	chrY:26594851~26634652:-
BRCA	trans	rs1816752	0.719	rs11841989	ENSG00000237917.1	PARP4P1	41.17	1.01e-220	1.23e-212	0.99	0.79	Obesity-related traits;	chr13:24423560	chrY:26594851~26634652:-
BRCA	trans	rs7949030	0.62	rs2428551	ENSG00000186676.3	EEF1GP1	40.83	1.96e-218	2.23e-210	1.06	0.78	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62562286	chr7:125033453~125035301:+
BRCA	trans	rs1816752	0.935	rs3816219	ENSG00000237917.1	PARP4P1	40.79	3.98e-218	4.36e-210	0.99	0.78	Obesity-related traits;	chr13:24442995	chrY:26594851~26634652:-
BRCA	trans	rs1816752	0.837	rs7139748	ENSG00000237917.1	PARP4P1	40.64	3.78e-217	4e-209	0.98	0.78	Obesity-related traits;	chr13:24411531	chrY:26594851~26634652:-
BRCA	trans	rs1816752	0.905	rs7571	ENSG00000237917.1	PARP4P1	40.61	6.67e-217	7.01e-209	0.99	0.78	Obesity-related traits;	chr13:24426479	chrY:26594851~26634652:-
BRCA	trans	rs1816752	0.905	rs9511249	ENSG00000237917.1	PARP4P1	40.6	7.81e-217	8.18e-209	0.98	0.78	Obesity-related traits;	chr13:24425457	chrY:26594851~26634652:-
BRCA	trans	rs7949030	0.653	rs17773169	ENSG00000186676.3	EEF1GP1	40.6	7.98e-217	8.34e-209	1.03	0.78	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62551058	chr7:125033453~125035301:+
BRCA	trans	rs6477998	0.557	rs3750534	ENSG00000238072.1	RP11-305M3.2	40.52	2.51e-216	2.57e-208	1.05	0.78	Hematology traits;	chr9:113297844	chr7:129410113~129410370:-
BRCA	trans	rs1816752	0.87	rs9318529	ENSG00000237917.1	PARP4P1	40.52	2.72e-216	2.78e-208	0.98	0.78	Obesity-related traits;	chr13:24424190	chrY:26594851~26634652:-
BRCA	trans	rs1816752	0.837	rs7324645	ENSG00000237917.1	PARP4P1	40.5	3.43e-216	3.49e-208	0.98	0.78	Obesity-related traits;	chr13:24426717	chrY:26594851~26634652:-
BRCA	trans	rs1816752	0.633	rs9578729	ENSG00000237917.1	PARP4P1	40.41	1.57e-215	1.58e-207	0.98	0.78	Obesity-related traits;	chr13:24425106	chrY:26594851~26634652:-
BRCA	trans	rs1816752	0.87	rs9581025	ENSG00000237917.1	PARP4P1	40.33	5.22e-215	5.21e-207	0.98	0.78	Obesity-related traits;	chr13:24423687	chrY:26594851~26634652:-
BRCA	trans	rs1816752	0.87	rs9581027	ENSG00000237917.1	PARP4P1	40.33	5.22e-215	5.21e-207	0.98	0.78	Obesity-related traits;	chr13:24423790	chrY:26594851~26634652:-
BRCA	trans	rs1816752	0.87	rs9581029	ENSG00000237917.1	PARP4P1	40.28	1.19e-214	1.19e-206	0.98	0.78	Obesity-related traits;	chr13:24425147	chrY:26594851~26634652:-
BRCA	trans	rs6477998	0.535	rs3750535	ENSG00000238072.1	RP11-305M3.2	40.23	2.51e-214	2.48e-206	1.05	0.78	Hematology traits;	chr9:113297453	chr7:129410113~129410370:-
BRCA	trans	rs6477998	0.58	rs3750532	ENSG00000238072.1	RP11-305M3.2	40.23	2.53e-214	2.5e-206	1.05	0.78	Hematology traits;	chr9:113298207	chr7:129410113~129410370:-
BRCA	trans	rs6477998	0.58	rs10981715	ENSG00000238072.1	RP11-305M3.2	40.11	1.61e-213	1.57e-205	1.05	0.78	Hematology traits;	chr9:113287218	chr7:129410113~129410370:-
BRCA	trans	rs1816752	0.905	rs7991450	ENSG00000237917.1	PARP4P1	39.85	1.02e-211	9.85e-204	0.98	0.78	Obesity-related traits;	chr13:24425898	chrY:26594851~26634652:-
BRCA	trans	rs1816752	0.774	rs7986162	ENSG00000237917.1	PARP4P1	39.85	1.02e-211	9.85e-204	0.98	0.78	Obesity-related traits;	chr13:24425941	chrY:26594851~26634652:-
BRCA	trans	rs1816752	0.905	rs4769352	ENSG00000237917.1	PARP4P1	39.73	7.38e-211	6.87e-203	0.98	0.78	Obesity-related traits;	chr13:24426237	chrY:26594851~26634652:-
BRCA	trans	rs1816752	0.805	rs4769353	ENSG00000237917.1	PARP4P1	39.73	7.38e-211	6.87e-203	0.98	0.78	Obesity-related traits;	chr13:24426318	chrY:26594851~26634652:-
BRCA	trans	rs1816752	0.935	rs4770676	ENSG00000237917.1	PARP4P1	39.56	1.08e-209	9.88e-202	0.97	0.77	Obesity-related traits;	chr13:24429745	chrY:26594851~26634652:-
BRCA	trans	rs13253073	0.723	rs12548344	ENSG00000260318.1	COX6CP1	39.55	1.09e-209	9.96e-202	1.17	0.77	Glucose homeostasis traits;	chr8:99868676	chr16:11903923~11904137:-
BRCA	trans	rs1816752	0.87	rs73469543	ENSG00000237917.1	PARP4P1	39.54	1.41e-209	1.28e-201	0.97	0.77	Obesity-related traits;	chr13:24424832	chrY:26594851~26634652:-
BRCA	trans	rs13177918	0.557	rs12520101	ENSG00000224114.1	RP11-343H5.4	39.44	6.68e-209	5.92e-201	1.17	0.77	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150431360	chr1:206695837~206696269:-
BRCA	trans	rs941207	0.724	rs1979325	ENSG00000121089.4	NACA3P	39.37	2.18e-208	1.91e-200	1.03	0.77	Platelet count;	chr12:56728152	chr4:164943290~164943937:+
BRCA	trans	rs6477998	0.58	rs4979231	ENSG00000238072.1	RP11-305M3.2	39.35	3.01e-208	2.62e-200	1.05	0.77	Hematology traits;	chr9:113286475	chr7:129410113~129410370:-
BRCA	trans	rs941207	0.756	rs2958149	ENSG00000121089.4	NACA3P	39.28	7.94e-208	6.89e-200	1.03	0.77	Platelet count;	chr12:56716008	chr4:164943290~164943937:+
BRCA	trans	rs941207	0.756	rs2926743	ENSG00000121089.4	NACA3P	39.17	5.05e-207	4.29e-199	1.02	0.77	Platelet count;	chr12:56720316	chr4:164943290~164943937:+
BRCA	trans	rs1816752	1	rs7326932	ENSG00000237917.1	PARP4P1	39.04	3.65e-206	3.09e-198	0.96	0.77	Obesity-related traits;	chr13:24430355	chrY:26594851~26634652:-
BRCA	trans	rs1816752	0.819	rs7400583	ENSG00000237917.1	PARP4P1	38.96	1.42e-205	1.19e-197	0.98	0.77	Obesity-related traits;	chr13:24415916	chrY:26594851~26634652:-
BRCA	trans	rs1816752	0.719	rs11843470	ENSG00000237917.1	PARP4P1	38.9	3.31e-205	2.76e-197	0.97	0.77	Obesity-related traits;	chr13:24423561	chrY:26594851~26634652:-
BRCA	trans	rs1816752	0.749	rs77832754	ENSG00000237917.1	PARP4P1	38.88	4.91e-205	4.08e-197	0.96	0.77	Obesity-related traits;	chr13:24416016	chrY:26594851~26634652:-
BRCA	trans	rs1816752	0.819	rs7985478	ENSG00000237917.1	PARP4P1	38.85	7.59e-205	6.29e-197	0.96	0.77	Obesity-related traits;	chr13:24417135	chrY:26594851~26634652:-
BRCA	trans	rs1816752	0.819	rs4770665	ENSG00000237917.1	PARP4P1	38.84	8.51e-205	7.04e-197	0.96	0.77	Obesity-related traits;	chr13:24414810	chrY:26594851~26634652:-
BRCA	trans	rs1816752	0.633	rs8002387	ENSG00000237917.1	PARP4P1	38.8	1.73e-204	1.42e-196	0.96	0.77	Obesity-related traits;	chr13:24416306	chrY:26594851~26634652:-
BRCA	trans	rs1816752	0.905	rs1348110	ENSG00000237917.1	PARP4P1	38.66	1.65e-203	1.35e-195	0.96	0.77	Obesity-related traits;	chr13:24406537	chrY:26594851~26634652:-
BRCA	trans	rs1816752	1	rs1816752	ENSG00000237917.1	PARP4P1	38.5	2.02e-202	1.63e-194	0.98	0.77	Obesity-related traits;	chr13:24406811	chrY:26594851~26634652:-
BRCA	trans	rs6477998	0.58	rs3750533	ENSG00000238072.1	RP11-305M3.2	38.05	2.45e-199	1.96e-191	1.04	0.76	Hematology traits;	chr9:113297941	chr7:129410113~129410370:-
BRCA	trans	rs1816752	0.721	rs7399656	ENSG00000237917.1	PARP4P1	38.02	4.02e-199	3.21e-191	0.95	0.76	Obesity-related traits;	chr13:24415708	chrY:26594851~26634652:-
BRCA	trans	rs941207	0.756	rs7978685	ENSG00000121089.4	NACA3P	37.97	8.86e-199	7.05e-191	1.03	0.76	Platelet count;	chr12:56709370	chr4:164943290~164943937:+
BRCA	trans	rs6477998	0.58	rs4979233	ENSG00000238072.1	RP11-305M3.2	37.73	4.6e-197	3.65e-189	1.04	0.76	Hematology traits;	chr9:113295501	chr7:129410113~129410370:-
BRCA	trans	rs1816752	1	rs9507341	ENSG00000237917.1	PARP4P1	-37.44	4.44e-195	3.5e-187	-0.94	-0.76	Obesity-related traits;	chr13:24432440	chrY:26594851~26634652:-
BRCA	trans	rs1816752	0.819	rs6490917	ENSG00000237917.1	PARP4P1	37.42	5.73e-195	4.5e-187	0.95	0.76	Obesity-related traits;	chr13:24423119	chrY:26594851~26634652:-
BRCA	trans	rs941207	0.756	rs10876915	ENSG00000121089.4	NACA3P	-37.28	5.36e-194	4.19e-186	-0.99	-0.76	Platelet count;	chr12:56655280	chr4:164943290~164943937:+
BRCA	trans	rs941207	0.756	rs7313074	ENSG00000121089.4	NACA3P	-37.24	1.08e-193	8.43e-186	-1.01	-0.76	Platelet count;	chr12:56760705	chr4:164943290~164943937:+
BRCA	trans	rs941207	0.756	rs67046307	ENSG00000121089.4	NACA3P	-37.21	1.76e-193	1.37e-185	-0.99	-0.76	Platelet count;	chr12:56651152	chr4:164943290~164943937:+
BRCA	trans	rs941207	0.756	rs2950388	ENSG00000121089.4	NACA3P	-37.1	9.42e-193	7.32e-185	-0.99	-0.75	Platelet count;	chr12:56639569	chr4:164943290~164943937:+
BRCA	trans	rs6477998	0.557	rs11789755	ENSG00000238072.1	RP11-305M3.2	37.07	1.53e-192	1.18e-184	1.03	0.75	Hematology traits;	chr9:113292796	chr7:129410113~129410370:-
BRCA	trans	rs941207	0.756	rs7315472	ENSG00000121089.4	NACA3P	-36.95	1.08e-191	8.29e-184	-0.98	-0.75	Platelet count;	chr12:56648276	chr4:164943290~164943937:+
BRCA	trans	rs13177918	0.677	rs4541646	ENSG00000239528.1	RPS14P8	36.57	4.78e-189	3.64e-181	1.06	0.75	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443355	chr5:116562562~116562930:+
BRCA	trans	rs13177918	0.677	rs3900644	ENSG00000239528.1	RPS14P8	36.57	4.78e-189	3.64e-181	1.06	0.75	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443359	chr5:116562562~116562930:+
BRCA	trans	rs6477998	0.58	rs12343629	ENSG00000238072.1	RP11-305M3.2	36.51	1.39e-188	1.05e-180	1	0.75	Hematology traits;	chr9:113279301	chr7:129410113~129410370:-
BRCA	trans	rs13177918	0.677	rs13161099	ENSG00000239528.1	RPS14P8	36.48	2.16e-188	1.6e-180	1.06	0.75	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442799	chr5:116562562~116562930:+
BRCA	trans	rs13177918	0.677	rs13161417	ENSG00000239528.1	RPS14P8	36.48	2.16e-188	1.6e-180	1.06	0.75	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442937	chr5:116562562~116562930:+
BRCA	trans	rs13177918	0.677	rs13161156	ENSG00000239528.1	RPS14P8	36.48	2.16e-188	1.6e-180	1.06	0.75	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443023	chr5:116562562~116562930:+
BRCA	trans	rs13177918	0.677	rs13181401	ENSG00000239528.1	RPS14P8	36.48	2.16e-188	1.6e-180	1.06	0.75	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443033	chr5:116562562~116562930:+
BRCA	trans	rs13177918	0.677	rs2070844	ENSG00000239528.1	RPS14P8	36.48	2.16e-188	1.6e-180	1.06	0.75	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444222	chr5:116562562~116562930:+
BRCA	trans	rs13177918	0.629	rs2070842	ENSG00000239528.1	RPS14P8	36.48	2.16e-188	1.6e-180	1.06	0.75	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444660	chr5:116562562~116562930:+
BRCA	trans	rs13177918	0.629	rs13161261	ENSG00000239528.1	RPS14P8	36.35	1.75e-187	1.3e-179	1.06	0.75	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442844	chr5:116562562~116562930:+
BRCA	trans	rs941207	0.756	rs2958153	ENSG00000121089.4	NACA3P	36.1	9.41e-186	6.9e-178	0.98	0.75	Platelet count;	chr12:56687733	chr4:164943290~164943937:+
BRCA	trans	rs13177918	0.677	rs3857421	ENSG00000239528.1	RPS14P8	-35.96	8.87e-185	6.41e-177	-1.05	-0.74	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443584	chr5:116562562~116562930:+
BRCA	trans	rs941207	0.789	rs2958145	ENSG00000121089.4	NACA3P	-35.27	5.43e-180	3.83e-172	-0.98	-0.74	Platelet count;	chr12:56662290	chr4:164943290~164943937:+
BRCA	trans	rs1816752	0.837	rs9318530	ENSG00000237917.1	PARP4P1	-35.03	2.53e-178	1.77e-170	-0.91	-0.74	Obesity-related traits;	chr13:24424419	chrY:26594851~26634652:-
BRCA	trans	rs941207	0.756	rs1465081	ENSG00000121089.4	NACA3P	-34.7	5.73e-176	3.87e-168	-0.97	-0.73	Platelet count;	chr12:56656390	chr4:164943290~164943937:+
BRCA	trans	rs941207	0.756	rs9634246	ENSG00000121089.4	NACA3P	-34.62	1.95e-175	1.31e-167	-0.98	-0.73	Platelet count;	chr12:56640604	chr4:164943290~164943937:+
BRCA	trans	rs941207	0.756	rs2950394	ENSG00000121089.4	NACA3P	-34.58	3.76e-175	2.5e-167	-0.97	-0.73	Platelet count;	chr12:56644548	chr4:164943290~164943937:+
BRCA	trans	rs1816752	0.905	rs3818938	ENSG00000237917.1	PARP4P1	34.12	6.84e-172	4.49e-164	0.9	0.73	Obesity-related traits;	chr13:24454945	chrY:26594851~26634652:-
BRCA	trans	rs12291225	0.679	rs11238	ENSG00000236360.2	RP11-334A14.2	-33.6	2.95e-168	1.88e-160	-0.98	-0.72	Sense of smell;	chr11:14266582	chr1:52993201~52993702:-
BRCA	trans	rs12291225	0.679	rs7934671	ENSG00000236360.2	RP11-334A14.2	33.48	1.85e-167	1.17e-159	0.99	0.72	Sense of smell;	chr11:14283555	chr1:52993201~52993702:-
BRCA	trans	rs9467773	0.62	rs2504571	ENSG00000242375.1	RP11-498P14.3	33.45	3.07e-167	1.94e-159	0.96	0.72	Intelligence (multi-trait analysis);	chr6:26643207	chr9:97195351~97197687:-
BRCA	trans	rs9467773	0.62	rs2451741	ENSG00000242375.1	RP11-498P14.3	33.44	3.6e-167	2.26e-159	0.96	0.72	Intelligence (multi-trait analysis);	chr6:26629176	chr9:97195351~97197687:-
BRCA	trans	rs12291225	0.679	rs10832240	ENSG00000236360.2	RP11-334A14.2	33.43	4.15e-167	2.61e-159	0.99	0.72	Sense of smell;	chr11:14283198	chr1:52993201~52993702:-
BRCA	trans	rs12291225	0.679	rs11023178	ENSG00000236360.2	RP11-334A14.2	33.38	9.8e-167	6.15e-159	0.99	0.72	Sense of smell;	chr11:14288736	chr1:52993201~52993702:-
BRCA	trans	rs12291225	0.679	rs11605531	ENSG00000236360.2	RP11-334A14.2	33.35	1.6e-166	1e-158	0.99	0.72	Sense of smell;	chr11:14270048	chr1:52993201~52993702:-
BRCA	trans	rs13177918	0.557	rs12520101	ENSG00000239528.1	RPS14P8	33.34	1.96e-166	1.23e-158	1.03	0.72	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150431360	chr5:116562562~116562930:+
BRCA	trans	rs12291225	0.753	rs1431374	ENSG00000236360.2	RP11-334A14.2	33.29	4.46e-166	2.78e-158	0.99	0.72	Sense of smell;	chr11:14282429	chr1:52993201~52993702:-
BRCA	trans	rs12291225	0.639	rs61883858	ENSG00000236360.2	RP11-334A14.2	33.26	6.95e-166	4.32e-158	0.98	0.72	Sense of smell;	chr11:14273162	chr1:52993201~52993702:-
BRCA	trans	rs12291225	0.637	rs8570	ENSG00000236360.2	RP11-334A14.2	33.2	1.77e-165	1.1e-157	0.98	0.72	Sense of smell;	chr11:14279213	chr1:52993201~52993702:-
BRCA	trans	rs12291225	0.679	rs34238445	ENSG00000236360.2	RP11-334A14.2	33.2	1.89e-165	1.16e-157	0.99	0.72	Sense of smell;	chr11:14294369	chr1:52993201~52993702:-
BRCA	trans	rs12291225	0.679	rs11023172	ENSG00000236360.2	RP11-334A14.2	33.14	4.42e-165	2.71e-157	0.98	0.72	Sense of smell;	chr11:14273821	chr1:52993201~52993702:-
BRCA	trans	rs12291225	0.679	rs4757245	ENSG00000236360.2	RP11-334A14.2	33.14	4.42e-165	2.71e-157	0.98	0.72	Sense of smell;	chr11:14276326	chr1:52993201~52993702:-
BRCA	trans	rs9467773	0.62	rs9295701	ENSG00000242375.1	RP11-498P14.3	33.14	4.88e-165	2.99e-157	0.96	0.72	Intelligence (multi-trait analysis);	chr6:26627280	chr9:97195351~97197687:-
BRCA	trans	rs9467773	0.62	rs2504592	ENSG00000242375.1	RP11-498P14.3	33.13	5.73e-165	3.5e-157	0.96	0.72	Intelligence (multi-trait analysis);	chr6:26640723	chr9:97195351~97197687:-
BRCA	trans	rs12291225	0.679	rs11023170	ENSG00000236360.2	RP11-334A14.2	33.12	7.02e-165	4.29e-157	0.98	0.72	Sense of smell;	chr11:14273363	chr1:52993201~52993702:-
BRCA	trans	rs9467773	0.62	rs2504599	ENSG00000242375.1	RP11-498P14.3	33.1	9.4e-165	5.73e-157	0.96	0.72	Intelligence (multi-trait analysis);	chr6:26640832	chr9:97195351~97197687:-
BRCA	trans	rs9467773	0.62	rs2451731	ENSG00000242375.1	RP11-498P14.3	33.06	1.83e-164	1.11e-156	0.96	0.72	Intelligence (multi-trait analysis);	chr6:26624594	chr9:97195351~97197687:-
BRCA	trans	rs12291225	0.679	rs11369	ENSG00000236360.2	RP11-334A14.2	32.98	6.31e-164	3.79e-156	0.97	0.71	Sense of smell;	chr11:14266550	chr1:52993201~52993702:-
BRCA	trans	rs9467773	0.62	rs2494700	ENSG00000242375.1	RP11-498P14.3	32.98	6.55e-164	3.9e-156	0.96	0.71	Intelligence (multi-trait analysis);	chr6:26631078	chr9:97195351~97197687:-
BRCA	trans	rs9467773	0.584	rs1021372	ENSG00000242375.1	RP11-498P14.3	32.98	6.55e-164	3.9e-156	0.96	0.71	Intelligence (multi-trait analysis);	chr6:26632216	chr9:97195351~97197687:-
BRCA	trans	rs9467773	0.583	rs1021373	ENSG00000242375.1	RP11-498P14.3	32.98	6.55e-164	3.9e-156	0.96	0.71	Intelligence (multi-trait analysis);	chr6:26632229	chr9:97195351~97197687:-
BRCA	trans	rs9467773	0.62	rs2451744	ENSG00000242375.1	RP11-498P14.3	32.98	6.55e-164	3.9e-156	0.96	0.71	Intelligence (multi-trait analysis);	chr6:26633235	chr9:97195351~97197687:-
BRCA	trans	rs9467773	0.62	rs2494701	ENSG00000242375.1	RP11-498P14.3	32.98	6.55e-164	3.9e-156	0.96	0.71	Intelligence (multi-trait analysis);	chr6:26634204	chr9:97195351~97197687:-
BRCA	trans	rs9467773	0.62	rs1027204	ENSG00000242375.1	RP11-498P14.3	32.98	6.55e-164	3.9e-156	0.96	0.71	Intelligence (multi-trait analysis);	chr6:26639385	chr9:97195351~97197687:-
BRCA	trans	rs9467773	0.62	rs2451711	ENSG00000242375.1	RP11-498P14.3	32.95	1.02e-163	6.05e-156	0.96	0.71	Intelligence (multi-trait analysis);	chr6:26662882	chr9:97195351~97197687:-
BRCA	trans	rs12291225	0.679	rs4756786	ENSG00000236360.2	RP11-334A14.2	32.93	1.42e-163	8.38e-156	0.98	0.71	Sense of smell;	chr11:14264354	chr1:52993201~52993702:-
BRCA	trans	rs9467773	0.62	rs2504540	ENSG00000242375.1	RP11-498P14.3	32.92	1.58e-163	9.29e-156	0.96	0.71	Intelligence (multi-trait analysis);	chr6:26641398	chr9:97195351~97197687:-
BRCA	trans	rs9467773	0.62	rs2504567	ENSG00000242375.1	RP11-498P14.3	32.84	5.8e-163	3.38e-155	0.96	0.71	Intelligence (multi-trait analysis);	chr6:26662692	chr9:97195351~97197687:-
BRCA	trans	rs9467773	0.596	rs2451750	ENSG00000242375.1	RP11-498P14.3	32.78	1.57e-162	9.09e-155	0.96	0.71	Intelligence (multi-trait analysis);	chr6:26646351	chr9:97195351~97197687:-
BRCA	trans	rs9467773	0.596	rs2451751	ENSG00000242375.1	RP11-498P14.3	32.78	1.57e-162	9.09e-155	0.96	0.71	Intelligence (multi-trait analysis);	chr6:26646486	chr9:97195351~97197687:-
BRCA	trans	rs12291225	0.645	rs3763950	ENSG00000236360.2	RP11-334A14.2	32.74	3.15e-162	1.81e-154	0.97	0.71	Sense of smell;	chr11:14256503	chr1:52993201~52993702:-
BRCA	trans	rs9467773	0.62	rs2504600	ENSG00000242375.1	RP11-498P14.3	32.71	4.76e-162	2.7e-154	0.96	0.71	Intelligence (multi-trait analysis);	chr6:26648106	chr9:97195351~97197687:-
BRCA	trans	rs9467773	0.62	rs2130657	ENSG00000242375.1	RP11-498P14.3	32.71	4.76e-162	2.7e-154	0.96	0.71	Intelligence (multi-trait analysis);	chr6:26650598	chr9:97195351~97197687:-
BRCA	trans	rs9467773	0.62	rs2498351	ENSG00000242375.1	RP11-498P14.3	32.71	4.76e-162	2.7e-154	0.96	0.71	Intelligence (multi-trait analysis);	chr6:26659414	chr9:97195351~97197687:-
BRCA	trans	rs9467773	0.62	rs2504566	ENSG00000242375.1	RP11-498P14.3	32.71	4.76e-162	2.7e-154	0.96	0.71	Intelligence (multi-trait analysis);	chr6:26660260	chr9:97195351~97197687:-
BRCA	trans	rs9467773	0.62	rs2494716	ENSG00000242375.1	RP11-498P14.3	32.71	5.18e-162	2.94e-154	0.96	0.71	Intelligence (multi-trait analysis);	chr6:26662508	chr9:97195351~97197687:-
BRCA	trans	rs9467773	0.62	rs2451732	ENSG00000242375.1	RP11-498P14.3	-32.62	2.16e-161	1.21e-153	-0.95	-0.71	Intelligence (multi-trait analysis);	chr6:26622676	chr9:97195351~97197687:-
BRCA	trans	rs9467773	0.62	rs2101581	ENSG00000242375.1	RP11-498P14.3	32.61	2.4e-161	1.34e-153	0.95	0.71	Intelligence (multi-trait analysis);	chr6:26622541	chr9:97195351~97197687:-
BRCA	trans	rs5022636	0.559	rs41302131	ENSG00000180764.13	PIPSL	32.53	8.39e-161	4.65e-153	0.88	0.71	Gut microbiota (functional units);	chr1:151267532	chr10:93958191~93961540:-
BRCA	trans	rs9467773	0.596	rs3001369	ENSG00000242375.1	RP11-498P14.3	32.49	1.65e-160	9.09e-153	0.96	0.71	Intelligence (multi-trait analysis);	chr6:26670741	chr9:97195351~97197687:-
BRCA	trans	rs2950393	0.509	rs10459247	ENSG00000121089.4	NACA3P	-32.45	3.14e-160	1.73e-152	-0.95	-0.71	Platelet distribution width;	chr12:56777732	chr4:164943290~164943937:+
BRCA	trans	rs9467773	0.62	rs2451737	ENSG00000242375.1	RP11-498P14.3	32.25	7.77e-159	4.18e-151	0.95	0.71	Intelligence (multi-trait analysis);	chr6:26618813	chr9:97195351~97197687:-
BRCA	trans	rs9467773	0.596	rs2494693	ENSG00000242375.1	RP11-498P14.3	32.25	7.77e-159	4.18e-151	0.95	0.71	Intelligence (multi-trait analysis);	chr6:26618998	chr9:97195351~97197687:-
BRCA	trans	rs9467773	0.62	rs2494694	ENSG00000242375.1	RP11-498P14.3	32.25	7.77e-159	4.18e-151	0.95	0.71	Intelligence (multi-trait analysis);	chr6:26619100	chr9:97195351~97197687:-
BRCA	trans	rs9467773	0.62	rs2504565	ENSG00000242375.1	RP11-498P14.3	32.24	9.4e-159	5.04e-151	0.95	0.71	Intelligence (multi-trait analysis);	chr6:26656662	chr9:97195351~97197687:-
BRCA	trans	rs9467773	0.595	rs2451736	ENSG00000242375.1	RP11-498P14.3	32.19	2.22e-158	1.19e-150	0.95	0.71	Intelligence (multi-trait analysis);	chr6:26620316	chr9:97195351~97197687:-
BRCA	trans	rs9467773	0.62	rs2494696	ENSG00000242375.1	RP11-498P14.3	32.14	5.19e-158	2.77e-150	0.95	0.71	Intelligence (multi-trait analysis);	chr6:26620666	chr9:97195351~97197687:-
BRCA	trans	rs9467773	0.583	rs2498380	ENSG00000242375.1	RP11-498P14.3	-31.77	1.8e-155	9.27e-148	-0.95	-0.7	Intelligence (multi-trait analysis);	chr6:26643768	chr9:97195351~97197687:-
BRCA	trans	rs9467773	0.62	rs2101582	ENSG00000242375.1	RP11-498P14.3	31.71	4.92e-155	2.53e-147	0.94	0.7	Intelligence (multi-trait analysis);	chr6:26622506	chr9:97195351~97197687:-
BRCA	trans	rs9467773	0.62	rs1490488	ENSG00000242375.1	RP11-498P14.3	31.67	9.4e-155	4.79e-147	0.95	0.7	Intelligence (multi-trait analysis);	chr6:26614580	chr9:97195351~97197687:-
BRCA	trans	rs9467773	0.62	rs2494692	ENSG00000242375.1	RP11-498P14.3	31.67	9.4e-155	4.79e-147	0.95	0.7	Intelligence (multi-trait analysis);	chr6:26614995	chr9:97195351~97197687:-
BRCA	trans	rs5022636	0.594	rs7489	ENSG00000180764.13	PIPSL	31.56	5.76e-154	2.88e-146	0.86	0.7	Gut microbiota (functional units);	chr1:151266575	chr10:93958191~93961540:-
BRCA	trans	rs7943191	0.81	rs7942154	ENSG00000186676.3	EEF1GP1	31.53	9.13e-154	4.54e-146	1.1	0.7	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr11:62569691	chr7:125033453~125035301:+
BRCA	trans	rs9467773	0.549	rs9467805	ENSG00000242375.1	RP11-498P14.3	31.45	3.33e-153	1.62e-145	0.93	0.7	Intelligence (multi-trait analysis);	chr6:26583138	chr9:97195351~97197687:-
BRCA	trans	rs9467773	0.62	rs2451738	ENSG00000242375.1	RP11-498P14.3	-31.39	8.97e-153	4.29e-145	-0.94	-0.7	Intelligence (multi-trait analysis);	chr6:26618231	chr9:97195351~97197687:-
BRCA	trans	rs9467773	0.62	rs9467810	ENSG00000242375.1	RP11-498P14.3	31.36	1.4e-152	6.67e-145	0.93	0.7	Intelligence (multi-trait analysis);	chr6:26608033	chr9:97195351~97197687:-
BRCA	trans	rs9467773	0.62	rs3800303	ENSG00000242375.1	RP11-498P14.3	31.35	1.76e-152	8.35e-145	0.93	0.7	Intelligence (multi-trait analysis);	chr6:26597960	chr9:97195351~97197687:-
BRCA	trans	rs9467773	0.595	rs7767847	ENSG00000242375.1	RP11-498P14.3	31.29	4.37e-152	2.05e-144	0.93	0.7	Intelligence (multi-trait analysis);	chr6:26597665	chr9:97195351~97197687:-
BRCA	trans	rs5022636	0.631	rs6587562	ENSG00000180764.13	PIPSL	-31.2	1.85e-151	8.57e-144	-0.86	-0.69	Gut microbiota (functional units);	chr1:151273765	chr10:93958191~93961540:-
BRCA	trans	rs7949030	0.523	rs12223627	ENSG00000186676.3	EEF1GP1	31.19	2.16e-151	9.98e-144	1.1	0.69	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62601085	chr7:125033453~125035301:+
BRCA	trans	rs9467773	0.596	rs62396201	ENSG00000242375.1	RP11-498P14.3	31.17	3.01e-151	1.38e-143	0.93	0.69	Intelligence (multi-trait analysis);	chr6:26667988	chr9:97195351~97197687:-
BRCA	trans	rs7943191	0.805	rs12226821	ENSG00000186676.3	EEF1GP1	31.12	7.12e-151	3.24e-143	1.1	0.69	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr11:62601546	chr7:125033453~125035301:+
BRCA	trans	rs7943191	0.768	rs34065644	ENSG00000186676.3	EEF1GP1	31.1	9.56e-151	4.33e-143	1.1	0.69	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr11:62604466	chr7:125033453~125035301:+
BRCA	trans	rs9467773	0.62	rs9461275	ENSG00000242375.1	RP11-498P14.3	31.01	3.81e-150	1.71e-142	0.93	0.69	Intelligence (multi-trait analysis);	chr6:26590573	chr9:97195351~97197687:-
BRCA	trans	rs7949030	0.626	rs35587183	ENSG00000186676.3	EEF1GP1	30.99	5.42e-150	2.43e-142	1.08	0.69	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62551184	chr7:125033453~125035301:+
BRCA	trans	rs9467773	0.62	rs6925087	ENSG00000242375.1	RP11-498P14.3	30.94	1.19e-149	5.28e-142	0.93	0.69	Intelligence (multi-trait analysis);	chr6:26592625	chr9:97195351~97197687:-
BRCA	trans	rs9467773	0.62	rs4368798	ENSG00000242375.1	RP11-498P14.3	30.94	1.19e-149	5.28e-142	0.93	0.69	Intelligence (multi-trait analysis);	chr6:26593243	chr9:97195351~97197687:-
BRCA	trans	rs9467773	0.62	rs9461276	ENSG00000242375.1	RP11-498P14.3	30.93	1.39e-149	6.17e-142	0.93	0.69	Intelligence (multi-trait analysis);	chr6:26594940	chr9:97195351~97197687:-
BRCA	trans	rs7943191	0.81	rs7942991	ENSG00000186676.3	EEF1GP1	-30.53	9.24e-147	3.98e-139	-1.05	-0.69	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr11:62569731	chr7:125033453~125035301:+
BRCA	trans	rs2950393	0.857	rs1563896	ENSG00000121089.4	NACA3P	30.11	8.29e-144	3.52e-136	0.82	0.68	Platelet distribution width;	chr12:56699312	chr4:164943290~164943937:+
BRCA	trans	rs9611565	0.694	rs106860	ENSG00000268568.1	AC007228.9	-30	4.79e-143	2.02e-135	-1.09	-0.68	Vitiligo;	chr22:41444403	chr19:56672574~56673901:-
BRCA	trans	rs5022636	0.594	rs11204791	ENSG00000180764.13	PIPSL	29.72	4.38e-141	1.83e-133	0.81	0.68	Gut microbiota (functional units);	chr1:151268066	chr10:93958191~93961540:-
BRCA	trans	rs9611565	0.694	rs202617	ENSG00000268568.1	AC007228.9	29.63	1.91e-140	7.94e-133	1.08	0.68	Vitiligo;	chr22:41426789	chr19:56672574~56673901:-
BRCA	trans	rs941207	0.526	rs4759028	ENSG00000121089.4	NACA3P	29.55	6.38e-140	2.63e-132	0.8	0.68	Platelet count;	chr12:56686399	chr4:164943290~164943937:+
BRCA	trans	rs941207	0.507	rs7297289	ENSG00000121089.4	NACA3P	29.53	1.02e-139	4.21e-132	0.8	0.67	Platelet count;	chr12:56682703	chr4:164943290~164943937:+
BRCA	trans	rs941207	0.526	rs7303216	ENSG00000121089.4	NACA3P	29.35	1.79e-138	7.17e-131	0.79	0.67	Platelet count;	chr12:56680909	chr4:164943290~164943937:+
BRCA	trans	rs1816752	0.875	rs59686377	ENSG00000237917.1	PARP4P1	29.12	6.69e-137	2.66e-129	0.86	0.67	Obesity-related traits;	chr13:24475869	chrY:26594851~26634652:-
BRCA	trans	rs941207	0.542	rs11171978	ENSG00000121089.4	NACA3P	29.11	8.15e-137	3.23e-129	0.83	0.67	Platelet count;	chr12:56800015	chr4:164943290~164943937:+
BRCA	trans	rs12291225	0.679	rs1043237	ENSG00000236360.2	RP11-334A14.2	29.08	1.38e-136	5.41e-129	0.92	0.67	Sense of smell;	chr11:14267507	chr1:52993201~52993702:-
BRCA	trans	rs1816752	0.875	rs17384871	ENSG00000237917.1	PARP4P1	29.07	1.53e-136	5.99e-129	0.86	0.67	Obesity-related traits;	chr13:24484959	chrY:26594851~26634652:-
BRCA	trans	rs928391	1	rs2644615	ENSG00000227183.3	HDGFP1	29.01	3.97e-136	1.55e-128	0.95	0.67	Platelet count;	chr1:156791826	chrX:131646639~131646890:+
BRCA	trans	rs941207	0.526	rs2950390	ENSG00000121089.4	NACA3P	28.88	3.12e-135	1.21e-127	0.79	0.67	Platelet count;	chr12:56661507	chr4:164943290~164943937:+
BRCA	trans	rs9467773	0.62	rs1027203	ENSG00000242375.1	RP11-498P14.3	28.85	4.96e-135	1.91e-127	0.92	0.67	Intelligence (multi-trait analysis);	chr6:26639104	chr9:97195351~97197687:-
BRCA	trans	rs9467773	0.595	rs2172007	ENSG00000242375.1	RP11-498P14.3	28.85	4.96e-135	1.91e-127	0.92	0.67	Intelligence (multi-trait analysis);	chr6:26639549	chr9:97195351~97197687:-
BRCA	trans	rs1816752	0.875	rs59531061	ENSG00000237917.1	PARP4P1	28.84	6.55e-135	2.52e-127	0.86	0.67	Obesity-related traits;	chr13:24507297	chrY:26594851~26634652:-
BRCA	trans	rs6477998	0.535	rs10981712	ENSG00000238072.1	RP11-305M3.2	28.83	7.43e-135	2.86e-127	0.96	0.67	Hematology traits;	chr9:113283846	chr7:129410113~129410370:-
BRCA	trans	rs9467773	0.549	rs9461273	ENSG00000242375.1	RP11-498P14.3	-28.76	2.4e-134	9.15e-127	-0.88	-0.67	Intelligence (multi-trait analysis);	chr6:26584298	chr9:97195351~97197687:-
BRCA	trans	rs2950393	0.895	rs2926740	ENSG00000121089.4	NACA3P	28.74	3.25e-134	1.24e-126	0.79	0.66	Platelet distribution width;	chr12:56666751	chr4:164943290~164943937:+
BRCA	trans	rs2950393	0.895	rs2958154	ENSG00000121089.4	NACA3P	-28.58	4.12e-133	1.56e-125	-0.78	-0.66	Platelet distribution width;	chr12:56671929	chr4:164943290~164943937:+
BRCA	trans	rs941207	0.526	rs11171916	ENSG00000121089.4	NACA3P	-28.32	2.82e-131	1.03e-123	-0.79	-0.66	Platelet count;	chr12:56653236	chr4:164943290~164943937:+
BRCA	trans	rs941207	0.542	rs6581102	ENSG00000121089.4	NACA3P	-28.32	2.83e-131	1.04e-123	-0.83	-0.66	Platelet count;	chr12:56790632	chr4:164943290~164943937:+
BRCA	trans	rs941207	0.542	rs6581103	ENSG00000121089.4	NACA3P	-28.32	2.83e-131	1.04e-123	-0.83	-0.66	Platelet count;	chr12:56790641	chr4:164943290~164943937:+
BRCA	trans	rs928391	1	rs2768767	ENSG00000227183.3	HDGFP1	28.29	4.46e-131	1.62e-123	0.95	0.66	Platelet count;	chr1:156797933	chrX:131646639~131646890:+
BRCA	trans	rs2950393	0.927	rs11171914	ENSG00000121089.4	NACA3P	-28.25	8.1e-131	2.92e-123	-0.79	-0.66	Platelet distribution width;	chr12:56649462	chr4:164943290~164943937:+
BRCA	trans	rs928391	1	rs2777929	ENSG00000227183.3	HDGFP1	28.25	8.69e-131	3.13e-123	0.95	0.66	Platelet count;	chr1:156797879	chrX:131646639~131646890:+
BRCA	trans	rs941207	0.526	rs2950393	ENSG00000121089.4	NACA3P	-28.22	1.38e-130	4.95e-123	-0.79	-0.66	Platelet count;	chr12:56642239	chr4:164943290~164943937:+
BRCA	trans	rs941207	0.542	rs7311381	ENSG00000121089.4	NACA3P	-28.21	1.57e-130	5.61e-123	-0.83	-0.66	Platelet count;	chr12:56800286	chr4:164943290~164943937:+
BRCA	trans	rs941207	0.542	rs6581107	ENSG00000121089.4	NACA3P	-28.2	1.68e-130	6.01e-123	-0.83	-0.66	Platelet count;	chr12:56801197	chr4:164943290~164943937:+
BRCA	trans	rs941207	0.542	rs6581106	ENSG00000121089.4	NACA3P	-28.15	3.95e-130	1.39e-122	-0.83	-0.66	Platelet count;	chr12:56796759	chr4:164943290~164943937:+
BRCA	trans	rs941207	0.542	rs12370142	ENSG00000121089.4	NACA3P	-28.13	5.92e-130	2.08e-122	-0.83	-0.66	Platelet count;	chr12:56790801	chr4:164943290~164943937:+
BRCA	trans	rs12367822	0.956	rs9706160	ENSG00000121089.4	NACA3P	-28.13	5.92e-130	2.08e-122	-0.83	-0.66	Platelet aggregation;	chr12:56791119	chr4:164943290~164943937:+
BRCA	trans	rs941207	0.526	rs12229457	ENSG00000121089.4	NACA3P	-28.11	7.16e-130	2.5e-122	-0.79	-0.66	Platelet count;	chr12:56639896	chr4:164943290~164943937:+
BRCA	trans	rs9611565	0.694	rs202664	ENSG00000268568.1	AC007228.9	28.08	1.21e-129	4.2e-122	0.98	0.66	Vitiligo;	chr22:41417882	chr19:56672574~56673901:-
BRCA	trans	rs941207	0.542	rs4277148	ENSG00000121089.4	NACA3P	-28.04	2.41e-129	8.3e-122	-0.83	-0.66	Platelet count;	chr12:56787071	chr4:164943290~164943937:+
BRCA	trans	rs941207	0.542	rs2888095	ENSG00000121089.4	NACA3P	-28.04	2.41e-129	8.3e-122	-0.83	-0.66	Platelet count;	chr12:56793689	chr4:164943290~164943937:+
BRCA	trans	rs941207	0.542	rs2888096	ENSG00000121089.4	NACA3P	-28.04	2.41e-129	8.3e-122	-0.83	-0.66	Platelet count;	chr12:56793851	chr4:164943290~164943937:+
BRCA	trans	rs7949030	1	rs10897289	ENSG00000186676.3	EEF1GP1	27.87	3.76e-128	1.25e-120	0.89	0.65	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62632544	chr7:125033453~125035301:+
BRCA	trans	rs9467773	0.595	rs12525810	ENSG00000242375.1	RP11-498P14.3	27.74	2.61e-127	8.58e-120	0.91	0.65	Intelligence (multi-trait analysis);	chr6:26623283	chr9:97195351~97197687:-
BRCA	trans	rs9467773	0.534	rs34453863	ENSG00000242375.1	RP11-498P14.3	27.73	3.33e-127	1.09e-119	0.93	0.65	Intelligence (multi-trait analysis);	chr6:26627777	chr9:97195351~97197687:-
BRCA	trans	rs6477998	0.535	rs4979232	ENSG00000238072.1	RP11-305M3.2	-27.7	5.07e-127	1.66e-119	-0.98	-0.65	Hematology traits;	chr9:113286594	chr7:129410113~129410370:-
BRCA	trans	rs9467773	0.595	rs13207371	ENSG00000242375.1	RP11-498P14.3	27.59	2.92e-126	9.47e-119	0.91	0.65	Intelligence (multi-trait analysis);	chr6:26590846	chr9:97195351~97197687:-
BRCA	trans	rs13177918	0.798	rs12514700	ENSG00000213058.3	RP4-765C7.2	27.41	5.42e-125	1.72e-117	0.97	0.65	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150466096	chr1:178411616~178411972:+
BRCA	trans	rs9611565	0.659	rs4822035	ENSG00000268568.1	AC007228.9	27.28	4.35e-124	1.33e-116	0.99	0.65	Vitiligo;	chr22:41539908	chr19:56672574~56673901:-
BRCA	trans	rs6477998	0.535	rs10817475	ENSG00000238072.1	RP11-305M3.2	27.25	7.36e-124	2.25e-116	0.96	0.65	Hematology traits;	chr9:113296774	chr7:129410113~129410370:-
BRCA	trans	rs13177918	0.798	rs12514700	ENSG00000224114.1	RP11-343H5.4	27.23	9.79e-124	2.98e-116	0.98	0.64	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150466096	chr1:206695837~206696269:-
BRCA	trans	rs941207	0.542	rs11171983	ENSG00000121089.4	NACA3P	-27.2	1.51e-123	4.57e-116	-0.82	-0.64	Platelet count;	chr12:56814461	chr4:164943290~164943937:+
BRCA	trans	rs9467773	0.572	rs62394558	ENSG00000242375.1	RP11-498P14.3	27.1	7.48e-123	2.23e-115	0.92	0.64	Intelligence (multi-trait analysis);	chr6:26604422	chr9:97195351~97197687:-
BRCA	trans	rs61990749	0.597	rs6574402	ENSG00000235400.1	RP4-641G12.4	26.98	4.77e-122	1.41e-114	1.1	0.64	Fibroblast growth factor basic levels;	chr14:77801607	chr1:78749073~78750659:+
BRCA	trans	rs9467773	0.523	rs2498399	ENSG00000242375.1	RP11-498P14.3	26.96	7.51e-122	2.2e-114	0.89	0.64	Intelligence (multi-trait analysis);	chr6:26795343	chr9:97195351~97197687:-
BRCA	trans	rs5022636	0.896	rs4971032	ENSG00000180764.13	PIPSL	26.92	1.27e-121	3.71e-114	0.8	0.64	Gut microbiota (functional units);	chr1:151317948	chr10:93958191~93961540:-
BRCA	trans	rs941207	0.542	rs11171979	ENSG00000121089.4	NACA3P	-26.92	1.27e-121	3.72e-114	-0.82	-0.64	Platelet count;	chr12:56802199	chr4:164943290~164943937:+
BRCA	trans	rs61990749	0.544	rs8003979	ENSG00000235400.1	RP4-641G12.4	26.86	3.71e-121	1.07e-113	1.09	0.64	Fibroblast growth factor basic levels;	chr14:77744947	chr1:78749073~78750659:+
BRCA	trans	rs61990749	0.597	rs8016416	ENSG00000235400.1	RP4-641G12.4	26.86	3.71e-121	1.07e-113	1.09	0.64	Fibroblast growth factor basic levels;	chr14:77746757	chr1:78749073~78750659:+
BRCA	trans	rs941207	0.542	rs11171980	ENSG00000121089.4	NACA3P	-26.85	3.96e-121	1.15e-113	-0.82	-0.64	Platelet count;	chr12:56806397	chr4:164943290~164943937:+
BRCA	trans	rs61990749	0.597	rs8016447	ENSG00000235400.1	RP4-641G12.4	26.85	4.16e-121	1.2e-113	1.08	0.64	Fibroblast growth factor basic levels;	chr14:77755725	chr1:78749073~78750659:+
BRCA	trans	rs941207	0.542	rs67808059	ENSG00000121089.4	NACA3P	-26.78	1.18e-120	3.36e-113	-0.82	-0.64	Platelet count;	chr12:56805228	chr4:164943290~164943937:+
BRCA	trans	rs9467773	0.572	rs13213953	ENSG00000242375.1	RP11-498P14.3	26.76	1.61e-120	4.57e-113	0.92	0.64	Intelligence (multi-trait analysis);	chr6:26594306	chr9:97195351~97197687:-
BRCA	trans	rs941207	0.542	rs12367339	ENSG00000121089.4	NACA3P	-26.76	1.7e-120	4.84e-113	-0.82	-0.64	Platelet count;	chr12:56809521	chr4:164943290~164943937:+
BRCA	trans	rs61990749	0.597	rs176946	ENSG00000235400.1	RP4-641G12.4	26.76	1.72e-120	4.88e-113	1.07	0.64	Fibroblast growth factor basic levels;	chr14:77712096	chr1:78749073~78750659:+
BRCA	trans	rs941207	0.542	rs2126068	ENSG00000121089.4	NACA3P	-26.75	2.14e-120	6.05e-113	-0.81	-0.64	Platelet count;	chr12:56804716	chr4:164943290~164943937:+
BRCA	trans	rs941207	0.514	rs6581105	ENSG00000121089.4	NACA3P	-26.72	3.12e-120	8.8e-113	-0.82	-0.64	Platelet count;	chr12:56792184	chr4:164943290~164943937:+
BRCA	trans	rs61990749	0.597	rs72685264	ENSG00000235400.1	RP4-641G12.4	-26.67	6.71e-120	1.88e-112	-1.09	-0.64	Fibroblast growth factor basic levels;	chr14:77686655	chr1:78749073~78750659:+
BRCA	trans	rs61990749	0.597	rs176943	ENSG00000235400.1	RP4-641G12.4	-26.66	8.6e-120	2.4e-112	-1.09	-0.64	Fibroblast growth factor basic levels;	chr14:77709454	chr1:78749073~78750659:+
BRCA	trans	rs941207	0.542	rs1870674	ENSG00000121089.4	NACA3P	-26.63	1.37e-119	3.81e-112	-0.82	-0.64	Platelet count;	chr12:56805721	chr4:164943290~164943937:+
BRCA	trans	rs61990749	0.597	rs2032781	ENSG00000235400.1	RP4-641G12.4	26.57	3.2e-119	8.87e-112	1.08	0.64	Fibroblast growth factor basic levels;	chr14:77748532	chr1:78749073~78750659:+
BRCA	trans	rs61990749	0.597	rs11624101	ENSG00000235400.1	RP4-641G12.4	-26.56	4.23e-119	1.17e-111	-1.1	-0.64	Fibroblast growth factor basic levels;	chr14:77671716	chr1:78749073~78750659:+
BRCA	trans	rs61990749	0.597	rs3783980	ENSG00000235400.1	RP4-641G12.4	26.54	5.85e-119	1.61e-111	1.08	0.64	Fibroblast growth factor basic levels;	chr14:77753464	chr1:78749073~78750659:+
BRCA	trans	rs61990749	0.597	rs1477262	ENSG00000235400.1	RP4-641G12.4	26.54	5.85e-119	1.61e-111	1.08	0.64	Fibroblast growth factor basic levels;	chr14:77760310	chr1:78749073~78750659:+
BRCA	trans	rs6477998	0.513	rs10981720	ENSG00000238072.1	RP11-305M3.2	26.52	7.42e-119	2.03e-111	0.98	0.63	Hematology traits;	chr9:113293831	chr7:129410113~129410370:-
BRCA	trans	rs61990749	0.597	rs4903643	ENSG00000235400.1	RP4-641G12.4	26.52	7.5e-119	2.05e-111	1.11	0.63	Fibroblast growth factor basic levels;	chr14:77788448	chr1:78749073~78750659:+
BRCA	trans	rs941207	0.542	rs12366897	ENSG00000121089.4	NACA3P	-26.51	8.4e-119	2.3e-111	-0.81	-0.63	Platelet count;	chr12:56808329	chr4:164943290~164943937:+
BRCA	trans	rs928391	0.948	rs2735657	ENSG00000227183.3	HDGFP1	26.5	9.88e-119	2.69e-111	0.85	0.63	Platelet count;	chr1:156810514	chrX:131646639~131646890:+
BRCA	trans	rs7811142	0.83	rs6955367	ENSG00000228546.2	CTA-313A17.3	26.46	1.89e-118	5.12e-111	1	0.63	Platelet count;	chr7:100363571	chr7:102337316~102339115:+
BRCA	trans	rs61990749	0.597	rs2112136	ENSG00000235400.1	RP4-641G12.4	26.46	1.92e-118	5.21e-111	1.09	0.63	Fibroblast growth factor basic levels;	chr14:77782609	chr1:78749073~78750659:+
BRCA	trans	rs61990749	0.597	rs2267761	ENSG00000235400.1	RP4-641G12.4	-26.46	2.08e-118	5.65e-111	-1.09	-0.63	Fibroblast growth factor basic levels;	chr14:77681506	chr1:78749073~78750659:+
BRCA	trans	rs61990749	0.597	rs1048147	ENSG00000235400.1	RP4-641G12.4	-26.45	2.34e-118	6.33e-111	-1.09	-0.63	Fibroblast growth factor basic levels;	chr14:77673645	chr1:78749073~78750659:+
BRCA	trans	rs941207	0.542	rs12367822	ENSG00000121089.4	NACA3P	-26.45	2.5e-118	6.76e-111	-0.81	-0.63	Platelet count;	chr12:56810376	chr4:164943290~164943937:+
BRCA	trans	rs61990749	0.597	rs2267758	ENSG00000235400.1	RP4-641G12.4	-26.43	2.95e-118	7.98e-111	-1.09	-0.63	Fibroblast growth factor basic levels;	chr14:77681086	chr1:78749073~78750659:+
BRCA	trans	rs941207	0.542	rs12367312	ENSG00000121089.4	NACA3P	-26.42	3.51e-118	9.48e-111	-0.81	-0.63	Platelet count;	chr12:56809369	chr4:164943290~164943937:+
BRCA	trans	rs61990749	0.544	rs7151211	ENSG00000235400.1	RP4-641G12.4	-26.4	5.22e-118	1.4e-110	-1.08	-0.63	Fibroblast growth factor basic levels;	chr14:77685558	chr1:78749073~78750659:+
BRCA	trans	rs61990749	0.597	rs7147516	ENSG00000235400.1	RP4-641G12.4	-26.4	5.22e-118	1.4e-110	-1.08	-0.63	Fibroblast growth factor basic levels;	chr14:77687637	chr1:78749073~78750659:+
BRCA	trans	rs61990749	0.597	rs6574391	ENSG00000235400.1	RP4-641G12.4	26.38	6.7e-118	1.8e-110	1.08	0.63	Fibroblast growth factor basic levels;	chr14:77741778	chr1:78749073~78750659:+
BRCA	trans	rs7811142	0.667	rs3873746	ENSG00000228546.2	CTA-313A17.3	26.32	1.84e-117	4.93e-110	1.01	0.63	Platelet count;	chr7:100337474	chr7:102337316~102339115:+
BRCA	trans	rs9611565	0.694	rs5758368	ENSG00000268568.1	AC007228.9	-26.29	2.99e-117	7.95e-110	-0.93	-0.63	Vitiligo;	chr22:41466284	chr19:56672574~56673901:-
BRCA	trans	rs7811142	0.562	rs7786844	ENSG00000228546.2	CTA-313A17.3	26.28	3.42e-117	9.1e-110	1.01	0.63	Platelet count;	chr7:100336385	chr7:102337316~102339115:+
BRCA	trans	rs61990749	0.544	rs176962	ENSG00000235400.1	RP4-641G12.4	26.25	5.72e-117	1.51e-109	1.07	0.63	Fibroblast growth factor basic levels;	chr14:77719167	chr1:78749073~78750659:+
BRCA	trans	rs9611565	0.659	rs1810460	ENSG00000268568.1	AC007228.9	-26.24	6.47e-117	1.71e-109	-0.96	-0.63	Vitiligo;	chr22:41531696	chr19:56672574~56673901:-
BRCA	trans	rs7811142	0.83	rs6975660	ENSG00000228546.2	CTA-313A17.3	26.23	7.85e-117	2.06e-109	1	0.63	Platelet count;	chr7:100377643	chr7:102337316~102339115:+
BRCA	trans	rs7811142	0.83	rs73401443	ENSG00000228546.2	CTA-313A17.3	26.23	7.85e-117	2.06e-109	1	0.63	Platelet count;	chr7:100379959	chr7:102337316~102339115:+
BRCA	trans	rs61990749	0.597	rs176971	ENSG00000235400.1	RP4-641G12.4	26.12	4.11e-116	1.06e-108	1.08	0.63	Fibroblast growth factor basic levels;	chr14:77725256	chr1:78749073~78750659:+
BRCA	trans	rs9611565	0.659	rs4822036	ENSG00000268568.1	AC007228.9	-26.11	5.13e-116	1.32e-108	-0.97	-0.63	Vitiligo;	chr22:41540015	chr19:56672574~56673901:-
BRCA	trans	rs7811142	0.83	rs10085549	ENSG00000228546.2	CTA-313A17.3	26.09	6.6e-116	1.69e-108	1	0.63	Platelet count;	chr7:100385512	chr7:102337316~102339115:+
BRCA	trans	rs9611565	0.659	rs12484228	ENSG00000268568.1	AC007228.9	-26.09	6.88e-116	1.76e-108	-0.97	-0.63	Vitiligo;	chr22:41543735	chr19:56672574~56673901:-
BRCA	trans	rs8010715	0.816	rs1134340	ENSG00000248988.1	RP11-815N9.2	26.04	1.47e-115	3.74e-108	0.77	0.63	IgG glycosylation;	chr14:24125004	chr4:159007119~159007835:+
BRCA	trans	rs7811142	0.83	rs11768967	ENSG00000228546.2	CTA-313A17.3	26.02	2.14e-115	5.4e-108	1	0.63	Platelet count;	chr7:100370021	chr7:102337316~102339115:+
BRCA	trans	rs7811142	0.775	rs1059129	ENSG00000228546.2	CTA-313A17.3	26.01	2.41e-115	6.1e-108	1.01	0.63	Platelet count;	chr7:100328899	chr7:102337316~102339115:+
BRCA	trans	rs7811142	0.83	rs7792959	ENSG00000228546.2	CTA-313A17.3	25.96	5.48e-115	1.38e-107	1	0.63	Platelet count;	chr7:100374780	chr7:102337316~102339115:+
BRCA	trans	rs7811142	0.83	rs6979910	ENSG00000228546.2	CTA-313A17.3	25.93	8.25e-115	2.07e-107	1.01	0.63	Platelet count;	chr7:100343007	chr7:102337316~102339115:+
BRCA	trans	rs5022636	1	rs5022636	ENSG00000180764.13	PIPSL	25.93	8.78e-115	2.2e-107	0.78	0.63	Gut microbiota (functional units);	chr1:151322585	chr10:93958191~93961540:-
BRCA	trans	rs9611565	0.694	rs202631	ENSG00000268568.1	AC007228.9	25.93	8.81e-115	2.21e-107	0.93	0.63	Vitiligo;	chr22:41467419	chr19:56672574~56673901:-
BRCA	trans	rs8010715	0.816	rs6573573	ENSG00000248988.1	RP11-815N9.2	25.9	1.38e-114	3.44e-107	0.77	0.63	IgG glycosylation;	chr14:24130048	chr4:159007119~159007835:+
BRCA	trans	rs2950393	0.804	rs1466382	ENSG00000121089.4	NACA3P	-25.89	1.6e-114	3.99e-107	-0.72	-0.63	Platelet distribution width;	chr12:56723050	chr4:164943290~164943937:+
BRCA	trans	rs5022636	0.927	rs10888409	ENSG00000180764.13	PIPSL	25.89	1.65e-114	4.1e-107	0.76	0.63	Gut microbiota (functional units);	chr1:151299306	chr10:93958191~93961540:-
BRCA	trans	rs7949030	0.754	rs36104523	ENSG00000186676.3	EEF1GP1	-25.88	1.97e-114	4.89e-107	-0.84	-0.63	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62628268	chr7:125033453~125035301:+
BRCA	trans	rs941207	0.542	rs7315786	ENSG00000121089.4	NACA3P	-25.83	4.36e-114	1.08e-106	-0.81	-0.62	Platelet count;	chr12:56801595	chr4:164943290~164943937:+
BRCA	trans	rs13177918	0.798	rs13182116	ENSG00000213058.3	RP4-765C7.2	-25.81	5.34e-114	1.32e-106	-0.93	-0.62	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150465963	chr1:178411616~178411972:+
BRCA	trans	rs1816752	0.875	rs3783076	ENSG00000237917.1	PARP4P1	25.74	1.66e-113	4.09e-106	0.8	0.62	Obesity-related traits;	chr13:24490319	chrY:26594851~26634652:-
BRCA	trans	rs5022636	1	rs4970948	ENSG00000180764.13	PIPSL	25.73	1.98e-113	4.89e-106	0.76	0.62	Gut microbiota (functional units);	chr1:151318767	chr10:93958191~93961540:-
BRCA	trans	rs5022636	0.927	rs943637	ENSG00000180764.13	PIPSL	25.72	2.37e-113	5.79e-106	0.76	0.62	Gut microbiota (functional units);	chr1:151310543	chr10:93958191~93961540:-
BRCA	trans	rs5022636	0.964	rs7518924	ENSG00000180764.13	PIPSL	25.72	2.37e-113	5.79e-106	0.76	0.62	Gut microbiota (functional units);	chr1:151319225	chr10:93958191~93961540:-
BRCA	trans	rs7554547	0.667	rs2336377	ENSG00000261819.1	RP11-680G24.4	-25.71	3e-113	7.33e-106	-0.82	-0.62	Nonsyndromic cleft lip with cleft palate;	chr1:11889913	chr16:14988259~14990160:-
BRCA	trans	rs9611565	0.694	rs202628	ENSG00000268568.1	AC007228.9	-25.58	2.23e-112	5.36e-105	-0.89	-0.62	Vitiligo;	chr22:41453509	chr19:56672574~56673901:-
BRCA	trans	rs61990749	0.597	rs2299930	ENSG00000235400.1	RP4-641G12.4	-25.57	2.47e-112	5.93e-105	-1.03	-0.62	Fibroblast growth factor basic levels;	chr14:77697379	chr1:78749073~78750659:+
BRCA	trans	rs941207	0.542	rs1813109	ENSG00000121089.4	NACA3P	-25.56	3.12e-112	7.5e-105	-0.8	-0.62	Platelet count;	chr12:56798079	chr4:164943290~164943937:+
BRCA	trans	rs7811142	0.666	rs28401739	ENSG00000228546.2	CTA-313A17.3	25.53	4.37e-112	1.05e-104	1	0.62	Platelet count;	chr7:100308061	chr7:102337316~102339115:+
BRCA	trans	rs61990749	0.597	rs1008988	ENSG00000235400.1	RP4-641G12.4	25.47	1.17e-111	2.79e-104	1.05	0.62	Fibroblast growth factor basic levels;	chr14:77794452	chr1:78749073~78750659:+
BRCA	trans	rs61990749	0.686	rs11159288	ENSG00000235400.1	RP4-641G12.4	25.32	1.25e-110	2.92e-103	1.04	0.62	Fibroblast growth factor basic levels;	chr14:77750629	chr1:78749073~78750659:+
BRCA	trans	rs928391	1	rs928392	ENSG00000227183.3	HDGFP1	25.25	4.1e-110	9.46e-103	0.84	0.62	Platelet count;	chr1:156801024	chrX:131646639~131646890:+
BRCA	trans	rs2950393	0.804	rs2290894	ENSG00000121089.4	NACA3P	25.24	4.27e-110	9.86e-103	0.71	0.62	Platelet distribution width;	chr12:56714911	chr4:164943290~164943937:+
BRCA	trans	rs7949030	1	rs7949030	ENSG00000186676.3	EEF1GP1	25.24	4.4e-110	1.01e-102	0.8	0.62	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62627409	chr7:125033453~125035301:+
BRCA	trans	rs2950393	0.777	rs2926747	ENSG00000121089.4	NACA3P	25.22	5.9e-110	1.36e-102	0.71	0.62	Platelet distribution width;	chr12:56716147	chr4:164943290~164943937:+
BRCA	trans	rs5022636	0.927	rs10788803	ENSG00000180764.13	PIPSL	25.21	6.73e-110	1.55e-102	0.75	0.62	Gut microbiota (functional units);	chr1:151291306	chr10:93958191~93961540:-
BRCA	trans	rs941207	0.542	rs1903370	ENSG00000121089.4	NACA3P	-25.21	7.04e-110	1.62e-102	-0.79	-0.62	Platelet count;	chr12:56812900	chr4:164943290~164943937:+
BRCA	trans	rs13177918	0.798	rs13182116	ENSG00000224114.1	RP11-343H5.4	-25.2	7.91e-110	1.81e-102	-0.93	-0.62	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150465963	chr1:206695837~206696269:-
BRCA	trans	rs928391	1	rs3765787	ENSG00000227183.3	HDGFP1	-25.19	9.47e-110	2.17e-102	-0.85	-0.62	Platelet count;	chr1:156784673	chrX:131646639~131646890:+
BRCA	trans	rs928391	1	rs10157555	ENSG00000227183.3	HDGFP1	-25.18	1.15e-109	2.63e-102	-0.83	-0.62	Platelet count;	chr1:156802060	chrX:131646639~131646890:+
BRCA	trans	rs7554547	0.667	rs4846072	ENSG00000261819.1	RP11-680G24.4	25.15	1.86e-109	4.26e-102	0.82	0.61	Nonsyndromic cleft lip with cleft palate;	chr1:11890334	chr16:14988259~14990160:-
BRCA	trans	rs2950393	0.804	rs2926752	ENSG00000121089.4	NACA3P	25.15	1.95e-109	4.44e-102	0.71	0.61	Platelet distribution width;	chr12:56710144	chr4:164943290~164943937:+
BRCA	trans	rs2950393	0.777	rs2958148	ENSG00000121089.4	NACA3P	25.15	1.95e-109	4.44e-102	0.71	0.61	Platelet distribution width;	chr12:56710153	chr4:164943290~164943937:+
BRCA	trans	rs8010715	0.785	rs2877611	ENSG00000248988.1	RP11-815N9.2	25.12	2.86e-109	6.52e-102	0.77	0.61	IgG glycosylation;	chr14:24126221	chr4:159007119~159007835:+
BRCA	trans	rs61990749	0.597	rs8003691	ENSG00000235400.1	RP4-641G12.4	25.08	5.47e-109	1.22e-101	1.03	0.61	Fibroblast growth factor basic levels;	chr14:77744882	chr1:78749073~78750659:+
BRCA	trans	rs61990749	0.597	rs176955	ENSG00000235400.1	RP4-641G12.4	25.07	6.24e-109	1.39e-101	1.03	0.61	Fibroblast growth factor basic levels;	chr14:77714877	chr1:78749073~78750659:+
BRCA	trans	rs8010715	0.816	rs6573565	ENSG00000248988.1	RP11-815N9.2	-25.06	7.75e-109	1.72e-101	-0.76	-0.61	IgG glycosylation;	chr14:24125524	chr4:159007119~159007835:+
BRCA	trans	rs61990749	0.597	rs117131659	ENSG00000235400.1	RP4-641G12.4	-25.06	7.99e-109	1.77e-101	-1.04	-0.61	Fibroblast growth factor basic levels;	chr14:77664783	chr1:78749073~78750659:+
BRCA	trans	rs8010715	0.816	rs8015168	ENSG00000248988.1	RP11-815N9.2	25.04	1.03e-108	2.29e-101	0.77	0.61	IgG glycosylation;	chr14:24130663	chr4:159007119~159007835:+
BRCA	trans	rs8010715	0.816	rs762093	ENSG00000248988.1	RP11-815N9.2	25.03	1.23e-108	2.74e-101	0.76	0.61	IgG glycosylation;	chr14:24122709	chr4:159007119~159007835:+
BRCA	trans	rs1816752	0.669	rs2862906	ENSG00000237917.1	PARP4P1	-25.01	1.62e-108	3.58e-101	-0.76	-0.61	Obesity-related traits;	chr13:24494482	chrY:26594851~26634652:-
BRCA	trans	rs61990749	0.544	rs176979	ENSG00000235400.1	RP4-641G12.4	24.99	2.12e-108	4.67e-101	1.02	0.61	Fibroblast growth factor basic levels;	chr14:77731729	chr1:78749073~78750659:+
BRCA	trans	rs61990749	0.597	rs1477260	ENSG00000235400.1	RP4-641G12.4	24.99	2.22e-108	4.9e-101	1.05	0.61	Fibroblast growth factor basic levels;	chr14:77790475	chr1:78749073~78750659:+
BRCA	trans	rs61990749	0.597	rs2267768	ENSG00000235400.1	RP4-641G12.4	24.98	2.52e-108	5.53e-101	1.02	0.61	Fibroblast growth factor basic levels;	chr14:77749671	chr1:78749073~78750659:+
BRCA	trans	rs61990749	0.597	rs1549119	ENSG00000235400.1	RP4-641G12.4	24.98	2.52e-108	5.53e-101	1.02	0.61	Fibroblast growth factor basic levels;	chr14:77753469	chr1:78749073~78750659:+
BRCA	trans	rs61990749	0.597	rs1978416	ENSG00000235400.1	RP4-641G12.4	24.98	2.52e-108	5.53e-101	1.02	0.61	Fibroblast growth factor basic levels;	chr14:77761558	chr1:78749073~78750659:+
BRCA	trans	rs61990749	0.544	rs3759728	ENSG00000235400.1	RP4-641G12.4	24.98	2.52e-108	5.53e-101	1.02	0.61	Fibroblast growth factor basic levels;	chr14:77763816	chr1:78749073~78750659:+
BRCA	trans	rs6477998	0.934	rs4979223	ENSG00000238072.1	RP11-305M3.2	24.94	4.97e-108	1.09e-100	0.78	0.61	Hematology traits;	chr9:113219836	chr7:129410113~129410370:-
BRCA	trans	rs8010715	0.816	rs11574503	ENSG00000248988.1	RP11-815N9.2	-24.93	5.48e-108	1.2e-100	-0.76	-0.61	IgG glycosylation;	chr14:24132109	chr4:159007119~159007835:+
BRCA	trans	rs2950393	0.804	rs3214051	ENSG00000121089.4	NACA3P	24.89	1.01e-107	2.18e-100	0.71	0.61	Platelet distribution width;	chr12:56725452	chr4:164943290~164943937:+
BRCA	trans	rs1816752	0.669	rs9553309	ENSG00000237917.1	PARP4P1	-24.89	1.04e-107	2.25e-100	-0.75	-0.61	Obesity-related traits;	chr13:24471476	chrY:26594851~26634652:-
BRCA	trans	rs61990749	0.597	rs28534379	ENSG00000235400.1	RP4-641G12.4	-24.89	1.08e-107	2.33e-100	-1.02	-0.61	Fibroblast growth factor basic levels;	chr14:77705797	chr1:78749073~78750659:+
BRCA	trans	rs61990749	0.597	rs176944	ENSG00000235400.1	RP4-641G12.4	-24.89	1.08e-107	2.33e-100	-1.02	-0.61	Fibroblast growth factor basic levels;	chr14:77709868	chr1:78749073~78750659:+
BRCA	trans	rs1816752	0.716	rs1539096	ENSG00000237917.1	PARP4P1	-24.88	1.36e-107	2.93e-100	-0.76	-0.61	Obesity-related traits;	chr13:24501721	chrY:26594851~26634652:-
BRCA	trans	rs61990749	0.597	rs176952	ENSG00000235400.1	RP4-641G12.4	24.86	1.67e-107	3.59e-100	1.02	0.61	Fibroblast growth factor basic levels;	chr14:77714393	chr1:78749073~78750659:+
BRCA	trans	rs61990749	0.544	rs2544566	ENSG00000235400.1	RP4-641G12.4	24.86	1.67e-107	3.59e-100	1.02	0.61	Fibroblast growth factor basic levels;	chr14:77715395	chr1:78749073~78750659:+
BRCA	trans	rs61990749	0.544	rs2544567	ENSG00000235400.1	RP4-641G12.4	24.86	1.67e-107	3.59e-100	1.02	0.61	Fibroblast growth factor basic levels;	chr14:77715396	chr1:78749073~78750659:+
BRCA	trans	rs61990749	0.597	rs12887282	ENSG00000235400.1	RP4-641G12.4	24.85	2.18e-107	4.68e-100	1.02	0.61	Fibroblast growth factor basic levels;	chr14:77734242	chr1:78749073~78750659:+
BRCA	trans	rs61990749	0.597	rs12887606	ENSG00000235400.1	RP4-641G12.4	24.85	2.18e-107	4.68e-100	1.02	0.61	Fibroblast growth factor basic levels;	chr14:77734277	chr1:78749073~78750659:+
BRCA	trans	rs2950393	0.929	rs10876916	ENSG00000121089.4	NACA3P	24.83	2.62e-107	5.62e-100	0.72	0.61	Platelet distribution width;	chr12:56692728	chr4:164943290~164943937:+
BRCA	trans	rs2950393	0.794	rs1563897	ENSG00000121089.4	NACA3P	24.83	2.62e-107	5.62e-100	0.72	0.61	Platelet distribution width;	chr12:56699316	chr4:164943290~164943937:+
BRCA	trans	rs7811142	0.943	rs28660238	ENSG00000228546.2	CTA-313A17.3	24.82	3.25e-107	6.97e-100	0.96	0.61	Platelet count;	chr7:100425685	chr7:102337316~102339115:+
BRCA	trans	rs7811142	1	rs28490152	ENSG00000228546.2	CTA-313A17.3	24.8	4.48e-107	9.56e-100	0.96	0.61	Platelet count;	chr7:100423359	chr7:102337316~102339115:+
BRCA	trans	rs1816752	0.692	rs2282409	ENSG00000237917.1	PARP4P1	-24.75	1.04e-106	2.21e-99	-0.75	-0.61	Obesity-related traits;	chr13:24512388	chrY:26594851~26634652:-
BRCA	trans	rs61990749	0.597	rs7142390	ENSG00000235400.1	RP4-641G12.4	24.74	1.12e-106	2.37e-99	1.08	0.61	Fibroblast growth factor basic levels;	chr14:77766537	chr1:78749073~78750659:+
BRCA	trans	rs6477998	0.903	rs4979226	ENSG00000238072.1	RP11-305M3.2	24.71	1.69e-106	3.59e-99	0.78	0.61	Hematology traits;	chr9:113239516	chr7:129410113~129410370:-
BRCA	trans	rs61990749	0.597	rs11623088	ENSG00000235400.1	RP4-641G12.4	-24.68	2.86e-106	6.04e-99	-1.02	-0.61	Fibroblast growth factor basic levels;	chr14:77671392	chr1:78749073~78750659:+
BRCA	trans	rs1816752	0.716	rs7995304	ENSG00000237917.1	PARP4P1	-24.67	3.12e-106	6.58e-99	-0.75	-0.61	Obesity-related traits;	chr13:24514284	chrY:26594851~26634652:-
BRCA	trans	rs61990749	0.597	rs176980	ENSG00000235400.1	RP4-641G12.4	-24.67	3.3e-106	6.96e-99	-1.01	-0.61	Fibroblast growth factor basic levels;	chr14:77732106	chr1:78749073~78750659:+
BRCA	trans	rs61990749	0.597	rs13379065	ENSG00000235400.1	RP4-641G12.4	-24.67	3.55e-106	7.47e-99	-1.02	-0.61	Fibroblast growth factor basic levels;	chr14:77674952	chr1:78749073~78750659:+
BRCA	trans	rs61990749	0.597	rs17106157	ENSG00000235400.1	RP4-641G12.4	-24.64	5.04e-106	1.05e-98	-1.02	-0.61	Fibroblast growth factor basic levels;	chr14:77680535	chr1:78749073~78750659:+
BRCA	trans	rs61990749	0.597	rs2267759	ENSG00000235400.1	RP4-641G12.4	-24.64	5.04e-106	1.05e-98	-1.02	-0.61	Fibroblast growth factor basic levels;	chr14:77681272	chr1:78749073~78750659:+
BRCA	trans	rs13253073	1	rs12541837	ENSG00000260318.1	COX6CP1	-24.62	7.04e-106	1.47e-98	-1.08	-0.61	Glucose homeostasis traits;	chr8:99869645	chr16:11903923~11904137:-
BRCA	trans	rs61990749	0.597	rs10136053	ENSG00000235400.1	RP4-641G12.4	-24.62	7.21e-106	1.5e-98	-1.01	-0.61	Fibroblast growth factor basic levels;	chr14:77688862	chr1:78749073~78750659:+
BRCA	trans	rs7811142	0.943	rs67483801	ENSG00000228546.2	CTA-313A17.3	24.59	1.22e-105	2.53e-98	0.96	0.61	Platelet count;	chr7:100434135	chr7:102337316~102339115:+
BRCA	trans	rs7811142	1	rs11761784	ENSG00000228546.2	CTA-313A17.3	24.59	1.22e-105	2.53e-98	0.96	0.61	Platelet count;	chr7:100442347	chr7:102337316~102339115:+
BRCA	trans	rs6477998	0.932	rs4129395	ENSG00000238072.1	RP11-305M3.2	24.59	1.23e-105	2.55e-98	0.78	0.61	Hematology traits;	chr9:113213109	chr7:129410113~129410370:-
BRCA	trans	rs6477998	0.966	rs7859354	ENSG00000238072.1	RP11-305M3.2	24.59	1.23e-105	2.55e-98	0.78	0.61	Hematology traits;	chr9:113214165	chr7:129410113~129410370:-
BRCA	trans	rs61990749	0.597	rs2364584	ENSG00000235400.1	RP4-641G12.4	-24.58	1.34e-105	2.78e-98	-1.02	-0.61	Fibroblast growth factor basic levels;	chr14:77685943	chr1:78749073~78750659:+
BRCA	trans	rs7811142	1	rs112317829	ENSG00000228546.2	CTA-313A17.3	24.57	1.59e-105	3.31e-98	0.96	0.61	Platelet count;	chr7:100445550	chr7:102337316~102339115:+
BRCA	trans	rs7811142	1	rs68116612	ENSG00000228546.2	CTA-313A17.3	24.56	1.89e-105	3.91e-98	0.96	0.61	Platelet count;	chr7:100408870	chr7:102337316~102339115:+
BRCA	trans	rs6477998	0.903	rs7041615	ENSG00000238072.1	RP11-305M3.2	24.54	2.6e-105	5.37e-98	0.78	0.61	Hematology traits;	chr9:113244747	chr7:129410113~129410370:-
BRCA	trans	rs1816752	0.716	rs1441058	ENSG00000237917.1	PARP4P1	-24.54	2.63e-105	5.44e-98	-0.74	-0.61	Obesity-related traits;	chr13:24516275	chrY:26594851~26634652:-
BRCA	trans	rs6477998	0.966	rs7851395	ENSG00000238072.1	RP11-305M3.2	24.53	2.79e-105	5.76e-98	0.78	0.61	Hematology traits;	chr9:113240184	chr7:129410113~129410370:-
BRCA	trans	rs5022636	0.821	rs4246525	ENSG00000180764.13	PIPSL	24.51	4.03e-105	8.32e-98	0.75	0.6	Gut microbiota (functional units);	chr1:151285263	chr10:93958191~93961540:-
BRCA	trans	rs6477998	1	rs10759636	ENSG00000238072.1	RP11-305M3.2	24.49	5.3e-105	1.09e-97	0.78	0.6	Hematology traits;	chr9:113256497	chr7:129410113~129410370:-
BRCA	trans	rs1816752	0.646	rs2862905	ENSG00000237917.1	PARP4P1	-24.49	5.91e-105	1.21e-97	-0.74	-0.6	Obesity-related traits;	chr13:24485142	chrY:26594851~26634652:-
BRCA	trans	rs13190036	1	rs4976682	ENSG00000217325.2	PRELID1P1	24.46	8.75e-105	1.8e-97	1.01	0.6	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177299001	chr6:126643488~126644390:+
BRCA	trans	rs6477998	1	rs10739388	ENSG00000238072.1	RP11-305M3.2	24.46	8.76e-105	1.8e-97	0.78	0.6	Hematology traits;	chr9:113214895	chr7:129410113~129410370:-
BRCA	trans	rs9467773	1	rs9467791	ENSG00000242375.1	RP11-498P14.3	-24.45	1.11e-104	2.27e-97	-0.83	-0.6	Intelligence (multi-trait analysis);	chr6:26562258	chr9:97195351~97197687:-
BRCA	trans	rs6477998	1	rs7038769	ENSG00000238072.1	RP11-305M3.2	24.39	2.43e-104	4.93e-97	0.78	0.6	Hematology traits;	chr9:113245303	chr7:129410113~129410370:-
BRCA	trans	rs6477998	1	rs7022397	ENSG00000238072.1	RP11-305M3.2	24.39	2.43e-104	4.93e-97	0.78	0.6	Hematology traits;	chr9:113245397	chr7:129410113~129410370:-
BRCA	trans	rs61990749	0.544	rs11628888	ENSG00000235400.1	RP4-641G12.4	-24.39	2.53e-104	5.12e-97	-1.02	-0.6	Fibroblast growth factor basic levels;	chr14:77695163	chr1:78749073~78750659:+
BRCA	trans	rs727563	0.635	rs5751141	ENSG00000268568.1	AC007228.9	24.38	3.18e-104	6.43e-97	0.94	0.6	Crohn's disease;Inflammatory bowel disease;	chr22:41711741	chr19:56672574~56673901:-
BRCA	trans	rs2950393	0.929	rs2958155	ENSG00000121089.4	NACA3P	24.35	4.78e-104	9.64e-97	0.69	0.6	Platelet distribution width;	chr12:56670761	chr4:164943290~164943937:+
BRCA	trans	rs916888	0.773	rs9896243	ENSG00000264070.1	DND1P1	24.35	5.1e-104	1.03e-96	0.99	0.6	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:45585871~45586929:+
BRCA	trans	rs7811142	0.943	rs67196635	ENSG00000228546.2	CTA-313A17.3	24.34	5.59e-104	1.12e-96	0.96	0.6	Platelet count;	chr7:100427941	chr7:102337316~102339115:+
BRCA	trans	rs7811142	1	rs6962151	ENSG00000228546.2	CTA-313A17.3	24.34	5.59e-104	1.12e-96	0.96	0.6	Platelet count;	chr7:100430861	chr7:102337316~102339115:+
BRCA	trans	rs7811142	0.943	rs111757992	ENSG00000228546.2	CTA-313A17.3	24.34	5.77e-104	1.16e-96	0.96	0.6	Platelet count;	chr7:100418731	chr7:102337316~102339115:+
BRCA	trans	rs7811142	1	rs67239991	ENSG00000228546.2	CTA-313A17.3	24.33	6.45e-104	1.29e-96	0.96	0.6	Platelet count;	chr7:100448881	chr7:102337316~102339115:+
BRCA	trans	rs6477998	0.868	rs10513189	ENSG00000238072.1	RP11-305M3.2	24.33	6.73e-104	1.35e-96	0.76	0.6	Hematology traits;	chr9:113227941	chr7:129410113~129410370:-
BRCA	trans	rs9611565	0.659	rs9611610	ENSG00000268568.1	AC007228.9	-24.32	7.38e-104	1.48e-96	-0.95	-0.6	Vitiligo;	chr22:41553255	chr19:56672574~56673901:-
BRCA	trans	rs2950393	0.777	rs7966391	ENSG00000121089.4	NACA3P	24.32	8.42e-104	1.68e-96	0.71	0.6	Platelet distribution width;	chr12:56745272	chr4:164943290~164943937:+
BRCA	trans	rs1816752	0.716	rs9553331	ENSG00000237917.1	PARP4P1	-24.31	8.57e-104	1.71e-96	-0.73	-0.6	Obesity-related traits;	chr13:24516030	chrY:26594851~26634652:-
BRCA	trans	rs10242455	0.702	rs3528	ENSG00000228834.1	RP11-249L21.4	24.31	8.83e-104	1.76e-96	1.34	0.6	Blood metabolite levels;	chr7:99458317	chr6:108907615~108907873:-
BRCA	trans	rs6477998	1	rs4560868	ENSG00000238072.1	RP11-305M3.2	-24.29	1.23e-103	2.44e-96	-0.77	-0.6	Hematology traits;	chr9:113223219	chr7:129410113~129410370:-
BRCA	trans	rs10242455	0.702	rs55927283	ENSG00000228834.1	RP11-249L21.4	24.28	1.34e-103	2.68e-96	1.35	0.6	Blood metabolite levels;	chr7:99459568	chr6:108907615~108907873:-
BRCA	trans	rs5022636	0.927	rs10888410	ENSG00000180764.13	PIPSL	24.28	1.5e-103	2.98e-96	0.73	0.6	Gut microbiota (functional units);	chr1:151299975	chr10:93958191~93961540:-
BRCA	trans	rs6477998	0.966	rs10759637	ENSG00000238072.1	RP11-305M3.2	24.26	1.85e-103	3.66e-96	0.78	0.6	Hematology traits;	chr9:113262744	chr7:129410113~129410370:-
BRCA	trans	rs61990749	0.597	rs10142722	ENSG00000235400.1	RP4-641G12.4	24.26	2.14e-103	4.24e-96	1.02	0.6	Fibroblast growth factor basic levels;	chr14:77809206	chr1:78749073~78750659:+
BRCA	trans	rs2950393	0.804	rs2926748	ENSG00000121089.4	NACA3P	24.24	2.8e-103	5.54e-96	0.7	0.6	Platelet distribution width;	chr12:56715628	chr4:164943290~164943937:+
BRCA	trans	rs9467773	0.873	rs9295698	ENSG00000242375.1	RP11-498P14.3	24.15	1.16e-102	2.28e-95	0.81	0.6	Intelligence (multi-trait analysis);	chr6:26565871	chr9:97195351~97197687:-
BRCA	trans	rs9467773	1	rs6456734	ENSG00000242375.1	RP11-498P14.3	24.14	1.29e-102	2.52e-95	0.82	0.6	Intelligence (multi-trait analysis);	chr6:26566737	chr9:97195351~97197687:-
BRCA	trans	rs9467773	0.967	rs7753565	ENSG00000242375.1	RP11-498P14.3	24.14	1.32e-102	2.59e-95	0.81	0.6	Intelligence (multi-trait analysis);	chr6:26559784	chr9:97195351~97197687:-
BRCA	trans	rs2950393	0.929	rs7980835	ENSG00000121089.4	NACA3P	24.14	1.34e-102	2.62e-95	0.69	0.6	Platelet distribution width;	chr12:56676847	chr4:164943290~164943937:+
BRCA	trans	rs2950393	0.929	rs10747769	ENSG00000121089.4	NACA3P	24.14	1.34e-102	2.62e-95	0.69	0.6	Platelet distribution width;	chr12:56677056	chr4:164943290~164943937:+
BRCA	trans	rs9467773	1	rs6925895	ENSG00000242375.1	RP11-498P14.3	24.13	1.44e-102	2.81e-95	0.82	0.6	Intelligence (multi-trait analysis);	chr6:26571937	chr9:97195351~97197687:-
BRCA	trans	rs9467773	1	rs6932156	ENSG00000242375.1	RP11-498P14.3	24.13	1.47e-102	2.86e-95	0.82	0.6	Intelligence (multi-trait analysis);	chr6:26571278	chr9:97195351~97197687:-
BRCA	trans	rs9467773	1	rs6924838	ENSG00000242375.1	RP11-498P14.3	24.13	1.47e-102	2.86e-95	0.82	0.6	Intelligence (multi-trait analysis);	chr6:26571528	chr9:97195351~97197687:-
BRCA	trans	rs9467773	1	rs1535277	ENSG00000242375.1	RP11-498P14.3	24.13	1.54e-102	2.97e-95	0.82	0.6	Intelligence (multi-trait analysis);	chr6:26567574	chr9:97195351~97197687:-
BRCA	trans	rs9467773	1	rs1884948	ENSG00000242375.1	RP11-498P14.3	24.13	1.54e-102	2.97e-95	0.82	0.6	Intelligence (multi-trait analysis);	chr6:26567760	chr9:97195351~97197687:-
BRCA	trans	rs9467773	1	rs1884949	ENSG00000242375.1	RP11-498P14.3	24.13	1.54e-102	2.97e-95	0.82	0.6	Intelligence (multi-trait analysis);	chr6:26567839	chr9:97195351~97197687:-
BRCA	trans	rs9467773	1	rs9467796	ENSG00000242375.1	RP11-498P14.3	24.13	1.54e-102	2.97e-95	0.82	0.6	Intelligence (multi-trait analysis);	chr6:26568183	chr9:97195351~97197687:-
BRCA	trans	rs9467773	1	rs9467797	ENSG00000242375.1	RP11-498P14.3	24.13	1.54e-102	2.97e-95	0.82	0.6	Intelligence (multi-trait analysis);	chr6:26568245	chr9:97195351~97197687:-
BRCA	trans	rs9467773	1	rs1078679	ENSG00000242375.1	RP11-498P14.3	24.13	1.54e-102	2.97e-95	0.82	0.6	Intelligence (multi-trait analysis);	chr6:26568513	chr9:97195351~97197687:-
BRCA	trans	rs7811142	0.943	rs111493473	ENSG00000228546.2	CTA-313A17.3	24.13	1.61e-102	3.11e-95	0.95	0.6	Platelet count;	chr7:100452119	chr7:102337316~102339115:+
BRCA	trans	rs1816752	0.692	rs6490944	ENSG00000237917.1	PARP4P1	-24.12	1.68e-102	3.25e-95	-0.73	-0.6	Obesity-related traits;	chr13:24513866	chrY:26594851~26634652:-
BRCA	trans	rs61990749	0.5	rs8011337	ENSG00000235400.1	RP4-641G12.4	24.12	1.81e-102	3.5e-95	1.01	0.6	Fibroblast growth factor basic levels;	chr14:77806283	chr1:78749073~78750659:+
BRCA	trans	rs9467773	1	rs6456733	ENSG00000242375.1	RP11-498P14.3	24.1	2.46e-102	4.74e-95	0.81	0.6	Intelligence (multi-trait analysis);	chr6:26566576	chr9:97195351~97197687:-
BRCA	trans	rs9467773	1	rs6940188	ENSG00000242375.1	RP11-498P14.3	24.1	2.49e-102	4.79e-95	0.81	0.6	Intelligence (multi-trait analysis);	chr6:26561801	chr9:97195351~97197687:-
BRCA	trans	rs9467773	1	rs6940053	ENSG00000242375.1	RP11-498P14.3	24.1	2.49e-102	4.8e-95	0.81	0.6	Intelligence (multi-trait analysis);	chr6:26561894	chr9:97195351~97197687:-
BRCA	trans	rs7811142	1	rs1000215	ENSG00000228546.2	CTA-313A17.3	24.08	3.42e-102	6.57e-95	0.95	0.6	Platelet count;	chr7:100406920	chr7:102337316~102339115:+
BRCA	trans	rs9467773	1	rs9461271	ENSG00000242375.1	RP11-498P14.3	24.07	3.54e-102	6.8e-95	0.81	0.6	Intelligence (multi-trait analysis);	chr6:26554740	chr9:97195351~97197687:-
BRCA	trans	rs7811142	1	rs4472444	ENSG00000228546.2	CTA-313A17.3	24.07	3.87e-102	7.41e-95	0.95	0.6	Platelet count;	chr7:100473135	chr7:102337316~102339115:+
BRCA	trans	rs7811142	1	rs7809801	ENSG00000228546.2	CTA-313A17.3	24.07	3.87e-102	7.41e-95	0.95	0.6	Platelet count;	chr7:100474408	chr7:102337316~102339115:+
BRCA	trans	rs7811142	1	rs11766752	ENSG00000228546.2	CTA-313A17.3	24.06	4.26e-102	8.16e-95	0.95	0.6	Platelet count;	chr7:100475669	chr7:102337316~102339115:+
BRCA	trans	rs1816752	0.646	rs9511309	ENSG00000237917.1	PARP4P1	-24.04	6.09e-102	1.16e-94	-0.73	-0.6	Obesity-related traits;	chr13:24515435	chrY:26594851~26634652:-
BRCA	trans	rs13177918	0.798	rs12514700	ENSG00000239528.1	RPS14P8	24.03	6.65e-102	1.27e-94	0.87	0.6	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150466096	chr5:116562562~116562930:+
BRCA	trans	rs9467773	0.967	rs6941022	ENSG00000242375.1	RP11-498P14.3	24.03	6.77e-102	1.29e-94	0.81	0.6	Intelligence (multi-trait analysis);	chr6:26553303	chr9:97195351~97197687:-
BRCA	trans	rs9467773	1	rs2224380	ENSG00000242375.1	RP11-498P14.3	24.03	6.77e-102	1.29e-94	0.81	0.6	Intelligence (multi-trait analysis);	chr6:26553715	chr9:97195351~97197687:-
BRCA	trans	rs9467773	1	rs6930120	ENSG00000242375.1	RP11-498P14.3	24.03	6.77e-102	1.29e-94	0.81	0.6	Intelligence (multi-trait analysis);	chr6:26555256	chr9:97195351~97197687:-
BRCA	trans	rs9467773	1	rs10214634	ENSG00000242375.1	RP11-498P14.3	24.03	6.86e-102	1.31e-94	0.81	0.6	Intelligence (multi-trait analysis);	chr6:26564354	chr9:97195351~97197687:-
BRCA	trans	rs9467773	1	rs767471	ENSG00000242375.1	RP11-498P14.3	24.02	8.52e-102	1.62e-94	0.81	0.6	Intelligence (multi-trait analysis);	chr6:26557626	chr9:97195351~97197687:-
BRCA	trans	rs2950393	0.804	rs2035081	ENSG00000121089.4	NACA3P	24.01	9.36e-102	1.78e-94	0.7	0.6	Platelet distribution width;	chr12:56732095	chr4:164943290~164943937:+
BRCA	trans	rs61990749	0.597	rs4632066	ENSG00000235400.1	RP4-641G12.4	-24	1.04e-101	1.98e-94	-0.96	-0.6	Fibroblast growth factor basic levels;	chr14:77780939	chr1:78749073~78750659:+
BRCA	trans	rs6477998	0.874	rs10739390	ENSG00000238072.1	RP11-305M3.2	24	1.1e-101	2.09e-94	0.77	0.6	Hematology traits;	chr9:113226209	chr7:129410113~129410370:-
BRCA	trans	rs7811142	0.943	rs28578163	ENSG00000228546.2	CTA-313A17.3	23.99	1.25e-101	2.36e-94	0.96	0.6	Platelet count;	chr7:100447131	chr7:102337316~102339115:+
BRCA	trans	rs6477998	0.9	rs7850357	ENSG00000238072.1	RP11-305M3.2	23.98	1.42e-101	2.69e-94	0.77	0.6	Hematology traits;	chr9:113222319	chr7:129410113~129410370:-
BRCA	trans	rs9467773	0.565	rs4343916	ENSG00000242375.1	RP11-498P14.3	23.97	1.76e-101	3.32e-94	0.85	0.6	Intelligence (multi-trait analysis);	chr6:26522447	chr9:97195351~97197687:-
BRCA	trans	rs2950393	0.804	rs898609	ENSG00000121089.4	NACA3P	23.97	1.85e-101	3.49e-94	0.69	0.6	Platelet distribution width;	chr12:56713026	chr4:164943290~164943937:+
BRCA	trans	rs2950393	0.804	rs4902	ENSG00000121089.4	NACA3P	23.97	1.85e-101	3.49e-94	0.69	0.6	Platelet distribution width;	chr12:56714419	chr4:164943290~164943937:+
BRCA	trans	rs9467773	1	rs9467787	ENSG00000242375.1	RP11-498P14.3	23.96	2.06e-101	3.88e-94	0.81	0.6	Intelligence (multi-trait analysis);	chr6:26556541	chr9:97195351~97197687:-
BRCA	trans	rs9467773	1	rs6922824	ENSG00000242375.1	RP11-498P14.3	-23.95	2.36e-101	4.43e-94	-0.8	-0.6	Intelligence (multi-trait analysis);	chr6:26553587	chr9:97195351~97197687:-
BRCA	trans	rs9467773	0.565	rs6925047	ENSG00000242375.1	RP11-498P14.3	23.94	2.8e-101	5.25e-94	0.85	0.6	Intelligence (multi-trait analysis);	chr6:26521207	chr9:97195351~97197687:-
BRCA	trans	rs13190036	1	rs71601343	ENSG00000217325.2	PRELID1P1	-23.94	2.99e-101	5.6e-94	-1.04	-0.6	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177205106	chr6:126643488~126644390:+
BRCA	trans	rs13190036	1	rs71601344	ENSG00000217325.2	PRELID1P1	-23.94	2.99e-101	5.6e-94	-1.04	-0.6	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177206492	chr6:126643488~126644390:+
BRCA	trans	rs9467773	0.525	rs1535274	ENSG00000242375.1	RP11-498P14.3	23.92	3.74e-101	6.98e-94	0.85	0.6	Intelligence (multi-trait analysis);	chr6:26520519	chr9:97195351~97197687:-
BRCA	trans	rs9467773	1	rs9357010	ENSG00000242375.1	RP11-498P14.3	23.91	4.28e-101	7.97e-94	0.8	0.6	Intelligence (multi-trait analysis);	chr6:26527717	chr9:97195351~97197687:-
BRCA	trans	rs9467773	1	rs9986382	ENSG00000242375.1	RP11-498P14.3	23.89	6.31e-101	1.17e-93	0.81	0.59	Intelligence (multi-trait analysis);	chr6:26550391	chr9:97195351~97197687:-
BRCA	trans	rs61990749	0.597	rs10148373	ENSG00000235400.1	RP4-641G12.4	23.84	1.36e-100	2.51e-93	1.07	0.59	Fibroblast growth factor basic levels;	chr14:77813856	chr1:78749073~78750659:+
BRCA	trans	rs13190036	1	rs13157667	ENSG00000217325.2	PRELID1P1	-23.83	1.59e-100	2.92e-93	-1.05	-0.59	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177186876	chr6:126643488~126644390:+
BRCA	trans	rs9611565	0.512	rs139561	ENSG00000268568.1	AC007228.9	23.82	1.69e-100	3.1e-93	0.96	0.59	Vitiligo;	chr22:41799406	chr19:56672574~56673901:-
BRCA	trans	rs9467773	1	rs10484442	ENSG00000242375.1	RP11-498P14.3	23.81	2.25e-100	4.12e-93	0.8	0.59	Intelligence (multi-trait analysis);	chr6:26555651	chr9:97195351~97197687:-
BRCA	trans	rs941207	0.542	rs10876928	ENSG00000121089.4	NACA3P	-23.74	5.8e-100	1.06e-92	-0.72	-0.59	Platelet count;	chr12:56813646	chr4:164943290~164943937:+
BRCA	trans	rs13190036	1	rs34446750	ENSG00000217325.2	PRELID1P1	-23.73	7.35e-100	1.34e-92	-1.04	-0.59	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177168079	chr6:126643488~126644390:+
BRCA	trans	rs2950393	0.804	rs1026565	ENSG00000121089.4	NACA3P	23.7	1.16e-99	2.09e-92	0.68	0.59	Platelet distribution width;	chr12:56744044	chr4:164943290~164943937:+
BRCA	trans	rs2950393	0.804	rs10783796	ENSG00000121089.4	NACA3P	23.7	1.19e-99	2.16e-92	0.69	0.59	Platelet distribution width;	chr12:56733387	chr4:164943290~164943937:+
BRCA	trans	rs9467773	1	rs4713006	ENSG00000242375.1	RP11-498P14.3	23.68	1.63e-99	2.94e-92	0.8	0.59	Intelligence (multi-trait analysis);	chr6:26519644	chr9:97195351~97197687:-
BRCA	trans	rs9467773	1	rs6910899	ENSG00000242375.1	RP11-498P14.3	23.68	1.63e-99	2.94e-92	0.8	0.59	Intelligence (multi-trait analysis);	chr6:26524111	chr9:97195351~97197687:-
BRCA	trans	rs13190036	1	rs3733875	ENSG00000217325.2	PRELID1P1	-23.67	1.69e-99	3.04e-92	-1.04	-0.59	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177210239	chr6:126643488~126644390:+
BRCA	trans	rs61990749	0.597	rs1006039	ENSG00000235400.1	RP4-641G12.4	-23.67	1.84e-99	3.3e-92	-0.98	-0.59	Fibroblast growth factor basic levels;	chr14:77796853	chr1:78749073~78750659:+
BRCA	trans	rs9467773	1	rs9393729	ENSG00000242375.1	RP11-498P14.3	23.67	1.9e-99	3.4e-92	0.8	0.59	Intelligence (multi-trait analysis);	chr6:26513938	chr9:97195351~97197687:-
BRCA	trans	rs13190036	0.901	rs28715668	ENSG00000217325.2	PRELID1P1	23.67	1.91e-99	3.42e-92	1.03	0.59	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177272267	chr6:126643488~126644390:+
BRCA	trans	rs9467773	0.967	rs6924865	ENSG00000242375.1	RP11-498P14.3	23.66	2e-99	3.58e-92	0.8	0.59	Intelligence (multi-trait analysis);	chr6:26521125	chr9:97195351~97197687:-
BRCA	trans	rs2950393	0.804	rs11171951	ENSG00000121089.4	NACA3P	23.66	2.3e-99	4.11e-92	0.69	0.59	Platelet distribution width;	chr12:56718853	chr4:164943290~164943937:+
BRCA	trans	rs9467773	0.967	rs6456732	ENSG00000242375.1	RP11-498P14.3	23.64	2.82e-99	5.03e-92	0.8	0.59	Intelligence (multi-trait analysis);	chr6:26514217	chr9:97195351~97197687:-
BRCA	trans	rs2950393	0.804	rs2958127	ENSG00000121089.4	NACA3P	23.64	3.09e-99	5.49e-92	0.69	0.59	Platelet distribution width;	chr12:56720523	chr4:164943290~164943937:+
BRCA	trans	rs9467773	1	rs6925703	ENSG00000242375.1	RP11-498P14.3	23.64	3.1e-99	5.52e-92	0.8	0.59	Intelligence (multi-trait analysis);	chr6:26521361	chr9:97195351~97197687:-
BRCA	trans	rs9467773	0.967	rs9295694	ENSG00000242375.1	RP11-498P14.3	23.63	3.62e-99	6.43e-92	0.8	0.59	Intelligence (multi-trait analysis);	chr6:26512766	chr9:97195351~97197687:-
BRCA	trans	rs9467773	0.967	rs9467775	ENSG00000242375.1	RP11-498P14.3	23.63	3.62e-99	6.43e-92	0.8	0.59	Intelligence (multi-trait analysis);	chr6:26513207	chr9:97195351~97197687:-
BRCA	trans	rs13190036	1	rs35535623	ENSG00000217325.2	PRELID1P1	-23.59	5.86e-99	1.04e-91	-1.03	-0.59	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177202295	chr6:126643488~126644390:+
BRCA	trans	rs9467773	0.967	rs1535276	ENSG00000242375.1	RP11-498P14.3	23.59	6.72e-99	1.19e-91	0.8	0.59	Intelligence (multi-trait analysis);	chr6:26520713	chr9:97195351~97197687:-
BRCA	trans	rs9467773	0.967	rs1056347	ENSG00000242375.1	RP11-498P14.3	23.56	9.49e-99	1.67e-91	0.8	0.59	Intelligence (multi-trait analysis);	chr6:26527296	chr9:97195351~97197687:-
BRCA	trans	rs10242455	0.557	rs45529541	ENSG00000228834.1	RP11-249L21.4	23.53	1.53e-98	2.7e-91	1.33	0.59	Blood metabolite levels;	chr7:99450520	chr6:108907615~108907873:-
BRCA	trans	rs9467773	0.967	rs9461267	ENSG00000242375.1	RP11-498P14.3	23.53	1.57e-98	2.77e-91	0.8	0.59	Intelligence (multi-trait analysis);	chr6:26525227	chr9:97195351~97197687:-
BRCA	trans	rs941207	0.507	rs73337030	ENSG00000121089.4	NACA3P	-23.53	1.68e-98	2.95e-91	-0.69	-0.59	Platelet count;	chr12:56652410	chr4:164943290~164943937:+
BRCA	trans	rs2950393	0.804	rs1131514	ENSG00000121089.4	NACA3P	-23.5	2.51e-98	4.4e-91	-0.69	-0.59	Platelet distribution width;	chr12:56739356	chr4:164943290~164943937:+
BRCA	trans	rs61990749	0.597	rs12896026	ENSG00000235400.1	RP4-641G12.4	23.47	3.75e-98	6.55e-91	0.96	0.59	Fibroblast growth factor basic levels;	chr14:77778093	chr1:78749073~78750659:+
BRCA	trans	rs61990749	0.544	rs12435761	ENSG00000235400.1	RP4-641G12.4	23.47	3.75e-98	6.55e-91	0.96	0.59	Fibroblast growth factor basic levels;	chr14:77779734	chr1:78749073~78750659:+
BRCA	trans	rs9611565	0.512	rs132767	ENSG00000268568.1	AC007228.9	-23.43	7.32e-98	1.27e-90	-0.94	-0.59	Vitiligo;	chr22:41613516	chr19:56672574~56673901:-
BRCA	trans	rs61990749	0.597	rs9323650	ENSG00000235400.1	RP4-641G12.4	23.43	7.82e-98	1.35e-90	0.97	0.59	Fibroblast growth factor basic levels;	chr14:77683993	chr1:78749073~78750659:+
BRCA	trans	rs1816752	0.716	rs9553330	ENSG00000237917.1	PARP4P1	-23.42	8.41e-98	1.45e-90	-0.72	-0.59	Obesity-related traits;	chr13:24516018	chrY:26594851~26634652:-
BRCA	trans	rs2950393	0.777	rs12828563	ENSG00000121089.4	NACA3P	23.39	1.45e-97	2.49e-90	0.69	0.59	Platelet distribution width;	chr12:56709378	chr4:164943290~164943937:+
BRCA	trans	rs941207	0.507	rs1107479	ENSG00000121089.4	NACA3P	-23.36	2.27e-97	3.91e-90	-0.69	-0.59	Platelet count;	chr12:56636902	chr4:164943290~164943937:+
BRCA	trans	rs9467773	1	rs6903973	ENSG00000242375.1	RP11-498P14.3	23.35	2.45e-97	4.22e-90	0.79	0.59	Intelligence (multi-trait analysis);	chr6:26499714	chr9:97195351~97197687:-
BRCA	trans	rs13190036	1	rs13167431	ENSG00000217325.2	PRELID1P1	-23.33	3.32e-97	5.69e-90	-1.02	-0.59	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177194074	chr6:126643488~126644390:+
BRCA	trans	rs13190036	1	rs13177748	ENSG00000217325.2	PRELID1P1	-23.32	4.07e-97	6.97e-90	-1.02	-0.59	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177216953	chr6:126643488~126644390:+
BRCA	trans	rs61990749	0.597	rs9788540	ENSG00000235400.1	RP4-641G12.4	-23.32	4.23e-97	7.24e-90	-0.97	-0.59	Fibroblast growth factor basic levels;	chr14:77665829	chr1:78749073~78750659:+
BRCA	trans	rs1816752	0.608	rs4770690	ENSG00000237917.1	PARP4P1	-23.31	4.83e-97	8.26e-90	-0.71	-0.59	Obesity-related traits;	chr13:24467049	chrY:26594851~26634652:-
BRCA	trans	rs13190036	1	rs34832871	ENSG00000217325.2	PRELID1P1	-23.3	5.14e-97	8.77e-90	-1.02	-0.59	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177228928	chr6:126643488~126644390:+
BRCA	trans	rs9467773	1	rs2393670	ENSG00000242375.1	RP11-498P14.3	23.3	5.49e-97	9.34e-90	0.79	0.59	Intelligence (multi-trait analysis);	chr6:26535313	chr9:97195351~97197687:-
BRCA	trans	rs9467773	1	rs11756120	ENSG00000242375.1	RP11-498P14.3	23.3	5.49e-97	9.34e-90	0.79	0.59	Intelligence (multi-trait analysis);	chr6:26529580	chr9:97195351~97197687:-
BRCA	trans	rs9467773	1	rs9393732	ENSG00000242375.1	RP11-498P14.3	23.3	5.49e-97	9.34e-90	0.79	0.59	Intelligence (multi-trait analysis);	chr6:26530670	chr9:97195351~97197687:-
BRCA	trans	rs9467773	0.967	rs9358954	ENSG00000242375.1	RP11-498P14.3	23.3	5.49e-97	9.34e-90	0.79	0.59	Intelligence (multi-trait analysis);	chr6:26530950	chr9:97195351~97197687:-
BRCA	trans	rs9467773	1	rs10946834	ENSG00000242375.1	RP11-498P14.3	23.3	5.49e-97	9.34e-90	0.79	0.59	Intelligence (multi-trait analysis);	chr6:26533436	chr9:97195351~97197687:-
BRCA	trans	rs9467773	1	rs10946835	ENSG00000242375.1	RP11-498P14.3	23.3	5.49e-97	9.34e-90	0.79	0.59	Intelligence (multi-trait analysis);	chr6:26533529	chr9:97195351~97197687:-
BRCA	trans	rs9467773	1	rs9467778	ENSG00000242375.1	RP11-498P14.3	23.3	5.49e-97	9.34e-90	0.79	0.59	Intelligence (multi-trait analysis);	chr6:26534515	chr9:97195351~97197687:-
BRCA	trans	rs9467773	1	rs9393731	ENSG00000242375.1	RP11-498P14.3	23.3	5.52e-97	9.37e-90	0.79	0.59	Intelligence (multi-trait analysis);	chr6:26529146	chr9:97195351~97197687:-
BRCA	trans	rs9467773	1	rs1321480	ENSG00000242375.1	RP11-498P14.3	23.29	6.75e-97	1.15e-89	0.79	0.59	Intelligence (multi-trait analysis);	chr6:26532514	chr9:97195351~97197687:-
BRCA	trans	rs9467773	1	rs28558133	ENSG00000242375.1	RP11-498P14.3	23.27	8.06e-97	1.36e-89	0.79	0.58	Intelligence (multi-trait analysis);	chr6:26531205	chr9:97195351~97197687:-
BRCA	trans	rs9467773	1	rs9295695	ENSG00000242375.1	RP11-498P14.3	-23.26	1.07e-96	1.8e-89	-0.8	-0.58	Intelligence (multi-trait analysis);	chr6:26528022	chr9:97195351~97197687:-
BRCA	trans	rs9467773	1	rs9467774	ENSG00000242375.1	RP11-498P14.3	23.24	1.39e-96	2.33e-89	0.79	0.58	Intelligence (multi-trait analysis);	chr6:26504808	chr9:97195351~97197687:-
BRCA	trans	rs9467773	1	rs2208331	ENSG00000242375.1	RP11-498P14.3	23.24	1.39e-96	2.33e-89	0.79	0.58	Intelligence (multi-trait analysis);	chr6:26507091	chr9:97195351~97197687:-
BRCA	trans	rs9467773	1	rs6926629	ENSG00000242375.1	RP11-498P14.3	23.23	1.48e-96	2.48e-89	0.79	0.58	Intelligence (multi-trait analysis);	chr6:26499675	chr9:97195351~97197687:-
BRCA	trans	rs9467773	1	rs9467773	ENSG00000242375.1	RP11-498P14.3	23.23	1.48e-96	2.49e-89	0.79	0.58	Intelligence (multi-trait analysis);	chr6:26498198	chr9:97195351~97197687:-
BRCA	trans	rs9467773	1	rs9393728	ENSG00000242375.1	RP11-498P14.3	23.23	1.68e-96	2.82e-89	0.79	0.58	Intelligence (multi-trait analysis);	chr6:26509102	chr9:97195351~97197687:-
BRCA	trans	rs9467773	1	rs1056667	ENSG00000242375.1	RP11-498P14.3	23.23	1.68e-96	2.82e-89	0.79	0.58	Intelligence (multi-trait analysis);	chr6:26510336	chr9:97195351~97197687:-
BRCA	trans	rs61990749	0.544	rs1477259	ENSG00000235400.1	RP4-641G12.4	23.21	2.07e-96	3.46e-89	0.97	0.58	Fibroblast growth factor basic levels;	chr14:77789795	chr1:78749073~78750659:+
BRCA	trans	rs1816752	0.646	rs4770700	ENSG00000237917.1	PARP4P1	-23.2	2.49e-96	4.16e-89	-0.72	-0.58	Obesity-related traits;	chr13:24494796	chrY:26594851~26634652:-
BRCA	trans	rs9467773	0.844	rs2393669	ENSG00000242375.1	RP11-498P14.3	23.2	2.59e-96	4.31e-89	0.78	0.58	Intelligence (multi-trait analysis);	chr6:26503645	chr9:97195351~97197687:-
BRCA	trans	rs9467773	1	rs9461259	ENSG00000242375.1	RP11-498P14.3	23.2	2.59e-96	4.31e-89	0.78	0.58	Intelligence (multi-trait analysis);	chr6:26504607	chr9:97195351~97197687:-
BRCA	trans	rs9467773	1	rs3736781	ENSG00000242375.1	RP11-498P14.3	23.2	2.59e-96	4.31e-89	0.78	0.58	Intelligence (multi-trait analysis);	chr6:26505134	chr9:97195351~97197687:-
BRCA	trans	rs9467773	1	rs3736782	ENSG00000242375.1	RP11-498P14.3	23.2	2.59e-96	4.31e-89	0.78	0.58	Intelligence (multi-trait analysis);	chr6:26505175	chr9:97195351~97197687:-
BRCA	trans	rs61990749	0.597	rs717683	ENSG00000235400.1	RP4-641G12.4	23.2	2.69e-96	4.47e-89	0.97	0.58	Fibroblast growth factor basic levels;	chr14:77789110	chr1:78749073~78750659:+
BRCA	trans	rs1816752	0.624	rs7330766	ENSG00000237917.1	PARP4P1	-23.16	4.61e-96	7.6e-89	-0.72	-0.58	Obesity-related traits;	chr13:24495579	chrY:26594851~26634652:-
BRCA	trans	rs1816752	0.603	rs7984094	ENSG00000237917.1	PARP4P1	-23.16	4.61e-96	7.6e-89	-0.72	-0.58	Obesity-related traits;	chr13:24496212	chrY:26594851~26634652:-
BRCA	trans	rs9467773	1	rs2255070	ENSG00000242375.1	RP11-498P14.3	23.14	6.38e-96	1.05e-88	0.79	0.58	Intelligence (multi-trait analysis);	chr6:26501549	chr9:97195351~97197687:-
BRCA	trans	rs1816752	0.524	rs7996445	ENSG00000237917.1	PARP4P1	-23.13	7.39e-96	1.21e-88	-0.71	-0.58	Obesity-related traits;	chr13:24475329	chrY:26594851~26634652:-
BRCA	trans	rs2950393	0.929	rs2290893	ENSG00000121089.4	NACA3P	23.13	7.55e-96	1.24e-88	0.68	0.58	Platelet distribution width;	chr12:56684836	chr4:164943290~164943937:+
BRCA	trans	rs2950393	0.804	rs2958130	ENSG00000121089.4	NACA3P	23.13	7.71e-96	1.26e-88	0.69	0.58	Platelet distribution width;	chr12:56746722	chr4:164943290~164943937:+
BRCA	trans	rs9467773	1	rs9467782	ENSG00000242375.1	RP11-498P14.3	23.11	1.05e-95	1.71e-88	0.79	0.58	Intelligence (multi-trait analysis);	chr6:26542545	chr9:97195351~97197687:-
BRCA	trans	rs61990749	0.597	rs759808	ENSG00000235400.1	RP4-641G12.4	23.1	1.12e-95	1.83e-88	0.96	0.58	Fibroblast growth factor basic levels;	chr14:77784502	chr1:78749073~78750659:+
BRCA	trans	rs9467773	0.967	rs6932865	ENSG00000242375.1	RP11-498P14.3	23.09	1.33e-95	2.17e-88	0.79	0.58	Intelligence (multi-trait analysis);	chr6:26539938	chr9:97195351~97197687:-
BRCA	trans	rs9467773	1	rs6933176	ENSG00000242375.1	RP11-498P14.3	23.09	1.33e-95	2.17e-88	0.79	0.58	Intelligence (multi-trait analysis);	chr6:26539950	chr9:97195351~97197687:-
BRCA	trans	rs9467773	1	rs1321481	ENSG00000242375.1	RP11-498P14.3	23.09	1.33e-95	2.17e-88	0.79	0.58	Intelligence (multi-trait analysis);	chr6:26537982	chr9:97195351~97197687:-
BRCA	trans	rs9467773	1	rs4713008	ENSG00000242375.1	RP11-498P14.3	23.09	1.33e-95	2.17e-88	0.79	0.58	Intelligence (multi-trait analysis);	chr6:26538040	chr9:97195351~97197687:-
BRCA	trans	rs1816752	0.646	rs7319207	ENSG00000237917.1	PARP4P1	-23.07	1.83e-95	2.98e-88	-0.71	-0.58	Obesity-related traits;	chr13:24473220	chrY:26594851~26634652:-
BRCA	trans	rs9467773	1	rs1884946	ENSG00000242375.1	RP11-498P14.3	23.07	1.97e-95	3.21e-88	0.79	0.58	Intelligence (multi-trait analysis);	chr6:26545080	chr9:97195351~97197687:-
BRCA	trans	rs9467773	0.935	rs9461270	ENSG00000242375.1	RP11-498P14.3	23.07	1.98e-95	3.23e-88	0.79	0.58	Intelligence (multi-trait analysis);	chr6:26543882	chr9:97195351~97197687:-
BRCA	trans	rs1816752	0.646	rs9511291	ENSG00000237917.1	PARP4P1	-23.05	2.57e-95	4.11e-88	-0.71	-0.58	Obesity-related traits;	chr13:24467609	chrY:26594851~26634652:-
BRCA	trans	rs1816752	0.646	rs9511292	ENSG00000237917.1	PARP4P1	-23.05	2.57e-95	4.11e-88	-0.71	-0.58	Obesity-related traits;	chr13:24467623	chrY:26594851~26634652:-
BRCA	trans	rs1816752	0.646	rs9511293	ENSG00000237917.1	PARP4P1	-23.05	2.57e-95	4.11e-88	-0.71	-0.58	Obesity-related traits;	chr13:24467747	chrY:26594851~26634652:-
BRCA	trans	rs1816752	0.646	rs9511294	ENSG00000237917.1	PARP4P1	-23.05	2.57e-95	4.11e-88	-0.71	-0.58	Obesity-related traits;	chr13:24467773	chrY:26594851~26634652:-
BRCA	trans	rs1816752	0.646	rs2862902	ENSG00000237917.1	PARP4P1	-23.05	2.57e-95	4.11e-88	-0.71	-0.58	Obesity-related traits;	chr13:24461965	chrY:26594851~26634652:-
BRCA	trans	rs1816752	0.646	rs734715	ENSG00000237917.1	PARP4P1	-23.05	2.57e-95	4.11e-88	-0.71	-0.58	Obesity-related traits;	chr13:24462041	chrY:26594851~26634652:-
BRCA	trans	rs1816752	0.646	rs730030	ENSG00000237917.1	PARP4P1	-23.05	2.57e-95	4.11e-88	-0.71	-0.58	Obesity-related traits;	chr13:24462509	chrY:26594851~26634652:-
BRCA	trans	rs1816752	0.609	rs7992667	ENSG00000237917.1	PARP4P1	-23.05	2.57e-95	4.11e-88	-0.71	-0.58	Obesity-related traits;	chr13:24462821	chrY:26594851~26634652:-
BRCA	trans	rs1816752	0.609	rs7995958	ENSG00000237917.1	PARP4P1	-23.05	2.57e-95	4.11e-88	-0.71	-0.58	Obesity-related traits;	chr13:24462895	chrY:26594851~26634652:-
BRCA	trans	rs1816752	0.609	rs8002741	ENSG00000237917.1	PARP4P1	-23.05	2.57e-95	4.11e-88	-0.71	-0.58	Obesity-related traits;	chr13:24462918	chrY:26594851~26634652:-
BRCA	trans	rs1816752	0.609	rs7998198	ENSG00000237917.1	PARP4P1	-23.05	2.57e-95	4.11e-88	-0.71	-0.58	Obesity-related traits;	chr13:24462979	chrY:26594851~26634652:-
BRCA	trans	rs1816752	0.609	rs7998203	ENSG00000237917.1	PARP4P1	-23.05	2.57e-95	4.11e-88	-0.71	-0.58	Obesity-related traits;	chr13:24462989	chrY:26594851~26634652:-
BRCA	trans	rs1816752	0.646	rs7998600	ENSG00000237917.1	PARP4P1	-23.05	2.57e-95	4.11e-88	-0.71	-0.58	Obesity-related traits;	chr13:24463222	chrY:26594851~26634652:-
BRCA	trans	rs1816752	0.624	rs9511282	ENSG00000237917.1	PARP4P1	-23.05	2.57e-95	4.11e-88	-0.71	-0.58	Obesity-related traits;	chr13:24463597	chrY:26594851~26634652:-
BRCA	trans	rs1816752	0.583	rs9511283	ENSG00000237917.1	PARP4P1	-23.05	2.57e-95	4.11e-88	-0.71	-0.58	Obesity-related traits;	chr13:24463656	chrY:26594851~26634652:-
BRCA	trans	rs1816752	0.646	rs9507351	ENSG00000237917.1	PARP4P1	-23.05	2.57e-95	4.11e-88	-0.71	-0.58	Obesity-related traits;	chr13:24465118	chrY:26594851~26634652:-
BRCA	trans	rs1816752	0.646	rs4770688	ENSG00000237917.1	PARP4P1	-23.05	2.57e-95	4.11e-88	-0.71	-0.58	Obesity-related traits;	chr13:24466007	chrY:26594851~26634652:-
BRCA	trans	rs1816752	0.646	rs4770689	ENSG00000237917.1	PARP4P1	-23.05	2.57e-95	4.11e-88	-0.71	-0.58	Obesity-related traits;	chr13:24466008	chrY:26594851~26634652:-
BRCA	trans	rs1816752	0.646	rs12431171	ENSG00000237917.1	PARP4P1	-23.05	2.57e-95	4.11e-88	-0.71	-0.58	Obesity-related traits;	chr13:24466380	chrY:26594851~26634652:-
BRCA	trans	rs1816752	0.646	rs12854523	ENSG00000237917.1	PARP4P1	-23.05	2.57e-95	4.11e-88	-0.71	-0.58	Obesity-related traits;	chr13:24466460	chrY:26594851~26634652:-
BRCA	trans	rs1816752	0.646	rs9578740	ENSG00000237917.1	PARP4P1	-23.05	2.57e-95	4.11e-88	-0.71	-0.58	Obesity-related traits;	chr13:24466692	chrY:26594851~26634652:-
BRCA	trans	rs1816752	0.631	rs4769358	ENSG00000237917.1	PARP4P1	-23.05	2.57e-95	4.11e-88	-0.71	-0.58	Obesity-related traits;	chr13:24466940	chrY:26594851~26634652:-
BRCA	trans	rs1816752	0.608	rs4769359	ENSG00000237917.1	PARP4P1	-23.05	2.57e-95	4.11e-88	-0.71	-0.58	Obesity-related traits;	chr13:24466966	chrY:26594851~26634652:-
BRCA	trans	rs1816752	0.608	rs4769360	ENSG00000237917.1	PARP4P1	-23.05	2.57e-95	4.11e-88	-0.71	-0.58	Obesity-related traits;	chr13:24467016	chrY:26594851~26634652:-
BRCA	trans	rs1816752	0.608	rs9511290	ENSG00000237917.1	PARP4P1	-23.05	2.57e-95	4.11e-88	-0.71	-0.58	Obesity-related traits;	chr13:24467189	chrY:26594851~26634652:-
BRCA	trans	rs1816752	0.646	rs750390	ENSG00000237917.1	PARP4P1	-23.04	2.96e-95	4.72e-88	-0.71	-0.58	Obesity-related traits;	chr13:24461603	chrY:26594851~26634652:-
BRCA	trans	rs1816752	0.646	rs4480642	ENSG00000237917.1	PARP4P1	-23.03	3.31e-95	5.24e-88	-0.71	-0.58	Obesity-related traits;	chr13:24471358	chrY:26594851~26634652:-
BRCA	trans	rs1816752	0.646	rs9551108	ENSG00000237917.1	PARP4P1	-23.03	3.31e-95	5.24e-88	-0.71	-0.58	Obesity-related traits;	chr13:24471434	chrY:26594851~26634652:-
BRCA	trans	rs1816752	0.603	rs4238178	ENSG00000237917.1	PARP4P1	-23.03	3.31e-95	5.24e-88	-0.71	-0.58	Obesity-related traits;	chr13:24472344	chrY:26594851~26634652:-
BRCA	trans	rs1816752	0.646	rs7995190	ENSG00000237917.1	PARP4P1	-23.02	4.16e-95	6.56e-88	-0.7	-0.58	Obesity-related traits;	chr13:24475709	chrY:26594851~26634652:-
BRCA	trans	rs1816752	0.646	rs9507355	ENSG00000237917.1	PARP4P1	23	5.27e-95	8.29e-88	0.69	0.58	Obesity-related traits;	chr13:24476819	chrY:26594851~26634652:-
BRCA	trans	rs1816752	0.624	rs2096093	ENSG00000237917.1	PARP4P1	-23	5.3e-95	8.33e-88	-0.71	-0.58	Obesity-related traits;	chr13:24472753	chrY:26594851~26634652:-
BRCA	trans	rs1816752	0.583	rs9553311	ENSG00000237917.1	PARP4P1	-23	5.44e-95	8.56e-88	-0.71	-0.58	Obesity-related traits;	chr13:24474016	chrY:26594851~26634652:-
BRCA	trans	rs9467773	1	rs4871	ENSG00000242375.1	RP11-498P14.3	23	5.71e-95	8.97e-88	0.79	0.58	Intelligence (multi-trait analysis);	chr6:26545404	chr9:97195351~97197687:-
BRCA	trans	rs1816752	0.646	rs2902359	ENSG00000237917.1	PARP4P1	-22.99	6.13e-95	9.62e-88	-0.7	-0.58	Obesity-related traits;	chr13:24461783	chrY:26594851~26634652:-
BRCA	trans	rs10242455	0.702	rs112475236	ENSG00000228834.1	RP11-249L21.4	22.99	6.37e-95	1e-87	1.34	0.58	Blood metabolite levels;	chr7:99447056	chr6:108907615~108907873:-
BRCA	trans	rs1816752	0.646	rs9511296	ENSG00000237917.1	PARP4P1	-22.99	6.69e-95	1.05e-87	-0.7	-0.58	Obesity-related traits;	chr13:24467962	chrY:26594851~26634652:-
BRCA	trans	rs1816752	0.646	rs9634401	ENSG00000237917.1	PARP4P1	-22.99	6.69e-95	1.05e-87	-0.7	-0.58	Obesity-related traits;	chr13:24468072	chrY:26594851~26634652:-
BRCA	trans	rs1816752	0.624	rs9634402	ENSG00000237917.1	PARP4P1	-22.99	6.69e-95	1.05e-87	-0.7	-0.58	Obesity-related traits;	chr13:24468119	chrY:26594851~26634652:-
BRCA	trans	rs1816752	0.624	rs9553312	ENSG00000237917.1	PARP4P1	-22.95	1.1e-94	1.72e-87	-0.71	-0.58	Obesity-related traits;	chr13:24474055	chrY:26594851~26634652:-
BRCA	trans	rs1816752	0.646	rs6490937	ENSG00000237917.1	PARP4P1	-22.95	1.15e-94	1.79e-87	-0.71	-0.58	Obesity-related traits;	chr13:24475834	chrY:26594851~26634652:-
BRCA	trans	rs1816752	0.646	rs2862903	ENSG00000237917.1	PARP4P1	-22.95	1.17e-94	1.83e-87	-0.71	-0.58	Obesity-related traits;	chr13:24473169	chrY:26594851~26634652:-
BRCA	trans	rs1816752	0.646	rs750388	ENSG00000237917.1	PARP4P1	-22.93	1.64e-94	2.56e-87	-0.71	-0.58	Obesity-related traits;	chr13:24461690	chrY:26594851~26634652:-
BRCA	trans	rs9467773	1	rs9467779	ENSG00000242375.1	RP11-498P14.3	-22.91	2.09e-94	3.26e-87	-0.78	-0.58	Intelligence (multi-trait analysis);	chr6:26536459	chr9:97195351~97197687:-
BRCA	trans	rs7399018	0.739	rs6580811	ENSG00000223825.5	DAZAP2P1	22.91	2.27e-94	3.52e-87	0.84	0.58	Cisplatin-induced ototoxicity;	chr12:51218717	chr2:202201384~202201886:-
BRCA	trans	rs1816752	0.583	rs9511284	ENSG00000237917.1	PARP4P1	-22.9	2.44e-94	3.79e-87	-0.7	-0.58	Obesity-related traits;	chr13:24463660	chrY:26594851~26634652:-
BRCA	trans	rs9467773	1	rs9467783	ENSG00000242375.1	RP11-498P14.3	22.89	2.95e-94	4.57e-87	0.78	0.58	Intelligence (multi-trait analysis);	chr6:26542666	chr9:97195351~97197687:-
BRCA	trans	rs1816752	0.646	rs9511295	ENSG00000237917.1	PARP4P1	-22.87	3.72e-94	5.76e-87	-0.7	-0.58	Obesity-related traits;	chr13:24467794	chrY:26594851~26634652:-
BRCA	trans	rs1816752	0.624	rs4770701	ENSG00000237917.1	PARP4P1	-22.87	3.97e-94	6.14e-87	-0.72	-0.58	Obesity-related traits;	chr13:24508806	chrY:26594851~26634652:-
BRCA	trans	rs2950393	0.857	rs9989034	ENSG00000121089.4	NACA3P	22.86	4.45e-94	6.87e-87	0.68	0.58	Platelet distribution width;	chr12:56674508	chr4:164943290~164943937:+
BRCA	trans	rs1816752	0.646	rs750389	ENSG00000237917.1	PARP4P1	-22.86	4.78e-94	7.36e-87	-0.7	-0.58	Obesity-related traits;	chr13:24461677	chrY:26594851~26634652:-
BRCA	trans	rs1816752	0.609	rs4769361	ENSG00000237917.1	PARP4P1	-22.85	5.21e-94	8.01e-87	-0.7	-0.58	Obesity-related traits;	chr13:24468834	chrY:26594851~26634652:-
BRCA	trans	rs1816752	0.609	rs4770693	ENSG00000237917.1	PARP4P1	-22.85	5.21e-94	8.01e-87	-0.7	-0.58	Obesity-related traits;	chr13:24468835	chrY:26594851~26634652:-
BRCA	trans	rs9467773	1	rs12526680	ENSG00000242375.1	RP11-498P14.3	22.84	5.89e-94	9.06e-87	0.78	0.58	Intelligence (multi-trait analysis);	chr6:26550726	chr9:97195351~97197687:-
BRCA	trans	rs1816752	0.646	rs9511279	ENSG00000237917.1	PARP4P1	-22.83	7.55e-94	1.16e-86	-0.7	-0.58	Obesity-related traits;	chr13:24463348	chrY:26594851~26634652:-
BRCA	trans	rs1816752	0.646	rs9511280	ENSG00000237917.1	PARP4P1	-22.83	7.55e-94	1.16e-86	-0.7	-0.58	Obesity-related traits;	chr13:24463364	chrY:26594851~26634652:-
BRCA	trans	rs1816752	0.646	rs9511281	ENSG00000237917.1	PARP4P1	-22.83	7.55e-94	1.16e-86	-0.7	-0.58	Obesity-related traits;	chr13:24463441	chrY:26594851~26634652:-
BRCA	trans	rs1816752	0.646	rs9634403	ENSG00000237917.1	PARP4P1	-22.82	8.5e-94	1.3e-86	-0.7	-0.58	Obesity-related traits;	chr13:24468211	chrY:26594851~26634652:-
BRCA	trans	rs1816752	0.646	rs9581064	ENSG00000237917.1	PARP4P1	-22.82	8.5e-94	1.3e-86	-0.7	-0.58	Obesity-related traits;	chr13:24468251	chrY:26594851~26634652:-
BRCA	trans	rs1816752	0.646	rs7328391	ENSG00000237917.1	PARP4P1	-22.81	9.2e-94	1.41e-86	-0.7	-0.58	Obesity-related traits;	chr13:24470325	chrY:26594851~26634652:-
BRCA	trans	rs1816752	0.609	rs4770695	ENSG00000237917.1	PARP4P1	-22.81	9.22e-94	1.41e-86	-0.7	-0.58	Obesity-related traits;	chr13:24468895	chrY:26594851~26634652:-
BRCA	trans	rs1816752	0.646	rs7337981	ENSG00000237917.1	PARP4P1	-22.81	9.22e-94	1.41e-86	-0.7	-0.58	Obesity-related traits;	chr13:24469245	chrY:26594851~26634652:-
BRCA	trans	rs1816752	0.608	rs7326664	ENSG00000237917.1	PARP4P1	-22.81	1.02e-93	1.56e-86	-0.7	-0.58	Obesity-related traits;	chr13:24475868	chrY:26594851~26634652:-
BRCA	trans	rs1816752	0.669	rs3783072	ENSG00000237917.1	PARP4P1	-22.79	1.41e-93	2.14e-86	-0.71	-0.58	Obesity-related traits;	chr13:24493258	chrY:26594851~26634652:-
BRCA	trans	rs1816752	0.646	rs9511301	ENSG00000237917.1	PARP4P1	-22.77	1.72e-93	2.61e-86	-0.7	-0.58	Obesity-related traits;	chr13:24477034	chrY:26594851~26634652:-
BRCA	trans	rs1816752	0.646	rs7332220	ENSG00000237917.1	PARP4P1	-22.77	1.72e-93	2.61e-86	-0.7	-0.58	Obesity-related traits;	chr13:24477081	chrY:26594851~26634652:-
BRCA	trans	rs1816752	0.646	rs8002599	ENSG00000237917.1	PARP4P1	-22.77	1.82e-93	2.75e-86	-0.7	-0.58	Obesity-related traits;	chr13:24478486	chrY:26594851~26634652:-
BRCA	trans	rs1816752	0.624	rs11149109	ENSG00000237917.1	PARP4P1	-22.77	1.88e-93	2.84e-86	-0.7	-0.58	Obesity-related traits;	chr13:24477290	chrY:26594851~26634652:-
BRCA	trans	rs1816752	0.646	rs9511302	ENSG00000237917.1	PARP4P1	-22.77	1.88e-93	2.84e-86	-0.7	-0.58	Obesity-related traits;	chr13:24477580	chrY:26594851~26634652:-
BRCA	trans	rs1816752	0.646	rs7322329	ENSG00000237917.1	PARP4P1	-22.76	2.15e-93	3.24e-86	-0.7	-0.58	Obesity-related traits;	chr13:24479193	chrY:26594851~26634652:-
BRCA	trans	rs1816752	0.609	rs4770692	ENSG00000237917.1	PARP4P1	-22.67	8.36e-93	1.25e-85	-0.7	-0.57	Obesity-related traits;	chr13:24468689	chrY:26594851~26634652:-
BRCA	trans	rs1816752	0.609	rs4770694	ENSG00000237917.1	PARP4P1	-22.67	8.58e-93	1.28e-85	-0.7	-0.57	Obesity-related traits;	chr13:24468891	chrY:26594851~26634652:-
BRCA	trans	rs1816752	0.624	rs9507354	ENSG00000237917.1	PARP4P1	-22.67	8.58e-93	1.28e-85	-0.7	-0.57	Obesity-related traits;	chr13:24469227	chrY:26594851~26634652:-
BRCA	trans	rs8010715	1	rs3742500	ENSG00000248988.1	RP11-815N9.2	22.63	1.58e-92	2.35e-85	0.75	0.57	IgG glycosylation;	chr14:24142769	chr4:159007119~159007835:+
BRCA	trans	rs13177918	0.798	rs13182116	ENSG00000239528.1	RPS14P8	-22.62	1.71e-92	2.56e-85	-0.83	-0.57	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150465963	chr5:116562562~116562930:+
BRCA	trans	rs1816752	0.646	rs7322323	ENSG00000237917.1	PARP4P1	-22.6	2.46e-92	3.67e-85	-0.69	-0.57	Obesity-related traits;	chr13:24479189	chrY:26594851~26634652:-
BRCA	trans	rs13177918	0.734	rs6579791	ENSG00000224114.1	RP11-343H5.4	22.54	5.55e-92	8.21e-85	0.82	0.57	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150464440	chr1:206695837~206696269:-
BRCA	trans	rs2950393	0.804	rs2958132	ENSG00000121089.4	NACA3P	22.5	1.03e-91	1.52e-84	0.67	0.57	Platelet distribution width;	chr12:56750749	chr4:164943290~164943937:+
BRCA	trans	rs7399018	0.643	rs6580810	ENSG00000223825.5	DAZAP2P1	22.5	1.08e-91	1.6e-84	0.81	0.57	Cisplatin-induced ototoxicity;	chr12:51216694	chr2:202201384~202201886:-
BRCA	trans	rs6477998	0.676	rs4978536	ENSG00000238072.1	RP11-305M3.2	22.45	2.17e-91	3.2e-84	0.79	0.57	Hematology traits;	chr9:113220123	chr7:129410113~129410370:-
BRCA	trans	rs13190036	1	rs655623	ENSG00000217325.2	PRELID1P1	22.43	3.3e-91	4.86e-84	0.94	0.57	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177107515	chr6:126643488~126644390:+
BRCA	trans	rs2950393	0.895	rs2958123	ENSG00000121089.4	NACA3P	22.4	4.88e-91	7.16e-84	0.67	0.57	Platelet distribution width;	chr12:56668441	chr4:164943290~164943937:+
BRCA	trans	rs7811142	0.83	rs7341507	ENSG00000228546.2	CTA-313A17.3	22.38	6.38e-91	9.34e-84	0.95	0.57	Platelet count;	chr7:100353692	chr7:102337316~102339115:+
BRCA	trans	rs7811142	0.775	rs1636980	ENSG00000228546.2	CTA-313A17.3	-22.37	7.89e-91	1.15e-83	-0.96	-0.57	Platelet count;	chr7:100341241	chr7:102337316~102339115:+
BRCA	trans	rs6477998	0.676	rs4979225	ENSG00000238072.1	RP11-305M3.2	22.37	8.15e-91	1.19e-83	0.78	0.57	Hematology traits;	chr9:113225130	chr7:129410113~129410370:-
BRCA	trans	rs7811142	0.83	rs6945952	ENSG00000228546.2	CTA-313A17.3	22.37	8.16e-91	1.19e-83	0.94	0.57	Platelet count;	chr7:100384152	chr7:102337316~102339115:+
BRCA	trans	rs7811142	0.83	rs73401451	ENSG00000228546.2	CTA-313A17.3	22.37	8.16e-91	1.19e-83	0.94	0.57	Platelet count;	chr7:100384272	chr7:102337316~102339115:+
BRCA	trans	rs6477998	0.676	rs4979224	ENSG00000238072.1	RP11-305M3.2	22.37	8.4e-91	1.23e-83	0.77	0.57	Hematology traits;	chr9:113219998	chr7:129410113~129410370:-
BRCA	trans	rs6477998	0.627	rs10114381	ENSG00000238072.1	RP11-305M3.2	22.28	2.99e-90	4.33e-83	0.78	0.57	Hematology traits;	chr9:113213692	chr7:129410113~129410370:-
BRCA	trans	rs6477998	0.651	rs10114423	ENSG00000238072.1	RP11-305M3.2	22.28	2.99e-90	4.33e-83	0.78	0.57	Hematology traits;	chr9:113213751	chr7:129410113~129410370:-
BRCA	trans	rs6477998	0.676	rs10817460	ENSG00000238072.1	RP11-305M3.2	22.28	2.99e-90	4.33e-83	0.78	0.57	Hematology traits;	chr9:113214118	chr7:129410113~129410370:-
BRCA	trans	rs6477998	0.603	rs7859189	ENSG00000238072.1	RP11-305M3.2	22.28	2.99e-90	4.33e-83	0.78	0.57	Hematology traits;	chr9:113217389	chr7:129410113~129410370:-
BRCA	trans	rs6477998	0.676	rs6477997	ENSG00000238072.1	RP11-305M3.2	22.28	2.99e-90	4.33e-83	0.78	0.57	Hematology traits;	chr9:113218833	chr7:129410113~129410370:-
BRCA	trans	rs6477998	0.627	rs3810914	ENSG00000238072.1	RP11-305M3.2	22.28	2.99e-90	4.33e-83	0.78	0.57	Hematology traits;	chr9:113219441	chr7:129410113~129410370:-
BRCA	trans	rs6477998	0.676	rs10981693	ENSG00000238072.1	RP11-305M3.2	-22.26	4.05e-90	5.87e-83	-0.78	-0.57	Hematology traits;	chr9:113223137	chr7:129410113~129410370:-
BRCA	trans	rs7811142	0.72	rs7795656	ENSG00000228546.2	CTA-313A17.3	22.26	4.19e-90	6.07e-83	0.95	0.57	Platelet count;	chr7:100352674	chr7:102337316~102339115:+
BRCA	trans	rs10242455	0.702	rs73403247	ENSG00000228834.1	RP11-249L21.4	22.24	5.58e-90	8.05e-83	1.39	0.57	Blood metabolite levels;	chr7:99491107	chr6:108907615~108907873:-
BRCA	trans	rs7811142	0.83	rs7792525	ENSG00000228546.2	CTA-313A17.3	22.23	6.64e-90	9.55e-83	0.96	0.57	Platelet count;	chr7:100374499	chr7:102337316~102339115:+
BRCA	trans	rs6477998	0.651	rs10121845	ENSG00000238072.1	RP11-305M3.2	22.22	7.77e-90	1.12e-82	0.78	0.57	Hematology traits;	chr9:113227443	chr7:129410113~129410370:-
BRCA	trans	rs7811142	0.83	rs6948685	ENSG00000228546.2	CTA-313A17.3	22.2	1.06e-89	1.53e-82	0.95	0.57	Platelet count;	chr7:100372565	chr7:102337316~102339115:+
BRCA	trans	rs7811142	0.83	rs41280971	ENSG00000228546.2	CTA-313A17.3	22.19	1.24e-89	1.77e-82	0.94	0.57	Platelet count;	chr7:100356834	chr7:102337316~102339115:+
BRCA	trans	rs7811142	0.83	rs11761426	ENSG00000228546.2	CTA-313A17.3	22.19	1.24e-89	1.77e-82	0.94	0.57	Platelet count;	chr7:100359270	chr7:102337316~102339115:+
BRCA	trans	rs7811142	0.83	rs77861211	ENSG00000228546.2	CTA-313A17.3	22.19	1.24e-89	1.77e-82	0.94	0.57	Platelet count;	chr7:100364473	chr7:102337316~102339115:+
BRCA	trans	rs7811142	0.83	rs73401450	ENSG00000228546.2	CTA-313A17.3	22.14	2.37e-89	3.37e-82	0.94	0.57	Platelet count;	chr7:100384236	chr7:102337316~102339115:+
BRCA	trans	rs7811142	0.83	rs78256546	ENSG00000228546.2	CTA-313A17.3	22.13	3.07e-89	4.37e-82	0.94	0.57	Platelet count;	chr7:100355347	chr7:102337316~102339115:+
BRCA	trans	rs7811142	0.83	rs3087502	ENSG00000228546.2	CTA-313A17.3	22.13	3.1e-89	4.41e-82	0.94	0.57	Platelet count;	chr7:100357741	chr7:102337316~102339115:+
BRCA	trans	rs7811142	0.83	rs61735533	ENSG00000228546.2	CTA-313A17.3	22.13	3.1e-89	4.41e-82	0.94	0.57	Platelet count;	chr7:100358243	chr7:102337316~102339115:+
BRCA	trans	rs10716881	1	rs10716881	ENSG00000121089.4	NACA3P	-22.12	3.36e-89	4.78e-82	-0.67	-0.57	High light scatter reticulocyte count;	chr12:56644387	chr4:164943290~164943937:+
BRCA	trans	rs2950393	0.804	rs7967600	ENSG00000121089.4	NACA3P	22.11	3.72e-89	5.29e-82	0.66	0.57	Platelet distribution width;	chr12:56768208	chr4:164943290~164943937:+
BRCA	trans	rs7811142	0.779	rs28680963	ENSG00000228546.2	CTA-313A17.3	22.09	5.73e-89	8.11e-82	0.96	0.56	Platelet count;	chr7:100307852	chr7:102337316~102339115:+
BRCA	trans	rs941207	0.526	rs2255074	ENSG00000121089.4	NACA3P	-22.08	5.99e-89	8.48e-82	-0.67	-0.56	Platelet count;	chr12:56636242	chr4:164943290~164943937:+
BRCA	trans	rs2950393	0.804	rs7980317	ENSG00000121089.4	NACA3P	22.08	5.99e-89	8.48e-82	0.66	0.56	Platelet distribution width;	chr12:56764399	chr4:164943290~164943937:+
BRCA	trans	rs2950393	0.804	rs898611	ENSG00000121089.4	NACA3P	-22.08	6.16e-89	8.71e-82	-0.65	-0.56	Platelet distribution width;	chr12:56769532	chr4:164943290~164943937:+
BRCA	trans	rs7811142	0.83	rs11769057	ENSG00000228546.2	CTA-313A17.3	22.04	1.07e-88	1.51e-81	0.94	0.56	Platelet count;	chr7:100367038	chr7:102337316~102339115:+
BRCA	trans	rs10242455	0.557	rs73401516	ENSG00000228834.1	RP11-249L21.4	22.03	1.3e-88	1.82e-81	1.34	0.56	Blood metabolite levels;	chr7:99470728	chr6:108907615~108907873:-
BRCA	trans	rs12291225	0.877	rs2303974	ENSG00000236360.2	RP11-334A14.2	21.96	3.57e-88	4.97e-81	0.79	0.56	Sense of smell;	chr11:14243433	chr1:52993201~52993702:-
BRCA	trans	rs2950393	0.929	rs7973157	ENSG00000121089.4	NACA3P	-21.95	4.4e-88	6.11e-81	-0.66	-0.56	Platelet distribution width;	chr12:56655409	chr4:164943290~164943937:+
BRCA	trans	rs55665837	0.559	rs11023209	ENSG00000236360.2	RP11-334A14.2	21.94	5.22e-88	7.25e-81	0.73	0.56	Vitamin D levels;	chr11:14401054	chr1:52993201~52993702:-
BRCA	trans	rs1816752	0.646	rs1361578	ENSG00000237917.1	PARP4P1	-21.93	6.36e-88	8.82e-81	-0.7	-0.56	Obesity-related traits;	chr13:24491117	chrY:26594851~26634652:-
BRCA	trans	rs13177918	0.734	rs6579791	ENSG00000213058.3	RP4-765C7.2	21.91	7.61e-88	1.05e-80	0.79	0.56	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150464440	chr1:178411616~178411972:+
BRCA	trans	rs10242455	0.702	rs59240302	ENSG00000228834.1	RP11-249L21.4	21.83	2.52e-87	3.47e-80	1.34	0.56	Blood metabolite levels;	chr7:99475368	chr6:108907615~108907873:-
BRCA	trans	rs55665837	0.559	rs9667144	ENSG00000236360.2	RP11-334A14.2	-21.81	3.54e-87	4.87e-80	-0.73	-0.56	Vitamin D levels;	chr11:14399555	chr1:52993201~52993702:-
BRCA	trans	rs10242455	0.557	rs2404487	ENSG00000228834.1	RP11-249L21.4	21.81	3.61e-87	4.96e-80	1.34	0.56	Blood metabolite levels;	chr7:99440434	chr6:108907615~108907873:-
BRCA	trans	rs10242455	0.702	rs73711280	ENSG00000228834.1	RP11-249L21.4	21.81	3.61e-87	4.96e-80	1.34	0.56	Blood metabolite levels;	chr7:99441981	chr6:108907615~108907873:-
BRCA	trans	rs10242455	0.702	rs73401510	ENSG00000228834.1	RP11-249L21.4	21.77	6.34e-87	8.7e-80	1.33	0.56	Blood metabolite levels;	chr7:99468189	chr6:108907615~108907873:-
BRCA	trans	rs7811142	0.83	rs1063945	ENSG00000228546.2	CTA-313A17.3	21.77	7.04e-87	9.66e-80	0.95	0.56	Platelet count;	chr7:100332824	chr7:102337316~102339115:+
BRCA	trans	rs6477998	0.676	rs10817470	ENSG00000238072.1	RP11-305M3.2	21.7	1.8e-86	2.47e-79	0.78	0.56	Hematology traits;	chr9:113252129	chr7:129410113~129410370:-
BRCA	trans	rs10242455	0.702	rs6974831	ENSG00000228834.1	RP11-249L21.4	21.7	1.84e-86	2.52e-79	1.37	0.56	Blood metabolite levels;	chr7:99533982	chr6:108907615~108907873:-
BRCA	trans	rs10242455	0.557	rs45492501	ENSG00000228834.1	RP11-249L21.4	21.67	3.04e-86	4.14e-79	1.33	0.56	Blood metabolite levels;	chr7:99449407	chr6:108907615~108907873:-
BRCA	trans	rs10242455	0.702	rs17854665	ENSG00000228834.1	RP11-249L21.4	21.67	3.04e-86	4.14e-79	1.33	0.56	Blood metabolite levels;	chr7:99452416	chr6:108907615~108907873:-
BRCA	trans	rs12291225	0.877	rs11023160	ENSG00000236360.2	RP11-334A14.2	21.63	5.62e-86	7.65e-79	0.79	0.56	Sense of smell;	chr11:14242679	chr1:52993201~52993702:-
BRCA	trans	rs55665837	0.559	rs11023210	ENSG00000236360.2	RP11-334A14.2	-21.62	6.13e-86	8.34e-79	-0.73	-0.56	Vitamin D levels;	chr11:14401216	chr1:52993201~52993702:-
BRCA	trans	rs6477998	0.676	rs10981698	ENSG00000238072.1	RP11-305M3.2	21.61	7.27e-86	9.88e-79	0.77	0.56	Hematology traits;	chr9:113233500	chr7:129410113~129410370:-
BRCA	trans	rs6477998	0.676	rs10759631	ENSG00000238072.1	RP11-305M3.2	21.61	7.27e-86	9.88e-79	0.77	0.56	Hematology traits;	chr9:113233764	chr7:129410113~129410370:-
BRCA	trans	rs10242455	0.557	rs77997620	ENSG00000228834.1	RP11-249L21.4	21.58	1.09e-85	1.48e-78	1.37	0.56	Blood metabolite levels;	chr7:99472792	chr6:108907615~108907873:-
BRCA	trans	rs7811142	0.779	rs111312383	ENSG00000228546.2	CTA-313A17.3	21.57	1.25e-85	1.69e-78	0.95	0.56	Platelet count;	chr7:100307702	chr7:102337316~102339115:+
BRCA	trans	rs6477998	0.676	rs10081797	ENSG00000238072.1	RP11-305M3.2	21.55	1.68e-85	2.27e-78	0.77	0.56	Hematology traits;	chr9:113237973	chr7:129410113~129410370:-
BRCA	trans	rs6477998	0.676	rs10759632	ENSG00000238072.1	RP11-305M3.2	21.55	1.68e-85	2.27e-78	0.77	0.56	Hematology traits;	chr9:113238703	chr7:129410113~129410370:-
BRCA	trans	rs10242455	0.702	rs45448997	ENSG00000228834.1	RP11-249L21.4	21.52	2.99e-85	4.03e-78	1.33	0.55	Blood metabolite levels;	chr7:99443975	chr6:108907615~108907873:-
BRCA	trans	rs7811142	0.83	rs11761253	ENSG00000228546.2	CTA-313A17.3	21.51	3.09e-85	4.17e-78	0.94	0.55	Platelet count;	chr7:100341698	chr7:102337316~102339115:+
BRCA	trans	rs9467773	1	rs1321479	ENSG00000242375.1	RP11-498P14.3	-21.5	3.7e-85	4.99e-78	-0.73	-0.55	Intelligence (multi-trait analysis);	chr6:26501669	chr9:97195351~97197687:-
BRCA	trans	rs5022636	0.896	rs744536	ENSG00000180764.13	PIPSL	21.49	4.62e-85	6.22e-78	0.66	0.55	Gut microbiota (functional units);	chr1:151356318	chr10:93958191~93961540:-
BRCA	trans	rs13177918	0.717	rs6874318	ENSG00000224114.1	RP11-343H5.4	-21.44	8.64e-85	1.16e-77	-0.77	-0.55	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150462836	chr1:206695837~206696269:-
BRCA	trans	rs7811142	0.83	rs11771936	ENSG00000228546.2	CTA-313A17.3	21.43	1.11e-84	1.49e-77	0.94	0.55	Platelet count;	chr7:100345660	chr7:102337316~102339115:+
BRCA	trans	rs7811142	0.779	rs77370288	ENSG00000228546.2	CTA-313A17.3	21.43	1.11e-84	1.49e-77	0.94	0.55	Platelet count;	chr7:100350274	chr7:102337316~102339115:+
BRCA	trans	rs941207	0.507	rs2958124	ENSG00000121089.4	NACA3P	-21.38	2.14e-84	2.86e-77	-0.66	-0.55	Platelet count;	chr12:56633837	chr4:164943290~164943937:+
BRCA	trans	rs7811142	1	rs66632384	ENSG00000228546.2	CTA-313A17.3	21.36	3.01e-84	4.01e-77	0.91	0.55	Platelet count;	chr7:100421281	chr7:102337316~102339115:+
BRCA	trans	rs7811142	0.943	rs73403312	ENSG00000228546.2	CTA-313A17.3	21.36	3.01e-84	4.01e-77	0.91	0.55	Platelet count;	chr7:100426530	chr7:102337316~102339115:+
BRCA	trans	rs7811142	1	rs11771419	ENSG00000228546.2	CTA-313A17.3	21.35	3.69e-84	4.92e-77	0.9	0.55	Platelet count;	chr7:100390780	chr7:102337316~102339115:+
BRCA	trans	rs7811142	0.83	rs28495773	ENSG00000228546.2	CTA-313A17.3	21.29	8.13e-84	1.08e-76	0.96	0.55	Platelet count;	chr7:100345960	chr7:102337316~102339115:+
BRCA	trans	rs7811142	1	rs7783550	ENSG00000228546.2	CTA-313A17.3	-21.26	1.31e-83	1.74e-76	-0.89	-0.55	Platelet count;	chr7:100390182	chr7:102337316~102339115:+
BRCA	trans	rs10242455	0.702	rs73397499	ENSG00000228834.1	RP11-249L21.4	21.23	2.08e-83	2.74e-76	1.35	0.55	Blood metabolite levels;	chr7:99442004	chr6:108907615~108907873:-
BRCA	trans	rs10242455	0.702	rs45461000	ENSG00000228834.1	RP11-249L21.4	21.23	2.08e-83	2.74e-76	1.35	0.55	Blood metabolite levels;	chr7:99455087	chr6:108907615~108907873:-
BRCA	trans	rs9611565	0.512	rs5758464	ENSG00000268568.1	AC007228.9	21.22	2.29e-83	3.03e-76	0.94	0.55	Vitiligo;	chr22:41775296	chr19:56672574~56673901:-
BRCA	trans	rs7811142	1	rs73161759	ENSG00000228546.2	CTA-313A17.3	21.21	3.02e-83	3.98e-76	0.9	0.55	Platelet count;	chr7:100412371	chr7:102337316~102339115:+
BRCA	trans	rs5022636	0.896	rs7531495	ENSG00000180764.13	PIPSL	21.18	4.17e-83	5.5e-76	0.66	0.55	Gut microbiota (functional units);	chr1:151352996	chr10:93958191~93961540:-
BRCA	trans	rs7811142	1	rs67163493	ENSG00000228546.2	CTA-313A17.3	21.15	6.74e-83	8.85e-76	0.9	0.55	Platelet count;	chr7:100426215	chr7:102337316~102339115:+
BRCA	trans	rs10242455	0.702	rs73403290	ENSG00000228834.1	RP11-249L21.4	21.15	7.14e-83	9.36e-76	1.35	0.55	Blood metabolite levels;	chr7:99560205	chr6:108907615~108907873:-
BRCA	trans	rs7811142	1	rs74460138	ENSG00000228546.2	CTA-313A17.3	21.14	8.06e-83	1.05e-75	0.91	0.55	Platelet count;	chr7:100429716	chr7:102337316~102339115:+
BRCA	trans	rs7811142	1	rs4989959	ENSG00000228546.2	CTA-313A17.3	21.14	8.06e-83	1.05e-75	0.91	0.55	Platelet count;	chr7:100434665	chr7:102337316~102339115:+
BRCA	trans	rs7811142	1	rs67471932	ENSG00000228546.2	CTA-313A17.3	21.1	1.49e-82	1.94e-75	0.9	0.55	Platelet count;	chr7:100412362	chr7:102337316~102339115:+
BRCA	trans	rs7811142	1	rs11763414	ENSG00000228546.2	CTA-313A17.3	21.1	1.53e-82	1.99e-75	0.9	0.55	Platelet count;	chr7:100419221	chr7:102337316~102339115:+
BRCA	trans	rs7811142	0.943	rs3900792	ENSG00000228546.2	CTA-313A17.3	21.02	4.72e-82	6.1e-75	0.89	0.55	Platelet count;	chr7:100406954	chr7:102337316~102339115:+
BRCA	trans	rs7811142	0.943	rs10241492	ENSG00000228546.2	CTA-313A17.3	20.98	8.08e-82	1.04e-74	0.9	0.55	Platelet count;	chr7:100397190	chr7:102337316~102339115:+
BRCA	trans	rs7811142	0.83	rs76798830	ENSG00000228546.2	CTA-313A17.3	20.94	1.43e-81	1.84e-74	0.97	0.54	Platelet count;	chr7:100355205	chr7:102337316~102339115:+
BRCA	trans	rs12291225	0.883	rs1864658	ENSG00000236360.2	RP11-334A14.2	-20.94	1.46e-81	1.88e-74	-0.75	-0.54	Sense of smell;	chr11:14234898	chr1:52993201~52993702:-
BRCA	trans	rs7811142	1	rs6975729	ENSG00000228546.2	CTA-313A17.3	20.94	1.64e-81	2.1e-74	0.91	0.54	Platelet count;	chr7:100430564	chr7:102337316~102339115:+
BRCA	trans	rs7811142	0.887	rs4074838	ENSG00000228546.2	CTA-313A17.3	20.93	1.73e-81	2.22e-74	0.91	0.54	Platelet count;	chr7:100435042	chr7:102337316~102339115:+
BRCA	trans	rs7811142	0.775	rs6946768	ENSG00000228546.2	CTA-313A17.3	20.93	1.79e-81	2.29e-74	0.96	0.54	Platelet count;	chr7:100356770	chr7:102337316~102339115:+
BRCA	trans	rs7811142	1	rs67315960	ENSG00000228546.2	CTA-313A17.3	20.93	1.81e-81	2.32e-74	0.9	0.54	Platelet count;	chr7:100417501	chr7:102337316~102339115:+
BRCA	trans	rs7811142	1	rs1073	ENSG00000228546.2	CTA-313A17.3	20.93	1.89e-81	2.42e-74	0.91	0.54	Platelet count;	chr7:100433989	chr7:102337316~102339115:+
BRCA	trans	rs7811142	1	rs11764818	ENSG00000228546.2	CTA-313A17.3	20.92	1.92e-81	2.46e-74	0.91	0.54	Platelet count;	chr7:100445432	chr7:102337316~102339115:+
BRCA	trans	rs7811142	0.83	rs705866	ENSG00000228546.2	CTA-313A17.3	20.92	2.08e-81	2.66e-74	0.97	0.54	Platelet count;	chr7:100367662	chr7:102337316~102339115:+
BRCA	trans	rs7811142	1	rs76913697	ENSG00000228546.2	CTA-313A17.3	20.91	2.22e-81	2.84e-74	0.9	0.54	Platelet count;	chr7:100405149	chr7:102337316~102339115:+
BRCA	trans	rs7811142	0.83	rs11765869	ENSG00000228546.2	CTA-313A17.3	20.89	3.12e-81	3.99e-74	0.97	0.54	Platelet count;	chr7:100367166	chr7:102337316~102339115:+
BRCA	trans	rs7811142	0.72	rs112622797	ENSG00000228546.2	CTA-313A17.3	20.87	4.27e-81	5.44e-74	0.99	0.54	Platelet count;	chr7:100319793	chr7:102337316~102339115:+
BRCA	trans	rs8010715	1	rs8010715	ENSG00000248988.1	RP11-815N9.2	20.87	4.44e-81	5.66e-74	0.72	0.54	IgG glycosylation;	chr14:24139938	chr4:159007119~159007835:+
BRCA	trans	rs7811142	1	rs60257855	ENSG00000228546.2	CTA-313A17.3	20.86	4.85e-81	6.18e-74	0.91	0.54	Platelet count;	chr7:100429157	chr7:102337316~102339115:+
BRCA	trans	rs9467773	0.933	rs35355150	ENSG00000242375.1	RP11-498P14.3	20.86	4.98e-81	6.35e-74	0.76	0.54	Intelligence (multi-trait analysis);	chr6:26525811	chr9:97195351~97197687:-
BRCA	trans	rs7811142	0.83	rs6965458	ENSG00000228546.2	CTA-313A17.3	20.85	5.45e-81	6.94e-74	0.97	0.54	Platelet count;	chr7:100375779	chr7:102337316~102339115:+
BRCA	trans	rs13190036	0.551	rs4976639	ENSG00000217325.2	PRELID1P1	20.82	9.18e-81	1.17e-73	0.87	0.54	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177123300	chr6:126643488~126644390:+
BRCA	trans	rs10242455	0.85	rs57367781	ENSG00000228834.1	RP11-249L21.4	20.81	1.12e-80	1.41e-73	1.38	0.54	Blood metabolite levels;	chr7:99519196	chr6:108907615~108907873:-
BRCA	trans	rs7811142	0.943	rs66958101	ENSG00000228546.2	CTA-313A17.3	20.78	1.69e-80	2.13e-73	0.89	0.54	Platelet count;	chr7:100476397	chr7:102337316~102339115:+
BRCA	trans	rs9467773	0.935	rs1884947	ENSG00000242375.1	RP11-498P14.3	20.75	2.53e-80	3.17e-73	0.78	0.54	Intelligence (multi-trait analysis);	chr6:26553045	chr9:97195351~97197687:-
BRCA	trans	rs1816752	0.646	rs3783073	ENSG00000237917.1	PARP4P1	-20.75	2.64e-80	3.31e-73	-0.67	-0.54	Obesity-related traits;	chr13:24493222	chrY:26594851~26634652:-
BRCA	trans	rs7811142	0.945	rs6955362	ENSG00000228546.2	CTA-313A17.3	20.73	3.16e-80	3.89e-73	0.89	0.54	Platelet count;	chr7:100458543	chr7:102337316~102339115:+
BRCA	trans	rs7811142	1	rs6975514	ENSG00000228546.2	CTA-313A17.3	20.73	3.16e-80	3.89e-73	0.89	0.54	Platelet count;	chr7:100458597	chr7:102337316~102339115:+
BRCA	trans	rs7811142	1	rs7811142	ENSG00000228546.2	CTA-313A17.3	20.73	3.58e-80	4.41e-73	0.89	0.54	Platelet count;	chr7:100467820	chr7:102337316~102339115:+
BRCA	trans	rs13177918	0.717	rs6874318	ENSG00000213058.3	RP4-765C7.2	-20.72	4.21e-80	5.18e-73	-0.73	-0.54	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150462836	chr1:178411616~178411972:+
BRCA	trans	rs7811142	1	rs11773661	ENSG00000228546.2	CTA-313A17.3	20.68	6.81e-80	8.33e-73	0.89	0.54	Platelet count;	chr7:100475446	chr7:102337316~102339115:+
BRCA	trans	rs10242455	0.702	rs73711293	ENSG00000228834.1	RP11-249L21.4	20.68	6.99e-80	8.55e-73	1.44	0.54	Blood metabolite levels;	chr7:99483972	chr6:108907615~108907873:-
BRCA	trans	rs877636	0.692	rs11171739	ENSG00000243403.1	RP11-330L19.1	20.61	1.9e-79	2.28e-72	0.62	0.54	Cognitive function;	chr12:56076841	chr15:64592979~64593326:+
BRCA	trans	rs9467773	0.935	rs11752946	ENSG00000242375.1	RP11-498P14.3	20.58	2.97e-79	3.55e-72	0.78	0.54	Intelligence (multi-trait analysis);	chr6:26560136	chr9:97195351~97197687:-
BRCA	trans	rs7399018	0.739	rs10747608	ENSG00000223825.5	DAZAP2P1	20.54	5.68e-79	6.73e-72	0.71	0.54	Cisplatin-induced ototoxicity;	chr12:51222798	chr2:202201384~202201886:-
BRCA	trans	rs928391	0.592	rs7522395	ENSG00000227183.3	HDGFP1	-20.48	1.35e-78	1.58e-71	-0.84	-0.54	Platelet count;	chr1:156826905	chrX:131646639~131646890:+
BRCA	trans	rs7811142	1	rs11771241	ENSG00000228546.2	CTA-313A17.3	20.47	1.61e-78	1.89e-71	0.89	0.54	Platelet count;	chr7:100397162	chr7:102337316~102339115:+
BRCA	trans	rs7811142	0.83	rs75636500	ENSG00000228546.2	CTA-313A17.3	20.43	2.81e-78	3.27e-71	0.97	0.53	Platelet count;	chr7:100350034	chr7:102337316~102339115:+
BRCA	trans	rs3740713	0.669	rs2896526	ENSG00000235847.2	LDHAP7	20.34	1e-77	1.14e-70	0.89	0.53	Amyotrophic lateral sclerosis (sporadic);	chr11:18398259	chr2:84777259~84778223:-
BRCA	trans	rs3740713	0.669	rs34740438	ENSG00000235847.2	LDHAP7	20.17	1.3e-76	1.45e-69	0.94	0.53	Amyotrophic lateral sclerosis (sporadic);	chr11:18393783	chr2:84777259~84778223:-
BRCA	trans	rs877636	0.692	rs11171739	ENSG00000225071.1	GS1-184P14.2	20.11	2.8e-76	3.1e-69	0.61	0.53	Cognitive function;	chr12:56076841	chrX:24429573~24429920:-
BRCA	trans	rs8010715	0.848	rs2277483	ENSG00000248988.1	RP11-815N9.2	20.09	4.02e-76	4.44e-69	0.67	0.53	IgG glycosylation;	chr14:24122683	chr4:159007119~159007835:+
BRCA	trans	rs1816752	0.603	rs9511278	ENSG00000237917.1	PARP4P1	-20.07	5.35e-76	5.89e-69	-0.66	-0.53	Obesity-related traits;	chr13:24455766	chrY:26594851~26634652:-
BRCA	trans	rs10242455	0.557	rs73403272	ENSG00000228834.1	RP11-249L21.4	20.06	6.07e-76	6.68e-69	1.22	0.53	Blood metabolite levels;	chr7:99536585	chr6:108907615~108907873:-
BRCA	trans	rs7503168	0.558	rs11656872	ENSG00000234130.2	RP13-88F20.1	-20.04	7.6e-76	8.34e-69	-1.07	-0.53	Plateletcrit;	chr17:35611585	chrX:93222220~93225015:-
BRCA	trans	rs13190036	0.551	rs28932178	ENSG00000217325.2	PRELID1P1	-19.99	1.63e-75	1.78e-68	-0.87	-0.53	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177210575	chr6:126643488~126644390:+
BRCA	trans	rs877636	0.692	rs2271194	ENSG00000243403.1	RP11-330L19.1	-19.97	2.14e-75	2.34e-68	-0.6	-0.53	Cognitive function;	chr12:56083910	chr15:64592979~64593326:+
BRCA	trans	rs616147	0.627	rs9871799	ENSG00000183298.5	RP11-556K13.1	19.95	2.81e-75	3.06e-68	0.71	0.53	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39442829	chr1:101786340~101787219:-
BRCA	trans	rs8010715	0.848	rs8009511	ENSG00000248988.1	RP11-815N9.2	19.93	4.03e-75	4.38e-68	0.66	0.53	IgG glycosylation;	chr14:24124771	chr4:159007119~159007835:+
BRCA	trans	rs8010715	0.804	rs1134334	ENSG00000248988.1	RP11-815N9.2	19.93	4.03e-75	4.38e-68	0.66	0.53	IgG glycosylation;	chr14:24124905	chr4:159007119~159007835:+
BRCA	trans	rs13190036	0.591	rs78523677	ENSG00000217325.2	PRELID1P1	-19.92	4.82e-75	5.24e-68	-0.85	-0.53	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177124102	chr6:126643488~126644390:+
BRCA	trans	rs10242455	0.702	rs2293256	ENSG00000228834.1	RP11-249L21.4	-19.84	1.44e-74	1.56e-67	-1.14	-0.52	Blood metabolite levels;	chr7:99460078	chr6:108907615~108907873:-
BRCA	trans	rs7811142	0.887	rs35111986	ENSG00000228546.2	CTA-313A17.3	19.84	1.48e-74	1.6e-67	0.93	0.52	Platelet count;	chr7:100402651	chr7:102337316~102339115:+
BRCA	trans	rs13190036	0.551	rs1052432	ENSG00000217325.2	PRELID1P1	-19.81	2.22e-74	2.39e-67	-0.85	-0.52	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177137188	chr6:126643488~126644390:+
BRCA	trans	rs7811142	1	rs7794485	ENSG00000228546.2	CTA-313A17.3	19.75	5.65e-74	6.05e-67	0.93	0.52	Platelet count;	chr7:100471313	chr7:102337316~102339115:+
BRCA	trans	rs7973618	1	rs7973618	ENSG00000121089.4	NACA3P	-19.73	7.27e-74	7.78e-67	-0.62	-0.52	Mean platelet volume;	chr12:56625659	chr4:164943290~164943937:+
BRCA	trans	rs13177918	0.734	rs6579791	ENSG00000239528.1	RPS14P8	19.71	9.82e-74	1.05e-66	0.72	0.52	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150464440	chr5:116562562~116562930:+
BRCA	trans	rs9467773	0.935	rs4573	ENSG00000242375.1	RP11-498P14.3	19.71	9.97e-74	1.06e-66	0.75	0.52	Intelligence (multi-trait analysis);	chr6:26546580	chr9:97195351~97197687:-
BRCA	trans	rs9467773	0.935	rs1056668	ENSG00000242375.1	RP11-498P14.3	19.7	1.05e-73	1.12e-66	0.75	0.52	Intelligence (multi-trait analysis);	chr6:26510377	chr9:97195351~97197687:-
BRCA	trans	rs7811142	1	rs7783159	ENSG00000228546.2	CTA-313A17.3	19.7	1.14e-73	1.21e-66	0.91	0.52	Platelet count;	chr7:100419831	chr7:102337316~102339115:+
BRCA	trans	rs941207	0.526	rs2950387	ENSG00000121089.4	NACA3P	-19.69	1.25e-73	1.33e-66	-0.62	-0.52	Platelet count;	chr12:56627222	chr4:164943290~164943937:+
BRCA	trans	rs7811142	1	rs11761725	ENSG00000228546.2	CTA-313A17.3	19.69	1.35e-73	1.43e-66	0.92	0.52	Platelet count;	chr7:100442192	chr7:102337316~102339115:+
BRCA	trans	rs10242455	0.702	rs7794068	ENSG00000228834.1	RP11-249L21.4	19.62	3.46e-73	3.67e-66	1.2	0.52	Blood metabolite levels;	chr7:99549250	chr6:108907615~108907873:-
BRCA	trans	rs8010715	0.848	rs927494	ENSG00000248988.1	RP11-815N9.2	19.61	3.8e-73	4.02e-66	0.65	0.52	IgG glycosylation;	chr14:24131181	chr4:159007119~159007835:+
BRCA	trans	rs7811142	1	rs2406255	ENSG00000228546.2	CTA-313A17.3	19.61	4.29e-73	4.53e-66	0.92	0.52	Platelet count;	chr7:100456067	chr7:102337316~102339115:+
BRCA	trans	rs2731664	0.792	rs2544809	ENSG00000215571.5	GRK6P1	19.56	7.66e-73	8.08e-66	0.67	0.52	Intelligence (multi-trait analysis);	chr5:177458498	chr13:21319156~21320866:+
BRCA	trans	rs941207	0.762	rs10450	ENSG00000121089.4	NACA3P	19.55	1.01e-72	1.06e-65	0.63	0.52	Platelet count;	chr12:56590822	chr4:164943290~164943937:+
BRCA	trans	rs7811142	1	rs73161762	ENSG00000228546.2	CTA-313A17.3	19.47	3.05e-72	3.19e-65	0.93	0.52	Platelet count;	chr7:100417223	chr7:102337316~102339115:+
BRCA	trans	rs10242455	0.702	rs3823813	ENSG00000228834.1	RP11-249L21.4	19.45	4.1e-72	4.28e-65	1.37	0.52	Blood metabolite levels;	chr7:99451766	chr6:108907615~108907873:-
BRCA	trans	rs7811142	1	rs7803454	ENSG00000228546.2	CTA-313A17.3	19.39	9.13e-72	9.44e-65	0.92	0.51	Platelet count;	chr7:100393925	chr7:102337316~102339115:+
BRCA	trans	rs7811142	0.943	rs11769886	ENSG00000228546.2	CTA-313A17.3	19.39	9.13e-72	9.44e-65	0.92	0.51	Platelet count;	chr7:100400984	chr7:102337316~102339115:+
BRCA	trans	rs2950393	0.572	rs10783794	ENSG00000121089.4	NACA3P	-19.32	2.46e-71	2.53e-64	-0.59	-0.51	Platelet distribution width;	chr12:56593395	chr4:164943290~164943937:+
BRCA	trans	rs2731664	0.765	rs2630766	ENSG00000215571.5	GRK6P1	19.3	3.39e-71	3.48e-64	0.66	0.51	Intelligence (multi-trait analysis);	chr5:177447940	chr13:21319156~21320866:+
BRCA	trans	rs2731664	0.792	rs2630765	ENSG00000215571.5	GRK6P1	19.28	4.75e-71	4.85e-64	0.66	0.51	Intelligence (multi-trait analysis);	chr5:177449824	chr13:21319156~21320866:+
BRCA	trans	rs9467773	0.838	rs3734540	ENSG00000242375.1	RP11-498P14.3	19.2	1.43e-70	1.43e-63	0.72	0.51	Intelligence (multi-trait analysis);	chr6:26463093	chr9:97195351~97197687:-
BRCA	trans	rs2657294	0.62	rs4746259	ENSG00000172974.11	AC007318.5	19.17	2.12e-70	2.12e-63	0.63	0.51	Pneumonia;	chr10:75082310	chr2:65205108~65205988:+
BRCA	trans	rs9611565	0.512	rs139572	ENSG00000268568.1	AC007228.9	-19.15	3.01e-70	3e-63	-0.9	-0.51	Vitiligo;	chr22:41818528	chr19:56672574~56673901:-
BRCA	trans	rs2657294	0.62	rs7475340	ENSG00000172974.11	AC007318.5	19.08	7.57e-70	7.44e-63	0.63	0.51	Pneumonia;	chr10:75079597	chr2:65205108~65205988:+
BRCA	trans	rs9467773	0.901	rs1407045	ENSG00000242375.1	RP11-498P14.3	19.06	9.84e-70	9.62e-63	0.72	0.51	Intelligence (multi-trait analysis);	chr6:26475927	chr9:97195351~97197687:-
BRCA	trans	rs12291225	0.839	rs4757244	ENSG00000236360.2	RP11-334A14.2	-18.99	2.57e-69	2.48e-62	-0.67	-0.51	Sense of smell;	chr11:14237109	chr1:52993201~52993702:-
BRCA	trans	rs2731664	0.792	rs466256	ENSG00000215571.5	GRK6P1	18.98	3.15e-69	3.03e-62	0.66	0.51	Intelligence (multi-trait analysis);	chr5:177448955	chr13:21319156~21320866:+
BRCA	trans	rs877636	0.692	rs2271194	ENSG00000225071.1	GS1-184P14.2	-18.97	3.46e-69	3.33e-62	-0.59	-0.51	Cognitive function;	chr12:56083910	chrX:24429573~24429920:-
BRCA	trans	rs941207	0.526	rs2242497	ENSG00000121089.4	NACA3P	-18.97	3.81e-69	3.66e-62	-0.61	-0.51	Platelet count;	chr12:56598846	chr4:164943290~164943937:+
BRCA	trans	rs877636	0.692	rs11171739	ENSG00000212994.5	RPS26P6	18.93	6.68e-69	6.4e-62	0.62	0.51	Cognitive function;	chr12:56076841	chr8:100895771~100896118:+
BRCA	trans	rs7258465	1	rs2278238	ENSG00000267533.1	RP11-815J4.7	18.92	7.18e-69	6.87e-62	0.67	0.51	Breast cancer;	chr19:18465674	chr18:12067173~12068417:-
BRCA	trans	rs10242455	0.702	rs73397481	ENSG00000228834.1	RP11-249L21.4	18.91	8.03e-69	7.67e-62	1.34	0.51	Blood metabolite levels;	chr7:99432485	chr6:108907615~108907873:-
BRCA	trans	rs13177918	0.717	rs6874318	ENSG00000239528.1	RPS14P8	-18.91	8.35e-69	7.96e-62	-0.67	-0.51	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150462836	chr5:116562562~116562930:+
BRCA	trans	rs9467773	0.649	rs2145318	ENSG00000242375.1	RP11-498P14.3	18.89	1.06e-68	1e-61	0.71	0.51	Intelligence (multi-trait analysis);	chr6:26496375	chr9:97195351~97197687:-
BRCA	trans	rs928391	0.744	rs2274503	ENSG00000227183.3	HDGFP1	-18.88	1.23e-68	1.17e-61	-0.67	-0.5	Platelet count;	chr1:156782256	chrX:131646639~131646890:+
BRCA	trans	rs2731664	0.792	rs2545795	ENSG00000215571.5	GRK6P1	18.88	1.32e-68	1.24e-61	0.65	0.5	Intelligence (multi-trait analysis);	chr5:177460105	chr13:21319156~21320866:+
BRCA	trans	rs7258465	1	rs10164323	ENSG00000267533.1	RP11-815J4.7	18.86	1.65e-68	1.55e-61	0.66	0.5	Breast cancer;	chr19:18458682	chr18:12067173~12068417:-
BRCA	trans	rs2731664	0.792	rs335466	ENSG00000215571.5	GRK6P1	18.86	1.65e-68	1.56e-61	0.65	0.5	Intelligence (multi-trait analysis);	chr5:177462529	chr13:21319156~21320866:+
BRCA	trans	rs2657294	0.62	rs9783273	ENSG00000172974.11	AC007318.5	18.85	1.87e-68	1.76e-61	0.62	0.5	Pneumonia;	chr10:75081982	chr2:65205108~65205988:+
BRCA	trans	rs7554547	0.871	rs11588551	ENSG00000261819.1	RP11-680G24.4	-18.85	1.91e-68	1.8e-61	-0.61	-0.5	Nonsyndromic cleft lip with cleft palate;	chr1:11881879	chr16:14988259~14990160:-
BRCA	trans	rs7258465	1	rs10425982	ENSG00000267533.1	RP11-815J4.7	18.85	1.97e-68	1.85e-61	0.66	0.5	Breast cancer;	chr19:18475709	chr18:12067173~12068417:-
BRCA	trans	rs7258465	0.965	rs7256534	ENSG00000267533.1	RP11-815J4.7	18.85	1.97e-68	1.85e-61	0.66	0.5	Breast cancer;	chr19:18475981	chr18:12067173~12068417:-
BRCA	trans	rs2657294	0.62	rs2395132	ENSG00000172974.11	AC007318.5	18.84	2.28e-68	2.13e-61	0.62	0.5	Pneumonia;	chr10:75080840	chr2:65205108~65205988:+
BRCA	trans	rs7258465	0.931	rs1560119	ENSG00000267533.1	RP11-815J4.7	18.78	5.46e-68	5.03e-61	0.66	0.5	Breast cancer;	chr19:18462865	chr18:12067173~12068417:-
BRCA	trans	rs2731664	0.792	rs2731662	ENSG00000215571.5	GRK6P1	-18.75	7.86e-68	7.2e-61	-0.64	-0.5	Intelligence (multi-trait analysis);	chr5:177445493	chr13:21319156~21320866:+
BRCA	trans	rs9611565	0.921	rs2143695	ENSG00000268568.1	AC007228.9	-18.74	9.96e-68	9.12e-61	-0.65	-0.5	Vitiligo;	chr22:41332616	chr19:56672574~56673901:-
BRCA	trans	rs7258465	1	rs34171762	ENSG00000267533.1	RP11-815J4.7	18.71	1.37e-67	1.25e-60	0.66	0.5	Breast cancer;	chr19:18448600	chr18:12067173~12068417:-
BRCA	trans	rs7312770	0.612	rs773114	ENSG00000243403.1	RP11-330L19.1	18.66	2.78e-67	2.53e-60	0.57	0.5	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr15:64592979~64593326:+
BRCA	trans	rs7258465	1	rs8109573	ENSG00000267533.1	RP11-815J4.7	18.63	4.36e-67	3.95e-60	0.65	0.5	Breast cancer;	chr19:18506341	chr18:12067173~12068417:-
BRCA	trans	rs7258465	0.965	rs7254249	ENSG00000267533.1	RP11-815J4.7	18.62	5.1e-67	4.61e-60	0.65	0.5	Breast cancer;	chr19:18480935	chr18:12067173~12068417:-
BRCA	trans	rs2731664	0.792	rs335435	ENSG00000215571.5	GRK6P1	18.61	5.56e-67	5.03e-60	0.65	0.5	Intelligence (multi-trait analysis);	chr5:177440942	chr13:21319156~21320866:+
BRCA	trans	rs7258465	0.965	rs8100767	ENSG00000267533.1	RP11-815J4.7	18.6	6.93e-67	6.25e-60	0.65	0.5	Breast cancer;	chr19:18478278	chr18:12067173~12068417:-
BRCA	trans	rs877636	0.669	rs7297175	ENSG00000243403.1	RP11-330L19.1	-18.58	8.92e-67	8.03e-60	-0.57	-0.5	Cognitive function;	chr12:56080024	chr15:64592979~64593326:+
BRCA	trans	rs7258465	1	rs10403249	ENSG00000267533.1	RP11-815J4.7	18.58	8.93e-67	8.05e-60	0.65	0.5	Breast cancer;	chr19:18494132	chr18:12067173~12068417:-
BRCA	trans	rs7258465	0.965	rs271628	ENSG00000267533.1	RP11-815J4.7	18.58	9.36e-67	8.43e-60	0.65	0.5	Breast cancer;	chr19:18513523	chr18:12067173~12068417:-
BRCA	trans	rs2731664	0.792	rs2630767	ENSG00000215571.5	GRK6P1	18.57	9.68e-67	8.71e-60	0.65	0.5	Intelligence (multi-trait analysis);	chr5:177443699	chr13:21319156~21320866:+
BRCA	trans	rs12709013	0.635	rs6993	ENSG00000230849.2	GOT2P2	18.55	1.32e-66	1.18e-59	0.65	0.5	Blood metabolite ratios;	chr16:58707463	chr1:173141100~173142350:-
BRCA	trans	rs7258465	1	rs10409483	ENSG00000267533.1	RP11-815J4.7	18.55	1.34e-66	1.21e-59	0.65	0.5	Breast cancer;	chr19:18479413	chr18:12067173~12068417:-
BRCA	trans	rs7258465	1	rs10409505	ENSG00000267533.1	RP11-815J4.7	18.55	1.34e-66	1.21e-59	0.65	0.5	Breast cancer;	chr19:18479441	chr18:12067173~12068417:-
BRCA	trans	rs2657294	0.62	rs4746261	ENSG00000172974.11	AC007318.5	-18.53	1.72e-66	1.54e-59	-0.6	-0.5	Pneumonia;	chr10:75085874	chr2:65205108~65205988:+
BRCA	trans	rs7258465	0.931	rs271629	ENSG00000267533.1	RP11-815J4.7	18.52	2.12e-66	1.9e-59	0.65	0.5	Breast cancer;	chr19:18512388	chr18:12067173~12068417:-
BRCA	trans	rs7258465	0.931	rs8107347	ENSG00000267533.1	RP11-815J4.7	18.51	2.27e-66	2.03e-59	0.65	0.5	Breast cancer;	chr19:18501938	chr18:12067173~12068417:-
BRCA	trans	rs7258465	0.931	rs8107351	ENSG00000267533.1	RP11-815J4.7	18.51	2.27e-66	2.03e-59	0.65	0.5	Breast cancer;	chr19:18501948	chr18:12067173~12068417:-
BRCA	trans	rs7258465	0.931	rs7249020	ENSG00000267533.1	RP11-815J4.7	18.51	2.39e-66	2.13e-59	0.65	0.5	Breast cancer;	chr19:18497337	chr18:12067173~12068417:-
BRCA	trans	rs7258465	0.931	rs875396	ENSG00000267533.1	RP11-815J4.7	18.5	2.58e-66	2.3e-59	0.65	0.5	Breast cancer;	chr19:18500337	chr18:12067173~12068417:-
BRCA	trans	rs7258465	0.965	rs7253990	ENSG00000267533.1	RP11-815J4.7	18.5	2.72e-66	2.43e-59	0.65	0.5	Breast cancer;	chr19:18493275	chr18:12067173~12068417:-
BRCA	trans	rs928391	0.744	rs11264555	ENSG00000227183.3	HDGFP1	-18.48	3.63e-66	3.23e-59	-0.65	-0.5	Platelet count;	chr1:156794246	chrX:131646639~131646890:+
BRCA	trans	rs7258465	1	rs7251653	ENSG00000267533.1	RP11-815J4.7	18.44	6.45e-66	5.7e-59	0.65	0.5	Breast cancer;	chr19:18497473	chr18:12067173~12068417:-
BRCA	trans	rs10242455	0.702	rs73713531	ENSG00000228834.1	RP11-249L21.4	18.43	7.17e-66	6.34e-59	1.27	0.5	Blood metabolite levels;	chr7:99624756	chr6:108907615~108907873:-
BRCA	trans	rs7258465	1	rs34256197	ENSG00000267533.1	RP11-815J4.7	18.42	7.78e-66	6.86e-59	0.65	0.5	Breast cancer;	chr19:18495662	chr18:12067173~12068417:-
BRCA	trans	rs2731664	0.792	rs163199	ENSG00000215571.5	GRK6P1	18.4	1.14e-65	9.99e-59	0.64	0.5	Intelligence (multi-trait analysis);	chr5:177463066	chr13:21319156~21320866:+
BRCA	trans	rs7258465	1	rs10405636	ENSG00000267533.1	RP11-815J4.7	18.38	1.41e-65	1.24e-58	0.65	0.49	Breast cancer;	chr19:18427932	chr18:12067173~12068417:-
BRCA	trans	rs7258465	1	rs10411009	ENSG00000267533.1	RP11-815J4.7	18.36	2e-65	1.75e-58	0.64	0.49	Breast cancer;	chr19:18495456	chr18:12067173~12068417:-
BRCA	trans	rs2731664	0.792	rs335452	ENSG00000215571.5	GRK6P1	18.33	3.02e-65	2.63e-58	0.64	0.49	Intelligence (multi-trait analysis);	chr5:177452670	chr13:21319156~21320866:+
BRCA	trans	rs7258465	1	rs4808133	ENSG00000267533.1	RP11-815J4.7	18.32	3.18e-65	2.78e-58	0.65	0.49	Breast cancer;	chr19:18497708	chr18:12067173~12068417:-
BRCA	trans	rs7258465	1	rs4808134	ENSG00000267533.1	RP11-815J4.7	18.32	3.18e-65	2.78e-58	0.65	0.49	Breast cancer;	chr19:18497769	chr18:12067173~12068417:-
BRCA	trans	rs928391	0.744	rs3765783	ENSG00000227183.3	HDGFP1	-18.32	3.26e-65	2.84e-58	-0.64	-0.49	Platelet count;	chr1:156796181	chrX:131646639~131646890:+
BRCA	trans	rs2731664	0.792	rs652242	ENSG00000215571.5	GRK6P1	18.32	3.29e-65	2.87e-58	0.64	0.49	Intelligence (multi-trait analysis);	chr5:177446009	chr13:21319156~21320866:+
BRCA	trans	rs2731664	0.792	rs385981	ENSG00000215571.5	GRK6P1	18.3	4.23e-65	3.68e-58	0.64	0.49	Intelligence (multi-trait analysis);	chr5:177459538	chr13:21319156~21320866:+
BRCA	trans	rs9611565	0.625	rs9607819	ENSG00000268568.1	AC007228.9	-18.29	4.83e-65	4.2e-58	-0.81	-0.49	Vitiligo;	chr22:41562858	chr19:56672574~56673901:-
BRCA	trans	rs2731664	0.792	rs335467	ENSG00000215571.5	GRK6P1	18.27	6.49e-65	5.63e-58	0.64	0.49	Intelligence (multi-trait analysis);	chr5:177463641	chr13:21319156~21320866:+
BRCA	trans	rs928391	0.744	rs6700964	ENSG00000227183.3	HDGFP1	-18.24	1.03e-64	8.9e-58	-0.64	-0.49	Platelet count;	chr1:156790244	chrX:131646639~131646890:+
BRCA	trans	rs2731664	0.792	rs465670	ENSG00000215571.5	GRK6P1	18.21	1.47e-64	1.27e-57	0.64	0.49	Intelligence (multi-trait analysis);	chr5:177450623	chr13:21319156~21320866:+
BRCA	trans	rs12200782	0.505	rs9295696	ENSG00000242375.1	RP11-498P14.3	18.17	2.52e-64	2.17e-57	0.8	0.49	Small cell lung carcinoma;	chr6:26550060	chr9:97195351~97197687:-
BRCA	trans	rs877636	0.669	rs7297175	ENSG00000225071.1	GS1-184P14.2	-18.14	3.79e-64	3.27e-57	-0.56	-0.49	Cognitive function;	chr12:56080024	chrX:24429573~24429920:-
BRCA	trans	rs7258465	0.931	rs271626	ENSG00000267533.1	RP11-815J4.7	-18.09	7.73e-64	6.63e-57	-0.65	-0.49	Breast cancer;	chr19:18516257	chr18:12067173~12068417:-
BRCA	trans	rs11039798	0.528	rs10839208	ENSG00000134612.10	FOLH1B	18.07	1.01e-63	8.64e-57	0.74	0.49	Axial length;	chr11:49008904	chr11:89639227~89698718:+
BRCA	trans	rs7258465	0.965	rs271622	ENSG00000267533.1	RP11-815J4.7	18.03	1.75e-63	1.5e-56	0.65	0.49	Breast cancer;	chr19:18518467	chr18:12067173~12068417:-
BRCA	trans	rs7312770	0.612	rs773114	ENSG00000212994.5	RPS26P6	18.02	2.15e-63	1.83e-56	0.6	0.49	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr8:100895771~100896118:+
BRCA	trans	rs10242455	0.702	rs59574285	ENSG00000228834.1	RP11-249L21.4	18.01	2.3e-63	1.96e-56	1.25	0.49	Blood metabolite levels;	chr7:99638528	chr6:108907615~108907873:-
BRCA	trans	rs10242455	0.702	rs73713580	ENSG00000228834.1	RP11-249L21.4	18.01	2.3e-63	1.96e-56	1.25	0.49	Blood metabolite levels;	chr7:99643987	chr6:108907615~108907873:-
BRCA	trans	rs877636	0.692	rs2271194	ENSG00000212994.5	RPS26P6	-17.99	3.33e-63	2.83e-56	-0.6	-0.49	Cognitive function;	chr12:56083910	chr8:100895771~100896118:+
BRCA	trans	rs7258465	1	rs76194	ENSG00000267533.1	RP11-815J4.7	17.99	3.37e-63	2.86e-56	0.64	0.49	Breast cancer;	chr19:18519770	chr18:12067173~12068417:-
BRCA	trans	rs7258465	1	rs271621	ENSG00000267533.1	RP11-815J4.7	17.99	3.37e-63	2.86e-56	0.64	0.49	Breast cancer;	chr19:18520522	chr18:12067173~12068417:-
BRCA	trans	rs10242455	0.702	rs6956305	ENSG00000228834.1	RP11-249L21.4	17.95	5.27e-63	4.46e-56	1.25	0.49	Blood metabolite levels;	chr7:99643687	chr6:108907615~108907873:-
BRCA	trans	rs10242455	0.702	rs6976017	ENSG00000228834.1	RP11-249L21.4	17.94	5.98e-63	5.06e-56	1.25	0.49	Blood metabolite levels;	chr7:99652376	chr6:108907615~108907873:-
BRCA	trans	rs12200782	0.505	rs1535275	ENSG00000242375.1	RP11-498P14.3	17.94	6.58e-63	5.56e-56	0.79	0.49	Small cell lung carcinoma;	chr6:26520539	chr9:97195351~97197687:-
BRCA	trans	rs7312770	0.612	rs1873914	ENSG00000243403.1	RP11-330L19.1	17.93	6.9e-63	5.83e-56	0.56	0.49	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr15:64592979~64593326:+
BRCA	trans	rs7258465	1	rs271623	ENSG00000267533.1	RP11-815J4.7	17.93	7.38e-63	6.23e-56	0.64	0.49	Breast cancer;	chr19:18518137	chr18:12067173~12068417:-
BRCA	trans	rs11039798	0.528	rs10769559	ENSG00000134612.10	FOLH1B	17.92	8.51e-63	7.17e-56	0.74	0.49	Axial length;	chr11:49010894	chr11:89639227~89698718:+
BRCA	trans	rs2731664	0.792	rs2630764	ENSG00000215571.5	GRK6P1	17.89	1.31e-62	1.1e-55	0.63	0.48	Intelligence (multi-trait analysis);	chr5:177453084	chr13:21319156~21320866:+
BRCA	trans	rs7258465	0.965	rs2561043	ENSG00000267533.1	RP11-815J4.7	17.88	1.51e-62	1.27e-55	0.63	0.48	Breast cancer;	chr19:18511873	chr18:12067173~12068417:-
BRCA	trans	rs11039798	0.512	rs28453037	ENSG00000134612.10	FOLH1B	17.85	2.26e-62	1.89e-55	0.74	0.48	Axial length;	chr11:48985377	chr11:89639227~89698718:+
BRCA	trans	rs11039798	0.588	rs1814768	ENSG00000134612.10	FOLH1B	17.84	2.53e-62	2.11e-55	0.74	0.48	Axial length;	chr11:48965903	chr11:89639227~89698718:+
BRCA	trans	rs2731664	0.792	rs335434	ENSG00000215571.5	GRK6P1	17.83	2.89e-62	2.41e-55	0.63	0.48	Intelligence (multi-trait analysis);	chr5:177440275	chr13:21319156~21320866:+
BRCA	trans	rs7258465	1	rs7252848	ENSG00000267533.1	RP11-815J4.7	17.82	3.19e-62	2.66e-55	0.63	0.48	Breast cancer;	chr19:18501541	chr18:12067173~12068417:-
BRCA	trans	rs12709013	0.635	rs6993	ENSG00000233719.3	GOT2P3	17.79	5.16e-62	4.3e-55	0.61	0.48	Blood metabolite ratios;	chr16:58707463	chr12:9641802~9643007:+
BRCA	trans	rs11039798	0.588	rs61932767	ENSG00000134612.10	FOLH1B	17.78	5.98e-62	4.98e-55	0.73	0.48	Axial length;	chr11:48683254	chr11:89639227~89698718:+
BRCA	trans	rs7258465	1	rs10164319	ENSG00000267533.1	RP11-815J4.7	17.74	9.68e-62	8.03e-55	0.63	0.48	Breast cancer;	chr19:18459023	chr18:12067173~12068417:-
BRCA	trans	rs7258465	0.965	rs1560118	ENSG00000267533.1	RP11-815J4.7	17.74	9.68e-62	8.03e-55	0.63	0.48	Breast cancer;	chr19:18459225	chr18:12067173~12068417:-
BRCA	trans	rs7258465	1	rs2007981	ENSG00000267533.1	RP11-815J4.7	17.74	9.91e-62	8.22e-55	0.63	0.48	Breast cancer;	chr19:18456745	chr18:12067173~12068417:-
BRCA	trans	rs7258465	1	rs8103622	ENSG00000267533.1	RP11-815J4.7	17.73	1.14e-61	9.49e-55	0.63	0.48	Breast cancer;	chr19:18462024	chr18:12067173~12068417:-
BRCA	trans	rs2731664	0.756	rs2545796	ENSG00000215571.5	GRK6P1	17.71	1.4e-61	1.16e-54	0.62	0.48	Intelligence (multi-trait analysis);	chr5:177437268	chr13:21319156~21320866:+
BRCA	trans	rs9467773	0.869	rs1796521	ENSG00000242375.1	RP11-498P14.3	-17.71	1.51e-61	1.25e-54	-0.69	-0.48	Intelligence (multi-trait analysis);	chr6:26421164	chr9:97195351~97197687:-
BRCA	trans	rs11039798	0.512	rs3974936	ENSG00000134612.10	FOLH1B	17.68	2.24e-61	1.85e-54	0.74	0.48	Axial length;	chr11:48983460	chr11:89639227~89698718:+
BRCA	trans	rs2731664	0.792	rs1130857	ENSG00000215571.5	GRK6P1	17.67	2.67e-61	2.2e-54	0.63	0.48	Intelligence (multi-trait analysis);	chr5:177436518	chr13:21319156~21320866:+
BRCA	trans	rs13190036	1	rs6880798	ENSG00000217325.2	PRELID1P1	17.66	3.04e-61	2.5e-54	0.76	0.48	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177277456	chr6:126643488~126644390:+
BRCA	trans	rs11039798	0.557	rs4441015	ENSG00000134612.10	FOLH1B	17.65	3.3e-61	2.71e-54	0.76	0.48	Axial length;	chr11:49005518	chr11:89639227~89698718:+
BRCA	trans	rs7258465	1	rs8107367	ENSG00000267533.1	RP11-815J4.7	17.63	4.39e-61	3.59e-54	0.62	0.48	Breast cancer;	chr19:18453895	chr18:12067173~12068417:-
BRCA	trans	rs13190036	1	rs4976682	ENSG00000226986.4	RP11-543B16.2	17.62	5.08e-61	4.15e-54	0.75	0.48	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177299001	chr1:211207239~211207897:+
BRCA	trans	rs7730934	1	rs35450255	ENSG00000227018.1	IL6STP1	17.61	6.14e-61	5.01e-54	0.93	0.48	Blood protein levels;	chr5:56006116	chr17:15783288~15784307:+
BRCA	trans	rs7730934	1	rs13177475	ENSG00000227018.1	IL6STP1	17.61	6.14e-61	5.01e-54	0.93	0.48	Blood protein levels;	chr5:56006580	chr17:15783288~15784307:+
BRCA	trans	rs7730934	1	rs13166487	ENSG00000227018.1	IL6STP1	17.61	6.14e-61	5.01e-54	0.93	0.48	Blood protein levels;	chr5:56008123	chr17:15783288~15784307:+
BRCA	trans	rs12200782	0.505	rs7765920	ENSG00000242375.1	RP11-498P14.3	17.6	6.3e-61	5.14e-54	0.76	0.48	Small cell lung carcinoma;	chr6:26514543	chr9:97195351~97197687:-
BRCA	trans	rs7312770	0.612	rs773114	ENSG00000225071.1	GS1-184P14.2	17.6	6.71e-61	5.47e-54	0.55	0.48	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chrX:24429573~24429920:-
BRCA	trans	rs7258465	1	rs7258465	ENSG00000267533.1	RP11-815J4.7	17.55	1.27e-60	1.03e-53	0.63	0.48	Breast cancer;	chr19:18422832	chr18:12067173~12068417:-
BRCA	trans	rs7730934	1	rs35682251	ENSG00000227018.1	IL6STP1	17.54	1.49e-60	1.21e-53	0.95	0.48	Blood protein levels;	chr5:56011217	chr17:15783288~15784307:+
BRCA	trans	rs12200782	0.53	rs9379892	ENSG00000242375.1	RP11-498P14.3	17.54	1.57e-60	1.27e-53	0.81	0.48	Small cell lung carcinoma;	chr6:26582186	chr9:97195351~97197687:-
BRCA	trans	rs7258465	1	rs4808801	ENSG00000267533.1	RP11-815J4.7	17.52	2.01e-60	1.63e-53	0.62	0.48	Breast cancer;	chr19:18460331	chr18:12067173~12068417:-
BRCA	trans	rs2731664	0.792	rs337374	ENSG00000215571.5	GRK6P1	-17.52	2.1e-60	1.7e-53	-0.62	-0.48	Intelligence (multi-trait analysis);	chr5:177463415	chr13:21319156~21320866:+
BRCA	trans	rs7730934	1	rs13170520	ENSG00000227018.1	IL6STP1	17.5	2.55e-60	2.06e-53	0.92	0.48	Blood protein levels;	chr5:55978014	chr17:15783288~15784307:+
BRCA	trans	rs7730934	1	rs11744301	ENSG00000227018.1	IL6STP1	17.5	2.55e-60	2.06e-53	0.92	0.48	Blood protein levels;	chr5:55978776	chr17:15783288~15784307:+
BRCA	trans	rs7730934	1	rs11748421	ENSG00000227018.1	IL6STP1	17.5	2.55e-60	2.06e-53	0.92	0.48	Blood protein levels;	chr5:55978844	chr17:15783288~15784307:+
BRCA	trans	rs7730934	1	rs11744523	ENSG00000227018.1	IL6STP1	17.5	2.55e-60	2.06e-53	0.92	0.48	Blood protein levels;	chr5:55980088	chr17:15783288~15784307:+
BRCA	trans	rs7730934	1	rs11574765	ENSG00000227018.1	IL6STP1	17.5	2.55e-60	2.06e-53	0.92	0.48	Blood protein levels;	chr5:55983139	chr17:15783288~15784307:+
BRCA	trans	rs7730934	1	rs35354044	ENSG00000227018.1	IL6STP1	17.5	2.55e-60	2.06e-53	0.92	0.48	Blood protein levels;	chr5:55986809	chr17:15783288~15784307:+
BRCA	trans	rs12200782	0.53	rs6929908	ENSG00000242375.1	RP11-498P14.3	17.48	3.26e-60	2.62e-53	0.81	0.48	Small cell lung carcinoma;	chr6:26555061	chr9:97195351~97197687:-
BRCA	trans	rs10940346	0.967	rs13154223	ENSG00000231752.4	EMBP1	17.48	3.52e-60	2.82e-53	0.6	0.48	Schizophrenia;	chr5:50403152	chr1:121519112~121571892:+
BRCA	trans	rs7258465	1	rs2303695	ENSG00000267533.1	RP11-815J4.7	17.46	4.39e-60	3.51e-53	0.62	0.48	Breast cancer;	chr19:18451814	chr18:12067173~12068417:-
BRCA	trans	rs10242455	0.702	rs6977165	ENSG00000228834.1	RP11-249L21.4	17.46	4.66e-60	3.73e-53	1.24	0.48	Blood metabolite levels;	chr7:99671774	chr6:108907615~108907873:-
BRCA	trans	rs10940346	0.875	rs13172257	ENSG00000231752.4	EMBP1	17.41	9.23e-60	7.33e-53	0.6	0.47	Schizophrenia;	chr5:50462916	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.875	rs13159506	ENSG00000231752.4	EMBP1	17.38	1.36e-59	1.08e-52	0.6	0.47	Schizophrenia;	chr5:50415061	chr1:121519112~121571892:+
BRCA	trans	rs9467773	0.869	rs1796520	ENSG00000242375.1	RP11-498P14.3	-17.38	1.37e-59	1.08e-52	-0.67	-0.47	Intelligence (multi-trait analysis);	chr6:26410572	chr9:97195351~97197687:-
BRCA	trans	rs55665837	1	rs10832268	ENSG00000236360.2	RP11-334A14.2	17.38	1.37e-59	1.08e-52	0.6	0.47	Vitamin D levels;	chr11:14443522	chr1:52993201~52993702:-
BRCA	trans	rs55665837	1	rs10832269	ENSG00000236360.2	RP11-334A14.2	17.38	1.37e-59	1.08e-52	0.6	0.47	Vitamin D levels;	chr11:14443523	chr1:52993201~52993702:-
BRCA	trans	rs55665837	1	rs10832271	ENSG00000236360.2	RP11-334A14.2	17.38	1.37e-59	1.08e-52	0.6	0.47	Vitamin D levels;	chr11:14445373	chr1:52993201~52993702:-
BRCA	trans	rs8010715	0.636	rs2277482	ENSG00000248988.1	RP11-815N9.2	17.36	1.81e-59	1.43e-52	0.62	0.47	IgG glycosylation;	chr14:24118586	chr4:159007119~159007835:+
BRCA	trans	rs4276421	0.587	rs4975957	ENSG00000231752.4	EMBP1	-17.35	1.84e-59	1.45e-52	-0.59	-0.47	P wave duration;	chr5:46265200	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.905	rs4030569	ENSG00000231752.4	EMBP1	17.35	2.04e-59	1.6e-52	0.59	0.47	Schizophrenia;	chr5:50371779	chr1:121519112~121571892:+
BRCA	trans	rs10940346	1	rs4030570	ENSG00000231752.4	EMBP1	17.35	2.04e-59	1.6e-52	0.59	0.47	Schizophrenia;	chr5:50371829	chr1:121519112~121571892:+
BRCA	trans	rs9467773	0.836	rs1624440	ENSG00000242375.1	RP11-498P14.3	-17.34	2.13e-59	1.67e-52	-0.67	-0.47	Intelligence (multi-trait analysis);	chr6:26433101	chr9:97195351~97197687:-
BRCA	trans	rs6477998	0.702	rs7861707	ENSG00000238072.1	RP11-305M3.2	17.34	2.25e-59	1.76e-52	0.64	0.47	Hematology traits;	chr9:113251428	chr7:129410113~129410370:-
BRCA	trans	rs13358908	0.596	rs9717195	ENSG00000231752.4	EMBP1	-17.34	2.31e-59	1.81e-52	-0.6	-0.47	Schizophrenia;	chr5:46302679	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.967	rs2271236	ENSG00000231752.4	EMBP1	17.33	2.55e-59	1.99e-52	0.59	0.47	Schizophrenia;	chr5:50405921	chr1:121519112~121571892:+
BRCA	trans	rs10940346	1	rs34044167	ENSG00000231752.4	EMBP1	17.33	2.55e-59	1.99e-52	0.59	0.47	Schizophrenia;	chr5:50410136	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.967	rs62365887	ENSG00000231752.4	EMBP1	17.33	2.63e-59	2.06e-52	0.59	0.47	Schizophrenia;	chr5:50408254	chr1:121519112~121571892:+
BRCA	trans	rs10940346	1	rs10074196	ENSG00000231752.4	EMBP1	17.33	2.65e-59	2.07e-52	0.59	0.47	Schizophrenia;	chr5:50464713	chr1:121519112~121571892:+
BRCA	trans	rs10940346	1	rs13186891	ENSG00000231752.4	EMBP1	17.33	2.65e-59	2.07e-52	0.59	0.47	Schizophrenia;	chr5:50467244	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.967	rs13173678	ENSG00000231752.4	EMBP1	17.33	2.68e-59	2.09e-52	0.59	0.47	Schizophrenia;	chr5:50422314	chr1:121519112~121571892:+
BRCA	trans	rs10940346	1	rs6450108	ENSG00000231752.4	EMBP1	17.33	2.68e-59	2.09e-52	0.59	0.47	Schizophrenia;	chr5:50434427	chr1:121519112~121571892:+
BRCA	trans	rs10940346	1	rs28445612	ENSG00000231752.4	EMBP1	17.33	2.68e-59	2.09e-52	0.59	0.47	Schizophrenia;	chr5:50439676	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.967	rs2353436	ENSG00000231752.4	EMBP1	17.33	2.68e-59	2.09e-52	0.59	0.47	Schizophrenia;	chr5:50445695	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.967	rs1849200	ENSG00000231752.4	EMBP1	17.33	2.68e-59	2.09e-52	0.59	0.47	Schizophrenia;	chr5:50448053	chr1:121519112~121571892:+
BRCA	trans	rs10940346	1	rs6899048	ENSG00000231752.4	EMBP1	17.33	2.68e-59	2.09e-52	0.59	0.47	Schizophrenia;	chr5:50451256	chr1:121519112~121571892:+
BRCA	trans	rs10940346	1	rs2102454	ENSG00000231752.4	EMBP1	17.33	2.68e-59	2.09e-52	0.59	0.47	Schizophrenia;	chr5:50452446	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.967	rs6450134	ENSG00000231752.4	EMBP1	-17.33	2.7e-59	2.11e-52	-0.59	-0.47	Schizophrenia;	chr5:50471121	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.967	rs4030572	ENSG00000231752.4	EMBP1	17.31	3.18e-59	2.48e-52	0.59	0.47	Schizophrenia;	chr5:50375897	chr1:121519112~121571892:+
BRCA	trans	rs8010715	0.636	rs3825584	ENSG00000248988.1	RP11-815N9.2	17.31	3.28e-59	2.55e-52	0.61	0.47	IgG glycosylation;	chr14:24118430	chr4:159007119~159007835:+
BRCA	trans	rs10242455	0.702	rs73397447	ENSG00000228834.1	RP11-249L21.4	17.31	3.58e-59	2.78e-52	1.19	0.47	Blood metabolite levels;	chr7:99413326	chr6:108907615~108907873:-
BRCA	trans	rs13358908	0.595	rs4975942	ENSG00000231752.4	EMBP1	-17.3	3.78e-59	2.94e-52	-0.6	-0.47	Schizophrenia;	chr5:46371833	chr1:121519112~121571892:+
BRCA	trans	rs7730934	1	rs7726239	ENSG00000227018.1	IL6STP1	17.29	4.38e-59	3.39e-52	0.82	0.47	Blood protein levels;	chr5:55999478	chr17:15783288~15784307:+
BRCA	trans	rs10940346	1	rs4865522	ENSG00000231752.4	EMBP1	-17.28	4.76e-59	3.68e-52	-0.59	-0.47	Schizophrenia;	chr5:50303674	chr1:121519112~121571892:+
BRCA	trans	rs959695	1	rs2442756	ENSG00000260318.1	COX6CP1	17.27	5.46e-59	4.22e-52	0.59	0.47	Hippocampal atrophy;	chr8:99816910	chr16:11903923~11904137:-
BRCA	trans	rs10940346	1	rs6874697	ENSG00000231752.4	EMBP1	17.27	5.58e-59	4.31e-52	0.59	0.47	Schizophrenia;	chr5:50344307	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.967	rs2353437	ENSG00000231752.4	EMBP1	17.27	5.78e-59	4.46e-52	0.59	0.47	Schizophrenia;	chr5:50452078	chr1:121519112~121571892:+
BRCA	trans	rs10940346	1	rs4643959	ENSG00000231752.4	EMBP1	17.27	5.89e-59	4.54e-52	0.59	0.47	Schizophrenia;	chr5:50391631	chr1:121519112~121571892:+
BRCA	trans	rs13358908	0.631	rs6882540	ENSG00000231752.4	EMBP1	-17.27	5.99e-59	4.61e-52	-0.6	-0.47	Schizophrenia;	chr5:46345971	chr1:121519112~121571892:+
BRCA	trans	rs11039798	0.591	rs74992349	ENSG00000134612.10	FOLH1B	17.27	6.11e-59	4.71e-52	0.74	0.47	Axial length;	chr11:48997700	chr11:89639227~89698718:+
BRCA	trans	rs13358908	0.632	rs35088345	ENSG00000231752.4	EMBP1	-17.26	6.49e-59	4.99e-52	-0.59	-0.47	Schizophrenia;	chr5:46372364	chr1:121519112~121571892:+
BRCA	trans	rs10940346	1	rs1328254	ENSG00000231752.4	EMBP1	-17.26	6.6e-59	5.07e-52	-0.59	-0.47	Schizophrenia;	chr5:50265025	chr1:121519112~121571892:+
BRCA	trans	rs10940346	1	rs7380816	ENSG00000231752.4	EMBP1	-17.25	7.43e-59	5.71e-52	-0.59	-0.47	Schizophrenia;	chr5:50472059	chr1:121519112~121571892:+
BRCA	trans	rs13358908	0.712	rs28873151	ENSG00000231752.4	EMBP1	-17.24	8.37e-59	6.42e-52	-0.59	-0.47	Schizophrenia;	chr5:46378558	chr1:121519112~121571892:+
BRCA	trans	rs13358908	0.621	rs28847123	ENSG00000231752.4	EMBP1	-17.24	8.37e-59	6.42e-52	-0.59	-0.47	Schizophrenia;	chr5:46378829	chr1:121519112~121571892:+
BRCA	trans	rs13358908	0.593	rs28855077	ENSG00000231752.4	EMBP1	-17.24	8.37e-59	6.42e-52	-0.59	-0.47	Schizophrenia;	chr5:46378855	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.936	rs10940171	ENSG00000231752.4	EMBP1	17.24	8.68e-59	6.65e-52	0.59	0.47	Schizophrenia;	chr5:50324613	chr1:121519112~121571892:+
BRCA	trans	rs7730934	1	rs6450357	ENSG00000227018.1	IL6STP1	17.24	9.13e-59	6.99e-52	0.81	0.47	Blood protein levels;	chr5:55974168	chr17:15783288~15784307:+
BRCA	trans	rs55665837	1	rs10832254	ENSG00000236360.2	RP11-334A14.2	17.23	9.4e-59	7.2e-52	0.6	0.47	Vitamin D levels;	chr11:14413152	chr1:52993201~52993702:-
BRCA	trans	rs55665837	1	rs11023214	ENSG00000236360.2	RP11-334A14.2	17.23	9.4e-59	7.2e-52	0.6	0.47	Vitamin D levels;	chr11:14414713	chr1:52993201~52993702:-
BRCA	trans	rs10940346	1	rs10040323	ENSG00000231752.4	EMBP1	17.23	9.78e-59	7.49e-52	0.59	0.47	Schizophrenia;	chr5:50336779	chr1:121519112~121571892:+
BRCA	trans	rs10940346	1	rs2055909	ENSG00000231752.4	EMBP1	17.23	9.78e-59	7.49e-52	0.59	0.47	Schizophrenia;	chr5:50337474	chr1:121519112~121571892:+
BRCA	trans	rs9467773	0.869	rs742090	ENSG00000242375.1	RP11-498P14.3	-17.23	9.82e-59	7.51e-52	-0.67	-0.47	Intelligence (multi-trait analysis);	chr6:26415409	chr9:97195351~97197687:-
BRCA	trans	rs55665837	1	rs11023216	ENSG00000236360.2	RP11-334A14.2	17.23	9.85e-59	7.53e-52	0.6	0.47	Vitamin D levels;	chr11:14415607	chr1:52993201~52993702:-
BRCA	trans	rs10940346	1	rs35250488	ENSG00000231752.4	EMBP1	17.23	9.86e-59	7.54e-52	0.59	0.47	Schizophrenia;	chr5:50331004	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.716	rs12656601	ENSG00000231752.4	EMBP1	17.23	1.04e-58	7.92e-52	0.59	0.47	P wave duration;	chr5:46124483	chr1:121519112~121571892:+
BRCA	trans	rs10940346	1	rs7721808	ENSG00000231752.4	EMBP1	17.23	1.05e-58	8.01e-52	0.59	0.47	Schizophrenia;	chr5:50363136	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.623	rs8188231	ENSG00000231752.4	EMBP1	17.22	1.08e-58	8.25e-52	0.59	0.47	P wave duration;	chr5:46186924	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.684	rs8188258	ENSG00000231752.4	EMBP1	17.22	1.08e-58	8.25e-52	0.59	0.47	P wave duration;	chr5:46187284	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.688	rs10065920	ENSG00000231752.4	EMBP1	17.22	1.08e-58	8.25e-52	0.59	0.47	P wave duration;	chr5:46190593	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.688	rs8188292	ENSG00000231752.4	EMBP1	17.22	1.08e-58	8.25e-52	0.59	0.47	P wave duration;	chr5:46191402	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.657	rs8175415	ENSG00000231752.4	EMBP1	17.22	1.08e-58	8.25e-52	0.59	0.47	P wave duration;	chr5:46193360	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.633	rs62370770	ENSG00000231752.4	EMBP1	17.22	1.08e-58	8.25e-52	0.59	0.47	P wave duration;	chr5:46195784	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.875	rs10076490	ENSG00000231752.4	EMBP1	17.22	1.1e-58	8.38e-52	0.59	0.47	Schizophrenia;	chr5:50389037	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.688	rs12697543	ENSG00000231752.4	EMBP1	17.22	1.17e-58	8.87e-52	0.59	0.47	P wave duration;	chr5:46235824	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.657	rs10941759	ENSG00000231752.4	EMBP1	-17.22	1.18e-58	8.93e-52	-0.59	-0.47	P wave duration;	chr5:46266862	chr1:121519112~121571892:+
BRCA	trans	rs10940346	1	rs2137132	ENSG00000231752.4	EMBP1	17.22	1.18e-58	8.95e-52	0.59	0.47	Schizophrenia;	chr5:50353988	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.967	rs1995795	ENSG00000231752.4	EMBP1	17.22	1.18e-58	8.95e-52	0.59	0.47	Schizophrenia;	chr5:50356233	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.967	rs6874829	ENSG00000231752.4	EMBP1	17.22	1.18e-58	8.95e-52	0.59	0.47	Schizophrenia;	chr5:50357573	chr1:121519112~121571892:+
BRCA	trans	rs10940346	1	rs13185587	ENSG00000231752.4	EMBP1	17.22	1.18e-58	8.95e-52	0.59	0.47	Schizophrenia;	chr5:50365409	chr1:121519112~121571892:+
BRCA	trans	rs10940346	1	rs3849670	ENSG00000231752.4	EMBP1	17.22	1.18e-58	8.95e-52	0.59	0.47	Schizophrenia;	chr5:50365641	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.967	rs10068272	ENSG00000231752.4	EMBP1	-17.22	1.19e-58	9.03e-52	-0.59	-0.47	Schizophrenia;	chr5:50313688	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.967	rs10940129	ENSG00000231752.4	EMBP1	-17.22	1.19e-58	9.03e-52	-0.59	-0.47	Schizophrenia;	chr5:50315257	chr1:121519112~121571892:+
BRCA	trans	rs11039798	0.512	rs11040205	ENSG00000134612.10	FOLH1B	17.22	1.21e-58	9.2e-52	0.74	0.47	Axial length;	chr11:48985808	chr11:89639227~89698718:+
BRCA	trans	rs2731664	0.756	rs4976695	ENSG00000215571.5	GRK6P1	17.21	1.24e-58	9.42e-52	0.62	0.47	Intelligence (multi-trait analysis);	chr5:177435962	chr13:21319156~21320866:+
BRCA	trans	rs13358908	0.599	rs34899679	ENSG00000231752.4	EMBP1	-17.21	1.38e-58	1.04e-51	-0.59	-0.47	Schizophrenia;	chr5:46372360	chr1:121519112~121571892:+
BRCA	trans	rs10940346	1	rs2036901	ENSG00000231752.4	EMBP1	17.2	1.41e-58	1.06e-51	0.59	0.47	Schizophrenia;	chr5:50401306	chr1:121519112~121571892:+
BRCA	trans	rs55665837	1	rs12792120	ENSG00000236360.2	RP11-334A14.2	17.2	1.42e-58	1.07e-51	0.6	0.47	Vitamin D levels;	chr11:14447897	chr1:52993201~52993702:-
BRCA	trans	rs10940346	1	rs2883164	ENSG00000231752.4	EMBP1	17.2	1.45e-58	1.1e-51	0.59	0.47	Schizophrenia;	chr5:50397624	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.657	rs10941760	ENSG00000231752.4	EMBP1	-17.2	1.55e-58	1.17e-51	-0.59	-0.47	P wave duration;	chr5:46267360	chr1:121519112~121571892:+
BRCA	trans	rs55665837	1	rs12295723	ENSG00000236360.2	RP11-334A14.2	17.2	1.56e-58	1.18e-51	0.6	0.47	Vitamin D levels;	chr11:14428655	chr1:52993201~52993702:-
BRCA	trans	rs55665837	1	rs12295888	ENSG00000236360.2	RP11-334A14.2	17.2	1.56e-58	1.18e-51	0.6	0.47	Vitamin D levels;	chr11:14428985	chr1:52993201~52993702:-
BRCA	trans	rs55665837	1	rs7121171	ENSG00000236360.2	RP11-334A14.2	17.19	1.59e-58	1.2e-51	0.6	0.47	Vitamin D levels;	chr11:14424874	chr1:52993201~52993702:-
BRCA	trans	rs4276421	0.688	rs8188050	ENSG00000231752.4	EMBP1	17.19	1.64e-58	1.24e-51	0.59	0.47	P wave duration;	chr5:46201372	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.656	rs13188786	ENSG00000231752.4	EMBP1	17.19	1.64e-58	1.24e-51	0.59	0.47	P wave duration;	chr5:46201856	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.688	rs10064792	ENSG00000231752.4	EMBP1	17.19	1.64e-58	1.24e-51	0.59	0.47	P wave duration;	chr5:46202002	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.597	rs10072776	ENSG00000231752.4	EMBP1	17.19	1.64e-58	1.24e-51	0.59	0.47	P wave duration;	chr5:46202178	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.688	rs13168431	ENSG00000231752.4	EMBP1	17.19	1.64e-58	1.24e-51	0.59	0.47	P wave duration;	chr5:46205598	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.656	rs10064681	ENSG00000231752.4	EMBP1	17.19	1.7e-58	1.28e-51	0.59	0.47	P wave duration;	chr5:46222829	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.623	rs12109835	ENSG00000231752.4	EMBP1	17.19	1.7e-58	1.28e-51	0.59	0.47	P wave duration;	chr5:46222967	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.657	rs8188010	ENSG00000231752.4	EMBP1	17.19	1.72e-58	1.29e-51	0.59	0.47	P wave duration;	chr5:46194057	chr1:121519112~121571892:+
BRCA	trans	rs10940346	1	rs1328253	ENSG00000231752.4	EMBP1	-17.19	1.8e-58	1.35e-51	-0.59	-0.47	Schizophrenia;	chr5:50286916	chr1:121519112~121571892:+
BRCA	trans	rs13190036	0.901	rs28715668	ENSG00000226986.4	RP11-543B16.2	17.18	1.85e-58	1.39e-51	0.77	0.47	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177272267	chr1:211207239~211207897:+
BRCA	trans	rs13358908	0.622	rs12652607	ENSG00000231752.4	EMBP1	-17.17	2.34e-58	1.76e-51	-0.59	-0.47	Schizophrenia;	chr5:46392338	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.574	rs80150384	ENSG00000231752.4	EMBP1	-17.16	2.38e-58	1.78e-51	-0.59	-0.47	P wave duration;	chr5:46296183	chr1:121519112~121571892:+
BRCA	trans	rs13358908	0.715	rs12522625	ENSG00000231752.4	EMBP1	-17.16	2.39e-58	1.79e-51	-0.59	-0.47	Schizophrenia;	chr5:46389266	chr1:121519112~121571892:+
BRCA	trans	rs13358908	0.712	rs10941823	ENSG00000231752.4	EMBP1	-17.16	2.39e-58	1.79e-51	-0.59	-0.47	Schizophrenia;	chr5:46389481	chr1:121519112~121571892:+
BRCA	trans	rs10940346	1	rs2016360	ENSG00000231752.4	EMBP1	-17.16	2.56e-58	1.92e-51	-0.59	-0.47	Schizophrenia;	chr5:50491064	chr1:121519112~121571892:+
BRCA	trans	rs10940346	1	rs7378983	ENSG00000231752.4	EMBP1	-17.16	2.56e-58	1.92e-51	-0.59	-0.47	Schizophrenia;	chr5:50491889	chr1:121519112~121571892:+
BRCA	trans	rs10940346	1	rs6450164	ENSG00000231752.4	EMBP1	-17.16	2.56e-58	1.92e-51	-0.59	-0.47	Schizophrenia;	chr5:50502814	chr1:121519112~121571892:+
BRCA	trans	rs10940346	1	rs1962832	ENSG00000231752.4	EMBP1	-17.16	2.56e-58	1.92e-51	-0.59	-0.47	Schizophrenia;	chr5:50502962	chr1:121519112~121571892:+
BRCA	trans	rs10940346	1	rs7708897	ENSG00000231752.4	EMBP1	-17.16	2.68e-58	2.01e-51	-0.59	-0.47	Schizophrenia;	chr5:50528209	chr1:121519112~121571892:+
BRCA	trans	rs7258465	1	rs28572537	ENSG00000267533.1	RP11-815J4.7	17.15	2.79e-58	2.08e-51	0.62	0.47	Breast cancer;	chr19:18441398	chr18:12067173~12068417:-
BRCA	trans	rs11039798	0.588	rs59777067	ENSG00000134612.10	FOLH1B	17.15	2.82e-58	2.11e-51	0.74	0.47	Axial length;	chr11:48993798	chr11:89639227~89698718:+
BRCA	trans	rs4276421	0.537	rs13166566	ENSG00000231752.4	EMBP1	17.15	2.94e-58	2.2e-51	0.59	0.47	P wave duration;	chr5:46210486	chr1:121519112~121571892:+
BRCA	trans	rs8010715	0.636	rs2277480	ENSG00000248988.1	RP11-815N9.2	17.15	3.01e-58	2.24e-51	0.61	0.47	IgG glycosylation;	chr14:24118306	chr4:159007119~159007835:+
BRCA	trans	rs4276421	0.625	rs61187820	ENSG00000231752.4	EMBP1	17.14	3.46e-58	2.58e-51	0.59	0.47	P wave duration;	chr5:46199336	chr1:121519112~121571892:+
BRCA	trans	rs7258465	1	rs7252707	ENSG00000267533.1	RP11-815J4.7	17.13	3.67e-58	2.73e-51	0.61	0.47	Breast cancer;	chr19:18501447	chr18:12067173~12068417:-
BRCA	trans	rs10940346	1	rs1812994	ENSG00000231752.4	EMBP1	17.13	3.73e-58	2.77e-51	0.59	0.47	Schizophrenia;	chr5:50364397	chr1:121519112~121571892:+
BRCA	trans	rs10940346	1	rs7380858	ENSG00000231752.4	EMBP1	-17.12	4.25e-58	3.15e-51	-0.59	-0.47	Schizophrenia;	chr5:50537022	chr1:121519112~121571892:+
BRCA	trans	rs13358908	0.652	rs7293494	ENSG00000231752.4	EMBP1	-17.12	4.37e-58	3.24e-51	-0.59	-0.47	Schizophrenia;	chr5:46313550	chr1:121519112~121571892:+
BRCA	trans	rs10940346	1	rs510897	ENSG00000231752.4	EMBP1	-17.12	4.5e-58	3.33e-51	-0.59	-0.47	Schizophrenia;	chr5:50263017	chr1:121519112~121571892:+
BRCA	trans	rs10940346	1	rs507396	ENSG00000231752.4	EMBP1	-17.12	4.5e-58	3.33e-51	-0.59	-0.47	Schizophrenia;	chr5:50263374	chr1:121519112~121571892:+
BRCA	trans	rs10940346	1	rs7712749	ENSG00000231752.4	EMBP1	17.12	4.58e-58	3.39e-51	0.59	0.47	Schizophrenia;	chr5:50400441	chr1:121519112~121571892:+
BRCA	trans	rs55665837	1	rs12288873	ENSG00000236360.2	RP11-334A14.2	17.11	5.19e-58	3.84e-51	0.6	0.47	Vitamin D levels;	chr11:14428919	chr1:52993201~52993702:-
BRCA	trans	rs4276421	0.657	rs8188296	ENSG00000231752.4	EMBP1	17.1	6.04e-58	4.46e-51	0.59	0.47	P wave duration;	chr5:46221948	chr1:121519112~121571892:+
BRCA	trans	rs13177918	0.677	rs4541646	ENSG00000226396.1	RP5-1056L3.3	17.09	6.15e-58	4.53e-51	0.53	0.47	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443355	chr1:19608114~19608568:+
BRCA	trans	rs13177918	0.677	rs3900644	ENSG00000226396.1	RP5-1056L3.3	17.09	6.15e-58	4.53e-51	0.53	0.47	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443359	chr1:19608114~19608568:+
BRCA	trans	rs11039798	0.512	rs1988465	ENSG00000134612.10	FOLH1B	17.09	6.65e-58	4.9e-51	0.74	0.47	Axial length;	chr11:48989751	chr11:89639227~89698718:+
BRCA	trans	rs10940346	0.818	rs472278	ENSG00000231752.4	EMBP1	-17.08	7.35e-58	5.41e-51	-0.59	-0.47	Schizophrenia;	chr5:50215972	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.684	rs10064829	ENSG00000231752.4	EMBP1	17.08	7.68e-58	5.66e-51	0.59	0.47	P wave duration;	chr5:46192959	chr1:121519112~121571892:+
BRCA	trans	rs7258465	0.965	rs10409003	ENSG00000267533.1	RP11-815J4.7	17.07	8.33e-58	6.13e-51	0.61	0.47	Breast cancer;	chr19:18432244	chr18:12067173~12068417:-
BRCA	trans	rs10242455	0.702	rs17161726	ENSG00000228834.1	RP11-249L21.4	17.07	8.59e-58	6.32e-51	1.09	0.47	Blood metabolite levels;	chr7:99410772	chr6:108907615~108907873:-
BRCA	trans	rs4276421	0.688	rs8188054	ENSG00000231752.4	EMBP1	17.07	8.89e-58	6.53e-51	0.59	0.47	P wave duration;	chr5:46215556	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.688	rs10061101	ENSG00000231752.4	EMBP1	17.07	8.89e-58	6.53e-51	0.59	0.47	P wave duration;	chr5:46217831	chr1:121519112~121571892:+
BRCA	trans	rs7258465	0.965	rs10408290	ENSG00000267533.1	RP11-815J4.7	17.07	8.95e-58	6.56e-51	0.61	0.47	Breast cancer;	chr19:18431891	chr18:12067173~12068417:-
BRCA	trans	rs10940346	0.716	rs8188088	ENSG00000231752.4	EMBP1	-17.07	8.95e-58	6.56e-51	-0.59	-0.47	Schizophrenia;	chr5:50215591	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.653	rs4371800	ENSG00000231752.4	EMBP1	-17.07	8.95e-58	6.56e-51	-0.59	-0.47	Schizophrenia;	chr5:50225349	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.584	rs496108	ENSG00000231752.4	EMBP1	-17.07	8.95e-58	6.56e-51	-0.59	-0.47	Schizophrenia;	chr5:50236794	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.744	rs498951	ENSG00000231752.4	EMBP1	-17.07	8.95e-58	6.56e-51	-0.59	-0.47	Schizophrenia;	chr5:50238681	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.846	rs8188203	ENSG00000231752.4	EMBP1	-17.07	8.96e-58	6.56e-51	-0.59	-0.47	Schizophrenia;	chr5:50161448	chr1:121519112~121571892:+
BRCA	trans	rs9611565	0.649	rs126092	ENSG00000268568.1	AC007228.9	17.07	8.98e-58	6.57e-51	0.66	0.47	Vitiligo;	chr22:41782437	chr19:56672574~56673901:-
BRCA	trans	rs10940346	0.905	rs10053631	ENSG00000231752.4	EMBP1	-17.07	9.07e-58	6.63e-51	-0.59	-0.47	Schizophrenia;	chr5:50164086	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.728	rs10053639	ENSG00000231752.4	EMBP1	-17.07	9.07e-58	6.63e-51	-0.59	-0.47	Schizophrenia;	chr5:50164113	chr1:121519112~121571892:+
BRCA	trans	rs13177918	0.677	rs13161099	ENSG00000226396.1	RP5-1056L3.3	17.06	1.01e-57	7.4e-51	0.53	0.47	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442799	chr1:19608114~19608568:+
BRCA	trans	rs13177918	0.677	rs13161417	ENSG00000226396.1	RP5-1056L3.3	17.06	1.01e-57	7.4e-51	0.53	0.47	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442937	chr1:19608114~19608568:+
BRCA	trans	rs13177918	0.677	rs13161156	ENSG00000226396.1	RP5-1056L3.3	17.06	1.01e-57	7.4e-51	0.53	0.47	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443023	chr1:19608114~19608568:+
BRCA	trans	rs13177918	0.677	rs13181401	ENSG00000226396.1	RP5-1056L3.3	17.06	1.01e-57	7.4e-51	0.53	0.47	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443033	chr1:19608114~19608568:+
BRCA	trans	rs13177918	0.677	rs2070844	ENSG00000226396.1	RP5-1056L3.3	17.06	1.01e-57	7.4e-51	0.53	0.47	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444222	chr1:19608114~19608568:+
BRCA	trans	rs13177918	0.629	rs2070842	ENSG00000226396.1	RP5-1056L3.3	17.06	1.01e-57	7.4e-51	0.53	0.47	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444660	chr1:19608114~19608568:+
BRCA	trans	rs13190036	1	rs3733875	ENSG00000226986.4	RP11-543B16.2	-17.05	1.11e-57	8.1e-51	-0.77	-0.47	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177210239	chr1:211207239~211207897:+
BRCA	trans	rs10940346	1	rs11960661	ENSG00000231752.4	EMBP1	-17.05	1.14e-57	8.31e-51	-0.58	-0.47	Schizophrenia;	chr5:50266528	chr1:121519112~121571892:+
BRCA	trans	rs10940346	1	rs489407	ENSG00000231752.4	EMBP1	-17.05	1.14e-57	8.31e-51	-0.58	-0.47	Schizophrenia;	chr5:50266701	chr1:121519112~121571892:+
BRCA	trans	rs10940346	1	rs491470	ENSG00000231752.4	EMBP1	-17.05	1.14e-57	8.31e-51	-0.58	-0.47	Schizophrenia;	chr5:50266988	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.902	rs4865727	ENSG00000231752.4	EMBP1	-17.04	1.2e-57	8.7e-51	-0.59	-0.47	Schizophrenia;	chr5:50145945	chr1:121519112~121571892:+
BRCA	trans	rs10940346	1	rs492337	ENSG00000231752.4	EMBP1	-17.04	1.21e-57	8.78e-51	-0.58	-0.47	Schizophrenia;	chr5:50274706	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.714	rs12523073	ENSG00000231752.4	EMBP1	-17.04	1.21e-57	8.78e-51	-0.59	-0.47	Schizophrenia;	chr5:50153697	chr1:121519112~121571892:+
BRCA	trans	rs55665837	1	rs10047429	ENSG00000236360.2	RP11-334A14.2	17.04	1.21e-57	8.79e-51	0.6	0.47	Vitamin D levels;	chr11:14417486	chr1:52993201~52993702:-
BRCA	trans	rs55665837	1	rs10047457	ENSG00000236360.2	RP11-334A14.2	17.04	1.21e-57	8.79e-51	0.6	0.47	Vitamin D levels;	chr11:14417913	chr1:52993201~52993702:-
BRCA	trans	rs10940346	0.936	rs7705285	ENSG00000231752.4	EMBP1	17.04	1.34e-57	9.71e-51	0.59	0.47	Schizophrenia;	chr5:50325579	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.578	rs8185314	ENSG00000231752.4	EMBP1	-17.03	1.43e-57	1.04e-50	-0.59	-0.47	P wave duration;	chr5:46299648	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.63	rs10054134	ENSG00000231752.4	EMBP1	-17.03	1.47e-57	1.06e-50	-0.59	-0.47	P wave duration;	chr5:46292175	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.656	rs7293337	ENSG00000231752.4	EMBP1	17.03	1.48e-57	1.08e-50	0.58	0.47	P wave duration;	chr5:46203395	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.656	rs11960110	ENSG00000231752.4	EMBP1	17.03	1.53e-57	1.11e-50	0.58	0.47	P wave duration;	chr5:46210055	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.656	rs13172097	ENSG00000231752.4	EMBP1	17.03	1.54e-57	1.12e-50	0.58	0.47	P wave duration;	chr5:46211694	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.653	rs72768421	ENSG00000231752.4	EMBP1	-17.02	1.56e-57	1.13e-50	-0.59	-0.47	Schizophrenia;	chr5:50246898	chr1:121519112~121571892:+
BRCA	trans	rs7730934	1	rs6875155	ENSG00000227018.1	IL6STP1	-17.02	1.56e-57	1.13e-50	-0.79	-0.47	Blood protein levels;	chr5:55975226	chr17:15783288~15784307:+
BRCA	trans	rs4276421	0.684	rs8185055	ENSG00000231752.4	EMBP1	-17.02	1.76e-57	1.27e-50	-0.59	-0.47	P wave duration;	chr5:46262149	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.609	rs4975911	ENSG00000231752.4	EMBP1	-17.01	1.87e-57	1.35e-50	-0.59	-0.47	P wave duration;	chr5:46297143	chr1:121519112~121571892:+
BRCA	trans	rs13177918	0.677	rs3857421	ENSG00000226396.1	RP5-1056L3.3	-17.01	1.92e-57	1.38e-50	-0.52	-0.47	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443584	chr1:19608114~19608568:+
BRCA	trans	rs13358908	0.715	rs8185301	ENSG00000231752.4	EMBP1	-17	2.14e-57	1.54e-50	-0.59	-0.47	Schizophrenia;	chr5:46312149	chr1:121519112~121571892:+
BRCA	trans	rs11039798	0.507	rs56994343	ENSG00000134612.10	FOLH1B	17	2.16e-57	1.55e-50	0.72	0.47	Axial length;	chr11:48875418	chr11:89639227~89698718:+
BRCA	trans	rs13190036	1	rs71601343	ENSG00000226986.4	RP11-543B16.2	-17	2.24e-57	1.61e-50	-0.77	-0.47	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177205106	chr1:211207239~211207897:+
BRCA	trans	rs13190036	1	rs71601344	ENSG00000226986.4	RP11-543B16.2	-17	2.24e-57	1.61e-50	-0.77	-0.47	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177206492	chr1:211207239~211207897:+
BRCA	trans	rs4276421	0.688	rs10040808	ENSG00000231752.4	EMBP1	16.98	2.7e-57	1.94e-50	0.58	0.47	P wave duration;	chr5:46123599	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.684	rs8175395	ENSG00000231752.4	EMBP1	16.98	2.79e-57	2.01e-50	0.58	0.47	P wave duration;	chr5:46125498	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.934	rs2353222	ENSG00000231752.4	EMBP1	-16.98	2.83e-57	2.03e-50	-0.59	-0.47	Schizophrenia;	chr5:50174249	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.656	rs8185376	ENSG00000231752.4	EMBP1	16.98	2.95e-57	2.12e-50	0.58	0.47	P wave duration;	chr5:46165191	chr1:121519112~121571892:+
BRCA	trans	rs13190036	0.551	rs7710269	ENSG00000217325.2	PRELID1P1	-16.96	3.63e-57	2.6e-50	-0.7	-0.47	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177187528	chr6:126643488~126644390:+
BRCA	trans	rs13177918	0.629	rs13161261	ENSG00000226396.1	RP5-1056L3.3	16.96	3.76e-57	2.69e-50	0.52	0.47	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442844	chr1:19608114~19608568:+
BRCA	trans	rs4276421	0.688	rs8185185	ENSG00000231752.4	EMBP1	16.95	3.96e-57	2.84e-50	0.58	0.47	P wave duration;	chr5:46214358	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.967	rs6449782	ENSG00000231752.4	EMBP1	-16.94	4.55e-57	3.25e-50	-0.58	-0.46	Schizophrenia;	chr5:50291694	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.652	rs8185226	ENSG00000231752.4	EMBP1	16.94	4.58e-57	3.28e-50	0.58	0.46	P wave duration;	chr5:46160685	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.695	rs8185255	ENSG00000231752.4	EMBP1	-16.93	5.65e-57	4.03e-50	-0.58	-0.46	P wave duration;	chr5:46263336	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.652	rs8188276	ENSG00000231752.4	EMBP1	16.92	5.96e-57	4.25e-50	0.58	0.46	P wave duration;	chr5:46182731	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.656	rs13188002	ENSG00000231752.4	EMBP1	16.92	5.96e-57	4.25e-50	0.58	0.46	P wave duration;	chr5:46184203	chr1:121519112~121571892:+
BRCA	trans	rs7258465	1	rs4808136	ENSG00000267533.1	RP11-815J4.7	-16.91	7.21e-57	5.13e-50	-0.6	-0.46	Breast cancer;	chr19:18508057	chr18:12067173~12068417:-
BRCA	trans	rs10940346	1	rs56387400	ENSG00000231752.4	EMBP1	-16.91	7.43e-57	5.28e-50	-0.59	-0.46	Schizophrenia;	chr5:50517577	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.684	rs10072945	ENSG00000231752.4	EMBP1	16.91	7.64e-57	5.42e-50	0.58	0.46	P wave duration;	chr5:46151307	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.716	rs13155082	ENSG00000231752.4	EMBP1	16.91	7.64e-57	5.42e-50	0.58	0.46	P wave duration;	chr5:46155135	chr1:121519112~121571892:+
BRCA	trans	rs11039798	0.582	rs60764175	ENSG00000134612.10	FOLH1B	16.9	8.23e-57	5.83e-50	0.72	0.46	Axial length;	chr11:48754304	chr11:89639227~89698718:+
BRCA	trans	rs4276421	0.656	rs8185101	ENSG00000231752.4	EMBP1	16.89	8.99e-57	6.36e-50	0.58	0.46	P wave duration;	chr5:46183248	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.744	rs13157345	ENSG00000231752.4	EMBP1	16.89	9.51e-57	6.72e-50	0.58	0.46	P wave duration;	chr5:46129304	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.805	rs7293302	ENSG00000231752.4	EMBP1	16.89	9.55e-57	6.74e-50	0.58	0.46	P wave duration;	chr5:46131077	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.688	rs4975961	ENSG00000231752.4	EMBP1	16.89	9.94e-57	7.02e-50	0.59	0.46	P wave duration;	chr5:46247615	chr1:121519112~121571892:+
BRCA	trans	rs7312770	0.612	rs1873914	ENSG00000225071.1	GS1-184P14.2	16.88	1.06e-56	7.49e-50	0.54	0.46	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chrX:24429573~24429920:-
BRCA	trans	rs7730934	1	rs11574777	ENSG00000227018.1	IL6STP1	-16.88	1.07e-56	7.55e-50	-0.85	-0.46	Blood protein levels;	chr5:55953115	chr17:15783288~15784307:+
BRCA	trans	rs4276421	0.716	rs34186279	ENSG00000231752.4	EMBP1	16.86	1.37e-56	9.64e-50	0.58	0.46	P wave duration;	chr5:46221966	chr1:121519112~121571892:+
BRCA	trans	rs7730934	1	rs11739853	ENSG00000227018.1	IL6STP1	16.86	1.41e-56	9.9e-50	0.9	0.46	Blood protein levels;	chr5:55961688	chr17:15783288~15784307:+
BRCA	trans	rs7730934	1	rs11574769	ENSG00000227018.1	IL6STP1	16.86	1.41e-56	9.9e-50	0.9	0.46	Blood protein levels;	chr5:55962393	chr17:15783288~15784307:+
BRCA	trans	rs7730934	1	rs11741953	ENSG00000227018.1	IL6STP1	16.86	1.43e-56	1.01e-49	0.81	0.46	Blood protein levels;	chr5:55971986	chr17:15783288~15784307:+
BRCA	trans	rs2731664	0.819	rs449351	ENSG00000215571.5	GRK6P1	16.86	1.49e-56	1.04e-49	0.6	0.46	Intelligence (multi-trait analysis);	chr5:177445590	chr13:21319156~21320866:+
BRCA	trans	rs11039798	0.512	rs1588069	ENSG00000134612.10	FOLH1B	16.84	1.75e-56	1.22e-49	0.72	0.46	Axial length;	chr11:48673319	chr11:89639227~89698718:+
BRCA	trans	rs11039798	0.623	rs7294273	ENSG00000134612.10	FOLH1B	16.84	1.75e-56	1.22e-49	0.72	0.46	Axial length;	chr11:48683822	chr11:89639227~89698718:+
BRCA	trans	rs7730934	1	rs6894414	ENSG00000227018.1	IL6STP1	16.84	1.9e-56	1.33e-49	0.81	0.46	Blood protein levels;	chr5:55956667	chr17:15783288~15784307:+
BRCA	trans	rs7730934	1	rs11739016	ENSG00000227018.1	IL6STP1	16.84	1.9e-56	1.33e-49	0.81	0.46	Blood protein levels;	chr5:55967545	chr17:15783288~15784307:+
BRCA	trans	rs7312770	0.612	rs1873914	ENSG00000212994.5	RPS26P6	16.83	1.99e-56	1.4e-49	0.58	0.46	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr8:100895771~100896118:+
BRCA	trans	rs55665837	1	rs12804549	ENSG00000236360.2	RP11-334A14.2	16.83	2e-56	1.4e-49	0.59	0.46	Vitamin D levels;	chr11:14416212	chr1:52993201~52993702:-
BRCA	trans	rs7395662	0.553	rs11040122	ENSG00000134612.10	FOLH1B	16.83	2.04e-56	1.43e-49	0.58	0.46	HDL cholesterol;	chr11:48879486	chr11:89639227~89698718:+
BRCA	trans	rs10940346	1	rs555458	ENSG00000231752.4	EMBP1	-16.82	2.42e-56	1.69e-49	-0.58	-0.46	Schizophrenia;	chr5:50262772	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.537	rs8188099	ENSG00000231752.4	EMBP1	-16.82	2.52e-56	1.76e-49	-0.59	-0.46	Schizophrenia;	chr5:50183445	chr1:121519112~121571892:+
BRCA	trans	rs13190036	1	rs13157667	ENSG00000226986.4	RP11-543B16.2	-16.8	2.96e-56	2.06e-49	-0.77	-0.46	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177186876	chr1:211207239~211207897:+
BRCA	trans	rs4276421	0.657	rs13186103	ENSG00000231752.4	EMBP1	16.79	3.73e-56	2.59e-49	0.58	0.46	P wave duration;	chr5:46131553	chr1:121519112~121571892:+
BRCA	trans	rs13358908	0.652	rs8185385	ENSG00000231752.4	EMBP1	-16.79	3.78e-56	2.62e-49	-0.59	-0.46	Schizophrenia;	chr5:46318532	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.688	rs7293424	ENSG00000231752.4	EMBP1	16.78	3.93e-56	2.72e-49	0.59	0.46	P wave duration;	chr5:46184874	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.716	rs13156708	ENSG00000231752.4	EMBP1	16.78	4.1e-56	2.84e-49	0.58	0.46	P wave duration;	chr5:46128924	chr1:121519112~121571892:+
BRCA	trans	rs13358908	0.715	rs10053628	ENSG00000231752.4	EMBP1	-16.78	4.25e-56	2.94e-49	-0.58	-0.46	Schizophrenia;	chr5:46383233	chr1:121519112~121571892:+
BRCA	trans	rs3740713	1	rs79199586	ENSG00000235847.2	LDHAP7	16.77	4.57e-56	3.17e-49	0.9	0.46	Amyotrophic lateral sclerosis (sporadic);	chr11:18430599	chr2:84777259~84778223:-
BRCA	trans	rs2727020	0.688	rs2734002	ENSG00000134612.10	FOLH1B	16.77	4.73e-56	3.27e-49	0.57	0.46	Coronary artery disease;	chr11:49212610	chr11:89639227~89698718:+
BRCA	trans	rs2731664	0.792	rs335420	ENSG00000215571.5	GRK6P1	-16.76	4.95e-56	3.42e-49	-0.6	-0.46	Intelligence (multi-trait analysis);	chr5:177471618	chr13:21319156~21320866:+
BRCA	trans	rs7730934	1	rs1445872	ENSG00000227018.1	IL6STP1	16.74	6.55e-56	4.52e-49	0.93	0.46	Blood protein levels;	chr5:55962032	chr17:15783288~15784307:+
BRCA	trans	rs4276421	0.688	rs10941746	ENSG00000231752.4	EMBP1	16.73	7.75e-56	5.35e-49	0.58	0.46	P wave duration;	chr5:46202737	chr1:121519112~121571892:+
BRCA	trans	rs7395662	0.791	rs4347396	ENSG00000134612.10	FOLH1B	16.73	7.98e-56	5.5e-49	0.58	0.46	HDL cholesterol;	chr11:48874377	chr11:89639227~89698718:+
BRCA	trans	rs7395662	0.759	rs4347397	ENSG00000134612.10	FOLH1B	16.73	7.98e-56	5.5e-49	0.58	0.46	HDL cholesterol;	chr11:48874394	chr11:89639227~89698718:+
BRCA	trans	rs4276421	0.688	rs13436334	ENSG00000231752.4	EMBP1	16.72	9.34e-56	6.43e-49	0.58	0.46	P wave duration;	chr5:46243759	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.684	rs11958686	ENSG00000231752.4	EMBP1	16.72	9.47e-56	6.51e-49	0.58	0.46	P wave duration;	chr5:46173456	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.688	rs11950077	ENSG00000231752.4	EMBP1	16.71	9.87e-56	6.79e-49	0.58	0.46	P wave duration;	chr5:46179798	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.654	rs8185114	ENSG00000231752.4	EMBP1	16.71	9.87e-56	6.79e-49	0.58	0.46	P wave duration;	chr5:46181843	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.656	rs13180509	ENSG00000231752.4	EMBP1	16.7	1.21e-55	8.34e-49	0.58	0.46	P wave duration;	chr5:46239147	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.656	rs8188149	ENSG00000231752.4	EMBP1	16.7	1.21e-55	8.34e-49	0.58	0.46	P wave duration;	chr5:46242641	chr1:121519112~121571892:+
BRCA	trans	rs7312770	1	rs7312770	ENSG00000225071.1	GS1-184P14.2	-16.69	1.36e-55	9.32e-49	-0.5	-0.46	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chrX:24429573~24429920:-
BRCA	trans	rs4276421	0.684	rs8185217	ENSG00000231752.4	EMBP1	16.69	1.37e-55	9.39e-49	0.58	0.46	P wave duration;	chr5:46169215	chr1:121519112~121571892:+
BRCA	trans	rs7730934	1	rs11742271	ENSG00000227018.1	IL6STP1	16.66	1.85e-55	1.27e-48	0.73	0.46	Blood protein levels;	chr5:55967454	chr17:15783288~15784307:+
BRCA	trans	rs2727020	0.612	rs603672	ENSG00000134612.10	FOLH1B	16.65	2.12e-55	1.45e-48	0.57	0.46	Coronary artery disease;	chr11:49213014	chr11:89639227~89698718:+
BRCA	trans	rs61990749	0.511	rs7146020	ENSG00000235400.1	RP4-641G12.4	16.65	2.16e-55	1.47e-48	0.79	0.46	Fibroblast growth factor basic levels;	chr14:77891976	chr1:78749073~78750659:+
BRCA	trans	rs7395662	0.784	rs79037165	ENSG00000134612.10	FOLH1B	16.65	2.23e-55	1.52e-48	0.57	0.46	HDL cholesterol;	chr11:48843912	chr11:89639227~89698718:+
BRCA	trans	rs4276421	0.713	rs8188193	ENSG00000231752.4	EMBP1	16.64	2.41e-55	1.64e-48	0.58	0.46	P wave duration;	chr5:46122428	chr1:121519112~121571892:+
BRCA	trans	rs7395662	0.889	rs11039972	ENSG00000134612.10	FOLH1B	16.64	2.52e-55	1.72e-48	0.57	0.46	HDL cholesterol;	chr11:48737700	chr11:89639227~89698718:+
BRCA	trans	rs13190036	1	rs34446750	ENSG00000226986.4	RP11-543B16.2	-16.63	3.02e-55	2.06e-48	-0.76	-0.46	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177168079	chr1:211207239~211207897:+
BRCA	trans	rs6477998	0.647	rs10981704	ENSG00000238072.1	RP11-305M3.2	-16.62	3.33e-55	2.26e-48	-0.6	-0.46	Hematology traits;	chr9:113253989	chr7:129410113~129410370:-
BRCA	trans	rs7395662	0.892	rs11040010	ENSG00000134612.10	FOLH1B	16.62	3.56e-55	2.41e-48	0.57	0.46	HDL cholesterol;	chr11:48755377	chr11:89639227~89698718:+
BRCA	trans	rs13190036	1	rs13177748	ENSG00000226986.4	RP11-543B16.2	-16.61	3.68e-55	2.5e-48	-0.75	-0.46	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177216953	chr1:211207239~211207897:+
BRCA	trans	rs7395662	0.784	rs75694945	ENSG00000134612.10	FOLH1B	16.61	3.78e-55	2.56e-48	0.58	0.46	HDL cholesterol;	chr11:48843911	chr11:89639227~89698718:+
BRCA	trans	rs4276421	0.656	rs10473416	ENSG00000231752.4	EMBP1	16.61	3.81e-55	2.58e-48	0.58	0.46	P wave duration;	chr5:46246868	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.777	rs8185098	ENSG00000231752.4	EMBP1	16.61	4.07e-55	2.76e-48	0.57	0.46	P wave duration;	chr5:46125388	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.805	rs13168838	ENSG00000231752.4	EMBP1	16.6	4.18e-55	2.83e-48	0.59	0.46	P wave duration;	chr5:46016815	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.774	rs4302598	ENSG00000231752.4	EMBP1	16.6	4.18e-55	2.83e-48	0.59	0.46	P wave duration;	chr5:46019065	chr1:121519112~121571892:+
BRCA	trans	rs2727020	0.729	rs10742932	ENSG00000134612.10	FOLH1B	-16.6	4.4e-55	2.98e-48	-0.57	-0.46	Coronary artery disease;	chr11:49151682	chr11:89639227~89698718:+
BRCA	trans	rs13190036	1	rs34832871	ENSG00000226986.4	RP11-543B16.2	-16.6	4.64e-55	3.13e-48	-0.75	-0.46	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177228928	chr1:211207239~211207897:+
BRCA	trans	rs4276421	0.714	rs8185016	ENSG00000231752.4	EMBP1	16.59	5.07e-55	3.43e-48	0.58	0.46	P wave duration;	chr5:46121704	chr1:121519112~121571892:+
BRCA	trans	rs1814175	0.538	rs1684260	ENSG00000134612.10	FOLH1B	16.57	6.22e-55	4.19e-48	0.57	0.46	Height;	chr11:49202679	chr11:89639227~89698718:+
BRCA	trans	rs2727020	0.729	rs6485965	ENSG00000134612.10	FOLH1B	16.57	6.69e-55	4.51e-48	0.56	0.46	Coronary artery disease;	chr11:49145178	chr11:89639227~89698718:+
BRCA	trans	rs7312770	1	rs7312770	ENSG00000243403.1	RP11-330L19.1	-16.56	7.57e-55	5.1e-48	-0.5	-0.46	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr15:64592979~64593326:+
BRCA	trans	rs7395662	0.617	rs1976509	ENSG00000134612.10	FOLH1B	16.55	8.68e-55	5.84e-48	0.57	0.46	HDL cholesterol;	chr11:48943051	chr11:89639227~89698718:+
BRCA	trans	rs2731664	0.792	rs335468	ENSG00000215571.5	GRK6P1	-16.54	9.11e-55	6.12e-48	-0.59	-0.46	Intelligence (multi-trait analysis);	chr5:177465348	chr13:21319156~21320866:+
BRCA	trans	rs13177918	0.557	rs12520101	ENSG00000226396.1	RP5-1056L3.3	16.54	9.95e-55	6.68e-48	0.52	0.46	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150431360	chr1:19608114~19608568:+
BRCA	trans	rs10940346	1	rs12520874	ENSG00000231752.4	EMBP1	-16.54	1e-54	6.72e-48	-0.57	-0.46	Schizophrenia;	chr5:50523857	chr1:121519112~121571892:+
BRCA	trans	rs2731664	0.756	rs335433	ENSG00000215571.5	GRK6P1	16.53	1.16e-54	7.79e-48	0.6	0.46	Intelligence (multi-trait analysis);	chr5:177440206	chr13:21319156~21320866:+
BRCA	trans	rs10037055	1	rs6886255	ENSG00000217325.2	PRELID1P1	16.52	1.26e-54	8.42e-48	0.64	0.46	Migraine without aura;	chr5:177291360	chr6:126643488~126644390:+
BRCA	trans	rs4276421	0.688	rs13155792	ENSG00000231752.4	EMBP1	16.51	1.5e-54	1.01e-47	0.57	0.46	P wave duration;	chr5:46176452	chr1:121519112~121571892:+
BRCA	trans	rs959695	1	rs959695	ENSG00000260318.1	COX6CP1	16.51	1.52e-54	1.02e-47	0.58	0.46	Hippocampal atrophy;	chr8:99822954	chr16:11903923~11904137:-
BRCA	trans	rs2727020	0.664	rs4929893	ENSG00000134612.10	FOLH1B	-16.5	1.6e-54	1.07e-47	-0.56	-0.46	Coronary artery disease;	chr11:49174780	chr11:89639227~89698718:+
BRCA	trans	rs13190036	1	rs35535623	ENSG00000226986.4	RP11-543B16.2	-16.5	1.66e-54	1.11e-47	-0.75	-0.46	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177202295	chr1:211207239~211207897:+
BRCA	trans	rs13190036	1	rs13167431	ENSG00000226986.4	RP11-543B16.2	-16.5	1.66e-54	1.11e-47	-0.75	-0.46	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177194074	chr1:211207239~211207897:+
BRCA	trans	rs2731664	0.721	rs2450333	ENSG00000215571.5	GRK6P1	16.49	1.77e-54	1.18e-47	0.6	0.45	Intelligence (multi-trait analysis);	chr5:177472545	chr13:21319156~21320866:+
BRCA	trans	rs11039798	0.588	rs1847640	ENSG00000134612.10	FOLH1B	16.49	1.8e-54	1.2e-47	0.71	0.45	Axial length;	chr11:48982473	chr11:89639227~89698718:+
BRCA	trans	rs2731664	0.74	rs2731670	ENSG00000215571.5	GRK6P1	-16.49	1.96e-54	1.31e-47	-0.59	-0.45	Intelligence (multi-trait analysis);	chr5:177421018	chr13:21319156~21320866:+
BRCA	trans	rs55665837	1	rs11023215	ENSG00000236360.2	RP11-334A14.2	16.47	2.36e-54	1.57e-47	0.59	0.45	Vitamin D levels;	chr11:14415424	chr1:52993201~52993702:-
BRCA	trans	rs7395662	0.963	rs9666932	ENSG00000134612.10	FOLH1B	16.47	2.48e-54	1.65e-47	0.57	0.45	HDL cholesterol;	chr11:48704688	chr11:89639227~89698718:+
BRCA	trans	rs7395662	0.926	rs7122869	ENSG00000134612.10	FOLH1B	16.47	2.48e-54	1.65e-47	0.57	0.45	HDL cholesterol;	chr11:48706447	chr11:89639227~89698718:+
BRCA	trans	rs7395662	0.892	rs9667579	ENSG00000134612.10	FOLH1B	16.47	2.48e-54	1.65e-47	0.57	0.45	HDL cholesterol;	chr11:48708596	chr11:89639227~89698718:+
BRCA	trans	rs7395662	0.963	rs8189076	ENSG00000134612.10	FOLH1B	16.47	2.48e-54	1.65e-47	0.57	0.45	HDL cholesterol;	chr11:48711423	chr11:89639227~89698718:+
BRCA	trans	rs7395662	0.857	rs3902433	ENSG00000134612.10	FOLH1B	16.47	2.48e-54	1.65e-47	0.57	0.45	HDL cholesterol;	chr11:48711772	chr11:89639227~89698718:+
BRCA	trans	rs61990749	0.571	rs11628049	ENSG00000235400.1	RP4-641G12.4	-16.46	2.61e-54	1.73e-47	-0.87	-0.45	Fibroblast growth factor basic levels;	chr14:77842108	chr1:78749073~78750659:+
BRCA	trans	rs7395662	1	rs10839171	ENSG00000134612.10	FOLH1B	16.45	3.11e-54	2.06e-47	0.57	0.45	HDL cholesterol;	chr11:48901482	chr11:89639227~89698718:+
BRCA	trans	rs7395662	0.791	rs7945791	ENSG00000134612.10	FOLH1B	16.45	3.11e-54	2.06e-47	0.57	0.45	HDL cholesterol;	chr11:48914788	chr11:89639227~89698718:+
BRCA	trans	rs7395662	0.791	rs11040136	ENSG00000134612.10	FOLH1B	16.45	3.11e-54	2.06e-47	0.57	0.45	HDL cholesterol;	chr11:48918239	chr11:89639227~89698718:+
BRCA	trans	rs10037055	1	rs10037055	ENSG00000217325.2	PRELID1P1	-16.45	3.22e-54	2.13e-47	-0.64	-0.45	Migraine without aura;	chr5:177264278	chr6:126643488~126644390:+
BRCA	trans	rs877636	0.669	rs7297175	ENSG00000212994.5	RPS26P6	-16.44	3.38e-54	2.24e-47	-0.56	-0.45	Cognitive function;	chr12:56080024	chr8:100895771~100896118:+
BRCA	trans	rs877636	1	rs877636	ENSG00000243403.1	RP11-330L19.1	-16.44	3.39e-54	2.24e-47	-0.54	-0.45	Cognitive function;	chr12:56086799	chr15:64592979~64593326:+
BRCA	trans	rs7395662	0.963	rs10454482	ENSG00000134612.10	FOLH1B	-16.44	3.47e-54	2.29e-47	-0.56	-0.45	HDL cholesterol;	chr11:48733425	chr11:89639227~89698718:+
BRCA	trans	rs7395662	0.895	rs4882238	ENSG00000134612.10	FOLH1B	-16.44	3.47e-54	2.29e-47	-0.56	-0.45	HDL cholesterol;	chr11:48733988	chr11:89639227~89698718:+
BRCA	trans	rs7395662	0.547	rs10769442	ENSG00000134612.10	FOLH1B	-16.44	3.47e-54	2.29e-47	-0.56	-0.45	HDL cholesterol;	chr11:48743475	chr11:89639227~89698718:+
BRCA	trans	rs7395662	0.746	rs8186207	ENSG00000134612.10	FOLH1B	-16.44	3.47e-54	2.29e-47	-0.56	-0.45	HDL cholesterol;	chr11:48743813	chr11:89639227~89698718:+
BRCA	trans	rs7395662	0.667	rs2865612	ENSG00000134612.10	FOLH1B	16.44	3.48e-54	2.3e-47	0.57	0.45	HDL cholesterol;	chr11:48758670	chr11:89639227~89698718:+
BRCA	trans	rs7395662	0.709	rs11040113	ENSG00000134612.10	FOLH1B	-16.44	3.49e-54	2.31e-47	-0.56	-0.45	HDL cholesterol;	chr11:48874101	chr11:89639227~89698718:+
BRCA	trans	rs4276421	0.688	rs10038249	ENSG00000231752.4	EMBP1	16.44	3.5e-54	2.31e-47	0.57	0.45	P wave duration;	chr5:46160595	chr1:121519112~121571892:+
BRCA	trans	rs7395662	1	rs2221559	ENSG00000134612.10	FOLH1B	16.44	3.57e-54	2.35e-47	0.57	0.45	HDL cholesterol;	chr11:48686421	chr11:89639227~89698718:+
BRCA	trans	rs7395662	0.963	rs11499897	ENSG00000134612.10	FOLH1B	16.44	3.57e-54	2.35e-47	0.57	0.45	HDL cholesterol;	chr11:48696314	chr11:89639227~89698718:+
BRCA	trans	rs7395662	0.895	rs3903506	ENSG00000134612.10	FOLH1B	16.44	3.57e-54	2.35e-47	0.57	0.45	HDL cholesterol;	chr11:48696961	chr11:89639227~89698718:+
BRCA	trans	rs7395662	0.724	rs10400308	ENSG00000134612.10	FOLH1B	-16.44	3.59e-54	2.36e-47	-0.56	-0.45	HDL cholesterol;	chr11:48869694	chr11:89639227~89698718:+
BRCA	trans	rs4276421	0.594	rs7293434	ENSG00000231752.4	EMBP1	16.44	3.69e-54	2.43e-47	0.57	0.45	P wave duration;	chr5:46257587	chr1:121519112~121571892:+
BRCA	trans	rs7395662	0.794	rs11511967	ENSG00000134612.10	FOLH1B	-16.43	4.15e-54	2.73e-47	-0.57	-0.45	HDL cholesterol;	chr11:48798901	chr11:89639227~89698718:+
BRCA	trans	rs7395662	0.697	rs11530291	ENSG00000134612.10	FOLH1B	16.42	4.88e-54	3.2e-47	0.57	0.45	HDL cholesterol;	chr11:48742651	chr11:89639227~89698718:+
BRCA	trans	rs7554547	0.905	rs4993564	ENSG00000261819.1	RP11-680G24.4	16.41	5.55e-54	3.64e-47	0.58	0.45	Nonsyndromic cleft lip with cleft palate;	chr1:11909934	chr16:14988259~14990160:-
BRCA	trans	rs7395662	0.963	rs60772766	ENSG00000134612.10	FOLH1B	-16.4	5.79e-54	3.8e-47	-0.56	-0.45	HDL cholesterol;	chr11:48699459	chr11:89639227~89698718:+
BRCA	trans	rs7395662	0.929	rs11493665	ENSG00000134612.10	FOLH1B	-16.4	5.79e-54	3.8e-47	-0.56	-0.45	HDL cholesterol;	chr11:48699483	chr11:89639227~89698718:+
BRCA	trans	rs13358908	0.602	rs4975977	ENSG00000231752.4	EMBP1	-16.39	6.75e-54	4.42e-47	-0.58	-0.45	Schizophrenia;	chr5:46307988	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.774	rs4499842	ENSG00000231752.4	EMBP1	16.39	7.06e-54	4.62e-47	0.58	0.45	P wave duration;	chr5:46034390	chr1:121519112~121571892:+
BRCA	trans	rs10940346	1	rs10940359	ENSG00000231752.4	EMBP1	-16.39	7.18e-54	4.69e-47	-0.57	-0.45	Schizophrenia;	chr5:50538645	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.936	rs303219	ENSG00000231752.4	EMBP1	16.37	8.95e-54	5.83e-47	0.58	0.45	Schizophrenia;	chr5:50407795	chr1:121519112~121571892:+
BRCA	trans	rs7395662	0.624	rs11040162	ENSG00000134612.10	FOLH1B	16.36	9.84e-54	6.39e-47	0.57	0.45	HDL cholesterol;	chr11:48938439	chr11:89639227~89698718:+
BRCA	trans	rs7395662	0.963	rs12418254	ENSG00000134612.10	FOLH1B	-16.36	1.03e-53	6.66e-47	-0.56	-0.45	HDL cholesterol;	chr11:48966710	chr11:89639227~89698718:+
BRCA	trans	rs7395662	0.819	rs12269855	ENSG00000134612.10	FOLH1B	-16.36	1.05e-53	6.84e-47	-0.56	-0.45	HDL cholesterol;	chr11:48757100	chr11:89639227~89698718:+
BRCA	trans	rs6477998	0.603	rs12338803	ENSG00000238072.1	RP11-305M3.2	16.36	1.07e-53	6.92e-47	0.7	0.45	Hematology traits;	chr9:113263148	chr7:129410113~129410370:-
BRCA	trans	rs7395662	0.781	rs11499902	ENSG00000134612.10	FOLH1B	-16.35	1.13e-53	7.34e-47	-0.56	-0.45	HDL cholesterol;	chr11:48721179	chr11:89639227~89698718:+
BRCA	trans	rs7395662	0.963	rs11039950	ENSG00000134612.10	FOLH1B	16.35	1.15e-53	7.42e-47	0.56	0.45	HDL cholesterol;	chr11:48715919	chr11:89639227~89698718:+
BRCA	trans	rs1045902	0.967	rs10207625	ENSG00000236165.1	PRADC1P1	16.35	1.18e-53	7.63e-47	0.58	0.45	Intelligence (multi-trait analysis);	chr2:73237680	chr3:36976316~36976840:+
BRCA	trans	rs7395662	0.963	rs2089209	ENSG00000134612.10	FOLH1B	-16.34	1.36e-53	8.77e-47	-0.56	-0.45	HDL cholesterol;	chr11:48965568	chr11:89639227~89698718:+
BRCA	trans	rs7395662	0.622	rs2865620	ENSG00000134612.10	FOLH1B	-16.34	1.37e-53	8.85e-47	-0.56	-0.45	HDL cholesterol;	chr11:48786359	chr11:89639227~89698718:+
BRCA	trans	rs7395662	0.895	rs1121000	ENSG00000134612.10	FOLH1B	-16.3	2.28e-53	1.46e-46	-0.56	-0.45	HDL cholesterol;	chr11:48690238	chr11:89639227~89698718:+
BRCA	trans	rs7395662	0.963	rs8189397	ENSG00000134612.10	FOLH1B	-16.3	2.28e-53	1.46e-46	-0.56	-0.45	HDL cholesterol;	chr11:48690318	chr11:89639227~89698718:+
BRCA	trans	rs7395662	0.895	rs8186350	ENSG00000134612.10	FOLH1B	-16.29	2.4e-53	1.54e-46	-0.56	-0.45	HDL cholesterol;	chr11:48717709	chr11:89639227~89698718:+
BRCA	trans	rs4276421	0.774	rs10042199	ENSG00000231752.4	EMBP1	-16.29	2.47e-53	1.59e-46	-0.58	-0.45	P wave duration;	chr5:46103946	chr1:121519112~121571892:+
BRCA	trans	rs13190036	1	rs655623	ENSG00000226986.4	RP11-543B16.2	16.29	2.48e-53	1.59e-46	0.7	0.45	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177107515	chr1:211207239~211207897:+
BRCA	trans	rs6477998	0.58	rs10817467	ENSG00000238072.1	RP11-305M3.2	16.29	2.56e-53	1.64e-46	0.68	0.45	Hematology traits;	chr9:113246803	chr7:129410113~129410370:-
BRCA	trans	rs7395662	0.658	rs2865610	ENSG00000134612.10	FOLH1B	-16.29	2.62e-53	1.68e-46	-0.56	-0.45	HDL cholesterol;	chr11:48751065	chr11:89639227~89698718:+
BRCA	trans	rs6732160	0.574	rs12465780	ENSG00000236165.1	PRADC1P1	-16.29	2.62e-53	1.68e-46	-0.58	-0.45	Intelligence (multi-trait analysis);	chr2:73244884	chr3:36976316~36976840:+
BRCA	trans	rs7395662	0.857	rs11040074	ENSG00000134612.10	FOLH1B	-16.29	2.65e-53	1.7e-46	-0.56	-0.45	HDL cholesterol;	chr11:48835174	chr11:89639227~89698718:+
BRCA	trans	rs1045902	0.967	rs1469530	ENSG00000236165.1	PRADC1P1	16.28	2.82e-53	1.8e-46	0.58	0.45	Intelligence (multi-trait analysis);	chr2:73237820	chr3:36976316~36976840:+
BRCA	trans	rs4276421	0.774	rs6884716	ENSG00000231752.4	EMBP1	16.28	2.91e-53	1.86e-46	0.58	0.45	P wave duration;	chr5:46115267	chr1:121519112~121571892:+
BRCA	trans	rs7395662	0.895	rs2221553	ENSG00000134612.10	FOLH1B	-16.27	3.24e-53	2.06e-46	-0.56	-0.45	HDL cholesterol;	chr11:48667232	chr11:89639227~89698718:+
BRCA	trans	rs7395662	0.817	rs1848151	ENSG00000134612.10	FOLH1B	-16.27	3.24e-53	2.06e-46	-0.56	-0.45	HDL cholesterol;	chr11:48671106	chr11:89639227~89698718:+
BRCA	trans	rs7395662	0.963	rs11039937	ENSG00000134612.10	FOLH1B	-16.27	3.24e-53	2.06e-46	-0.56	-0.45	HDL cholesterol;	chr11:48691030	chr11:89639227~89698718:+
BRCA	trans	rs7395662	0.895	rs1827971	ENSG00000134612.10	FOLH1B	-16.27	3.24e-53	2.06e-46	-0.56	-0.45	HDL cholesterol;	chr11:48696950	chr11:89639227~89698718:+
BRCA	trans	rs7395662	0.963	rs4882170	ENSG00000134612.10	FOLH1B	-16.27	3.24e-53	2.06e-46	-0.56	-0.45	HDL cholesterol;	chr11:48702662	chr11:89639227~89698718:+
BRCA	trans	rs7395662	0.963	rs2865923	ENSG00000134612.10	FOLH1B	-16.27	3.24e-53	2.06e-46	-0.56	-0.45	HDL cholesterol;	chr11:48703403	chr11:89639227~89698718:+
BRCA	trans	rs7395662	0.7	rs11493668	ENSG00000134612.10	FOLH1B	-16.27	3.24e-53	2.06e-46	-0.56	-0.45	HDL cholesterol;	chr11:48706030	chr11:89639227~89698718:+
BRCA	trans	rs7395662	0.963	rs2135681	ENSG00000134612.10	FOLH1B	-16.27	3.24e-53	2.06e-46	-0.56	-0.45	HDL cholesterol;	chr11:48706836	chr11:89639227~89698718:+
BRCA	trans	rs7395662	0.963	rs2135680	ENSG00000134612.10	FOLH1B	-16.27	3.24e-53	2.06e-46	-0.56	-0.45	HDL cholesterol;	chr11:48706873	chr11:89639227~89698718:+
BRCA	trans	rs10242455	0.702	rs57832867	ENSG00000228834.1	RP11-249L21.4	16.27	3.27e-53	2.08e-46	1.17	0.45	Blood metabolite levels;	chr7:99368773	chr6:108907615~108907873:-
BRCA	trans	rs7395662	0.889	rs1848158	ENSG00000134612.10	FOLH1B	-16.27	3.33e-53	2.12e-46	-0.56	-0.45	HDL cholesterol;	chr11:48675742	chr11:89639227~89698718:+
BRCA	trans	rs4276421	0.695	rs4498260	ENSG00000231752.4	EMBP1	-16.27	3.44e-53	2.18e-46	-0.58	-0.45	P wave duration;	chr5:46079235	chr1:121519112~121571892:+
BRCA	trans	rs7395662	1	rs1809986	ENSG00000134612.10	FOLH1B	-16.26	3.56e-53	2.26e-46	-0.56	-0.45	HDL cholesterol;	chr11:48965987	chr11:89639227~89698718:+
BRCA	trans	rs10242455	0.702	rs917152	ENSG00000228834.1	RP11-249L21.4	16.26	3.68e-53	2.34e-46	1.15	0.45	Blood metabolite levels;	chr7:99406874	chr6:108907615~108907873:-
BRCA	trans	rs2731664	0.792	rs335432	ENSG00000215571.5	GRK6P1	16.26	3.74e-53	2.37e-46	0.59	0.45	Intelligence (multi-trait analysis);	chr5:177439257	chr13:21319156~21320866:+
BRCA	trans	rs7395662	1	rs7479498	ENSG00000134612.10	FOLH1B	-16.25	4.3e-53	2.72e-46	-0.56	-0.45	HDL cholesterol;	chr11:48638947	chr11:89639227~89698718:+
BRCA	trans	rs4276421	0.682	rs10054419	ENSG00000231752.4	EMBP1	16.25	4.34e-53	2.75e-46	0.58	0.45	P wave duration;	chr5:46036863	chr1:121519112~121571892:+
BRCA	trans	rs7395662	0.597	rs2135684	ENSG00000134612.10	FOLH1B	-16.24	4.78e-53	3.02e-46	-0.56	-0.45	HDL cholesterol;	chr11:48726917	chr11:89639227~89698718:+
BRCA	trans	rs7395662	0.929	rs8186263	ENSG00000134612.10	FOLH1B	-16.24	5.13e-53	3.24e-46	-0.56	-0.45	HDL cholesterol;	chr11:48716383	chr11:89639227~89698718:+
BRCA	trans	rs7395662	0.963	rs1857786	ENSG00000134612.10	FOLH1B	-16.24	5.18e-53	3.27e-46	-0.56	-0.45	HDL cholesterol;	chr11:48945872	chr11:89639227~89698718:+
BRCA	trans	rs4276421	0.774	rs72755668	ENSG00000231752.4	EMBP1	-16.23	5.21e-53	3.28e-46	-0.58	-0.45	P wave duration;	chr5:46102658	chr1:121519112~121571892:+
BRCA	trans	rs7395662	0.963	rs11040172	ENSG00000134612.10	FOLH1B	-16.23	5.45e-53	3.44e-46	-0.56	-0.45	HDL cholesterol;	chr11:48946945	chr11:89639227~89698718:+
BRCA	trans	rs7395662	0.824	rs12787989	ENSG00000134612.10	FOLH1B	-16.23	5.45e-53	3.44e-46	-0.56	-0.45	HDL cholesterol;	chr11:48949335	chr11:89639227~89698718:+
BRCA	trans	rs7395662	0.824	rs12785858	ENSG00000134612.10	FOLH1B	-16.23	5.48e-53	3.45e-46	-0.56	-0.45	HDL cholesterol;	chr11:48757254	chr11:89639227~89698718:+
BRCA	trans	rs9876781	1	rs9838618	ENSG00000235912.1	RP1-159A19.3	-16.23	5.67e-53	3.57e-46	-0.52	-0.45	Longevity;	chr3:48445949	chr1:27649419~27649610:+
BRCA	trans	rs4276421	0.774	rs10066479	ENSG00000231752.4	EMBP1	-16.22	6.13e-53	3.86e-46	-0.57	-0.45	P wave duration;	chr5:46097385	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.774	rs12515804	ENSG00000231752.4	EMBP1	-16.22	6.27e-53	3.94e-46	-0.57	-0.45	P wave duration;	chr5:46098504	chr1:121519112~121571892:+
BRCA	trans	rs72615157	0.628	rs7801070	ENSG00000228546.2	CTA-313A17.3	16.21	6.75e-53	4.24e-46	0.69	0.45	Lung function (FEV1/FVC);	chr7:100249524	chr7:102337316~102339115:+
BRCA	trans	rs10940346	0.935	rs2353959	ENSG00000231752.4	EMBP1	-16.21	7.16e-53	4.49e-46	-0.58	-0.45	Schizophrenia;	chr5:50473217	chr1:121519112~121571892:+
BRCA	trans	rs10940346	1	rs2668024	ENSG00000231752.4	EMBP1	-16.2	7.99e-53	5.01e-46	-0.59	-0.45	Schizophrenia;	chr5:50414421	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.623	rs12654375	ENSG00000231752.4	EMBP1	16.2	8.1e-53	5.07e-46	0.57	0.45	P wave duration;	chr5:46036452	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.623	rs4409106	ENSG00000231752.4	EMBP1	16.2	8.21e-53	5.14e-46	0.57	0.45	P wave duration;	chr5:46038004	chr1:121519112~121571892:+
BRCA	trans	rs3740713	1	rs75740864	ENSG00000235847.2	LDHAP7	16.2	8.32e-53	5.2e-46	0.8	0.45	Amyotrophic lateral sclerosis (sporadic);	chr11:18449142	chr2:84777259~84778223:-
BRCA	trans	rs4276421	0.774	rs10050829	ENSG00000231752.4	EMBP1	-16.19	9.47e-53	5.92e-46	-0.57	-0.45	P wave duration;	chr5:46072628	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.688	rs10067655	ENSG00000231752.4	EMBP1	-16.19	9.47e-53	5.92e-46	-0.57	-0.45	P wave duration;	chr5:46072803	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.745	rs13354272	ENSG00000231752.4	EMBP1	-16.18	1e-52	6.26e-46	-0.57	-0.45	P wave duration;	chr5:46078020	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.774	rs13361118	ENSG00000231752.4	EMBP1	-16.18	1.01e-52	6.33e-46	-0.57	-0.45	P wave duration;	chr5:46078308	chr1:121519112~121571892:+
BRCA	trans	rs10940346	1	rs13360100	ENSG00000231752.4	EMBP1	-16.18	1.06e-52	6.61e-46	-0.58	-0.45	Schizophrenia;	chr5:50323389	chr1:121519112~121571892:+
BRCA	trans	rs10940346	1	rs4865674	ENSG00000231752.4	EMBP1	-16.18	1.12e-52	7e-46	-0.58	-0.45	Schizophrenia;	chr5:50277531	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.846	rs2663076	ENSG00000231752.4	EMBP1	16.17	1.23e-52	7.69e-46	0.58	0.45	Schizophrenia;	chr5:50430593	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.934	rs303231	ENSG00000231752.4	EMBP1	16.17	1.23e-52	7.69e-46	0.58	0.45	Schizophrenia;	chr5:50447369	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.661	rs10059426	ENSG00000231752.4	EMBP1	-16.16	1.35e-52	8.41e-46	-0.57	-0.45	P wave duration;	chr5:46090412	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.774	rs7720482	ENSG00000231752.4	EMBP1	-16.16	1.38e-52	8.6e-46	-0.57	-0.45	P wave duration;	chr5:46106061	chr1:121519112~121571892:+
BRCA	trans	rs10242455	0.702	rs28668326	ENSG00000228834.1	RP11-249L21.4	16.15	1.65e-52	1.02e-45	1.15	0.45	Blood metabolite levels;	chr7:99400530	chr6:108907615~108907873:-
BRCA	trans	rs7395662	0.818	rs34486360	ENSG00000134612.10	FOLH1B	-16.14	1.68e-52	1.04e-45	-0.56	-0.45	HDL cholesterol;	chr11:48760920	chr11:89639227~89698718:+
BRCA	trans	rs10242455	0.702	rs28753399	ENSG00000228834.1	RP11-249L21.4	16.14	1.72e-52	1.07e-45	1.15	0.45	Blood metabolite levels;	chr7:99399636	chr6:108907615~108907873:-
BRCA	trans	rs7395662	0.963	rs7120743	ENSG00000134612.10	FOLH1B	-16.14	1.73e-52	1.07e-45	-0.56	-0.45	HDL cholesterol;	chr11:48901093	chr11:89639227~89698718:+
BRCA	trans	rs7395662	0.963	rs7119550	ENSG00000134612.10	FOLH1B	-16.14	1.73e-52	1.07e-45	-0.56	-0.45	HDL cholesterol;	chr11:48906102	chr11:89639227~89698718:+
BRCA	trans	rs7395662	0.929	rs10839173	ENSG00000134612.10	FOLH1B	-16.14	1.73e-52	1.07e-45	-0.56	-0.45	HDL cholesterol;	chr11:48909206	chr11:89639227~89698718:+
BRCA	trans	rs3740713	1	rs73440615	ENSG00000235847.2	LDHAP7	16.14	1.74e-52	1.08e-45	0.79	0.45	Amyotrophic lateral sclerosis (sporadic);	chr11:18445736	chr2:84777259~84778223:-
BRCA	trans	rs4276421	0.774	rs8188064	ENSG00000231752.4	EMBP1	16.14	1.89e-52	1.17e-45	0.57	0.45	P wave duration;	chr5:46045249	chr1:121519112~121571892:+
BRCA	trans	rs7395662	0.824	rs4882180	ENSG00000134612.10	FOLH1B	-16.13	1.97e-52	1.22e-45	-0.56	-0.45	HDL cholesterol;	chr11:48727805	chr11:89639227~89698718:+
BRCA	trans	rs4276421	0.774	rs4370277	ENSG00000231752.4	EMBP1	16.12	2.28e-52	1.41e-45	0.57	0.45	P wave duration;	chr5:46048566	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.745	rs4441886	ENSG00000231752.4	EMBP1	-16.12	2.36e-52	1.46e-45	-0.57	-0.45	P wave duration;	chr5:46063034	chr1:121519112~121571892:+
BRCA	trans	rs6732160	0.574	rs7557055	ENSG00000236165.1	PRADC1P1	16.12	2.37e-52	1.47e-45	0.57	0.45	Intelligence (multi-trait analysis);	chr2:73245542	chr3:36976316~36976840:+
BRCA	trans	rs2727020	0.729	rs685789	ENSG00000134612.10	FOLH1B	16.11	2.48e-52	1.53e-45	0.55	0.45	Coronary artery disease;	chr11:49219676	chr11:89639227~89698718:+
BRCA	trans	rs7395662	0.816	rs12420341	ENSG00000134612.10	FOLH1B	-16.11	2.49e-52	1.53e-45	-0.56	-0.45	HDL cholesterol;	chr11:48871832	chr11:89639227~89698718:+
BRCA	trans	rs7395662	0.658	rs11493304	ENSG00000134612.10	FOLH1B	-16.11	2.49e-52	1.53e-45	-0.56	-0.45	HDL cholesterol;	chr11:48874039	chr11:89639227~89698718:+
BRCA	trans	rs6732160	0.525	rs2303907	ENSG00000236165.1	PRADC1P1	16.1	2.99e-52	1.84e-45	0.58	0.45	Intelligence (multi-trait analysis);	chr2:73243369	chr3:36976316~36976840:+
BRCA	trans	rs7395662	1	rs6485907	ENSG00000134612.10	FOLH1B	-16.09	3.22e-52	1.98e-45	-0.56	-0.45	HDL cholesterol;	chr11:48630143	chr11:89639227~89698718:+
BRCA	trans	rs7395662	0.963	rs4882146	ENSG00000134612.10	FOLH1B	-16.08	3.77e-52	2.31e-45	-0.56	-0.45	HDL cholesterol;	chr11:48638617	chr11:89639227~89698718:+
BRCA	trans	rs10940346	0.721	rs60147402	ENSG00000231752.4	EMBP1	-16.08	3.92e-52	2.4e-45	-0.58	-0.45	Schizophrenia;	chr5:50230794	chr1:121519112~121571892:+
BRCA	trans	rs1816752	0.524	rs1965154	ENSG00000237917.1	PARP4P1	-16.08	3.93e-52	2.41e-45	-0.56	-0.45	Obesity-related traits;	chr13:24498062	chrY:26594851~26634652:-
BRCA	trans	rs10940346	0.557	rs2168922	ENSG00000231752.4	EMBP1	-16.08	4.11e-52	2.52e-45	-0.58	-0.45	Schizophrenia;	chr5:50151950	chr1:121519112~121571892:+
BRCA	trans	rs7395662	1	rs11039890	ENSG00000134612.10	FOLH1B	-16.06	4.75e-52	2.91e-45	-0.56	-0.45	HDL cholesterol;	chr11:48631916	chr11:89639227~89698718:+
BRCA	trans	rs11039798	0.588	rs7116858	ENSG00000134612.10	FOLH1B	16.06	4.75e-52	2.91e-45	0.67	0.45	Axial length;	chr11:48522368	chr11:89639227~89698718:+
BRCA	trans	rs10242455	0.702	rs17161700	ENSG00000228834.1	RP11-249L21.4	16.06	4.79e-52	2.93e-45	1.15	0.45	Blood metabolite levels;	chr7:99379444	chr6:108907615~108907873:-
BRCA	trans	rs6732160	0.593	rs2288630	ENSG00000236165.1	PRADC1P1	16.06	4.92e-52	3.01e-45	0.57	0.45	Intelligence (multi-trait analysis);	chr2:73230424	chr3:36976316~36976840:+
BRCA	trans	rs616147	0.627	rs9871799	ENSG00000214263.2	RPSAP53	16.06	5.02e-52	3.07e-45	0.57	0.45	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39442829	chr13:67266845~67267706:-
BRCA	trans	rs7395662	0.963	rs6485900	ENSG00000134612.10	FOLH1B	-16.05	5.39e-52	3.29e-45	-0.56	-0.45	HDL cholesterol;	chr11:48615863	chr11:89639227~89698718:+
BRCA	trans	rs7395662	1	rs6485903	ENSG00000134612.10	FOLH1B	-16.05	5.39e-52	3.29e-45	-0.56	-0.45	HDL cholesterol;	chr11:48617452	chr11:89639227~89698718:+
BRCA	trans	rs10940346	0.846	rs13356208	ENSG00000231752.4	EMBP1	-16.05	5.5e-52	3.36e-45	-0.58	-0.45	Schizophrenia;	chr5:50197970	chr1:121519112~121571892:+
BRCA	trans	rs10940346	1	rs12514818	ENSG00000231752.4	EMBP1	-16.05	6.05e-52	3.69e-45	-0.57	-0.45	Schizophrenia;	chr5:50349925	chr1:121519112~121571892:+
BRCA	trans	rs7395662	1	rs9645642	ENSG00000134612.10	FOLH1B	-16.03	6.95e-52	4.24e-45	-0.55	-0.44	HDL cholesterol;	chr11:48683903	chr11:89639227~89698718:+
BRCA	trans	rs7395662	0.711	rs11512405	ENSG00000134612.10	FOLH1B	-16.03	7.26e-52	4.42e-45	-0.55	-0.44	HDL cholesterol;	chr11:48914805	chr11:89639227~89698718:+
BRCA	trans	rs6732160	0.549	rs6744529	ENSG00000236165.1	PRADC1P1	16.03	7.63e-52	4.64e-45	0.57	0.44	Intelligence (multi-trait analysis);	chr2:73253741	chr3:36976316~36976840:+
BRCA	trans	rs7395662	0.963	rs6485906	ENSG00000134612.10	FOLH1B	-16.02	8.22e-52	5e-45	-0.55	-0.44	HDL cholesterol;	chr11:48630109	chr11:89639227~89698718:+
BRCA	trans	rs4276421	0.745	rs10041478	ENSG00000231752.4	EMBP1	-16.01	9.47e-52	5.75e-45	-0.57	-0.44	P wave duration;	chr5:46103187	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.745	rs10941722	ENSG00000231752.4	EMBP1	-16.01	9.55e-52	5.8e-45	-0.57	-0.44	P wave duration;	chr5:46067527	chr1:121519112~121571892:+
BRCA	trans	rs7395662	1	rs12806328	ENSG00000134612.10	FOLH1B	-16.01	9.9e-52	6e-45	-0.55	-0.44	HDL cholesterol;	chr11:48626419	chr11:89639227~89698718:+
BRCA	trans	rs877636	0.692	rs11171739	ENSG00000234513.1	AC073072.7	16.01	9.94e-52	6.02e-45	0.52	0.44	Cognitive function;	chr12:56076841	chr7:22773646~22773993:-
BRCA	trans	rs4276421	0.661	rs4455569	ENSG00000231752.4	EMBP1	-16.01	1.02e-51	6.16e-45	-0.57	-0.44	P wave duration;	chr5:46081782	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.657	rs4975885	ENSG00000231752.4	EMBP1	-16.01	1.02e-51	6.16e-45	-0.57	-0.44	P wave duration;	chr5:46083476	chr1:121519112~121571892:+
BRCA	trans	rs6477998	0.58	rs7851623	ENSG00000238072.1	RP11-305M3.2	16.01	1.02e-51	6.18e-45	0.68	0.44	Hematology traits;	chr9:113240285	chr7:129410113~129410370:-
BRCA	trans	rs7395662	1	rs7938880	ENSG00000134612.10	FOLH1B	-16	1.07e-51	6.5e-45	-0.55	-0.44	HDL cholesterol;	chr11:48620602	chr11:89639227~89698718:+
BRCA	trans	rs7395662	0.819	rs11039913	ENSG00000134612.10	FOLH1B	-15.99	1.27e-51	7.67e-45	-0.55	-0.44	HDL cholesterol;	chr11:48670529	chr11:89639227~89698718:+
BRCA	trans	rs7395662	0.864	rs11039917	ENSG00000134612.10	FOLH1B	-15.99	1.27e-51	7.67e-45	-0.55	-0.44	HDL cholesterol;	chr11:48673876	chr11:89639227~89698718:+
BRCA	trans	rs7395662	1	rs7925955	ENSG00000134612.10	FOLH1B	-15.98	1.37e-51	8.25e-45	-0.55	-0.44	HDL cholesterol;	chr11:48625981	chr11:89639227~89698718:+
BRCA	trans	rs6732160	0.574	rs1991612	ENSG00000236165.1	PRADC1P1	15.98	1.47e-51	8.87e-45	0.57	0.44	Intelligence (multi-trait analysis);	chr2:73253373	chr3:36976316~36976840:+
BRCA	trans	rs10242455	0.702	rs28460612	ENSG00000228834.1	RP11-249L21.4	15.97	1.52e-51	9.15e-45	1.15	0.44	Blood metabolite levels;	chr7:99395582	chr6:108907615~108907873:-
BRCA	trans	rs4276421	0.743	rs4455568	ENSG00000231752.4	EMBP1	15.97	1.6e-51	9.61e-45	0.56	0.44	P wave duration;	chr5:46079755	chr1:121519112~121571892:+
BRCA	trans	rs7395662	0.687	rs11602892	ENSG00000134612.10	FOLH1B	-15.95	2.03e-51	1.22e-44	-0.55	-0.44	HDL cholesterol;	chr11:48937600	chr11:89639227~89698718:+
BRCA	trans	rs11039798	0.588	rs12284168	ENSG00000134612.10	FOLH1B	15.95	2.03e-51	1.22e-44	0.67	0.44	Axial length;	chr11:48534075	chr11:89639227~89698718:+
BRCA	trans	rs11039798	0.588	rs6485857	ENSG00000134612.10	FOLH1B	15.95	2.03e-51	1.22e-44	0.67	0.44	Axial length;	chr11:48534959	chr11:89639227~89698718:+
BRCA	trans	rs11039798	0.588	rs11039781	ENSG00000134612.10	FOLH1B	15.95	2.13e-51	1.28e-44	0.67	0.44	Axial length;	chr11:48501533	chr11:89639227~89698718:+
BRCA	trans	rs11039798	0.588	rs11039782	ENSG00000134612.10	FOLH1B	15.95	2.13e-51	1.28e-44	0.67	0.44	Axial length;	chr11:48503233	chr11:89639227~89698718:+
BRCA	trans	rs7258465	0.931	rs76195	ENSG00000267533.1	RP11-815J4.7	15.94	2.34e-51	1.4e-44	0.59	0.44	Breast cancer;	chr19:18519020	chr18:12067173~12068417:-
BRCA	trans	rs11039798	0.565	rs7118675	ENSG00000134612.10	FOLH1B	15.93	2.71e-51	1.62e-44	0.67	0.44	Axial length;	chr11:48510511	chr11:89639227~89698718:+
BRCA	trans	rs7395662	0.963	rs4882072	ENSG00000134612.10	FOLH1B	-15.93	2.76e-51	1.65e-44	-0.55	-0.44	HDL cholesterol;	chr11:48458339	chr11:89639227~89698718:+
BRCA	trans	rs4276421	0.904	rs4489075	ENSG00000231752.4	EMBP1	15.92	3.01e-51	1.8e-44	0.57	0.44	P wave duration;	chr5:46018903	chr1:121519112~121571892:+
BRCA	trans	rs11039798	0.544	rs114343057	ENSG00000134612.10	FOLH1B	15.92	3.01e-51	1.8e-44	0.67	0.44	Axial length;	chr11:48536620	chr11:89639227~89698718:+
BRCA	trans	rs10940346	0.934	rs2353960	ENSG00000231752.4	EMBP1	-15.92	3.03e-51	1.8e-44	-0.57	-0.44	Schizophrenia;	chr5:50481153	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.935	rs4971258	ENSG00000231752.4	EMBP1	-15.92	3.03e-51	1.8e-44	-0.57	-0.44	Schizophrenia;	chr5:50498560	chr1:121519112~121571892:+
BRCA	trans	rs7730934	1	rs11574770	ENSG00000227018.1	IL6STP1	15.92	3.1e-51	1.85e-44	0.9	0.44	Blood protein levels;	chr5:55956788	chr17:15783288~15784307:+
BRCA	trans	rs4276421	0.694	rs10941732	ENSG00000231752.4	EMBP1	-15.91	3.49e-51	2.07e-44	-0.56	-0.44	P wave duration;	chr5:46080260	chr1:121519112~121571892:+
BRCA	trans	rs11039798	0.588	rs7946443	ENSG00000134612.10	FOLH1B	15.91	3.65e-51	2.17e-44	0.67	0.44	Axial length;	chr11:48523952	chr11:89639227~89698718:+
BRCA	trans	rs7395662	1	rs7478900	ENSG00000134612.10	FOLH1B	-15.9	3.88e-51	2.31e-44	-0.55	-0.44	HDL cholesterol;	chr11:48522451	chr11:89639227~89698718:+
BRCA	trans	rs10940346	1	rs11948752	ENSG00000231752.4	EMBP1	-15.89	4.25e-51	2.52e-44	-0.57	-0.44	Schizophrenia;	chr5:50504082	chr1:121519112~121571892:+
BRCA	trans	rs7395662	0.963	rs4882094	ENSG00000134612.10	FOLH1B	-15.89	4.4e-51	2.61e-44	-0.55	-0.44	HDL cholesterol;	chr11:48510908	chr11:89639227~89698718:+
BRCA	trans	rs9611519	0.78	rs2235852	ENSG00000268568.1	AC007228.9	-15.88	4.96e-51	2.94e-44	-0.58	-0.44	Neuroticism;	chr22:41265150	chr19:56672574~56673901:-
BRCA	trans	rs4276421	0.745	rs11957047	ENSG00000231752.4	EMBP1	-15.88	5.01e-51	2.97e-44	-0.56	-0.44	P wave duration;	chr5:46080090	chr1:121519112~121571892:+
BRCA	trans	rs7395662	1	rs10838931	ENSG00000134612.10	FOLH1B	-15.88	5.3e-51	3.13e-44	-0.55	-0.44	HDL cholesterol;	chr11:48519421	chr11:89639227~89698718:+
BRCA	trans	rs7395662	1	rs10769371	ENSG00000134612.10	FOLH1B	-15.87	5.65e-51	3.33e-44	-0.55	-0.44	HDL cholesterol;	chr11:48509632	chr11:89639227~89698718:+
BRCA	trans	rs7395662	1	rs4882096	ENSG00000134612.10	FOLH1B	-15.87	5.65e-51	3.33e-44	-0.55	-0.44	HDL cholesterol;	chr11:48512550	chr11:89639227~89698718:+
BRCA	trans	rs4276421	0.774	rs11949490	ENSG00000231752.4	EMBP1	-15.87	5.73e-51	3.38e-44	-0.56	-0.44	P wave duration;	chr5:46085951	chr1:121519112~121571892:+
BRCA	trans	rs9876781	1	rs1109227	ENSG00000235912.1	RP1-159A19.3	-15.86	6.22e-51	3.67e-44	-0.51	-0.44	Longevity;	chr3:48437797	chr1:27649419~27649610:+
BRCA	trans	rs7395662	0.929	rs11039903	ENSG00000134612.10	FOLH1B	-15.86	6.44e-51	3.79e-44	-0.55	-0.44	HDL cholesterol;	chr11:48658153	chr11:89639227~89698718:+
BRCA	trans	rs4276421	0.714	rs4259174	ENSG00000231752.4	EMBP1	-15.86	6.45e-51	3.8e-44	-0.56	-0.44	P wave duration;	chr5:46074351	chr1:121519112~121571892:+
BRCA	trans	rs11039798	0.588	rs7479642	ENSG00000134612.10	FOLH1B	15.86	6.7e-51	3.95e-44	0.67	0.44	Axial length;	chr11:48532256	chr11:89639227~89698718:+
BRCA	trans	rs4276421	0.744	rs4431354	ENSG00000231752.4	EMBP1	15.85	7.49e-51	4.41e-44	0.57	0.44	P wave duration;	chr5:46051284	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.7	rs10070274	ENSG00000231752.4	EMBP1	15.85	7.59e-51	4.46e-44	0.57	0.44	P wave duration;	chr5:46030675	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.683	rs4484447	ENSG00000231752.4	EMBP1	15.84	7.99e-51	4.69e-44	0.57	0.44	P wave duration;	chr5:46048757	chr1:121519112~121571892:+
BRCA	trans	rs10242455	0.571	rs117370443	ENSG00000228834.1	RP11-249L21.4	15.84	8.7e-51	5.11e-44	1.17	0.44	Blood metabolite levels;	chr7:99377635	chr6:108907615~108907873:-
BRCA	trans	rs11039798	0.588	rs11039807	ENSG00000134612.10	FOLH1B	15.84	8.9e-51	5.22e-44	0.66	0.44	Axial length;	chr11:48527839	chr11:89639227~89698718:+
BRCA	trans	rs7395662	1	rs7482528	ENSG00000134612.10	FOLH1B	-15.83	9.45e-51	5.54e-44	-0.55	-0.44	HDL cholesterol;	chr11:48618500	chr11:89639227~89698718:+
BRCA	trans	rs9876781	0.9	rs1037773	ENSG00000235912.1	RP1-159A19.3	-15.83	1.02e-50	5.98e-44	-0.51	-0.44	Longevity;	chr3:48426493	chr1:27649419~27649610:+
BRCA	trans	rs9876781	1	rs2279077	ENSG00000235912.1	RP1-159A19.3	-15.83	1.02e-50	5.98e-44	-0.51	-0.44	Longevity;	chr3:48432839	chr1:27649419~27649610:+
BRCA	trans	rs7395662	0.713	rs11512404	ENSG00000134612.10	FOLH1B	-15.83	1.03e-50	6.02e-44	-0.55	-0.44	HDL cholesterol;	chr11:48914619	chr11:89639227~89698718:+
BRCA	trans	rs7395662	0.889	rs11517696	ENSG00000134612.10	FOLH1B	-15.83	1.03e-50	6.02e-44	-0.55	-0.44	HDL cholesterol;	chr11:48918521	chr11:89639227~89698718:+
BRCA	trans	rs9876781	1	rs9883759	ENSG00000235912.1	RP1-159A19.3	-15.82	1.03e-50	6.05e-44	-0.51	-0.44	Longevity;	chr3:48422209	chr1:27649419~27649610:+
BRCA	trans	rs9876781	1	rs6442120	ENSG00000235912.1	RP1-159A19.3	-15.82	1.03e-50	6.05e-44	-0.51	-0.44	Longevity;	chr3:48423094	chr1:27649419~27649610:+
BRCA	trans	rs7395662	1	rs11039779	ENSG00000134612.10	FOLH1B	-15.82	1.05e-50	6.13e-44	-0.55	-0.44	HDL cholesterol;	chr11:48496343	chr11:89639227~89698718:+
BRCA	trans	rs9876781	1	rs3774808	ENSG00000235912.1	RP1-159A19.3	-15.82	1.1e-50	6.41e-44	-0.51	-0.44	Longevity;	chr3:48440237	chr1:27649419~27649610:+
BRCA	trans	rs4276421	0.688	rs7713759	ENSG00000231752.4	EMBP1	15.82	1.1e-50	6.43e-44	0.55	0.44	P wave duration;	chr5:46143447	chr1:121519112~121571892:+
BRCA	trans	rs877636	0.692	rs11171739	ENSG00000235459.5	RPS26P31	15.82	1.11e-50	6.51e-44	0.5	0.44	Cognitive function;	chr12:56076841	chr7:122681315~122681662:+
BRCA	trans	rs11039798	0.545	rs7118670	ENSG00000134612.10	FOLH1B	15.82	1.15e-50	6.74e-44	0.67	0.44	Axial length;	chr11:48510504	chr11:89639227~89698718:+
BRCA	trans	rs9876781	1	rs9881491	ENSG00000235912.1	RP1-159A19.3	-15.81	1.19e-50	6.98e-44	-0.51	-0.44	Longevity;	chr3:48446507	chr1:27649419~27649610:+
BRCA	trans	rs7395662	0.816	rs11039764	ENSG00000134612.10	FOLH1B	-15.81	1.29e-50	7.55e-44	-0.54	-0.44	HDL cholesterol;	chr11:48463064	chr11:89639227~89698718:+
BRCA	trans	rs7395662	1	rs11039777	ENSG00000134612.10	FOLH1B	-15.8	1.36e-50	7.93e-44	-0.55	-0.44	HDL cholesterol;	chr11:48495497	chr11:89639227~89698718:+
BRCA	trans	rs3740713	1	rs1848048	ENSG00000235847.2	LDHAP7	15.8	1.36e-50	7.93e-44	0.79	0.44	Amyotrophic lateral sclerosis (sporadic);	chr11:18447449	chr2:84777259~84778223:-
BRCA	trans	rs3740713	1	rs16935432	ENSG00000235847.2	LDHAP7	15.8	1.36e-50	7.93e-44	0.79	0.44	Amyotrophic lateral sclerosis (sporadic);	chr11:18448940	chr2:84777259~84778223:-
BRCA	trans	rs3740713	1	rs73440625	ENSG00000235847.2	LDHAP7	15.8	1.36e-50	7.93e-44	0.79	0.44	Amyotrophic lateral sclerosis (sporadic);	chr11:18449253	chr2:84777259~84778223:-
BRCA	trans	rs3740713	1	rs76599129	ENSG00000235847.2	LDHAP7	15.8	1.36e-50	7.93e-44	0.79	0.44	Amyotrophic lateral sclerosis (sporadic);	chr11:18450080	chr2:84777259~84778223:-
BRCA	trans	rs7395662	0.929	rs12366252	ENSG00000134612.10	FOLH1B	-15.8	1.44e-50	8.37e-44	-0.54	-0.44	HDL cholesterol;	chr11:48520766	chr11:89639227~89698718:+
BRCA	trans	rs11039798	0.588	rs12294395	ENSG00000134612.10	FOLH1B	15.8	1.47e-50	8.54e-44	0.67	0.44	Axial length;	chr11:48455308	chr11:89639227~89698718:+
BRCA	trans	rs6732160	0.631	rs7557285	ENSG00000236165.1	PRADC1P1	15.79	1.52e-50	8.83e-44	0.57	0.44	Intelligence (multi-trait analysis);	chr2:73215684	chr3:36976316~36976840:+
BRCA	trans	rs7395662	0.926	rs10742848	ENSG00000134612.10	FOLH1B	-15.79	1.59e-50	9.22e-44	-0.55	-0.44	HDL cholesterol;	chr11:48447236	chr11:89639227~89698718:+
BRCA	trans	rs7395662	0.889	rs11039754	ENSG00000134612.10	FOLH1B	-15.79	1.59e-50	9.22e-44	-0.55	-0.44	HDL cholesterol;	chr11:48453661	chr11:89639227~89698718:+
BRCA	trans	rs7395662	1	rs7949348	ENSG00000134612.10	FOLH1B	-15.79	1.6e-50	9.31e-44	-0.54	-0.44	HDL cholesterol;	chr11:48472249	chr11:89639227~89698718:+
BRCA	trans	rs7395662	1	rs10838912	ENSG00000134612.10	FOLH1B	-15.79	1.6e-50	9.31e-44	-0.54	-0.44	HDL cholesterol;	chr11:48474925	chr11:89639227~89698718:+
BRCA	trans	rs4276421	0.662	rs4367307	ENSG00000231752.4	EMBP1	-15.79	1.66e-50	9.62e-44	-0.57	-0.44	P wave duration;	chr5:46065857	chr1:121519112~121571892:+
BRCA	trans	rs7395662	0.927	rs12793888	ENSG00000134612.10	FOLH1B	-15.79	1.69e-50	9.78e-44	-0.54	-0.44	HDL cholesterol;	chr11:48466504	chr11:89639227~89698718:+
BRCA	trans	rs3740713	1	rs35593189	ENSG00000235847.2	LDHAP7	15.78	1.8e-50	1.04e-43	0.78	0.44	Amyotrophic lateral sclerosis (sporadic);	chr11:18446831	chr2:84777259~84778223:-
BRCA	trans	rs7395662	0.864	rs7483617	ENSG00000134612.10	FOLH1B	-15.78	1.89e-50	1.1e-43	-0.55	-0.44	HDL cholesterol;	chr11:48530107	chr11:89639227~89698718:+
BRCA	trans	rs4276421	0.6	rs4426925	ENSG00000231752.4	EMBP1	15.78	1.93e-50	1.12e-43	0.56	0.44	P wave duration;	chr5:46055499	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.816	rs6451835	ENSG00000231752.4	EMBP1	15.77	1.96e-50	1.14e-43	0.57	0.44	P wave duration;	chr5:45928735	chr1:121519112~121571892:+
BRCA	trans	rs7395662	1	rs12365220	ENSG00000134612.10	FOLH1B	-15.77	1.96e-50	1.14e-43	-0.55	-0.44	HDL cholesterol;	chr11:48534405	chr11:89639227~89698718:+
BRCA	trans	rs7395662	0.929	rs12363679	ENSG00000134612.10	FOLH1B	-15.77	1.96e-50	1.14e-43	-0.55	-0.44	HDL cholesterol;	chr11:48534471	chr11:89639227~89698718:+
BRCA	trans	rs9876781	1	rs6442119	ENSG00000235912.1	RP1-159A19.3	-15.77	1.98e-50	1.14e-43	-0.5	-0.44	Longevity;	chr3:48398713	chr1:27649419~27649610:+
BRCA	trans	rs7395662	0.963	rs11039774	ENSG00000134612.10	FOLH1B	-15.77	2.04e-50	1.18e-43	-0.54	-0.44	HDL cholesterol;	chr11:48492407	chr11:89639227~89698718:+
BRCA	trans	rs7395662	0.963	rs11039772	ENSG00000134612.10	FOLH1B	-15.77	2.14e-50	1.23e-43	-0.55	-0.44	HDL cholesterol;	chr11:48492340	chr11:89639227~89698718:+
BRCA	trans	rs7395662	0.963	rs11039773	ENSG00000134612.10	FOLH1B	-15.77	2.14e-50	1.23e-43	-0.55	-0.44	HDL cholesterol;	chr11:48492379	chr11:89639227~89698718:+
BRCA	trans	rs7395662	0.963	rs4882002	ENSG00000134612.10	FOLH1B	-15.76	2.26e-50	1.3e-43	-0.55	-0.44	HDL cholesterol;	chr11:48525179	chr11:89639227~89698718:+
BRCA	trans	rs7395662	0.89	rs11039806	ENSG00000134612.10	FOLH1B	-15.76	2.26e-50	1.3e-43	-0.55	-0.44	HDL cholesterol;	chr11:48526164	chr11:89639227~89698718:+
BRCA	trans	rs7395662	0.963	rs7125110	ENSG00000134612.10	FOLH1B	-15.76	2.42e-50	1.39e-43	-0.55	-0.44	HDL cholesterol;	chr11:48523955	chr11:89639227~89698718:+
BRCA	trans	rs7395662	0.895	rs1945183	ENSG00000134612.10	FOLH1B	-15.76	2.5e-50	1.44e-43	-0.54	-0.44	HDL cholesterol;	chr11:48480875	chr11:89639227~89698718:+
BRCA	trans	rs7395662	1	rs10838917	ENSG00000134612.10	FOLH1B	-15.76	2.5e-50	1.44e-43	-0.54	-0.44	HDL cholesterol;	chr11:48481575	chr11:89639227~89698718:+
BRCA	trans	rs4276421	0.967	rs10069793	ENSG00000231752.4	EMBP1	15.76	2.51e-50	1.44e-43	0.57	0.44	P wave duration;	chr5:45803049	chr1:121519112~121571892:+
BRCA	trans	rs10940346	1	rs7704686	ENSG00000231752.4	EMBP1	-15.76	2.52e-50	1.45e-43	-0.55	-0.44	Schizophrenia;	chr5:50548995	chr1:121519112~121571892:+
BRCA	trans	rs3740713	1	rs75487138	ENSG00000235847.2	LDHAP7	15.75	2.66e-50	1.53e-43	0.8	0.44	Amyotrophic lateral sclerosis (sporadic);	chr11:18440331	chr2:84777259~84778223:-
BRCA	trans	rs877636	1	rs2292239	ENSG00000243403.1	RP11-330L19.1	15.75	2.76e-50	1.58e-43	0.51	0.44	Cognitive function;	chr12:56088396	chr15:64592979~64593326:+
BRCA	trans	rs7395662	1	rs11039745	ENSG00000134612.10	FOLH1B	-15.74	2.97e-50	1.71e-43	-0.55	-0.44	HDL cholesterol;	chr11:48442259	chr11:89639227~89698718:+
BRCA	trans	rs11039798	0.588	rs7483361	ENSG00000134612.10	FOLH1B	15.74	3.03e-50	1.74e-43	0.65	0.44	Axial length;	chr11:48572234	chr11:89639227~89698718:+
BRCA	trans	rs11039798	0.588	rs10160381	ENSG00000134612.10	FOLH1B	15.74	3.03e-50	1.74e-43	0.65	0.44	Axial length;	chr11:48577939	chr11:89639227~89698718:+
BRCA	trans	rs7395662	1	rs4882111	ENSG00000134612.10	FOLH1B	-15.73	3.41e-50	1.95e-43	-0.55	-0.44	HDL cholesterol;	chr11:48536895	chr11:89639227~89698718:+
BRCA	trans	rs4276421	0.712	rs4389698	ENSG00000231752.4	EMBP1	15.73	3.51e-50	2.01e-43	0.56	0.44	P wave duration;	chr5:46051566	chr1:121519112~121571892:+
BRCA	trans	rs7395662	1	rs10838943	ENSG00000134612.10	FOLH1B	-15.73	3.6e-50	2.05e-43	-0.55	-0.44	HDL cholesterol;	chr11:48535890	chr11:89639227~89698718:+
BRCA	trans	rs7395662	0.963	rs4882109	ENSG00000134612.10	FOLH1B	-15.73	3.6e-50	2.05e-43	-0.55	-0.44	HDL cholesterol;	chr11:48536133	chr11:89639227~89698718:+
BRCA	trans	rs7395662	1	rs4882010	ENSG00000134612.10	FOLH1B	-15.73	3.67e-50	2.09e-43	-0.55	-0.44	HDL cholesterol;	chr11:48537621	chr11:89639227~89698718:+
BRCA	trans	rs7395662	1	rs10838944	ENSG00000134612.10	FOLH1B	-15.73	3.67e-50	2.09e-43	-0.55	-0.44	HDL cholesterol;	chr11:48538019	chr11:89639227~89698718:+
BRCA	trans	rs7395662	1	rs4881994	ENSG00000134612.10	FOLH1B	-15.72	4.01e-50	2.28e-43	-0.54	-0.44	HDL cholesterol;	chr11:48476587	chr11:89639227~89698718:+
BRCA	trans	rs4276421	0.904	rs4274988	ENSG00000231752.4	EMBP1	15.72	4.17e-50	2.37e-43	0.56	0.44	P wave duration;	chr5:45926339	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.935	rs7725537	ENSG00000231752.4	EMBP1	15.72	4.17e-50	2.37e-43	0.56	0.44	P wave duration;	chr5:45927191	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.935	rs35730142	ENSG00000231752.4	EMBP1	15.72	4.17e-50	2.37e-43	0.56	0.44	P wave duration;	chr5:45927453	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.807	rs12520938	ENSG00000231752.4	EMBP1	-15.71	4.63e-50	2.63e-43	-0.56	-0.44	P wave duration;	chr5:46098683	chr1:121519112~121571892:+
BRCA	trans	rs7395662	0.963	rs12365014	ENSG00000134612.10	FOLH1B	-15.7	5.07e-50	2.88e-43	-0.54	-0.44	HDL cholesterol;	chr11:48607882	chr11:89639227~89698718:+
BRCA	trans	rs10940346	0.846	rs8175378	ENSG00000231752.4	EMBP1	-15.7	5.12e-50	2.91e-43	-0.55	-0.44	Schizophrenia;	chr5:50182876	chr1:121519112~121571892:+
BRCA	trans	rs2657294	0.796	rs2804535	ENSG00000172974.11	AC007318.5	-15.7	5.2e-50	2.95e-43	-0.53	-0.44	Pneumonia;	chr10:75212086	chr2:65205108~65205988:+
BRCA	trans	rs7395662	0.593	rs8188975	ENSG00000134612.10	FOLH1B	15.69	5.54e-50	3.14e-43	0.54	0.44	HDL cholesterol;	chr11:48870325	chr11:89639227~89698718:+
BRCA	trans	rs4276421	0.904	rs7444405	ENSG00000231752.4	EMBP1	15.69	5.69e-50	3.23e-43	0.56	0.44	P wave duration;	chr5:45915373	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.874	rs4569881	ENSG00000231752.4	EMBP1	15.69	6.03e-50	3.42e-43	0.56	0.44	P wave duration;	chr5:46011667	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.837	rs6451829	ENSG00000231752.4	EMBP1	15.69	6.09e-50	3.45e-43	0.56	0.44	P wave duration;	chr5:45893260	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.904	rs7716296	ENSG00000231752.4	EMBP1	15.69	6.09e-50	3.45e-43	0.56	0.44	P wave duration;	chr5:45895783	chr1:121519112~121571892:+
BRCA	trans	rs9876781	1	rs7651407	ENSG00000235912.1	RP1-159A19.3	-15.67	7.43e-50	4.2e-43	-0.51	-0.44	Longevity;	chr3:48402409	chr1:27649419~27649610:+
BRCA	trans	rs3740713	1	rs73440614	ENSG00000235847.2	LDHAP7	15.67	7.78e-50	4.39e-43	0.79	0.44	Amyotrophic lateral sclerosis (sporadic);	chr11:18445153	chr2:84777259~84778223:-
BRCA	trans	rs4276421	0.704	rs57407363	ENSG00000231752.4	EMBP1	-15.66	8.49e-50	4.79e-43	-0.56	-0.44	P wave duration;	chr5:46073845	chr1:121519112~121571892:+
BRCA	trans	rs7395662	1	rs7121460	ENSG00000134612.10	FOLH1B	-15.66	8.54e-50	4.82e-43	-0.54	-0.44	HDL cholesterol;	chr11:48523680	chr11:89639227~89698718:+
BRCA	trans	rs7395662	0.929	rs10838934	ENSG00000134612.10	FOLH1B	-15.66	8.75e-50	4.93e-43	-0.54	-0.44	HDL cholesterol;	chr11:48525520	chr11:89639227~89698718:+
BRCA	trans	rs4276421	0.816	rs13362078	ENSG00000231752.4	EMBP1	15.65	9.12e-50	5.14e-43	0.56	0.44	P wave duration;	chr5:46013351	chr1:121519112~121571892:+
BRCA	trans	rs3740713	1	rs60376560	ENSG00000235847.2	LDHAP7	15.65	9.2e-50	5.18e-43	0.79	0.44	Amyotrophic lateral sclerosis (sporadic);	chr11:18432195	chr2:84777259~84778223:-
BRCA	trans	rs4276421	0.807	rs10941740	ENSG00000231752.4	EMBP1	-15.65	9.62e-50	5.42e-43	-0.56	-0.44	P wave duration;	chr5:46100208	chr1:121519112~121571892:+
BRCA	trans	rs6732160	0.691	rs13402225	ENSG00000236165.1	PRADC1P1	15.64	1.04e-49	5.87e-43	0.56	0.44	Intelligence (multi-trait analysis);	chr2:73189778	chr3:36976316~36976840:+
BRCA	trans	rs11039798	0.588	rs6485869	ENSG00000134612.10	FOLH1B	15.64	1.08e-49	6.1e-43	0.65	0.44	Axial length;	chr11:48555351	chr11:89639227~89698718:+
BRCA	trans	rs6732160	0.691	rs13432787	ENSG00000236165.1	PRADC1P1	15.64	1.17e-49	6.55e-43	0.56	0.44	Intelligence (multi-trait analysis);	chr2:73203106	chr3:36976316~36976840:+
BRCA	trans	rs6732160	0.691	rs4536673	ENSG00000236165.1	PRADC1P1	15.63	1.21e-49	6.77e-43	0.56	0.44	Intelligence (multi-trait analysis);	chr2:73186334	chr3:36976316~36976840:+
BRCA	trans	rs4276421	0.935	rs6882139	ENSG00000231752.4	EMBP1	15.63	1.23e-49	6.92e-43	0.56	0.44	P wave duration;	chr5:45897149	chr1:121519112~121571892:+
BRCA	trans	rs7258465	1	rs8105994	ENSG00000267533.1	RP11-815J4.7	15.63	1.24e-49	6.98e-43	0.56	0.44	Breast cancer;	chr19:18482743	chr18:12067173~12068417:-
BRCA	trans	rs9876781	1	rs13091785	ENSG00000235912.1	RP1-159A19.3	-15.62	1.37e-49	7.66e-43	-0.51	-0.44	Longevity;	chr3:48452692	chr1:27649419~27649610:+
BRCA	trans	rs4276421	0.904	rs4569880	ENSG00000231752.4	EMBP1	15.62	1.41e-49	7.9e-43	0.56	0.44	P wave duration;	chr5:46011373	chr1:121519112~121571892:+
BRCA	trans	rs11039798	0.588	rs11039818	ENSG00000134612.10	FOLH1B	15.61	1.56e-49	8.71e-43	0.65	0.44	Axial length;	chr11:48540568	chr11:89639227~89698718:+
BRCA	trans	rs2657294	0.726	rs4746275	ENSG00000172974.11	AC007318.5	15.6	1.87e-49	1.04e-42	0.53	0.44	Pneumonia;	chr10:75214940	chr2:65205108~65205988:+
BRCA	trans	rs11039798	0.588	rs10437592	ENSG00000134612.10	FOLH1B	15.6	1.88e-49	1.05e-42	0.65	0.44	Axial length;	chr11:48577307	chr11:89639227~89698718:+
BRCA	trans	rs3740713	1	rs73436668	ENSG00000235847.2	LDHAP7	15.59	2.11e-49	1.18e-42	0.78	0.43	Amyotrophic lateral sclerosis (sporadic);	chr11:18421546	chr2:84777259~84778223:-
BRCA	trans	rs7395662	0.963	rs7951432	ENSG00000134612.10	FOLH1B	-15.59	2.17e-49	1.21e-42	-0.54	-0.43	HDL cholesterol;	chr11:48569728	chr11:89639227~89698718:+
BRCA	trans	rs7395662	1	rs12361812	ENSG00000134612.10	FOLH1B	-15.58	2.23e-49	1.24e-42	-0.54	-0.43	HDL cholesterol;	chr11:48541552	chr11:89639227~89698718:+
BRCA	trans	rs7395662	0.963	rs4882112	ENSG00000134612.10	FOLH1B	-15.58	2.28e-49	1.27e-42	-0.54	-0.43	HDL cholesterol;	chr11:48539531	chr11:89639227~89698718:+
BRCA	trans	rs7395662	1	rs11039817	ENSG00000134612.10	FOLH1B	-15.58	2.28e-49	1.27e-42	-0.54	-0.43	HDL cholesterol;	chr11:48539928	chr11:89639227~89698718:+
BRCA	trans	rs7395662	0.963	rs4882137	ENSG00000134612.10	FOLH1B	-15.58	2.43e-49	1.35e-42	-0.54	-0.43	HDL cholesterol;	chr11:48594119	chr11:89639227~89698718:+
BRCA	trans	rs7395662	0.963	rs7483713	ENSG00000134612.10	FOLH1B	-15.57	2.54e-49	1.41e-42	-0.54	-0.43	HDL cholesterol;	chr11:48607662	chr11:89639227~89698718:+
BRCA	trans	rs7395662	1	rs11039851	ENSG00000134612.10	FOLH1B	-15.57	2.65e-49	1.47e-42	-0.54	-0.43	HDL cholesterol;	chr11:48579287	chr11:89639227~89698718:+
BRCA	trans	rs4240897	0.935	rs1474868	ENSG00000261819.1	RP11-680G24.4	-15.57	2.65e-49	1.47e-42	-0.54	-0.43	Tuberculosis;	chr1:11984107	chr16:14988259~14990160:-
BRCA	trans	rs4276421	0.774	rs8188072	ENSG00000231752.4	EMBP1	15.57	2.65e-49	1.47e-42	0.56	0.43	P wave duration;	chr5:46061883	chr1:121519112~121571892:+
BRCA	trans	rs7395662	1	rs55834832	ENSG00000134612.10	FOLH1B	-15.57	2.71e-49	1.5e-42	-0.54	-0.43	HDL cholesterol;	chr11:48541031	chr11:89639227~89698718:+
BRCA	trans	rs7395662	1	rs11039821	ENSG00000134612.10	FOLH1B	-15.57	2.71e-49	1.5e-42	-0.54	-0.43	HDL cholesterol;	chr11:48541323	chr11:89639227~89698718:+
BRCA	trans	rs7395662	1	rs7121992	ENSG00000134612.10	FOLH1B	-15.56	2.94e-49	1.62e-42	-0.54	-0.43	HDL cholesterol;	chr11:48571030	chr11:89639227~89698718:+
BRCA	trans	rs7395662	0.89	rs4882133	ENSG00000134612.10	FOLH1B	-15.56	2.94e-49	1.62e-42	-0.54	-0.43	HDL cholesterol;	chr11:48571898	chr11:89639227~89698718:+
BRCA	trans	rs7395662	0.963	rs10838967	ENSG00000134612.10	FOLH1B	-15.56	2.94e-49	1.62e-42	-0.54	-0.43	HDL cholesterol;	chr11:48573455	chr11:89639227~89698718:+
BRCA	trans	rs7395662	1	rs7481308	ENSG00000134612.10	FOLH1B	-15.56	2.94e-49	1.62e-42	-0.54	-0.43	HDL cholesterol;	chr11:48578515	chr11:89639227~89698718:+
BRCA	trans	rs9876781	1	rs11130170	ENSG00000235912.1	RP1-159A19.3	-15.56	3.03e-49	1.67e-42	-0.5	-0.43	Longevity;	chr3:48408490	chr1:27649419~27649610:+
BRCA	trans	rs4276421	0.935	rs35163964	ENSG00000231752.4	EMBP1	15.56	3.07e-49	1.7e-42	0.56	0.43	P wave duration;	chr5:45904860	chr1:121519112~121571892:+
BRCA	trans	rs2657294	0.765	rs2804533	ENSG00000172974.11	AC007318.5	15.54	3.67e-49	2.02e-42	0.52	0.43	Pneumonia;	chr10:75207723	chr2:65205108~65205988:+
BRCA	trans	rs7395662	1	rs7948486	ENSG00000134612.10	FOLH1B	15.54	3.91e-49	2.14e-42	0.55	0.43	HDL cholesterol;	chr11:48890588	chr11:89639227~89698718:+
BRCA	trans	rs4276421	0.904	rs6862657	ENSG00000231752.4	EMBP1	-15.54	4.13e-49	2.26e-42	-0.56	-0.43	P wave duration;	chr5:45905895	chr1:121519112~121571892:+
BRCA	trans	rs7395662	1	rs4882016	ENSG00000134612.10	FOLH1B	-15.53	4.22e-49	2.31e-42	-0.54	-0.43	HDL cholesterol;	chr11:48548573	chr11:89639227~89698718:+
BRCA	trans	rs7395662	1	rs6485875	ENSG00000134612.10	FOLH1B	-15.53	4.27e-49	2.34e-42	-0.54	-0.43	HDL cholesterol;	chr11:48559482	chr11:89639227~89698718:+
BRCA	trans	rs7395662	1	rs10838954	ENSG00000134612.10	FOLH1B	-15.53	4.36e-49	2.39e-42	-0.54	-0.43	HDL cholesterol;	chr11:48557771	chr11:89639227~89698718:+
BRCA	trans	rs7395662	0.864	rs10838951	ENSG00000134612.10	FOLH1B	-15.53	4.57e-49	2.5e-42	-0.54	-0.43	HDL cholesterol;	chr11:48549536	chr11:89639227~89698718:+
BRCA	trans	rs4276421	0.845	rs4371763	ENSG00000231752.4	EMBP1	15.53	4.61e-49	2.52e-42	0.56	0.43	P wave duration;	chr5:45983120	chr1:121519112~121571892:+
BRCA	trans	rs7395662	1	rs7931984	ENSG00000134612.10	FOLH1B	-15.53	4.63e-49	2.53e-42	-0.54	-0.43	HDL cholesterol;	chr11:48559283	chr11:89639227~89698718:+
BRCA	trans	rs7395662	1	rs7395662	ENSG00000134612.10	FOLH1B	15.52	4.92e-49	2.69e-42	0.54	0.43	HDL cholesterol;	chr11:48497341	chr11:89639227~89698718:+
BRCA	trans	rs7395662	1	rs4882120	ENSG00000134612.10	FOLH1B	-15.52	4.95e-49	2.7e-42	-0.54	-0.43	HDL cholesterol;	chr11:48551977	chr11:89639227~89698718:+
BRCA	trans	rs7395662	1	rs4882123	ENSG00000134612.10	FOLH1B	-15.52	4.95e-49	2.7e-42	-0.54	-0.43	HDL cholesterol;	chr11:48554187	chr11:89639227~89698718:+
BRCA	trans	rs877636	1	rs4759229	ENSG00000243403.1	RP11-330L19.1	-15.51	5.45e-49	2.96e-42	-0.53	-0.43	Cognitive function;	chr12:56080696	chr15:64592979~64593326:+
BRCA	trans	rs7395662	0.929	rs7952580	ENSG00000134612.10	FOLH1B	-15.51	5.52e-49	3e-42	-0.54	-0.43	HDL cholesterol;	chr11:48573654	chr11:89639227~89698718:+
BRCA	trans	rs7395662	1	rs4882019	ENSG00000134612.10	FOLH1B	-15.51	5.52e-49	3e-42	-0.54	-0.43	HDL cholesterol;	chr11:48577196	chr11:89639227~89698718:+
BRCA	trans	rs7395662	1	rs4882134	ENSG00000134612.10	FOLH1B	-15.51	5.52e-49	3e-42	-0.54	-0.43	HDL cholesterol;	chr11:48577243	chr11:89639227~89698718:+
BRCA	trans	rs7395662	1	rs7483920	ENSG00000134612.10	FOLH1B	-15.51	5.52e-49	3e-42	-0.54	-0.43	HDL cholesterol;	chr11:48578417	chr11:89639227~89698718:+
BRCA	trans	rs877636	0.859	rs3741499	ENSG00000243403.1	RP11-330L19.1	-15.51	5.93e-49	3.22e-42	-0.52	-0.43	Cognitive function;	chr12:56080595	chr15:64592979~64593326:+
BRCA	trans	rs7395662	0.929	rs34584314	ENSG00000134612.10	FOLH1B	-15.5	6.11e-49	3.32e-42	-0.54	-0.43	HDL cholesterol;	chr11:48606134	chr11:89639227~89698718:+
BRCA	trans	rs7395662	0.747	rs11040106	ENSG00000134612.10	FOLH1B	15.5	6.16e-49	3.34e-42	0.54	0.43	HDL cholesterol;	chr11:48867574	chr11:89639227~89698718:+
BRCA	trans	rs4276421	0.845	rs4492122	ENSG00000231752.4	EMBP1	15.5	6.28e-49	3.41e-42	0.56	0.43	P wave duration;	chr5:45982952	chr1:121519112~121571892:+
BRCA	trans	rs7395662	1	rs12419576	ENSG00000134612.10	FOLH1B	-15.5	6.76e-49	3.66e-42	-0.54	-0.43	HDL cholesterol;	chr11:48560092	chr11:89639227~89698718:+
BRCA	trans	rs7395662	0.963	rs61930968	ENSG00000134612.10	FOLH1B	-15.5	6.76e-49	3.66e-42	-0.54	-0.43	HDL cholesterol;	chr11:48560097	chr11:89639227~89698718:+
BRCA	trans	rs7395662	0.963	rs11039870	ENSG00000134612.10	FOLH1B	-15.49	7.28e-49	3.94e-42	-0.54	-0.43	HDL cholesterol;	chr11:48604926	chr11:89639227~89698718:+
BRCA	trans	rs11039798	0.588	rs3924476	ENSG00000134612.10	FOLH1B	15.49	7.34e-49	3.96e-42	0.65	0.43	Axial length;	chr11:48560181	chr11:89639227~89698718:+
BRCA	trans	rs4276421	0.967	rs4866979	ENSG00000231752.4	EMBP1	-15.49	7.77e-49	4.19e-42	-0.55	-0.43	P wave duration;	chr5:45804745	chr1:121519112~121571892:+
BRCA	trans	rs7395662	0.864	rs11039872	ENSG00000134612.10	FOLH1B	-15.48	8.23e-49	4.44e-42	-0.54	-0.43	HDL cholesterol;	chr11:48607981	chr11:89639227~89698718:+
BRCA	trans	rs7395662	0.864	rs12366262	ENSG00000134612.10	FOLH1B	-15.48	8.44e-49	4.54e-42	-0.53	-0.43	HDL cholesterol;	chr11:48541920	chr11:89639227~89698718:+
BRCA	trans	rs7395662	1	rs4882117	ENSG00000134612.10	FOLH1B	-15.48	8.44e-49	4.54e-42	-0.53	-0.43	HDL cholesterol;	chr11:48543916	chr11:89639227~89698718:+
BRCA	trans	rs7395662	1	rs4882015	ENSG00000134612.10	FOLH1B	-15.48	8.44e-49	4.54e-42	-0.53	-0.43	HDL cholesterol;	chr11:48544021	chr11:89639227~89698718:+
BRCA	trans	rs4276421	0.845	rs62372987	ENSG00000231752.4	EMBP1	15.48	8.65e-49	4.65e-42	0.56	0.43	P wave duration;	chr5:45979889	chr1:121519112~121571892:+
BRCA	trans	rs7395662	1	rs12366208	ENSG00000134612.10	FOLH1B	-15.48	8.75e-49	4.71e-42	-0.53	-0.43	HDL cholesterol;	chr11:48541576	chr11:89639227~89698718:+
BRCA	trans	rs7395662	0.929	rs10838956	ENSG00000134612.10	FOLH1B	-15.47	9.12e-49	4.89e-42	-0.54	-0.43	HDL cholesterol;	chr11:48560213	chr11:89639227~89698718:+
BRCA	trans	rs7395662	1	rs7949554	ENSG00000134612.10	FOLH1B	-15.47	9.12e-49	4.89e-42	-0.54	-0.43	HDL cholesterol;	chr11:48560440	chr11:89639227~89698718:+
BRCA	trans	rs7395662	0.895	rs7924481	ENSG00000134612.10	FOLH1B	-15.47	9.12e-49	4.89e-42	-0.54	-0.43	HDL cholesterol;	chr11:48560905	chr11:89639227~89698718:+
BRCA	trans	rs7395662	0.929	rs10838959	ENSG00000134612.10	FOLH1B	-15.47	9.12e-49	4.89e-42	-0.54	-0.43	HDL cholesterol;	chr11:48563180	chr11:89639227~89698718:+
BRCA	trans	rs7395662	1	rs4882129	ENSG00000134612.10	FOLH1B	-15.47	9.12e-49	4.89e-42	-0.54	-0.43	HDL cholesterol;	chr11:48567222	chr11:89639227~89698718:+
BRCA	trans	rs7395662	1	rs4882130	ENSG00000134612.10	FOLH1B	-15.47	9.12e-49	4.89e-42	-0.54	-0.43	HDL cholesterol;	chr11:48567402	chr11:89639227~89698718:+
BRCA	trans	rs7395662	1	rs10838966	ENSG00000134612.10	FOLH1B	-15.47	9.12e-49	4.89e-42	-0.54	-0.43	HDL cholesterol;	chr11:48568171	chr11:89639227~89698718:+
BRCA	trans	rs7395662	1	rs34636547	ENSG00000134612.10	FOLH1B	-15.47	9.12e-49	4.89e-42	-0.54	-0.43	HDL cholesterol;	chr11:48568551	chr11:89639227~89698718:+
BRCA	trans	rs7395662	0.963	rs10769382	ENSG00000134612.10	FOLH1B	-15.47	9.12e-49	4.89e-42	-0.54	-0.43	HDL cholesterol;	chr11:48568863	chr11:89639227~89698718:+
BRCA	trans	rs7312770	0.612	rs773114	ENSG00000235459.5	RPS26P31	15.47	9.49e-49	5.08e-42	0.49	0.43	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr7:122681315~122681662:+
BRCA	trans	rs7395662	0.963	rs11039826	ENSG00000134612.10	FOLH1B	-15.46	1.01e-48	5.39e-42	-0.53	-0.43	HDL cholesterol;	chr11:48550846	chr11:89639227~89698718:+
BRCA	trans	rs4276421	0.874	rs4501347	ENSG00000231752.4	EMBP1	15.46	1.08e-48	5.75e-42	0.56	0.43	P wave duration;	chr5:45974779	chr1:121519112~121571892:+
BRCA	trans	rs7395662	0.963	rs6485865	ENSG00000134612.10	FOLH1B	-15.46	1.09e-48	5.8e-42	-0.53	-0.43	HDL cholesterol;	chr11:48554437	chr11:89639227~89698718:+
BRCA	trans	rs7395662	1	rs7107184	ENSG00000134612.10	FOLH1B	-15.46	1.09e-48	5.8e-42	-0.53	-0.43	HDL cholesterol;	chr11:48555517	chr11:89639227~89698718:+
BRCA	trans	rs7395662	1	rs11039854	ENSG00000134612.10	FOLH1B	-15.46	1.1e-48	5.85e-42	-0.54	-0.43	HDL cholesterol;	chr11:48586136	chr11:89639227~89698718:+
BRCA	trans	rs7395662	0.777	rs7114291	ENSG00000134612.10	FOLH1B	-15.46	1.1e-48	5.85e-42	-0.54	-0.43	HDL cholesterol;	chr11:48586699	chr11:89639227~89698718:+
BRCA	trans	rs7395662	0.963	rs6485889	ENSG00000134612.10	FOLH1B	-15.46	1.1e-48	5.85e-42	-0.54	-0.43	HDL cholesterol;	chr11:48587233	chr11:89639227~89698718:+
BRCA	trans	rs7395662	1	rs7481880	ENSG00000134612.10	FOLH1B	-15.46	1.1e-48	5.85e-42	-0.54	-0.43	HDL cholesterol;	chr11:48587795	chr11:89639227~89698718:+
BRCA	trans	rs7395662	0.929	rs7946248	ENSG00000134612.10	FOLH1B	-15.46	1.1e-48	5.85e-42	-0.54	-0.43	HDL cholesterol;	chr11:48591964	chr11:89639227~89698718:+
BRCA	trans	rs7395662	1	rs4882136	ENSG00000134612.10	FOLH1B	-15.46	1.1e-48	5.85e-42	-0.54	-0.43	HDL cholesterol;	chr11:48593759	chr11:89639227~89698718:+
BRCA	trans	rs7395662	0.963	rs10769389	ENSG00000134612.10	FOLH1B	-15.46	1.1e-48	5.85e-42	-0.54	-0.43	HDL cholesterol;	chr11:48596459	chr11:89639227~89698718:+
BRCA	trans	rs7395662	1	rs10769390	ENSG00000134612.10	FOLH1B	-15.46	1.1e-48	5.85e-42	-0.54	-0.43	HDL cholesterol;	chr11:48596670	chr11:89639227~89698718:+
BRCA	trans	rs7395662	1	rs11039868	ENSG00000134612.10	FOLH1B	-15.46	1.1e-48	5.85e-42	-0.54	-0.43	HDL cholesterol;	chr11:48600594	chr11:89639227~89698718:+
BRCA	trans	rs7395662	0.895	rs11039869	ENSG00000134612.10	FOLH1B	-15.46	1.1e-48	5.85e-42	-0.54	-0.43	HDL cholesterol;	chr11:48600760	chr11:89639227~89698718:+
BRCA	trans	rs7395662	1	rs12421159	ENSG00000134612.10	FOLH1B	-15.46	1.1e-48	5.85e-42	-0.54	-0.43	HDL cholesterol;	chr11:48603289	chr11:89639227~89698718:+
BRCA	trans	rs7395662	1	rs7479134	ENSG00000134612.10	FOLH1B	-15.46	1.1e-48	5.85e-42	-0.54	-0.43	HDL cholesterol;	chr11:48603857	chr11:89639227~89698718:+
BRCA	trans	rs13190036	0.551	rs4976639	ENSG00000226986.4	RP11-543B16.2	15.45	1.21e-48	6.43e-42	0.65	0.43	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177123300	chr1:211207239~211207897:+
BRCA	trans	rs11039798	0.66	rs28435129	ENSG00000134612.10	FOLH1B	15.44	1.31e-48	6.95e-42	0.65	0.43	Axial length;	chr11:48608243	chr11:89639227~89698718:+
BRCA	trans	rs7395662	0.581	rs10769445	ENSG00000134612.10	FOLH1B	15.44	1.33e-48	7.04e-42	0.54	0.43	HDL cholesterol;	chr11:48744042	chr11:89639227~89698718:+
BRCA	trans	rs7395662	1	rs11039820	ENSG00000134612.10	FOLH1B	-15.44	1.37e-48	7.23e-42	-0.54	-0.43	HDL cholesterol;	chr11:48540700	chr11:89639227~89698718:+
BRCA	trans	rs7395662	0.929	rs7108559	ENSG00000134612.10	FOLH1B	-15.44	1.44e-48	7.64e-42	-0.54	-0.43	HDL cholesterol;	chr11:48597599	chr11:89639227~89698718:+
BRCA	trans	rs7395662	0.654	rs12289625	ENSG00000134612.10	FOLH1B	15.44	1.44e-48	7.64e-42	0.54	0.43	HDL cholesterol;	chr11:48795690	chr11:89639227~89698718:+
BRCA	trans	rs4276421	0.774	rs4428422	ENSG00000231752.4	EMBP1	15.43	1.59e-48	8.38e-42	0.55	0.43	P wave duration;	chr5:46017216	chr1:121519112~121571892:+
BRCA	trans	rs11039798	0.588	rs12278284	ENSG00000134612.10	FOLH1B	15.43	1.59e-48	8.4e-42	0.65	0.43	Axial length;	chr11:48590511	chr11:89639227~89698718:+
BRCA	trans	rs4276421	0.904	rs7293482	ENSG00000231752.4	EMBP1	15.43	1.6e-48	8.44e-42	0.56	0.43	P wave duration;	chr5:46003984	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.744	rs4541667	ENSG00000231752.4	EMBP1	15.42	1.67e-48	8.8e-42	0.55	0.43	P wave duration;	chr5:46060767	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.934	rs6451840	ENSG00000231752.4	EMBP1	15.42	1.73e-48	9.1e-42	0.55	0.43	P wave duration;	chr5:45935584	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.87	rs6451842	ENSG00000231752.4	EMBP1	15.42	1.73e-48	9.1e-42	0.55	0.43	P wave duration;	chr5:45936431	chr1:121519112~121571892:+
BRCA	trans	rs2657294	0.796	rs2657290	ENSG00000172974.11	AC007318.5	15.42	1.85e-48	9.73e-42	0.52	0.43	Pneumonia;	chr10:75207404	chr2:65205108~65205988:+
BRCA	trans	rs4276421	0.695	rs4421114	ENSG00000231752.4	EMBP1	-15.42	1.85e-48	9.73e-42	-0.55	-0.43	P wave duration;	chr5:46069241	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.715	rs10043248	ENSG00000231752.4	EMBP1	15.41	1.99e-48	1.04e-41	0.56	0.43	P wave duration;	chr5:46025930	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.901	rs10056175	ENSG00000231752.4	EMBP1	15.41	2e-48	1.05e-41	0.55	0.43	P wave duration;	chr5:45934503	chr1:121519112~121571892:+
BRCA	trans	rs11039798	0.588	rs7108164	ENSG00000134612.10	FOLH1B	15.41	2.07e-48	1.09e-41	0.65	0.43	Axial length;	chr11:48604811	chr11:89639227~89698718:+
BRCA	trans	rs11039798	0.588	rs10838979	ENSG00000134612.10	FOLH1B	15.41	2.07e-48	1.09e-41	0.65	0.43	Axial length;	chr11:48605258	chr11:89639227~89698718:+
BRCA	trans	rs7395662	1	rs12420372	ENSG00000134612.10	FOLH1B	15.41	2.09e-48	1.09e-41	0.53	0.43	HDL cholesterol;	chr11:48476051	chr11:89639227~89698718:+
BRCA	trans	rs4276421	0.904	rs57299032	ENSG00000231752.4	EMBP1	15.41	2.12e-48	1.11e-41	0.55	0.43	P wave duration;	chr5:45998162	chr1:121519112~121571892:+
BRCA	trans	rs877636	1	rs877636	ENSG00000225071.1	GS1-184P14.2	-15.4	2.22e-48	1.16e-41	-0.52	-0.43	Cognitive function;	chr12:56086799	chrX:24429573~24429920:-
BRCA	trans	rs7395662	0.655	rs2202458	ENSG00000134612.10	FOLH1B	15.4	2.37e-48	1.24e-41	0.54	0.43	HDL cholesterol;	chr11:48834995	chr11:89639227~89698718:+
BRCA	trans	rs7395662	1	rs6485888	ENSG00000134612.10	FOLH1B	-15.39	2.61e-48	1.36e-41	-0.53	-0.43	HDL cholesterol;	chr11:48583787	chr11:89639227~89698718:+
BRCA	trans	rs7395662	1	rs10838971	ENSG00000134612.10	FOLH1B	-15.39	2.61e-48	1.36e-41	-0.53	-0.43	HDL cholesterol;	chr11:48585072	chr11:89639227~89698718:+
BRCA	trans	rs7395662	1	rs7944356	ENSG00000134612.10	FOLH1B	-15.39	2.61e-48	1.36e-41	-0.53	-0.43	HDL cholesterol;	chr11:48588602	chr11:89639227~89698718:+
BRCA	trans	rs7395662	1	rs11039857	ENSG00000134612.10	FOLH1B	-15.39	2.61e-48	1.36e-41	-0.53	-0.43	HDL cholesterol;	chr11:48589301	chr11:89639227~89698718:+
BRCA	trans	rs7395662	1	rs11039859	ENSG00000134612.10	FOLH1B	-15.39	2.61e-48	1.36e-41	-0.53	-0.43	HDL cholesterol;	chr11:48590436	chr11:89639227~89698718:+
BRCA	trans	rs7395662	1	rs7928083	ENSG00000134612.10	FOLH1B	-15.39	2.61e-48	1.36e-41	-0.53	-0.43	HDL cholesterol;	chr11:48591596	chr11:89639227~89698718:+
BRCA	trans	rs7395662	1	rs4882021	ENSG00000134612.10	FOLH1B	-15.39	2.61e-48	1.36e-41	-0.53	-0.43	HDL cholesterol;	chr11:48594414	chr11:89639227~89698718:+
BRCA	trans	rs7395662	1	rs7129386	ENSG00000134612.10	FOLH1B	-15.39	2.61e-48	1.36e-41	-0.53	-0.43	HDL cholesterol;	chr11:48595142	chr11:89639227~89698718:+
BRCA	trans	rs7395662	1	rs10838975	ENSG00000134612.10	FOLH1B	-15.39	2.61e-48	1.36e-41	-0.53	-0.43	HDL cholesterol;	chr11:48596063	chr11:89639227~89698718:+
BRCA	trans	rs7395662	0.963	rs12418721	ENSG00000134612.10	FOLH1B	-15.39	2.61e-48	1.36e-41	-0.53	-0.43	HDL cholesterol;	chr11:48596899	chr11:89639227~89698718:+
BRCA	trans	rs7395662	0.864	rs7482764	ENSG00000134612.10	FOLH1B	-15.39	2.61e-48	1.36e-41	-0.53	-0.43	HDL cholesterol;	chr11:48604306	chr11:89639227~89698718:+
BRCA	trans	rs877636	0.692	rs2271194	ENSG00000235459.5	RPS26P31	-15.39	2.64e-48	1.38e-41	-0.49	-0.43	Cognitive function;	chr12:56083910	chr7:122681315~122681662:+
BRCA	trans	rs7395662	1	rs6485872	ENSG00000134612.10	FOLH1B	-15.39	2.71e-48	1.41e-41	-0.53	-0.43	HDL cholesterol;	chr11:48558158	chr11:89639227~89698718:+
BRCA	trans	rs7395662	0.927	rs2135690	ENSG00000134612.10	FOLH1B	15.38	2.76e-48	1.44e-41	0.54	0.43	HDL cholesterol;	chr11:48712049	chr11:89639227~89698718:+
BRCA	trans	rs7395662	0.658	rs8189235	ENSG00000134612.10	FOLH1B	15.38	2.76e-48	1.44e-41	0.54	0.43	HDL cholesterol;	chr11:48718512	chr11:89639227~89698718:+
BRCA	trans	rs877636	1	rs705696	ENSG00000243403.1	RP11-330L19.1	15.38	2.9e-48	1.51e-41	0.55	0.43	Cognitive function;	chr12:56086864	chr15:64592979~64593326:+
BRCA	trans	rs11039798	0.588	rs10838970	ENSG00000134612.10	FOLH1B	15.38	3.08e-48	1.6e-41	0.65	0.43	Axial length;	chr11:48584715	chr11:89639227~89698718:+
BRCA	trans	rs4276421	0.967	rs7725171	ENSG00000231752.4	EMBP1	15.38	3.11e-48	1.62e-41	0.55	0.43	P wave duration;	chr5:45923684	chr1:121519112~121571892:+
BRCA	trans	rs2657294	0.796	rs4746272	ENSG00000172974.11	AC007318.5	15.36	3.7e-48	1.92e-41	0.52	0.43	Pneumonia;	chr10:75203869	chr2:65205108~65205988:+
BRCA	trans	rs11039798	0.557	rs683180	ENSG00000134612.10	FOLH1B	-15.36	3.91e-48	2.03e-41	-0.63	-0.43	Axial length;	chr11:48442397	chr11:89639227~89698718:+
BRCA	trans	rs7395662	0.609	rs10839190	ENSG00000134612.10	FOLH1B	15.35	4.07e-48	2.1e-41	0.54	0.43	HDL cholesterol;	chr11:48935456	chr11:89639227~89698718:+
BRCA	trans	rs7395662	0.759	rs11529442	ENSG00000134612.10	FOLH1B	15.35	4.07e-48	2.11e-41	0.54	0.43	HDL cholesterol;	chr11:48798434	chr11:89639227~89698718:+
BRCA	trans	rs7395662	0.791	rs12273724	ENSG00000134612.10	FOLH1B	15.35	4.19e-48	2.16e-41	0.54	0.43	HDL cholesterol;	chr11:48824158	chr11:89639227~89698718:+
BRCA	trans	rs7395662	0.611	rs11040073	ENSG00000134612.10	FOLH1B	15.35	4.38e-48	2.26e-41	0.54	0.43	HDL cholesterol;	chr11:48834072	chr11:89639227~89698718:+
BRCA	trans	rs7395662	1	rs11039862	ENSG00000134612.10	FOLH1B	-15.35	4.42e-48	2.28e-41	-0.54	-0.43	HDL cholesterol;	chr11:48596754	chr11:89639227~89698718:+
BRCA	trans	rs11039798	0.588	rs666165	ENSG00000134612.10	FOLH1B	-15.34	4.56e-48	2.35e-41	-0.63	-0.43	Axial length;	chr11:48435887	chr11:89639227~89698718:+
BRCA	trans	rs7395662	0.963	rs12800770	ENSG00000134612.10	FOLH1B	-15.34	5e-48	2.58e-41	-0.53	-0.43	HDL cholesterol;	chr11:48583375	chr11:89639227~89698718:+
BRCA	trans	rs6732160	0.691	rs7599223	ENSG00000236165.1	PRADC1P1	15.34	5.04e-48	2.6e-41	0.56	0.43	Intelligence (multi-trait analysis);	chr2:73199975	chr3:36976316~36976840:+
BRCA	trans	rs11039798	0.623	rs6485879	ENSG00000134612.10	FOLH1B	15.33	5.18e-48	2.67e-41	0.64	0.43	Axial length;	chr11:48566432	chr11:89639227~89698718:+
BRCA	trans	rs7395662	0.963	rs7952491	ENSG00000134612.10	FOLH1B	-15.33	5.19e-48	2.67e-41	-0.54	-0.43	HDL cholesterol;	chr11:48641743	chr11:89639227~89698718:+
BRCA	trans	rs7395662	0.963	rs1588068	ENSG00000134612.10	FOLH1B	-15.33	5.19e-48	2.67e-41	-0.54	-0.43	HDL cholesterol;	chr11:48650193	chr11:89639227~89698718:+
BRCA	trans	rs7395662	1	rs1605364	ENSG00000134612.10	FOLH1B	-15.33	5.19e-48	2.67e-41	-0.54	-0.43	HDL cholesterol;	chr11:48663291	chr11:89639227~89698718:+
BRCA	trans	rs7395662	0.926	rs12288788	ENSG00000134612.10	FOLH1B	-15.33	5.19e-48	2.67e-41	-0.54	-0.43	HDL cholesterol;	chr11:48665311	chr11:89639227~89698718:+
BRCA	trans	rs7395662	0.927	rs8188938	ENSG00000134612.10	FOLH1B	15.33	5.19e-48	2.67e-41	0.54	0.43	HDL cholesterol;	chr11:48669314	chr11:89639227~89698718:+
BRCA	trans	rs1614887	1	rs1614887	ENSG00000242375.1	RP11-498P14.3	15.33	5.42e-48	2.78e-41	0.61	0.43	Lobe attachment (rater-scored or self-reported);Intelligence (multi-trait analysis);	chr6:26392793	chr9:97195351~97197687:-
BRCA	trans	rs7395662	1	rs4882017	ENSG00000134612.10	FOLH1B	15.33	5.82e-48	2.99e-41	0.53	0.43	HDL cholesterol;	chr11:48548630	chr11:89639227~89698718:+
BRCA	trans	rs4276421	0.745	rs10079238	ENSG00000231752.4	EMBP1	-15.32	5.86e-48	3.01e-41	-0.55	-0.43	P wave duration;	chr5:46066531	chr1:121519112~121571892:+
BRCA	trans	rs2657294	0.796	rs1259501	ENSG00000172974.11	AC007318.5	15.32	6.28e-48	3.22e-41	0.52	0.43	Pneumonia;	chr10:75230427	chr2:65205108~65205988:+
BRCA	trans	rs9467773	0.804	rs2073526	ENSG00000242375.1	RP11-498P14.3	-15.32	6.28e-48	3.22e-41	-0.61	-0.43	Intelligence (multi-trait analysis);	chr6:26374430	chr9:97195351~97197687:-
BRCA	trans	rs10940346	1	rs10940346	ENSG00000231752.4	EMBP1	-15.32	6.33e-48	3.24e-41	-0.55	-0.43	Schizophrenia;	chr5:50510208	chr1:121519112~121571892:+
BRCA	trans	rs6732160	0.691	rs10197935	ENSG00000236165.1	PRADC1P1	15.32	6.64e-48	3.4e-41	0.55	0.43	Intelligence (multi-trait analysis);	chr2:73185234	chr3:36976316~36976840:+
BRCA	trans	rs4276421	0.904	rs10067132	ENSG00000231752.4	EMBP1	15.3	7.57e-48	3.88e-41	0.55	0.43	P wave duration;	chr5:46027600	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.874	rs7727331	ENSG00000231752.4	EMBP1	15.3	7.58e-48	3.88e-41	0.55	0.43	P wave duration;	chr5:45945199	chr1:121519112~121571892:+
BRCA	trans	rs916888	0.773	rs9896243	ENSG00000214425.5	LRRC37A4P	-15.3	8.24e-48	4.21e-41	-0.61	-0.43	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:45506741~45550335:-
BRCA	trans	rs7395662	1	rs7482176	ENSG00000134612.10	FOLH1B	-15.29	8.88e-48	4.53e-41	-0.54	-0.43	HDL cholesterol;	chr11:48583068	chr11:89639227~89698718:+
BRCA	trans	rs6732160	0.657	rs10171459	ENSG00000236165.1	PRADC1P1	15.29	9.28e-48	4.74e-41	0.55	0.43	Intelligence (multi-trait analysis);	chr2:73207600	chr3:36976316~36976840:+
BRCA	trans	rs7395662	0.625	rs11040006	ENSG00000134612.10	FOLH1B	15.29	9.37e-48	4.78e-41	0.54	0.43	HDL cholesterol;	chr11:48752750	chr11:89639227~89698718:+
BRCA	trans	rs7554547	0.765	rs4845886	ENSG00000261819.1	RP11-680G24.4	15.28	1.05e-47	5.33e-41	0.54	0.43	Nonsyndromic cleft lip with cleft palate;	chr1:11888603	chr16:14988259~14990160:-
BRCA	trans	rs7554547	0.791	rs4846069	ENSG00000261819.1	RP11-680G24.4	15.28	1.05e-47	5.33e-41	0.54	0.43	Nonsyndromic cleft lip with cleft palate;	chr1:11888974	chr16:14988259~14990160:-
BRCA	trans	rs7554547	0.791	rs11121837	ENSG00000261819.1	RP11-680G24.4	15.28	1.05e-47	5.33e-41	0.54	0.43	Nonsyndromic cleft lip with cleft palate;	chr1:11889414	chr16:14988259~14990160:-
BRCA	trans	rs7554547	0.765	rs4846070	ENSG00000261819.1	RP11-680G24.4	15.28	1.05e-47	5.33e-41	0.54	0.43	Nonsyndromic cleft lip with cleft palate;	chr1:11889464	chr16:14988259~14990160:-
BRCA	trans	rs7312770	1	rs7312770	ENSG00000212994.5	RPS26P6	-15.27	1.1e-47	5.61e-41	-0.5	-0.43	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr8:100895771~100896118:+
BRCA	trans	rs11039798	0.588	rs6485891	ENSG00000134612.10	FOLH1B	15.27	1.13e-47	5.75e-41	0.65	0.43	Axial length;	chr11:48590472	chr11:89639227~89698718:+
BRCA	trans	rs9876781	1	rs6776700	ENSG00000235912.1	RP1-159A19.3	-15.27	1.19e-47	6.06e-41	-0.5	-0.43	Longevity;	chr3:48455358	chr1:27649419~27649610:+
BRCA	trans	rs4276421	0.934	rs6451838	ENSG00000231752.4	EMBP1	15.26	1.28e-47	6.5e-41	0.55	0.43	P wave duration;	chr5:45935060	chr1:121519112~121571892:+
BRCA	trans	rs7395662	0.5	rs7947055	ENSG00000134612.10	FOLH1B	15.26	1.29e-47	6.55e-41	0.54	0.43	HDL cholesterol;	chr11:48955534	chr11:89639227~89698718:+
BRCA	trans	rs7554547	0.739	rs61527718	ENSG00000261819.1	RP11-680G24.4	15.26	1.3e-47	6.6e-41	0.54	0.43	Nonsyndromic cleft lip with cleft palate;	chr1:11889583	chr16:14988259~14990160:-
BRCA	trans	rs4276421	0.935	rs6451834	ENSG00000231752.4	EMBP1	15.26	1.37e-47	6.94e-41	0.55	0.43	P wave duration;	chr5:45927208	chr1:121519112~121571892:+
BRCA	trans	rs7395662	0.892	rs11040014	ENSG00000134612.10	FOLH1B	15.25	1.52e-47	7.68e-41	0.54	0.43	HDL cholesterol;	chr11:48761505	chr11:89639227~89698718:+
BRCA	trans	rs4276421	0.967	rs4541666	ENSG00000231752.4	EMBP1	15.24	1.6e-47	8.11e-41	0.55	0.43	P wave duration;	chr5:45857027	chr1:121519112~121571892:+
BRCA	trans	rs7395662	0.963	rs11040016	ENSG00000134612.10	FOLH1B	15.24	1.64e-47	8.29e-41	0.54	0.43	HDL cholesterol;	chr11:48761945	chr11:89639227~89698718:+
BRCA	trans	rs4240897	0.835	rs4845891	ENSG00000261819.1	RP11-680G24.4	15.24	1.73e-47	8.72e-41	0.53	0.43	Tuberculosis;	chr1:11982449	chr16:14988259~14990160:-
BRCA	trans	rs6732160	0.691	rs11886257	ENSG00000236165.1	PRADC1P1	15.23	1.87e-47	9.4e-41	0.56	0.43	Intelligence (multi-trait analysis);	chr2:73189745	chr3:36976316~36976840:+
BRCA	trans	rs6732160	0.691	rs1960233	ENSG00000236165.1	PRADC1P1	15.23	1.87e-47	9.4e-41	0.56	0.43	Intelligence (multi-trait analysis);	chr2:73194250	chr3:36976316~36976840:+
BRCA	trans	rs6732160	0.691	rs2007191	ENSG00000236165.1	PRADC1P1	15.23	1.87e-47	9.4e-41	0.56	0.43	Intelligence (multi-trait analysis);	chr2:73194335	chr3:36976316~36976840:+
BRCA	trans	rs9876781	1	rs11712561	ENSG00000235912.1	RP1-159A19.3	-15.23	1.89e-47	9.49e-41	-0.5	-0.43	Longevity;	chr3:48393807	chr1:27649419~27649610:+
BRCA	trans	rs2727020	0.558	rs1164675	ENSG00000134612.10	FOLH1B	15.22	2.17e-47	1.09e-40	0.53	0.43	Coronary artery disease;	chr11:49304420	chr11:89639227~89698718:+
BRCA	trans	rs4276421	0.935	rs6898824	ENSG00000231752.4	EMBP1	-15.2	2.82e-47	1.41e-40	-0.55	-0.43	P wave duration;	chr5:45842058	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.967	rs6878425	ENSG00000231752.4	EMBP1	15.2	2.82e-47	1.41e-40	0.55	0.43	P wave duration;	chr5:45843153	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.774	rs4601053	ENSG00000231752.4	EMBP1	15.2	2.85e-47	1.42e-40	0.54	0.43	P wave duration;	chr5:46101734	chr1:121519112~121571892:+
BRCA	trans	rs7395662	1	rs11039871	ENSG00000134612.10	FOLH1B	15.2	2.89e-47	1.44e-40	0.53	0.43	HDL cholesterol;	chr11:48605068	chr11:89639227~89698718:+
BRCA	trans	rs877636	0.702	rs61937249	ENSG00000243403.1	RP11-330L19.1	15.2	2.96e-47	1.47e-40	0.55	0.43	Cognitive function;	chr12:55988132	chr15:64592979~64593326:+
BRCA	trans	rs877636	0.692	rs2271194	ENSG00000234513.1	AC073072.7	-15.19	3.14e-47	1.56e-40	-0.5	-0.43	Cognitive function;	chr12:56083910	chr7:22773646~22773993:-
BRCA	trans	rs4276421	0.904	rs34462057	ENSG00000231752.4	EMBP1	15.19	3.28e-47	1.63e-40	0.55	0.43	P wave duration;	chr5:45900215	chr1:121519112~121571892:+
BRCA	trans	rs9876781	1	rs9864371	ENSG00000235912.1	RP1-159A19.3	-15.18	3.52e-47	1.75e-40	-0.5	-0.43	Longevity;	chr3:48385276	chr1:27649419~27649610:+
BRCA	trans	rs1814175	0.654	rs1164676	ENSG00000134612.10	FOLH1B	15.18	3.64e-47	1.81e-40	0.52	0.43	Height;	chr11:49303316	chr11:89639227~89698718:+
BRCA	trans	rs7554547	0.714	rs4846071	ENSG00000261819.1	RP11-680G24.4	15.18	3.71e-47	1.84e-40	0.53	0.43	Nonsyndromic cleft lip with cleft palate;	chr1:11889612	chr16:14988259~14990160:-
BRCA	trans	rs7554547	0.791	rs57678332	ENSG00000261819.1	RP11-680G24.4	15.16	4.35e-47	2.16e-40	0.53	0.43	Nonsyndromic cleft lip with cleft palate;	chr1:11890834	chr16:14988259~14990160:-
BRCA	trans	rs877636	0.702	rs773109	ENSG00000243403.1	RP11-330L19.1	15.15	4.94e-47	2.44e-40	0.55	0.42	Cognitive function;	chr12:55980911	chr15:64592979~64593326:+
BRCA	trans	rs877636	0.74	rs705702	ENSG00000243403.1	RP11-330L19.1	-15.15	4.94e-47	2.44e-40	-0.54	-0.42	Cognitive function;	chr12:55996852	chr15:64592979~64593326:+
BRCA	trans	rs877636	0.702	rs773110	ENSG00000243403.1	RP11-330L19.1	15.15	5.18e-47	2.56e-40	0.55	0.42	Cognitive function;	chr12:55981353	chr15:64592979~64593326:+
BRCA	trans	rs877636	0.702	rs773112	ENSG00000243403.1	RP11-330L19.1	15.14	6.06e-47	2.98e-40	0.55	0.42	Cognitive function;	chr12:55982097	chr15:64592979~64593326:+
BRCA	trans	rs4276421	0.874	rs34501453	ENSG00000231752.4	EMBP1	15.14	6.08e-47	2.99e-40	0.55	0.42	P wave duration;	chr5:45947338	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.967	rs35648163	ENSG00000231752.4	EMBP1	15.14	6.23e-47	3.06e-40	0.54	0.42	P wave duration;	chr5:45945778	chr1:121519112~121571892:+
BRCA	trans	rs877636	0.702	rs773111	ENSG00000243403.1	RP11-330L19.1	15.14	6.3e-47	3.1e-40	0.55	0.42	Cognitive function;	chr12:55981956	chr15:64592979~64593326:+
BRCA	trans	rs9876781	0.967	rs9876891	ENSG00000235912.1	RP1-159A19.3	-15.13	6.44e-47	3.17e-40	-0.5	-0.42	Longevity;	chr3:48440024	chr1:27649419~27649610:+
BRCA	trans	rs13190036	0.591	rs78523677	ENSG00000226986.4	RP11-543B16.2	-15.13	6.63e-47	3.26e-40	-0.65	-0.42	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177124102	chr1:211207239~211207897:+
BRCA	trans	rs4276421	0.805	rs13165481	ENSG00000231752.4	EMBP1	15.13	7.06e-47	3.47e-40	0.54	0.42	P wave duration;	chr5:46034214	chr1:121519112~121571892:+
BRCA	trans	rs7395662	1	rs11039800	ENSG00000134612.10	FOLH1B	15.13	7.11e-47	3.49e-40	0.53	0.42	HDL cholesterol;	chr11:48521027	chr11:89639227~89698718:+
BRCA	trans	rs2657294	0.796	rs1259499	ENSG00000172974.11	AC007318.5	15.13	7.13e-47	3.5e-40	0.52	0.42	Pneumonia;	chr10:75228308	chr2:65205108~65205988:+
BRCA	trans	rs4276421	0.736	rs7445572	ENSG00000231752.4	EMBP1	15.12	7.83e-47	3.84e-40	0.54	0.42	P wave duration;	chr5:45920315	chr1:121519112~121571892:+
BRCA	trans	rs7554547	0.739	rs4846073	ENSG00000261819.1	RP11-680G24.4	15.11	8.33e-47	4.09e-40	0.53	0.42	Nonsyndromic cleft lip with cleft palate;	chr1:11890521	chr16:14988259~14990160:-
BRCA	trans	rs4276421	1	rs13175559	ENSG00000231752.4	EMBP1	15.1	9.44e-47	4.63e-40	0.54	0.42	P wave duration;	chr5:45854525	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.682	rs12657581	ENSG00000231752.4	EMBP1	15.1	1.01e-46	4.94e-40	0.54	0.42	P wave duration;	chr5:46080471	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.874	rs6451830	ENSG00000231752.4	EMBP1	15.09	1.06e-46	5.2e-40	0.54	0.42	P wave duration;	chr5:45893354	chr1:121519112~121571892:+
BRCA	trans	rs877636	0.859	rs3741499	ENSG00000225071.1	GS1-184P14.2	-15.08	1.22e-46	5.93e-40	-0.51	-0.42	Cognitive function;	chr12:56080595	chrX:24429573~24429920:-
BRCA	trans	rs9876781	1	rs3214041	ENSG00000235912.1	RP1-159A19.3	-15.07	1.5e-46	7.3e-40	-0.49	-0.42	Longevity;	chr3:48413059	chr1:27649419~27649610:+
BRCA	trans	rs7312770	0.612	rs1873914	ENSG00000235459.5	RPS26P31	15.06	1.58e-46	7.68e-40	0.48	0.42	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr7:122681315~122681662:+
BRCA	trans	rs7395662	1	rs4882132	ENSG00000134612.10	FOLH1B	-15.06	1.62e-46	7.9e-40	-0.53	-0.42	HDL cholesterol;	chr11:48571573	chr11:89639227~89698718:+
BRCA	trans	rs7554547	0.765	rs57176983	ENSG00000261819.1	RP11-680G24.4	15.06	1.63e-46	7.94e-40	0.53	0.42	Nonsyndromic cleft lip with cleft palate;	chr1:11891041	chr16:14988259~14990160:-
BRCA	trans	rs4276421	0.935	rs12109652	ENSG00000231752.4	EMBP1	15.05	1.72e-46	8.37e-40	0.54	0.42	P wave duration;	chr5:45878206	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.659	rs8188026	ENSG00000231752.4	EMBP1	15.05	1.75e-46	8.51e-40	0.55	0.42	P wave duration;	chr5:46053462	chr1:121519112~121571892:+
BRCA	trans	rs10242455	0.702	rs41385645	ENSG00000228834.1	RP11-249L21.4	15.05	1.75e-46	8.51e-40	1.02	0.42	Blood metabolite levels;	chr7:99376415	chr6:108907615~108907873:-
BRCA	trans	rs4276421	0.638	rs4551075	ENSG00000231752.4	EMBP1	15.05	1.76e-46	8.52e-40	0.54	0.42	P wave duration;	chr5:46011710	chr1:121519112~121571892:+
BRCA	trans	rs9876781	1	rs10470686	ENSG00000235912.1	RP1-159A19.3	-15.05	1.79e-46	8.7e-40	-0.49	-0.42	Longevity;	chr3:48408549	chr1:27649419~27649610:+
BRCA	trans	rs9876781	1	rs6442118	ENSG00000235912.1	RP1-159A19.3	-15.04	2e-46	9.69e-40	-0.49	-0.42	Longevity;	chr3:48398582	chr1:27649419~27649610:+
BRCA	trans	rs3740713	1	rs3740713	ENSG00000235847.2	LDHAP7	15.04	2.06e-46	9.98e-40	0.83	0.42	Amyotrophic lateral sclerosis (sporadic);	chr11:18429549	chr2:84777259~84778223:-
BRCA	trans	rs7395662	1	rs10742862	ENSG00000134612.10	FOLH1B	-15.04	2.07e-46	1e-39	-0.53	-0.42	HDL cholesterol;	chr11:48627764	chr11:89639227~89698718:+
BRCA	trans	rs4276421	0.805	rs6451810	ENSG00000231752.4	EMBP1	15.04	2.18e-46	1.06e-39	0.55	0.42	P wave duration;	chr5:45633898	chr1:121519112~121571892:+
BRCA	trans	rs72615157	0.613	rs56089143	ENSG00000228546.2	CTA-313A17.3	15.03	2.21e-46	1.07e-39	0.66	0.42	Lung function (FEV1/FVC);	chr7:100222221	chr7:102337316~102339115:+
BRCA	trans	rs7395662	1	rs11039819	ENSG00000134612.10	FOLH1B	-15.03	2.22e-46	1.07e-39	-0.52	-0.42	HDL cholesterol;	chr11:48540629	chr11:89639227~89698718:+
BRCA	trans	rs7554547	0.714	rs4845890	ENSG00000261819.1	RP11-680G24.4	15.03	2.32e-46	1.12e-39	0.54	0.42	Nonsyndromic cleft lip with cleft palate;	chr1:11912612	chr16:14988259~14990160:-
BRCA	trans	rs7554547	0.69	rs7516708	ENSG00000261819.1	RP11-680G24.4	15.03	2.34e-46	1.13e-39	0.53	0.42	Nonsyndromic cleft lip with cleft palate;	chr1:11890148	chr16:14988259~14990160:-
BRCA	trans	rs72615157	0.664	rs6953580	ENSG00000228546.2	CTA-313A17.3	15.02	2.68e-46	1.29e-39	0.66	0.42	Lung function (FEV1/FVC);	chr7:100227652	chr7:102337316~102339115:+
BRCA	trans	rs4276421	0.904	rs6451843	ENSG00000231752.4	EMBP1	15.01	2.81e-46	1.36e-39	0.54	0.42	P wave duration;	chr5:45946683	chr1:121519112~121571892:+
BRCA	trans	rs7554547	0.791	rs1321072	ENSG00000261819.1	RP11-680G24.4	15.01	3.08e-46	1.49e-39	0.53	0.42	Nonsyndromic cleft lip with cleft palate;	chr1:11891261	chr16:14988259~14990160:-
BRCA	trans	rs10037055	0.853	rs10035180	ENSG00000217325.2	PRELID1P1	-15.01	3.14e-46	1.51e-39	-0.59	-0.42	Migraine without aura;	chr5:177171501	chr6:126643488~126644390:+
BRCA	trans	rs916888	0.773	rs9896243	ENSG00000280022.1	RP11-707O23.1	15	3.18e-46	1.54e-39	0.68	0.42	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:45592621~45593369:+
BRCA	trans	rs6732160	0.65	rs7560224	ENSG00000236165.1	PRADC1P1	15	3.43e-46	1.66e-39	0.55	0.42	Intelligence (multi-trait analysis);	chr2:73179054	chr3:36976316~36976840:+
BRCA	trans	rs4276421	1	rs4331911	ENSG00000231752.4	EMBP1	14.99	3.62e-46	1.75e-39	0.54	0.42	P wave duration;	chr5:45859273	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.869	rs1527831	ENSG00000231752.4	EMBP1	14.99	3.84e-46	1.85e-39	0.54	0.42	P wave duration;	chr5:45656821	chr1:121519112~121571892:+
BRCA	trans	rs11039798	0.588	rs10838923	ENSG00000134612.10	FOLH1B	14.99	4.02e-46	1.94e-39	0.63	0.42	Axial length;	chr11:48513312	chr11:89639227~89698718:+
BRCA	trans	rs4276421	0.55	rs34812524	ENSG00000231752.4	EMBP1	14.98	4.49e-46	2.16e-39	0.54	0.42	P wave duration;	chr5:46054030	chr1:121519112~121571892:+
BRCA	trans	rs877636	0.74	rs772920	ENSG00000243403.1	RP11-330L19.1	14.97	4.62e-46	2.22e-39	0.55	0.42	Cognitive function;	chr12:55996580	chr15:64592979~64593326:+
BRCA	trans	rs877636	0.692	rs11171739	ENSG00000223416.3	RPS26P15	14.97	4.82e-46	2.32e-39	0.48	0.42	Cognitive function;	chr12:56076841	chr1:58056133~58056480:-
BRCA	trans	rs4276421	0.935	rs6451827	ENSG00000231752.4	EMBP1	14.95	5.93e-46	2.85e-39	0.54	0.42	P wave duration;	chr5:45879496	chr1:121519112~121571892:+
BRCA	trans	rs11039798	0.623	rs588700	ENSG00000134612.10	FOLH1B	-14.95	6e-46	2.88e-39	-0.65	-0.42	Axial length;	chr11:48428337	chr11:89639227~89698718:+
BRCA	trans	rs4276421	1	rs6895191	ENSG00000231752.4	EMBP1	14.93	7.7e-46	3.69e-39	0.54	0.42	P wave duration;	chr5:45877572	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.837	rs2580260	ENSG00000231752.4	EMBP1	14.93	8.15e-46	3.9e-39	0.54	0.42	P wave duration;	chr5:45638527	chr1:121519112~121571892:+
BRCA	trans	rs13358908	0.556	rs55638678	ENSG00000231752.4	EMBP1	-14.93	8.4e-46	4.02e-39	-0.54	-0.42	Schizophrenia;	chr5:46332618	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.635	rs12186454	ENSG00000231752.4	EMBP1	-14.92	8.56e-46	4.1e-39	-0.54	-0.42	P wave duration;	chr5:46067621	chr1:121519112~121571892:+
BRCA	trans	rs4240897	0.935	rs3766744	ENSG00000261819.1	RP11-680G24.4	14.92	9.52e-46	4.56e-39	0.52	0.42	Tuberculosis;	chr1:11983660	chr16:14988259~14990160:-
BRCA	trans	rs2657294	0.761	rs1259498	ENSG00000172974.11	AC007318.5	14.91	1.05e-45	5.01e-39	0.51	0.42	Pneumonia;	chr10:75226983	chr2:65205108~65205988:+
BRCA	trans	rs7395662	1	rs6485911	ENSG00000134612.10	FOLH1B	-14.91	1.05e-45	5.04e-39	-0.53	-0.42	HDL cholesterol;	chr11:48633232	chr11:89639227~89698718:+
BRCA	trans	rs4276421	0.967	rs10755272	ENSG00000231752.4	EMBP1	-14.91	1.09e-45	5.21e-39	-0.53	-0.42	P wave duration;	chr5:45815434	chr1:121519112~121571892:+
BRCA	trans	rs6732160	0.691	rs6728147	ENSG00000236165.1	PRADC1P1	-14.9	1.1e-45	5.28e-39	-0.54	-0.42	Intelligence (multi-trait analysis);	chr2:73196362	chr3:36976316~36976840:+
BRCA	trans	rs4276421	1	rs4866982	ENSG00000231752.4	EMBP1	-14.9	1.19e-45	5.68e-39	-0.53	-0.42	P wave duration;	chr5:45816754	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.837	rs6893773	ENSG00000231752.4	EMBP1	14.89	1.28e-45	6.11e-39	0.54	0.42	P wave duration;	chr5:45622394	chr1:121519112~121571892:+
BRCA	trans	rs9611519	0.964	rs2179744	ENSG00000268568.1	AC007228.9	-14.89	1.32e-45	6.3e-39	-0.55	-0.42	Neuroticism;	chr22:41225710	chr19:56672574~56673901:-
BRCA	trans	rs4276421	1	rs11748089	ENSG00000231752.4	EMBP1	-14.88	1.43e-45	6.83e-39	-0.54	-0.42	P wave duration;	chr5:45810733	chr1:121519112~121571892:+
BRCA	trans	rs4276421	1	rs10037766	ENSG00000231752.4	EMBP1	-14.88	1.43e-45	6.83e-39	-0.54	-0.42	P wave duration;	chr5:45813215	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.839	rs7719401	ENSG00000231752.4	EMBP1	14.87	1.74e-45	8.26e-39	0.53	0.42	P wave duration;	chr5:45938713	chr1:121519112~121571892:+
BRCA	trans	rs10940346	1	rs1423645	ENSG00000231752.4	EMBP1	-14.86	1.88e-45	8.95e-39	-0.53	-0.42	Schizophrenia;	chr5:50540881	chr1:121519112~121571892:+
BRCA	trans	rs877636	1	rs2292239	ENSG00000225071.1	GS1-184P14.2	14.86	2.02e-45	9.6e-39	0.49	0.42	Cognitive function;	chr12:56088396	chrX:24429573~24429920:-
BRCA	trans	rs7554547	0.791	rs4846074	ENSG00000261819.1	RP11-680G24.4	14.85	2.08e-45	9.87e-39	0.53	0.42	Nonsyndromic cleft lip with cleft palate;	chr1:11896172	chr16:14988259~14990160:-
BRCA	trans	rs7554547	0.765	rs34175640	ENSG00000261819.1	RP11-680G24.4	-14.85	2.14e-45	1.02e-38	-0.53	-0.42	Nonsyndromic cleft lip with cleft palate;	chr1:11892155	chr16:14988259~14990160:-
BRCA	trans	rs7554547	0.791	rs4492637	ENSG00000261819.1	RP11-680G24.4	14.85	2.18e-45	1.04e-38	0.53	0.42	Nonsyndromic cleft lip with cleft palate;	chr1:11895787	chr16:14988259~14990160:-
BRCA	trans	rs72615157	0.612	rs7786505	ENSG00000228546.2	CTA-313A17.3	14.85	2.25e-45	1.07e-38	0.65	0.42	Lung function (FEV1/FVC);	chr7:100219962	chr7:102337316~102339115:+
BRCA	trans	rs9611519	1	rs5758268	ENSG00000268568.1	AC007228.9	-14.82	3.13e-45	1.48e-38	-0.54	-0.42	Neuroticism;	chr22:41226415	chr19:56672574~56673901:-
BRCA	trans	rs4276421	0.845	rs10434580	ENSG00000231752.4	EMBP1	14.81	3.4e-45	1.61e-38	0.54	0.42	P wave duration;	chr5:46010910	chr1:121519112~121571892:+
BRCA	trans	rs9876781	1	rs7630741	ENSG00000235912.1	RP1-159A19.3	-14.81	3.62e-45	1.71e-38	-0.49	-0.42	Longevity;	chr3:48378233	chr1:27649419~27649610:+
BRCA	trans	rs11039798	0.557	rs4436575	ENSG00000134612.10	FOLH1B	-14.8	3.76e-45	1.78e-38	-0.64	-0.42	Axial length;	chr11:48377342	chr11:89639227~89698718:+
BRCA	trans	rs11039798	0.623	rs635632	ENSG00000134612.10	FOLH1B	-14.8	3.76e-45	1.78e-38	-0.64	-0.42	Axial length;	chr11:48377980	chr11:89639227~89698718:+
BRCA	trans	rs11039798	0.623	rs594615	ENSG00000134612.10	FOLH1B	-14.8	3.81e-45	1.8e-38	-0.64	-0.42	Axial length;	chr11:48381252	chr11:89639227~89698718:+
BRCA	trans	rs9876781	1	rs13071337	ENSG00000235912.1	RP1-159A19.3	-14.8	3.85e-45	1.81e-38	-0.48	-0.42	Longevity;	chr3:48396724	chr1:27649419~27649610:+
BRCA	trans	rs9876781	1	rs1563736	ENSG00000235912.1	RP1-159A19.3	-14.8	3.93e-45	1.85e-38	-0.48	-0.42	Longevity;	chr3:48395329	chr1:27649419~27649610:+
BRCA	trans	rs11039798	0.588	rs643668	ENSG00000134612.10	FOLH1B	-14.8	3.94e-45	1.86e-38	-0.63	-0.42	Axial length;	chr11:48391847	chr11:89639227~89698718:+
BRCA	trans	rs9876781	1	rs13314659	ENSG00000235912.1	RP1-159A19.3	14.79	4.39e-45	2.06e-38	0.48	0.42	Longevity;	chr3:48407742	chr1:27649419~27649610:+
BRCA	trans	rs11039798	0.511	rs717896	ENSG00000134612.10	FOLH1B	-14.79	4.41e-45	2.07e-38	-0.64	-0.42	Axial length;	chr11:48353783	chr11:89639227~89698718:+
BRCA	trans	rs4276421	0.967	rs6865429	ENSG00000231752.4	EMBP1	-14.79	4.61e-45	2.17e-38	-0.53	-0.42	P wave duration;	chr5:45830406	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.967	rs4282324	ENSG00000231752.4	EMBP1	14.79	4.75e-45	2.23e-38	0.53	0.42	P wave duration;	chr5:45865330	chr1:121519112~121571892:+
BRCA	trans	rs4276421	1	rs10039283	ENSG00000231752.4	EMBP1	14.78	4.81e-45	2.26e-38	0.53	0.42	P wave duration;	chr5:45864741	chr1:121519112~121571892:+
BRCA	trans	rs4276421	1	rs28657933	ENSG00000231752.4	EMBP1	14.78	5.38e-45	2.52e-38	0.53	0.42	P wave duration;	chr5:45863597	chr1:121519112~121571892:+
BRCA	trans	rs11039798	0.582	rs1483119	ENSG00000134612.10	FOLH1B	-14.77	5.57e-45	2.61e-38	-0.64	-0.42	Axial length;	chr11:48360782	chr11:89639227~89698718:+
BRCA	trans	rs8175379	0.506	rs8188256	ENSG00000231752.4	EMBP1	-14.76	6.62e-45	3.09e-38	-0.54	-0.42	Interleukin-7 levels;	chr5:46372404	chr1:121519112~121571892:+
BRCA	trans	rs11039798	0.588	rs584899	ENSG00000134612.10	FOLH1B	-14.76	6.64e-45	3.1e-38	-0.63	-0.42	Axial length;	chr11:48409856	chr11:89639227~89698718:+
BRCA	trans	rs6732160	0.684	rs2043095	ENSG00000236165.1	PRADC1P1	14.75	6.94e-45	3.23e-38	0.54	0.42	Intelligence (multi-trait analysis);	chr2:73180314	chr3:36976316~36976840:+
BRCA	trans	rs7395662	1	rs4929903	ENSG00000134612.10	FOLH1B	-14.75	7.3e-45	3.39e-38	-0.52	-0.42	HDL cholesterol;	chr11:48891780	chr11:89639227~89698718:+
BRCA	trans	rs7554547	0.791	rs1321073	ENSG00000261819.1	RP11-680G24.4	14.75	7.33e-45	3.41e-38	0.52	0.42	Nonsyndromic cleft lip with cleft palate;	chr1:11891569	chr16:14988259~14990160:-
BRCA	trans	rs13358908	0.503	rs10073687	ENSG00000231752.4	EMBP1	-14.75	7.77e-45	3.61e-38	-0.54	-0.42	Schizophrenia;	chr5:46352187	chr1:121519112~121571892:+
BRCA	trans	rs9876781	1	rs9826195	ENSG00000235912.1	RP1-159A19.3	-14.74	8.16e-45	3.79e-38	-0.48	-0.42	Longevity;	chr3:48392157	chr1:27649419~27649610:+
BRCA	trans	rs9876781	0.967	rs9864815	ENSG00000235912.1	RP1-159A19.3	-14.74	8.16e-45	3.79e-38	-0.48	-0.42	Longevity;	chr3:48392588	chr1:27649419~27649610:+
BRCA	trans	rs9876781	1	rs9809843	ENSG00000235912.1	RP1-159A19.3	-14.74	8.16e-45	3.79e-38	-0.48	-0.42	Longevity;	chr3:48392923	chr1:27649419~27649610:+
BRCA	trans	rs11039798	0.588	rs11039855	ENSG00000134612.10	FOLH1B	14.74	8.4e-45	3.9e-38	0.64	0.42	Axial length;	chr11:48588539	chr11:89639227~89698718:+
BRCA	trans	rs7395662	0.819	rs1473579	ENSG00000134612.10	FOLH1B	-14.74	8.45e-45	3.92e-38	-0.52	-0.42	HDL cholesterol;	chr11:48880001	chr11:89639227~89698718:+
BRCA	trans	rs2589161	1	rs2589161	ENSG00000231752.4	EMBP1	14.74	8.53e-45	3.96e-38	0.54	0.42	Breast cancer;	chr5:45653810	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.869	rs1405918	ENSG00000231752.4	EMBP1	14.74	8.53e-45	3.96e-38	0.54	0.42	P wave duration;	chr5:45654968	chr1:121519112~121571892:+
BRCA	trans	rs7554547	0.791	rs6665662	ENSG00000261819.1	RP11-680G24.4	14.74	8.76e-45	4.07e-38	0.52	0.42	Nonsyndromic cleft lip with cleft palate;	chr1:11891804	chr16:14988259~14990160:-
BRCA	trans	rs9611519	0.828	rs28814423	ENSG00000268568.1	AC007228.9	-14.73	9.02e-45	4.18e-38	-0.59	-0.42	Neuroticism;	chr22:41056297	chr19:56672574~56673901:-
BRCA	trans	rs4276421	0.839	rs28885449	ENSG00000231752.4	EMBP1	14.73	9.12e-45	4.23e-38	0.53	0.42	P wave duration;	chr5:45994103	chr1:121519112~121571892:+
BRCA	trans	rs7554547	0.791	rs34117126	ENSG00000261819.1	RP11-680G24.4	14.73	9.48e-45	4.39e-38	0.52	0.42	Nonsyndromic cleft lip with cleft palate;	chr1:11892138	chr16:14988259~14990160:-
BRCA	trans	rs7554547	0.791	rs17037520	ENSG00000261819.1	RP11-680G24.4	14.73	9.48e-45	4.39e-38	0.52	0.42	Nonsyndromic cleft lip with cleft palate;	chr1:11892349	chr16:14988259~14990160:-
BRCA	trans	rs7554547	0.791	rs12749498	ENSG00000261819.1	RP11-680G24.4	14.73	9.48e-45	4.39e-38	0.52	0.42	Nonsyndromic cleft lip with cleft palate;	chr1:11892570	chr16:14988259~14990160:-
BRCA	trans	rs7554547	0.791	rs12036266	ENSG00000261819.1	RP11-680G24.4	14.73	9.48e-45	4.39e-38	0.52	0.42	Nonsyndromic cleft lip with cleft palate;	chr1:11893257	chr16:14988259~14990160:-
BRCA	trans	rs7554547	0.791	rs2065611	ENSG00000261819.1	RP11-680G24.4	14.73	9.48e-45	4.39e-38	0.52	0.42	Nonsyndromic cleft lip with cleft palate;	chr1:11893469	chr16:14988259~14990160:-
BRCA	trans	rs11039798	0.588	rs589834	ENSG00000134612.10	FOLH1B	-14.73	9.57e-45	4.43e-38	-0.63	-0.42	Axial length;	chr11:48397830	chr11:89639227~89698718:+
BRCA	trans	rs9611519	0.894	rs4821990	ENSG00000268568.1	AC007228.9	-14.73	9.72e-45	4.5e-38	-0.58	-0.42	Neuroticism;	chr22:41042706	chr19:56672574~56673901:-
BRCA	trans	rs877636	0.669	rs7297175	ENSG00000235459.5	RPS26P31	-14.72	1.06e-44	4.91e-38	-0.46	-0.41	Cognitive function;	chr12:56080024	chr7:122681315~122681662:+
BRCA	trans	rs877636	1	rs705696	ENSG00000225071.1	GS1-184P14.2	14.72	1.07e-44	4.93e-38	0.54	0.41	Cognitive function;	chr12:56086864	chrX:24429573~24429920:-
BRCA	trans	rs8175379	0.515	rs8185067	ENSG00000231752.4	EMBP1	-14.72	1.08e-44	4.96e-38	-0.53	-0.41	Interleukin-7 levels;	chr5:46337722	chr1:121519112~121571892:+
BRCA	trans	rs6732160	0.656	rs2043093	ENSG00000236165.1	PRADC1P1	14.72	1.09e-44	5.02e-38	0.54	0.41	Intelligence (multi-trait analysis);	chr2:73180214	chr3:36976316~36976840:+
BRCA	trans	rs13358908	0.526	rs4975974	ENSG00000231752.4	EMBP1	-14.72	1.11e-44	5.1e-38	-0.53	-0.41	Schizophrenia;	chr5:46307464	chr1:121519112~121571892:+
BRCA	trans	rs7937890	0.9	rs7118682	ENSG00000236360.2	RP11-334A14.2	-14.71	1.14e-44	5.26e-38	-0.52	-0.41	Mitochondrial DNA levels;	chr11:14253004	chr1:52993201~52993702:-
BRCA	trans	rs9876781	1	rs28824259	ENSG00000235912.1	RP1-159A19.3	-14.71	1.22e-44	5.64e-38	-0.48	-0.41	Longevity;	chr3:48384185	chr1:27649419~27649610:+
BRCA	trans	rs9876781	1	rs12487542	ENSG00000235912.1	RP1-159A19.3	-14.71	1.22e-44	5.64e-38	-0.48	-0.41	Longevity;	chr3:48384586	chr1:27649419~27649610:+
BRCA	trans	rs9876781	1	rs73074358	ENSG00000235912.1	RP1-159A19.3	-14.71	1.22e-44	5.64e-38	-0.48	-0.41	Longevity;	chr3:48385757	chr1:27649419~27649610:+
BRCA	trans	rs9876781	0.967	rs34761139	ENSG00000235912.1	RP1-159A19.3	-14.71	1.22e-44	5.64e-38	-0.48	-0.41	Longevity;	chr3:48386489	chr1:27649419~27649610:+
BRCA	trans	rs9876781	0.868	rs9875280	ENSG00000235912.1	RP1-159A19.3	-14.71	1.22e-44	5.64e-38	-0.48	-0.41	Longevity;	chr3:48387420	chr1:27649419~27649610:+
BRCA	trans	rs9876781	1	rs6796491	ENSG00000235912.1	RP1-159A19.3	-14.71	1.22e-44	5.64e-38	-0.48	-0.41	Longevity;	chr3:48388977	chr1:27649419~27649610:+
BRCA	trans	rs7554547	0.791	rs4846076	ENSG00000261819.1	RP11-680G24.4	14.71	1.26e-44	5.8e-38	0.52	0.41	Nonsyndromic cleft lip with cleft palate;	chr1:11896708	chr16:14988259~14990160:-
BRCA	trans	rs7395662	0.736	rs4882036	ENSG00000134612.10	FOLH1B	-14.7	1.28e-44	5.89e-38	-0.52	-0.41	HDL cholesterol;	chr11:48727832	chr11:89639227~89698718:+
BRCA	trans	rs10940346	1	rs11739291	ENSG00000231752.4	EMBP1	-14.7	1.28e-44	5.89e-38	-0.52	-0.41	Schizophrenia;	chr5:50550394	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.869	rs2589162	ENSG00000231752.4	EMBP1	-14.7	1.39e-44	6.37e-38	-0.54	-0.41	P wave duration;	chr5:45655791	chr1:121519112~121571892:+
BRCA	trans	rs8175379	0.509	rs4128583	ENSG00000231752.4	EMBP1	14.7	1.42e-44	6.53e-38	0.53	0.41	Interleukin-7 levels;	chr5:46251985	chr1:121519112~121571892:+
BRCA	trans	rs1039766	0.929	rs55843720	ENSG00000224334.1	AP000357.4	14.69	1.48e-44	6.79e-38	0.66	0.41	Lung adenocarcinoma;Lung cancer;	chr2:65268436	chr22:24686923~24688087:+
BRCA	trans	rs4276421	0.682	rs10067983	ENSG00000231752.4	EMBP1	14.69	1.52e-44	6.97e-38	0.53	0.41	P wave duration;	chr5:46064294	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.743	rs10060199	ENSG00000231752.4	EMBP1	14.69	1.57e-44	7.19e-38	0.53	0.41	P wave duration;	chr5:46064524	chr1:121519112~121571892:+
BRCA	trans	rs10242455	0.571	rs11734	ENSG00000228834.1	RP11-249L21.4	-14.69	1.59e-44	7.26e-38	-0.93	-0.41	Blood metabolite levels;	chr7:99632145	chr6:108907615~108907873:-
BRCA	trans	rs7554547	0.791	rs2064614	ENSG00000261819.1	RP11-680G24.4	14.68	1.65e-44	7.52e-38	0.52	0.41	Nonsyndromic cleft lip with cleft palate;	chr1:11893883	chr16:14988259~14990160:-
BRCA	trans	rs13358908	0.511	rs34101830	ENSG00000231752.4	EMBP1	-14.67	2.03e-44	9.2e-38	-0.53	-0.41	Schizophrenia;	chr5:46349001	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.837	rs2337483	ENSG00000231752.4	EMBP1	14.66	2.09e-44	9.47e-38	0.53	0.41	P wave duration;	chr5:45608220	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.837	rs2696013	ENSG00000231752.4	EMBP1	14.65	2.38e-44	1.07e-37	0.53	0.41	P wave duration;	chr5:45603104	chr1:121519112~121571892:+
BRCA	trans	rs7395662	0.75	rs10838985	ENSG00000134612.10	FOLH1B	-14.65	2.38e-44	1.07e-37	-0.52	-0.41	HDL cholesterol;	chr11:48623533	chr11:89639227~89698718:+
BRCA	trans	rs8175379	0.542	rs12657764	ENSG00000231752.4	EMBP1	-14.65	2.63e-44	1.18e-37	-0.53	-0.41	Interleukin-7 levels;	chr5:46281165	chr1:121519112~121571892:+
BRCA	trans	rs7395662	0.782	rs66468703	ENSG00000134612.10	FOLH1B	-14.64	2.81e-44	1.27e-37	-0.51	-0.41	HDL cholesterol;	chr11:48717221	chr11:89639227~89698718:+
BRCA	trans	rs1039766	1	rs1039766	ENSG00000224334.1	AP000357.4	-14.64	2.84e-44	1.28e-37	-0.66	-0.41	Lung adenocarcinoma;Lung cancer;	chr2:65293011	chr22:24686923~24688087:+
BRCA	trans	rs13358908	0.507	rs12521357	ENSG00000231752.4	EMBP1	-14.64	2.89e-44	1.3e-37	-0.53	-0.41	Schizophrenia;	chr5:46403146	chr1:121519112~121571892:+
BRCA	trans	rs8175379	0.506	rs10035927	ENSG00000231752.4	EMBP1	-14.64	2.89e-44	1.3e-37	-0.53	-0.41	Interleukin-7 levels;	chr5:46404107	chr1:121519112~121571892:+
BRCA	trans	rs8175379	0.584	rs8185180	ENSG00000231752.4	EMBP1	-14.63	3.07e-44	1.38e-37	-0.54	-0.41	Interleukin-7 levels;	chr5:46300291	chr1:121519112~121571892:+
BRCA	trans	rs8175379	0.575	rs8185283	ENSG00000231752.4	EMBP1	-14.63	3.19e-44	1.43e-37	-0.53	-0.41	Interleukin-7 levels;	chr5:46337706	chr1:121519112~121571892:+
BRCA	trans	rs4276421	1	rs13340341	ENSG00000231752.4	EMBP1	14.63	3.24e-44	1.45e-37	0.52	0.41	P wave duration;	chr5:45860834	chr1:121519112~121571892:+
BRCA	trans	rs877636	0.692	rs11171739	ENSG00000196933.5	RPS26P11	14.62	3.48e-44	1.56e-37	0.49	0.41	Cognitive function;	chr12:56076841	chrX:72044545~72044892:+
BRCA	trans	rs4276421	0.837	rs6451807	ENSG00000231752.4	EMBP1	14.62	3.68e-44	1.65e-37	0.53	0.41	P wave duration;	chr5:45534321	chr1:121519112~121571892:+
BRCA	trans	rs13190036	0.551	rs28932178	ENSG00000226986.4	RP11-543B16.2	-14.62	3.74e-44	1.67e-37	-0.64	-0.41	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177210575	chr1:211207239~211207897:+
BRCA	trans	rs13358908	0.51	rs4975991	ENSG00000231752.4	EMBP1	-14.61	3.85e-44	1.72e-37	-0.53	-0.41	Schizophrenia;	chr5:46328545	chr1:121519112~121571892:+
BRCA	trans	rs9876781	1	rs9815103	ENSG00000235912.1	RP1-159A19.3	-14.6	4.48e-44	2e-37	-0.48	-0.41	Longevity;	chr3:48372725	chr1:27649419~27649610:+
BRCA	trans	rs8175379	0.551	rs4975969	ENSG00000231752.4	EMBP1	-14.6	4.65e-44	2.07e-37	-0.53	-0.41	Interleukin-7 levels;	chr5:46295887	chr1:121519112~121571892:+
BRCA	trans	rs7395662	0.804	rs8186428	ENSG00000134612.10	FOLH1B	-14.6	4.81e-44	2.14e-37	-0.51	-0.41	HDL cholesterol;	chr11:48713125	chr11:89639227~89698718:+
BRCA	trans	rs4240897	0.935	rs4846082	ENSG00000261819.1	RP11-680G24.4	14.6	4.87e-44	2.17e-37	0.51	0.41	Tuberculosis;	chr1:11982386	chr16:14988259~14990160:-
BRCA	trans	rs8175379	0.522	rs8185256	ENSG00000231752.4	EMBP1	-14.59	5.05e-44	2.24e-37	-0.53	-0.41	Interleukin-7 levels;	chr5:46298301	chr1:121519112~121571892:+
BRCA	trans	rs7395662	0.833	rs1963073	ENSG00000134612.10	FOLH1B	-14.59	5.13e-44	2.27e-37	-0.51	-0.41	HDL cholesterol;	chr11:48953542	chr11:89639227~89698718:+
BRCA	trans	rs9611519	0.929	rs12484971	ENSG00000268568.1	AC007228.9	-14.59	5.33e-44	2.36e-37	-0.58	-0.41	Neuroticism;	chr22:41043300	chr19:56672574~56673901:-
BRCA	trans	rs4276421	0.901	rs4455566	ENSG00000231752.4	EMBP1	14.59	5.44e-44	2.41e-37	0.53	0.41	P wave duration;	chr5:45752760	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.901	rs9687260	ENSG00000231752.4	EMBP1	14.59	5.44e-44	2.41e-37	0.53	0.41	P wave duration;	chr5:45759774	chr1:121519112~121571892:+
BRCA	trans	rs7395662	0.571	rs1605358	ENSG00000134612.10	FOLH1B	-14.58	5.62e-44	2.49e-37	-0.51	-0.41	HDL cholesterol;	chr11:48667766	chr11:89639227~89698718:+
BRCA	trans	rs877636	1	rs4759229	ENSG00000225071.1	GS1-184P14.2	-14.57	6.59e-44	2.91e-37	-0.5	-0.41	Cognitive function;	chr12:56080696	chrX:24429573~24429920:-
BRCA	trans	rs1039766	1	rs268862	ENSG00000224334.1	AP000357.4	14.57	6.6e-44	2.92e-37	0.66	0.41	Lung adenocarcinoma;Lung cancer;	chr2:65261404	chr22:24686923~24688087:+
BRCA	trans	rs7395662	0.926	rs11039893	ENSG00000134612.10	FOLH1B	-14.57	6.61e-44	2.92e-37	-0.51	-0.41	HDL cholesterol;	chr11:48636202	chr11:89639227~89698718:+
BRCA	trans	rs2727020	0.729	rs7924782	ENSG00000134612.10	FOLH1B	-14.56	7.55e-44	3.32e-37	-0.51	-0.41	Coronary artery disease;	chr11:49245697	chr11:89639227~89698718:+
BRCA	trans	rs8175379	0.521	rs10037109	ENSG00000231752.4	EMBP1	14.54	9.49e-44	4.15e-37	0.53	0.41	Interleukin-7 levels;	chr5:46328343	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.776	rs10473392	ENSG00000231752.4	EMBP1	14.54	9.79e-44	4.28e-37	0.53	0.41	P wave duration;	chr5:45709959	chr1:121519112~121571892:+
BRCA	trans	rs2657294	0.796	rs2804534	ENSG00000172974.11	AC007318.5	-14.54	9.99e-44	4.36e-37	-0.49	-0.41	Pneumonia;	chr10:75208023	chr2:65205108~65205988:+
BRCA	trans	rs7554547	0.69	rs4846064	ENSG00000261819.1	RP11-680G24.4	14.53	1.03e-43	4.51e-37	0.51	0.41	Nonsyndromic cleft lip with cleft palate;	chr1:11874785	chr16:14988259~14990160:-
BRCA	trans	rs4276421	0.869	rs2337952	ENSG00000231752.4	EMBP1	14.53	1.04e-43	4.53e-37	0.53	0.41	P wave duration;	chr5:45722022	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.869	rs2879074	ENSG00000231752.4	EMBP1	14.53	1.04e-43	4.56e-37	0.53	0.41	P wave duration;	chr5:45716107	chr1:121519112~121571892:+
BRCA	trans	rs13190036	0.551	rs1052432	ENSG00000226986.4	RP11-543B16.2	-14.52	1.24e-43	5.38e-37	-0.63	-0.41	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177137188	chr1:211207239~211207897:+
BRCA	trans	rs9876781	1	rs6804774	ENSG00000235912.1	RP1-159A19.3	-14.52	1.25e-43	5.45e-37	-0.48	-0.41	Longevity;	chr3:48389129	chr1:27649419~27649610:+
BRCA	trans	rs1039766	1	rs72822431	ENSG00000224334.1	AP000357.4	-14.51	1.43e-43	6.2e-37	-0.67	-0.41	Lung adenocarcinoma;Lung cancer;	chr2:65294682	chr22:24686923~24688087:+
BRCA	trans	rs9876781	0.967	rs7618883	ENSG00000235912.1	RP1-159A19.3	-14.51	1.45e-43	6.32e-37	-0.48	-0.41	Longevity;	chr3:48457056	chr1:27649419~27649610:+
BRCA	trans	rs9611519	0.929	rs4821991	ENSG00000268568.1	AC007228.9	-14.5	1.48e-43	6.45e-37	-0.58	-0.41	Neuroticism;	chr22:41044679	chr19:56672574~56673901:-
BRCA	trans	rs4276421	0.901	rs7447717	ENSG00000231752.4	EMBP1	-14.5	1.51e-43	6.53e-37	-0.53	-0.41	P wave duration;	chr5:45770150	chr1:121519112~121571892:+
BRCA	trans	rs8175379	0.501	rs12514178	ENSG00000231752.4	EMBP1	-14.5	1.55e-43	6.71e-37	-0.53	-0.41	Interleukin-7 levels;	chr5:46309072	chr1:121519112~121571892:+
BRCA	trans	rs8175379	0.501	rs8185192	ENSG00000231752.4	EMBP1	-14.5	1.55e-43	6.71e-37	-0.53	-0.41	Interleukin-7 levels;	chr5:46309722	chr1:121519112~121571892:+
BRCA	trans	rs7395662	0.929	rs10838982	ENSG00000134612.10	FOLH1B	-14.5	1.63e-43	7.04e-37	-0.51	-0.41	HDL cholesterol;	chr11:48618616	chr11:89639227~89698718:+
BRCA	trans	rs9611519	1	rs5758267	ENSG00000268568.1	AC007228.9	14.48	1.89e-43	8.14e-37	0.53	0.41	Neuroticism;	chr22:41223346	chr19:56672574~56673901:-
BRCA	trans	rs9611519	0.929	rs73174660	ENSG00000268568.1	AC007228.9	-14.48	1.91e-43	8.26e-37	-0.58	-0.41	Neuroticism;	chr22:41041300	chr19:56672574~56673901:-
BRCA	trans	rs1039766	1	rs10116	ENSG00000224334.1	AP000357.4	14.48	2.02e-43	8.71e-37	0.65	0.41	Lung adenocarcinoma;Lung cancer;	chr2:65269595	chr22:24686923~24688087:+
BRCA	trans	rs1039766	0.929	rs268881	ENSG00000224334.1	AP000357.4	14.48	2.02e-43	8.71e-37	0.65	0.41	Lung adenocarcinoma;Lung cancer;	chr2:65274249	chr22:24686923~24688087:+
BRCA	trans	rs4276421	0.869	rs6892627	ENSG00000231752.4	EMBP1	14.47	2.21e-43	9.53e-37	0.54	0.41	P wave duration;	chr5:45722892	chr1:121519112~121571892:+
BRCA	trans	rs1039766	1	rs268878	ENSG00000224334.1	AP000357.4	14.47	2.25e-43	9.7e-37	0.65	0.41	Lung adenocarcinoma;Lung cancer;	chr2:65270437	chr22:24686923~24688087:+
BRCA	trans	rs9611519	0.929	rs13055800	ENSG00000268568.1	AC007228.9	-14.47	2.26e-43	9.72e-37	-0.58	-0.41	Neuroticism;	chr22:41044420	chr19:56672574~56673901:-
BRCA	trans	rs4276421	1	rs4276421	ENSG00000231752.4	EMBP1	-14.46	2.44e-43	1.05e-36	-0.52	-0.41	P wave duration;	chr5:45801977	chr1:121519112~121571892:+
BRCA	trans	rs7937890	0.904	rs67623158	ENSG00000236360.2	RP11-334A14.2	-14.45	2.92e-43	1.25e-36	-0.51	-0.41	Mitochondrial DNA levels;	chr11:14273650	chr1:52993201~52993702:-
BRCA	trans	rs7395662	0.681	rs2865641	ENSG00000134612.10	FOLH1B	-14.44	3.25e-43	1.39e-36	-0.51	-0.41	HDL cholesterol;	chr11:48919547	chr11:89639227~89698718:+
BRCA	trans	rs616147	0.85	rs631312	ENSG00000183298.5	RP11-556K13.1	-14.44	3.34e-43	1.43e-36	-0.62	-0.41	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39467477	chr1:101786340~101787219:-
BRCA	trans	rs4276421	0.845	rs34040576	ENSG00000231752.4	EMBP1	14.44	3.39e-43	1.45e-36	0.53	0.41	P wave duration;	chr5:46005596	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.904	rs13360955	ENSG00000231752.4	EMBP1	14.44	3.39e-43	1.45e-36	0.53	0.41	P wave duration;	chr5:46005842	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.904	rs10070596	ENSG00000231752.4	EMBP1	14.43	3.45e-43	1.48e-36	0.53	0.41	P wave duration;	chr5:46004129	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.837	rs1384732	ENSG00000231752.4	EMBP1	14.43	3.52e-43	1.51e-36	0.52	0.41	P wave duration;	chr5:45553285	chr1:121519112~121571892:+
BRCA	trans	rs877636	0.692	rs2271194	ENSG00000196933.5	RPS26P11	-14.43	3.64e-43	1.56e-36	-0.49	-0.41	Cognitive function;	chr12:56083910	chrX:72044545~72044892:+
BRCA	trans	rs7395662	0.786	rs12791074	ENSG00000134612.10	FOLH1B	-14.43	3.75e-43	1.6e-36	-0.5	-0.41	HDL cholesterol;	chr11:48983471	chr11:89639227~89698718:+
BRCA	trans	rs877636	0.692	rs2271194	ENSG00000196656.7	AC004057.1	-14.43	3.78e-43	1.62e-36	-0.47	-0.41	Cognitive function;	chr12:56083910	chr4:113214046~113217170:-
BRCA	trans	rs8175379	0.509	rs7293427	ENSG00000231752.4	EMBP1	14.42	4.05e-43	1.73e-36	0.52	0.41	Interleukin-7 levels;	chr5:46253335	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.87	rs7706116	ENSG00000231752.4	EMBP1	14.41	4.53e-43	1.93e-36	0.52	0.41	P wave duration;	chr5:45742522	chr1:121519112~121571892:+
BRCA	trans	rs7937890	0.904	rs11023169	ENSG00000236360.2	RP11-334A14.2	-14.41	4.63e-43	1.98e-36	-0.52	-0.41	Mitochondrial DNA levels;	chr11:14269439	chr1:52993201~52993702:-
BRCA	trans	rs9876781	1	rs7634377	ENSG00000235912.1	RP1-159A19.3	-14.4	4.92e-43	2.1e-36	-0.47	-0.41	Longevity;	chr3:48379768	chr1:27649419~27649610:+
BRCA	trans	rs877636	0.692	rs11171739	ENSG00000196656.7	AC004057.1	14.4	5e-43	2.13e-36	0.47	0.41	Cognitive function;	chr12:56076841	chr4:113214046~113217170:-
BRCA	trans	rs877636	0.692	rs11171739	ENSG00000227887.1	RPS26P13	14.4	5.34e-43	2.28e-36	0.48	0.41	Cognitive function;	chr12:56076841	chr1:208697369~208697698:-
BRCA	trans	rs4276421	0.869	rs7705696	ENSG00000231752.4	EMBP1	14.4	5.47e-43	2.33e-36	0.52	0.41	P wave duration;	chr5:45712387	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.837	rs1483303	ENSG00000231752.4	EMBP1	14.39	5.72e-43	2.44e-36	0.52	0.41	P wave duration;	chr5:45571997	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.837	rs10078625	ENSG00000231752.4	EMBP1	14.39	5.85e-43	2.49e-36	0.52	0.41	P wave duration;	chr5:45707015	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.869	rs2337951	ENSG00000231752.4	EMBP1	14.39	5.93e-43	2.53e-36	0.52	0.41	P wave duration;	chr5:45717834	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.869	rs13187565	ENSG00000231752.4	EMBP1	14.39	5.98e-43	2.55e-36	0.52	0.41	P wave duration;	chr5:45707436	chr1:121519112~121571892:+
BRCA	trans	rs877636	1	rs877636	ENSG00000212994.5	RPS26P6	-14.39	6.06e-43	2.58e-36	-0.52	-0.41	Cognitive function;	chr12:56086799	chr8:100895771~100896118:+
BRCA	trans	rs4276421	0.869	rs7718785	ENSG00000231752.4	EMBP1	14.39	6.13e-43	2.61e-36	0.52	0.41	P wave duration;	chr5:45725495	chr1:121519112~121571892:+
BRCA	trans	rs1039766	1	rs268882	ENSG00000224334.1	AP000357.4	-14.38	6.94e-43	2.95e-36	-0.63	-0.41	Lung adenocarcinoma;Lung cancer;	chr2:65275668	chr22:24686923~24688087:+
BRCA	trans	rs877636	0.692	rs11171739	ENSG00000233778.3	RP11-777J24.1	14.37	7.29e-43	3.1e-36	0.46	0.41	Cognitive function;	chr12:56076841	chr8:92144088~92144435:-
BRCA	trans	rs7395662	1	rs6485882	ENSG00000134612.10	FOLH1B	14.37	7.76e-43	3.29e-36	0.49	0.41	HDL cholesterol;	chr11:48570883	chr11:89639227~89698718:+
BRCA	trans	rs9876781	1	rs9311423	ENSG00000235912.1	RP1-159A19.3	-14.36	8.18e-43	3.47e-36	-0.47	-0.41	Longevity;	chr3:48378818	chr1:27649419~27649610:+
BRCA	trans	rs877636	0.669	rs7297175	ENSG00000234513.1	AC073072.7	-14.35	8.98e-43	3.81e-36	-0.47	-0.41	Cognitive function;	chr12:56080024	chr7:22773646~22773993:-
BRCA	trans	rs6132905	0.52	rs2422823	ENSG00000235559.1	NOP56P1	-14.34	1.04e-42	4.4e-36	-0.48	-0.41	Mumps;	chr20:2665687	chr6:28783633~28784004:-
BRCA	trans	rs8175379	0.502	rs8185361	ENSG00000231752.4	EMBP1	-14.33	1.17e-42	4.94e-36	-0.52	-0.41	Interleukin-7 levels;	chr5:46300238	chr1:121519112~121571892:+
BRCA	trans	rs7395662	0.864	rs10839201	ENSG00000134612.10	FOLH1B	14.32	1.38e-42	5.84e-36	0.5	0.41	HDL cholesterol;	chr11:48967865	chr11:89639227~89698718:+
BRCA	trans	rs4276421	0.81	rs13190242	ENSG00000231752.4	EMBP1	14.31	1.53e-42	6.47e-36	0.53	0.41	P wave duration;	chr5:46054443	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.753	rs7443976	ENSG00000231752.4	EMBP1	14.31	1.54e-42	6.51e-36	0.52	0.41	P wave duration;	chr5:45936323	chr1:121519112~121571892:+
BRCA	trans	rs1039766	1	rs268861	ENSG00000224334.1	AP000357.4	14.3	1.68e-42	7.07e-36	0.65	0.41	Lung adenocarcinoma;Lung cancer;	chr2:65261026	chr22:24686923~24688087:+
BRCA	trans	rs9581094	0.505	rs6490945	ENSG00000237917.1	PARP4P1	14.3	1.82e-42	7.67e-36	0.53	0.4	Sudden cardiac arrest;	chr13:24514056	chrY:26594851~26634652:-
BRCA	trans	rs4276421	0.869	rs6451812	ENSG00000231752.4	EMBP1	14.29	1.85e-42	7.82e-36	0.52	0.4	P wave duration;	chr5:45692206	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.967	rs4541665	ENSG00000231752.4	EMBP1	-14.29	1.86e-42	7.84e-36	-0.52	-0.4	P wave duration;	chr5:45796444	chr1:121519112~121571892:+
BRCA	trans	rs1039766	0.925	rs268863	ENSG00000224334.1	AP000357.4	14.29	1.94e-42	8.18e-36	0.65	0.4	Lung adenocarcinoma;Lung cancer;	chr2:65261669	chr22:24686923~24688087:+
BRCA	trans	rs4276421	0.869	rs6451814	ENSG00000231752.4	EMBP1	14.26	2.65e-42	1.11e-35	0.52	0.4	P wave duration;	chr5:45734981	chr1:121519112~121571892:+
BRCA	trans	rs9611519	1	rs3818003	ENSG00000268568.1	AC007228.9	-14.26	2.66e-42	1.12e-35	-0.52	-0.4	Neuroticism;	chr22:41213686	chr19:56672574~56673901:-
BRCA	trans	rs7312770	0.612	rs773114	ENSG00000223416.3	RPS26P15	14.25	3.04e-42	1.28e-35	0.46	0.4	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr1:58056133~58056480:-
BRCA	trans	rs1814175	0.935	rs11040465	ENSG00000134612.10	FOLH1B	-14.25	3.05e-42	1.28e-35	-0.49	-0.4	Height;	chr11:49667771	chr11:89639227~89698718:+
BRCA	trans	rs2727020	0.553	rs7479975	ENSG00000134612.10	FOLH1B	-14.25	3.22e-42	1.35e-35	-0.49	-0.4	Coronary artery disease;	chr11:49560412	chr11:89639227~89698718:+
BRCA	trans	rs9425766	0.679	rs7552939	ENSG00000213331.4	RP11-713C19.2	14.25	3.24e-42	1.36e-35	0.46	0.4	Life satisfaction;	chr1:173798305	chr4:187970273~187971284:+
BRCA	trans	rs4276421	0.869	rs10036065	ENSG00000231752.4	EMBP1	-14.24	3.59e-42	1.5e-35	-0.52	-0.4	P wave duration;	chr5:45701926	chr1:121519112~121571892:+
BRCA	trans	rs9876781	1	rs6442117	ENSG00000235912.1	RP1-159A19.3	14.23	3.82e-42	1.6e-35	0.46	0.4	Longevity;	chr3:48378407	chr1:27649419~27649610:+
BRCA	trans	rs10908521	0.685	rs1998977	ENSG00000227183.3	HDGFP1	-14.23	3.95e-42	1.65e-35	-0.52	-0.4	Uric acid clearance;	chr1:156834329	chrX:131646639~131646890:+
BRCA	trans	rs9611519	1	rs4820433	ENSG00000268568.1	AC007228.9	-14.23	4.11e-42	1.72e-35	-0.52	-0.4	Neuroticism;	chr22:41211061	chr19:56672574~56673901:-
BRCA	trans	rs7395662	0.745	rs10838830	ENSG00000134612.10	FOLH1B	14.22	4.79e-42	2e-35	0.51	0.4	HDL cholesterol;	chr11:48212380	chr11:89639227~89698718:+
BRCA	trans	rs4276421	0.736	rs8188290	ENSG00000231752.4	EMBP1	14.21	5.1e-42	2.13e-35	0.52	0.4	P wave duration;	chr5:46047215	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.901	rs10044479	ENSG00000231752.4	EMBP1	14.21	5.1e-42	2.13e-35	0.53	0.4	P wave duration;	chr5:45751434	chr1:121519112~121571892:+
BRCA	trans	rs6132905	0.52	rs2422824	ENSG00000235559.1	NOP56P1	14.2	6.01e-42	2.51e-35	0.47	0.4	Mumps;	chr20:2666724	chr6:28783633~28784004:-
BRCA	trans	rs4276421	0.806	rs6451804	ENSG00000231752.4	EMBP1	14.17	8.13e-42	3.38e-35	0.52	0.4	P wave duration;	chr5:45492103	chr1:121519112~121571892:+
BRCA	trans	rs77688320	0.535	rs6435084	ENSG00000235105.1	RP11-329A14.1	14.16	8.79e-42	3.66e-35	0.49	0.4	Breast cancer;	chr2:201461274	chr1:48435967~48437223:+
BRCA	trans	rs877636	0.74	rs705698	ENSG00000243403.1	RP11-330L19.1	14.16	9.28e-42	3.86e-35	0.52	0.4	Cognitive function;	chr12:55990903	chr15:64592979~64593326:+
BRCA	trans	rs877636	0.692	rs2271194	ENSG00000223416.3	RPS26P15	-14.15	1.07e-41	4.42e-35	-0.46	-0.4	Cognitive function;	chr12:56083910	chr1:58056133~58056480:-
BRCA	trans	rs7662987	1	rs7683704	ENSG00000233859.2	ADH5P4	14.13	1.31e-41	5.43e-35	0.78	0.4	Smoking initiation;	chr4:99083075	chr6:65836930~65838039:-
BRCA	trans	rs6732160	0.619	rs12105975	ENSG00000236165.1	PRADC1P1	14.12	1.49e-41	6.16e-35	0.5	0.4	Intelligence (multi-trait analysis);	chr2:73178921	chr3:36976316~36976840:+
BRCA	trans	rs4276421	0.87	rs4257782	ENSG00000231752.4	EMBP1	14.12	1.57e-41	6.47e-35	0.51	0.4	P wave duration;	chr5:45750292	chr1:121519112~121571892:+
BRCA	trans	rs7395662	0.927	rs4882141	ENSG00000134612.10	FOLH1B	-14.11	1.7e-41	7.03e-35	-0.51	-0.4	HDL cholesterol;	chr11:48605973	chr11:89639227~89698718:+
BRCA	trans	rs77688320	0.517	rs2287054	ENSG00000235105.1	RP11-329A14.1	14.1	1.91e-41	7.9e-35	0.49	0.4	Breast cancer;	chr2:201454315	chr1:48435967~48437223:+
BRCA	trans	rs77688320	0.5	rs10931948	ENSG00000235105.1	RP11-329A14.1	14.1	1.91e-41	7.9e-35	0.49	0.4	Breast cancer;	chr2:201459199	chr1:48435967~48437223:+
BRCA	trans	rs9876781	1	rs725310	ENSG00000235912.1	RP1-159A19.3	14.09	2.06e-41	8.5e-35	0.45	0.4	Longevity;	chr3:48377081	chr1:27649419~27649610:+
BRCA	trans	rs77688320	0.517	rs2270315	ENSG00000235105.1	RP11-329A14.1	14.08	2.32e-41	9.59e-35	0.49	0.4	Breast cancer;	chr2:201452542	chr1:48435967~48437223:+
BRCA	trans	rs4276421	0.869	rs7736561	ENSG00000231752.4	EMBP1	14.08	2.5e-41	1.03e-34	0.52	0.4	P wave duration;	chr5:45716294	chr1:121519112~121571892:+
BRCA	trans	rs5022636	0.533	rs1752387	ENSG00000180764.13	PIPSL	-14.08	2.53e-41	1.04e-34	-0.57	-0.4	Gut microbiota (functional units);	chr1:151341903	chr10:93958191~93961540:-
BRCA	trans	rs7395662	0.853	rs10769356	ENSG00000134612.10	FOLH1B	-14.06	2.93e-41	1.21e-34	-0.5	-0.4	HDL cholesterol;	chr11:48423102	chr11:89639227~89698718:+
BRCA	trans	rs7395662	0.853	rs35255233	ENSG00000134612.10	FOLH1B	-14.06	3.15e-41	1.3e-34	-0.5	-0.4	HDL cholesterol;	chr11:48421318	chr11:89639227~89698718:+
BRCA	trans	rs9876781	1	rs2885510	ENSG00000235912.1	RP1-159A19.3	14.05	3.28e-41	1.35e-34	0.45	0.4	Longevity;	chr3:48376736	chr1:27649419~27649610:+
BRCA	trans	rs9876781	1	rs725309	ENSG00000235912.1	RP1-159A19.3	14.05	3.28e-41	1.35e-34	0.45	0.4	Longevity;	chr3:48377218	chr1:27649419~27649610:+
BRCA	trans	rs4276421	0.869	rs2580258	ENSG00000231752.4	EMBP1	14.05	3.29e-41	1.36e-34	0.52	0.4	P wave duration;	chr5:45586815	chr1:121519112~121571892:+
BRCA	trans	rs11039571	0.588	rs61917001	ENSG00000134612.10	FOLH1B	14.04	3.92e-41	1.61e-34	0.61	0.4	D-dimer levels;	chr11:48212115	chr11:89639227~89698718:+
BRCA	trans	rs877636	0.669	rs7297175	ENSG00000233778.3	RP11-777J24.1	-14.03	4.46e-41	1.83e-34	-0.45	-0.4	Cognitive function;	chr12:56080024	chr8:92144088~92144435:-
BRCA	trans	rs4276421	0.776	rs13175193	ENSG00000231752.4	EMBP1	14.03	4.47e-41	1.84e-34	0.51	0.4	P wave duration;	chr5:45408894	chr1:121519112~121571892:+
BRCA	trans	rs77688320	0.517	rs10497868	ENSG00000235105.1	RP11-329A14.1	-14.03	4.61e-41	1.9e-34	-0.48	-0.4	Breast cancer;	chr2:201439317	chr1:48435967~48437223:+
BRCA	trans	rs7395662	0.853	rs10838885	ENSG00000134612.10	FOLH1B	-14.02	4.79e-41	1.97e-34	-0.5	-0.4	HDL cholesterol;	chr11:48377254	chr11:89639227~89698718:+
BRCA	trans	rs10940346	0.601	rs7712849	ENSG00000231752.4	EMBP1	14.02	4.93e-41	2.03e-34	0.51	0.4	Schizophrenia;	chr5:50407774	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.869	rs1351720	ENSG00000231752.4	EMBP1	14.02	4.96e-41	2.04e-34	0.51	0.4	P wave duration;	chr5:45561801	chr1:121519112~121571892:+
BRCA	trans	rs1039766	1	rs268864	ENSG00000224334.1	AP000357.4	-14.02	5.03e-41	2.07e-34	-0.64	-0.4	Lung adenocarcinoma;Lung cancer;	chr2:65262608	chr22:24686923~24688087:+
BRCA	trans	rs4276421	0.806	rs13162651	ENSG00000231752.4	EMBP1	14	5.99e-41	2.45e-34	0.51	0.4	P wave duration;	chr5:45409798	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.901	rs12110137	ENSG00000231752.4	EMBP1	14	6.46e-41	2.65e-34	0.51	0.4	P wave duration;	chr5:45727764	chr1:121519112~121571892:+
BRCA	trans	rs7554547	0.69	rs1474577	ENSG00000261819.1	RP11-680G24.4	13.99	6.61e-41	2.7e-34	0.51	0.4	Nonsyndromic cleft lip with cleft palate;	chr1:11887712	chr16:14988259~14990160:-
BRCA	trans	rs9876781	1	rs7653691	ENSG00000235912.1	RP1-159A19.3	13.99	6.9e-41	2.82e-34	0.45	0.4	Longevity;	chr3:48378199	chr1:27649419~27649610:+
BRCA	trans	rs4276421	0.845	rs4426926	ENSG00000231752.4	EMBP1	13.97	8.7e-41	3.55e-34	0.51	0.4	P wave duration;	chr5:45994241	chr1:121519112~121571892:+
BRCA	trans	rs7312770	0.612	rs773114	ENSG00000234513.1	AC073072.7	13.97	9.03e-41	3.69e-34	0.47	0.4	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr7:22773646~22773993:-
BRCA	trans	rs4276421	0.901	rs35381866	ENSG00000231752.4	EMBP1	13.95	1.16e-40	4.71e-34	0.5	0.4	P wave duration;	chr5:45690085	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.776	rs4133429	ENSG00000231752.4	EMBP1	13.93	1.42e-40	5.76e-34	0.51	0.4	P wave duration;	chr5:45403633	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.806	rs6451801	ENSG00000231752.4	EMBP1	13.93	1.42e-40	5.78e-34	0.5	0.4	P wave duration;	chr5:45439331	chr1:121519112~121571892:+
BRCA	trans	rs11039798	0.66	rs717897	ENSG00000134612.10	FOLH1B	-13.92	1.58e-40	6.44e-34	-0.6	-0.4	Axial length;	chr11:48354052	chr11:89639227~89698718:+
BRCA	trans	rs9876781	0.967	rs2885509	ENSG00000235912.1	RP1-159A19.3	13.91	1.86e-40	7.57e-34	0.45	0.4	Longevity;	chr3:48376729	chr1:27649419~27649610:+
BRCA	trans	rs7662987	0.793	rs28730602	ENSG00000233859.2	ADH5P4	13.91	1.87e-40	7.6e-34	0.69	0.4	Smoking initiation;	chr4:99080531	chr6:65836930~65838039:-
BRCA	trans	rs7312770	1	rs7312770	ENSG00000235459.5	RPS26P31	-13.89	2.29e-40	9.28e-34	-0.42	-0.4	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr7:122681315~122681662:+
BRCA	trans	rs4276421	0.805	rs13354798	ENSG00000231752.4	EMBP1	13.89	2.4e-40	9.73e-34	0.51	0.4	P wave duration;	chr5:45456975	chr1:121519112~121571892:+
BRCA	trans	rs7554547	0.69	rs6667637	ENSG00000261819.1	RP11-680G24.4	13.88	2.63e-40	1.06e-33	0.5	0.39	Nonsyndromic cleft lip with cleft palate;	chr1:11887900	chr16:14988259~14990160:-
BRCA	trans	rs7937890	0.874	rs2303972	ENSG00000236360.2	RP11-334A14.2	-13.87	3.03e-40	1.22e-33	-0.51	-0.39	Mitochondrial DNA levels;	chr11:14281736	chr1:52993201~52993702:-
BRCA	trans	rs4276421	0.806	rs6892290	ENSG00000231752.4	EMBP1	13.87	3.03e-40	1.23e-33	0.5	0.39	P wave duration;	chr5:45427035	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.806	rs13169726	ENSG00000231752.4	EMBP1	13.85	3.75e-40	1.51e-33	0.5	0.39	P wave duration;	chr5:45444967	chr1:121519112~121571892:+
BRCA	trans	rs9876781	1	rs9849509	ENSG00000235912.1	RP1-159A19.3	-13.84	4.19e-40	1.69e-33	-0.45	-0.39	Longevity;	chr3:48442021	chr1:27649419~27649610:+
BRCA	trans	rs9876781	1	rs60512868	ENSG00000235912.1	RP1-159A19.3	-13.84	4.19e-40	1.69e-33	-0.45	-0.39	Longevity;	chr3:48442035	chr1:27649419~27649610:+
BRCA	trans	rs7937890	0.904	rs7484197	ENSG00000236360.2	RP11-334A14.2	13.83	4.44e-40	1.79e-33	0.5	0.39	Mitochondrial DNA levels;	chr11:14262108	chr1:52993201~52993702:-
BRCA	trans	rs877636	0.692	rs2271194	ENSG00000233778.3	RP11-777J24.1	-13.82	5.11e-40	2.06e-33	-0.45	-0.39	Cognitive function;	chr12:56083910	chr8:92144088~92144435:-
BRCA	trans	rs4276421	0.806	rs2337412	ENSG00000231752.4	EMBP1	13.8	6.29e-40	2.53e-33	0.5	0.39	P wave duration;	chr5:45483410	chr1:121519112~121571892:+
BRCA	trans	rs2657294	0.965	rs10824286	ENSG00000172974.11	AC007318.5	13.8	6.35e-40	2.55e-33	0.47	0.39	Pneumonia;	chr10:75172251	chr2:65205108~65205988:+
BRCA	trans	rs877636	1	rs2292239	ENSG00000212994.5	RPS26P6	13.8	6.44e-40	2.59e-33	0.5	0.39	Cognitive function;	chr12:56088396	chr8:100895771~100896118:+
BRCA	trans	rs4276421	0.806	rs7732970	ENSG00000231752.4	EMBP1	13.79	7.12e-40	2.86e-33	0.5	0.39	P wave duration;	chr5:45452044	chr1:121519112~121571892:+
BRCA	trans	rs9876781	1	rs7636044	ENSG00000235912.1	RP1-159A19.3	-13.79	7.18e-40	2.88e-33	-0.45	-0.39	Longevity;	chr3:48443151	chr1:27649419~27649610:+
BRCA	trans	rs9876781	1	rs4490383	ENSG00000235912.1	RP1-159A19.3	-13.79	7.18e-40	2.88e-33	-0.45	-0.39	Longevity;	chr3:48443275	chr1:27649419~27649610:+
BRCA	trans	rs877636	0.692	rs2271194	ENSG00000227887.1	RPS26P13	-13.79	7.52e-40	3.02e-33	-0.46	-0.39	Cognitive function;	chr12:56083910	chr1:208697369~208697698:-
BRCA	trans	rs9876781	1	rs9817615	ENSG00000235912.1	RP1-159A19.3	-13.79	7.8e-40	3.13e-33	-0.45	-0.39	Longevity;	chr3:48429347	chr1:27649419~27649610:+
BRCA	trans	rs4276421	0.806	rs12520124	ENSG00000231752.4	EMBP1	13.78	8.28e-40	3.32e-33	0.5	0.39	P wave duration;	chr5:45434917	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.967	rs10941703	ENSG00000231752.4	EMBP1	-13.78	8.32e-40	3.33e-33	-0.5	-0.39	P wave duration;	chr5:45781770	chr1:121519112~121571892:+
BRCA	trans	rs877636	0.702	rs773111	ENSG00000225071.1	GS1-184P14.2	13.78	8.52e-40	3.41e-33	0.51	0.39	Cognitive function;	chr12:55981956	chrX:24429573~24429920:-
BRCA	trans	rs877636	0.692	rs11171739	ENSG00000204652.6	RPS26P8	13.77	8.87e-40	3.55e-33	0.47	0.39	Cognitive function;	chr12:56076841	chr17:45608571~45608918:+
BRCA	trans	rs877636	0.702	rs773110	ENSG00000225071.1	GS1-184P14.2	13.77	9.49e-40	3.79e-33	0.51	0.39	Cognitive function;	chr12:55981353	chrX:24429573~24429920:-
BRCA	trans	rs4276421	0.776	rs7723380	ENSG00000231752.4	EMBP1	13.77	9.5e-40	3.8e-33	0.5	0.39	P wave duration;	chr5:45428433	chr1:121519112~121571892:+
BRCA	trans	rs10037055	0.853	rs10077929	ENSG00000217325.2	PRELID1P1	13.77	9.54e-40	3.81e-33	0.53	0.39	Migraine without aura;	chr5:177270843	chr6:126643488~126644390:+
BRCA	trans	rs4276421	0.806	rs6860200	ENSG00000231752.4	EMBP1	13.77	9.61e-40	3.84e-33	0.5	0.39	P wave duration;	chr5:45440241	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.776	rs7717787	ENSG00000231752.4	EMBP1	13.76	1.03e-39	4.13e-33	0.5	0.39	P wave duration;	chr5:45466514	chr1:121519112~121571892:+
BRCA	trans	rs877636	0.74	rs705702	ENSG00000225071.1	GS1-184P14.2	-13.75	1.15e-39	4.57e-33	-0.51	-0.39	Cognitive function;	chr12:55996852	chrX:24429573~24429920:-
BRCA	trans	rs616147	1	rs616147	ENSG00000183298.5	RP11-556K13.1	-13.74	1.35e-39	5.37e-33	-0.6	-0.39	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39492990	chr1:101786340~101787219:-
BRCA	trans	rs10940346	0.601	rs4398636	ENSG00000231752.4	EMBP1	13.73	1.47e-39	5.84e-33	0.5	0.39	Schizophrenia;	chr5:50391957	chr1:121519112~121571892:+
BRCA	trans	rs9876781	1	rs11130171	ENSG00000235912.1	RP1-159A19.3	-13.73	1.5e-39	5.98e-33	-0.45	-0.39	Longevity;	chr3:48421052	chr1:27649419~27649610:+
BRCA	trans	rs9876781	1	rs9883927	ENSG00000235912.1	RP1-159A19.3	-13.73	1.5e-39	5.98e-33	-0.45	-0.39	Longevity;	chr3:48422302	chr1:27649419~27649610:+
BRCA	trans	rs877636	0.702	rs773112	ENSG00000225071.1	GS1-184P14.2	13.73	1.51e-39	6.03e-33	0.51	0.39	Cognitive function;	chr12:55982097	chrX:24429573~24429920:-
BRCA	trans	rs4276421	0.806	rs6414906	ENSG00000231752.4	EMBP1	13.73	1.55e-39	6.17e-33	0.51	0.39	P wave duration;	chr5:45406219	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.524	rs35601537	ENSG00000231752.4	EMBP1	-13.72	1.6e-39	6.37e-33	-0.5	-0.39	Schizophrenia;	chr5:50509460	chr1:121519112~121571892:+
BRCA	trans	rs1039766	0.925	rs268850	ENSG00000224334.1	AP000357.4	13.72	1.65e-39	6.54e-33	0.63	0.39	Lung adenocarcinoma;Lung cancer;	chr2:65281152	chr22:24686923~24688087:+
BRCA	trans	rs1814175	0.817	rs10769598	ENSG00000134612.10	FOLH1B	-13.72	1.66e-39	6.59e-33	-0.48	-0.39	Height;	chr11:49647774	chr11:89639227~89698718:+
BRCA	trans	rs77688320	0.535	rs2540441	ENSG00000235105.1	RP11-329A14.1	-13.72	1.74e-39	6.89e-33	-0.49	-0.39	Breast cancer;	chr2:201481946	chr1:48435967~48437223:+
BRCA	trans	rs10940346	0.601	rs13175165	ENSG00000231752.4	EMBP1	-13.7	2.02e-39	8.01e-33	-0.5	-0.39	Schizophrenia;	chr5:50151463	chr1:121519112~121571892:+
BRCA	trans	rs9876781	1	rs13076076	ENSG00000235912.1	RP1-159A19.3	-13.7	2.04e-39	8.07e-33	-0.44	-0.39	Longevity;	chr3:48437629	chr1:27649419~27649610:+
BRCA	trans	rs7554547	0.69	rs12087996	ENSG00000261819.1	RP11-680G24.4	13.7	2.14e-39	8.48e-33	0.51	0.39	Nonsyndromic cleft lip with cleft palate;	chr1:11897152	chr16:14988259~14990160:-
BRCA	trans	rs4276421	0.719	rs6451802	ENSG00000231752.4	EMBP1	13.69	2.28e-39	9.01e-33	0.51	0.39	P wave duration;	chr5:45440925	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.525	rs7728419	ENSG00000231752.4	EMBP1	-13.68	2.81e-39	1.11e-32	-0.5	-0.39	Schizophrenia;	chr5:50474238	chr1:121519112~121571892:+
BRCA	trans	rs877636	0.702	rs773109	ENSG00000225071.1	GS1-184P14.2	13.67	2.84e-39	1.12e-32	0.51	0.39	Cognitive function;	chr12:55980911	chrX:24429573~24429920:-
BRCA	trans	rs77688320	0.553	rs10804114	ENSG00000235105.1	RP11-329A14.1	13.67	2.97e-39	1.17e-32	0.49	0.39	Breast cancer;	chr2:201402139	chr1:48435967~48437223:+
BRCA	trans	rs877636	0.74	rs772920	ENSG00000225071.1	GS1-184P14.2	13.67	3.05e-39	1.2e-32	0.51	0.39	Cognitive function;	chr12:55996580	chrX:24429573~24429920:-
BRCA	trans	rs4276421	0.837	rs7727890	ENSG00000231752.4	EMBP1	13.67	3.11e-39	1.23e-32	0.5	0.39	P wave duration;	chr5:45478669	chr1:121519112~121571892:+
BRCA	trans	rs9876781	1	rs2290822	ENSG00000235912.1	RP1-159A19.3	-13.67	3.12e-39	1.23e-32	-0.44	-0.39	Longevity;	chr3:48431794	chr1:27649419~27649610:+
BRCA	trans	rs7395662	0.818	rs2200181	ENSG00000134612.10	FOLH1B	-13.66	3.43e-39	1.35e-32	-0.49	-0.39	HDL cholesterol;	chr11:48391623	chr11:89639227~89698718:+
BRCA	trans	rs877636	0.702	rs61937249	ENSG00000225071.1	GS1-184P14.2	13.66	3.53e-39	1.39e-32	0.51	0.39	Cognitive function;	chr12:55988132	chrX:24429573~24429920:-
BRCA	trans	rs10940346	0.601	rs9291925	ENSG00000231752.4	EMBP1	13.65	3.73e-39	1.46e-32	0.5	0.39	Schizophrenia;	chr5:50320129	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.521	rs7730857	ENSG00000231752.4	EMBP1	13.65	3.73e-39	1.46e-32	0.49	0.39	Schizophrenia;	chr5:50361516	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.502	rs77189370	ENSG00000231752.4	EMBP1	13.65	3.95e-39	1.55e-32	0.49	0.39	Schizophrenia;	chr5:50334920	chr1:121519112~121571892:+
BRCA	trans	rs7554547	0.69	rs7524721	ENSG00000261819.1	RP11-680G24.4	13.65	3.97e-39	1.56e-32	0.5	0.39	Nonsyndromic cleft lip with cleft palate;	chr1:11890119	chr16:14988259~14990160:-
BRCA	trans	rs10940346	0.601	rs4637546	ENSG00000231752.4	EMBP1	13.64	4.08e-39	1.6e-32	0.49	0.39	Schizophrenia;	chr5:50358359	chr1:121519112~121571892:+
BRCA	trans	rs877636	0.702	rs773111	ENSG00000212994.5	RPS26P6	13.64	4.28e-39	1.67e-32	0.54	0.39	Cognitive function;	chr12:55981956	chr8:100895771~100896118:+
BRCA	trans	rs10940346	0.601	rs10940242	ENSG00000231752.4	EMBP1	13.64	4.36e-39	1.7e-32	0.49	0.39	Schizophrenia;	chr5:50351018	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.56	rs10039233	ENSG00000231752.4	EMBP1	13.64	4.36e-39	1.7e-32	0.49	0.39	Schizophrenia;	chr5:50351630	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.601	rs11959569	ENSG00000231752.4	EMBP1	13.63	4.59e-39	1.79e-32	0.49	0.39	Schizophrenia;	chr5:50369429	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.601	rs7710841	ENSG00000231752.4	EMBP1	13.63	4.6e-39	1.8e-32	0.49	0.39	Schizophrenia;	chr5:50349986	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.601	rs7722623	ENSG00000231752.4	EMBP1	13.63	4.6e-39	1.8e-32	0.49	0.39	Schizophrenia;	chr5:50350496	chr1:121519112~121571892:+
BRCA	trans	rs2727020	0.513	rs10839307	ENSG00000134612.10	FOLH1B	-13.63	4.73e-39	1.85e-32	-0.48	-0.39	Coronary artery disease;	chr11:49588291	chr11:89639227~89698718:+
BRCA	trans	rs9876781	1	rs2242150	ENSG00000235912.1	RP1-159A19.3	13.63	4.78e-39	1.87e-32	0.44	0.39	Longevity;	chr3:48464565	chr1:27649419~27649610:+
BRCA	trans	rs10940346	0.601	rs10054503	ENSG00000231752.4	EMBP1	13.63	5e-39	1.95e-32	0.49	0.39	Schizophrenia;	chr5:50326746	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.776	rs56908114	ENSG00000231752.4	EMBP1	13.63	5.05e-39	1.97e-32	0.5	0.39	P wave duration;	chr5:45416692	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.54	rs10039622	ENSG00000231752.4	EMBP1	13.62	5.11e-39	1.99e-32	0.49	0.39	Schizophrenia;	chr5:50336720	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.601	rs10064702	ENSG00000231752.4	EMBP1	13.62	5.11e-39	1.99e-32	0.49	0.39	Schizophrenia;	chr5:50336928	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.601	rs13160697	ENSG00000231752.4	EMBP1	13.62	5.11e-39	1.99e-32	0.49	0.39	Schizophrenia;	chr5:50339822	chr1:121519112~121571892:+
BRCA	trans	rs877636	0.702	rs773110	ENSG00000212994.5	RPS26P6	13.62	5.15e-39	2.01e-32	0.54	0.39	Cognitive function;	chr12:55981353	chr8:100895771~100896118:+
BRCA	trans	rs877636	0.702	rs773109	ENSG00000212994.5	RPS26P6	13.62	5.15e-39	2.01e-32	0.54	0.39	Cognitive function;	chr12:55980911	chr8:100895771~100896118:+
BRCA	trans	rs10940346	0.51	rs10038023	ENSG00000231752.4	EMBP1	-13.62	5.17e-39	2.02e-32	-0.49	-0.39	Schizophrenia;	chr5:50280387	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.56	rs6892613	ENSG00000231752.4	EMBP1	13.62	5.28e-39	2.06e-32	0.49	0.39	Schizophrenia;	chr5:50353678	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.601	rs6450056	ENSG00000231752.4	EMBP1	13.62	5.28e-39	2.06e-32	0.49	0.39	Schizophrenia;	chr5:50356692	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.601	rs10073591	ENSG00000231752.4	EMBP1	13.62	5.28e-39	2.06e-32	0.49	0.39	Schizophrenia;	chr5:50359010	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.58	rs10071725	ENSG00000231752.4	EMBP1	13.62	5.28e-39	2.06e-32	0.49	0.39	Schizophrenia;	chr5:50361986	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.601	rs7732000	ENSG00000231752.4	EMBP1	13.62	5.28e-39	2.06e-32	0.49	0.39	Schizophrenia;	chr5:50364779	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.601	rs6450063	ENSG00000231752.4	EMBP1	13.62	5.28e-39	2.06e-32	0.49	0.39	Schizophrenia;	chr5:50374147	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.601	rs10042504	ENSG00000231752.4	EMBP1	13.62	5.28e-39	2.06e-32	0.49	0.39	Schizophrenia;	chr5:50386329	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.601	rs4029989	ENSG00000231752.4	EMBP1	-13.62	5.29e-39	2.06e-32	-0.5	-0.39	Schizophrenia;	chr5:50474501	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.56	rs7293410	ENSG00000231752.4	EMBP1	-13.62	5.39e-39	2.1e-32	-0.5	-0.39	Schizophrenia;	chr5:50163036	chr1:121519112~121571892:+
BRCA	trans	rs616147	0.816	rs1768190	ENSG00000183298.5	RP11-556K13.1	13.62	5.51e-39	2.14e-32	0.59	0.39	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39467949	chr1:101786340~101787219:-
BRCA	trans	rs877636	0.702	rs773112	ENSG00000212994.5	RPS26P6	13.62	5.53e-39	2.15e-32	0.54	0.39	Cognitive function;	chr12:55982097	chr8:100895771~100896118:+
BRCA	trans	rs10940346	0.623	rs6863840	ENSG00000231752.4	EMBP1	13.62	5.53e-39	2.15e-32	0.49	0.39	Schizophrenia;	chr5:50328070	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.58	rs6871761	ENSG00000231752.4	EMBP1	13.62	5.53e-39	2.15e-32	0.49	0.39	Schizophrenia;	chr5:50328134	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.601	rs6877713	ENSG00000231752.4	EMBP1	13.62	5.53e-39	2.15e-32	0.49	0.39	Schizophrenia;	chr5:50329254	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.601	rs4337857	ENSG00000231752.4	EMBP1	13.62	5.53e-39	2.15e-32	0.49	0.39	Schizophrenia;	chr5:50329735	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.562	rs34601168	ENSG00000231752.4	EMBP1	13.62	5.53e-39	2.15e-32	0.49	0.39	Schizophrenia;	chr5:50330561	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.601	rs35740733	ENSG00000231752.4	EMBP1	13.62	5.53e-39	2.15e-32	0.49	0.39	Schizophrenia;	chr5:50330771	chr1:121519112~121571892:+
BRCA	trans	rs877636	0.702	rs61937249	ENSG00000212994.5	RPS26P6	13.61	6.05e-39	2.35e-32	0.54	0.39	Cognitive function;	chr12:55988132	chr8:100895771~100896118:+
BRCA	trans	rs10940346	0.584	rs10061339	ENSG00000231752.4	EMBP1	-13.61	6.16e-39	2.39e-32	-0.5	-0.39	Schizophrenia;	chr5:50475952	chr1:121519112~121571892:+
BRCA	trans	rs9876781	1	rs1459242	ENSG00000235912.1	RP1-159A19.3	13.61	6.17e-39	2.39e-32	0.44	0.39	Longevity;	chr3:48372047	chr1:27649419~27649610:+
BRCA	trans	rs10940346	0.562	rs34950042	ENSG00000231752.4	EMBP1	-13.61	6.19e-39	2.4e-32	-0.5	-0.39	Schizophrenia;	chr5:50479299	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.601	rs3845167	ENSG00000231752.4	EMBP1	-13.61	6.19e-39	2.4e-32	-0.5	-0.39	Schizophrenia;	chr5:50480297	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.601	rs1833900	ENSG00000231752.4	EMBP1	-13.61	6.21e-39	2.41e-32	-0.5	-0.39	Schizophrenia;	chr5:50504668	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.601	rs7722742	ENSG00000231752.4	EMBP1	13.61	6.22e-39	2.41e-32	0.49	0.39	Schizophrenia;	chr5:50320312	chr1:121519112~121571892:+
BRCA	trans	rs1039766	1	rs268870	ENSG00000224334.1	AP000357.4	13.61	6.33e-39	2.45e-32	0.63	0.39	Lung adenocarcinoma;Lung cancer;	chr2:65256415	chr22:24686923~24688087:+
BRCA	trans	rs10940346	0.601	rs494540	ENSG00000231752.4	EMBP1	-13.61	6.36e-39	2.46e-32	-0.49	-0.39	Schizophrenia;	chr5:50280228	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.601	rs471455	ENSG00000231752.4	EMBP1	-13.61	6.36e-39	2.46e-32	-0.49	-0.39	Schizophrenia;	chr5:50280427	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.601	rs13360551	ENSG00000231752.4	EMBP1	-13.61	6.36e-39	2.46e-32	-0.49	-0.39	Schizophrenia;	chr5:50287350	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.601	rs4865700	ENSG00000231752.4	EMBP1	-13.6	6.95e-39	2.68e-32	-0.49	-0.39	Schizophrenia;	chr5:50303862	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.601	rs13178993	ENSG00000231752.4	EMBP1	-13.6	6.95e-39	2.68e-32	-0.49	-0.39	Schizophrenia;	chr5:50305256	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.562	rs7736775	ENSG00000231752.4	EMBP1	-13.6	6.95e-39	2.68e-32	-0.49	-0.39	Schizophrenia;	chr5:50472463	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.562	rs6449961	ENSG00000231752.4	EMBP1	13.59	7.22e-39	2.79e-32	0.49	0.39	Schizophrenia;	chr5:50320867	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.601	rs507761	ENSG00000231752.4	EMBP1	-13.59	7.35e-39	2.83e-32	-0.49	-0.39	Schizophrenia;	chr5:50279558	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.601	rs4865685	ENSG00000231752.4	EMBP1	-13.59	7.35e-39	2.83e-32	-0.49	-0.39	Schizophrenia;	chr5:50290682	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.601	rs6449779	ENSG00000231752.4	EMBP1	-13.59	7.35e-39	2.83e-32	-0.49	-0.39	Schizophrenia;	chr5:50290876	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.58	rs9688065	ENSG00000231752.4	EMBP1	-13.59	7.54e-39	2.91e-32	-0.5	-0.39	Schizophrenia;	chr5:50147444	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.601	rs4865699	ENSG00000231752.4	EMBP1	-13.59	7.6e-39	2.93e-32	-0.49	-0.39	Schizophrenia;	chr5:50303347	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.837	rs7706140	ENSG00000231752.4	EMBP1	13.59	7.92e-39	3.05e-32	0.5	0.39	P wave duration;	chr5:45474712	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.562	rs10940336	ENSG00000231752.4	EMBP1	-13.59	8.04e-39	3.1e-32	-0.5	-0.39	Schizophrenia;	chr5:50505020	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.601	rs4865698	ENSG00000231752.4	EMBP1	-13.58	8.06e-39	3.1e-32	-0.49	-0.39	Schizophrenia;	chr5:50303332	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.507	rs7293474	ENSG00000231752.4	EMBP1	-13.58	8.4e-39	3.23e-32	-0.5	-0.39	P wave duration;	chr5:46286705	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.601	rs7446951	ENSG00000231752.4	EMBP1	-13.58	8.63e-39	3.32e-32	-0.5	-0.39	Schizophrenia;	chr5:50314949	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.519	rs10940514	ENSG00000231752.4	EMBP1	-13.58	8.72e-39	3.35e-32	-0.5	-0.39	Schizophrenia;	chr5:50146166	chr1:121519112~121571892:+
BRCA	trans	rs877636	0.692	rs11171739	ENSG00000242970.2	AC068522.4	13.58	8.78e-39	3.38e-32	0.51	0.39	Cognitive function;	chr12:56076841	chr8:58588420~58588764:-
BRCA	trans	rs10940346	0.562	rs4379243	ENSG00000231752.4	EMBP1	-13.57	9.91e-39	3.8e-32	-0.49	-0.39	Schizophrenia;	chr5:50149933	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.837	rs755048	ENSG00000231752.4	EMBP1	-13.57	9.95e-39	3.82e-32	-0.51	-0.39	P wave duration;	chr5:45596256	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.837	rs10069510	ENSG00000231752.4	EMBP1	-13.57	9.95e-39	3.82e-32	-0.51	-0.39	P wave duration;	chr5:45596937	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.601	rs6450098	ENSG00000231752.4	EMBP1	13.56	1.03e-38	3.95e-32	0.49	0.39	Schizophrenia;	chr5:50420076	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.601	rs2036902	ENSG00000231752.4	EMBP1	13.56	1.05e-38	4.01e-32	0.49	0.39	Schizophrenia;	chr5:50401098	chr1:121519112~121571892:+
BRCA	trans	rs2657294	0.965	rs10824285	ENSG00000172974.11	AC007318.5	13.56	1.06e-38	4.05e-32	0.46	0.39	Pneumonia;	chr10:75153271	chr2:65205108~65205988:+
BRCA	trans	rs7554547	0.667	rs12567187	ENSG00000261819.1	RP11-680G24.4	13.56	1.06e-38	4.08e-32	0.5	0.39	Nonsyndromic cleft lip with cleft palate;	chr1:11896095	chr16:14988259~14990160:-
BRCA	trans	rs7937890	1	rs2970334	ENSG00000236360.2	RP11-334A14.2	-13.56	1.07e-38	4.11e-32	-0.48	-0.39	Mitochondrial DNA levels;	chr11:14307809	chr1:52993201~52993702:-
BRCA	trans	rs10940346	0.601	rs1841103	ENSG00000231752.4	EMBP1	-13.56	1.09e-38	4.16e-32	-0.49	-0.39	Schizophrenia;	chr5:50263913	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.562	rs504773	ENSG00000231752.4	EMBP1	-13.56	1.09e-38	4.16e-32	-0.49	-0.39	Schizophrenia;	chr5:50264656	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.54	rs2199089	ENSG00000231752.4	EMBP1	-13.56	1.09e-38	4.16e-32	-0.49	-0.39	Schizophrenia;	chr5:50199332	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.601	rs4145844	ENSG00000231752.4	EMBP1	-13.56	1.11e-38	4.25e-32	-0.5	-0.39	Schizophrenia;	chr5:50478019	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.58	rs7447926	ENSG00000231752.4	EMBP1	-13.55	1.14e-38	4.35e-32	-0.49	-0.39	Schizophrenia;	chr5:50310902	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.601	rs5011669	ENSG00000231752.4	EMBP1	-13.55	1.16e-38	4.42e-32	-0.5	-0.39	Schizophrenia;	chr5:50311788	chr1:121519112~121571892:+
BRCA	trans	rs2657294	0.965	rs7899946	ENSG00000172974.11	AC007318.5	13.55	1.21e-38	4.62e-32	0.46	0.39	Pneumonia;	chr10:75166013	chr2:65205108~65205988:+
BRCA	trans	rs10940346	0.601	rs7341010	ENSG00000231752.4	EMBP1	-13.55	1.24e-38	4.72e-32	-0.49	-0.39	Schizophrenia;	chr5:50317811	chr1:121519112~121571892:+
BRCA	trans	rs2657294	1	rs2657294	ENSG00000172974.11	AC007318.5	13.55	1.26e-38	4.79e-32	0.47	0.39	Pneumonia;	chr10:75193267	chr2:65205108~65205988:+
BRCA	trans	rs10940346	0.601	rs1511738	ENSG00000231752.4	EMBP1	-13.55	1.28e-38	4.85e-32	-0.49	-0.39	Schizophrenia;	chr5:50313444	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.601	rs10062032	ENSG00000231752.4	EMBP1	-13.55	1.28e-38	4.85e-32	-0.49	-0.39	Schizophrenia;	chr5:50316138	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.601	rs10074359	ENSG00000231752.4	EMBP1	-13.55	1.28e-38	4.85e-32	-0.49	-0.39	Schizophrenia;	chr5:50316423	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.601	rs1606224	ENSG00000231752.4	EMBP1	-13.55	1.28e-38	4.85e-32	-0.49	-0.39	Schizophrenia;	chr5:50317405	chr1:121519112~121571892:+
BRCA	trans	rs9876781	1	rs6794875	ENSG00000235912.1	RP1-159A19.3	-13.54	1.29e-38	4.91e-32	-0.44	-0.39	Longevity;	chr3:48414217	chr1:27649419~27649610:+
BRCA	trans	rs10940346	0.601	rs4495185	ENSG00000231752.4	EMBP1	13.54	1.3e-38	4.94e-32	0.49	0.39	Schizophrenia;	chr5:50415453	chr1:121519112~121571892:+
BRCA	trans	rs877636	1	rs705696	ENSG00000235459.5	RPS26P31	13.54	1.32e-38	5.01e-32	0.49	0.39	Cognitive function;	chr12:56086864	chr7:122681315~122681662:+
BRCA	trans	rs10940346	0.58	rs10940533	ENSG00000231752.4	EMBP1	-13.54	1.32e-38	5.02e-32	-0.49	-0.39	Schizophrenia;	chr5:50146552	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.58	rs4865801	ENSG00000231752.4	EMBP1	-13.54	1.35e-38	5.12e-32	-0.49	-0.39	Schizophrenia;	chr5:50163364	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.584	rs7293449	ENSG00000231752.4	EMBP1	-13.54	1.36e-38	5.16e-32	-0.49	-0.39	Schizophrenia;	chr5:50259959	chr1:121519112~121571892:+
BRCA	trans	rs8175379	0.521	rs8175430	ENSG00000231752.4	EMBP1	-13.54	1.37e-38	5.21e-32	-0.5	-0.39	Interleukin-7 levels;	chr5:46305095	chr1:121519112~121571892:+
BRCA	trans	rs2657294	0.965	rs4746270	ENSG00000172974.11	AC007318.5	13.54	1.38e-38	5.21e-32	0.46	0.39	Pneumonia;	chr10:75185189	chr2:65205108~65205988:+
BRCA	trans	rs10940346	0.601	rs1858343	ENSG00000231752.4	EMBP1	-13.54	1.39e-38	5.28e-32	-0.49	-0.39	Schizophrenia;	chr5:50290180	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.58	rs1858344	ENSG00000231752.4	EMBP1	-13.54	1.39e-38	5.28e-32	-0.49	-0.39	Schizophrenia;	chr5:50290345	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.601	rs526329	ENSG00000231752.4	EMBP1	-13.53	1.44e-38	5.46e-32	-0.49	-0.39	Schizophrenia;	chr5:50276141	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.58	rs6868713	ENSG00000231752.4	EMBP1	-13.53	1.44e-38	5.46e-32	-0.49	-0.39	Schizophrenia;	chr5:50276741	chr1:121519112~121571892:+
BRCA	trans	rs9876781	1	rs898225	ENSG00000235912.1	RP1-159A19.3	13.53	1.47e-38	5.54e-32	0.44	0.39	Longevity;	chr3:48371689	chr1:27649419~27649610:+
BRCA	trans	rs10940346	0.601	rs7717982	ENSG00000231752.4	EMBP1	13.53	1.49e-38	5.64e-32	0.49	0.39	Schizophrenia;	chr5:50401488	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.837	rs2049656	ENSG00000231752.4	EMBP1	-13.53	1.49e-38	5.64e-32	-0.51	-0.39	P wave duration;	chr5:45579590	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.601	rs4865675	ENSG00000231752.4	EMBP1	-13.53	1.61e-38	6.06e-32	-0.49	-0.39	Schizophrenia;	chr5:50279300	chr1:121519112~121571892:+
BRCA	trans	rs11039571	0.544	rs7947811	ENSG00000134612.10	FOLH1B	-13.52	1.62e-38	6.12e-32	-0.59	-0.39	D-dimer levels;	chr11:48146186	chr11:89639227~89698718:+
BRCA	trans	rs10940346	0.601	rs506919	ENSG00000231752.4	EMBP1	-13.52	1.64e-38	6.16e-32	-0.49	-0.39	Schizophrenia;	chr5:50279635	chr1:121519112~121571892:+
BRCA	trans	rs72615157	0.716	rs75779608	ENSG00000228546.2	CTA-313A17.3	13.52	1.65e-38	6.2e-32	0.64	0.39	Lung function (FEV1/FVC);	chr7:100171334	chr7:102337316~102339115:+
BRCA	trans	rs10940346	0.601	rs1458766	ENSG00000231752.4	EMBP1	-13.52	1.7e-38	6.38e-32	-0.49	-0.39	Schizophrenia;	chr5:50266457	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.601	rs514195	ENSG00000231752.4	EMBP1	-13.52	1.7e-38	6.38e-32	-0.49	-0.39	Schizophrenia;	chr5:50267123	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.601	rs62365896	ENSG00000231752.4	EMBP1	13.52	1.75e-38	6.56e-32	0.49	0.39	Schizophrenia;	chr5:50422243	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.806	rs34666220	ENSG00000231752.4	EMBP1	13.52	1.78e-38	6.68e-32	0.49	0.39	P wave duration;	chr5:45435884	chr1:121519112~121571892:+
BRCA	trans	rs7937890	0.967	rs963212	ENSG00000236360.2	RP11-334A14.2	-13.52	1.79e-38	6.72e-32	-0.48	-0.39	Mitochondrial DNA levels;	chr11:14303186	chr1:52993201~52993702:-
BRCA	trans	rs3779195	0.929	rs10953259	ENSG00000225169.1	BRI3P1	-13.52	1.81e-38	6.79e-32	-0.6	-0.39	Sex hormone-binding globulin levels;	chr7:98383795	chr1:100213293~100213670:+
BRCA	trans	rs4276421	0.806	rs6892594	ENSG00000231752.4	EMBP1	13.51	1.81e-38	6.81e-32	0.49	0.39	P wave duration;	chr5:45427071	chr1:121519112~121571892:+
BRCA	trans	rs9876781	1	rs6442123	ENSG00000235912.1	RP1-159A19.3	-13.51	1.82e-38	6.82e-32	-0.44	-0.39	Longevity;	chr3:48458887	chr1:27649419~27649610:+
BRCA	trans	rs9876781	1	rs922075	ENSG00000235912.1	RP1-159A19.3	13.51	1.88e-38	7.04e-32	0.44	0.39	Longevity;	chr3:48447994	chr1:27649419~27649610:+
BRCA	trans	rs10940346	0.601	rs1016620	ENSG00000231752.4	EMBP1	-13.51	1.91e-38	7.15e-32	-0.49	-0.39	Schizophrenia;	chr5:50490763	chr1:121519112~121571892:+
BRCA	trans	rs7312770	0.612	rs773114	ENSG00000196933.5	RPS26P11	13.51	1.91e-38	7.15e-32	0.46	0.39	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chrX:72044545~72044892:+
BRCA	trans	rs10940346	0.562	rs563750	ENSG00000231752.4	EMBP1	-13.51	1.93e-38	7.24e-32	-0.49	-0.39	Schizophrenia;	chr5:50278004	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.52	rs7293339	ENSG00000231752.4	EMBP1	-13.5	2.06e-38	7.72e-32	-0.5	-0.39	Schizophrenia;	chr5:50207465	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.607	rs8188210	ENSG00000231752.4	EMBP1	-13.5	2.06e-38	7.72e-32	-0.5	-0.39	Schizophrenia;	chr5:50211664	chr1:121519112~121571892:+
BRCA	trans	rs6132905	0.52	rs2422823	ENSG00000257956.1	NOP56P3	-13.5	2.09e-38	7.78e-32	-0.5	-0.39	Mumps;	chr20:2665687	chr12:79558782~79559166:+
BRCA	trans	rs10940346	0.601	rs10755228	ENSG00000231752.4	EMBP1	-13.5	2.13e-38	7.94e-32	-0.49	-0.39	Schizophrenia;	chr5:50493498	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.562	rs56251178	ENSG00000231752.4	EMBP1	-13.5	2.13e-38	7.94e-32	-0.49	-0.39	Schizophrenia;	chr5:50494837	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.601	rs6861461	ENSG00000231752.4	EMBP1	13.5	2.15e-38	8.01e-32	0.49	0.39	Schizophrenia;	chr5:50348493	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.58	rs12332500	ENSG00000231752.4	EMBP1	13.5	2.15e-38	8.01e-32	0.49	0.39	Schizophrenia;	chr5:50349021	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.56	rs6450107	ENSG00000231752.4	EMBP1	13.5	2.2e-38	8.17e-32	0.49	0.39	Schizophrenia;	chr5:50430069	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.58	rs58756661	ENSG00000231752.4	EMBP1	13.5	2.2e-38	8.17e-32	0.49	0.39	Schizophrenia;	chr5:50436837	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.56	rs16879094	ENSG00000231752.4	EMBP1	13.5	2.2e-38	8.17e-32	0.49	0.39	Schizophrenia;	chr5:50442603	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.601	rs7720960	ENSG00000231752.4	EMBP1	13.5	2.2e-38	8.17e-32	0.49	0.39	Schizophrenia;	chr5:50450489	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.601	rs6863108	ENSG00000231752.4	EMBP1	13.5	2.2e-38	8.17e-32	0.49	0.39	Schizophrenia;	chr5:50451450	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.56	rs13180267	ENSG00000231752.4	EMBP1	13.5	2.2e-38	8.17e-32	0.49	0.39	Schizophrenia;	chr5:50452300	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.58	rs10044979	ENSG00000231752.4	EMBP1	13.5	2.2e-38	8.17e-32	0.49	0.39	Schizophrenia;	chr5:50464074	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.601	rs10045034	ENSG00000231752.4	EMBP1	13.5	2.2e-38	8.17e-32	0.49	0.39	Schizophrenia;	chr5:50464323	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.54	rs59940663	ENSG00000231752.4	EMBP1	13.5	2.2e-38	8.17e-32	0.49	0.39	Schizophrenia;	chr5:50467345	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.58	rs34586987	ENSG00000231752.4	EMBP1	13.5	2.2e-38	8.17e-32	0.49	0.39	Schizophrenia;	chr5:50467574	chr1:121519112~121571892:+
BRCA	trans	rs2657294	0.965	rs2047951	ENSG00000172974.11	AC007318.5	13.5	2.2e-38	8.17e-32	0.46	0.39	Pneumonia;	chr10:75161310	chr2:65205108~65205988:+
BRCA	trans	rs10940346	0.601	rs552892	ENSG00000231752.4	EMBP1	-13.5	2.22e-38	8.22e-32	-0.49	-0.39	Schizophrenia;	chr5:50269093	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.601	rs496230	ENSG00000231752.4	EMBP1	-13.5	2.22e-38	8.22e-32	-0.49	-0.39	Schizophrenia;	chr5:50275179	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.601	rs35815956	ENSG00000231752.4	EMBP1	13.5	2.25e-38	8.32e-32	0.49	0.39	Schizophrenia;	chr5:50350905	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.58	rs13357429	ENSG00000231752.4	EMBP1	13.49	2.34e-38	8.65e-32	0.49	0.39	Schizophrenia;	chr5:50413616	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.601	rs2353961	ENSG00000231752.4	EMBP1	-13.49	2.4e-38	8.86e-32	-0.49	-0.39	Schizophrenia;	chr5:50491604	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.601	rs7379514	ENSG00000231752.4	EMBP1	-13.49	2.4e-38	8.86e-32	-0.49	-0.39	Schizophrenia;	chr5:50492052	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.601	rs34371354	ENSG00000231752.4	EMBP1	-13.49	2.4e-38	8.86e-32	-0.49	-0.39	Schizophrenia;	chr5:50494203	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.601	rs55843201	ENSG00000231752.4	EMBP1	-13.49	2.4e-38	8.86e-32	-0.49	-0.39	Schizophrenia;	chr5:50494254	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.645	rs6450162	ENSG00000231752.4	EMBP1	-13.49	2.4e-38	8.86e-32	-0.49	-0.39	Schizophrenia;	chr5:50498547	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.601	rs7706105	ENSG00000231752.4	EMBP1	-13.49	2.4e-38	8.86e-32	-0.49	-0.39	Schizophrenia;	chr5:50501745	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.601	rs11948302	ENSG00000231752.4	EMBP1	-13.49	2.4e-38	8.86e-32	-0.49	-0.39	Schizophrenia;	chr5:50502317	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.601	rs10940335	ENSG00000231752.4	EMBP1	-13.49	2.4e-38	8.86e-32	-0.49	-0.39	Schizophrenia;	chr5:50502595	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.58	rs6876902	ENSG00000231752.4	EMBP1	13.49	2.41e-38	8.92e-32	0.49	0.39	Schizophrenia;	chr5:50320934	chr1:121519112~121571892:+
BRCA	trans	rs7662987	0.793	rs4699700	ENSG00000233859.2	ADH5P4	13.49	2.45e-38	9.05e-32	0.67	0.39	Smoking initiation;	chr4:99077184	chr6:65836930~65838039:-
BRCA	trans	rs10940346	0.601	rs7723480	ENSG00000231752.4	EMBP1	13.49	2.48e-38	9.15e-32	0.49	0.39	Schizophrenia;	chr5:50350324	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.562	rs549751	ENSG00000231752.4	EMBP1	-13.48	2.58e-38	9.51e-32	-0.49	-0.39	Schizophrenia;	chr5:50262114	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.601	rs12513730	ENSG00000231752.4	EMBP1	-13.48	2.59e-38	9.55e-32	-0.49	-0.39	Schizophrenia;	chr5:50302800	chr1:121519112~121571892:+
BRCA	trans	rs9876781	0.967	rs1870444	ENSG00000235912.1	RP1-159A19.3	-13.48	2.61e-38	9.64e-32	-0.44	-0.39	Longevity;	chr3:48445369	chr1:27649419~27649610:+
BRCA	trans	rs7937890	1	rs2970335	ENSG00000236360.2	RP11-334A14.2	13.48	2.68e-38	9.88e-32	0.48	0.39	Mitochondrial DNA levels;	chr11:14303855	chr1:52993201~52993702:-
BRCA	trans	rs10940346	0.623	rs4865519	ENSG00000231752.4	EMBP1	-13.48	2.79e-38	1.03e-31	-0.49	-0.39	Schizophrenia;	chr5:50293002	chr1:121519112~121571892:+
BRCA	trans	rs116095464	0.558	rs10065239	ENSG00000185986.11	SDHAP3	13.48	2.82e-38	1.04e-31	0.57	0.39	Breast cancer;	chr5:275173	chr5:1572222~1594620:-
BRCA	trans	rs10940346	0.541	rs10041893	ENSG00000231752.4	EMBP1	13.48	2.83e-38	1.04e-31	0.49	0.39	Schizophrenia;	chr5:50460740	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.58	rs7705284	ENSG00000231752.4	EMBP1	13.47	2.99e-38	1.1e-31	0.49	0.39	Schizophrenia;	chr5:50325574	chr1:121519112~121571892:+
BRCA	trans	rs116095464	0.558	rs56298907	ENSG00000185986.11	SDHAP3	13.47	3.02e-38	1.11e-31	0.57	0.39	Breast cancer;	chr5:283165	chr5:1572222~1594620:-
BRCA	trans	rs116095464	0.558	rs7356535	ENSG00000185986.11	SDHAP3	13.47	3.02e-38	1.11e-31	0.57	0.39	Breast cancer;	chr5:284002	chr5:1572222~1594620:-
BRCA	trans	rs116095464	0.558	rs55833259	ENSG00000185986.11	SDHAP3	13.47	3.02e-38	1.11e-31	0.57	0.39	Breast cancer;	chr5:286613	chr5:1572222~1594620:-
BRCA	trans	rs10940346	0.56	rs2137134	ENSG00000231752.4	EMBP1	13.47	3.16e-38	1.16e-31	0.49	0.39	Schizophrenia;	chr5:50354188	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.54	rs57137858	ENSG00000231752.4	EMBP1	13.47	3.16e-38	1.16e-31	0.49	0.39	Schizophrenia;	chr5:50369737	chr1:121519112~121571892:+
BRCA	trans	rs9876781	1	rs6784322	ENSG00000235912.1	RP1-159A19.3	-13.47	3.22e-38	1.18e-31	-0.45	-0.38	Longevity;	chr3:48380745	chr1:27649419~27649610:+
BRCA	trans	rs10940346	0.623	rs7736990	ENSG00000231752.4	EMBP1	-13.46	3.23e-38	1.19e-31	-0.49	-0.38	Schizophrenia;	chr5:50300008	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.601	rs10079897	ENSG00000231752.4	EMBP1	-13.46	3.23e-38	1.19e-31	-0.49	-0.38	Schizophrenia;	chr5:50300032	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.58	rs28528780	ENSG00000231752.4	EMBP1	13.46	3.32e-38	1.22e-31	0.49	0.38	Schizophrenia;	chr5:50441293	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.601	rs7378969	ENSG00000231752.4	EMBP1	-13.46	3.37e-38	1.24e-31	-0.49	-0.38	Schizophrenia;	chr5:50471925	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.601	rs7724645	ENSG00000231752.4	EMBP1	-13.45	3.62e-38	1.33e-31	-0.49	-0.38	Schizophrenia;	chr5:50299846	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.601	rs524184	ENSG00000231752.4	EMBP1	-13.45	3.75e-38	1.37e-31	-0.49	-0.38	Schizophrenia;	chr5:50276256	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.562	rs555704	ENSG00000231752.4	EMBP1	-13.45	3.75e-38	1.37e-31	-0.49	-0.38	Schizophrenia;	chr5:50277066	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.571	rs6414908	ENSG00000231752.4	EMBP1	13.45	3.79e-38	1.39e-31	0.51	0.38	P wave duration;	chr5:45879332	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.562	rs559096	ENSG00000231752.4	EMBP1	-13.45	3.87e-38	1.42e-31	-0.49	-0.38	Schizophrenia;	chr5:50226512	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.601	rs2353221	ENSG00000231752.4	EMBP1	-13.45	3.87e-38	1.42e-31	-0.49	-0.38	Schizophrenia;	chr5:50299085	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.541	rs4865914	ENSG00000231752.4	EMBP1	-13.45	3.92e-38	1.43e-31	-0.49	-0.38	Schizophrenia;	chr5:50173322	chr1:121519112~121571892:+
BRCA	trans	rs9876781	1	rs6770470	ENSG00000235912.1	RP1-159A19.3	-13.45	3.95e-38	1.45e-31	-0.44	-0.38	Longevity;	chr3:48393659	chr1:27649419~27649610:+
BRCA	trans	rs9876781	1	rs6810060	ENSG00000235912.1	RP1-159A19.3	-13.45	3.99e-38	1.46e-31	-0.44	-0.38	Longevity;	chr3:48393284	chr1:27649419~27649610:+
BRCA	trans	rs10940346	0.542	rs2219452	ENSG00000231752.4	EMBP1	-13.45	4.05e-38	1.48e-31	-0.5	-0.38	Schizophrenia;	chr5:50209813	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.601	rs1511737	ENSG00000231752.4	EMBP1	-13.44	4.1e-38	1.5e-31	-0.49	-0.38	Schizophrenia;	chr5:50312308	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.524	rs1458763	ENSG00000231752.4	EMBP1	-13.44	4.41e-38	1.61e-31	-0.49	-0.38	Schizophrenia;	chr5:50265531	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.601	rs1458765	ENSG00000231752.4	EMBP1	-13.44	4.41e-38	1.61e-31	-0.49	-0.38	Schizophrenia;	chr5:50266141	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.601	rs13174293	ENSG00000231752.4	EMBP1	13.43	4.62e-38	1.69e-31	0.49	0.38	Schizophrenia;	chr5:50352191	chr1:121519112~121571892:+
BRCA	trans	rs2657294	0.931	rs2804522	ENSG00000172974.11	AC007318.5	13.43	4.82e-38	1.76e-31	0.46	0.38	Pneumonia;	chr10:75159132	chr2:65205108~65205988:+
BRCA	trans	rs10940346	0.601	rs62365901	ENSG00000231752.4	EMBP1	13.42	5.37e-38	1.96e-31	0.49	0.38	Schizophrenia;	chr5:50434497	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.601	rs28500170	ENSG00000231752.4	EMBP1	13.42	5.37e-38	1.96e-31	0.49	0.38	Schizophrenia;	chr5:50441594	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.58	rs13157992	ENSG00000231752.4	EMBP1	13.42	5.37e-38	1.96e-31	0.49	0.38	Schizophrenia;	chr5:50444074	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.601	rs57300567	ENSG00000231752.4	EMBP1	13.42	5.37e-38	1.96e-31	0.49	0.38	Schizophrenia;	chr5:50467359	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.562	rs1674514	ENSG00000231752.4	EMBP1	-13.41	5.74e-38	2.09e-31	-0.49	-0.38	Schizophrenia;	chr5:50269291	chr1:121519112~121571892:+
BRCA	trans	rs7395662	0.853	rs4882054	ENSG00000134612.10	FOLH1B	-13.4	6.47e-38	2.35e-31	-0.48	-0.38	HDL cholesterol;	chr11:48378347	chr11:89639227~89698718:+
BRCA	trans	rs10940346	0.601	rs1674512	ENSG00000231752.4	EMBP1	13.4	6.56e-38	2.38e-31	0.49	0.38	Schizophrenia;	chr5:50268794	chr1:121519112~121571892:+
BRCA	trans	rs1814175	0.791	rs10769625	ENSG00000134612.10	FOLH1B	-13.4	6.81e-38	2.47e-31	-0.46	-0.38	Height;	chr11:49848335	chr11:89639227~89698718:+
BRCA	trans	rs1814175	0.817	rs7947286	ENSG00000134612.10	FOLH1B	-13.4	6.81e-38	2.47e-31	-0.46	-0.38	Height;	chr11:49853105	chr11:89639227~89698718:+
BRCA	trans	rs1814175	0.781	rs2866734	ENSG00000134612.10	FOLH1B	-13.4	6.81e-38	2.47e-31	-0.46	-0.38	Height;	chr11:49864786	chr11:89639227~89698718:+
BRCA	trans	rs10940346	0.537	rs7293378	ENSG00000231752.4	EMBP1	-13.39	7.22e-38	2.61e-31	-0.49	-0.38	Schizophrenia;	chr5:50192402	chr1:121519112~121571892:+
BRCA	trans	rs877636	0.702	rs773112	ENSG00000235459.5	RPS26P31	13.39	7.37e-38	2.66e-31	0.49	0.38	Cognitive function;	chr12:55982097	chr7:122681315~122681662:+
BRCA	trans	rs2657294	0.965	rs7079694	ENSG00000172974.11	AC007318.5	13.39	7.79e-38	2.81e-31	0.46	0.38	Pneumonia;	chr10:75136804	chr2:65205108~65205988:+
BRCA	trans	rs2657294	0.965	rs2395140	ENSG00000172974.11	AC007318.5	13.38	8.21e-38	2.96e-31	0.46	0.38	Pneumonia;	chr10:75139253	chr2:65205108~65205988:+
BRCA	trans	rs2657294	0.965	rs9299525	ENSG00000172974.11	AC007318.5	13.38	8.22e-38	2.97e-31	0.46	0.38	Pneumonia;	chr10:75118267	chr2:65205108~65205988:+
BRCA	trans	rs2657294	0.965	rs2997754	ENSG00000172974.11	AC007318.5	13.38	8.28e-38	2.99e-31	0.46	0.38	Pneumonia;	chr10:75144379	chr2:65205108~65205988:+
BRCA	trans	rs9876781	1	rs2362450	ENSG00000235912.1	RP1-159A19.3	-13.38	8.37e-38	3.02e-31	-0.44	-0.38	Longevity;	chr3:48419904	chr1:27649419~27649610:+
BRCA	trans	rs9876781	1	rs2045554	ENSG00000235912.1	RP1-159A19.3	13.38	8.38e-38	3.02e-31	0.44	0.38	Longevity;	chr3:48453142	chr1:27649419~27649610:+
BRCA	trans	rs877636	0.702	rs773111	ENSG00000235459.5	RPS26P31	13.37	9.31e-38	3.35e-31	0.49	0.38	Cognitive function;	chr12:55981956	chr7:122681315~122681662:+
BRCA	trans	rs2657294	0.965	rs2657285	ENSG00000172974.11	AC007318.5	13.37	9.59e-38	3.45e-31	0.46	0.38	Pneumonia;	chr10:75164166	chr2:65205108~65205988:+
BRCA	trans	rs2657294	0.965	rs2804523	ENSG00000172974.11	AC007318.5	13.37	9.6e-38	3.45e-31	0.46	0.38	Pneumonia;	chr10:75161584	chr2:65205108~65205988:+
BRCA	trans	rs877636	0.669	rs7297175	ENSG00000227887.1	RPS26P13	-13.36	1.03e-37	3.71e-31	-0.44	-0.38	Cognitive function;	chr12:56080024	chr1:208697369~208697698:-
BRCA	trans	rs3779195	0.627	rs6950023	ENSG00000225169.1	BRI3P1	13.36	1.07e-37	3.83e-31	0.62	0.38	Sex hormone-binding globulin levels;	chr7:98286323	chr1:100213293~100213670:+
BRCA	trans	rs3779195	0.627	rs6967728	ENSG00000225169.1	BRI3P1	13.36	1.07e-37	3.83e-31	0.62	0.38	Sex hormone-binding globulin levels;	chr7:98286325	chr1:100213293~100213670:+
BRCA	trans	rs10940346	0.601	rs7709906	ENSG00000231752.4	EMBP1	13.36	1.07e-37	3.84e-31	0.49	0.38	Schizophrenia;	chr5:50299936	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.58	rs9292005	ENSG00000231752.4	EMBP1	13.36	1.1e-37	3.95e-31	0.49	0.38	Schizophrenia;	chr5:50430521	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.601	rs6449802	ENSG00000231752.4	EMBP1	-13.36	1.14e-37	4.07e-31	-0.48	-0.38	Schizophrenia;	chr5:50299390	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.601	rs2137129	ENSG00000231752.4	EMBP1	-13.36	1.14e-37	4.07e-31	-0.48	-0.38	Schizophrenia;	chr5:50300962	chr1:121519112~121571892:+
BRCA	trans	rs55665837	1	rs4412729	ENSG00000236360.2	RP11-334A14.2	13.35	1.21e-37	4.32e-31	0.51	0.38	Vitamin D levels;	chr11:14417454	chr1:52993201~52993702:-
BRCA	trans	rs10940346	0.601	rs62365902	ENSG00000231752.4	EMBP1	13.35	1.27e-37	4.55e-31	0.49	0.38	Schizophrenia;	chr5:50434594	chr1:121519112~121571892:+
BRCA	trans	rs7662987	0.793	rs28730632	ENSG00000233859.2	ADH5P4	13.33	1.47e-37	5.26e-31	0.67	0.38	Smoking initiation;	chr4:99074552	chr6:65836930~65838039:-
BRCA	trans	rs10917477	0.624	rs2745217	ENSG00000224237.1	MINOS1P3	-13.33	1.49e-37	5.33e-31	-0.45	-0.38	Thyroid function;	chr1:19595253	chr3:27214816~27215018:-
BRCA	trans	rs877636	0.692	rs11171739	ENSG00000243538.1	CTB-55B8.1	13.33	1.51e-37	5.4e-31	0.43	0.38	Cognitive function;	chr12:56076841	chr5:16902294~16902641:-
BRCA	trans	rs877636	0.702	rs773110	ENSG00000235459.5	RPS26P31	13.33	1.54e-37	5.51e-31	0.49	0.38	Cognitive function;	chr12:55981353	chr7:122681315~122681662:+
BRCA	trans	rs877636	1	rs877636	ENSG00000235459.5	RPS26P31	-13.32	1.62e-37	5.78e-31	-0.45	-0.38	Cognitive function;	chr12:56086799	chr7:122681315~122681662:+
BRCA	trans	rs77688320	0.553	rs2540331	ENSG00000235105.1	RP11-329A14.1	-13.32	1.65e-37	5.89e-31	-0.48	-0.38	Breast cancer;	chr2:201388150	chr1:48435967~48437223:+
BRCA	trans	rs9876781	0.967	rs1459249	ENSG00000235912.1	RP1-159A19.3	-13.32	1.7e-37	6.07e-31	-0.43	-0.38	Longevity;	chr3:48438208	chr1:27649419~27649610:+
BRCA	trans	rs2657294	0.895	rs2395137	ENSG00000172974.11	AC007318.5	13.32	1.72e-37	6.14e-31	0.45	0.38	Pneumonia;	chr10:75088235	chr2:65205108~65205988:+
BRCA	trans	rs72615157	0.561	rs113844570	ENSG00000228546.2	CTA-313A17.3	13.32	1.78e-37	6.33e-31	0.65	0.38	Lung function (FEV1/FVC);	chr7:100276155	chr7:102337316~102339115:+
BRCA	trans	rs877636	0.692	rs2271194	ENSG00000242970.2	AC068522.4	-13.32	1.8e-37	6.39e-31	-0.5	-0.38	Cognitive function;	chr12:56083910	chr8:58588420~58588764:-
BRCA	trans	rs10940346	0.601	rs2005573	ENSG00000231752.4	EMBP1	-13.31	1.87e-37	6.67e-31	-0.49	-0.38	Schizophrenia;	chr5:50301614	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.601	rs2011540	ENSG00000231752.4	EMBP1	-13.31	1.87e-37	6.67e-31	-0.49	-0.38	Schizophrenia;	chr5:50301634	chr1:121519112~121571892:+
BRCA	trans	rs3779195	0.697	rs1688606	ENSG00000225169.1	BRI3P1	13.31	1.88e-37	6.68e-31	0.6	0.38	Sex hormone-binding globulin levels;	chr7:98345539	chr1:100213293~100213670:+
BRCA	trans	rs10940346	0.601	rs1344339	ENSG00000231752.4	EMBP1	-13.3	2.07e-37	7.36e-31	-0.49	-0.38	Schizophrenia;	chr5:50327987	chr1:121519112~121571892:+
BRCA	trans	rs77688320	0.553	rs2244438	ENSG00000235105.1	RP11-329A14.1	-13.3	2.09e-37	7.42e-31	-0.48	-0.38	Breast cancer;	chr2:201387816	chr1:48435967~48437223:+
BRCA	trans	rs2657294	0.965	rs4746264	ENSG00000172974.11	AC007318.5	13.3	2.21e-37	7.86e-31	0.46	0.38	Pneumonia;	chr10:75114194	chr2:65205108~65205988:+
BRCA	trans	rs2657294	0.796	rs7082123	ENSG00000172974.11	AC007318.5	13.29	2.35e-37	8.34e-31	0.45	0.38	Pneumonia;	chr10:75091101	chr2:65205108~65205988:+
BRCA	trans	rs10940346	0.562	rs7380318	ENSG00000231752.4	EMBP1	-13.29	2.47e-37	8.76e-31	-0.49	-0.38	Schizophrenia;	chr5:50510557	chr1:121519112~121571892:+
BRCA	trans	rs13014235	0.667	rs2540328	ENSG00000235105.1	RP11-329A14.1	-13.29	2.54e-37	9e-31	-0.48	-0.38	Basal cell carcinoma;	chr2:201384337	chr1:48435967~48437223:+
BRCA	trans	rs77688320	0.509	rs2714487	ENSG00000235105.1	RP11-329A14.1	-13.29	2.54e-37	9e-31	-0.48	-0.38	Breast cancer;	chr2:201384837	chr1:48435967~48437223:+
BRCA	trans	rs7662987	0.793	rs12106	ENSG00000233859.2	ADH5P4	13.28	2.55e-37	9.05e-31	0.66	0.38	Smoking initiation;	chr4:99072199	chr6:65836930~65838039:-
BRCA	trans	rs877636	0.702	rs773109	ENSG00000235459.5	RPS26P31	13.28	2.64e-37	9.35e-31	0.49	0.38	Cognitive function;	chr12:55980911	chr7:122681315~122681662:+
BRCA	trans	rs10940346	0.601	rs3849669	ENSG00000231752.4	EMBP1	13.28	2.7e-37	9.56e-31	0.49	0.38	Schizophrenia;	chr5:50365710	chr1:121519112~121571892:+
BRCA	trans	rs2657294	0.895	rs3088142	ENSG00000172974.11	AC007318.5	13.28	2.77e-37	9.82e-31	0.45	0.38	Pneumonia;	chr10:75094806	chr2:65205108~65205988:+
BRCA	trans	rs77688320	0.553	rs2540330	ENSG00000235105.1	RP11-329A14.1	-13.28	2.82e-37	9.97e-31	-0.48	-0.38	Breast cancer;	chr2:201388133	chr1:48435967~48437223:+
BRCA	trans	rs4276421	0.837	rs7446182	ENSG00000231752.4	EMBP1	-13.27	2.97e-37	1.05e-30	-0.48	-0.38	P wave duration;	chr5:45401715	chr1:121519112~121571892:+
BRCA	trans	rs7395662	0.782	rs4882064	ENSG00000134612.10	FOLH1B	13.27	3.18e-37	1.12e-30	0.47	0.38	HDL cholesterol;	chr11:48434205	chr11:89639227~89698718:+
BRCA	trans	rs77688320	0.553	rs12473387	ENSG00000235105.1	RP11-329A14.1	13.26	3.27e-37	1.15e-30	0.47	0.38	Breast cancer;	chr2:201415778	chr1:48435967~48437223:+
BRCA	trans	rs77688320	0.553	rs4507084	ENSG00000235105.1	RP11-329A14.1	13.26	3.27e-37	1.15e-30	0.47	0.38	Breast cancer;	chr2:201420377	chr1:48435967~48437223:+
BRCA	trans	rs7662987	0.793	rs7669660	ENSG00000233859.2	ADH5P4	13.26	3.52e-37	1.24e-30	0.65	0.38	Smoking initiation;	chr4:99071451	chr6:65836930~65838039:-
BRCA	trans	rs10940346	0.601	rs12697055	ENSG00000231752.4	EMBP1	13.26	3.55e-37	1.25e-30	0.48	0.38	Schizophrenia;	chr5:50317827	chr1:121519112~121571892:+
BRCA	trans	rs877636	0.74	rs772920	ENSG00000212994.5	RPS26P6	13.25	3.75e-37	1.32e-30	0.53	0.38	Cognitive function;	chr12:55996580	chr8:100895771~100896118:+
BRCA	trans	rs9876781	1	rs9876781	ENSG00000235912.1	RP1-159A19.3	-13.24	4.19e-37	1.48e-30	-0.43	-0.38	Longevity;	chr3:48445934	chr1:27649419~27649610:+
BRCA	trans	rs877636	0.74	rs705702	ENSG00000212994.5	RPS26P6	-13.24	4.21e-37	1.48e-30	-0.52	-0.38	Cognitive function;	chr12:55996852	chr8:100895771~100896118:+
BRCA	trans	rs7662987	0.793	rs12697	ENSG00000233859.2	ADH5P4	-13.24	4.28e-37	1.51e-30	-0.66	-0.38	Smoking initiation;	chr4:99072225	chr6:65836930~65838039:-
BRCA	trans	rs10940346	0.54	rs12521033	ENSG00000231752.4	EMBP1	-13.23	4.91e-37	1.73e-30	-0.49	-0.38	Schizophrenia;	chr5:50145974	chr1:121519112~121571892:+
BRCA	trans	rs2657294	0.861	rs6480769	ENSG00000172974.11	AC007318.5	13.23	4.93e-37	1.73e-30	0.45	0.38	Pneumonia;	chr10:75091745	chr2:65205108~65205988:+
BRCA	trans	rs4276421	0.837	rs10073636	ENSG00000231752.4	EMBP1	-13.23	5.02e-37	1.77e-30	-0.5	-0.38	P wave duration;	chr5:45537197	chr1:121519112~121571892:+
BRCA	trans	rs6132905	0.52	rs2422824	ENSG00000257956.1	NOP56P3	13.22	5.13e-37	1.8e-30	0.48	0.38	Mumps;	chr20:2666724	chr12:79558782~79559166:+
BRCA	trans	rs116095464	0.558	rs10056628	ENSG00000185986.11	SDHAP3	13.22	5.23e-37	1.84e-30	0.55	0.38	Breast cancer;	chr5:279397	chr5:1572222~1594620:-
BRCA	trans	rs10940346	0.601	rs4865676	ENSG00000231752.4	EMBP1	13.22	5.32e-37	1.87e-30	0.48	0.38	Schizophrenia;	chr5:50279343	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.601	rs7448495	ENSG00000231752.4	EMBP1	-13.22	5.34e-37	1.88e-30	-0.48	-0.38	Schizophrenia;	chr5:50300238	chr1:121519112~121571892:+
BRCA	trans	rs7312770	0.612	rs1873914	ENSG00000234513.1	AC073072.7	13.22	5.45e-37	1.91e-30	0.45	0.38	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr7:22773646~22773993:-
BRCA	trans	rs72615157	0.561	rs113401658	ENSG00000228546.2	CTA-313A17.3	13.22	5.47e-37	1.92e-30	0.64	0.38	Lung function (FEV1/FVC);	chr7:100260882	chr7:102337316~102339115:+
BRCA	trans	rs616147	0.962	rs1708104	ENSG00000183298.5	RP11-556K13.1	-13.21	6.3e-37	2.21e-30	-0.57	-0.38	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39493251	chr1:101786340~101787219:-
BRCA	trans	rs3779195	0.929	rs2906184	ENSG00000225169.1	BRI3P1	-13.21	6.3e-37	2.21e-30	-0.6	-0.38	Sex hormone-binding globulin levels;	chr7:98310675	chr1:100213293~100213670:+
BRCA	trans	rs10940346	0.601	rs11960276	ENSG00000231752.4	EMBP1	-13.2	6.68e-37	2.34e-30	-0.48	-0.38	Schizophrenia;	chr5:50265194	chr1:121519112~121571892:+
BRCA	trans	rs877636	0.74	rs772920	ENSG00000235459.5	RPS26P31	13.2	6.71e-37	2.35e-30	0.48	0.38	Cognitive function;	chr12:55996580	chr7:122681315~122681662:+
BRCA	trans	rs2657294	0.929	rs6480771	ENSG00000172974.11	AC007318.5	13.19	7.14e-37	2.5e-30	0.46	0.38	Pneumonia;	chr10:75101922	chr2:65205108~65205988:+
BRCA	trans	rs7395662	0.853	rs4882062	ENSG00000134612.10	FOLH1B	13.19	7.37e-37	2.58e-30	0.47	0.38	HDL cholesterol;	chr11:48431719	chr11:89639227~89698718:+
BRCA	trans	rs877636	0.702	rs61937249	ENSG00000235459.5	RPS26P31	13.19	7.42e-37	2.6e-30	0.48	0.38	Cognitive function;	chr12:55988132	chr7:122681315~122681662:+
BRCA	trans	rs13190036	1	rs6880798	ENSG00000226986.4	RP11-543B16.2	13.19	7.47e-37	2.62e-30	0.57	0.38	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177277456	chr1:211207239~211207897:+
BRCA	trans	rs7395662	0.526	rs4882001	ENSG00000134612.10	FOLH1B	-13.19	7.71e-37	2.7e-30	-0.47	-0.38	HDL cholesterol;	chr11:48525123	chr11:89639227~89698718:+
BRCA	trans	rs2657294	0.965	rs10762658	ENSG00000172974.11	AC007318.5	13.19	7.89e-37	2.76e-30	0.46	0.38	Pneumonia;	chr10:75119804	chr2:65205108~65205988:+
BRCA	trans	rs6732160	0.845	rs6718690	ENSG00000236165.1	PRADC1P1	-13.18	8.15e-37	2.85e-30	-0.49	-0.38	Intelligence (multi-trait analysis);	chr2:73160034	chr3:36976316~36976840:+
BRCA	trans	rs877636	1	rs2292239	ENSG00000235459.5	RPS26P31	13.17	9.6e-37	3.35e-30	0.44	0.38	Cognitive function;	chr12:56088396	chr7:122681315~122681662:+
BRCA	trans	rs10940346	0.58	rs12188257	ENSG00000231752.4	EMBP1	-13.17	9.68e-37	3.38e-30	-0.49	-0.38	Schizophrenia;	chr5:50147242	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.519	rs7293422	ENSG00000231752.4	EMBP1	-13.15	1.21e-36	4.22e-30	-0.49	-0.38	Schizophrenia;	chr5:50146010	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.601	rs1033108	ENSG00000231752.4	EMBP1	13.15	1.24e-36	4.33e-30	0.48	0.38	Schizophrenia;	chr5:50327764	chr1:121519112~121571892:+
BRCA	trans	rs877636	1	rs705696	ENSG00000212994.5	RPS26P6	13.13	1.46e-36	5.07e-30	0.52	0.38	Cognitive function;	chr12:56086864	chr8:100895771~100896118:+
BRCA	trans	rs6732160	0.809	rs13387480	ENSG00000236165.1	PRADC1P1	13.13	1.55e-36	5.39e-30	0.49	0.38	Intelligence (multi-trait analysis);	chr2:73143879	chr3:36976316~36976840:+
BRCA	trans	rs4276421	0.593	rs7448901	ENSG00000231752.4	EMBP1	13.1	2.11e-36	7.32e-30	0.5	0.38	P wave duration;	chr5:45941482	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.615	rs7445658	ENSG00000231752.4	EMBP1	13.1	2.11e-36	7.32e-30	0.5	0.38	P wave duration;	chr5:45941513	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.593	rs10076636	ENSG00000231752.4	EMBP1	13.1	2.11e-36	7.32e-30	0.5	0.38	P wave duration;	chr5:45942052	chr1:121519112~121571892:+
BRCA	trans	rs3779195	0.86	rs12704986	ENSG00000225169.1	BRI3P1	13.09	2.45e-36	8.47e-30	0.59	0.38	Sex hormone-binding globulin levels;	chr7:98357118	chr1:100213293~100213670:+
BRCA	trans	rs3779195	0.858	rs3779196	ENSG00000225169.1	BRI3P1	13.09	2.45e-36	8.47e-30	0.59	0.38	Sex hormone-binding globulin levels;	chr7:98360794	chr1:100213293~100213670:+
BRCA	trans	rs3779195	0.789	rs6965424	ENSG00000225169.1	BRI3P1	13.09	2.45e-36	8.47e-30	0.59	0.38	Sex hormone-binding globulin levels;	chr7:98361813	chr1:100213293~100213670:+
BRCA	trans	rs877636	0.859	rs3741499	ENSG00000212994.5	RPS26P6	-13.08	2.71e-36	9.36e-30	-0.49	-0.38	Cognitive function;	chr12:56080595	chr8:100895771~100896118:+
BRCA	trans	rs7395662	0.784	rs2170661	ENSG00000134612.10	FOLH1B	-13.07	2.79e-36	9.63e-30	-0.47	-0.38	HDL cholesterol;	chr11:48356634	chr11:89639227~89698718:+
BRCA	trans	rs2288327	0.643	rs1559908	ENSG00000269800.1	PLEKHA3P1	-13.07	2.89e-36	9.99e-30	-0.54	-0.38	Atrial fibrillation;	chr2:178471620	chr19:41521043~41521989:-
BRCA	trans	rs4276421	0.869	rs11741075	ENSG00000231752.4	EMBP1	-13.06	3.27e-36	1.13e-29	-0.49	-0.38	P wave duration;	chr5:45556276	chr1:121519112~121571892:+
BRCA	trans	rs77688320	0.553	rs2714488	ENSG00000235105.1	RP11-329A14.1	-13.05	3.67e-36	1.26e-29	-0.47	-0.37	Breast cancer;	chr2:201405050	chr1:48435967~48437223:+
BRCA	trans	rs77688320	0.553	rs2249868	ENSG00000235105.1	RP11-329A14.1	-13.05	3.67e-36	1.26e-29	-0.47	-0.37	Breast cancer;	chr2:201412503	chr1:48435967~48437223:+
BRCA	trans	rs7937890	1	rs7937890	ENSG00000236360.2	RP11-334A14.2	13.04	3.91e-36	1.34e-29	0.47	0.37	Mitochondrial DNA levels;	chr11:14374939	chr1:52993201~52993702:-
BRCA	trans	rs9876781	1	rs9812647	ENSG00000235912.1	RP1-159A19.3	13.04	3.93e-36	1.35e-29	0.44	0.37	Longevity;	chr3:48407507	chr1:27649419~27649610:+
BRCA	trans	rs10940346	0.601	rs10940075	ENSG00000231752.4	EMBP1	-13.04	3.94e-36	1.36e-29	-0.48	-0.37	Schizophrenia;	chr5:50304547	chr1:121519112~121571892:+
BRCA	trans	rs7312770	0.612	rs773114	ENSG00000227887.1	RPS26P13	13.04	4.04e-36	1.39e-29	0.44	0.37	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr1:208697369~208697698:-
BRCA	trans	rs77688320	0.553	rs1558637	ENSG00000235105.1	RP11-329A14.1	-13.04	4.12e-36	1.42e-29	-0.47	-0.37	Breast cancer;	chr2:201398651	chr1:48435967~48437223:+
BRCA	trans	rs3779195	0.929	rs1635612	ENSG00000225169.1	BRI3P1	13.04	4.23e-36	1.45e-29	0.59	0.37	Sex hormone-binding globulin levels;	chr7:98385737	chr1:100213293~100213670:+
BRCA	trans	rs877636	0.859	rs3741499	ENSG00000235459.5	RPS26P31	-13.04	4.27e-36	1.47e-29	-0.44	-0.37	Cognitive function;	chr12:56080595	chr7:122681315~122681662:+
BRCA	trans	rs616147	0.962	rs1513219	ENSG00000183298.5	RP11-556K13.1	13.03	4.51e-36	1.55e-29	0.56	0.37	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39492268	chr1:101786340~101787219:-
BRCA	trans	rs7662987	0.793	rs7684735	ENSG00000233859.2	ADH5P4	13.01	5.76e-36	1.97e-29	0.64	0.37	Smoking initiation;	chr4:99070355	chr6:65836930~65838039:-
BRCA	trans	rs72615157	0.645	rs76281814	ENSG00000228546.2	CTA-313A17.3	13.01	6.04e-36	2.07e-29	0.63	0.37	Lung function (FEV1/FVC);	chr7:100248791	chr7:102337316~102339115:+
BRCA	trans	rs72615157	0.595	rs112241539	ENSG00000228546.2	CTA-313A17.3	13.01	6.04e-36	2.07e-29	0.63	0.37	Lung function (FEV1/FVC);	chr7:100249614	chr7:102337316~102339115:+
BRCA	trans	rs77688320	0.553	rs2540339	ENSG00000235105.1	RP11-329A14.1	-13	6.48e-36	2.22e-29	-0.47	-0.37	Breast cancer;	chr2:201415725	chr1:48435967~48437223:+
BRCA	trans	rs77688320	0.553	rs2540340	ENSG00000235105.1	RP11-329A14.1	-13	6.48e-36	2.22e-29	-0.47	-0.37	Breast cancer;	chr2:201416477	chr1:48435967~48437223:+
BRCA	trans	rs10940346	0.505	rs2219453	ENSG00000231752.4	EMBP1	-13	6.8e-36	2.33e-29	-0.49	-0.37	Schizophrenia;	chr5:50212774	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.601	rs579279	ENSG00000231752.4	EMBP1	-12.99	6.93e-36	2.37e-29	-0.47	-0.37	Schizophrenia;	chr5:50277308	chr1:121519112~121571892:+
BRCA	trans	rs116095464	0.558	rs10065584	ENSG00000185986.11	SDHAP3	12.99	7.47e-36	2.55e-29	0.55	0.37	Breast cancer;	chr5:253882	chr5:1572222~1594620:-
BRCA	trans	rs877636	0.692	rs11171739	ENSG00000234354.3	RPS26P47	12.98	7.7e-36	2.63e-29	0.46	0.37	Cognitive function;	chr12:56076841	chr13:100539901~100540248:-
BRCA	trans	rs877636	0.74	rs705698	ENSG00000225071.1	GS1-184P14.2	12.98	8.34e-36	2.84e-29	0.48	0.37	Cognitive function;	chr12:55990903	chrX:24429573~24429920:-
BRCA	trans	rs12138950	0.681	rs10799822	ENSG00000224237.1	MINOS1P3	12.98	8.52e-36	2.91e-29	0.49	0.37	Hypothyroidism;Thyroid volume;	chr1:19513327	chr3:27214816~27215018:-
BRCA	trans	rs6732160	0.774	rs1367291	ENSG00000236165.1	PRADC1P1	12.97	8.67e-36	2.96e-29	0.48	0.37	Intelligence (multi-trait analysis);	chr2:73147737	chr3:36976316~36976840:+
BRCA	trans	rs12138950	0.711	rs10799821	ENSG00000224237.1	MINOS1P3	12.96	9.91e-36	3.37e-29	0.49	0.37	Hypothyroidism;Thyroid volume;	chr1:19511475	chr3:27214816~27215018:-
BRCA	trans	rs11039798	0.511	rs7948129	ENSG00000134612.10	FOLH1B	-12.95	1.11e-35	3.78e-29	-0.57	-0.37	Axial length;	chr11:48146276	chr11:89639227~89698718:+
BRCA	trans	rs77688320	0.553	rs2080320	ENSG00000235105.1	RP11-329A14.1	12.95	1.16e-35	3.93e-29	0.47	0.37	Breast cancer;	chr2:201514450	chr1:48435967~48437223:+
BRCA	trans	rs77688320	0.553	rs7582946	ENSG00000235105.1	RP11-329A14.1	12.94	1.21e-35	4.12e-29	0.47	0.37	Breast cancer;	chr2:201423969	chr1:48435967~48437223:+
BRCA	trans	rs6732160	0.838	rs13411380	ENSG00000236165.1	PRADC1P1	12.93	1.37e-35	4.65e-29	0.48	0.37	Intelligence (multi-trait analysis);	chr2:73155718	chr3:36976316~36976840:+
BRCA	trans	rs12138950	0.681	rs60066365	ENSG00000224237.1	MINOS1P3	12.93	1.43e-35	4.85e-29	0.48	0.37	Hypothyroidism;Thyroid volume;	chr1:19512191	chr3:27214816~27215018:-
BRCA	trans	rs3779195	0.697	rs13232861	ENSG00000225169.1	BRI3P1	12.92	1.56e-35	5.27e-29	0.59	0.37	Sex hormone-binding globulin levels;	chr7:98299769	chr1:100213293~100213670:+
BRCA	trans	rs877636	0.692	rs2271194	ENSG00000204652.6	RPS26P8	-12.92	1.62e-35	5.48e-29	-0.45	-0.37	Cognitive function;	chr12:56083910	chr17:45608571~45608918:+
BRCA	trans	rs116095464	0.558	rs56081398	ENSG00000185986.11	SDHAP3	12.91	1.68e-35	5.68e-29	0.55	0.37	Breast cancer;	chr5:247203	chr5:1572222~1594620:-
BRCA	trans	rs5022636	0.507	rs2800953	ENSG00000180764.13	PIPSL	-12.91	1.7e-35	5.73e-29	-0.53	-0.37	Gut microbiota (functional units);	chr1:151366094	chr10:93958191~93961540:-
BRCA	trans	rs7312770	0.612	rs1873914	ENSG00000227887.1	RPS26P13	12.91	1.72e-35	5.82e-29	0.44	0.37	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr1:208697369~208697698:-
BRCA	trans	rs10242455	0.717	rs58649180	ENSG00000228834.1	RP11-249L21.4	12.91	1.73e-35	5.86e-29	0.78	0.37	Blood metabolite levels;	chr7:99738422	chr6:108907615~108907873:-
BRCA	trans	rs12138950	0.681	rs4362008	ENSG00000224237.1	MINOS1P3	12.9	1.91e-35	6.46e-29	0.48	0.37	Hypothyroidism;Thyroid volume;	chr1:19511064	chr3:27214816~27215018:-
BRCA	trans	rs6732160	0.845	rs72807999	ENSG00000236165.1	PRADC1P1	12.9	1.94e-35	6.56e-29	0.48	0.37	Intelligence (multi-trait analysis);	chr2:73164567	chr3:36976316~36976840:+
BRCA	trans	rs77688320	0.535	rs10186894	ENSG00000235105.1	RP11-329A14.1	12.9	2.04e-35	6.89e-29	0.47	0.37	Breast cancer;	chr2:201440909	chr1:48435967~48437223:+
BRCA	trans	rs6732160	0.845	rs11894833	ENSG00000236165.1	PRADC1P1	-12.9	2.06e-35	6.95e-29	-0.48	-0.37	Intelligence (multi-trait analysis);	chr2:73161290	chr3:36976316~36976840:+
BRCA	trans	rs6732160	0.809	rs13406142	ENSG00000236165.1	PRADC1P1	12.88	2.41e-35	8.14e-29	0.48	0.37	Intelligence (multi-trait analysis);	chr2:73156970	chr3:36976316~36976840:+
BRCA	trans	rs6732160	0.845	rs6546809	ENSG00000236165.1	PRADC1P1	12.88	2.51e-35	8.44e-29	0.48	0.37	Intelligence (multi-trait analysis);	chr2:73162553	chr3:36976316~36976840:+
BRCA	trans	rs6732160	0.845	rs13413175	ENSG00000236165.1	PRADC1P1	12.88	2.59e-35	8.73e-29	0.48	0.37	Intelligence (multi-trait analysis);	chr2:73162788	chr3:36976316~36976840:+
BRCA	trans	rs72615157	0.634	rs74774557	ENSG00000228546.2	CTA-313A17.3	12.87	2.75e-35	9.25e-29	0.6	0.37	Lung function (FEV1/FVC);	chr7:100212802	chr7:102337316~102339115:+
BRCA	trans	rs10908521	1	rs10908521	ENSG00000227183.3	HDGFP1	12.87	2.83e-35	9.51e-29	0.5	0.37	Uric acid clearance;	chr1:156843858	chrX:131646639~131646890:+
BRCA	trans	rs7312770	1	rs7312770	ENSG00000234513.1	AC073072.7	-12.85	3.51e-35	1.18e-28	-0.41	-0.37	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr7:22773646~22773993:-
BRCA	trans	rs6732160	0.741	rs6546806	ENSG00000236165.1	PRADC1P1	12.84	3.95e-35	1.32e-28	0.48	0.37	Intelligence (multi-trait analysis);	chr2:73159032	chr3:36976316~36976840:+
BRCA	trans	rs9876781	1	rs4858817	ENSG00000235912.1	RP1-159A19.3	12.84	4.04e-35	1.35e-28	0.42	0.37	Longevity;	chr3:48375266	chr1:27649419~27649610:+
BRCA	trans	rs877636	0.859	rs3741499	ENSG00000233778.3	RP11-777J24.1	-12.83	4.2e-35	1.41e-28	-0.44	-0.37	Cognitive function;	chr12:56080595	chr8:92144088~92144435:-
BRCA	trans	rs4276421	0.638	rs6895453	ENSG00000231752.4	EMBP1	12.82	4.84e-35	1.62e-28	0.49	0.37	P wave duration;	chr5:45850134	chr1:121519112~121571892:+
BRCA	trans	rs77688320	0.553	rs2540449	ENSG00000235105.1	RP11-329A14.1	-12.82	4.85e-35	1.62e-28	-0.46	-0.37	Breast cancer;	chr2:201451036	chr1:48435967~48437223:+
BRCA	trans	rs13177918	0.798	rs12514700	ENSG00000226396.1	RP5-1056L3.3	12.82	4.9e-35	1.64e-28	0.43	0.37	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150466096	chr1:19608114~19608568:+
BRCA	trans	rs77688320	0.573	rs2080327	ENSG00000235105.1	RP11-329A14.1	-12.81	5.2e-35	1.73e-28	-0.46	-0.37	Breast cancer;	chr2:201461495	chr1:48435967~48437223:+
BRCA	trans	rs877636	0.74	rs705702	ENSG00000235459.5	RPS26P31	-12.81	5.37e-35	1.79e-28	-0.47	-0.37	Cognitive function;	chr12:55996852	chr7:122681315~122681662:+
BRCA	trans	rs10242455	0.717	rs72494455	ENSG00000228834.1	RP11-249L21.4	12.81	5.5e-35	1.83e-28	0.77	0.37	Blood metabolite levels;	chr7:99739154	chr6:108907615~108907873:-
BRCA	trans	rs7312770	0.612	rs1873914	ENSG00000223416.3	RPS26P15	12.81	5.62e-35	1.87e-28	0.43	0.37	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr1:58056133~58056480:-
BRCA	trans	rs6732160	0.809	rs6728959	ENSG00000236165.1	PRADC1P1	12.8	5.78e-35	1.92e-28	0.48	0.37	Intelligence (multi-trait analysis);	chr2:73156199	chr3:36976316~36976840:+
BRCA	trans	rs5022636	0.507	rs4579761	ENSG00000180764.13	PIPSL	12.8	5.84e-35	1.94e-28	0.53	0.37	Gut microbiota (functional units);	chr1:151363433	chr10:93958191~93961540:-
BRCA	trans	rs4276421	0.615	rs4626346	ENSG00000231752.4	EMBP1	12.8	6.09e-35	2.02e-28	0.49	0.37	P wave duration;	chr5:45857435	chr1:121519112~121571892:+
BRCA	trans	rs9876781	0.933	rs6442124	ENSG00000235912.1	RP1-159A19.3	-12.79	6.72e-35	2.23e-28	-0.43	-0.37	Longevity;	chr3:48463903	chr1:27649419~27649610:+
BRCA	trans	rs7399018	1	rs7399018	ENSG00000223825.5	DAZAP2P1	-12.79	6.97e-35	2.31e-28	-0.51	-0.37	Cisplatin-induced ototoxicity;	chr12:51216581	chr2:202201384~202201886:-
BRCA	trans	rs6732160	0.774	rs11890053	ENSG00000236165.1	PRADC1P1	12.78	7.16e-35	2.37e-28	0.48	0.37	Intelligence (multi-trait analysis);	chr2:73146320	chr3:36976316~36976840:+
BRCA	trans	rs77688320	0.553	rs2243791	ENSG00000235105.1	RP11-329A14.1	-12.78	7.28e-35	2.41e-28	-0.47	-0.37	Breast cancer;	chr2:201478079	chr1:48435967~48437223:+
BRCA	trans	rs877636	1	rs4759229	ENSG00000212994.5	RPS26P6	-12.78	7.4e-35	2.45e-28	-0.48	-0.37	Cognitive function;	chr12:56080696	chr8:100895771~100896118:+
BRCA	trans	rs10940346	0.601	rs7442762	ENSG00000231752.4	EMBP1	12.78	7.41e-35	2.45e-28	0.48	0.37	Schizophrenia;	chr5:50358137	chr1:121519112~121571892:+
BRCA	trans	rs12138950	0.681	rs28630511	ENSG00000224237.1	MINOS1P3	12.78	7.54e-35	2.49e-28	0.48	0.37	Hypothyroidism;Thyroid volume;	chr1:19516538	chr3:27214816~27215018:-
BRCA	trans	rs10940346	0.601	rs1841104	ENSG00000231752.4	EMBP1	-12.77	8.1e-35	2.68e-28	-0.48	-0.37	Schizophrenia;	chr5:50263930	chr1:121519112~121571892:+
BRCA	trans	rs1039766	1	rs268871	ENSG00000224334.1	AP000357.4	12.77	8.36e-35	2.76e-28	0.58	0.37	Lung adenocarcinoma;Lung cancer;	chr2:65253874	chr22:24686923~24688087:+
BRCA	trans	rs7312770	0.612	rs773114	ENSG00000196656.7	AC004057.1	12.77	8.65e-35	2.85e-28	0.42	0.37	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr4:113214046~113217170:-
BRCA	trans	rs10940346	0.601	rs1039798	ENSG00000231752.4	EMBP1	12.76	9.31e-35	3.07e-28	0.48	0.37	Schizophrenia;	chr5:50355909	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.601	rs10072182	ENSG00000231752.4	EMBP1	12.76	9.31e-35	3.07e-28	0.48	0.37	Schizophrenia;	chr5:50356818	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.56	rs10073530	ENSG00000231752.4	EMBP1	12.76	9.31e-35	3.07e-28	0.48	0.37	Schizophrenia;	chr5:50358823	chr1:121519112~121571892:+
BRCA	trans	rs877636	0.669	rs7297175	ENSG00000196656.7	AC004057.1	-12.76	9.7e-35	3.2e-28	-0.42	-0.37	Cognitive function;	chr12:56080024	chr4:113214046~113217170:-
BRCA	trans	rs11098499	0.909	rs2127821	ENSG00000275858.1	RP11-291L22.8	12.75	1.03e-34	3.4e-28	0.46	0.37	Corneal astigmatism;	chr4:119473380	chr10:38450738~38451069:-
BRCA	trans	rs2899832	0.568	rs8017676	ENSG00000229083.1	PSMA6P2	12.75	1.06e-34	3.48e-28	0.64	0.37	Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:35293460	chrX:12825840~12826833:+
BRCA	trans	rs877636	1	rs2292239	ENSG00000233778.3	RP11-777J24.1	12.74	1.13e-34	3.71e-28	0.43	0.37	Cognitive function;	chr12:56088396	chr8:92144088~92144435:-
BRCA	trans	rs4276421	0.638	rs10061699	ENSG00000231752.4	EMBP1	12.74	1.16e-34	3.82e-28	0.48	0.37	P wave duration;	chr5:45864788	chr1:121519112~121571892:+
BRCA	trans	rs877636	1	rs2292239	ENSG00000227887.1	RPS26P13	12.74	1.23e-34	4.04e-28	0.44	0.37	Cognitive function;	chr12:56088396	chr1:208697369~208697698:-
BRCA	trans	rs3779195	1	rs3779195	ENSG00000225169.1	BRI3P1	-12.74	1.24e-34	4.06e-28	-0.6	-0.37	Sex hormone-binding globulin levels;	chr7:98364050	chr1:100213293~100213670:+
BRCA	trans	rs77688320	0.553	rs2908763	ENSG00000235105.1	RP11-329A14.1	-12.73	1.3e-34	4.26e-28	-0.46	-0.37	Breast cancer;	chr2:201503860	chr1:48435967~48437223:+
BRCA	trans	rs116095464	0.558	rs10055993	ENSG00000185986.11	SDHAP3	12.73	1.36e-34	4.44e-28	0.57	0.37	Breast cancer;	chr5:264181	chr5:1572222~1594620:-
BRCA	trans	rs77688320	0.535	rs60148247	ENSG00000235105.1	RP11-329A14.1	-12.72	1.46e-34	4.79e-28	-0.46	-0.37	Breast cancer;	chr2:201513770	chr1:48435967~48437223:+
BRCA	trans	rs77688320	0.553	rs2080324	ENSG00000235105.1	RP11-329A14.1	-12.72	1.46e-34	4.79e-28	-0.46	-0.37	Breast cancer;	chr2:201514089	chr1:48435967~48437223:+
BRCA	trans	rs77688320	0.553	rs2080323	ENSG00000235105.1	RP11-329A14.1	-12.72	1.46e-34	4.79e-28	-0.46	-0.37	Breast cancer;	chr2:201514126	chr1:48435967~48437223:+
BRCA	trans	rs77688320	0.553	rs2080322	ENSG00000235105.1	RP11-329A14.1	-12.72	1.46e-34	4.79e-28	-0.46	-0.37	Breast cancer;	chr2:201514317	chr1:48435967~48437223:+
BRCA	trans	rs877636	1	rs4759229	ENSG00000227887.1	RPS26P13	-12.72	1.53e-34	5e-28	-0.46	-0.37	Cognitive function;	chr12:56080696	chr1:208697369~208697698:-
BRCA	trans	rs116095464	0.558	rs9687621	ENSG00000185986.11	SDHAP3	12.71	1.59e-34	5.18e-28	0.53	0.37	Breast cancer;	chr5:229079	chr5:1572222~1594620:-
BRCA	trans	rs10940346	1	rs6874016	ENSG00000231752.4	EMBP1	-12.71	1.63e-34	5.33e-28	-0.45	-0.37	Schizophrenia;	chr5:50549640	chr1:121519112~121571892:+
BRCA	trans	rs77688320	0.553	rs6722889	ENSG00000235105.1	RP11-329A14.1	-12.71	1.65e-34	5.39e-28	-0.47	-0.37	Breast cancer;	chr2:201439359	chr1:48435967~48437223:+
BRCA	trans	rs11098499	0.954	rs10008459	ENSG00000275858.1	RP11-291L22.8	12.7	1.78e-34	5.82e-28	0.45	0.37	Corneal astigmatism;	chr4:119473076	chr10:38450738~38451069:-
BRCA	trans	rs877636	1	rs4759229	ENSG00000235459.5	RPS26P31	-12.7	1.79e-34	5.85e-28	-0.44	-0.37	Cognitive function;	chr12:56080696	chr7:122681315~122681662:+
BRCA	trans	rs11098499	0.954	rs7436506	ENSG00000275858.1	RP11-291L22.8	12.7	1.81e-34	5.91e-28	0.45	0.37	Corneal astigmatism;	chr4:119472614	chr10:38450738~38451069:-
BRCA	trans	rs13190036	0.551	rs7710269	ENSG00000226986.4	RP11-543B16.2	-12.7	1.85e-34	6.02e-28	-0.52	-0.37	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177187528	chr1:211207239~211207897:+
BRCA	trans	rs77688320	0.553	rs2540432	ENSG00000235105.1	RP11-329A14.1	-12.69	2.11e-34	6.86e-28	-0.46	-0.37	Breast cancer;	chr2:201500171	chr1:48435967~48437223:+
BRCA	trans	rs10940346	0.601	rs12651834	ENSG00000231752.4	EMBP1	12.68	2.3e-34	7.49e-28	0.48	0.37	Schizophrenia;	chr5:50351199	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.601	rs13172932	ENSG00000231752.4	EMBP1	12.68	2.31e-34	7.5e-28	0.47	0.37	Schizophrenia;	chr5:50345364	chr1:121519112~121571892:+
BRCA	trans	rs9876781	1	rs2362452	ENSG00000235912.1	RP1-159A19.3	12.68	2.32e-34	7.56e-28	0.42	0.37	Longevity;	chr3:48376724	chr1:27649419~27649610:+
BRCA	trans	rs10940346	0.54	rs12109228	ENSG00000231752.4	EMBP1	12.67	2.48e-34	8.07e-28	0.47	0.37	Schizophrenia;	chr5:50383135	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.601	rs34616519	ENSG00000231752.4	EMBP1	12.67	2.55e-34	8.28e-28	0.47	0.37	Schizophrenia;	chr5:50353638	chr1:121519112~121571892:+
BRCA	trans	rs877636	0.74	rs705698	ENSG00000212994.5	RPS26P6	12.67	2.63e-34	8.53e-28	0.51	0.37	Cognitive function;	chr12:55990903	chr8:100895771~100896118:+
BRCA	trans	rs77688320	0.573	rs2714480	ENSG00000235105.1	RP11-329A14.1	-12.66	2.72e-34	8.84e-28	-0.46	-0.37	Breast cancer;	chr2:201486286	chr1:48435967~48437223:+
BRCA	trans	rs12138950	0.596	rs10917471	ENSG00000224237.1	MINOS1P3	12.66	2.88e-34	9.34e-28	0.48	0.37	Hypothyroidism;Thyroid volume;	chr1:19521118	chr3:27214816~27215018:-
BRCA	trans	rs10940346	0.601	rs6868380	ENSG00000231752.4	EMBP1	12.66	2.92e-34	9.49e-28	0.47	0.37	Schizophrenia;	chr5:50328473	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.593	rs9292929	ENSG00000231752.4	EMBP1	12.65	3.16e-34	1.02e-27	0.49	0.36	P wave duration;	chr5:45894168	chr1:121519112~121571892:+
BRCA	trans	rs11098499	0.954	rs12508504	ENSG00000275858.1	RP11-291L22.8	12.65	3.17e-34	1.03e-27	0.45	0.36	Corneal astigmatism;	chr4:119489452	chr10:38450738~38451069:-
BRCA	trans	rs877636	0.692	rs2271194	ENSG00000243538.1	CTB-55B8.1	-12.65	3.3e-34	1.07e-27	-0.42	-0.36	Cognitive function;	chr12:56083910	chr5:16902294~16902641:-
BRCA	trans	rs2288327	0.643	rs16866334	ENSG00000269800.1	PLEKHA3P1	12.64	3.61e-34	1.17e-27	0.53	0.36	Atrial fibrillation;	chr2:178471945	chr19:41521043~41521989:-
BRCA	trans	rs4276421	0.593	rs10223123	ENSG00000231752.4	EMBP1	12.64	3.72e-34	1.2e-27	0.49	0.36	P wave duration;	chr5:45893554	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.562	rs13182357	ENSG00000231752.4	EMBP1	12.63	3.86e-34	1.25e-27	0.47	0.36	Schizophrenia;	chr5:50404060	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.601	rs6860503	ENSG00000231752.4	EMBP1	12.63	3.86e-34	1.25e-27	0.47	0.36	Schizophrenia;	chr5:50446340	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.58	rs34185098	ENSG00000231752.4	EMBP1	12.62	4.21e-34	1.36e-27	0.47	0.36	Schizophrenia;	chr5:50330100	chr1:121519112~121571892:+
BRCA	trans	rs11098499	0.954	rs17006190	ENSG00000275858.1	RP11-291L22.8	12.62	4.35e-34	1.4e-27	0.46	0.36	Corneal astigmatism;	chr4:119497683	chr10:38450738~38451069:-
BRCA	trans	rs877636	0.692	rs2271194	ENSG00000234354.3	RPS26P47	-12.62	4.41e-34	1.42e-27	-0.45	-0.36	Cognitive function;	chr12:56083910	chr13:100539901~100540248:-
BRCA	trans	rs616147	0.816	rs1768190	ENSG00000214263.2	RPSAP53	12.62	4.42e-34	1.42e-27	0.53	0.36	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39467949	chr13:67266845~67267706:-
BRCA	trans	rs2657294	0.965	rs2657286	ENSG00000172974.11	AC007318.5	-12.61	4.88e-34	1.57e-27	-0.44	-0.36	Pneumonia;	chr10:75145940	chr2:65205108~65205988:+
BRCA	trans	rs714543	0.61	rs4724320	ENSG00000226038.5	PPIAP21	-12.61	4.97e-34	1.6e-27	-0.43	-0.36	Plateletcrit;	chr7:44775735	chr20:43230760~43231260:+
BRCA	trans	rs10940346	0.601	rs6892142	ENSG00000231752.4	EMBP1	-12.61	5.03e-34	1.62e-27	-0.47	-0.36	Schizophrenia;	chr5:50276518	chr1:121519112~121571892:+
BRCA	trans	rs877636	1	rs877636	ENSG00000227887.1	RPS26P13	-12.61	5.05e-34	1.62e-27	-0.44	-0.36	Cognitive function;	chr12:56086799	chr1:208697369~208697698:-
BRCA	trans	rs10940346	0.54	rs34645496	ENSG00000231752.4	EMBP1	12.61	5.11e-34	1.64e-27	0.47	0.36	Schizophrenia;	chr5:50322419	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.601	rs35330444	ENSG00000231752.4	EMBP1	12.61	5.11e-34	1.64e-27	0.47	0.36	Schizophrenia;	chr5:50322606	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.601	rs6875734	ENSG00000231752.4	EMBP1	12.61	5.11e-34	1.64e-27	0.47	0.36	Schizophrenia;	chr5:50323203	chr1:121519112~121571892:+
BRCA	trans	rs11098499	0.954	rs3733519	ENSG00000275858.1	RP11-291L22.8	12.6	5.55e-34	1.78e-27	0.46	0.36	Corneal astigmatism;	chr4:119502293	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.954	rs10006525	ENSG00000275858.1	RP11-291L22.8	12.59	5.88e-34	1.89e-27	0.45	0.36	Corneal astigmatism;	chr4:119487776	chr10:38450738~38451069:-
BRCA	trans	rs10940346	0.601	rs10042601	ENSG00000231752.4	EMBP1	-12.59	5.91e-34	1.9e-27	-0.47	-0.36	Schizophrenia;	chr5:50315248	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.55	rs4478331	ENSG00000231752.4	EMBP1	12.59	6.04e-34	1.94e-27	0.49	0.36	P wave duration;	chr5:46005323	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.571	rs4368738	ENSG00000231752.4	EMBP1	12.58	6.85e-34	2.19e-27	0.48	0.36	P wave duration;	chr5:45892686	chr1:121519112~121571892:+
BRCA	trans	rs10940346	0.562	rs10051529	ENSG00000231752.4	EMBP1	-12.58	7.09e-34	2.27e-27	-0.47	-0.36	Schizophrenia;	chr5:50303103	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.577	rs10054424	ENSG00000231752.4	EMBP1	12.57	7.27e-34	2.33e-27	0.48	0.36	P wave duration;	chr5:45748769	chr1:121519112~121571892:+
BRCA	trans	rs11098499	0.954	rs12499324	ENSG00000275858.1	RP11-291L22.8	12.57	7.44e-34	2.38e-27	0.45	0.36	Corneal astigmatism;	chr4:119472631	chr10:38450738~38451069:-
BRCA	trans	rs6732160	0.845	rs9989755	ENSG00000236165.1	PRADC1P1	12.57	7.59e-34	2.43e-27	0.48	0.36	Intelligence (multi-trait analysis);	chr2:73134820	chr3:36976316~36976840:+
BRCA	trans	rs10940346	0.668	rs6884426	ENSG00000231752.4	EMBP1	-12.56	8.21e-34	2.63e-27	-0.47	-0.36	Schizophrenia;	chr5:50492782	chr1:121519112~121571892:+
BRCA	trans	rs9876781	1	rs7635522	ENSG00000235912.1	RP1-159A19.3	-12.56	8.4e-34	2.69e-27	-0.42	-0.36	Longevity;	chr3:48382166	chr1:27649419~27649610:+
BRCA	trans	rs77688320	0.535	rs10460403	ENSG00000235105.1	RP11-329A14.1	12.56	8.51e-34	2.72e-27	0.44	0.36	Breast cancer;	chr2:201478014	chr1:48435967~48437223:+
BRCA	trans	rs9876781	0.874	rs56298324	ENSG00000235912.1	RP1-159A19.3	12.56	8.51e-34	2.72e-27	0.42	0.36	Longevity;	chr3:48393626	chr1:27649419~27649610:+
BRCA	trans	rs2899832	0.568	rs77796720	ENSG00000229083.1	PSMA6P2	12.56	8.52e-34	2.72e-27	0.64	0.36	Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:35314500	chrX:12825840~12826833:+
BRCA	trans	rs10940346	0.601	rs16879414	ENSG00000231752.4	EMBP1	12.56	8.8e-34	2.81e-27	0.48	0.36	Schizophrenia;	chr5:50337969	chr1:121519112~121571892:+
BRCA	trans	rs11098499	0.954	rs12506546	ENSG00000275858.1	RP11-291L22.8	12.56	8.87e-34	2.83e-27	0.45	0.36	Corneal astigmatism;	chr4:119380463	chr10:38450738~38451069:-
BRCA	trans	rs10940346	0.601	rs567248	ENSG00000231752.4	EMBP1	-12.55	9.07e-34	2.9e-27	-0.47	-0.36	Schizophrenia;	chr5:50277650	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.615	rs12109205	ENSG00000231752.4	EMBP1	12.55	9.68e-34	3.09e-27	0.48	0.36	P wave duration;	chr5:45876576	chr1:121519112~121571892:+
BRCA	trans	rs877636	0.669	rs7297175	ENSG00000242970.2	AC068522.4	-12.55	9.7e-34	3.1e-27	-0.47	-0.36	Cognitive function;	chr12:56080024	chr8:58588420~58588764:-
BRCA	trans	rs6732160	0.741	rs10203600	ENSG00000236165.1	PRADC1P1	12.55	9.92e-34	3.17e-27	0.48	0.36	Intelligence (multi-trait analysis);	chr2:73134270	chr3:36976316~36976840:+
BRCA	trans	rs6732160	0.845	rs6752507	ENSG00000236165.1	PRADC1P1	12.55	1e-33	3.19e-27	0.47	0.36	Intelligence (multi-trait analysis);	chr2:73158030	chr3:36976316~36976840:+
BRCA	trans	rs11098499	0.954	rs10518328	ENSG00000275858.1	RP11-291L22.8	12.54	1.01e-33	3.23e-27	0.45	0.36	Corneal astigmatism;	chr4:119480624	chr10:38450738~38451069:-
BRCA	trans	rs6732160	0.809	rs4299358	ENSG00000236165.1	PRADC1P1	12.54	1.08e-33	3.45e-27	0.47	0.36	Intelligence (multi-trait analysis);	chr2:73132213	chr3:36976316~36976840:+
BRCA	trans	rs9876781	1	rs7636782	ENSG00000235912.1	RP1-159A19.3	-12.53	1.22e-33	3.87e-27	-0.41	-0.36	Longevity;	chr3:48379897	chr1:27649419~27649610:+
BRCA	trans	rs11098499	0.954	rs6822679	ENSG00000275858.1	RP11-291L22.8	12.53	1.25e-33	3.97e-27	0.45	0.36	Corneal astigmatism;	chr4:119481547	chr10:38450738~38451069:-
BRCA	trans	rs77688320	0.517	rs10931949	ENSG00000235105.1	RP11-329A14.1	12.52	1.35e-33	4.29e-27	0.43	0.36	Breast cancer;	chr2:201459730	chr1:48435967~48437223:+
BRCA	trans	rs77688320	0.5	rs6755428	ENSG00000235105.1	RP11-329A14.1	12.52	1.35e-33	4.3e-27	0.43	0.36	Breast cancer;	chr2:201431043	chr1:48435967~48437223:+
BRCA	trans	rs77688320	0.5	rs4129010	ENSG00000235105.1	RP11-329A14.1	12.51	1.46e-33	4.65e-27	0.43	0.36	Breast cancer;	chr2:201443602	chr1:48435967~48437223:+
BRCA	trans	rs77688320	0.5	rs4129011	ENSG00000235105.1	RP11-329A14.1	12.51	1.46e-33	4.65e-27	0.43	0.36	Breast cancer;	chr2:201443863	chr1:48435967~48437223:+
BRCA	trans	rs11098499	0.954	rs10006706	ENSG00000275858.1	RP11-291L22.8	12.51	1.47e-33	4.66e-27	0.45	0.36	Corneal astigmatism;	chr4:119487997	chr10:38450738~38451069:-
BRCA	trans	rs77688320	0.517	rs6717641	ENSG00000235105.1	RP11-329A14.1	12.51	1.5e-33	4.77e-27	0.43	0.36	Breast cancer;	chr2:201450484	chr1:48435967~48437223:+
BRCA	trans	rs77688320	0.517	rs7573536	ENSG00000235105.1	RP11-329A14.1	12.51	1.53e-33	4.84e-27	0.43	0.36	Breast cancer;	chr2:201469676	chr1:48435967~48437223:+
BRCA	trans	rs1355223	0.545	rs7106831	ENSG00000225531.1	RP11-196I18.3	12.51	1.54e-33	4.87e-27	0.5	0.36	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34857995	chr9:107116829~107117557:+
BRCA	trans	rs11098499	0.954	rs4577559	ENSG00000275858.1	RP11-291L22.8	12.5	1.75e-33	5.53e-27	0.45	0.36	Corneal astigmatism;	chr4:119482888	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.954	rs7656252	ENSG00000275858.1	RP11-291L22.8	12.5	1.75e-33	5.53e-27	0.45	0.36	Corneal astigmatism;	chr4:119483113	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.865	rs28845498	ENSG00000275858.1	RP11-291L22.8	12.5	1.75e-33	5.53e-27	0.45	0.36	Corneal astigmatism;	chr4:119484031	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.954	rs56270433	ENSG00000275858.1	RP11-291L22.8	12.5	1.75e-33	5.53e-27	0.45	0.36	Corneal astigmatism;	chr4:119484875	chr10:38450738~38451069:-
BRCA	trans	rs8175379	0.53	rs12516847	ENSG00000231752.4	EMBP1	-12.49	1.86e-33	5.88e-27	-0.47	-0.36	Interleukin-7 levels;	chr5:46300736	chr1:121519112~121571892:+
BRCA	trans	rs6732160	0.845	rs6546805	ENSG00000236165.1	PRADC1P1	12.49	1.87e-33	5.92e-27	0.47	0.36	Intelligence (multi-trait analysis);	chr2:73158987	chr3:36976316~36976840:+
BRCA	trans	rs4276421	0.638	rs62371967	ENSG00000231752.4	EMBP1	12.49	1.91e-33	6.03e-27	0.48	0.36	P wave duration;	chr5:45897706	chr1:121519112~121571892:+
BRCA	trans	rs11098499	0.954	rs11940028	ENSG00000275858.1	RP11-291L22.8	12.48	1.95e-33	6.17e-27	0.45	0.36	Corneal astigmatism;	chr4:119490752	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.954	rs11935596	ENSG00000275858.1	RP11-291L22.8	12.48	1.95e-33	6.17e-27	0.45	0.36	Corneal astigmatism;	chr4:119491302	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.954	rs12507964	ENSG00000275858.1	RP11-291L22.8	12.48	1.95e-33	6.17e-27	0.45	0.36	Corneal astigmatism;	chr4:119491906	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.909	rs11098530	ENSG00000275858.1	RP11-291L22.8	12.48	1.95e-33	6.17e-27	0.45	0.36	Corneal astigmatism;	chr4:119491999	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.954	rs9998585	ENSG00000275858.1	RP11-291L22.8	12.48	1.98e-33	6.24e-27	0.45	0.36	Corneal astigmatism;	chr4:119475647	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.909	rs6842762	ENSG00000275858.1	RP11-291L22.8	12.48	1.98e-33	6.24e-27	0.45	0.36	Corneal astigmatism;	chr4:119477081	chr10:38450738~38451069:-
BRCA	trans	rs7312770	1	rs7312770	ENSG00000233778.3	RP11-777J24.1	-12.48	2.02e-33	6.37e-27	-0.39	-0.36	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr8:92144088~92144435:-
BRCA	trans	rs11098499	0.954	rs6848389	ENSG00000275858.1	RP11-291L22.8	12.47	2.25e-33	7.1e-27	0.44	0.36	Corneal astigmatism;	chr4:119481467	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.954	rs7681544	ENSG00000275858.1	RP11-291L22.8	12.47	2.4e-33	7.55e-27	0.45	0.36	Corneal astigmatism;	chr4:119490100	chr10:38450738~38451069:-
BRCA	trans	rs4276421	0.615	rs7733616	ENSG00000231752.4	EMBP1	-12.46	2.44e-33	7.7e-27	-0.47	-0.36	P wave duration;	chr5:45798621	chr1:121519112~121571892:+
BRCA	trans	rs4263408	0.654	rs305827	ENSG00000237550.5	UBE2Q2P6	12.46	2.52e-33	7.93e-27	0.47	0.36	Plasma amyloid beta peptide concentrations (ABx-40);	chr4:39758369	chr15:82372196~82372912:-
BRCA	trans	rs77688320	0.529	rs2540438	ENSG00000235105.1	RP11-329A14.1	-12.46	2.52e-33	7.93e-27	-0.46	-0.36	Breast cancer;	chr2:201485833	chr1:48435967~48437223:+
BRCA	trans	rs7395662	0.591	rs7483212	ENSG00000134612.10	FOLH1B	-12.46	2.58e-33	8.1e-27	-0.46	-0.36	HDL cholesterol;	chr11:48585630	chr11:89639227~89698718:+
BRCA	trans	rs7395662	0.591	rs7482521	ENSG00000134612.10	FOLH1B	-12.46	2.58e-33	8.1e-27	-0.46	-0.36	HDL cholesterol;	chr11:48588183	chr11:89639227~89698718:+
BRCA	trans	rs7395662	0.591	rs10838972	ENSG00000134612.10	FOLH1B	-12.46	2.58e-33	8.1e-27	-0.46	-0.36	HDL cholesterol;	chr11:48589848	chr11:89639227~89698718:+
BRCA	trans	rs7395662	0.571	rs4882020	ENSG00000134612.10	FOLH1B	-12.46	2.58e-33	8.1e-27	-0.46	-0.36	HDL cholesterol;	chr11:48594106	chr11:89639227~89698718:+
BRCA	trans	rs7395662	0.591	rs4882138	ENSG00000134612.10	FOLH1B	-12.46	2.58e-33	8.1e-27	-0.46	-0.36	HDL cholesterol;	chr11:48597769	chr11:89639227~89698718:+
BRCA	trans	rs11098499	0.908	rs11098527	ENSG00000275858.1	RP11-291L22.8	12.46	2.69e-33	8.44e-27	0.45	0.36	Corneal astigmatism;	chr4:119478751	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.954	rs6834796	ENSG00000275858.1	RP11-291L22.8	12.45	2.72e-33	8.53e-27	0.45	0.36	Corneal astigmatism;	chr4:119493538	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.954	rs11734241	ENSG00000275858.1	RP11-291L22.8	12.45	2.72e-33	8.53e-27	0.45	0.36	Corneal astigmatism;	chr4:119495717	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.865	rs28753180	ENSG00000275858.1	RP11-291L22.8	12.45	2.87e-33	9.01e-27	0.45	0.36	Corneal astigmatism;	chr4:119484212	chr10:38450738~38451069:-
BRCA	trans	rs13177918	0.798	rs13182116	ENSG00000226396.1	RP5-1056L3.3	-12.45	2.89e-33	9.08e-27	-0.42	-0.36	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150465963	chr1:19608114~19608568:+
BRCA	trans	rs11098499	0.954	rs17005535	ENSG00000275858.1	RP11-291L22.8	12.45	2.96e-33	9.28e-27	0.44	0.36	Corneal astigmatism;	chr4:119490407	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.954	rs11729521	ENSG00000275858.1	RP11-291L22.8	12.44	3.16e-33	9.89e-27	0.45	0.36	Corneal astigmatism;	chr4:119495633	chr10:38450738~38451069:-
BRCA	trans	rs7312770	0.612	rs773114	ENSG00000242970.2	AC068522.4	12.44	3.2e-33	1e-26	0.47	0.36	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr8:58588420~58588764:-
BRCA	trans	rs877636	0.74	rs705698	ENSG00000235459.5	RPS26P31	12.43	3.45e-33	1.08e-26	0.46	0.36	Cognitive function;	chr12:55990903	chr7:122681315~122681662:+
BRCA	trans	rs1355223	0.506	rs7130678	ENSG00000225531.1	RP11-196I18.3	12.43	3.6e-33	1.13e-26	0.49	0.36	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34847634	chr9:107116829~107117557:+
BRCA	trans	rs11039798	0.511	rs2047812	ENSG00000134612.10	FOLH1B	-12.41	4.2e-33	1.31e-26	-0.55	-0.36	Axial length;	chr11:48140490	chr11:89639227~89698718:+
BRCA	trans	rs11098499	0.954	rs9993199	ENSG00000275858.1	RP11-291L22.8	-12.41	4.28e-33	1.34e-26	-0.44	-0.36	Corneal astigmatism;	chr4:119471718	chr10:38450738~38451069:-
BRCA	trans	rs12138950	0.681	rs10917468	ENSG00000224237.1	MINOS1P3	-12.41	4.41e-33	1.37e-26	-0.47	-0.36	Hypothyroidism;Thyroid volume;	chr1:19516860	chr3:27214816~27215018:-
BRCA	trans	rs11098499	0.505	rs75122014	ENSG00000275858.1	RP11-291L22.8	12.41	4.51e-33	1.4e-26	0.44	0.36	Corneal astigmatism;	chr4:119441271	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.954	rs10518331	ENSG00000275858.1	RP11-291L22.8	12.4	4.72e-33	1.47e-26	0.44	0.36	Corneal astigmatism;	chr4:119402440	chr10:38450738~38451069:-
BRCA	trans	rs7395662	0.591	rs11039858	ENSG00000134612.10	FOLH1B	-12.4	4.96e-33	1.54e-26	-0.46	-0.36	HDL cholesterol;	chr11:48590099	chr11:89639227~89698718:+
BRCA	trans	rs11098499	0.954	rs28685688	ENSG00000275858.1	RP11-291L22.8	12.4	4.99e-33	1.55e-26	0.45	0.36	Corneal astigmatism;	chr4:119499179	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.954	rs7687843	ENSG00000275858.1	RP11-291L22.8	12.4	4.99e-33	1.55e-26	0.45	0.36	Corneal astigmatism;	chr4:119500056	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.954	rs17009122	ENSG00000275858.1	RP11-291L22.8	12.4	5.07e-33	1.58e-26	0.44	0.36	Corneal astigmatism;	chr4:119441248	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.954	rs13133522	ENSG00000275858.1	RP11-291L22.8	12.4	5.18e-33	1.61e-26	0.44	0.36	Corneal astigmatism;	chr4:119403269	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.954	rs35091806	ENSG00000275858.1	RP11-291L22.8	12.4	5.18e-33	1.61e-26	0.44	0.36	Corneal astigmatism;	chr4:119404374	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.909	rs35165976	ENSG00000275858.1	RP11-291L22.8	12.4	5.18e-33	1.61e-26	0.44	0.36	Corneal astigmatism;	chr4:119404475	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.954	rs6846442	ENSG00000275858.1	RP11-291L22.8	12.4	5.18e-33	1.61e-26	0.44	0.36	Corneal astigmatism;	chr4:119405168	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.954	rs71614438	ENSG00000275858.1	RP11-291L22.8	12.4	5.18e-33	1.61e-26	0.44	0.36	Corneal astigmatism;	chr4:119450097	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.954	rs66506550	ENSG00000275858.1	RP11-291L22.8	12.4	5.18e-33	1.61e-26	0.44	0.36	Corneal astigmatism;	chr4:119450290	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.909	rs7659501	ENSG00000275858.1	RP11-291L22.8	12.4	5.18e-33	1.61e-26	0.44	0.36	Corneal astigmatism;	chr4:119450397	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.657	rs71614442	ENSG00000275858.1	RP11-291L22.8	12.39	5.47e-33	1.69e-26	0.44	0.36	Corneal astigmatism;	chr4:119458191	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.954	rs2892848	ENSG00000275858.1	RP11-291L22.8	12.39	5.47e-33	1.69e-26	0.44	0.36	Corneal astigmatism;	chr4:119460186	chr10:38450738~38451069:-
BRCA	trans	rs77688320	0.517	rs12991600	ENSG00000235105.1	RP11-329A14.1	12.39	5.62e-33	1.74e-26	0.43	0.36	Breast cancer;	chr2:201472513	chr1:48435967~48437223:+
BRCA	trans	rs11098499	0.779	rs28495013	ENSG00000275858.1	RP11-291L22.8	12.39	5.73e-33	1.77e-26	0.44	0.36	Corneal astigmatism;	chr4:119454676	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.738	rs34566984	ENSG00000275858.1	RP11-291L22.8	12.38	6.26e-33	1.93e-26	0.44	0.36	Corneal astigmatism;	chr4:119440115	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.954	rs9685777	ENSG00000275858.1	RP11-291L22.8	12.38	6.26e-33	1.93e-26	0.44	0.36	Corneal astigmatism;	chr4:119444810	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.954	rs10031483	ENSG00000275858.1	RP11-291L22.8	12.38	6.44e-33	1.99e-26	0.45	0.36	Corneal astigmatism;	chr4:119501481	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.954	rs10031665	ENSG00000275858.1	RP11-291L22.8	12.38	6.44e-33	1.99e-26	0.45	0.36	Corneal astigmatism;	chr4:119501697	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.954	rs3733523	ENSG00000275858.1	RP11-291L22.8	12.38	6.44e-33	1.99e-26	0.45	0.36	Corneal astigmatism;	chr4:119502564	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.954	rs10017543	ENSG00000275858.1	RP11-291L22.8	12.37	6.75e-33	2.08e-26	0.44	0.36	Corneal astigmatism;	chr4:119400265	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.909	rs11723839	ENSG00000275858.1	RP11-291L22.8	12.37	6.77e-33	2.09e-26	0.44	0.36	Corneal astigmatism;	chr4:119378518	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.779	rs7699346	ENSG00000275858.1	RP11-291L22.8	12.37	6.77e-33	2.09e-26	0.44	0.36	Corneal astigmatism;	chr4:119389387	chr10:38450738~38451069:-
BRCA	trans	rs13190036	1	rs4976682	ENSG00000228305.2	AC016734.2	12.37	7e-33	2.16e-26	0.49	0.36	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177299001	chr2:63622178~63622831:-
BRCA	trans	rs11098499	0.908	rs28559989	ENSG00000275858.1	RP11-291L22.8	12.37	7.06e-33	2.18e-26	0.44	0.36	Corneal astigmatism;	chr4:119465472	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.738	rs34965784	ENSG00000275858.1	RP11-291L22.8	12.36	7.26e-33	2.24e-26	0.44	0.36	Corneal astigmatism;	chr4:119440431	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.954	rs2306455	ENSG00000275858.1	RP11-291L22.8	12.36	7.58e-33	2.34e-26	0.45	0.36	Corneal astigmatism;	chr4:119500814	chr10:38450738~38451069:-
BRCA	trans	rs877636	0.859	rs3741499	ENSG00000227887.1	RPS26P13	-12.36	7.68e-33	2.36e-26	-0.44	-0.36	Cognitive function;	chr12:56080595	chr1:208697369~208697698:-
BRCA	trans	rs11098499	0.954	rs10008392	ENSG00000275858.1	RP11-291L22.8	12.36	7.88e-33	2.42e-26	0.44	0.36	Corneal astigmatism;	chr4:119397684	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.863	rs12508173	ENSG00000275858.1	RP11-291L22.8	12.35	8.32e-33	2.56e-26	0.44	0.36	Corneal astigmatism;	chr4:119397371	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.908	rs12504149	ENSG00000275858.1	RP11-291L22.8	12.35	8.32e-33	2.56e-26	0.44	0.36	Corneal astigmatism;	chr4:119397422	chr10:38450738~38451069:-
BRCA	trans	rs877636	0.692	rs11171739	ENSG00000212829.8	RPS26P3	12.35	8.72e-33	2.68e-26	0.43	0.36	Cognitive function;	chr12:56076841	chr9:9090898~9091245:+
BRCA	trans	rs11098499	0.954	rs6849561	ENSG00000275858.1	RP11-291L22.8	-12.34	9.14e-33	2.81e-26	-0.46	-0.36	Corneal astigmatism;	chr4:119488539	chr10:38450738~38451069:-
BRCA	trans	rs77688320	0.573	rs59674665	ENSG00000235105.1	RP11-329A14.1	-12.34	9.49e-33	2.91e-26	-0.46	-0.36	Breast cancer;	chr2:201514881	chr1:48435967~48437223:+
BRCA	trans	rs877636	1	rs4759229	ENSG00000233778.3	RP11-777J24.1	-12.34	9.82e-33	3.01e-26	-0.43	-0.36	Cognitive function;	chr12:56080696	chr8:92144088~92144435:-
BRCA	trans	rs72615157	0.634	rs7789890	ENSG00000228546.2	CTA-313A17.3	12.33	1e-32	3.07e-26	0.57	0.36	Lung function (FEV1/FVC);	chr7:100202936	chr7:102337316~102339115:+
BRCA	trans	rs877636	0.669	rs7297175	ENSG00000223416.3	RPS26P15	-12.33	1.01e-32	3.08e-26	-0.41	-0.36	Cognitive function;	chr12:56080024	chr1:58056133~58056480:-
BRCA	trans	rs11098499	0.58	rs12509234	ENSG00000275858.1	RP11-291L22.8	12.33	1.03e-32	3.17e-26	0.44	0.36	Corneal astigmatism;	chr4:119398279	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.909	rs10014719	ENSG00000275858.1	RP11-291L22.8	12.33	1.03e-32	3.17e-26	0.44	0.36	Corneal astigmatism;	chr4:119399560	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.954	rs11098525	ENSG00000275858.1	RP11-291L22.8	12.33	1.04e-32	3.2e-26	0.44	0.36	Corneal astigmatism;	chr4:119468997	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.908	rs7695996	ENSG00000275858.1	RP11-291L22.8	12.33	1.07e-32	3.28e-26	0.44	0.36	Corneal astigmatism;	chr4:119400878	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.697	rs11941899	ENSG00000275858.1	RP11-291L22.8	12.32	1.14e-32	3.49e-26	0.44	0.36	Corneal astigmatism;	chr4:119461603	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.909	rs7681978	ENSG00000275858.1	RP11-291L22.8	12.32	1.14e-32	3.49e-26	0.44	0.36	Corneal astigmatism;	chr4:119462620	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.821	rs28665282	ENSG00000275858.1	RP11-291L22.8	12.32	1.14e-32	3.49e-26	0.44	0.36	Corneal astigmatism;	chr4:119463031	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.738	rs10026493	ENSG00000275858.1	RP11-291L22.8	12.32	1.14e-32	3.49e-26	0.44	0.36	Corneal astigmatism;	chr4:119463039	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.909	rs7681214	ENSG00000275858.1	RP11-291L22.8	12.32	1.14e-32	3.49e-26	0.44	0.36	Corneal astigmatism;	chr4:119464165	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.909	rs28632018	ENSG00000275858.1	RP11-291L22.8	12.32	1.14e-32	3.49e-26	0.44	0.36	Corneal astigmatism;	chr4:119465575	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.908	rs71614449	ENSG00000275858.1	RP11-291L22.8	12.32	1.14e-32	3.49e-26	0.44	0.36	Corneal astigmatism;	chr4:119465900	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.954	rs35063680	ENSG00000275858.1	RP11-291L22.8	12.32	1.14e-32	3.49e-26	0.44	0.36	Corneal astigmatism;	chr4:119465947	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.954	rs34858317	ENSG00000275858.1	RP11-291L22.8	12.32	1.14e-32	3.49e-26	0.44	0.36	Corneal astigmatism;	chr4:119465955	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.954	rs17046116	ENSG00000275858.1	RP11-291L22.8	12.32	1.14e-32	3.49e-26	0.44	0.36	Corneal astigmatism;	chr4:119466104	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.909	rs17046118	ENSG00000275858.1	RP11-291L22.8	12.32	1.14e-32	3.49e-26	0.44	0.36	Corneal astigmatism;	chr4:119466341	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.954	rs7654587	ENSG00000275858.1	RP11-291L22.8	12.32	1.14e-32	3.49e-26	0.44	0.36	Corneal astigmatism;	chr4:119467251	chr10:38450738~38451069:-
BRCA	trans	rs10908521	0.611	rs7516736	ENSG00000227183.3	HDGFP1	-12.32	1.15e-32	3.51e-26	-0.46	-0.36	Uric acid clearance;	chr1:156825994	chrX:131646639~131646890:+
BRCA	trans	rs4276421	0.571	rs7293493	ENSG00000231752.4	EMBP1	12.32	1.21e-32	3.69e-26	0.48	0.36	P wave duration;	chr5:46028749	chr1:121519112~121571892:+
BRCA	trans	rs7312770	0.612	rs1873914	ENSG00000242970.2	AC068522.4	12.31	1.3e-32	3.97e-26	0.47	0.36	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr8:58588420~58588764:-
BRCA	trans	rs11098499	0.954	rs12502423	ENSG00000275858.1	RP11-291L22.8	12.31	1.32e-32	4.02e-26	0.45	0.36	Corneal astigmatism;	chr4:119503017	chr10:38450738~38451069:-
BRCA	trans	rs13190036	1	rs13177748	ENSG00000228305.2	AC016734.2	-12.3	1.42e-32	4.33e-26	-0.51	-0.36	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177216953	chr2:63622178~63622831:-
BRCA	trans	rs77688320	0.5	rs7603584	ENSG00000235105.1	RP11-329A14.1	12.3	1.42e-32	4.33e-26	0.42	0.36	Breast cancer;	chr2:201440422	chr1:48435967~48437223:+
BRCA	trans	rs877636	1	rs877636	ENSG00000233778.3	RP11-777J24.1	-12.3	1.45e-32	4.42e-26	-0.42	-0.36	Cognitive function;	chr12:56086799	chr8:92144088~92144435:-
BRCA	trans	rs116095464	0.558	rs9312978	ENSG00000185986.11	SDHAP3	12.3	1.45e-32	4.43e-26	0.52	0.36	Breast cancer;	chr5:221815	chr5:1572222~1594620:-
BRCA	trans	rs116095464	0.558	rs9312979	ENSG00000185986.11	SDHAP3	12.3	1.45e-32	4.43e-26	0.52	0.36	Breast cancer;	chr5:221942	chr5:1572222~1594620:-
BRCA	trans	rs11098499	0.954	rs6838814	ENSG00000275858.1	RP11-291L22.8	12.3	1.52e-32	4.62e-26	0.44	0.36	Corneal astigmatism;	chr4:119471288	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.779	rs80242894	ENSG00000275858.1	RP11-291L22.8	12.29	1.65e-32	5.01e-26	0.44	0.36	Corneal astigmatism;	chr4:119454597	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.821	rs10032151	ENSG00000275858.1	RP11-291L22.8	12.28	1.72e-32	5.23e-26	0.44	0.36	Corneal astigmatism;	chr4:119470473	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.865	rs10032158	ENSG00000275858.1	RP11-291L22.8	12.28	1.72e-32	5.23e-26	0.44	0.36	Corneal astigmatism;	chr4:119470477	chr10:38450738~38451069:-
BRCA	trans	rs4276421	0.904	rs4388219	ENSG00000231752.4	EMBP1	12.28	1.77e-32	5.38e-26	0.48	0.36	P wave duration;	chr5:45780648	chr1:121519112~121571892:+
BRCA	trans	rs2727020	0.576	rs11040223	ENSG00000134612.10	FOLH1B	-12.27	1.94e-32	5.88e-26	-0.45	-0.36	Coronary artery disease;	chr11:49013081	chr11:89639227~89698718:+
BRCA	trans	rs7312770	0.612	rs1873914	ENSG00000233778.3	RP11-777J24.1	12.27	1.95e-32	5.93e-26	0.41	0.36	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr8:92144088~92144435:-
BRCA	trans	rs13190036	1	rs71601343	ENSG00000228305.2	AC016734.2	-12.27	1.96e-32	5.95e-26	-0.51	-0.36	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177205106	chr2:63622178~63622831:-
BRCA	trans	rs13190036	1	rs71601344	ENSG00000228305.2	AC016734.2	-12.27	1.96e-32	5.95e-26	-0.51	-0.36	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177206492	chr2:63622178~63622831:-
BRCA	trans	rs11098499	0.954	rs71629403	ENSG00000275858.1	RP11-291L22.8	12.27	2.05e-32	6.21e-26	0.44	0.36	Corneal astigmatism;	chr4:119451412	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.909	rs28571712	ENSG00000275858.1	RP11-291L22.8	12.27	2.05e-32	6.21e-26	0.44	0.36	Corneal astigmatism;	chr4:119454825	chr10:38450738~38451069:-
BRCA	trans	rs2899832	0.568	rs10144186	ENSG00000229083.1	PSMA6P2	12.27	2.09e-32	6.32e-26	0.63	0.36	Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:35295199	chrX:12825840~12826833:+
BRCA	trans	rs7312770	1	rs7312770	ENSG00000227887.1	RPS26P13	-12.27	2.09e-32	6.33e-26	-0.39	-0.36	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr1:208697369~208697698:-
BRCA	trans	rs11098499	0.954	rs10034623	ENSG00000275858.1	RP11-291L22.8	12.26	2.13e-32	6.46e-26	0.43	0.36	Corneal astigmatism;	chr4:119476674	chr10:38450738~38451069:-
BRCA	trans	rs877636	1	rs2292239	ENSG00000234513.1	AC073072.7	12.26	2.13e-32	6.47e-26	0.43	0.36	Cognitive function;	chr12:56088396	chr7:22773646~22773993:-
BRCA	trans	rs616147	0.85	rs631312	ENSG00000214263.2	RPSAP53	-12.26	2.14e-32	6.5e-26	-0.52	-0.36	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39467477	chr13:67266845~67267706:-
BRCA	trans	rs7312770	0.612	rs773114	ENSG00000204652.6	RPS26P8	12.26	2.17e-32	6.56e-26	0.42	0.36	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr17:45608571~45608918:+
BRCA	trans	rs11098499	0.865	rs9994730	ENSG00000275858.1	RP11-291L22.8	12.26	2.2e-32	6.66e-26	0.44	0.36	Corneal astigmatism;	chr4:119460409	chr10:38450738~38451069:-
BRCA	trans	rs3779195	0.929	rs4268041	ENSG00000225169.1	BRI3P1	-12.25	2.41e-32	7.29e-26	-0.54	-0.35	Sex hormone-binding globulin levels;	chr7:98376226	chr1:100213293~100213670:+
BRCA	trans	rs2899832	0.568	rs2277460	ENSG00000229083.1	PSMA6P2	12.25	2.47e-32	7.48e-26	0.64	0.35	Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:35292367	chrX:12825840~12826833:+
BRCA	trans	rs2899832	0.568	rs17458583	ENSG00000229083.1	PSMA6P2	12.25	2.47e-32	7.48e-26	0.64	0.35	Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:35293295	chrX:12825840~12826833:+
BRCA	trans	rs11098499	0.954	rs2389802	ENSG00000275858.1	RP11-291L22.8	12.25	2.5e-32	7.54e-26	0.44	0.35	Corneal astigmatism;	chr4:119404577	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.954	rs3890049	ENSG00000275858.1	RP11-291L22.8	12.25	2.55e-32	7.71e-26	0.44	0.35	Corneal astigmatism;	chr4:119405128	chr10:38450738~38451069:-
BRCA	trans	rs1355223	0.506	rs7131229	ENSG00000225531.1	RP11-196I18.3	-12.25	2.55e-32	7.72e-26	-0.49	-0.35	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34847781	chr9:107116829~107117557:+
BRCA	trans	rs11039798	0.777	rs2202454	ENSG00000134612.10	FOLH1B	12.25	2.6e-32	7.84e-26	0.61	0.35	Axial length;	chr11:48989457	chr11:89639227~89698718:+
BRCA	trans	rs11098499	0.865	rs28634456	ENSG00000275858.1	RP11-291L22.8	12.25	2.63e-32	7.96e-26	0.44	0.35	Corneal astigmatism;	chr4:119454623	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.954	rs1480931	ENSG00000275858.1	RP11-291L22.8	12.24	2.68e-32	8.11e-26	0.44	0.35	Corneal astigmatism;	chr4:119474654	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.697	rs28655325	ENSG00000275858.1	RP11-291L22.8	12.24	2.72e-32	8.2e-26	0.44	0.35	Corneal astigmatism;	chr4:119451844	chr10:38450738~38451069:-
BRCA	trans	rs877636	1	rs877636	ENSG00000223416.3	RPS26P15	-12.23	3.09e-32	9.31e-26	-0.43	-0.35	Cognitive function;	chr12:56086799	chr1:58056133~58056480:-
BRCA	trans	rs2899832	0.5	rs10151128	ENSG00000229083.1	PSMA6P2	12.23	3.16e-32	9.54e-26	0.63	0.35	Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:35306578	chrX:12825840~12826833:+
BRCA	trans	rs13190036	1	rs3733875	ENSG00000228305.2	AC016734.2	-12.23	3.26e-32	9.82e-26	-0.51	-0.35	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177210239	chr2:63622178~63622831:-
BRCA	trans	rs7312770	0.612	rs773114	ENSG00000233778.3	RP11-777J24.1	12.22	3.51e-32	1.05e-25	0.4	0.35	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr8:92144088~92144435:-
BRCA	trans	rs7312770	0.612	rs773114	ENSG00000234354.3	RPS26P47	12.22	3.53e-32	1.06e-25	0.43	0.35	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr13:100539901~100540248:-
BRCA	trans	rs877636	1	rs877636	ENSG00000234513.1	AC073072.7	-12.22	3.63e-32	1.09e-25	-0.44	-0.35	Cognitive function;	chr12:56086799	chr7:22773646~22773993:-
BRCA	trans	rs7312770	0.612	rs773114	ENSG00000243538.1	CTB-55B8.1	12.21	3.77e-32	1.13e-25	0.4	0.35	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr5:16902294~16902641:-
BRCA	trans	rs1355223	0.506	rs11032899	ENSG00000225531.1	RP11-196I18.3	12.21	3.93e-32	1.18e-25	0.48	0.35	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34848687	chr9:107116829~107117557:+
BRCA	trans	rs1355223	0.506	rs11032898	ENSG00000225531.1	RP11-196I18.3	12.2	4.08e-32	1.22e-25	0.48	0.35	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34848564	chr9:107116829~107117557:+
BRCA	trans	rs1355223	0.506	rs1828299	ENSG00000225531.1	RP11-196I18.3	12.2	4.08e-32	1.22e-25	0.48	0.35	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34848871	chr9:107116829~107117557:+
BRCA	trans	rs11098499	0.954	rs10006877	ENSG00000275858.1	RP11-291L22.8	12.2	4.27e-32	1.28e-25	0.44	0.35	Corneal astigmatism;	chr4:119321638	chr10:38450738~38451069:-
BRCA	trans	rs72615157	0.634	rs2272343	ENSG00000228546.2	CTA-313A17.3	12.2	4.31e-32	1.29e-25	0.56	0.35	Lung function (FEV1/FVC);	chr7:100180662	chr7:102337316~102339115:+
BRCA	trans	rs11098499	0.908	rs7696649	ENSG00000275858.1	RP11-291L22.8	12.19	4.58e-32	1.37e-25	0.44	0.35	Corneal astigmatism;	chr4:119401022	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.908	rs2017057	ENSG00000275858.1	RP11-291L22.8	12.19	4.73e-32	1.42e-25	0.44	0.35	Corneal astigmatism;	chr4:119336556	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.909	rs78332141	ENSG00000275858.1	RP11-291L22.8	12.19	4.77e-32	1.43e-25	0.44	0.35	Corneal astigmatism;	chr4:119454627	chr10:38450738~38451069:-
BRCA	trans	rs13190036	1	rs34832871	ENSG00000228305.2	AC016734.2	-12.19	5e-32	1.49e-25	-0.51	-0.35	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177228928	chr2:63622178~63622831:-
BRCA	trans	rs11098499	0.954	rs10017371	ENSG00000275858.1	RP11-291L22.8	12.18	5.32e-32	1.59e-25	0.44	0.35	Corneal astigmatism;	chr4:119372621	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.954	rs878373	ENSG00000275858.1	RP11-291L22.8	12.17	5.62e-32	1.68e-25	0.44	0.35	Corneal astigmatism;	chr4:119316329	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.954	rs11098526	ENSG00000275858.1	RP11-291L22.8	12.16	6.43e-32	1.91e-25	0.44	0.35	Corneal astigmatism;	chr4:119469204	chr10:38450738~38451069:-
BRCA	trans	rs1355223	0.525	rs10836316	ENSG00000225531.1	RP11-196I18.3	12.16	6.5e-32	1.93e-25	0.48	0.35	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34852748	chr9:107116829~107117557:+
BRCA	trans	rs13190036	1	rs35535623	ENSG00000228305.2	AC016734.2	-12.16	6.68e-32	1.99e-25	-0.51	-0.35	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177202295	chr2:63622178~63622831:-
BRCA	trans	rs7312770	1	rs7312770	ENSG00000242970.2	AC068522.4	-12.16	6.73e-32	2e-25	-0.44	-0.35	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr8:58588420~58588764:-
BRCA	trans	rs11098499	0.954	rs6849171	ENSG00000275858.1	RP11-291L22.8	12.16	6.9e-32	2.05e-25	0.43	0.35	Corneal astigmatism;	chr4:119488394	chr10:38450738~38451069:-
BRCA	trans	rs7395662	0.57	rs11039737	ENSG00000134612.10	FOLH1B	-12.15	7.03e-32	2.09e-25	-0.45	-0.35	HDL cholesterol;	chr11:48428648	chr11:89639227~89698718:+
BRCA	trans	rs11039798	0.614	rs2174703	ENSG00000134612.10	FOLH1B	12.15	7.12e-32	2.12e-25	0.6	0.35	Axial length;	chr11:48766690	chr11:89639227~89698718:+
BRCA	trans	rs11098499	0.78	rs7680914	ENSG00000275858.1	RP11-291L22.8	12.15	7.14e-32	2.12e-25	0.45	0.35	Corneal astigmatism;	chr4:119641898	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.909	rs9759478	ENSG00000275858.1	RP11-291L22.8	12.15	7.36e-32	2.19e-25	0.44	0.35	Corneal astigmatism;	chr4:119446843	chr10:38450738~38451069:-
BRCA	trans	rs1355223	0.545	rs7123029	ENSG00000225531.1	RP11-196I18.3	12.15	7.37e-32	2.19e-25	0.48	0.35	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34853268	chr9:107116829~107117557:+
BRCA	trans	rs1355223	0.545	rs7111695	ENSG00000225531.1	RP11-196I18.3	12.15	7.37e-32	2.19e-25	0.48	0.35	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34853359	chr9:107116829~107117557:+
BRCA	trans	rs1355223	0.507	rs11032903	ENSG00000225531.1	RP11-196I18.3	12.15	7.37e-32	2.19e-25	0.48	0.35	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34854629	chr9:107116829~107117557:+
BRCA	trans	rs1355223	0.545	rs12278318	ENSG00000225531.1	RP11-196I18.3	12.15	7.37e-32	2.19e-25	0.48	0.35	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34854960	chr9:107116829~107117557:+
BRCA	trans	rs1355223	0.506	rs1509660	ENSG00000225531.1	RP11-196I18.3	12.14	7.79e-32	2.31e-25	0.48	0.35	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34843470	chr9:107116829~107117557:+
BRCA	trans	rs1355223	0.506	rs1509659	ENSG00000225531.1	RP11-196I18.3	12.14	7.79e-32	2.31e-25	0.48	0.35	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34843586	chr9:107116829~107117557:+
BRCA	trans	rs1355223	0.506	rs11032894	ENSG00000225531.1	RP11-196I18.3	12.14	7.79e-32	2.31e-25	0.48	0.35	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34843997	chr9:107116829~107117557:+
BRCA	trans	rs1355223	0.506	rs7947848	ENSG00000225531.1	RP11-196I18.3	12.14	7.79e-32	2.31e-25	0.48	0.35	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34844673	chr9:107116829~107117557:+
BRCA	trans	rs11098499	0.78	rs12504773	ENSG00000275858.1	RP11-291L22.8	12.14	8.12e-32	2.41e-25	0.45	0.35	Corneal astigmatism;	chr4:119640994	chr10:38450738~38451069:-
BRCA	trans	rs1355223	0.525	rs7129517	ENSG00000225531.1	RP11-196I18.3	12.14	8.34e-32	2.47e-25	0.48	0.35	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34850689	chr9:107116829~107117557:+
BRCA	trans	rs72615157	0.634	rs74742883	ENSG00000228546.2	CTA-313A17.3	12.13	8.92e-32	2.64e-25	0.56	0.35	Lung function (FEV1/FVC);	chr7:100188142	chr7:102337316~102339115:+
BRCA	trans	rs11098499	0.954	rs1546505	ENSG00000275858.1	RP11-291L22.8	12.13	9.1e-32	2.69e-25	0.43	0.35	Corneal astigmatism;	chr4:119320069	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.954	rs12505469	ENSG00000275858.1	RP11-291L22.8	12.13	9.25e-32	2.74e-25	0.44	0.35	Corneal astigmatism;	chr4:119328430	chr10:38450738~38451069:-
BRCA	trans	rs72615157	0.634	rs79986079	ENSG00000228546.2	CTA-313A17.3	12.13	9.51e-32	2.81e-25	0.57	0.35	Lung function (FEV1/FVC);	chr7:100204421	chr7:102337316~102339115:+
BRCA	trans	rs4276421	0.615	rs10064278	ENSG00000231752.4	EMBP1	-12.12	9.58e-32	2.83e-25	-0.46	-0.35	P wave duration;	chr5:45786496	chr1:121519112~121571892:+
BRCA	trans	rs11098499	0.909	rs71614422	ENSG00000275858.1	RP11-291L22.8	12.12	9.74e-32	2.88e-25	0.43	0.35	Corneal astigmatism;	chr4:119438185	chr10:38450738~38451069:-
BRCA	trans	rs2899832	0.568	rs10467708	ENSG00000229083.1	PSMA6P2	12.12	1.01e-31	2.99e-25	0.63	0.35	Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:35317808	chrX:12825840~12826833:+
BRCA	trans	rs7395662	0.674	rs7124275	ENSG00000134612.10	FOLH1B	-12.12	1.04e-31	3.06e-25	-0.44	-0.35	HDL cholesterol;	chr11:48140753	chr11:89639227~89698718:+
BRCA	trans	rs4276421	0.615	rs7730617	ENSG00000231752.4	EMBP1	12.12	1.06e-31	3.12e-25	0.46	0.35	P wave duration;	chr5:45840201	chr1:121519112~121571892:+
BRCA	trans	rs72615157	0.634	rs11762932	ENSG00000228546.2	CTA-313A17.3	-12.11	1.08e-31	3.19e-25	-0.56	-0.35	Lung function (FEV1/FVC);	chr7:100195043	chr7:102337316~102339115:+
BRCA	trans	rs1355223	0.525	rs7129533	ENSG00000225531.1	RP11-196I18.3	12.11	1.09e-31	3.21e-25	0.48	0.35	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34850745	chr9:107116829~107117557:+
BRCA	trans	rs1355223	0.525	rs55796371	ENSG00000225531.1	RP11-196I18.3	12.11	1.09e-31	3.21e-25	0.48	0.35	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34851222	chr9:107116829~107117557:+
BRCA	trans	rs1355223	0.525	rs12280958	ENSG00000225531.1	RP11-196I18.3	12.11	1.09e-31	3.21e-25	0.48	0.35	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34851252	chr9:107116829~107117557:+
BRCA	trans	rs8175379	0.509	rs8185010	ENSG00000231752.4	EMBP1	-12.11	1.13e-31	3.33e-25	-0.46	-0.35	Interleukin-7 levels;	chr5:46306373	chr1:121519112~121571892:+
BRCA	trans	rs77688320	0.553	rs2540430	ENSG00000235105.1	RP11-329A14.1	-12.11	1.16e-31	3.43e-25	-0.44	-0.35	Breast cancer;	chr2:201503791	chr1:48435967~48437223:+
BRCA	trans	rs13190036	1	rs13167431	ENSG00000228305.2	AC016734.2	-12.1	1.22e-31	3.6e-25	-0.51	-0.35	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177194074	chr2:63622178~63622831:-
BRCA	trans	rs877636	1	rs705696	ENSG00000227887.1	RPS26P13	12.09	1.33e-31	3.92e-25	0.46	0.35	Cognitive function;	chr12:56086864	chr1:208697369~208697698:-
BRCA	trans	rs13190036	1	rs13157667	ENSG00000228305.2	AC016734.2	-12.09	1.34e-31	3.93e-25	-0.51	-0.35	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177186876	chr2:63622178~63622831:-
BRCA	trans	rs11098499	0.954	rs12510138	ENSG00000275858.1	RP11-291L22.8	12.09	1.42e-31	4.16e-25	0.43	0.35	Corneal astigmatism;	chr4:119502780	chr10:38450738~38451069:-
BRCA	trans	rs7395662	0.525	rs1945189	ENSG00000134612.10	FOLH1B	-12.09	1.44e-31	4.23e-25	-0.45	-0.35	HDL cholesterol;	chr11:48397337	chr11:89639227~89698718:+
BRCA	trans	rs7395662	0.504	rs2019666	ENSG00000134612.10	FOLH1B	-12.09	1.46e-31	4.28e-25	-0.45	-0.35	HDL cholesterol;	chr11:48416177	chr11:89639227~89698718:+
BRCA	trans	rs4276421	0.555	rs2589181	ENSG00000231752.4	EMBP1	12.08	1.48e-31	4.33e-25	0.46	0.35	P wave duration;	chr5:45611931	chr1:121519112~121571892:+
BRCA	trans	rs11098499	0.909	rs73842633	ENSG00000275858.1	RP11-291L22.8	12.08	1.56e-31	4.55e-25	0.44	0.35	Corneal astigmatism;	chr4:119454309	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.909	rs1546504	ENSG00000275858.1	RP11-291L22.8	12.07	1.76e-31	5.14e-25	0.43	0.35	Corneal astigmatism;	chr4:119320024	chr10:38450738~38451069:-
BRCA	trans	rs9876781	1	rs4858793	ENSG00000235912.1	RP1-159A19.3	12.06	1.93e-31	5.64e-25	0.41	0.35	Longevity;	chr3:48373517	chr1:27649419~27649610:+
BRCA	trans	rs13190036	0.901	rs28715668	ENSG00000228305.2	AC016734.2	12.06	1.95e-31	5.68e-25	0.5	0.35	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177272267	chr2:63622178~63622831:-
BRCA	trans	rs10940346	0.644	rs62365309	ENSG00000231752.4	EMBP1	-12.06	1.95e-31	5.7e-25	-0.45	-0.35	Schizophrenia;	chr5:50568902	chr1:121519112~121571892:+
BRCA	trans	rs11098499	0.954	rs28572238	ENSG00000275858.1	RP11-291L22.8	12.05	2.21e-31	6.45e-25	0.43	0.35	Corneal astigmatism;	chr4:119395531	chr10:38450738~38451069:-
BRCA	trans	rs1039766	0.706	rs72822420	ENSG00000224334.1	AP000357.4	-12.04	2.41e-31	7.01e-25	-0.75	-0.35	Lung adenocarcinoma;Lung cancer;	chr2:65286633	chr22:24686923~24688087:+
BRCA	trans	rs10940346	0.807	rs4865843	ENSG00000231752.4	EMBP1	-12.04	2.45e-31	7.1e-25	-0.45	-0.35	Schizophrenia;	chr5:50569681	chr1:121519112~121571892:+
BRCA	trans	rs13190036	1	rs34446750	ENSG00000228305.2	AC016734.2	-12.04	2.48e-31	7.19e-25	-0.51	-0.35	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177168079	chr2:63622178~63622831:-
BRCA	trans	rs11098499	0.908	rs1002152	ENSG00000275858.1	RP11-291L22.8	12.03	2.6e-31	7.53e-25	0.43	0.35	Corneal astigmatism;	chr4:119352232	chr10:38450738~38451069:-
BRCA	trans	rs7121616	0.733	rs10790554	ENSG00000234176.1	HSPA8P1	12.03	2.67e-31	7.73e-25	0.4	0.35	Breast cancer;	chr11:123130376	chrX:121203182~121205014:-
BRCA	trans	rs72615157	0.697	rs2056726	ENSG00000228546.2	CTA-313A17.3	12.01	3.19e-31	9.24e-25	0.56	0.35	Lung function (FEV1/FVC);	chr7:100182660	chr7:102337316~102339115:+
BRCA	trans	rs877636	0.702	rs773112	ENSG00000227887.1	RPS26P13	12.01	3.3e-31	9.53e-25	0.46	0.35	Cognitive function;	chr12:55982097	chr1:208697369~208697698:-
BRCA	trans	rs55665837	0.54	rs10128681	ENSG00000236360.2	RP11-334A14.2	12	3.77e-31	1.09e-24	0.45	0.35	Vitamin D levels;	chr11:14680030	chr1:52993201~52993702:-
BRCA	trans	rs11039798	0.687	rs11499938	ENSG00000134612.10	FOLH1B	11.99	3.92e-31	1.13e-24	0.59	0.35	Axial length;	chr11:48935745	chr11:89639227~89698718:+
BRCA	trans	rs11039798	0.841	rs10839174	ENSG00000134612.10	FOLH1B	11.97	4.76e-31	1.37e-24	0.59	0.35	Axial length;	chr11:48909633	chr11:89639227~89698718:+
BRCA	trans	rs11039798	0.925	rs7929225	ENSG00000134612.10	FOLH1B	11.97	4.76e-31	1.37e-24	0.59	0.35	Axial length;	chr11:48910187	chr11:89639227~89698718:+
BRCA	trans	rs11039798	0.844	rs7126949	ENSG00000134612.10	FOLH1B	11.97	4.76e-31	1.37e-24	0.59	0.35	Axial length;	chr11:48950614	chr11:89639227~89698718:+
BRCA	trans	rs11039798	0.92	rs116109043	ENSG00000134612.10	FOLH1B	11.97	4.76e-31	1.37e-24	0.59	0.35	Axial length;	chr11:48955388	chr11:89639227~89698718:+
BRCA	trans	rs3956705	0.762	rs13311608	ENSG00000176826.14	FKBP9P1	11.97	4.84e-31	1.39e-24	0.43	0.35	Red cell distribution width;	chr7:32959989	chr7:55681074~55713252:-
BRCA	trans	rs2899832	0.568	rs17597267	ENSG00000229083.1	PSMA6P2	11.97	5.1e-31	1.46e-24	0.63	0.35	Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:35312698	chrX:12825840~12826833:+
BRCA	trans	rs11039798	0.778	rs7944523	ENSG00000134612.10	FOLH1B	11.96	5.37e-31	1.54e-24	0.59	0.35	Axial length;	chr11:48889467	chr11:89639227~89698718:+
BRCA	trans	rs11039798	0.925	rs12277669	ENSG00000134612.10	FOLH1B	11.96	5.37e-31	1.54e-24	0.59	0.35	Axial length;	chr11:48903764	chr11:89639227~89698718:+
BRCA	trans	rs11039798	0.764	rs76882342	ENSG00000134612.10	FOLH1B	11.96	5.37e-31	1.54e-24	0.59	0.35	Axial length;	chr11:48917539	chr11:89639227~89698718:+
BRCA	trans	rs11039798	0.844	rs11040177	ENSG00000134612.10	FOLH1B	11.96	5.37e-31	1.54e-24	0.59	0.35	Axial length;	chr11:48954659	chr11:89639227~89698718:+
BRCA	trans	rs77688320	0.535	rs7579853	ENSG00000235105.1	RP11-329A14.1	11.96	5.38e-31	1.54e-24	0.42	0.35	Breast cancer;	chr2:201384256	chr1:48435967~48437223:+
BRCA	trans	rs11039798	0.614	rs11039954	ENSG00000134612.10	FOLH1B	11.96	5.56e-31	1.59e-24	0.59	0.35	Axial length;	chr11:48720266	chr11:89639227~89698718:+
BRCA	trans	rs877636	0.702	rs773111	ENSG00000227887.1	RPS26P13	11.96	5.67e-31	1.62e-24	0.46	0.35	Cognitive function;	chr12:55981956	chr1:208697369~208697698:-
BRCA	trans	rs11039798	0.92	rs11040013	ENSG00000134612.10	FOLH1B	11.96	5.74e-31	1.64e-24	0.6	0.35	Axial length;	chr11:48761310	chr11:89639227~89698718:+
BRCA	trans	rs55665837	0.54	rs7938266	ENSG00000236360.2	RP11-334A14.2	11.96	5.78e-31	1.65e-24	0.45	0.35	Vitamin D levels;	chr11:14687778	chr1:52993201~52993702:-
BRCA	trans	rs11039798	1	rs11039978	ENSG00000134612.10	FOLH1B	11.96	5.8e-31	1.66e-24	0.59	0.35	Axial length;	chr11:48738685	chr11:89639227~89698718:+
BRCA	trans	rs11039798	1	rs115429994	ENSG00000134612.10	FOLH1B	11.96	5.8e-31	1.66e-24	0.59	0.35	Axial length;	chr11:48739631	chr11:89639227~89698718:+
BRCA	trans	rs11039798	0.764	rs7294013	ENSG00000134612.10	FOLH1B	11.96	5.8e-31	1.66e-24	0.59	0.35	Axial length;	chr11:48740864	chr11:89639227~89698718:+
BRCA	trans	rs11039798	0.92	rs8186465	ENSG00000134612.10	FOLH1B	11.96	5.8e-31	1.66e-24	0.59	0.35	Axial length;	chr11:48775219	chr11:89639227~89698718:+
BRCA	trans	rs11039798	0.764	rs11040030	ENSG00000134612.10	FOLH1B	11.96	5.8e-31	1.66e-24	0.59	0.35	Axial length;	chr11:48779433	chr11:89639227~89698718:+
BRCA	trans	rs11039798	0.688	rs12277029	ENSG00000134612.10	FOLH1B	11.96	5.8e-31	1.66e-24	0.59	0.35	Axial length;	chr11:48831281	chr11:89639227~89698718:+
BRCA	trans	rs77688320	0.553	rs3795966	ENSG00000235105.1	RP11-329A14.1	11.95	6.09e-31	1.74e-24	0.42	0.35	Breast cancer;	chr2:201380521	chr1:48435967~48437223:+
BRCA	trans	rs6732160	0.809	rs13416592	ENSG00000236165.1	PRADC1P1	11.95	6.36e-31	1.81e-24	0.45	0.35	Intelligence (multi-trait analysis);	chr2:73137928	chr3:36976316~36976840:+
BRCA	trans	rs11039798	0.688	rs8188953	ENSG00000134612.10	FOLH1B	11.94	6.54e-31	1.86e-24	0.59	0.35	Axial length;	chr11:48727649	chr11:89639227~89698718:+
BRCA	trans	rs11039798	1	rs12225599	ENSG00000134612.10	FOLH1B	11.94	6.54e-31	1.86e-24	0.59	0.35	Axial length;	chr11:48734316	chr11:89639227~89698718:+
BRCA	trans	rs11039798	0.541	rs12283728	ENSG00000134612.10	FOLH1B	11.94	6.54e-31	1.86e-24	0.59	0.35	Axial length;	chr11:48774855	chr11:89639227~89698718:+
BRCA	trans	rs55665837	0.54	rs4757261	ENSG00000236360.2	RP11-334A14.2	11.94	6.67e-31	1.9e-24	0.45	0.35	Vitamin D levels;	chr11:14648256	chr1:52993201~52993702:-
BRCA	trans	rs55665837	0.54	rs11023302	ENSG00000236360.2	RP11-334A14.2	11.94	6.71e-31	1.91e-24	0.45	0.35	Vitamin D levels;	chr11:14672389	chr1:52993201~52993702:-
BRCA	trans	rs11039798	0.841	rs11500573	ENSG00000134612.10	FOLH1B	11.94	6.82e-31	1.94e-24	0.59	0.35	Axial length;	chr11:48692348	chr11:89639227~89698718:+
BRCA	trans	rs11039798	0.92	rs11039940	ENSG00000134612.10	FOLH1B	11.94	6.82e-31	1.94e-24	0.59	0.35	Axial length;	chr11:48694764	chr11:89639227~89698718:+
BRCA	trans	rs11098499	0.954	rs3733520	ENSG00000275858.1	RP11-291L22.8	11.94	6.93e-31	1.97e-24	0.42	0.35	Corneal astigmatism;	chr4:119502325	chr10:38450738~38451069:-
BRCA	trans	rs877636	0.702	rs773110	ENSG00000227887.1	RPS26P13	11.94	7.04e-31	2e-24	0.46	0.35	Cognitive function;	chr12:55981353	chr1:208697369~208697698:-
BRCA	trans	rs77688320	0.517	rs7605375	ENSG00000235105.1	RP11-329A14.1	11.94	7.08e-31	2.01e-24	0.42	0.35	Breast cancer;	chr2:201465907	chr1:48435967~48437223:+
BRCA	trans	rs11098499	0.908	rs9995234	ENSG00000275858.1	RP11-291L22.8	11.94	7.11e-31	2.02e-24	0.45	0.35	Corneal astigmatism;	chr4:119400672	chr10:38450738~38451069:-
BRCA	trans	rs11039798	1	rs8188963	ENSG00000134612.10	FOLH1B	11.94	7.16e-31	2.03e-24	0.59	0.35	Axial length;	chr11:48664141	chr11:89639227~89698718:+
BRCA	trans	rs11039798	0.92	rs9667596	ENSG00000134612.10	FOLH1B	11.94	7.16e-31	2.03e-24	0.59	0.35	Axial length;	chr11:48669641	chr11:89639227~89698718:+
BRCA	trans	rs11098499	0.909	rs10026736	ENSG00000275858.1	RP11-291L22.8	11.93	7.49e-31	2.12e-24	0.44	0.35	Corneal astigmatism;	chr4:119463167	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.532	rs4833624	ENSG00000275858.1	RP11-291L22.8	11.93	7.55e-31	2.14e-24	0.42	0.35	Corneal astigmatism;	chr4:119664342	chr10:38450738~38451069:-
BRCA	trans	rs11039798	0.764	rs12277213	ENSG00000134612.10	FOLH1B	11.93	7.6e-31	2.15e-24	0.59	0.35	Axial length;	chr11:48760624	chr11:89639227~89698718:+
BRCA	trans	rs11039798	0.92	rs11500574	ENSG00000134612.10	FOLH1B	11.93	7.62e-31	2.16e-24	0.59	0.35	Axial length;	chr11:48692434	chr11:89639227~89698718:+
BRCA	trans	rs11098499	0.909	rs28714195	ENSG00000275858.1	RP11-291L22.8	11.93	7.69e-31	2.18e-24	0.42	0.35	Corneal astigmatism;	chr4:119395795	chr10:38450738~38451069:-
BRCA	trans	rs11039798	0.764	rs11039929	ENSG00000134612.10	FOLH1B	11.93	8.01e-31	2.27e-24	0.59	0.35	Axial length;	chr11:48681737	chr11:89639227~89698718:+
BRCA	trans	rs11039798	0.764	rs1121450	ENSG00000134612.10	FOLH1B	11.92	8.07e-31	2.28e-24	0.59	0.35	Axial length;	chr11:48875924	chr11:89639227~89698718:+
BRCA	trans	rs11098499	0.863	rs13136462	ENSG00000275858.1	RP11-291L22.8	11.92	8.34e-31	2.36e-24	0.44	0.35	Corneal astigmatism;	chr4:119622018	chr10:38450738~38451069:-
BRCA	trans	rs9425766	0.962	rs9425430	ENSG00000213331.4	RP11-713C19.2	11.91	8.91e-31	2.52e-24	0.41	0.35	Life satisfaction;	chr1:173888145	chr4:187970273~187971284:+
BRCA	trans	rs4276421	0.555	rs2247112	ENSG00000231752.4	EMBP1	11.91	9.26e-31	2.61e-24	0.45	0.35	P wave duration;	chr5:45628908	chr1:121519112~121571892:+
BRCA	trans	rs10838798	0.504	rs11039634	ENSG00000134612.10	FOLH1B	-11.9	9.98e-31	2.81e-24	-0.44	-0.35	Height;	chr11:48276291	chr11:89639227~89698718:+
BRCA	trans	rs2727020	0.704	rs2988340	ENSG00000134612.10	FOLH1B	-11.9	1.03e-30	2.9e-24	-0.43	-0.35	Coronary artery disease;	chr11:49154505	chr11:89639227~89698718:+
BRCA	trans	rs11039798	0.614	rs8188910	ENSG00000134612.10	FOLH1B	11.9	1.07e-30	3.02e-24	0.59	0.35	Axial length;	chr11:48804188	chr11:89639227~89698718:+
BRCA	trans	rs11039798	1	rs11039904	ENSG00000134612.10	FOLH1B	11.9	1.09e-30	3.06e-24	0.6	0.35	Axial length;	chr11:48661045	chr11:89639227~89698718:+
BRCA	trans	rs10037055	1	rs6886255	ENSG00000226986.4	RP11-543B16.2	11.9	1.09e-30	3.08e-24	0.46	0.35	Migraine without aura;	chr5:177291360	chr1:211207239~211207897:+
BRCA	trans	rs11098499	0.909	rs10020034	ENSG00000275858.1	RP11-291L22.8	11.89	1.11e-30	3.13e-24	0.43	0.35	Corneal astigmatism;	chr4:119373176	chr10:38450738~38451069:-
BRCA	trans	rs77688320	0.517	rs12623282	ENSG00000235105.1	RP11-329A14.1	11.89	1.15e-30	3.24e-24	0.42	0.35	Breast cancer;	chr2:201382734	chr1:48435967~48437223:+
BRCA	trans	rs11098499	0.82	rs13122709	ENSG00000275858.1	RP11-291L22.8	11.89	1.17e-30	3.27e-24	0.43	0.35	Corneal astigmatism;	chr4:119634201	chr10:38450738~38451069:-
BRCA	trans	rs11039798	0.764	rs2089208	ENSG00000134612.10	FOLH1B	11.89	1.21e-30	3.39e-24	0.59	0.35	Axial length;	chr11:48878308	chr11:89639227~89698718:+
BRCA	trans	rs11098499	0.954	rs13107475	ENSG00000275858.1	RP11-291L22.8	11.88	1.24e-30	3.48e-24	0.42	0.35	Corneal astigmatism;	chr4:119471856	chr10:38450738~38451069:-
BRCA	trans	rs10940346	0.777	rs11744698	ENSG00000231752.4	EMBP1	-11.88	1.27e-30	3.55e-24	-0.45	-0.35	Schizophrenia;	chr5:50586024	chr1:121519112~121571892:+
BRCA	trans	rs11098499	0.909	rs1546502	ENSG00000275858.1	RP11-291L22.8	11.88	1.28e-30	3.58e-24	0.43	0.35	Corneal astigmatism;	chr4:119314743	chr10:38450738~38451069:-
BRCA	trans	rs11039798	0.61	rs11530356	ENSG00000134612.10	FOLH1B	11.88	1.31e-30	3.67e-24	0.59	0.35	Axial length;	chr11:48814738	chr11:89639227~89698718:+
BRCA	trans	rs77688320	0.535	rs7561048	ENSG00000235105.1	RP11-329A14.1	11.88	1.32e-30	3.69e-24	0.42	0.35	Breast cancer;	chr2:201388316	chr1:48435967~48437223:+
BRCA	trans	rs2899832	0.5	rs112106731	ENSG00000229083.1	PSMA6P2	11.88	1.33e-30	3.72e-24	0.61	0.35	Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:35298279	chrX:12825840~12826833:+
BRCA	trans	rs2899832	0.568	rs10142113	ENSG00000229083.1	PSMA6P2	11.88	1.33e-30	3.72e-24	0.61	0.35	Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:35298623	chrX:12825840~12826833:+
BRCA	trans	rs11098499	0.954	rs59394118	ENSG00000275858.1	RP11-291L22.8	11.88	1.35e-30	3.78e-24	0.43	0.35	Corneal astigmatism;	chr4:119374396	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.865	rs9996417	ENSG00000275858.1	RP11-291L22.8	11.88	1.35e-30	3.78e-24	0.43	0.35	Corneal astigmatism;	chr4:119374707	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.954	rs3733524	ENSG00000275858.1	RP11-291L22.8	11.87	1.36e-30	3.8e-24	0.45	0.35	Corneal astigmatism;	chr4:119502574	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.954	rs4309825	ENSG00000275858.1	RP11-291L22.8	-11.87	1.4e-30	3.91e-24	-0.42	-0.35	Corneal astigmatism;	chr4:119393726	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.866	rs3756156	ENSG00000275858.1	RP11-291L22.8	11.87	1.41e-30	3.93e-24	0.44	0.35	Corneal astigmatism;	chr4:119603686	chr10:38450738~38451069:-
BRCA	trans	rs4276421	0.806	rs10079739	ENSG00000231752.4	EMBP1	-11.87	1.44e-30	4.03e-24	-0.46	-0.35	P wave duration;	chr5:45607597	chr1:121519112~121571892:+
BRCA	trans	rs877636	0.702	rs773109	ENSG00000227887.1	RPS26P13	11.87	1.5e-30	4.2e-24	0.46	0.35	Cognitive function;	chr12:55980911	chr1:208697369~208697698:-
BRCA	trans	rs616147	0.962	rs1708104	ENSG00000214263.2	RPSAP53	-11.86	1.56e-30	4.35e-24	-0.49	-0.34	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39493251	chr13:67266845~67267706:-
BRCA	trans	rs11098499	0.954	rs11722872	ENSG00000275858.1	RP11-291L22.8	11.85	1.71e-30	4.77e-24	0.43	0.34	Corneal astigmatism;	chr4:119311875	chr10:38450738~38451069:-
BRCA	trans	rs10940346	0.601	rs1033109	ENSG00000231752.4	EMBP1	11.85	1.8e-30	5e-24	0.44	0.34	Schizophrenia;	chr5:50327705	chr1:121519112~121571892:+
BRCA	trans	rs11098499	0.865	rs11098513	ENSG00000275858.1	RP11-291L22.8	11.84	1.92e-30	5.32e-24	0.42	0.34	Corneal astigmatism;	chr4:119394920	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.738	rs28408407	ENSG00000275858.1	RP11-291L22.8	11.84	2.01e-30	5.58e-24	0.42	0.34	Corneal astigmatism;	chr4:119454875	chr10:38450738~38451069:-
BRCA	trans	rs877636	0.702	rs61937249	ENSG00000227887.1	RPS26P13	11.84	2.02e-30	5.61e-24	0.45	0.34	Cognitive function;	chr12:55988132	chr1:208697369~208697698:-
BRCA	trans	rs11098499	0.618	rs28491261	ENSG00000275858.1	RP11-291L22.8	11.84	2.06e-30	5.71e-24	0.43	0.34	Corneal astigmatism;	chr4:119373745	chr10:38450738~38451069:-
BRCA	trans	rs877636	1	rs877636	ENSG00000196656.7	AC004057.1	-11.83	2.13e-30	5.9e-24	-0.41	-0.34	Cognitive function;	chr12:56086799	chr4:113214046~113217170:-
BRCA	trans	rs11098499	0.954	rs7437420	ENSG00000275858.1	RP11-291L22.8	11.83	2.16e-30	5.99e-24	0.42	0.34	Corneal astigmatism;	chr4:119391748	chr10:38450738~38451069:-
BRCA	trans	rs1079467	0.735	rs75941265	ENSG00000233426.3	EIF3FP3	-11.83	2.28e-30	6.31e-24	-0.61	-0.34	Response to anti-TNF therapy in rheumatoid arthritis;	chr11:7949542	chr2:58251440~58252525:+
BRCA	trans	rs2899832	0.568	rs8014594	ENSG00000229083.1	PSMA6P2	11.83	2.29e-30	6.35e-24	0.63	0.34	Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:35296623	chrX:12825840~12826833:+
BRCA	trans	rs10242455	1	rs2301889	ENSG00000228834.1	RP11-249L21.4	11.82	2.32e-30	6.42e-24	0.73	0.34	Blood metabolite levels;	chr7:99333482	chr6:108907615~108907873:-
BRCA	trans	rs11098499	0.909	rs11723757	ENSG00000275858.1	RP11-291L22.8	11.82	2.46e-30	6.81e-24	0.42	0.34	Corneal astigmatism;	chr4:119378514	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.738	rs72918577	ENSG00000275858.1	RP11-291L22.8	11.82	2.55e-30	7.05e-24	0.42	0.34	Corneal astigmatism;	chr4:119405546	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.954	rs59866101	ENSG00000275858.1	RP11-291L22.8	11.81	2.57e-30	7.08e-24	0.42	0.34	Corneal astigmatism;	chr4:119375436	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.618	rs6858383	ENSG00000275858.1	RP11-291L22.8	11.81	2.57e-30	7.08e-24	0.42	0.34	Corneal astigmatism;	chr4:119375617	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.697	rs6832410	ENSG00000275858.1	RP11-291L22.8	11.81	2.57e-30	7.08e-24	0.42	0.34	Corneal astigmatism;	chr4:119375645	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.865	rs1112817	ENSG00000275858.1	RP11-291L22.8	11.81	2.57e-30	7.08e-24	0.42	0.34	Corneal astigmatism;	chr4:119376645	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.779	rs10016060	ENSG00000275858.1	RP11-291L22.8	11.81	2.57e-30	7.08e-24	0.42	0.34	Corneal astigmatism;	chr4:119377257	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.954	rs10005644	ENSG00000275858.1	RP11-291L22.8	11.81	2.57e-30	7.08e-24	0.42	0.34	Corneal astigmatism;	chr4:119377322	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.697	rs10016448	ENSG00000275858.1	RP11-291L22.8	11.81	2.57e-30	7.08e-24	0.42	0.34	Corneal astigmatism;	chr4:119377690	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.657	rs9996569	ENSG00000275858.1	RP11-291L22.8	11.81	2.57e-30	7.08e-24	0.42	0.34	Corneal astigmatism;	chr4:119377849	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.908	rs11729050	ENSG00000275858.1	RP11-291L22.8	11.81	2.57e-30	7.08e-24	0.42	0.34	Corneal astigmatism;	chr4:119378911	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.954	rs28429722	ENSG00000275858.1	RP11-291L22.8	11.81	2.57e-30	7.08e-24	0.42	0.34	Corneal astigmatism;	chr4:119378938	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.954	rs10014845	ENSG00000275858.1	RP11-291L22.8	11.81	2.57e-30	7.08e-24	0.42	0.34	Corneal astigmatism;	chr4:119379922	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.779	rs7674500	ENSG00000275858.1	RP11-291L22.8	11.81	2.57e-30	7.08e-24	0.42	0.34	Corneal astigmatism;	chr4:119382438	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.909	rs28884220	ENSG00000275858.1	RP11-291L22.8	11.81	2.57e-30	7.08e-24	0.42	0.34	Corneal astigmatism;	chr4:119386056	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.909	rs28793658	ENSG00000275858.1	RP11-291L22.8	11.81	2.57e-30	7.08e-24	0.42	0.34	Corneal astigmatism;	chr4:119386059	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.697	rs4373140	ENSG00000275858.1	RP11-291L22.8	11.81	2.57e-30	7.08e-24	0.42	0.34	Corneal astigmatism;	chr4:119386543	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.954	rs13113483	ENSG00000275858.1	RP11-291L22.8	11.81	2.57e-30	7.08e-24	0.42	0.34	Corneal astigmatism;	chr4:119387884	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.542	rs10440343	ENSG00000275858.1	RP11-291L22.8	11.81	2.57e-30	7.08e-24	0.42	0.34	Corneal astigmatism;	chr4:119388632	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.779	rs10011097	ENSG00000275858.1	RP11-291L22.8	11.81	2.57e-30	7.08e-24	0.42	0.34	Corneal astigmatism;	chr4:119389204	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.542	rs7677836	ENSG00000275858.1	RP11-291L22.8	11.81	2.57e-30	7.08e-24	0.42	0.34	Corneal astigmatism;	chr4:119389483	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.909	rs10002083	ENSG00000275858.1	RP11-291L22.8	11.81	2.57e-30	7.08e-24	0.42	0.34	Corneal astigmatism;	chr4:119389997	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.954	rs10024844	ENSG00000275858.1	RP11-291L22.8	11.81	2.57e-30	7.08e-24	0.42	0.34	Corneal astigmatism;	chr4:119390373	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.954	rs4345162	ENSG00000275858.1	RP11-291L22.8	11.81	2.57e-30	7.08e-24	0.42	0.34	Corneal astigmatism;	chr4:119391804	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.657	rs4463052	ENSG00000275858.1	RP11-291L22.8	11.81	2.57e-30	7.08e-24	0.42	0.34	Corneal astigmatism;	chr4:119392103	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.954	rs13151285	ENSG00000275858.1	RP11-291L22.8	11.81	2.57e-30	7.08e-24	0.42	0.34	Corneal astigmatism;	chr4:119393586	chr10:38450738~38451069:-
BRCA	trans	rs1079467	0.73	rs74933956	ENSG00000233426.3	EIF3FP3	-11.81	2.66e-30	7.32e-24	-0.61	-0.34	Response to anti-TNF therapy in rheumatoid arthritis;	chr11:7950507	chr2:58251440~58252525:+
BRCA	trans	rs1079467	0.73	rs77880011	ENSG00000233426.3	EIF3FP3	-11.81	2.66e-30	7.32e-24	-0.61	-0.34	Response to anti-TNF therapy in rheumatoid arthritis;	chr11:7950656	chr2:58251440~58252525:+
BRCA	trans	rs11098499	0.909	rs1809406	ENSG00000275858.1	RP11-291L22.8	11.81	2.76e-30	7.59e-24	0.42	0.34	Corneal astigmatism;	chr4:119455967	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.865	rs2389809	ENSG00000275858.1	RP11-291L22.8	11.81	2.76e-30	7.59e-24	0.42	0.34	Corneal astigmatism;	chr4:119456244	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.909	rs9994810	ENSG00000275858.1	RP11-291L22.8	11.81	2.76e-30	7.59e-24	0.42	0.34	Corneal astigmatism;	chr4:119460435	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.697	rs10020027	ENSG00000275858.1	RP11-291L22.8	11.81	2.76e-30	7.59e-24	0.42	0.34	Corneal astigmatism;	chr4:119460724	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.779	rs7356491	ENSG00000275858.1	RP11-291L22.8	11.81	2.76e-30	7.59e-24	0.42	0.34	Corneal astigmatism;	chr4:119460819	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.954	rs67265404	ENSG00000275858.1	RP11-291L22.8	11.81	2.79e-30	7.67e-24	0.43	0.34	Corneal astigmatism;	chr4:119438115	chr10:38450738~38451069:-
BRCA	trans	rs3806843	0.676	rs2563304	ENSG00000231043.3	AC007238.1	11.81	2.81e-30	7.73e-24	0.4	0.34	Depressive symptoms (multi-trait analysis);	chr5:140692472	chr2:58460292~58462032:-
BRCA	trans	rs3806843	0.735	rs3776129	ENSG00000231043.3	AC007238.1	11.81	2.81e-30	7.73e-24	0.4	0.34	Depressive symptoms (multi-trait analysis);	chr5:140692707	chr2:58460292~58462032:-
BRCA	trans	rs3806843	0.706	rs1089305	ENSG00000231043.3	AC007238.1	11.8	2.92e-30	8.02e-24	0.4	0.34	Depressive symptoms (multi-trait analysis);	chr5:140686721	chr2:58460292~58462032:-
BRCA	trans	rs3806843	0.735	rs801185	ENSG00000231043.3	AC007238.1	11.8	2.93e-30	8.06e-24	0.4	0.34	Depressive symptoms (multi-trait analysis);	chr5:140689284	chr2:58460292~58462032:-
BRCA	trans	rs9425766	0.962	rs1322777	ENSG00000213331.4	RP11-713C19.2	11.8	2.99e-30	8.21e-24	0.4	0.34	Life satisfaction;	chr1:173889962	chr4:187970273~187971284:+
BRCA	trans	rs4276421	0.571	rs7703405	ENSG00000231752.4	EMBP1	-11.8	3.07e-30	8.44e-24	-0.45	-0.34	P wave duration;	chr5:45872218	chr1:121519112~121571892:+
BRCA	trans	rs11098499	0.566	rs17051356	ENSG00000275858.1	RP11-291L22.8	11.8	3.11e-30	8.53e-24	0.45	0.34	Corneal astigmatism;	chr4:119664153	chr10:38450738~38451069:-
BRCA	trans	rs877636	1	rs877636	ENSG00000196933.5	RPS26P11	-11.79	3.15e-30	8.65e-24	-0.43	-0.34	Cognitive function;	chr12:56086799	chrX:72044545~72044892:+
BRCA	trans	rs3806843	0.735	rs2563306	ENSG00000231043.3	AC007238.1	11.79	3.23e-30	8.85e-24	0.4	0.34	Depressive symptoms (multi-trait analysis);	chr5:140690432	chr2:58460292~58462032:-
BRCA	trans	rs3806843	0.735	rs813897	ENSG00000231043.3	AC007238.1	11.79	3.23e-30	8.85e-24	0.4	0.34	Depressive symptoms (multi-trait analysis);	chr5:140690444	chr2:58460292~58462032:-
BRCA	trans	rs11098499	0.909	rs28668716	ENSG00000275858.1	RP11-291L22.8	11.79	3.37e-30	9.23e-24	0.42	0.34	Corneal astigmatism;	chr4:119388720	chr10:38450738~38451069:-
BRCA	trans	rs2899832	0.568	rs7158019	ENSG00000229083.1	PSMA6P2	11.79	3.47e-30	9.5e-24	0.63	0.34	Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:35305912	chrX:12825840~12826833:+
BRCA	trans	rs877636	0.74	rs772920	ENSG00000227887.1	RPS26P13	11.78	3.57e-30	9.77e-24	0.45	0.34	Cognitive function;	chr12:55996580	chr1:208697369~208697698:-
BRCA	trans	rs11098499	0.604	rs2389886	ENSG00000275858.1	RP11-291L22.8	11.78	3.58e-30	9.79e-24	0.45	0.34	Corneal astigmatism;	chr4:119649267	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.532	rs4504231	ENSG00000275858.1	RP11-291L22.8	11.78	3.75e-30	1.03e-23	0.42	0.34	Corneal astigmatism;	chr4:119665736	chr10:38450738~38451069:-
BRCA	trans	rs6732160	0.845	rs10203125	ENSG00000236165.1	PRADC1P1	11.78	3.82e-30	1.04e-23	0.45	0.34	Intelligence (multi-trait analysis);	chr2:73134023	chr3:36976316~36976840:+
BRCA	trans	rs11098499	0.908	rs28499576	ENSG00000275858.1	RP11-291L22.8	11.78	3.84e-30	1.05e-23	0.42	0.34	Corneal astigmatism;	chr4:119465522	chr10:38450738~38451069:-
BRCA	trans	rs6732160	0.845	rs10203718	ENSG00000236165.1	PRADC1P1	11.78	3.86e-30	1.06e-23	0.45	0.34	Intelligence (multi-trait analysis);	chr2:73134387	chr3:36976316~36976840:+
BRCA	trans	rs55665837	0.54	rs12290926	ENSG00000236360.2	RP11-334A14.2	11.77	4.01e-30	1.1e-23	0.45	0.34	Vitamin D levels;	chr11:14673500	chr1:52993201~52993702:-
BRCA	trans	rs3806843	0.735	rs2530240	ENSG00000231043.3	AC007238.1	11.77	4.15e-30	1.13e-23	0.4	0.34	Depressive symptoms (multi-trait analysis);	chr5:140680962	chr2:58460292~58462032:-
BRCA	trans	rs3806843	0.801	rs2531358	ENSG00000231043.3	AC007238.1	11.77	4.18e-30	1.14e-23	0.4	0.34	Depressive symptoms (multi-trait analysis);	chr5:140737852	chr2:58460292~58462032:-
BRCA	trans	rs55665837	0.52	rs10766189	ENSG00000236360.2	RP11-334A14.2	11.77	4.27e-30	1.17e-23	0.45	0.34	Vitamin D levels;	chr11:14712377	chr1:52993201~52993702:-
BRCA	trans	rs11098499	0.82	rs28394116	ENSG00000275858.1	RP11-291L22.8	11.77	4.28e-30	1.17e-23	0.43	0.34	Corneal astigmatism;	chr4:119603128	chr10:38450738~38451069:-
BRCA	trans	rs3806843	0.706	rs2563302	ENSG00000231043.3	AC007238.1	11.76	4.41e-30	1.21e-23	0.4	0.34	Depressive symptoms (multi-trait analysis);	chr5:140699466	chr2:58460292~58462032:-
BRCA	trans	rs2657294	0.965	rs2657291	ENSG00000172974.11	AC007318.5	11.76	4.53e-30	1.24e-23	0.42	0.34	Pneumonia;	chr10:75166945	chr2:65205108~65205988:+
BRCA	trans	rs11098499	0.909	rs10017335	ENSG00000275858.1	RP11-291L22.8	-11.76	4.59e-30	1.25e-23	-0.43	-0.34	Corneal astigmatism;	chr4:119460368	chr10:38450738~38451069:-
BRCA	trans	rs7312770	0.612	rs1873914	ENSG00000196933.5	RPS26P11	11.75	4.79e-30	1.31e-23	0.41	0.34	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chrX:72044545~72044892:+
BRCA	trans	rs11023332	0.832	rs10832289	ENSG00000236360.2	RP11-334A14.2	-11.75	4.81e-30	1.31e-23	-0.44	-0.34	Vitamin D levels;Adiponectin levels;	chr11:14647950	chr1:52993201~52993702:-
BRCA	trans	rs3806843	0.705	rs35614340	ENSG00000231043.3	AC007238.1	11.75	4.92e-30	1.34e-23	0.4	0.34	Depressive symptoms (multi-trait analysis);	chr5:140664033	chr2:58460292~58462032:-
BRCA	trans	rs10940346	0.807	rs6898102	ENSG00000231752.4	EMBP1	-11.75	4.95e-30	1.35e-23	-0.44	-0.34	Schizophrenia;	chr5:50578496	chr1:121519112~121571892:+
BRCA	trans	rs3806843	1	rs4451093	ENSG00000231043.3	AC007238.1	11.75	5.18e-30	1.41e-23	0.39	0.34	Depressive symptoms (multi-trait analysis);	chr5:140778957	chr2:58460292~58462032:-
BRCA	trans	rs1079467	0.73	rs72846600	ENSG00000233426.3	EIF3FP3	-11.74	5.34e-30	1.45e-23	-0.59	-0.34	Response to anti-TNF therapy in rheumatoid arthritis;	chr11:7952994	chr2:58251440~58252525:+
BRCA	trans	rs11098499	0.532	rs12512646	ENSG00000275858.1	RP11-291L22.8	11.74	5.34e-30	1.46e-23	0.42	0.34	Corneal astigmatism;	chr4:119664578	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.604	rs2389887	ENSG00000275858.1	RP11-291L22.8	11.74	5.64e-30	1.54e-23	0.44	0.34	Corneal astigmatism;	chr4:119649489	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.604	rs34278750	ENSG00000275858.1	RP11-291L22.8	11.74	5.64e-30	1.54e-23	0.44	0.34	Corneal astigmatism;	chr4:119649981	chr10:38450738~38451069:-
BRCA	trans	rs10838798	0.504	rs11039627	ENSG00000134612.10	FOLH1B	-11.73	6.43e-30	1.75e-23	-0.44	-0.34	Height;	chr11:48272379	chr11:89639227~89698718:+
BRCA	trans	rs3806843	0.735	rs801180	ENSG00000231043.3	AC007238.1	11.73	6.46e-30	1.76e-23	0.4	0.34	Depressive symptoms (multi-trait analysis);	chr5:140713318	chr2:58460292~58462032:-
BRCA	trans	rs3806843	0.735	rs801183	ENSG00000231043.3	AC007238.1	-11.72	6.58e-30	1.79e-23	-0.4	-0.34	Depressive symptoms (multi-trait analysis);	chr5:140711530	chr2:58460292~58462032:-
BRCA	trans	rs11039798	0.925	rs10769373	ENSG00000134612.10	FOLH1B	11.72	6.6e-30	1.79e-23	0.58	0.34	Axial length;	chr11:48510428	chr11:89639227~89698718:+
BRCA	trans	rs13014235	0.592	rs55860809	ENSG00000235105.1	RP11-329A14.1	11.72	6.78e-30	1.84e-23	0.41	0.34	Basal cell carcinoma;	chr2:201394347	chr1:48435967~48437223:+
BRCA	trans	rs1355223	0.506	rs7131272	ENSG00000225531.1	RP11-196I18.3	-11.72	7.12e-30	1.93e-23	-0.47	-0.34	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34848001	chr9:107116829~107117557:+
BRCA	trans	rs11098499	0.604	rs10022185	ENSG00000275858.1	RP11-291L22.8	11.72	7.17e-30	1.95e-23	0.44	0.34	Corneal astigmatism;	chr4:119650610	chr10:38450738~38451069:-
BRCA	trans	rs77688320	0.535	rs11680694	ENSG00000235105.1	RP11-329A14.1	11.72	7.18e-30	1.95e-23	0.41	0.34	Breast cancer;	chr2:201393498	chr1:48435967~48437223:+
BRCA	trans	rs55665837	0.523	rs10832301	ENSG00000236360.2	RP11-334A14.2	11.71	7.27e-30	1.97e-23	0.45	0.34	Vitamin D levels;	chr11:14767418	chr1:52993201~52993702:-
BRCA	trans	rs77688320	0.535	rs7579617	ENSG00000235105.1	RP11-329A14.1	11.7	8.07e-30	2.19e-23	0.41	0.34	Breast cancer;	chr2:201384065	chr1:48435967~48437223:+
BRCA	trans	rs55665837	0.54	rs10832294	ENSG00000236360.2	RP11-334A14.2	11.7	8.52e-30	2.31e-23	0.45	0.34	Vitamin D levels;	chr11:14725881	chr1:52993201~52993702:-
BRCA	trans	rs3806843	0.735	rs801189	ENSG00000231043.3	AC007238.1	11.69	9.04e-30	2.45e-23	0.4	0.34	Depressive symptoms (multi-trait analysis);	chr5:140683506	chr2:58460292~58462032:-
BRCA	trans	rs6498068	0.594	rs1875928	ENSG00000278702.1	Metazoa_SRP	11.69	9.21e-30	2.49e-23	0.47	0.34	Metabolite levels (MHPG);	chr16:10528028	chr1:35399997~35400319:+
BRCA	trans	rs11098499	0.954	rs2389803	ENSG00000275858.1	RP11-291L22.8	-11.69	9.26e-30	2.51e-23	-0.42	-0.34	Corneal astigmatism;	chr4:119472356	chr10:38450738~38451069:-
BRCA	trans	rs55665837	0.54	rs12416696	ENSG00000236360.2	RP11-334A14.2	11.69	9.9e-30	2.68e-23	0.44	0.34	Vitamin D levels;	chr11:14769343	chr1:52993201~52993702:-
BRCA	trans	rs11098499	0.865	rs4507344	ENSG00000275858.1	RP11-291L22.8	11.68	9.99e-30	2.7e-23	0.42	0.34	Corneal astigmatism;	chr4:119386330	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.82	rs28578366	ENSG00000275858.1	RP11-291L22.8	-11.68	1.02e-29	2.77e-23	-0.42	-0.34	Corneal astigmatism;	chr4:119615750	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.863	rs1552095	ENSG00000275858.1	RP11-291L22.8	11.68	1.03e-29	2.78e-23	0.44	0.34	Corneal astigmatism;	chr4:119539151	chr10:38450738~38451069:-
BRCA	trans	rs3806843	0.735	rs6849	ENSG00000231043.3	AC007238.1	11.68	1.04e-29	2.81e-23	0.4	0.34	Depressive symptoms (multi-trait analysis);	chr5:140706606	chr2:58460292~58462032:-
BRCA	trans	rs877636	0.859	rs3741499	ENSG00000234513.1	AC073072.7	-11.68	1.07e-29	2.89e-23	-0.42	-0.34	Cognitive function;	chr12:56080595	chr7:22773646~22773993:-
BRCA	trans	rs7312770	0.612	rs1873914	ENSG00000196656.7	AC004057.1	11.68	1.09e-29	2.93e-23	0.4	0.34	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr4:113214046~113217170:-
BRCA	trans	rs747782	0.582	rs11039571	ENSG00000134612.10	FOLH1B	11.67	1.11e-29	3e-23	0.55	0.34	Intraocular pressure;	chr11:48185707	chr11:89639227~89698718:+
BRCA	trans	rs55665837	0.54	rs4144487	ENSG00000236360.2	RP11-334A14.2	11.67	1.17e-29	3.16e-23	0.45	0.34	Vitamin D levels;	chr11:14728905	chr1:52993201~52993702:-
BRCA	trans	rs55665837	0.54	rs12788030	ENSG00000236360.2	RP11-334A14.2	11.67	1.17e-29	3.16e-23	0.45	0.34	Vitamin D levels;	chr11:14743138	chr1:52993201~52993702:-
BRCA	trans	rs3806843	0.735	rs2563314	ENSG00000231043.3	AC007238.1	11.67	1.21e-29	3.27e-23	0.4	0.34	Depressive symptoms (multi-trait analysis);	chr5:140667704	chr2:58460292~58462032:-
BRCA	trans	rs1355223	0.506	rs12294339	ENSG00000225531.1	RP11-196I18.3	11.65	1.49e-29	4e-23	0.47	0.34	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34838652	chr9:107116829~107117557:+
BRCA	trans	rs55665837	0.519	rs1451677	ENSG00000236360.2	RP11-334A14.2	11.65	1.49e-29	4.02e-23	0.45	0.34	Vitamin D levels;	chr11:14724466	chr1:52993201~52993702:-
BRCA	trans	rs55665837	0.54	rs10219313	ENSG00000236360.2	RP11-334A14.2	11.64	1.5e-29	4.05e-23	0.45	0.34	Vitamin D levels;	chr11:14728303	chr1:52993201~52993702:-
BRCA	trans	rs55665837	0.519	rs10832297	ENSG00000236360.2	RP11-334A14.2	11.64	1.5e-29	4.05e-23	0.45	0.34	Vitamin D levels;	chr11:14736191	chr1:52993201~52993702:-
BRCA	trans	rs11098499	0.954	rs1022145	ENSG00000275858.1	RP11-291L22.8	11.64	1.52e-29	4.08e-23	0.42	0.34	Corneal astigmatism;	chr4:119309824	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.863	rs6534139	ENSG00000275858.1	RP11-291L22.8	-11.64	1.64e-29	4.41e-23	-0.44	-0.34	Corneal astigmatism;	chr4:119528301	chr10:38450738~38451069:-
BRCA	trans	rs877636	0.74	rs705698	ENSG00000227887.1	RPS26P13	11.63	1.78e-29	4.78e-23	0.45	0.34	Cognitive function;	chr12:55990903	chr1:208697369~208697698:-
BRCA	trans	rs77688320	0.535	rs2241118	ENSG00000235105.1	RP11-329A14.1	11.62	1.94e-29	5.22e-23	0.41	0.34	Breast cancer;	chr2:201388993	chr1:48435967~48437223:+
BRCA	trans	rs3806843	0.735	rs702394	ENSG00000231043.3	AC007238.1	11.62	1.97e-29	5.28e-23	0.4	0.34	Depressive symptoms (multi-trait analysis);	chr5:140707201	chr2:58460292~58462032:-
BRCA	trans	rs4512344	0.509	rs2409784	ENSG00000253893.2	FAM85B	11.61	2.12e-29	5.7e-23	0.42	0.34	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:11539347	chr8:8167819~8226614:-
BRCA	trans	rs55665837	0.54	rs10832299	ENSG00000236360.2	RP11-334A14.2	11.61	2.13e-29	5.7e-23	0.44	0.34	Vitamin D levels;	chr11:14747846	chr1:52993201~52993702:-
BRCA	trans	rs11098499	0.865	rs11722183	ENSG00000275858.1	RP11-291L22.8	11.6	2.29e-29	6.12e-23	0.42	0.34	Corneal astigmatism;	chr4:119359442	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.697	rs4560394	ENSG00000275858.1	RP11-291L22.8	11.6	2.3e-29	6.15e-23	0.42	0.34	Corneal astigmatism;	chr4:119392280	chr10:38450738~38451069:-
BRCA	trans	rs10242455	1	rs73395557	ENSG00000228834.1	RP11-249L21.4	11.6	2.34e-29	6.28e-23	0.72	0.34	Blood metabolite levels;	chr7:99336801	chr6:108907615~108907873:-
BRCA	trans	rs77688320	0.535	rs11691118	ENSG00000235105.1	RP11-329A14.1	11.6	2.35e-29	6.28e-23	0.41	0.34	Breast cancer;	chr2:201405121	chr1:48435967~48437223:+
BRCA	trans	rs10242455	1	rs6948775	ENSG00000228834.1	RP11-249L21.4	11.6	2.39e-29	6.41e-23	0.72	0.34	Blood metabolite levels;	chr7:99347857	chr6:108907615~108907873:-
BRCA	trans	rs3806843	0.735	rs778596	ENSG00000231043.3	AC007238.1	11.6	2.42e-29	6.48e-23	0.4	0.34	Depressive symptoms (multi-trait analysis);	chr5:140657687	chr2:58460292~58462032:-
BRCA	trans	rs11098499	0.604	rs17051352	ENSG00000275858.1	RP11-291L22.8	11.6	2.52e-29	6.73e-23	0.44	0.34	Corneal astigmatism;	chr4:119660272	chr10:38450738~38451069:-
BRCA	trans	rs7395662	0.517	rs10454483	ENSG00000134612.10	FOLH1B	-11.59	2.52e-29	6.75e-23	-0.43	-0.34	HDL cholesterol;	chr11:48733445	chr11:89639227~89698718:+
BRCA	trans	rs11039798	1	rs7125913	ENSG00000134612.10	FOLH1B	11.59	2.63e-29	7.03e-23	0.58	0.34	Axial length;	chr11:48962766	chr11:89639227~89698718:+
BRCA	trans	rs1355223	0.506	rs7130774	ENSG00000225531.1	RP11-196I18.3	11.59	2.79e-29	7.45e-23	0.46	0.34	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34847720	chr9:107116829~107117557:+
BRCA	trans	rs55665837	0.54	rs3206554	ENSG00000236360.2	RP11-334A14.2	11.58	2.8e-29	7.48e-23	0.44	0.34	Vitamin D levels;	chr11:14776399	chr1:52993201~52993702:-
BRCA	trans	rs11039798	1	rs7125559	ENSG00000134612.10	FOLH1B	11.58	2.94e-29	7.84e-23	0.58	0.34	Axial length;	chr11:48962655	chr11:89639227~89698718:+
BRCA	trans	rs1045902	0.583	rs36106493	ENSG00000236165.1	PRADC1P1	11.58	3.06e-29	8.16e-23	0.43	0.34	Intelligence (multi-trait analysis);	chr2:73215211	chr3:36976316~36976840:+
BRCA	trans	rs3806843	0.657	rs2563283	ENSG00000231043.3	AC007238.1	11.58	3.07e-29	8.19e-23	0.4	0.34	Depressive symptoms (multi-trait analysis);	chr5:140726393	chr2:58460292~58462032:-
BRCA	trans	rs3806843	0.771	rs2563336	ENSG00000231043.3	AC007238.1	11.58	3.07e-29	8.19e-23	0.4	0.34	Depressive symptoms (multi-trait analysis);	chr5:140727614	chr2:58460292~58462032:-
BRCA	trans	rs11039798	1	rs10838918	ENSG00000134612.10	FOLH1B	11.58	3.09e-29	8.23e-23	0.57	0.34	Axial length;	chr11:48485897	chr11:89639227~89698718:+
BRCA	trans	rs11039798	1	rs10769370	ENSG00000134612.10	FOLH1B	11.57	3.12e-29	8.32e-23	0.57	0.34	Axial length;	chr11:48493878	chr11:89639227~89698718:+
BRCA	trans	rs616147	0.962	rs1513219	ENSG00000214263.2	RPSAP53	11.57	3.25e-29	8.66e-23	0.48	0.34	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39492268	chr13:67266845~67267706:-
BRCA	trans	rs55665837	0.54	rs1007392	ENSG00000236360.2	RP11-334A14.2	11.57	3.34e-29	8.89e-23	0.44	0.34	Vitamin D levels;	chr11:14753045	chr1:52993201~52993702:-
BRCA	trans	rs1355223	0.506	rs6484738	ENSG00000225531.1	RP11-196I18.3	11.57	3.42e-29	9.1e-23	0.46	0.34	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34839311	chr9:107116829~107117557:+
BRCA	trans	rs11098499	0.863	rs3822192	ENSG00000275858.1	RP11-291L22.8	11.55	4.08e-29	1.09e-22	0.43	0.34	Corneal astigmatism;	chr4:119524565	chr10:38450738~38451069:-
BRCA	trans	rs6498068	0.594	rs12996	ENSG00000278702.1	Metazoa_SRP	11.55	4.15e-29	1.1e-22	0.46	0.34	Metabolite levels (MHPG);	chr16:10529447	chr1:35399997~35400319:+
BRCA	trans	rs3806843	0.735	rs2563335	ENSG00000231043.3	AC007238.1	-11.55	4.18e-29	1.11e-22	-0.4	-0.34	Depressive symptoms (multi-trait analysis);	chr5:140664707	chr2:58460292~58462032:-
BRCA	trans	rs6498068	0.594	rs1875929	ENSG00000278702.1	Metazoa_SRP	11.54	4.28e-29	1.14e-22	0.46	0.34	Metabolite levels (MHPG);	chr16:10528202	chr1:35399997~35400319:+
BRCA	trans	rs10242455	1	rs73395547	ENSG00000228834.1	RP11-249L21.4	11.54	4.33e-29	1.15e-22	0.71	0.34	Blood metabolite levels;	chr7:99325123	chr6:108907615~108907873:-
BRCA	trans	rs3806843	0.735	rs809635	ENSG00000231043.3	AC007238.1	11.54	4.52e-29	1.2e-22	0.4	0.34	Depressive symptoms (multi-trait analysis);	chr5:140702206	chr2:58460292~58462032:-
BRCA	trans	rs3806843	0.648	rs2530233	ENSG00000231043.3	AC007238.1	11.54	4.52e-29	1.2e-22	0.4	0.34	Depressive symptoms (multi-trait analysis);	chr5:140703291	chr2:58460292~58462032:-
BRCA	trans	rs55665837	0.54	rs10766192	ENSG00000236360.2	RP11-334A14.2	11.53	5.14e-29	1.36e-22	0.44	0.34	Vitamin D levels;	chr11:14790140	chr1:52993201~52993702:-
BRCA	trans	rs9611519	0.58	rs7286603	ENSG00000268568.1	AC007228.9	-11.53	5.19e-29	1.37e-22	-0.42	-0.34	Neuroticism;	chr22:41044057	chr19:56672574~56673901:-
BRCA	trans	rs9611519	0.558	rs8137906	ENSG00000268568.1	AC007228.9	-11.53	5.19e-29	1.37e-22	-0.42	-0.34	Neuroticism;	chr22:41046562	chr19:56672574~56673901:-
BRCA	trans	rs2899832	0.568	rs17597281	ENSG00000229083.1	PSMA6P2	-11.52	5.22e-29	1.38e-22	-0.61	-0.34	Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:35313094	chrX:12825840~12826833:+
BRCA	trans	rs7395662	0.5	rs10838984	ENSG00000134612.10	FOLH1B	-11.52	5.34e-29	1.41e-22	-0.43	-0.34	HDL cholesterol;	chr11:48618933	chr11:89639227~89698718:+
BRCA	trans	rs77688320	0.535	rs7575721	ENSG00000235105.1	RP11-329A14.1	11.52	5.42e-29	1.44e-22	0.4	0.34	Breast cancer;	chr2:201392055	chr1:48435967~48437223:+
BRCA	trans	rs10037055	1	rs10037055	ENSG00000226986.4	RP11-543B16.2	-11.52	5.51e-29	1.46e-22	-0.44	-0.34	Migraine without aura;	chr5:177264278	chr1:211207239~211207897:+
BRCA	trans	rs77688320	0.535	rs6751543	ENSG00000235105.1	RP11-329A14.1	11.52	5.64e-29	1.49e-22	0.4	0.34	Breast cancer;	chr2:201400210	chr1:48435967~48437223:+
BRCA	trans	rs7395662	0.5	rs1605360	ENSG00000134612.10	FOLH1B	-11.51	5.8e-29	1.53e-22	-0.42	-0.34	HDL cholesterol;	chr11:48664162	chr11:89639227~89698718:+
BRCA	trans	rs77688320	0.535	rs13027669	ENSG00000235105.1	RP11-329A14.1	11.51	5.85e-29	1.55e-22	0.4	0.34	Breast cancer;	chr2:201382596	chr1:48435967~48437223:+
BRCA	trans	rs9329221	0.537	rs6986911	ENSG00000253893.2	FAM85B	-11.51	6e-29	1.59e-22	-0.41	-0.34	Neuroticism;	chr8:10121013	chr8:8167819~8226614:-
BRCA	trans	rs11098499	0.618	rs35265692	ENSG00000275858.1	RP11-291L22.8	11.51	6.01e-29	1.59e-22	0.42	0.34	Corneal astigmatism;	chr4:119403980	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.866	rs72676074	ENSG00000275858.1	RP11-291L22.8	11.51	6.01e-29	1.59e-22	0.41	0.34	Corneal astigmatism;	chr4:119438686	chr10:38450738~38451069:-
BRCA	trans	rs4276421	0.555	rs10041767	ENSG00000231752.4	EMBP1	11.5	7.03e-29	1.85e-22	0.44	0.34	P wave duration;	chr5:45767317	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.555	rs10041772	ENSG00000231752.4	EMBP1	11.5	7.03e-29	1.85e-22	0.44	0.34	P wave duration;	chr5:45767386	chr1:121519112~121571892:+
BRCA	trans	rs877636	0.74	rs705702	ENSG00000227887.1	RPS26P13	-11.49	7.36e-29	1.94e-22	-0.44	-0.34	Cognitive function;	chr12:55996852	chr1:208697369~208697698:-
BRCA	trans	rs7944735	0.517	rs12274550	ENSG00000134612.10	FOLH1B	11.48	7.85e-29	2.07e-22	0.55	0.34	Intraocular pressure;	chr11:48175200	chr11:89639227~89698718:+
BRCA	trans	rs7944735	0.517	rs7952205	ENSG00000134612.10	FOLH1B	11.48	7.85e-29	2.07e-22	0.55	0.34	Intraocular pressure;	chr11:48177675	chr11:89639227~89698718:+
BRCA	trans	rs77688320	0.553	rs6761777	ENSG00000235105.1	RP11-329A14.1	11.48	7.91e-29	2.08e-22	0.4	0.34	Breast cancer;	chr2:201399879	chr1:48435967~48437223:+
BRCA	trans	rs77688320	0.535	rs10804115	ENSG00000235105.1	RP11-329A14.1	11.48	8.29e-29	2.18e-22	0.4	0.34	Breast cancer;	chr2:201415510	chr1:48435967~48437223:+
BRCA	trans	rs77688320	0.535	rs13001194	ENSG00000235105.1	RP11-329A14.1	11.48	8.6e-29	2.26e-22	0.4	0.33	Breast cancer;	chr2:201396452	chr1:48435967~48437223:+
BRCA	trans	rs77688320	0.535	rs7597850	ENSG00000235105.1	RP11-329A14.1	11.48	8.6e-29	2.26e-22	0.4	0.33	Breast cancer;	chr2:201396679	chr1:48435967~48437223:+
BRCA	trans	rs77688320	0.535	rs7571761	ENSG00000235105.1	RP11-329A14.1	11.48	8.6e-29	2.26e-22	0.4	0.33	Breast cancer;	chr2:201396837	chr1:48435967~48437223:+
BRCA	trans	rs77688320	0.535	rs10931944	ENSG00000235105.1	RP11-329A14.1	11.48	8.6e-29	2.26e-22	0.4	0.33	Breast cancer;	chr2:201398875	chr1:48435967~48437223:+
BRCA	trans	rs77688320	0.553	rs11681526	ENSG00000235105.1	RP11-329A14.1	11.48	8.6e-29	2.26e-22	0.4	0.33	Breast cancer;	chr2:201399037	chr1:48435967~48437223:+
BRCA	trans	rs77688320	0.535	rs13022344	ENSG00000235105.1	RP11-329A14.1	11.48	8.6e-29	2.26e-22	0.4	0.33	Breast cancer;	chr2:201399433	chr1:48435967~48437223:+
BRCA	trans	rs77688320	0.535	rs6732993	ENSG00000235105.1	RP11-329A14.1	11.48	8.6e-29	2.26e-22	0.4	0.33	Breast cancer;	chr2:201399593	chr1:48435967~48437223:+
BRCA	trans	rs7395662	0.517	rs11039885	ENSG00000134612.10	FOLH1B	-11.47	9.04e-29	2.38e-22	-0.42	-0.33	HDL cholesterol;	chr11:48625555	chr11:89639227~89698718:+
BRCA	trans	rs6498068	0.594	rs3087620	ENSG00000278702.1	Metazoa_SRP	11.47	9.52e-29	2.5e-22	0.45	0.33	Metabolite levels (MHPG);	chr16:10529475	chr1:35399997~35400319:+
BRCA	trans	rs11098499	0.863	rs6833334	ENSG00000275858.1	RP11-291L22.8	11.47	9.52e-29	2.5e-22	0.42	0.33	Corneal astigmatism;	chr4:119583072	chr10:38450738~38451069:-
BRCA	trans	rs77688320	0.535	rs3815515	ENSG00000235105.1	RP11-329A14.1	11.46	9.97e-29	2.62e-22	0.4	0.33	Breast cancer;	chr2:201393207	chr1:48435967~48437223:+
BRCA	trans	rs11098499	0.954	rs13145352	ENSG00000275858.1	RP11-291L22.8	-11.46	1.02e-28	2.68e-22	-0.42	-0.33	Corneal astigmatism;	chr4:119488808	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.863	rs10019674	ENSG00000275858.1	RP11-291L22.8	-11.46	1.03e-28	2.69e-22	-0.43	-0.33	Corneal astigmatism;	chr4:119522334	chr10:38450738~38451069:-
BRCA	trans	rs7662987	1	rs28730595	ENSG00000233859.2	ADH5P4	11.44	1.22e-28	3.19e-22	0.73	0.33	Smoking initiation;	chr4:99082182	chr6:65836930~65838039:-
BRCA	trans	rs7662987	0.938	rs28730592	ENSG00000233859.2	ADH5P4	11.44	1.22e-28	3.19e-22	0.73	0.33	Smoking initiation;	chr4:99082592	chr6:65836930~65838039:-
BRCA	trans	rs7662987	1	rs28730591	ENSG00000233859.2	ADH5P4	11.44	1.22e-28	3.19e-22	0.73	0.33	Smoking initiation;	chr4:99082596	chr6:65836930~65838039:-
BRCA	trans	rs11098499	0.73	rs12505735	ENSG00000275858.1	RP11-291L22.8	11.44	1.23e-28	3.22e-22	0.42	0.33	Corneal astigmatism;	chr4:119611801	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.863	rs59732491	ENSG00000275858.1	RP11-291L22.8	11.44	1.25e-28	3.27e-22	0.42	0.33	Corneal astigmatism;	chr4:119568433	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.863	rs11723090	ENSG00000275858.1	RP11-291L22.8	11.44	1.25e-28	3.27e-22	0.42	0.33	Corneal astigmatism;	chr4:119569437	chr10:38450738~38451069:-
BRCA	trans	rs11039798	1	rs6485848	ENSG00000134612.10	FOLH1B	11.44	1.29e-28	3.37e-22	0.55	0.33	Axial length;	chr11:48519965	chr11:89639227~89698718:+
BRCA	trans	rs877636	0.669	rs7297175	ENSG00000196933.5	RPS26P11	-11.43	1.32e-28	3.44e-22	-0.39	-0.33	Cognitive function;	chr12:56080024	chrX:72044545~72044892:+
BRCA	trans	rs11098499	0.863	rs10013305	ENSG00000275858.1	RP11-291L22.8	11.43	1.35e-28	3.53e-22	0.42	0.33	Corneal astigmatism;	chr4:119529269	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.863	rs3775849	ENSG00000275858.1	RP11-291L22.8	11.43	1.35e-28	3.53e-22	0.42	0.33	Corneal astigmatism;	chr4:119529753	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.818	rs7688802	ENSG00000275858.1	RP11-291L22.8	11.43	1.35e-28	3.53e-22	0.42	0.33	Corneal astigmatism;	chr4:119530513	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.863	rs7695620	ENSG00000275858.1	RP11-291L22.8	11.43	1.35e-28	3.53e-22	0.42	0.33	Corneal astigmatism;	chr4:119531621	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.863	rs12502389	ENSG00000275858.1	RP11-291L22.8	11.43	1.35e-28	3.53e-22	0.42	0.33	Corneal astigmatism;	chr4:119533036	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.821	rs3775852	ENSG00000275858.1	RP11-291L22.8	11.43	1.35e-28	3.53e-22	0.42	0.33	Corneal astigmatism;	chr4:119533401	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.82	rs6534140	ENSG00000275858.1	RP11-291L22.8	11.43	1.35e-28	3.53e-22	0.42	0.33	Corneal astigmatism;	chr4:119534156	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.863	rs7657849	ENSG00000275858.1	RP11-291L22.8	11.43	1.35e-28	3.53e-22	0.42	0.33	Corneal astigmatism;	chr4:119534339	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.863	rs10034450	ENSG00000275858.1	RP11-291L22.8	11.43	1.35e-28	3.53e-22	0.42	0.33	Corneal astigmatism;	chr4:119534494	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.863	rs1480939	ENSG00000275858.1	RP11-291L22.8	11.43	1.35e-28	3.53e-22	0.42	0.33	Corneal astigmatism;	chr4:119535772	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.865	rs4001305	ENSG00000275858.1	RP11-291L22.8	11.43	1.43e-28	3.72e-22	0.41	0.33	Corneal astigmatism;	chr4:119438081	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.863	rs1552092	ENSG00000275858.1	RP11-291L22.8	11.42	1.5e-28	3.9e-22	0.42	0.33	Corneal astigmatism;	chr4:119567341	chr10:38450738~38451069:-
BRCA	trans	rs4240897	1	rs4240897	ENSG00000261819.1	RP11-680G24.4	-11.42	1.59e-28	4.14e-22	-0.41	-0.33	Tuberculosis;	chr1:11982698	chr16:14988259~14990160:-
BRCA	trans	rs2950393	0.804	rs2926748	ENSG00000228224.3	NACAP1	11.41	1.67e-28	4.34e-22	0.37	0.33	Platelet distribution width;	chr12:56715628	chr8:101361794~101372707:+
BRCA	trans	rs11098499	0.863	rs58452170	ENSG00000275858.1	RP11-291L22.8	11.41	1.67e-28	4.35e-22	0.42	0.33	Corneal astigmatism;	chr4:119538519	chr10:38450738~38451069:-
BRCA	trans	rs11023332	1	rs11023332	ENSG00000236360.2	RP11-334A14.2	11.41	1.67e-28	4.35e-22	0.44	0.33	Vitamin D levels;Adiponectin levels;	chr11:14762564	chr1:52993201~52993702:-
BRCA	trans	rs11098499	0.863	rs3733525	ENSG00000275858.1	RP11-291L22.8	11.41	1.7e-28	4.42e-22	0.42	0.33	Corneal astigmatism;	chr4:119525893	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.863	rs3775847	ENSG00000275858.1	RP11-291L22.8	11.41	1.7e-28	4.42e-22	0.42	0.33	Corneal astigmatism;	chr4:119526487	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.863	rs3775848	ENSG00000275858.1	RP11-291L22.8	11.41	1.7e-28	4.42e-22	0.42	0.33	Corneal astigmatism;	chr4:119526569	chr10:38450738~38451069:-
BRCA	trans	rs3779195	0.585	rs56694862	ENSG00000225169.1	BRI3P1	-11.41	1.75e-28	4.56e-22	-0.58	-0.33	Sex hormone-binding globulin levels;	chr7:98267808	chr1:100213293~100213670:+
BRCA	trans	rs11098499	0.863	rs1010740	ENSG00000275858.1	RP11-291L22.8	-11.41	1.77e-28	4.6e-22	-0.42	-0.33	Corneal astigmatism;	chr4:119542254	chr10:38450738~38451069:-
BRCA	trans	rs9611519	0.565	rs8135524	ENSG00000268568.1	AC007228.9	-11.4	1.8e-28	4.65e-22	-0.43	-0.33	Neuroticism;	chr22:41040438	chr19:56672574~56673901:-
BRCA	trans	rs747782	0.582	rs7949865	ENSG00000134612.10	FOLH1B	-11.39	1.99e-28	5.14e-22	-0.55	-0.33	Intraocular pressure;	chr11:48324650	chr11:89639227~89698718:+
BRCA	trans	rs74781061	0.932	rs11629749	ENSG00000227288.3	RP5-837I24.1	11.39	2.17e-28	5.61e-22	0.47	0.33	Endometriosis;	chr15:74627252	chr1:81501794~81503468:+
BRCA	trans	rs10242455	0.717	rs4646461	ENSG00000228834.1	RP11-249L21.4	11.38	2.21e-28	5.7e-22	0.67	0.33	Blood metabolite levels;	chr7:99733850	chr6:108907615~108907873:-
BRCA	trans	rs3779195	0.585	rs73709460	ENSG00000225169.1	BRI3P1	-11.38	2.25e-28	5.82e-22	-0.58	-0.33	Sex hormone-binding globulin levels;	chr7:98265942	chr1:100213293~100213670:+
BRCA	trans	rs747782	0.528	rs10838881	ENSG00000134612.10	FOLH1B	11.38	2.29e-28	5.89e-22	0.56	0.33	Intraocular pressure;	chr11:48365723	chr11:89639227~89698718:+
BRCA	trans	rs11039798	0.764	rs10838882	ENSG00000134612.10	FOLH1B	11.38	2.29e-28	5.89e-22	0.56	0.33	Axial length;	chr11:48371483	chr11:89639227~89698718:+
BRCA	trans	rs877636	1	rs705696	ENSG00000233778.3	RP11-777J24.1	11.38	2.33e-28	6.02e-22	0.42	0.33	Cognitive function;	chr12:56086864	chr8:92144088~92144435:-
BRCA	trans	rs11098499	0.863	rs2306456	ENSG00000275858.1	RP11-291L22.8	11.38	2.35e-28	6.05e-22	0.42	0.33	Corneal astigmatism;	chr4:119551267	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.863	rs11947234	ENSG00000275858.1	RP11-291L22.8	11.38	2.35e-28	6.05e-22	0.42	0.33	Corneal astigmatism;	chr4:119553704	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.863	rs11933966	ENSG00000275858.1	RP11-291L22.8	11.38	2.35e-28	6.05e-22	0.42	0.33	Corneal astigmatism;	chr4:119555560	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.863	rs36040693	ENSG00000275858.1	RP11-291L22.8	11.38	2.35e-28	6.05e-22	0.42	0.33	Corneal astigmatism;	chr4:119556461	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.863	rs11098531	ENSG00000275858.1	RP11-291L22.8	11.37	2.44e-28	6.29e-22	0.42	0.33	Corneal astigmatism;	chr4:119543846	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.863	rs28718422	ENSG00000275858.1	RP11-291L22.8	11.37	2.44e-28	6.29e-22	0.42	0.33	Corneal astigmatism;	chr4:119545149	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.818	rs12498599	ENSG00000275858.1	RP11-291L22.8	11.37	2.44e-28	6.29e-22	0.42	0.33	Corneal astigmatism;	chr4:119547348	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.863	rs10009626	ENSG00000275858.1	RP11-291L22.8	11.37	2.44e-28	6.29e-22	0.42	0.33	Corneal astigmatism;	chr4:119548850	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.69	rs34818745	ENSG00000275858.1	RP11-291L22.8	11.37	2.47e-28	6.35e-22	0.41	0.33	Corneal astigmatism;	chr4:119335900	chr10:38450738~38451069:-
BRCA	trans	rs11039798	1	rs12223271	ENSG00000134612.10	FOLH1B	11.37	2.48e-28	6.38e-22	0.56	0.33	Axial length;	chr11:48395868	chr11:89639227~89698718:+
BRCA	trans	rs747782	0.528	rs4370963	ENSG00000134612.10	FOLH1B	11.37	2.51e-28	6.46e-22	0.56	0.33	Intraocular pressure;	chr11:48412391	chr11:89639227~89698718:+
BRCA	trans	rs8175379	0.509	rs10074483	ENSG00000231752.4	EMBP1	11.37	2.57e-28	6.61e-22	0.44	0.33	Interleukin-7 levels;	chr5:46238631	chr1:121519112~121571892:+
BRCA	trans	rs7395662	0.504	rs1814158	ENSG00000134612.10	FOLH1B	-11.37	2.61e-28	6.72e-22	-0.43	-0.33	HDL cholesterol;	chr11:48416385	chr11:89639227~89698718:+
BRCA	trans	rs3779195	0.524	rs76976120	ENSG00000225169.1	BRI3P1	-11.36	2.79e-28	7.16e-22	-0.58	-0.33	Sex hormone-binding globulin levels;	chr7:98264860	chr1:100213293~100213670:+
BRCA	trans	rs11039798	0.92	rs11040015	ENSG00000134612.10	FOLH1B	11.36	2.81e-28	7.21e-22	0.57	0.33	Axial length;	chr11:48761578	chr11:89639227~89698718:+
BRCA	trans	rs2950393	0.804	rs2035081	ENSG00000228224.3	NACAP1	11.35	2.98e-28	7.63e-22	0.37	0.33	Platelet distribution width;	chr12:56732095	chr8:101361794~101372707:+
BRCA	trans	rs11098499	0.863	rs7678400	ENSG00000275858.1	RP11-291L22.8	11.35	2.99e-28	7.67e-22	0.42	0.33	Corneal astigmatism;	chr4:119540802	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.863	rs1480936	ENSG00000275858.1	RP11-291L22.8	11.35	2.99e-28	7.67e-22	0.42	0.33	Corneal astigmatism;	chr4:119541706	chr10:38450738~38451069:-
BRCA	trans	rs941207	0.526	rs7303216	ENSG00000228224.3	NACAP1	11.35	3.06e-28	7.84e-22	0.38	0.33	Platelet count;	chr12:56680909	chr8:101361794~101372707:+
BRCA	trans	rs8010715	0.816	rs6573565	ENSG00000238000.1	RP11-274E7.2	-11.35	3.09e-28	7.93e-22	-0.36	-0.33	IgG glycosylation;	chr14:24125524	chr5:98213402~98214121:+
BRCA	trans	rs77688320	0.535	rs34625194	ENSG00000235105.1	RP11-329A14.1	11.35	3.22e-28	8.25e-22	0.4	0.33	Breast cancer;	chr2:201406815	chr1:48435967~48437223:+
BRCA	trans	rs77688320	0.535	rs11691859	ENSG00000235105.1	RP11-329A14.1	11.35	3.22e-28	8.25e-22	0.4	0.33	Breast cancer;	chr2:201407268	chr1:48435967~48437223:+
BRCA	trans	rs77688320	0.517	rs11691865	ENSG00000235105.1	RP11-329A14.1	11.35	3.22e-28	8.25e-22	0.4	0.33	Breast cancer;	chr2:201407309	chr1:48435967~48437223:+
BRCA	trans	rs11039798	1	rs7123704	ENSG00000134612.10	FOLH1B	11.34	3.36e-28	8.61e-22	0.55	0.33	Axial length;	chr11:48558983	chr11:89639227~89698718:+
BRCA	trans	rs877636	0.702	rs773110	ENSG00000233778.3	RP11-777J24.1	11.34	3.43e-28	8.79e-22	0.43	0.33	Cognitive function;	chr12:55981353	chr8:92144088~92144435:-
BRCA	trans	rs877636	0.702	rs773112	ENSG00000233778.3	RP11-777J24.1	11.34	3.56e-28	9.11e-22	0.42	0.33	Cognitive function;	chr12:55982097	chr8:92144088~92144435:-
BRCA	trans	rs7312770	0.612	rs1873914	ENSG00000234354.3	RPS26P47	11.33	3.9e-28	9.96e-22	0.41	0.33	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr13:100539901~100540248:-
BRCA	trans	rs8010715	0.816	rs11574503	ENSG00000238000.1	RP11-274E7.2	-11.33	3.95e-28	1.01e-21	-0.36	-0.33	IgG glycosylation;	chr14:24132109	chr5:98213402~98214121:+
BRCA	trans	rs2950393	0.895	rs2958154	ENSG00000228224.3	NACAP1	-11.32	4.04e-28	1.03e-21	-0.37	-0.33	Platelet distribution width;	chr12:56671929	chr8:101361794~101372707:+
BRCA	trans	rs877636	0.702	rs773111	ENSG00000233778.3	RP11-777J24.1	11.32	4.12e-28	1.05e-21	0.42	0.33	Cognitive function;	chr12:55981956	chr8:92144088~92144435:-
BRCA	trans	rs11098499	0.604	rs2389882	ENSG00000275858.1	RP11-291L22.8	11.32	4.13e-28	1.05e-21	0.42	0.33	Corneal astigmatism;	chr4:119645578	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.863	rs13140391	ENSG00000275858.1	RP11-291L22.8	11.32	4.22e-28	1.08e-21	0.42	0.33	Corneal astigmatism;	chr4:119582282	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.863	rs13140409	ENSG00000275858.1	RP11-291L22.8	11.32	4.22e-28	1.08e-21	0.42	0.33	Corneal astigmatism;	chr4:119582305	chr10:38450738~38451069:-
BRCA	trans	rs2950393	0.857	rs9989034	ENSG00000228224.3	NACAP1	11.32	4.3e-28	1.1e-21	0.37	0.33	Platelet distribution width;	chr12:56674508	chr8:101361794~101372707:+
BRCA	trans	rs11098499	0.863	rs34868248	ENSG00000275858.1	RP11-291L22.8	11.32	4.3e-28	1.1e-21	0.42	0.33	Corneal astigmatism;	chr4:119521275	chr10:38450738~38451069:-
BRCA	trans	rs9611519	0.507	rs12484525	ENSG00000268568.1	AC007228.9	-11.32	4.32e-28	1.1e-21	-0.41	-0.33	Neuroticism;	chr22:41047873	chr19:56672574~56673901:-
BRCA	trans	rs877636	1	rs4759229	ENSG00000234513.1	AC073072.7	-11.32	4.34e-28	1.11e-21	-0.41	-0.33	Cognitive function;	chr12:56080696	chr7:22773646~22773993:-
BRCA	trans	rs4276421	0.577	rs4367308	ENSG00000231752.4	EMBP1	-11.31	4.57e-28	1.16e-21	-0.43	-0.33	P wave duration;	chr5:45715651	chr1:121519112~121571892:+
BRCA	trans	rs11098499	0.566	rs7664440	ENSG00000275858.1	RP11-291L22.8	11.31	4.7e-28	1.2e-21	0.43	0.33	Corneal astigmatism;	chr4:119657385	chr10:38450738~38451069:-
BRCA	trans	rs72615157	0.606	rs941288	ENSG00000228546.2	CTA-313A17.3	11.31	4.78e-28	1.22e-21	0.53	0.33	Lung function (FEV1/FVC);	chr7:100179185	chr7:102337316~102339115:+
BRCA	trans	rs9876781	1	rs9838618	ENSG00000225528.1	RP3-370M22.8	-11.31	4.82e-28	1.23e-21	-0.36	-0.33	Longevity;	chr3:48445949	chr22:39960397~39964683:+
BRCA	trans	rs2950393	0.777	rs12828563	ENSG00000228224.3	NACAP1	11.3	4.94e-28	1.26e-21	0.37	0.33	Platelet distribution width;	chr12:56709378	chr8:101361794~101372707:+
BRCA	trans	rs877636	0.692	rs2271194	ENSG00000212829.8	RPS26P3	-11.3	4.95e-28	1.26e-21	-0.4	-0.33	Cognitive function;	chr12:56083910	chr9:9090898~9091245:+
BRCA	trans	rs11098499	0.863	rs1480940	ENSG00000275858.1	RP11-291L22.8	11.3	5.01e-28	1.28e-21	0.42	0.33	Corneal astigmatism;	chr4:119536527	chr10:38450738~38451069:-
BRCA	trans	rs9329221	0.537	rs2062331	ENSG00000253893.2	FAM85B	11.3	5.1e-28	1.3e-21	0.4	0.33	Neuroticism;	chr8:10122482	chr8:8167819~8226614:-
BRCA	trans	rs2950393	0.895	rs2926740	ENSG00000228224.3	NACAP1	11.3	5.24e-28	1.33e-21	0.38	0.33	Platelet distribution width;	chr12:56666751	chr8:101361794~101372707:+
BRCA	trans	rs453301	0.571	rs330048	ENSG00000253893.2	FAM85B	11.3	5.3e-28	1.35e-21	0.4	0.33	Joint mobility (Beighton score);	chr8:9229768	chr8:8167819~8226614:-
BRCA	trans	rs7662987	1	rs28730640	ENSG00000233859.2	ADH5P4	11.3	5.35e-28	1.36e-21	0.71	0.33	Smoking initiation;	chr4:99072902	chr6:65836930~65838039:-
BRCA	trans	rs7662987	1	rs7658118	ENSG00000233859.2	ADH5P4	11.3	5.35e-28	1.36e-21	0.71	0.33	Smoking initiation;	chr4:99073457	chr6:65836930~65838039:-
BRCA	trans	rs11098499	0.955	rs35434465	ENSG00000275858.1	RP11-291L22.8	11.29	5.65e-28	1.43e-21	0.42	0.33	Corneal astigmatism;	chr4:119248223	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.863	rs3775843	ENSG00000275858.1	RP11-291L22.8	11.29	5.66e-28	1.44e-21	0.42	0.33	Corneal astigmatism;	chr4:119506689	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.863	rs3775844	ENSG00000275858.1	RP11-291L22.8	11.29	5.66e-28	1.44e-21	0.42	0.33	Corneal astigmatism;	chr4:119506878	chr10:38450738~38451069:-
BRCA	trans	rs8010715	0.816	rs8015168	ENSG00000238000.1	RP11-274E7.2	11.29	5.73e-28	1.45e-21	0.36	0.33	IgG glycosylation;	chr14:24130663	chr5:98213402~98214121:+
BRCA	trans	rs7662987	1	rs11547772	ENSG00000233859.2	ADH5P4	11.29	5.82e-28	1.48e-21	0.71	0.33	Smoking initiation;	chr4:99071642	chr6:65836930~65838039:-
BRCA	trans	rs11098499	0.863	rs3775845	ENSG00000275858.1	RP11-291L22.8	11.29	5.86e-28	1.49e-21	0.42	0.33	Corneal astigmatism;	chr4:119511292	chr10:38450738~38451069:-
BRCA	trans	rs2950393	0.804	rs898609	ENSG00000228224.3	NACAP1	11.29	5.92e-28	1.5e-21	0.37	0.33	Platelet distribution width;	chr12:56713026	chr8:101361794~101372707:+
BRCA	trans	rs2950393	0.804	rs4902	ENSG00000228224.3	NACAP1	11.29	5.92e-28	1.5e-21	0.37	0.33	Platelet distribution width;	chr12:56714419	chr8:101361794~101372707:+
BRCA	trans	rs8010715	0.816	rs762093	ENSG00000238000.1	RP11-274E7.2	11.29	5.94e-28	1.51e-21	0.36	0.33	IgG glycosylation;	chr14:24122709	chr5:98213402~98214121:+
BRCA	trans	rs7662987	1	rs6852848	ENSG00000233859.2	ADH5P4	-11.29	6.01e-28	1.52e-21	-0.71	-0.33	Smoking initiation;	chr4:99080781	chr6:65836930~65838039:-
BRCA	trans	rs2950393	0.804	rs2958127	ENSG00000228224.3	NACAP1	11.28	6.19e-28	1.57e-21	0.37	0.33	Platelet distribution width;	chr12:56720523	chr8:101361794~101372707:+
BRCA	trans	rs7662987	0.938	rs28730605	ENSG00000233859.2	ADH5P4	11.28	6.19e-28	1.57e-21	0.72	0.33	Smoking initiation;	chr4:99080389	chr6:65836930~65838039:-
BRCA	trans	rs7662987	0.818	rs4699701	ENSG00000233859.2	ADH5P4	11.28	6.34e-28	1.6e-21	0.72	0.33	Smoking initiation;	chr4:99077296	chr6:65836930~65838039:-
BRCA	trans	rs7662987	1	rs13146416	ENSG00000233859.2	ADH5P4	11.28	6.34e-28	1.6e-21	0.72	0.33	Smoking initiation;	chr4:99078009	chr6:65836930~65838039:-
BRCA	trans	rs2950393	0.857	rs1563896	ENSG00000228224.3	NACAP1	11.28	6.44e-28	1.63e-21	0.38	0.33	Platelet distribution width;	chr12:56699312	chr8:101361794~101372707:+
BRCA	trans	rs7312770	1	rs7312770	ENSG00000223416.3	RPS26P15	-11.28	6.49e-28	1.64e-21	-0.36	-0.33	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr1:58056133~58056480:-
BRCA	trans	rs13177918	0.734	rs6579791	ENSG00000226396.1	RP5-1056L3.3	11.28	6.57e-28	1.66e-21	0.36	0.33	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150464440	chr1:19608114~19608568:+
BRCA	trans	rs11098499	0.82	rs28535956	ENSG00000275858.1	RP11-291L22.8	-11.28	6.66e-28	1.68e-21	-0.42	-0.33	Corneal astigmatism;	chr4:119615703	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.863	rs10030660	ENSG00000275858.1	RP11-291L22.8	11.27	6.68e-28	1.69e-21	0.42	0.33	Corneal astigmatism;	chr4:119515549	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.863	rs13149407	ENSG00000275858.1	RP11-291L22.8	11.27	6.68e-28	1.69e-21	0.42	0.33	Corneal astigmatism;	chr4:119516670	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.863	rs11098532	ENSG00000275858.1	RP11-291L22.8	11.27	6.71e-28	1.69e-21	0.41	0.33	Corneal astigmatism;	chr4:119569571	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.863	rs1383532	ENSG00000275858.1	RP11-291L22.8	-11.27	7.03e-28	1.77e-21	-0.41	-0.33	Corneal astigmatism;	chr4:119513249	chr10:38450738~38451069:-
BRCA	trans	rs877636	0.692	rs2271194	ENSG00000244604.1	RP11-713H12.1	-11.27	7.07e-28	1.78e-21	-0.37	-0.33	Cognitive function;	chr12:56083910	chr17:8561230~8561576:+
BRCA	trans	rs2950393	0.804	rs1466382	ENSG00000228224.3	NACAP1	-11.26	7.49e-28	1.89e-21	-0.37	-0.33	Platelet distribution width;	chr12:56723050	chr8:101361794~101372707:+
BRCA	trans	rs6498068	0.633	rs7194566	ENSG00000278702.1	Metazoa_SRP	11.26	7.49e-28	1.89e-21	0.46	0.33	Metabolite levels (MHPG);	chr16:10532140	chr1:35399997~35400319:+
BRCA	trans	rs941207	0.526	rs11171916	ENSG00000228224.3	NACAP1	-11.26	7.61e-28	1.92e-21	-0.38	-0.33	Platelet count;	chr12:56653236	chr8:101361794~101372707:+
BRCA	trans	rs2950393	0.929	rs2290893	ENSG00000228224.3	NACAP1	11.26	7.63e-28	1.92e-21	0.37	0.33	Platelet distribution width;	chr12:56684836	chr8:101361794~101372707:+
BRCA	trans	rs941207	0.507	rs7297289	ENSG00000228224.3	NACAP1	11.26	7.83e-28	1.97e-21	0.37	0.33	Platelet count;	chr12:56682703	chr8:101361794~101372707:+
BRCA	trans	rs8010715	0.785	rs2877611	ENSG00000238000.1	RP11-274E7.2	11.26	7.96e-28	2e-21	0.36	0.33	IgG glycosylation;	chr14:24126221	chr5:98213402~98214121:+
BRCA	trans	rs11098499	0.863	rs7664986	ENSG00000275858.1	RP11-291L22.8	11.26	8.01e-28	2.01e-21	0.42	0.33	Corneal astigmatism;	chr4:119508797	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.818	rs10008791	ENSG00000275858.1	RP11-291L22.8	11.26	8.01e-28	2.01e-21	0.42	0.33	Corneal astigmatism;	chr4:119510314	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.863	rs11736416	ENSG00000275858.1	RP11-291L22.8	11.26	8.01e-28	2.01e-21	0.42	0.33	Corneal astigmatism;	chr4:119510506	chr10:38450738~38451069:-
BRCA	trans	rs11039798	1	rs12281162	ENSG00000134612.10	FOLH1B	11.26	8.04e-28	2.02e-21	0.54	0.33	Axial length;	chr11:48628939	chr11:89639227~89698718:+
BRCA	trans	rs2950393	0.804	rs2926752	ENSG00000228224.3	NACAP1	11.25	8.21e-28	2.06e-21	0.37	0.33	Platelet distribution width;	chr12:56710144	chr8:101361794~101372707:+
BRCA	trans	rs2950393	0.777	rs2958148	ENSG00000228224.3	NACAP1	11.25	8.21e-28	2.06e-21	0.37	0.33	Platelet distribution width;	chr12:56710153	chr8:101361794~101372707:+
BRCA	trans	rs9425766	0.962	rs941989	ENSG00000213331.4	RP11-713C19.2	-11.25	8.22e-28	2.06e-21	-0.39	-0.33	Life satisfaction;	chr1:173912733	chr4:187970273~187971284:+
BRCA	trans	rs11098499	0.863	rs13134665	ENSG00000275858.1	RP11-291L22.8	11.25	8.28e-28	2.08e-21	0.42	0.33	Corneal astigmatism;	chr4:119505275	chr10:38450738~38451069:-
BRCA	trans	rs941207	0.526	rs4759028	ENSG00000228224.3	NACAP1	11.25	8.4e-28	2.11e-21	0.37	0.33	Platelet count;	chr12:56686399	chr8:101361794~101372707:+
BRCA	trans	rs11098499	0.818	rs55825515	ENSG00000275858.1	RP11-291L22.8	11.25	8.46e-28	2.12e-21	0.42	0.33	Corneal astigmatism;	chr4:119565247	chr10:38450738~38451069:-
BRCA	trans	rs55665837	0.539	rs10766196	ENSG00000236360.2	RP11-334A14.2	11.25	8.47e-28	2.12e-21	0.44	0.33	Vitamin D levels;	chr11:14891585	chr1:52993201~52993702:-
BRCA	trans	rs877636	0.702	rs773109	ENSG00000233778.3	RP11-777J24.1	11.24	9.14e-28	2.29e-21	0.42	0.33	Cognitive function;	chr12:55980911	chr8:92144088~92144435:-
BRCA	trans	rs11098499	0.909	rs79026312	ENSG00000275858.1	RP11-291L22.8	11.24	9.16e-28	2.29e-21	0.42	0.33	Corneal astigmatism;	chr4:119519522	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.909	rs35111518	ENSG00000275858.1	RP11-291L22.8	11.24	9.16e-28	2.29e-21	0.42	0.33	Corneal astigmatism;	chr4:119519527	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.863	rs6835635	ENSG00000275858.1	RP11-291L22.8	11.24	9.26e-28	2.32e-21	0.42	0.33	Corneal astigmatism;	chr4:119537712	chr10:38450738~38451069:-
BRCA	trans	rs8175379	0.501	rs10064455	ENSG00000231752.4	EMBP1	-11.24	9.27e-28	2.32e-21	-0.44	-0.33	Interleukin-7 levels;	chr5:46293430	chr1:121519112~121571892:+
BRCA	trans	rs3806843	0.735	rs801168	ENSG00000231043.3	AC007238.1	11.23	1.01e-27	2.52e-21	0.38	0.33	Depressive symptoms (multi-trait analysis);	chr5:140700713	chr2:58460292~58462032:-
BRCA	trans	rs2950393	0.804	rs3214051	ENSG00000228224.3	NACAP1	11.23	1.07e-27	2.67e-21	0.37	0.33	Platelet distribution width;	chr12:56725452	chr8:101361794~101372707:+
BRCA	trans	rs55665837	0.502	rs12795794	ENSG00000236360.2	RP11-334A14.2	11.23	1.08e-27	2.68e-21	0.44	0.33	Vitamin D levels;	chr11:14825327	chr1:52993201~52993702:-
BRCA	trans	rs2950393	0.804	rs11171951	ENSG00000228224.3	NACAP1	11.23	1.1e-27	2.73e-21	0.37	0.33	Platelet distribution width;	chr12:56718853	chr8:101361794~101372707:+
BRCA	trans	rs2950393	0.777	rs2926747	ENSG00000228224.3	NACAP1	11.22	1.13e-27	2.81e-21	0.37	0.33	Platelet distribution width;	chr12:56716147	chr8:101361794~101372707:+
BRCA	trans	rs11098499	1	rs7659194	ENSG00000275858.1	RP11-291L22.8	11.22	1.22e-27	3.03e-21	0.41	0.33	Corneal astigmatism;	chr4:119285992	chr10:38450738~38451069:-
BRCA	trans	rs7395662	0.525	rs4882060	ENSG00000134612.10	FOLH1B	-11.21	1.25e-27	3.09e-21	-0.41	-0.33	HDL cholesterol;	chr11:48420322	chr11:89639227~89698718:+
BRCA	trans	rs55665837	0.539	rs10832310	ENSG00000236360.2	RP11-334A14.2	11.21	1.27e-27	3.16e-21	0.44	0.33	Vitamin D levels;	chr11:14856896	chr1:52993201~52993702:-
BRCA	trans	rs2950393	0.804	rs10783796	ENSG00000228224.3	NACAP1	11.21	1.27e-27	3.16e-21	0.37	0.33	Platelet distribution width;	chr12:56733387	chr8:101361794~101372707:+
BRCA	trans	rs877636	0.692	rs11171739	ENSG00000244604.1	RP11-713H12.1	11.21	1.28e-27	3.17e-21	0.36	0.33	Cognitive function;	chr12:56076841	chr17:8561230~8561576:+
BRCA	trans	rs7312770	0.612	rs773114	ENSG00000212829.8	RPS26P3	11.21	1.3e-27	3.21e-21	0.4	0.33	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr9:9090898~9091245:+
BRCA	trans	rs2950393	0.804	rs2290894	ENSG00000228224.3	NACAP1	11.21	1.3e-27	3.21e-21	0.37	0.33	Platelet distribution width;	chr12:56714911	chr8:101361794~101372707:+
BRCA	trans	rs714543	0.811	rs13238404	ENSG00000226038.5	PPIAP21	11.21	1.33e-27	3.29e-21	0.39	0.33	Plateletcrit;	chr7:44811812	chr20:43230760~43231260:+
BRCA	trans	rs11098499	0.604	rs12642411	ENSG00000275858.1	RP11-291L22.8	11.2	1.38e-27	3.41e-21	0.43	0.33	Corneal astigmatism;	chr4:119659370	chr10:38450738~38451069:-
BRCA	trans	rs3806843	0.966	rs2563267	ENSG00000231043.3	AC007238.1	11.2	1.43e-27	3.54e-21	0.38	0.33	Depressive symptoms (multi-trait analysis);	chr5:140757328	chr2:58460292~58462032:-
BRCA	trans	rs3806843	0.966	rs2563266	ENSG00000231043.3	AC007238.1	11.2	1.43e-27	3.54e-21	0.38	0.33	Depressive symptoms (multi-trait analysis);	chr5:140757330	chr2:58460292~58462032:-
BRCA	trans	rs11098499	0.863	rs1383533	ENSG00000275858.1	RP11-291L22.8	11.2	1.43e-27	3.55e-21	0.41	0.33	Corneal astigmatism;	chr4:119513421	chr10:38450738~38451069:-
BRCA	trans	rs8175379	0.505	rs10073477	ENSG00000231752.4	EMBP1	-11.2	1.47e-27	3.63e-21	-0.43	-0.33	Interleukin-7 levels;	chr5:46338025	chr1:121519112~121571892:+
BRCA	trans	rs2950393	0.929	rs10876916	ENSG00000228224.3	NACAP1	11.2	1.48e-27	3.65e-21	0.37	0.33	Platelet distribution width;	chr12:56692728	chr8:101361794~101372707:+
BRCA	trans	rs2950393	0.794	rs1563897	ENSG00000228224.3	NACAP1	11.2	1.48e-27	3.65e-21	0.37	0.33	Platelet distribution width;	chr12:56699316	chr8:101361794~101372707:+
BRCA	trans	rs11098499	0.82	rs6829903	ENSG00000275858.1	RP11-291L22.8	11.2	1.49e-27	3.67e-21	0.41	0.33	Corneal astigmatism;	chr4:119585729	chr10:38450738~38451069:-
BRCA	trans	rs11098499	1	rs11098499	ENSG00000275858.1	RP11-291L22.8	11.19	1.51e-27	3.71e-21	0.41	0.33	Corneal astigmatism;	chr4:119266456	chr10:38450738~38451069:-
BRCA	trans	rs747782	0.585	rs1316604	ENSG00000134612.10	FOLH1B	11.19	1.53e-27	3.77e-21	0.54	0.33	Intraocular pressure;	chr11:48258244	chr11:89639227~89698718:+
BRCA	trans	rs11098499	0.863	rs2291185	ENSG00000275858.1	RP11-291L22.8	11.19	1.54e-27	3.79e-21	0.41	0.33	Corneal astigmatism;	chr4:119513678	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.909	rs28555550	ENSG00000275858.1	RP11-291L22.8	11.19	1.57e-27	3.85e-21	0.41	0.33	Corneal astigmatism;	chr4:119289885	chr10:38450738~38451069:-
BRCA	trans	rs11098499	1	rs28419773	ENSG00000275858.1	RP11-291L22.8	11.19	1.57e-27	3.85e-21	0.41	0.33	Corneal astigmatism;	chr4:119289906	chr10:38450738~38451069:-
BRCA	trans	rs7554547	0.6	rs2180180	ENSG00000261819.1	RP11-680G24.4	-11.19	1.61e-27	3.95e-21	-0.43	-0.33	Nonsyndromic cleft lip with cleft palate;	chr1:11959312	chr16:14988259~14990160:-
BRCA	trans	rs11098499	0.82	rs11737395	ENSG00000275858.1	RP11-291L22.8	11.19	1.65e-27	4.05e-21	0.41	0.33	Corneal astigmatism;	chr4:119599549	chr10:38450738~38451069:-
BRCA	trans	rs864643	0.524	rs9822783	ENSG00000183298.5	RP11-556K13.1	11.18	1.67e-27	4.1e-21	0.63	0.33	Attention deficit hyperactivity disorder;	chr3:39463311	chr1:101786340~101787219:-
BRCA	trans	rs877636	0.702	rs61937249	ENSG00000233778.3	RP11-777J24.1	11.18	1.69e-27	4.16e-21	0.42	0.33	Cognitive function;	chr12:55988132	chr8:92144088~92144435:-
BRCA	trans	rs55665837	0.539	rs10832311	ENSG00000236360.2	RP11-334A14.2	11.18	1.71e-27	4.18e-21	0.44	0.33	Vitamin D levels;	chr11:14860380	chr1:52993201~52993702:-
BRCA	trans	rs11098499	0.863	rs7669520	ENSG00000275858.1	RP11-291L22.8	11.18	1.71e-27	4.2e-21	0.41	0.33	Corneal astigmatism;	chr4:119594123	chr10:38450738~38451069:-
BRCA	trans	rs9611519	0.531	rs1967708	ENSG00000268568.1	AC007228.9	-11.17	1.89e-27	4.61e-21	-0.41	-0.33	Neuroticism;	chr22:41048440	chr19:56672574~56673901:-
BRCA	trans	rs55665837	0.539	rs731042	ENSG00000236360.2	RP11-334A14.2	11.17	1.89e-27	4.61e-21	0.44	0.33	Vitamin D levels;	chr11:14853429	chr1:52993201~52993702:-
BRCA	trans	rs747782	0.528	rs11039669	ENSG00000134612.10	FOLH1B	11.17	1.92e-27	4.67e-21	0.54	0.33	Intraocular pressure;	chr11:48307266	chr11:89639227~89698718:+
BRCA	trans	rs11039798	0.858	rs7121333	ENSG00000134612.10	FOLH1B	11.17	1.92e-27	4.67e-21	0.54	0.33	Axial length;	chr11:48310586	chr11:89639227~89698718:+
BRCA	trans	rs747782	0.528	rs11039674	ENSG00000134612.10	FOLH1B	11.17	1.92e-27	4.67e-21	0.54	0.33	Intraocular pressure;	chr11:48314564	chr11:89639227~89698718:+
BRCA	trans	rs11098499	0.863	rs3775841	ENSG00000275858.1	RP11-291L22.8	11.16	2.04e-27	4.97e-21	0.41	0.33	Corneal astigmatism;	chr4:119504622	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.955	rs1511019	ENSG00000275858.1	RP11-291L22.8	11.16	2.1e-27	5.11e-21	0.41	0.33	Corneal astigmatism;	chr4:119244852	chr10:38450738~38451069:-
BRCA	trans	rs877636	1	rs705696	ENSG00000234513.1	AC073072.7	11.16	2.15e-27	5.22e-21	0.43	0.33	Cognitive function;	chr12:56086864	chr7:22773646~22773993:-
BRCA	trans	rs3806843	0.932	rs2563269	ENSG00000231043.3	AC007238.1	11.16	2.19e-27	5.31e-21	0.38	0.33	Depressive symptoms (multi-trait analysis);	chr5:140756883	chr2:58460292~58462032:-
BRCA	trans	rs2950393	0.929	rs7980835	ENSG00000228224.3	NACAP1	11.16	2.2e-27	5.34e-21	0.37	0.33	Platelet distribution width;	chr12:56676847	chr8:101361794~101372707:+
BRCA	trans	rs2950393	0.929	rs10747769	ENSG00000228224.3	NACAP1	11.16	2.2e-27	5.34e-21	0.37	0.33	Platelet distribution width;	chr12:56677056	chr8:101361794~101372707:+
BRCA	trans	rs11098499	0.955	rs1511018	ENSG00000275858.1	RP11-291L22.8	11.15	2.25e-27	5.46e-21	0.41	0.33	Corneal astigmatism;	chr4:119240425	chr10:38450738~38451069:-
BRCA	trans	rs2950393	0.895	rs2958123	ENSG00000228224.3	NACAP1	11.15	2.25e-27	5.46e-21	0.37	0.33	Platelet distribution width;	chr12:56668441	chr8:101361794~101372707:+
BRCA	trans	rs7395662	0.504	rs11039701	ENSG00000134612.10	FOLH1B	-11.15	2.31e-27	5.6e-21	-0.41	-0.33	HDL cholesterol;	chr11:48368286	chr11:89639227~89698718:+
BRCA	trans	rs11098499	0.82	rs13128602	ENSG00000275858.1	RP11-291L22.8	-11.15	2.35e-27	5.71e-21	-0.41	-0.33	Corneal astigmatism;	chr4:119538211	chr10:38450738~38451069:-
BRCA	trans	rs11039798	1	rs7104642	ENSG00000134612.10	FOLH1B	11.15	2.39e-27	5.79e-21	0.54	0.33	Axial length;	chr11:48566982	chr11:89639227~89698718:+
BRCA	trans	rs11039798	1	rs7928243	ENSG00000134612.10	FOLH1B	11.15	2.39e-27	5.79e-21	0.54	0.33	Axial length;	chr11:48567640	chr11:89639227~89698718:+
BRCA	trans	rs2950393	0.929	rs2958155	ENSG00000228224.3	NACAP1	11.15	2.43e-27	5.88e-21	0.36	0.33	Platelet distribution width;	chr12:56670761	chr8:101361794~101372707:+
BRCA	trans	rs3806843	0.735	rs801167	ENSG00000231043.3	AC007238.1	-11.15	2.43e-27	5.89e-21	-0.38	-0.33	Depressive symptoms (multi-trait analysis);	chr5:140701838	chr2:58460292~58462032:-
BRCA	trans	rs10037055	0.853	rs10035180	ENSG00000226986.4	RP11-543B16.2	-11.14	2.53e-27	6.13e-21	-0.43	-0.33	Migraine without aura;	chr5:177171501	chr1:211207239~211207897:+
BRCA	trans	rs8175379	0.509	rs8188019	ENSG00000231752.4	EMBP1	11.14	2.56e-27	6.2e-21	0.43	0.33	Interleukin-7 levels;	chr5:46130910	chr1:121519112~121571892:+
BRCA	trans	rs11039798	0.844	rs6485820	ENSG00000134612.10	FOLH1B	11.14	2.67e-27	6.45e-21	0.54	0.33	Axial length;	chr11:48243159	chr11:89639227~89698718:+
BRCA	trans	rs11039798	0.699	rs7120775	ENSG00000134612.10	FOLH1B	11.14	2.67e-27	6.45e-21	0.54	0.33	Axial length;	chr11:48245184	chr11:89639227~89698718:+
BRCA	trans	rs941207	0.526	rs2950390	ENSG00000228224.3	NACAP1	11.13	2.75e-27	6.64e-21	0.37	0.33	Platelet count;	chr12:56661507	chr8:101361794~101372707:+
BRCA	trans	rs11098499	0.754	rs878376	ENSG00000275858.1	RP11-291L22.8	11.13	2.77e-27	6.69e-21	0.39	0.33	Corneal astigmatism;	chr4:119316547	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.863	rs3822195	ENSG00000275858.1	RP11-291L22.8	11.13	2.78e-27	6.71e-21	0.41	0.33	Corneal astigmatism;	chr4:119550505	chr10:38450738~38451069:-
BRCA	trans	rs13358908	0.506	rs7293471	ENSG00000231752.4	EMBP1	-11.13	2.95e-27	7.09e-21	-0.43	-0.33	Schizophrenia;	chr5:46404446	chr1:121519112~121571892:+
BRCA	trans	rs11098499	1	rs11726229	ENSG00000275858.1	RP11-291L22.8	11.13	3e-27	7.23e-21	0.41	0.33	Corneal astigmatism;	chr4:119290425	chr10:38450738~38451069:-
BRCA	trans	rs11039798	1	rs6485908	ENSG00000134612.10	FOLH1B	-11.13	3.02e-27	7.27e-21	-0.53	-0.33	Axial length;	chr11:48630646	chr11:89639227~89698718:+
BRCA	trans	rs55665837	0.539	rs12794714	ENSG00000236360.2	RP11-334A14.2	11.12	3.14e-27	7.53e-21	0.43	0.33	Vitamin D levels;	chr11:14892029	chr1:52993201~52993702:-
BRCA	trans	rs55665837	0.502	rs4757269	ENSG00000236360.2	RP11-334A14.2	11.12	3.2e-27	7.65e-21	0.43	0.33	Vitamin D levels;	chr11:14814646	chr1:52993201~52993702:-
BRCA	trans	rs11098499	0.863	rs7699064	ENSG00000275858.1	RP11-291L22.8	-11.12	3.21e-27	7.67e-21	-0.41	-0.33	Corneal astigmatism;	chr4:119507154	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.954	rs6847248	ENSG00000275858.1	RP11-291L22.8	11.12	3.21e-27	7.68e-21	0.44	0.33	Corneal astigmatism;	chr4:119304800	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.863	rs2306457	ENSG00000275858.1	RP11-291L22.8	11.12	3.23e-27	7.72e-21	0.41	0.33	Corneal astigmatism;	chr4:119551684	chr10:38450738~38451069:-
BRCA	trans	rs11098499	1	rs11098500	ENSG00000275858.1	RP11-291L22.8	11.12	3.31e-27	7.91e-21	0.41	0.33	Corneal astigmatism;	chr4:119298084	chr10:38450738~38451069:-
BRCA	trans	rs11039798	0.92	rs12279378	ENSG00000134612.10	FOLH1B	11.12	3.32e-27	7.94e-21	0.53	0.33	Axial length;	chr11:48549478	chr11:89639227~89698718:+
BRCA	trans	rs11039798	0.92	rs12292685	ENSG00000134612.10	FOLH1B	11.12	3.32e-27	7.94e-21	0.53	0.33	Axial length;	chr11:48549480	chr11:89639227~89698718:+
BRCA	trans	rs11098499	0.863	rs3775854	ENSG00000275858.1	RP11-291L22.8	11.11	3.38e-27	8.07e-21	0.41	0.33	Corneal astigmatism;	chr4:119550816	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.863	rs6853998	ENSG00000275858.1	RP11-291L22.8	11.11	3.38e-27	8.07e-21	0.41	0.33	Corneal astigmatism;	chr4:119554705	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.863	rs6858777	ENSG00000275858.1	RP11-291L22.8	11.11	3.38e-27	8.07e-21	0.41	0.33	Corneal astigmatism;	chr4:119554811	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.863	rs11731756	ENSG00000275858.1	RP11-291L22.8	11.11	3.38e-27	8.07e-21	0.41	0.33	Corneal astigmatism;	chr4:119557541	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.863	rs34308924	ENSG00000275858.1	RP11-291L22.8	11.11	3.38e-27	8.07e-21	0.41	0.33	Corneal astigmatism;	chr4:119560276	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.863	rs2170276	ENSG00000275858.1	RP11-291L22.8	11.11	3.38e-27	8.07e-21	0.41	0.33	Corneal astigmatism;	chr4:119564669	chr10:38450738~38451069:-
BRCA	trans	rs747782	0.528	rs624348	ENSG00000134612.10	FOLH1B	-11.11	3.4e-27	8.11e-21	-0.54	-0.33	Intraocular pressure;	chr11:48379243	chr11:89639227~89698718:+
BRCA	trans	rs11039798	0.623	rs584851	ENSG00000134612.10	FOLH1B	-11.11	3.4e-27	8.11e-21	-0.54	-0.33	Axial length;	chr11:48394769	chr11:89639227~89698718:+
BRCA	trans	rs11098499	0.82	rs2389885	ENSG00000275858.1	RP11-291L22.8	11.11	3.43e-27	8.17e-21	0.43	0.33	Corneal astigmatism;	chr4:119612776	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.863	rs12498539	ENSG00000275858.1	RP11-291L22.8	11.11	3.49e-27	8.31e-21	0.41	0.33	Corneal astigmatism;	chr4:119547215	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.863	rs3822194	ENSG00000275858.1	RP11-291L22.8	11.11	3.49e-27	8.31e-21	0.41	0.33	Corneal astigmatism;	chr4:119550493	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.754	rs938056	ENSG00000275858.1	RP11-291L22.8	11.11	3.51e-27	8.37e-21	0.39	0.33	Corneal astigmatism;	chr4:119316298	chr10:38450738~38451069:-
BRCA	trans	rs2950393	0.929	rs7973157	ENSG00000228224.3	NACAP1	-11.11	3.51e-27	8.37e-21	-0.37	-0.33	Platelet distribution width;	chr12:56655409	chr8:101361794~101372707:+
BRCA	trans	rs877636	0.669	rs7297175	ENSG00000234354.3	RPS26P47	-11.1	3.76e-27	8.95e-21	-0.39	-0.33	Cognitive function;	chr12:56080024	chr13:100539901~100540248:-
BRCA	trans	rs9329221	0.868	rs7831557	ENSG00000253893.2	FAM85B	11.1	3.85e-27	9.15e-21	0.43	0.33	Neuroticism;	chr8:10422718	chr8:8167819~8226614:-
BRCA	trans	rs11220082	0.666	rs12224788	ENSG00000236257.1	EI24P2	-11.1	4.06e-27	9.64e-21	-0.39	-0.33	Schizophrenia;	chr11:125459165	chr1:158454198~158455273:+
BRCA	trans	rs8175379	1	rs8175379	ENSG00000231752.4	EMBP1	-11.09	4.21e-27	1e-20	-0.43	-0.32	Interleukin-7 levels;	chr5:46263441	chr1:121519112~121571892:+
BRCA	trans	rs1351696	1	rs1351696	ENSG00000134612.10	FOLH1B	-11.09	4.32e-27	1.02e-20	-0.54	-0.32	D-dimer levels;	chr11:48360919	chr11:89639227~89698718:+
BRCA	trans	rs2950393	0.927	rs11171914	ENSG00000228224.3	NACAP1	-11.09	4.32e-27	1.02e-20	-0.37	-0.32	Platelet distribution width;	chr12:56649462	chr8:101361794~101372707:+
BRCA	trans	rs7312770	1	rs7312770	ENSG00000196656.7	AC004057.1	-11.09	4.32e-27	1.02e-20	-0.35	-0.32	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr4:113214046~113217170:-
BRCA	trans	rs11039798	0.62	rs10838833	ENSG00000134612.10	FOLH1B	11.09	4.51e-27	1.07e-20	0.54	0.32	Axial length;	chr11:48217328	chr11:89639227~89698718:+
BRCA	trans	rs3806843	0.966	rs2563260	ENSG00000231043.3	AC007238.1	11.08	4.53e-27	1.07e-20	0.37	0.32	Depressive symptoms (multi-trait analysis);	chr5:140758282	chr2:58460292~58462032:-
BRCA	trans	rs3806843	0.735	rs2530241	ENSG00000231043.3	AC007238.1	11.08	4.62e-27	1.09e-20	0.38	0.32	Depressive symptoms (multi-trait analysis);	chr5:140674900	chr2:58460292~58462032:-
BRCA	trans	rs941207	0.507	rs73337030	ENSG00000228224.3	NACAP1	-11.08	4.81e-27	1.14e-20	-0.37	-0.32	Platelet count;	chr12:56652410	chr8:101361794~101372707:+
BRCA	trans	rs877636	0.74	rs705698	ENSG00000223416.3	RPS26P15	11.08	4.83e-27	1.14e-20	0.42	0.32	Cognitive function;	chr12:55990903	chr1:58056133~58056480:-
BRCA	trans	rs3806843	0.735	rs2530242	ENSG00000231043.3	AC007238.1	11.08	4.87e-27	1.15e-20	0.38	0.32	Depressive symptoms (multi-trait analysis);	chr5:140673766	chr2:58460292~58462032:-
BRCA	trans	rs2950393	0.804	rs2958130	ENSG00000228224.3	NACAP1	11.07	5.05e-27	1.19e-20	0.37	0.32	Platelet distribution width;	chr12:56746722	chr8:101361794~101372707:+
BRCA	trans	rs2950393	0.804	rs7967600	ENSG00000228224.3	NACAP1	11.07	5.23e-27	1.24e-20	0.37	0.32	Platelet distribution width;	chr12:56768208	chr8:101361794~101372707:+
BRCA	trans	rs7662987	1	rs13125919	ENSG00000233859.2	ADH5P4	11.07	5.28e-27	1.25e-20	0.72	0.32	Smoking initiation;	chr4:99078697	chr6:65836930~65838039:-
BRCA	trans	rs941207	0.526	rs2950393	ENSG00000228224.3	NACAP1	-11.06	5.55e-27	1.31e-20	-0.37	-0.32	Platelet count;	chr12:56642239	chr8:101361794~101372707:+
BRCA	trans	rs877636	1	rs705696	ENSG00000223416.3	RPS26P15	11.06	5.8e-27	1.37e-20	0.42	0.32	Cognitive function;	chr12:56086864	chr1:58056133~58056480:-
BRCA	trans	rs8175379	0.509	rs8185053	ENSG00000231752.4	EMBP1	-11.06	5.85e-27	1.38e-20	-0.43	-0.32	Interleukin-7 levels;	chr5:46261842	chr1:121519112~121571892:+
BRCA	trans	rs7662987	1	rs7683802	ENSG00000233859.2	ADH5P4	11.06	5.86e-27	1.38e-20	0.7	0.32	Smoking initiation;	chr4:99073987	chr6:65836930~65838039:-
BRCA	trans	rs7662987	1	rs4699699	ENSG00000233859.2	ADH5P4	11.06	5.99e-27	1.41e-20	0.71	0.32	Smoking initiation;	chr4:99076028	chr6:65836930~65838039:-
BRCA	trans	rs7662987	0.938	rs13118409	ENSG00000233859.2	ADH5P4	11.06	5.99e-27	1.41e-20	0.71	0.32	Smoking initiation;	chr4:99077585	chr6:65836930~65838039:-
BRCA	trans	rs7662987	1	rs13119035	ENSG00000233859.2	ADH5P4	11.06	5.99e-27	1.41e-20	0.71	0.32	Smoking initiation;	chr4:99077979	chr6:65836930~65838039:-
BRCA	trans	rs11098499	0.644	rs28787668	ENSG00000275858.1	RP11-291L22.8	11.05	6.19e-27	1.46e-20	0.39	0.32	Corneal astigmatism;	chr4:119633532	chr10:38450738~38451069:-
BRCA	trans	rs7819412	0.525	rs10086521	ENSG00000253893.2	FAM85B	11.05	6.38e-27	1.5e-20	0.43	0.32	Triglycerides;	chr8:10926259	chr8:8167819~8226614:-
BRCA	trans	rs11039798	0.698	rs76315297	ENSG00000134612.10	FOLH1B	11.05	6.41e-27	1.5e-20	0.54	0.32	Axial length;	chr11:48218923	chr11:89639227~89698718:+
BRCA	trans	rs10838798	0.504	rs1483123	ENSG00000134612.10	FOLH1B	-11.05	6.72e-27	1.58e-20	-0.41	-0.32	Height;	chr11:48305221	chr11:89639227~89698718:+
BRCA	trans	rs864643	0.678	rs1768206	ENSG00000183298.5	RP11-556K13.1	11.04	6.82e-27	1.6e-20	0.53	0.32	Attention deficit hyperactivity disorder;	chr3:39480342	chr1:101786340~101787219:-
BRCA	trans	rs11039798	0.764	rs11039771	ENSG00000134612.10	FOLH1B	11.04	6.86e-27	1.61e-20	0.54	0.32	Axial length;	chr11:48491721	chr11:89639227~89698718:+
BRCA	trans	rs8175379	0.505	rs12189292	ENSG00000231752.4	EMBP1	-11.04	6.99e-27	1.64e-20	-0.43	-0.32	Interleukin-7 levels;	chr5:46340498	chr1:121519112~121571892:+
BRCA	trans	rs9611519	0.566	rs4821981	ENSG00000268568.1	AC007228.9	11.04	7e-27	1.64e-20	0.4	0.32	Neuroticism;	chr22:41019640	chr19:56672574~56673901:-
BRCA	trans	rs11098499	1	rs6837898	ENSG00000275858.1	RP11-291L22.8	11.04	7.08e-27	1.66e-20	0.41	0.32	Corneal astigmatism;	chr4:119257999	chr10:38450738~38451069:-
BRCA	trans	rs9611519	0.639	rs7290458	ENSG00000268568.1	AC007228.9	11.04	7.24e-27	1.7e-20	0.4	0.32	Neuroticism;	chr22:41080333	chr19:56672574~56673901:-
BRCA	trans	rs11039798	0.764	rs4357721	ENSG00000134612.10	FOLH1B	-11.03	7.65e-27	1.79e-20	-0.54	-0.32	Axial length;	chr11:48333355	chr11:89639227~89698718:+
BRCA	trans	rs941207	0.526	rs2255074	ENSG00000228224.3	NACAP1	-11.02	8.69e-27	2.03e-20	-0.37	-0.32	Platelet count;	chr12:56636242	chr8:101361794~101372707:+
BRCA	trans	rs941207	0.526	rs12229457	ENSG00000228224.3	NACAP1	-11.02	8.81e-27	2.06e-20	-0.38	-0.32	Platelet count;	chr12:56639896	chr8:101361794~101372707:+
BRCA	trans	rs11098499	0.863	rs9884402	ENSG00000275858.1	RP11-291L22.8	11.02	8.85e-27	2.07e-20	0.4	0.32	Corneal astigmatism;	chr4:119568827	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.731	rs9995026	ENSG00000275858.1	RP11-291L22.8	11.02	8.85e-27	2.07e-20	0.4	0.32	Corneal astigmatism;	chr4:119569344	chr10:38450738~38451069:-
BRCA	trans	rs10838798	0.504	rs7479393	ENSG00000134612.10	FOLH1B	-11.02	8.87e-27	2.07e-20	-0.41	-0.32	Height;	chr11:48273751	chr11:89639227~89698718:+
BRCA	trans	rs3806843	0.735	rs2530235	ENSG00000231043.3	AC007238.1	11.02	8.95e-27	2.09e-20	0.38	0.32	Depressive symptoms (multi-trait analysis);	chr5:140693062	chr2:58460292~58462032:-
BRCA	trans	rs7662987	1	rs28730587	ENSG00000233859.2	ADH5P4	11.01	9.61e-27	2.24e-20	0.72	0.32	Smoking initiation;	chr4:99083190	chr6:65836930~65838039:-
BRCA	trans	rs2950393	0.804	rs2958132	ENSG00000228224.3	NACAP1	11.01	9.67e-27	2.25e-20	0.36	0.32	Platelet distribution width;	chr12:56750749	chr8:101361794~101372707:+
BRCA	trans	rs9650657	0.529	rs10108618	ENSG00000253893.2	FAM85B	11.01	9.72e-27	2.26e-20	0.42	0.32	Neuroticism;	chr8:11095582	chr8:8167819~8226614:-
BRCA	trans	rs10242455	0.867	rs73410654	ENSG00000228834.1	RP11-249L21.4	11	1.04e-26	2.42e-20	0.59	0.32	Blood metabolite levels;	chr7:99729040	chr6:108907615~108907873:-
BRCA	trans	rs10838798	0.504	rs10838852	ENSG00000134612.10	FOLH1B	-11	1.06e-26	2.46e-20	-0.41	-0.32	Height;	chr11:48264704	chr11:89639227~89698718:+
BRCA	trans	rs3806843	0.735	rs778595	ENSG00000231043.3	AC007238.1	11	1.08e-26	2.52e-20	0.38	0.32	Depressive symptoms (multi-trait analysis);	chr5:140657096	chr2:58460292~58462032:-
BRCA	trans	rs11039798	1	rs9667626	ENSG00000134612.10	FOLH1B	11	1.08e-26	2.52e-20	0.54	0.32	Axial length;	chr11:48464325	chr11:89639227~89698718:+
BRCA	trans	rs3806843	0.9	rs2337983	ENSG00000231043.3	AC007238.1	10.99	1.18e-26	2.74e-20	0.37	0.32	Depressive symptoms (multi-trait analysis);	chr5:140757223	chr2:58460292~58462032:-
BRCA	trans	rs7824557	0.505	rs2736313	ENSG00000253893.2	FAM85B	-10.99	1.2e-26	2.78e-20	-0.41	-0.32	Retinal vascular caliber;	chr8:11229433	chr8:8167819~8226614:-
BRCA	trans	rs747782	0.528	rs7937670	ENSG00000134612.10	FOLH1B	10.98	1.34e-26	3.1e-20	0.54	0.32	Intraocular pressure;	chr11:48291664	chr11:89639227~89698718:+
BRCA	trans	rs8175379	0.509	rs7293453	ENSG00000231752.4	EMBP1	10.97	1.38e-26	3.19e-20	0.42	0.32	Interleukin-7 levels;	chr5:46253007	chr1:121519112~121571892:+
BRCA	trans	rs3806843	0.735	rs801188	ENSG00000231043.3	AC007238.1	10.97	1.48e-26	3.42e-20	0.38	0.32	Depressive symptoms (multi-trait analysis);	chr5:140687331	chr2:58460292~58462032:-
BRCA	trans	rs3806843	0.735	rs778597	ENSG00000231043.3	AC007238.1	-10.96	1.55e-26	3.59e-20	-0.38	-0.32	Depressive symptoms (multi-trait analysis);	chr5:140661080	chr2:58460292~58462032:-
BRCA	trans	rs11098499	0.57	rs6832740	ENSG00000275858.1	RP11-291L22.8	10.96	1.58e-26	3.65e-20	0.39	0.32	Corneal astigmatism;	chr4:119624981	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.644	rs6855918	ENSG00000275858.1	RP11-291L22.8	10.96	1.58e-26	3.65e-20	0.39	0.32	Corneal astigmatism;	chr4:119625144	chr10:38450738~38451069:-
BRCA	trans	rs9329221	0.537	rs6983332	ENSG00000253893.2	FAM85B	10.96	1.62e-26	3.75e-20	0.39	0.32	Neuroticism;	chr8:10120408	chr8:8167819~8226614:-
BRCA	trans	rs3806843	0.966	rs2337986	ENSG00000231043.3	AC007238.1	-10.95	1.66e-26	3.82e-20	-0.37	-0.32	Depressive symptoms (multi-trait analysis);	chr5:140781037	chr2:58460292~58462032:-
BRCA	trans	rs3806843	1	rs1548701	ENSG00000231043.3	AC007238.1	-10.95	1.66e-26	3.82e-20	-0.37	-0.32	Depressive symptoms (multi-trait analysis);	chr5:140784972	chr2:58460292~58462032:-
BRCA	trans	rs3806843	1	rs3756342	ENSG00000231043.3	AC007238.1	-10.95	1.66e-26	3.82e-20	-0.37	-0.32	Depressive symptoms (multi-trait analysis);	chr5:140786039	chr2:58460292~58462032:-
BRCA	trans	rs3806843	0.933	rs2240696	ENSG00000231043.3	AC007238.1	-10.95	1.66e-26	3.82e-20	-0.37	-0.32	Depressive symptoms (multi-trait analysis);	chr5:140788485	chr2:58460292~58462032:-
BRCA	trans	rs3806843	0.966	rs6579965	ENSG00000231043.3	AC007238.1	-10.95	1.66e-26	3.82e-20	-0.37	-0.32	Depressive symptoms (multi-trait analysis);	chr5:140789226	chr2:58460292~58462032:-
BRCA	trans	rs3806843	1	rs6898906	ENSG00000231043.3	AC007238.1	-10.95	1.66e-26	3.82e-20	-0.37	-0.32	Depressive symptoms (multi-trait analysis);	chr5:140789714	chr2:58460292~58462032:-
BRCA	trans	rs8175379	0.509	rs10078317	ENSG00000231752.4	EMBP1	10.95	1.68e-26	3.88e-20	0.42	0.32	Interleukin-7 levels;	chr5:46254038	chr1:121519112~121571892:+
BRCA	trans	rs10716881	1	rs10716881	ENSG00000228224.3	NACAP1	-10.95	1.69e-26	3.88e-20	-0.36	-0.32	High light scatter reticulocyte count;	chr12:56644387	chr8:101361794~101372707:+
BRCA	trans	rs2950393	0.804	rs898611	ENSG00000228224.3	NACAP1	-10.95	1.71e-26	3.94e-20	-0.36	-0.32	Platelet distribution width;	chr12:56769532	chr8:101361794~101372707:+
BRCA	trans	rs11098499	0.863	rs1010739	ENSG00000275858.1	RP11-291L22.8	10.95	1.72e-26	3.96e-20	0.41	0.32	Corneal astigmatism;	chr4:119542316	chr10:38450738~38451069:-
BRCA	trans	rs8175379	0.509	rs4128582	ENSG00000231752.4	EMBP1	10.94	1.84e-26	4.24e-20	0.42	0.32	Interleukin-7 levels;	chr5:46252001	chr1:121519112~121571892:+
BRCA	trans	rs10242455	0.867	rs45624139	ENSG00000228834.1	RP11-249L21.4	10.94	1.87e-26	4.3e-20	0.58	0.32	Blood metabolite levels;	chr7:99721872	chr6:108907615~108907873:-
BRCA	trans	rs10242455	1	rs17161692	ENSG00000228834.1	RP11-249L21.4	-10.94	1.89e-26	4.36e-20	-0.65	-0.32	Blood metabolite levels;	chr7:99356240	chr6:108907615~108907873:-
BRCA	trans	rs11098499	0.644	rs7676296	ENSG00000275858.1	RP11-291L22.8	10.94	1.95e-26	4.47e-20	0.38	0.32	Corneal astigmatism;	chr4:119634532	chr10:38450738~38451069:-
BRCA	trans	rs2950393	0.777	rs7966391	ENSG00000228224.3	NACAP1	10.94	1.99e-26	4.56e-20	0.36	0.32	Platelet distribution width;	chr12:56745272	chr8:101361794~101372707:+
BRCA	trans	rs2727020	0.656	rs7925524	ENSG00000134612.10	FOLH1B	-10.94	2e-26	4.59e-20	-0.42	-0.32	Coronary artery disease;	chr11:49415990	chr11:89639227~89698718:+
BRCA	trans	rs3806843	1	rs6870764	ENSG00000231043.3	AC007238.1	-10.93	2.03e-26	4.66e-20	-0.37	-0.32	Depressive symptoms (multi-trait analysis);	chr5:140792205	chr2:58460292~58462032:-
BRCA	trans	rs3806843	1	rs6891995	ENSG00000231043.3	AC007238.1	-10.93	2.03e-26	4.66e-20	-0.37	-0.32	Depressive symptoms (multi-trait analysis);	chr5:140792423	chr2:58460292~58462032:-
BRCA	trans	rs3806843	1	rs13184940	ENSG00000231043.3	AC007238.1	-10.93	2.03e-26	4.66e-20	-0.37	-0.32	Depressive symptoms (multi-trait analysis);	chr5:140793333	chr2:58460292~58462032:-
BRCA	trans	rs3806843	1	rs9686540	ENSG00000231043.3	AC007238.1	-10.93	2.03e-26	4.66e-20	-0.37	-0.32	Depressive symptoms (multi-trait analysis);	chr5:140795037	chr2:58460292~58462032:-
BRCA	trans	rs3806843	0.966	rs3756341	ENSG00000231043.3	AC007238.1	-10.93	2.03e-26	4.67e-20	-0.37	-0.32	Depressive symptoms (multi-trait analysis);	chr5:140791609	chr2:58460292~58462032:-
BRCA	trans	rs11098499	0.644	rs7693919	ENSG00000275858.1	RP11-291L22.8	10.93	2.03e-26	4.67e-20	0.39	0.32	Corneal astigmatism;	chr4:119619416	chr10:38450738~38451069:-
BRCA	trans	rs3806843	1	rs12717860	ENSG00000231043.3	AC007238.1	-10.93	2.05e-26	4.7e-20	-0.37	-0.32	Depressive symptoms (multi-trait analysis);	chr5:140791857	chr2:58460292~58462032:-
BRCA	trans	rs11039798	1	rs3902927	ENSG00000134612.10	FOLH1B	10.93	2.05e-26	4.7e-20	0.52	0.32	Axial length;	chr11:48559905	chr11:89639227~89698718:+
BRCA	trans	rs11039798	1	rs3902928	ENSG00000134612.10	FOLH1B	10.93	2.05e-26	4.7e-20	0.52	0.32	Axial length;	chr11:48559906	chr11:89639227~89698718:+
BRCA	trans	rs7312770	0.612	rs773114	ENSG00000244604.1	RP11-713H12.1	10.93	2.06e-26	4.72e-20	0.36	0.32	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr17:8561230~8561576:+
BRCA	trans	rs877636	0.702	rs773110	ENSG00000223416.3	RPS26P15	10.93	2.09e-26	4.78e-20	0.42	0.32	Cognitive function;	chr12:55981353	chr1:58056133~58056480:-
BRCA	trans	rs877636	0.74	rs705702	ENSG00000233778.3	RP11-777J24.1	-10.92	2.28e-26	5.21e-20	-0.41	-0.32	Cognitive function;	chr12:55996852	chr8:92144088~92144435:-
BRCA	trans	rs2727020	0.894	rs2866361	ENSG00000134612.10	FOLH1B	-10.92	2.42e-26	5.53e-20	-0.44	-0.32	Coronary artery disease;	chr11:49350929	chr11:89639227~89698718:+
BRCA	trans	rs877636	0.702	rs773112	ENSG00000223416.3	RPS26P15	10.92	2.44e-26	5.56e-20	0.42	0.32	Cognitive function;	chr12:55982097	chr1:58056133~58056480:-
BRCA	trans	rs8175379	0.509	rs8185235	ENSG00000231752.4	EMBP1	10.91	2.51e-26	5.73e-20	0.42	0.32	Interleukin-7 levels;	chr5:46252306	chr1:121519112~121571892:+
BRCA	trans	rs1580019	0.587	rs10951338	ENSG00000176826.14	FKBP9P1	-10.91	2.55e-26	5.81e-20	-0.4	-0.32	Cognitive ability;	chr7:32520477	chr7:55681074~55713252:-
BRCA	trans	rs877636	0.702	rs773111	ENSG00000223416.3	RPS26P15	10.91	2.55e-26	5.82e-20	0.42	0.32	Cognitive function;	chr12:55981956	chr1:58056133~58056480:-
BRCA	trans	rs616147	1	rs616147	ENSG00000214263.2	RPSAP53	-10.91	2.57e-26	5.85e-20	-0.46	-0.32	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39492990	chr13:67266845~67267706:-
BRCA	trans	rs3806843	1	rs10073974	ENSG00000231043.3	AC007238.1	-10.91	2.61e-26	5.95e-20	-0.37	-0.32	Depressive symptoms (multi-trait analysis);	chr5:140785646	chr2:58460292~58462032:-
BRCA	trans	rs3806843	1	rs2240695	ENSG00000231043.3	AC007238.1	-10.91	2.61e-26	5.95e-20	-0.37	-0.32	Depressive symptoms (multi-trait analysis);	chr5:140788566	chr2:58460292~58462032:-
BRCA	trans	rs11098499	0.754	rs10213554	ENSG00000275858.1	RP11-291L22.8	-10.9	2.71e-26	6.17e-20	-0.39	-0.32	Corneal astigmatism;	chr4:119339630	chr10:38450738~38451069:-
BRCA	trans	rs877636	1	rs2292239	ENSG00000242970.2	AC068522.4	10.9	2.73e-26	6.22e-20	0.43	0.32	Cognitive function;	chr12:56088396	chr8:58588420~58588764:-
BRCA	trans	rs1580019	0.539	rs11769109	ENSG00000176826.14	FKBP9P1	-10.9	2.73e-26	6.22e-20	-0.4	-0.32	Cognitive ability;	chr7:32531740	chr7:55681074~55713252:-
BRCA	trans	rs1580019	0.563	rs4723169	ENSG00000176826.14	FKBP9P1	-10.9	2.79e-26	6.35e-20	-0.4	-0.32	Cognitive ability;	chr7:32527965	chr7:55681074~55713252:-
BRCA	trans	rs3806843	0.9	rs2261651	ENSG00000231043.3	AC007238.1	10.9	2.85e-26	6.48e-20	0.37	0.32	Depressive symptoms (multi-trait analysis);	chr5:140757219	chr2:58460292~58462032:-
BRCA	trans	rs7312770	0.612	rs1873914	ENSG00000243538.1	CTB-55B8.1	10.9	2.86e-26	6.5e-20	0.37	0.32	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr5:16902294~16902641:-
BRCA	trans	rs941207	0.507	rs2958124	ENSG00000228224.3	NACAP1	-10.9	2.91e-26	6.62e-20	-0.37	-0.32	Platelet count;	chr12:56633837	chr8:101361794~101372707:+
BRCA	trans	rs6498068	0.522	rs10775284	ENSG00000278702.1	Metazoa_SRP	10.89	3.02e-26	6.85e-20	0.42	0.32	Metabolite levels (MHPG);	chr16:10535402	chr1:35399997~35400319:+
BRCA	trans	rs2727020	0.894	rs1880438	ENSG00000134612.10	FOLH1B	-10.89	3.03e-26	6.88e-20	-0.44	-0.32	Coronary artery disease;	chr11:49349146	chr11:89639227~89698718:+
BRCA	trans	rs11098499	1	rs58601355	ENSG00000275858.1	RP11-291L22.8	10.89	3.12e-26	7.08e-20	0.4	0.32	Corneal astigmatism;	chr4:119265212	chr10:38450738~38451069:-
BRCA	trans	rs3806843	1	rs1476768	ENSG00000231043.3	AC007238.1	-10.89	3.2e-26	7.26e-20	-0.37	-0.32	Depressive symptoms (multi-trait analysis);	chr5:140794012	chr2:58460292~58462032:-
BRCA	trans	rs3806843	1	rs3756339	ENSG00000231043.3	AC007238.1	-10.89	3.2e-26	7.26e-20	-0.37	-0.32	Depressive symptoms (multi-trait analysis);	chr5:140800952	chr2:58460292~58462032:-
BRCA	trans	rs3806843	1	rs3733708	ENSG00000231043.3	AC007238.1	-10.89	3.2e-26	7.26e-20	-0.37	-0.32	Depressive symptoms (multi-trait analysis);	chr5:140802149	chr2:58460292~58462032:-
BRCA	trans	rs3806843	1	rs2240694	ENSG00000231043.3	AC007238.1	-10.89	3.2e-26	7.26e-20	-0.37	-0.32	Depressive symptoms (multi-trait analysis);	chr5:140803473	chr2:58460292~58462032:-
BRCA	trans	rs3806843	1	rs3733710	ENSG00000231043.3	AC007238.1	-10.89	3.2e-26	7.26e-20	-0.37	-0.32	Depressive symptoms (multi-trait analysis);	chr5:140787878	chr2:58460292~58462032:-
BRCA	trans	rs3806843	1	rs2337985	ENSG00000231043.3	AC007238.1	-10.89	3.23e-26	7.32e-20	-0.37	-0.32	Depressive symptoms (multi-trait analysis);	chr5:140778276	chr2:58460292~58462032:-
BRCA	trans	rs7662987	1	rs13145727	ENSG00000233859.2	ADH5P4	10.88	3.54e-26	8.01e-20	0.71	0.32	Smoking initiation;	chr4:99077715	chr6:65836930~65838039:-
BRCA	trans	rs1580019	0.563	rs34201720	ENSG00000176826.14	FKBP9P1	-10.88	3.54e-26	8.02e-20	-0.4	-0.32	Cognitive ability;	chr7:32529323	chr7:55681074~55713252:-
BRCA	trans	rs9611519	0.579	rs8136274	ENSG00000268568.1	AC007228.9	-10.87	3.91e-26	8.84e-20	-0.4	-0.32	Neuroticism;	chr22:41019307	chr19:56672574~56673901:-
BRCA	trans	rs9611519	0.59	rs4821980	ENSG00000268568.1	AC007228.9	-10.87	3.91e-26	8.84e-20	-0.4	-0.32	Neuroticism;	chr22:41019475	chr19:56672574~56673901:-
BRCA	trans	rs7662987	1	rs7662987	ENSG00000233859.2	ADH5P4	10.87	3.92e-26	8.86e-20	0.7	0.32	Smoking initiation;	chr4:99070491	chr6:65836930~65838039:-
BRCA	trans	rs4263408	0.967	rs11947966	ENSG00000237550.5	UBE2Q2P6	10.87	3.97e-26	8.96e-20	0.38	0.32	Plasma amyloid beta peptide concentrations (ABx-40);	chr4:39765721	chr15:82372196~82372912:-
BRCA	trans	rs3806843	1	rs10057161	ENSG00000231043.3	AC007238.1	-10.86	4.04e-26	9.12e-20	-0.37	-0.32	Depressive symptoms (multi-trait analysis);	chr5:140777246	chr2:58460292~58462032:-
BRCA	trans	rs11098499	0.754	rs714899	ENSG00000275858.1	RP11-291L22.8	10.86	4.11e-26	9.27e-20	0.38	0.32	Corneal astigmatism;	chr4:119321880	chr10:38450738~38451069:-
BRCA	trans	rs877636	0.669	rs7297175	ENSG00000243538.1	CTB-55B8.1	-10.86	4.13e-26	9.32e-20	-0.36	-0.32	Cognitive function;	chr12:56080024	chr5:16902294~16902641:-
BRCA	trans	rs8010715	0.816	rs1134340	ENSG00000238000.1	RP11-274E7.2	10.86	4.24e-26	9.56e-20	0.34	0.32	IgG glycosylation;	chr14:24125004	chr5:98213402~98214121:+
BRCA	trans	rs2950393	0.804	rs1131514	ENSG00000228224.3	NACAP1	-10.86	4.32e-26	9.75e-20	-0.36	-0.32	Platelet distribution width;	chr12:56739356	chr8:101361794~101372707:+
BRCA	trans	rs2899832	0.568	rs7144747	ENSG00000229083.1	PSMA6P2	10.86	4.34e-26	9.78e-20	0.54	0.32	Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:35168305	chrX:12825840~12826833:+
BRCA	trans	rs9650657	0.504	rs7813802	ENSG00000253893.2	FAM85B	-10.86	4.37e-26	9.84e-20	-0.39	-0.32	Neuroticism;	chr8:11176467	chr8:8167819~8226614:-
BRCA	trans	rs13190036	0.551	rs4976639	ENSG00000228305.2	AC016734.2	10.86	4.41e-26	9.93e-20	0.42	0.32	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177123300	chr2:63622178~63622831:-
BRCA	trans	rs3806843	1	rs10477034	ENSG00000231043.3	AC007238.1	-10.85	4.47e-26	1.01e-19	-0.37	-0.32	Depressive symptoms (multi-trait analysis);	chr5:140790145	chr2:58460292~58462032:-
BRCA	trans	rs877636	0.702	rs773109	ENSG00000223416.3	RPS26P15	10.85	4.48e-26	1.01e-19	0.42	0.32	Cognitive function;	chr12:55980911	chr1:58056133~58056480:-
BRCA	trans	rs877636	0.74	rs772920	ENSG00000233778.3	RP11-777J24.1	10.85	4.51e-26	1.02e-19	0.41	0.32	Cognitive function;	chr12:55996580	chr8:92144088~92144435:-
BRCA	trans	rs1580019	0.587	rs7805311	ENSG00000176826.14	FKBP9P1	10.85	4.61e-26	1.04e-19	0.4	0.32	Cognitive ability;	chr7:32518690	chr7:55681074~55713252:-
BRCA	trans	rs3806843	0.933	rs10069930	ENSG00000231043.3	AC007238.1	-10.85	4.62e-26	1.04e-19	-0.37	-0.32	Depressive symptoms (multi-trait analysis);	chr5:140783743	chr2:58460292~58462032:-
BRCA	trans	rs941207	0.507	rs1107479	ENSG00000228224.3	NACAP1	-10.85	4.63e-26	1.04e-19	-0.36	-0.32	Platelet count;	chr12:56636902	chr8:101361794~101372707:+
BRCA	trans	rs3806843	0.868	rs2262574	ENSG00000231043.3	AC007238.1	10.85	4.83e-26	1.09e-19	0.37	0.32	Depressive symptoms (multi-trait analysis);	chr5:140744050	chr2:58460292~58462032:-
BRCA	trans	rs11098499	0.754	rs9999724	ENSG00000275858.1	RP11-291L22.8	10.84	5.01e-26	1.13e-19	0.38	0.32	Corneal astigmatism;	chr4:119318789	chr10:38450738~38451069:-
BRCA	trans	rs9611519	0.542	rs8139770	ENSG00000268568.1	AC007228.9	-10.84	5.02e-26	1.13e-19	-0.4	-0.32	Neuroticism;	chr22:41020177	chr19:56672574~56673901:-
BRCA	trans	rs747782	0.585	rs1604655	ENSG00000134612.10	FOLH1B	10.84	5.17e-26	1.16e-19	0.52	0.32	Intraocular pressure;	chr11:48253226	chr11:89639227~89698718:+
BRCA	trans	rs11098499	0.955	rs13113112	ENSG00000275858.1	RP11-291L22.8	10.84	5.17e-26	1.16e-19	0.41	0.32	Corneal astigmatism;	chr4:119234885	chr10:38450738~38451069:-
BRCA	trans	rs1347297	0.789	rs7589565	ENSG00000269800.1	PLEKHA3P1	10.84	5.27e-26	1.18e-19	0.34	0.32	Alzheimer disease and age of onset;	chr2:178417610	chr19:41521043~41521989:-
BRCA	trans	rs714543	0.61	rs4724320	ENSG00000267258.1	CTC-448F2.3	-10.84	5.29e-26	1.19e-19	-0.36	-0.32	Plateletcrit;	chr7:44775735	chr19:29921182~29921653:+
BRCA	trans	rs877636	0.702	rs61937249	ENSG00000223416.3	RPS26P15	10.84	5.33e-26	1.19e-19	0.41	0.32	Cognitive function;	chr12:55988132	chr1:58056133~58056480:-
BRCA	trans	rs7113874	0.592	rs10500703	ENSG00000266891.1	RP11-692N5.2	10.83	5.38e-26	1.21e-19	0.46	0.32	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8412317	chr18:9734882~9735602:-
BRCA	trans	rs7662987	1	rs7658127	ENSG00000233859.2	ADH5P4	10.83	5.52e-26	1.24e-19	0.7	0.32	Smoking initiation;	chr4:99073471	chr6:65836930~65838039:-
BRCA	trans	rs4263408	0.967	rs4974948	ENSG00000237550.5	UBE2Q2P6	10.83	5.87e-26	1.31e-19	0.38	0.32	Plasma amyloid beta peptide concentrations (ABx-40);	chr4:39751016	chr15:82372196~82372912:-
BRCA	trans	rs9876781	1	rs9881491	ENSG00000225528.1	RP3-370M22.8	-10.82	6.02e-26	1.34e-19	-0.35	-0.32	Longevity;	chr3:48446507	chr22:39960397~39964683:+
BRCA	trans	rs7032940	0.626	rs4314718	ENSG00000228236.2	TXNP5	10.82	6.07e-26	1.36e-19	0.38	0.32	Height;	chr9:110211368	chr2:149068596~149068910:-
BRCA	trans	rs55665837	0.539	rs11023350	ENSG00000236360.2	RP11-334A14.2	10.82	6.09e-26	1.36e-19	0.43	0.32	Vitamin D levels;	chr11:14839971	chr1:52993201~52993702:-
BRCA	trans	rs3806843	0.771	rs801174	ENSG00000231043.3	AC007238.1	10.82	6.31e-26	1.41e-19	0.38	0.32	Depressive symptoms (multi-trait analysis);	chr5:140733127	chr2:58460292~58462032:-
BRCA	trans	rs9467773	0.626	rs6935803	ENSG00000242375.1	RP11-498P14.3	-10.81	6.55e-26	1.46e-19	-0.44	-0.32	Intelligence (multi-trait analysis);	chr6:26350267	chr9:97195351~97197687:-
BRCA	trans	rs9467773	0.626	rs6936006	ENSG00000242375.1	RP11-498P14.3	-10.81	6.55e-26	1.46e-19	-0.44	-0.32	Intelligence (multi-trait analysis);	chr6:26350337	chr9:97195351~97197687:-
BRCA	trans	rs2950393	0.804	rs7980317	ENSG00000228224.3	NACAP1	10.81	6.56e-26	1.46e-19	0.36	0.32	Platelet distribution width;	chr12:56764399	chr8:101361794~101372707:+
BRCA	trans	rs7113874	0.625	rs16938253	ENSG00000266891.1	RP11-692N5.2	10.81	6.56e-26	1.46e-19	0.47	0.32	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8478833	chr18:9734882~9735602:-
BRCA	trans	rs7944735	0.517	rs1827503	ENSG00000134612.10	FOLH1B	10.81	6.82e-26	1.52e-19	0.54	0.32	Intraocular pressure;	chr11:48203563	chr11:89639227~89698718:+
BRCA	trans	rs9876781	1	rs6442119	ENSG00000225528.1	RP3-370M22.8	-10.8	7.27e-26	1.62e-19	-0.34	-0.32	Longevity;	chr3:48398713	chr22:39960397~39964683:+
BRCA	trans	rs2727020	0.857	rs1917324	ENSG00000134612.10	FOLH1B	-10.8	7.37e-26	1.64e-19	-0.43	-0.32	Coronary artery disease;	chr11:49350207	chr11:89639227~89698718:+
BRCA	trans	rs3806843	0.741	rs2563293	ENSG00000231043.3	AC007238.1	10.8	7.45e-26	1.66e-19	0.38	0.32	Depressive symptoms (multi-trait analysis);	chr5:140730951	chr2:58460292~58462032:-
BRCA	trans	rs11098499	0.754	rs1980025	ENSG00000275858.1	RP11-291L22.8	-10.8	7.49e-26	1.67e-19	-0.37	-0.32	Corneal astigmatism;	chr4:119331651	chr10:38450738~38451069:-
BRCA	trans	rs4263408	0.935	rs62310123	ENSG00000237550.5	UBE2Q2P6	10.8	7.65e-26	1.7e-19	0.38	0.32	Plasma amyloid beta peptide concentrations (ABx-40);	chr4:39744462	chr15:82372196~82372912:-
BRCA	trans	rs747782	0.528	rs16905753	ENSG00000134612.10	FOLH1B	10.79	8.24e-26	1.83e-19	0.52	0.32	Intraocular pressure;	chr11:48264354	chr11:89639227~89698718:+
BRCA	trans	rs9876781	1	rs13091785	ENSG00000225528.1	RP3-370M22.8	-10.79	8.25e-26	1.83e-19	-0.35	-0.32	Longevity;	chr3:48452692	chr22:39960397~39964683:+
BRCA	trans	rs2950393	0.804	rs1026565	ENSG00000228224.3	NACAP1	10.79	8.63e-26	1.91e-19	0.35	0.32	Platelet distribution width;	chr12:56744044	chr8:101361794~101372707:+
BRCA	trans	rs1580019	0.562	rs4720064	ENSG00000176826.14	FKBP9P1	-10.78	8.78e-26	1.95e-19	-0.4	-0.32	Cognitive ability;	chr7:32520026	chr7:55681074~55713252:-
BRCA	trans	rs3096299	0.692	rs4785565	ENSG00000215030.5	RPL13P12	-10.78	8.88e-26	1.97e-19	-0.32	-0.32	Multiple myeloma (IgH translocation);	chr16:89449351	chr17:17383377~17384012:-
BRCA	trans	rs3806843	0.838	rs2563289	ENSG00000231043.3	AC007238.1	10.78	8.97e-26	1.99e-19	0.37	0.32	Depressive symptoms (multi-trait analysis);	chr5:140743181	chr2:58460292~58462032:-
BRCA	trans	rs11098499	0.644	rs10050092	ENSG00000275858.1	RP11-291L22.8	10.78	9.01e-26	1.99e-19	0.38	0.32	Corneal astigmatism;	chr4:119610930	chr10:38450738~38451069:-
BRCA	trans	rs3806843	0.705	rs2530230	ENSG00000231043.3	AC007238.1	10.78	9.11e-26	2.01e-19	0.38	0.32	Depressive symptoms (multi-trait analysis);	chr5:140708546	chr2:58460292~58462032:-
BRCA	trans	rs1580019	0.563	rs764483	ENSG00000176826.14	FKBP9P1	-10.78	9.15e-26	2.02e-19	-0.4	-0.32	Cognitive ability;	chr7:32538538	chr7:55681074~55713252:-
BRCA	trans	rs3806843	0.676	rs1583005	ENSG00000231043.3	AC007238.1	10.78	9.16e-26	2.02e-19	0.38	0.32	Depressive symptoms (multi-trait analysis);	chr5:140651952	chr2:58460292~58462032:-
BRCA	trans	rs9611519	0.639	rs7289989	ENSG00000268568.1	AC007228.9	-10.78	9.41e-26	2.08e-19	-0.39	-0.32	Neuroticism;	chr22:41080795	chr19:56672574~56673901:-
BRCA	trans	rs11098499	0.863	rs3822190	ENSG00000275858.1	RP11-291L22.8	10.78	9.49e-26	2.1e-19	0.4	0.32	Corneal astigmatism;	chr4:119506943	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.863	rs3822191	ENSG00000275858.1	RP11-291L22.8	10.78	9.49e-26	2.1e-19	0.4	0.32	Corneal astigmatism;	chr4:119506946	chr10:38450738~38451069:-
BRCA	trans	rs877636	0.74	rs705698	ENSG00000233778.3	RP11-777J24.1	10.78	9.54e-26	2.11e-19	0.4	0.32	Cognitive function;	chr12:55990903	chr8:92144088~92144435:-
BRCA	trans	rs11098499	0.954	rs6857105	ENSG00000275858.1	RP11-291L22.8	10.78	9.62e-26	2.13e-19	0.39	0.32	Corneal astigmatism;	chr4:119301143	chr10:38450738~38451069:-
BRCA	trans	rs864643	0.524	rs6810264	ENSG00000183298.5	RP11-556K13.1	10.77	9.94e-26	2.19e-19	0.63	0.32	Attention deficit hyperactivity disorder;	chr3:39471605	chr1:101786340~101787219:-
BRCA	trans	rs864643	0.524	rs11706953	ENSG00000183298.5	RP11-556K13.1	10.77	9.94e-26	2.19e-19	0.63	0.32	Attention deficit hyperactivity disorder;	chr3:39472119	chr1:101786340~101787219:-
BRCA	trans	rs2727020	0.894	rs10839265	ENSG00000134612.10	FOLH1B	-10.77	1.02e-25	2.26e-19	-0.43	-0.32	Coronary artery disease;	chr11:49348181	chr11:89639227~89698718:+
BRCA	trans	rs1580019	0.51	rs4723162	ENSG00000176826.14	FKBP9P1	-10.76	1.11e-25	2.44e-19	-0.4	-0.32	Cognitive ability;	chr7:32504192	chr7:55681074~55713252:-
BRCA	trans	rs1580019	0.522	rs10951340	ENSG00000176826.14	FKBP9P1	-10.76	1.11e-25	2.45e-19	-0.4	-0.32	Cognitive ability;	chr7:32522796	chr7:55681074~55713252:-
BRCA	trans	rs864643	0.524	rs78956370	ENSG00000183298.5	RP11-556K13.1	10.76	1.15e-25	2.54e-19	0.66	0.32	Attention deficit hyperactivity disorder;	chr3:39463883	chr1:101786340~101787219:-
BRCA	trans	rs877636	1	rs877636	ENSG00000204652.6	RPS26P8	-10.76	1.15e-25	2.54e-19	-0.4	-0.32	Cognitive function;	chr12:56086799	chr17:45608571~45608918:+
BRCA	trans	rs9611519	0.589	rs8138917	ENSG00000268568.1	AC007228.9	-10.76	1.16e-25	2.55e-19	-0.39	-0.32	Neuroticism;	chr22:41016421	chr19:56672574~56673901:-
BRCA	trans	rs1580019	0.563	rs2392071	ENSG00000176826.14	FKBP9P1	-10.76	1.16e-25	2.56e-19	-0.4	-0.32	Cognitive ability;	chr7:32532924	chr7:55681074~55713252:-
BRCA	trans	rs2727020	0.617	rs7102702	ENSG00000134612.10	FOLH1B	-10.76	1.16e-25	2.56e-19	-0.41	-0.32	Coronary artery disease;	chr11:49379573	chr11:89639227~89698718:+
BRCA	trans	rs11098499	0.657	rs10434028	ENSG00000275858.1	RP11-291L22.8	10.76	1.17e-25	2.57e-19	0.38	0.32	Corneal astigmatism;	chr4:119373309	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.575	rs907204	ENSG00000275858.1	RP11-291L22.8	10.75	1.21e-25	2.66e-19	0.38	0.32	Corneal astigmatism;	chr4:119317499	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.575	rs907205	ENSG00000275858.1	RP11-291L22.8	10.75	1.21e-25	2.66e-19	0.38	0.32	Corneal astigmatism;	chr4:119317509	chr10:38450738~38451069:-
BRCA	trans	rs8010715	0.816	rs6573573	ENSG00000238000.1	RP11-274E7.2	10.75	1.22e-25	2.69e-19	0.34	0.32	IgG glycosylation;	chr14:24130048	chr5:98213402~98214121:+
BRCA	trans	rs1580019	0.587	rs1597555	ENSG00000176826.14	FKBP9P1	-10.75	1.25e-25	2.75e-19	-0.4	-0.32	Cognitive ability;	chr7:32506506	chr7:55681074~55713252:-
BRCA	trans	rs1580019	0.534	rs13237495	ENSG00000176826.14	FKBP9P1	-10.75	1.27e-25	2.79e-19	-0.4	-0.32	Cognitive ability;	chr7:32521075	chr7:55681074~55713252:-
BRCA	trans	rs3779195	0.524	rs80195155	ENSG00000225169.1	BRI3P1	-10.75	1.27e-25	2.8e-19	-0.53	-0.32	Sex hormone-binding globulin levels;	chr7:98248841	chr1:100213293~100213670:+
BRCA	trans	rs11039798	0.841	rs7950737	ENSG00000134612.10	FOLH1B	10.74	1.31e-25	2.89e-19	0.52	0.32	Axial length;	chr11:48569126	chr11:89639227~89698718:+
BRCA	trans	rs13190036	0.551	rs28932178	ENSG00000228305.2	AC016734.2	-10.74	1.32e-25	2.91e-19	-0.43	-0.32	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177210575	chr2:63622178~63622831:-
BRCA	trans	rs1580019	0.587	rs7804457	ENSG00000176826.14	FKBP9P1	-10.74	1.33e-25	2.92e-19	-0.4	-0.32	Cognitive ability;	chr7:32518369	chr7:55681074~55713252:-
BRCA	trans	rs77688320	0.535	rs12468504	ENSG00000235105.1	RP11-329A14.1	-10.74	1.34e-25	2.94e-19	-0.38	-0.32	Breast cancer;	chr2:201393746	chr1:48435967~48437223:+
BRCA	trans	rs13217239	0.646	rs7451149	ENSG00000242375.1	RP11-498P14.3	-10.74	1.35e-25	2.97e-19	-0.44	-0.32	Schizophrenia;	chr6:27089739	chr9:97195351~97197687:-
BRCA	trans	rs877636	1	rs2292239	ENSG00000223416.3	RPS26P15	10.74	1.36e-25	3e-19	0.37	0.32	Cognitive function;	chr12:56088396	chr1:58056133~58056480:-
BRCA	trans	rs7944735	0.786	rs7123436	ENSG00000134612.10	FOLH1B	10.74	1.41e-25	3.09e-19	0.48	0.32	Intraocular pressure;	chr11:47991932	chr11:89639227~89698718:+
BRCA	trans	rs9650657	0.562	rs10090444	ENSG00000253893.2	FAM85B	-10.74	1.42e-25	3.11e-19	-0.4	-0.32	Neuroticism;	chr8:10887959	chr8:8167819~8226614:-
BRCA	trans	rs10838798	0.523	rs4752917	ENSG00000134612.10	FOLH1B	-10.73	1.44e-25	3.16e-19	-0.39	-0.32	Height;	chr11:48220087	chr11:89639227~89698718:+
BRCA	trans	rs13190036	1	rs655623	ENSG00000228305.2	AC016734.2	10.73	1.46e-25	3.19e-19	0.43	0.32	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177107515	chr2:63622178~63622831:-
BRCA	trans	rs1580019	0.587	rs2392069	ENSG00000176826.14	FKBP9P1	-10.73	1.46e-25	3.2e-19	-0.4	-0.32	Cognitive ability;	chr7:32507542	chr7:55681074~55713252:-
BRCA	trans	rs1580019	0.587	rs34488151	ENSG00000176826.14	FKBP9P1	-10.73	1.46e-25	3.2e-19	-0.4	-0.32	Cognitive ability;	chr7:32508534	chr7:55681074~55713252:-
BRCA	trans	rs1580019	0.587	rs6951955	ENSG00000176826.14	FKBP9P1	-10.73	1.46e-25	3.2e-19	-0.4	-0.32	Cognitive ability;	chr7:32509149	chr7:55681074~55713252:-
BRCA	trans	rs1580019	0.587	rs6972365	ENSG00000176826.14	FKBP9P1	-10.73	1.46e-25	3.2e-19	-0.4	-0.32	Cognitive ability;	chr7:32509319	chr7:55681074~55713252:-
BRCA	trans	rs4276421	0.593	rs6898646	ENSG00000231752.4	EMBP1	10.73	1.49e-25	3.26e-19	0.42	0.32	P wave duration;	chr5:45841837	chr1:121519112~121571892:+
BRCA	trans	rs1580019	0.587	rs7806941	ENSG00000176826.14	FKBP9P1	-10.73	1.53e-25	3.34e-19	-0.4	-0.32	Cognitive ability;	chr7:32513707	chr7:55681074~55713252:-
BRCA	trans	rs941207	0.756	rs10876915	ENSG00000228224.3	NACAP1	-10.72	1.59e-25	3.47e-19	-0.4	-0.32	Platelet count;	chr12:56655280	chr8:101361794~101372707:+
BRCA	trans	rs11098499	0.754	rs12506610	ENSG00000275858.1	RP11-291L22.8	10.72	1.62e-25	3.53e-19	0.37	0.32	Corneal astigmatism;	chr4:119320504	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.743	rs10003567	ENSG00000275858.1	RP11-291L22.8	10.72	1.62e-25	3.53e-19	0.37	0.32	Corneal astigmatism;	chr4:119320519	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.754	rs10006259	ENSG00000275858.1	RP11-291L22.8	10.72	1.62e-25	3.53e-19	0.37	0.32	Corneal astigmatism;	chr4:119320990	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.754	rs28652763	ENSG00000275858.1	RP11-291L22.8	10.72	1.62e-25	3.53e-19	0.37	0.32	Corneal astigmatism;	chr4:119321157	chr10:38450738~38451069:-
BRCA	trans	rs3806843	0.676	rs2569159	ENSG00000231043.3	AC007238.1	10.72	1.65e-25	3.61e-19	0.37	0.32	Depressive symptoms (multi-trait analysis);	chr5:140651125	chr2:58460292~58462032:-
BRCA	trans	rs747782	0.527	rs12289516	ENSG00000134612.10	FOLH1B	10.72	1.67e-25	3.65e-19	0.53	0.32	Intraocular pressure;	chr11:48213128	chr11:89639227~89698718:+
BRCA	trans	rs1580019	0.587	rs7806113	ENSG00000176826.14	FKBP9P1	-10.72	1.69e-25	3.68e-19	-0.4	-0.32	Cognitive ability;	chr7:32513472	chr7:55681074~55713252:-
BRCA	trans	rs3806843	0.741	rs4912597	ENSG00000231043.3	AC007238.1	10.72	1.7e-25	3.71e-19	0.37	0.32	Depressive symptoms (multi-trait analysis);	chr5:140727272	chr2:58460292~58462032:-
BRCA	trans	rs3806843	0.771	rs2563334	ENSG00000231043.3	AC007238.1	10.72	1.7e-25	3.71e-19	0.37	0.32	Depressive symptoms (multi-trait analysis);	chr5:140727480	chr2:58460292~58462032:-
BRCA	trans	rs11098499	0.754	rs12711071	ENSG00000275858.1	RP11-291L22.8	10.72	1.73e-25	3.76e-19	0.37	0.32	Corneal astigmatism;	chr4:119319779	chr10:38450738~38451069:-
BRCA	trans	rs13217239	0.646	rs7768407	ENSG00000242375.1	RP11-498P14.3	10.71	1.75e-25	3.8e-19	0.44	0.32	Schizophrenia;	chr6:27049016	chr9:97195351~97197687:-
BRCA	trans	rs11098499	0.754	rs11732087	ENSG00000275858.1	RP11-291L22.8	10.71	1.86e-25	4.02e-19	0.37	0.31	Corneal astigmatism;	chr4:119318676	chr10:38450738~38451069:-
BRCA	trans	rs1347297	0.774	rs9973732	ENSG00000269800.1	PLEKHA3P1	10.71	1.89e-25	4.1e-19	0.34	0.31	Alzheimer disease and age of onset;	chr2:178416708	chr19:41521043~41521989:-
BRCA	trans	rs3806843	0.568	rs2530232	ENSG00000231043.3	AC007238.1	10.7	1.92e-25	4.16e-19	0.38	0.31	Depressive symptoms (multi-trait analysis);	chr5:140703293	chr2:58460292~58462032:-
BRCA	trans	rs11098499	0.789	rs9991166	ENSG00000275858.1	RP11-291L22.8	10.7	1.95e-25	4.22e-19	0.37	0.31	Corneal astigmatism;	chr4:119316696	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.708	rs10005237	ENSG00000275858.1	RP11-291L22.8	10.7	1.95e-25	4.22e-19	0.37	0.31	Corneal astigmatism;	chr4:119316742	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.754	rs10213267	ENSG00000275858.1	RP11-291L22.8	10.7	1.95e-25	4.22e-19	0.37	0.31	Corneal astigmatism;	chr4:119317919	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.754	rs10212775	ENSG00000275858.1	RP11-291L22.8	10.7	1.95e-25	4.22e-19	0.37	0.31	Corneal astigmatism;	chr4:119318089	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.754	rs2964	ENSG00000275858.1	RP11-291L22.8	10.7	1.95e-25	4.22e-19	0.37	0.31	Corneal astigmatism;	chr4:119318976	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.754	rs1511025	ENSG00000275858.1	RP11-291L22.8	10.7	1.95e-25	4.22e-19	0.37	0.31	Corneal astigmatism;	chr4:119319083	chr10:38450738~38451069:-
BRCA	trans	rs877636	0.74	rs772920	ENSG00000223416.3	RPS26P15	10.7	1.96e-25	4.23e-19	0.41	0.31	Cognitive function;	chr12:55996580	chr1:58056133~58056480:-
BRCA	trans	rs11098499	0.754	rs12510269	ENSG00000275858.1	RP11-291L22.8	10.7	1.98e-25	4.28e-19	0.37	0.31	Corneal astigmatism;	chr4:119320491	chr10:38450738~38451069:-
BRCA	trans	rs10028773	0.515	rs9994488	ENSG00000275858.1	RP11-291L22.8	10.7	2e-25	4.32e-19	0.37	0.31	Educational attainment;	chr4:119666626	chr10:38450738~38451069:-
BRCA	trans	rs3806843	0.832	rs2531360	ENSG00000231043.3	AC007238.1	10.7	2.01e-25	4.34e-19	0.37	0.31	Depressive symptoms (multi-trait analysis);	chr5:140737079	chr2:58460292~58462032:-
BRCA	trans	rs1580019	0.587	rs9638880	ENSG00000176826.14	FKBP9P1	-10.7	2.01e-25	4.34e-19	-0.4	-0.31	Cognitive ability;	chr7:32512789	chr7:55681074~55713252:-
BRCA	trans	rs11098499	0.754	rs878372	ENSG00000275858.1	RP11-291L22.8	10.7	2.02e-25	4.37e-19	0.37	0.31	Corneal astigmatism;	chr4:119317625	chr10:38450738~38451069:-
BRCA	trans	rs7312770	0.612	rs1873914	ENSG00000212829.8	RPS26P3	10.7	2.03e-25	4.39e-19	0.39	0.31	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr9:9090898~9091245:+
BRCA	trans	rs9329221	0.537	rs1351876	ENSG00000253893.2	FAM85B	10.7	2.07e-25	4.47e-19	0.39	0.31	Neuroticism;	chr8:10127267	chr8:8167819~8226614:-
BRCA	trans	rs3806843	1	rs13157397	ENSG00000231043.3	AC007238.1	-10.7	2.11e-25	4.55e-19	-0.37	-0.31	Depressive symptoms (multi-trait analysis);	chr5:140804857	chr2:58460292~58462032:-
BRCA	trans	rs3806843	0.966	rs4141841	ENSG00000231043.3	AC007238.1	-10.69	2.11e-25	4.56e-19	-0.36	-0.31	Depressive symptoms (multi-trait analysis);	chr5:140823847	chr2:58460292~58462032:-
BRCA	trans	rs3806843	1	rs10050455	ENSG00000231043.3	AC007238.1	-10.69	2.11e-25	4.56e-19	-0.36	-0.31	Depressive symptoms (multi-trait analysis);	chr5:140825065	chr2:58460292~58462032:-
BRCA	trans	rs11098499	0.754	rs1546503	ENSG00000275858.1	RP11-291L22.8	10.69	2.15e-25	4.64e-19	0.37	0.31	Corneal astigmatism;	chr4:119320012	chr10:38450738~38451069:-
BRCA	trans	rs877636	1	rs4759229	ENSG00000196656.7	AC004057.1	-10.69	2.22e-25	4.76e-19	-0.39	-0.31	Cognitive function;	chr12:56080696	chr4:113214046~113217170:-
BRCA	trans	rs11098499	0.754	rs66900435	ENSG00000275858.1	RP11-291L22.8	10.69	2.23e-25	4.77e-19	0.38	0.31	Corneal astigmatism;	chr4:119328270	chr10:38450738~38451069:-
BRCA	trans	rs7662987	1	rs7684986	ENSG00000233859.2	ADH5P4	10.69	2.29e-25	4.89e-19	0.69	0.31	Smoking initiation;	chr4:99070525	chr6:65836930~65838039:-
BRCA	trans	rs7662987	1	rs1061187	ENSG00000233859.2	ADH5P4	10.69	2.29e-25	4.89e-19	0.69	0.31	Smoking initiation;	chr4:99071702	chr6:65836930~65838039:-
BRCA	trans	rs7927370	1	rs61919623	ENSG00000134612.10	FOLH1B	10.68	2.38e-25	5.08e-19	0.8	0.31	Systemic lupus erythematosus;	chr11:55566629	chr11:89639227~89698718:+
BRCA	trans	rs11098499	0.754	rs1980027	ENSG00000275858.1	RP11-291L22.8	10.68	2.49e-25	5.31e-19	0.38	0.31	Corneal astigmatism;	chr4:119330422	chr10:38450738~38451069:-
BRCA	trans	rs7927370	1	rs61917397	ENSG00000134612.10	FOLH1B	10.67	2.62e-25	5.55e-19	0.87	0.31	Systemic lupus erythematosus;	chr11:55400929	chr11:89639227~89698718:+
BRCA	trans	rs3806843	1	rs10072015	ENSG00000231043.3	AC007238.1	10.67	2.69e-25	5.7e-19	0.36	0.31	Depressive symptoms (multi-trait analysis);	chr5:140791070	chr2:58460292~58462032:-
BRCA	trans	rs11098499	0.754	rs2036860	ENSG00000275858.1	RP11-291L22.8	10.67	2.7e-25	5.71e-19	0.37	0.31	Corneal astigmatism;	chr4:119327779	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.754	rs17595608	ENSG00000275858.1	RP11-291L22.8	10.67	2.72e-25	5.76e-19	0.38	0.31	Corneal astigmatism;	chr4:119329351	chr10:38450738~38451069:-
BRCA	trans	rs9876781	1	rs1109227	ENSG00000225528.1	RP3-370M22.8	-10.67	2.76e-25	5.83e-19	-0.35	-0.31	Longevity;	chr3:48437797	chr22:39960397~39964683:+
BRCA	trans	rs2727020	0.724	rs4109837	ENSG00000134612.10	FOLH1B	-10.67	2.76e-25	5.83e-19	-0.43	-0.31	Coronary artery disease;	chr11:49350499	chr11:89639227~89698718:+
BRCA	trans	rs11098499	0.754	rs9991959	ENSG00000275858.1	RP11-291L22.8	-10.67	2.8e-25	5.92e-19	-0.37	-0.31	Corneal astigmatism;	chr4:119332618	chr10:38450738~38451069:-
BRCA	trans	rs864643	0.524	rs17038918	ENSG00000183298.5	RP11-556K13.1	10.66	2.87e-25	6.07e-19	0.62	0.31	Attention deficit hyperactivity disorder;	chr3:39480975	chr1:101786340~101787219:-
BRCA	trans	rs7312770	0.612	rs1873914	ENSG00000244604.1	RP11-713H12.1	10.66	2.89e-25	6.09e-19	0.35	0.31	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr17:8561230~8561576:+
BRCA	trans	rs10028773	0.7	rs7671797	ENSG00000275858.1	RP11-291L22.8	10.66	2.89e-25	6.1e-19	0.38	0.31	Educational attainment;	chr4:119327002	chr10:38450738~38451069:-
BRCA	trans	rs864643	0.625	rs1707958	ENSG00000183298.5	RP11-556K13.1	10.66	2.93e-25	6.18e-19	0.48	0.31	Attention deficit hyperactivity disorder;	chr3:39481931	chr1:101786340~101787219:-
BRCA	trans	rs877636	1	rs877636	ENSG00000242970.2	AC068522.4	-10.66	2.96e-25	6.24e-19	-0.43	-0.31	Cognitive function;	chr12:56086799	chr8:58588420~58588764:-
BRCA	trans	rs73108077	0.607	rs6057566	ENSG00000279352.1	RP11-411B10.7	10.66	3.01e-25	6.34e-19	0.55	0.31	Red blood cell density in sickle cell anemia;	chr20:31227621	chr18:14010054~14010917:+
BRCA	trans	rs11098499	0.826	rs4472123	ENSG00000275858.1	RP11-291L22.8	10.65	3.14e-25	6.61e-19	0.38	0.31	Corneal astigmatism;	chr4:119315475	chr10:38450738~38451069:-
BRCA	trans	rs11039798	1	rs10769383	ENSG00000134612.10	FOLH1B	10.65	3.14e-25	6.61e-19	0.5	0.31	Axial length;	chr11:48570958	chr11:89639227~89698718:+
BRCA	trans	rs2899832	0.568	rs74043845	ENSG00000229083.1	PSMA6P2	10.65	3.18e-25	6.69e-19	0.53	0.31	Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:35161263	chrX:12825840~12826833:+
BRCA	trans	rs9876781	0.9	rs1037773	ENSG00000225528.1	RP3-370M22.8	-10.65	3.18e-25	6.69e-19	-0.35	-0.31	Longevity;	chr3:48426493	chr22:39960397~39964683:+
BRCA	trans	rs9876781	1	rs2279077	ENSG00000225528.1	RP3-370M22.8	-10.65	3.18e-25	6.69e-19	-0.35	-0.31	Longevity;	chr3:48432839	chr22:39960397~39964683:+
BRCA	trans	rs864643	0.524	rs11715885	ENSG00000183298.5	RP11-556K13.1	10.65	3.22e-25	6.77e-19	0.66	0.31	Attention deficit hyperactivity disorder;	chr3:39475107	chr1:101786340~101787219:-
BRCA	trans	rs9611519	0.603	rs9607764	ENSG00000268568.1	AC007228.9	-10.65	3.25e-25	6.84e-19	-0.39	-0.31	Neuroticism;	chr22:41015800	chr19:56672574~56673901:-
BRCA	trans	rs9611519	0.58	rs8138349	ENSG00000268568.1	AC007228.9	-10.65	3.25e-25	6.84e-19	-0.39	-0.31	Neuroticism;	chr22:41016719	chr19:56672574~56673901:-
BRCA	trans	rs9611519	0.602	rs8138520	ENSG00000268568.1	AC007228.9	-10.65	3.25e-25	6.84e-19	-0.39	-0.31	Neuroticism;	chr22:41016924	chr19:56672574~56673901:-
BRCA	trans	rs4276421	0.571	rs7724350	ENSG00000231752.4	EMBP1	-10.65	3.25e-25	6.84e-19	-0.41	-0.31	P wave duration;	chr5:45939572	chr1:121519112~121571892:+
BRCA	trans	rs9876781	1	rs3774808	ENSG00000225528.1	RP3-370M22.8	-10.65	3.29e-25	6.92e-19	-0.35	-0.31	Longevity;	chr3:48440237	chr22:39960397~39964683:+
BRCA	trans	rs11098499	0.754	rs7672594	ENSG00000275858.1	RP11-291L22.8	10.64	3.51e-25	7.37e-19	0.37	0.31	Corneal astigmatism;	chr4:119327388	chr10:38450738~38451069:-
BRCA	trans	rs4263408	0.934	rs2381428	ENSG00000237550.5	UBE2Q2P6	10.64	3.58e-25	7.51e-19	0.38	0.31	Plasma amyloid beta peptide concentrations (ABx-40);	chr4:39761846	chr15:82372196~82372912:-
BRCA	trans	rs7927370	1	rs17579895	ENSG00000134612.10	FOLH1B	-10.64	3.64e-25	7.64e-19	-0.82	-0.31	Systemic lupus erythematosus;	chr11:55510624	chr11:89639227~89698718:+
BRCA	trans	rs4263408	1	rs7656037	ENSG00000237550.5	UBE2Q2P6	10.64	3.68e-25	7.71e-19	0.38	0.31	Plasma amyloid beta peptide concentrations (ABx-40);	chr4:39716345	chr15:82372196~82372912:-
BRCA	trans	rs9876781	1	rs9883759	ENSG00000225528.1	RP3-370M22.8	-10.64	3.68e-25	7.71e-19	-0.34	-0.31	Longevity;	chr3:48422209	chr22:39960397~39964683:+
BRCA	trans	rs9876781	1	rs6442120	ENSG00000225528.1	RP3-370M22.8	-10.64	3.68e-25	7.71e-19	-0.34	-0.31	Longevity;	chr3:48423094	chr22:39960397~39964683:+
BRCA	trans	rs3806843	0.868	rs2563291	ENSG00000231043.3	AC007238.1	10.64	3.68e-25	7.72e-19	0.36	0.31	Depressive symptoms (multi-trait analysis);	chr5:140740014	chr2:58460292~58462032:-
BRCA	trans	rs3806843	0.75	rs2563285	ENSG00000231043.3	AC007238.1	10.64	3.73e-25	7.82e-19	0.37	0.31	Depressive symptoms (multi-trait analysis);	chr5:140746552	chr2:58460292~58462032:-
BRCA	trans	rs864643	0.524	rs78956370	ENSG00000188856.6	RPSAP47	10.63	3.78e-25	7.91e-19	0.61	0.31	Attention deficit hyperactivity disorder;	chr3:39463883	chr8:80558870~80559757:+
BRCA	trans	rs9467773	0.587	rs12214031	ENSG00000242375.1	RP11-498P14.3	-10.63	3.81e-25	7.97e-19	-0.44	-0.31	Intelligence (multi-trait analysis);	chr6:26376400	chr9:97195351~97197687:-
BRCA	trans	rs3806843	0.868	rs2262573	ENSG00000231043.3	AC007238.1	10.63	3.89e-25	8.13e-19	0.37	0.31	Depressive symptoms (multi-trait analysis);	chr5:140744042	chr2:58460292~58462032:-
BRCA	trans	rs2657294	0.659	rs1259500	ENSG00000172974.11	AC007318.5	10.63	3.9e-25	8.15e-19	0.4	0.31	Pneumonia;	chr10:75230355	chr2:65205108~65205988:+
BRCA	trans	rs7927370	1	rs77219956	ENSG00000134612.10	FOLH1B	10.63	4.03e-25	8.42e-19	0.85	0.31	Systemic lupus erythematosus;	chr11:55416417	chr11:89639227~89698718:+
BRCA	trans	rs714543	0.61	rs4724320	ENSG00000219797.2	PPIAP9	-10.63	4.07e-25	8.5e-19	-0.36	-0.31	Plateletcrit;	chr7:44775735	chr6:31519480~31520291:-
BRCA	trans	rs7927370	1	rs55884431	ENSG00000134612.10	FOLH1B	10.63	4.09e-25	8.54e-19	0.85	0.31	Systemic lupus erythematosus;	chr11:55384346	chr11:89639227~89698718:+
BRCA	trans	rs11098499	0.754	rs28643450	ENSG00000275858.1	RP11-291L22.8	10.63	4.13e-25	8.62e-19	0.37	0.31	Corneal astigmatism;	chr4:119324087	chr10:38450738~38451069:-
BRCA	trans	rs3806843	0.766	rs6848	ENSG00000231043.3	AC007238.1	10.62	4.18e-25	8.73e-19	0.36	0.31	Depressive symptoms (multi-trait analysis);	chr5:140706477	chr2:58460292~58462032:-
BRCA	trans	rs7927370	1	rs61918251	ENSG00000134612.10	FOLH1B	10.62	4.26e-25	8.9e-19	0.84	0.31	Systemic lupus erythematosus;	chr11:55432399	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs17578388	ENSG00000134612.10	FOLH1B	10.62	4.26e-25	8.9e-19	0.84	0.31	Systemic lupus erythematosus;	chr11:55432957	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs17493596	ENSG00000134612.10	FOLH1B	10.62	4.26e-25	8.9e-19	0.84	0.31	Systemic lupus erythematosus;	chr11:55433134	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61918254	ENSG00000134612.10	FOLH1B	10.62	4.26e-25	8.9e-19	0.84	0.31	Systemic lupus erythematosus;	chr11:55434941	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs56190422	ENSG00000134612.10	FOLH1B	10.62	4.26e-25	8.9e-19	0.84	0.31	Systemic lupus erythematosus;	chr11:55435167	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61916223	ENSG00000134612.10	FOLH1B	10.62	4.34e-25	9.04e-19	0.85	0.31	Systemic lupus erythematosus;	chr11:55385574	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs56182407	ENSG00000134612.10	FOLH1B	10.62	4.34e-25	9.04e-19	0.85	0.31	Systemic lupus erythematosus;	chr11:55388321	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs56160445	ENSG00000134612.10	FOLH1B	10.62	4.34e-25	9.04e-19	0.85	0.31	Systemic lupus erythematosus;	chr11:55388339	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61916231	ENSG00000134612.10	FOLH1B	10.62	4.34e-25	9.04e-19	0.85	0.31	Systemic lupus erythematosus;	chr11:55389465	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.867	rs61916232	ENSG00000134612.10	FOLH1B	10.62	4.34e-25	9.04e-19	0.85	0.31	Systemic lupus erythematosus;	chr11:55390396	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61917375	ENSG00000134612.10	FOLH1B	10.62	4.34e-25	9.04e-19	0.85	0.31	Systemic lupus erythematosus;	chr11:55391848	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61917376	ENSG00000134612.10	FOLH1B	10.62	4.34e-25	9.04e-19	0.85	0.31	Systemic lupus erythematosus;	chr11:55392201	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61917377	ENSG00000134612.10	FOLH1B	10.62	4.34e-25	9.04e-19	0.85	0.31	Systemic lupus erythematosus;	chr11:55392564	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61917378	ENSG00000134612.10	FOLH1B	10.62	4.34e-25	9.04e-19	0.85	0.31	Systemic lupus erythematosus;	chr11:55392716	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.557	rs61917394	ENSG00000134612.10	FOLH1B	10.62	4.34e-25	9.04e-19	0.85	0.31	Systemic lupus erythematosus;	chr11:55399913	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61917395	ENSG00000134612.10	FOLH1B	10.62	4.34e-25	9.04e-19	0.85	0.31	Systemic lupus erythematosus;	chr11:55400297	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs7117005	ENSG00000134612.10	FOLH1B	10.62	4.34e-25	9.04e-19	0.85	0.31	Systemic lupus erythematosus;	chr11:55401527	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.85	rs7117108	ENSG00000134612.10	FOLH1B	10.62	4.34e-25	9.04e-19	0.85	0.31	Systemic lupus erythematosus;	chr11:55401548	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61917398	ENSG00000134612.10	FOLH1B	10.62	4.34e-25	9.04e-19	0.85	0.31	Systemic lupus erythematosus;	chr11:55402540	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.85	rs61917399	ENSG00000134612.10	FOLH1B	10.62	4.37e-25	9.09e-19	0.85	0.31	Systemic lupus erythematosus;	chr11:55403243	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs7925927	ENSG00000134612.10	FOLH1B	10.62	4.37e-25	9.09e-19	0.85	0.31	Systemic lupus erythematosus;	chr11:55403684	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs17493401	ENSG00000134612.10	FOLH1B	10.62	4.37e-25	9.09e-19	0.85	0.31	Systemic lupus erythematosus;	chr11:55404454	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61917404	ENSG00000134612.10	FOLH1B	10.62	4.37e-25	9.09e-19	0.85	0.31	Systemic lupus erythematosus;	chr11:55405177	chr11:89639227~89698718:+
BRCA	trans	rs1459104	0.714	rs36018195	ENSG00000134612.10	FOLH1B	10.62	4.37e-25	9.09e-19	0.85	0.31	Body mass index;	chr11:55405380	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61917431	ENSG00000134612.10	FOLH1B	10.62	4.37e-25	9.09e-19	0.85	0.31	Systemic lupus erythematosus;	chr11:55405479	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs78875307	ENSG00000134612.10	FOLH1B	10.62	4.37e-25	9.09e-19	0.85	0.31	Systemic lupus erythematosus;	chr11:55406193	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61917439	ENSG00000134612.10	FOLH1B	10.62	4.37e-25	9.09e-19	0.85	0.31	Systemic lupus erythematosus;	chr11:55407551	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs7950848	ENSG00000134612.10	FOLH1B	10.62	4.37e-25	9.09e-19	0.85	0.31	Systemic lupus erythematosus;	chr11:55408126	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs7125205	ENSG00000134612.10	FOLH1B	10.62	4.37e-25	9.09e-19	0.85	0.31	Systemic lupus erythematosus;	chr11:55411516	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs6591439	ENSG00000134612.10	FOLH1B	10.62	4.37e-25	9.09e-19	0.85	0.31	Systemic lupus erythematosus;	chr11:55411732	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs55917312	ENSG00000134612.10	FOLH1B	10.62	4.37e-25	9.09e-19	0.85	0.31	Systemic lupus erythematosus;	chr11:55412580	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs56184662	ENSG00000134612.10	FOLH1B	10.62	4.37e-25	9.09e-19	0.85	0.31	Systemic lupus erythematosus;	chr11:55413340	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.85	rs61917450	ENSG00000134612.10	FOLH1B	10.62	4.37e-25	9.09e-19	0.85	0.31	Systemic lupus erythematosus;	chr11:55415074	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61917451	ENSG00000134612.10	FOLH1B	10.62	4.37e-25	9.09e-19	0.85	0.31	Systemic lupus erythematosus;	chr11:55415293	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61917454	ENSG00000134612.10	FOLH1B	10.62	4.37e-25	9.09e-19	0.85	0.31	Systemic lupus erythematosus;	chr11:55416067	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61917455	ENSG00000134612.10	FOLH1B	10.62	4.37e-25	9.09e-19	0.85	0.31	Systemic lupus erythematosus;	chr11:55416229	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61917457	ENSG00000134612.10	FOLH1B	10.62	4.37e-25	9.09e-19	0.85	0.31	Systemic lupus erythematosus;	chr11:55416283	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61917458	ENSG00000134612.10	FOLH1B	10.62	4.37e-25	9.09e-19	0.85	0.31	Systemic lupus erythematosus;	chr11:55416720	chr11:89639227~89698718:+
BRCA	trans	rs7833986	0.501	rs2719258	ENSG00000236862.1	RPS20P24	10.62	4.48e-25	9.31e-19	0.4	0.31	Height;	chr8:56028830	chr9:72655832~72656192:-
BRCA	trans	rs7833986	0.501	rs2719259	ENSG00000236862.1	RPS20P24	10.62	4.48e-25	9.31e-19	0.4	0.31	Height;	chr8:56029071	chr9:72655832~72656192:-
BRCA	trans	rs1580019	0.563	rs13225132	ENSG00000176826.14	FKBP9P1	-10.62	4.57e-25	9.48e-19	-0.39	-0.31	Cognitive ability;	chr7:32761363	chr7:55681074~55713252:-
BRCA	trans	rs4263408	0.934	rs4975036	ENSG00000237550.5	UBE2Q2P6	10.62	4.58e-25	9.49e-19	0.38	0.31	Plasma amyloid beta peptide concentrations (ABx-40);	chr4:39713470	chr15:82372196~82372912:-
BRCA	trans	rs77686669	1	rs77686669	ENSG00000228546.2	CTA-313A17.3	10.61	4.62e-25	9.59e-19	0.45	0.31	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr7:100146949	chr7:102337316~102339115:+
BRCA	trans	rs9611519	0.603	rs8142276	ENSG00000268568.1	AC007228.9	-10.61	4.76e-25	9.87e-19	-0.39	-0.31	Neuroticism;	chr22:41075443	chr19:56672574~56673901:-
BRCA	trans	rs9611519	0.567	rs8141730	ENSG00000268568.1	AC007228.9	-10.61	4.76e-25	9.87e-19	-0.39	-0.31	Neuroticism;	chr22:41077057	chr19:56672574~56673901:-
BRCA	trans	rs7927370	1	rs61894895	ENSG00000134612.10	FOLH1B	10.61	4.79e-25	9.92e-19	0.85	0.31	Systemic lupus erythematosus;	chr11:55269966	chr11:89639227~89698718:+
BRCA	trans	rs11039798	0.925	rs7482967	ENSG00000134612.10	FOLH1B	10.61	4.83e-25	1e-18	0.51	0.31	Axial length;	chr11:48591975	chr11:89639227~89698718:+
BRCA	trans	rs11039798	1	rs12280020	ENSG00000134612.10	FOLH1B	10.61	4.83e-25	1e-18	0.51	0.31	Axial length;	chr11:48597292	chr11:89639227~89698718:+
BRCA	trans	rs11098499	0.754	rs7672778	ENSG00000275858.1	RP11-291L22.8	10.61	4.84e-25	1e-18	0.37	0.31	Corneal astigmatism;	chr4:119327430	chr10:38450738~38451069:-
BRCA	trans	rs2899832	0.568	rs75796373	ENSG00000229083.1	PSMA6P2	10.61	4.88e-25	1.01e-18	0.53	0.31	Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:35166056	chrX:12825840~12826833:+
BRCA	trans	rs2899832	0.568	rs75256382	ENSG00000229083.1	PSMA6P2	10.61	4.88e-25	1.01e-18	0.53	0.31	Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:35166074	chrX:12825840~12826833:+
BRCA	trans	rs11098499	1	rs35643470	ENSG00000275858.1	RP11-291L22.8	10.61	4.88e-25	1.01e-18	0.39	0.31	Corneal astigmatism;	chr4:119263793	chr10:38450738~38451069:-
BRCA	trans	rs3806843	0.966	rs2563265	ENSG00000231043.3	AC007238.1	10.61	4.89e-25	1.01e-18	0.36	0.31	Depressive symptoms (multi-trait analysis);	chr5:140757420	chr2:58460292~58462032:-
BRCA	trans	rs11098499	1	rs3749591	ENSG00000275858.1	RP11-291L22.8	10.61	4.92e-25	1.02e-18	0.41	0.31	Corneal astigmatism;	chr4:119292875	chr10:38450738~38451069:-
BRCA	trans	rs7927370	1	rs61918160	ENSG00000134612.10	FOLH1B	10.61	4.93e-25	1.02e-18	0.85	0.31	Systemic lupus erythematosus;	chr11:55417191	chr11:89639227~89698718:+
BRCA	trans	rs3806843	0.733	rs801181	ENSG00000231043.3	AC007238.1	10.61	4.98e-25	1.03e-18	0.36	0.31	Depressive symptoms (multi-trait analysis);	chr5:140713229	chr2:58460292~58462032:-
BRCA	trans	rs4276421	0.571	rs62371969	ENSG00000231752.4	EMBP1	10.61	5.03e-25	1.04e-18	0.43	0.31	P wave duration;	chr5:45904700	chr1:121519112~121571892:+
BRCA	trans	rs11098499	0.708	rs1546506	ENSG00000275858.1	RP11-291L22.8	10.6	5.06e-25	1.04e-18	0.37	0.31	Corneal astigmatism;	chr4:119320085	chr10:38450738~38451069:-
BRCA	trans	rs7927370	1	rs55667318	ENSG00000134612.10	FOLH1B	10.6	5.06e-25	1.05e-18	0.83	0.31	Systemic lupus erythematosus;	chr11:55442815	chr11:89639227~89698718:+
BRCA	trans	rs10028773	0.515	rs9994651	ENSG00000275858.1	RP11-291L22.8	10.6	5.46e-25	1.12e-18	0.37	0.31	Educational attainment;	chr4:119666648	chr10:38450738~38451069:-
BRCA	trans	rs2727020	0.894	rs1917328	ENSG00000134612.10	FOLH1B	-10.6	5.49e-25	1.13e-18	-0.42	-0.31	Coronary artery disease;	chr11:49338054	chr11:89639227~89698718:+
BRCA	trans	rs9876781	0.967	rs9876891	ENSG00000225528.1	RP3-370M22.8	-10.6	5.5e-25	1.13e-18	-0.35	-0.31	Longevity;	chr3:48440024	chr22:39960397~39964683:+
BRCA	trans	rs11098499	0.644	rs2389880	ENSG00000275858.1	RP11-291L22.8	10.59	5.7e-25	1.17e-18	0.37	0.31	Corneal astigmatism;	chr4:119638715	chr10:38450738~38451069:-
BRCA	trans	rs877636	1	rs705696	ENSG00000196656.7	AC004057.1	10.59	5.81e-25	1.2e-18	0.4	0.31	Cognitive function;	chr12:56086864	chr4:113214046~113217170:-
BRCA	trans	rs9611519	0.603	rs4821999	ENSG00000268568.1	AC007228.9	-10.59	5.88e-25	1.21e-18	-0.39	-0.31	Neuroticism;	chr22:41073997	chr19:56672574~56673901:-
BRCA	trans	rs11098499	0.955	rs35197422	ENSG00000275858.1	RP11-291L22.8	10.59	5.88e-25	1.21e-18	0.39	0.31	Corneal astigmatism;	chr4:119248159	chr10:38450738~38451069:-
BRCA	trans	rs2657294	0.632	rs1259503	ENSG00000172974.11	AC007318.5	10.59	5.93e-25	1.21e-18	0.4	0.31	Pneumonia;	chr10:75232686	chr2:65205108~65205988:+
BRCA	trans	rs11098499	0.619	rs28502463	ENSG00000275858.1	RP11-291L22.8	10.59	6.01e-25	1.23e-18	0.37	0.31	Corneal astigmatism;	chr4:119335868	chr10:38450738~38451069:-
BRCA	trans	rs7927370	1	rs55837706	ENSG00000134612.10	FOLH1B	10.58	6.14e-25	1.26e-18	0.84	0.31	Systemic lupus erythematosus;	chr11:55374636	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs117431413	ENSG00000134612.10	FOLH1B	10.58	6.14e-25	1.26e-18	0.84	0.31	Systemic lupus erythematosus;	chr11:55379993	chr11:89639227~89698718:+
BRCA	trans	rs7258465	0.563	rs10854166	ENSG00000267533.1	RP11-815J4.7	-10.58	6.15e-25	1.26e-18	-0.4	-0.31	Breast cancer;	chr19:18542034	chr18:12067173~12068417:-
BRCA	trans	rs7927370	1	rs61919260	ENSG00000134612.10	FOLH1B	10.58	6.27e-25	1.28e-18	0.82	0.31	Systemic lupus erythematosus;	chr11:55438152	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs7938739	ENSG00000134612.10	FOLH1B	10.58	6.27e-25	1.28e-18	0.82	0.31	Systemic lupus erythematosus;	chr11:55439354	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61916362	ENSG00000134612.10	FOLH1B	10.58	6.27e-25	1.28e-18	0.82	0.31	Systemic lupus erythematosus;	chr11:55439907	chr11:89639227~89698718:+
BRCA	trans	rs11098499	0.754	rs4107728	ENSG00000275858.1	RP11-291L22.8	10.58	6.31e-25	1.29e-18	0.37	0.31	Corneal astigmatism;	chr4:119332755	chr10:38450738~38451069:-
BRCA	trans	rs7927370	0.85	rs7946775	ENSG00000134612.10	FOLH1B	10.58	6.31e-25	1.29e-18	0.84	0.31	Systemic lupus erythematosus;	chr11:55234856	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs117696469	ENSG00000134612.10	FOLH1B	10.58	6.31e-25	1.29e-18	0.84	0.31	Systemic lupus erythematosus;	chr11:55235957	chr11:89639227~89698718:+
BRCA	trans	rs11098499	0.789	rs1980024	ENSG00000275858.1	RP11-291L22.8	10.58	6.36e-25	1.3e-18	0.37	0.31	Corneal astigmatism;	chr4:119331892	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.754	rs34425882	ENSG00000275858.1	RP11-291L22.8	10.58	6.36e-25	1.3e-18	0.37	0.31	Corneal astigmatism;	chr4:119332022	chr10:38450738~38451069:-
BRCA	trans	rs7927370	1	rs61894909	ENSG00000134612.10	FOLH1B	10.58	6.36e-25	1.3e-18	0.84	0.31	Systemic lupus erythematosus;	chr11:55276793	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.85	rs61895982	ENSG00000134612.10	FOLH1B	10.58	6.36e-25	1.3e-18	0.84	0.31	Systemic lupus erythematosus;	chr11:55293699	chr11:89639227~89698718:+
BRCA	trans	rs7833986	0.534	rs17814089	ENSG00000236862.1	RPS20P24	-10.58	6.44e-25	1.31e-18	-0.4	-0.31	Height;	chr8:56053004	chr9:72655832~72656192:-
BRCA	trans	rs4263408	1	rs7661070	ENSG00000237550.5	UBE2Q2P6	10.58	6.45e-25	1.32e-18	0.38	0.31	Plasma amyloid beta peptide concentrations (ABx-40);	chr4:39722745	chr15:82372196~82372912:-
BRCA	trans	rs11098499	0.675	rs11098534	ENSG00000275858.1	RP11-291L22.8	10.58	6.53e-25	1.33e-18	0.37	0.31	Corneal astigmatism;	chr4:119635617	chr10:38450738~38451069:-
BRCA	trans	rs3799378	0.582	rs1796518	ENSG00000242375.1	RP11-498P14.3	-10.58	6.59e-25	1.34e-18	-0.45	-0.31	Intelligence (multi-trait analysis);	chr6:26388444	chr9:97195351~97197687:-
BRCA	trans	rs7833986	0.501	rs2719261	ENSG00000236862.1	RPS20P24	10.58	6.68e-25	1.36e-18	0.39	0.31	Height;	chr8:56029423	chr9:72655832~72656192:-
BRCA	trans	rs9650657	0.547	rs11250099	ENSG00000253893.2	FAM85B	-10.58	6.68e-25	1.36e-18	-0.4	-0.31	Neuroticism;	chr8:10961147	chr8:8167819~8226614:-
BRCA	trans	rs7927370	1	rs61918228	ENSG00000134612.10	FOLH1B	10.58	6.69e-25	1.36e-18	0.83	0.31	Systemic lupus erythematosus;	chr11:55426927	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs55993784	ENSG00000134612.10	FOLH1B	10.58	6.69e-25	1.36e-18	0.83	0.31	Systemic lupus erythematosus;	chr11:55428397	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs55775069	ENSG00000134612.10	FOLH1B	10.58	6.69e-25	1.36e-18	0.83	0.31	Systemic lupus erythematosus;	chr11:55430180	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs7933811	ENSG00000134612.10	FOLH1B	10.58	6.69e-25	1.36e-18	0.84	0.31	Systemic lupus erythematosus;	chr11:55530789	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61917897	ENSG00000134612.10	FOLH1B	10.58	6.69e-25	1.36e-18	0.84	0.31	Systemic lupus erythematosus;	chr11:55531057	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs7102958	ENSG00000134612.10	FOLH1B	10.58	6.69e-25	1.36e-18	0.84	0.31	Systemic lupus erythematosus;	chr11:55531155	chr11:89639227~89698718:+
BRCA	trans	rs3779195	0.591	rs77968419	ENSG00000225169.1	BRI3P1	-10.58	6.73e-25	1.37e-18	-0.53	-0.31	Sex hormone-binding globulin levels;	chr7:98237168	chr1:100213293~100213670:+
BRCA	trans	rs13217239	0.646	rs10456351	ENSG00000242375.1	RP11-498P14.3	10.58	6.74e-25	1.37e-18	0.43	0.31	Schizophrenia;	chr6:27019013	chr9:97195351~97197687:-
BRCA	trans	rs1580019	0.563	rs10486509	ENSG00000176826.14	FKBP9P1	10.57	6.76e-25	1.38e-18	0.39	0.31	Cognitive ability;	chr7:32545831	chr7:55681074~55713252:-
BRCA	trans	rs11098499	0.644	rs34835603	ENSG00000275858.1	RP11-291L22.8	10.57	6.77e-25	1.38e-18	0.37	0.31	Corneal astigmatism;	chr4:119632273	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.615	rs28850368	ENSG00000275858.1	RP11-291L22.8	10.57	6.77e-25	1.38e-18	0.37	0.31	Corneal astigmatism;	chr4:119633158	chr10:38450738~38451069:-
BRCA	trans	rs7927370	1	rs55900934	ENSG00000134612.10	FOLH1B	10.57	6.77e-25	1.38e-18	0.84	0.31	Systemic lupus erythematosus;	chr11:55298131	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs117808016	ENSG00000134612.10	FOLH1B	10.57	6.77e-25	1.38e-18	0.84	0.31	Systemic lupus erythematosus;	chr11:55302598	chr11:89639227~89698718:+
BRCA	trans	rs7833986	0.501	rs72653941	ENSG00000236862.1	RPS20P24	10.57	6.78e-25	1.38e-18	0.39	0.31	Height;	chr8:56029688	chr9:72655832~72656192:-
BRCA	trans	rs7927370	1	rs17579348	ENSG00000134612.10	FOLH1B	10.57	6.8e-25	1.38e-18	0.83	0.31	Systemic lupus erythematosus;	chr11:55493762	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61919686	ENSG00000134612.10	FOLH1B	10.57	6.8e-25	1.38e-18	0.83	0.31	Systemic lupus erythematosus;	chr11:55495434	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61919688	ENSG00000134612.10	FOLH1B	10.57	6.8e-25	1.38e-18	0.83	0.31	Systemic lupus erythematosus;	chr11:55495748	chr11:89639227~89698718:+
BRCA	trans	rs3806843	0.966	rs10060640	ENSG00000231043.3	AC007238.1	-10.57	6.85e-25	1.39e-18	-0.36	-0.31	Depressive symptoms (multi-trait analysis);	chr5:140831641	chr2:58460292~58462032:-
BRCA	trans	rs7927370	0.85	rs17578661	ENSG00000134612.10	FOLH1B	10.57	6.85e-25	1.39e-18	0.78	0.31	Systemic lupus erythematosus;	chr11:55437849	chr11:89639227~89698718:+
BRCA	trans	rs877636	0.859	rs3741499	ENSG00000196656.7	AC004057.1	-10.57	6.89e-25	1.4e-18	-0.38	-0.31	Cognitive function;	chr12:56080595	chr4:113214046~113217170:-
BRCA	trans	rs11098499	0.754	rs17049949	ENSG00000275858.1	RP11-291L22.8	10.57	7.03e-25	1.43e-18	0.37	0.31	Corneal astigmatism;	chr4:119334135	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.754	rs7689729	ENSG00000275858.1	RP11-291L22.8	10.57	7.03e-25	1.43e-18	0.37	0.31	Corneal astigmatism;	chr4:119335037	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.865	rs3956464	ENSG00000275858.1	RP11-291L22.8	10.57	7.03e-25	1.43e-18	0.37	0.31	Corneal astigmatism;	chr4:119335609	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.648	rs2002047	ENSG00000275858.1	RP11-291L22.8	10.57	7.03e-25	1.43e-18	0.37	0.31	Corneal astigmatism;	chr4:119336073	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.775	rs2002049	ENSG00000275858.1	RP11-291L22.8	10.57	7.03e-25	1.43e-18	0.37	0.31	Corneal astigmatism;	chr4:119336262	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.955	rs11944880	ENSG00000275858.1	RP11-291L22.8	-10.57	7.04e-25	1.43e-18	-0.38	-0.31	Corneal astigmatism;	chr4:119238179	chr10:38450738~38451069:-
BRCA	trans	rs7927370	1	rs116415674	ENSG00000134612.10	FOLH1B	10.57	7.19e-25	1.46e-18	0.81	0.31	Systemic lupus erythematosus;	chr11:55288314	chr11:89639227~89698718:+
BRCA	trans	rs1580019	0.563	rs896137	ENSG00000176826.14	FKBP9P1	-10.57	7.3e-25	1.48e-18	-0.4	-0.31	Cognitive ability;	chr7:32539733	chr7:55681074~55713252:-
BRCA	trans	rs1580019	0.523	rs9791770	ENSG00000176826.14	FKBP9P1	-10.57	7.3e-25	1.48e-18	-0.4	-0.31	Cognitive ability;	chr7:32542640	chr7:55681074~55713252:-
BRCA	trans	rs11098499	0.691	rs9996644	ENSG00000275858.1	RP11-291L22.8	10.57	7.35e-25	1.49e-18	0.37	0.31	Corneal astigmatism;	chr4:119317722	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.691	rs9996494	ENSG00000275858.1	RP11-291L22.8	10.57	7.35e-25	1.49e-18	0.37	0.31	Corneal astigmatism;	chr4:119317725	chr10:38450738~38451069:-
BRCA	trans	rs7927370	1	rs77298220	ENSG00000134612.10	FOLH1B	10.57	7.38e-25	1.49e-18	0.83	0.31	Systemic lupus erythematosus;	chr11:55522892	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs17495303	ENSG00000134612.10	FOLH1B	10.56	7.47e-25	1.51e-18	0.83	0.31	Systemic lupus erythematosus;	chr11:55522535	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61916351	ENSG00000134612.10	FOLH1B	10.56	7.47e-25	1.51e-18	0.83	0.31	Systemic lupus erythematosus;	chr11:55523251	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs117533468	ENSG00000134612.10	FOLH1B	10.56	7.47e-25	1.51e-18	0.83	0.31	Systemic lupus erythematosus;	chr11:55525717	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61917891	ENSG00000134612.10	FOLH1B	10.56	7.47e-25	1.51e-18	0.83	0.31	Systemic lupus erythematosus;	chr11:55527807	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs56082718	ENSG00000134612.10	FOLH1B	10.56	7.47e-25	1.51e-18	0.83	0.31	Systemic lupus erythematosus;	chr11:55528842	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs55912300	ENSG00000134612.10	FOLH1B	10.56	7.47e-25	1.51e-18	0.83	0.31	Systemic lupus erythematosus;	chr11:55529651	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs55686425	ENSG00000134612.10	FOLH1B	10.56	7.47e-25	1.51e-18	0.83	0.31	Systemic lupus erythematosus;	chr11:55529794	chr11:89639227~89698718:+
BRCA	trans	rs11098499	0.754	rs7672372	ENSG00000275858.1	RP11-291L22.8	10.56	7.52e-25	1.52e-18	0.37	0.31	Corneal astigmatism;	chr4:119327251	chr10:38450738~38451069:-
BRCA	trans	rs7927370	1	rs61895962	ENSG00000134612.10	FOLH1B	10.56	7.55e-25	1.52e-18	0.84	0.31	Systemic lupus erythematosus;	chr11:55283120	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61895965	ENSG00000134612.10	FOLH1B	10.56	7.55e-25	1.52e-18	0.84	0.31	Systemic lupus erythematosus;	chr11:55286256	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61895971	ENSG00000134612.10	FOLH1B	10.56	7.55e-25	1.52e-18	0.84	0.31	Systemic lupus erythematosus;	chr11:55289696	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61895978	ENSG00000134612.10	FOLH1B	10.56	7.55e-25	1.52e-18	0.84	0.31	Systemic lupus erythematosus;	chr11:55292489	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.702	rs61895981	ENSG00000134612.10	FOLH1B	10.56	7.55e-25	1.52e-18	0.84	0.31	Systemic lupus erythematosus;	chr11:55293675	chr11:89639227~89698718:+
BRCA	trans	rs1580019	0.523	rs13236410	ENSG00000176826.14	FKBP9P1	-10.56	7.66e-25	1.54e-18	-0.4	-0.31	Cognitive ability;	chr7:32651051	chr7:55681074~55713252:-
BRCA	trans	rs3806843	0.897	rs2531338	ENSG00000231043.3	AC007238.1	10.56	7.87e-25	1.58e-18	0.36	0.31	Depressive symptoms (multi-trait analysis);	chr5:140757372	chr2:58460292~58462032:-
BRCA	trans	rs1045902	0.583	rs2303904	ENSG00000236165.1	PRADC1P1	-10.56	8e-25	1.61e-18	-0.4	-0.31	Intelligence (multi-trait analysis);	chr2:73220647	chr3:36976316~36976840:+
BRCA	trans	rs7927370	1	rs61916171	ENSG00000134612.10	FOLH1B	10.56	8.04e-25	1.62e-18	0.84	0.31	Systemic lupus erythematosus;	chr11:55354636	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs116912712	ENSG00000134612.10	FOLH1B	10.56	8.04e-25	1.62e-18	0.84	0.31	Systemic lupus erythematosus;	chr11:55356013	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61916177	ENSG00000134612.10	FOLH1B	10.56	8.04e-25	1.62e-18	0.84	0.31	Systemic lupus erythematosus;	chr11:55358026	chr11:89639227~89698718:+
BRCA	trans	rs9876781	1	rs6776700	ENSG00000225528.1	RP3-370M22.8	-10.56	8.14e-25	1.64e-18	-0.35	-0.31	Longevity;	chr3:48455358	chr22:39960397~39964683:+
BRCA	trans	rs864643	0.678	rs1768201	ENSG00000183298.5	RP11-556K13.1	10.56	8.16e-25	1.64e-18	0.49	0.31	Attention deficit hyperactivity disorder;	chr3:39476050	chr1:101786340~101787219:-
BRCA	trans	rs11098499	0.913	rs11098496	ENSG00000275858.1	RP11-291L22.8	10.56	8.16e-25	1.64e-18	0.39	0.31	Corneal astigmatism;	chr4:119246311	chr10:38450738~38451069:-
BRCA	trans	rs3806843	0.9	rs2563286	ENSG00000231043.3	AC007238.1	10.55	8.42e-25	1.69e-18	0.36	0.31	Depressive symptoms (multi-trait analysis);	chr5:140745614	chr2:58460292~58462032:-
BRCA	trans	rs11098499	0.754	rs12513083	ENSG00000275858.1	RP11-291L22.8	10.55	8.87e-25	1.78e-18	0.37	0.31	Corneal astigmatism;	chr4:119328457	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.754	rs12509621	ENSG00000275858.1	RP11-291L22.8	10.55	8.87e-25	1.78e-18	0.37	0.31	Corneal astigmatism;	chr4:119328505	chr10:38450738~38451069:-
BRCA	trans	rs10028773	0.7	rs7690338	ENSG00000275858.1	RP11-291L22.8	10.55	8.91e-25	1.78e-18	0.37	0.31	Educational attainment;	chr4:119335313	chr10:38450738~38451069:-
BRCA	trans	rs2898290	0.5	rs11998678	ENSG00000253893.2	FAM85B	10.55	8.98e-25	1.8e-18	0.4	0.31	Systolic blood pressure;	chr8:11972641	chr8:8167819~8226614:-
BRCA	trans	rs7927370	0.85	rs56319311	ENSG00000134612.10	FOLH1B	10.54	9.19e-25	1.84e-18	0.84	0.31	Systemic lupus erythematosus;	chr11:55361964	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs17492564	ENSG00000134612.10	FOLH1B	10.54	9.19e-25	1.84e-18	0.84	0.31	Systemic lupus erythematosus;	chr11:55362322	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.85	rs116987455	ENSG00000134612.10	FOLH1B	10.54	9.19e-25	1.84e-18	0.84	0.31	Systemic lupus erythematosus;	chr11:55366303	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.85	rs117690436	ENSG00000134612.10	FOLH1B	10.54	9.19e-25	1.84e-18	0.84	0.31	Systemic lupus erythematosus;	chr11:55366726	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs55716293	ENSG00000134612.10	FOLH1B	10.54	9.19e-25	1.84e-18	0.84	0.31	Systemic lupus erythematosus;	chr11:55367010	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.85	rs56254738	ENSG00000134612.10	FOLH1B	10.54	9.19e-25	1.84e-18	0.84	0.31	Systemic lupus erythematosus;	chr11:55367137	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs117352062	ENSG00000134612.10	FOLH1B	10.54	9.19e-25	1.84e-18	0.84	0.31	Systemic lupus erythematosus;	chr11:55367543	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs77053681	ENSG00000134612.10	FOLH1B	10.54	9.19e-25	1.84e-18	0.84	0.31	Systemic lupus erythematosus;	chr11:55367577	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61916184	ENSG00000134612.10	FOLH1B	10.54	9.19e-25	1.84e-18	0.84	0.31	Systemic lupus erythematosus;	chr11:55368213	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs7927370	ENSG00000134612.10	FOLH1B	10.54	9.19e-25	1.84e-18	0.84	0.31	Systemic lupus erythematosus;	chr11:55368743	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs7122234	ENSG00000134612.10	FOLH1B	10.54	9.19e-25	1.84e-18	0.84	0.31	Systemic lupus erythematosus;	chr11:55370239	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61916211	ENSG00000134612.10	FOLH1B	10.54	9.19e-25	1.84e-18	0.84	0.31	Systemic lupus erythematosus;	chr11:55371234	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs1425192	ENSG00000134612.10	FOLH1B	10.54	9.19e-25	1.84e-18	0.84	0.31	Systemic lupus erythematosus;	chr11:55372518	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs7103234	ENSG00000134612.10	FOLH1B	10.54	9.19e-25	1.84e-18	0.84	0.31	Systemic lupus erythematosus;	chr11:55373822	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.85	rs7109436	ENSG00000134612.10	FOLH1B	10.54	9.19e-25	1.84e-18	0.84	0.31	Systemic lupus erythematosus;	chr11:55373873	chr11:89639227~89698718:+
BRCA	trans	rs11098499	0.754	rs2036857	ENSG00000275858.1	RP11-291L22.8	10.54	9.21e-25	1.84e-18	0.37	0.31	Corneal astigmatism;	chr4:119328085	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.754	rs2036856	ENSG00000275858.1	RP11-291L22.8	10.54	9.21e-25	1.84e-18	0.37	0.31	Corneal astigmatism;	chr4:119328133	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.754	rs4443261	ENSG00000275858.1	RP11-291L22.8	10.54	9.21e-25	1.84e-18	0.37	0.31	Corneal astigmatism;	chr4:119328146	chr10:38450738~38451069:-
BRCA	trans	rs7927370	0.85	rs61896025	ENSG00000134612.10	FOLH1B	10.54	9.34e-25	1.86e-18	0.84	0.31	Systemic lupus erythematosus;	chr11:55302966	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61918369	ENSG00000134612.10	FOLH1B	10.54	9.34e-25	1.86e-18	0.84	0.31	Systemic lupus erythematosus;	chr11:55305296	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61918380	ENSG00000134612.10	FOLH1B	10.54	9.34e-25	1.86e-18	0.84	0.31	Systemic lupus erythematosus;	chr11:55311841	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61918383	ENSG00000134612.10	FOLH1B	10.54	9.34e-25	1.86e-18	0.84	0.31	Systemic lupus erythematosus;	chr11:55314454	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61918384	ENSG00000134612.10	FOLH1B	10.54	9.34e-25	1.86e-18	0.84	0.31	Systemic lupus erythematosus;	chr11:55314856	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61918385	ENSG00000134612.10	FOLH1B	10.54	9.34e-25	1.86e-18	0.84	0.31	Systemic lupus erythematosus;	chr11:55315383	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.85	rs56016821	ENSG00000134612.10	FOLH1B	10.54	9.34e-25	1.86e-18	0.84	0.31	Systemic lupus erythematosus;	chr11:55324417	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.85	rs61918393	ENSG00000134612.10	FOLH1B	10.54	9.34e-25	1.86e-18	0.84	0.31	Systemic lupus erythematosus;	chr11:55325772	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.85	rs61918408	ENSG00000134612.10	FOLH1B	10.54	9.34e-25	1.86e-18	0.84	0.31	Systemic lupus erythematosus;	chr11:55340504	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.702	rs61918409	ENSG00000134612.10	FOLH1B	10.54	9.34e-25	1.86e-18	0.84	0.31	Systemic lupus erythematosus;	chr11:55341516	chr11:89639227~89698718:+
BRCA	trans	rs9876781	0.967	rs7618883	ENSG00000225528.1	RP3-370M22.8	-10.54	9.37e-25	1.87e-18	-0.34	-0.31	Longevity;	chr3:48457056	chr22:39960397~39964683:+
BRCA	trans	rs4276421	0.593	rs4569882	ENSG00000231752.4	EMBP1	10.54	9.65e-25	1.92e-18	0.44	0.31	P wave duration;	chr5:46011875	chr1:121519112~121571892:+
BRCA	trans	rs7944735	0.938	rs59185955	ENSG00000134612.10	FOLH1B	10.54	9.8e-25	1.95e-18	0.46	0.31	Intraocular pressure;	chr11:47940014	chr11:89639227~89698718:+
BRCA	trans	rs11098499	0.754	rs1511017	ENSG00000275858.1	RP11-291L22.8	10.54	9.83e-25	1.95e-18	0.37	0.31	Corneal astigmatism;	chr4:119329650	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.789	rs12498994	ENSG00000275858.1	RP11-291L22.8	10.54	9.83e-25	1.95e-18	0.37	0.31	Corneal astigmatism;	chr4:119329663	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.754	rs12507565	ENSG00000275858.1	RP11-291L22.8	10.54	9.83e-25	1.95e-18	0.37	0.31	Corneal astigmatism;	chr4:119329966	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.826	rs12511640	ENSG00000275858.1	RP11-291L22.8	10.54	9.83e-25	1.95e-18	0.37	0.31	Corneal astigmatism;	chr4:119330093	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.754	rs1980026	ENSG00000275858.1	RP11-291L22.8	10.54	9.83e-25	1.95e-18	0.37	0.31	Corneal astigmatism;	chr4:119330488	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.743	rs11098501	ENSG00000275858.1	RP11-291L22.8	10.54	9.83e-25	1.95e-18	0.37	0.31	Corneal astigmatism;	chr4:119330862	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.754	rs11098502	ENSG00000275858.1	RP11-291L22.8	10.54	9.83e-25	1.95e-18	0.37	0.31	Corneal astigmatism;	chr4:119330908	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.708	rs11732686	ENSG00000275858.1	RP11-291L22.8	10.54	9.83e-25	1.95e-18	0.37	0.31	Corneal astigmatism;	chr4:119331175	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.754	rs11724409	ENSG00000275858.1	RP11-291L22.8	10.54	9.83e-25	1.95e-18	0.37	0.31	Corneal astigmatism;	chr4:119331206	chr10:38450738~38451069:-
BRCA	trans	rs12145833	1	rs12145833	ENSG00000154608.12	CEP170P1	10.54	9.9e-25	1.97e-18	0.43	0.31	Obesity (early onset extreme);	chr1:243320452	chr4:118467590~118554204:+
BRCA	trans	rs2899832	0.568	rs76518732	ENSG00000229083.1	PSMA6P2	10.53	1.01e-24	2.01e-18	0.53	0.31	Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:35165655	chrX:12825840~12826833:+
BRCA	trans	rs7927370	0.867	rs7120226	ENSG00000134612.10	FOLH1B	10.53	1.02e-24	2.03e-18	0.84	0.31	Systemic lupus erythematosus;	chr11:55262023	chr11:89639227~89698718:+
BRCA	trans	rs1580019	0.563	rs34319173	ENSG00000176826.14	FKBP9P1	-10.53	1.02e-24	2.03e-18	-0.39	-0.31	Cognitive ability;	chr7:32546292	chr7:55681074~55713252:-
BRCA	trans	rs7927370	1	rs7114530	ENSG00000134612.10	FOLH1B	10.53	1.03e-24	2.04e-18	0.84	0.31	Systemic lupus erythematosus;	chr11:55263518	chr11:89639227~89698718:+
BRCA	trans	rs4276421	0.53	rs10078485	ENSG00000231752.4	EMBP1	10.53	1.04e-24	2.06e-18	0.43	0.31	P wave duration;	chr5:45879307	chr1:121519112~121571892:+
BRCA	trans	rs13217239	0.646	rs7747454	ENSG00000242375.1	RP11-498P14.3	-10.53	1.05e-24	2.08e-18	-0.43	-0.31	Schizophrenia;	chr6:27066474	chr9:97195351~97197687:-
BRCA	trans	rs877636	0.74	rs705702	ENSG00000223416.3	RPS26P15	-10.53	1.06e-24	2.1e-18	-0.4	-0.31	Cognitive function;	chr12:55996852	chr1:58056133~58056480:-
BRCA	trans	rs11098499	0.955	rs6815725	ENSG00000275858.1	RP11-291L22.8	10.53	1.06e-24	2.11e-18	0.39	0.31	Corneal astigmatism;	chr4:119237255	chr10:38450738~38451069:-
BRCA	trans	rs7927370	1	rs17495071	ENSG00000134612.10	FOLH1B	10.53	1.07e-24	2.13e-18	0.82	0.31	Systemic lupus erythematosus;	chr11:55510971	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61916297	ENSG00000134612.10	FOLH1B	10.53	1.07e-24	2.13e-18	0.82	0.31	Systemic lupus erythematosus;	chr11:55511906	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61916299	ENSG00000134612.10	FOLH1B	10.53	1.07e-24	2.13e-18	0.82	0.31	Systemic lupus erythematosus;	chr11:55513699	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61916320	ENSG00000134612.10	FOLH1B	10.53	1.07e-24	2.13e-18	0.82	0.31	Systemic lupus erythematosus;	chr11:55514817	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61916321	ENSG00000134612.10	FOLH1B	10.53	1.07e-24	2.13e-18	0.82	0.31	Systemic lupus erythematosus;	chr11:55514895	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs17495142	ENSG00000134612.10	FOLH1B	10.53	1.07e-24	2.13e-18	0.82	0.31	Systemic lupus erythematosus;	chr11:55515118	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs78785256	ENSG00000134612.10	FOLH1B	10.53	1.07e-24	2.13e-18	0.82	0.31	Systemic lupus erythematosus;	chr11:55515167	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61916322	ENSG00000134612.10	FOLH1B	10.53	1.07e-24	2.13e-18	0.82	0.31	Systemic lupus erythematosus;	chr11:55515211	chr11:89639227~89698718:+
BRCA	trans	rs7944735	0.517	rs74763661	ENSG00000134612.10	FOLH1B	10.53	1.08e-24	2.14e-18	0.51	0.31	Intraocular pressure;	chr11:48212220	chr11:89639227~89698718:+
BRCA	trans	rs11098499	0.955	rs1397608	ENSG00000275858.1	RP11-291L22.8	10.53	1.08e-24	2.14e-18	0.38	0.31	Corneal astigmatism;	chr4:119240589	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.955	rs7685268	ENSG00000275858.1	RP11-291L22.8	10.53	1.08e-24	2.14e-18	0.38	0.31	Corneal astigmatism;	chr4:119241033	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.955	rs7684942	ENSG00000275858.1	RP11-291L22.8	10.53	1.08e-24	2.14e-18	0.38	0.31	Corneal astigmatism;	chr4:119241046	chr10:38450738~38451069:-
BRCA	trans	rs7927370	1	rs61918236	ENSG00000134612.10	FOLH1B	10.52	1.11e-24	2.19e-18	0.83	0.31	Systemic lupus erythematosus;	chr11:55430951	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs55854157	ENSG00000134612.10	FOLH1B	10.52	1.11e-24	2.19e-18	0.84	0.31	Systemic lupus erythematosus;	chr11:55424988	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs56055236	ENSG00000134612.10	FOLH1B	10.52	1.11e-24	2.19e-18	0.84	0.31	Systemic lupus erythematosus;	chr11:55425278	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs55889092	ENSG00000134612.10	FOLH1B	10.52	1.11e-24	2.19e-18	0.84	0.31	Systemic lupus erythematosus;	chr11:55425396	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs56410859	ENSG00000134612.10	FOLH1B	10.52	1.11e-24	2.19e-18	0.84	0.31	Systemic lupus erythematosus;	chr11:55425710	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61918227	ENSG00000134612.10	FOLH1B	10.52	1.11e-24	2.19e-18	0.84	0.31	Systemic lupus erythematosus;	chr11:55426203	chr11:89639227~89698718:+
BRCA	trans	rs2657294	0.606	rs10824290	ENSG00000172974.11	AC007318.5	10.52	1.13e-24	2.23e-18	0.4	0.31	Pneumonia;	chr10:75204210	chr2:65205108~65205988:+
BRCA	trans	rs7927370	0.85	rs7109113	ENSG00000134612.10	FOLH1B	10.52	1.13e-24	2.23e-18	0.81	0.31	Systemic lupus erythematosus;	chr11:55702917	chr11:89639227~89698718:+
BRCA	trans	rs941207	0.756	rs2950388	ENSG00000228224.3	NACAP1	-10.52	1.13e-24	2.24e-18	-0.39	-0.31	Platelet count;	chr12:56639569	chr8:101361794~101372707:+
BRCA	trans	rs4263408	0.935	rs62310129	ENSG00000237550.5	UBE2Q2P6	10.52	1.15e-24	2.27e-18	0.37	0.31	Plasma amyloid beta peptide concentrations (ABx-40);	chr4:39772802	chr15:82372196~82372912:-
BRCA	trans	rs7927370	0.51	rs11559578	ENSG00000134612.10	FOLH1B	10.52	1.16e-24	2.3e-18	0.5	0.31	Systemic lupus erythematosus;	chr11:55227499	chr11:89639227~89698718:+
BRCA	trans	rs13217239	0.646	rs6456767	ENSG00000242375.1	RP11-498P14.3	-10.52	1.17e-24	2.31e-18	-0.43	-0.31	Schizophrenia;	chr6:27102764	chr9:97195351~97197687:-
BRCA	trans	rs7833986	0.501	rs2719257	ENSG00000236862.1	RPS20P24	10.52	1.17e-24	2.31e-18	0.4	0.31	Height;	chr8:56027614	chr9:72655832~72656192:-
BRCA	trans	rs1580019	0.537	rs7804609	ENSG00000176826.14	FKBP9P1	-10.52	1.18e-24	2.32e-18	-0.4	-0.31	Cognitive ability;	chr7:32518482	chr7:55681074~55713252:-
BRCA	trans	rs2727020	0.786	rs10839263	ENSG00000134612.10	FOLH1B	-10.52	1.18e-24	2.33e-18	-0.42	-0.31	Coronary artery disease;	chr11:49332910	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs116858638	ENSG00000134612.10	FOLH1B	10.52	1.18e-24	2.33e-18	0.84	0.31	Systemic lupus erythematosus;	chr11:55417383	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.702	rs61918161	ENSG00000134612.10	FOLH1B	10.52	1.18e-24	2.33e-18	0.84	0.31	Systemic lupus erythematosus;	chr11:55417742	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs117788647	ENSG00000134612.10	FOLH1B	10.52	1.18e-24	2.33e-18	0.84	0.31	Systemic lupus erythematosus;	chr11:55419725	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61918212	ENSG00000134612.10	FOLH1B	10.52	1.18e-24	2.33e-18	0.84	0.31	Systemic lupus erythematosus;	chr11:55420471	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61918213	ENSG00000134612.10	FOLH1B	10.52	1.18e-24	2.33e-18	0.84	0.31	Systemic lupus erythematosus;	chr11:55420497	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.85	rs61918215	ENSG00000134612.10	FOLH1B	10.52	1.18e-24	2.33e-18	0.84	0.31	Systemic lupus erythematosus;	chr11:55421083	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.85	rs61918216	ENSG00000134612.10	FOLH1B	10.52	1.18e-24	2.33e-18	0.84	0.31	Systemic lupus erythematosus;	chr11:55421104	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61918217	ENSG00000134612.10	FOLH1B	10.52	1.18e-24	2.33e-18	0.84	0.31	Systemic lupus erythematosus;	chr11:55421342	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs117427130	ENSG00000134612.10	FOLH1B	10.52	1.18e-24	2.33e-18	0.84	0.31	Systemic lupus erythematosus;	chr11:55422459	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61918222	ENSG00000134612.10	FOLH1B	10.52	1.18e-24	2.33e-18	0.84	0.31	Systemic lupus erythematosus;	chr11:55423640	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs55999106	ENSG00000134612.10	FOLH1B	10.51	1.22e-24	2.41e-18	0.84	0.31	Systemic lupus erythematosus;	chr11:55490489	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61919681	ENSG00000134612.10	FOLH1B	10.51	1.22e-24	2.41e-18	0.84	0.31	Systemic lupus erythematosus;	chr11:55490587	chr11:89639227~89698718:+
BRCA	trans	rs13217239	0.646	rs11756275	ENSG00000242375.1	RP11-498P14.3	-10.51	1.22e-24	2.41e-18	-0.43	-0.31	Schizophrenia;	chr6:27039334	chr9:97195351~97197687:-
BRCA	trans	rs7927370	1	rs61916375	ENSG00000134612.10	FOLH1B	10.51	1.24e-24	2.43e-18	0.83	0.31	Systemic lupus erythematosus;	chr11:55443539	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs7935445	ENSG00000134612.10	FOLH1B	10.51	1.25e-24	2.46e-18	0.83	0.31	Systemic lupus erythematosus;	chr11:55521304	chr11:89639227~89698718:+
BRCA	trans	rs11098499	0.955	rs11931312	ENSG00000275858.1	RP11-291L22.8	10.5	1.33e-24	2.6e-18	0.38	0.31	Corneal astigmatism;	chr4:119237868	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.955	rs1551	ENSG00000275858.1	RP11-291L22.8	10.5	1.33e-24	2.61e-18	0.38	0.31	Corneal astigmatism;	chr4:119237345	chr10:38450738~38451069:-
BRCA	trans	rs13217239	0.646	rs35691005	ENSG00000242375.1	RP11-498P14.3	10.5	1.33e-24	2.62e-18	0.43	0.31	Schizophrenia;	chr6:27004291	chr9:97195351~97197687:-
BRCA	trans	rs13217239	0.646	rs10946891	ENSG00000242375.1	RP11-498P14.3	10.5	1.33e-24	2.62e-18	0.43	0.31	Schizophrenia;	chr6:27005436	chr9:97195351~97197687:-
BRCA	trans	rs13217239	0.646	rs12201393	ENSG00000242375.1	RP11-498P14.3	10.5	1.33e-24	2.62e-18	0.43	0.31	Schizophrenia;	chr6:27007911	chr9:97195351~97197687:-
BRCA	trans	rs11098499	0.913	rs10010696	ENSG00000275858.1	RP11-291L22.8	10.5	1.35e-24	2.64e-18	0.39	0.31	Corneal astigmatism;	chr4:119243148	chr10:38450738~38451069:-
BRCA	trans	rs55665837	0.701	rs1522633	ENSG00000236360.2	RP11-334A14.2	10.5	1.37e-24	2.69e-18	0.41	0.31	Vitamin D levels;	chr11:14623692	chr1:52993201~52993702:-
BRCA	trans	rs13217239	0.572	rs9379958	ENSG00000242375.1	RP11-498P14.3	-10.5	1.4e-24	2.75e-18	-0.43	-0.31	Schizophrenia;	chr6:27098384	chr9:97195351~97197687:-
BRCA	trans	rs34421088	0.548	rs2618443	ENSG00000253893.2	FAM85B	10.5	1.41e-24	2.76e-18	0.39	0.31	Neuroticism;	chr8:11527047	chr8:8167819~8226614:-
BRCA	trans	rs13217239	0.646	rs9393789	ENSG00000242375.1	RP11-498P14.3	-10.5	1.42e-24	2.79e-18	-0.43	-0.31	Schizophrenia;	chr6:27099249	chr9:97195351~97197687:-
BRCA	trans	rs13217239	0.646	rs10946888	ENSG00000242375.1	RP11-498P14.3	10.5	1.45e-24	2.83e-18	0.43	0.31	Schizophrenia;	chr6:26983899	chr9:97195351~97197687:-
BRCA	trans	rs11098499	0.866	rs6847778	ENSG00000275858.1	RP11-291L22.8	10.5	1.45e-24	2.83e-18	0.37	0.31	Corneal astigmatism;	chr4:119372427	chr10:38450738~38451069:-
BRCA	trans	rs941207	0.724	rs4788	ENSG00000228224.3	NACAP1	10.49	1.56e-24	3.05e-18	0.39	0.31	Platelet count;	chr12:56712876	chr8:101361794~101372707:+
BRCA	trans	rs9467773	0.587	rs10946812	ENSG00000242375.1	RP11-498P14.3	-10.49	1.56e-24	3.05e-18	-0.42	-0.31	Intelligence (multi-trait analysis);	chr6:26344747	chr9:97195351~97197687:-
BRCA	trans	rs7927370	1	rs7122704	ENSG00000134612.10	FOLH1B	10.49	1.57e-24	3.06e-18	0.84	0.31	Systemic lupus erythematosus;	chr11:55383130	chr11:89639227~89698718:+
BRCA	trans	rs7833986	0.501	rs72653948	ENSG00000236862.1	RPS20P24	10.49	1.58e-24	3.08e-18	0.39	0.31	Height;	chr8:56043130	chr9:72655832~72656192:-
BRCA	trans	rs3806843	0.966	rs2563262	ENSG00000231043.3	AC007238.1	10.49	1.6e-24	3.12e-18	0.36	0.31	Depressive symptoms (multi-trait analysis);	chr5:140758127	chr2:58460292~58462032:-
BRCA	trans	rs3806843	0.966	rs2563264	ENSG00000231043.3	AC007238.1	10.49	1.6e-24	3.12e-18	0.36	0.31	Depressive symptoms (multi-trait analysis);	chr5:140757918	chr2:58460292~58462032:-
BRCA	trans	rs2657294	0.632	rs2657289	ENSG00000172974.11	AC007318.5	10.48	1.65e-24	3.23e-18	0.4	0.31	Pneumonia;	chr10:75206705	chr2:65205108~65205988:+
BRCA	trans	rs1391708	1	rs7957145	ENSG00000121089.4	NACA3P	-10.48	1.66e-24	3.24e-18	-0.51	-0.31	Airway wall thickness;	chr12:56908336	chr4:164943290~164943937:+
BRCA	trans	rs7927370	1	rs7943092	ENSG00000134612.10	FOLH1B	10.48	1.69e-24	3.3e-18	0.83	0.31	Systemic lupus erythematosus;	chr11:55493628	chr11:89639227~89698718:+
BRCA	trans	rs1190596	0.525	rs35350456	ENSG00000181359.5	HSP90AA6P	-10.48	1.7e-24	3.31e-18	-0.41	-0.31	Behavioural disinhibition (generation interaction);	chr14:102238414	chr4:170581470~170605450:-
BRCA	trans	rs7927370	1	rs61916173	ENSG00000134612.10	FOLH1B	10.48	1.74e-24	3.38e-18	0.79	0.31	Systemic lupus erythematosus;	chr11:55356110	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61916175	ENSG00000134612.10	FOLH1B	10.48	1.74e-24	3.38e-18	0.79	0.31	Systemic lupus erythematosus;	chr11:55356612	chr11:89639227~89698718:+
BRCA	trans	rs11098499	0.731	rs6846966	ENSG00000275858.1	RP11-291L22.8	10.48	1.74e-24	3.4e-18	0.37	0.31	Corneal astigmatism;	chr4:119372053	chr10:38450738~38451069:-
BRCA	trans	rs9876781	1	rs9815103	ENSG00000225528.1	RP3-370M22.8	-10.47	1.78e-24	3.48e-18	-0.34	-0.31	Longevity;	chr3:48372725	chr22:39960397~39964683:+
BRCA	trans	rs7927370	1	rs7119050	ENSG00000134612.10	FOLH1B	10.47	1.8e-24	3.51e-18	0.79	0.31	Systemic lupus erythematosus;	chr11:55297095	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs7111837	ENSG00000134612.10	FOLH1B	10.47	1.8e-24	3.51e-18	0.79	0.31	Systemic lupus erythematosus;	chr11:55298790	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61919683	ENSG00000134612.10	FOLH1B	10.47	1.81e-24	3.52e-18	0.83	0.31	Systemic lupus erythematosus;	chr11:55491233	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs7950685	ENSG00000134612.10	FOLH1B	10.47	1.81e-24	3.52e-18	0.83	0.31	Systemic lupus erythematosus;	chr11:55493215	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs56068831	ENSG00000134612.10	FOLH1B	10.47	1.84e-24	3.57e-18	0.8	0.31	Systemic lupus erythematosus;	chr11:55277887	chr11:89639227~89698718:+
BRCA	trans	rs941207	0.756	rs67046307	ENSG00000228224.3	NACAP1	-10.47	1.85e-24	3.59e-18	-0.39	-0.31	Platelet count;	chr12:56651152	chr8:101361794~101372707:+
BRCA	trans	rs7927370	1	rs17492571	ENSG00000134612.10	FOLH1B	10.47	1.85e-24	3.6e-18	0.8	0.31	Systemic lupus erythematosus;	chr11:55362518	chr11:89639227~89698718:+
BRCA	trans	rs9329221	0.741	rs534523	ENSG00000253893.2	FAM85B	10.47	1.89e-24	3.67e-18	0.38	0.31	Neuroticism;	chr8:10027489	chr8:8167819~8226614:-
BRCA	trans	rs2727020	0.894	rs11040333	ENSG00000134612.10	FOLH1B	-10.47	1.89e-24	3.68e-18	-0.42	-0.31	Coronary artery disease;	chr11:49324780	chr11:89639227~89698718:+
BRCA	trans	rs11098499	1	rs13116504	ENSG00000275858.1	RP11-291L22.8	10.47	1.9e-24	3.7e-18	0.38	0.31	Corneal astigmatism;	chr4:119288257	chr10:38450738~38451069:-
BRCA	trans	rs1391708	1	rs1391708	ENSG00000121089.4	NACA3P	-10.47	1.91e-24	3.71e-18	-0.51	-0.31	Airway wall thickness;	chr12:56911796	chr4:164943290~164943937:+
BRCA	trans	rs864643	0.524	rs80322842	ENSG00000183298.5	RP11-556K13.1	10.46	1.95e-24	3.78e-18	0.61	0.31	Attention deficit hyperactivity disorder;	chr3:39483682	chr1:101786340~101787219:-
BRCA	trans	rs3806843	0.868	rs2531349	ENSG00000231043.3	AC007238.1	10.46	1.99e-24	3.86e-18	0.36	0.31	Depressive symptoms (multi-trait analysis);	chr5:140741368	chr2:58460292~58462032:-
BRCA	trans	rs877636	0.669	rs7297175	ENSG00000212829.8	RPS26P3	-10.46	2.02e-24	3.91e-18	-0.37	-0.31	Cognitive function;	chr12:56080024	chr9:9090898~9091245:+
BRCA	trans	rs3806843	0.766	rs2530239	ENSG00000231043.3	AC007238.1	10.46	2.08e-24	4.02e-18	0.36	0.31	Depressive symptoms (multi-trait analysis);	chr5:140682962	chr2:58460292~58462032:-
BRCA	trans	rs11098499	0.865	rs10213221	ENSG00000275858.1	RP11-291L22.8	10.46	2.11e-24	4.08e-18	0.37	0.31	Corneal astigmatism;	chr4:119334771	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.955	rs1511015	ENSG00000275858.1	RP11-291L22.8	10.46	2.11e-24	4.09e-18	0.38	0.31	Corneal astigmatism;	chr4:119249318	chr10:38450738~38451069:-
BRCA	trans	rs3806843	0.808	rs6893708	ENSG00000231043.3	AC007238.1	10.45	2.15e-24	4.16e-18	0.36	0.31	Depressive symptoms (multi-trait analysis);	chr5:140746337	chr2:58460292~58462032:-
BRCA	trans	rs11098499	0.663	rs9996501	ENSG00000275858.1	RP11-291L22.8	10.45	2.22e-24	4.29e-18	0.37	0.31	Corneal astigmatism;	chr4:119317763	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.697	rs28458294	ENSG00000275858.1	RP11-291L22.8	10.45	2.22e-24	4.29e-18	0.37	0.31	Corneal astigmatism;	chr4:119317769	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.663	rs28369503	ENSG00000275858.1	RP11-291L22.8	10.45	2.22e-24	4.29e-18	0.37	0.31	Corneal astigmatism;	chr4:119317770	chr10:38450738~38451069:-
BRCA	trans	rs7927370	1	rs116849536	ENSG00000134612.10	FOLH1B	10.45	2.25e-24	4.34e-18	0.83	0.31	Systemic lupus erythematosus;	chr11:55706399	chr11:89639227~89698718:+
BRCA	trans	rs7819412	0.745	rs4841498	ENSG00000253893.2	FAM85B	10.45	2.25e-24	4.36e-18	0.39	0.31	Triglycerides;	chr8:11127922	chr8:8167819~8226614:-
BRCA	trans	rs9467773	0.566	rs66972160	ENSG00000242375.1	RP11-498P14.3	-10.45	2.26e-24	4.37e-18	-0.43	-0.31	Intelligence (multi-trait analysis);	chr6:26359078	chr9:97195351~97197687:-
BRCA	trans	rs9467773	0.526	rs9348710	ENSG00000242375.1	RP11-498P14.3	-10.45	2.26e-24	4.37e-18	-0.43	-0.31	Intelligence (multi-trait analysis);	chr6:26360258	chr9:97195351~97197687:-
BRCA	trans	rs7927370	1	rs1580922	ENSG00000134612.10	FOLH1B	10.45	2.28e-24	4.39e-18	0.81	0.31	Systemic lupus erythematosus;	chr11:55556662	chr11:89639227~89698718:+
BRCA	trans	rs11098499	1	rs10029750	ENSG00000275858.1	RP11-291L22.8	10.45	2.31e-24	4.45e-18	0.38	0.31	Corneal astigmatism;	chr4:119251388	chr10:38450738~38451069:-
BRCA	trans	rs7927370	1	rs4316524	ENSG00000134612.10	FOLH1B	-10.45	2.31e-24	4.46e-18	-0.83	-0.31	Systemic lupus erythematosus;	chr11:55392489	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs56400349	ENSG00000134612.10	FOLH1B	10.45	2.31e-24	4.46e-18	0.84	0.31	Systemic lupus erythematosus;	chr11:55668486	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs7947870	ENSG00000134612.10	FOLH1B	10.45	2.31e-24	4.46e-18	0.84	0.31	Systemic lupus erythematosus;	chr11:55677038	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs7945896	ENSG00000134612.10	FOLH1B	10.45	2.31e-24	4.46e-18	0.84	0.31	Systemic lupus erythematosus;	chr11:55677767	chr11:89639227~89698718:+
BRCA	trans	rs11098499	0.644	rs3806808	ENSG00000275858.1	RP11-291L22.8	10.44	2.35e-24	4.52e-18	0.37	0.31	Corneal astigmatism;	chr4:119629930	chr10:38450738~38451069:-
BRCA	trans	rs864643	0.524	rs11715885	ENSG00000188856.6	RPSAP47	10.44	2.35e-24	4.53e-18	0.6	0.31	Attention deficit hyperactivity disorder;	chr3:39475107	chr8:80558870~80559757:+
BRCA	trans	rs9876781	1	rs9876781	ENSG00000225528.1	RP3-370M22.8	-10.44	2.39e-24	4.6e-18	-0.33	-0.31	Longevity;	chr3:48445934	chr22:39960397~39964683:+
BRCA	trans	rs3806843	0.766	rs702397	ENSG00000231043.3	AC007238.1	10.44	2.4e-24	4.62e-18	0.36	0.31	Depressive symptoms (multi-trait analysis);	chr5:140670680	chr2:58460292~58462032:-
BRCA	trans	rs16937956	0.597	rs35022013	ENSG00000266891.1	RP11-692N5.2	10.44	2.41e-24	4.65e-18	0.42	0.31	Body mass index;	chr11:8395956	chr18:9734882~9735602:-
BRCA	trans	rs7927370	0.85	rs61894907	ENSG00000134612.10	FOLH1B	10.44	2.42e-24	4.66e-18	0.8	0.31	Systemic lupus erythematosus;	chr11:55276669	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61894946	ENSG00000134612.10	FOLH1B	10.44	2.42e-24	4.66e-18	0.8	0.31	Systemic lupus erythematosus;	chr11:55279401	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61894947	ENSG00000134612.10	FOLH1B	10.44	2.42e-24	4.66e-18	0.8	0.31	Systemic lupus erythematosus;	chr11:55279556	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61894948	ENSG00000134612.10	FOLH1B	10.44	2.42e-24	4.66e-18	0.8	0.31	Systemic lupus erythematosus;	chr11:55279571	chr11:89639227~89698718:+
BRCA	trans	rs3806843	0.766	rs2251860	ENSG00000231043.3	AC007238.1	10.44	2.46e-24	4.73e-18	0.36	0.31	Depressive symptoms (multi-trait analysis);	chr5:140668624	chr2:58460292~58462032:-
BRCA	trans	rs7927370	1	rs61919574	ENSG00000134612.10	FOLH1B	10.44	2.46e-24	4.74e-18	0.81	0.31	Systemic lupus erythematosus;	chr11:55557228	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61919575	ENSG00000134612.10	FOLH1B	10.44	2.46e-24	4.74e-18	0.81	0.31	Systemic lupus erythematosus;	chr11:55557386	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.85	rs79896638	ENSG00000134612.10	FOLH1B	10.44	2.46e-24	4.74e-18	0.81	0.31	Systemic lupus erythematosus;	chr11:55557484	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs75619483	ENSG00000134612.10	FOLH1B	10.44	2.48e-24	4.77e-18	0.79	0.31	Systemic lupus erythematosus;	chr11:55311534	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.85	rs7943624	ENSG00000134612.10	FOLH1B	10.44	2.48e-24	4.77e-18	0.79	0.31	Systemic lupus erythematosus;	chr11:55312374	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.85	rs75398777	ENSG00000134612.10	FOLH1B	10.44	2.48e-24	4.77e-18	0.79	0.31	Systemic lupus erythematosus;	chr11:55313067	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs55721957	ENSG00000134612.10	FOLH1B	10.44	2.48e-24	4.77e-18	0.79	0.31	Systemic lupus erythematosus;	chr11:55313371	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs56053002	ENSG00000134612.10	FOLH1B	10.44	2.48e-24	4.77e-18	0.79	0.31	Systemic lupus erythematosus;	chr11:55317851	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.85	rs4567485	ENSG00000134612.10	FOLH1B	10.44	2.48e-24	4.77e-18	0.79	0.31	Systemic lupus erythematosus;	chr11:55320139	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61918390	ENSG00000134612.10	FOLH1B	10.44	2.48e-24	4.77e-18	0.79	0.31	Systemic lupus erythematosus;	chr11:55323671	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs17492508	ENSG00000134612.10	FOLH1B	10.44	2.48e-24	4.77e-18	0.79	0.31	Systemic lupus erythematosus;	chr11:55324143	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs56101935	ENSG00000134612.10	FOLH1B	10.44	2.48e-24	4.77e-18	0.79	0.31	Systemic lupus erythematosus;	chr11:55328613	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.702	rs7112124	ENSG00000134612.10	FOLH1B	10.44	2.48e-24	4.77e-18	0.79	0.31	Systemic lupus erythematosus;	chr11:55345837	chr11:89639227~89698718:+
BRCA	trans	rs7944735	1	rs7944735	ENSG00000134612.10	FOLH1B	10.44	2.49e-24	4.78e-18	0.46	0.31	Intraocular pressure;	chr11:47934056	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61919618	ENSG00000134612.10	FOLH1B	10.44	2.55e-24	4.89e-18	0.81	0.31	Systemic lupus erythematosus;	chr11:55565211	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61919619	ENSG00000134612.10	FOLH1B	10.44	2.55e-24	4.89e-18	0.81	0.31	Systemic lupus erythematosus;	chr11:55565809	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61919620	ENSG00000134612.10	FOLH1B	10.44	2.55e-24	4.89e-18	0.81	0.31	Systemic lupus erythematosus;	chr11:55565963	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61919621	ENSG00000134612.10	FOLH1B	10.44	2.55e-24	4.89e-18	0.81	0.31	Systemic lupus erythematosus;	chr11:55566137	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61919622	ENSG00000134612.10	FOLH1B	10.44	2.55e-24	4.89e-18	0.81	0.31	Systemic lupus erythematosus;	chr11:55566419	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61919624	ENSG00000134612.10	FOLH1B	10.44	2.55e-24	4.89e-18	0.81	0.31	Systemic lupus erythematosus;	chr11:55566703	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.557	rs76653064	ENSG00000134612.10	FOLH1B	10.44	2.55e-24	4.89e-18	0.81	0.31	Systemic lupus erythematosus;	chr11:55567984	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61916561	ENSG00000134612.10	FOLH1B	10.44	2.55e-24	4.89e-18	0.81	0.31	Systemic lupus erythematosus;	chr11:55568727	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61916562	ENSG00000134612.10	FOLH1B	10.44	2.55e-24	4.89e-18	0.81	0.31	Systemic lupus erythematosus;	chr11:55568731	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61916563	ENSG00000134612.10	FOLH1B	10.44	2.55e-24	4.89e-18	0.81	0.31	Systemic lupus erythematosus;	chr11:55569551	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs56127747	ENSG00000134612.10	FOLH1B	10.44	2.55e-24	4.89e-18	0.81	0.31	Systemic lupus erythematosus;	chr11:55569783	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61916564	ENSG00000134612.10	FOLH1B	10.44	2.55e-24	4.89e-18	0.81	0.31	Systemic lupus erythematosus;	chr11:55570306	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61916565	ENSG00000134612.10	FOLH1B	10.44	2.55e-24	4.89e-18	0.81	0.31	Systemic lupus erythematosus;	chr11:55570619	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61916566	ENSG00000134612.10	FOLH1B	10.44	2.55e-24	4.89e-18	0.81	0.31	Systemic lupus erythematosus;	chr11:55570959	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61916567	ENSG00000134612.10	FOLH1B	10.44	2.55e-24	4.89e-18	0.81	0.31	Systemic lupus erythematosus;	chr11:55571766	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.85	rs17582140	ENSG00000134612.10	FOLH1B	10.44	2.55e-24	4.89e-18	0.81	0.31	Systemic lupus erythematosus;	chr11:55571909	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs80123215	ENSG00000134612.10	FOLH1B	10.44	2.55e-24	4.89e-18	0.81	0.31	Systemic lupus erythematosus;	chr11:55571990	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs78612916	ENSG00000134612.10	FOLH1B	10.44	2.55e-24	4.89e-18	0.81	0.31	Systemic lupus erythematosus;	chr11:55572228	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs75881957	ENSG00000134612.10	FOLH1B	10.44	2.55e-24	4.89e-18	0.81	0.31	Systemic lupus erythematosus;	chr11:55572236	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs80210585	ENSG00000134612.10	FOLH1B	10.44	2.55e-24	4.89e-18	0.81	0.31	Systemic lupus erythematosus;	chr11:55572264	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61916568	ENSG00000134612.10	FOLH1B	10.44	2.55e-24	4.89e-18	0.81	0.31	Systemic lupus erythematosus;	chr11:55572694	chr11:89639227~89698718:+
BRCA	trans	rs13217239	0.646	rs10946898	ENSG00000242375.1	RP11-498P14.3	10.44	2.57e-24	4.92e-18	0.43	0.31	Schizophrenia;	chr6:27036105	chr9:97195351~97197687:-
BRCA	trans	rs11098499	0.863	rs3736115	ENSG00000275858.1	RP11-291L22.8	-10.44	2.57e-24	4.93e-18	-0.38	-0.31	Corneal astigmatism;	chr4:119567548	chr10:38450738~38451069:-
BRCA	trans	rs13217239	0.646	rs12209886	ENSG00000242375.1	RP11-498P14.3	10.43	2.6e-24	4.98e-18	0.43	0.31	Schizophrenia;	chr6:27016978	chr9:97195351~97197687:-
BRCA	trans	rs6940638	0.531	rs12211984	ENSG00000242375.1	RP11-498P14.3	10.43	2.6e-24	4.98e-18	0.43	0.31	Intelligence (multi-trait analysis);	chr6:27018275	chr9:97195351~97197687:-
BRCA	trans	rs26067	0.74	rs26079	ENSG00000231752.4	EMBP1	-10.43	2.61e-24	5.01e-18	-0.43	-0.31	Breast cancer;	chr5:50863180	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.593	rs10066821	ENSG00000231752.4	EMBP1	10.43	2.64e-24	5.07e-18	0.43	0.31	P wave duration;	chr5:45844236	chr1:121519112~121571892:+
BRCA	trans	rs7662987	1	rs17595424	ENSG00000233859.2	ADH5P4	10.43	2.65e-24	5.09e-18	0.63	0.31	Smoking initiation;	chr4:99072718	chr6:65836930~65838039:-
BRCA	trans	rs7927370	0.557	rs61916167	ENSG00000134612.10	FOLH1B	10.43	2.66e-24	5.1e-18	0.85	0.31	Systemic lupus erythematosus;	chr11:55350711	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.85	rs61916168	ENSG00000134612.10	FOLH1B	10.43	2.66e-24	5.1e-18	0.85	0.31	Systemic lupus erythematosus;	chr11:55351033	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs75519906	ENSG00000134612.10	FOLH1B	10.43	2.67e-24	5.13e-18	0.85	0.31	Systemic lupus erythematosus;	chr11:55348135	chr11:89639227~89698718:+
BRCA	trans	rs13217239	0.646	rs62401067	ENSG00000242375.1	RP11-498P14.3	10.43	2.73e-24	5.22e-18	0.43	0.31	Schizophrenia;	chr6:27050322	chr9:97195351~97197687:-
BRCA	trans	rs7927370	1	rs61917993	ENSG00000134612.10	FOLH1B	10.43	2.73e-24	5.22e-18	0.82	0.31	Systemic lupus erythematosus;	chr11:55474539	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61917994	ENSG00000134612.10	FOLH1B	10.43	2.73e-24	5.22e-18	0.82	0.31	Systemic lupus erythematosus;	chr11:55474609	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61917995	ENSG00000134612.10	FOLH1B	10.43	2.73e-24	5.22e-18	0.82	0.31	Systemic lupus erythematosus;	chr11:55474983	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61917996	ENSG00000134612.10	FOLH1B	10.43	2.73e-24	5.22e-18	0.82	0.31	Systemic lupus erythematosus;	chr11:55475080	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61917997	ENSG00000134612.10	FOLH1B	10.43	2.73e-24	5.22e-18	0.82	0.31	Systemic lupus erythematosus;	chr11:55475250	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61917998	ENSG00000134612.10	FOLH1B	10.43	2.73e-24	5.22e-18	0.82	0.31	Systemic lupus erythematosus;	chr11:55475774	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61917999	ENSG00000134612.10	FOLH1B	10.43	2.73e-24	5.22e-18	0.82	0.31	Systemic lupus erythematosus;	chr11:55476220	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs7128605	ENSG00000134612.10	FOLH1B	10.43	2.73e-24	5.22e-18	0.82	0.31	Systemic lupus erythematosus;	chr11:55478129	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs7128617	ENSG00000134612.10	FOLH1B	10.43	2.73e-24	5.22e-18	0.82	0.31	Systemic lupus erythematosus;	chr11:55478174	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61918001	ENSG00000134612.10	FOLH1B	10.43	2.73e-24	5.22e-18	0.82	0.31	Systemic lupus erythematosus;	chr11:55478565	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs7127570	ENSG00000134612.10	FOLH1B	10.43	2.73e-24	5.22e-18	0.82	0.31	Systemic lupus erythematosus;	chr11:55479700	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61918008	ENSG00000134612.10	FOLH1B	10.43	2.73e-24	5.22e-18	0.82	0.31	Systemic lupus erythematosus;	chr11:55482008	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61919675	ENSG00000134612.10	FOLH1B	10.43	2.73e-24	5.22e-18	0.82	0.31	Systemic lupus erythematosus;	chr11:55483073	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs77718339	ENSG00000134612.10	FOLH1B	10.43	2.73e-24	5.22e-18	0.82	0.31	Systemic lupus erythematosus;	chr11:55484830	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs2125587	ENSG00000134612.10	FOLH1B	10.43	2.73e-24	5.22e-18	0.82	0.31	Systemic lupus erythematosus;	chr11:55486102	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.85	rs2169004	ENSG00000134612.10	FOLH1B	10.43	2.73e-24	5.22e-18	0.82	0.31	Systemic lupus erythematosus;	chr11:55486216	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61919676	ENSG00000134612.10	FOLH1B	10.43	2.73e-24	5.22e-18	0.82	0.31	Systemic lupus erythematosus;	chr11:55486639	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61919678	ENSG00000134612.10	FOLH1B	10.43	2.73e-24	5.22e-18	0.82	0.31	Systemic lupus erythematosus;	chr11:55487844	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.85	rs61919679	ENSG00000134612.10	FOLH1B	10.43	2.73e-24	5.22e-18	0.82	0.31	Systemic lupus erythematosus;	chr11:55489404	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs7942480	ENSG00000134612.10	FOLH1B	10.43	2.73e-24	5.22e-18	0.82	0.31	Systemic lupus erythematosus;	chr11:55490004	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs56045005	ENSG00000134612.10	FOLH1B	10.43	2.73e-24	5.22e-18	0.82	0.31	Systemic lupus erythematosus;	chr11:55490322	chr11:89639227~89698718:+
BRCA	trans	rs9467773	0.626	rs9379860	ENSG00000242375.1	RP11-498P14.3	-10.43	2.73e-24	5.23e-18	-0.43	-0.31	Intelligence (multi-trait analysis);	chr6:26370377	chr9:97195351~97197687:-
BRCA	trans	rs9329221	0.655	rs656319	ENSG00000253893.2	FAM85B	10.43	2.74e-24	5.24e-18	0.38	0.31	Neuroticism;	chr8:9956901	chr8:8167819~8226614:-
BRCA	trans	rs7927370	1	rs117110854	ENSG00000134612.10	FOLH1B	10.43	2.75e-24	5.25e-18	0.81	0.31	Systemic lupus erythematosus;	chr11:55558287	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.85	rs75752693	ENSG00000134612.10	FOLH1B	10.43	2.75e-24	5.25e-18	0.81	0.31	Systemic lupus erythematosus;	chr11:55558390	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61919578	ENSG00000134612.10	FOLH1B	10.43	2.75e-24	5.25e-18	0.81	0.31	Systemic lupus erythematosus;	chr11:55558903	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61919579	ENSG00000134612.10	FOLH1B	10.43	2.75e-24	5.25e-18	0.81	0.31	Systemic lupus erythematosus;	chr11:55558978	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61919580	ENSG00000134612.10	FOLH1B	10.43	2.75e-24	5.25e-18	0.81	0.31	Systemic lupus erythematosus;	chr11:55558982	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs17581742	ENSG00000134612.10	FOLH1B	10.43	2.75e-24	5.25e-18	0.81	0.31	Systemic lupus erythematosus;	chr11:55559048	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61919581	ENSG00000134612.10	FOLH1B	10.43	2.75e-24	5.25e-18	0.81	0.31	Systemic lupus erythematosus;	chr11:55560186	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.557	rs61919582	ENSG00000134612.10	FOLH1B	10.43	2.75e-24	5.25e-18	0.81	0.31	Systemic lupus erythematosus;	chr11:55560455	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61919583	ENSG00000134612.10	FOLH1B	10.43	2.75e-24	5.25e-18	0.81	0.31	Systemic lupus erythematosus;	chr11:55560577	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61919585	ENSG00000134612.10	FOLH1B	10.43	2.75e-24	5.25e-18	0.81	0.31	Systemic lupus erythematosus;	chr11:55560924	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61919586	ENSG00000134612.10	FOLH1B	10.43	2.75e-24	5.25e-18	0.81	0.31	Systemic lupus erythematosus;	chr11:55561074	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61919587	ENSG00000134612.10	FOLH1B	10.43	2.75e-24	5.25e-18	0.81	0.31	Systemic lupus erythematosus;	chr11:55561430	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61919613	ENSG00000134612.10	FOLH1B	10.43	2.75e-24	5.25e-18	0.81	0.31	Systemic lupus erythematosus;	chr11:55561629	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61919614	ENSG00000134612.10	FOLH1B	10.43	2.75e-24	5.25e-18	0.81	0.31	Systemic lupus erythematosus;	chr11:55561735	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs76097560	ENSG00000134612.10	FOLH1B	10.43	2.75e-24	5.25e-18	0.81	0.31	Systemic lupus erythematosus;	chr11:55562377	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs76388671	ENSG00000134612.10	FOLH1B	10.43	2.75e-24	5.25e-18	0.81	0.31	Systemic lupus erythematosus;	chr11:55562378	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61919616	ENSG00000134612.10	FOLH1B	10.43	2.75e-24	5.25e-18	0.81	0.31	Systemic lupus erythematosus;	chr11:55562612	chr11:89639227~89698718:+
BRCA	trans	rs864643	0.524	rs72869124	ENSG00000183298.5	RP11-556K13.1	10.43	2.75e-24	5.26e-18	0.61	0.31	Attention deficit hyperactivity disorder;	chr3:39469788	chr1:101786340~101787219:-
BRCA	trans	rs5751901	1	rs5751901	ENSG00000280208.1	RP11-341D18.4	-10.43	2.76e-24	5.28e-18	-0.35	-0.31	Protein quantitative trait loci;	chr22:24596299	chr13:18253526~18270822:-
BRCA	trans	rs55665837	0.539	rs10500804	ENSG00000236360.2	RP11-334A14.2	10.43	2.83e-24	5.4e-18	0.41	0.31	Vitamin D levels;	chr11:14888727	chr1:52993201~52993702:-
BRCA	trans	rs877636	0.702	rs773110	ENSG00000242970.2	AC068522.4	10.42	2.85e-24	5.44e-18	0.46	0.31	Cognitive function;	chr12:55981353	chr8:58588420~58588764:-
BRCA	trans	rs2727020	0.894	rs3862342	ENSG00000134612.10	FOLH1B	-10.42	2.87e-24	5.48e-18	-0.42	-0.31	Coronary artery disease;	chr11:49335491	chr11:89639227~89698718:+
BRCA	trans	rs9650657	0.504	rs10109167	ENSG00000253893.2	FAM85B	10.42	2.87e-24	5.49e-18	0.39	0.31	Neuroticism;	chr8:11176016	chr8:8167819~8226614:-
BRCA	trans	rs7927370	0.867	rs61894886	ENSG00000134612.10	FOLH1B	10.42	2.91e-24	5.55e-18	0.8	0.31	Systemic lupus erythematosus;	chr11:55264591	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61894222	ENSG00000134612.10	FOLH1B	10.42	2.95e-24	5.62e-18	0.8	0.31	Systemic lupus erythematosus;	chr11:55576817	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.702	rs56111016	ENSG00000134612.10	FOLH1B	10.42	2.99e-24	5.71e-18	0.8	0.31	Systemic lupus erythematosus;	chr11:55572990	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.85	rs56352135	ENSG00000134612.10	FOLH1B	10.42	2.99e-24	5.71e-18	0.8	0.31	Systemic lupus erythematosus;	chr11:55573076	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs55636526	ENSG00000134612.10	FOLH1B	10.42	2.99e-24	5.71e-18	0.8	0.31	Systemic lupus erythematosus;	chr11:55574250	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs56118676	ENSG00000134612.10	FOLH1B	10.42	2.99e-24	5.71e-18	0.8	0.31	Systemic lupus erythematosus;	chr11:55574259	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs7112674	ENSG00000134612.10	FOLH1B	10.42	2.99e-24	5.71e-18	0.8	0.31	Systemic lupus erythematosus;	chr11:55574591	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.85	rs117436302	ENSG00000134612.10	FOLH1B	10.42	2.99e-24	5.71e-18	0.8	0.31	Systemic lupus erythematosus;	chr11:55575831	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs78253765	ENSG00000134612.10	FOLH1B	10.42	2.99e-24	5.71e-18	0.8	0.31	Systemic lupus erythematosus;	chr11:55575871	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61894220	ENSG00000134612.10	FOLH1B	10.42	2.99e-24	5.71e-18	0.8	0.31	Systemic lupus erythematosus;	chr11:55575978	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61894221	ENSG00000134612.10	FOLH1B	10.42	2.99e-24	5.71e-18	0.8	0.31	Systemic lupus erythematosus;	chr11:55576333	chr11:89639227~89698718:+
BRCA	trans	rs877636	0.702	rs773111	ENSG00000242970.2	AC068522.4	10.42	3e-24	5.72e-18	0.45	0.31	Cognitive function;	chr12:55981956	chr8:58588420~58588764:-
BRCA	trans	rs7927370	1	rs55654725	ENSG00000134612.10	FOLH1B	10.42	3.01e-24	5.73e-18	0.81	0.31	Systemic lupus erythematosus;	chr11:55563753	chr11:89639227~89698718:+
BRCA	trans	rs4276421	0.597	rs8188245	ENSG00000231752.4	EMBP1	-10.42	3.05e-24	5.81e-18	-0.41	-0.31	P wave duration;	chr5:46174762	chr1:121519112~121571892:+
BRCA	trans	rs7927370	1	rs117154767	ENSG00000134612.10	FOLH1B	10.42	3.08e-24	5.87e-18	0.84	0.31	Systemic lupus erythematosus;	chr11:55589265	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61895200	ENSG00000134612.10	FOLH1B	10.42	3.08e-24	5.87e-18	0.84	0.31	Systemic lupus erythematosus;	chr11:55589872	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61895201	ENSG00000134612.10	FOLH1B	10.42	3.08e-24	5.87e-18	0.84	0.31	Systemic lupus erythematosus;	chr11:55590688	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61895202	ENSG00000134612.10	FOLH1B	10.42	3.08e-24	5.87e-18	0.84	0.31	Systemic lupus erythematosus;	chr11:55590980	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61895203	ENSG00000134612.10	FOLH1B	10.42	3.08e-24	5.87e-18	0.84	0.31	Systemic lupus erythematosus;	chr11:55592252	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61895204	ENSG00000134612.10	FOLH1B	10.42	3.08e-24	5.87e-18	0.84	0.31	Systemic lupus erythematosus;	chr11:55592449	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs7128331	ENSG00000134612.10	FOLH1B	10.42	3.08e-24	5.87e-18	0.84	0.31	Systemic lupus erythematosus;	chr11:55593680	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs7124611	ENSG00000134612.10	FOLH1B	10.42	3.08e-24	5.87e-18	0.84	0.31	Systemic lupus erythematosus;	chr11:55593713	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs7124739	ENSG00000134612.10	FOLH1B	10.42	3.08e-24	5.87e-18	0.84	0.31	Systemic lupus erythematosus;	chr11:55593796	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs55669714	ENSG00000134612.10	FOLH1B	10.42	3.08e-24	5.87e-18	0.84	0.31	Systemic lupus erythematosus;	chr11:55594917	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs56058343	ENSG00000134612.10	FOLH1B	10.42	3.08e-24	5.87e-18	0.84	0.31	Systemic lupus erythematosus;	chr11:55594952	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61895206	ENSG00000134612.10	FOLH1B	10.42	3.08e-24	5.87e-18	0.84	0.31	Systemic lupus erythematosus;	chr11:55595111	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61895207	ENSG00000134612.10	FOLH1B	10.42	3.08e-24	5.87e-18	0.84	0.31	Systemic lupus erythematosus;	chr11:55595350	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.867	rs74924666	ENSG00000134612.10	FOLH1B	10.42	3.08e-24	5.87e-18	0.84	0.31	Systemic lupus erythematosus;	chr11:55595568	chr11:89639227~89698718:+
BRCA	trans	rs11098499	0.722	rs28713555	ENSG00000275858.1	RP11-291L22.8	10.41	3.12e-24	5.94e-18	0.37	0.31	Corneal astigmatism;	chr4:119330840	chr10:38450738~38451069:-
BRCA	trans	rs3806843	1	rs10477033	ENSG00000231043.3	AC007238.1	-10.41	3.14e-24	5.97e-18	-0.36	-0.31	Depressive symptoms (multi-trait analysis);	chr5:140790018	chr2:58460292~58462032:-
BRCA	trans	rs13217239	0.646	rs9379956	ENSG00000242375.1	RP11-498P14.3	-10.41	3.23e-24	6.14e-18	-0.43	-0.31	Schizophrenia;	chr6:27065956	chr9:97195351~97197687:-
BRCA	trans	rs7927370	0.702	rs61894223	ENSG00000134612.10	FOLH1B	10.41	3.26e-24	6.2e-18	0.8	0.31	Systemic lupus erythematosus;	chr11:55577173	chr11:89639227~89698718:+
BRCA	trans	rs9329221	0.683	rs688491	ENSG00000253893.2	FAM85B	10.41	3.27e-24	6.21e-18	0.38	0.31	Neuroticism;	chr8:10027313	chr8:8167819~8226614:-
BRCA	trans	rs747782	0.639	rs17198985	ENSG00000134612.10	FOLH1B	10.41	3.3e-24	6.27e-18	0.52	0.31	Intraocular pressure;	chr11:48162013	chr11:89639227~89698718:+
BRCA	trans	rs11098499	0.779	rs10857066	ENSG00000275858.1	RP11-291L22.8	10.41	3.32e-24	6.3e-18	0.37	0.31	Corneal astigmatism;	chr4:119365441	chr10:38450738~38451069:-
BRCA	trans	rs2727020	1	rs2727020	ENSG00000134612.10	FOLH1B	10.41	3.33e-24	6.32e-18	0.42	0.31	Coronary artery disease;	chr11:49089855	chr11:89639227~89698718:+
BRCA	trans	rs9876781	1	rs7651407	ENSG00000225528.1	RP3-370M22.8	-10.4	3.45e-24	6.55e-18	-0.34	-0.31	Longevity;	chr3:48402409	chr22:39960397~39964683:+
BRCA	trans	rs9650657	0.504	rs10108347	ENSG00000253893.2	FAM85B	10.4	3.46e-24	6.56e-18	0.39	0.31	Neuroticism;	chr8:11176008	chr8:8167819~8226614:-
BRCA	trans	rs877636	0.702	rs773112	ENSG00000242970.2	AC068522.4	10.4	3.47e-24	6.59e-18	0.45	0.31	Cognitive function;	chr12:55982097	chr8:58588420~58588764:-
BRCA	trans	rs11098499	0.789	rs10212719	ENSG00000275858.1	RP11-291L22.8	10.4	3.53e-24	6.69e-18	0.37	0.31	Corneal astigmatism;	chr4:119333282	chr10:38450738~38451069:-
BRCA	trans	rs9876781	1	rs28824259	ENSG00000225528.1	RP3-370M22.8	-10.4	3.54e-24	6.71e-18	-0.34	-0.31	Longevity;	chr3:48384185	chr22:39960397~39964683:+
BRCA	trans	rs9876781	1	rs12487542	ENSG00000225528.1	RP3-370M22.8	-10.4	3.54e-24	6.71e-18	-0.34	-0.31	Longevity;	chr3:48384586	chr22:39960397~39964683:+
BRCA	trans	rs9876781	1	rs73074358	ENSG00000225528.1	RP3-370M22.8	-10.4	3.54e-24	6.71e-18	-0.34	-0.31	Longevity;	chr3:48385757	chr22:39960397~39964683:+
BRCA	trans	rs9876781	0.967	rs34761139	ENSG00000225528.1	RP3-370M22.8	-10.4	3.54e-24	6.71e-18	-0.34	-0.31	Longevity;	chr3:48386489	chr22:39960397~39964683:+
BRCA	trans	rs9876781	0.868	rs9875280	ENSG00000225528.1	RP3-370M22.8	-10.4	3.54e-24	6.71e-18	-0.34	-0.31	Longevity;	chr3:48387420	chr22:39960397~39964683:+
BRCA	trans	rs9876781	1	rs6796491	ENSG00000225528.1	RP3-370M22.8	-10.4	3.54e-24	6.71e-18	-0.34	-0.31	Longevity;	chr3:48388977	chr22:39960397~39964683:+
BRCA	trans	rs4276421	0.509	rs10062391	ENSG00000231752.4	EMBP1	10.4	3.54e-24	6.71e-18	0.43	0.31	P wave duration;	chr5:45994818	chr1:121519112~121571892:+
BRCA	trans	rs864643	0.678	rs625898	ENSG00000183298.5	RP11-556K13.1	-10.4	3.58e-24	6.79e-18	-0.47	-0.31	Attention deficit hyperactivity disorder;	chr3:39471624	chr1:101786340~101787219:-
BRCA	trans	rs7927370	1	rs61916376	ENSG00000134612.10	FOLH1B	10.4	3.58e-24	6.79e-18	0.82	0.31	Systemic lupus erythematosus;	chr11:55444449	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs117311484	ENSG00000134612.10	FOLH1B	10.4	3.65e-24	6.92e-18	0.82	0.31	Systemic lupus erythematosus;	chr11:55457259	chr11:89639227~89698718:+
BRCA	trans	rs4276421	0.53	rs4552614	ENSG00000231752.4	EMBP1	10.4	3.74e-24	7.08e-18	0.43	0.31	P wave duration;	chr5:46017620	chr1:121519112~121571892:+
BRCA	trans	rs13217239	0.608	rs6930508	ENSG00000242375.1	RP11-498P14.3	-10.39	3.89e-24	7.35e-18	-0.43	-0.31	Schizophrenia;	chr6:27085363	chr9:97195351~97197687:-
BRCA	trans	rs13217239	0.646	rs2142685	ENSG00000242375.1	RP11-498P14.3	-10.39	3.89e-24	7.35e-18	-0.43	-0.31	Schizophrenia;	chr6:27086718	chr9:97195351~97197687:-
BRCA	trans	rs7927370	1	rs56291726	ENSG00000134612.10	FOLH1B	10.39	3.94e-24	7.45e-18	0.77	0.31	Systemic lupus erythematosus;	chr11:55443109	chr11:89639227~89698718:+
BRCA	trans	rs11098499	0.564	rs11098507	ENSG00000275858.1	RP11-291L22.8	10.39	3.95e-24	7.46e-18	0.37	0.31	Corneal astigmatism;	chr4:119367131	chr10:38450738~38451069:-
BRCA	trans	rs877636	0.702	rs773109	ENSG00000242970.2	AC068522.4	10.39	4.01e-24	7.57e-18	0.45	0.31	Cognitive function;	chr12:55980911	chr8:58588420~58588764:-
BRCA	trans	rs7944735	0.767	rs1017875	ENSG00000134612.10	FOLH1B	10.39	4.11e-24	7.77e-18	0.46	0.31	Intraocular pressure;	chr11:47977666	chr11:89639227~89698718:+
BRCA	trans	rs3806843	0.932	rs2563257	ENSG00000231043.3	AC007238.1	10.38	4.16e-24	7.86e-18	0.36	0.31	Depressive symptoms (multi-trait analysis);	chr5:140760944	chr2:58460292~58462032:-
BRCA	trans	rs3806843	0.766	rs801399	ENSG00000231043.3	AC007238.1	10.38	4.27e-24	8.06e-18	0.36	0.31	Depressive symptoms (multi-trait analysis);	chr5:140655259	chr2:58460292~58462032:-
BRCA	trans	rs7927370	1	rs61916396	ENSG00000134612.10	FOLH1B	10.38	4.29e-24	8.08e-18	0.82	0.31	Systemic lupus erythematosus;	chr11:55445135	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs6591466	ENSG00000134612.10	FOLH1B	10.38	4.29e-24	8.08e-18	0.82	0.31	Systemic lupus erythematosus;	chr11:55445730	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs116969778	ENSG00000134612.10	FOLH1B	10.38	4.29e-24	8.08e-18	0.82	0.31	Systemic lupus erythematosus;	chr11:55446446	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61916398	ENSG00000134612.10	FOLH1B	10.38	4.29e-24	8.08e-18	0.82	0.31	Systemic lupus erythematosus;	chr11:55448772	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61916400	ENSG00000134612.10	FOLH1B	10.38	4.29e-24	8.08e-18	0.82	0.31	Systemic lupus erythematosus;	chr11:55450670	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61916402	ENSG00000134612.10	FOLH1B	10.38	4.29e-24	8.08e-18	0.82	0.31	Systemic lupus erythematosus;	chr11:55452238	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61916404	ENSG00000134612.10	FOLH1B	10.38	4.29e-24	8.08e-18	0.82	0.31	Systemic lupus erythematosus;	chr11:55454100	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61916405	ENSG00000134612.10	FOLH1B	10.38	4.29e-24	8.08e-18	0.82	0.31	Systemic lupus erythematosus;	chr11:55454300	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs76906133	ENSG00000134612.10	FOLH1B	10.38	4.29e-24	8.08e-18	0.82	0.31	Systemic lupus erythematosus;	chr11:55457219	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61916411	ENSG00000134612.10	FOLH1B	10.38	4.29e-24	8.08e-18	0.82	0.31	Systemic lupus erythematosus;	chr11:55457429	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs116966729	ENSG00000134612.10	FOLH1B	10.38	4.29e-24	8.08e-18	0.82	0.31	Systemic lupus erythematosus;	chr11:55458355	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs74625780	ENSG00000134612.10	FOLH1B	10.38	4.29e-24	8.08e-18	0.82	0.31	Systemic lupus erythematosus;	chr11:55458397	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs76426677	ENSG00000134612.10	FOLH1B	10.38	4.29e-24	8.08e-18	0.82	0.31	Systemic lupus erythematosus;	chr11:55458445	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.702	rs61916413	ENSG00000134612.10	FOLH1B	10.38	4.29e-24	8.08e-18	0.82	0.31	Systemic lupus erythematosus;	chr11:55458916	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.702	rs118083243	ENSG00000134612.10	FOLH1B	10.38	4.29e-24	8.08e-18	0.82	0.31	Systemic lupus erythematosus;	chr11:55460242	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61916453	ENSG00000134612.10	FOLH1B	10.38	4.29e-24	8.08e-18	0.82	0.31	Systemic lupus erythematosus;	chr11:55466250	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.702	rs61916455	ENSG00000134612.10	FOLH1B	10.38	4.29e-24	8.08e-18	0.82	0.31	Systemic lupus erythematosus;	chr11:55466356	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.85	rs61916456	ENSG00000134612.10	FOLH1B	10.38	4.29e-24	8.08e-18	0.82	0.31	Systemic lupus erythematosus;	chr11:55466686	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61916457	ENSG00000134612.10	FOLH1B	10.38	4.29e-24	8.08e-18	0.82	0.31	Systemic lupus erythematosus;	chr11:55466710	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61917983	ENSG00000134612.10	FOLH1B	10.38	4.29e-24	8.08e-18	0.82	0.31	Systemic lupus erythematosus;	chr11:55468336	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61917984	ENSG00000134612.10	FOLH1B	10.38	4.29e-24	8.08e-18	0.82	0.31	Systemic lupus erythematosus;	chr11:55470253	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.85	rs61917985	ENSG00000134612.10	FOLH1B	10.38	4.29e-24	8.08e-18	0.82	0.31	Systemic lupus erythematosus;	chr11:55470587	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.85	rs55873524	ENSG00000134612.10	FOLH1B	10.38	4.29e-24	8.08e-18	0.82	0.31	Systemic lupus erythematosus;	chr11:55472039	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61917991	ENSG00000134612.10	FOLH1B	10.38	4.29e-24	8.08e-18	0.82	0.31	Systemic lupus erythematosus;	chr11:55473504	chr11:89639227~89698718:+
BRCA	trans	rs11098499	0.866	rs6857892	ENSG00000275858.1	RP11-291L22.8	10.38	4.31e-24	8.1e-18	0.37	0.31	Corneal astigmatism;	chr4:119361541	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.909	rs28581362	ENSG00000275858.1	RP11-291L22.8	10.38	4.31e-24	8.1e-18	0.37	0.31	Corneal astigmatism;	chr4:119362393	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.82	rs12503082	ENSG00000275858.1	RP11-291L22.8	10.38	4.31e-24	8.1e-18	0.37	0.31	Corneal astigmatism;	chr4:119363162	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.866	rs12499602	ENSG00000275858.1	RP11-291L22.8	10.38	4.31e-24	8.1e-18	0.37	0.31	Corneal astigmatism;	chr4:119363232	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.774	rs11098505	ENSG00000275858.1	RP11-291L22.8	10.38	4.31e-24	8.1e-18	0.37	0.31	Corneal astigmatism;	chr4:119363472	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.866	rs13105020	ENSG00000275858.1	RP11-291L22.8	10.38	4.31e-24	8.1e-18	0.37	0.31	Corneal astigmatism;	chr4:119364533	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.866	rs6824111	ENSG00000275858.1	RP11-291L22.8	10.38	4.31e-24	8.1e-18	0.37	0.31	Corneal astigmatism;	chr4:119364813	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.775	rs10029303	ENSG00000275858.1	RP11-291L22.8	10.38	4.31e-24	8.1e-18	0.37	0.31	Corneal astigmatism;	chr4:119365600	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.866	rs9995136	ENSG00000275858.1	RP11-291L22.8	10.38	4.31e-24	8.1e-18	0.37	0.31	Corneal astigmatism;	chr4:119365690	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.866	rs13125526	ENSG00000275858.1	RP11-291L22.8	10.38	4.31e-24	8.1e-18	0.37	0.31	Corneal astigmatism;	chr4:119366864	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.866	rs12513310	ENSG00000275858.1	RP11-291L22.8	10.38	4.31e-24	8.1e-18	0.37	0.31	Corneal astigmatism;	chr4:119366884	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.866	rs12510451	ENSG00000275858.1	RP11-291L22.8	10.38	4.31e-24	8.1e-18	0.37	0.31	Corneal astigmatism;	chr4:119367988	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.774	rs73842616	ENSG00000275858.1	RP11-291L22.8	10.38	4.31e-24	8.1e-18	0.37	0.31	Corneal astigmatism;	chr4:119369528	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.645	rs72676059	ENSG00000275858.1	RP11-291L22.8	10.38	4.31e-24	8.1e-18	0.37	0.31	Corneal astigmatism;	chr4:119369673	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.569	rs55845118	ENSG00000275858.1	RP11-291L22.8	10.38	4.31e-24	8.1e-18	0.37	0.31	Corneal astigmatism;	chr4:119369758	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.866	rs7677068	ENSG00000275858.1	RP11-291L22.8	10.38	4.31e-24	8.1e-18	0.37	0.31	Corneal astigmatism;	chr4:119370549	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.866	rs9991221	ENSG00000275858.1	RP11-291L22.8	10.38	4.31e-24	8.1e-18	0.37	0.31	Corneal astigmatism;	chr4:119370952	chr10:38450738~38451069:-
BRCA	trans	rs4276421	0.55	rs10473403	ENSG00000231752.4	EMBP1	10.38	4.38e-24	8.24e-18	0.43	0.31	P wave duration;	chr5:45921272	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.511	rs62371976	ENSG00000231752.4	EMBP1	10.38	4.47e-24	8.4e-18	0.43	0.31	P wave duration;	chr5:45914178	chr1:121519112~121571892:+
BRCA	trans	rs9876781	0.624	rs12491849	ENSG00000235912.1	RP1-159A19.3	-10.38	4.51e-24	8.48e-18	-0.39	-0.31	Longevity;	chr3:48489975	chr1:27649419~27649610:+
BRCA	trans	rs13190036	0.591	rs78523677	ENSG00000228305.2	AC016734.2	-10.37	4.6e-24	8.64e-18	-0.41	-0.31	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177124102	chr2:63622178~63622831:-
BRCA	trans	rs7927370	1	rs55708507	ENSG00000134612.10	FOLH1B	10.37	4.67e-24	8.76e-18	0.8	0.31	Systemic lupus erythematosus;	chr11:55573678	chr11:89639227~89698718:+
BRCA	trans	rs877636	0.702	rs61937249	ENSG00000242970.2	AC068522.4	10.37	4.69e-24	8.8e-18	0.45	0.31	Cognitive function;	chr12:55988132	chr8:58588420~58588764:-
BRCA	trans	rs11098499	0.863	rs6858592	ENSG00000275858.1	RP11-291L22.8	10.37	4.69e-24	8.81e-18	0.37	0.31	Corneal astigmatism;	chr4:119537537	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.738	rs28687057	ENSG00000275858.1	RP11-291L22.8	10.37	4.79e-24	8.99e-18	0.37	0.31	Corneal astigmatism;	chr4:119359657	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.775	rs67281037	ENSG00000275858.1	RP11-291L22.8	10.37	4.79e-24	8.99e-18	0.37	0.31	Corneal astigmatism;	chr4:119360002	chr10:38450738~38451069:-
BRCA	trans	rs10028773	0.506	rs12374346	ENSG00000275858.1	RP11-291L22.8	10.37	4.79e-24	8.99e-18	0.37	0.31	Educational attainment;	chr4:119360550	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.866	rs12374244	ENSG00000275858.1	RP11-291L22.8	10.37	4.79e-24	8.99e-18	0.37	0.31	Corneal astigmatism;	chr4:119360817	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.866	rs12374352	ENSG00000275858.1	RP11-291L22.8	10.37	4.79e-24	8.99e-18	0.37	0.31	Corneal astigmatism;	chr4:119360822	chr10:38450738~38451069:-
BRCA	trans	rs941207	0.756	rs7315472	ENSG00000228224.3	NACAP1	-10.37	4.88e-24	9.15e-18	-0.39	-0.31	Platelet count;	chr12:56648276	chr8:101361794~101372707:+
BRCA	trans	rs4276421	0.55	rs62373044	ENSG00000231752.4	EMBP1	10.37	4.96e-24	9.31e-18	0.43	0.31	P wave duration;	chr5:46005052	chr1:121519112~121571892:+
BRCA	trans	rs11098499	0.863	rs1155576	ENSG00000275858.1	RP11-291L22.8	10.37	5.01e-24	9.4e-18	0.37	0.31	Corneal astigmatism;	chr4:119529004	chr10:38450738~38451069:-
BRCA	trans	rs7927370	1	rs61919569	ENSG00000134612.10	FOLH1B	10.37	5.01e-24	9.4e-18	0.79	0.31	Systemic lupus erythematosus;	chr11:55554988	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61919570	ENSG00000134612.10	FOLH1B	10.37	5.01e-24	9.4e-18	0.79	0.31	Systemic lupus erythematosus;	chr11:55555014	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs17581700	ENSG00000134612.10	FOLH1B	10.37	5.01e-24	9.4e-18	0.79	0.31	Systemic lupus erythematosus;	chr11:55555130	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61919571	ENSG00000134612.10	FOLH1B	10.37	5.01e-24	9.4e-18	0.79	0.31	Systemic lupus erythematosus;	chr11:55555426	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs77650525	ENSG00000134612.10	FOLH1B	10.37	5.01e-24	9.4e-18	0.79	0.31	Systemic lupus erythematosus;	chr11:55555445	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61919573	ENSG00000134612.10	FOLH1B	10.37	5.01e-24	9.4e-18	0.79	0.31	Systemic lupus erythematosus;	chr11:55555871	chr11:89639227~89698718:+
BRCA	trans	rs3806843	0.966	rs10036519	ENSG00000231043.3	AC007238.1	10.37	5.02e-24	9.4e-18	0.36	0.31	Depressive symptoms (multi-trait analysis);	chr5:140772116	chr2:58460292~58462032:-
BRCA	trans	rs7927370	1	rs7109010	ENSG00000134612.10	FOLH1B	10.36	5.04e-24	9.44e-18	0.82	0.31	Systemic lupus erythematosus;	chr11:55369910	chr11:89639227~89698718:+
BRCA	trans	rs877636	0.74	rs772920	ENSG00000242970.2	AC068522.4	10.36	5.08e-24	9.52e-18	0.45	0.31	Cognitive function;	chr12:55996580	chr8:58588420~58588764:-
BRCA	trans	rs11098499	0.697	rs35280960	ENSG00000275858.1	RP11-291L22.8	10.36	5.1e-24	9.54e-18	0.37	0.31	Corneal astigmatism;	chr4:119335904	chr10:38450738~38451069:-
BRCA	trans	rs7927370	1	rs55770365	ENSG00000134612.10	FOLH1B	10.36	5.12e-24	9.57e-18	0.81	0.31	Systemic lupus erythematosus;	chr11:55509404	chr11:89639227~89698718:+
BRCA	trans	rs16937956	0.626	rs34922792	ENSG00000266891.1	RP11-692N5.2	10.36	5.16e-24	9.64e-18	0.42	0.31	Body mass index;	chr11:8394952	chr18:9734882~9735602:-
BRCA	trans	rs4276421	0.571	rs4431353	ENSG00000231752.4	EMBP1	10.36	5.19e-24	9.68e-18	0.43	0.31	P wave duration;	chr5:45926171	chr1:121519112~121571892:+
BRCA	trans	rs11098499	0.863	rs10018280	ENSG00000275858.1	RP11-291L22.8	10.36	5.22e-24	9.74e-18	0.37	0.31	Corneal astigmatism;	chr4:119556984	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.863	rs6534141	ENSG00000275858.1	RP11-291L22.8	10.36	5.22e-24	9.74e-18	0.37	0.31	Corneal astigmatism;	chr4:119564068	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.863	rs2127823	ENSG00000275858.1	RP11-291L22.8	10.36	5.22e-24	9.74e-18	0.37	0.31	Corneal astigmatism;	chr4:119564515	chr10:38450738~38451069:-
BRCA	trans	rs9876781	1	rs9826195	ENSG00000225528.1	RP3-370M22.8	-10.36	5.28e-24	9.84e-18	-0.34	-0.31	Longevity;	chr3:48392157	chr22:39960397~39964683:+
BRCA	trans	rs9876781	0.967	rs9864815	ENSG00000225528.1	RP3-370M22.8	-10.36	5.28e-24	9.84e-18	-0.34	-0.31	Longevity;	chr3:48392588	chr22:39960397~39964683:+
BRCA	trans	rs9876781	1	rs9809843	ENSG00000225528.1	RP3-370M22.8	-10.36	5.28e-24	9.84e-18	-0.34	-0.31	Longevity;	chr3:48392923	chr22:39960397~39964683:+
BRCA	trans	rs11098499	0.775	rs10021601	ENSG00000275858.1	RP11-291L22.8	10.36	5.28e-24	9.85e-18	0.37	0.31	Corneal astigmatism;	chr4:119361408	chr10:38450738~38451069:-
BRCA	trans	rs9329221	0.592	rs7832708	ENSG00000253893.2	FAM85B	-10.36	5.31e-24	9.91e-18	-0.38	-0.31	Neuroticism;	chr8:10332530	chr8:8167819~8226614:-
BRCA	trans	rs7927370	1	rs55828496	ENSG00000134612.10	FOLH1B	10.36	5.49e-24	1.02e-17	0.79	0.31	Systemic lupus erythematosus;	chr11:55554185	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs17496724	ENSG00000134612.10	FOLH1B	10.36	5.49e-24	1.02e-17	0.79	0.31	Systemic lupus erythematosus;	chr11:55554623	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs74331841	ENSG00000134612.10	FOLH1B	10.36	5.49e-24	1.02e-17	0.79	0.31	Systemic lupus erythematosus;	chr11:55554946	chr11:89639227~89698718:+
BRCA	trans	rs13217239	0.646	rs12527111	ENSG00000242375.1	RP11-498P14.3	10.35	5.57e-24	1.04e-17	0.43	0.31	Schizophrenia;	chr6:27038696	chr9:97195351~97197687:-
BRCA	trans	rs6424115	1	rs4237	ENSG00000228217.1	AL390877.1	-10.35	5.64e-24	1.05e-17	-0.37	-0.31	Immature fraction of reticulocytes;	chr1:23787639	chr1:117778087~117778506:-
BRCA	trans	rs13190036	0.551	rs1052432	ENSG00000228305.2	AC016734.2	-10.35	5.69e-24	1.06e-17	-0.41	-0.31	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177137188	chr2:63622178~63622831:-
BRCA	trans	rs3806843	0.966	rs7737424	ENSG00000231043.3	AC007238.1	-10.35	5.72e-24	1.07e-17	-0.36	-0.31	Depressive symptoms (multi-trait analysis);	chr5:140766760	chr2:58460292~58462032:-
BRCA	trans	rs3806843	0.966	rs12659129	ENSG00000231043.3	AC007238.1	-10.35	5.72e-24	1.07e-17	-0.36	-0.31	Depressive symptoms (multi-trait analysis);	chr5:140767663	chr2:58460292~58462032:-
BRCA	trans	rs3806843	0.932	rs2563256	ENSG00000231043.3	AC007238.1	10.35	5.72e-24	1.07e-17	0.36	0.31	Depressive symptoms (multi-trait analysis);	chr5:140762194	chr2:58460292~58462032:-
BRCA	trans	rs3806843	0.966	rs2563255	ENSG00000231043.3	AC007238.1	10.35	5.72e-24	1.07e-17	0.36	0.31	Depressive symptoms (multi-trait analysis);	chr5:140762962	chr2:58460292~58462032:-
BRCA	trans	rs3806843	0.9	rs2563254	ENSG00000231043.3	AC007238.1	10.35	5.72e-24	1.07e-17	0.36	0.31	Depressive symptoms (multi-trait analysis);	chr5:140763116	chr2:58460292~58462032:-
BRCA	trans	rs877636	0.692	rs11171739	ENSG00000224553.1	AC008065.1	10.35	5.72e-24	1.07e-17	0.34	0.31	Cognitive function;	chr12:56076841	chr2:171374931~171375278:-
BRCA	trans	rs13217239	0.646	rs10946897	ENSG00000242375.1	RP11-498P14.3	10.35	5.99e-24	1.11e-17	0.42	0.31	Schizophrenia;	chr6:27027472	chr9:97195351~97197687:-
BRCA	trans	rs74781061	0.929	rs12441932	ENSG00000227288.3	RP5-837I24.1	10.35	6.01e-24	1.12e-17	0.51	0.31	Endometriosis;	chr15:74617658	chr1:81501794~81503468:+
BRCA	trans	rs9876781	1	rs6442118	ENSG00000225528.1	RP3-370M22.8	-10.35	6.05e-24	1.13e-17	-0.33	-0.31	Longevity;	chr3:48398582	chr22:39960397~39964683:+
BRCA	trans	rs7113874	0.802	rs10128597	ENSG00000266891.1	RP11-692N5.2	10.34	6.15e-24	1.14e-17	0.41	0.31	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8673283	chr18:9734882~9735602:-
BRCA	trans	rs11098499	0.863	rs3775858	ENSG00000275858.1	RP11-291L22.8	10.34	6.19e-24	1.15e-17	0.37	0.31	Corneal astigmatism;	chr4:119564873	chr10:38450738~38451069:-
BRCA	trans	rs877636	0.859	rs3741499	ENSG00000242970.2	AC068522.4	-10.34	6.26e-24	1.16e-17	-0.42	-0.31	Cognitive function;	chr12:56080595	chr8:58588420~58588764:-
BRCA	trans	rs9876781	1	rs11712561	ENSG00000225528.1	RP3-370M22.8	-10.34	6.33e-24	1.18e-17	-0.34	-0.31	Longevity;	chr3:48393807	chr22:39960397~39964683:+
BRCA	trans	rs864643	0.524	rs72869131	ENSG00000183298.5	RP11-556K13.1	10.34	6.34e-24	1.18e-17	0.59	0.31	Attention deficit hyperactivity disorder;	chr3:39472959	chr1:101786340~101787219:-
BRCA	trans	rs7927370	1	rs56266612	ENSG00000134612.10	FOLH1B	10.34	6.4e-24	1.19e-17	0.79	0.31	Systemic lupus erythematosus;	chr11:55537486	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61917927	ENSG00000134612.10	FOLH1B	10.34	6.4e-24	1.19e-17	0.79	0.31	Systemic lupus erythematosus;	chr11:55537694	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs56152577	ENSG00000134612.10	FOLH1B	10.34	6.4e-24	1.19e-17	0.79	0.31	Systemic lupus erythematosus;	chr11:55540304	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.85	rs61917934	ENSG00000134612.10	FOLH1B	10.34	6.4e-24	1.19e-17	0.79	0.31	Systemic lupus erythematosus;	chr11:55542372	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs17496054	ENSG00000134612.10	FOLH1B	10.34	6.4e-24	1.19e-17	0.79	0.31	Systemic lupus erythematosus;	chr11:55542804	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs55881253	ENSG00000134612.10	FOLH1B	10.34	6.4e-24	1.19e-17	0.79	0.31	Systemic lupus erythematosus;	chr11:55543267	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61917936	ENSG00000134612.10	FOLH1B	10.34	6.4e-24	1.19e-17	0.79	0.31	Systemic lupus erythematosus;	chr11:55543941	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.85	rs61917937	ENSG00000134612.10	FOLH1B	10.34	6.4e-24	1.19e-17	0.79	0.31	Systemic lupus erythematosus;	chr11:55544109	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs77792938	ENSG00000134612.10	FOLH1B	10.34	6.4e-24	1.19e-17	0.79	0.31	Systemic lupus erythematosus;	chr11:55545353	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61917940	ENSG00000134612.10	FOLH1B	10.34	6.4e-24	1.19e-17	0.79	0.31	Systemic lupus erythematosus;	chr11:55545930	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61917941	ENSG00000134612.10	FOLH1B	10.34	6.4e-24	1.19e-17	0.79	0.31	Systemic lupus erythematosus;	chr11:55546929	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs77611127	ENSG00000134612.10	FOLH1B	10.34	6.4e-24	1.19e-17	0.79	0.31	Systemic lupus erythematosus;	chr11:55547095	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs10501336	ENSG00000134612.10	FOLH1B	10.34	6.4e-24	1.19e-17	0.79	0.31	Systemic lupus erythematosus;	chr11:55548043	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs17581191	ENSG00000134612.10	FOLH1B	10.34	6.4e-24	1.19e-17	0.79	0.31	Systemic lupus erythematosus;	chr11:55548547	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs55869276	ENSG00000134612.10	FOLH1B	10.34	6.4e-24	1.19e-17	0.79	0.31	Systemic lupus erythematosus;	chr11:55548936	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs1459105	ENSG00000134612.10	FOLH1B	10.34	6.4e-24	1.19e-17	0.79	0.31	Systemic lupus erythematosus;	chr11:55550141	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs1459106	ENSG00000134612.10	FOLH1B	10.34	6.4e-24	1.19e-17	0.79	0.31	Systemic lupus erythematosus;	chr11:55550338	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs17581261	ENSG00000134612.10	FOLH1B	10.34	6.4e-24	1.19e-17	0.79	0.31	Systemic lupus erythematosus;	chr11:55550734	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61917958	ENSG00000134612.10	FOLH1B	10.34	6.4e-24	1.19e-17	0.79	0.31	Systemic lupus erythematosus;	chr11:55551016	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs17581303	ENSG00000134612.10	FOLH1B	10.34	6.4e-24	1.19e-17	0.79	0.31	Systemic lupus erythematosus;	chr11:55551222	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61917959	ENSG00000134612.10	FOLH1B	10.34	6.4e-24	1.19e-17	0.79	0.31	Systemic lupus erythematosus;	chr11:55551306	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs17496444	ENSG00000134612.10	FOLH1B	10.34	6.4e-24	1.19e-17	0.79	0.31	Systemic lupus erythematosus;	chr11:55551536	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61919565	ENSG00000134612.10	FOLH1B	10.34	6.4e-24	1.19e-17	0.79	0.31	Systemic lupus erythematosus;	chr11:55552509	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs982276	ENSG00000134612.10	FOLH1B	10.34	6.4e-24	1.19e-17	0.79	0.31	Systemic lupus erythematosus;	chr11:55552623	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs982277	ENSG00000134612.10	FOLH1B	10.34	6.4e-24	1.19e-17	0.79	0.31	Systemic lupus erythematosus;	chr11:55552918	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs55972122	ENSG00000134612.10	FOLH1B	10.34	6.4e-24	1.19e-17	0.79	0.31	Systemic lupus erythematosus;	chr11:55553358	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs1504671	ENSG00000134612.10	FOLH1B	10.34	6.4e-24	1.19e-17	0.79	0.31	Systemic lupus erythematosus;	chr11:55553680	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs1504670	ENSG00000134612.10	FOLH1B	10.34	6.4e-24	1.19e-17	0.79	0.31	Systemic lupus erythematosus;	chr11:55553778	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs11828245	ENSG00000134612.10	FOLH1B	10.34	6.41e-24	1.19e-17	0.81	0.31	Systemic lupus erythematosus;	chr11:55349465	chr11:89639227~89698718:+
BRCA	trans	rs877636	0.702	rs773111	ENSG00000234513.1	AC073072.7	10.34	6.41e-24	1.19e-17	0.41	0.31	Cognitive function;	chr12:55981956	chr7:22773646~22773993:-
BRCA	trans	rs13217239	0.646	rs10456352	ENSG00000242375.1	RP11-498P14.3	10.34	6.43e-24	1.19e-17	0.42	0.31	Schizophrenia;	chr6:27022579	chr9:97195351~97197687:-
BRCA	trans	rs13217239	0.646	rs4583981	ENSG00000242375.1	RP11-498P14.3	10.34	6.43e-24	1.19e-17	0.42	0.31	Schizophrenia;	chr6:27024244	chr9:97195351~97197687:-
BRCA	trans	rs9876781	1	rs1563736	ENSG00000225528.1	RP3-370M22.8	-10.34	6.51e-24	1.21e-17	-0.33	-0.3	Longevity;	chr3:48395329	chr22:39960397~39964683:+
BRCA	trans	rs11098499	0.644	rs10012252	ENSG00000275858.1	RP11-291L22.8	10.34	6.61e-24	1.22e-17	0.36	0.3	Corneal astigmatism;	chr4:119637984	chr10:38450738~38451069:-
BRCA	trans	rs1580019	0.52	rs6945238	ENSG00000176826.14	FKBP9P1	10.33	6.68e-24	1.24e-17	0.42	0.3	Cognitive ability;	chr7:32606484	chr7:55681074~55713252:-
BRCA	trans	rs11098499	0.662	rs13108589	ENSG00000275858.1	RP11-291L22.8	10.33	6.75e-24	1.25e-17	0.37	0.3	Corneal astigmatism;	chr4:119346947	chr10:38450738~38451069:-
BRCA	trans	rs7927370	0.557	rs61897511	ENSG00000134612.10	FOLH1B	10.33	6.88e-24	1.27e-17	0.78	0.3	Systemic lupus erythematosus;	chr11:55243473	chr11:89639227~89698718:+
BRCA	trans	rs1347297	0.789	rs11688081	ENSG00000269800.1	PLEKHA3P1	10.33	7.09e-24	1.31e-17	0.34	0.3	Alzheimer disease and age of onset;	chr2:178416072	chr19:41521043~41521989:-
BRCA	trans	rs11098499	0.863	rs9997631	ENSG00000275858.1	RP11-291L22.8	10.33	7.21e-24	1.33e-17	0.37	0.3	Corneal astigmatism;	chr4:119548840	chr10:38450738~38451069:-
BRCA	trans	rs877636	0.74	rs772920	ENSG00000234513.1	AC073072.7	10.33	7.28e-24	1.34e-17	0.41	0.3	Cognitive function;	chr12:55996580	chr7:22773646~22773993:-
BRCA	trans	rs4276421	0.509	rs10067206	ENSG00000231752.4	EMBP1	10.33	7.32e-24	1.35e-17	0.43	0.3	P wave duration;	chr5:46027737	chr1:121519112~121571892:+
BRCA	trans	rs7927370	1	rs61894765	ENSG00000134612.10	FOLH1B	10.32	7.33e-24	1.35e-17	0.84	0.3	Systemic lupus erythematosus;	chr11:55692536	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61894766	ENSG00000134612.10	FOLH1B	10.32	7.33e-24	1.35e-17	0.84	0.3	Systemic lupus erythematosus;	chr11:55694997	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.85	rs61894767	ENSG00000134612.10	FOLH1B	10.32	7.33e-24	1.35e-17	0.84	0.3	Systemic lupus erythematosus;	chr11:55695448	chr11:89639227~89698718:+
BRCA	trans	rs13217239	0.574	rs9366680	ENSG00000242375.1	RP11-498P14.3	10.32	7.38e-24	1.36e-17	0.43	0.3	Schizophrenia;	chr6:27038344	chr9:97195351~97197687:-
BRCA	trans	rs7927370	1	rs61895197	ENSG00000134612.10	FOLH1B	10.32	7.44e-24	1.37e-17	0.81	0.3	Systemic lupus erythematosus;	chr11:55588259	chr11:89639227~89698718:+
BRCA	trans	rs877636	0.859	rs3741499	ENSG00000223416.3	RPS26P15	-10.32	7.48e-24	1.38e-17	-0.37	-0.3	Cognitive function;	chr12:56080595	chr1:58056133~58056480:-
BRCA	trans	rs7927370	1	rs61894224	ENSG00000134612.10	FOLH1B	10.32	7.52e-24	1.39e-17	0.81	0.3	Systemic lupus erythematosus;	chr11:55577349	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.702	rs61894226	ENSG00000134612.10	FOLH1B	10.32	7.52e-24	1.39e-17	0.81	0.3	Systemic lupus erythematosus;	chr11:55577520	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs118079991	ENSG00000134612.10	FOLH1B	10.32	7.52e-24	1.39e-17	0.81	0.3	Systemic lupus erythematosus;	chr11:55580017	chr11:89639227~89698718:+
BRCA	trans	rs11098499	0.866	rs11098506	ENSG00000275858.1	RP11-291L22.8	10.32	7.57e-24	1.39e-17	0.37	0.3	Corneal astigmatism;	chr4:119363816	chr10:38450738~38451069:-
BRCA	trans	rs7927370	1	rs117904544	ENSG00000134612.10	FOLH1B	10.32	7.67e-24	1.41e-17	0.77	0.3	Systemic lupus erythematosus;	chr11:55511619	chr11:89639227~89698718:+
BRCA	trans	rs9876781	1	rs9864371	ENSG00000225528.1	RP3-370M22.8	-10.32	7.69e-24	1.42e-17	-0.34	-0.3	Longevity;	chr3:48385276	chr22:39960397~39964683:+
BRCA	trans	rs9876781	1	rs13071337	ENSG00000225528.1	RP3-370M22.8	-10.32	7.74e-24	1.43e-17	-0.33	-0.3	Longevity;	chr3:48396724	chr22:39960397~39964683:+
BRCA	trans	rs4276421	0.615	rs6877477	ENSG00000231752.4	EMBP1	10.32	8.02e-24	1.47e-17	0.42	0.3	P wave duration;	chr5:45825707	chr1:121519112~121571892:+
BRCA	trans	rs6424115	0.83	rs3123554	ENSG00000228217.1	AL390877.1	10.31	8.14e-24	1.5e-17	0.37	0.3	Immature fraction of reticulocytes;	chr1:23869911	chr1:117778087~117778506:-
BRCA	trans	rs877636	0.702	rs773110	ENSG00000234513.1	AC073072.7	10.31	8.18e-24	1.5e-17	0.41	0.3	Cognitive function;	chr12:55981353	chr7:22773646~22773993:-
BRCA	trans	rs7927370	1	rs61894241	ENSG00000134612.10	FOLH1B	10.31	8.24e-24	1.51e-17	0.81	0.3	Systemic lupus erythematosus;	chr11:55583621	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61894242	ENSG00000134612.10	FOLH1B	10.31	8.24e-24	1.51e-17	0.81	0.3	Systemic lupus erythematosus;	chr11:55583677	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61894243	ENSG00000134612.10	FOLH1B	10.31	8.24e-24	1.51e-17	0.81	0.3	Systemic lupus erythematosus;	chr11:55583768	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61894244	ENSG00000134612.10	FOLH1B	10.31	8.24e-24	1.51e-17	0.81	0.3	Systemic lupus erythematosus;	chr11:55584052	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs56056425	ENSG00000134612.10	FOLH1B	10.31	8.24e-24	1.51e-17	0.81	0.3	Systemic lupus erythematosus;	chr11:55584751	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs55959477	ENSG00000134612.10	FOLH1B	10.31	8.24e-24	1.51e-17	0.81	0.3	Systemic lupus erythematosus;	chr11:55584813	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs55720733	ENSG00000134612.10	FOLH1B	10.31	8.24e-24	1.51e-17	0.81	0.3	Systemic lupus erythematosus;	chr11:55584990	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61895191	ENSG00000134612.10	FOLH1B	10.31	8.24e-24	1.51e-17	0.81	0.3	Systemic lupus erythematosus;	chr11:55585310	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs116868501	ENSG00000134612.10	FOLH1B	10.31	8.24e-24	1.51e-17	0.81	0.3	Systemic lupus erythematosus;	chr11:55586244	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61895192	ENSG00000134612.10	FOLH1B	10.31	8.24e-24	1.51e-17	0.81	0.3	Systemic lupus erythematosus;	chr11:55586632	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61895193	ENSG00000134612.10	FOLH1B	10.31	8.24e-24	1.51e-17	0.81	0.3	Systemic lupus erythematosus;	chr11:55586763	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61895194	ENSG00000134612.10	FOLH1B	10.31	8.24e-24	1.51e-17	0.81	0.3	Systemic lupus erythematosus;	chr11:55586959	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61895195	ENSG00000134612.10	FOLH1B	10.31	8.24e-24	1.51e-17	0.81	0.3	Systemic lupus erythematosus;	chr11:55587160	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61895196	ENSG00000134612.10	FOLH1B	10.31	8.24e-24	1.51e-17	0.81	0.3	Systemic lupus erythematosus;	chr11:55587832	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.867	rs61895198	ENSG00000134612.10	FOLH1B	10.31	8.24e-24	1.51e-17	0.81	0.3	Systemic lupus erythematosus;	chr11:55588280	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.85	rs117199360	ENSG00000134612.10	FOLH1B	10.31	8.24e-24	1.51e-17	0.81	0.3	Systemic lupus erythematosus;	chr11:55588431	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61895199	ENSG00000134612.10	FOLH1B	10.31	8.24e-24	1.51e-17	0.81	0.3	Systemic lupus erythematosus;	chr11:55589020	chr11:89639227~89698718:+
BRCA	trans	rs2727020	0.718	rs1404366	ENSG00000134612.10	FOLH1B	-10.31	8.24e-24	1.51e-17	-0.4	-0.3	Coronary artery disease;	chr11:49394347	chr11:89639227~89698718:+
BRCA	trans	rs4263408	1	rs4263408	ENSG00000237550.5	UBE2Q2P6	10.31	8.32e-24	1.53e-17	0.37	0.3	Plasma amyloid beta peptide concentrations (ABx-40);	chr4:39783656	chr15:82372196~82372912:-
BRCA	trans	rs877636	0.702	rs773112	ENSG00000234513.1	AC073072.7	10.31	8.33e-24	1.53e-17	0.41	0.3	Cognitive function;	chr12:55982097	chr7:22773646~22773993:-
BRCA	trans	rs9329221	0.736	rs11249999	ENSG00000253893.2	FAM85B	10.31	8.33e-24	1.53e-17	0.4	0.3	Neuroticism;	chr8:10393755	chr8:8167819~8226614:-
BRCA	trans	rs11098499	0.687	rs71610270	ENSG00000275858.1	RP11-291L22.8	10.31	8.39e-24	1.54e-17	0.36	0.3	Corneal astigmatism;	chr4:119366281	chr10:38450738~38451069:-
BRCA	trans	rs4263408	1	rs7687557	ENSG00000237550.5	UBE2Q2P6	10.31	8.44e-24	1.55e-17	0.36	0.3	Plasma amyloid beta peptide concentrations (ABx-40);	chr4:39767640	chr15:82372196~82372912:-
BRCA	trans	rs7927370	1	rs55902215	ENSG00000134612.10	FOLH1B	10.31	8.45e-24	1.55e-17	0.81	0.3	Systemic lupus erythematosus;	chr11:55585007	chr11:89639227~89698718:+
BRCA	trans	rs864643	0.524	rs12106854	ENSG00000183298.5	RP11-556K13.1	10.31	8.45e-24	1.55e-17	0.6	0.3	Attention deficit hyperactivity disorder;	chr3:39487321	chr1:101786340~101787219:-
BRCA	trans	rs864643	0.524	rs17038967	ENSG00000183298.5	RP11-556K13.1	10.31	8.45e-24	1.55e-17	0.6	0.3	Attention deficit hyperactivity disorder;	chr3:39489530	chr1:101786340~101787219:-
BRCA	trans	rs11098499	1	rs12506395	ENSG00000275858.1	RP11-291L22.8	10.31	8.47e-24	1.55e-17	0.38	0.3	Corneal astigmatism;	chr4:119263939	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.535	rs7671759	ENSG00000275858.1	RP11-291L22.8	10.31	8.51e-24	1.56e-17	0.37	0.3	Corneal astigmatism;	chr4:119326939	chr10:38450738~38451069:-
BRCA	trans	rs877636	1	rs4759229	ENSG00000242970.2	AC068522.4	-10.31	8.54e-24	1.57e-17	-0.42	-0.3	Cognitive function;	chr12:56080696	chr8:58588420~58588764:-
BRCA	trans	rs9329221	0.662	rs13254942	ENSG00000253893.2	FAM85B	10.31	8.61e-24	1.58e-17	0.39	0.3	Neuroticism;	chr8:10400168	chr8:8167819~8226614:-
BRCA	trans	rs7927370	1	rs75226237	ENSG00000134612.10	FOLH1B	10.31	8.63e-24	1.58e-17	0.79	0.3	Systemic lupus erythematosus;	chr11:55391312	chr11:89639227~89698718:+
BRCA	trans	rs6424115	0.964	rs2473375	ENSG00000228217.1	AL390877.1	-10.31	8.64e-24	1.58e-17	-0.38	-0.3	Immature fraction of reticulocytes;	chr1:23810055	chr1:117778087~117778506:-
BRCA	trans	rs877636	0.74	rs705702	ENSG00000242970.2	AC068522.4	-10.31	8.71e-24	1.6e-17	-0.45	-0.3	Cognitive function;	chr12:55996852	chr8:58588420~58588764:-
BRCA	trans	rs7927370	0.702	rs61916163	ENSG00000134612.10	FOLH1B	10.3	8.88e-24	1.63e-17	0.8	0.3	Systemic lupus erythematosus;	chr11:55347814	chr11:89639227~89698718:+
BRCA	trans	rs3806843	0.966	rs3806844	ENSG00000231043.3	AC007238.1	-10.3	9e-24	1.65e-17	-0.35	-0.3	Depressive symptoms (multi-trait analysis);	chr5:140826678	chr2:58460292~58462032:-
BRCA	trans	rs1190596	0.525	rs7153005	ENSG00000181359.5	HSP90AA6P	10.3	9.06e-24	1.66e-17	0.39	0.3	Behavioural disinhibition (generation interaction);	chr14:102232262	chr4:170581470~170605450:-
BRCA	trans	rs11098499	0.722	rs7673476	ENSG00000275858.1	RP11-291L22.8	10.3	9.18e-24	1.68e-17	0.36	0.3	Corneal astigmatism;	chr4:119327528	chr10:38450738~38451069:-
BRCA	trans	rs11098499	1	rs28374891	ENSG00000275858.1	RP11-291L22.8	10.3	9.42e-24	1.72e-17	0.38	0.3	Corneal astigmatism;	chr4:119262395	chr10:38450738~38451069:-
BRCA	trans	rs7927370	1	rs17496160	ENSG00000134612.10	FOLH1B	10.3	9.52e-24	1.74e-17	0.79	0.3	Systemic lupus erythematosus;	chr11:55546597	chr11:89639227~89698718:+
BRCA	trans	rs4276421	0.593	rs10062641	ENSG00000231752.4	EMBP1	10.3	9.59e-24	1.75e-17	0.42	0.3	P wave duration;	chr5:45930240	chr1:121519112~121571892:+
BRCA	trans	rs877636	1	rs705696	ENSG00000242970.2	AC068522.4	10.29	1.01e-23	1.84e-17	0.45	0.3	Cognitive function;	chr12:56086864	chr8:58588420~58588764:-
BRCA	trans	rs13177918	0.717	rs6874318	ENSG00000226396.1	RP5-1056L3.3	-10.29	1.06e-23	1.93e-17	-0.32	-0.3	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150462836	chr1:19608114~19608568:+
BRCA	trans	rs9329221	0.772	rs7824675	ENSG00000253893.2	FAM85B	10.29	1.07e-23	1.95e-17	0.37	0.3	Neuroticism;	chr8:10385908	chr8:8167819~8226614:-
BRCA	trans	rs7927370	0.557	rs61919685	ENSG00000134612.10	FOLH1B	10.29	1.07e-23	1.95e-17	0.82	0.3	Systemic lupus erythematosus;	chr11:55492877	chr11:89639227~89698718:+
BRCA	trans	rs877636	0.74	rs705698	ENSG00000242970.2	AC068522.4	10.28	1.07e-23	1.96e-17	0.45	0.3	Cognitive function;	chr12:55990903	chr8:58588420~58588764:-
BRCA	trans	rs9876781	1	rs10470686	ENSG00000225528.1	RP3-370M22.8	-10.28	1.09e-23	1.98e-17	-0.33	-0.3	Longevity;	chr3:48408549	chr22:39960397~39964683:+
BRCA	trans	rs864643	0.524	rs9822783	ENSG00000188856.6	RPSAP47	10.28	1.1e-23	2.01e-17	0.54	0.3	Attention deficit hyperactivity disorder;	chr3:39463311	chr8:80558870~80559757:+
BRCA	trans	rs11098499	1	rs6849889	ENSG00000275858.1	RP11-291L22.8	10.28	1.11e-23	2.02e-17	0.38	0.3	Corneal astigmatism;	chr4:119265193	chr10:38450738~38451069:-
BRCA	trans	rs853679	0.607	rs13208096	ENSG00000253570.1	RNF5P1	10.28	1.12e-23	2.03e-17	0.9	0.3	Depression;	chr6:28257533	chr8:38600661~38601200:-
BRCA	trans	rs11220082	0.666	rs2241514	ENSG00000236257.1	EI24P2	-10.28	1.12e-23	2.05e-17	-0.37	-0.3	Schizophrenia;	chr11:125456130	chr1:158454198~158455273:+
BRCA	trans	rs7927370	1	rs56147666	ENSG00000134612.10	FOLH1B	10.28	1.12e-23	2.05e-17	0.76	0.3	Systemic lupus erythematosus;	chr11:55443075	chr11:89639227~89698718:+
BRCA	trans	rs7312770	0.612	rs1873914	ENSG00000204652.6	RPS26P8	10.28	1.13e-23	2.06e-17	0.37	0.3	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr17:45608571~45608918:+
BRCA	trans	rs9876781	1	rs3214041	ENSG00000225528.1	RP3-370M22.8	-10.28	1.14e-23	2.07e-17	-0.33	-0.3	Longevity;	chr3:48413059	chr22:39960397~39964683:+
BRCA	trans	rs7833986	0.501	rs2667999	ENSG00000236862.1	RPS20P24	10.28	1.15e-23	2.09e-17	0.39	0.3	Height;	chr8:56037915	chr9:72655832~72656192:-
BRCA	trans	rs74781061	0.929	rs10459648	ENSG00000227288.3	RP5-837I24.1	-10.28	1.17e-23	2.13e-17	-0.47	-0.3	Endometriosis;	chr15:74573099	chr1:81501794~81503468:+
BRCA	trans	rs7927370	0.85	rs61894768	ENSG00000134612.10	FOLH1B	10.28	1.17e-23	2.13e-17	0.84	0.3	Systemic lupus erythematosus;	chr11:55696654	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61894769	ENSG00000134612.10	FOLH1B	10.28	1.17e-23	2.13e-17	0.84	0.3	Systemic lupus erythematosus;	chr11:55698508	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61894770	ENSG00000134612.10	FOLH1B	10.28	1.17e-23	2.13e-17	0.84	0.3	Systemic lupus erythematosus;	chr11:55701583	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61894771	ENSG00000134612.10	FOLH1B	10.28	1.17e-23	2.13e-17	0.84	0.3	Systemic lupus erythematosus;	chr11:55701667	chr11:89639227~89698718:+
BRCA	trans	rs877636	0.702	rs773109	ENSG00000234513.1	AC073072.7	10.28	1.17e-23	2.14e-17	0.4	0.3	Cognitive function;	chr12:55980911	chr7:22773646~22773993:-
BRCA	trans	rs9329221	0.736	rs2001338	ENSG00000253893.2	FAM85B	-10.27	1.18e-23	2.14e-17	-0.4	-0.3	Neuroticism;	chr8:10393707	chr8:8167819~8226614:-
BRCA	trans	rs864643	0.574	rs1768192	ENSG00000183298.5	RP11-556K13.1	10.27	1.18e-23	2.15e-17	0.47	0.3	Attention deficit hyperactivity disorder;	chr3:39470669	chr1:101786340~101787219:-
BRCA	trans	rs9876781	1	rs11130170	ENSG00000225528.1	RP3-370M22.8	-10.27	1.19e-23	2.16e-17	-0.33	-0.3	Longevity;	chr3:48408490	chr22:39960397~39964683:+
BRCA	trans	rs747782	0.527	rs75915859	ENSG00000134612.10	FOLH1B	10.27	1.21e-23	2.19e-17	0.52	0.3	Intraocular pressure;	chr11:48211379	chr11:89639227~89698718:+
BRCA	trans	rs9467773	0.587	rs9467722	ENSG00000242375.1	RP11-498P14.3	-10.27	1.23e-23	2.23e-17	-0.42	-0.3	Intelligence (multi-trait analysis);	chr6:26352338	chr9:97195351~97197687:-
BRCA	trans	rs9329221	0.736	rs11250002	ENSG00000253893.2	FAM85B	-10.27	1.23e-23	2.23e-17	-0.4	-0.3	Neuroticism;	chr8:10399531	chr8:8167819~8226614:-
BRCA	trans	rs7927370	0.764	rs61895226	ENSG00000134612.10	FOLH1B	10.27	1.23e-23	2.25e-17	0.83	0.3	Systemic lupus erythematosus;	chr11:55599899	chr11:89639227~89698718:+
BRCA	trans	rs3806843	0.966	rs11953833	ENSG00000231043.3	AC007238.1	-10.27	1.24e-23	2.26e-17	-0.35	-0.3	Depressive symptoms (multi-trait analysis);	chr5:140775538	chr2:58460292~58462032:-
BRCA	trans	rs864643	0.678	rs1707957	ENSG00000183298.5	RP11-556K13.1	10.27	1.25e-23	2.27e-17	0.47	0.3	Attention deficit hyperactivity disorder;	chr3:39482000	chr1:101786340~101787219:-
BRCA	trans	rs7733403	1	rs7733403	ENSG00000231043.3	AC007238.1	-10.27	1.25e-23	2.28e-17	-0.35	-0.3	Schizophrenia;	chr5:140774630	chr2:58460292~58462032:-
BRCA	trans	rs4276421	0.593	rs72750046	ENSG00000231752.4	EMBP1	10.27	1.25e-23	2.28e-17	0.42	0.3	P wave duration;	chr5:45930775	chr1:121519112~121571892:+
BRCA	trans	rs11098499	1	rs1011054	ENSG00000275858.1	RP11-291L22.8	-10.27	1.26e-23	2.3e-17	-0.39	-0.3	Corneal astigmatism;	chr4:119281232	chr10:38450738~38451069:-
BRCA	trans	rs864643	0.524	rs77309543	ENSG00000183298.5	RP11-556K13.1	10.27	1.29e-23	2.34e-17	0.64	0.3	Attention deficit hyperactivity disorder;	chr3:39489578	chr1:101786340~101787219:-
BRCA	trans	rs3806843	0.931	rs13168670	ENSG00000231043.3	AC007238.1	-10.27	1.29e-23	2.34e-17	-0.35	-0.3	Depressive symptoms (multi-trait analysis);	chr5:140767314	chr2:58460292~58462032:-
BRCA	trans	rs11098499	0.863	rs10004484	ENSG00000275858.1	RP11-291L22.8	10.26	1.32e-23	2.4e-17	0.37	0.3	Corneal astigmatism;	chr4:119521273	chr10:38450738~38451069:-
BRCA	trans	rs7927370	1	rs61918258	ENSG00000134612.10	FOLH1B	10.26	1.32e-23	2.4e-17	0.75	0.3	Systemic lupus erythematosus;	chr11:55437922	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs7946976	ENSG00000134612.10	FOLH1B	10.26	1.32e-23	2.4e-17	0.75	0.3	Systemic lupus erythematosus;	chr11:55439444	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.85	rs117291952	ENSG00000134612.10	FOLH1B	10.26	1.32e-23	2.4e-17	0.75	0.3	Systemic lupus erythematosus;	chr11:55440042	chr11:89639227~89698718:+
BRCA	trans	rs3806843	0.868	rs2531345	ENSG00000231043.3	AC007238.1	10.26	1.34e-23	2.44e-17	0.35	0.3	Depressive symptoms (multi-trait analysis);	chr5:140747196	chr2:58460292~58462032:-
BRCA	trans	rs9329221	0.683	rs555200	ENSG00000253893.2	FAM85B	10.26	1.37e-23	2.49e-17	0.37	0.3	Neuroticism;	chr8:10031219	chr8:8167819~8226614:-
BRCA	trans	rs7833986	0.501	rs2953911	ENSG00000236862.1	RPS20P24	10.26	1.38e-23	2.5e-17	0.39	0.3	Height;	chr8:56035450	chr9:72655832~72656192:-
BRCA	trans	rs3806843	1	rs10037757	ENSG00000231043.3	AC007238.1	-10.26	1.4e-23	2.53e-17	-0.35	-0.3	Depressive symptoms (multi-trait analysis);	chr5:140817637	chr2:58460292~58462032:-
BRCA	trans	rs7927370	1	rs28867852	ENSG00000134612.10	FOLH1B	10.26	1.4e-23	2.53e-17	0.84	0.3	Systemic lupus erythematosus;	chr11:55027642	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61895804	ENSG00000134612.10	FOLH1B	10.26	1.4e-23	2.53e-17	0.84	0.3	Systemic lupus erythematosus;	chr11:55030714	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs56182790	ENSG00000134612.10	FOLH1B	10.26	1.4e-23	2.53e-17	0.84	0.3	Systemic lupus erythematosus;	chr11:55032515	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs55663900	ENSG00000134612.10	FOLH1B	10.26	1.4e-23	2.53e-17	0.84	0.3	Systemic lupus erythematosus;	chr11:55032636	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs77021942	ENSG00000134612.10	FOLH1B	10.26	1.4e-23	2.53e-17	0.84	0.3	Systemic lupus erythematosus;	chr11:55033442	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61895808	ENSG00000134612.10	FOLH1B	10.26	1.4e-23	2.53e-17	0.84	0.3	Systemic lupus erythematosus;	chr11:55034524	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.717	rs61895809	ENSG00000134612.10	FOLH1B	10.26	1.4e-23	2.53e-17	0.84	0.3	Systemic lupus erythematosus;	chr11:55035279	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61895817	ENSG00000134612.10	FOLH1B	10.26	1.4e-23	2.53e-17	0.84	0.3	Systemic lupus erythematosus;	chr11:55036835	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs117975165	ENSG00000134612.10	FOLH1B	10.26	1.4e-23	2.53e-17	0.84	0.3	Systemic lupus erythematosus;	chr11:55040015	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61895830	ENSG00000134612.10	FOLH1B	10.26	1.4e-23	2.53e-17	0.84	0.3	Systemic lupus erythematosus;	chr11:55043129	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61895833	ENSG00000134612.10	FOLH1B	10.26	1.4e-23	2.53e-17	0.84	0.3	Systemic lupus erythematosus;	chr11:55044671	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61895834	ENSG00000134612.10	FOLH1B	10.26	1.4e-23	2.53e-17	0.84	0.3	Systemic lupus erythematosus;	chr11:55044777	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs28846177	ENSG00000134612.10	FOLH1B	10.26	1.4e-23	2.53e-17	0.84	0.3	Systemic lupus erythematosus;	chr11:55046374	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61895839	ENSG00000134612.10	FOLH1B	10.26	1.4e-23	2.53e-17	0.84	0.3	Systemic lupus erythematosus;	chr11:55052724	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs75287308	ENSG00000134612.10	FOLH1B	10.26	1.4e-23	2.53e-17	0.84	0.3	Systemic lupus erythematosus;	chr11:55056426	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs117961171	ENSG00000134612.10	FOLH1B	10.26	1.4e-23	2.53e-17	0.84	0.3	Systemic lupus erythematosus;	chr11:55060836	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61895859	ENSG00000134612.10	FOLH1B	10.26	1.4e-23	2.53e-17	0.84	0.3	Systemic lupus erythematosus;	chr11:55061185	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.702	rs117318629	ENSG00000134612.10	FOLH1B	10.26	1.4e-23	2.53e-17	0.84	0.3	Systemic lupus erythematosus;	chr11:55061880	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61898060	ENSG00000134612.10	FOLH1B	10.26	1.4e-23	2.53e-17	0.84	0.3	Systemic lupus erythematosus;	chr11:55062545	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61898061	ENSG00000134612.10	FOLH1B	10.26	1.4e-23	2.53e-17	0.84	0.3	Systemic lupus erythematosus;	chr11:55062624	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.702	rs61898069	ENSG00000134612.10	FOLH1B	10.26	1.4e-23	2.53e-17	0.84	0.3	Systemic lupus erythematosus;	chr11:55067069	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs55637752	ENSG00000134612.10	FOLH1B	10.26	1.4e-23	2.53e-17	0.84	0.3	Systemic lupus erythematosus;	chr11:55071145	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs78036162	ENSG00000134612.10	FOLH1B	10.26	1.4e-23	2.53e-17	0.84	0.3	Systemic lupus erythematosus;	chr11:55072449	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs79577263	ENSG00000134612.10	FOLH1B	10.26	1.4e-23	2.53e-17	0.84	0.3	Systemic lupus erythematosus;	chr11:55073103	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs117722297	ENSG00000134612.10	FOLH1B	10.26	1.4e-23	2.53e-17	0.84	0.3	Systemic lupus erythematosus;	chr11:55074230	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.85	rs117303677	ENSG00000134612.10	FOLH1B	10.26	1.4e-23	2.53e-17	0.84	0.3	Systemic lupus erythematosus;	chr11:55075727	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs118186653	ENSG00000134612.10	FOLH1B	10.26	1.4e-23	2.53e-17	0.84	0.3	Systemic lupus erythematosus;	chr11:55078795	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61898077	ENSG00000134612.10	FOLH1B	10.26	1.4e-23	2.53e-17	0.84	0.3	Systemic lupus erythematosus;	chr11:55082178	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs9666206	ENSG00000134612.10	FOLH1B	10.26	1.4e-23	2.53e-17	0.84	0.3	Systemic lupus erythematosus;	chr11:55083456	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs79551837	ENSG00000134612.10	FOLH1B	10.26	1.4e-23	2.53e-17	0.84	0.3	Systemic lupus erythematosus;	chr11:55090757	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.85	rs56270386	ENSG00000134612.10	FOLH1B	10.26	1.4e-23	2.53e-17	0.84	0.3	Systemic lupus erythematosus;	chr11:55094488	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61898116	ENSG00000134612.10	FOLH1B	10.26	1.4e-23	2.53e-17	0.84	0.3	Systemic lupus erythematosus;	chr11:55095914	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61898130	ENSG00000134612.10	FOLH1B	10.26	1.4e-23	2.53e-17	0.84	0.3	Systemic lupus erythematosus;	chr11:55098663	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs56234219	ENSG00000134612.10	FOLH1B	10.26	1.4e-23	2.53e-17	0.84	0.3	Systemic lupus erythematosus;	chr11:55098798	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.85	rs61898132	ENSG00000134612.10	FOLH1B	10.26	1.4e-23	2.53e-17	0.84	0.3	Systemic lupus erythematosus;	chr11:55102299	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.85	rs61898139	ENSG00000134612.10	FOLH1B	10.26	1.4e-23	2.53e-17	0.84	0.3	Systemic lupus erythematosus;	chr11:55107857	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61898140	ENSG00000134612.10	FOLH1B	10.26	1.4e-23	2.53e-17	0.84	0.3	Systemic lupus erythematosus;	chr11:55108053	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61898141	ENSG00000134612.10	FOLH1B	10.26	1.4e-23	2.53e-17	0.84	0.3	Systemic lupus erythematosus;	chr11:55108093	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61898149	ENSG00000134612.10	FOLH1B	10.26	1.4e-23	2.53e-17	0.84	0.3	Systemic lupus erythematosus;	chr11:55113477	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs116984732	ENSG00000134612.10	FOLH1B	10.26	1.4e-23	2.53e-17	0.84	0.3	Systemic lupus erythematosus;	chr11:55134013	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.702	rs61895923	ENSG00000134612.10	FOLH1B	10.26	1.4e-23	2.53e-17	0.84	0.3	Systemic lupus erythematosus;	chr11:55148573	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.557	rs7127125	ENSG00000134612.10	FOLH1B	10.26	1.4e-23	2.53e-17	0.84	0.3	Systemic lupus erythematosus;	chr11:55153663	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs2204238	ENSG00000134612.10	FOLH1B	10.26	1.4e-23	2.53e-17	0.84	0.3	Systemic lupus erythematosus;	chr11:55155044	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.85	rs61895943	ENSG00000134612.10	FOLH1B	10.26	1.4e-23	2.53e-17	0.84	0.3	Systemic lupus erythematosus;	chr11:55156089	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.702	rs61895949	ENSG00000134612.10	FOLH1B	10.26	1.4e-23	2.53e-17	0.84	0.3	Systemic lupus erythematosus;	chr11:55159317	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.702	rs56136558	ENSG00000134612.10	FOLH1B	10.26	1.4e-23	2.53e-17	0.84	0.3	Systemic lupus erythematosus;	chr11:55162217	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61897266	ENSG00000134612.10	FOLH1B	10.26	1.4e-23	2.53e-17	0.84	0.3	Systemic lupus erythematosus;	chr11:55164038	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.85	rs61897284	ENSG00000134612.10	FOLH1B	10.26	1.4e-23	2.53e-17	0.84	0.3	Systemic lupus erythematosus;	chr11:55175605	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.557	rs61897285	ENSG00000134612.10	FOLH1B	10.26	1.4e-23	2.53e-17	0.84	0.3	Systemic lupus erythematosus;	chr11:55175639	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61897286	ENSG00000134612.10	FOLH1B	10.26	1.4e-23	2.53e-17	0.84	0.3	Systemic lupus erythematosus;	chr11:55175727	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.702	rs61897289	ENSG00000134612.10	FOLH1B	10.26	1.4e-23	2.53e-17	0.84	0.3	Systemic lupus erythematosus;	chr11:55178164	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.572	rs61897310	ENSG00000134612.10	FOLH1B	10.26	1.4e-23	2.53e-17	0.84	0.3	Systemic lupus erythematosus;	chr11:55178507	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.85	rs61897312	ENSG00000134612.10	FOLH1B	10.26	1.4e-23	2.53e-17	0.84	0.3	Systemic lupus erythematosus;	chr11:55180051	chr11:89639227~89698718:+
BRCA	trans	rs16937956	0.657	rs3751095	ENSG00000266891.1	RP11-692N5.2	10.26	1.4e-23	2.53e-17	0.41	0.3	Body mass index;	chr11:8413530	chr18:9734882~9735602:-
BRCA	trans	rs16937956	0.657	rs3751096	ENSG00000266891.1	RP11-692N5.2	10.26	1.4e-23	2.53e-17	0.41	0.3	Body mass index;	chr11:8413531	chr18:9734882~9735602:-
BRCA	trans	rs3942852	0.774	rs2270990	ENSG00000134612.10	FOLH1B	-10.26	1.42e-23	2.56e-17	-0.41	-0.3	Acute lymphoblastic leukemia (childhood);	chr11:48163431	chr11:89639227~89698718:+
BRCA	trans	rs13217239	0.621	rs12527231	ENSG00000242375.1	RP11-498P14.3	10.25	1.44e-23	2.6e-17	0.42	0.3	Schizophrenia;	chr6:27033509	chr9:97195351~97197687:-
BRCA	trans	rs13217239	0.646	rs12523820	ENSG00000242375.1	RP11-498P14.3	10.25	1.44e-23	2.6e-17	0.42	0.3	Schizophrenia;	chr6:27033723	chr9:97195351~97197687:-
BRCA	trans	rs13217239	0.646	rs6937880	ENSG00000242375.1	RP11-498P14.3	10.25	1.45e-23	2.62e-17	0.42	0.3	Schizophrenia;	chr6:27032457	chr9:97195351~97197687:-
BRCA	trans	rs7927370	0.702	rs61896268	ENSG00000134612.10	FOLH1B	10.25	1.47e-23	2.65e-17	0.84	0.3	Systemic lupus erythematosus;	chr11:55216142	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.702	rs61896275	ENSG00000134612.10	FOLH1B	10.25	1.47e-23	2.65e-17	0.84	0.3	Systemic lupus erythematosus;	chr11:55218022	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs117987119	ENSG00000134612.10	FOLH1B	10.25	1.47e-23	2.65e-17	0.84	0.3	Systemic lupus erythematosus;	chr11:55219125	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.85	rs61896280	ENSG00000134612.10	FOLH1B	10.25	1.47e-23	2.65e-17	0.84	0.3	Systemic lupus erythematosus;	chr11:55219824	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.85	rs77014386	ENSG00000134612.10	FOLH1B	10.25	1.47e-23	2.65e-17	0.84	0.3	Systemic lupus erythematosus;	chr11:55225489	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs9666078	ENSG00000134612.10	FOLH1B	10.25	1.5e-23	2.7e-17	0.84	0.3	Systemic lupus erythematosus;	chr11:55132747	chr11:89639227~89698718:+
BRCA	trans	rs11098499	0.955	rs13114751	ENSG00000275858.1	RP11-291L22.8	10.25	1.51e-23	2.72e-17	0.38	0.3	Corneal astigmatism;	chr4:119235462	chr10:38450738~38451069:-
BRCA	trans	rs2727020	0.754	rs1851990	ENSG00000134612.10	FOLH1B	-10.25	1.52e-23	2.74e-17	-0.39	-0.3	Coronary artery disease;	chr11:49391784	chr11:89639227~89698718:+
BRCA	trans	rs2727020	0.612	rs9787891	ENSG00000134612.10	FOLH1B	-10.25	1.52e-23	2.74e-17	-0.39	-0.3	Coronary artery disease;	chr11:49391942	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.764	rs55902354	ENSG00000134612.10	FOLH1B	10.25	1.53e-23	2.75e-17	0.83	0.3	Systemic lupus erythematosus;	chr11:55655810	chr11:89639227~89698718:+
BRCA	trans	rs13217239	0.646	rs4403259	ENSG00000242375.1	RP11-498P14.3	10.24	1.64e-23	2.94e-17	0.42	0.3	Schizophrenia;	chr6:27029838	chr9:97195351~97197687:-
BRCA	trans	rs9876781	0.563	rs4858821	ENSG00000235912.1	RP1-159A19.3	10.24	1.68e-23	3.01e-17	0.39	0.3	Longevity;	chr3:48512515	chr1:27649419~27649610:+
BRCA	trans	rs11098499	0.754	rs10212714	ENSG00000275858.1	RP11-291L22.8	10.24	1.68e-23	3.02e-17	0.36	0.3	Corneal astigmatism;	chr4:119333147	chr10:38450738~38451069:-
BRCA	trans	rs4276421	0.509	rs8185343	ENSG00000231752.4	EMBP1	10.23	1.71e-23	3.08e-17	0.42	0.3	P wave duration;	chr5:46012100	chr1:121519112~121571892:+
BRCA	trans	rs7113874	0.659	rs7935453	ENSG00000266891.1	RP11-692N5.2	10.23	1.76e-23	3.16e-17	0.41	0.3	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8625216	chr18:9734882~9735602:-
BRCA	trans	rs9650657	0.538	rs11250093	ENSG00000253893.2	FAM85B	-10.23	1.77e-23	3.17e-17	-0.38	-0.3	Neuroticism;	chr8:10941318	chr8:8167819~8226614:-
BRCA	trans	rs3806843	1	rs4404730	ENSG00000231043.3	AC007238.1	-10.23	1.77e-23	3.17e-17	-0.35	-0.3	Depressive symptoms (multi-trait analysis);	chr5:140783025	chr2:58460292~58462032:-
BRCA	trans	rs7833986	0.501	rs72653951	ENSG00000236862.1	RPS20P24	10.23	1.77e-23	3.17e-17	0.38	0.3	Height;	chr8:56049278	chr9:72655832~72656192:-
BRCA	trans	rs877636	1	rs4759229	ENSG00000223416.3	RPS26P15	-10.23	1.8e-23	3.23e-17	-0.37	-0.3	Cognitive function;	chr12:56080696	chr1:58056133~58056480:-
BRCA	trans	rs4276421	0.593	rs61012768	ENSG00000231752.4	EMBP1	10.23	1.83e-23	3.28e-17	0.42	0.3	P wave duration;	chr5:45941000	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.593	rs7448897	ENSG00000231752.4	EMBP1	10.23	1.83e-23	3.28e-17	0.42	0.3	P wave duration;	chr5:45941347	chr1:121519112~121571892:+
BRCA	trans	rs11098499	0.866	rs12501602	ENSG00000275858.1	RP11-291L22.8	10.23	1.84e-23	3.3e-17	0.37	0.3	Corneal astigmatism;	chr4:119366780	chr10:38450738~38451069:-
BRCA	trans	rs7927370	1	rs118121544	ENSG00000134612.10	FOLH1B	10.23	1.88e-23	3.36e-17	0.79	0.3	Systemic lupus erythematosus;	chr11:55496317	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61919689	ENSG00000134612.10	FOLH1B	10.23	1.88e-23	3.36e-17	0.79	0.3	Systemic lupus erythematosus;	chr11:55496472	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs56381852	ENSG00000134612.10	FOLH1B	10.23	1.88e-23	3.36e-17	0.79	0.3	Systemic lupus erythematosus;	chr11:55496979	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs55696537	ENSG00000134612.10	FOLH1B	10.23	1.88e-23	3.36e-17	0.79	0.3	Systemic lupus erythematosus;	chr11:55497129	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs7112469	ENSG00000134612.10	FOLH1B	10.23	1.88e-23	3.36e-17	0.79	0.3	Systemic lupus erythematosus;	chr11:55499124	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs7941275	ENSG00000134612.10	FOLH1B	10.23	1.88e-23	3.36e-17	0.79	0.3	Systemic lupus erythematosus;	chr11:55502210	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs7930341	ENSG00000134612.10	FOLH1B	10.23	1.88e-23	3.36e-17	0.79	0.3	Systemic lupus erythematosus;	chr11:55502340	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs7941839	ENSG00000134612.10	FOLH1B	10.23	1.88e-23	3.36e-17	0.79	0.3	Systemic lupus erythematosus;	chr11:55502678	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61916286	ENSG00000134612.10	FOLH1B	10.23	1.88e-23	3.36e-17	0.79	0.3	Systemic lupus erythematosus;	chr11:55504223	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs9666260	ENSG00000134612.10	FOLH1B	10.23	1.88e-23	3.36e-17	0.79	0.3	Systemic lupus erythematosus;	chr11:55504934	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs17579755	ENSG00000134612.10	FOLH1B	10.23	1.88e-23	3.36e-17	0.79	0.3	Systemic lupus erythematosus;	chr11:55505714	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61916290	ENSG00000134612.10	FOLH1B	10.23	1.88e-23	3.36e-17	0.79	0.3	Systemic lupus erythematosus;	chr11:55507212	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs7940290	ENSG00000134612.10	FOLH1B	10.23	1.88e-23	3.36e-17	0.79	0.3	Systemic lupus erythematosus;	chr11:55507373	chr11:89639227~89698718:+
BRCA	trans	rs4276421	0.593	rs13176359	ENSG00000231752.4	EMBP1	-10.22	1.89e-23	3.38e-17	-0.41	-0.3	P wave duration;	chr5:45814173	chr1:121519112~121571892:+
BRCA	trans	rs73108077	0.736	rs6119276	ENSG00000279352.1	RP11-411B10.7	10.22	1.89e-23	3.39e-17	0.51	0.3	Red blood cell density in sickle cell anemia;	chr20:31363733	chr18:14010054~14010917:+
BRCA	trans	rs2069408	1	rs2069408	ENSG00000243403.1	RP11-330L19.1	-10.22	1.9e-23	3.4e-17	-0.39	-0.3	Asthma;	chr12:55970537	chr15:64592979~64593326:+
BRCA	trans	rs3779195	0.52	rs17169479	ENSG00000225169.1	BRI3P1	10.22	1.92e-23	3.45e-17	0.5	0.3	Sex hormone-binding globulin levels;	chr7:98238721	chr1:100213293~100213670:+
BRCA	trans	rs11098499	0.955	rs4145951	ENSG00000275858.1	RP11-291L22.8	10.22	1.94e-23	3.48e-17	0.38	0.3	Corneal astigmatism;	chr4:119234662	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.955	rs35916640	ENSG00000275858.1	RP11-291L22.8	10.22	1.94e-23	3.48e-17	0.38	0.3	Corneal astigmatism;	chr4:119234697	chr10:38450738~38451069:-
BRCA	trans	rs7927370	0.764	rs295642	ENSG00000134612.10	FOLH1B	10.22	1.96e-23	3.51e-17	0.82	0.3	Systemic lupus erythematosus;	chr11:55685307	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.764	rs295603	ENSG00000134612.10	FOLH1B	10.22	2.04e-23	3.64e-17	0.82	0.3	Systemic lupus erythematosus;	chr11:55663054	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs1119153	ENSG00000134612.10	FOLH1B	10.21	2.11e-23	3.78e-17	0.79	0.3	Systemic lupus erythematosus;	chr11:55556658	chr11:89639227~89698718:+
BRCA	trans	rs3096299	0.685	rs8050512	ENSG00000215030.5	RPL13P12	-10.21	2.16e-23	3.86e-17	-0.3	-0.3	Multiple myeloma (IgH translocation);	chr16:89485912	chr17:17383377~17384012:-
BRCA	trans	rs877636	1	rs877636	ENSG00000243538.1	CTB-55B8.1	-10.21	2.18e-23	3.9e-17	-0.36	-0.3	Cognitive function;	chr12:56086799	chr5:16902294~16902641:-
BRCA	trans	rs864643	0.678	rs568085	ENSG00000183298.5	RP11-556K13.1	10.21	2.19e-23	3.91e-17	0.47	0.3	Attention deficit hyperactivity disorder;	chr3:39472661	chr1:101786340~101787219:-
BRCA	trans	rs864643	0.625	rs628725	ENSG00000183298.5	RP11-556K13.1	10.21	2.19e-23	3.91e-17	0.47	0.3	Attention deficit hyperactivity disorder;	chr3:39472887	chr1:101786340~101787219:-
BRCA	trans	rs864643	0.625	rs570136	ENSG00000183298.5	RP11-556K13.1	10.21	2.19e-23	3.91e-17	0.47	0.3	Attention deficit hyperactivity disorder;	chr3:39472922	chr1:101786340~101787219:-
BRCA	trans	rs864643	0.678	rs7615732	ENSG00000183298.5	RP11-556K13.1	10.21	2.19e-23	3.91e-17	0.47	0.3	Attention deficit hyperactivity disorder;	chr3:39473732	chr1:101786340~101787219:-
BRCA	trans	rs11098499	0.644	rs10009566	ENSG00000275858.1	RP11-291L22.8	10.21	2.23e-23	3.99e-17	0.36	0.3	Corneal astigmatism;	chr4:119637453	chr10:38450738~38451069:-
BRCA	trans	rs864643	0.524	rs17038918	ENSG00000188856.6	RPSAP47	10.21	2.25e-23	4.01e-17	0.56	0.3	Attention deficit hyperactivity disorder;	chr3:39480975	chr8:80558870~80559757:+
BRCA	trans	rs6940638	0.513	rs4424065	ENSG00000242375.1	RP11-498P14.3	-10.21	2.26e-23	4.04e-17	-0.42	-0.3	Intelligence (multi-trait analysis);	chr6:27068677	chr9:97195351~97197687:-
BRCA	trans	rs714543	0.585	rs9655458	ENSG00000226038.5	PPIAP21	10.2	2.29e-23	4.09e-17	0.36	0.3	Plateletcrit;	chr7:44771386	chr20:43230760~43231260:+
BRCA	trans	rs7927370	1	rs61918259	ENSG00000134612.10	FOLH1B	10.2	2.32e-23	4.13e-17	0.75	0.3	Systemic lupus erythematosus;	chr11:55438102	chr11:89639227~89698718:+
BRCA	trans	rs16937956	0.657	rs35976355	ENSG00000266891.1	RP11-692N5.2	10.2	2.33e-23	4.16e-17	0.41	0.3	Body mass index;	chr11:8407110	chr18:9734882~9735602:-
BRCA	trans	rs9876781	1	rs7630741	ENSG00000225528.1	RP3-370M22.8	-10.2	2.37e-23	4.23e-17	-0.33	-0.3	Longevity;	chr3:48378233	chr22:39960397~39964683:+
BRCA	trans	rs7927370	1	rs2217761	ENSG00000134612.10	FOLH1B	10.2	2.4e-23	4.27e-17	0.77	0.3	Systemic lupus erythematosus;	chr11:55160996	chr11:89639227~89698718:+
BRCA	trans	rs3942852	0.774	rs1039481	ENSG00000134612.10	FOLH1B	-10.2	2.41e-23	4.29e-17	-0.41	-0.3	Acute lymphoblastic leukemia (childhood);	chr11:48160685	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs11828784	ENSG00000134612.10	FOLH1B	10.2	2.45e-23	4.36e-17	0.77	0.3	Systemic lupus erythematosus;	chr11:55099245	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs9666022	ENSG00000134612.10	FOLH1B	10.2	2.45e-23	4.36e-17	0.77	0.3	Systemic lupus erythematosus;	chr11:55104508	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61898135	ENSG00000134612.10	FOLH1B	10.2	2.45e-23	4.36e-17	0.77	0.3	Systemic lupus erythematosus;	chr11:55105541	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs9666612	ENSG00000134612.10	FOLH1B	10.2	2.45e-23	4.36e-17	0.77	0.3	Systemic lupus erythematosus;	chr11:55108804	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61898148	ENSG00000134612.10	FOLH1B	10.2	2.45e-23	4.36e-17	0.77	0.3	Systemic lupus erythematosus;	chr11:55113138	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61898150	ENSG00000134612.10	FOLH1B	10.2	2.45e-23	4.36e-17	0.77	0.3	Systemic lupus erythematosus;	chr11:55113832	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.702	rs112459724	ENSG00000134612.10	FOLH1B	10.2	2.45e-23	4.36e-17	0.77	0.3	Systemic lupus erythematosus;	chr11:55115862	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs2878332	ENSG00000134612.10	FOLH1B	10.2	2.45e-23	4.36e-17	0.77	0.3	Systemic lupus erythematosus;	chr11:55132907	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs4517536	ENSG00000134612.10	FOLH1B	10.2	2.45e-23	4.36e-17	0.77	0.3	Systemic lupus erythematosus;	chr11:55133093	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61895863	ENSG00000134612.10	FOLH1B	10.2	2.45e-23	4.36e-17	0.77	0.3	Systemic lupus erythematosus;	chr11:55133896	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.702	rs61895873	ENSG00000134612.10	FOLH1B	10.2	2.45e-23	4.36e-17	0.77	0.3	Systemic lupus erythematosus;	chr11:55138483	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.85	rs61895936	ENSG00000134612.10	FOLH1B	10.2	2.45e-23	4.36e-17	0.77	0.3	Systemic lupus erythematosus;	chr11:55151674	chr11:89639227~89698718:+
BRCA	trans	rs864643	0.678	rs1707959	ENSG00000183298.5	RP11-556K13.1	10.2	2.46e-23	4.37e-17	0.47	0.3	Attention deficit hyperactivity disorder;	chr3:39481807	chr1:101786340~101787219:-
BRCA	trans	rs1347297	0.756	rs10173183	ENSG00000269800.1	PLEKHA3P1	10.2	2.48e-23	4.41e-17	0.33	0.3	Alzheimer disease and age of onset;	chr2:178411700	chr19:41521043~41521989:-
BRCA	trans	rs11098499	0.955	rs56386062	ENSG00000275858.1	RP11-291L22.8	10.19	2.51e-23	4.46e-17	0.38	0.3	Corneal astigmatism;	chr4:119233980	chr10:38450738~38451069:-
BRCA	trans	rs1580019	0.563	rs13244332	ENSG00000176826.14	FKBP9P1	-10.19	2.53e-23	4.5e-17	-0.39	-0.3	Cognitive ability;	chr7:32498067	chr7:55681074~55713252:-
BRCA	trans	rs7927370	0.702	rs61896300	ENSG00000134612.10	FOLH1B	10.19	2.56e-23	4.55e-17	0.84	0.3	Systemic lupus erythematosus;	chr11:55229473	chr11:89639227~89698718:+
BRCA	trans	rs864643	0.524	rs6810264	ENSG00000188856.6	RPSAP47	10.19	2.58e-23	4.58e-17	0.55	0.3	Attention deficit hyperactivity disorder;	chr3:39471605	chr8:80558870~80559757:+
BRCA	trans	rs864643	0.524	rs11706953	ENSG00000188856.6	RPSAP47	10.19	2.58e-23	4.58e-17	0.55	0.3	Attention deficit hyperactivity disorder;	chr3:39472119	chr8:80558870~80559757:+
BRCA	trans	rs864643	0.678	rs1398668	ENSG00000183298.5	RP11-556K13.1	10.19	2.65e-23	4.7e-17	0.47	0.3	Attention deficit hyperactivity disorder;	chr3:39475753	chr1:101786340~101787219:-
BRCA	trans	rs7833986	0.501	rs2953909	ENSG00000236862.1	RPS20P24	10.19	2.7e-23	4.79e-17	0.39	0.3	Height;	chr8:56055641	chr9:72655832~72656192:-
BRCA	trans	rs7833986	0.501	rs2953910	ENSG00000236862.1	RPS20P24	10.19	2.7e-23	4.79e-17	0.39	0.3	Height;	chr8:56056202	chr9:72655832~72656192:-
BRCA	trans	rs3806843	0.9	rs2563287	ENSG00000231043.3	AC007238.1	-10.19	2.7e-23	4.79e-17	-0.35	-0.3	Depressive symptoms (multi-trait analysis);	chr5:140745201	chr2:58460292~58462032:-
BRCA	trans	rs11098499	0.722	rs1814814	ENSG00000275858.1	RP11-291L22.8	10.19	2.72e-23	4.82e-17	0.35	0.3	Corneal astigmatism;	chr4:119336969	chr10:38450738~38451069:-
BRCA	trans	rs864643	0.678	rs6779639	ENSG00000183298.5	RP11-556K13.1	10.19	2.72e-23	4.82e-17	0.47	0.3	Attention deficit hyperactivity disorder;	chr3:39477191	chr1:101786340~101787219:-
BRCA	trans	rs864643	0.678	rs6782255	ENSG00000183298.5	RP11-556K13.1	10.19	2.72e-23	4.82e-17	0.47	0.3	Attention deficit hyperactivity disorder;	chr3:39477236	chr1:101786340~101787219:-
BRCA	trans	rs7927370	1	rs61916374	ENSG00000134612.10	FOLH1B	10.18	2.77e-23	4.92e-17	0.76	0.3	Systemic lupus erythematosus;	chr11:55443466	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61897323	ENSG00000134612.10	FOLH1B	10.18	2.91e-23	5.16e-17	0.83	0.3	Systemic lupus erythematosus;	chr11:55187823	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.85	rs77977417	ENSG00000134612.10	FOLH1B	10.18	2.91e-23	5.16e-17	0.83	0.3	Systemic lupus erythematosus;	chr11:55206005	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.85	rs77742782	ENSG00000134612.10	FOLH1B	10.18	2.91e-23	5.16e-17	0.83	0.3	Systemic lupus erythematosus;	chr11:55212621	chr11:89639227~89698718:+
BRCA	trans	rs7833986	0.501	rs2976012	ENSG00000236862.1	RPS20P24	10.18	2.93e-23	5.18e-17	0.39	0.3	Height;	chr8:56061784	chr9:72655832~72656192:-
BRCA	trans	rs7833986	0.501	rs2953922	ENSG00000236862.1	RPS20P24	10.18	2.93e-23	5.18e-17	0.39	0.3	Height;	chr8:56064926	chr9:72655832~72656192:-
BRCA	trans	rs7833986	0.501	rs2953897	ENSG00000236862.1	RPS20P24	10.18	2.93e-23	5.18e-17	0.39	0.3	Height;	chr8:56068010	chr9:72655832~72656192:-
BRCA	trans	rs7833986	0.501	rs2953901	ENSG00000236862.1	RPS20P24	10.18	2.93e-23	5.18e-17	0.39	0.3	Height;	chr8:56069265	chr9:72655832~72656192:-
BRCA	trans	rs864643	0.678	rs1768203	ENSG00000183298.5	RP11-556K13.1	10.18	2.93e-23	5.18e-17	0.47	0.3	Attention deficit hyperactivity disorder;	chr3:39476377	chr1:101786340~101787219:-
BRCA	trans	rs864643	0.678	rs1708100	ENSG00000183298.5	RP11-556K13.1	10.18	2.93e-23	5.18e-17	0.47	0.3	Attention deficit hyperactivity disorder;	chr3:39476400	chr1:101786340~101787219:-
BRCA	trans	rs864643	0.625	rs7613883	ENSG00000183298.5	RP11-556K13.1	10.18	2.93e-23	5.18e-17	0.47	0.3	Attention deficit hyperactivity disorder;	chr3:39476825	chr1:101786340~101787219:-
BRCA	trans	rs941207	0.789	rs2958145	ENSG00000228224.3	NACAP1	-10.17	3.04e-23	5.38e-17	-0.38	-0.3	Platelet count;	chr12:56662290	chr8:101361794~101372707:+
BRCA	trans	rs877636	0.702	rs61937249	ENSG00000234513.1	AC073072.7	10.17	3.05e-23	5.39e-17	0.4	0.3	Cognitive function;	chr12:55988132	chr7:22773646~22773993:-
BRCA	trans	rs7927370	0.85	rs2335084	ENSG00000134612.10	FOLH1B	10.17	3.06e-23	5.42e-17	0.77	0.3	Systemic lupus erythematosus;	chr11:55145620	chr11:89639227~89698718:+
BRCA	trans	rs4276421	0.615	rs12108961	ENSG00000231752.4	EMBP1	10.17	3.16e-23	5.59e-17	0.42	0.3	P wave duration;	chr5:45845859	chr1:121519112~121571892:+
BRCA	trans	rs7833986	0.501	rs72653953	ENSG00000236862.1	RPS20P24	10.17	3.19e-23	5.63e-17	0.39	0.3	Height;	chr8:56058236	chr9:72655832~72656192:-
BRCA	trans	rs714543	0.61	rs4724320	ENSG00000214975.4	PPIAP29	-10.17	3.22e-23	5.69e-17	-0.33	-0.3	Plateletcrit;	chr7:44775735	chr6:24976419~24976982:+
BRCA	trans	rs11098499	0.955	rs13129661	ENSG00000275858.1	RP11-291L22.8	10.17	3.22e-23	5.69e-17	0.38	0.3	Corneal astigmatism;	chr4:119231754	chr10:38450738~38451069:-
BRCA	trans	rs7927370	1	rs11821647	ENSG00000134612.10	FOLH1B	10.17	3.24e-23	5.72e-17	0.79	0.3	Systemic lupus erythematosus;	chr11:55211133	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.85	rs61896274	ENSG00000134612.10	FOLH1B	10.17	3.24e-23	5.72e-17	0.79	0.3	Systemic lupus erythematosus;	chr11:55218016	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs117292063	ENSG00000134612.10	FOLH1B	10.17	3.24e-23	5.72e-17	0.79	0.3	Systemic lupus erythematosus;	chr11:55219609	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.85	rs4534599	ENSG00000134612.10	FOLH1B	10.17	3.24e-23	5.72e-17	0.79	0.3	Systemic lupus erythematosus;	chr11:55225564	chr11:89639227~89698718:+
BRCA	trans	rs67340775	0.834	rs13218875	ENSG00000253570.1	RNF5P1	10.17	3.28e-23	5.79e-17	0.88	0.3	Lung cancer in ever smokers;	chr6:27916234	chr8:38600661~38601200:-
BRCA	trans	rs7927370	1	rs17581051	ENSG00000134612.10	FOLH1B	10.16	3.32e-23	5.86e-17	0.74	0.3	Systemic lupus erythematosus;	chr11:55546827	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs56333107	ENSG00000134612.10	FOLH1B	10.16	3.32e-23	5.86e-17	0.74	0.3	Systemic lupus erythematosus;	chr11:55547278	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs11827117	ENSG00000134612.10	FOLH1B	10.16	3.32e-23	5.86e-17	0.74	0.3	Systemic lupus erythematosus;	chr11:55548129	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs17581337	ENSG00000134612.10	FOLH1B	10.16	3.32e-23	5.86e-17	0.74	0.3	Systemic lupus erythematosus;	chr11:55552406	chr11:89639227~89698718:+
BRCA	trans	rs877636	0.692	rs2271194	ENSG00000224553.1	AC008065.1	-10.16	3.4e-23	5.99e-17	-0.34	-0.3	Cognitive function;	chr12:56083910	chr2:171374931~171375278:-
BRCA	trans	rs11098499	0.78	rs10013652	ENSG00000275858.1	RP11-291L22.8	10.16	3.48e-23	6.13e-17	0.36	0.3	Corneal astigmatism;	chr4:119371101	chr10:38450738~38451069:-
BRCA	trans	rs864643	0.678	rs1768198	ENSG00000183298.5	RP11-556K13.1	10.16	3.5e-23	6.18e-17	0.46	0.3	Attention deficit hyperactivity disorder;	chr3:39474994	chr1:101786340~101787219:-
BRCA	trans	rs3942852	0.622	rs6485806	ENSG00000134612.10	FOLH1B	10.16	3.53e-23	6.21e-17	0.42	0.3	Acute lymphoblastic leukemia (childhood);	chr11:48081254	chr11:89639227~89698718:+
BRCA	trans	rs864643	0.678	rs1707960	ENSG00000183298.5	RP11-556K13.1	-10.16	3.59e-23	6.33e-17	-0.46	-0.3	Attention deficit hyperactivity disorder;	chr3:39481761	chr1:101786340~101787219:-
BRCA	trans	rs7927370	1	rs55705038	ENSG00000134612.10	FOLH1B	10.15	3.63e-23	6.39e-17	0.76	0.3	Systemic lupus erythematosus;	chr11:55535021	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs55675343	ENSG00000134612.10	FOLH1B	10.15	3.63e-23	6.39e-17	0.76	0.3	Systemic lupus erythematosus;	chr11:55535186	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs56073785	ENSG00000134612.10	FOLH1B	10.15	3.63e-23	6.39e-17	0.76	0.3	Systemic lupus erythematosus;	chr11:55535197	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs17580581	ENSG00000134612.10	FOLH1B	10.15	3.63e-23	6.39e-17	0.76	0.3	Systemic lupus erythematosus;	chr11:55535823	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs17580623	ENSG00000134612.10	FOLH1B	10.15	3.63e-23	6.39e-17	0.76	0.3	Systemic lupus erythematosus;	chr11:55536010	chr11:89639227~89698718:+
BRCA	trans	rs11039798	1	rs7942284	ENSG00000134612.10	FOLH1B	-10.15	3.63e-23	6.39e-17	-0.5	-0.3	Axial length;	chr11:48498872	chr11:89639227~89698718:+
BRCA	trans	rs7824557	0.547	rs2409745	ENSG00000253893.2	FAM85B	-10.15	3.7e-23	6.52e-17	-0.39	-0.3	Retinal vascular caliber;	chr8:11219126	chr8:8167819~8226614:-
BRCA	trans	rs7927370	1	rs61916349	ENSG00000134612.10	FOLH1B	10.15	3.79e-23	6.67e-17	0.76	0.3	Systemic lupus erythematosus;	chr11:55522743	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.85	rs61916350	ENSG00000134612.10	FOLH1B	10.15	3.79e-23	6.67e-17	0.76	0.3	Systemic lupus erythematosus;	chr11:55523012	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs7950542	ENSG00000134612.10	FOLH1B	10.15	3.79e-23	6.67e-17	0.76	0.3	Systemic lupus erythematosus;	chr11:55525129	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs114037190	ENSG00000134612.10	FOLH1B	10.15	3.79e-23	6.67e-17	0.76	0.3	Systemic lupus erythematosus;	chr11:55525743	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61917884	ENSG00000134612.10	FOLH1B	10.15	3.79e-23	6.67e-17	0.76	0.3	Systemic lupus erythematosus;	chr11:55526768	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61917892	ENSG00000134612.10	FOLH1B	10.15	3.79e-23	6.67e-17	0.76	0.3	Systemic lupus erythematosus;	chr11:55528493	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs56037431	ENSG00000134612.10	FOLH1B	10.15	3.79e-23	6.67e-17	0.76	0.3	Systemic lupus erythematosus;	chr11:55528598	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs17580294	ENSG00000134612.10	FOLH1B	10.15	3.79e-23	6.67e-17	0.76	0.3	Systemic lupus erythematosus;	chr11:55528630	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs11826609	ENSG00000134612.10	FOLH1B	10.15	3.79e-23	6.67e-17	0.76	0.3	Systemic lupus erythematosus;	chr11:55530159	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs17579334	ENSG00000134612.10	FOLH1B	10.15	3.82e-23	6.72e-17	0.79	0.3	Systemic lupus erythematosus;	chr11:55493670	chr11:89639227~89698718:+
BRCA	trans	rs73108077	0.621	rs7261582	ENSG00000279352.1	RP11-411B10.7	10.15	3.94e-23	6.92e-17	0.64	0.3	Red blood cell density in sickle cell anemia;	chr20:31226977	chr18:14010054~14010917:+
BRCA	trans	rs7927370	1	rs17494102	ENSG00000134612.10	FOLH1B	10.14	3.99e-23	7e-17	0.76	0.3	Systemic lupus erythematosus;	chr11:55490720	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61919682	ENSG00000134612.10	FOLH1B	10.14	3.99e-23	7e-17	0.76	0.3	Systemic lupus erythematosus;	chr11:55490777	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs17494249	ENSG00000134612.10	FOLH1B	10.14	3.99e-23	7e-17	0.76	0.3	Systemic lupus erythematosus;	chr11:55491405	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61919684	ENSG00000134612.10	FOLH1B	10.14	3.99e-23	7e-17	0.76	0.3	Systemic lupus erythematosus;	chr11:55492469	chr11:89639227~89698718:+
BRCA	trans	rs853679	0.607	rs34662244	ENSG00000253570.1	RNF5P1	10.14	4.05e-23	7.11e-17	0.91	0.3	Depression;	chr6:28106103	chr8:38600661~38601200:-
BRCA	trans	rs35952432	1	rs35952432	ENSG00000253570.1	RNF5P1	10.14	4.05e-23	7.11e-17	0.91	0.3	Lung cancer;	chr6:28107123	chr8:38600661~38601200:-
BRCA	trans	rs864643	0.678	rs512923	ENSG00000183298.5	RP11-556K13.1	10.14	4.12e-23	7.23e-17	0.47	0.3	Attention deficit hyperactivity disorder;	chr3:39480472	chr1:101786340~101787219:-
BRCA	trans	rs864643	0.678	rs621842	ENSG00000183298.5	RP11-556K13.1	10.14	4.12e-23	7.23e-17	0.47	0.3	Attention deficit hyperactivity disorder;	chr3:39480785	chr1:101786340~101787219:-
BRCA	trans	rs7927370	0.85	rs55875907	ENSG00000134612.10	FOLH1B	10.14	4.19e-23	7.34e-17	0.78	0.3	Systemic lupus erythematosus;	chr11:55145902	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.85	rs61895944	ENSG00000134612.10	FOLH1B	10.14	4.19e-23	7.34e-17	0.78	0.3	Systemic lupus erythematosus;	chr11:55156242	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.557	rs61895950	ENSG00000134612.10	FOLH1B	10.14	4.19e-23	7.34e-17	0.78	0.3	Systemic lupus erythematosus;	chr11:55160491	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.702	rs7938008	ENSG00000134612.10	FOLH1B	10.14	4.19e-23	7.34e-17	0.78	0.3	Systemic lupus erythematosus;	chr11:55162998	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.85	rs61897267	ENSG00000134612.10	FOLH1B	10.14	4.19e-23	7.34e-17	0.78	0.3	Systemic lupus erythematosus;	chr11:55164144	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.85	rs117740157	ENSG00000134612.10	FOLH1B	10.14	4.19e-23	7.34e-17	0.78	0.3	Systemic lupus erythematosus;	chr11:55170152	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.85	rs7949776	ENSG00000134612.10	FOLH1B	10.14	4.19e-23	7.34e-17	0.78	0.3	Systemic lupus erythematosus;	chr11:55170168	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.557	rs7937954	ENSG00000134612.10	FOLH1B	10.14	4.19e-23	7.34e-17	0.78	0.3	Systemic lupus erythematosus;	chr11:55170182	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.85	rs28822115	ENSG00000134612.10	FOLH1B	10.14	4.21e-23	7.37e-17	0.79	0.3	Systemic lupus erythematosus;	chr11:55047612	chr11:89639227~89698718:+
BRCA	trans	rs9329221	0.678	rs560638	ENSG00000253893.2	FAM85B	10.14	4.25e-23	7.44e-17	0.38	0.3	Neuroticism;	chr8:10025257	chr8:8167819~8226614:-
BRCA	trans	rs3806843	0.864	rs2531343	ENSG00000231043.3	AC007238.1	10.14	4.36e-23	7.62e-17	0.35	0.3	Depressive symptoms (multi-trait analysis);	chr5:140749761	chr2:58460292~58462032:-
BRCA	trans	rs7927370	1	rs76670300	ENSG00000134612.10	FOLH1B	10.13	4.42e-23	7.73e-17	0.74	0.3	Systemic lupus erythematosus;	chr11:55576716	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.85	rs74475658	ENSG00000134612.10	FOLH1B	10.13	4.42e-23	7.73e-17	0.76	0.3	Systemic lupus erythematosus;	chr11:55233257	chr11:89639227~89698718:+
BRCA	trans	rs3806843	0.966	rs2563261	ENSG00000231043.3	AC007238.1	10.13	4.44e-23	7.76e-17	0.35	0.3	Depressive symptoms (multi-trait analysis);	chr5:140758128	chr2:58460292~58462032:-
BRCA	trans	rs73108077	0.57	rs73119526	ENSG00000279352.1	RP11-411B10.7	10.13	4.46e-23	7.8e-17	0.64	0.3	Red blood cell density in sickle cell anemia;	chr20:31252117	chr18:14010054~14010917:+
BRCA	trans	rs4276421	0.615	rs60927048	ENSG00000231752.4	EMBP1	10.13	4.47e-23	7.81e-17	0.41	0.3	P wave duration;	chr5:45854618	chr1:121519112~121571892:+
BRCA	trans	rs11098499	0.913	rs35271032	ENSG00000275858.1	RP11-291L22.8	10.13	4.48e-23	7.82e-17	0.38	0.3	Corneal astigmatism;	chr4:119235504	chr10:38450738~38451069:-
BRCA	trans	rs853679	0.607	rs67040724	ENSG00000253570.1	RNF5P1	10.13	4.5e-23	7.87e-17	0.88	0.3	Depression;	chr6:27937731	chr8:38600661~38601200:-
BRCA	trans	rs864643	0.678	rs610006	ENSG00000183298.5	RP11-556K13.1	10.13	4.59e-23	8.02e-17	0.47	0.3	Attention deficit hyperactivity disorder;	chr3:39481104	chr1:101786340~101787219:-
BRCA	trans	rs7312770	0.612	rs1873914	ENSG00000224553.1	AC008065.1	10.13	4.6e-23	8.03e-17	0.34	0.3	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr2:171374931~171375278:-
BRCA	trans	rs7312770	1	rs7312770	ENSG00000243538.1	CTB-55B8.1	-10.13	4.63e-23	8.09e-17	-0.32	-0.3	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr5:16902294~16902641:-
BRCA	trans	rs7927370	1	rs61916300	ENSG00000134612.10	FOLH1B	10.13	4.71e-23	8.23e-17	0.75	0.3	Systemic lupus erythematosus;	chr11:55513722	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61916301	ENSG00000134612.10	FOLH1B	10.13	4.71e-23	8.23e-17	0.75	0.3	Systemic lupus erythematosus;	chr11:55513915	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61916302	ENSG00000134612.10	FOLH1B	10.13	4.71e-23	8.23e-17	0.75	0.3	Systemic lupus erythematosus;	chr11:55514191	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61916319	ENSG00000134612.10	FOLH1B	10.13	4.71e-23	8.23e-17	0.75	0.3	Systemic lupus erythematosus;	chr11:55514642	chr11:89639227~89698718:+
BRCA	trans	rs4276421	0.593	rs13359915	ENSG00000231752.4	EMBP1	-10.13	4.75e-23	8.29e-17	-0.42	-0.3	P wave duration;	chr5:45769816	chr1:121519112~121571892:+
BRCA	trans	rs941207	0.756	rs1465081	ENSG00000228224.3	NACAP1	-10.13	4.76e-23	8.3e-17	-0.38	-0.3	Platelet count;	chr12:56656390	chr8:101361794~101372707:+
BRCA	trans	rs7927370	1	rs1364762	ENSG00000134612.10	FOLH1B	-10.13	4.76e-23	8.3e-17	-0.76	-0.3	Systemic lupus erythematosus;	chr11:55430437	chr11:89639227~89698718:+
BRCA	trans	rs9876781	1	rs6804774	ENSG00000225528.1	RP3-370M22.8	-10.12	4.92e-23	8.58e-17	-0.33	-0.3	Longevity;	chr3:48389129	chr22:39960397~39964683:+
BRCA	trans	rs864643	0.577	rs76395532	ENSG00000183298.5	RP11-556K13.1	10.12	4.95e-23	8.63e-17	0.62	0.3	Attention deficit hyperactivity disorder;	chr3:39490370	chr1:101786340~101787219:-
BRCA	trans	rs9876781	1	rs6442123	ENSG00000225528.1	RP3-370M22.8	-10.12	5.01e-23	8.73e-17	-0.33	-0.3	Longevity;	chr3:48458887	chr22:39960397~39964683:+
BRCA	trans	rs7927370	1	rs4537777	ENSG00000134612.10	FOLH1B	10.12	5.02e-23	8.74e-17	0.75	0.3	Systemic lupus erythematosus;	chr11:55474080	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs505338	ENSG00000134612.10	FOLH1B	-10.12	5.06e-23	8.82e-17	-0.74	-0.3	Systemic lupus erythematosus;	chr11:55553107	chr11:89639227~89698718:+
BRCA	trans	rs9876781	1	rs7634377	ENSG00000225528.1	RP3-370M22.8	-10.12	5.06e-23	8.82e-17	-0.33	-0.3	Longevity;	chr3:48379768	chr22:39960397~39964683:+
BRCA	trans	rs4276421	0.593	rs6451822	ENSG00000231752.4	EMBP1	-10.12	5.08e-23	8.85e-17	-0.41	-0.3	P wave duration;	chr5:45804888	chr1:121519112~121571892:+
BRCA	trans	rs7833986	0.501	rs2953898	ENSG00000236862.1	RPS20P24	10.12	5.08e-23	8.85e-17	0.39	0.3	Height;	chr8:56068244	chr9:72655832~72656192:-
BRCA	trans	rs7927370	0.85	rs61896277	ENSG00000134612.10	FOLH1B	10.11	5.27e-23	9.17e-17	0.76	0.3	Systemic lupus erythematosus;	chr11:55218883	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.867	rs2217762	ENSG00000134612.10	FOLH1B	10.11	5.27e-23	9.17e-17	0.76	0.3	Systemic lupus erythematosus;	chr11:55223086	chr11:89639227~89698718:+
BRCA	trans	rs73108077	0.736	rs6060596	ENSG00000279352.1	RP11-411B10.7	10.11	5.33e-23	9.28e-17	0.52	0.3	Red blood cell density in sickle cell anemia;	chr20:31261457	chr18:14010054~14010917:+
BRCA	trans	rs73108077	0.736	rs6060617	ENSG00000279352.1	RP11-411B10.7	10.11	5.33e-23	9.28e-17	0.52	0.3	Red blood cell density in sickle cell anemia;	chr20:31261849	chr18:14010054~14010917:+
BRCA	trans	rs73108077	0.736	rs77855283	ENSG00000279352.1	RP11-411B10.7	10.11	5.33e-23	9.28e-17	0.52	0.3	Red blood cell density in sickle cell anemia;	chr20:31262576	chr18:14010054~14010917:+
BRCA	trans	rs7927370	1	rs55895944	ENSG00000134612.10	FOLH1B	10.11	5.37e-23	9.34e-17	0.75	0.3	Systemic lupus erythematosus;	chr11:55474240	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs11822057	ENSG00000134612.10	FOLH1B	10.11	5.37e-23	9.34e-17	0.75	0.3	Systemic lupus erythematosus;	chr11:55475019	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs113732116	ENSG00000134612.10	FOLH1B	10.11	5.37e-23	9.34e-17	0.75	0.3	Systemic lupus erythematosus;	chr11:55475470	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61918003	ENSG00000134612.10	FOLH1B	10.11	5.37e-23	9.34e-17	0.75	0.3	Systemic lupus erythematosus;	chr11:55480214	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61918004	ENSG00000134612.10	FOLH1B	10.11	5.37e-23	9.34e-17	0.75	0.3	Systemic lupus erythematosus;	chr11:55481506	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61918005	ENSG00000134612.10	FOLH1B	10.11	5.37e-23	9.34e-17	0.75	0.3	Systemic lupus erythematosus;	chr11:55481766	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61918007	ENSG00000134612.10	FOLH1B	10.11	5.37e-23	9.34e-17	0.75	0.3	Systemic lupus erythematosus;	chr11:55481959	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61919673	ENSG00000134612.10	FOLH1B	10.11	5.37e-23	9.34e-17	0.75	0.3	Systemic lupus erythematosus;	chr11:55482899	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61919674	ENSG00000134612.10	FOLH1B	10.11	5.37e-23	9.34e-17	0.75	0.3	Systemic lupus erythematosus;	chr11:55482951	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs7943676	ENSG00000134612.10	FOLH1B	10.11	5.37e-23	9.34e-17	0.75	0.3	Systemic lupus erythematosus;	chr11:55483729	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs7927738	ENSG00000134612.10	FOLH1B	10.11	5.37e-23	9.34e-17	0.75	0.3	Systemic lupus erythematosus;	chr11:55484069	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs7935599	ENSG00000134612.10	FOLH1B	10.11	5.37e-23	9.34e-17	0.75	0.3	Systemic lupus erythematosus;	chr11:55484070	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs78414330	ENSG00000134612.10	FOLH1B	10.11	5.37e-23	9.34e-17	0.75	0.3	Systemic lupus erythematosus;	chr11:55484767	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61919677	ENSG00000134612.10	FOLH1B	10.11	5.37e-23	9.34e-17	0.75	0.3	Systemic lupus erythematosus;	chr11:55487034	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs1841165	ENSG00000134612.10	FOLH1B	10.11	5.37e-23	9.34e-17	0.75	0.3	Systemic lupus erythematosus;	chr11:55488608	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs1459111	ENSG00000134612.10	FOLH1B	10.11	5.37e-23	9.34e-17	0.75	0.3	Systemic lupus erythematosus;	chr11:55489256	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.85	rs1459110	ENSG00000134612.10	FOLH1B	10.11	5.37e-23	9.34e-17	0.75	0.3	Systemic lupus erythematosus;	chr11:55489294	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61919672	ENSG00000134612.10	FOLH1B	10.11	5.41e-23	9.4e-17	0.75	0.3	Systemic lupus erythematosus;	chr11:55482358	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61918002	ENSG00000134612.10	FOLH1B	10.11	5.54e-23	9.63e-17	0.75	0.3	Systemic lupus erythematosus;	chr11:55479041	chr11:89639227~89698718:+
BRCA	trans	rs864643	0.524	rs77060785	ENSG00000183298.5	RP11-556K13.1	10.11	5.67e-23	9.84e-17	0.62	0.3	Attention deficit hyperactivity disorder;	chr3:39491177	chr1:101786340~101787219:-
BRCA	trans	rs4276421	0.509	rs10041094	ENSG00000231752.4	EMBP1	10.11	5.68e-23	9.87e-17	0.42	0.3	P wave duration;	chr5:45996800	chr1:121519112~121571892:+
BRCA	trans	rs7927370	0.85	rs61896292	ENSG00000134612.10	FOLH1B	10.11	5.73e-23	9.95e-17	0.77	0.3	Systemic lupus erythematosus;	chr11:55225455	chr11:89639227~89698718:+
BRCA	trans	rs877636	1	rs877636	ENSG00000234354.3	RPS26P47	-10.1	5.79e-23	1.01e-16	-0.38	-0.3	Cognitive function;	chr12:56086799	chr13:100539901~100540248:-
BRCA	trans	rs4276421	0.593	rs4866973	ENSG00000231752.4	EMBP1	-10.1	5.79e-23	1.01e-16	-0.41	-0.3	P wave duration;	chr5:45816584	chr1:121519112~121571892:+
BRCA	trans	rs11098499	0.754	rs1849457	ENSG00000275858.1	RP11-291L22.8	10.1	5.85e-23	1.01e-16	0.36	0.3	Corneal astigmatism;	chr4:119333200	chr10:38450738~38451069:-
BRCA	trans	rs26067	0.74	rs27683	ENSG00000231752.4	EMBP1	10.1	6.05e-23	1.05e-16	0.42	0.3	Breast cancer;	chr5:50865708	chr1:121519112~121571892:+
BRCA	trans	rs3942852	0.774	rs10838812	ENSG00000134612.10	FOLH1B	-10.1	6.08e-23	1.05e-16	-0.41	-0.3	Acute lymphoblastic leukemia (childhood);	chr11:48165372	chr11:89639227~89698718:+
BRCA	trans	rs3942852	0.774	rs10838813	ENSG00000134612.10	FOLH1B	-10.1	6.08e-23	1.05e-16	-0.41	-0.3	Acute lymphoblastic leukemia (childhood);	chr11:48165417	chr11:89639227~89698718:+
BRCA	trans	rs3942852	0.774	rs10838814	ENSG00000134612.10	FOLH1B	-10.1	6.08e-23	1.05e-16	-0.41	-0.3	Acute lymphoblastic leukemia (childhood);	chr11:48165626	chr11:89639227~89698718:+
BRCA	trans	rs3806843	0.966	rs7710380	ENSG00000231043.3	AC007238.1	-10.1	6.18e-23	1.07e-16	-0.35	-0.3	Depressive symptoms (multi-trait analysis);	chr5:140776679	chr2:58460292~58462032:-
BRCA	trans	rs7927370	1	rs7952701	ENSG00000134612.10	FOLH1B	10.1	6.19e-23	1.07e-16	0.76	0.3	Systemic lupus erythematosus;	chr11:55521530	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.867	rs55961791	ENSG00000134612.10	FOLH1B	10.1	6.19e-23	1.07e-16	0.76	0.3	Systemic lupus erythematosus;	chr11:55521861	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs55853559	ENSG00000134612.10	FOLH1B	10.1	6.19e-23	1.07e-16	0.76	0.3	Systemic lupus erythematosus;	chr11:55521862	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs56098095	ENSG00000134612.10	FOLH1B	10.1	6.19e-23	1.07e-16	0.76	0.3	Systemic lupus erythematosus;	chr11:55521937	chr11:89639227~89698718:+
BRCA	trans	rs9329221	0.65	rs657913	ENSG00000253893.2	FAM85B	10.1	6.19e-23	1.07e-16	0.37	0.3	Neuroticism;	chr8:10025065	chr8:8167819~8226614:-
BRCA	trans	rs877636	0.74	rs772920	ENSG00000196933.5	RPS26P11	10.09	6.52e-23	1.13e-16	0.4	0.3	Cognitive function;	chr12:55996580	chrX:72044545~72044892:+
BRCA	trans	rs877636	0.74	rs705698	ENSG00000234513.1	AC073072.7	10.09	6.54e-23	1.13e-16	0.4	0.3	Cognitive function;	chr12:55990903	chr7:22773646~22773993:-
BRCA	trans	rs7927370	0.85	rs61897311	ENSG00000134612.10	FOLH1B	10.09	6.61e-23	1.14e-16	0.76	0.3	Systemic lupus erythematosus;	chr11:55178899	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.702	rs61897316	ENSG00000134612.10	FOLH1B	10.09	6.61e-23	1.14e-16	0.76	0.3	Systemic lupus erythematosus;	chr11:55182855	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.85	rs76726553	ENSG00000134612.10	FOLH1B	10.09	6.61e-23	1.14e-16	0.76	0.3	Systemic lupus erythematosus;	chr11:55183365	chr11:89639227~89698718:+
BRCA	trans	rs16937956	0.597	rs34617462	ENSG00000266891.1	RP11-692N5.2	10.09	6.7e-23	1.16e-16	0.41	0.3	Body mass index;	chr11:8403484	chr18:9734882~9735602:-
BRCA	trans	rs9467773	0.587	rs10946813	ENSG00000242375.1	RP11-498P14.3	10.09	6.73e-23	1.16e-16	0.41	0.3	Intelligence (multi-trait analysis);	chr6:26344913	chr9:97195351~97197687:-
BRCA	trans	rs3942852	0.696	rs4597030	ENSG00000134612.10	FOLH1B	-10.09	6.8e-23	1.18e-16	-0.4	-0.3	Acute lymphoblastic leukemia (childhood);	chr11:48155021	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs2155029	ENSG00000134612.10	FOLH1B	10.09	6.9e-23	1.19e-16	0.75	0.3	Systemic lupus erythematosus;	chr11:55444335	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs2186595	ENSG00000134612.10	FOLH1B	10.09	6.9e-23	1.19e-16	0.75	0.3	Systemic lupus erythematosus;	chr11:55444557	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs3949112	ENSG00000134612.10	FOLH1B	10.09	6.9e-23	1.19e-16	0.75	0.3	Systemic lupus erythematosus;	chr11:55444617	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs4488212	ENSG00000134612.10	FOLH1B	10.09	6.9e-23	1.19e-16	0.75	0.3	Systemic lupus erythematosus;	chr11:55444620	chr11:89639227~89698718:+
BRCA	trans	rs877636	0.74	rs705702	ENSG00000234513.1	AC073072.7	-10.08	7.01e-23	1.21e-16	-0.39	-0.3	Cognitive function;	chr12:55996852	chr7:22773646~22773993:-
BRCA	trans	rs3806843	0.966	rs10053945	ENSG00000231043.3	AC007238.1	-10.08	7.04e-23	1.22e-16	-0.35	-0.3	Depressive symptoms (multi-trait analysis);	chr5:140780542	chr2:58460292~58462032:-
BRCA	trans	rs3806843	1	rs1548700	ENSG00000231043.3	AC007238.1	-10.08	7.04e-23	1.22e-16	-0.35	-0.3	Depressive symptoms (multi-trait analysis);	chr5:140785304	chr2:58460292~58462032:-
BRCA	trans	rs3806843	1	rs1548699	ENSG00000231043.3	AC007238.1	-10.08	7.04e-23	1.22e-16	-0.35	-0.3	Depressive symptoms (multi-trait analysis);	chr5:140785333	chr2:58460292~58462032:-
BRCA	trans	rs3806843	1	rs12055222	ENSG00000231043.3	AC007238.1	-10.08	7.04e-23	1.22e-16	-0.35	-0.3	Depressive symptoms (multi-trait analysis);	chr5:140785983	chr2:58460292~58462032:-
BRCA	trans	rs3806843	1	rs6898939	ENSG00000231043.3	AC007238.1	-10.08	7.04e-23	1.22e-16	-0.35	-0.3	Depressive symptoms (multi-trait analysis);	chr5:140789770	chr2:58460292~58462032:-
BRCA	trans	rs6424115	0.8	rs4649123	ENSG00000228217.1	AL390877.1	-10.08	7.04e-23	1.22e-16	-0.37	-0.3	Immature fraction of reticulocytes;	chr1:23871206	chr1:117778087~117778506:-
BRCA	trans	rs11098499	0.863	rs17050695	ENSG00000275858.1	RP11-291L22.8	10.08	7.25e-23	1.25e-16	0.36	0.3	Corneal astigmatism;	chr4:119568372	chr10:38450738~38451069:-
BRCA	trans	rs7927370	1	rs55647117	ENSG00000134612.10	FOLH1B	10.08	7.3e-23	1.26e-16	0.73	0.3	Systemic lupus erythematosus;	chr11:55573420	chr11:89639227~89698718:+
BRCA	trans	rs3779195	0.585	rs58699591	ENSG00000225169.1	BRI3P1	-10.08	7.59e-23	1.31e-16	-0.49	-0.3	Sex hormone-binding globulin levels;	chr7:98247392	chr1:100213293~100213670:+
BRCA	trans	rs3096299	0.719	rs2911262	ENSG00000215030.5	RPL13P12	-10.07	7.73e-23	1.33e-16	-0.3	-0.3	Multiple myeloma (IgH translocation);	chr16:89448633	chr17:17383377~17384012:-
BRCA	trans	rs7927370	0.702	rs78900595	ENSG00000134612.10	FOLH1B	10.07	7.79e-23	1.34e-16	0.8	0.3	Systemic lupus erythematosus;	chr11:55711929	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.702	rs61894776	ENSG00000134612.10	FOLH1B	10.07	7.79e-23	1.34e-16	0.8	0.3	Systemic lupus erythematosus;	chr11:55712298	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.85	rs17590884	ENSG00000134612.10	FOLH1B	10.07	7.79e-23	1.34e-16	0.8	0.3	Systemic lupus erythematosus;	chr11:55718954	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61894789	ENSG00000134612.10	FOLH1B	10.07	7.79e-23	1.34e-16	0.8	0.3	Systemic lupus erythematosus;	chr11:55719443	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs7944383	ENSG00000134612.10	FOLH1B	10.07	7.79e-23	1.34e-16	0.8	0.3	Systemic lupus erythematosus;	chr11:55719776	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs7944525	ENSG00000134612.10	FOLH1B	10.07	7.79e-23	1.34e-16	0.8	0.3	Systemic lupus erythematosus;	chr11:55719915	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61894790	ENSG00000134612.10	FOLH1B	10.07	7.79e-23	1.34e-16	0.8	0.3	Systemic lupus erythematosus;	chr11:55720576	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61916395	ENSG00000134612.10	FOLH1B	10.07	7.85e-23	1.35e-16	0.74	0.3	Systemic lupus erythematosus;	chr11:55445029	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs7116208	ENSG00000134612.10	FOLH1B	10.07	7.85e-23	1.35e-16	0.74	0.3	Systemic lupus erythematosus;	chr11:55445340	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs11823346	ENSG00000134612.10	FOLH1B	10.07	7.85e-23	1.35e-16	0.74	0.3	Systemic lupus erythematosus;	chr11:55447212	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.702	rs7125031	ENSG00000134612.10	FOLH1B	10.07	7.85e-23	1.35e-16	0.74	0.3	Systemic lupus erythematosus;	chr11:55447598	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs7940928	ENSG00000134612.10	FOLH1B	10.07	7.85e-23	1.35e-16	0.74	0.3	Systemic lupus erythematosus;	chr11:55450002	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs7111663	ENSG00000134612.10	FOLH1B	10.07	7.85e-23	1.35e-16	0.74	0.3	Systemic lupus erythematosus;	chr11:55451446	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs7111681	ENSG00000134612.10	FOLH1B	10.07	7.85e-23	1.35e-16	0.74	0.3	Systemic lupus erythematosus;	chr11:55451502	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs7106100	ENSG00000134612.10	FOLH1B	10.07	7.85e-23	1.35e-16	0.74	0.3	Systemic lupus erythematosus;	chr11:55451906	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs7109287	ENSG00000134612.10	FOLH1B	10.07	7.85e-23	1.35e-16	0.74	0.3	Systemic lupus erythematosus;	chr11:55451956	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61916403	ENSG00000134612.10	FOLH1B	10.07	7.85e-23	1.35e-16	0.74	0.3	Systemic lupus erythematosus;	chr11:55453753	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs7924882	ENSG00000134612.10	FOLH1B	10.07	7.85e-23	1.35e-16	0.74	0.3	Systemic lupus erythematosus;	chr11:55454585	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61916407	ENSG00000134612.10	FOLH1B	10.07	7.85e-23	1.35e-16	0.74	0.3	Systemic lupus erythematosus;	chr11:55454994	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs2042591	ENSG00000134612.10	FOLH1B	10.07	7.85e-23	1.35e-16	0.74	0.3	Systemic lupus erythematosus;	chr11:55455514	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.85	rs61916409	ENSG00000134612.10	FOLH1B	10.07	7.85e-23	1.35e-16	0.74	0.3	Systemic lupus erythematosus;	chr11:55456234	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs79277988	ENSG00000134612.10	FOLH1B	10.07	7.85e-23	1.35e-16	0.74	0.3	Systemic lupus erythematosus;	chr11:55456849	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs79633274	ENSG00000134612.10	FOLH1B	10.07	7.85e-23	1.35e-16	0.74	0.3	Systemic lupus erythematosus;	chr11:55456920	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61916410	ENSG00000134612.10	FOLH1B	10.07	7.85e-23	1.35e-16	0.74	0.3	Systemic lupus erythematosus;	chr11:55457393	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs5025344	ENSG00000134612.10	FOLH1B	10.07	7.85e-23	1.35e-16	0.74	0.3	Systemic lupus erythematosus;	chr11:55457548	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs76046642	ENSG00000134612.10	FOLH1B	10.07	7.85e-23	1.35e-16	0.74	0.3	Systemic lupus erythematosus;	chr11:55457941	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.85	rs111804449	ENSG00000134612.10	FOLH1B	10.07	7.85e-23	1.35e-16	0.74	0.3	Systemic lupus erythematosus;	chr11:55460211	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61916458	ENSG00000134612.10	FOLH1B	10.07	7.85e-23	1.35e-16	0.74	0.3	Systemic lupus erythematosus;	chr11:55466930	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.867	rs61916459	ENSG00000134612.10	FOLH1B	10.07	7.85e-23	1.35e-16	0.74	0.3	Systemic lupus erythematosus;	chr11:55467246	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.867	rs61917960	ENSG00000134612.10	FOLH1B	10.07	7.85e-23	1.35e-16	0.74	0.3	Systemic lupus erythematosus;	chr11:55467262	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.717	rs61917961	ENSG00000134612.10	FOLH1B	10.07	7.85e-23	1.35e-16	0.74	0.3	Systemic lupus erythematosus;	chr11:55467345	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.85	rs61917962	ENSG00000134612.10	FOLH1B	10.07	7.85e-23	1.35e-16	0.74	0.3	Systemic lupus erythematosus;	chr11:55467356	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61917963	ENSG00000134612.10	FOLH1B	10.07	7.85e-23	1.35e-16	0.74	0.3	Systemic lupus erythematosus;	chr11:55468283	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs2216993	ENSG00000134612.10	FOLH1B	10.07	7.85e-23	1.35e-16	0.74	0.3	Systemic lupus erythematosus;	chr11:55469478	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs2194835	ENSG00000134612.10	FOLH1B	10.07	7.85e-23	1.35e-16	0.74	0.3	Systemic lupus erythematosus;	chr11:55469789	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs11820245	ENSG00000134612.10	FOLH1B	10.07	7.85e-23	1.35e-16	0.74	0.3	Systemic lupus erythematosus;	chr11:55473419	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs11820246	ENSG00000134612.10	FOLH1B	10.07	7.85e-23	1.35e-16	0.74	0.3	Systemic lupus erythematosus;	chr11:55473425	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs55736192	ENSG00000134612.10	FOLH1B	10.07	7.85e-23	1.35e-16	0.74	0.3	Systemic lupus erythematosus;	chr11:55473647	chr11:89639227~89698718:+
BRCA	trans	rs7312770	1	rs7312770	ENSG00000212829.8	RPS26P3	-10.07	7.9e-23	1.36e-16	-0.34	-0.3	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr9:9090898~9091245:+
BRCA	trans	rs9876781	1	rs13076076	ENSG00000225528.1	RP3-370M22.8	-10.07	8.04e-23	1.38e-16	-0.32	-0.3	Longevity;	chr3:48437629	chr22:39960397~39964683:+
BRCA	trans	rs3942852	0.726	rs1503171	ENSG00000134612.10	FOLH1B	-10.07	8.09e-23	1.39e-16	-0.4	-0.3	Acute lymphoblastic leukemia (childhood);	chr11:48153600	chr11:89639227~89698718:+
BRCA	trans	rs3942852	0.726	rs10742836	ENSG00000134612.10	FOLH1B	-10.07	8.09e-23	1.39e-16	-0.4	-0.3	Acute lymphoblastic leukemia (childhood);	chr11:48154279	chr11:89639227~89698718:+
BRCA	trans	rs3942852	0.774	rs10838811	ENSG00000134612.10	FOLH1B	-10.07	8.23e-23	1.41e-16	-0.4	-0.3	Acute lymphoblastic leukemia (childhood);	chr11:48165243	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs17494990	ENSG00000134612.10	FOLH1B	10.06	8.5e-23	1.46e-16	0.77	0.3	Systemic lupus erythematosus;	chr11:55510285	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61916169	ENSG00000134612.10	FOLH1B	10.06	8.62e-23	1.48e-16	0.75	0.3	Systemic lupus erythematosus;	chr11:55353977	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61916170	ENSG00000134612.10	FOLH1B	10.06	8.62e-23	1.48e-16	0.75	0.3	Systemic lupus erythematosus;	chr11:55354409	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61916172	ENSG00000134612.10	FOLH1B	10.06	8.62e-23	1.48e-16	0.75	0.3	Systemic lupus erythematosus;	chr11:55355313	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61916174	ENSG00000134612.10	FOLH1B	10.06	8.62e-23	1.48e-16	0.75	0.3	Systemic lupus erythematosus;	chr11:55356134	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.557	rs61916176	ENSG00000134612.10	FOLH1B	10.06	8.62e-23	1.48e-16	0.75	0.3	Systemic lupus erythematosus;	chr11:55356894	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs56229188	ENSG00000134612.10	FOLH1B	10.06	8.75e-23	1.5e-16	0.76	0.3	Systemic lupus erythematosus;	chr11:55313622	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs11821230	ENSG00000134612.10	FOLH1B	10.06	8.76e-23	1.5e-16	0.75	0.3	Systemic lupus erythematosus;	chr11:55297491	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs1836287	ENSG00000134612.10	FOLH1B	10.06	8.76e-23	1.5e-16	0.75	0.3	Systemic lupus erythematosus;	chr11:55299211	chr11:89639227~89698718:+
BRCA	trans	rs330048	0.545	rs11249913	ENSG00000253893.2	FAM85B	10.06	8.87e-23	1.52e-16	0.38	0.3	Systemic lupus erythematosus;	chr8:9286011	chr8:8167819~8226614:-
BRCA	trans	rs9876781	1	rs13314659	ENSG00000225528.1	RP3-370M22.8	10.06	8.97e-23	1.54e-16	0.32	0.3	Longevity;	chr3:48407742	chr22:39960397~39964683:+
BRCA	trans	rs1347297	0.614	rs4894017	ENSG00000269800.1	PLEKHA3P1	10.06	9.15e-23	1.57e-16	0.31	0.3	Alzheimer disease and age of onset;	chr2:178416335	chr19:41521043~41521989:-
BRCA	trans	rs7927370	1	rs78057082	ENSG00000134612.10	FOLH1B	10.05	9.25e-23	1.58e-16	0.76	0.3	Systemic lupus erythematosus;	chr11:55311851	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs7943639	ENSG00000134612.10	FOLH1B	10.05	9.25e-23	1.58e-16	0.76	0.3	Systemic lupus erythematosus;	chr11:55312421	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61918386	ENSG00000134612.10	FOLH1B	10.05	9.25e-23	1.58e-16	0.76	0.3	Systemic lupus erythematosus;	chr11:55316891	chr11:89639227~89698718:+
BRCA	trans	rs4276421	0.571	rs4560554	ENSG00000231752.4	EMBP1	10.05	9.27e-23	1.58e-16	0.41	0.3	P wave duration;	chr5:45867574	chr1:121519112~121571892:+
BRCA	trans	rs7927370	1	rs7112787	ENSG00000134612.10	FOLH1B	10.05	9.36e-23	1.6e-16	0.73	0.3	Systemic lupus erythematosus;	chr11:55574679	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.85	rs61898111	ENSG00000134612.10	FOLH1B	10.05	9.36e-23	1.6e-16	0.78	0.3	Systemic lupus erythematosus;	chr11:55091084	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.702	rs9667029	ENSG00000134612.10	FOLH1B	10.05	9.36e-23	1.6e-16	0.78	0.3	Systemic lupus erythematosus;	chr11:55091597	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61898112	ENSG00000134612.10	FOLH1B	10.05	9.36e-23	1.6e-16	0.78	0.3	Systemic lupus erythematosus;	chr11:55092119	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.867	rs55956850	ENSG00000134612.10	FOLH1B	10.05	9.36e-23	1.6e-16	0.78	0.3	Systemic lupus erythematosus;	chr11:55094755	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.557	rs61898129	ENSG00000134612.10	FOLH1B	10.05	9.36e-23	1.6e-16	0.78	0.3	Systemic lupus erythematosus;	chr11:55096782	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs4341558	ENSG00000134612.10	FOLH1B	10.05	9.36e-23	1.6e-16	0.78	0.3	Systemic lupus erythematosus;	chr11:55101902	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs55744313	ENSG00000134612.10	FOLH1B	10.05	9.36e-23	1.6e-16	0.78	0.3	Systemic lupus erythematosus;	chr11:55104850	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61898136	ENSG00000134612.10	FOLH1B	10.05	9.36e-23	1.6e-16	0.78	0.3	Systemic lupus erythematosus;	chr11:55105576	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.85	rs61898138	ENSG00000134612.10	FOLH1B	10.05	9.36e-23	1.6e-16	0.78	0.3	Systemic lupus erythematosus;	chr11:55107768	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.702	rs78466400	ENSG00000134612.10	FOLH1B	10.05	9.36e-23	1.6e-16	0.78	0.3	Systemic lupus erythematosus;	chr11:55116915	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.867	rs7942656	ENSG00000134612.10	FOLH1B	10.05	9.84e-23	1.68e-16	0.75	0.3	Systemic lupus erythematosus;	chr11:55364976	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs55791965	ENSG00000134612.10	FOLH1B	10.05	9.84e-23	1.68e-16	0.75	0.3	Systemic lupus erythematosus;	chr11:55365183	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs7101448	ENSG00000134612.10	FOLH1B	10.05	9.84e-23	1.68e-16	0.75	0.3	Systemic lupus erythematosus;	chr11:55365746	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.702	rs56016316	ENSG00000134612.10	FOLH1B	10.05	9.84e-23	1.68e-16	0.75	0.3	Systemic lupus erythematosus;	chr11:55367120	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs55864866	ENSG00000134612.10	FOLH1B	10.05	9.84e-23	1.68e-16	0.75	0.3	Systemic lupus erythematosus;	chr11:55367419	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.85	rs112715158	ENSG00000134612.10	FOLH1B	10.05	9.84e-23	1.68e-16	0.75	0.3	Systemic lupus erythematosus;	chr11:55367486	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs113334225	ENSG00000134612.10	FOLH1B	10.05	9.84e-23	1.68e-16	0.75	0.3	Systemic lupus erythematosus;	chr11:55367504	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs113150368	ENSG00000134612.10	FOLH1B	10.05	9.84e-23	1.68e-16	0.75	0.3	Systemic lupus erythematosus;	chr11:55367569	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs7935986	ENSG00000134612.10	FOLH1B	10.05	9.84e-23	1.68e-16	0.75	0.3	Systemic lupus erythematosus;	chr11:55369086	chr11:89639227~89698718:+
BRCA	trans	rs8010715	1	rs3742500	ENSG00000238000.1	RP11-274E7.2	10.04	1.03e-22	1.75e-16	0.34	0.3	IgG glycosylation;	chr14:24142769	chr5:98213402~98214121:+
BRCA	trans	rs9876781	0.933	rs6442124	ENSG00000225528.1	RP3-370M22.8	-10.04	1.03e-22	1.76e-16	-0.33	-0.3	Longevity;	chr3:48463903	chr22:39960397~39964683:+
BRCA	trans	rs864643	0.678	rs7631217	ENSG00000183298.5	RP11-556K13.1	-10.04	1.03e-22	1.76e-16	-0.46	-0.3	Attention deficit hyperactivity disorder;	chr3:39478568	chr1:101786340~101787219:-
BRCA	trans	rs7927370	1	rs61919576	ENSG00000134612.10	FOLH1B	10.04	1.05e-22	1.79e-16	0.74	0.3	Systemic lupus erythematosus;	chr11:55557416	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs56063920	ENSG00000134612.10	FOLH1B	10.04	1.05e-22	1.79e-16	0.74	0.3	Systemic lupus erythematosus;	chr11:55558773	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs56299119	ENSG00000134612.10	FOLH1B	10.04	1.05e-22	1.79e-16	0.74	0.3	Systemic lupus erythematosus;	chr11:55560872	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.702	rs61918406	ENSG00000134612.10	FOLH1B	10.04	1.06e-22	1.8e-16	0.75	0.3	Systemic lupus erythematosus;	chr11:55336183	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs7118951	ENSG00000134612.10	FOLH1B	10.04	1.06e-22	1.8e-16	0.75	0.3	Systemic lupus erythematosus;	chr11:55337831	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61918407	ENSG00000134612.10	FOLH1B	10.04	1.06e-22	1.8e-16	0.75	0.3	Systemic lupus erythematosus;	chr11:55340028	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61918410	ENSG00000134612.10	FOLH1B	10.04	1.06e-22	1.8e-16	0.75	0.3	Systemic lupus erythematosus;	chr11:55342084	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs7121804	ENSG00000134612.10	FOLH1B	10.04	1.06e-22	1.8e-16	0.75	0.3	Systemic lupus erythematosus;	chr11:55343746	chr11:89639227~89698718:+
BRCA	trans	rs7937890	0.559	rs2575853	ENSG00000236360.2	RP11-334A14.2	10.04	1.07e-22	1.81e-16	0.39	0.3	Mitochondrial DNA levels;	chr11:14512417	chr1:52993201~52993702:-
BRCA	trans	rs7927370	1	rs61898110	ENSG00000134612.10	FOLH1B	10.04	1.07e-22	1.82e-16	0.75	0.3	Systemic lupus erythematosus;	chr11:55091061	chr11:89639227~89698718:+
BRCA	trans	rs1190596	0.525	rs2236493	ENSG00000181359.5	HSP90AA6P	-10.04	1.07e-22	1.82e-16	-0.38	-0.3	Behavioural disinhibition (generation interaction);	chr14:102229356	chr4:170581470~170605450:-
BRCA	trans	rs7927370	0.557	rs61894950	ENSG00000134612.10	FOLH1B	10.04	1.07e-22	1.82e-16	0.75	0.3	Systemic lupus erythematosus;	chr11:55279875	chr11:89639227~89698718:+
BRCA	trans	rs4276421	0.593	rs7718780	ENSG00000231752.4	EMBP1	-10.04	1.08e-22	1.82e-16	-0.41	-0.3	P wave duration;	chr5:45804191	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.53	rs72751925	ENSG00000231752.4	EMBP1	10.04	1.09e-22	1.85e-16	0.42	0.3	P wave duration;	chr5:45962607	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.593	rs9687374	ENSG00000231752.4	EMBP1	-10.04	1.1e-22	1.86e-16	-0.41	-0.3	P wave duration;	chr5:45796838	chr1:121519112~121571892:+
BRCA	trans	rs7927370	1	rs61894774	ENSG00000134612.10	FOLH1B	10.04	1.1e-22	1.86e-16	0.79	0.3	Systemic lupus erythematosus;	chr11:55710616	chr11:89639227~89698718:+
BRCA	trans	rs11098499	0.754	rs1814813	ENSG00000275858.1	RP11-291L22.8	-10.03	1.12e-22	1.89e-16	-0.34	-0.3	Corneal astigmatism;	chr4:119337052	chr10:38450738~38451069:-
BRCA	trans	rs7927370	1	rs28752322	ENSG00000134612.10	FOLH1B	10.03	1.12e-22	1.89e-16	0.77	0.3	Systemic lupus erythematosus;	chr11:55030967	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs28848478	ENSG00000134612.10	FOLH1B	10.03	1.12e-22	1.89e-16	0.77	0.3	Systemic lupus erythematosus;	chr11:55031826	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs28839871	ENSG00000134612.10	FOLH1B	10.03	1.12e-22	1.89e-16	0.77	0.3	Systemic lupus erythematosus;	chr11:55032755	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61895825	ENSG00000134612.10	FOLH1B	10.03	1.12e-22	1.89e-16	0.77	0.3	Systemic lupus erythematosus;	chr11:55040850	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs55899800	ENSG00000134612.10	FOLH1B	10.03	1.12e-22	1.89e-16	0.77	0.3	Systemic lupus erythematosus;	chr11:55042774	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs56189573	ENSG00000134612.10	FOLH1B	10.03	1.12e-22	1.89e-16	0.77	0.3	Systemic lupus erythematosus;	chr11:55042985	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs114635668	ENSG00000134612.10	FOLH1B	10.03	1.12e-22	1.89e-16	0.77	0.3	Systemic lupus erythematosus;	chr11:55045369	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs28805394	ENSG00000134612.10	FOLH1B	10.03	1.12e-22	1.89e-16	0.77	0.3	Systemic lupus erythematosus;	chr11:55046300	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.85	rs116759423	ENSG00000134612.10	FOLH1B	10.03	1.12e-22	1.89e-16	0.77	0.3	Systemic lupus erythematosus;	chr11:55050133	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61895838	ENSG00000134612.10	FOLH1B	10.03	1.12e-22	1.89e-16	0.77	0.3	Systemic lupus erythematosus;	chr11:55051952	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.702	rs28852151	ENSG00000134612.10	FOLH1B	10.03	1.12e-22	1.89e-16	0.77	0.3	Systemic lupus erythematosus;	chr11:55052631	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs56080803	ENSG00000134612.10	FOLH1B	10.03	1.12e-22	1.89e-16	0.77	0.3	Systemic lupus erythematosus;	chr11:55053896	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs28871886	ENSG00000134612.10	FOLH1B	10.03	1.12e-22	1.89e-16	0.77	0.3	Systemic lupus erythematosus;	chr11:55054914	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs28809233	ENSG00000134612.10	FOLH1B	10.03	1.12e-22	1.89e-16	0.77	0.3	Systemic lupus erythematosus;	chr11:55057042	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61898062	ENSG00000134612.10	FOLH1B	10.03	1.12e-22	1.89e-16	0.77	0.3	Systemic lupus erythematosus;	chr11:55062664	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.702	rs61898068	ENSG00000134612.10	FOLH1B	10.03	1.12e-22	1.89e-16	0.77	0.3	Systemic lupus erythematosus;	chr11:55066252	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61898073	ENSG00000134612.10	FOLH1B	10.03	1.12e-22	1.89e-16	0.77	0.3	Systemic lupus erythematosus;	chr11:55072811	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs76515019	ENSG00000134612.10	FOLH1B	10.03	1.12e-22	1.89e-16	0.77	0.3	Systemic lupus erythematosus;	chr11:55074549	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61898074	ENSG00000134612.10	FOLH1B	10.03	1.12e-22	1.89e-16	0.77	0.3	Systemic lupus erythematosus;	chr11:55074704	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.85	rs61898075	ENSG00000134612.10	FOLH1B	10.03	1.12e-22	1.89e-16	0.77	0.3	Systemic lupus erythematosus;	chr11:55078191	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61898076	ENSG00000134612.10	FOLH1B	10.03	1.12e-22	1.89e-16	0.77	0.3	Systemic lupus erythematosus;	chr11:55080060	chr11:89639227~89698718:+
BRCA	trans	rs9876781	1	rs7636044	ENSG00000225528.1	RP3-370M22.8	-10.03	1.14e-22	1.93e-16	-0.32	-0.3	Longevity;	chr3:48443151	chr22:39960397~39964683:+
BRCA	trans	rs9876781	1	rs4490383	ENSG00000225528.1	RP3-370M22.8	-10.03	1.14e-22	1.93e-16	-0.32	-0.3	Longevity;	chr3:48443275	chr22:39960397~39964683:+
BRCA	trans	rs7927370	1	rs11828054	ENSG00000134612.10	FOLH1B	10.03	1.15e-22	1.93e-16	0.76	0.3	Systemic lupus erythematosus;	chr11:55530086	chr11:89639227~89698718:+
BRCA	trans	rs867371	0.762	rs12905578	ENSG00000235370.6	DNM1P51	10.03	1.16e-22	1.95e-16	0.34	0.3	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82288923	chr15:84398316~84411701:-
BRCA	trans	rs7927370	1	rs77797466	ENSG00000134612.10	FOLH1B	10.03	1.2e-22	2.02e-16	0.75	0.3	Systemic lupus erythematosus;	chr11:55303617	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61896026	ENSG00000134612.10	FOLH1B	10.03	1.2e-22	2.02e-16	0.75	0.3	Systemic lupus erythematosus;	chr11:55303906	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs11821737	ENSG00000134612.10	FOLH1B	10.03	1.2e-22	2.02e-16	0.75	0.3	Systemic lupus erythematosus;	chr11:55310289	chr11:89639227~89698718:+
BRCA	trans	rs4276421	0.593	rs4551074	ENSG00000231752.4	EMBP1	-10.03	1.21e-22	2.03e-16	-0.41	-0.3	P wave duration;	chr5:45792651	chr1:121519112~121571892:+
BRCA	trans	rs73108077	0.736	rs6060993	ENSG00000279352.1	RP11-411B10.7	10.02	1.22e-22	2.05e-16	0.52	0.3	Red blood cell density in sickle cell anemia;	chr20:31278917	chr18:14010054~14010917:+
BRCA	trans	rs3942852	0.688	rs10742834	ENSG00000134612.10	FOLH1B	-10.02	1.22e-22	2.06e-16	-0.4	-0.3	Acute lymphoblastic leukemia (childhood);	chr11:48148165	chr11:89639227~89698718:+
BRCA	trans	rs4276421	0.593	rs6872194	ENSG00000231752.4	EMBP1	-10.02	1.26e-22	2.13e-16	-0.41	-0.3	P wave duration;	chr5:45792959	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.593	rs10058269	ENSG00000231752.4	EMBP1	10.02	1.27e-22	2.14e-16	0.41	0.3	P wave duration;	chr5:45750039	chr1:121519112~121571892:+
BRCA	trans	rs7927370	0.85	rs1364761	ENSG00000134612.10	FOLH1B	10.02	1.27e-22	2.14e-16	0.74	0.3	Systemic lupus erythematosus;	chr11:55430474	chr11:89639227~89698718:+
BRCA	trans	rs3096299	0.685	rs4329923	ENSG00000215030.5	RPL13P12	-10.02	1.27e-22	2.14e-16	-0.31	-0.3	Multiple myeloma (IgH translocation);	chr16:89493770	chr17:17383377~17384012:-
BRCA	trans	rs9876781	1	rs9311423	ENSG00000225528.1	RP3-370M22.8	-10.01	1.34e-22	2.25e-16	-0.32	-0.3	Longevity;	chr3:48378818	chr22:39960397~39964683:+
BRCA	trans	rs12200782	1	rs3800304	ENSG00000242375.1	RP11-498P14.3	-10.01	1.35e-22	2.27e-16	-0.72	-0.3	Small cell lung carcinoma;	chr6:26598570	chr9:97195351~97197687:-
BRCA	trans	rs12200782	1	rs72844495	ENSG00000242375.1	RP11-498P14.3	-10.01	1.35e-22	2.27e-16	-0.72	-0.3	Small cell lung carcinoma;	chr6:26610412	chr9:97195351~97197687:-
BRCA	trans	rs12200782	1	rs72844496	ENSG00000242375.1	RP11-498P14.3	-10.01	1.35e-22	2.27e-16	-0.72	-0.3	Small cell lung carcinoma;	chr6:26611380	chr9:97195351~97197687:-
BRCA	trans	rs7927370	1	rs28826070	ENSG00000134612.10	FOLH1B	10.01	1.39e-22	2.33e-16	0.74	0.3	Systemic lupus erythematosus;	chr11:55034073	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs28897249	ENSG00000134612.10	FOLH1B	10.01	1.39e-22	2.33e-16	0.74	0.3	Systemic lupus erythematosus;	chr11:55046808	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs115582955	ENSG00000134612.10	FOLH1B	10.01	1.39e-22	2.33e-16	0.74	0.3	Systemic lupus erythematosus;	chr11:55055915	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs11825077	ENSG00000134612.10	FOLH1B	10.01	1.39e-22	2.33e-16	0.74	0.3	Systemic lupus erythematosus;	chr11:55070558	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs55693437	ENSG00000134612.10	FOLH1B	10.01	1.39e-22	2.33e-16	0.74	0.3	Systemic lupus erythematosus;	chr11:55071605	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.702	rs2204231	ENSG00000134612.10	FOLH1B	10.01	1.39e-22	2.33e-16	0.74	0.3	Systemic lupus erythematosus;	chr11:55076983	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs11819957	ENSG00000134612.10	FOLH1B	10.01	1.39e-22	2.33e-16	0.74	0.3	Systemic lupus erythematosus;	chr11:55536786	chr11:89639227~89698718:+
BRCA	trans	rs4276421	0.593	rs6451820	ENSG00000231752.4	EMBP1	-10.01	1.4e-22	2.34e-16	-0.41	-0.3	P wave duration;	chr5:45775207	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.593	rs7706676	ENSG00000231752.4	EMBP1	-10.01	1.4e-22	2.36e-16	-0.41	-0.3	P wave duration;	chr5:45784368	chr1:121519112~121571892:+
BRCA	trans	rs7927370	1	rs35195107	ENSG00000134612.10	FOLH1B	10.01	1.41e-22	2.36e-16	0.75	0.3	Systemic lupus erythematosus;	chr11:55279239	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.85	rs61894957	ENSG00000134612.10	FOLH1B	10.01	1.41e-22	2.36e-16	0.75	0.3	Systemic lupus erythematosus;	chr11:55281935	chr11:89639227~89698718:+
BRCA	trans	rs4276421	0.54	rs4242125	ENSG00000231752.4	EMBP1	-10.01	1.42e-22	2.38e-16	-0.41	-0.3	P wave duration;	chr5:45820055	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.593	rs6898480	ENSG00000231752.4	EMBP1	-10.01	1.42e-22	2.38e-16	-0.41	-0.3	P wave duration;	chr5:45825479	chr1:121519112~121571892:+
BRCA	trans	rs7833986	0.501	rs72653957	ENSG00000236862.1	RPS20P24	10.01	1.44e-22	2.42e-16	0.39	0.3	Height;	chr8:56077489	chr9:72655832~72656192:-
BRCA	trans	rs4276421	0.593	rs4132311	ENSG00000231752.4	EMBP1	10	1.48e-22	2.47e-16	0.41	0.3	P wave duration;	chr5:45867992	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.554	rs7724971	ENSG00000231752.4	EMBP1	-10	1.48e-22	2.48e-16	-0.4	-0.3	P wave duration;	chr5:45814638	chr1:121519112~121571892:+
BRCA	trans	rs1580019	0.52	rs13228793	ENSG00000176826.14	FKBP9P1	-10	1.5e-22	2.51e-16	-0.41	-0.3	Cognitive ability;	chr7:32671853	chr7:55681074~55713252:-
BRCA	trans	rs9876781	1	rs2290822	ENSG00000225528.1	RP3-370M22.8	-10	1.52e-22	2.54e-16	-0.32	-0.3	Longevity;	chr3:48431794	chr22:39960397~39964683:+
BRCA	trans	rs941207	0.526	rs2950387	ENSG00000228224.3	NACAP1	-10	1.54e-22	2.58e-16	-0.34	-0.3	Platelet count;	chr12:56627222	chr8:101361794~101372707:+
BRCA	trans	rs9329221	0.683	rs814359	ENSG00000253893.2	FAM85B	10	1.55e-22	2.59e-16	0.37	0.3	Neuroticism;	chr8:10025622	chr8:8167819~8226614:-
BRCA	trans	rs853679	0.546	rs71537572	ENSG00000253570.1	RNF5P1	10	1.56e-22	2.61e-16	0.87	0.3	Depression;	chr6:28002937	chr8:38600661~38601200:-
BRCA	trans	rs3942852	0.806	rs10769316	ENSG00000134612.10	FOLH1B	-10	1.56e-22	2.62e-16	-0.39	-0.3	Acute lymphoblastic leukemia (childhood);	chr11:48098193	chr11:89639227~89698718:+
BRCA	trans	rs7937890	0.561	rs2575849	ENSG00000236360.2	RP11-334A14.2	10	1.57e-22	2.62e-16	0.39	0.3	Mitochondrial DNA levels;	chr11:14518093	chr1:52993201~52993702:-
BRCA	trans	rs3096299	0.719	rs2965817	ENSG00000215030.5	RPL13P12	-10	1.58e-22	2.64e-16	-0.3	-0.3	Multiple myeloma (IgH translocation);	chr16:89446826	chr17:17383377~17384012:-
BRCA	trans	rs2069408	1	rs2069408	ENSG00000235459.5	RPS26P31	-10	1.58e-22	2.64e-16	-0.37	-0.3	Asthma;	chr12:55970537	chr7:122681315~122681662:+
BRCA	trans	rs8010715	1	rs8010715	ENSG00000238000.1	RP11-274E7.2	10	1.58e-22	2.65e-16	0.34	0.3	IgG glycosylation;	chr14:24139938	chr5:98213402~98214121:+
BRCA	trans	rs3096299	0.685	rs12446145	ENSG00000215030.5	RPL13P12	-9.99	1.61e-22	2.68e-16	-0.3	-0.3	Multiple myeloma (IgH translocation);	chr16:89476287	chr17:17383377~17384012:-
BRCA	trans	rs864643	0.524	rs72869124	ENSG00000188856.6	RPSAP47	9.99	1.61e-22	2.68e-16	0.55	0.3	Attention deficit hyperactivity disorder;	chr3:39469788	chr8:80558870~80559757:+
BRCA	trans	rs3806843	0.966	rs6891559	ENSG00000231043.3	AC007238.1	-9.99	1.61e-22	2.69e-16	-0.35	-0.3	Depressive symptoms (multi-trait analysis);	chr5:140765621	chr2:58460292~58462032:-
BRCA	trans	rs3806843	0.966	rs11741994	ENSG00000231043.3	AC007238.1	-9.99	1.61e-22	2.69e-16	-0.35	-0.3	Depressive symptoms (multi-trait analysis);	chr5:140766364	chr2:58460292~58462032:-
BRCA	trans	rs7927370	1	rs76202438	ENSG00000134612.10	FOLH1B	9.99	1.64e-22	2.73e-16	0.8	0.3	Systemic lupus erythematosus;	chr11:55034091	chr11:89639227~89698718:+
BRCA	trans	rs4276421	0.571	rs10074470	ENSG00000231752.4	EMBP1	9.99	1.66e-22	2.77e-16	0.41	0.3	P wave duration;	chr5:45940922	chr1:121519112~121571892:+
BRCA	trans	rs7032940	0.533	rs7868072	ENSG00000228236.2	TXNP5	9.99	1.66e-22	2.77e-16	0.34	0.3	Height;	chr9:110205824	chr2:149068596~149068910:-
BRCA	trans	rs12200782	0.932	rs12212145	ENSG00000242375.1	RP11-498P14.3	-9.99	1.67e-22	2.78e-16	-0.72	-0.3	Small cell lung carcinoma;	chr6:26646190	chr9:97195351~97197687:-
BRCA	trans	rs12200782	0.799	rs72845515	ENSG00000242375.1	RP11-498P14.3	-9.99	1.67e-22	2.78e-16	-0.72	-0.3	Small cell lung carcinoma;	chr6:26646643	chr9:97195351~97197687:-
BRCA	trans	rs12210905	0.8	rs12209651	ENSG00000242375.1	RP11-498P14.3	-9.99	1.67e-22	2.78e-16	-0.72	-0.3	Hip circumference adjusted for BMI;	chr6:26660697	chr9:97195351~97197687:-
BRCA	trans	rs12210905	0.8	rs12201890	ENSG00000242375.1	RP11-498P14.3	-9.99	1.67e-22	2.78e-16	-0.72	-0.3	Hip circumference adjusted for BMI;	chr6:26662398	chr9:97195351~97197687:-
BRCA	trans	rs7927370	1	rs117619703	ENSG00000134612.10	FOLH1B	9.99	1.69e-22	2.82e-16	0.76	0.3	Systemic lupus erythematosus;	chr11:55420323	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs77352583	ENSG00000134612.10	FOLH1B	9.99	1.69e-22	2.82e-16	0.76	0.3	Systemic lupus erythematosus;	chr11:55420327	chr11:89639227~89698718:+
BRCA	trans	rs3806843	1	rs10223116	ENSG00000231043.3	AC007238.1	-9.99	1.7e-22	2.83e-16	-0.34	-0.3	Depressive symptoms (multi-trait analysis);	chr5:140813058	chr2:58460292~58462032:-
BRCA	trans	rs7937890	0.559	rs2597219	ENSG00000236360.2	RP11-334A14.2	9.99	1.71e-22	2.85e-16	0.39	0.3	Mitochondrial DNA levels;	chr11:14509320	chr1:52993201~52993702:-
BRCA	trans	rs7937890	0.559	rs2575852	ENSG00000236360.2	RP11-334A14.2	9.99	1.71e-22	2.85e-16	0.39	0.3	Mitochondrial DNA levels;	chr11:14511822	chr1:52993201~52993702:-
BRCA	trans	rs7937890	0.531	rs2597216	ENSG00000236360.2	RP11-334A14.2	9.99	1.71e-22	2.85e-16	0.39	0.3	Mitochondrial DNA levels;	chr11:14512370	chr1:52993201~52993702:-
BRCA	trans	rs7937890	0.559	rs1548074	ENSG00000236360.2	RP11-334A14.2	9.99	1.71e-22	2.85e-16	0.39	0.3	Mitochondrial DNA levels;	chr11:14513279	chr1:52993201~52993702:-
BRCA	trans	rs7927370	0.702	rs61898413	ENSG00000134612.10	FOLH1B	9.99	1.71e-22	2.85e-16	0.75	0.3	Systemic lupus erythematosus;	chr11:55260619	chr11:89639227~89698718:+
BRCA	trans	rs3942852	0.806	rs4752893	ENSG00000134612.10	FOLH1B	-9.99	1.72e-22	2.86e-16	-0.39	-0.3	Acute lymphoblastic leukemia (childhood);	chr11:48097052	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.702	rs61894903	ENSG00000134612.10	FOLH1B	9.99	1.72e-22	2.86e-16	0.75	0.3	Systemic lupus erythematosus;	chr11:55274992	chr11:89639227~89698718:+
BRCA	trans	rs4276421	0.593	rs7706959	ENSG00000231752.4	EMBP1	-9.99	1.73e-22	2.87e-16	-0.42	-0.3	P wave duration;	chr5:45793689	chr1:121519112~121571892:+
BRCA	trans	rs12200782	1	rs4292511	ENSG00000242375.1	RP11-498P14.3	-9.99	1.74e-22	2.9e-16	-0.72	-0.3	Small cell lung carcinoma;	chr6:26622062	chr9:97195351~97197687:-
BRCA	trans	rs9876781	1	rs898225	ENSG00000225528.1	RP3-370M22.8	9.98	1.75e-22	2.91e-16	0.32	0.3	Longevity;	chr3:48371689	chr22:39960397~39964683:+
BRCA	trans	rs9329221	0.617	rs483916	ENSG00000253893.2	FAM85B	9.98	1.75e-22	2.91e-16	0.36	0.3	Neuroticism;	chr8:9936091	chr8:8167819~8226614:-
BRCA	trans	rs877636	1	rs2292239	ENSG00000196656.7	AC004057.1	9.98	1.76e-22	2.93e-16	0.35	0.3	Cognitive function;	chr12:56088396	chr4:113214046~113217170:-
BRCA	trans	rs11098499	0.874	rs7661020	ENSG00000275858.1	RP11-291L22.8	9.98	1.8e-22	2.99e-16	0.39	0.3	Corneal astigmatism;	chr4:119185827	chr10:38450738~38451069:-
BRCA	trans	rs853679	0.607	rs67662114	ENSG00000253570.1	RNF5P1	9.98	1.8e-22	2.99e-16	0.87	0.3	Depression;	chr6:27964523	chr8:38600661~38601200:-
BRCA	trans	rs853679	0.607	rs13216117	ENSG00000253570.1	RNF5P1	9.98	1.8e-22	2.99e-16	0.87	0.3	Depression;	chr6:27970706	chr8:38600661~38601200:-
BRCA	trans	rs853679	0.607	rs36101351	ENSG00000253570.1	RNF5P1	9.98	1.8e-22	2.99e-16	0.87	0.3	Depression;	chr6:27975591	chr8:38600661~38601200:-
BRCA	trans	rs853679	0.607	rs28360499	ENSG00000253570.1	RNF5P1	9.98	1.8e-22	2.99e-16	0.87	0.3	Depression;	chr6:27977618	chr8:38600661~38601200:-
BRCA	trans	rs13014235	0.562	rs2080325	ENSG00000235105.1	RP11-329A14.1	-9.98	1.8e-22	3e-16	-0.36	-0.3	Basal cell carcinoma;	chr2:201513640	chr1:48435967~48437223:+
BRCA	trans	rs7927370	1	rs58893672	ENSG00000134612.10	FOLH1B	9.98	1.8e-22	3e-16	0.73	0.3	Systemic lupus erythematosus;	chr11:55540829	chr11:89639227~89698718:+
BRCA	trans	rs3806843	1	rs10066278	ENSG00000231043.3	AC007238.1	-9.98	1.81e-22	3.01e-16	-0.35	-0.3	Depressive symptoms (multi-trait analysis);	chr5:140776733	chr2:58460292~58462032:-
BRCA	trans	rs7927370	1	rs61894225	ENSG00000134612.10	FOLH1B	9.98	1.83e-22	3.03e-16	0.73	0.3	Systemic lupus erythematosus;	chr11:55577452	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.717	rs61898411	ENSG00000134612.10	FOLH1B	9.98	1.85e-22	3.07e-16	0.75	0.3	Systemic lupus erythematosus;	chr11:55260133	chr11:89639227~89698718:+
BRCA	trans	rs3806843	0.9	rs2563280	ENSG00000231043.3	AC007238.1	9.98	1.86e-22	3.08e-16	0.35	0.3	Depressive symptoms (multi-trait analysis);	chr5:140751945	chr2:58460292~58462032:-
BRCA	trans	rs10865397	0.539	rs13414338	ENSG00000236165.1	PRADC1P1	9.98	1.86e-22	3.08e-16	0.39	0.3	Intelligence (multi-trait analysis);	chr2:73156247	chr3:36976316~36976840:+
BRCA	trans	rs877636	0.702	rs61937249	ENSG00000196933.5	RPS26P11	9.98	1.86e-22	3.09e-16	0.4	0.3	Cognitive function;	chr12:55988132	chrX:72044545~72044892:+
BRCA	trans	rs7927370	1	rs61894885	ENSG00000134612.10	FOLH1B	9.98	1.86e-22	3.09e-16	0.75	0.3	Systemic lupus erythematosus;	chr11:55263654	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61917926	ENSG00000134612.10	FOLH1B	9.98	1.88e-22	3.11e-16	0.73	0.3	Systemic lupus erythematosus;	chr11:55537684	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs34099327	ENSG00000134612.10	FOLH1B	9.98	1.88e-22	3.11e-16	0.73	0.3	Systemic lupus erythematosus;	chr11:55537774	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs35968796	ENSG00000134612.10	FOLH1B	9.98	1.88e-22	3.11e-16	0.73	0.3	Systemic lupus erythematosus;	chr11:55537846	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.867	rs17495950	ENSG00000134612.10	FOLH1B	9.98	1.88e-22	3.11e-16	0.73	0.3	Systemic lupus erythematosus;	chr11:55539072	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs10501335	ENSG00000134612.10	FOLH1B	9.98	1.88e-22	3.11e-16	0.73	0.3	Systemic lupus erythematosus;	chr11:55539101	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs17580938	ENSG00000134612.10	FOLH1B	9.98	1.88e-22	3.11e-16	0.73	0.3	Systemic lupus erythematosus;	chr11:55544504	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61917939	ENSG00000134612.10	FOLH1B	9.98	1.88e-22	3.11e-16	0.73	0.3	Systemic lupus erythematosus;	chr11:55545143	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs78301054	ENSG00000134612.10	FOLH1B	9.98	1.88e-22	3.11e-16	0.73	0.3	Systemic lupus erythematosus;	chr11:55545449	chr11:89639227~89698718:+
BRCA	trans	rs11098499	0.913	rs67073020	ENSG00000275858.1	RP11-291L22.8	9.98	1.88e-22	3.11e-16	0.38	0.3	Corneal astigmatism;	chr4:119231402	chr10:38450738~38451069:-
BRCA	trans	rs12200782	1	rs6456742	ENSG00000242375.1	RP11-498P14.3	-9.98	1.9e-22	3.14e-16	-0.72	-0.3	Small cell lung carcinoma;	chr6:26616847	chr9:97195351~97197687:-
BRCA	trans	rs12200782	1	rs4515370	ENSG00000242375.1	RP11-498P14.3	-9.98	1.9e-22	3.14e-16	-0.72	-0.3	Small cell lung carcinoma;	chr6:26625091	chr9:97195351~97197687:-
BRCA	trans	rs12200782	1	rs12205909	ENSG00000242375.1	RP11-498P14.3	-9.98	1.9e-22	3.14e-16	-0.72	-0.3	Small cell lung carcinoma;	chr6:26630771	chr9:97195351~97197687:-
BRCA	trans	rs12200782	1	rs72845509	ENSG00000242375.1	RP11-498P14.3	-9.98	1.9e-22	3.14e-16	-0.72	-0.3	Small cell lung carcinoma;	chr6:26639637	chr9:97195351~97197687:-
BRCA	trans	rs4276421	0.55	rs1534392	ENSG00000231752.4	EMBP1	9.98	1.91e-22	3.17e-16	0.41	0.3	P wave duration;	chr5:45633255	chr1:121519112~121571892:+
BRCA	trans	rs3749237	0.595	rs1050088	ENSG00000197582.5	GPX1P1	-9.97	1.92e-22	3.19e-16	-0.3	-0.3	Resting heart rate;	chr3:49533449	chrX:13378735~13379340:-
BRCA	trans	rs867371	0.717	rs3858954	ENSG00000235370.6	DNM1P51	-9.97	1.94e-22	3.21e-16	-0.34	-0.3	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82265693	chr15:84398316~84411701:-
BRCA	trans	rs7927370	1	rs9667732	ENSG00000134612.10	FOLH1B	9.97	1.94e-22	3.21e-16	0.73	0.3	Systemic lupus erythematosus;	chr11:55505044	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs56063922	ENSG00000134612.10	FOLH1B	9.97	1.94e-22	3.21e-16	0.73	0.3	Systemic lupus erythematosus;	chr11:55505377	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.867	rs11828727	ENSG00000134612.10	FOLH1B	9.97	1.94e-22	3.21e-16	0.73	0.3	Systemic lupus erythematosus;	chr11:55506414	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61916289	ENSG00000134612.10	FOLH1B	9.97	1.94e-22	3.21e-16	0.73	0.3	Systemic lupus erythematosus;	chr11:55506803	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs11823401	ENSG00000134612.10	FOLH1B	9.97	1.94e-22	3.21e-16	0.73	0.3	Systemic lupus erythematosus;	chr11:55507268	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs7929606	ENSG00000134612.10	FOLH1B	9.97	1.94e-22	3.21e-16	0.73	0.3	Systemic lupus erythematosus;	chr11:55507760	chr11:89639227~89698718:+
BRCA	trans	rs7833986	0.501	rs17814658	ENSG00000236862.1	RPS20P24	9.97	1.95e-22	3.23e-16	0.39	0.3	Height;	chr8:56076571	chr9:72655832~72656192:-
BRCA	trans	rs9650657	0.589	rs6985109	ENSG00000253893.2	FAM85B	-9.97	1.97e-22	3.25e-16	-0.37	-0.3	Neuroticism;	chr8:10904075	chr8:8167819~8226614:-
BRCA	trans	rs7927370	1	rs17578479	ENSG00000134612.10	FOLH1B	9.97	1.98e-22	3.28e-16	0.73	0.3	Systemic lupus erythematosus;	chr11:55436196	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs17578535	ENSG00000134612.10	FOLH1B	9.97	1.98e-22	3.28e-16	0.73	0.3	Systemic lupus erythematosus;	chr11:55436546	chr11:89639227~89698718:+
BRCA	trans	rs11098499	0.874	rs6822498	ENSG00000275858.1	RP11-291L22.8	9.97	1.98e-22	3.28e-16	0.39	0.3	Corneal astigmatism;	chr4:119199028	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.913	rs68128210	ENSG00000275858.1	RP11-291L22.8	9.97	2e-22	3.3e-16	0.39	0.3	Corneal astigmatism;	chr4:119216664	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.913	rs13126596	ENSG00000275858.1	RP11-291L22.8	9.97	2e-22	3.3e-16	0.39	0.3	Corneal astigmatism;	chr4:119219574	chr10:38450738~38451069:-
BRCA	trans	rs867371	0.762	rs1846910	ENSG00000235370.6	DNM1P51	-9.97	2e-22	3.3e-16	-0.34	-0.3	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82279439	chr15:84398316~84411701:-
BRCA	trans	rs7927370	1	rs61894245	ENSG00000134612.10	FOLH1B	9.97	2e-22	3.32e-16	0.73	0.3	Systemic lupus erythematosus;	chr11:55584155	chr11:89639227~89698718:+
BRCA	trans	rs9876781	1	rs9849509	ENSG00000225528.1	RP3-370M22.8	-9.97	2.01e-22	3.32e-16	-0.32	-0.3	Longevity;	chr3:48442021	chr22:39960397~39964683:+
BRCA	trans	rs9876781	1	rs60512868	ENSG00000225528.1	RP3-370M22.8	-9.97	2.01e-22	3.32e-16	-0.32	-0.3	Longevity;	chr3:48442035	chr22:39960397~39964683:+
BRCA	trans	rs11098499	0.874	rs17839089	ENSG00000275858.1	RP11-291L22.8	9.97	2.08e-22	3.44e-16	0.39	0.29	Corneal astigmatism;	chr4:119189914	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.874	rs6826823	ENSG00000275858.1	RP11-291L22.8	9.97	2.08e-22	3.44e-16	0.39	0.29	Corneal astigmatism;	chr4:119190943	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.874	rs12509054	ENSG00000275858.1	RP11-291L22.8	9.97	2.08e-22	3.44e-16	0.39	0.29	Corneal astigmatism;	chr4:119193920	chr10:38450738~38451069:-
BRCA	trans	rs12200782	1	rs6456741	ENSG00000242375.1	RP11-498P14.3	-9.97	2.09e-22	3.45e-16	-0.71	-0.29	Small cell lung carcinoma;	chr6:26616830	chr9:97195351~97197687:-
BRCA	trans	rs3806843	0.9	rs2531341	ENSG00000231043.3	AC007238.1	9.97	2.09e-22	3.46e-16	0.35	0.29	Depressive symptoms (multi-trait analysis);	chr5:140751309	chr2:58460292~58462032:-
BRCA	trans	rs3806843	0.9	rs2531340	ENSG00000231043.3	AC007238.1	9.97	2.09e-22	3.46e-16	0.35	0.29	Depressive symptoms (multi-trait analysis);	chr5:140751461	chr2:58460292~58462032:-
BRCA	trans	rs3806843	0.868	rs2563281	ENSG00000231043.3	AC007238.1	9.97	2.09e-22	3.46e-16	0.35	0.29	Depressive symptoms (multi-trait analysis);	chr5:140751634	chr2:58460292~58462032:-
BRCA	trans	rs3806843	0.838	rs2262567	ENSG00000231043.3	AC007238.1	9.97	2.09e-22	3.46e-16	0.35	0.29	Depressive symptoms (multi-trait analysis);	chr5:140752549	chr2:58460292~58462032:-
BRCA	trans	rs3096299	0.685	rs4238830	ENSG00000215030.5	RPL13P12	-9.96	2.11e-22	3.48e-16	-0.3	-0.29	Multiple myeloma (IgH translocation);	chr16:89473833	chr17:17383377~17384012:-
BRCA	trans	rs7973618	1	rs7973618	ENSG00000228224.3	NACAP1	-9.96	2.12e-22	3.5e-16	-0.34	-0.29	Mean platelet volume;	chr12:56625659	chr8:101361794~101372707:+
BRCA	trans	rs7927370	1	rs111693873	ENSG00000134612.10	FOLH1B	9.96	2.15e-22	3.55e-16	0.76	0.29	Systemic lupus erythematosus;	chr11:55420360	chr11:89639227~89698718:+
BRCA	trans	rs4276421	0.593	rs10074312	ENSG00000231752.4	EMBP1	9.96	2.16e-22	3.57e-16	0.4	0.29	P wave duration;	chr5:45671565	chr1:121519112~121571892:+
BRCA	trans	rs11098499	0.913	rs56122576	ENSG00000275858.1	RP11-291L22.8	9.96	2.18e-22	3.59e-16	0.39	0.29	Corneal astigmatism;	chr4:119208181	chr10:38450738~38451069:-
BRCA	trans	rs4276421	0.593	rs2337954	ENSG00000231752.4	EMBP1	9.96	2.2e-22	3.64e-16	0.41	0.29	P wave duration;	chr5:45651767	chr1:121519112~121571892:+
BRCA	trans	rs7927370	0.85	rs117404944	ENSG00000134612.10	FOLH1B	9.96	2.21e-22	3.64e-16	0.83	0.29	Systemic lupus erythematosus;	chr11:55231949	chr11:89639227~89698718:+
BRCA	trans	rs864643	0.947	rs704962	ENSG00000183298.5	RP11-556K13.1	-9.96	2.23e-22	3.68e-16	-0.45	-0.29	Attention deficit hyperactivity disorder;	chr3:39515629	chr1:101786340~101787219:-
BRCA	trans	rs7927370	1	rs61896314	ENSG00000134612.10	FOLH1B	9.96	2.25e-22	3.72e-16	0.78	0.29	Systemic lupus erythematosus;	chr11:55806228	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61896315	ENSG00000134612.10	FOLH1B	9.96	2.25e-22	3.72e-16	0.78	0.29	Systemic lupus erythematosus;	chr11:55808476	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61896316	ENSG00000134612.10	FOLH1B	9.96	2.25e-22	3.72e-16	0.78	0.29	Systemic lupus erythematosus;	chr11:55809077	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.717	rs61896319	ENSG00000134612.10	FOLH1B	9.96	2.25e-22	3.72e-16	0.78	0.29	Systemic lupus erythematosus;	chr11:55813095	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61896320	ENSG00000134612.10	FOLH1B	9.96	2.25e-22	3.72e-16	0.78	0.29	Systemic lupus erythematosus;	chr11:55813112	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.702	rs7118321	ENSG00000134612.10	FOLH1B	9.96	2.25e-22	3.72e-16	0.78	0.29	Systemic lupus erythematosus;	chr11:55816694	chr11:89639227~89698718:+
BRCA	trans	rs11098499	0.874	rs6832670	ENSG00000275858.1	RP11-291L22.8	9.96	2.28e-22	3.75e-16	0.39	0.29	Corneal astigmatism;	chr4:119197637	chr10:38450738~38451069:-
BRCA	trans	rs10865397	0.506	rs6546807	ENSG00000236165.1	PRADC1P1	9.96	2.28e-22	3.75e-16	0.39	0.29	Intelligence (multi-trait analysis);	chr2:73159084	chr3:36976316~36976840:+
BRCA	trans	rs11098499	0.874	rs10022508	ENSG00000275858.1	RP11-291L22.8	9.95	2.32e-22	3.82e-16	0.39	0.29	Corneal astigmatism;	chr4:119194073	chr10:38450738~38451069:-
BRCA	trans	rs9876781	1	rs6770470	ENSG00000225528.1	RP3-370M22.8	-9.95	2.36e-22	3.89e-16	-0.32	-0.29	Longevity;	chr3:48393659	chr22:39960397~39964683:+
BRCA	trans	rs9876781	1	rs6810060	ENSG00000225528.1	RP3-370M22.8	-9.95	2.36e-22	3.89e-16	-0.32	-0.29	Longevity;	chr3:48393284	chr22:39960397~39964683:+
BRCA	trans	rs7927370	1	rs7940435	ENSG00000134612.10	FOLH1B	9.95	2.36e-22	3.89e-16	0.73	0.29	Systemic lupus erythematosus;	chr11:55507493	chr11:89639227~89698718:+
BRCA	trans	rs3806843	0.766	rs801176	ENSG00000231043.3	AC007238.1	-9.95	2.39e-22	3.94e-16	-0.34	-0.29	Depressive symptoms (multi-trait analysis);	chr5:140707425	chr2:58460292~58462032:-
BRCA	trans	rs877636	1	rs2292239	ENSG00000196933.5	RPS26P11	9.95	2.4e-22	3.95e-16	0.36	0.29	Cognitive function;	chr12:56088396	chrX:72044545~72044892:+
BRCA	trans	rs7927370	0.85	rs7948629	ENSG00000134612.10	FOLH1B	9.95	2.42e-22	3.98e-16	0.78	0.29	Systemic lupus erythematosus;	chr11:55819736	chr11:89639227~89698718:+
BRCA	trans	rs864643	0.524	rs72869131	ENSG00000188856.6	RPSAP47	9.95	2.46e-22	4.04e-16	0.53	0.29	Attention deficit hyperactivity disorder;	chr3:39472959	chr8:80558870~80559757:+
BRCA	trans	rs9876781	1	rs9817615	ENSG00000225528.1	RP3-370M22.8	-9.95	2.49e-22	4.1e-16	-0.32	-0.29	Longevity;	chr3:48429347	chr22:39960397~39964683:+
BRCA	trans	rs7937890	0.507	rs4463820	ENSG00000236360.2	RP11-334A14.2	9.95	2.51e-22	4.13e-16	0.39	0.29	Mitochondrial DNA levels;	chr11:14534796	chr1:52993201~52993702:-
BRCA	trans	rs801193	0.591	rs9986881	ENSG00000164669.11	INTS4P1	-9.94	2.55e-22	4.19e-16	-0.37	-0.29	Aortic root size;	chr7:66708053	chr7:65141225~65234216:+
BRCA	trans	rs864643	0.524	rs77309543	ENSG00000188856.6	RPSAP47	9.94	2.58e-22	4.24e-16	0.58	0.29	Attention deficit hyperactivity disorder;	chr3:39489578	chr8:80558870~80559757:+
BRCA	trans	rs7937890	0.559	rs2597188	ENSG00000236360.2	RP11-334A14.2	9.94	2.58e-22	4.25e-16	0.38	0.29	Mitochondrial DNA levels;	chr11:14495360	chr1:52993201~52993702:-
BRCA	trans	rs7937890	0.559	rs2597187	ENSG00000236360.2	RP11-334A14.2	9.94	2.58e-22	4.25e-16	0.38	0.29	Mitochondrial DNA levels;	chr11:14495473	chr1:52993201~52993702:-
BRCA	trans	rs11098499	0.866	rs10518329	ENSG00000275858.1	RP11-291L22.8	9.94	2.6e-22	4.27e-16	0.35	0.29	Corneal astigmatism;	chr4:119480680	chr10:38450738~38451069:-
BRCA	trans	rs7937890	0.559	rs6486197	ENSG00000236360.2	RP11-334A14.2	9.94	2.63e-22	4.32e-16	0.38	0.29	Mitochondrial DNA levels;	chr11:14508328	chr1:52993201~52993702:-
BRCA	trans	rs877636	0.702	rs773112	ENSG00000196933.5	RPS26P11	9.94	2.63e-22	4.32e-16	0.4	0.29	Cognitive function;	chr12:55982097	chrX:72044545~72044892:+
BRCA	trans	rs7927370	1	rs61916218	ENSG00000134612.10	FOLH1B	9.94	2.66e-22	4.36e-16	0.74	0.29	Systemic lupus erythematosus;	chr11:55380793	chr11:89639227~89698718:+
BRCA	trans	rs11098499	0.874	rs6851169	ENSG00000275858.1	RP11-291L22.8	9.94	2.68e-22	4.41e-16	0.38	0.29	Corneal astigmatism;	chr4:119196355	chr10:38450738~38451069:-
BRCA	trans	rs2250402	0.51	rs6492926	ENSG00000234106.3	RP11-288E14.2	9.94	2.7e-22	4.43e-16	0.64	0.29	Corneal curvature;	chr15:40033628	chr11:93535468~93535816:+
BRCA	trans	rs7937890	0.532	rs2575833	ENSG00000236360.2	RP11-334A14.2	9.94	2.71e-22	4.45e-16	0.38	0.29	Mitochondrial DNA levels;	chr11:14470959	chr1:52993201~52993702:-
BRCA	trans	rs7927370	0.85	rs61917449	ENSG00000134612.10	FOLH1B	9.94	2.74e-22	4.5e-16	0.74	0.29	Systemic lupus erythematosus;	chr11:55414918	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61917452	ENSG00000134612.10	FOLH1B	9.94	2.74e-22	4.5e-16	0.74	0.29	Systemic lupus erythematosus;	chr11:55415531	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61917453	ENSG00000134612.10	FOLH1B	9.94	2.74e-22	4.5e-16	0.74	0.29	Systemic lupus erythematosus;	chr11:55415953	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61917456	ENSG00000134612.10	FOLH1B	9.94	2.74e-22	4.5e-16	0.74	0.29	Systemic lupus erythematosus;	chr11:55416277	chr11:89639227~89698718:+
BRCA	trans	rs853679	0.607	rs34166054	ENSG00000253570.1	RNF5P1	9.94	2.76e-22	4.52e-16	0.89	0.29	Depression;	chr6:28098023	chr8:38600661~38601200:-
BRCA	trans	rs853679	0.607	rs13203816	ENSG00000253570.1	RNF5P1	9.94	2.76e-22	4.52e-16	0.89	0.29	Depression;	chr6:28111820	chr8:38600661~38601200:-
BRCA	trans	rs853679	0.556	rs34588114	ENSG00000253570.1	RNF5P1	9.94	2.76e-22	4.52e-16	0.89	0.29	Depression;	chr6:28112850	chr8:38600661~38601200:-
BRCA	trans	rs853679	0.607	rs68188794	ENSG00000253570.1	RNF5P1	9.94	2.76e-22	4.52e-16	0.89	0.29	Depression;	chr6:28112999	chr8:38600661~38601200:-
BRCA	trans	rs853679	0.546	rs34371502	ENSG00000253570.1	RNF5P1	9.94	2.76e-22	4.52e-16	0.89	0.29	Depression;	chr6:28113980	chr8:38600661~38601200:-
BRCA	trans	rs853679	0.607	rs66886492	ENSG00000253570.1	RNF5P1	9.94	2.76e-22	4.52e-16	0.89	0.29	Depression;	chr6:28121953	chr8:38600661~38601200:-
BRCA	trans	rs853679	0.607	rs35345226	ENSG00000253570.1	RNF5P1	9.94	2.76e-22	4.52e-16	0.89	0.29	Depression;	chr6:28123802	chr8:38600661~38601200:-
BRCA	trans	rs7927370	0.85	rs117452995	ENSG00000134612.10	FOLH1B	9.93	2.77e-22	4.55e-16	0.78	0.29	Systemic lupus erythematosus;	chr11:55823408	chr11:89639227~89698718:+
BRCA	trans	rs864643	0.577	rs76395532	ENSG00000188856.6	RPSAP47	9.93	2.79e-22	4.57e-16	0.57	0.29	Attention deficit hyperactivity disorder;	chr3:39490370	chr8:80558870~80559757:+
BRCA	trans	rs3806843	1	rs10053586	ENSG00000231043.3	AC007238.1	-9.93	2.79e-22	4.57e-16	-0.34	-0.29	Depressive symptoms (multi-trait analysis);	chr5:140831175	chr2:58460292~58462032:-
BRCA	trans	rs7927370	1	rs61919690	ENSG00000134612.10	FOLH1B	9.93	2.79e-22	4.58e-16	0.72	0.29	Systemic lupus erythematosus;	chr11:55497375	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61919691	ENSG00000134612.10	FOLH1B	9.93	2.79e-22	4.58e-16	0.72	0.29	Systemic lupus erythematosus;	chr11:55497738	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.85	rs61919692	ENSG00000134612.10	FOLH1B	9.93	2.79e-22	4.58e-16	0.72	0.29	Systemic lupus erythematosus;	chr11:55498491	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61916282	ENSG00000134612.10	FOLH1B	9.93	2.79e-22	4.58e-16	0.72	0.29	Systemic lupus erythematosus;	chr11:55501170	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs7121555	ENSG00000134612.10	FOLH1B	9.93	2.79e-22	4.58e-16	0.72	0.29	Systemic lupus erythematosus;	chr11:55501458	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs7950755	ENSG00000134612.10	FOLH1B	9.93	2.79e-22	4.58e-16	0.72	0.29	Systemic lupus erythematosus;	chr11:55502514	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.702	rs7950956	ENSG00000134612.10	FOLH1B	9.93	2.79e-22	4.58e-16	0.72	0.29	Systemic lupus erythematosus;	chr11:55502661	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs7941860	ENSG00000134612.10	FOLH1B	9.93	2.79e-22	4.58e-16	0.72	0.29	Systemic lupus erythematosus;	chr11:55502712	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs7119347	ENSG00000134612.10	FOLH1B	9.93	2.79e-22	4.58e-16	0.72	0.29	Systemic lupus erythematosus;	chr11:55503109	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.85	rs7110861	ENSG00000134612.10	FOLH1B	9.93	2.79e-22	4.58e-16	0.72	0.29	Systemic lupus erythematosus;	chr11:55503203	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61916283	ENSG00000134612.10	FOLH1B	9.93	2.79e-22	4.58e-16	0.72	0.29	Systemic lupus erythematosus;	chr11:55503724	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61916284	ENSG00000134612.10	FOLH1B	9.93	2.79e-22	4.58e-16	0.72	0.29	Systemic lupus erythematosus;	chr11:55504024	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61916285	ENSG00000134612.10	FOLH1B	9.93	2.79e-22	4.58e-16	0.72	0.29	Systemic lupus erythematosus;	chr11:55504205	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs9666121	ENSG00000134612.10	FOLH1B	9.93	2.79e-22	4.58e-16	0.72	0.29	Systemic lupus erythematosus;	chr11:55504972	chr11:89639227~89698718:+
BRCA	trans	rs4276421	0.593	rs7719703	ENSG00000231752.4	EMBP1	-9.93	2.8e-22	4.59e-16	-0.4	-0.29	P wave duration;	chr5:45781860	chr1:121519112~121571892:+
BRCA	trans	rs7927370	1	rs61917459	ENSG00000134612.10	FOLH1B	9.93	2.82e-22	4.63e-16	0.74	0.29	Systemic lupus erythematosus;	chr11:55417188	chr11:89639227~89698718:+
BRCA	trans	rs3806843	0.648	rs702399	ENSG00000231043.3	AC007238.1	9.93	2.83e-22	4.63e-16	0.35	0.29	Depressive symptoms (multi-trait analysis);	chr5:140644847	chr2:58460292~58462032:-
BRCA	trans	rs7927370	1	rs61916219	ENSG00000134612.10	FOLH1B	9.93	2.84e-22	4.64e-16	0.74	0.29	Systemic lupus erythematosus;	chr11:55381247	chr11:89639227~89698718:+
BRCA	trans	rs4276421	0.593	rs28473745	ENSG00000231752.4	EMBP1	9.93	2.88e-22	4.71e-16	0.4	0.29	P wave duration;	chr5:45740468	chr1:121519112~121571892:+
BRCA	trans	rs7927370	1	rs7931450	ENSG00000134612.10	FOLH1B	9.93	2.9e-22	4.75e-16	0.77	0.29	Systemic lupus erythematosus;	chr11:55797883	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.85	rs7934927	ENSG00000134612.10	FOLH1B	9.93	2.9e-22	4.75e-16	0.77	0.29	Systemic lupus erythematosus;	chr11:55797944	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61896311	ENSG00000134612.10	FOLH1B	9.93	2.9e-22	4.75e-16	0.77	0.29	Systemic lupus erythematosus;	chr11:55799732	chr11:89639227~89698718:+
BRCA	trans	rs9650657	0.537	rs11250092	ENSG00000253893.2	FAM85B	-9.93	2.91e-22	4.76e-16	-0.37	-0.29	Neuroticism;	chr8:10929033	chr8:8167819~8226614:-
BRCA	trans	rs11098499	0.874	rs12502503	ENSG00000275858.1	RP11-291L22.8	9.93	2.91e-22	4.77e-16	0.38	0.29	Corneal astigmatism;	chr4:119195100	chr10:38450738~38451069:-
BRCA	trans	rs853679	0.607	rs72846780	ENSG00000253570.1	RNF5P1	9.93	2.93e-22	4.79e-16	0.88	0.29	Depression;	chr6:28151277	chr8:38600661~38601200:-
BRCA	trans	rs853679	0.607	rs13205911	ENSG00000253570.1	RNF5P1	9.93	2.93e-22	4.79e-16	0.88	0.29	Depression;	chr6:28156336	chr8:38600661~38601200:-
BRCA	trans	rs853679	0.607	rs13197176	ENSG00000253570.1	RNF5P1	9.93	2.93e-22	4.79e-16	0.88	0.29	Depression;	chr6:28161454	chr8:38600661~38601200:-
BRCA	trans	rs853679	0.607	rs13201308	ENSG00000253570.1	RNF5P1	9.93	2.93e-22	4.79e-16	0.88	0.29	Depression;	chr6:28162311	chr8:38600661~38601200:-
BRCA	trans	rs853679	0.607	rs34505829	ENSG00000253570.1	RNF5P1	9.93	2.93e-22	4.79e-16	0.88	0.29	Depression;	chr6:28165461	chr8:38600661~38601200:-
BRCA	trans	rs853679	0.607	rs35098436	ENSG00000253570.1	RNF5P1	9.93	2.93e-22	4.79e-16	0.88	0.29	Depression;	chr6:28166443	chr8:38600661~38601200:-
BRCA	trans	rs853679	0.607	rs72846794	ENSG00000253570.1	RNF5P1	9.93	2.93e-22	4.79e-16	0.88	0.29	Depression;	chr6:28169721	chr8:38600661~38601200:-
BRCA	trans	rs853679	0.607	rs13217984	ENSG00000253570.1	RNF5P1	9.93	2.93e-22	4.79e-16	0.88	0.29	Depression;	chr6:28171932	chr8:38600661~38601200:-
BRCA	trans	rs853679	0.505	rs35781323	ENSG00000253570.1	RNF5P1	9.93	2.93e-22	4.79e-16	0.88	0.29	Depression;	chr6:28177054	chr8:38600661~38601200:-
BRCA	trans	rs7927370	1	rs55657388	ENSG00000134612.10	FOLH1B	9.93	2.93e-22	4.79e-16	0.73	0.29	Systemic lupus erythematosus;	chr11:55435641	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61916222	ENSG00000134612.10	FOLH1B	9.93	2.96e-22	4.84e-16	0.74	0.29	Systemic lupus erythematosus;	chr11:55385312	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.85	rs55778392	ENSG00000134612.10	FOLH1B	9.93	2.96e-22	4.84e-16	0.74	0.29	Systemic lupus erythematosus;	chr11:55388011	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs56131310	ENSG00000134612.10	FOLH1B	9.93	2.96e-22	4.84e-16	0.74	0.29	Systemic lupus erythematosus;	chr11:55388589	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61916229	ENSG00000134612.10	FOLH1B	9.93	2.96e-22	4.84e-16	0.74	0.29	Systemic lupus erythematosus;	chr11:55388648	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs2113914	ENSG00000134612.10	FOLH1B	9.93	2.96e-22	4.84e-16	0.74	0.29	Systemic lupus erythematosus;	chr11:55389846	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs1974929	ENSG00000134612.10	FOLH1B	9.93	2.96e-22	4.84e-16	0.74	0.29	Systemic lupus erythematosus;	chr11:55389905	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs112752859	ENSG00000134612.10	FOLH1B	9.93	2.96e-22	4.84e-16	0.74	0.29	Systemic lupus erythematosus;	chr11:55390808	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs78799386	ENSG00000134612.10	FOLH1B	9.93	2.96e-22	4.84e-16	0.74	0.29	Systemic lupus erythematosus;	chr11:55390858	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.85	rs61917374	ENSG00000134612.10	FOLH1B	9.93	2.96e-22	4.84e-16	0.74	0.29	Systemic lupus erythematosus;	chr11:55391183	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs11823212	ENSG00000134612.10	FOLH1B	9.93	2.96e-22	4.84e-16	0.74	0.29	Systemic lupus erythematosus;	chr11:55392368	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs56406459	ENSG00000134612.10	FOLH1B	9.93	2.96e-22	4.84e-16	0.74	0.29	Systemic lupus erythematosus;	chr11:55392864	chr11:89639227~89698718:+
BRCA	trans	rs877636	0.702	rs773111	ENSG00000196933.5	RPS26P11	9.93	2.98e-22	4.87e-16	0.39	0.29	Cognitive function;	chr12:55981956	chrX:72044545~72044892:+
BRCA	trans	rs7927370	1	rs7943036	ENSG00000134612.10	FOLH1B	9.93	2.98e-22	4.87e-16	0.74	0.29	Systemic lupus erythematosus;	chr11:55403717	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61917432	ENSG00000134612.10	FOLH1B	9.93	2.98e-22	4.87e-16	0.74	0.29	Systemic lupus erythematosus;	chr11:55405573	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61917433	ENSG00000134612.10	FOLH1B	9.93	2.98e-22	4.87e-16	0.74	0.29	Systemic lupus erythematosus;	chr11:55405583	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.85	rs11822905	ENSG00000134612.10	FOLH1B	9.93	2.98e-22	4.87e-16	0.74	0.29	Systemic lupus erythematosus;	chr11:55406593	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61917438	ENSG00000134612.10	FOLH1B	9.93	2.98e-22	4.87e-16	0.74	0.29	Systemic lupus erythematosus;	chr11:55407504	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs7128574	ENSG00000134612.10	FOLH1B	9.93	2.98e-22	4.87e-16	0.74	0.29	Systemic lupus erythematosus;	chr11:55409521	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.702	rs11828589	ENSG00000134612.10	FOLH1B	9.93	2.98e-22	4.87e-16	0.74	0.29	Systemic lupus erythematosus;	chr11:55410582	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs11824035	ENSG00000134612.10	FOLH1B	9.93	2.98e-22	4.87e-16	0.74	0.29	Systemic lupus erythematosus;	chr11:55413200	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.557	rs61917448	ENSG00000134612.10	FOLH1B	9.93	2.98e-22	4.87e-16	0.74	0.29	Systemic lupus erythematosus;	chr11:55414318	chr11:89639227~89698718:+
BRCA	trans	rs4276421	0.554	rs35304078	ENSG00000231752.4	EMBP1	9.93	2.99e-22	4.88e-16	0.4	0.29	P wave duration;	chr5:45685489	chr1:121519112~121571892:+
BRCA	trans	rs2250402	0.51	rs2291619	ENSG00000234106.3	RP11-288E14.2	-9.92	3.07e-22	5.01e-16	-0.64	-0.29	Corneal curvature;	chr15:40036832	chr11:93535468~93535816:+
BRCA	trans	rs7927370	0.619	rs11820751	ENSG00000134612.10	FOLH1B	9.92	3.09e-22	5.04e-16	0.74	0.29	Systemic lupus erythematosus;	chr11:55413416	chr11:89639227~89698718:+
BRCA	trans	rs11098499	0.913	rs10006304	ENSG00000275858.1	RP11-291L22.8	9.92	3.11e-22	5.07e-16	0.39	0.29	Corneal astigmatism;	chr4:119203150	chr10:38450738~38451069:-
BRCA	trans	rs941207	0.756	rs9634246	ENSG00000228224.3	NACAP1	-9.92	3.13e-22	5.1e-16	-0.38	-0.29	Platelet count;	chr12:56640604	chr8:101361794~101372707:+
BRCA	trans	rs9876781	1	rs11130171	ENSG00000225528.1	RP3-370M22.8	-9.92	3.13e-22	5.11e-16	-0.32	-0.29	Longevity;	chr3:48421052	chr22:39960397~39964683:+
BRCA	trans	rs9876781	1	rs9883927	ENSG00000225528.1	RP3-370M22.8	-9.92	3.13e-22	5.11e-16	-0.32	-0.29	Longevity;	chr3:48422302	chr22:39960397~39964683:+
BRCA	trans	rs7927370	1	rs61896312	ENSG00000134612.10	FOLH1B	9.92	3.14e-22	5.13e-16	0.78	0.29	Systemic lupus erythematosus;	chr11:55805222	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs7103342	ENSG00000134612.10	FOLH1B	9.92	3.15e-22	5.14e-16	0.72	0.29	Systemic lupus erythematosus;	chr11:55501329	chr11:89639227~89698718:+
BRCA	trans	rs9876781	0.967	rs2885509	ENSG00000225528.1	RP3-370M22.8	9.92	3.15e-22	5.14e-16	0.32	0.29	Longevity;	chr3:48376729	chr22:39960397~39964683:+
BRCA	trans	rs7937890	0.559	rs2597197	ENSG00000236360.2	RP11-334A14.2	9.92	3.16e-22	5.15e-16	0.38	0.29	Mitochondrial DNA levels;	chr11:14468286	chr1:52993201~52993702:-
BRCA	trans	rs2336384	1	rs2103876	ENSG00000261819.1	RP11-680G24.4	9.92	3.16e-22	5.16e-16	0.39	0.29	Platelet count;	chr1:11993043	chr16:14988259~14990160:-
BRCA	trans	rs7937890	0.559	rs2597217	ENSG00000236360.2	RP11-334A14.2	9.92	3.18e-22	5.18e-16	0.38	0.29	Mitochondrial DNA levels;	chr11:14511337	chr1:52993201~52993702:-
BRCA	trans	rs4276421	0.593	rs10462095	ENSG00000231752.4	EMBP1	-9.92	3.18e-22	5.19e-16	-0.41	-0.29	P wave duration;	chr5:45797500	chr1:121519112~121571892:+
BRCA	trans	rs7927370	1	rs17593355	ENSG00000134612.10	FOLH1B	9.92	3.2e-22	5.22e-16	0.78	0.29	Systemic lupus erythematosus;	chr11:55825398	chr11:89639227~89698718:+
BRCA	trans	rs7937890	0.504	rs2575822	ENSG00000236360.2	RP11-334A14.2	9.92	3.21e-22	5.23e-16	0.38	0.29	Mitochondrial DNA levels;	chr11:14498305	chr1:52993201~52993702:-
BRCA	trans	rs7937890	0.559	rs2575823	ENSG00000236360.2	RP11-334A14.2	9.92	3.21e-22	5.23e-16	0.38	0.29	Mitochondrial DNA levels;	chr11:14499808	chr1:52993201~52993702:-
BRCA	trans	rs7937890	0.559	rs2597221	ENSG00000236360.2	RP11-334A14.2	9.92	3.21e-22	5.23e-16	0.38	0.29	Mitochondrial DNA levels;	chr11:14505529	chr1:52993201~52993702:-
BRCA	trans	rs4276421	0.593	rs6873359	ENSG00000231752.4	EMBP1	9.92	3.23e-22	5.27e-16	0.4	0.29	P wave duration;	chr5:45694473	chr1:121519112~121571892:+
BRCA	trans	rs3779195	0.585	rs7777991	ENSG00000225169.1	BRI3P1	-9.92	3.24e-22	5.28e-16	-0.49	-0.29	Sex hormone-binding globulin levels;	chr7:98236445	chr1:100213293~100213670:+
BRCA	trans	rs7944735	0.517	rs11039520	ENSG00000134612.10	FOLH1B	9.92	3.25e-22	5.29e-16	0.51	0.29	Intraocular pressure;	chr11:48109242	chr11:89639227~89698718:+
BRCA	trans	rs3942852	0.806	rs4752807	ENSG00000134612.10	FOLH1B	-9.92	3.29e-22	5.36e-16	-0.39	-0.29	Acute lymphoblastic leukemia (childhood);	chr11:48107199	chr11:89639227~89698718:+
BRCA	trans	rs3942852	0.774	rs11039519	ENSG00000134612.10	FOLH1B	-9.92	3.29e-22	5.36e-16	-0.39	-0.29	Acute lymphoblastic leukemia (childhood);	chr11:48108542	chr11:89639227~89698718:+
BRCA	trans	rs11098499	0.73	rs78971550	ENSG00000275858.1	RP11-291L22.8	9.92	3.29e-22	5.36e-16	0.36	0.29	Corneal astigmatism;	chr4:119359886	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.645	rs78422072	ENSG00000275858.1	RP11-291L22.8	9.92	3.29e-22	5.36e-16	0.36	0.29	Corneal astigmatism;	chr4:119359887	chr10:38450738~38451069:-
BRCA	trans	rs7927370	1	rs61918253	ENSG00000134612.10	FOLH1B	9.92	3.32e-22	5.4e-16	0.73	0.29	Systemic lupus erythematosus;	chr11:55433971	chr11:89639227~89698718:+
BRCA	trans	rs3806843	0.9	rs2337984	ENSG00000231043.3	AC007238.1	9.92	3.32e-22	5.41e-16	0.35	0.29	Depressive symptoms (multi-trait analysis);	chr5:140757226	chr2:58460292~58462032:-
BRCA	trans	rs11098499	0.874	rs13123591	ENSG00000275858.1	RP11-291L22.8	9.91	3.36e-22	5.47e-16	0.38	0.29	Corneal astigmatism;	chr4:119184835	chr10:38450738~38451069:-
BRCA	trans	rs7927370	1	rs61916162	ENSG00000134612.10	FOLH1B	9.91	3.41e-22	5.54e-16	0.76	0.29	Systemic lupus erythematosus;	chr11:55347321	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61916164	ENSG00000134612.10	FOLH1B	9.91	3.41e-22	5.54e-16	0.76	0.29	Systemic lupus erythematosus;	chr11:55348324	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61916165	ENSG00000134612.10	FOLH1B	9.91	3.41e-22	5.54e-16	0.76	0.29	Systemic lupus erythematosus;	chr11:55348637	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61916166	ENSG00000134612.10	FOLH1B	9.91	3.41e-22	5.54e-16	0.76	0.29	Systemic lupus erythematosus;	chr11:55348975	chr11:89639227~89698718:+
BRCA	trans	rs11098499	0.874	rs9995277	ENSG00000275858.1	RP11-291L22.8	9.91	3.42e-22	5.56e-16	0.38	0.29	Corneal astigmatism;	chr4:119187448	chr10:38450738~38451069:-
BRCA	trans	rs7927370	1	rs7121552	ENSG00000134612.10	FOLH1B	9.91	3.56e-22	5.78e-16	0.74	0.29	Systemic lupus erythematosus;	chr11:55373674	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61916212	ENSG00000134612.10	FOLH1B	9.91	3.56e-22	5.78e-16	0.74	0.29	Systemic lupus erythematosus;	chr11:55374548	chr11:89639227~89698718:+
BRCA	trans	rs7937890	0.559	rs2597201	ENSG00000236360.2	RP11-334A14.2	9.91	3.56e-22	5.78e-16	0.38	0.29	Mitochondrial DNA levels;	chr11:14463858	chr1:52993201~52993702:-
BRCA	trans	rs7937890	0.532	rs2575832	ENSG00000236360.2	RP11-334A14.2	9.91	3.56e-22	5.78e-16	0.38	0.29	Mitochondrial DNA levels;	chr11:14467264	chr1:52993201~52993702:-
BRCA	trans	rs12210905	0.841	rs12206996	ENSG00000242375.1	RP11-498P14.3	-9.91	3.57e-22	5.8e-16	-0.72	-0.29	Hip circumference adjusted for BMI;	chr6:27098636	chr9:97195351~97197687:-
BRCA	trans	rs12210905	1	rs72842200	ENSG00000242375.1	RP11-498P14.3	-9.91	3.57e-22	5.8e-16	-0.72	-0.29	Hip circumference adjusted for BMI;	chr6:27100257	chr9:97195351~97197687:-
BRCA	trans	rs9876781	1	rs2242150	ENSG00000225528.1	RP3-370M22.8	9.91	3.59e-22	5.84e-16	0.32	0.29	Longevity;	chr3:48464565	chr22:39960397~39964683:+
BRCA	trans	rs864643	0.524	rs77060785	ENSG00000188856.6	RPSAP47	9.91	3.62e-22	5.88e-16	0.57	0.29	Attention deficit hyperactivity disorder;	chr3:39491177	chr8:80558870~80559757:+
BRCA	trans	rs941207	0.756	rs2950394	ENSG00000228224.3	NACAP1	-9.9	3.64e-22	5.92e-16	-0.38	-0.29	Platelet count;	chr12:56644548	chr8:101361794~101372707:+
BRCA	trans	rs867371	0.722	rs8033050	ENSG00000235370.6	DNM1P51	-9.9	3.66e-22	5.94e-16	-0.34	-0.29	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82269648	chr15:84398316~84411701:-
BRCA	trans	rs941207	0.756	rs7313074	ENSG00000228224.3	NACAP1	-9.9	3.67e-22	5.95e-16	-0.38	-0.29	Platelet count;	chr12:56760705	chr8:101361794~101372707:+
BRCA	trans	rs941207	0.756	rs2958153	ENSG00000228224.3	NACAP1	9.9	3.7e-22	6.01e-16	0.37	0.29	Platelet count;	chr12:56687733	chr8:101361794~101372707:+
BRCA	trans	rs6498068	0.633	rs1504884	ENSG00000278702.1	Metazoa_SRP	9.9	3.71e-22	6.02e-16	0.41	0.29	Metabolite levels (MHPG);	chr16:10538128	chr1:35399997~35400319:+
BRCA	trans	rs4276421	0.593	rs10056041	ENSG00000231752.4	EMBP1	-9.9	3.75e-22	6.08e-16	-0.41	-0.29	P wave duration;	chr5:45786075	chr1:121519112~121571892:+
BRCA	trans	rs877636	0.74	rs705702	ENSG00000196933.5	RPS26P11	-9.9	3.77e-22	6.12e-16	-0.39	-0.29	Cognitive function;	chr12:55996852	chrX:72044545~72044892:+
BRCA	trans	rs7927370	1	rs61894851	ENSG00000134612.10	FOLH1B	9.9	3.77e-22	6.12e-16	0.79	0.29	Systemic lupus erythematosus;	chr11:55769880	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61894852	ENSG00000134612.10	FOLH1B	9.9	3.77e-22	6.12e-16	0.79	0.29	Systemic lupus erythematosus;	chr11:55770037	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61894853	ENSG00000134612.10	FOLH1B	9.9	3.77e-22	6.12e-16	0.79	0.29	Systemic lupus erythematosus;	chr11:55771149	chr11:89639227~89698718:+
BRCA	trans	rs3806843	0.676	rs2245640	ENSG00000231043.3	AC007238.1	9.9	3.83e-22	6.21e-16	0.35	0.29	Depressive symptoms (multi-trait analysis);	chr5:140650373	chr2:58460292~58462032:-
BRCA	trans	rs7927370	1	rs56254109	ENSG00000134612.10	FOLH1B	9.9	3.87e-22	6.27e-16	0.72	0.29	Systemic lupus erythematosus;	chr11:55538139	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs55967107	ENSG00000134612.10	FOLH1B	9.9	3.87e-22	6.27e-16	0.72	0.29	Systemic lupus erythematosus;	chr11:55538143	chr11:89639227~89698718:+
BRCA	trans	rs2250402	0.51	rs8031319	ENSG00000234106.3	RP11-288E14.2	9.9	3.93e-22	6.36e-16	0.63	0.29	Corneal curvature;	chr15:40031491	chr11:93535468~93535816:+
BRCA	trans	rs4276421	0.571	rs28405556	ENSG00000231752.4	EMBP1	9.9	3.93e-22	6.37e-16	0.4	0.29	P wave duration;	chr5:45636684	chr1:121519112~121571892:+
BRCA	trans	rs7927370	0.702	rs61894795	ENSG00000134612.10	FOLH1B	9.9	3.94e-22	6.37e-16	0.78	0.29	Systemic lupus erythematosus;	chr11:55743131	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs7951100	ENSG00000134612.10	FOLH1B	9.9	3.94e-22	6.38e-16	0.74	0.29	Systemic lupus erythematosus;	chr11:55822820	chr11:89639227~89698718:+
BRCA	trans	rs4276421	0.593	rs6886950	ENSG00000231752.4	EMBP1	9.9	3.97e-22	6.43e-16	0.4	0.29	P wave duration;	chr5:45742867	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.55	rs6898825	ENSG00000231752.4	EMBP1	-9.89	4e-22	6.46e-16	-0.45	-0.29	P wave duration;	chr5:45842061	chr1:121519112~121571892:+
BRCA	trans	rs7944735	0.69	rs7927682	ENSG00000134612.10	FOLH1B	9.89	4.01e-22	6.48e-16	0.44	0.29	Intraocular pressure;	chr11:47926106	chr11:89639227~89698718:+
BRCA	trans	rs6732160	0.51	rs57825971	ENSG00000236165.1	PRADC1P1	9.89	4.02e-22	6.49e-16	0.39	0.29	Intelligence (multi-trait analysis);	chr2:73157668	chr3:36976316~36976840:+
BRCA	trans	rs10865397	0.506	rs60764301	ENSG00000236165.1	PRADC1P1	9.89	4.02e-22	6.49e-16	0.39	0.29	Intelligence (multi-trait analysis);	chr2:73157722	chr3:36976316~36976840:+
BRCA	trans	rs7927370	1	rs17501618	ENSG00000134612.10	FOLH1B	-9.89	4.07e-22	6.58e-16	-0.76	-0.29	Systemic lupus erythematosus;	chr11:55800740	chr11:89639227~89698718:+
BRCA	trans	rs11250098	0.574	rs4240672	ENSG00000253893.2	FAM85B	9.89	4.1e-22	6.62e-16	0.36	0.29	Morning vs. evening chronotype;	chr8:10910407	chr8:8167819~8226614:-
BRCA	trans	rs4276421	0.593	rs6894784	ENSG00000231752.4	EMBP1	9.89	4.11e-22	6.65e-16	0.4	0.29	P wave duration;	chr5:45710935	chr1:121519112~121571892:+
BRCA	trans	rs9467773	0.595	rs3846845	ENSG00000242375.1	RP11-498P14.3	-9.89	4.12e-22	6.66e-16	-0.42	-0.29	Intelligence (multi-trait analysis);	chr6:26444687	chr9:97195351~97197687:-
BRCA	trans	rs9467773	0.572	rs3846846	ENSG00000242375.1	RP11-498P14.3	-9.89	4.12e-22	6.66e-16	-0.42	-0.29	Intelligence (multi-trait analysis);	chr6:26444811	chr9:97195351~97197687:-
BRCA	trans	rs7937890	0.559	rs2575831	ENSG00000236360.2	RP11-334A14.2	9.89	4.15e-22	6.7e-16	0.38	0.29	Mitochondrial DNA levels;	chr11:14464648	chr1:52993201~52993702:-
BRCA	trans	rs9581094	0.591	rs9553318	ENSG00000237917.1	PARP4P1	-9.89	4.16e-22	6.72e-16	-0.44	-0.29	Sudden cardiac arrest;	chr13:24477107	chrY:26594851~26634652:-
BRCA	trans	rs4276421	0.593	rs6871250	ENSG00000231752.4	EMBP1	-9.89	4.17e-22	6.73e-16	-0.41	-0.29	P wave duration;	chr5:45801662	chr1:121519112~121571892:+
BRCA	trans	rs877636	0.669	rs7297175	ENSG00000224553.1	AC008065.1	-9.89	4.17e-22	6.74e-16	-0.33	-0.29	Cognitive function;	chr12:56080024	chr2:171374931~171375278:-
BRCA	trans	rs9876781	1	rs1459242	ENSG00000225528.1	RP3-370M22.8	9.89	4.2e-22	6.79e-16	0.32	0.29	Longevity;	chr3:48372047	chr22:39960397~39964683:+
BRCA	trans	rs7937890	0.531	rs2575859	ENSG00000236360.2	RP11-334A14.2	9.89	4.32e-22	6.97e-16	0.38	0.29	Mitochondrial DNA levels;	chr11:14489190	chr1:52993201~52993702:-
BRCA	trans	rs7937890	0.559	rs2597206	ENSG00000236360.2	RP11-334A14.2	9.89	4.35e-22	7.02e-16	0.38	0.29	Mitochondrial DNA levels;	chr11:14455992	chr1:52993201~52993702:-
BRCA	trans	rs7927370	1	rs55833102	ENSG00000134612.10	FOLH1B	9.88	4.44e-22	7.16e-16	0.78	0.29	Systemic lupus erythematosus;	chr11:55744700	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs56148636	ENSG00000134612.10	FOLH1B	9.88	4.44e-22	7.17e-16	0.73	0.29	Systemic lupus erythematosus;	chr11:55428324	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs113079896	ENSG00000134612.10	FOLH1B	9.88	4.44e-22	7.17e-16	0.73	0.29	Systemic lupus erythematosus;	chr11:55429207	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61918233	ENSG00000134612.10	FOLH1B	9.88	4.44e-22	7.17e-16	0.73	0.29	Systemic lupus erythematosus;	chr11:55429507	chr11:89639227~89698718:+
BRCA	trans	rs4883201	0.518	rs887782	ENSG00000179899.8	PHC1P1	-9.88	4.55e-22	7.34e-16	-0.36	-0.29	Total cholesterol levels;Cholesterol, total;	chr12:8932082	chr12:55411727~55414787:-
BRCA	trans	rs9876781	1	rs2885510	ENSG00000225528.1	RP3-370M22.8	9.88	4.61e-22	7.43e-16	0.31	0.29	Longevity;	chr3:48376736	chr22:39960397~39964683:+
BRCA	trans	rs9876781	1	rs725309	ENSG00000225528.1	RP3-370M22.8	9.88	4.61e-22	7.43e-16	0.31	0.29	Longevity;	chr3:48377218	chr22:39960397~39964683:+
BRCA	trans	rs9876781	0.967	rs1459249	ENSG00000225528.1	RP3-370M22.8	-9.88	4.61e-22	7.43e-16	-0.32	-0.29	Longevity;	chr3:48438208	chr22:39960397~39964683:+
BRCA	trans	rs7937890	0.559	rs2597208	ENSG00000236360.2	RP11-334A14.2	9.88	4.61e-22	7.44e-16	0.38	0.29	Mitochondrial DNA levels;	chr11:14450783	chr1:52993201~52993702:-
BRCA	trans	rs12210905	1	rs7759955	ENSG00000242375.1	RP11-498P14.3	-9.88	4.63e-22	7.46e-16	-0.71	-0.29	Hip circumference adjusted for BMI;	chr6:26792463	chr9:97195351~97197687:-
BRCA	trans	rs853679	0.607	rs71559070	ENSG00000253570.1	RNF5P1	9.88	4.65e-22	7.49e-16	0.88	0.29	Depression;	chr6:28071151	chr8:38600661~38601200:-
BRCA	trans	rs853679	0.607	rs35902873	ENSG00000253570.1	RNF5P1	9.88	4.65e-22	7.49e-16	0.88	0.29	Depression;	chr6:28091171	chr8:38600661~38601200:-
BRCA	trans	rs853679	0.607	rs13197574	ENSG00000253570.1	RNF5P1	9.88	4.65e-22	7.49e-16	0.88	0.29	Depression;	chr6:28092461	chr8:38600661~38601200:-
BRCA	trans	rs864643	0.524	rs80322842	ENSG00000188856.6	RPSAP47	9.88	4.67e-22	7.52e-16	0.54	0.29	Attention deficit hyperactivity disorder;	chr3:39483682	chr8:80558870~80559757:+
BRCA	trans	rs7927370	1	rs11819779	ENSG00000134612.10	FOLH1B	9.88	4.69e-22	7.55e-16	0.72	0.29	Systemic lupus erythematosus;	chr11:55297716	chr11:89639227~89698718:+
BRCA	trans	rs2336384	1	rs6672267	ENSG00000261819.1	RP11-680G24.4	9.88	4.71e-22	7.59e-16	0.39	0.29	Platelet count;	chr1:11994854	chr16:14988259~14990160:-
BRCA	trans	rs10037055	0.853	rs10077929	ENSG00000226986.4	RP11-543B16.2	9.88	4.72e-22	7.6e-16	0.37	0.29	Migraine without aura;	chr5:177270843	chr1:211207239~211207897:+
BRCA	trans	rs12200782	0.932	rs12202419	ENSG00000242375.1	RP11-498P14.3	9.87	4.79e-22	7.72e-16	0.69	0.29	Small cell lung carcinoma;	chr6:26465156	chr9:97195351~97197687:-
BRCA	trans	rs10865397	0.506	rs13414160	ENSG00000236165.1	PRADC1P1	9.87	4.86e-22	7.82e-16	0.39	0.29	Intelligence (multi-trait analysis);	chr2:73156133	chr3:36976316~36976840:+
BRCA	trans	rs877636	0.702	rs773110	ENSG00000196933.5	RPS26P11	9.87	4.88e-22	7.86e-16	0.39	0.29	Cognitive function;	chr12:55981353	chrX:72044545~72044892:+
BRCA	trans	rs4276421	0.533	rs35197327	ENSG00000231752.4	EMBP1	9.87	4.92e-22	7.92e-16	0.4	0.29	P wave duration;	chr5:45616911	chr1:121519112~121571892:+
BRCA	trans	rs941207	0.756	rs2958149	ENSG00000228224.3	NACAP1	9.87	5.05e-22	8.13e-16	0.37	0.29	Platelet count;	chr12:56716008	chr8:101361794~101372707:+
BRCA	trans	rs12200782	1	rs12195971	ENSG00000242375.1	RP11-498P14.3	-9.87	5.06e-22	8.14e-16	-0.71	-0.29	Small cell lung carcinoma;	chr6:26460196	chr9:97195351~97197687:-
BRCA	trans	rs12200782	1	rs12211201	ENSG00000242375.1	RP11-498P14.3	-9.87	5.06e-22	8.14e-16	-0.71	-0.29	Small cell lung carcinoma;	chr6:26461233	chr9:97195351~97197687:-
BRCA	trans	rs3806843	0.676	rs778593	ENSG00000231043.3	AC007238.1	9.87	5.12e-22	8.23e-16	0.35	0.29	Depressive symptoms (multi-trait analysis);	chr5:140647631	chr2:58460292~58462032:-
BRCA	trans	rs3806843	0.676	rs778594	ENSG00000231043.3	AC007238.1	9.87	5.12e-22	8.23e-16	0.35	0.29	Depressive symptoms (multi-trait analysis);	chr5:140647719	chr2:58460292~58462032:-
BRCA	trans	rs9876781	1	rs7635522	ENSG00000225528.1	RP3-370M22.8	-9.87	5.19e-22	8.35e-16	-0.32	-0.29	Longevity;	chr3:48382166	chr22:39960397~39964683:+
BRCA	trans	rs9876781	1	rs2045554	ENSG00000225528.1	RP3-370M22.8	9.87	5.2e-22	8.36e-16	0.32	0.29	Longevity;	chr3:48453142	chr22:39960397~39964683:+
BRCA	trans	rs12210905	1	rs72838266	ENSG00000242375.1	RP11-498P14.3	-9.87	5.21e-22	8.37e-16	-0.72	-0.29	Hip circumference adjusted for BMI;	chr6:27047273	chr9:97195351~97197687:-
BRCA	trans	rs7927370	1	rs7124871	ENSG00000134612.10	FOLH1B	9.87	5.24e-22	8.43e-16	0.78	0.29	Systemic lupus erythematosus;	chr11:55774144	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.867	rs76119917	ENSG00000134612.10	FOLH1B	9.87	5.24e-22	8.43e-16	0.78	0.29	Systemic lupus erythematosus;	chr11:55780310	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61894854	ENSG00000134612.10	FOLH1B	9.87	5.24e-22	8.43e-16	0.78	0.29	Systemic lupus erythematosus;	chr11:55780977	chr11:89639227~89698718:+
BRCA	trans	rs9467773	0.595	rs4320356	ENSG00000242375.1	RP11-498P14.3	-9.86	5.25e-22	8.44e-16	-0.42	-0.29	Intelligence (multi-trait analysis);	chr6:26423332	chr9:97195351~97197687:-
BRCA	trans	rs7312770	1	rs7312770	ENSG00000196933.5	RPS26P11	-9.86	5.26e-22	8.45e-16	-0.33	-0.29	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chrX:72044545~72044892:+
BRCA	trans	rs4276421	0.571	rs12109155	ENSG00000231752.4	EMBP1	9.86	5.29e-22	8.5e-16	0.4	0.29	P wave duration;	chr5:45727897	chr1:121519112~121571892:+
BRCA	trans	rs7927370	1	rs113745672	ENSG00000134612.10	FOLH1B	9.86	5.47e-22	8.78e-16	0.72	0.29	Systemic lupus erythematosus;	chr11:55284262	chr11:89639227~89698718:+
BRCA	trans	rs4276421	0.593	rs16902199	ENSG00000231752.4	EMBP1	9.86	5.58e-22	8.96e-16	0.4	0.29	P wave duration;	chr5:45648655	chr1:121519112~121571892:+
BRCA	trans	rs7113874	0.802	rs10840102	ENSG00000266891.1	RP11-692N5.2	9.86	5.62e-22	9.03e-16	0.38	0.29	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8654691	chr18:9734882~9735602:-
BRCA	trans	rs7927370	1	rs61895829	ENSG00000134612.10	FOLH1B	9.86	5.63e-22	9.04e-16	0.73	0.29	Systemic lupus erythematosus;	chr11:55043013	chr11:89639227~89698718:+
BRCA	trans	rs4276421	0.593	rs16902221	ENSG00000231752.4	EMBP1	9.86	5.63e-22	9.05e-16	0.4	0.29	P wave duration;	chr5:45739938	chr1:121519112~121571892:+
BRCA	trans	rs11098499	0.866	rs7665125	ENSG00000275858.1	RP11-291L22.8	9.85	5.82e-22	9.34e-16	0.35	0.29	Corneal astigmatism;	chr4:119480924	chr10:38450738~38451069:-
BRCA	trans	rs7927370	1	rs11827405	ENSG00000134612.10	FOLH1B	9.85	5.84e-22	9.37e-16	0.74	0.29	Systemic lupus erythematosus;	chr11:55419111	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.867	rs11827428	ENSG00000134612.10	FOLH1B	9.85	5.84e-22	9.37e-16	0.74	0.29	Systemic lupus erythematosus;	chr11:55419251	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61918210	ENSG00000134612.10	FOLH1B	9.85	5.84e-22	9.37e-16	0.74	0.29	Systemic lupus erythematosus;	chr11:55419955	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs78502527	ENSG00000134612.10	FOLH1B	9.85	5.84e-22	9.37e-16	0.74	0.29	Systemic lupus erythematosus;	chr11:55420104	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.85	rs78875731	ENSG00000134612.10	FOLH1B	9.85	5.84e-22	9.37e-16	0.74	0.29	Systemic lupus erythematosus;	chr11:55420462	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61918214	ENSG00000134612.10	FOLH1B	9.85	5.84e-22	9.37e-16	0.74	0.29	Systemic lupus erythematosus;	chr11:55420555	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61918207	ENSG00000134612.10	FOLH1B	9.85	5.88e-22	9.43e-16	0.74	0.29	Systemic lupus erythematosus;	chr11:55417756	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61918208	ENSG00000134612.10	FOLH1B	9.85	5.88e-22	9.43e-16	0.74	0.29	Systemic lupus erythematosus;	chr11:55417973	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.867	rs61918209	ENSG00000134612.10	FOLH1B	9.85	5.88e-22	9.43e-16	0.74	0.29	Systemic lupus erythematosus;	chr11:55418433	chr11:89639227~89698718:+
BRCA	trans	rs877636	0.702	rs773109	ENSG00000196933.5	RPS26P11	9.85	5.93e-22	9.5e-16	0.39	0.29	Cognitive function;	chr12:55980911	chrX:72044545~72044892:+
BRCA	trans	rs7927370	1	rs79883073	ENSG00000134612.10	FOLH1B	9.85	6.03e-22	9.67e-16	0.74	0.29	Systemic lupus erythematosus;	chr11:55417269	chr11:89639227~89698718:+
BRCA	trans	rs9467773	0.587	rs3208733	ENSG00000242375.1	RP11-498P14.3	-9.85	6.1e-22	9.77e-16	-0.41	-0.29	Intelligence (multi-trait analysis);	chr6:26414197	chr9:97195351~97197687:-
BRCA	trans	rs4276421	0.53	rs16902217	ENSG00000231752.4	EMBP1	9.85	6.21e-22	9.94e-16	0.4	0.29	P wave duration;	chr5:45719223	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.593	rs13361609	ENSG00000231752.4	EMBP1	9.84	6.31e-22	1.01e-15	0.4	0.29	P wave duration;	chr5:45697360	chr1:121519112~121571892:+
BRCA	trans	rs3942852	0.806	rs10838805	ENSG00000134612.10	FOLH1B	-9.84	6.34e-22	1.01e-15	-0.39	-0.29	Acute lymphoblastic leukemia (childhood);	chr11:48097441	chr11:89639227~89698718:+
BRCA	trans	rs877636	0.669	rs7297175	ENSG00000204652.6	RPS26P8	-9.84	6.35e-22	1.02e-15	-0.35	-0.29	Cognitive function;	chr12:56080024	chr17:45608571~45608918:+
BRCA	trans	rs7927370	1	rs11825313	ENSG00000134612.10	FOLH1B	9.84	6.35e-22	1.02e-15	0.74	0.29	Systemic lupus erythematosus;	chr11:55421411	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61918218	ENSG00000134612.10	FOLH1B	9.84	6.35e-22	1.02e-15	0.74	0.29	Systemic lupus erythematosus;	chr11:55422199	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61918219	ENSG00000134612.10	FOLH1B	9.84	6.35e-22	1.02e-15	0.74	0.29	Systemic lupus erythematosus;	chr11:55422357	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs56078420	ENSG00000134612.10	FOLH1B	9.84	6.35e-22	1.02e-15	0.74	0.29	Systemic lupus erythematosus;	chr11:55422493	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61918221	ENSG00000134612.10	FOLH1B	9.84	6.35e-22	1.02e-15	0.74	0.29	Systemic lupus erythematosus;	chr11:55423232	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.702	rs6591636	ENSG00000134612.10	FOLH1B	9.84	6.44e-22	1.03e-15	0.77	0.29	Systemic lupus erythematosus;	chr11:55722796	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs17499703	ENSG00000134612.10	FOLH1B	9.84	6.44e-22	1.03e-15	0.77	0.29	Systemic lupus erythematosus;	chr11:55724915	chr11:89639227~89698718:+
BRCA	trans	rs3806843	1	rs2098058	ENSG00000231043.3	AC007238.1	9.84	6.51e-22	1.04e-15	0.34	0.29	Depressive symptoms (multi-trait analysis);	chr5:140777842	chr2:58460292~58462032:-
BRCA	trans	rs7937890	0.531	rs2575828	ENSG00000236360.2	RP11-334A14.2	9.84	6.52e-22	1.04e-15	0.38	0.29	Mitochondrial DNA levels;	chr11:14462646	chr1:52993201~52993702:-
BRCA	trans	rs7937890	0.559	rs2575829	ENSG00000236360.2	RP11-334A14.2	9.84	6.52e-22	1.04e-15	0.38	0.29	Mitochondrial DNA levels;	chr11:14463475	chr1:52993201~52993702:-
BRCA	trans	rs7937890	0.559	rs2597200	ENSG00000236360.2	RP11-334A14.2	9.84	6.52e-22	1.04e-15	0.38	0.29	Mitochondrial DNA levels;	chr11:14464054	chr1:52993201~52993702:-
BRCA	trans	rs7937890	0.559	rs2575830	ENSG00000236360.2	RP11-334A14.2	9.84	6.52e-22	1.04e-15	0.38	0.29	Mitochondrial DNA levels;	chr11:14464056	chr1:52993201~52993702:-
BRCA	trans	rs2336384	1	rs6668386	ENSG00000261819.1	RP11-680G24.4	9.84	6.57e-22	1.05e-15	0.39	0.29	Platelet count;	chr1:11987176	chr16:14988259~14990160:-
BRCA	trans	rs7927370	0.85	rs61918223	ENSG00000134612.10	FOLH1B	9.84	6.67e-22	1.06e-15	0.74	0.29	Systemic lupus erythematosus;	chr11:55424293	chr11:89639227~89698718:+
BRCA	trans	rs11039798	0.841	rs12221667	ENSG00000134612.10	FOLH1B	9.84	6.79e-22	1.08e-15	0.59	0.29	Axial length;	chr11:48526997	chr11:89639227~89698718:+
BRCA	trans	rs7937890	0.559	rs10766184	ENSG00000236360.2	RP11-334A14.2	9.84	6.82e-22	1.09e-15	0.38	0.29	Mitochondrial DNA levels;	chr11:14521031	chr1:52993201~52993702:-
BRCA	trans	rs9467773	0.595	rs6907924	ENSG00000242375.1	RP11-498P14.3	-9.84	6.88e-22	1.1e-15	-0.41	-0.29	Intelligence (multi-trait analysis);	chr6:26438589	chr9:97195351~97197687:-
BRCA	trans	rs9467773	0.55	rs9379874	ENSG00000242375.1	RP11-498P14.3	-9.84	6.88e-22	1.1e-15	-0.41	-0.29	Intelligence (multi-trait analysis);	chr6:26440201	chr9:97195351~97197687:-
BRCA	trans	rs941207	0.724	rs1979325	ENSG00000228224.3	NACAP1	9.83	6.94e-22	1.11e-15	0.37	0.29	Platelet count;	chr12:56728152	chr8:101361794~101372707:+
BRCA	trans	rs941207	0.756	rs7978685	ENSG00000228224.3	NACAP1	9.83	6.95e-22	1.11e-15	0.38	0.29	Platelet count;	chr12:56709370	chr8:101361794~101372707:+
BRCA	trans	rs7937890	0.535	rs2575857	ENSG00000236360.2	RP11-334A14.2	9.83	6.99e-22	1.11e-15	0.38	0.29	Mitochondrial DNA levels;	chr11:14479750	chr1:52993201~52993702:-
BRCA	trans	rs9876781	0.967	rs1870444	ENSG00000225528.1	RP3-370M22.8	-9.83	7.05e-22	1.12e-15	-0.32	-0.29	Longevity;	chr3:48445369	chr22:39960397~39964683:+
BRCA	trans	rs12210905	1	rs12209393	ENSG00000242375.1	RP11-498P14.3	-9.83	7.28e-22	1.16e-15	-0.72	-0.29	Hip circumference adjusted for BMI;	chr6:27117294	chr9:97195351~97197687:-
BRCA	trans	rs12210905	1	rs12214930	ENSG00000242375.1	RP11-498P14.3	-9.83	7.28e-22	1.16e-15	-0.72	-0.29	Hip circumference adjusted for BMI;	chr6:27125936	chr9:97195351~97197687:-
BRCA	trans	rs12210905	1	rs3531	ENSG00000242375.1	RP11-498P14.3	-9.83	7.28e-22	1.16e-15	-0.72	-0.29	Hip circumference adjusted for BMI;	chr6:27127534	chr9:97195351~97197687:-
BRCA	trans	rs3942852	0.774	rs924715	ENSG00000134612.10	FOLH1B	-9.83	7.37e-22	1.17e-15	-0.4	-0.29	Acute lymphoblastic leukemia (childhood);	chr11:48159508	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.867	rs61894843	ENSG00000134612.10	FOLH1B	9.83	7.38e-22	1.17e-15	0.8	0.29	Systemic lupus erythematosus;	chr11:55758815	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61894847	ENSG00000134612.10	FOLH1B	9.83	7.38e-22	1.17e-15	0.8	0.29	Systemic lupus erythematosus;	chr11:55763300	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs17592197	ENSG00000134612.10	FOLH1B	9.83	7.38e-22	1.17e-15	0.8	0.29	Systemic lupus erythematosus;	chr11:55763848	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.85	rs61894848	ENSG00000134612.10	FOLH1B	9.83	7.38e-22	1.17e-15	0.8	0.29	Systemic lupus erythematosus;	chr11:55763939	chr11:89639227~89698718:+
BRCA	trans	rs9876781	1	rs922075	ENSG00000225528.1	RP3-370M22.8	9.82	7.73e-22	1.23e-15	0.32	0.29	Longevity;	chr3:48447994	chr22:39960397~39964683:+
BRCA	trans	rs1816752	0.646	rs3783073	ENSG00000224976.2	PARP4P2	9.82	7.87e-22	1.25e-15	0.36	0.29	Obesity-related traits;	chr13:24493222	chr13:19349137~19407962:+
BRCA	trans	rs7113874	0.802	rs7941510	ENSG00000266891.1	RP11-692N5.2	9.82	7.87e-22	1.25e-15	0.38	0.29	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8655516	chr18:9734882~9735602:-
BRCA	trans	rs7927370	1	rs17581532	ENSG00000134612.10	FOLH1B	9.82	7.93e-22	1.26e-15	0.76	0.29	Systemic lupus erythematosus;	chr11:55554347	chr11:89639227~89698718:+
BRCA	trans	rs1580019	0.587	rs6968990	ENSG00000176826.14	FKBP9P1	9.82	8.15e-22	1.3e-15	0.37	0.29	Cognitive ability;	chr7:32512547	chr7:55681074~55713252:-
BRCA	trans	rs7937890	0.559	rs2575836	ENSG00000236360.2	RP11-334A14.2	9.82	8.23e-22	1.31e-15	0.38	0.29	Mitochondrial DNA levels;	chr11:14476318	chr1:52993201~52993702:-
BRCA	trans	rs4276421	0.593	rs13178796	ENSG00000231752.4	EMBP1	9.82	8.23e-22	1.31e-15	0.4	0.29	P wave duration;	chr5:45684414	chr1:121519112~121571892:+
BRCA	trans	rs12210905	0.925	rs12214640	ENSG00000242375.1	RP11-498P14.3	-9.82	8.26e-22	1.31e-15	-0.71	-0.29	Hip circumference adjusted for BMI;	chr6:26739806	chr9:97195351~97197687:-
BRCA	trans	rs9329221	0.736	rs34381075	ENSG00000253893.2	FAM85B	-9.81	8.3e-22	1.32e-15	-0.39	-0.29	Neuroticism;	chr8:10386275	chr8:8167819~8226614:-
BRCA	trans	rs6424115	0.83	rs2502999	ENSG00000228217.1	AL390877.1	-9.81	8.31e-22	1.32e-15	-0.36	-0.29	Immature fraction of reticulocytes;	chr1:23871831	chr1:117778087~117778506:-
BRCA	trans	rs6424115	0.793	rs2502998	ENSG00000228217.1	AL390877.1	-9.81	8.31e-22	1.32e-15	-0.36	-0.29	Immature fraction of reticulocytes;	chr1:23871837	chr1:117778087~117778506:-
BRCA	trans	rs7113874	0.802	rs35319120	ENSG00000266891.1	RP11-692N5.2	9.81	8.38e-22	1.33e-15	0.38	0.29	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8648147	chr18:9734882~9735602:-
BRCA	trans	rs13190036	1	rs6880798	ENSG00000228305.2	AC016734.2	9.81	8.51e-22	1.35e-15	0.38	0.29	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177277456	chr2:63622178~63622831:-
BRCA	trans	rs747782	0.527	rs3741410	ENSG00000134612.10	FOLH1B	9.81	8.55e-22	1.36e-15	0.47	0.29	Intraocular pressure;	chr11:48147112	chr11:89639227~89698718:+
BRCA	trans	rs73108077	0.736	rs6058492	ENSG00000279352.1	RP11-411B10.7	9.81	8.61e-22	1.37e-15	0.51	0.29	Red blood cell density in sickle cell anemia;	chr20:31286965	chr18:14010054~14010917:+
BRCA	trans	rs6424115	0.83	rs2503000	ENSG00000228217.1	AL390877.1	-9.81	8.73e-22	1.39e-15	-0.35	-0.29	Immature fraction of reticulocytes;	chr1:23871408	chr1:117778087~117778506:-
BRCA	trans	rs9876781	1	rs2362450	ENSG00000225528.1	RP3-370M22.8	-9.81	8.74e-22	1.39e-15	-0.31	-0.29	Longevity;	chr3:48419904	chr22:39960397~39964683:+
BRCA	trans	rs9876781	1	rs6784322	ENSG00000225528.1	RP3-370M22.8	-9.81	9.01e-22	1.43e-15	-0.33	-0.29	Longevity;	chr3:48380745	chr22:39960397~39964683:+
BRCA	trans	rs4276421	0.593	rs4866978	ENSG00000231752.4	EMBP1	-9.8	9.13e-22	1.45e-15	-0.4	-0.29	P wave duration;	chr5:45800636	chr1:121519112~121571892:+
BRCA	trans	rs7927370	0.85	rs17500359	ENSG00000134612.10	FOLH1B	9.8	9.22e-22	1.46e-15	0.78	0.29	Systemic lupus erythematosus;	chr11:55736589	chr11:89639227~89698718:+
BRCA	trans	rs3096299	0.685	rs4785675	ENSG00000215030.5	RPL13P12	-9.8	9.5e-22	1.51e-15	-0.3	-0.29	Multiple myeloma (IgH translocation);	chr16:89473566	chr17:17383377~17384012:-
BRCA	trans	rs9876781	1	rs725310	ENSG00000225528.1	RP3-370M22.8	9.8	9.51e-22	1.51e-15	0.31	0.29	Longevity;	chr3:48377081	chr22:39960397~39964683:+
BRCA	trans	rs11098499	1	rs13435802	ENSG00000275858.1	RP11-291L22.8	-9.8	9.56e-22	1.52e-15	-0.36	-0.29	Corneal astigmatism;	chr4:119256805	chr10:38450738~38451069:-
BRCA	trans	rs11039798	1	rs7924372	ENSG00000134612.10	FOLH1B	9.8	9.58e-22	1.52e-15	0.59	0.29	Axial length;	chr11:48534767	chr11:89639227~89698718:+
BRCA	trans	rs12210905	1	rs12192049	ENSG00000242375.1	RP11-498P14.3	-9.8	9.68e-22	1.53e-15	-0.72	-0.29	Hip circumference adjusted for BMI;	chr6:27088960	chr9:97195351~97197687:-
BRCA	trans	rs7937890	0.504	rs2575847	ENSG00000236360.2	RP11-334A14.2	9.8	9.75e-22	1.55e-15	0.38	0.29	Mitochondrial DNA levels;	chr11:14449626	chr1:52993201~52993702:-
BRCA	trans	rs7937890	0.559	rs2575825	ENSG00000236360.2	RP11-334A14.2	9.8	9.75e-22	1.55e-15	0.38	0.29	Mitochondrial DNA levels;	chr11:14450550	chr1:52993201~52993702:-
BRCA	trans	rs12210905	1	rs12201498	ENSG00000242375.1	RP11-498P14.3	-9.79	1.02e-21	1.62e-15	-0.72	-0.29	Hip circumference adjusted for BMI;	chr6:27062305	chr9:97195351~97197687:-
BRCA	trans	rs12210905	1	rs12203728	ENSG00000242375.1	RP11-498P14.3	-9.79	1.02e-21	1.62e-15	-0.72	-0.29	Hip circumference adjusted for BMI;	chr6:27083971	chr9:97195351~97197687:-
BRCA	trans	rs58106596	0.95	rs11695646	ENSG00000259020.3	RP11-529H20.3	-9.79	1.02e-21	1.62e-15	-0.38	-0.29	Lymphocyte counts;White blood cell count;	chr2:231720097	chr14:92026566~92026887:+
BRCA	trans	rs877636	0.669	rs7297175	ENSG00000244604.1	RP11-713H12.1	-9.79	1.02e-21	1.62e-15	-0.32	-0.29	Cognitive function;	chr12:56080024	chr17:8561230~8561576:+
BRCA	trans	rs7937890	0.532	rs2575827	ENSG00000236360.2	RP11-334A14.2	9.79	1.03e-21	1.63e-15	0.38	0.29	Mitochondrial DNA levels;	chr11:14453969	chr1:52993201~52993702:-
BRCA	trans	rs7927370	1	rs1230338	ENSG00000134612.10	FOLH1B	-9.79	1.04e-21	1.65e-15	-0.73	-0.29	Systemic lupus erythematosus;	chr11:55405585	chr11:89639227~89698718:+
BRCA	trans	rs3806843	1	rs1030165	ENSG00000231043.3	AC007238.1	-9.79	1.06e-21	1.68e-15	-0.35	-0.29	Depressive symptoms (multi-trait analysis);	chr5:140805863	chr2:58460292~58462032:-
BRCA	trans	rs3806843	0.966	rs1030166	ENSG00000231043.3	AC007238.1	-9.79	1.06e-21	1.68e-15	-0.35	-0.29	Depressive symptoms (multi-trait analysis);	chr5:140805888	chr2:58460292~58462032:-
BRCA	trans	rs73108077	0.736	rs7273790	ENSG00000279352.1	RP11-411B10.7	-9.78	1.11e-21	1.76e-15	-0.61	-0.29	Red blood cell density in sickle cell anemia;	chr20:31312478	chr18:14010054~14010917:+
BRCA	trans	rs1347297	0.614	rs7605289	ENSG00000269800.1	PLEKHA3P1	9.78	1.12e-21	1.76e-15	0.31	0.29	Alzheimer disease and age of onset;	chr2:178395228	chr19:41521043~41521989:-
BRCA	trans	rs7937890	0.559	rs2167160	ENSG00000236360.2	RP11-334A14.2	9.78	1.14e-21	1.81e-15	0.38	0.29	Mitochondrial DNA levels;	chr11:14485903	chr1:52993201~52993702:-
BRCA	trans	rs73108077	0.736	rs1997741	ENSG00000279352.1	RP11-411B10.7	9.77	1.23e-21	1.94e-15	0.5	0.29	Red blood cell density in sickle cell anemia;	chr20:31323198	chr18:14010054~14010917:+
BRCA	trans	rs4276421	0.593	rs4437383	ENSG00000231752.4	EMBP1	9.77	1.24e-21	1.97e-15	0.4	0.29	P wave duration;	chr5:45679534	chr1:121519112~121571892:+
BRCA	trans	rs3942852	0.806	rs1875696	ENSG00000134612.10	FOLH1B	-9.77	1.27e-21	2e-15	-0.39	-0.29	Acute lymphoblastic leukemia (childhood);	chr11:48111974	chr11:89639227~89698718:+
BRCA	trans	rs941207	0.756	rs2926743	ENSG00000228224.3	NACAP1	9.77	1.29e-21	2.04e-15	0.37	0.29	Platelet count;	chr12:56720316	chr8:101361794~101372707:+
BRCA	trans	rs747782	0.527	rs7113857	ENSG00000134612.10	FOLH1B	9.76	1.32e-21	2.08e-15	0.51	0.29	Intraocular pressure;	chr11:48120307	chr11:89639227~89698718:+
BRCA	trans	rs2727020	0.635	rs7124266	ENSG00000134612.10	FOLH1B	9.76	1.33e-21	2.1e-15	0.39	0.29	Coronary artery disease;	chr11:49259305	chr11:89639227~89698718:+
BRCA	trans	rs9329221	1	rs9329221	ENSG00000253893.2	FAM85B	-9.76	1.34e-21	2.11e-15	-0.35	-0.29	Neuroticism;	chr8:10382692	chr8:8167819~8226614:-
BRCA	trans	rs7927370	1	rs17592698	ENSG00000134612.10	FOLH1B	9.76	1.34e-21	2.12e-15	0.76	0.29	Systemic lupus erythematosus;	chr11:55791328	chr11:89639227~89698718:+
BRCA	trans	rs3942852	0.774	rs2279823	ENSG00000134612.10	FOLH1B	-9.76	1.34e-21	2.12e-15	-0.39	-0.29	Acute lymphoblastic leukemia (childhood);	chr11:48124540	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.557	rs61894855	ENSG00000134612.10	FOLH1B	9.76	1.34e-21	2.12e-15	0.76	0.29	Systemic lupus erythematosus;	chr11:55782671	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61894856	ENSG00000134612.10	FOLH1B	9.76	1.34e-21	2.12e-15	0.76	0.29	Systemic lupus erythematosus;	chr11:55782756	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.702	rs56390555	ENSG00000134612.10	FOLH1B	9.76	1.34e-21	2.12e-15	0.76	0.29	Systemic lupus erythematosus;	chr11:55784128	chr11:89639227~89698718:+
BRCA	trans	rs6424115	0.729	rs586173	ENSG00000228217.1	AL390877.1	9.76	1.39e-21	2.19e-15	0.35	0.29	Immature fraction of reticulocytes;	chr1:23729228	chr1:117778087~117778506:-
BRCA	trans	rs3806843	1	rs1030164	ENSG00000231043.3	AC007238.1	-9.76	1.39e-21	2.19e-15	-0.34	-0.29	Depressive symptoms (multi-trait analysis);	chr5:140805687	chr2:58460292~58462032:-
BRCA	trans	rs7927370	1	rs55657490	ENSG00000134612.10	FOLH1B	9.76	1.41e-21	2.22e-15	0.72	0.29	Systemic lupus erythematosus;	chr11:55428342	chr11:89639227~89698718:+
BRCA	trans	rs7937890	0.559	rs2034480	ENSG00000236360.2	RP11-334A14.2	9.76	1.41e-21	2.22e-15	0.37	0.29	Mitochondrial DNA levels;	chr11:14445377	chr1:52993201~52993702:-
BRCA	trans	rs73108077	0.736	rs6058546	ENSG00000279352.1	RP11-411B10.7	9.76	1.41e-21	2.23e-15	0.5	0.29	Red blood cell density in sickle cell anemia;	chr20:31314582	chr18:14010054~14010917:+
BRCA	trans	rs11098499	0.722	rs17595727	ENSG00000275858.1	RP11-291L22.8	-9.75	1.42e-21	2.24e-15	-0.34	-0.29	Corneal astigmatism;	chr4:119340919	chr10:38450738~38451069:-
BRCA	trans	rs9329221	0.662	rs35472251	ENSG00000253893.2	FAM85B	-9.75	1.44e-21	2.26e-15	-0.39	-0.29	Neuroticism;	chr8:10389159	chr8:8167819~8226614:-
BRCA	trans	rs10865397	0.506	rs6546810	ENSG00000236165.1	PRADC1P1	9.75	1.44e-21	2.27e-15	0.38	0.29	Intelligence (multi-trait analysis);	chr2:73162588	chr3:36976316~36976840:+
BRCA	trans	rs3806843	1	rs4151682	ENSG00000231043.3	AC007238.1	-9.75	1.44e-21	2.27e-15	-0.34	-0.29	Depressive symptoms (multi-trait analysis);	chr5:140821679	chr2:58460292~58462032:-
BRCA	trans	rs3806843	0.966	rs11958868	ENSG00000231043.3	AC007238.1	-9.75	1.45e-21	2.28e-15	-0.34	-0.29	Depressive symptoms (multi-trait analysis);	chr5:140821835	chr2:58460292~58462032:-
BRCA	trans	rs12210905	1	rs12192446	ENSG00000242375.1	RP11-498P14.3	-9.75	1.46e-21	2.29e-15	-0.71	-0.29	Hip circumference adjusted for BMI;	chr6:27027859	chr9:97195351~97197687:-
BRCA	trans	rs7312770	0.612	rs773114	ENSG00000224553.1	AC008065.1	9.75	1.46e-21	2.3e-15	0.32	0.29	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr2:171374931~171375278:-
BRCA	trans	rs2727020	0.757	rs7924526	ENSG00000134612.10	FOLH1B	9.75	1.49e-21	2.34e-15	0.39	0.29	Coronary artery disease;	chr11:49245491	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61896307	ENSG00000134612.10	FOLH1B	9.75	1.49e-21	2.35e-15	0.76	0.29	Systemic lupus erythematosus;	chr11:55792950	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61896308	ENSG00000134612.10	FOLH1B	9.75	1.49e-21	2.35e-15	0.76	0.29	Systemic lupus erythematosus;	chr11:55793007	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs17501535	ENSG00000134612.10	FOLH1B	9.75	1.49e-21	2.35e-15	0.76	0.29	Systemic lupus erythematosus;	chr11:55794417	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61896309	ENSG00000134612.10	FOLH1B	9.75	1.49e-21	2.35e-15	0.76	0.29	Systemic lupus erythematosus;	chr11:55796285	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61896310	ENSG00000134612.10	FOLH1B	9.75	1.49e-21	2.35e-15	0.76	0.29	Systemic lupus erythematosus;	chr11:55796370	chr11:89639227~89698718:+
BRCA	trans	rs73108077	0.736	rs6121224	ENSG00000279352.1	RP11-411B10.7	9.75	1.51e-21	2.37e-15	0.5	0.29	Red blood cell density in sickle cell anemia;	chr20:31272881	chr18:14010054~14010917:+
BRCA	trans	rs7937890	0.559	rs2575838	ENSG00000236360.2	RP11-334A14.2	9.75	1.51e-21	2.37e-15	0.38	0.29	Mitochondrial DNA levels;	chr11:14476675	chr1:52993201~52993702:-
BRCA	trans	rs6424115	1	rs7514394	ENSG00000228217.1	AL390877.1	9.75	1.55e-21	2.44e-15	0.35	0.29	Immature fraction of reticulocytes;	chr1:23773733	chr1:117778087~117778506:-
BRCA	trans	rs9650657	0.645	rs4841409	ENSG00000253893.2	FAM85B	-9.75	1.55e-21	2.44e-15	-0.37	-0.29	Neuroticism;	chr8:10658864	chr8:8167819~8226614:-
BRCA	trans	rs7833986	0.534	rs10504198	ENSG00000236862.1	RPS20P24	9.75	1.56e-21	2.45e-15	0.38	0.29	Height;	chr8:56093695	chr9:72655832~72656192:-
BRCA	trans	rs7833986	0.534	rs2976022	ENSG00000236862.1	RPS20P24	9.75	1.56e-21	2.45e-15	0.38	0.29	Height;	chr8:56095284	chr9:72655832~72656192:-
BRCA	trans	rs7833986	0.501	rs2976018	ENSG00000236862.1	RPS20P24	9.75	1.56e-21	2.45e-15	0.38	0.29	Height;	chr8:56102193	chr9:72655832~72656192:-
BRCA	trans	rs3096299	0.754	rs2965816	ENSG00000215030.5	RPL13P12	9.74	1.56e-21	2.45e-15	0.29	0.29	Multiple myeloma (IgH translocation);	chr16:89447775	chr17:17383377~17384012:-
BRCA	trans	rs9329221	0.662	rs9650650	ENSG00000253893.2	FAM85B	-9.74	1.56e-21	2.46e-15	-0.39	-0.29	Neuroticism;	chr8:10390466	chr8:8167819~8226614:-
BRCA	trans	rs853679	0.546	rs13213152	ENSG00000253570.1	RNF5P1	9.74	1.6e-21	2.51e-15	0.87	0.29	Depression;	chr6:28381921	chr8:38600661~38601200:-
BRCA	trans	rs12200782	1	rs12213722	ENSG00000242375.1	RP11-498P14.3	-9.74	1.6e-21	2.52e-15	-0.69	-0.29	Small cell lung carcinoma;	chr6:26472855	chr9:97195351~97197687:-
BRCA	trans	rs853679	0.546	rs13213986	ENSG00000253570.1	RNF5P1	9.74	1.61e-21	2.53e-15	0.87	0.29	Depression;	chr6:28390232	chr8:38600661~38601200:-
BRCA	trans	rs853679	0.546	rs34546986	ENSG00000253570.1	RNF5P1	9.74	1.61e-21	2.53e-15	0.87	0.29	Depression;	chr6:28394532	chr8:38600661~38601200:-
BRCA	trans	rs853679	0.546	rs34871267	ENSG00000253570.1	RNF5P1	9.74	1.61e-21	2.53e-15	0.87	0.29	Depression;	chr6:28396455	chr8:38600661~38601200:-
BRCA	trans	rs853679	0.546	rs35883476	ENSG00000253570.1	RNF5P1	9.74	1.61e-21	2.53e-15	0.87	0.29	Depression;	chr6:28400731	chr8:38600661~38601200:-
BRCA	trans	rs12210905	1	rs12209456	ENSG00000242375.1	RP11-498P14.3	-9.74	1.61e-21	2.54e-15	-0.72	-0.29	Hip circumference adjusted for BMI;	chr6:27117446	chr9:97195351~97197687:-
BRCA	trans	rs9650657	0.585	rs4841401	ENSG00000253893.2	FAM85B	9.74	1.62e-21	2.54e-15	0.4	0.29	Neuroticism;	chr8:10632082	chr8:8167819~8226614:-
BRCA	trans	rs7937890	0.532	rs2256884	ENSG00000236360.2	RP11-334A14.2	9.74	1.62e-21	2.54e-15	0.37	0.29	Mitochondrial DNA levels;	chr11:14454856	chr1:52993201~52993702:-
BRCA	trans	rs3096299	0.632	rs4399533	ENSG00000215030.5	RPL13P12	-9.74	1.62e-21	2.54e-15	-0.3	-0.29	Multiple myeloma (IgH translocation);	chr16:89472974	chr17:17383377~17384012:-
BRCA	trans	rs7927370	1	rs116777062	ENSG00000134612.10	FOLH1B	9.74	1.62e-21	2.55e-15	0.72	0.29	Systemic lupus erythematosus;	chr11:55035476	chr11:89639227~89698718:+
BRCA	trans	rs9467773	0.595	rs2237236	ENSG00000242375.1	RP11-498P14.3	-9.74	1.62e-21	2.55e-15	-0.41	-0.29	Intelligence (multi-trait analysis);	chr6:26451325	chr9:97195351~97197687:-
BRCA	trans	rs853679	0.607	rs35749575	ENSG00000253570.1	RNF5P1	9.74	1.64e-21	2.57e-15	0.86	0.29	Depression;	chr6:28147040	chr8:38600661~38601200:-
BRCA	trans	rs3806843	1	rs6885319	ENSG00000231043.3	AC007238.1	-9.74	1.65e-21	2.59e-15	-0.34	-0.29	Depressive symptoms (multi-trait analysis);	chr5:140821026	chr2:58460292~58462032:-
BRCA	trans	rs7937890	0.559	rs2575837	ENSG00000236360.2	RP11-334A14.2	9.74	1.65e-21	2.6e-15	0.38	0.29	Mitochondrial DNA levels;	chr11:14476455	chr1:52993201~52993702:-
BRCA	trans	rs3806843	0.838	rs2337514	ENSG00000231043.3	AC007238.1	9.74	1.66e-21	2.61e-15	0.34	0.29	Depressive symptoms (multi-trait analysis);	chr5:140753147	chr2:58460292~58462032:-
BRCA	trans	rs1580019	0.547	rs56981934	ENSG00000176826.14	FKBP9P1	-9.74	1.68e-21	2.64e-15	-0.37	-0.29	Cognitive ability;	chr7:32495590	chr7:55681074~55713252:-
BRCA	trans	rs73108077	0.736	rs732860	ENSG00000279352.1	RP11-411B10.7	9.73	1.71e-21	2.69e-15	0.5	0.29	Red blood cell density in sickle cell anemia;	chr20:31269641	chr18:14010054~14010917:+
BRCA	trans	rs3806843	1	rs3756340	ENSG00000231043.3	AC007238.1	-9.73	1.73e-21	2.71e-15	-0.34	-0.29	Depressive symptoms (multi-trait analysis);	chr5:140800866	chr2:58460292~58462032:-
BRCA	trans	rs3806843	1	rs7701755	ENSG00000231043.3	AC007238.1	-9.73	1.73e-21	2.71e-15	-0.34	-0.29	Depressive symptoms (multi-trait analysis);	chr5:140802516	chr2:58460292~58462032:-
BRCA	trans	rs11250098	0.567	rs4326350	ENSG00000253893.2	FAM85B	-9.73	1.73e-21	2.72e-15	-0.36	-0.29	Morning vs. evening chronotype;	chr8:10906145	chr8:8167819~8226614:-
BRCA	trans	rs3806843	0.966	rs2240693	ENSG00000231043.3	AC007238.1	-9.73	1.75e-21	2.75e-15	-0.34	-0.29	Depressive symptoms (multi-trait analysis);	chr5:140803740	chr2:58460292~58462032:-
BRCA	trans	rs714543	0.783	rs7806283	ENSG00000226038.5	PPIAP21	-9.73	1.77e-21	2.78e-15	-0.35	-0.29	Plateletcrit;	chr7:44779104	chr20:43230760~43231260:+
BRCA	trans	rs9876781	1	rs6442117	ENSG00000225528.1	RP3-370M22.8	9.73	1.8e-21	2.83e-15	0.31	0.29	Longevity;	chr3:48378407	chr22:39960397~39964683:+
BRCA	trans	rs9467773	0.595	rs9366657	ENSG00000242375.1	RP11-498P14.3	9.73	1.81e-21	2.84e-15	0.41	0.29	Intelligence (multi-trait analysis);	chr6:26434686	chr9:97195351~97197687:-
BRCA	trans	rs7927370	0.764	rs507668	ENSG00000134612.10	FOLH1B	-9.73	1.81e-21	2.84e-15	-0.69	-0.29	Systemic lupus erythematosus;	chr11:55483033	chr11:89639227~89698718:+
BRCA	trans	rs3806843	1	rs2240692	ENSG00000231043.3	AC007238.1	-9.72	1.88e-21	2.95e-15	-0.34	-0.29	Depressive symptoms (multi-trait analysis);	chr5:140804000	chr2:58460292~58462032:-
BRCA	trans	rs3806843	1	rs6579987	ENSG00000231043.3	AC007238.1	-9.72	1.88e-21	2.95e-15	-0.34	-0.29	Depressive symptoms (multi-trait analysis);	chr5:140804074	chr2:58460292~58462032:-
BRCA	trans	rs3806843	0.966	rs1030163	ENSG00000231043.3	AC007238.1	-9.72	1.88e-21	2.95e-15	-0.34	-0.29	Depressive symptoms (multi-trait analysis);	chr5:140805547	chr2:58460292~58462032:-
BRCA	trans	rs3806843	1	rs4151680	ENSG00000231043.3	AC007238.1	-9.72	1.88e-21	2.95e-15	-0.34	-0.29	Depressive symptoms (multi-trait analysis);	chr5:140807072	chr2:58460292~58462032:-
BRCA	trans	rs3806843	1	rs3822346	ENSG00000231043.3	AC007238.1	-9.72	1.88e-21	2.95e-15	-0.34	-0.29	Depressive symptoms (multi-trait analysis);	chr5:140807737	chr2:58460292~58462032:-
BRCA	trans	rs3806843	0.933	rs2337987	ENSG00000231043.3	AC007238.1	-9.72	1.88e-21	2.95e-15	-0.34	-0.29	Depressive symptoms (multi-trait analysis);	chr5:140808798	chr2:58460292~58462032:-
BRCA	trans	rs3806843	0.933	rs2879087	ENSG00000231043.3	AC007238.1	-9.72	1.88e-21	2.95e-15	-0.34	-0.29	Depressive symptoms (multi-trait analysis);	chr5:140808990	chr2:58460292~58462032:-
BRCA	trans	rs7833986	0.501	rs72653959	ENSG00000236862.1	RPS20P24	9.72	1.93e-21	3.03e-15	0.38	0.29	Height;	chr8:56083957	chr9:72655832~72656192:-
BRCA	trans	rs7833986	0.501	rs72653962	ENSG00000236862.1	RPS20P24	9.72	1.93e-21	3.03e-15	0.38	0.29	Height;	chr8:56084946	chr9:72655832~72656192:-
BRCA	trans	rs7833986	0.501	rs72653967	ENSG00000236862.1	RPS20P24	9.72	1.93e-21	3.03e-15	0.38	0.29	Height;	chr8:56086873	chr9:72655832~72656192:-
BRCA	trans	rs2336384	1	rs7551874	ENSG00000261819.1	RP11-680G24.4	9.72	1.94e-21	3.03e-15	0.38	0.29	Platelet count;	chr1:11988073	chr16:14988259~14990160:-
BRCA	trans	rs7833986	0.501	rs72653978	ENSG00000236862.1	RPS20P24	9.72	1.97e-21	3.08e-15	0.38	0.29	Height;	chr8:56105834	chr9:72655832~72656192:-
BRCA	trans	rs7833986	0.501	rs72653981	ENSG00000236862.1	RPS20P24	9.72	1.97e-21	3.08e-15	0.38	0.29	Height;	chr8:56115255	chr9:72655832~72656192:-
BRCA	trans	rs7833986	0.501	rs2976036	ENSG00000236862.1	RPS20P24	9.72	1.97e-21	3.08e-15	0.38	0.29	Height;	chr8:56119162	chr9:72655832~72656192:-
BRCA	trans	rs7927370	1	rs17580994	ENSG00000134612.10	FOLH1B	-9.72	1.98e-21	3.1e-15	-0.7	-0.29	Systemic lupus erythematosus;	chr11:55545421	chr11:89639227~89698718:+
BRCA	trans	rs2336384	1	rs61776516	ENSG00000261819.1	RP11-680G24.4	9.72	1.99e-21	3.12e-15	0.38	0.29	Platelet count;	chr1:11986971	chr16:14988259~14990160:-
BRCA	trans	rs7927370	1	rs531971	ENSG00000134612.10	FOLH1B	9.72	2.04e-21	3.19e-15	0.7	0.29	Systemic lupus erythematosus;	chr11:55492107	chr11:89639227~89698718:+
BRCA	trans	rs9329221	0.71	rs11779205	ENSG00000253893.2	FAM85B	-9.71	2.05e-21	3.21e-15	-0.38	-0.29	Neuroticism;	chr8:10402590	chr8:8167819~8226614:-
BRCA	trans	rs2336384	1	rs4846085	ENSG00000261819.1	RP11-680G24.4	9.71	2.08e-21	3.25e-15	0.38	0.29	Platelet count;	chr1:11990577	chr16:14988259~14990160:-
BRCA	trans	rs7927370	1	rs61894793	ENSG00000134612.10	FOLH1B	9.71	2.08e-21	3.26e-15	0.77	0.29	Systemic lupus erythematosus;	chr11:55732626	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61894794	ENSG00000134612.10	FOLH1B	9.71	2.08e-21	3.26e-15	0.77	0.29	Systemic lupus erythematosus;	chr11:55735462	chr11:89639227~89698718:+
BRCA	trans	rs11039798	0.698	rs78553793	ENSG00000134612.10	FOLH1B	9.71	2.11e-21	3.3e-15	0.58	0.29	Axial length;	chr11:48925784	chr11:89639227~89698718:+
BRCA	trans	rs7833986	0.501	rs2976038	ENSG00000236862.1	RPS20P24	9.71	2.14e-21	3.35e-15	0.38	0.29	Height;	chr8:56116305	chr9:72655832~72656192:-
BRCA	trans	rs6424115	0.83	rs2503002	ENSG00000228217.1	AL390877.1	-9.71	2.17e-21	3.39e-15	-0.35	-0.29	Immature fraction of reticulocytes;	chr1:23870467	chr1:117778087~117778506:-
BRCA	trans	rs3942852	0.806	rs11039515	ENSG00000134612.10	FOLH1B	9.71	2.17e-21	3.4e-15	0.38	0.29	Acute lymphoblastic leukemia (childhood);	chr11:48097922	chr11:89639227~89698718:+
BRCA	trans	rs11098499	0.954	rs6820115	ENSG00000275858.1	RP11-291L22.8	9.71	2.19e-21	3.42e-15	0.34	0.29	Corneal astigmatism;	chr4:119477027	chr10:38450738~38451069:-
BRCA	trans	rs2727020	0.823	rs7102374	ENSG00000134612.10	FOLH1B	9.71	2.2e-21	3.44e-15	0.39	0.29	Coronary artery disease;	chr11:49240243	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs61894792	ENSG00000134612.10	FOLH1B	9.71	2.22e-21	3.47e-15	0.77	0.29	Systemic lupus erythematosus;	chr11:55731183	chr11:89639227~89698718:+
BRCA	trans	rs3806843	1	rs11167609	ENSG00000231043.3	AC007238.1	-9.7	2.24e-21	3.5e-15	-0.34	-0.29	Depressive symptoms (multi-trait analysis);	chr5:140820841	chr2:58460292~58462032:-
BRCA	trans	rs3806843	1	rs7732179	ENSG00000231043.3	AC007238.1	-9.7	2.25e-21	3.51e-15	-0.34	-0.29	Depressive symptoms (multi-trait analysis);	chr5:140819454	chr2:58460292~58462032:-
BRCA	trans	rs73108077	0.736	rs2376545	ENSG00000279352.1	RP11-411B10.7	9.7	2.28e-21	3.55e-15	0.5	0.29	Red blood cell density in sickle cell anemia;	chr20:31293314	chr18:14010054~14010917:+
BRCA	trans	rs73108077	0.736	rs13433373	ENSG00000279352.1	RP11-411B10.7	9.7	2.28e-21	3.55e-15	0.5	0.29	Red blood cell density in sickle cell anemia;	chr20:31296736	chr18:14010054~14010917:+
BRCA	trans	rs73108077	0.736	rs6061028	ENSG00000279352.1	RP11-411B10.7	9.7	2.28e-21	3.56e-15	0.5	0.29	Red blood cell density in sickle cell anemia;	chr20:31285774	chr18:14010054~14010917:+
BRCA	trans	rs7927370	1	rs61894797	ENSG00000134612.10	FOLH1B	9.7	2.32e-21	3.61e-15	0.77	0.29	Systemic lupus erythematosus;	chr11:55746842	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs76914796	ENSG00000134612.10	FOLH1B	9.7	2.32e-21	3.61e-15	0.77	0.29	Systemic lupus erythematosus;	chr11:55754506	chr11:89639227~89698718:+
BRCA	trans	rs2727020	0.701	rs7949044	ENSG00000134612.10	FOLH1B	-9.7	2.32e-21	3.62e-15	-0.37	-0.29	Coronary artery disease;	chr11:49575782	chr11:89639227~89698718:+
BRCA	trans	rs877636	1	rs705696	ENSG00000196933.5	RPS26P11	9.7	2.36e-21	3.68e-15	0.38	0.29	Cognitive function;	chr12:56086864	chrX:72044545~72044892:+
BRCA	trans	rs3806843	1	rs7710794	ENSG00000231043.3	AC007238.1	-9.7	2.39e-21	3.72e-15	-0.34	-0.29	Depressive symptoms (multi-trait analysis);	chr5:140829882	chr2:58460292~58462032:-
BRCA	trans	rs7927370	0.85	rs17591177	ENSG00000134612.10	FOLH1B	-9.7	2.39e-21	3.73e-15	-0.72	-0.29	Systemic lupus erythematosus;	chr11:55728514	chr11:89639227~89698718:+
BRCA	trans	rs73108077	0.736	rs6058637	ENSG00000279352.1	RP11-411B10.7	9.7	2.42e-21	3.77e-15	0.5	0.29	Red blood cell density in sickle cell anemia;	chr20:31325430	chr18:14010054~14010917:+
BRCA	trans	rs9650657	0.537	rs7016385	ENSG00000253893.2	FAM85B	-9.7	2.42e-21	3.78e-15	-0.36	-0.29	Neuroticism;	chr8:10921962	chr8:8167819~8226614:-
BRCA	trans	rs12200782	0.929	rs72843734	ENSG00000242375.1	RP11-498P14.3	-9.7	2.44e-21	3.8e-15	-0.7	-0.29	Small cell lung carcinoma;	chr6:26448116	chr9:97195351~97197687:-
BRCA	trans	rs7833986	0.534	rs17759244	ENSG00000236862.1	RPS20P24	9.69	2.49e-21	3.89e-15	0.38	0.29	Height;	chr8:56121209	chr9:72655832~72656192:-
BRCA	trans	rs7927370	1	rs492647	ENSG00000134612.10	FOLH1B	9.69	2.52e-21	3.93e-15	0.69	0.29	Systemic lupus erythematosus;	chr11:55486153	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.85	rs509763	ENSG00000134612.10	FOLH1B	9.69	2.52e-21	3.93e-15	0.69	0.29	Systemic lupus erythematosus;	chr11:55489393	chr11:89639227~89698718:+
BRCA	trans	rs9876781	0.53	rs11708617	ENSG00000235912.1	RP1-159A19.3	-9.69	2.63e-21	4.09e-15	-0.35	-0.29	Longevity;	chr3:48354819	chr1:27649419~27649610:+
BRCA	trans	rs12200782	1	rs12207181	ENSG00000242375.1	RP11-498P14.3	-9.69	2.64e-21	4.1e-15	-0.7	-0.29	Small cell lung carcinoma;	chr6:26431057	chr9:97195351~97197687:-
BRCA	trans	rs12200782	1	rs12199239	ENSG00000242375.1	RP11-498P14.3	-9.69	2.64e-21	4.1e-15	-0.7	-0.29	Small cell lung carcinoma;	chr6:26432342	chr9:97195351~97197687:-
BRCA	trans	rs12200782	1	rs10456330	ENSG00000242375.1	RP11-498P14.3	-9.69	2.64e-21	4.1e-15	-0.7	-0.29	Small cell lung carcinoma;	chr6:26436464	chr9:97195351~97197687:-
BRCA	trans	rs12200782	1	rs12208390	ENSG00000242375.1	RP11-498P14.3	-9.69	2.64e-21	4.1e-15	-0.7	-0.29	Small cell lung carcinoma;	chr6:26436878	chr9:97195351~97197687:-
BRCA	trans	rs7819412	0.594	rs7460507	ENSG00000253893.2	FAM85B	9.68	2.69e-21	4.19e-15	0.38	0.29	Triglycerides;	chr8:11111565	chr8:8167819~8226614:-
BRCA	trans	rs7927370	1	rs639903	ENSG00000134612.10	FOLH1B	9.68	2.72e-21	4.23e-15	0.69	0.29	Systemic lupus erythematosus;	chr11:55484949	chr11:89639227~89698718:+
BRCA	trans	rs11098499	0.569	rs10023641	ENSG00000275858.1	RP11-291L22.8	9.68	2.74e-21	4.26e-15	0.33	0.29	Corneal astigmatism;	chr4:119337255	chr10:38450738~38451069:-
BRCA	trans	rs7944735	0.817	rs6485788	ENSG00000134612.10	FOLH1B	-9.68	2.77e-21	4.31e-15	-0.41	-0.29	Intraocular pressure;	chr11:47852331	chr11:89639227~89698718:+
BRCA	trans	rs864643	0.524	rs12106854	ENSG00000188856.6	RPSAP47	9.68	2.78e-21	4.32e-15	0.53	0.29	Attention deficit hyperactivity disorder;	chr3:39487321	chr8:80558870~80559757:+
BRCA	trans	rs864643	0.524	rs17038967	ENSG00000188856.6	RPSAP47	9.68	2.78e-21	4.32e-15	0.53	0.29	Attention deficit hyperactivity disorder;	chr3:39489530	chr8:80558870~80559757:+
BRCA	trans	rs11039798	1	rs11039798	ENSG00000134612.10	FOLH1B	9.68	2.79e-21	4.34e-15	0.58	0.29	Axial length;	chr11:48518671	chr11:89639227~89698718:+
BRCA	trans	rs9329221	0.71	rs11785061	ENSG00000253893.2	FAM85B	-9.68	2.81e-21	4.37e-15	-0.38	-0.29	Neuroticism;	chr8:10402018	chr8:8167819~8226614:-
BRCA	trans	rs7927370	0.717	rs569315	ENSG00000134612.10	FOLH1B	-9.68	2.9e-21	4.51e-15	-0.69	-0.29	Systemic lupus erythematosus;	chr11:55480253	chr11:89639227~89698718:+
BRCA	trans	rs9329221	0.698	rs35388602	ENSG00000253893.2	FAM85B	-9.67	2.98e-21	4.63e-15	-0.38	-0.29	Neuroticism;	chr8:10401678	chr8:8167819~8226614:-
BRCA	trans	rs7927370	1	rs11819980	ENSG00000134612.10	FOLH1B	9.67	2.98e-21	4.64e-15	0.71	0.29	Systemic lupus erythematosus;	chr11:55536923	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.85	rs61916224	ENSG00000134612.10	FOLH1B	9.67	2.99e-21	4.65e-15	0.7	0.29	Systemic lupus erythematosus;	chr11:55385956	chr11:89639227~89698718:+
BRCA	trans	rs7833986	0.534	rs17813240	ENSG00000236862.1	RPS20P24	9.67	3e-21	4.66e-15	0.38	0.29	Height;	chr8:56013232	chr9:72655832~72656192:-
BRCA	trans	rs9329221	0.662	rs11249996	ENSG00000253893.2	FAM85B	9.67	3.03e-21	4.71e-15	0.38	0.29	Neuroticism;	chr8:10387953	chr8:8167819~8226614:-
BRCA	trans	rs4276421	0.593	rs7719500	ENSG00000231752.4	EMBP1	9.67	3.05e-21	4.74e-15	0.4	0.29	P wave duration;	chr5:45577870	chr1:121519112~121571892:+
BRCA	trans	rs9876781	1	rs2362452	ENSG00000225528.1	RP3-370M22.8	9.67	3.1e-21	4.82e-15	0.31	0.29	Longevity;	chr3:48376724	chr22:39960397~39964683:+
BRCA	trans	rs7824557	0.724	rs2572398	ENSG00000253893.2	FAM85B	-9.66	3.31e-21	5.14e-15	-0.37	-0.29	Retinal vascular caliber;	chr8:11320584	chr8:8167819~8226614:-
BRCA	trans	rs9876781	0.507	rs1824362	ENSG00000235912.1	RP1-159A19.3	9.66	3.32e-21	5.15e-15	0.33	0.29	Longevity;	chr3:48360459	chr1:27649419~27649610:+
BRCA	trans	rs11023332	0.706	rs11023380	ENSG00000236360.2	RP11-334A14.2	9.66	3.35e-21	5.2e-15	0.38	0.29	Vitamin D levels;Adiponectin levels;	chr11:14908512	chr1:52993201~52993702:-
BRCA	trans	rs73108077	0.688	rs6061150	ENSG00000279352.1	RP11-411B10.7	9.66	3.36e-21	5.22e-15	0.5	0.29	Red blood cell density in sickle cell anemia;	chr20:31301527	chr18:14010054~14010917:+
BRCA	trans	rs73108077	0.736	rs6057561	ENSG00000279352.1	RP11-411B10.7	9.66	3.4e-21	5.27e-15	0.5	0.29	Red blood cell density in sickle cell anemia;	chr20:31327238	chr18:14010054~14010917:+
BRCA	trans	rs73108077	0.736	rs6119830	ENSG00000279352.1	RP11-411B10.7	9.66	3.4e-21	5.27e-15	0.5	0.29	Red blood cell density in sickle cell anemia;	chr20:31327636	chr18:14010054~14010917:+
BRCA	trans	rs73108077	0.736	rs6119831	ENSG00000279352.1	RP11-411B10.7	9.66	3.4e-21	5.27e-15	0.5	0.29	Red blood cell density in sickle cell anemia;	chr20:31328473	chr18:14010054~14010917:+
BRCA	trans	rs7833986	0.501	rs72653986	ENSG00000236862.1	RPS20P24	9.66	3.48e-21	5.4e-15	0.38	0.29	Height;	chr8:56122489	chr9:72655832~72656192:-
BRCA	trans	rs9876781	1	rs6794875	ENSG00000225528.1	RP3-370M22.8	-9.66	3.5e-21	5.42e-15	-0.31	-0.29	Longevity;	chr3:48414217	chr22:39960397~39964683:+
BRCA	trans	rs11098499	0.644	rs3986377	ENSG00000275858.1	RP11-291L22.8	9.65	3.55e-21	5.51e-15	0.33	0.29	Corneal astigmatism;	chr4:119339115	chr10:38450738~38451069:-
BRCA	trans	rs10028773	0.556	rs4473640	ENSG00000275858.1	RP11-291L22.8	9.65	3.55e-21	5.51e-15	0.33	0.29	Educational attainment;	chr4:119339282	chr10:38450738~38451069:-
BRCA	trans	rs6424115	0.546	rs35993651	ENSG00000228217.1	AL390877.1	9.65	3.56e-21	5.52e-15	0.35	0.29	Immature fraction of reticulocytes;	chr1:23854123	chr1:117778087~117778506:-
BRCA	trans	rs6424115	0.557	rs35904775	ENSG00000228217.1	AL390877.1	9.65	3.56e-21	5.52e-15	0.35	0.29	Immature fraction of reticulocytes;	chr1:23854133	chr1:117778087~117778506:-
BRCA	trans	rs11023332	0.706	rs10766197	ENSG00000236360.2	RP11-334A14.2	9.65	3.58e-21	5.55e-15	0.38	0.29	Vitamin D levels;Adiponectin levels;	chr11:14900334	chr1:52993201~52993702:-
BRCA	trans	rs1190596	0.562	rs1307671	ENSG00000181359.5	HSP90AA6P	9.65	3.61e-21	5.6e-15	0.46	0.29	Behavioural disinhibition (generation interaction);	chr14:102176116	chr4:170581470~170605450:-
BRCA	trans	rs7824557	0.872	rs2572417	ENSG00000253893.2	FAM85B	9.65	3.73e-21	5.77e-15	0.35	0.29	Retinal vascular caliber;	chr8:11253953	chr8:8167819~8226614:-
BRCA	trans	rs7927370	1	rs17579825	ENSG00000134612.10	FOLH1B	9.65	3.82e-21	5.92e-15	0.7	0.29	Systemic lupus erythematosus;	chr11:55510141	chr11:89639227~89698718:+
BRCA	trans	rs747782	0.537	rs10838835	ENSG00000134612.10	FOLH1B	-9.65	3.82e-21	5.92e-15	-0.46	-0.29	Intraocular pressure;	chr11:48224905	chr11:89639227~89698718:+
BRCA	trans	rs941207	0.542	rs11171978	ENSG00000228224.3	NACAP1	9.64	3.84e-21	5.95e-15	0.34	0.29	Platelet count;	chr12:56800015	chr8:101361794~101372707:+
BRCA	trans	rs7927370	1	rs17580694	ENSG00000134612.10	FOLH1B	-9.64	3.84e-21	5.95e-15	-0.69	-0.29	Systemic lupus erythematosus;	chr11:55536723	chr11:89639227~89698718:+
BRCA	trans	rs7944735	0.817	rs747782	ENSG00000134612.10	FOLH1B	9.64	3.91e-21	6.05e-15	0.41	0.29	Intraocular pressure;	chr11:47919373	chr11:89639227~89698718:+
BRCA	trans	rs9876781	1	rs7653691	ENSG00000225528.1	RP3-370M22.8	9.64	3.99e-21	6.18e-15	0.31	0.29	Longevity;	chr3:48378199	chr22:39960397~39964683:+
BRCA	trans	rs1580019	0.665	rs34147895	ENSG00000176826.14	FKBP9P1	-9.64	4.02e-21	6.23e-15	-0.38	-0.29	Cognitive ability;	chr7:32492184	chr7:55681074~55713252:-
BRCA	trans	rs3806843	0.966	rs2563263	ENSG00000231043.3	AC007238.1	-9.64	4.03e-21	6.24e-15	-0.34	-0.29	Depressive symptoms (multi-trait analysis);	chr5:140758059	chr2:58460292~58462032:-
BRCA	trans	rs7312770	1	rs7312770	ENSG00000234354.3	RPS26P47	-9.64	4.07e-21	6.3e-15	-0.33	-0.29	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr13:100539901~100540248:-
BRCA	trans	rs3942852	0.806	rs10734562	ENSG00000134612.10	FOLH1B	9.64	4.1e-21	6.35e-15	0.38	0.29	Acute lymphoblastic leukemia (childhood);	chr11:48106637	chr11:89639227~89698718:+
BRCA	trans	rs7113874	0.802	rs7118611	ENSG00000266891.1	RP11-692N5.2	9.64	4.11e-21	6.36e-15	0.38	0.29	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8664138	chr18:9734882~9735602:-
BRCA	trans	rs7937890	0.559	rs2597196	ENSG00000236360.2	RP11-334A14.2	-9.63	4.21e-21	6.52e-15	-0.37	-0.29	Mitochondrial DNA levels;	chr11:14470055	chr1:52993201~52993702:-
BRCA	trans	rs3806843	1	rs10038174	ENSG00000231043.3	AC007238.1	-9.63	4.27e-21	6.6e-15	-0.34	-0.29	Depressive symptoms (multi-trait analysis);	chr5:140831031	chr2:58460292~58462032:-
BRCA	trans	rs7662987	1	rs7683704	ENSG00000228407.2	RP4-800M22.1	9.63	4.29e-21	6.64e-15	0.56	0.29	Smoking initiation;	chr4:99083075	chr1:52160261~52160600:-
BRCA	trans	rs875971	0.502	rs2465121	ENSG00000164669.11	INTS4P1	9.63	4.32e-21	6.69e-15	0.41	0.29	Aortic root size;	chr7:66156017	chr7:65141225~65234216:+
BRCA	trans	rs73108077	0.736	rs56047717	ENSG00000279352.1	RP11-411B10.7	9.63	4.54e-21	7.01e-15	0.49	0.29	Red blood cell density in sickle cell anemia;	chr20:31279756	chr18:14010054~14010917:+
BRCA	trans	rs9425766	0.64	rs9425756	ENSG00000213331.4	RP11-713C19.2	9.63	4.57e-21	7.06e-15	0.35	0.29	Life satisfaction;	chr1:173847448	chr4:187970273~187971284:+
BRCA	trans	rs3806843	1	rs3806845	ENSG00000231043.3	AC007238.1	-9.62	4.58e-21	7.08e-15	-0.34	-0.29	Depressive symptoms (multi-trait analysis);	chr5:140801152	chr2:58460292~58462032:-
BRCA	trans	rs3806843	1	rs3733707	ENSG00000231043.3	AC007238.1	-9.62	4.58e-21	7.08e-15	-0.34	-0.29	Depressive symptoms (multi-trait analysis);	chr5:140802307	chr2:58460292~58462032:-
BRCA	trans	rs7312770	1	rs7312770	ENSG00000244604.1	RP11-713H12.1	-9.62	4.62e-21	7.14e-15	-0.3	-0.29	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr17:8561230~8561576:+
BRCA	trans	rs9876781	1	rs7636782	ENSG00000225528.1	RP3-370M22.8	-9.62	4.65e-21	7.18e-15	-0.31	-0.29	Longevity;	chr3:48379897	chr22:39960397~39964683:+
BRCA	trans	rs7927370	1	rs7127405	ENSG00000134612.10	FOLH1B	-9.62	4.82e-21	7.44e-15	-0.69	-0.29	Systemic lupus erythematosus;	chr11:55365307	chr11:89639227~89698718:+
BRCA	trans	rs3806843	0.966	rs3756338	ENSG00000231043.3	AC007238.1	-9.62	4.84e-21	7.46e-15	-0.34	-0.29	Depressive symptoms (multi-trait analysis);	chr5:140800976	chr2:58460292~58462032:-
BRCA	trans	rs9329221	0.651	rs2975648	ENSG00000253893.2	FAM85B	9.62	4.88e-21	7.52e-15	0.35	0.29	Neuroticism;	chr8:10278466	chr8:8167819~8226614:-
BRCA	trans	rs11023332	0.8	rs12271890	ENSG00000236360.2	RP11-334A14.2	9.61	5.09e-21	7.85e-15	0.38	0.29	Vitamin D levels;Adiponectin levels;	chr11:14913140	chr1:52993201~52993702:-
BRCA	trans	rs7929679	0.602	rs10501135	ENSG00000225531.1	RP11-196I18.3	9.61	5.17e-21	7.97e-15	0.37	0.29	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;	chr11:34789633	chr9:107116829~107117557:+
BRCA	trans	rs11098499	0.691	rs10010355	ENSG00000275858.1	RP11-291L22.8	9.61	5.18e-21	7.99e-15	0.33	0.29	Corneal astigmatism;	chr4:119339888	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.691	rs9307471	ENSG00000275858.1	RP11-291L22.8	9.61	5.18e-21	7.99e-15	0.33	0.29	Corneal astigmatism;	chr4:119340107	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.698	rs4422403	ENSG00000275858.1	RP11-291L22.8	9.61	5.18e-21	7.99e-15	0.33	0.29	Corneal astigmatism;	chr4:119337039	chr10:38450738~38451069:-
BRCA	trans	rs7927370	1	rs530679	ENSG00000134612.10	FOLH1B	9.61	5.19e-21	8.01e-15	0.68	0.29	Systemic lupus erythematosus;	chr11:55503896	chr11:89639227~89698718:+
BRCA	trans	rs3806843	1	rs11167600	ENSG00000231043.3	AC007238.1	-9.61	5.28e-21	8.13e-15	-0.34	-0.29	Depressive symptoms (multi-trait analysis);	chr5:140795280	chr2:58460292~58462032:-
BRCA	trans	rs11098499	0.874	rs28452522	ENSG00000275858.1	RP11-291L22.8	9.61	5.31e-21	8.19e-15	0.38	0.29	Corneal astigmatism;	chr4:119189629	chr10:38450738~38451069:-
BRCA	trans	rs2336384	1	rs4846083	ENSG00000261819.1	RP11-680G24.4	9.61	5.41e-21	8.34e-15	0.38	0.29	Platelet count;	chr1:11985498	chr16:14988259~14990160:-
BRCA	trans	rs3806843	1	rs2879089	ENSG00000231043.3	AC007238.1	-9.6	5.48e-21	8.44e-15	-0.34	-0.29	Depressive symptoms (multi-trait analysis);	chr5:140812308	chr2:58460292~58462032:-
BRCA	trans	rs7258465	0.511	rs11668719	ENSG00000267533.1	RP11-815J4.7	9.6	5.57e-21	8.57e-15	0.37	0.29	Breast cancer;	chr19:18404931	chr18:12067173~12068417:-
BRCA	trans	rs12210905	1	rs12205921	ENSG00000242375.1	RP11-498P14.3	-9.6	5.57e-21	8.58e-15	-0.7	-0.29	Hip circumference adjusted for BMI;	chr6:27145761	chr9:97195351~97197687:-
BRCA	trans	rs11920570	0.526	rs3828362	ENSG00000267076.1	CCDC58P3	-9.6	5.66e-21	8.72e-15	-0.33	-0.29	Resting heart rate;	chr3:122412930	chr18:12211378~12211807:+
BRCA	trans	rs7927370	0.557	rs523832	ENSG00000134612.10	FOLH1B	9.6	5.71e-21	8.79e-15	0.69	0.29	Systemic lupus erythematosus;	chr11:55492874	chr11:89639227~89698718:+
BRCA	trans	rs4276421	0.571	rs7712920	ENSG00000231752.4	EMBP1	9.6	5.72e-21	8.81e-15	0.4	0.29	P wave duration;	chr5:45589104	chr1:121519112~121571892:+
BRCA	trans	rs1962073	0.623	rs7459532	ENSG00000253893.2	FAM85B	9.6	5.79e-21	8.91e-15	0.35	0.29	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);	chr8:10403558	chr8:8167819~8226614:-
BRCA	trans	rs12200782	0.79	rs72840194	ENSG00000242375.1	RP11-498P14.3	-9.6	5.91e-21	9.1e-15	-0.71	-0.28	Small cell lung carcinoma;	chr6:26361141	chr9:97195351~97197687:-
BRCA	trans	rs12210905	1	rs115268625	ENSG00000242375.1	RP11-498P14.3	-9.6	5.95e-21	9.15e-15	-0.7	-0.28	Hip circumference adjusted for BMI;	chr6:26980450	chr9:97195351~97197687:-
BRCA	trans	rs9425766	0.546	rs6691001	ENSG00000213331.4	RP11-713C19.2	9.59	6.02e-21	9.26e-15	0.35	0.28	Life satisfaction;	chr1:173849938	chr4:187970273~187971284:+
BRCA	trans	rs4276421	0.593	rs4380674	ENSG00000231752.4	EMBP1	9.59	6.11e-21	9.41e-15	0.39	0.28	P wave duration;	chr5:45769295	chr1:121519112~121571892:+
BRCA	trans	rs12210905	1	rs76889265	ENSG00000242375.1	RP11-498P14.3	-9.59	6.16e-21	9.47e-15	-0.69	-0.28	Hip circumference adjusted for BMI;	chr6:27041056	chr9:97195351~97197687:-
BRCA	trans	rs12210905	1	rs72843607	ENSG00000242375.1	RP11-498P14.3	-9.59	6.26e-21	9.62e-15	-0.7	-0.28	Hip circumference adjusted for BMI;	chr6:27142936	chr9:97195351~97197687:-
BRCA	trans	rs6732160	0.967	rs6760964	ENSG00000236165.1	PRADC1P1	9.59	6.41e-21	9.86e-15	0.36	0.28	Intelligence (multi-trait analysis);	chr2:73160258	chr3:36976316~36976840:+
BRCA	trans	rs9467773	0.595	rs3799379	ENSG00000242375.1	RP11-498P14.3	-9.59	6.43e-21	9.89e-15	-0.41	-0.28	Intelligence (multi-trait analysis);	chr6:26404466	chr9:97195351~97197687:-
BRCA	trans	rs61990749	1	rs17106604	ENSG00000235400.1	RP4-641G12.4	9.58	6.66e-21	1.02e-14	0.56	0.28	Fibroblast growth factor basic levels;	chr14:77912813	chr1:78749073~78750659:+
BRCA	trans	rs7819412	0.806	rs6980856	ENSG00000253893.2	FAM85B	-9.58	6.75e-21	1.04e-14	-0.37	-0.28	Triglycerides;	chr8:11080750	chr8:8167819~8226614:-
BRCA	trans	rs7927370	1	rs2113916	ENSG00000134612.10	FOLH1B	-9.58	6.78e-21	1.04e-14	-0.68	-0.28	Systemic lupus erythematosus;	chr11:55430196	chr11:89639227~89698718:+
BRCA	trans	rs13190036	0.551	rs7710269	ENSG00000228305.2	AC016734.2	-9.58	6.86e-21	1.05e-14	-0.35	-0.28	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177187528	chr2:63622178~63622831:-
BRCA	trans	rs6424115	0.594	rs10799802	ENSG00000228217.1	AL390877.1	-9.58	7.07e-21	1.09e-14	-0.37	-0.28	Immature fraction of reticulocytes;	chr1:23683054	chr1:117778087~117778506:-
BRCA	trans	rs7927370	1	rs9666744	ENSG00000134612.10	FOLH1B	-9.58	7.07e-21	1.09e-14	-0.69	-0.28	Systemic lupus erythematosus;	chr11:55509126	chr11:89639227~89698718:+
BRCA	trans	rs26067	0.689	rs152839	ENSG00000231752.4	EMBP1	-9.57	7.22e-21	1.11e-14	-0.39	-0.28	Breast cancer;	chr5:50849432	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.571	rs10473389	ENSG00000231752.4	EMBP1	9.57	7.24e-21	1.11e-14	0.39	0.28	P wave duration;	chr5:45561699	chr1:121519112~121571892:+
BRCA	trans	rs9329221	0.935	rs6601450	ENSG00000253893.2	FAM85B	-9.57	7.26e-21	1.11e-14	-0.35	-0.28	Neuroticism;	chr8:10385591	chr8:8167819~8226614:-
BRCA	trans	rs4276421	0.55	rs10214369	ENSG00000231752.4	EMBP1	-9.57	7.74e-21	1.19e-14	-0.39	-0.28	P wave duration;	chr5:45638409	chr1:121519112~121571892:+
BRCA	trans	rs7927370	1	rs548768	ENSG00000134612.10	FOLH1B	9.56	7.83e-21	1.2e-14	0.67	0.28	Systemic lupus erythematosus;	chr11:55501886	chr11:89639227~89698718:+
BRCA	trans	rs6732160	1	rs6732160	ENSG00000236165.1	PRADC1P1	9.56	7.97e-21	1.22e-14	0.35	0.28	Intelligence (multi-trait analysis);	chr2:73160100	chr3:36976316~36976840:+
BRCA	trans	rs11098499	0.644	rs17517414	ENSG00000275858.1	RP11-291L22.8	9.56	8.05e-21	1.23e-14	0.33	0.28	Corneal astigmatism;	chr4:119340946	chr10:38450738~38451069:-
BRCA	trans	rs7927370	1	rs1364759	ENSG00000134612.10	FOLH1B	-9.56	8.07e-21	1.24e-14	-0.68	-0.28	Systemic lupus erythematosus;	chr11:55449434	chr11:89639227~89698718:+
BRCA	trans	rs9329221	0.662	rs4240645	ENSG00000253893.2	FAM85B	9.56	8.15e-21	1.25e-14	0.38	0.28	Neuroticism;	chr8:10396953	chr8:8167819~8226614:-
BRCA	trans	rs9876781	0.874	rs56298324	ENSG00000225528.1	RP3-370M22.8	9.56	8.32e-21	1.27e-14	0.31	0.28	Longevity;	chr3:48393626	chr22:39960397~39964683:+
BRCA	trans	rs7113874	0.802	rs11042030	ENSG00000266891.1	RP11-692N5.2	9.56	8.45e-21	1.29e-14	0.37	0.28	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8669171	chr18:9734882~9735602:-
BRCA	trans	rs7927370	1	rs979111	ENSG00000134612.10	FOLH1B	-9.56	8.52e-21	1.3e-14	-0.69	-0.28	Systemic lupus erythematosus;	chr11:55403551	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs1216240	ENSG00000134612.10	FOLH1B	-9.56	8.52e-21	1.3e-14	-0.69	-0.28	Systemic lupus erythematosus;	chr11:55410591	chr11:89639227~89698718:+
BRCA	trans	rs7937890	0.505	rs4403769	ENSG00000236360.2	RP11-334A14.2	9.55	8.53e-21	1.31e-14	0.36	0.28	Mitochondrial DNA levels;	chr11:14428630	chr1:52993201~52993702:-
BRCA	trans	rs11098499	0.754	rs10518300	ENSG00000275858.1	RP11-291L22.8	-9.55	8.54e-21	1.31e-14	-0.34	-0.28	Corneal astigmatism;	chr4:119328344	chr10:38450738~38451069:-
BRCA	trans	rs2250402	0.51	rs2291621	ENSG00000234106.3	RP11-288E14.2	9.55	8.64e-21	1.32e-14	0.62	0.28	Corneal curvature;	chr15:40032636	chr11:93535468~93535816:+
BRCA	trans	rs11098499	0.588	rs2389874	ENSG00000275858.1	RP11-291L22.8	-9.55	8.72e-21	1.33e-14	-0.33	-0.28	Corneal astigmatism;	chr4:119633836	chr10:38450738~38451069:-
BRCA	trans	rs864643	0.678	rs521139	ENSG00000183298.5	RP11-556K13.1	9.55	8.75e-21	1.34e-14	0.44	0.28	Attention deficit hyperactivity disorder;	chr3:39486128	chr1:101786340~101787219:-
BRCA	trans	rs3806843	0.966	rs2337516	ENSG00000231043.3	AC007238.1	9.55	8.75e-21	1.34e-14	0.34	0.28	Depressive symptoms (multi-trait analysis);	chr5:140761268	chr2:58460292~58462032:-
BRCA	trans	rs2727020	0.93	rs1164686	ENSG00000134612.10	FOLH1B	9.55	8.77e-21	1.34e-14	0.38	0.28	Coronary artery disease;	chr11:49270270	chr11:89639227~89698718:+
BRCA	trans	rs7824557	0.507	rs7010590	ENSG00000253893.2	FAM85B	-9.55	8.82e-21	1.35e-14	-0.36	-0.28	Retinal vascular caliber;	chr8:11205373	chr8:8167819~8226614:-
BRCA	trans	rs2727020	0.93	rs1164688	ENSG00000134612.10	FOLH1B	9.55	8.86e-21	1.36e-14	0.37	0.28	Coronary artery disease;	chr11:49269052	chr11:89639227~89698718:+
BRCA	trans	rs2727020	0.567	rs1164687	ENSG00000134612.10	FOLH1B	9.55	8.86e-21	1.36e-14	0.37	0.28	Coronary artery disease;	chr11:49269117	chr11:89639227~89698718:+
BRCA	trans	rs4276421	0.571	rs6894273	ENSG00000231752.4	EMBP1	9.55	9.21e-21	1.41e-14	0.39	0.28	P wave duration;	chr5:45701407	chr1:121519112~121571892:+
BRCA	trans	rs11039798	0.844	rs41431447	ENSG00000134612.10	FOLH1B	9.55	9.25e-21	1.41e-14	0.57	0.28	Axial length;	chr11:48961647	chr11:89639227~89698718:+
BRCA	trans	rs12210905	1	rs12208534	ENSG00000242375.1	RP11-498P14.3	-9.55	9.3e-21	1.42e-14	-0.68	-0.28	Hip circumference adjusted for BMI;	chr6:27098980	chr9:97195351~97197687:-
BRCA	trans	rs1816752	0.646	rs750390	ENSG00000224976.2	PARP4P2	9.54	9.63e-21	1.47e-14	0.34	0.28	Obesity-related traits;	chr13:24461603	chr13:19349137~19407962:+
BRCA	trans	rs7312770	1	rs7312770	ENSG00000224553.1	AC008065.1	-9.54	9.75e-21	1.49e-14	-0.3	-0.28	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr2:171374931~171375278:-
BRCA	trans	rs11039798	0.841	rs11039760	ENSG00000134612.10	FOLH1B	9.54	9.99e-21	1.53e-14	0.58	0.28	Axial length;	chr11:48457457	chr11:89639227~89698718:+
BRCA	trans	rs877636	1	rs4759229	ENSG00000196933.5	RPS26P11	-9.53	1.04e-20	1.58e-14	-0.36	-0.28	Cognitive function;	chr12:56080696	chrX:72044545~72044892:+
BRCA	trans	rs12200782	1	rs41267923	ENSG00000242375.1	RP11-498P14.3	-9.53	1.1e-20	1.67e-14	-0.7	-0.28	Small cell lung carcinoma;	chr6:26452719	chr9:97195351~97197687:-
BRCA	trans	rs1816752	0.609	rs4770692	ENSG00000224976.2	PARP4P2	9.53	1.1e-20	1.69e-14	0.34	0.28	Obesity-related traits;	chr13:24468689	chr13:19349137~19407962:+
BRCA	trans	rs875971	0.545	rs316328	ENSG00000164669.11	INTS4P1	9.52	1.12e-20	1.71e-14	0.37	0.28	Aortic root size;	chr7:66143851	chr7:65141225~65234216:+
BRCA	trans	rs11951515	0.509	rs12521249	ENSG00000174977.8	AC026271.5	9.52	1.13e-20	1.73e-14	0.34	0.28	Metabolite levels  (X-11787);	chr5:43558527	chr17:18650195~18651542:+
BRCA	trans	rs26067	0.563	rs11950885	ENSG00000231752.4	EMBP1	-9.52	1.13e-20	1.73e-14	-0.38	-0.28	Breast cancer;	chr5:50611824	chr1:121519112~121571892:+
BRCA	trans	rs1816752	0.609	rs4770694	ENSG00000224976.2	PARP4P2	9.52	1.14e-20	1.74e-14	0.34	0.28	Obesity-related traits;	chr13:24468891	chr13:19349137~19407962:+
BRCA	trans	rs1816752	0.624	rs9507354	ENSG00000224976.2	PARP4P2	9.52	1.14e-20	1.74e-14	0.34	0.28	Obesity-related traits;	chr13:24469227	chr13:19349137~19407962:+
BRCA	trans	rs867371	0.892	rs4344697	ENSG00000235370.6	DNM1P51	-9.52	1.17e-20	1.78e-14	-0.32	-0.28	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82252873	chr15:84398316~84411701:-
BRCA	trans	rs12210905	1	rs12209800	ENSG00000242375.1	RP11-498P14.3	9.52	1.2e-20	1.83e-14	0.67	0.28	Hip circumference adjusted for BMI;	chr6:27221738	chr9:97195351~97197687:-
BRCA	trans	rs11098499	0.562	rs13101722	ENSG00000275858.1	RP11-291L22.8	-9.52	1.2e-20	1.83e-14	-0.33	-0.28	Corneal astigmatism;	chr4:119634820	chr10:38450738~38451069:-
BRCA	trans	rs656319	0.559	rs17689037	ENSG00000253893.2	FAM85B	9.51	1.25e-20	1.91e-14	0.35	0.28	Myopia (pathological);	chr8:10117348	chr8:8167819~8226614:-
BRCA	trans	rs73108077	0.736	rs73104095	ENSG00000279352.1	RP11-411B10.7	9.51	1.32e-20	2e-14	0.59	0.28	Red blood cell density in sickle cell anemia;	chr20:31312074	chr18:14010054~14010917:+
BRCA	trans	rs7939886	0.841	rs11231800	ENSG00000134612.10	FOLH1B	9.51	1.33e-20	2.02e-14	0.58	0.28	Myopia (pathological);	chr11:56003454	chr11:89639227~89698718:+
BRCA	trans	rs9876781	1	rs9812647	ENSG00000225528.1	RP3-370M22.8	9.5	1.36e-20	2.06e-14	0.32	0.28	Longevity;	chr3:48407507	chr22:39960397~39964683:+
BRCA	trans	rs7927370	0.702	rs6591332	ENSG00000134612.10	FOLH1B	9.5	1.37e-20	2.09e-14	0.66	0.28	Systemic lupus erythematosus;	chr11:55262794	chr11:89639227~89698718:+
BRCA	trans	rs7927370	1	rs17494536	ENSG00000134612.10	FOLH1B	9.5	1.39e-20	2.12e-14	0.71	0.28	Systemic lupus erythematosus;	chr11:55493796	chr11:89639227~89698718:+
BRCA	trans	rs7944735	0.517	rs11039538	ENSG00000134612.10	FOLH1B	9.5	1.39e-20	2.12e-14	0.5	0.28	Intraocular pressure;	chr11:48133438	chr11:89639227~89698718:+
BRCA	trans	rs9329221	0.686	rs35406700	ENSG00000253893.2	FAM85B	-9.5	1.44e-20	2.2e-14	-0.37	-0.28	Neuroticism;	chr8:10387083	chr8:8167819~8226614:-
BRCA	trans	rs7833986	0.501	rs2719255	ENSG00000236862.1	RPS20P24	9.5	1.45e-20	2.2e-14	0.37	0.28	Height;	chr8:56124099	chr9:72655832~72656192:-
BRCA	trans	rs7833986	0.501	rs72653990	ENSG00000236862.1	RPS20P24	9.5	1.45e-20	2.2e-14	0.37	0.28	Height;	chr8:56124556	chr9:72655832~72656192:-
BRCA	trans	rs7833986	0.501	rs17815934	ENSG00000236862.1	RPS20P24	9.5	1.45e-20	2.2e-14	0.37	0.28	Height;	chr8:56125836	chr9:72655832~72656192:-
BRCA	trans	rs1816752	0.646	rs9511295	ENSG00000224976.2	PARP4P2	9.49	1.45e-20	2.21e-14	0.34	0.28	Obesity-related traits;	chr13:24467794	chr13:19349137~19407962:+
BRCA	trans	rs12200782	1	rs72843802	ENSG00000242375.1	RP11-498P14.3	-9.49	1.47e-20	2.23e-14	-0.68	-0.28	Small cell lung carcinoma;	chr6:26517287	chr9:97195351~97197687:-
BRCA	trans	rs12200782	0.674	rs12207224	ENSG00000242375.1	RP11-498P14.3	-9.49	1.47e-20	2.23e-14	-0.68	-0.28	Small cell lung carcinoma;	chr6:26519052	chr9:97195351~97197687:-
BRCA	trans	rs941207	0.526	rs2242497	ENSG00000228224.3	NACAP1	-9.49	1.48e-20	2.24e-14	-0.33	-0.28	Platelet count;	chr12:56598846	chr8:101361794~101372707:+
BRCA	trans	rs2336384	1	rs2336384	ENSG00000261819.1	RP11-680G24.4	-9.49	1.52e-20	2.31e-14	-0.37	-0.28	Platelet count;	chr1:11986006	chr16:14988259~14990160:-
BRCA	trans	rs1347297	0.666	rs1560870	ENSG00000269800.1	PLEKHA3P1	9.49	1.52e-20	2.31e-14	0.3	0.28	Alzheimer disease and age of onset;	chr2:178397705	chr19:41521043~41521989:-
BRCA	trans	rs12210905	1	rs9348752	ENSG00000242375.1	RP11-498P14.3	-9.49	1.55e-20	2.35e-14	-0.62	-0.28	Hip circumference adjusted for BMI;	chr6:27107704	chr9:97195351~97197687:-
BRCA	trans	rs6424115	0.965	rs2502986	ENSG00000228217.1	AL390877.1	-9.49	1.57e-20	2.38e-14	-0.34	-0.28	Immature fraction of reticulocytes;	chr1:23808802	chr1:117778087~117778506:-
BRCA	trans	rs3806843	0.762	rs3756337	ENSG00000231043.3	AC007238.1	-9.49	1.57e-20	2.39e-14	-0.33	-0.28	Depressive symptoms (multi-trait analysis);	chr5:140806853	chr2:58460292~58462032:-
BRCA	trans	rs867371	1	rs6495642	ENSG00000235370.6	DNM1P51	-9.49	1.58e-20	2.39e-14	-0.32	-0.28	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82165156	chr15:84398316~84411701:-
BRCA	trans	rs1816752	0.646	rs9507355	ENSG00000224976.2	PARP4P2	-9.49	1.58e-20	2.39e-14	-0.33	-0.28	Obesity-related traits;	chr13:24476819	chr13:19349137~19407962:+
BRCA	trans	rs12210905	0.92	rs6911234	ENSG00000242375.1	RP11-498P14.3	-9.49	1.58e-20	2.4e-14	-0.68	-0.28	Hip circumference adjusted for BMI;	chr6:27119080	chr9:97195351~97197687:-
BRCA	trans	rs12210905	1	rs12189835	ENSG00000242375.1	RP11-498P14.3	-9.48	1.61e-20	2.43e-14	-0.67	-0.28	Hip circumference adjusted for BMI;	chr6:27230492	chr9:97195351~97197687:-
BRCA	trans	rs12210905	1	rs72843640	ENSG00000242375.1	RP11-498P14.3	-9.48	1.61e-20	2.43e-14	-0.67	-0.28	Hip circumference adjusted for BMI;	chr6:27234314	chr9:97195351~97197687:-
BRCA	trans	rs4276421	0.509	rs1351719	ENSG00000231752.4	EMBP1	9.48	1.61e-20	2.44e-14	0.4	0.28	P wave duration;	chr5:45520383	chr1:121519112~121571892:+
BRCA	trans	rs1816752	0.583	rs9511284	ENSG00000224976.2	PARP4P2	9.48	1.65e-20	2.49e-14	0.34	0.28	Obesity-related traits;	chr13:24463660	chr13:19349137~19407962:+
BRCA	trans	rs6464772	0.54	rs10952668	ENSG00000238222.3	MKRN4P	9.48	1.67e-20	2.53e-14	0.33	0.28	Creatinine levels in ischemic stroke;	chr7:140443720	chrX:40834485~40836005:+
BRCA	trans	rs867371	1	rs7180584	ENSG00000235370.6	DNM1P51	-9.48	1.68e-20	2.54e-14	-0.32	-0.28	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82163493	chr15:84398316~84411701:-
BRCA	trans	rs7819412	0.875	rs11250121	ENSG00000253893.2	FAM85B	9.48	1.7e-20	2.58e-14	0.36	0.28	Triglycerides;	chr8:11202802	chr8:8167819~8226614:-
BRCA	trans	rs7944735	0.817	rs7942031	ENSG00000134612.10	FOLH1B	9.47	1.76e-20	2.67e-14	0.4	0.28	Intraocular pressure;	chr11:47846922	chr11:89639227~89698718:+
BRCA	trans	rs12210905	0.764	rs72835248	ENSG00000242375.1	RP11-498P14.3	-9.47	1.77e-20	2.68e-14	-0.7	-0.28	Hip circumference adjusted for BMI;	chr6:26964038	chr9:97195351~97197687:-
BRCA	trans	rs867371	1	rs7181655	ENSG00000235370.6	DNM1P51	-9.47	1.77e-20	2.68e-14	-0.32	-0.28	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82163275	chr15:84398316~84411701:-
BRCA	trans	rs6424115	1	rs12031592	ENSG00000228217.1	AL390877.1	-9.47	1.79e-20	2.7e-14	-0.34	-0.28	Immature fraction of reticulocytes;	chr1:23801374	chr1:117778087~117778506:-
BRCA	trans	rs16937956	0.657	rs16938063	ENSG00000266891.1	RP11-692N5.2	-9.47	1.8e-20	2.72e-14	-0.39	-0.28	Body mass index;	chr11:8410110	chr18:9734882~9735602:-
BRCA	trans	rs73108077	0.736	rs73119530	ENSG00000279352.1	RP11-411B10.7	9.47	1.82e-20	2.75e-14	0.6	0.28	Red blood cell density in sickle cell anemia;	chr20:31258810	chr18:14010054~14010917:+
BRCA	trans	rs73108077	0.736	rs17325435	ENSG00000279352.1	RP11-411B10.7	9.47	1.82e-20	2.75e-14	0.6	0.28	Red blood cell density in sickle cell anemia;	chr20:31259887	chr18:14010054~14010917:+
BRCA	trans	rs73108077	0.736	rs73119535	ENSG00000279352.1	RP11-411B10.7	9.47	1.82e-20	2.75e-14	0.6	0.28	Red blood cell density in sickle cell anemia;	chr20:31260483	chr18:14010054~14010917:+
BRCA	trans	rs73108077	0.704	rs73119542	ENSG00000279352.1	RP11-411B10.7	9.47	1.85e-20	2.8e-14	0.6	0.28	Red blood cell density in sickle cell anemia;	chr20:31268950	chr18:14010054~14010917:+
BRCA	trans	rs12210905	1	rs72843641	ENSG00000242375.1	RP11-498P14.3	-9.47	1.86e-20	2.81e-14	-0.67	-0.28	Hip circumference adjusted for BMI;	chr6:27235556	chr9:97195351~97197687:-
BRCA	trans	rs9329221	0.725	rs11250001	ENSG00000253893.2	FAM85B	9.47	1.88e-20	2.83e-14	0.37	0.28	Neuroticism;	chr8:10398391	chr8:8167819~8226614:-
BRCA	trans	rs12210905	1	rs12196084	ENSG00000242375.1	RP11-498P14.3	-9.47	1.88e-20	2.84e-14	-0.67	-0.28	Hip circumference adjusted for BMI;	chr6:27230425	chr9:97195351~97197687:-
BRCA	trans	rs10028773	0.666	rs12498657	ENSG00000275858.1	RP11-291L22.8	9.47	1.88e-20	2.84e-14	0.33	0.28	Educational attainment;	chr4:119341711	chr10:38450738~38451069:-
BRCA	trans	rs73108077	0.79	rs73104050	ENSG00000279352.1	RP11-411B10.7	9.46	1.9e-20	2.87e-14	0.6	0.28	Red blood cell density in sickle cell anemia;	chr20:31289961	chr18:14010054~14010917:+
BRCA	trans	rs7927370	0.867	rs1364765	ENSG00000134612.10	FOLH1B	-9.46	2e-20	3.02e-14	-0.67	-0.28	Systemic lupus erythematosus;	chr11:55429342	chr11:89639227~89698718:+
BRCA	trans	rs4276421	0.509	rs4532370	ENSG00000231752.4	EMBP1	-9.46	2.02e-20	3.04e-14	-0.4	-0.28	P wave duration;	chr5:45506716	chr1:121519112~121571892:+
BRCA	trans	rs1816752	0.646	rs2902359	ENSG00000224976.2	PARP4P2	9.46	2.04e-20	3.08e-14	0.34	0.28	Obesity-related traits;	chr13:24461783	chr13:19349137~19407962:+
BRCA	trans	rs9329221	0.638	rs7460436	ENSG00000253893.2	FAM85B	-9.45	2.07e-20	3.12e-14	-0.38	-0.28	Neuroticism;	chr8:10396812	chr8:8167819~8226614:-
BRCA	trans	rs7112043	0.838	rs11032839	ENSG00000225531.1	RP11-196I18.3	9.45	2.09e-20	3.16e-14	0.38	0.28	Lung disease severity in cystic fibrosis;	chr11:34756178	chr9:107116829~107117557:+
BRCA	trans	rs747782	0.527	rs2270993	ENSG00000134612.10	FOLH1B	9.44	2.26e-20	3.41e-14	0.5	0.28	Intraocular pressure;	chr11:48123614	chr11:89639227~89698718:+
BRCA	trans	rs1347297	0.666	rs10204497	ENSG00000269800.1	PLEKHA3P1	9.44	2.27e-20	3.41e-14	0.3	0.28	Alzheimer disease and age of onset;	chr2:178401400	chr19:41521043~41521989:-
BRCA	trans	rs7927370	0.867	rs1216206	ENSG00000134612.10	FOLH1B	-9.44	2.27e-20	3.41e-14	-0.68	-0.28	Systemic lupus erythematosus;	chr11:55425152	chr11:89639227~89698718:+
BRCA	trans	rs9876781	1	rs4858817	ENSG00000225528.1	RP3-370M22.8	9.44	2.29e-20	3.44e-14	0.3	0.28	Longevity;	chr3:48375266	chr22:39960397~39964683:+
BRCA	trans	rs1816752	0.646	rs1361578	ENSG00000224976.2	PARP4P2	9.44	2.3e-20	3.46e-14	0.35	0.28	Obesity-related traits;	chr13:24491117	chr13:19349137~19407962:+
BRCA	trans	rs26067	0.643	rs693082	ENSG00000231752.4	EMBP1	9.44	2.32e-20	3.48e-14	0.38	0.28	Breast cancer;	chr5:50808537	chr1:121519112~121571892:+
BRCA	trans	rs11098499	0.691	rs28396837	ENSG00000275858.1	RP11-291L22.8	9.44	2.36e-20	3.55e-14	0.33	0.28	Corneal astigmatism;	chr4:119350386	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.629	rs28369518	ENSG00000275858.1	RP11-291L22.8	9.44	2.36e-20	3.55e-14	0.33	0.28	Corneal astigmatism;	chr4:119350475	chr10:38450738~38451069:-
BRCA	trans	rs73108077	0.79	rs73102048	ENSG00000279352.1	RP11-411B10.7	9.44	2.37e-20	3.56e-14	0.59	0.28	Red blood cell density in sickle cell anemia;	chr20:31277508	chr18:14010054~14010917:+
BRCA	trans	rs73108077	0.704	rs7273922	ENSG00000279352.1	RP11-411B10.7	9.44	2.37e-20	3.56e-14	0.59	0.28	Red blood cell density in sickle cell anemia;	chr20:31282601	chr18:14010054~14010917:+
BRCA	trans	rs1347297	0.666	rs2114581	ENSG00000269800.1	PLEKHA3P1	9.44	2.37e-20	3.57e-14	0.3	0.28	Alzheimer disease and age of onset;	chr2:178404951	chr19:41521043~41521989:-
BRCA	trans	rs11098499	0.722	rs10006192	ENSG00000275858.1	RP11-291L22.8	9.43	2.49e-20	3.75e-14	0.33	0.28	Corneal astigmatism;	chr4:119341867	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.615	rs28551750	ENSG00000275858.1	RP11-291L22.8	9.43	2.49e-20	3.75e-14	0.33	0.28	Corneal astigmatism;	chr4:119343746	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.691	rs9995716	ENSG00000275858.1	RP11-291L22.8	9.43	2.49e-20	3.75e-14	0.33	0.28	Corneal astigmatism;	chr4:119343841	chr10:38450738~38451069:-
BRCA	trans	rs6424115	1	rs2256179	ENSG00000228217.1	AL390877.1	9.43	2.51e-20	3.77e-14	0.33	0.28	Immature fraction of reticulocytes;	chr1:23805815	chr1:117778087~117778506:-
BRCA	trans	rs11098499	0.615	rs59867181	ENSG00000275858.1	RP11-291L22.8	-9.43	2.51e-20	3.77e-14	-0.33	-0.28	Corneal astigmatism;	chr4:119635312	chr10:38450738~38451069:-
BRCA	trans	rs4276421	0.533	rs34930360	ENSG00000231752.4	EMBP1	9.43	2.51e-20	3.77e-14	0.44	0.28	P wave duration;	chr5:46120740	chr1:121519112~121571892:+
BRCA	trans	rs1816752	0.646	rs7322323	ENSG00000224976.2	PARP4P2	9.43	2.52e-20	3.78e-14	0.34	0.28	Obesity-related traits;	chr13:24479189	chr13:19349137~19407962:+
BRCA	trans	rs73108077	0.79	rs73102082	ENSG00000279352.1	RP11-411B10.7	9.43	2.54e-20	3.81e-14	0.59	0.28	Red blood cell density in sickle cell anemia;	chr20:31288687	chr18:14010054~14010917:+
BRCA	trans	rs11098499	0.691	rs12502524	ENSG00000275858.1	RP11-291L22.8	9.43	2.58e-20	3.88e-14	0.33	0.28	Corneal astigmatism;	chr4:119350259	chr10:38450738~38451069:-
BRCA	trans	rs3806843	1	rs991918	ENSG00000231043.3	AC007238.1	-9.42	2.72e-20	4.08e-14	-0.33	-0.28	Depressive symptoms (multi-trait analysis);	chr5:140815273	chr2:58460292~58462032:-
BRCA	trans	rs9329221	0.527	rs4841352	ENSG00000253893.2	FAM85B	-9.42	2.74e-20	4.11e-14	-0.35	-0.28	Neuroticism;	chr8:10470080	chr8:8167819~8226614:-
BRCA	trans	rs66887589	0.616	rs7659403	ENSG00000275858.1	RP11-291L22.8	9.42	2.74e-20	4.12e-14	0.32	0.28	Diastolic blood pressure;	chr4:119286099	chr10:38450738~38451069:-
BRCA	trans	rs73108077	0.736	rs6060436	ENSG00000279352.1	RP11-411B10.7	9.42	2.75e-20	4.12e-14	0.48	0.28	Red blood cell density in sickle cell anemia;	chr20:31258500	chr18:14010054~14010917:+
BRCA	trans	rs11098499	0.722	rs10025925	ENSG00000275858.1	RP11-291L22.8	9.42	2.75e-20	4.12e-14	0.33	0.28	Corneal astigmatism;	chr4:119350589	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.731	rs10015579	ENSG00000275858.1	RP11-291L22.8	9.42	2.75e-20	4.12e-14	0.33	0.28	Corneal astigmatism;	chr4:119350647	chr10:38450738~38451069:-
BRCA	trans	rs867371	1	rs9944197	ENSG00000235370.6	DNM1P51	-9.42	2.8e-20	4.2e-14	-0.31	-0.28	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82158261	chr15:84398316~84411701:-
BRCA	trans	rs1347297	0.666	rs4019558	ENSG00000269800.1	PLEKHA3P1	9.42	2.8e-20	4.2e-14	0.3	0.28	Alzheimer disease and age of onset;	chr2:178406156	chr19:41521043~41521989:-
BRCA	trans	rs2336384	1	rs873457	ENSG00000261819.1	RP11-680G24.4	9.41	3.05e-20	4.56e-14	0.36	0.28	Platelet count;	chr1:11986277	chr16:14988259~14990160:-
BRCA	trans	rs12200782	0.932	rs72844476	ENSG00000242375.1	RP11-498P14.3	-9.41	3.06e-20	4.58e-14	-0.68	-0.28	Small cell lung carcinoma;	chr6:26573922	chr9:97195351~97197687:-
BRCA	trans	rs12210905	1	rs12192320	ENSG00000242375.1	RP11-498P14.3	-9.41	3.06e-20	4.58e-14	-0.68	-0.28	Hip circumference adjusted for BMI;	chr6:27122526	chr9:97195351~97197687:-
BRCA	trans	rs11098499	0.691	rs10028773	ENSG00000275858.1	RP11-291L22.8	-9.41	3.16e-20	4.74e-14	-0.32	-0.28	Corneal astigmatism;	chr4:119344104	chr10:38450738~38451069:-
BRCA	trans	rs2950393	0.509	rs10459247	ENSG00000228224.3	NACAP1	-9.41	3.17e-20	4.74e-14	-0.36	-0.28	Platelet distribution width;	chr12:56777732	chr8:101361794~101372707:+
BRCA	trans	rs714543	0.566	rs13231886	ENSG00000226038.5	PPIAP21	-9.41	3.19e-20	4.77e-14	-0.34	-0.28	Plateletcrit;	chr7:44774573	chr20:43230760~43231260:+
BRCA	trans	rs12210905	1	rs12209429	ENSG00000242375.1	RP11-498P14.3	-9.4	3.21e-20	4.8e-14	-0.68	-0.28	Hip circumference adjusted for BMI;	chr6:27087088	chr9:97195351~97197687:-
BRCA	trans	rs11098499	0.691	rs12510133	ENSG00000275858.1	RP11-291L22.8	9.4	3.21e-20	4.8e-14	0.33	0.28	Corneal astigmatism;	chr4:119350189	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.754	rs12506487	ENSG00000275858.1	RP11-291L22.8	9.4	3.21e-20	4.8e-14	0.33	0.28	Corneal astigmatism;	chr4:119350206	chr10:38450738~38451069:-
BRCA	trans	rs73108077	0.79	rs73105930	ENSG00000279352.1	RP11-411B10.7	9.4	3.21e-20	4.8e-14	0.59	0.28	Red blood cell density in sickle cell anemia;	chr20:31327265	chr18:14010054~14010917:+
BRCA	trans	rs1580019	0.713	rs2122632	ENSG00000176826.14	FKBP9P1	9.4	3.22e-20	4.81e-14	0.36	0.28	Cognitive ability;	chr7:32485074	chr7:55681074~55713252:-
BRCA	trans	rs864643	0.945	rs1707972	ENSG00000183298.5	RP11-556K13.1	9.4	3.26e-20	4.87e-14	0.44	0.28	Attention deficit hyperactivity disorder;	chr3:39507243	chr1:101786340~101787219:-
BRCA	trans	rs875971	0.545	rs73146609	ENSG00000164669.11	INTS4P1	-9.4	3.26e-20	4.88e-14	-0.4	-0.28	Aortic root size;	chr7:66302477	chr7:65141225~65234216:+
BRCA	trans	rs875971	0.545	rs2173571	ENSG00000164669.11	INTS4P1	-9.4	3.26e-20	4.88e-14	-0.4	-0.28	Aortic root size;	chr7:66305392	chr7:65141225~65234216:+
BRCA	trans	rs7662987	0.793	rs28730602	ENSG00000228407.2	RP4-800M22.1	9.4	3.27e-20	4.89e-14	0.5	0.28	Smoking initiation;	chr4:99080531	chr1:52160261~52160600:-
BRCA	trans	rs853679	0.546	rs35819751	ENSG00000253570.1	RNF5P1	9.4	3.37e-20	5.04e-14	0.83	0.28	Depression;	chr6:27842791	chr8:38600661~38601200:-
BRCA	trans	rs7944735	0.817	rs2305983	ENSG00000134612.10	FOLH1B	9.4	3.44e-20	5.14e-14	0.39	0.28	Intraocular pressure;	chr11:47837203	chr11:89639227~89698718:+
BRCA	trans	rs66887589	0.87	rs10518336	ENSG00000275858.1	RP11-291L22.8	9.4	3.47e-20	5.18e-14	0.32	0.28	Diastolic blood pressure;	chr4:119601779	chr10:38450738~38451069:-
BRCA	trans	rs66887589	0.616	rs11098497	ENSG00000275858.1	RP11-291L22.8	9.39	3.54e-20	5.29e-14	0.32	0.28	Diastolic blood pressure;	chr4:119265913	chr10:38450738~38451069:-
BRCA	trans	rs6424115	1	rs1018396	ENSG00000228217.1	AL390877.1	-9.39	3.61e-20	5.39e-14	-0.34	-0.28	Immature fraction of reticulocytes;	chr1:23807122	chr1:117778087~117778506:-
BRCA	trans	rs875971	0.545	rs6969224	ENSG00000164669.11	INTS4P1	-9.39	3.62e-20	5.4e-14	-0.4	-0.28	Aortic root size;	chr7:66370011	chr7:65141225~65234216:+
BRCA	trans	rs7662987	0.793	rs28730632	ENSG00000228407.2	RP4-800M22.1	9.39	3.69e-20	5.5e-14	0.5	0.28	Smoking initiation;	chr4:99074552	chr1:52160261~52160600:-
BRCA	trans	rs12210905	1	rs12201774	ENSG00000242375.1	RP11-498P14.3	-9.39	3.75e-20	5.6e-14	-0.67	-0.28	Hip circumference adjusted for BMI;	chr6:27090533	chr9:97195351~97197687:-
BRCA	trans	rs1347297	0.526	rs10201175	ENSG00000269800.1	PLEKHA3P1	9.38	3.9e-20	5.81e-14	0.29	0.28	Alzheimer disease and age of onset;	chr2:178400621	chr19:41521043~41521989:-
BRCA	trans	rs864643	1	rs864643	ENSG00000183298.5	RP11-556K13.1	9.38	3.9e-20	5.81e-14	0.43	0.28	Attention deficit hyperactivity disorder;	chr3:39514089	chr1:101786340~101787219:-
BRCA	trans	rs747782	0.527	rs2279822	ENSG00000134612.10	FOLH1B	9.38	3.91e-20	5.83e-14	0.49	0.28	Intraocular pressure;	chr11:48124562	chr11:89639227~89698718:+
BRCA	trans	rs11039798	0.92	rs7478904	ENSG00000134612.10	FOLH1B	9.38	3.91e-20	5.83e-14	0.56	0.28	Axial length;	chr11:48608771	chr11:89639227~89698718:+
BRCA	trans	rs11098499	0.691	rs17009144	ENSG00000275858.1	RP11-291L22.8	-9.38	3.97e-20	5.91e-14	-0.32	-0.28	Corneal astigmatism;	chr4:119349640	chr10:38450738~38451069:-
BRCA	trans	rs6743068	0.541	rs6435079	ENSG00000235105.1	RP11-329A14.1	9.38	3.97e-20	5.91e-14	0.34	0.28	Lymphocyte percentage of white cells;	chr2:201335608	chr1:48435967~48437223:+
BRCA	trans	rs73108077	0.79	rs8122544	ENSG00000279352.1	RP11-411B10.7	9.38	4.02e-20	5.99e-14	0.59	0.28	Red blood cell density in sickle cell anemia;	chr20:31346428	chr18:14010054~14010917:+
BRCA	trans	rs1391708	0.834	rs58911887	ENSG00000121089.4	NACA3P	-9.38	4.07e-20	6.07e-14	-0.46	-0.28	Airway wall thickness;	chr12:56884858	chr4:164943290~164943937:+
BRCA	trans	rs11039798	0.92	rs11039848	ENSG00000134612.10	FOLH1B	9.38	4.14e-20	6.17e-14	0.56	0.28	Axial length;	chr11:48576691	chr11:89639227~89698718:+
BRCA	trans	rs73108077	0.79	rs73104055	ENSG00000279352.1	RP11-411B10.7	9.37	4.23e-20	6.29e-14	0.59	0.28	Red blood cell density in sickle cell anemia;	chr20:31293082	chr18:14010054~14010917:+
BRCA	trans	rs73108077	0.79	rs73104064	ENSG00000279352.1	RP11-411B10.7	9.37	4.23e-20	6.29e-14	0.59	0.28	Red blood cell density in sickle cell anemia;	chr20:31297920	chr18:14010054~14010917:+
BRCA	trans	rs10028773	0.6	rs4001390	ENSG00000275858.1	RP11-291L22.8	9.37	4.24e-20	6.31e-14	0.32	0.28	Educational attainment;	chr4:119344628	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.691	rs2136911	ENSG00000275858.1	RP11-291L22.8	9.37	4.24e-20	6.31e-14	0.32	0.28	Corneal astigmatism;	chr4:119344704	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.779	rs6815934	ENSG00000275858.1	RP11-291L22.8	9.37	4.24e-20	6.31e-14	0.32	0.28	Corneal astigmatism;	chr4:119346155	chr10:38450738~38451069:-
BRCA	trans	rs10028773	0.568	rs6838457	ENSG00000275858.1	RP11-291L22.8	9.37	4.24e-20	6.31e-14	0.32	0.28	Educational attainment;	chr4:119346212	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.535	rs10005542	ENSG00000275858.1	RP11-291L22.8	9.37	4.24e-20	6.31e-14	0.32	0.28	Corneal astigmatism;	chr4:119347147	chr10:38450738~38451069:-
BRCA	trans	rs12200782	1	rs3927423	ENSG00000242375.1	RP11-498P14.3	-9.37	4.29e-20	6.39e-14	-0.68	-0.28	Small cell lung carcinoma;	chr6:26393259	chr9:97195351~97197687:-
BRCA	trans	rs12200782	1	rs12201802	ENSG00000242375.1	RP11-498P14.3	-9.37	4.29e-20	6.39e-14	-0.68	-0.28	Small cell lung carcinoma;	chr6:26398436	chr9:97195351~97197687:-
BRCA	trans	rs6424115	1	rs974698	ENSG00000228217.1	AL390877.1	-9.37	4.31e-20	6.42e-14	-0.34	-0.28	Immature fraction of reticulocytes;	chr1:23806295	chr1:117778087~117778506:-
BRCA	trans	rs7824557	0.767	rs4559208	ENSG00000253893.2	FAM85B	-9.37	4.39e-20	6.53e-14	-0.38	-0.28	Retinal vascular caliber;	chr8:11296416	chr8:8167819~8226614:-
BRCA	trans	rs3806843	0.676	rs2245643	ENSG00000231043.3	AC007238.1	9.37	4.47e-20	6.65e-14	0.33	0.28	Depressive symptoms (multi-trait analysis);	chr5:140650195	chr2:58460292~58462032:-
BRCA	trans	rs867371	1	rs1392976	ENSG00000235370.6	DNM1P51	9.37	4.48e-20	6.66e-14	0.31	0.28	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82153834	chr15:84398316~84411701:-
BRCA	trans	rs11098499	0.554	rs2175381	ENSG00000275858.1	RP11-291L22.8	9.36	4.66e-20	6.93e-14	0.32	0.28	Corneal astigmatism;	chr4:119344812	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.599	rs3864142	ENSG00000275858.1	RP11-291L22.8	9.36	4.66e-20	6.93e-14	0.32	0.28	Corneal astigmatism;	chr4:119345036	chr10:38450738~38451069:-
BRCA	trans	rs11023332	0.706	rs11023379	ENSG00000236360.2	RP11-334A14.2	9.36	4.81e-20	7.14e-14	0.37	0.28	Vitamin D levels;Adiponectin levels;	chr11:14908414	chr1:52993201~52993702:-
BRCA	trans	rs877636	0.859	rs3741499	ENSG00000196933.5	RPS26P11	-9.36	4.85e-20	7.2e-14	-0.35	-0.28	Cognitive function;	chr12:56080595	chrX:72044545~72044892:+
BRCA	trans	rs7662987	0.793	rs12697	ENSG00000228407.2	RP4-800M22.1	-9.36	4.86e-20	7.21e-14	-0.49	-0.28	Smoking initiation;	chr4:99072225	chr1:52160261~52160600:-
BRCA	trans	rs3806843	0.9	rs3756334	ENSG00000231043.3	AC007238.1	-9.35	5.01e-20	7.44e-14	-0.33	-0.28	Depressive symptoms (multi-trait analysis);	chr5:140834211	chr2:58460292~58462032:-
BRCA	trans	rs6732160	0.834	rs57456443	ENSG00000236165.1	PRADC1P1	9.35	5.04e-20	7.48e-14	0.35	0.28	Intelligence (multi-trait analysis);	chr2:73139313	chr3:36976316~36976840:+
BRCA	trans	rs1391708	0.834	rs34465459	ENSG00000121089.4	NACA3P	-9.35	5.06e-20	7.51e-14	-0.46	-0.28	Airway wall thickness;	chr12:56885552	chr4:164943290~164943937:+
BRCA	trans	rs867371	1	rs1174543	ENSG00000235370.6	DNM1P51	9.35	5.09e-20	7.55e-14	0.31	0.28	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82155732	chr15:84398316~84411701:-
BRCA	trans	rs867371	1	rs11855089	ENSG00000235370.6	DNM1P51	-9.35	5.12e-20	7.6e-14	-0.31	-0.28	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82154924	chr15:84398316~84411701:-
BRCA	trans	rs875971	0.545	rs73142265	ENSG00000164669.11	INTS4P1	-9.35	5.2e-20	7.71e-14	-0.39	-0.28	Aortic root size;	chr7:66234510	chr7:65141225~65234216:+
BRCA	trans	rs6732160	0.932	rs6546802	ENSG00000236165.1	PRADC1P1	9.35	5.2e-20	7.71e-14	0.35	0.28	Intelligence (multi-trait analysis);	chr2:73152436	chr3:36976316~36976840:+
BRCA	trans	rs6732160	0.932	rs13417029	ENSG00000236165.1	PRADC1P1	9.35	5.2e-20	7.71e-14	0.35	0.28	Intelligence (multi-trait analysis);	chr2:73153295	chr3:36976316~36976840:+
BRCA	trans	rs6732160	0.932	rs6546803	ENSG00000236165.1	PRADC1P1	9.35	5.2e-20	7.71e-14	0.35	0.28	Intelligence (multi-trait analysis);	chr2:73154187	chr3:36976316~36976840:+
BRCA	trans	rs12200782	0.932	rs12189841	ENSG00000242375.1	RP11-498P14.3	-9.35	5.22e-20	7.74e-14	-0.68	-0.28	Small cell lung carcinoma;	chr6:26544570	chr9:97195351~97197687:-
BRCA	trans	rs9876781	1	rs4858793	ENSG00000225528.1	RP3-370M22.8	9.35	5.23e-20	7.76e-14	0.31	0.28	Longevity;	chr3:48373517	chr22:39960397~39964683:+
BRCA	trans	rs12210905	1	rs72843611	ENSG00000242375.1	RP11-498P14.3	-9.35	5.26e-20	7.79e-14	-0.67	-0.28	Hip circumference adjusted for BMI;	chr6:27163603	chr9:97195351~97197687:-
BRCA	trans	rs11098499	0.874	rs13139045	ENSG00000275858.1	RP11-291L22.8	9.34	5.41e-20	8.02e-14	0.33	0.28	Corneal astigmatism;	chr4:119247433	chr10:38450738~38451069:-
BRCA	trans	rs330048	0.545	rs11774353	ENSG00000253893.2	FAM85B	-9.34	5.43e-20	8.05e-14	-0.37	-0.28	Systemic lupus erythematosus;	chr8:9295617	chr8:8167819~8226614:-
BRCA	trans	rs11098499	0.661	rs10015965	ENSG00000275858.1	RP11-291L22.8	9.34	5.44e-20	8.05e-14	0.32	0.28	Corneal astigmatism;	chr4:119347082	chr10:38450738~38451069:-
BRCA	trans	rs875971	0.545	rs6970498	ENSG00000164669.11	INTS4P1	-9.34	5.44e-20	8.06e-14	-0.4	-0.28	Aortic root size;	chr7:66275908	chr7:65141225~65234216:+
BRCA	trans	rs864643	0.678	rs1707953	ENSG00000183298.5	RP11-556K13.1	9.34	5.53e-20	8.19e-14	0.43	0.28	Attention deficit hyperactivity disorder;	chr3:39483918	chr1:101786340~101787219:-
BRCA	trans	rs864643	0.678	rs683089	ENSG00000183298.5	RP11-556K13.1	9.34	5.53e-20	8.19e-14	0.43	0.28	Attention deficit hyperactivity disorder;	chr3:39484334	chr1:101786340~101787219:-
BRCA	trans	rs864643	0.678	rs590805	ENSG00000183298.5	RP11-556K13.1	9.34	5.53e-20	8.19e-14	0.43	0.28	Attention deficit hyperactivity disorder;	chr3:39485463	chr1:101786340~101787219:-
BRCA	trans	rs7833986	0.534	rs72653924	ENSG00000236862.1	RPS20P24	9.34	5.8e-20	8.59e-14	0.36	0.28	Height;	chr8:55993529	chr9:72655832~72656192:-
BRCA	trans	rs7833986	0.534	rs2667972	ENSG00000236862.1	RPS20P24	9.34	5.8e-20	8.59e-14	0.36	0.28	Height;	chr8:55994102	chr9:72655832~72656192:-
BRCA	trans	rs2336384	0.929	rs2236056	ENSG00000261819.1	RP11-680G24.4	9.33	5.93e-20	8.77e-14	0.38	0.28	Platelet count;	chr1:11996383	chr16:14988259~14990160:-
BRCA	trans	rs7824557	0.564	rs2736295	ENSG00000253893.2	FAM85B	-9.33	5.99e-20	8.87e-14	-0.34	-0.28	Retinal vascular caliber;	chr8:11377271	chr8:8167819~8226614:-
BRCA	trans	rs7937890	0.559	rs1116739	ENSG00000236360.2	RP11-334A14.2	9.33	6.05e-20	8.95e-14	0.36	0.28	Mitochondrial DNA levels;	chr11:14467636	chr1:52993201~52993702:-
BRCA	trans	rs9329221	0.527	rs6989657	ENSG00000253893.2	FAM85B	-9.33	6.07e-20	8.97e-14	-0.35	-0.28	Neuroticism;	chr8:10473363	chr8:8167819~8226614:-
BRCA	trans	rs11638815	0.52	rs4779032	ENSG00000235370.6	DNM1P51	-9.33	6.14e-20	9.07e-14	-0.29	-0.28	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82576576	chr15:84398316~84411701:-
BRCA	trans	rs875971	0.545	rs4718325	ENSG00000164669.11	INTS4P1	-9.33	6.28e-20	9.29e-14	-0.39	-0.28	Aortic root size;	chr7:66215323	chr7:65141225~65234216:+
BRCA	trans	rs9329221	0.527	rs4841351	ENSG00000253893.2	FAM85B	9.33	6.3e-20	9.31e-14	0.36	0.28	Neuroticism;	chr8:10469857	chr8:8167819~8226614:-
BRCA	trans	rs2069408	1	rs2069408	ENSG00000225071.1	GS1-184P14.2	-9.33	6.42e-20	9.49e-14	-0.36	-0.28	Asthma;	chr12:55970537	chrX:24429573~24429920:-
BRCA	trans	rs12200782	0.929	rs116018523	ENSG00000242375.1	RP11-498P14.3	-9.33	6.43e-20	9.5e-14	-0.64	-0.28	Small cell lung carcinoma;	chr6:26357006	chr9:97195351~97197687:-
BRCA	trans	rs7662987	0.793	rs4699700	ENSG00000228407.2	RP4-800M22.1	9.32	6.6e-20	9.75e-14	0.49	0.28	Smoking initiation;	chr4:99077184	chr1:52160261~52160600:-
BRCA	trans	rs1816752	0.608	rs7326664	ENSG00000224976.2	PARP4P2	9.32	6.71e-20	9.92e-14	0.33	0.28	Obesity-related traits;	chr13:24475868	chr13:19349137~19407962:+
BRCA	trans	rs7833986	0.501	rs2719226	ENSG00000236862.1	RPS20P24	9.32	6.77e-20	1e-13	0.37	0.28	Height;	chr8:56131507	chr9:72655832~72656192:-
BRCA	trans	rs867371	1	rs13380317	ENSG00000235370.6	DNM1P51	9.32	6.84e-20	1.01e-13	0.31	0.28	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82214449	chr15:84398316~84411701:-
BRCA	trans	rs875971	0.545	rs73142233	ENSG00000164669.11	INTS4P1	-9.32	6.84e-20	1.01e-13	-0.39	-0.28	Aortic root size;	chr7:66221293	chr7:65141225~65234216:+
BRCA	trans	rs11098499	0.562	rs2389879	ENSG00000275858.1	RP11-291L22.8	-9.32	6.91e-20	1.02e-13	-0.32	-0.28	Corneal astigmatism;	chr4:119636529	chr10:38450738~38451069:-
BRCA	trans	rs1580019	0.713	rs2167274	ENSG00000176826.14	FKBP9P1	-9.32	7.02e-20	1.04e-13	-0.36	-0.28	Cognitive ability;	chr7:32485232	chr7:55681074~55713252:-
BRCA	trans	rs12200782	1	rs12204145	ENSG00000242375.1	RP11-498P14.3	-9.32	7.03e-20	1.04e-13	-0.65	-0.28	Small cell lung carcinoma;	chr6:26599928	chr9:97195351~97197687:-
BRCA	trans	rs867371	0.826	rs2047678	ENSG00000235370.6	DNM1P51	-9.31	7.12e-20	1.05e-13	-0.32	-0.28	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82205857	chr15:84398316~84411701:-
BRCA	trans	rs8010715	0.848	rs2277483	ENSG00000238000.1	RP11-274E7.2	9.31	7.14e-20	1.05e-13	0.3	0.28	IgG glycosylation;	chr14:24122683	chr5:98213402~98214121:+
BRCA	trans	rs2899832	0.659	rs55758852	ENSG00000229083.1	PSMA6P2	9.31	7.24e-20	1.07e-13	0.41	0.28	Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:35167694	chrX:12825840~12826833:+
BRCA	trans	rs3806843	0.619	rs2569160	ENSG00000231043.3	AC007238.1	9.31	7.34e-20	1.08e-13	0.33	0.28	Depressive symptoms (multi-trait analysis);	chr5:140649189	chr2:58460292~58462032:-
BRCA	trans	rs1347297	0.526	rs6757186	ENSG00000269800.1	PLEKHA3P1	9.31	7.49e-20	1.1e-13	0.29	0.28	Alzheimer disease and age of onset;	chr2:178394992	chr19:41521043~41521989:-
BRCA	trans	rs9329221	0.686	rs35840352	ENSG00000253893.2	FAM85B	-9.31	7.66e-20	1.13e-13	-0.37	-0.28	Neuroticism;	chr8:10382297	chr8:8167819~8226614:-
BRCA	trans	rs864643	0.678	rs3856566	ENSG00000183298.5	RP11-556K13.1	9.3	7.71e-20	1.14e-13	0.43	0.28	Attention deficit hyperactivity disorder;	chr3:39491097	chr1:101786340~101787219:-
BRCA	trans	rs7939886	0.92	rs58405266	ENSG00000134612.10	FOLH1B	9.3	7.85e-20	1.16e-13	0.53	0.28	Myopia (pathological);	chr11:56095749	chr11:89639227~89698718:+
BRCA	trans	rs1190596	0.666	rs12892927	ENSG00000181359.5	HSP90AA6P	-9.3	7.93e-20	1.17e-13	-0.44	-0.28	Behavioural disinhibition (generation interaction);	chr14:102297705	chr4:170581470~170605450:-
BRCA	trans	rs7927370	0.558	rs12277000	ENSG00000134612.10	FOLH1B	9.3	7.93e-20	1.17e-13	0.69	0.28	Systemic lupus erythematosus;	chr11:55736789	chr11:89639227~89698718:+
BRCA	trans	rs3808502	0.549	rs7831039	ENSG00000253893.2	FAM85B	9.3	7.97e-20	1.17e-13	0.36	0.28	Neuroticism;	chr8:11570128	chr8:8167819~8226614:-
BRCA	trans	rs9329221	0.686	rs60755617	ENSG00000253893.2	FAM85B	-9.3	8.23e-20	1.21e-13	-0.38	-0.28	Neuroticism;	chr8:10385817	chr8:8167819~8226614:-
BRCA	trans	rs747782	0.527	rs7129364	ENSG00000134612.10	FOLH1B	9.3	8.3e-20	1.22e-13	0.49	0.28	Intraocular pressure;	chr11:48129024	chr11:89639227~89698718:+
BRCA	trans	rs1814175	0.754	rs7103235	ENSG00000134612.10	FOLH1B	-9.3	8.34e-20	1.23e-13	-0.35	-0.28	Height;	chr11:49677639	chr11:89639227~89698718:+
BRCA	trans	rs875971	0.545	rs3936065	ENSG00000164669.11	INTS4P1	-9.29	8.45e-20	1.24e-13	-0.39	-0.28	Aortic root size;	chr7:66325577	chr7:65141225~65234216:+
BRCA	trans	rs875971	0.545	rs4718335	ENSG00000164669.11	INTS4P1	-9.29	8.45e-20	1.24e-13	-0.39	-0.28	Aortic root size;	chr7:66339619	chr7:65141225~65234216:+
BRCA	trans	rs875971	0.545	rs73142245	ENSG00000164669.11	INTS4P1	-9.29	8.6e-20	1.26e-13	-0.39	-0.28	Aortic root size;	chr7:66226662	chr7:65141225~65234216:+
BRCA	trans	rs7833986	0.501	rs9650314	ENSG00000236862.1	RPS20P24	9.29	8.66e-20	1.27e-13	0.36	0.28	Height;	chr8:55991051	chr9:72655832~72656192:-
BRCA	trans	rs864643	0.678	rs519385	ENSG00000183298.5	RP11-556K13.1	9.29	8.92e-20	1.31e-13	0.43	0.28	Attention deficit hyperactivity disorder;	chr3:39486304	chr1:101786340~101787219:-
BRCA	trans	rs864643	0.678	rs604831	ENSG00000183298.5	RP11-556K13.1	9.29	8.92e-20	1.31e-13	0.43	0.28	Attention deficit hyperactivity disorder;	chr3:39486327	chr1:101786340~101787219:-
BRCA	trans	rs11246602	1	rs11246602	ENSG00000134612.10	FOLH1B	9.29	9.09e-20	1.34e-13	0.53	0.28	HDL cholesterol levels;HDL cholesterol;	chr11:54607190	chr11:89639227~89698718:+
BRCA	trans	rs3096299	0.658	rs3934737	ENSG00000215030.5	RPL13P12	-9.28	9.13e-20	1.34e-13	-0.29	-0.28	Multiple myeloma (IgH translocation);	chr16:89493801	chr17:17383377~17384012:-
BRCA	trans	rs66887589	0.616	rs6843509	ENSG00000275858.1	RP11-291L22.8	9.28	9.14e-20	1.34e-13	0.32	0.28	Diastolic blood pressure;	chr4:119299041	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.562	rs58583086	ENSG00000275858.1	RP11-291L22.8	-9.28	9.18e-20	1.35e-13	-0.32	-0.28	Corneal astigmatism;	chr4:119635207	chr10:38450738~38451069:-
BRCA	trans	rs9425766	0.64	rs2295366	ENSG00000213331.4	RP11-713C19.2	9.28	9.22e-20	1.35e-13	0.34	0.28	Life satisfaction;	chr1:173856554	chr4:187970273~187971284:+
BRCA	trans	rs1816752	0.669	rs3783072	ENSG00000224976.2	PARP4P2	9.28	9.32e-20	1.37e-13	0.34	0.28	Obesity-related traits;	chr13:24493258	chr13:19349137~19407962:+
BRCA	trans	rs3849046	0.817	rs409273	ENSG00000226666.1	HSPA9P1	-9.28	9.36e-20	1.37e-13	-0.32	-0.28	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138578193	chr2:221961737~221963765:+
BRCA	trans	rs7937890	0.559	rs4369365	ENSG00000236360.2	RP11-334A14.2	9.28	9.37e-20	1.38e-13	0.36	0.28	Mitochondrial DNA levels;	chr11:14422969	chr1:52993201~52993702:-
BRCA	trans	rs7939886	0.92	rs1552151	ENSG00000134612.10	FOLH1B	-9.28	9.51e-20	1.4e-13	-0.52	-0.28	Myopia (pathological);	chr11:56013475	chr11:89639227~89698718:+
BRCA	trans	rs6732160	0.932	rs768851	ENSG00000236165.1	PRADC1P1	9.28	9.55e-20	1.4e-13	0.35	0.28	Intelligence (multi-trait analysis);	chr2:73151113	chr3:36976316~36976840:+
BRCA	trans	rs6732160	0.934	rs2421390	ENSG00000236165.1	PRADC1P1	9.28	9.55e-20	1.4e-13	0.35	0.28	Intelligence (multi-trait analysis);	chr2:73151975	chr3:36976316~36976840:+
BRCA	trans	rs1347297	0.666	rs4404314	ENSG00000269800.1	PLEKHA3P1	9.28	9.59e-20	1.41e-13	0.3	0.28	Alzheimer disease and age of onset;	chr2:178386113	chr19:41521043~41521989:-
BRCA	trans	rs7819412	0.875	rs6981523	ENSG00000253893.2	FAM85B	9.28	9.73e-20	1.43e-13	0.36	0.28	Triglycerides;	chr8:11204283	chr8:8167819~8226614:-
BRCA	trans	rs877636	1	rs2292239	ENSG00000243538.1	CTB-55B8.1	9.28	9.75e-20	1.43e-13	0.32	0.28	Cognitive function;	chr12:56088396	chr5:16902294~16902641:-
BRCA	trans	rs9467773	0.526	rs10946817	ENSG00000242375.1	RP11-498P14.3	-9.28	9.85e-20	1.45e-13	-0.38	-0.28	Intelligence (multi-trait analysis);	chr6:26363828	chr9:97195351~97197687:-
BRCA	trans	rs714543	0.811	rs13238404	ENSG00000267258.1	CTC-448F2.3	9.28	9.93e-20	1.46e-13	0.31	0.28	Plateletcrit;	chr7:44811812	chr19:29921182~29921653:+
BRCA	trans	rs1816752	0.609	rs4769361	ENSG00000224976.2	PARP4P2	9.27	1.01e-19	1.48e-13	0.33	0.28	Obesity-related traits;	chr13:24468834	chr13:19349137~19407962:+
BRCA	trans	rs1816752	0.609	rs4770693	ENSG00000224976.2	PARP4P2	9.27	1.01e-19	1.48e-13	0.33	0.28	Obesity-related traits;	chr13:24468835	chr13:19349137~19407962:+
BRCA	trans	rs7939886	0.92	rs11227145	ENSG00000134612.10	FOLH1B	9.27	1.01e-19	1.48e-13	0.52	0.28	Myopia (pathological);	chr11:56071802	chr11:89639227~89698718:+
BRCA	trans	rs7939886	0.92	rs11227180	ENSG00000134612.10	FOLH1B	9.27	1.01e-19	1.48e-13	0.52	0.28	Myopia (pathological);	chr11:56088135	chr11:89639227~89698718:+
BRCA	trans	rs3096299	0.658	rs4785679	ENSG00000215030.5	RPL13P12	-9.27	1.02e-19	1.49e-13	-0.28	-0.28	Multiple myeloma (IgH translocation);	chr16:89499705	chr17:17383377~17384012:-
BRCA	trans	rs864643	0.678	rs521226	ENSG00000183298.5	RP11-556K13.1	9.27	1.03e-19	1.51e-13	0.43	0.28	Attention deficit hyperactivity disorder;	chr3:39486099	chr1:101786340~101787219:-
BRCA	trans	rs864643	0.625	rs517376	ENSG00000183298.5	RP11-556K13.1	9.27	1.03e-19	1.51e-13	0.43	0.28	Attention deficit hyperactivity disorder;	chr3:39486571	chr1:101786340~101787219:-
BRCA	trans	rs1816752	0.646	rs7995190	ENSG00000224976.2	PARP4P2	9.27	1.03e-19	1.51e-13	0.33	0.28	Obesity-related traits;	chr13:24475709	chr13:19349137~19407962:+
BRCA	trans	rs7824557	0.652	rs12677504	ENSG00000253893.2	FAM85B	9.27	1.04e-19	1.52e-13	0.37	0.28	Retinal vascular caliber;	chr8:11275666	chr8:8167819~8226614:-
BRCA	trans	rs73108077	0.79	rs73104067	ENSG00000279352.1	RP11-411B10.7	9.27	1.05e-19	1.54e-13	0.58	0.28	Red blood cell density in sickle cell anemia;	chr20:31298693	chr18:14010054~14010917:+
BRCA	trans	rs73108077	0.736	rs73104088	ENSG00000279352.1	RP11-411B10.7	9.27	1.06e-19	1.55e-13	0.6	0.28	Red blood cell density in sickle cell anemia;	chr20:31311110	chr18:14010054~14010917:+
BRCA	trans	rs7833986	0.534	rs72653928	ENSG00000236862.1	RPS20P24	9.27	1.08e-19	1.58e-13	0.36	0.28	Height;	chr8:55995176	chr9:72655832~72656192:-
BRCA	trans	rs867371	1	rs13380319	ENSG00000235370.6	DNM1P51	-9.27	1.08e-19	1.58e-13	-0.31	-0.28	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82214526	chr15:84398316~84411701:-
BRCA	trans	rs2899832	0.733	rs73236913	ENSG00000229083.1	PSMA6P2	9.26	1.09e-19	1.59e-13	0.41	0.28	Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:35166290	chrX:12825840~12826833:+
BRCA	trans	rs2899832	0.733	rs80341278	ENSG00000229083.1	PSMA6P2	9.26	1.09e-19	1.59e-13	0.41	0.28	Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:35166354	chrX:12825840~12826833:+
BRCA	trans	rs867371	1	rs8037224	ENSG00000235370.6	DNM1P51	-9.26	1.09e-19	1.6e-13	-0.31	-0.28	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82172189	chr15:84398316~84411701:-
BRCA	trans	rs714543	0.585	rs9655458	ENSG00000267258.1	CTC-448F2.3	9.26	1.09e-19	1.6e-13	0.32	0.28	Plateletcrit;	chr7:44771386	chr19:29921182~29921653:+
BRCA	trans	rs12210905	0.925	rs12193820	ENSG00000242375.1	RP11-498P14.3	-9.26	1.1e-19	1.61e-13	-0.66	-0.28	Hip circumference adjusted for BMI;	chr6:27146032	chr9:97195351~97197687:-
BRCA	trans	rs12200782	0.929	rs72836467	ENSG00000242375.1	RP11-498P14.3	-9.26	1.12e-19	1.63e-13	-0.64	-0.28	Small cell lung carcinoma;	chr6:26353699	chr9:97195351~97197687:-
BRCA	trans	rs11098499	0.588	rs6534149	ENSG00000275858.1	RP11-291L22.8	-9.26	1.15e-19	1.68e-13	-0.32	-0.28	Corneal astigmatism;	chr4:119638137	chr10:38450738~38451069:-
BRCA	trans	rs7113874	0.797	rs4503528	ENSG00000266891.1	RP11-692N5.2	-9.26	1.15e-19	1.68e-13	-0.36	-0.28	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8642907	chr18:9734882~9735602:-
BRCA	trans	rs2336384	1	rs1810563	ENSG00000261819.1	RP11-680G24.4	-9.26	1.17e-19	1.72e-13	-0.37	-0.28	Platelet count;	chr1:11993973	chr16:14988259~14990160:-
BRCA	trans	rs66887589	0.616	rs10032299	ENSG00000275858.1	RP11-291L22.8	9.25	1.2e-19	1.75e-13	0.32	0.28	Diastolic blood pressure;	chr4:119285264	chr10:38450738~38451069:-
BRCA	trans	rs7824557	0.751	rs2099456	ENSG00000253893.2	FAM85B	-9.25	1.21e-19	1.77e-13	-0.36	-0.28	Retinal vascular caliber;	chr8:11269492	chr8:8167819~8226614:-
BRCA	trans	rs12210905	1	rs72843609	ENSG00000242375.1	RP11-498P14.3	-9.25	1.22e-19	1.78e-13	-0.66	-0.28	Hip circumference adjusted for BMI;	chr6:27158098	chr9:97195351~97197687:-
BRCA	trans	rs4276421	0.509	rs17293295	ENSG00000231752.4	EMBP1	9.25	1.22e-19	1.78e-13	0.39	0.28	P wave duration;	chr5:45509473	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.509	rs12656485	ENSG00000231752.4	EMBP1	9.25	1.22e-19	1.78e-13	0.39	0.28	P wave duration;	chr5:45513518	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.509	rs1483311	ENSG00000231752.4	EMBP1	9.25	1.22e-19	1.78e-13	0.39	0.28	P wave duration;	chr5:45514872	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.509	rs1483312	ENSG00000231752.4	EMBP1	9.25	1.22e-19	1.78e-13	0.39	0.28	P wave duration;	chr5:45514982	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.509	rs1483313	ENSG00000231752.4	EMBP1	9.25	1.22e-19	1.78e-13	0.39	0.28	P wave duration;	chr5:45515322	chr1:121519112~121571892:+
BRCA	trans	rs6424115	0.867	rs11588187	ENSG00000228217.1	AL390877.1	-9.25	1.22e-19	1.78e-13	-0.34	-0.28	Immature fraction of reticulocytes;	chr1:23818557	chr1:117778087~117778506:-
BRCA	trans	rs875971	0.545	rs11770063	ENSG00000164669.11	INTS4P1	-9.25	1.22e-19	1.79e-13	-0.39	-0.28	Aortic root size;	chr7:66318029	chr7:65141225~65234216:+
BRCA	trans	rs12210905	1	rs4636015	ENSG00000242375.1	RP11-498P14.3	-9.25	1.23e-19	1.8e-13	-0.66	-0.28	Hip circumference adjusted for BMI;	chr6:27129537	chr9:97195351~97197687:-
BRCA	trans	rs12210905	1	rs41269245	ENSG00000242375.1	RP11-498P14.3	-9.25	1.23e-19	1.8e-13	-0.66	-0.28	Hip circumference adjusted for BMI;	chr6:27132317	chr9:97195351~97197687:-
BRCA	trans	rs12210905	1	rs7756481	ENSG00000242375.1	RP11-498P14.3	-9.25	1.23e-19	1.8e-13	-0.66	-0.28	Hip circumference adjusted for BMI;	chr6:27147290	chr9:97195351~97197687:-
BRCA	trans	rs4276421	0.593	rs12659948	ENSG00000231752.4	EMBP1	-9.25	1.26e-19	1.84e-13	-0.38	-0.28	P wave duration;	chr5:45739534	chr1:121519112~121571892:+
BRCA	trans	rs7819412	0.74	rs7844536	ENSG00000253893.2	FAM85B	9.25	1.26e-19	1.84e-13	0.35	0.28	Triglycerides;	chr8:11176519	chr8:8167819~8226614:-
BRCA	trans	rs3849046	0.846	rs256007	ENSG00000226666.1	HSPA9P1	9.25	1.27e-19	1.85e-13	0.32	0.28	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138561900	chr2:221961737~221963765:+
BRCA	trans	rs867371	1	rs1846911	ENSG00000235370.6	DNM1P51	-9.24	1.3e-19	1.9e-13	-0.31	-0.28	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82176309	chr15:84398316~84411701:-
BRCA	trans	rs7939886	0.92	rs11227158	ENSG00000134612.10	FOLH1B	9.24	1.32e-19	1.93e-13	0.52	0.28	Myopia (pathological);	chr11:56076319	chr11:89639227~89698718:+
BRCA	trans	rs73108077	0.736	rs6058479	ENSG00000279352.1	RP11-411B10.7	9.24	1.33e-19	1.94e-13	0.47	0.28	Red blood cell density in sickle cell anemia;	chr20:31282419	chr18:14010054~14010917:+
BRCA	trans	rs853679	0.607	rs13194781	ENSG00000253570.1	RNF5P1	9.24	1.35e-19	1.97e-13	0.81	0.28	Depression;	chr6:27847861	chr8:38600661~38601200:-
BRCA	trans	rs916888	0.773	rs9896243	ENSG00000204650.12	CRHR1-IT1	9.24	1.37e-19	1.99e-13	0.41	0.28	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:45620328~45648216:+
BRCA	trans	rs877636	1	rs2292239	ENSG00000234354.3	RPS26P47	9.24	1.37e-19	2e-13	0.34	0.28	Cognitive function;	chr12:56088396	chr13:100539901~100540248:-
BRCA	trans	rs853679	0.607	rs67340775	ENSG00000253570.1	RNF5P1	9.24	1.37e-19	2e-13	0.78	0.28	Depression;	chr6:28336607	chr8:38600661~38601200:-
BRCA	trans	rs877636	0.74	rs705698	ENSG00000196933.5	RPS26P11	9.24	1.38e-19	2.02e-13	0.37	0.28	Cognitive function;	chr12:55990903	chrX:72044545~72044892:+
BRCA	trans	rs2899832	0.733	rs7144806	ENSG00000229083.1	PSMA6P2	9.24	1.39e-19	2.02e-13	0.41	0.28	Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:35168511	chrX:12825840~12826833:+
BRCA	trans	rs1816752	0.624	rs4770701	ENSG00000224976.2	PARP4P2	9.23	1.41e-19	2.06e-13	0.34	0.28	Obesity-related traits;	chr13:24508806	chr13:19349137~19407962:+
BRCA	trans	rs66887589	0.616	rs11731675	ENSG00000275858.1	RP11-291L22.8	9.23	1.42e-19	2.07e-13	0.31	0.28	Diastolic blood pressure;	chr4:119291359	chr10:38450738~38451069:-
BRCA	trans	rs1816752	0.716	rs9553330	ENSG00000224976.2	PARP4P2	9.23	1.45e-19	2.11e-13	0.33	0.27	Obesity-related traits;	chr13:24516018	chr13:19349137~19407962:+
BRCA	trans	rs7944735	0.817	rs7924699	ENSG00000134612.10	FOLH1B	9.23	1.45e-19	2.11e-13	0.39	0.27	Intraocular pressure;	chr11:47871568	chr11:89639227~89698718:+
BRCA	trans	rs2899832	0.733	rs74043851	ENSG00000229083.1	PSMA6P2	9.23	1.46e-19	2.13e-13	0.41	0.27	Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:35167317	chrX:12825840~12826833:+
BRCA	trans	rs7939886	0.92	rs12223248	ENSG00000134612.10	FOLH1B	9.23	1.51e-19	2.2e-13	0.52	0.27	Myopia (pathological);	chr11:56120157	chr11:89639227~89698718:+
BRCA	trans	rs66887589	0.616	rs11098498	ENSG00000275858.1	RP11-291L22.8	9.23	1.53e-19	2.23e-13	0.31	0.27	Diastolic blood pressure;	chr4:119265964	chr10:38450738~38451069:-
BRCA	trans	rs9467773	0.506	rs9393709	ENSG00000242375.1	RP11-498P14.3	-9.22	1.61e-19	2.34e-13	-0.38	-0.27	Intelligence (multi-trait analysis);	chr6:26364919	chr9:97195351~97197687:-
BRCA	trans	rs9467773	0.526	rs12199613	ENSG00000242375.1	RP11-498P14.3	-9.22	1.61e-19	2.34e-13	-0.38	-0.27	Intelligence (multi-trait analysis);	chr6:26366990	chr9:97195351~97197687:-
BRCA	trans	rs9467773	0.526	rs9688946	ENSG00000242375.1	RP11-498P14.3	-9.22	1.61e-19	2.34e-13	-0.38	-0.27	Intelligence (multi-trait analysis);	chr6:26367217	chr9:97195351~97197687:-
BRCA	trans	rs13014235	0.532	rs3731709	ENSG00000235105.1	RP11-329A14.1	9.22	1.62e-19	2.35e-13	0.33	0.27	Basal cell carcinoma;	chr2:201381311	chr1:48435967~48437223:+
BRCA	trans	rs2899832	0.733	rs59482644	ENSG00000229083.1	PSMA6P2	9.22	1.62e-19	2.36e-13	0.41	0.27	Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:35166821	chrX:12825840~12826833:+
BRCA	trans	rs66887589	0.616	rs11732621	ENSG00000275858.1	RP11-291L22.8	9.22	1.66e-19	2.41e-13	0.31	0.27	Diastolic blood pressure;	chr4:119291728	chr10:38450738~38451069:-
BRCA	trans	rs141670911	1	rs141670911	ENSG00000242375.1	RP11-498P14.3	-9.22	1.66e-19	2.41e-13	-0.68	-0.27	Small cell lung carcinoma;	chr6:26581030	chr9:97195351~97197687:-
BRCA	trans	rs1816752	0.646	rs750388	ENSG00000224976.2	PARP4P2	9.21	1.67e-19	2.43e-13	0.33	0.27	Obesity-related traits;	chr13:24461690	chr13:19349137~19407962:+
BRCA	trans	rs867371	1	rs7166570	ENSG00000235370.6	DNM1P51	-9.21	1.68e-19	2.44e-13	-0.31	-0.27	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82173880	chr15:84398316~84411701:-
BRCA	trans	rs867371	1	rs8041868	ENSG00000235370.6	DNM1P51	-9.21	1.68e-19	2.45e-13	-0.31	-0.27	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82179985	chr15:84398316~84411701:-
BRCA	trans	rs853679	0.769	rs17720293	ENSG00000253570.1	RNF5P1	9.21	1.68e-19	2.45e-13	0.69	0.27	Depression;	chr6:28246920	chr8:38600661~38601200:-
BRCA	trans	rs7939886	0.92	rs79521305	ENSG00000134612.10	FOLH1B	9.21	1.71e-19	2.48e-13	0.53	0.27	Myopia (pathological);	chr11:56043856	chr11:89639227~89698718:+
BRCA	trans	rs1816752	0.624	rs11149109	ENSG00000224976.2	PARP4P2	9.21	1.72e-19	2.5e-13	0.33	0.27	Obesity-related traits;	chr13:24477290	chr13:19349137~19407962:+
BRCA	trans	rs1816752	0.646	rs9511302	ENSG00000224976.2	PARP4P2	9.21	1.72e-19	2.5e-13	0.33	0.27	Obesity-related traits;	chr13:24477580	chr13:19349137~19407962:+
BRCA	trans	rs1816752	0.646	rs8002599	ENSG00000224976.2	PARP4P2	9.21	1.73e-19	2.51e-13	0.33	0.27	Obesity-related traits;	chr13:24478486	chr13:19349137~19407962:+
BRCA	trans	rs867371	1	rs2088858	ENSG00000235370.6	DNM1P51	-9.21	1.73e-19	2.52e-13	-0.31	-0.27	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82182408	chr15:84398316~84411701:-
BRCA	trans	rs867371	1	rs4778982	ENSG00000235370.6	DNM1P51	-9.21	1.73e-19	2.52e-13	-0.31	-0.27	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82182931	chr15:84398316~84411701:-
BRCA	trans	rs867371	1	rs2867579	ENSG00000235370.6	DNM1P51	-9.21	1.73e-19	2.52e-13	-0.31	-0.27	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82183043	chr15:84398316~84411701:-
BRCA	trans	rs867371	1	rs881308	ENSG00000235370.6	DNM1P51	-9.21	1.73e-19	2.52e-13	-0.31	-0.27	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82183456	chr15:84398316~84411701:-
BRCA	trans	rs714543	0.66	rs13224222	ENSG00000226038.5	PPIAP21	9.21	1.73e-19	2.52e-13	0.33	0.27	Plateletcrit;	chr7:44772739	chr20:43230760~43231260:+
BRCA	trans	rs6743068	0.521	rs2349078	ENSG00000235105.1	RP11-329A14.1	9.21	1.77e-19	2.57e-13	0.33	0.27	Lymphocyte percentage of white cells;	chr2:201369342	chr1:48435967~48437223:+
BRCA	trans	rs1816752	0.646	rs9634403	ENSG00000224976.2	PARP4P2	9.21	1.78e-19	2.59e-13	0.33	0.27	Obesity-related traits;	chr13:24468211	chr13:19349137~19407962:+
BRCA	trans	rs1816752	0.646	rs9581064	ENSG00000224976.2	PARP4P2	9.21	1.78e-19	2.59e-13	0.33	0.27	Obesity-related traits;	chr13:24468251	chr13:19349137~19407962:+
BRCA	trans	rs7113874	0.802	rs11042025	ENSG00000266891.1	RP11-692N5.2	-9.21	1.79e-19	2.6e-13	-0.35	-0.27	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8653928	chr18:9734882~9735602:-
BRCA	trans	rs1478897	0.804	rs9329246	ENSG00000253893.2	FAM85B	-9.21	1.8e-19	2.61e-13	-0.35	-0.27	Systemic lupus erythematosus;	chr8:11535371	chr8:8167819~8226614:-
BRCA	trans	rs867371	1	rs8041924	ENSG00000235370.6	DNM1P51	-9.2	1.82e-19	2.65e-13	-0.31	-0.27	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82181320	chr15:84398316~84411701:-
BRCA	trans	rs1816752	0.609	rs4770695	ENSG00000224976.2	PARP4P2	9.2	1.86e-19	2.7e-13	0.33	0.27	Obesity-related traits;	chr13:24468895	chr13:19349137~19407962:+
BRCA	trans	rs1816752	0.646	rs7337981	ENSG00000224976.2	PARP4P2	9.2	1.86e-19	2.7e-13	0.33	0.27	Obesity-related traits;	chr13:24469245	chr13:19349137~19407962:+
BRCA	trans	rs1816752	0.646	rs7328391	ENSG00000224976.2	PARP4P2	9.2	1.86e-19	2.7e-13	0.33	0.27	Obesity-related traits;	chr13:24470325	chr13:19349137~19407962:+
BRCA	trans	rs853679	0.556	rs34706883	ENSG00000253570.1	RNF5P1	9.2	1.87e-19	2.72e-13	0.8	0.27	Depression;	chr6:27837477	chr8:38600661~38601200:-
BRCA	trans	rs1816752	0.646	rs9511279	ENSG00000224976.2	PARP4P2	9.2	1.9e-19	2.75e-13	0.33	0.27	Obesity-related traits;	chr13:24463348	chr13:19349137~19407962:+
BRCA	trans	rs1816752	0.646	rs9511280	ENSG00000224976.2	PARP4P2	9.2	1.9e-19	2.75e-13	0.33	0.27	Obesity-related traits;	chr13:24463364	chr13:19349137~19407962:+
BRCA	trans	rs1816752	0.646	rs9511281	ENSG00000224976.2	PARP4P2	9.2	1.9e-19	2.75e-13	0.33	0.27	Obesity-related traits;	chr13:24463441	chr13:19349137~19407962:+
BRCA	trans	rs2736345	0.788	rs2618476	ENSG00000253893.2	FAM85B	-9.2	1.93e-19	2.8e-13	-0.37	-0.27	Systemic lupus erythematosus;Sjögren's syndrome;	chr8:11495032	chr8:8167819~8226614:-
BRCA	trans	rs867371	1	rs6495643	ENSG00000235370.6	DNM1P51	-9.2	1.96e-19	2.83e-13	-0.31	-0.27	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82186913	chr15:84398316~84411701:-
BRCA	trans	rs7939886	0.92	rs12417606	ENSG00000134612.10	FOLH1B	9.2	1.97e-19	2.85e-13	0.53	0.27	Myopia (pathological);	chr11:55983003	chr11:89639227~89698718:+
BRCA	trans	rs7939886	0.764	rs79601668	ENSG00000134612.10	FOLH1B	9.2	1.97e-19	2.85e-13	0.53	0.27	Myopia (pathological);	chr11:55986291	chr11:89639227~89698718:+
BRCA	trans	rs7939886	0.92	rs10501343	ENSG00000134612.10	FOLH1B	9.2	1.97e-19	2.85e-13	0.53	0.27	Myopia (pathological);	chr11:55992097	chr11:89639227~89698718:+
BRCA	trans	rs1816752	0.624	rs2096093	ENSG00000224976.2	PARP4P2	9.2	1.97e-19	2.86e-13	0.33	0.27	Obesity-related traits;	chr13:24472753	chr13:19349137~19407962:+
BRCA	trans	rs7746199	0.736	rs13202295	ENSG00000253570.1	RNF5P1	9.2	1.98e-19	2.86e-13	0.81	0.27	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27731058	chr8:38600661~38601200:-
BRCA	trans	rs3096299	0.632	rs8051537	ENSG00000215030.5	RPL13P12	-9.19	1.99e-19	2.88e-13	-0.28	-0.27	Multiple myeloma (IgH translocation);	chr16:89477976	chr17:17383377~17384012:-
BRCA	trans	rs1816752	0.646	rs750389	ENSG00000224976.2	PARP4P2	9.19	1.99e-19	2.89e-13	0.33	0.27	Obesity-related traits;	chr13:24461677	chr13:19349137~19407962:+
BRCA	trans	rs3849046	0.846	rs462783	ENSG00000226666.1	HSPA9P1	-9.19	2.01e-19	2.91e-13	-0.31	-0.27	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138536427	chr2:221961737~221963765:+
BRCA	trans	rs867371	0.896	rs6495647	ENSG00000235370.6	DNM1P51	-9.19	2.04e-19	2.95e-13	-0.31	-0.27	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82244708	chr15:84398316~84411701:-
BRCA	trans	rs11023332	0.617	rs1879888	ENSG00000236360.2	RP11-334A14.2	9.19	2.05e-19	2.96e-13	0.34	0.27	Vitamin D levels;Adiponectin levels;	chr11:14657701	chr1:52993201~52993702:-
BRCA	trans	rs867371	0.964	rs7169961	ENSG00000235370.6	DNM1P51	-9.19	2.08e-19	3.01e-13	-0.31	-0.27	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82186588	chr15:84398316~84411701:-
BRCA	trans	rs864643	1	rs634338	ENSG00000183298.5	RP11-556K13.1	9.19	2.09e-19	3.02e-13	0.42	0.27	Attention deficit hyperactivity disorder;	chr3:39522752	chr1:101786340~101787219:-
BRCA	trans	rs7939886	0.92	rs17150038	ENSG00000134612.10	FOLH1B	9.19	2.09e-19	3.03e-13	0.52	0.27	Myopia (pathological);	chr11:56095938	chr11:89639227~89698718:+
BRCA	trans	rs7939886	0.92	rs7112964	ENSG00000134612.10	FOLH1B	9.19	2.09e-19	3.03e-13	0.52	0.27	Myopia (pathological);	chr11:56098932	chr11:89639227~89698718:+
BRCA	trans	rs7824557	0.707	rs3808519	ENSG00000253893.2	FAM85B	-9.19	2.15e-19	3.1e-13	-0.36	-0.27	Retinal vascular caliber;	chr8:11285461	chr8:8167819~8226614:-
BRCA	trans	rs7769051	1	rs9493454	ENSG00000227615.1	RP11-864N7.2	-9.19	2.15e-19	3.1e-13	-0.39	-0.27	Type 2 diabetes nephropathy;	chr6:132823490	chr11:74745716~74746114:-
BRCA	trans	rs66887589	0.616	rs1052633	ENSG00000275858.1	RP11-291L22.8	9.19	2.16e-19	3.12e-13	0.31	0.27	Diastolic blood pressure;	chr4:119294159	chr10:38450738~38451069:-
BRCA	trans	rs6743068	0.541	rs7578456	ENSG00000235105.1	RP11-329A14.1	9.18	2.2e-19	3.18e-13	0.33	0.27	Lymphocyte percentage of white cells;	chr2:201370625	chr1:48435967~48437223:+
BRCA	trans	rs7833986	0.501	rs2976044	ENSG00000236862.1	RPS20P24	9.18	2.23e-19	3.23e-13	0.32	0.27	Height;	chr8:56074178	chr9:72655832~72656192:-
BRCA	trans	rs7113874	0.802	rs10769938	ENSG00000266891.1	RP11-692N5.2	9.18	2.24e-19	3.23e-13	0.35	0.27	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8650000	chr18:9734882~9735602:-
BRCA	trans	rs875971	0.502	rs11769702	ENSG00000164669.11	INTS4P1	-9.18	2.26e-19	3.26e-13	-0.39	-0.27	Aortic root size;	chr7:66255529	chr7:65141225~65234216:+
BRCA	trans	rs66887589	0.592	rs2175383	ENSG00000275858.1	RP11-291L22.8	9.18	2.26e-19	3.27e-13	0.31	0.27	Diastolic blood pressure;	chr4:119294681	chr10:38450738~38451069:-
BRCA	trans	rs1816752	0.608	rs4770690	ENSG00000224976.2	PARP4P2	9.18	2.26e-19	3.27e-13	0.33	0.27	Obesity-related traits;	chr13:24467049	chr13:19349137~19407962:+
BRCA	trans	rs11039798	1	rs11530232	ENSG00000134612.10	FOLH1B	9.18	2.29e-19	3.31e-13	0.55	0.27	Axial length;	chr11:48600824	chr11:89639227~89698718:+
BRCA	trans	rs7944735	0.817	rs6485784	ENSG00000134612.10	FOLH1B	9.18	2.32e-19	3.35e-13	0.38	0.27	Intraocular pressure;	chr11:47810708	chr11:89639227~89698718:+
BRCA	trans	rs7769051	1	rs7769051	ENSG00000227615.1	RP11-864N7.2	9.17	2.38e-19	3.43e-13	0.4	0.27	Type 2 diabetes nephropathy;	chr6:132825657	chr11:74745716~74746114:-
BRCA	trans	rs867371	0.82	rs7164362	ENSG00000235370.6	DNM1P51	-9.17	2.49e-19	3.6e-13	-0.31	-0.27	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82194401	chr15:84398316~84411701:-
BRCA	trans	rs867371	0.929	rs7176075	ENSG00000235370.6	DNM1P51	-9.17	2.51e-19	3.61e-13	-0.31	-0.27	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82178998	chr15:84398316~84411701:-
BRCA	trans	rs2069408	1	rs2069408	ENSG00000212994.5	RPS26P6	-9.17	2.52e-19	3.62e-13	-0.38	-0.27	Asthma;	chr12:55970537	chr8:100895771~100896118:+
BRCA	trans	rs7939886	0.92	rs11227212	ENSG00000134612.10	FOLH1B	9.16	2.6e-19	3.74e-13	0.52	0.27	Myopia (pathological);	chr11:56105858	chr11:89639227~89698718:+
BRCA	trans	rs7939886	0.92	rs7940563	ENSG00000134612.10	FOLH1B	9.16	2.6e-19	3.74e-13	0.52	0.27	Myopia (pathological);	chr11:56107657	chr11:89639227~89698718:+
BRCA	trans	rs1816752	0.624	rs9553312	ENSG00000224976.2	PARP4P2	9.16	2.6e-19	3.75e-13	0.33	0.27	Obesity-related traits;	chr13:24474055	chr13:19349137~19407962:+
BRCA	trans	rs7939886	0.92	rs7946368	ENSG00000134612.10	FOLH1B	9.16	2.61e-19	3.75e-13	0.53	0.27	Myopia (pathological);	chr11:56036743	chr11:89639227~89698718:+
BRCA	trans	rs1816752	0.646	rs2862902	ENSG00000224976.2	PARP4P2	9.16	2.63e-19	3.79e-13	0.33	0.27	Obesity-related traits;	chr13:24461965	chr13:19349137~19407962:+
BRCA	trans	rs1816752	0.646	rs734715	ENSG00000224976.2	PARP4P2	9.16	2.63e-19	3.79e-13	0.33	0.27	Obesity-related traits;	chr13:24462041	chr13:19349137~19407962:+
BRCA	trans	rs1816752	0.646	rs730030	ENSG00000224976.2	PARP4P2	9.16	2.63e-19	3.79e-13	0.33	0.27	Obesity-related traits;	chr13:24462509	chr13:19349137~19407962:+
BRCA	trans	rs1816752	0.609	rs7992667	ENSG00000224976.2	PARP4P2	9.16	2.63e-19	3.79e-13	0.33	0.27	Obesity-related traits;	chr13:24462821	chr13:19349137~19407962:+
BRCA	trans	rs1816752	0.609	rs7995958	ENSG00000224976.2	PARP4P2	9.16	2.63e-19	3.79e-13	0.33	0.27	Obesity-related traits;	chr13:24462895	chr13:19349137~19407962:+
BRCA	trans	rs1816752	0.609	rs8002741	ENSG00000224976.2	PARP4P2	9.16	2.63e-19	3.79e-13	0.33	0.27	Obesity-related traits;	chr13:24462918	chr13:19349137~19407962:+
BRCA	trans	rs1816752	0.609	rs7998198	ENSG00000224976.2	PARP4P2	9.16	2.63e-19	3.79e-13	0.33	0.27	Obesity-related traits;	chr13:24462979	chr13:19349137~19407962:+
BRCA	trans	rs1816752	0.609	rs7998203	ENSG00000224976.2	PARP4P2	9.16	2.63e-19	3.79e-13	0.33	0.27	Obesity-related traits;	chr13:24462989	chr13:19349137~19407962:+
BRCA	trans	rs1816752	0.646	rs7998600	ENSG00000224976.2	PARP4P2	9.16	2.63e-19	3.79e-13	0.33	0.27	Obesity-related traits;	chr13:24463222	chr13:19349137~19407962:+
BRCA	trans	rs1816752	0.624	rs9511282	ENSG00000224976.2	PARP4P2	9.16	2.63e-19	3.79e-13	0.33	0.27	Obesity-related traits;	chr13:24463597	chr13:19349137~19407962:+
BRCA	trans	rs1816752	0.583	rs9511283	ENSG00000224976.2	PARP4P2	9.16	2.63e-19	3.79e-13	0.33	0.27	Obesity-related traits;	chr13:24463656	chr13:19349137~19407962:+
BRCA	trans	rs1816752	0.646	rs9507351	ENSG00000224976.2	PARP4P2	9.16	2.63e-19	3.79e-13	0.33	0.27	Obesity-related traits;	chr13:24465118	chr13:19349137~19407962:+
BRCA	trans	rs1816752	0.646	rs4770688	ENSG00000224976.2	PARP4P2	9.16	2.63e-19	3.79e-13	0.33	0.27	Obesity-related traits;	chr13:24466007	chr13:19349137~19407962:+
BRCA	trans	rs1816752	0.646	rs4770689	ENSG00000224976.2	PARP4P2	9.16	2.63e-19	3.79e-13	0.33	0.27	Obesity-related traits;	chr13:24466008	chr13:19349137~19407962:+
BRCA	trans	rs1816752	0.646	rs12431171	ENSG00000224976.2	PARP4P2	9.16	2.63e-19	3.79e-13	0.33	0.27	Obesity-related traits;	chr13:24466380	chr13:19349137~19407962:+
BRCA	trans	rs1816752	0.646	rs12854523	ENSG00000224976.2	PARP4P2	9.16	2.63e-19	3.79e-13	0.33	0.27	Obesity-related traits;	chr13:24466460	chr13:19349137~19407962:+
BRCA	trans	rs1816752	0.646	rs9578740	ENSG00000224976.2	PARP4P2	9.16	2.63e-19	3.79e-13	0.33	0.27	Obesity-related traits;	chr13:24466692	chr13:19349137~19407962:+
BRCA	trans	rs1816752	0.631	rs4769358	ENSG00000224976.2	PARP4P2	9.16	2.63e-19	3.79e-13	0.33	0.27	Obesity-related traits;	chr13:24466940	chr13:19349137~19407962:+
BRCA	trans	rs1816752	0.608	rs4769359	ENSG00000224976.2	PARP4P2	9.16	2.63e-19	3.79e-13	0.33	0.27	Obesity-related traits;	chr13:24466966	chr13:19349137~19407962:+
BRCA	trans	rs1816752	0.608	rs4769360	ENSG00000224976.2	PARP4P2	9.16	2.63e-19	3.79e-13	0.33	0.27	Obesity-related traits;	chr13:24467016	chr13:19349137~19407962:+
BRCA	trans	rs1816752	0.608	rs9511290	ENSG00000224976.2	PARP4P2	9.16	2.63e-19	3.79e-13	0.33	0.27	Obesity-related traits;	chr13:24467189	chr13:19349137~19407962:+
BRCA	trans	rs1816752	0.646	rs9511291	ENSG00000224976.2	PARP4P2	9.16	2.67e-19	3.84e-13	0.33	0.27	Obesity-related traits;	chr13:24467609	chr13:19349137~19407962:+
BRCA	trans	rs1816752	0.646	rs9511292	ENSG00000224976.2	PARP4P2	9.16	2.67e-19	3.84e-13	0.33	0.27	Obesity-related traits;	chr13:24467623	chr13:19349137~19407962:+
BRCA	trans	rs1816752	0.646	rs9511293	ENSG00000224976.2	PARP4P2	9.16	2.67e-19	3.84e-13	0.33	0.27	Obesity-related traits;	chr13:24467747	chr13:19349137~19407962:+
BRCA	trans	rs1816752	0.646	rs9511294	ENSG00000224976.2	PARP4P2	9.16	2.67e-19	3.84e-13	0.33	0.27	Obesity-related traits;	chr13:24467773	chr13:19349137~19407962:+
BRCA	trans	rs9329221	0.506	rs6993610	ENSG00000253893.2	FAM85B	9.16	2.7e-19	3.88e-13	0.36	0.27	Neuroticism;	chr8:10473484	chr8:8167819~8226614:-
BRCA	trans	rs11098499	0.605	rs6833140	ENSG00000275858.1	RP11-291L22.8	9.16	2.7e-19	3.89e-13	0.32	0.27	Corneal astigmatism;	chr4:119345667	chr10:38450738~38451069:-
BRCA	trans	rs6964833	0.935	rs13238996	ENSG00000214544.6	GTF2IRD2P1	-9.16	2.72e-19	3.91e-13	-0.42	-0.27	Menarche (age at onset);	chr7:74655318	chr7:73242751~73280119:-
BRCA	trans	rs1816752	0.646	rs9511301	ENSG00000224976.2	PARP4P2	9.16	2.72e-19	3.91e-13	0.33	0.27	Obesity-related traits;	chr13:24477034	chr13:19349137~19407962:+
BRCA	trans	rs1816752	0.646	rs7332220	ENSG00000224976.2	PARP4P2	9.16	2.72e-19	3.91e-13	0.33	0.27	Obesity-related traits;	chr13:24477081	chr13:19349137~19407962:+
BRCA	trans	rs1816752	0.716	rs9553331	ENSG00000224976.2	PARP4P2	9.16	2.74e-19	3.94e-13	0.33	0.27	Obesity-related traits;	chr13:24516030	chr13:19349137~19407962:+
BRCA	trans	rs875971	0.545	rs6460281	ENSG00000164669.11	INTS4P1	-9.16	2.76e-19	3.97e-13	-0.38	-0.27	Aortic root size;	chr7:66216128	chr7:65141225~65234216:+
BRCA	trans	rs7662987	0.793	rs12106	ENSG00000228407.2	RP4-800M22.1	9.16	2.77e-19	3.98e-13	0.48	0.27	Smoking initiation;	chr4:99072199	chr1:52160261~52160600:-
BRCA	trans	rs9329221	0.736	rs12548025	ENSG00000253893.2	FAM85B	-9.16	2.77e-19	3.98e-13	-0.37	-0.27	Neuroticism;	chr8:10403411	chr8:8167819~8226614:-
BRCA	trans	rs7833986	0.501	rs72653917	ENSG00000236862.1	RPS20P24	9.16	2.78e-19	3.99e-13	0.36	0.27	Height;	chr8:55980285	chr9:72655832~72656192:-
BRCA	trans	rs1816752	0.646	rs7322329	ENSG00000224976.2	PARP4P2	9.16	2.78e-19	3.99e-13	0.33	0.27	Obesity-related traits;	chr13:24479193	chr13:19349137~19407962:+
BRCA	trans	rs11098499	0.526	rs10026625	ENSG00000275858.1	RP11-291L22.8	9.16	2.78e-19	3.99e-13	0.31	0.27	Corneal astigmatism;	chr4:119358981	chr10:38450738~38451069:-
BRCA	trans	rs7939886	0.92	rs11227222	ENSG00000134612.10	FOLH1B	-9.16	2.79e-19	4.01e-13	-0.52	-0.27	Myopia (pathological);	chr11:56108917	chr11:89639227~89698718:+
BRCA	trans	rs1816752	0.646	rs7319207	ENSG00000224976.2	PARP4P2	9.15	2.81e-19	4.03e-13	0.33	0.27	Obesity-related traits;	chr13:24473220	chr13:19349137~19407962:+
BRCA	trans	rs853679	0.546	rs35017208	ENSG00000253570.1	RNF5P1	9.15	2.81e-19	4.03e-13	0.8	0.27	Depression;	chr6:28377505	chr8:38600661~38601200:-
BRCA	trans	rs853679	0.546	rs36092177	ENSG00000253570.1	RNF5P1	9.15	2.84e-19	4.08e-13	0.8	0.27	Depression;	chr6:28390030	chr8:38600661~38601200:-
BRCA	trans	rs853679	0.546	rs2232429	ENSG00000253570.1	RNF5P1	9.15	2.84e-19	4.08e-13	0.8	0.27	Depression;	chr6:28391855	chr8:38600661~38601200:-
BRCA	trans	rs853679	0.546	rs2232426	ENSG00000253570.1	RNF5P1	9.15	2.84e-19	4.08e-13	0.8	0.27	Depression;	chr6:28392882	chr8:38600661~38601200:-
BRCA	trans	rs853679	0.546	rs2232423	ENSG00000253570.1	RNF5P1	9.15	2.84e-19	4.08e-13	0.8	0.27	Depression;	chr6:28398374	chr8:38600661~38601200:-
BRCA	trans	rs11039798	0.698	rs6485805	ENSG00000134612.10	FOLH1B	9.15	2.86e-19	4.11e-13	0.48	0.27	Axial length;	chr11:48080171	chr11:89639227~89698718:+
BRCA	trans	rs1190596	0.614	rs4322602	ENSG00000181359.5	HSP90AA6P	9.15	2.9e-19	4.16e-13	0.42	0.27	Behavioural disinhibition (generation interaction);	chr14:102299146	chr4:170581470~170605450:-
BRCA	trans	rs453301	0.624	rs330049	ENSG00000253893.2	FAM85B	-9.15	2.91e-19	4.17e-13	-0.33	-0.27	Joint mobility (Beighton score);	chr8:9229789	chr8:8167819~8226614:-
BRCA	trans	rs45509595	0.841	rs17751184	ENSG00000253570.1	RNF5P1	9.15	2.91e-19	4.18e-13	0.79	0.27	Breast cancer;	chr6:27807250	chr8:38600661~38601200:-
BRCA	trans	rs6732160	0.624	rs10865397	ENSG00000236165.1	PRADC1P1	9.15	2.93e-19	4.21e-13	0.34	0.27	Intelligence (multi-trait analysis);	chr2:73131164	chr3:36976316~36976840:+
BRCA	trans	rs7746199	0.736	rs35848276	ENSG00000253570.1	RNF5P1	9.15	2.94e-19	4.22e-13	0.81	0.27	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27553317	chr8:38600661~38601200:-
BRCA	trans	rs1391708	0.834	rs4612852	ENSG00000121089.4	NACA3P	-9.15	3.01e-19	4.32e-13	-0.47	-0.27	Airway wall thickness;	chr12:56902257	chr4:164943290~164943937:+
BRCA	trans	rs7939886	0.92	rs11231885	ENSG00000134612.10	FOLH1B	9.14	3.05e-19	4.37e-13	0.53	0.27	Myopia (pathological);	chr11:56036546	chr11:89639227~89698718:+
BRCA	trans	rs7939886	0.92	rs10792448	ENSG00000134612.10	FOLH1B	9.14	3.05e-19	4.37e-13	0.53	0.27	Myopia (pathological);	chr11:56037066	chr11:89639227~89698718:+
BRCA	trans	rs714543	0.811	rs13238404	ENSG00000214975.4	PPIAP29	9.14	3.18e-19	4.55e-13	0.3	0.27	Plateletcrit;	chr7:44811812	chr6:24976419~24976982:+
BRCA	trans	rs1816752	0.646	rs2862903	ENSG00000224976.2	PARP4P2	9.14	3.19e-19	4.57e-13	0.33	0.27	Obesity-related traits;	chr13:24473169	chr13:19349137~19407962:+
BRCA	trans	rs7939886	0.92	rs1905069	ENSG00000134612.10	FOLH1B	9.14	3.19e-19	4.58e-13	0.52	0.27	Myopia (pathological);	chr11:56119659	chr11:89639227~89698718:+
BRCA	trans	rs1816752	0.646	rs9511309	ENSG00000224976.2	PARP4P2	9.14	3.2e-19	4.59e-13	0.33	0.27	Obesity-related traits;	chr13:24515435	chr13:19349137~19407962:+
BRCA	trans	rs7824557	0.872	rs2572431	ENSG00000253893.2	FAM85B	9.14	3.21e-19	4.6e-13	0.35	0.27	Retinal vascular caliber;	chr8:11247568	chr8:8167819~8226614:-
BRCA	trans	rs9329221	0.698	rs12547997	ENSG00000253893.2	FAM85B	-9.14	3.25e-19	4.65e-13	-0.35	-0.27	Neuroticism;	chr8:10403327	chr8:8167819~8226614:-
BRCA	trans	rs13014235	0.905	rs6730666	ENSG00000235105.1	RP11-329A14.1	9.14	3.25e-19	4.66e-13	0.33	0.27	Basal cell carcinoma;	chr2:201374076	chr1:48435967~48437223:+
BRCA	trans	rs7824557	0.707	rs3808518	ENSG00000253893.2	FAM85B	9.13	3.36e-19	4.81e-13	0.36	0.27	Retinal vascular caliber;	chr8:11285763	chr8:8167819~8226614:-
BRCA	trans	rs7939886	0.92	rs1482009	ENSG00000134612.10	FOLH1B	9.13	3.37e-19	4.82e-13	0.52	0.27	Myopia (pathological);	chr11:56117214	chr11:89639227~89698718:+
BRCA	trans	rs941207	0.542	rs6581102	ENSG00000228224.3	NACAP1	-9.13	3.39e-19	4.84e-13	-0.33	-0.27	Platelet count;	chr12:56790632	chr8:101361794~101372707:+
BRCA	trans	rs941207	0.542	rs6581103	ENSG00000228224.3	NACAP1	-9.13	3.39e-19	4.84e-13	-0.33	-0.27	Platelet count;	chr12:56790641	chr8:101361794~101372707:+
BRCA	trans	rs7944735	0.817	rs6485774	ENSG00000134612.10	FOLH1B	9.13	3.39e-19	4.86e-13	0.38	0.27	Intraocular pressure;	chr11:47751674	chr11:89639227~89698718:+
BRCA	trans	rs11951515	0.508	rs11958046	ENSG00000174977.8	AC026271.5	-9.13	3.45e-19	4.94e-13	-0.32	-0.27	Metabolite levels  (X-11787);	chr5:43583287	chr17:18650195~18651542:+
BRCA	trans	rs853679	0.556	rs45509595	ENSG00000253570.1	RNF5P1	9.13	3.46e-19	4.95e-13	0.82	0.27	Depression;	chr6:27873148	chr8:38600661~38601200:-
BRCA	trans	rs1816752	0.646	rs4480642	ENSG00000224976.2	PARP4P2	9.13	3.47e-19	4.96e-13	0.33	0.27	Obesity-related traits;	chr13:24471358	chr13:19349137~19407962:+
BRCA	trans	rs1816752	0.646	rs9551108	ENSG00000224976.2	PARP4P2	9.13	3.47e-19	4.96e-13	0.33	0.27	Obesity-related traits;	chr13:24471434	chr13:19349137~19407962:+
BRCA	trans	rs1816752	0.603	rs4238178	ENSG00000224976.2	PARP4P2	9.13	3.47e-19	4.96e-13	0.33	0.27	Obesity-related traits;	chr13:24472344	chr13:19349137~19407962:+
BRCA	trans	rs1347297	0.526	rs890579	ENSG00000269800.1	PLEKHA3P1	9.13	3.51e-19	5.02e-13	0.28	0.27	Alzheimer disease and age of onset;	chr2:178398560	chr19:41521043~41521989:-
BRCA	trans	rs1816752	0.646	rs9511296	ENSG00000224976.2	PARP4P2	9.13	3.56e-19	5.09e-13	0.33	0.27	Obesity-related traits;	chr13:24467962	chr13:19349137~19407962:+
BRCA	trans	rs1816752	0.646	rs9634401	ENSG00000224976.2	PARP4P2	9.13	3.56e-19	5.09e-13	0.33	0.27	Obesity-related traits;	chr13:24468072	chr13:19349137~19407962:+
BRCA	trans	rs1816752	0.624	rs9634402	ENSG00000224976.2	PARP4P2	9.13	3.56e-19	5.09e-13	0.33	0.27	Obesity-related traits;	chr13:24468119	chr13:19349137~19407962:+
BRCA	trans	rs941207	0.542	rs11171983	ENSG00000228224.3	NACAP1	-9.13	3.61e-19	5.15e-13	-0.33	-0.27	Platelet count;	chr12:56814461	chr8:101361794~101372707:+
BRCA	trans	rs6964833	1	rs36044436	ENSG00000214544.6	GTF2IRD2P1	-9.13	3.62e-19	5.17e-13	-0.41	-0.27	Menarche (age at onset);	chr7:74675495	chr7:73242751~73280119:-
BRCA	trans	rs7939886	0.92	rs11534518	ENSG00000134612.10	FOLH1B	9.12	3.62e-19	5.17e-13	0.52	0.27	Myopia (pathological);	chr11:56040670	chr11:89639227~89698718:+
BRCA	trans	rs7939886	0.844	rs17150088	ENSG00000134612.10	FOLH1B	9.12	3.63e-19	5.19e-13	0.52	0.27	Myopia (pathological);	chr11:56127386	chr11:89639227~89698718:+
BRCA	trans	rs7939886	0.92	rs11231794	ENSG00000134612.10	FOLH1B	9.12	3.64e-19	5.2e-13	0.53	0.27	Myopia (pathological);	chr11:55998300	chr11:89639227~89698718:+
BRCA	trans	rs7939886	0.92	rs12224086	ENSG00000134612.10	FOLH1B	9.12	3.64e-19	5.2e-13	0.53	0.27	Myopia (pathological);	chr11:56030783	chr11:89639227~89698718:+
BRCA	trans	rs8010715	0.848	rs8009511	ENSG00000238000.1	RP11-274E7.2	9.12	3.74e-19	5.34e-13	0.3	0.27	IgG glycosylation;	chr14:24124771	chr5:98213402~98214121:+
BRCA	trans	rs8010715	0.804	rs1134334	ENSG00000238000.1	RP11-274E7.2	9.12	3.74e-19	5.34e-13	0.3	0.27	IgG glycosylation;	chr14:24124905	chr5:98213402~98214121:+
BRCA	trans	rs13014235	0.532	rs13029007	ENSG00000235105.1	RP11-329A14.1	9.12	3.77e-19	5.38e-13	0.33	0.27	Basal cell carcinoma;	chr2:201400154	chr1:48435967~48437223:+
BRCA	trans	rs7939886	0.92	rs11231821	ENSG00000134612.10	FOLH1B	9.12	3.79e-19	5.41e-13	0.53	0.27	Myopia (pathological);	chr11:56009576	chr11:89639227~89698718:+
BRCA	trans	rs3806843	0.9	rs2563279	ENSG00000231043.3	AC007238.1	9.11	4.02e-19	5.74e-13	0.32	0.27	Depressive symptoms (multi-trait analysis);	chr5:140751950	chr2:58460292~58462032:-
BRCA	trans	rs867371	1	rs1501372	ENSG00000235370.6	DNM1P51	-9.11	4.03e-19	5.74e-13	-0.31	-0.27	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82176114	chr15:84398316~84411701:-
BRCA	trans	rs875971	0.545	rs10261710	ENSG00000164669.11	INTS4P1	-9.11	4.05e-19	5.77e-13	-0.39	-0.27	Aortic root size;	chr7:66249202	chr7:65141225~65234216:+
BRCA	trans	rs6743068	0.541	rs10206231	ENSG00000235105.1	RP11-329A14.1	9.11	4.06e-19	5.78e-13	0.33	0.27	Lymphocyte percentage of white cells;	chr2:201364502	chr1:48435967~48437223:+
BRCA	trans	rs3096299	0.658	rs34590044	ENSG00000215030.5	RPL13P12	-9.11	4.13e-19	5.88e-13	-0.28	-0.27	Multiple myeloma (IgH translocation);	chr16:89476749	chr17:17383377~17384012:-
BRCA	trans	rs6743068	0.522	rs6757783	ENSG00000235105.1	RP11-329A14.1	9.11	4.14e-19	5.9e-13	0.33	0.27	Lymphocyte percentage of white cells;	chr2:201335101	chr1:48435967~48437223:+
BRCA	trans	rs853679	0.546	rs36116761	ENSG00000253570.1	RNF5P1	9.1	4.31e-19	6.14e-13	0.8	0.27	Depression;	chr6:27850704	chr8:38600661~38601200:-
BRCA	trans	rs853679	0.546	rs34194357	ENSG00000253570.1	RNF5P1	9.1	4.31e-19	6.14e-13	0.8	0.27	Depression;	chr6:27850757	chr8:38600661~38601200:-
BRCA	trans	rs7032940	0.677	rs1331310	ENSG00000228236.2	TXNP5	9.1	4.31e-19	6.14e-13	0.31	0.27	Height;	chr9:110179601	chr2:149068596~149068910:-
BRCA	trans	rs13014235	0.905	rs6435082	ENSG00000235105.1	RP11-329A14.1	9.1	4.35e-19	6.19e-13	0.33	0.27	Basal cell carcinoma;	chr2:201372558	chr1:48435967~48437223:+
BRCA	trans	rs66887589	0.592	rs62320740	ENSG00000275858.1	RP11-291L22.8	9.1	4.37e-19	6.23e-13	0.31	0.27	Diastolic blood pressure;	chr4:119358331	chr10:38450738~38451069:-
BRCA	trans	rs66887589	0.592	rs28580295	ENSG00000275858.1	RP11-291L22.8	9.1	4.42e-19	6.29e-13	0.3	0.27	Diastolic blood pressure;	chr4:119357718	chr10:38450738~38451069:-
BRCA	trans	rs875971	0.545	rs7787063	ENSG00000164669.11	INTS4P1	-9.1	4.43e-19	6.31e-13	-0.38	-0.27	Aortic root size;	chr7:66164012	chr7:65141225~65234216:+
BRCA	trans	rs875971	0.545	rs12673308	ENSG00000164669.11	INTS4P1	-9.1	4.43e-19	6.31e-13	-0.38	-0.27	Aortic root size;	chr7:66166374	chr7:65141225~65234216:+
BRCA	trans	rs3806843	0.868	rs2531342	ENSG00000231043.3	AC007238.1	9.1	4.46e-19	6.35e-13	0.32	0.27	Depressive symptoms (multi-trait analysis);	chr5:140751027	chr2:58460292~58462032:-
BRCA	trans	rs7746199	0.736	rs10484399	ENSG00000253570.1	RNF5P1	9.1	4.5e-19	6.4e-13	0.75	0.27	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27566749	chr8:38600661~38601200:-
BRCA	trans	rs13014235	0.532	rs11681592	ENSG00000235105.1	RP11-329A14.1	9.1	4.58e-19	6.51e-13	0.33	0.27	Basal cell carcinoma;	chr2:201399178	chr1:48435967~48437223:+
BRCA	trans	rs3942852	0.915	rs905477	ENSG00000134612.10	FOLH1B	-9.1	4.6e-19	6.54e-13	-0.37	-0.27	Acute lymphoblastic leukemia (childhood);	chr11:48127054	chr11:89639227~89698718:+
BRCA	trans	rs875971	0.545	rs2420456	ENSG00000164669.11	INTS4P1	-9.1	4.62e-19	6.57e-13	-0.38	-0.27	Aortic root size;	chr7:66280619	chr7:65141225~65234216:+
BRCA	trans	rs877636	0.74	rs772920	ENSG00000196656.7	AC004057.1	9.1	4.64e-19	6.6e-13	0.35	0.27	Cognitive function;	chr12:55996580	chr4:113214046~113217170:-
BRCA	trans	rs9467773	0.609	rs12663780	ENSG00000242375.1	RP11-498P14.3	-9.09	4.69e-19	6.66e-13	-0.39	-0.27	Intelligence (multi-trait analysis);	chr6:26397345	chr9:97195351~97197687:-
BRCA	trans	rs3808502	0.525	rs9650661	ENSG00000253893.2	FAM85B	9.09	4.72e-19	6.71e-13	0.35	0.27	Neuroticism;	chr8:11569624	chr8:8167819~8226614:-
BRCA	trans	rs7930295	1	rs7930295	ENSG00000236257.1	EI24P2	9.09	4.74e-19	6.73e-13	0.44	0.27	Schizophrenia;	chr11:125443703	chr1:158454198~158455273:+
BRCA	trans	rs875971	0.545	rs10950025	ENSG00000164669.11	INTS4P1	-9.09	4.84e-19	6.88e-13	-0.38	-0.27	Aortic root size;	chr7:66158946	chr7:65141225~65234216:+
BRCA	trans	rs875971	0.52	rs12666485	ENSG00000164669.11	INTS4P1	-9.09	4.84e-19	6.88e-13	-0.38	-0.27	Aortic root size;	chr7:66160135	chr7:65141225~65234216:+
BRCA	trans	rs875971	0.545	rs67688847	ENSG00000164669.11	INTS4P1	-9.09	4.84e-19	6.88e-13	-0.38	-0.27	Aortic root size;	chr7:66161064	chr7:65141225~65234216:+
BRCA	trans	rs9467773	0.572	rs2076029	ENSG00000242375.1	RP11-498P14.3	-9.09	4.85e-19	6.9e-13	-0.38	-0.27	Intelligence (multi-trait analysis);	chr6:26390602	chr9:97195351~97197687:-
BRCA	trans	rs73108077	0.736	rs73105954	ENSG00000279352.1	RP11-411B10.7	9.09	4.92e-19	6.99e-13	0.57	0.27	Red blood cell density in sickle cell anemia;	chr20:31355903	chr18:14010054~14010917:+
BRCA	trans	rs7939886	0.92	rs77391761	ENSG00000134612.10	FOLH1B	9.09	4.96e-19	7.04e-13	0.52	0.27	Myopia (pathological);	chr11:56047420	chr11:89639227~89698718:+
BRCA	trans	rs875971	0.545	rs316306	ENSG00000164669.11	INTS4P1	9.09	5.01e-19	7.11e-13	0.37	0.27	Aortic root size;	chr7:66153687	chr7:65141225~65234216:+
BRCA	trans	rs875971	0.545	rs67775320	ENSG00000164669.11	INTS4P1	-9.09	5.03e-19	7.15e-13	-0.38	-0.27	Aortic root size;	chr7:66193792	chr7:65141225~65234216:+
BRCA	trans	rs6940638	1	rs6940638	ENSG00000242375.1	RP11-498P14.3	-9.09	5.05e-19	7.17e-13	-0.45	-0.27	Intelligence (multi-trait analysis);	chr6:27078471	chr9:97195351~97197687:-
BRCA	trans	rs875971	0.545	rs67397473	ENSG00000164669.11	INTS4P1	-9.09	5.05e-19	7.17e-13	-0.37	-0.27	Aortic root size;	chr7:66168318	chr7:65141225~65234216:+
BRCA	trans	rs6743068	0.541	rs6435081	ENSG00000235105.1	RP11-329A14.1	9.09	5.06e-19	7.18e-13	0.32	0.27	Lymphocyte percentage of white cells;	chr2:201355900	chr1:48435967~48437223:+
BRCA	trans	rs864643	0.891	rs1068953	ENSG00000183298.5	RP11-556K13.1	9.09	5.09e-19	7.22e-13	0.43	0.27	Attention deficit hyperactivity disorder;	chr3:39515070	chr1:101786340~101787219:-
BRCA	trans	rs7113874	0.802	rs4272783	ENSG00000266891.1	RP11-692N5.2	9.08	5.1e-19	7.24e-13	0.35	0.27	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8663846	chr18:9734882~9735602:-
BRCA	trans	rs1816752	0.624	rs7330766	ENSG00000224976.2	PARP4P2	9.08	5.13e-19	7.28e-13	0.33	0.27	Obesity-related traits;	chr13:24495579	chr13:19349137~19407962:+
BRCA	trans	rs1816752	0.603	rs7984094	ENSG00000224976.2	PARP4P2	9.08	5.13e-19	7.28e-13	0.33	0.27	Obesity-related traits;	chr13:24496212	chr13:19349137~19407962:+
BRCA	trans	rs877636	1	rs877636	ENSG00000244604.1	RP11-713H12.1	-9.08	5.18e-19	7.35e-13	-0.31	-0.27	Cognitive function;	chr12:56086799	chr17:8561230~8561576:+
BRCA	trans	rs7927370	1	rs17580966	ENSG00000134612.10	FOLH1B	-9.08	5.26e-19	7.47e-13	-0.64	-0.27	Systemic lupus erythematosus;	chr11:55545074	chr11:89639227~89698718:+
BRCA	trans	rs875971	0.545	rs2279757	ENSG00000164669.11	INTS4P1	-9.08	5.4e-19	7.65e-13	-0.39	-0.27	Aortic root size;	chr7:66363676	chr7:65141225~65234216:+
BRCA	trans	rs875971	0.545	rs11766183	ENSG00000164669.11	INTS4P1	-9.08	5.4e-19	7.65e-13	-0.39	-0.27	Aortic root size;	chr7:66374173	chr7:65141225~65234216:+
BRCA	trans	rs875971	0.545	rs1065265	ENSG00000164669.11	INTS4P1	-9.08	5.4e-19	7.65e-13	-0.39	-0.27	Aortic root size;	chr7:66376216	chr7:65141225~65234216:+
BRCA	trans	rs6743068	0.521	rs9288318	ENSG00000235105.1	RP11-329A14.1	9.08	5.41e-19	7.66e-13	0.33	0.27	Lymphocyte percentage of white cells;	chr2:201331340	chr1:48435967~48437223:+
BRCA	trans	rs7824557	0.701	rs4568582	ENSG00000253893.2	FAM85B	-9.08	5.42e-19	7.68e-13	-0.38	-0.27	Retinal vascular caliber;	chr8:11302986	chr8:8167819~8226614:-
BRCA	trans	rs6743068	0.541	rs10178982	ENSG00000235105.1	RP11-329A14.1	9.08	5.48e-19	7.76e-13	0.33	0.27	Lymphocyte percentage of white cells;	chr2:201362917	chr1:48435967~48437223:+
BRCA	trans	rs1816752	0.716	rs1441058	ENSG00000224976.2	PARP4P2	9.08	5.49e-19	7.78e-13	0.33	0.27	Obesity-related traits;	chr13:24516275	chr13:19349137~19407962:+
BRCA	trans	rs7939886	0.92	rs12223014	ENSG00000134612.10	FOLH1B	9.07	5.6e-19	7.93e-13	0.52	0.27	Myopia (pathological);	chr11:56110814	chr11:89639227~89698718:+
BRCA	trans	rs7833986	0.501	rs2668007	ENSG00000236862.1	RPS20P24	9.07	5.63e-19	7.97e-13	0.36	0.27	Height;	chr8:56031552	chr9:72655832~72656192:-
BRCA	trans	rs7939886	0.92	rs11227273	ENSG00000134612.10	FOLH1B	9.07	5.71e-19	8.09e-13	0.52	0.27	Myopia (pathological);	chr11:56125558	chr11:89639227~89698718:+
BRCA	trans	rs6743068	0.521	rs6705845	ENSG00000235105.1	RP11-329A14.1	9.07	5.76e-19	8.16e-13	0.31	0.27	Lymphocyte percentage of white cells;	chr2:201354316	chr1:48435967~48437223:+
BRCA	trans	rs864643	1	rs1707968	ENSG00000183298.5	RP11-556K13.1	9.07	5.77e-19	8.16e-13	0.43	0.27	Attention deficit hyperactivity disorder;	chr3:39506914	chr1:101786340~101787219:-
BRCA	trans	rs875971	0.545	rs7811204	ENSG00000164669.11	INTS4P1	-9.07	5.77e-19	8.17e-13	-0.39	-0.27	Aortic root size;	chr7:66387213	chr7:65141225~65234216:+
BRCA	trans	rs546131	0.928	rs572690	ENSG00000225531.1	RP11-196I18.3	9.06	6.21e-19	8.78e-13	0.38	0.27	Lung disease severity in cystic fibrosis;	chr11:34812067	chr9:107116829~107117557:+
BRCA	trans	rs6743068	0.541	rs13014235	ENSG00000235105.1	RP11-329A14.1	9.06	6.34e-19	8.96e-13	0.32	0.27	Lymphocyte percentage of white cells;	chr2:201350769	chr1:48435967~48437223:+
BRCA	trans	rs875971	0.545	rs10950027	ENSG00000164669.11	INTS4P1	-9.06	6.34e-19	8.96e-13	-0.37	-0.27	Aortic root size;	chr7:66169164	chr7:65141225~65234216:+
BRCA	trans	rs7746199	0.673	rs72847313	ENSG00000253570.1	RNF5P1	9.06	6.38e-19	9.01e-13	0.79	0.27	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27762303	chr8:38600661~38601200:-
BRCA	trans	rs7746199	0.611	rs17750747	ENSG00000253570.1	RNF5P1	9.06	6.38e-19	9.01e-13	0.79	0.27	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27762555	chr8:38600661~38601200:-
BRCA	trans	rs12210905	1	rs72843629	ENSG00000242375.1	RP11-498P14.3	-9.06	6.42e-19	9.08e-13	-0.64	-0.27	Hip circumference adjusted for BMI;	chr6:27207436	chr9:97195351~97197687:-
BRCA	trans	rs864643	1	rs1768252	ENSG00000183298.5	RP11-556K13.1	9.05	6.57e-19	9.28e-13	0.44	0.27	Attention deficit hyperactivity disorder;	chr3:39506768	chr1:101786340~101787219:-
BRCA	trans	rs7939886	0.688	rs11227290	ENSG00000134612.10	FOLH1B	9.05	6.63e-19	9.37e-13	0.51	0.27	Myopia (pathological);	chr11:56129101	chr11:89639227~89698718:+
BRCA	trans	rs7929679	0.521	rs10836304	ENSG00000225531.1	RP11-196I18.3	-9.05	6.65e-19	9.39e-13	-0.35	-0.27	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;	chr11:34772477	chr9:107116829~107117557:+
BRCA	trans	rs6743068	0.541	rs6737085	ENSG00000235105.1	RP11-329A14.1	9.05	6.71e-19	9.48e-13	0.32	0.27	Lymphocyte percentage of white cells;	chr2:201356718	chr1:48435967~48437223:+
BRCA	trans	rs877636	0.702	rs773112	ENSG00000234354.3	RPS26P47	9.05	6.91e-19	9.75e-13	0.37	0.27	Cognitive function;	chr12:55982097	chr13:100539901~100540248:-
BRCA	trans	rs875971	0.545	rs2460427	ENSG00000164669.11	INTS4P1	9.05	6.91e-19	9.76e-13	0.37	0.27	Aortic root size;	chr7:66154218	chr7:65141225~65234216:+
BRCA	trans	rs864643	0.678	rs1609647	ENSG00000183298.5	RP11-556K13.1	9.05	7.05e-19	9.94e-13	0.42	0.27	Attention deficit hyperactivity disorder;	chr3:39491580	chr1:101786340~101787219:-
BRCA	trans	rs7824557	0.836	rs1435278	ENSG00000253893.2	FAM85B	9.05	7.06e-19	9.96e-13	0.37	0.27	Retinal vascular caliber;	chr8:11265520	chr8:8167819~8226614:-
BRCA	trans	rs2898290	0.592	rs2736342	ENSG00000253893.2	FAM85B	9.05	7.09e-19	1e-12	0.33	0.27	Systolic blood pressure;	chr8:11489780	chr8:8167819~8226614:-
BRCA	trans	rs875971	0.545	rs73376401	ENSG00000164669.11	INTS4P1	-9.05	7.15e-19	1.01e-12	-0.37	-0.27	Aortic root size;	chr7:66174841	chr7:65141225~65234216:+
BRCA	trans	rs11023332	0.617	rs1451678	ENSG00000236360.2	RP11-334A14.2	9.05	7.15e-19	1.01e-12	0.33	0.27	Vitamin D levels;Adiponectin levels;	chr11:14760075	chr1:52993201~52993702:-
BRCA	trans	rs714543	0.875	rs35585318	ENSG00000226038.5	PPIAP21	-9.04	7.18e-19	1.01e-12	-0.34	-0.27	Plateletcrit;	chr7:44852220	chr20:43230760~43231260:+
BRCA	trans	rs6743068	0.541	rs6761514	ENSG00000235105.1	RP11-329A14.1	9.04	7.2e-19	1.02e-12	0.32	0.27	Lymphocyte percentage of white cells;	chr2:201362826	chr1:48435967~48437223:+
BRCA	trans	rs877636	0.702	rs773111	ENSG00000234354.3	RPS26P47	9.04	7.27e-19	1.02e-12	0.37	0.27	Cognitive function;	chr12:55981956	chr13:100539901~100540248:-
BRCA	trans	rs875971	0.545	rs11767262	ENSG00000164669.11	INTS4P1	-9.04	7.32e-19	1.03e-12	-0.38	-0.27	Aortic root size;	chr7:66302237	chr7:65141225~65234216:+
BRCA	trans	rs12210905	1	rs72843608	ENSG00000242375.1	RP11-498P14.3	-9.04	7.52e-19	1.06e-12	-0.65	-0.27	Hip circumference adjusted for BMI;	chr6:27154971	chr9:97195351~97197687:-
BRCA	trans	rs864643	1	rs1707969	ENSG00000183298.5	RP11-556K13.1	9.04	7.54e-19	1.06e-12	0.43	0.27	Attention deficit hyperactivity disorder;	chr3:39506998	chr1:101786340~101787219:-
BRCA	trans	rs864643	1	rs1707973	ENSG00000183298.5	RP11-556K13.1	9.04	7.56e-19	1.06e-12	0.42	0.27	Attention deficit hyperactivity disorder;	chr3:39507275	chr1:101786340~101787219:-
BRCA	trans	rs7824557	1	rs7824557	ENSG00000253893.2	FAM85B	9.04	7.61e-19	1.07e-12	0.36	0.27	Retinal vascular caliber;	chr8:11246602	chr8:8167819~8226614:-
BRCA	trans	rs4276421	0.53	rs62371973	ENSG00000231752.4	EMBP1	9.04	7.65e-19	1.08e-12	0.42	0.27	P wave duration;	chr5:45907824	chr1:121519112~121571892:+
BRCA	trans	rs9467773	0.529	rs7356988	ENSG00000242375.1	RP11-498P14.3	-9.04	7.73e-19	1.09e-12	-0.38	-0.27	Intelligence (multi-trait analysis);	chr6:26396499	chr9:97195351~97197687:-
BRCA	trans	rs875971	0.545	rs7810213	ENSG00000164669.11	INTS4P1	-9.04	7.75e-19	1.09e-12	-0.38	-0.27	Aortic root size;	chr7:66481592	chr7:65141225~65234216:+
BRCA	trans	rs7824557	0.806	rs10503418	ENSG00000253893.2	FAM85B	9.03	7.88e-19	1.11e-12	0.36	0.27	Retinal vascular caliber;	chr8:11261474	chr8:8167819~8226614:-
BRCA	trans	rs7927370	1	rs1216215	ENSG00000134612.10	FOLH1B	-9.03	7.93e-19	1.12e-12	-0.61	-0.27	Systemic lupus erythematosus;	chr11:55417028	chr11:89639227~89698718:+
BRCA	trans	rs7939886	0.92	rs12226441	ENSG00000134612.10	FOLH1B	9.03	8.2e-19	1.15e-12	0.51	0.27	Myopia (pathological);	chr11:56100346	chr11:89639227~89698718:+
BRCA	trans	rs7113874	0.659	rs57757082	ENSG00000266891.1	RP11-692N5.2	9.03	8.21e-19	1.15e-12	0.36	0.27	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8507106	chr18:9734882~9735602:-
BRCA	trans	rs1391708	0.834	rs34263825	ENSG00000121089.4	NACA3P	-9.03	8.41e-19	1.18e-12	-0.42	-0.27	Airway wall thickness;	chr12:56902465	chr4:164943290~164943937:+
BRCA	trans	rs7824557	0.836	rs765731	ENSG00000253893.2	FAM85B	9.03	8.45e-19	1.19e-12	0.37	0.27	Retinal vascular caliber;	chr8:11263989	chr8:8167819~8226614:-
BRCA	trans	rs7939886	0.92	rs17149859	ENSG00000134612.10	FOLH1B	9.02	8.49e-19	1.19e-12	0.53	0.27	Myopia (pathological);	chr11:56027880	chr11:89639227~89698718:+
BRCA	trans	rs3096299	0.719	rs2965945	ENSG00000215030.5	RPL13P12	-9.02	8.55e-19	1.2e-12	-0.28	-0.27	Multiple myeloma (IgH translocation);	chr16:89447609	chr17:17383377~17384012:-
BRCA	trans	rs7746199	0.736	rs13193542	ENSG00000253570.1	RNF5P1	9.02	8.62e-19	1.21e-12	0.79	0.27	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27734646	chr8:38600661~38601200:-
BRCA	trans	rs7746199	0.736	rs13193480	ENSG00000253570.1	RNF5P1	9.02	8.62e-19	1.21e-12	0.79	0.27	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27734782	chr8:38600661~38601200:-
BRCA	trans	rs877636	0.702	rs773110	ENSG00000234354.3	RPS26P47	9.02	8.63e-19	1.21e-12	0.37	0.27	Cognitive function;	chr12:55981353	chr13:100539901~100540248:-
BRCA	trans	rs9876781	0.559	rs11130167	ENSG00000235912.1	RP1-159A19.3	-9.02	8.74e-19	1.23e-12	-0.32	-0.27	Longevity;	chr3:48358570	chr1:27649419~27649610:+
BRCA	trans	rs6743068	0.541	rs1966423	ENSG00000235105.1	RP11-329A14.1	9.02	8.74e-19	1.23e-12	0.31	0.27	Lymphocyte percentage of white cells;	chr2:201351938	chr1:48435967~48437223:+
BRCA	trans	rs1816752	0.646	rs4770700	ENSG00000224976.2	PARP4P2	9.02	8.85e-19	1.24e-12	0.33	0.27	Obesity-related traits;	chr13:24494796	chr13:19349137~19407962:+
BRCA	trans	rs867371	1	rs7173339	ENSG00000235370.6	DNM1P51	-9.02	8.87e-19	1.25e-12	-0.31	-0.27	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82175253	chr15:84398316~84411701:-
BRCA	trans	rs864643	1	rs704963	ENSG00000183298.5	RP11-556K13.1	-9.02	8.91e-19	1.25e-12	-0.42	-0.27	Attention deficit hyperactivity disorder;	chr3:39515747	chr1:101786340~101787219:-
BRCA	trans	rs13014235	0.532	rs6729982	ENSG00000235105.1	RP11-329A14.1	9.02	9.16e-19	1.29e-12	0.32	0.27	Basal cell carcinoma;	chr2:201416413	chr1:48435967~48437223:+
BRCA	trans	rs13014235	0.532	rs10497867	ENSG00000235105.1	RP11-329A14.1	9.02	9.16e-19	1.29e-12	0.32	0.27	Basal cell carcinoma;	chr2:201420144	chr1:48435967~48437223:+
BRCA	trans	rs877636	0.702	rs61937249	ENSG00000234354.3	RPS26P47	9.02	9.21e-19	1.29e-12	0.37	0.27	Cognitive function;	chr12:55988132	chr13:100539901~100540248:-
BRCA	trans	rs853679	0.607	rs34878803	ENSG00000253570.1	RNF5P1	9.01	9.3e-19	1.31e-12	0.75	0.27	Depression;	chr6:28282402	chr8:38600661~38601200:-
BRCA	trans	rs853679	0.607	rs34396849	ENSG00000253570.1	RNF5P1	9.01	9.3e-19	1.31e-12	0.75	0.27	Depression;	chr6:28283178	chr8:38600661~38601200:-
BRCA	trans	rs7939886	0.92	rs11231901	ENSG00000134612.10	FOLH1B	9.01	9.52e-19	1.34e-12	0.52	0.27	Myopia (pathological);	chr11:56044053	chr11:89639227~89698718:+
BRCA	trans	rs875971	0.571	rs78668714	ENSG00000164669.11	INTS4P1	-9.01	9.66e-19	1.36e-12	-0.38	-0.27	Aortic root size;	chr7:66474464	chr7:65141225~65234216:+
BRCA	trans	rs12210905	1	rs9348756	ENSG00000242375.1	RP11-498P14.3	-9.01	9.67e-19	1.36e-12	-0.67	-0.27	Hip circumference adjusted for BMI;	chr6:27260480	chr9:97195351~97197687:-
BRCA	trans	rs867371	0.929	rs7173852	ENSG00000235370.6	DNM1P51	-9.01	9.87e-19	1.38e-12	-0.3	-0.27	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82169512	chr15:84398316~84411701:-
BRCA	trans	rs546131	0.963	rs539044	ENSG00000225531.1	RP11-196I18.3	9.01	9.91e-19	1.39e-12	0.37	0.27	Lung disease severity in cystic fibrosis;	chr11:34819995	chr9:107116829~107117557:+
BRCA	trans	rs7113874	0.802	rs885114	ENSG00000266891.1	RP11-692N5.2	9	1.01e-18	1.41e-12	0.35	0.27	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8657209	chr18:9734882~9735602:-
BRCA	trans	rs864643	1	rs816490	ENSG00000183298.5	RP11-556K13.1	9	1.01e-18	1.42e-12	0.42	0.27	Attention deficit hyperactivity disorder;	chr3:39512993	chr1:101786340~101787219:-
BRCA	trans	rs941207	0.542	rs2126068	ENSG00000228224.3	NACAP1	-9	1.01e-18	1.42e-12	-0.33	-0.27	Platelet count;	chr12:56804716	chr8:101361794~101372707:+
BRCA	trans	rs853679	0.607	rs13211507	ENSG00000253570.1	RNF5P1	9	1.01e-18	1.42e-12	0.75	0.27	Depression;	chr6:28289600	chr8:38600661~38601200:-
BRCA	trans	rs853679	0.607	rs34691223	ENSG00000253570.1	RNF5P1	9	1.01e-18	1.42e-12	0.75	0.27	Depression;	chr6:28290431	chr8:38600661~38601200:-
BRCA	trans	rs7746199	0.736	rs34064842	ENSG00000253570.1	RNF5P1	9	1.02e-18	1.43e-12	0.77	0.27	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27720846	chr8:38600661~38601200:-
BRCA	trans	rs7662987	0.793	rs7669660	ENSG00000228407.2	RP4-800M22.1	9	1.03e-18	1.44e-12	0.47	0.27	Smoking initiation;	chr4:99071451	chr1:52160261~52160600:-
BRCA	trans	rs1816752	0.646	rs6490937	ENSG00000224976.2	PARP4P2	9	1.04e-18	1.46e-12	0.32	0.27	Obesity-related traits;	chr13:24475834	chr13:19349137~19407962:+
BRCA	trans	rs6743068	0.522	rs7597617	ENSG00000235105.1	RP11-329A14.1	9	1.05e-18	1.47e-12	0.32	0.27	Lymphocyte percentage of white cells;	chr2:201338512	chr1:48435967~48437223:+
BRCA	trans	rs875971	0.545	rs17138156	ENSG00000164669.11	INTS4P1	-9	1.07e-18	1.5e-12	-0.37	-0.27	Aortic root size;	chr7:66249708	chr7:65141225~65234216:+
BRCA	trans	rs7927370	1	rs17493710	ENSG00000134612.10	FOLH1B	-9	1.09e-18	1.52e-12	-0.58	-0.27	Systemic lupus erythematosus;	chr11:55437282	chr11:89639227~89698718:+
BRCA	trans	rs1816752	0.692	rs6490944	ENSG00000224976.2	PARP4P2	9	1.09e-18	1.52e-12	0.32	0.27	Obesity-related traits;	chr13:24513866	chr13:19349137~19407962:+
BRCA	trans	rs941207	0.542	rs6581106	ENSG00000228224.3	NACAP1	-8.99	1.1e-18	1.53e-12	-0.33	-0.27	Platelet count;	chr12:56796759	chr8:101361794~101372707:+
BRCA	trans	rs877636	0.702	rs773111	ENSG00000196656.7	AC004057.1	8.99	1.1e-18	1.54e-12	0.35	0.27	Cognitive function;	chr12:55981956	chr4:113214046~113217170:-
BRCA	trans	rs875971	0.545	rs6979636	ENSG00000164669.11	INTS4P1	-8.99	1.1e-18	1.55e-12	-0.38	-0.27	Aortic root size;	chr7:66276638	chr7:65141225~65234216:+
BRCA	trans	rs7746199	0.736	rs34965299	ENSG00000253570.1	RNF5P1	8.99	1.14e-18	1.59e-12	0.76	0.27	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27554077	chr8:38600661~38601200:-
BRCA	trans	rs9876781	0.559	rs1841178	ENSG00000235912.1	RP1-159A19.3	-8.99	1.15e-18	1.6e-12	-0.32	-0.27	Longevity;	chr3:48355556	chr1:27649419~27649610:+
BRCA	trans	rs864643	0.678	rs617068	ENSG00000183298.5	RP11-556K13.1	-8.98	1.19e-18	1.66e-12	-0.41	-0.27	Attention deficit hyperactivity disorder;	chr3:39492781	chr1:101786340~101787219:-
BRCA	trans	rs6964833	0.935	rs34630792	ENSG00000214544.6	GTF2IRD2P1	-8.98	1.2e-18	1.68e-12	-0.4	-0.27	Menarche (age at onset);	chr7:74646869	chr7:73242751~73280119:-
BRCA	trans	rs853679	0.546	rs13214023	ENSG00000253570.1	RNF5P1	-8.98	1.21e-18	1.69e-12	-0.7	-0.27	Depression;	chr6:28364364	chr8:38600661~38601200:-
BRCA	trans	rs877636	0.702	rs773109	ENSG00000234354.3	RPS26P47	8.98	1.22e-18	1.7e-12	0.37	0.27	Cognitive function;	chr12:55980911	chr13:100539901~100540248:-
BRCA	trans	rs7929679	0.551	rs906902	ENSG00000225531.1	RP11-196I18.3	-8.98	1.25e-18	1.74e-12	-0.35	-0.27	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;	chr11:34758731	chr9:107116829~107117557:+
BRCA	trans	rs714543	1	rs10278679	ENSG00000226038.5	PPIAP21	-8.98	1.25e-18	1.75e-12	-0.33	-0.27	Plateletcrit;	chr7:44825465	chr20:43230760~43231260:+
BRCA	trans	rs7113874	0.802	rs4291677	ENSG00000266891.1	RP11-692N5.2	8.98	1.26e-18	1.75e-12	0.35	0.27	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8659344	chr18:9734882~9735602:-
BRCA	trans	rs875971	0.545	rs7783889	ENSG00000164669.11	INTS4P1	-8.98	1.27e-18	1.77e-12	-0.38	-0.27	Aortic root size;	chr7:66283366	chr7:65141225~65234216:+
BRCA	trans	rs7939886	0.764	rs11227350	ENSG00000134612.10	FOLH1B	8.98	1.28e-18	1.78e-12	0.53	0.27	Myopia (pathological);	chr11:56144813	chr11:89639227~89698718:+
BRCA	trans	rs7939886	0.92	rs74699881	ENSG00000134612.10	FOLH1B	8.98	1.28e-18	1.78e-12	0.53	0.27	Myopia (pathological);	chr11:56146376	chr11:89639227~89698718:+
BRCA	trans	rs7939886	0.92	rs12223067	ENSG00000134612.10	FOLH1B	8.98	1.28e-18	1.78e-12	0.53	0.27	Myopia (pathological);	chr11:56147944	chr11:89639227~89698718:+
BRCA	trans	rs6601450	0.547	rs10105843	ENSG00000253893.2	FAM85B	-8.98	1.28e-18	1.79e-12	-0.34	-0.27	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;	chr8:10340353	chr8:8167819~8226614:-
BRCA	trans	rs877636	0.74	rs772920	ENSG00000234354.3	RPS26P47	8.98	1.28e-18	1.79e-12	0.37	0.27	Cognitive function;	chr12:55996580	chr13:100539901~100540248:-
BRCA	trans	rs7944735	0.578	rs7949985	ENSG00000134612.10	FOLH1B	8.98	1.29e-18	1.8e-12	0.47	0.27	Intraocular pressure;	chr11:48040897	chr11:89639227~89698718:+
BRCA	trans	rs3096299	0.685	rs3803682	ENSG00000215030.5	RPL13P12	-8.98	1.29e-18	1.8e-12	-0.28	-0.27	Multiple myeloma (IgH translocation);	chr16:89478228	chr17:17383377~17384012:-
BRCA	trans	rs7113874	0.578	rs7924477	ENSG00000266891.1	RP11-692N5.2	8.97	1.29e-18	1.81e-12	0.36	0.27	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8516700	chr18:9734882~9735602:-
BRCA	trans	rs7113874	0.659	rs7931834	ENSG00000266891.1	RP11-692N5.2	8.97	1.3e-18	1.81e-12	0.36	0.27	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8503746	chr18:9734882~9735602:-
BRCA	trans	rs12200782	1	rs10946822	ENSG00000242375.1	RP11-498P14.3	-8.97	1.31e-18	1.82e-12	-0.58	-0.27	Small cell lung carcinoma;	chr6:26414450	chr9:97195351~97197687:-
BRCA	trans	rs875971	0.545	rs73150604	ENSG00000164669.11	INTS4P1	-8.97	1.32e-18	1.85e-12	-0.38	-0.27	Aortic root size;	chr7:66480545	chr7:65141225~65234216:+
BRCA	trans	rs7939886	0.92	rs17150095	ENSG00000134612.10	FOLH1B	8.97	1.33e-18	1.85e-12	0.53	0.27	Myopia (pathological);	chr11:56135424	chr11:89639227~89698718:+
BRCA	trans	rs7939886	0.92	rs17150096	ENSG00000134612.10	FOLH1B	8.97	1.33e-18	1.85e-12	0.53	0.27	Myopia (pathological);	chr11:56135520	chr11:89639227~89698718:+
BRCA	trans	rs7939886	0.92	rs17150102	ENSG00000134612.10	FOLH1B	8.97	1.33e-18	1.85e-12	0.53	0.27	Myopia (pathological);	chr11:56136906	chr11:89639227~89698718:+
BRCA	trans	rs7939886	0.92	rs11227321	ENSG00000134612.10	FOLH1B	8.97	1.33e-18	1.85e-12	0.53	0.27	Myopia (pathological);	chr11:56137352	chr11:89639227~89698718:+
BRCA	trans	rs7939886	0.92	rs61742348	ENSG00000134612.10	FOLH1B	8.97	1.33e-18	1.85e-12	0.53	0.27	Myopia (pathological);	chr11:56137602	chr11:89639227~89698718:+
BRCA	trans	rs45509595	0.556	rs34409918	ENSG00000253570.1	RNF5P1	8.97	1.34e-18	1.87e-12	0.78	0.27	Breast cancer;	chr6:27717569	chr8:38600661~38601200:-
BRCA	trans	rs9876781	0.559	rs7611415	ENSG00000235912.1	RP1-159A19.3	-8.97	1.35e-18	1.88e-12	-0.32	-0.27	Longevity;	chr3:48363659	chr1:27649419~27649610:+
BRCA	trans	rs4276421	0.55	rs62367712	ENSG00000231752.4	EMBP1	8.97	1.35e-18	1.88e-12	0.41	0.27	P wave duration;	chr5:45766262	chr1:121519112~121571892:+
BRCA	trans	rs1816752	0.524	rs7996445	ENSG00000224976.2	PARP4P2	8.97	1.37e-18	1.91e-12	0.32	0.27	Obesity-related traits;	chr13:24475329	chr13:19349137~19407962:+
BRCA	trans	rs7113874	0.659	rs12274454	ENSG00000266891.1	RP11-692N5.2	8.97	1.37e-18	1.91e-12	0.36	0.27	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8500419	chr18:9734882~9735602:-
BRCA	trans	rs714543	0.967	rs10951776	ENSG00000226038.5	PPIAP21	-8.97	1.37e-18	1.91e-12	-0.33	-0.27	Plateletcrit;	chr7:44858152	chr20:43230760~43231260:+
BRCA	trans	rs941207	0.542	rs4277148	ENSG00000228224.3	NACAP1	-8.97	1.37e-18	1.91e-12	-0.32	-0.27	Platelet count;	chr12:56787071	chr8:101361794~101372707:+
BRCA	trans	rs941207	0.542	rs2888095	ENSG00000228224.3	NACAP1	-8.97	1.37e-18	1.91e-12	-0.32	-0.27	Platelet count;	chr12:56793689	chr8:101361794~101372707:+
BRCA	trans	rs941207	0.542	rs2888096	ENSG00000228224.3	NACAP1	-8.97	1.37e-18	1.91e-12	-0.32	-0.27	Platelet count;	chr12:56793851	chr8:101361794~101372707:+
BRCA	trans	rs3740713	0.669	rs2896526	ENSG00000214110.3	LDHAP4	8.97	1.38e-18	1.92e-12	0.46	0.27	Amyotrophic lateral sclerosis (sporadic);	chr11:18398259	chr9:14921337~14922334:-
BRCA	trans	rs853679	0.607	rs13199906	ENSG00000253570.1	RNF5P1	8.97	1.38e-18	1.93e-12	0.8	0.27	Depression;	chr6:27866361	chr8:38600661~38601200:-
BRCA	trans	rs877636	0.702	rs773110	ENSG00000196656.7	AC004057.1	8.97	1.39e-18	1.94e-12	0.35	0.27	Cognitive function;	chr12:55981353	chr4:113214046~113217170:-
BRCA	trans	rs7746199	0.736	rs13212318	ENSG00000253570.1	RNF5P1	8.97	1.4e-18	1.94e-12	0.78	0.27	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27721062	chr8:38600661~38601200:-
BRCA	trans	rs875971	0.545	rs6460276	ENSG00000164669.11	INTS4P1	-8.97	1.4e-18	1.95e-12	-0.37	-0.27	Aortic root size;	chr7:66182290	chr7:65141225~65234216:+
BRCA	trans	rs730566	1	rs4858819	ENSG00000235912.1	RP1-159A19.3	8.97	1.4e-18	1.95e-12	0.36	0.27	Prion diseases;	chr3:48436678	chr1:27649419~27649610:+
BRCA	trans	rs853679	0.607	rs17763089	ENSG00000253570.1	RNF5P1	8.97	1.41e-18	1.96e-12	0.79	0.27	Depression;	chr6:27867440	chr8:38600661~38601200:-
BRCA	trans	rs853679	0.546	rs17695758	ENSG00000253570.1	RNF5P1	8.97	1.41e-18	1.96e-12	0.79	0.27	Depression;	chr6:27869405	chr8:38600661~38601200:-
BRCA	trans	rs747782	0.639	rs61649224	ENSG00000134612.10	FOLH1B	8.96	1.42e-18	1.98e-12	0.47	0.27	Intraocular pressure;	chr11:48036088	chr11:89639227~89698718:+
BRCA	trans	rs2336384	1	rs2878677	ENSG00000261819.1	RP11-680G24.4	-8.96	1.43e-18	1.99e-12	-0.35	-0.27	Platelet count;	chr1:11993207	chr16:14988259~14990160:-
BRCA	trans	rs875971	0.545	rs1547529	ENSG00000164669.11	INTS4P1	-8.96	1.44e-18	2.01e-12	-0.37	-0.27	Aortic root size;	chr7:66258859	chr7:65141225~65234216:+
BRCA	trans	rs9467773	0.572	rs9467737	ENSG00000242375.1	RP11-498P14.3	-8.96	1.45e-18	2.01e-12	-0.38	-0.27	Intelligence (multi-trait analysis);	chr6:26381402	chr9:97195351~97197687:-
BRCA	trans	rs7819412	0.595	rs2409712	ENSG00000253893.2	FAM85B	8.96	1.46e-18	2.03e-12	0.34	0.27	Triglycerides;	chr8:11129327	chr8:8167819~8226614:-
BRCA	trans	rs714543	0.967	rs11762008	ENSG00000226038.5	PPIAP21	-8.96	1.48e-18	2.06e-12	-0.33	-0.27	Plateletcrit;	chr7:44864065	chr20:43230760~43231260:+
BRCA	trans	rs875971	0.545	rs2420612	ENSG00000164669.11	INTS4P1	-8.96	1.5e-18	2.09e-12	-0.38	-0.27	Aortic root size;	chr7:66536825	chr7:65141225~65234216:+
BRCA	trans	rs3808502	0.516	rs6983727	ENSG00000253893.2	FAM85B	-8.96	1.52e-18	2.11e-12	-0.34	-0.27	Neuroticism;	chr8:11558303	chr8:8167819~8226614:-
BRCA	trans	rs6964833	1	rs4717906	ENSG00000214544.6	GTF2IRD2P1	-8.96	1.52e-18	2.11e-12	-0.39	-0.27	Menarche (age at onset);	chr7:74671923	chr7:73242751~73280119:-
BRCA	trans	rs7746199	0.736	rs13209332	ENSG00000253570.1	RNF5P1	8.95	1.57e-18	2.18e-12	0.78	0.27	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27552973	chr8:38600661~38601200:-
BRCA	trans	rs714543	0.811	rs13238404	ENSG00000219797.2	PPIAP9	8.95	1.57e-18	2.19e-12	0.31	0.27	Plateletcrit;	chr7:44811812	chr6:31519480~31520291:-
BRCA	trans	rs7746199	0.673	rs35501037	ENSG00000253570.1	RNF5P1	8.95	1.58e-18	2.19e-12	0.75	0.27	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27771787	chr8:38600661~38601200:-
BRCA	trans	rs941207	0.542	rs67808059	ENSG00000228224.3	NACAP1	-8.95	1.58e-18	2.2e-12	-0.33	-0.27	Platelet count;	chr12:56805228	chr8:101361794~101372707:+
BRCA	trans	rs7746199	0.736	rs13202291	ENSG00000253570.1	RNF5P1	8.95	1.59e-18	2.2e-12	0.78	0.27	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27731078	chr8:38600661~38601200:-
BRCA	trans	rs7746199	0.736	rs17750424	ENSG00000253570.1	RNF5P1	8.95	1.59e-18	2.2e-12	0.78	0.27	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27733343	chr8:38600661~38601200:-
BRCA	trans	rs877636	0.702	rs61937249	ENSG00000196656.7	AC004057.1	8.95	1.59e-18	2.21e-12	0.35	0.27	Cognitive function;	chr12:55988132	chr4:113214046~113217170:-
BRCA	trans	rs12200782	1	rs12200782	ENSG00000242375.1	RP11-498P14.3	-8.95	1.6e-18	2.22e-12	-0.64	-0.27	Small cell lung carcinoma;	chr6:26402808	chr9:97195351~97197687:-
BRCA	trans	rs853679	0.607	rs13199772	ENSG00000253570.1	RNF5P1	8.95	1.6e-18	2.23e-12	0.8	0.27	Depression;	chr6:27866307	chr8:38600661~38601200:-
BRCA	trans	rs7113874	0.659	rs12577287	ENSG00000266891.1	RP11-692N5.2	8.95	1.61e-18	2.23e-12	0.36	0.27	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8498370	chr18:9734882~9735602:-
BRCA	trans	rs28647808	0.881	rs4962139	ENSG00000234981.1	RP11-534L20.4	-8.95	1.64e-18	2.28e-12	-0.46	-0.27	Blood protein levels;	chr9:133402740	chr1:206528915~206529706:+
BRCA	trans	rs6831352	0.819	rs13832	ENSG00000233859.2	ADH5P4	-8.95	1.66e-18	2.3e-12	-0.35	-0.27	Alcohol dependence;	chr4:99071924	chr6:65836930~65838039:-
BRCA	trans	rs875971	0.545	rs316324	ENSG00000164669.11	INTS4P1	8.94	1.68e-18	2.33e-12	0.37	0.27	Aortic root size;	chr7:66145627	chr7:65141225~65234216:+
BRCA	trans	rs875971	0.545	rs316323	ENSG00000164669.11	INTS4P1	8.94	1.68e-18	2.33e-12	0.37	0.27	Aortic root size;	chr7:66146002	chr7:65141225~65234216:+
BRCA	trans	rs7929679	0.551	rs10466455	ENSG00000225531.1	RP11-196I18.3	-8.94	1.68e-18	2.33e-12	-0.35	-0.27	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;	chr11:34759389	chr9:107116829~107117557:+
BRCA	trans	rs7939886	0.92	rs11227372	ENSG00000134612.10	FOLH1B	8.94	1.7e-18	2.35e-12	0.53	0.27	Myopia (pathological);	chr11:56152206	chr11:89639227~89698718:+
BRCA	trans	rs7113874	0.545	rs2084187	ENSG00000266891.1	RP11-692N5.2	8.94	1.7e-18	2.36e-12	0.36	0.27	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8515394	chr18:9734882~9735602:-
BRCA	trans	rs7113874	0.613	rs2100067	ENSG00000266891.1	RP11-692N5.2	8.94	1.7e-18	2.36e-12	0.36	0.27	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8515503	chr18:9734882~9735602:-
BRCA	trans	rs714543	0.967	rs12536807	ENSG00000226038.5	PPIAP21	-8.94	1.77e-18	2.45e-12	-0.33	-0.27	Plateletcrit;	chr7:44838675	chr20:43230760~43231260:+
BRCA	trans	rs714543	1	rs714543	ENSG00000226038.5	PPIAP21	-8.94	1.77e-18	2.45e-12	-0.33	-0.27	Plateletcrit;	chr7:44847477	chr20:43230760~43231260:+
BRCA	trans	rs714543	1	rs757693	ENSG00000226038.5	PPIAP21	-8.94	1.77e-18	2.45e-12	-0.33	-0.27	Plateletcrit;	chr7:44848430	chr20:43230760~43231260:+
BRCA	trans	rs853679	0.607	rs67998226	ENSG00000253570.1	RNF5P1	8.94	1.77e-18	2.46e-12	0.75	0.27	Depression;	chr6:28270281	chr8:38600661~38601200:-
BRCA	trans	rs877636	0.702	rs773112	ENSG00000196656.7	AC004057.1	8.94	1.77e-18	2.46e-12	0.35	0.27	Cognitive function;	chr12:55982097	chr4:113214046~113217170:-
BRCA	trans	rs875971	0.545	rs75577046	ENSG00000164669.11	INTS4P1	-8.94	1.78e-18	2.47e-12	-0.37	-0.27	Aortic root size;	chr7:66493729	chr7:65141225~65234216:+
BRCA	trans	rs941207	0.542	rs6581107	ENSG00000228224.3	NACAP1	-8.94	1.81e-18	2.5e-12	-0.32	-0.27	Platelet count;	chr12:56801197	chr8:101361794~101372707:+
BRCA	trans	rs9876781	0.559	rs13073692	ENSG00000235912.1	RP1-159A19.3	-8.93	1.81e-18	2.51e-12	-0.32	-0.27	Longevity;	chr3:48361812	chr1:27649419~27649610:+
BRCA	trans	rs9467711	0.79	rs35400317	ENSG00000253570.1	RNF5P1	8.93	1.82e-18	2.52e-12	0.77	0.27	Autism spectrum disorder or schizophrenia;	chr6:26593047	chr8:38600661~38601200:-
BRCA	trans	rs6743068	0.541	rs2349075	ENSG00000235105.1	RP11-329A14.1	8.93	1.83e-18	2.53e-12	0.32	0.27	Lymphocyte percentage of white cells;	chr2:201358843	chr1:48435967~48437223:+
BRCA	trans	rs875971	0.545	rs10950029	ENSG00000164669.11	INTS4P1	-8.93	1.84e-18	2.55e-12	-0.37	-0.27	Aortic root size;	chr7:66169334	chr7:65141225~65234216:+
BRCA	trans	rs7824557	0.583	rs2736306	ENSG00000253893.2	FAM85B	-8.93	1.84e-18	2.55e-12	-0.36	-0.27	Retinal vascular caliber;	chr8:11382253	chr8:8167819~8226614:-
BRCA	trans	rs877636	1	rs705696	ENSG00000243538.1	CTB-55B8.1	8.93	1.85e-18	2.55e-12	0.34	0.27	Cognitive function;	chr12:56086864	chr5:16902294~16902641:-
BRCA	trans	rs877636	0.702	rs773109	ENSG00000196656.7	AC004057.1	8.93	1.85e-18	2.56e-12	0.35	0.27	Cognitive function;	chr12:55980911	chr4:113214046~113217170:-
BRCA	trans	rs1816752	0.692	rs2282409	ENSG00000224976.2	PARP4P2	8.93	1.86e-18	2.57e-12	0.33	0.27	Obesity-related traits;	chr13:24512388	chr13:19349137~19407962:+
BRCA	trans	rs35491132	1	rs35491132	ENSG00000253570.1	RNF5P1	8.93	1.88e-18	2.6e-12	0.75	0.27	Urinary tract infection frequency;	chr6:27559449	chr8:38600661~38601200:-
BRCA	trans	rs864643	1	rs1708055	ENSG00000183298.5	RP11-556K13.1	8.93	1.88e-18	2.6e-12	0.42	0.27	Attention deficit hyperactivity disorder;	chr3:39531672	chr1:101786340~101787219:-
BRCA	trans	rs864643	1	rs1615046	ENSG00000183298.5	RP11-556K13.1	8.93	1.88e-18	2.6e-12	0.42	0.27	Attention deficit hyperactivity disorder;	chr3:39532309	chr1:101786340~101787219:-
BRCA	trans	rs864643	1	rs1615994	ENSG00000183298.5	RP11-556K13.1	8.93	1.88e-18	2.6e-12	0.42	0.27	Attention deficit hyperactivity disorder;	chr3:39532428	chr1:101786340~101787219:-
BRCA	trans	rs6940638	1	rs12215241	ENSG00000242375.1	RP11-498P14.3	-8.93	1.88e-18	2.61e-12	-0.45	-0.27	Intelligence (multi-trait analysis);	chr6:27055302	chr9:97195351~97197687:-
BRCA	trans	rs7939886	0.92	rs1586014	ENSG00000134612.10	FOLH1B	8.93	1.91e-18	2.65e-12	0.52	0.27	Myopia (pathological);	chr11:56004064	chr11:89639227~89698718:+
BRCA	trans	rs877636	1	rs705696	ENSG00000234354.3	RPS26P47	8.93	1.92e-18	2.65e-12	0.37	0.27	Cognitive function;	chr12:56086864	chr13:100539901~100540248:-
BRCA	trans	rs1816752	0.716	rs1539096	ENSG00000224976.2	PARP4P2	8.93	1.92e-18	2.66e-12	0.33	0.27	Obesity-related traits;	chr13:24501721	chr13:19349137~19407962:+
BRCA	trans	rs714543	1	rs13245012	ENSG00000226038.5	PPIAP21	-8.93	1.94e-18	2.69e-12	-0.33	-0.27	Plateletcrit;	chr7:44826120	chr20:43230760~43231260:+
BRCA	trans	rs11023332	0.641	rs4281505	ENSG00000236360.2	RP11-334A14.2	8.93	1.95e-18	2.7e-12	0.33	0.27	Vitamin D levels;Adiponectin levels;	chr11:14779114	chr1:52993201~52993702:-
BRCA	trans	rs11023332	0.65	rs2122942	ENSG00000236360.2	RP11-334A14.2	8.93	1.95e-18	2.7e-12	0.33	0.27	Vitamin D levels;Adiponectin levels;	chr11:14785829	chr1:52993201~52993702:-
BRCA	trans	rs7824557	0.767	rs3808513	ENSG00000253893.2	FAM85B	8.93	1.96e-18	2.71e-12	0.36	0.27	Retinal vascular caliber;	chr8:11299951	chr8:8167819~8226614:-
BRCA	trans	rs2727020	0.729	rs10839283	ENSG00000134612.10	FOLH1B	8.93	1.96e-18	2.71e-12	0.34	0.27	Coronary artery disease;	chr11:49469391	chr11:89639227~89698718:+
BRCA	trans	rs875971	0.545	rs1909508	ENSG00000164669.11	INTS4P1	-8.92	1.99e-18	2.76e-12	-0.37	-0.27	Aortic root size;	chr7:66301366	chr7:65141225~65234216:+
BRCA	trans	rs673253	1	rs673253	ENSG00000231007.5	CDC20P1	8.92	2.02e-18	2.79e-12	0.35	0.27	Intelligence (multi-trait analysis);	chr1:43596483	chr9:87011652~87013151:+
BRCA	trans	rs66887589	0.616	rs6822808	ENSG00000275858.1	RP11-291L22.8	8.92	2.04e-18	2.82e-12	0.31	0.27	Diastolic blood pressure;	chr4:119296210	chr10:38450738~38451069:-
BRCA	trans	rs7824557	0.767	rs3808509	ENSG00000253893.2	FAM85B	-8.92	2.09e-18	2.88e-12	-0.37	-0.27	Retinal vascular caliber;	chr8:11305747	chr8:8167819~8226614:-
BRCA	trans	rs7662987	1	rs1803037	ENSG00000233859.2	ADH5P4	8.92	2.1e-18	2.9e-12	0.54	0.27	Smoking initiation;	chr4:99072000	chr6:65836930~65838039:-
BRCA	trans	rs9467711	0.79	rs67777156	ENSG00000253570.1	RNF5P1	8.91	2.15e-18	2.97e-12	0.77	0.27	Autism spectrum disorder or schizophrenia;	chr6:26633483	chr8:38600661~38601200:-
BRCA	trans	rs7927370	1	rs61898066	ENSG00000134612.10	FOLH1B	8.91	2.16e-18	2.98e-12	0.65	0.27	Systemic lupus erythematosus;	chr11:55066089	chr11:89639227~89698718:+
BRCA	trans	rs7929679	0.571	rs7942701	ENSG00000225531.1	RP11-196I18.3	8.91	2.16e-18	2.99e-12	0.34	0.27	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;	chr11:34777336	chr9:107116829~107117557:+
BRCA	trans	rs6964833	1	rs4717907	ENSG00000214544.6	GTF2IRD2P1	-8.91	2.2e-18	3.03e-12	-0.38	-0.27	Menarche (age at onset);	chr7:74672169	chr7:73242751~73280119:-
BRCA	trans	rs875971	0.545	rs316305	ENSG00000164669.11	INTS4P1	8.91	2.21e-18	3.04e-12	0.37	0.27	Aortic root size;	chr7:66152984	chr7:65141225~65234216:+
BRCA	trans	rs7929679	0.551	rs11032849	ENSG00000225531.1	RP11-196I18.3	8.91	2.23e-18	3.08e-12	0.35	0.27	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;	chr11:34764193	chr9:107116829~107117557:+
BRCA	trans	rs7929679	0.521	rs11032852	ENSG00000225531.1	RP11-196I18.3	8.91	2.23e-18	3.08e-12	0.35	0.27	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;	chr11:34766761	chr9:107116829~107117557:+
BRCA	trans	rs7929679	0.521	rs11499809	ENSG00000225531.1	RP11-196I18.3	8.91	2.23e-18	3.08e-12	0.35	0.27	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;	chr11:34769196	chr9:107116829~107117557:+
BRCA	trans	rs7929679	0.521	rs1509667	ENSG00000225531.1	RP11-196I18.3	8.91	2.23e-18	3.08e-12	0.35	0.27	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;	chr11:34769756	chr9:107116829~107117557:+
BRCA	trans	rs7929679	0.551	rs10836302	ENSG00000225531.1	RP11-196I18.3	8.91	2.23e-18	3.08e-12	0.35	0.27	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;	chr11:34770350	chr9:107116829~107117557:+
BRCA	trans	rs7929679	0.521	rs10768094	ENSG00000225531.1	RP11-196I18.3	8.91	2.23e-18	3.08e-12	0.35	0.27	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;	chr11:34770642	chr9:107116829~107117557:+
BRCA	trans	rs7929679	0.551	rs10836303	ENSG00000225531.1	RP11-196I18.3	8.91	2.23e-18	3.08e-12	0.35	0.27	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;	chr11:34771155	chr9:107116829~107117557:+
BRCA	trans	rs7929679	0.521	rs10768097	ENSG00000225531.1	RP11-196I18.3	8.91	2.23e-18	3.08e-12	0.35	0.27	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;	chr11:34771355	chr9:107116829~107117557:+
BRCA	trans	rs7112043	1	rs7112043	ENSG00000225531.1	RP11-196I18.3	8.91	2.25e-18	3.11e-12	0.35	0.27	Lung disease severity in cystic fibrosis;	chr11:34767839	chr9:107116829~107117557:+
BRCA	trans	rs9329221	0.527	rs34308302	ENSG00000253893.2	FAM85B	8.91	2.27e-18	3.12e-12	0.35	0.27	Neuroticism;	chr8:10474512	chr8:8167819~8226614:-
BRCA	trans	rs6964833	1	rs34324835	ENSG00000214544.6	GTF2IRD2P1	-8.91	2.31e-18	3.18e-12	-0.4	-0.27	Menarche (age at onset);	chr7:74717986	chr7:73242751~73280119:-
BRCA	trans	rs12210905	1	rs1062834	ENSG00000242375.1	RP11-498P14.3	-8.91	2.32e-18	3.2e-12	-0.66	-0.27	Hip circumference adjusted for BMI;	chr6:27254760	chr9:97195351~97197687:-
BRCA	trans	rs875971	0.545	rs75840613	ENSG00000164669.11	INTS4P1	-8.9	2.34e-18	3.23e-12	-0.37	-0.27	Aortic root size;	chr7:66376399	chr7:65141225~65234216:+
BRCA	trans	rs853679	0.607	rs34661125	ENSG00000253570.1	RNF5P1	8.9	2.35e-18	3.24e-12	0.75	0.27	Depression;	chr6:28314117	chr8:38600661~38601200:-
BRCA	trans	rs853679	0.607	rs13190888	ENSG00000253570.1	RNF5P1	8.9	2.35e-18	3.24e-12	0.75	0.27	Depression;	chr6:28318208	chr8:38600661~38601200:-
BRCA	trans	rs714543	1	rs2898	ENSG00000226038.5	PPIAP21	-8.9	2.46e-18	3.38e-12	-0.33	-0.27	Plateletcrit;	chr7:44827034	chr20:43230760~43231260:+
BRCA	trans	rs9329221	0.527	rs10903328	ENSG00000253893.2	FAM85B	-8.9	2.48e-18	3.42e-12	-0.34	-0.27	Neuroticism;	chr8:10474657	chr8:8167819~8226614:-
BRCA	trans	rs9650657	0.655	rs10093774	ENSG00000253893.2	FAM85B	-8.9	2.5e-18	3.43e-12	-0.32	-0.27	Neuroticism;	chr8:10845783	chr8:8167819~8226614:-
BRCA	trans	rs6743068	0.521	rs2349074	ENSG00000235105.1	RP11-329A14.1	8.9	2.5e-18	3.44e-12	0.31	0.27	Lymphocyte percentage of white cells;	chr2:201357784	chr1:48435967~48437223:+
BRCA	trans	rs12210905	1	rs9357034	ENSG00000242375.1	RP11-498P14.3	-8.9	2.51e-18	3.45e-12	-0.64	-0.27	Hip circumference adjusted for BMI;	chr6:27275646	chr9:97195351~97197687:-
BRCA	trans	rs7113874	0.613	rs4326784	ENSG00000266891.1	RP11-692N5.2	8.89	2.53e-18	3.48e-12	0.36	0.27	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8511602	chr18:9734882~9735602:-
BRCA	trans	rs1816752	0.716	rs7995304	ENSG00000224976.2	PARP4P2	8.89	2.6e-18	3.58e-12	0.32	0.27	Obesity-related traits;	chr13:24514284	chr13:19349137~19407962:+
BRCA	trans	rs875971	0.545	rs66594357	ENSG00000164669.11	INTS4P1	-8.89	2.61e-18	3.59e-12	-0.37	-0.27	Aortic root size;	chr7:66327797	chr7:65141225~65234216:+
BRCA	trans	rs714543	1	rs10267576	ENSG00000226038.5	PPIAP21	-8.89	2.64e-18	3.62e-12	-0.33	-0.27	Plateletcrit;	chr7:44831334	chr20:43230760~43231260:+
BRCA	trans	rs8010715	0.848	rs927494	ENSG00000238000.1	RP11-274E7.2	8.89	2.73e-18	3.75e-12	0.29	0.27	IgG glycosylation;	chr14:24131181	chr5:98213402~98214121:+
BRCA	trans	rs10037055	1	rs10037055	ENSG00000228305.2	AC016734.2	-8.89	2.73e-18	3.75e-12	-0.31	-0.27	Migraine without aura;	chr5:177264278	chr2:63622178~63622831:-
BRCA	trans	rs12210905	1	rs12205628	ENSG00000242375.1	RP11-498P14.3	-8.88	2.79e-18	3.83e-12	-0.66	-0.27	Hip circumference adjusted for BMI;	chr6:27258180	chr9:97195351~97197687:-
BRCA	trans	rs7929679	0.521	rs7122506	ENSG00000225531.1	RP11-196I18.3	8.88	2.83e-18	3.89e-12	0.35	0.27	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;	chr11:34765306	chr9:107116829~107117557:+
BRCA	trans	rs941207	0.542	rs7311381	ENSG00000228224.3	NACAP1	-8.88	2.86e-18	3.93e-12	-0.32	-0.27	Platelet count;	chr12:56800286	chr8:101361794~101372707:+
BRCA	trans	rs67340775	0.748	rs13212651	ENSG00000253570.1	RNF5P1	8.88	2.87e-18	3.94e-12	0.77	0.27	Lung cancer in ever smokers;	chr6:27839207	chr8:38600661~38601200:-
BRCA	trans	rs875971	0.545	rs316316	ENSG00000164669.11	INTS4P1	8.88	2.87e-18	3.94e-12	0.37	0.27	Aortic root size;	chr7:66149270	chr7:65141225~65234216:+
BRCA	trans	rs12210905	1	rs6902012	ENSG00000242375.1	RP11-498P14.3	8.88	2.89e-18	3.96e-12	0.63	0.27	Hip circumference adjusted for BMI;	chr6:27275988	chr9:97195351~97197687:-
BRCA	trans	rs853679	0.607	rs67101035	ENSG00000253570.1	RNF5P1	8.88	2.92e-18	4e-12	0.77	0.27	Depression;	chr6:27831109	chr8:38600661~38601200:-
BRCA	trans	rs877636	0.859	rs3741499	ENSG00000234354.3	RPS26P47	-8.88	2.96e-18	4.06e-12	-0.34	-0.27	Cognitive function;	chr12:56080595	chr13:100539901~100540248:-
BRCA	trans	rs875971	0.545	rs6460298	ENSG00000164669.11	INTS4P1	-8.87	3.02e-18	4.14e-12	-0.37	-0.27	Aortic root size;	chr7:66442783	chr7:65141225~65234216:+
BRCA	trans	rs9467711	0.722	rs13201782	ENSG00000253570.1	RNF5P1	8.87	3.08e-18	4.23e-12	0.77	0.27	Autism spectrum disorder or schizophrenia;	chr6:26650825	chr8:38600661~38601200:-
BRCA	trans	rs864643	1	rs816494	ENSG00000183298.5	RP11-556K13.1	8.87	3.14e-18	4.3e-12	0.42	0.26	Attention deficit hyperactivity disorder;	chr3:39515354	chr1:101786340~101787219:-
BRCA	trans	rs7929679	0.571	rs10768100	ENSG00000225531.1	RP11-196I18.3	8.87	3.16e-18	4.33e-12	0.35	0.26	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;	chr11:34777388	chr9:107116829~107117557:+
BRCA	trans	rs7113874	0.802	rs10769936	ENSG00000266891.1	RP11-692N5.2	8.87	3.2e-18	4.38e-12	0.34	0.26	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8632981	chr18:9734882~9735602:-
BRCA	trans	rs875971	0.545	rs3735147	ENSG00000164669.11	INTS4P1	-8.86	3.31e-18	4.53e-12	-0.37	-0.26	Aortic root size;	chr7:66505541	chr7:65141225~65234216:+
BRCA	trans	rs6964833	1	rs17515241	ENSG00000214544.6	GTF2IRD2P1	8.86	3.32e-18	4.54e-12	0.39	0.26	Menarche (age at onset);	chr7:74717695	chr7:73242751~73280119:-
BRCA	trans	rs7929679	0.571	rs12280698	ENSG00000225531.1	RP11-196I18.3	8.86	3.35e-18	4.59e-12	0.34	0.26	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;	chr11:34776874	chr9:107116829~107117557:+
BRCA	trans	rs7929679	0.546	rs7942593	ENSG00000225531.1	RP11-196I18.3	8.86	3.35e-18	4.59e-12	0.34	0.26	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;	chr11:34777247	chr9:107116829~107117557:+
BRCA	trans	rs9876781	0.559	rs7630053	ENSG00000235912.1	RP1-159A19.3	-8.86	3.5e-18	4.79e-12	-0.32	-0.26	Longevity;	chr3:48357096	chr1:27649419~27649610:+
BRCA	trans	rs7944735	0.567	rs7111404	ENSG00000134612.10	FOLH1B	8.86	3.52e-18	4.82e-12	0.45	0.26	Intraocular pressure;	chr11:47989731	chr11:89639227~89698718:+
BRCA	trans	rs7112043	0.778	rs1472975	ENSG00000225531.1	RP11-196I18.3	8.85	3.55e-18	4.86e-12	0.35	0.26	Lung disease severity in cystic fibrosis;	chr11:34755096	chr9:107116829~107117557:+
BRCA	trans	rs11098499	0.78	rs7692994	ENSG00000275858.1	RP11-291L22.8	8.85	3.56e-18	4.88e-12	0.32	0.26	Corneal astigmatism;	chr4:119506334	chr10:38450738~38451069:-
BRCA	trans	rs7112043	0.868	rs10768093	ENSG00000225531.1	RP11-196I18.3	8.85	3.59e-18	4.91e-12	0.35	0.26	Lung disease severity in cystic fibrosis;	chr11:34756012	chr9:107116829~107117557:+
BRCA	trans	rs1816752	0.583	rs9553311	ENSG00000224976.2	PARP4P2	8.85	3.61e-18	4.95e-12	0.32	0.26	Obesity-related traits;	chr13:24474016	chr13:19349137~19407962:+
BRCA	trans	rs7746199	0.736	rs13195636	ENSG00000253570.1	RNF5P1	8.85	3.65e-18	5e-12	0.77	0.26	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27541714	chr8:38600661~38601200:-
BRCA	trans	rs7929679	0.551	rs11032840	ENSG00000225531.1	RP11-196I18.3	8.85	3.66e-18	5.01e-12	0.35	0.26	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;	chr11:34757917	chr9:107116829~107117557:+
BRCA	trans	rs7929679	0.571	rs12286940	ENSG00000225531.1	RP11-196I18.3	-8.85	3.67e-18	5.03e-12	-0.34	-0.26	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;	chr11:34777063	chr9:107116829~107117557:+
BRCA	trans	rs2840044	0.711	rs225301	ENSG00000234130.2	RP13-88F20.1	-8.85	3.72e-18	5.09e-12	-0.35	-0.26	Response to radiotherapy in cancer (late toxicity);	chr17:35595392	chrX:93222220~93225015:-
BRCA	trans	rs13014235	0.934	rs10202963	ENSG00000235105.1	RP11-329A14.1	8.85	3.76e-18	5.13e-12	0.31	0.26	Basal cell carcinoma;	chr2:201377184	chr1:48435967~48437223:+
BRCA	trans	rs7746199	0.736	rs34105070	ENSG00000253570.1	RNF5P1	8.84	3.86e-18	5.27e-12	0.77	0.26	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27593026	chr8:38600661~38601200:-
BRCA	trans	rs9329221	0.527	rs7833781	ENSG00000253893.2	FAM85B	-8.84	3.93e-18	5.36e-12	-0.34	-0.26	Neuroticism;	chr8:10475967	chr8:8167819~8226614:-
BRCA	trans	rs546131	0.928	rs550313	ENSG00000225531.1	RP11-196I18.3	8.84	3.96e-18	5.41e-12	0.37	0.26	Lung disease severity in cystic fibrosis;	chr11:34809372	chr9:107116829~107117557:+
BRCA	trans	rs941207	0.542	rs12367339	ENSG00000228224.3	NACAP1	-8.84	3.97e-18	5.42e-12	-0.33	-0.26	Platelet count;	chr12:56809521	chr8:101361794~101372707:+
BRCA	trans	rs4378355	1	rs4378355	ENSG00000225531.1	RP11-196I18.3	8.84	3.97e-18	5.42e-12	0.36	0.26	Prostate-specific antigen levels;	chr11:34761870	chr9:107116829~107117557:+
BRCA	trans	rs3096299	0.685	rs3803681	ENSG00000215030.5	RPL13P12	-8.84	4.02e-18	5.48e-12	-0.27	-0.26	Multiple myeloma (IgH translocation);	chr16:89478348	chr17:17383377~17384012:-
BRCA	trans	rs7746199	0.736	rs58616630	ENSG00000253570.1	RNF5P1	8.84	4.02e-18	5.49e-12	0.77	0.26	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27506936	chr8:38600661~38601200:-
BRCA	trans	rs7824557	0.778	rs6601572	ENSG00000253893.2	FAM85B	8.84	4.07e-18	5.55e-12	0.34	0.26	Retinal vascular caliber;	chr8:11235828	chr8:8167819~8226614:-
BRCA	trans	rs7746199	0.736	rs13192965	ENSG00000253570.1	RNF5P1	8.84	4.1e-18	5.6e-12	0.77	0.26	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27704046	chr8:38600661~38601200:-
BRCA	trans	rs526821	0.789	rs10896993	ENSG00000134612.10	FOLH1B	-8.84	4.11e-18	5.61e-12	-0.34	-0.26	Pediatric bone mineral density (spine);	chr11:55535934	chr11:89639227~89698718:+
BRCA	trans	rs9467711	0.606	rs9393718	ENSG00000253570.1	RNF5P1	8.84	4.14e-18	5.65e-12	0.65	0.26	Autism spectrum disorder or schizophrenia;	chr6:26407254	chr8:38600661~38601200:-
BRCA	trans	rs7746199	0.736	rs13212093	ENSG00000253570.1	RNF5P1	8.83	4.2e-18	5.73e-12	0.77	0.26	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27638937	chr8:38600661~38601200:-
BRCA	trans	rs7746199	0.736	rs34038546	ENSG00000253570.1	RNF5P1	8.83	4.2e-18	5.73e-12	0.77	0.26	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27639881	chr8:38600661~38601200:-
BRCA	trans	rs141342723	1	rs141342723	ENSG00000253570.1	RNF5P1	8.83	4.2e-18	5.73e-12	0.77	0.26	Autism spectrum disorder or schizophrenia;	chr6:27654305	chr8:38600661~38601200:-
BRCA	trans	rs7746199	0.736	rs34543938	ENSG00000253570.1	RNF5P1	8.83	4.2e-18	5.73e-12	0.77	0.26	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27656861	chr8:38600661~38601200:-
BRCA	trans	rs7746199	0.736	rs56405707	ENSG00000253570.1	RNF5P1	8.83	4.2e-18	5.73e-12	0.77	0.26	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27672467	chr8:38600661~38601200:-
BRCA	trans	rs1580019	0.813	rs2044839	ENSG00000176826.14	FKBP9P1	-8.83	4.3e-18	5.86e-12	-0.35	-0.26	Cognitive ability;	chr7:32461193	chr7:55681074~55713252:-
BRCA	trans	rs941207	0.542	rs12370142	ENSG00000228224.3	NACAP1	-8.83	4.3e-18	5.86e-12	-0.32	-0.26	Platelet count;	chr12:56790801	chr8:101361794~101372707:+
BRCA	trans	rs12367822	0.956	rs9706160	ENSG00000228224.3	NACAP1	-8.83	4.3e-18	5.86e-12	-0.32	-0.26	Platelet aggregation;	chr12:56791119	chr8:101361794~101372707:+
BRCA	trans	rs7746199	0.736	rs34573979	ENSG00000253570.1	RNF5P1	8.83	4.31e-18	5.87e-12	0.77	0.26	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27512747	chr8:38600661~38601200:-
BRCA	trans	rs714543	1	rs1990053	ENSG00000226038.5	PPIAP21	-8.83	4.37e-18	5.96e-12	-0.33	-0.26	Plateletcrit;	chr7:44886297	chr20:43230760~43231260:+
BRCA	trans	rs8010715	0.636	rs2277482	ENSG00000238000.1	RP11-274E7.2	8.83	4.39e-18	5.98e-12	0.3	0.26	IgG glycosylation;	chr14:24118586	chr5:98213402~98214121:+
BRCA	trans	rs877636	1	rs4759229	ENSG00000234354.3	RPS26P47	-8.83	4.46e-18	6.07e-12	-0.34	-0.26	Cognitive function;	chr12:56080696	chr13:100539901~100540248:-
BRCA	trans	rs7929679	0.602	rs11032872	ENSG00000225531.1	RP11-196I18.3	8.83	4.47e-18	6.09e-12	0.34	0.26	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;	chr11:34784645	chr9:107116829~107117557:+
BRCA	trans	rs875971	0.502	rs1796227	ENSG00000164669.11	INTS4P1	8.83	4.48e-18	6.09e-12	0.38	0.26	Aortic root size;	chr7:66622032	chr7:65141225~65234216:+
BRCA	trans	rs4276421	0.55	rs16902186	ENSG00000231752.4	EMBP1	8.83	4.51e-18	6.14e-12	0.39	0.26	P wave duration;	chr5:45611886	chr1:121519112~121571892:+
BRCA	trans	rs3749237	1	rs4768	ENSG00000197582.5	GPX1P1	8.82	4.65e-18	6.32e-12	0.28	0.26	Resting heart rate;	chr3:49721331	chrX:13378735~13379340:-
BRCA	trans	rs7746199	0.736	rs13210634	ENSG00000253570.1	RNF5P1	8.82	4.67e-18	6.35e-12	0.77	0.26	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27678713	chr8:38600661~38601200:-
BRCA	trans	rs7746199	0.736	rs13215275	ENSG00000253570.1	RNF5P1	8.82	4.67e-18	6.35e-12	0.77	0.26	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27679730	chr8:38600661~38601200:-
BRCA	trans	rs7746199	0.736	rs17749927	ENSG00000253570.1	RNF5P1	8.82	4.67e-18	6.35e-12	0.77	0.26	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27702197	chr8:38600661~38601200:-
BRCA	trans	rs7113874	0.612	rs11517715	ENSG00000266891.1	RP11-692N5.2	8.82	4.71e-18	6.41e-12	0.35	0.26	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8490341	chr18:9734882~9735602:-
BRCA	trans	rs546131	0.928	rs552171	ENSG00000225531.1	RP11-196I18.3	8.82	4.77e-18	6.48e-12	0.37	0.26	Lung disease severity in cystic fibrosis;	chr11:34809162	chr9:107116829~107117557:+
BRCA	trans	rs10037055	1	rs6886255	ENSG00000228305.2	AC016734.2	8.82	4.83e-18	6.57e-12	0.31	0.26	Migraine without aura;	chr5:177291360	chr2:63622178~63622831:-
BRCA	trans	rs7833986	0.501	rs72651502	ENSG00000236862.1	RPS20P24	8.82	4.83e-18	6.57e-12	0.35	0.26	Height;	chr8:55962974	chr9:72655832~72656192:-
BRCA	trans	rs7944735	0.567	rs7946766	ENSG00000134612.10	FOLH1B	8.81	4.94e-18	6.72e-12	0.45	0.26	Intraocular pressure;	chr11:47982817	chr11:89639227~89698718:+
BRCA	trans	rs546131	0.928	rs483976	ENSG00000225531.1	RP11-196I18.3	8.81	4.99e-18	6.79e-12	0.36	0.26	Lung disease severity in cystic fibrosis;	chr11:34818620	chr9:107116829~107117557:+
BRCA	trans	rs7929679	0.577	rs10836306	ENSG00000225531.1	RP11-196I18.3	8.81	5.23e-18	7.1e-12	0.34	0.26	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;	chr11:34776415	chr9:107116829~107117557:+
BRCA	trans	rs941207	0.542	rs11171980	ENSG00000228224.3	NACAP1	-8.81	5.24e-18	7.12e-12	-0.33	-0.26	Platelet count;	chr12:56806397	chr8:101361794~101372707:+
BRCA	trans	rs6601450	0.522	rs7837979	ENSG00000253893.2	FAM85B	-8.81	5.25e-18	7.14e-12	-0.33	-0.26	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;	chr8:10341024	chr8:8167819~8226614:-
BRCA	trans	rs7819412	0.811	rs2409691	ENSG00000253893.2	FAM85B	8.81	5.32e-18	7.22e-12	0.34	0.26	Triglycerides;	chr8:11085766	chr8:8167819~8226614:-
BRCA	trans	rs1580019	0.844	rs1584615	ENSG00000176826.14	FKBP9P1	-8.8	5.36e-18	7.28e-12	-0.35	-0.26	Cognitive ability;	chr7:32463646	chr7:55681074~55713252:-
BRCA	trans	rs546131	0.928	rs499183	ENSG00000225531.1	RP11-196I18.3	8.8	5.39e-18	7.32e-12	0.36	0.26	Lung disease severity in cystic fibrosis;	chr11:34815131	chr9:107116829~107117557:+
BRCA	trans	rs867371	0.929	rs1045508	ENSG00000235370.6	DNM1P51	8.8	5.45e-18	7.39e-12	0.29	0.26	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82157565	chr15:84398316~84411701:-
BRCA	trans	rs875971	0.502	rs6460311	ENSG00000164669.11	INTS4P1	8.8	5.47e-18	7.43e-12	0.37	0.26	Aortic root size;	chr7:66646886	chr7:65141225~65234216:+
BRCA	trans	rs546131	0.928	rs552868	ENSG00000225531.1	RP11-196I18.3	8.8	5.55e-18	7.53e-12	0.36	0.26	Lung disease severity in cystic fibrosis;	chr11:34809147	chr9:107116829~107117557:+
BRCA	trans	rs714543	0.934	rs10275962	ENSG00000226038.5	PPIAP21	-8.8	5.56e-18	7.54e-12	-0.33	-0.26	Plateletcrit;	chr7:44809141	chr20:43230760~43231260:+
BRCA	trans	rs7944735	0.702	rs60515486	ENSG00000134612.10	FOLH1B	8.8	5.61e-18	7.61e-12	0.37	0.26	Intraocular pressure;	chr11:47661173	chr11:89639227~89698718:+
BRCA	trans	rs2899832	0.733	rs10498331	ENSG00000229083.1	PSMA6P2	8.8	5.62e-18	7.62e-12	0.39	0.26	Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:35167163	chrX:12825840~12826833:+
BRCA	trans	rs9467711	0.79	rs13220495	ENSG00000253570.1	RNF5P1	8.79	5.83e-18	7.9e-12	0.76	0.26	Autism spectrum disorder or schizophrenia;	chr6:26441412	chr8:38600661~38601200:-
BRCA	trans	rs7746199	0.673	rs72845046	ENSG00000253570.1	RNF5P1	8.79	5.88e-18	7.97e-12	0.77	0.26	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27607489	chr8:38600661~38601200:-
BRCA	trans	rs7746199	0.736	rs67652222	ENSG00000253570.1	RNF5P1	8.79	5.98e-18	8.1e-12	0.77	0.26	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27618441	chr8:38600661~38601200:-
BRCA	trans	rs877636	0.74	rs705702	ENSG00000196656.7	AC004057.1	-8.79	6.13e-18	8.31e-12	-0.34	-0.26	Cognitive function;	chr12:55996852	chr4:113214046~113217170:-
BRCA	trans	rs7819412	0.595	rs4841500	ENSG00000253893.2	FAM85B	8.79	6.17e-18	8.35e-12	0.34	0.26	Triglycerides;	chr8:11130765	chr8:8167819~8226614:-
BRCA	trans	rs7824557	0.836	rs2736378	ENSG00000253893.2	FAM85B	8.79	6.24e-18	8.45e-12	0.36	0.26	Retinal vascular caliber;	chr8:11262251	chr8:8167819~8226614:-
BRCA	trans	rs7929679	0.571	rs11032860	ENSG00000225531.1	RP11-196I18.3	8.79	6.32e-18	8.56e-12	0.34	0.26	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;	chr11:34777798	chr9:107116829~107117557:+
BRCA	trans	rs7929679	0.521	rs10836307	ENSG00000225531.1	RP11-196I18.3	8.78	6.33e-18	8.57e-12	0.34	0.26	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;	chr11:34778681	chr9:107116829~107117557:+
BRCA	trans	rs875971	0.545	rs17138149	ENSG00000164669.11	INTS4P1	-8.78	6.42e-18	8.68e-12	-0.36	-0.26	Aortic root size;	chr7:66228193	chr7:65141225~65234216:+
BRCA	trans	rs1391708	0.834	rs4259865	ENSG00000121089.4	NACA3P	8.78	6.43e-18	8.7e-12	0.41	0.26	Airway wall thickness;	chr12:56881229	chr4:164943290~164943937:+
BRCA	trans	rs1391708	0.834	rs7358569	ENSG00000121089.4	NACA3P	8.78	6.43e-18	8.7e-12	0.41	0.26	Airway wall thickness;	chr12:56883608	chr4:164943290~164943937:+
BRCA	trans	rs546131	0.928	rs553789	ENSG00000225531.1	RP11-196I18.3	8.78	6.5e-18	8.8e-12	0.36	0.26	Lung disease severity in cystic fibrosis;	chr11:34806032	chr9:107116829~107117557:+
BRCA	trans	rs7929679	0.571	rs10768099	ENSG00000225531.1	RP11-196I18.3	8.78	6.76e-18	9.13e-12	0.34	0.26	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;	chr11:34775787	chr9:107116829~107117557:+
BRCA	trans	rs875971	0.545	rs1638724	ENSG00000164669.11	INTS4P1	8.78	6.81e-18	9.21e-12	0.37	0.26	Aortic root size;	chr7:66575494	chr7:65141225~65234216:+
BRCA	trans	rs853679	0.607	rs34950484	ENSG00000253570.1	RNF5P1	8.77	7.06e-18	9.53e-12	0.75	0.26	Depression;	chr6:28310911	chr8:38600661~38601200:-
BRCA	trans	rs12200782	0.872	rs10484440	ENSG00000242375.1	RP11-498P14.3	8.77	7.18e-18	9.7e-12	0.52	0.26	Small cell lung carcinoma;	chr6:26453514	chr9:97195351~97197687:-
BRCA	trans	rs7929679	0.602	rs11032866	ENSG00000225531.1	RP11-196I18.3	8.77	7.3e-18	9.85e-12	0.34	0.26	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;	chr11:34781885	chr9:107116829~107117557:+
BRCA	trans	rs7929679	0.602	rs1396885	ENSG00000225531.1	RP11-196I18.3	8.77	7.3e-18	9.85e-12	0.34	0.26	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;	chr11:34783663	chr9:107116829~107117557:+
BRCA	trans	rs941207	0.542	rs12367822	ENSG00000228224.3	NACAP1	-8.76	7.59e-18	1.02e-11	-0.32	-0.26	Platelet count;	chr12:56810376	chr8:101361794~101372707:+
BRCA	trans	rs7824557	0.767	rs28507159	ENSG00000253893.2	FAM85B	-8.76	7.63e-18	1.03e-11	-0.37	-0.26	Retinal vascular caliber;	chr8:11308567	chr8:8167819~8226614:-
BRCA	trans	rs7746199	0.736	rs17693963	ENSG00000253570.1	RNF5P1	8.76	7.72e-18	1.04e-11	0.7	0.26	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27742386	chr8:38600661~38601200:-
BRCA	trans	rs9650657	0.655	rs1991651	ENSG00000253893.2	FAM85B	-8.76	7.73e-18	1.04e-11	-0.33	-0.26	Neuroticism;	chr8:10848901	chr8:8167819~8226614:-
BRCA	trans	rs6964833	0.935	rs35735900	ENSG00000214544.6	GTF2IRD2P1	-8.76	7.75e-18	1.04e-11	-0.39	-0.26	Menarche (age at onset);	chr7:74651887	chr7:73242751~73280119:-
BRCA	trans	rs3749237	1	rs6804655	ENSG00000197582.5	GPX1P1	8.76	7.88e-18	1.06e-11	0.28	0.26	Resting heart rate;	chr3:49701512	chrX:13378735~13379340:-
BRCA	trans	rs877636	0.74	rs705698	ENSG00000234354.3	RPS26P47	8.76	7.9e-18	1.06e-11	0.36	0.26	Cognitive function;	chr12:55990903	chr13:100539901~100540248:-
BRCA	trans	rs7824557	0.767	rs2060463	ENSG00000253893.2	FAM85B	-8.76	7.92e-18	1.07e-11	-0.36	-0.26	Retinal vascular caliber;	chr8:11304101	chr8:8167819~8226614:-
BRCA	trans	rs2069408	1	rs2069408	ENSG00000196933.5	RPS26P11	-8.75	8.14e-18	1.1e-11	-0.35	-0.26	Asthma;	chr12:55970537	chrX:72044545~72044892:+
BRCA	trans	rs941207	0.542	rs1870674	ENSG00000228224.3	NACAP1	-8.75	8.15e-18	1.1e-11	-0.32	-0.26	Platelet count;	chr12:56805721	chr8:101361794~101372707:+
BRCA	trans	rs9425766	0.678	rs1951625	ENSG00000213331.4	RP11-713C19.2	8.75	8.19e-18	1.1e-11	0.33	0.26	Life satisfaction;	chr1:173867464	chr4:187970273~187971284:+
BRCA	trans	rs7944735	0.817	rs7101582	ENSG00000134612.10	FOLH1B	8.75	8.23e-18	1.11e-11	0.37	0.26	Intraocular pressure;	chr11:47693058	chr11:89639227~89698718:+
BRCA	trans	rs867371	0.82	rs12443224	ENSG00000235370.6	DNM1P51	-8.75	8.25e-18	1.11e-11	-0.29	-0.26	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82203269	chr15:84398316~84411701:-
BRCA	trans	rs7824557	0.701	rs2060465	ENSG00000253893.2	FAM85B	-8.75	8.32e-18	1.12e-11	-0.36	-0.26	Retinal vascular caliber;	chr8:11305100	chr8:8167819~8226614:-
BRCA	trans	rs9650657	0.74	rs7002282	ENSG00000253893.2	FAM85B	8.75	8.34e-18	1.12e-11	0.33	0.26	Neuroticism;	chr8:10809483	chr8:8167819~8226614:-
BRCA	trans	rs864643	1	rs1708056	ENSG00000183298.5	RP11-556K13.1	8.75	8.37e-18	1.13e-11	0.41	0.26	Attention deficit hyperactivity disorder;	chr3:39531662	chr1:101786340~101787219:-
BRCA	trans	rs941207	0.542	rs10876928	ENSG00000228224.3	NACAP1	-8.75	8.59e-18	1.16e-11	-0.31	-0.26	Platelet count;	chr12:56813646	chr8:101361794~101372707:+
BRCA	trans	rs7662987	0.793	rs7684735	ENSG00000228407.2	RP4-800M22.1	8.75	8.6e-18	1.16e-11	0.46	0.26	Smoking initiation;	chr4:99070355	chr1:52160261~52160600:-
BRCA	trans	rs7929679	0.545	rs2421740	ENSG00000225531.1	RP11-196I18.3	8.75	8.75e-18	1.18e-11	0.34	0.26	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;	chr11:34775207	chr9:107116829~107117557:+
BRCA	trans	rs7929679	0.571	rs2136508	ENSG00000225531.1	RP11-196I18.3	8.75	8.75e-18	1.18e-11	0.34	0.26	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;	chr11:34775299	chr9:107116829~107117557:+
BRCA	trans	rs941207	0.542	rs12367312	ENSG00000228224.3	NACAP1	-8.74	9.07e-18	1.22e-11	-0.32	-0.26	Platelet count;	chr12:56809369	chr8:101361794~101372707:+
BRCA	trans	rs7113874	0.659	rs12295855	ENSG00000266891.1	RP11-692N5.2	8.74	9.17e-18	1.23e-11	0.35	0.26	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8505871	chr18:9734882~9735602:-
BRCA	trans	rs6964833	0.786	rs35633336	ENSG00000214544.6	GTF2IRD2P1	-8.74	9.2e-18	1.24e-11	-0.39	-0.26	Menarche (age at onset);	chr7:74643961	chr7:73242751~73280119:-
BRCA	trans	rs867371	0.896	rs8033831	ENSG00000235370.6	DNM1P51	-8.74	9.25e-18	1.24e-11	-0.29	-0.26	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82220953	chr15:84398316~84411701:-
BRCA	trans	rs9467711	0.79	rs13195401	ENSG00000253570.1	RNF5P1	8.74	9.27e-18	1.25e-11	0.75	0.26	Autism spectrum disorder or schizophrenia;	chr6:26463346	chr8:38600661~38601200:-
BRCA	trans	rs9467711	0.79	rs13195402	ENSG00000253570.1	RNF5P1	8.74	9.27e-18	1.25e-11	0.75	0.26	Autism spectrum disorder or schizophrenia;	chr6:26463347	chr8:38600661~38601200:-
BRCA	trans	rs7824557	0.767	rs11775635	ENSG00000253893.2	FAM85B	-8.74	9.37e-18	1.26e-11	-0.36	-0.26	Retinal vascular caliber;	chr8:11307356	chr8:8167819~8226614:-
BRCA	trans	rs875971	0.545	rs1796222	ENSG00000164669.11	INTS4P1	8.74	9.44e-18	1.27e-11	0.37	0.26	Aortic root size;	chr7:66592167	chr7:65141225~65234216:+
BRCA	trans	rs6964833	0.872	rs4717903	ENSG00000214544.6	GTF2IRD2P1	-8.73	9.73e-18	1.31e-11	-0.39	-0.26	Menarche (age at onset);	chr7:74653827	chr7:73242751~73280119:-
BRCA	trans	rs875971	0.545	rs35459055	ENSG00000164669.11	INTS4P1	-8.73	1.01e-17	1.35e-11	-0.36	-0.26	Aortic root size;	chr7:66479399	chr7:65141225~65234216:+
BRCA	trans	rs7824557	0.736	rs35392635	ENSG00000253893.2	FAM85B	-8.73	1.02e-17	1.37e-11	-0.36	-0.26	Retinal vascular caliber;	chr8:11306840	chr8:8167819~8226614:-
BRCA	trans	rs6743068	0.521	rs6710974	ENSG00000235105.1	RP11-329A14.1	8.72	1.05e-17	1.4e-11	0.3	0.26	Lymphocyte percentage of white cells;	chr2:201348659	chr1:48435967~48437223:+
BRCA	trans	rs7929679	0.602	rs11032870	ENSG00000225531.1	RP11-196I18.3	8.72	1.07e-17	1.44e-11	0.34	0.26	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;	chr11:34783977	chr9:107116829~107117557:+
BRCA	trans	rs66887589	0.776	rs10518337	ENSG00000275858.1	RP11-291L22.8	-8.72	1.08e-17	1.44e-11	-0.3	-0.26	Diastolic blood pressure;	chr4:119653719	chr10:38450738~38451069:-
BRCA	trans	rs6458375	1	rs6458375	ENSG00000205940.8	HSP90AB2P	8.72	1.08e-17	1.44e-11	0.36	0.26	Interleukin-10 levels;	chr6:44234615	chr4:13333414~13338657:+
BRCA	trans	rs656319	0.559	rs17689007	ENSG00000253893.2	FAM85B	8.72	1.08e-17	1.45e-11	0.32	0.26	Myopia (pathological);	chr8:10117314	chr8:8167819~8226614:-
BRCA	trans	rs3096299	0.685	rs12935112	ENSG00000215030.5	RPL13P12	8.72	1.09e-17	1.46e-11	0.26	0.26	Multiple myeloma (IgH translocation);	chr16:89476450	chr17:17383377~17384012:-
BRCA	trans	rs3749237	1	rs11130216	ENSG00000197582.5	GPX1P1	8.72	1.11e-17	1.49e-11	0.28	0.26	Resting heart rate;	chr3:49698739	chrX:13378735~13379340:-
BRCA	trans	rs877636	0.74	rs705702	ENSG00000234354.3	RPS26P47	-8.72	1.12e-17	1.49e-11	-0.36	-0.26	Cognitive function;	chr12:55996852	chr13:100539901~100540248:-
BRCA	trans	rs864643	0.891	rs1708032	ENSG00000183298.5	RP11-556K13.1	8.72	1.12e-17	1.5e-11	0.4	0.26	Attention deficit hyperactivity disorder;	chr3:39497642	chr1:101786340~101787219:-
BRCA	trans	rs875971	0.545	rs73148639	ENSG00000164669.11	INTS4P1	-8.72	1.13e-17	1.51e-11	-0.36	-0.26	Aortic root size;	chr7:66390342	chr7:65141225~65234216:+
BRCA	trans	rs7944735	0.508	rs76472587	ENSG00000134612.10	FOLH1B	8.71	1.14e-17	1.52e-11	0.42	0.26	Intraocular pressure;	chr11:47859935	chr11:89639227~89698718:+
BRCA	trans	rs875971	0.545	rs6950988	ENSG00000164669.11	INTS4P1	-8.71	1.14e-17	1.53e-11	-0.36	-0.26	Aortic root size;	chr7:66511428	chr7:65141225~65234216:+
BRCA	trans	rs9425766	0.64	rs1322774	ENSG00000213331.4	RP11-713C19.2	8.71	1.15e-17	1.53e-11	0.33	0.26	Life satisfaction;	chr1:173870102	chr4:187970273~187971284:+
BRCA	trans	rs7824557	1	rs2736371	ENSG00000253893.2	FAM85B	8.71	1.16e-17	1.56e-11	0.35	0.26	Retinal vascular caliber;	chr8:11248020	chr8:8167819~8226614:-
BRCA	trans	rs7927370	1	rs7115527	ENSG00000134612.10	FOLH1B	-8.71	1.17e-17	1.57e-11	-0.6	-0.26	Systemic lupus erythematosus;	chr11:55501379	chr11:89639227~89698718:+
BRCA	trans	rs4276421	0.55	rs7722380	ENSG00000231752.4	EMBP1	-8.71	1.18e-17	1.58e-11	-0.38	-0.26	P wave duration;	chr5:45678276	chr1:121519112~121571892:+
BRCA	trans	rs941207	0.542	rs12366897	ENSG00000228224.3	NACAP1	-8.71	1.2e-17	1.6e-11	-0.32	-0.26	Platelet count;	chr12:56808329	chr8:101361794~101372707:+
BRCA	trans	rs7824557	0.806	rs34171564	ENSG00000253893.2	FAM85B	8.7	1.23e-17	1.65e-11	0.34	0.26	Retinal vascular caliber;	chr8:11237837	chr8:8167819~8226614:-
BRCA	trans	rs2950393	0.572	rs10783794	ENSG00000228224.3	NACAP1	-8.7	1.27e-17	1.69e-11	-0.29	-0.26	Platelet distribution width;	chr12:56593395	chr8:101361794~101372707:+
BRCA	trans	rs1580019	0.844	rs4723159	ENSG00000176826.14	FKBP9P1	-8.7	1.27e-17	1.7e-11	-0.35	-0.26	Cognitive ability;	chr7:32473192	chr7:55681074~55713252:-
BRCA	trans	rs7824557	0.767	rs2164272	ENSG00000253893.2	FAM85B	-8.7	1.28e-17	1.71e-11	-0.36	-0.26	Retinal vascular caliber;	chr8:11304987	chr8:8167819~8226614:-
BRCA	trans	rs864643	0.947	rs1417147	ENSG00000183298.5	RP11-556K13.1	8.7	1.29e-17	1.72e-11	0.4	0.26	Attention deficit hyperactivity disorder;	chr3:39499236	chr1:101786340~101787219:-
BRCA	trans	rs2069408	1	rs2069408	ENSG00000223416.3	RPS26P15	-8.7	1.29e-17	1.72e-11	-0.33	-0.26	Asthma;	chr12:55970537	chr1:58056133~58056480:-
BRCA	trans	rs3749237	0.964	rs34522271	ENSG00000197582.5	GPX1P1	8.7	1.29e-17	1.73e-11	0.28	0.26	Resting heart rate;	chr3:49771084	chrX:13378735~13379340:-
BRCA	trans	rs9467711	0.79	rs13198716	ENSG00000253570.1	RNF5P1	-8.69	1.36e-17	1.81e-11	-0.71	-0.26	Autism spectrum disorder or schizophrenia;	chr6:26581807	chr8:38600661~38601200:-
BRCA	trans	rs875971	0.545	rs10950036	ENSG00000164669.11	INTS4P1	-8.69	1.38e-17	1.84e-11	-0.36	-0.26	Aortic root size;	chr7:66353241	chr7:65141225~65234216:+
BRCA	trans	rs2736345	0.788	rs998683	ENSG00000253893.2	FAM85B	8.69	1.38e-17	1.85e-11	0.36	0.26	Systemic lupus erythematosus;Sjögren's syndrome;	chr8:11495491	chr8:8167819~8226614:-
BRCA	trans	rs7929679	0.602	rs1588354	ENSG00000225531.1	RP11-196I18.3	8.69	1.39e-17	1.85e-11	0.34	0.26	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;	chr11:34786939	chr9:107116829~107117557:+
BRCA	trans	rs1816752	0.646	rs2862905	ENSG00000224976.2	PARP4P2	8.69	1.4e-17	1.86e-11	0.32	0.26	Obesity-related traits;	chr13:24485142	chr13:19349137~19407962:+
BRCA	trans	rs7113874	0.659	rs12574009	ENSG00000266891.1	RP11-692N5.2	8.69	1.42e-17	1.89e-11	0.35	0.26	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8498406	chr18:9734882~9735602:-
BRCA	trans	rs714543	1	rs8840	ENSG00000226038.5	PPIAP21	8.69	1.43e-17	1.9e-11	0.32	0.26	Plateletcrit;	chr7:44877441	chr20:43230760~43231260:+
BRCA	trans	rs7929679	0.602	rs10836310	ENSG00000225531.1	RP11-196I18.3	8.69	1.44e-17	1.91e-11	0.34	0.26	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;	chr11:34787373	chr9:107116829~107117557:+
BRCA	trans	rs7824557	0.872	rs1347410	ENSG00000253893.2	FAM85B	8.69	1.44e-17	1.92e-11	0.34	0.26	Retinal vascular caliber;	chr8:11253733	chr8:8167819~8226614:-
BRCA	trans	rs877636	0.859	rs3741499	ENSG00000243538.1	CTB-55B8.1	-8.68	1.45e-17	1.93e-11	-0.31	-0.26	Cognitive function;	chr12:56080595	chr5:16902294~16902641:-
BRCA	trans	rs6831352	0.734	rs1154400	ENSG00000233859.2	ADH5P4	-8.68	1.46e-17	1.94e-11	-0.35	-0.26	Alcohol dependence;	chr4:99088859	chr6:65836930~65838039:-
BRCA	trans	rs867371	0.929	rs1501371	ENSG00000235370.6	DNM1P51	-8.68	1.49e-17	1.98e-11	-0.29	-0.26	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82168099	chr15:84398316~84411701:-
BRCA	trans	rs4276421	0.55	rs4242126	ENSG00000231752.4	EMBP1	-8.68	1.49e-17	1.98e-11	-0.38	-0.26	P wave duration;	chr5:45826271	chr1:121519112~121571892:+
BRCA	trans	rs6831352	0.819	rs1230155	ENSG00000233859.2	ADH5P4	-8.68	1.49e-17	1.99e-11	-0.35	-0.26	Alcohol dependence;	chr4:99068108	chr6:65836930~65838039:-
BRCA	trans	rs12477438	0.52	rs34766932	ENSG00000276576.1	MRPL30P1	8.68	1.5e-17	2e-11	0.33	0.26	Chronic sinus infection;	chr2:99120810	chr6:57029521~57029988:+
BRCA	trans	rs4276421	0.593	rs10941704	ENSG00000231752.4	EMBP1	-8.68	1.5e-17	2e-11	-0.4	-0.26	P wave duration;	chr5:45783404	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.55	rs34423213	ENSG00000231752.4	EMBP1	8.68	1.51e-17	2.01e-11	0.39	0.26	P wave duration;	chr5:45680866	chr1:121519112~121571892:+
BRCA	trans	rs9329221	0.62	rs6601427	ENSG00000253893.2	FAM85B	8.68	1.51e-17	2.02e-11	0.32	0.26	Neuroticism;	chr8:10298515	chr8:8167819~8226614:-
BRCA	trans	rs546131	0.928	rs535719	ENSG00000225531.1	RP11-196I18.3	8.68	1.53e-17	2.04e-11	0.36	0.26	Lung disease severity in cystic fibrosis;	chr11:34831835	chr9:107116829~107117557:+
BRCA	trans	rs941207	0.542	rs11171979	ENSG00000228224.3	NACAP1	-8.67	1.6e-17	2.12e-11	-0.32	-0.26	Platelet count;	chr12:56802199	chr8:101361794~101372707:+
BRCA	trans	rs7113874	0.613	rs10840066	ENSG00000266891.1	RP11-692N5.2	8.67	1.6e-17	2.13e-11	0.35	0.26	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8510456	chr18:9734882~9735602:-
BRCA	trans	rs7824557	0.767	rs17797443	ENSG00000253893.2	FAM85B	-8.67	1.61e-17	2.14e-11	-0.36	-0.26	Retinal vascular caliber;	chr8:11306503	chr8:8167819~8226614:-
BRCA	trans	rs7819412	0.595	rs10106914	ENSG00000253893.2	FAM85B	8.67	1.63e-17	2.17e-11	0.33	0.26	Triglycerides;	chr8:11130141	chr8:8167819~8226614:-
BRCA	trans	rs1816752	0.669	rs9553309	ENSG00000224976.2	PARP4P2	8.67	1.64e-17	2.18e-11	0.32	0.26	Obesity-related traits;	chr13:24471476	chr13:19349137~19407962:+
BRCA	trans	rs2665103	0.715	rs7403041	ENSG00000235370.6	DNM1P51	8.67	1.66e-17	2.2e-11	0.28	0.26	Intelligence (multi-trait analysis);	chr15:82287841	chr15:84398316~84411701:-
BRCA	trans	rs864643	1	rs574074	ENSG00000183298.5	RP11-556K13.1	8.67	1.66e-17	2.21e-11	0.45	0.26	Attention deficit hyperactivity disorder;	chr3:39520090	chr1:101786340~101787219:-
BRCA	trans	rs3749237	0.964	rs11714957	ENSG00000197582.5	GPX1P1	8.67	1.68e-17	2.23e-11	0.27	0.26	Resting heart rate;	chr3:49738745	chrX:13378735~13379340:-
BRCA	trans	rs4276421	0.55	rs1852598	ENSG00000231752.4	EMBP1	8.66	1.74e-17	2.32e-11	0.39	0.26	P wave duration;	chr5:45602874	chr1:121519112~121571892:+
BRCA	trans	rs66887589	0.807	rs7694483	ENSG00000275858.1	RP11-291L22.8	8.66	1.75e-17	2.32e-11	0.29	0.26	Diastolic blood pressure;	chr4:119484774	chr10:38450738~38451069:-
BRCA	trans	rs10420951	0.617	rs3746176	ENSG00000267533.1	RP11-815J4.7	8.66	1.76e-17	2.33e-11	0.46	0.26	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr19:18458141	chr18:12067173~12068417:-
BRCA	trans	rs7113874	0.659	rs2166470	ENSG00000266891.1	RP11-692N5.2	-8.65	1.87e-17	2.48e-11	-0.34	-0.26	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8501625	chr18:9734882~9735602:-
BRCA	trans	rs1816752	0.669	rs2862906	ENSG00000224976.2	PARP4P2	8.65	1.89e-17	2.51e-11	0.32	0.26	Obesity-related traits;	chr13:24494482	chr13:19349137~19407962:+
BRCA	trans	rs9467773	0.526	rs3734536	ENSG00000242375.1	RP11-498P14.3	-8.64	2.03e-17	2.69e-11	-0.36	-0.26	Intelligence (multi-trait analysis);	chr6:26365118	chr9:97195351~97197687:-
BRCA	trans	rs7929679	0.602	rs10836311	ENSG00000225531.1	RP11-196I18.3	8.64	2.04e-17	2.7e-11	0.34	0.26	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;	chr11:34787619	chr9:107116829~107117557:+
BRCA	trans	rs6831352	0.734	rs2602856	ENSG00000233859.2	ADH5P4	-8.64	2.07e-17	2.73e-11	-0.33	-0.26	Alcohol dependence;	chr4:99107994	chr6:65836930~65838039:-
BRCA	trans	rs3749237	0.964	rs35210174	ENSG00000197582.5	GPX1P1	8.64	2.09e-17	2.76e-11	0.27	0.26	Resting heart rate;	chr3:49775173	chrX:13378735~13379340:-
BRCA	trans	rs7113874	0.802	rs1502317	ENSG00000266891.1	RP11-692N5.2	8.64	2.09e-17	2.77e-11	0.33	0.26	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8660471	chr18:9734882~9735602:-
BRCA	trans	rs7819412	0.668	rs920047	ENSG00000253893.2	FAM85B	8.64	2.09e-17	2.77e-11	0.33	0.26	Triglycerides;	chr8:11229966	chr8:8167819~8226614:-
BRCA	trans	rs12477438	0.52	rs13035311	ENSG00000276576.1	MRPL30P1	8.64	2.11e-17	2.78e-11	0.33	0.26	Chronic sinus infection;	chr2:99100859	chr6:57029521~57029988:+
BRCA	trans	rs9329221	0.638	rs12543645	ENSG00000253893.2	FAM85B	8.64	2.13e-17	2.81e-11	0.34	0.26	Neuroticism;	chr8:10388815	chr8:8167819~8226614:-
BRCA	trans	rs877636	0.74	rs705698	ENSG00000196656.7	AC004057.1	8.63	2.21e-17	2.91e-11	0.34	0.26	Cognitive function;	chr12:55990903	chr4:113214046~113217170:-
BRCA	trans	rs1580019	0.885	rs1610141	ENSG00000176826.14	FKBP9P1	-8.63	2.23e-17	2.94e-11	-0.34	-0.26	Cognitive ability;	chr7:32458823	chr7:55681074~55713252:-
BRCA	trans	rs13014235	0.846	rs10454127	ENSG00000235105.1	RP11-329A14.1	8.63	2.24e-17	2.96e-11	0.31	0.26	Basal cell carcinoma;	chr2:201347651	chr1:48435967~48437223:+
BRCA	trans	rs8010715	0.636	rs2277480	ENSG00000238000.1	RP11-274E7.2	8.63	2.26e-17	2.98e-11	0.29	0.26	IgG glycosylation;	chr14:24118306	chr5:98213402~98214121:+
BRCA	trans	rs1580019	0.844	rs1037322	ENSG00000176826.14	FKBP9P1	-8.63	2.31e-17	3.05e-11	-0.34	-0.26	Cognitive ability;	chr7:32462245	chr7:55681074~55713252:-
BRCA	trans	rs9876781	0.56	rs2362451	ENSG00000235912.1	RP1-159A19.3	8.63	2.33e-17	3.07e-11	0.29	0.26	Longevity;	chr3:48358338	chr1:27649419~27649610:+
BRCA	trans	rs6831352	0.819	rs2851274	ENSG00000233859.2	ADH5P4	-8.63	2.34e-17	3.08e-11	-0.33	-0.26	Alcohol dependence;	chr4:99104715	chr6:65836930~65838039:-
BRCA	trans	rs864643	0.678	rs500507	ENSG00000183298.5	RP11-556K13.1	8.62	2.36e-17	3.11e-11	0.4	0.26	Attention deficit hyperactivity disorder;	chr3:39492886	chr1:101786340~101787219:-
BRCA	trans	rs6743068	0.521	rs12472273	ENSG00000235105.1	RP11-329A14.1	8.62	2.45e-17	3.23e-11	0.3	0.26	Lymphocyte percentage of white cells;	chr2:201346972	chr1:48435967~48437223:+
BRCA	trans	rs1580019	0.844	rs1901202	ENSG00000176826.14	FKBP9P1	-8.62	2.51e-17	3.3e-11	-0.34	-0.26	Cognitive ability;	chr7:32464112	chr7:55681074~55713252:-
BRCA	trans	rs9425766	0.64	rs2208850	ENSG00000213331.4	RP11-713C19.2	8.62	2.52e-17	3.32e-11	0.32	0.26	Life satisfaction;	chr1:173862569	chr4:187970273~187971284:+
BRCA	trans	rs877636	0.702	rs61937249	ENSG00000243538.1	CTB-55B8.1	8.62	2.55e-17	3.36e-11	0.33	0.26	Cognitive function;	chr12:55988132	chr5:16902294~16902641:-
BRCA	trans	rs12210905	0.841	rs28410967	ENSG00000242375.1	RP11-498P14.3	-8.61	2.59e-17	3.41e-11	-0.65	-0.26	Hip circumference adjusted for BMI;	chr6:27297456	chr9:97195351~97197687:-
BRCA	trans	rs12210905	0.92	rs72839451	ENSG00000242375.1	RP11-498P14.3	-8.61	2.59e-17	3.41e-11	-0.65	-0.26	Hip circumference adjusted for BMI;	chr6:27297658	chr9:97195351~97197687:-
BRCA	trans	rs2069408	1	rs2069408	ENSG00000227887.1	RPS26P13	-8.61	2.65e-17	3.48e-11	-0.34	-0.26	Asthma;	chr12:55970537	chr1:208697369~208697698:-
BRCA	trans	rs10420951	0.542	rs2303693	ENSG00000267533.1	RP11-815J4.7	-8.61	2.69e-17	3.54e-11	-0.45	-0.26	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr19:18446863	chr18:12067173~12068417:-
BRCA	trans	rs11250097	0.507	rs2409779	ENSG00000253893.2	FAM85B	8.6	2.78e-17	3.65e-11	0.35	0.26	Neuroticism;	chr8:11453831	chr8:8167819~8226614:-
BRCA	trans	rs875971	0.545	rs12670811	ENSG00000164669.11	INTS4P1	-8.6	2.86e-17	3.76e-11	-0.36	-0.26	Aortic root size;	chr7:66358032	chr7:65141225~65234216:+
BRCA	trans	rs875971	0.545	rs13311962	ENSG00000164669.11	INTS4P1	8.6	2.88e-17	3.78e-11	0.36	0.26	Aortic root size;	chr7:66603142	chr7:65141225~65234216:+
BRCA	trans	rs6831352	0.819	rs1154401	ENSG00000233859.2	ADH5P4	-8.6	2.89e-17	3.8e-11	-0.33	-0.26	Alcohol dependence;	chr4:99088587	chr6:65836930~65838039:-
BRCA	trans	rs6831352	0.819	rs1230158	ENSG00000233859.2	ADH5P4	-8.6	2.95e-17	3.87e-11	-0.34	-0.26	Alcohol dependence;	chr4:99069035	chr6:65836930~65838039:-
BRCA	trans	rs7824557	0.806	rs7007394	ENSG00000253893.2	FAM85B	8.6	2.96e-17	3.88e-11	0.34	0.26	Retinal vascular caliber;	chr8:11237057	chr8:8167819~8226614:-
BRCA	trans	rs12477438	0.52	rs6708576	ENSG00000276576.1	MRPL30P1	8.6	2.99e-17	3.92e-11	0.32	0.26	Chronic sinus infection;	chr2:99184845	chr6:57029521~57029988:+
BRCA	trans	rs10242455	0.614	rs2014764	ENSG00000228834.1	RP11-249L21.4	-8.6	3e-17	3.93e-11	-0.4	-0.26	Blood metabolite levels;	chr7:99749883	chr6:108907615~108907873:-
BRCA	trans	rs7824557	0.806	rs6601574	ENSG00000253893.2	FAM85B	8.6	3e-17	3.93e-11	0.34	0.26	Retinal vascular caliber;	chr8:11237376	chr8:8167819~8226614:-
BRCA	trans	rs1045902	0.574	rs1474298	ENSG00000236165.1	PRADC1P1	8.59	3.03e-17	3.97e-11	0.37	0.26	Intelligence (multi-trait analysis);	chr2:73239464	chr3:36976316~36976840:+
BRCA	trans	rs9393777	0.92	rs67859638	ENSG00000253570.1	RNF5P1	8.59	3.03e-17	3.98e-11	0.78	0.26	Intelligence (multi-trait analysis);	chr6:27390199	chr8:38600661~38601200:-
BRCA	trans	rs3749237	0.964	rs7431078	ENSG00000197582.5	GPX1P1	8.59	3.08e-17	4.04e-11	0.27	0.26	Resting heart rate;	chr3:49770757	chrX:13378735~13379340:-
BRCA	trans	rs3749237	1	rs11710675	ENSG00000197582.5	GPX1P1	8.59	3.08e-17	4.04e-11	0.27	0.26	Resting heart rate;	chr3:49714467	chrX:13378735~13379340:-
BRCA	trans	rs11992162	0.967	rs10088415	ENSG00000253893.2	FAM85B	8.59	3.12e-17	4.08e-11	0.32	0.26	Monocyte count;	chr8:11973316	chr8:8167819~8226614:-
BRCA	trans	rs877636	0.74	rs705702	ENSG00000243538.1	CTB-55B8.1	-8.58	3.28e-17	4.29e-11	-0.33	-0.26	Cognitive function;	chr12:55996852	chr5:16902294~16902641:-
BRCA	trans	rs12155039	1	rs12155039	ENSG00000226038.5	PPIAP21	-8.58	3.28e-17	4.3e-11	-0.32	-0.26	Mean platelet volume;	chr7:44833526	chr20:43230760~43231260:+
BRCA	trans	rs7944735	0.508	rs77073917	ENSG00000134612.10	FOLH1B	8.58	3.31e-17	4.33e-11	0.41	0.26	Intraocular pressure;	chr11:47833423	chr11:89639227~89698718:+
BRCA	trans	rs546131	0.82	rs744841	ENSG00000225531.1	RP11-196I18.3	8.58	3.42e-17	4.47e-11	0.36	0.26	Lung disease severity in cystic fibrosis;	chr11:34836120	chr9:107116829~107117557:+
BRCA	trans	rs9650657	0.74	rs12676417	ENSG00000253893.2	FAM85B	-8.58	3.45e-17	4.51e-11	-0.32	-0.26	Neuroticism;	chr8:10811124	chr8:8167819~8226614:-
BRCA	trans	rs875971	0.545	rs6961853	ENSG00000164669.11	INTS4P1	-8.58	3.49e-17	4.56e-11	-0.36	-0.26	Aortic root size;	chr7:66537035	chr7:65141225~65234216:+
BRCA	trans	rs66887589	0.72	rs11724758	ENSG00000275858.1	RP11-291L22.8	8.58	3.53e-17	4.62e-11	0.29	0.26	Diastolic blood pressure;	chr4:119318723	chr10:38450738~38451069:-
BRCA	trans	rs12477438	0.52	rs11678456	ENSG00000276576.1	MRPL30P1	8.57	3.62e-17	4.73e-11	0.32	0.26	Chronic sinus infection;	chr2:99091774	chr6:57029521~57029988:+
BRCA	trans	rs877636	0.74	rs705702	ENSG00000204652.6	RPS26P8	-8.57	3.63e-17	4.74e-11	-0.35	-0.26	Cognitive function;	chr12:55996852	chr17:45608571~45608918:+
BRCA	trans	rs7824557	0.767	rs1897950	ENSG00000253893.2	FAM85B	-8.57	3.76e-17	4.91e-11	-0.36	-0.26	Retinal vascular caliber;	chr8:11312042	chr8:8167819~8226614:-
BRCA	trans	rs546131	0.89	rs485845	ENSG00000225531.1	RP11-196I18.3	-8.57	3.77e-17	4.92e-11	-0.36	-0.26	Lung disease severity in cystic fibrosis;	chr11:34808842	chr9:107116829~107117557:+
BRCA	trans	rs875971	0.545	rs1796217	ENSG00000164669.11	INTS4P1	8.57	3.78e-17	4.94e-11	0.36	0.26	Aortic root size;	chr7:66620931	chr7:65141225~65234216:+
BRCA	trans	rs1580019	0.885	rs3801331	ENSG00000176826.14	FKBP9P1	8.56	3.86e-17	5.03e-11	0.34	0.26	Cognitive ability;	chr7:32457427	chr7:55681074~55713252:-
BRCA	trans	rs6831352	0.734	rs3018046	ENSG00000233859.2	ADH5P4	-8.56	3.89e-17	5.08e-11	-0.34	-0.26	Alcohol dependence;	chr4:99109237	chr6:65836930~65838039:-
BRCA	trans	rs877636	0.74	rs772920	ENSG00000243538.1	CTB-55B8.1	8.56	3.94e-17	5.13e-11	0.33	0.26	Cognitive function;	chr12:55996580	chr5:16902294~16902641:-
BRCA	trans	rs9467711	0.606	rs9379875	ENSG00000253570.1	RNF5P1	8.56	4.02e-17	5.24e-11	0.62	0.26	Autism spectrum disorder or schizophrenia;	chr6:26444504	chr8:38600661~38601200:-
BRCA	trans	rs9467711	0.538	rs35942482	ENSG00000253570.1	RNF5P1	8.56	4.02e-17	5.24e-11	0.62	0.26	Autism spectrum disorder or schizophrenia;	chr6:26444710	chr8:38600661~38601200:-
BRCA	trans	rs6831352	0.703	rs2602854	ENSG00000233859.2	ADH5P4	-8.56	4.04e-17	5.26e-11	-0.34	-0.26	Alcohol dependence;	chr4:99107500	chr6:65836930~65838039:-
BRCA	trans	rs7944735	0.567	rs76477746	ENSG00000134612.10	FOLH1B	8.56	4.05e-17	5.28e-11	0.52	0.26	Intraocular pressure;	chr11:48081816	chr11:89639227~89698718:+
BRCA	trans	rs546131	0.928	rs516228	ENSG00000225531.1	RP11-196I18.3	8.56	4.14e-17	5.39e-11	0.35	0.26	Lung disease severity in cystic fibrosis;	chr11:34817276	chr9:107116829~107117557:+
BRCA	trans	rs7824557	0.767	rs1897951	ENSG00000253893.2	FAM85B	-8.55	4.26e-17	5.55e-11	-0.35	-0.26	Retinal vascular caliber;	chr8:11312345	chr8:8167819~8226614:-
BRCA	trans	rs875971	0.545	rs2707851	ENSG00000164669.11	INTS4P1	8.55	4.27e-17	5.55e-11	0.36	0.26	Aortic root size;	chr7:66624178	chr7:65141225~65234216:+
BRCA	trans	rs6831352	0.734	rs2602857	ENSG00000233859.2	ADH5P4	-8.55	4.28e-17	5.57e-11	-0.34	-0.26	Alcohol dependence;	chr4:99109167	chr6:65836930~65838039:-
BRCA	trans	rs66887589	0.967	rs59516282	ENSG00000275858.1	RP11-291L22.8	-8.55	4.38e-17	5.7e-11	-0.28	-0.26	Diastolic blood pressure;	chr4:119580861	chr10:38450738~38451069:-
BRCA	trans	rs9650657	0.836	rs6601523	ENSG00000253893.2	FAM85B	8.55	4.4e-17	5.73e-11	0.33	0.26	Neuroticism;	chr8:10777631	chr8:8167819~8226614:-
BRCA	trans	rs12477438	0.52	rs11123761	ENSG00000276576.1	MRPL30P1	8.55	4.42e-17	5.76e-11	0.32	0.26	Chronic sinus infection;	chr2:99089440	chr6:57029521~57029988:+
BRCA	trans	rs875971	0.545	rs73152714	ENSG00000164669.11	INTS4P1	-8.55	4.47e-17	5.81e-11	-0.36	-0.26	Aortic root size;	chr7:66534641	chr7:65141225~65234216:+
BRCA	trans	rs875971	0.545	rs4718364	ENSG00000164669.11	INTS4P1	-8.55	4.47e-17	5.81e-11	-0.36	-0.26	Aortic root size;	chr7:66536353	chr7:65141225~65234216:+
BRCA	trans	rs875971	0.545	rs801199	ENSG00000164669.11	INTS4P1	8.55	4.47e-17	5.81e-11	0.36	0.26	Aortic root size;	chr7:66560286	chr7:65141225~65234216:+
BRCA	trans	rs11220237	0.62	rs11220184	ENSG00000236257.1	EI24P2	8.54	4.56e-17	5.93e-11	0.41	0.26	Itch intensity from mosquito bite adjusted by bite size;	chr11:125681713	chr1:158454198~158455273:+
BRCA	trans	rs12477438	0.52	rs4402818	ENSG00000276576.1	MRPL30P1	8.54	4.61e-17	5.99e-11	0.32	0.26	Chronic sinus infection;	chr2:99101145	chr6:57029521~57029988:+
BRCA	trans	rs7824557	0.806	rs6601573	ENSG00000253893.2	FAM85B	8.54	4.61e-17	5.99e-11	0.33	0.26	Retinal vascular caliber;	chr8:11237242	chr8:8167819~8226614:-
BRCA	trans	rs10420951	0.617	rs79888481	ENSG00000267533.1	RP11-815J4.7	8.54	4.63e-17	6.01e-11	0.45	0.26	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr19:18459147	chr18:12067173~12068417:-
BRCA	trans	rs875971	0.545	rs1267814	ENSG00000164669.11	INTS4P1	8.54	4.77e-17	6.19e-11	0.36	0.26	Aortic root size;	chr7:66579422	chr7:65141225~65234216:+
BRCA	trans	rs875971	0.597	rs11763224	ENSG00000164669.11	INTS4P1	-8.54	4.87e-17	6.32e-11	-0.36	-0.26	Aortic root size;	chr7:66518628	chr7:65141225~65234216:+
BRCA	trans	rs714543	0.585	rs9655458	ENSG00000214975.4	PPIAP29	8.54	4.88e-17	6.34e-11	0.29	0.26	Plateletcrit;	chr7:44771386	chr6:24976419~24976982:+
BRCA	trans	rs6831352	0.734	rs3100630	ENSG00000233859.2	ADH5P4	-8.53	4.93e-17	6.4e-11	-0.34	-0.26	Alcohol dependence;	chr4:99110564	chr6:65836930~65838039:-
BRCA	trans	rs6831352	0.703	rs3133152	ENSG00000233859.2	ADH5P4	-8.53	4.93e-17	6.4e-11	-0.34	-0.26	Alcohol dependence;	chr4:99110570	chr6:65836930~65838039:-
BRCA	trans	rs7944735	0.507	rs7396592	ENSG00000134612.10	FOLH1B	-8.53	5.01e-17	6.5e-11	-0.35	-0.26	Intraocular pressure;	chr11:48079285	chr11:89639227~89698718:+
BRCA	trans	rs10420951	0.579	rs75445489	ENSG00000267533.1	RP11-815J4.7	8.53	5.1e-17	6.61e-11	0.45	0.26	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr19:18460340	chr18:12067173~12068417:-
BRCA	trans	rs73108077	0.831	rs73116281	ENSG00000279352.1	RP11-411B10.7	8.53	5.13e-17	6.65e-11	0.61	0.26	Red blood cell density in sickle cell anemia;	chr20:31478547	chr18:14010054~14010917:+
BRCA	trans	rs864643	0.945	rs1768254	ENSG00000183298.5	RP11-556K13.1	8.53	5.13e-17	6.65e-11	0.43	0.26	Attention deficit hyperactivity disorder;	chr3:39506929	chr1:101786340~101787219:-
BRCA	trans	rs7824557	0.767	rs7837036	ENSG00000253893.2	FAM85B	-8.53	5.14e-17	6.66e-11	-0.36	-0.26	Retinal vascular caliber;	chr8:11317980	chr8:8167819~8226614:-
BRCA	trans	rs7824557	0.767	rs6991606	ENSG00000253893.2	FAM85B	-8.53	5.23e-17	6.78e-11	-0.35	-0.26	Retinal vascular caliber;	chr8:11318650	chr8:8167819~8226614:-
BRCA	trans	rs7824557	0.734	rs2293856	ENSG00000253893.2	FAM85B	-8.52	5.31e-17	6.87e-11	-0.35	-0.26	Retinal vascular caliber;	chr8:11319938	chr8:8167819~8226614:-
BRCA	trans	rs4276421	0.55	rs1405916	ENSG00000231752.4	EMBP1	8.52	5.31e-17	6.88e-11	0.39	0.26	P wave duration;	chr5:45673782	chr1:121519112~121571892:+
BRCA	trans	rs7929679	0.602	rs10742326	ENSG00000225531.1	RP11-196I18.3	8.52	5.32e-17	6.89e-11	0.33	0.26	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;	chr11:34788463	chr9:107116829~107117557:+
BRCA	trans	rs7929679	0.602	rs10836312	ENSG00000225531.1	RP11-196I18.3	8.52	5.32e-17	6.89e-11	0.33	0.26	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;	chr11:34788896	chr9:107116829~107117557:+
BRCA	trans	rs3096299	0.563	rs4600467	ENSG00000215030.5	RPL13P12	-8.52	5.34e-17	6.91e-11	-0.27	-0.26	Multiple myeloma (IgH translocation);	chr16:89496108	chr17:17383377~17384012:-
BRCA	trans	rs66887589	0.616	rs13113885	ENSG00000275858.1	RP11-291L22.8	8.52	5.4e-17	6.98e-11	0.3	0.26	Diastolic blood pressure;	chr4:119300021	chr10:38450738~38451069:-
BRCA	trans	rs9467711	0.606	rs2393667	ENSG00000253570.1	RNF5P1	8.52	5.49e-17	7.1e-11	0.62	0.26	Autism spectrum disorder or schizophrenia;	chr6:26421117	chr8:38600661~38601200:-
BRCA	trans	rs66887589	0.934	rs7672519	ENSG00000275858.1	RP11-291L22.8	-8.52	5.51e-17	7.12e-11	-0.29	-0.26	Diastolic blood pressure;	chr4:119622957	chr10:38450738~38451069:-
BRCA	trans	rs1190596	0.567	rs8005884	ENSG00000181359.5	HSP90AA6P	-8.52	5.55e-17	7.17e-11	-0.38	-0.26	Behavioural disinhibition (generation interaction);	chr14:102226670	chr4:170581470~170605450:-
BRCA	trans	rs9467711	0.606	rs2076030	ENSG00000253570.1	RNF5P1	8.52	5.58e-17	7.22e-11	0.62	0.26	Autism spectrum disorder or schizophrenia;	chr6:26426628	chr8:38600661~38601200:-
BRCA	trans	rs66887589	0.934	rs6817317	ENSG00000275858.1	RP11-291L22.8	-8.52	5.61e-17	7.25e-11	-0.29	-0.26	Diastolic blood pressure;	chr4:119621672	chr10:38450738~38451069:-
BRCA	trans	rs66887589	0.87	rs59590064	ENSG00000275858.1	RP11-291L22.8	-8.52	5.72e-17	7.39e-11	-0.29	-0.26	Diastolic blood pressure;	chr4:119618598	chr10:38450738~38451069:-
BRCA	trans	rs12477438	0.501	rs9941561	ENSG00000276576.1	MRPL30P1	8.52	5.74e-17	7.42e-11	0.32	0.26	Chronic sinus infection;	chr2:99137366	chr6:57029521~57029988:+
BRCA	trans	rs11250097	0.549	rs11778177	ENSG00000253893.2	FAM85B	8.51	5.79e-17	7.48e-11	0.34	0.26	Neuroticism;	chr8:11452853	chr8:8167819~8226614:-
BRCA	trans	rs11250097	0.549	rs11784897	ENSG00000253893.2	FAM85B	8.51	5.82e-17	7.51e-11	0.34	0.26	Neuroticism;	chr8:11452933	chr8:8167819~8226614:-
BRCA	trans	rs12477438	0.501	rs12995473	ENSG00000276576.1	MRPL30P1	8.51	5.89e-17	7.6e-11	0.32	0.25	Chronic sinus infection;	chr2:99148421	chr6:57029521~57029988:+
BRCA	trans	rs12477438	0.501	rs11685756	ENSG00000276576.1	MRPL30P1	8.51	5.89e-17	7.6e-11	0.32	0.25	Chronic sinus infection;	chr2:99149752	chr6:57029521~57029988:+
BRCA	trans	rs714543	0.585	rs9655458	ENSG00000219797.2	PPIAP9	8.51	5.9e-17	7.62e-11	0.3	0.25	Plateletcrit;	chr7:44771386	chr6:31519480~31520291:-
BRCA	trans	rs1580019	0.961	rs3801328	ENSG00000176826.14	FKBP9P1	-8.51	5.92e-17	7.64e-11	-0.32	-0.25	Cognitive ability;	chr7:32457318	chr7:55681074~55713252:-
BRCA	trans	rs1580019	0.961	rs1580022	ENSG00000176826.14	FKBP9P1	-8.51	5.92e-17	7.64e-11	-0.32	-0.25	Cognitive ability;	chr7:32458100	chr7:55681074~55713252:-
BRCA	trans	rs1580019	0.961	rs1610143	ENSG00000176826.14	FKBP9P1	-8.51	5.92e-17	7.64e-11	-0.32	-0.25	Cognitive ability;	chr7:32458719	chr7:55681074~55713252:-
BRCA	trans	rs875971	0.545	rs1796219	ENSG00000164669.11	INTS4P1	8.51	6.09e-17	7.86e-11	0.37	0.25	Aortic root size;	chr7:66645977	chr7:65141225~65234216:+
BRCA	trans	rs3740713	0.669	rs34740438	ENSG00000214110.3	LDHAP4	8.51	6.11e-17	7.89e-11	0.47	0.25	Amyotrophic lateral sclerosis (sporadic);	chr11:18393783	chr9:14921337~14922334:-
BRCA	trans	rs12477438	0.52	rs6542869	ENSG00000276576.1	MRPL30P1	8.51	6.16e-17	7.94e-11	0.32	0.25	Chronic sinus infection;	chr2:99166940	chr6:57029521~57029988:+
BRCA	trans	rs1580019	0.961	rs2392056	ENSG00000176826.14	FKBP9P1	-8.51	6.17e-17	7.95e-11	-0.32	-0.25	Cognitive ability;	chr7:32459341	chr7:55681074~55713252:-
BRCA	trans	rs877636	0.702	rs773112	ENSG00000243538.1	CTB-55B8.1	8.5	6.24e-17	8.04e-11	0.33	0.25	Cognitive function;	chr12:55982097	chr5:16902294~16902641:-
BRCA	trans	rs1580019	0.921	rs1580023	ENSG00000176826.14	FKBP9P1	-8.5	6.26e-17	8.08e-11	-0.32	-0.25	Cognitive ability;	chr7:32458269	chr7:55681074~55713252:-
BRCA	trans	rs7824557	0.737	rs2293855	ENSG00000253893.2	FAM85B	-8.5	6.29e-17	8.11e-11	-0.35	-0.25	Retinal vascular caliber;	chr8:11319901	chr8:8167819~8226614:-
BRCA	trans	rs7944735	0.508	rs4752877	ENSG00000134612.10	FOLH1B	8.5	6.29e-17	8.11e-11	0.41	0.25	Intraocular pressure;	chr11:47864613	chr11:89639227~89698718:+
BRCA	trans	rs6831352	0.734	rs1311620	ENSG00000233859.2	ADH5P4	-8.5	6.29e-17	8.12e-11	-0.34	-0.25	Alcohol dependence;	chr4:99091940	chr6:65836930~65838039:-
BRCA	trans	rs2524005	1	rs2524005	ENSG00000253570.1	RNF5P1	8.5	6.35e-17	8.19e-11	0.45	0.25	Bipolar disorder and schizophrenia;	chr6:29931900	chr8:38600661~38601200:-
BRCA	trans	rs2060793	0.712	rs11023310	ENSG00000236360.2	RP11-334A14.2	8.5	6.61e-17	8.51e-11	0.32	0.25	Vitamin D levels;	chr11:14703717	chr1:52993201~52993702:-
BRCA	trans	rs1580019	0.961	rs1580021	ENSG00000176826.14	FKBP9P1	-8.5	6.7e-17	8.62e-11	-0.32	-0.25	Cognitive ability;	chr7:32458090	chr7:55681074~55713252:-
BRCA	trans	rs11920570	0.959	rs12633068	ENSG00000267076.1	CCDC58P3	-8.49	6.81e-17	8.77e-11	-0.34	-0.25	Resting heart rate;	chr3:122376727	chr18:12211378~12211807:+
BRCA	trans	rs12200782	0.79	rs72836480	ENSG00000242375.1	RP11-498P14.3	-8.49	6.91e-17	8.89e-11	-0.71	-0.25	Small cell lung carcinoma;	chr6:26358368	chr9:97195351~97197687:-
BRCA	trans	rs7944735	0.508	rs79368019	ENSG00000134612.10	FOLH1B	8.49	6.91e-17	8.89e-11	0.41	0.25	Intraocular pressure;	chr11:47792268	chr11:89639227~89698718:+
BRCA	trans	rs6831352	0.734	rs2851259	ENSG00000233859.2	ADH5P4	-8.49	6.92e-17	8.9e-11	-0.34	-0.25	Alcohol dependence;	chr4:99112835	chr6:65836930~65838039:-
BRCA	trans	rs6831352	0.703	rs4235435	ENSG00000233859.2	ADH5P4	-8.49	6.92e-17	8.9e-11	-0.34	-0.25	Alcohol dependence;	chr4:99118427	chr6:65836930~65838039:-
BRCA	trans	rs12210905	0.92	rs858995	ENSG00000242375.1	RP11-498P14.3	8.49	6.96e-17	8.95e-11	0.58	0.25	Hip circumference adjusted for BMI;	chr6:27213922	chr9:97195351~97197687:-
BRCA	trans	rs6743068	0.521	rs1406122	ENSG00000235105.1	RP11-329A14.1	-8.49	6.96e-17	8.95e-11	-0.3	-0.25	Lymphocyte percentage of white cells;	chr2:201346720	chr1:48435967~48437223:+
BRCA	trans	rs546131	1	rs546131	ENSG00000225531.1	RP11-196I18.3	8.49	7.08e-17	9.11e-11	0.35	0.25	Lung disease severity in cystic fibrosis;	chr11:34830213	chr9:107116829~107117557:+
BRCA	trans	rs9584850	0.834	rs3783005	ENSG00000230079.1	STK24P1	-8.49	7.09e-17	9.12e-11	-0.33	-0.25	Neuroticism;	chr13:98459083	chrX:136295690~136300298:-
BRCA	trans	rs9467711	0.606	rs2235251	ENSG00000253570.1	RNF5P1	8.49	7.14e-17	9.18e-11	0.62	0.25	Autism spectrum disorder or schizophrenia;	chr6:26431754	chr8:38600661~38601200:-
BRCA	trans	rs66887589	0.774	rs9307477	ENSG00000275858.1	RP11-291L22.8	8.49	7.19e-17	9.25e-11	0.29	0.25	Diastolic blood pressure;	chr4:119500654	chr10:38450738~38451069:-
BRCA	trans	rs875971	0.545	rs1796226	ENSG00000164669.11	INTS4P1	-8.49	7.21e-17	9.27e-11	-0.35	-0.25	Aortic root size;	chr7:66622723	chr7:65141225~65234216:+
BRCA	trans	rs6831352	0.693	rs2602875	ENSG00000233859.2	ADH5P4	-8.48	7.5e-17	9.64e-11	-0.34	-0.25	Alcohol dependence;	chr4:99118344	chr6:65836930~65838039:-
BRCA	trans	rs7773004	0.601	rs13210340	ENSG00000253570.1	RNF5P1	8.48	7.6e-17	9.76e-11	0.78	0.25	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;	chr6:26326086	chr8:38600661~38601200:-
BRCA	trans	rs877636	0.702	rs773111	ENSG00000243538.1	CTB-55B8.1	8.48	7.74e-17	9.94e-11	0.33	0.25	Cognitive function;	chr12:55981956	chr5:16902294~16902641:-
BRCA	trans	rs941207	0.514	rs6581105	ENSG00000228224.3	NACAP1	-8.48	7.79e-17	1e-10	-0.31	-0.25	Platelet count;	chr12:56792184	chr8:101361794~101372707:+
BRCA	trans	rs7824557	0.767	rs11250127	ENSG00000253893.2	FAM85B	-8.48	7.79e-17	1e-10	-0.35	-0.25	Retinal vascular caliber;	chr8:11312700	chr8:8167819~8226614:-
BRCA	trans	rs6831352	0.703	rs2602862	ENSG00000233859.2	ADH5P4	-8.48	7.8e-17	1e-10	-0.33	-0.25	Alcohol dependence;	chr4:99112070	chr6:65836930~65838039:-
BRCA	trans	rs12210905	0.925	rs858985	ENSG00000242375.1	RP11-498P14.3	8.47	8.05e-17	1.03e-10	0.55	0.25	Hip circumference adjusted for BMI;	chr6:27210249	chr9:97195351~97197687:-
BRCA	trans	rs7944735	0.507	rs17198607	ENSG00000134612.10	FOLH1B	-8.47	8.17e-17	1.05e-10	-0.43	-0.25	Intraocular pressure;	chr11:48006791	chr11:89639227~89698718:+
BRCA	trans	rs1580019	0.961	rs766657	ENSG00000176826.14	FKBP9P1	-8.47	8.22e-17	1.06e-10	-0.32	-0.25	Cognitive ability;	chr7:32459898	chr7:55681074~55713252:-
BRCA	trans	rs12477438	0.52	rs11123764	ENSG00000276576.1	MRPL30P1	8.47	8.24e-17	1.06e-10	0.32	0.25	Chronic sinus infection;	chr2:99134214	chr6:57029521~57029988:+
BRCA	trans	rs877636	1	rs705696	ENSG00000204652.6	RPS26P8	8.47	8.3e-17	1.06e-10	0.34	0.25	Cognitive function;	chr12:56086864	chr17:45608571~45608918:+
BRCA	trans	rs7927370	1	rs488213	ENSG00000134612.10	FOLH1B	8.47	8.34e-17	1.07e-10	0.56	0.25	Systemic lupus erythematosus;	chr11:55503931	chr11:89639227~89698718:+
BRCA	trans	rs2060793	0.741	rs10741656	ENSG00000236360.2	RP11-334A14.2	8.47	8.4e-17	1.08e-10	0.32	0.25	Vitamin D levels;	chr11:14803699	chr1:52993201~52993702:-
BRCA	trans	rs12210905	0.858	rs858988	ENSG00000242375.1	RP11-498P14.3	8.47	8.41e-17	1.08e-10	0.55	0.25	Hip circumference adjusted for BMI;	chr6:27211416	chr9:97195351~97197687:-
BRCA	trans	rs877636	1	rs4759229	ENSG00000243538.1	CTB-55B8.1	-8.47	8.48e-17	1.09e-10	-0.31	-0.25	Cognitive function;	chr12:56080696	chr5:16902294~16902641:-
BRCA	trans	rs875971	0.528	rs801213	ENSG00000164669.11	INTS4P1	8.47	8.51e-17	1.09e-10	0.35	0.25	Aortic root size;	chr7:66549931	chr7:65141225~65234216:+
BRCA	trans	rs875971	0.545	rs801212	ENSG00000164669.11	INTS4P1	8.47	8.51e-17	1.09e-10	0.35	0.25	Aortic root size;	chr7:66550643	chr7:65141225~65234216:+
BRCA	trans	rs877636	0.702	rs773110	ENSG00000243538.1	CTB-55B8.1	8.46	8.8e-17	1.13e-10	0.32	0.25	Cognitive function;	chr12:55981353	chr5:16902294~16902641:-
BRCA	trans	rs7937890	0.505	rs1403248	ENSG00000236360.2	RP11-334A14.2	8.46	9.06e-17	1.16e-10	0.32	0.25	Mitochondrial DNA levels;	chr11:14657471	chr1:52993201~52993702:-
BRCA	trans	rs7819412	0.668	rs2409714	ENSG00000253893.2	FAM85B	8.46	9.22e-17	1.18e-10	0.32	0.25	Triglycerides;	chr8:11152608	chr8:8167819~8226614:-
BRCA	trans	rs6743068	0.521	rs7578970	ENSG00000235105.1	RP11-329A14.1	8.45	9.52e-17	1.22e-10	0.3	0.25	Lymphocyte percentage of white cells;	chr2:201365061	chr1:48435967~48437223:+
BRCA	trans	rs66887589	0.775	rs6843229	ENSG00000275858.1	RP11-291L22.8	8.45	9.61e-17	1.23e-10	0.29	0.25	Diastolic blood pressure;	chr4:119502932	chr10:38450738~38451069:-
BRCA	trans	rs7944735	0.508	rs4752871	ENSG00000134612.10	FOLH1B	8.45	9.88e-17	1.26e-10	0.41	0.25	Intraocular pressure;	chr11:47827880	chr11:89639227~89698718:+
BRCA	trans	rs9467711	0.606	rs9366656	ENSG00000253570.1	RNF5P1	8.45	1.01e-16	1.29e-10	0.62	0.25	Autism spectrum disorder or schizophrenia;	chr6:26434402	chr8:38600661~38601200:-
BRCA	trans	rs11920570	1	rs11920570	ENSG00000267076.1	CCDC58P3	-8.44	1.02e-16	1.3e-10	-0.34	-0.25	Resting heart rate;	chr3:122371255	chr18:12211378~12211807:+
BRCA	trans	rs7929679	0.542	rs10742325	ENSG00000225531.1	RP11-196I18.3	8.44	1.02e-16	1.3e-10	0.33	0.25	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;	chr11:34788079	chr9:107116829~107117557:+
BRCA	trans	rs9467711	0.606	rs34273322	ENSG00000253570.1	RNF5P1	8.44	1.03e-16	1.32e-10	0.62	0.25	Autism spectrum disorder or schizophrenia;	chr6:26415181	chr8:38600661~38601200:-
BRCA	trans	rs9467711	0.606	rs9358939	ENSG00000253570.1	RNF5P1	8.44	1.03e-16	1.32e-10	0.62	0.25	Autism spectrum disorder or schizophrenia;	chr6:26416559	chr8:38600661~38601200:-
BRCA	trans	rs3808502	0.605	rs11784572	ENSG00000253893.2	FAM85B	8.44	1.06e-16	1.36e-10	0.32	0.25	Neuroticism;	chr8:11316975	chr8:8167819~8226614:-
BRCA	trans	rs7944735	0.508	rs2305982	ENSG00000134612.10	FOLH1B	8.44	1.06e-16	1.36e-10	0.41	0.25	Intraocular pressure;	chr11:47835616	chr11:89639227~89698718:+
BRCA	trans	rs6831352	0.734	rs1453872	ENSG00000233859.2	ADH5P4	-8.44	1.07e-16	1.37e-10	-0.33	-0.25	Alcohol dependence;	chr4:99101331	chr6:65836930~65838039:-
BRCA	trans	rs6424115	0.708	rs12748109	ENSG00000228217.1	AL390877.1	8.44	1.09e-16	1.4e-10	0.33	0.25	Immature fraction of reticulocytes;	chr1:23854687	chr1:117778087~117778506:-
BRCA	trans	rs73108077	0.92	rs73248560	ENSG00000279352.1	RP11-411B10.7	8.43	1.12e-16	1.43e-10	0.51	0.25	Red blood cell density in sickle cell anemia;	chr20:31436938	chr18:14010054~14010917:+
BRCA	trans	rs12477438	0.52	rs1044575	ENSG00000276576.1	MRPL30P1	8.43	1.14e-16	1.46e-10	0.32	0.25	Chronic sinus infection;	chr2:99195607	chr6:57029521~57029988:+
BRCA	trans	rs2060793	0.741	rs4344519	ENSG00000236360.2	RP11-334A14.2	8.43	1.17e-16	1.49e-10	0.32	0.25	Vitamin D levels;	chr11:14701347	chr1:52993201~52993702:-
BRCA	trans	rs66887589	0.807	rs13134517	ENSG00000275858.1	RP11-291L22.8	8.43	1.18e-16	1.5e-10	0.28	0.25	Diastolic blood pressure;	chr4:119484107	chr10:38450738~38451069:-
BRCA	trans	rs66887589	0.837	rs6534135	ENSG00000275858.1	RP11-291L22.8	8.43	1.18e-16	1.5e-10	0.28	0.25	Diastolic blood pressure;	chr4:119485147	chr10:38450738~38451069:-
BRCA	trans	rs12477438	0.52	rs2516829	ENSG00000276576.1	MRPL30P1	8.42	1.28e-16	1.63e-10	0.32	0.25	Chronic sinus infection;	chr2:99156738	chr6:57029521~57029988:+
BRCA	trans	rs66887589	0.934	rs12648182	ENSG00000275858.1	RP11-291L22.8	-8.42	1.28e-16	1.63e-10	-0.28	-0.25	Diastolic blood pressure;	chr4:119582736	chr10:38450738~38451069:-
BRCA	trans	rs3849046	0.817	rs6596438	ENSG00000226666.1	HSPA9P1	8.41	1.29e-16	1.64e-10	0.29	0.25	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138569759	chr2:221961737~221963765:+
BRCA	trans	rs2060793	0.774	rs1403249	ENSG00000236360.2	RP11-334A14.2	8.41	1.29e-16	1.65e-10	0.32	0.25	Vitamin D levels;	chr11:14651438	chr1:52993201~52993702:-
BRCA	trans	rs2060793	0.712	rs10832290	ENSG00000236360.2	RP11-334A14.2	8.41	1.29e-16	1.65e-10	0.32	0.25	Vitamin D levels;	chr11:14650684	chr1:52993201~52993702:-
BRCA	trans	rs6831352	0.734	rs12502237	ENSG00000233859.2	ADH5P4	-8.41	1.29e-16	1.65e-10	-0.34	-0.25	Alcohol dependence;	chr4:99094524	chr6:65836930~65838039:-
BRCA	trans	rs7824557	0.843	rs2736375	ENSG00000253893.2	FAM85B	8.41	1.32e-16	1.68e-10	0.33	0.25	Retinal vascular caliber;	chr8:11258240	chr8:8167819~8226614:-
BRCA	trans	rs35851103	0.507	rs6601649	ENSG00000253893.2	FAM85B	8.41	1.32e-16	1.68e-10	0.33	0.25	Neuroticism;	chr8:11999808	chr8:8167819~8226614:-
BRCA	trans	rs747782	0.646	rs61914719	ENSG00000134612.10	FOLH1B	8.41	1.32e-16	1.68e-10	0.45	0.25	Intraocular pressure;	chr11:48037539	chr11:89639227~89698718:+
BRCA	trans	rs7824557	0.603	rs2249804	ENSG00000253893.2	FAM85B	-8.41	1.32e-16	1.68e-10	-0.31	-0.25	Retinal vascular caliber;	chr8:11358108	chr8:8167819~8226614:-
BRCA	trans	rs9329221	0.716	rs11989640	ENSG00000253893.2	FAM85B	8.41	1.32e-16	1.69e-10	0.35	0.25	Neuroticism;	chr8:10398544	chr8:8167819~8226614:-
BRCA	trans	rs7824557	0.767	rs7003241	ENSG00000253893.2	FAM85B	-8.41	1.33e-16	1.69e-10	-0.35	-0.25	Retinal vascular caliber;	chr8:11311566	chr8:8167819~8226614:-
BRCA	trans	rs66887589	0.934	rs7681980	ENSG00000275858.1	RP11-291L22.8	-8.41	1.33e-16	1.7e-10	-0.28	-0.25	Diastolic blood pressure;	chr4:119612068	chr10:38450738~38451069:-
BRCA	trans	rs73108077	0.92	rs6057657	ENSG00000279352.1	RP11-411B10.7	-8.41	1.37e-16	1.75e-10	-0.44	-0.25	Red blood cell density in sickle cell anemia;	chr20:31376027	chr18:14010054~14010917:+
BRCA	trans	rs7944735	0.508	rs7124949	ENSG00000134612.10	FOLH1B	8.41	1.39e-16	1.76e-10	0.4	0.25	Intraocular pressure;	chr11:47804420	chr11:89639227~89698718:+
BRCA	trans	rs7944735	0.508	rs6485783	ENSG00000134612.10	FOLH1B	8.41	1.39e-16	1.76e-10	0.4	0.25	Intraocular pressure;	chr11:47807793	chr11:89639227~89698718:+
BRCA	trans	rs1580019	0.885	rs4460269	ENSG00000176826.14	FKBP9P1	-8.4	1.39e-16	1.77e-10	-0.32	-0.25	Cognitive ability;	chr7:32456833	chr7:55681074~55713252:-
BRCA	trans	rs1580019	0.885	rs4460270	ENSG00000176826.14	FKBP9P1	-8.4	1.39e-16	1.77e-10	-0.32	-0.25	Cognitive ability;	chr7:32456838	chr7:55681074~55713252:-
BRCA	trans	rs877636	0.702	rs61937249	ENSG00000204652.6	RPS26P8	8.4	1.4e-16	1.78e-10	0.34	0.25	Cognitive function;	chr12:55988132	chr17:45608571~45608918:+
BRCA	trans	rs6424115	0.708	rs11803575	ENSG00000228217.1	AL390877.1	8.4	1.4e-16	1.78e-10	0.33	0.25	Immature fraction of reticulocytes;	chr1:23855858	chr1:117778087~117778506:-
BRCA	trans	rs66887589	0.72	rs2036858	ENSG00000275858.1	RP11-291L22.8	8.4	1.4e-16	1.78e-10	0.28	0.25	Diastolic blood pressure;	chr4:119328082	chr10:38450738~38451069:-
BRCA	trans	rs7824557	0.606	rs1435277	ENSG00000253893.2	FAM85B	-8.4	1.42e-16	1.8e-10	-0.31	-0.25	Retinal vascular caliber;	chr8:11339461	chr8:8167819~8226614:-
BRCA	trans	rs11951515	0.508	rs7706431	ENSG00000174977.8	AC026271.5	-8.4	1.43e-16	1.81e-10	-0.3	-0.25	Metabolite levels  (X-11787);	chr5:43582321	chr17:18650195~18651542:+
BRCA	trans	rs877636	0.702	rs773109	ENSG00000204652.6	RPS26P8	8.4	1.43e-16	1.81e-10	0.34	0.25	Cognitive function;	chr12:55980911	chr17:45608571~45608918:+
BRCA	trans	rs853679	0.769	rs7752608	ENSG00000253570.1	RNF5P1	8.4	1.44e-16	1.82e-10	0.59	0.25	Depression;	chr6:28333418	chr8:38600661~38601200:-
BRCA	trans	rs1816752	0.524	rs1965154	ENSG00000224976.2	PARP4P2	8.4	1.44e-16	1.83e-10	0.31	0.25	Obesity-related traits;	chr13:24498062	chr13:19349137~19407962:+
BRCA	trans	rs2060793	0.741	rs10741653	ENSG00000236360.2	RP11-334A14.2	8.4	1.46e-16	1.85e-10	0.32	0.25	Vitamin D levels;	chr11:14683294	chr1:52993201~52993702:-
BRCA	trans	rs11098499	0.739	rs951570	ENSG00000275858.1	RP11-291L22.8	-8.4	1.46e-16	1.86e-10	-0.31	-0.25	Corneal astigmatism;	chr4:119229312	chr10:38450738~38451069:-
BRCA	trans	rs2060793	0.712	rs10741654	ENSG00000236360.2	RP11-334A14.2	8.4	1.49e-16	1.89e-10	0.32	0.25	Vitamin D levels;	chr11:14726506	chr1:52993201~52993702:-
BRCA	trans	rs877636	0.702	rs773109	ENSG00000243538.1	CTB-55B8.1	8.39	1.51e-16	1.91e-10	0.32	0.25	Cognitive function;	chr12:55980911	chr5:16902294~16902641:-
BRCA	trans	rs3849046	0.817	rs4835687	ENSG00000226666.1	HSPA9P1	-8.39	1.52e-16	1.92e-10	-0.29	-0.25	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138536367	chr2:221961737~221963765:+
BRCA	trans	rs9650657	0.683	rs7005905	ENSG00000253893.2	FAM85B	-8.39	1.57e-16	1.99e-10	-0.31	-0.25	Neuroticism;	chr8:10727634	chr8:8167819~8226614:-
BRCA	trans	rs66887589	0.934	rs2389873	ENSG00000275858.1	RP11-291L22.8	-8.39	1.58e-16	2e-10	-0.28	-0.25	Diastolic blood pressure;	chr4:119633559	chr10:38450738~38451069:-
BRCA	trans	rs66887589	0.934	rs4834792	ENSG00000275858.1	RP11-291L22.8	-8.39	1.58e-16	2e-10	-0.28	-0.25	Diastolic blood pressure;	chr4:119634541	chr10:38450738~38451069:-
BRCA	trans	rs1580019	0.844	rs1376290	ENSG00000176826.14	FKBP9P1	-8.39	1.58e-16	2e-10	-0.34	-0.25	Cognitive ability;	chr7:32447310	chr7:55681074~55713252:-
BRCA	trans	rs7937890	0.505	rs9971395	ENSG00000236360.2	RP11-334A14.2	8.39	1.58e-16	2e-10	0.32	0.25	Mitochondrial DNA levels;	chr11:14745580	chr1:52993201~52993702:-
BRCA	trans	rs6498068	0.677	rs2279871	ENSG00000278702.1	Metazoa_SRP	-8.39	1.58e-16	2e-10	-0.37	-0.25	Metabolite levels (MHPG);	chr16:10538518	chr1:35399997~35400319:+
BRCA	trans	rs7113874	0.802	rs11042029	ENSG00000266891.1	RP11-692N5.2	8.39	1.6e-16	2.03e-10	0.32	0.25	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8666578	chr18:9734882~9735602:-
BRCA	trans	rs864643	0.891	rs816493	ENSG00000183298.5	RP11-556K13.1	8.39	1.6e-16	2.03e-10	0.42	0.25	Attention deficit hyperactivity disorder;	chr3:39514702	chr1:101786340~101787219:-
BRCA	trans	rs864643	1	rs673426	ENSG00000183298.5	RP11-556K13.1	8.39	1.61e-16	2.03e-10	0.43	0.25	Attention deficit hyperactivity disorder;	chr3:39520286	chr1:101786340~101787219:-
BRCA	trans	rs7937890	0.506	rs10741655	ENSG00000236360.2	RP11-334A14.2	8.39	1.61e-16	2.04e-10	0.32	0.25	Mitochondrial DNA levels;	chr11:14746838	chr1:52993201~52993702:-
BRCA	trans	rs73108077	0.831	rs118117155	ENSG00000279352.1	RP11-411B10.7	8.39	1.61e-16	2.04e-10	0.61	0.25	Red blood cell density in sickle cell anemia;	chr20:31468921	chr18:14010054~14010917:+
BRCA	trans	rs9650657	0.645	rs9969657	ENSG00000253893.2	FAM85B	-8.39	1.61e-16	2.04e-10	-0.31	-0.25	Neuroticism;	chr8:10657768	chr8:8167819~8226614:-
BRCA	trans	rs7833986	0.501	rs2719227	ENSG00000236862.1	RPS20P24	-8.39	1.62e-16	2.06e-10	-0.33	-0.25	Height;	chr8:56131235	chr9:72655832~72656192:-
BRCA	trans	rs1580019	0.922	rs766658	ENSG00000176826.14	FKBP9P1	-8.38	1.65e-16	2.09e-10	-0.32	-0.25	Cognitive ability;	chr7:32459779	chr7:55681074~55713252:-
BRCA	trans	rs3849046	0.817	rs13160755	ENSG00000226666.1	HSPA9P1	8.38	1.66e-16	2.1e-10	0.29	0.25	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138549942	chr2:221961737~221963765:+
BRCA	trans	rs875971	0.66	rs801193	ENSG00000164669.11	INTS4P1	8.38	1.7e-16	2.16e-10	0.31	0.25	Aortic root size;	chr7:66565625	chr7:65141225~65234216:+
BRCA	trans	rs801193	1	rs13239306	ENSG00000164669.11	INTS4P1	8.38	1.71e-16	2.16e-10	0.31	0.25	Aortic root size;	chr7:66671030	chr7:65141225~65234216:+
BRCA	trans	rs877636	0.702	rs773112	ENSG00000204652.6	RPS26P8	8.38	1.71e-16	2.16e-10	0.34	0.25	Cognitive function;	chr12:55982097	chr17:45608571~45608918:+
BRCA	trans	rs1580019	0.961	rs766660	ENSG00000176826.14	FKBP9P1	-8.38	1.71e-16	2.16e-10	-0.32	-0.25	Cognitive ability;	chr7:32459465	chr7:55681074~55713252:-
BRCA	trans	rs1580019	0.922	rs59938271	ENSG00000176826.14	FKBP9P1	-8.38	1.71e-16	2.17e-10	-0.34	-0.25	Cognitive ability;	chr7:32445232	chr7:55681074~55713252:-
BRCA	trans	rs1580019	0.922	rs1466147	ENSG00000176826.14	FKBP9P1	-8.38	1.71e-16	2.17e-10	-0.34	-0.25	Cognitive ability;	chr7:32446650	chr7:55681074~55713252:-
BRCA	trans	rs877636	0.702	rs773111	ENSG00000204652.6	RPS26P8	8.38	1.71e-16	2.17e-10	0.34	0.25	Cognitive function;	chr12:55981956	chr17:45608571~45608918:+
BRCA	trans	rs941207	0.542	rs1903370	ENSG00000228224.3	NACAP1	-8.38	1.73e-16	2.19e-10	-0.31	-0.25	Platelet count;	chr12:56812900	chr8:101361794~101372707:+
BRCA	trans	rs864643	0.891	rs4129648	ENSG00000183298.5	RP11-556K13.1	8.38	1.76e-16	2.23e-10	0.43	0.25	Attention deficit hyperactivity disorder;	chr3:39519319	chr1:101786340~101787219:-
BRCA	trans	rs1580019	0.961	rs4320456	ENSG00000176826.14	FKBP9P1	-8.37	1.83e-16	2.32e-10	-0.32	-0.25	Cognitive ability;	chr7:32456391	chr7:55681074~55713252:-
BRCA	trans	rs1580019	0.961	rs4357201	ENSG00000176826.14	FKBP9P1	-8.37	1.83e-16	2.32e-10	-0.32	-0.25	Cognitive ability;	chr7:32456721	chr7:55681074~55713252:-
BRCA	trans	rs1580019	0.961	rs4255041	ENSG00000176826.14	FKBP9P1	-8.37	1.83e-16	2.32e-10	-0.32	-0.25	Cognitive ability;	chr7:32456771	chr7:55681074~55713252:-
BRCA	trans	rs1580019	0.961	rs4460271	ENSG00000176826.14	FKBP9P1	-8.37	1.83e-16	2.32e-10	-0.32	-0.25	Cognitive ability;	chr7:32456891	chr7:55681074~55713252:-
BRCA	trans	rs714543	0.61	rs4724320	ENSG00000234397.3	RP11-415K20.1	-8.37	1.85e-16	2.34e-10	-0.28	-0.25	Plateletcrit;	chr7:44775735	chr1:22322840~22323331:-
BRCA	trans	rs2060793	0.741	rs7119073	ENSG00000236360.2	RP11-334A14.2	8.37	1.89e-16	2.39e-10	0.32	0.25	Vitamin D levels;	chr11:14669416	chr1:52993201~52993702:-
BRCA	trans	rs877636	0.702	rs773110	ENSG00000204652.6	RPS26P8	8.37	1.89e-16	2.39e-10	0.34	0.25	Cognitive function;	chr12:55981353	chr17:45608571~45608918:+
BRCA	trans	rs6964833	0.935	rs34762099	ENSG00000214544.6	GTF2IRD2P1	-8.37	1.9e-16	2.4e-10	-0.38	-0.25	Menarche (age at onset);	chr7:74636378	chr7:73242751~73280119:-
BRCA	trans	rs10037055	0.853	rs10035180	ENSG00000228305.2	AC016734.2	-8.37	1.9e-16	2.4e-10	-0.29	-0.25	Migraine without aura;	chr5:177171501	chr2:63622178~63622831:-
BRCA	trans	rs6424115	0.708	rs13551	ENSG00000228217.1	AL390877.1	8.36	1.91e-16	2.42e-10	0.33	0.25	Immature fraction of reticulocytes;	chr1:23854472	chr1:117778087~117778506:-
BRCA	trans	rs7944735	0.508	rs1872167	ENSG00000134612.10	FOLH1B	8.36	1.96e-16	2.48e-10	0.41	0.25	Intraocular pressure;	chr11:47879717	chr11:89639227~89698718:+
BRCA	trans	rs10420951	0.617	rs2303694	ENSG00000267533.1	RP11-815J4.7	8.36	1.98e-16	2.49e-10	0.44	0.25	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr19:18451628	chr18:12067173~12068417:-
BRCA	trans	rs10420951	0.617	rs79257623	ENSG00000267533.1	RP11-815J4.7	8.36	1.98e-16	2.49e-10	0.44	0.25	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr19:18452904	chr18:12067173~12068417:-
BRCA	trans	rs10420951	0.617	rs8103520	ENSG00000267533.1	RP11-815J4.7	8.36	1.98e-16	2.49e-10	0.44	0.25	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr19:18453160	chr18:12067173~12068417:-
BRCA	trans	rs12210905	0.92	rs9348763	ENSG00000242375.1	RP11-498P14.3	-8.36	1.98e-16	2.5e-10	-0.63	-0.25	Hip circumference adjusted for BMI;	chr6:27335140	chr9:97195351~97197687:-
BRCA	trans	rs3096299	0.658	rs4291902	ENSG00000215030.5	RPL13P12	-8.36	1.99e-16	2.51e-10	-0.26	-0.25	Multiple myeloma (IgH translocation);	chr16:89493907	chr17:17383377~17384012:-
BRCA	trans	rs10783779	0.647	rs705708	ENSG00000243403.1	RP11-330L19.1	8.36	2e-16	2.53e-10	0.29	0.25	Educational attainment;	chr12:56095129	chr15:64592979~64593326:+
BRCA	trans	rs12210905	0.925	rs72838263	ENSG00000242375.1	RP11-498P14.3	-8.36	2.02e-16	2.54e-10	-0.55	-0.25	Hip circumference adjusted for BMI;	chr6:27041115	chr9:97195351~97197687:-
BRCA	trans	rs9467711	0.659	rs34605993	ENSG00000253570.1	RNF5P1	8.36	2.02e-16	2.55e-10	0.68	0.25	Autism spectrum disorder or schizophrenia;	chr6:26454135	chr8:38600661~38601200:-
BRCA	trans	rs3749237	1	rs2291542	ENSG00000197582.5	GPX1P1	8.35	2.08e-16	2.62e-10	0.26	0.25	Resting heart rate;	chr3:49714152	chrX:13378735~13379340:-
BRCA	trans	rs2060793	0.741	rs2060794	ENSG00000236360.2	RP11-334A14.2	8.35	2.12e-16	2.67e-10	0.32	0.25	Vitamin D levels;	chr11:14791437	chr1:52993201~52993702:-
BRCA	trans	rs2060793	0.741	rs3740823	ENSG00000236360.2	RP11-334A14.2	8.35	2.12e-16	2.67e-10	0.32	0.25	Vitamin D levels;	chr11:14804158	chr1:52993201~52993702:-
BRCA	trans	rs12210905	0.858	rs72838249	ENSG00000242375.1	RP11-498P14.3	-8.35	2.12e-16	2.68e-10	-0.56	-0.25	Hip circumference adjusted for BMI;	chr6:27030710	chr9:97195351~97197687:-
BRCA	trans	rs3806843	0.569	rs753279	ENSG00000231043.3	AC007238.1	8.35	2.13e-16	2.68e-10	0.29	0.25	Depressive symptoms (multi-trait analysis);	chr5:140644233	chr2:58460292~58462032:-
BRCA	trans	rs7824557	0.569	rs35418978	ENSG00000253893.2	FAM85B	-8.35	2.18e-16	2.75e-10	-0.32	-0.25	Retinal vascular caliber;	chr8:11328944	chr8:8167819~8226614:-
BRCA	trans	rs73108077	0.831	rs2233826	ENSG00000279352.1	RP11-411B10.7	8.35	2.22e-16	2.79e-10	0.59	0.25	Red blood cell density in sickle cell anemia;	chr20:31475539	chr18:14010054~14010917:+
BRCA	trans	rs12210905	0.92	rs72839469	ENSG00000242375.1	RP11-498P14.3	-8.34	2.27e-16	2.86e-10	-0.63	-0.25	Hip circumference adjusted for BMI;	chr6:27336760	chr9:97195351~97197687:-
BRCA	trans	rs546131	0.928	rs558967	ENSG00000225531.1	RP11-196I18.3	8.34	2.33e-16	2.94e-10	0.35	0.25	Lung disease severity in cystic fibrosis;	chr11:34805621	chr9:107116829~107117557:+
BRCA	trans	rs864643	0.945	rs614453	ENSG00000183298.5	RP11-556K13.1	8.34	2.35e-16	2.96e-10	0.43	0.25	Attention deficit hyperactivity disorder;	chr3:39541076	chr1:101786340~101787219:-
BRCA	trans	rs66887589	0.967	rs7678973	ENSG00000275858.1	RP11-291L22.8	-8.34	2.39e-16	3e-10	-0.28	-0.25	Diastolic blood pressure;	chr4:119590662	chr10:38450738~38451069:-
BRCA	trans	rs877636	0.74	rs772920	ENSG00000204652.6	RPS26P8	8.34	2.39e-16	3e-10	0.34	0.25	Cognitive function;	chr12:55996580	chr17:45608571~45608918:+
BRCA	trans	rs875971	0.545	rs1638735	ENSG00000164669.11	INTS4P1	-8.34	2.39e-16	3.01e-10	-0.34	-0.25	Aortic root size;	chr7:66630751	chr7:65141225~65234216:+
BRCA	trans	rs7824557	0.606	rs2736264	ENSG00000253893.2	FAM85B	-8.34	2.42e-16	3.04e-10	-0.31	-0.25	Retinal vascular caliber;	chr8:11329130	chr8:8167819~8226614:-
BRCA	trans	rs864643	1	rs546031	ENSG00000183298.5	RP11-556K13.1	8.33	2.43e-16	3.06e-10	0.42	0.25	Attention deficit hyperactivity disorder;	chr3:39529886	chr1:101786340~101787219:-
BRCA	trans	rs864643	1	rs569888	ENSG00000183298.5	RP11-556K13.1	8.33	2.43e-16	3.06e-10	0.42	0.25	Attention deficit hyperactivity disorder;	chr3:39530165	chr1:101786340~101787219:-
BRCA	trans	rs864643	1	rs946409	ENSG00000183298.5	RP11-556K13.1	8.33	2.43e-16	3.06e-10	0.42	0.25	Attention deficit hyperactivity disorder;	chr3:39531549	chr1:101786340~101787219:-
BRCA	trans	rs12210905	0.858	rs2023467	ENSG00000242375.1	RP11-498P14.3	-8.33	2.46e-16	3.1e-10	-0.53	-0.25	Hip circumference adjusted for BMI;	chr6:27219224	chr9:97195351~97197687:-
BRCA	trans	rs6743068	0.541	rs12052257	ENSG00000235105.1	RP11-329A14.1	-8.33	2.47e-16	3.1e-10	-0.3	-0.25	Lymphocyte percentage of white cells;	chr2:201376871	chr1:48435967~48437223:+
BRCA	trans	rs6940638	0.956	rs10946899	ENSG00000242375.1	RP11-498P14.3	-8.33	2.52e-16	3.16e-10	-0.4	-0.25	Intelligence (multi-trait analysis);	chr6:27055915	chr9:97195351~97197687:-
BRCA	trans	rs66887589	0.967	rs1480933	ENSG00000275858.1	RP11-291L22.8	8.33	2.56e-16	3.22e-10	0.28	0.25	Diastolic blood pressure;	chr4:119512093	chr10:38450738~38451069:-
BRCA	trans	rs7819412	0.691	rs73198970	ENSG00000253893.2	FAM85B	8.33	2.6e-16	3.27e-10	0.32	0.25	Triglycerides;	chr8:11182707	chr8:8167819~8226614:-
BRCA	trans	rs66887589	0.837	rs7661498	ENSG00000275858.1	RP11-291L22.8	8.33	2.62e-16	3.29e-10	0.28	0.25	Diastolic blood pressure;	chr4:119486953	chr10:38450738~38451069:-
BRCA	trans	rs11951515	0.508	rs10065689	ENSG00000174977.8	AC026271.5	-8.32	2.64e-16	3.31e-10	-0.3	-0.25	Metabolite levels  (X-11787);	chr5:43604156	chr17:18650195~18651542:+
BRCA	trans	rs864643	0.945	rs529839	ENSG00000183298.5	RP11-556K13.1	8.32	2.64e-16	3.32e-10	0.42	0.25	Attention deficit hyperactivity disorder;	chr3:39525267	chr1:101786340~101787219:-
BRCA	trans	rs7113874	0.921	rs10769931	ENSG00000266891.1	RP11-692N5.2	-8.32	2.74e-16	3.44e-10	-0.31	-0.25	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8614558	chr18:9734882~9735602:-
BRCA	trans	rs11098499	0.739	rs7441137	ENSG00000275858.1	RP11-291L22.8	-8.32	2.76e-16	3.46e-10	-0.31	-0.25	Corneal astigmatism;	chr4:119212066	chr10:38450738~38451069:-
BRCA	trans	rs3942852	0.606	rs10734561	ENSG00000134612.10	FOLH1B	-8.32	2.81e-16	3.52e-10	-0.34	-0.25	Acute lymphoblastic leukemia (childhood);	chr11:48075928	chr11:89639227~89698718:+
BRCA	trans	rs8010715	0.636	rs3825584	ENSG00000238000.1	RP11-274E7.2	8.31	2.87e-16	3.6e-10	0.28	0.25	IgG glycosylation;	chr14:24118430	chr5:98213402~98214121:+
BRCA	trans	rs1580019	0.961	rs11768506	ENSG00000176826.14	FKBP9P1	-8.31	2.88e-16	3.6e-10	-0.32	-0.25	Cognitive ability;	chr7:32455176	chr7:55681074~55713252:-
BRCA	trans	rs1580019	0.961	rs11765387	ENSG00000176826.14	FKBP9P1	-8.31	2.88e-16	3.6e-10	-0.32	-0.25	Cognitive ability;	chr7:32455178	chr7:55681074~55713252:-
BRCA	trans	rs11098499	0.739	rs4833612	ENSG00000275858.1	RP11-291L22.8	-8.31	2.91e-16	3.65e-10	-0.31	-0.25	Corneal astigmatism;	chr4:119226441	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.739	rs10013032	ENSG00000275858.1	RP11-291L22.8	-8.31	2.91e-16	3.65e-10	-0.31	-0.25	Corneal astigmatism;	chr4:119228264	chr10:38450738~38451069:-
BRCA	trans	rs1391708	0.834	rs4759040	ENSG00000121089.4	NACA3P	8.31	2.91e-16	3.65e-10	0.4	0.25	Airway wall thickness;	chr12:56887746	chr4:164943290~164943937:+
BRCA	trans	rs1391708	0.764	rs4759265	ENSG00000121089.4	NACA3P	8.31	2.91e-16	3.65e-10	0.4	0.25	Airway wall thickness;	chr12:56887788	chr4:164943290~164943937:+
BRCA	trans	rs3849046	0.817	rs6874487	ENSG00000226666.1	HSPA9P1	8.31	2.99e-16	3.74e-10	0.28	0.25	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138571317	chr2:221961737~221963765:+
BRCA	trans	rs12210905	0.92	rs72839468	ENSG00000242375.1	RP11-498P14.3	-8.3	3.11e-16	3.89e-10	-0.62	-0.25	Hip circumference adjusted for BMI;	chr6:27333955	chr9:97195351~97197687:-
BRCA	trans	rs66887589	0.934	rs41464847	ENSG00000275858.1	RP11-291L22.8	-8.3	3.12e-16	3.91e-10	-0.28	-0.25	Diastolic blood pressure;	chr4:119611246	chr10:38450738~38451069:-
BRCA	trans	rs10420951	0.617	rs7246328	ENSG00000267533.1	RP11-815J4.7	8.3	3.13e-16	3.92e-10	0.43	0.25	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr19:18508247	chr18:12067173~12068417:-
BRCA	trans	rs12210905	0.8	rs11758585	ENSG00000242375.1	RP11-498P14.3	-8.3	3.13e-16	3.92e-10	-0.52	-0.25	Hip circumference adjusted for BMI;	chr6:27222475	chr9:97195351~97197687:-
BRCA	trans	rs6743068	0.541	rs6714736	ENSG00000235105.1	RP11-329A14.1	-8.3	3.13e-16	3.92e-10	-0.31	-0.25	Lymphocyte percentage of white cells;	chr2:201349425	chr1:48435967~48437223:+
BRCA	trans	rs7819412	0.74	rs11250119	ENSG00000253893.2	FAM85B	8.3	3.15e-16	3.95e-10	0.32	0.25	Triglycerides;	chr8:11179525	chr8:8167819~8226614:-
BRCA	trans	rs1580019	0.883	rs6945294	ENSG00000176826.14	FKBP9P1	-8.3	3.16e-16	3.95e-10	-0.33	-0.25	Cognitive ability;	chr7:32432487	chr7:55681074~55713252:-
BRCA	trans	rs11951515	0.508	rs6898866	ENSG00000174977.8	AC026271.5	-8.3	3.22e-16	4.02e-10	-0.3	-0.25	Metabolite levels  (X-11787);	chr5:43586273	chr17:18650195~18651542:+
BRCA	trans	rs66887589	0.627	rs3872807	ENSG00000275858.1	RP11-291L22.8	8.29	3.4e-16	4.25e-10	0.28	0.25	Diastolic blood pressure;	chr4:119439096	chr10:38450738~38451069:-
BRCA	trans	rs66887589	1	rs66887589	ENSG00000275858.1	RP11-291L22.8	-8.29	3.41e-16	4.25e-10	-0.28	-0.25	Diastolic blood pressure;	chr4:119588124	chr10:38450738~38451069:-
BRCA	trans	rs12210905	0.858	rs12200798	ENSG00000242375.1	RP11-498P14.3	-8.29	3.46e-16	4.32e-10	-0.52	-0.25	Hip circumference adjusted for BMI;	chr6:27220688	chr9:97195351~97197687:-
BRCA	trans	rs2060793	0.55	rs1037378	ENSG00000236360.2	RP11-334A14.2	8.29	3.59e-16	4.48e-10	0.31	0.25	Vitamin D levels;	chr11:14830944	chr1:52993201~52993702:-
BRCA	trans	rs877636	1	rs2292239	ENSG00000204652.6	RPS26P8	8.28	3.63e-16	4.53e-10	0.31	0.25	Cognitive function;	chr12:56088396	chr17:45608571~45608918:+
BRCA	trans	rs11098499	0.739	rs6534130	ENSG00000275858.1	RP11-291L22.8	-8.28	3.67e-16	4.58e-10	-0.31	-0.25	Corneal astigmatism;	chr4:119210184	chr10:38450738~38451069:-
BRCA	trans	rs9467711	0.659	rs66757203	ENSG00000253570.1	RNF5P1	8.28	3.82e-16	4.77e-10	0.68	0.25	Autism spectrum disorder or schizophrenia;	chr6:26454728	chr8:38600661~38601200:-
BRCA	trans	rs10940346	0.517	rs12659073	ENSG00000231752.4	EMBP1	-8.27	3.96e-16	4.93e-10	-0.32	-0.25	Schizophrenia;	chr5:50558564	chr1:121519112~121571892:+
BRCA	trans	rs4276421	0.571	rs1527833	ENSG00000231752.4	EMBP1	-8.27	3.98e-16	4.95e-10	-0.34	-0.25	P wave duration;	chr5:45570915	chr1:121519112~121571892:+
BRCA	trans	rs66887589	0.967	rs56173225	ENSG00000275858.1	RP11-291L22.8	-8.27	3.99e-16	4.96e-10	-0.28	-0.25	Diastolic blood pressure;	chr4:119588817	chr10:38450738~38451069:-
BRCA	trans	rs7819412	0.645	rs10156356	ENSG00000253893.2	FAM85B	8.27	4.02e-16	5.01e-10	0.32	0.25	Triglycerides;	chr8:11188700	chr8:8167819~8226614:-
BRCA	trans	rs864643	1	rs559349	ENSG00000183298.5	RP11-556K13.1	8.27	4.03e-16	5.02e-10	0.41	0.25	Attention deficit hyperactivity disorder;	chr3:39505562	chr1:101786340~101787219:-
BRCA	trans	rs7312770	0.612	rs773114	ENSG00000227586.5	RP11-162A23.5	8.27	4.04e-16	5.03e-10	0.29	0.25	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr10:123171535~123171875:-
BRCA	trans	rs3749237	1	rs11717256	ENSG00000197582.5	GPX1P1	8.26	4.32e-16	5.37e-10	0.26	0.25	Resting heart rate;	chr3:49831087	chrX:13378735~13379340:-
BRCA	trans	rs2736345	0.516	rs7844858	ENSG00000253893.2	FAM85B	-8.26	4.33e-16	5.38e-10	-0.31	-0.25	Systemic lupus erythematosus;Sjögren's syndrome;	chr8:11535150	chr8:8167819~8226614:-
BRCA	trans	rs7824557	0.606	rs2736273	ENSG00000253893.2	FAM85B	-8.26	4.33e-16	5.39e-10	-0.31	-0.25	Retinal vascular caliber;	chr8:11342429	chr8:8167819~8226614:-
BRCA	trans	rs1580019	1	rs1580019	ENSG00000176826.14	FKBP9P1	8.26	4.36e-16	5.42e-10	0.32	0.25	Cognitive ability;	chr7:32453557	chr7:55681074~55713252:-
BRCA	trans	rs1478897	0.575	rs12679960	ENSG00000253893.2	FAM85B	-8.26	4.36e-16	5.43e-10	-0.34	-0.25	Systemic lupus erythematosus;	chr8:11573481	chr8:8167819~8226614:-
BRCA	trans	rs6940638	0.956	rs3922717	ENSG00000242375.1	RP11-498P14.3	-8.26	4.39e-16	5.46e-10	-0.41	-0.25	Intelligence (multi-trait analysis);	chr6:27063145	chr9:97195351~97197687:-
BRCA	trans	rs6940638	0.956	rs13207365	ENSG00000242375.1	RP11-498P14.3	-8.26	4.39e-16	5.46e-10	-0.41	-0.25	Intelligence (multi-trait analysis);	chr6:27063201	chr9:97195351~97197687:-
BRCA	trans	rs6940638	0.956	rs12203454	ENSG00000242375.1	RP11-498P14.3	-8.26	4.39e-16	5.46e-10	-0.41	-0.25	Intelligence (multi-trait analysis);	chr6:27063321	chr9:97195351~97197687:-
BRCA	trans	rs4276421	0.571	rs1483308	ENSG00000231752.4	EMBP1	-8.26	4.41e-16	5.48e-10	-0.33	-0.25	P wave duration;	chr5:45538282	chr1:121519112~121571892:+
BRCA	trans	rs7113874	1	rs10769939	ENSG00000266891.1	RP11-692N5.2	8.26	4.48e-16	5.57e-10	0.31	0.25	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8662092	chr18:9734882~9735602:-
BRCA	trans	rs7819412	0.522	rs10088853	ENSG00000253893.2	FAM85B	8.25	4.57e-16	5.68e-10	0.33	0.25	Triglycerides;	chr8:11130457	chr8:8167819~8226614:-
BRCA	trans	rs9393777	0.92	rs13195040	ENSG00000253570.1	RNF5P1	-8.25	4.58e-16	5.68e-10	-0.63	-0.25	Intelligence (multi-trait analysis);	chr6:27446145	chr8:38600661~38601200:-
BRCA	trans	rs877636	0.702	rs61937249	ENSG00000244604.1	RP11-713H12.1	8.25	4.58e-16	5.69e-10	0.31	0.25	Cognitive function;	chr12:55988132	chr17:8561230~8561576:+
BRCA	trans	rs6940638	1	rs12204280	ENSG00000242375.1	RP11-498P14.3	-8.25	4.68e-16	5.81e-10	-0.41	-0.25	Intelligence (multi-trait analysis);	chr6:27065325	chr9:97195351~97197687:-
BRCA	trans	rs66887589	0.934	rs56843000	ENSG00000275858.1	RP11-291L22.8	-8.25	4.7e-16	5.84e-10	-0.28	-0.25	Diastolic blood pressure;	chr4:119595442	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.71	rs6851130	ENSG00000275858.1	RP11-291L22.8	-8.25	4.72e-16	5.85e-10	-0.31	-0.25	Corneal astigmatism;	chr4:119212557	chr10:38450738~38451069:-
BRCA	trans	rs12210905	0.925	rs72838258	ENSG00000242375.1	RP11-498P14.3	-8.25	4.77e-16	5.92e-10	-0.55	-0.25	Hip circumference adjusted for BMI;	chr6:27039902	chr9:97195351~97197687:-
BRCA	trans	rs877636	0.74	rs705702	ENSG00000244604.1	RP11-713H12.1	-8.25	4.86e-16	6.03e-10	-0.31	-0.25	Cognitive function;	chr12:55996852	chr17:8561230~8561576:+
BRCA	trans	rs1580019	0.885	rs4580942	ENSG00000176826.14	FKBP9P1	-8.25	4.87e-16	6.04e-10	-0.32	-0.25	Cognitive ability;	chr7:32456823	chr7:55681074~55713252:-
BRCA	trans	rs875971	0.545	rs12671152	ENSG00000164669.11	INTS4P1	-8.25	4.93e-16	6.12e-10	-0.35	-0.25	Aortic root size;	chr7:66311140	chr7:65141225~65234216:+
BRCA	trans	rs3749237	0.964	rs2234385	ENSG00000197582.5	GPX1P1	8.24	4.98e-16	6.17e-10	0.26	0.25	Resting heart rate;	chr3:49808608	chrX:13378735~13379340:-
BRCA	trans	rs3749237	0.964	rs1799843	ENSG00000197582.5	GPX1P1	8.24	4.98e-16	6.17e-10	0.26	0.25	Resting heart rate;	chr3:49812290	chrX:13378735~13379340:-
BRCA	trans	rs2069408	1	rs2069408	ENSG00000233778.3	RP11-777J24.1	-8.24	5e-16	6.2e-10	-0.31	-0.25	Asthma;	chr12:55970537	chr8:92144088~92144435:-
BRCA	trans	rs877636	0.702	rs773112	ENSG00000244604.1	RP11-713H12.1	8.24	5.01e-16	6.21e-10	0.31	0.25	Cognitive function;	chr12:55982097	chr17:8561230~8561576:+
BRCA	trans	rs877636	1	rs705696	ENSG00000244604.1	RP11-713H12.1	8.24	5.02e-16	6.22e-10	0.31	0.25	Cognitive function;	chr12:56086864	chr17:8561230~8561576:+
BRCA	trans	rs7944735	0.508	rs59652089	ENSG00000134612.10	FOLH1B	8.24	5.06e-16	6.27e-10	0.42	0.25	Intraocular pressure;	chr11:47885798	chr11:89639227~89698718:+
BRCA	trans	rs2665103	0.715	rs16973457	ENSG00000235370.6	DNM1P51	-8.24	5.12e-16	6.35e-10	-0.27	-0.25	Intelligence (multi-trait analysis);	chr15:82271650	chr15:84398316~84411701:-
BRCA	trans	rs2060793	0.526	rs10766194	ENSG00000236360.2	RP11-334A14.2	8.24	5.14e-16	6.37e-10	0.31	0.25	Vitamin D levels;	chr11:14842668	chr1:52993201~52993702:-
BRCA	trans	rs877636	1	rs2292239	ENSG00000244604.1	RP11-713H12.1	8.24	5.24e-16	6.5e-10	0.28	0.25	Cognitive function;	chr12:56088396	chr17:8561230~8561576:+
BRCA	trans	rs7819412	0.595	rs10503416	ENSG00000253893.2	FAM85B	-8.24	5.28e-16	6.54e-10	-0.31	-0.25	Triglycerides;	chr8:11130043	chr8:8167819~8226614:-
BRCA	trans	rs6424115	0.679	rs2076345	ENSG00000228217.1	AL390877.1	8.24	5.3e-16	6.56e-10	0.33	0.25	Immature fraction of reticulocytes;	chr1:23757004	chr1:117778087~117778506:-
BRCA	trans	rs7113874	0.921	rs4929923	ENSG00000266891.1	RP11-692N5.2	-8.24	5.3e-16	6.56e-10	-0.3	-0.25	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8617653	chr18:9734882~9735602:-
BRCA	trans	rs4276421	0.571	rs10805694	ENSG00000231752.4	EMBP1	-8.23	5.4e-16	6.68e-10	-0.34	-0.25	P wave duration;	chr5:45539757	chr1:121519112~121571892:+
BRCA	trans	rs7833986	0.501	rs2667978	ENSG00000236862.1	RPS20P24	8.23	5.5e-16	6.8e-10	0.31	0.25	Height;	chr8:55985392	chr9:72655832~72656192:-
BRCA	trans	rs35847492	1	rs17730481	ENSG00000253893.2	FAM85B	8.23	5.61e-16	6.95e-10	0.35	0.25	Neuroticism;	chr8:9418653	chr8:8167819~8226614:-
BRCA	trans	rs3749237	1	rs11130214	ENSG00000197582.5	GPX1P1	-8.23	5.68e-16	7.02e-10	-0.26	-0.25	Resting heart rate;	chr3:49698313	chrX:13378735~13379340:-
BRCA	trans	rs66887589	0.592	rs11731571	ENSG00000275858.1	RP11-291L22.8	8.23	5.74e-16	7.1e-10	0.28	0.25	Diastolic blood pressure;	chr4:119300030	chr10:38450738~38451069:-
BRCA	trans	rs9467711	0.659	rs36162392	ENSG00000253570.1	RNF5P1	8.23	5.75e-16	7.11e-10	0.64	0.25	Autism spectrum disorder or schizophrenia;	chr6:26568907	chr8:38600661~38601200:-
BRCA	trans	rs66887589	0.967	rs2892869	ENSG00000275858.1	RP11-291L22.8	-8.22	5.78e-16	7.14e-10	-0.28	-0.25	Diastolic blood pressure;	chr4:119600142	chr10:38450738~38451069:-
BRCA	trans	rs9467711	0.659	rs35680819	ENSG00000253570.1	RNF5P1	8.22	6.04e-16	7.46e-10	0.67	0.25	Autism spectrum disorder or schizophrenia;	chr6:26455586	chr8:38600661~38601200:-
BRCA	trans	rs1580019	0.961	rs958217	ENSG00000176826.14	FKBP9P1	-8.22	6.14e-16	7.58e-10	-0.32	-0.25	Cognitive ability;	chr7:32453805	chr7:55681074~55713252:-
BRCA	trans	rs3749237	0.964	rs2352967	ENSG00000197582.5	GPX1P1	8.22	6.14e-16	7.59e-10	0.26	0.25	Resting heart rate;	chr3:49834208	chrX:13378735~13379340:-
BRCA	trans	rs2665103	0.687	rs11633000	ENSG00000235370.6	DNM1P51	-8.22	6.17e-16	7.63e-10	-0.27	-0.25	Intelligence (multi-trait analysis);	chr15:82269320	chr15:84398316~84411701:-
BRCA	trans	rs6424115	0.767	rs11591202	ENSG00000228217.1	AL390877.1	8.22	6.19e-16	7.64e-10	0.32	0.25	Immature fraction of reticulocytes;	chr1:23775590	chr1:117778087~117778506:-
BRCA	trans	rs7944735	0.508	rs4752791	ENSG00000134612.10	FOLH1B	-8.21	6.33e-16	7.81e-10	-0.39	-0.25	Intraocular pressure;	chr11:47714471	chr11:89639227~89698718:+
BRCA	trans	rs7939886	0.92	rs2460212	ENSG00000134612.10	FOLH1B	-8.21	6.39e-16	7.88e-10	-0.46	-0.25	Myopia (pathological);	chr11:56118679	chr11:89639227~89698718:+
BRCA	trans	rs12210905	0.925	rs12190201	ENSG00000242375.1	RP11-498P14.3	-8.21	6.47e-16	7.98e-10	-0.55	-0.25	Hip circumference adjusted for BMI;	chr6:27033679	chr9:97195351~97197687:-
BRCA	trans	rs12210905	0.925	rs4541737	ENSG00000242375.1	RP11-498P14.3	-8.21	6.47e-16	7.98e-10	-0.55	-0.25	Hip circumference adjusted for BMI;	chr6:27035042	chr9:97195351~97197687:-
BRCA	trans	rs546131	0.928	rs546521	ENSG00000225531.1	RP11-196I18.3	8.21	6.5e-16	8.02e-10	0.34	0.25	Lung disease severity in cystic fibrosis;	chr11:34803226	chr9:107116829~107117557:+
BRCA	trans	rs11098499	0.739	rs9884728	ENSG00000275858.1	RP11-291L22.8	-8.21	6.54e-16	8.07e-10	-0.3	-0.25	Corneal astigmatism;	chr4:119205924	chr10:38450738~38451069:-
BRCA	trans	rs1045902	0.537	rs1018342	ENSG00000236165.1	PRADC1P1	8.21	6.54e-16	8.07e-10	0.35	0.25	Intelligence (multi-trait analysis);	chr2:73244525	chr3:36976316~36976840:+
BRCA	trans	rs3849046	0.934	rs7714751	ENSG00000226666.1	HSPA9P1	-8.21	6.56e-16	8.09e-10	-0.28	-0.25	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138513377	chr2:221961737~221963765:+
BRCA	trans	rs12210905	0.92	rs77380818	ENSG00000242375.1	RP11-498P14.3	-8.21	6.61e-16	8.15e-10	-0.62	-0.25	Hip circumference adjusted for BMI;	chr6:27337719	chr9:97195351~97197687:-
BRCA	trans	rs7944735	0.508	rs2869531	ENSG00000134612.10	FOLH1B	8.21	6.64e-16	8.19e-10	0.4	0.25	Intraocular pressure;	chr11:47775850	chr11:89639227~89698718:+
BRCA	trans	rs11098499	0.739	rs9996382	ENSG00000275858.1	RP11-291L22.8	8.21	6.65e-16	8.2e-10	0.3	0.25	Corneal astigmatism;	chr4:119229857	chr10:38450738~38451069:-
BRCA	trans	rs12210905	0.925	rs72838262	ENSG00000242375.1	RP11-498P14.3	-8.21	6.66e-16	8.22e-10	-0.55	-0.25	Hip circumference adjusted for BMI;	chr6:27040738	chr9:97195351~97197687:-
BRCA	trans	rs12210905	1	rs7757680	ENSG00000242375.1	RP11-498P14.3	-8.2	6.84e-16	8.43e-10	-0.54	-0.25	Hip circumference adjusted for BMI;	chr6:27038061	chr9:97195351~97197687:-
BRCA	trans	rs1045902	0.532	rs2288631	ENSG00000236165.1	PRADC1P1	8.2	6.9e-16	8.51e-10	0.36	0.25	Intelligence (multi-trait analysis);	chr2:73228619	chr3:36976316~36976840:+
BRCA	trans	rs1045902	0.532	rs10185579	ENSG00000236165.1	PRADC1P1	8.2	6.9e-16	8.51e-10	0.36	0.25	Intelligence (multi-trait analysis);	chr2:73229214	chr3:36976316~36976840:+
BRCA	trans	rs7939886	0.844	rs2512784	ENSG00000134612.10	FOLH1B	-8.2	6.96e-16	8.58e-10	-0.46	-0.25	Myopia (pathological);	chr11:56126710	chr11:89639227~89698718:+
BRCA	trans	rs7944735	0.507	rs10742827	ENSG00000134612.10	FOLH1B	8.2	6.97e-16	8.59e-10	0.33	0.25	Intraocular pressure;	chr11:48080798	chr11:89639227~89698718:+
BRCA	trans	rs877636	0.702	rs773111	ENSG00000244604.1	RP11-713H12.1	8.2	6.99e-16	8.61e-10	0.31	0.25	Cognitive function;	chr12:55981956	chr17:8561230~8561576:+
BRCA	trans	rs941207	0.542	rs1813109	ENSG00000228224.3	NACAP1	-8.2	7.09e-16	8.73e-10	-0.31	-0.25	Platelet count;	chr12:56798079	chr8:101361794~101372707:+
BRCA	trans	rs7113874	0.659	rs1867810	ENSG00000266891.1	RP11-692N5.2	8.2	7.11e-16	8.75e-10	0.33	0.25	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8483981	chr18:9734882~9735602:-
BRCA	trans	rs877636	0.74	rs772920	ENSG00000244604.1	RP11-713H12.1	8.2	7.14e-16	8.79e-10	0.31	0.25	Cognitive function;	chr12:55996580	chr17:8561230~8561576:+
BRCA	trans	rs7927370	1	rs1425195	ENSG00000134612.10	FOLH1B	8.2	7.18e-16	8.84e-10	0.56	0.25	Systemic lupus erythematosus;	chr11:55427779	chr11:89639227~89698718:+
BRCA	trans	rs7819412	0.594	rs17724226	ENSG00000253893.2	FAM85B	8.19	7.35e-16	9.05e-10	0.32	0.25	Triglycerides;	chr8:11111416	chr8:8167819~8226614:-
BRCA	trans	rs10420951	0.579	rs79341622	ENSG00000267533.1	RP11-815J4.7	8.19	7.44e-16	9.15e-10	0.43	0.25	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr19:18487403	chr18:12067173~12068417:-
BRCA	trans	rs941207	0.542	rs7315786	ENSG00000228224.3	NACAP1	-8.19	7.64e-16	9.39e-10	-0.31	-0.25	Platelet count;	chr12:56801595	chr8:101361794~101372707:+
BRCA	trans	rs9467711	0.72	rs35627490	ENSG00000253570.1	RNF5P1	8.19	7.69e-16	9.45e-10	0.67	0.25	Autism spectrum disorder or schizophrenia;	chr6:26461876	chr8:38600661~38601200:-
BRCA	trans	rs10420951	0.617	rs8101992	ENSG00000267533.1	RP11-815J4.7	8.19	7.87e-16	9.67e-10	0.43	0.25	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr19:18503613	chr18:12067173~12068417:-
BRCA	trans	rs2665103	0.715	rs11639440	ENSG00000235370.6	DNM1P51	-8.18	7.92e-16	9.73e-10	-0.27	-0.25	Intelligence (multi-trait analysis);	chr15:82278705	chr15:84398316~84411701:-
BRCA	trans	rs546131	0.928	rs552627	ENSG00000225531.1	RP11-196I18.3	8.18	8e-16	9.83e-10	0.34	0.25	Lung disease severity in cystic fibrosis;	chr11:34805133	chr9:107116829~107117557:+
BRCA	trans	rs1580019	0.922	rs1376289	ENSG00000176826.14	FKBP9P1	8.18	8.24e-16	1.01e-09	0.33	0.25	Cognitive ability;	chr7:32447368	chr7:55681074~55713252:-
BRCA	trans	rs3749237	1	rs3749237	ENSG00000197582.5	GPX1P1	8.18	8.35e-16	1.03e-09	0.26	0.25	Resting heart rate;	chr3:49732599	chrX:13378735~13379340:-
BRCA	trans	rs3849046	1	rs13155345	ENSG00000226666.1	HSPA9P1	-8.18	8.5e-16	1.04e-09	-0.28	-0.25	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138519235	chr2:221961737~221963765:+
BRCA	trans	rs12210905	0.925	rs11966939	ENSG00000242375.1	RP11-498P14.3	-8.17	8.6e-16	1.06e-09	-0.54	-0.25	Hip circumference adjusted for BMI;	chr6:27035970	chr9:97195351~97197687:-
BRCA	trans	rs1190596	0.567	rs56870778	ENSG00000181359.5	HSP90AA6P	-8.17	8.72e-16	1.07e-09	-0.36	-0.25	Behavioural disinhibition (generation interaction);	chr14:102241864	chr4:170581470~170605450:-
BRCA	trans	rs747782	0.536	rs59205786	ENSG00000134612.10	FOLH1B	8.16	9.26e-16	1.13e-09	0.39	0.25	Intraocular pressure;	chr11:47736600	chr11:89639227~89698718:+
BRCA	trans	rs2060793	0.684	rs1597689	ENSG00000236360.2	RP11-334A14.2	8.16	9.3e-16	1.14e-09	0.32	0.25	Vitamin D levels;	chr11:14824638	chr1:52993201~52993702:-
BRCA	trans	rs877636	0.702	rs773110	ENSG00000244604.1	RP11-713H12.1	8.16	9.41e-16	1.15e-09	0.31	0.25	Cognitive function;	chr12:55981353	chr17:8561230~8561576:+
BRCA	trans	rs11098499	0.739	rs2203039	ENSG00000275858.1	RP11-291L22.8	-8.16	9.48e-16	1.16e-09	-0.3	-0.25	Corneal astigmatism;	chr4:119211192	chr10:38450738~38451069:-
BRCA	trans	rs12210905	0.925	rs12200985	ENSG00000242375.1	RP11-498P14.3	-8.16	9.56e-16	1.17e-09	-0.54	-0.25	Hip circumference adjusted for BMI;	chr6:27037113	chr9:97195351~97197687:-
BRCA	trans	rs7944735	0.508	rs11819979	ENSG00000134612.10	FOLH1B	8.16	9.58e-16	1.17e-09	0.4	0.25	Intraocular pressure;	chr11:47751655	chr11:89639227~89698718:+
BRCA	trans	rs10940346	0.506	rs12659667	ENSG00000231752.4	EMBP1	-8.16	9.94e-16	1.22e-09	-0.31	-0.24	Schizophrenia;	chr5:50566091	chr1:121519112~121571892:+
BRCA	trans	rs12200782	0.872	rs41266837	ENSG00000242375.1	RP11-498P14.3	-8.16	9.96e-16	1.22e-09	-0.52	-0.24	Small cell lung carcinoma;	chr6:26409501	chr9:97195351~97197687:-
BRCA	trans	rs60515486	0.702	rs61000762	ENSG00000134612.10	FOLH1B	8.15	1.03e-15	1.27e-09	0.4	0.24	Lymphocyte counts;	chr11:47410410	chr11:89639227~89698718:+
BRCA	trans	rs9393777	0.92	rs34150729	ENSG00000253570.1	RNF5P1	8.15	1.04e-15	1.27e-09	0.7	0.24	Intelligence (multi-trait analysis);	chr6:27420975	chr8:38600661~38601200:-
BRCA	trans	rs9393777	0.92	rs13191227	ENSG00000253570.1	RNF5P1	8.15	1.04e-15	1.27e-09	0.7	0.24	Intelligence (multi-trait analysis);	chr6:27422336	chr8:38600661~38601200:-
BRCA	trans	rs73108077	1	rs73108027	ENSG00000279352.1	RP11-411B10.7	8.15	1.04e-15	1.27e-09	0.54	0.24	Red blood cell density in sickle cell anemia;	chr20:31398778	chr18:14010054~14010917:+
BRCA	trans	rs17711722	0.523	rs365896	ENSG00000234585.5	CCT6P3	-8.15	1.04e-15	1.27e-09	-0.24	-0.24	Calcium levels;	chr7:66045710	chr7:65038354~65074713:+
BRCA	trans	rs9467711	0.659	rs3823158	ENSG00000253570.1	RNF5P1	8.15	1.06e-15	1.29e-09	0.65	0.24	Autism spectrum disorder or schizophrenia;	chr6:26463043	chr8:38600661~38601200:-
BRCA	trans	rs3749237	1	rs2307021	ENSG00000197582.5	GPX1P1	8.14	1.08e-15	1.32e-09	0.27	0.24	Resting heart rate;	chr3:49728050	chrX:13378735~13379340:-
BRCA	trans	rs71537559	1	rs71537559	ENSG00000253570.1	RNF5P1	8.14	1.08e-15	1.32e-09	0.65	0.24	Squamous cell lung carcinoma;	chr6:27342000	chr8:38600661~38601200:-
BRCA	trans	rs9650657	0.601	rs10903330	ENSG00000253893.2	FAM85B	-8.14	1.09e-15	1.33e-09	-0.32	-0.24	Neuroticism;	chr8:10815594	chr8:8167819~8226614:-
BRCA	trans	rs7944735	0.508	rs57436966	ENSG00000134612.10	FOLH1B	8.14	1.1e-15	1.34e-09	0.39	0.24	Intraocular pressure;	chr11:47737989	chr11:89639227~89698718:+
BRCA	trans	rs7113874	0.959	rs11042023	ENSG00000266891.1	RP11-692N5.2	-8.14	1.1e-15	1.35e-09	-0.3	-0.24	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8640969	chr18:9734882~9735602:-
BRCA	trans	rs10420951	0.617	rs7251067	ENSG00000267533.1	RP11-815J4.7	8.14	1.13e-15	1.38e-09	0.43	0.24	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr19:18489246	chr18:12067173~12068417:-
BRCA	trans	rs9467711	0.606	rs34104395	ENSG00000253570.1	RNF5P1	8.14	1.15e-15	1.41e-09	0.64	0.24	Autism spectrum disorder or schizophrenia;	chr6:26478024	chr8:38600661~38601200:-
BRCA	trans	rs877636	0.702	rs773109	ENSG00000244604.1	RP11-713H12.1	8.13	1.17e-15	1.43e-09	0.31	0.24	Cognitive function;	chr12:55980911	chr17:8561230~8561576:+
BRCA	trans	rs12200782	0.769	rs10456329	ENSG00000242375.1	RP11-498P14.3	-8.13	1.18e-15	1.44e-09	-0.52	-0.24	Small cell lung carcinoma;	chr6:26436171	chr9:97195351~97197687:-
BRCA	trans	rs11992162	0.636	rs11250182	ENSG00000253893.2	FAM85B	8.13	1.2e-15	1.47e-09	0.3	0.24	Monocyte count;	chr8:11950067	chr8:8167819~8226614:-
BRCA	trans	rs10940346	0.506	rs7721806	ENSG00000231752.4	EMBP1	-8.13	1.21e-15	1.47e-09	-0.31	-0.24	Schizophrenia;	chr5:50576182	chr1:121519112~121571892:+
BRCA	trans	rs12200782	0.872	rs59438701	ENSG00000242375.1	RP11-498P14.3	-8.13	1.25e-15	1.53e-09	-0.52	-0.24	Small cell lung carcinoma;	chr6:26412299	chr9:97195351~97197687:-
BRCA	trans	rs1045902	0.516	rs7851	ENSG00000236165.1	PRADC1P1	8.13	1.26e-15	1.53e-09	0.35	0.24	Intelligence (multi-trait analysis);	chr2:73251333	chr3:36976316~36976840:+
BRCA	trans	rs9467711	0.659	rs36033628	ENSG00000253570.1	RNF5P1	8.13	1.26e-15	1.53e-09	0.67	0.24	Autism spectrum disorder or schizophrenia;	chr6:26455846	chr8:38600661~38601200:-
BRCA	trans	rs1580019	0.922	rs34545272	ENSG00000176826.14	FKBP9P1	-8.12	1.27e-15	1.55e-09	-0.32	-0.24	Cognitive ability;	chr7:32421018	chr7:55681074~55713252:-
BRCA	trans	rs7113874	0.625	rs10743073	ENSG00000266891.1	RP11-692N5.2	-8.12	1.28e-15	1.56e-09	-0.33	-0.24	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8483072	chr18:9734882~9735602:-
BRCA	trans	rs10037055	0.853	rs10077929	ENSG00000228305.2	AC016734.2	8.12	1.28e-15	1.57e-09	0.27	0.24	Migraine without aura;	chr5:177270843	chr2:63622178~63622831:-
BRCA	trans	rs7944735	0.508	rs77685652	ENSG00000134612.10	FOLH1B	8.12	1.29e-15	1.57e-09	0.39	0.24	Intraocular pressure;	chr11:47757225	chr11:89639227~89698718:+
BRCA	trans	rs7944735	0.508	rs11820480	ENSG00000134612.10	FOLH1B	8.12	1.29e-15	1.57e-09	0.39	0.24	Intraocular pressure;	chr11:47757918	chr11:89639227~89698718:+
BRCA	trans	rs7819412	0.561	rs2001328	ENSG00000253893.2	FAM85B	8.12	1.29e-15	1.58e-09	0.31	0.24	Triglycerides;	chr8:11129689	chr8:8167819~8226614:-
BRCA	trans	rs66887589	0.87	rs2389875	ENSG00000275858.1	RP11-291L22.8	-8.12	1.3e-15	1.58e-09	-0.28	-0.24	Diastolic blood pressure;	chr4:119635859	chr10:38450738~38451069:-
BRCA	trans	rs12210905	0.858	rs11758615	ENSG00000242375.1	RP11-498P14.3	-8.12	1.31e-15	1.59e-09	-0.51	-0.24	Hip circumference adjusted for BMI;	chr6:27224603	chr9:97195351~97197687:-
BRCA	trans	rs7819412	0.749	rs11991118	ENSG00000253893.2	FAM85B	-8.12	1.32e-15	1.61e-09	-0.31	-0.24	Triglycerides;	chr8:11081763	chr8:8167819~8226614:-
BRCA	trans	rs7944735	0.507	rs7114598	ENSG00000134612.10	FOLH1B	8.12	1.33e-15	1.61e-09	0.32	0.24	Intraocular pressure;	chr11:48080214	chr11:89639227~89698718:+
BRCA	trans	rs6743068	0.6	rs1035140	ENSG00000235105.1	RP11-329A14.1	8.12	1.34e-15	1.63e-09	0.29	0.24	Lymphocyte percentage of white cells;	chr2:201287768	chr1:48435967~48437223:+
BRCA	trans	rs875971	0.545	rs73376394	ENSG00000164669.11	INTS4P1	-8.12	1.34e-15	1.63e-09	-0.34	-0.24	Aortic root size;	chr7:66172694	chr7:65141225~65234216:+
BRCA	trans	rs12210905	0.858	rs3800306	ENSG00000242375.1	RP11-498P14.3	-8.11	1.39e-15	1.69e-09	-0.52	-0.24	Hip circumference adjusted for BMI;	chr6:27217947	chr9:97195351~97197687:-
BRCA	trans	rs11098499	0.575	rs9996586	ENSG00000275858.1	RP11-291L22.8	8.11	1.43e-15	1.74e-09	0.27	0.24	Corneal astigmatism;	chr4:119405787	chr10:38450738~38451069:-
BRCA	trans	rs875971	0.545	rs4718348	ENSG00000164669.11	INTS4P1	-8.11	1.46e-15	1.77e-09	-0.35	-0.24	Aortic root size;	chr7:66441589	chr7:65141225~65234216:+
BRCA	trans	rs864643	0.947	rs1708073	ENSG00000183298.5	RP11-556K13.1	8.11	1.46e-15	1.78e-09	0.38	0.24	Attention deficit hyperactivity disorder;	chr3:39501530	chr1:101786340~101787219:-
BRCA	trans	rs7113874	1	rs10840099	ENSG00000266891.1	RP11-692N5.2	-8.1	1.49e-15	1.82e-09	-0.3	-0.24	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8646133	chr18:9734882~9735602:-
BRCA	trans	rs9467711	0.606	rs13190739	ENSG00000253570.1	RNF5P1	8.1	1.5e-15	1.83e-09	0.64	0.24	Autism spectrum disorder or schizophrenia;	chr6:26587145	chr8:38600661~38601200:-
BRCA	trans	rs9467711	0.606	rs34781270	ENSG00000253570.1	RNF5P1	8.1	1.5e-15	1.83e-09	0.64	0.24	Autism spectrum disorder or schizophrenia;	chr6:26592809	chr8:38600661~38601200:-
BRCA	trans	rs1580019	0.961	rs6949851	ENSG00000176826.14	FKBP9P1	-8.1	1.52e-15	1.85e-09	-0.31	-0.24	Cognitive ability;	chr7:32454195	chr7:55681074~55713252:-
BRCA	trans	rs9329221	0.509	rs3088186	ENSG00000253893.2	FAM85B	-8.1	1.53e-15	1.86e-09	-0.34	-0.24	Neuroticism;	chr8:10368845	chr8:8167819~8226614:-
BRCA	trans	rs2060793	0.741	rs10734227	ENSG00000236360.2	RP11-334A14.2	8.1	1.53e-15	1.86e-09	0.31	0.24	Vitamin D levels;	chr11:14767471	chr1:52993201~52993702:-
BRCA	trans	rs73108077	1	rs73108077	ENSG00000279352.1	RP11-411B10.7	8.1	1.54e-15	1.87e-09	0.54	0.24	Red blood cell density in sickle cell anemia;	chr20:31419056	chr18:14010054~14010917:+
BRCA	trans	rs66887589	0.967	rs1155577	ENSG00000275858.1	RP11-291L22.8	-8.1	1.56e-15	1.9e-09	-0.27	-0.24	Diastolic blood pressure;	chr4:119528655	chr10:38450738~38451069:-
BRCA	trans	rs12477438	0.52	rs6717729	ENSG00000276576.1	MRPL30P1	8.1	1.57e-15	1.91e-09	0.3	0.24	Chronic sinus infection;	chr2:99140478	chr6:57029521~57029988:+
BRCA	trans	rs9467711	0.606	rs35076545	ENSG00000253570.1	RNF5P1	8.1	1.57e-15	1.91e-09	0.64	0.24	Autism spectrum disorder or schizophrenia;	chr6:26603696	chr8:38600661~38601200:-
BRCA	trans	rs6940638	0.662	rs7759694	ENSG00000242375.1	RP11-498P14.3	-8.09	1.61e-15	1.95e-09	-0.34	-0.24	Intelligence (multi-trait analysis);	chr6:27273177	chr9:97195351~97197687:-
BRCA	trans	rs6940638	0.956	rs36048693	ENSG00000242375.1	RP11-498P14.3	-8.09	1.63e-15	1.98e-09	-0.4	-0.24	Intelligence (multi-trait analysis);	chr6:27064932	chr9:97195351~97197687:-
BRCA	trans	rs7944735	0.507	rs10838802	ENSG00000134612.10	FOLH1B	8.09	1.64e-15	1.99e-09	0.32	0.24	Intraocular pressure;	chr11:48080926	chr11:89639227~89698718:+
BRCA	trans	rs9467711	0.659	rs72844462	ENSG00000253570.1	RNF5P1	8.09	1.67e-15	2.03e-09	0.64	0.24	Autism spectrum disorder or schizophrenia;	chr6:26563636	chr8:38600661~38601200:-
BRCA	trans	rs747782	0.646	rs17198158	ENSG00000134612.10	FOLH1B	8.09	1.68e-15	2.03e-09	0.37	0.24	Intraocular pressure;	chr11:47456297	chr11:89639227~89698718:+
BRCA	trans	rs73108077	0.736	rs2206384	ENSG00000279352.1	RP11-411B10.7	8.09	1.69e-15	2.05e-09	0.41	0.24	Red blood cell density in sickle cell anemia;	chr20:31339363	chr18:14010054~14010917:+
BRCA	trans	rs12210905	0.858	rs858992	ENSG00000242375.1	RP11-498P14.3	8.08	1.73e-15	2.1e-09	0.52	0.24	Hip circumference adjusted for BMI;	chr6:27213048	chr9:97195351~97197687:-
BRCA	trans	rs66887589	0.56	rs9684327	ENSG00000275858.1	RP11-291L22.8	8.08	1.75e-15	2.12e-09	0.27	0.24	Diastolic blood pressure;	chr4:119444286	chr10:38450738~38451069:-
BRCA	trans	rs7930295	1	rs10893380	ENSG00000236257.1	EI24P2	-8.08	1.81e-15	2.19e-09	-0.37	-0.24	Schizophrenia;	chr11:125441778	chr1:158454198~158455273:+
BRCA	trans	rs1933488	0.804	rs9397586	ENSG00000278974.1	RP11-756P10.6	-8.07	1.85e-15	2.25e-09	-0.32	-0.24	Prostate cancer;	chr6:153093152	chr4:188740507~188741281:-
BRCA	trans	rs73108077	1	rs73108009	ENSG00000279352.1	RP11-411B10.7	8.07	1.86e-15	2.26e-09	0.55	0.24	Red blood cell density in sickle cell anemia;	chr20:31390409	chr18:14010054~14010917:+
BRCA	trans	rs7824557	0.564	rs7839307	ENSG00000253893.2	FAM85B	-8.07	1.87e-15	2.26e-09	-0.3	-0.24	Retinal vascular caliber;	chr8:11341283	chr8:8167819~8226614:-
BRCA	trans	rs35847492	1	rs35847492	ENSG00000253893.2	FAM85B	-8.07	1.89e-15	2.29e-09	-0.33	-0.24	Neuroticism;	chr8:9418515	chr8:8167819~8226614:-
BRCA	trans	rs66887589	0.807	rs9799664	ENSG00000275858.1	RP11-291L22.8	8.07	1.91e-15	2.31e-09	0.27	0.24	Diastolic blood pressure;	chr4:119405523	chr10:38450738~38451069:-
BRCA	trans	rs3749237	0.964	rs10865959	ENSG00000197582.5	GPX1P1	8.07	1.91e-15	2.32e-09	0.26	0.24	Resting heart rate;	chr3:49853569	chrX:13378735~13379340:-
BRCA	trans	rs1962073	0.528	rs9329223	ENSG00000253893.2	FAM85B	8.07	1.99e-15	2.41e-09	0.3	0.24	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);	chr8:10474244	chr8:8167819~8226614:-
BRCA	trans	rs66887589	0.967	rs3775842	ENSG00000275858.1	RP11-291L22.8	8.07	2e-15	2.42e-09	0.27	0.24	Diastolic blood pressure;	chr4:119506577	chr10:38450738~38451069:-
BRCA	trans	rs9650657	0.737	rs4841436	ENSG00000253893.2	FAM85B	-8.06	2.08e-15	2.51e-09	-0.31	-0.24	Neuroticism;	chr8:10736964	chr8:8167819~8226614:-
BRCA	trans	rs9467711	0.659	rs3734542	ENSG00000253570.1	RNF5P1	8.05	2.18e-15	2.63e-09	0.63	0.24	Autism spectrum disorder or schizophrenia;	chr6:26468098	chr8:38600661~38601200:-
BRCA	trans	rs73108077	1	rs73105971	ENSG00000279352.1	RP11-411B10.7	8.05	2.19e-15	2.65e-09	0.44	0.24	Red blood cell density in sickle cell anemia;	chr20:31369934	chr18:14010054~14010917:+
BRCA	trans	rs9393777	0.92	rs13207689	ENSG00000253570.1	RNF5P1	8.05	2.2e-15	2.66e-09	0.69	0.24	Intelligence (multi-trait analysis);	chr6:27401925	chr8:38600661~38601200:-
BRCA	trans	rs9393777	0.92	rs13196692	ENSG00000253570.1	RNF5P1	8.05	2.22e-15	2.68e-09	0.69	0.24	Intelligence (multi-trait analysis);	chr6:27411340	chr8:38600661~38601200:-
BRCA	trans	rs3749237	0.964	rs13084243	ENSG00000197582.5	GPX1P1	8.05	2.26e-15	2.72e-09	0.26	0.24	Resting heart rate;	chr3:49784445	chrX:13378735~13379340:-
BRCA	trans	rs3749237	1	rs11920900	ENSG00000197582.5	GPX1P1	8.05	2.26e-15	2.72e-09	0.26	0.24	Resting heart rate;	chr3:49785591	chrX:13378735~13379340:-
BRCA	trans	rs9467711	0.659	rs13195509	ENSG00000253570.1	RNF5P1	8.05	2.27e-15	2.74e-09	0.63	0.24	Autism spectrum disorder or schizophrenia;	chr6:26463432	chr8:38600661~38601200:-
BRCA	trans	rs3849046	1	rs13164092	ENSG00000226666.1	HSPA9P1	-8.05	2.29e-15	2.76e-09	-0.27	-0.24	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138505171	chr2:221961737~221963765:+
BRCA	trans	rs3849046	0.967	rs55985421	ENSG00000226666.1	HSPA9P1	-8.05	2.29e-15	2.76e-09	-0.27	-0.24	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138505574	chr2:221961737~221963765:+
BRCA	trans	rs864643	0.678	rs1768206	ENSG00000188856.6	RPSAP47	8.05	2.3e-15	2.77e-09	0.37	0.24	Attention deficit hyperactivity disorder;	chr3:39480342	chr8:80558870~80559757:+
BRCA	trans	rs7662987	1	rs28730640	ENSG00000228407.2	RP4-800M22.1	8.05	2.3e-15	2.78e-09	0.53	0.24	Smoking initiation;	chr4:99072902	chr1:52160261~52160600:-
BRCA	trans	rs7662987	1	rs7658118	ENSG00000228407.2	RP4-800M22.1	8.05	2.3e-15	2.78e-09	0.53	0.24	Smoking initiation;	chr4:99073457	chr1:52160261~52160600:-
BRCA	trans	rs73108077	1	rs73108061	ENSG00000279352.1	RP11-411B10.7	8.04	2.34e-15	2.83e-09	0.54	0.24	Red blood cell density in sickle cell anemia;	chr20:31413650	chr18:14010054~14010917:+
BRCA	trans	rs877636	1	rs877636	ENSG00000212829.8	RPS26P3	-8.04	2.4e-15	2.89e-09	-0.31	-0.24	Cognitive function;	chr12:56086799	chr9:9090898~9091245:+
BRCA	trans	rs801193	0.591	rs9986881	ENSG00000273024.4	INTS4P2	-8.04	2.49e-15	3e-09	-0.27	-0.24	Aortic root size;	chr7:66708053	chr7:65647864~65715661:+
BRCA	trans	rs877636	0.692	rs11171739	ENSG00000227586.5	RP11-162A23.5	8.04	2.49e-15	3e-09	0.28	0.24	Cognitive function;	chr12:56076841	chr10:123171535~123171875:-
BRCA	trans	rs7113874	1	rs10840100	ENSG00000266891.1	RP11-692N5.2	8.04	2.51e-15	3.02e-09	0.3	0.24	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8647890	chr18:9734882~9735602:-
BRCA	trans	rs73108077	1	rs73105976	ENSG00000279352.1	RP11-411B10.7	8.03	2.55e-15	3.07e-09	0.54	0.24	Red blood cell density in sickle cell anemia;	chr20:31378130	chr18:14010054~14010917:+
BRCA	trans	rs1190596	0.567	rs11844941	ENSG00000181359.5	HSP90AA6P	-8.03	2.56e-15	3.08e-09	-0.36	-0.24	Behavioural disinhibition (generation interaction);	chr14:102235933	chr4:170581470~170605450:-
BRCA	trans	rs2060793	0.659	rs1839834	ENSG00000236360.2	RP11-334A14.2	8.03	2.6e-15	3.13e-09	0.31	0.24	Vitamin D levels;	chr11:14807914	chr1:52993201~52993702:-
BRCA	trans	rs11920570	0.959	rs6438726	ENSG00000267076.1	CCDC58P3	8.03	2.71e-15	3.26e-09	0.32	0.24	Resting heart rate;	chr3:122392074	chr18:12211378~12211807:+
BRCA	trans	rs9393777	0.92	rs41269265	ENSG00000253570.1	RNF5P1	8.03	2.71e-15	3.26e-09	0.64	0.24	Intelligence (multi-trait analysis);	chr6:27457570	chr8:38600661~38601200:-
BRCA	trans	rs3740713	1	rs73440615	ENSG00000214110.3	LDHAP4	8.02	2.73e-15	3.29e-09	0.44	0.24	Amyotrophic lateral sclerosis (sporadic);	chr11:18445736	chr9:14921337~14922334:-
BRCA	trans	rs864643	0.947	rs482495	ENSG00000183298.5	RP11-556K13.1	8.02	2.75e-15	3.31e-09	0.37	0.24	Attention deficit hyperactivity disorder;	chr3:39498924	chr1:101786340~101787219:-
BRCA	trans	rs864643	0.947	rs645403	ENSG00000183298.5	RP11-556K13.1	8.02	2.75e-15	3.31e-09	0.37	0.24	Attention deficit hyperactivity disorder;	chr3:39498968	chr1:101786340~101787219:-
BRCA	trans	rs11098499	0.909	rs73842633	ENSG00000276997.3	RP11-378J18.9	8.02	2.86e-15	3.44e-09	0.3	0.24	Corneal astigmatism;	chr4:119454309	chr1:222477252~222504622:-
BRCA	trans	rs2060793	0.712	rs6486202	ENSG00000236360.2	RP11-334A14.2	8.01	2.98e-15	3.57e-09	0.31	0.24	Vitamin D levels;	chr11:14777260	chr1:52993201~52993702:-
BRCA	trans	rs13016963	0.546	rs11898821	ENSG00000235105.1	RP11-329A14.1	8.01	2.99e-15	3.58e-09	0.29	0.24	Esophageal squamous cell carcinoma;Melanoma;	chr2:201334965	chr1:48435967~48437223:+
BRCA	trans	rs7833986	0.534	rs17814089	ENSG00000244245.1	RP11-120B7.1	-8.01	3.02e-15	3.62e-09	-0.3	-0.24	Height;	chr8:56053004	chr5:108593609~108593967:+
BRCA	trans	rs877636	1	rs4759229	ENSG00000204652.6	RPS26P8	-8.01	3.05e-15	3.66e-09	-0.31	-0.24	Cognitive function;	chr12:56080696	chr17:45608571~45608918:+
BRCA	trans	rs9467711	0.659	rs13220261	ENSG00000253570.1	RNF5P1	8.01	3.05e-15	3.66e-09	0.64	0.24	Autism spectrum disorder or schizophrenia;	chr6:26498957	chr8:38600661~38601200:-
BRCA	trans	rs9467711	0.659	rs35555795	ENSG00000253570.1	RNF5P1	8.01	3.05e-15	3.66e-09	0.64	0.24	Autism spectrum disorder or schizophrenia;	chr6:26509154	chr8:38600661~38601200:-
BRCA	trans	rs11098499	0.954	rs10017543	ENSG00000276997.3	RP11-378J18.9	8.01	3.07e-15	3.68e-09	0.3	0.24	Corneal astigmatism;	chr4:119400265	chr1:222477252~222504622:-
BRCA	trans	rs7113874	1	rs4256980	ENSG00000266891.1	RP11-692N5.2	-8.01	3.09e-15	3.7e-09	-0.3	-0.24	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8652392	chr18:9734882~9735602:-
BRCA	trans	rs1580019	0.961	rs1868777	ENSG00000176826.14	FKBP9P1	-8.01	3.11e-15	3.72e-09	-0.31	-0.24	Cognitive ability;	chr7:32454464	chr7:55681074~55713252:-
BRCA	trans	rs7824557	0.675	rs2736265	ENSG00000253893.2	FAM85B	-8	3.21e-15	3.84e-09	-0.3	-0.24	Retinal vascular caliber;	chr8:11329165	chr8:8167819~8226614:-
BRCA	trans	rs2060793	0.741	rs1542291	ENSG00000236360.2	RP11-334A14.2	8	3.22e-15	3.85e-09	0.31	0.24	Vitamin D levels;	chr11:14784720	chr1:52993201~52993702:-
BRCA	trans	rs11920570	0.839	rs7646110	ENSG00000267076.1	CCDC58P3	-8	3.23e-15	3.87e-09	-0.32	-0.24	Resting heart rate;	chr3:122391831	chr18:12211378~12211807:+
BRCA	trans	rs12477438	0.501	rs7349217	ENSG00000276576.1	MRPL30P1	8	3.3e-15	3.95e-09	0.3	0.24	Chronic sinus infection;	chr2:99198683	chr6:57029521~57029988:+
BRCA	trans	rs1045902	0.574	rs1053329	ENSG00000236165.1	PRADC1P1	8	3.37e-15	4.03e-09	0.36	0.24	Intelligence (multi-trait analysis);	chr2:73234355	chr3:36976316~36976840:+
BRCA	trans	rs4879656	0.564	rs20583	ENSG00000215007.3	DNAJA1P3	7.99	3.46e-15	4.13e-09	0.29	0.24	Menopause (age at onset);	chr9:33026574	chrX:107351650~107352843:-
BRCA	trans	rs9650657	0.644	rs4395858	ENSG00000253893.2	FAM85B	-7.98	3.76e-15	4.48e-09	-0.3	-0.24	Neuroticism;	chr8:10663511	chr8:8167819~8226614:-
BRCA	trans	rs9987353	0.518	rs4841110	ENSG00000253893.2	FAM85B	-7.98	3.82e-15	4.55e-09	-0.3	-0.24	Recombination measurement;	chr8:9228513	chr8:8167819~8226614:-
BRCA	trans	rs12210905	0.858	rs3800305	ENSG00000242375.1	RP11-498P14.3	-7.98	3.88e-15	4.62e-09	-0.49	-0.24	Hip circumference adjusted for BMI;	chr6:27217797	chr9:97195351~97197687:-
BRCA	trans	rs2243480	1	rs4718269	ENSG00000273142.1	RP11-458F8.4	7.98	3.89e-15	4.64e-09	0.32	0.24	Diabetic kidney disease;	chr7:65735810	chr7:66902857~66906297:+
BRCA	trans	rs7113874	1	rs6486253	ENSG00000266891.1	RP11-692N5.2	-7.97	3.99e-15	4.75e-09	-0.29	-0.24	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8646803	chr18:9734882~9735602:-
BRCA	trans	rs11098499	0.908	rs7695996	ENSG00000276997.3	RP11-378J18.9	7.97	4.01e-15	4.77e-09	0.29	0.24	Corneal astigmatism;	chr4:119400878	chr1:222477252~222504622:-
BRCA	trans	rs9368481	0.743	rs9368480	ENSG00000242375.1	RP11-498P14.3	7.97	4.01e-15	4.78e-09	0.35	0.24	Autism spectrum disorder or schizophrenia;	chr6:26987971	chr9:97195351~97197687:-
BRCA	trans	rs9467711	0.659	rs35277236	ENSG00000253570.1	RNF5P1	7.97	4.12e-15	4.9e-09	0.63	0.24	Autism spectrum disorder or schizophrenia;	chr6:26562041	chr8:38600661~38601200:-
BRCA	trans	rs11098499	0.954	rs10008392	ENSG00000276997.3	RP11-378J18.9	7.97	4.16e-15	4.94e-09	0.3	0.24	Corneal astigmatism;	chr4:119397684	chr1:222477252~222504622:-
BRCA	trans	rs1814175	0.645	rs10742953	ENSG00000134612.10	FOLH1B	7.97	4.23e-15	5.03e-09	0.29	0.24	Height;	chr11:49785939	chr11:89639227~89698718:+
BRCA	trans	rs9467711	0.659	rs34246779	ENSG00000253570.1	RNF5P1	7.97	4.27e-15	5.08e-09	0.63	0.24	Autism spectrum disorder or schizophrenia;	chr6:26548984	chr8:38600661~38601200:-
BRCA	trans	rs7824557	0.933	rs6601576	ENSG00000253893.2	FAM85B	7.97	4.29e-15	5.1e-09	0.32	0.24	Retinal vascular caliber;	chr8:11242766	chr8:8167819~8226614:-
BRCA	trans	rs66887589	0.967	rs13104219	ENSG00000275858.1	RP11-291L22.8	7.96	4.31e-15	5.12e-09	0.27	0.24	Diastolic blood pressure;	chr4:119517019	chr10:38450738~38451069:-
BRCA	trans	rs9467711	0.659	rs35433030	ENSG00000253570.1	RNF5P1	7.96	4.32e-15	5.13e-09	0.63	0.24	Autism spectrum disorder or schizophrenia;	chr6:26529662	chr8:38600661~38601200:-
BRCA	trans	rs9467711	0.659	rs66941101	ENSG00000253570.1	RNF5P1	7.96	4.32e-15	5.13e-09	0.63	0.24	Autism spectrum disorder or schizophrenia;	chr6:26530148	chr8:38600661~38601200:-
BRCA	trans	rs1580019	0.961	rs1868776	ENSG00000176826.14	FKBP9P1	7.96	4.4e-15	5.22e-09	0.3	0.24	Cognitive ability;	chr7:32454823	chr7:55681074~55713252:-
BRCA	trans	rs66887589	0.967	rs6844263	ENSG00000275858.1	RP11-291L22.8	7.96	4.48e-15	5.32e-09	0.27	0.24	Diastolic blood pressure;	chr4:119512652	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.954	rs3890049	ENSG00000276997.3	RP11-378J18.9	7.96	4.49e-15	5.32e-09	0.29	0.24	Corneal astigmatism;	chr4:119405128	chr1:222477252~222504622:-
BRCA	trans	rs13014235	0.652	rs6435080	ENSG00000235105.1	RP11-329A14.1	7.96	4.58e-15	5.43e-09	0.29	0.24	Basal cell carcinoma;	chr2:201341597	chr1:48435967~48437223:+
BRCA	trans	rs9467711	0.79	rs13204572	ENSG00000253570.1	RNF5P1	7.96	4.63e-15	5.49e-09	0.72	0.24	Autism spectrum disorder or schizophrenia;	chr6:26189128	chr8:38600661~38601200:-
BRCA	trans	rs11098499	0.954	rs71629403	ENSG00000276997.3	RP11-378J18.9	7.95	4.65e-15	5.52e-09	0.29	0.24	Corneal astigmatism;	chr4:119451412	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.909	rs28571712	ENSG00000276997.3	RP11-378J18.9	7.95	4.65e-15	5.52e-09	0.29	0.24	Corneal astigmatism;	chr4:119454825	chr1:222477252~222504622:-
BRCA	trans	rs864643	0.678	rs1768201	ENSG00000188856.6	RPSAP47	7.95	4.69e-15	5.56e-09	0.35	0.24	Attention deficit hyperactivity disorder;	chr3:39476050	chr8:80558870~80559757:+
BRCA	trans	rs864643	0.947	rs1708015	ENSG00000183298.5	RP11-556K13.1	7.95	4.83e-15	5.72e-09	0.37	0.24	Attention deficit hyperactivity disorder;	chr3:39496891	chr1:101786340~101787219:-
BRCA	trans	rs864643	0.891	rs1708018	ENSG00000183298.5	RP11-556K13.1	7.95	4.83e-15	5.72e-09	0.37	0.24	Attention deficit hyperactivity disorder;	chr3:39496978	chr1:101786340~101787219:-
BRCA	trans	rs864643	0.947	rs535220	ENSG00000183298.5	RP11-556K13.1	7.95	4.83e-15	5.72e-09	0.37	0.24	Attention deficit hyperactivity disorder;	chr3:39497234	chr1:101786340~101787219:-
BRCA	trans	rs864643	0.947	rs538214	ENSG00000183298.5	RP11-556K13.1	7.95	4.83e-15	5.72e-09	0.37	0.24	Attention deficit hyperactivity disorder;	chr3:39497603	chr1:101786340~101787219:-
BRCA	trans	rs864643	0.947	rs538972	ENSG00000183298.5	RP11-556K13.1	7.95	4.83e-15	5.72e-09	0.37	0.24	Attention deficit hyperactivity disorder;	chr3:39497652	chr1:101786340~101787219:-
BRCA	trans	rs864643	0.947	rs614359	ENSG00000183298.5	RP11-556K13.1	7.95	4.83e-15	5.72e-09	0.37	0.24	Attention deficit hyperactivity disorder;	chr3:39498035	chr1:101786340~101787219:-
BRCA	trans	rs9467711	0.659	rs72845428	ENSG00000253570.1	RNF5P1	7.95	4.86e-15	5.76e-09	0.63	0.24	Autism spectrum disorder or schizophrenia;	chr6:26549916	chr8:38600661~38601200:-
BRCA	trans	rs864643	0.891	rs55780606	ENSG00000183298.5	RP11-556K13.1	7.95	4.92e-15	5.83e-09	0.37	0.24	Attention deficit hyperactivity disorder;	chr3:39496599	chr1:101786340~101787219:-
BRCA	trans	rs7944735	0.508	rs4147730	ENSG00000134612.10	FOLH1B	7.95	4.97e-15	5.89e-09	0.38	0.24	Intraocular pressure;	chr11:47583875	chr11:89639227~89698718:+
BRCA	trans	rs9329221	0.657	rs17694485	ENSG00000253893.2	FAM85B	-7.94	5.07e-15	6.01e-09	-0.32	-0.24	Neuroticism;	chr8:10256948	chr8:8167819~8226614:-
BRCA	trans	rs877636	0.702	rs773112	ENSG00000212829.8	RPS26P3	7.94	5.17e-15	6.11e-09	0.33	0.24	Cognitive function;	chr12:55982097	chr9:9090898~9091245:+
BRCA	trans	rs7824557	0.564	rs13260727	ENSG00000253893.2	FAM85B	-7.94	5.25e-15	6.21e-09	-0.31	-0.24	Retinal vascular caliber;	chr8:11375351	chr8:8167819~8226614:-
BRCA	trans	rs7312770	1	rs7312770	ENSG00000204652.6	RPS26P8	-7.94	5.27e-15	6.23e-09	-0.27	-0.24	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr17:45608571~45608918:+
BRCA	trans	rs11098499	0.58	rs12509234	ENSG00000276997.3	RP11-378J18.9	7.94	5.34e-15	6.32e-09	0.29	0.24	Corneal astigmatism;	chr4:119398279	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.909	rs10014719	ENSG00000276997.3	RP11-378J18.9	7.94	5.34e-15	6.32e-09	0.29	0.24	Corneal astigmatism;	chr4:119399560	chr1:222477252~222504622:-
BRCA	trans	rs877636	0.702	rs61937249	ENSG00000212829.8	RPS26P3	7.93	5.5e-15	6.5e-09	0.33	0.24	Cognitive function;	chr12:55988132	chr9:9090898~9091245:+
BRCA	trans	rs12477438	0.52	rs6741772	ENSG00000276576.1	MRPL30P1	7.93	5.52e-15	6.52e-09	0.3	0.24	Chronic sinus infection;	chr2:99122498	chr6:57029521~57029988:+
BRCA	trans	rs12477438	0.52	rs6741773	ENSG00000276576.1	MRPL30P1	7.93	5.52e-15	6.52e-09	0.3	0.24	Chronic sinus infection;	chr2:99122499	chr6:57029521~57029988:+
BRCA	trans	rs877636	0.859	rs3741499	ENSG00000204652.6	RPS26P8	-7.93	5.68e-15	6.7e-09	-0.3	-0.24	Cognitive function;	chr12:56080595	chr17:45608571~45608918:+
BRCA	trans	rs546131	0.928	rs547504	ENSG00000225531.1	RP11-196I18.3	7.93	5.78e-15	6.82e-09	0.33	0.24	Lung disease severity in cystic fibrosis;	chr11:34825678	chr9:107116829~107117557:+
BRCA	trans	rs877636	0.702	rs773111	ENSG00000212829.8	RPS26P3	7.93	5.78e-15	6.82e-09	0.33	0.24	Cognitive function;	chr12:55981956	chr9:9090898~9091245:+
BRCA	trans	rs9650657	0.803	rs13276026	ENSG00000253893.2	FAM85B	7.93	5.82e-15	6.86e-09	0.29	0.24	Neuroticism;	chr8:10752445	chr8:8167819~8226614:-
BRCA	trans	rs11098499	0.908	rs7696649	ENSG00000276997.3	RP11-378J18.9	7.92	5.92e-15	6.97e-09	0.29	0.24	Corneal astigmatism;	chr4:119401022	chr1:222477252~222504622:-
BRCA	trans	rs2060793	0.741	rs4757268	ENSG00000236360.2	RP11-334A14.2	7.92	5.97e-15	7.03e-09	0.3	0.24	Vitamin D levels;	chr11:14789216	chr1:52993201~52993702:-
BRCA	trans	rs6940638	0.956	rs12199218	ENSG00000242375.1	RP11-498P14.3	-7.92	5.99e-15	7.05e-09	-0.39	-0.24	Intelligence (multi-trait analysis);	chr6:27057502	chr9:97195351~97197687:-
BRCA	trans	rs902774	0.818	rs4919740	ENSG00000248568.1	KRT8P48	-7.92	6.01e-15	7.08e-09	-0.45	-0.24	Prostate cancer;	chr12:52877187	chr5:146706381~146707600:-
BRCA	trans	rs7824557	0.67	rs2736381	ENSG00000253893.2	FAM85B	7.92	6.03e-15	7.1e-09	0.31	0.24	Retinal vascular caliber;	chr8:11275257	chr8:8167819~8226614:-
BRCA	trans	rs747782	0.591	rs79476064	ENSG00000134612.10	FOLH1B	7.92	6.06e-15	7.14e-09	0.39	0.24	Intraocular pressure;	chr11:47699760	chr11:89639227~89698718:+
BRCA	trans	rs730566	1	rs730566	ENSG00000235912.1	RP1-159A19.3	7.92	6.07e-15	7.14e-09	0.31	0.24	Prion diseases;	chr3:48445644	chr1:27649419~27649610:+
BRCA	trans	rs875971	0.66	rs12698534	ENSG00000164669.11	INTS4P1	-7.92	6.08e-15	7.16e-09	-0.29	-0.24	Aortic root size;	chr7:66521858	chr7:65141225~65234216:+
BRCA	trans	rs12210905	0.92	rs12191414	ENSG00000242375.1	RP11-498P14.3	-7.92	6.09e-15	7.16e-09	-0.63	-0.24	Hip circumference adjusted for BMI;	chr6:27310855	chr9:97195351~97197687:-
BRCA	trans	rs877636	0.702	rs773109	ENSG00000212829.8	RPS26P3	7.92	6.09e-15	7.17e-09	0.33	0.24	Cognitive function;	chr12:55980911	chr9:9090898~9091245:+
BRCA	trans	rs9650657	0.524	rs2163379	ENSG00000253893.2	FAM85B	-7.92	6.23e-15	7.33e-09	-0.31	-0.24	Neuroticism;	chr8:10874540	chr8:8167819~8226614:-
BRCA	trans	rs875971	0.66	rs801217	ENSG00000164669.11	INTS4P1	7.91	6.32e-15	7.43e-09	0.29	0.24	Aortic root size;	chr7:66545590	chr7:65141225~65234216:+
BRCA	trans	rs875971	0.638	rs801216	ENSG00000164669.11	INTS4P1	7.91	6.32e-15	7.43e-09	0.29	0.24	Aortic root size;	chr7:66546680	chr7:65141225~65234216:+
BRCA	trans	rs875971	0.66	rs13224319	ENSG00000164669.11	INTS4P1	-7.91	6.32e-15	7.43e-09	-0.29	-0.24	Aortic root size;	chr7:66542376	chr7:65141225~65234216:+
BRCA	trans	rs816535	1	rs816535	ENSG00000279352.1	RP11-411B10.7	7.91	6.34e-15	7.45e-09	0.38	0.24	Parkinson disease and lewy body pathology;	chr20:26275360	chr18:14010054~14010917:+
BRCA	trans	rs875971	0.66	rs62465434	ENSG00000164669.11	INTS4P1	-7.91	6.34e-15	7.46e-09	-0.29	-0.24	Aortic root size;	chr7:66540165	chr7:65141225~65234216:+
BRCA	trans	rs546131	0.89	rs496558	ENSG00000225531.1	RP11-196I18.3	7.91	6.35e-15	7.46e-09	0.33	0.24	Lung disease severity in cystic fibrosis;	chr11:34804878	chr9:107116829~107117557:+
BRCA	trans	rs6952407	1	rs6952407	ENSG00000164669.11	INTS4P1	7.91	6.38e-15	7.5e-09	0.29	0.24	Cotinine glucuronidation;	chr7:66580525	chr7:65141225~65234216:+
BRCA	trans	rs12210905	0.925	rs114172511	ENSG00000242375.1	RP11-498P14.3	-7.91	6.38e-15	7.5e-09	-0.52	-0.24	Hip circumference adjusted for BMI;	chr6:26996522	chr9:97195351~97197687:-
BRCA	trans	rs12210905	0.925	rs115507154	ENSG00000242375.1	RP11-498P14.3	-7.91	6.38e-15	7.5e-09	-0.52	-0.24	Hip circumference adjusted for BMI;	chr6:27003032	chr9:97195351~97197687:-
BRCA	trans	rs12210905	0.925	rs72838236	ENSG00000242375.1	RP11-498P14.3	-7.91	6.38e-15	7.5e-09	-0.52	-0.24	Hip circumference adjusted for BMI;	chr6:27003423	chr9:97195351~97197687:-
BRCA	trans	rs12210905	0.925	rs72838238	ENSG00000242375.1	RP11-498P14.3	-7.91	6.38e-15	7.5e-09	-0.52	-0.24	Hip circumference adjusted for BMI;	chr6:27003902	chr9:97195351~97197687:-
BRCA	trans	rs12210905	0.925	rs10456349	ENSG00000242375.1	RP11-498P14.3	-7.91	6.38e-15	7.5e-09	-0.52	-0.24	Hip circumference adjusted for BMI;	chr6:27007680	chr9:97195351~97197687:-
BRCA	trans	rs12210905	0.843	rs12208039	ENSG00000242375.1	RP11-498P14.3	-7.91	6.38e-15	7.5e-09	-0.52	-0.24	Hip circumference adjusted for BMI;	chr6:27016225	chr9:97195351~97197687:-
BRCA	trans	rs12210905	0.925	rs72838243	ENSG00000242375.1	RP11-498P14.3	-7.91	6.38e-15	7.5e-09	-0.52	-0.24	Hip circumference adjusted for BMI;	chr6:27016419	chr9:97195351~97197687:-
BRCA	trans	rs12210905	0.925	rs7753284	ENSG00000242375.1	RP11-498P14.3	-7.91	6.38e-15	7.5e-09	-0.52	-0.24	Hip circumference adjusted for BMI;	chr6:27023836	chr9:97195351~97197687:-
BRCA	trans	rs12210905	0.925	rs11961179	ENSG00000242375.1	RP11-498P14.3	-7.91	6.38e-15	7.5e-09	-0.52	-0.24	Hip circumference adjusted for BMI;	chr6:27026378	chr9:97195351~97197687:-
BRCA	trans	rs351855	0.642	rs2546095	ENSG00000217325.2	PRELID1P1	7.91	6.39e-15	7.51e-09	0.3	0.24	Waist-to-hip ratio adjusted for body mass index;	chr5:177082583	chr6:126643488~126644390:+
BRCA	trans	rs3849046	0.68	rs11746692	ENSG00000226666.1	HSPA9P1	-7.91	6.45e-15	7.57e-09	-0.27	-0.24	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138610666	chr2:221961737~221963765:+
BRCA	trans	rs11920570	0.959	rs7635930	ENSG00000267076.1	CCDC58P3	-7.91	6.46e-15	7.58e-09	-0.31	-0.24	Resting heart rate;	chr3:122393710	chr18:12211378~12211807:+
BRCA	trans	rs7032940	0.626	rs4314718	ENSG00000262519.1	TXNP4	7.91	6.6e-15	7.75e-09	0.29	0.24	Height;	chr9:110211368	chr17:4572206~4572515:+
BRCA	trans	rs11220237	1	rs11220261	ENSG00000236257.1	EI24P2	7.91	6.63e-15	7.78e-09	0.35	0.24	Itch intensity from mosquito bite adjusted by bite size;	chr11:125877574	chr1:158454198~158455273:+
BRCA	trans	rs7662987	1	rs7683802	ENSG00000228407.2	RP4-800M22.1	7.91	6.66e-15	7.81e-09	0.52	0.24	Smoking initiation;	chr4:99073987	chr1:52160261~52160600:-
BRCA	trans	rs864643	0.574	rs1768192	ENSG00000188856.6	RPSAP47	7.91	6.68e-15	7.83e-09	0.34	0.24	Attention deficit hyperactivity disorder;	chr3:39470669	chr8:80558870~80559757:+
BRCA	trans	rs875971	0.66	rs801211	ENSG00000164669.11	INTS4P1	7.91	6.69e-15	7.85e-09	0.29	0.24	Aortic root size;	chr7:66550702	chr7:65141225~65234216:+
BRCA	trans	rs875971	0.638	rs801205	ENSG00000164669.11	INTS4P1	7.91	6.69e-15	7.85e-09	0.29	0.24	Aortic root size;	chr7:66557157	chr7:65141225~65234216:+
BRCA	trans	rs875971	0.617	rs810400	ENSG00000164669.11	INTS4P1	7.91	6.69e-15	7.85e-09	0.29	0.24	Aortic root size;	chr7:66557902	chr7:65141225~65234216:+
BRCA	trans	rs9467711	0.606	rs2072803	ENSG00000253570.1	RNF5P1	7.91	6.79e-15	7.96e-09	0.55	0.24	Autism spectrum disorder or schizophrenia;	chr6:26392287	chr8:38600661~38601200:-
BRCA	trans	rs7113874	1	rs4929926	ENSG00000266891.1	RP11-692N5.2	-7.9	6.87e-15	8.06e-09	-0.29	-0.24	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8636829	chr18:9734882~9735602:-
BRCA	trans	rs7113874	1	rs4929927	ENSG00000266891.1	RP11-692N5.2	-7.9	6.87e-15	8.06e-09	-0.29	-0.24	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8636938	chr18:9734882~9735602:-
BRCA	trans	rs11295209	1	rs11295209	ENSG00000275858.1	RP11-291L22.8	-7.9	6.91e-15	8.09e-09	-0.26	-0.24	Plateletcrit;	chr4:119559079	chr10:38450738~38451069:-
BRCA	trans	rs13016963	0.564	rs2110690	ENSG00000235105.1	RP11-329A14.1	7.9	6.94e-15	8.13e-09	0.29	0.24	Esophageal squamous cell carcinoma;Melanoma;	chr2:201320409	chr1:48435967~48437223:+
BRCA	trans	rs7113874	0.921	rs34867877	ENSG00000266891.1	RP11-692N5.2	-7.9	7.08e-15	8.28e-09	-0.29	-0.24	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8655654	chr18:9734882~9735602:-
BRCA	trans	rs7113874	1	rs36092927	ENSG00000266891.1	RP11-692N5.2	7.9	7.22e-15	8.44e-09	0.3	0.24	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8670792	chr18:9734882~9735602:-
BRCA	trans	rs3806843	0.576	rs155363	ENSG00000231043.3	AC007238.1	-7.89	7.33e-15	8.56e-09	-0.28	-0.24	Depressive symptoms (multi-trait analysis);	chr5:140921958	chr2:58460292~58462032:-
BRCA	trans	rs7769051	1	rs7769051	ENSG00000213303.3	CTC-398G3.2	7.89	7.36e-15	8.59e-09	0.39	0.24	Type 2 diabetes nephropathy;	chr6:132825657	chr19:11523436~11523831:+
BRCA	trans	rs877636	0.859	rs3741499	ENSG00000212829.8	RPS26P3	-7.89	7.39e-15	8.63e-09	-0.3	-0.24	Cognitive function;	chr12:56080595	chr9:9090898~9091245:+
BRCA	trans	rs13016963	0.546	rs10186527	ENSG00000235105.1	RP11-329A14.1	7.89	7.55e-15	8.81e-09	0.28	0.24	Esophageal squamous cell carcinoma;Melanoma;	chr2:201335852	chr1:48435967~48437223:+
BRCA	trans	rs7113874	1	rs12575252	ENSG00000266891.1	RP11-692N5.2	7.89	7.55e-15	8.81e-09	0.29	0.24	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8672526	chr18:9734882~9735602:-
BRCA	trans	rs73108077	0.915	rs17328705	ENSG00000279352.1	RP11-411B10.7	7.89	7.56e-15	8.82e-09	0.53	0.24	Red blood cell density in sickle cell anemia;	chr20:31438570	chr18:14010054~14010917:+
BRCA	trans	rs9467711	0.606	rs13212985	ENSG00000253570.1	RNF5P1	7.89	7.77e-15	9.06e-09	0.63	0.24	Autism spectrum disorder or schizophrenia;	chr6:26609761	chr8:38600661~38601200:-
BRCA	trans	rs12210905	0.841	rs72839470	ENSG00000242375.1	RP11-498P14.3	-7.89	7.8e-15	9.08e-09	-0.61	-0.24	Hip circumference adjusted for BMI;	chr6:27341525	chr9:97195351~97197687:-
BRCA	trans	rs12210905	1	rs12191280	ENSG00000242375.1	RP11-498P14.3	-7.89	7.83e-15	9.11e-09	-0.5	-0.24	Hip circumference adjusted for BMI;	chr6:27215538	chr9:97195351~97197687:-
BRCA	trans	rs12210905	0.687	rs12204768	ENSG00000242375.1	RP11-498P14.3	-7.89	7.83e-15	9.11e-09	-0.5	-0.24	Hip circumference adjusted for BMI;	chr6:27215784	chr9:97195351~97197687:-
BRCA	trans	rs12200782	0.929	rs72841519	ENSG00000242375.1	RP11-498P14.3	-7.89	7.84e-15	9.12e-09	-0.52	-0.24	Small cell lung carcinoma;	chr6:26371673	chr9:97195351~97197687:-
BRCA	trans	rs60515486	0.702	rs78524236	ENSG00000134612.10	FOLH1B	7.89	7.85e-15	9.14e-09	0.39	0.24	Lymphocyte counts;	chr11:47394344	chr11:89639227~89698718:+
BRCA	trans	rs864643	0.898	rs636476	ENSG00000183298.5	RP11-556K13.1	7.89	7.86e-15	9.14e-09	0.36	0.24	Attention deficit hyperactivity disorder;	chr3:39549841	chr1:101786340~101787219:-
BRCA	trans	rs877636	0.702	rs773110	ENSG00000212829.8	RPS26P3	7.89	7.87e-15	9.16e-09	0.33	0.24	Cognitive function;	chr12:55981353	chr9:9090898~9091245:+
BRCA	trans	rs12477438	0.52	rs7605843	ENSG00000276576.1	MRPL30P1	7.89	7.88e-15	9.17e-09	0.3	0.24	Chronic sinus infection;	chr2:99195431	chr6:57029521~57029988:+
BRCA	trans	rs12477438	0.52	rs13798	ENSG00000276576.1	MRPL30P1	7.89	7.88e-15	9.17e-09	0.3	0.24	Chronic sinus infection;	chr2:99197151	chr6:57029521~57029988:+
BRCA	trans	rs11098499	0.863	rs12508173	ENSG00000276997.3	RP11-378J18.9	7.88	7.93e-15	9.22e-09	0.29	0.24	Corneal astigmatism;	chr4:119397371	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.908	rs12504149	ENSG00000276997.3	RP11-378J18.9	7.88	7.93e-15	9.22e-09	0.29	0.24	Corneal astigmatism;	chr4:119397422	chr1:222477252~222504622:-
BRCA	trans	rs7927370	0.558	rs117325273	ENSG00000134612.10	FOLH1B	7.88	8.24e-15	9.56e-09	0.55	0.24	Systemic lupus erythematosus;	chr11:55860273	chr11:89639227~89698718:+
BRCA	trans	rs546131	0.642	rs537873	ENSG00000225531.1	RP11-196I18.3	7.88	8.27e-15	9.59e-09	0.34	0.24	Lung disease severity in cystic fibrosis;	chr11:34813574	chr9:107116829~107117557:+
BRCA	trans	rs12477438	0.52	rs11123762	ENSG00000276576.1	MRPL30P1	7.88	8.38e-15	9.71e-09	0.29	0.24	Chronic sinus infection;	chr2:99111326	chr6:57029521~57029988:+
BRCA	trans	rs12477438	0.52	rs6739579	ENSG00000276576.1	MRPL30P1	7.88	8.4e-15	9.74e-09	0.29	0.24	Chronic sinus infection;	chr2:99115089	chr6:57029521~57029988:+
BRCA	trans	rs864643	0.947	rs1768237	ENSG00000183298.5	RP11-556K13.1	7.88	8.45e-15	9.8e-09	0.37	0.24	Attention deficit hyperactivity disorder;	chr3:39498712	chr1:101786340~101787219:-
BRCA	trans	rs877636	0.692	rs2271194	ENSG00000227586.5	RP11-162A23.5	-7.87	8.64e-15	1e-08	-0.28	-0.24	Cognitive function;	chr12:56083910	chr10:123171535~123171875:-
BRCA	trans	rs7819412	0.668	rs2409721	ENSG00000253893.2	FAM85B	7.87	8.7e-15	1.01e-08	0.31	0.24	Triglycerides;	chr8:11180735	chr8:8167819~8226614:-
BRCA	trans	rs864643	0.947	rs645457	ENSG00000183298.5	RP11-556K13.1	7.87	8.82e-15	1.02e-08	0.37	0.24	Attention deficit hyperactivity disorder;	chr3:39499006	chr1:101786340~101787219:-
BRCA	trans	rs7929679	0.655	rs7939918	ENSG00000225531.1	RP11-196I18.3	7.87	8.96e-15	1.04e-08	0.3	0.24	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;	chr11:34754985	chr9:107116829~107117557:+
BRCA	trans	rs6915893	0.967	rs9477631	ENSG00000267156.1	TPMTP1	7.87	8.96e-15	1.04e-08	0.3	0.24	Intrinsic epigenetic age acceleration;	chr6:18123541	chr18:47630112~47630848:+
BRCA	trans	rs12210905	0.925	rs72838245	ENSG00000242375.1	RP11-498P14.3	-7.87	9.12e-15	1.05e-08	-0.52	-0.24	Hip circumference adjusted for BMI;	chr6:27019537	chr9:97195351~97197687:-
BRCA	trans	rs12210905	0.925	rs10946896	ENSG00000242375.1	RP11-498P14.3	-7.87	9.12e-15	1.05e-08	-0.52	-0.24	Hip circumference adjusted for BMI;	chr6:27020797	chr9:97195351~97197687:-
BRCA	trans	rs12210905	0.925	rs11961181	ENSG00000242375.1	RP11-498P14.3	-7.87	9.12e-15	1.05e-08	-0.52	-0.24	Hip circumference adjusted for BMI;	chr6:27026384	chr9:97195351~97197687:-
BRCA	trans	rs4276421	0.509	rs6451806	ENSG00000231752.4	EMBP1	-7.87	9.16e-15	1.06e-08	-0.33	-0.24	P wave duration;	chr5:45530059	chr1:121519112~121571892:+
BRCA	trans	rs7929679	0.683	rs12418978	ENSG00000225531.1	RP11-196I18.3	7.86	9.21e-15	1.06e-08	0.3	0.24	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;	chr11:34755945	chr9:107116829~107117557:+
BRCA	trans	rs12210905	0.688	rs12205044	ENSG00000242375.1	RP11-498P14.3	-7.86	9.24e-15	1.07e-08	-0.62	-0.24	Hip circumference adjusted for BMI;	chr6:27511211	chr9:97195351~97197687:-
BRCA	trans	rs546131	0.6	rs502857	ENSG00000225531.1	RP11-196I18.3	7.86	9.28e-15	1.07e-08	0.33	0.24	Lung disease severity in cystic fibrosis;	chr11:34833115	chr9:107116829~107117557:+
BRCA	trans	rs12210905	0.925	rs72838228	ENSG00000242375.1	RP11-498P14.3	-7.86	9.36e-15	1.08e-08	-0.52	-0.24	Hip circumference adjusted for BMI;	chr6:26978141	chr9:97195351~97197687:-
BRCA	trans	rs7113874	0.921	rs10769932	ENSG00000266891.1	RP11-692N5.2	-7.86	9.51e-15	1.1e-08	-0.29	-0.24	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8614792	chr18:9734882~9735602:-
BRCA	trans	rs12210905	0.925	rs17345718	ENSG00000242375.1	RP11-498P14.3	-7.86	9.52e-15	1.1e-08	-0.52	-0.24	Hip circumference adjusted for BMI;	chr6:26996479	chr9:97195351~97197687:-
BRCA	trans	rs12477438	0.52	rs6542864	ENSG00000276576.1	MRPL30P1	7.85	9.95e-15	1.15e-08	0.29	0.24	Chronic sinus infection;	chr2:99108760	chr6:57029521~57029988:+
BRCA	trans	rs11098499	0.909	rs78332141	ENSG00000276997.3	RP11-378J18.9	7.85	1e-14	1.15e-08	0.29	0.24	Corneal astigmatism;	chr4:119454627	chr1:222477252~222504622:-
BRCA	trans	rs7939886	0.92	rs61887958	ENSG00000134612.10	FOLH1B	7.85	1.01e-14	1.16e-08	0.54	0.24	Myopia (pathological);	chr11:56170758	chr11:89639227~89698718:+
BRCA	trans	rs11098499	0.954	rs3733524	ENSG00000120555.12	SEPT7P9	7.85	1.01e-14	1.16e-08	0.31	0.24	Corneal astigmatism;	chr4:119502574	chr10:38383069~38402916:-
BRCA	trans	rs864643	0.947	rs1708064	ENSG00000183298.5	RP11-556K13.1	7.85	1.04e-14	1.2e-08	0.37	0.24	Attention deficit hyperactivity disorder;	chr3:39500679	chr1:101786340~101787219:-
BRCA	trans	rs864643	0.678	rs568085	ENSG00000188856.6	RPSAP47	7.85	1.04e-14	1.2e-08	0.34	0.24	Attention deficit hyperactivity disorder;	chr3:39472661	chr8:80558870~80559757:+
BRCA	trans	rs864643	0.625	rs628725	ENSG00000188856.6	RPSAP47	7.85	1.04e-14	1.2e-08	0.34	0.24	Attention deficit hyperactivity disorder;	chr3:39472887	chr8:80558870~80559757:+
BRCA	trans	rs864643	0.625	rs570136	ENSG00000188856.6	RPSAP47	7.85	1.04e-14	1.2e-08	0.34	0.24	Attention deficit hyperactivity disorder;	chr3:39472922	chr8:80558870~80559757:+
BRCA	trans	rs864643	0.678	rs7615732	ENSG00000188856.6	RPSAP47	7.85	1.04e-14	1.2e-08	0.34	0.24	Attention deficit hyperactivity disorder;	chr3:39473732	chr8:80558870~80559757:+
BRCA	trans	rs7113874	1	rs2316901	ENSG00000266891.1	RP11-692N5.2	7.85	1.04e-14	1.2e-08	0.29	0.24	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8657469	chr18:9734882~9735602:-
BRCA	trans	rs1933488	0.898	rs11155895	ENSG00000278974.1	RP11-756P10.6	-7.85	1.05e-14	1.2e-08	-0.31	-0.24	Prostate cancer;	chr6:153100410	chr4:188740507~188741281:-
BRCA	trans	rs3806843	0.576	rs251370	ENSG00000231043.3	AC007238.1	7.85	1.05e-14	1.21e-08	0.29	0.24	Depressive symptoms (multi-trait analysis);	chr5:140866702	chr2:58460292~58462032:-
BRCA	trans	rs7824557	0.767	rs2164273	ENSG00000253893.2	FAM85B	-7.85	1.06e-14	1.21e-08	-0.32	-0.24	Retinal vascular caliber;	chr8:11310990	chr8:8167819~8226614:-
BRCA	trans	rs4929949	0.565	rs11517718	ENSG00000266891.1	RP11-692N5.2	7.85	1.07e-14	1.23e-08	0.29	0.24	Body mass index;	chr11:8671858	chr18:9734882~9735602:-
BRCA	trans	rs11098499	0.865	rs28634456	ENSG00000276997.3	RP11-378J18.9	7.84	1.07e-14	1.23e-08	0.29	0.24	Corneal astigmatism;	chr4:119454623	chr1:222477252~222504622:-
BRCA	trans	rs60515486	0.702	rs11821917	ENSG00000134612.10	FOLH1B	7.84	1.07e-14	1.23e-08	0.38	0.24	Lymphocyte counts;	chr11:47388615	chr11:89639227~89698718:+
BRCA	trans	rs3740713	1	rs75740864	ENSG00000214110.3	LDHAP4	7.84	1.09e-14	1.25e-08	0.43	0.24	Amyotrophic lateral sclerosis (sporadic);	chr11:18449142	chr9:14921337~14922334:-
BRCA	trans	rs11951515	0.508	rs67261887	ENSG00000174977.8	AC026271.5	-7.84	1.09e-14	1.25e-08	-0.28	-0.24	Metabolite levels  (X-11787);	chr5:43612339	chr17:18650195~18651542:+
BRCA	trans	rs3849046	0.68	rs13165665	ENSG00000226666.1	HSPA9P1	-7.84	1.09e-14	1.25e-08	-0.27	-0.24	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138610811	chr2:221961737~221963765:+
BRCA	trans	rs875971	0.642	rs35526611	ENSG00000164669.11	INTS4P1	7.84	1.12e-14	1.29e-08	0.29	0.24	Aortic root size;	chr7:66629021	chr7:65141225~65234216:+
BRCA	trans	rs875971	0.638	rs3898855	ENSG00000164669.11	INTS4P1	7.84	1.13e-14	1.29e-08	0.29	0.24	Aortic root size;	chr7:66571411	chr7:65141225~65234216:+
BRCA	trans	rs875971	0.638	rs10278816	ENSG00000164669.11	INTS4P1	7.84	1.13e-14	1.29e-08	0.29	0.24	Aortic root size;	chr7:66572000	chr7:65141225~65234216:+
BRCA	trans	rs875971	0.66	rs10281080	ENSG00000164669.11	INTS4P1	7.84	1.13e-14	1.29e-08	0.29	0.24	Aortic root size;	chr7:66577454	chr7:65141225~65234216:+
BRCA	trans	rs875971	0.66	rs10950044	ENSG00000164669.11	INTS4P1	7.84	1.13e-14	1.29e-08	0.29	0.24	Aortic root size;	chr7:66577989	chr7:65141225~65234216:+
BRCA	trans	rs747782	0.536	rs6485772	ENSG00000134612.10	FOLH1B	7.84	1.13e-14	1.3e-08	0.38	0.24	Intraocular pressure;	chr11:47706522	chr11:89639227~89698718:+
BRCA	trans	rs11098499	0.865	rs9994730	ENSG00000276997.3	RP11-378J18.9	7.84	1.13e-14	1.3e-08	0.29	0.24	Corneal astigmatism;	chr4:119460409	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.779	rs80242894	ENSG00000276997.3	RP11-378J18.9	7.83	1.17e-14	1.34e-08	0.29	0.24	Corneal astigmatism;	chr4:119454597	chr1:222477252~222504622:-
BRCA	trans	rs864643	0.678	rs610006	ENSG00000188856.6	RPSAP47	7.83	1.18e-14	1.35e-08	0.34	0.24	Attention deficit hyperactivity disorder;	chr3:39481104	chr8:80558870~80559757:+
BRCA	trans	rs3806843	0.576	rs251376	ENSG00000231043.3	AC007238.1	7.83	1.18e-14	1.35e-08	0.28	0.24	Depressive symptoms (multi-trait analysis);	chr5:140874104	chr2:58460292~58462032:-
BRCA	trans	rs7944735	0.508	rs1474056	ENSG00000134612.10	FOLH1B	7.83	1.18e-14	1.36e-08	0.37	0.24	Intraocular pressure;	chr11:47611155	chr11:89639227~89698718:+
BRCA	trans	rs7944735	0.508	rs7931089	ENSG00000134612.10	FOLH1B	7.83	1.18e-14	1.36e-08	0.37	0.24	Intraocular pressure;	chr11:47611954	chr11:89639227~89698718:+
BRCA	trans	rs7824557	0.591	rs2736283	ENSG00000253893.2	FAM85B	7.83	1.19e-14	1.36e-08	0.3	0.24	Retinal vascular caliber;	chr8:11368401	chr8:8167819~8226614:-
BRCA	trans	rs3849046	0.817	rs11953219	ENSG00000226666.1	HSPA9P1	7.83	1.2e-14	1.38e-08	0.27	0.24	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138592481	chr2:221961737~221963765:+
BRCA	trans	rs3749237	0.964	rs1799845	ENSG00000197582.5	GPX1P1	7.83	1.22e-14	1.4e-08	0.26	0.24	Resting heart rate;	chr3:49810190	chrX:13378735~13379340:-
BRCA	trans	rs12477438	0.52	rs11692699	ENSG00000276576.1	MRPL30P1	7.83	1.23e-14	1.4e-08	0.29	0.24	Chronic sinus infection;	chr2:99114194	chr6:57029521~57029988:+
BRCA	trans	rs12477438	0.52	rs13022329	ENSG00000276576.1	MRPL30P1	7.83	1.23e-14	1.4e-08	0.29	0.24	Chronic sinus infection;	chr2:99114726	chr6:57029521~57029988:+
BRCA	trans	rs864643	0.678	rs6779639	ENSG00000188856.6	RPSAP47	7.83	1.23e-14	1.41e-08	0.34	0.24	Attention deficit hyperactivity disorder;	chr3:39477191	chr8:80558870~80559757:+
BRCA	trans	rs864643	0.678	rs6782255	ENSG00000188856.6	RPSAP47	7.83	1.23e-14	1.41e-08	0.34	0.24	Attention deficit hyperactivity disorder;	chr3:39477236	chr8:80558870~80559757:+
BRCA	trans	rs60515486	0.702	rs11824864	ENSG00000134612.10	FOLH1B	7.83	1.24e-14	1.42e-08	0.38	0.24	Lymphocyte counts;	chr11:47390185	chr11:89639227~89698718:+
BRCA	trans	rs902774	0.818	rs4919740	ENSG00000255815.3	KRT8P11	-7.82	1.24e-14	1.42e-08	-0.43	-0.24	Prostate cancer;	chr12:52877187	chr9:99305176~99306611:+
BRCA	trans	rs7662987	0.818	rs4699701	ENSG00000228407.2	RP4-800M22.1	7.82	1.24e-14	1.42e-08	0.52	0.24	Smoking initiation;	chr4:99077296	chr1:52160261~52160600:-
BRCA	trans	rs7662987	1	rs13146416	ENSG00000228407.2	RP4-800M22.1	7.82	1.24e-14	1.42e-08	0.52	0.24	Smoking initiation;	chr4:99078009	chr1:52160261~52160600:-
BRCA	trans	rs13016963	0.526	rs1406121	ENSG00000235105.1	RP11-329A14.1	7.82	1.3e-14	1.48e-08	0.29	0.24	Esophageal squamous cell carcinoma;Melanoma;	chr2:201330307	chr1:48435967~48437223:+
BRCA	trans	rs7824557	0.628	rs11782706	ENSG00000253893.2	FAM85B	-7.82	1.3e-14	1.48e-08	-0.31	-0.24	Retinal vascular caliber;	chr8:11328706	chr8:8167819~8226614:-
BRCA	trans	rs875971	0.522	rs1968127	ENSG00000164669.11	INTS4P1	7.82	1.31e-14	1.5e-08	0.29	0.24	Aortic root size;	chr7:66591816	chr7:65141225~65234216:+
BRCA	trans	rs7113874	1	rs4929925	ENSG00000266891.1	RP11-692N5.2	-7.82	1.32e-14	1.51e-08	-0.29	-0.24	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8633640	chr18:9734882~9735602:-
BRCA	trans	rs17807624	0.78	rs11250152	ENSG00000253893.2	FAM85B	7.82	1.33e-14	1.51e-08	0.32	0.24	Systemic lupus erythematosus;	chr8:11596691	chr8:8167819~8226614:-
BRCA	trans	rs875971	0.66	rs79009421	ENSG00000164669.11	INTS4P1	7.82	1.33e-14	1.52e-08	0.29	0.24	Aortic root size;	chr7:66603522	chr7:65141225~65234216:+
BRCA	trans	rs9467711	0.606	rs16891727	ENSG00000253570.1	RNF5P1	7.81	1.35e-14	1.54e-08	0.54	0.24	Autism spectrum disorder or schizophrenia;	chr6:26488632	chr8:38600661~38601200:-
BRCA	trans	rs875971	0.66	rs6460308	ENSG00000164669.11	INTS4P1	7.81	1.35e-14	1.54e-08	0.29	0.24	Aortic root size;	chr7:66619753	chr7:65141225~65234216:+
BRCA	trans	rs7113874	0.959	rs4929948	ENSG00000266891.1	RP11-692N5.2	-7.81	1.35e-14	1.55e-08	-0.29	-0.24	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8622983	chr18:9734882~9735602:-
BRCA	trans	rs875971	0.638	rs35986979	ENSG00000164669.11	INTS4P1	7.81	1.36e-14	1.55e-08	0.29	0.24	Aortic root size;	chr7:66624003	chr7:65141225~65234216:+
BRCA	trans	rs864643	0.947	rs1768243	ENSG00000183298.5	RP11-556K13.1	7.81	1.37e-14	1.56e-08	0.36	0.24	Attention deficit hyperactivity disorder;	chr3:39500306	chr1:101786340~101787219:-
BRCA	trans	rs4720118	0.875	rs3779239	ENSG00000213492.2	NT5C3AP1	7.81	1.37e-14	1.57e-08	0.3	0.24	Leprosy;	chr7:33390659	chr4:117574512~117576174:-
BRCA	trans	rs7927370	0.558	rs55915740	ENSG00000134612.10	FOLH1B	7.81	1.38e-14	1.57e-08	0.55	0.24	Systemic lupus erythematosus;	chr11:55841398	chr11:89639227~89698718:+
BRCA	trans	rs11098499	0.909	rs10026736	ENSG00000276997.3	RP11-378J18.9	7.81	1.39e-14	1.58e-08	0.3	0.24	Corneal astigmatism;	chr4:119463167	chr1:222477252~222504622:-
BRCA	trans	rs1707322	0.752	rs4586014	ENSG00000255397.1	AC022182.2	-7.81	1.39e-14	1.58e-08	-0.32	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45684771	chr8:60937705~60939871:-
BRCA	trans	rs1707322	0.648	rs4439382	ENSG00000255397.1	AC022182.2	-7.81	1.39e-14	1.58e-08	-0.32	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45685133	chr8:60937705~60939871:-
BRCA	trans	rs875971	0.545	rs73378304	ENSG00000164669.11	INTS4P1	-7.81	1.41e-14	1.61e-08	-0.32	-0.24	Aortic root size;	chr7:66175760	chr7:65141225~65234216:+
BRCA	trans	rs7944735	0.508	rs17791016	ENSG00000134612.10	FOLH1B	7.81	1.42e-14	1.62e-08	0.38	0.24	Intraocular pressure;	chr11:47706038	chr11:89639227~89698718:+
BRCA	trans	rs10435719	0.902	rs4840599	ENSG00000253893.2	FAM85B	7.81	1.43e-14	1.63e-08	0.29	0.24	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11947871	chr8:8167819~8226614:-
BRCA	trans	rs7929679	0.777	rs1396889	ENSG00000225531.1	RP11-196I18.3	7.81	1.43e-14	1.63e-08	0.3	0.24	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;	chr11:34772751	chr9:107116829~107117557:+
BRCA	trans	rs7929679	0.777	rs1396888	ENSG00000225531.1	RP11-196I18.3	7.81	1.43e-14	1.63e-08	0.3	0.24	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;	chr11:34772885	chr9:107116829~107117557:+
BRCA	trans	rs7662987	1	rs28730595	ENSG00000228407.2	RP4-800M22.1	7.8	1.47e-14	1.67e-08	0.52	0.23	Smoking initiation;	chr4:99082182	chr1:52160261~52160600:-
BRCA	trans	rs7662987	0.938	rs28730592	ENSG00000228407.2	RP4-800M22.1	7.8	1.47e-14	1.67e-08	0.52	0.23	Smoking initiation;	chr4:99082592	chr1:52160261~52160600:-
BRCA	trans	rs7662987	1	rs28730591	ENSG00000228407.2	RP4-800M22.1	7.8	1.47e-14	1.67e-08	0.52	0.23	Smoking initiation;	chr4:99082596	chr1:52160261~52160600:-
BRCA	trans	rs12477438	0.52	rs13009147	ENSG00000276576.1	MRPL30P1	7.8	1.47e-14	1.67e-08	0.29	0.23	Chronic sinus infection;	chr2:99187535	chr6:57029521~57029988:+
BRCA	trans	rs11098499	0.955	rs11944880	ENSG00000120555.12	SEPT7P9	-7.8	1.48e-14	1.69e-08	-0.29	-0.23	Corneal astigmatism;	chr4:119238179	chr10:38383069~38402916:-
BRCA	trans	rs7200543	1	rs16966952	ENSG00000250569.1	NTAN1P2	7.8	1.5e-14	1.71e-08	0.26	0.23	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15042086	chr8:86481754~86483002:-
BRCA	trans	rs7824557	0.767	rs10104728	ENSG00000253893.2	FAM85B	-7.8	1.51e-14	1.71e-08	-0.33	-0.23	Retinal vascular caliber;	chr8:11313791	chr8:8167819~8226614:-
BRCA	trans	rs10940346	0.506	rs7704183	ENSG00000231752.4	EMBP1	-7.8	1.52e-14	1.73e-08	-0.31	-0.23	Schizophrenia;	chr5:50576738	chr1:121519112~121571892:+
BRCA	trans	rs7944735	0.508	rs11819955	ENSG00000134612.10	FOLH1B	7.8	1.52e-14	1.73e-08	0.37	0.23	Intraocular pressure;	chr11:47517656	chr11:89639227~89698718:+
BRCA	trans	rs615632	0.57	rs17734541	ENSG00000253893.2	FAM85B	-7.8	1.53e-14	1.74e-08	-0.3	-0.23	Neuroticism;	chr8:9850923	chr8:8167819~8226614:-
BRCA	trans	rs3849046	0.901	rs11956240	ENSG00000226666.1	HSPA9P1	7.8	1.54e-14	1.75e-08	0.26	0.23	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138504604	chr2:221961737~221963765:+
BRCA	trans	rs58106596	0.517	rs56272010	ENSG00000259020.3	RP11-529H20.3	7.8	1.55e-14	1.76e-08	0.35	0.23	Lymphocyte counts;White blood cell count;	chr2:231800253	chr14:92026566~92026887:+
BRCA	trans	rs7944735	0.508	rs7120737	ENSG00000134612.10	FOLH1B	7.79	1.56e-14	1.77e-08	0.38	0.23	Intraocular pressure;	chr11:47680843	chr11:89639227~89698718:+
BRCA	trans	rs73108077	1	rs6059305	ENSG00000279352.1	RP11-411B10.7	7.79	1.56e-14	1.77e-08	0.52	0.23	Red blood cell density in sickle cell anemia;	chr20:31432624	chr18:14010054~14010917:+
BRCA	trans	rs875971	0.619	rs12533585	ENSG00000164669.11	INTS4P1	-7.79	1.56e-14	1.78e-08	-0.29	-0.23	Aortic root size;	chr7:66519618	chr7:65141225~65234216:+
BRCA	trans	rs11098499	0.779	rs28495013	ENSG00000276997.3	RP11-378J18.9	7.79	1.56e-14	1.78e-08	0.29	0.23	Corneal astigmatism;	chr4:119454676	chr1:222477252~222504622:-
BRCA	trans	rs11122895	0.61	rs13397902	ENSG00000204745.3	AC083899.3	7.79	1.57e-14	1.78e-08	0.28	0.23	Allergic sensitization;	chr2:111849928	chr2:87125390~87196647:+
BRCA	trans	rs9393777	0.841	rs13191474	ENSG00000253570.1	RNF5P1	7.79	1.58e-14	1.79e-08	0.63	0.23	Intelligence (multi-trait analysis);	chr6:27445566	chr8:38600661~38601200:-
BRCA	trans	rs864643	0.678	rs512923	ENSG00000188856.6	RPSAP47	7.79	1.59e-14	1.8e-08	0.34	0.23	Attention deficit hyperactivity disorder;	chr3:39480472	chr8:80558870~80559757:+
BRCA	trans	rs864643	0.678	rs621842	ENSG00000188856.6	RPSAP47	7.79	1.59e-14	1.8e-08	0.34	0.23	Attention deficit hyperactivity disorder;	chr3:39480785	chr8:80558870~80559757:+
BRCA	trans	rs875971	0.66	rs28698552	ENSG00000164669.11	INTS4P1	-7.79	1.59e-14	1.81e-08	-0.29	-0.23	Aortic root size;	chr7:66540031	chr7:65141225~65234216:+
BRCA	trans	rs12210905	0.622	rs116198502	ENSG00000242375.1	RP11-498P14.3	-7.79	1.62e-14	1.84e-08	-0.52	-0.23	Hip circumference adjusted for BMI;	chr6:26947236	chr9:97195351~97197687:-
BRCA	trans	rs864643	0.947	rs645488	ENSG00000183298.5	RP11-556K13.1	7.79	1.63e-14	1.85e-08	0.37	0.23	Attention deficit hyperactivity disorder;	chr3:39499028	chr1:101786340~101787219:-
BRCA	trans	rs7113874	0.959	rs4929928	ENSG00000266891.1	RP11-692N5.2	-7.79	1.65e-14	1.87e-08	-0.29	-0.23	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8653539	chr18:9734882~9735602:-
BRCA	trans	rs714543	0.688	rs12702087	ENSG00000226038.5	PPIAP21	-7.79	1.66e-14	1.88e-08	-0.29	-0.23	Plateletcrit;	chr7:44773008	chr20:43230760~43231260:+
BRCA	trans	rs6940638	0.956	rs12190473	ENSG00000242375.1	RP11-498P14.3	-7.79	1.66e-14	1.88e-08	-0.38	-0.23	Intelligence (multi-trait analysis);	chr6:27056908	chr9:97195351~97197687:-
BRCA	trans	rs875971	0.66	rs10272357	ENSG00000164669.11	INTS4P1	7.78	1.68e-14	1.9e-08	0.29	0.23	Aortic root size;	chr7:66598087	chr7:65141225~65234216:+
BRCA	trans	rs17040773	1	rs17040773	ENSG00000204745.3	AC083899.3	7.78	1.69e-14	1.92e-08	0.34	0.23	Bone mineral density;	chr2:111742458	chr2:87125390~87196647:+
BRCA	trans	rs864643	1	rs552724	ENSG00000183298.5	RP11-556K13.1	-7.78	1.7e-14	1.92e-08	-0.39	-0.23	Attention deficit hyperactivity disorder;	chr3:39513455	chr1:101786340~101787219:-
BRCA	trans	rs11098499	0.739	rs10031033	ENSG00000275858.1	RP11-291L22.8	7.78	1.7e-14	1.93e-08	0.28	0.23	Corneal astigmatism;	chr4:119230297	chr10:38450738~38451069:-
BRCA	trans	rs7927370	0.558	rs61896326	ENSG00000134612.10	FOLH1B	7.78	1.71e-14	1.93e-08	0.55	0.23	Systemic lupus erythematosus;	chr11:55839581	chr11:89639227~89698718:+
BRCA	trans	rs875971	0.619	rs10278371	ENSG00000164669.11	INTS4P1	7.78	1.71e-14	1.94e-08	0.29	0.23	Aortic root size;	chr7:66586553	chr7:65141225~65234216:+
BRCA	trans	rs864643	0.678	rs1768203	ENSG00000188856.6	RPSAP47	7.78	1.73e-14	1.96e-08	0.34	0.23	Attention deficit hyperactivity disorder;	chr3:39476377	chr8:80558870~80559757:+
BRCA	trans	rs864643	0.678	rs1708100	ENSG00000188856.6	RPSAP47	7.78	1.73e-14	1.96e-08	0.34	0.23	Attention deficit hyperactivity disorder;	chr3:39476400	chr8:80558870~80559757:+
BRCA	trans	rs864643	0.625	rs7613883	ENSG00000188856.6	RPSAP47	7.78	1.73e-14	1.96e-08	0.34	0.23	Attention deficit hyperactivity disorder;	chr3:39476825	chr8:80558870~80559757:+
BRCA	trans	rs11098499	0.955	rs35434465	ENSG00000120555.12	SEPT7P9	7.78	1.76e-14	1.99e-08	0.29	0.23	Corneal astigmatism;	chr4:119248223	chr10:38383069~38402916:-
BRCA	trans	rs11638815	0.626	rs11635624	ENSG00000235370.6	DNM1P51	-7.78	1.77e-14	2e-08	-0.26	-0.23	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82646980	chr15:84398316~84411701:-
BRCA	trans	rs7944735	0.508	rs7115371	ENSG00000134612.10	FOLH1B	7.78	1.78e-14	2.02e-08	0.37	0.23	Intraocular pressure;	chr11:47543035	chr11:89639227~89698718:+
BRCA	trans	rs877636	1	rs2292239	ENSG00000212829.8	RPS26P3	7.78	1.79e-14	2.03e-08	0.29	0.23	Cognitive function;	chr12:56088396	chr9:9090898~9091245:+
BRCA	trans	rs11098499	0.954	rs13133522	ENSG00000276997.3	RP11-378J18.9	7.77	1.82e-14	2.05e-08	0.29	0.23	Corneal astigmatism;	chr4:119403269	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.954	rs35091806	ENSG00000276997.3	RP11-378J18.9	7.77	1.82e-14	2.05e-08	0.29	0.23	Corneal astigmatism;	chr4:119404374	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.909	rs35165976	ENSG00000276997.3	RP11-378J18.9	7.77	1.82e-14	2.05e-08	0.29	0.23	Corneal astigmatism;	chr4:119404475	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.954	rs6846442	ENSG00000276997.3	RP11-378J18.9	7.77	1.82e-14	2.05e-08	0.29	0.23	Corneal astigmatism;	chr4:119405168	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.954	rs71614438	ENSG00000276997.3	RP11-378J18.9	7.77	1.82e-14	2.05e-08	0.29	0.23	Corneal astigmatism;	chr4:119450097	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.954	rs66506550	ENSG00000276997.3	RP11-378J18.9	7.77	1.82e-14	2.05e-08	0.29	0.23	Corneal astigmatism;	chr4:119450290	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.909	rs7659501	ENSG00000276997.3	RP11-378J18.9	7.77	1.82e-14	2.05e-08	0.29	0.23	Corneal astigmatism;	chr4:119450397	chr1:222477252~222504622:-
BRCA	trans	rs3849046	0.817	rs12654060	ENSG00000226666.1	HSPA9P1	7.77	1.83e-14	2.07e-08	0.27	0.23	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138600025	chr2:221961737~221963765:+
BRCA	trans	rs877636	0.74	rs705698	ENSG00000204652.6	RPS26P8	7.77	1.83e-14	2.07e-08	0.32	0.23	Cognitive function;	chr12:55990903	chr17:45608571~45608918:+
BRCA	trans	rs11098499	0.738	rs34566984	ENSG00000276997.3	RP11-378J18.9	7.77	1.84e-14	2.08e-08	0.29	0.23	Corneal astigmatism;	chr4:119440115	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.954	rs9685777	ENSG00000276997.3	RP11-378J18.9	7.77	1.84e-14	2.08e-08	0.29	0.23	Corneal astigmatism;	chr4:119444810	chr1:222477252~222504622:-
BRCA	trans	rs12477438	0.52	rs10865029	ENSG00000276576.1	MRPL30P1	7.77	1.87e-14	2.11e-08	0.29	0.23	Chronic sinus infection;	chr2:99101835	chr6:57029521~57029988:+
BRCA	trans	rs12477438	0.52	rs6712704	ENSG00000276576.1	MRPL30P1	7.77	1.87e-14	2.11e-08	0.29	0.23	Chronic sinus infection;	chr2:99103224	chr6:57029521~57029988:+
BRCA	trans	rs12477438	0.52	rs6542863	ENSG00000276576.1	MRPL30P1	7.77	1.87e-14	2.11e-08	0.29	0.23	Chronic sinus infection;	chr2:99108675	chr6:57029521~57029988:+
BRCA	trans	rs13016963	0.604	rs13009885	ENSG00000235105.1	RP11-329A14.1	7.77	1.88e-14	2.12e-08	0.3	0.23	Esophageal squamous cell carcinoma;Melanoma;	chr2:201296913	chr1:48435967~48437223:+
BRCA	trans	rs2060793	0.769	rs7125781	ENSG00000236360.2	RP11-334A14.2	7.77	1.9e-14	2.14e-08	0.31	0.23	Vitamin D levels;	chr11:14856401	chr1:52993201~52993702:-
BRCA	trans	rs2060793	0.87	rs6486205	ENSG00000236360.2	RP11-334A14.2	7.77	1.9e-14	2.14e-08	0.31	0.23	Vitamin D levels;	chr11:14859710	chr1:52993201~52993702:-
BRCA	trans	rs2060793	0.87	rs7116978	ENSG00000236360.2	RP11-334A14.2	7.77	1.9e-14	2.14e-08	0.31	0.23	Vitamin D levels;	chr11:14860225	chr1:52993201~52993702:-
BRCA	trans	rs902774	0.818	rs4919740	ENSG00000224520.2	KRT8P45	-7.77	1.9e-14	2.15e-08	-0.42	-0.23	Prostate cancer;	chr12:52877187	chr1:157073257~157074703:+
BRCA	trans	rs11098499	0.954	rs17009122	ENSG00000276997.3	RP11-378J18.9	7.77	1.92e-14	2.17e-08	0.29	0.23	Corneal astigmatism;	chr4:119441248	chr1:222477252~222504622:-
BRCA	trans	rs11951515	0.508	rs1366410	ENSG00000174977.8	AC026271.5	-7.76	1.95e-14	2.2e-08	-0.28	-0.23	Metabolite levels  (X-11787);	chr5:43601508	chr17:18650195~18651542:+
BRCA	trans	rs7200543	1	rs14347	ENSG00000250569.1	NTAN1P2	7.76	1.96e-14	2.21e-08	0.26	0.23	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15040032	chr8:86481754~86483002:-
BRCA	trans	rs7929679	0.777	rs10836300	ENSG00000225531.1	RP11-196I18.3	7.76	1.97e-14	2.22e-08	0.3	0.23	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;	chr11:34767167	chr9:107116829~107117557:+
BRCA	trans	rs7929679	0.807	rs1113588	ENSG00000225531.1	RP11-196I18.3	7.76	1.97e-14	2.22e-08	0.3	0.23	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;	chr11:34768486	chr9:107116829~107117557:+
BRCA	trans	rs7929679	0.777	rs1509668	ENSG00000225531.1	RP11-196I18.3	7.76	1.97e-14	2.22e-08	0.3	0.23	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;	chr11:34769615	chr9:107116829~107117557:+
BRCA	trans	rs864643	0.891	rs1708057	ENSG00000183298.5	RP11-556K13.1	7.76	1.98e-14	2.23e-08	0.36	0.23	Attention deficit hyperactivity disorder;	chr3:39499895	chr1:101786340~101787219:-
BRCA	trans	rs864643	0.947	rs1768241	ENSG00000183298.5	RP11-556K13.1	7.76	1.98e-14	2.23e-08	0.36	0.23	Attention deficit hyperactivity disorder;	chr3:39499987	chr1:101786340~101787219:-
BRCA	trans	rs864643	0.891	rs1708059	ENSG00000183298.5	RP11-556K13.1	7.76	1.98e-14	2.23e-08	0.36	0.23	Attention deficit hyperactivity disorder;	chr3:39500059	chr1:101786340~101787219:-
BRCA	trans	rs864643	0.947	rs1768242	ENSG00000183298.5	RP11-556K13.1	7.76	1.98e-14	2.23e-08	0.36	0.23	Attention deficit hyperactivity disorder;	chr3:39500222	chr1:101786340~101787219:-
BRCA	trans	rs73108077	0.915	rs746053	ENSG00000279352.1	RP11-411B10.7	7.76	1.99e-14	2.24e-08	0.52	0.23	Red blood cell density in sickle cell anemia;	chr20:31440944	chr18:14010054~14010917:+
BRCA	trans	rs7929679	0.712	rs1509666	ENSG00000225531.1	RP11-196I18.3	7.76	1.99e-14	2.24e-08	0.3	0.23	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;	chr11:34771903	chr9:107116829~107117557:+
BRCA	trans	rs66887589	0.748	rs28439855	ENSG00000275858.1	RP11-291L22.8	7.76	2e-14	2.24e-08	0.26	0.23	Diastolic blood pressure;	chr4:119341101	chr10:38450738~38451069:-
BRCA	trans	rs875971	0.638	rs6960778	ENSG00000164669.11	INTS4P1	7.76	2e-14	2.24e-08	0.29	0.23	Aortic root size;	chr7:66606610	chr7:65141225~65234216:+
BRCA	trans	rs73108077	1	rs73108095	ENSG00000279352.1	RP11-411B10.7	7.76	2e-14	2.24e-08	0.52	0.23	Red blood cell density in sickle cell anemia;	chr20:31428519	chr18:14010054~14010917:+
BRCA	trans	rs73108077	1	rs73110016	ENSG00000279352.1	RP11-411B10.7	7.76	2e-14	2.24e-08	0.52	0.23	Red blood cell density in sickle cell anemia;	chr20:31432402	chr18:14010054~14010917:+
BRCA	trans	rs73108077	0.915	rs73110028	ENSG00000279352.1	RP11-411B10.7	7.76	2e-14	2.24e-08	0.52	0.23	Red blood cell density in sickle cell anemia;	chr20:31439633	chr18:14010054~14010917:+
BRCA	trans	rs11098499	0.954	rs12502423	ENSG00000120555.12	SEPT7P9	7.76	2.03e-14	2.28e-08	0.29	0.23	Corneal astigmatism;	chr4:119503017	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.954	rs10017371	ENSG00000276997.3	RP11-378J18.9	7.76	2.04e-14	2.29e-08	0.29	0.23	Corneal astigmatism;	chr4:119372621	chr1:222477252~222504622:-
BRCA	trans	rs801193	1	rs3778909	ENSG00000224316.1	RP11-479O9.2	7.76	2.05e-14	2.3e-08	0.23	0.23	Aortic root size;	chr7:66790659	chr7:65773620~65802067:+
BRCA	trans	rs1568889	0.838	rs7943538	ENSG00000174912.7	METTL15P1	7.76	2.05e-14	2.3e-08	0.24	0.23	Bipolar disorder;	chr11:28267408	chr3:156713884~156714928:-
BRCA	trans	rs12477438	0.52	rs11883676	ENSG00000276576.1	MRPL30P1	7.76	2.05e-14	2.3e-08	0.29	0.23	Chronic sinus infection;	chr2:99184351	chr6:57029521~57029988:+
BRCA	trans	rs12477438	0.501	rs6753063	ENSG00000276576.1	MRPL30P1	7.76	2.05e-14	2.3e-08	0.29	0.23	Chronic sinus infection;	chr2:99185006	chr6:57029521~57029988:+
BRCA	trans	rs12477438	0.52	rs6756650	ENSG00000276576.1	MRPL30P1	7.76	2.05e-14	2.3e-08	0.29	0.23	Chronic sinus infection;	chr2:99185337	chr6:57029521~57029988:+
BRCA	trans	rs11098499	0.909	rs11723839	ENSG00000276997.3	RP11-378J18.9	7.76	2.06e-14	2.31e-08	0.29	0.23	Corneal astigmatism;	chr4:119378518	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.779	rs7699346	ENSG00000276997.3	RP11-378J18.9	7.76	2.06e-14	2.31e-08	0.29	0.23	Corneal astigmatism;	chr4:119389387	chr1:222477252~222504622:-
BRCA	trans	rs17711722	0.523	rs313812	ENSG00000234585.5	CCT6P3	-7.76	2.07e-14	2.32e-08	-0.23	-0.23	Calcium levels;	chr7:66040056	chr7:65038354~65074713:+
BRCA	trans	rs875971	0.66	rs10263935	ENSG00000164669.11	INTS4P1	-7.76	2.08e-14	2.32e-08	-0.28	-0.23	Aortic root size;	chr7:66631041	chr7:65141225~65234216:+
BRCA	trans	rs875971	0.66	rs7807944	ENSG00000164669.11	INTS4P1	7.76	2.09e-14	2.34e-08	0.29	0.23	Aortic root size;	chr7:66622208	chr7:65141225~65234216:+
BRCA	trans	rs73108077	0.92	rs73108088	ENSG00000279352.1	RP11-411B10.7	7.75	2.11e-14	2.36e-08	0.52	0.23	Red blood cell density in sickle cell anemia;	chr20:31424444	chr18:14010054~14010917:+
BRCA	trans	rs673253	0.557	rs34898652	ENSG00000231007.5	CDC20P1	7.75	2.12e-14	2.37e-08	0.3	0.23	Intelligence (multi-trait analysis);	chr1:43508420	chr9:87011652~87013151:+
BRCA	trans	rs4720118	0.508	rs6944723	ENSG00000213492.2	NT5C3AP1	7.75	2.14e-14	2.39e-08	0.29	0.23	Leprosy;	chr7:33384348	chr4:117574512~117576174:-
BRCA	trans	rs7200543	1	rs4985124	ENSG00000250569.1	NTAN1P2	7.75	2.14e-14	2.39e-08	0.25	0.23	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15031584	chr8:86481754~86483002:-
BRCA	trans	rs864643	0.678	rs1707959	ENSG00000188856.6	RPSAP47	7.75	2.16e-14	2.41e-08	0.34	0.23	Attention deficit hyperactivity disorder;	chr3:39481807	chr8:80558870~80559757:+
BRCA	trans	rs7824557	0.628	rs7820301	ENSG00000253893.2	FAM85B	-7.75	2.17e-14	2.43e-08	-0.3	-0.23	Retinal vascular caliber;	chr8:11371163	chr8:8167819~8226614:-
BRCA	trans	rs11098499	0.865	rs28753180	ENSG00000276997.3	RP11-378J18.9	7.75	2.18e-14	2.43e-08	0.29	0.23	Corneal astigmatism;	chr4:119484212	chr1:222477252~222504622:-
BRCA	trans	rs801193	0.904	rs4718403	ENSG00000224316.1	RP11-479O9.2	7.75	2.18e-14	2.44e-08	0.23	0.23	Aortic root size;	chr7:66777742	chr7:65773620~65802067:+
BRCA	trans	rs2980436	1	rs2980436	ENSG00000270154.1	RP11-419I17.1	-7.75	2.2e-14	2.45e-08	-0.28	-0.23	Schizophrenia;	chr8:8234503	chr8:12476462~12477122:+
BRCA	trans	rs875971	0.66	rs3764903	ENSG00000164669.11	INTS4P1	7.75	2.2e-14	2.46e-08	0.29	0.23	Aortic root size;	chr7:66633495	chr7:65141225~65234216:+
BRCA	trans	rs73108077	1	rs73116222	ENSG00000279352.1	RP11-411B10.7	7.75	2.21e-14	2.46e-08	0.52	0.23	Red blood cell density in sickle cell anemia;	chr20:31444393	chr18:14010054~14010917:+
BRCA	trans	rs73108077	1	rs73116224	ENSG00000279352.1	RP11-411B10.7	7.75	2.21e-14	2.46e-08	0.52	0.23	Red blood cell density in sickle cell anemia;	chr20:31444913	chr18:14010054~14010917:+
BRCA	trans	rs73108077	1	rs73116226	ENSG00000279352.1	RP11-411B10.7	7.75	2.21e-14	2.46e-08	0.52	0.23	Red blood cell density in sickle cell anemia;	chr20:31445905	chr18:14010054~14010917:+
BRCA	trans	rs73108077	1	rs73116229	ENSG00000279352.1	RP11-411B10.7	7.75	2.21e-14	2.46e-08	0.52	0.23	Red blood cell density in sickle cell anemia;	chr20:31446433	chr18:14010054~14010917:+
BRCA	trans	rs2060793	0.867	rs2122941	ENSG00000236360.2	RP11-334A14.2	7.75	2.21e-14	2.47e-08	0.3	0.23	Vitamin D levels;	chr11:14834821	chr1:52993201~52993702:-
BRCA	trans	rs12477438	0.52	rs6743355	ENSG00000276576.1	MRPL30P1	7.75	2.23e-14	2.49e-08	0.29	0.23	Chronic sinus infection;	chr2:99115897	chr6:57029521~57029988:+
BRCA	trans	rs12477438	0.52	rs13004491	ENSG00000276576.1	MRPL30P1	7.75	2.23e-14	2.49e-08	0.29	0.23	Chronic sinus infection;	chr2:99121545	chr6:57029521~57029988:+
BRCA	trans	rs73108077	1	rs73116233	ENSG00000279352.1	RP11-411B10.7	7.75	2.24e-14	2.5e-08	0.52	0.23	Red blood cell density in sickle cell anemia;	chr20:31448538	chr18:14010054~14010917:+
BRCA	trans	rs73108077	1	rs73116235	ENSG00000279352.1	RP11-411B10.7	7.75	2.24e-14	2.5e-08	0.52	0.23	Red blood cell density in sickle cell anemia;	chr20:31449052	chr18:14010054~14010917:+
BRCA	trans	rs73108077	1	rs75231340	ENSG00000279352.1	RP11-411B10.7	7.75	2.24e-14	2.5e-08	0.52	0.23	Red blood cell density in sickle cell anemia;	chr20:31449114	chr18:14010054~14010917:+
BRCA	trans	rs73108077	0.92	rs45520534	ENSG00000279352.1	RP11-411B10.7	7.75	2.24e-14	2.5e-08	0.52	0.23	Red blood cell density in sickle cell anemia;	chr20:31450235	chr18:14010054~14010917:+
BRCA	trans	rs875971	0.66	rs1860470	ENSG00000164669.11	INTS4P1	7.75	2.24e-14	2.5e-08	0.29	0.23	Aortic root size;	chr7:66638707	chr7:65141225~65234216:+
BRCA	trans	rs11098499	0.954	rs12506546	ENSG00000120555.12	SEPT7P9	7.74	2.27e-14	2.54e-08	0.29	0.23	Corneal astigmatism;	chr4:119380463	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.955	rs1511018	ENSG00000120555.12	SEPT7P9	7.74	2.3e-14	2.56e-08	0.29	0.23	Corneal astigmatism;	chr4:119240425	chr10:38383069~38402916:-
BRCA	trans	rs3740713	0.669	rs2896526	ENSG00000236090.2	LDHAP3	7.74	2.31e-14	2.58e-08	0.41	0.23	Amyotrophic lateral sclerosis (sporadic);	chr11:18398259	chr2:41819747~41820754:+
BRCA	trans	rs34421088	0.532	rs2736258	ENSG00000253893.2	FAM85B	-7.74	2.33e-14	2.6e-08	-0.33	-0.23	Neuroticism;	chr8:11312940	chr8:8167819~8226614:-
BRCA	trans	rs877636	1	rs4759229	ENSG00000244604.1	RP11-713H12.1	-7.74	2.35e-14	2.61e-08	-0.28	-0.23	Cognitive function;	chr12:56080696	chr17:8561230~8561576:+
BRCA	trans	rs1933488	0.931	rs9479510	ENSG00000278974.1	RP11-756P10.6	7.74	2.37e-14	2.64e-08	0.31	0.23	Prostate cancer;	chr6:153106382	chr4:188740507~188741281:-
BRCA	trans	rs11098499	0.909	rs9759478	ENSG00000276997.3	RP11-378J18.9	7.74	2.41e-14	2.68e-08	0.29	0.23	Corneal astigmatism;	chr4:119446843	chr1:222477252~222504622:-
BRCA	trans	rs9467711	0.606	rs2072806	ENSG00000253570.1	RNF5P1	7.73	2.44e-14	2.71e-08	0.54	0.23	Autism spectrum disorder or schizophrenia;	chr6:26384865	chr8:38600661~38601200:-
BRCA	trans	rs7824557	0.527	rs2409756	ENSG00000253893.2	FAM85B	7.73	2.44e-14	2.72e-08	0.29	0.23	Retinal vascular caliber;	chr8:11384516	chr8:8167819~8226614:-
BRCA	trans	rs11098499	0.954	rs10006706	ENSG00000276997.3	RP11-378J18.9	7.73	2.45e-14	2.73e-08	0.29	0.23	Corneal astigmatism;	chr4:119487997	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.954	rs6822679	ENSG00000276997.3	RP11-378J18.9	7.73	2.46e-14	2.74e-08	0.29	0.23	Corneal astigmatism;	chr4:119481547	chr1:222477252~222504622:-
BRCA	trans	rs7927370	0.541	rs7932242	ENSG00000134612.10	FOLH1B	7.73	2.48e-14	2.76e-08	0.55	0.23	Systemic lupus erythematosus;	chr11:55849695	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.541	rs7932244	ENSG00000134612.10	FOLH1B	7.73	2.48e-14	2.76e-08	0.55	0.23	Systemic lupus erythematosus;	chr11:55849697	chr11:89639227~89698718:+
BRCA	trans	rs11098499	0.505	rs75122014	ENSG00000276997.3	RP11-378J18.9	7.73	2.49e-14	2.77e-08	0.29	0.23	Corneal astigmatism;	chr4:119441271	chr1:222477252~222504622:-
BRCA	trans	rs12477438	0.52	rs4340581	ENSG00000276576.1	MRPL30P1	7.73	2.51e-14	2.8e-08	0.29	0.23	Chronic sinus infection;	chr2:99108562	chr6:57029521~57029988:+
BRCA	trans	rs11920570	0.92	rs12374168	ENSG00000267076.1	CCDC58P3	-7.73	2.52e-14	2.81e-08	-0.31	-0.23	Resting heart rate;	chr3:122398642	chr18:12211378~12211807:+
BRCA	trans	rs7260598	0.535	rs13343732	ENSG00000261770.1	CTC-459F4.1	7.73	2.52e-14	2.81e-08	0.35	0.23	Response to taxane treatment (placlitaxel);	chr19:23928479	chr19:27757184~27760849:-
BRCA	trans	rs11098499	0.955	rs1511019	ENSG00000120555.12	SEPT7P9	7.73	2.52e-14	2.81e-08	0.29	0.23	Corneal astigmatism;	chr4:119244852	chr10:38383069~38402916:-
BRCA	trans	rs1707322	0.752	rs61784793	ENSG00000255397.1	AC022182.2	-7.73	2.54e-14	2.82e-08	-0.31	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45683613	chr8:60937705~60939871:-
BRCA	trans	rs11098499	0.697	rs28655325	ENSG00000276997.3	RP11-378J18.9	7.73	2.54e-14	2.82e-08	0.28	0.23	Corneal astigmatism;	chr4:119451844	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.954	rs10518331	ENSG00000276997.3	RP11-378J18.9	7.73	2.54e-14	2.83e-08	0.28	0.23	Corneal astigmatism;	chr4:119402440	chr1:222477252~222504622:-
BRCA	trans	rs12210905	0.925	rs12193463	ENSG00000242375.1	RP11-498P14.3	-7.73	2.55e-14	2.84e-08	-0.52	-0.23	Hip circumference adjusted for BMI;	chr6:26994103	chr9:97195351~97197687:-
BRCA	trans	rs66887589	0.777	rs1814815	ENSG00000275858.1	RP11-291L22.8	7.73	2.6e-14	2.89e-08	0.26	0.23	Diastolic blood pressure;	chr4:119336936	chr10:38450738~38451069:-
BRCA	trans	rs11098499	0.954	rs12506546	ENSG00000276997.3	RP11-378J18.9	7.73	2.61e-14	2.89e-08	0.29	0.23	Corneal astigmatism;	chr4:119380463	chr1:222477252~222504622:-
BRCA	trans	rs13016963	0.604	rs7596930	ENSG00000235105.1	RP11-329A14.1	7.73	2.62e-14	2.91e-08	0.29	0.23	Esophageal squamous cell carcinoma;Melanoma;	chr2:201315319	chr1:48435967~48437223:+
BRCA	trans	rs7929679	0.777	rs7124685	ENSG00000225531.1	RP11-196I18.3	7.72	2.66e-14	2.96e-08	0.3	0.23	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;	chr11:34770552	chr9:107116829~107117557:+
BRCA	trans	rs877636	0.859	rs3741499	ENSG00000244604.1	RP11-713H12.1	-7.72	2.67e-14	2.96e-08	-0.27	-0.23	Cognitive function;	chr12:56080595	chr17:8561230~8561576:+
BRCA	trans	rs7746199	0.736	rs6904596	ENSG00000253570.1	RNF5P1	7.72	2.69e-14	2.98e-08	0.55	0.23	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27523520	chr8:38600661~38601200:-
BRCA	trans	rs877636	0.74	rs772920	ENSG00000212829.8	RPS26P3	7.72	2.7e-14	2.99e-08	0.32	0.23	Cognitive function;	chr12:55996580	chr9:9090898~9091245:+
BRCA	trans	rs9581094	1	rs9581094	ENSG00000237917.1	PARP4P1	-7.72	2.71e-14	3.01e-08	-0.43	-0.23	Sudden cardiac arrest;	chr13:24508492	chrY:26594851~26634652:-
BRCA	trans	rs11098499	0.908	rs1002152	ENSG00000276997.3	RP11-378J18.9	7.72	2.78e-14	3.08e-08	0.29	0.23	Corneal astigmatism;	chr4:119352232	chr1:222477252~222504622:-
BRCA	trans	rs7662987	1	rs11547772	ENSG00000228407.2	RP4-800M22.1	7.72	2.78e-14	3.08e-08	0.51	0.23	Smoking initiation;	chr4:99071642	chr1:52160261~52160600:-
BRCA	trans	rs747782	0.582	rs4752843	ENSG00000134612.10	FOLH1B	7.72	2.8e-14	3.1e-08	0.37	0.23	Intraocular pressure;	chr11:47510332	chr11:89639227~89698718:+
BRCA	trans	rs11098499	0.954	rs4577559	ENSG00000276997.3	RP11-378J18.9	7.71	2.83e-14	3.13e-08	0.29	0.23	Corneal astigmatism;	chr4:119482888	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.954	rs7656252	ENSG00000276997.3	RP11-378J18.9	7.71	2.83e-14	3.13e-08	0.29	0.23	Corneal astigmatism;	chr4:119483113	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.865	rs28845498	ENSG00000276997.3	RP11-378J18.9	7.71	2.83e-14	3.13e-08	0.29	0.23	Corneal astigmatism;	chr4:119484031	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.954	rs56270433	ENSG00000276997.3	RP11-378J18.9	7.71	2.83e-14	3.13e-08	0.29	0.23	Corneal astigmatism;	chr4:119484875	chr1:222477252~222504622:-
BRCA	trans	rs641862	1	rs641862	ENSG00000247400.3	DNAJC3-AS1	7.71	2.83e-14	3.13e-08	0.45	0.23	Obesity-related traits;	chr13:110137885	chr13:95648733~95676925:-
BRCA	trans	rs7113874	0.959	rs11042017	ENSG00000266891.1	RP11-692N5.2	-7.71	2.84e-14	3.14e-08	-0.29	-0.23	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8628144	chr18:9734882~9735602:-
BRCA	trans	rs7113874	0.959	rs12803166	ENSG00000266891.1	RP11-692N5.2	-7.71	2.86e-14	3.16e-08	-0.29	-0.23	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8624690	chr18:9734882~9735602:-
BRCA	trans	rs7769051	1	rs9493454	ENSG00000213087.3	RP11-613F7.1	-7.71	2.86e-14	3.16e-08	-0.33	-0.23	Type 2 diabetes nephropathy;	chr6:132823490	chr6:151225550~151225947:-
BRCA	trans	rs875971	0.66	rs801192	ENSG00000164669.11	INTS4P1	7.71	2.87e-14	3.18e-08	0.28	0.23	Aortic root size;	chr7:66566965	chr7:65141225~65234216:+
BRCA	trans	rs875971	0.66	rs801190	ENSG00000164669.11	INTS4P1	7.71	2.87e-14	3.18e-08	0.28	0.23	Aortic root size;	chr7:66568046	chr7:65141225~65234216:+
BRCA	trans	rs875971	0.66	rs3857686	ENSG00000164669.11	INTS4P1	7.71	2.87e-14	3.18e-08	0.28	0.23	Aortic root size;	chr7:66571204	chr7:65141225~65234216:+
BRCA	trans	rs7824557	0.591	rs2043510	ENSG00000253893.2	FAM85B	7.71	2.88e-14	3.18e-08	0.3	0.23	Retinal vascular caliber;	chr8:11367659	chr8:8167819~8226614:-
BRCA	trans	rs2060793	0.87	rs1868997	ENSG00000236360.2	RP11-334A14.2	7.71	2.88e-14	3.19e-08	0.3	0.23	Vitamin D levels;	chr11:14872674	chr1:52993201~52993702:-
BRCA	trans	rs7824557	0.767	rs6985460	ENSG00000253893.2	FAM85B	-7.71	2.89e-14	3.2e-08	-0.31	-0.23	Retinal vascular caliber;	chr8:11313578	chr8:8167819~8226614:-
BRCA	trans	rs11098499	0.954	rs10518328	ENSG00000276997.3	RP11-378J18.9	7.71	2.91e-14	3.22e-08	0.29	0.23	Corneal astigmatism;	chr4:119480624	chr1:222477252~222504622:-
BRCA	trans	rs6915893	1	rs9477630	ENSG00000267156.1	TPMTP1	7.71	2.91e-14	3.22e-08	0.3	0.23	Intrinsic epigenetic age acceleration;	chr6:18117867	chr18:47630112~47630848:+
BRCA	trans	rs7833986	0.501	rs2667999	ENSG00000244245.1	RP11-120B7.1	7.71	2.92e-14	3.23e-08	0.3	0.23	Height;	chr8:56037915	chr5:108593609~108593967:+
BRCA	trans	rs12210905	0.688	rs12215289	ENSG00000242375.1	RP11-498P14.3	-7.71	2.95e-14	3.26e-08	-0.6	-0.23	Hip circumference adjusted for BMI;	chr6:27500926	chr9:97195351~97197687:-
BRCA	trans	rs7944735	0.564	rs60929305	ENSG00000134612.10	FOLH1B	7.71	2.96e-14	3.26e-08	0.37	0.23	Intraocular pressure;	chr11:47502037	chr11:89639227~89698718:+
BRCA	trans	rs7927370	0.558	rs61897473	ENSG00000134612.10	FOLH1B	7.71	2.97e-14	3.29e-08	0.54	0.23	Systemic lupus erythematosus;	chr11:55844035	chr11:89639227~89698718:+
BRCA	trans	rs9650657	0.801	rs4841437	ENSG00000253893.2	FAM85B	7.71	2.98e-14	3.29e-08	0.29	0.23	Neuroticism;	chr8:10739285	chr8:8167819~8226614:-
BRCA	trans	rs12477438	0.52	rs36071868	ENSG00000276576.1	MRPL30P1	7.71	2.99e-14	3.3e-08	0.29	0.23	Chronic sinus infection;	chr2:99120657	chr6:57029521~57029988:+
BRCA	trans	rs12477438	0.52	rs34252185	ENSG00000276576.1	MRPL30P1	7.71	2.99e-14	3.3e-08	0.29	0.23	Chronic sinus infection;	chr2:99121183	chr6:57029521~57029988:+
BRCA	trans	rs12477438	0.52	rs13023744	ENSG00000276576.1	MRPL30P1	7.71	2.99e-14	3.3e-08	0.29	0.23	Chronic sinus infection;	chr2:99121761	chr6:57029521~57029988:+
BRCA	trans	rs12477438	0.501	rs6751927	ENSG00000276576.1	MRPL30P1	7.71	2.99e-14	3.3e-08	0.29	0.23	Chronic sinus infection;	chr2:99123712	chr6:57029521~57029988:+
BRCA	trans	rs2060793	0.87	rs10732460	ENSG00000236360.2	RP11-334A14.2	7.71	2.99e-14	3.3e-08	0.3	0.23	Vitamin D levels;	chr11:14854025	chr1:52993201~52993702:-
BRCA	trans	rs12477438	0.52	rs4588238	ENSG00000276576.1	MRPL30P1	7.71	3.01e-14	3.32e-08	0.29	0.23	Chronic sinus infection;	chr2:99132887	chr6:57029521~57029988:+
BRCA	trans	rs12477438	0.52	rs13018891	ENSG00000276576.1	MRPL30P1	7.71	3.01e-14	3.32e-08	0.29	0.23	Chronic sinus infection;	chr2:99138636	chr6:57029521~57029988:+
BRCA	trans	rs12477438	0.52	rs6542865	ENSG00000276576.1	MRPL30P1	7.71	3.01e-14	3.32e-08	0.29	0.23	Chronic sinus infection;	chr2:99148058	chr6:57029521~57029988:+
BRCA	trans	rs7200543	1	rs1135999	ENSG00000250569.1	NTAN1P2	7.71	3.03e-14	3.34e-08	0.26	0.23	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15038105	chr8:86481754~86483002:-
BRCA	trans	rs2243480	0.706	rs6460257	ENSG00000273142.1	RP11-458F8.4	-7.7	3.05e-14	3.37e-08	-0.27	-0.23	Diabetic kidney disease;	chr7:65731813	chr7:66902857~66906297:+
BRCA	trans	rs546131	0.642	rs508062	ENSG00000225531.1	RP11-196I18.3	7.7	3.07e-14	3.39e-08	0.34	0.23	Lung disease severity in cystic fibrosis;	chr11:34822273	chr9:107116829~107117557:+
BRCA	trans	rs875971	0.638	rs10249404	ENSG00000164669.11	INTS4P1	7.7	3.08e-14	3.4e-08	0.29	0.23	Aortic root size;	chr7:66581737	chr7:65141225~65234216:+
BRCA	trans	rs11098499	0.909	rs1546504	ENSG00000276997.3	RP11-378J18.9	7.7	3.08e-14	3.4e-08	0.28	0.23	Corneal astigmatism;	chr4:119320024	chr1:222477252~222504622:-
BRCA	trans	rs7929679	0.777	rs7124826	ENSG00000225531.1	RP11-196I18.3	7.7	3.1e-14	3.42e-08	0.3	0.23	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;	chr11:34770690	chr9:107116829~107117557:+
BRCA	trans	rs60515486	0.646	rs4752992	ENSG00000134612.10	FOLH1B	7.7	3.1e-14	3.42e-08	0.38	0.23	Lymphocyte counts;	chr11:47389200	chr11:89639227~89698718:+
BRCA	trans	rs714543	0.783	rs7806283	ENSG00000267258.1	CTC-448F2.3	-7.7	3.11e-14	3.43e-08	-0.27	-0.23	Plateletcrit;	chr7:44779104	chr19:29921182~29921653:+
BRCA	trans	rs7662987	0.938	rs28730605	ENSG00000228407.2	RP4-800M22.1	7.7	3.12e-14	3.44e-08	0.51	0.23	Smoking initiation;	chr4:99080389	chr1:52160261~52160600:-
BRCA	trans	rs864643	0.678	rs1707957	ENSG00000188856.6	RPSAP47	7.7	3.12e-14	3.44e-08	0.34	0.23	Attention deficit hyperactivity disorder;	chr3:39482000	chr8:80558870~80559757:+
BRCA	trans	rs73108077	1	rs115577082	ENSG00000279352.1	RP11-411B10.7	7.7	3.12e-14	3.44e-08	0.52	0.23	Red blood cell density in sickle cell anemia;	chr20:31433893	chr18:14010054~14010917:+
BRCA	trans	rs2069408	1	rs2069408	ENSG00000204652.6	RPS26P8	-7.7	3.17e-14	3.49e-08	-0.31	-0.23	Asthma;	chr12:55970537	chr17:45608571~45608918:+
BRCA	trans	rs67180937	0.645	rs2270707	ENSG00000219201.4	RP11-181C21.4	7.7	3.18e-14	3.5e-08	0.29	0.23	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222664252	chr1:77810861~77811781:-
BRCA	trans	rs9584850	0.834	rs17574378	ENSG00000230079.1	STK24P1	7.7	3.18e-14	3.5e-08	0.3	0.23	Neuroticism;	chr13:98464130	chrX:136295690~136300298:-
BRCA	trans	rs864643	0.678	rs1398668	ENSG00000188856.6	RPSAP47	7.7	3.19e-14	3.51e-08	0.34	0.23	Attention deficit hyperactivity disorder;	chr3:39475753	chr8:80558870~80559757:+
BRCA	trans	rs11098499	0.738	rs34965784	ENSG00000276997.3	RP11-378J18.9	7.7	3.19e-14	3.51e-08	0.28	0.23	Corneal astigmatism;	chr4:119440431	chr1:222477252~222504622:-
BRCA	trans	rs9425766	0.679	rs4652234	ENSG00000213331.4	RP11-713C19.2	7.7	3.2e-14	3.53e-08	0.26	0.23	Life satisfaction;	chr1:174181712	chr4:187970273~187971284:+
BRCA	trans	rs864643	0.678	rs625898	ENSG00000188856.6	RPSAP47	-7.7	3.21e-14	3.53e-08	-0.33	-0.23	Attention deficit hyperactivity disorder;	chr3:39471624	chr8:80558870~80559757:+
BRCA	trans	rs7113874	1	rs7113874	ENSG00000266891.1	RP11-692N5.2	7.7	3.24e-14	3.57e-08	0.29	0.23	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8666469	chr18:9734882~9735602:-
BRCA	trans	rs12477438	0.52	rs11695751	ENSG00000276576.1	MRPL30P1	7.7	3.25e-14	3.58e-08	0.29	0.23	Chronic sinus infection;	chr2:99091784	chr6:57029521~57029988:+
BRCA	trans	rs13016963	0.604	rs2110691	ENSG00000235105.1	RP11-329A14.1	7.7	3.26e-14	3.59e-08	0.29	0.23	Esophageal squamous cell carcinoma;Melanoma;	chr2:201320439	chr1:48435967~48437223:+
BRCA	trans	rs11172055	0.807	rs7314567	ENSG00000121089.4	NACA3P	7.69	3.29e-14	3.62e-08	0.26	0.23	Migraine;	chr12:56864231	chr4:164943290~164943937:+
BRCA	trans	rs801193	1	rs4717319	ENSG00000224316.1	RP11-479O9.2	7.69	3.3e-14	3.63e-08	0.23	0.23	Aortic root size;	chr7:66777606	chr7:65773620~65802067:+
BRCA	trans	rs875971	0.638	rs6460305	ENSG00000164669.11	INTS4P1	7.69	3.35e-14	3.68e-08	0.28	0.23	Aortic root size;	chr7:66595421	chr7:65141225~65234216:+
BRCA	trans	rs864643	0.947	rs1708053	ENSG00000183298.5	RP11-556K13.1	7.69	3.4e-14	3.73e-08	0.36	0.23	Attention deficit hyperactivity disorder;	chr3:39499706	chr1:101786340~101787219:-
BRCA	trans	rs7929679	0.875	rs1396887	ENSG00000225531.1	RP11-196I18.3	7.69	3.44e-14	3.77e-08	0.3	0.23	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;	chr11:34773891	chr9:107116829~107117557:+
BRCA	trans	rs11098499	0.954	rs3733519	ENSG00000120555.12	SEPT7P9	7.69	3.44e-14	3.78e-08	0.29	0.23	Corneal astigmatism;	chr4:119502293	chr10:38383069~38402916:-
BRCA	trans	rs875971	0.66	rs7807930	ENSG00000164669.11	INTS4P1	7.69	3.49e-14	3.82e-08	0.28	0.23	Aortic root size;	chr7:66622178	chr7:65141225~65234216:+
BRCA	trans	rs66887589	0.777	rs2017058	ENSG00000275858.1	RP11-291L22.8	7.68	3.58e-14	3.92e-08	0.26	0.23	Diastolic blood pressure;	chr4:119336584	chr10:38450738~38451069:-
BRCA	trans	rs714543	0.66	rs13224222	ENSG00000267258.1	CTC-448F2.3	7.68	3.59e-14	3.92e-08	0.26	0.23	Plateletcrit;	chr7:44772739	chr19:29921182~29921653:+
BRCA	trans	rs877636	0.74	rs772920	ENSG00000224553.1	AC008065.1	7.68	3.6e-14	3.94e-08	0.29	0.23	Cognitive function;	chr12:55996580	chr2:171374931~171375278:-
BRCA	trans	rs11098499	0.954	rs12508504	ENSG00000276997.3	RP11-378J18.9	7.68	3.61e-14	3.95e-08	0.29	0.23	Corneal astigmatism;	chr4:119489452	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.954	rs17006190	ENSG00000120555.12	SEPT7P9	7.68	3.63e-14	3.96e-08	0.29	0.23	Corneal astigmatism;	chr4:119497683	chr10:38383069~38402916:-
BRCA	trans	rs877636	0.702	rs773109	ENSG00000224553.1	AC008065.1	7.68	3.64e-14	3.98e-08	0.29	0.23	Cognitive function;	chr12:55980911	chr2:171374931~171375278:-
BRCA	trans	rs13016963	0.604	rs11679181	ENSG00000235105.1	RP11-329A14.1	7.68	3.66e-14	4e-08	0.29	0.23	Esophageal squamous cell carcinoma;Melanoma;	chr2:201297615	chr1:48435967~48437223:+
BRCA	trans	rs747782	0.646	rs3847503	ENSG00000134612.10	FOLH1B	7.68	3.67e-14	4.01e-08	0.38	0.23	Intraocular pressure;	chr11:47442967	chr11:89639227~89698718:+
BRCA	trans	rs7113874	0.921	rs4929924	ENSG00000266891.1	RP11-692N5.2	-7.68	3.68e-14	4.02e-08	-0.28	-0.23	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8617778	chr18:9734882~9735602:-
BRCA	trans	rs11098499	0.954	rs2389802	ENSG00000276997.3	RP11-378J18.9	7.68	3.7e-14	4.04e-08	0.28	0.23	Corneal astigmatism;	chr4:119404577	chr1:222477252~222504622:-
BRCA	trans	rs10940346	0.506	rs4605740	ENSG00000231752.4	EMBP1	-7.68	3.75e-14	4.09e-08	-0.3	-0.23	Schizophrenia;	chr5:50574869	chr1:121519112~121571892:+
BRCA	trans	rs877636	0.74	rs705702	ENSG00000212829.8	RPS26P3	-7.68	3.78e-14	4.12e-08	-0.31	-0.23	Cognitive function;	chr12:55996852	chr9:9090898~9091245:+
BRCA	trans	rs11098499	0.909	rs11723839	ENSG00000120555.12	SEPT7P9	7.67	3.83e-14	4.17e-08	0.29	0.23	Corneal astigmatism;	chr4:119378518	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.779	rs7699346	ENSG00000120555.12	SEPT7P9	7.67	3.83e-14	4.17e-08	0.29	0.23	Corneal astigmatism;	chr4:119389387	chr10:38383069~38402916:-
BRCA	trans	rs7200543	1	rs4985154	ENSG00000250569.1	NTAN1P2	7.67	3.87e-14	4.21e-08	0.26	0.23	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15037785	chr8:86481754~86483002:-
BRCA	trans	rs11098499	0.954	rs1546505	ENSG00000276997.3	RP11-378J18.9	7.67	3.89e-14	4.23e-08	0.28	0.23	Corneal astigmatism;	chr4:119320069	chr1:222477252~222504622:-
BRCA	trans	rs17742757	0.522	rs899364	ENSG00000253893.2	FAM85B	7.67	3.91e-14	4.25e-08	0.31	0.23	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:11472035	chr8:8167819~8226614:-
BRCA	trans	rs3806843	0.576	rs155361	ENSG00000231043.3	AC007238.1	-7.67	3.92e-14	4.26e-08	-0.28	-0.23	Depressive symptoms (multi-trait analysis);	chr5:140927699	chr2:58460292~58462032:-
BRCA	trans	rs875971	0.66	rs10215132	ENSG00000164669.11	INTS4P1	7.67	3.96e-14	4.3e-08	0.29	0.23	Aortic root size;	chr7:66589419	chr7:65141225~65234216:+
BRCA	trans	rs12477438	0.52	rs11123766	ENSG00000276576.1	MRPL30P1	7.67	4e-14	4.35e-08	0.29	0.23	Chronic sinus infection;	chr2:99164452	chr6:57029521~57029988:+
BRCA	trans	rs12477438	0.52	rs2964969	ENSG00000276576.1	MRPL30P1	7.67	4e-14	4.35e-08	0.29	0.23	Chronic sinus infection;	chr2:99166348	chr6:57029521~57029988:+
BRCA	trans	rs12477438	0.52	rs2171359	ENSG00000276576.1	MRPL30P1	7.67	4e-14	4.35e-08	0.29	0.23	Chronic sinus infection;	chr2:99178897	chr6:57029521~57029988:+
BRCA	trans	rs3806843	0.576	rs265316	ENSG00000231043.3	AC007238.1	-7.67	4.07e-14	4.42e-08	-0.28	-0.23	Depressive symptoms (multi-trait analysis);	chr5:140911258	chr2:58460292~58462032:-
BRCA	trans	rs3806843	0.52	rs265312	ENSG00000231043.3	AC007238.1	-7.67	4.07e-14	4.42e-08	-0.28	-0.23	Depressive symptoms (multi-trait analysis);	chr5:140916687	chr2:58460292~58462032:-
BRCA	trans	rs11098499	0.954	rs11098526	ENSG00000276997.3	RP11-378J18.9	7.67	4.08e-14	4.43e-08	0.29	0.23	Corneal astigmatism;	chr4:119469204	chr1:222477252~222504622:-
BRCA	trans	rs12210905	0.688	rs12212632	ENSG00000242375.1	RP11-498P14.3	-7.66	4.1e-14	4.45e-08	-0.59	-0.23	Hip circumference adjusted for BMI;	chr6:27504637	chr9:97195351~97197687:-
BRCA	trans	rs12210905	0.688	rs12189640	ENSG00000242375.1	RP11-498P14.3	-7.66	4.1e-14	4.45e-08	-0.59	-0.23	Hip circumference adjusted for BMI;	chr6:27506878	chr9:97195351~97197687:-
BRCA	trans	rs12210905	0.688	rs75968505	ENSG00000242375.1	RP11-498P14.3	-7.66	4.1e-14	4.45e-08	-0.59	-0.23	Hip circumference adjusted for BMI;	chr6:27509217	chr9:97195351~97197687:-
BRCA	trans	rs546131	0.642	rs2956073	ENSG00000225531.1	RP11-196I18.3	7.66	4.11e-14	4.46e-08	0.34	0.23	Lung disease severity in cystic fibrosis;	chr11:34821336	chr9:107116829~107117557:+
BRCA	trans	rs11638815	0.626	rs11633829	ENSG00000235370.6	DNM1P51	7.66	4.14e-14	4.49e-08	0.26	0.23	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82658186	chr15:84398316~84411701:-
BRCA	trans	rs11098499	0.954	rs10006706	ENSG00000120555.12	SEPT7P9	7.66	4.18e-14	4.54e-08	0.28	0.23	Corneal astigmatism;	chr4:119487997	chr10:38383069~38402916:-
BRCA	trans	rs9467711	0.79	rs34158769	ENSG00000253570.1	RNF5P1	7.66	4.19e-14	4.55e-08	0.59	0.23	Autism spectrum disorder or schizophrenia;	chr6:26336344	chr8:38600661~38601200:-
BRCA	trans	rs877636	1	rs2292239	ENSG00000224553.1	AC008065.1	7.66	4.2e-14	4.56e-08	0.27	0.23	Cognitive function;	chr12:56088396	chr2:171374931~171375278:-
BRCA	trans	rs3749237	0.964	rs11717463	ENSG00000197582.5	GPX1P1	7.66	4.2e-14	4.56e-08	0.25	0.23	Resting heart rate;	chr3:49771548	chrX:13378735~13379340:-
BRCA	trans	rs7113874	1	rs7126235	ENSG00000266891.1	RP11-692N5.2	7.66	4.24e-14	4.59e-08	0.29	0.23	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8667789	chr18:9734882~9735602:-
BRCA	trans	rs11098499	0.657	rs71614442	ENSG00000276997.3	RP11-378J18.9	7.66	4.28e-14	4.63e-08	0.28	0.23	Corneal astigmatism;	chr4:119458191	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.954	rs2892848	ENSG00000276997.3	RP11-378J18.9	7.66	4.28e-14	4.63e-08	0.28	0.23	Corneal astigmatism;	chr4:119460186	chr1:222477252~222504622:-
BRCA	trans	rs3806843	0.551	rs184996	ENSG00000231043.3	AC007238.1	-7.66	4.28e-14	4.64e-08	-0.28	-0.23	Depressive symptoms (multi-trait analysis);	chr5:140944188	chr2:58460292~58462032:-
BRCA	trans	rs6831352	1	rs10017466	ENSG00000233859.2	ADH5P4	-7.66	4.28e-14	4.64e-08	-0.3	-0.23	Alcohol dependence;	chr4:99134649	chr6:65836930~65838039:-
BRCA	trans	rs7833986	0.501	rs2953911	ENSG00000244245.1	RP11-120B7.1	7.66	4.29e-14	4.65e-08	0.29	0.23	Height;	chr8:56035450	chr5:108593609~108593967:+
BRCA	trans	rs9467711	0.559	rs9348721	ENSG00000253570.1	RNF5P1	7.66	4.29e-14	4.65e-08	0.53	0.23	Autism spectrum disorder or schizophrenia;	chr6:26485345	chr8:38600661~38601200:-
BRCA	trans	rs3806843	0.606	rs251377	ENSG00000231043.3	AC007238.1	7.66	4.34e-14	4.7e-08	0.28	0.23	Depressive symptoms (multi-trait analysis);	chr5:140876207	chr2:58460292~58462032:-
BRCA	trans	rs9650657	0.771	rs6601513	ENSG00000253893.2	FAM85B	7.66	4.36e-14	4.72e-08	0.29	0.23	Neuroticism;	chr8:10737333	chr8:8167819~8226614:-
BRCA	trans	rs877636	0.702	rs61937249	ENSG00000224553.1	AC008065.1	7.66	4.39e-14	4.76e-08	0.29	0.23	Cognitive function;	chr12:55988132	chr2:171374931~171375278:-
BRCA	trans	rs12477438	0.501	rs12992218	ENSG00000276576.1	MRPL30P1	7.65	4.41e-14	4.77e-08	0.29	0.23	Chronic sinus infection;	chr2:99137371	chr6:57029521~57029988:+
BRCA	trans	rs12477438	0.52	rs11677247	ENSG00000276576.1	MRPL30P1	7.65	4.41e-14	4.77e-08	0.29	0.23	Chronic sinus infection;	chr2:99139895	chr6:57029521~57029988:+
BRCA	trans	rs12477438	0.52	rs11890338	ENSG00000276576.1	MRPL30P1	7.65	4.41e-14	4.77e-08	0.29	0.23	Chronic sinus infection;	chr2:99151405	chr6:57029521~57029988:+
BRCA	trans	rs12477438	0.508	rs2516832	ENSG00000276576.1	MRPL30P1	7.65	4.41e-14	4.77e-08	0.29	0.23	Chronic sinus infection;	chr2:99154805	chr6:57029521~57029988:+
BRCA	trans	rs12477438	0.52	rs2516827	ENSG00000276576.1	MRPL30P1	7.65	4.41e-14	4.77e-08	0.29	0.23	Chronic sinus infection;	chr2:99156102	chr6:57029521~57029988:+
BRCA	trans	rs7200543	1	rs34614532	ENSG00000250569.1	NTAN1P2	7.65	4.41e-14	4.77e-08	0.26	0.23	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15039051	chr8:86481754~86483002:-
BRCA	trans	rs11098499	0.913	rs10010696	ENSG00000120555.12	SEPT7P9	7.65	4.41e-14	4.77e-08	0.29	0.23	Corneal astigmatism;	chr4:119243148	chr10:38383069~38402916:-
BRCA	trans	rs6915893	0.903	rs6921836	ENSG00000267156.1	TPMTP1	7.65	4.41e-14	4.77e-08	0.3	0.23	Intrinsic epigenetic age acceleration;	chr6:18104045	chr18:47630112~47630848:+
BRCA	trans	rs877636	0.74	rs705698	ENSG00000224553.1	AC008065.1	7.65	4.46e-14	4.82e-08	0.29	0.23	Cognitive function;	chr12:55990903	chr2:171374931~171375278:-
BRCA	trans	rs11098499	1	rs6837898	ENSG00000120555.12	SEPT7P9	7.65	4.48e-14	4.85e-08	0.29	0.23	Corneal astigmatism;	chr4:119257999	chr10:38383069~38402916:-
BRCA	trans	rs2069408	1	rs2069408	ENSG00000244604.1	RP11-713H12.1	-7.65	4.5e-14	4.87e-08	-0.29	-0.23	Asthma;	chr12:55970537	chr17:8561230~8561576:+
BRCA	trans	rs7769051	1	rs9493454	ENSG00000213303.3	CTC-398G3.2	-7.65	4.51e-14	4.88e-08	-0.37	-0.23	Type 2 diabetes nephropathy;	chr6:132823490	chr19:11523436~11523831:+
BRCA	trans	rs7824557	0.591	rs2736282	ENSG00000253893.2	FAM85B	-7.65	4.53e-14	4.9e-08	-0.29	-0.23	Retinal vascular caliber;	chr8:11367971	chr8:8167819~8226614:-
BRCA	trans	rs6915893	0.669	rs10456213	ENSG00000267156.1	TPMTP1	7.65	4.54e-14	4.9e-08	0.29	0.23	Intrinsic epigenetic age acceleration;	chr6:18118881	chr18:47630112~47630848:+
BRCA	trans	rs3849046	0.79	rs10793825	ENSG00000226666.1	HSPA9P1	7.65	4.6e-14	4.97e-08	0.27	0.23	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138598882	chr2:221961737~221963765:+
BRCA	trans	rs11098499	0.955	rs35197422	ENSG00000120555.12	SEPT7P9	7.65	4.61e-14	4.98e-08	0.29	0.23	Corneal astigmatism;	chr4:119248159	chr10:38383069~38402916:-
BRCA	trans	rs877636	0.702	rs773111	ENSG00000224553.1	AC008065.1	7.65	4.61e-14	4.98e-08	0.29	0.23	Cognitive function;	chr12:55981956	chr2:171374931~171375278:-
BRCA	trans	rs58106596	0.517	rs17271845	ENSG00000259020.3	RP11-529H20.3	7.65	4.66e-14	5.03e-08	0.35	0.23	Lymphocyte counts;White blood cell count;	chr2:231788463	chr14:92026566~92026887:+
BRCA	trans	rs3806843	0.576	rs246064	ENSG00000231043.3	AC007238.1	-7.65	4.67e-14	5.04e-08	-0.28	-0.23	Depressive symptoms (multi-trait analysis);	chr5:140944724	chr2:58460292~58462032:-
BRCA	trans	rs7113874	0.885	rs7950166	ENSG00000266891.1	RP11-692N5.2	-7.65	4.72e-14	5.1e-08	-0.28	-0.23	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8620671	chr18:9734882~9735602:-
BRCA	trans	rs12477438	0.52	rs6542870	ENSG00000276576.1	MRPL30P1	7.64	4.77e-14	5.14e-08	0.29	0.23	Chronic sinus infection;	chr2:99180175	chr6:57029521~57029988:+
BRCA	trans	rs3849046	0.738	rs57958956	ENSG00000226666.1	HSPA9P1	7.64	4.81e-14	5.18e-08	0.26	0.23	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138590952	chr2:221961737~221963765:+
BRCA	trans	rs864643	0.678	rs7631217	ENSG00000188856.6	RPSAP47	-7.64	4.82e-14	5.2e-08	-0.33	-0.23	Attention deficit hyperactivity disorder;	chr3:39478568	chr8:80558870~80559757:+
BRCA	trans	rs6424115	0.679	rs2294495	ENSG00000228217.1	AL390877.1	7.64	4.85e-14	5.23e-08	0.31	0.23	Immature fraction of reticulocytes;	chr1:23749386	chr1:117778087~117778506:-
BRCA	trans	rs12210905	0.688	rs12191373	ENSG00000242375.1	RP11-498P14.3	-7.64	4.87e-14	5.25e-08	-0.6	-0.23	Hip circumference adjusted for BMI;	chr6:27516551	chr9:97195351~97197687:-
BRCA	trans	rs13016963	0.604	rs10931940	ENSG00000235105.1	RP11-329A14.1	7.64	5.01e-14	5.39e-08	0.29	0.23	Esophageal squamous cell carcinoma;Melanoma;	chr2:201313949	chr1:48435967~48437223:+
BRCA	trans	rs13016963	0.604	rs11688692	ENSG00000235105.1	RP11-329A14.1	7.64	5.02e-14	5.41e-08	0.29	0.23	Esophageal squamous cell carcinoma;Melanoma;	chr2:201324728	chr1:48435967~48437223:+
BRCA	trans	rs11172055	0.902	rs10783807	ENSG00000121089.4	NACA3P	-7.63	5.2e-14	5.6e-08	-0.26	-0.23	Migraine;	chr12:56872529	chr4:164943290~164943937:+
BRCA	trans	rs13016963	0.604	rs7609223	ENSG00000235105.1	RP11-329A14.1	7.63	5.28e-14	5.68e-08	0.29	0.23	Esophageal squamous cell carcinoma;Melanoma;	chr2:201311672	chr1:48435967~48437223:+
BRCA	trans	rs1478897	0.898	rs2248932	ENSG00000253893.2	FAM85B	7.63	5.3e-14	5.7e-08	0.29	0.23	Systemic lupus erythematosus;	chr8:11534141	chr8:8167819~8226614:-
BRCA	trans	rs12477438	0.52	rs2632276	ENSG00000276576.1	MRPL30P1	7.63	5.32e-14	5.72e-08	0.29	0.23	Chronic sinus infection;	chr2:99163192	chr6:57029521~57029988:+
BRCA	trans	rs12477438	0.52	rs11695379	ENSG00000276576.1	MRPL30P1	7.63	5.33e-14	5.73e-08	0.28	0.23	Chronic sinus infection;	chr2:99125698	chr6:57029521~57029988:+
BRCA	trans	rs11098499	0.954	rs67265404	ENSG00000276997.3	RP11-378J18.9	7.63	5.34e-14	5.74e-08	0.28	0.23	Corneal astigmatism;	chr4:119438115	chr1:222477252~222504622:-
BRCA	trans	rs9650657	0.74	rs10481451	ENSG00000253893.2	FAM85B	7.63	5.38e-14	5.79e-08	0.29	0.23	Neuroticism;	chr8:10791818	chr8:8167819~8226614:-
BRCA	trans	rs877636	0.859	rs3741499	ENSG00000224553.1	AC008065.1	-7.63	5.4e-14	5.8e-08	-0.27	-0.23	Cognitive function;	chr12:56080595	chr2:171374931~171375278:-
BRCA	trans	rs546131	0.642	rs512013	ENSG00000225531.1	RP11-196I18.3	7.63	5.42e-14	5.82e-08	0.34	0.23	Lung disease severity in cystic fibrosis;	chr11:34820678	chr9:107116829~107117557:+
BRCA	trans	rs714543	0.875	rs35585318	ENSG00000267258.1	CTC-448F2.3	-7.63	5.47e-14	5.88e-08	-0.28	-0.23	Plateletcrit;	chr7:44852220	chr19:29921182~29921653:+
BRCA	trans	rs7200543	1	rs1136001	ENSG00000250569.1	NTAN1P2	7.63	5.48e-14	5.89e-08	0.25	0.23	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15038117	chr8:86481754~86483002:-
BRCA	trans	rs877636	0.702	rs773112	ENSG00000224553.1	AC008065.1	7.62	5.5e-14	5.91e-08	0.29	0.23	Cognitive function;	chr12:55982097	chr2:171374931~171375278:-
BRCA	trans	rs11098499	0.954	rs11940028	ENSG00000120555.12	SEPT7P9	7.62	5.5e-14	5.91e-08	0.29	0.23	Corneal astigmatism;	chr4:119490752	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.954	rs11935596	ENSG00000120555.12	SEPT7P9	7.62	5.5e-14	5.91e-08	0.29	0.23	Corneal astigmatism;	chr4:119491302	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.954	rs12507964	ENSG00000120555.12	SEPT7P9	7.62	5.5e-14	5.91e-08	0.29	0.23	Corneal astigmatism;	chr4:119491906	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.909	rs11098530	ENSG00000120555.12	SEPT7P9	7.62	5.5e-14	5.91e-08	0.29	0.23	Corneal astigmatism;	chr4:119491999	chr10:38383069~38402916:-
BRCA	trans	rs3806843	0.547	rs246065	ENSG00000231043.3	AC007238.1	-7.62	5.54e-14	5.95e-08	-0.28	-0.23	Depressive symptoms (multi-trait analysis);	chr5:140944053	chr2:58460292~58462032:-
BRCA	trans	rs3806843	0.576	rs155358	ENSG00000231043.3	AC007238.1	-7.62	5.56e-14	5.97e-08	-0.28	-0.23	Depressive symptoms (multi-trait analysis);	chr5:140917447	chr2:58460292~58462032:-
BRCA	trans	rs877636	0.702	rs773110	ENSG00000224553.1	AC008065.1	7.62	5.61e-14	6.01e-08	0.29	0.23	Cognitive function;	chr12:55981353	chr2:171374931~171375278:-
BRCA	trans	rs67180937	0.645	rs1909197	ENSG00000219201.4	RP11-181C21.4	-7.62	5.69e-14	6.1e-08	-0.29	-0.23	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222645879	chr1:77810861~77811781:-
BRCA	trans	rs13016963	0.604	rs11674814	ENSG00000235105.1	RP11-329A14.1	-7.62	5.77e-14	6.18e-08	-0.29	-0.23	Esophageal squamous cell carcinoma;Melanoma;	chr2:201289123	chr1:48435967~48437223:+
BRCA	trans	rs6601327	0.898	rs1458942	ENSG00000253893.2	FAM85B	7.62	5.79e-14	6.21e-08	0.31	0.23	Multiple myeloma (hyperdiploidy);	chr8:9549092	chr8:8167819~8226614:-
BRCA	trans	rs12210905	0.688	rs72841376	ENSG00000242375.1	RP11-498P14.3	-7.62	5.79e-14	6.21e-08	-0.6	-0.23	Hip circumference adjusted for BMI;	chr6:27488542	chr9:97195351~97197687:-
BRCA	trans	rs11172055	0.775	rs10876940	ENSG00000121089.4	NACA3P	7.62	5.8e-14	6.22e-08	0.26	0.23	Migraine;	chr12:56871233	chr4:164943290~164943937:+
BRCA	trans	rs853679	0.824	rs34712084	ENSG00000253570.1	RNF5P1	7.62	5.82e-14	6.23e-08	0.53	0.23	Depression;	chr6:28076050	chr8:38600661~38601200:-
BRCA	trans	rs853679	0.824	rs1321505	ENSG00000253570.1	RNF5P1	7.62	5.82e-14	6.23e-08	0.53	0.23	Depression;	chr6:28085045	chr8:38600661~38601200:-
BRCA	trans	rs11098499	0.913	rs11098496	ENSG00000120555.12	SEPT7P9	7.62	5.82e-14	6.24e-08	0.28	0.23	Corneal astigmatism;	chr4:119246311	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.954	rs12510138	ENSG00000276997.3	RP11-378J18.9	7.62	5.83e-14	6.25e-08	0.28	0.23	Corneal astigmatism;	chr4:119502780	chr1:222477252~222504622:-
BRCA	trans	rs3806843	0.576	rs251373	ENSG00000231043.3	AC007238.1	7.62	5.84e-14	6.25e-08	0.28	0.23	Depressive symptoms (multi-trait analysis);	chr5:140873030	chr2:58460292~58462032:-
BRCA	trans	rs3806843	0.545	rs251375	ENSG00000231043.3	AC007238.1	7.62	5.84e-14	6.25e-08	0.28	0.23	Depressive symptoms (multi-trait analysis);	chr5:140873375	chr2:58460292~58462032:-
BRCA	trans	rs13016963	0.604	rs12622439	ENSG00000235105.1	RP11-329A14.1	7.62	5.88e-14	6.3e-08	0.29	0.23	Esophageal squamous cell carcinoma;Melanoma;	chr2:201311179	chr1:48435967~48437223:+
BRCA	trans	rs1707322	0.717	rs11211161	ENSG00000255397.1	AC022182.2	-7.62	5.88e-14	6.3e-08	-0.31	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45682466	chr8:60937705~60939871:-
BRCA	trans	rs3849046	0.781	rs10070909	ENSG00000226666.1	HSPA9P1	7.61	5.96e-14	6.38e-08	0.26	0.23	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138581104	chr2:221961737~221963765:+
BRCA	trans	rs3849046	0.817	rs9968657	ENSG00000226666.1	HSPA9P1	7.61	5.96e-14	6.38e-08	0.26	0.23	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138584741	chr2:221961737~221963765:+
BRCA	trans	rs7929679	0.846	rs7933927	ENSG00000225531.1	RP11-196I18.3	7.61	5.99e-14	6.41e-08	0.29	0.23	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;	chr11:34778252	chr9:107116829~107117557:+
BRCA	trans	rs1707322	0.752	rs28550303	ENSG00000255397.1	AC022182.2	-7.61	5.99e-14	6.42e-08	-0.31	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45723242	chr8:60937705~60939871:-
BRCA	trans	rs12477438	0.52	rs11123763	ENSG00000276576.1	MRPL30P1	7.61	6.05e-14	6.47e-08	0.29	0.23	Chronic sinus infection;	chr2:99134210	chr6:57029521~57029988:+
BRCA	trans	rs11098499	0.954	rs17006190	ENSG00000276997.3	RP11-378J18.9	7.61	6.09e-14	6.51e-08	0.29	0.23	Corneal astigmatism;	chr4:119497683	chr1:222477252~222504622:-
BRCA	trans	rs13016963	0.526	rs11687854	ENSG00000235105.1	RP11-329A14.1	7.61	6.1e-14	6.52e-08	0.28	0.23	Esophageal squamous cell carcinoma;Melanoma;	chr2:201363879	chr1:48435967~48437223:+
BRCA	trans	rs3849046	0.817	rs4835689	ENSG00000226666.1	HSPA9P1	7.61	6.16e-14	6.58e-08	0.26	0.23	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138580078	chr2:221961737~221963765:+
BRCA	trans	rs7200543	1	rs16966953	ENSG00000250569.1	NTAN1P2	7.61	6.17e-14	6.6e-08	0.25	0.23	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15041997	chr8:86481754~86483002:-
BRCA	trans	rs11098499	0.908	rs28559989	ENSG00000276997.3	RP11-378J18.9	7.61	6.2e-14	6.63e-08	0.28	0.23	Corneal astigmatism;	chr4:119465472	chr1:222477252~222504622:-
BRCA	trans	rs3849046	0.817	rs9327813	ENSG00000226666.1	HSPA9P1	7.61	6.22e-14	6.65e-08	0.26	0.23	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138528732	chr2:221961737~221963765:+
BRCA	trans	rs3849046	0.817	rs7711958	ENSG00000226666.1	HSPA9P1	7.61	6.3e-14	6.72e-08	0.26	0.23	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138565812	chr2:221961737~221963765:+
BRCA	trans	rs26067	0.689	rs285529	ENSG00000231752.4	EMBP1	-7.6	6.4e-14	6.83e-08	-0.3	-0.23	Breast cancer;	chr5:50843452	chr1:121519112~121571892:+
BRCA	trans	rs1816752	0.875	rs3783076	ENSG00000224976.2	PARP4P2	-7.6	6.41e-14	6.84e-08	-0.29	-0.23	Obesity-related traits;	chr13:24490319	chr13:19349137~19407962:+
BRCA	trans	rs60515486	0.646	rs753812	ENSG00000134612.10	FOLH1B	7.6	6.45e-14	6.88e-08	0.37	0.23	Lymphocyte counts;	chr11:47409978	chr11:89639227~89698718:+
BRCA	trans	rs11951515	0.508	rs6860493	ENSG00000174977.8	AC026271.5	-7.6	6.45e-14	6.89e-08	-0.27	-0.23	Metabolite levels  (X-11787);	chr5:43602611	chr17:18650195~18651542:+
BRCA	trans	rs11098499	0.954	rs7681544	ENSG00000120555.12	SEPT7P9	7.6	6.47e-14	6.9e-08	0.28	0.23	Corneal astigmatism;	chr4:119490100	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.954	rs10006877	ENSG00000276997.3	RP11-378J18.9	7.6	6.48e-14	6.91e-08	0.28	0.23	Corneal astigmatism;	chr4:119321638	chr1:222477252~222504622:-
BRCA	trans	rs877636	0.74	rs705698	ENSG00000243538.1	CTB-55B8.1	7.6	6.53e-14	6.96e-08	0.29	0.23	Cognitive function;	chr12:55990903	chr5:16902294~16902641:-
BRCA	trans	rs66887589	0.777	rs10015883	ENSG00000275858.1	RP11-291L22.8	7.6	6.55e-14	6.99e-08	0.25	0.23	Diastolic blood pressure;	chr4:119346991	chr10:38450738~38451069:-
BRCA	trans	rs7200543	1	rs7200543	ENSG00000250569.1	NTAN1P2	-7.6	6.56e-14	6.99e-08	-0.25	-0.23	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15036113	chr8:86481754~86483002:-
BRCA	trans	rs11098499	0.954	rs878373	ENSG00000276997.3	RP11-378J18.9	7.6	6.56e-14	7e-08	0.28	0.23	Corneal astigmatism;	chr4:119316329	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.954	rs10031483	ENSG00000120555.12	SEPT7P9	7.6	6.59e-14	7.02e-08	0.29	0.23	Corneal astigmatism;	chr4:119501481	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.954	rs10031665	ENSG00000120555.12	SEPT7P9	7.6	6.59e-14	7.02e-08	0.29	0.23	Corneal astigmatism;	chr4:119501697	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.954	rs3733523	ENSG00000120555.12	SEPT7P9	7.6	6.59e-14	7.02e-08	0.29	0.23	Corneal astigmatism;	chr4:119502564	chr10:38383069~38402916:-
BRCA	trans	rs6011368	0.585	rs13043326	ENSG00000226210.3	WASH7P	7.6	6.68e-14	7.12e-08	0.26	0.23	Clozapine-induced cytotoxicity;	chr20:64282739	chr12:14522~32015:-
BRCA	trans	rs864643	0.735	rs76417541	ENSG00000188856.6	RPSAP47	7.6	6.69e-14	7.13e-08	0.46	0.23	Attention deficit hyperactivity disorder;	chr3:39519802	chr8:80558870~80559757:+
BRCA	trans	rs11098499	0.954	rs7681544	ENSG00000276997.3	RP11-378J18.9	7.6	6.7e-14	7.15e-08	0.28	0.23	Corneal astigmatism;	chr4:119490100	chr1:222477252~222504622:-
BRCA	trans	rs13016963	0.604	rs2080302	ENSG00000235105.1	RP11-329A14.1	7.6	6.72e-14	7.16e-08	0.29	0.23	Esophageal squamous cell carcinoma;Melanoma;	chr2:201300358	chr1:48435967~48437223:+
BRCA	trans	rs4295623	0.531	rs2898295	ENSG00000253893.2	FAM85B	7.6	6.75e-14	7.19e-08	0.29	0.23	Morning vs. evening chronotype;	chr8:11738460	chr8:8167819~8226614:-
BRCA	trans	rs12477438	0.52	rs7604557	ENSG00000276576.1	MRPL30P1	7.6	6.79e-14	7.23e-08	0.28	0.23	Chronic sinus infection;	chr2:99131366	chr6:57029521~57029988:+
BRCA	trans	rs12477438	0.52	rs11685759	ENSG00000276576.1	MRPL30P1	7.6	6.79e-14	7.23e-08	0.28	0.23	Chronic sinus infection;	chr2:99149754	chr6:57029521~57029988:+
BRCA	trans	rs12477438	0.52	rs11123765	ENSG00000276576.1	MRPL30P1	7.6	6.79e-14	7.23e-08	0.28	0.23	Chronic sinus infection;	chr2:99151601	chr6:57029521~57029988:+
BRCA	trans	rs12477438	0.501	rs2632260	ENSG00000276576.1	MRPL30P1	7.6	6.79e-14	7.23e-08	0.28	0.23	Chronic sinus infection;	chr2:99155127	chr6:57029521~57029988:+
BRCA	trans	rs13016963	0.604	rs7570324	ENSG00000235105.1	RP11-329A14.1	-7.6	6.82e-14	7.27e-08	-0.28	-0.23	Esophageal squamous cell carcinoma;Melanoma;	chr2:201320881	chr1:48435967~48437223:+
BRCA	trans	rs11098499	0.954	rs6834796	ENSG00000120555.12	SEPT7P9	7.59	6.9e-14	7.35e-08	0.28	0.23	Corneal astigmatism;	chr4:119493538	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.954	rs11734241	ENSG00000120555.12	SEPT7P9	7.59	6.9e-14	7.35e-08	0.28	0.23	Corneal astigmatism;	chr4:119495717	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.954	rs28685688	ENSG00000120555.12	SEPT7P9	7.59	6.9e-14	7.35e-08	0.29	0.23	Corneal astigmatism;	chr4:119499179	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.954	rs7687843	ENSG00000120555.12	SEPT7P9	7.59	6.9e-14	7.35e-08	0.29	0.23	Corneal astigmatism;	chr4:119500056	chr10:38383069~38402916:-
BRCA	trans	rs801193	0.967	rs2707853	ENSG00000164669.11	INTS4P1	-7.59	6.93e-14	7.38e-08	-0.28	-0.23	Aortic root size;	chr7:66749023	chr7:65141225~65234216:+
BRCA	trans	rs12210905	0.688	rs10456051	ENSG00000242375.1	RP11-498P14.3	-7.59	6.93e-14	7.38e-08	-0.59	-0.23	Hip circumference adjusted for BMI;	chr6:27495657	chr9:97195351~97197687:-
BRCA	trans	rs12210905	0.541	rs62617138	ENSG00000242375.1	RP11-498P14.3	-7.59	6.93e-14	7.38e-08	-0.59	-0.23	Hip circumference adjusted for BMI;	chr6:27495987	chr9:97195351~97197687:-
BRCA	trans	rs11098499	0.954	rs12502423	ENSG00000276997.3	RP11-378J18.9	7.59	6.95e-14	7.4e-08	0.28	0.23	Corneal astigmatism;	chr4:119503017	chr1:222477252~222504622:-
BRCA	trans	rs9914988	0.832	rs12946132	ENSG00000267449.1	RP11-264B14.2	7.59	6.96e-14	7.41e-08	0.32	0.23	Glycated hemoglobin levels;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr17:28830344	chr17:61069856~61070356:-
BRCA	trans	rs9914988	0.832	rs34267753	ENSG00000267449.1	RP11-264B14.2	7.59	6.96e-14	7.41e-08	0.32	0.23	Glycated hemoglobin levels;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr17:28830568	chr17:61069856~61070356:-
BRCA	trans	rs9914988	0.943	rs2874253	ENSG00000267449.1	RP11-264B14.2	7.59	6.96e-14	7.41e-08	0.32	0.23	Glycated hemoglobin levels;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr17:28830845	chr17:61069856~61070356:-
BRCA	trans	rs7200543	1	rs2740	ENSG00000250569.1	NTAN1P2	7.59	7e-14	7.45e-08	0.25	0.23	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15038251	chr8:86481754~86483002:-
BRCA	trans	rs7944735	0.508	rs75814357	ENSG00000134612.10	FOLH1B	7.59	7.03e-14	7.49e-08	0.43	0.23	Intraocular pressure;	chr11:47867077	chr11:89639227~89698718:+
BRCA	trans	rs4720118	0.875	rs9784973	ENSG00000213492.2	NT5C3AP1	-7.59	7.08e-14	7.53e-08	-0.29	-0.23	Leprosy;	chr7:33350077	chr4:117574512~117576174:-
BRCA	trans	rs9467711	0.606	rs1977	ENSG00000253570.1	RNF5P1	7.59	7.08e-14	7.53e-08	0.53	0.23	Autism spectrum disorder or schizophrenia;	chr6:26377318	chr8:38600661~38601200:-
BRCA	trans	rs12477438	0.52	rs6717723	ENSG00000276576.1	MRPL30P1	7.59	7.1e-14	7.55e-08	0.28	0.23	Chronic sinus infection;	chr2:99140467	chr6:57029521~57029988:+
BRCA	trans	rs1707322	0.752	rs12062535	ENSG00000255397.1	AC022182.2	-7.59	7.12e-14	7.57e-08	-0.31	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45757208	chr8:60937705~60939871:-
BRCA	trans	rs1707322	0.716	rs10890342	ENSG00000255397.1	AC022182.2	-7.59	7.12e-14	7.58e-08	-0.31	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45691415	chr8:60937705~60939871:-
BRCA	trans	rs1707322	0.752	rs6658700	ENSG00000255397.1	AC022182.2	-7.59	7.12e-14	7.58e-08	-0.31	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45694588	chr8:60937705~60939871:-
BRCA	trans	rs1707322	0.752	rs12047629	ENSG00000255397.1	AC022182.2	-7.59	7.12e-14	7.58e-08	-0.31	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45697130	chr8:60937705~60939871:-
BRCA	trans	rs1707322	0.752	rs11211171	ENSG00000255397.1	AC022182.2	-7.59	7.12e-14	7.58e-08	-0.31	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45702970	chr8:60937705~60939871:-
BRCA	trans	rs1707322	0.752	rs28623463	ENSG00000255397.1	AC022182.2	-7.59	7.12e-14	7.58e-08	-0.31	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45705086	chr8:60937705~60939871:-
BRCA	trans	rs1707322	0.716	rs28370457	ENSG00000255397.1	AC022182.2	-7.59	7.12e-14	7.58e-08	-0.31	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45706390	chr8:60937705~60939871:-
BRCA	trans	rs546131	0.642	rs523246	ENSG00000225531.1	RP11-196I18.3	7.59	7.16e-14	7.61e-08	0.34	0.23	Lung disease severity in cystic fibrosis;	chr11:34823464	chr9:107116829~107117557:+
BRCA	trans	rs4879656	0.564	rs1537253	ENSG00000215007.3	DNAJA1P3	-7.59	7.22e-14	7.67e-08	-0.27	-0.23	Menopause (age at onset);	chr9:32983373	chrX:107351650~107352843:-
BRCA	trans	rs641862	1	rs641862	ENSG00000276248.1	RP11-230F18.5	7.59	7.24e-14	7.69e-08	0.41	0.23	Obesity-related traits;	chr13:110137885	chr13:113527260~113530621:+
BRCA	trans	rs1459104	0.778	rs67930054	ENSG00000134612.10	FOLH1B	7.59	7.26e-14	7.69e-08	0.54	0.23	Body mass index;	chr11:56033116	chr11:89639227~89698718:+
BRCA	trans	rs7939886	0.92	rs7946368	ENSG00000134612.10	FOLH1B	7.59	7.26e-14	7.69e-08	0.54	0.23	Myopia (pathological);	chr11:56036743	chr11:89639227~89698718:+
BRCA	trans	rs941207	0.762	rs10450	ENSG00000228224.3	NACAP1	7.59	7.3e-14	7.74e-08	0.27	0.23	Platelet count;	chr12:56590822	chr8:101361794~101372707:+
BRCA	trans	rs877636	1	rs4759229	ENSG00000224553.1	AC008065.1	-7.58	7.52e-14	7.95e-08	-0.27	-0.23	Cognitive function;	chr12:56080696	chr2:171374931~171375278:-
BRCA	trans	rs3849046	0.817	rs2304057	ENSG00000226666.1	HSPA9P1	7.58	7.61e-14	8.04e-08	0.26	0.23	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138561485	chr2:221961737~221963765:+
BRCA	trans	rs7833986	0.501	rs72653957	ENSG00000244245.1	RP11-120B7.1	7.58	7.66e-14	8.1e-08	0.29	0.23	Height;	chr8:56077489	chr5:108593609~108593967:+
BRCA	trans	rs11098499	0.909	rs71614422	ENSG00000276997.3	RP11-378J18.9	7.58	7.69e-14	8.12e-08	0.28	0.23	Corneal astigmatism;	chr4:119438185	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.954	rs2306455	ENSG00000120555.12	SEPT7P9	7.58	7.8e-14	8.24e-08	0.29	0.23	Corneal astigmatism;	chr4:119500814	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.954	rs11729521	ENSG00000120555.12	SEPT7P9	7.58	7.85e-14	8.29e-08	0.28	0.23	Corneal astigmatism;	chr4:119495633	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.955	rs1397608	ENSG00000120555.12	SEPT7P9	7.58	7.88e-14	8.32e-08	0.28	0.23	Corneal astigmatism;	chr4:119240589	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.955	rs7685268	ENSG00000120555.12	SEPT7P9	7.58	7.88e-14	8.32e-08	0.28	0.23	Corneal astigmatism;	chr4:119241033	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.955	rs7684942	ENSG00000120555.12	SEPT7P9	7.58	7.88e-14	8.32e-08	0.28	0.23	Corneal astigmatism;	chr4:119241046	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.954	rs6834796	ENSG00000276997.3	RP11-378J18.9	7.57	7.91e-14	8.35e-08	0.28	0.23	Corneal astigmatism;	chr4:119493538	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.954	rs11734241	ENSG00000276997.3	RP11-378J18.9	7.57	7.91e-14	8.35e-08	0.28	0.23	Corneal astigmatism;	chr4:119495717	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.954	rs11940028	ENSG00000276997.3	RP11-378J18.9	7.57	7.92e-14	8.35e-08	0.28	0.23	Corneal astigmatism;	chr4:119490752	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.954	rs11935596	ENSG00000276997.3	RP11-378J18.9	7.57	7.92e-14	8.35e-08	0.28	0.23	Corneal astigmatism;	chr4:119491302	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.954	rs12507964	ENSG00000276997.3	RP11-378J18.9	7.57	7.92e-14	8.35e-08	0.28	0.23	Corneal astigmatism;	chr4:119491906	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.909	rs11098530	ENSG00000276997.3	RP11-378J18.9	7.57	7.92e-14	8.35e-08	0.28	0.23	Corneal astigmatism;	chr4:119491999	chr1:222477252~222504622:-
BRCA	trans	rs1707322	0.717	rs3014246	ENSG00000255397.1	AC022182.2	7.57	7.92e-14	8.36e-08	0.31	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45620405	chr8:60937705~60939871:-
BRCA	trans	rs3096299	0.582	rs12935119	ENSG00000215030.5	RPL13P12	-7.57	7.93e-14	8.36e-08	-0.23	-0.23	Multiple myeloma (IgH translocation);	chr16:89476466	chr17:17383377~17384012:-
BRCA	trans	rs11098499	0.863	rs10019674	ENSG00000276997.3	RP11-378J18.9	-7.57	7.98e-14	8.42e-08	-0.29	-0.23	Corneal astigmatism;	chr4:119522334	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.954	rs1480931	ENSG00000276997.3	RP11-378J18.9	7.57	8.02e-14	8.46e-08	0.28	0.23	Corneal astigmatism;	chr4:119474654	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.954	rs12499324	ENSG00000276997.3	RP11-378J18.9	7.57	8.02e-14	8.46e-08	0.28	0.23	Corneal astigmatism;	chr4:119472631	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.954	rs9998585	ENSG00000276997.3	RP11-378J18.9	7.57	8.03e-14	8.46e-08	0.28	0.23	Corneal astigmatism;	chr4:119475647	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.909	rs6842762	ENSG00000276997.3	RP11-378J18.9	7.57	8.03e-14	8.46e-08	0.28	0.23	Corneal astigmatism;	chr4:119477081	chr1:222477252~222504622:-
BRCA	trans	rs7200543	1	rs1121	ENSG00000250569.1	NTAN1P2	7.57	8.04e-14	8.47e-08	0.25	0.23	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15037219	chr8:86481754~86483002:-
BRCA	trans	rs11512640	1	rs11220120	ENSG00000236257.1	EI24P2	7.57	8.1e-14	8.53e-08	0.51	0.23	Peripheral arterial disease (traffic-related air pollution interaction);	chr11:125529894	chr1:158454198~158455273:+
BRCA	trans	rs9584850	0.718	rs6491427	ENSG00000230079.1	STK24P1	7.57	8.11e-14	8.55e-08	0.31	0.23	Neuroticism;	chr13:98460912	chrX:136295690~136300298:-
BRCA	trans	rs12477438	0.52	rs11689265	ENSG00000276576.1	MRPL30P1	7.57	8.12e-14	8.55e-08	0.28	0.23	Chronic sinus infection;	chr2:99182804	chr6:57029521~57029988:+
BRCA	trans	rs11098499	0.908	rs2017057	ENSG00000276997.3	RP11-378J18.9	7.57	8.14e-14	8.58e-08	0.28	0.23	Corneal astigmatism;	chr4:119336556	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.909	rs9759478	ENSG00000120555.12	SEPT7P9	7.57	8.18e-14	8.62e-08	0.29	0.23	Corneal astigmatism;	chr4:119446843	chr10:38383069~38402916:-
BRCA	trans	rs3849046	0.817	rs34629616	ENSG00000226666.1	HSPA9P1	7.57	8.22e-14	8.66e-08	0.26	0.23	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138532917	chr2:221961737~221963765:+
BRCA	trans	rs3806843	0.576	rs246066	ENSG00000231043.3	AC007238.1	-7.57	8.3e-14	8.75e-08	-0.28	-0.23	Depressive symptoms (multi-trait analysis);	chr5:140943562	chr2:58460292~58462032:-
BRCA	trans	rs7833986	0.501	rs72653953	ENSG00000244245.1	RP11-120B7.1	7.57	8.32e-14	8.76e-08	0.29	0.23	Height;	chr8:56058236	chr5:108593609~108593967:+
BRCA	trans	rs1707322	0.752	rs11211169	ENSG00000255397.1	AC022182.2	-7.57	8.35e-14	8.79e-08	-0.31	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45701037	chr8:60937705~60939871:-
BRCA	trans	rs2243480	1	rs6460260	ENSG00000273142.1	RP11-458F8.4	7.57	8.4e-14	8.84e-08	0.31	0.23	Diabetic kidney disease;	chr7:65750468	chr7:66902857~66906297:+
BRCA	trans	rs2243480	1	rs6460261	ENSG00000273142.1	RP11-458F8.4	7.57	8.4e-14	8.84e-08	0.31	0.23	Diabetic kidney disease;	chr7:65750593	chr7:66902857~66906297:+
BRCA	trans	rs864643	0.678	rs1707953	ENSG00000188856.6	RPSAP47	7.57	8.42e-14	8.86e-08	0.33	0.23	Attention deficit hyperactivity disorder;	chr3:39483918	chr8:80558870~80559757:+
BRCA	trans	rs864643	0.678	rs683089	ENSG00000188856.6	RPSAP47	7.57	8.42e-14	8.86e-08	0.33	0.23	Attention deficit hyperactivity disorder;	chr3:39484334	chr8:80558870~80559757:+
BRCA	trans	rs864643	0.678	rs590805	ENSG00000188856.6	RPSAP47	7.57	8.42e-14	8.86e-08	0.33	0.23	Attention deficit hyperactivity disorder;	chr3:39485463	chr8:80558870~80559757:+
BRCA	trans	rs11098499	0.863	rs6534139	ENSG00000276997.3	RP11-378J18.9	-7.57	8.44e-14	8.89e-08	-0.29	-0.23	Corneal astigmatism;	chr4:119528301	chr1:222477252~222504622:-
BRCA	trans	rs9329221	0.572	rs4841295	ENSG00000253893.2	FAM85B	-7.56	8.58e-14	9.03e-08	-0.29	-0.23	Neuroticism;	chr8:10247605	chr8:8167819~8226614:-
BRCA	trans	rs801193	1	rs2659889	ENSG00000164669.11	INTS4P1	-7.56	8.61e-14	9.06e-08	-0.28	-0.23	Aortic root size;	chr7:66752125	chr7:65141225~65234216:+
BRCA	trans	rs73108077	1	rs75774213	ENSG00000279352.1	RP11-411B10.7	7.56	8.63e-14	9.08e-08	0.51	0.23	Red blood cell density in sickle cell anemia;	chr20:31462439	chr18:14010054~14010917:+
BRCA	trans	rs656319	0.629	rs10111315	ENSG00000253893.2	FAM85B	7.56	8.7e-14	9.15e-08	0.29	0.23	Myopia (pathological);	chr8:10008078	chr8:8167819~8226614:-
BRCA	trans	rs11098499	0.954	rs6849561	ENSG00000276997.3	RP11-378J18.9	-7.56	8.7e-14	9.15e-08	-0.29	-0.23	Corneal astigmatism;	chr4:119488539	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.954	rs11729521	ENSG00000276997.3	RP11-378J18.9	7.56	8.71e-14	9.16e-08	0.28	0.23	Corneal astigmatism;	chr4:119495633	chr1:222477252~222504622:-
BRCA	trans	rs2736345	0.755	rs2736340	ENSG00000253893.2	FAM85B	-7.56	8.72e-14	9.17e-08	-0.34	-0.23	Systemic lupus erythematosus;Sjögren's syndrome;	chr8:11486464	chr8:8167819~8226614:-
BRCA	trans	rs11098499	0.954	rs6848389	ENSG00000276997.3	RP11-378J18.9	7.56	8.88e-14	9.34e-08	0.28	0.23	Corneal astigmatism;	chr4:119481467	chr1:222477252~222504622:-
BRCA	trans	rs7824557	0.815	rs958648	ENSG00000253893.2	FAM85B	7.56	8.9e-14	9.36e-08	0.28	0.23	Retinal vascular caliber;	chr8:11246386	chr8:8167819~8226614:-
BRCA	trans	rs13014235	0.579	rs6745435	ENSG00000235105.1	RP11-329A14.1	7.56	8.98e-14	9.44e-08	0.27	0.23	Basal cell carcinoma;	chr2:201337840	chr1:48435967~48437223:+
BRCA	trans	rs13014235	0.644	rs10201587	ENSG00000235105.1	RP11-329A14.1	7.56	8.98e-14	9.44e-08	0.27	0.23	Basal cell carcinoma;	chr2:201338068	chr1:48435967~48437223:+
BRCA	trans	rs11920570	0.959	rs11922454	ENSG00000267076.1	CCDC58P3	-7.56	9e-14	9.45e-08	-0.3	-0.23	Resting heart rate;	chr3:122443594	chr18:12211378~12211807:+
BRCA	trans	rs801193	1	rs3778909	ENSG00000164669.11	INTS4P1	-7.56	9.04e-14	9.5e-08	-0.28	-0.23	Aortic root size;	chr7:66790659	chr7:65141225~65234216:+
BRCA	trans	rs9914988	0.943	rs67327562	ENSG00000267449.1	RP11-264B14.2	7.56	9.04e-14	9.5e-08	0.32	0.23	Glycated hemoglobin levels;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr17:28781810	chr17:61069856~61070356:-
BRCA	trans	rs9914988	0.725	rs66531973	ENSG00000267449.1	RP11-264B14.2	7.56	9.04e-14	9.5e-08	0.32	0.23	Glycated hemoglobin levels;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr17:28798975	chr17:61069856~61070356:-
BRCA	trans	rs7929679	0.846	rs2136509	ENSG00000225531.1	RP11-196I18.3	7.56	9.07e-14	9.53e-08	0.29	0.23	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;	chr11:34775257	chr9:107116829~107117557:+
BRCA	trans	rs7929679	0.846	rs7116210	ENSG00000225531.1	RP11-196I18.3	7.56	9.07e-14	9.53e-08	0.29	0.23	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;	chr11:34775808	chr9:107116829~107117557:+
BRCA	trans	rs877636	1	rs705696	ENSG00000224553.1	AC008065.1	7.56	9.08e-14	9.53e-08	0.29	0.23	Cognitive function;	chr12:56086864	chr2:171374931~171375278:-
BRCA	trans	rs1707322	0.752	rs28890893	ENSG00000255397.1	AC022182.2	-7.56	9.13e-14	9.58e-08	-0.31	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45720904	chr8:60937705~60939871:-
BRCA	trans	rs11098499	0.909	rs11723757	ENSG00000120555.12	SEPT7P9	7.56	9.13e-14	9.59e-08	0.28	0.23	Corneal astigmatism;	chr4:119378514	chr10:38383069~38402916:-
BRCA	trans	rs1933488	1	rs4083914	ENSG00000278974.1	RP11-756P10.6	7.55	9.15e-14	9.61e-08	0.3	0.23	Prostate cancer;	chr6:153106571	chr4:188740507~188741281:-
BRCA	trans	rs6915893	0.967	rs12199316	ENSG00000267156.1	TPMTP1	7.55	9.16e-14	9.61e-08	0.28	0.23	Intrinsic epigenetic age acceleration;	chr6:18123271	chr18:47630112~47630848:+
BRCA	trans	rs12477438	0.52	rs13010904	ENSG00000276576.1	MRPL30P1	7.55	9.24e-14	9.7e-08	0.28	0.23	Chronic sinus infection;	chr2:99137826	chr6:57029521~57029988:+
BRCA	trans	rs12477438	0.52	rs13012481	ENSG00000276576.1	MRPL30P1	7.55	9.24e-14	9.7e-08	0.28	0.23	Chronic sinus infection;	chr2:99137827	chr6:57029521~57029988:+
BRCA	trans	rs11098499	0.954	rs4577559	ENSG00000120555.12	SEPT7P9	7.55	9.25e-14	9.71e-08	0.28	0.23	Corneal astigmatism;	chr4:119482888	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.954	rs7656252	ENSG00000120555.12	SEPT7P9	7.55	9.25e-14	9.71e-08	0.28	0.23	Corneal astigmatism;	chr4:119483113	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.865	rs28845498	ENSG00000120555.12	SEPT7P9	7.55	9.25e-14	9.71e-08	0.28	0.23	Corneal astigmatism;	chr4:119484031	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.954	rs56270433	ENSG00000120555.12	SEPT7P9	7.55	9.25e-14	9.71e-08	0.28	0.23	Corneal astigmatism;	chr4:119484875	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.954	rs10518328	ENSG00000120555.12	SEPT7P9	7.55	9.26e-14	9.72e-08	0.28	0.23	Corneal astigmatism;	chr4:119480624	chr10:38383069~38402916:-
BRCA	trans	rs3806843	0.583	rs408652	ENSG00000231043.3	AC007238.1	-7.55	9.27e-14	9.73e-08	-0.27	-0.23	Depressive symptoms (multi-trait analysis);	chr5:140950428	chr2:58460292~58462032:-
BRCA	trans	rs3849046	0.79	rs13187637	ENSG00000226666.1	HSPA9P1	7.55	9.3e-14	9.77e-08	0.26	0.23	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138540962	chr2:221961737~221963765:+
BRCA	trans	rs7833986	0.501	rs17814658	ENSG00000244245.1	RP11-120B7.1	7.55	9.43e-14	9.89e-08	0.29	0.23	Height;	chr8:56076571	chr5:108593609~108593967:+
BRCA	trans	rs10783779	0.647	rs705708	ENSG00000225071.1	GS1-184P14.2	7.55	9.62e-14	1.01e-07	0.26	0.23	Educational attainment;	chr12:56095129	chrX:24429573~24429920:-
BRCA	trans	rs7944735	0.508	rs4752786	ENSG00000134612.10	FOLH1B	7.55	9.64e-14	1.01e-07	0.36	0.23	Intraocular pressure;	chr11:47606984	chr11:89639227~89698718:+
BRCA	trans	rs3806843	0.576	rs246074	ENSG00000231043.3	AC007238.1	-7.55	9.66e-14	1.01e-07	-0.27	-0.23	Depressive symptoms (multi-trait analysis);	chr5:140928384	chr2:58460292~58462032:-
BRCA	trans	rs2288327	0.673	rs35504893	ENSG00000269800.1	PLEKHA3P1	7.55	9.67e-14	1.01e-07	0.29	0.23	Atrial fibrillation;	chr2:178556567	chr19:41521043~41521989:-
BRCA	trans	rs11098499	0.954	rs12499324	ENSG00000120555.12	SEPT7P9	7.55	9.67e-14	1.01e-07	0.28	0.23	Corneal astigmatism;	chr4:119472631	chr10:38383069~38402916:-
BRCA	trans	rs1707322	0.716	rs28375469	ENSG00000255397.1	AC022182.2	-7.55	9.81e-14	1.03e-07	-0.31	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45729703	chr8:60937705~60939871:-
BRCA	trans	rs1707322	0.752	rs28545085	ENSG00000255397.1	AC022182.2	-7.55	9.81e-14	1.03e-07	-0.31	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45736278	chr8:60937705~60939871:-
BRCA	trans	rs1707322	0.752	rs28812624	ENSG00000255397.1	AC022182.2	-7.55	9.81e-14	1.03e-07	-0.31	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45738064	chr8:60937705~60939871:-
BRCA	trans	rs1707322	0.752	rs28507722	ENSG00000255397.1	AC022182.2	-7.55	9.81e-14	1.03e-07	-0.31	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45740868	chr8:60937705~60939871:-
BRCA	trans	rs1707322	0.752	rs28568986	ENSG00000255397.1	AC022182.2	-7.55	9.81e-14	1.03e-07	-0.31	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45742071	chr8:60937705~60939871:-
BRCA	trans	rs1707322	0.717	rs28396194	ENSG00000255397.1	AC022182.2	-7.55	9.81e-14	1.03e-07	-0.31	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45747555	chr8:60937705~60939871:-
BRCA	trans	rs1707322	0.717	rs28752166	ENSG00000255397.1	AC022182.2	-7.55	9.81e-14	1.03e-07	-0.31	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45747637	chr8:60937705~60939871:-
BRCA	trans	rs1707322	0.717	rs10890345	ENSG00000255397.1	AC022182.2	-7.55	9.81e-14	1.03e-07	-0.31	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45748255	chr8:60937705~60939871:-
BRCA	trans	rs1707322	0.721	rs10789471	ENSG00000255397.1	AC022182.2	-7.55	9.81e-14	1.03e-07	-0.31	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45749947	chr8:60937705~60939871:-
BRCA	trans	rs1707322	0.752	rs11211173	ENSG00000255397.1	AC022182.2	-7.55	9.81e-14	1.03e-07	-0.31	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45753704	chr8:60937705~60939871:-
BRCA	trans	rs66887589	0.777	rs4643791	ENSG00000275858.1	RP11-291L22.8	-7.54	9.86e-14	1.03e-07	-0.25	-0.23	Diastolic blood pressure;	chr4:119344464	chr10:38450738~38451069:-
BRCA	trans	rs1707322	0.721	rs4559551	ENSG00000255397.1	AC022182.2	-7.54	9.9e-14	1.04e-07	-0.31	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45701861	chr8:60937705~60939871:-
BRCA	trans	rs11638815	0.668	rs1877242	ENSG00000235370.6	DNM1P51	7.54	9.93e-14	1.04e-07	0.26	0.23	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82728706	chr15:84398316~84411701:-
BRCA	trans	rs6732160	0.588	rs2043101	ENSG00000236165.1	PRADC1P1	7.54	9.94e-14	1.04e-07	0.31	0.23	Intelligence (multi-trait analysis);	chr2:73146922	chr3:36976316~36976840:+
BRCA	trans	rs7833986	0.501	rs2953909	ENSG00000244245.1	RP11-120B7.1	7.54	1e-13	1.05e-07	0.29	0.23	Height;	chr8:56055641	chr5:108593609~108593967:+
BRCA	trans	rs7833986	0.501	rs2953910	ENSG00000244245.1	RP11-120B7.1	7.54	1e-13	1.05e-07	0.29	0.23	Height;	chr8:56056202	chr5:108593609~108593967:+
BRCA	trans	rs864643	0.729	rs7616236	ENSG00000188856.6	RPSAP47	7.54	1e-13	1.05e-07	0.45	0.23	Attention deficit hyperactivity disorder;	chr3:39500645	chr8:80558870~80559757:+
BRCA	trans	rs7113874	0.885	rs11042016	ENSG00000266891.1	RP11-692N5.2	-7.54	1.01e-13	1.06e-07	-0.28	-0.23	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8625577	chr18:9734882~9735602:-
BRCA	trans	rs1707322	0.752	rs28719889	ENSG00000255397.1	AC022182.2	-7.54	1.01e-13	1.06e-07	-0.31	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45736611	chr8:60937705~60939871:-
BRCA	trans	rs11920570	0.959	rs7639260	ENSG00000267076.1	CCDC58P3	-7.54	1.02e-13	1.06e-07	-0.3	-0.23	Resting heart rate;	chr3:122449268	chr18:12211378~12211807:+
BRCA	trans	rs11920570	0.959	rs6438730	ENSG00000267076.1	CCDC58P3	-7.54	1.02e-13	1.06e-07	-0.3	-0.23	Resting heart rate;	chr3:122450801	chr18:12211378~12211807:+
BRCA	trans	rs11098499	0.908	rs11098527	ENSG00000276997.3	RP11-378J18.9	7.54	1.03e-13	1.07e-07	0.28	0.23	Corneal astigmatism;	chr4:119478751	chr1:222477252~222504622:-
BRCA	trans	rs6831352	0.959	rs1139490	ENSG00000233859.2	ADH5P4	-7.54	1.03e-13	1.07e-07	-0.3	-0.23	Alcohol dependence;	chr4:99123990	chr6:65836930~65838039:-
BRCA	trans	rs6732160	0.588	rs7578991	ENSG00000236165.1	PRADC1P1	7.54	1.04e-13	1.08e-07	0.3	0.23	Intelligence (multi-trait analysis);	chr2:73149043	chr3:36976316~36976840:+
BRCA	trans	rs6732160	0.564	rs7605716	ENSG00000236165.1	PRADC1P1	7.54	1.04e-13	1.08e-07	0.3	0.23	Intelligence (multi-trait analysis);	chr2:73149122	chr3:36976316~36976840:+
BRCA	trans	rs2736337	0.53	rs2003422	ENSG00000253893.2	FAM85B	-7.54	1.04e-13	1.09e-07	-0.3	-0.23	Rheumatoid arthritis;	chr8:11445628	chr8:8167819~8226614:-
BRCA	trans	rs3806843	0.521	rs192231	ENSG00000231043.3	AC007238.1	7.54	1.04e-13	1.09e-07	0.28	0.23	Depressive symptoms (multi-trait analysis);	chr5:140868954	chr2:58460292~58462032:-
BRCA	trans	rs864643	0.678	rs519385	ENSG00000188856.6	RPSAP47	7.54	1.05e-13	1.09e-07	0.33	0.23	Attention deficit hyperactivity disorder;	chr3:39486304	chr8:80558870~80559757:+
BRCA	trans	rs864643	0.678	rs604831	ENSG00000188856.6	RPSAP47	7.54	1.05e-13	1.09e-07	0.33	0.23	Attention deficit hyperactivity disorder;	chr3:39486327	chr8:80558870~80559757:+
BRCA	trans	rs656319	0.559	rs17689289	ENSG00000253893.2	FAM85B	-7.54	1.05e-13	1.1e-07	-0.28	-0.23	Myopia (pathological);	chr8:10120470	chr8:8167819~8226614:-
BRCA	trans	rs11920570	0.959	rs3749213	ENSG00000267076.1	CCDC58P3	-7.53	1.08e-13	1.13e-07	-0.3	-0.23	Resting heart rate;	chr3:122414983	chr18:12211378~12211807:+
BRCA	trans	rs11098499	1	rs11726229	ENSG00000120555.12	SEPT7P9	7.53	1.08e-13	1.13e-07	0.28	0.23	Corneal astigmatism;	chr4:119290425	chr10:38383069~38402916:-
BRCA	trans	rs6732160	0.588	rs2043100	ENSG00000236165.1	PRADC1P1	7.53	1.08e-13	1.13e-07	0.3	0.23	Intelligence (multi-trait analysis);	chr2:73146968	chr3:36976316~36976840:+
BRCA	trans	rs6732160	0.588	rs2043099	ENSG00000236165.1	PRADC1P1	7.53	1.08e-13	1.13e-07	0.3	0.23	Intelligence (multi-trait analysis);	chr2:73147028	chr3:36976316~36976840:+
BRCA	trans	rs6732160	0.588	rs11126392	ENSG00000236165.1	PRADC1P1	7.53	1.08e-13	1.13e-07	0.3	0.23	Intelligence (multi-trait analysis);	chr2:73147326	chr3:36976316~36976840:+
BRCA	trans	rs11098499	0.954	rs17005535	ENSG00000120555.12	SEPT7P9	7.53	1.08e-13	1.13e-07	0.28	0.23	Corneal astigmatism;	chr4:119490407	chr10:38383069~38402916:-
BRCA	trans	rs7929679	1	rs7929789	ENSG00000225531.1	RP11-196I18.3	7.53	1.08e-13	1.13e-07	0.29	0.23	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;	chr11:34784301	chr9:107116829~107117557:+
BRCA	trans	rs7929679	1	rs7929679	ENSG00000225531.1	RP11-196I18.3	7.53	1.08e-13	1.13e-07	0.29	0.23	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;	chr11:34784302	chr9:107116829~107117557:+
BRCA	trans	rs11098499	0.954	rs6822679	ENSG00000120555.12	SEPT7P9	7.53	1.09e-13	1.14e-07	0.28	0.23	Corneal astigmatism;	chr4:119481547	chr10:38383069~38402916:-
BRCA	trans	rs12210905	0.688	rs72845232	ENSG00000242375.1	RP11-498P14.3	-7.53	1.09e-13	1.14e-07	-0.59	-0.23	Hip circumference adjusted for BMI;	chr6:27460347	chr9:97195351~97197687:-
BRCA	trans	rs11098499	1	rs10029750	ENSG00000120555.12	SEPT7P9	7.53	1.09e-13	1.14e-07	0.28	0.23	Corneal astigmatism;	chr4:119251388	chr10:38383069~38402916:-
BRCA	trans	rs864643	0.898	rs1768144	ENSG00000183298.5	RP11-556K13.1	7.53	1.1e-13	1.15e-07	0.34	0.23	Attention deficit hyperactivity disorder;	chr3:39550569	chr1:101786340~101787219:-
BRCA	trans	rs11098499	0.954	rs7437420	ENSG00000120555.12	SEPT7P9	7.53	1.1e-13	1.15e-07	0.28	0.23	Corneal astigmatism;	chr4:119391748	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.955	rs1511015	ENSG00000120555.12	SEPT7P9	7.53	1.11e-13	1.16e-07	0.28	0.23	Corneal astigmatism;	chr4:119249318	chr10:38383069~38402916:-
BRCA	trans	rs13016963	0.604	rs12986657	ENSG00000235105.1	RP11-329A14.1	7.53	1.11e-13	1.16e-07	0.29	0.23	Esophageal squamous cell carcinoma;Melanoma;	chr2:201313366	chr1:48435967~48437223:+
BRCA	trans	rs1707322	0.717	rs3014237	ENSG00000255397.1	AC022182.2	7.53	1.12e-13	1.17e-07	0.31	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45624580	chr8:60937705~60939871:-
BRCA	trans	rs11098499	0.955	rs11931312	ENSG00000120555.12	SEPT7P9	7.53	1.12e-13	1.17e-07	0.28	0.23	Corneal astigmatism;	chr4:119237868	chr10:38383069~38402916:-
BRCA	trans	rs4713118	0.615	rs9348772	ENSG00000204709.4	LINC01556	7.53	1.13e-13	1.18e-07	0.29	0.23	Parkinson's disease;	chr6:27688311	chr6:28943877~28944537:+
BRCA	trans	rs4879656	0.564	rs1888869	ENSG00000215007.3	DNAJA1P3	-7.52	1.14e-13	1.19e-07	-0.27	-0.23	Menopause (age at onset);	chr9:32998239	chrX:107351650~107352843:-
BRCA	trans	rs11920570	0.959	rs4677951	ENSG00000267076.1	CCDC58P3	-7.52	1.15e-13	1.2e-07	-0.3	-0.23	Resting heart rate;	chr3:122440393	chr18:12211378~12211807:+
BRCA	trans	rs11920570	0.959	rs76170335	ENSG00000267076.1	CCDC58P3	-7.52	1.15e-13	1.2e-07	-0.3	-0.23	Resting heart rate;	chr3:122443244	chr18:12211378~12211807:+
BRCA	trans	rs801193	0.904	rs4718403	ENSG00000164669.11	INTS4P1	-7.52	1.15e-13	1.2e-07	-0.28	-0.23	Aortic root size;	chr7:66777742	chr7:65141225~65234216:+
BRCA	trans	rs2122469	0.655	rs17603934	ENSG00000253200.1	RP11-582J16.5	7.52	1.17e-13	1.21e-07	0.29	0.23	Serum tamsulosin hydrochloride concentration;	chr8:20718833	chr8:22613908~22616657:-
BRCA	trans	rs864643	0.735	rs76417541	ENSG00000183298.5	RP11-556K13.1	7.52	1.17e-13	1.21e-07	0.48	0.23	Attention deficit hyperactivity disorder;	chr3:39519802	chr1:101786340~101787219:-
BRCA	trans	rs7662987	1	rs7658127	ENSG00000228407.2	RP4-800M22.1	7.52	1.17e-13	1.21e-07	0.51	0.23	Smoking initiation;	chr4:99073471	chr1:52160261~52160600:-
BRCA	trans	rs11098499	0.954	rs12505469	ENSG00000276997.3	RP11-378J18.9	7.52	1.17e-13	1.22e-07	0.28	0.23	Corneal astigmatism;	chr4:119328430	chr1:222477252~222504622:-
BRCA	trans	rs7662987	1	rs6852848	ENSG00000228407.2	RP4-800M22.1	-7.52	1.17e-13	1.22e-07	-0.5	-0.23	Smoking initiation;	chr4:99080781	chr1:52160261~52160600:-
BRCA	trans	rs1707322	0.65	rs4553239	ENSG00000255397.1	AC022182.2	-7.52	1.17e-13	1.22e-07	-0.3	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45684814	chr8:60937705~60939871:-
BRCA	trans	rs9308062	1	rs9308062	ENSG00000232467.2	TMA16P2	7.52	1.18e-13	1.23e-07	0.29	0.23	Small cell lung carcinoma;	chr4:163517048	chr1:45846994~45847594:-
BRCA	trans	rs13016963	0.604	rs7569952	ENSG00000235105.1	RP11-329A14.1	7.52	1.18e-13	1.23e-07	0.29	0.23	Esophageal squamous cell carcinoma;Melanoma;	chr2:201320709	chr1:48435967~48437223:+
BRCA	trans	rs12210905	0.925	rs858984	ENSG00000242375.1	RP11-498P14.3	7.52	1.18e-13	1.23e-07	0.48	0.23	Hip circumference adjusted for BMI;	chr6:27209582	chr9:97195351~97197687:-
BRCA	trans	rs11098499	0.954	rs11098525	ENSG00000276997.3	RP11-378J18.9	7.52	1.19e-13	1.23e-07	0.28	0.23	Corneal astigmatism;	chr4:119468997	chr1:222477252~222504622:-
BRCA	trans	rs7824557	0.614	rs2736277	ENSG00000253893.2	FAM85B	7.52	1.19e-13	1.24e-07	0.28	0.23	Retinal vascular caliber;	chr8:11361384	chr8:8167819~8226614:-
BRCA	trans	rs7824557	0.872	rs6601577	ENSG00000253893.2	FAM85B	-7.52	1.19e-13	1.24e-07	-0.28	-0.23	Retinal vascular caliber;	chr8:11245173	chr8:8167819~8226614:-
BRCA	trans	rs9467711	0.79	rs35162296	ENSG00000253570.1	RNF5P1	7.52	1.19e-13	1.24e-07	0.57	0.23	Autism spectrum disorder or schizophrenia;	chr6:26318034	chr8:38600661~38601200:-
BRCA	trans	rs7769051	1	rs7769051	ENSG00000213087.3	RP11-613F7.1	7.52	1.2e-13	1.25e-07	0.33	0.23	Type 2 diabetes nephropathy;	chr6:132825657	chr6:151225550~151225947:-
BRCA	trans	rs9914988	0.943	rs59461345	ENSG00000267449.1	RP11-264B14.2	7.52	1.2e-13	1.25e-07	0.31	0.23	Glycated hemoglobin levels;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr17:28824834	chr17:61069856~61070356:-
BRCA	trans	rs9914988	0.943	rs11656256	ENSG00000267449.1	RP11-264B14.2	7.52	1.2e-13	1.25e-07	0.31	0.23	Glycated hemoglobin levels;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr17:28826535	chr17:61069856~61070356:-
BRCA	trans	rs9914988	0.887	rs12947735	ENSG00000267449.1	RP11-264B14.2	7.52	1.2e-13	1.25e-07	0.31	0.23	Glycated hemoglobin levels;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr17:28829848	chr17:61069856~61070356:-
BRCA	trans	rs11098499	0.954	rs59866101	ENSG00000120555.12	SEPT7P9	7.52	1.21e-13	1.25e-07	0.28	0.23	Corneal astigmatism;	chr4:119375436	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.618	rs6858383	ENSG00000120555.12	SEPT7P9	7.52	1.21e-13	1.25e-07	0.28	0.23	Corneal astigmatism;	chr4:119375617	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.697	rs6832410	ENSG00000120555.12	SEPT7P9	7.52	1.21e-13	1.25e-07	0.28	0.23	Corneal astigmatism;	chr4:119375645	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.865	rs1112817	ENSG00000120555.12	SEPT7P9	7.52	1.21e-13	1.25e-07	0.28	0.23	Corneal astigmatism;	chr4:119376645	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.779	rs10016060	ENSG00000120555.12	SEPT7P9	7.52	1.21e-13	1.25e-07	0.28	0.23	Corneal astigmatism;	chr4:119377257	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.954	rs10005644	ENSG00000120555.12	SEPT7P9	7.52	1.21e-13	1.25e-07	0.28	0.23	Corneal astigmatism;	chr4:119377322	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.697	rs10016448	ENSG00000120555.12	SEPT7P9	7.52	1.21e-13	1.25e-07	0.28	0.23	Corneal astigmatism;	chr4:119377690	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.657	rs9996569	ENSG00000120555.12	SEPT7P9	7.52	1.21e-13	1.25e-07	0.28	0.23	Corneal astigmatism;	chr4:119377849	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.908	rs11729050	ENSG00000120555.12	SEPT7P9	7.52	1.21e-13	1.25e-07	0.28	0.23	Corneal astigmatism;	chr4:119378911	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.954	rs28429722	ENSG00000120555.12	SEPT7P9	7.52	1.21e-13	1.25e-07	0.28	0.23	Corneal astigmatism;	chr4:119378938	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.954	rs10014845	ENSG00000120555.12	SEPT7P9	7.52	1.21e-13	1.25e-07	0.28	0.23	Corneal astigmatism;	chr4:119379922	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.779	rs7674500	ENSG00000120555.12	SEPT7P9	7.52	1.21e-13	1.25e-07	0.28	0.23	Corneal astigmatism;	chr4:119382438	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.909	rs28884220	ENSG00000120555.12	SEPT7P9	7.52	1.21e-13	1.25e-07	0.28	0.23	Corneal astigmatism;	chr4:119386056	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.909	rs28793658	ENSG00000120555.12	SEPT7P9	7.52	1.21e-13	1.25e-07	0.28	0.23	Corneal astigmatism;	chr4:119386059	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.697	rs4373140	ENSG00000120555.12	SEPT7P9	7.52	1.21e-13	1.25e-07	0.28	0.23	Corneal astigmatism;	chr4:119386543	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.954	rs13113483	ENSG00000120555.12	SEPT7P9	7.52	1.21e-13	1.25e-07	0.28	0.23	Corneal astigmatism;	chr4:119387884	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.542	rs10440343	ENSG00000120555.12	SEPT7P9	7.52	1.21e-13	1.25e-07	0.28	0.23	Corneal astigmatism;	chr4:119388632	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.779	rs10011097	ENSG00000120555.12	SEPT7P9	7.52	1.21e-13	1.25e-07	0.28	0.23	Corneal astigmatism;	chr4:119389204	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.542	rs7677836	ENSG00000120555.12	SEPT7P9	7.52	1.21e-13	1.25e-07	0.28	0.23	Corneal astigmatism;	chr4:119389483	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.909	rs10002083	ENSG00000120555.12	SEPT7P9	7.52	1.21e-13	1.25e-07	0.28	0.23	Corneal astigmatism;	chr4:119389997	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.954	rs10024844	ENSG00000120555.12	SEPT7P9	7.52	1.21e-13	1.25e-07	0.28	0.23	Corneal astigmatism;	chr4:119390373	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.954	rs4345162	ENSG00000120555.12	SEPT7P9	7.52	1.21e-13	1.25e-07	0.28	0.23	Corneal astigmatism;	chr4:119391804	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.657	rs4463052	ENSG00000120555.12	SEPT7P9	7.52	1.21e-13	1.25e-07	0.28	0.23	Corneal astigmatism;	chr4:119392103	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.954	rs13151285	ENSG00000120555.12	SEPT7P9	7.52	1.21e-13	1.25e-07	0.28	0.23	Corneal astigmatism;	chr4:119393586	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.865	rs28753180	ENSG00000120555.12	SEPT7P9	7.52	1.21e-13	1.25e-07	0.28	0.23	Corneal astigmatism;	chr4:119484212	chr10:38383069~38402916:-
BRCA	trans	rs9914988	0.943	rs66588554	ENSG00000267449.1	RP11-264B14.2	7.52	1.21e-13	1.25e-07	0.32	0.23	Glycated hemoglobin levels;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr17:28814092	chr17:61069856~61070356:-
BRCA	trans	rs11920570	0.881	rs73188396	ENSG00000267076.1	CCDC58P3	-7.52	1.22e-13	1.26e-07	-0.3	-0.23	Resting heart rate;	chr3:122417157	chr18:12211378~12211807:+
BRCA	trans	rs11098499	0.909	rs28668716	ENSG00000120555.12	SEPT7P9	7.52	1.22e-13	1.27e-07	0.28	0.23	Corneal astigmatism;	chr4:119388720	chr10:38383069~38402916:-
BRCA	trans	rs9467711	0.591	rs9461219	ENSG00000253570.1	RNF5P1	-7.52	1.22e-13	1.27e-07	-0.56	-0.23	Autism spectrum disorder or schizophrenia;	chr6:25836699	chr8:38600661~38601200:-
BRCA	trans	rs864643	0.625	rs1707958	ENSG00000188856.6	RPSAP47	7.51	1.22e-13	1.27e-07	0.32	0.23	Attention deficit hyperactivity disorder;	chr3:39481931	chr8:80558870~80559757:+
BRCA	trans	rs73191547	0.965	rs12548428	ENSG00000253893.2	FAM85B	7.51	1.22e-13	1.27e-07	0.3	0.23	Schizophrenia;	chr8:10173188	chr8:8167819~8226614:-
BRCA	trans	rs1933488	0.835	rs9371280	ENSG00000278974.1	RP11-756P10.6	-7.51	1.23e-13	1.27e-07	-0.29	-0.23	Prostate cancer;	chr6:153093138	chr4:188740507~188741281:-
BRCA	trans	rs1933488	0.898	rs6557261	ENSG00000278974.1	RP11-756P10.6	-7.51	1.23e-13	1.27e-07	-0.29	-0.23	Prostate cancer;	chr6:153094233	chr4:188740507~188741281:-
BRCA	trans	rs1933488	0.898	rs9479505	ENSG00000278974.1	RP11-756P10.6	-7.51	1.23e-13	1.27e-07	-0.29	-0.23	Prostate cancer;	chr6:153094516	chr4:188740507~188741281:-
BRCA	trans	rs1933488	0.866	rs7756810	ENSG00000278974.1	RP11-756P10.6	-7.51	1.23e-13	1.27e-07	-0.29	-0.23	Prostate cancer;	chr6:153094998	chr4:188740507~188741281:-
BRCA	trans	rs6732160	0.588	rs3891890	ENSG00000236165.1	PRADC1P1	7.51	1.23e-13	1.28e-07	0.31	0.23	Intelligence (multi-trait analysis);	chr2:73150921	chr3:36976316~36976840:+
BRCA	trans	rs1933488	0.898	rs1971152	ENSG00000278974.1	RP11-756P10.6	-7.51	1.23e-13	1.28e-07	-0.29	-0.23	Prostate cancer;	chr6:153104109	chr4:188740507~188741281:-
BRCA	trans	rs12477438	0.52	rs4851187	ENSG00000276576.1	MRPL30P1	-7.51	1.23e-13	1.28e-07	-0.28	-0.23	Chronic sinus infection;	chr2:99129397	chr6:57029521~57029988:+
BRCA	trans	rs7824557	0.628	rs7841394	ENSG00000253893.2	FAM85B	-7.51	1.24e-13	1.29e-07	-0.29	-0.23	Retinal vascular caliber;	chr8:11328162	chr8:8167819~8226614:-
BRCA	trans	rs9834975	0.605	rs7623967	ENSG00000267076.1	CCDC58P3	-7.51	1.25e-13	1.29e-07	-0.27	-0.23	Diastolic blood pressure;	chr3:122502569	chr18:12211378~12211807:+
BRCA	trans	rs11098499	0.697	rs11941899	ENSG00000276997.3	RP11-378J18.9	7.51	1.25e-13	1.3e-07	0.28	0.23	Corneal astigmatism;	chr4:119461603	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.909	rs7681978	ENSG00000276997.3	RP11-378J18.9	7.51	1.25e-13	1.3e-07	0.28	0.23	Corneal astigmatism;	chr4:119462620	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.821	rs28665282	ENSG00000276997.3	RP11-378J18.9	7.51	1.25e-13	1.3e-07	0.28	0.23	Corneal astigmatism;	chr4:119463031	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.738	rs10026493	ENSG00000276997.3	RP11-378J18.9	7.51	1.25e-13	1.3e-07	0.28	0.23	Corneal astigmatism;	chr4:119463039	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.909	rs7681214	ENSG00000276997.3	RP11-378J18.9	7.51	1.25e-13	1.3e-07	0.28	0.23	Corneal astigmatism;	chr4:119464165	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.909	rs28632018	ENSG00000276997.3	RP11-378J18.9	7.51	1.25e-13	1.3e-07	0.28	0.23	Corneal astigmatism;	chr4:119465575	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.908	rs71614449	ENSG00000276997.3	RP11-378J18.9	7.51	1.25e-13	1.3e-07	0.28	0.23	Corneal astigmatism;	chr4:119465900	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.954	rs35063680	ENSG00000276997.3	RP11-378J18.9	7.51	1.25e-13	1.3e-07	0.28	0.23	Corneal astigmatism;	chr4:119465947	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.954	rs34858317	ENSG00000276997.3	RP11-378J18.9	7.51	1.25e-13	1.3e-07	0.28	0.23	Corneal astigmatism;	chr4:119465955	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.954	rs17046116	ENSG00000276997.3	RP11-378J18.9	7.51	1.25e-13	1.3e-07	0.28	0.23	Corneal astigmatism;	chr4:119466104	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.909	rs17046118	ENSG00000276997.3	RP11-378J18.9	7.51	1.25e-13	1.3e-07	0.28	0.23	Corneal astigmatism;	chr4:119466341	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.954	rs7654587	ENSG00000276997.3	RP11-378J18.9	7.51	1.25e-13	1.3e-07	0.28	0.23	Corneal astigmatism;	chr4:119467251	chr1:222477252~222504622:-
BRCA	trans	rs804280	1	rs804280	ENSG00000253893.2	FAM85B	-7.51	1.25e-13	1.3e-07	-0.28	-0.23	Myopia (pathological);	chr8:11755189	chr8:8167819~8226614:-
BRCA	trans	rs12477438	0.52	rs13030961	ENSG00000276576.1	MRPL30P1	7.51	1.26e-13	1.3e-07	0.28	0.23	Chronic sinus infection;	chr2:99183057	chr6:57029521~57029988:+
BRCA	trans	rs1568889	0.838	rs6484347	ENSG00000174912.7	METTL15P1	-7.51	1.26e-13	1.31e-07	-0.23	-0.23	Bipolar disorder;	chr11:28019422	chr3:156713884~156714928:-
BRCA	trans	rs11098499	0.618	rs35265692	ENSG00000276997.3	RP11-378J18.9	7.51	1.27e-13	1.31e-07	0.28	0.23	Corneal astigmatism;	chr4:119403980	chr1:222477252~222504622:-
BRCA	trans	rs3806843	0.576	rs246002	ENSG00000231043.3	AC007238.1	-7.51	1.27e-13	1.31e-07	-0.27	-0.23	Depressive symptoms (multi-trait analysis);	chr5:140961519	chr2:58460292~58462032:-
BRCA	trans	rs3806843	0.576	rs246041	ENSG00000231043.3	AC007238.1	-7.51	1.27e-13	1.31e-07	-0.27	-0.23	Depressive symptoms (multi-trait analysis);	chr5:140951543	chr2:58460292~58462032:-
BRCA	trans	rs17507216	0.718	rs4779034	ENSG00000259295.5	CSPG4P12	-7.51	1.27e-13	1.31e-07	-0.34	-0.23	Excessive daytime sleepiness;	chr15:82576799	chr15:85191438~85213905:+
BRCA	trans	rs2288327	1	rs890578	ENSG00000269800.1	PLEKHA3P1	7.51	1.27e-13	1.32e-07	0.31	0.23	Atrial fibrillation;	chr2:178549906	chr19:41521043~41521989:-
BRCA	trans	rs7103648	0.603	rs3740688	ENSG00000134612.10	FOLH1B	7.51	1.28e-13	1.32e-07	0.28	0.23	Systolic blood pressure;Diastolic blood pressure;	chr11:47358789	chr11:89639227~89698718:+
BRCA	trans	rs7824557	0.815	rs2736372	ENSG00000253893.2	FAM85B	7.51	1.28e-13	1.32e-07	0.28	0.23	Retinal vascular caliber;	chr8:11248532	chr8:8167819~8226614:-
BRCA	trans	rs801193	1	rs1553609	ENSG00000164669.11	INTS4P1	-7.51	1.28e-13	1.33e-07	-0.28	-0.23	Aortic root size;	chr7:66732152	chr7:65141225~65234216:+
BRCA	trans	rs11098499	0.954	rs28685688	ENSG00000276997.3	RP11-378J18.9	7.51	1.28e-13	1.33e-07	0.28	0.23	Corneal astigmatism;	chr4:119499179	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.954	rs7687843	ENSG00000276997.3	RP11-378J18.9	7.51	1.28e-13	1.33e-07	0.28	0.23	Corneal astigmatism;	chr4:119500056	chr1:222477252~222504622:-
BRCA	trans	rs9914988	0.943	rs7215310	ENSG00000267449.1	RP11-264B14.2	7.51	1.28e-13	1.33e-07	0.31	0.23	Glycated hemoglobin levels;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr17:28761608	chr17:61069856~61070356:-
BRCA	trans	rs7113874	1	rs11042018	ENSG00000266891.1	RP11-692N5.2	-7.51	1.28e-13	1.33e-07	-0.28	-0.23	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8628160	chr18:9734882~9735602:-
BRCA	trans	rs1707322	0.686	rs3014235	ENSG00000255397.1	AC022182.2	7.51	1.29e-13	1.33e-07	0.3	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45625840	chr8:60937705~60939871:-
BRCA	trans	rs1707322	0.717	rs1135850	ENSG00000255397.1	AC022182.2	-7.51	1.29e-13	1.33e-07	-0.3	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45628020	chr8:60937705~60939871:-
BRCA	trans	rs11098499	0.954	rs9998585	ENSG00000120555.12	SEPT7P9	7.51	1.29e-13	1.34e-07	0.28	0.23	Corneal astigmatism;	chr4:119475647	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.909	rs6842762	ENSG00000120555.12	SEPT7P9	7.51	1.29e-13	1.34e-07	0.28	0.23	Corneal astigmatism;	chr4:119477081	chr10:38383069~38402916:-
BRCA	trans	rs875971	0.66	rs1860468	ENSG00000164669.11	INTS4P1	7.51	1.3e-13	1.34e-07	0.28	0.23	Aortic root size;	chr7:66642265	chr7:65141225~65234216:+
BRCA	trans	rs13016963	0.604	rs13113	ENSG00000235105.1	RP11-329A14.1	7.51	1.3e-13	1.34e-07	0.29	0.23	Esophageal squamous cell carcinoma;Melanoma;	chr2:201287439	chr1:48435967~48437223:+
BRCA	trans	rs12477438	0.539	rs720228	ENSG00000276576.1	MRPL30P1	7.51	1.3e-13	1.35e-07	0.28	0.23	Chronic sinus infection;	chr2:99088084	chr6:57029521~57029988:+
BRCA	trans	rs864643	0.678	rs521226	ENSG00000188856.6	RPSAP47	7.51	1.3e-13	1.35e-07	0.33	0.23	Attention deficit hyperactivity disorder;	chr3:39486099	chr8:80558870~80559757:+
BRCA	trans	rs864643	0.625	rs517376	ENSG00000188856.6	RPSAP47	7.51	1.3e-13	1.35e-07	0.33	0.23	Attention deficit hyperactivity disorder;	chr3:39486571	chr8:80558870~80559757:+
BRCA	trans	rs11920570	0.959	rs6765287	ENSG00000267076.1	CCDC58P3	-7.5	1.32e-13	1.36e-07	-0.3	-0.23	Resting heart rate;	chr3:122500724	chr18:12211378~12211807:+
BRCA	trans	rs9467711	0.606	rs9379855	ENSG00000253570.1	RNF5P1	-7.5	1.32e-13	1.36e-07	-0.52	-0.23	Autism spectrum disorder or schizophrenia;	chr6:26364702	chr8:38600661~38601200:-
BRCA	trans	rs3806843	0.576	rs246063	ENSG00000231043.3	AC007238.1	-7.5	1.32e-13	1.36e-07	-0.27	-0.23	Depressive symptoms (multi-trait analysis);	chr5:140944907	chr2:58460292~58462032:-
BRCA	trans	rs3806843	0.576	rs246062	ENSG00000231043.3	AC007238.1	-7.5	1.32e-13	1.36e-07	-0.27	-0.23	Depressive symptoms (multi-trait analysis);	chr5:140944995	chr2:58460292~58462032:-
BRCA	trans	rs3806843	0.521	rs246061	ENSG00000231043.3	AC007238.1	-7.5	1.32e-13	1.36e-07	-0.27	-0.23	Depressive symptoms (multi-trait analysis);	chr5:140945071	chr2:58460292~58462032:-
BRCA	trans	rs3806843	0.607	rs246060	ENSG00000231043.3	AC007238.1	-7.5	1.32e-13	1.36e-07	-0.27	-0.23	Depressive symptoms (multi-trait analysis);	chr5:140945164	chr2:58460292~58462032:-
BRCA	trans	rs3806843	0.576	rs246059	ENSG00000231043.3	AC007238.1	-7.5	1.32e-13	1.36e-07	-0.27	-0.23	Depressive symptoms (multi-trait analysis);	chr5:140945425	chr2:58460292~58462032:-
BRCA	trans	rs3806843	0.548	rs246058	ENSG00000231043.3	AC007238.1	-7.5	1.32e-13	1.36e-07	-0.27	-0.23	Depressive symptoms (multi-trait analysis);	chr5:140945549	chr2:58460292~58462032:-
BRCA	trans	rs3806843	0.548	rs246057	ENSG00000231043.3	AC007238.1	-7.5	1.32e-13	1.36e-07	-0.27	-0.23	Depressive symptoms (multi-trait analysis);	chr5:140945998	chr2:58460292~58462032:-
BRCA	trans	rs3806843	0.548	rs246055	ENSG00000231043.3	AC007238.1	-7.5	1.32e-13	1.36e-07	-0.27	-0.23	Depressive symptoms (multi-trait analysis);	chr5:140946077	chr2:58460292~58462032:-
BRCA	trans	rs3806843	0.547	rs246054	ENSG00000231043.3	AC007238.1	-7.5	1.32e-13	1.36e-07	-0.27	-0.23	Depressive symptoms (multi-trait analysis);	chr5:140946574	chr2:58460292~58462032:-
BRCA	trans	rs3806843	0.548	rs246052	ENSG00000231043.3	AC007238.1	-7.5	1.32e-13	1.36e-07	-0.27	-0.23	Depressive symptoms (multi-trait analysis);	chr5:140946828	chr2:58460292~58462032:-
BRCA	trans	rs3806843	0.52	rs246051	ENSG00000231043.3	AC007238.1	-7.5	1.32e-13	1.36e-07	-0.27	-0.23	Depressive symptoms (multi-trait analysis);	chr5:140946879	chr2:58460292~58462032:-
BRCA	trans	rs31872	0.521	rs246050	ENSG00000231043.3	AC007238.1	-7.5	1.32e-13	1.36e-07	-0.27	-0.23	Visceral adipose tissue adjusted for BMI;	chr5:140947275	chr2:58460292~58462032:-
BRCA	trans	rs3806843	0.576	rs246049	ENSG00000231043.3	AC007238.1	-7.5	1.32e-13	1.36e-07	-0.27	-0.23	Depressive symptoms (multi-trait analysis);	chr5:140948005	chr2:58460292~58462032:-
BRCA	trans	rs3806843	0.576	rs246047	ENSG00000231043.3	AC007238.1	-7.5	1.32e-13	1.36e-07	-0.27	-0.23	Depressive symptoms (multi-trait analysis);	chr5:140948752	chr2:58460292~58462032:-
BRCA	trans	rs3806843	0.576	rs246046	ENSG00000231043.3	AC007238.1	-7.5	1.32e-13	1.36e-07	-0.27	-0.23	Depressive symptoms (multi-trait analysis);	chr5:140949679	chr2:58460292~58462032:-
BRCA	trans	rs3806843	0.576	rs246045	ENSG00000231043.3	AC007238.1	-7.5	1.32e-13	1.36e-07	-0.27	-0.23	Depressive symptoms (multi-trait analysis);	chr5:140950299	chr2:58460292~58462032:-
BRCA	trans	rs3806843	0.576	rs246043	ENSG00000231043.3	AC007238.1	-7.5	1.32e-13	1.36e-07	-0.27	-0.23	Depressive symptoms (multi-trait analysis);	chr5:140951339	chr2:58460292~58462032:-
BRCA	trans	rs3806843	0.608	rs246042	ENSG00000231043.3	AC007238.1	-7.5	1.32e-13	1.36e-07	-0.27	-0.23	Depressive symptoms (multi-trait analysis);	chr5:140951382	chr2:58460292~58462032:-
BRCA	trans	rs3806843	0.548	rs246038	ENSG00000231043.3	AC007238.1	-7.5	1.32e-13	1.36e-07	-0.27	-0.23	Depressive symptoms (multi-trait analysis);	chr5:140952114	chr2:58460292~58462032:-
BRCA	trans	rs3806843	0.576	rs246037	ENSG00000231043.3	AC007238.1	-7.5	1.32e-13	1.36e-07	-0.27	-0.23	Depressive symptoms (multi-trait analysis);	chr5:140952261	chr2:58460292~58462032:-
BRCA	trans	rs3806843	0.576	rs246036	ENSG00000231043.3	AC007238.1	-7.5	1.32e-13	1.36e-07	-0.27	-0.23	Depressive symptoms (multi-trait analysis);	chr5:140952301	chr2:58460292~58462032:-
BRCA	trans	rs3806843	0.576	rs246034	ENSG00000231043.3	AC007238.1	-7.5	1.32e-13	1.36e-07	-0.27	-0.23	Depressive symptoms (multi-trait analysis);	chr5:140952479	chr2:58460292~58462032:-
BRCA	trans	rs3806843	0.547	rs246033	ENSG00000231043.3	AC007238.1	-7.5	1.32e-13	1.36e-07	-0.27	-0.23	Depressive symptoms (multi-trait analysis);	chr5:140952530	chr2:58460292~58462032:-
BRCA	trans	rs3806843	0.576	rs246032	ENSG00000231043.3	AC007238.1	-7.5	1.32e-13	1.36e-07	-0.27	-0.23	Depressive symptoms (multi-trait analysis);	chr5:140952962	chr2:58460292~58462032:-
BRCA	trans	rs3806843	0.517	rs246031	ENSG00000231043.3	AC007238.1	-7.5	1.32e-13	1.36e-07	-0.27	-0.23	Depressive symptoms (multi-trait analysis);	chr5:140953522	chr2:58460292~58462032:-
BRCA	trans	rs3806843	0.576	rs246030	ENSG00000231043.3	AC007238.1	-7.5	1.32e-13	1.36e-07	-0.27	-0.23	Depressive symptoms (multi-trait analysis);	chr5:140953569	chr2:58460292~58462032:-
BRCA	trans	rs3806843	0.576	rs246029	ENSG00000231043.3	AC007238.1	-7.5	1.32e-13	1.36e-07	-0.27	-0.23	Depressive symptoms (multi-trait analysis);	chr5:140953641	chr2:58460292~58462032:-
BRCA	trans	rs3806843	0.576	rs246028	ENSG00000231043.3	AC007238.1	-7.5	1.32e-13	1.36e-07	-0.27	-0.23	Depressive symptoms (multi-trait analysis);	chr5:140953928	chr2:58460292~58462032:-
BRCA	trans	rs3806843	0.576	rs246027	ENSG00000231043.3	AC007238.1	-7.5	1.32e-13	1.36e-07	-0.27	-0.23	Depressive symptoms (multi-trait analysis);	chr5:140954016	chr2:58460292~58462032:-
BRCA	trans	rs3806843	0.576	rs246021	ENSG00000231043.3	AC007238.1	-7.5	1.32e-13	1.36e-07	-0.27	-0.23	Depressive symptoms (multi-trait analysis);	chr5:140954919	chr2:58460292~58462032:-
BRCA	trans	rs3806843	0.576	rs246020	ENSG00000231043.3	AC007238.1	-7.5	1.32e-13	1.36e-07	-0.27	-0.23	Depressive symptoms (multi-trait analysis);	chr5:140955186	chr2:58460292~58462032:-
BRCA	trans	rs3806843	0.551	rs246018	ENSG00000231043.3	AC007238.1	-7.5	1.32e-13	1.36e-07	-0.27	-0.23	Depressive symptoms (multi-trait analysis);	chr5:140955458	chr2:58460292~58462032:-
BRCA	trans	rs3806843	0.518	rs173471	ENSG00000231043.3	AC007238.1	-7.5	1.32e-13	1.36e-07	-0.27	-0.23	Depressive symptoms (multi-trait analysis);	chr5:140955641	chr2:58460292~58462032:-
BRCA	trans	rs3806843	0.549	rs246012	ENSG00000231043.3	AC007238.1	-7.5	1.32e-13	1.36e-07	-0.27	-0.23	Depressive symptoms (multi-trait analysis);	chr5:140956692	chr2:58460292~58462032:-
BRCA	trans	rs3806843	0.576	rs246011	ENSG00000231043.3	AC007238.1	-7.5	1.32e-13	1.36e-07	-0.27	-0.23	Depressive symptoms (multi-trait analysis);	chr5:140956820	chr2:58460292~58462032:-
BRCA	trans	rs3806843	0.547	rs246010	ENSG00000231043.3	AC007238.1	-7.5	1.32e-13	1.36e-07	-0.27	-0.23	Depressive symptoms (multi-trait analysis);	chr5:140957050	chr2:58460292~58462032:-
BRCA	trans	rs9581094	0.591	rs73154356	ENSG00000237917.1	PARP4P1	-7.5	1.33e-13	1.38e-07	-0.46	-0.23	Sudden cardiac arrest;	chr13:24489662	chrY:26594851~26634652:-
BRCA	trans	rs9581094	0.591	rs73154358	ENSG00000237917.1	PARP4P1	-7.5	1.33e-13	1.38e-07	-0.46	-0.23	Sudden cardiac arrest;	chr13:24489776	chrY:26594851~26634652:-
BRCA	trans	rs11098499	0.909	rs1546502	ENSG00000276997.3	RP11-378J18.9	7.5	1.34e-13	1.39e-07	0.28	0.23	Corneal astigmatism;	chr4:119314743	chr1:222477252~222504622:-
BRCA	trans	rs3849046	0.817	rs2268439	ENSG00000226666.1	HSPA9P1	7.5	1.36e-13	1.4e-07	0.26	0.23	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138545103	chr2:221961737~221963765:+
BRCA	trans	rs3779195	0.584	rs1688605	ENSG00000225169.1	BRI3P1	-7.5	1.37e-13	1.41e-07	-0.38	-0.23	Sex hormone-binding globulin levels;	chr7:98410534	chr1:100213293~100213670:+
BRCA	trans	rs1933488	0.931	rs7740777	ENSG00000278974.1	RP11-756P10.6	7.5	1.37e-13	1.41e-07	0.29	0.23	Prostate cancer;	chr6:153092174	chr4:188740507~188741281:-
BRCA	trans	rs2243480	0.908	rs4718273	ENSG00000273142.1	RP11-458F8.4	7.5	1.37e-13	1.42e-07	0.31	0.23	Diabetic kidney disease;	chr7:65751112	chr7:66902857~66906297:+
BRCA	trans	rs656319	0.605	rs17747335	ENSG00000253893.2	FAM85B	7.5	1.39e-13	1.43e-07	0.29	0.23	Myopia (pathological);	chr8:10145676	chr8:8167819~8226614:-
BRCA	trans	rs4720118	0.875	rs3884597	ENSG00000213492.2	NT5C3AP1	-7.5	1.41e-13	1.45e-07	-0.29	-0.23	Leprosy;	chr7:33345650	chr4:117574512~117576174:-
BRCA	trans	rs7200543	1	rs35574015	ENSG00000250569.1	NTAN1P2	7.5	1.41e-13	1.46e-07	0.25	0.23	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15052204	chr8:86481754~86483002:-
BRCA	trans	rs9393777	0.92	rs35716472	ENSG00000253570.1	RNF5P1	7.49	1.42e-13	1.46e-07	0.59	0.23	Intelligence (multi-trait analysis);	chr6:27438828	chr8:38600661~38601200:-
BRCA	trans	rs11098499	0.908	rs7696649	ENSG00000120555.12	SEPT7P9	7.49	1.43e-13	1.47e-07	0.28	0.23	Corneal astigmatism;	chr4:119401022	chr10:38383069~38402916:-
BRCA	trans	rs12210905	0.61	rs12204953	ENSG00000242375.1	RP11-498P14.3	-7.49	1.44e-13	1.48e-07	-0.59	-0.23	Hip circumference adjusted for BMI;	chr6:27428958	chr9:97195351~97197687:-
BRCA	trans	rs714543	0.566	rs13231886	ENSG00000267258.1	CTC-448F2.3	-7.49	1.44e-13	1.48e-07	-0.26	-0.23	Plateletcrit;	chr7:44774573	chr19:29921182~29921653:+
BRCA	trans	rs6915893	1	rs12189658	ENSG00000267156.1	TPMTP1	7.49	1.45e-13	1.49e-07	0.29	0.23	Intrinsic epigenetic age acceleration;	chr6:18103106	chr18:47630112~47630848:+
BRCA	trans	rs3849046	0.817	rs4835690	ENSG00000226666.1	HSPA9P1	7.49	1.45e-13	1.5e-07	0.26	0.23	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138594081	chr2:221961737~221963765:+
BRCA	trans	rs9834975	0.565	rs2877601	ENSG00000267076.1	CCDC58P3	-7.49	1.46e-13	1.5e-07	-0.26	-0.23	Diastolic blood pressure;	chr3:122398719	chr18:12211378~12211807:+
BRCA	trans	rs6915893	0.74	rs12194394	ENSG00000267156.1	TPMTP1	-7.49	1.46e-13	1.5e-07	-0.28	-0.23	Intrinsic epigenetic age acceleration;	chr6:18103050	chr18:47630112~47630848:+
BRCA	trans	rs801193	1	rs10252765	ENSG00000164669.11	INTS4P1	-7.49	1.47e-13	1.51e-07	-0.28	-0.23	Aortic root size;	chr7:66763745	chr7:65141225~65234216:+
BRCA	trans	rs864643	0.678	rs3856566	ENSG00000188856.6	RPSAP47	7.49	1.48e-13	1.52e-07	0.33	0.23	Attention deficit hyperactivity disorder;	chr3:39491097	chr8:80558870~80559757:+
BRCA	trans	rs877636	1	rs877636	ENSG00000224553.1	AC008065.1	-7.49	1.48e-13	1.53e-07	-0.26	-0.23	Cognitive function;	chr12:56086799	chr2:171374931~171375278:-
BRCA	trans	rs2288327	0.818	rs12618265	ENSG00000269800.1	PLEKHA3P1	7.49	1.48e-13	1.53e-07	0.35	0.23	Atrial fibrillation;	chr2:178518082	chr19:41521043~41521989:-
BRCA	trans	rs7824557	0.591	rs2572452	ENSG00000253893.2	FAM85B	7.49	1.51e-13	1.55e-07	0.29	0.23	Retinal vascular caliber;	chr8:11370745	chr8:8167819~8226614:-
BRCA	trans	rs538867	1	rs1708099	ENSG00000214263.2	RPSAP53	7.49	1.51e-13	1.56e-07	0.59	0.23	Alzheimer's disease (cognitive decline);	chr3:39476278	chr13:67266845~67267706:-
BRCA	trans	rs1707322	0.655	rs3014240	ENSG00000255397.1	AC022182.2	7.49	1.51e-13	1.56e-07	0.3	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45623553	chr8:60937705~60939871:-
BRCA	trans	rs11098499	0.909	rs28555550	ENSG00000120555.12	SEPT7P9	7.48	1.53e-13	1.57e-07	0.28	0.23	Corneal astigmatism;	chr4:119289885	chr10:38383069~38402916:-
BRCA	trans	rs11098499	1	rs28419773	ENSG00000120555.12	SEPT7P9	7.48	1.53e-13	1.57e-07	0.28	0.23	Corneal astigmatism;	chr4:119289906	chr10:38383069~38402916:-
BRCA	trans	rs9650657	0.771	rs12542888	ENSG00000253893.2	FAM85B	7.48	1.53e-13	1.57e-07	0.29	0.23	Neuroticism;	chr8:10805045	chr8:8167819~8226614:-
BRCA	trans	rs2243480	0.901	rs2900904	ENSG00000273142.1	RP11-458F8.4	-7.48	1.53e-13	1.58e-07	-0.31	-0.23	Diabetic kidney disease;	chr7:65739282	chr7:66902857~66906297:+
BRCA	trans	rs11098499	0.863	rs12508173	ENSG00000120555.12	SEPT7P9	7.48	1.55e-13	1.59e-07	0.28	0.23	Corneal astigmatism;	chr4:119397371	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.908	rs12504149	ENSG00000120555.12	SEPT7P9	7.48	1.55e-13	1.59e-07	0.28	0.23	Corneal astigmatism;	chr4:119397422	chr10:38383069~38402916:-
BRCA	trans	rs12477438	0.52	rs7572660	ENSG00000276576.1	MRPL30P1	7.48	1.55e-13	1.59e-07	0.28	0.23	Chronic sinus infection;	chr2:99172119	chr6:57029521~57029988:+
BRCA	trans	rs11098499	1	rs58601355	ENSG00000120555.12	SEPT7P9	7.48	1.56e-13	1.6e-07	0.28	0.23	Corneal astigmatism;	chr4:119265212	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.908	rs9995234	ENSG00000120555.12	SEPT7P9	7.48	1.56e-13	1.61e-07	0.29	0.23	Corneal astigmatism;	chr4:119400672	chr10:38383069~38402916:-
BRCA	trans	rs1568889	0.838	rs10835304	ENSG00000174912.7	METTL15P1	7.48	1.56e-13	1.61e-07	0.23	0.23	Bipolar disorder;	chr11:28274982	chr3:156713884~156714928:-
BRCA	trans	rs13016963	0.584	rs1918881	ENSG00000235105.1	RP11-329A14.1	7.48	1.57e-13	1.61e-07	0.29	0.23	Esophageal squamous cell carcinoma;Melanoma;	chr2:201325945	chr1:48435967~48437223:+
BRCA	trans	rs6915893	0.548	rs6899431	ENSG00000267156.1	TPMTP1	7.48	1.57e-13	1.62e-07	0.29	0.23	Intrinsic epigenetic age acceleration;	chr6:18110212	chr18:47630112~47630848:+
BRCA	trans	rs11098499	0.954	rs3733519	ENSG00000276997.3	RP11-378J18.9	7.48	1.58e-13	1.62e-07	0.28	0.23	Corneal astigmatism;	chr4:119502293	chr1:222477252~222504622:-
BRCA	trans	rs11951515	0.508	rs7705166	ENSG00000174977.8	AC026271.5	-7.48	1.58e-13	1.62e-07	-0.27	-0.23	Metabolite levels  (X-11787);	chr5:43587346	chr17:18650195~18651542:+
BRCA	trans	rs12210905	0.61	rs72845208	ENSG00000242375.1	RP11-498P14.3	-7.48	1.6e-13	1.64e-07	-0.59	-0.23	Hip circumference adjusted for BMI;	chr6:27427885	chr9:97195351~97197687:-
BRCA	trans	rs1568889	0.838	rs11030265	ENSG00000174912.7	METTL15P1	7.48	1.6e-13	1.64e-07	0.23	0.23	Bipolar disorder;	chr11:28274621	chr3:156713884~156714928:-
BRCA	trans	rs4948102	0.595	rs7793921	ENSG00000186940.6	CHCHD2P9	-7.48	1.61e-13	1.65e-07	-0.27	-0.23	Plasma homocysteine levels (post-methionine load test);	chr7:56053188	chr9:79391304~79391759:+
BRCA	trans	rs1933488	1	rs1933488	ENSG00000278974.1	RP11-756P10.6	-7.48	1.61e-13	1.65e-07	-0.29	-0.23	Prostate cancer;	chr6:153119944	chr4:188740507~188741281:-
BRCA	trans	rs877636	0.74	rs705702	ENSG00000224553.1	AC008065.1	-7.48	1.62e-13	1.66e-07	-0.28	-0.23	Cognitive function;	chr12:55996852	chr2:171374931~171375278:-
BRCA	trans	rs12210905	0.688	rs72843191	ENSG00000242375.1	RP11-498P14.3	-7.48	1.62e-13	1.66e-07	-0.59	-0.23	Hip circumference adjusted for BMI;	chr6:27415522	chr9:97195351~97197687:-
BRCA	trans	rs13016963	0.625	rs13015294	ENSG00000235105.1	RP11-329A14.1	7.48	1.62e-13	1.66e-07	0.29	0.23	Esophageal squamous cell carcinoma;Melanoma;	chr2:201310267	chr1:48435967~48437223:+
BRCA	trans	rs7200543	0.961	rs1741	ENSG00000250569.1	NTAN1P2	7.48	1.63e-13	1.67e-07	0.25	0.23	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15036494	chr8:86481754~86483002:-
BRCA	trans	rs3806843	0.576	rs246008	ENSG00000231043.3	AC007238.1	-7.47	1.64e-13	1.68e-07	-0.27	-0.23	Depressive symptoms (multi-trait analysis);	chr5:140958900	chr2:58460292~58462032:-
BRCA	trans	rs801193	1	rs4717319	ENSG00000164669.11	INTS4P1	-7.47	1.64e-13	1.68e-07	-0.28	-0.23	Aortic root size;	chr7:66777606	chr7:65141225~65234216:+
BRCA	trans	rs10940346	0.506	rs10454829	ENSG00000231752.4	EMBP1	-7.47	1.67e-13	1.71e-07	-0.29	-0.23	Schizophrenia;	chr5:50585120	chr1:121519112~121571892:+
BRCA	trans	rs3806843	0.576	rs246007	ENSG00000231043.3	AC007238.1	-7.47	1.68e-13	1.72e-07	-0.27	-0.23	Depressive symptoms (multi-trait analysis);	chr5:140959163	chr2:58460292~58462032:-
BRCA	trans	rs3806843	0.576	rs246006	ENSG00000231043.3	AC007238.1	-7.47	1.68e-13	1.72e-07	-0.27	-0.23	Depressive symptoms (multi-trait analysis);	chr5:140959643	chr2:58460292~58462032:-
BRCA	trans	rs3806843	0.576	rs246005	ENSG00000231043.3	AC007238.1	-7.47	1.68e-13	1.72e-07	-0.27	-0.23	Depressive symptoms (multi-trait analysis);	chr5:140960299	chr2:58460292~58462032:-
BRCA	trans	rs3806843	0.576	rs246003	ENSG00000231043.3	AC007238.1	-7.47	1.68e-13	1.72e-07	-0.27	-0.23	Depressive symptoms (multi-trait analysis);	chr5:140961280	chr2:58460292~58462032:-
BRCA	trans	rs14057	0.929	rs12755051	ENSG00000215869.3	RP11-364B6.1	7.47	1.7e-13	1.74e-07	0.31	0.23	Systolic blood pressure;	chr1:6658318	chr1:104073023~104077087:+
BRCA	trans	rs12210905	0.688	rs12209905	ENSG00000242375.1	RP11-498P14.3	-7.47	1.7e-13	1.74e-07	-0.59	-0.23	Hip circumference adjusted for BMI;	chr6:27436813	chr9:97195351~97197687:-
BRCA	trans	rs12210905	0.688	rs12213471	ENSG00000242375.1	RP11-498P14.3	-7.47	1.7e-13	1.74e-07	-0.59	-0.23	Hip circumference adjusted for BMI;	chr6:27438284	chr9:97195351~97197687:-
BRCA	trans	rs12210905	0.688	rs12215386	ENSG00000242375.1	RP11-498P14.3	-7.47	1.7e-13	1.74e-07	-0.59	-0.23	Hip circumference adjusted for BMI;	chr6:27439098	chr9:97195351~97197687:-
BRCA	trans	rs12210905	0.688	rs12215353	ENSG00000242375.1	RP11-498P14.3	-7.47	1.7e-13	1.74e-07	-0.59	-0.23	Hip circumference adjusted for BMI;	chr6:27439243	chr9:97195351~97197687:-
BRCA	trans	rs12210905	0.687	rs12191649	ENSG00000242375.1	RP11-498P14.3	-7.47	1.7e-13	1.74e-07	-0.59	-0.23	Hip circumference adjusted for BMI;	chr6:27453429	chr9:97195351~97197687:-
BRCA	trans	rs11098499	0.955	rs1551	ENSG00000120555.12	SEPT7P9	7.47	1.71e-13	1.75e-07	0.28	0.23	Corneal astigmatism;	chr4:119237345	chr10:38383069~38402916:-
BRCA	trans	rs877636	0.74	rs705698	ENSG00000244604.1	RP11-713H12.1	7.47	1.71e-13	1.75e-07	0.28	0.23	Cognitive function;	chr12:55990903	chr17:8561230~8561576:+
BRCA	trans	rs6921919	0.887	rs7766356	ENSG00000228078.1	HLA-U	-7.47	1.74e-13	1.78e-07	-0.4	-0.23	Autism spectrum disorder or schizophrenia;	chr6:28432761	chr6:29934101~29934286:+
BRCA	trans	rs4879656	0.564	rs4879657	ENSG00000215007.3	DNAJA1P3	7.47	1.74e-13	1.78e-07	0.27	0.23	Menopause (age at onset);	chr9:33012467	chrX:107351650~107352843:-
BRCA	trans	rs9584850	0.794	rs17470961	ENSG00000230079.1	STK24P1	7.47	1.74e-13	1.78e-07	0.29	0.23	Neuroticism;	chr13:98483060	chrX:136295690~136300298:-
BRCA	trans	rs9914988	0.943	rs4795457	ENSG00000267449.1	RP11-264B14.2	7.47	1.75e-13	1.78e-07	0.31	0.23	Glycated hemoglobin levels;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr17:28760911	chr17:61069856~61070356:-
BRCA	trans	rs11098499	1	rs12506395	ENSG00000120555.12	SEPT7P9	7.47	1.75e-13	1.78e-07	0.28	0.23	Corneal astigmatism;	chr4:119263939	chr10:38383069~38402916:-
BRCA	trans	rs7662987	1	rs28730587	ENSG00000228407.2	RP4-800M22.1	7.46	1.76e-13	1.8e-07	0.51	0.23	Smoking initiation;	chr4:99083190	chr1:52160261~52160600:-
BRCA	trans	rs7833986	0.501	rs2976012	ENSG00000244245.1	RP11-120B7.1	7.46	1.76e-13	1.8e-07	0.29	0.23	Height;	chr8:56061784	chr5:108593609~108593967:+
BRCA	trans	rs7833986	0.501	rs2953922	ENSG00000244245.1	RP11-120B7.1	7.46	1.76e-13	1.8e-07	0.29	0.23	Height;	chr8:56064926	chr5:108593609~108593967:+
BRCA	trans	rs7833986	0.501	rs2953897	ENSG00000244245.1	RP11-120B7.1	7.46	1.76e-13	1.8e-07	0.29	0.23	Height;	chr8:56068010	chr5:108593609~108593967:+
BRCA	trans	rs7833986	0.501	rs2953901	ENSG00000244245.1	RP11-120B7.1	7.46	1.76e-13	1.8e-07	0.29	0.23	Height;	chr8:56069265	chr5:108593609~108593967:+
BRCA	trans	rs12210905	0.688	rs114188783	ENSG00000242375.1	RP11-498P14.3	-7.46	1.77e-13	1.81e-07	-0.58	-0.23	Hip circumference adjusted for BMI;	chr6:27481825	chr9:97195351~97197687:-
BRCA	trans	rs12210905	0.688	rs114843651	ENSG00000242375.1	RP11-498P14.3	-7.46	1.77e-13	1.81e-07	-0.58	-0.23	Hip circumference adjusted for BMI;	chr6:27481832	chr9:97195351~97197687:-
BRCA	trans	rs1933488	0.931	rs3870365	ENSG00000278974.1	RP11-756P10.6	-7.46	1.78e-13	1.81e-07	-0.29	-0.23	Prostate cancer;	chr6:153105797	chr4:188740507~188741281:-
BRCA	trans	rs11992162	0.967	rs10108320	ENSG00000253893.2	FAM85B	7.46	1.79e-13	1.83e-07	0.28	0.23	Monocyte count;	chr8:11974754	chr8:8167819~8226614:-
BRCA	trans	rs10783779	0.647	rs705708	ENSG00000233778.3	RP11-777J24.1	7.46	1.79e-13	1.83e-07	0.26	0.23	Educational attainment;	chr12:56095129	chr8:92144088~92144435:-
BRCA	trans	rs6915893	0.933	rs4588678	ENSG00000267156.1	TPMTP1	7.46	1.8e-13	1.83e-07	0.29	0.23	Intrinsic epigenetic age acceleration;	chr6:18119246	chr18:47630112~47630848:+
BRCA	trans	rs4948102	0.595	rs10255049	ENSG00000186940.6	CHCHD2P9	-7.46	1.8e-13	1.84e-07	-0.27	-0.23	Plasma homocysteine levels (post-methionine load test);	chr7:56053611	chr9:79391304~79391759:+
BRCA	trans	rs12210905	0.925	rs7740207	ENSG00000242375.1	RP11-498P14.3	-7.46	1.8e-13	1.84e-07	-0.49	-0.23	Hip circumference adjusted for BMI;	chr6:27033844	chr9:97195351~97197687:-
BRCA	trans	rs11098499	0.954	rs67265404	ENSG00000120555.12	SEPT7P9	7.46	1.81e-13	1.84e-07	0.28	0.23	Corneal astigmatism;	chr4:119438115	chr10:38383069~38402916:-
BRCA	trans	rs9425766	0.679	rs4650945	ENSG00000213331.4	RP11-713C19.2	-7.46	1.81e-13	1.84e-07	-0.25	-0.23	Life satisfaction;	chr1:174114966	chr4:187970273~187971284:+
BRCA	trans	rs9834975	0.608	rs9289193	ENSG00000267076.1	CCDC58P3	-7.46	1.81e-13	1.85e-07	-0.27	-0.23	Diastolic blood pressure;	chr3:122416042	chr18:12211378~12211807:+
BRCA	trans	rs11920570	0.92	rs7628052	ENSG00000267076.1	CCDC58P3	-7.46	1.82e-13	1.85e-07	-0.3	-0.23	Resting heart rate;	chr3:122528759	chr18:12211378~12211807:+
BRCA	trans	rs3806843	0.576	rs155359	ENSG00000231043.3	AC007238.1	-7.46	1.83e-13	1.86e-07	-0.27	-0.23	Depressive symptoms (multi-trait analysis);	chr5:140935840	chr2:58460292~58462032:-
BRCA	trans	rs9914988	0.943	rs7215000	ENSG00000267449.1	RP11-264B14.2	7.46	1.83e-13	1.86e-07	0.31	0.23	Glycated hemoglobin levels;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr17:28761418	chr17:61069856~61070356:-
BRCA	trans	rs11098499	0.865	rs11098513	ENSG00000120555.12	SEPT7P9	7.46	1.83e-13	1.87e-07	0.28	0.23	Corneal astigmatism;	chr4:119394920	chr10:38383069~38402916:-
BRCA	trans	rs1568889	0.774	rs11030235	ENSG00000174912.7	METTL15P1	7.46	1.83e-13	1.87e-07	0.23	0.23	Bipolar disorder;	chr11:28190828	chr3:156713884~156714928:-
BRCA	trans	rs9467711	0.606	rs1978	ENSG00000253570.1	RNF5P1	7.46	1.83e-13	1.87e-07	0.51	0.23	Autism spectrum disorder or schizophrenia;	chr6:26377345	chr8:38600661~38601200:-
BRCA	trans	rs9467711	0.79	rs1979	ENSG00000253570.1	RNF5P1	7.46	1.84e-13	1.87e-07	0.53	0.23	Autism spectrum disorder or schizophrenia;	chr6:26377363	chr8:38600661~38601200:-
BRCA	trans	rs801193	1	rs3800812	ENSG00000164669.11	INTS4P1	-7.46	1.84e-13	1.87e-07	-0.28	-0.23	Aortic root size;	chr7:66758474	chr7:65141225~65234216:+
BRCA	trans	rs801193	1	rs4279493	ENSG00000164669.11	INTS4P1	-7.46	1.84e-13	1.87e-07	-0.28	-0.23	Aortic root size;	chr7:66761633	chr7:65141225~65234216:+
BRCA	trans	rs28541881	0.536	rs117295911	ENSG00000270983.1	RP11-137J7.3	-7.46	1.84e-13	1.88e-07	-0.46	-0.23	Colorectal cancer;	chr19:34376524	chr6:142062717~142063053:+
BRCA	trans	rs9581094	0.591	rs73154385	ENSG00000237917.1	PARP4P1	-7.46	1.84e-13	1.88e-07	-0.46	-0.23	Sudden cardiac arrest;	chr13:24502579	chrY:26594851~26634652:-
BRCA	trans	rs11098499	0.908	rs7695996	ENSG00000120555.12	SEPT7P9	7.46	1.85e-13	1.88e-07	0.28	0.23	Corneal astigmatism;	chr4:119400878	chr10:38383069~38402916:-
BRCA	trans	rs1707322	0.721	rs10890341	ENSG00000255397.1	AC022182.2	-7.46	1.87e-13	1.91e-07	-0.3	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45681568	chr8:60937705~60939871:-
BRCA	trans	rs7617773	0.817	rs9830016	ENSG00000235912.1	RP1-159A19.3	-7.46	1.87e-13	1.91e-07	-0.28	-0.23	Coronary artery disease;	chr3:48241004	chr1:27649419~27649610:+
BRCA	trans	rs11098499	0.954	rs2389803	ENSG00000276997.3	RP11-378J18.9	-7.46	1.88e-13	1.92e-07	-0.27	-0.23	Corneal astigmatism;	chr4:119472356	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.821	rs10032151	ENSG00000276997.3	RP11-378J18.9	7.46	1.89e-13	1.92e-07	0.28	0.23	Corneal astigmatism;	chr4:119470473	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.865	rs10032158	ENSG00000276997.3	RP11-378J18.9	7.46	1.89e-13	1.92e-07	0.28	0.23	Corneal astigmatism;	chr4:119470477	chr1:222477252~222504622:-
BRCA	trans	rs11098499	1	rs3749591	ENSG00000120555.12	SEPT7P9	7.45	1.89e-13	1.93e-07	0.29	0.23	Corneal astigmatism;	chr4:119292875	chr10:38383069~38402916:-
BRCA	trans	rs3806843	0.576	rs246024	ENSG00000231043.3	AC007238.1	-7.45	1.9e-13	1.94e-07	-0.27	-0.22	Depressive symptoms (multi-trait analysis);	chr5:140954367	chr2:58460292~58462032:-
BRCA	trans	rs3806843	0.546	rs246023	ENSG00000231043.3	AC007238.1	-7.45	1.9e-13	1.94e-07	-0.27	-0.22	Depressive symptoms (multi-trait analysis);	chr5:140954405	chr2:58460292~58462032:-
BRCA	trans	rs11920570	0.959	rs12488797	ENSG00000267076.1	CCDC58P3	-7.45	1.91e-13	1.94e-07	-0.3	-0.22	Resting heart rate;	chr3:122455957	chr18:12211378~12211807:+
BRCA	trans	rs11920570	0.881	rs73190122	ENSG00000267076.1	CCDC58P3	-7.45	1.91e-13	1.94e-07	-0.3	-0.22	Resting heart rate;	chr3:122459050	chr18:12211378~12211807:+
BRCA	trans	rs11920570	0.959	rs11927245	ENSG00000267076.1	CCDC58P3	-7.45	1.91e-13	1.94e-07	-0.3	-0.22	Resting heart rate;	chr3:122465786	chr18:12211378~12211807:+
BRCA	trans	rs11920570	0.959	rs6773720	ENSG00000267076.1	CCDC58P3	-7.45	1.91e-13	1.94e-07	-0.3	-0.22	Resting heart rate;	chr3:122473066	chr18:12211378~12211807:+
BRCA	trans	rs11920570	0.959	rs73190134	ENSG00000267076.1	CCDC58P3	-7.45	1.91e-13	1.94e-07	-0.3	-0.22	Resting heart rate;	chr3:122473792	chr18:12211378~12211807:+
BRCA	trans	rs12477438	0.52	rs8179690	ENSG00000276576.1	MRPL30P1	-7.45	1.91e-13	1.95e-07	-0.28	-0.22	Chronic sinus infection;	chr2:99178837	chr6:57029521~57029988:+
BRCA	trans	rs11920570	0.959	rs10934592	ENSG00000267076.1	CCDC58P3	-7.45	1.92e-13	1.96e-07	-0.3	-0.22	Resting heart rate;	chr3:122416395	chr18:12211378~12211807:+
BRCA	trans	rs11098499	0.954	rs6838814	ENSG00000276997.3	RP11-378J18.9	7.45	1.93e-13	1.97e-07	0.28	0.22	Corneal astigmatism;	chr4:119471288	chr1:222477252~222504622:-
BRCA	trans	rs10940346	0.506	rs12187591	ENSG00000231752.4	EMBP1	-7.45	1.94e-13	1.97e-07	-0.29	-0.22	Schizophrenia;	chr5:50586789	chr1:121519112~121571892:+
BRCA	trans	rs6732160	0.588	rs72841902	ENSG00000236165.1	PRADC1P1	7.45	1.94e-13	1.97e-07	0.3	0.22	Intelligence (multi-trait analysis);	chr2:73145084	chr3:36976316~36976840:+
BRCA	trans	rs4713118	0.523	rs2179096	ENSG00000204709.4	LINC01556	7.45	1.94e-13	1.97e-07	0.29	0.22	Parkinson's disease;	chr6:27698141	chr6:28943877~28944537:+
BRCA	trans	rs2243480	0.901	rs3813708	ENSG00000273142.1	RP11-458F8.4	-7.45	1.95e-13	1.99e-07	-0.31	-0.22	Diabetic kidney disease;	chr7:65840645	chr7:66902857~66906297:+
BRCA	trans	rs11775334	0.599	rs11774836	ENSG00000253893.2	FAM85B	7.45	1.95e-13	1.99e-07	0.29	0.22	Hypertension;	chr8:10205033	chr8:8167819~8226614:-
BRCA	trans	rs4879656	0.564	rs7864363	ENSG00000215007.3	DNAJA1P3	-7.45	1.95e-13	1.99e-07	-0.27	-0.22	Menopause (age at onset);	chr9:33022002	chrX:107351650~107352843:-
BRCA	trans	rs9467711	0.606	rs9358930	ENSG00000253570.1	RNF5P1	7.45	1.97e-13	2e-07	0.54	0.22	Autism spectrum disorder or schizophrenia;	chr6:26356783	chr8:38600661~38601200:-
BRCA	trans	rs9467711	0.606	rs9379852	ENSG00000253570.1	RNF5P1	7.45	1.97e-13	2e-07	0.54	0.22	Autism spectrum disorder or schizophrenia;	chr6:26357050	chr8:38600661~38601200:-
BRCA	trans	rs9467711	0.523	rs9379853	ENSG00000253570.1	RNF5P1	7.45	1.97e-13	2e-07	0.54	0.22	Autism spectrum disorder or schizophrenia;	chr6:26357407	chr8:38600661~38601200:-
BRCA	trans	rs9379850	0.527	rs9393704	ENSG00000253570.1	RNF5P1	7.45	1.97e-13	2e-07	0.54	0.22	Intelligence (multi-trait analysis);	chr6:26358547	chr8:38600661~38601200:-
BRCA	trans	rs9467711	0.606	rs72836482	ENSG00000253570.1	RNF5P1	7.45	1.97e-13	2e-07	0.54	0.22	Autism spectrum disorder or schizophrenia;	chr6:26359013	chr8:38600661~38601200:-
BRCA	trans	rs9467711	0.606	rs9348709	ENSG00000253570.1	RNF5P1	7.45	1.97e-13	2e-07	0.54	0.22	Autism spectrum disorder or schizophrenia;	chr6:26360083	chr8:38600661~38601200:-
BRCA	trans	rs9467711	0.606	rs9393705	ENSG00000253570.1	RNF5P1	7.45	1.97e-13	2e-07	0.54	0.22	Autism spectrum disorder or schizophrenia;	chr6:26360783	chr8:38600661~38601200:-
BRCA	trans	rs9467711	0.606	rs9393706	ENSG00000253570.1	RNF5P1	7.45	1.97e-13	2e-07	0.54	0.22	Autism spectrum disorder or schizophrenia;	chr6:26361272	chr8:38600661~38601200:-
BRCA	trans	rs4720118	0.508	rs2392232	ENSG00000213492.2	NT5C3AP1	7.45	1.98e-13	2.02e-07	0.29	0.22	Leprosy;	chr7:33397224	chr4:117574512~117576174:-
BRCA	trans	rs11098499	0.954	rs71629403	ENSG00000120555.12	SEPT7P9	7.45	1.99e-13	2.02e-07	0.28	0.22	Corneal astigmatism;	chr4:119451412	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.909	rs28571712	ENSG00000120555.12	SEPT7P9	7.45	1.99e-13	2.02e-07	0.28	0.22	Corneal astigmatism;	chr4:119454825	chr10:38383069~38402916:-
BRCA	trans	rs1933488	0.931	rs9397587	ENSG00000278974.1	RP11-756P10.6	-7.45	1.99e-13	2.02e-07	-0.29	-0.22	Prostate cancer;	chr6:153095777	chr4:188740507~188741281:-
BRCA	trans	rs7662987	1	rs13125919	ENSG00000228407.2	RP4-800M22.1	7.45	1.99e-13	2.02e-07	0.5	0.22	Smoking initiation;	chr4:99078697	chr1:52160261~52160600:-
BRCA	trans	rs12210905	0.925	rs72838260	ENSG00000242375.1	RP11-498P14.3	-7.45	2.01e-13	2.04e-07	-0.49	-0.22	Hip circumference adjusted for BMI;	chr6:27040389	chr9:97195351~97197687:-
BRCA	trans	rs1568889	0.775	rs35243076	ENSG00000174912.7	METTL15P1	7.45	2.01e-13	2.05e-07	0.23	0.22	Bipolar disorder;	chr11:28229071	chr3:156713884~156714928:-
BRCA	trans	rs10838687	1	rs10838687	ENSG00000134612.10	FOLH1B	7.45	2.01e-13	2.05e-07	0.32	0.22	Proinsulin levels;	chr11:47291341	chr11:89639227~89698718:+
BRCA	trans	rs7819412	0.521	rs9329238	ENSG00000253893.2	FAM85B	7.45	2.02e-13	2.05e-07	0.29	0.22	Triglycerides;	chr8:11176228	chr8:8167819~8226614:-
BRCA	trans	rs877636	1	rs4759229	ENSG00000212829.8	RPS26P3	-7.44	2.05e-13	2.08e-07	-0.29	-0.22	Cognitive function;	chr12:56080696	chr9:9090898~9091245:+
BRCA	trans	rs12210905	0.688	rs12199806	ENSG00000242375.1	RP11-498P14.3	-7.44	2.06e-13	2.09e-07	-0.58	-0.22	Hip circumference adjusted for BMI;	chr6:27468164	chr9:97195351~97197687:-
BRCA	trans	rs12210905	0.688	rs12193557	ENSG00000242375.1	RP11-498P14.3	-7.44	2.06e-13	2.09e-07	-0.58	-0.22	Hip circumference adjusted for BMI;	chr6:27468165	chr9:97195351~97197687:-
BRCA	trans	rs12210905	0.688	rs12209174	ENSG00000242375.1	RP11-498P14.3	-7.44	2.06e-13	2.09e-07	-0.58	-0.22	Hip circumference adjusted for BMI;	chr6:27476173	chr9:97195351~97197687:-
BRCA	trans	rs11098499	0.863	rs13136462	ENSG00000120555.12	SEPT7P9	7.44	2.07e-13	2.1e-07	0.28	0.22	Corneal astigmatism;	chr4:119622018	chr10:38383069~38402916:-
BRCA	trans	rs11920570	0.959	rs73190173	ENSG00000267076.1	CCDC58P3	-7.44	2.08e-13	2.11e-07	-0.3	-0.22	Resting heart rate;	chr3:122504978	chr18:12211378~12211807:+
BRCA	trans	rs9584850	0.834	rs7334078	ENSG00000230079.1	STK24P1	-7.44	2.12e-13	2.15e-07	-0.29	-0.22	Neuroticism;	chr13:98468230	chrX:136295690~136300298:-
BRCA	trans	rs7662987	1	rs4699699	ENSG00000228407.2	RP4-800M22.1	7.44	2.14e-13	2.17e-07	0.5	0.22	Smoking initiation;	chr4:99076028	chr1:52160261~52160600:-
BRCA	trans	rs7662987	0.938	rs13118409	ENSG00000228407.2	RP4-800M22.1	7.44	2.14e-13	2.17e-07	0.5	0.22	Smoking initiation;	chr4:99077585	chr1:52160261~52160600:-
BRCA	trans	rs7662987	1	rs13119035	ENSG00000228407.2	RP4-800M22.1	7.44	2.14e-13	2.17e-07	0.5	0.22	Smoking initiation;	chr4:99077979	chr1:52160261~52160600:-
BRCA	trans	rs11638815	0.668	rs11635460	ENSG00000235370.6	DNM1P51	-7.44	2.14e-13	2.18e-07	-0.25	-0.22	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82725801	chr15:84398316~84411701:-
BRCA	trans	rs6732160	0.588	rs62151795	ENSG00000236165.1	PRADC1P1	7.44	2.15e-13	2.18e-07	0.3	0.22	Intelligence (multi-trait analysis);	chr2:73149712	chr3:36976316~36976840:+
BRCA	trans	rs11098499	0.58	rs12509234	ENSG00000120555.12	SEPT7P9	7.44	2.16e-13	2.19e-07	0.28	0.22	Corneal astigmatism;	chr4:119398279	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.909	rs10014719	ENSG00000120555.12	SEPT7P9	7.44	2.16e-13	2.19e-07	0.28	0.22	Corneal astigmatism;	chr4:119399560	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.954	rs6847248	ENSG00000120555.12	SEPT7P9	7.44	2.16e-13	2.2e-07	0.3	0.22	Corneal astigmatism;	chr4:119304800	chr10:38383069~38402916:-
BRCA	trans	rs2069408	1	rs2069408	ENSG00000234513.1	AC073072.7	-7.44	2.17e-13	2.2e-07	-0.3	-0.22	Asthma;	chr12:55970537	chr7:22773646~22773993:-
BRCA	trans	rs801193	1	rs10234018	ENSG00000164669.11	INTS4P1	7.43	2.19e-13	2.22e-07	0.28	0.22	Aortic root size;	chr7:66681297	chr7:65141225~65234216:+
BRCA	trans	rs6732160	0.588	rs1430344	ENSG00000236165.1	PRADC1P1	7.43	2.22e-13	2.25e-07	0.3	0.22	Intelligence (multi-trait analysis);	chr2:73146216	chr3:36976316~36976840:+
BRCA	trans	rs10838708	1	rs10838708	ENSG00000134612.10	FOLH1B	-7.43	2.22e-13	2.25e-07	-0.28	-0.22	Height;	chr11:47419962	chr11:89639227~89698718:+
BRCA	trans	rs11098499	1	rs28374891	ENSG00000120555.12	SEPT7P9	7.43	2.24e-13	2.26e-07	0.28	0.22	Corneal astigmatism;	chr4:119262395	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.908	rs11098527	ENSG00000120555.12	SEPT7P9	7.43	2.24e-13	2.27e-07	0.28	0.22	Corneal astigmatism;	chr4:119478751	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.954	rs17005535	ENSG00000276997.3	RP11-378J18.9	7.43	2.24e-13	2.27e-07	0.27	0.22	Corneal astigmatism;	chr4:119490407	chr1:222477252~222504622:-
BRCA	trans	rs10028773	0.546	rs13117947	ENSG00000275858.1	RP11-291L22.8	7.43	2.26e-13	2.29e-07	0.25	0.22	Educational attainment;	chr4:119335905	chr10:38450738~38451069:-
BRCA	trans	rs6732160	0.564	rs1430346	ENSG00000236165.1	PRADC1P1	7.43	2.26e-13	2.29e-07	0.31	0.22	Intelligence (multi-trait analysis);	chr2:73140117	chr3:36976316~36976840:+
BRCA	trans	rs11098499	0.954	rs12510138	ENSG00000120555.12	SEPT7P9	7.43	2.26e-13	2.29e-07	0.28	0.22	Corneal astigmatism;	chr4:119502780	chr10:38383069~38402916:-
BRCA	trans	rs9581094	1	rs73154395	ENSG00000237917.1	PARP4P1	-7.43	2.27e-13	2.3e-07	-0.45	-0.22	Sudden cardiac arrest;	chr13:24507665	chrY:26594851~26634652:-
BRCA	trans	rs875971	0.66	rs2013222	ENSG00000164669.11	INTS4P1	7.43	2.27e-13	2.3e-07	0.27	0.22	Aortic root size;	chr7:66570949	chr7:65141225~65234216:+
BRCA	trans	rs3799379	0.53	rs10456045	ENSG00000242375.1	RP11-498P14.3	7.43	2.28e-13	2.3e-07	0.36	0.22	Intelligence (multi-trait analysis);	chr6:26404730	chr9:97195351~97197687:-
BRCA	trans	rs801193	0.761	rs2659888	ENSG00000164669.11	INTS4P1	-7.43	2.28e-13	2.3e-07	-0.27	-0.22	Aortic root size;	chr7:66765184	chr7:65141225~65234216:+
BRCA	trans	rs864643	0.898	rs1631776	ENSG00000183298.5	RP11-556K13.1	7.43	2.28e-13	2.31e-07	0.34	0.22	Attention deficit hyperactivity disorder;	chr3:39548704	chr1:101786340~101787219:-
BRCA	trans	rs4879656	0.525	rs7852206	ENSG00000215007.3	DNAJA1P3	7.43	2.28e-13	2.31e-07	0.27	0.22	Menopause (age at onset);	chr9:33017383	chrX:107351650~107352843:-
BRCA	trans	rs801193	0.935	rs2659899	ENSG00000164669.11	INTS4P1	-7.43	2.29e-13	2.31e-07	-0.27	-0.22	Aortic root size;	chr7:66721734	chr7:65141225~65234216:+
BRCA	trans	rs7200543	0.961	rs3803573	ENSG00000250569.1	NTAN1P2	7.43	2.29e-13	2.31e-07	0.25	0.22	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15044556	chr8:86481754~86483002:-
BRCA	trans	rs11920570	0.959	rs73190168	ENSG00000267076.1	CCDC58P3	-7.43	2.29e-13	2.32e-07	-0.29	-0.22	Resting heart rate;	chr3:122503250	chr18:12211378~12211807:+
BRCA	trans	rs1707322	0.682	rs12037459	ENSG00000255397.1	AC022182.2	-7.43	2.31e-13	2.33e-07	-0.3	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45629287	chr8:60937705~60939871:-
BRCA	trans	rs7200543	1	rs3803575	ENSG00000250569.1	NTAN1P2	7.43	2.32e-13	2.34e-07	0.24	0.22	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15044590	chr8:86481754~86483002:-
BRCA	trans	rs62436127	0.818	rs4870153	ENSG00000278974.1	RP11-756P10.6	7.43	2.32e-13	2.34e-07	0.4	0.22	Morning vs. evening chronotype;	chr6:152948137	chr4:188740507~188741281:-
BRCA	trans	rs3740713	1	rs79199586	ENSG00000214110.3	LDHAP4	7.43	2.34e-13	2.36e-07	0.45	0.22	Amyotrophic lateral sclerosis (sporadic);	chr11:18430599	chr9:14921337~14922334:-
BRCA	trans	rs67340775	0.541	rs200965	ENSG00000204709.4	LINC01556	7.43	2.34e-13	2.36e-07	0.38	0.22	Lung cancer in ever smokers;	chr6:27898606	chr6:28943877~28944537:+
BRCA	trans	rs801193	1	rs2055682	ENSG00000224316.1	RP11-479O9.2	7.43	2.34e-13	2.36e-07	0.22	0.22	Aortic root size;	chr7:66795302	chr7:65773620~65802067:+
BRCA	trans	rs4883201	0.656	rs1805248	ENSG00000179899.8	PHC1P1	7.42	2.34e-13	2.37e-07	0.27	0.22	Total cholesterol levels;Cholesterol, total;	chr12:8948541	chr12:55411727~55414787:-
BRCA	trans	rs801193	1	rs7785213	ENSG00000164669.11	INTS4P1	7.42	2.35e-13	2.37e-07	0.28	0.22	Aortic root size;	chr7:66673991	chr7:65141225~65234216:+
BRCA	trans	rs11098499	0.954	rs10006525	ENSG00000276997.3	RP11-378J18.9	7.42	2.35e-13	2.37e-07	0.27	0.22	Corneal astigmatism;	chr4:119487776	chr1:222477252~222504622:-
BRCA	trans	rs801193	0.967	rs2707841	ENSG00000164669.11	INTS4P1	-7.42	2.37e-13	2.4e-07	-0.27	-0.22	Aortic root size;	chr7:66692033	chr7:65141225~65234216:+
BRCA	trans	rs801193	1	rs4717310	ENSG00000164669.11	INTS4P1	-7.42	2.37e-13	2.4e-07	-0.27	-0.22	Aortic root size;	chr7:66696020	chr7:65141225~65234216:+
BRCA	trans	rs9581094	0.591	rs73154388	ENSG00000237917.1	PARP4P1	-7.42	2.38e-13	2.4e-07	-0.46	-0.22	Sudden cardiac arrest;	chr13:24503004	chrY:26594851~26634652:-
BRCA	trans	rs9581094	0.591	rs28569917	ENSG00000237917.1	PARP4P1	-7.42	2.38e-13	2.4e-07	-0.46	-0.22	Sudden cardiac arrest;	chr13:24504227	chrY:26594851~26634652:-
BRCA	trans	rs2243480	1	rs4718270	ENSG00000273142.1	RP11-458F8.4	-7.42	2.39e-13	2.42e-07	-0.31	-0.22	Diabetic kidney disease;	chr7:65737415	chr7:66902857~66906297:+
BRCA	trans	rs1933488	1	rs6901126	ENSG00000278974.1	RP11-756P10.6	7.42	2.41e-13	2.44e-07	0.29	0.22	Prostate cancer;	chr6:153118927	chr4:188740507~188741281:-
BRCA	trans	rs12477438	0.501	rs2632284	ENSG00000276576.1	MRPL30P1	7.42	2.41e-13	2.44e-07	0.28	0.22	Chronic sinus infection;	chr2:99159402	chr6:57029521~57029988:+
BRCA	trans	rs12477438	0.52	rs2969379	ENSG00000276576.1	MRPL30P1	7.42	2.41e-13	2.44e-07	0.28	0.22	Chronic sinus infection;	chr2:99160223	chr6:57029521~57029988:+
BRCA	trans	rs12477438	0.52	rs12621007	ENSG00000276576.1	MRPL30P1	7.42	2.41e-13	2.44e-07	0.28	0.22	Chronic sinus infection;	chr2:99175483	chr6:57029521~57029988:+
BRCA	trans	rs3806843	0.612	rs246075	ENSG00000231043.3	AC007238.1	-7.42	2.42e-13	2.44e-07	-0.27	-0.22	Depressive symptoms (multi-trait analysis);	chr5:140920972	chr2:58460292~58462032:-
BRCA	trans	rs2069408	1	rs2069408	ENSG00000242970.2	AC068522.4	-7.42	2.42e-13	2.44e-07	-0.33	-0.22	Asthma;	chr12:55970537	chr8:58588420~58588764:-
BRCA	trans	rs11098499	0.954	rs3890049	ENSG00000120555.12	SEPT7P9	7.42	2.42e-13	2.45e-07	0.28	0.22	Corneal astigmatism;	chr4:119405128	chr10:38383069~38402916:-
BRCA	trans	rs2002594	0.816	rs6438734	ENSG00000267076.1	CCDC58P3	-7.42	2.43e-13	2.45e-07	-0.26	-0.22	Risky sexual behaviors (alcohol dependence interaction);	chr3:122500414	chr18:12211378~12211807:+
BRCA	trans	rs1568889	0.838	rs10767708	ENSG00000174912.7	METTL15P1	7.42	2.45e-13	2.47e-07	0.23	0.22	Bipolar disorder;	chr11:28273300	chr3:156713884~156714928:-
BRCA	trans	rs12210905	0.614	rs12199685	ENSG00000242375.1	RP11-498P14.3	-7.42	2.48e-13	2.51e-07	-0.59	-0.22	Hip circumference adjusted for BMI;	chr6:27355707	chr9:97195351~97197687:-
BRCA	trans	rs12210905	0.688	rs72839474	ENSG00000242375.1	RP11-498P14.3	-7.42	2.48e-13	2.51e-07	-0.59	-0.22	Hip circumference adjusted for BMI;	chr6:27356978	chr9:97195351~97197687:-
BRCA	trans	rs12210905	0.688	rs12212389	ENSG00000242375.1	RP11-498P14.3	-7.42	2.48e-13	2.51e-07	-0.59	-0.22	Hip circumference adjusted for BMI;	chr6:27358618	chr9:97195351~97197687:-
BRCA	trans	rs12210905	0.688	rs114157955	ENSG00000242375.1	RP11-498P14.3	-7.42	2.48e-13	2.51e-07	-0.59	-0.22	Hip circumference adjusted for BMI;	chr6:27362099	chr9:97195351~97197687:-
BRCA	trans	rs12210905	0.688	rs12196452	ENSG00000242375.1	RP11-498P14.3	-7.42	2.48e-13	2.51e-07	-0.59	-0.22	Hip circumference adjusted for BMI;	chr6:27376636	chr9:97195351~97197687:-
BRCA	trans	rs12210905	0.688	rs12213533	ENSG00000242375.1	RP11-498P14.3	-7.42	2.48e-13	2.51e-07	-0.59	-0.22	Hip circumference adjusted for BMI;	chr6:27378242	chr9:97195351~97197687:-
BRCA	trans	rs9393777	0.841	rs34332556	ENSG00000253570.1	RNF5P1	7.42	2.48e-13	2.51e-07	0.59	0.22	Intelligence (multi-trait analysis);	chr6:27389635	chr8:38600661~38601200:-
BRCA	trans	rs13016963	0.526	rs6726823	ENSG00000235105.1	RP11-329A14.1	7.42	2.49e-13	2.51e-07	0.27	0.22	Esophageal squamous cell carcinoma;Melanoma;	chr2:201352193	chr1:48435967~48437223:+
BRCA	trans	rs1933488	0.931	rs3870364	ENSG00000278974.1	RP11-756P10.6	-7.42	2.51e-13	2.53e-07	-0.29	-0.22	Prostate cancer;	chr6:153105544	chr4:188740507~188741281:-
BRCA	trans	rs3806843	0.576	rs155360	ENSG00000231043.3	AC007238.1	-7.41	2.52e-13	2.54e-07	-0.27	-0.22	Depressive symptoms (multi-trait analysis);	chr5:140929431	chr2:58460292~58462032:-
BRCA	trans	rs11098499	0.954	rs10017543	ENSG00000120555.12	SEPT7P9	7.41	2.52e-13	2.54e-07	0.28	0.22	Corneal astigmatism;	chr4:119400265	chr10:38383069~38402916:-
BRCA	trans	rs7833986	0.501	rs2953898	ENSG00000244245.1	RP11-120B7.1	7.41	2.53e-13	2.55e-07	0.29	0.22	Height;	chr8:56068244	chr5:108593609~108593967:+
BRCA	trans	rs11098499	0.865	rs9994730	ENSG00000120555.12	SEPT7P9	7.41	2.53e-13	2.55e-07	0.28	0.22	Corneal astigmatism;	chr4:119460409	chr10:38383069~38402916:-
BRCA	trans	rs2243480	1	rs3885839	ENSG00000273142.1	RP11-458F8.4	-7.41	2.54e-13	2.56e-07	-0.31	-0.22	Diabetic kidney disease;	chr7:65825416	chr7:66902857~66906297:+
BRCA	trans	rs11098499	1	rs6849889	ENSG00000120555.12	SEPT7P9	7.41	2.56e-13	2.58e-07	0.28	0.22	Corneal astigmatism;	chr4:119265193	chr10:38383069~38402916:-
BRCA	trans	rs9581094	0.591	rs9581084	ENSG00000237917.1	PARP4P1	-7.41	2.56e-13	2.58e-07	-0.45	-0.22	Sudden cardiac arrest;	chr13:24498801	chrY:26594851~26634652:-
BRCA	trans	rs11098499	0.954	rs2306455	ENSG00000276997.3	RP11-378J18.9	7.41	2.58e-13	2.6e-07	0.28	0.22	Corneal astigmatism;	chr4:119500814	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.954	rs1022145	ENSG00000276997.3	RP11-378J18.9	7.41	2.58e-13	2.6e-07	0.28	0.22	Corneal astigmatism;	chr4:119309824	chr1:222477252~222504622:-
BRCA	trans	rs546131	0.642	rs566798	ENSG00000225531.1	RP11-196I18.3	-7.41	2.61e-13	2.63e-07	-0.32	-0.22	Lung disease severity in cystic fibrosis;	chr11:34830730	chr9:107116829~107117557:+
BRCA	trans	rs1707322	0.686	rs3014236	ENSG00000255397.1	AC022182.2	7.41	2.61e-13	2.63e-07	0.3	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45625633	chr8:60937705~60939871:-
BRCA	trans	rs1707322	0.752	rs11211168	ENSG00000255397.1	AC022182.2	-7.41	2.62e-13	2.64e-07	-0.3	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45697975	chr8:60937705~60939871:-
BRCA	trans	rs13016963	0.546	rs11691602	ENSG00000235105.1	RP11-329A14.1	7.41	2.64e-13	2.65e-07	0.27	0.22	Esophageal squamous cell carcinoma;Melanoma;	chr2:201362976	chr1:48435967~48437223:+
BRCA	trans	rs1040555	0.516	rs242547	ENSG00000253915.1	MAPRE1P1	7.41	2.65e-13	2.67e-07	0.29	0.22	Lymphocyte percentage of white cells;	chr20:32830775	chr8:135625185~135625981:-
BRCA	trans	rs11098499	1	rs7659194	ENSG00000120555.12	SEPT7P9	7.41	2.66e-13	2.68e-07	0.28	0.22	Corneal astigmatism;	chr4:119285992	chr10:38383069~38402916:-
BRCA	trans	rs11638815	0.581	rs783537	ENSG00000235370.6	DNM1P51	-7.41	2.66e-13	2.68e-07	-0.25	-0.22	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82584058	chr15:84398316~84411701:-
BRCA	trans	rs864643	0.898	rs66860744	ENSG00000183298.5	RP11-556K13.1	7.41	2.66e-13	2.68e-07	0.34	0.22	Attention deficit hyperactivity disorder;	chr3:39548245	chr1:101786340~101787219:-
BRCA	trans	rs9329221	0.967	rs7005363	ENSG00000253893.2	FAM85B	7.41	2.67e-13	2.68e-07	0.28	0.22	Neuroticism;	chr8:10426238	chr8:8167819~8226614:-
BRCA	trans	rs2243480	1	rs73142122	ENSG00000273142.1	RP11-458F8.4	-7.41	2.68e-13	2.7e-07	-0.31	-0.22	Diabetic kidney disease;	chr7:65846311	chr7:66902857~66906297:+
BRCA	trans	rs2243480	0.901	rs73142137	ENSG00000273142.1	RP11-458F8.4	-7.41	2.68e-13	2.7e-07	-0.31	-0.22	Diabetic kidney disease;	chr7:65878455	chr7:66902857~66906297:+
BRCA	trans	rs2243480	1	rs13247184	ENSG00000273142.1	RP11-458F8.4	-7.41	2.68e-13	2.7e-07	-0.31	-0.22	Diabetic kidney disease;	chr7:65893941	chr7:66902857~66906297:+
BRCA	trans	rs2243480	1	rs35283677	ENSG00000273142.1	RP11-458F8.4	-7.41	2.68e-13	2.7e-07	-0.31	-0.22	Diabetic kidney disease;	chr7:65894246	chr7:66902857~66906297:+
BRCA	trans	rs2243480	1	rs35421653	ENSG00000273142.1	RP11-458F8.4	-7.41	2.68e-13	2.7e-07	-0.31	-0.22	Diabetic kidney disease;	chr7:65898442	chr7:66902857~66906297:+
BRCA	trans	rs6915893	1	rs6915893	ENSG00000267156.1	TPMTP1	7.41	2.69e-13	2.7e-07	0.29	0.22	Intrinsic epigenetic age acceleration;	chr6:18110325	chr18:47630112~47630848:+
BRCA	trans	rs801193	1	rs62466794	ENSG00000164669.11	INTS4P1	-7.41	2.69e-13	2.71e-07	-0.27	-0.22	Aortic root size;	chr7:66726592	chr7:65141225~65234216:+
BRCA	trans	rs6732160	0.564	rs2043096	ENSG00000236165.1	PRADC1P1	7.41	2.7e-13	2.72e-07	0.3	0.22	Intelligence (multi-trait analysis);	chr2:73148595	chr3:36976316~36976840:+
BRCA	trans	rs10946940	0.632	rs9366698	ENSG00000204709.4	LINC01556	7.41	2.7e-13	2.72e-07	0.3	0.22	Systemic lupus erythematosus;	chr6:27704256	chr6:28943877~28944537:+
BRCA	trans	rs12210905	0.841	rs116485609	ENSG00000242375.1	RP11-498P14.3	-7.4	2.71e-13	2.72e-07	-0.5	-0.22	Hip circumference adjusted for BMI;	chr6:26896426	chr9:97195351~97197687:-
BRCA	trans	rs9914988	0.943	rs9890377	ENSG00000267449.1	RP11-264B14.2	7.4	2.71e-13	2.72e-07	0.31	0.22	Glycated hemoglobin levels;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr17:28784093	chr17:61069856~61070356:-
BRCA	trans	rs9584850	0.834	rs7985565	ENSG00000230079.1	STK24P1	7.4	2.71e-13	2.72e-07	0.3	0.22	Neuroticism;	chr13:98461217	chrX:136295690~136300298:-
BRCA	trans	rs1707322	0.682	rs3014241	ENSG00000255397.1	AC022182.2	7.4	2.71e-13	2.73e-07	0.3	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45622207	chr8:60937705~60939871:-
BRCA	trans	rs6915893	0.692	rs4074443	ENSG00000267156.1	TPMTP1	7.4	2.73e-13	2.74e-07	0.29	0.22	Intrinsic epigenetic age acceleration;	chr6:18106371	chr18:47630112~47630848:+
BRCA	trans	rs3806843	0.576	rs246072	ENSG00000231043.3	AC007238.1	-7.4	2.74e-13	2.76e-07	-0.27	-0.22	Depressive symptoms (multi-trait analysis);	chr5:140940841	chr2:58460292~58462032:-
BRCA	trans	rs11098499	0.954	rs10008459	ENSG00000276997.3	RP11-378J18.9	7.4	2.75e-13	2.77e-07	0.27	0.22	Corneal astigmatism;	chr4:119473076	chr1:222477252~222504622:-
BRCA	trans	rs9914988	0.943	rs9913801	ENSG00000267449.1	RP11-264B14.2	7.4	2.76e-13	2.77e-07	0.31	0.22	Glycated hemoglobin levels;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr17:28805087	chr17:61069856~61070356:-
BRCA	trans	rs2243480	0.706	rs6460257	ENSG00000232546.1	RP11-458F8.1	-7.4	2.76e-13	2.77e-07	-0.25	-0.22	Diabetic kidney disease;	chr7:65731813	chr7:66848496~66858136:+
BRCA	trans	rs9467711	0.606	rs9366655	ENSG00000253570.1	RNF5P1	7.4	2.77e-13	2.78e-07	0.52	0.22	Autism spectrum disorder or schizophrenia;	chr6:26377157	chr8:38600661~38601200:-
BRCA	trans	rs6915893	1	rs4294009	ENSG00000267156.1	TPMTP1	7.4	2.77e-13	2.78e-07	0.29	0.22	Intrinsic epigenetic age acceleration;	chr6:18105845	chr18:47630112~47630848:+
BRCA	trans	rs11098499	0.954	rs7436506	ENSG00000276997.3	RP11-378J18.9	7.4	2.8e-13	2.81e-07	0.27	0.22	Corneal astigmatism;	chr4:119472614	chr1:222477252~222504622:-
BRCA	trans	rs801193	1	rs2003301	ENSG00000164669.11	INTS4P1	7.4	2.8e-13	2.82e-07	0.27	0.22	Aortic root size;	chr7:66682669	chr7:65141225~65234216:+
BRCA	trans	rs11920570	0.959	rs6805271	ENSG00000267076.1	CCDC58P3	-7.4	2.83e-13	2.84e-07	-0.29	-0.22	Resting heart rate;	chr3:122494112	chr18:12211378~12211807:+
BRCA	trans	rs11098499	1	rs11098499	ENSG00000120555.12	SEPT7P9	7.4	2.83e-13	2.85e-07	0.28	0.22	Corneal astigmatism;	chr4:119266456	chr10:38383069~38402916:-
BRCA	trans	rs1568889	0.838	rs1483858	ENSG00000174912.7	METTL15P1	7.4	2.84e-13	2.85e-07	0.23	0.22	Bipolar disorder;	chr11:28168092	chr3:156713884~156714928:-
BRCA	trans	rs9914988	0.943	rs9908881	ENSG00000267449.1	RP11-264B14.2	7.4	2.85e-13	2.86e-07	0.31	0.22	Glycated hemoglobin levels;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr17:28773906	chr17:61069856~61070356:-
BRCA	trans	rs9914988	0.943	rs9891925	ENSG00000267449.1	RP11-264B14.2	7.4	2.85e-13	2.86e-07	0.31	0.22	Glycated hemoglobin levels;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr17:28777522	chr17:61069856~61070356:-
BRCA	trans	rs9914988	0.943	rs9893782	ENSG00000267449.1	RP11-264B14.2	7.4	2.85e-13	2.86e-07	0.31	0.22	Glycated hemoglobin levels;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr17:28781114	chr17:61069856~61070356:-
BRCA	trans	rs9914988	0.778	rs4794837	ENSG00000267449.1	RP11-264B14.2	7.4	2.85e-13	2.86e-07	0.31	0.22	Glycated hemoglobin levels;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr17:28783006	chr17:61069856~61070356:-
BRCA	trans	rs9914988	0.887	rs12451790	ENSG00000267449.1	RP11-264B14.2	7.4	2.85e-13	2.86e-07	0.31	0.22	Glycated hemoglobin levels;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr17:28784982	chr17:61069856~61070356:-
BRCA	trans	rs9914988	0.943	rs4795459	ENSG00000267449.1	RP11-264B14.2	7.4	2.85e-13	2.86e-07	0.31	0.22	Glycated hemoglobin levels;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr17:28786708	chr17:61069856~61070356:-
BRCA	trans	rs9914988	0.943	rs12453504	ENSG00000267449.1	RP11-264B14.2	7.4	2.85e-13	2.86e-07	0.31	0.22	Glycated hemoglobin levels;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr17:28792506	chr17:61069856~61070356:-
BRCA	trans	rs9914988	0.778	rs9907185	ENSG00000267449.1	RP11-264B14.2	7.4	2.85e-13	2.86e-07	0.31	0.22	Glycated hemoglobin levels;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr17:28795396	chr17:61069856~61070356:-
BRCA	trans	rs9914988	0.778	rs9907192	ENSG00000267449.1	RP11-264B14.2	7.4	2.85e-13	2.86e-07	0.31	0.22	Glycated hemoglobin levels;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr17:28795408	chr17:61069856~61070356:-
BRCA	trans	rs9914988	0.778	rs35398767	ENSG00000267449.1	RP11-264B14.2	7.4	2.85e-13	2.86e-07	0.31	0.22	Glycated hemoglobin levels;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr17:28795942	chr17:61069856~61070356:-
BRCA	trans	rs9914988	0.943	rs9890155	ENSG00000267449.1	RP11-264B14.2	7.4	2.85e-13	2.86e-07	0.31	0.22	Glycated hemoglobin levels;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr17:28798449	chr17:61069856~61070356:-
BRCA	trans	rs9914988	0.832	rs9903248	ENSG00000267449.1	RP11-264B14.2	7.4	2.85e-13	2.86e-07	0.31	0.22	Glycated hemoglobin levels;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr17:28800421	chr17:61069856~61070356:-
BRCA	trans	rs7944735	0.508	rs2138767	ENSG00000134612.10	FOLH1B	7.4	2.86e-13	2.87e-07	0.35	0.22	Intraocular pressure;	chr11:47608241	chr11:89639227~89698718:+
BRCA	trans	rs12210905	0.565	rs9689239	ENSG00000242375.1	RP11-498P14.3	-7.4	2.89e-13	2.9e-07	-0.5	-0.22	Hip circumference adjusted for BMI;	chr6:26914100	chr9:97195351~97197687:-
BRCA	trans	rs11098499	0.954	rs59394118	ENSG00000276997.3	RP11-378J18.9	7.39	2.92e-13	2.93e-07	0.27	0.22	Corneal astigmatism;	chr4:119374396	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.865	rs9996417	ENSG00000276997.3	RP11-378J18.9	7.39	2.92e-13	2.93e-07	0.27	0.22	Corneal astigmatism;	chr4:119374707	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.954	rs28572238	ENSG00000120555.12	SEPT7P9	7.39	2.93e-13	2.93e-07	0.27	0.22	Corneal astigmatism;	chr4:119395531	chr10:38383069~38402916:-
BRCA	trans	rs902774	0.818	rs4919743	ENSG00000230716.3	KRT8P7	-7.39	2.93e-13	2.94e-07	-0.39	-0.22	Prostate cancer;	chr12:52915800	chr11:119602875~119604306:-
BRCA	trans	rs853679	0.882	rs3757188	ENSG00000253570.1	RNF5P1	7.39	2.95e-13	2.95e-07	0.51	0.22	Depression;	chr6:28139579	chr8:38600661~38601200:-
BRCA	trans	rs9650657	0.596	rs2409674	ENSG00000253893.2	FAM85B	7.39	2.97e-13	2.98e-07	0.28	0.22	Neuroticism;	chr8:10738368	chr8:8167819~8226614:-
BRCA	trans	rs10838687	1	rs6485751	ENSG00000134612.10	FOLH1B	7.39	2.99e-13	3e-07	0.31	0.22	Proinsulin levels;	chr11:47314891	chr11:89639227~89698718:+
BRCA	trans	rs7944735	0.508	rs74335517	ENSG00000134612.10	FOLH1B	7.39	3e-13	3.01e-07	0.36	0.22	Intraocular pressure;	chr11:47457616	chr11:89639227~89698718:+
BRCA	trans	rs1707322	0.721	rs6697821	ENSG00000255397.1	AC022182.2	-7.39	3.02e-13	3.02e-07	-0.3	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45751050	chr8:60937705~60939871:-
BRCA	trans	rs12439619	0.846	rs28470877	ENSG00000259295.5	CSPG4P12	-7.39	3.02e-13	3.02e-07	-0.35	-0.22	Intelligence (multi-trait analysis);	chr15:82245797	chr15:85191438~85213905:+
BRCA	trans	rs13016963	0.625	rs11681399	ENSG00000235105.1	RP11-329A14.1	7.39	3.03e-13	3.04e-07	0.28	0.22	Esophageal squamous cell carcinoma;Melanoma;	chr2:201280883	chr1:48435967~48437223:+
BRCA	trans	rs66887589	0.934	rs2715016	ENSG00000275858.1	RP11-291L22.8	-7.39	3.04e-13	3.04e-07	-0.25	-0.22	Diastolic blood pressure;	chr4:119531201	chr10:38450738~38451069:-
BRCA	trans	rs804280	0.56	rs10503426	ENSG00000253893.2	FAM85B	-7.39	3.04e-13	3.05e-07	-0.29	-0.22	Myopia (pathological);	chr8:11731874	chr8:8167819~8226614:-
BRCA	trans	rs9467711	0.56	rs6900665	ENSG00000253570.1	RNF5P1	7.39	3.06e-13	3.06e-07	0.49	0.22	Autism spectrum disorder or schizophrenia;	chr6:26486941	chr8:38600661~38601200:-
BRCA	trans	rs714543	1	rs8840	ENSG00000267258.1	CTC-448F2.3	7.39	3.06e-13	3.06e-07	0.26	0.22	Plateletcrit;	chr7:44877441	chr19:29921182~29921653:+
BRCA	trans	rs1707322	0.686	rs3014239	ENSG00000255397.1	AC022182.2	7.39	3.08e-13	3.08e-07	0.3	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45624129	chr8:60937705~60939871:-
BRCA	trans	rs801193	0.935	rs3800820	ENSG00000164669.11	INTS4P1	7.39	3.1e-13	3.1e-07	0.27	0.22	Aortic root size;	chr7:66682191	chr7:65141225~65234216:+
BRCA	trans	rs7200543	1	rs6498540	ENSG00000250569.1	NTAN1P2	7.39	3.11e-13	3.12e-07	0.25	0.22	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15036737	chr8:86481754~86483002:-
BRCA	trans	rs714543	0.967	rs10951776	ENSG00000267258.1	CTC-448F2.3	-7.38	3.12e-13	3.12e-07	-0.26	-0.22	Plateletcrit;	chr7:44858152	chr19:29921182~29921653:+
BRCA	trans	rs11098499	0.909	rs2127821	ENSG00000276997.3	RP11-378J18.9	7.38	3.13e-13	3.13e-07	0.27	0.22	Corneal astigmatism;	chr4:119473380	chr1:222477252~222504622:-
BRCA	trans	rs9393777	0.92	rs34953377	ENSG00000253570.1	RNF5P1	7.38	3.13e-13	3.13e-07	0.59	0.22	Intelligence (multi-trait analysis);	chr6:27413881	chr8:38600661~38601200:-
BRCA	trans	rs9393777	0.778	rs66841633	ENSG00000253570.1	RNF5P1	7.38	3.13e-13	3.13e-07	0.59	0.22	Intelligence (multi-trait analysis);	chr6:27414607	chr8:38600661~38601200:-
BRCA	trans	rs1933488	1	rs3870366	ENSG00000278974.1	RP11-756P10.6	-7.38	3.13e-13	3.13e-07	-0.29	-0.22	Prostate cancer;	chr6:153118632	chr4:188740507~188741281:-
BRCA	trans	rs1933488	0.898	rs6939447	ENSG00000278974.1	RP11-756P10.6	-7.38	3.13e-13	3.13e-07	-0.29	-0.22	Prostate cancer;	chr6:153118864	chr4:188740507~188741281:-
BRCA	trans	rs1933488	1	rs6917538	ENSG00000278974.1	RP11-756P10.6	-7.38	3.13e-13	3.13e-07	-0.29	-0.22	Prostate cancer;	chr6:153119062	chr4:188740507~188741281:-
BRCA	trans	rs1933488	1	rs7740380	ENSG00000278974.1	RP11-756P10.6	-7.38	3.13e-13	3.13e-07	-0.29	-0.22	Prostate cancer;	chr6:153119576	chr4:188740507~188741281:-
BRCA	trans	rs9329221	0.576	rs1986972	ENSG00000253893.2	FAM85B	-7.38	3.15e-13	3.15e-07	-0.29	-0.22	Neuroticism;	chr8:10411295	chr8:8167819~8226614:-
BRCA	trans	rs1707322	0.721	rs4415615	ENSG00000255397.1	AC022182.2	-7.38	3.16e-13	3.16e-07	-0.3	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45666437	chr8:60937705~60939871:-
BRCA	trans	rs9914988	0.943	rs1035989	ENSG00000267449.1	RP11-264B14.2	7.38	3.17e-13	3.17e-07	0.31	0.22	Glycated hemoglobin levels;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr17:28816792	chr17:61069856~61070356:-
BRCA	trans	rs9914988	0.887	rs11652710	ENSG00000267449.1	RP11-264B14.2	7.38	3.17e-13	3.17e-07	0.31	0.22	Glycated hemoglobin levels;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr17:28818057	chr17:61069856~61070356:-
BRCA	trans	rs9914988	0.887	rs8078402	ENSG00000267449.1	RP11-264B14.2	7.38	3.17e-13	3.17e-07	0.31	0.22	Glycated hemoglobin levels;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr17:28818106	chr17:61069856~61070356:-
BRCA	trans	rs9914988	0.887	rs4795463	ENSG00000267449.1	RP11-264B14.2	7.38	3.17e-13	3.17e-07	0.31	0.22	Glycated hemoglobin levels;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr17:28819371	chr17:61069856~61070356:-
BRCA	trans	rs9467711	0.606	rs12176317	ENSG00000253570.1	RNF5P1	7.38	3.18e-13	3.17e-07	0.53	0.22	Autism spectrum disorder or schizophrenia;	chr6:26372558	chr8:38600661~38601200:-
BRCA	trans	rs9467711	0.606	rs12174602	ENSG00000253570.1	RNF5P1	7.38	3.18e-13	3.17e-07	0.53	0.22	Autism spectrum disorder or schizophrenia;	chr6:26372599	chr8:38600661~38601200:-
BRCA	trans	rs9467711	0.606	rs12174623	ENSG00000253570.1	RNF5P1	7.38	3.18e-13	3.17e-07	0.53	0.22	Autism spectrum disorder or schizophrenia;	chr6:26372858	chr8:38600661~38601200:-
BRCA	trans	rs9467711	0.606	rs12174639	ENSG00000253570.1	RNF5P1	7.38	3.18e-13	3.17e-07	0.53	0.22	Autism spectrum disorder or schizophrenia;	chr6:26372893	chr8:38600661~38601200:-
BRCA	trans	rs9467711	0.606	rs12174631	ENSG00000253570.1	RNF5P1	7.38	3.18e-13	3.17e-07	0.53	0.22	Autism spectrum disorder or schizophrenia;	chr6:26372922	chr8:38600661~38601200:-
BRCA	trans	rs9467711	0.659	rs13216828	ENSG00000253570.1	RNF5P1	7.38	3.18e-13	3.17e-07	0.53	0.22	Autism spectrum disorder or schizophrenia;	chr6:26373279	chr8:38600661~38601200:-
BRCA	trans	rs9467711	0.606	rs9393714	ENSG00000253570.1	RNF5P1	7.38	3.18e-13	3.17e-07	0.53	0.22	Autism spectrum disorder or schizophrenia;	chr6:26373512	chr8:38600661~38601200:-
BRCA	trans	rs9467711	0.606	rs9358937	ENSG00000253570.1	RNF5P1	7.38	3.18e-13	3.17e-07	0.53	0.22	Autism spectrum disorder or schizophrenia;	chr6:26374046	chr8:38600661~38601200:-
BRCA	trans	rs9834975	0.605	rs2332180	ENSG00000267076.1	CCDC58P3	-7.38	3.2e-13	3.19e-07	-0.26	-0.22	Diastolic blood pressure;	chr3:122440051	chr18:12211378~12211807:+
BRCA	trans	rs9834975	0.565	rs9881393	ENSG00000267076.1	CCDC58P3	-7.38	3.2e-13	3.19e-07	-0.26	-0.22	Diastolic blood pressure;	chr3:122442914	chr18:12211378~12211807:+
BRCA	trans	rs1933488	0.931	rs6557272	ENSG00000278974.1	RP11-756P10.6	-7.38	3.2e-13	3.2e-07	-0.29	-0.22	Prostate cancer;	chr6:153116979	chr4:188740507~188741281:-
BRCA	trans	rs714543	0.967	rs11762008	ENSG00000267258.1	CTC-448F2.3	-7.38	3.21e-13	3.21e-07	-0.26	-0.22	Plateletcrit;	chr7:44864065	chr19:29921182~29921653:+
BRCA	trans	rs3806843	0.576	rs246009	ENSG00000231043.3	AC007238.1	7.38	3.24e-13	3.24e-07	0.27	0.22	Depressive symptoms (multi-trait analysis);	chr5:140958484	chr2:58460292~58462032:-
BRCA	trans	rs13016963	0.604	rs12612166	ENSG00000235105.1	RP11-329A14.1	7.38	3.24e-13	3.24e-07	0.29	0.22	Esophageal squamous cell carcinoma;Melanoma;	chr2:201314035	chr1:48435967~48437223:+
BRCA	trans	rs9834975	0.565	rs7637324	ENSG00000267076.1	CCDC58P3	-7.38	3.25e-13	3.25e-07	-0.26	-0.22	Diastolic blood pressure;	chr3:122485009	chr18:12211378~12211807:+
BRCA	trans	rs9581094	0.591	rs73154389	ENSG00000237917.1	PARP4P1	-7.38	3.27e-13	3.26e-07	-0.46	-0.22	Sudden cardiac arrest;	chr13:24505174	chrY:26594851~26634652:-
BRCA	trans	rs1933488	1	rs9384082	ENSG00000278974.1	RP11-756P10.6	-7.38	3.27e-13	3.27e-07	-0.29	-0.22	Prostate cancer;	chr6:153119380	chr4:188740507~188741281:-
BRCA	trans	rs9834975	0.605	rs6438731	ENSG00000267076.1	CCDC58P3	-7.38	3.28e-13	3.27e-07	-0.26	-0.22	Diastolic blood pressure;	chr3:122462103	chr18:12211378~12211807:+
BRCA	trans	rs11098499	0.954	rs10031483	ENSG00000276997.3	RP11-378J18.9	7.38	3.28e-13	3.28e-07	0.28	0.22	Corneal astigmatism;	chr4:119501481	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.954	rs10031665	ENSG00000276997.3	RP11-378J18.9	7.38	3.28e-13	3.28e-07	0.28	0.22	Corneal astigmatism;	chr4:119501697	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.954	rs3733523	ENSG00000276997.3	RP11-378J18.9	7.38	3.28e-13	3.28e-07	0.28	0.22	Corneal astigmatism;	chr4:119502564	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.908	rs2017057	ENSG00000120555.12	SEPT7P9	7.38	3.28e-13	3.28e-07	0.28	0.22	Corneal astigmatism;	chr4:119336556	chr10:38383069~38402916:-
BRCA	trans	rs13016963	0.526	rs7577057	ENSG00000235105.1	RP11-329A14.1	7.38	3.28e-13	3.28e-07	0.27	0.22	Esophageal squamous cell carcinoma;Melanoma;	chr2:201343270	chr1:48435967~48437223:+
BRCA	trans	rs11098499	0.866	rs3756156	ENSG00000120555.12	SEPT7P9	7.38	3.31e-13	3.31e-07	0.28	0.22	Corneal astigmatism;	chr4:119603686	chr10:38383069~38402916:-
BRCA	trans	rs7833986	0.501	rs2719257	ENSG00000244245.1	RP11-120B7.1	7.37	3.36e-13	3.35e-07	0.28	0.22	Height;	chr8:56027614	chr5:108593609~108593967:+
BRCA	trans	rs9393777	0.92	rs34071253	ENSG00000253570.1	RNF5P1	7.37	3.36e-13	3.36e-07	0.57	0.22	Intelligence (multi-trait analysis);	chr6:27424023	chr8:38600661~38601200:-
BRCA	trans	rs9914988	0.943	rs4262997	ENSG00000267449.1	RP11-264B14.2	7.37	3.37e-13	3.37e-07	0.31	0.22	Glycated hemoglobin levels;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr17:28802544	chr17:61069856~61070356:-
BRCA	trans	rs12439619	0.774	rs2867649	ENSG00000259295.5	CSPG4P12	-7.37	3.37e-13	3.37e-07	-0.35	-0.22	Intelligence (multi-trait analysis);	chr15:82262331	chr15:85191438~85213905:+
BRCA	trans	rs714543	0.967	rs12536807	ENSG00000267258.1	CTC-448F2.3	-7.37	3.38e-13	3.37e-07	-0.26	-0.22	Plateletcrit;	chr7:44838675	chr19:29921182~29921653:+
BRCA	trans	rs714543	1	rs714543	ENSG00000267258.1	CTC-448F2.3	-7.37	3.38e-13	3.37e-07	-0.26	-0.22	Plateletcrit;	chr7:44847477	chr19:29921182~29921653:+
BRCA	trans	rs714543	1	rs757693	ENSG00000267258.1	CTC-448F2.3	-7.37	3.38e-13	3.37e-07	-0.26	-0.22	Plateletcrit;	chr7:44848430	chr19:29921182~29921653:+
BRCA	trans	rs11098499	0.618	rs28491261	ENSG00000120555.12	SEPT7P9	7.37	3.38e-13	3.37e-07	0.28	0.22	Corneal astigmatism;	chr4:119373745	chr10:38383069~38402916:-
BRCA	trans	rs1707322	0.752	rs11211152	ENSG00000255397.1	AC022182.2	-7.37	3.39e-13	3.38e-07	-0.29	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45648485	chr8:60937705~60939871:-
BRCA	trans	rs1707322	0.752	rs4607935	ENSG00000255397.1	AC022182.2	-7.37	3.39e-13	3.38e-07	-0.29	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45651489	chr8:60937705~60939871:-
BRCA	trans	rs1707322	0.681	rs12048866	ENSG00000255397.1	AC022182.2	-7.37	3.39e-13	3.38e-07	-0.29	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45651820	chr8:60937705~60939871:-
BRCA	trans	rs1707322	0.752	rs3811436	ENSG00000255397.1	AC022182.2	-7.37	3.39e-13	3.38e-07	-0.29	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45660208	chr8:60937705~60939871:-
BRCA	trans	rs1707322	0.752	rs12024590	ENSG00000255397.1	AC022182.2	-7.37	3.39e-13	3.38e-07	-0.29	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45661824	chr8:60937705~60939871:-
BRCA	trans	rs1707322	0.752	rs12027622	ENSG00000255397.1	AC022182.2	-7.37	3.39e-13	3.38e-07	-0.29	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45664580	chr8:60937705~60939871:-
BRCA	trans	rs1707322	0.752	rs7529699	ENSG00000255397.1	AC022182.2	-7.37	3.39e-13	3.38e-07	-0.29	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45668962	chr8:60937705~60939871:-
BRCA	trans	rs1707322	0.716	rs6699444	ENSG00000255397.1	AC022182.2	-7.37	3.39e-13	3.38e-07	-0.29	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45669448	chr8:60937705~60939871:-
BRCA	trans	rs1707322	0.752	rs10430105	ENSG00000255397.1	AC022182.2	-7.37	3.39e-13	3.38e-07	-0.29	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45673204	chr8:60937705~60939871:-
BRCA	trans	rs1568889	0.838	rs3812738	ENSG00000174912.7	METTL15P1	7.37	3.43e-13	3.42e-07	0.23	0.22	Bipolar disorder;	chr11:28108435	chr3:156713884~156714928:-
BRCA	trans	rs9914988	0.943	rs11658884	ENSG00000267449.1	RP11-264B14.2	-7.37	3.44e-13	3.43e-07	-0.31	-0.22	Glycated hemoglobin levels;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr17:28805724	chr17:61069856~61070356:-
BRCA	trans	rs9914988	0.943	rs9907178	ENSG00000267449.1	RP11-264B14.2	7.37	3.44e-13	3.43e-07	0.31	0.22	Glycated hemoglobin levels;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr17:28797289	chr17:61069856~61070356:-
BRCA	trans	rs12210905	0.61	rs12216370	ENSG00000242375.1	RP11-498P14.3	-7.37	3.46e-13	3.44e-07	-0.5	-0.22	Hip circumference adjusted for BMI;	chr6:26911151	chr9:97195351~97197687:-
BRCA	trans	rs11920570	0.92	rs6780909	ENSG00000267076.1	CCDC58P3	-7.37	3.48e-13	3.47e-07	-0.29	-0.22	Resting heart rate;	chr3:122531317	chr18:12211378~12211807:+
BRCA	trans	rs11920570	0.959	rs6769837	ENSG00000267076.1	CCDC58P3	-7.37	3.51e-13	3.5e-07	-0.29	-0.22	Resting heart rate;	chr3:122479137	chr18:12211378~12211807:+
BRCA	trans	rs12210905	0.688	rs9393814	ENSG00000242375.1	RP11-498P14.3	-7.37	3.54e-13	3.52e-07	-0.58	-0.22	Hip circumference adjusted for BMI;	chr6:27405199	chr9:97195351~97197687:-
BRCA	trans	rs11098499	0.954	rs4309825	ENSG00000120555.12	SEPT7P9	-7.37	3.58e-13	3.57e-07	-0.27	-0.22	Corneal astigmatism;	chr4:119393726	chr10:38383069~38402916:-
BRCA	trans	rs60515486	0.702	rs11828339	ENSG00000134612.10	FOLH1B	7.37	3.59e-13	3.57e-07	0.35	0.22	Lymphocyte counts;	chr11:47382763	chr11:89639227~89698718:+
BRCA	trans	rs1023500	1	rs1023500	ENSG00000268568.1	AC007228.9	7.36	3.6e-13	3.58e-07	0.33	0.22	Schizophrenia;	chr22:41944840	chr19:56672574~56673901:-
BRCA	trans	rs12210905	0.688	rs72843177	ENSG00000242375.1	RP11-498P14.3	-7.36	3.6e-13	3.58e-07	-0.58	-0.22	Hip circumference adjusted for BMI;	chr6:27399635	chr9:97195351~97197687:-
BRCA	trans	rs12210905	0.688	rs12194842	ENSG00000242375.1	RP11-498P14.3	-7.36	3.6e-13	3.58e-07	-0.58	-0.22	Hip circumference adjusted for BMI;	chr6:27400199	chr9:97195351~97197687:-
BRCA	trans	rs1568889	0.838	rs11030230	ENSG00000174912.7	METTL15P1	7.36	3.61e-13	3.59e-07	0.23	0.22	Bipolar disorder;	chr11:28153084	chr3:156713884~156714928:-
BRCA	trans	rs1707322	0.717	rs1135812	ENSG00000255397.1	AC022182.2	-7.36	3.62e-13	3.6e-07	-0.3	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45629600	chr8:60937705~60939871:-
BRCA	trans	rs1707322	0.752	rs6703748	ENSG00000255397.1	AC022182.2	-7.36	3.62e-13	3.6e-07	-0.3	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45630304	chr8:60937705~60939871:-
BRCA	trans	rs11098499	0.954	rs59394118	ENSG00000120555.12	SEPT7P9	7.36	3.63e-13	3.61e-07	0.27	0.22	Corneal astigmatism;	chr4:119374396	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.865	rs9996417	ENSG00000120555.12	SEPT7P9	7.36	3.63e-13	3.61e-07	0.27	0.22	Corneal astigmatism;	chr4:119374707	chr10:38383069~38402916:-
BRCA	trans	rs1707322	0.686	rs1084086	ENSG00000255397.1	AC022182.2	7.36	3.66e-13	3.64e-07	0.3	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45575428	chr8:60937705~60939871:-
BRCA	trans	rs14057	0.792	rs78728410	ENSG00000215869.3	RP11-364B6.1	7.36	3.67e-13	3.65e-07	0.3	0.22	Systolic blood pressure;	chr1:6602971	chr1:104073023~104077087:+
BRCA	trans	rs9914988	0.887	rs12948575	ENSG00000267449.1	RP11-264B14.2	7.36	3.68e-13	3.66e-07	0.31	0.22	Glycated hemoglobin levels;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr17:28803502	chr17:61069856~61070356:-
BRCA	trans	rs9914988	0.832	rs4795462	ENSG00000267449.1	RP11-264B14.2	7.36	3.68e-13	3.66e-07	0.31	0.22	Glycated hemoglobin levels;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr17:28803973	chr17:61069856~61070356:-
BRCA	trans	rs9914988	0.943	rs4794839	ENSG00000267449.1	RP11-264B14.2	7.36	3.68e-13	3.66e-07	0.31	0.22	Glycated hemoglobin levels;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr17:28804375	chr17:61069856~61070356:-
BRCA	trans	rs9914988	0.943	rs12951232	ENSG00000267449.1	RP11-264B14.2	7.36	3.68e-13	3.66e-07	0.31	0.22	Glycated hemoglobin levels;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr17:28805620	chr17:61069856~61070356:-
BRCA	trans	rs9914988	0.943	rs9915673	ENSG00000267449.1	RP11-264B14.2	7.36	3.68e-13	3.66e-07	0.31	0.22	Glycated hemoglobin levels;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr17:28805875	chr17:61069856~61070356:-
BRCA	trans	rs6732160	0.588	rs13407363	ENSG00000236165.1	PRADC1P1	7.36	3.68e-13	3.66e-07	0.3	0.22	Intelligence (multi-trait analysis);	chr2:73145430	chr3:36976316~36976840:+
BRCA	trans	rs902774	0.818	rs4919740	ENSG00000223940.1	KRT8P8	-7.36	3.69e-13	3.67e-07	-0.4	-0.22	Prostate cancer;	chr12:52877187	chrX:152479577~152481024:+
BRCA	trans	rs9581094	0.591	rs9581082	ENSG00000237917.1	PARP4P1	-7.36	3.69e-13	3.67e-07	-0.45	-0.22	Sudden cardiac arrest;	chr13:24498720	chrY:26594851~26634652:-
BRCA	trans	rs9581094	0.591	rs9581083	ENSG00000237917.1	PARP4P1	-7.36	3.69e-13	3.67e-07	-0.45	-0.22	Sudden cardiac arrest;	chr13:24498739	chrY:26594851~26634652:-
BRCA	trans	rs6915893	0.967	rs10949483	ENSG00000267156.1	TPMTP1	7.36	3.71e-13	3.68e-07	0.29	0.22	Intrinsic epigenetic age acceleration;	chr6:18122275	chr18:47630112~47630848:+
BRCA	trans	rs1707322	0.721	rs11211165	ENSG00000255397.1	AC022182.2	-7.36	3.71e-13	3.69e-07	-0.3	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692234	chr8:60937705~60939871:-
BRCA	trans	rs1707322	0.721	rs11211166	ENSG00000255397.1	AC022182.2	-7.36	3.71e-13	3.69e-07	-0.3	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692270	chr8:60937705~60939871:-
BRCA	trans	rs7461897	0.511	rs1383916	ENSG00000253200.1	RP11-582J16.5	7.36	3.72e-13	3.7e-07	0.29	0.22	Epilepsy and lamotrigine-induced maculopapular eruptions;	chr8:26967728	chr8:22613908~22616657:-
BRCA	trans	rs1707322	0.685	rs28617418	ENSG00000255397.1	AC022182.2	-7.36	3.72e-13	3.7e-07	-0.3	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45723854	chr8:60937705~60939871:-
BRCA	trans	rs10838687	1	rs4752979	ENSG00000134612.10	FOLH1B	7.36	3.73e-13	3.7e-07	0.31	0.22	Proinsulin levels;	chr11:47317629	chr11:89639227~89698718:+
BRCA	trans	rs11951515	0.508	rs10059993	ENSG00000174977.8	AC026271.5	-7.36	3.76e-13	3.74e-07	-0.26	-0.22	Metabolite levels  (X-11787);	chr5:43598250	chr17:18650195~18651542:+
BRCA	trans	rs11920570	0.959	rs7638174	ENSG00000267076.1	CCDC58P3	-7.36	3.79e-13	3.76e-07	-0.29	-0.22	Resting heart rate;	chr3:122512022	chr18:12211378~12211807:+
BRCA	trans	rs11920570	0.878	rs80047419	ENSG00000267076.1	CCDC58P3	-7.36	3.79e-13	3.76e-07	-0.29	-0.22	Resting heart rate;	chr3:122513552	chr18:12211378~12211807:+
BRCA	trans	rs11920570	0.919	rs73190185	ENSG00000267076.1	CCDC58P3	-7.36	3.79e-13	3.76e-07	-0.29	-0.22	Resting heart rate;	chr3:122513580	chr18:12211378~12211807:+
BRCA	trans	rs9581094	0.591	rs73172140	ENSG00000237917.1	PARP4P1	-7.36	3.79e-13	3.76e-07	-0.45	-0.22	Sudden cardiac arrest;	chr13:24454975	chrY:26594851~26634652:-
BRCA	trans	rs11098499	0.863	rs3733525	ENSG00000276997.3	RP11-378J18.9	7.36	3.8e-13	3.77e-07	0.28	0.22	Corneal astigmatism;	chr4:119525893	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.863	rs3775847	ENSG00000276997.3	RP11-378J18.9	7.36	3.8e-13	3.77e-07	0.28	0.22	Corneal astigmatism;	chr4:119526487	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.863	rs3775848	ENSG00000276997.3	RP11-378J18.9	7.36	3.8e-13	3.77e-07	0.28	0.22	Corneal astigmatism;	chr4:119526569	chr1:222477252~222504622:-
BRCA	trans	rs60515486	0.702	rs11827106	ENSG00000134612.10	FOLH1B	7.36	3.81e-13	3.78e-07	0.36	0.22	Lymphocyte counts;	chr11:47381064	chr11:89639227~89698718:+
BRCA	trans	rs1707322	0.686	rs3014242	ENSG00000255397.1	AC022182.2	7.36	3.81e-13	3.78e-07	0.3	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45621905	chr8:60937705~60939871:-
BRCA	trans	rs12210905	0.688	rs12212348	ENSG00000242375.1	RP11-498P14.3	-7.36	3.81e-13	3.78e-07	-0.57	-0.22	Hip circumference adjusted for BMI;	chr6:27393463	chr9:97195351~97197687:-
BRCA	trans	rs11920570	0.959	rs9821819	ENSG00000267076.1	CCDC58P3	-7.36	3.84e-13	3.81e-07	-0.28	-0.22	Resting heart rate;	chr3:122350791	chr18:12211378~12211807:+
BRCA	trans	rs1568889	0.838	rs10835276	ENSG00000174912.7	METTL15P1	7.36	3.84e-13	3.81e-07	0.23	0.22	Bipolar disorder;	chr11:28145600	chr3:156713884~156714928:-
BRCA	trans	rs6732160	0.588	rs28626211	ENSG00000236165.1	PRADC1P1	7.36	3.85e-13	3.82e-07	0.3	0.22	Intelligence (multi-trait analysis);	chr2:73151394	chr3:36976316~36976840:+
BRCA	trans	rs11098499	0.865	rs4507344	ENSG00000120555.12	SEPT7P9	7.36	3.85e-13	3.82e-07	0.27	0.22	Corneal astigmatism;	chr4:119386330	chr10:38383069~38402916:-
BRCA	trans	rs11920570	0.919	rs75917970	ENSG00000267076.1	CCDC58P3	-7.36	3.85e-13	3.82e-07	-0.29	-0.22	Resting heart rate;	chr3:122477359	chr18:12211378~12211807:+
BRCA	trans	rs9914988	0.887	rs28873200	ENSG00000267449.1	RP11-264B14.2	7.35	3.87e-13	3.84e-07	0.31	0.22	Glycated hemoglobin levels;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr17:28822494	chr17:61069856~61070356:-
BRCA	trans	rs9914988	0.943	rs9898892	ENSG00000267449.1	RP11-264B14.2	7.35	3.87e-13	3.84e-07	0.31	0.22	Glycated hemoglobin levels;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr17:28823732	chr17:61069856~61070356:-
BRCA	trans	rs1707322	0.721	rs11211163	ENSG00000255397.1	AC022182.2	-7.35	3.9e-13	3.86e-07	-0.3	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45687876	chr8:60937705~60939871:-
BRCA	trans	rs1707322	0.721	rs12037803	ENSG00000255397.1	AC022182.2	-7.35	3.9e-13	3.86e-07	-0.3	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45690820	chr8:60937705~60939871:-
BRCA	trans	rs1707322	0.721	rs61784796	ENSG00000255397.1	AC022182.2	-7.35	3.9e-13	3.86e-07	-0.3	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45697584	chr8:60937705~60939871:-
BRCA	trans	rs1707322	0.721	rs10749856	ENSG00000255397.1	AC022182.2	-7.35	3.9e-13	3.86e-07	-0.3	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45699174	chr8:60937705~60939871:-
BRCA	trans	rs1707322	0.721	rs10890344	ENSG00000255397.1	AC022182.2	-7.35	3.9e-13	3.86e-07	-0.3	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45700418	chr8:60937705~60939871:-
BRCA	trans	rs1707322	0.721	rs4564187	ENSG00000255397.1	AC022182.2	-7.35	3.9e-13	3.86e-07	-0.3	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45701189	chr8:60937705~60939871:-
BRCA	trans	rs1707322	0.752	rs28438704	ENSG00000255397.1	AC022182.2	-7.35	3.9e-13	3.86e-07	-0.3	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45704872	chr8:60937705~60939871:-
BRCA	trans	rs1707322	0.721	rs28442079	ENSG00000255397.1	AC022182.2	-7.35	3.9e-13	3.86e-07	-0.3	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45706329	chr8:60937705~60939871:-
BRCA	trans	rs11098499	0.954	rs6849171	ENSG00000120555.12	SEPT7P9	7.35	3.93e-13	3.89e-07	0.27	0.22	Corneal astigmatism;	chr4:119488394	chr10:38383069~38402916:-
BRCA	trans	rs14057	0.929	rs11122114	ENSG00000215869.3	RP11-364B6.1	7.35	3.95e-13	3.91e-07	0.31	0.22	Systolic blood pressure;	chr1:6654626	chr1:104073023~104077087:+
BRCA	trans	rs11920570	0.92	rs73190177	ENSG00000267076.1	CCDC58P3	-7.35	3.96e-13	3.92e-07	-0.29	-0.22	Resting heart rate;	chr3:122508524	chr18:12211378~12211807:+
BRCA	trans	rs12439619	0.846	rs28697264	ENSG00000259295.5	CSPG4P12	-7.35	3.97e-13	3.93e-07	-0.35	-0.22	Intelligence (multi-trait analysis);	chr15:82265559	chr15:85191438~85213905:+
BRCA	trans	rs1707322	0.721	rs10789470	ENSG00000255397.1	AC022182.2	-7.35	3.97e-13	3.93e-07	-0.3	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692659	chr8:60937705~60939871:-
BRCA	trans	rs11098499	0.863	rs10013305	ENSG00000276997.3	RP11-378J18.9	7.35	3.99e-13	3.95e-07	0.28	0.22	Corneal astigmatism;	chr4:119529269	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.863	rs3775849	ENSG00000276997.3	RP11-378J18.9	7.35	3.99e-13	3.95e-07	0.28	0.22	Corneal astigmatism;	chr4:119529753	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.818	rs7688802	ENSG00000276997.3	RP11-378J18.9	7.35	3.99e-13	3.95e-07	0.28	0.22	Corneal astigmatism;	chr4:119530513	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.863	rs7695620	ENSG00000276997.3	RP11-378J18.9	7.35	3.99e-13	3.95e-07	0.28	0.22	Corneal astigmatism;	chr4:119531621	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.863	rs12502389	ENSG00000276997.3	RP11-378J18.9	7.35	3.99e-13	3.95e-07	0.28	0.22	Corneal astigmatism;	chr4:119533036	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.821	rs3775852	ENSG00000276997.3	RP11-378J18.9	7.35	3.99e-13	3.95e-07	0.28	0.22	Corneal astigmatism;	chr4:119533401	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.82	rs6534140	ENSG00000276997.3	RP11-378J18.9	7.35	3.99e-13	3.95e-07	0.28	0.22	Corneal astigmatism;	chr4:119534156	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.863	rs7657849	ENSG00000276997.3	RP11-378J18.9	7.35	3.99e-13	3.95e-07	0.28	0.22	Corneal astigmatism;	chr4:119534339	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.863	rs10034450	ENSG00000276997.3	RP11-378J18.9	7.35	3.99e-13	3.95e-07	0.28	0.22	Corneal astigmatism;	chr4:119534494	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.863	rs1480939	ENSG00000276997.3	RP11-378J18.9	7.35	3.99e-13	3.95e-07	0.28	0.22	Corneal astigmatism;	chr4:119535772	chr1:222477252~222504622:-
BRCA	trans	rs9834975	0.565	rs2002594	ENSG00000267076.1	CCDC58P3	-7.35	3.99e-13	3.95e-07	-0.26	-0.22	Diastolic blood pressure;	chr3:122392714	chr18:12211378~12211807:+
BRCA	trans	rs7662987	1	rs7662987	ENSG00000228407.2	RP4-800M22.1	7.35	4e-13	3.96e-07	0.49	0.22	Smoking initiation;	chr4:99070491	chr1:52160261~52160600:-
BRCA	trans	rs13016963	0.526	rs2110684	ENSG00000235105.1	RP11-329A14.1	7.35	4.01e-13	3.97e-07	0.27	0.22	Esophageal squamous cell carcinoma;Melanoma;	chr2:201357198	chr1:48435967~48437223:+
BRCA	trans	rs9581094	0.591	rs9581087	ENSG00000237917.1	PARP4P1	-7.35	4.04e-13	4e-07	-0.45	-0.22	Sudden cardiac arrest;	chr13:24500096	chrY:26594851~26634652:-
BRCA	trans	rs9581094	0.591	rs9581088	ENSG00000237917.1	PARP4P1	-7.35	4.04e-13	4e-07	-0.45	-0.22	Sudden cardiac arrest;	chr13:24500270	chrY:26594851~26634652:-
BRCA	trans	rs9581094	0.591	rs9578751	ENSG00000237917.1	PARP4P1	-7.35	4.04e-13	4e-07	-0.45	-0.22	Sudden cardiac arrest;	chr13:24500352	chrY:26594851~26634652:-
BRCA	trans	rs9581094	0.591	rs73154379	ENSG00000237917.1	PARP4P1	-7.35	4.04e-13	4e-07	-0.45	-0.22	Sudden cardiac arrest;	chr13:24500430	chrY:26594851~26634652:-
BRCA	trans	rs9581094	0.591	rs2275662	ENSG00000237917.1	PARP4P1	-7.35	4.04e-13	4e-07	-0.45	-0.22	Sudden cardiac arrest;	chr13:24500562	chrY:26594851~26634652:-
BRCA	trans	rs9581094	0.591	rs9581089	ENSG00000237917.1	PARP4P1	-7.35	4.04e-13	4e-07	-0.45	-0.22	Sudden cardiac arrest;	chr13:24501556	chrY:26594851~26634652:-
BRCA	trans	rs9581094	0.591	rs9581090	ENSG00000237917.1	PARP4P1	-7.35	4.04e-13	4e-07	-0.45	-0.22	Sudden cardiac arrest;	chr13:24502051	chrY:26594851~26634652:-
BRCA	trans	rs1707322	0.682	rs10890334	ENSG00000255397.1	AC022182.2	-7.35	4.04e-13	4e-07	-0.29	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634706	chr8:60937705~60939871:-
BRCA	trans	rs12210905	0.688	rs12202956	ENSG00000242375.1	RP11-498P14.3	-7.35	4.06e-13	4.01e-07	-0.57	-0.22	Hip circumference adjusted for BMI;	chr6:27388697	chr9:97195351~97197687:-
BRCA	trans	rs12210905	0.688	rs72843151	ENSG00000242375.1	RP11-498P14.3	-7.35	4.06e-13	4.01e-07	-0.57	-0.22	Hip circumference adjusted for BMI;	chr6:27391489	chr9:97195351~97197687:-
BRCA	trans	rs1707322	0.682	rs10890335	ENSG00000255397.1	AC022182.2	-7.35	4.08e-13	4.04e-07	-0.29	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634722	chr8:60937705~60939871:-
BRCA	trans	rs1568889	0.838	rs7131053	ENSG00000174912.7	METTL15P1	7.35	4.1e-13	4.05e-07	0.23	0.22	Bipolar disorder;	chr11:28121765	chr3:156713884~156714928:-
BRCA	trans	rs1707322	0.752	rs6678444	ENSG00000255397.1	AC022182.2	-7.35	4.13e-13	4.08e-07	-0.3	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45764175	chr8:60937705~60939871:-
BRCA	trans	rs867371	0.656	rs2665103	ENSG00000235370.6	DNM1P51	7.35	4.13e-13	4.09e-07	0.24	0.22	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82140374	chr15:84398316~84411701:-
BRCA	trans	rs1568889	0.838	rs11030229	ENSG00000174912.7	METTL15P1	7.35	4.14e-13	4.09e-07	0.23	0.22	Bipolar disorder;	chr11:28152087	chr3:156713884~156714928:-
BRCA	trans	rs9467711	0.606	rs9393713	ENSG00000253570.1	RNF5P1	7.35	4.14e-13	4.09e-07	0.53	0.22	Autism spectrum disorder or schizophrenia;	chr6:26373450	chr8:38600661~38601200:-
BRCA	trans	rs1568889	0.838	rs11030220	ENSG00000174912.7	METTL15P1	7.34	4.18e-13	4.13e-07	0.23	0.22	Bipolar disorder;	chr11:28124222	chr3:156713884~156714928:-
BRCA	trans	rs7833986	0.501	rs72653951	ENSG00000244245.1	RP11-120B7.1	7.34	4.19e-13	4.14e-07	0.27	0.22	Height;	chr8:56049278	chr5:108593609~108593967:+
BRCA	trans	rs11920570	0.959	rs7641530	ENSG00000267076.1	CCDC58P3	-7.34	4.2e-13	4.15e-07	-0.29	-0.22	Resting heart rate;	chr3:122511416	chr18:12211378~12211807:+
BRCA	trans	rs9581094	0.591	rs9318598	ENSG00000237917.1	PARP4P1	-7.34	4.21e-13	4.16e-07	-0.45	-0.22	Sudden cardiac arrest;	chr13:24492849	chrY:26594851~26634652:-
BRCA	trans	rs13016963	0.526	rs11681616	ENSG00000235105.1	RP11-329A14.1	7.34	4.21e-13	4.16e-07	0.27	0.22	Esophageal squamous cell carcinoma;Melanoma;	chr2:201360013	chr1:48435967~48437223:+
BRCA	trans	rs11098499	0.863	rs1552095	ENSG00000276997.3	RP11-378J18.9	7.34	4.23e-13	4.18e-07	0.28	0.22	Corneal astigmatism;	chr4:119539151	chr1:222477252~222504622:-
BRCA	trans	rs853679	0.882	rs9468287	ENSG00000253570.1	RNF5P1	7.34	4.24e-13	4.18e-07	0.51	0.22	Depression;	chr6:28111963	chr8:38600661~38601200:-
BRCA	trans	rs801193	1	rs6975195	ENSG00000164669.11	INTS4P1	7.34	4.25e-13	4.19e-07	0.27	0.22	Aortic root size;	chr7:66659787	chr7:65141225~65234216:+
BRCA	trans	rs11098499	1	rs13116504	ENSG00000120555.12	SEPT7P9	7.34	4.27e-13	4.22e-07	0.28	0.22	Corneal astigmatism;	chr4:119288257	chr10:38383069~38402916:-
BRCA	trans	rs7929679	0.875	rs11032874	ENSG00000225531.1	RP11-196I18.3	7.34	4.28e-13	4.23e-07	0.28	0.22	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;	chr11:34785060	chr9:107116829~107117557:+
BRCA	trans	rs9581094	0.591	rs117954245	ENSG00000237917.1	PARP4P1	-7.34	4.29e-13	4.23e-07	-0.45	-0.22	Sudden cardiac arrest;	chr13:24487960	chrY:26594851~26634652:-
BRCA	trans	rs9581094	0.591	rs7329368	ENSG00000237917.1	PARP4P1	-7.34	4.29e-13	4.23e-07	-0.45	-0.22	Sudden cardiac arrest;	chr13:24488933	chrY:26594851~26634652:-
BRCA	trans	rs9581094	0.591	rs7329957	ENSG00000237917.1	PARP4P1	-7.34	4.29e-13	4.23e-07	-0.45	-0.22	Sudden cardiac arrest;	chr13:24489173	chrY:26594851~26634652:-
BRCA	trans	rs2243480	1	rs7456042	ENSG00000273142.1	RP11-458F8.4	-7.34	4.3e-13	4.24e-07	-0.3	-0.22	Diabetic kidney disease;	chr7:65834791	chr7:66902857~66906297:+
BRCA	trans	rs2243480	1	rs73142121	ENSG00000273142.1	RP11-458F8.4	-7.34	4.3e-13	4.24e-07	-0.3	-0.22	Diabetic kidney disease;	chr7:65846219	chr7:66902857~66906297:+
BRCA	trans	rs2243480	1	rs34702770	ENSG00000273142.1	RP11-458F8.4	-7.34	4.3e-13	4.24e-07	-0.3	-0.22	Diabetic kidney disease;	chr7:65879836	chr7:66902857~66906297:+
BRCA	trans	rs2243480	1	rs34637256	ENSG00000273142.1	RP11-458F8.4	-7.34	4.3e-13	4.24e-07	-0.3	-0.22	Diabetic kidney disease;	chr7:65895144	chr7:66902857~66906297:+
BRCA	trans	rs9581094	0.591	rs7981053	ENSG00000237917.1	PARP4P1	-7.34	4.36e-13	4.3e-07	-0.45	-0.22	Sudden cardiac arrest;	chr13:24485950	chrY:26594851~26634652:-
BRCA	trans	rs864643	0.678	rs617068	ENSG00000188856.6	RPSAP47	-7.34	4.38e-13	4.32e-07	-0.32	-0.22	Attention deficit hyperactivity disorder;	chr3:39492781	chr8:80558870~80559757:+
BRCA	trans	rs1707322	0.685	rs11211177	ENSG00000255397.1	AC022182.2	-7.34	4.41e-13	4.35e-07	-0.3	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45760677	chr8:60937705~60939871:-
BRCA	trans	rs11098499	0.954	rs7436506	ENSG00000120555.12	SEPT7P9	7.34	4.44e-13	4.37e-07	0.27	0.22	Corneal astigmatism;	chr4:119472614	chr10:38383069~38402916:-
BRCA	trans	rs3750082	0.632	rs35165932	ENSG00000176826.14	FKBP9P1	7.33	4.48e-13	4.42e-07	0.3	0.22	Glomerular filtration rate (creatinine);	chr7:32886648	chr7:55681074~55713252:-
BRCA	trans	rs3750082	0.692	rs10248993	ENSG00000176826.14	FKBP9P1	7.33	4.48e-13	4.42e-07	0.3	0.22	Glomerular filtration rate (creatinine);	chr7:32887535	chr7:55681074~55713252:-
BRCA	trans	rs11098499	0.954	rs10006525	ENSG00000120555.12	SEPT7P9	7.33	4.49e-13	4.42e-07	0.27	0.22	Corneal astigmatism;	chr4:119487776	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.909	rs28668716	ENSG00000276997.3	RP11-378J18.9	7.33	4.49e-13	4.42e-07	0.27	0.22	Corneal astigmatism;	chr4:119388720	chr1:222477252~222504622:-
BRCA	trans	rs76228276	0.609	rs10504988	ENSG00000260318.1	COX6CP1	7.33	4.5e-13	4.43e-07	0.59	0.22	Childhood ear infection;	chr8:99374974	chr16:11903923~11904137:-
BRCA	trans	rs9467711	0.606	rs9379863	ENSG00000253570.1	RNF5P1	7.33	4.51e-13	4.44e-07	0.53	0.22	Autism spectrum disorder or schizophrenia;	chr6:26372199	chr8:38600661~38601200:-
BRCA	trans	rs9467711	0.606	rs9379864	ENSG00000253570.1	RNF5P1	7.33	4.51e-13	4.44e-07	0.53	0.22	Autism spectrum disorder or schizophrenia;	chr6:26372356	chr8:38600661~38601200:-
BRCA	trans	rs11098499	0.954	rs11722872	ENSG00000276997.3	RP11-378J18.9	7.33	4.53e-13	4.45e-07	0.27	0.22	Corneal astigmatism;	chr4:119311875	chr1:222477252~222504622:-
BRCA	trans	rs9650657	0.571	rs2409672	ENSG00000253893.2	FAM85B	7.33	4.53e-13	4.46e-07	0.27	0.22	Neuroticism;	chr8:10741270	chr8:8167819~8226614:-
BRCA	trans	rs67340775	0.541	rs200964	ENSG00000204709.4	LINC01556	7.33	4.53e-13	4.46e-07	0.37	0.22	Lung cancer in ever smokers;	chr6:27899165	chr6:28943877~28944537:+
BRCA	trans	rs1707322	0.716	rs6694889	ENSG00000255397.1	AC022182.2	-7.33	4.53e-13	4.46e-07	-0.29	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45636134	chr8:60937705~60939871:-
BRCA	trans	rs1707322	0.682	rs12041197	ENSG00000255397.1	AC022182.2	-7.33	4.53e-13	4.46e-07	-0.29	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45638792	chr8:60937705~60939871:-
BRCA	trans	rs10940346	0.506	rs11741135	ENSG00000231752.4	EMBP1	-7.33	4.54e-13	4.47e-07	-0.29	-0.22	Schizophrenia;	chr5:50579604	chr1:121519112~121571892:+
BRCA	trans	rs9914988	0.943	rs11651867	ENSG00000267449.1	RP11-264B14.2	7.33	4.56e-13	4.48e-07	0.31	0.22	Glycated hemoglobin levels;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr17:28820230	chr17:61069856~61070356:-
BRCA	trans	rs11098499	0.954	rs9993199	ENSG00000276997.3	RP11-378J18.9	-7.33	4.56e-13	4.49e-07	-0.27	-0.22	Corneal astigmatism;	chr4:119471718	chr1:222477252~222504622:-
BRCA	trans	rs11920570	0.959	rs6773243	ENSG00000267076.1	CCDC58P3	-7.33	4.56e-13	4.49e-07	-0.29	-0.22	Resting heart rate;	chr3:122483387	chr18:12211378~12211807:+
BRCA	trans	rs673253	0.686	rs17371903	ENSG00000231007.5	CDC20P1	7.33	4.59e-13	4.51e-07	0.29	0.22	Intelligence (multi-trait analysis);	chr1:43605020	chr9:87011652~87013151:+
BRCA	trans	rs11098499	0.909	rs73842633	ENSG00000120555.12	SEPT7P9	7.33	4.6e-13	4.52e-07	0.28	0.22	Corneal astigmatism;	chr4:119454309	chr10:38383069~38402916:-
BRCA	trans	rs616147	0.627	rs9871799	ENSG00000243904.1	RP11-600F24.1	7.33	4.6e-13	4.52e-07	0.26	0.22	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39442829	chr14:103374033~103374916:-
BRCA	trans	rs14057	0.894	rs2076365	ENSG00000215869.3	RP11-364B6.1	7.33	4.65e-13	4.56e-07	0.31	0.22	Systolic blood pressure;	chr1:6645511	chr1:104073023~104077087:+
BRCA	trans	rs1707322	0.752	rs11211146	ENSG00000255397.1	AC022182.2	-7.33	4.65e-13	4.57e-07	-0.29	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45644122	chr8:60937705~60939871:-
BRCA	trans	rs1707322	0.752	rs11211147	ENSG00000255397.1	AC022182.2	-7.33	4.65e-13	4.57e-07	-0.29	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45644422	chr8:60937705~60939871:-
BRCA	trans	rs9581094	0.591	rs7331373	ENSG00000237917.1	PARP4P1	-7.33	4.67e-13	4.58e-07	-0.45	-0.22	Sudden cardiac arrest;	chr13:24489227	chrY:26594851~26634652:-
BRCA	trans	rs11098499	0.954	rs2389802	ENSG00000120555.12	SEPT7P9	7.33	4.67e-13	4.58e-07	0.27	0.22	Corneal astigmatism;	chr4:119404577	chr10:38383069~38402916:-
BRCA	trans	rs641862	1	rs641862	ENSG00000224418.1	STK24-AS1	7.33	4.67e-13	4.58e-07	0.38	0.22	Obesity-related traits;	chr13:110137885	chr13:98577244~98578830:+
BRCA	trans	rs2060793	0.835	rs1037379	ENSG00000236360.2	RP11-334A14.2	7.33	4.67e-13	4.59e-07	0.29	0.22	Vitamin D levels;	chr11:14831238	chr1:52993201~52993702:-
BRCA	trans	rs864643	0.678	rs521139	ENSG00000188856.6	RPSAP47	7.33	4.71e-13	4.63e-07	0.32	0.22	Attention deficit hyperactivity disorder;	chr3:39486128	chr8:80558870~80559757:+
BRCA	trans	rs3806843	0.607	rs246044	ENSG00000231043.3	AC007238.1	-7.32	4.78e-13	4.7e-07	-0.27	-0.22	Depressive symptoms (multi-trait analysis);	chr5:140951071	chr2:58460292~58462032:-
BRCA	trans	rs3806843	0.548	rs246056	ENSG00000231043.3	AC007238.1	-7.32	4.79e-13	4.7e-07	-0.27	-0.22	Depressive symptoms (multi-trait analysis);	chr5:140946015	chr2:58460292~58462032:-
BRCA	trans	rs9581094	0.591	rs73154391	ENSG00000237917.1	PARP4P1	-7.32	4.82e-13	4.73e-07	-0.46	-0.22	Sudden cardiac arrest;	chr13:24505581	chrY:26594851~26634652:-
BRCA	trans	rs13016963	0.526	rs13027605	ENSG00000235105.1	RP11-329A14.1	7.32	4.85e-13	4.75e-07	0.28	0.22	Esophageal squamous cell carcinoma;Melanoma;	chr2:201278534	chr1:48435967~48437223:+
BRCA	trans	rs9914988	0.943	rs2046759	ENSG00000267449.1	RP11-264B14.2	7.32	4.85e-13	4.76e-07	0.31	0.22	Glycated hemoglobin levels;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr17:28811799	chr17:61069856~61070356:-
BRCA	trans	rs1707322	0.691	rs61784799	ENSG00000255397.1	AC022182.2	7.32	4.86e-13	4.76e-07	0.3	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45712076	chr8:60937705~60939871:-
BRCA	trans	rs11920570	0.959	rs7648255	ENSG00000267076.1	CCDC58P3	7.32	4.86e-13	4.77e-07	0.29	0.22	Resting heart rate;	chr3:122448833	chr18:12211378~12211807:+
BRCA	trans	rs11098499	0.955	rs6815725	ENSG00000120555.12	SEPT7P9	7.32	4.88e-13	4.79e-07	0.27	0.22	Corneal astigmatism;	chr4:119237255	chr10:38383069~38402916:-
BRCA	trans	rs9467711	0.606	rs9379851	ENSG00000253570.1	RNF5P1	7.32	4.9e-13	4.81e-07	0.51	0.22	Autism spectrum disorder or schizophrenia;	chr6:26354552	chr8:38600661~38601200:-
BRCA	trans	rs11098499	0.954	rs59866101	ENSG00000276997.3	RP11-378J18.9	7.32	4.93e-13	4.82e-07	0.27	0.22	Corneal astigmatism;	chr4:119375436	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.618	rs6858383	ENSG00000276997.3	RP11-378J18.9	7.32	4.93e-13	4.82e-07	0.27	0.22	Corneal astigmatism;	chr4:119375617	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.697	rs6832410	ENSG00000276997.3	RP11-378J18.9	7.32	4.93e-13	4.82e-07	0.27	0.22	Corneal astigmatism;	chr4:119375645	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.865	rs1112817	ENSG00000276997.3	RP11-378J18.9	7.32	4.93e-13	4.82e-07	0.27	0.22	Corneal astigmatism;	chr4:119376645	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.779	rs10016060	ENSG00000276997.3	RP11-378J18.9	7.32	4.93e-13	4.82e-07	0.27	0.22	Corneal astigmatism;	chr4:119377257	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.954	rs10005644	ENSG00000276997.3	RP11-378J18.9	7.32	4.93e-13	4.82e-07	0.27	0.22	Corneal astigmatism;	chr4:119377322	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.697	rs10016448	ENSG00000276997.3	RP11-378J18.9	7.32	4.93e-13	4.82e-07	0.27	0.22	Corneal astigmatism;	chr4:119377690	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.657	rs9996569	ENSG00000276997.3	RP11-378J18.9	7.32	4.93e-13	4.82e-07	0.27	0.22	Corneal astigmatism;	chr4:119377849	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.908	rs11729050	ENSG00000276997.3	RP11-378J18.9	7.32	4.93e-13	4.82e-07	0.27	0.22	Corneal astigmatism;	chr4:119378911	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.954	rs28429722	ENSG00000276997.3	RP11-378J18.9	7.32	4.93e-13	4.82e-07	0.27	0.22	Corneal astigmatism;	chr4:119378938	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.954	rs10014845	ENSG00000276997.3	RP11-378J18.9	7.32	4.93e-13	4.82e-07	0.27	0.22	Corneal astigmatism;	chr4:119379922	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.779	rs7674500	ENSG00000276997.3	RP11-378J18.9	7.32	4.93e-13	4.82e-07	0.27	0.22	Corneal astigmatism;	chr4:119382438	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.909	rs28884220	ENSG00000276997.3	RP11-378J18.9	7.32	4.93e-13	4.82e-07	0.27	0.22	Corneal astigmatism;	chr4:119386056	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.909	rs28793658	ENSG00000276997.3	RP11-378J18.9	7.32	4.93e-13	4.82e-07	0.27	0.22	Corneal astigmatism;	chr4:119386059	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.697	rs4373140	ENSG00000276997.3	RP11-378J18.9	7.32	4.93e-13	4.82e-07	0.27	0.22	Corneal astigmatism;	chr4:119386543	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.954	rs13113483	ENSG00000276997.3	RP11-378J18.9	7.32	4.93e-13	4.82e-07	0.27	0.22	Corneal astigmatism;	chr4:119387884	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.542	rs10440343	ENSG00000276997.3	RP11-378J18.9	7.32	4.93e-13	4.82e-07	0.27	0.22	Corneal astigmatism;	chr4:119388632	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.779	rs10011097	ENSG00000276997.3	RP11-378J18.9	7.32	4.93e-13	4.82e-07	0.27	0.22	Corneal astigmatism;	chr4:119389204	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.542	rs7677836	ENSG00000276997.3	RP11-378J18.9	7.32	4.93e-13	4.82e-07	0.27	0.22	Corneal astigmatism;	chr4:119389483	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.909	rs10002083	ENSG00000276997.3	RP11-378J18.9	7.32	4.93e-13	4.82e-07	0.27	0.22	Corneal astigmatism;	chr4:119389997	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.954	rs10024844	ENSG00000276997.3	RP11-378J18.9	7.32	4.93e-13	4.82e-07	0.27	0.22	Corneal astigmatism;	chr4:119390373	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.954	rs4345162	ENSG00000276997.3	RP11-378J18.9	7.32	4.93e-13	4.82e-07	0.27	0.22	Corneal astigmatism;	chr4:119391804	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.657	rs4463052	ENSG00000276997.3	RP11-378J18.9	7.32	4.93e-13	4.82e-07	0.27	0.22	Corneal astigmatism;	chr4:119392103	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.954	rs13151285	ENSG00000276997.3	RP11-378J18.9	7.32	4.93e-13	4.82e-07	0.27	0.22	Corneal astigmatism;	chr4:119393586	chr1:222477252~222504622:-
BRCA	trans	rs2736337	0.532	rs6998387	ENSG00000253893.2	FAM85B	-7.32	4.93e-13	4.83e-07	-0.28	-0.22	Rheumatoid arthritis;	chr8:11435949	chr8:8167819~8226614:-
BRCA	trans	rs7833986	0.501	rs72653959	ENSG00000244245.1	RP11-120B7.1	7.32	4.94e-13	4.84e-07	0.28	0.22	Height;	chr8:56083957	chr5:108593609~108593967:+
BRCA	trans	rs7833986	0.501	rs72653962	ENSG00000244245.1	RP11-120B7.1	7.32	4.94e-13	4.84e-07	0.28	0.22	Height;	chr8:56084946	chr5:108593609~108593967:+
BRCA	trans	rs7833986	0.501	rs72653967	ENSG00000244245.1	RP11-120B7.1	7.32	4.94e-13	4.84e-07	0.28	0.22	Height;	chr8:56086873	chr5:108593609~108593967:+
BRCA	trans	rs11098499	0.863	rs34868248	ENSG00000276997.3	RP11-378J18.9	7.32	4.95e-13	4.84e-07	0.28	0.22	Corneal astigmatism;	chr4:119521275	chr1:222477252~222504622:-
BRCA	trans	rs1707322	0.691	rs61784803	ENSG00000255397.1	AC022182.2	7.32	4.96e-13	4.85e-07	0.3	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45713599	chr8:60937705~60939871:-
BRCA	trans	rs1707322	0.663	rs3935296	ENSG00000255397.1	AC022182.2	7.32	4.96e-13	4.85e-07	0.3	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45714798	chr8:60937705~60939871:-
BRCA	trans	rs1707322	0.721	rs28817701	ENSG00000255397.1	AC022182.2	-7.32	4.96e-13	4.85e-07	-0.3	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45720378	chr8:60937705~60939871:-
BRCA	trans	rs1707322	0.691	rs28495425	ENSG00000255397.1	AC022182.2	-7.32	4.96e-13	4.85e-07	-0.3	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45721648	chr8:60937705~60939871:-
BRCA	trans	rs17711722	0.503	rs453835	ENSG00000234585.5	CCT6P3	-7.32	4.97e-13	4.86e-07	-0.22	-0.22	Calcium levels;	chr7:66046172	chr7:65038354~65074713:+
BRCA	trans	rs11098499	0.909	rs28714195	ENSG00000120555.12	SEPT7P9	7.32	5.01e-13	4.89e-07	0.27	0.22	Corneal astigmatism;	chr4:119395795	chr10:38383069~38402916:-
BRCA	trans	rs7929679	0.875	rs11032867	ENSG00000225531.1	RP11-196I18.3	7.32	5.07e-13	4.95e-07	0.28	0.22	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;	chr11:34782001	chr9:107116829~107117557:+
BRCA	trans	rs853679	0.766	rs9368561	ENSG00000253570.1	RNF5P1	7.32	5.09e-13	4.97e-07	0.51	0.22	Depression;	chr6:28200565	chr8:38600661~38601200:-
BRCA	trans	rs1707322	0.717	rs3014249	ENSG00000255397.1	AC022182.2	7.31	5.15e-13	5.03e-07	0.29	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613821	chr8:60937705~60939871:-
BRCA	trans	rs9914988	0.887	rs11650282	ENSG00000267449.1	RP11-264B14.2	7.31	5.15e-13	5.03e-07	0.31	0.22	Glycated hemoglobin levels;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr17:28763723	chr17:61069856~61070356:-
BRCA	trans	rs9914988	0.887	rs11656272	ENSG00000267449.1	RP11-264B14.2	7.31	5.15e-13	5.03e-07	0.31	0.22	Glycated hemoglobin levels;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr17:28764135	chr17:61069856~61070356:-
BRCA	trans	rs9914988	0.725	rs9905510	ENSG00000267449.1	RP11-264B14.2	7.31	5.15e-13	5.03e-07	0.31	0.22	Glycated hemoglobin levels;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr17:28765307	chr17:61069856~61070356:-
BRCA	trans	rs11098499	0.697	rs4560394	ENSG00000120555.12	SEPT7P9	7.31	5.15e-13	5.03e-07	0.27	0.22	Corneal astigmatism;	chr4:119392280	chr10:38383069~38402916:-
BRCA	trans	rs4713118	0.614	rs9468209	ENSG00000204709.4	LINC01556	7.31	5.16e-13	5.03e-07	0.29	0.22	Parkinson's disease;	chr6:27726642	chr6:28943877~28944537:+
BRCA	trans	rs6732160	0.613	rs57208378	ENSG00000236165.1	PRADC1P1	7.31	5.23e-13	5.1e-07	0.3	0.22	Intelligence (multi-trait analysis);	chr2:73162871	chr3:36976316~36976840:+
BRCA	trans	rs11098499	0.82	rs28394116	ENSG00000120555.12	SEPT7P9	7.31	5.24e-13	5.11e-07	0.28	0.22	Corneal astigmatism;	chr4:119603128	chr10:38383069~38402916:-
BRCA	trans	rs1933488	0.931	rs7750498	ENSG00000278974.1	RP11-756P10.6	-7.31	5.27e-13	5.14e-07	-0.29	-0.22	Prostate cancer;	chr6:153102920	chr4:188740507~188741281:-
BRCA	trans	rs4713118	0.669	rs200997	ENSG00000204709.4	LINC01556	7.31	5.28e-13	5.15e-07	0.3	0.22	Parkinson's disease;	chr6:27844037	chr6:28943877~28944537:+
BRCA	trans	rs2060793	0.506	rs10741658	ENSG00000236360.2	RP11-334A14.2	7.31	5.3e-13	5.17e-07	0.28	0.22	Vitamin D levels;	chr11:14903190	chr1:52993201~52993702:-
BRCA	trans	rs1707322	0.682	rs28490344	ENSG00000255397.1	AC022182.2	-7.31	5.3e-13	5.17e-07	-0.3	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45732276	chr8:60937705~60939871:-
BRCA	trans	rs1707322	0.721	rs28641748	ENSG00000255397.1	AC022182.2	-7.31	5.3e-13	5.17e-07	-0.3	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45747164	chr8:60937705~60939871:-
BRCA	trans	rs1707322	0.721	rs4330955	ENSG00000255397.1	AC022182.2	-7.31	5.3e-13	5.17e-07	-0.3	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45751813	chr8:60937705~60939871:-
BRCA	trans	rs1707322	0.691	rs12031182	ENSG00000255397.1	AC022182.2	-7.31	5.3e-13	5.17e-07	-0.3	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755327	chr8:60937705~60939871:-
BRCA	trans	rs1707322	0.721	rs10430123	ENSG00000255397.1	AC022182.2	-7.31	5.3e-13	5.17e-07	-0.3	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755768	chr8:60937705~60939871:-
BRCA	trans	rs11098499	0.909	rs1546502	ENSG00000120555.12	SEPT7P9	7.31	5.39e-13	5.26e-07	0.27	0.22	Corneal astigmatism;	chr4:119314743	chr10:38383069~38402916:-
BRCA	trans	rs9581094	0.591	rs73154384	ENSG00000237917.1	PARP4P1	-7.31	5.4e-13	5.26e-07	-0.44	-0.22	Sudden cardiac arrest;	chr13:24502302	chrY:26594851~26634652:-
BRCA	trans	rs801193	1	rs7782320	ENSG00000164669.11	INTS4P1	-7.31	5.41e-13	5.27e-07	-0.27	-0.22	Aortic root size;	chr7:66712111	chr7:65141225~65234216:+
BRCA	trans	rs11098499	0.954	rs878373	ENSG00000120555.12	SEPT7P9	7.31	5.43e-13	5.29e-07	0.27	0.22	Corneal astigmatism;	chr4:119316329	chr10:38383069~38402916:-
BRCA	trans	rs1568889	0.838	rs11030206	ENSG00000174912.7	METTL15P1	7.31	5.44e-13	5.3e-07	0.22	0.22	Bipolar disorder;	chr11:28078200	chr3:156713884~156714928:-
BRCA	trans	rs4948102	0.642	rs766333	ENSG00000186940.6	CHCHD2P9	-7.31	5.44e-13	5.3e-07	-0.27	-0.22	Plasma homocysteine levels (post-methionine load test);	chr7:56059011	chr9:79391304~79391759:+
BRCA	trans	rs11098499	0.954	rs10008459	ENSG00000120555.12	SEPT7P9	7.31	5.46e-13	5.32e-07	0.27	0.22	Corneal astigmatism;	chr4:119473076	chr10:38383069~38402916:-
BRCA	trans	rs9467711	0.606	rs2073529	ENSG00000253570.1	RNF5P1	-7.31	5.47e-13	5.33e-07	-0.51	-0.22	Autism spectrum disorder or schizophrenia;	chr6:26374931	chr8:38600661~38601200:-
BRCA	trans	rs11098499	0.697	rs28655325	ENSG00000120555.12	SEPT7P9	7.31	5.5e-13	5.35e-07	0.27	0.22	Corneal astigmatism;	chr4:119451844	chr10:38383069~38402916:-
BRCA	trans	rs76228276	0.737	rs6982694	ENSG00000260318.1	COX6CP1	7.31	5.5e-13	5.36e-07	0.59	0.22	Childhood ear infection;	chr8:99400531	chr16:11903923~11904137:-
BRCA	trans	rs11098499	0.954	rs6857105	ENSG00000276997.3	RP11-378J18.9	7.3	5.53e-13	5.38e-07	0.27	0.22	Corneal astigmatism;	chr4:119301143	chr1:222477252~222504622:-
BRCA	trans	rs1707322	0.506	rs2991983	ENSG00000255397.1	AC022182.2	7.3	5.58e-13	5.43e-07	0.29	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613719	chr8:60937705~60939871:-
BRCA	trans	rs11098499	0.954	rs10017371	ENSG00000120555.12	SEPT7P9	7.3	5.59e-13	5.44e-07	0.28	0.22	Corneal astigmatism;	chr4:119372621	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.954	rs7437420	ENSG00000276997.3	RP11-378J18.9	7.3	5.6e-13	5.45e-07	0.27	0.22	Corneal astigmatism;	chr4:119391748	chr1:222477252~222504622:-
BRCA	trans	rs1568889	0.838	rs11030185	ENSG00000174912.7	METTL15P1	7.3	5.64e-13	5.49e-07	0.22	0.22	Bipolar disorder;	chr11:28020357	chr3:156713884~156714928:-
BRCA	trans	rs1568889	0.838	rs12273631	ENSG00000174912.7	METTL15P1	7.3	5.64e-13	5.49e-07	0.22	0.22	Bipolar disorder;	chr11:28020588	chr3:156713884~156714928:-
BRCA	trans	rs2243480	1	rs34703416	ENSG00000273142.1	RP11-458F8.4	-7.3	5.64e-13	5.49e-07	-0.3	-0.22	Diabetic kidney disease;	chr7:65835655	chr7:66902857~66906297:+
BRCA	trans	rs875971	0.638	rs7793569	ENSG00000164669.11	INTS4P1	7.3	5.67e-13	5.51e-07	0.27	0.22	Aortic root size;	chr7:66651646	chr7:65141225~65234216:+
BRCA	trans	rs801193	1	rs3857688	ENSG00000164669.11	INTS4P1	7.3	5.67e-13	5.51e-07	0.27	0.22	Aortic root size;	chr7:66662819	chr7:65141225~65234216:+
BRCA	trans	rs801193	1	rs2286684	ENSG00000164669.11	INTS4P1	7.3	5.67e-13	5.51e-07	0.27	0.22	Aortic root size;	chr7:66664843	chr7:65141225~65234216:+
BRCA	trans	rs801193	0.935	rs2286683	ENSG00000164669.11	INTS4P1	7.3	5.67e-13	5.51e-07	0.27	0.22	Aortic root size;	chr7:66664856	chr7:65141225~65234216:+
BRCA	trans	rs801193	1	rs10274773	ENSG00000164669.11	INTS4P1	7.3	5.67e-13	5.51e-07	0.27	0.22	Aortic root size;	chr7:66668591	chr7:65141225~65234216:+
BRCA	trans	rs7944735	0.568	rs59631865	ENSG00000134612.10	FOLH1B	7.3	5.68e-13	5.52e-07	0.36	0.22	Intraocular pressure;	chr11:47480067	chr11:89639227~89698718:+
BRCA	trans	rs11098499	0.909	rs11723757	ENSG00000276997.3	RP11-378J18.9	7.3	5.7e-13	5.54e-07	0.27	0.22	Corneal astigmatism;	chr4:119378514	chr1:222477252~222504622:-
BRCA	trans	rs7662987	1	rs13145727	ENSG00000228407.2	RP4-800M22.1	7.3	5.71e-13	5.55e-07	0.5	0.22	Smoking initiation;	chr4:99077715	chr1:52160261~52160600:-
BRCA	trans	rs11098499	0.618	rs28491261	ENSG00000276997.3	RP11-378J18.9	7.3	5.72e-13	5.56e-07	0.27	0.22	Corneal astigmatism;	chr4:119373745	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.954	rs10008392	ENSG00000120555.12	SEPT7P9	7.3	5.73e-13	5.57e-07	0.27	0.22	Corneal astigmatism;	chr4:119397684	chr10:38383069~38402916:-
BRCA	trans	rs12210905	1	rs3999221	ENSG00000242375.1	RP11-498P14.3	-7.3	5.75e-13	5.59e-07	-0.48	-0.22	Hip circumference adjusted for BMI;	chr6:26991543	chr9:97195351~97197687:-
BRCA	trans	rs1933488	1	rs9383649	ENSG00000278974.1	RP11-756P10.6	-7.3	5.76e-13	5.59e-07	-0.28	-0.22	Prostate cancer;	chr6:153106967	chr4:188740507~188741281:-
BRCA	trans	rs1933488	1	rs7747003	ENSG00000278974.1	RP11-756P10.6	-7.3	5.76e-13	5.59e-07	-0.28	-0.22	Prostate cancer;	chr6:153107847	chr4:188740507~188741281:-
BRCA	trans	rs11098499	0.954	rs10006877	ENSG00000120555.12	SEPT7P9	7.3	5.78e-13	5.61e-07	0.27	0.22	Corneal astigmatism;	chr4:119321638	chr10:38383069~38402916:-
BRCA	trans	rs1707322	0.686	rs1250	ENSG00000255397.1	AC022182.2	-7.3	5.8e-13	5.64e-07	-0.29	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45628355	chr8:60937705~60939871:-
BRCA	trans	rs12477438	0.52	rs2309581	ENSG00000276576.1	MRPL30P1	-7.3	5.8e-13	5.64e-07	-0.28	-0.22	Chronic sinus infection;	chr2:99167829	chr6:57029521~57029988:+
BRCA	trans	rs76228276	0.737	rs79230117	ENSG00000260318.1	COX6CP1	7.3	5.81e-13	5.64e-07	0.59	0.22	Childhood ear infection;	chr8:99416201	chr16:11903923~11904137:-
BRCA	trans	rs11098499	1	rs11098500	ENSG00000120555.12	SEPT7P9	7.3	5.82e-13	5.65e-07	0.28	0.22	Corneal astigmatism;	chr4:119298084	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.954	rs11722872	ENSG00000120555.12	SEPT7P9	7.3	5.84e-13	5.67e-07	0.27	0.22	Corneal astigmatism;	chr4:119311875	chr10:38383069~38402916:-
BRCA	trans	rs864643	0.838	rs58141864	ENSG00000188856.6	RPSAP47	7.3	5.87e-13	5.7e-07	0.43	0.22	Attention deficit hyperactivity disorder;	chr3:39505344	chr8:80558870~80559757:+
BRCA	trans	rs9581094	0.527	rs73154357	ENSG00000237917.1	PARP4P1	-7.3	5.9e-13	5.73e-07	-0.44	-0.22	Sudden cardiac arrest;	chr13:24489700	chrY:26594851~26634652:-
BRCA	trans	rs9581094	0.591	rs56039816	ENSG00000237917.1	PARP4P1	-7.3	5.9e-13	5.73e-07	-0.44	-0.22	Sudden cardiac arrest;	chr13:24489862	chrY:26594851~26634652:-
BRCA	trans	rs9581094	0.591	rs17470243	ENSG00000237917.1	PARP4P1	-7.3	5.91e-13	5.73e-07	-0.44	-0.22	Sudden cardiac arrest;	chr13:24498043	chrY:26594851~26634652:-
BRCA	trans	rs1816752	0.524	rs1965154	ENSG00000237917.1	PARP4P1	-7.3	5.91e-13	5.73e-07	-0.44	-0.22	Obesity-related traits;	chr13:24498062	chrY:26594851~26634652:-
BRCA	trans	rs864643	0.678	rs1707960	ENSG00000188856.6	RPSAP47	-7.29	5.91e-13	5.73e-07	-0.32	-0.22	Attention deficit hyperactivity disorder;	chr3:39481761	chr8:80558870~80559757:+
BRCA	trans	rs7824557	0.767	rs6985460	ENSG00000270154.1	RP11-419I17.1	7.29	5.91e-13	5.74e-07	0.27	0.22	Retinal vascular caliber;	chr8:11313578	chr8:12476462~12477122:+
BRCA	trans	rs714543	1	rs2898	ENSG00000267258.1	CTC-448F2.3	-7.29	5.95e-13	5.77e-07	-0.26	-0.22	Plateletcrit;	chr7:44827034	chr19:29921182~29921653:+
BRCA	trans	rs7312770	0.612	rs1873914	ENSG00000227586.5	RP11-162A23.5	7.29	5.96e-13	5.78e-07	0.26	0.22	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr10:123171535~123171875:-
BRCA	trans	rs1933488	0.965	rs28642896	ENSG00000278974.1	RP11-756P10.6	-7.29	5.96e-13	5.78e-07	-0.29	-0.22	Prostate cancer;	chr6:153106933	chr4:188740507~188741281:-
BRCA	trans	rs9581094	0.591	rs9581085	ENSG00000237917.1	PARP4P1	-7.29	5.98e-13	5.8e-07	-0.44	-0.22	Sudden cardiac arrest;	chr13:24499970	chrY:26594851~26634652:-
BRCA	trans	rs9581094	0.591	rs9581086	ENSG00000237917.1	PARP4P1	-7.29	5.98e-13	5.8e-07	-0.44	-0.22	Sudden cardiac arrest;	chr13:24500020	chrY:26594851~26634652:-
BRCA	trans	rs714543	1	rs10267576	ENSG00000267258.1	CTC-448F2.3	-7.29	6e-13	5.82e-07	-0.26	-0.22	Plateletcrit;	chr7:44831334	chr19:29921182~29921653:+
BRCA	trans	rs7824557	0.815	rs2572430	ENSG00000253893.2	FAM85B	-7.29	6.02e-13	5.84e-07	-0.27	-0.22	Retinal vascular caliber;	chr8:11247795	chr8:8167819~8226614:-
BRCA	trans	rs2060793	0.601	rs35321904	ENSG00000236360.2	RP11-334A14.2	7.29	6.02e-13	5.84e-07	0.29	0.22	Vitamin D levels;	chr11:14854914	chr1:52993201~52993702:-
BRCA	trans	rs1681630	0.545	rs1228001	ENSG00000134612.10	FOLH1B	-7.29	6.04e-13	5.85e-07	-0.27	-0.22	Height;	chr11:47965442	chr11:89639227~89698718:+
BRCA	trans	rs6732160	0.588	rs13403748	ENSG00000236165.1	PRADC1P1	7.29	6.04e-13	5.86e-07	0.3	0.22	Intelligence (multi-trait analysis);	chr2:73144347	chr3:36976316~36976840:+
BRCA	trans	rs1707322	0.627	rs3014213	ENSG00000255397.1	AC022182.2	7.29	6.06e-13	5.88e-07	0.3	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45579850	chr8:60937705~60939871:-
BRCA	trans	rs9467711	0.606	rs9393708	ENSG00000253570.1	RNF5P1	-7.29	6.1e-13	5.91e-07	-0.51	-0.22	Autism spectrum disorder or schizophrenia;	chr6:26362415	chr8:38600661~38601200:-
BRCA	trans	rs9581094	0.591	rs9581073	ENSG00000237917.1	PARP4P1	-7.29	6.12e-13	5.93e-07	-0.41	-0.22	Sudden cardiac arrest;	chr13:24490516	chrY:26594851~26634652:-
BRCA	trans	rs7833986	0.534	rs10504198	ENSG00000244245.1	RP11-120B7.1	7.29	6.12e-13	5.93e-07	0.28	0.22	Height;	chr8:56093695	chr5:108593609~108593967:+
BRCA	trans	rs7833986	0.534	rs2976022	ENSG00000244245.1	RP11-120B7.1	7.29	6.12e-13	5.93e-07	0.28	0.22	Height;	chr8:56095284	chr5:108593609~108593967:+
BRCA	trans	rs7833986	0.501	rs2976018	ENSG00000244245.1	RP11-120B7.1	7.29	6.12e-13	5.93e-07	0.28	0.22	Height;	chr8:56102193	chr5:108593609~108593967:+
BRCA	trans	rs801193	1	rs1553610	ENSG00000164669.11	INTS4P1	-7.29	6.12e-13	5.93e-07	-0.27	-0.22	Aortic root size;	chr7:66732246	chr7:65141225~65234216:+
BRCA	trans	rs801193	1	rs2707845	ENSG00000164669.11	INTS4P1	-7.29	6.12e-13	5.93e-07	-0.27	-0.22	Aortic root size;	chr7:66733811	chr7:65141225~65234216:+
BRCA	trans	rs801193	1	rs2707850	ENSG00000164669.11	INTS4P1	-7.29	6.12e-13	5.93e-07	-0.27	-0.22	Aortic root size;	chr7:66738883	chr7:65141225~65234216:+
BRCA	trans	rs801193	0.967	rs1110414	ENSG00000164669.11	INTS4P1	-7.29	6.12e-13	5.93e-07	-0.27	-0.22	Aortic root size;	chr7:66740595	chr7:65141225~65234216:+
BRCA	trans	rs801193	1	rs7783924	ENSG00000164669.11	INTS4P1	-7.29	6.12e-13	5.93e-07	-0.27	-0.22	Aortic root size;	chr7:66744070	chr7:65141225~65234216:+
BRCA	trans	rs801193	1	rs7789184	ENSG00000164669.11	INTS4P1	-7.29	6.12e-13	5.93e-07	-0.27	-0.22	Aortic root size;	chr7:66745208	chr7:65141225~65234216:+
BRCA	trans	rs801193	1	rs2707854	ENSG00000164669.11	INTS4P1	-7.29	6.12e-13	5.93e-07	-0.27	-0.22	Aortic root size;	chr7:66747610	chr7:65141225~65234216:+
BRCA	trans	rs7929679	0.846	rs2116086	ENSG00000225531.1	RP11-196I18.3	7.29	6.14e-13	5.95e-07	0.28	0.22	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;	chr11:34797982	chr9:107116829~107117557:+
BRCA	trans	rs8177876	0.822	rs10514514	ENSG00000226040.3	AC005740.3	7.29	6.18e-13	5.99e-07	0.45	0.22	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081668	chr5:141896168~141896689:-
BRCA	trans	rs2069408	1	rs2069408	ENSG00000196656.7	AC004057.1	-7.29	6.22e-13	6.02e-07	-0.28	-0.22	Asthma;	chr12:55970537	chr4:113214046~113217170:-
BRCA	trans	rs1707322	0.721	rs11211157	ENSG00000255397.1	AC022182.2	-7.29	6.3e-13	6.09e-07	-0.29	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45667172	chr8:60937705~60939871:-
BRCA	trans	rs1707322	0.721	rs11211158	ENSG00000255397.1	AC022182.2	-7.29	6.3e-13	6.09e-07	-0.29	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45667178	chr8:60937705~60939871:-
BRCA	trans	rs1707322	0.721	rs6429575	ENSG00000255397.1	AC022182.2	-7.29	6.3e-13	6.09e-07	-0.29	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45668544	chr8:60937705~60939871:-
BRCA	trans	rs11098499	0.863	rs2306457	ENSG00000276997.3	RP11-378J18.9	7.29	6.3e-13	6.1e-07	0.27	0.22	Corneal astigmatism;	chr4:119551684	chr1:222477252~222504622:-
BRCA	trans	rs4720118	0.508	rs3823763	ENSG00000213492.2	NT5C3AP1	7.29	6.3e-13	6.1e-07	0.28	0.22	Leprosy;	chr7:33368282	chr4:117574512~117576174:-
BRCA	trans	rs11098499	0.909	rs71614422	ENSG00000120555.12	SEPT7P9	7.29	6.31e-13	6.11e-07	0.27	0.22	Corneal astigmatism;	chr4:119438185	chr10:38383069~38402916:-
BRCA	trans	rs1707322	0.686	rs2152078	ENSG00000255397.1	AC022182.2	7.28	6.38e-13	6.17e-07	0.3	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45589928	chr8:60937705~60939871:-
BRCA	trans	rs1707322	0.686	rs2991979	ENSG00000255397.1	AC022182.2	7.28	6.38e-13	6.17e-07	0.3	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45590186	chr8:60937705~60939871:-
BRCA	trans	rs7929679	0.875	rs10836314	ENSG00000225531.1	RP11-196I18.3	7.28	6.4e-13	6.19e-07	0.28	0.22	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;	chr11:34796040	chr9:107116829~107117557:+
BRCA	trans	rs11098499	0.954	rs12505469	ENSG00000120555.12	SEPT7P9	7.28	6.41e-13	6.2e-07	0.27	0.22	Corneal astigmatism;	chr4:119328430	chr10:38383069~38402916:-
BRCA	trans	rs7169223	0.653	rs1976007	ENSG00000274376.3	ADAMTS7P1	7.28	6.42e-13	6.21e-07	0.29	0.22	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78792681	chr15:82298553~82334609:+
BRCA	trans	rs17507216	0.718	rs72751675	ENSG00000259295.5	CSPG4P12	-7.28	6.51e-13	6.3e-07	-0.37	-0.22	Excessive daytime sleepiness;	chr15:82630452	chr15:85191438~85213905:+
BRCA	trans	rs11098499	0.954	rs3733520	ENSG00000120555.12	SEPT7P9	7.28	6.56e-13	6.34e-07	0.27	0.22	Corneal astigmatism;	chr4:119502325	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.909	rs28714195	ENSG00000276997.3	RP11-378J18.9	7.28	6.61e-13	6.39e-07	0.27	0.22	Corneal astigmatism;	chr4:119395795	chr1:222477252~222504622:-
BRCA	trans	rs9650657	0.596	rs2409675	ENSG00000253893.2	FAM85B	7.28	6.65e-13	6.42e-07	0.27	0.22	Neuroticism;	chr8:10737749	chr8:8167819~8226614:-
BRCA	trans	rs9368481	0.761	rs9348746	ENSG00000242375.1	RP11-498P14.3	-7.28	6.68e-13	6.45e-07	-0.32	-0.22	Autism spectrum disorder or schizophrenia;	chr6:27002578	chr9:97195351~97197687:-
BRCA	trans	rs6732160	0.588	rs13390460	ENSG00000236165.1	PRADC1P1	7.28	6.73e-13	6.5e-07	0.3	0.22	Intelligence (multi-trait analysis);	chr2:73144348	chr3:36976316~36976840:+
BRCA	trans	rs1707322	0.721	rs10890336	ENSG00000255397.1	AC022182.2	-7.28	6.74e-13	6.51e-07	-0.29	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45645384	chr8:60937705~60939871:-
BRCA	trans	rs1707322	0.721	rs11211151	ENSG00000255397.1	AC022182.2	-7.28	6.74e-13	6.51e-07	-0.29	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45647080	chr8:60937705~60939871:-
BRCA	trans	rs1707322	0.721	rs12045096	ENSG00000255397.1	AC022182.2	-7.28	6.74e-13	6.51e-07	-0.29	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45648756	chr8:60937705~60939871:-
BRCA	trans	rs1707322	0.721	rs4609469	ENSG00000255397.1	AC022182.2	-7.28	6.74e-13	6.51e-07	-0.29	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45651513	chr8:60937705~60939871:-
BRCA	trans	rs1707322	0.721	rs12049027	ENSG00000255397.1	AC022182.2	-7.28	6.74e-13	6.51e-07	-0.29	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45652512	chr8:60937705~60939871:-
BRCA	trans	rs1707322	0.752	rs10789467	ENSG00000255397.1	AC022182.2	-7.28	6.74e-13	6.51e-07	-0.29	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45653073	chr8:60937705~60939871:-
BRCA	trans	rs1707322	0.721	rs10890337	ENSG00000255397.1	AC022182.2	-7.28	6.74e-13	6.51e-07	-0.29	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45658855	chr8:60937705~60939871:-
BRCA	trans	rs1707322	0.752	rs3811435	ENSG00000255397.1	AC022182.2	-7.28	6.74e-13	6.51e-07	-0.29	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45660118	chr8:60937705~60939871:-
BRCA	trans	rs1707322	0.721	rs9793568	ENSG00000255397.1	AC022182.2	-7.28	6.74e-13	6.51e-07	-0.29	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45664701	chr8:60937705~60939871:-
BRCA	trans	rs1707322	0.685	rs6690926	ENSG00000255397.1	AC022182.2	-7.28	6.74e-13	6.51e-07	-0.29	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45669306	chr8:60937705~60939871:-
BRCA	trans	rs1707322	0.752	rs8179402	ENSG00000255397.1	AC022182.2	-7.28	6.74e-13	6.51e-07	-0.29	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45676794	chr8:60937705~60939871:-
BRCA	trans	rs1707322	0.752	rs8179296	ENSG00000255397.1	AC022182.2	-7.28	6.74e-13	6.51e-07	-0.29	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45678119	chr8:60937705~60939871:-
BRCA	trans	rs1568889	0.838	rs4614434	ENSG00000174912.7	METTL15P1	7.28	6.76e-13	6.53e-07	0.22	0.22	Bipolar disorder;	chr11:28280687	chr3:156713884~156714928:-
BRCA	trans	rs1568889	0.712	rs10835306	ENSG00000174912.7	METTL15P1	7.28	6.76e-13	6.53e-07	0.22	0.22	Bipolar disorder;	chr11:28280863	chr3:156713884~156714928:-
BRCA	trans	rs9584850	0.789	rs7988345	ENSG00000230079.1	STK24P1	7.28	6.77e-13	6.54e-07	0.29	0.22	Neuroticism;	chr13:98465431	chrX:136295690~136300298:-
BRCA	trans	rs7929679	0.875	rs7932115	ENSG00000225531.1	RP11-196I18.3	7.27	6.8e-13	6.57e-07	0.28	0.22	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;	chr11:34796965	chr9:107116829~107117557:+
BRCA	trans	rs9834975	0.565	rs2332181	ENSG00000267076.1	CCDC58P3	-7.27	6.82e-13	6.58e-07	-0.26	-0.22	Diastolic blood pressure;	chr3:122396019	chr18:12211378~12211807:+
BRCA	trans	rs747782	0.639	rs4752872	ENSG00000134612.10	FOLH1B	7.27	6.86e-13	6.61e-07	0.41	0.22	Intraocular pressure;	chr11:47832243	chr11:89639227~89698718:+
BRCA	trans	rs1707322	0.721	rs28501477	ENSG00000255397.1	AC022182.2	-7.27	6.87e-13	6.63e-07	-0.29	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45733412	chr8:60937705~60939871:-
BRCA	trans	rs11098499	0.954	rs28572238	ENSG00000276997.3	RP11-378J18.9	7.27	6.91e-13	6.67e-07	0.27	0.22	Corneal astigmatism;	chr4:119395531	chr1:222477252~222504622:-
BRCA	trans	rs714543	0.783	rs7806283	ENSG00000219797.2	PPIAP9	-7.27	6.92e-13	6.68e-07	-0.26	-0.22	Plateletcrit;	chr7:44779104	chr6:31519480~31520291:-
BRCA	trans	rs9914988	0.943	rs2242345	ENSG00000267449.1	RP11-264B14.2	-7.27	6.95e-13	6.7e-07	-0.3	-0.22	Glycated hemoglobin levels;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr17:28858809	chr17:61069856~61070356:-
BRCA	trans	rs4948102	0.597	rs12669623	ENSG00000186940.6	CHCHD2P9	-7.27	6.95e-13	6.7e-07	-0.27	-0.22	Plasma homocysteine levels (post-methionine load test);	chr7:56071486	chr9:79391304~79391759:+
BRCA	trans	rs9834975	0.565	rs4494873	ENSG00000267076.1	CCDC58P3	-7.27	6.97e-13	6.72e-07	-0.25	-0.22	Diastolic blood pressure;	chr3:122393177	chr18:12211378~12211807:+
BRCA	trans	rs1933488	1	rs1442744	ENSG00000278974.1	RP11-756P10.6	-7.27	6.97e-13	6.72e-07	-0.28	-0.22	Prostate cancer;	chr6:153120598	chr4:188740507~188741281:-
BRCA	trans	rs1933488	1	rs6927516	ENSG00000278974.1	RP11-756P10.6	-7.27	6.97e-13	6.72e-07	-0.28	-0.22	Prostate cancer;	chr6:153120696	chr4:188740507~188741281:-
BRCA	trans	rs11098499	0.908	rs9995234	ENSG00000276997.3	RP11-378J18.9	7.27	7.02e-13	6.77e-07	0.28	0.22	Corneal astigmatism;	chr4:119400672	chr1:222477252~222504622:-
BRCA	trans	rs1568889	0.838	rs6484359	ENSG00000174912.7	METTL15P1	7.27	7.03e-13	6.78e-07	0.22	0.22	Bipolar disorder;	chr11:28240781	chr3:156713884~156714928:-
BRCA	trans	rs17507216	0.718	rs28587782	ENSG00000259295.5	CSPG4P12	-7.27	7.03e-13	6.78e-07	-0.35	-0.22	Excessive daytime sleepiness;	chr15:82576881	chr15:85191438~85213905:+
BRCA	trans	rs11098499	0.738	rs28408407	ENSG00000276997.3	RP11-378J18.9	7.27	7.06e-13	6.8e-07	0.26	0.22	Corneal astigmatism;	chr4:119454875	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.818	rs55825515	ENSG00000276997.3	RP11-378J18.9	7.27	7.06e-13	6.81e-07	0.28	0.22	Corneal astigmatism;	chr4:119565247	chr1:222477252~222504622:-
BRCA	trans	rs9467711	0.606	rs9379871	ENSG00000253570.1	RNF5P1	7.27	7.11e-13	6.85e-07	0.52	0.22	Autism spectrum disorder or schizophrenia;	chr6:26375626	chr8:38600661~38601200:-
BRCA	trans	rs7833986	0.501	rs72653978	ENSG00000244245.1	RP11-120B7.1	7.27	7.13e-13	6.87e-07	0.28	0.22	Height;	chr8:56105834	chr5:108593609~108593967:+
BRCA	trans	rs3808502	0.527	rs4410870	ENSG00000253893.2	FAM85B	7.27	7.16e-13	6.89e-07	0.29	0.22	Neuroticism;	chr8:11298611	chr8:8167819~8226614:-
BRCA	trans	rs11098499	0.909	rs10020034	ENSG00000276997.3	RP11-378J18.9	7.27	7.17e-13	6.9e-07	0.27	0.22	Corneal astigmatism;	chr4:119373176	chr1:222477252~222504622:-
BRCA	trans	rs9581094	0.591	rs9578747	ENSG00000237917.1	PARP4P1	-7.27	7.18e-13	6.91e-07	-0.44	-0.22	Sudden cardiac arrest;	chr13:24495467	chrY:26594851~26634652:-
BRCA	trans	rs11920570	0.959	rs6780306	ENSG00000267076.1	CCDC58P3	-7.27	7.23e-13	6.96e-07	-0.29	-0.22	Resting heart rate;	chr3:122506607	chr18:12211378~12211807:+
BRCA	trans	rs714543	1	rs10278679	ENSG00000267258.1	CTC-448F2.3	-7.27	7.24e-13	6.97e-07	-0.26	-0.22	Plateletcrit;	chr7:44825465	chr19:29921182~29921653:+
BRCA	trans	rs875971	0.619	rs2302918	ENSG00000164669.11	INTS4P1	-7.27	7.28e-13	7e-07	-0.27	-0.22	Aortic root size;	chr7:66535945	chr7:65141225~65234216:+
BRCA	trans	rs1568889	0.838	rs7125749	ENSG00000174912.7	METTL15P1	7.27	7.28e-13	7.01e-07	0.22	0.22	Bipolar disorder;	chr11:28133145	chr3:156713884~156714928:-
BRCA	trans	rs1568889	0.838	rs10835273	ENSG00000174912.7	METTL15P1	7.27	7.28e-13	7.01e-07	0.22	0.22	Bipolar disorder;	chr11:28135051	chr3:156713884~156714928:-
BRCA	trans	rs12210905	0.688	rs12195783	ENSG00000242375.1	RP11-498P14.3	-7.26	7.4e-13	7.12e-07	-0.54	-0.22	Hip circumference adjusted for BMI;	chr6:27476566	chr9:97195351~97197687:-
BRCA	trans	rs12210905	0.925	rs7753123	ENSG00000242375.1	RP11-498P14.3	-7.26	7.44e-13	7.15e-07	-0.47	-0.22	Hip circumference adjusted for BMI;	chr6:27023761	chr9:97195351~97197687:-
BRCA	trans	rs12210905	0.925	rs9467965	ENSG00000242375.1	RP11-498P14.3	-7.26	7.44e-13	7.15e-07	-0.47	-0.22	Hip circumference adjusted for BMI;	chr6:27024760	chr9:97195351~97197687:-
BRCA	trans	rs12210905	0.844	rs7773336	ENSG00000242375.1	RP11-498P14.3	-7.26	7.44e-13	7.15e-07	-0.47	-0.22	Hip circumference adjusted for BMI;	chr6:27025776	chr9:97195351~97197687:-
BRCA	trans	rs11098499	0.738	rs72918577	ENSG00000276997.3	RP11-378J18.9	7.26	7.45e-13	7.16e-07	0.27	0.22	Corneal astigmatism;	chr4:119405546	chr1:222477252~222504622:-
BRCA	trans	rs7833986	0.501	rs72653948	ENSG00000244245.1	RP11-120B7.1	7.26	7.45e-13	7.17e-07	0.27	0.22	Height;	chr8:56043130	chr5:108593609~108593967:+
BRCA	trans	rs9581094	0.591	rs9578746	ENSG00000237917.1	PARP4P1	-7.26	7.51e-13	7.22e-07	-0.44	-0.22	Sudden cardiac arrest;	chr13:24491043	chrY:26594851~26634652:-
BRCA	trans	rs6732160	0.588	rs1430345	ENSG00000236165.1	PRADC1P1	7.26	7.51e-13	7.22e-07	0.29	0.22	Intelligence (multi-trait analysis);	chr2:73143554	chr3:36976316~36976840:+
BRCA	trans	rs1707322	0.717	rs2253862	ENSG00000255397.1	AC022182.2	7.26	7.52e-13	7.22e-07	0.29	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45616288	chr8:60937705~60939871:-
BRCA	trans	rs1707322	0.717	rs2991988	ENSG00000255397.1	AC022182.2	7.26	7.52e-13	7.22e-07	0.29	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45616759	chr8:60937705~60939871:-
BRCA	trans	rs1707322	0.717	rs2991989	ENSG00000255397.1	AC022182.2	7.26	7.52e-13	7.22e-07	0.29	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45617293	chr8:60937705~60939871:-
BRCA	trans	rs11098499	0.779	rs80242894	ENSG00000120555.12	SEPT7P9	7.26	7.53e-13	7.24e-07	0.27	0.22	Corneal astigmatism;	chr4:119454597	chr10:38383069~38402916:-
BRCA	trans	rs3740713	0.669	rs34740438	ENSG00000236090.2	LDHAP3	7.26	7.54e-13	7.24e-07	0.41	0.22	Amyotrophic lateral sclerosis (sporadic);	chr11:18393783	chr2:41819747~41820754:+
BRCA	trans	rs801193	0.901	rs4273746	ENSG00000224316.1	RP11-479O9.2	-7.26	7.54e-13	7.25e-07	-0.22	-0.22	Aortic root size;	chr7:66836124	chr7:65773620~65802067:+
BRCA	trans	rs7927370	1	rs11827201	ENSG00000134612.10	FOLH1B	-7.26	7.56e-13	7.26e-07	-0.43	-0.22	Systemic lupus erythematosus;	chr11:55470820	chr11:89639227~89698718:+
BRCA	trans	rs1707322	0.656	rs9429172	ENSG00000255397.1	AC022182.2	7.26	7.56e-13	7.26e-07	0.29	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45626804	chr8:60937705~60939871:-
BRCA	trans	rs9914988	0.943	rs9894335	ENSG00000267449.1	RP11-264B14.2	7.26	7.57e-13	7.28e-07	0.3	0.22	Glycated hemoglobin levels;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr17:28811465	chr17:61069856~61070356:-
BRCA	trans	rs7169223	0.653	rs1994017	ENSG00000274376.3	ADAMTS7P1	7.26	7.61e-13	7.31e-07	0.28	0.22	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78787964	chr15:82298553~82334609:+
BRCA	trans	rs2288327	0.915	rs12614435	ENSG00000269800.1	PLEKHA3P1	7.26	7.62e-13	7.32e-07	0.3	0.22	Atrial fibrillation;	chr2:178624999	chr19:41521043~41521989:-
BRCA	trans	rs9650657	0.631	rs1124010	ENSG00000253893.2	FAM85B	7.26	7.63e-13	7.33e-07	0.27	0.22	Neuroticism;	chr8:10737992	chr8:8167819~8226614:-
BRCA	trans	rs7944735	0.508	rs111228939	ENSG00000134612.10	FOLH1B	7.26	7.65e-13	7.35e-07	0.38	0.22	Intraocular pressure;	chr11:47434516	chr11:89639227~89698718:+
BRCA	trans	rs11098499	0.863	rs3822192	ENSG00000276997.3	RP11-378J18.9	7.26	7.68e-13	7.37e-07	0.28	0.22	Corneal astigmatism;	chr4:119524565	chr1:222477252~222504622:-
BRCA	trans	rs12210905	0.688	rs78285097	ENSG00000242375.1	RP11-498P14.3	-7.26	7.71e-13	7.41e-07	-0.57	-0.22	Hip circumference adjusted for BMI;	chr6:27406865	chr9:97195351~97197687:-
BRCA	trans	rs9581094	0.591	rs73154390	ENSG00000237917.1	PARP4P1	-7.26	7.73e-13	7.42e-07	-0.44	-0.22	Sudden cardiac arrest;	chr13:24505332	chrY:26594851~26634652:-
BRCA	trans	rs7824557	0.592	rs920044	ENSG00000253893.2	FAM85B	-7.26	7.75e-13	7.44e-07	-0.28	-0.22	Retinal vascular caliber;	chr8:11366804	chr8:8167819~8226614:-
BRCA	trans	rs3740713	1	rs73440615	ENSG00000236090.2	LDHAP3	7.26	7.75e-13	7.44e-07	0.41	0.22	Amyotrophic lateral sclerosis (sporadic);	chr11:18445736	chr2:41819747~41820754:+
BRCA	trans	rs2134046	0.587	rs11854289	ENSG00000235370.6	DNM1P51	7.26	7.76e-13	7.45e-07	0.24	0.22	Cognitive ability;	chr15:82266461	chr15:84398316~84411701:-
BRCA	trans	rs9368481	0.761	rs12661756	ENSG00000242375.1	RP11-498P14.3	7.26	7.78e-13	7.47e-07	0.32	0.22	Autism spectrum disorder or schizophrenia;	chr6:27035704	chr9:97195351~97197687:-
BRCA	trans	rs853679	0.546	rs13213152	ENSG00000281831.1	HCP5B	7.26	7.82e-13	7.51e-07	0.57	0.22	Depression;	chr6:28381921	chr6:29871895~29873783:-
BRCA	trans	rs9467711	0.606	rs2073527	ENSG00000253570.1	RNF5P1	7.26	7.83e-13	7.51e-07	0.52	0.22	Autism spectrum disorder or schizophrenia;	chr6:26374750	chr8:38600661~38601200:-
BRCA	trans	rs9467711	0.606	rs2073531	ENSG00000253570.1	RNF5P1	7.26	7.83e-13	7.51e-07	0.52	0.22	Autism spectrum disorder or schizophrenia;	chr6:26375028	chr8:38600661~38601200:-
BRCA	trans	rs11098499	0.779	rs28495013	ENSG00000120555.12	SEPT7P9	7.25	7.86e-13	7.55e-07	0.27	0.22	Corneal astigmatism;	chr4:119454676	chr10:38383069~38402916:-
BRCA	trans	rs853679	0.546	rs13213986	ENSG00000281831.1	HCP5B	7.25	7.94e-13	7.62e-07	0.57	0.22	Depression;	chr6:28390232	chr6:29871895~29873783:-
BRCA	trans	rs853679	0.546	rs34546986	ENSG00000281831.1	HCP5B	7.25	7.94e-13	7.62e-07	0.57	0.22	Depression;	chr6:28394532	chr6:29871895~29873783:-
BRCA	trans	rs853679	0.546	rs34871267	ENSG00000281831.1	HCP5B	7.25	7.94e-13	7.62e-07	0.57	0.22	Depression;	chr6:28396455	chr6:29871895~29873783:-
BRCA	trans	rs853679	0.546	rs35883476	ENSG00000281831.1	HCP5B	7.25	7.94e-13	7.62e-07	0.57	0.22	Depression;	chr6:28400731	chr6:29871895~29873783:-
BRCA	trans	rs9467711	0.606	rs9366653	ENSG00000253570.1	RNF5P1	7.25	7.94e-13	7.62e-07	0.52	0.22	Autism spectrum disorder or schizophrenia;	chr6:26354019	chr8:38600661~38601200:-
BRCA	trans	rs7200543	1	rs72774845	ENSG00000250569.1	NTAN1P2	7.25	8.02e-13	7.7e-07	0.24	0.22	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15054097	chr8:86481754~86483002:-
BRCA	trans	rs11098499	0.865	rs11722183	ENSG00000276997.3	RP11-378J18.9	7.25	8.05e-13	7.72e-07	0.27	0.22	Corneal astigmatism;	chr4:119359442	chr1:222477252~222504622:-
BRCA	trans	rs10783779	0.647	rs705708	ENSG00000235459.5	RPS26P31	7.25	8.05e-13	7.73e-07	0.25	0.22	Educational attainment;	chr12:56095129	chr7:122681315~122681662:+
BRCA	trans	rs9914988	0.943	rs34693224	ENSG00000267449.1	RP11-264B14.2	7.25	8.12e-13	7.78e-07	0.31	0.22	Glycated hemoglobin levels;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr17:28752537	chr17:61069856~61070356:-
BRCA	trans	rs11098499	0.954	rs10518331	ENSG00000120555.12	SEPT7P9	7.25	8.13e-13	7.79e-07	0.27	0.22	Corneal astigmatism;	chr4:119402440	chr10:38383069~38402916:-
BRCA	trans	rs10940346	0.506	rs12657678	ENSG00000231752.4	EMBP1	7.25	8.19e-13	7.85e-07	0.28	0.22	Schizophrenia;	chr5:50564284	chr1:121519112~121571892:+
BRCA	trans	rs9467711	0.606	rs28362606	ENSG00000253570.1	RNF5P1	7.25	8.19e-13	7.85e-07	0.52	0.22	Autism spectrum disorder or schizophrenia;	chr6:26365358	chr8:38600661~38601200:-
BRCA	trans	rs9467711	0.606	rs66827971	ENSG00000253570.1	RNF5P1	7.25	8.19e-13	7.85e-07	0.52	0.22	Autism spectrum disorder or schizophrenia;	chr6:26365538	chr8:38600661~38601200:-
BRCA	trans	rs9467711	0.606	rs71557334	ENSG00000253570.1	RNF5P1	7.25	8.19e-13	7.85e-07	0.52	0.22	Autism spectrum disorder or schizophrenia;	chr6:26365685	chr8:38600661~38601200:-
BRCA	trans	rs9467711	0.606	rs9348712	ENSG00000253570.1	RNF5P1	7.25	8.19e-13	7.85e-07	0.52	0.22	Autism spectrum disorder or schizophrenia;	chr6:26366283	chr8:38600661~38601200:-
BRCA	trans	rs9467711	0.606	rs9379856	ENSG00000253570.1	RNF5P1	7.25	8.19e-13	7.85e-07	0.52	0.22	Autism spectrum disorder or schizophrenia;	chr6:26366608	chr8:38600661~38601200:-
BRCA	trans	rs9467711	0.606	rs9379857	ENSG00000253570.1	RNF5P1	7.25	8.19e-13	7.85e-07	0.52	0.22	Autism spectrum disorder or schizophrenia;	chr6:26367426	chr8:38600661~38601200:-
BRCA	trans	rs9467711	0.606	rs9379858	ENSG00000253570.1	RNF5P1	7.25	8.19e-13	7.85e-07	0.52	0.22	Autism spectrum disorder or schizophrenia;	chr6:26367461	chr8:38600661~38601200:-
BRCA	trans	rs9467711	0.606	rs9393710	ENSG00000253570.1	RNF5P1	7.25	8.19e-13	7.85e-07	0.52	0.22	Autism spectrum disorder or schizophrenia;	chr6:26367605	chr8:38600661~38601200:-
BRCA	trans	rs9467711	0.606	rs9379859	ENSG00000253570.1	RNF5P1	7.25	8.19e-13	7.85e-07	0.52	0.22	Autism spectrum disorder or schizophrenia;	chr6:26369321	chr8:38600661~38601200:-
BRCA	trans	rs9467711	0.606	rs9358935	ENSG00000253570.1	RNF5P1	7.25	8.19e-13	7.85e-07	0.52	0.22	Autism spectrum disorder or schizophrenia;	chr6:26369359	chr8:38600661~38601200:-
BRCA	trans	rs9467711	0.539	rs34436535	ENSG00000253570.1	RNF5P1	7.25	8.19e-13	7.85e-07	0.52	0.22	Autism spectrum disorder or schizophrenia;	chr6:26370137	chr8:38600661~38601200:-
BRCA	trans	rs9467711	0.606	rs35307327	ENSG00000253570.1	RNF5P1	7.25	8.19e-13	7.85e-07	0.52	0.22	Autism spectrum disorder or schizophrenia;	chr6:26370246	chr8:38600661~38601200:-
BRCA	trans	rs9467711	0.606	rs34878490	ENSG00000253570.1	RNF5P1	7.25	8.19e-13	7.85e-07	0.52	0.22	Autism spectrum disorder or schizophrenia;	chr6:26370344	chr8:38600661~38601200:-
BRCA	trans	rs9467711	0.606	rs9358936	ENSG00000253570.1	RNF5P1	7.25	8.19e-13	7.85e-07	0.52	0.22	Autism spectrum disorder or schizophrenia;	chr6:26370429	chr8:38600661~38601200:-
BRCA	trans	rs9467711	0.606	rs9393711	ENSG00000253570.1	RNF5P1	7.25	8.19e-13	7.85e-07	0.52	0.22	Autism spectrum disorder or schizophrenia;	chr6:26370431	chr8:38600661~38601200:-
BRCA	trans	rs9467711	0.606	rs9393712	ENSG00000253570.1	RNF5P1	7.25	8.19e-13	7.85e-07	0.52	0.22	Autism spectrum disorder or schizophrenia;	chr6:26370772	chr8:38600661~38601200:-
BRCA	trans	rs9467711	0.606	rs12173854	ENSG00000253570.1	RNF5P1	7.25	8.19e-13	7.85e-07	0.52	0.22	Autism spectrum disorder or schizophrenia;	chr6:26371451	chr8:38600661~38601200:-
BRCA	trans	rs1707322	0.717	rs1547925	ENSG00000255397.1	AC022182.2	7.25	8.25e-13	7.91e-07	0.3	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45619684	chr8:60937705~60939871:-
BRCA	trans	rs1568889	0.838	rs7127069	ENSG00000174912.7	METTL15P1	7.25	8.26e-13	7.91e-07	0.22	0.22	Bipolar disorder;	chr11:28303865	chr3:156713884~156714928:-
BRCA	trans	rs28551159	1	rs28551159	ENSG00000253570.1	RNF5P1	7.24	8.44e-13	8.08e-07	0.52	0.22	Urinary tract infection frequency;	chr6:26376140	chr8:38600661~38601200:-
BRCA	trans	rs9914988	0.887	rs9895625	ENSG00000267449.1	RP11-264B14.2	7.24	8.47e-13	8.11e-07	0.31	0.22	Glycated hemoglobin levels;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr17:28781498	chr17:61069856~61070356:-
BRCA	trans	rs1707322	1	rs1613296	ENSG00000255397.1	AC022182.2	7.24	8.51e-13	8.14e-07	0.28	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46081180	chr8:60937705~60939871:-
BRCA	trans	rs9650657	0.571	rs4840512	ENSG00000253893.2	FAM85B	7.24	8.52e-13	8.15e-07	0.27	0.22	Neuroticism;	chr8:10739315	chr8:8167819~8226614:-
BRCA	trans	rs17507216	1	rs17356118	ENSG00000259295.5	CSPG4P12	-7.24	8.53e-13	8.17e-07	-0.32	-0.22	Excessive daytime sleepiness;	chr15:82569149	chr15:85191438~85213905:+
BRCA	trans	rs6732160	0.613	rs59979991	ENSG00000236165.1	PRADC1P1	7.24	8.54e-13	8.18e-07	0.3	0.22	Intelligence (multi-trait analysis);	chr2:73157294	chr3:36976316~36976840:+
BRCA	trans	rs9914988	0.943	rs4795465	ENSG00000267449.1	RP11-264B14.2	-7.24	8.55e-13	8.18e-07	-0.3	-0.22	Glycated hemoglobin levels;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr17:28824480	chr17:61069856~61070356:-
BRCA	trans	rs853679	0.882	rs4713139	ENSG00000253570.1	RNF5P1	7.24	8.55e-13	8.18e-07	0.49	0.22	Depression;	chr6:28124907	chr8:38600661~38601200:-
BRCA	trans	rs9914988	0.943	rs9902953	ENSG00000267449.1	RP11-264B14.2	7.24	8.6e-13	8.23e-07	0.3	0.22	Glycated hemoglobin levels;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr17:28812816	chr17:61069856~61070356:-
BRCA	trans	rs9834975	0.544	rs6438741	ENSG00000267076.1	CCDC58P3	-7.24	8.61e-13	8.23e-07	-0.26	-0.22	Diastolic blood pressure;	chr3:122562494	chr18:12211378~12211807:+
BRCA	trans	rs4263408	0.755	rs13108552	ENSG00000237550.5	UBE2Q2P6	7.24	8.68e-13	8.3e-07	0.27	0.22	Plasma amyloid beta peptide concentrations (ABx-40);	chr4:39650252	chr15:82372196~82372912:-
BRCA	trans	rs902774	0.818	rs4919740	ENSG00000240668.1	KRT8P36	-7.24	8.71e-13	8.33e-07	-0.4	-0.22	Prostate cancer;	chr12:52877187	chr3:138101478~138102917:-
BRCA	trans	rs801193	0.935	rs2659916	ENSG00000164669.11	INTS4P1	-7.24	8.81e-13	8.42e-07	-0.27	-0.22	Aortic root size;	chr7:66686365	chr7:65141225~65234216:+
BRCA	trans	rs11098499	0.954	rs13133522	ENSG00000120555.12	SEPT7P9	7.24	8.84e-13	8.45e-07	0.27	0.22	Corneal astigmatism;	chr4:119403269	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.954	rs35091806	ENSG00000120555.12	SEPT7P9	7.24	8.84e-13	8.45e-07	0.27	0.22	Corneal astigmatism;	chr4:119404374	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.909	rs35165976	ENSG00000120555.12	SEPT7P9	7.24	8.84e-13	8.45e-07	0.27	0.22	Corneal astigmatism;	chr4:119404475	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.954	rs6846442	ENSG00000120555.12	SEPT7P9	7.24	8.84e-13	8.45e-07	0.27	0.22	Corneal astigmatism;	chr4:119405168	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.954	rs71614438	ENSG00000120555.12	SEPT7P9	7.24	8.84e-13	8.45e-07	0.27	0.22	Corneal astigmatism;	chr4:119450097	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.954	rs66506550	ENSG00000120555.12	SEPT7P9	7.24	8.84e-13	8.45e-07	0.27	0.22	Corneal astigmatism;	chr4:119450290	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.909	rs7659501	ENSG00000120555.12	SEPT7P9	7.24	8.84e-13	8.45e-07	0.27	0.22	Corneal astigmatism;	chr4:119450397	chr10:38383069~38402916:-
BRCA	trans	rs6601327	0.602	rs7829463	ENSG00000253893.2	FAM85B	7.24	8.86e-13	8.46e-07	0.28	0.22	Multiple myeloma (hyperdiploidy);	chr8:9792181	chr8:8167819~8226614:-
BRCA	trans	rs1707322	0.691	rs11211174	ENSG00000255397.1	AC022182.2	-7.24	8.89e-13	8.49e-07	-0.29	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755144	chr8:60937705~60939871:-
BRCA	trans	rs7833986	0.501	rs72653981	ENSG00000244245.1	RP11-120B7.1	7.24	8.92e-13	8.52e-07	0.28	0.22	Height;	chr8:56115255	chr5:108593609~108593967:+
BRCA	trans	rs7833986	0.501	rs2976036	ENSG00000244245.1	RP11-120B7.1	7.24	8.92e-13	8.52e-07	0.28	0.22	Height;	chr8:56119162	chr5:108593609~108593967:+
BRCA	trans	rs11098499	0.738	rs34566984	ENSG00000120555.12	SEPT7P9	7.24	8.93e-13	8.52e-07	0.27	0.22	Corneal astigmatism;	chr4:119440115	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.954	rs9685777	ENSG00000120555.12	SEPT7P9	7.24	8.93e-13	8.52e-07	0.27	0.22	Corneal astigmatism;	chr4:119444810	chr10:38383069~38402916:-
BRCA	trans	rs1707322	0.721	rs12043945	ENSG00000255397.1	AC022182.2	-7.24	9.01e-13	8.6e-07	-0.29	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45641250	chr8:60937705~60939871:-
BRCA	trans	rs1707322	0.721	rs12091503	ENSG00000255397.1	AC022182.2	-7.24	9.01e-13	8.6e-07	-0.29	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45642196	chr8:60937705~60939871:-
BRCA	trans	rs12210905	0.688	rs12374649	ENSG00000242375.1	RP11-498P14.3	-7.23	9.03e-13	8.62e-07	-0.57	-0.22	Hip circumference adjusted for BMI;	chr6:27375947	chr9:97195351~97197687:-
BRCA	trans	rs11920570	0.92	rs73192103	ENSG00000267076.1	CCDC58P3	-7.23	9.03e-13	8.62e-07	-0.29	-0.22	Resting heart rate;	chr3:122533533	chr18:12211378~12211807:+
BRCA	trans	rs9467711	0.659	rs35304979	ENSG00000253570.1	RNF5P1	7.23	9.03e-13	8.62e-07	0.52	0.22	Autism spectrum disorder or schizophrenia;	chr6:26356119	chr8:38600661~38601200:-
BRCA	trans	rs11098499	0.909	rs78332141	ENSG00000120555.12	SEPT7P9	7.23	9.04e-13	8.63e-07	0.27	0.22	Corneal astigmatism;	chr4:119454627	chr10:38383069~38402916:-
BRCA	trans	rs13016963	0.506	rs11684505	ENSG00000235105.1	RP11-329A14.1	7.23	9.06e-13	8.65e-07	0.27	0.22	Esophageal squamous cell carcinoma;Melanoma;	chr2:201376440	chr1:48435967~48437223:+
BRCA	trans	rs2965280	0.655	rs78892828	ENSG00000270983.1	RP11-137J7.3	-7.23	9.07e-13	8.65e-07	-0.44	-0.22	Colorectal cancer;	chr19:34437780	chr6:142062717~142063053:+
BRCA	trans	rs11098499	0.82	rs28578366	ENSG00000276997.3	RP11-378J18.9	-7.23	9.07e-13	8.66e-07	-0.27	-0.22	Corneal astigmatism;	chr4:119615750	chr1:222477252~222504622:-
BRCA	trans	rs76228276	0.737	rs77968816	ENSG00000260318.1	COX6CP1	7.23	9.23e-13	8.81e-07	0.58	0.22	Childhood ear infection;	chr8:99524112	chr16:11903923~11904137:-
BRCA	trans	rs714543	1	rs13245012	ENSG00000267258.1	CTC-448F2.3	-7.23	9.29e-13	8.85e-07	-0.26	-0.22	Plateletcrit;	chr7:44826120	chr19:29921182~29921653:+
BRCA	trans	rs9581094	0.591	rs111662141	ENSG00000237917.1	PARP4P1	-7.23	9.3e-13	8.87e-07	-0.44	-0.22	Sudden cardiac arrest;	chr13:24502742	chrY:26594851~26634652:-
BRCA	trans	rs11098499	0.865	rs28634456	ENSG00000120555.12	SEPT7P9	7.23	9.31e-13	8.87e-07	0.27	0.22	Corneal astigmatism;	chr4:119454623	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.909	rs10020034	ENSG00000120555.12	SEPT7P9	7.23	9.32e-13	8.88e-07	0.27	0.22	Corneal astigmatism;	chr4:119373176	chr10:38383069~38402916:-
BRCA	trans	rs9834975	0.565	rs6786512	ENSG00000267076.1	CCDC58P3	-7.23	9.36e-13	8.92e-07	-0.25	-0.22	Diastolic blood pressure;	chr3:122399243	chr18:12211378~12211807:+
BRCA	trans	rs853679	0.882	rs9393908	ENSG00000253570.1	RNF5P1	7.23	9.37e-13	8.92e-07	0.51	0.22	Depression;	chr6:28223052	chr8:38600661~38601200:-
BRCA	trans	rs853679	0.882	rs9366717	ENSG00000253570.1	RNF5P1	7.23	9.37e-13	8.92e-07	0.51	0.22	Depression;	chr6:28223279	chr8:38600661~38601200:-
BRCA	trans	rs9914988	0.887	rs4795464	ENSG00000267449.1	RP11-264B14.2	7.23	9.46e-13	9.01e-07	0.31	0.22	Glycated hemoglobin levels;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr17:28819479	chr17:61069856~61070356:-
BRCA	trans	rs1816752	0.875	rs59531061	ENSG00000224976.2	PARP4P2	-7.23	9.51e-13	9.06e-07	-0.28	-0.22	Obesity-related traits;	chr13:24507297	chr13:19349137~19407962:+
BRCA	trans	rs3750082	0.692	rs34737146	ENSG00000176826.14	FKBP9P1	7.23	9.53e-13	9.08e-07	0.3	0.22	Glomerular filtration rate (creatinine);	chr7:32896314	chr7:55681074~55713252:-
BRCA	trans	rs9584850	0.834	rs7339274	ENSG00000230079.1	STK24P1	-7.23	9.53e-13	9.08e-07	-0.28	-0.22	Neuroticism;	chr13:98468018	chrX:136295690~136300298:-
BRCA	trans	rs11098499	0.865	rs11098513	ENSG00000276997.3	RP11-378J18.9	7.23	9.54e-13	9.09e-07	0.27	0.22	Corneal astigmatism;	chr4:119394920	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.954	rs12508504	ENSG00000120555.12	SEPT7P9	7.23	9.54e-13	9.09e-07	0.27	0.22	Corneal astigmatism;	chr4:119489452	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.863	rs1552092	ENSG00000276997.3	RP11-378J18.9	7.23	9.56e-13	9.11e-07	0.27	0.22	Corneal astigmatism;	chr4:119567341	chr1:222477252~222504622:-
BRCA	trans	rs14057	0.965	rs2294528	ENSG00000215869.3	RP11-364B6.1	7.23	9.58e-13	9.13e-07	0.3	0.22	Systolic blood pressure;	chr1:6669689	chr1:104073023~104077087:+
BRCA	trans	rs1707322	0.721	rs10890333	ENSG00000255397.1	AC022182.2	-7.23	9.6e-13	9.14e-07	-0.29	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634650	chr8:60937705~60939871:-
BRCA	trans	rs801193	1	rs2659915	ENSG00000164669.11	INTS4P1	-7.23	9.62e-13	9.16e-07	-0.27	-0.22	Aortic root size;	chr7:66688114	chr7:65141225~65234216:+
BRCA	trans	rs11098499	0.954	rs1546505	ENSG00000120555.12	SEPT7P9	7.23	9.65e-13	9.19e-07	0.27	0.22	Corneal astigmatism;	chr4:119320069	chr10:38383069~38402916:-
BRCA	trans	rs1707322	0.752	rs7541962	ENSG00000255397.1	AC022182.2	-7.23	9.65e-13	9.19e-07	-0.29	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45769445	chr8:60937705~60939871:-
BRCA	trans	rs9348721	0.673	rs9358934	ENSG00000253570.1	RNF5P1	7.23	9.65e-13	9.19e-07	0.52	0.22	Intelligence (multi-trait analysis);	chr6:26363527	chr8:38600661~38601200:-
BRCA	trans	rs9467711	0.606	rs9357006	ENSG00000253570.1	RNF5P1	7.23	9.65e-13	9.19e-07	0.52	0.22	Autism spectrum disorder or schizophrenia;	chr6:26364400	chr8:38600661~38601200:-
BRCA	trans	rs1568889	0.887	rs2062269	ENSG00000174912.7	METTL15P1	7.22	9.69e-13	9.22e-07	0.22	0.22	Bipolar disorder;	chr11:28094990	chr3:156713884~156714928:-
BRCA	trans	rs11638815	0.668	rs7182320	ENSG00000235370.6	DNM1P51	7.22	9.73e-13	9.27e-07	0.25	0.22	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82719000	chr15:84398316~84411701:-
BRCA	trans	rs9467711	0.606	rs67509210	ENSG00000253570.1	RNF5P1	7.22	9.75e-13	9.28e-07	0.52	0.22	Autism spectrum disorder or schizophrenia;	chr6:26353872	chr8:38600661~38601200:-
BRCA	trans	rs9467711	0.606	rs9393707	ENSG00000253570.1	RNF5P1	7.22	9.83e-13	9.34e-07	0.52	0.22	Autism spectrum disorder or schizophrenia;	chr6:26362258	chr8:38600661~38601200:-
BRCA	trans	rs9467711	0.606	rs9379854	ENSG00000253570.1	RNF5P1	7.22	9.83e-13	9.34e-07	0.52	0.22	Autism spectrum disorder or schizophrenia;	chr6:26362626	chr8:38600661~38601200:-
BRCA	trans	rs1568889	0.838	rs10835283	ENSG00000174912.7	METTL15P1	7.22	9.86e-13	9.37e-07	0.22	0.22	Bipolar disorder;	chr11:28193438	chr3:156713884~156714928:-
BRCA	trans	rs11098499	0.82	rs28535956	ENSG00000276997.3	RP11-378J18.9	-7.22	9.93e-13	9.44e-07	-0.28	-0.22	Corneal astigmatism;	chr4:119615703	chr1:222477252~222504622:-
BRCA	trans	rs2242330	0.798	rs13115359	ENSG00000226982.4	CENPCP1	7.22	9.93e-13	9.44e-07	0.29	0.22	Parkinson's disease;	chr4:67567088	chr12:89500093~89502670:+
BRCA	trans	rs9581094	0.591	rs7326065	ENSG00000237917.1	PARP4P1	-7.22	9.93e-13	9.44e-07	-0.43	-0.22	Sudden cardiac arrest;	chr13:24491991	chrY:26594851~26634652:-
BRCA	trans	rs9581094	0.591	rs10162064	ENSG00000237917.1	PARP4P1	-7.22	9.93e-13	9.44e-07	-0.43	-0.22	Sudden cardiac arrest;	chr13:24492717	chrY:26594851~26634652:-
BRCA	trans	rs9581094	0.591	rs9318599	ENSG00000237917.1	PARP4P1	-7.22	9.93e-13	9.44e-07	-0.43	-0.22	Sudden cardiac arrest;	chr13:24492865	chrY:26594851~26634652:-
BRCA	trans	rs9581094	0.591	rs9578753	ENSG00000237917.1	PARP4P1	7.22	9.95e-13	9.45e-07	0.42	0.22	Sudden cardiac arrest;	chr13:24501582	chrY:26594851~26634652:-
BRCA	trans	rs6940638	0.688	rs9393795	ENSG00000242375.1	RP11-498P14.3	-7.22	9.96e-13	9.46e-07	-0.32	-0.22	Intelligence (multi-trait analysis);	chr6:27249940	chr9:97195351~97197687:-
BRCA	trans	rs853679	0.825	rs8180562	ENSG00000253570.1	RNF5P1	7.22	9.97e-13	9.47e-07	0.5	0.22	Depression;	chr6:28173682	chr8:38600661~38601200:-
BRCA	trans	rs853679	0.882	rs9380064	ENSG00000253570.1	RNF5P1	7.22	9.97e-13	9.47e-07	0.5	0.22	Depression;	chr6:28175340	chr8:38600661~38601200:-
BRCA	trans	rs9581094	0.527	rs9318596	ENSG00000237917.1	PARP4P1	-7.22	1e-12	9.52e-07	-0.43	-0.22	Sudden cardiac arrest;	chr13:24491291	chrY:26594851~26634652:-
BRCA	trans	rs17507216	0.671	rs28582623	ENSG00000259295.5	CSPG4P12	-7.22	1.01e-12	9.58e-07	-0.33	-0.22	Excessive daytime sleepiness;	chr15:82577381	chr15:85191438~85213905:+
BRCA	trans	rs11098499	0.909	rs2127821	ENSG00000120555.12	SEPT7P9	7.22	1.02e-12	9.7e-07	0.27	0.22	Corneal astigmatism;	chr4:119473380	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.863	rs3822195	ENSG00000276997.3	RP11-378J18.9	7.22	1.02e-12	9.72e-07	0.27	0.22	Corneal astigmatism;	chr4:119550505	chr1:222477252~222504622:-
BRCA	trans	rs1707322	0.686	rs2230659	ENSG00000255397.1	AC022182.2	7.22	1.03e-12	9.76e-07	0.29	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613212	chr8:60937705~60939871:-
BRCA	trans	rs11098499	0.863	rs2306456	ENSG00000276997.3	RP11-378J18.9	7.22	1.03e-12	9.79e-07	0.27	0.22	Corneal astigmatism;	chr4:119551267	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.863	rs11947234	ENSG00000276997.3	RP11-378J18.9	7.22	1.03e-12	9.79e-07	0.27	0.22	Corneal astigmatism;	chr4:119553704	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.863	rs11933966	ENSG00000276997.3	RP11-378J18.9	7.22	1.03e-12	9.79e-07	0.27	0.22	Corneal astigmatism;	chr4:119555560	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.863	rs36040693	ENSG00000276997.3	RP11-378J18.9	7.22	1.03e-12	9.79e-07	0.27	0.22	Corneal astigmatism;	chr4:119556461	chr1:222477252~222504622:-
BRCA	trans	rs14057	0.965	rs2294526	ENSG00000215869.3	RP11-364B6.1	7.22	1.03e-12	9.82e-07	0.3	0.22	Systolic blood pressure;	chr1:6675642	chr1:104073023~104077087:+
BRCA	trans	rs801193	1	rs11773829	ENSG00000164669.11	INTS4P1	7.21	1.04e-12	9.84e-07	0.27	0.22	Aortic root size;	chr7:66676087	chr7:65141225~65234216:+
BRCA	trans	rs7833986	0.534	rs17759244	ENSG00000244245.1	RP11-120B7.1	7.21	1.04e-12	9.87e-07	0.28	0.22	Height;	chr8:56121209	chr5:108593609~108593967:+
BRCA	trans	rs1707322	0.685	rs56177313	ENSG00000255397.1	AC022182.2	-7.21	1.04e-12	9.88e-07	-0.29	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45760134	chr8:60937705~60939871:-
BRCA	trans	rs864643	0.729	rs7616236	ENSG00000183298.5	RP11-556K13.1	7.21	1.04e-12	9.9e-07	0.46	0.22	Attention deficit hyperactivity disorder;	chr3:39500645	chr1:101786340~101787219:-
BRCA	trans	rs17301013	0.861	rs1793319	ENSG00000213331.4	RP11-713C19.2	7.21	1.04e-12	9.91e-07	0.25	0.22	Systemic lupus erythematosus;	chr1:174795470	chr4:187970273~187971284:+
BRCA	trans	rs7662987	1	rs7684986	ENSG00000228407.2	RP4-800M22.1	7.21	1.05e-12	9.93e-07	0.49	0.22	Smoking initiation;	chr4:99070525	chr1:52160261~52160600:-
BRCA	trans	rs7662987	1	rs1061187	ENSG00000228407.2	RP4-800M22.1	7.21	1.05e-12	9.93e-07	0.49	0.22	Smoking initiation;	chr4:99071702	chr1:52160261~52160600:-
BRCA	trans	rs9834975	0.565	rs7647266	ENSG00000267076.1	CCDC58P3	-7.21	1.05e-12	9.95e-07	-0.25	-0.22	Diastolic blood pressure;	chr3:122393534	chr18:12211378~12211807:+
BRCA	trans	rs3806843	0.576	rs405192	ENSG00000231043.3	AC007238.1	-7.21	1.05e-12	9.96e-07	-0.26	-0.22	Depressive symptoms (multi-trait analysis);	chr5:140945125	chr2:58460292~58462032:-
BRCA	trans	rs9581094	0.591	rs9318600	ENSG00000237917.1	PARP4P1	-7.21	1.05e-12	9.98e-07	-0.43	-0.22	Sudden cardiac arrest;	chr13:24494670	chrY:26594851~26634652:-
BRCA	trans	rs9581094	0.591	rs9581074	ENSG00000237917.1	PARP4P1	-7.21	1.05e-12	9.98e-07	-0.43	-0.22	Sudden cardiac arrest;	chr13:24495151	chrY:26594851~26634652:-
BRCA	trans	rs801193	1	rs6958520	ENSG00000164669.11	INTS4P1	-7.21	1.05e-12	1e-06	-0.27	-0.22	Aortic root size;	chr7:66686466	chr7:65141225~65234216:+
BRCA	trans	rs12200782	0.725	rs6912853	ENSG00000242375.1	RP11-498P14.3	7.21	1.06e-12	1e-06	0.41	0.22	Small cell lung carcinoma;	chr6:26401210	chr9:97195351~97197687:-
BRCA	trans	rs6601450	0.54	rs7824225	ENSG00000253893.2	FAM85B	7.21	1.06e-12	1.01e-06	0.28	0.22	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;	chr8:10415736	chr8:8167819~8226614:-
BRCA	trans	rs9467711	0.524	rs13216484	ENSG00000253570.1	RNF5P1	7.21	1.06e-12	1.01e-06	0.57	0.22	Autism spectrum disorder or schizophrenia;	chr6:26739799	chr8:38600661~38601200:-
BRCA	trans	rs9467711	0.584	rs34244947	ENSG00000253570.1	RNF5P1	7.21	1.06e-12	1.01e-06	0.57	0.22	Autism spectrum disorder or schizophrenia;	chr6:26740141	chr8:38600661~38601200:-
BRCA	trans	rs9467711	0.606	rs9393715	ENSG00000253570.1	RNF5P1	7.21	1.06e-12	1.01e-06	0.52	0.22	Autism spectrum disorder or schizophrenia;	chr6:26375417	chr8:38600661~38601200:-
BRCA	trans	rs9467711	0.72	rs9348716	ENSG00000253570.1	RNF5P1	7.21	1.06e-12	1.01e-06	0.52	0.22	Autism spectrum disorder or schizophrenia;	chr6:26375430	chr8:38600661~38601200:-
BRCA	trans	rs2235573	0.551	rs139892	ENSG00000258501.1	EIF3LP1	-7.21	1.07e-12	1.01e-06	-0.25	-0.22	Glioma;Glioblastoma;	chr22:37992196	chr14:81916231~81917888:+
BRCA	trans	rs9368481	0.761	rs9379952	ENSG00000242375.1	RP11-498P14.3	-7.21	1.07e-12	1.01e-06	-0.32	-0.22	Autism spectrum disorder or schizophrenia;	chr6:27020121	chr9:97195351~97197687:-
BRCA	trans	rs11098499	0.863	rs10030660	ENSG00000276997.3	RP11-378J18.9	7.21	1.07e-12	1.01e-06	0.27	0.22	Corneal astigmatism;	chr4:119515549	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.863	rs13149407	ENSG00000276997.3	RP11-378J18.9	7.21	1.07e-12	1.01e-06	0.27	0.22	Corneal astigmatism;	chr4:119516670	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.863	rs3775854	ENSG00000276997.3	RP11-378J18.9	7.21	1.07e-12	1.02e-06	0.27	0.22	Corneal astigmatism;	chr4:119550816	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.863	rs6853998	ENSG00000276997.3	RP11-378J18.9	7.21	1.07e-12	1.02e-06	0.27	0.22	Corneal astigmatism;	chr4:119554705	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.863	rs6858777	ENSG00000276997.3	RP11-378J18.9	7.21	1.07e-12	1.02e-06	0.27	0.22	Corneal astigmatism;	chr4:119554811	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.863	rs11731756	ENSG00000276997.3	RP11-378J18.9	7.21	1.07e-12	1.02e-06	0.27	0.22	Corneal astigmatism;	chr4:119557541	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.863	rs34308924	ENSG00000276997.3	RP11-378J18.9	7.21	1.07e-12	1.02e-06	0.27	0.22	Corneal astigmatism;	chr4:119560276	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.863	rs2170276	ENSG00000276997.3	RP11-378J18.9	7.21	1.07e-12	1.02e-06	0.27	0.22	Corneal astigmatism;	chr4:119564669	chr1:222477252~222504622:-
BRCA	trans	rs6732160	0.588	rs10192654	ENSG00000236165.1	PRADC1P1	-7.21	1.07e-12	1.02e-06	-0.29	-0.22	Intelligence (multi-trait analysis);	chr2:73143754	chr3:36976316~36976840:+
BRCA	trans	rs9368481	0.761	rs9357030	ENSG00000242375.1	RP11-498P14.3	-7.21	1.08e-12	1.02e-06	-0.32	-0.22	Autism spectrum disorder or schizophrenia;	chr6:27017247	chr9:97195351~97197687:-
BRCA	trans	rs6915893	0.74	rs6910353	ENSG00000267156.1	TPMTP1	-7.21	1.08e-12	1.02e-06	-0.27	-0.22	Intrinsic epigenetic age acceleration;	chr6:18102327	chr18:47630112~47630848:+
BRCA	trans	rs9914988	0.943	rs4794838	ENSG00000267449.1	RP11-264B14.2	7.21	1.09e-12	1.03e-06	0.3	0.22	Glycated hemoglobin levels;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr17:28804077	chr17:61069856~61070356:-
BRCA	trans	rs7200543	0.583	rs4985149	ENSG00000250569.1	NTAN1P2	7.21	1.09e-12	1.03e-06	0.24	0.22	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15053481	chr8:86481754~86483002:-
BRCA	trans	rs6732160	0.613	rs62151837	ENSG00000236165.1	PRADC1P1	7.21	1.09e-12	1.03e-06	0.29	0.22	Intelligence (multi-trait analysis);	chr2:73163268	chr3:36976316~36976840:+
BRCA	trans	rs11098499	0.955	rs13113112	ENSG00000120555.12	SEPT7P9	7.21	1.1e-12	1.04e-06	0.28	0.22	Corneal astigmatism;	chr4:119234885	chr10:38383069~38402916:-
BRCA	trans	rs9467711	0.606	rs68072215	ENSG00000253570.1	RNF5P1	7.21	1.1e-12	1.04e-06	0.52	0.22	Autism spectrum disorder or schizophrenia;	chr6:26377699	chr8:38600661~38601200:-
BRCA	trans	rs11098499	0.866	rs6847778	ENSG00000276997.3	RP11-378J18.9	7.21	1.1e-12	1.04e-06	0.26	0.22	Corneal astigmatism;	chr4:119372427	chr1:222477252~222504622:-
BRCA	trans	rs6915893	0.74	rs12189652	ENSG00000267156.1	TPMTP1	7.21	1.11e-12	1.05e-06	0.27	0.22	Intrinsic epigenetic age acceleration;	chr6:18103080	chr18:47630112~47630848:+
BRCA	trans	rs11098499	0.657	rs71614442	ENSG00000120555.12	SEPT7P9	7.21	1.11e-12	1.05e-06	0.27	0.22	Corneal astigmatism;	chr4:119458191	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.954	rs2892848	ENSG00000120555.12	SEPT7P9	7.21	1.11e-12	1.05e-06	0.27	0.22	Corneal astigmatism;	chr4:119460186	chr10:38383069~38402916:-
BRCA	trans	rs801193	1	rs2707836	ENSG00000164669.11	INTS4P1	-7.2	1.11e-12	1.05e-06	-0.26	-0.22	Aortic root size;	chr7:66695448	chr7:65141225~65234216:+
BRCA	trans	rs801193	0.844	rs7779971	ENSG00000164669.11	INTS4P1	-7.2	1.11e-12	1.05e-06	-0.26	-0.22	Aortic root size;	chr7:66696803	chr7:65141225~65234216:+
BRCA	trans	rs864643	0.678	rs1768198	ENSG00000188856.6	RPSAP47	7.2	1.11e-12	1.05e-06	0.31	0.22	Attention deficit hyperactivity disorder;	chr3:39474994	chr8:80558870~80559757:+
BRCA	trans	rs867371	0.614	rs1814739	ENSG00000235370.6	DNM1P51	-7.2	1.12e-12	1.06e-06	-0.27	-0.22	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82234283	chr15:84398316~84411701:-
BRCA	trans	rs11098499	0.863	rs58452170	ENSG00000276997.3	RP11-378J18.9	7.2	1.12e-12	1.06e-06	0.27	0.22	Corneal astigmatism;	chr4:119538519	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.909	rs1546504	ENSG00000120555.12	SEPT7P9	7.2	1.13e-12	1.07e-06	0.27	0.22	Corneal astigmatism;	chr4:119320024	chr10:38383069~38402916:-
BRCA	trans	rs76228276	0.737	rs11989337	ENSG00000260318.1	COX6CP1	7.2	1.13e-12	1.07e-06	0.58	0.22	Childhood ear infection;	chr8:99383956	chr16:11903923~11904137:-
BRCA	trans	rs17507216	0.718	rs7161977	ENSG00000259295.5	CSPG4P12	-7.2	1.13e-12	1.07e-06	-0.36	-0.22	Excessive daytime sleepiness;	chr15:82646782	chr15:85191438~85213905:+
BRCA	trans	rs11098499	0.865	rs4507344	ENSG00000276997.3	RP11-378J18.9	7.2	1.14e-12	1.08e-06	0.27	0.22	Corneal astigmatism;	chr4:119386330	chr1:222477252~222504622:-
BRCA	trans	rs9467711	0.606	rs2073530	ENSG00000253570.1	RNF5P1	7.2	1.15e-12	1.08e-06	0.52	0.22	Autism spectrum disorder or schizophrenia;	chr6:26375015	chr8:38600661~38601200:-
BRCA	trans	rs9581094	0.527	rs10047721	ENSG00000237917.1	PARP4P1	-7.2	1.15e-12	1.08e-06	-0.44	-0.22	Sudden cardiac arrest;	chr13:24455473	chrY:26594851~26634652:-
BRCA	trans	rs11098499	0.954	rs1022145	ENSG00000120555.12	SEPT7P9	7.2	1.15e-12	1.08e-06	0.27	0.22	Corneal astigmatism;	chr4:119309824	chr10:38383069~38402916:-
BRCA	trans	rs4948102	0.642	rs4948104	ENSG00000186940.6	CHCHD2P9	-7.2	1.15e-12	1.09e-06	-0.27	-0.22	Plasma homocysteine levels (post-methionine load test);	chr7:56074826	chr9:79391304~79391759:+
BRCA	trans	rs11098499	0.863	rs2291185	ENSG00000276997.3	RP11-378J18.9	7.2	1.15e-12	1.09e-06	0.27	0.22	Corneal astigmatism;	chr4:119513678	chr1:222477252~222504622:-
BRCA	trans	rs747782	0.646	rs75129833	ENSG00000134612.10	FOLH1B	7.2	1.15e-12	1.09e-06	0.4	0.22	Intraocular pressure;	chr11:47824650	chr11:89639227~89698718:+
BRCA	trans	rs11098499	0.863	rs1010740	ENSG00000276997.3	RP11-378J18.9	-7.2	1.16e-12	1.1e-06	-0.27	-0.22	Corneal astigmatism;	chr4:119542254	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.954	rs1480931	ENSG00000120555.12	SEPT7P9	7.2	1.17e-12	1.1e-06	0.27	0.22	Corneal astigmatism;	chr4:119474654	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.954	rs6848389	ENSG00000120555.12	SEPT7P9	7.2	1.17e-12	1.1e-06	0.27	0.22	Corneal astigmatism;	chr4:119481467	chr10:38383069~38402916:-
BRCA	trans	rs7200543	1	rs16966947	ENSG00000250569.1	NTAN1P2	7.2	1.18e-12	1.11e-06	0.24	0.22	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15047188	chr8:86481754~86483002:-
BRCA	trans	rs11098499	0.731	rs6846966	ENSG00000276997.3	RP11-378J18.9	7.2	1.19e-12	1.12e-06	0.26	0.22	Corneal astigmatism;	chr4:119372053	chr1:222477252~222504622:-
BRCA	trans	rs10783779	0.647	rs705708	ENSG00000212994.5	RPS26P6	7.19	1.2e-12	1.13e-06	0.27	0.22	Educational attainment;	chr12:56095129	chr8:100895771~100896118:+
BRCA	trans	rs12210905	0.925	rs12212317	ENSG00000242375.1	RP11-498P14.3	-7.19	1.2e-12	1.13e-06	-0.47	-0.22	Hip circumference adjusted for BMI;	chr6:27018774	chr9:97195351~97197687:-
BRCA	trans	rs12210905	0.925	rs6920115	ENSG00000242375.1	RP11-498P14.3	-7.19	1.2e-12	1.13e-06	-0.47	-0.22	Hip circumference adjusted for BMI;	chr6:27020638	chr9:97195351~97197687:-
BRCA	trans	rs11098499	0.909	rs79026312	ENSG00000276997.3	RP11-378J18.9	7.19	1.2e-12	1.13e-06	0.27	0.22	Corneal astigmatism;	chr4:119519522	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.909	rs35111518	ENSG00000276997.3	RP11-378J18.9	7.19	1.2e-12	1.13e-06	0.27	0.22	Corneal astigmatism;	chr4:119519527	chr1:222477252~222504622:-
BRCA	trans	rs11172055	1	rs11172055	ENSG00000121089.4	NACA3P	7.19	1.2e-12	1.13e-06	0.24	0.22	Migraine;	chr12:56914476	chr4:164943290~164943937:+
BRCA	trans	rs11098499	0.564	rs11098507	ENSG00000276997.3	RP11-378J18.9	7.19	1.21e-12	1.14e-06	0.26	0.22	Corneal astigmatism;	chr4:119367131	chr1:222477252~222504622:-
BRCA	trans	rs1933488	1	rs6557266	ENSG00000278974.1	RP11-756P10.6	-7.19	1.22e-12	1.15e-06	-0.28	-0.22	Prostate cancer;	chr6:153112399	chr4:188740507~188741281:-
BRCA	trans	rs1933488	1	rs6907823	ENSG00000278974.1	RP11-756P10.6	-7.19	1.22e-12	1.15e-06	-0.28	-0.22	Prostate cancer;	chr6:153112407	chr4:188740507~188741281:-
BRCA	trans	rs1707322	0.721	rs11211178	ENSG00000255397.1	AC022182.2	-7.19	1.22e-12	1.15e-06	-0.29	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45761894	chr8:60937705~60939871:-
BRCA	trans	rs1933488	1	rs7743683	ENSG00000278974.1	RP11-756P10.6	-7.19	1.22e-12	1.15e-06	-0.28	-0.22	Prostate cancer;	chr6:153111850	chr4:188740507~188741281:-
BRCA	trans	rs1933488	1	rs6557265	ENSG00000278974.1	RP11-756P10.6	-7.19	1.22e-12	1.15e-06	-0.28	-0.22	Prostate cancer;	chr6:153112267	chr4:188740507~188741281:-
BRCA	trans	rs864643	0.678	rs1609647	ENSG00000188856.6	RPSAP47	7.19	1.23e-12	1.16e-06	0.31	0.22	Attention deficit hyperactivity disorder;	chr3:39491580	chr8:80558870~80559757:+
BRCA	trans	rs1707322	0.717	rs3014245	ENSG00000255397.1	AC022182.2	7.19	1.23e-12	1.16e-06	0.29	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45621241	chr8:60937705~60939871:-
BRCA	trans	rs1568889	0.838	rs7933991	ENSG00000174912.7	METTL15P1	7.19	1.24e-12	1.16e-06	0.22	0.22	Bipolar disorder;	chr11:28038214	chr3:156713884~156714928:-
BRCA	trans	rs11098499	0.738	rs34965784	ENSG00000120555.12	SEPT7P9	7.19	1.24e-12	1.17e-06	0.27	0.22	Corneal astigmatism;	chr4:119440431	chr10:38383069~38402916:-
BRCA	trans	rs4948102	0.667	rs7811270	ENSG00000186940.6	CHCHD2P9	-7.19	1.24e-12	1.17e-06	-0.27	-0.22	Plasma homocysteine levels (post-methionine load test);	chr7:56072297	chr9:79391304~79391759:+
BRCA	trans	rs11098499	0.908	rs1002152	ENSG00000120555.12	SEPT7P9	7.19	1.24e-12	1.17e-06	0.27	0.22	Corneal astigmatism;	chr4:119352232	chr10:38383069~38402916:-
BRCA	trans	rs853679	0.882	rs9461432	ENSG00000253570.1	RNF5P1	7.19	1.24e-12	1.17e-06	0.49	0.22	Depression;	chr6:28119105	chr8:38600661~38601200:-
BRCA	trans	rs76228276	0.609	rs4735611	ENSG00000260318.1	COX6CP1	7.19	1.25e-12	1.17e-06	0.58	0.22	Childhood ear infection;	chr8:99332285	chr16:11903923~11904137:-
BRCA	trans	rs76228276	0.737	rs11990072	ENSG00000260318.1	COX6CP1	7.19	1.25e-12	1.17e-06	0.58	0.22	Childhood ear infection;	chr8:99339526	chr16:11903923~11904137:-
BRCA	trans	rs6732160	0.613	rs10179063	ENSG00000236165.1	PRADC1P1	7.19	1.25e-12	1.17e-06	0.29	0.22	Intelligence (multi-trait analysis);	chr2:73157983	chr3:36976316~36976840:+
BRCA	trans	rs11098499	0.82	rs13122709	ENSG00000120555.12	SEPT7P9	7.19	1.25e-12	1.18e-06	0.27	0.22	Corneal astigmatism;	chr4:119634201	chr10:38383069~38402916:-
BRCA	trans	rs7032940	0.533	rs7868072	ENSG00000262519.1	TXNP4	7.19	1.26e-12	1.18e-06	0.26	0.22	Height;	chr9:110205824	chr17:4572206~4572515:+
BRCA	trans	rs801193	1	rs62466793	ENSG00000164669.11	INTS4P1	-7.19	1.26e-12	1.18e-06	-0.26	-0.22	Aortic root size;	chr7:66726530	chr7:65141225~65234216:+
BRCA	trans	rs6732160	0.613	rs6546804	ENSG00000236165.1	PRADC1P1	7.19	1.27e-12	1.19e-06	0.29	0.22	Intelligence (multi-trait analysis);	chr2:73158791	chr3:36976316~36976840:+
BRCA	trans	rs14057	0.965	rs3789572	ENSG00000215869.3	RP11-364B6.1	7.19	1.27e-12	1.19e-06	0.31	0.22	Systolic blood pressure;	chr1:6672508	chr1:104073023~104077087:+
BRCA	trans	rs11098499	0.863	rs1383532	ENSG00000276997.3	RP11-378J18.9	-7.18	1.28e-12	1.2e-06	-0.27	-0.22	Corneal astigmatism;	chr4:119513249	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.954	rs10034623	ENSG00000120555.12	SEPT7P9	7.18	1.28e-12	1.2e-06	0.27	0.22	Corneal astigmatism;	chr4:119476674	chr10:38383069~38402916:-
BRCA	trans	rs11920570	0.919	rs1986617	ENSG00000267076.1	CCDC58P3	-7.18	1.29e-12	1.21e-06	-0.29	-0.22	Resting heart rate;	chr3:122397710	chr18:12211378~12211807:+
BRCA	trans	rs1568889	0.73	rs6484350	ENSG00000174912.7	METTL15P1	-7.18	1.29e-12	1.21e-06	-0.22	-0.22	Bipolar disorder;	chr11:28092111	chr3:156713884~156714928:-
BRCA	trans	rs673253	0.71	rs673242	ENSG00000231007.5	CDC20P1	7.18	1.29e-12	1.21e-06	0.29	0.22	Intelligence (multi-trait analysis);	chr1:43596488	chr9:87011652~87013151:+
BRCA	trans	rs11782517	0.883	rs13258235	ENSG00000253893.2	FAM85B	7.18	1.29e-12	1.21e-06	0.35	0.22	Nose size;	chr8:10248993	chr8:8167819~8226614:-
BRCA	trans	rs1707322	0.752	rs11488313	ENSG00000255397.1	AC022182.2	-7.18	1.3e-12	1.22e-06	-0.29	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45759108	chr8:60937705~60939871:-
BRCA	trans	rs7833986	0.501	rs2976038	ENSG00000244245.1	RP11-120B7.1	7.18	1.32e-12	1.24e-06	0.28	0.22	Height;	chr8:56116305	chr5:108593609~108593967:+
BRCA	trans	rs673253	0.71	rs56175694	ENSG00000231007.5	CDC20P1	7.18	1.32e-12	1.24e-06	0.29	0.22	Intelligence (multi-trait analysis);	chr1:43599477	chr9:87011652~87013151:+
BRCA	trans	rs546131	0.642	rs568529	ENSG00000225531.1	RP11-196I18.3	7.18	1.32e-12	1.24e-06	0.31	0.22	Lung disease severity in cystic fibrosis;	chr11:34820959	chr9:107116829~107117557:+
BRCA	trans	rs801193	0.967	rs2707849	ENSG00000164669.11	INTS4P1	-7.18	1.33e-12	1.25e-06	-0.26	-0.22	Aortic root size;	chr7:66687725	chr7:65141225~65234216:+
BRCA	trans	rs9581094	0.527	rs9581054	ENSG00000237917.1	PARP4P1	-7.18	1.34e-12	1.26e-06	-0.43	-0.22	Sudden cardiac arrest;	chr13:24455867	chrY:26594851~26634652:-
BRCA	trans	rs11098499	0.775	rs10021601	ENSG00000276997.3	RP11-378J18.9	7.18	1.34e-12	1.26e-06	0.26	0.22	Corneal astigmatism;	chr4:119361408	chr1:222477252~222504622:-
BRCA	trans	rs1933488	1	rs17083581	ENSG00000278974.1	RP11-756P10.6	-7.18	1.34e-12	1.26e-06	-0.28	-0.22	Prostate cancer;	chr6:153108312	chr4:188740507~188741281:-
BRCA	trans	rs9834975	0.565	rs6788377	ENSG00000267076.1	CCDC58P3	-7.18	1.35e-12	1.26e-06	-0.25	-0.22	Diastolic blood pressure;	chr3:122387538	chr18:12211378~12211807:+
BRCA	trans	rs11098499	0.863	rs1383533	ENSG00000276997.3	RP11-378J18.9	7.18	1.36e-12	1.27e-06	0.27	0.22	Corneal astigmatism;	chr4:119513421	chr1:222477252~222504622:-
BRCA	trans	rs14057	0.93	rs3789573	ENSG00000215869.3	RP11-364B6.1	7.18	1.36e-12	1.27e-06	0.3	0.22	Systolic blood pressure;	chr1:6670845	chr1:104073023~104077087:+
BRCA	trans	rs4948102	0.599	rs2230197	ENSG00000186940.6	CHCHD2P9	-7.18	1.37e-12	1.28e-06	-0.27	-0.22	Plasma homocysteine levels (post-methionine load test);	chr7:56058667	chr9:79391304~79391759:+
BRCA	trans	rs11098499	0.505	rs75122014	ENSG00000120555.12	SEPT7P9	7.18	1.37e-12	1.28e-06	0.27	0.22	Corneal astigmatism;	chr4:119441271	chr10:38383069~38402916:-
BRCA	trans	rs1933488	1	rs6931160	ENSG00000278974.1	RP11-756P10.6	-7.18	1.37e-12	1.28e-06	-0.28	-0.22	Prostate cancer;	chr6:153109316	chr4:188740507~188741281:-
BRCA	trans	rs11098499	0.863	rs11098531	ENSG00000276997.3	RP11-378J18.9	7.18	1.37e-12	1.28e-06	0.27	0.22	Corneal astigmatism;	chr4:119543846	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.863	rs28718422	ENSG00000276997.3	RP11-378J18.9	7.18	1.37e-12	1.28e-06	0.27	0.22	Corneal astigmatism;	chr4:119545149	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.818	rs12498599	ENSG00000276997.3	RP11-378J18.9	7.18	1.37e-12	1.28e-06	0.27	0.22	Corneal astigmatism;	chr4:119547348	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.863	rs10009626	ENSG00000276997.3	RP11-378J18.9	7.18	1.37e-12	1.28e-06	0.27	0.22	Corneal astigmatism;	chr4:119548850	chr1:222477252~222504622:-
BRCA	trans	rs7200543	0.883	rs4985148	ENSG00000250569.1	NTAN1P2	7.17	1.38e-12	1.29e-06	0.24	0.22	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15053931	chr8:86481754~86483002:-
BRCA	trans	rs11220082	0.661	rs2321158	ENSG00000236257.1	EI24P2	7.17	1.39e-12	1.3e-06	0.26	0.22	Schizophrenia;	chr11:125414990	chr1:158454198~158455273:+
BRCA	trans	rs9581094	0.591	rs77347282	ENSG00000237917.1	PARP4P1	-7.17	1.39e-12	1.3e-06	-0.44	-0.22	Sudden cardiac arrest;	chr13:24506872	chrY:26594851~26634652:-
BRCA	trans	rs67340775	0.541	rs200975	ENSG00000204709.4	LINC01556	7.17	1.4e-12	1.31e-06	0.36	0.22	Lung cancer in ever smokers;	chr6:27887847	chr6:28943877~28944537:+
BRCA	trans	rs67340775	0.541	rs200974	ENSG00000204709.4	LINC01556	7.17	1.4e-12	1.31e-06	0.36	0.22	Lung cancer in ever smokers;	chr6:27888067	chr6:28943877~28944537:+
BRCA	trans	rs546131	0.642	rs7946980	ENSG00000225531.1	RP11-196I18.3	7.17	1.4e-12	1.32e-06	0.31	0.22	Lung disease severity in cystic fibrosis;	chr11:34798891	chr9:107116829~107117557:+
BRCA	trans	rs11098499	0.863	rs59732491	ENSG00000276997.3	RP11-378J18.9	7.17	1.41e-12	1.32e-06	0.27	0.22	Corneal astigmatism;	chr4:119568433	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.863	rs11723090	ENSG00000276997.3	RP11-378J18.9	7.17	1.41e-12	1.32e-06	0.27	0.22	Corneal astigmatism;	chr4:119569437	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.863	rs12498539	ENSG00000276997.3	RP11-378J18.9	7.17	1.41e-12	1.32e-06	0.27	0.22	Corneal astigmatism;	chr4:119547215	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.863	rs3822194	ENSG00000276997.3	RP11-378J18.9	7.17	1.41e-12	1.32e-06	0.27	0.22	Corneal astigmatism;	chr4:119550493	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.866	rs6857892	ENSG00000276997.3	RP11-378J18.9	7.17	1.42e-12	1.33e-06	0.26	0.22	Corneal astigmatism;	chr4:119361541	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.909	rs28581362	ENSG00000276997.3	RP11-378J18.9	7.17	1.42e-12	1.33e-06	0.26	0.22	Corneal astigmatism;	chr4:119362393	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.82	rs12503082	ENSG00000276997.3	RP11-378J18.9	7.17	1.42e-12	1.33e-06	0.26	0.22	Corneal astigmatism;	chr4:119363162	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.866	rs12499602	ENSG00000276997.3	RP11-378J18.9	7.17	1.42e-12	1.33e-06	0.26	0.22	Corneal astigmatism;	chr4:119363232	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.774	rs11098505	ENSG00000276997.3	RP11-378J18.9	7.17	1.42e-12	1.33e-06	0.26	0.22	Corneal astigmatism;	chr4:119363472	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.866	rs13105020	ENSG00000276997.3	RP11-378J18.9	7.17	1.42e-12	1.33e-06	0.26	0.22	Corneal astigmatism;	chr4:119364533	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.866	rs6824111	ENSG00000276997.3	RP11-378J18.9	7.17	1.42e-12	1.33e-06	0.26	0.22	Corneal astigmatism;	chr4:119364813	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.775	rs10029303	ENSG00000276997.3	RP11-378J18.9	7.17	1.42e-12	1.33e-06	0.26	0.22	Corneal astigmatism;	chr4:119365600	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.866	rs9995136	ENSG00000276997.3	RP11-378J18.9	7.17	1.42e-12	1.33e-06	0.26	0.22	Corneal astigmatism;	chr4:119365690	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.866	rs13125526	ENSG00000276997.3	RP11-378J18.9	7.17	1.42e-12	1.33e-06	0.26	0.22	Corneal astigmatism;	chr4:119366864	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.866	rs12513310	ENSG00000276997.3	RP11-378J18.9	7.17	1.42e-12	1.33e-06	0.26	0.22	Corneal astigmatism;	chr4:119366884	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.866	rs12510451	ENSG00000276997.3	RP11-378J18.9	7.17	1.42e-12	1.33e-06	0.26	0.22	Corneal astigmatism;	chr4:119367988	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.774	rs73842616	ENSG00000276997.3	RP11-378J18.9	7.17	1.42e-12	1.33e-06	0.26	0.22	Corneal astigmatism;	chr4:119369528	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.645	rs72676059	ENSG00000276997.3	RP11-378J18.9	7.17	1.42e-12	1.33e-06	0.26	0.22	Corneal astigmatism;	chr4:119369673	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.569	rs55845118	ENSG00000276997.3	RP11-378J18.9	7.17	1.42e-12	1.33e-06	0.26	0.22	Corneal astigmatism;	chr4:119369758	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.866	rs7677068	ENSG00000276997.3	RP11-378J18.9	7.17	1.42e-12	1.33e-06	0.26	0.22	Corneal astigmatism;	chr4:119370549	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.866	rs9991221	ENSG00000276997.3	RP11-378J18.9	7.17	1.42e-12	1.33e-06	0.26	0.22	Corneal astigmatism;	chr4:119370952	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.954	rs17009122	ENSG00000120555.12	SEPT7P9	7.17	1.42e-12	1.33e-06	0.27	0.22	Corneal astigmatism;	chr4:119441248	chr10:38383069~38402916:-
BRCA	trans	rs714543	0.783	rs7806283	ENSG00000214975.4	PPIAP29	-7.17	1.42e-12	1.33e-06	-0.25	-0.22	Plateletcrit;	chr7:44779104	chr6:24976419~24976982:+
BRCA	trans	rs11098499	0.863	rs1552095	ENSG00000120555.12	SEPT7P9	7.17	1.44e-12	1.35e-06	0.28	0.22	Corneal astigmatism;	chr4:119539151	chr10:38383069~38402916:-
BRCA	trans	rs12477438	0.52	rs2632277	ENSG00000276576.1	MRPL30P1	7.17	1.45e-12	1.36e-06	0.27	0.22	Chronic sinus infection;	chr2:99162522	chr6:57029521~57029988:+
BRCA	trans	rs801193	1	rs2707856	ENSG00000164669.11	INTS4P1	-7.17	1.45e-12	1.36e-06	-0.26	-0.22	Aortic root size;	chr7:66746023	chr7:65141225~65234216:+
BRCA	trans	rs801193	1	rs2659912	ENSG00000164669.11	INTS4P1	-7.16	1.48e-12	1.38e-06	-0.26	-0.22	Aortic root size;	chr7:66693012	chr7:65141225~65234216:+
BRCA	trans	rs11098499	0.863	rs1480940	ENSG00000276997.3	RP11-378J18.9	7.16	1.48e-12	1.38e-06	0.27	0.22	Corneal astigmatism;	chr4:119536527	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.779	rs10857066	ENSG00000276997.3	RP11-378J18.9	7.16	1.49e-12	1.39e-06	0.26	0.22	Corneal astigmatism;	chr4:119365441	chr1:222477252~222504622:-
BRCA	trans	rs9584850	0.834	rs3803253	ENSG00000230079.1	STK24P1	7.16	1.5e-12	1.4e-06	0.29	0.22	Neuroticism;	chr13:98464895	chrX:136295690~136300298:-
BRCA	trans	rs7824557	0.767	rs6985146	ENSG00000253893.2	FAM85B	-7.16	1.5e-12	1.4e-06	-0.29	-0.22	Retinal vascular caliber;	chr8:11313212	chr8:8167819~8226614:-
BRCA	trans	rs11098499	0.863	rs3822192	ENSG00000120555.12	SEPT7P9	7.16	1.5e-12	1.4e-06	0.28	0.22	Corneal astigmatism;	chr4:119524565	chr10:38383069~38402916:-
BRCA	trans	rs9834975	0.605	rs13316042	ENSG00000267076.1	CCDC58P3	-7.16	1.51e-12	1.41e-06	-0.26	-0.22	Diastolic blood pressure;	chr3:122508624	chr18:12211378~12211807:+
BRCA	trans	rs801193	1	rs7788576	ENSG00000164669.11	INTS4P1	7.16	1.52e-12	1.42e-06	0.26	0.22	Aortic root size;	chr7:66683315	chr7:65141225~65234216:+
BRCA	trans	rs11098499	0.863	rs3822195	ENSG00000120555.12	SEPT7P9	7.16	1.52e-12	1.42e-06	0.27	0.22	Corneal astigmatism;	chr4:119550505	chr10:38383069~38402916:-
BRCA	trans	rs4911253	0.527	rs853859	ENSG00000253915.1	MAPRE1P1	7.16	1.53e-12	1.43e-06	0.28	0.22	Lymphocyte counts;	chr20:32814463	chr8:135625185~135625981:-
BRCA	trans	rs11098499	0.863	rs3775854	ENSG00000120555.12	SEPT7P9	7.16	1.54e-12	1.44e-06	0.27	0.22	Corneal astigmatism;	chr4:119550816	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.863	rs6853998	ENSG00000120555.12	SEPT7P9	7.16	1.54e-12	1.44e-06	0.27	0.22	Corneal astigmatism;	chr4:119554705	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.863	rs6858777	ENSG00000120555.12	SEPT7P9	7.16	1.54e-12	1.44e-06	0.27	0.22	Corneal astigmatism;	chr4:119554811	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.863	rs11731756	ENSG00000120555.12	SEPT7P9	7.16	1.54e-12	1.44e-06	0.27	0.22	Corneal astigmatism;	chr4:119557541	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.863	rs34308924	ENSG00000120555.12	SEPT7P9	7.16	1.54e-12	1.44e-06	0.27	0.22	Corneal astigmatism;	chr4:119560276	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.863	rs2170276	ENSG00000120555.12	SEPT7P9	7.16	1.54e-12	1.44e-06	0.27	0.22	Corneal astigmatism;	chr4:119564669	chr10:38383069~38402916:-
BRCA	trans	rs9834975	0.565	rs4678190	ENSG00000267076.1	CCDC58P3	-7.16	1.54e-12	1.44e-06	-0.25	-0.22	Diastolic blood pressure;	chr3:122398191	chr18:12211378~12211807:+
BRCA	trans	rs11098499	0.863	rs12498539	ENSG00000120555.12	SEPT7P9	7.16	1.56e-12	1.46e-06	0.27	0.22	Corneal astigmatism;	chr4:119547215	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.863	rs3822194	ENSG00000120555.12	SEPT7P9	7.16	1.56e-12	1.46e-06	0.27	0.22	Corneal astigmatism;	chr4:119550493	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.82	rs6829903	ENSG00000120555.12	SEPT7P9	7.15	1.58e-12	1.48e-06	0.27	0.22	Corneal astigmatism;	chr4:119585729	chr10:38383069~38402916:-
BRCA	trans	rs9581094	0.591	rs7322794	ENSG00000237917.1	PARP4P1	-7.15	1.58e-12	1.48e-06	-0.43	-0.22	Sudden cardiac arrest;	chr13:24491606	chrY:26594851~26634652:-
BRCA	trans	rs801193	1	rs2659906	ENSG00000164669.11	INTS4P1	-7.15	1.6e-12	1.49e-06	-0.26	-0.22	Aortic root size;	chr7:66700323	chr7:65141225~65234216:+
BRCA	trans	rs2122469	0.655	rs17603934	ENSG00000246089.3	RP11-115C21.2	7.15	1.6e-12	1.5e-06	0.36	0.22	Serum tamsulosin hydrochloride concentration;	chr8:20718833	chr8:6403551~6407142:-
BRCA	trans	rs11098499	0.863	rs7669520	ENSG00000120555.12	SEPT7P9	7.15	1.6e-12	1.5e-06	0.27	0.22	Corneal astigmatism;	chr4:119594123	chr10:38383069~38402916:-
BRCA	trans	rs1707322	0.686	rs3014251	ENSG00000255397.1	AC022182.2	7.15	1.61e-12	1.5e-06	0.29	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45611756	chr8:60937705~60939871:-
BRCA	trans	rs9467711	0.606	rs72841536	ENSG00000253570.1	RNF5P1	7.15	1.62e-12	1.51e-06	0.52	0.22	Autism spectrum disorder or schizophrenia;	chr6:26378060	chr8:38600661~38601200:-
BRCA	trans	rs2235573	0.551	rs139891	ENSG00000258501.1	EIF3LP1	-7.15	1.62e-12	1.51e-06	-0.24	-0.22	Glioma;Glioblastoma;	chr22:37991907	chr14:81916231~81917888:+
BRCA	trans	rs11512640	1	rs12363935	ENSG00000236257.1	EI24P2	7.15	1.64e-12	1.53e-06	0.49	0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr11:125558406	chr1:158454198~158455273:+
BRCA	trans	rs4713118	0.615	rs9295747	ENSG00000204709.4	LINC01556	-7.15	1.64e-12	1.53e-06	-0.28	-0.22	Parkinson's disease;	chr6:27769214	chr6:28943877~28944537:+
BRCA	trans	rs7200543	1	rs6498541	ENSG00000250569.1	NTAN1P2	7.15	1.64e-12	1.53e-06	0.24	0.22	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15046800	chr8:86481754~86483002:-
BRCA	trans	rs14057	0.864	rs3827729	ENSG00000215869.3	RP11-364B6.1	7.15	1.65e-12	1.53e-06	0.3	0.22	Systolic blood pressure;	chr1:6696374	chr1:104073023~104077087:+
BRCA	trans	rs3740713	1	rs75740864	ENSG00000236090.2	LDHAP3	7.15	1.66e-12	1.55e-06	0.41	0.22	Amyotrophic lateral sclerosis (sporadic);	chr11:18449142	chr2:41819747~41820754:+
BRCA	trans	rs1933488	1	rs12055786	ENSG00000278974.1	RP11-756P10.6	-7.15	1.67e-12	1.55e-06	-0.28	-0.22	Prostate cancer;	chr6:153109990	chr4:188740507~188741281:-
BRCA	trans	rs6940638	0.688	rs7764984	ENSG00000242375.1	RP11-498P14.3	-7.15	1.68e-12	1.57e-06	-0.31	-0.22	Intelligence (multi-trait analysis);	chr6:27066402	chr9:97195351~97197687:-
BRCA	trans	rs11098499	0.863	rs7678400	ENSG00000276997.3	RP11-378J18.9	7.15	1.68e-12	1.57e-06	0.27	0.22	Corneal astigmatism;	chr4:119540802	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.863	rs1480936	ENSG00000276997.3	RP11-378J18.9	7.15	1.68e-12	1.57e-06	0.27	0.22	Corneal astigmatism;	chr4:119541706	chr1:222477252~222504622:-
BRCA	trans	rs2235573	0.551	rs139898	ENSG00000258501.1	EIF3LP1	-7.14	1.7e-12	1.58e-06	-0.25	-0.22	Glioma;Glioblastoma;	chr22:38003972	chr14:81916231~81917888:+
BRCA	trans	rs853679	0.882	rs9468300	ENSG00000253570.1	RNF5P1	7.14	1.7e-12	1.58e-06	0.49	0.22	Depression;	chr6:28159062	chr8:38600661~38601200:-
BRCA	trans	rs853679	0.546	rs483143	ENSG00000253570.1	RNF5P1	7.14	1.7e-12	1.58e-06	0.49	0.22	Depression;	chr6:27878966	chr8:38600661~38601200:-
BRCA	trans	rs9834975	0.584	rs9289195	ENSG00000267076.1	CCDC58P3	-7.14	1.71e-12	1.59e-06	-0.26	-0.22	Diastolic blood pressure;	chr3:122547737	chr18:12211378~12211807:+
BRCA	trans	rs4948102	0.551	rs4275190	ENSG00000186940.6	CHCHD2P9	-7.14	1.71e-12	1.6e-06	-0.27	-0.22	Plasma homocysteine levels (post-methionine load test);	chr7:56036695	chr9:79391304~79391759:+
BRCA	trans	rs673253	0.608	rs605709	ENSG00000231007.5	CDC20P1	7.14	1.72e-12	1.6e-06	0.28	0.22	Intelligence (multi-trait analysis);	chr1:43592796	chr9:87011652~87013151:+
BRCA	trans	rs673253	0.686	rs72673082	ENSG00000231007.5	CDC20P1	7.14	1.72e-12	1.6e-06	0.28	0.22	Intelligence (multi-trait analysis);	chr1:43593571	chr9:87011652~87013151:+
BRCA	trans	rs673253	0.71	rs583040	ENSG00000231007.5	CDC20P1	7.14	1.72e-12	1.6e-06	0.28	0.22	Intelligence (multi-trait analysis);	chr1:43594812	chr9:87011652~87013151:+
BRCA	trans	rs9467711	0.538	rs35934643	ENSG00000253570.1	RNF5P1	7.14	1.72e-12	1.6e-06	0.51	0.22	Autism spectrum disorder or schizophrenia;	chr6:26354866	chr8:38600661~38601200:-
BRCA	trans	rs11098499	0.909	rs1809406	ENSG00000276997.3	RP11-378J18.9	7.14	1.72e-12	1.6e-06	0.26	0.22	Corneal astigmatism;	chr4:119455967	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.865	rs2389809	ENSG00000276997.3	RP11-378J18.9	7.14	1.72e-12	1.6e-06	0.26	0.22	Corneal astigmatism;	chr4:119456244	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.909	rs9994810	ENSG00000276997.3	RP11-378J18.9	7.14	1.72e-12	1.6e-06	0.26	0.22	Corneal astigmatism;	chr4:119460435	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.697	rs10020027	ENSG00000276997.3	RP11-378J18.9	7.14	1.72e-12	1.6e-06	0.26	0.22	Corneal astigmatism;	chr4:119460724	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.779	rs7356491	ENSG00000276997.3	RP11-378J18.9	7.14	1.72e-12	1.6e-06	0.26	0.22	Corneal astigmatism;	chr4:119460819	chr1:222477252~222504622:-
BRCA	trans	rs9581094	0.591	rs73154369	ENSG00000237917.1	PARP4P1	-7.14	1.73e-12	1.61e-06	-0.43	-0.22	Sudden cardiac arrest;	chr13:24493939	chrY:26594851~26634652:-
BRCA	trans	rs9581094	0.591	rs3783071	ENSG00000237917.1	PARP4P1	-7.14	1.73e-12	1.61e-06	-0.43	-0.22	Sudden cardiac arrest;	chr13:24494108	chrY:26594851~26634652:-
BRCA	trans	rs9581094	0.591	rs73154372	ENSG00000237917.1	PARP4P1	-7.14	1.73e-12	1.61e-06	-0.43	-0.22	Sudden cardiac arrest;	chr13:24494357	chrY:26594851~26634652:-
BRCA	trans	rs11098499	0.954	rs6857105	ENSG00000120555.12	SEPT7P9	7.14	1.74e-12	1.62e-06	0.27	0.22	Corneal astigmatism;	chr4:119301143	chr10:38383069~38402916:-
BRCA	trans	rs11098499	1	rs1011054	ENSG00000120555.12	SEPT7P9	-7.14	1.74e-12	1.62e-06	-0.28	-0.22	Corneal astigmatism;	chr4:119281232	chr10:38383069~38402916:-
BRCA	trans	rs1707322	0.821	rs11211182	ENSG00000255397.1	AC022182.2	-7.14	1.74e-12	1.62e-06	-0.29	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45774498	chr8:60937705~60939871:-
BRCA	trans	rs11098499	0.954	rs11098526	ENSG00000120555.12	SEPT7P9	7.14	1.76e-12	1.64e-06	0.27	0.22	Corneal astigmatism;	chr4:119469204	chr10:38383069~38402916:-
BRCA	trans	rs1707322	0.686	rs2230658	ENSG00000255397.1	AC022182.2	7.14	1.77e-12	1.65e-06	0.29	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613182	chr8:60937705~60939871:-
BRCA	trans	rs10783779	0.647	rs705708	ENSG00000196656.7	AC004057.1	7.14	1.77e-12	1.65e-06	0.25	0.22	Educational attainment;	chr12:56095129	chr4:113214046~113217170:-
BRCA	trans	rs7833986	0.501	rs72653986	ENSG00000244245.1	RP11-120B7.1	7.14	1.78e-12	1.65e-06	0.28	0.22	Height;	chr8:56122489	chr5:108593609~108593967:+
BRCA	trans	rs4713118	0.591	rs2056924	ENSG00000204709.4	LINC01556	7.14	1.78e-12	1.66e-06	0.28	0.22	Parkinson's disease;	chr6:27722395	chr6:28943877~28944537:+
BRCA	trans	rs877636	1	rs705696	ENSG00000212829.8	RPS26P3	7.14	1.79e-12	1.67e-06	0.29	0.22	Cognitive function;	chr12:56086864	chr9:9090898~9091245:+
BRCA	trans	rs1933488	1	rs2119992	ENSG00000278974.1	RP11-756P10.6	-7.14	1.8e-12	1.67e-06	-0.28	-0.22	Prostate cancer;	chr6:153128535	chr4:188740507~188741281:-
BRCA	trans	rs853679	0.607	rs13208096	ENSG00000281831.1	HCP5B	7.14	1.81e-12	1.68e-06	0.56	0.22	Depression;	chr6:28257533	chr6:29871895~29873783:-
BRCA	trans	rs6915893	0.844	rs6910196	ENSG00000267156.1	TPMTP1	-7.13	1.82e-12	1.7e-06	-0.29	-0.22	Intrinsic epigenetic age acceleration;	chr6:18102276	chr18:47630112~47630848:+
BRCA	trans	rs4948102	0.642	rs6593297	ENSG00000186940.6	CHCHD2P9	7.13	1.84e-12	1.71e-06	0.26	0.22	Plasma homocysteine levels (post-methionine load test);	chr7:56054365	chr9:79391304~79391759:+
BRCA	trans	rs1707322	0.721	rs4660314	ENSG00000255397.1	AC022182.2	-7.13	1.84e-12	1.71e-06	-0.29	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45764213	chr8:60937705~60939871:-
BRCA	trans	rs4883201	0.572	rs1805735	ENSG00000179899.8	PHC1P1	7.13	1.85e-12	1.72e-06	0.29	0.22	Total cholesterol levels;Cholesterol, total;	chr12:8934087	chr12:55411727~55414787:-
BRCA	trans	rs11098499	0.687	rs71610270	ENSG00000276997.3	RP11-378J18.9	7.13	1.86e-12	1.73e-06	0.26	0.22	Corneal astigmatism;	chr4:119366281	chr1:222477252~222504622:-
BRCA	trans	rs6981523	0.553	rs11783045	ENSG00000253893.2	FAM85B	7.13	1.87e-12	1.74e-06	0.28	0.22	Neuroticism;	chr8:11198666	chr8:8167819~8226614:-
BRCA	trans	rs11098499	0.913	rs56122576	ENSG00000120555.12	SEPT7P9	7.13	1.92e-12	1.78e-06	0.28	0.22	Corneal astigmatism;	chr4:119208181	chr10:38383069~38402916:-
BRCA	trans	rs1707322	0.721	rs11211149	ENSG00000255397.1	AC022182.2	-7.13	1.92e-12	1.79e-06	-0.29	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45646546	chr8:60937705~60939871:-
BRCA	trans	rs12439619	0.846	rs62013464	ENSG00000259295.5	CSPG4P12	-7.12	1.95e-12	1.81e-06	-0.34	-0.22	Intelligence (multi-trait analysis);	chr15:82288250	chr15:85191438~85213905:+
BRCA	trans	rs877636	1	rs877636	ENSG00000227586.5	RP11-162A23.5	-7.12	1.95e-12	1.81e-06	-0.26	-0.22	Cognitive function;	chr12:56086799	chr10:123171535~123171875:-
BRCA	trans	rs9467711	0.606	rs34550936	ENSG00000253570.1	RNF5P1	7.12	1.96e-12	1.82e-06	0.51	0.22	Autism spectrum disorder or schizophrenia;	chr6:26361757	chr8:38600661~38601200:-
BRCA	trans	rs9467711	0.606	rs34622023	ENSG00000253570.1	RNF5P1	7.12	1.96e-12	1.82e-06	0.51	0.22	Autism spectrum disorder or schizophrenia;	chr6:26361891	chr8:38600661~38601200:-
BRCA	trans	rs1707322	0.686	rs61784833	ENSG00000255397.1	AC022182.2	-7.12	1.96e-12	1.82e-06	-0.29	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45768100	chr8:60937705~60939871:-
BRCA	trans	rs12477438	0.52	rs1453563	ENSG00000276576.1	MRPL30P1	7.12	1.97e-12	1.83e-06	0.26	0.22	Chronic sinus infection;	chr2:99103804	chr6:57029521~57029988:+
BRCA	trans	rs12477438	0.501	rs11683188	ENSG00000276576.1	MRPL30P1	7.12	1.97e-12	1.83e-06	0.26	0.22	Chronic sinus infection;	chr2:99108049	chr6:57029521~57029988:+
BRCA	trans	rs11098499	0.71	rs4145952	ENSG00000275858.1	RP11-291L22.8	7.12	1.99e-12	1.84e-06	0.25	0.22	Corneal astigmatism;	chr4:119234651	chr10:38450738~38451069:-
BRCA	trans	rs1707322	0.721	rs12069121	ENSG00000255397.1	AC022182.2	-7.12	2e-12	1.85e-06	-0.29	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45766312	chr8:60937705~60939871:-
BRCA	trans	rs11920570	0.92	rs4678196	ENSG00000267076.1	CCDC58P3	-7.12	2e-12	1.86e-06	-0.29	-0.22	Resting heart rate;	chr3:122554490	chr18:12211378~12211807:+
BRCA	trans	rs1568889	1	rs10767693	ENSG00000174912.7	METTL15P1	7.12	2.01e-12	1.87e-06	0.22	0.22	Bipolar disorder;	chr11:28072379	chr3:156713884~156714928:-
BRCA	trans	rs12439619	0.846	rs62012003	ENSG00000259295.5	CSPG4P12	-7.12	2.02e-12	1.88e-06	-0.34	-0.22	Intelligence (multi-trait analysis);	chr15:82183236	chr15:85191438~85213905:+
BRCA	trans	rs9581094	0.591	rs9581055	ENSG00000237917.1	PARP4P1	-7.12	2.02e-12	1.88e-06	-0.43	-0.22	Sudden cardiac arrest;	chr13:24456088	chrY:26594851~26634652:-
BRCA	trans	rs9581094	0.519	rs9581056	ENSG00000237917.1	PARP4P1	-7.12	2.02e-12	1.88e-06	-0.43	-0.22	Sudden cardiac arrest;	chr13:24456119	chrY:26594851~26634652:-
BRCA	trans	rs11098499	0.82	rs11737395	ENSG00000120555.12	SEPT7P9	7.12	2.03e-12	1.88e-06	0.27	0.22	Corneal astigmatism;	chr4:119599549	chr10:38383069~38402916:-
BRCA	trans	rs12477438	0.559	rs6733285	ENSG00000276576.1	MRPL30P1	7.12	2.04e-12	1.89e-06	0.26	0.22	Chronic sinus infection;	chr2:99109112	chr6:57029521~57029988:+
BRCA	trans	rs673253	0.581	rs2152113	ENSG00000231007.5	CDC20P1	-7.12	2.05e-12	1.9e-06	-0.28	-0.22	Intelligence (multi-trait analysis);	chr1:43517898	chr9:87011652~87013151:+
BRCA	trans	rs6915893	1	rs4074444	ENSG00000267156.1	TPMTP1	7.12	2.06e-12	1.91e-06	0.28	0.22	Intrinsic epigenetic age acceleration;	chr6:18106258	chr18:47630112~47630848:+
BRCA	trans	rs67340775	0.541	rs200968	ENSG00000204709.4	LINC01556	7.12	2.06e-12	1.91e-06	0.36	0.22	Lung cancer in ever smokers;	chr6:27891790	chr6:28943877~28944537:+
BRCA	trans	rs6011368	0.607	rs6062363	ENSG00000226210.3	WASH7P	7.12	2.06e-12	1.91e-06	0.24	0.22	Clozapine-induced cytotoxicity;	chr20:64281110	chr12:14522~32015:-
BRCA	trans	rs1023500	1	rs7293091	ENSG00000268568.1	AC007228.9	-7.12	2.08e-12	1.92e-06	-0.32	-0.22	Schizophrenia;	chr22:41945304	chr19:56672574~56673901:-
BRCA	trans	rs11098499	0.78	rs12504773	ENSG00000120555.12	SEPT7P9	7.12	2.08e-12	1.92e-06	0.27	0.22	Corneal astigmatism;	chr4:119640994	chr10:38383069~38402916:-
BRCA	trans	rs9467603	1	rs9467606	ENSG00000253570.1	RNF5P1	7.11	2.09e-12	1.94e-06	0.56	0.22	Intelligence (multi-trait analysis);	chr6:25808990	chr8:38600661~38601200:-
BRCA	trans	rs9467603	1	rs9467607	ENSG00000253570.1	RNF5P1	7.11	2.09e-12	1.94e-06	0.56	0.22	Intelligence (multi-trait analysis);	chr6:25809249	chr8:38600661~38601200:-
BRCA	trans	rs9467603	1	rs9467609	ENSG00000253570.1	RNF5P1	7.11	2.09e-12	1.94e-06	0.56	0.22	Intelligence (multi-trait analysis);	chr6:25809523	chr8:38600661~38601200:-
BRCA	trans	rs1707322	0.686	rs2991987	ENSG00000255397.1	AC022182.2	7.11	2.11e-12	1.96e-06	0.29	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45615750	chr8:60937705~60939871:-
BRCA	trans	rs12543645	0.598	rs17767186	ENSG00000253893.2	FAM85B	-7.11	2.13e-12	1.97e-06	-0.29	-0.22	Schizophrenia;	chr8:10419984	chr8:8167819~8226614:-
BRCA	trans	rs867371	0.614	rs7183805	ENSG00000235370.6	DNM1P51	-7.11	2.13e-12	1.97e-06	-0.27	-0.22	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82247090	chr15:84398316~84411701:-
BRCA	trans	rs1933488	0.866	rs63739861	ENSG00000278974.1	RP11-756P10.6	-7.11	2.14e-12	1.98e-06	-0.28	-0.22	Prostate cancer;	chr6:153109733	chr4:188740507~188741281:-
BRCA	trans	rs11098499	0.738	rs28687057	ENSG00000276997.3	RP11-378J18.9	7.11	2.16e-12	2e-06	0.26	0.22	Corneal astigmatism;	chr4:119359657	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.775	rs67281037	ENSG00000276997.3	RP11-378J18.9	7.11	2.16e-12	2e-06	0.26	0.22	Corneal astigmatism;	chr4:119360002	chr1:222477252~222504622:-
BRCA	trans	rs10028773	0.506	rs12374346	ENSG00000276997.3	RP11-378J18.9	7.11	2.16e-12	2e-06	0.26	0.22	Educational attainment;	chr4:119360550	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.866	rs12374244	ENSG00000276997.3	RP11-378J18.9	7.11	2.16e-12	2e-06	0.26	0.22	Corneal astigmatism;	chr4:119360817	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.866	rs12374352	ENSG00000276997.3	RP11-378J18.9	7.11	2.16e-12	2e-06	0.26	0.22	Corneal astigmatism;	chr4:119360822	chr1:222477252~222504622:-
BRCA	trans	rs9467603	1	rs9461216	ENSG00000253570.1	RNF5P1	7.11	2.16e-12	2e-06	0.56	0.22	Intelligence (multi-trait analysis);	chr6:25808515	chr8:38600661~38601200:-
BRCA	trans	rs6732160	0.588	rs13394018	ENSG00000236165.1	PRADC1P1	7.11	2.16e-12	2e-06	0.29	0.22	Intelligence (multi-trait analysis);	chr2:73145477	chr3:36976316~36976840:+
BRCA	trans	rs12439619	0.81	rs28876157	ENSG00000259295.5	CSPG4P12	-7.11	2.18e-12	2.02e-06	-0.34	-0.22	Intelligence (multi-trait analysis);	chr15:82216708	chr15:85191438~85213905:+
BRCA	trans	rs11098499	1	rs35643470	ENSG00000120555.12	SEPT7P9	7.11	2.2e-12	2.03e-06	0.27	0.22	Corneal astigmatism;	chr4:119263793	chr10:38383069~38402916:-
BRCA	trans	rs2235573	0.551	rs139897	ENSG00000258501.1	EIF3LP1	-7.11	2.21e-12	2.05e-06	-0.26	-0.21	Glioma;Glioblastoma;	chr22:38003091	chr14:81916231~81917888:+
BRCA	trans	rs9467603	1	rs9467603	ENSG00000253570.1	RNF5P1	7.1	2.23e-12	2.06e-06	0.56	0.21	Intelligence (multi-trait analysis);	chr6:25803484	chr8:38600661~38601200:-
BRCA	trans	rs673253	0.686	rs2782641	ENSG00000231007.5	CDC20P1	7.1	2.23e-12	2.06e-06	0.26	0.21	Intelligence (multi-trait analysis);	chr1:43547684	chr9:87011652~87013151:+
BRCA	trans	rs546131	0.642	rs2915186	ENSG00000225531.1	RP11-196I18.3	7.1	2.28e-12	2.11e-06	0.31	0.21	Lung disease severity in cystic fibrosis;	chr11:34829636	chr9:107116829~107117557:+
BRCA	trans	rs2288327	0.818	rs2303539	ENSG00000269800.1	PLEKHA3P1	7.1	2.29e-12	2.12e-06	0.34	0.21	Atrial fibrillation;	chr2:178538866	chr19:41521043~41521989:-
BRCA	trans	rs11098499	0.909	rs10026736	ENSG00000120555.12	SEPT7P9	7.1	2.3e-12	2.12e-06	0.27	0.21	Corneal astigmatism;	chr4:119463167	chr10:38383069~38402916:-
BRCA	trans	rs12477438	0.501	rs34272114	ENSG00000276576.1	MRPL30P1	7.1	2.31e-12	2.13e-06	0.26	0.21	Chronic sinus infection;	chr2:99120980	chr6:57029521~57029988:+
BRCA	trans	rs7113874	0.921	rs4929947	ENSG00000266891.1	RP11-692N5.2	7.1	2.31e-12	2.13e-06	0.26	0.21	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8618447	chr18:9734882~9735602:-
BRCA	trans	rs11638815	0.603	rs2678448	ENSG00000235370.6	DNM1P51	-7.1	2.31e-12	2.14e-06	-0.24	-0.21	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82594655	chr15:84398316~84411701:-
BRCA	trans	rs11098499	0.863	rs11098532	ENSG00000276997.3	RP11-378J18.9	7.1	2.32e-12	2.14e-06	0.27	0.21	Corneal astigmatism;	chr4:119569571	chr1:222477252~222504622:-
BRCA	trans	rs1568889	0.838	rs10458896	ENSG00000174912.7	METTL15P1	7.1	2.33e-12	2.15e-06	0.22	0.21	Bipolar disorder;	chr11:28036410	chr3:156713884~156714928:-
BRCA	trans	rs9467603	1	rs6939997	ENSG00000253570.1	RNF5P1	7.1	2.34e-12	2.16e-06	0.55	0.21	Intelligence (multi-trait analysis);	chr6:25820996	chr8:38600661~38601200:-
BRCA	trans	rs11098499	0.863	rs9884402	ENSG00000276997.3	RP11-378J18.9	7.1	2.34e-12	2.16e-06	0.26	0.21	Corneal astigmatism;	chr4:119568827	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.731	rs9995026	ENSG00000276997.3	RP11-378J18.9	7.1	2.34e-12	2.16e-06	0.26	0.21	Corneal astigmatism;	chr4:119569344	chr1:222477252~222504622:-
BRCA	trans	rs2288327	0.818	rs16866365	ENSG00000269800.1	PLEKHA3P1	7.1	2.35e-12	2.17e-06	0.33	0.21	Atrial fibrillation;	chr2:178521125	chr19:41521043~41521989:-
BRCA	trans	rs2288327	0.818	rs13034990	ENSG00000269800.1	PLEKHA3P1	7.1	2.35e-12	2.17e-06	0.33	0.21	Atrial fibrillation;	chr2:178521513	chr19:41521043~41521989:-
BRCA	trans	rs9467603	1	rs6940698	ENSG00000253570.1	RNF5P1	-7.1	2.36e-12	2.17e-06	-0.54	-0.21	Intelligence (multi-trait analysis);	chr6:25821352	chr8:38600661~38601200:-
BRCA	trans	rs11098499	0.863	rs7669520	ENSG00000276997.3	RP11-378J18.9	7.1	2.36e-12	2.18e-06	0.27	0.21	Corneal astigmatism;	chr4:119594123	chr1:222477252~222504622:-
BRCA	trans	rs7833986	0.501	rs2719261	ENSG00000244245.1	RP11-120B7.1	7.1	2.36e-12	2.18e-06	0.27	0.21	Height;	chr8:56029423	chr5:108593609~108593967:+
BRCA	trans	rs1707322	0.647	rs6686944	ENSG00000255397.1	AC022182.2	-7.1	2.37e-12	2.19e-06	-0.29	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45690636	chr8:60937705~60939871:-
BRCA	trans	rs2134046	0.555	rs11854483	ENSG00000235370.6	DNM1P51	-7.1	2.38e-12	2.19e-06	-0.23	-0.21	Cognitive ability;	chr15:82267217	chr15:84398316~84411701:-
BRCA	trans	rs12477438	0.52	rs4347885	ENSG00000276576.1	MRPL30P1	7.09	2.39e-12	2.2e-06	0.26	0.21	Chronic sinus infection;	chr2:99187544	chr6:57029521~57029988:+
BRCA	trans	rs1933488	1	rs9479517	ENSG00000278974.1	RP11-756P10.6	-7.09	2.39e-12	2.21e-06	-0.28	-0.21	Prostate cancer;	chr6:153121654	chr4:188740507~188741281:-
BRCA	trans	rs1707322	0.721	rs10890346	ENSG00000255397.1	AC022182.2	7.09	2.42e-12	2.23e-06	0.29	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45758220	chr8:60937705~60939871:-
BRCA	trans	rs11098499	0.697	rs4560394	ENSG00000276997.3	RP11-378J18.9	7.09	2.43e-12	2.24e-06	0.26	0.21	Corneal astigmatism;	chr4:119392280	chr1:222477252~222504622:-
BRCA	trans	rs4720118	0.508	rs4604335	ENSG00000213492.2	NT5C3AP1	7.09	2.44e-12	2.25e-06	0.27	0.21	Leprosy;	chr7:33349739	chr4:117574512~117576174:-
BRCA	trans	rs853679	0.599	rs188015	ENSG00000253570.1	RNF5P1	7.09	2.44e-12	2.25e-06	0.49	0.21	Depression;	chr6:27909668	chr8:38600661~38601200:-
BRCA	trans	rs801193	0.935	rs11772264	ENSG00000164669.11	INTS4P1	-7.09	2.48e-12	2.28e-06	-0.26	-0.21	Aortic root size;	chr7:66711400	chr7:65141225~65234216:+
BRCA	trans	rs6940638	1	rs12215241	ENSG00000204709.4	LINC01556	7.09	2.48e-12	2.29e-06	0.33	0.21	Intelligence (multi-trait analysis);	chr6:27055302	chr6:28943877~28944537:+
BRCA	trans	rs14057	0.864	rs12126058	ENSG00000215869.3	RP11-364B6.1	7.09	2.49e-12	2.3e-06	0.3	0.21	Systolic blood pressure;	chr1:6684649	chr1:104073023~104077087:+
BRCA	trans	rs11098499	0.955	rs13129661	ENSG00000120555.12	SEPT7P9	7.09	2.51e-12	2.31e-06	0.27	0.21	Corneal astigmatism;	chr4:119231754	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.865	rs11722183	ENSG00000120555.12	SEPT7P9	7.09	2.51e-12	2.31e-06	0.26	0.21	Corneal astigmatism;	chr4:119359442	chr10:38383069~38402916:-
BRCA	trans	rs6732160	0.564	rs60796597	ENSG00000236165.1	PRADC1P1	7.09	2.52e-12	2.32e-06	0.29	0.21	Intelligence (multi-trait analysis);	chr2:73155786	chr3:36976316~36976840:+
BRCA	trans	rs2736340	0.539	rs9644687	ENSG00000253893.2	FAM85B	7.09	2.52e-12	2.32e-06	0.28	0.21	Systemic lupus erythematosus;Systemic lupus erythematosus or rheumatoid arthritis;Kawasaki disease;Systemic lupus erythematosus and Systemic sclerosis;Rheumatoid arthritis;	chr8:11465516	chr8:8167819~8226614:-
BRCA	trans	rs11098499	0.866	rs11098506	ENSG00000276997.3	RP11-378J18.9	7.09	2.52e-12	2.32e-06	0.25	0.21	Corneal astigmatism;	chr4:119363816	chr1:222477252~222504622:-
BRCA	trans	rs7169223	0.653	rs12905740	ENSG00000274376.3	ADAMTS7P1	-7.09	2.54e-12	2.34e-06	-0.29	-0.21	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78790022	chr15:82298553~82334609:+
BRCA	trans	rs11098499	0.818	rs55825515	ENSG00000120555.12	SEPT7P9	7.09	2.55e-12	2.35e-06	0.27	0.21	Corneal astigmatism;	chr4:119565247	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.78	rs10013652	ENSG00000276997.3	RP11-378J18.9	7.09	2.55e-12	2.35e-06	0.25	0.21	Corneal astigmatism;	chr4:119371101	chr1:222477252~222504622:-
BRCA	trans	rs853679	0.546	rs13213986	ENSG00000228078.1	HLA-U	-7.09	2.55e-12	2.35e-06	-0.59	-0.21	Depression;	chr6:28390232	chr6:29934101~29934286:+
BRCA	trans	rs853679	0.546	rs34546986	ENSG00000228078.1	HLA-U	-7.09	2.55e-12	2.35e-06	-0.59	-0.21	Depression;	chr6:28394532	chr6:29934101~29934286:+
BRCA	trans	rs853679	0.546	rs34871267	ENSG00000228078.1	HLA-U	-7.09	2.55e-12	2.35e-06	-0.59	-0.21	Depression;	chr6:28396455	chr6:29934101~29934286:+
BRCA	trans	rs853679	0.546	rs35883476	ENSG00000228078.1	HLA-U	-7.09	2.55e-12	2.35e-06	-0.59	-0.21	Depression;	chr6:28400731	chr6:29934101~29934286:+
BRCA	trans	rs1707322	0.662	rs11211160	ENSG00000255397.1	AC022182.2	-7.08	2.56e-12	2.35e-06	-0.28	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45680557	chr8:60937705~60939871:-
BRCA	trans	rs11098499	0.82	rs6829903	ENSG00000276997.3	RP11-378J18.9	7.08	2.58e-12	2.38e-06	0.26	0.21	Corneal astigmatism;	chr4:119585729	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.863	rs1010740	ENSG00000120555.12	SEPT7P9	-7.08	2.62e-12	2.41e-06	-0.27	-0.21	Corneal astigmatism;	chr4:119542254	chr10:38383069~38402916:-
BRCA	trans	rs8028182	0.537	rs4371118	ENSG00000214646.7	RP11-114H24.4	7.08	2.62e-12	2.41e-06	0.3	0.21	Sudden cardiac arrest;	chr15:75606549	chr15:77941442~77944582:-
BRCA	trans	rs673253	0.556	rs11577403	ENSG00000231007.5	CDC20P1	7.08	2.63e-12	2.42e-06	0.28	0.21	Intelligence (multi-trait analysis);	chr1:43524102	chr9:87011652~87013151:+
BRCA	trans	rs546131	0.614	rs473885	ENSG00000225531.1	RP11-196I18.3	7.08	2.66e-12	2.44e-06	0.31	0.21	Lung disease severity in cystic fibrosis;	chr11:34830414	chr9:107116829~107117557:+
BRCA	trans	rs546131	0.642	rs473848	ENSG00000225531.1	RP11-196I18.3	7.08	2.66e-12	2.44e-06	0.31	0.21	Lung disease severity in cystic fibrosis;	chr11:34830430	chr9:107116829~107117557:+
BRCA	trans	rs728478	0.845	rs7207830	ENSG00000187870.7	RNFT1P3	7.08	2.66e-12	2.44e-06	0.27	0.21	QT interval;	chr17:59402382	chr17:20743333~20754501:-
BRCA	trans	rs11098499	0.909	rs10017335	ENSG00000276997.3	RP11-378J18.9	-7.08	2.69e-12	2.47e-06	-0.27	-0.21	Corneal astigmatism;	chr4:119460368	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.863	rs3736115	ENSG00000276997.3	RP11-378J18.9	-7.08	2.69e-12	2.48e-06	-0.27	-0.21	Corneal astigmatism;	chr4:119567548	chr1:222477252~222504622:-
BRCA	trans	rs9584850	0.834	rs745639	ENSG00000230079.1	STK24P1	7.08	2.7e-12	2.48e-06	0.28	0.21	Neuroticism;	chr13:98467025	chrX:136295690~136300298:-
BRCA	trans	rs11098499	0.913	rs35271032	ENSG00000120555.12	SEPT7P9	7.08	2.7e-12	2.49e-06	0.27	0.21	Corneal astigmatism;	chr4:119235504	chr10:38383069~38402916:-
BRCA	trans	rs17767294	0.708	rs61744109	ENSG00000242375.1	RP11-498P14.3	-7.07	2.74e-12	2.52e-06	-0.63	-0.21	Parkinson's disease;	chr6:28107741	chr9:97195351~97197687:-
BRCA	trans	rs17767294	0.708	rs72851168	ENSG00000242375.1	RP11-498P14.3	-7.07	2.74e-12	2.52e-06	-0.63	-0.21	Parkinson's disease;	chr6:28112230	chr9:97195351~97197687:-
BRCA	trans	rs17767294	0.708	rs77450054	ENSG00000242375.1	RP11-498P14.3	-7.07	2.74e-12	2.52e-06	-0.63	-0.21	Parkinson's disease;	chr6:28116171	chr9:97195351~97197687:-
BRCA	trans	rs2288327	0.818	rs13029629	ENSG00000269800.1	PLEKHA3P1	7.07	2.74e-12	2.52e-06	0.33	0.21	Atrial fibrillation;	chr2:178515438	chr19:41521043~41521989:-
BRCA	trans	rs1568889	0.838	rs11030187	ENSG00000174912.7	METTL15P1	7.07	2.78e-12	2.55e-06	0.22	0.21	Bipolar disorder;	chr11:28022844	chr3:156713884~156714928:-
BRCA	trans	rs9834975	0.605	rs9825383	ENSG00000267076.1	CCDC58P3	-7.07	2.78e-12	2.55e-06	-0.25	-0.21	Diastolic blood pressure;	chr3:122539209	chr18:12211378~12211807:+
BRCA	trans	rs4713118	0.615	rs57252182	ENSG00000204709.4	LINC01556	7.07	2.8e-12	2.57e-06	0.28	0.21	Parkinson's disease;	chr6:27752470	chr6:28943877~28944537:+
BRCA	trans	rs546131	0.642	rs561477	ENSG00000225531.1	RP11-196I18.3	7.07	2.81e-12	2.58e-06	0.31	0.21	Lung disease severity in cystic fibrosis;	chr11:34830605	chr9:107116829~107117557:+
BRCA	trans	rs17767294	0.708	rs72851138	ENSG00000242375.1	RP11-498P14.3	-7.07	2.82e-12	2.59e-06	-0.63	-0.21	Parkinson's disease;	chr6:28074876	chr9:97195351~97197687:-
BRCA	trans	rs17767294	0.708	rs72851139	ENSG00000242375.1	RP11-498P14.3	-7.07	2.82e-12	2.59e-06	-0.63	-0.21	Parkinson's disease;	chr6:28074920	chr9:97195351~97197687:-
BRCA	trans	rs17767294	0.708	rs72851156	ENSG00000242375.1	RP11-498P14.3	-7.07	2.82e-12	2.59e-06	-0.63	-0.21	Parkinson's disease;	chr6:28092308	chr9:97195351~97197687:-
BRCA	trans	rs17767294	0.708	rs72851158	ENSG00000242375.1	RP11-498P14.3	-7.07	2.82e-12	2.59e-06	-0.63	-0.21	Parkinson's disease;	chr6:28092707	chr9:97195351~97197687:-
BRCA	trans	rs17767294	0.708	rs72851160	ENSG00000242375.1	RP11-498P14.3	-7.07	2.82e-12	2.59e-06	-0.63	-0.21	Parkinson's disease;	chr6:28100063	chr9:97195351~97197687:-
BRCA	trans	rs9468199	0.51	rs72851161	ENSG00000242375.1	RP11-498P14.3	-7.07	2.82e-12	2.59e-06	-0.63	-0.21	Parkinson's disease;	chr6:28103345	chr9:97195351~97197687:-
BRCA	trans	rs17767294	0.708	rs77689085	ENSG00000242375.1	RP11-498P14.3	-7.07	2.82e-12	2.59e-06	-0.63	-0.21	Parkinson's disease;	chr6:28104758	chr9:97195351~97197687:-
BRCA	trans	rs853679	0.607	rs34662244	ENSG00000281831.1	HCP5B	7.07	2.82e-12	2.59e-06	0.56	0.21	Depression;	chr6:28106103	chr6:29871895~29873783:-
BRCA	trans	rs35952432	1	rs35952432	ENSG00000281831.1	HCP5B	7.07	2.82e-12	2.59e-06	0.56	0.21	Lung cancer;	chr6:28107123	chr6:29871895~29873783:-
BRCA	trans	rs9467711	0.559	rs13208916	ENSG00000253570.1	RNF5P1	7.07	2.82e-12	2.59e-06	0.47	0.21	Autism spectrum disorder or schizophrenia;	chr6:26601712	chr8:38600661~38601200:-
BRCA	trans	rs9914988	0.887	rs2070265	ENSG00000267449.1	RP11-264B14.2	-7.07	2.82e-12	2.59e-06	-0.29	-0.21	Glycated hemoglobin levels;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr17:28748405	chr17:61069856~61070356:-
BRCA	trans	rs7200543	1	rs4500751	ENSG00000250569.1	NTAN1P2	7.07	2.83e-12	2.6e-06	0.23	0.21	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15046354	chr8:86481754~86483002:-
BRCA	trans	rs11782517	0.883	rs13274653	ENSG00000253893.2	FAM85B	-7.07	2.84e-12	2.61e-06	-0.34	-0.21	Nose size;	chr8:10249291	chr8:8167819~8226614:-
BRCA	trans	rs853679	0.546	rs13213152	ENSG00000228078.1	HLA-U	-7.07	2.85e-12	2.61e-06	-0.59	-0.21	Depression;	chr6:28381921	chr6:29934101~29934286:+
BRCA	trans	rs11992162	0.591	rs35657308	ENSG00000253893.2	FAM85B	7.07	2.86e-12	2.63e-06	0.27	0.21	Monocyte count;	chr8:11946893	chr8:8167819~8226614:-
BRCA	trans	rs656319	0.638	rs670044	ENSG00000253893.2	FAM85B	-7.07	2.87e-12	2.63e-06	-0.27	-0.21	Myopia (pathological);	chr8:10035019	chr8:8167819~8226614:-
BRCA	trans	rs9467711	0.606	rs16891725	ENSG00000253570.1	RNF5P1	7.07	2.88e-12	2.64e-06	0.47	0.21	Autism spectrum disorder or schizophrenia;	chr6:26478922	chr8:38600661~38601200:-
BRCA	trans	rs34034915	1	rs34034915	ENSG00000204709.4	LINC01556	7.07	2.88e-12	2.64e-06	0.28	0.21	Hepatitis A;	chr6:27752924	chr6:28943877~28944537:+
BRCA	trans	rs4713118	0.527	rs36042294	ENSG00000204709.4	LINC01556	7.07	2.88e-12	2.64e-06	0.28	0.21	Parkinson's disease;	chr6:27752933	chr6:28943877~28944537:+
BRCA	trans	rs17711722	0.503	rs453835	ENSG00000213640.3	EEF1DP4	7.07	2.91e-12	2.67e-06	0.28	0.21	Calcium levels;	chr7:66046172	chr7:64862999~64864370:+
BRCA	trans	rs17507216	0.681	rs28877110	ENSG00000259295.5	CSPG4P12	-7.07	2.92e-12	2.67e-06	-0.35	-0.21	Excessive daytime sleepiness;	chr15:82672111	chr15:85191438~85213905:+
BRCA	trans	rs9425766	0.64	rs2281486	ENSG00000213331.4	RP11-713C19.2	7.07	2.92e-12	2.68e-06	0.28	0.21	Life satisfaction;	chr1:173853083	chr4:187970273~187971284:+
BRCA	trans	rs9425766	0.64	rs16846439	ENSG00000213331.4	RP11-713C19.2	7.07	2.92e-12	2.68e-06	0.28	0.21	Life satisfaction;	chr1:173854900	chr4:187970273~187971284:+
BRCA	trans	rs9650657	0.529	rs6601521	ENSG00000253893.2	FAM85B	7.07	2.93e-12	2.68e-06	0.25	0.21	Neuroticism;	chr8:10771437	chr8:8167819~8226614:-
BRCA	trans	rs11098499	0.866	rs72676074	ENSG00000120555.12	SEPT7P9	7.06	2.95e-12	2.7e-06	0.26	0.21	Corneal astigmatism;	chr4:119438686	chr10:38383069~38402916:-
BRCA	trans	rs12541491	0.506	rs11250007	ENSG00000253893.2	FAM85B	7.06	2.98e-12	2.73e-06	0.28	0.21	Schizophrenia;	chr8:10427576	chr8:8167819~8226614:-
BRCA	trans	rs11098499	0.863	rs10013305	ENSG00000120555.12	SEPT7P9	7.06	2.98e-12	2.73e-06	0.27	0.21	Corneal astigmatism;	chr4:119529269	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.863	rs3775849	ENSG00000120555.12	SEPT7P9	7.06	2.98e-12	2.73e-06	0.27	0.21	Corneal astigmatism;	chr4:119529753	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.818	rs7688802	ENSG00000120555.12	SEPT7P9	7.06	2.98e-12	2.73e-06	0.27	0.21	Corneal astigmatism;	chr4:119530513	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.863	rs7695620	ENSG00000120555.12	SEPT7P9	7.06	2.98e-12	2.73e-06	0.27	0.21	Corneal astigmatism;	chr4:119531621	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.863	rs12502389	ENSG00000120555.12	SEPT7P9	7.06	2.98e-12	2.73e-06	0.27	0.21	Corneal astigmatism;	chr4:119533036	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.821	rs3775852	ENSG00000120555.12	SEPT7P9	7.06	2.98e-12	2.73e-06	0.27	0.21	Corneal astigmatism;	chr4:119533401	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.82	rs6534140	ENSG00000120555.12	SEPT7P9	7.06	2.98e-12	2.73e-06	0.27	0.21	Corneal astigmatism;	chr4:119534156	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.863	rs7657849	ENSG00000120555.12	SEPT7P9	7.06	2.98e-12	2.73e-06	0.27	0.21	Corneal astigmatism;	chr4:119534339	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.863	rs10034450	ENSG00000120555.12	SEPT7P9	7.06	2.98e-12	2.73e-06	0.27	0.21	Corneal astigmatism;	chr4:119534494	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.863	rs1480939	ENSG00000120555.12	SEPT7P9	7.06	2.98e-12	2.73e-06	0.27	0.21	Corneal astigmatism;	chr4:119535772	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.863	rs13140391	ENSG00000276997.3	RP11-378J18.9	7.06	3e-12	2.74e-06	0.27	0.21	Corneal astigmatism;	chr4:119582282	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.863	rs13140409	ENSG00000276997.3	RP11-378J18.9	7.06	3e-12	2.74e-06	0.27	0.21	Corneal astigmatism;	chr4:119582305	chr1:222477252~222504622:-
BRCA	trans	rs17767294	0.708	rs72848791	ENSG00000242375.1	RP11-498P14.3	-7.06	3e-12	2.75e-06	-0.62	-0.21	Parkinson's disease;	chr6:28018421	chr9:97195351~97197687:-
BRCA	trans	rs14057	0.827	rs61780562	ENSG00000215869.3	RP11-364B6.1	7.06	3.01e-12	2.75e-06	0.3	0.21	Systolic blood pressure;	chr1:6698080	chr1:104073023~104077087:+
BRCA	trans	rs2736340	0.539	rs11250138	ENSG00000253893.2	FAM85B	7.06	3.03e-12	2.77e-06	0.28	0.21	Systemic lupus erythematosus;Systemic lupus erythematosus or rheumatoid arthritis;Kawasaki disease;Systemic lupus erythematosus and Systemic sclerosis;Rheumatoid arthritis;	chr8:11465803	chr8:8167819~8226614:-
BRCA	trans	rs11098499	0.863	rs2306456	ENSG00000120555.12	SEPT7P9	7.06	3.06e-12	2.8e-06	0.27	0.21	Corneal astigmatism;	chr4:119551267	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.863	rs11947234	ENSG00000120555.12	SEPT7P9	7.06	3.06e-12	2.8e-06	0.27	0.21	Corneal astigmatism;	chr4:119553704	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.863	rs11933966	ENSG00000120555.12	SEPT7P9	7.06	3.06e-12	2.8e-06	0.27	0.21	Corneal astigmatism;	chr4:119555560	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.863	rs36040693	ENSG00000120555.12	SEPT7P9	7.06	3.06e-12	2.8e-06	0.27	0.21	Corneal astigmatism;	chr4:119556461	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.863	rs3775858	ENSG00000120555.12	SEPT7P9	7.06	3.08e-12	2.82e-06	0.26	0.21	Corneal astigmatism;	chr4:119564873	chr10:38383069~38402916:-
BRCA	trans	rs1707322	0.721	rs4660883	ENSG00000255397.1	AC022182.2	-7.06	3.1e-12	2.84e-06	-0.28	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45770426	chr8:60937705~60939871:-
BRCA	trans	rs11098499	0.863	rs11098531	ENSG00000120555.12	SEPT7P9	7.06	3.12e-12	2.85e-06	0.27	0.21	Corneal astigmatism;	chr4:119543846	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.863	rs28718422	ENSG00000120555.12	SEPT7P9	7.06	3.12e-12	2.85e-06	0.27	0.21	Corneal astigmatism;	chr4:119545149	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.818	rs12498599	ENSG00000120555.12	SEPT7P9	7.06	3.12e-12	2.85e-06	0.27	0.21	Corneal astigmatism;	chr4:119547348	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.863	rs10009626	ENSG00000120555.12	SEPT7P9	7.06	3.12e-12	2.85e-06	0.27	0.21	Corneal astigmatism;	chr4:119548850	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.863	rs7678400	ENSG00000120555.12	SEPT7P9	7.06	3.14e-12	2.87e-06	0.27	0.21	Corneal astigmatism;	chr4:119540802	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.863	rs1480936	ENSG00000120555.12	SEPT7P9	7.06	3.14e-12	2.87e-06	0.27	0.21	Corneal astigmatism;	chr4:119541706	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.955	rs56386062	ENSG00000120555.12	SEPT7P9	7.06	3.14e-12	2.87e-06	0.27	0.21	Corneal astigmatism;	chr4:119233980	chr10:38383069~38402916:-
BRCA	trans	rs67340775	0.541	rs200966	ENSG00000204709.4	LINC01556	7.05	3.16e-12	2.89e-06	0.35	0.21	Lung cancer in ever smokers;	chr6:27894374	chr6:28943877~28944537:+
BRCA	trans	rs11098499	0.863	rs3733525	ENSG00000120555.12	SEPT7P9	7.05	3.18e-12	2.9e-06	0.27	0.21	Corneal astigmatism;	chr4:119525893	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.863	rs3775847	ENSG00000120555.12	SEPT7P9	7.05	3.18e-12	2.9e-06	0.27	0.21	Corneal astigmatism;	chr4:119526487	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.863	rs3775848	ENSG00000120555.12	SEPT7P9	7.05	3.18e-12	2.9e-06	0.27	0.21	Corneal astigmatism;	chr4:119526569	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.955	rs13114751	ENSG00000120555.12	SEPT7P9	7.05	3.18e-12	2.91e-06	0.27	0.21	Corneal astigmatism;	chr4:119235462	chr10:38383069~38402916:-
BRCA	trans	rs9425766	0.679	rs6670617	ENSG00000213331.4	RP11-713C19.2	7.05	3.18e-12	2.91e-06	0.24	0.21	Life satisfaction;	chr1:174277574	chr4:187970273~187971284:+
BRCA	trans	rs902774	0.818	rs4919743	ENSG00000255815.3	KRT8P11	-7.05	3.19e-12	2.91e-06	-0.38	-0.21	Prostate cancer;	chr12:52915800	chr9:99305176~99306611:+
BRCA	trans	rs7746199	0.668	rs7749305	ENSG00000253570.1	RNF5P1	7.05	3.21e-12	2.93e-06	0.53	0.21	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27478787	chr8:38600661~38601200:-
BRCA	trans	rs1933488	0.965	rs7742238	ENSG00000278974.1	RP11-756P10.6	-7.05	3.22e-12	2.94e-06	-0.28	-0.21	Prostate cancer;	chr6:153107476	chr4:188740507~188741281:-
BRCA	trans	rs149866169	1	rs149866169	ENSG00000253570.1	RNF5P1	7.05	3.25e-12	2.96e-06	0.53	0.21	Subjective well-being (multi-trait analysis);Lung cancer;Neuroticism (multi-trait analysis);Lung cancer in ever smokers;Squamous cell lung carcinoma;	chr6:27473944	chr8:38600661~38601200:-
BRCA	trans	rs11098499	0.78	rs7680914	ENSG00000120555.12	SEPT7P9	7.05	3.26e-12	2.98e-06	0.27	0.21	Corneal astigmatism;	chr4:119641898	chr10:38383069~38402916:-
BRCA	trans	rs1347297	1	rs72953347	ENSG00000269800.1	PLEKHA3P1	7.05	3.26e-12	2.98e-06	0.27	0.21	Alzheimer disease and age of onset;	chr2:178410102	chr19:41521043~41521989:-
BRCA	trans	rs11098499	0.955	rs4145951	ENSG00000120555.12	SEPT7P9	7.05	3.29e-12	3e-06	0.27	0.21	Corneal astigmatism;	chr4:119234662	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.955	rs35916640	ENSG00000120555.12	SEPT7P9	7.05	3.29e-12	3e-06	0.27	0.21	Corneal astigmatism;	chr4:119234697	chr10:38383069~38402916:-
BRCA	trans	rs9467603	1	rs13200921	ENSG00000253570.1	RNF5P1	7.05	3.33e-12	3.03e-06	0.58	0.21	Intelligence (multi-trait analysis);	chr6:25790150	chr8:38600661~38601200:-
BRCA	trans	rs9584850	0.834	rs9584854	ENSG00000230079.1	STK24P1	7.05	3.33e-12	3.04e-06	0.28	0.21	Neuroticism;	chr13:98466336	chrX:136295690~136300298:-
BRCA	trans	rs1707322	0.686	rs1541131	ENSG00000255397.1	AC022182.2	7.05	3.35e-12	3.06e-06	0.28	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45619262	chr8:60937705~60939871:-
BRCA	trans	rs6940638	1	rs6940638	ENSG00000204709.4	LINC01556	7.04	3.37e-12	3.07e-06	0.32	0.21	Intelligence (multi-trait analysis);	chr6:27078471	chr6:28943877~28944537:+
BRCA	trans	rs11098499	0.908	rs28499576	ENSG00000276997.3	RP11-378J18.9	7.04	3.41e-12	3.11e-06	0.26	0.21	Corneal astigmatism;	chr4:119465522	chr1:222477252~222504622:-
BRCA	trans	rs641862	1	rs641862	ENSG00000228889.5	UBAC2-AS1	7.04	3.42e-12	3.11e-06	0.46	0.21	Obesity-related traits;	chr13:110137885	chr13:99196377~99200710:-
BRCA	trans	rs1568889	0.838	rs716366	ENSG00000174912.7	METTL15P1	7.04	3.42e-12	3.12e-06	0.22	0.21	Bipolar disorder;	chr11:28099989	chr3:156713884~156714928:-
BRCA	trans	rs7833986	0.501	rs72653941	ENSG00000244245.1	RP11-120B7.1	7.04	3.44e-12	3.14e-06	0.26	0.21	Height;	chr8:56029688	chr5:108593609~108593967:+
BRCA	trans	rs11098499	0.863	rs10018280	ENSG00000120555.12	SEPT7P9	7.04	3.44e-12	3.14e-06	0.26	0.21	Corneal astigmatism;	chr4:119556984	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.863	rs6534141	ENSG00000120555.12	SEPT7P9	7.04	3.44e-12	3.14e-06	0.26	0.21	Corneal astigmatism;	chr4:119564068	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.863	rs2127823	ENSG00000120555.12	SEPT7P9	7.04	3.44e-12	3.14e-06	0.26	0.21	Corneal astigmatism;	chr4:119564515	chr10:38383069~38402916:-
BRCA	trans	rs9292918	0.853	rs1392973	ENSG00000231752.4	EMBP1	7.04	3.45e-12	3.15e-06	0.31	0.21	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:45307131	chr1:121519112~121571892:+
BRCA	trans	rs11920570	0.92	rs73192127	ENSG00000267076.1	CCDC58P3	-7.04	3.48e-12	3.17e-06	-0.29	-0.21	Resting heart rate;	chr3:122555910	chr18:12211378~12211807:+
BRCA	trans	rs1707322	0.721	rs7519900	ENSG00000255397.1	AC022182.2	-7.04	3.48e-12	3.17e-06	-0.29	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45769275	chr8:60937705~60939871:-
BRCA	trans	rs11098499	0.863	rs1010739	ENSG00000276997.3	RP11-378J18.9	7.04	3.51e-12	3.2e-06	0.27	0.21	Corneal astigmatism;	chr4:119542316	chr1:222477252~222504622:-
BRCA	trans	rs7746199	0.668	rs34864796	ENSG00000253570.1	RNF5P1	7.04	3.51e-12	3.2e-06	0.53	0.21	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27492144	chr8:38600661~38601200:-
BRCA	trans	rs11098499	0.82	rs2389885	ENSG00000120555.12	SEPT7P9	7.04	3.52e-12	3.2e-06	0.28	0.21	Corneal astigmatism;	chr4:119612776	chr10:38383069~38402916:-
BRCA	trans	rs7617773	0.817	rs936426	ENSG00000235912.1	RP1-159A19.3	-7.04	3.54e-12	3.22e-06	-0.27	-0.21	Coronary artery disease;	chr3:48173763	chr1:27649419~27649610:+
BRCA	trans	rs11098499	0.863	rs58452170	ENSG00000120555.12	SEPT7P9	7.04	3.54e-12	3.23e-06	0.27	0.21	Corneal astigmatism;	chr4:119538519	chr10:38383069~38402916:-
BRCA	trans	rs12477438	0.501	rs6708878	ENSG00000276576.1	MRPL30P1	7.04	3.56e-12	3.25e-06	0.26	0.21	Chronic sinus infection;	chr2:99185101	chr6:57029521~57029988:+
BRCA	trans	rs11098499	0.73	rs12505735	ENSG00000276997.3	RP11-378J18.9	7.04	3.6e-12	3.28e-06	0.26	0.21	Corneal astigmatism;	chr4:119611801	chr1:222477252~222504622:-
BRCA	trans	rs11920570	0.92	rs73192132	ENSG00000267076.1	CCDC58P3	-7.03	3.64e-12	3.31e-06	-0.29	-0.21	Resting heart rate;	chr3:122561613	chr18:12211378~12211807:+
BRCA	trans	rs11098499	0.863	rs6833334	ENSG00000276997.3	RP11-378J18.9	7.03	3.65e-12	3.32e-06	0.27	0.21	Corneal astigmatism;	chr4:119583072	chr1:222477252~222504622:-
BRCA	trans	rs7169223	0.653	rs1564499	ENSG00000274376.3	ADAMTS7P1	-7.03	3.66e-12	3.33e-06	-0.27	-0.21	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78792466	chr15:82298553~82334609:+
BRCA	trans	rs3096299	0.685	rs4785571	ENSG00000215030.5	RPL13P12	-7.03	3.67e-12	3.34e-06	-0.22	-0.21	Multiple myeloma (IgH translocation);	chr16:89498761	chr17:17383377~17384012:-
BRCA	trans	rs11098499	0.863	rs1552092	ENSG00000120555.12	SEPT7P9	7.03	3.68e-12	3.34e-06	0.27	0.21	Corneal astigmatism;	chr4:119567341	chr10:38383069~38402916:-
BRCA	trans	rs546131	0.642	rs579926	ENSG00000225531.1	RP11-196I18.3	7.03	3.68e-12	3.35e-06	0.31	0.21	Lung disease severity in cystic fibrosis;	chr11:34831608	chr9:107116829~107117557:+
BRCA	trans	rs11638815	0.626	rs4779041	ENSG00000235370.6	DNM1P51	7.03	3.69e-12	3.36e-06	0.23	0.21	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82668307	chr15:84398316~84411701:-
BRCA	trans	rs1707322	0.686	rs1547924	ENSG00000255397.1	AC022182.2	-7.03	3.72e-12	3.38e-06	-0.28	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45619440	chr8:60937705~60939871:-
BRCA	trans	rs11098499	0.913	rs67073020	ENSG00000120555.12	SEPT7P9	7.03	3.73e-12	3.39e-06	0.27	0.21	Corneal astigmatism;	chr4:119231402	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.874	rs28452522	ENSG00000120555.12	SEPT7P9	7.03	3.74e-12	3.4e-06	0.28	0.21	Corneal astigmatism;	chr4:119189629	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.82	rs28394116	ENSG00000276997.3	RP11-378J18.9	7.03	3.74e-12	3.4e-06	0.27	0.21	Corneal astigmatism;	chr4:119603128	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.863	rs3775845	ENSG00000276997.3	RP11-378J18.9	7.03	3.77e-12	3.43e-06	0.27	0.21	Corneal astigmatism;	chr4:119511292	chr1:222477252~222504622:-
BRCA	trans	rs877636	0.74	rs705698	ENSG00000212829.8	RPS26P3	7.03	3.79e-12	3.44e-06	0.29	0.21	Cognitive function;	chr12:55990903	chr9:9090898~9091245:+
BRCA	trans	rs17783634	0.509	rs11775489	ENSG00000253893.2	FAM85B	7.03	3.79e-12	3.44e-06	0.28	0.21	Subjective well-being;	chr8:11179334	chr8:8167819~8226614:-
BRCA	trans	rs9467711	0.651	rs67554133	ENSG00000253570.1	RNF5P1	7.03	3.81e-12	3.47e-06	0.6	0.21	Autism spectrum disorder or schizophrenia;	chr6:25866004	chr8:38600661~38601200:-
BRCA	trans	rs9467711	0.651	rs68194335	ENSG00000253570.1	RNF5P1	7.03	3.81e-12	3.47e-06	0.6	0.21	Autism spectrum disorder or schizophrenia;	chr6:25866015	chr8:38600661~38601200:-
BRCA	trans	rs9467603	1	rs9467613	ENSG00000253570.1	RNF5P1	7.03	3.83e-12	3.48e-06	0.55	0.21	Intelligence (multi-trait analysis);	chr6:25812413	chr8:38600661~38601200:-
BRCA	trans	rs11098499	0.69	rs34818745	ENSG00000276997.3	RP11-378J18.9	7.03	3.83e-12	3.48e-06	0.26	0.21	Corneal astigmatism;	chr4:119335900	chr1:222477252~222504622:-
BRCA	trans	rs1707322	0.717	rs2275086	ENSG00000255397.1	AC022182.2	7.03	3.84e-12	3.48e-06	0.28	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45620207	chr8:60937705~60939871:-
BRCA	trans	rs11920570	0.92	rs78969144	ENSG00000267076.1	CCDC58P3	-7.03	3.85e-12	3.49e-06	-0.29	-0.21	Resting heart rate;	chr3:122559005	chr18:12211378~12211807:+
BRCA	trans	rs7833986	0.501	rs2719255	ENSG00000244245.1	RP11-120B7.1	7.03	3.86e-12	3.5e-06	0.28	0.21	Height;	chr8:56124099	chr5:108593609~108593967:+
BRCA	trans	rs7833986	0.501	rs72653990	ENSG00000244245.1	RP11-120B7.1	7.03	3.86e-12	3.5e-06	0.28	0.21	Height;	chr8:56124556	chr5:108593609~108593967:+
BRCA	trans	rs7833986	0.501	rs17815934	ENSG00000244245.1	RP11-120B7.1	7.03	3.86e-12	3.5e-06	0.28	0.21	Height;	chr8:56125836	chr5:108593609~108593967:+
BRCA	trans	rs853679	1	rs6905391	ENSG00000253570.1	RNF5P1	7.02	3.87e-12	3.51e-06	0.41	0.21	Depression;	chr6:28294909	chr8:38600661~38601200:-
BRCA	trans	rs801193	1	rs2420824	ENSG00000164669.11	INTS4P1	7.02	3.89e-12	3.53e-06	0.26	0.21	Aortic root size;	chr7:66666129	chr7:65141225~65234216:+
BRCA	trans	rs714543	1	rs1990053	ENSG00000267258.1	CTC-448F2.3	-7.02	3.91e-12	3.55e-06	-0.26	-0.21	Plateletcrit;	chr7:44886297	chr19:29921182~29921653:+
BRCA	trans	rs10838687	0.932	rs4752973	ENSG00000134612.10	FOLH1B	7.02	3.91e-12	3.55e-06	0.31	0.21	Proinsulin levels;	chr11:47247608	chr11:89639227~89698718:+
BRCA	trans	rs902774	0.818	rs4919743	ENSG00000248568.1	KRT8P48	-7.02	3.93e-12	3.56e-06	-0.38	-0.21	Prostate cancer;	chr12:52915800	chr5:146706381~146707600:-
BRCA	trans	rs9581094	0.591	rs9581062	ENSG00000237917.1	PARP4P1	-7.02	4.01e-12	3.64e-06	-0.43	-0.21	Sudden cardiac arrest;	chr13:24466027	chrY:26594851~26634652:-
BRCA	trans	rs11098499	0.866	rs3756156	ENSG00000276997.3	RP11-378J18.9	7.02	4.02e-12	3.64e-06	0.27	0.21	Corneal astigmatism;	chr4:119603686	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.863	rs13136462	ENSG00000276997.3	RP11-378J18.9	7.02	4.02e-12	3.64e-06	0.27	0.21	Corneal astigmatism;	chr4:119622018	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.863	rs3775841	ENSG00000276997.3	RP11-378J18.9	7.02	4.02e-12	3.64e-06	0.26	0.21	Corneal astigmatism;	chr4:119504622	chr1:222477252~222504622:-
BRCA	trans	rs9581094	0.591	rs7325273	ENSG00000237917.1	PARP4P1	-7.02	4.03e-12	3.65e-06	-0.42	-0.21	Sudden cardiac arrest;	chr13:24457969	chrY:26594851~26634652:-
BRCA	trans	rs9581094	0.591	rs67794370	ENSG00000237917.1	PARP4P1	-7.02	4.03e-12	3.65e-06	-0.42	-0.21	Sudden cardiac arrest;	chr13:24458062	chrY:26594851~26634652:-
BRCA	trans	rs747782	0.702	rs2242511	ENSG00000134612.10	FOLH1B	7.02	4.05e-12	3.67e-06	0.4	0.21	Intraocular pressure;	chr11:47420113	chr11:89639227~89698718:+
BRCA	trans	rs11098499	0.863	rs9997631	ENSG00000120555.12	SEPT7P9	7.02	4.12e-12	3.73e-06	0.26	0.21	Corneal astigmatism;	chr4:119548840	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.874	rs7661020	ENSG00000120555.12	SEPT7P9	7.02	4.13e-12	3.74e-06	0.28	0.21	Corneal astigmatism;	chr4:119185827	chr10:38383069~38402916:-
BRCA	trans	rs14057	0.864	rs11122118	ENSG00000215869.3	RP11-364B6.1	7.01	4.15e-12	3.75e-06	0.3	0.21	Systolic blood pressure;	chr1:6704747	chr1:104073023~104077087:+
BRCA	trans	rs17507216	0.609	rs1431716	ENSG00000259295.5	CSPG4P12	-7.01	4.15e-12	3.76e-06	-0.35	-0.21	Excessive daytime sleepiness;	chr15:82676180	chr15:85191438~85213905:+
BRCA	trans	rs11098499	0.863	rs1155576	ENSG00000120555.12	SEPT7P9	7.01	4.16e-12	3.77e-06	0.26	0.21	Corneal astigmatism;	chr4:119529004	chr10:38383069~38402916:-
BRCA	trans	rs1707322	0.721	rs10430124	ENSG00000255397.1	AC022182.2	-7.01	4.17e-12	3.77e-06	-0.28	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755945	chr8:60937705~60939871:-
BRCA	trans	rs11782517	0.924	rs35222693	ENSG00000253893.2	FAM85B	-7.01	4.19e-12	3.8e-06	-0.31	-0.21	Nose size;	chr8:10251280	chr8:8167819~8226614:-
BRCA	trans	rs14057	0.929	rs7549198	ENSG00000215869.3	RP11-364B6.1	7.01	4.21e-12	3.81e-06	0.29	0.21	Systolic blood pressure;	chr1:6649550	chr1:104073023~104077087:+
BRCA	trans	rs9292918	0.95	rs7735655	ENSG00000231752.4	EMBP1	7.01	4.25e-12	3.84e-06	0.31	0.21	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:45309411	chr1:121519112~121571892:+
BRCA	trans	rs12439619	0.693	rs8034801	ENSG00000259295.5	CSPG4P12	-7.01	4.25e-12	3.85e-06	-0.31	-0.21	Intelligence (multi-trait analysis);	chr15:82183996	chr15:85191438~85213905:+
BRCA	trans	rs11098499	0.738	rs28408407	ENSG00000120555.12	SEPT7P9	7.01	4.25e-12	3.85e-06	0.26	0.21	Corneal astigmatism;	chr4:119454875	chr10:38383069~38402916:-
BRCA	trans	rs7260598	0.792	rs73021412	ENSG00000261770.1	CTC-459F4.1	7.01	4.27e-12	3.86e-06	0.36	0.21	Response to taxane treatment (placlitaxel);	chr19:24070755	chr19:27757184~27760849:-
BRCA	trans	rs11098499	0.863	rs1480940	ENSG00000120555.12	SEPT7P9	7.01	4.27e-12	3.86e-06	0.27	0.21	Corneal astigmatism;	chr4:119536527	chr10:38383069~38402916:-
BRCA	trans	rs673253	0.686	rs2842185	ENSG00000231007.5	CDC20P1	-7.01	4.28e-12	3.88e-06	-0.28	-0.21	Intelligence (multi-trait analysis);	chr1:43554060	chr9:87011652~87013151:+
BRCA	trans	rs11122895	0.61	rs13397902	ENSG00000233673.5	ANAPC1P1	7.01	4.29e-12	3.88e-06	0.25	0.21	Allergic sensitization;	chr2:111849928	chr2:86861825~86922693:+
BRCA	trans	rs11098499	0.604	rs10022185	ENSG00000120555.12	SEPT7P9	7.01	4.32e-12	3.91e-06	0.27	0.21	Corneal astigmatism;	chr4:119650610	chr10:38383069~38402916:-
BRCA	trans	rs916888	0.773	rs9896243	ENSG00000204652.6	RPS26P8	7.01	4.32e-12	3.91e-06	0.33	0.21	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:45608571~45608918:+
BRCA	trans	rs12210905	0.688	rs9368509	ENSG00000242375.1	RP11-498P14.3	7.01	4.34e-12	3.93e-06	0.54	0.21	Hip circumference adjusted for BMI;	chr6:27411643	chr9:97195351~97197687:-
BRCA	trans	rs11098499	0.863	rs6534139	ENSG00000120555.12	SEPT7P9	-7.01	4.35e-12	3.93e-06	-0.27	-0.21	Corneal astigmatism;	chr4:119528301	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.954	rs6849171	ENSG00000276997.3	RP11-378J18.9	7.01	4.37e-12	3.95e-06	0.26	0.21	Corneal astigmatism;	chr4:119488394	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.954	rs13107475	ENSG00000276997.3	RP11-378J18.9	7.01	4.39e-12	3.97e-06	0.26	0.21	Corneal astigmatism;	chr4:119471856	chr1:222477252~222504622:-
BRCA	trans	rs616147	0.627	rs9871799	ENSG00000188856.6	RPSAP47	7.01	4.4e-12	3.98e-06	0.27	0.21	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39442829	chr8:80558870~80559757:+
BRCA	trans	rs11098499	1	rs11726229	ENSG00000276997.3	RP11-378J18.9	7.01	4.4e-12	3.98e-06	0.26	0.21	Corneal astigmatism;	chr4:119290425	chr1:222477252~222504622:-
BRCA	trans	rs2288327	0.73	rs16866358	ENSG00000269800.1	PLEKHA3P1	7.01	4.41e-12	3.98e-06	0.33	0.21	Atrial fibrillation;	chr2:178515369	chr19:41521043~41521989:-
BRCA	trans	rs11782517	0.883	rs13267960	ENSG00000253893.2	FAM85B	-7.01	4.41e-12	3.99e-06	-0.34	-0.21	Nose size;	chr8:10249554	chr8:8167819~8226614:-
BRCA	trans	rs801193	1	rs2659909	ENSG00000164669.11	INTS4P1	-7.01	4.42e-12	4e-06	-0.25	-0.21	Aortic root size;	chr7:66695292	chr7:65141225~65234216:+
BRCA	trans	rs17507216	1	rs17507216	ENSG00000235370.6	DNM1P51	7	4.44e-12	4.01e-06	0.28	0.21	Excessive daytime sleepiness;	chr15:82558175	chr15:84398316~84411701:-
BRCA	trans	rs11638815	0.626	rs4779039	ENSG00000235370.6	DNM1P51	7	4.44e-12	4.01e-06	0.23	0.21	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82649016	chr15:84398316~84411701:-
BRCA	trans	rs6940638	0.662	rs6915678	ENSG00000242375.1	RP11-498P14.3	-7	4.45e-12	4.02e-06	-0.3	-0.21	Intelligence (multi-trait analysis);	chr6:27268087	chr9:97195351~97197687:-
BRCA	trans	rs12477438	0.52	rs4850897	ENSG00000276576.1	MRPL30P1	7	4.46e-12	4.03e-06	0.26	0.21	Chronic sinus infection;	chr2:99151956	chr6:57029521~57029988:+
BRCA	trans	rs9581094	0.591	rs118023494	ENSG00000237917.1	PARP4P1	-7	4.46e-12	4.03e-06	-0.48	-0.21	Sudden cardiac arrest;	chr13:24506921	chrY:26594851~26634652:-
BRCA	trans	rs7944735	0.508	rs75334064	ENSG00000134612.10	FOLH1B	7	4.49e-12	4.05e-06	0.39	0.21	Intraocular pressure;	chr11:47738038	chr11:89639227~89698718:+
BRCA	trans	rs864643	0.838	rs58141864	ENSG00000183298.5	RP11-556K13.1	7	4.51e-12	4.07e-06	0.45	0.21	Attention deficit hyperactivity disorder;	chr3:39505344	chr1:101786340~101787219:-
BRCA	trans	rs11098499	0.954	rs4309825	ENSG00000276997.3	RP11-378J18.9	-7	4.51e-12	4.07e-06	-0.26	-0.21	Corneal astigmatism;	chr4:119393726	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.863	rs6858592	ENSG00000120555.12	SEPT7P9	7	4.54e-12	4.1e-06	0.26	0.21	Corneal astigmatism;	chr4:119537537	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.865	rs4001305	ENSG00000120555.12	SEPT7P9	7	4.56e-12	4.12e-06	0.26	0.21	Corneal astigmatism;	chr4:119438081	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.863	rs6833334	ENSG00000120555.12	SEPT7P9	7	4.56e-12	4.12e-06	0.27	0.21	Corneal astigmatism;	chr4:119583072	chr10:38383069~38402916:-
BRCA	trans	rs12477438	0.501	rs11692336	ENSG00000276576.1	MRPL30P1	7	4.6e-12	4.15e-06	0.26	0.21	Chronic sinus infection;	chr2:99124143	chr6:57029521~57029988:+
BRCA	trans	rs12477438	0.52	rs1133978	ENSG00000276576.1	MRPL30P1	7	4.6e-12	4.15e-06	0.26	0.21	Chronic sinus infection;	chr2:99125501	chr6:57029521~57029988:+
BRCA	trans	rs1568889	0.838	rs1525717	ENSG00000174912.7	METTL15P1	7	4.62e-12	4.17e-06	0.21	0.21	Bipolar disorder;	chr11:28059658	chr3:156713884~156714928:-
BRCA	trans	rs1568889	0.838	rs7131379	ENSG00000174912.7	METTL15P1	7	4.62e-12	4.17e-06	0.21	0.21	Bipolar disorder;	chr11:28064242	chr3:156713884~156714928:-
BRCA	trans	rs714543	0.811	rs13238404	ENSG00000234397.3	RP11-415K20.1	7	4.66e-12	4.2e-06	0.24	0.21	Plateletcrit;	chr7:44811812	chr1:22322840~22323331:-
BRCA	trans	rs11098499	0.618	rs35265692	ENSG00000120555.12	SEPT7P9	7	4.68e-12	4.23e-06	0.26	0.21	Corneal astigmatism;	chr4:119403980	chr10:38383069~38402916:-
BRCA	trans	rs6921919	0.945	rs7765989	ENSG00000228078.1	HLA-U	-7	4.7e-12	4.24e-06	-0.34	-0.21	Autism spectrum disorder or schizophrenia;	chr6:28432518	chr6:29934101~29934286:+
BRCA	trans	rs11098499	0.913	rs68128210	ENSG00000120555.12	SEPT7P9	7	4.71e-12	4.25e-06	0.28	0.21	Corneal astigmatism;	chr4:119216664	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.913	rs13126596	ENSG00000120555.12	SEPT7P9	7	4.71e-12	4.25e-06	0.28	0.21	Corneal astigmatism;	chr4:119219574	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.604	rs2389887	ENSG00000120555.12	SEPT7P9	7	4.71e-12	4.25e-06	0.27	0.21	Corneal astigmatism;	chr4:119649489	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.604	rs34278750	ENSG00000120555.12	SEPT7P9	7	4.71e-12	4.25e-06	0.27	0.21	Corneal astigmatism;	chr4:119649981	chr10:38383069~38402916:-
BRCA	trans	rs7833986	0.534	rs17813240	ENSG00000244245.1	RP11-120B7.1	6.99	4.78e-12	4.31e-06	0.27	0.21	Height;	chr8:56013232	chr5:108593609~108593967:+
BRCA	trans	rs60515486	0.527	rs56756748	ENSG00000134612.10	FOLH1B	6.99	4.81e-12	4.34e-06	0.33	0.21	Lymphocyte counts;	chr11:47371017	chr11:89639227~89698718:+
BRCA	trans	rs2243480	1	rs34815098	ENSG00000273142.1	RP11-458F8.4	-6.99	4.83e-12	4.35e-06	-0.29	-0.21	Diabetic kidney disease;	chr7:65827267	chr7:66902857~66906297:+
BRCA	trans	rs2243480	1	rs35735127	ENSG00000273142.1	RP11-458F8.4	-6.99	4.83e-12	4.35e-06	-0.29	-0.21	Diabetic kidney disease;	chr7:65835436	chr7:66902857~66906297:+
BRCA	trans	rs2243480	0.901	rs35256305	ENSG00000273142.1	RP11-458F8.4	-6.99	4.83e-12	4.35e-06	-0.29	-0.21	Diabetic kidney disease;	chr7:65841418	chr7:66902857~66906297:+
BRCA	trans	rs2243480	0.803	rs34004500	ENSG00000273142.1	RP11-458F8.4	-6.99	4.83e-12	4.35e-06	-0.29	-0.21	Diabetic kidney disease;	chr7:65847191	chr7:66902857~66906297:+
BRCA	trans	rs2243480	1	rs35825738	ENSG00000273142.1	RP11-458F8.4	-6.99	4.83e-12	4.35e-06	-0.29	-0.21	Diabetic kidney disease;	chr7:65853040	chr7:66902857~66906297:+
BRCA	trans	rs2235573	0.527	rs139885	ENSG00000258501.1	EIF3LP1	-6.99	4.83e-12	4.36e-06	-0.24	-0.21	Glioma;Glioblastoma;	chr22:37975032	chr14:81916231~81917888:+
BRCA	trans	rs12477438	0.501	rs13008171	ENSG00000276576.1	MRPL30P1	6.99	4.89e-12	4.4e-06	0.26	0.21	Chronic sinus infection;	chr2:99126956	chr6:57029521~57029988:+
BRCA	trans	rs1816752	0.875	rs17384871	ENSG00000224976.2	PARP4P2	-6.99	4.89e-12	4.4e-06	-0.27	-0.21	Obesity-related traits;	chr13:24484959	chr13:19349137~19407962:+
BRCA	trans	rs714543	0.585	rs9655458	ENSG00000234397.3	RP11-415K20.1	6.99	4.91e-12	4.42e-06	0.24	0.21	Plateletcrit;	chr7:44771386	chr1:22322840~22323331:-
BRCA	trans	rs11098499	0.82	rs28578366	ENSG00000120555.12	SEPT7P9	-6.99	4.92e-12	4.43e-06	-0.26	-0.21	Corneal astigmatism;	chr4:119615750	chr10:38383069~38402916:-
BRCA	trans	rs853679	0.546	rs13214023	ENSG00000281831.1	HCP5B	-6.99	4.94e-12	4.45e-06	-0.48	-0.21	Depression;	chr6:28364364	chr6:29871895~29873783:-
BRCA	trans	rs2243480	0.803	rs35480979	ENSG00000273142.1	RP11-458F8.4	-6.99	4.96e-12	4.47e-06	-0.29	-0.21	Diabetic kidney disease;	chr7:65892097	chr7:66902857~66906297:+
BRCA	trans	rs2243480	1	rs35391607	ENSG00000273142.1	RP11-458F8.4	-6.99	4.96e-12	4.47e-06	-0.29	-0.21	Diabetic kidney disease;	chr7:65895842	chr7:66902857~66906297:+
BRCA	trans	rs2243480	1	rs13220979	ENSG00000273142.1	RP11-458F8.4	-6.99	4.96e-12	4.47e-06	-0.29	-0.21	Diabetic kidney disease;	chr7:65898217	chr7:66902857~66906297:+
BRCA	trans	rs2243480	1	rs34974928	ENSG00000273142.1	RP11-458F8.4	-6.99	4.96e-12	4.47e-06	-0.29	-0.21	Diabetic kidney disease;	chr7:65899019	chr7:66902857~66906297:+
BRCA	trans	rs9467711	0.675	rs58825580	ENSG00000253570.1	RNF5P1	6.99	4.97e-12	4.47e-06	0.48	0.21	Autism spectrum disorder or schizophrenia;	chr6:26365451	chr8:38600661~38601200:-
BRCA	trans	rs11098499	0.863	rs9884402	ENSG00000120555.12	SEPT7P9	6.99	4.98e-12	4.48e-06	0.26	0.21	Corneal astigmatism;	chr4:119568827	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.731	rs9995026	ENSG00000120555.12	SEPT7P9	6.99	4.98e-12	4.48e-06	0.26	0.21	Corneal astigmatism;	chr4:119569344	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.874	rs17839089	ENSG00000120555.12	SEPT7P9	6.99	4.99e-12	4.5e-06	0.28	0.21	Corneal astigmatism;	chr4:119189914	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.874	rs6826823	ENSG00000120555.12	SEPT7P9	6.99	4.99e-12	4.5e-06	0.28	0.21	Corneal astigmatism;	chr4:119190943	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.874	rs12509054	ENSG00000120555.12	SEPT7P9	6.99	4.99e-12	4.5e-06	0.28	0.21	Corneal astigmatism;	chr4:119193920	chr10:38383069~38402916:-
BRCA	trans	rs1707322	0.752	rs4660313	ENSG00000255397.1	AC022182.2	6.99	5.02e-12	4.52e-06	0.28	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45645169	chr8:60937705~60939871:-
BRCA	trans	rs12439619	0.768	rs28694364	ENSG00000259295.5	CSPG4P12	-6.99	5.06e-12	4.56e-06	-0.33	-0.21	Intelligence (multi-trait analysis);	chr15:82208119	chr15:85191438~85213905:+
BRCA	trans	rs12477438	0.501	rs11688004	ENSG00000276576.1	MRPL30P1	6.99	5.07e-12	4.56e-06	0.26	0.21	Chronic sinus infection;	chr2:99118589	chr6:57029521~57029988:+
BRCA	trans	rs12477438	0.501	rs17759607	ENSG00000276576.1	MRPL30P1	6.99	5.07e-12	4.56e-06	0.26	0.21	Chronic sinus infection;	chr2:99120542	chr6:57029521~57029988:+
BRCA	trans	rs6915893	0.74	rs9477622	ENSG00000267156.1	TPMTP1	-6.98	5.07e-12	4.57e-06	-0.27	-0.21	Intrinsic epigenetic age acceleration;	chr6:18103430	chr18:47630112~47630848:+
BRCA	trans	rs11098499	0.697	rs11941899	ENSG00000120555.12	SEPT7P9	6.98	5.12e-12	4.61e-06	0.26	0.21	Corneal astigmatism;	chr4:119461603	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.909	rs7681978	ENSG00000120555.12	SEPT7P9	6.98	5.12e-12	4.61e-06	0.26	0.21	Corneal astigmatism;	chr4:119462620	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.821	rs28665282	ENSG00000120555.12	SEPT7P9	6.98	5.12e-12	4.61e-06	0.26	0.21	Corneal astigmatism;	chr4:119463031	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.738	rs10026493	ENSG00000120555.12	SEPT7P9	6.98	5.12e-12	4.61e-06	0.26	0.21	Corneal astigmatism;	chr4:119463039	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.909	rs7681214	ENSG00000120555.12	SEPT7P9	6.98	5.12e-12	4.61e-06	0.26	0.21	Corneal astigmatism;	chr4:119464165	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.909	rs28632018	ENSG00000120555.12	SEPT7P9	6.98	5.12e-12	4.61e-06	0.26	0.21	Corneal astigmatism;	chr4:119465575	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.908	rs71614449	ENSG00000120555.12	SEPT7P9	6.98	5.12e-12	4.61e-06	0.26	0.21	Corneal astigmatism;	chr4:119465900	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.954	rs35063680	ENSG00000120555.12	SEPT7P9	6.98	5.12e-12	4.61e-06	0.26	0.21	Corneal astigmatism;	chr4:119465947	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.954	rs34858317	ENSG00000120555.12	SEPT7P9	6.98	5.12e-12	4.61e-06	0.26	0.21	Corneal astigmatism;	chr4:119465955	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.954	rs17046116	ENSG00000120555.12	SEPT7P9	6.98	5.12e-12	4.61e-06	0.26	0.21	Corneal astigmatism;	chr4:119466104	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.909	rs17046118	ENSG00000120555.12	SEPT7P9	6.98	5.12e-12	4.61e-06	0.26	0.21	Corneal astigmatism;	chr4:119466341	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.954	rs7654587	ENSG00000120555.12	SEPT7P9	6.98	5.12e-12	4.61e-06	0.26	0.21	Corneal astigmatism;	chr4:119467251	chr10:38383069~38402916:-
BRCA	trans	rs853679	0.546	rs36092177	ENSG00000228078.1	HLA-U	-6.98	5.15e-12	4.63e-06	-0.56	-0.21	Depression;	chr6:28390030	chr6:29934101~29934286:+
BRCA	trans	rs853679	0.546	rs2232429	ENSG00000228078.1	HLA-U	-6.98	5.15e-12	4.63e-06	-0.56	-0.21	Depression;	chr6:28391855	chr6:29934101~29934286:+
BRCA	trans	rs853679	0.546	rs2232426	ENSG00000228078.1	HLA-U	-6.98	5.15e-12	4.63e-06	-0.56	-0.21	Depression;	chr6:28392882	chr6:29934101~29934286:+
BRCA	trans	rs853679	0.546	rs2232423	ENSG00000228078.1	HLA-U	-6.98	5.15e-12	4.63e-06	-0.56	-0.21	Depression;	chr6:28398374	chr6:29934101~29934286:+
BRCA	trans	rs12477438	0.501	rs1133977	ENSG00000276576.1	MRPL30P1	-6.98	5.19e-12	4.67e-06	-0.26	-0.21	Chronic sinus infection;	chr2:99125521	chr6:57029521~57029988:+
BRCA	trans	rs17507216	1	rs3850610	ENSG00000259295.5	CSPG4P12	6.98	5.21e-12	4.68e-06	0.29	0.21	Excessive daytime sleepiness;	chr15:82552642	chr15:85191438~85213905:+
BRCA	trans	rs4879656	0.564	rs2183870	ENSG00000215007.3	DNAJA1P3	-6.98	5.23e-12	4.7e-06	-0.25	-0.21	Menopause (age at onset);	chr9:32994502	chrX:107351650~107352843:-
BRCA	trans	rs11098499	0.863	rs7664986	ENSG00000276997.3	RP11-378J18.9	6.98	5.23e-12	4.7e-06	0.26	0.21	Corneal astigmatism;	chr4:119508797	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.818	rs10008791	ENSG00000276997.3	RP11-378J18.9	6.98	5.23e-12	4.7e-06	0.26	0.21	Corneal astigmatism;	chr4:119510314	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.863	rs11736416	ENSG00000276997.3	RP11-378J18.9	6.98	5.23e-12	4.7e-06	0.26	0.21	Corneal astigmatism;	chr4:119510506	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.913	rs10006304	ENSG00000120555.12	SEPT7P9	6.98	5.25e-12	4.71e-06	0.28	0.21	Corneal astigmatism;	chr4:119203150	chr10:38383069~38402916:-
BRCA	trans	rs67340775	0.541	rs200979	ENSG00000204709.4	LINC01556	6.98	5.25e-12	4.72e-06	0.36	0.21	Lung cancer in ever smokers;	chr6:27884579	chr6:28943877~28944537:+
BRCA	trans	rs11098499	0.863	rs2306457	ENSG00000120555.12	SEPT7P9	6.98	5.28e-12	4.74e-06	0.26	0.21	Corneal astigmatism;	chr4:119551684	chr10:38383069~38402916:-
BRCA	trans	rs67340775	0.541	rs200973	ENSG00000204709.4	LINC01556	6.98	5.28e-12	4.74e-06	0.35	0.21	Lung cancer in ever smokers;	chr6:27890643	chr6:28943877~28944537:+
BRCA	trans	rs9650657	0.623	rs6601517	ENSG00000253893.2	FAM85B	6.98	5.3e-12	4.76e-06	0.26	0.21	Neuroticism;	chr8:10746283	chr8:8167819~8226614:-
BRCA	trans	rs11098499	0.754	rs1814813	ENSG00000276997.3	RP11-378J18.9	-6.98	5.3e-12	4.76e-06	-0.24	-0.21	Corneal astigmatism;	chr4:119337052	chr1:222477252~222504622:-
BRCA	trans	rs14057	0.832	rs12567649	ENSG00000215869.3	RP11-364B6.1	6.98	5.33e-12	4.78e-06	0.3	0.21	Systolic blood pressure;	chr1:6700137	chr1:104073023~104077087:+
BRCA	trans	rs11098499	0.874	rs10022508	ENSG00000120555.12	SEPT7P9	6.98	5.33e-12	4.79e-06	0.28	0.21	Corneal astigmatism;	chr4:119194073	chr10:38383069~38402916:-
BRCA	trans	rs14057	0.864	rs3761925	ENSG00000215869.3	RP11-364B6.1	6.98	5.33e-12	4.79e-06	0.3	0.21	Systolic blood pressure;	chr1:6701642	chr1:104073023~104077087:+
BRCA	trans	rs11098499	0.954	rs10034623	ENSG00000276997.3	RP11-378J18.9	6.98	5.33e-12	4.79e-06	0.26	0.21	Corneal astigmatism;	chr4:119476674	chr1:222477252~222504622:-
BRCA	trans	rs14057	0.864	rs34559878	ENSG00000215869.3	RP11-364B6.1	6.98	5.37e-12	4.82e-06	0.3	0.21	Systolic blood pressure;	chr1:6699035	chr1:104073023~104077087:+
BRCA	trans	rs9581094	0.591	rs55991110	ENSG00000237917.1	PARP4P1	-6.98	5.41e-12	4.86e-06	-0.47	-0.21	Sudden cardiac arrest;	chr13:24490190	chrY:26594851~26634652:-
BRCA	trans	rs4713118	0.568	rs9468213	ENSG00000204709.4	LINC01556	6.97	5.43e-12	4.88e-06	0.27	0.21	Parkinson's disease;	chr6:27738401	chr6:28943877~28944537:+
BRCA	trans	rs11098499	0.874	rs13123591	ENSG00000120555.12	SEPT7P9	6.97	5.45e-12	4.89e-06	0.28	0.21	Corneal astigmatism;	chr4:119184835	chr10:38383069~38402916:-
BRCA	trans	rs7833986	0.501	rs2719226	ENSG00000244245.1	RP11-120B7.1	6.97	5.46e-12	4.9e-06	0.27	0.21	Height;	chr8:56131507	chr5:108593609~108593967:+
BRCA	trans	rs11098499	0.78	rs12504773	ENSG00000276997.3	RP11-378J18.9	6.97	5.52e-12	4.95e-06	0.27	0.21	Corneal astigmatism;	chr4:119640994	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.874	rs6851169	ENSG00000120555.12	SEPT7P9	6.97	5.52e-12	4.95e-06	0.28	0.21	Corneal astigmatism;	chr4:119196355	chr10:38383069~38402916:-
BRCA	trans	rs12439619	0.693	rs7165536	ENSG00000259295.5	CSPG4P12	-6.97	5.53e-12	4.96e-06	-0.31	-0.21	Intelligence (multi-trait analysis);	chr15:82273743	chr15:85191438~85213905:+
BRCA	trans	rs11098499	0.863	rs59732491	ENSG00000120555.12	SEPT7P9	6.97	5.53e-12	4.96e-06	0.27	0.21	Corneal astigmatism;	chr4:119568433	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.863	rs11723090	ENSG00000120555.12	SEPT7P9	6.97	5.53e-12	4.96e-06	0.27	0.21	Corneal astigmatism;	chr4:119569437	chr10:38383069~38402916:-
BRCA	trans	rs1991651	0.578	rs11778453	ENSG00000253893.2	FAM85B	6.97	5.56e-12	4.98e-06	0.27	0.21	Sum neutrophil eosinophil counts;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Granulocyte count;	chr8:10632326	chr8:8167819~8226614:-
BRCA	trans	rs7824557	0.767	rs10104728	ENSG00000270154.1	RP11-419I17.1	6.97	5.66e-12	5.08e-06	0.27	0.21	Retinal vascular caliber;	chr8:11313791	chr8:12476462~12477122:+
BRCA	trans	rs6921919	0.887	rs16894116	ENSG00000228078.1	HLA-U	-6.97	5.67e-12	5.09e-06	-0.34	-0.21	Autism spectrum disorder or schizophrenia;	chr6:28447190	chr6:29934101~29934286:+
BRCA	trans	rs11098499	0.909	rs28555550	ENSG00000276997.3	RP11-378J18.9	6.97	5.71e-12	5.12e-06	0.26	0.21	Corneal astigmatism;	chr4:119289885	chr1:222477252~222504622:-
BRCA	trans	rs11098499	1	rs28419773	ENSG00000276997.3	RP11-378J18.9	6.97	5.71e-12	5.12e-06	0.26	0.21	Corneal astigmatism;	chr4:119289906	chr1:222477252~222504622:-
BRCA	trans	rs2235573	0.527	rs139883	ENSG00000258501.1	EIF3LP1	-6.97	5.72e-12	5.12e-06	-0.24	-0.21	Glioma;Glioblastoma;	chr22:37973020	chr14:81916231~81917888:+
BRCA	trans	rs853679	0.546	rs35017208	ENSG00000228078.1	HLA-U	-6.97	5.75e-12	5.15e-06	-0.56	-0.21	Depression;	chr6:28377505	chr6:29934101~29934286:+
BRCA	trans	rs9468199	0.51	rs72847322	ENSG00000242375.1	RP11-498P14.3	-6.97	5.76e-12	5.16e-06	-0.62	-0.21	Parkinson's disease;	chr6:27772275	chr9:97195351~97197687:-
BRCA	trans	rs17507216	1	rs17507216	ENSG00000259295.5	CSPG4P12	6.97	5.79e-12	5.18e-06	0.31	0.21	Excessive daytime sleepiness;	chr15:82558175	chr15:85191438~85213905:+
BRCA	trans	rs12477438	0.501	rs12619780	ENSG00000276576.1	MRPL30P1	6.97	5.8e-12	5.19e-06	0.26	0.21	Chronic sinus infection;	chr2:99090844	chr6:57029521~57029988:+
BRCA	trans	rs11098499	0.863	rs3775841	ENSG00000120555.12	SEPT7P9	6.97	5.8e-12	5.19e-06	0.26	0.21	Corneal astigmatism;	chr4:119504622	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.909	rs1809406	ENSG00000120555.12	SEPT7P9	6.96	5.81e-12	5.2e-06	0.26	0.21	Corneal astigmatism;	chr4:119455967	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.865	rs2389809	ENSG00000120555.12	SEPT7P9	6.96	5.81e-12	5.2e-06	0.26	0.21	Corneal astigmatism;	chr4:119456244	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.909	rs9994810	ENSG00000120555.12	SEPT7P9	6.96	5.81e-12	5.2e-06	0.26	0.21	Corneal astigmatism;	chr4:119460435	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.697	rs10020027	ENSG00000120555.12	SEPT7P9	6.96	5.81e-12	5.2e-06	0.26	0.21	Corneal astigmatism;	chr4:119460724	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.779	rs7356491	ENSG00000120555.12	SEPT7P9	6.96	5.81e-12	5.2e-06	0.26	0.21	Corneal astigmatism;	chr4:119460819	chr10:38383069~38402916:-
BRCA	trans	rs2235573	0.527	rs139887	ENSG00000258501.1	EIF3LP1	-6.96	5.84e-12	5.22e-06	-0.24	-0.21	Glioma;Glioblastoma;	chr22:37975389	chr14:81916231~81917888:+
BRCA	trans	rs11098499	0.954	rs6849561	ENSG00000120555.12	SEPT7P9	-6.96	5.84e-12	5.23e-06	-0.27	-0.21	Corneal astigmatism;	chr4:119488539	chr10:38383069~38402916:-
BRCA	trans	rs6981523	0.553	rs11989369	ENSG00000253893.2	FAM85B	-6.96	5.84e-12	5.23e-06	-0.3	-0.21	Neuroticism;	chr8:11197876	chr8:8167819~8226614:-
BRCA	trans	rs11098499	0.908	rs28559989	ENSG00000120555.12	SEPT7P9	6.96	5.88e-12	5.26e-06	0.26	0.21	Corneal astigmatism;	chr4:119465472	chr10:38383069~38402916:-
BRCA	trans	rs6921919	0.945	rs61289879	ENSG00000228078.1	HLA-U	-6.96	5.88e-12	5.26e-06	-0.34	-0.21	Autism spectrum disorder or schizophrenia;	chr6:28451385	chr6:29934101~29934286:+
BRCA	trans	rs804280	0.509	rs12719915	ENSG00000253893.2	FAM85B	6.96	5.94e-12	5.31e-06	0.27	0.21	Myopia (pathological);	chr8:11928746	chr8:8167819~8226614:-
BRCA	trans	rs9467711	0.606	rs9358932	ENSG00000253570.1	RNF5P1	-6.96	5.96e-12	5.33e-06	-0.49	-0.21	Autism spectrum disorder or schizophrenia;	chr6:26362477	chr8:38600661~38601200:-
BRCA	trans	rs673253	0.581	rs11210860	ENSG00000231007.5	CDC20P1	-6.96	5.99e-12	5.36e-06	-0.27	-0.21	Intelligence (multi-trait analysis);	chr1:43516856	chr9:87011652~87013151:+
BRCA	trans	rs2235573	0.527	rs139865	ENSG00000258501.1	EIF3LP1	-6.96	6.03e-12	5.39e-06	-0.24	-0.21	Glioma;Glioblastoma;	chr22:37957925	chr14:81916231~81917888:+
BRCA	trans	rs11098499	0.874	rs6822498	ENSG00000120555.12	SEPT7P9	6.96	6.03e-12	5.4e-06	0.28	0.21	Corneal astigmatism;	chr4:119199028	chr10:38383069~38402916:-
BRCA	trans	rs7903456	0.648	rs9420431	ENSG00000232706.3	NUTM2HP	6.96	6.04e-12	5.4e-06	0.3	0.21	Gout;Renal underexcretion gout;	chr10:87067639	chr10:50676743~50686326:+
BRCA	trans	rs9467711	0.606	rs9379897	ENSG00000253570.1	RNF5P1	6.96	6.1e-12	5.45e-06	0.47	0.21	Autism spectrum disorder or schizophrenia;	chr6:26601298	chr8:38600661~38601200:-
BRCA	trans	rs9467711	0.606	rs28360517	ENSG00000253570.1	RNF5P1	6.96	6.1e-12	5.45e-06	0.47	0.21	Autism spectrum disorder or schizophrenia;	chr6:26602225	chr8:38600661~38601200:-
BRCA	trans	rs7169223	0.653	rs3743057	ENSG00000274376.3	ADAMTS7P1	6.96	6.17e-12	5.51e-06	0.28	0.21	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78796665	chr15:82298553~82334609:+
BRCA	trans	rs11098499	0.78	rs7680914	ENSG00000276997.3	RP11-378J18.9	6.96	6.19e-12	5.53e-06	0.27	0.21	Corneal astigmatism;	chr4:119641898	chr1:222477252~222504622:-
BRCA	trans	rs3806843	0.576	rs251368	ENSG00000231043.3	AC007238.1	6.96	6.19e-12	5.53e-06	0.26	0.21	Depressive symptoms (multi-trait analysis);	chr5:140861442	chr2:58460292~58462032:-
BRCA	trans	rs853679	0.607	rs72846780	ENSG00000281831.1	HCP5B	6.96	6.19e-12	5.53e-06	0.55	0.21	Depression;	chr6:28151277	chr6:29871895~29873783:-
BRCA	trans	rs853679	0.607	rs13205911	ENSG00000281831.1	HCP5B	6.96	6.19e-12	5.53e-06	0.55	0.21	Depression;	chr6:28156336	chr6:29871895~29873783:-
BRCA	trans	rs853679	0.607	rs13197176	ENSG00000281831.1	HCP5B	6.96	6.19e-12	5.53e-06	0.55	0.21	Depression;	chr6:28161454	chr6:29871895~29873783:-
BRCA	trans	rs853679	0.607	rs13201308	ENSG00000281831.1	HCP5B	6.96	6.19e-12	5.53e-06	0.55	0.21	Depression;	chr6:28162311	chr6:29871895~29873783:-
BRCA	trans	rs853679	0.607	rs34505829	ENSG00000281831.1	HCP5B	6.96	6.19e-12	5.53e-06	0.55	0.21	Depression;	chr6:28165461	chr6:29871895~29873783:-
BRCA	trans	rs853679	0.607	rs35098436	ENSG00000281831.1	HCP5B	6.96	6.19e-12	5.53e-06	0.55	0.21	Depression;	chr6:28166443	chr6:29871895~29873783:-
BRCA	trans	rs853679	0.607	rs72846794	ENSG00000281831.1	HCP5B	6.96	6.19e-12	5.53e-06	0.55	0.21	Depression;	chr6:28169721	chr6:29871895~29873783:-
BRCA	trans	rs853679	0.607	rs13217984	ENSG00000281831.1	HCP5B	6.96	6.19e-12	5.53e-06	0.55	0.21	Depression;	chr6:28171932	chr6:29871895~29873783:-
BRCA	trans	rs853679	0.505	rs35781323	ENSG00000281831.1	HCP5B	6.96	6.19e-12	5.53e-06	0.55	0.21	Depression;	chr6:28177054	chr6:29871895~29873783:-
BRCA	trans	rs11098499	0.865	rs4001305	ENSG00000276997.3	RP11-378J18.9	6.95	6.22e-12	5.56e-06	0.26	0.21	Corneal astigmatism;	chr4:119438081	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.82	rs13122709	ENSG00000276997.3	RP11-378J18.9	6.95	6.27e-12	5.6e-06	0.26	0.21	Corneal astigmatism;	chr4:119634201	chr1:222477252~222504622:-
BRCA	trans	rs9581094	0.591	rs73154380	ENSG00000237917.1	PARP4P1	-6.95	6.28e-12	5.61e-06	-0.47	-0.21	Sudden cardiac arrest;	chr13:24500588	chrY:26594851~26634652:-
BRCA	trans	rs9581094	0.591	rs17385717	ENSG00000237917.1	PARP4P1	-6.95	6.28e-12	5.61e-06	-0.47	-0.21	Sudden cardiac arrest;	chr13:24500881	chrY:26594851~26634652:-
BRCA	trans	rs1933488	0.965	rs13215402	ENSG00000278974.1	RP11-756P10.6	-6.95	6.32e-12	5.64e-06	-0.27	-0.21	Prostate cancer;	chr6:153126415	chr4:188740507~188741281:-
BRCA	trans	rs17767294	0.708	rs72851182	ENSG00000242375.1	RP11-498P14.3	-6.95	6.34e-12	5.65e-06	-0.61	-0.21	Parkinson's disease;	chr6:28138921	chr9:97195351~97197687:-
BRCA	trans	rs17767294	0.708	rs75543204	ENSG00000242375.1	RP11-498P14.3	-6.95	6.34e-12	5.65e-06	-0.61	-0.21	Parkinson's disease;	chr6:28141038	chr9:97195351~97197687:-
BRCA	trans	rs11098499	0.874	rs6832670	ENSG00000120555.12	SEPT7P9	6.95	6.34e-12	5.65e-06	0.27	0.21	Corneal astigmatism;	chr4:119197637	chr10:38383069~38402916:-
BRCA	trans	rs1023500	1	rs1023499	ENSG00000268568.1	AC007228.9	-6.95	6.38e-12	5.69e-06	-0.31	-0.21	Schizophrenia;	chr22:41944578	chr19:56672574~56673901:-
BRCA	trans	rs2002594	0.714	rs9857710	ENSG00000267076.1	CCDC58P3	-6.95	6.4e-12	5.71e-06	-0.24	-0.21	Risky sexual behaviors (alcohol dependence interaction);	chr3:122362813	chr18:12211378~12211807:+
BRCA	trans	rs1707322	0.927	rs6690386	ENSG00000255397.1	AC022182.2	-6.95	6.47e-12	5.77e-06	-0.28	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45787339	chr8:60937705~60939871:-
BRCA	trans	rs853679	0.607	rs67040724	ENSG00000281831.1	HCP5B	6.95	6.49e-12	5.79e-06	0.54	0.21	Depression;	chr6:27937731	chr6:29871895~29873783:-
BRCA	trans	rs17767294	0.708	rs72847323	ENSG00000242375.1	RP11-498P14.3	-6.95	6.5e-12	5.79e-06	-0.62	-0.21	Parkinson's disease;	chr6:27776711	chr9:97195351~97197687:-
BRCA	trans	rs9834975	0.565	rs1961957	ENSG00000267076.1	CCDC58P3	-6.95	6.57e-12	5.85e-06	-0.24	-0.21	Diastolic blood pressure;	chr3:122385275	chr18:12211378~12211807:+
BRCA	trans	rs673253	0.686	rs3791136	ENSG00000231007.5	CDC20P1	6.95	6.59e-12	5.87e-06	0.27	0.21	Intelligence (multi-trait analysis);	chr1:43584276	chr9:87011652~87013151:+
BRCA	trans	rs72615157	0.539	rs12673441	ENSG00000228546.2	CTA-313A17.3	6.95	6.59e-12	5.87e-06	0.3	0.21	Lung function (FEV1/FVC);	chr7:100072705	chr7:102337316~102339115:+
BRCA	trans	rs3747547	0.591	rs12345012	ENSG00000229007.1	EXOSC3P1	-6.95	6.63e-12	5.9e-06	-0.37	-0.21	Metabolite levels (Dihydroxy docosatrienoic acid);	chr9:37902489	chr21:32496812~32497311:+
BRCA	trans	rs12210905	0.565	rs2393805	ENSG00000242375.1	RP11-498P14.3	-6.95	6.64e-12	5.92e-06	-0.46	-0.21	Hip circumference adjusted for BMI;	chr6:26860885	chr9:97195351~97197687:-
BRCA	trans	rs4911259	0.513	rs4287835	ENSG00000253915.1	MAPRE1P1	-6.95	6.65e-12	5.92e-06	-0.25	-0.21	Inflammatory bowel disease;	chr20:32869531	chr8:135625185~135625981:-
BRCA	trans	rs1707322	1	rs1612419	ENSG00000255397.1	AC022182.2	6.94	6.66e-12	5.93e-06	0.28	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46081273	chr8:60937705~60939871:-
BRCA	trans	rs6921919	0.945	rs16901847	ENSG00000228078.1	HLA-U	-6.94	6.69e-12	5.95e-06	-0.33	-0.21	Autism spectrum disorder or schizophrenia;	chr6:28408074	chr6:29934101~29934286:+
BRCA	trans	rs801193	0.967	rs34356500	ENSG00000164669.11	INTS4P1	-6.94	6.69e-12	5.96e-06	-0.25	-0.21	Aortic root size;	chr7:66771620	chr7:65141225~65234216:+
BRCA	trans	rs12477438	0.52	rs2516830	ENSG00000276576.1	MRPL30P1	6.94	6.69e-12	5.96e-06	0.26	0.21	Chronic sinus infection;	chr2:99157239	chr6:57029521~57029988:+
BRCA	trans	rs12477438	0.52	rs2632283	ENSG00000276576.1	MRPL30P1	6.94	6.69e-12	5.96e-06	0.26	0.21	Chronic sinus infection;	chr2:99159537	chr6:57029521~57029988:+
BRCA	trans	rs12477438	0.501	rs2516833	ENSG00000276576.1	MRPL30P1	6.94	6.69e-12	5.96e-06	0.26	0.21	Chronic sinus infection;	chr2:99160942	chr6:57029521~57029988:+
BRCA	trans	rs12477438	0.52	rs2516835	ENSG00000276576.1	MRPL30P1	6.94	6.69e-12	5.96e-06	0.26	0.21	Chronic sinus infection;	chr2:99162668	chr6:57029521~57029988:+
BRCA	trans	rs12477438	0.501	rs7608938	ENSG00000276576.1	MRPL30P1	6.94	6.69e-12	5.96e-06	0.26	0.21	Chronic sinus infection;	chr2:99165763	chr6:57029521~57029988:+
BRCA	trans	rs12477438	0.501	rs6542868	ENSG00000276576.1	MRPL30P1	6.94	6.69e-12	5.96e-06	0.26	0.21	Chronic sinus infection;	chr2:99166385	chr6:57029521~57029988:+
BRCA	trans	rs12477438	0.501	rs6727749	ENSG00000276576.1	MRPL30P1	6.94	6.69e-12	5.96e-06	0.26	0.21	Chronic sinus infection;	chr2:99177127	chr6:57029521~57029988:+
BRCA	trans	rs12477438	0.501	rs13033012	ENSG00000276576.1	MRPL30P1	6.94	6.69e-12	5.96e-06	0.26	0.21	Chronic sinus infection;	chr2:99178686	chr6:57029521~57029988:+
BRCA	trans	rs12477438	0.501	rs13000731	ENSG00000276576.1	MRPL30P1	6.94	6.69e-12	5.96e-06	0.26	0.21	Chronic sinus infection;	chr2:99178768	chr6:57029521~57029988:+
BRCA	trans	rs902774	0.818	rs4919740	ENSG00000230716.3	KRT8P7	-6.94	6.7e-12	5.97e-06	-0.38	-0.21	Prostate cancer;	chr12:52877187	chr11:119602875~119604306:-
BRCA	trans	rs11098499	0.604	rs2389886	ENSG00000120555.12	SEPT7P9	6.94	6.78e-12	6.03e-06	0.27	0.21	Corneal astigmatism;	chr4:119649267	chr10:38383069~38402916:-
BRCA	trans	rs1707322	0.752	rs11211145	ENSG00000255397.1	AC022182.2	-6.94	6.84e-12	6.09e-06	-0.28	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45642819	chr8:60937705~60939871:-
BRCA	trans	rs2060793	1	rs2060793	ENSG00000236360.2	RP11-334A14.2	6.94	6.86e-12	6.1e-06	0.27	0.21	Vitamin D levels;	chr11:14893764	chr1:52993201~52993702:-
BRCA	trans	rs11098499	0.604	rs12642411	ENSG00000120555.12	SEPT7P9	6.94	6.87e-12	6.11e-06	0.28	0.21	Corneal astigmatism;	chr4:119659370	chr10:38383069~38402916:-
BRCA	trans	rs17507216	0.718	rs4779033	ENSG00000259295.5	CSPG4P12	6.94	6.9e-12	6.14e-06	0.34	0.21	Excessive daytime sleepiness;	chr15:82576634	chr15:85191438~85213905:+
BRCA	trans	rs11098499	0.821	rs10032151	ENSG00000120555.12	SEPT7P9	6.94	6.91e-12	6.14e-06	0.26	0.21	Corneal astigmatism;	chr4:119470473	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.865	rs10032158	ENSG00000120555.12	SEPT7P9	6.94	6.91e-12	6.14e-06	0.26	0.21	Corneal astigmatism;	chr4:119470477	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.909	rs79026312	ENSG00000120555.12	SEPT7P9	6.94	6.91e-12	6.14e-06	0.27	0.21	Corneal astigmatism;	chr4:119519522	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.909	rs35111518	ENSG00000120555.12	SEPT7P9	6.94	6.91e-12	6.14e-06	0.27	0.21	Corneal astigmatism;	chr4:119519527	chr10:38383069~38402916:-
BRCA	trans	rs7833986	0.501	rs2719258	ENSG00000244245.1	RP11-120B7.1	6.94	6.95e-12	6.18e-06	0.26	0.21	Height;	chr8:56028830	chr5:108593609~108593967:+
BRCA	trans	rs7833986	0.501	rs2719259	ENSG00000244245.1	RP11-120B7.1	6.94	6.95e-12	6.18e-06	0.26	0.21	Height;	chr8:56029071	chr5:108593609~108593967:+
BRCA	trans	rs673253	0.662	rs11210869	ENSG00000231007.5	CDC20P1	6.94	6.96e-12	6.19e-06	0.27	0.21	Intelligence (multi-trait analysis);	chr1:43560369	chr9:87011652~87013151:+
BRCA	trans	rs1933488	0.931	rs6934121	ENSG00000278974.1	RP11-756P10.6	-6.94	6.97e-12	6.2e-06	-0.27	-0.21	Prostate cancer;	chr6:153127117	chr4:188740507~188741281:-
BRCA	trans	rs673253	0.686	rs6698389	ENSG00000231007.5	CDC20P1	6.94	7e-12	6.22e-06	0.27	0.21	Intelligence (multi-trait analysis);	chr1:43585903	chr9:87011652~87013151:+
BRCA	trans	rs11098499	0.82	rs11737395	ENSG00000276997.3	RP11-378J18.9	6.94	7.04e-12	6.26e-06	0.26	0.21	Corneal astigmatism;	chr4:119599549	chr1:222477252~222504622:-
BRCA	trans	rs11098499	1	rs13435802	ENSG00000120555.12	SEPT7P9	-6.94	7.05e-12	6.26e-06	-0.26	-0.21	Corneal astigmatism;	chr4:119256805	chr10:38383069~38402916:-
BRCA	trans	rs9467603	1	rs9467600	ENSG00000253570.1	RNF5P1	6.94	7.06e-12	6.27e-06	0.54	0.21	Intelligence (multi-trait analysis);	chr6:25792540	chr8:38600661~38601200:-
BRCA	trans	rs9834975	0.605	rs6810306	ENSG00000267076.1	CCDC58P3	6.94	7.12e-12	6.32e-06	0.24	0.21	Diastolic blood pressure;	chr3:122529863	chr18:12211378~12211807:+
BRCA	trans	rs7169223	0.653	rs3971703	ENSG00000274376.3	ADAMTS7P1	6.93	7.23e-12	6.42e-06	0.27	0.21	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78800139	chr15:82298553~82334609:+
BRCA	trans	rs2122469	0.655	rs17603934	ENSG00000272240.1	RP5-855D21.1	6.93	7.24e-12	6.43e-06	0.29	0.21	Serum tamsulosin hydrochloride concentration;	chr8:20718833	chr8:234347~234887:-
BRCA	trans	rs7260598	0.792	rs17620072	ENSG00000261770.1	CTC-459F4.1	6.93	7.31e-12	6.49e-06	0.36	0.21	Response to taxane treatment (placlitaxel);	chr19:24177850	chr19:27757184~27760849:-
BRCA	trans	rs7260598	0.792	rs73031010	ENSG00000261770.1	CTC-459F4.1	6.93	7.31e-12	6.49e-06	0.36	0.21	Response to taxane treatment (placlitaxel);	chr19:24178160	chr19:27757184~27760849:-
BRCA	trans	rs7260598	0.792	rs7260592	ENSG00000261770.1	CTC-459F4.1	6.93	7.31e-12	6.49e-06	0.36	0.21	Response to taxane treatment (placlitaxel);	chr19:24178786	chr19:27757184~27760849:-
BRCA	trans	rs17767294	0.708	rs72845896	ENSG00000242375.1	RP11-498P14.3	-6.93	7.38e-12	6.55e-06	-0.61	-0.21	Parkinson's disease;	chr6:27729866	chr9:97195351~97197687:-
BRCA	trans	rs17767294	0.708	rs72845897	ENSG00000242375.1	RP11-498P14.3	-6.93	7.38e-12	6.55e-06	-0.61	-0.21	Parkinson's disease;	chr6:27731578	chr9:97195351~97197687:-
BRCA	trans	rs1707322	0.821	rs10749857	ENSG00000255397.1	AC022182.2	-6.93	7.49e-12	6.65e-06	-0.28	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45782471	chr8:60937705~60939871:-
BRCA	trans	rs11098499	0.863	rs34868248	ENSG00000120555.12	SEPT7P9	6.93	7.5e-12	6.65e-06	0.26	0.21	Corneal astigmatism;	chr4:119521275	chr10:38383069~38402916:-
BRCA	trans	rs9467603	0.925	rs13199775	ENSG00000253570.1	RNF5P1	6.93	7.51e-12	6.66e-06	0.53	0.21	Intelligence (multi-trait analysis);	chr6:25828554	chr8:38600661~38601200:-
BRCA	trans	rs9467711	0.591	rs34351439	ENSG00000253570.1	RNF5P1	6.93	7.51e-12	6.66e-06	0.53	0.21	Autism spectrum disorder or schizophrenia;	chr6:25832782	chr8:38600661~38601200:-
BRCA	trans	rs17711722	0.565	rs73372653	ENSG00000213640.3	EEF1DP4	-6.93	7.52e-12	6.67e-06	-0.27	-0.21	Calcium levels;	chr7:65977808	chr7:64862999~64864370:+
BRCA	trans	rs67340775	0.834	rs13218875	ENSG00000281831.1	HCP5B	6.93	7.55e-12	6.7e-06	0.54	0.21	Lung cancer in ever smokers;	chr6:27916234	chr6:29871895~29873783:-
BRCA	trans	rs17767294	0.708	rs72848790	ENSG00000242375.1	RP11-498P14.3	-6.93	7.55e-12	6.7e-06	-0.63	-0.21	Parkinson's disease;	chr6:28018074	chr9:97195351~97197687:-
BRCA	trans	rs11098499	1	rs7659194	ENSG00000276997.3	RP11-378J18.9	6.92	7.73e-12	6.85e-06	0.26	0.21	Corneal astigmatism;	chr4:119285992	chr1:222477252~222504622:-
BRCA	trans	rs673253	0.686	rs501299	ENSG00000231007.5	CDC20P1	6.92	7.75e-12	6.87e-06	0.27	0.21	Intelligence (multi-trait analysis);	chr1:43586163	chr9:87011652~87013151:+
BRCA	trans	rs2288327	0.818	rs3731749	ENSG00000269800.1	PLEKHA3P1	6.92	7.75e-12	6.87e-06	0.32	0.21	Atrial fibrillation;	chr2:178541464	chr19:41521043~41521989:-
BRCA	trans	rs1707322	1	rs785510	ENSG00000255397.1	AC022182.2	6.92	7.85e-12	6.96e-06	0.28	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46062946	chr8:60937705~60939871:-
BRCA	trans	rs11098499	1	rs11098499	ENSG00000276997.3	RP11-378J18.9	6.92	7.85e-12	6.96e-06	0.26	0.21	Corneal astigmatism;	chr4:119266456	chr1:222477252~222504622:-
BRCA	trans	rs11638815	0.626	rs1313492	ENSG00000235370.6	DNM1P51	-6.92	7.86e-12	6.96e-06	-0.23	-0.21	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82604206	chr15:84398316~84411701:-
BRCA	trans	rs7819412	0.521	rs11777887	ENSG00000253893.2	FAM85B	-6.92	7.86e-12	6.96e-06	-0.28	-0.21	Triglycerides;	chr8:11179290	chr8:8167819~8226614:-
BRCA	trans	rs11098499	0.863	rs13140391	ENSG00000120555.12	SEPT7P9	6.92	7.86e-12	6.96e-06	0.26	0.21	Corneal astigmatism;	chr4:119582282	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.863	rs13140409	ENSG00000120555.12	SEPT7P9	6.92	7.86e-12	6.96e-06	0.26	0.21	Corneal astigmatism;	chr4:119582305	chr10:38383069~38402916:-
BRCA	trans	rs9425766	0.679	rs4650990	ENSG00000213331.4	RP11-713C19.2	6.92	7.9e-12	7e-06	0.23	0.21	Life satisfaction;	chr1:174289943	chr4:187970273~187971284:+
BRCA	trans	rs11992162	0.613	rs56094399	ENSG00000253893.2	FAM85B	6.92	7.9e-12	7e-06	0.26	0.21	Monocyte count;	chr8:11939961	chr8:8167819~8226614:-
BRCA	trans	rs11122895	0.509	rs6708131	ENSG00000204745.3	AC083899.3	6.92	7.9e-12	7e-06	0.25	0.21	Allergic sensitization;	chr2:111688082	chr2:87125390~87196647:+
BRCA	trans	rs7260598	0.792	rs73021416	ENSG00000261770.1	CTC-459F4.1	6.92	7.92e-12	7.01e-06	0.36	0.21	Response to taxane treatment (placlitaxel);	chr19:24081849	chr19:27757184~27760849:-
BRCA	trans	rs11098499	0.954	rs11098525	ENSG00000120555.12	SEPT7P9	6.92	7.94e-12	7.03e-06	0.26	0.21	Corneal astigmatism;	chr4:119468997	chr10:38383069~38402916:-
BRCA	trans	rs9292918	1	rs6864928	ENSG00000231752.4	EMBP1	-6.92	8.01e-12	7.09e-06	-0.31	-0.21	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:45298509	chr1:121519112~121571892:+
BRCA	trans	rs11172055	0.967	rs10876953	ENSG00000121089.4	NACA3P	6.92	8.05e-12	7.13e-06	0.23	0.21	Migraine;	chr12:56916418	chr4:164943290~164943937:+
BRCA	trans	rs12155039	1	rs12155039	ENSG00000267258.1	CTC-448F2.3	-6.92	8.12e-12	7.18e-06	-0.25	-0.21	Mean platelet volume;	chr7:44833526	chr19:29921182~29921653:+
BRCA	trans	rs11098499	0.566	rs7664440	ENSG00000120555.12	SEPT7P9	6.91	8.16e-12	7.21e-06	0.27	0.21	Corneal astigmatism;	chr4:119657385	chr10:38383069~38402916:-
BRCA	trans	rs2055729	0.645	rs12544019	ENSG00000253893.2	FAM85B	-6.91	8.24e-12	7.28e-06	-0.31	-0.21	Multiple myeloma (hyperdiploidy);	chr8:9885068	chr8:8167819~8226614:-
BRCA	trans	rs11098499	0.954	rs6838814	ENSG00000120555.12	SEPT7P9	6.91	8.29e-12	7.33e-06	0.26	0.21	Corneal astigmatism;	chr4:119471288	chr10:38383069~38402916:-
BRCA	trans	rs9581094	0.527	rs73154361	ENSG00000237917.1	PARP4P1	-6.91	8.32e-12	7.35e-06	-0.47	-0.21	Sudden cardiac arrest;	chr13:24491019	chrY:26594851~26634652:-
BRCA	trans	rs1568889	0.838	rs7121937	ENSG00000174912.7	METTL15P1	6.91	8.35e-12	7.38e-06	0.21	0.21	Bipolar disorder;	chr11:28338311	chr3:156713884~156714928:-
BRCA	trans	rs11098499	0.82	rs28535956	ENSG00000120555.12	SEPT7P9	-6.91	8.35e-12	7.38e-06	-0.27	-0.21	Corneal astigmatism;	chr4:119615703	chr10:38383069~38402916:-
BRCA	trans	rs9467711	0.651	rs9467623	ENSG00000253570.1	RNF5P1	6.91	8.52e-12	7.53e-06	0.54	0.21	Autism spectrum disorder or schizophrenia;	chr6:25860352	chr8:38600661~38601200:-
BRCA	trans	rs853679	0.607	rs35749575	ENSG00000281831.1	HCP5B	6.91	8.52e-12	7.53e-06	0.54	0.21	Depression;	chr6:28147040	chr6:29871895~29873783:-
BRCA	trans	rs12439619	0.693	rs9944185	ENSG00000259295.5	CSPG4P12	-6.91	8.55e-12	7.55e-06	-0.3	-0.21	Intelligence (multi-trait analysis);	chr15:82157927	chr15:85191438~85213905:+
BRCA	trans	rs9468186	1	rs9468186	ENSG00000204709.4	LINC01556	6.91	8.63e-12	7.62e-06	0.28	0.21	Neuroticism;	chr6:27658852	chr6:28943877~28944537:+
BRCA	trans	rs673253	0.686	rs2842187	ENSG00000231007.5	CDC20P1	-6.91	8.66e-12	7.64e-06	-0.28	-0.21	Intelligence (multi-trait analysis);	chr1:43549278	chr9:87011652~87013151:+
BRCA	trans	rs12439619	0.693	rs4778989	ENSG00000259295.5	CSPG4P12	-6.91	8.67e-12	7.66e-06	-0.31	-0.21	Intelligence (multi-trait analysis);	chr15:82276963	chr15:85191438~85213905:+
BRCA	trans	rs12477438	0.52	rs4851188	ENSG00000276576.1	MRPL30P1	6.91	8.7e-12	7.68e-06	0.25	0.21	Chronic sinus infection;	chr2:99129435	chr6:57029521~57029988:+
BRCA	trans	rs12477438	0.501	rs11683107	ENSG00000276576.1	MRPL30P1	6.91	8.7e-12	7.68e-06	0.25	0.21	Chronic sinus infection;	chr2:99142772	chr6:57029521~57029988:+
BRCA	trans	rs12477438	0.52	rs6542866	ENSG00000276576.1	MRPL30P1	6.91	8.7e-12	7.68e-06	0.25	0.21	Chronic sinus infection;	chr2:99148129	chr6:57029521~57029988:+
BRCA	trans	rs673253	0.638	rs3791140	ENSG00000231007.5	CDC20P1	6.91	8.7e-12	7.68e-06	0.27	0.21	Intelligence (multi-trait analysis);	chr1:43586107	chr9:87011652~87013151:+
BRCA	trans	rs7260598	0.685	rs73021422	ENSG00000261770.1	CTC-459F4.1	6.91	8.71e-12	7.69e-06	0.36	0.21	Response to taxane treatment (placlitaxel);	chr19:24082919	chr19:27757184~27760849:-
BRCA	trans	rs11122895	0.509	rs10174353	ENSG00000204745.3	AC083899.3	6.9	8.72e-12	7.69e-06	0.24	0.21	Allergic sensitization;	chr2:111690311	chr2:87125390~87196647:+
BRCA	trans	rs76228276	0.737	rs75079359	ENSG00000260318.1	COX6CP1	6.9	8.74e-12	7.71e-06	0.57	0.21	Childhood ear infection;	chr8:99265692	chr16:11903923~11904137:-
BRCA	trans	rs76228276	0.737	rs11984531	ENSG00000260318.1	COX6CP1	6.9	8.74e-12	7.71e-06	0.57	0.21	Childhood ear infection;	chr8:99269658	chr16:11903923~11904137:-
BRCA	trans	rs67340775	0.541	rs169287	ENSG00000204709.4	LINC01556	6.9	8.74e-12	7.71e-06	0.35	0.21	Lung cancer in ever smokers;	chr6:27886982	chr6:28943877~28944537:+
BRCA	trans	rs7903456	0.648	rs9420429	ENSG00000232706.3	NUTM2HP	6.9	8.78e-12	7.75e-06	0.3	0.21	Gout;Renal underexcretion gout;	chr10:87049058	chr10:50676743~50686326:+
BRCA	trans	rs7903456	0.648	rs9421565	ENSG00000232706.3	NUTM2HP	6.9	8.8e-12	7.77e-06	0.3	0.21	Gout;Renal underexcretion gout;	chr10:87045655	chr10:50676743~50686326:+
BRCA	trans	rs7260598	0.792	rs11669171	ENSG00000261770.1	CTC-459F4.1	6.9	8.81e-12	7.77e-06	0.35	0.21	Response to taxane treatment (placlitaxel);	chr19:24153957	chr19:27757184~27760849:-
BRCA	trans	rs11098499	0.874	rs12502503	ENSG00000120555.12	SEPT7P9	6.9	8.82e-12	7.78e-06	0.27	0.21	Corneal astigmatism;	chr4:119195100	chr10:38383069~38402916:-
BRCA	trans	rs1079467	0.735	rs75941265	ENSG00000275945.1	EIF3S5P1	-6.9	8.84e-12	7.8e-06	-0.37	-0.21	Response to anti-TNF therapy in rheumatoid arthritis;	chr11:7949542	chr21:10330732~10331537:+
BRCA	trans	rs6732160	0.613	rs58317144	ENSG00000236165.1	PRADC1P1	6.9	8.87e-12	7.82e-06	0.28	0.21	Intelligence (multi-trait analysis);	chr2:73161025	chr3:36976316~36976840:+
BRCA	trans	rs7260598	0.792	rs10500223	ENSG00000261770.1	CTC-459F4.1	6.9	8.9e-12	7.85e-06	0.36	0.21	Response to taxane treatment (placlitaxel);	chr19:24163222	chr19:27757184~27760849:-
BRCA	trans	rs11098499	0.954	rs13107475	ENSG00000120555.12	SEPT7P9	6.9	8.99e-12	7.93e-06	0.25	0.21	Corneal astigmatism;	chr4:119471856	chr10:38383069~38402916:-
BRCA	trans	rs853679	0.607	rs34166054	ENSG00000281831.1	HCP5B	6.9	9.1e-12	8.02e-06	0.55	0.21	Depression;	chr6:28098023	chr6:29871895~29873783:-
BRCA	trans	rs853679	0.607	rs13203816	ENSG00000281831.1	HCP5B	6.9	9.1e-12	8.02e-06	0.55	0.21	Depression;	chr6:28111820	chr6:29871895~29873783:-
BRCA	trans	rs853679	0.556	rs34588114	ENSG00000281831.1	HCP5B	6.9	9.1e-12	8.02e-06	0.55	0.21	Depression;	chr6:28112850	chr6:29871895~29873783:-
BRCA	trans	rs853679	0.607	rs68188794	ENSG00000281831.1	HCP5B	6.9	9.1e-12	8.02e-06	0.55	0.21	Depression;	chr6:28112999	chr6:29871895~29873783:-
BRCA	trans	rs853679	0.546	rs34371502	ENSG00000281831.1	HCP5B	6.9	9.1e-12	8.02e-06	0.55	0.21	Depression;	chr6:28113980	chr6:29871895~29873783:-
BRCA	trans	rs853679	0.607	rs66886492	ENSG00000281831.1	HCP5B	6.9	9.1e-12	8.02e-06	0.55	0.21	Depression;	chr6:28121953	chr6:29871895~29873783:-
BRCA	trans	rs853679	0.607	rs35345226	ENSG00000281831.1	HCP5B	6.9	9.1e-12	8.02e-06	0.55	0.21	Depression;	chr6:28123802	chr6:29871895~29873783:-
BRCA	trans	rs2980439	0.818	rs2948294	ENSG00000270154.1	RP11-419I17.1	6.9	9.15e-12	8.06e-06	0.25	0.21	Neuroticism;	chr8:8237439	chr8:12476462~12477122:+
BRCA	trans	rs11098499	0.566	rs17051356	ENSG00000120555.12	SEPT7P9	6.9	9.23e-12	8.14e-06	0.27	0.21	Corneal astigmatism;	chr4:119664153	chr10:38383069~38402916:-
BRCA	trans	rs7260598	0.792	rs11672981	ENSG00000261770.1	CTC-459F4.1	6.9	9.25e-12	8.15e-06	0.36	0.21	Response to taxane treatment (placlitaxel);	chr19:24144735	chr19:27757184~27760849:-
BRCA	trans	rs7260598	0.685	rs73021424	ENSG00000261770.1	CTC-459F4.1	6.9	9.28e-12	8.18e-06	0.36	0.21	Response to taxane treatment (placlitaxel);	chr19:24090897	chr19:27757184~27760849:-
BRCA	trans	rs7260598	0.685	rs11667970	ENSG00000261770.1	CTC-459F4.1	6.9	9.28e-12	8.18e-06	0.36	0.21	Response to taxane treatment (placlitaxel);	chr19:24094893	chr19:27757184~27760849:-
BRCA	trans	rs7260598	0.581	rs73021432	ENSG00000261770.1	CTC-459F4.1	6.9	9.28e-12	8.18e-06	0.36	0.21	Response to taxane treatment (placlitaxel);	chr19:24101827	chr19:27757184~27760849:-
BRCA	trans	rs7260598	0.792	rs11669295	ENSG00000261770.1	CTC-459F4.1	6.89	9.34e-12	8.23e-06	0.35	0.21	Response to taxane treatment (placlitaxel);	chr19:24154184	chr19:27757184~27760849:-
BRCA	trans	rs7260598	0.792	rs11670299	ENSG00000261770.1	CTC-459F4.1	6.89	9.34e-12	8.23e-06	0.35	0.21	Response to taxane treatment (placlitaxel);	chr19:24154959	chr19:27757184~27760849:-
BRCA	trans	rs9368481	1	rs9368481	ENSG00000242375.1	RP11-498P14.3	-6.89	9.36e-12	8.24e-06	-0.3	-0.21	Autism spectrum disorder or schizophrenia;	chr6:26993982	chr9:97195351~97197687:-
BRCA	trans	rs864643	0.947	rs704962	ENSG00000188856.6	RPSAP47	-6.89	9.4e-12	8.28e-06	-0.3	-0.21	Attention deficit hyperactivity disorder;	chr3:39515629	chr8:80558870~80559757:+
BRCA	trans	rs11098499	0.82	rs13128602	ENSG00000276997.3	RP11-378J18.9	-6.89	9.46e-12	8.33e-06	-0.26	-0.21	Corneal astigmatism;	chr4:119538211	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.874	rs9995277	ENSG00000120555.12	SEPT7P9	6.89	9.5e-12	8.36e-06	0.27	0.21	Corneal astigmatism;	chr4:119187448	chr10:38383069~38402916:-
BRCA	trans	rs9467711	0.606	rs13203358	ENSG00000253570.1	RNF5P1	6.89	9.5e-12	8.36e-06	0.47	0.21	Autism spectrum disorder or schizophrenia;	chr6:26590350	chr8:38600661~38601200:-
BRCA	trans	rs546131	0.642	rs836950	ENSG00000225531.1	RP11-196I18.3	-6.89	9.55e-12	8.4e-06	-0.3	-0.21	Lung disease severity in cystic fibrosis;	chr11:34830473	chr9:107116829~107117557:+
BRCA	trans	rs4911259	0.552	rs62208880	ENSG00000253915.1	MAPRE1P1	-6.89	9.68e-12	8.52e-06	-0.25	-0.21	Inflammatory bowel disease;	chr20:32875478	chr8:135625185~135625981:-
BRCA	trans	rs11098499	0.863	rs1155576	ENSG00000276997.3	RP11-378J18.9	6.89	9.74e-12	8.57e-06	0.25	0.21	Corneal astigmatism;	chr4:119529004	chr1:222477252~222504622:-
BRCA	trans	rs1079467	0.73	rs74933956	ENSG00000275945.1	EIF3S5P1	-6.89	9.82e-12	8.63e-06	-0.37	-0.21	Response to anti-TNF therapy in rheumatoid arthritis;	chr11:7950507	chr21:10330732~10331537:+
BRCA	trans	rs1079467	0.73	rs77880011	ENSG00000275945.1	EIF3S5P1	-6.89	9.82e-12	8.63e-06	-0.37	-0.21	Response to anti-TNF therapy in rheumatoid arthritis;	chr11:7950656	chr21:10330732~10331537:+
BRCA	trans	rs1707322	1	rs1707317	ENSG00000255397.1	AC022182.2	6.89	9.94e-12	8.74e-06	0.28	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46044970	chr8:60937705~60939871:-
BRCA	trans	rs7200543	1	rs55727637	ENSG00000250569.1	NTAN1P2	6.89	9.94e-12	8.74e-06	0.23	0.21	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15051395	chr8:86481754~86483002:-
BRCA	trans	rs7260598	0.792	rs73021467	ENSG00000261770.1	CTC-459F4.1	6.88	9.98e-12	8.77e-06	0.36	0.21	Response to taxane treatment (placlitaxel);	chr19:24142863	chr19:27757184~27760849:-
BRCA	trans	rs7260598	0.792	rs4019979	ENSG00000261770.1	CTC-459F4.1	6.88	9.98e-12	8.77e-06	0.36	0.21	Response to taxane treatment (placlitaxel);	chr19:24143881	chr19:27757184~27760849:-
BRCA	trans	rs11098499	0.863	rs10004484	ENSG00000120555.12	SEPT7P9	6.88	1e-11	8.81e-06	0.25	0.21	Corneal astigmatism;	chr4:119521273	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.863	rs11098532	ENSG00000120555.12	SEPT7P9	6.88	1e-11	8.82e-06	0.26	0.21	Corneal astigmatism;	chr4:119569571	chr10:38383069~38402916:-
BRCA	trans	rs1816752	0.603	rs9511278	ENSG00000224976.2	PARP4P2	6.88	1.01e-11	8.89e-06	0.26	0.21	Obesity-related traits;	chr13:24455766	chr13:19349137~19407962:+
BRCA	trans	rs11638815	0.581	rs783535	ENSG00000235370.6	DNM1P51	-6.88	1.02e-11	8.96e-06	-0.23	-0.21	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82581676	chr15:84398316~84411701:-
BRCA	trans	rs9393777	1	rs9393777	ENSG00000253570.1	RNF5P1	6.88	1.03e-11	9e-06	0.43	0.21	Intelligence (multi-trait analysis);	chr6:26974248	chr8:38600661~38601200:-
BRCA	trans	rs11098499	0.909	rs10017335	ENSG00000120555.12	SEPT7P9	-6.88	1.03e-11	9.02e-06	-0.26	-0.21	Corneal astigmatism;	chr4:119460368	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.863	rs3775843	ENSG00000276997.3	RP11-378J18.9	6.88	1.03e-11	9.02e-06	0.26	0.21	Corneal astigmatism;	chr4:119506689	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.863	rs3775844	ENSG00000276997.3	RP11-378J18.9	6.88	1.03e-11	9.02e-06	0.26	0.21	Corneal astigmatism;	chr4:119506878	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.863	rs13134665	ENSG00000276997.3	RP11-378J18.9	6.88	1.03e-11	9.05e-06	0.26	0.21	Corneal astigmatism;	chr4:119505275	chr1:222477252~222504622:-
BRCA	trans	rs1816752	0.875	rs59686377	ENSG00000224976.2	PARP4P2	-6.88	1.03e-11	9.09e-06	-0.26	-0.21	Obesity-related traits;	chr13:24475869	chr13:19349137~19407962:+
BRCA	trans	rs9650657	0.623	rs10091636	ENSG00000253893.2	FAM85B	6.88	1.04e-11	9.14e-06	0.25	0.21	Neuroticism;	chr8:10745456	chr8:8167819~8226614:-
BRCA	trans	rs9650657	0.54	rs10094732	ENSG00000253893.2	FAM85B	6.88	1.04e-11	9.14e-06	0.25	0.21	Neuroticism;	chr8:10745505	chr8:8167819~8226614:-
BRCA	trans	rs3740713	1	rs75487138	ENSG00000214110.3	LDHAP4	6.88	1.06e-11	9.26e-06	0.39	0.21	Amyotrophic lateral sclerosis (sporadic);	chr11:18440331	chr9:14921337~14922334:-
BRCA	trans	rs864643	0.945	rs1707972	ENSG00000188856.6	RPSAP47	6.88	1.06e-11	9.34e-06	0.3	0.21	Attention deficit hyperactivity disorder;	chr3:39507243	chr8:80558870~80559757:+
BRCA	trans	rs7617773	0.817	rs9847953	ENSG00000235912.1	RP1-159A19.3	-6.88	1.07e-11	9.35e-06	-0.26	-0.21	Coronary artery disease;	chr3:48241205	chr1:27649419~27649610:+
BRCA	trans	rs11098499	0.866	rs72676074	ENSG00000276997.3	RP11-378J18.9	6.87	1.07e-11	9.4e-06	0.25	0.21	Corneal astigmatism;	chr4:119438686	chr1:222477252~222504622:-
BRCA	trans	rs673253	0.686	rs11580258	ENSG00000231007.5	CDC20P1	6.87	1.07e-11	9.4e-06	0.27	0.21	Intelligence (multi-trait analysis);	chr1:43550344	chr9:87011652~87013151:+
BRCA	trans	rs1707322	0.717	rs1972410	ENSG00000255397.1	AC022182.2	-6.87	1.08e-11	9.44e-06	-0.27	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45615275	chr8:60937705~60939871:-
BRCA	trans	rs673253	0.686	rs2842188	ENSG00000231007.5	CDC20P1	-6.87	1.08e-11	9.46e-06	-0.27	-0.21	Intelligence (multi-trait analysis);	chr1:43548609	chr9:87011652~87013151:+
BRCA	trans	rs17507216	0.718	rs17158403	ENSG00000259295.5	CSPG4P12	-6.87	1.09e-11	9.52e-06	-0.33	-0.21	Excessive daytime sleepiness;	chr15:82572478	chr15:85191438~85213905:+
BRCA	trans	rs10838687	0.867	rs2633082	ENSG00000134612.10	FOLH1B	-6.87	1.1e-11	9.62e-06	-0.3	-0.21	Proinsulin levels;	chr11:47226499	chr11:89639227~89698718:+
BRCA	trans	rs17767294	0.708	rs72846777	ENSG00000242375.1	RP11-498P14.3	-6.87	1.1e-11	9.64e-06	-0.61	-0.21	Parkinson's disease;	chr6:28147032	chr9:97195351~97197687:-
BRCA	trans	rs17767294	0.708	rs62620226	ENSG00000242375.1	RP11-498P14.3	-6.87	1.1e-11	9.64e-06	-0.61	-0.21	Parkinson's disease;	chr6:28153500	chr9:97195351~97197687:-
BRCA	trans	rs17767294	0.708	rs72846788	ENSG00000242375.1	RP11-498P14.3	-6.87	1.1e-11	9.64e-06	-0.61	-0.21	Parkinson's disease;	chr6:28163065	chr9:97195351~97197687:-
BRCA	trans	rs17767294	0.708	rs72846792	ENSG00000242375.1	RP11-498P14.3	-6.87	1.1e-11	9.64e-06	-0.61	-0.21	Parkinson's disease;	chr6:28165533	chr9:97195351~97197687:-
BRCA	trans	rs17767294	0.708	rs74756732	ENSG00000242375.1	RP11-498P14.3	-6.87	1.1e-11	9.64e-06	-0.61	-0.21	Parkinson's disease;	chr6:28184769	chr9:97195351~97197687:-
BRCA	trans	rs17507216	0.718	rs7165690	ENSG00000259295.5	CSPG4P12	-6.87	1.1e-11	9.65e-06	-0.33	-0.21	Excessive daytime sleepiness;	chr15:82654804	chr15:85191438~85213905:+
BRCA	trans	rs7903456	0.648	rs9421576	ENSG00000232706.3	NUTM2HP	6.87	1.11e-11	9.72e-06	0.3	0.21	Gout;Renal underexcretion gout;	chr10:87069444	chr10:50676743~50686326:+
BRCA	trans	rs7260598	0.685	rs11671000	ENSG00000261770.1	CTC-459F4.1	6.87	1.12e-11	9.78e-06	0.35	0.21	Response to taxane treatment (placlitaxel);	chr19:24110025	chr19:27757184~27760849:-
BRCA	trans	rs7260598	0.792	rs73021445	ENSG00000261770.1	CTC-459F4.1	6.87	1.12e-11	9.78e-06	0.35	0.21	Response to taxane treatment (placlitaxel);	chr19:24121306	chr19:27757184~27760849:-
BRCA	trans	rs7260598	0.792	rs7252836	ENSG00000261770.1	CTC-459F4.1	6.87	1.12e-11	9.78e-06	0.35	0.21	Response to taxane treatment (placlitaxel);	chr19:24122787	chr19:27757184~27760849:-
BRCA	trans	rs7260598	0.792	rs61737180	ENSG00000261770.1	CTC-459F4.1	6.87	1.12e-11	9.78e-06	0.35	0.21	Response to taxane treatment (placlitaxel);	chr19:24127230	chr19:27757184~27760849:-
BRCA	trans	rs9581094	0.591	rs117077381	ENSG00000237917.1	PARP4P1	-6.87	1.12e-11	9.79e-06	-0.46	-0.21	Sudden cardiac arrest;	chr13:24487516	chrY:26594851~26634652:-
BRCA	trans	rs9425766	0.679	rs4650989	ENSG00000213331.4	RP11-713C19.2	6.87	1.12e-11	9.85e-06	0.23	0.21	Life satisfaction;	chr1:174289739	chr4:187970273~187971284:+
BRCA	trans	rs1707322	0.686	rs2050376	ENSG00000255397.1	AC022182.2	-6.87	1.13e-11	9.88e-06	-0.28	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45612958	chr8:60937705~60939871:-
BRCA	trans	rs1707322	0.752	rs4660880	ENSG00000255397.1	AC022182.2	-6.86	1.14e-11	1e-05	-0.28	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45645368	chr8:60937705~60939871:-
BRCA	trans	rs9581094	0.591	rs73154375	ENSG00000237917.1	PARP4P1	-6.86	1.15e-11	1e-05	-0.46	-0.21	Sudden cardiac arrest;	chr13:24497390	chrY:26594851~26634652:-
BRCA	trans	rs17767294	0.708	rs72847377	ENSG00000242375.1	RP11-498P14.3	-6.86	1.15e-11	1.01e-05	-0.6	-0.21	Parkinson's disease;	chr6:27898411	chr9:97195351~97197687:-
BRCA	trans	rs7260598	0.792	rs11669251	ENSG00000261770.1	CTC-459F4.1	6.86	1.16e-11	1.02e-05	0.35	0.21	Response to taxane treatment (placlitaxel);	chr19:24154192	chr19:27757184~27760849:-
BRCA	trans	rs3740713	1	rs1848048	ENSG00000214110.3	LDHAP4	6.86	1.16e-11	1.02e-05	0.39	0.21	Amyotrophic lateral sclerosis (sporadic);	chr11:18447449	chr9:14921337~14922334:-
BRCA	trans	rs3740713	1	rs16935432	ENSG00000214110.3	LDHAP4	6.86	1.16e-11	1.02e-05	0.39	0.21	Amyotrophic lateral sclerosis (sporadic);	chr11:18448940	chr9:14921337~14922334:-
BRCA	trans	rs3740713	1	rs73440625	ENSG00000214110.3	LDHAP4	6.86	1.16e-11	1.02e-05	0.39	0.21	Amyotrophic lateral sclerosis (sporadic);	chr11:18449253	chr9:14921337~14922334:-
BRCA	trans	rs3740713	1	rs76599129	ENSG00000214110.3	LDHAP4	6.86	1.16e-11	1.02e-05	0.39	0.21	Amyotrophic lateral sclerosis (sporadic);	chr11:18450080	chr9:14921337~14922334:-
BRCA	trans	rs11098499	0.863	rs10004484	ENSG00000276997.3	RP11-378J18.9	6.86	1.17e-11	1.02e-05	0.25	0.21	Corneal astigmatism;	chr4:119521273	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.863	rs10030660	ENSG00000120555.12	SEPT7P9	6.86	1.17e-11	1.03e-05	0.26	0.21	Corneal astigmatism;	chr4:119515549	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.863	rs13149407	ENSG00000120555.12	SEPT7P9	6.86	1.17e-11	1.03e-05	0.26	0.21	Corneal astigmatism;	chr4:119516670	chr10:38383069~38402916:-
BRCA	trans	rs7260598	0.792	rs11672468	ENSG00000261770.1	CTC-459F4.1	6.86	1.18e-11	1.03e-05	0.35	0.21	Response to taxane treatment (placlitaxel);	chr19:24119770	chr19:27757184~27760849:-
BRCA	trans	rs9650657	0.623	rs7004066	ENSG00000253893.2	FAM85B	6.86	1.19e-11	1.04e-05	0.26	0.21	Neuroticism;	chr8:10743233	chr8:8167819~8226614:-
BRCA	trans	rs714543	0.688	rs12702087	ENSG00000267258.1	CTC-448F2.3	-6.86	1.19e-11	1.04e-05	-0.24	-0.21	Plateletcrit;	chr7:44773008	chr19:29921182~29921653:+
BRCA	trans	rs3806843	0.576	rs550475	ENSG00000231043.3	AC007238.1	-6.86	1.19e-11	1.04e-05	-0.25	-0.21	Depressive symptoms (multi-trait analysis);	chr5:140893943	chr2:58460292~58462032:-
BRCA	trans	rs9581094	0.591	rs1807110	ENSG00000237917.1	PARP4P1	-6.86	1.2e-11	1.05e-05	-0.42	-0.21	Sudden cardiac arrest;	chr13:24471060	chrY:26594851~26634652:-
BRCA	trans	rs3942852	0.91	rs10742829	ENSG00000134612.10	FOLH1B	6.86	1.21e-11	1.06e-05	0.29	0.21	Acute lymphoblastic leukemia (childhood);	chr11:48094285	chr11:89639227~89698718:+
BRCA	trans	rs6921919	1	rs35875412	ENSG00000228078.1	HLA-U	-6.86	1.21e-11	1.06e-05	-0.33	-0.21	Autism spectrum disorder or schizophrenia;	chr6:28364041	chr6:29934101~29934286:+
BRCA	trans	rs11098499	0.863	rs3775843	ENSG00000120555.12	SEPT7P9	6.86	1.21e-11	1.06e-05	0.26	0.21	Corneal astigmatism;	chr4:119506689	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.863	rs3775844	ENSG00000120555.12	SEPT7P9	6.86	1.21e-11	1.06e-05	0.26	0.21	Corneal astigmatism;	chr4:119506878	chr10:38383069~38402916:-
BRCA	trans	rs7819412	0.505	rs17782536	ENSG00000253893.2	FAM85B	6.86	1.21e-11	1.06e-05	0.28	0.21	Triglycerides;	chr8:11164172	chr8:8167819~8226614:-
BRCA	trans	rs7903456	0.648	rs2296061	ENSG00000232706.3	NUTM2HP	6.85	1.22e-11	1.07e-05	0.3	0.21	Gout;Renal underexcretion gout;	chr10:87068293	chr10:50676743~50686326:+
BRCA	trans	rs14057	0.86	rs731024	ENSG00000215869.3	RP11-364B6.1	-6.85	1.22e-11	1.07e-05	-0.29	-0.21	Systolic blood pressure;	chr1:6584663	chr1:104073023~104077087:+
BRCA	trans	rs11098499	0.863	rs7664986	ENSG00000120555.12	SEPT7P9	6.85	1.23e-11	1.07e-05	0.26	0.21	Corneal astigmatism;	chr4:119508797	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.818	rs10008791	ENSG00000120555.12	SEPT7P9	6.85	1.23e-11	1.07e-05	0.26	0.21	Corneal astigmatism;	chr4:119510314	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.863	rs11736416	ENSG00000120555.12	SEPT7P9	6.85	1.23e-11	1.07e-05	0.26	0.21	Corneal astigmatism;	chr4:119510506	chr10:38383069~38402916:-
BRCA	trans	rs1707322	0.717	rs12023439	ENSG00000255397.1	AC022182.2	-6.85	1.23e-11	1.07e-05	-0.28	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45638964	chr8:60937705~60939871:-
BRCA	trans	rs7824557	0.737	rs2293855	ENSG00000270154.1	RP11-419I17.1	6.85	1.24e-11	1.08e-05	0.26	0.21	Retinal vascular caliber;	chr8:11319901	chr8:12476462~12477122:+
BRCA	trans	rs17507216	0.671	rs4779035	ENSG00000259295.5	CSPG4P12	-6.85	1.24e-11	1.09e-05	-0.34	-0.21	Excessive daytime sleepiness;	chr15:82591686	chr15:85191438~85213905:+
BRCA	trans	rs11098499	0.863	rs3775845	ENSG00000120555.12	SEPT7P9	6.85	1.24e-11	1.09e-05	0.26	0.21	Corneal astigmatism;	chr4:119511292	chr10:38383069~38402916:-
BRCA	trans	rs9368481	0.729	rs9379950	ENSG00000242375.1	RP11-498P14.3	-6.85	1.25e-11	1.09e-05	-0.3	-0.21	Autism spectrum disorder or schizophrenia;	chr6:26993769	chr9:97195351~97197687:-
BRCA	trans	rs11098499	0.863	rs6835635	ENSG00000276997.3	RP11-378J18.9	6.85	1.26e-11	1.1e-05	0.27	0.21	Corneal astigmatism;	chr4:119537712	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.908	rs28499576	ENSG00000120555.12	SEPT7P9	6.85	1.26e-11	1.1e-05	0.25	0.21	Corneal astigmatism;	chr4:119465522	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.738	rs72918577	ENSG00000120555.12	SEPT7P9	6.85	1.27e-11	1.11e-05	0.25	0.21	Corneal astigmatism;	chr4:119405546	chr10:38383069~38402916:-
BRCA	trans	rs9467711	0.606	rs9379901	ENSG00000253570.1	RNF5P1	6.85	1.28e-11	1.12e-05	0.46	0.21	Autism spectrum disorder or schizophrenia;	chr6:26603638	chr8:38600661~38601200:-
BRCA	trans	rs10838687	0.867	rs2957873	ENSG00000134612.10	FOLH1B	-6.85	1.28e-11	1.12e-05	-0.3	-0.21	Proinsulin levels;	chr11:47227743	chr11:89639227~89698718:+
BRCA	trans	rs4929949	0.639	rs12785939	ENSG00000266891.1	RP11-692N5.2	6.85	1.29e-11	1.12e-05	0.25	0.21	Body mass index;	chr11:8543846	chr18:9734882~9735602:-
BRCA	trans	rs1707322	0.686	rs2991986	ENSG00000255397.1	AC022182.2	6.85	1.3e-11	1.13e-05	0.28	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45615610	chr8:60937705~60939871:-
BRCA	trans	rs9467711	0.606	rs9348726	ENSG00000253570.1	RNF5P1	6.85	1.3e-11	1.13e-05	0.46	0.21	Autism spectrum disorder or schizophrenia;	chr6:26604978	chr8:38600661~38601200:-
BRCA	trans	rs9644568	0.599	rs12679834	ENSG00000246089.3	RP11-115C21.2	6.84	1.31e-11	1.15e-05	0.3	0.21	Hypertriglyceridemia;HDL cholesterol;	chr8:19962922	chr8:6403551~6407142:-
BRCA	trans	rs12477438	0.501	rs12613624	ENSG00000276576.1	MRPL30P1	-6.84	1.35e-11	1.17e-05	-0.25	-0.21	Chronic sinus infection;	chr2:99116278	chr6:57029521~57029988:+
BRCA	trans	rs11098499	0.866	rs12501602	ENSG00000276997.3	RP11-378J18.9	6.84	1.35e-11	1.17e-05	0.25	0.21	Corneal astigmatism;	chr4:119366780	chr1:222477252~222504622:-
BRCA	trans	rs747782	0.702	rs17790804	ENSG00000134612.10	FOLH1B	6.84	1.35e-11	1.18e-05	0.39	0.21	Intraocular pressure;	chr11:47425651	chr11:89639227~89698718:+
BRCA	trans	rs12543645	0.609	rs35112858	ENSG00000253893.2	FAM85B	-6.84	1.35e-11	1.18e-05	-0.29	-0.21	Schizophrenia;	chr8:10419759	chr8:8167819~8226614:-
BRCA	trans	rs11098499	0.863	rs1383533	ENSG00000120555.12	SEPT7P9	6.84	1.35e-11	1.18e-05	0.26	0.21	Corneal astigmatism;	chr4:119513421	chr10:38383069~38402916:-
BRCA	trans	rs9584850	0.834	rs745638	ENSG00000230079.1	STK24P1	-6.84	1.36e-11	1.19e-05	-0.27	-0.21	Neuroticism;	chr13:98467053	chrX:136295690~136300298:-
BRCA	trans	rs17767294	0.708	rs72848792	ENSG00000242375.1	RP11-498P14.3	-6.84	1.36e-11	1.19e-05	-0.62	-0.21	Parkinson's disease;	chr6:28029878	chr9:97195351~97197687:-
BRCA	trans	rs9468199	0.505	rs72848793	ENSG00000242375.1	RP11-498P14.3	-6.84	1.36e-11	1.19e-05	-0.62	-0.21	Parkinson's disease;	chr6:28031800	chr9:97195351~97197687:-
BRCA	trans	rs9368481	0.554	rs2754603	ENSG00000242375.1	RP11-498P14.3	-6.84	1.36e-11	1.19e-05	-0.3	-0.21	Autism spectrum disorder or schizophrenia;	chr6:26997360	chr9:97195351~97197687:-
BRCA	trans	rs11098499	0.863	rs2291185	ENSG00000120555.12	SEPT7P9	6.84	1.37e-11	1.19e-05	0.26	0.21	Corneal astigmatism;	chr4:119513678	chr10:38383069~38402916:-
BRCA	trans	rs9581094	0.591	rs73172136	ENSG00000237917.1	PARP4P1	-6.84	1.37e-11	1.19e-05	-0.47	-0.21	Sudden cardiac arrest;	chr13:24454347	chrY:26594851~26634652:-
BRCA	trans	rs3740713	1	rs60376560	ENSG00000214110.3	LDHAP4	6.84	1.38e-11	1.2e-05	0.39	0.21	Amyotrophic lateral sclerosis (sporadic);	chr11:18432195	chr9:14921337~14922334:-
BRCA	trans	rs11098499	0.863	rs13134665	ENSG00000120555.12	SEPT7P9	6.84	1.38e-11	1.2e-05	0.26	0.21	Corneal astigmatism;	chr4:119505275	chr10:38383069~38402916:-
BRCA	trans	rs7260598	0.792	rs73021454	ENSG00000261770.1	CTC-459F4.1	6.84	1.38e-11	1.2e-05	0.35	0.21	Response to taxane treatment (placlitaxel);	chr19:24133074	chr19:27757184~27760849:-
BRCA	trans	rs7260598	0.792	rs11671960	ENSG00000261770.1	CTC-459F4.1	6.84	1.38e-11	1.2e-05	0.35	0.21	Response to taxane treatment (placlitaxel);	chr19:24135019	chr19:27757184~27760849:-
BRCA	trans	rs7260598	0.792	rs59756985	ENSG00000261770.1	CTC-459F4.1	6.84	1.38e-11	1.2e-05	0.35	0.21	Response to taxane treatment (placlitaxel);	chr19:24141664	chr19:27757184~27760849:-
BRCA	trans	rs1707322	0.963	rs4630155	ENSG00000255397.1	AC022182.2	-6.83	1.4e-11	1.22e-05	-0.28	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45791438	chr8:60937705~60939871:-
BRCA	trans	rs1707322	0.963	rs12076580	ENSG00000255397.1	AC022182.2	-6.83	1.4e-11	1.22e-05	-0.28	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45792487	chr8:60937705~60939871:-
BRCA	trans	rs2277458	0.623	rs1998194	ENSG00000214249.3	CTAGE11P	-6.83	1.4e-11	1.22e-05	-0.32	-0.21	Vitamin D levels;	chr14:39221650	chr13:75237944~75240296:-
BRCA	trans	rs9914988	0.943	rs2043032	ENSG00000267449.1	RP11-264B14.2	6.83	1.41e-11	1.22e-05	0.3	0.21	Glycated hemoglobin levels;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr17:28809674	chr17:61069856~61070356:-
BRCA	trans	rs9468199	0.523	rs9468152	ENSG00000242375.1	RP11-498P14.3	-6.83	1.42e-11	1.24e-05	-0.39	-0.21	Parkinson's disease;	chr6:27525127	chr9:97195351~97197687:-
BRCA	trans	rs7260598	0.792	rs73029291	ENSG00000261770.1	CTC-459F4.1	6.83	1.43e-11	1.24e-05	0.35	0.21	Response to taxane treatment (placlitaxel);	chr19:24171866	chr19:27757184~27760849:-
BRCA	trans	rs11098499	0.604	rs17051352	ENSG00000120555.12	SEPT7P9	6.83	1.43e-11	1.24e-05	0.27	0.21	Corneal astigmatism;	chr4:119660272	chr10:38383069~38402916:-
BRCA	trans	rs3740713	1	rs73440614	ENSG00000214110.3	LDHAP4	6.83	1.43e-11	1.24e-05	0.39	0.21	Amyotrophic lateral sclerosis (sporadic);	chr11:18445153	chr9:14921337~14922334:-
BRCA	trans	rs7819412	0.521	rs10110684	ENSG00000253893.2	FAM85B	6.83	1.43e-11	1.25e-05	0.27	0.21	Triglycerides;	chr8:11181650	chr8:8167819~8226614:-
BRCA	trans	rs76228276	0.737	rs77745880	ENSG00000260318.1	COX6CP1	6.83	1.44e-11	1.25e-05	0.56	0.21	Childhood ear infection;	chr8:99245830	chr16:11903923~11904137:-
BRCA	trans	rs76228276	0.737	rs79132217	ENSG00000260318.1	COX6CP1	6.83	1.44e-11	1.25e-05	0.56	0.21	Childhood ear infection;	chr8:99252581	chr16:11903923~11904137:-
BRCA	trans	rs76228276	0.737	rs79013399	ENSG00000260318.1	COX6CP1	6.83	1.44e-11	1.25e-05	0.56	0.21	Childhood ear infection;	chr8:99254480	chr16:11903923~11904137:-
BRCA	trans	rs9368481	0.761	rs9357028	ENSG00000242375.1	RP11-498P14.3	-6.83	1.44e-11	1.25e-05	-0.3	-0.21	Autism spectrum disorder or schizophrenia;	chr6:26999445	chr9:97195351~97197687:-
BRCA	trans	rs7824557	0.614	rs2736286	ENSG00000253893.2	FAM85B	6.83	1.45e-11	1.26e-05	0.26	0.21	Retinal vascular caliber;	chr8:11369595	chr8:8167819~8226614:-
BRCA	trans	rs11122895	0.509	rs55937046	ENSG00000204745.3	AC083899.3	6.83	1.45e-11	1.26e-05	0.24	0.21	Allergic sensitization;	chr2:111689719	chr2:87125390~87196647:+
BRCA	trans	rs7824557	0.767	rs3808513	ENSG00000270154.1	RP11-419I17.1	-6.83	1.46e-11	1.27e-05	-0.26	-0.21	Retinal vascular caliber;	chr8:11299951	chr8:12476462~12477122:+
BRCA	trans	rs2288327	0.818	rs2288325	ENSG00000269800.1	PLEKHA3P1	6.83	1.46e-11	1.27e-05	0.31	0.21	Atrial fibrillation;	chr2:178540059	chr19:41521043~41521989:-
BRCA	trans	rs11920570	0.92	rs1500530	ENSG00000267076.1	CCDC58P3	-6.83	1.47e-11	1.27e-05	-0.28	-0.21	Resting heart rate;	chr3:122556625	chr18:12211378~12211807:+
BRCA	trans	rs7819412	0.54	rs2409726	ENSG00000253893.2	FAM85B	6.83	1.47e-11	1.28e-05	0.27	0.21	Triglycerides;	chr8:11185629	chr8:8167819~8226614:-
BRCA	trans	rs380904	0.519	rs10102146	ENSG00000213130.3	EEF1DP5	6.83	1.48e-11	1.28e-05	0.27	0.21	Venous thromboembolism (SNP x SNP interaction);	chr8:143566986	chr6:128580113~128580884:-
BRCA	trans	rs76228276	0.737	rs4734429	ENSG00000260318.1	COX6CP1	-6.83	1.49e-11	1.29e-05	-0.56	-0.21	Childhood ear infection;	chr8:99281515	chr16:11903923~11904137:-
BRCA	trans	rs853679	0.546	rs493161	ENSG00000253570.1	RNF5P1	6.83	1.49e-11	1.29e-05	0.48	0.21	Depression;	chr6:27882936	chr8:38600661~38601200:-
BRCA	trans	rs7819412	0.54	rs2409725	ENSG00000253893.2	FAM85B	6.83	1.49e-11	1.29e-05	0.27	0.21	Triglycerides;	chr8:11184152	chr8:8167819~8226614:-
BRCA	trans	rs12439619	0.846	rs62012056	ENSG00000259295.5	CSPG4P12	-6.82	1.49e-11	1.29e-05	-0.32	-0.21	Intelligence (multi-trait analysis);	chr15:82247278	chr15:85191438~85213905:+
BRCA	trans	rs9834975	0.51	rs6798113	ENSG00000267076.1	CCDC58P3	-6.82	1.49e-11	1.3e-05	-0.24	-0.21	Diastolic blood pressure;	chr3:122471289	chr18:12211378~12211807:+
BRCA	trans	rs7819412	0.502	rs4841499	ENSG00000253893.2	FAM85B	6.82	1.49e-11	1.3e-05	0.3	0.21	Triglycerides;	chr8:11130628	chr8:8167819~8226614:-
BRCA	trans	rs902774	0.818	rs73110471	ENSG00000254285.3	KRT8P3	-6.82	1.5e-11	1.3e-05	-0.41	-0.21	Prostate cancer;	chr12:52923037	chr8:61578220~61579668:+
BRCA	trans	rs4911259	0.552	rs6057663	ENSG00000253915.1	MAPRE1P1	-6.82	1.51e-11	1.31e-05	-0.25	-0.21	Inflammatory bowel disease;	chr20:32875265	chr8:135625185~135625981:-
BRCA	trans	rs4911259	0.513	rs6057665	ENSG00000253915.1	MAPRE1P1	-6.82	1.51e-11	1.31e-05	-0.25	-0.21	Inflammatory bowel disease;	chr20:32875654	chr8:135625185~135625981:-
BRCA	trans	rs4929949	0.809	rs10743082	ENSG00000266891.1	RP11-692N5.2	6.82	1.52e-11	1.32e-05	0.24	0.21	Body mass index;	chr11:8603448	chr18:9734882~9735602:-
BRCA	trans	rs7617773	0.817	rs745116	ENSG00000235912.1	RP1-159A19.3	-6.82	1.52e-11	1.32e-05	-0.26	-0.21	Coronary artery disease;	chr3:48231046	chr1:27649419~27649610:+
BRCA	trans	rs12439619	0.693	rs28689861	ENSG00000259295.5	CSPG4P12	-6.82	1.53e-11	1.33e-05	-0.3	-0.21	Intelligence (multi-trait analysis);	chr15:82206369	chr15:85191438~85213905:+
BRCA	trans	rs2980439	0.846	rs2980437	ENSG00000270154.1	RP11-419I17.1	-6.82	1.53e-11	1.33e-05	-0.24	-0.21	Neuroticism;	chr8:8237241	chr8:12476462~12477122:+
BRCA	trans	rs656319	0.729	rs471480	ENSG00000253893.2	FAM85B	6.82	1.57e-11	1.36e-05	0.27	0.21	Myopia (pathological);	chr8:9954952	chr8:8167819~8226614:-
BRCA	trans	rs656319	0.58	rs13272793	ENSG00000253893.2	FAM85B	6.82	1.58e-11	1.37e-05	0.27	0.21	Myopia (pathological);	chr8:10144517	chr8:8167819~8226614:-
BRCA	trans	rs11098499	0.69	rs34818745	ENSG00000120555.12	SEPT7P9	6.82	1.58e-11	1.37e-05	0.26	0.21	Corneal astigmatism;	chr4:119335900	chr10:38383069~38402916:-
BRCA	trans	rs1707322	0.785	rs10890348	ENSG00000255397.1	AC022182.2	-6.82	1.58e-11	1.37e-05	-0.28	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45776751	chr8:60937705~60939871:-
BRCA	trans	rs7824557	0.767	rs1897951	ENSG00000270154.1	RP11-419I17.1	6.81	1.6e-11	1.39e-05	0.26	0.21	Retinal vascular caliber;	chr8:11312345	chr8:12476462~12477122:+
BRCA	trans	rs7824557	0.767	rs7003241	ENSG00000270154.1	RP11-419I17.1	6.81	1.62e-11	1.4e-05	0.26	0.21	Retinal vascular caliber;	chr8:11311566	chr8:12476462~12477122:+
BRCA	trans	rs2235573	0.625	rs139905	ENSG00000258501.1	EIF3LP1	6.81	1.64e-11	1.42e-05	0.23	0.21	Glioma;Glioblastoma;	chr22:38013589	chr14:81916231~81917888:+
BRCA	trans	rs11098499	0.954	rs9993199	ENSG00000120555.12	SEPT7P9	-6.81	1.65e-11	1.43e-05	-0.25	-0.21	Corneal astigmatism;	chr4:119471718	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.863	rs6858592	ENSG00000276997.3	RP11-378J18.9	6.81	1.65e-11	1.43e-05	0.25	0.21	Corneal astigmatism;	chr4:119537537	chr1:222477252~222504622:-
BRCA	trans	rs4911259	0.552	rs13041458	ENSG00000253915.1	MAPRE1P1	-6.81	1.66e-11	1.43e-05	-0.25	-0.21	Inflammatory bowel disease;	chr20:32879570	chr8:135625185~135625981:-
BRCA	trans	rs4911259	0.552	rs13042651	ENSG00000253915.1	MAPRE1P1	-6.81	1.66e-11	1.43e-05	-0.25	-0.21	Inflammatory bowel disease;	chr20:32879617	chr8:135625185~135625981:-
BRCA	trans	rs1707322	1	rs785507	ENSG00000255397.1	AC022182.2	6.81	1.66e-11	1.44e-05	0.28	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46075886	chr8:60937705~60939871:-
BRCA	trans	rs11920570	0.959	rs4315641	ENSG00000267076.1	CCDC58P3	-6.81	1.66e-11	1.44e-05	-0.25	-0.21	Resting heart rate;	chr3:122350028	chr18:12211378~12211807:+
BRCA	trans	rs11098499	0.73	rs12505735	ENSG00000120555.12	SEPT7P9	6.81	1.67e-11	1.44e-05	0.26	0.21	Corneal astigmatism;	chr4:119611801	chr10:38383069~38402916:-
BRCA	trans	rs7617773	0.746	rs11713476	ENSG00000235912.1	RP1-159A19.3	-6.81	1.67e-11	1.45e-05	-0.26	-0.21	Coronary artery disease;	chr3:48333944	chr1:27649419~27649610:+
BRCA	trans	rs17507216	0.718	rs72751657	ENSG00000259295.5	CSPG4P12	-6.81	1.68e-11	1.45e-05	-0.34	-0.21	Excessive daytime sleepiness;	chr15:82581259	chr15:85191438~85213905:+
BRCA	trans	rs7824557	0.767	rs6991606	ENSG00000270154.1	RP11-419I17.1	6.81	1.69e-11	1.46e-05	0.26	0.21	Retinal vascular caliber;	chr8:11318650	chr8:12476462~12477122:+
BRCA	trans	rs2965280	0.793	rs8108083	ENSG00000270983.1	RP11-137J7.3	-6.81	1.7e-11	1.47e-05	-0.46	-0.21	Colorectal cancer;	chr19:34364378	chr6:142062717~142063053:+
BRCA	trans	rs8177876	0.642	rs10514513	ENSG00000226040.3	AC005740.3	6.8	1.71e-11	1.48e-05	0.4	0.21	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81080578	chr5:141896168~141896689:-
BRCA	trans	rs12439619	0.846	rs62012059	ENSG00000259295.5	CSPG4P12	-6.8	1.71e-11	1.48e-05	-0.33	-0.21	Intelligence (multi-trait analysis);	chr15:82251669	chr15:85191438~85213905:+
BRCA	trans	rs4929949	0.901	rs12577859	ENSG00000266891.1	RP11-692N5.2	6.8	1.71e-11	1.48e-05	0.24	0.21	Body mass index;	chr11:8537305	chr18:9734882~9735602:-
BRCA	trans	rs4911259	0.552	rs13038017	ENSG00000253915.1	MAPRE1P1	-6.8	1.71e-11	1.48e-05	-0.25	-0.21	Inflammatory bowel disease;	chr20:32879745	chr8:135625185~135625981:-
BRCA	trans	rs1707322	1	rs785467	ENSG00000255397.1	AC022182.2	6.8	1.72e-11	1.49e-05	0.27	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46055887	chr8:60937705~60939871:-
BRCA	trans	rs1707322	0.827	rs6694302	ENSG00000255397.1	AC022182.2	-6.8	1.73e-11	1.49e-05	-0.28	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45779973	chr8:60937705~60939871:-
BRCA	trans	rs1707322	0.827	rs12125508	ENSG00000255397.1	AC022182.2	-6.8	1.73e-11	1.49e-05	-0.28	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45780338	chr8:60937705~60939871:-
BRCA	trans	rs11785693	0.862	rs11782343	ENSG00000246089.3	RP11-115C21.2	-6.8	1.74e-11	1.5e-05	-0.29	-0.21	Neuroticism (multi-trait analysis);Neuroticism;	chr8:5144120	chr8:6403551~6407142:-
BRCA	trans	rs28541881	0.536	rs60061147	ENSG00000270983.1	RP11-137J7.3	-6.8	1.74e-11	1.5e-05	-0.42	-0.21	Colorectal cancer;	chr19:34313515	chr6:142062717~142063053:+
BRCA	trans	rs2122469	0.655	rs17603934	ENSG00000223508.5	RPL23AP53	6.8	1.74e-11	1.5e-05	0.37	0.21	Serum tamsulosin hydrochloride concentration;	chr8:20718833	chr8:213186~232231:-
BRCA	trans	rs12477438	0.52	rs720229	ENSG00000276576.1	MRPL30P1	6.8	1.75e-11	1.51e-05	0.25	0.21	Chronic sinus infection;	chr2:99087810	chr6:57029521~57029988:+
BRCA	trans	rs11098499	1	rs11098500	ENSG00000276997.3	RP11-378J18.9	6.8	1.75e-11	1.51e-05	0.26	0.21	Corneal astigmatism;	chr4:119298084	chr1:222477252~222504622:-
BRCA	trans	rs7260598	0.685	rs73021420	ENSG00000261770.1	CTC-459F4.1	6.8	1.75e-11	1.51e-05	0.36	0.21	Response to taxane treatment (placlitaxel);	chr19:24082833	chr19:27757184~27760849:-
BRCA	trans	rs7824557	0.767	rs11250127	ENSG00000270154.1	RP11-419I17.1	6.8	1.76e-11	1.52e-05	0.26	0.21	Retinal vascular caliber;	chr8:11312700	chr8:12476462~12477122:+
BRCA	trans	rs7260598	0.685	rs73524177	ENSG00000261770.1	CTC-459F4.1	6.8	1.76e-11	1.52e-05	0.35	0.21	Response to taxane treatment (placlitaxel);	chr19:24156376	chr19:27757184~27760849:-
BRCA	trans	rs2060793	0.519	rs2597212	ENSG00000236360.2	RP11-334A14.2	-6.8	1.77e-11	1.53e-05	-0.25	-0.21	Vitamin D levels;	chr11:14560216	chr1:52993201~52993702:-
BRCA	trans	rs9467711	0.606	rs4634439	ENSG00000253570.1	RNF5P1	-6.8	1.77e-11	1.53e-05	-0.44	-0.21	Autism spectrum disorder or schizophrenia;	chr6:26597776	chr8:38600661~38601200:-
BRCA	trans	rs14057	0.896	rs12028517	ENSG00000215869.3	RP11-364B6.1	6.8	1.77e-11	1.53e-05	0.29	0.21	Systolic blood pressure;	chr1:6601672	chr1:104073023~104077087:+
BRCA	trans	rs9467711	0.559	rs2295593	ENSG00000253570.1	RNF5P1	6.8	1.78e-11	1.54e-05	0.43	0.21	Autism spectrum disorder or schizophrenia;	chr6:26501540	chr8:38600661~38601200:-
BRCA	trans	rs9650657	0.623	rs11250066	ENSG00000253893.2	FAM85B	6.8	1.78e-11	1.54e-05	0.25	0.21	Neuroticism;	chr8:10742957	chr8:8167819~8226614:-
BRCA	trans	rs7903456	0.648	rs4934290	ENSG00000232706.3	NUTM2HP	6.8	1.79e-11	1.54e-05	0.28	0.21	Gout;Renal underexcretion gout;	chr10:87040504	chr10:50676743~50686326:+
BRCA	trans	rs1023500	1	rs1023497	ENSG00000268568.1	AC007228.9	-6.8	1.79e-11	1.55e-05	-0.3	-0.21	Schizophrenia;	chr22:41944504	chr19:56672574~56673901:-
BRCA	trans	rs11098499	0.863	rs3822190	ENSG00000276997.3	RP11-378J18.9	6.8	1.79e-11	1.55e-05	0.26	0.21	Corneal astigmatism;	chr4:119506943	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.863	rs3822191	ENSG00000276997.3	RP11-378J18.9	6.8	1.79e-11	1.55e-05	0.26	0.21	Corneal astigmatism;	chr4:119506946	chr1:222477252~222504622:-
BRCA	trans	rs864643	1	rs634338	ENSG00000188856.6	RPSAP47	6.8	1.81e-11	1.56e-05	0.29	0.21	Attention deficit hyperactivity disorder;	chr3:39522752	chr8:80558870~80559757:+
BRCA	trans	rs12439619	0.693	rs17269819	ENSG00000259295.5	CSPG4P12	-6.79	1.84e-11	1.59e-05	-0.3	-0.21	Intelligence (multi-trait analysis);	chr15:82174660	chr15:85191438~85213905:+
BRCA	trans	rs1568889	0.887	rs7102237	ENSG00000174912.7	METTL15P1	6.79	1.85e-11	1.6e-05	0.21	0.21	Bipolar disorder;	chr11:28322749	chr3:156713884~156714928:-
BRCA	trans	rs7903456	0.648	rs1923938	ENSG00000232706.3	NUTM2HP	6.79	1.85e-11	1.6e-05	0.3	0.21	Gout;Renal underexcretion gout;	chr10:87077623	chr10:50676743~50686326:+
BRCA	trans	rs9834975	0.647	rs6807375	ENSG00000267076.1	CCDC58P3	-6.79	1.86e-11	1.61e-05	-0.24	-0.21	Diastolic blood pressure;	chr3:122363428	chr18:12211378~12211807:+
BRCA	trans	rs864643	1	rs864643	ENSG00000188856.6	RPSAP47	6.79	1.87e-11	1.62e-05	0.3	0.21	Attention deficit hyperactivity disorder;	chr3:39514089	chr8:80558870~80559757:+
BRCA	trans	rs3849046	1	rs3849046	ENSG00000226666.1	HSPA9P1	6.79	1.91e-11	1.65e-05	0.22	0.21	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138515503	chr2:221961737~221963765:+
BRCA	trans	rs1707322	0.789	rs10789473	ENSG00000255397.1	AC022182.2	-6.79	1.92e-11	1.66e-05	-0.28	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45782459	chr8:60937705~60939871:-
BRCA	trans	rs4929949	0.809	rs12805671	ENSG00000266891.1	RP11-692N5.2	6.79	1.93e-11	1.66e-05	0.24	0.21	Body mass index;	chr11:8544287	chr18:9734882~9735602:-
BRCA	trans	rs1707322	1	rs6672115	ENSG00000255397.1	AC022182.2	-6.79	1.93e-11	1.66e-05	-0.28	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45807207	chr8:60937705~60939871:-
BRCA	trans	rs11098499	0.863	rs6835635	ENSG00000120555.12	SEPT7P9	6.79	1.94e-11	1.67e-05	0.26	0.21	Corneal astigmatism;	chr4:119537712	chr10:38383069~38402916:-
BRCA	trans	rs481331	0.741	rs683538	ENSG00000272128.1	KB-1836B5.4	-6.78	1.96e-11	1.69e-05	-0.29	-0.21	Systemic juvenile idiopathic arthritis;	chr10:42653406	chr8:38099471~38099931:+
BRCA	trans	rs864643	0.891	rs1068953	ENSG00000188856.6	RPSAP47	6.78	1.96e-11	1.69e-05	0.3	0.21	Attention deficit hyperactivity disorder;	chr3:39515070	chr8:80558870~80559757:+
BRCA	trans	rs9467711	0.559	rs9393727	ENSG00000253570.1	RNF5P1	6.78	1.97e-11	1.7e-05	0.43	0.21	Autism spectrum disorder or schizophrenia;	chr6:26499783	chr8:38600661~38601200:-
BRCA	trans	rs860295	1	rs822490	ENSG00000241627.3	UBQLN4P1	-6.78	1.98e-11	1.71e-05	-0.21	-0.21	Body mass index;	chr1:155853180	chr3:148985868~148987668:-
BRCA	trans	rs11098499	0.863	rs10018280	ENSG00000276997.3	RP11-378J18.9	6.78	2e-11	1.72e-05	0.25	0.21	Corneal astigmatism;	chr4:119556984	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.863	rs6534141	ENSG00000276997.3	RP11-378J18.9	6.78	2e-11	1.72e-05	0.25	0.21	Corneal astigmatism;	chr4:119564068	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.863	rs2127823	ENSG00000276997.3	RP11-378J18.9	6.78	2e-11	1.72e-05	0.25	0.21	Corneal astigmatism;	chr4:119564515	chr1:222477252~222504622:-
BRCA	trans	rs7032940	0.784	rs10980253	ENSG00000228236.2	TXNP5	6.78	2e-11	1.73e-05	0.27	0.21	Height;	chr9:110205555	chr2:149068596~149068910:-
BRCA	trans	rs7617773	0.817	rs3731513	ENSG00000235912.1	RP1-159A19.3	-6.78	2.01e-11	1.73e-05	-0.28	-0.21	Coronary artery disease;	chr3:48178047	chr1:27649419~27649610:+
BRCA	trans	rs9834975	0.647	rs12152287	ENSG00000267076.1	CCDC58P3	-6.78	2.01e-11	1.73e-05	-0.24	-0.21	Diastolic blood pressure;	chr3:122381494	chr18:12211378~12211807:+
BRCA	trans	rs1707322	0.963	rs4508055	ENSG00000255397.1	AC022182.2	-6.78	2.02e-11	1.74e-05	-0.28	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45792059	chr8:60937705~60939871:-
BRCA	trans	rs9581094	0.591	rs7318176	ENSG00000237917.1	PARP4P1	-6.78	2.03e-11	1.74e-05	-0.4	-0.21	Sudden cardiac arrest;	chr13:24456976	chrY:26594851~26634652:-
BRCA	trans	rs3806843	0.547	rs183679	ENSG00000231043.3	AC007238.1	6.78	2.05e-11	1.76e-05	0.25	0.21	Depressive symptoms (multi-trait analysis);	chr5:140891432	chr2:58460292~58462032:-
BRCA	trans	rs12543645	0.598	rs35338507	ENSG00000253893.2	FAM85B	-6.78	2.06e-11	1.77e-05	-0.29	-0.21	Schizophrenia;	chr8:10420472	chr8:8167819~8226614:-
BRCA	trans	rs11098499	0.863	rs3775858	ENSG00000276997.3	RP11-378J18.9	6.77	2.08e-11	1.79e-05	0.25	0.21	Corneal astigmatism;	chr4:119564873	chr1:222477252~222504622:-
BRCA	trans	rs875971	0.545	rs6970498	ENSG00000234585.5	CCT6P3	6.77	2.08e-11	1.79e-05	0.23	0.21	Aortic root size;	chr7:66275908	chr7:65038354~65074713:+
BRCA	trans	rs714543	0.66	rs13224222	ENSG00000219797.2	PPIAP9	6.77	2.08e-11	1.79e-05	0.24	0.21	Plateletcrit;	chr7:44772739	chr6:31519480~31520291:-
BRCA	trans	rs6940638	0.956	rs36048693	ENSG00000204709.4	LINC01556	6.77	2.09e-11	1.8e-05	0.3	0.21	Intelligence (multi-trait analysis);	chr6:27064932	chr6:28943877~28944537:+
BRCA	trans	rs2060793	0.519	rs10766187	ENSG00000236360.2	RP11-334A14.2	6.77	2.1e-11	1.8e-05	0.25	0.21	Vitamin D levels;	chr11:14603836	chr1:52993201~52993702:-
BRCA	trans	rs1568889	0.838	rs4572130	ENSG00000174912.7	METTL15P1	6.77	2.11e-11	1.81e-05	0.21	0.21	Bipolar disorder;	chr11:28350247	chr3:156713884~156714928:-
BRCA	trans	rs853679	0.607	rs200489	ENSG00000253570.1	RNF5P1	6.77	2.11e-11	1.81e-05	0.46	0.21	Depression;	chr6:27830479	chr8:38600661~38601200:-
BRCA	trans	rs11098499	0.863	rs3822190	ENSG00000120555.12	SEPT7P9	6.77	2.15e-11	1.85e-05	0.26	0.21	Corneal astigmatism;	chr4:119506943	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.863	rs3822191	ENSG00000120555.12	SEPT7P9	6.77	2.15e-11	1.85e-05	0.26	0.21	Corneal astigmatism;	chr4:119506946	chr10:38383069~38402916:-
BRCA	trans	rs9834975	0.647	rs3749212	ENSG00000267076.1	CCDC58P3	-6.77	2.17e-11	1.87e-05	-0.24	-0.21	Diastolic blood pressure;	chr3:122368113	chr18:12211378~12211807:+
BRCA	trans	rs9834975	0.647	rs7646227	ENSG00000267076.1	CCDC58P3	-6.77	2.17e-11	1.87e-05	-0.24	-0.21	Diastolic blood pressure;	chr3:122374030	chr18:12211378~12211807:+
BRCA	trans	rs9834975	0.647	rs9876015	ENSG00000267076.1	CCDC58P3	-6.77	2.17e-11	1.87e-05	-0.24	-0.21	Diastolic blood pressure;	chr3:122376923	chr18:12211378~12211807:+
BRCA	trans	rs714543	0.934	rs10275962	ENSG00000267258.1	CTC-448F2.3	-6.77	2.18e-11	1.88e-05	-0.24	-0.21	Plateletcrit;	chr7:44809141	chr19:29921182~29921653:+
BRCA	trans	rs9467711	0.606	rs9379899	ENSG00000253570.1	RNF5P1	6.77	2.2e-11	1.89e-05	0.46	0.21	Autism spectrum disorder or schizophrenia;	chr6:26602787	chr8:38600661~38601200:-
BRCA	trans	rs9834975	0.544	rs6805448	ENSG00000267076.1	CCDC58P3	-6.77	2.2e-11	1.89e-05	-0.24	-0.21	Diastolic blood pressure;	chr3:122563636	chr18:12211378~12211807:+
BRCA	trans	rs853679	0.546	rs71537572	ENSG00000281831.1	HCP5B	6.77	2.21e-11	1.9e-05	0.53	0.21	Depression;	chr6:28002937	chr6:29871895~29873783:-
BRCA	trans	rs673253	0.686	rs2819336	ENSG00000231007.5	CDC20P1	-6.77	2.21e-11	1.9e-05	-0.27	-0.21	Intelligence (multi-trait analysis);	chr1:43550138	chr9:87011652~87013151:+
BRCA	trans	rs3942852	0.91	rs10742831	ENSG00000134612.10	FOLH1B	-6.77	2.22e-11	1.9e-05	-0.29	-0.21	Acute lymphoblastic leukemia (childhood);	chr11:48098139	chr11:89639227~89698718:+
BRCA	trans	rs11098499	0.73	rs78971550	ENSG00000276997.3	RP11-378J18.9	6.77	2.22e-11	1.9e-05	0.25	0.21	Corneal astigmatism;	chr4:119359886	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.645	rs78422072	ENSG00000276997.3	RP11-378J18.9	6.77	2.22e-11	1.9e-05	0.25	0.21	Corneal astigmatism;	chr4:119359887	chr1:222477252~222504622:-
BRCA	trans	rs9834975	0.605	rs1962046	ENSG00000267076.1	CCDC58P3	-6.76	2.22e-11	1.91e-05	-0.24	-0.21	Diastolic blood pressure;	chr3:122423056	chr18:12211378~12211807:+
BRCA	trans	rs72615157	0.539	rs2261360	ENSG00000228546.2	CTA-313A17.3	6.76	2.25e-11	1.93e-05	0.31	0.21	Lung function (FEV1/FVC);	chr7:100095370	chr7:102337316~102339115:+
BRCA	trans	rs7260598	0.792	rs11670331	ENSG00000261770.1	CTC-459F4.1	6.76	2.26e-11	1.94e-05	0.35	0.21	Response to taxane treatment (placlitaxel);	chr19:24155040	chr19:27757184~27760849:-
BRCA	trans	rs17507216	0.958	rs28648832	ENSG00000259295.5	CSPG4P12	-6.76	2.26e-11	1.94e-05	-0.31	-0.21	Excessive daytime sleepiness;	chr15:82567642	chr15:85191438~85213905:+
BRCA	trans	rs1707322	0.827	rs6683274	ENSG00000255397.1	AC022182.2	-6.76	2.27e-11	1.95e-05	-0.27	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45775966	chr8:60937705~60939871:-
BRCA	trans	rs546131	0.6	rs525202	ENSG00000225531.1	RP11-196I18.3	6.76	2.27e-11	1.95e-05	0.29	0.21	Lung disease severity in cystic fibrosis;	chr11:34800401	chr9:107116829~107117557:+
BRCA	trans	rs7824557	0.767	rs1897950	ENSG00000270154.1	RP11-419I17.1	6.76	2.3e-11	1.97e-05	0.26	0.2	Retinal vascular caliber;	chr8:11312042	chr8:12476462~12477122:+
BRCA	trans	rs8177876	0.822	rs16954582	ENSG00000226040.3	AC005740.3	6.76	2.34e-11	2e-05	0.39	0.2	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81080552	chr5:141896168~141896689:-
BRCA	trans	rs7824557	0.767	rs7837036	ENSG00000270154.1	RP11-419I17.1	6.76	2.37e-11	2.03e-05	0.26	0.2	Retinal vascular caliber;	chr8:11317980	chr8:12476462~12477122:+
BRCA	trans	rs4929949	0.78	rs4520598	ENSG00000266891.1	RP11-692N5.2	6.76	2.37e-11	2.03e-05	0.24	0.2	Body mass index;	chr11:8592119	chr18:9734882~9735602:-
BRCA	trans	rs14057	0.759	rs11122119	ENSG00000215869.3	RP11-364B6.1	6.75	2.39e-11	2.05e-05	0.28	0.2	Systolic blood pressure;	chr1:6708796	chr1:104073023~104077087:+
BRCA	trans	rs11098499	0.657	rs10434028	ENSG00000276997.3	RP11-378J18.9	6.75	2.39e-11	2.05e-05	0.25	0.2	Corneal astigmatism;	chr4:119373309	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.604	rs2389882	ENSG00000120555.12	SEPT7P9	6.75	2.41e-11	2.07e-05	0.26	0.2	Corneal astigmatism;	chr4:119645578	chr10:38383069~38402916:-
BRCA	trans	rs4929949	0.78	rs10769919	ENSG00000266891.1	RP11-692N5.2	-6.75	2.44e-11	2.09e-05	-0.24	-0.2	Body mass index;	chr11:8589023	chr18:9734882~9735602:-
BRCA	trans	rs1707322	1	rs10890376	ENSG00000255397.1	AC022182.2	-6.75	2.46e-11	2.11e-05	-0.28	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45940910	chr8:60937705~60939871:-
BRCA	trans	rs853679	0.546	rs35017208	ENSG00000281831.1	HCP5B	6.75	2.47e-11	2.11e-05	0.52	0.2	Depression;	chr6:28377505	chr6:29871895~29873783:-
BRCA	trans	rs853679	1	rs1936365	ENSG00000253570.1	RNF5P1	-6.75	2.47e-11	2.12e-05	-0.39	-0.2	Depression;	chr6:28300675	chr8:38600661~38601200:-
BRCA	trans	rs7032940	0.954	rs10816937	ENSG00000228236.2	TXNP5	-6.75	2.5e-11	2.14e-05	-0.27	-0.2	Height;	chr9:110189709	chr2:149068596~149068910:-
BRCA	trans	rs853679	0.546	rs36092177	ENSG00000281831.1	HCP5B	6.75	2.51e-11	2.15e-05	0.52	0.2	Depression;	chr6:28390030	chr6:29871895~29873783:-
BRCA	trans	rs853679	0.546	rs2232429	ENSG00000281831.1	HCP5B	6.75	2.51e-11	2.15e-05	0.52	0.2	Depression;	chr6:28391855	chr6:29871895~29873783:-
BRCA	trans	rs853679	0.546	rs2232426	ENSG00000281831.1	HCP5B	6.75	2.51e-11	2.15e-05	0.52	0.2	Depression;	chr6:28392882	chr6:29871895~29873783:-
BRCA	trans	rs853679	0.546	rs2232423	ENSG00000281831.1	HCP5B	6.75	2.51e-11	2.15e-05	0.52	0.2	Depression;	chr6:28398374	chr6:29871895~29873783:-
BRCA	trans	rs853679	0.546	rs200977	ENSG00000253570.1	RNF5P1	6.74	2.55e-11	2.18e-05	0.47	0.2	Depression;	chr6:27886523	chr8:38600661~38601200:-
BRCA	trans	rs7903456	0.648	rs9420432	ENSG00000232706.3	NUTM2HP	6.74	2.56e-11	2.19e-05	0.3	0.2	Gout;Renal underexcretion gout;	chr10:87072473	chr10:50676743~50686326:+
BRCA	trans	rs7260598	0.792	rs11671489	ENSG00000261770.1	CTC-459F4.1	6.74	2.57e-11	2.2e-05	0.35	0.2	Response to taxane treatment (placlitaxel);	chr19:24156070	chr19:27757184~27760849:-
BRCA	trans	rs7260598	0.792	rs60773823	ENSG00000261770.1	CTC-459F4.1	6.74	2.57e-11	2.2e-05	0.35	0.2	Response to taxane treatment (placlitaxel);	chr19:24156730	chr19:27757184~27760849:-
BRCA	trans	rs17767294	0.708	rs72846802	ENSG00000242375.1	RP11-498P14.3	-6.74	2.57e-11	2.2e-05	-0.6	-0.2	Parkinson's disease;	chr6:28197064	chr9:97195351~97197687:-
BRCA	trans	rs12200782	0.722	rs12216155	ENSG00000242375.1	RP11-498P14.3	-6.74	2.59e-11	2.21e-05	-0.52	-0.2	Small cell lung carcinoma;	chr6:26373715	chr9:97195351~97197687:-
BRCA	trans	rs2288327	0.818	rs3829747	ENSG00000269800.1	PLEKHA3P1	6.74	2.59e-11	2.22e-05	0.31	0.2	Atrial fibrillation;	chr2:178532834	chr19:41521043~41521989:-
BRCA	trans	rs673253	0.686	rs596522	ENSG00000231007.5	CDC20P1	6.74	2.6e-11	2.22e-05	0.27	0.2	Intelligence (multi-trait analysis);	chr1:43600753	chr9:87011652~87013151:+
BRCA	trans	rs864643	1	rs1707968	ENSG00000188856.6	RPSAP47	6.74	2.61e-11	2.24e-05	0.3	0.2	Attention deficit hyperactivity disorder;	chr3:39506914	chr8:80558870~80559757:+
BRCA	trans	rs9650657	0.623	rs7004253	ENSG00000253893.2	FAM85B	6.74	2.63e-11	2.25e-05	0.25	0.2	Neuroticism;	chr8:10743347	chr8:8167819~8226614:-
BRCA	trans	rs673253	0.662	rs61769611	ENSG00000231007.5	CDC20P1	6.74	2.63e-11	2.25e-05	0.27	0.2	Intelligence (multi-trait analysis);	chr1:43563242	chr9:87011652~87013151:+
BRCA	trans	rs9467711	0.591	rs6913795	ENSG00000253570.1	RNF5P1	6.74	2.63e-11	2.25e-05	0.53	0.2	Autism spectrum disorder or schizophrenia;	chr6:25847797	chr8:38600661~38601200:-
BRCA	trans	rs9467711	0.591	rs9467621	ENSG00000253570.1	RNF5P1	6.74	2.63e-11	2.25e-05	0.53	0.2	Autism spectrum disorder or schizophrenia;	chr6:25851110	chr8:38600661~38601200:-
BRCA	trans	rs9467711	0.591	rs9467622	ENSG00000253570.1	RNF5P1	6.74	2.65e-11	2.26e-05	0.53	0.2	Autism spectrum disorder or schizophrenia;	chr6:25854416	chr8:38600661~38601200:-
BRCA	trans	rs7819412	0.521	rs10100660	ENSG00000253893.2	FAM85B	6.74	2.65e-11	2.27e-05	0.27	0.2	Triglycerides;	chr8:11181376	chr8:8167819~8226614:-
BRCA	trans	rs1707322	1	rs10789485	ENSG00000255397.1	AC022182.2	-6.74	2.68e-11	2.29e-05	-0.27	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45941636	chr8:60937705~60939871:-
BRCA	trans	rs2220004	1	rs2035406	ENSG00000134612.10	FOLH1B	-6.74	2.7e-11	2.31e-05	-0.27	-0.2	Odorant perception (&beta-damascenone);	chr11:56067311	chr11:89639227~89698718:+
BRCA	trans	rs853679	1	rs853694	ENSG00000253570.1	RNF5P1	6.74	2.7e-11	2.31e-05	0.4	0.2	Depression;	chr6:28311323	chr8:38600661~38601200:-
BRCA	trans	rs11098499	0.863	rs7699064	ENSG00000120555.12	SEPT7P9	-6.73	2.72e-11	2.32e-05	-0.26	-0.2	Corneal astigmatism;	chr4:119507154	chr10:38383069~38402916:-
BRCA	trans	rs1707322	0.964	rs785516	ENSG00000255397.1	AC022182.2	6.73	2.72e-11	2.32e-05	0.27	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46099086	chr8:60937705~60939871:-
BRCA	trans	rs1707322	1	rs785517	ENSG00000255397.1	AC022182.2	6.73	2.72e-11	2.32e-05	0.27	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46101863	chr8:60937705~60939871:-
BRCA	trans	rs1707322	1	rs785484	ENSG00000255397.1	AC022182.2	6.73	2.72e-11	2.32e-05	0.27	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46108343	chr8:60937705~60939871:-
BRCA	trans	rs9467711	0.559	rs6920256	ENSG00000253570.1	RNF5P1	6.73	2.72e-11	2.33e-05	0.44	0.2	Autism spectrum disorder or schizophrenia;	chr6:26537573	chr8:38600661~38601200:-
BRCA	trans	rs2965280	0.793	rs11879119	ENSG00000270983.1	RP11-137J7.3	-6.73	2.72e-11	2.33e-05	-0.45	-0.2	Colorectal cancer;	chr19:34358034	chr6:142062717~142063053:+
BRCA	trans	rs6921919	0.832	rs17312661	ENSG00000228078.1	HLA-U	-6.73	2.72e-11	2.33e-05	-0.35	-0.2	Autism spectrum disorder or schizophrenia;	chr6:28332559	chr6:29934101~29934286:+
BRCA	trans	rs9650657	0.623	rs10094497	ENSG00000253893.2	FAM85B	-6.73	2.75e-11	2.35e-05	-0.24	-0.2	Neuroticism;	chr8:10745319	chr8:8167819~8226614:-
BRCA	trans	rs6940638	0.956	rs3922717	ENSG00000204709.4	LINC01556	6.73	2.75e-11	2.35e-05	0.31	0.2	Intelligence (multi-trait analysis);	chr6:27063145	chr6:28943877~28944537:+
BRCA	trans	rs6940638	0.956	rs13207365	ENSG00000204709.4	LINC01556	6.73	2.75e-11	2.35e-05	0.31	0.2	Intelligence (multi-trait analysis);	chr6:27063201	chr6:28943877~28944537:+
BRCA	trans	rs6940638	0.956	rs12203454	ENSG00000204709.4	LINC01556	6.73	2.75e-11	2.35e-05	0.31	0.2	Intelligence (multi-trait analysis);	chr6:27063321	chr6:28943877~28944537:+
BRCA	trans	rs7824557	0.701	rs4568582	ENSG00000270154.1	RP11-419I17.1	6.73	2.76e-11	2.36e-05	0.26	0.2	Retinal vascular caliber;	chr8:11302986	chr8:12476462~12477122:+
BRCA	trans	rs875971	0.502	rs11769702	ENSG00000234585.5	CCT6P3	6.73	2.78e-11	2.38e-05	0.23	0.2	Aortic root size;	chr7:66255529	chr7:65038354~65074713:+
BRCA	trans	rs9425766	0.54	rs2294492	ENSG00000213331.4	RP11-713C19.2	6.73	2.8e-11	2.39e-05	0.23	0.2	Life satisfaction;	chr1:174157884	chr4:187970273~187971284:+
BRCA	trans	rs2967605	1	rs2967605	ENSG00000227097.5	RPS28P7	6.73	2.8e-11	2.39e-05	0.3	0.2	HDL cholesterol;	chr19:8404854	chr11:82689559~82689768:+
BRCA	trans	rs11098499	0.954	rs3733520	ENSG00000276997.3	RP11-378J18.9	6.73	2.81e-11	2.4e-05	0.25	0.2	Corneal astigmatism;	chr4:119502325	chr1:222477252~222504622:-
BRCA	trans	rs801193	0.904	rs4718405	ENSG00000224316.1	RP11-479O9.2	6.73	2.83e-11	2.42e-05	0.2	0.2	Aortic root size;	chr7:66789659	chr7:65773620~65802067:+
BRCA	trans	rs11098499	1	rs58601355	ENSG00000276997.3	RP11-378J18.9	6.73	2.83e-11	2.42e-05	0.26	0.2	Corneal astigmatism;	chr4:119265212	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.82	rs13128602	ENSG00000120555.12	SEPT7P9	-6.73	2.84e-11	2.42e-05	-0.26	-0.2	Corneal astigmatism;	chr4:119538211	chr10:38383069~38402916:-
BRCA	trans	rs853679	0.546	rs200490	ENSG00000253570.1	RNF5P1	6.73	2.85e-11	2.43e-05	0.45	0.2	Depression;	chr6:27829157	chr8:38600661~38601200:-
BRCA	trans	rs12200782	0.722	rs12194095	ENSG00000242375.1	RP11-498P14.3	-6.73	2.86e-11	2.44e-05	-0.52	-0.2	Small cell lung carcinoma;	chr6:26364292	chr9:97195351~97197687:-
BRCA	trans	rs12200782	0.722	rs12205731	ENSG00000242375.1	RP11-498P14.3	-6.73	2.86e-11	2.44e-05	-0.52	-0.2	Small cell lung carcinoma;	chr6:26370432	chr9:97195351~97197687:-
BRCA	trans	rs11098499	0.863	rs9997631	ENSG00000276997.3	RP11-378J18.9	6.73	2.86e-11	2.44e-05	0.25	0.2	Corneal astigmatism;	chr4:119548840	chr1:222477252~222504622:-
BRCA	trans	rs7617773	0.817	rs9818937	ENSG00000235912.1	RP1-159A19.3	-6.73	2.87e-11	2.45e-05	-0.26	-0.2	Coronary artery disease;	chr3:48283791	chr1:27649419~27649610:+
BRCA	trans	rs7833986	0.501	rs2667978	ENSG00000244245.1	RP11-120B7.1	6.73	2.89e-11	2.46e-05	0.25	0.2	Height;	chr8:55985392	chr5:108593609~108593967:+
BRCA	trans	rs853679	0.607	rs71559070	ENSG00000281831.1	HCP5B	6.72	2.89e-11	2.47e-05	0.53	0.2	Depression;	chr6:28071151	chr6:29871895~29873783:-
BRCA	trans	rs853679	0.607	rs35902873	ENSG00000281831.1	HCP5B	6.72	2.89e-11	2.47e-05	0.53	0.2	Depression;	chr6:28091171	chr6:29871895~29873783:-
BRCA	trans	rs853679	0.607	rs13197574	ENSG00000281831.1	HCP5B	6.72	2.89e-11	2.47e-05	0.53	0.2	Depression;	chr6:28092461	chr6:29871895~29873783:-
BRCA	trans	rs875971	0.502	rs2465121	ENSG00000234585.5	CCT6P3	-6.72	2.89e-11	2.47e-05	-0.22	-0.2	Aortic root size;	chr7:66156017	chr7:65038354~65074713:+
BRCA	trans	rs7617773	0.817	rs3937	ENSG00000235912.1	RP1-159A19.3	-6.72	2.97e-11	2.53e-05	-0.26	-0.2	Coronary artery disease;	chr3:48270912	chr1:27649419~27649610:+
BRCA	trans	rs673253	0.686	rs2819333	ENSG00000231007.5	CDC20P1	6.72	2.97e-11	2.54e-05	0.24	0.2	Intelligence (multi-trait analysis);	chr1:43548902	chr9:87011652~87013151:+
BRCA	trans	rs9834975	0.647	rs12488155	ENSG00000267076.1	CCDC58P3	-6.72	2.98e-11	2.54e-05	-0.24	-0.2	Diastolic blood pressure;	chr3:122363991	chr18:12211378~12211807:+
BRCA	trans	rs2122469	0.655	rs17603934	ENSG00000245281.5	CTD-2547L16.1	6.72	2.98e-11	2.54e-05	0.35	0.2	Serum tamsulosin hydrochloride concentration;	chr8:20718833	chr8:18084868~18096394:+
BRCA	trans	rs16937956	0.536	rs12362113	ENSG00000266891.1	RP11-692N5.2	-6.72	3.02e-11	2.57e-05	-0.25	-0.2	Body mass index;	chr11:8379019	chr18:9734882~9735602:-
BRCA	trans	rs2965280	0.793	rs10418601	ENSG00000270983.1	RP11-137J7.3	-6.72	3.03e-11	2.58e-05	-0.45	-0.2	Colorectal cancer;	chr19:34359094	chr6:142062717~142063053:+
BRCA	trans	rs4883201	0.572	rs987917	ENSG00000179899.8	PHC1P1	6.72	3.03e-11	2.58e-05	0.24	0.2	Total cholesterol levels;Cholesterol, total;	chr12:8949979	chr12:55411727~55414787:-
BRCA	trans	rs864643	1	rs1707973	ENSG00000188856.6	RPSAP47	6.72	3.05e-11	2.6e-05	0.3	0.2	Attention deficit hyperactivity disorder;	chr3:39507275	chr8:80558870~80559757:+
BRCA	trans	rs17507216	1	rs17158413	ENSG00000259295.5	CSPG4P12	-6.72	3.05e-11	2.6e-05	-0.3	-0.2	Excessive daytime sleepiness;	chr15:82566658	chr15:85191438~85213905:+
BRCA	trans	rs1707322	1	rs7539800	ENSG00000255397.1	AC022182.2	6.72	3.06e-11	2.61e-05	0.27	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45796457	chr8:60937705~60939871:-
BRCA	trans	rs17301013	0.861	rs61826916	ENSG00000213331.4	RP11-713C19.2	6.72	3.07e-11	2.61e-05	0.23	0.2	Systemic lupus erythematosus;	chr1:174616048	chr4:187970273~187971284:+
BRCA	trans	rs853679	1	rs853679	ENSG00000253570.1	RNF5P1	6.72	3.07e-11	2.62e-05	0.39	0.2	Depression;	chr6:28329086	chr8:38600661~38601200:-
BRCA	trans	rs853679	1	rs853678	ENSG00000253570.1	RNF5P1	6.72	3.07e-11	2.62e-05	0.39	0.2	Depression;	chr6:28329536	chr8:38600661~38601200:-
BRCA	trans	rs7260598	0.792	rs17620048	ENSG00000261770.1	CTC-459F4.1	6.71	3.09e-11	2.63e-05	0.34	0.2	Response to taxane treatment (placlitaxel);	chr19:24174677	chr19:27757184~27760849:-
BRCA	trans	rs11098499	0.566	rs17051356	ENSG00000276997.3	RP11-378J18.9	6.71	3.09e-11	2.63e-05	0.26	0.2	Corneal astigmatism;	chr4:119664153	chr1:222477252~222504622:-
BRCA	trans	rs864643	1	rs1707969	ENSG00000188856.6	RPSAP47	6.71	3.11e-11	2.65e-05	0.3	0.2	Attention deficit hyperactivity disorder;	chr3:39506998	chr8:80558870~80559757:+
BRCA	trans	rs11098499	0.863	rs7699064	ENSG00000276997.3	RP11-378J18.9	-6.71	3.12e-11	2.65e-05	-0.26	-0.2	Corneal astigmatism;	chr4:119507154	chr1:222477252~222504622:-
BRCA	trans	rs17767294	0.614	rs41269291	ENSG00000242375.1	RP11-498P14.3	-6.71	3.14e-11	2.67e-05	-0.61	-0.2	Parkinson's disease;	chr6:28283762	chr9:97195351~97197687:-
BRCA	trans	rs17767294	0.614	rs72854506	ENSG00000242375.1	RP11-498P14.3	-6.71	3.14e-11	2.67e-05	-0.61	-0.2	Parkinson's disease;	chr6:28284720	chr9:97195351~97197687:-
BRCA	trans	rs6940638	1	rs12204280	ENSG00000204709.4	LINC01556	6.71	3.14e-11	2.67e-05	0.3	0.2	Intelligence (multi-trait analysis);	chr6:27065325	chr6:28943877~28944537:+
BRCA	trans	rs7662987	1	rs17595424	ENSG00000228407.2	RP4-800M22.1	6.71	3.17e-11	2.7e-05	0.43	0.2	Smoking initiation;	chr4:99072718	chr1:52160261~52160600:-
BRCA	trans	rs877636	0.847	rs2017445	ENSG00000225071.1	GS1-184P14.2	6.71	3.2e-11	2.73e-05	0.39	0.2	Cognitive function;	chr12:56013288	chrX:24429573~24429920:-
BRCA	trans	rs941207	0.756	rs7313074	ENSG00000257210.1	NACAP3	-6.71	3.22e-11	2.74e-05	-0.28	-0.2	Platelet count;	chr12:56760705	chr12:93124063~93124543:-
BRCA	trans	rs902774	0.818	rs4919743	ENSG00000254285.3	KRT8P3	-6.71	3.24e-11	2.76e-05	-0.35	-0.2	Prostate cancer;	chr12:52915800	chr8:61578220~61579668:+
BRCA	trans	rs1707322	0.826	rs10890349	ENSG00000255397.1	AC022182.2	-6.71	3.24e-11	2.76e-05	-0.27	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45784283	chr8:60937705~60939871:-
BRCA	trans	rs1707322	0.758	rs10789474	ENSG00000255397.1	AC022182.2	-6.71	3.24e-11	2.76e-05	-0.27	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45784368	chr8:60937705~60939871:-
BRCA	trans	rs7260598	0.792	rs73021461	ENSG00000261770.1	CTC-459F4.1	6.71	3.26e-11	2.77e-05	0.35	0.2	Response to taxane treatment (placlitaxel);	chr19:24140154	chr19:27757184~27760849:-
BRCA	trans	rs853679	0.607	rs67662114	ENSG00000281831.1	HCP5B	6.7	3.3e-11	2.8e-05	0.52	0.2	Depression;	chr6:27964523	chr6:29871895~29873783:-
BRCA	trans	rs853679	0.607	rs13216117	ENSG00000281831.1	HCP5B	6.7	3.3e-11	2.8e-05	0.52	0.2	Depression;	chr6:27970706	chr6:29871895~29873783:-
BRCA	trans	rs853679	0.607	rs36101351	ENSG00000281831.1	HCP5B	6.7	3.3e-11	2.8e-05	0.52	0.2	Depression;	chr6:27975591	chr6:29871895~29873783:-
BRCA	trans	rs853679	0.607	rs28360499	ENSG00000281831.1	HCP5B	6.7	3.3e-11	2.8e-05	0.52	0.2	Depression;	chr6:27977618	chr6:29871895~29873783:-
BRCA	trans	rs2243480	1	rs4548056	ENSG00000273142.1	RP11-458F8.4	-6.7	3.33e-11	2.83e-05	-0.28	-0.2	Diabetic kidney disease;	chr7:65833886	chr7:66902857~66906297:+
BRCA	trans	rs714543	0.967	rs12536807	ENSG00000214975.4	PPIAP29	-6.7	3.33e-11	2.83e-05	-0.24	-0.2	Plateletcrit;	chr7:44838675	chr6:24976419~24976982:+
BRCA	trans	rs714543	1	rs714543	ENSG00000214975.4	PPIAP29	-6.7	3.33e-11	2.83e-05	-0.24	-0.2	Plateletcrit;	chr7:44847477	chr6:24976419~24976982:+
BRCA	trans	rs714543	1	rs757693	ENSG00000214975.4	PPIAP29	-6.7	3.33e-11	2.83e-05	-0.24	-0.2	Plateletcrit;	chr7:44848430	chr6:24976419~24976982:+
BRCA	trans	rs3812762	0.912	rs11042058	ENSG00000266891.1	RP11-692N5.2	6.7	3.35e-11	2.85e-05	0.27	0.2	Hypospadias;	chr11:8742268	chr18:9734882~9735602:-
BRCA	trans	rs4929949	0.78	rs7126934	ENSG00000266891.1	RP11-692N5.2	6.7	3.36e-11	2.85e-05	0.24	0.2	Body mass index;	chr11:8540947	chr18:9734882~9735602:-
BRCA	trans	rs17767294	0.615	rs72845058	ENSG00000242375.1	RP11-498P14.3	-6.7	3.36e-11	2.86e-05	-0.59	-0.2	Parkinson's disease;	chr6:27679641	chr9:97195351~97197687:-
BRCA	trans	rs9468199	0.51	rs72845064	ENSG00000242375.1	RP11-498P14.3	-6.7	3.36e-11	2.86e-05	-0.59	-0.2	Parkinson's disease;	chr6:27687191	chr9:97195351~97197687:-
BRCA	trans	rs17767294	0.614	rs72845068	ENSG00000242375.1	RP11-498P14.3	-6.7	3.36e-11	2.86e-05	-0.59	-0.2	Parkinson's disease;	chr6:27700368	chr9:97195351~97197687:-
BRCA	trans	rs11098499	0.954	rs6820115	ENSG00000276997.3	RP11-378J18.9	6.7	3.36e-11	2.86e-05	0.24	0.2	Corneal astigmatism;	chr4:119477027	chr1:222477252~222504622:-
BRCA	trans	rs9650657	0.623	rs11250065	ENSG00000253893.2	FAM85B	6.7	3.38e-11	2.87e-05	0.25	0.2	Neuroticism;	chr8:10742871	chr8:8167819~8226614:-
BRCA	trans	rs10815468	0.624	rs7037259	ENSG00000215210.3	RBMXP2	-6.7	3.4e-11	2.89e-05	-0.26	-0.2	Bipolar disorder and schizophrenia;	chr9:6784144	chr9:30689105~30690272:+
BRCA	trans	rs3740713	1	rs73436668	ENSG00000214110.3	LDHAP4	6.7	3.41e-11	2.9e-05	0.38	0.2	Amyotrophic lateral sclerosis (sporadic);	chr11:18421546	chr9:14921337~14922334:-
BRCA	trans	rs1707322	1	rs1707322	ENSG00000255397.1	AC022182.2	-6.7	3.43e-11	2.91e-05	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46039475	chr8:60937705~60939871:-
BRCA	trans	rs11638815	0.603	rs10162807	ENSG00000235370.6	DNM1P51	-6.7	3.43e-11	2.91e-05	-0.23	-0.2	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82620430	chr15:84398316~84411701:-
BRCA	trans	rs13217239	0.511	rs4546474	ENSG00000242375.1	RP11-498P14.3	6.7	3.43e-11	2.92e-05	0.28	0.2	Schizophrenia;	chr6:27256854	chr9:97195351~97197687:-
BRCA	trans	rs9834975	0.544	rs9811581	ENSG00000267076.1	CCDC58P3	6.7	3.44e-11	2.92e-05	0.23	0.2	Diastolic blood pressure;	chr3:122561899	chr18:12211378~12211807:+
BRCA	trans	rs9650657	0.538	rs11250093	ENSG00000254153.1	CTA-398F10.2	6.7	3.45e-11	2.93e-05	0.25	0.2	Neuroticism;	chr8:10941318	chr8:8456909~8461337:-
BRCA	trans	rs2288327	0.818	rs3731751	ENSG00000269800.1	PLEKHA3P1	6.7	3.46e-11	2.94e-05	0.31	0.2	Atrial fibrillation;	chr2:178541158	chr19:41521043~41521989:-
BRCA	trans	rs17767294	0.708	rs72847342	ENSG00000242375.1	RP11-498P14.3	-6.7	3.49e-11	2.96e-05	-0.6	-0.2	Parkinson's disease;	chr6:27821492	chr9:97195351~97197687:-
BRCA	trans	rs17767294	0.708	rs72847343	ENSG00000242375.1	RP11-498P14.3	-6.7	3.49e-11	2.96e-05	-0.6	-0.2	Parkinson's disease;	chr6:27823055	chr9:97195351~97197687:-
BRCA	trans	rs17767294	0.708	rs72847348	ENSG00000242375.1	RP11-498P14.3	-6.7	3.49e-11	2.96e-05	-0.6	-0.2	Parkinson's disease;	chr6:27834075	chr9:97195351~97197687:-
BRCA	trans	rs9468199	0.51	rs72847349	ENSG00000242375.1	RP11-498P14.3	-6.7	3.49e-11	2.96e-05	-0.6	-0.2	Parkinson's disease;	chr6:27837525	chr9:97195351~97197687:-
BRCA	trans	rs1079467	0.73	rs72846600	ENSG00000275945.1	EIF3S5P1	-6.7	3.51e-11	2.98e-05	-0.35	-0.2	Response to anti-TNF therapy in rheumatoid arthritis;	chr11:7952994	chr21:10330732~10331537:+
BRCA	trans	rs9834975	0.565	rs9809886	ENSG00000267076.1	CCDC58P3	6.69	3.53e-11	2.99e-05	0.23	0.2	Diastolic blood pressure;	chr3:122497443	chr18:12211378~12211807:+
BRCA	trans	rs875971	0.558	rs4433015	ENSG00000164669.11	INTS4P1	6.69	3.54e-11	3e-05	0.25	0.2	Aortic root size;	chr7:66174736	chr7:65141225~65234216:+
BRCA	trans	rs11098499	0.954	rs3733524	ENSG00000276997.3	RP11-378J18.9	6.69	3.55e-11	3.01e-05	0.26	0.2	Corneal astigmatism;	chr4:119502574	chr1:222477252~222504622:-
BRCA	trans	rs9650657	0.771	rs4840516	ENSG00000253893.2	FAM85B	-6.69	3.59e-11	3.04e-05	-0.26	-0.2	Neuroticism;	chr8:10809825	chr8:8167819~8226614:-
BRCA	trans	rs7927370	0.614	rs17594092	ENSG00000134612.10	FOLH1B	-6.69	3.6e-11	3.05e-05	-0.44	-0.2	Systemic lupus erythematosus;	chr11:55855486	chr11:89639227~89698718:+
BRCA	trans	rs864643	1	rs816490	ENSG00000188856.6	RPSAP47	6.69	3.62e-11	3.07e-05	0.3	0.2	Attention deficit hyperactivity disorder;	chr3:39512993	chr8:80558870~80559757:+
BRCA	trans	rs2060793	1	rs10741657	ENSG00000236360.2	RP11-334A14.2	6.69	3.63e-11	3.08e-05	0.26	0.2	Vitamin D levels;	chr11:14893332	chr1:52993201~52993702:-
BRCA	trans	rs1707322	0.721	rs10890343	ENSG00000255397.1	AC022182.2	-6.69	3.64e-11	3.09e-05	-0.27	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692250	chr8:60937705~60939871:-
BRCA	trans	rs11250098	0.547	rs2409764	ENSG00000253893.2	FAM85B	-6.69	3.68e-11	3.12e-05	-0.26	-0.2	Morning vs. evening chronotype;	chr8:11423764	chr8:8167819~8226614:-
BRCA	trans	rs7829975	0.659	rs4382480	ENSG00000270154.1	RP11-419I17.1	6.69	3.69e-11	3.12e-05	0.23	0.2	Mood instability;	chr8:8863963	chr8:12476462~12477122:+
BRCA	trans	rs66887589	0.616	rs10032299	ENSG00000120555.12	SEPT7P9	6.69	3.71e-11	3.14e-05	0.23	0.2	Diastolic blood pressure;	chr4:119285264	chr10:38383069~38402916:-
BRCA	trans	rs7929679	0.846	rs1588355	ENSG00000225531.1	RP11-196I18.3	6.69	3.71e-11	3.15e-05	0.26	0.2	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;	chr11:34779554	chr9:107116829~107117557:+
BRCA	trans	rs17767294	0.614	rs72847329	ENSG00000242375.1	RP11-498P14.3	-6.69	3.72e-11	3.15e-05	-0.6	-0.2	Parkinson's disease;	chr6:27799268	chr9:97195351~97197687:-
BRCA	trans	rs9834975	0.565	rs9859250	ENSG00000267076.1	CCDC58P3	-6.69	3.74e-11	3.17e-05	-0.23	-0.2	Diastolic blood pressure;	chr3:122556301	chr18:12211378~12211807:+
BRCA	trans	rs2965280	0.793	rs10411051	ENSG00000270983.1	RP11-137J7.3	-6.68	3.78e-11	3.2e-05	-0.44	-0.2	Colorectal cancer;	chr19:34357811	chr6:142062717~142063053:+
BRCA	trans	rs11098499	0.954	rs13145352	ENSG00000120555.12	SEPT7P9	-6.68	3.8e-11	3.22e-05	-0.25	-0.2	Corneal astigmatism;	chr4:119488808	chr10:38383069~38402916:-
BRCA	trans	rs9834975	0.647	rs7616785	ENSG00000267076.1	CCDC58P3	6.68	3.82e-11	3.23e-05	0.24	0.2	Diastolic blood pressure;	chr3:122354032	chr18:12211378~12211807:+
BRCA	trans	rs6940638	0.615	rs9393801	ENSG00000242375.1	RP11-498P14.3	-6.68	3.84e-11	3.25e-05	-0.28	-0.2	Intelligence (multi-trait analysis);	chr6:27274902	chr9:97195351~97197687:-
BRCA	trans	rs28541881	0.536	rs7247747	ENSG00000270983.1	RP11-137J7.3	-6.68	3.85e-11	3.26e-05	-0.42	-0.2	Colorectal cancer;	chr19:34296239	chr6:142062717~142063053:+
BRCA	trans	rs17767294	0.708	rs72848760	ENSG00000242375.1	RP11-498P14.3	-6.68	3.85e-11	3.26e-05	-0.6	-0.2	Parkinson's disease;	chr6:27919099	chr9:97195351~97197687:-
BRCA	trans	rs17767294	0.708	rs72848763	ENSG00000242375.1	RP11-498P14.3	-6.68	3.85e-11	3.26e-05	-0.6	-0.2	Parkinson's disease;	chr6:27934710	chr9:97195351~97197687:-
BRCA	trans	rs17767294	0.708	rs72848766	ENSG00000242375.1	RP11-498P14.3	-6.68	3.85e-11	3.26e-05	-0.6	-0.2	Parkinson's disease;	chr6:27940978	chr9:97195351~97197687:-
BRCA	trans	rs17767294	0.708	rs72848767	ENSG00000242375.1	RP11-498P14.3	-6.68	3.85e-11	3.26e-05	-0.6	-0.2	Parkinson's disease;	chr6:27941509	chr9:97195351~97197687:-
BRCA	trans	rs17767294	0.708	rs72848769	ENSG00000242375.1	RP11-498P14.3	-6.68	3.85e-11	3.26e-05	-0.6	-0.2	Parkinson's disease;	chr6:27950601	chr9:97195351~97197687:-
BRCA	trans	rs17767294	0.708	rs72848770	ENSG00000242375.1	RP11-498P14.3	-6.68	3.85e-11	3.26e-05	-0.6	-0.2	Parkinson's disease;	chr6:27951371	chr9:97195351~97197687:-
BRCA	trans	rs17767294	0.708	rs72848772	ENSG00000242375.1	RP11-498P14.3	-6.68	3.85e-11	3.26e-05	-0.6	-0.2	Parkinson's disease;	chr6:27953170	chr9:97195351~97197687:-
BRCA	trans	rs1707322	0.964	rs12067716	ENSG00000255397.1	AC022182.2	-6.68	3.87e-11	3.28e-05	-0.27	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45968756	chr8:60937705~60939871:-
BRCA	trans	rs2055729	0.645	rs62489486	ENSG00000253893.2	FAM85B	-6.68	3.91e-11	3.31e-05	-0.3	-0.2	Multiple myeloma (hyperdiploidy);	chr8:9884415	chr8:8167819~8226614:-
BRCA	trans	rs1707322	0.721	rs6699418	ENSG00000255397.1	AC022182.2	-6.68	3.93e-11	3.32e-05	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634509	chr8:60937705~60939871:-
BRCA	trans	rs1707322	0.721	rs4431884	ENSG00000255397.1	AC022182.2	-6.68	3.93e-11	3.32e-05	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45635651	chr8:60937705~60939871:-
BRCA	trans	rs1707322	0.65	rs4660879	ENSG00000255397.1	AC022182.2	-6.68	3.93e-11	3.32e-05	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45639729	chr8:60937705~60939871:-
BRCA	trans	rs17507216	0.718	rs72751662	ENSG00000259295.5	CSPG4P12	-6.68	3.98e-11	3.37e-05	-0.34	-0.2	Excessive daytime sleepiness;	chr15:82594705	chr15:85191438~85213905:+
BRCA	trans	rs9425766	0.679	rs2901785	ENSG00000213331.4	RP11-713C19.2	6.68	4e-11	3.38e-05	0.22	0.2	Life satisfaction;	chr1:174135605	chr4:187970273~187971284:+
BRCA	trans	rs9834975	0.647	rs9858348	ENSG00000267076.1	CCDC58P3	-6.68	4e-11	3.39e-05	-0.24	-0.2	Diastolic blood pressure;	chr3:122376862	chr18:12211378~12211807:+
BRCA	trans	rs10815468	0.624	rs7045291	ENSG00000215210.3	RBMXP2	6.67	4.01e-11	3.39e-05	0.27	0.2	Bipolar disorder and schizophrenia;	chr9:6786418	chr9:30689105~30690272:+
BRCA	trans	rs7833986	0.501	rs72653917	ENSG00000244245.1	RP11-120B7.1	6.67	4.03e-11	3.41e-05	0.26	0.2	Height;	chr8:55980285	chr5:108593609~108593967:+
BRCA	trans	rs1707322	1	rs785493	ENSG00000255397.1	AC022182.2	6.67	4.04e-11	3.41e-05	0.28	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46119187	chr8:60937705~60939871:-
BRCA	trans	rs1707322	0.964	rs785496	ENSG00000255397.1	AC022182.2	6.67	4.04e-11	3.41e-05	0.28	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46122334	chr8:60937705~60939871:-
BRCA	trans	rs1707322	1	rs785497	ENSG00000255397.1	AC022182.2	6.67	4.04e-11	3.41e-05	0.28	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46126231	chr8:60937705~60939871:-
BRCA	trans	rs17767294	0.708	rs72848784	ENSG00000242375.1	RP11-498P14.3	-6.67	4.04e-11	3.42e-05	-0.61	-0.2	Parkinson's disease;	chr6:28003005	chr9:97195351~97197687:-
BRCA	trans	rs12439619	0.846	rs28470877	ENSG00000235370.6	DNM1P51	-6.67	4.04e-11	3.42e-05	-0.28	-0.2	Intelligence (multi-trait analysis);	chr15:82245797	chr15:84398316~84411701:-
BRCA	trans	rs28541881	0.536	rs7255455	ENSG00000270983.1	RP11-137J7.3	-6.67	4.07e-11	3.44e-05	-0.41	-0.2	Colorectal cancer;	chr19:34339584	chr6:142062717~142063053:+
BRCA	trans	rs673253	0.638	rs552638	ENSG00000231007.5	CDC20P1	6.67	4.07e-11	3.44e-05	0.26	0.2	Intelligence (multi-trait analysis);	chr1:43577721	chr9:87011652~87013151:+
BRCA	trans	rs7200543	0.848	rs62039480	ENSG00000250569.1	NTAN1P2	6.67	4.07e-11	3.44e-05	0.21	0.2	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15043593	chr8:86481754~86483002:-
BRCA	trans	rs9467711	0.559	rs3799383	ENSG00000253570.1	RNF5P1	6.67	4.11e-11	3.48e-05	0.42	0.2	Autism spectrum disorder or schizophrenia;	chr6:26510520	chr8:38600661~38601200:-
BRCA	trans	rs7833986	0.534	rs72653924	ENSG00000244245.1	RP11-120B7.1	6.67	4.14e-11	3.5e-05	0.26	0.2	Height;	chr8:55993529	chr5:108593609~108593967:+
BRCA	trans	rs7833986	0.534	rs2667972	ENSG00000244245.1	RP11-120B7.1	6.67	4.14e-11	3.5e-05	0.26	0.2	Height;	chr8:55994102	chr5:108593609~108593967:+
BRCA	trans	rs11098499	0.82	rs2389885	ENSG00000276997.3	RP11-378J18.9	6.67	4.15e-11	3.51e-05	0.26	0.2	Corneal astigmatism;	chr4:119612776	chr1:222477252~222504622:-
BRCA	trans	rs9584850	0.834	rs9584855	ENSG00000230079.1	STK24P1	-6.67	4.16e-11	3.51e-05	-0.26	-0.2	Neuroticism;	chr13:98466746	chrX:136295690~136300298:-
BRCA	trans	rs673253	0.686	rs1887402	ENSG00000231007.5	CDC20P1	6.67	4.17e-11	3.52e-05	0.26	0.2	Intelligence (multi-trait analysis);	chr1:43570414	chr9:87011652~87013151:+
BRCA	trans	rs741738	1	rs741738	ENSG00000236562.4	RP11-396M11.1	-6.67	4.19e-11	3.54e-05	-0.28	-0.2	Granulocyte percentage of myeloid white cells;	chr11:309508	chr4:66094142~66094526:+
BRCA	trans	rs2965280	0.793	rs10402237	ENSG00000270983.1	RP11-137J7.3	-6.67	4.21e-11	3.55e-05	-0.45	-0.2	Colorectal cancer;	chr19:34371181	chr6:142062717~142063053:+
BRCA	trans	rs7903456	0.648	rs9421561	ENSG00000232706.3	NUTM2HP	-6.67	4.27e-11	3.61e-05	-0.29	-0.2	Gout;Renal underexcretion gout;	chr10:87039315	chr10:50676743~50686326:+
BRCA	trans	rs34421088	0.623	rs2572433	ENSG00000253893.2	FAM85B	-6.66	4.28e-11	3.62e-05	-0.27	-0.2	Neuroticism;	chr8:11243532	chr8:8167819~8226614:-
BRCA	trans	rs7824557	0.592	rs2572371	ENSG00000253893.2	FAM85B	-6.66	4.28e-11	3.62e-05	-0.25	-0.2	Retinal vascular caliber;	chr8:11366284	chr8:8167819~8226614:-
BRCA	trans	rs7944735	0.506	rs10742816	ENSG00000134612.10	FOLH1B	-6.66	4.32e-11	3.65e-05	-0.31	-0.2	Intraocular pressure;	chr11:47585432	chr11:89639227~89698718:+
BRCA	trans	rs2965280	0.793	rs16969156	ENSG00000270983.1	RP11-137J7.3	-6.66	4.33e-11	3.65e-05	-0.45	-0.2	Colorectal cancer;	chr19:34284548	chr6:142062717~142063053:+
BRCA	trans	rs1864585	0.806	rs17778223	ENSG00000246089.3	RP11-115C21.2	6.66	4.33e-11	3.66e-05	0.25	0.2	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr8:10872182	chr8:6403551~6407142:-
BRCA	trans	rs875971	0.545	rs73142265	ENSG00000234585.5	CCT6P3	6.66	4.35e-11	3.67e-05	0.22	0.2	Aortic root size;	chr7:66234510	chr7:65038354~65074713:+
BRCA	trans	rs853679	0.882	rs4713140	ENSG00000253570.1	RNF5P1	6.66	4.36e-11	3.68e-05	0.45	0.2	Depression;	chr6:28129415	chr8:38600661~38601200:-
BRCA	trans	rs12439619	0.846	rs62012004	ENSG00000259295.5	CSPG4P12	-6.66	4.37e-11	3.69e-05	-0.32	-0.2	Intelligence (multi-trait analysis);	chr15:82183924	chr15:85191438~85213905:+
BRCA	trans	rs1707322	0.964	rs785499	ENSG00000255397.1	AC022182.2	6.66	4.38e-11	3.69e-05	0.28	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46126748	chr8:60937705~60939871:-
BRCA	trans	rs673253	0.571	rs55684236	ENSG00000231007.5	CDC20P1	6.66	4.39e-11	3.7e-05	0.27	0.2	Intelligence (multi-trait analysis);	chr1:43614338	chr9:87011652~87013151:+
BRCA	trans	rs9581094	0.591	rs73154308	ENSG00000237917.1	PARP4P1	-6.66	4.46e-11	3.76e-05	-0.44	-0.2	Sudden cardiac arrest;	chr13:24462161	chrY:26594851~26634652:-
BRCA	trans	rs7833986	0.501	rs9650314	ENSG00000244245.1	RP11-120B7.1	6.66	4.46e-11	3.77e-05	0.26	0.2	Height;	chr8:55991051	chr5:108593609~108593967:+
BRCA	trans	rs13261217	0.645	rs7832586	ENSG00000253982.1	CTD-2336O2.1	-6.66	4.48e-11	3.78e-05	-0.23	-0.2	Schizophrenia;	chr8:4353224	chr8:1761990~1764502:-
BRCA	trans	rs7617773	0.817	rs11130163	ENSG00000235912.1	RP1-159A19.3	-6.66	4.5e-11	3.8e-05	-0.24	-0.2	Coronary artery disease;	chr3:48271168	chr1:27649419~27649610:+
BRCA	trans	rs1580019	0.587	rs7805311	ENSG00000213492.2	NT5C3AP1	6.66	4.51e-11	3.8e-05	0.27	0.2	Cognitive ability;	chr7:32518690	chr4:117574512~117576174:-
BRCA	trans	rs7617773	0.784	rs9850672	ENSG00000235912.1	RP1-159A19.3	-6.66	4.55e-11	3.84e-05	-0.25	-0.2	Coronary artery disease;	chr3:48259682	chr1:27649419~27649610:+
BRCA	trans	rs7617773	0.851	rs6775179	ENSG00000235912.1	RP1-159A19.3	-6.66	4.57e-11	3.85e-05	-0.25	-0.2	Coronary artery disease;	chr3:48271928	chr1:27649419~27649610:+
BRCA	trans	rs4929949	0.752	rs4758067	ENSG00000266891.1	RP11-692N5.2	6.65	4.57e-11	3.86e-05	0.24	0.2	Body mass index;	chr11:8471882	chr18:9734882~9735602:-
BRCA	trans	rs3740713	1	rs35593189	ENSG00000214110.3	LDHAP4	6.65	4.59e-11	3.86e-05	0.37	0.2	Amyotrophic lateral sclerosis (sporadic);	chr11:18446831	chr9:14921337~14922334:-
BRCA	trans	rs2288327	0.818	rs3829748	ENSG00000269800.1	PLEKHA3P1	6.65	4.59e-11	3.87e-05	0.3	0.2	Atrial fibrillation;	chr2:178531627	chr19:41521043~41521989:-
BRCA	trans	rs2288327	0.818	rs2857265	ENSG00000269800.1	PLEKHA3P1	6.65	4.59e-11	3.87e-05	0.3	0.2	Atrial fibrillation;	chr2:178534096	chr19:41521043~41521989:-
BRCA	trans	rs853679	0.546	rs200953	ENSG00000253570.1	RNF5P1	6.65	4.6e-11	3.88e-05	0.45	0.2	Depression;	chr6:27869489	chr8:38600661~38601200:-
BRCA	trans	rs2060793	0.552	rs939968	ENSG00000236360.2	RP11-334A14.2	6.65	4.64e-11	3.91e-05	0.25	0.2	Vitamin D levels;	chr11:14608134	chr1:52993201~52993702:-
BRCA	trans	rs801193	0.591	rs9986881	ENSG00000234585.5	CCT6P3	6.65	4.65e-11	3.91e-05	0.2	0.2	Aortic root size;	chr7:66708053	chr7:65038354~65074713:+
BRCA	trans	rs2060793	1	rs1993116	ENSG00000236360.2	RP11-334A14.2	6.65	4.74e-11	4e-05	0.26	0.2	Vitamin D levels;	chr11:14888688	chr1:52993201~52993702:-
BRCA	trans	rs714543	0.967	rs11762008	ENSG00000214975.4	PPIAP29	-6.65	4.79e-11	4.03e-05	-0.23	-0.2	Plateletcrit;	chr7:44864065	chr6:24976419~24976982:+
BRCA	trans	rs12439619	0.846	rs62010071	ENSG00000259295.5	CSPG4P12	-6.65	4.85e-11	4.08e-05	-0.32	-0.2	Intelligence (multi-trait analysis);	chr15:82289442	chr15:85191438~85213905:+
BRCA	trans	rs12439619	0.508	rs11856561	ENSG00000259295.5	CSPG4P12	-6.65	4.85e-11	4.08e-05	-0.25	-0.2	Intelligence (multi-trait analysis);	chr15:82161415	chr15:85191438~85213905:+
BRCA	trans	rs11098499	0.604	rs2389887	ENSG00000276997.3	RP11-378J18.9	6.65	4.87e-11	4.1e-05	0.26	0.2	Corneal astigmatism;	chr4:119649489	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.604	rs34278750	ENSG00000276997.3	RP11-378J18.9	6.65	4.87e-11	4.1e-05	0.26	0.2	Corneal astigmatism;	chr4:119649981	chr1:222477252~222504622:-
BRCA	trans	rs2220004	0.964	rs2512931	ENSG00000134612.10	FOLH1B	6.64	4.91e-11	4.13e-05	0.27	0.2	Odorant perception (&beta-damascenone);	chr11:56140520	chr11:89639227~89698718:+
BRCA	trans	rs9834975	0.584	rs7638172	ENSG00000267076.1	CCDC58P3	-6.64	4.93e-11	4.15e-05	-0.23	-0.2	Diastolic blood pressure;	chr3:122431437	chr18:12211378~12211807:+
BRCA	trans	rs7833986	0.501	rs2719227	ENSG00000244245.1	RP11-120B7.1	-6.64	4.97e-11	4.18e-05	-0.26	-0.2	Height;	chr8:56131235	chr5:108593609~108593967:+
BRCA	trans	rs1707322	1	rs2458400	ENSG00000255397.1	AC022182.2	6.64	4.98e-11	4.19e-05	0.26	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46065126	chr8:60937705~60939871:-
BRCA	trans	rs4929949	0.78	rs12226478	ENSG00000266891.1	RP11-692N5.2	6.64	4.98e-11	4.19e-05	0.24	0.2	Body mass index;	chr11:8533742	chr18:9734882~9735602:-
BRCA	trans	rs801193	0.904	rs4718405	ENSG00000164669.11	INTS4P1	-6.64	5.01e-11	4.21e-05	-0.24	-0.2	Aortic root size;	chr7:66789659	chr7:65141225~65234216:+
BRCA	trans	rs9581094	0.591	rs9581057	ENSG00000237917.1	PARP4P1	-6.64	5.04e-11	4.24e-05	-0.38	-0.2	Sudden cardiac arrest;	chr13:24456309	chrY:26594851~26634652:-
BRCA	trans	rs673253	0.556	rs35393217	ENSG00000231007.5	CDC20P1	6.64	5.04e-11	4.24e-05	0.26	0.2	Intelligence (multi-trait analysis);	chr1:43635977	chr9:87011652~87013151:+
BRCA	trans	rs673253	0.593	rs3791151	ENSG00000231007.5	CDC20P1	6.64	5.08e-11	4.27e-05	0.26	0.2	Intelligence (multi-trait analysis);	chr1:43612931	chr9:87011652~87013151:+
BRCA	trans	rs3747547	0.636	rs4878724	ENSG00000229007.1	EXOSC3P1	-6.64	5.08e-11	4.27e-05	-0.35	-0.2	Metabolite levels (Dihydroxy docosatrienoic acid);	chr9:37901886	chr21:32496812~32497311:+
BRCA	trans	rs2220004	1	rs10896042	ENSG00000134612.10	FOLH1B	6.64	5.12e-11	4.3e-05	0.27	0.2	Odorant perception (&beta-damascenone);	chr11:56131112	chr11:89639227~89698718:+
BRCA	trans	rs538867	1	rs1768141	ENSG00000214263.2	RPSAP53	6.64	5.14e-11	4.32e-05	0.46	0.2	Alzheimer's disease (cognitive decline);	chr3:39548800	chr13:67266845~67267706:-
BRCA	trans	rs875971	0.577	rs35072105	ENSG00000164669.11	INTS4P1	6.64	5.14e-11	4.32e-05	0.25	0.2	Aortic root size;	chr7:66144830	chr7:65141225~65234216:+
BRCA	trans	rs902774	0.818	rs4919743	ENSG00000224520.2	KRT8P45	-6.64	5.18e-11	4.35e-05	-0.35	-0.2	Prostate cancer;	chr12:52915800	chr1:157073257~157074703:+
BRCA	trans	rs2235573	0.527	rs139886	ENSG00000258501.1	EIF3LP1	-6.64	5.2e-11	4.37e-05	-0.23	-0.2	Glioma;Glioblastoma;	chr22:37975321	chr14:81916231~81917888:+
BRCA	trans	rs9467711	0.606	rs9379900	ENSG00000253570.1	RNF5P1	6.63	5.23e-11	4.39e-05	0.45	0.2	Autism spectrum disorder or schizophrenia;	chr6:26603583	chr8:38600661~38601200:-
BRCA	trans	rs1707322	0.964	rs1768802	ENSG00000255397.1	AC022182.2	6.63	5.26e-11	4.42e-05	0.26	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46082196	chr8:60937705~60939871:-
BRCA	trans	rs1707322	1	rs1588663	ENSG00000255397.1	AC022182.2	6.63	5.26e-11	4.42e-05	0.26	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46083153	chr8:60937705~60939871:-
BRCA	trans	rs1707322	1	rs1768801	ENSG00000255397.1	AC022182.2	6.63	5.26e-11	4.42e-05	0.26	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46083465	chr8:60937705~60939871:-
BRCA	trans	rs1707322	1	rs1768800	ENSG00000255397.1	AC022182.2	6.63	5.26e-11	4.42e-05	0.26	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46083516	chr8:60937705~60939871:-
BRCA	trans	rs1707322	0.721	rs6429574	ENSG00000255397.1	AC022182.2	-6.63	5.28e-11	4.43e-05	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45668382	chr8:60937705~60939871:-
BRCA	trans	rs875971	0.545	rs73142245	ENSG00000234585.5	CCT6P3	6.63	5.28e-11	4.44e-05	0.22	0.2	Aortic root size;	chr7:66226662	chr7:65038354~65074713:+
BRCA	trans	rs1039766	0.706	rs72822420	ENSG00000213985.4	AC078899.1	-6.63	5.33e-11	4.48e-05	-0.38	-0.2	Lung adenocarcinoma;Lung cancer;	chr2:65286633	chr19:20257720~20259418:+
BRCA	trans	rs2220004	1	rs7121974	ENSG00000134612.10	FOLH1B	-6.63	5.34e-11	4.49e-05	-0.27	-0.2	Odorant perception (&beta-damascenone);	chr11:56053562	chr11:89639227~89698718:+
BRCA	trans	rs3942852	0.868	rs6485808	ENSG00000134612.10	FOLH1B	-6.63	5.36e-11	4.5e-05	-0.3	-0.2	Acute lymphoblastic leukemia (childhood);	chr11:48087599	chr11:89639227~89698718:+
BRCA	trans	rs1707322	1	rs4074225	ENSG00000255397.1	AC022182.2	-6.63	5.37e-11	4.51e-05	-0.27	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45926692	chr8:60937705~60939871:-
BRCA	trans	rs6601327	0.585	rs11249934	ENSG00000253893.2	FAM85B	-6.63	5.39e-11	4.53e-05	-0.25	-0.2	Multiple myeloma (hyperdiploidy);	chr8:9653320	chr8:8167819~8226614:-
BRCA	trans	rs7944735	0.508	rs4752783	ENSG00000134612.10	FOLH1B	6.63	5.4e-11	4.54e-05	0.38	0.2	Intraocular pressure;	chr11:47536668	chr11:89639227~89698718:+
BRCA	trans	rs72615157	0.539	rs72615159	ENSG00000228546.2	CTA-313A17.3	6.63	5.43e-11	4.56e-05	0.29	0.2	Lung function (FEV1/FVC);	chr7:100076663	chr7:102337316~102339115:+
BRCA	trans	rs875971	0.545	rs73142233	ENSG00000234585.5	CCT6P3	6.63	5.43e-11	4.56e-05	0.22	0.2	Aortic root size;	chr7:66221293	chr7:65038354~65074713:+
BRCA	trans	rs17767294	0.614	rs72850302	ENSG00000242375.1	RP11-498P14.3	-6.63	5.48e-11	4.6e-05	-0.6	-0.2	Parkinson's disease;	chr6:28273621	chr9:97195351~97197687:-
BRCA	trans	rs1707322	0.721	rs10789468	ENSG00000255397.1	AC022182.2	-6.63	5.55e-11	4.65e-05	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45658886	chr8:60937705~60939871:-
BRCA	trans	rs7617773	0.817	rs6800492	ENSG00000235912.1	RP1-159A19.3	-6.62	5.59e-11	4.69e-05	-0.26	-0.2	Coronary artery disease;	chr3:48282400	chr1:27649419~27649610:+
BRCA	trans	rs9693857	0.553	rs10100760	ENSG00000253893.2	FAM85B	6.62	5.78e-11	4.84e-05	0.24	0.2	Systolic blood pressure;	chr8:9513049	chr8:8167819~8226614:-
BRCA	trans	rs12439619	0.508	rs11856561	ENSG00000235370.6	DNM1P51	-6.62	5.79e-11	4.85e-05	-0.22	-0.2	Intelligence (multi-trait analysis);	chr15:82161415	chr15:84398316~84411701:-
BRCA	trans	rs7617773	0.817	rs3731555	ENSG00000235912.1	RP1-159A19.3	-6.62	5.79e-11	4.85e-05	-0.27	-0.2	Coronary artery disease;	chr3:48164612	chr1:27649419~27649610:+
BRCA	trans	rs1707322	1	rs1707338	ENSG00000255397.1	AC022182.2	6.62	5.79e-11	4.86e-05	0.26	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46046309	chr8:60937705~60939871:-
BRCA	trans	rs1707322	0.964	rs1707339	ENSG00000255397.1	AC022182.2	6.62	5.79e-11	4.86e-05	0.26	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46047507	chr8:60937705~60939871:-
BRCA	trans	rs1707322	1	rs1768818	ENSG00000255397.1	AC022182.2	6.62	5.79e-11	4.86e-05	0.26	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46048614	chr8:60937705~60939871:-
BRCA	trans	rs1707322	1	rs1768817	ENSG00000255397.1	AC022182.2	6.62	5.79e-11	4.86e-05	0.26	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46048862	chr8:60937705~60939871:-
BRCA	trans	rs7617773	0.694	rs13099560	ENSG00000235912.1	RP1-159A19.3	6.62	5.8e-11	4.86e-05	0.24	0.2	Coronary artery disease;	chr3:48163278	chr1:27649419~27649610:+
BRCA	trans	rs7617773	0.817	rs11710861	ENSG00000235912.1	RP1-159A19.3	-6.62	5.83e-11	4.88e-05	-0.25	-0.2	Coronary artery disease;	chr3:48256070	chr1:27649419~27649610:+
BRCA	trans	rs4929949	0.707	rs4929929	ENSG00000266891.1	RP11-692N5.2	-6.62	5.84e-11	4.89e-05	-0.24	-0.2	Body mass index;	chr11:8588654	chr18:9734882~9735602:-
BRCA	trans	rs2220004	1	rs2512783	ENSG00000134612.10	FOLH1B	-6.62	5.84e-11	4.89e-05	-0.26	-0.2	Odorant perception (&beta-damascenone);	chr11:56127645	chr11:89639227~89698718:+
BRCA	trans	rs714543	0.967	rs10951776	ENSG00000214975.4	PPIAP29	-6.62	5.84e-11	4.89e-05	-0.23	-0.2	Plateletcrit;	chr7:44858152	chr6:24976419~24976982:+
BRCA	trans	rs6601327	0.736	rs4840426	ENSG00000253893.2	FAM85B	-6.62	5.9e-11	4.94e-05	-0.25	-0.2	Multiple myeloma (hyperdiploidy);	chr8:9551468	chr8:8167819~8226614:-
BRCA	trans	rs17767294	0.708	rs115714358	ENSG00000242375.1	RP11-498P14.3	-6.62	5.91e-11	4.95e-05	-0.6	-0.2	Parkinson's disease;	chr6:27996554	chr9:97195351~97197687:-
BRCA	trans	rs11098499	0.955	rs35434465	ENSG00000276997.3	RP11-378J18.9	6.61	5.93e-11	4.97e-05	0.25	0.2	Corneal astigmatism;	chr4:119248223	chr1:222477252~222504622:-
BRCA	trans	rs11098499	1	rs35643470	ENSG00000276997.3	RP11-378J18.9	6.61	5.96e-11	4.99e-05	0.25	0.2	Corneal astigmatism;	chr4:119263793	chr1:222477252~222504622:-
BRCA	trans	rs875971	0.545	rs4718325	ENSG00000234585.5	CCT6P3	6.61	5.97e-11	5e-05	0.22	0.2	Aortic root size;	chr7:66215323	chr7:65038354~65074713:+
BRCA	trans	rs1707322	1	rs12124847	ENSG00000255397.1	AC022182.2	-6.61	5.98e-11	5.01e-05	-0.27	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45915178	chr8:60937705~60939871:-
BRCA	trans	rs1707322	0.89	rs2297883	ENSG00000255397.1	AC022182.2	6.61	5.98e-11	5.01e-05	0.26	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46045815	chr8:60937705~60939871:-
BRCA	trans	rs714543	0.566	rs13231886	ENSG00000219797.2	PPIAP9	-6.61	6.04e-11	5.06e-05	-0.24	-0.2	Plateletcrit;	chr7:44774573	chr6:31519480~31520291:-
BRCA	trans	rs1347297	1	rs10930830	ENSG00000269800.1	PLEKHA3P1	6.61	6.08e-11	5.09e-05	0.25	0.2	Alzheimer disease and age of onset;	chr2:178386903	chr19:41521043~41521989:-
BRCA	trans	rs950776	0.642	rs12905641	ENSG00000274376.3	ADAMTS7P1	6.61	6.08e-11	5.09e-05	0.23	0.2	Sudden cardiac arrest;	chr15:78672020	chr15:82298553~82334609:+
BRCA	trans	rs1707322	0.656	rs3014210	ENSG00000255397.1	AC022182.2	6.61	6.09e-11	5.1e-05	0.26	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45600936	chr8:60937705~60939871:-
BRCA	trans	rs9649213	0.574	rs7802560	ENSG00000225169.1	BRI3P1	-6.61	6.14e-11	5.13e-05	-0.26	-0.2	Prostate cancer (SNP x SNP interaction);	chr7:98274494	chr1:100213293~100213670:+
BRCA	trans	rs7032940	0.954	rs10816936	ENSG00000228236.2	TXNP5	6.61	6.23e-11	5.2e-05	0.27	0.2	Height;	chr9:110189687	chr2:149068596~149068910:-
BRCA	trans	rs4929949	0.707	rs9284150	ENSG00000266891.1	RP11-692N5.2	-6.61	6.23e-11	5.21e-05	-0.24	-0.2	Body mass index;	chr11:8577426	chr18:9734882~9735602:-
BRCA	trans	rs9467711	0.79	rs13195401	ENSG00000281831.1	HCP5B	6.61	6.24e-11	5.21e-05	0.5	0.2	Autism spectrum disorder or schizophrenia;	chr6:26463346	chr6:29871895~29873783:-
BRCA	trans	rs9467711	0.79	rs13195402	ENSG00000281831.1	HCP5B	6.61	6.24e-11	5.21e-05	0.5	0.2	Autism spectrum disorder or schizophrenia;	chr6:26463347	chr6:29871895~29873783:-
BRCA	trans	rs7617773	0.78	rs3731550	ENSG00000235912.1	RP1-159A19.3	-6.61	6.25e-11	5.23e-05	-0.27	-0.2	Coronary artery disease;	chr3:48165093	chr1:27649419~27649610:+
BRCA	trans	rs7617773	0.817	rs3731534	ENSG00000235912.1	RP1-159A19.3	-6.61	6.25e-11	5.23e-05	-0.27	-0.2	Coronary artery disease;	chr3:48170287	chr1:27649419~27649610:+
BRCA	trans	rs3812762	0.879	rs1079452	ENSG00000266891.1	RP11-692N5.2	6.61	6.26e-11	5.24e-05	0.24	0.2	Hypospadias;	chr11:8757625	chr18:9734882~9735602:-
BRCA	trans	rs2220004	1	rs7106787	ENSG00000134612.10	FOLH1B	-6.61	6.26e-11	5.24e-05	-0.26	-0.2	Odorant perception (&beta-damascenone);	chr11:56056100	chr11:89639227~89698718:+
BRCA	trans	rs853679	1	rs9986596	ENSG00000253570.1	RNF5P1	6.61	6.27e-11	5.24e-05	0.39	0.2	Depression;	chr6:28251883	chr8:38600661~38601200:-
BRCA	trans	rs7617773	0.78	rs6442111	ENSG00000235912.1	RP1-159A19.3	-6.61	6.3e-11	5.26e-05	-0.25	-0.2	Coronary artery disease;	chr3:48270570	chr1:27649419~27649610:+
BRCA	trans	rs7617773	0.817	rs3731497	ENSG00000235912.1	RP1-159A19.3	-6.6	6.34e-11	5.3e-05	-0.26	-0.2	Coronary artery disease;	chr3:48185063	chr1:27649419~27649610:+
BRCA	trans	rs11098499	0.955	rs13113112	ENSG00000276997.3	RP11-378J18.9	6.6	6.44e-11	5.38e-05	0.25	0.2	Corneal astigmatism;	chr4:119234885	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.955	rs1511019	ENSG00000276997.3	RP11-378J18.9	6.6	6.47e-11	5.4e-05	0.25	0.2	Corneal astigmatism;	chr4:119244852	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.866	rs10518329	ENSG00000276997.3	RP11-378J18.9	6.6	6.49e-11	5.42e-05	0.24	0.2	Corneal astigmatism;	chr4:119480680	chr1:222477252~222504622:-
BRCA	trans	rs2220004	1	rs12420542	ENSG00000134612.10	FOLH1B	-6.6	6.49e-11	5.42e-05	-0.26	-0.2	Odorant perception (&beta-damascenone);	chr11:56055818	chr11:89639227~89698718:+
BRCA	trans	rs11098499	0.863	rs10019674	ENSG00000120555.12	SEPT7P9	-6.6	6.5e-11	5.43e-05	-0.26	-0.2	Corneal astigmatism;	chr4:119522334	chr10:38383069~38402916:-
BRCA	trans	rs7824557	0.701	rs2060465	ENSG00000270154.1	RP11-419I17.1	6.6	6.52e-11	5.44e-05	0.25	0.2	Retinal vascular caliber;	chr8:11305100	chr8:12476462~12477122:+
BRCA	trans	rs17767294	0.708	rs72849204	ENSG00000242375.1	RP11-498P14.3	-6.6	6.52e-11	5.45e-05	-0.59	-0.2	Parkinson's disease;	chr6:28203165	chr9:97195351~97197687:-
BRCA	trans	rs17767294	0.708	rs72849205	ENSG00000242375.1	RP11-498P14.3	-6.6	6.52e-11	5.45e-05	-0.59	-0.2	Parkinson's disease;	chr6:28203751	chr9:97195351~97197687:-
BRCA	trans	rs17767294	0.708	rs72849206	ENSG00000242375.1	RP11-498P14.3	-6.6	6.52e-11	5.45e-05	-0.59	-0.2	Parkinson's disease;	chr6:28204926	chr9:97195351~97197687:-
BRCA	trans	rs7819412	0.522	rs3021495	ENSG00000253893.2	FAM85B	6.6	6.52e-11	5.45e-05	0.29	0.2	Triglycerides;	chr8:11137233	chr8:8167819~8226614:-
BRCA	trans	rs7824557	0.767	rs6985146	ENSG00000270154.1	RP11-419I17.1	6.6	6.54e-11	5.46e-05	0.25	0.2	Retinal vascular caliber;	chr8:11313212	chr8:12476462~12477122:+
BRCA	trans	rs853679	0.546	rs200981	ENSG00000253570.1	RNF5P1	6.6	6.58e-11	5.49e-05	0.44	0.2	Depression;	chr6:27865396	chr8:38600661~38601200:-
BRCA	trans	rs7903456	0.648	rs4275529	ENSG00000232706.3	NUTM2HP	6.6	6.58e-11	5.5e-05	0.27	0.2	Gout;Renal underexcretion gout;	chr10:87069031	chr10:50676743~50686326:+
BRCA	trans	rs11098499	0.604	rs2389882	ENSG00000276997.3	RP11-378J18.9	6.6	6.59e-11	5.5e-05	0.25	0.2	Corneal astigmatism;	chr4:119645578	chr1:222477252~222504622:-
BRCA	trans	rs2220004	1	rs7925738	ENSG00000134612.10	FOLH1B	-6.6	6.6e-11	5.51e-05	-0.26	-0.2	Odorant perception (&beta-damascenone);	chr11:56061280	chr11:89639227~89698718:+
BRCA	trans	rs17507216	0.958	rs72751643	ENSG00000259295.5	CSPG4P12	-6.6	6.69e-11	5.58e-05	-0.3	-0.2	Excessive daytime sleepiness;	chr15:82559444	chr15:85191438~85213905:+
BRCA	trans	rs1707322	1	rs785490	ENSG00000255397.1	AC022182.2	6.6	6.73e-11	5.62e-05	0.27	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46111452	chr8:60937705~60939871:-
BRCA	trans	rs714543	1	rs10278679	ENSG00000214975.4	PPIAP29	-6.59	6.75e-11	5.63e-05	-0.23	-0.2	Plateletcrit;	chr7:44825465	chr6:24976419~24976982:+
BRCA	trans	rs860295	0.812	rs4278368	ENSG00000241627.3	UBQLN4P1	-6.59	6.77e-11	5.64e-05	-0.21	-0.2	Body mass index;	chr1:155752766	chr3:148985868~148987668:-
BRCA	trans	rs9581094	0.591	rs73154339	ENSG00000237917.1	PARP4P1	-6.59	6.77e-11	5.65e-05	-0.44	-0.2	Sudden cardiac arrest;	chr13:24472441	chrY:26594851~26634652:-
BRCA	trans	rs9581094	0.591	rs1130941	ENSG00000237917.1	PARP4P1	-6.59	6.79e-11	5.66e-05	-0.4	-0.2	Sudden cardiac arrest;	chr13:24459062	chrY:26594851~26634652:-
BRCA	trans	rs9581094	0.591	rs1050107	ENSG00000237917.1	PARP4P1	-6.59	6.79e-11	5.66e-05	-0.4	-0.2	Sudden cardiac arrest;	chr13:24459089	chrY:26594851~26634652:-
BRCA	trans	rs4883201	0.611	rs2377671	ENSG00000179899.8	PHC1P1	6.59	6.86e-11	5.72e-05	0.24	0.2	Total cholesterol levels;Cholesterol, total;	chr12:8951246	chr12:55411727~55414787:-
BRCA	trans	rs2288327	0.818	rs16866373	ENSG00000269800.1	PLEKHA3P1	6.59	6.88e-11	5.74e-05	0.31	0.2	Atrial fibrillation;	chr2:178527353	chr19:41521043~41521989:-
BRCA	trans	rs853679	1	rs853685	ENSG00000253570.1	RNF5P1	6.59	6.92e-11	5.77e-05	0.39	0.2	Depression;	chr6:28321008	chr8:38600661~38601200:-
BRCA	trans	rs2069408	1	rs2069408	ENSG00000224553.1	AC008065.1	-6.59	6.94e-11	5.79e-05	-0.25	-0.2	Asthma;	chr12:55970537	chr2:171374931~171375278:-
BRCA	trans	rs17507216	0.588	rs28864981	ENSG00000259295.5	CSPG4P12	-6.59	6.95e-11	5.79e-05	-0.33	-0.2	Excessive daytime sleepiness;	chr15:82695420	chr15:85191438~85213905:+
BRCA	trans	rs17507216	0.628	rs8032321	ENSG00000259295.5	CSPG4P12	-6.59	6.95e-11	5.79e-05	-0.33	-0.2	Excessive daytime sleepiness;	chr15:82698956	chr15:85191438~85213905:+
BRCA	trans	rs17507216	0.628	rs8040488	ENSG00000259295.5	CSPG4P12	-6.59	6.95e-11	5.79e-05	-0.33	-0.2	Excessive daytime sleepiness;	chr15:82699081	chr15:85191438~85213905:+
BRCA	trans	rs7819412	0.54	rs11777355	ENSG00000253893.2	FAM85B	6.59	6.96e-11	5.8e-05	0.26	0.2	Triglycerides;	chr8:11187180	chr8:8167819~8226614:-
BRCA	trans	rs10815468	0.585	rs4742263	ENSG00000215210.3	RBMXP2	6.59	6.97e-11	5.81e-05	0.27	0.2	Bipolar disorder and schizophrenia;	chr9:6782225	chr9:30689105~30690272:+
BRCA	trans	rs17767294	0.708	rs79956881	ENSG00000242375.1	RP11-498P14.3	-6.59	7.03e-11	5.85e-05	-0.6	-0.2	Parkinson's disease;	chr6:28062372	chr9:97195351~97197687:-
BRCA	trans	rs853679	0.546	rs200952	ENSG00000253570.1	RNF5P1	6.59	7.03e-11	5.86e-05	0.45	0.2	Depression;	chr6:27869198	chr8:38600661~38601200:-
BRCA	trans	rs12439619	0.81	rs62012049	ENSG00000259295.5	CSPG4P12	-6.59	7.05e-11	5.87e-05	-0.31	-0.2	Intelligence (multi-trait analysis);	chr15:82237722	chr15:85191438~85213905:+
BRCA	trans	rs1707322	0.686	rs2275085	ENSG00000255397.1	AC022182.2	6.59	7.1e-11	5.91e-05	0.27	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45620180	chr8:60937705~60939871:-
BRCA	trans	rs7833986	0.534	rs72653928	ENSG00000244245.1	RP11-120B7.1	6.59	7.11e-11	5.92e-05	0.26	0.2	Height;	chr8:55995176	chr5:108593609~108593967:+
BRCA	trans	rs1707322	1	rs1622208	ENSG00000255397.1	AC022182.2	6.59	7.14e-11	5.94e-05	0.27	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46032703	chr8:60937705~60939871:-
BRCA	trans	rs1707322	1	rs785470	ENSG00000255397.1	AC022182.2	6.59	7.17e-11	5.97e-05	0.26	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46053950	chr8:60937705~60939871:-
BRCA	trans	rs7824557	0.767	rs2164272	ENSG00000270154.1	RP11-419I17.1	6.58	7.23e-11	6.01e-05	0.25	0.2	Retinal vascular caliber;	chr8:11304987	chr8:12476462~12477122:+
BRCA	trans	rs673253	0.593	rs3791134	ENSG00000231007.5	CDC20P1	6.58	7.24e-11	6.02e-05	0.25	0.2	Intelligence (multi-trait analysis);	chr1:43583485	chr9:87011652~87013151:+
BRCA	trans	rs4929949	0.752	rs1446464	ENSG00000266891.1	RP11-692N5.2	6.58	7.24e-11	6.02e-05	0.24	0.2	Body mass index;	chr11:8464763	chr18:9734882~9735602:-
BRCA	trans	rs9467711	0.517	rs16901784	ENSG00000253570.1	RNF5P1	6.58	7.26e-11	6.04e-05	0.43	0.2	Autism spectrum disorder or schizophrenia;	chr6:26555205	chr8:38600661~38601200:-
BRCA	trans	rs7819412	0.521	rs4451268	ENSG00000253893.2	FAM85B	6.58	7.26e-11	6.04e-05	0.26	0.2	Triglycerides;	chr8:11177350	chr8:8167819~8226614:-
BRCA	trans	rs17767294	0.708	rs72847379	ENSG00000242375.1	RP11-498P14.3	-6.58	7.29e-11	6.07e-05	-0.59	-0.2	Parkinson's disease;	chr6:27905312	chr9:97195351~97197687:-
BRCA	trans	rs11512640	1	rs11512640	ENSG00000236257.1	EI24P2	-6.58	7.31e-11	6.08e-05	-0.42	-0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr11:125556427	chr1:158454198~158455273:+
BRCA	trans	rs2220004	0.964	rs2512939	ENSG00000134612.10	FOLH1B	6.58	7.32e-11	6.09e-05	0.27	0.2	Odorant perception (&beta-damascenone);	chr11:56136338	chr11:89639227~89698718:+
BRCA	trans	rs2220004	1	rs7950964	ENSG00000134612.10	FOLH1B	-6.58	7.35e-11	6.11e-05	-0.26	-0.2	Odorant perception (&beta-damascenone);	chr11:56079165	chr11:89639227~89698718:+
BRCA	trans	rs2220004	0.963	rs4938819	ENSG00000134612.10	FOLH1B	-6.58	7.35e-11	6.12e-05	-0.26	-0.2	Odorant perception (&beta-damascenone);	chr11:56077378	chr11:89639227~89698718:+
BRCA	trans	rs17767294	0.708	rs72847332	ENSG00000242375.1	RP11-498P14.3	-6.58	7.35e-11	6.12e-05	-0.59	-0.2	Parkinson's disease;	chr6:27805998	chr9:97195351~97197687:-
BRCA	trans	rs17767294	0.708	rs72847355	ENSG00000242375.1	RP11-498P14.3	-6.58	7.35e-11	6.12e-05	-0.59	-0.2	Parkinson's disease;	chr6:27857398	chr9:97195351~97197687:-
BRCA	trans	rs17767294	0.708	rs72847356	ENSG00000242375.1	RP11-498P14.3	-6.58	7.35e-11	6.12e-05	-0.59	-0.2	Parkinson's disease;	chr6:27857816	chr9:97195351~97197687:-
BRCA	trans	rs2288327	0.818	rs3731748	ENSG00000269800.1	PLEKHA3P1	6.58	7.38e-11	6.14e-05	0.3	0.2	Atrial fibrillation;	chr2:178548383	chr19:41521043~41521989:-
BRCA	trans	rs7824557	0.603	rs6995404	ENSG00000253893.2	FAM85B	-6.58	7.38e-11	6.14e-05	-0.25	-0.2	Retinal vascular caliber;	chr8:11324639	chr8:8167819~8226614:-
BRCA	trans	rs6940638	0.956	rs12190473	ENSG00000204709.4	LINC01556	6.58	7.39e-11	6.15e-05	0.29	0.2	Intelligence (multi-trait analysis);	chr6:27056908	chr6:28943877~28944537:+
BRCA	trans	rs1580019	0.52	rs6945238	ENSG00000213492.2	NT5C3AP1	6.58	7.42e-11	6.17e-05	0.29	0.2	Cognitive ability;	chr7:32606484	chr4:117574512~117576174:-
BRCA	trans	rs673253	0.662	rs61769642	ENSG00000231007.5	CDC20P1	6.58	7.45e-11	6.19e-05	0.25	0.2	Intelligence (multi-trait analysis);	chr1:43585959	chr9:87011652~87013151:+
BRCA	trans	rs11098499	1	rs6837898	ENSG00000276997.3	RP11-378J18.9	6.58	7.45e-11	6.19e-05	0.25	0.2	Corneal astigmatism;	chr4:119257999	chr1:222477252~222504622:-
BRCA	trans	rs6940638	0.956	rs12199218	ENSG00000204709.4	LINC01556	6.58	7.58e-11	6.3e-05	0.3	0.2	Intelligence (multi-trait analysis);	chr6:27057502	chr6:28943877~28944537:+
BRCA	trans	rs7617773	0.817	rs6806112	ENSG00000235912.1	RP1-159A19.3	-6.58	7.63e-11	6.34e-05	-0.24	-0.2	Coronary artery disease;	chr3:48234587	chr1:27649419~27649610:+
BRCA	trans	rs6601327	0.571	rs7838571	ENSG00000253893.2	FAM85B	-6.58	7.66e-11	6.36e-05	-0.25	-0.2	Multiple myeloma (hyperdiploidy);	chr8:9790286	chr8:8167819~8226614:-
BRCA	trans	rs875971	0.545	rs73146609	ENSG00000234585.5	CCT6P3	6.58	7.66e-11	6.36e-05	0.22	0.2	Aortic root size;	chr7:66302477	chr7:65038354~65074713:+
BRCA	trans	rs875971	0.545	rs2173571	ENSG00000234585.5	CCT6P3	6.58	7.66e-11	6.36e-05	0.22	0.2	Aortic root size;	chr7:66305392	chr7:65038354~65074713:+
BRCA	trans	rs7260598	0.792	rs17620029	ENSG00000261770.1	CTC-459F4.1	6.57	7.71e-11	6.4e-05	0.34	0.2	Response to taxane treatment (placlitaxel);	chr19:24171510	chr19:27757184~27760849:-
BRCA	trans	rs12439619	0.921	rs4778672	ENSG00000259774.1	RP11-182J1.13	-6.57	7.78e-11	6.46e-05	-0.26	-0.2	Intelligence (multi-trait analysis);	chr15:82245013	chr15:84422618~84425882:+
BRCA	trans	rs1707322	1	rs785506	ENSG00000255397.1	AC022182.2	6.57	7.81e-11	6.49e-05	0.26	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46074980	chr8:60937705~60939871:-
BRCA	trans	rs12439619	0.739	rs62012046	ENSG00000259295.5	CSPG4P12	-6.57	7.83e-11	6.5e-05	-0.31	-0.2	Intelligence (multi-trait analysis);	chr15:82236824	chr15:85191438~85213905:+
BRCA	trans	rs12439619	0.774	rs62012047	ENSG00000259295.5	CSPG4P12	-6.57	7.83e-11	6.5e-05	-0.31	-0.2	Intelligence (multi-trait analysis);	chr15:82236852	chr15:85191438~85213905:+
BRCA	trans	rs1707322	1	rs1707337	ENSG00000255397.1	AC022182.2	6.57	7.84e-11	6.5e-05	0.26	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46043097	chr8:60937705~60939871:-
BRCA	trans	rs1707322	1	rs1768807	ENSG00000255397.1	AC022182.2	6.57	7.84e-11	6.5e-05	0.26	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46044898	chr8:60937705~60939871:-
BRCA	trans	rs11098499	1	rs13116504	ENSG00000276997.3	RP11-378J18.9	6.57	7.85e-11	6.52e-05	0.25	0.2	Corneal astigmatism;	chr4:119288257	chr1:222477252~222504622:-
BRCA	trans	rs1707322	1	rs4134387	ENSG00000255397.1	AC022182.2	-6.57	7.87e-11	6.53e-05	-0.27	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45929486	chr8:60937705~60939871:-
BRCA	trans	rs2727020	0.59	rs7949936	ENSG00000134612.10	FOLH1B	-6.57	7.93e-11	6.58e-05	-0.29	-0.2	Coronary artery disease;	chr11:49357350	chr11:89639227~89698718:+
BRCA	trans	rs6831352	0.842	rs1230156	ENSG00000233859.2	ADH5P4	-6.57	7.95e-11	6.6e-05	-0.29	-0.2	Alcohol dependence;	chr4:99068475	chr6:65836930~65838039:-
BRCA	trans	rs902774	0.818	rs73110471	ENSG00000255815.3	KRT8P11	-6.57	7.96e-11	6.6e-05	-0.4	-0.2	Prostate cancer;	chr12:52923037	chr9:99305176~99306611:+
BRCA	trans	rs714543	1	rs10267576	ENSG00000214975.4	PPIAP29	-6.57	7.97e-11	6.61e-05	-0.23	-0.2	Plateletcrit;	chr7:44831334	chr6:24976419~24976982:+
BRCA	trans	rs9292918	1	rs10473384	ENSG00000231752.4	EMBP1	-6.57	7.98e-11	6.62e-05	-0.29	-0.2	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:45343708	chr1:121519112~121571892:+
BRCA	trans	rs4929949	0.752	rs2289923	ENSG00000266891.1	RP11-692N5.2	-6.57	7.99e-11	6.63e-05	-0.24	-0.2	Body mass index;	chr11:8474969	chr18:9734882~9735602:-
BRCA	trans	rs875971	0.545	rs316328	ENSG00000234585.5	CCT6P3	-6.57	8.11e-11	6.73e-05	-0.2	-0.2	Aortic root size;	chr7:66143851	chr7:65038354~65074713:+
BRCA	trans	rs714543	1	rs2898	ENSG00000214975.4	PPIAP29	-6.56	8.2e-11	6.8e-05	-0.23	-0.2	Plateletcrit;	chr7:44827034	chr6:24976419~24976982:+
BRCA	trans	rs7824557	0.767	rs2060463	ENSG00000270154.1	RP11-419I17.1	6.56	8.26e-11	6.85e-05	0.25	0.2	Retinal vascular caliber;	chr8:11304101	chr8:12476462~12477122:+
BRCA	trans	rs875971	0.545	rs6969224	ENSG00000234585.5	CCT6P3	6.56	8.27e-11	6.85e-05	0.22	0.2	Aortic root size;	chr7:66370011	chr7:65038354~65074713:+
BRCA	trans	rs7903456	0.648	rs1923939	ENSG00000232706.3	NUTM2HP	6.56	8.27e-11	6.86e-05	0.27	0.2	Gout;Renal underexcretion gout;	chr10:87068411	chr10:50676743~50686326:+
BRCA	trans	rs17767294	0.708	rs72851105	ENSG00000242375.1	RP11-498P14.3	-6.56	8.3e-11	6.88e-05	-0.6	-0.2	Parkinson's disease;	chr6:28068630	chr9:97195351~97197687:-
BRCA	trans	rs853679	0.546	rs200954	ENSG00000253570.1	RNF5P1	6.56	8.31e-11	6.89e-05	0.45	0.2	Depression;	chr6:27870986	chr8:38600661~38601200:-
BRCA	trans	rs1707322	0.656	rs2991981	ENSG00000255397.1	AC022182.2	6.56	8.34e-11	6.91e-05	0.26	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45591472	chr8:60937705~60939871:-
BRCA	trans	rs2220004	1	rs2460211	ENSG00000134612.10	FOLH1B	-6.56	8.35e-11	6.92e-05	-0.26	-0.2	Odorant perception (&beta-damascenone);	chr11:56127357	chr11:89639227~89698718:+
BRCA	trans	rs7169223	0.615	rs8038189	ENSG00000274376.3	ADAMTS7P1	6.56	8.37e-11	6.94e-05	0.26	0.2	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78806684	chr15:82298553~82334609:+
BRCA	trans	rs9834975	0.631	rs4678189	ENSG00000267076.1	CCDC58P3	-6.56	8.4e-11	6.96e-05	-0.23	-0.2	Diastolic blood pressure;	chr3:122359476	chr18:12211378~12211807:+
BRCA	trans	rs2048656	0.6	rs1976671	ENSG00000253893.2	FAM85B	-6.56	8.4e-11	6.96e-05	-0.25	-0.2	Schizophrenia;	chr8:9822124	chr8:8167819~8226614:-
BRCA	trans	rs1707322	0.963	rs10789478	ENSG00000255397.1	AC022182.2	-6.56	8.44e-11	6.99e-05	-0.27	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45884834	chr8:60937705~60939871:-
BRCA	trans	rs17767294	0.614	rs72850298	ENSG00000242375.1	RP11-498P14.3	-6.56	8.59e-11	7.12e-05	-0.59	-0.2	Parkinson's disease;	chr6:28254778	chr9:97195351~97197687:-
BRCA	trans	rs11098499	0.604	rs17051352	ENSG00000276997.3	RP11-378J18.9	6.56	8.6e-11	7.12e-05	0.26	0.2	Corneal astigmatism;	chr4:119660272	chr1:222477252~222504622:-
BRCA	trans	rs875971	0.545	rs6979636	ENSG00000234585.5	CCT6P3	6.56	8.6e-11	7.12e-05	0.22	0.2	Aortic root size;	chr7:66276638	chr7:65038354~65074713:+
BRCA	trans	rs2060793	0.519	rs1403247	ENSG00000236360.2	RP11-334A14.2	-6.56	8.61e-11	7.13e-05	-0.25	-0.2	Vitamin D levels;	chr11:14611024	chr1:52993201~52993702:-
BRCA	trans	rs4929949	0.78	rs9300094	ENSG00000266891.1	RP11-692N5.2	6.56	8.72e-11	7.22e-05	0.23	0.2	Body mass index;	chr11:8573942	chr18:9734882~9735602:-
BRCA	trans	rs7819412	0.505	rs17726209	ENSG00000253893.2	FAM85B	-6.56	8.73e-11	7.23e-05	-0.27	-0.2	Triglycerides;	chr8:11164675	chr8:8167819~8226614:-
BRCA	trans	rs11098499	0.863	rs1383532	ENSG00000120555.12	SEPT7P9	-6.55	8.76e-11	7.25e-05	-0.25	-0.2	Corneal astigmatism;	chr4:119513249	chr10:38383069~38402916:-
BRCA	trans	rs7617773	0.779	rs9833309	ENSG00000235912.1	RP1-159A19.3	-6.55	8.8e-11	7.28e-05	-0.25	-0.2	Coronary artery disease;	chr3:48285960	chr1:27649419~27649610:+
BRCA	trans	rs7617773	0.817	rs9853804	ENSG00000235912.1	RP1-159A19.3	-6.55	8.8e-11	7.28e-05	-0.25	-0.2	Coronary artery disease;	chr3:48286239	chr1:27649419~27649610:+
BRCA	trans	rs7617773	0.817	rs9834095	ENSG00000235912.1	RP1-159A19.3	-6.55	8.8e-11	7.28e-05	-0.25	-0.2	Coronary artery disease;	chr3:48286261	chr1:27649419~27649610:+
BRCA	trans	rs1707322	0.686	rs2991977	ENSG00000255397.1	AC022182.2	6.55	8.81e-11	7.29e-05	0.26	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45588011	chr8:60937705~60939871:-
BRCA	trans	rs2840044	1	rs11656138	ENSG00000234130.2	RP13-88F20.1	6.55	8.85e-11	7.32e-05	0.22	0.2	Response to radiotherapy in cancer (late toxicity);	chr17:35583199	chrX:93222220~93225015:-
BRCA	trans	rs2840044	1	rs9900378	ENSG00000234130.2	RP13-88F20.1	6.55	8.85e-11	7.32e-05	0.22	0.2	Response to radiotherapy in cancer (late toxicity);	chr17:35584283	chrX:93222220~93225015:-
BRCA	trans	rs673253	0.686	rs3791139	ENSG00000231007.5	CDC20P1	6.55	8.87e-11	7.34e-05	0.25	0.2	Intelligence (multi-trait analysis);	chr1:43586100	chr9:87011652~87013151:+
BRCA	trans	rs853679	0.599	rs156743	ENSG00000253570.1	RNF5P1	6.55	8.88e-11	7.34e-05	0.45	0.2	Depression;	chr6:27999311	chr8:38600661~38601200:-
BRCA	trans	rs1580019	0.52	rs13228793	ENSG00000213492.2	NT5C3AP1	-6.55	8.95e-11	7.4e-05	-0.3	-0.2	Cognitive ability;	chr7:32671853	chr4:117574512~117576174:-
BRCA	trans	rs641862	1	rs641862	ENSG00000235280.2	MCF2L-AS1	6.55	9.02e-11	7.45e-05	0.44	0.2	Obesity-related traits;	chr13:110137885	chr13:112967484~112968824:-
BRCA	trans	rs7617773	0.817	rs11720622	ENSG00000235912.1	RP1-159A19.3	-6.55	9.06e-11	7.49e-05	-0.23	-0.2	Coronary artery disease;	chr3:48205189	chr1:27649419~27649610:+
BRCA	trans	rs11098499	0.955	rs1511018	ENSG00000276997.3	RP11-378J18.9	6.55	9.09e-11	7.51e-05	0.25	0.2	Corneal astigmatism;	chr4:119240425	chr1:222477252~222504622:-
BRCA	trans	rs2055729	0.614	rs17150693	ENSG00000253893.2	FAM85B	-6.55	9.2e-11	7.6e-05	-0.29	-0.2	Multiple myeloma (hyperdiploidy);	chr8:9884142	chr8:8167819~8226614:-
BRCA	trans	rs875971	1	rs2420820	ENSG00000164669.11	INTS4P1	6.55	9.21e-11	7.61e-05	0.25	0.2	Aortic root size;	chr7:66626920	chr7:65141225~65234216:+
BRCA	trans	rs864643	1	rs704963	ENSG00000188856.6	RPSAP47	-6.55	9.21e-11	7.61e-05	-0.29	-0.2	Attention deficit hyperactivity disorder;	chr3:39515747	chr8:80558870~80559757:+
BRCA	trans	rs11098499	0.954	rs13145352	ENSG00000276997.3	RP11-378J18.9	-6.54	9.34e-11	7.72e-05	-0.25	-0.2	Corneal astigmatism;	chr4:119488808	chr1:222477252~222504622:-
BRCA	trans	rs9581094	0.591	rs73172129	ENSG00000237917.1	PARP4P1	-6.54	9.38e-11	7.75e-05	-0.45	-0.2	Sudden cardiac arrest;	chr13:24449890	chrY:26594851~26634652:-
BRCA	trans	rs7568458	0.837	rs35565292	ENSG00000223886.3	RP11-251G23.2	6.54	9.44e-11	7.79e-05	0.23	0.2	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr2:85563193	chr7:105530209~105530671:+
BRCA	trans	rs9834975	0.565	rs11553085	ENSG00000267076.1	CCDC58P3	-6.54	9.48e-11	7.82e-05	-0.23	-0.2	Diastolic blood pressure;	chr3:122411904	chr18:12211378~12211807:+
BRCA	trans	rs4929949	0.752	rs11041929	ENSG00000266891.1	RP11-692N5.2	6.54	9.48e-11	7.83e-05	0.23	0.2	Body mass index;	chr11:8454128	chr18:9734882~9735602:-
BRCA	trans	rs7927771	0.965	rs17788930	ENSG00000134612.10	FOLH1B	-6.54	9.52e-11	7.85e-05	-0.27	-0.2	Subjective well-being;	chr11:47731223	chr11:89639227~89698718:+
BRCA	trans	rs17767294	0.614	rs116420641	ENSG00000242375.1	RP11-498P14.3	-6.54	9.55e-11	7.88e-05	-0.6	-0.2	Parkinson's disease;	chr6:28307681	chr9:97195351~97197687:-
BRCA	trans	rs17767294	0.614	rs78521938	ENSG00000242375.1	RP11-498P14.3	-6.54	9.55e-11	7.88e-05	-0.6	-0.2	Parkinson's disease;	chr6:28312046	chr9:97195351~97197687:-
BRCA	trans	rs17767294	0.614	rs72854521	ENSG00000242375.1	RP11-498P14.3	-6.54	9.55e-11	7.88e-05	-0.6	-0.2	Parkinson's disease;	chr6:28317021	chr9:97195351~97197687:-
BRCA	trans	rs1580019	0.537	rs7804609	ENSG00000213492.2	NT5C3AP1	-6.54	9.64e-11	7.95e-05	-0.27	-0.2	Cognitive ability;	chr7:32518482	chr4:117574512~117576174:-
BRCA	trans	rs875971	0.545	rs11770063	ENSG00000234585.5	CCT6P3	6.54	9.67e-11	7.98e-05	0.22	0.2	Aortic root size;	chr7:66318029	chr7:65038354~65074713:+
BRCA	trans	rs12439619	0.846	rs62012056	ENSG00000235370.6	DNM1P51	-6.54	9.67e-11	7.98e-05	-0.28	-0.2	Intelligence (multi-trait analysis);	chr15:82247278	chr15:84398316~84411701:-
BRCA	trans	rs7824557	0.767	rs11775635	ENSG00000270154.1	RP11-419I17.1	6.54	9.74e-11	8.03e-05	0.25	0.2	Retinal vascular caliber;	chr8:11307356	chr8:12476462~12477122:+
BRCA	trans	rs2069408	1	rs2069408	ENSG00000234354.3	RPS26P47	-6.54	9.84e-11	8.11e-05	-0.27	-0.2	Asthma;	chr12:55970537	chr13:100539901~100540248:-
BRCA	trans	rs2965280	0.793	rs8104344	ENSG00000270983.1	RP11-137J7.3	-6.54	9.84e-11	8.11e-05	-0.44	-0.2	Colorectal cancer;	chr19:34349323	chr6:142062717~142063053:+
BRCA	trans	rs2220004	1	rs2449149	ENSG00000134612.10	FOLH1B	-6.54	9.85e-11	8.12e-05	-0.26	-0.2	Odorant perception (&beta-damascenone);	chr11:56108784	chr11:89639227~89698718:+
BRCA	trans	rs1707322	1	rs9429186	ENSG00000255397.1	AC022182.2	6.54	9.86e-11	8.13e-05	0.26	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46074015	chr8:60937705~60939871:-
BRCA	trans	rs34421088	0.506	rs4841518	ENSG00000253893.2	FAM85B	-6.54	9.87e-11	8.14e-05	-0.26	-0.2	Neuroticism;	chr8:11288454	chr8:8167819~8226614:-
BRCA	trans	rs3942852	0.868	rs7122335	ENSG00000134612.10	FOLH1B	-6.54	9.93e-11	8.18e-05	-0.29	-0.2	Acute lymphoblastic leukemia (childhood);	chr11:48084934	chr11:89639227~89698718:+
BRCA	trans	rs1707322	1	rs4660332	ENSG00000255397.1	AC022182.2	-6.53	9.94e-11	8.19e-05	-0.27	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45995746	chr8:60937705~60939871:-
BRCA	trans	rs6940638	0.956	rs10946899	ENSG00000204709.4	LINC01556	6.53	1e-10	8.25e-05	0.29	0.2	Intelligence (multi-trait analysis);	chr6:27055915	chr6:28943877~28944537:+
BRCA	trans	rs853679	0.546	rs175597	ENSG00000253570.1	RNF5P1	6.53	1.01e-10	8.32e-05	0.45	0.2	Depression;	chr6:27842848	chr8:38600661~38601200:-
BRCA	trans	rs7824557	0.767	rs28507159	ENSG00000270154.1	RP11-419I17.1	6.53	1.02e-10	8.39e-05	0.25	0.2	Retinal vascular caliber;	chr8:11308567	chr8:12476462~12477122:+
BRCA	trans	rs941207	0.756	rs2958149	ENSG00000257210.1	NACAP3	6.53	1.02e-10	8.39e-05	0.27	0.2	Platelet count;	chr12:56716008	chr12:93124063~93124543:-
BRCA	trans	rs9379945	1	rs9379945	ENSG00000253570.1	RNF5P1	6.53	1.03e-10	8.46e-05	0.41	0.2	Intelligence (multi-trait analysis);	chr6:26940052	chr8:38600661~38601200:-
BRCA	trans	rs1707322	1	rs11211232	ENSG00000255397.1	AC022182.2	-6.53	1.03e-10	8.48e-05	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45945474	chr8:60937705~60939871:-
BRCA	trans	rs853679	1	rs853676	ENSG00000253570.1	RNF5P1	6.53	1.04e-10	8.52e-05	0.39	0.2	Depression;	chr6:28331910	chr8:38600661~38601200:-
BRCA	trans	rs2840044	1	rs225304	ENSG00000234130.2	RP13-88F20.1	-6.53	1.04e-10	8.56e-05	-0.22	-0.2	Response to radiotherapy in cancer (late toxicity);	chr17:35594838	chrX:93222220~93225015:-
BRCA	trans	rs34421088	0.564	rs6983129	ENSG00000253893.2	FAM85B	-6.53	1.04e-10	8.56e-05	-0.24	-0.2	Neuroticism;	chr8:11733627	chr8:8167819~8226614:-
BRCA	trans	rs11098499	0.604	rs10022185	ENSG00000276997.3	RP11-378J18.9	6.53	1.05e-10	8.68e-05	0.25	0.2	Corneal astigmatism;	chr4:119650610	chr1:222477252~222504622:-
BRCA	trans	rs4929949	0.78	rs11041947	ENSG00000266891.1	RP11-692N5.2	6.53	1.06e-10	8.71e-05	0.23	0.2	Body mass index;	chr11:8485325	chr18:9734882~9735602:-
BRCA	trans	rs941207	0.724	rs1979325	ENSG00000257210.1	NACAP3	6.53	1.06e-10	8.71e-05	0.27	0.2	Platelet count;	chr12:56728152	chr12:93124063~93124543:-
BRCA	trans	rs11098499	0.754	rs938056	ENSG00000120555.12	SEPT7P9	6.52	1.06e-10	8.72e-05	0.24	0.2	Corneal astigmatism;	chr4:119316298	chr10:38383069~38402916:-
BRCA	trans	rs1707322	1	rs4606257	ENSG00000255397.1	AC022182.2	-6.52	1.06e-10	8.72e-05	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45841596	chr8:60937705~60939871:-
BRCA	trans	rs12439619	0.81	rs28876157	ENSG00000235370.6	DNM1P51	-6.52	1.06e-10	8.76e-05	-0.28	-0.2	Intelligence (multi-trait analysis);	chr15:82216708	chr15:84398316~84411701:-
BRCA	trans	rs1864585	0.806	rs17778223	ENSG00000173295.6	FAM86B3P	6.52	1.07e-10	8.79e-05	0.23	0.2	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr8:10872182	chr8:8228595~8244865:+
BRCA	trans	rs17767294	0.708	rs78094982	ENSG00000242375.1	RP11-498P14.3	-6.52	1.08e-10	8.85e-05	-0.59	-0.2	Parkinson's disease;	chr6:28000572	chr9:97195351~97197687:-
BRCA	trans	rs17767294	0.708	rs72848785	ENSG00000242375.1	RP11-498P14.3	-6.52	1.08e-10	8.85e-05	-0.59	-0.2	Parkinson's disease;	chr6:28009825	chr9:97195351~97197687:-
BRCA	trans	rs7617773	0.744	rs2125482	ENSG00000235912.1	RP1-159A19.3	-6.52	1.08e-10	8.91e-05	-0.25	-0.2	Coronary artery disease;	chr3:48281643	chr1:27649419~27649610:+
BRCA	trans	rs1707322	0.963	rs1768815	ENSG00000255397.1	AC022182.2	6.52	1.09e-10	8.98e-05	0.26	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46062931	chr8:60937705~60939871:-
BRCA	trans	rs2066819	1	rs17118439	ENSG00000273654.1	CTB-52I2.4	-6.52	1.1e-10	9.04e-05	-0.49	-0.2	Psoriasis vulgaris;	chr12:56273820	chr19:18022403~18032099:+
BRCA	trans	rs10815468	0.585	rs4742264	ENSG00000215210.3	RBMXP2	6.52	1.11e-10	9.1e-05	0.26	0.2	Bipolar disorder and schizophrenia;	chr9:6783414	chr9:30689105~30690272:+
BRCA	trans	rs1816752	0.905	rs3818938	ENSG00000224976.2	PARP4P2	-6.52	1.11e-10	9.16e-05	-0.24	-0.2	Obesity-related traits;	chr13:24454945	chr13:19349137~19407962:+
BRCA	trans	rs7824557	0.767	rs3808509	ENSG00000270154.1	RP11-419I17.1	6.52	1.12e-10	9.23e-05	0.25	0.2	Retinal vascular caliber;	chr8:11305747	chr8:12476462~12477122:+
BRCA	trans	rs1476679	0.962	rs34995835	ENSG00000228546.2	CTA-313A17.3	6.52	1.12e-10	9.23e-05	0.29	0.2	Alzheimer's disease (late onset);	chr7:100392741	chr7:102337316~102339115:+
BRCA	trans	rs853679	0.567	rs13196606	ENSG00000228078.1	HLA-U	-6.52	1.12e-10	9.23e-05	-0.29	-0.2	Depression;	chr6:28402301	chr6:29934101~29934286:+
BRCA	trans	rs2840044	1	rs11653310	ENSG00000234130.2	RP13-88F20.1	-6.51	1.13e-10	9.28e-05	-0.22	-0.2	Response to radiotherapy in cancer (late toxicity);	chr17:35566359	chrX:93222220~93225015:-
BRCA	trans	rs4929949	0.78	rs10769920	ENSG00000266891.1	RP11-692N5.2	-6.51	1.13e-10	9.31e-05	-0.24	-0.2	Body mass index;	chr11:8589293	chr18:9734882~9735602:-
BRCA	trans	rs12439619	0.774	rs2867649	ENSG00000235370.6	DNM1P51	-6.51	1.14e-10	9.35e-05	-0.28	-0.2	Intelligence (multi-trait analysis);	chr15:82262331	chr15:84398316~84411701:-
BRCA	trans	rs864643	0.891	rs1708032	ENSG00000188856.6	RPSAP47	6.51	1.14e-10	9.35e-05	0.28	0.2	Attention deficit hyperactivity disorder;	chr3:39497642	chr8:80558870~80559757:+
BRCA	trans	rs2840044	1	rs1671656	ENSG00000234130.2	RP13-88F20.1	-6.51	1.15e-10	9.43e-05	-0.22	-0.2	Response to radiotherapy in cancer (late toxicity);	chr17:35612642	chrX:93222220~93225015:-
BRCA	trans	rs2220004	0.963	rs2512787	ENSG00000134612.10	FOLH1B	-6.51	1.15e-10	9.44e-05	-0.26	-0.2	Odorant perception (&beta-damascenone);	chr11:56123538	chr11:89639227~89698718:+
BRCA	trans	rs864643	0.678	rs500507	ENSG00000188856.6	RPSAP47	6.51	1.15e-10	9.45e-05	0.28	0.2	Attention deficit hyperactivity disorder;	chr3:39492886	chr8:80558870~80559757:+
BRCA	trans	rs853679	0.546	rs200948	ENSG00000253570.1	RNF5P1	6.51	1.15e-10	9.46e-05	0.44	0.2	Depression;	chr6:27867494	chr8:38600661~38601200:-
BRCA	trans	rs853679	0.546	rs200950	ENSG00000253570.1	RNF5P1	6.51	1.15e-10	9.46e-05	0.44	0.2	Depression;	chr6:27867994	chr8:38600661~38601200:-
BRCA	trans	rs864643	1	rs816494	ENSG00000188856.6	RPSAP47	6.51	1.15e-10	9.46e-05	0.29	0.2	Attention deficit hyperactivity disorder;	chr3:39515354	chr8:80558870~80559757:+
BRCA	trans	rs7903456	0.648	rs9421580	ENSG00000232706.3	NUTM2HP	6.51	1.16e-10	9.49e-05	0.28	0.2	Gout;Renal underexcretion gout;	chr10:87075497	chr10:50676743~50686326:+
BRCA	trans	rs9581094	0.591	rs4986819	ENSG00000237917.1	PARP4P1	-6.51	1.18e-10	9.64e-05	-0.39	-0.2	Sudden cardiac arrest;	chr13:24459152	chrY:26594851~26634652:-
BRCA	trans	rs9581094	0.591	rs9581061	ENSG00000237917.1	PARP4P1	-6.51	1.18e-10	9.64e-05	-0.39	-0.2	Sudden cardiac arrest;	chr13:24459255	chrY:26594851~26634652:-
BRCA	trans	rs9581094	0.591	rs3783078	ENSG00000237917.1	PARP4P1	-6.51	1.18e-10	9.64e-05	-0.39	-0.2	Sudden cardiac arrest;	chr13:24459332	chrY:26594851~26634652:-
BRCA	trans	rs17767294	0.708	rs72848786	ENSG00000242375.1	RP11-498P14.3	-6.51	1.18e-10	9.65e-05	-0.58	-0.2	Parkinson's disease;	chr6:28012239	chr9:97195351~97197687:-
BRCA	trans	rs4883201	0.656	rs10743568	ENSG00000179899.8	PHC1P1	6.51	1.18e-10	9.7e-05	0.26	0.2	Total cholesterol levels;Cholesterol, total;	chr12:8958196	chr12:55411727~55414787:-
BRCA	trans	rs902774	0.818	rs73110471	ENSG00000248568.1	KRT8P48	-6.51	1.19e-10	9.75e-05	-0.4	-0.2	Prostate cancer;	chr12:52923037	chr5:146706381~146707600:-
BRCA	trans	rs1707322	0.964	rs785508	ENSG00000255397.1	AC022182.2	6.51	1.19e-10	9.76e-05	0.26	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46061487	chr8:60937705~60939871:-
BRCA	trans	rs1707322	0.964	rs785509	ENSG00000255397.1	AC022182.2	6.51	1.19e-10	9.76e-05	0.26	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46061628	chr8:60937705~60939871:-
BRCA	trans	rs2060793	0.519	rs7931291	ENSG00000236360.2	RP11-334A14.2	-6.51	1.19e-10	9.77e-05	-0.25	-0.2	Vitamin D levels;	chr11:14622880	chr1:52993201~52993702:-
BRCA	trans	rs11098499	0.604	rs2389886	ENSG00000276997.3	RP11-378J18.9	6.51	1.2e-10	9.81e-05	0.25	0.2	Corneal astigmatism;	chr4:119649267	chr1:222477252~222504622:-
BRCA	trans	rs875971	0.502	rs1796227	ENSG00000234585.5	CCT6P3	-6.51	1.2e-10	9.83e-05	-0.22	-0.2	Aortic root size;	chr7:66622032	chr7:65038354~65074713:+
BRCA	trans	rs7617773	0.817	rs6787500	ENSG00000235912.1	RP1-159A19.3	-6.51	1.2e-10	9.84e-05	-0.23	-0.2	Coronary artery disease;	chr3:48257949	chr1:27649419~27649610:+
BRCA	trans	rs7169223	0.653	rs2904228	ENSG00000274376.3	ADAMTS7P1	-6.5	1.23e-10	0.000101	-0.28	-0.2	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78793757	chr15:82298553~82334609:+
BRCA	trans	rs7826222	0.589	rs4509327	ENSG00000253893.2	FAM85B	6.5	1.23e-10	0.000101	0.35	0.2	Adiposity;	chr8:10005427	chr8:8167819~8226614:-
BRCA	trans	rs12497850	0.764	rs6784111	ENSG00000197582.5	GPX1P1	6.5	1.23e-10	0.000101	0.21	0.2	Parkinson's disease;	chr3:49141413	chrX:13378735~13379340:-
BRCA	trans	rs3812762	0.871	rs11042068	ENSG00000266891.1	RP11-692N5.2	6.5	1.23e-10	0.000101	0.25	0.2	Hypospadias;	chr11:8794052	chr18:9734882~9735602:-
BRCA	trans	rs7824557	0.734	rs2293856	ENSG00000270154.1	RP11-419I17.1	6.5	1.24e-10	0.000102	0.25	0.2	Retinal vascular caliber;	chr8:11319938	chr8:12476462~12477122:+
BRCA	trans	rs1707322	1	rs10890381	ENSG00000255397.1	AC022182.2	-6.5	1.25e-10	0.000102	-0.27	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45986099	chr8:60937705~60939871:-
BRCA	trans	rs11098499	0.754	rs878376	ENSG00000120555.12	SEPT7P9	6.5	1.25e-10	0.000102	0.24	0.2	Corneal astigmatism;	chr4:119316547	chr10:38383069~38402916:-
BRCA	trans	rs2965280	0.793	rs1864139	ENSG00000270983.1	RP11-137J7.3	6.5	1.25e-10	0.000103	0.43	0.2	Colorectal cancer;	chr19:34381477	chr6:142062717~142063053:+
BRCA	trans	rs9467711	0.538	rs9467626	ENSG00000253570.1	RNF5P1	6.5	1.26e-10	0.000103	0.51	0.2	Autism spectrum disorder or schizophrenia;	chr6:25873518	chr8:38600661~38601200:-
BRCA	trans	rs902774	0.818	rs56095813	ENSG00000248568.1	KRT8P48	-6.49	1.28e-10	0.000105	-0.42	-0.2	Prostate cancer;	chr12:52900963	chr5:146706381~146707600:-
BRCA	trans	rs875971	0.545	rs73142233	ENSG00000213640.3	EEF1DP4	-6.49	1.29e-10	0.000106	-0.28	-0.2	Aortic root size;	chr7:66221293	chr7:64862999~64864370:+
BRCA	trans	rs941207	0.756	rs7978685	ENSG00000257210.1	NACAP3	6.49	1.3e-10	0.000106	0.27	0.2	Platelet count;	chr12:56709370	chr12:93124063~93124543:-
BRCA	trans	rs864643	1	rs1708055	ENSG00000188856.6	RPSAP47	6.49	1.3e-10	0.000106	0.29	0.2	Attention deficit hyperactivity disorder;	chr3:39531672	chr8:80558870~80559757:+
BRCA	trans	rs864643	1	rs1615046	ENSG00000188856.6	RPSAP47	6.49	1.3e-10	0.000106	0.29	0.2	Attention deficit hyperactivity disorder;	chr3:39532309	chr8:80558870~80559757:+
BRCA	trans	rs864643	1	rs1615994	ENSG00000188856.6	RPSAP47	6.49	1.3e-10	0.000106	0.29	0.2	Attention deficit hyperactivity disorder;	chr3:39532428	chr8:80558870~80559757:+
BRCA	trans	rs875971	0.545	rs73142245	ENSG00000213640.3	EEF1DP4	-6.49	1.3e-10	0.000106	-0.28	-0.2	Aortic root size;	chr7:66226662	chr7:64862999~64864370:+
BRCA	trans	rs1707322	1	rs4660335	ENSG00000255397.1	AC022182.2	-6.49	1.3e-10	0.000107	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46009046	chr8:60937705~60939871:-
BRCA	trans	rs4929949	0.752	rs7931604	ENSG00000266891.1	RP11-692N5.2	6.49	1.3e-10	0.000107	0.23	0.2	Body mass index;	chr11:8473474	chr18:9734882~9735602:-
BRCA	trans	rs1707322	0.963	rs6429581	ENSG00000255397.1	AC022182.2	-6.49	1.3e-10	0.000107	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45853424	chr8:60937705~60939871:-
BRCA	trans	rs2066819	1	rs11171803	ENSG00000273654.1	CTB-52I2.4	6.49	1.31e-10	0.000107	0.51	0.2	Psoriasis vulgaris;	chr12:56324638	chr19:18022403~18032099:+
BRCA	trans	rs2122469	0.655	rs17603934	ENSG00000228451.3	SDAD1P1	6.49	1.31e-10	0.000107	0.34	0.2	Serum tamsulosin hydrochloride concentration;	chr8:20718833	chr8:26379259~26382953:-
BRCA	trans	rs4929949	0.752	rs1374263	ENSG00000266891.1	RP11-692N5.2	6.49	1.31e-10	0.000107	0.23	0.2	Body mass index;	chr11:8437719	chr18:9734882~9735602:-
BRCA	trans	rs853679	0.546	rs200989	ENSG00000253570.1	RNF5P1	6.49	1.31e-10	0.000107	0.44	0.2	Depression;	chr6:27848664	chr8:38600661~38601200:-
BRCA	trans	rs6981523	0.553	rs11783890	ENSG00000253893.2	FAM85B	6.49	1.33e-10	0.000109	0.28	0.2	Neuroticism;	chr8:11198879	chr8:8167819~8226614:-
BRCA	trans	rs17301013	0.932	rs1754355	ENSG00000213331.4	RP11-713C19.2	-6.49	1.34e-10	0.000109	-0.22	-0.2	Systemic lupus erythematosus;	chr1:174807407	chr4:187970273~187971284:+
BRCA	trans	rs17767294	0.708	rs72847383	ENSG00000242375.1	RP11-498P14.3	-6.49	1.34e-10	0.00011	-0.58	-0.2	Parkinson's disease;	chr6:27907863	chr9:97195351~97197687:-
BRCA	trans	rs7824557	0.736	rs35392635	ENSG00000270154.1	RP11-419I17.1	6.49	1.34e-10	0.00011	0.25	0.2	Retinal vascular caliber;	chr8:11306840	chr8:12476462~12477122:+
BRCA	trans	rs4929949	0.677	rs7126013	ENSG00000266891.1	RP11-692N5.2	-6.49	1.34e-10	0.00011	-0.23	-0.2	Body mass index;	chr11:8473639	chr18:9734882~9735602:-
BRCA	trans	rs17711722	0.523	rs313812	ENSG00000213640.3	EEF1DP4	6.49	1.35e-10	0.00011	0.25	0.2	Calcium levels;	chr7:66040056	chr7:64862999~64864370:+
BRCA	trans	rs11098499	0.863	rs1010739	ENSG00000120555.12	SEPT7P9	6.49	1.35e-10	0.00011	0.25	0.2	Corneal astigmatism;	chr4:119542316	chr10:38383069~38402916:-
BRCA	trans	rs1707322	0.963	rs12145287	ENSG00000255397.1	AC022182.2	-6.49	1.36e-10	0.000111	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45859330	chr8:60937705~60939871:-
BRCA	trans	rs875971	0.545	rs3936065	ENSG00000234585.5	CCT6P3	6.49	1.36e-10	0.000111	0.22	0.2	Aortic root size;	chr7:66325577	chr7:65038354~65074713:+
BRCA	trans	rs875971	0.545	rs4718335	ENSG00000234585.5	CCT6P3	6.49	1.36e-10	0.000111	0.22	0.2	Aortic root size;	chr7:66339619	chr7:65038354~65074713:+
BRCA	trans	rs34421088	0.585	rs1390950	ENSG00000253893.2	FAM85B	6.48	1.38e-10	0.000113	0.26	0.2	Neuroticism;	chr8:11738320	chr8:8167819~8226614:-
BRCA	trans	rs7617773	0.817	rs4131361	ENSG00000235912.1	RP1-159A19.3	-6.48	1.38e-10	0.000113	-0.25	-0.2	Coronary artery disease;	chr3:48287322	chr1:27649419~27649610:+
BRCA	trans	rs538867	1	rs1708044	ENSG00000214263.2	RPSAP53	6.48	1.38e-10	0.000113	0.47	0.2	Alzheimer's disease (cognitive decline);	chr3:39545261	chr13:67266845~67267706:-
BRCA	trans	rs4929949	0.724	rs7129357	ENSG00000266891.1	RP11-692N5.2	6.48	1.39e-10	0.000113	0.23	0.2	Body mass index;	chr11:8449835	chr18:9734882~9735602:-
BRCA	trans	rs2243480	0.901	rs3813708	ENSG00000232546.1	RP11-458F8.1	-6.48	1.39e-10	0.000113	-0.26	-0.2	Diabetic kidney disease;	chr7:65840645	chr7:66848496~66858136:+
BRCA	trans	rs34421088	0.532	rs1545073	ENSG00000253893.2	FAM85B	-6.48	1.39e-10	0.000114	-0.26	-0.2	Neuroticism;	chr8:11310191	chr8:8167819~8226614:-
BRCA	trans	rs7617773	0.817	rs6791930	ENSG00000235912.1	RP1-159A19.3	-6.48	1.4e-10	0.000114	-0.25	-0.2	Coronary artery disease;	chr3:48288410	chr1:27649419~27649610:+
BRCA	trans	rs7617773	0.817	rs6794644	ENSG00000235912.1	RP1-159A19.3	-6.48	1.4e-10	0.000114	-0.25	-0.2	Coronary artery disease;	chr3:48288547	chr1:27649419~27649610:+
BRCA	trans	rs875971	0.545	rs73146609	ENSG00000213640.3	EEF1DP4	-6.48	1.42e-10	0.000116	-0.28	-0.2	Aortic root size;	chr7:66302477	chr7:64862999~64864370:+
BRCA	trans	rs875971	0.545	rs2173571	ENSG00000213640.3	EEF1DP4	-6.48	1.42e-10	0.000116	-0.28	-0.2	Aortic root size;	chr7:66305392	chr7:64862999~64864370:+
BRCA	trans	rs1707322	1	rs785469	ENSG00000255397.1	AC022182.2	6.48	1.43e-10	0.000116	0.25	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46055419	chr8:60937705~60939871:-
BRCA	trans	rs1707322	1	rs785468	ENSG00000255397.1	AC022182.2	6.48	1.43e-10	0.000116	0.25	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46055845	chr8:60937705~60939871:-
BRCA	trans	rs2288327	0.818	rs16866397	ENSG00000269800.1	PLEKHA3P1	-6.48	1.43e-10	0.000117	-0.29	-0.2	Atrial fibrillation;	chr2:178556743	chr19:41521043~41521989:-
BRCA	trans	rs902774	0.818	rs4919740	ENSG00000220378.3	KRT8P42	-6.48	1.43e-10	0.000117	-0.37	-0.2	Prostate cancer;	chr12:52877187	chr6:134296997~134298695:-
BRCA	trans	rs2899832	0.568	rs10467708	ENSG00000215414.4	PSMA6P1	6.48	1.43e-10	0.000117	0.35	0.2	Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:35317808	chrY:13286638~13287378:+
BRCA	trans	rs12439619	0.846	rs62011975	ENSG00000259295.5	CSPG4P12	-6.48	1.44e-10	0.000117	-0.31	-0.2	Intelligence (multi-trait analysis);	chr15:82159213	chr15:85191438~85213905:+
BRCA	trans	rs1864585	0.806	rs17778223	ENSG00000253981.4	ALG1L13P	6.48	1.44e-10	0.000117	0.25	0.2	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr8:10872182	chr8:8236003~8244667:-
BRCA	trans	rs7617773	0.78	rs13090538	ENSG00000235912.1	RP1-159A19.3	-6.48	1.45e-10	0.000118	-0.26	-0.2	Coronary artery disease;	chr3:48329279	chr1:27649419~27649610:+
BRCA	trans	rs853679	0.546	rs200990	ENSG00000253570.1	RNF5P1	6.47	1.46e-10	0.000119	0.43	0.2	Depression;	chr6:27848045	chr8:38600661~38601200:-
BRCA	trans	rs7617773	0.746	rs6796343	ENSG00000235912.1	RP1-159A19.3	-6.47	1.47e-10	0.00012	-0.26	-0.2	Coronary artery disease;	chr3:48240531	chr1:27649419~27649610:+
BRCA	trans	rs2963482	0.507	rs4704942	ENSG00000187952.9	HS6ST1P1	-6.47	1.47e-10	0.00012	-0.21	-0.2	Nonsyndromic cleft lip with or without cleft palate;	chr5:158466352	chr1:21428303~21429536:+
BRCA	trans	rs673253	0.556	rs35290231	ENSG00000231007.5	CDC20P1	6.47	1.47e-10	0.00012	0.26	0.2	Intelligence (multi-trait analysis);	chr1:43637362	chr9:87011652~87013151:+
BRCA	trans	rs2243480	1	rs73142122	ENSG00000232546.1	RP11-458F8.1	-6.47	1.47e-10	0.00012	-0.26	-0.2	Diabetic kidney disease;	chr7:65846311	chr7:66848496~66858136:+
BRCA	trans	rs7617773	0.817	rs11130162	ENSG00000235912.1	RP1-159A19.3	-6.47	1.48e-10	0.00012	-0.23	-0.2	Coronary artery disease;	chr3:48256121	chr1:27649419~27649610:+
BRCA	trans	rs3812762	0.833	rs10500705	ENSG00000266891.1	RP11-692N5.2	6.47	1.48e-10	0.00012	0.25	0.2	Hypospadias;	chr11:8783714	chr18:9734882~9735602:-
BRCA	trans	rs34421088	0.506	rs4841519	ENSG00000253893.2	FAM85B	-6.47	1.49e-10	0.000121	-0.25	-0.2	Neuroticism;	chr8:11288719	chr8:8167819~8226614:-
BRCA	trans	rs2060793	0.519	rs10832285	ENSG00000236360.2	RP11-334A14.2	6.47	1.5e-10	0.000122	0.24	0.2	Vitamin D levels;	chr11:14628031	chr1:52993201~52993702:-
BRCA	trans	rs11098499	0.874	rs13139045	ENSG00000120555.12	SEPT7P9	6.47	1.51e-10	0.000123	0.24	0.2	Corneal astigmatism;	chr4:119247433	chr10:38383069~38402916:-
BRCA	trans	rs2965280	0.793	rs7251027	ENSG00000270983.1	RP11-137J7.3	-6.47	1.52e-10	0.000124	-0.44	-0.2	Colorectal cancer;	chr19:34309693	chr6:142062717~142063053:+
BRCA	trans	rs2965280	0.793	rs8106201	ENSG00000270983.1	RP11-137J7.3	-6.47	1.52e-10	0.000124	-0.44	-0.2	Colorectal cancer;	chr19:34345984	chr6:142062717~142063053:+
BRCA	trans	rs17767294	0.708	rs9380018	ENSG00000242375.1	RP11-498P14.3	-6.47	1.53e-10	0.000124	-0.5	-0.2	Parkinson's disease;	chr6:27772867	chr9:97195351~97197687:-
BRCA	trans	rs1707322	1	rs785465	ENSG00000255397.1	AC022182.2	-6.47	1.53e-10	0.000124	-0.25	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46056905	chr8:60937705~60939871:-
BRCA	trans	rs714543	1	rs8840	ENSG00000214975.4	PPIAP29	6.47	1.53e-10	0.000124	0.23	0.2	Plateletcrit;	chr7:44877441	chr6:24976419~24976982:+
BRCA	trans	rs12439619	0.846	rs28697264	ENSG00000235370.6	DNM1P51	-6.47	1.53e-10	0.000125	-0.27	-0.2	Intelligence (multi-trait analysis);	chr15:82265559	chr15:84398316~84411701:-
BRCA	trans	rs9393777	0.778	rs35608615	ENSG00000253570.1	RNF5P1	6.47	1.53e-10	0.000125	0.45	0.2	Intelligence (multi-trait analysis);	chr6:27072623	chr8:38600661~38601200:-
BRCA	trans	rs9468199	0.505	rs72847381	ENSG00000242375.1	RP11-498P14.3	-6.47	1.54e-10	0.000125	-0.52	-0.2	Parkinson's disease;	chr6:27906153	chr9:97195351~97197687:-
BRCA	trans	rs9834975	0.527	rs7631799	ENSG00000267076.1	CCDC58P3	-6.47	1.54e-10	0.000125	-0.22	-0.2	Diastolic blood pressure;	chr3:122492875	chr18:12211378~12211807:+
BRCA	trans	rs9425766	0.64	rs3791020	ENSG00000213331.4	RP11-713C19.2	-6.47	1.54e-10	0.000125	-0.26	-0.2	Life satisfaction;	chr1:173844059	chr4:187970273~187971284:+
BRCA	trans	rs2055729	0.557	rs7000542	ENSG00000253893.2	FAM85B	-6.47	1.54e-10	0.000125	-0.27	-0.2	Multiple myeloma (hyperdiploidy);	chr8:10023625	chr8:8167819~8226614:-
BRCA	trans	rs9834975	0.565	rs10934601	ENSG00000267076.1	CCDC58P3	-6.47	1.55e-10	0.000126	-0.22	-0.2	Diastolic blood pressure;	chr3:122489446	chr18:12211378~12211807:+
BRCA	trans	rs9834975	0.565	rs3749209	ENSG00000267076.1	CCDC58P3	-6.46	1.55e-10	0.000126	-0.22	-0.2	Diastolic blood pressure;	chr3:122449494	chr18:12211378~12211807:+
BRCA	trans	rs6984305	0.541	rs17716118	ENSG00000223508.5	RPL23AP53	6.46	1.55e-10	0.000126	0.4	0.2	Liver enzyme levels (alkaline phosphatase);	chr8:9322624	chr8:213186~232231:-
BRCA	trans	rs875971	0.545	rs73142265	ENSG00000213640.3	EEF1DP4	-6.46	1.56e-10	0.000127	-0.28	-0.2	Aortic root size;	chr7:66234510	chr7:64862999~64864370:+
BRCA	trans	rs7617773	0.851	rs7647817	ENSG00000235912.1	RP1-159A19.3	-6.46	1.56e-10	0.000127	-0.26	-0.2	Coronary artery disease;	chr3:48195017	chr1:27649419~27649610:+
BRCA	trans	rs9834975	0.565	rs10934599	ENSG00000267076.1	CCDC58P3	-6.46	1.56e-10	0.000127	-0.22	-0.2	Diastolic blood pressure;	chr3:122477075	chr18:12211378~12211807:+
BRCA	trans	rs10838687	0.673	rs59567949	ENSG00000134612.10	FOLH1B	6.46	1.57e-10	0.000127	0.29	0.2	Proinsulin levels;	chr11:47278604	chr11:89639227~89698718:+
BRCA	trans	rs7662987	0.517	rs2602876	ENSG00000233859.2	ADH5P4	-6.46	1.57e-10	0.000128	-0.28	-0.2	Smoking initiation;	chr4:99118384	chr6:65836930~65838039:-
BRCA	trans	rs17507216	0.628	rs28737193	ENSG00000259295.5	CSPG4P12	-6.46	1.58e-10	0.000128	-0.32	-0.2	Excessive daytime sleepiness;	chr15:82701318	chr15:85191438~85213905:+
BRCA	trans	rs9834975	0.565	rs4677957	ENSG00000267076.1	CCDC58P3	-6.46	1.58e-10	0.000128	-0.22	-0.2	Diastolic blood pressure;	chr3:122538920	chr18:12211378~12211807:+
BRCA	trans	rs17301013	0.861	rs332770	ENSG00000213331.4	RP11-713C19.2	6.46	1.58e-10	0.000129	0.22	0.2	Systemic lupus erythematosus;	chr1:174681511	chr4:187970273~187971284:+
BRCA	trans	rs941207	0.756	rs2926743	ENSG00000257210.1	NACAP3	6.46	1.59e-10	0.000129	0.26	0.2	Platelet count;	chr12:56720316	chr12:93124063~93124543:-
BRCA	trans	rs7647973	1	rs62259933	ENSG00000197582.5	GPX1P1	-6.46	1.59e-10	0.000129	-0.22	-0.2	Menarche (age at onset);	chr3:49432270	chrX:13378735~13379340:-
BRCA	trans	rs7617773	0.78	rs3731489	ENSG00000235912.1	RP1-159A19.3	-6.46	1.59e-10	0.000129	-0.26	-0.2	Coronary artery disease;	chr3:48187416	chr1:27649419~27649610:+
BRCA	trans	rs6984305	0.541	rs17716118	ENSG00000272240.1	RP5-855D21.1	6.46	1.59e-10	0.000129	0.32	0.2	Liver enzyme levels (alkaline phosphatase);	chr8:9322624	chr8:234347~234887:-
BRCA	trans	rs2220004	1	rs10897517	ENSG00000134612.10	FOLH1B	-6.46	1.59e-10	0.000129	-0.26	-0.2	Odorant perception (&beta-damascenone);	chr11:56012258	chr11:89639227~89698718:+
BRCA	trans	rs714543	1	rs13245012	ENSG00000214975.4	PPIAP29	-6.46	1.59e-10	0.000129	-0.23	-0.2	Plateletcrit;	chr7:44826120	chr6:24976419~24976982:+
BRCA	trans	rs9834975	0.565	rs6793824	ENSG00000267076.1	CCDC58P3	-6.46	1.6e-10	0.00013	-0.22	-0.2	Diastolic blood pressure;	chr3:122482102	chr18:12211378~12211807:+
BRCA	trans	rs9834975	0.586	rs6769593	ENSG00000267076.1	CCDC58P3	-6.46	1.6e-10	0.00013	-0.22	-0.2	Diastolic blood pressure;	chr3:122482332	chr18:12211378~12211807:+
BRCA	trans	rs9834975	0.565	rs10049133	ENSG00000267076.1	CCDC58P3	-6.46	1.6e-10	0.00013	-0.22	-0.2	Diastolic blood pressure;	chr3:122483334	chr18:12211378~12211807:+
BRCA	trans	rs9834975	0.565	rs4470444	ENSG00000267076.1	CCDC58P3	-6.46	1.6e-10	0.00013	-0.22	-0.2	Diastolic blood pressure;	chr3:122509405	chr18:12211378~12211807:+
BRCA	trans	rs2243480	1	rs3885839	ENSG00000232546.1	RP11-458F8.1	-6.46	1.62e-10	0.000132	-0.26	-0.2	Diabetic kidney disease;	chr7:65825416	chr7:66848496~66858136:+
BRCA	trans	rs380904	0.519	rs1377663	ENSG00000213130.3	EEF1DP5	-6.46	1.65e-10	0.000134	-0.25	-0.2	Venous thromboembolism (SNP x SNP interaction);	chr8:143562617	chr6:128580113~128580884:-
BRCA	trans	rs1707322	0.896	rs785512	ENSG00000255397.1	AC022182.2	6.46	1.65e-10	0.000134	0.26	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46068871	chr8:60937705~60939871:-
BRCA	trans	rs9393777	0.622	rs13191326	ENSG00000253570.1	RNF5P1	6.45	1.66e-10	0.000134	0.45	0.2	Intelligence (multi-trait analysis);	chr6:27063250	chr8:38600661~38601200:-
BRCA	trans	rs864643	0.947	rs1417147	ENSG00000188856.6	RPSAP47	6.45	1.66e-10	0.000135	0.28	0.2	Attention deficit hyperactivity disorder;	chr3:39499236	chr8:80558870~80559757:+
BRCA	trans	rs1707322	0.721	rs6665808	ENSG00000255397.1	AC022182.2	-6.45	1.67e-10	0.000135	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45696611	chr8:60937705~60939871:-
BRCA	trans	rs875971	0.545	rs2279757	ENSG00000234585.5	CCT6P3	6.45	1.67e-10	0.000135	0.22	0.2	Aortic root size;	chr7:66363676	chr7:65038354~65074713:+
BRCA	trans	rs875971	0.545	rs11766183	ENSG00000234585.5	CCT6P3	6.45	1.67e-10	0.000135	0.22	0.2	Aortic root size;	chr7:66374173	chr7:65038354~65074713:+
BRCA	trans	rs875971	0.545	rs1065265	ENSG00000234585.5	CCT6P3	6.45	1.67e-10	0.000135	0.22	0.2	Aortic root size;	chr7:66376216	chr7:65038354~65074713:+
BRCA	trans	rs7617773	0.817	rs11707606	ENSG00000235912.1	RP1-159A19.3	-6.45	1.67e-10	0.000136	-0.26	-0.2	Coronary artery disease;	chr3:48195597	chr1:27649419~27649610:+
BRCA	trans	rs864643	0.891	rs55780606	ENSG00000188856.6	RPSAP47	6.45	1.68e-10	0.000136	0.28	0.2	Attention deficit hyperactivity disorder;	chr3:39496599	chr8:80558870~80559757:+
BRCA	trans	rs12439619	0.846	rs62012003	ENSG00000235370.6	DNM1P51	-6.45	1.68e-10	0.000136	-0.27	-0.2	Intelligence (multi-trait analysis);	chr15:82183236	chr15:84398316~84411701:-
BRCA	trans	rs875971	0.545	rs7811204	ENSG00000234585.5	CCT6P3	6.45	1.68e-10	0.000136	0.22	0.2	Aortic root size;	chr7:66387213	chr7:65038354~65074713:+
BRCA	trans	rs12439619	0.846	rs62012059	ENSG00000235370.6	DNM1P51	-6.45	1.68e-10	0.000136	-0.28	-0.2	Intelligence (multi-trait analysis);	chr15:82251669	chr15:84398316~84411701:-
BRCA	trans	rs11098499	0.754	rs10212714	ENSG00000120555.12	SEPT7P9	6.45	1.68e-10	0.000136	0.24	0.2	Corneal astigmatism;	chr4:119333147	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.954	rs2389803	ENSG00000120555.12	SEPT7P9	-6.45	1.71e-10	0.000139	-0.24	-0.2	Corneal astigmatism;	chr4:119472356	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.789	rs10212719	ENSG00000120555.12	SEPT7P9	6.45	1.71e-10	0.000139	0.23	0.2	Corneal astigmatism;	chr4:119333282	chr10:38383069~38402916:-
BRCA	trans	rs17711722	0.523	rs365896	ENSG00000213640.3	EEF1DP4	6.45	1.72e-10	0.000139	0.25	0.2	Calcium levels;	chr7:66045710	chr7:64862999~64864370:+
BRCA	trans	rs17767294	0.708	rs72848752	ENSG00000242375.1	RP11-498P14.3	-6.45	1.72e-10	0.000139	-0.51	-0.2	Parkinson's disease;	chr6:27910490	chr9:97195351~97197687:-
BRCA	trans	rs10838687	0.8	rs4752983	ENSG00000134612.10	FOLH1B	6.45	1.72e-10	0.000139	0.29	0.2	Proinsulin levels;	chr11:47330587	chr11:89639227~89698718:+
BRCA	trans	rs10838687	0.8	rs3729805	ENSG00000134612.10	FOLH1B	6.45	1.72e-10	0.000139	0.29	0.2	Proinsulin levels;	chr11:47331206	chr11:89639227~89698718:+
BRCA	trans	rs2220004	1	rs12289998	ENSG00000134612.10	FOLH1B	-6.45	1.73e-10	0.00014	-0.26	-0.2	Odorant perception (&beta-damascenone);	chr11:56080422	chr11:89639227~89698718:+
BRCA	trans	rs1580019	0.587	rs7804457	ENSG00000213492.2	NT5C3AP1	-6.45	1.73e-10	0.00014	-0.26	-0.2	Cognitive ability;	chr7:32518369	chr4:117574512~117576174:-
BRCA	trans	rs1707322	0.964	rs796773	ENSG00000255397.1	AC022182.2	6.45	1.75e-10	0.000142	0.26	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46098803	chr8:60937705~60939871:-
BRCA	trans	rs1707322	0.896	rs785518	ENSG00000255397.1	AC022182.2	6.45	1.75e-10	0.000142	0.26	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46102750	chr8:60937705~60939871:-
BRCA	trans	rs1707322	1	rs785519	ENSG00000255397.1	AC022182.2	6.45	1.75e-10	0.000142	0.26	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46102890	chr8:60937705~60939871:-
BRCA	trans	rs902774	0.818	rs55914512	ENSG00000248568.1	KRT8P48	-6.45	1.75e-10	0.000142	-0.42	-0.2	Prostate cancer;	chr12:52888490	chr5:146706381~146707600:-
BRCA	trans	rs902774	0.818	rs73108466	ENSG00000248568.1	KRT8P48	-6.45	1.75e-10	0.000142	-0.42	-0.2	Prostate cancer;	chr12:52889857	chr5:146706381~146707600:-
BRCA	trans	rs17301013	0.932	rs11804941	ENSG00000213331.4	RP11-713C19.2	-6.45	1.76e-10	0.000142	-0.22	-0.2	Systemic lupus erythematosus;	chr1:174624074	chr4:187970273~187971284:+
BRCA	trans	rs902774	0.818	rs73108429	ENSG00000248568.1	KRT8P48	-6.45	1.76e-10	0.000142	-0.42	-0.2	Prostate cancer;	chr12:52877887	chr5:146706381~146707600:-
BRCA	trans	rs6601327	0.573	rs13278824	ENSG00000253893.2	FAM85B	-6.44	1.76e-10	0.000143	-0.24	-0.2	Multiple myeloma (hyperdiploidy);	chr8:9788609	chr8:8167819~8226614:-
BRCA	trans	rs902774	0.818	rs55999178	ENSG00000248568.1	KRT8P48	-6.44	1.77e-10	0.000143	-0.42	-0.2	Prostate cancer;	chr12:52890576	chr5:146706381~146707600:-
BRCA	trans	rs7824557	0.628	rs11250129	ENSG00000253893.2	FAM85B	-6.44	1.77e-10	0.000143	-0.25	-0.2	Retinal vascular caliber;	chr8:11344645	chr8:8167819~8226614:-
BRCA	trans	rs7617773	0.817	rs3729577	ENSG00000235912.1	RP1-159A19.3	-6.44	1.78e-10	0.000144	-0.26	-0.2	Coronary artery disease;	chr3:48187504	chr1:27649419~27649610:+
BRCA	trans	rs875971	0.628	rs6974355	ENSG00000164669.11	INTS4P1	-6.44	1.78e-10	0.000144	-0.24	-0.2	Aortic root size;	chr7:66376994	chr7:65141225~65234216:+
BRCA	trans	rs641862	1	rs641862	ENSG00000225083.1	GRTP1-AS1	6.44	1.78e-10	0.000144	0.36	0.2	Obesity-related traits;	chr13:110137885	chr13:113351673~113361868:+
BRCA	trans	rs1707322	0.963	rs12022335	ENSG00000255397.1	AC022182.2	-6.44	1.78e-10	0.000144	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45937060	chr8:60937705~60939871:-
BRCA	trans	rs714543	0.934	rs10275962	ENSG00000214975.4	PPIAP29	-6.44	1.79e-10	0.000144	-0.23	-0.2	Plateletcrit;	chr7:44809141	chr6:24976419~24976982:+
BRCA	trans	rs4883201	0.611	rs4639983	ENSG00000179899.8	PHC1P1	6.44	1.79e-10	0.000145	0.26	0.2	Total cholesterol levels;Cholesterol, total;	chr12:8951611	chr12:55411727~55414787:-
BRCA	trans	rs1707322	0.721	rs56255771	ENSG00000255397.1	AC022182.2	-6.44	1.8e-10	0.000145	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45758647	chr8:60937705~60939871:-
BRCA	trans	rs17301013	0.932	rs1653627	ENSG00000213331.4	RP11-713C19.2	-6.44	1.8e-10	0.000145	-0.22	-0.2	Systemic lupus erythematosus;	chr1:174771879	chr4:187970273~187971284:+
BRCA	trans	rs12439619	0.768	rs28694364	ENSG00000235370.6	DNM1P51	-6.44	1.8e-10	0.000145	-0.27	-0.2	Intelligence (multi-trait analysis);	chr15:82208119	chr15:84398316~84411701:-
BRCA	trans	rs902774	0.759	rs4919707	ENSG00000248568.1	KRT8P48	-6.44	1.8e-10	0.000146	-0.42	-0.2	Prostate cancer;	chr12:52895864	chr5:146706381~146707600:-
BRCA	trans	rs3942852	0.955	rs1532754	ENSG00000134612.10	FOLH1B	-6.44	1.81e-10	0.000146	-0.28	-0.2	Acute lymphoblastic leukemia (childhood);	chr11:48093727	chr11:89639227~89698718:+
BRCA	trans	rs17301013	0.896	rs3118980	ENSG00000213331.4	RP11-713C19.2	-6.44	1.81e-10	0.000146	-0.22	-0.2	Systemic lupus erythematosus;	chr1:174793701	chr4:187970273~187971284:+
BRCA	trans	rs2965280	1	rs2965280	ENSG00000270983.1	RP11-137J7.3	-6.44	1.81e-10	0.000146	-0.43	-0.2	Colorectal cancer;	chr19:34426795	chr6:142062717~142063053:+
BRCA	trans	rs864643	0.947	rs1708015	ENSG00000188856.6	RPSAP47	6.44	1.82e-10	0.000147	0.28	0.2	Attention deficit hyperactivity disorder;	chr3:39496891	chr8:80558870~80559757:+
BRCA	trans	rs864643	0.891	rs1708018	ENSG00000188856.6	RPSAP47	6.44	1.82e-10	0.000147	0.28	0.2	Attention deficit hyperactivity disorder;	chr3:39496978	chr8:80558870~80559757:+
BRCA	trans	rs864643	0.947	rs535220	ENSG00000188856.6	RPSAP47	6.44	1.82e-10	0.000147	0.28	0.2	Attention deficit hyperactivity disorder;	chr3:39497234	chr8:80558870~80559757:+
BRCA	trans	rs864643	0.947	rs538214	ENSG00000188856.6	RPSAP47	6.44	1.82e-10	0.000147	0.28	0.2	Attention deficit hyperactivity disorder;	chr3:39497603	chr8:80558870~80559757:+
BRCA	trans	rs864643	0.947	rs538972	ENSG00000188856.6	RPSAP47	6.44	1.82e-10	0.000147	0.28	0.2	Attention deficit hyperactivity disorder;	chr3:39497652	chr8:80558870~80559757:+
BRCA	trans	rs864643	0.947	rs614359	ENSG00000188856.6	RPSAP47	6.44	1.82e-10	0.000147	0.28	0.2	Attention deficit hyperactivity disorder;	chr3:39498035	chr8:80558870~80559757:+
BRCA	trans	rs714543	1	rs1990053	ENSG00000214975.4	PPIAP29	-6.44	1.84e-10	0.000149	-0.23	-0.2	Plateletcrit;	chr7:44886297	chr6:24976419~24976982:+
BRCA	trans	rs7647973	1	rs6805609	ENSG00000235912.1	RP1-159A19.3	6.44	1.84e-10	0.000149	0.26	0.2	Menarche (age at onset);	chr3:49434089	chr1:27649419~27649610:+
BRCA	trans	rs860295	0.812	rs3820594	ENSG00000241627.3	UBQLN4P1	-6.44	1.84e-10	0.000149	-0.21	-0.2	Body mass index;	chr1:155859720	chr3:148985868~148987668:-
BRCA	trans	rs2122469	0.655	rs17603934	ENSG00000259366.1	CTD-2647L4.4	6.44	1.86e-10	0.00015	0.21	0.2	Serum tamsulosin hydrochloride concentration;	chr8:20718833	chr8:29055935~29056685:+
BRCA	trans	rs11098499	0.566	rs7664440	ENSG00000276997.3	RP11-378J18.9	6.44	1.86e-10	0.00015	0.25	0.2	Corneal astigmatism;	chr4:119657385	chr1:222477252~222504622:-
BRCA	trans	rs4929949	0.78	rs10743079	ENSG00000266891.1	RP11-692N5.2	-6.44	1.87e-10	0.000151	-0.23	-0.2	Body mass index;	chr11:8581813	chr18:9734882~9735602:-
BRCA	trans	rs804280	0.525	rs1004712	ENSG00000253893.2	FAM85B	-6.44	1.87e-10	0.000151	-0.24	-0.2	Myopia (pathological);	chr8:11764784	chr8:8167819~8226614:-
BRCA	trans	rs7260598	0.792	rs73031013	ENSG00000261770.1	CTC-459F4.1	6.44	1.87e-10	0.000151	0.34	0.2	Response to taxane treatment (placlitaxel);	chr19:24182049	chr19:27757184~27760849:-
BRCA	trans	rs11098499	0.754	rs17049949	ENSG00000120555.12	SEPT7P9	6.44	1.88e-10	0.000151	0.23	0.2	Corneal astigmatism;	chr4:119334135	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.754	rs7689729	ENSG00000120555.12	SEPT7P9	6.44	1.88e-10	0.000151	0.23	0.2	Corneal astigmatism;	chr4:119335037	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.865	rs3956464	ENSG00000120555.12	SEPT7P9	6.44	1.88e-10	0.000151	0.23	0.2	Corneal astigmatism;	chr4:119335609	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.648	rs2002047	ENSG00000120555.12	SEPT7P9	6.44	1.88e-10	0.000151	0.23	0.2	Corneal astigmatism;	chr4:119336073	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.775	rs2002049	ENSG00000120555.12	SEPT7P9	6.44	1.88e-10	0.000151	0.23	0.2	Corneal astigmatism;	chr4:119336262	chr10:38383069~38402916:-
BRCA	trans	rs9467711	0.591	rs13207673	ENSG00000253570.1	RNF5P1	6.43	1.88e-10	0.000152	0.49	0.2	Autism spectrum disorder or schizophrenia;	chr6:25900905	chr8:38600661~38601200:-
BRCA	trans	rs12210905	0.925	rs858986	ENSG00000242375.1	RP11-498P14.3	6.43	1.89e-10	0.000152	0.37	0.2	Hip circumference adjusted for BMI;	chr6:27210744	chr9:97195351~97197687:-
BRCA	trans	rs875971	0.502	rs2465121	ENSG00000213640.3	EEF1DP4	6.43	1.89e-10	0.000153	0.28	0.2	Aortic root size;	chr7:66156017	chr7:64862999~64864370:+
BRCA	trans	rs853679	0.599	rs149990	ENSG00000253570.1	RNF5P1	6.43	1.9e-10	0.000153	0.44	0.2	Depression;	chr6:28030480	chr8:38600661~38601200:-
BRCA	trans	rs7617773	0.817	rs6801801	ENSG00000235912.1	RP1-159A19.3	-6.43	1.91e-10	0.000154	-0.25	-0.2	Coronary artery disease;	chr3:48284943	chr1:27649419~27649610:+
BRCA	trans	rs875971	1	rs1544549	ENSG00000164669.11	INTS4P1	6.43	1.92e-10	0.000155	0.24	0.2	Aortic root size;	chr7:66625676	chr7:65141225~65234216:+
BRCA	trans	rs2220004	0.963	rs7120128	ENSG00000134612.10	FOLH1B	-6.43	1.93e-10	0.000155	-0.26	-0.2	Odorant perception (&beta-damascenone);	chr11:56095502	chr11:89639227~89698718:+
BRCA	trans	rs17767294	0.708	rs72848773	ENSG00000242375.1	RP11-498P14.3	-6.43	1.95e-10	0.000157	-0.58	-0.2	Parkinson's disease;	chr6:27958742	chr9:97195351~97197687:-
BRCA	trans	rs17767294	0.708	rs76223516	ENSG00000242375.1	RP11-498P14.3	-6.43	1.95e-10	0.000157	-0.58	-0.2	Parkinson's disease;	chr6:27971697	chr9:97195351~97197687:-
BRCA	trans	rs17767294	0.708	rs72848776	ENSG00000242375.1	RP11-498P14.3	-6.43	1.95e-10	0.000157	-0.58	-0.2	Parkinson's disease;	chr6:27987048	chr9:97195351~97197687:-
BRCA	trans	rs7617773	0.779	rs3731487	ENSG00000235912.1	RP1-159A19.3	-6.43	1.98e-10	0.000159	-0.26	-0.2	Coronary artery disease;	chr3:48188134	chr1:27649419~27649610:+
BRCA	trans	rs1707322	1	rs7538978	ENSG00000255397.1	AC022182.2	6.43	1.99e-10	0.00016	0.26	0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46039382	chr8:60937705~60939871:-
BRCA	trans	rs2048656	0.523	rs1976673	ENSG00000253893.2	FAM85B	-6.43	2e-10	0.000161	-0.25	-0.2	Schizophrenia;	chr8:9822270	chr8:8167819~8226614:-
BRCA	trans	rs2220004	0.964	rs10896083	ENSG00000134612.10	FOLH1B	6.43	2e-10	0.000161	0.26	0.2	Odorant perception (&beta-damascenone);	chr11:56166024	chr11:89639227~89698718:+
BRCA	trans	rs2220004	0.964	rs10896084	ENSG00000134612.10	FOLH1B	6.43	2e-10	0.000161	0.26	0.2	Odorant perception (&beta-damascenone);	chr11:56166137	chr11:89639227~89698718:+
BRCA	trans	rs804280	0.662	rs11784693	ENSG00000253893.2	FAM85B	6.42	2.01e-10	0.000162	0.27	0.2	Myopia (pathological);	chr8:11753165	chr8:8167819~8226614:-
BRCA	trans	rs875971	0.545	rs7783889	ENSG00000234585.5	CCT6P3	6.42	2.02e-10	0.000162	0.21	0.2	Aortic root size;	chr7:66283366	chr7:65038354~65074713:+
BRCA	trans	rs7647973	1	rs6783003	ENSG00000235912.1	RP1-159A19.3	6.42	2.02e-10	0.000163	0.26	0.2	Menarche (age at onset);	chr3:49487345	chr1:27649419~27649610:+
BRCA	trans	rs902774	0.818	rs73110471	ENSG00000230716.3	KRT8P7	-6.42	2.02e-10	0.000163	-0.38	-0.2	Prostate cancer;	chr12:52923037	chr11:119602875~119604306:-
BRCA	trans	rs902774	0.818	rs4919737	ENSG00000248568.1	KRT8P48	-6.42	2.03e-10	0.000163	-0.42	-0.2	Prostate cancer;	chr12:52877011	chr5:146706381~146707600:-
BRCA	trans	rs11098499	0.691	rs9996644	ENSG00000120555.12	SEPT7P9	6.42	2.03e-10	0.000164	0.23	0.2	Corneal astigmatism;	chr4:119317722	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.691	rs9996494	ENSG00000120555.12	SEPT7P9	6.42	2.03e-10	0.000164	0.23	0.2	Corneal astigmatism;	chr4:119317725	chr10:38383069~38402916:-
BRCA	trans	rs7617773	0.743	rs11715876	ENSG00000235912.1	RP1-159A19.3	-6.42	2.03e-10	0.000164	-0.27	-0.2	Coronary artery disease;	chr3:48336432	chr1:27649419~27649610:+
BRCA	trans	rs9467711	0.591	rs13208859	ENSG00000253570.1	RNF5P1	6.42	2.04e-10	0.000164	0.49	0.2	Autism spectrum disorder or schizophrenia;	chr6:25894381	chr8:38600661~38601200:-
BRCA	trans	rs7927771	0.757	rs1057233	ENSG00000134612.10	FOLH1B	6.42	2.04e-10	0.000164	0.26	0.2	Subjective well-being;	chr11:47354897	chr11:89639227~89698718:+
BRCA	trans	rs875971	0.545	rs10950027	ENSG00000234585.5	CCT6P3	6.42	2.06e-10	0.000165	0.21	0.2	Aortic root size;	chr7:66169164	chr7:65038354~65074713:+
BRCA	trans	rs1707322	0.963	rs10890373	ENSG00000255397.1	AC022182.2	-6.42	2.08e-10	0.000167	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45928083	chr8:60937705~60939871:-
BRCA	trans	rs864643	0.947	rs1708073	ENSG00000188856.6	RPSAP47	6.42	2.08e-10	0.000168	0.28	0.2	Attention deficit hyperactivity disorder;	chr3:39501530	chr8:80558870~80559757:+
BRCA	trans	rs66887589	0.592	rs28580295	ENSG00000276997.3	RP11-378J18.9	6.42	2.1e-10	0.000168	0.22	0.19	Diastolic blood pressure;	chr4:119357718	chr1:222477252~222504622:-
BRCA	trans	rs9834975	0.565	rs4413264	ENSG00000267076.1	CCDC58P3	-6.42	2.1e-10	0.000168	-0.22	-0.19	Diastolic blood pressure;	chr3:122445004	chr18:12211378~12211807:+
BRCA	trans	rs2002594	0.844	rs9846687	ENSG00000267076.1	CCDC58P3	-6.42	2.1e-10	0.000168	-0.22	-0.19	Risky sexual behaviors (alcohol dependence interaction);	chr3:122455617	chr18:12211378~12211807:+
BRCA	trans	rs1707322	0.827	rs10890347	ENSG00000255397.1	AC022182.2	6.42	2.1e-10	0.000168	0.26	0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45776660	chr8:60937705~60939871:-
BRCA	trans	rs6831352	0.918	rs13107558	ENSG00000233859.2	ADH5P4	6.42	2.1e-10	0.000169	0.27	0.19	Alcohol dependence;	chr4:99129049	chr6:65836930~65838039:-
BRCA	trans	rs7944735	0.564	rs58357937	ENSG00000134612.10	FOLH1B	6.42	2.11e-10	0.000169	0.36	0.19	Intraocular pressure;	chr11:47670608	chr11:89639227~89698718:+
BRCA	trans	rs3735478	0.611	rs2289379	ENSG00000226038.5	PPIAP21	6.42	2.13e-10	0.000171	0.24	0.19	Intelligence (multi-trait analysis);	chr7:44764626	chr20:43230760~43231260:+
BRCA	trans	rs3849046	0.967	rs2242599	ENSG00000226666.1	HSPA9P1	6.42	2.13e-10	0.000171	0.22	0.19	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138508585	chr2:221961737~221963765:+
BRCA	trans	rs7169223	0.653	rs8029039	ENSG00000274376.3	ADAMTS7P1	6.41	2.16e-10	0.000173	0.27	0.19	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78808529	chr15:82298553~82334609:+
BRCA	trans	rs875971	0.545	rs1796222	ENSG00000234585.5	CCT6P3	-6.41	2.16e-10	0.000174	-0.21	-0.19	Aortic root size;	chr7:66592167	chr7:65038354~65074713:+
BRCA	trans	rs12439619	0.846	rs62013464	ENSG00000235370.6	DNM1P51	-6.41	2.17e-10	0.000174	-0.27	-0.19	Intelligence (multi-trait analysis);	chr15:82288250	chr15:84398316~84411701:-
BRCA	trans	rs1707322	1	rs10789486	ENSG00000255397.1	AC022182.2	-6.41	2.17e-10	0.000174	-0.25	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45942995	chr8:60937705~60939871:-
BRCA	trans	rs17507216	0.718	rs7161977	ENSG00000235370.6	DNM1P51	-6.41	2.18e-10	0.000175	-0.29	-0.19	Excessive daytime sleepiness;	chr15:82646782	chr15:84398316~84411701:-
BRCA	trans	rs7617773	0.78	rs11720026	ENSG00000235912.1	RP1-159A19.3	-6.41	2.18e-10	0.000175	-0.27	-0.19	Coronary artery disease;	chr3:48336431	chr1:27649419~27649610:+
BRCA	trans	rs860295	0.812	rs2297775	ENSG00000241627.3	UBQLN4P1	6.41	2.19e-10	0.000175	0.2	0.19	Body mass index;	chr1:155765221	chr3:148985868~148987668:-
BRCA	trans	rs1707322	0.964	rs785483	ENSG00000255397.1	AC022182.2	6.41	2.2e-10	0.000176	0.25	0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46093499	chr8:60937705~60939871:-
BRCA	trans	rs1707322	0.682	rs28508523	ENSG00000255397.1	AC022182.2	-6.41	2.2e-10	0.000177	-0.26	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45723953	chr8:60937705~60939871:-
BRCA	trans	rs875971	0.545	rs4718325	ENSG00000213640.3	EEF1DP4	-6.41	2.2e-10	0.000177	-0.28	-0.19	Aortic root size;	chr7:66215323	chr7:64862999~64864370:+
BRCA	trans	rs11098499	0.866	rs7665125	ENSG00000276997.3	RP11-378J18.9	6.41	2.21e-10	0.000177	0.23	0.19	Corneal astigmatism;	chr4:119480924	chr1:222477252~222504622:-
BRCA	trans	rs864643	0.947	rs482495	ENSG00000188856.6	RPSAP47	6.41	2.21e-10	0.000177	0.28	0.19	Attention deficit hyperactivity disorder;	chr3:39498924	chr8:80558870~80559757:+
BRCA	trans	rs864643	0.947	rs645403	ENSG00000188856.6	RPSAP47	6.41	2.21e-10	0.000177	0.28	0.19	Attention deficit hyperactivity disorder;	chr3:39498968	chr8:80558870~80559757:+
BRCA	trans	rs7829975	0.623	rs10087493	ENSG00000270154.1	RP11-419I17.1	-6.41	2.21e-10	0.000177	-0.22	-0.19	Mood instability;	chr8:8516047	chr8:12476462~12477122:+
BRCA	trans	rs1476679	1	rs1476679	ENSG00000228546.2	CTA-313A17.3	6.41	2.22e-10	0.000178	0.28	0.19	Alzheimer's disease (late onset);	chr7:100406823	chr7:102337316~102339115:+
BRCA	trans	rs7824557	0.767	rs17797443	ENSG00000270154.1	RP11-419I17.1	6.41	2.22e-10	0.000178	0.25	0.19	Retinal vascular caliber;	chr8:11306503	chr8:12476462~12477122:+
BRCA	trans	rs9581094	0.591	rs73154323	ENSG00000237917.1	PARP4P1	-6.41	2.22e-10	0.000178	-0.42	-0.19	Sudden cardiac arrest;	chr13:24467019	chrY:26594851~26634652:-
BRCA	trans	rs12497850	0.864	rs12493001	ENSG00000197582.5	GPX1P1	6.41	2.22e-10	0.000178	0.21	0.19	Parkinson's disease;	chr3:49144452	chrX:13378735~13379340:-
BRCA	trans	rs12497850	0.829	rs12636030	ENSG00000197582.5	GPX1P1	6.41	2.22e-10	0.000178	0.21	0.19	Parkinson's disease;	chr3:49144804	chrX:13378735~13379340:-
BRCA	trans	rs11098499	0.754	rs4107728	ENSG00000120555.12	SEPT7P9	6.41	2.23e-10	0.000178	0.23	0.19	Corneal astigmatism;	chr4:119332755	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.754	rs2036857	ENSG00000120555.12	SEPT7P9	6.41	2.24e-10	0.000179	0.23	0.19	Corneal astigmatism;	chr4:119328085	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.754	rs2036856	ENSG00000120555.12	SEPT7P9	6.41	2.24e-10	0.000179	0.23	0.19	Corneal astigmatism;	chr4:119328133	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.754	rs4443261	ENSG00000120555.12	SEPT7P9	6.41	2.24e-10	0.000179	0.23	0.19	Corneal astigmatism;	chr4:119328146	chr10:38383069~38402916:-
BRCA	trans	rs1707322	0.721	rs61784800	ENSG00000255397.1	AC022182.2	6.41	2.24e-10	0.000179	0.26	0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45712440	chr8:60937705~60939871:-
BRCA	trans	rs2727020	0.675	rs7929401	ENSG00000134612.10	FOLH1B	-6.41	2.24e-10	0.000179	-0.28	-0.19	Coronary artery disease;	chr11:49329280	chr11:89639227~89698718:+
BRCA	trans	rs66887589	0.616	rs7659403	ENSG00000120555.12	SEPT7P9	6.41	2.25e-10	0.00018	0.22	0.19	Diastolic blood pressure;	chr4:119286099	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.866	rs7665125	ENSG00000120555.12	SEPT7P9	6.41	2.26e-10	0.000181	0.23	0.19	Corneal astigmatism;	chr4:119480924	chr10:38383069~38402916:-
BRCA	trans	rs4929949	0.767	rs4929950	ENSG00000266891.1	RP11-692N5.2	-6.41	2.26e-10	0.000181	-0.23	-0.19	Body mass index;	chr11:8583251	chr18:9734882~9735602:-
BRCA	trans	rs875971	0.545	rs6970498	ENSG00000213640.3	EEF1DP4	-6.41	2.26e-10	0.000181	-0.28	-0.19	Aortic root size;	chr7:66275908	chr7:64862999~64864370:+
BRCA	trans	rs12439619	0.705	rs17354185	ENSG00000259295.5	CSPG4P12	6.41	2.26e-10	0.000181	0.32	0.19	Intelligence (multi-trait analysis);	chr15:82133829	chr15:85191438~85213905:+
BRCA	trans	rs853679	0.567	rs1005126	ENSG00000228078.1	HLA-U	-6.41	2.27e-10	0.000181	-0.29	-0.19	Depression;	chr6:28399846	chr6:29934101~29934286:+
BRCA	trans	rs17301013	0.932	rs4233195	ENSG00000213331.4	RP11-713C19.2	-6.41	2.27e-10	0.000182	-0.22	-0.19	Systemic lupus erythematosus;	chr1:174806736	chr4:187970273~187971284:+
BRCA	trans	rs9834975	0.565	rs9851180	ENSG00000267076.1	CCDC58P3	6.4	2.27e-10	0.000182	0.22	0.19	Diastolic blood pressure;	chr3:122540759	chr18:12211378~12211807:+
BRCA	trans	rs2965280	0.546	rs8108038	ENSG00000270983.1	RP11-137J7.3	6.4	2.28e-10	0.000183	0.43	0.19	Colorectal cancer;	chr19:34394101	chr6:142062717~142063053:+
BRCA	trans	rs853679	0.607	rs67340775	ENSG00000281831.1	HCP5B	6.4	2.29e-10	0.000183	0.48	0.19	Depression;	chr6:28336607	chr6:29871895~29873783:-
BRCA	trans	rs4929949	0.78	rs10160318	ENSG00000266891.1	RP11-692N5.2	-6.4	2.29e-10	0.000183	-0.23	-0.19	Body mass index;	chr11:8578314	chr18:9734882~9735602:-
BRCA	trans	rs2055729	0.645	rs7828229	ENSG00000253893.2	FAM85B	6.4	2.29e-10	0.000183	0.27	0.19	Multiple myeloma (hyperdiploidy);	chr8:9885331	chr8:8167819~8226614:-
BRCA	trans	rs853679	1	rs1679709	ENSG00000253570.1	RNF5P1	-6.4	2.29e-10	0.000183	-0.38	-0.19	Depression;	chr6:28260564	chr8:38600661~38601200:-
BRCA	trans	rs10838687	0.736	rs1449626	ENSG00000134612.10	FOLH1B	6.4	2.29e-10	0.000183	0.29	0.19	Proinsulin levels;	chr11:47269208	chr11:89639227~89698718:+
BRCA	trans	rs9581094	0.591	rs1807111	ENSG00000237917.1	PARP4P1	-6.4	2.3e-10	0.000184	-0.42	-0.19	Sudden cardiac arrest;	chr13:24471020	chrY:26594851~26634652:-
BRCA	trans	rs902774	0.818	rs4919742	ENSG00000248568.1	KRT8P48	-6.4	2.3e-10	0.000184	-0.42	-0.19	Prostate cancer;	chr12:52879180	chr5:146706381~146707600:-
BRCA	trans	rs66887589	0.616	rs11098498	ENSG00000120555.12	SEPT7P9	6.4	2.3e-10	0.000184	0.22	0.19	Diastolic blood pressure;	chr4:119265964	chr10:38383069~38402916:-
BRCA	trans	rs7617773	0.817	rs9837228	ENSG00000235912.1	RP1-159A19.3	6.4	2.31e-10	0.000185	0.24	0.19	Coronary artery disease;	chr3:48282976	chr1:27649419~27649610:+
BRCA	trans	rs1347297	0.901	rs12473789	ENSG00000269800.1	PLEKHA3P1	6.4	2.32e-10	0.000186	0.25	0.19	Alzheimer disease and age of onset;	chr2:178386015	chr19:41521043~41521989:-
BRCA	trans	rs7647973	1	rs7613491	ENSG00000235912.1	RP1-159A19.3	6.4	2.32e-10	0.000186	0.26	0.19	Menarche (age at onset);	chr3:49471543	chr1:27649419~27649610:+
BRCA	trans	rs7647973	1	rs7647973	ENSG00000235912.1	RP1-159A19.3	6.4	2.32e-10	0.000186	0.26	0.19	Menarche (age at onset);	chr3:49473498	chr1:27649419~27649610:+
BRCA	trans	rs864643	1	rs1768252	ENSG00000188856.6	RPSAP47	6.4	2.32e-10	0.000186	0.29	0.19	Attention deficit hyperactivity disorder;	chr3:39506768	chr8:80558870~80559757:+
BRCA	trans	rs9467711	0.591	rs35169013	ENSG00000253570.1	RNF5P1	6.4	2.33e-10	0.000186	0.49	0.19	Autism spectrum disorder or schizophrenia;	chr6:25917799	chr8:38600661~38601200:-
BRCA	trans	rs875971	0.502	rs11769702	ENSG00000213640.3	EEF1DP4	-6.4	2.33e-10	0.000187	-0.28	-0.19	Aortic root size;	chr7:66255529	chr7:64862999~64864370:+
BRCA	trans	rs11098499	0.619	rs28502463	ENSG00000120555.12	SEPT7P9	6.4	2.34e-10	0.000187	0.23	0.19	Corneal astigmatism;	chr4:119335868	chr10:38383069~38402916:-
BRCA	trans	rs2220004	1	rs1842701	ENSG00000134612.10	FOLH1B	-6.4	2.35e-10	0.000188	-0.26	-0.19	Odorant perception (&beta-damascenone);	chr11:56100666	chr11:89639227~89698718:+
BRCA	trans	rs2220004	0.964	rs2449157	ENSG00000134612.10	FOLH1B	-6.4	2.35e-10	0.000188	-0.26	-0.19	Odorant perception (&beta-damascenone);	chr11:56103402	chr11:89639227~89698718:+
BRCA	trans	rs10028773	0.7	rs7690338	ENSG00000120555.12	SEPT7P9	6.4	2.35e-10	0.000188	0.23	0.19	Educational attainment;	chr4:119335313	chr10:38383069~38402916:-
BRCA	trans	rs4883201	0.536	rs7961355	ENSG00000179899.8	PHC1P1	6.4	2.35e-10	0.000188	0.26	0.19	Total cholesterol levels;Cholesterol, total;	chr12:8962035	chr12:55411727~55414787:-
BRCA	trans	rs7032940	0.954	rs9722603	ENSG00000228236.2	TXNP5	6.4	2.36e-10	0.000189	0.27	0.19	Height;	chr9:110191400	chr2:149068596~149068910:-
BRCA	trans	rs2840044	1	rs9913003	ENSG00000234130.2	RP13-88F20.1	6.4	2.36e-10	0.000189	0.22	0.19	Response to radiotherapy in cancer (late toxicity);	chr17:35566885	chrX:93222220~93225015:-
BRCA	trans	rs2899832	0.568	rs2277460	ENSG00000215414.4	PSMA6P1	6.4	2.36e-10	0.000189	0.34	0.19	Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:35292367	chrY:13286638~13287378:+
BRCA	trans	rs2899832	0.568	rs17458583	ENSG00000215414.4	PSMA6P1	6.4	2.36e-10	0.000189	0.34	0.19	Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:35293295	chrY:13286638~13287378:+
BRCA	trans	rs4713118	0.588	rs200994	ENSG00000204709.4	LINC01556	-6.4	2.37e-10	0.000189	-0.28	-0.19	Parkinson's disease;	chr6:27846035	chr6:28943877~28944537:+
BRCA	trans	rs12155039	1	rs12155039	ENSG00000214975.4	PPIAP29	-6.4	2.37e-10	0.000189	-0.23	-0.19	Mean platelet volume;	chr7:44833526	chr6:24976419~24976982:+
BRCA	trans	rs1707322	1	rs12097761	ENSG00000255397.1	AC022182.2	-6.4	2.38e-10	0.00019	-0.26	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45825490	chr8:60937705~60939871:-
BRCA	trans	rs11098499	0.789	rs1980024	ENSG00000120555.12	SEPT7P9	6.4	2.39e-10	0.000191	0.23	0.19	Corneal astigmatism;	chr4:119331892	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.754	rs34425882	ENSG00000120555.12	SEPT7P9	6.4	2.39e-10	0.000191	0.23	0.19	Corneal astigmatism;	chr4:119332022	chr10:38383069~38402916:-
BRCA	trans	rs7617773	0.746	rs7619865	ENSG00000235912.1	RP1-159A19.3	-6.4	2.4e-10	0.000192	-0.23	-0.19	Coronary artery disease;	chr3:48329090	chr1:27649419~27649610:+
BRCA	trans	rs4929949	0.78	rs10840081	ENSG00000266891.1	RP11-692N5.2	-6.4	2.4e-10	0.000192	-0.23	-0.19	Body mass index;	chr11:8586277	chr18:9734882~9735602:-
BRCA	trans	rs875971	0.545	rs3936065	ENSG00000213640.3	EEF1DP4	-6.4	2.4e-10	0.000192	-0.28	-0.19	Aortic root size;	chr7:66325577	chr7:64862999~64864370:+
BRCA	trans	rs875971	0.545	rs4718335	ENSG00000213640.3	EEF1DP4	-6.4	2.4e-10	0.000192	-0.28	-0.19	Aortic root size;	chr7:66339619	chr7:64862999~64864370:+
BRCA	trans	rs7032940	0.953	rs7036157	ENSG00000228236.2	TXNP5	6.4	2.41e-10	0.000193	0.26	0.19	Height;	chr9:110183494	chr2:149068596~149068910:-
BRCA	trans	rs4883201	0.656	rs4883203	ENSG00000179899.8	PHC1P1	6.4	2.41e-10	0.000193	0.26	0.19	Total cholesterol levels;Cholesterol, total;	chr12:8959201	chr12:55411727~55414787:-
BRCA	trans	rs66887589	0.616	rs11098497	ENSG00000120555.12	SEPT7P9	6.4	2.42e-10	0.000193	0.22	0.19	Diastolic blood pressure;	chr4:119265913	chr10:38383069~38402916:-
BRCA	trans	rs7824557	0.724	rs2572398	ENSG00000254153.1	CTA-398F10.2	6.39	2.42e-10	0.000193	0.24	0.19	Retinal vascular caliber;	chr8:11320584	chr8:8456909~8461337:-
BRCA	trans	rs7617773	0.817	rs13068265	ENSG00000235912.1	RP1-159A19.3	-6.39	2.43e-10	0.000194	-0.26	-0.19	Coronary artery disease;	chr3:48260124	chr1:27649419~27649610:+
BRCA	trans	rs853679	1	rs6901575	ENSG00000253570.1	RNF5P1	6.39	2.43e-10	0.000194	0.38	0.19	Depression;	chr6:28283207	chr8:38600661~38601200:-
BRCA	trans	rs853679	0.567	rs3799499	ENSG00000228078.1	HLA-U	-6.39	2.43e-10	0.000194	-0.29	-0.19	Depression;	chr6:28386473	chr6:29934101~29934286:+
BRCA	trans	rs853679	0.567	rs2232427	ENSG00000228078.1	HLA-U	-6.39	2.43e-10	0.000194	-0.29	-0.19	Depression;	chr6:28391932	chr6:29934101~29934286:+
BRCA	trans	rs9650657	0.65	rs2898248	ENSG00000253893.2	FAM85B	-6.39	2.44e-10	0.000195	-0.24	-0.19	Neuroticism;	chr8:10779240	chr8:8167819~8226614:-
BRCA	trans	rs11098499	0.663	rs9996501	ENSG00000120555.12	SEPT7P9	6.39	2.44e-10	0.000195	0.23	0.19	Corneal astigmatism;	chr4:119317763	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.697	rs28458294	ENSG00000120555.12	SEPT7P9	6.39	2.44e-10	0.000195	0.23	0.19	Corneal astigmatism;	chr4:119317769	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.663	rs28369503	ENSG00000120555.12	SEPT7P9	6.39	2.44e-10	0.000195	0.23	0.19	Corneal astigmatism;	chr4:119317770	chr10:38383069~38402916:-
BRCA	trans	rs8177876	0.642	rs12445303	ENSG00000226040.3	AC005740.3	-6.39	2.45e-10	0.000196	-0.36	-0.19	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081968	chr5:141896168~141896689:-
BRCA	trans	rs875971	0.545	rs1547529	ENSG00000234585.5	CCT6P3	6.39	2.45e-10	0.000196	0.21	0.19	Aortic root size;	chr7:66258859	chr7:65038354~65074713:+
BRCA	trans	rs4929949	0.752	rs12806736	ENSG00000266891.1	RP11-692N5.2	6.39	2.45e-10	0.000196	0.23	0.19	Body mass index;	chr11:8482627	chr18:9734882~9735602:-
BRCA	trans	rs17767294	0.708	rs17693877	ENSG00000242375.1	RP11-498P14.3	-6.39	2.47e-10	0.000197	-0.49	-0.19	Parkinson's disease;	chr6:27739267	chr9:97195351~97197687:-
BRCA	trans	rs1707322	0.964	rs7512395	ENSG00000255397.1	AC022182.2	-6.39	2.48e-10	0.000198	-0.26	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45895505	chr8:60937705~60939871:-
BRCA	trans	rs66887589	0.592	rs62320740	ENSG00000276997.3	RP11-378J18.9	6.39	2.48e-10	0.000198	0.22	0.19	Diastolic blood pressure;	chr4:119358331	chr1:222477252~222504622:-
BRCA	trans	rs2965280	0.793	rs10412701	ENSG00000270983.1	RP11-137J7.3	-6.39	2.49e-10	0.000198	-0.43	-0.19	Colorectal cancer;	chr19:34310997	chr6:142062717~142063053:+
BRCA	trans	rs2965280	0.793	rs28723643	ENSG00000270983.1	RP11-137J7.3	-6.39	2.49e-10	0.000198	-0.43	-0.19	Colorectal cancer;	chr19:34312254	chr6:142062717~142063053:+
BRCA	trans	rs2220004	1	rs7120068	ENSG00000134612.10	FOLH1B	-6.39	2.5e-10	0.000199	-0.25	-0.19	Odorant perception (&beta-damascenone);	chr11:55985795	chr11:89639227~89698718:+
BRCA	trans	rs7568458	0.837	rs12714145	ENSG00000223886.3	RP11-251G23.2	6.39	2.5e-10	0.000199	0.22	0.19	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr2:85560218	chr7:105530209~105530671:+
BRCA	trans	rs7568458	0.905	rs10172544	ENSG00000223886.3	RP11-251G23.2	6.39	2.5e-10	0.000199	0.22	0.19	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr2:85561147	chr7:105530209~105530671:+
BRCA	trans	rs941207	0.724	rs4788	ENSG00000257210.1	NACAP3	6.39	2.5e-10	2e-04	0.26	0.19	Platelet count;	chr12:56712876	chr12:93124063~93124543:-
BRCA	trans	rs2899832	0.568	rs8014594	ENSG00000215414.4	PSMA6P1	6.39	2.52e-10	0.000201	0.35	0.19	Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:35296623	chrY:13286638~13287378:+
BRCA	trans	rs875971	0.545	rs11770063	ENSG00000213640.3	EEF1DP4	-6.39	2.53e-10	0.000202	-0.28	-0.19	Aortic root size;	chr7:66318029	chr7:64862999~64864370:+
BRCA	trans	rs11638815	0.626	rs1367841	ENSG00000235370.6	DNM1P51	6.39	2.53e-10	0.000202	0.21	0.19	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82641874	chr15:84398316~84411701:-
BRCA	trans	rs9368481	0.761	rs6918835	ENSG00000242375.1	RP11-498P14.3	-6.39	2.53e-10	0.000202	-0.29	-0.19	Autism spectrum disorder or schizophrenia;	chr6:27050048	chr9:97195351~97197687:-
BRCA	trans	rs902774	0.818	rs4919763	ENSG00000248568.1	KRT8P48	-6.39	2.54e-10	0.000202	-0.42	-0.19	Prostate cancer;	chr12:52885839	chr5:146706381~146707600:-
BRCA	trans	rs9467711	0.591	rs13195279	ENSG00000253570.1	RNF5P1	6.39	2.54e-10	0.000202	0.48	0.19	Autism spectrum disorder or schizophrenia;	chr6:25919203	chr8:38600661~38601200:-
BRCA	trans	rs9581094	0.591	rs9578738	ENSG00000237917.1	PARP4P1	-6.39	2.57e-10	0.000205	-0.38	-0.19	Sudden cardiac arrest;	chr13:24458715	chrY:26594851~26634652:-
BRCA	trans	rs2220004	1	rs4578407	ENSG00000134612.10	FOLH1B	6.38	2.59e-10	0.000206	0.26	0.19	Odorant perception (&beta-damascenone);	chr11:56170478	chr11:89639227~89698718:+
BRCA	trans	rs2220004	1	rs4939026	ENSG00000134612.10	FOLH1B	6.38	2.59e-10	0.000206	0.26	0.19	Odorant perception (&beta-damascenone);	chr11:56175135	chr11:89639227~89698718:+
BRCA	trans	rs1580019	0.51	rs4723162	ENSG00000213492.2	NT5C3AP1	-6.38	2.6e-10	0.000207	-0.26	-0.19	Cognitive ability;	chr7:32504192	chr4:117574512~117576174:-
BRCA	trans	rs1580019	0.562	rs4720064	ENSG00000213492.2	NT5C3AP1	-6.38	2.6e-10	0.000207	-0.26	-0.19	Cognitive ability;	chr7:32520026	chr4:117574512~117576174:-
BRCA	trans	rs11098499	0.575	rs907204	ENSG00000120555.12	SEPT7P9	6.38	2.6e-10	0.000207	0.23	0.19	Corneal astigmatism;	chr4:119317499	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.575	rs907205	ENSG00000120555.12	SEPT7P9	6.38	2.6e-10	0.000207	0.23	0.19	Corneal astigmatism;	chr4:119317509	chr10:38383069~38402916:-
BRCA	trans	rs210142	1	rs210142	ENSG00000175730.8	BAK1P1	6.38	2.63e-10	0.000209	0.27	0.19	Platelet count;Plateletcrit;Chronic lymphocytic leukemia;	chr6:33579060	chr20:32690180~32690815:-
BRCA	trans	rs210143	1	rs210143	ENSG00000175730.8	BAK1P1	6.38	2.63e-10	0.000209	0.27	0.19	B-cell malignancies (chronic lymphocytic leukemia, Hodgkin lymphoma or multiple myeloma) (pleiotropy);Chronic lymphocytic leukemia;Neutrophil percentage of granulocytes;	chr6:33579153	chr20:32690180~32690815:-
BRCA	trans	rs17301013	0.861	rs34819375	ENSG00000213331.4	RP11-713C19.2	6.38	2.63e-10	0.00021	0.22	0.19	Systemic lupus erythematosus;	chr1:174654958	chr4:187970273~187971284:+
BRCA	trans	rs7617773	0.78	rs13084616	ENSG00000235912.1	RP1-159A19.3	6.38	2.64e-10	0.00021	0.26	0.19	Coronary artery disease;	chr3:48298209	chr1:27649419~27649610:+
BRCA	trans	rs7927771	0.756	rs2856661	ENSG00000134612.10	FOLH1B	6.38	2.64e-10	0.00021	0.26	0.19	Subjective well-being;	chr11:47353447	chr11:89639227~89698718:+
BRCA	trans	rs11098499	0.754	rs2036860	ENSG00000120555.12	SEPT7P9	6.38	2.65e-10	0.00021	0.23	0.19	Corneal astigmatism;	chr4:119327779	chr10:38383069~38402916:-
BRCA	trans	rs17767294	0.708	rs72847365	ENSG00000242375.1	RP11-498P14.3	-6.38	2.65e-10	0.000211	-0.58	-0.19	Parkinson's disease;	chr6:27869449	chr9:97195351~97197687:-
BRCA	trans	rs17301013	0.932	rs444678	ENSG00000213331.4	RP11-713C19.2	6.38	2.65e-10	0.000211	0.22	0.19	Systemic lupus erythematosus;	chr1:174706080	chr4:187970273~187971284:+
BRCA	trans	rs7032940	0.953	rs10816934	ENSG00000228236.2	TXNP5	6.38	2.66e-10	0.000212	0.26	0.19	Height;	chr9:110180540	chr2:149068596~149068910:-
BRCA	trans	rs113793030	0.661	rs7923117	ENSG00000253785.1	CTC-308K20.3	-6.38	2.67e-10	0.000212	-0.51	-0.19	Cognitive decline rate in late mild cognitive impairment;	chr10:70252649	chr5:172975511~172976374:+
BRCA	trans	rs6499244	0.552	rs7196917	ENSG00000196796.5	CTB-134H23.2	6.38	2.67e-10	0.000213	0.2	0.19	Menarche (age at onset);	chr16:69862624	chr16:29038655~29052726:+
BRCA	trans	rs11098499	0.754	rs9999724	ENSG00000120555.12	SEPT7P9	6.38	2.68e-10	0.000213	0.23	0.19	Corneal astigmatism;	chr4:119318789	chr10:38383069~38402916:-
BRCA	trans	rs3762427	1	rs3762427	ENSG00000255627.1	RP11-547L9.1	6.38	2.69e-10	0.000214	0.39	0.19	Serum uric acid levels in response to allopurinol in gout;	chr1:151895084	chr12:22008348~22008880:+
BRCA	trans	rs9650657	0.623	rs6601514	ENSG00000253893.2	FAM85B	6.38	2.7e-10	0.000215	0.24	0.19	Neuroticism;	chr8:10743771	chr8:8167819~8226614:-
BRCA	trans	rs6981523	0.553	rs2409730	ENSG00000253893.2	FAM85B	6.38	2.71e-10	0.000215	0.26	0.19	Neuroticism;	chr8:11203129	chr8:8167819~8226614:-
BRCA	trans	rs9393777	0.778	rs4452638	ENSG00000253570.1	RNF5P1	-6.38	2.71e-10	0.000216	-0.44	-0.19	Intelligence (multi-trait analysis);	chr6:27261486	chr8:38600661~38601200:-
BRCA	trans	rs7617773	0.707	rs13061269	ENSG00000235912.1	RP1-159A19.3	-6.38	2.72e-10	0.000216	-0.26	-0.19	Coronary artery disease;	chr3:48331853	chr1:27649419~27649610:+
BRCA	trans	rs7617773	0.78	rs71323395	ENSG00000235912.1	RP1-159A19.3	-6.38	2.72e-10	0.000216	-0.26	-0.19	Coronary artery disease;	chr3:48332587	chr1:27649419~27649610:+
BRCA	trans	rs7617773	0.743	rs71323397	ENSG00000235912.1	RP1-159A19.3	-6.38	2.72e-10	0.000216	-0.26	-0.19	Coronary artery disease;	chr3:48333384	chr1:27649419~27649610:+
BRCA	trans	rs7617773	0.817	rs17786132	ENSG00000235912.1	RP1-159A19.3	-6.38	2.73e-10	0.000217	-0.26	-0.19	Coronary artery disease;	chr3:48207930	chr1:27649419~27649610:+
BRCA	trans	rs7617773	0.817	rs35456569	ENSG00000235912.1	RP1-159A19.3	-6.38	2.73e-10	0.000217	-0.26	-0.19	Coronary artery disease;	chr3:48209409	chr1:27649419~27649610:+
BRCA	trans	rs7617773	0.78	rs35297486	ENSG00000235912.1	RP1-159A19.3	-6.38	2.74e-10	0.000217	-0.26	-0.19	Coronary artery disease;	chr3:48336657	chr1:27649419~27649610:+
BRCA	trans	rs7617773	0.817	rs13059037	ENSG00000235912.1	RP1-159A19.3	-6.38	2.74e-10	0.000218	-0.26	-0.19	Coronary artery disease;	chr3:48246389	chr1:27649419~27649610:+
BRCA	trans	rs11992162	1	rs7460395	ENSG00000253981.4	ALG1L13P	6.37	2.74e-10	0.000218	0.23	0.19	Monocyte count;	chr8:11977866	chr8:8236003~8244667:-
BRCA	trans	rs864643	1	rs552724	ENSG00000188856.6	RPSAP47	-6.37	2.77e-10	0.00022	-0.3	-0.19	Attention deficit hyperactivity disorder;	chr3:39513455	chr8:80558870~80559757:+
BRCA	trans	rs11098499	0.754	rs714899	ENSG00000120555.12	SEPT7P9	6.37	2.78e-10	0.000221	0.23	0.19	Corneal astigmatism;	chr4:119321880	chr10:38383069~38402916:-
BRCA	trans	rs17767294	0.708	rs41269275	ENSG00000242375.1	RP11-498P14.3	-6.37	2.79e-10	0.000221	-0.57	-0.19	Parkinson's disease;	chr6:27865537	chr9:97195351~97197687:-
BRCA	trans	rs17767294	0.708	rs72847361	ENSG00000242375.1	RP11-498P14.3	-6.37	2.79e-10	0.000221	-0.57	-0.19	Parkinson's disease;	chr6:27866438	chr9:97195351~97197687:-
BRCA	trans	rs1707322	0.928	rs6681068	ENSG00000255397.1	AC022182.2	-6.37	2.79e-10	0.000221	-0.25	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45932710	chr8:60937705~60939871:-
BRCA	trans	rs11098499	0.754	rs878372	ENSG00000120555.12	SEPT7P9	6.37	2.79e-10	0.000222	0.23	0.19	Corneal astigmatism;	chr4:119317625	chr10:38383069~38402916:-
BRCA	trans	rs731945	1	rs731945	ENSG00000267533.1	RP11-815J4.7	-6.37	2.79e-10	0.000222	-0.27	-0.19	Self-reported allergy;	chr19:18456229	chr18:12067173~12068417:-
BRCA	trans	rs11098499	0.826	rs4472123	ENSG00000120555.12	SEPT7P9	6.37	2.81e-10	0.000223	0.23	0.19	Corneal astigmatism;	chr4:119315475	chr10:38383069~38402916:-
BRCA	trans	rs853679	1	rs68141011	ENSG00000253570.1	RNF5P1	6.37	2.81e-10	0.000223	0.38	0.19	Depression;	chr6:28250019	chr8:38600661~38601200:-
BRCA	trans	rs853679	1	rs13200462	ENSG00000253570.1	RNF5P1	6.37	2.81e-10	0.000223	0.38	0.19	Depression;	chr6:28250421	chr8:38600661~38601200:-
BRCA	trans	rs7617773	0.71	rs36064160	ENSG00000235912.1	RP1-159A19.3	-6.37	2.83e-10	0.000225	-0.26	-0.19	Coronary artery disease;	chr3:48201611	chr1:27649419~27649610:+
BRCA	trans	rs4883201	0.656	rs10129061	ENSG00000179899.8	PHC1P1	6.37	2.84e-10	0.000225	0.26	0.19	Total cholesterol levels;Cholesterol, total;	chr12:8953239	chr12:55411727~55414787:-
BRCA	trans	rs12546962	0.551	rs28457812	ENSG00000253893.2	FAM85B	-6.37	2.84e-10	0.000226	-0.28	-0.19	Body mass index;	chr8:9353656	chr8:8167819~8226614:-
BRCA	trans	rs11098499	0.865	rs10213221	ENSG00000120555.12	SEPT7P9	6.37	2.86e-10	0.000227	0.23	0.19	Corneal astigmatism;	chr4:119334771	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.866	rs6847778	ENSG00000120555.12	SEPT7P9	6.37	2.87e-10	0.000228	0.23	0.19	Corneal astigmatism;	chr4:119372427	chr10:38383069~38402916:-
BRCA	trans	rs2220004	0.896	rs7114729	ENSG00000134612.10	FOLH1B	6.37	2.88e-10	0.000228	0.26	0.19	Odorant perception (&beta-damascenone);	chr11:56172918	chr11:89639227~89698718:+
BRCA	trans	rs2220004	1	rs10791857	ENSG00000134612.10	FOLH1B	6.37	2.88e-10	0.000228	0.26	0.19	Odorant perception (&beta-damascenone);	chr11:56173408	chr11:89639227~89698718:+
BRCA	trans	rs9649213	0.555	rs6955259	ENSG00000225169.1	BRI3P1	6.37	2.9e-10	0.00023	0.25	0.19	Prostate cancer (SNP x SNP interaction);	chr7:98263044	chr1:100213293~100213670:+
BRCA	trans	rs7617773	0.78	rs13082158	ENSG00000235912.1	RP1-159A19.3	-6.37	2.91e-10	0.000231	-0.26	-0.19	Coronary artery disease;	chr3:48330980	chr1:27649419~27649610:+
BRCA	trans	rs7617773	0.78	rs11710257	ENSG00000235912.1	RP1-159A19.3	-6.37	2.91e-10	0.000231	-0.26	-0.19	Coronary artery disease;	chr3:48331724	chr1:27649419~27649610:+
BRCA	trans	rs714543	1	rs1990053	ENSG00000219797.2	PPIAP9	-6.36	2.93e-10	0.000232	-0.24	-0.19	Plateletcrit;	chr7:44886297	chr6:31519480~31520291:-
BRCA	trans	rs11098499	0.731	rs6846966	ENSG00000120555.12	SEPT7P9	6.36	2.94e-10	0.000233	0.23	0.19	Corneal astigmatism;	chr4:119372053	chr10:38383069~38402916:-
BRCA	trans	rs703108	0.731	rs7898954	ENSG00000229465.1	ACTG1P11	6.36	2.96e-10	0.000234	0.24	0.19	Monocyte percentage of white cells;	chr10:22034717	chrY:18147884~18149008:+
BRCA	trans	rs2965280	0.546	rs10417893	ENSG00000270983.1	RP11-137J7.3	-6.36	2.96e-10	0.000234	-0.44	-0.19	Colorectal cancer;	chr19:34285731	chr6:142062717~142063053:+
BRCA	trans	rs864643	0.947	rs1768237	ENSG00000188856.6	RPSAP47	6.36	2.97e-10	0.000235	0.28	0.19	Attention deficit hyperactivity disorder;	chr3:39498712	chr8:80558870~80559757:+
BRCA	trans	rs1707322	0.964	rs10437063	ENSG00000255397.1	AC022182.2	-6.36	2.97e-10	0.000235	-0.25	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45807994	chr8:60937705~60939871:-
BRCA	trans	rs1707322	1	rs6676982	ENSG00000255397.1	AC022182.2	-6.36	2.97e-10	0.000235	-0.25	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45809729	chr8:60937705~60939871:-
BRCA	trans	rs1933488	0.542	rs607335	ENSG00000278974.1	RP11-756P10.6	6.36	2.98e-10	0.000236	0.26	0.19	Prostate cancer;	chr6:153144095	chr4:188740507~188741281:-
BRCA	trans	rs17301013	0.761	rs332805	ENSG00000213331.4	RP11-713C19.2	6.36	2.98e-10	0.000236	0.22	0.19	Systemic lupus erythematosus;	chr1:174652487	chr4:187970273~187971284:+
BRCA	trans	rs7647973	1	rs1982861	ENSG00000197582.5	GPX1P1	6.36	3.01e-10	0.000238	0.21	0.19	Menarche (age at onset);	chr3:49540232	chrX:13378735~13379340:-
BRCA	trans	rs4834770	0.746	rs2389747	ENSG00000275858.1	RP11-291L22.8	6.36	3.02e-10	0.000239	0.22	0.19	Blood protein levels;	chr4:119314947	chr10:38450738~38451069:-
BRCA	trans	rs4834770	0.717	rs1022146	ENSG00000275858.1	RP11-291L22.8	6.36	3.02e-10	0.000239	0.22	0.19	Blood protein levels;	chr4:119314948	chr10:38450738~38451069:-
BRCA	trans	rs9329221	0.868	rs7831557	ENSG00000255046.1	RP11-297N6.4	6.36	3.02e-10	0.000239	0.24	0.19	Neuroticism;	chr8:10422718	chr8:11797928~11802568:-
BRCA	trans	rs11098499	0.954	rs6820115	ENSG00000120555.12	SEPT7P9	6.36	3.02e-10	0.000239	0.23	0.19	Corneal astigmatism;	chr4:119477027	chr10:38383069~38402916:-
BRCA	trans	rs1707322	1	rs10890375	ENSG00000255397.1	AC022182.2	-6.36	3.04e-10	0.000241	-0.25	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45940909	chr8:60937705~60939871:-
BRCA	trans	rs1707322	1	rs10890377	ENSG00000255397.1	AC022182.2	-6.36	3.04e-10	0.000241	-0.25	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45940922	chr8:60937705~60939871:-
BRCA	trans	rs9649213	0.574	rs34817002	ENSG00000225169.1	BRI3P1	6.36	3.04e-10	0.000241	0.25	0.19	Prostate cancer (SNP x SNP interaction);	chr7:98257739	chr1:100213293~100213670:+
BRCA	trans	rs7032940	0.859	rs11793349	ENSG00000228236.2	TXNP5	6.36	3.04e-10	0.000241	0.27	0.19	Height;	chr9:110191406	chr2:149068596~149068910:-
BRCA	trans	rs1707322	1	rs4390216	ENSG00000255397.1	AC022182.2	-6.36	3.04e-10	0.000241	-0.25	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45800784	chr8:60937705~60939871:-
BRCA	trans	rs4879656	0.8	rs1537041	ENSG00000215007.3	DNAJA1P3	6.36	3.05e-10	0.000241	0.23	0.19	Menopause (age at onset);	chr9:33060418	chrX:107351650~107352843:-
BRCA	trans	rs2066819	1	rs80317430	ENSG00000273654.1	CTB-52I2.4	6.36	3.06e-10	0.000242	0.5	0.19	Psoriasis vulgaris;	chr12:56333921	chr19:18022403~18032099:+
BRCA	trans	rs2066819	1	rs79824801	ENSG00000273654.1	CTB-52I2.4	6.36	3.06e-10	0.000242	0.5	0.19	Psoriasis vulgaris;	chr12:56334353	chr19:18022403~18032099:+
BRCA	trans	rs2066819	1	rs79101914	ENSG00000273654.1	CTB-52I2.4	6.36	3.06e-10	0.000242	0.5	0.19	Psoriasis vulgaris;	chr12:56335955	chr19:18022403~18032099:+
BRCA	trans	rs2965280	0.793	rs111921454	ENSG00000270983.1	RP11-137J7.3	-6.36	3.07e-10	0.000243	-0.43	-0.19	Colorectal cancer;	chr19:34328391	chr6:142062717~142063053:+
BRCA	trans	rs2965280	0.793	rs8101748	ENSG00000270983.1	RP11-137J7.3	-6.36	3.07e-10	0.000243	-0.43	-0.19	Colorectal cancer;	chr19:34331426	chr6:142062717~142063053:+
BRCA	trans	rs2965280	0.793	rs11879050	ENSG00000270983.1	RP11-137J7.3	-6.36	3.07e-10	0.000243	-0.43	-0.19	Colorectal cancer;	chr19:34332328	chr6:142062717~142063053:+
BRCA	trans	rs2066819	1	rs59811639	ENSG00000273654.1	CTB-52I2.4	6.36	3.08e-10	0.000243	0.5	0.19	Psoriasis vulgaris;	chr12:56302170	chr19:18022403~18032099:+
BRCA	trans	rs2066819	1	rs57279772	ENSG00000273654.1	CTB-52I2.4	6.36	3.08e-10	0.000243	0.5	0.19	Psoriasis vulgaris;	chr12:56305176	chr19:18022403~18032099:+
BRCA	trans	rs2066819	1	rs76430365	ENSG00000273654.1	CTB-52I2.4	6.36	3.08e-10	0.000243	0.5	0.19	Psoriasis vulgaris;	chr12:56306209	chr19:18022403~18032099:+
BRCA	trans	rs2066819	1	rs79750959	ENSG00000273654.1	CTB-52I2.4	6.36	3.08e-10	0.000243	0.5	0.19	Psoriasis vulgaris;	chr12:56308228	chr19:18022403~18032099:+
BRCA	trans	rs2066819	1	rs58852079	ENSG00000273654.1	CTB-52I2.4	6.36	3.08e-10	0.000243	0.5	0.19	Psoriasis vulgaris;	chr12:56313138	chr19:18022403~18032099:+
BRCA	trans	rs2066819	1	rs59295315	ENSG00000273654.1	CTB-52I2.4	6.36	3.08e-10	0.000243	0.5	0.19	Psoriasis vulgaris;	chr12:56314792	chr19:18022403~18032099:+
BRCA	trans	rs2066819	1	rs2291361	ENSG00000273654.1	CTB-52I2.4	6.36	3.08e-10	0.000243	0.5	0.19	Psoriasis vulgaris;	chr12:56324021	chr19:18022403~18032099:+
BRCA	trans	rs2066819	1	rs76466034	ENSG00000273654.1	CTB-52I2.4	6.36	3.08e-10	0.000243	0.5	0.19	Psoriasis vulgaris;	chr12:56325666	chr19:18022403~18032099:+
BRCA	trans	rs2066819	1	rs77768890	ENSG00000273654.1	CTB-52I2.4	6.36	3.08e-10	0.000243	0.5	0.19	Psoriasis vulgaris;	chr12:56331337	chr19:18022403~18032099:+
BRCA	trans	rs2066819	1	rs75754909	ENSG00000273654.1	CTB-52I2.4	6.36	3.08e-10	0.000243	0.5	0.19	Psoriasis vulgaris;	chr12:56332565	chr19:18022403~18032099:+
BRCA	trans	rs11098499	0.754	rs7672594	ENSG00000120555.12	SEPT7P9	6.36	3.08e-10	0.000244	0.23	0.19	Corneal astigmatism;	chr4:119327388	chr10:38383069~38402916:-
BRCA	trans	rs3750082	0.926	rs11762628	ENSG00000176826.14	FKBP9P1	6.36	3.09e-10	0.000244	0.24	0.19	Glomerular filtration rate (creatinine);	chr7:32886959	chr7:55681074~55713252:-
BRCA	trans	rs1707322	0.691	rs11211175	ENSG00000255397.1	AC022182.2	-6.35	3.12e-10	0.000246	-0.25	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755212	chr8:60937705~60939871:-
BRCA	trans	rs875971	0.545	rs10950029	ENSG00000234585.5	CCT6P3	6.35	3.12e-10	0.000247	0.21	0.19	Aortic root size;	chr7:66169334	chr7:65038354~65074713:+
BRCA	trans	rs2220004	1	rs2512777	ENSG00000134612.10	FOLH1B	-6.35	3.13e-10	0.000247	-0.26	-0.19	Odorant perception (&beta-damascenone);	chr11:56107204	chr11:89639227~89698718:+
BRCA	trans	rs7647973	1	rs56127630	ENSG00000197582.5	GPX1P1	-6.35	3.14e-10	0.000248	-0.21	-0.19	Menarche (age at onset);	chr3:49400603	chrX:13378735~13379340:-
BRCA	trans	rs864643	0.947	rs645457	ENSG00000188856.6	RPSAP47	6.35	3.15e-10	0.000249	0.28	0.19	Attention deficit hyperactivity disorder;	chr3:39499006	chr8:80558870~80559757:+
BRCA	trans	rs9468199	0.51	rs77576207	ENSG00000242375.1	RP11-498P14.3	-6.35	3.15e-10	0.000249	-0.57	-0.19	Parkinson's disease;	chr6:27874377	chr9:97195351~97197687:-
BRCA	trans	rs7617773	0.817	rs34728236	ENSG00000235912.1	RP1-159A19.3	-6.35	3.16e-10	0.000249	-0.26	-0.19	Coronary artery disease;	chr3:48217618	chr1:27649419~27649610:+
BRCA	trans	rs7617773	0.817	rs79310258	ENSG00000235912.1	RP1-159A19.3	-6.35	3.16e-10	0.000249	-0.26	-0.19	Coronary artery disease;	chr3:48218177	chr1:27649419~27649610:+
BRCA	trans	rs7617773	0.676	rs13060020	ENSG00000235912.1	RP1-159A19.3	-6.35	3.16e-10	0.00025	-0.26	-0.19	Coronary artery disease;	chr3:48331156	chr1:27649419~27649610:+
BRCA	trans	rs1075232	1	rs16956838	ENSG00000270055.1	CTD-3092A11.2	-6.35	3.17e-10	0.00025	-0.39	-0.19	Survival in colorectal cancer (non-distant metastatic);	chr15:31527492	chr15:30487963~30490313:+
BRCA	trans	rs1707322	0.963	rs10789484	ENSG00000255397.1	AC022182.2	-6.35	3.17e-10	0.00025	-0.25	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45941306	chr8:60937705~60939871:-
BRCA	trans	rs2899832	0.568	rs17597267	ENSG00000215414.4	PSMA6P1	6.35	3.18e-10	0.000251	0.34	0.19	Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:35312698	chrY:13286638~13287378:+
BRCA	trans	rs11098499	0.604	rs12642411	ENSG00000276997.3	RP11-378J18.9	6.35	3.19e-10	0.000252	0.25	0.19	Corneal astigmatism;	chr4:119659370	chr1:222477252~222504622:-
BRCA	trans	rs6601327	0.67	rs4128198	ENSG00000253893.2	FAM85B	-6.35	3.19e-10	0.000252	-0.24	-0.19	Multiple myeloma (hyperdiploidy);	chr8:9575989	chr8:8167819~8226614:-
BRCA	trans	rs3750082	1	rs3750082	ENSG00000176826.14	FKBP9P1	6.35	3.2e-10	0.000252	0.24	0.19	Glomerular filtration rate (creatinine);	chr7:32880315	chr7:55681074~55713252:-
BRCA	trans	rs7617773	0.778	rs11707997	ENSG00000235912.1	RP1-159A19.3	-6.35	3.21e-10	0.000253	-0.26	-0.19	Coronary artery disease;	chr3:48336385	chr1:27649419~27649610:+
BRCA	trans	rs853679	1	rs1778508	ENSG00000253570.1	RNF5P1	-6.35	3.22e-10	0.000254	-0.37	-0.19	Depression;	chr6:28262103	chr8:38600661~38601200:-
BRCA	trans	rs2066819	1	rs116849218	ENSG00000273654.1	CTB-52I2.4	6.35	3.23e-10	0.000254	0.5	0.19	Psoriasis vulgaris;	chr12:56290191	chr19:18022403~18032099:+
BRCA	trans	rs2066819	1	rs79436528	ENSG00000273654.1	CTB-52I2.4	6.35	3.23e-10	0.000254	0.5	0.19	Psoriasis vulgaris;	chr12:56293213	chr19:18022403~18032099:+
BRCA	trans	rs2066819	1	rs77853814	ENSG00000273654.1	CTB-52I2.4	6.35	3.23e-10	0.000254	0.5	0.19	Psoriasis vulgaris;	chr12:56293788	chr19:18022403~18032099:+
BRCA	trans	rs12439619	0.846	rs62012004	ENSG00000235370.6	DNM1P51	-6.35	3.24e-10	0.000255	-0.27	-0.19	Intelligence (multi-trait analysis);	chr15:82183924	chr15:84398316~84411701:-
BRCA	trans	rs1707322	0.865	rs785501	ENSG00000255397.1	AC022182.2	6.35	3.24e-10	0.000256	0.26	0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46113939	chr8:60937705~60939871:-
BRCA	trans	rs7617773	0.815	rs9825637	ENSG00000235912.1	RP1-159A19.3	-6.35	3.24e-10	0.000256	-0.25	-0.19	Coronary artery disease;	chr3:48330792	chr1:27649419~27649610:+
BRCA	trans	rs1707322	0.752	rs6662164	ENSG00000255397.1	AC022182.2	-6.35	3.25e-10	0.000256	-0.25	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45680558	chr8:60937705~60939871:-
BRCA	trans	rs1707322	1	rs10789479	ENSG00000255397.1	AC022182.2	-6.35	3.25e-10	0.000256	-0.26	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45886828	chr8:60937705~60939871:-
BRCA	trans	rs7647973	1	rs6446275	ENSG00000197582.5	GPX1P1	-6.35	3.25e-10	0.000257	-0.22	-0.19	Menarche (age at onset);	chr3:49429438	chrX:13378735~13379340:-
BRCA	trans	rs11098499	0.532	rs12512646	ENSG00000276805.1	RP11-291L22.6	6.35	3.26e-10	0.000257	0.22	0.19	Corneal astigmatism;	chr4:119664578	chr10:38451030~38451785:+
BRCA	trans	rs853679	0.546	rs200949	ENSG00000253570.1	RNF5P1	6.35	3.26e-10	0.000257	0.41	0.19	Depression;	chr6:27867657	chr8:38600661~38601200:-
BRCA	trans	rs1707322	1	rs4660905	ENSG00000255397.1	AC022182.2	6.35	3.28e-10	0.000258	0.25	0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45995915	chr8:60937705~60939871:-
BRCA	trans	rs4929949	0.78	rs10743078	ENSG00000266891.1	RP11-692N5.2	-6.35	3.28e-10	0.000258	-0.23	-0.19	Body mass index;	chr11:8580800	chr18:9734882~9735602:-
BRCA	trans	rs875971	0.651	rs313829	ENSG00000234585.5	CCT6P3	-6.35	3.28e-10	0.000259	-0.2	-0.19	Aortic root size;	chr7:66087510	chr7:65038354~65074713:+
BRCA	trans	rs7647973	1	rs12583	ENSG00000197582.5	GPX1P1	-6.35	3.3e-10	0.00026	-0.22	-0.19	Menarche (age at onset);	chr3:49534029	chrX:13378735~13379340:-
BRCA	trans	rs9581094	0.591	rs116985356	ENSG00000237917.1	PARP4P1	-6.35	3.3e-10	0.00026	-0.42	-0.19	Sudden cardiac arrest;	chr13:24465545	chrY:26594851~26634652:-
BRCA	trans	rs853679	0.599	rs149943	ENSG00000253570.1	RNF5P1	6.35	3.3e-10	0.00026	0.44	0.19	Depression;	chr6:28034610	chr8:38600661~38601200:-
BRCA	trans	rs875971	0.545	rs7811204	ENSG00000213640.3	EEF1DP4	-6.34	3.31e-10	0.000261	-0.28	-0.19	Aortic root size;	chr7:66387213	chr7:64862999~64864370:+
BRCA	trans	rs11098499	0.789	rs9991166	ENSG00000120555.12	SEPT7P9	6.34	3.32e-10	0.000262	0.23	0.19	Corneal astigmatism;	chr4:119316696	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.708	rs10005237	ENSG00000120555.12	SEPT7P9	6.34	3.32e-10	0.000262	0.23	0.19	Corneal astigmatism;	chr4:119316742	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.754	rs10213267	ENSG00000120555.12	SEPT7P9	6.34	3.32e-10	0.000262	0.23	0.19	Corneal astigmatism;	chr4:119317919	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.754	rs10212775	ENSG00000120555.12	SEPT7P9	6.34	3.32e-10	0.000262	0.23	0.19	Corneal astigmatism;	chr4:119318089	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.754	rs2964	ENSG00000120555.12	SEPT7P9	6.34	3.32e-10	0.000262	0.23	0.19	Corneal astigmatism;	chr4:119318976	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.754	rs1511025	ENSG00000120555.12	SEPT7P9	6.34	3.32e-10	0.000262	0.23	0.19	Corneal astigmatism;	chr4:119319083	chr10:38383069~38402916:-
BRCA	trans	rs7927771	1	rs2290850	ENSG00000134612.10	FOLH1B	-6.34	3.33e-10	0.000262	-0.26	-0.19	Subjective well-being;	chr11:47786222	chr11:89639227~89698718:+
BRCA	trans	rs1580019	0.587	rs2392069	ENSG00000213492.2	NT5C3AP1	-6.34	3.33e-10	0.000263	-0.26	-0.19	Cognitive ability;	chr7:32507542	chr4:117574512~117576174:-
BRCA	trans	rs1580019	0.587	rs34488151	ENSG00000213492.2	NT5C3AP1	-6.34	3.33e-10	0.000263	-0.26	-0.19	Cognitive ability;	chr7:32508534	chr4:117574512~117576174:-
BRCA	trans	rs1580019	0.587	rs6951955	ENSG00000213492.2	NT5C3AP1	-6.34	3.33e-10	0.000263	-0.26	-0.19	Cognitive ability;	chr7:32509149	chr4:117574512~117576174:-
BRCA	trans	rs1580019	0.587	rs6972365	ENSG00000213492.2	NT5C3AP1	-6.34	3.33e-10	0.000263	-0.26	-0.19	Cognitive ability;	chr7:32509319	chr4:117574512~117576174:-
BRCA	trans	rs11920570	0.92	rs12486285	ENSG00000267076.1	CCDC58P3	-6.34	3.33e-10	0.000263	-0.26	-0.19	Resting heart rate;	chr3:122567313	chr18:12211378~12211807:+
BRCA	trans	rs6011368	0.765	rs6062682	ENSG00000226210.3	WASH7P	6.34	3.34e-10	0.000263	0.21	0.19	Clozapine-induced cytotoxicity;	chr20:64260467	chr12:14522~32015:-
BRCA	trans	rs9649213	0.574	rs7789440	ENSG00000225169.1	BRI3P1	6.34	3.34e-10	0.000263	0.25	0.19	Prostate cancer (SNP x SNP interaction);	chr7:98259486	chr1:100213293~100213670:+
BRCA	trans	rs7647973	0.506	rs11920251	ENSG00000197582.5	GPX1P1	6.34	3.34e-10	0.000263	0.19	0.19	Menarche (age at onset);	chr3:49319238	chrX:13378735~13379340:-
BRCA	trans	rs853679	1	rs7740487	ENSG00000253570.1	RNF5P1	6.34	3.35e-10	0.000264	0.38	0.19	Depression;	chr6:28248708	chr8:38600661~38601200:-
BRCA	trans	rs12497850	0.864	rs6779394	ENSG00000197582.5	GPX1P1	6.34	3.36e-10	0.000264	0.21	0.19	Parkinson's disease;	chr3:49120338	chrX:13378735~13379340:-
BRCA	trans	rs1707322	1	rs785504	ENSG00000255397.1	AC022182.2	6.34	3.36e-10	0.000265	0.26	0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46130024	chr8:60937705~60939871:-
BRCA	trans	rs9467711	0.591	rs13220488	ENSG00000253570.1	RNF5P1	6.34	3.37e-10	0.000265	0.48	0.19	Autism spectrum disorder or schizophrenia;	chr6:25896679	chr8:38600661~38601200:-
BRCA	trans	rs11098499	0.754	rs1546503	ENSG00000120555.12	SEPT7P9	6.34	3.38e-10	0.000266	0.23	0.19	Corneal astigmatism;	chr4:119320012	chr10:38383069~38402916:-
BRCA	trans	rs1580019	0.587	rs7806113	ENSG00000213492.2	NT5C3AP1	-6.34	3.38e-10	0.000266	-0.26	-0.19	Cognitive ability;	chr7:32513472	chr4:117574512~117576174:-
BRCA	trans	rs7746199	0.736	rs13202295	ENSG00000281831.1	HCP5B	6.34	3.38e-10	0.000266	0.5	0.19	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27731058	chr6:29871895~29873783:-
BRCA	trans	rs10838687	0.8	rs3729802	ENSG00000134612.10	FOLH1B	6.34	3.42e-10	0.000269	0.29	0.19	Proinsulin levels;	chr11:47332517	chr11:89639227~89698718:+
BRCA	trans	rs17301013	0.612	rs56199565	ENSG00000213331.4	RP11-713C19.2	6.34	3.43e-10	0.00027	0.21	0.19	Systemic lupus erythematosus;	chr1:174640992	chr4:187970273~187971284:+
BRCA	trans	rs11098499	0.532	rs4833624	ENSG00000276805.1	RP11-291L22.6	6.34	3.43e-10	0.00027	0.22	0.19	Corneal astigmatism;	chr4:119664342	chr10:38451030~38451785:+
BRCA	trans	rs7617773	0.778	rs11715776	ENSG00000235912.1	RP1-159A19.3	-6.34	3.43e-10	0.00027	-0.26	-0.19	Coronary artery disease;	chr3:48336121	chr1:27649419~27649610:+
BRCA	trans	rs2066819	0.786	rs116934693	ENSG00000273654.1	CTB-52I2.4	6.34	3.44e-10	0.00027	0.5	0.19	Psoriasis vulgaris;	chr12:56302761	chr19:18022403~18032099:+
BRCA	trans	rs11098499	0.754	rs12506610	ENSG00000120555.12	SEPT7P9	6.34	3.44e-10	0.00027	0.23	0.19	Corneal astigmatism;	chr4:119320504	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.743	rs10003567	ENSG00000120555.12	SEPT7P9	6.34	3.44e-10	0.00027	0.23	0.19	Corneal astigmatism;	chr4:119320519	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.754	rs10006259	ENSG00000120555.12	SEPT7P9	6.34	3.44e-10	0.00027	0.23	0.19	Corneal astigmatism;	chr4:119320990	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.754	rs28652763	ENSG00000120555.12	SEPT7P9	6.34	3.44e-10	0.00027	0.23	0.19	Corneal astigmatism;	chr4:119321157	chr10:38383069~38402916:-
BRCA	trans	rs17301013	0.896	rs332773	ENSG00000213331.4	RP11-713C19.2	6.34	3.45e-10	0.000271	0.21	0.19	Systemic lupus erythematosus;	chr1:174695711	chr4:187970273~187971284:+
BRCA	trans	rs17301013	0.896	rs332791	ENSG00000213331.4	RP11-713C19.2	6.34	3.45e-10	0.000271	0.21	0.19	Systemic lupus erythematosus;	chr1:174709784	chr4:187970273~187971284:+
BRCA	trans	rs1580019	0.587	rs7806941	ENSG00000213492.2	NT5C3AP1	-6.34	3.45e-10	0.000271	-0.26	-0.19	Cognitive ability;	chr7:32513707	chr4:117574512~117576174:-
BRCA	trans	rs11231420	1	rs11231420	ENSG00000134612.10	FOLH1B	6.34	3.45e-10	0.000271	0.27	0.19	Pelvic organ prolapse (moderate/severe);	chr11:55877258	chr11:89639227~89698718:+
BRCA	trans	rs860295	0.557	rs915181	ENSG00000241627.3	UBQLN4P1	-6.34	3.46e-10	0.000272	-0.21	-0.19	Body mass index;	chr1:155944981	chr3:148985868~148987668:-
BRCA	trans	rs860295	0.58	rs2282301	ENSG00000241627.3	UBQLN4P1	6.34	3.46e-10	0.000272	0.21	0.19	Body mass index;	chr1:155898834	chr3:148985868~148987668:-
BRCA	trans	rs2220004	1	rs66595819	ENSG00000134612.10	FOLH1B	-6.34	3.47e-10	0.000273	-0.25	-0.19	Odorant perception (&beta-damascenone);	chr11:55980078	chr11:89639227~89698718:+
BRCA	trans	rs2899832	0.568	rs77796720	ENSG00000215414.4	PSMA6P1	6.34	3.48e-10	0.000274	0.33	0.19	Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:35314500	chrY:13286638~13287378:+
BRCA	trans	rs7617773	0.78	rs13066044	ENSG00000235912.1	RP1-159A19.3	-6.34	3.48e-10	0.000274	-0.26	-0.19	Coronary artery disease;	chr3:48335786	chr1:27649419~27649610:+
BRCA	trans	rs2220004	1	rs4939018	ENSG00000134612.10	FOLH1B	-6.34	3.49e-10	0.000274	-0.25	-0.19	Odorant perception (&beta-damascenone);	chr11:56048769	chr11:89639227~89698718:+
BRCA	trans	rs2220004	1	rs11227471	ENSG00000134612.10	FOLH1B	6.34	3.49e-10	0.000274	0.26	0.19	Odorant perception (&beta-damascenone);	chr11:56191673	chr11:89639227~89698718:+
BRCA	trans	rs875971	0.929	rs34406470	ENSG00000164669.11	INTS4P1	-6.34	3.5e-10	0.000275	-0.24	-0.19	Aortic root size;	chr7:66464969	chr7:65141225~65234216:+
BRCA	trans	rs902774	0.818	rs56095813	ENSG00000255815.3	KRT8P11	-6.34	3.5e-10	0.000275	-0.4	-0.19	Prostate cancer;	chr12:52900963	chr9:99305176~99306611:+
BRCA	trans	rs1707322	1	rs11211228	ENSG00000255397.1	AC022182.2	-6.34	3.51e-10	0.000276	-0.25	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45934168	chr8:60937705~60939871:-
BRCA	trans	rs1707322	0.963	rs11211229	ENSG00000255397.1	AC022182.2	-6.34	3.51e-10	0.000276	-0.25	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45934845	chr8:60937705~60939871:-
BRCA	trans	rs1707322	1	rs9803784	ENSG00000255397.1	AC022182.2	-6.34	3.51e-10	0.000276	-0.25	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45936235	chr8:60937705~60939871:-
BRCA	trans	rs9467711	0.79	rs35400317	ENSG00000281831.1	HCP5B	6.34	3.52e-10	0.000276	0.48	0.19	Autism spectrum disorder or schizophrenia;	chr6:26593047	chr6:29871895~29873783:-
BRCA	trans	rs1580019	0.587	rs1597555	ENSG00000213492.2	NT5C3AP1	-6.33	3.53e-10	0.000277	-0.26	-0.19	Cognitive ability;	chr7:32506506	chr4:117574512~117576174:-
BRCA	trans	rs2965280	0.793	rs10415025	ENSG00000270983.1	RP11-137J7.3	-6.33	3.54e-10	0.000278	-0.44	-0.19	Colorectal cancer;	chr19:34285103	chr6:142062717~142063053:+
BRCA	trans	rs9693857	0.52	rs10107887	ENSG00000253893.2	FAM85B	-6.33	3.54e-10	0.000278	-0.27	-0.19	Systolic blood pressure;	chr8:9507154	chr8:8167819~8226614:-
BRCA	trans	rs875971	0.571	rs78668714	ENSG00000213640.3	EEF1DP4	-6.33	3.55e-10	0.000279	-0.28	-0.19	Aortic root size;	chr7:66474464	chr7:64862999~64864370:+
BRCA	trans	rs860295	0.812	rs10908481	ENSG00000241627.3	UBQLN4P1	-6.33	3.55e-10	0.000279	-0.21	-0.19	Body mass index;	chr1:155743859	chr3:148985868~148987668:-
BRCA	trans	rs11122895	0.509	rs3860380	ENSG00000204745.3	AC083899.3	-6.33	3.56e-10	0.000279	-0.22	-0.19	Allergic sensitization;	chr2:111693810	chr2:87125390~87196647:+
BRCA	trans	rs17301013	0.932	rs10912813	ENSG00000213331.4	RP11-713C19.2	6.33	3.57e-10	0.00028	0.22	0.19	Systemic lupus erythematosus;	chr1:174607342	chr4:187970273~187971284:+
BRCA	trans	rs860295	0.535	rs2297649	ENSG00000241627.3	UBQLN4P1	6.33	3.58e-10	0.000281	0.22	0.19	Body mass index;	chr1:155965453	chr3:148985868~148987668:-
BRCA	trans	rs714543	0.66	rs13224222	ENSG00000214975.4	PPIAP29	6.33	3.58e-10	0.000281	0.22	0.19	Plateletcrit;	chr7:44772739	chr6:24976419~24976982:+
BRCA	trans	rs12546962	0.654	rs9329191	ENSG00000253893.2	FAM85B	6.33	3.6e-10	0.000282	0.27	0.19	Body mass index;	chr8:9359074	chr8:8167819~8226614:-
BRCA	trans	rs11098499	0.57	rs6832740	ENSG00000120555.12	SEPT7P9	6.33	3.6e-10	0.000282	0.23	0.19	Corneal astigmatism;	chr4:119624981	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.644	rs6855918	ENSG00000120555.12	SEPT7P9	6.33	3.6e-10	0.000282	0.23	0.19	Corneal astigmatism;	chr4:119625144	chr10:38383069~38402916:-
BRCA	trans	rs9649213	0.531	rs35216698	ENSG00000225169.1	BRI3P1	6.33	3.6e-10	0.000282	0.25	0.19	Prostate cancer (SNP x SNP interaction);	chr7:98266863	chr1:100213293~100213670:+
BRCA	trans	rs7647973	1	rs6785045	ENSG00000197582.5	GPX1P1	-6.33	3.61e-10	0.000283	-0.21	-0.19	Menarche (age at onset);	chr3:49397810	chrX:13378735~13379340:-
BRCA	trans	rs7647973	1	rs7648995	ENSG00000197582.5	GPX1P1	-6.33	3.61e-10	0.000283	-0.21	-0.19	Menarche (age at onset);	chr3:49401370	chrX:13378735~13379340:-
BRCA	trans	rs7647973	1	rs2140270	ENSG00000197582.5	GPX1P1	-6.33	3.61e-10	0.000283	-0.21	-0.19	Menarche (age at onset);	chr3:49402007	chrX:13378735~13379340:-
BRCA	trans	rs7647973	1	rs2177268	ENSG00000197582.5	GPX1P1	-6.33	3.61e-10	0.000283	-0.21	-0.19	Menarche (age at onset);	chr3:49402292	chrX:13378735~13379340:-
BRCA	trans	rs9329221	0.502	rs11777364	ENSG00000253981.4	ALG1L13P	6.33	3.61e-10	0.000284	0.22	0.19	Neuroticism;	chr8:10431036	chr8:8236003~8244667:-
BRCA	trans	rs4713118	0.699	rs200969	ENSG00000204709.4	LINC01556	6.33	3.63e-10	0.000285	0.29	0.19	Parkinson's disease;	chr6:27891675	chr6:28943877~28944537:+
BRCA	trans	rs7824557	0.767	rs6985460	ENSG00000254153.1	CTA-398F10.2	6.33	3.64e-10	0.000285	0.25	0.19	Retinal vascular caliber;	chr8:11313578	chr8:8456909~8461337:-
BRCA	trans	rs7617773	0.817	rs4131362	ENSG00000235912.1	RP1-159A19.3	-6.33	3.64e-10	0.000286	-0.25	-0.19	Coronary artery disease;	chr3:48287546	chr1:27649419~27649610:+
BRCA	trans	rs2572431	0.543	rs2256016	ENSG00000253893.2	FAM85B	-6.33	3.65e-10	0.000286	-0.25	-0.19	Neuroticism;	chr8:11305093	chr8:8167819~8226614:-
BRCA	trans	rs9393777	0.778	rs35526527	ENSG00000253570.1	RNF5P1	6.33	3.66e-10	0.000287	0.44	0.19	Intelligence (multi-trait analysis);	chr6:27074508	chr8:38600661~38601200:-
BRCA	trans	rs11098499	1	rs6849889	ENSG00000276997.3	RP11-378J18.9	6.33	3.66e-10	0.000287	0.24	0.19	Corneal astigmatism;	chr4:119265193	chr1:222477252~222504622:-
BRCA	trans	rs1933488	0.931	rs7740777	ENSG00000180015.12	RP11-756P10.3	6.33	3.67e-10	0.000287	0.24	0.19	Prostate cancer;	chr6:153092174	chr4:188738373~188739494:+
BRCA	trans	rs7830939	0.586	rs28734832	ENSG00000253893.2	FAM85B	-6.33	3.67e-10	0.000287	-0.26	-0.19	Neuroticism;	chr8:9464437	chr8:8167819~8226614:-
BRCA	trans	rs7617773	0.817	rs9819094	ENSG00000235912.1	RP1-159A19.3	-6.33	3.67e-10	0.000288	-0.24	-0.19	Coronary artery disease;	chr3:48278068	chr1:27649419~27649610:+
BRCA	trans	rs875971	0.545	rs67397473	ENSG00000234585.5	CCT6P3	6.33	3.67e-10	0.000288	0.21	0.19	Aortic root size;	chr7:66168318	chr7:65038354~65074713:+
BRCA	trans	rs2060793	0.519	rs1357332	ENSG00000236360.2	RP11-334A14.2	6.33	3.68e-10	0.000289	0.24	0.19	Vitamin D levels;	chr11:14618570	chr1:52993201~52993702:-
BRCA	trans	rs13196561	0.855	rs71539015	ENSG00000216895.7	AC009403.2	6.33	3.68e-10	0.000289	0.28	0.19	Menarche (age at onset);	chr6:100255617	chr7:155611231~155645205:-
BRCA	trans	rs17767294	0.614	rs72845061	ENSG00000242375.1	RP11-498P14.3	-6.33	3.69e-10	0.000289	-0.53	-0.19	Parkinson's disease;	chr6:27685482	chr9:97195351~97197687:-
BRCA	trans	rs875971	0.502	rs6460311	ENSG00000234585.5	CCT6P3	-6.33	3.69e-10	0.000289	-0.21	-0.19	Aortic root size;	chr7:66646886	chr7:65038354~65074713:+
BRCA	trans	rs2243480	0.908	rs4718273	ENSG00000232546.1	RP11-458F8.1	6.33	3.7e-10	0.00029	0.25	0.19	Diabetic kidney disease;	chr7:65751112	chr7:66848496~66858136:+
BRCA	trans	rs2243480	1	rs6460260	ENSG00000232546.1	RP11-458F8.1	6.33	3.7e-10	0.00029	0.25	0.19	Diabetic kidney disease;	chr7:65750468	chr7:66848496~66858136:+
BRCA	trans	rs2243480	1	rs6460261	ENSG00000232546.1	RP11-458F8.1	6.33	3.7e-10	0.00029	0.25	0.19	Diabetic kidney disease;	chr7:65750593	chr7:66848496~66858136:+
BRCA	trans	rs11098499	0.526	rs10026625	ENSG00000276997.3	RP11-378J18.9	6.33	3.71e-10	0.000291	0.22	0.19	Corneal astigmatism;	chr4:119358981	chr1:222477252~222504622:-
BRCA	trans	rs875971	0.545	rs2460427	ENSG00000234585.5	CCT6P3	-6.33	3.71e-10	0.000291	-0.21	-0.19	Aortic root size;	chr7:66154218	chr7:65038354~65074713:+
BRCA	trans	rs7662987	0.517	rs2602872	ENSG00000233859.2	ADH5P4	-6.33	3.72e-10	0.000291	-0.27	-0.19	Smoking initiation;	chr4:99117845	chr6:65836930~65838039:-
BRCA	trans	rs17301013	0.932	rs67967476	ENSG00000213331.4	RP11-713C19.2	6.33	3.72e-10	0.000291	0.22	0.19	Systemic lupus erythematosus;	chr1:174616119	chr4:187970273~187971284:+
BRCA	trans	rs7568458	0.87	rs1972297	ENSG00000223886.3	RP11-251G23.2	6.33	3.72e-10	0.000291	0.22	0.19	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr2:85581450	chr7:105530209~105530671:+
BRCA	trans	rs7617773	0.78	rs11716848	ENSG00000235912.1	RP1-159A19.3	-6.33	3.73e-10	0.000292	-0.26	-0.19	Coronary artery disease;	chr3:48337010	chr1:27649419~27649610:+
BRCA	trans	rs1707322	0.686	rs11211179	ENSG00000255397.1	AC022182.2	-6.33	3.73e-10	0.000292	-0.25	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45762410	chr8:60937705~60939871:-
BRCA	trans	rs1707322	0.721	rs10157795	ENSG00000255397.1	AC022182.2	-6.33	3.73e-10	0.000292	-0.25	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45762520	chr8:60937705~60939871:-
BRCA	trans	rs9467711	0.559	rs12176129	ENSG00000253570.1	RNF5P1	6.33	3.74e-10	0.000293	0.41	0.19	Autism spectrum disorder or schizophrenia;	chr6:26514712	chr8:38600661~38601200:-
BRCA	trans	rs2899832	0.568	rs7158019	ENSG00000215414.4	PSMA6P1	6.33	3.74e-10	0.000293	0.34	0.19	Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:35305912	chrY:13286638~13287378:+
BRCA	trans	rs9393777	0.72	rs13217285	ENSG00000253570.1	RNF5P1	6.32	3.75e-10	0.000294	0.43	0.19	Intelligence (multi-trait analysis);	chr6:27032066	chr8:38600661~38601200:-
BRCA	trans	rs616147	0.627	rs9871799	ENSG00000239269.1	RPSAP4	6.32	3.77e-10	0.000295	0.21	0.19	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39442829	chr14:94726288~94727175:+
BRCA	trans	rs7824557	0.65	rs2572406	ENSG00000253893.2	FAM85B	-6.32	3.81e-10	0.000298	-0.23	-0.19	Retinal vascular caliber;	chr8:11234743	chr8:8167819~8226614:-
BRCA	trans	rs877636	0.847	rs2017445	ENSG00000212994.5	RPS26P6	6.32	3.81e-10	0.000299	0.4	0.19	Cognitive function;	chr12:56013288	chr8:100895771~100896118:+
BRCA	trans	rs9329221	0.617	rs483916	ENSG00000255046.1	RP11-297N6.4	6.32	3.83e-10	0.000299	0.22	0.19	Neuroticism;	chr8:9936091	chr8:11797928~11802568:-
BRCA	trans	rs1707322	1	rs6429580	ENSG00000255397.1	AC022182.2	-6.32	3.84e-10	3e-04	-0.25	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45809976	chr8:60937705~60939871:-
BRCA	trans	rs7617773	0.817	rs13100815	ENSG00000235912.1	RP1-159A19.3	-6.32	3.85e-10	0.000301	-0.26	-0.19	Coronary artery disease;	chr3:48245959	chr1:27649419~27649610:+
BRCA	trans	rs875971	0.545	rs6969224	ENSG00000213640.3	EEF1DP4	-6.32	3.86e-10	0.000302	-0.28	-0.19	Aortic root size;	chr7:66370011	chr7:64862999~64864370:+
BRCA	trans	rs860295	0.812	rs12081192	ENSG00000241627.3	UBQLN4P1	-6.32	3.86e-10	0.000302	-0.2	-0.19	Body mass index;	chr1:155768253	chr3:148985868~148987668:-
BRCA	trans	rs9649213	0.574	rs34830366	ENSG00000225169.1	BRI3P1	6.32	3.86e-10	0.000302	0.25	0.19	Prostate cancer (SNP x SNP interaction);	chr7:98270223	chr1:100213293~100213670:+
BRCA	trans	rs9649213	0.593	rs34776142	ENSG00000225169.1	BRI3P1	6.32	3.86e-10	0.000302	0.25	0.19	Prostate cancer (SNP x SNP interaction);	chr7:98270561	chr1:100213293~100213670:+
BRCA	trans	rs2272306	0.539	rs1852446	ENSG00000228753.1	EIF4BP2	6.32	3.87e-10	0.000303	0.29	0.19	Obesity-related traits;	chr12:53134791	chr10:21028999~21030792:+
BRCA	trans	rs11638815	0.581	rs28808991	ENSG00000235370.6	DNM1P51	-6.32	3.87e-10	0.000303	-0.21	-0.19	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82592229	chr15:84398316~84411701:-
BRCA	trans	rs7617773	0.817	rs11709691	ENSG00000235912.1	RP1-159A19.3	-6.32	3.89e-10	0.000304	-0.26	-0.19	Coronary artery disease;	chr3:48262179	chr1:27649419~27649610:+
BRCA	trans	rs11098499	0.644	rs7693919	ENSG00000120555.12	SEPT7P9	6.32	3.89e-10	0.000304	0.23	0.19	Corneal astigmatism;	chr4:119619416	chr10:38383069~38402916:-
BRCA	trans	rs7617773	0.784	rs11715799	ENSG00000235912.1	RP1-159A19.3	-6.32	3.89e-10	0.000304	-0.26	-0.19	Coronary artery disease;	chr3:48213730	chr1:27649419~27649610:+
BRCA	trans	rs1707322	1	rs10890382	ENSG00000255397.1	AC022182.2	-6.32	3.89e-10	0.000304	-0.26	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46004002	chr8:60937705~60939871:-
BRCA	trans	rs875971	0.545	rs10261710	ENSG00000213640.3	EEF1DP4	-6.32	3.9e-10	0.000305	-0.28	-0.19	Aortic root size;	chr7:66249202	chr7:64862999~64864370:+
BRCA	trans	rs7830939	0.586	rs28586878	ENSG00000253893.2	FAM85B	-6.32	3.91e-10	0.000305	-0.26	-0.19	Neuroticism;	chr8:9464634	chr8:8167819~8226614:-
BRCA	trans	rs17301013	0.9	rs1754351	ENSG00000213331.4	RP11-713C19.2	-6.32	3.91e-10	0.000306	-0.21	-0.19	Systemic lupus erythematosus;	chr1:174762458	chr4:187970273~187971284:+
BRCA	trans	rs9393777	0.92	rs67859638	ENSG00000281831.1	HCP5B	6.32	3.92e-10	0.000306	0.51	0.19	Intelligence (multi-trait analysis);	chr6:27390199	chr6:29871895~29873783:-
BRCA	trans	rs875971	0.545	rs7810213	ENSG00000213640.3	EEF1DP4	-6.32	3.92e-10	0.000306	-0.28	-0.19	Aortic root size;	chr7:66481592	chr7:64862999~64864370:+
BRCA	trans	rs875971	0.666	rs13242072	ENSG00000164669.11	INTS4P1	6.32	3.93e-10	0.000307	0.24	0.19	Aortic root size;	chr7:66301001	chr7:65141225~65234216:+
BRCA	trans	rs11098499	0.754	rs11732087	ENSG00000120555.12	SEPT7P9	6.32	3.93e-10	0.000307	0.23	0.19	Corneal astigmatism;	chr4:119318676	chr10:38383069~38402916:-
BRCA	trans	rs860295	0.812	rs12407800	ENSG00000241627.3	UBQLN4P1	-6.32	3.94e-10	0.000308	-0.2	-0.19	Body mass index;	chr1:155790951	chr3:148985868~148987668:-
BRCA	trans	rs1707322	1	rs11211190	ENSG00000255397.1	AC022182.2	-6.32	3.94e-10	0.000308	-0.25	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45800583	chr8:60937705~60939871:-
BRCA	trans	rs2220004	0.963	rs10897536	ENSG00000134612.10	FOLH1B	-6.32	3.94e-10	0.000308	-0.25	-0.19	Odorant perception (&beta-damascenone);	chr11:56042967	chr11:89639227~89698718:+
BRCA	trans	rs11098499	0.754	rs1849457	ENSG00000120555.12	SEPT7P9	6.32	3.95e-10	0.000309	0.23	0.19	Corneal astigmatism;	chr4:119333200	chr10:38383069~38402916:-
BRCA	trans	rs1580019	0.587	rs9638880	ENSG00000213492.2	NT5C3AP1	-6.32	3.95e-10	0.000309	-0.26	-0.19	Cognitive ability;	chr7:32512789	chr4:117574512~117576174:-
BRCA	trans	rs7617773	0.817	rs35414021	ENSG00000235912.1	RP1-159A19.3	-6.32	3.96e-10	0.000309	-0.25	-0.19	Coronary artery disease;	chr3:48252034	chr1:27649419~27649610:+
BRCA	trans	rs2122469	0.655	rs17603934	ENSG00000173295.6	FAM86B3P	6.32	3.97e-10	0.00031	0.29	0.19	Serum tamsulosin hydrochloride concentration;	chr8:20718833	chr8:8228595~8244865:+
BRCA	trans	rs7032940	0.954	rs12553530	ENSG00000228236.2	TXNP5	6.32	3.98e-10	0.000311	0.26	0.19	Height;	chr9:110188455	chr2:149068596~149068910:-
BRCA	trans	rs2117029	0.555	rs7958241	ENSG00000214391.3	TUBAP2	-6.31	3.99e-10	0.000312	-0.18	-0.19	Intelligence (multi-trait analysis);	chr12:49115479	chr11:90282560~90284172:+
BRCA	trans	rs7829975	0.606	rs11776838	ENSG00000270154.1	RP11-419I17.1	-6.31	4.02e-10	0.000314	-0.21	-0.19	Mood instability;	chr8:8937291	chr8:12476462~12477122:+
BRCA	trans	rs11638815	0.859	rs12437785	ENSG00000235370.6	DNM1P51	6.31	4.02e-10	0.000314	0.24	0.19	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82718605	chr15:84398316~84411701:-
BRCA	trans	rs11638815	0.603	rs783520	ENSG00000235370.6	DNM1P51	-6.31	4.03e-10	0.000314	-0.21	-0.19	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82610755	chr15:84398316~84411701:-
BRCA	trans	rs2002594	0.816	rs57542866	ENSG00000267076.1	CCDC58P3	-6.31	4.04e-10	0.000315	-0.22	-0.19	Risky sexual behaviors (alcohol dependence interaction);	chr3:122519606	chr18:12211378~12211807:+
BRCA	trans	rs7826222	0.632	rs1962448	ENSG00000253893.2	FAM85B	6.31	4.04e-10	0.000316	0.34	0.19	Adiposity;	chr8:10014461	chr8:8167819~8226614:-
BRCA	trans	rs9462846	0.919	rs9462844	ENSG00000231579.3	RPL7P21	6.31	4.05e-10	0.000316	0.27	0.19	Blood protein levels;	chr6:42888764	chr5:143332605~143333239:+
BRCA	trans	rs875971	0.545	rs2420612	ENSG00000234585.5	CCT6P3	6.31	4.05e-10	0.000316	0.21	0.19	Aortic root size;	chr7:66536825	chr7:65038354~65074713:+
BRCA	trans	rs7927771	0.793	rs3740686	ENSG00000134612.10	FOLH1B	6.31	4.06e-10	0.000317	0.25	0.19	Subjective well-being;	chr11:47354812	chr11:89639227~89698718:+
BRCA	trans	rs1707322	0.964	rs6675259	ENSG00000255397.1	AC022182.2	6.31	4.06e-10	0.000317	0.26	0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46036623	chr8:60937705~60939871:-
BRCA	trans	rs875971	0.545	rs2279757	ENSG00000213640.3	EEF1DP4	-6.31	4.07e-10	0.000317	-0.28	-0.19	Aortic root size;	chr7:66363676	chr7:64862999~64864370:+
BRCA	trans	rs875971	0.545	rs11766183	ENSG00000213640.3	EEF1DP4	-6.31	4.07e-10	0.000317	-0.28	-0.19	Aortic root size;	chr7:66374173	chr7:64862999~64864370:+
BRCA	trans	rs875971	0.545	rs1065265	ENSG00000213640.3	EEF1DP4	-6.31	4.07e-10	0.000317	-0.28	-0.19	Aortic root size;	chr7:66376216	chr7:64862999~64864370:+
BRCA	trans	rs11098499	0.754	rs66900435	ENSG00000120555.12	SEPT7P9	6.31	4.09e-10	0.000319	0.23	0.19	Corneal astigmatism;	chr4:119328270	chr10:38383069~38402916:-
BRCA	trans	rs4879656	0.872	rs10813930	ENSG00000215007.3	DNAJA1P3	6.31	4.1e-10	0.000319	0.23	0.19	Menopause (age at onset);	chr9:33064338	chrX:107351650~107352843:-
BRCA	trans	rs7647973	1	rs9842132	ENSG00000197582.5	GPX1P1	-6.31	4.1e-10	0.00032	-0.21	-0.19	Menarche (age at onset);	chr3:49390500	chrX:13378735~13379340:-
BRCA	trans	rs2242330	0.906	rs6829533	ENSG00000226982.4	CENPCP1	6.31	4.1e-10	0.00032	0.27	0.19	Parkinson's disease;	chr4:67534028	chr12:89500093~89502670:+
BRCA	trans	rs2242330	0.906	rs1157087	ENSG00000226982.4	CENPCP1	6.31	4.1e-10	0.00032	0.27	0.19	Parkinson's disease;	chr4:67537244	chr12:89500093~89502670:+
BRCA	trans	rs2242330	0.862	rs1157088	ENSG00000226982.4	CENPCP1	6.31	4.1e-10	0.00032	0.27	0.19	Parkinson's disease;	chr4:67537256	chr12:89500093~89502670:+
BRCA	trans	rs714543	1	rs10278679	ENSG00000219797.2	PPIAP9	-6.31	4.1e-10	0.00032	-0.24	-0.19	Plateletcrit;	chr7:44825465	chr6:31519480~31520291:-
BRCA	trans	rs853679	1	rs2799077	ENSG00000253570.1	RNF5P1	6.31	4.11e-10	0.00032	0.37	0.19	Depression;	chr6:28266819	chr8:38600661~38601200:-
BRCA	trans	rs11098499	1	rs3749591	ENSG00000276997.3	RP11-378J18.9	6.31	4.12e-10	0.000321	0.25	0.19	Corneal astigmatism;	chr4:119292875	chr1:222477252~222504622:-
BRCA	trans	rs902774	0.759	rs4919707	ENSG00000255815.3	KRT8P11	-6.31	4.13e-10	0.000322	-0.41	-0.19	Prostate cancer;	chr12:52895864	chr9:99305176~99306611:+
BRCA	trans	rs17301013	0.932	rs12074753	ENSG00000213331.4	RP11-713C19.2	6.31	4.14e-10	0.000323	0.21	0.19	Systemic lupus erythematosus;	chr1:174565768	chr4:187970273~187971284:+
BRCA	trans	rs17301013	0.932	rs1016466	ENSG00000213331.4	RP11-713C19.2	6.31	4.14e-10	0.000323	0.21	0.19	Systemic lupus erythematosus;	chr1:174570652	chr4:187970273~187971284:+
BRCA	trans	rs17301013	0.932	rs10753086	ENSG00000213331.4	RP11-713C19.2	6.31	4.14e-10	0.000323	0.21	0.19	Systemic lupus erythematosus;	chr1:174580802	chr4:187970273~187971284:+
BRCA	trans	rs853679	0.546	rs200996	ENSG00000253570.1	RNF5P1	6.31	4.16e-10	0.000324	0.43	0.19	Depression;	chr6:27844050	chr8:38600661~38601200:-
BRCA	trans	rs4929949	0.78	rs9284151	ENSG00000266891.1	RP11-692N5.2	-6.31	4.19e-10	0.000327	-0.23	-0.19	Body mass index;	chr11:8577453	chr18:9734882~9735602:-
BRCA	trans	rs853679	1	rs1778511	ENSG00000253570.1	RNF5P1	-6.31	4.21e-10	0.000328	-0.37	-0.19	Depression;	chr6:28261633	chr8:38600661~38601200:-
BRCA	trans	rs902774	0.818	rs56095813	ENSG00000254285.3	KRT8P3	-6.31	4.21e-10	0.000328	-0.39	-0.19	Prostate cancer;	chr12:52900963	chr8:61578220~61579668:+
BRCA	trans	rs4879656	0.872	rs1537039	ENSG00000215007.3	DNAJA1P3	6.3	4.25e-10	0.000331	0.23	0.19	Menopause (age at onset);	chr9:33061718	chrX:107351650~107352843:-
BRCA	trans	rs875971	1	rs7792762	ENSG00000164669.11	INTS4P1	-6.3	4.27e-10	0.000332	-0.24	-0.19	Aortic root size;	chr7:66539151	chr7:65141225~65234216:+
BRCA	trans	rs2840044	1	rs225243	ENSG00000234130.2	RP13-88F20.1	-6.3	4.27e-10	0.000332	-0.22	-0.19	Response to radiotherapy in cancer (late toxicity);	chr17:35620193	chrX:93222220~93225015:-
BRCA	trans	rs3812762	0.871	rs2173999	ENSG00000266891.1	RP11-692N5.2	-6.3	4.27e-10	0.000333	-0.23	-0.19	Hypospadias;	chr11:8756530	chr18:9734882~9735602:-
BRCA	trans	rs12210905	1	rs9368493	ENSG00000242375.1	RP11-498P14.3	-6.3	4.28e-10	0.000333	-0.4	-0.19	Hip circumference adjusted for BMI;	chr6:27260521	chr9:97195351~97197687:-
BRCA	trans	rs7824557	0.564	rs13260727	ENSG00000254153.1	CTA-398F10.2	6.3	4.3e-10	0.000335	0.24	0.19	Retinal vascular caliber;	chr8:11375351	chr8:8456909~8461337:-
BRCA	trans	rs875971	0.545	rs73150604	ENSG00000213640.3	EEF1DP4	-6.3	4.3e-10	0.000335	-0.27	-0.19	Aortic root size;	chr7:66480545	chr7:64862999~64864370:+
BRCA	trans	rs7819412	0.521	rs2409720	ENSG00000253893.2	FAM85B	6.3	4.31e-10	0.000336	0.25	0.19	Triglycerides;	chr8:11180394	chr8:8167819~8226614:-
BRCA	trans	rs11098499	0.754	rs1980027	ENSG00000120555.12	SEPT7P9	6.3	4.32e-10	0.000336	0.23	0.19	Corneal astigmatism;	chr4:119330422	chr10:38383069~38402916:-
BRCA	trans	rs1707322	1	rs10890365	ENSG00000255397.1	AC022182.2	-6.3	4.32e-10	0.000336	-0.25	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45893676	chr8:60937705~60939871:-
BRCA	trans	rs2220004	1	rs2220004	ENSG00000134612.10	FOLH1B	6.3	4.34e-10	0.000338	0.25	0.19	Odorant perception (&beta-damascenone);	chr11:56128269	chr11:89639227~89698718:+
BRCA	trans	rs4834770	1	rs878374	ENSG00000275858.1	RP11-291L22.8	6.3	4.35e-10	0.000338	0.22	0.19	Blood protein levels;	chr4:119316409	chr10:38450738~38451069:-
BRCA	trans	rs1391708	0.688	rs7304127	ENSG00000121089.4	NACA3P	-6.3	4.36e-10	0.000339	-0.28	-0.19	Airway wall thickness;	chr12:56925098	chr4:164943290~164943937:+
BRCA	trans	rs11785693	0.862	rs10503292	ENSG00000246089.3	RP11-115C21.2	-6.3	4.38e-10	0.00034	-0.27	-0.19	Neuroticism (multi-trait analysis);Neuroticism;	chr8:5134753	chr8:6403551~6407142:-
BRCA	trans	rs4930561	0.765	rs7931502	ENSG00000155070.8	UNC93B2	6.3	4.38e-10	0.00034	0.22	0.19	Breast cancer in childhood cancer survivors;IgG glycosylation;	chr11:68192140	chr7:6855485~6859830:-
BRCA	trans	rs9467711	0.606	rs67234939	ENSG00000253570.1	RNF5P1	6.3	4.41e-10	0.000343	0.4	0.19	Autism spectrum disorder or schizophrenia;	chr6:26530191	chr8:38600661~38601200:-
BRCA	trans	rs17301013	0.932	rs7542389	ENSG00000213331.4	RP11-713C19.2	6.3	4.41e-10	0.000343	0.21	0.19	Systemic lupus erythematosus;	chr1:174565104	chr4:187970273~187971284:+
BRCA	trans	rs902774	0.818	rs55999178	ENSG00000255815.3	KRT8P11	-6.3	4.43e-10	0.000344	-0.41	-0.19	Prostate cancer;	chr12:52890576	chr9:99305176~99306611:+
BRCA	trans	rs853679	0.546	rs34295134	ENSG00000253570.1	RNF5P1	6.3	4.45e-10	0.000346	0.43	0.19	Depression;	chr6:27860373	chr8:38600661~38601200:-
BRCA	trans	rs1707322	0.721	rs11211181	ENSG00000255397.1	AC022182.2	-6.3	4.46e-10	0.000347	-0.25	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45771128	chr8:60937705~60939871:-
BRCA	trans	rs902774	0.818	rs4919743	ENSG00000240668.1	KRT8P36	-6.3	4.48e-10	0.000348	-0.34	-0.19	Prostate cancer;	chr12:52915800	chr3:138101478~138102917:-
BRCA	trans	rs17507216	0.628	rs4627310	ENSG00000259295.5	CSPG4P12	-6.3	4.5e-10	0.000349	-0.31	-0.19	Excessive daytime sleepiness;	chr15:82708330	chr15:85191438~85213905:+
BRCA	trans	rs2220004	0.963	rs2460218	ENSG00000134612.10	FOLH1B	-6.3	4.5e-10	0.00035	-0.25	-0.19	Odorant perception (&beta-damascenone);	chr11:56104846	chr11:89639227~89698718:+
BRCA	trans	rs1707322	0.896	rs809774	ENSG00000255397.1	AC022182.2	6.3	4.51e-10	0.00035	0.25	0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46094572	chr8:60937705~60939871:-
BRCA	trans	rs1707322	0.927	rs11211194	ENSG00000255397.1	AC022182.2	-6.29	4.53e-10	0.000352	-0.25	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45816412	chr8:60937705~60939871:-
BRCA	trans	rs2965280	0.793	rs10426139	ENSG00000270983.1	RP11-137J7.3	-6.29	4.53e-10	0.000352	-0.44	-0.19	Colorectal cancer;	chr19:34295230	chr6:142062717~142063053:+
BRCA	trans	rs4929949	0.78	rs4131072	ENSG00000266891.1	RP11-692N5.2	-6.29	4.54e-10	0.000352	-0.23	-0.19	Body mass index;	chr11:8580905	chr18:9734882~9735602:-
BRCA	trans	rs9834975	0.565	rs4485669	ENSG00000267076.1	CCDC58P3	-6.29	4.54e-10	0.000353	-0.22	-0.19	Diastolic blood pressure;	chr3:122515768	chr18:12211378~12211807:+
BRCA	trans	rs10838687	0.8	rs4752977	ENSG00000134612.10	FOLH1B	6.29	4.55e-10	0.000354	0.28	0.19	Proinsulin levels;	chr11:47278878	chr11:89639227~89698718:+
BRCA	trans	rs9914988	0.619	rs9898529	ENSG00000267449.1	RP11-264B14.2	6.29	4.58e-10	0.000356	0.28	0.19	Glycated hemoglobin levels;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr17:28991843	chr17:61069856~61070356:-
BRCA	trans	rs11039389	1	rs11039389	ENSG00000134612.10	FOLH1B	-6.29	4.59e-10	0.000357	-0.26	-0.19	Neuroticism;	chr11:47774510	chr11:89639227~89698718:+
BRCA	trans	rs11098499	0.754	rs28643450	ENSG00000120555.12	SEPT7P9	6.29	4.6e-10	0.000357	0.23	0.19	Corneal astigmatism;	chr4:119324087	chr10:38383069~38402916:-
BRCA	trans	rs12439619	0.739	rs62012046	ENSG00000235370.6	DNM1P51	-6.29	4.6e-10	0.000357	-0.27	-0.19	Intelligence (multi-trait analysis);	chr15:82236824	chr15:84398316~84411701:-
BRCA	trans	rs12439619	0.774	rs62012047	ENSG00000235370.6	DNM1P51	-6.29	4.6e-10	0.000357	-0.27	-0.19	Intelligence (multi-trait analysis);	chr15:82236852	chr15:84398316~84411701:-
BRCA	trans	rs875971	0.545	rs73150604	ENSG00000234585.5	CCT6P3	6.29	4.61e-10	0.000358	0.21	0.19	Aortic root size;	chr7:66480545	chr7:65038354~65074713:+
BRCA	trans	rs7260598	0.818	rs11666653	ENSG00000261770.1	CTC-459F4.1	6.29	4.61e-10	0.000358	0.32	0.19	Response to taxane treatment (placlitaxel);	chr19:24037440	chr19:27757184~27760849:-
BRCA	trans	rs12439619	0.81	rs62012049	ENSG00000235370.6	DNM1P51	-6.29	4.61e-10	0.000358	-0.27	-0.19	Intelligence (multi-trait analysis);	chr15:82237722	chr15:84398316~84411701:-
BRCA	trans	rs875971	0.706	rs1643374	ENSG00000164669.11	INTS4P1	-6.29	4.62e-10	0.000359	-0.24	-0.19	Aortic root size;	chr7:66407695	chr7:65141225~65234216:+
BRCA	trans	rs14057	0.827	rs6682920	ENSG00000215869.3	RP11-364B6.1	6.29	4.62e-10	0.000359	0.25	0.19	Systolic blood pressure;	chr1:6585807	chr1:104073023~104077087:+
BRCA	trans	rs11098499	0.754	rs7672778	ENSG00000120555.12	SEPT7P9	6.29	4.63e-10	0.00036	0.23	0.19	Corneal astigmatism;	chr4:119327430	chr10:38383069~38402916:-
BRCA	trans	rs6921919	1	rs6921919	ENSG00000228078.1	HLA-U	-6.29	4.66e-10	0.000361	-0.3	-0.19	Autism spectrum disorder or schizophrenia;	chr6:28357424	chr6:29934101~29934286:+
BRCA	trans	rs1707322	1	rs4073847	ENSG00000255397.1	AC022182.2	6.29	4.69e-10	0.000364	0.25	0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45997340	chr8:60937705~60939871:-
BRCA	trans	rs2899832	0.568	rs8017676	ENSG00000215414.4	PSMA6P1	6.29	4.7e-10	0.000364	0.33	0.19	Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:35293460	chrY:13286638~13287378:+
BRCA	trans	rs1707322	1	rs10890370	ENSG00000255397.1	AC022182.2	-6.29	4.71e-10	0.000366	-0.25	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45923545	chr8:60937705~60939871:-
BRCA	trans	rs17507216	0.718	rs72751675	ENSG00000235370.6	DNM1P51	-6.29	4.71e-10	0.000366	-0.28	-0.19	Excessive daytime sleepiness;	chr15:82630452	chr15:84398316~84411701:-
BRCA	trans	rs11098499	0.754	rs10213554	ENSG00000120555.12	SEPT7P9	-6.29	4.72e-10	0.000366	-0.23	-0.19	Corneal astigmatism;	chr4:119339630	chr10:38383069~38402916:-
BRCA	trans	rs2220004	1	rs10896103	ENSG00000134612.10	FOLH1B	6.29	4.73e-10	0.000367	0.25	0.19	Odorant perception (&beta-damascenone);	chr11:56176572	chr11:89639227~89698718:+
BRCA	trans	rs7647973	1	rs3448	ENSG00000197582.5	GPX1P1	6.29	4.73e-10	0.000367	0.21	0.19	Menarche (age at onset);	chr3:49359318	chrX:13378735~13379340:-
BRCA	trans	rs7647973	1	rs11130190	ENSG00000197582.5	GPX1P1	6.29	4.73e-10	0.000367	0.21	0.19	Menarche (age at onset);	chr3:49364704	chrX:13378735~13379340:-
BRCA	trans	rs1707322	1	rs12077974	ENSG00000255397.1	AC022182.2	-6.29	4.74e-10	0.000367	-0.26	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45918469	chr8:60937705~60939871:-
BRCA	trans	rs864643	1	rs574074	ENSG00000188856.6	RPSAP47	6.29	4.76e-10	0.000369	0.31	0.19	Attention deficit hyperactivity disorder;	chr3:39520090	chr8:80558870~80559757:+
BRCA	trans	rs875971	0.545	rs6979636	ENSG00000213640.3	EEF1DP4	-6.29	4.76e-10	0.000369	-0.27	-0.19	Aortic root size;	chr7:66276638	chr7:64862999~64864370:+
BRCA	trans	rs7113874	0.545	rs7122890	ENSG00000266891.1	RP11-692N5.2	6.29	4.76e-10	0.000369	0.23	0.19	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8382059	chr18:9734882~9735602:-
BRCA	trans	rs7617773	0.817	rs13072018	ENSG00000235912.1	RP1-159A19.3	-6.29	4.77e-10	0.00037	-0.25	-0.19	Coronary artery disease;	chr3:48278842	chr1:27649419~27649610:+
BRCA	trans	rs13196561	0.855	rs13213230	ENSG00000216895.7	AC009403.2	6.29	4.78e-10	0.00037	0.27	0.19	Menarche (age at onset);	chr6:100250904	chr7:155611231~155645205:-
BRCA	trans	rs6011368	0.74	rs6062679	ENSG00000226210.3	WASH7P	6.29	4.79e-10	0.000371	0.21	0.19	Clozapine-induced cytotoxicity;	chr20:64258638	chr12:14522~32015:-
BRCA	trans	rs7617773	0.817	rs34225441	ENSG00000235912.1	RP1-159A19.3	-6.29	4.8e-10	0.000372	-0.26	-0.19	Coronary artery disease;	chr3:48267401	chr1:27649419~27649610:+
BRCA	trans	rs902774	0.818	rs55914512	ENSG00000255815.3	KRT8P11	-6.29	4.8e-10	0.000372	-0.41	-0.19	Prostate cancer;	chr12:52888490	chr9:99305176~99306611:+
BRCA	trans	rs902774	0.818	rs73108466	ENSG00000255815.3	KRT8P11	-6.29	4.8e-10	0.000372	-0.41	-0.19	Prostate cancer;	chr12:52889857	chr9:99305176~99306611:+
BRCA	trans	rs1223245	0.74	rs360063	ENSG00000235655.3	H3F3AP4	-6.29	4.81e-10	0.000373	-0.22	-0.19	Preschool internalizing problems;	chr1:225848608	chr2:174719908~174720318:+
BRCA	trans	rs2066819	1	rs41423244	ENSG00000273654.1	CTB-52I2.4	-6.28	4.81e-10	0.000373	-0.49	-0.19	Psoriasis vulgaris;	chr12:56299736	chr19:18022403~18032099:+
BRCA	trans	rs2055729	0.736	rs11249965	ENSG00000253893.2	FAM85B	6.28	4.82e-10	0.000373	0.25	0.19	Multiple myeloma (hyperdiploidy);	chr8:9883353	chr8:8167819~8226614:-
BRCA	trans	rs4930561	0.765	rs1894204	ENSG00000155070.8	UNC93B2	-6.28	4.82e-10	0.000373	-0.22	-0.19	Breast cancer in childhood cancer survivors;IgG glycosylation;	chr11:68162204	chr7:6855485~6859830:-
BRCA	trans	rs17301013	0.932	rs1793297	ENSG00000213331.4	RP11-713C19.2	-6.28	4.86e-10	0.000376	-0.21	-0.19	Systemic lupus erythematosus;	chr1:174784411	chr4:187970273~187971284:+
BRCA	trans	rs4879656	0.8	rs10971379	ENSG00000215007.3	DNAJA1P3	6.28	4.86e-10	0.000376	0.23	0.19	Menopause (age at onset);	chr9:33064932	chrX:107351650~107352843:-
BRCA	trans	rs1933488	0.504	rs1281958	ENSG00000278974.1	RP11-756P10.6	6.28	4.86e-10	0.000377	0.25	0.19	Prostate cancer;	chr6:153136545	chr4:188740507~188741281:-
BRCA	trans	rs1580019	0.563	rs13225132	ENSG00000213492.2	NT5C3AP1	-6.28	4.88e-10	0.000378	-0.26	-0.19	Cognitive ability;	chr7:32761363	chr4:117574512~117576174:-
BRCA	trans	rs853679	1	rs1679732	ENSG00000253570.1	RNF5P1	-6.28	4.9e-10	0.00038	-0.37	-0.19	Depression;	chr6:28253486	chr8:38600661~38601200:-
BRCA	trans	rs12210905	1	rs9368492	ENSG00000242375.1	RP11-498P14.3	-6.28	4.95e-10	0.000383	-0.4	-0.19	Hip circumference adjusted for BMI;	chr6:27253739	chr9:97195351~97197687:-
BRCA	trans	rs1707322	1	rs785486	ENSG00000255397.1	AC022182.2	6.28	4.96e-10	0.000384	0.25	0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46109476	chr8:60937705~60939871:-
BRCA	trans	rs4879656	0.872	rs7876033	ENSG00000215007.3	DNAJA1P3	6.28	4.97e-10	0.000385	0.23	0.19	Menopause (age at onset);	chr9:33058561	chrX:107351650~107352843:-
BRCA	trans	rs7647973	0.922	rs7620024	ENSG00000197582.5	GPX1P1	-6.28	5.01e-10	0.000387	-0.21	-0.19	Menarche (age at onset);	chr3:49414258	chrX:13378735~13379340:-
BRCA	trans	rs511515	1	rs511515	ENSG00000175730.8	BAK1P1	6.28	5.01e-10	0.000388	0.26	0.19	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr6:33573730	chr20:32690180~32690815:-
BRCA	trans	rs875971	0.545	rs17138156	ENSG00000234585.5	CCT6P3	6.28	5.05e-10	0.00039	0.21	0.19	Aortic root size;	chr7:66249708	chr7:65038354~65074713:+
BRCA	trans	rs864643	0.945	rs1768254	ENSG00000188856.6	RPSAP47	6.28	5.05e-10	0.000391	0.3	0.19	Attention deficit hyperactivity disorder;	chr3:39506929	chr8:80558870~80559757:+
BRCA	trans	rs380904	0.517	rs11775744	ENSG00000213130.3	EEF1DP5	-6.28	5.05e-10	0.000391	-0.23	-0.19	Venous thromboembolism (SNP x SNP interaction);	chr8:143567022	chr6:128580113~128580884:-
BRCA	trans	rs2965280	1	rs2910412	ENSG00000270983.1	RP11-137J7.3	-6.28	5.06e-10	0.000392	-0.43	-0.19	Colorectal cancer;	chr19:34430256	chr6:142062717~142063053:+
BRCA	trans	rs12439619	0.693	rs28689861	ENSG00000235370.6	DNM1P51	-6.28	5.1e-10	0.000394	-0.25	-0.19	Intelligence (multi-trait analysis);	chr15:82206369	chr15:84398316~84411701:-
BRCA	trans	rs11098499	0.754	rs12513083	ENSG00000120555.12	SEPT7P9	6.28	5.11e-10	0.000395	0.23	0.19	Corneal astigmatism;	chr4:119328457	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.754	rs12509621	ENSG00000120555.12	SEPT7P9	6.28	5.11e-10	0.000395	0.23	0.19	Corneal astigmatism;	chr4:119328505	chr10:38383069~38402916:-
BRCA	trans	rs2243480	1	rs4718269	ENSG00000232546.1	RP11-458F8.1	6.28	5.11e-10	0.000395	0.24	0.19	Diabetic kidney disease;	chr7:65735810	chr7:66848496~66858136:+
BRCA	trans	rs66887589	0.616	rs6822808	ENSG00000120555.12	SEPT7P9	6.27	5.12e-10	0.000396	0.22	0.19	Diastolic blood pressure;	chr4:119296210	chr10:38383069~38402916:-
BRCA	trans	rs864643	0.947	rs1708064	ENSG00000188856.6	RPSAP47	6.27	5.13e-10	0.000396	0.28	0.19	Attention deficit hyperactivity disorder;	chr3:39500679	chr8:80558870~80559757:+
BRCA	trans	rs10838687	0.8	rs2290146	ENSG00000134612.10	FOLH1B	6.27	5.16e-10	0.000399	0.28	0.19	Proinsulin levels;	chr11:47331947	chr11:89639227~89698718:+
BRCA	trans	rs6940638	0.688	rs7764984	ENSG00000204709.4	LINC01556	6.27	5.17e-10	4e-04	0.25	0.19	Intelligence (multi-trait analysis);	chr6:27066402	chr6:28943877~28944537:+
BRCA	trans	rs6011368	0.84	rs6062361	ENSG00000226210.3	WASH7P	-6.27	5.18e-10	4e-04	-0.21	-0.19	Clozapine-induced cytotoxicity;	chr20:64273189	chr12:14522~32015:-
BRCA	trans	rs11098499	0.754	rs17595608	ENSG00000120555.12	SEPT7P9	6.27	5.18e-10	4e-04	0.23	0.19	Corneal astigmatism;	chr4:119329351	chr10:38383069~38402916:-
BRCA	trans	rs11992162	0.591	rs4240678	ENSG00000253893.2	FAM85B	6.27	5.19e-10	0.000401	0.23	0.19	Monocyte count;	chr8:11944917	chr8:8167819~8226614:-
BRCA	trans	rs17301013	0.932	rs7555533	ENSG00000213331.4	RP11-713C19.2	6.27	5.2e-10	0.000402	0.21	0.19	Systemic lupus erythematosus;	chr1:174589983	chr4:187970273~187971284:+
BRCA	trans	rs17301013	0.932	rs6671824	ENSG00000213331.4	RP11-713C19.2	6.27	5.2e-10	0.000402	0.21	0.19	Systemic lupus erythematosus;	chr1:174603721	chr4:187970273~187971284:+
BRCA	trans	rs17301013	0.861	rs6672148	ENSG00000213331.4	RP11-713C19.2	6.27	5.2e-10	0.000402	0.21	0.19	Systemic lupus erythematosus;	chr1:174604016	chr4:187970273~187971284:+
BRCA	trans	rs860295	0.756	rs7546258	ENSG00000241627.3	UBQLN4P1	-6.27	5.21e-10	0.000402	-0.2	-0.19	Body mass index;	chr1:155728854	chr3:148985868~148987668:-
BRCA	trans	rs1707322	1	rs1707303	ENSG00000255397.1	AC022182.2	6.27	5.21e-10	0.000402	0.26	0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46132601	chr8:60937705~60939871:-
BRCA	trans	rs902774	0.818	rs55999178	ENSG00000254285.3	KRT8P3	-6.27	5.22e-10	0.000404	-0.4	-0.19	Prostate cancer;	chr12:52890576	chr8:61578220~61579668:+
BRCA	trans	rs1391708	0.688	rs67377945	ENSG00000121089.4	NACA3P	-6.27	5.24e-10	0.000405	-0.28	-0.19	Airway wall thickness;	chr12:56925023	chr4:164943290~164943937:+
BRCA	trans	rs12545912	0.77	rs4841196	ENSG00000253893.2	FAM85B	6.27	5.27e-10	0.000407	0.23	0.19	Multiple myeloma (hyperdiploidy);	chr8:9697582	chr8:8167819~8226614:-
BRCA	trans	rs875971	0.545	rs6460276	ENSG00000234585.5	CCT6P3	6.27	5.29e-10	0.000408	0.21	0.19	Aortic root size;	chr7:66182290	chr7:65038354~65074713:+
BRCA	trans	rs875971	0.571	rs78668714	ENSG00000234585.5	CCT6P3	6.27	5.29e-10	0.000409	0.21	0.19	Aortic root size;	chr7:66474464	chr7:65038354~65074713:+
BRCA	trans	rs7903456	0.648	rs6586053	ENSG00000232706.3	NUTM2HP	6.27	5.31e-10	0.00041	0.25	0.19	Gout;Renal underexcretion gout;	chr10:87070115	chr10:50676743~50686326:+
BRCA	trans	rs11098499	0.754	rs1511017	ENSG00000120555.12	SEPT7P9	6.27	5.33e-10	0.000411	0.23	0.19	Corneal astigmatism;	chr4:119329650	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.789	rs12498994	ENSG00000120555.12	SEPT7P9	6.27	5.33e-10	0.000411	0.23	0.19	Corneal astigmatism;	chr4:119329663	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.754	rs12507565	ENSG00000120555.12	SEPT7P9	6.27	5.33e-10	0.000411	0.23	0.19	Corneal astigmatism;	chr4:119329966	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.826	rs12511640	ENSG00000120555.12	SEPT7P9	6.27	5.33e-10	0.000411	0.23	0.19	Corneal astigmatism;	chr4:119330093	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.754	rs1980026	ENSG00000120555.12	SEPT7P9	6.27	5.33e-10	0.000411	0.23	0.19	Corneal astigmatism;	chr4:119330488	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.743	rs11098501	ENSG00000120555.12	SEPT7P9	6.27	5.33e-10	0.000411	0.23	0.19	Corneal astigmatism;	chr4:119330862	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.754	rs11098502	ENSG00000120555.12	SEPT7P9	6.27	5.33e-10	0.000411	0.23	0.19	Corneal astigmatism;	chr4:119330908	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.708	rs11732686	ENSG00000120555.12	SEPT7P9	6.27	5.33e-10	0.000411	0.23	0.19	Corneal astigmatism;	chr4:119331175	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.754	rs11724409	ENSG00000120555.12	SEPT7P9	6.27	5.33e-10	0.000411	0.23	0.19	Corneal astigmatism;	chr4:119331206	chr10:38383069~38402916:-
BRCA	trans	rs853679	0.538	rs13199081	ENSG00000228078.1	HLA-U	-6.27	5.34e-10	0.000412	-0.28	-0.19	Depression;	chr6:28364057	chr6:29934101~29934286:+
BRCA	trans	rs875971	0.545	rs7787063	ENSG00000234585.5	CCT6P3	6.27	5.35e-10	0.000413	0.21	0.19	Aortic root size;	chr7:66164012	chr7:65038354~65074713:+
BRCA	trans	rs875971	0.545	rs12673308	ENSG00000234585.5	CCT6P3	6.27	5.35e-10	0.000413	0.21	0.19	Aortic root size;	chr7:66166374	chr7:65038354~65074713:+
BRCA	trans	rs546131	0.642	rs1949048	ENSG00000225531.1	RP11-196I18.3	-6.27	5.36e-10	0.000414	-0.31	-0.19	Lung disease severity in cystic fibrosis;	chr11:34815427	chr9:107116829~107117557:+
BRCA	trans	rs546131	0.642	rs1949046	ENSG00000225531.1	RP11-196I18.3	-6.27	5.36e-10	0.000414	-0.31	-0.19	Lung disease severity in cystic fibrosis;	chr11:34815442	chr9:107116829~107117557:+
BRCA	trans	rs9393777	0.92	rs13207689	ENSG00000281831.1	HCP5B	6.27	5.38e-10	0.000415	0.47	0.19	Intelligence (multi-trait analysis);	chr6:27401925	chr6:29871895~29873783:-
BRCA	trans	rs875971	0.545	rs7810213	ENSG00000234585.5	CCT6P3	6.27	5.4e-10	0.000417	0.21	0.19	Aortic root size;	chr7:66481592	chr7:65038354~65074713:+
BRCA	trans	rs17301013	0.932	rs6683602	ENSG00000213331.4	RP11-713C19.2	6.27	5.41e-10	0.000417	0.21	0.19	Systemic lupus erythematosus;	chr1:174617615	chr4:187970273~187971284:+
BRCA	trans	rs17301013	0.932	rs6696197	ENSG00000213331.4	RP11-713C19.2	6.27	5.41e-10	0.000417	0.21	0.19	Systemic lupus erythematosus;	chr1:174617860	chr4:187970273~187971284:+
BRCA	trans	rs1707322	0.929	rs785500	ENSG00000255397.1	AC022182.2	6.27	5.41e-10	0.000417	0.25	0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46127372	chr8:60937705~60939871:-
BRCA	trans	rs7927771	0.832	rs10838698	ENSG00000134612.10	FOLH1B	6.27	5.42e-10	0.000418	0.24	0.19	Subjective well-being;	chr11:47364372	chr11:89639227~89698718:+
BRCA	trans	rs4713118	0.869	rs9468214	ENSG00000204709.4	LINC01556	6.27	5.42e-10	0.000418	0.26	0.19	Parkinson's disease;	chr6:27745520	chr6:28943877~28944537:+
BRCA	trans	rs902774	0.759	rs4919707	ENSG00000254285.3	KRT8P3	-6.27	5.43e-10	0.000419	-0.4	-0.19	Prostate cancer;	chr12:52895864	chr8:61578220~61579668:+
BRCA	trans	rs10028773	0.7	rs7671797	ENSG00000120555.12	SEPT7P9	6.27	5.43e-10	0.000419	0.23	0.19	Educational attainment;	chr4:119327002	chr10:38383069~38402916:-
BRCA	trans	rs3740713	1	rs79199586	ENSG00000236090.2	LDHAP3	6.27	5.44e-10	0.000419	0.39	0.19	Amyotrophic lateral sclerosis (sporadic);	chr11:18430599	chr2:41819747~41820754:+
BRCA	trans	rs1707322	1	rs7517560	ENSG00000255397.1	AC022182.2	-6.27	5.44e-10	0.000419	-0.25	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45960271	chr8:60937705~60939871:-
BRCA	trans	rs6499255	0.951	rs16959025	ENSG00000257513.6	NPIPB1P	-6.27	5.45e-10	0.00042	-0.29	-0.19	IgE levels;	chr16:69661686	chr18:11619509~11639699:-
BRCA	trans	rs11098499	0.754	rs7672372	ENSG00000120555.12	SEPT7P9	6.26	5.45e-10	0.00042	0.23	0.19	Corneal astigmatism;	chr4:119327251	chr10:38383069~38402916:-
BRCA	trans	rs1707322	1	rs4454479	ENSG00000255397.1	AC022182.2	-6.26	5.45e-10	0.00042	-0.25	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45957883	chr8:60937705~60939871:-
BRCA	trans	rs1707322	1	rs12077546	ENSG00000255397.1	AC022182.2	-6.26	5.45e-10	0.00042	-0.25	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45966134	chr8:60937705~60939871:-
BRCA	trans	rs1707322	1	rs12124291	ENSG00000255397.1	AC022182.2	-6.26	5.45e-10	0.00042	-0.25	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45966460	chr8:60937705~60939871:-
BRCA	trans	rs4929949	0.752	rs726007	ENSG00000266891.1	RP11-692N5.2	6.26	5.47e-10	0.000421	0.23	0.19	Body mass index;	chr11:8444416	chr18:9734882~9735602:-
BRCA	trans	rs7927771	1	rs12363232	ENSG00000134612.10	FOLH1B	-6.26	5.47e-10	0.000422	-0.26	-0.19	Subjective well-being;	chr11:47602338	chr11:89639227~89698718:+
BRCA	trans	rs66887589	0.66	rs4833613	ENSG00000275858.1	RP11-291L22.8	-6.26	5.47e-10	0.000422	-0.22	-0.19	Diastolic blood pressure;	chr4:119229001	chr10:38450738~38451069:-
BRCA	trans	rs7647973	0.961	rs62259943	ENSG00000235912.1	RP1-159A19.3	6.26	5.5e-10	0.000424	0.26	0.19	Menarche (age at onset);	chr3:49387734	chr1:27649419~27649610:+
BRCA	trans	rs11098499	0.863	rs17050695	ENSG00000276997.3	RP11-378J18.9	6.26	5.52e-10	0.000426	0.22	0.19	Corneal astigmatism;	chr4:119568372	chr1:222477252~222504622:-
BRCA	trans	rs2242330	0.862	rs28754895	ENSG00000226982.4	CENPCP1	6.26	5.55e-10	0.000428	0.27	0.19	Parkinson's disease;	chr4:67498710	chr12:89500093~89502670:+
BRCA	trans	rs1707322	1	rs11211243	ENSG00000255397.1	AC022182.2	-6.26	5.55e-10	0.000428	-0.25	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45989761	chr8:60937705~60939871:-
BRCA	trans	rs1707322	1	rs11211244	ENSG00000255397.1	AC022182.2	-6.26	5.55e-10	0.000428	-0.25	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45991001	chr8:60937705~60939871:-
BRCA	trans	rs1707322	1	rs4660903	ENSG00000255397.1	AC022182.2	-6.26	5.56e-10	0.000428	-0.25	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45991929	chr8:60937705~60939871:-
BRCA	trans	rs2243480	1	rs4718270	ENSG00000232546.1	RP11-458F8.1	-6.26	5.57e-10	0.000429	-0.25	-0.19	Diabetic kidney disease;	chr7:65737415	chr7:66848496~66858136:+
BRCA	trans	rs11098499	1	rs12506395	ENSG00000276997.3	RP11-378J18.9	6.26	5.58e-10	0.000429	0.23	0.19	Corneal astigmatism;	chr4:119263939	chr1:222477252~222504622:-
BRCA	trans	rs3849046	0.967	rs154072	ENSG00000226666.1	HSPA9P1	6.26	5.59e-10	0.00043	0.21	0.19	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138520684	chr2:221961737~221963765:+
BRCA	trans	rs875971	0.545	rs316306	ENSG00000234585.5	CCT6P3	-6.26	5.59e-10	0.00043	-0.2	-0.19	Aortic root size;	chr7:66153687	chr7:65038354~65074713:+
BRCA	trans	rs13196561	0.813	rs13217178	ENSG00000216895.7	AC009403.2	6.26	5.59e-10	0.000431	0.27	0.19	Menarche (age at onset);	chr6:100252359	chr7:155611231~155645205:-
BRCA	trans	rs1580019	0.587	rs10951338	ENSG00000213492.2	NT5C3AP1	-6.26	5.63e-10	0.000434	-0.26	-0.19	Cognitive ability;	chr7:32520477	chr4:117574512~117576174:-
BRCA	trans	rs950776	1	rs950776	ENSG00000274376.3	ADAMTS7P1	-6.26	5.64e-10	0.000434	-0.23	-0.19	Sudden cardiac arrest;	chr15:78633676	chr15:82298553~82334609:+
BRCA	trans	rs2965280	0.793	rs10410548	ENSG00000270983.1	RP11-137J7.3	-6.26	5.64e-10	0.000434	-0.44	-0.19	Colorectal cancer;	chr19:34292587	chr6:142062717~142063053:+
BRCA	trans	rs2965280	0.793	rs8105411	ENSG00000270983.1	RP11-137J7.3	-6.26	5.64e-10	0.000434	-0.44	-0.19	Colorectal cancer;	chr19:34293603	chr6:142062717~142063053:+
BRCA	trans	rs2965280	0.793	rs75447986	ENSG00000270983.1	RP11-137J7.3	-6.26	5.64e-10	0.000434	-0.44	-0.19	Colorectal cancer;	chr19:34303090	chr6:142062717~142063053:+
BRCA	trans	rs11098499	0.866	rs12501602	ENSG00000120555.12	SEPT7P9	6.26	5.65e-10	0.000435	0.23	0.19	Corneal astigmatism;	chr4:119366780	chr10:38383069~38402916:-
BRCA	trans	rs10838687	0.673	rs2290148	ENSG00000134612.10	FOLH1B	6.26	5.65e-10	0.000435	0.28	0.19	Proinsulin levels;	chr11:47324594	chr11:89639227~89698718:+
BRCA	trans	rs1580019	0.563	rs4723169	ENSG00000213492.2	NT5C3AP1	-6.26	5.68e-10	0.000437	-0.26	-0.19	Cognitive ability;	chr7:32527965	chr4:117574512~117576174:-
BRCA	trans	rs9733	0.744	rs12568757	ENSG00000180764.13	PIPSL	6.26	5.73e-10	0.000441	0.24	0.19	Tonsillectomy;	chr1:150757317	chr10:93958191~93961540:-
BRCA	trans	rs864643	0.947	rs645488	ENSG00000188856.6	RPSAP47	6.26	5.73e-10	0.000441	0.28	0.19	Attention deficit hyperactivity disorder;	chr3:39499028	chr8:80558870~80559757:+
BRCA	trans	rs1707322	0.963	rs10890371	ENSG00000255397.1	AC022182.2	-6.26	5.74e-10	0.000441	-0.25	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45925225	chr8:60937705~60939871:-
BRCA	trans	rs1707322	1	rs10890372	ENSG00000255397.1	AC022182.2	-6.26	5.74e-10	0.000441	-0.25	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45925348	chr8:60937705~60939871:-
BRCA	trans	rs8177876	0.822	rs8177959	ENSG00000226040.3	AC005740.3	6.26	5.75e-10	0.000442	0.37	0.19	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81082082	chr5:141896168~141896689:-
BRCA	trans	rs9467711	0.722	rs13201782	ENSG00000281831.1	HCP5B	6.26	5.76e-10	0.000443	0.48	0.19	Autism spectrum disorder or schizophrenia;	chr6:26650825	chr6:29871895~29873783:-
BRCA	trans	rs7260598	0.579	rs9676579	ENSG00000261770.1	CTC-459F4.1	6.26	5.77e-10	0.000443	0.32	0.19	Response to taxane treatment (placlitaxel);	chr19:24029180	chr19:27757184~27760849:-
BRCA	trans	rs7032940	0.677	rs1331310	ENSG00000262519.1	TXNP4	6.26	5.77e-10	0.000444	0.23	0.19	Height;	chr9:110179601	chr17:4572206~4572515:+
BRCA	trans	rs11098499	0.954	rs6847248	ENSG00000276997.3	RP11-378J18.9	6.26	5.77e-10	0.000444	0.25	0.19	Corneal astigmatism;	chr4:119304800	chr1:222477252~222504622:-
BRCA	trans	rs877636	0.669	rs7297175	ENSG00000227586.5	RP11-162A23.5	-6.26	5.78e-10	0.000445	-0.22	-0.19	Cognitive function;	chr12:56080024	chr10:123171535~123171875:-
BRCA	trans	rs2243480	0.901	rs2900904	ENSG00000232546.1	RP11-458F8.1	-6.26	5.79e-10	0.000445	-0.25	-0.19	Diabetic kidney disease;	chr7:65739282	chr7:66848496~66858136:+
BRCA	trans	rs1707322	1	rs7527079	ENSG00000255397.1	AC022182.2	-6.25	5.8e-10	0.000446	-0.25	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45947778	chr8:60937705~60939871:-
BRCA	trans	rs1707322	1	rs34446427	ENSG00000255397.1	AC022182.2	-6.25	5.8e-10	0.000446	-0.25	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45951983	chr8:60937705~60939871:-
BRCA	trans	rs1707322	0.963	rs4660900	ENSG00000255397.1	AC022182.2	-6.25	5.8e-10	0.000446	-0.25	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45953933	chr8:60937705~60939871:-
BRCA	trans	rs902774	0.818	rs4919743	ENSG00000223940.1	KRT8P8	-6.25	5.8e-10	0.000446	-0.33	-0.19	Prostate cancer;	chr12:52915800	chrX:152479577~152481024:+
BRCA	trans	rs12439619	0.846	rs62010071	ENSG00000235370.6	DNM1P51	-6.25	5.81e-10	0.000446	-0.27	-0.19	Intelligence (multi-trait analysis);	chr15:82289442	chr15:84398316~84411701:-
BRCA	trans	rs1232027	0.7	rs836823	ENSG00000188985.6	DHFRP1	-6.25	5.81e-10	0.000446	-0.24	-0.19	Huntington's disease progression;	chr5:80647895	chr18:26170726~26171284:-
BRCA	trans	rs714543	0.967	rs10951776	ENSG00000219797.2	PPIAP9	-6.25	5.82e-10	0.000447	-0.23	-0.19	Plateletcrit;	chr7:44858152	chr6:31519480~31520291:-
BRCA	trans	rs6981523	0.5	rs4412337	ENSG00000253893.2	FAM85B	-6.25	5.84e-10	0.000449	-0.26	-0.19	Neuroticism;	chr8:11214511	chr8:8167819~8226614:-
BRCA	trans	rs7927771	1	rs10838757	ENSG00000134612.10	FOLH1B	-6.25	5.86e-10	0.00045	-0.26	-0.19	Subjective well-being;	chr11:47741464	chr11:89639227~89698718:+
BRCA	trans	rs2965280	1	rs2910413	ENSG00000270983.1	RP11-137J7.3	-6.25	5.87e-10	0.000451	-0.43	-0.19	Colorectal cancer;	chr19:34458127	chr6:142062717~142063053:+
BRCA	trans	rs11098499	0.754	rs9991959	ENSG00000120555.12	SEPT7P9	-6.25	5.89e-10	0.000452	-0.22	-0.19	Corneal astigmatism;	chr4:119332618	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.754	rs12510269	ENSG00000120555.12	SEPT7P9	6.25	5.9e-10	0.000453	0.23	0.19	Corneal astigmatism;	chr4:119320491	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.691	rs17009144	ENSG00000276997.3	RP11-378J18.9	-6.25	5.92e-10	0.000455	-0.22	-0.19	Corneal astigmatism;	chr4:119349640	chr1:222477252~222504622:-
BRCA	trans	rs7927771	0.832	rs10838699	ENSG00000134612.10	FOLH1B	6.25	5.93e-10	0.000455	0.24	0.19	Subjective well-being;	chr11:47364522	chr11:89639227~89698718:+
BRCA	trans	rs11098499	0.708	rs1546506	ENSG00000120555.12	SEPT7P9	6.25	6.01e-10	0.000461	0.22	0.19	Corneal astigmatism;	chr4:119320085	chr10:38383069~38402916:-
BRCA	trans	rs6011368	0.74	rs6062678	ENSG00000226210.3	WASH7P	6.25	6.01e-10	0.000461	0.21	0.19	Clozapine-induced cytotoxicity;	chr20:64257449	chr12:14522~32015:-
BRCA	trans	rs7824557	0.767	rs6991606	ENSG00000254153.1	CTA-398F10.2	6.25	6.03e-10	0.000463	0.25	0.19	Retinal vascular caliber;	chr8:11318650	chr8:8456909~8461337:-
BRCA	trans	rs2242330	0.822	rs62301094	ENSG00000226982.4	CENPCP1	6.25	6.06e-10	0.000465	0.27	0.19	Parkinson's disease;	chr4:67504173	chr12:89500093~89502670:+
BRCA	trans	rs2242330	0.862	rs9992020	ENSG00000226982.4	CENPCP1	6.25	6.06e-10	0.000465	0.27	0.19	Parkinson's disease;	chr4:67512755	chr12:89500093~89502670:+
BRCA	trans	rs1707322	1	rs6671754	ENSG00000255397.1	AC022182.2	-6.25	6.07e-10	0.000466	-0.25	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45968318	chr8:60937705~60939871:-
BRCA	trans	rs1707322	0.963	rs6666763	ENSG00000255397.1	AC022182.2	-6.25	6.07e-10	0.000466	-0.25	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45970779	chr8:60937705~60939871:-
BRCA	trans	rs1707322	1	rs4489497	ENSG00000255397.1	AC022182.2	-6.25	6.07e-10	0.000466	-0.25	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45973026	chr8:60937705~60939871:-
BRCA	trans	rs1707322	1	rs11211235	ENSG00000255397.1	AC022182.2	-6.25	6.07e-10	0.000466	-0.25	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45974703	chr8:60937705~60939871:-
BRCA	trans	rs1707322	0.893	rs9919275	ENSG00000255397.1	AC022182.2	-6.25	6.07e-10	0.000466	-0.25	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45975688	chr8:60937705~60939871:-
BRCA	trans	rs1707322	1	rs11211236	ENSG00000255397.1	AC022182.2	-6.25	6.07e-10	0.000466	-0.25	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45978095	chr8:60937705~60939871:-
BRCA	trans	rs1707322	1	rs4660328	ENSG00000255397.1	AC022182.2	-6.25	6.07e-10	0.000466	-0.25	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45979159	chr8:60937705~60939871:-
BRCA	trans	rs1707322	0.928	rs61785614	ENSG00000255397.1	AC022182.2	-6.25	6.07e-10	0.000466	-0.25	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45980375	chr8:60937705~60939871:-
BRCA	trans	rs1707322	1	rs9793167	ENSG00000255397.1	AC022182.2	-6.25	6.07e-10	0.000466	-0.25	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45981128	chr8:60937705~60939871:-
BRCA	trans	rs1707322	1	rs11211237	ENSG00000255397.1	AC022182.2	-6.25	6.07e-10	0.000466	-0.25	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45981657	chr8:60937705~60939871:-
BRCA	trans	rs1707322	0.963	rs11211238	ENSG00000255397.1	AC022182.2	-6.25	6.07e-10	0.000466	-0.25	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45983743	chr8:60937705~60939871:-
BRCA	trans	rs1707322	1	rs4460583	ENSG00000255397.1	AC022182.2	-6.25	6.07e-10	0.000466	-0.25	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45984246	chr8:60937705~60939871:-
BRCA	trans	rs1707322	0.963	rs4459051	ENSG00000255397.1	AC022182.2	-6.25	6.07e-10	0.000466	-0.25	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45985531	chr8:60937705~60939871:-
BRCA	trans	rs1707322	1	rs11211239	ENSG00000255397.1	AC022182.2	-6.25	6.07e-10	0.000466	-0.25	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45986275	chr8:60937705~60939871:-
BRCA	trans	rs9467711	0.79	rs13220495	ENSG00000281831.1	HCP5B	6.25	6.07e-10	0.000466	0.48	0.19	Autism spectrum disorder or schizophrenia;	chr6:26441412	chr6:29871895~29873783:-
BRCA	trans	rs2899832	0.568	rs10144186	ENSG00000215414.4	PSMA6P1	6.25	6.13e-10	0.00047	0.33	0.19	Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:35295199	chrY:13286638~13287378:+
BRCA	trans	rs4930561	0.714	rs7950451	ENSG00000155070.8	UNC93B2	-6.25	6.13e-10	0.00047	-0.22	-0.19	Breast cancer in childhood cancer survivors;IgG glycosylation;	chr11:68194939	chr7:6855485~6859830:-
BRCA	trans	rs4930561	0.714	rs7950452	ENSG00000155070.8	UNC93B2	-6.25	6.13e-10	0.00047	-0.22	-0.19	Breast cancer in childhood cancer survivors;IgG glycosylation;	chr11:68194940	chr7:6855485~6859830:-
BRCA	trans	rs4930561	0.765	rs34493482	ENSG00000155070.8	UNC93B2	-6.25	6.13e-10	0.00047	-0.22	-0.19	Breast cancer in childhood cancer survivors;IgG glycosylation;	chr11:68202041	chr7:6855485~6859830:-
BRCA	trans	rs2840044	0.963	rs225247	ENSG00000234130.2	RP13-88F20.1	-6.25	6.13e-10	0.00047	-0.21	-0.19	Response to radiotherapy in cancer (late toxicity);	chr17:35617571	chrX:93222220~93225015:-
BRCA	trans	rs853679	0.556	rs45509595	ENSG00000281831.1	HCP5B	6.25	6.15e-10	0.000471	0.5	0.19	Depression;	chr6:27873148	chr6:29871895~29873783:-
BRCA	trans	rs902774	1	rs11831942	ENSG00000248568.1	KRT8P48	-6.24	6.18e-10	0.000474	-0.34	-0.19	Prostate cancer;	chr12:52878329	chr5:146706381~146707600:-
BRCA	trans	rs17507216	0.958	rs72751643	ENSG00000235370.6	DNM1P51	-6.24	6.2e-10	0.000475	-0.25	-0.19	Excessive daytime sleepiness;	chr15:82559444	chr15:84398316~84411701:-
BRCA	trans	rs3942852	0.955	rs1910364	ENSG00000134612.10	FOLH1B	-6.24	6.21e-10	0.000476	-0.27	-0.19	Acute lymphoblastic leukemia (childhood);	chr11:48091680	chr11:89639227~89698718:+
BRCA	trans	rs7824557	0.872	rs2572417	ENSG00000254153.1	CTA-398F10.2	-6.24	6.21e-10	0.000476	-0.23	-0.19	Retinal vascular caliber;	chr8:11253953	chr8:8456909~8461337:-
BRCA	trans	rs7819412	0.505	rs17782554	ENSG00000253893.2	FAM85B	6.24	6.21e-10	0.000476	0.25	0.19	Triglycerides;	chr8:11164596	chr8:8167819~8226614:-
BRCA	trans	rs11098499	0.955	rs11944880	ENSG00000276997.3	RP11-378J18.9	-6.24	6.22e-10	0.000477	-0.23	-0.19	Corneal astigmatism;	chr4:119238179	chr1:222477252~222504622:-
BRCA	trans	rs2220004	0.963	rs10501345	ENSG00000134612.10	FOLH1B	-6.24	6.24e-10	0.000478	-0.25	-0.19	Odorant perception (&beta-damascenone);	chr11:56021065	chr11:89639227~89698718:+
BRCA	trans	rs7927771	1	rs11605774	ENSG00000134612.10	FOLH1B	-6.24	6.27e-10	0.00048	-0.26	-0.19	Subjective well-being;	chr11:47811241	chr11:89639227~89698718:+
BRCA	trans	rs902774	0.818	rs55914512	ENSG00000254285.3	KRT8P3	-6.24	6.27e-10	0.000481	-0.39	-0.19	Prostate cancer;	chr12:52888490	chr8:61578220~61579668:+
BRCA	trans	rs902774	0.818	rs73108466	ENSG00000254285.3	KRT8P3	-6.24	6.27e-10	0.000481	-0.39	-0.19	Prostate cancer;	chr12:52889857	chr8:61578220~61579668:+
BRCA	trans	rs17767294	0.522	rs41270589	ENSG00000242375.1	RP11-498P14.3	-6.24	6.34e-10	0.000485	-0.58	-0.19	Parkinson's disease;	chr6:28435663	chr9:97195351~97197687:-
BRCA	trans	rs2164273	0.528	rs3824212	ENSG00000253893.2	FAM85B	-6.24	6.35e-10	0.000486	-0.25	-0.19	Extraversion;	chr8:11285409	chr8:8167819~8226614:-
BRCA	trans	rs2066819	1	rs78121408	ENSG00000273654.1	CTB-52I2.4	6.24	6.35e-10	0.000487	0.49	0.19	Psoriasis vulgaris;	chr12:56291014	chr19:18022403~18032099:+
BRCA	trans	rs2066819	1	rs77447765	ENSG00000273654.1	CTB-52I2.4	6.24	6.35e-10	0.000487	0.49	0.19	Psoriasis vulgaris;	chr12:56296878	chr19:18022403~18032099:+
BRCA	trans	rs11172055	0.902	rs12422981	ENSG00000121089.4	NACA3P	6.24	6.38e-10	0.000488	0.21	0.19	Migraine;	chr12:56900282	chr4:164943290~164943937:+
BRCA	trans	rs10838687	0.8	rs7124958	ENSG00000134612.10	FOLH1B	6.24	6.4e-10	0.00049	0.28	0.19	Proinsulin levels;	chr11:47325709	chr11:89639227~89698718:+
BRCA	trans	rs864643	0.947	rs1768243	ENSG00000188856.6	RPSAP47	6.24	6.41e-10	0.00049	0.27	0.19	Attention deficit hyperactivity disorder;	chr3:39500306	chr8:80558870~80559757:+
BRCA	trans	rs3849046	0.967	rs154073	ENSG00000226666.1	HSPA9P1	6.24	6.44e-10	0.000492	0.21	0.19	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138522378	chr2:221961737~221963765:+
BRCA	trans	rs2066819	1	rs78149779	ENSG00000273654.1	CTB-52I2.4	6.24	6.45e-10	0.000494	0.49	0.19	Psoriasis vulgaris;	chr12:56301033	chr19:18022403~18032099:+
BRCA	trans	rs2066819	1	rs74496027	ENSG00000273654.1	CTB-52I2.4	6.24	6.45e-10	0.000494	0.49	0.19	Psoriasis vulgaris;	chr12:56332556	chr19:18022403~18032099:+
BRCA	trans	rs4713118	0.869	rs6902689	ENSG00000204709.4	LINC01556	6.24	6.45e-10	0.000494	0.26	0.19	Parkinson's disease;	chr6:27741662	chr6:28943877~28944537:+
BRCA	trans	rs875971	0.545	rs10950025	ENSG00000234585.5	CCT6P3	6.24	6.45e-10	0.000494	0.2	0.19	Aortic root size;	chr7:66158946	chr7:65038354~65074713:+
BRCA	trans	rs875971	0.52	rs12666485	ENSG00000234585.5	CCT6P3	6.24	6.45e-10	0.000494	0.2	0.19	Aortic root size;	chr7:66160135	chr7:65038354~65074713:+
BRCA	trans	rs875971	0.545	rs67688847	ENSG00000234585.5	CCT6P3	6.24	6.45e-10	0.000494	0.2	0.19	Aortic root size;	chr7:66161064	chr7:65038354~65074713:+
BRCA	trans	rs1816854	0.515	rs35980560	ENSG00000178082.6	TWF1P1	6.24	6.54e-10	5e-04	0.25	0.19	Inflammatory bowel disease;	chr12:43791775	chr17:29203426~29204474:-
BRCA	trans	rs641862	1	rs641862	ENSG00000233613.4	DCUN1D2-AS	6.24	6.55e-10	0.000501	0.38	0.19	Obesity-related traits;	chr13:110137885	chr13:113468901~113476135:+
BRCA	trans	rs2066819	1	rs1802236	ENSG00000273654.1	CTB-52I2.4	6.23	6.56e-10	0.000502	0.49	0.19	Psoriasis vulgaris;	chr12:56285967	chr19:18022403~18032099:+
BRCA	trans	rs2066819	1	rs77032009	ENSG00000273654.1	CTB-52I2.4	6.23	6.56e-10	0.000502	0.49	0.19	Psoriasis vulgaris;	chr12:56286187	chr19:18022403~18032099:+
BRCA	trans	rs2066819	1	rs2306693	ENSG00000273654.1	CTB-52I2.4	6.23	6.56e-10	0.000502	0.49	0.19	Psoriasis vulgaris;	chr12:56286747	chr19:18022403~18032099:+
BRCA	trans	rs2965280	0.793	rs10405398	ENSG00000270983.1	RP11-137J7.3	-6.23	6.56e-10	0.000502	-0.43	-0.19	Colorectal cancer;	chr19:34317325	chr6:142062717~142063053:+
BRCA	trans	rs6601327	0.613	rs10094989	ENSG00000253893.2	FAM85B	-6.23	6.57e-10	0.000503	-0.24	-0.19	Multiple myeloma (hyperdiploidy);	chr8:9754499	chr8:8167819~8226614:-
BRCA	trans	rs7746199	0.736	rs34965299	ENSG00000204709.4	LINC01556	6.23	6.59e-10	0.000504	0.49	0.19	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27554077	chr6:28943877~28944537:+
BRCA	trans	rs62436127	0.641	rs4869772	ENSG00000278974.1	RP11-756P10.6	-6.23	6.59e-10	0.000504	-0.34	-0.19	Morning vs. evening chronotype;	chr6:152919492	chr4:188740507~188741281:-
BRCA	trans	rs902774	0.818	rs4919737	ENSG00000255815.3	KRT8P11	-6.23	6.65e-10	0.000508	-0.4	-0.19	Prostate cancer;	chr12:52877011	chr9:99305176~99306611:+
BRCA	trans	rs3812762	0.871	rs3862352	ENSG00000266891.1	RP11-692N5.2	6.23	6.68e-10	0.00051	0.24	0.19	Hypospadias;	chr11:8796473	chr18:9734882~9735602:-
BRCA	trans	rs11098499	0.775	rs10021601	ENSG00000120555.12	SEPT7P9	6.23	6.69e-10	0.000511	0.23	0.19	Corneal astigmatism;	chr4:119361408	chr10:38383069~38402916:-
BRCA	trans	rs6601327	0.586	rs6601340	ENSG00000253893.2	FAM85B	6.23	6.7e-10	0.000512	0.24	0.19	Multiple myeloma (hyperdiploidy);	chr8:9603805	chr8:8167819~8226614:-
BRCA	trans	rs10838687	0.8	rs1051006	ENSG00000134612.10	FOLH1B	6.23	6.72e-10	0.000513	0.28	0.19	Proinsulin levels;	chr11:47285034	chr11:89639227~89698718:+
BRCA	trans	rs2235573	0.551	rs139895	ENSG00000258501.1	EIF3LP1	6.23	6.72e-10	0.000513	0.22	0.19	Glioma;Glioblastoma;	chr22:38001027	chr14:81916231~81917888:+
BRCA	trans	rs2840044	1	rs10068	ENSG00000234130.2	RP13-88F20.1	6.23	6.75e-10	0.000516	0.21	0.19	Response to radiotherapy in cancer (late toxicity);	chr17:35574946	chrX:93222220~93225015:-
BRCA	trans	rs3740713	1	rs3740713	ENSG00000214110.3	LDHAP4	6.23	6.76e-10	0.000516	0.38	0.19	Amyotrophic lateral sclerosis (sporadic);	chr11:18429549	chr9:14921337~14922334:-
BRCA	trans	rs853679	0.505	rs200992	ENSG00000253570.1	RNF5P1	6.23	6.79e-10	0.000518	0.43	0.19	Depression;	chr6:27846899	chr8:38600661~38601200:-
BRCA	trans	rs2066819	0.892	rs17118431	ENSG00000273654.1	CTB-52I2.4	6.23	6.82e-10	0.00052	0.48	0.19	Psoriasis vulgaris;	chr12:56273316	chr19:18022403~18032099:+
BRCA	trans	rs11098499	0.779	rs10857066	ENSG00000120555.12	SEPT7P9	6.23	6.83e-10	0.000522	0.23	0.19	Corneal astigmatism;	chr4:119365441	chr10:38383069~38402916:-
BRCA	trans	rs2237234	0.813	rs34565965	ENSG00000242375.1	RP11-498P14.3	-6.23	6.85e-10	0.000523	-0.33	-0.19	Autism spectrum disorder or schizophrenia;	chr6:26350582	chr9:97195351~97197687:-
BRCA	trans	rs9425766	0.64	rs9660881	ENSG00000213331.4	RP11-713C19.2	6.23	6.86e-10	0.000523	0.26	0.19	Life satisfaction;	chr1:173867378	chr4:187970273~187971284:+
BRCA	trans	rs9425766	0.678	rs55829688	ENSG00000213331.4	RP11-713C19.2	6.23	6.86e-10	0.000523	0.26	0.19	Life satisfaction;	chr1:173868168	chr4:187970273~187971284:+
BRCA	trans	rs2965280	0.793	rs7259821	ENSG00000270983.1	RP11-137J7.3	-6.23	6.86e-10	0.000523	-0.43	-0.19	Colorectal cancer;	chr19:34286592	chr6:142062717~142063053:+
BRCA	trans	rs7824557	0.767	rs2164273	ENSG00000270154.1	RP11-419I17.1	6.23	6.87e-10	0.000524	0.24	0.19	Retinal vascular caliber;	chr8:11310990	chr8:12476462~12477122:+
BRCA	trans	rs6011368	0.765	rs6062683	ENSG00000226210.3	WASH7P	6.23	6.87e-10	0.000524	0.21	0.19	Clozapine-induced cytotoxicity;	chr20:64260534	chr12:14522~32015:-
BRCA	trans	rs853679	0.713	rs200991	ENSG00000253570.1	RNF5P1	-6.23	6.88e-10	0.000525	-0.35	-0.19	Depression;	chr6:27847716	chr8:38600661~38601200:-
BRCA	trans	rs12210905	1	rs9393796	ENSG00000242375.1	RP11-498P14.3	-6.23	6.88e-10	0.000525	-0.39	-0.19	Hip circumference adjusted for BMI;	chr6:27259186	chr9:97195351~97197687:-
BRCA	trans	rs12210905	1	rs9379965	ENSG00000242375.1	RP11-498P14.3	-6.23	6.88e-10	0.000525	-0.39	-0.19	Hip circumference adjusted for BMI;	chr6:27259282	chr9:97195351~97197687:-
BRCA	trans	rs2288327	0.591	rs2562845	ENSG00000269800.1	PLEKHA3P1	6.23	6.89e-10	0.000526	0.25	0.19	Atrial fibrillation;	chr2:178649706	chr19:41521043~41521989:-
BRCA	trans	rs3740713	1	rs60376560	ENSG00000236090.2	LDHAP3	6.23	6.9e-10	0.000526	0.36	0.19	Amyotrophic lateral sclerosis (sporadic);	chr11:18432195	chr2:41819747~41820754:+
BRCA	trans	rs7647973	1	rs6446262	ENSG00000235912.1	RP1-159A19.3	-6.23	6.92e-10	0.000528	-0.25	-0.19	Menarche (age at onset);	chr3:49363720	chr1:27649419~27649610:+
BRCA	trans	rs7647973	1	rs62259947	ENSG00000235912.1	RP1-159A19.3	6.23	6.92e-10	0.000528	0.25	0.19	Menarche (age at onset);	chr3:49402491	chr1:27649419~27649610:+
BRCA	trans	rs11122895	0.527	rs10186692	ENSG00000204745.3	AC083899.3	6.23	6.93e-10	0.000528	0.22	0.19	Allergic sensitization;	chr2:111686719	chr2:87125390~87196647:+
BRCA	trans	rs17301013	0.73	rs12060177	ENSG00000213331.4	RP11-713C19.2	6.23	6.94e-10	0.000529	0.21	0.19	Systemic lupus erythematosus;	chr1:174618545	chr4:187970273~187971284:+
BRCA	trans	rs902774	0.818	rs4919740	ENSG00000254285.3	KRT8P3	-6.23	6.95e-10	0.00053	-0.34	-0.19	Prostate cancer;	chr12:52877187	chr8:61578220~61579668:+
BRCA	trans	rs7647973	1	rs9860055	ENSG00000197582.5	GPX1P1	-6.22	6.98e-10	0.000532	-0.21	-0.19	Menarche (age at onset);	chr3:49469467	chrX:13378735~13379340:-
BRCA	trans	rs7647973	1	rs74471041	ENSG00000197582.5	GPX1P1	-6.22	6.98e-10	0.000532	-0.21	-0.19	Menarche (age at onset);	chr3:49505110	chrX:13378735~13379340:-
BRCA	trans	rs7647973	1	rs7644148	ENSG00000197582.5	GPX1P1	-6.22	6.98e-10	0.000532	-0.21	-0.19	Menarche (age at onset);	chr3:49507808	chrX:13378735~13379340:-
BRCA	trans	rs17507216	0.609	rs1431716	ENSG00000235370.6	DNM1P51	-6.22	6.98e-10	0.000532	-0.28	-0.19	Excessive daytime sleepiness;	chr15:82676180	chr15:84398316~84411701:-
BRCA	trans	rs714543	0.967	rs11762008	ENSG00000219797.2	PPIAP9	-6.22	7e-10	0.000534	-0.23	-0.19	Plateletcrit;	chr7:44864065	chr6:31519480~31520291:-
BRCA	trans	rs9467711	0.79	rs67777156	ENSG00000281831.1	HCP5B	6.22	7.01e-10	0.000534	0.48	0.19	Autism spectrum disorder or schizophrenia;	chr6:26633483	chr6:29871895~29873783:-
BRCA	trans	rs7617773	0.78	rs9846818	ENSG00000235912.1	RP1-159A19.3	-6.22	7.05e-10	0.000537	-0.23	-0.19	Coronary artery disease;	chr3:48334195	chr1:27649419~27649610:+
BRCA	trans	rs853679	1	rs1419183	ENSG00000253570.1	RNF5P1	6.22	7.07e-10	0.000539	0.37	0.19	Depression;	chr6:28275017	chr8:38600661~38601200:-
BRCA	trans	rs853679	0.567	rs7774981	ENSG00000228078.1	HLA-U	-6.22	7.09e-10	0.00054	-0.28	-0.19	Depression;	chr6:28379133	chr6:29934101~29934286:+
BRCA	trans	rs853679	0.567	rs7754960	ENSG00000228078.1	HLA-U	-6.22	7.09e-10	0.00054	-0.28	-0.19	Depression;	chr6:28379168	chr6:29934101~29934286:+
BRCA	trans	rs2069408	1	rs2069408	ENSG00000212829.8	RPS26P3	-6.22	7.12e-10	0.000542	-0.26	-0.19	Asthma;	chr12:55970537	chr9:9090898~9091245:+
BRCA	trans	rs902774	0.818	rs4919763	ENSG00000255815.3	KRT8P11	-6.22	7.15e-10	0.000544	-0.4	-0.19	Prostate cancer;	chr12:52885839	chr9:99305176~99306611:+
BRCA	trans	rs11098499	0.78	rs7692994	ENSG00000276997.3	RP11-378J18.9	6.22	7.21e-10	0.000549	0.22	0.19	Corneal astigmatism;	chr4:119506334	chr1:222477252~222504622:-
BRCA	trans	rs7647973	0.516	rs4955418	ENSG00000197582.5	GPX1P1	6.22	7.26e-10	0.000553	0.19	0.19	Menarche (age at onset);	chr3:49163194	chrX:13378735~13379340:-
BRCA	trans	rs17507216	0.591	rs7163848	ENSG00000235370.6	DNM1P51	-6.22	7.26e-10	0.000553	-0.27	-0.19	Excessive daytime sleepiness;	chr15:82729563	chr15:84398316~84411701:-
BRCA	trans	rs9467711	0.651	rs13220395	ENSG00000253570.1	RNF5P1	-6.22	7.34e-10	0.000558	-0.46	-0.19	Autism spectrum disorder or schizophrenia;	chr6:26055140	chr8:38600661~38601200:-
BRCA	trans	rs7260598	0.892	rs60186040	ENSG00000261770.1	CTC-459F4.1	6.22	7.36e-10	0.00056	0.32	0.19	Response to taxane treatment (placlitaxel);	chr19:24024068	chr19:27757184~27760849:-
BRCA	trans	rs3849046	0.967	rs154067	ENSG00000226666.1	HSPA9P1	6.22	7.37e-10	0.000561	0.21	0.19	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138514370	chr2:221961737~221963765:+
BRCA	trans	rs1707322	1	rs11211248	ENSG00000255397.1	AC022182.2	-6.22	7.37e-10	0.000561	-0.24	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46011172	chr8:60937705~60939871:-
BRCA	trans	rs3849046	0.967	rs10077407	ENSG00000226666.1	HSPA9P1	6.22	7.38e-10	0.000561	0.21	0.19	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:138513837	chr2:221961737~221963765:+
BRCA	trans	rs11098499	0.913	rs35271032	ENSG00000276997.3	RP11-378J18.9	6.22	7.38e-10	0.000562	0.24	0.19	Corneal astigmatism;	chr4:119235504	chr1:222477252~222504622:-
BRCA	trans	rs7647973	0.516	rs4536858	ENSG00000197582.5	GPX1P1	6.21	7.42e-10	0.000564	0.19	0.19	Menarche (age at onset);	chr3:49155648	chrX:13378735~13379340:-
BRCA	trans	rs9914988	0.576	rs11080075	ENSG00000267449.1	RP11-264B14.2	-6.21	7.42e-10	0.000564	-0.28	-0.19	Glycated hemoglobin levels;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr17:28995423	chr17:61069856~61070356:-
BRCA	trans	rs2066819	0.892	rs112931321	ENSG00000273654.1	CTB-52I2.4	6.21	7.46e-10	0.000567	0.49	0.19	Psoriasis vulgaris;	chr12:56274110	chr19:18022403~18032099:+
BRCA	trans	rs11098499	0.866	rs10518329	ENSG00000120555.12	SEPT7P9	6.21	7.47e-10	0.000568	0.23	0.19	Corneal astigmatism;	chr4:119480680	chr10:38383069~38402916:-
BRCA	trans	rs714543	0.783	rs7806283	ENSG00000234397.3	RP11-415K20.1	-6.21	7.49e-10	0.000569	-0.22	-0.19	Plateletcrit;	chr7:44779104	chr1:22322840~22323331:-
BRCA	trans	rs1580019	0.523	rs13236410	ENSG00000213492.2	NT5C3AP1	-6.21	7.5e-10	0.00057	-0.26	-0.19	Cognitive ability;	chr7:32651051	chr4:117574512~117576174:-
BRCA	trans	rs673253	0.556	rs9787076	ENSG00000231007.5	CDC20P1	6.21	7.5e-10	0.00057	0.25	0.19	Intelligence (multi-trait analysis);	chr1:43675478	chr9:87011652~87013151:+
BRCA	trans	rs860295	0.58	rs2016251	ENSG00000241627.3	UBQLN4P1	-6.21	7.5e-10	0.000571	-0.21	-0.19	Body mass index;	chr1:155945197	chr3:148985868~148987668:-
BRCA	trans	rs7929679	0.875	rs11032877	ENSG00000225531.1	RP11-196I18.3	-6.21	7.53e-10	0.000572	-0.25	-0.19	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;	chr11:34793552	chr9:107116829~107117557:+
BRCA	trans	rs941207	0.789	rs2958145	ENSG00000257210.1	NACAP3	-6.21	7.53e-10	0.000572	-0.25	-0.19	Platelet count;	chr12:56662290	chr12:93124063~93124543:-
BRCA	trans	rs2066819	1	rs118130855	ENSG00000273654.1	CTB-52I2.4	6.21	7.55e-10	0.000574	0.49	0.19	Psoriasis vulgaris;	chr12:56284195	chr19:18022403~18032099:+
BRCA	trans	rs7662987	1	rs1803037	ENSG00000228407.2	RP4-800M22.1	6.21	7.58e-10	0.000576	0.39	0.19	Smoking initiation;	chr4:99072000	chr1:52160261~52160600:-
BRCA	trans	rs7824557	0.767	rs1897950	ENSG00000254153.1	CTA-398F10.2	6.21	7.61e-10	0.000579	0.25	0.19	Retinal vascular caliber;	chr8:11312042	chr8:8456909~8461337:-
BRCA	trans	rs801193	0.66	rs1962050	ENSG00000164669.11	INTS4P1	6.21	7.61e-10	0.000579	0.23	0.19	Aortic root size;	chr7:66775021	chr7:65141225~65234216:+
BRCA	trans	rs6683419	1	rs2314146	ENSG00000224237.1	MINOS1P3	6.21	7.62e-10	0.000579	0.2	0.19	Serum thyroid-stimulating hormone levels;	chr1:19497514	chr3:27214816~27215018:-
BRCA	trans	rs3740713	1	rs75487138	ENSG00000236090.2	LDHAP3	6.21	7.62e-10	0.000579	0.36	0.19	Amyotrophic lateral sclerosis (sporadic);	chr11:18440331	chr2:41819747~41820754:+
BRCA	trans	rs902774	0.818	rs4919763	ENSG00000254285.3	KRT8P3	-6.21	7.62e-10	0.000579	-0.39	-0.19	Prostate cancer;	chr12:52885839	chr8:61578220~61579668:+
BRCA	trans	rs1580019	0.539	rs11769109	ENSG00000213492.2	NT5C3AP1	-6.21	7.63e-10	0.00058	-0.25	-0.19	Cognitive ability;	chr7:32531740	chr4:117574512~117576174:-
BRCA	trans	rs7113874	0.524	rs11041981	ENSG00000266891.1	RP11-692N5.2	6.21	7.65e-10	0.000581	0.22	0.19	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8557661	chr18:9734882~9735602:-
BRCA	trans	rs2242330	0.862	rs7684846	ENSG00000226982.4	CENPCP1	6.21	7.65e-10	0.000581	0.27	0.19	Parkinson's disease;	chr4:67500827	chr12:89500093~89502670:+
BRCA	trans	rs7647973	1	rs73088137	ENSG00000235912.1	RP1-159A19.3	6.21	7.67e-10	0.000582	0.25	0.19	Menarche (age at onset);	chr3:49410990	chr1:27649419~27649610:+
BRCA	trans	rs11098499	0.722	rs1814814	ENSG00000276997.3	RP11-378J18.9	6.21	7.67e-10	0.000583	0.22	0.19	Corneal astigmatism;	chr4:119336969	chr1:222477252~222504622:-
BRCA	trans	rs2336384	0.929	rs56243319	ENSG00000261819.1	RP11-680G24.4	6.21	7.69e-10	0.000584	0.24	0.19	Platelet count;	chr1:11988538	chr16:14988259~14990160:-
BRCA	trans	rs6011368	0.765	rs6062681	ENSG00000226210.3	WASH7P	6.21	7.78e-10	0.00059	0.21	0.19	Clozapine-induced cytotoxicity;	chr20:64260450	chr12:14522~32015:-
BRCA	trans	rs1580019	0.563	rs34201720	ENSG00000213492.2	NT5C3AP1	-6.21	7.78e-10	0.000591	-0.25	-0.19	Cognitive ability;	chr7:32529323	chr4:117574512~117576174:-
BRCA	trans	rs17507216	0.628	rs28371837	ENSG00000259295.5	CSPG4P12	-6.21	7.79e-10	0.000592	-0.31	-0.19	Excessive daytime sleepiness;	chr15:82714435	chr15:85191438~85213905:+
BRCA	trans	rs3942852	0.868	rs58407618	ENSG00000134612.10	FOLH1B	-6.21	7.81e-10	0.000593	-0.27	-0.19	Acute lymphoblastic leukemia (childhood);	chr11:48082615	chr11:89639227~89698718:+
BRCA	trans	rs941207	0.756	rs7315472	ENSG00000257210.1	NACAP3	-6.21	7.88e-10	0.000598	-0.25	-0.19	Platelet count;	chr12:56648276	chr12:93124063~93124543:-
BRCA	trans	rs714543	1	rs2898	ENSG00000219797.2	PPIAP9	-6.2	7.9e-10	0.000599	-0.23	-0.19	Plateletcrit;	chr7:44827034	chr6:31519480~31520291:-
BRCA	trans	rs2950393	0.895	rs2926740	ENSG00000257210.1	NACAP3	6.2	7.9e-10	6e-04	0.23	0.19	Platelet distribution width;	chr12:56666751	chr12:93124063~93124543:-
BRCA	trans	rs902774	0.818	rs4919740	ENSG00000259500.1	KRT8P24	-6.2	7.94e-10	0.000602	-0.35	-0.19	Prostate cancer;	chr12:52877187	chr15:48971803~48973361:+
BRCA	trans	rs714543	0.934	rs10275962	ENSG00000219797.2	PPIAP9	-6.2	7.94e-10	0.000602	-0.23	-0.19	Plateletcrit;	chr7:44809141	chr6:31519480~31520291:-
BRCA	trans	rs62436127	0.818	rs4870153	ENSG00000180015.12	RP11-756P10.3	6.2	7.96e-10	0.000603	0.34	0.19	Morning vs. evening chronotype;	chr6:152948137	chr4:188738373~188739494:+
BRCA	trans	rs11098499	0.866	rs6857892	ENSG00000120555.12	SEPT7P9	6.2	7.96e-10	0.000603	0.23	0.19	Corneal astigmatism;	chr4:119361541	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.909	rs28581362	ENSG00000120555.12	SEPT7P9	6.2	7.96e-10	0.000603	0.23	0.19	Corneal astigmatism;	chr4:119362393	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.82	rs12503082	ENSG00000120555.12	SEPT7P9	6.2	7.96e-10	0.000603	0.23	0.19	Corneal astigmatism;	chr4:119363162	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.866	rs12499602	ENSG00000120555.12	SEPT7P9	6.2	7.96e-10	0.000603	0.23	0.19	Corneal astigmatism;	chr4:119363232	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.774	rs11098505	ENSG00000120555.12	SEPT7P9	6.2	7.96e-10	0.000603	0.23	0.19	Corneal astigmatism;	chr4:119363472	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.866	rs13105020	ENSG00000120555.12	SEPT7P9	6.2	7.96e-10	0.000603	0.23	0.19	Corneal astigmatism;	chr4:119364533	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.866	rs6824111	ENSG00000120555.12	SEPT7P9	6.2	7.96e-10	0.000603	0.23	0.19	Corneal astigmatism;	chr4:119364813	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.775	rs10029303	ENSG00000120555.12	SEPT7P9	6.2	7.96e-10	0.000603	0.23	0.19	Corneal astigmatism;	chr4:119365600	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.866	rs9995136	ENSG00000120555.12	SEPT7P9	6.2	7.96e-10	0.000603	0.23	0.19	Corneal astigmatism;	chr4:119365690	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.866	rs13125526	ENSG00000120555.12	SEPT7P9	6.2	7.96e-10	0.000603	0.23	0.19	Corneal astigmatism;	chr4:119366864	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.866	rs12513310	ENSG00000120555.12	SEPT7P9	6.2	7.96e-10	0.000603	0.23	0.19	Corneal astigmatism;	chr4:119366884	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.866	rs12510451	ENSG00000120555.12	SEPT7P9	6.2	7.96e-10	0.000603	0.23	0.19	Corneal astigmatism;	chr4:119367988	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.774	rs73842616	ENSG00000120555.12	SEPT7P9	6.2	7.96e-10	0.000603	0.23	0.19	Corneal astigmatism;	chr4:119369528	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.645	rs72676059	ENSG00000120555.12	SEPT7P9	6.2	7.96e-10	0.000603	0.23	0.19	Corneal astigmatism;	chr4:119369673	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.569	rs55845118	ENSG00000120555.12	SEPT7P9	6.2	7.96e-10	0.000603	0.23	0.19	Corneal astigmatism;	chr4:119369758	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.866	rs7677068	ENSG00000120555.12	SEPT7P9	6.2	7.96e-10	0.000603	0.23	0.19	Corneal astigmatism;	chr4:119370549	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.866	rs9991221	ENSG00000120555.12	SEPT7P9	6.2	7.96e-10	0.000603	0.23	0.19	Corneal astigmatism;	chr4:119370952	chr10:38383069~38402916:-
BRCA	trans	rs7113874	0.518	rs7112091	ENSG00000266891.1	RP11-692N5.2	6.2	7.96e-10	0.000604	0.22	0.19	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8381845	chr18:9734882~9735602:-
BRCA	trans	rs1707322	1	rs785498	ENSG00000255397.1	AC022182.2	6.2	7.96e-10	0.000604	0.25	0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46126742	chr8:60937705~60939871:-
BRCA	trans	rs7826222	0.55	rs481958	ENSG00000253893.2	FAM85B	6.2	8.02e-10	0.000608	0.34	0.19	Adiposity;	chr8:10011304	chr8:8167819~8226614:-
BRCA	trans	rs673253	0.686	rs943513	ENSG00000231007.5	CDC20P1	6.2	8.03e-10	0.000608	0.24	0.19	Intelligence (multi-trait analysis);	chr1:43569801	chr9:87011652~87013151:+
BRCA	trans	rs4930561	0.765	rs10896304	ENSG00000155070.8	UNC93B2	-6.2	8.1e-10	0.000613	-0.22	-0.19	Breast cancer in childhood cancer survivors;IgG glycosylation;	chr11:68214247	chr7:6855485~6859830:-
BRCA	trans	rs2965280	1	rs79943809	ENSG00000270983.1	RP11-137J7.3	-6.2	8.11e-10	0.000614	-0.42	-0.19	Colorectal cancer;	chr19:34436699	chr6:142062717~142063053:+
BRCA	trans	rs2965280	1	rs8106423	ENSG00000270983.1	RP11-137J7.3	-6.2	8.11e-10	0.000614	-0.42	-0.19	Colorectal cancer;	chr19:34441913	chr6:142062717~142063053:+
BRCA	trans	rs875971	0.545	rs4441996	ENSG00000213640.3	EEF1DP4	6.2	8.13e-10	0.000616	0.26	0.19	Aortic root size;	chr7:66123233	chr7:64862999~64864370:+
BRCA	trans	rs2965280	0.793	rs10402497	ENSG00000270983.1	RP11-137J7.3	-6.2	8.14e-10	0.000617	-0.42	-0.19	Colorectal cancer;	chr19:34322035	chr6:142062717~142063053:+
BRCA	trans	rs12210905	1	rs6938397	ENSG00000242375.1	RP11-498P14.3	-6.2	8.2e-10	0.000621	-0.39	-0.19	Hip circumference adjusted for BMI;	chr6:27263445	chr9:97195351~97197687:-
BRCA	trans	rs1707322	1	rs6682683	ENSG00000255397.1	AC022182.2	-6.2	8.23e-10	0.000623	-0.24	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45876665	chr8:60937705~60939871:-
BRCA	trans	rs1707322	1	rs4660906	ENSG00000255397.1	AC022182.2	-6.2	8.25e-10	0.000625	-0.25	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46005188	chr8:60937705~60939871:-
BRCA	trans	rs864643	1	rs559349	ENSG00000188856.6	RPSAP47	6.2	8.27e-10	0.000626	0.29	0.19	Attention deficit hyperactivity disorder;	chr3:39505562	chr8:80558870~80559757:+
BRCA	trans	rs714543	1	rs10267576	ENSG00000219797.2	PPIAP9	-6.2	8.28e-10	0.000626	-0.23	-0.19	Plateletcrit;	chr7:44831334	chr6:31519480~31520291:-
BRCA	trans	rs875971	0.545	rs1909508	ENSG00000234585.5	CCT6P3	6.2	8.29e-10	0.000627	0.2	0.19	Aortic root size;	chr7:66301366	chr7:65038354~65074713:+
BRCA	trans	rs453301	0.571	rs330048	ENSG00000255046.1	RP11-297N6.4	6.2	8.29e-10	0.000627	0.21	0.19	Joint mobility (Beighton score);	chr8:9229768	chr8:11797928~11802568:-
BRCA	trans	rs7568458	0.709	rs1446669	ENSG00000223886.3	RP11-251G23.2	6.2	8.29e-10	0.000627	0.23	0.19	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr2:85535086	chr7:105530209~105530671:+
BRCA	trans	rs853679	0.607	rs13208096	ENSG00000228078.1	HLA-U	-6.2	8.29e-10	0.000627	-0.51	-0.19	Depression;	chr6:28257533	chr6:29934101~29934286:+
BRCA	trans	rs714543	0.967	rs12536807	ENSG00000219797.2	PPIAP9	-6.2	8.31e-10	0.000628	-0.23	-0.19	Plateletcrit;	chr7:44838675	chr6:31519480~31520291:-
BRCA	trans	rs714543	1	rs714543	ENSG00000219797.2	PPIAP9	-6.2	8.31e-10	0.000628	-0.23	-0.19	Plateletcrit;	chr7:44847477	chr6:31519480~31520291:-
BRCA	trans	rs714543	1	rs757693	ENSG00000219797.2	PPIAP9	-6.2	8.31e-10	0.000628	-0.23	-0.19	Plateletcrit;	chr7:44848430	chr6:31519480~31520291:-
BRCA	trans	rs9467711	0.591	rs10484435	ENSG00000253570.1	RNF5P1	6.2	8.32e-10	0.000629	0.45	0.19	Autism spectrum disorder or schizophrenia;	chr6:26031583	chr8:38600661~38601200:-
BRCA	trans	rs7830939	0.586	rs9918737	ENSG00000253893.2	FAM85B	-6.2	8.35e-10	0.000632	-0.26	-0.19	Neuroticism;	chr8:9464033	chr8:8167819~8226614:-
BRCA	trans	rs1707322	1	rs6675222	ENSG00000255397.1	AC022182.2	-6.2	8.36e-10	0.000632	-0.24	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45860904	chr8:60937705~60939871:-
BRCA	trans	rs1707322	1	rs4660895	ENSG00000255397.1	AC022182.2	-6.2	8.36e-10	0.000632	-0.24	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45864067	chr8:60937705~60939871:-
BRCA	trans	rs1707322	1	rs4660318	ENSG00000255397.1	AC022182.2	-6.2	8.36e-10	0.000632	-0.24	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45869204	chr8:60937705~60939871:-
BRCA	trans	rs1707322	1	rs10890360	ENSG00000255397.1	AC022182.2	-6.2	8.36e-10	0.000632	-0.24	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45872772	chr8:60937705~60939871:-
BRCA	trans	rs9834975	0.544	rs12485294	ENSG00000267076.1	CCDC58P3	-6.19	8.38e-10	0.000634	-0.22	-0.19	Diastolic blood pressure;	chr3:122566158	chr18:12211378~12211807:+
BRCA	trans	rs2066819	0.786	rs111580405	ENSG00000273654.1	CTB-52I2.4	6.19	8.39e-10	0.000635	0.49	0.19	Psoriasis vulgaris;	chr12:56345773	chr19:18022403~18032099:+
BRCA	trans	rs1707322	1	rs7547189	ENSG00000255397.1	AC022182.2	-6.19	8.4e-10	0.000635	-0.24	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45853842	chr8:60937705~60939871:-
BRCA	trans	rs1707322	1	rs7547284	ENSG00000255397.1	AC022182.2	-6.19	8.4e-10	0.000635	-0.24	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45853893	chr8:60937705~60939871:-
BRCA	trans	rs1707322	1	rs11211205	ENSG00000255397.1	AC022182.2	-6.19	8.4e-10	0.000635	-0.24	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45856202	chr8:60937705~60939871:-
BRCA	trans	rs2242330	0.862	rs10003115	ENSG00000226982.4	CENPCP1	6.19	8.41e-10	0.000636	0.27	0.19	Parkinson's disease;	chr4:67520510	chr12:89500093~89502670:+
BRCA	trans	rs2242330	0.815	rs10003368	ENSG00000226982.4	CENPCP1	6.19	8.41e-10	0.000636	0.27	0.19	Parkinson's disease;	chr4:67521343	chr12:89500093~89502670:+
BRCA	trans	rs2242330	0.815	rs1391110	ENSG00000226982.4	CENPCP1	6.19	8.41e-10	0.000636	0.27	0.19	Parkinson's disease;	chr4:67530669	chr12:89500093~89502670:+
BRCA	trans	rs7032940	0.954	rs10980249	ENSG00000228236.2	TXNP5	6.19	8.42e-10	0.000637	0.25	0.19	Height;	chr9:110190494	chr2:149068596~149068910:-
BRCA	trans	rs9858542	0.953	rs6446272	ENSG00000197582.5	GPX1P1	-6.19	8.42e-10	0.000637	-0.21	-0.19	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49425854	chrX:13378735~13379340:-
BRCA	trans	rs1816854	0.515	rs11182269	ENSG00000178082.6	TWF1P1	6.19	8.43e-10	0.000637	0.25	0.19	Inflammatory bowel disease;	chr12:43801186	chr17:29203426~29204474:-
BRCA	trans	rs1707322	1	rs7532204	ENSG00000255397.1	AC022182.2	6.19	8.45e-10	0.000639	0.24	0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46019403	chr8:60937705~60939871:-
BRCA	trans	rs2242330	0.822	rs6552102	ENSG00000226982.4	CENPCP1	6.19	8.5e-10	0.000643	0.27	0.19	Parkinson's disease;	chr4:67487744	chr12:89500093~89502670:+
BRCA	trans	rs1707322	1	rs4660331	ENSG00000255397.1	AC022182.2	-6.19	8.52e-10	0.000644	-0.25	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45993111	chr8:60937705~60939871:-
BRCA	trans	rs1707322	1	rs12097799	ENSG00000255397.1	AC022182.2	-6.19	8.52e-10	0.000644	-0.25	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45994214	chr8:60937705~60939871:-
BRCA	trans	rs11098499	0.644	rs2389880	ENSG00000120555.12	SEPT7P9	6.19	8.53e-10	0.000645	0.22	0.19	Corneal astigmatism;	chr4:119638715	chr10:38383069~38402916:-
BRCA	trans	rs1707322	1	rs6687301	ENSG00000255397.1	AC022182.2	-6.19	8.54e-10	0.000645	-0.25	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45917180	chr8:60937705~60939871:-
BRCA	trans	rs11098499	0.532	rs4504231	ENSG00000276805.1	RP11-291L22.6	6.19	8.54e-10	0.000646	0.22	0.19	Corneal astigmatism;	chr4:119665736	chr10:38451030~38451785:+
BRCA	trans	rs7746199	0.736	rs34064842	ENSG00000204709.4	LINC01556	6.19	8.55e-10	0.000646	0.49	0.19	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27720846	chr6:28943877~28944537:+
BRCA	trans	rs6831352	0.734	rs2602856	ENSG00000228407.2	RP4-800M22.1	-6.19	8.55e-10	0.000646	-0.25	-0.19	Alcohol dependence;	chr4:99107994	chr1:52160261~52160600:-
BRCA	trans	rs7568458	0.87	rs1058588	ENSG00000223886.3	RP11-251G23.2	-6.19	8.55e-10	0.000646	-0.21	-0.19	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr2:85581748	chr7:105530209~105530671:+
BRCA	trans	rs875971	0.545	rs73376401	ENSG00000234585.5	CCT6P3	6.19	8.57e-10	0.000648	0.2	0.19	Aortic root size;	chr7:66174841	chr7:65038354~65074713:+
BRCA	trans	rs9834975	0.565	rs28719935	ENSG00000267076.1	CCDC58P3	-6.19	8.61e-10	0.00065	-0.21	-0.19	Diastolic blood pressure;	chr3:122533461	chr18:12211378~12211807:+
BRCA	trans	rs17507216	0.628	rs4627310	ENSG00000235370.6	DNM1P51	-6.19	8.63e-10	0.000651	-0.27	-0.19	Excessive daytime sleepiness;	chr15:82708330	chr15:84398316~84411701:-
BRCA	trans	rs2117029	0.586	rs10783307	ENSG00000214391.3	TUBAP2	6.19	8.63e-10	0.000652	0.18	0.19	Intelligence (multi-trait analysis);	chr12:49135822	chr11:90282560~90284172:+
BRCA	trans	rs9834975	0.565	rs6792726	ENSG00000267076.1	CCDC58P3	-6.19	8.64e-10	0.000653	-0.21	-0.19	Diastolic blood pressure;	chr3:122531633	chr18:12211378~12211807:+
BRCA	trans	rs11098499	0.738	rs28687057	ENSG00000120555.12	SEPT7P9	6.19	8.7e-10	0.000656	0.23	0.19	Corneal astigmatism;	chr4:119359657	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.775	rs67281037	ENSG00000120555.12	SEPT7P9	6.19	8.7e-10	0.000656	0.23	0.19	Corneal astigmatism;	chr4:119360002	chr10:38383069~38402916:-
BRCA	trans	rs10028773	0.506	rs12374346	ENSG00000120555.12	SEPT7P9	6.19	8.7e-10	0.000656	0.23	0.19	Educational attainment;	chr4:119360550	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.866	rs12374244	ENSG00000120555.12	SEPT7P9	6.19	8.7e-10	0.000656	0.23	0.19	Corneal astigmatism;	chr4:119360817	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.866	rs12374352	ENSG00000120555.12	SEPT7P9	6.19	8.7e-10	0.000656	0.23	0.19	Corneal astigmatism;	chr4:119360822	chr10:38383069~38402916:-
BRCA	trans	rs8073060	0.521	rs225254	ENSG00000234130.2	RP13-88F20.1	-6.19	8.71e-10	0.000657	-0.21	-0.19	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35626365	chrX:93222220~93225015:-
BRCA	trans	rs11098499	0.564	rs11098507	ENSG00000120555.12	SEPT7P9	6.19	8.76e-10	0.000661	0.23	0.19	Corneal astigmatism;	chr4:119367131	chr10:38383069~38402916:-
BRCA	trans	rs875971	0.545	rs67775320	ENSG00000213640.3	EEF1DP4	-6.19	8.83e-10	0.000666	-0.26	-0.19	Aortic root size;	chr7:66193792	chr7:64862999~64864370:+
BRCA	trans	rs875971	0.545	rs11767262	ENSG00000234585.5	CCT6P3	6.19	8.83e-10	0.000667	0.2	0.19	Aortic root size;	chr7:66302237	chr7:65038354~65074713:+
BRCA	trans	rs1707322	1	rs6657720	ENSG00000255397.1	AC022182.2	-6.19	8.84e-10	0.000667	-0.25	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45920597	chr8:60937705~60939871:-
BRCA	trans	rs1707322	1	rs7526369	ENSG00000255397.1	AC022182.2	-6.19	8.84e-10	0.000667	-0.25	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45924888	chr8:60937705~60939871:-
BRCA	trans	rs2727020	0.675	rs1684258	ENSG00000134612.10	FOLH1B	6.19	8.88e-10	0.00067	0.27	0.19	Coronary artery disease;	chr11:49318468	chr11:89639227~89698718:+
BRCA	trans	rs2899832	0.5	rs10151128	ENSG00000215414.4	PSMA6P1	6.19	8.89e-10	0.000671	0.33	0.19	Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:35306578	chrY:13286638~13287378:+
BRCA	trans	rs1707322	1	rs7519181	ENSG00000255397.1	AC022182.2	-6.19	8.9e-10	0.000671	-0.25	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45922157	chr8:60937705~60939871:-
BRCA	trans	rs7113874	0.569	rs11041980	ENSG00000266891.1	RP11-692N5.2	6.19	8.9e-10	0.000671	0.22	0.19	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8557534	chr18:9734882~9735602:-
BRCA	trans	rs6831352	0.819	rs2851274	ENSG00000228407.2	RP4-800M22.1	-6.18	8.97e-10	0.000677	-0.25	-0.19	Alcohol dependence;	chr4:99104715	chr1:52160261~52160600:-
BRCA	trans	rs1707322	1	rs4660336	ENSG00000255397.1	AC022182.2	6.18	9e-10	0.000679	0.24	0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46022304	chr8:60937705~60939871:-
BRCA	trans	rs875971	0.545	rs316316	ENSG00000234585.5	CCT6P3	-6.18	9.01e-10	0.000679	-0.2	-0.19	Aortic root size;	chr7:66149270	chr7:65038354~65074713:+
BRCA	trans	rs2965280	0.744	rs115698911	ENSG00000270983.1	RP11-137J7.3	-6.18	9.01e-10	0.000679	-0.42	-0.19	Colorectal cancer;	chr19:34453798	chr6:142062717~142063053:+
BRCA	trans	rs1707322	1	rs10890355	ENSG00000255397.1	AC022182.2	-6.18	9.06e-10	0.000683	-0.24	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45851676	chr8:60937705~60939871:-
BRCA	trans	rs1707322	1	rs11211204	ENSG00000255397.1	AC022182.2	-6.18	9.06e-10	0.000683	-0.24	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45852192	chr8:60937705~60939871:-
BRCA	trans	rs2242330	0.862	rs13135430	ENSG00000226982.4	CENPCP1	6.18	9.07e-10	0.000684	0.26	0.19	Parkinson's disease;	chr4:67544895	chr12:89500093~89502670:+
BRCA	trans	rs853679	0.567	rs9969098	ENSG00000228078.1	HLA-U	-6.18	9.11e-10	0.000687	-0.28	-0.19	Depression;	chr6:28430971	chr6:29934101~29934286:+
BRCA	trans	rs853679	0.567	rs16894106	ENSG00000228078.1	HLA-U	-6.18	9.11e-10	0.000687	-0.28	-0.19	Depression;	chr6:28432562	chr6:29934101~29934286:+
BRCA	trans	rs875971	0.597	rs11763224	ENSG00000234585.5	CCT6P3	6.18	9.14e-10	0.000688	0.21	0.19	Aortic root size;	chr7:66518628	chr7:65038354~65074713:+
BRCA	trans	rs864643	1	rs1708056	ENSG00000188856.6	RPSAP47	6.18	9.14e-10	0.000689	0.27	0.19	Attention deficit hyperactivity disorder;	chr3:39531662	chr8:80558870~80559757:+
BRCA	trans	rs16837677	0.649	rs16837622	ENSG00000227183.3	HDGFP1	6.18	9.16e-10	0.00069	0.43	0.19	Sjögren's syndrome;	chr1:156725712	chrX:131646639~131646890:+
BRCA	trans	rs1933488	0.804	rs9397586	ENSG00000180015.12	RP11-756P10.3	-6.18	9.17e-10	0.00069	-0.25	-0.19	Prostate cancer;	chr6:153093152	chr4:188738373~188739494:+
BRCA	trans	rs1707322	1	rs6661500	ENSG00000255397.1	AC022182.2	-6.18	9.17e-10	0.000691	-0.25	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45999990	chr8:60937705~60939871:-
BRCA	trans	rs11098499	0.955	rs6815725	ENSG00000276997.3	RP11-378J18.9	6.18	9.2e-10	0.000693	0.23	0.19	Corneal astigmatism;	chr4:119237255	chr1:222477252~222504622:-
BRCA	trans	rs7617773	0.78	rs71323396	ENSG00000235912.1	RP1-159A19.3	-6.18	9.22e-10	0.000694	-0.25	-0.19	Coronary artery disease;	chr3:48333244	chr1:27649419~27649610:+
BRCA	trans	rs11098499	0.955	rs4145951	ENSG00000276997.3	RP11-378J18.9	6.18	9.23e-10	0.000695	0.23	0.19	Corneal astigmatism;	chr4:119234662	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.955	rs35916640	ENSG00000276997.3	RP11-378J18.9	6.18	9.23e-10	0.000695	0.23	0.19	Corneal astigmatism;	chr4:119234697	chr1:222477252~222504622:-
BRCA	trans	rs875971	0.545	rs316305	ENSG00000234585.5	CCT6P3	-6.18	9.24e-10	0.000696	-0.2	-0.19	Aortic root size;	chr7:66152984	chr7:65038354~65074713:+
BRCA	trans	rs11098499	0.604	rs2389887	ENSG00000253326.2	RP11-261C10.7	6.18	9.27e-10	0.000698	0.27	0.19	Corneal astigmatism;	chr4:119649489	chr1:243054861~243056394:-
BRCA	trans	rs11098499	0.604	rs34278750	ENSG00000253326.2	RP11-261C10.7	6.18	9.27e-10	0.000698	0.27	0.19	Corneal astigmatism;	chr4:119649981	chr1:243054861~243056394:-
BRCA	trans	rs714543	1	rs13245012	ENSG00000219797.2	PPIAP9	-6.18	9.3e-10	7e-04	-0.23	-0.19	Plateletcrit;	chr7:44826120	chr6:31519480~31520291:-
BRCA	trans	rs1707322	1	rs10890380	ENSG00000255397.1	AC022182.2	-6.18	9.3e-10	7e-04	-0.25	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45983797	chr8:60937705~60939871:-
BRCA	trans	rs11098499	0.657	rs10434028	ENSG00000120555.12	SEPT7P9	6.18	9.32e-10	0.000702	0.23	0.19	Corneal astigmatism;	chr4:119373309	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.955	rs56386062	ENSG00000276997.3	RP11-378J18.9	6.18	9.37e-10	0.000705	0.23	0.19	Corneal astigmatism;	chr4:119233980	chr1:222477252~222504622:-
BRCA	trans	rs6601327	0.641	rs10102170	ENSG00000253893.2	FAM85B	-6.18	9.37e-10	0.000705	-0.24	-0.19	Multiple myeloma (hyperdiploidy);	chr8:9753960	chr8:8167819~8226614:-
BRCA	trans	rs7617773	0.743	rs4632568	ENSG00000235912.1	RP1-159A19.3	-6.18	9.39e-10	0.000706	-0.25	-0.19	Coronary artery disease;	chr3:48326329	chr1:27649419~27649610:+
BRCA	trans	rs7647973	1	rs10865956	ENSG00000197582.5	GPX1P1	6.18	9.39e-10	0.000707	0.21	0.19	Menarche (age at onset);	chr3:49544126	chrX:13378735~13379340:-
BRCA	trans	rs9693857	0.52	rs6601320	ENSG00000253893.2	FAM85B	-6.18	9.41e-10	0.000708	-0.26	-0.19	Systolic blood pressure;	chr8:9498378	chr8:8167819~8226614:-
BRCA	trans	rs1707322	1	rs785478	ENSG00000255397.1	AC022182.2	6.18	9.43e-10	0.000709	0.24	0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46025963	chr8:60937705~60939871:-
BRCA	trans	rs2242330	0.862	rs7341003	ENSG00000226982.4	CENPCP1	6.17	9.47e-10	0.000713	0.27	0.19	Parkinson's disease;	chr4:67495866	chr12:89500093~89502670:+
BRCA	trans	rs7260598	1	rs7260598	ENSG00000261770.1	CTC-459F4.1	-6.17	9.48e-10	0.000713	-0.31	-0.19	Response to taxane treatment (placlitaxel);	chr19:24039984	chr19:27757184~27760849:-
BRCA	trans	rs1707322	0.835	rs946525	ENSG00000255397.1	AC022182.2	6.17	9.49e-10	0.000714	0.24	0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46021605	chr8:60937705~60939871:-
BRCA	trans	rs1707322	1	rs946524	ENSG00000255397.1	AC022182.2	6.17	9.49e-10	0.000714	0.24	0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46021888	chr8:60937705~60939871:-
BRCA	trans	rs6011368	0.84	rs2427638	ENSG00000226210.3	WASH7P	6.17	9.5e-10	0.000714	0.21	0.19	Clozapine-induced cytotoxicity;	chr20:64269364	chr12:14522~32015:-
BRCA	trans	rs902774	0.818	rs73110471	ENSG00000224520.2	KRT8P45	-6.17	9.55e-10	0.000718	-0.37	-0.19	Prostate cancer;	chr12:52923037	chr1:157073257~157074703:+
BRCA	trans	rs7647973	0.516	rs4499638	ENSG00000197582.5	GPX1P1	6.17	9.56e-10	0.000719	0.19	0.19	Menarche (age at onset);	chr3:49165349	chrX:13378735~13379340:-
BRCA	trans	rs9858542	0.953	rs11922013	ENSG00000197582.5	GPX1P1	-6.17	9.56e-10	0.000719	-0.21	-0.19	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49420922	chrX:13378735~13379340:-
BRCA	trans	rs3812762	1	rs3812762	ENSG00000266891.1	RP11-692N5.2	6.17	9.61e-10	0.000723	0.24	0.19	Hypospadias;	chr11:8730093	chr18:9734882~9735602:-
BRCA	trans	rs9393777	0.92	rs13196692	ENSG00000281831.1	HCP5B	6.17	9.62e-10	0.000723	0.47	0.19	Intelligence (multi-trait analysis);	chr6:27411340	chr6:29871895~29873783:-
BRCA	trans	rs7824557	0.737	rs2293855	ENSG00000254153.1	CTA-398F10.2	6.17	9.62e-10	0.000723	0.25	0.19	Retinal vascular caliber;	chr8:11319901	chr8:8456909~8461337:-
BRCA	trans	rs1671400	1	rs919586	ENSG00000246089.3	RP11-115C21.2	6.17	9.66e-10	0.000726	0.28	0.19	Obesity-related traits;	chr8:13317162	chr8:6403551~6407142:-
BRCA	trans	rs860295	0.812	rs7556519	ENSG00000241627.3	UBQLN4P1	-6.17	9.68e-10	0.000727	-0.2	-0.19	Body mass index;	chr1:155857755	chr3:148985868~148987668:-
BRCA	trans	rs7927771	0.832	rs935914	ENSG00000134612.10	FOLH1B	6.17	9.68e-10	0.000728	0.24	0.19	Subjective well-being;	chr11:47366048	chr11:89639227~89698718:+
BRCA	trans	rs12478296	0.591	rs12468297	ENSG00000260923.4	AC137934.1	-6.17	9.69e-10	0.000728	-0.26	-0.19	Obesity-related traits;	chr2:242054323	chr16:90185997~90222678:+
BRCA	trans	rs4834770	1	rs878375	ENSG00000275858.1	RP11-291L22.8	6.17	9.69e-10	0.000728	0.21	0.19	Blood protein levels;	chr4:119316419	chr10:38450738~38451069:-
BRCA	trans	rs1707322	1	rs12403666	ENSG00000255397.1	AC022182.2	-6.17	9.7e-10	0.000729	-0.25	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45965949	chr8:60937705~60939871:-
BRCA	trans	rs2220004	1	rs4939012	ENSG00000134612.10	FOLH1B	-6.17	9.76e-10	0.000733	-0.25	-0.19	Odorant perception (&beta-damascenone);	chr11:56028122	chr11:89639227~89698718:+
BRCA	trans	rs7617773	0.78	rs13067450	ENSG00000235912.1	RP1-159A19.3	-6.17	9.79e-10	0.000736	-0.25	-0.19	Coronary artery disease;	chr3:48295716	chr1:27649419~27649610:+
BRCA	trans	rs7617773	0.78	rs4479622	ENSG00000235912.1	RP1-159A19.3	-6.17	9.79e-10	0.000736	-0.25	-0.19	Coronary artery disease;	chr3:48296683	chr1:27649419~27649610:+
BRCA	trans	rs7617773	0.78	rs34946886	ENSG00000235912.1	RP1-159A19.3	-6.17	9.79e-10	0.000736	-0.25	-0.19	Coronary artery disease;	chr3:48296997	chr1:27649419~27649610:+
BRCA	trans	rs7617773	0.78	rs34589064	ENSG00000235912.1	RP1-159A19.3	-6.17	9.79e-10	0.000736	-0.25	-0.19	Coronary artery disease;	chr3:48298059	chr1:27649419~27649610:+
BRCA	trans	rs7617773	0.78	rs2541	ENSG00000235912.1	RP1-159A19.3	-6.17	9.79e-10	0.000736	-0.25	-0.19	Coronary artery disease;	chr3:48298128	chr1:27649419~27649610:+
BRCA	trans	rs7617773	0.78	rs13085251	ENSG00000235912.1	RP1-159A19.3	-6.17	9.79e-10	0.000736	-0.25	-0.19	Coronary artery disease;	chr3:48298555	chr1:27649419~27649610:+
BRCA	trans	rs2243480	1	rs6460260	ENSG00000230295.1	RP11-458F8.2	6.17	9.84e-10	0.000739	0.25	0.19	Diabetic kidney disease;	chr7:65750468	chr7:66880708~66882981:+
BRCA	trans	rs2243480	1	rs6460261	ENSG00000230295.1	RP11-458F8.2	6.17	9.84e-10	0.000739	0.25	0.19	Diabetic kidney disease;	chr7:65750593	chr7:66880708~66882981:+
BRCA	trans	rs66887589	0.616	rs11731675	ENSG00000120555.12	SEPT7P9	6.17	9.84e-10	0.000739	0.21	0.19	Diastolic blood pressure;	chr4:119291359	chr10:38383069~38402916:-
BRCA	trans	rs7570469	0.644	rs1122268	ENSG00000276390.1	RP1-197B17.5	6.17	9.85e-10	0.000739	0.24	0.19	Response to antipsychotic treatment;	chr2:79447334	chr12:47699401~47699917:-
BRCA	trans	rs902774	0.818	rs73108429	ENSG00000255815.3	KRT8P11	-6.17	9.94e-10	0.000746	-0.4	-0.19	Prostate cancer;	chr12:52877887	chr9:99305176~99306611:+
BRCA	trans	rs7824557	0.767	rs1897951	ENSG00000254153.1	CTA-398F10.2	6.17	9.98e-10	0.000749	0.25	0.19	Retinal vascular caliber;	chr8:11312345	chr8:8456909~8461337:-
BRCA	trans	rs875971	1	rs2420591	ENSG00000164669.11	INTS4P1	-6.17	1e-09	0.000751	-0.23	-0.19	Aortic root size;	chr7:66447394	chr7:65141225~65234216:+
BRCA	trans	rs6601327	0.602	rs7820917	ENSG00000253893.2	FAM85B	-6.17	1e-09	0.000752	-0.23	-0.19	Multiple myeloma (hyperdiploidy);	chr8:9790358	chr8:8167819~8226614:-
BRCA	trans	rs7647973	0.961	rs7626076	ENSG00000235912.1	RP1-159A19.3	-6.17	1e-09	0.000753	-0.25	-0.19	Menarche (age at onset);	chr3:49260706	chr1:27649419~27649610:+
BRCA	trans	rs11098499	0.644	rs3806808	ENSG00000276997.3	RP11-378J18.9	6.17	1.01e-09	0.000755	0.22	0.19	Corneal astigmatism;	chr4:119629930	chr1:222477252~222504622:-
BRCA	trans	rs1391708	0.688	rs35944841	ENSG00000121089.4	NACA3P	-6.16	1.01e-09	0.000758	-0.27	-0.19	Airway wall thickness;	chr12:56924673	chr4:164943290~164943937:+
BRCA	trans	rs7617773	0.743	rs6804986	ENSG00000235912.1	RP1-159A19.3	-6.16	1.01e-09	0.000761	-0.24	-0.19	Coronary artery disease;	chr3:48322105	chr1:27649419~27649610:+
BRCA	trans	rs2066819	1	rs77131854	ENSG00000273654.1	CTB-52I2.4	6.16	1.02e-09	0.000762	0.48	0.19	Psoriasis vulgaris;	chr12:56270447	chr19:18022403~18032099:+
BRCA	trans	rs853679	0.607	rs201002	ENSG00000253570.1	RNF5P1	6.16	1.02e-09	0.000762	0.4	0.19	Depression;	chr6:27840414	chr8:38600661~38601200:-
BRCA	trans	rs1568889	1	rs1568889	ENSG00000174912.7	METTL15P1	6.16	1.02e-09	0.000765	0.22	0.19	Bipolar disorder;	chr11:27987916	chr3:156713884~156714928:-
BRCA	trans	rs860295	0.58	rs66466805	ENSG00000241627.3	UBQLN4P1	-6.16	1.02e-09	0.000766	-0.21	-0.19	Body mass index;	chr1:155918875	chr3:148985868~148987668:-
BRCA	trans	rs7568458	0.905	rs10187424	ENSG00000223886.3	RP11-251G23.2	6.16	1.02e-09	0.000767	0.22	0.19	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr2:85567174	chr7:105530209~105530671:+
BRCA	trans	rs11098499	0.604	rs10022185	ENSG00000253326.2	RP11-261C10.7	6.16	1.03e-09	0.000772	0.27	0.19	Corneal astigmatism;	chr4:119650610	chr1:243054861~243056394:-
BRCA	trans	rs1707322	1	rs6677777	ENSG00000255397.1	AC022182.2	-6.16	1.04e-09	0.000777	-0.25	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46010164	chr8:60937705~60939871:-
BRCA	trans	rs9914988	0.576	rs67777803	ENSG00000267449.1	RP11-264B14.2	6.16	1.04e-09	0.000778	0.28	0.19	Glycated hemoglobin levels;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr17:28996304	chr17:61069856~61070356:-
BRCA	trans	rs7927771	0.832	rs10769258	ENSG00000134612.10	FOLH1B	6.16	1.04e-09	0.00078	0.24	0.19	Subjective well-being;	chr11:47369488	chr11:89639227~89698718:+
BRCA	trans	rs1707322	1	rs10890353	ENSG00000255397.1	AC022182.2	-6.16	1.05e-09	0.000786	-0.24	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45832711	chr8:60937705~60939871:-
BRCA	trans	rs7927771	0.832	rs4992357	ENSG00000134612.10	FOLH1B	-6.16	1.05e-09	0.000786	-0.24	-0.19	Subjective well-being;	chr11:47372087	chr11:89639227~89698718:+
BRCA	trans	rs875971	0.545	rs6961853	ENSG00000234585.5	CCT6P3	6.16	1.06e-09	0.000795	0.2	0.19	Aortic root size;	chr7:66537035	chr7:65038354~65074713:+
BRCA	trans	rs7260598	0.901	rs7251567	ENSG00000261770.1	CTC-459F4.1	6.16	1.06e-09	0.000795	0.32	0.19	Response to taxane treatment (placlitaxel);	chr19:24034489	chr19:27757184~27760849:-
BRCA	trans	rs481331	0.741	rs683538	ENSG00000272092.1	RP11-350N15.5	-6.16	1.06e-09	0.000796	-0.27	-0.19	Systemic juvenile idiopathic arthritis;	chr10:42653406	chr8:38382364~38383461:+
BRCA	trans	rs9467711	0.79	rs13195401	ENSG00000204709.4	LINC01556	6.16	1.06e-09	0.000796	0.49	0.19	Autism spectrum disorder or schizophrenia;	chr6:26463346	chr6:28943877~28944537:+
BRCA	trans	rs9467711	0.79	rs13195402	ENSG00000204709.4	LINC01556	6.16	1.06e-09	0.000796	0.49	0.19	Autism spectrum disorder or schizophrenia;	chr6:26463347	chr6:28943877~28944537:+
BRCA	trans	rs11098499	0.955	rs35197422	ENSG00000276997.3	RP11-378J18.9	6.16	1.06e-09	0.000797	0.23	0.19	Corneal astigmatism;	chr4:119248159	chr1:222477252~222504622:-
BRCA	trans	rs864643	1	rs673426	ENSG00000188856.6	RPSAP47	6.16	1.06e-09	0.000797	0.3	0.19	Attention deficit hyperactivity disorder;	chr3:39520286	chr8:80558870~80559757:+
BRCA	trans	rs11098499	0.687	rs71610270	ENSG00000120555.12	SEPT7P9	6.16	1.07e-09	8e-04	0.22	0.19	Corneal astigmatism;	chr4:119366281	chr10:38383069~38402916:-
BRCA	trans	rs875971	0.545	rs66594357	ENSG00000234585.5	CCT6P3	6.15	1.07e-09	0.000802	0.2	0.19	Aortic root size;	chr7:66327797	chr7:65038354~65074713:+
BRCA	trans	rs941207	0.756	rs2950394	ENSG00000257210.1	NACAP3	-6.15	1.08e-09	0.000806	-0.25	-0.19	Platelet count;	chr12:56644548	chr12:93124063~93124543:-
BRCA	trans	rs6683419	1	rs7512774	ENSG00000224237.1	MINOS1P3	6.15	1.08e-09	0.000808	0.2	0.19	Serum thyroid-stimulating hormone levels;	chr1:19498532	chr3:27214816~27215018:-
BRCA	trans	rs6683419	0.967	rs12077734	ENSG00000224237.1	MINOS1P3	6.15	1.08e-09	0.000808	0.2	0.19	Serum thyroid-stimulating hormone levels;	chr1:19499206	chr3:27214816~27215018:-
BRCA	trans	rs7617773	0.817	rs13094727	ENSG00000235912.1	RP1-159A19.3	-6.15	1.08e-09	0.000809	-0.25	-0.19	Coronary artery disease;	chr3:48281999	chr1:27649419~27649610:+
BRCA	trans	rs12439619	0.693	rs8034801	ENSG00000235370.6	DNM1P51	-6.15	1.08e-09	0.000811	-0.24	-0.19	Intelligence (multi-trait analysis);	chr15:82183996	chr15:84398316~84411701:-
BRCA	trans	rs11782517	0.92	rs13248589	ENSG00000253893.2	FAM85B	-6.15	1.08e-09	0.000812	-0.27	-0.19	Nose size;	chr8:10248089	chr8:8167819~8226614:-
BRCA	trans	rs2243480	0.908	rs4718273	ENSG00000230295.1	RP11-458F8.2	6.15	1.09e-09	0.000813	0.25	0.19	Diabetic kidney disease;	chr7:65751112	chr7:66880708~66882981:+
BRCA	trans	rs11098499	0.535	rs7671759	ENSG00000120555.12	SEPT7P9	6.15	1.09e-09	0.000814	0.23	0.19	Corneal astigmatism;	chr4:119326939	chr10:38383069~38402916:-
BRCA	trans	rs7927771	0.864	rs2053979	ENSG00000134612.10	FOLH1B	-6.15	1.09e-09	0.000814	-0.25	-0.19	Subjective well-being;	chr11:47417893	chr11:89639227~89698718:+
BRCA	trans	rs875971	0.545	rs801199	ENSG00000234585.5	CCT6P3	-6.15	1.09e-09	0.000815	-0.2	-0.19	Aortic root size;	chr7:66560286	chr7:65038354~65074713:+
BRCA	trans	rs875971	0.545	rs73152714	ENSG00000234585.5	CCT6P3	6.15	1.09e-09	0.000815	0.2	0.19	Aortic root size;	chr7:66534641	chr7:65038354~65074713:+
BRCA	trans	rs875971	0.545	rs4718364	ENSG00000234585.5	CCT6P3	6.15	1.09e-09	0.000815	0.2	0.19	Aortic root size;	chr7:66536353	chr7:65038354~65074713:+
BRCA	trans	rs12614435	0.512	rs16866420	ENSG00000269800.1	PLEKHA3P1	6.15	1.09e-09	0.000815	0.22	0.19	Atrial fibrillation;	chr2:178626508	chr19:41521043~41521989:-
BRCA	trans	rs1580019	0.563	rs2392071	ENSG00000213492.2	NT5C3AP1	-6.15	1.09e-09	0.000816	-0.25	-0.19	Cognitive ability;	chr7:32532924	chr4:117574512~117576174:-
BRCA	trans	rs7746199	0.673	rs35501037	ENSG00000228078.1	HLA-U	-6.15	1.09e-09	0.000819	-0.48	-0.19	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27771787	chr6:29934101~29934286:+
BRCA	trans	rs1707322	1	rs6695421	ENSG00000255397.1	AC022182.2	-6.15	1.1e-09	0.000819	-0.24	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45914535	chr8:60937705~60939871:-
BRCA	trans	rs941207	0.507	rs73337030	ENSG00000257210.1	NACAP3	-6.15	1.1e-09	0.00082	-0.22	-0.19	Platelet count;	chr12:56652410	chr12:93124063~93124543:-
BRCA	trans	rs1707322	0.964	rs6697830	ENSG00000255397.1	AC022182.2	-6.15	1.1e-09	0.000821	-0.24	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45824805	chr8:60937705~60939871:-
BRCA	trans	rs2069408	1	rs2069408	ENSG00000243538.1	CTB-55B8.1	-6.15	1.1e-09	0.000822	-0.24	-0.19	Asthma;	chr12:55970537	chr5:16902294~16902641:-
BRCA	trans	rs2840044	1	rs9891800	ENSG00000234130.2	RP13-88F20.1	6.15	1.1e-09	0.000822	0.21	0.19	Response to radiotherapy in cancer (late toxicity);	chr17:35567996	chrX:93222220~93225015:-
BRCA	trans	rs7617773	0.78	rs7645425	ENSG00000235912.1	RP1-159A19.3	-6.15	1.1e-09	0.000823	-0.25	-0.19	Coronary artery disease;	chr3:48320879	chr1:27649419~27649610:+
BRCA	trans	rs7617773	0.743	rs11716371	ENSG00000235912.1	RP1-159A19.3	-6.15	1.1e-09	0.000823	-0.25	-0.19	Coronary artery disease;	chr3:48321260	chr1:27649419~27649610:+
BRCA	trans	rs7617773	0.78	rs6793223	ENSG00000235912.1	RP1-159A19.3	-6.15	1.1e-09	0.000823	-0.25	-0.19	Coronary artery disease;	chr3:48322611	chr1:27649419~27649610:+
BRCA	trans	rs7617773	0.78	rs11714944	ENSG00000235912.1	RP1-159A19.3	-6.15	1.1e-09	0.000823	-0.25	-0.19	Coronary artery disease;	chr3:48325481	chr1:27649419~27649610:+
BRCA	trans	rs7617773	0.78	rs7653336	ENSG00000235912.1	RP1-159A19.3	-6.15	1.1e-09	0.000823	-0.25	-0.19	Coronary artery disease;	chr3:48327974	chr1:27649419~27649610:+
BRCA	trans	rs11098499	0.913	rs10010696	ENSG00000276997.3	RP11-378J18.9	6.15	1.1e-09	0.000825	0.23	0.19	Corneal astigmatism;	chr4:119243148	chr1:222477252~222504622:-
BRCA	trans	rs1707322	1	rs11211223	ENSG00000255397.1	AC022182.2	-6.15	1.1e-09	0.000826	-0.24	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45914933	chr8:60937705~60939871:-
BRCA	trans	rs2965280	0.744	rs80296376	ENSG00000270983.1	RP11-137J7.3	-6.15	1.11e-09	0.000827	-0.42	-0.19	Colorectal cancer;	chr19:34420469	chr6:142062717~142063053:+
BRCA	trans	rs6831352	0.819	rs13832	ENSG00000228407.2	RP4-800M22.1	-6.15	1.11e-09	0.000827	-0.25	-0.19	Alcohol dependence;	chr4:99071924	chr1:52160261~52160600:-
BRCA	trans	rs875971	0.895	rs10755833	ENSG00000164669.11	INTS4P1	-6.15	1.11e-09	0.000827	-0.23	-0.19	Aortic root size;	chr7:66448930	chr7:65141225~65234216:+
BRCA	trans	rs875971	0.895	rs1833495	ENSG00000164669.11	INTS4P1	-6.15	1.11e-09	0.000827	-0.23	-0.19	Aortic root size;	chr7:66456608	chr7:65141225~65234216:+
BRCA	trans	rs875971	0.964	rs6945032	ENSG00000164669.11	INTS4P1	-6.15	1.11e-09	0.000827	-0.23	-0.19	Aortic root size;	chr7:66457499	chr7:65141225~65234216:+
BRCA	trans	rs875971	0.929	rs12673810	ENSG00000164669.11	INTS4P1	-6.15	1.11e-09	0.000827	-0.23	-0.19	Aortic root size;	chr7:66458866	chr7:65141225~65234216:+
BRCA	trans	rs875971	1	rs6961155	ENSG00000164669.11	INTS4P1	-6.15	1.11e-09	0.000827	-0.23	-0.19	Aortic root size;	chr7:66468308	chr7:65141225~65234216:+
BRCA	trans	rs875971	1	rs7789768	ENSG00000164669.11	INTS4P1	-6.15	1.11e-09	0.000827	-0.23	-0.19	Aortic root size;	chr7:66473993	chr7:65141225~65234216:+
BRCA	trans	rs875971	1	rs1363055	ENSG00000164669.11	INTS4P1	-6.15	1.11e-09	0.000827	-0.23	-0.19	Aortic root size;	chr7:66478288	chr7:65141225~65234216:+
BRCA	trans	rs875971	0.964	rs9691480	ENSG00000164669.11	INTS4P1	-6.15	1.11e-09	0.000827	-0.23	-0.19	Aortic root size;	chr7:66479319	chr7:65141225~65234216:+
BRCA	trans	rs9467711	0.659	rs3823158	ENSG00000281831.1	HCP5B	6.15	1.11e-09	0.000827	0.43	0.19	Autism spectrum disorder or schizophrenia;	chr6:26463043	chr6:29871895~29873783:-
BRCA	trans	rs853679	0.607	rs13211507	ENSG00000281831.1	HCP5B	6.15	1.11e-09	0.000828	0.45	0.19	Depression;	chr6:28289600	chr6:29871895~29873783:-
BRCA	trans	rs853679	0.607	rs34691223	ENSG00000281831.1	HCP5B	6.15	1.11e-09	0.000828	0.45	0.19	Depression;	chr6:28290431	chr6:29871895~29873783:-
BRCA	trans	rs1816854	0.515	rs73093785	ENSG00000178082.6	TWF1P1	6.15	1.11e-09	0.000831	0.24	0.19	Inflammatory bowel disease;	chr12:43792824	chr17:29203426~29204474:-
BRCA	trans	rs11098499	0.644	rs10050092	ENSG00000120555.12	SEPT7P9	6.15	1.12e-09	0.000833	0.22	0.19	Corneal astigmatism;	chr4:119610930	chr10:38383069~38402916:-
BRCA	trans	rs4713118	0.869	rs6914924	ENSG00000204709.4	LINC01556	6.15	1.12e-09	0.000834	0.26	0.19	Parkinson's disease;	chr6:27743751	chr6:28943877~28944537:+
BRCA	trans	rs2637030	0.502	rs12656684	ENSG00000275328.1	RP11-730B22.4	-6.15	1.12e-09	0.000834	-0.27	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr5:53517167	chr7:5031608~5037831:-
BRCA	trans	rs7927771	0.698	rs34467936	ENSG00000134612.10	FOLH1B	-6.15	1.12e-09	0.000835	-0.25	-0.19	Subjective well-being;	chr11:47893747	chr11:89639227~89698718:+
BRCA	trans	rs875971	1	rs12698523	ENSG00000164669.11	INTS4P1	-6.15	1.12e-09	0.000838	-0.23	-0.19	Aortic root size;	chr7:66503126	chr7:65141225~65234216:+
BRCA	trans	rs11992162	1	rs7460395	ENSG00000253893.2	FAM85B	-6.15	1.12e-09	0.000839	-0.24	-0.19	Monocyte count;	chr8:11977866	chr8:8167819~8226614:-
BRCA	trans	rs546131	0.642	rs61881103	ENSG00000225531.1	RP11-196I18.3	-6.15	1.12e-09	0.000839	-0.29	-0.19	Lung disease severity in cystic fibrosis;	chr11:34816717	chr9:107116829~107117557:+
BRCA	trans	rs673253	0.662	rs11586016	ENSG00000231007.5	CDC20P1	6.15	1.13e-09	0.00084	0.23	0.19	Intelligence (multi-trait analysis);	chr1:43566122	chr9:87011652~87013151:+
BRCA	trans	rs875971	0.545	rs73376394	ENSG00000234585.5	CCT6P3	6.15	1.13e-09	0.00084	0.2	0.19	Aortic root size;	chr7:66172694	chr7:65038354~65074713:+
BRCA	trans	rs11098499	0.913	rs11098496	ENSG00000276997.3	RP11-378J18.9	6.15	1.13e-09	0.000841	0.23	0.19	Corneal astigmatism;	chr4:119246311	chr1:222477252~222504622:-
BRCA	trans	rs7927771	1	rs12787330	ENSG00000134612.10	FOLH1B	-6.15	1.13e-09	0.000841	-0.25	-0.19	Subjective well-being;	chr11:47790759	chr11:89639227~89698718:+
BRCA	trans	rs875971	0.964	rs6978429	ENSG00000164669.11	INTS4P1	-6.15	1.13e-09	0.000843	-0.23	-0.19	Aortic root size;	chr7:66494889	chr7:65141225~65234216:+
BRCA	trans	rs875971	1	rs4718357	ENSG00000164669.11	INTS4P1	-6.15	1.13e-09	0.000843	-0.23	-0.19	Aortic root size;	chr7:66495891	chr7:65141225~65234216:+
BRCA	trans	rs2117029	0.586	rs11168884	ENSG00000214391.3	TUBAP2	6.15	1.13e-09	0.000844	0.18	0.19	Intelligence (multi-trait analysis);	chr12:49146109	chr11:90282560~90284172:+
BRCA	trans	rs7927771	1	rs7105282	ENSG00000134612.10	FOLH1B	-6.15	1.14e-09	0.000847	-0.25	-0.19	Subjective well-being;	chr11:47784062	chr11:89639227~89698718:+
BRCA	trans	rs7568458	0.87	rs2366639	ENSG00000223886.3	RP11-251G23.2	6.14	1.14e-09	0.000849	0.21	0.19	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr2:85582832	chr7:105530209~105530671:+
BRCA	trans	rs853679	0.546	rs200995	ENSG00000253570.1	RNF5P1	-6.14	1.14e-09	0.00085	-0.42	-0.19	Depression;	chr6:27845916	chr8:38600661~38601200:-
BRCA	trans	rs875971	0.528	rs801213	ENSG00000234585.5	CCT6P3	-6.14	1.14e-09	0.000851	-0.2	-0.19	Aortic root size;	chr7:66549931	chr7:65038354~65074713:+
BRCA	trans	rs875971	0.545	rs801212	ENSG00000234585.5	CCT6P3	-6.14	1.14e-09	0.000851	-0.2	-0.19	Aortic root size;	chr7:66550643	chr7:65038354~65074713:+
BRCA	trans	rs11098499	0.955	rs13129661	ENSG00000276997.3	RP11-378J18.9	6.14	1.14e-09	0.000852	0.23	0.19	Corneal astigmatism;	chr4:119231754	chr1:222477252~222504622:-
BRCA	trans	rs7617773	0.78	rs13079728	ENSG00000235912.1	RP1-159A19.3	-6.14	1.14e-09	0.000852	-0.25	-0.19	Coronary artery disease;	chr3:48297870	chr1:27649419~27649610:+
BRCA	trans	rs9393777	0.92	rs13195040	ENSG00000281831.1	HCP5B	-6.14	1.14e-09	0.000853	-0.41	-0.19	Intelligence (multi-trait analysis);	chr6:27446145	chr6:29871895~29873783:-
BRCA	trans	rs11098499	1	rs28374891	ENSG00000276997.3	RP11-378J18.9	6.14	1.14e-09	0.000853	0.23	0.19	Corneal astigmatism;	chr4:119262395	chr1:222477252~222504622:-
BRCA	trans	rs875971	0.964	rs6945019	ENSG00000164669.11	INTS4P1	-6.14	1.14e-09	0.000853	-0.23	-0.19	Aortic root size;	chr7:66457471	chr7:65141225~65234216:+
BRCA	trans	rs703108	0.731	rs7898954	ENSG00000241411.1	RP11-192C21.1	-6.14	1.15e-09	0.000854	-0.21	-0.19	Monocyte percentage of white cells;	chr10:22034717	chr4:134952259~134952889:-
BRCA	trans	rs2840044	1	rs7212704	ENSG00000234130.2	RP13-88F20.1	6.14	1.15e-09	0.000859	0.21	0.19	Response to radiotherapy in cancer (late toxicity);	chr17:35571878	chrX:93222220~93225015:-
BRCA	trans	rs2840044	1	rs11080357	ENSG00000234130.2	RP13-88F20.1	6.14	1.15e-09	0.000859	0.21	0.19	Response to radiotherapy in cancer (late toxicity);	chr17:35571914	chrX:93222220~93225015:-
BRCA	trans	rs877636	0.847	rs2017445	ENSG00000243403.1	RP11-330L19.1	6.14	1.16e-09	0.000862	0.36	0.19	Cognitive function;	chr12:56013288	chr15:64592979~64593326:+
BRCA	trans	rs7617773	0.779	rs77957078	ENSG00000235912.1	RP1-159A19.3	-6.14	1.16e-09	0.000862	-0.25	-0.19	Coronary artery disease;	chr3:48289796	chr1:27649419~27649610:+
BRCA	trans	rs1707322	1	rs10890378	ENSG00000255397.1	AC022182.2	6.14	1.16e-09	0.000865	0.24	0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45944985	chr8:60937705~60939871:-
BRCA	trans	rs875971	0.929	rs12535036	ENSG00000164669.11	INTS4P1	-6.14	1.16e-09	0.000865	-0.23	-0.19	Aortic root size;	chr7:66499076	chr7:65141225~65234216:+
BRCA	trans	rs875971	1	rs6970030	ENSG00000164669.11	INTS4P1	-6.14	1.16e-09	0.000865	-0.23	-0.19	Aortic root size;	chr7:66503692	chr7:65141225~65234216:+
BRCA	trans	rs875971	0.928	rs6970357	ENSG00000164669.11	INTS4P1	-6.14	1.16e-09	0.000865	-0.23	-0.19	Aortic root size;	chr7:66503891	chr7:65141225~65234216:+
BRCA	trans	rs864643	0.891	rs1708057	ENSG00000188856.6	RPSAP47	6.14	1.16e-09	0.000865	0.27	0.19	Attention deficit hyperactivity disorder;	chr3:39499895	chr8:80558870~80559757:+
BRCA	trans	rs864643	0.947	rs1768241	ENSG00000188856.6	RPSAP47	6.14	1.16e-09	0.000865	0.27	0.19	Attention deficit hyperactivity disorder;	chr3:39499987	chr8:80558870~80559757:+
BRCA	trans	rs864643	0.891	rs1708059	ENSG00000188856.6	RPSAP47	6.14	1.16e-09	0.000865	0.27	0.19	Attention deficit hyperactivity disorder;	chr3:39500059	chr8:80558870~80559757:+
BRCA	trans	rs864643	0.947	rs1768242	ENSG00000188856.6	RPSAP47	6.14	1.16e-09	0.000865	0.27	0.19	Attention deficit hyperactivity disorder;	chr3:39500222	chr8:80558870~80559757:+
BRCA	trans	rs11098499	0.78	rs7680914	ENSG00000253326.2	RP11-261C10.7	6.14	1.16e-09	0.000868	0.27	0.19	Corneal astigmatism;	chr4:119641898	chr1:243054861~243056394:-
BRCA	trans	rs7568458	1	rs7568458	ENSG00000223886.3	RP11-251G23.2	6.14	1.17e-09	0.000868	0.22	0.19	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr2:85561052	chr7:105530209~105530671:+
BRCA	trans	rs875971	0.545	rs67775320	ENSG00000234585.5	CCT6P3	6.14	1.17e-09	0.000872	0.2	0.19	Aortic root size;	chr7:66193792	chr7:65038354~65074713:+
BRCA	trans	rs7617773	0.78	rs4541431	ENSG00000235912.1	RP1-159A19.3	-6.14	1.17e-09	0.000873	-0.25	-0.19	Coronary artery disease;	chr3:48323728	chr1:27649419~27649610:+
BRCA	trans	rs7617773	0.743	rs13071960	ENSG00000235912.1	RP1-159A19.3	-6.14	1.17e-09	0.000873	-0.25	-0.19	Coronary artery disease;	chr3:48326047	chr1:27649419~27649610:+
BRCA	trans	rs7617773	0.78	rs11130164	ENSG00000235912.1	RP1-159A19.3	-6.14	1.17e-09	0.000873	-0.25	-0.19	Coronary artery disease;	chr3:48327544	chr1:27649419~27649610:+
BRCA	trans	rs875971	0.545	rs316324	ENSG00000213640.3	EEF1DP4	6.14	1.18e-09	0.000875	0.26	0.19	Aortic root size;	chr7:66145627	chr7:64862999~64864370:+
BRCA	trans	rs875971	0.545	rs316323	ENSG00000213640.3	EEF1DP4	6.14	1.18e-09	0.000875	0.26	0.19	Aortic root size;	chr7:66146002	chr7:64862999~64864370:+
BRCA	trans	rs11098499	0.722	rs28713555	ENSG00000120555.12	SEPT7P9	6.14	1.18e-09	0.000876	0.22	0.19	Corneal astigmatism;	chr4:119330840	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.754	rs938056	ENSG00000276997.3	RP11-378J18.9	6.14	1.18e-09	0.00088	0.22	0.19	Corneal astigmatism;	chr4:119316298	chr1:222477252~222504622:-
BRCA	trans	rs17507216	0.681	rs28877110	ENSG00000235370.6	DNM1P51	-6.14	1.18e-09	0.00088	-0.28	-0.19	Excessive daytime sleepiness;	chr15:82672111	chr15:84398316~84411701:-
BRCA	trans	rs1707322	1	rs6429588	ENSG00000255397.1	AC022182.2	-6.14	1.18e-09	0.000882	-0.25	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45988386	chr8:60937705~60939871:-
BRCA	trans	rs875971	0.545	rs2420456	ENSG00000234585.5	CCT6P3	6.14	1.18e-09	0.000882	0.2	0.19	Aortic root size;	chr7:66280619	chr7:65038354~65074713:+
BRCA	trans	rs7570469	0.689	rs1451543	ENSG00000276390.1	RP1-197B17.5	6.14	1.19e-09	0.000883	0.24	0.19	Response to antipsychotic treatment;	chr2:79442405	chr12:47699401~47699917:-
BRCA	trans	rs6121246	0.559	rs6119650	ENSG00000279352.1	RP11-411B10.7	6.14	1.19e-09	0.000885	0.27	0.19	Mean corpuscular hemoglobin;	chr20:31670677	chr18:14010054~14010917:+
BRCA	trans	rs7260598	0.892	rs67180860	ENSG00000261770.1	CTC-459F4.1	6.14	1.19e-09	0.000887	0.32	0.19	Response to taxane treatment (placlitaxel);	chr19:24023433	chr19:27757184~27760849:-
BRCA	trans	rs7647973	1	rs8897	ENSG00000197582.5	GPX1P1	6.14	1.2e-09	0.000891	0.2	0.19	Menarche (age at onset);	chr3:49422974	chrX:13378735~13379340:-
BRCA	trans	rs11098499	0.644	rs34835603	ENSG00000276997.3	RP11-378J18.9	6.14	1.2e-09	0.000893	0.22	0.19	Corneal astigmatism;	chr4:119632273	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.615	rs28850368	ENSG00000276997.3	RP11-378J18.9	6.14	1.2e-09	0.000893	0.22	0.19	Corneal astigmatism;	chr4:119633158	chr1:222477252~222504622:-
BRCA	trans	rs875971	0.545	rs316324	ENSG00000234585.5	CCT6P3	-6.14	1.2e-09	0.000894	-0.2	-0.19	Aortic root size;	chr7:66145627	chr7:65038354~65074713:+
BRCA	trans	rs875971	0.545	rs316323	ENSG00000234585.5	CCT6P3	-6.14	1.2e-09	0.000894	-0.2	-0.19	Aortic root size;	chr7:66146002	chr7:65038354~65074713:+
BRCA	trans	rs875971	0.545	rs73376401	ENSG00000213640.3	EEF1DP4	-6.14	1.2e-09	0.000894	-0.26	-0.19	Aortic root size;	chr7:66174841	chr7:64862999~64864370:+
BRCA	trans	rs4713118	0.869	rs10214440	ENSG00000204709.4	LINC01556	6.14	1.2e-09	0.000895	0.26	0.19	Parkinson's disease;	chr6:27734661	chr6:28943877~28944537:+
BRCA	trans	rs1707322	1	rs12060274	ENSG00000255397.1	AC022182.2	-6.14	1.21e-09	0.000898	-0.24	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45825390	chr8:60937705~60939871:-
BRCA	trans	rs2066819	0.892	rs117305040	ENSG00000273654.1	CTB-52I2.4	6.14	1.21e-09	0.000898	0.48	0.19	Psoriasis vulgaris;	chr12:56264104	chr19:18022403~18032099:+
BRCA	trans	rs2242330	0.862	rs10440481	ENSG00000226982.4	CENPCP1	6.13	1.21e-09	0.000899	0.27	0.19	Parkinson's disease;	chr4:67497372	chr12:89500093~89502670:+
BRCA	trans	rs2117029	0.554	rs12306494	ENSG00000214391.3	TUBAP2	6.13	1.22e-09	0.000903	0.18	0.19	Intelligence (multi-trait analysis);	chr12:49136998	chr11:90282560~90284172:+
BRCA	trans	rs2840044	1	rs225251	ENSG00000234130.2	RP13-88F20.1	-6.13	1.22e-09	0.000905	-0.21	-0.19	Response to radiotherapy in cancer (late toxicity);	chr17:35624209	chrX:93222220~93225015:-
BRCA	trans	rs1459104	1	rs66510003	ENSG00000134612.10	FOLH1B	-6.13	1.22e-09	0.000906	-0.38	-0.19	Body mass index;	chr11:55392720	chr11:89639227~89698718:+
BRCA	trans	rs875971	0.545	rs6460281	ENSG00000234585.5	CCT6P3	6.13	1.22e-09	0.000909	0.2	0.19	Aortic root size;	chr7:66216128	chr7:65038354~65074713:+
BRCA	trans	rs877636	0.847	rs2017445	ENSG00000234513.1	AC073072.7	6.13	1.23e-09	0.000913	0.37	0.19	Cognitive function;	chr12:56013288	chr7:22773646~22773993:-
BRCA	trans	rs875971	1	rs12532998	ENSG00000164669.11	INTS4P1	-6.13	1.23e-09	0.000916	-0.23	-0.19	Aortic root size;	chr7:66502472	chr7:65141225~65234216:+
BRCA	trans	rs11098499	0.955	rs13114751	ENSG00000276997.3	RP11-378J18.9	6.13	1.23e-09	0.000916	0.23	0.19	Corneal astigmatism;	chr4:119235462	chr1:222477252~222504622:-
BRCA	trans	rs7570469	0.762	rs12623907	ENSG00000276390.1	RP1-197B17.5	6.13	1.23e-09	0.000916	0.24	0.19	Response to antipsychotic treatment;	chr2:79445305	chr12:47699401~47699917:-
BRCA	trans	rs7570469	0.762	rs588259	ENSG00000276390.1	RP1-197B17.5	6.13	1.23e-09	0.000918	0.24	0.19	Response to antipsychotic treatment;	chr2:79451025	chr12:47699401~47699917:-
BRCA	trans	rs17507216	0.628	rs28371837	ENSG00000235370.6	DNM1P51	-6.13	1.24e-09	0.000918	-0.27	-0.19	Excessive daytime sleepiness;	chr15:82714435	chr15:84398316~84411701:-
BRCA	trans	rs11098499	0.863	rs3736115	ENSG00000120555.12	SEPT7P9	-6.13	1.24e-09	0.000918	-0.23	-0.19	Corneal astigmatism;	chr4:119567548	chr10:38383069~38402916:-
BRCA	trans	rs11168854	0.719	rs11168890	ENSG00000214391.3	TUBAP2	6.13	1.24e-09	0.00092	0.18	0.19	Body mass index;	chr12:49150130	chr11:90282560~90284172:+
BRCA	trans	rs1580019	0.522	rs10951340	ENSG00000213492.2	NT5C3AP1	-6.13	1.24e-09	0.000923	-0.25	-0.19	Cognitive ability;	chr7:32522796	chr4:117574512~117576174:-
BRCA	trans	rs875971	0.545	rs2420612	ENSG00000213640.3	EEF1DP4	-6.13	1.24e-09	0.000923	-0.27	-0.19	Aortic root size;	chr7:66536825	chr7:64862999~64864370:+
BRCA	trans	rs864643	0.891	rs4129648	ENSG00000188856.6	RPSAP47	6.13	1.24e-09	0.000923	0.29	0.19	Attention deficit hyperactivity disorder;	chr3:39519319	chr8:80558870~80559757:+
BRCA	trans	rs11098499	0.754	rs1980025	ENSG00000120555.12	SEPT7P9	-6.13	1.25e-09	0.000926	-0.22	-0.19	Corneal astigmatism;	chr4:119331651	chr10:38383069~38402916:-
BRCA	trans	rs673253	0.556	rs55666439	ENSG00000231007.5	CDC20P1	6.13	1.25e-09	0.000928	0.25	0.19	Intelligence (multi-trait analysis);	chr1:43645541	chr9:87011652~87013151:+
BRCA	trans	rs673253	0.571	rs61768370	ENSG00000231007.5	CDC20P1	6.13	1.25e-09	0.000928	0.25	0.19	Intelligence (multi-trait analysis);	chr1:43646292	chr9:87011652~87013151:+
BRCA	trans	rs11098499	0.754	rs878376	ENSG00000276997.3	RP11-378J18.9	6.13	1.25e-09	0.000928	0.22	0.19	Corneal astigmatism;	chr4:119316547	chr1:222477252~222504622:-
BRCA	trans	rs9858542	0.953	rs1801143	ENSG00000197582.5	GPX1P1	-6.13	1.25e-09	0.00093	-0.21	-0.19	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49532767	chrX:13378735~13379340:-
BRCA	trans	rs1707322	1	rs10158032	ENSG00000255397.1	AC022182.2	-6.13	1.25e-09	0.00093	-0.24	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45867029	chr8:60937705~60939871:-
BRCA	trans	rs1707322	0.929	rs785513	ENSG00000255397.1	AC022182.2	6.13	1.25e-09	0.000931	0.24	0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46072648	chr8:60937705~60939871:-
BRCA	trans	rs7824557	0.767	rs4559208	ENSG00000270154.1	RP11-419I17.1	6.13	1.25e-09	0.000931	0.23	0.19	Retinal vascular caliber;	chr8:11296416	chr8:12476462~12477122:+
BRCA	trans	rs2220004	0.507	rs11231560	ENSG00000134612.10	FOLH1B	-6.13	1.26e-09	0.000932	-0.3	-0.19	Odorant perception (&beta-damascenone);	chr11:55922223	chr11:89639227~89698718:+
BRCA	trans	rs4713118	0.869	rs9283883	ENSG00000204709.4	LINC01556	6.13	1.26e-09	0.000935	0.26	0.19	Parkinson's disease;	chr6:27747691	chr6:28943877~28944537:+
BRCA	trans	rs2965280	0.546	rs10422771	ENSG00000270983.1	RP11-137J7.3	-6.13	1.26e-09	0.000935	-0.43	-0.19	Colorectal cancer;	chr19:34298849	chr6:142062717~142063053:+
BRCA	trans	rs2242330	0.862	rs10019340	ENSG00000226982.4	CENPCP1	6.13	1.26e-09	0.000938	0.26	0.19	Parkinson's disease;	chr4:67481185	chr12:89500093~89502670:+
BRCA	trans	rs2242330	0.862	rs13117786	ENSG00000226982.4	CENPCP1	6.13	1.26e-09	0.000938	0.26	0.19	Parkinson's disease;	chr4:67481858	chr12:89500093~89502670:+
BRCA	trans	rs1707322	1	rs4524994	ENSG00000255397.1	AC022182.2	-6.13	1.27e-09	0.000941	-0.24	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45904591	chr8:60937705~60939871:-
BRCA	trans	rs17301013	0.869	rs3133270	ENSG00000213331.4	RP11-713C19.2	-6.13	1.27e-09	0.000942	-0.21	-0.19	Systemic lupus erythematosus;	chr1:174819547	chr4:187970273~187971284:+
BRCA	trans	rs11782517	0.92	rs4288376	ENSG00000253893.2	FAM85B	-6.13	1.27e-09	0.000944	-0.27	-0.19	Nose size;	chr8:10247310	chr8:8167819~8226614:-
BRCA	trans	rs12546962	0.731	rs9329185	ENSG00000253893.2	FAM85B	-6.13	1.27e-09	0.000944	-0.25	-0.19	Body mass index;	chr8:9346915	chr8:8167819~8226614:-
BRCA	trans	rs1707322	1	rs11211217	ENSG00000255397.1	AC022182.2	-6.13	1.28e-09	0.000946	-0.24	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45882557	chr8:60937705~60939871:-
BRCA	trans	rs1707322	0.896	rs946528	ENSG00000255397.1	AC022182.2	6.13	1.28e-09	0.00095	0.24	0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46019890	chr8:60937705~60939871:-
BRCA	trans	rs7824557	0.872	rs1347410	ENSG00000254153.1	CTA-398F10.2	-6.12	1.28e-09	0.000952	-0.23	-0.19	Retinal vascular caliber;	chr8:11253733	chr8:8456909~8461337:-
BRCA	trans	rs2243480	1	rs7456042	ENSG00000232546.1	RP11-458F8.1	-6.12	1.29e-09	0.000954	-0.24	-0.19	Diabetic kidney disease;	chr7:65834791	chr7:66848496~66858136:+
BRCA	trans	rs2243480	1	rs73142121	ENSG00000232546.1	RP11-458F8.1	-6.12	1.29e-09	0.000954	-0.24	-0.19	Diabetic kidney disease;	chr7:65846219	chr7:66848496~66858136:+
BRCA	trans	rs7568458	0.684	rs60012532	ENSG00000223886.3	RP11-251G23.2	6.12	1.29e-09	0.000954	0.23	0.19	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr2:85525351	chr7:105530209~105530671:+
BRCA	trans	rs1707322	1	rs4539075	ENSG00000255397.1	AC022182.2	-6.12	1.29e-09	0.000956	-0.24	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45892338	chr8:60937705~60939871:-
BRCA	trans	rs4427176	0.507	rs13273033	ENSG00000253893.2	FAM85B	-6.12	1.3e-09	0.000963	-0.25	-0.19	Mosquito bite size;	chr8:9683183	chr8:8167819~8226614:-
BRCA	trans	rs11098499	0.78	rs12504773	ENSG00000253326.2	RP11-261C10.7	6.12	1.3e-09	0.000963	0.27	0.19	Corneal astigmatism;	chr4:119640994	chr1:243054861~243056394:-
BRCA	trans	rs3740713	1	rs73440614	ENSG00000236090.2	LDHAP3	6.12	1.3e-09	0.000965	0.36	0.19	Amyotrophic lateral sclerosis (sporadic);	chr11:18445153	chr2:41819747~41820754:+
BRCA	trans	rs6011368	0.678	rs6089801	ENSG00000226210.3	WASH7P	6.12	1.3e-09	0.000966	0.2	0.19	Clozapine-induced cytotoxicity;	chr20:64280038	chr12:14522~32015:-
BRCA	trans	rs9393777	0.92	rs34150729	ENSG00000281831.1	HCP5B	6.12	1.31e-09	0.000968	0.46	0.19	Intelligence (multi-trait analysis);	chr6:27420975	chr6:29871895~29873783:-
BRCA	trans	rs9393777	0.92	rs13191227	ENSG00000281831.1	HCP5B	6.12	1.31e-09	0.000968	0.46	0.19	Intelligence (multi-trait analysis);	chr6:27422336	chr6:29871895~29873783:-
BRCA	trans	rs4427176	0.507	rs7010270	ENSG00000219470.1	RP3-337H4.6	-6.12	1.31e-09	0.000968	-0.2	-0.19	Mosquito bite size;	chr8:9699337	chr6:43538822~43539703:-
BRCA	trans	rs7570469	0.689	rs416985	ENSG00000276390.1	RP1-197B17.5	6.12	1.31e-09	0.000971	0.24	0.19	Response to antipsychotic treatment;	chr2:79453011	chr12:47699401~47699917:-
BRCA	trans	rs1459104	0.925	rs114730832	ENSG00000134612.10	FOLH1B	-6.12	1.31e-09	0.000973	-0.38	-0.19	Body mass index;	chr11:55422166	chr11:89639227~89698718:+
BRCA	trans	rs7568458	0.837	rs35215812	ENSG00000223886.3	RP11-251G23.2	6.12	1.31e-09	0.000973	0.22	0.19	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr2:85565261	chr7:105530209~105530671:+
BRCA	trans	rs6831352	0.589	rs1133483	ENSG00000233859.2	ADH5P4	-6.12	1.31e-09	0.000974	-0.23	-0.19	Alcohol dependence;	chr4:99102772	chr6:65836930~65838039:-
BRCA	trans	rs7824557	0.767	rs11250127	ENSG00000254153.1	CTA-398F10.2	6.12	1.32e-09	0.000976	0.25	0.19	Retinal vascular caliber;	chr8:11312700	chr8:8456909~8461337:-
BRCA	trans	rs860295	0.58	rs867550	ENSG00000241627.3	UBQLN4P1	-6.12	1.32e-09	0.000977	-0.21	-0.19	Body mass index;	chr1:155910600	chr3:148985868~148987668:-
BRCA	trans	rs853679	1	rs11965538	ENSG00000253570.1	RNF5P1	6.12	1.32e-09	0.00098	0.36	0.19	Depression;	chr6:28272137	chr8:38600661~38601200:-
BRCA	trans	rs875971	0.545	rs221986	ENSG00000213640.3	EEF1DP4	6.12	1.33e-09	0.000981	0.26	0.19	Aortic root size;	chr7:66105323	chr7:64862999~64864370:+
BRCA	trans	rs6921919	0.789	rs17301128	ENSG00000253570.1	RNF5P1	6.12	1.33e-09	0.000983	0.3	0.19	Autism spectrum disorder or schizophrenia;	chr6:28340257	chr8:38600661~38601200:-
BRCA	trans	rs1707322	1	rs3922887	ENSG00000255397.1	AC022182.2	-6.12	1.33e-09	0.000984	-0.24	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46008130	chr8:60937705~60939871:-
BRCA	trans	rs1707322	1	rs3922886	ENSG00000255397.1	AC022182.2	-6.12	1.33e-09	0.000984	-0.24	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46008230	chr8:60937705~60939871:-
BRCA	trans	rs2117029	0.586	rs7954521	ENSG00000214391.3	TUBAP2	6.12	1.33e-09	0.000986	0.18	0.19	Intelligence (multi-trait analysis);	chr12:49151857	chr11:90282560~90284172:+
BRCA	trans	rs2117029	0.553	rs2162644	ENSG00000214391.3	TUBAP2	6.12	1.33e-09	0.000986	0.18	0.19	Intelligence (multi-trait analysis);	chr12:49154407	chr11:90282560~90284172:+
BRCA	trans	rs7617773	0.747	rs34076262	ENSG00000235912.1	RP1-159A19.3	-6.12	1.33e-09	0.000987	-0.25	-0.19	Coronary artery disease;	chr3:48328926	chr1:27649419~27649610:+
BRCA	trans	rs12542260	0.871	rs4128469	ENSG00000234369.1	TATDN1P1	6.12	1.33e-09	0.000987	0.25	0.19	Colonoscopy-negative controls vs population controls;	chr8:124467234	chr10:63222155~63223045:+
BRCA	trans	rs7927771	1	rs34910028	ENSG00000134612.10	FOLH1B	-6.12	1.33e-09	0.000987	-0.25	-0.19	Subjective well-being;	chr11:47736897	chr11:89639227~89698718:+
BRCA	trans	rs11602339	1	rs11602339	ENSG00000134612.10	FOLH1B	-6.12	1.33e-09	0.000987	-0.25	-0.19	Body mass index;	chr11:47739919	chr11:89639227~89698718:+
BRCA	trans	rs7927771	1	rs12421210	ENSG00000134612.10	FOLH1B	-6.12	1.33e-09	0.000987	-0.25	-0.19	Subjective well-being;	chr11:47758034	chr11:89639227~89698718:+
BRCA	trans	rs7927771	1	rs7927771	ENSG00000134612.10	FOLH1B	-6.12	1.33e-09	0.000987	-0.25	-0.19	Subjective well-being;	chr11:47759754	chr11:89639227~89698718:+
BRCA	trans	rs7927771	1	rs12361031	ENSG00000134612.10	FOLH1B	-6.12	1.33e-09	0.000987	-0.25	-0.19	Subjective well-being;	chr11:47761524	chr11:89639227~89698718:+
BRCA	trans	rs7927771	1	rs7947730	ENSG00000134612.10	FOLH1B	-6.12	1.33e-09	0.000987	-0.25	-0.19	Subjective well-being;	chr11:47764632	chr11:89639227~89698718:+
BRCA	trans	rs7927771	1	rs35902101	ENSG00000134612.10	FOLH1B	-6.12	1.33e-09	0.000987	-0.25	-0.19	Subjective well-being;	chr11:47773617	chr11:89639227~89698718:+
BRCA	trans	rs7927771	1	rs11039390	ENSG00000134612.10	FOLH1B	-6.12	1.33e-09	0.000987	-0.25	-0.19	Subjective well-being;	chr11:47774743	chr11:89639227~89698718:+
BRCA	trans	rs864643	1	rs546031	ENSG00000188856.6	RPSAP47	6.12	1.34e-09	0.000989	0.29	0.19	Attention deficit hyperactivity disorder;	chr3:39529886	chr8:80558870~80559757:+
BRCA	trans	rs864643	1	rs569888	ENSG00000188856.6	RPSAP47	6.12	1.34e-09	0.000989	0.29	0.19	Attention deficit hyperactivity disorder;	chr3:39530165	chr8:80558870~80559757:+
BRCA	trans	rs864643	1	rs946409	ENSG00000188856.6	RPSAP47	6.12	1.34e-09	0.000989	0.29	0.19	Attention deficit hyperactivity disorder;	chr3:39531549	chr8:80558870~80559757:+
BRCA	trans	rs7730262	1	rs7730262	ENSG00000254473.1	RP11-522I20.3	6.12	1.36e-09	0.001	0.53	0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr5:88892421	chr9:83707594~83713378:+
BRCA	trans	rs2965280	0.793	rs10422415	ENSG00000270983.1	RP11-137J7.3	-6.12	1.36e-09	0.001	-0.43	-0.19	Colorectal cancer;	chr19:34291453	chr6:142062717~142063053:+
BRCA	trans	rs9644568	0.599	rs12679834	ENSG00000253200.1	RP11-582J16.5	6.12	1.36e-09	0.00101	0.21	0.19	Hypertriglyceridemia;HDL cholesterol;	chr8:19962922	chr8:22613908~22616657:-
BRCA	trans	rs801193	0.901	rs4273746	ENSG00000164669.11	INTS4P1	6.12	1.36e-09	0.00101	0.23	0.19	Aortic root size;	chr7:66836124	chr7:65141225~65234216:+
BRCA	trans	rs7824557	0.734	rs2293856	ENSG00000254153.1	CTA-398F10.2	6.11	1.37e-09	0.00101	0.25	0.19	Retinal vascular caliber;	chr8:11319938	chr8:8456909~8461337:-
BRCA	trans	rs4929949	0.78	rs4929941	ENSG00000266891.1	RP11-692N5.2	6.11	1.37e-09	0.00101	0.21	0.19	Body mass index;	chr11:8603404	chr18:9734882~9735602:-
BRCA	trans	rs11098499	0.955	rs1511015	ENSG00000276997.3	RP11-378J18.9	6.11	1.37e-09	0.00101	0.23	0.19	Corneal astigmatism;	chr4:119249318	chr1:222477252~222504622:-
BRCA	trans	rs864643	0.891	rs816493	ENSG00000188856.6	RPSAP47	6.11	1.37e-09	0.00101	0.29	0.19	Attention deficit hyperactivity disorder;	chr3:39514702	chr8:80558870~80559757:+
BRCA	trans	rs2242330	0.859	rs10015022	ENSG00000226982.4	CENPCP1	6.11	1.37e-09	0.00101	0.27	0.19	Parkinson's disease;	chr4:67529489	chr12:89500093~89502670:+
BRCA	trans	rs853679	0.607	rs34878803	ENSG00000281831.1	HCP5B	6.11	1.38e-09	0.00102	0.45	0.19	Depression;	chr6:28282402	chr6:29871895~29873783:-
BRCA	trans	rs853679	0.607	rs34396849	ENSG00000281831.1	HCP5B	6.11	1.38e-09	0.00102	0.45	0.19	Depression;	chr6:28283178	chr6:29871895~29873783:-
BRCA	trans	rs703108	0.731	rs7898954	ENSG00000267934.1	CTB-176F20.3	6.11	1.38e-09	0.00102	0.2	0.19	Monocyte percentage of white cells;	chr10:22034717	chr19:23323968~23329101:+
BRCA	trans	rs2220004	1	rs6591833	ENSG00000134612.10	FOLH1B	-6.11	1.39e-09	0.00102	-0.24	-0.19	Odorant perception (&beta-damascenone);	chr11:56026485	chr11:89639227~89698718:+
BRCA	trans	rs9650657	0.65	rs2898248	ENSG00000255495.1	AC145124.2	6.11	1.39e-09	0.00103	0.21	0.19	Neuroticism;	chr8:10779240	chr8:12194467~12196280:+
BRCA	trans	rs1707322	0.963	rs11211202	ENSG00000255397.1	AC022182.2	-6.11	1.39e-09	0.00103	-0.24	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45826710	chr8:60937705~60939871:-
BRCA	trans	rs34421088	0.506	rs2572426	ENSG00000253893.2	FAM85B	-6.11	1.41e-09	0.00104	-0.26	-0.19	Neuroticism;	chr8:11289614	chr8:8167819~8226614:-
BRCA	trans	rs11098499	0.866	rs11098506	ENSG00000120555.12	SEPT7P9	6.11	1.41e-09	0.00104	0.22	0.19	Corneal astigmatism;	chr4:119363816	chr10:38383069~38402916:-
BRCA	trans	rs2242330	0.749	rs13110187	ENSG00000226982.4	CENPCP1	6.11	1.41e-09	0.00104	0.25	0.19	Parkinson's disease;	chr4:67575857	chr12:89500093~89502670:+
BRCA	trans	rs7927771	1	rs9909	ENSG00000134612.10	FOLH1B	-6.11	1.42e-09	0.00104	-0.25	-0.19	Subjective well-being;	chr11:47778223	chr11:89639227~89698718:+
BRCA	trans	rs1707322	0.721	rs7520123	ENSG00000255397.1	AC022182.2	-6.11	1.42e-09	0.00105	-0.24	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45769547	chr8:60937705~60939871:-
BRCA	trans	rs877636	1	rs705696	ENSG00000227586.5	RP11-162A23.5	6.11	1.42e-09	0.00105	0.25	0.19	Cognitive function;	chr12:56086864	chr10:123171535~123171875:-
BRCA	trans	rs7829975	0.626	rs907183	ENSG00000270154.1	RP11-419I17.1	-6.11	1.43e-09	0.00105	-0.21	-0.19	Mood instability;	chr8:8872251	chr8:12476462~12477122:+
BRCA	trans	rs1707322	1	rs7553924	ENSG00000255397.1	AC022182.2	-6.11	1.43e-09	0.00105	-0.24	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45886952	chr8:60937705~60939871:-
BRCA	trans	rs1707322	1	rs4641257	ENSG00000255397.1	AC022182.2	-6.11	1.43e-09	0.00105	-0.24	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45887917	chr8:60937705~60939871:-
BRCA	trans	rs1707322	1	rs6693336	ENSG00000255397.1	AC022182.2	-6.11	1.43e-09	0.00105	-0.24	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45888923	chr8:60937705~60939871:-
BRCA	trans	rs853679	1	rs10456362	ENSG00000253570.1	RNF5P1	-6.11	1.43e-09	0.00106	-0.34	-0.19	Depression;	chr6:28254038	chr8:38600661~38601200:-
BRCA	trans	rs9467711	0.79	rs13220495	ENSG00000204709.4	LINC01556	6.11	1.43e-09	0.00106	0.49	0.19	Autism spectrum disorder or schizophrenia;	chr6:26441412	chr6:28943877~28944537:+
BRCA	trans	rs3808502	0.527	rs2736374	ENSG00000254153.1	CTA-398F10.2	-6.11	1.43e-09	0.00106	-0.23	-0.19	Neuroticism;	chr8:11256319	chr8:8456909~8461337:-
BRCA	trans	rs941207	0.756	rs9634246	ENSG00000257210.1	NACAP3	-6.11	1.44e-09	0.00106	-0.25	-0.19	Platelet count;	chr12:56640604	chr12:93124063~93124543:-
BRCA	trans	rs546131	0.642	rs1594425	ENSG00000225531.1	RP11-196I18.3	-6.11	1.44e-09	0.00106	-0.3	-0.19	Lung disease severity in cystic fibrosis;	chr11:34811775	chr9:107116829~107117557:+
BRCA	trans	rs875971	0.545	rs316305	ENSG00000213640.3	EEF1DP4	6.11	1.44e-09	0.00106	0.26	0.19	Aortic root size;	chr7:66152984	chr7:64862999~64864370:+
BRCA	trans	rs7927771	1	rs10838748	ENSG00000134612.10	FOLH1B	-6.11	1.45e-09	0.00107	-0.25	-0.19	Subjective well-being;	chr11:47694829	chr11:89639227~89698718:+
BRCA	trans	rs1707322	1	rs4660889	ENSG00000255397.1	AC022182.2	-6.11	1.45e-09	0.00107	-0.24	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45831659	chr8:60937705~60939871:-
BRCA	trans	rs875971	1	rs3735148	ENSG00000164669.11	INTS4P1	-6.1	1.45e-09	0.00107	-0.23	-0.19	Aortic root size;	chr7:66506022	chr7:65141225~65234216:+
BRCA	trans	rs2965280	0.793	rs8104407	ENSG00000270983.1	RP11-137J7.3	-6.1	1.45e-09	0.00107	-0.42	-0.19	Colorectal cancer;	chr19:34309178	chr6:142062717~142063053:+
BRCA	trans	rs4930561	0.765	rs4930564	ENSG00000155070.8	UNC93B2	6.1	1.45e-09	0.00107	0.21	0.19	Breast cancer in childhood cancer survivors;IgG glycosylation;	chr11:68215814	chr7:6855485~6859830:-
BRCA	trans	rs7617773	0.779	rs11718329	ENSG00000235912.1	RP1-159A19.3	-6.1	1.45e-09	0.00107	-0.23	-0.19	Coronary artery disease;	chr3:48268338	chr1:27649419~27649610:+
BRCA	trans	rs2242330	0.862	rs55924366	ENSG00000226982.4	CENPCP1	6.1	1.46e-09	0.00107	0.26	0.19	Parkinson's disease;	chr4:67450775	chr12:89500093~89502670:+
BRCA	trans	rs801193	0.66	rs974239	ENSG00000164669.11	INTS4P1	-6.1	1.46e-09	0.00107	-0.23	-0.19	Aortic root size;	chr7:66748504	chr7:65141225~65234216:+
BRCA	trans	rs875971	0.545	rs2460427	ENSG00000213640.3	EEF1DP4	6.1	1.46e-09	0.00108	0.26	0.19	Aortic root size;	chr7:66154218	chr7:64862999~64864370:+
BRCA	trans	rs902774	0.818	rs4919742	ENSG00000255815.3	KRT8P11	-6.1	1.47e-09	0.00108	-0.4	-0.19	Prostate cancer;	chr12:52879180	chr9:99305176~99306611:+
BRCA	trans	rs801193	1	rs2055682	ENSG00000164669.11	INTS4P1	-6.1	1.47e-09	0.00108	-0.23	-0.19	Aortic root size;	chr7:66795302	chr7:65141225~65234216:+
BRCA	trans	rs12439619	1	rs12439619	ENSG00000259774.1	RP11-182J1.13	6.1	1.47e-09	0.00108	0.24	0.19	Intelligence (multi-trait analysis);	chr15:82254605	chr15:84422618~84425882:+
BRCA	trans	rs2220004	1	rs4939541	ENSG00000134612.10	FOLH1B	-6.1	1.48e-09	0.00109	-0.24	-0.19	Odorant perception (&beta-damascenone);	chr11:55956909	chr11:89639227~89698718:+
BRCA	trans	rs2220004	0.964	rs10792425	ENSG00000134612.10	FOLH1B	-6.1	1.48e-09	0.00109	-0.24	-0.19	Odorant perception (&beta-damascenone);	chr11:55957104	chr11:89639227~89698718:+
BRCA	trans	rs2840044	1	rs2840044	ENSG00000234130.2	RP13-88F20.1	6.1	1.48e-09	0.00109	0.2	0.19	Response to radiotherapy in cancer (late toxicity);	chr17:35565049	chrX:93222220~93225015:-
BRCA	trans	rs78944489	0.867	rs62149564	ENSG00000236165.1	PRADC1P1	6.1	1.48e-09	0.00109	0.37	0.19	Schizophrenia;	chr2:73227949	chr3:36976316~36976840:+
BRCA	trans	rs7746199	0.736	rs35848276	ENSG00000281831.1	HCP5B	6.1	1.48e-09	0.00109	0.48	0.19	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27553317	chr6:29871895~29873783:-
BRCA	trans	rs1707322	1	rs11211222	ENSG00000255397.1	AC022182.2	-6.1	1.48e-09	0.00109	-0.24	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45902085	chr8:60937705~60939871:-
BRCA	trans	rs1707322	0.963	rs9787412	ENSG00000255397.1	AC022182.2	-6.1	1.48e-09	0.00109	-0.24	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45905924	chr8:60937705~60939871:-
BRCA	trans	rs1707322	1	rs4660896	ENSG00000255397.1	AC022182.2	-6.1	1.48e-09	0.00109	-0.24	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45906744	chr8:60937705~60939871:-
BRCA	trans	rs1707322	1	rs12133129	ENSG00000255397.1	AC022182.2	-6.1	1.48e-09	0.00109	-0.24	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45907676	chr8:60937705~60939871:-
BRCA	trans	rs1707322	0.963	rs4553121	ENSG00000255397.1	AC022182.2	-6.1	1.48e-09	0.00109	-0.24	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45909581	chr8:60937705~60939871:-
BRCA	trans	rs1707322	0.963	rs6690652	ENSG00000255397.1	AC022182.2	-6.1	1.48e-09	0.00109	-0.24	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45911020	chr8:60937705~60939871:-
BRCA	trans	rs1459104	1	rs35525598	ENSG00000134612.10	FOLH1B	-6.1	1.49e-09	0.00109	-0.35	-0.19	Body mass index;	chr11:55390225	chr11:89639227~89698718:+
BRCA	trans	rs2117029	0.619	rs9325145	ENSG00000214391.3	TUBAP2	6.1	1.49e-09	0.00109	0.18	0.19	Intelligence (multi-trait analysis);	chr12:49132101	chr11:90282560~90284172:+
BRCA	trans	rs4879656	0.872	rs1537040	ENSG00000215007.3	DNAJA1P3	6.1	1.49e-09	0.0011	0.22	0.19	Menopause (age at onset);	chr9:33061442	chrX:107351650~107352843:-
BRCA	trans	rs11992162	1	rs7460395	ENSG00000173295.6	FAM86B3P	6.1	1.49e-09	0.0011	0.2	0.19	Monocyte count;	chr8:11977866	chr8:8228595~8244865:+
BRCA	trans	rs2117029	0.553	rs11168909	ENSG00000214391.3	TUBAP2	6.1	1.49e-09	0.0011	0.18	0.19	Intelligence (multi-trait analysis);	chr12:49183092	chr11:90282560~90284172:+
BRCA	trans	rs875971	0.545	rs6460281	ENSG00000213640.3	EEF1DP4	-6.1	1.49e-09	0.0011	-0.26	-0.19	Aortic root size;	chr7:66216128	chr7:64862999~64864370:+
BRCA	trans	rs875971	1	rs4717292	ENSG00000164669.11	INTS4P1	-6.1	1.49e-09	0.0011	-0.23	-0.19	Aortic root size;	chr7:66430611	chr7:65141225~65234216:+
BRCA	trans	rs875971	1	rs35149210	ENSG00000164669.11	INTS4P1	-6.1	1.49e-09	0.0011	-0.23	-0.19	Aortic root size;	chr7:66464938	chr7:65141225~65234216:+
BRCA	trans	rs1580019	0.563	rs764483	ENSG00000213492.2	NT5C3AP1	-6.1	1.5e-09	0.0011	-0.25	-0.19	Cognitive ability;	chr7:32538538	chr4:117574512~117576174:-
BRCA	trans	rs9693857	0.52	rs11249928	ENSG00000253893.2	FAM85B	-6.1	1.5e-09	0.0011	-0.26	-0.19	Systolic blood pressure;	chr8:9505750	chr8:8167819~8226614:-
BRCA	trans	rs3740713	1	rs1848048	ENSG00000236090.2	LDHAP3	6.1	1.5e-09	0.00111	0.35	0.19	Amyotrophic lateral sclerosis (sporadic);	chr11:18447449	chr2:41819747~41820754:+
BRCA	trans	rs3740713	1	rs16935432	ENSG00000236090.2	LDHAP3	6.1	1.5e-09	0.00111	0.35	0.19	Amyotrophic lateral sclerosis (sporadic);	chr11:18448940	chr2:41819747~41820754:+
BRCA	trans	rs3740713	1	rs73440625	ENSG00000236090.2	LDHAP3	6.1	1.5e-09	0.00111	0.35	0.19	Amyotrophic lateral sclerosis (sporadic);	chr11:18449253	chr2:41819747~41820754:+
BRCA	trans	rs3740713	1	rs76599129	ENSG00000236090.2	LDHAP3	6.1	1.5e-09	0.00111	0.35	0.19	Amyotrophic lateral sclerosis (sporadic);	chr11:18450080	chr2:41819747~41820754:+
BRCA	trans	rs1707322	1	rs11211219	ENSG00000255397.1	AC022182.2	-6.1	1.51e-09	0.00111	-0.24	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45893806	chr8:60937705~60939871:-
BRCA	trans	rs875971	1	rs7789554	ENSG00000164669.11	INTS4P1	-6.1	1.51e-09	0.00111	-0.23	-0.19	Aortic root size;	chr7:66481051	chr7:65141225~65234216:+
BRCA	trans	rs875971	1	rs4717300	ENSG00000164669.11	INTS4P1	-6.1	1.51e-09	0.00111	-0.23	-0.19	Aortic root size;	chr7:66482393	chr7:65141225~65234216:+
BRCA	trans	rs875971	0.895	rs1974769	ENSG00000164669.11	INTS4P1	-6.1	1.51e-09	0.00111	-0.23	-0.19	Aortic root size;	chr7:66485627	chr7:65141225~65234216:+
BRCA	trans	rs875971	0.895	rs6460300	ENSG00000164669.11	INTS4P1	-6.1	1.51e-09	0.00111	-0.23	-0.19	Aortic root size;	chr7:66487937	chr7:65141225~65234216:+
BRCA	trans	rs875971	0.862	rs7803416	ENSG00000164669.11	INTS4P1	-6.1	1.51e-09	0.00111	-0.23	-0.19	Aortic root size;	chr7:66489212	chr7:65141225~65234216:+
BRCA	trans	rs875971	0.964	rs2277911	ENSG00000164669.11	INTS4P1	-6.1	1.51e-09	0.00111	-0.23	-0.19	Aortic root size;	chr7:66493638	chr7:65141225~65234216:+
BRCA	trans	rs12802244	1	rs12802244	ENSG00000134612.10	FOLH1B	-6.1	1.51e-09	0.00111	-0.25	-0.19	Neuroticism;	chr11:47911114	chr11:89639227~89698718:+
BRCA	trans	rs1707322	0.928	rs7527244	ENSG00000255397.1	AC022182.2	-6.1	1.51e-09	0.00111	-0.24	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45903100	chr8:60937705~60939871:-
BRCA	trans	rs2117029	0.554	rs2334931	ENSG00000214391.3	TUBAP2	6.1	1.51e-09	0.00111	0.18	0.19	Intelligence (multi-trait analysis);	chr12:49174130	chr11:90282560~90284172:+
BRCA	trans	rs2117029	0.586	rs10875929	ENSG00000214391.3	TUBAP2	6.1	1.51e-09	0.00111	0.18	0.19	Intelligence (multi-trait analysis);	chr12:49174605	chr11:90282560~90284172:+
BRCA	trans	rs2117029	0.586	rs11168904	ENSG00000214391.3	TUBAP2	6.1	1.51e-09	0.00111	0.18	0.19	Intelligence (multi-trait analysis);	chr12:49177234	chr11:90282560~90284172:+
BRCA	trans	rs2117029	0.586	rs10875931	ENSG00000214391.3	TUBAP2	6.1	1.51e-09	0.00111	0.18	0.19	Intelligence (multi-trait analysis);	chr12:49179513	chr11:90282560~90284172:+
BRCA	trans	rs2117029	0.554	rs7954530	ENSG00000214391.3	TUBAP2	6.1	1.51e-09	0.00111	0.18	0.19	Intelligence (multi-trait analysis);	chr12:49179742	chr11:90282560~90284172:+
BRCA	trans	rs9467711	0.659	rs66757203	ENSG00000281831.1	HCP5B	6.1	1.51e-09	0.00111	0.44	0.19	Autism spectrum disorder or schizophrenia;	chr6:26454728	chr6:29871895~29873783:-
BRCA	trans	rs875971	0.964	rs12668936	ENSG00000164669.11	INTS4P1	-6.1	1.52e-09	0.00112	-0.23	-0.19	Aortic root size;	chr7:66449417	chr7:65141225~65234216:+
BRCA	trans	rs7617773	0.78	rs3197223	ENSG00000235912.1	RP1-159A19.3	-6.1	1.52e-09	0.00112	-0.25	-0.19	Coronary artery disease;	chr3:48294367	chr1:27649419~27649610:+
BRCA	trans	rs2220004	1	rs10792426	ENSG00000134612.10	FOLH1B	-6.1	1.53e-09	0.00112	-0.24	-0.19	Odorant perception (&beta-damascenone);	chr11:55957579	chr11:89639227~89698718:+
BRCA	trans	rs902774	0.818	rs73110471	ENSG00000240668.1	KRT8P36	-6.1	1.53e-09	0.00112	-0.37	-0.19	Prostate cancer;	chr12:52923037	chr3:138101478~138102917:-
BRCA	trans	rs11098499	0.662	rs13108589	ENSG00000120555.12	SEPT7P9	6.1	1.53e-09	0.00112	0.22	0.19	Corneal astigmatism;	chr4:119346947	chr10:38383069~38402916:-
BRCA	trans	rs1707322	0.928	rs10732844	ENSG00000255397.1	AC022182.2	-6.1	1.54e-09	0.00113	-0.24	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45907016	chr8:60937705~60939871:-
BRCA	trans	rs11098499	0.78	rs7692994	ENSG00000120555.12	SEPT7P9	6.1	1.54e-09	0.00113	0.22	0.19	Corneal astigmatism;	chr4:119506334	chr10:38383069~38402916:-
BRCA	trans	rs1478173	0.592	rs1155394	ENSG00000204934.9	ATP6V0E2-AS1	-6.09	1.54e-09	0.00113	-0.24	-0.19	JT interval (sulfonylurea treatment interaction);	chr3:162555415	chr7:149867697~149880610:-
BRCA	trans	rs9644568	0.599	rs12679834	ENSG00000253982.1	CTD-2336O2.1	6.09	1.54e-09	0.00113	0.25	0.19	Hypertriglyceridemia;HDL cholesterol;	chr8:19962922	chr8:1761990~1764502:-
BRCA	trans	rs875971	0.545	rs316316	ENSG00000213640.3	EEF1DP4	6.09	1.55e-09	0.00114	0.26	0.19	Aortic root size;	chr7:66149270	chr7:64862999~64864370:+
BRCA	trans	rs4929949	0.901	rs9705083	ENSG00000266891.1	RP11-692N5.2	6.09	1.55e-09	0.00114	0.22	0.19	Body mass index;	chr11:8565225	chr18:9734882~9735602:-
BRCA	trans	rs2122469	0.655	rs17603934	ENSG00000246477.3	AF131216.6	6.09	1.55e-09	0.00114	0.25	0.19	Serum tamsulosin hydrochloride concentration;	chr8:20718833	chr8:11315859~11325429:-
BRCA	trans	rs2242330	0.862	rs35161455	ENSG00000226982.4	CENPCP1	6.09	1.55e-09	0.00114	0.26	0.19	Parkinson's disease;	chr4:67476008	chr12:89500093~89502670:+
BRCA	trans	rs7830939	0.553	rs10105543	ENSG00000253893.2	FAM85B	-6.09	1.56e-09	0.00115	-0.25	-0.19	Neuroticism;	chr8:9466005	chr8:8167819~8226614:-
BRCA	trans	rs6831352	1	rs1126670	ENSG00000233859.2	ADH5P4	-6.09	1.56e-09	0.00115	-0.25	-0.19	Alcohol dependence;	chr4:99131582	chr6:65836930~65838039:-
BRCA	trans	rs2950393	0.927	rs11171914	ENSG00000257210.1	NACAP3	-6.09	1.56e-09	0.00115	-0.23	-0.19	Platelet distribution width;	chr12:56649462	chr12:93124063~93124543:-
BRCA	trans	rs6121246	0.559	rs6058468	ENSG00000279352.1	RP11-411B10.7	6.09	1.56e-09	0.00115	0.27	0.19	Mean corpuscular hemoglobin;	chr20:31818645	chr18:14010054~14010917:+
BRCA	trans	rs11098499	0.604	rs2389887	ENSG00000276805.1	RP11-291L22.6	6.09	1.56e-09	0.00115	0.23	0.19	Corneal astigmatism;	chr4:119649489	chr10:38451030~38451785:+
BRCA	trans	rs11098499	0.604	rs34278750	ENSG00000276805.1	RP11-291L22.6	6.09	1.56e-09	0.00115	0.23	0.19	Corneal astigmatism;	chr4:119649981	chr10:38451030~38451785:+
BRCA	trans	rs6831352	0.734	rs2602857	ENSG00000228407.2	RP4-800M22.1	-6.09	1.57e-09	0.00115	-0.25	-0.19	Alcohol dependence;	chr4:99109167	chr1:52160261~52160600:-
BRCA	trans	rs875971	0.571	rs160641	ENSG00000234585.5	CCT6P3	-6.09	1.57e-09	0.00115	-0.2	-0.19	Aortic root size;	chr7:66112359	chr7:65038354~65074713:+
BRCA	trans	rs902774	0.818	rs11831919	ENSG00000248568.1	KRT8P48	-6.09	1.57e-09	0.00115	-0.39	-0.19	Prostate cancer;	chr12:52878231	chr5:146706381~146707600:-
BRCA	trans	rs875971	0.545	rs67397473	ENSG00000213640.3	EEF1DP4	-6.09	1.57e-09	0.00115	-0.26	-0.19	Aortic root size;	chr7:66168318	chr7:64862999~64864370:+
BRCA	trans	rs1707322	1	rs11211200	ENSG00000255397.1	AC022182.2	-6.09	1.57e-09	0.00115	-0.24	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45822680	chr8:60937705~60939871:-
BRCA	trans	rs3750082	0.852	rs10260000	ENSG00000176826.14	FKBP9P1	6.09	1.57e-09	0.00115	0.23	0.19	Glomerular filtration rate (creatinine);	chr7:32858622	chr7:55681074~55713252:-
BRCA	trans	rs7927771	0.832	rs6485753	ENSG00000134612.10	FOLH1B	6.09	1.58e-09	0.00116	0.25	0.19	Subjective well-being;	chr11:47388649	chr11:89639227~89698718:+
BRCA	trans	rs6601327	0.585	rs1394	ENSG00000253893.2	FAM85B	6.09	1.58e-09	0.00116	0.23	0.19	Multiple myeloma (hyperdiploidy);	chr8:9654144	chr8:8167819~8226614:-
BRCA	trans	rs875971	0.545	rs316306	ENSG00000213640.3	EEF1DP4	6.09	1.59e-09	0.00116	0.26	0.19	Aortic root size;	chr7:66153687	chr7:64862999~64864370:+
BRCA	trans	rs11098499	0.644	rs10050092	ENSG00000276997.3	RP11-378J18.9	6.09	1.59e-09	0.00116	0.22	0.19	Corneal astigmatism;	chr4:119610930	chr1:222477252~222504622:-
BRCA	trans	rs7826222	0.632	rs814360	ENSG00000253893.2	FAM85B	6.09	1.59e-09	0.00117	0.33	0.19	Adiposity;	chr8:10025642	chr8:8167819~8226614:-
BRCA	trans	rs941207	0.526	rs2950390	ENSG00000257210.1	NACAP3	6.09	1.59e-09	0.00117	0.22	0.19	Platelet count;	chr12:56661507	chr12:93124063~93124543:-
BRCA	trans	rs34421088	0.576	rs2572432	ENSG00000253893.2	FAM85B	6.09	1.6e-09	0.00117	0.25	0.19	Neuroticism;	chr8:11244214	chr8:8167819~8226614:-
BRCA	trans	rs12210905	1	rs67310631	ENSG00000242375.1	RP11-498P14.3	-6.09	1.6e-09	0.00117	-0.38	-0.19	Hip circumference adjusted for BMI;	chr6:27265464	chr9:97195351~97197687:-
BRCA	trans	rs12210905	1	rs9379967	ENSG00000242375.1	RP11-498P14.3	-6.09	1.6e-09	0.00117	-0.38	-0.19	Hip circumference adjusted for BMI;	chr6:27265648	chr9:97195351~97197687:-
BRCA	trans	rs864643	0.947	rs1708053	ENSG00000188856.6	RPSAP47	6.09	1.6e-09	0.00117	0.27	0.19	Attention deficit hyperactivity disorder;	chr3:39499706	chr8:80558870~80559757:+
BRCA	trans	rs11098499	1	rs10029750	ENSG00000276997.3	RP11-378J18.9	6.09	1.6e-09	0.00118	0.23	0.19	Corneal astigmatism;	chr4:119251388	chr1:222477252~222504622:-
BRCA	trans	rs2117029	0.586	rs10783308	ENSG00000214391.3	TUBAP2	6.09	1.61e-09	0.00118	0.18	0.19	Intelligence (multi-trait analysis);	chr12:49137675	chr11:90282560~90284172:+
BRCA	trans	rs7824557	0.767	rs7837036	ENSG00000254153.1	CTA-398F10.2	6.09	1.61e-09	0.00118	0.25	0.19	Retinal vascular caliber;	chr8:11317980	chr8:8456909~8461337:-
BRCA	trans	rs9393777	0.545	rs56303243	ENSG00000277241.1	RP11-114M1.3	6.09	1.62e-09	0.00119	0.29	0.19	Intelligence (multi-trait analysis);	chr6:26485499	chr3:177700346~177701072:-
BRCA	trans	rs9858542	0.953	rs9827021	ENSG00000197582.5	GPX1P1	-6.09	1.62e-09	0.00119	-0.21	-0.19	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49477331	chrX:13378735~13379340:-
BRCA	trans	rs9858542	0.953	rs9818590	ENSG00000197582.5	GPX1P1	-6.09	1.62e-09	0.00119	-0.21	-0.19	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49487663	chrX:13378735~13379340:-
BRCA	trans	rs9858542	0.953	rs35261698	ENSG00000197582.5	GPX1P1	-6.09	1.62e-09	0.00119	-0.21	-0.19	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49500406	chrX:13378735~13379340:-
BRCA	trans	rs9858542	0.953	rs6766131	ENSG00000197582.5	GPX1P1	-6.09	1.62e-09	0.00119	-0.21	-0.19	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49501499	chrX:13378735~13379340:-
BRCA	trans	rs9858542	0.953	rs9821311	ENSG00000197582.5	GPX1P1	-6.09	1.62e-09	0.00119	-0.21	-0.19	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49506223	chrX:13378735~13379340:-
BRCA	trans	rs1707322	1	rs4298677	ENSG00000255397.1	AC022182.2	-6.09	1.62e-09	0.00119	-0.24	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45840947	chr8:60937705~60939871:-
BRCA	trans	rs7927771	1	rs11039255	ENSG00000134612.10	FOLH1B	-6.09	1.63e-09	0.00119	-0.25	-0.19	Subjective well-being;	chr11:47474194	chr11:89639227~89698718:+
BRCA	trans	rs11098499	0.955	rs1397608	ENSG00000276997.3	RP11-378J18.9	6.09	1.63e-09	0.00119	0.23	0.19	Corneal astigmatism;	chr4:119240589	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.955	rs7685268	ENSG00000276997.3	RP11-378J18.9	6.09	1.63e-09	0.00119	0.23	0.19	Corneal astigmatism;	chr4:119241033	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.955	rs7684942	ENSG00000276997.3	RP11-378J18.9	6.09	1.63e-09	0.00119	0.23	0.19	Corneal astigmatism;	chr4:119241046	chr1:222477252~222504622:-
BRCA	trans	rs7570469	0.734	rs422478	ENSG00000276390.1	RP1-197B17.5	6.09	1.63e-09	0.00119	0.24	0.19	Response to antipsychotic treatment;	chr2:79456113	chr12:47699401~47699917:-
BRCA	trans	rs1707322	1	rs7531911	ENSG00000255397.1	AC022182.2	-6.09	1.63e-09	0.0012	-0.24	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45864751	chr8:60937705~60939871:-
BRCA	trans	rs1707322	1	rs10890359	ENSG00000255397.1	AC022182.2	-6.09	1.63e-09	0.0012	-0.24	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45870963	chr8:60937705~60939871:-
BRCA	trans	rs7617773	0.674	rs13069029	ENSG00000235912.1	RP1-159A19.3	-6.08	1.64e-09	0.0012	-0.25	-0.19	Coronary artery disease;	chr3:48313534	chr1:27649419~27649610:+
BRCA	trans	rs941207	0.526	rs2950393	ENSG00000257210.1	NACAP3	-6.08	1.64e-09	0.0012	-0.23	-0.19	Platelet count;	chr12:56642239	chr12:93124063~93124543:-
BRCA	trans	rs875971	0.929	rs6970860	ENSG00000164669.11	INTS4P1	-6.08	1.65e-09	0.00121	-0.23	-0.19	Aortic root size;	chr7:66511647	chr7:65141225~65234216:+
BRCA	trans	rs864643	0.945	rs529839	ENSG00000188856.6	RPSAP47	6.08	1.65e-09	0.00121	0.29	0.19	Attention deficit hyperactivity disorder;	chr3:39525267	chr8:80558870~80559757:+
BRCA	trans	rs875971	0.571	rs160647	ENSG00000213640.3	EEF1DP4	6.08	1.65e-09	0.00121	0.26	0.19	Aortic root size;	chr7:66089365	chr7:64862999~64864370:+
BRCA	trans	rs853679	0.769	rs17720293	ENSG00000228078.1	HLA-U	-6.08	1.65e-09	0.00121	-0.42	-0.19	Depression;	chr6:28246920	chr6:29934101~29934286:+
BRCA	trans	rs2840044	1	rs17637907	ENSG00000234130.2	RP13-88F20.1	6.08	1.66e-09	0.00122	0.2	0.19	Response to radiotherapy in cancer (late toxicity);	chr17:35564367	chrX:93222220~93225015:-
BRCA	trans	rs853679	0.567	rs7740429	ENSG00000228078.1	HLA-U	-6.08	1.67e-09	0.00122	-0.28	-0.19	Depression;	chr6:28431469	chr6:29934101~29934286:+
BRCA	trans	rs7260598	1	rs11666415	ENSG00000261770.1	CTC-459F4.1	6.08	1.68e-09	0.00123	0.31	0.19	Response to taxane treatment (placlitaxel);	chr19:24045710	chr19:27757184~27760849:-
BRCA	trans	rs2066819	1	rs41392645	ENSG00000273654.1	CTB-52I2.4	6.08	1.68e-09	0.00123	0.47	0.19	Psoriasis vulgaris;	chr12:56302958	chr19:18022403~18032099:+
BRCA	trans	rs7570469	0.762	rs11126727	ENSG00000276390.1	RP1-197B17.5	6.08	1.68e-09	0.00123	0.24	0.19	Response to antipsychotic treatment;	chr2:79427309	chr12:47699401~47699917:-
BRCA	trans	rs7260598	0.636	rs62114769	ENSG00000261770.1	CTC-459F4.1	6.08	1.68e-09	0.00123	0.29	0.19	Response to taxane treatment (placlitaxel);	chr19:24052658	chr19:27757184~27760849:-
BRCA	trans	rs10783779	0.647	rs705708	ENSG00000227887.1	RPS26P13	6.08	1.68e-09	0.00123	0.22	0.19	Educational attainment;	chr12:56095129	chr1:208697369~208697698:-
BRCA	trans	rs7647973	1	rs9871024	ENSG00000197582.5	GPX1P1	-6.08	1.68e-09	0.00123	-0.21	-0.19	Menarche (age at onset);	chr3:49516808	chrX:13378735~13379340:-
BRCA	trans	rs7647973	1	rs13322887	ENSG00000197582.5	GPX1P1	-6.08	1.68e-09	0.00123	-0.21	-0.19	Menarche (age at onset);	chr3:49518150	chrX:13378735~13379340:-
BRCA	trans	rs2066819	1	rs744051	ENSG00000273654.1	CTB-52I2.4	-6.08	1.68e-09	0.00123	-0.47	-0.19	Psoriasis vulgaris;	chr12:56273514	chr19:18022403~18032099:+
BRCA	trans	rs11666377	0.943	rs7249435	ENSG00000197320.5	AC060834.2	6.08	1.69e-09	0.00123	0.29	0.19	Brain lesion load;	chr19:17003335	chr7:9726241~9728272:+
BRCA	trans	rs1707322	0.964	rs10890358	ENSG00000255397.1	AC022182.2	-6.08	1.69e-09	0.00124	-0.24	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45853353	chr8:60937705~60939871:-
BRCA	trans	rs4713118	0.869	rs6922574	ENSG00000204709.4	LINC01556	6.08	1.7e-09	0.00124	0.26	0.19	Parkinson's disease;	chr6:27725224	chr6:28943877~28944537:+
BRCA	trans	rs2242330	0.862	rs13107873	ENSG00000226982.4	CENPCP1	6.08	1.71e-09	0.00125	0.26	0.19	Parkinson's disease;	chr4:67447864	chr12:89500093~89502670:+
BRCA	trans	rs2242330	0.862	rs9999572	ENSG00000226982.4	CENPCP1	6.08	1.71e-09	0.00125	0.26	0.19	Parkinson's disease;	chr4:67464757	chr12:89500093~89502670:+
BRCA	trans	rs2242330	0.862	rs6552098	ENSG00000226982.4	CENPCP1	6.08	1.71e-09	0.00125	0.26	0.19	Parkinson's disease;	chr4:67467615	chr12:89500093~89502670:+
BRCA	trans	rs2242330	0.862	rs6552099	ENSG00000226982.4	CENPCP1	6.08	1.71e-09	0.00125	0.26	0.19	Parkinson's disease;	chr4:67467705	chr12:89500093~89502670:+
BRCA	trans	rs6831352	1	rs1126673	ENSG00000233859.2	ADH5P4	-6.08	1.71e-09	0.00125	-0.25	-0.19	Alcohol dependence;	chr4:99124465	chr6:65836930~65838039:-
BRCA	trans	rs1391708	0.688	rs12812221	ENSG00000121089.4	NACA3P	-6.08	1.71e-09	0.00125	-0.27	-0.19	Airway wall thickness;	chr12:56925552	chr4:164943290~164943937:+
BRCA	trans	rs6121246	0.559	rs6121243	ENSG00000279352.1	RP11-411B10.7	6.08	1.72e-09	0.00125	0.27	0.19	Mean corpuscular hemoglobin;	chr20:31827291	chr18:14010054~14010917:+
BRCA	trans	rs380904	0.552	rs10099003	ENSG00000213130.3	EEF1DP5	-6.08	1.72e-09	0.00125	-0.22	-0.18	Venous thromboembolism (SNP x SNP interaction);	chr8:143563290	chr6:128580113~128580884:-
BRCA	trans	rs10838687	0.8	rs10769253	ENSG00000134612.10	FOLH1B	6.08	1.72e-09	0.00126	0.28	0.18	Proinsulin levels;	chr11:47340788	chr11:89639227~89698718:+
BRCA	trans	rs7824557	0.767	rs3808513	ENSG00000254153.1	CTA-398F10.2	-6.08	1.72e-09	0.00126	-0.24	-0.18	Retinal vascular caliber;	chr8:11299951	chr8:8456909~8461337:-
BRCA	trans	rs9733	0.687	rs11204735	ENSG00000180764.13	PIPSL	6.08	1.72e-09	0.00126	0.23	0.18	Tonsillectomy;	chr1:150869191	chr10:93958191~93961540:-
BRCA	trans	rs9733	0.744	rs12758227	ENSG00000180764.13	PIPSL	6.08	1.72e-09	0.00126	0.23	0.18	Tonsillectomy;	chr1:150872107	chr10:93958191~93961540:-
BRCA	trans	rs853679	0.599	rs149949	ENSG00000253570.1	RNF5P1	6.08	1.73e-09	0.00126	0.41	0.18	Depression;	chr6:28043738	chr8:38600661~38601200:-
BRCA	trans	rs7647973	0.769	rs11130181	ENSG00000235912.1	RP1-159A19.3	-6.08	1.73e-09	0.00126	-0.24	-0.18	Menarche (age at onset);	chr3:49072486	chr1:27649419~27649610:+
BRCA	trans	rs9329221	0.537	rs2062331	ENSG00000154316.13	TDH	6.08	1.73e-09	0.00126	0.23	0.18	Neuroticism;	chr8:10122482	chr8:11339637~11368452:+
BRCA	trans	rs941207	0.756	rs67046307	ENSG00000257210.1	NACAP3	-6.08	1.73e-09	0.00126	-0.25	-0.18	Platelet count;	chr12:56651152	chr12:93124063~93124543:-
BRCA	trans	rs6011368	0.678	rs6090105	ENSG00000226210.3	WASH7P	6.08	1.73e-09	0.00126	0.2	0.18	Clozapine-induced cytotoxicity;	chr20:64279990	chr12:14522~32015:-
BRCA	trans	rs11098499	0.566	rs17051356	ENSG00000276805.1	RP11-291L22.6	6.08	1.73e-09	0.00126	0.23	0.18	Corneal astigmatism;	chr4:119664153	chr10:38451030~38451785:+
BRCA	trans	rs6940638	0.662	rs7759694	ENSG00000204709.4	LINC01556	6.08	1.73e-09	0.00127	0.24	0.18	Intelligence (multi-trait analysis);	chr6:27273177	chr6:28943877~28944537:+
BRCA	trans	rs853679	0.882	rs9380069	ENSG00000253570.1	RNF5P1	6.07	1.74e-09	0.00127	0.38	0.18	Depression;	chr6:28235522	chr8:38600661~38601200:-
BRCA	trans	rs1459104	0.866	rs66989058	ENSG00000134612.10	FOLH1B	-6.07	1.74e-09	0.00127	-0.33	-0.18	Body mass index;	chr11:55055567	chr11:89639227~89698718:+
BRCA	trans	rs1459104	0.866	rs34179570	ENSG00000134612.10	FOLH1B	-6.07	1.74e-09	0.00127	-0.33	-0.18	Body mass index;	chr11:55055665	chr11:89639227~89698718:+
BRCA	trans	rs1459104	1	rs17578206	ENSG00000134612.10	FOLH1B	-6.07	1.75e-09	0.00127	-0.37	-0.18	Body mass index;	chr11:55404201	chr11:89639227~89698718:+
BRCA	trans	rs3812762	0.912	rs10769953	ENSG00000266891.1	RP11-692N5.2	-6.07	1.75e-09	0.00127	-0.22	-0.18	Hypospadias;	chr11:8756805	chr18:9734882~9735602:-
BRCA	trans	rs4883201	0.561	rs1805725	ENSG00000179899.8	PHC1P1	6.07	1.75e-09	0.00128	0.25	0.18	Total cholesterol levels;Cholesterol, total;	chr12:8945337	chr12:55411727~55414787:-
BRCA	trans	rs853679	0.607	rs34661125	ENSG00000281831.1	HCP5B	6.07	1.75e-09	0.00128	0.46	0.18	Depression;	chr6:28314117	chr6:29871895~29873783:-
BRCA	trans	rs853679	0.607	rs13190888	ENSG00000281831.1	HCP5B	6.07	1.75e-09	0.00128	0.46	0.18	Depression;	chr6:28318208	chr6:29871895~29873783:-
BRCA	trans	rs2242330	0.749	rs17088473	ENSG00000226982.4	CENPCP1	6.07	1.75e-09	0.00128	0.24	0.18	Parkinson's disease;	chr4:67577590	chr12:89500093~89502670:+
BRCA	trans	rs2117029	0.586	rs2114846	ENSG00000214391.3	TUBAP2	6.07	1.77e-09	0.00129	0.18	0.18	Intelligence (multi-trait analysis);	chr12:49154493	chr11:90282560~90284172:+
BRCA	trans	rs875971	0.545	rs10950025	ENSG00000213640.3	EEF1DP4	-6.07	1.77e-09	0.00129	-0.26	-0.18	Aortic root size;	chr7:66158946	chr7:64862999~64864370:+
BRCA	trans	rs875971	0.52	rs12666485	ENSG00000213640.3	EEF1DP4	-6.07	1.77e-09	0.00129	-0.26	-0.18	Aortic root size;	chr7:66160135	chr7:64862999~64864370:+
BRCA	trans	rs875971	0.545	rs67688847	ENSG00000213640.3	EEF1DP4	-6.07	1.77e-09	0.00129	-0.26	-0.18	Aortic root size;	chr7:66161064	chr7:64862999~64864370:+
BRCA	trans	rs6831352	0.918	rs29001199	ENSG00000233859.2	ADH5P4	6.07	1.79e-09	0.0013	0.26	0.18	Alcohol dependence;	chr4:99132740	chr6:65836930~65838039:-
BRCA	trans	rs615632	0.53	rs10092464	ENSG00000253893.2	FAM85B	6.07	1.79e-09	0.0013	0.25	0.18	Neuroticism;	chr8:9946675	chr8:8167819~8226614:-
BRCA	trans	rs1580019	0.587	rs6968990	ENSG00000213492.2	NT5C3AP1	6.07	1.79e-09	0.00131	0.25	0.18	Cognitive ability;	chr7:32512547	chr4:117574512~117576174:-
BRCA	trans	rs4879656	0.835	rs13290323	ENSG00000215007.3	DNAJA1P3	6.07	1.81e-09	0.00132	0.22	0.18	Menopause (age at onset);	chr9:33062293	chrX:107351650~107352843:-
BRCA	trans	rs1816854	0.515	rs17121283	ENSG00000178082.6	TWF1P1	6.07	1.81e-09	0.00132	0.23	0.18	Inflammatory bowel disease;	chr12:43791790	chr17:29203426~29204474:-
BRCA	trans	rs2243480	1	rs34703416	ENSG00000232546.1	RP11-458F8.1	-6.07	1.82e-09	0.00132	-0.24	-0.18	Diabetic kidney disease;	chr7:65835655	chr7:66848496~66858136:+
BRCA	trans	rs67340775	0.834	rs13218875	ENSG00000204338.7	CYP21A1P	-6.07	1.82e-09	0.00132	-0.43	-0.18	Lung cancer in ever smokers;	chr6:27916234	chr6:32005636~32008451:+
BRCA	trans	rs2055729	0.528	rs11987861	ENSG00000253893.2	FAM85B	6.07	1.82e-09	0.00132	0.26	0.18	Multiple myeloma (hyperdiploidy);	chr8:9884696	chr8:8167819~8226614:-
BRCA	trans	rs11098499	0.955	rs11931312	ENSG00000276997.3	RP11-378J18.9	6.07	1.82e-09	0.00133	0.23	0.18	Corneal astigmatism;	chr4:119237868	chr1:222477252~222504622:-
BRCA	trans	rs6831352	0.959	rs6848050	ENSG00000233859.2	ADH5P4	-6.07	1.82e-09	0.00133	-0.25	-0.18	Alcohol dependence;	chr4:99132582	chr6:65836930~65838039:-
BRCA	trans	rs6831352	1	rs6532798	ENSG00000233859.2	ADH5P4	-6.07	1.82e-09	0.00133	-0.25	-0.18	Alcohol dependence;	chr4:99133676	chr6:65836930~65838039:-
BRCA	trans	rs875971	0.545	rs73148639	ENSG00000234585.5	CCT6P3	6.07	1.82e-09	0.00133	0.2	0.18	Aortic root size;	chr7:66390342	chr7:65038354~65074713:+
BRCA	trans	rs7824557	0.736	rs35392635	ENSG00000254153.1	CTA-398F10.2	6.07	1.82e-09	0.00133	0.25	0.18	Retinal vascular caliber;	chr8:11306840	chr8:8456909~8461337:-
BRCA	trans	rs7568458	0.709	rs11895399	ENSG00000223886.3	RP11-251G23.2	6.07	1.83e-09	0.00133	0.23	0.18	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr2:85526683	chr7:105530209~105530671:+
BRCA	trans	rs7568458	0.709	rs11895401	ENSG00000223886.3	RP11-251G23.2	6.07	1.83e-09	0.00133	0.23	0.18	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr2:85526724	chr7:105530209~105530671:+
BRCA	trans	rs902774	1	rs11831942	ENSG00000224520.2	KRT8P45	-6.07	1.83e-09	0.00133	-0.31	-0.18	Prostate cancer;	chr12:52878329	chr1:157073257~157074703:+
BRCA	trans	rs875971	0.545	rs7787063	ENSG00000213640.3	EEF1DP4	-6.07	1.83e-09	0.00133	-0.26	-0.18	Aortic root size;	chr7:66164012	chr7:64862999~64864370:+
BRCA	trans	rs875971	0.545	rs12673308	ENSG00000213640.3	EEF1DP4	-6.07	1.83e-09	0.00133	-0.26	-0.18	Aortic root size;	chr7:66166374	chr7:64862999~64864370:+
BRCA	trans	rs2117029	0.553	rs731350	ENSG00000214391.3	TUBAP2	6.06	1.84e-09	0.00134	0.18	0.18	Intelligence (multi-trait analysis);	chr12:49130804	chr11:90282560~90284172:+
BRCA	trans	rs875971	0.895	rs3857684	ENSG00000164669.11	INTS4P1	-6.06	1.84e-09	0.00134	-0.23	-0.18	Aortic root size;	chr7:66473171	chr7:65141225~65234216:+
BRCA	trans	rs7568458	0.684	rs67988001	ENSG00000223886.3	RP11-251G23.2	6.06	1.84e-09	0.00134	0.23	0.18	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr2:85560000	chr7:105530209~105530671:+
BRCA	trans	rs1707322	1	rs785480	ENSG00000255397.1	AC022182.2	-6.06	1.85e-09	0.00135	-0.24	-0.18	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46026492	chr8:60937705~60939871:-
BRCA	trans	rs7570469	0.722	rs6742990	ENSG00000276390.1	RP1-197B17.5	6.06	1.85e-09	0.00135	0.24	0.18	Response to antipsychotic treatment;	chr2:79428355	chr12:47699401~47699917:-
BRCA	trans	rs7570469	0.762	rs6714410	ENSG00000276390.1	RP1-197B17.5	6.06	1.85e-09	0.00135	0.24	0.18	Response to antipsychotic treatment;	chr2:79428409	chr12:47699401~47699917:-
BRCA	trans	rs7570469	0.722	rs62156962	ENSG00000276390.1	RP1-197B17.5	6.06	1.85e-09	0.00135	0.24	0.18	Response to antipsychotic treatment;	chr2:79428658	chr12:47699401~47699917:-
BRCA	trans	rs2048656	0.635	rs7830613	ENSG00000253893.2	FAM85B	6.06	1.85e-09	0.00135	0.24	0.18	Schizophrenia;	chr8:9792259	chr8:8167819~8226614:-
BRCA	trans	rs7570469	0.722	rs28616218	ENSG00000276390.1	RP1-197B17.5	6.06	1.86e-09	0.00136	0.24	0.18	Response to antipsychotic treatment;	chr2:79427890	chr12:47699401~47699917:-
BRCA	trans	rs7570469	0.722	rs1376623	ENSG00000276390.1	RP1-197B17.5	6.06	1.86e-09	0.00136	0.24	0.18	Response to antipsychotic treatment;	chr2:79427891	chr12:47699401~47699917:-
BRCA	trans	rs7746199	0.673	rs35501037	ENSG00000281831.1	HCP5B	6.06	1.87e-09	0.00136	0.45	0.18	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27771787	chr6:29871895~29873783:-
BRCA	trans	rs2243480	0.901	rs2900904	ENSG00000230295.1	RP11-458F8.2	-6.06	1.87e-09	0.00136	-0.24	-0.18	Diabetic kidney disease;	chr7:65739282	chr7:66880708~66882981:+
BRCA	trans	rs7338174	0.655	rs9316535	ENSG00000170919.14	TPT1-AS1	6.06	1.88e-09	0.00136	0.35	0.18	Mitochondrial DNA levels;	chr13:51329329	chr13:45341345~45393413:+
BRCA	trans	rs12210905	1	rs6917419	ENSG00000242375.1	RP11-498P14.3	-6.06	1.88e-09	0.00136	-0.37	-0.18	Hip circumference adjusted for BMI;	chr6:27275701	chr9:97195351~97197687:-
BRCA	trans	rs4834770	1	rs4336213	ENSG00000275858.1	RP11-291L22.8	6.06	1.88e-09	0.00136	0.21	0.18	Blood protein levels;	chr4:119315314	chr10:38450738~38451069:-
BRCA	trans	rs7570469	0.762	rs11126730	ENSG00000276390.1	RP1-197B17.5	6.06	1.89e-09	0.00138	0.24	0.18	Response to antipsychotic treatment;	chr2:79430515	chr12:47699401~47699917:-
BRCA	trans	rs3750082	0.889	rs970673	ENSG00000176826.14	FKBP9P1	6.06	1.89e-09	0.00138	0.23	0.18	Glomerular filtration rate (creatinine);	chr7:32888115	chr7:55681074~55713252:-
BRCA	trans	rs2242330	0.798	rs13119230	ENSG00000226982.4	CENPCP1	6.06	1.9e-09	0.00138	0.24	0.18	Parkinson's disease;	chr4:67579559	chr12:89500093~89502670:+
BRCA	trans	rs6489882	0.867	rs1859336	ENSG00000250770.2	RP5-1063M23.1	-6.06	1.9e-09	0.00138	-0.25	-0.18	Chronic lymphocytic leukemia;	chr12:112929504	chr12:3296202~3300224:-
BRCA	trans	rs7570469	0.762	rs6709617	ENSG00000276390.1	RP1-197B17.5	6.06	1.9e-09	0.00138	0.24	0.18	Response to antipsychotic treatment;	chr2:79430858	chr12:47699401~47699917:-
BRCA	trans	rs4930561	0.739	rs12225316	ENSG00000155070.8	UNC93B2	-6.06	1.91e-09	0.00139	-0.22	-0.18	Breast cancer in childhood cancer survivors;IgG glycosylation;	chr11:68208536	chr7:6855485~6859830:-
BRCA	trans	rs2243480	1	rs4718270	ENSG00000230295.1	RP11-458F8.2	-6.06	1.92e-09	0.0014	-0.24	-0.18	Diabetic kidney disease;	chr7:65737415	chr7:66880708~66882981:+
BRCA	trans	rs853679	0.607	rs67040724	ENSG00000204338.7	CYP21A1P	-6.06	1.92e-09	0.0014	-0.43	-0.18	Depression;	chr6:27937731	chr6:32005636~32008451:+
BRCA	trans	rs11098499	0.697	rs35280960	ENSG00000120555.12	SEPT7P9	6.06	1.92e-09	0.0014	0.22	0.18	Corneal astigmatism;	chr4:119335904	chr10:38383069~38402916:-
BRCA	trans	rs875971	0.545	rs10261710	ENSG00000234585.5	CCT6P3	6.06	1.93e-09	0.0014	0.21	0.18	Aortic root size;	chr7:66249202	chr7:65038354~65074713:+
BRCA	trans	rs875971	0.545	rs313830	ENSG00000213640.3	EEF1DP4	6.06	1.93e-09	0.0014	0.26	0.18	Aortic root size;	chr7:66086944	chr7:64862999~64864370:+
BRCA	trans	rs941207	0.756	rs1465081	ENSG00000257210.1	NACAP3	-6.06	1.93e-09	0.0014	-0.25	-0.18	Platelet count;	chr12:56656390	chr12:93124063~93124543:-
BRCA	trans	rs7833986	0.501	rs2668007	ENSG00000244245.1	RP11-120B7.1	6.06	1.93e-09	0.0014	0.24	0.18	Height;	chr8:56031552	chr5:108593609~108593967:+
BRCA	trans	rs7617773	0.643	rs78159520	ENSG00000235912.1	RP1-159A19.3	-6.06	1.93e-09	0.00141	-0.25	-0.18	Coronary artery disease;	chr3:48307533	chr1:27649419~27649610:+
BRCA	trans	rs853679	0.882	rs2743555	ENSG00000253570.1	RNF5P1	6.06	1.94e-09	0.00141	0.36	0.18	Depression;	chr6:28273304	chr8:38600661~38601200:-
BRCA	trans	rs9693857	0.52	rs13267391	ENSG00000253893.2	FAM85B	-6.06	1.94e-09	0.00141	-0.26	-0.18	Systolic blood pressure;	chr8:9499204	chr8:8167819~8226614:-
BRCA	trans	rs1707322	1	rs34444543	ENSG00000255397.1	AC022182.2	-6.06	1.95e-09	0.00142	-0.24	-0.18	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45893190	chr8:60937705~60939871:-
BRCA	trans	rs11666377	0.882	rs11086050	ENSG00000197320.5	AC060834.2	6.06	1.95e-09	0.00142	0.28	0.18	Brain lesion load;	chr19:17004912	chr7:9726241~9728272:+
BRCA	trans	rs4930561	0.739	rs10896303	ENSG00000155070.8	UNC93B2	-6.06	1.95e-09	0.00142	-0.22	-0.18	Breast cancer in childhood cancer survivors;IgG glycosylation;	chr11:68206825	chr7:6855485~6859830:-
BRCA	trans	rs860295	0.58	rs867548	ENSG00000241627.3	UBQLN4P1	-6.06	1.96e-09	0.00142	-0.21	-0.18	Body mass index;	chr1:155910217	chr3:148985868~148987668:-
BRCA	trans	rs6011368	0.654	rs1570521	ENSG00000226210.3	WASH7P	6.06	1.96e-09	0.00142	0.2	0.18	Clozapine-induced cytotoxicity;	chr20:64279666	chr12:14522~32015:-
BRCA	trans	rs1459104	0.57	rs56152290	ENSG00000134612.10	FOLH1B	-6.05	1.96e-09	0.00142	-0.34	-0.18	Body mass index;	chr11:55090597	chr11:89639227~89698718:+
BRCA	trans	rs2272306	0.636	rs7298527	ENSG00000228753.1	EIF4BP2	6.05	1.96e-09	0.00143	0.27	0.18	Obesity-related traits;	chr12:53137588	chr10:21028999~21030792:+
BRCA	trans	rs546131	0.642	rs10501136	ENSG00000225531.1	RP11-196I18.3	6.05	1.97e-09	0.00143	0.3	0.18	Lung disease severity in cystic fibrosis;	chr11:34824969	chr9:107116829~107117557:+
BRCA	trans	rs1707322	0.964	rs7546237	ENSG00000255397.1	AC022182.2	-6.05	1.98e-09	0.00143	-0.24	-0.18	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45819938	chr8:60937705~60939871:-
BRCA	trans	rs902774	0.818	rs56095813	ENSG00000223940.1	KRT8P8	-6.05	1.98e-09	0.00143	-0.38	-0.18	Prostate cancer;	chr12:52900963	chrX:152479577~152481024:+
BRCA	trans	rs4713118	0.869	rs9348775	ENSG00000204709.4	LINC01556	6.05	1.98e-09	0.00144	0.25	0.18	Parkinson's disease;	chr6:27727550	chr6:28943877~28944537:+
BRCA	trans	rs2117029	0.586	rs10875928	ENSG00000214391.3	TUBAP2	6.05	1.98e-09	0.00144	0.18	0.18	Intelligence (multi-trait analysis);	chr12:49162520	chr11:90282560~90284172:+
BRCA	trans	rs875971	0.545	rs10950036	ENSG00000234585.5	CCT6P3	6.05	1.98e-09	0.00144	0.2	0.18	Aortic root size;	chr7:66353241	chr7:65038354~65074713:+
BRCA	trans	rs3942852	0.955	rs6485809	ENSG00000134612.10	FOLH1B	-6.05	1.98e-09	0.00144	-0.26	-0.18	Acute lymphoblastic leukemia (childhood);	chr11:48090916	chr11:89639227~89698718:+
BRCA	trans	rs2122469	0.655	rs17603934	ENSG00000253981.4	ALG1L13P	6.05	1.99e-09	0.00145	0.31	0.18	Serum tamsulosin hydrochloride concentration;	chr8:20718833	chr8:8236003~8244667:-
BRCA	trans	rs3812762	0.871	rs11603335	ENSG00000266891.1	RP11-692N5.2	-6.05	1.99e-09	0.00145	-0.22	-0.18	Hypospadias;	chr11:8788297	chr18:9734882~9735602:-
BRCA	trans	rs673253	0.52	rs3791034	ENSG00000231007.5	CDC20P1	6.05	2e-09	0.00145	0.24	0.18	Intelligence (multi-trait analysis);	chr1:43679459	chr9:87011652~87013151:+
BRCA	trans	rs875971	0.545	rs6460276	ENSG00000213640.3	EEF1DP4	-6.05	2e-09	0.00145	-0.26	-0.18	Aortic root size;	chr7:66182290	chr7:64862999~64864370:+
BRCA	trans	rs6921919	1	rs6922111	ENSG00000228078.1	HLA-U	-6.05	2e-09	0.00145	-0.28	-0.18	Autism spectrum disorder or schizophrenia;	chr6:28357531	chr6:29934101~29934286:+
BRCA	trans	rs2242330	0.862	rs6834849	ENSG00000226982.4	CENPCP1	6.05	2e-09	0.00145	0.26	0.18	Parkinson's disease;	chr4:67435727	chr12:89500093~89502670:+
BRCA	trans	rs9693857	0.52	rs4841163	ENSG00000253893.2	FAM85B	-6.05	2.01e-09	0.00146	-0.25	-0.18	Systolic blood pressure;	chr8:9508668	chr8:8167819~8226614:-
BRCA	trans	rs34421088	0.506	rs2572428	ENSG00000253893.2	FAM85B	-6.05	2.01e-09	0.00146	-0.24	-0.18	Neuroticism;	chr8:11289163	chr8:8167819~8226614:-
BRCA	trans	rs11992162	1	rs7460395	ENSG00000254153.1	CTA-398F10.2	6.05	2.01e-09	0.00146	0.23	0.18	Monocyte count;	chr8:11977866	chr8:8456909~8461337:-
BRCA	trans	rs7927771	0.832	rs1542321	ENSG00000134612.10	FOLH1B	6.05	2.01e-09	0.00146	0.24	0.18	Subjective well-being;	chr11:47358064	chr11:89639227~89698718:+
BRCA	trans	rs11098499	0.675	rs11098534	ENSG00000276997.3	RP11-378J18.9	6.05	2.02e-09	0.00146	0.22	0.18	Corneal astigmatism;	chr4:119635617	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.644	rs7676296	ENSG00000120555.12	SEPT7P9	6.05	2.02e-09	0.00146	0.22	0.18	Corneal astigmatism;	chr4:119634532	chr10:38383069~38402916:-
BRCA	trans	rs12439619	0.846	rs62011975	ENSG00000235370.6	DNM1P51	-6.05	2.02e-09	0.00147	-0.26	-0.18	Intelligence (multi-trait analysis);	chr15:82159213	chr15:84398316~84411701:-
BRCA	trans	rs11098499	0.604	rs10022185	ENSG00000276805.1	RP11-291L22.6	6.05	2.02e-09	0.00147	0.23	0.18	Corneal astigmatism;	chr4:119650610	chr10:38451030~38451785:+
BRCA	trans	rs941207	0.756	rs10876915	ENSG00000257210.1	NACAP3	-6.05	2.03e-09	0.00147	-0.24	-0.18	Platelet count;	chr12:56655280	chr12:93124063~93124543:-
BRCA	trans	rs875971	0.862	rs1981799	ENSG00000164669.11	INTS4P1	-6.05	2.03e-09	0.00147	-0.23	-0.18	Aortic root size;	chr7:66490572	chr7:65141225~65234216:+
BRCA	trans	rs7927771	0.832	rs11605672	ENSG00000134612.10	FOLH1B	-6.05	2.03e-09	0.00147	-0.24	-0.18	Subjective well-being;	chr11:47392182	chr11:89639227~89698718:+
BRCA	trans	rs875971	0.52	rs160645	ENSG00000213640.3	EEF1DP4	6.05	2.05e-09	0.00148	0.26	0.18	Aortic root size;	chr7:66091320	chr7:64862999~64864370:+
BRCA	trans	rs546131	0.571	rs11601422	ENSG00000225531.1	RP11-196I18.3	-6.05	2.05e-09	0.00149	-0.3	-0.18	Lung disease severity in cystic fibrosis;	chr11:34772212	chr9:107116829~107117557:+
BRCA	trans	rs6934970	1	rs7739145	ENSG00000267560.1	RP11-173A16.1	-6.05	2.05e-09	0.00149	-0.23	-0.18	Bipolar disorder (body mass index interaction);	chr6:112819706	chr18:62300036~62300998:-
BRCA	trans	rs6831352	0.918	rs17218560	ENSG00000233859.2	ADH5P4	-6.05	2.05e-09	0.00149	-0.26	-0.18	Alcohol dependence;	chr4:99139643	chr6:65836930~65838039:-
BRCA	trans	rs11098499	0.604	rs12642411	ENSG00000253326.2	RP11-261C10.7	6.05	2.06e-09	0.00149	0.27	0.18	Corneal astigmatism;	chr4:119659370	chr1:243054861~243056394:-
BRCA	trans	rs16975963	0.639	rs112997435	ENSG00000247498.8	RP11-392P7.6	6.05	2.06e-09	0.00149	0.33	0.18	Longevity;	chr19:37713730	chr12:12927726~12984645:+
BRCA	trans	rs11666377	0.891	rs8107156	ENSG00000197320.5	AC060834.2	6.05	2.06e-09	0.00149	0.26	0.18	Brain lesion load;	chr19:16994247	chr7:9726241~9728272:+
BRCA	trans	rs875971	0.571	rs160641	ENSG00000213640.3	EEF1DP4	6.05	2.06e-09	0.00149	0.26	0.18	Aortic root size;	chr7:66112359	chr7:64862999~64864370:+
BRCA	trans	rs7260598	0.681	rs62114776	ENSG00000261770.1	CTC-459F4.1	6.05	2.06e-09	0.00149	0.3	0.18	Response to taxane treatment (placlitaxel);	chr19:24054513	chr19:27757184~27760849:-
BRCA	trans	rs902774	0.818	rs73110471	ENSG00000223940.1	KRT8P8	-6.05	2.07e-09	0.0015	-0.36	-0.18	Prostate cancer;	chr12:52923037	chrX:152479577~152481024:+
BRCA	trans	rs7824557	0.767	rs6985146	ENSG00000254153.1	CTA-398F10.2	6.05	2.07e-09	0.0015	0.24	0.18	Retinal vascular caliber;	chr8:11313212	chr8:8456909~8461337:-
BRCA	trans	rs4929949	0.901	rs9737312	ENSG00000266891.1	RP11-692N5.2	6.05	2.07e-09	0.0015	0.21	0.18	Body mass index;	chr11:8564142	chr18:9734882~9735602:-
BRCA	trans	rs12546962	0.92	rs12548931	ENSG00000253893.2	FAM85B	-6.05	2.08e-09	0.0015	-0.25	-0.18	Body mass index;	chr8:9343181	chr8:8167819~8226614:-
BRCA	trans	rs875971	0.545	rs12671152	ENSG00000213640.3	EEF1DP4	-6.05	2.08e-09	0.0015	-0.26	-0.18	Aortic root size;	chr7:66311140	chr7:64862999~64864370:+
BRCA	trans	rs1985732	1	rs1985732	ENSG00000242375.1	RP11-498P14.3	-6.04	2.08e-09	0.00151	-0.28	-0.18	Depressive symptoms (multi-trait analysis);	chr6:26375933	chr9:97195351~97197687:-
BRCA	trans	rs875971	0.545	rs13311962	ENSG00000234585.5	CCT6P3	-6.04	2.09e-09	0.00151	-0.2	-0.18	Aortic root size;	chr7:66603142	chr7:65038354~65074713:+
BRCA	trans	rs7927771	0.832	rs4752994	ENSG00000134612.10	FOLH1B	6.04	2.1e-09	0.00152	0.24	0.18	Subjective well-being;	chr11:47389514	chr11:89639227~89698718:+
BRCA	trans	rs7927771	0.832	rs10769262	ENSG00000134612.10	FOLH1B	6.04	2.1e-09	0.00152	0.24	0.18	Subjective well-being;	chr11:47390030	chr11:89639227~89698718:+
BRCA	trans	rs2237234	1	rs2237234	ENSG00000242375.1	RP11-498P14.3	-6.04	2.11e-09	0.00153	-0.28	-0.18	Autism spectrum disorder or schizophrenia;	chr6:26391166	chr9:97195351~97197687:-
BRCA	trans	rs11098499	0.754	rs17595608	ENSG00000276997.3	RP11-378J18.9	6.04	2.12e-09	0.00153	0.22	0.18	Corneal astigmatism;	chr4:119329351	chr1:222477252~222504622:-
BRCA	trans	rs4713118	0.911	rs2394000	ENSG00000204709.4	LINC01556	6.04	2.12e-09	0.00153	0.26	0.18	Parkinson's disease;	chr6:27719212	chr6:28943877~28944537:+
BRCA	trans	rs4713118	0.955	rs9393847	ENSG00000204709.4	LINC01556	6.04	2.12e-09	0.00153	0.26	0.18	Parkinson's disease;	chr6:27720194	chr6:28943877~28944537:+
BRCA	trans	rs875971	0.895	rs4718349	ENSG00000164669.11	INTS4P1	-6.04	2.13e-09	0.00154	-0.22	-0.18	Aortic root size;	chr7:66444024	chr7:65141225~65234216:+
BRCA	trans	rs875971	1	rs2042133	ENSG00000164669.11	INTS4P1	-6.04	2.13e-09	0.00154	-0.22	-0.18	Aortic root size;	chr7:66466935	chr7:65141225~65234216:+
BRCA	trans	rs875971	0.964	rs2161065	ENSG00000164669.11	INTS4P1	-6.04	2.13e-09	0.00154	-0.22	-0.18	Aortic root size;	chr7:66467918	chr7:65141225~65234216:+
BRCA	trans	rs875971	0.862	rs12698521	ENSG00000164669.11	INTS4P1	-6.04	2.13e-09	0.00154	-0.22	-0.18	Aortic root size;	chr7:66474502	chr7:65141225~65234216:+
BRCA	trans	rs2117029	0.653	rs1476137	ENSG00000214391.3	TUBAP2	6.04	2.13e-09	0.00154	0.18	0.18	Intelligence (multi-trait analysis);	chr12:49129930	chr11:90282560~90284172:+
BRCA	trans	rs875971	0.502	rs2946580	ENSG00000213640.3	EEF1DP4	6.04	2.14e-09	0.00154	0.26	0.18	Aortic root size;	chr7:66066855	chr7:64862999~64864370:+
BRCA	trans	rs7570469	0.762	rs376763	ENSG00000276390.1	RP1-197B17.5	6.04	2.14e-09	0.00155	0.24	0.18	Response to antipsychotic treatment;	chr2:79452805	chr12:47699401~47699917:-
BRCA	trans	rs875971	0.545	rs4441996	ENSG00000234585.5	CCT6P3	-6.04	2.14e-09	0.00155	-0.2	-0.18	Aortic root size;	chr7:66123233	chr7:65038354~65074713:+
BRCA	trans	rs1707322	1	rs4660334	ENSG00000255397.1	AC022182.2	-6.04	2.16e-09	0.00156	-0.24	-0.18	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45996454	chr8:60937705~60939871:-
BRCA	trans	rs11098499	0.754	rs2036857	ENSG00000276997.3	RP11-378J18.9	6.04	2.17e-09	0.00157	0.22	0.18	Corneal astigmatism;	chr4:119328085	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.754	rs2036856	ENSG00000276997.3	RP11-378J18.9	6.04	2.17e-09	0.00157	0.22	0.18	Corneal astigmatism;	chr4:119328133	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.754	rs4443261	ENSG00000276997.3	RP11-378J18.9	6.04	2.17e-09	0.00157	0.22	0.18	Corneal astigmatism;	chr4:119328146	chr1:222477252~222504622:-
BRCA	trans	rs9733	0.744	rs2089081	ENSG00000180764.13	PIPSL	6.04	2.17e-09	0.00157	0.23	0.18	Tonsillectomy;	chr1:150827641	chr10:93958191~93961540:-
BRCA	trans	rs7260598	1	rs7254349	ENSG00000261770.1	CTC-459F4.1	6.04	2.17e-09	0.00157	0.3	0.18	Response to taxane treatment (placlitaxel);	chr19:24047541	chr19:27757184~27760849:-
BRCA	trans	rs12439619	0.921	rs56042848	ENSG00000259774.1	RP11-182J1.13	6.04	2.18e-09	0.00157	0.24	0.18	Intelligence (multi-trait analysis);	chr15:82235244	chr15:84422618~84425882:+
BRCA	trans	rs35491132	1	rs35491132	ENSG00000204709.4	LINC01556	6.04	2.18e-09	0.00158	0.47	0.18	Urinary tract infection frequency;	chr6:27559449	chr6:28943877~28944537:+
BRCA	trans	rs6921919	0.848	rs6903652	ENSG00000228078.1	HLA-U	-6.04	2.19e-09	0.00158	-0.27	-0.18	Autism spectrum disorder or schizophrenia;	chr6:28354343	chr6:29934101~29934286:+
BRCA	trans	rs875971	0.895	rs12698520	ENSG00000164669.11	INTS4P1	-6.04	2.19e-09	0.00158	-0.23	-0.18	Aortic root size;	chr7:66453720	chr7:65141225~65234216:+
BRCA	trans	rs941207	0.756	rs2958153	ENSG00000257210.1	NACAP3	6.04	2.19e-09	0.00158	0.25	0.18	Platelet count;	chr12:56687733	chr12:93124063~93124543:-
BRCA	trans	rs4879656	0.797	rs7872744	ENSG00000215007.3	DNAJA1P3	6.04	2.2e-09	0.00159	0.22	0.18	Menopause (age at onset);	chr9:33054164	chrX:107351650~107352843:-
BRCA	trans	rs2066819	1	rs11171806	ENSG00000273654.1	CTB-52I2.4	-6.04	2.2e-09	0.00159	-0.47	-0.18	Psoriasis vulgaris;	chr12:56339747	chr19:18022403~18032099:+
BRCA	trans	rs4948102	0.69	rs35844144	ENSG00000186940.6	CHCHD2P9	-6.04	2.2e-09	0.00159	-0.23	-0.18	Plasma homocysteine levels (post-methionine load test);	chr7:55982832	chr9:79391304~79391759:+
BRCA	trans	rs11098499	0.78	rs12504773	ENSG00000276805.1	RP11-291L22.6	6.04	2.2e-09	0.00159	0.22	0.18	Corneal astigmatism;	chr4:119640994	chr10:38451030~38451785:+
BRCA	trans	rs7833986	0.941	rs13278255	ENSG00000236862.1	RPS20P24	6.03	2.21e-09	0.00159	0.24	0.18	Height;	chr8:56155416	chr9:72655832~72656192:-
BRCA	trans	rs9467711	0.659	rs35680819	ENSG00000281831.1	HCP5B	6.03	2.21e-09	0.0016	0.43	0.18	Autism spectrum disorder or schizophrenia;	chr6:26455586	chr6:29871895~29873783:-
BRCA	trans	rs7927771	0.864	rs60075622	ENSG00000134612.10	FOLH1B	-6.03	2.22e-09	0.0016	-0.24	-0.18	Subjective well-being;	chr11:47427550	chr11:89639227~89698718:+
BRCA	trans	rs875971	1	rs12533997	ENSG00000164669.11	INTS4P1	-6.03	2.22e-09	0.0016	-0.22	-0.18	Aortic root size;	chr7:66500390	chr7:65141225~65234216:+
BRCA	trans	rs7570469	0.725	rs17040656	ENSG00000276390.1	RP1-197B17.5	6.03	2.22e-09	0.0016	0.24	0.18	Response to antipsychotic treatment;	chr2:79436229	chr12:47699401~47699917:-
BRCA	trans	rs7570469	0.689	rs62156994	ENSG00000276390.1	RP1-197B17.5	6.03	2.22e-09	0.0016	0.24	0.18	Response to antipsychotic treatment;	chr2:79436364	chr12:47699401~47699917:-
BRCA	trans	rs4713118	0.955	rs9468200	ENSG00000204709.4	LINC01556	6.03	2.23e-09	0.00161	0.26	0.18	Parkinson's disease;	chr6:27715284	chr6:28943877~28944537:+
BRCA	trans	rs11098499	0.955	rs1551	ENSG00000276997.3	RP11-378J18.9	6.03	2.23e-09	0.00161	0.23	0.18	Corneal astigmatism;	chr4:119237345	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.644	rs10009566	ENSG00000120555.12	SEPT7P9	6.03	2.23e-09	0.00161	0.22	0.18	Corneal astigmatism;	chr4:119637453	chr10:38383069~38402916:-
BRCA	trans	rs875971	0.545	rs73136346	ENSG00000213640.3	EEF1DP4	6.03	2.23e-09	0.00161	0.26	0.18	Aortic root size;	chr7:66101095	chr7:64862999~64864370:+
BRCA	trans	rs4713118	0.955	rs34752872	ENSG00000204709.4	LINC01556	6.03	2.24e-09	0.00161	0.26	0.18	Parkinson's disease;	chr6:27715465	chr6:28943877~28944537:+
BRCA	trans	rs4948102	0.924	rs13241866	ENSG00000186940.6	CHCHD2P9	-6.03	2.24e-09	0.00161	-0.23	-0.18	Plasma homocysteine levels (post-methionine load test);	chr7:56023185	chr9:79391304~79391759:+
BRCA	trans	rs875971	1	rs6957199	ENSG00000164669.11	INTS4P1	-6.03	2.24e-09	0.00161	-0.23	-0.18	Aortic root size;	chr7:66513532	chr7:65141225~65234216:+
BRCA	trans	rs6831352	1	rs1126671	ENSG00000233859.2	ADH5P4	-6.03	2.25e-09	0.00162	-0.25	-0.18	Alcohol dependence;	chr4:99127263	chr6:65836930~65838039:-
BRCA	trans	rs6831352	1	rs6837685	ENSG00000233859.2	ADH5P4	-6.03	2.25e-09	0.00162	-0.25	-0.18	Alcohol dependence;	chr4:99127994	chr6:65836930~65838039:-
BRCA	trans	rs6831352	0.959	rs4699710	ENSG00000233859.2	ADH5P4	-6.03	2.25e-09	0.00162	-0.25	-0.18	Alcohol dependence;	chr4:99130668	chr6:65836930~65838039:-
BRCA	trans	rs6831352	0.703	rs2602854	ENSG00000228407.2	RP4-800M22.1	-6.03	2.26e-09	0.00163	-0.25	-0.18	Alcohol dependence;	chr4:99107500	chr1:52160261~52160600:-
BRCA	trans	rs4713118	0.955	rs9393848	ENSG00000204709.4	LINC01556	6.03	2.26e-09	0.00163	0.26	0.18	Parkinson's disease;	chr6:27720590	chr6:28943877~28944537:+
BRCA	trans	rs4713118	0.739	rs2893931	ENSG00000204709.4	LINC01556	6.03	2.27e-09	0.00163	0.26	0.18	Parkinson's disease;	chr6:27780231	chr6:28943877~28944537:+
BRCA	trans	rs9852859	0.665	rs7612213	ENSG00000261353.1	CTA-14H9.5	6.03	2.27e-09	0.00163	0.26	0.18	Body mass index;	chr3:85740704	chr6:26527063~26527404:+
BRCA	trans	rs1336472	0.509	rs4916032	ENSG00000263535.1	AK4P1	-6.03	2.27e-09	0.00164	-0.23	-0.18	Venous thromboembolism (SNP x SNP interaction);	chr1:65215939	chr17:31345521~31346187:+
BRCA	trans	rs4929949	0.546	rs2121312	ENSG00000266891.1	RP11-692N5.2	6.03	2.28e-09	0.00164	0.22	0.18	Body mass index;	chr11:8432047	chr18:9734882~9735602:-
BRCA	trans	rs7617773	0.817	rs6796490	ENSG00000235912.1	RP1-159A19.3	-6.03	2.28e-09	0.00164	-0.22	-0.18	Coronary artery disease;	chr3:48195614	chr1:27649419~27649610:+
BRCA	trans	rs11666377	0.714	rs12973786	ENSG00000197320.5	AC060834.2	6.03	2.29e-09	0.00165	0.28	0.18	Brain lesion load;	chr19:17004772	chr7:9726241~9728272:+
BRCA	trans	rs2950393	0.857	rs1563896	ENSG00000257210.1	NACAP3	6.03	2.29e-09	0.00165	0.22	0.18	Platelet distribution width;	chr12:56699312	chr12:93124063~93124543:-
BRCA	trans	rs7617773	0.817	rs11928691	ENSG00000235912.1	RP1-159A19.3	-6.03	2.29e-09	0.00165	-0.23	-0.18	Coronary artery disease;	chr3:48245275	chr1:27649419~27649610:+
BRCA	trans	rs11098499	0.754	rs714899	ENSG00000276997.3	RP11-378J18.9	6.03	2.3e-09	0.00166	0.22	0.18	Corneal astigmatism;	chr4:119321880	chr1:222477252~222504622:-
BRCA	trans	rs7570469	0.762	rs388990	ENSG00000276390.1	RP1-197B17.5	6.03	2.3e-09	0.00166	0.24	0.18	Response to antipsychotic treatment;	chr2:79457821	chr12:47699401~47699917:-
BRCA	trans	rs11098499	0.644	rs28787668	ENSG00000120555.12	SEPT7P9	6.03	2.31e-09	0.00166	0.22	0.18	Corneal astigmatism;	chr4:119633532	chr10:38383069~38402916:-
BRCA	trans	rs6939532	0.522	rs13218591	ENSG00000242375.1	RP11-498P14.3	-6.03	2.31e-09	0.00166	-0.27	-0.18	Autism spectrum disorder or schizophrenia;	chr6:26376604	chr9:97195351~97197687:-
BRCA	trans	rs2060793	0.539	rs962025	ENSG00000236360.2	RP11-334A14.2	6.03	2.31e-09	0.00166	0.23	0.18	Vitamin D levels;	chr11:14618744	chr1:52993201~52993702:-
BRCA	trans	rs902774	0.818	rs4919742	ENSG00000254285.3	KRT8P3	-6.03	2.32e-09	0.00167	-0.38	-0.18	Prostate cancer;	chr12:52879180	chr8:61578220~61579668:+
BRCA	trans	rs78944489	0.867	rs2231421	ENSG00000236165.1	PRADC1P1	6.03	2.32e-09	0.00167	0.37	0.18	Schizophrenia;	chr2:73233995	chr3:36976316~36976840:+
BRCA	trans	rs11098499	0.604	rs17051352	ENSG00000276805.1	RP11-291L22.6	6.03	2.32e-09	0.00167	0.23	0.18	Corneal astigmatism;	chr4:119660272	chr10:38451030~38451785:+
BRCA	trans	rs11098499	0.754	rs9999724	ENSG00000276997.3	RP11-378J18.9	6.03	2.33e-09	0.00168	0.22	0.18	Corneal astigmatism;	chr4:119318789	chr1:222477252~222504622:-
BRCA	trans	rs66887589	0.616	rs1052633	ENSG00000120555.12	SEPT7P9	6.03	2.34e-09	0.00168	0.21	0.18	Diastolic blood pressure;	chr4:119294159	chr10:38383069~38402916:-
BRCA	trans	rs11098499	1	rs13435802	ENSG00000276997.3	RP11-378J18.9	-6.03	2.34e-09	0.00168	-0.23	-0.18	Corneal astigmatism;	chr4:119256805	chr1:222477252~222504622:-
BRCA	trans	rs9860340	0.77	rs7643337	ENSG00000259370.2	RP11-1069G10.1	6.03	2.34e-09	0.00168	0.21	0.18	Electroencephalographic traits in alcoholism;	chr3:87672020	chr15:62827675~62884034:-
BRCA	trans	rs66887589	0.616	rs6843509	ENSG00000120555.12	SEPT7P9	6.03	2.34e-09	0.00168	0.21	0.18	Diastolic blood pressure;	chr4:119299041	chr10:38383069~38402916:-
BRCA	trans	rs4713118	0.824	rs2092075	ENSG00000204709.4	LINC01556	6.02	2.35e-09	0.00169	0.26	0.18	Parkinson's disease;	chr6:27781551	chr6:28943877~28944537:+
BRCA	trans	rs7829975	0.742	rs1533058	ENSG00000270154.1	RP11-419I17.1	6.02	2.36e-09	0.0017	0.21	0.18	Mood instability;	chr8:8827680	chr8:12476462~12477122:+
BRCA	trans	rs4713118	0.699	rs200978	ENSG00000204709.4	LINC01556	6.02	2.37e-09	0.0017	0.27	0.18	Parkinson's disease;	chr6:27885390	chr6:28943877~28944537:+
BRCA	trans	rs11098499	0.644	rs3806808	ENSG00000120555.12	SEPT7P9	6.02	2.37e-09	0.0017	0.22	0.18	Corneal astigmatism;	chr4:119629930	chr10:38383069~38402916:-
BRCA	trans	rs853679	0.607	rs34662244	ENSG00000204338.7	CYP21A1P	-6.02	2.38e-09	0.00171	-0.44	-0.18	Depression;	chr6:28106103	chr6:32005636~32008451:+
BRCA	trans	rs35952432	1	rs35952432	ENSG00000204338.7	CYP21A1P	-6.02	2.38e-09	0.00171	-0.44	-0.18	Lung cancer;	chr6:28107123	chr6:32005636~32008451:+
BRCA	trans	rs902774	0.818	rs4919740	ENSG00000259470.2	KRT8P9	-6.02	2.39e-09	0.00172	-0.33	-0.18	Prostate cancer;	chr12:52877187	chr15:70858714~70860162:+
BRCA	trans	rs902774	0.818	rs79377635	ENSG00000248568.1	KRT8P48	-6.02	2.39e-09	0.00172	-0.38	-0.18	Prostate cancer;	chr12:52883148	chr5:146706381~146707600:-
BRCA	trans	rs6921919	0.848	rs56131013	ENSG00000228078.1	HLA-U	-6.02	2.39e-09	0.00172	-0.27	-0.18	Autism spectrum disorder or schizophrenia;	chr6:28352900	chr6:29934101~29934286:+
BRCA	trans	rs673253	0.65	rs2819335	ENSG00000231007.5	CDC20P1	-6.02	2.4e-09	0.00173	-0.23	-0.18	Intelligence (multi-trait analysis);	chr1:43549154	chr9:87011652~87013151:+
BRCA	trans	rs7824557	0.767	rs10104728	ENSG00000254153.1	CTA-398F10.2	6.02	2.4e-09	0.00173	0.25	0.18	Retinal vascular caliber;	chr8:11313791	chr8:8456909~8461337:-
BRCA	trans	rs6121246	0.559	rs6087782	ENSG00000279352.1	RP11-411B10.7	6.02	2.41e-09	0.00173	0.26	0.18	Mean corpuscular hemoglobin;	chr20:31803777	chr18:14010054~14010917:+
BRCA	trans	rs7570469	0.762	rs6751188	ENSG00000276390.1	RP1-197B17.5	6.02	2.41e-09	0.00173	0.24	0.18	Response to antipsychotic treatment;	chr2:79430260	chr12:47699401~47699917:-
BRCA	trans	rs7570469	0.762	rs6751596	ENSG00000276390.1	RP1-197B17.5	6.02	2.41e-09	0.00173	0.24	0.18	Response to antipsychotic treatment;	chr2:79430785	chr12:47699401~47699917:-
BRCA	trans	rs7570469	0.762	rs62156991	ENSG00000276390.1	RP1-197B17.5	6.02	2.41e-09	0.00173	0.24	0.18	Response to antipsychotic treatment;	chr2:79431376	chr12:47699401~47699917:-
BRCA	trans	rs7570469	0.726	rs55784904	ENSG00000276390.1	RP1-197B17.5	6.02	2.41e-09	0.00173	0.24	0.18	Response to antipsychotic treatment;	chr2:79431623	chr12:47699401~47699917:-
BRCA	trans	rs7927771	0.832	rs7105851	ENSG00000134612.10	FOLH1B	6.02	2.41e-09	0.00173	0.24	0.18	Subjective well-being;	chr11:47361724	chr11:89639227~89698718:+
BRCA	trans	rs2055729	0.677	rs59880252	ENSG00000253893.2	FAM85B	-6.02	2.42e-09	0.00174	-0.27	-0.18	Multiple myeloma (hyperdiploidy);	chr8:9883522	chr8:8167819~8226614:-
BRCA	trans	rs11098499	0.604	rs2389886	ENSG00000276805.1	RP11-291L22.6	6.02	2.42e-09	0.00174	0.23	0.18	Corneal astigmatism;	chr4:119649267	chr10:38451030~38451785:+
BRCA	trans	rs867371	0.896	rs8033831	ENSG00000259295.5	CSPG4P12	-6.02	2.42e-09	0.00174	-0.23	-0.18	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82220953	chr15:85191438~85213905:+
BRCA	trans	rs4713118	0.869	rs7776351	ENSG00000204709.4	LINC01556	-6.02	2.43e-09	0.00174	-0.25	-0.18	Parkinson's disease;	chr6:27758952	chr6:28943877~28944537:+
BRCA	trans	rs11098499	0.644	rs28787668	ENSG00000276997.3	RP11-378J18.9	6.02	2.43e-09	0.00174	0.22	0.18	Corneal astigmatism;	chr4:119633532	chr1:222477252~222504622:-
BRCA	trans	rs1580019	0.534	rs13237495	ENSG00000213492.2	NT5C3AP1	-6.02	2.43e-09	0.00175	-0.25	-0.18	Cognitive ability;	chr7:32521075	chr4:117574512~117576174:-
BRCA	trans	rs2117029	0.554	rs2334930	ENSG00000214391.3	TUBAP2	6.02	2.43e-09	0.00175	0.18	0.18	Intelligence (multi-trait analysis);	chr12:49175528	chr11:90282560~90284172:+
BRCA	trans	rs2117029	0.586	rs7957998	ENSG00000214391.3	TUBAP2	6.02	2.43e-09	0.00175	0.18	0.18	Intelligence (multi-trait analysis);	chr12:49180240	chr11:90282560~90284172:+
BRCA	trans	rs1707322	1	rs34694458	ENSG00000255397.1	AC022182.2	-6.02	2.43e-09	0.00175	-0.24	-0.18	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45867024	chr8:60937705~60939871:-
BRCA	trans	rs9328573	1	rs9920711	ENSG00000279048.1	RP11-511H23.2	-6.02	2.44e-09	0.00175	-0.18	-0.18	Urate levels in lean individuals;	chr15:99970273	chr7:17940503~17942922:+
BRCA	trans	rs902774	0.818	rs73108429	ENSG00000254285.3	KRT8P3	-6.02	2.44e-09	0.00175	-0.38	-0.18	Prostate cancer;	chr12:52877887	chr8:61578220~61579668:+
BRCA	trans	rs6831352	0.734	rs3018046	ENSG00000228407.2	RP4-800M22.1	-6.02	2.44e-09	0.00175	-0.25	-0.18	Alcohol dependence;	chr4:99109237	chr1:52160261~52160600:-
BRCA	trans	rs853679	0.607	rs67340775	ENSG00000228078.1	HLA-U	-6.02	2.45e-09	0.00176	-0.47	-0.18	Depression;	chr6:28336607	chr6:29934101~29934286:+
BRCA	trans	rs56114371	0.53	rs2056923	ENSG00000253570.1	RNF5P1	6.02	2.45e-09	0.00176	0.34	0.18	Breast cancer;	chr6:27722160	chr8:38600661~38601200:-
BRCA	trans	rs7647973	1	rs4241407	ENSG00000197582.5	GPX1P1	6.02	2.46e-09	0.00176	0.2	0.18	Menarche (age at onset);	chr3:49562886	chrX:13378735~13379340:-
BRCA	trans	rs941207	0.756	rs2950388	ENSG00000257210.1	NACAP3	-6.02	2.46e-09	0.00176	-0.25	-0.18	Platelet count;	chr12:56639569	chr12:93124063~93124543:-
BRCA	trans	rs7260598	1	rs62117633	ENSG00000261770.1	CTC-459F4.1	6.02	2.46e-09	0.00176	0.31	0.18	Response to taxane treatment (placlitaxel);	chr19:24036672	chr19:27757184~27760849:-
BRCA	trans	rs7647973	1	rs2312462	ENSG00000197582.5	GPX1P1	6.02	2.46e-09	0.00177	0.2	0.18	Menarche (age at onset);	chr3:49563822	chrX:13378735~13379340:-
BRCA	trans	rs4879656	0.872	rs2274767	ENSG00000215007.3	DNAJA1P3	6.02	2.46e-09	0.00177	0.22	0.18	Menopause (age at onset);	chr9:33047400	chrX:107351650~107352843:-
BRCA	trans	rs11098499	0.754	rs66900435	ENSG00000276997.3	RP11-378J18.9	6.02	2.47e-09	0.00177	0.22	0.18	Corneal astigmatism;	chr4:119328270	chr1:222477252~222504622:-
BRCA	trans	rs9368481	0.761	rs7775041	ENSG00000242375.1	RP11-498P14.3	-6.02	2.47e-09	0.00177	-0.27	-0.18	Autism spectrum disorder or schizophrenia;	chr6:27041733	chr9:97195351~97197687:-
BRCA	trans	rs9467711	0.659	rs34605993	ENSG00000281831.1	HCP5B	6.02	2.48e-09	0.00178	0.43	0.18	Autism spectrum disorder or schizophrenia;	chr6:26454135	chr6:29871895~29873783:-
BRCA	trans	rs11098499	0.675	rs11098534	ENSG00000120555.12	SEPT7P9	6.01	2.49e-09	0.00178	0.22	0.18	Corneal astigmatism;	chr4:119635617	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.78	rs7680914	ENSG00000276805.1	RP11-291L22.6	6.01	2.49e-09	0.00179	0.22	0.18	Corneal astigmatism;	chr4:119641898	chr10:38451030~38451785:+
BRCA	trans	rs11098499	0.644	rs10012252	ENSG00000120555.12	SEPT7P9	6.01	2.5e-09	0.00179	0.22	0.18	Corneal astigmatism;	chr4:119637984	chr10:38383069~38402916:-
BRCA	trans	rs12439619	0.883	rs62012045	ENSG00000259774.1	RP11-182J1.13	6.01	2.5e-09	0.00179	0.24	0.18	Intelligence (multi-trait analysis);	chr15:82229366	chr15:84422618~84425882:+
BRCA	trans	rs4879656	0.831	rs13289835	ENSG00000215007.3	DNAJA1P3	6.01	2.5e-09	0.0018	0.22	0.18	Menopause (age at onset);	chr9:33069183	chrX:107351650~107352843:-
BRCA	trans	rs853679	0.607	rs34950484	ENSG00000281831.1	HCP5B	6.01	2.51e-09	0.0018	0.45	0.18	Depression;	chr6:28310911	chr6:29871895~29873783:-
BRCA	trans	rs6011368	0.792	rs6512309	ENSG00000226210.3	WASH7P	6.01	2.51e-09	0.0018	0.2	0.18	Clozapine-induced cytotoxicity;	chr20:64261231	chr12:14522~32015:-
BRCA	trans	rs4713118	0.824	rs13211701	ENSG00000204709.4	LINC01556	6.01	2.51e-09	0.0018	0.26	0.18	Parkinson's disease;	chr6:27782300	chr6:28943877~28944537:+
BRCA	trans	rs4713118	0.824	rs9468229	ENSG00000204709.4	LINC01556	6.01	2.51e-09	0.0018	0.26	0.18	Parkinson's disease;	chr6:27782307	chr6:28943877~28944537:+
BRCA	trans	rs6831352	1	rs6822348	ENSG00000233859.2	ADH5P4	-6.01	2.51e-09	0.0018	-0.25	-0.18	Alcohol dependence;	chr4:99132743	chr6:65836930~65838039:-
BRCA	trans	rs7568458	0.66	rs2289972	ENSG00000223886.3	RP11-251G23.2	6.01	2.51e-09	0.0018	0.23	0.18	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr2:85539422	chr7:105530209~105530671:+
BRCA	trans	rs11098499	0.57	rs6832740	ENSG00000276997.3	RP11-378J18.9	6.01	2.52e-09	0.0018	0.22	0.18	Corneal astigmatism;	chr4:119624981	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.644	rs6855918	ENSG00000276997.3	RP11-378J18.9	6.01	2.52e-09	0.0018	0.22	0.18	Corneal astigmatism;	chr4:119625144	chr1:222477252~222504622:-
BRCA	trans	rs9852859	0.634	rs9825885	ENSG00000261353.1	CTA-14H9.5	6.01	2.52e-09	0.00181	0.26	0.18	Body mass index;	chr3:85739415	chr6:26527063~26527404:+
BRCA	trans	rs4713118	0.955	rs9368528	ENSG00000204709.4	LINC01556	6.01	2.52e-09	0.00181	0.26	0.18	Parkinson's disease;	chr6:27716019	chr6:28943877~28944537:+
BRCA	trans	rs4713118	0.955	rs9380011	ENSG00000204709.4	LINC01556	6.01	2.52e-09	0.00181	0.26	0.18	Parkinson's disease;	chr6:27716145	chr6:28943877~28944537:+
BRCA	trans	rs4713118	0.955	rs9380012	ENSG00000204709.4	LINC01556	6.01	2.52e-09	0.00181	0.26	0.18	Parkinson's disease;	chr6:27716875	chr6:28943877~28944537:+
BRCA	trans	rs875971	0.545	rs10950027	ENSG00000213640.3	EEF1DP4	-6.01	2.53e-09	0.00181	-0.25	-0.18	Aortic root size;	chr7:66169164	chr7:64862999~64864370:+
BRCA	trans	rs9393777	0.92	rs67859638	ENSG00000204709.4	LINC01556	6.01	2.53e-09	0.00181	0.5	0.18	Intelligence (multi-trait analysis);	chr6:27390199	chr6:28943877~28944537:+
BRCA	trans	rs7113874	0.524	rs10769918	ENSG00000266891.1	RP11-692N5.2	-6.01	2.53e-09	0.00181	-0.21	-0.18	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8588163	chr18:9734882~9735602:-
BRCA	trans	rs875971	0.502	rs1796227	ENSG00000213640.3	EEF1DP4	6.01	2.53e-09	0.00181	0.26	0.18	Aortic root size;	chr7:66622032	chr7:64862999~64864370:+
BRCA	trans	rs11098499	0.754	rs7672778	ENSG00000276997.3	RP11-378J18.9	6.01	2.54e-09	0.00182	0.22	0.18	Corneal astigmatism;	chr4:119327430	chr1:222477252~222504622:-
BRCA	trans	rs7927771	0.832	rs4752993	ENSG00000134612.10	FOLH1B	6.01	2.55e-09	0.00182	0.24	0.18	Subjective well-being;	chr11:47389400	chr11:89639227~89698718:+
BRCA	trans	rs6831352	0.734	rs2851259	ENSG00000228407.2	RP4-800M22.1	-6.01	2.55e-09	0.00182	-0.24	-0.18	Alcohol dependence;	chr4:99112835	chr1:52160261~52160600:-
BRCA	trans	rs6831352	0.703	rs4235435	ENSG00000228407.2	RP4-800M22.1	-6.01	2.55e-09	0.00182	-0.24	-0.18	Alcohol dependence;	chr4:99118427	chr1:52160261~52160600:-
BRCA	trans	rs1707322	1	rs946527	ENSG00000255397.1	AC022182.2	-6.01	2.56e-09	0.00183	-0.24	-0.18	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46020298	chr8:60937705~60939871:-
BRCA	trans	rs853679	0.567	rs13209596	ENSG00000228078.1	HLA-U	-6.01	2.58e-09	0.00185	-0.27	-0.18	Depression;	chr6:28428413	chr6:29934101~29934286:+
BRCA	trans	rs17767294	0.708	rs72848753	ENSG00000242375.1	RP11-498P14.3	-6.01	2.58e-09	0.00185	-0.51	-0.18	Parkinson's disease;	chr6:27910491	chr9:97195351~97197687:-
BRCA	trans	rs17767294	0.708	rs72848754	ENSG00000242375.1	RP11-498P14.3	-6.01	2.58e-09	0.00185	-0.51	-0.18	Parkinson's disease;	chr6:27910680	chr9:97195351~97197687:-
BRCA	trans	rs17767294	0.708	rs72848755	ENSG00000242375.1	RP11-498P14.3	-6.01	2.58e-09	0.00185	-0.51	-0.18	Parkinson's disease;	chr6:27910775	chr9:97195351~97197687:-
BRCA	trans	rs17767294	0.708	rs34957169	ENSG00000242375.1	RP11-498P14.3	-6.01	2.58e-09	0.00185	-0.51	-0.18	Parkinson's disease;	chr6:27911619	chr9:97195351~97197687:-
BRCA	trans	rs9467711	0.651	rs35069699	ENSG00000253570.1	RNF5P1	6.01	2.59e-09	0.00185	0.48	0.18	Autism spectrum disorder or schizophrenia;	chr6:25957054	chr8:38600661~38601200:-
BRCA	trans	rs853679	0.545	rs35949109	ENSG00000253570.1	RNF5P1	6.01	2.61e-09	0.00186	0.4	0.18	Depression;	chr6:28058148	chr8:38600661~38601200:-
BRCA	trans	rs7927771	0.864	rs2868459	ENSG00000134612.10	FOLH1B	-6.01	2.61e-09	0.00186	-0.24	-0.18	Subjective well-being;	chr11:47433421	chr11:89639227~89698718:+
BRCA	trans	rs7829975	0.742	rs12547493	ENSG00000270154.1	RP11-419I17.1	-6.01	2.62e-09	0.00187	-0.21	-0.18	Mood instability;	chr8:8804024	chr8:12476462~12477122:+
BRCA	trans	rs875971	0.545	rs75577046	ENSG00000213640.3	EEF1DP4	-6.01	2.62e-09	0.00187	-0.26	-0.18	Aortic root size;	chr7:66493729	chr7:64862999~64864370:+
BRCA	trans	rs7260598	0.892	rs58931976	ENSG00000261770.1	CTC-459F4.1	6.01	2.62e-09	0.00187	0.32	0.18	Response to taxane treatment (placlitaxel);	chr19:24008247	chr19:27757184~27760849:-
BRCA	trans	rs7260598	0.892	rs59831281	ENSG00000261770.1	CTC-459F4.1	6.01	2.62e-09	0.00187	0.32	0.18	Response to taxane treatment (placlitaxel);	chr19:24008258	chr19:27757184~27760849:-
BRCA	trans	rs9467711	0.651	rs13191776	ENSG00000253570.1	RNF5P1	6.01	2.63e-09	0.00188	0.47	0.18	Autism spectrum disorder or schizophrenia;	chr6:25955513	chr8:38600661~38601200:-
BRCA	trans	rs66887589	0.592	rs2175383	ENSG00000120555.12	SEPT7P9	6.01	2.63e-09	0.00188	0.21	0.18	Diastolic blood pressure;	chr4:119294681	chr10:38383069~38402916:-
BRCA	trans	rs7829975	0.688	rs7827182	ENSG00000270154.1	RP11-419I17.1	6.01	2.64e-09	0.00188	0.21	0.18	Mood instability;	chr8:8522961	chr8:12476462~12477122:+
BRCA	trans	rs7824557	0.767	rs11775635	ENSG00000254153.1	CTA-398F10.2	6	2.65e-09	0.00189	0.25	0.18	Retinal vascular caliber;	chr8:11307356	chr8:8456909~8461337:-
BRCA	trans	rs4879656	0.835	rs7036559	ENSG00000215007.3	DNAJA1P3	6	2.65e-09	0.00189	0.22	0.18	Menopause (age at onset);	chr9:33064929	chrX:107351650~107352843:-
BRCA	trans	rs67340775	0.748	rs13212651	ENSG00000281831.1	HCP5B	6	2.66e-09	0.0019	0.46	0.18	Lung cancer in ever smokers;	chr6:27839207	chr6:29871895~29873783:-
BRCA	trans	rs7824557	0.583	rs2736306	ENSG00000270154.1	RP11-419I17.1	6	2.66e-09	0.0019	0.23	0.18	Retinal vascular caliber;	chr8:11382253	chr8:12476462~12477122:+
BRCA	trans	rs11098499	0.863	rs17050695	ENSG00000120555.12	SEPT7P9	6	2.67e-09	0.0019	0.22	0.18	Corneal astigmatism;	chr4:119568372	chr10:38383069~38402916:-
BRCA	trans	rs34421088	0.532	rs3808515	ENSG00000253893.2	FAM85B	-6	2.67e-09	0.00191	-0.24	-0.18	Neuroticism;	chr8:11298532	chr8:8167819~8226614:-
BRCA	trans	rs17711722	0.653	rs2460421	ENSG00000213640.3	EEF1DP4	6	2.68e-09	0.00191	0.23	0.18	Calcium levels;	chr7:66026136	chr7:64862999~64864370:+
BRCA	trans	rs7260598	0.786	rs59387271	ENSG00000261770.1	CTC-459F4.1	6	2.68e-09	0.00191	0.32	0.18	Response to taxane treatment (placlitaxel);	chr19:24009130	chr19:27757184~27760849:-
BRCA	trans	rs6121246	0.512	rs45443696	ENSG00000279352.1	RP11-411B10.7	6	2.69e-09	0.00192	0.27	0.18	Mean corpuscular hemoglobin;	chr20:31723593	chr18:14010054~14010917:+
BRCA	trans	rs11666377	0.714	rs11086048	ENSG00000197320.5	AC060834.2	6	2.7e-09	0.00192	0.28	0.18	Brain lesion load;	chr19:17004894	chr7:9726241~9728272:+
BRCA	trans	rs4713118	0.955	rs9380010	ENSG00000204709.4	LINC01556	6	2.7e-09	0.00193	0.26	0.18	Parkinson's disease;	chr6:27715793	chr6:28943877~28944537:+
BRCA	trans	rs11098499	0.913	rs67073020	ENSG00000276997.3	RP11-378J18.9	6	2.7e-09	0.00193	0.23	0.18	Corneal astigmatism;	chr4:119231402	chr1:222477252~222504622:-
BRCA	trans	rs853679	0.607	rs67998226	ENSG00000281831.1	HCP5B	6	2.7e-09	0.00193	0.44	0.18	Depression;	chr6:28270281	chr6:29871895~29873783:-
BRCA	trans	rs2117029	0.587	rs57853986	ENSG00000214391.3	TUBAP2	6	2.71e-09	0.00193	0.18	0.18	Intelligence (multi-trait analysis);	chr12:49124612	chr11:90282560~90284172:+
BRCA	trans	rs1707322	1	rs10890350	ENSG00000255397.1	AC022182.2	-6	2.71e-09	0.00193	-0.24	-0.18	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45796706	chr8:60937705~60939871:-
BRCA	trans	rs9834975	0.608	rs9811298	ENSG00000267076.1	CCDC58P3	-6	2.71e-09	0.00193	-0.21	-0.18	Diastolic blood pressure;	chr3:122348735	chr18:12211378~12211807:+
BRCA	trans	rs9834975	0.669	rs9811446	ENSG00000267076.1	CCDC58P3	-6	2.71e-09	0.00193	-0.21	-0.18	Diastolic blood pressure;	chr3:122348844	chr18:12211378~12211807:+
BRCA	trans	rs10838687	0.8	rs7928073	ENSG00000134612.10	FOLH1B	6	2.72e-09	0.00194	0.28	0.18	Proinsulin levels;	chr11:47340306	chr11:89639227~89698718:+
BRCA	trans	rs7568458	0.709	rs2592551	ENSG00000223886.3	RP11-251G23.2	6	2.73e-09	0.00194	0.23	0.18	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr2:85553008	chr7:105530209~105530671:+
BRCA	trans	rs7568458	0.709	rs762684	ENSG00000223886.3	RP11-251G23.2	6	2.73e-09	0.00194	0.23	0.18	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr2:85554900	chr7:105530209~105530671:+
BRCA	trans	rs2066819	1	rs2306694	ENSG00000273654.1	CTB-52I2.4	-6	2.73e-09	0.00194	-0.46	-0.18	Psoriasis vulgaris;	chr12:56286852	chr19:18022403~18032099:+
BRCA	trans	rs11782517	0.803	rs12549696	ENSG00000253893.2	FAM85B	-6	2.73e-09	0.00195	-0.27	-0.18	Nose size;	chr8:10249512	chr8:8167819~8226614:-
BRCA	trans	rs853679	0.607	rs67101035	ENSG00000281831.1	HCP5B	6	2.74e-09	0.00195	0.46	0.18	Depression;	chr6:27831109	chr6:29871895~29873783:-
BRCA	trans	rs34421088	0.532	rs2736388	ENSG00000253893.2	FAM85B	-6	2.74e-09	0.00196	-0.25	-0.18	Neuroticism;	chr8:11302079	chr8:8167819~8226614:-
BRCA	trans	rs2117029	0.586	rs6580701	ENSG00000214391.3	TUBAP2	6	2.75e-09	0.00196	0.18	0.18	Intelligence (multi-trait analysis);	chr12:49163482	chr11:90282560~90284172:+
BRCA	trans	rs11098499	0.644	rs7693919	ENSG00000276997.3	RP11-378J18.9	6	2.75e-09	0.00196	0.22	0.18	Corneal astigmatism;	chr4:119619416	chr1:222477252~222504622:-
BRCA	trans	rs2117029	0.561	rs7957983	ENSG00000214391.3	TUBAP2	6	2.75e-09	0.00196	0.18	0.18	Intelligence (multi-trait analysis);	chr12:49115204	chr11:90282560~90284172:+
BRCA	trans	rs2117029	0.587	rs7958572	ENSG00000214391.3	TUBAP2	6	2.75e-09	0.00196	0.18	0.18	Intelligence (multi-trait analysis);	chr12:49115658	chr11:90282560~90284172:+
BRCA	trans	rs6831352	0.693	rs2602875	ENSG00000228407.2	RP4-800M22.1	-6	2.75e-09	0.00196	-0.24	-0.18	Alcohol dependence;	chr4:99118344	chr1:52160261~52160600:-
BRCA	trans	rs11098499	0.754	rs1980027	ENSG00000276997.3	RP11-378J18.9	6	2.76e-09	0.00196	0.22	0.18	Corneal astigmatism;	chr4:119330422	chr1:222477252~222504622:-
BRCA	trans	rs7570469	0.762	rs10496225	ENSG00000276390.1	RP1-197B17.5	6	2.76e-09	0.00197	0.24	0.18	Response to antipsychotic treatment;	chr2:79432518	chr12:47699401~47699917:-
BRCA	trans	rs7570469	0.762	rs10496226	ENSG00000276390.1	RP1-197B17.5	6	2.76e-09	0.00197	0.24	0.18	Response to antipsychotic treatment;	chr2:79432905	chr12:47699401~47699917:-
BRCA	trans	rs10946940	0.965	rs6921256	ENSG00000204709.4	LINC01556	6	2.77e-09	0.00197	0.24	0.18	Systemic lupus erythematosus;	chr6:27619739	chr6:28943877~28944537:+
BRCA	trans	rs801193	0.844	rs2244022	ENSG00000273024.4	INTS4P2	-6	2.77e-09	0.00197	-0.2	-0.18	Aortic root size;	chr7:66737443	chr7:65647864~65715661:+
BRCA	trans	rs9467711	0.659	rs13195509	ENSG00000281831.1	HCP5B	6	2.77e-09	0.00198	0.42	0.18	Autism spectrum disorder or schizophrenia;	chr6:26463432	chr6:29871895~29873783:-
BRCA	trans	rs7746199	0.736	rs13193542	ENSG00000281831.1	HCP5B	6	2.78e-09	0.00198	0.47	0.18	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27734646	chr6:29871895~29873783:-
BRCA	trans	rs7746199	0.736	rs13193480	ENSG00000281831.1	HCP5B	6	2.78e-09	0.00198	0.47	0.18	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27734782	chr6:29871895~29873783:-
BRCA	trans	rs7746199	0.736	rs13212093	ENSG00000204709.4	LINC01556	6	2.78e-09	0.00198	0.48	0.18	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27638937	chr6:28943877~28944537:+
BRCA	trans	rs7746199	0.736	rs34038546	ENSG00000204709.4	LINC01556	6	2.78e-09	0.00198	0.48	0.18	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27639881	chr6:28943877~28944537:+
BRCA	trans	rs141342723	1	rs141342723	ENSG00000204709.4	LINC01556	6	2.78e-09	0.00198	0.48	0.18	Autism spectrum disorder or schizophrenia;	chr6:27654305	chr6:28943877~28944537:+
BRCA	trans	rs7746199	0.736	rs34543938	ENSG00000204709.4	LINC01556	6	2.78e-09	0.00198	0.48	0.18	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27656861	chr6:28943877~28944537:+
BRCA	trans	rs7746199	0.736	rs56405707	ENSG00000204709.4	LINC01556	6	2.78e-09	0.00198	0.48	0.18	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27672467	chr6:28943877~28944537:+
BRCA	trans	rs10946940	0.965	rs62401383	ENSG00000204709.4	LINC01556	-6	2.78e-09	0.00198	-0.23	-0.18	Systemic lupus erythematosus;	chr6:27596768	chr6:28943877~28944537:+
BRCA	trans	rs2117029	0.586	rs1874908	ENSG00000214391.3	TUBAP2	6	2.79e-09	0.00199	0.18	0.18	Intelligence (multi-trait analysis);	chr12:49190247	chr11:90282560~90284172:+
BRCA	trans	rs11098499	0.754	rs1980025	ENSG00000276997.3	RP11-378J18.9	-6	2.79e-09	0.00199	-0.21	-0.18	Corneal astigmatism;	chr4:119331651	chr1:222477252~222504622:-
BRCA	trans	rs853679	0.567	rs6905380	ENSG00000228078.1	HLA-U	-6	2.8e-09	0.00199	-0.27	-0.18	Depression;	chr6:28407125	chr6:29934101~29934286:+
BRCA	trans	rs11098499	0.722	rs7673476	ENSG00000120555.12	SEPT7P9	6	2.8e-09	0.00199	0.22	0.18	Corneal astigmatism;	chr4:119327528	chr10:38383069~38402916:-
BRCA	trans	rs6984305	0.541	rs17716118	ENSG00000253200.1	RP11-582J16.5	6	2.8e-09	0.00199	0.27	0.18	Liver enzyme levels (alkaline phosphatase);	chr8:9322624	chr8:22613908~22616657:-
BRCA	trans	rs11638815	0.668	rs7182320	ENSG00000259774.1	RP11-182J1.13	5.99	2.8e-09	0.002	0.22	0.18	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82719000	chr15:84422618~84425882:+
BRCA	trans	rs3740713	1	rs35593189	ENSG00000236090.2	LDHAP3	5.99	2.81e-09	0.002	0.34	0.18	Amyotrophic lateral sclerosis (sporadic);	chr11:18446831	chr2:41819747~41820754:+
BRCA	trans	rs7746199	0.736	rs34105070	ENSG00000204709.4	LINC01556	5.99	2.82e-09	0.00201	0.48	0.18	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27593026	chr6:28943877~28944537:+
BRCA	trans	rs4713118	0.869	rs9461405	ENSG00000204709.4	LINC01556	5.99	2.82e-09	0.00201	0.25	0.18	Parkinson's disease;	chr6:27751596	chr6:28943877~28944537:+
BRCA	trans	rs4930561	0.765	rs4930229	ENSG00000155070.8	UNC93B2	-5.99	2.83e-09	0.00201	-0.21	-0.18	Breast cancer in childhood cancer survivors;IgG glycosylation;	chr11:68176613	chr7:6855485~6859830:-
BRCA	trans	rs7647973	1	rs892974	ENSG00000235912.1	RP1-159A19.3	-5.99	2.83e-09	0.00201	-0.24	-0.18	Menarche (age at onset);	chr3:49361081	chr1:27649419~27649610:+
BRCA	trans	rs2066819	1	rs76745316	ENSG00000273654.1	CTB-52I2.4	5.99	2.84e-09	0.00202	0.48	0.18	Psoriasis vulgaris;	chr12:56233868	chr19:18022403~18032099:+
BRCA	trans	rs1933488	0.504	rs1281949	ENSG00000278974.1	RP11-756P10.6	5.99	2.86e-09	0.00203	0.24	0.18	Prostate cancer;	chr6:153147598	chr4:188740507~188741281:-
BRCA	trans	rs875971	1	rs6460296	ENSG00000164669.11	INTS4P1	-5.99	2.86e-09	0.00203	-0.22	-0.18	Aortic root size;	chr7:66430152	chr7:65141225~65234216:+
BRCA	trans	rs7824557	0.836	rs1435278	ENSG00000254153.1	CTA-398F10.2	-5.99	2.87e-09	0.00204	-0.24	-0.18	Retinal vascular caliber;	chr8:11265520	chr8:8456909~8461337:-
BRCA	trans	rs1933488	0.504	rs1281955	ENSG00000278974.1	RP11-756P10.6	5.99	2.87e-09	0.00204	0.24	0.18	Prostate cancer;	chr6:153138309	chr4:188740507~188741281:-
BRCA	trans	rs4713118	0.955	rs9468206	ENSG00000204709.4	LINC01556	5.99	2.87e-09	0.00204	0.26	0.18	Parkinson's disease;	chr6:27722674	chr6:28943877~28944537:+
BRCA	trans	rs714543	0.875	rs35585318	ENSG00000219797.2	PPIAP9	-5.99	2.87e-09	0.00204	-0.23	-0.18	Plateletcrit;	chr7:44852220	chr6:31519480~31520291:-
BRCA	trans	rs9649213	0.593	rs6465672	ENSG00000225169.1	BRI3P1	-5.99	2.87e-09	0.00204	-0.23	-0.18	Prostate cancer (SNP x SNP interaction);	chr7:98334405	chr1:100213293~100213670:+
BRCA	trans	rs7570469	0.689	rs13017219	ENSG00000276390.1	RP1-197B17.5	5.99	2.87e-09	0.00204	0.24	0.18	Response to antipsychotic treatment;	chr2:79434724	chr12:47699401~47699917:-
BRCA	trans	rs6831352	0.703	rs2602862	ENSG00000228407.2	RP4-800M22.1	-5.99	2.87e-09	0.00204	-0.24	-0.18	Alcohol dependence;	chr4:99112070	chr1:52160261~52160600:-
BRCA	trans	rs6831352	0.734	rs3100630	ENSG00000228407.2	RP4-800M22.1	-5.99	2.9e-09	0.00206	-0.24	-0.18	Alcohol dependence;	chr4:99110564	chr1:52160261~52160600:-
BRCA	trans	rs6831352	0.703	rs3133152	ENSG00000228407.2	RP4-800M22.1	-5.99	2.9e-09	0.00206	-0.24	-0.18	Alcohol dependence;	chr4:99110570	chr1:52160261~52160600:-
BRCA	trans	rs546131	0.614	rs35357012	ENSG00000225531.1	RP11-196I18.3	-5.99	2.9e-09	0.00206	-0.3	-0.18	Lung disease severity in cystic fibrosis;	chr11:34771837	chr9:107116829~107117557:+
BRCA	trans	rs9393777	0.623	rs34313099	ENSG00000277241.1	RP11-114M1.3	5.99	2.9e-09	0.00206	0.28	0.18	Intelligence (multi-trait analysis);	chr6:26489379	chr3:177700346~177701072:-
BRCA	trans	rs16975963	0.594	rs73039018	ENSG00000247498.8	RP11-392P7.6	5.99	2.91e-09	0.00207	0.32	0.18	Longevity;	chr19:37726993	chr12:12927726~12984645:+
BRCA	trans	rs853679	0.546	rs35819751	ENSG00000243753.4	HLA-L	-5.99	2.92e-09	0.00207	-0.49	-0.18	Depression;	chr6:27842791	chr6:30259584~30293014:+
BRCA	trans	rs9733	0.744	rs4970976	ENSG00000180764.13	PIPSL	5.99	2.92e-09	0.00207	0.23	0.18	Tonsillectomy;	chr1:150807048	chr10:93958191~93961540:-
BRCA	trans	rs6831352	0.734	rs1453872	ENSG00000228407.2	RP4-800M22.1	-5.99	2.93e-09	0.00208	-0.24	-0.18	Alcohol dependence;	chr4:99101331	chr1:52160261~52160600:-
BRCA	trans	rs875971	0.895	rs778700	ENSG00000164669.11	INTS4P1	-5.99	2.93e-09	0.00208	-0.22	-0.18	Aortic root size;	chr7:66401463	chr7:65141225~65234216:+
BRCA	trans	rs875971	1	rs778699	ENSG00000164669.11	INTS4P1	-5.99	2.93e-09	0.00208	-0.22	-0.18	Aortic root size;	chr7:66403303	chr7:65141225~65234216:+
BRCA	trans	rs7746199	0.736	rs34064842	ENSG00000281831.1	HCP5B	5.99	2.93e-09	0.00208	0.45	0.18	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27720846	chr6:29871895~29873783:-
BRCA	trans	rs3732378	0.666	rs11710546	ENSG00000183298.5	RP11-556K13.1	5.99	2.94e-09	0.00209	0.29	0.18	Monocyte count;Lymphocyte counts;Granulocyte percentage of myeloid white cells;Monocyte percentage of white cells;	chr3:39264728	chr1:101786340~101787219:-
BRCA	trans	rs3732378	0.666	rs1050592	ENSG00000183298.5	RP11-556K13.1	5.99	2.94e-09	0.00209	0.29	0.18	Monocyte count;Lymphocyte counts;Granulocyte percentage of myeloid white cells;Monocyte percentage of white cells;	chr3:39265293	chr1:101786340~101787219:-
BRCA	trans	rs3732378	0.666	rs3732379	ENSG00000183298.5	RP11-556K13.1	5.99	2.94e-09	0.00209	0.29	0.18	Monocyte count;Lymphocyte counts;Granulocyte percentage of myeloid white cells;Monocyte percentage of white cells;	chr3:39265765	chr1:101786340~101787219:-
BRCA	trans	rs12439619	0.693	rs7165536	ENSG00000235370.6	DNM1P51	-5.99	2.95e-09	0.00209	-0.24	-0.18	Intelligence (multi-trait analysis);	chr15:82273743	chr15:84398316~84411701:-
BRCA	trans	rs7746199	0.673	rs72847313	ENSG00000281831.1	HCP5B	5.99	2.97e-09	0.0021	0.46	0.18	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27762303	chr6:29871895~29873783:-
BRCA	trans	rs7746199	0.611	rs17750747	ENSG00000281831.1	HCP5B	5.99	2.97e-09	0.0021	0.46	0.18	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27762555	chr6:29871895~29873783:-
BRCA	trans	rs875971	0.545	rs1909508	ENSG00000213640.3	EEF1DP4	-5.99	2.97e-09	0.00211	-0.25	-0.18	Aortic root size;	chr7:66301366	chr7:64862999~64864370:+
BRCA	trans	rs875971	0.545	rs6460298	ENSG00000213640.3	EEF1DP4	-5.98	2.98e-09	0.00211	-0.26	-0.18	Aortic root size;	chr7:66442783	chr7:64862999~64864370:+
BRCA	trans	rs7568458	0.709	rs56819945	ENSG00000223886.3	RP11-251G23.2	5.98	2.98e-09	0.00211	0.23	0.18	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr2:85528016	chr7:105530209~105530671:+
BRCA	trans	rs4713118	0.955	rs9368529	ENSG00000204709.4	LINC01556	5.98	2.99e-09	0.00212	0.26	0.18	Parkinson's disease;	chr6:27716852	chr6:28943877~28944537:+
BRCA	trans	rs7927771	1	rs12418852	ENSG00000134612.10	FOLH1B	-5.98	2.99e-09	0.00212	-0.25	-0.18	Subjective well-being;	chr11:47847301	chr11:89639227~89698718:+
BRCA	trans	rs16975963	0.644	rs7248397	ENSG00000247498.8	RP11-392P7.6	5.98	3e-09	0.00213	0.32	0.18	Longevity;	chr19:37642310	chr12:12927726~12984645:+
BRCA	trans	rs2243480	1	rs4718269	ENSG00000230295.1	RP11-458F8.2	5.98	3.01e-09	0.00213	0.23	0.18	Diabetic kidney disease;	chr7:65735810	chr7:66880708~66882981:+
BRCA	trans	rs1707322	0.789	rs7540578	ENSG00000255397.1	AC022182.2	-5.98	3.01e-09	0.00214	-0.24	-0.18	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45786472	chr8:60937705~60939871:-
BRCA	trans	rs10028773	0.7	rs7671797	ENSG00000276997.3	RP11-378J18.9	5.98	3.02e-09	0.00214	0.22	0.18	Educational attainment;	chr4:119327002	chr1:222477252~222504622:-
BRCA	trans	rs875971	1	rs2077593	ENSG00000164669.11	INTS4P1	-5.98	3.02e-09	0.00214	-0.22	-0.18	Aortic root size;	chr7:66427543	chr7:65141225~65234216:+
BRCA	trans	rs902774	0.818	rs56095813	ENSG00000224520.2	KRT8P45	-5.98	3.03e-09	0.00215	-0.37	-0.18	Prostate cancer;	chr12:52900963	chr1:157073257~157074703:+
BRCA	trans	rs3812762	0.912	rs10769954	ENSG00000266891.1	RP11-692N5.2	-5.98	3.04e-09	0.00216	-0.22	-0.18	Hypospadias;	chr11:8762166	chr18:9734882~9735602:-
BRCA	trans	rs7824557	0.767	rs7003241	ENSG00000254153.1	CTA-398F10.2	5.98	3.04e-09	0.00216	0.25	0.18	Retinal vascular caliber;	chr8:11311566	chr8:8456909~8461337:-
BRCA	trans	rs9733	0.744	rs11204737	ENSG00000180764.13	PIPSL	5.98	3.04e-09	0.00216	0.23	0.18	Tonsillectomy;	chr1:150875171	chr10:93958191~93961540:-
BRCA	trans	rs7260598	1	rs62114762	ENSG00000261770.1	CTC-459F4.1	5.98	3.04e-09	0.00216	0.3	0.18	Response to taxane treatment (placlitaxel);	chr19:24051066	chr19:27757184~27760849:-
BRCA	trans	rs9693857	0.52	rs7830572	ENSG00000253893.2	FAM85B	-5.98	3.05e-09	0.00216	-0.25	-0.18	Systolic blood pressure;	chr8:9499292	chr8:8167819~8226614:-
BRCA	trans	rs7617773	0.817	rs9311421	ENSG00000235912.1	RP1-159A19.3	-5.98	3.05e-09	0.00216	-0.23	-0.18	Coronary artery disease;	chr3:48251588	chr1:27649419~27649610:+
BRCA	trans	rs73110464	0.591	rs11829997	ENSG00000228753.1	EIF4BP2	5.98	3.06e-09	0.00217	0.39	0.18	Cancer (pleiotropy);	chr12:52921875	chr10:21028999~21030792:+
BRCA	trans	rs875971	0.545	rs11767262	ENSG00000213640.3	EEF1DP4	-5.98	3.06e-09	0.00217	-0.26	-0.18	Aortic root size;	chr7:66302237	chr7:64862999~64864370:+
BRCA	trans	rs6754311	0.861	rs12475139	ENSG00000224043.6	CCNT2-AS1	-5.98	3.06e-09	0.00217	-0.25	-0.18	Mosquito bite size;	chr2:136029081	chr2:134735464~134918710:-
BRCA	trans	rs875971	0.545	rs2420456	ENSG00000213640.3	EEF1DP4	-5.98	3.06e-09	0.00217	-0.26	-0.18	Aortic root size;	chr7:66280619	chr7:64862999~64864370:+
BRCA	trans	rs2602836	0.83	rs2602874	ENSG00000233859.2	ADH5P4	-5.98	3.06e-09	0.00217	-0.22	-0.18	HDL cholesterol;HDL cholesterol levels;	chr4:99118245	chr6:65836930~65838039:-
BRCA	trans	rs7568458	0.527	rs35416445	ENSG00000223886.3	RP11-251G23.2	5.98	3.06e-09	0.00217	0.23	0.18	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr2:85546536	chr7:105530209~105530671:+
BRCA	trans	rs7568458	0.709	rs2028898	ENSG00000223886.3	RP11-251G23.2	5.98	3.06e-09	0.00217	0.23	0.18	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr2:85550147	chr7:105530209~105530671:+
BRCA	trans	rs7927771	1	rs7120333	ENSG00000134612.10	FOLH1B	-5.98	3.07e-09	0.00217	-0.25	-0.18	Subjective well-being;	chr11:47795889	chr11:89639227~89698718:+
BRCA	trans	rs7647973	0.516	rs12490393	ENSG00000197582.5	GPX1P1	5.98	3.07e-09	0.00217	0.18	0.18	Menarche (age at onset);	chr3:49158699	chrX:13378735~13379340:-
BRCA	trans	rs853679	1	rs2799079	ENSG00000253570.1	RNF5P1	5.98	3.08e-09	0.00218	0.34	0.18	Depression;	chr6:28267398	chr8:38600661~38601200:-
BRCA	trans	rs7260598	0.581	rs17311328	ENSG00000261770.1	CTC-459F4.1	5.98	3.08e-09	0.00218	0.33	0.18	Response to taxane treatment (placlitaxel);	chr19:24186640	chr19:27757184~27760849:-
BRCA	trans	rs3750082	0.78	rs9638884	ENSG00000176826.14	FKBP9P1	5.98	3.1e-09	0.00219	0.22	0.18	Glomerular filtration rate (creatinine);	chr7:32874000	chr7:55681074~55713252:-
BRCA	trans	rs3750082	0.889	rs4437549	ENSG00000176826.14	FKBP9P1	5.98	3.1e-09	0.00219	0.22	0.18	Glomerular filtration rate (creatinine);	chr7:32875353	chr7:55681074~55713252:-
BRCA	trans	rs3750082	0.889	rs7785065	ENSG00000176826.14	FKBP9P1	5.98	3.1e-09	0.00219	0.22	0.18	Glomerular filtration rate (creatinine);	chr7:32875592	chr7:55681074~55713252:-
BRCA	trans	rs875971	0.545	rs1267814	ENSG00000234585.5	CCT6P3	-5.98	3.11e-09	0.0022	-0.2	-0.18	Aortic root size;	chr7:66579422	chr7:65038354~65074713:+
BRCA	trans	rs875971	0.502	rs6460311	ENSG00000213640.3	EEF1DP4	5.98	3.11e-09	0.0022	0.26	0.18	Aortic root size;	chr7:66646886	chr7:64862999~64864370:+
BRCA	trans	rs6121246	0.559	rs6060950	ENSG00000279352.1	RP11-411B10.7	5.98	3.12e-09	0.00221	0.26	0.18	Mean corpuscular hemoglobin;	chr20:31790228	chr18:14010054~14010917:+
BRCA	trans	rs7927771	0.864	rs11600581	ENSG00000134612.10	FOLH1B	-5.98	3.12e-09	0.00221	-0.24	-0.18	Subjective well-being;	chr11:47426946	chr11:89639227~89698718:+
BRCA	trans	rs7568458	0.684	rs7608074	ENSG00000223886.3	RP11-251G23.2	5.98	3.12e-09	0.00221	0.23	0.18	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr2:85582580	chr7:105530209~105530671:+
BRCA	trans	rs2117029	0.587	rs1865157	ENSG00000214391.3	TUBAP2	5.98	3.12e-09	0.00221	0.18	0.18	Intelligence (multi-trait analysis);	chr12:49129003	chr11:90282560~90284172:+
BRCA	trans	rs1459104	1	rs35449391	ENSG00000134612.10	FOLH1B	-5.98	3.13e-09	0.00221	-0.34	-0.18	Body mass index;	chr11:55562925	chr11:89639227~89698718:+
BRCA	trans	rs7570469	0.762	rs11126731	ENSG00000276390.1	RP1-197B17.5	-5.98	3.14e-09	0.00222	-0.23	-0.18	Response to antipsychotic treatment;	chr2:79434964	chr12:47699401~47699917:-
BRCA	trans	rs875971	0.929	rs10950041	ENSG00000164669.11	INTS4P1	-5.98	3.15e-09	0.00223	-0.22	-0.18	Aortic root size;	chr7:66508888	chr7:65141225~65234216:+
BRCA	trans	rs6601327	0.613	rs11785458	ENSG00000253893.2	FAM85B	5.98	3.15e-09	0.00223	0.23	0.18	Multiple myeloma (hyperdiploidy);	chr8:9649300	chr8:8167819~8226614:-
BRCA	trans	rs875971	0.964	rs1643388	ENSG00000164669.11	INTS4P1	-5.97	3.16e-09	0.00223	-0.22	-0.18	Aortic root size;	chr7:66379575	chr7:65141225~65234216:+
BRCA	trans	rs875971	1	rs778722	ENSG00000164669.11	INTS4P1	-5.97	3.16e-09	0.00223	-0.22	-0.18	Aortic root size;	chr7:66379841	chr7:65141225~65234216:+
BRCA	trans	rs11666377	0.714	rs11086049	ENSG00000197320.5	AC060834.2	5.97	3.16e-09	0.00223	0.28	0.18	Brain lesion load;	chr19:17004896	chr7:9726241~9728272:+
BRCA	trans	rs1459104	1	rs35726021	ENSG00000134612.10	FOLH1B	-5.97	3.16e-09	0.00223	-0.37	-0.18	Body mass index;	chr11:55423730	chr11:89639227~89698718:+
BRCA	trans	rs875971	0.545	rs7783889	ENSG00000213640.3	EEF1DP4	-5.97	3.17e-09	0.00224	-0.26	-0.18	Aortic root size;	chr7:66283366	chr7:64862999~64864370:+
BRCA	trans	rs875971	0.964	rs778721	ENSG00000164669.11	INTS4P1	-5.97	3.18e-09	0.00224	-0.22	-0.18	Aortic root size;	chr7:66380410	chr7:65141225~65234216:+
BRCA	trans	rs6121246	0.559	rs1062794	ENSG00000279352.1	RP11-411B10.7	5.97	3.18e-09	0.00224	0.26	0.18	Mean corpuscular hemoglobin;	chr20:31793955	chr18:14010054~14010917:+
BRCA	trans	rs7824557	0.767	rs28507159	ENSG00000254153.1	CTA-398F10.2	5.97	3.19e-09	0.00225	0.25	0.18	Retinal vascular caliber;	chr8:11308567	chr8:8456909~8461337:-
BRCA	trans	rs2122469	0.655	rs17603934	ENSG00000246582.2	RP11-1149O23.3	5.97	3.2e-09	0.00226	0.34	0.18	Serum tamsulosin hydrochloride concentration;	chr8:20718833	chr8:23224471~23230926:+
BRCA	trans	rs11098499	0.604	rs17051352	ENSG00000253326.2	RP11-261C10.7	5.97	3.2e-09	0.00226	0.27	0.18	Corneal astigmatism;	chr4:119660272	chr1:243054861~243056394:-
BRCA	trans	rs9860340	0.77	rs60838448	ENSG00000259370.2	RP11-1069G10.1	5.97	3.2e-09	0.00226	0.21	0.18	Electroencephalographic traits in alcoholism;	chr3:87662758	chr15:62827675~62884034:-
BRCA	trans	rs875971	0.545	rs313828	ENSG00000213640.3	EEF1DP4	5.97	3.2e-09	0.00226	0.26	0.18	Aortic root size;	chr7:66087627	chr7:64862999~64864370:+
BRCA	trans	rs9328573	1	rs9920482	ENSG00000279048.1	RP11-511H23.2	-5.97	3.2e-09	0.00226	-0.18	-0.18	Urate levels in lean individuals;	chr15:99970272	chr7:17940503~17942922:+
BRCA	trans	rs853679	0.607	rs67101035	ENSG00000243753.4	HLA-L	-5.97	3.22e-09	0.00227	-0.48	-0.18	Depression;	chr6:27831109	chr6:30259584~30293014:+
BRCA	trans	rs1459104	0.925	rs67465952	ENSG00000134612.10	FOLH1B	-5.97	3.22e-09	0.00227	-0.37	-0.18	Body mass index;	chr11:55426569	chr11:89639227~89698718:+
BRCA	trans	rs902774	0.818	rs4919737	ENSG00000254285.3	KRT8P3	-5.97	3.24e-09	0.00229	-0.37	-0.18	Prostate cancer;	chr12:52877011	chr8:61578220~61579668:+
BRCA	trans	rs2524276	1	rs2524276	ENSG00000230521.1	HCG4P7	5.97	3.24e-09	0.00229	0.44	0.18	Capecitabine sensitivity;	chr6:31440488	chr6:29887294~29888268:-
BRCA	trans	rs9467711	0.606	rs13212985	ENSG00000220721.1	OR1F12	5.97	3.24e-09	0.00229	0.39	0.18	Autism spectrum disorder or schizophrenia;	chr6:26609761	chr6:28073316~28074233:+
BRCA	trans	rs7746199	0.736	rs13209332	ENSG00000204709.4	LINC01556	5.97	3.24e-09	0.00229	0.48	0.18	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27552973	chr6:28943877~28944537:+
BRCA	trans	rs7829975	0.606	rs10112585	ENSG00000270154.1	RP11-419I17.1	-5.97	3.25e-09	0.00229	-0.2	-0.18	Mood instability;	chr8:8937520	chr8:12476462~12477122:+
BRCA	trans	rs7927771	1	rs10838747	ENSG00000134612.10	FOLH1B	-5.97	3.25e-09	0.00229	-0.25	-0.18	Subjective well-being;	chr11:47694772	chr11:89639227~89698718:+
BRCA	trans	rs6121246	0.559	rs6060962	ENSG00000279352.1	RP11-411B10.7	5.97	3.25e-09	0.00229	0.26	0.18	Mean corpuscular hemoglobin;	chr20:31810044	chr18:14010054~14010917:+
BRCA	trans	rs1167827	1	rs1167827	ENSG00000106133.16	NSUN5P2	-5.97	3.26e-09	0.0023	-0.18	-0.18	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75533848	chr7:72947581~72954790:-
BRCA	trans	rs875971	0.545	rs17138156	ENSG00000213640.3	EEF1DP4	-5.97	3.26e-09	0.0023	-0.25	-0.18	Aortic root size;	chr7:66249708	chr7:64862999~64864370:+
BRCA	trans	rs801193	0.66	rs1962050	ENSG00000224316.1	RP11-479O9.2	-5.97	3.26e-09	0.0023	-0.18	-0.18	Aortic root size;	chr7:66775021	chr7:65773620~65802067:+
BRCA	trans	rs1568889	1	rs9783375	ENSG00000174912.7	METTL15P1	5.97	3.26e-09	0.0023	0.21	0.18	Bipolar disorder;	chr11:28012120	chr3:156713884~156714928:-
BRCA	trans	rs714543	1	rs8840	ENSG00000219797.2	PPIAP9	5.97	3.26e-09	0.0023	0.22	0.18	Plateletcrit;	chr7:44877441	chr6:31519480~31520291:-
BRCA	trans	rs1459104	1	rs66654577	ENSG00000134612.10	FOLH1B	-5.97	3.28e-09	0.00231	-0.37	-0.18	Body mass index;	chr11:55401063	chr11:89639227~89698718:+
BRCA	trans	rs875971	0.545	rs1547529	ENSG00000213640.3	EEF1DP4	-5.97	3.28e-09	0.00231	-0.25	-0.18	Aortic root size;	chr7:66258859	chr7:64862999~64864370:+
BRCA	trans	rs66887589	0.616	rs11732621	ENSG00000120555.12	SEPT7P9	5.97	3.28e-09	0.00232	0.21	0.18	Diastolic blood pressure;	chr4:119291728	chr10:38383069~38402916:-
BRCA	trans	rs7617773	0.78	rs35411187	ENSG00000235912.1	RP1-159A19.3	-5.97	3.29e-09	0.00232	-0.25	-0.18	Coronary artery disease;	chr3:48318527	chr1:27649419~27649610:+
BRCA	trans	rs7617773	0.78	rs11714176	ENSG00000235912.1	RP1-159A19.3	-5.97	3.29e-09	0.00232	-0.25	-0.18	Coronary artery disease;	chr3:48319372	chr1:27649419~27649610:+
BRCA	trans	rs6831352	0.734	rs12502237	ENSG00000228407.2	RP4-800M22.1	-5.97	3.29e-09	0.00232	-0.25	-0.18	Alcohol dependence;	chr4:99094524	chr1:52160261~52160600:-
BRCA	trans	rs875971	0.545	rs1638735	ENSG00000234585.5	CCT6P3	5.97	3.31e-09	0.00233	0.19	0.18	Aortic root size;	chr7:66630751	chr7:65038354~65074713:+
BRCA	trans	rs7927771	0.826	rs7925389	ENSG00000134612.10	FOLH1B	-5.97	3.31e-09	0.00233	-0.24	-0.18	Subjective well-being;	chr11:47445238	chr11:89639227~89698718:+
BRCA	trans	rs7746199	0.736	rs10484399	ENSG00000228078.1	HLA-U	-5.97	3.31e-09	0.00233	-0.46	-0.18	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27566749	chr6:29934101~29934286:+
BRCA	trans	rs9467711	0.591	rs28360595	ENSG00000253570.1	RNF5P1	5.97	3.31e-09	0.00233	0.45	0.18	Autism spectrum disorder or schizophrenia;	chr6:26029816	chr8:38600661~38601200:-
BRCA	trans	rs3750082	0.889	rs13244998	ENSG00000176826.14	FKBP9P1	5.97	3.34e-09	0.00235	0.22	0.18	Glomerular filtration rate (creatinine);	chr7:32873298	chr7:55681074~55713252:-
BRCA	trans	rs3750082	0.889	rs9639669	ENSG00000176826.14	FKBP9P1	5.97	3.34e-09	0.00235	0.22	0.18	Glomerular filtration rate (creatinine);	chr7:32873783	chr7:55681074~55713252:-
BRCA	trans	rs45509595	0.841	rs17751184	ENSG00000243753.4	HLA-L	-5.96	3.35e-09	0.00236	-0.48	-0.18	Breast cancer;	chr6:27807250	chr6:30259584~30293014:+
BRCA	trans	rs12155039	1	rs12155039	ENSG00000219797.2	PPIAP9	-5.96	3.35e-09	0.00236	-0.22	-0.18	Mean platelet volume;	chr7:44833526	chr6:31519480~31520291:-
BRCA	trans	rs6121246	0.511	rs879982	ENSG00000279352.1	RP11-411B10.7	5.96	3.36e-09	0.00236	0.26	0.18	Mean corpuscular hemoglobin;	chr20:31810707	chr18:14010054~14010917:+
BRCA	trans	rs7647973	0.925	rs6446257	ENSG00000235912.1	RP1-159A19.3	5.96	3.36e-09	0.00236	0.24	0.18	Menarche (age at onset);	chr3:49216059	chr1:27649419~27649610:+
BRCA	trans	rs853679	0.599	rs202906	ENSG00000253570.1	RNF5P1	-5.96	3.36e-09	0.00236	-0.38	-0.18	Depression;	chr6:28043874	chr8:38600661~38601200:-
BRCA	trans	rs875971	0.545	rs2707851	ENSG00000234585.5	CCT6P3	-5.96	3.36e-09	0.00236	-0.2	-0.18	Aortic root size;	chr7:66624178	chr7:65038354~65074713:+
BRCA	trans	rs10946940	0.93	rs10807029	ENSG00000204709.4	LINC01556	-5.96	3.36e-09	0.00237	-0.23	-0.18	Systemic lupus erythematosus;	chr6:27605684	chr6:28943877~28944537:+
BRCA	trans	rs4834770	1	rs10034579	ENSG00000275858.1	RP11-291L22.8	5.96	3.38e-09	0.00238	0.21	0.18	Blood protein levels;	chr4:119322874	chr10:38450738~38451069:-
BRCA	trans	rs1336472	0.509	rs4916031	ENSG00000263535.1	AK4P1	-5.96	3.38e-09	0.00238	-0.24	-0.18	Venous thromboembolism (SNP x SNP interaction);	chr1:65215860	chr17:31345521~31346187:+
BRCA	trans	rs67340775	0.748	rs13212651	ENSG00000243753.4	HLA-L	-5.96	3.4e-09	0.0024	-0.48	-0.18	Lung cancer in ever smokers;	chr6:27839207	chr6:30259584~30293014:+
BRCA	trans	rs7833986	0.501	rs2976044	ENSG00000244086.1	RPS20P35	5.96	3.4e-09	0.0024	0.25	0.18	Height;	chr8:56074178	chr17:38855314~38855670:+
BRCA	trans	rs902774	1	rs11831942	ENSG00000255815.3	KRT8P11	-5.96	3.4e-09	0.0024	-0.32	-0.18	Prostate cancer;	chr12:52878329	chr9:99305176~99306611:+
BRCA	trans	rs853679	0.607	rs67040724	ENSG00000204709.4	LINC01556	5.96	3.42e-09	0.00241	0.48	0.18	Depression;	chr6:27937731	chr6:28943877~28944537:+
BRCA	trans	rs875971	1	rs778706	ENSG00000164669.11	INTS4P1	-5.96	3.43e-09	0.00241	-0.22	-0.18	Aortic root size;	chr7:66395437	chr7:65141225~65234216:+
BRCA	trans	rs7113874	0.543	rs10840047	ENSG00000266891.1	RP11-692N5.2	5.96	3.44e-09	0.00242	0.21	0.18	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8439350	chr18:9734882~9735602:-
BRCA	trans	rs10946940	0.965	rs6910838	ENSG00000204709.4	LINC01556	-5.96	3.44e-09	0.00242	-0.23	-0.18	Systemic lupus erythematosus;	chr6:27547740	chr6:28943877~28944537:+
BRCA	trans	rs546131	0.642	rs61881097	ENSG00000225531.1	RP11-196I18.3	-5.96	3.45e-09	0.00242	-0.3	-0.18	Lung disease severity in cystic fibrosis;	chr11:34800051	chr9:107116829~107117557:+
BRCA	trans	rs7260598	0.892	rs2116956	ENSG00000261770.1	CTC-459F4.1	5.96	3.45e-09	0.00243	0.31	0.18	Response to taxane treatment (placlitaxel);	chr19:24005987	chr19:27757184~27760849:-
BRCA	trans	rs351855	0.642	rs2546095	ENSG00000226986.4	RP11-543B16.2	5.96	3.45e-09	0.00243	0.22	0.18	Waist-to-hip ratio adjusted for body mass index;	chr5:177082583	chr1:211207239~211207897:+
BRCA	trans	rs7824557	0.767	rs2164272	ENSG00000254153.1	CTA-398F10.2	5.96	3.46e-09	0.00243	0.24	0.18	Retinal vascular caliber;	chr8:11304987	chr8:8456909~8461337:-
BRCA	trans	rs11782517	0.92	rs13266832	ENSG00000253893.2	FAM85B	-5.96	3.46e-09	0.00243	-0.27	-0.18	Nose size;	chr8:10249558	chr8:8167819~8226614:-
BRCA	trans	rs875971	0.545	rs35459055	ENSG00000234585.5	CCT6P3	5.96	3.46e-09	0.00244	0.2	0.18	Aortic root size;	chr7:66479399	chr7:65038354~65074713:+
BRCA	trans	rs1933488	0.523	rs623428	ENSG00000278974.1	RP11-756P10.6	5.96	3.48e-09	0.00245	0.24	0.18	Prostate cancer;	chr6:153145343	chr4:188740507~188741281:-
BRCA	trans	rs4538475	0.79	rs11934811	ENSG00000249936.3	RAC1P2	5.96	3.49e-09	0.00246	0.3	0.18	Parkinson's disease;	chr4:15736630	chr4:46723830~46724408:-
BRCA	trans	rs4713118	0.955	rs9468203	ENSG00000204709.4	LINC01556	5.96	3.52e-09	0.00247	0.25	0.18	Parkinson's disease;	chr6:27720888	chr6:28943877~28944537:+
BRCA	trans	rs11098499	0.644	rs7676296	ENSG00000276997.3	RP11-378J18.9	5.96	3.52e-09	0.00247	0.22	0.18	Corneal astigmatism;	chr4:119634532	chr1:222477252~222504622:-
BRCA	trans	rs902774	0.818	rs73110471	ENSG00000220378.3	KRT8P42	-5.96	3.54e-09	0.00249	-0.37	-0.18	Prostate cancer;	chr12:52923037	chr6:134296997~134298695:-
BRCA	trans	rs3750082	0.889	rs13230763	ENSG00000176826.14	FKBP9P1	5.96	3.54e-09	0.00249	0.22	0.18	Glomerular filtration rate (creatinine);	chr7:32873353	chr7:55681074~55713252:-
BRCA	trans	rs11098499	0.863	rs13136462	ENSG00000253326.2	RP11-261C10.7	5.96	3.54e-09	0.00249	0.26	0.18	Corneal astigmatism;	chr4:119622018	chr1:243054861~243056394:-
BRCA	trans	rs7746199	0.736	rs34064842	ENSG00000228078.1	HLA-U	-5.95	3.56e-09	0.0025	-0.47	-0.18	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27720846	chr6:29934101~29934286:+
BRCA	trans	rs7617773	0.78	rs11718350	ENSG00000235912.1	RP1-159A19.3	-5.95	3.56e-09	0.0025	-0.25	-0.18	Coronary artery disease;	chr3:48319502	chr1:27649419~27649610:+
BRCA	trans	rs875971	0.545	rs6950988	ENSG00000234585.5	CCT6P3	5.95	3.57e-09	0.00251	0.2	0.18	Aortic root size;	chr7:66511428	chr7:65038354~65074713:+
BRCA	trans	rs11098499	0.863	rs3775843	ENSG00000253326.2	RP11-261C10.7	5.95	3.58e-09	0.00251	0.26	0.18	Corneal astigmatism;	chr4:119506689	chr1:243054861~243056394:-
BRCA	trans	rs11098499	0.863	rs3775844	ENSG00000253326.2	RP11-261C10.7	5.95	3.58e-09	0.00251	0.26	0.18	Corneal astigmatism;	chr4:119506878	chr1:243054861~243056394:-
BRCA	trans	rs2066819	1	rs77120931	ENSG00000273654.1	CTB-52I2.4	5.95	3.58e-09	0.00251	0.46	0.18	Psoriasis vulgaris;	chr12:56252429	chr19:18022403~18032099:+
BRCA	trans	rs7927771	1	rs35624992	ENSG00000134612.10	FOLH1B	-5.95	3.58e-09	0.00251	-0.24	-0.18	Subjective well-being;	chr11:47594246	chr11:89639227~89698718:+
BRCA	trans	rs1459104	1	rs67831168	ENSG00000134612.10	FOLH1B	-5.95	3.61e-09	0.00253	-0.34	-0.18	Body mass index;	chr11:55468127	chr11:89639227~89698718:+
BRCA	trans	rs7927771	0.965	rs34958982	ENSG00000134612.10	FOLH1B	-5.95	3.61e-09	0.00253	-0.24	-0.18	Subjective well-being;	chr11:47525494	chr11:89639227~89698718:+
BRCA	trans	rs7927771	0.929	rs66749409	ENSG00000134612.10	FOLH1B	-5.95	3.61e-09	0.00253	-0.24	-0.18	Subjective well-being;	chr11:47546522	chr11:89639227~89698718:+
BRCA	trans	rs7927771	0.894	rs12798346	ENSG00000134612.10	FOLH1B	-5.95	3.61e-09	0.00253	-0.24	-0.18	Subjective well-being;	chr11:47561569	chr11:89639227~89698718:+
BRCA	trans	rs7824557	0.767	rs4559208	ENSG00000254153.1	CTA-398F10.2	5.95	3.61e-09	0.00253	0.24	0.18	Retinal vascular caliber;	chr8:11296416	chr8:8456909~8461337:-
BRCA	trans	rs7829975	0.567	rs6601273	ENSG00000270154.1	RP11-419I17.1	-5.95	3.62e-09	0.00254	-0.2	-0.18	Mood instability;	chr8:8939009	chr8:12476462~12477122:+
BRCA	trans	rs7568458	0.684	rs1048740	ENSG00000223886.3	RP11-251G23.2	5.95	3.62e-09	0.00254	0.22	0.18	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr2:85537843	chr7:105530209~105530671:+
BRCA	trans	rs7568458	0.684	rs1048739	ENSG00000223886.3	RP11-251G23.2	5.95	3.62e-09	0.00254	0.22	0.18	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr2:85537845	chr7:105530209~105530671:+
BRCA	trans	rs6831352	0.819	rs1230158	ENSG00000228407.2	RP4-800M22.1	-5.95	3.64e-09	0.00255	-0.24	-0.18	Alcohol dependence;	chr4:99069035	chr1:52160261~52160600:-
BRCA	trans	rs875971	0.545	rs3735147	ENSG00000213640.3	EEF1DP4	-5.95	3.64e-09	0.00255	-0.25	-0.18	Aortic root size;	chr7:66505541	chr7:64862999~64864370:+
BRCA	trans	rs6831352	0.918	rs7694646	ENSG00000233859.2	ADH5P4	5.95	3.66e-09	0.00256	0.26	0.18	Alcohol dependence;	chr4:99138581	chr6:65836930~65838039:-
BRCA	trans	rs6831352	0.918	rs7670638	ENSG00000233859.2	ADH5P4	5.95	3.66e-09	0.00256	0.26	0.18	Alcohol dependence;	chr4:99138656	chr6:65836930~65838039:-
BRCA	trans	rs1568889	0.938	rs1464898	ENSG00000174912.7	METTL15P1	5.95	3.66e-09	0.00257	0.2	0.18	Bipolar disorder;	chr11:28013201	chr3:156713884~156714928:-
BRCA	trans	rs1568889	1	rs1464897	ENSG00000174912.7	METTL15P1	5.95	3.66e-09	0.00257	0.2	0.18	Bipolar disorder;	chr11:28013297	chr3:156713884~156714928:-
BRCA	trans	rs3942852	0.955	rs4752897	ENSG00000134612.10	FOLH1B	-5.95	3.66e-09	0.00257	-0.25	-0.18	Acute lymphoblastic leukemia (childhood);	chr11:48115438	chr11:89639227~89698718:+
BRCA	trans	rs76228276	0.737	rs11991039	ENSG00000260318.1	COX6CP1	5.95	3.66e-09	0.00257	0.46	0.18	Childhood ear infection;	chr8:99363319	chr16:11903923~11904137:-
BRCA	trans	rs1459104	0.714	rs36018195	ENSG00000134612.10	FOLH1B	-5.95	3.66e-09	0.00257	-0.37	-0.18	Body mass index;	chr11:55405380	chr11:89639227~89698718:+
BRCA	trans	rs875971	0.545	rs12670811	ENSG00000213640.3	EEF1DP4	-5.95	3.67e-09	0.00257	-0.25	-0.18	Aortic root size;	chr7:66358032	chr7:64862999~64864370:+
BRCA	trans	rs875971	0.895	rs7788984	ENSG00000164669.11	INTS4P1	-5.95	3.67e-09	0.00258	-0.22	-0.18	Aortic root size;	chr7:66450629	chr7:65141225~65234216:+
BRCA	trans	rs7746199	0.736	rs13195636	ENSG00000204709.4	LINC01556	5.95	3.71e-09	0.0026	0.48	0.18	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27541714	chr6:28943877~28944537:+
BRCA	trans	rs2504916	1	rs2457570	ENSG00000228214.5	LINC00693	5.95	3.72e-09	0.0026	0.26	0.18	Response to hepatitis C treatment;	chr6:160408486	chr3:28574791~28758340:+
BRCA	trans	rs6831352	0.918	rs2851247	ENSG00000233859.2	ADH5P4	5.95	3.72e-09	0.0026	0.26	0.18	Alcohol dependence;	chr4:99124940	chr6:65836930~65838039:-
BRCA	trans	rs875971	0.545	rs4718348	ENSG00000213640.3	EEF1DP4	-5.95	3.72e-09	0.00261	-0.26	-0.18	Aortic root size;	chr7:66441589	chr7:64862999~64864370:+
BRCA	trans	rs7927771	0.8	rs35996350	ENSG00000134612.10	FOLH1B	-5.95	3.73e-09	0.00261	-0.24	-0.18	Subjective well-being;	chr11:47367672	chr11:89639227~89698718:+
BRCA	trans	rs853679	0.607	rs13194781	ENSG00000243753.4	HLA-L	-5.95	3.73e-09	0.00261	-0.49	-0.18	Depression;	chr6:27847861	chr6:30259584~30293014:+
BRCA	trans	rs1459104	0.925	rs17157459	ENSG00000134612.10	FOLH1B	-5.95	3.74e-09	0.00262	-0.34	-0.18	Body mass index;	chr11:55373942	chr11:89639227~89698718:+
BRCA	trans	rs9650657	0.547	rs11250099	ENSG00000254153.1	CTA-398F10.2	5.95	3.75e-09	0.00262	0.23	0.18	Neuroticism;	chr8:10961147	chr8:8456909~8461337:-
BRCA	trans	rs11782517	0.883	rs12544801	ENSG00000253893.2	FAM85B	-5.95	3.75e-09	0.00262	-0.26	-0.18	Nose size;	chr8:10249872	chr8:8167819~8226614:-
BRCA	trans	rs875971	1	rs6945843	ENSG00000164669.11	INTS4P1	5.95	3.75e-09	0.00263	0.22	0.18	Aortic root size;	chr7:66269796	chr7:65141225~65234216:+
BRCA	trans	rs853679	0.607	rs34878803	ENSG00000228078.1	HLA-U	-5.95	3.75e-09	0.00263	-0.46	-0.18	Depression;	chr6:28282402	chr6:29934101~29934286:+
BRCA	trans	rs853679	0.607	rs34396849	ENSG00000228078.1	HLA-U	-5.95	3.75e-09	0.00263	-0.46	-0.18	Depression;	chr6:28283178	chr6:29934101~29934286:+
BRCA	trans	rs2066819	1	rs2371454	ENSG00000273654.1	CTB-52I2.4	-5.95	3.76e-09	0.00263	-0.46	-0.18	Psoriasis vulgaris;	chr12:56253459	chr19:18022403~18032099:+
BRCA	trans	rs941207	0.526	rs11171916	ENSG00000257210.1	NACAP3	-5.94	3.78e-09	0.00265	-0.22	-0.18	Platelet count;	chr12:56653236	chr12:93124063~93124543:-
BRCA	trans	rs67340775	0.834	rs13218875	ENSG00000204709.4	LINC01556	5.94	3.78e-09	0.00265	0.48	0.18	Lung cancer in ever smokers;	chr6:27916234	chr6:28943877~28944537:+
BRCA	trans	rs7927771	0.965	rs56400411	ENSG00000134612.10	FOLH1B	-5.94	3.78e-09	0.00265	-0.24	-0.18	Subjective well-being;	chr11:47564824	chr11:89639227~89698718:+
BRCA	trans	rs875971	0.545	rs12671152	ENSG00000234585.5	CCT6P3	5.94	3.79e-09	0.00265	0.2	0.18	Aortic root size;	chr7:66311140	chr7:65038354~65074713:+
BRCA	trans	rs11098499	0.532	rs4833624	ENSG00000120555.12	SEPT7P9	5.94	3.8e-09	0.00266	0.22	0.18	Corneal astigmatism;	chr4:119664342	chr10:38383069~38402916:-
BRCA	trans	rs853679	0.607	rs13194781	ENSG00000228078.1	HLA-U	-5.94	3.8e-09	0.00266	-0.49	-0.18	Depression;	chr6:27847861	chr6:29934101~29934286:+
BRCA	trans	rs7824557	0.767	rs3808509	ENSG00000254153.1	CTA-398F10.2	5.94	3.81e-09	0.00266	0.24	0.18	Retinal vascular caliber;	chr8:11305747	chr8:8456909~8461337:-
BRCA	trans	rs16975963	0.604	rs17305326	ENSG00000247498.8	RP11-392P7.6	5.94	3.81e-09	0.00266	0.32	0.18	Longevity;	chr19:37628646	chr12:12927726~12984645:+
BRCA	trans	rs78944489	0.867	rs77296312	ENSG00000236165.1	PRADC1P1	5.94	3.81e-09	0.00266	0.37	0.18	Schizophrenia;	chr2:73243809	chr3:36976316~36976840:+
BRCA	trans	rs10028773	0.515	rs9994488	ENSG00000276805.1	RP11-291L22.6	5.94	3.85e-09	0.00269	0.21	0.18	Educational attainment;	chr4:119666626	chr10:38451030~38451785:+
BRCA	trans	rs319204	1	rs319226	ENSG00000226498.2	RP11-182B22.2	5.94	3.85e-09	0.00269	0.2	0.18	Schizophrenia;	chr5:146867491	chr1:236819634~236820518:+
BRCA	trans	rs7113874	0.589	rs935370	ENSG00000266891.1	RP11-692N5.2	-5.94	3.86e-09	0.0027	-0.21	-0.18	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8465299	chr18:9734882~9735602:-
BRCA	trans	rs7570469	0.762	rs35490405	ENSG00000276390.1	RP1-197B17.5	5.94	3.86e-09	0.0027	0.24	0.18	Response to antipsychotic treatment;	chr2:79437296	chr12:47699401~47699917:-
BRCA	trans	rs6121246	0.559	rs6058465	ENSG00000279352.1	RP11-411B10.7	5.94	3.86e-09	0.0027	0.26	0.18	Mean corpuscular hemoglobin;	chr20:31809888	chr18:14010054~14010917:+
BRCA	trans	rs714543	0.566	rs13231886	ENSG00000214975.4	PPIAP29	-5.94	3.87e-09	0.0027	-0.21	-0.18	Plateletcrit;	chr7:44774573	chr6:24976419~24976982:+
BRCA	trans	rs853679	0.607	rs13208096	ENSG00000243753.4	HLA-L	-5.94	3.87e-09	0.00271	-0.49	-0.18	Depression;	chr6:28257533	chr6:30259584~30293014:+
BRCA	trans	rs875971	0.545	rs1796219	ENSG00000234585.5	CCT6P3	-5.94	3.88e-09	0.00271	-0.2	-0.18	Aortic root size;	chr7:66645977	chr7:65038354~65074713:+
BRCA	trans	rs853679	0.546	rs35819751	ENSG00000281831.1	HCP5B	5.94	3.88e-09	0.00271	0.47	0.18	Depression;	chr6:27842791	chr6:29871895~29873783:-
BRCA	trans	rs902774	0.818	rs4919737	ENSG00000228753.1	EIF4BP2	5.94	3.92e-09	0.00274	0.36	0.18	Prostate cancer;	chr12:52877011	chr10:21028999~21030792:+
BRCA	trans	rs1459104	0.925	rs12576020	ENSG00000134612.10	FOLH1B	-5.94	3.92e-09	0.00274	-0.37	-0.18	Body mass index;	chr11:55454024	chr11:89639227~89698718:+
BRCA	trans	rs875971	0.929	rs778692	ENSG00000164669.11	INTS4P1	-5.94	3.93e-09	0.00274	-0.22	-0.18	Aortic root size;	chr7:66407462	chr7:65141225~65234216:+
BRCA	trans	rs875971	1	rs4718343	ENSG00000164669.11	INTS4P1	-5.94	3.93e-09	0.00274	-0.22	-0.18	Aortic root size;	chr7:66409301	chr7:65141225~65234216:+
BRCA	trans	rs875971	1	rs1968225	ENSG00000164669.11	INTS4P1	-5.94	3.93e-09	0.00274	-0.22	-0.18	Aortic root size;	chr7:66409786	chr7:65141225~65234216:+
BRCA	trans	rs875971	1	rs6460295	ENSG00000164669.11	INTS4P1	-5.94	3.93e-09	0.00274	-0.22	-0.18	Aortic root size;	chr7:66417741	chr7:65141225~65234216:+
BRCA	trans	rs875971	0.964	rs6978721	ENSG00000164669.11	INTS4P1	-5.94	3.93e-09	0.00274	-0.22	-0.18	Aortic root size;	chr7:66418217	chr7:65141225~65234216:+
BRCA	trans	rs7746199	0.736	rs34573979	ENSG00000204709.4	LINC01556	5.94	3.93e-09	0.00275	0.48	0.18	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27512747	chr6:28943877~28944537:+
BRCA	trans	rs2237234	0.848	rs2237235	ENSG00000242375.1	RP11-498P14.3	-5.94	3.94e-09	0.00275	-0.3	-0.18	Autism spectrum disorder or schizophrenia;	chr6:26391167	chr9:97195351~97197687:-
BRCA	trans	rs8177876	0.658	rs2316730	ENSG00000226040.3	AC005740.3	5.94	3.94e-09	0.00275	0.39	0.18	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81106035	chr5:141896168~141896689:-
BRCA	trans	rs6121246	0.559	rs6060716	ENSG00000279352.1	RP11-411B10.7	5.94	3.94e-09	0.00275	0.26	0.18	Mean corpuscular hemoglobin;	chr20:31687044	chr18:14010054~14010917:+
BRCA	trans	rs4834770	1	rs6823963	ENSG00000275858.1	RP11-291L22.8	5.94	3.94e-09	0.00275	0.21	0.18	Blood protein levels;	chr4:119321009	chr10:38450738~38451069:-
BRCA	trans	rs4834770	1	rs4834771	ENSG00000275858.1	RP11-291L22.8	5.94	3.94e-09	0.00275	0.21	0.18	Blood protein levels;	chr4:119321617	chr10:38450738~38451069:-
BRCA	trans	rs4834770	1	rs1397613	ENSG00000275858.1	RP11-291L22.8	5.94	3.94e-09	0.00275	0.21	0.18	Blood protein levels;	chr4:119321774	chr10:38450738~38451069:-
BRCA	trans	rs4834770	1	rs6857641	ENSG00000275858.1	RP11-291L22.8	5.94	3.94e-09	0.00275	0.21	0.18	Blood protein levels;	chr4:119322356	chr10:38450738~38451069:-
BRCA	trans	rs4834770	1	rs2282688	ENSG00000275858.1	RP11-291L22.8	5.94	3.94e-09	0.00275	0.21	0.18	Blood protein levels;	chr4:119322567	chr10:38450738~38451069:-
BRCA	trans	rs10946940	0.965	rs6915266	ENSG00000204709.4	LINC01556	-5.94	3.94e-09	0.00275	-0.23	-0.18	Systemic lupus erythematosus;	chr6:27560864	chr6:28943877~28944537:+
BRCA	trans	rs7833986	0.501	rs72651502	ENSG00000244245.1	RP11-120B7.1	5.94	3.96e-09	0.00276	0.24	0.18	Height;	chr8:55962974	chr5:108593609~108593967:+
BRCA	trans	rs546131	0.642	rs11602886	ENSG00000225531.1	RP11-196I18.3	-5.94	3.96e-09	0.00277	-0.29	-0.18	Lung disease severity in cystic fibrosis;	chr11:34820296	chr9:107116829~107117557:+
BRCA	trans	rs546131	0.642	rs11602870	ENSG00000225531.1	RP11-196I18.3	-5.94	3.96e-09	0.00277	-0.29	-0.18	Lung disease severity in cystic fibrosis;	chr11:34820355	chr9:107116829~107117557:+
BRCA	trans	rs11098499	0.73	rs12505735	ENSG00000253326.2	RP11-261C10.7	5.94	3.96e-09	0.00277	0.25	0.18	Corneal astigmatism;	chr4:119611801	chr1:243054861~243056394:-
BRCA	trans	rs6601450	0.534	rs1133184	ENSG00000253893.2	FAM85B	5.94	3.97e-09	0.00277	0.23	0.18	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;	chr8:10369050	chr8:8167819~8226614:-
BRCA	trans	rs7570469	0.762	rs12472215	ENSG00000276390.1	RP1-197B17.5	5.94	3.98e-09	0.00278	0.24	0.18	Response to antipsychotic treatment;	chr2:79425802	chr12:47699401~47699917:-
BRCA	trans	rs330048	0.545	rs11774353	ENSG00000270154.1	RP11-419I17.1	5.94	3.98e-09	0.00278	0.22	0.18	Systemic lupus erythematosus;	chr8:9295617	chr8:12476462~12477122:+
BRCA	trans	rs6831352	0.918	rs4699713	ENSG00000233859.2	ADH5P4	5.94	3.98e-09	0.00278	0.26	0.18	Alcohol dependence;	chr4:99139362	chr6:65836930~65838039:-
BRCA	trans	rs6831352	0.918	rs4699714	ENSG00000233859.2	ADH5P4	5.94	3.98e-09	0.00278	0.26	0.18	Alcohol dependence;	chr4:99139387	chr6:65836930~65838039:-
BRCA	trans	rs6831352	0.84	rs17817868	ENSG00000233859.2	ADH5P4	5.94	3.98e-09	0.00278	0.26	0.18	Alcohol dependence;	chr4:99139472	chr6:65836930~65838039:-
BRCA	trans	rs641862	1	rs641862	ENSG00000233325.3	MIPEPP3	5.94	3.99e-09	0.00278	0.38	0.18	Obesity-related traits;	chr13:110137885	chr13:21298139~21306373:+
BRCA	trans	rs7927771	0.965	rs4752845	ENSG00000134612.10	FOLH1B	-5.94	3.99e-09	0.00279	-0.24	-0.18	Subjective well-being;	chr11:47518145	chr11:89639227~89698718:+
BRCA	trans	rs11098499	0.644	rs10012252	ENSG00000276997.3	RP11-378J18.9	5.93	4e-09	0.00279	0.21	0.18	Corneal astigmatism;	chr4:119637984	chr1:222477252~222504622:-
BRCA	trans	rs6831352	0.879	rs29001208	ENSG00000233859.2	ADH5P4	5.93	4.01e-09	0.0028	0.26	0.18	Alcohol dependence;	chr4:99131388	chr6:65836930~65838039:-
BRCA	trans	rs902774	0.818	rs4919737	ENSG00000223940.1	KRT8P8	-5.93	4.01e-09	0.0028	-0.37	-0.18	Prostate cancer;	chr12:52877011	chrX:152479577~152481024:+
BRCA	trans	rs875971	0.545	rs35459055	ENSG00000213640.3	EEF1DP4	-5.93	4.01e-09	0.0028	-0.25	-0.18	Aortic root size;	chr7:66479399	chr7:64862999~64864370:+
BRCA	trans	rs11098499	0.78	rs10013652	ENSG00000120555.12	SEPT7P9	5.93	4.02e-09	0.0028	0.22	0.18	Corneal astigmatism;	chr4:119371101	chr10:38383069~38402916:-
BRCA	trans	rs71537559	1	rs71537559	ENSG00000228078.1	HLA-U	-5.93	4.02e-09	0.0028	-0.44	-0.18	Squamous cell lung carcinoma;	chr6:27342000	chr6:29934101~29934286:+
BRCA	trans	rs6499244	0.552	rs7196917	ENSG00000257513.6	NPIPB1P	5.93	4.02e-09	0.0028	0.2	0.18	Menarche (age at onset);	chr16:69862624	chr18:11619509~11639699:-
BRCA	trans	rs7746199	0.736	rs67652222	ENSG00000204709.4	LINC01556	5.93	4.02e-09	0.0028	0.48	0.18	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27618441	chr6:28943877~28944537:+
BRCA	trans	rs7927771	0.896	rs12794570	ENSG00000134612.10	FOLH1B	-5.93	4.02e-09	0.00281	-0.25	-0.18	Subjective well-being;	chr11:47636762	chr11:89639227~89698718:+
BRCA	trans	rs9467711	0.72	rs35627490	ENSG00000281831.1	HCP5B	5.93	4.02e-09	0.00281	0.43	0.18	Autism spectrum disorder or schizophrenia;	chr6:26461876	chr6:29871895~29873783:-
BRCA	trans	rs941207	0.507	rs1107479	ENSG00000257210.1	NACAP3	-5.93	4.02e-09	0.00281	-0.22	-0.18	Platelet count;	chr12:56636902	chr12:93124063~93124543:-
BRCA	trans	rs4713118	0.824	rs9468225	ENSG00000204709.4	LINC01556	5.93	4.02e-09	0.00281	0.25	0.18	Parkinson's disease;	chr6:27777940	chr6:28943877~28944537:+
BRCA	trans	rs16975963	0.644	rs73033117	ENSG00000247498.8	RP11-392P7.6	5.93	4.03e-09	0.00281	0.32	0.18	Longevity;	chr19:37582245	chr12:12927726~12984645:+
BRCA	trans	rs2242330	0.798	rs3775866	ENSG00000226982.4	CENPCP1	5.93	4.03e-09	0.00281	0.24	0.18	Parkinson's disease;	chr4:67578462	chr12:89500093~89502670:+
BRCA	trans	rs12439619	0.693	rs17269819	ENSG00000235370.6	DNM1P51	-5.93	4.04e-09	0.00282	-0.24	-0.18	Intelligence (multi-trait analysis);	chr15:82174660	chr15:84398316~84411701:-
BRCA	trans	rs2243480	0.901	rs3813708	ENSG00000230295.1	RP11-458F8.2	-5.93	4.04e-09	0.00282	-0.24	-0.18	Diabetic kidney disease;	chr7:65840645	chr7:66880708~66882981:+
BRCA	trans	rs7927771	0.832	rs7940536	ENSG00000134612.10	FOLH1B	5.93	4.05e-09	0.00282	0.24	0.18	Subjective well-being;	chr11:47373689	chr11:89639227~89698718:+
BRCA	trans	rs12542260	0.871	rs7834203	ENSG00000234369.1	TATDN1P1	5.93	4.05e-09	0.00282	0.25	0.18	Colonoscopy-negative controls vs population controls;	chr8:124470655	chr10:63222155~63223045:+
BRCA	trans	rs12542260	0.871	rs62527884	ENSG00000234369.1	TATDN1P1	5.93	4.05e-09	0.00282	0.25	0.18	Colonoscopy-negative controls vs population controls;	chr8:124471103	chr10:63222155~63223045:+
BRCA	trans	rs12542260	0.871	rs72713049	ENSG00000234369.1	TATDN1P1	5.93	4.05e-09	0.00282	0.25	0.18	Colonoscopy-negative controls vs population controls;	chr8:124471847	chr10:63222155~63223045:+
BRCA	trans	rs853679	0.546	rs71537572	ENSG00000228078.1	HLA-U	-5.93	4.05e-09	0.00283	-0.49	-0.18	Depression;	chr6:28002937	chr6:29934101~29934286:+
BRCA	trans	rs7647973	0.925	rs9881860	ENSG00000235912.1	RP1-159A19.3	-5.93	4.07e-09	0.00283	-0.24	-0.18	Menarche (age at onset);	chr3:49315089	chr1:27649419~27649610:+
BRCA	trans	rs7829975	0.572	rs7005000	ENSG00000270154.1	RP11-419I17.1	-5.93	4.07e-09	0.00283	-0.2	-0.18	Mood instability;	chr8:8939092	chr8:12476462~12477122:+
BRCA	trans	rs3750082	0.855	rs6462430	ENSG00000176826.14	FKBP9P1	5.93	4.07e-09	0.00283	0.22	0.18	Glomerular filtration rate (creatinine);	chr7:32882219	chr7:55681074~55713252:-
BRCA	trans	rs3750082	0.889	rs7781915	ENSG00000176826.14	FKBP9P1	5.93	4.07e-09	0.00283	0.22	0.18	Glomerular filtration rate (creatinine);	chr7:32883547	chr7:55681074~55713252:-
BRCA	trans	rs3750082	0.889	rs12154586	ENSG00000176826.14	FKBP9P1	5.93	4.07e-09	0.00283	0.22	0.18	Glomerular filtration rate (creatinine);	chr7:32883759	chr7:55681074~55713252:-
BRCA	trans	rs7617773	0.78	rs7632297	ENSG00000235912.1	RP1-159A19.3	-5.93	4.07e-09	0.00284	-0.24	-0.18	Coronary artery disease;	chr3:48306673	chr1:27649419~27649610:+
BRCA	trans	rs875971	1	rs6958271	ENSG00000164669.11	INTS4P1	-5.93	4.07e-09	0.00284	-0.22	-0.18	Aortic root size;	chr7:66514344	chr7:65141225~65234216:+
BRCA	trans	rs875971	1	rs6958277	ENSG00000164669.11	INTS4P1	-5.93	4.07e-09	0.00284	-0.22	-0.18	Aortic root size;	chr7:66514362	chr7:65141225~65234216:+
BRCA	trans	rs12210905	0.925	rs9467971	ENSG00000242375.1	RP11-498P14.3	-5.93	4.09e-09	0.00285	-0.39	-0.18	Hip circumference adjusted for BMI;	chr6:27031673	chr9:97195351~97197687:-
BRCA	trans	rs7829975	0.606	rs7819827	ENSG00000270154.1	RP11-419I17.1	-5.93	4.09e-09	0.00285	-0.2	-0.18	Mood instability;	chr8:8939545	chr8:12476462~12477122:+
BRCA	trans	rs7829975	0.573	rs7842359	ENSG00000270154.1	RP11-419I17.1	-5.93	4.09e-09	0.00285	-0.2	-0.18	Mood instability;	chr8:8939568	chr8:12476462~12477122:+
BRCA	trans	rs7617773	0.78	rs36075665	ENSG00000235912.1	RP1-159A19.3	-5.93	4.1e-09	0.00286	-0.24	-0.18	Coronary artery disease;	chr3:48301597	chr1:27649419~27649610:+
BRCA	trans	rs6121246	0.559	rs6060599	ENSG00000279352.1	RP11-411B10.7	5.93	4.13e-09	0.00287	0.26	0.18	Mean corpuscular hemoglobin;	chr20:31669951	chr18:14010054~14010917:+
BRCA	trans	rs853679	0.607	rs67662114	ENSG00000228078.1	HLA-U	-5.93	4.13e-09	0.00287	-0.49	-0.18	Depression;	chr6:27964523	chr6:29934101~29934286:+
BRCA	trans	rs853679	0.607	rs13216117	ENSG00000228078.1	HLA-U	-5.93	4.13e-09	0.00287	-0.49	-0.18	Depression;	chr6:27970706	chr6:29934101~29934286:+
BRCA	trans	rs853679	0.607	rs36101351	ENSG00000228078.1	HLA-U	-5.93	4.13e-09	0.00287	-0.49	-0.18	Depression;	chr6:27975591	chr6:29934101~29934286:+
BRCA	trans	rs853679	0.607	rs28360499	ENSG00000228078.1	HLA-U	-5.93	4.13e-09	0.00287	-0.49	-0.18	Depression;	chr6:27977618	chr6:29934101~29934286:+
BRCA	trans	rs6831352	0.918	rs29001209	ENSG00000233859.2	ADH5P4	5.93	4.13e-09	0.00287	0.26	0.18	Alcohol dependence;	chr4:99131189	chr6:65836930~65838039:-
BRCA	trans	rs4713118	0.955	rs9468204	ENSG00000204709.4	LINC01556	5.93	4.14e-09	0.00288	0.25	0.18	Parkinson's disease;	chr6:27721030	chr6:28943877~28944537:+
BRCA	trans	rs2117029	0.556	rs1057725	ENSG00000214391.3	TUBAP2	5.93	4.14e-09	0.00288	0.18	0.18	Intelligence (multi-trait analysis);	chr12:49128795	chr11:90282560~90284172:+
BRCA	trans	rs941207	0.526	rs2950387	ENSG00000257210.1	NACAP3	-5.93	4.14e-09	0.00288	-0.22	-0.18	Platelet count;	chr12:56627222	chr12:93124063~93124543:-
BRCA	trans	rs801193	0.636	rs10233806	ENSG00000164669.11	INTS4P1	5.93	4.14e-09	0.00288	0.22	0.18	Aortic root size;	chr7:66653261	chr7:65141225~65234216:+
BRCA	trans	rs9693857	0.52	rs4557706	ENSG00000253893.2	FAM85B	-5.93	4.15e-09	0.00289	-0.25	-0.18	Systolic blood pressure;	chr8:9499859	chr8:8167819~8226614:-
BRCA	trans	rs2055729	0.645	rs12056944	ENSG00000253893.2	FAM85B	-5.93	4.16e-09	0.0029	-0.25	-0.18	Multiple myeloma (hyperdiploidy);	chr8:9885015	chr8:8167819~8226614:-
BRCA	trans	rs7824557	0.707	rs3808519	ENSG00000254153.1	CTA-398F10.2	5.93	4.17e-09	0.0029	0.23	0.18	Retinal vascular caliber;	chr8:11285461	chr8:8456909~8461337:-
BRCA	trans	rs6831352	0.918	rs29001211	ENSG00000233859.2	ADH5P4	5.93	4.17e-09	0.0029	0.26	0.18	Alcohol dependence;	chr4:99130790	chr6:65836930~65838039:-
BRCA	trans	rs12439619	0.693	rs4778989	ENSG00000235370.6	DNM1P51	-5.93	4.18e-09	0.00291	-0.24	-0.18	Intelligence (multi-trait analysis);	chr15:82276963	chr15:84398316~84411701:-
BRCA	trans	rs6831352	0.918	rs13127582	ENSG00000233859.2	ADH5P4	5.93	4.18e-09	0.00291	0.26	0.18	Alcohol dependence;	chr4:99137043	chr6:65836930~65838039:-
BRCA	trans	rs7746199	0.673	rs72845046	ENSG00000204709.4	LINC01556	5.93	4.19e-09	0.00291	0.48	0.18	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27607489	chr6:28943877~28944537:+
BRCA	trans	rs16975963	0.545	rs12461753	ENSG00000247498.8	RP11-392P7.6	5.93	4.2e-09	0.00292	0.33	0.18	Longevity;	chr19:37711614	chr12:12927726~12984645:+
BRCA	trans	rs9860340	0.77	rs12632280	ENSG00000259370.2	RP11-1069G10.1	5.93	4.2e-09	0.00292	0.21	0.18	Electroencephalographic traits in alcoholism;	chr3:87673104	chr15:62827675~62884034:-
BRCA	trans	rs6568490	1	rs1527871	ENSG00000228057.1	SEC63P1	5.93	4.21e-09	0.00293	0.27	0.18	Lymphocyte counts;	chr6:107732702	chr1:97545701~97546958:+
BRCA	trans	rs7568458	0.66	rs6722691	ENSG00000223886.3	RP11-251G23.2	5.93	4.22e-09	0.00294	0.22	0.18	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr2:85531229	chr7:105530209~105530671:+
BRCA	trans	rs875971	1	rs778726	ENSG00000164669.11	INTS4P1	-5.93	4.22e-09	0.00294	-0.22	-0.18	Aortic root size;	chr7:66363744	chr7:65141225~65234216:+
BRCA	trans	rs875971	0.767	rs1695815	ENSG00000164669.11	INTS4P1	-5.93	4.22e-09	0.00294	-0.22	-0.18	Aortic root size;	chr7:66366357	chr7:65141225~65234216:+
BRCA	trans	rs875971	1	rs778685	ENSG00000164669.11	INTS4P1	-5.93	4.22e-09	0.00294	-0.22	-0.18	Aortic root size;	chr7:66371189	chr7:65141225~65234216:+
BRCA	trans	rs875971	0.929	rs778682	ENSG00000164669.11	INTS4P1	-5.93	4.22e-09	0.00294	-0.22	-0.18	Aortic root size;	chr7:66372947	chr7:65141225~65234216:+
BRCA	trans	rs875971	0.964	rs11765965	ENSG00000164669.11	INTS4P1	-5.93	4.22e-09	0.00294	-0.22	-0.18	Aortic root size;	chr7:66377234	chr7:65141225~65234216:+
BRCA	trans	rs10751647	0.804	rs3809112	ENSG00000213275.2	IFITM9P	-5.93	4.23e-09	0.00294	-0.21	-0.18	Monocyte count;	chr11:307036	chr11:69303412~69303807:-
BRCA	trans	rs7746199	0.736	rs13212318	ENSG00000204709.4	LINC01556	5.92	4.24e-09	0.00295	0.48	0.18	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27721062	chr6:28943877~28944537:+
BRCA	trans	rs9393777	0.623	rs2093169	ENSG00000277241.1	RP11-114M1.3	5.92	4.24e-09	0.00295	0.28	0.18	Intelligence (multi-trait analysis);	chr6:26494871	chr3:177700346~177701072:-
BRCA	trans	rs714543	0.875	rs35585318	ENSG00000214975.4	PPIAP29	-5.92	4.24e-09	0.00295	-0.21	-0.18	Plateletcrit;	chr7:44852220	chr6:24976419~24976982:+
BRCA	trans	rs9393777	0.92	rs13207689	ENSG00000204709.4	LINC01556	5.92	4.25e-09	0.00295	0.47	0.18	Intelligence (multi-trait analysis);	chr6:27401925	chr6:28943877~28944537:+
BRCA	trans	rs3750082	0.621	rs7778110	ENSG00000176826.14	FKBP9P1	5.92	4.25e-09	0.00295	0.24	0.18	Glomerular filtration rate (creatinine);	chr7:32909389	chr7:55681074~55713252:-
BRCA	trans	rs7927771	0.725	rs11039265	ENSG00000134612.10	FOLH1B	-5.92	4.26e-09	0.00296	-0.24	-0.18	Subjective well-being;	chr11:47501662	chr11:89639227~89698718:+
BRCA	trans	rs7746199	0.736	rs13193542	ENSG00000204709.4	LINC01556	5.92	4.26e-09	0.00296	0.48	0.18	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27734646	chr6:28943877~28944537:+
BRCA	trans	rs7746199	0.736	rs13193480	ENSG00000204709.4	LINC01556	5.92	4.26e-09	0.00296	0.48	0.18	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27734782	chr6:28943877~28944537:+
BRCA	trans	rs67340775	0.834	rs13218875	ENSG00000228078.1	HLA-U	-5.92	4.27e-09	0.00297	-0.48	-0.18	Lung cancer in ever smokers;	chr6:27916234	chr6:29934101~29934286:+
BRCA	trans	rs7568458	0.684	rs6731700	ENSG00000223886.3	RP11-251G23.2	5.92	4.29e-09	0.00298	0.22	0.18	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr2:85533868	chr7:105530209~105530671:+
BRCA	trans	rs9852859	0.634	rs9858244	ENSG00000261353.1	CTA-14H9.5	5.92	4.29e-09	0.00298	0.25	0.18	Body mass index;	chr3:85738249	chr6:26527063~26527404:+
BRCA	trans	rs7617773	0.78	rs34523942	ENSG00000235912.1	RP1-159A19.3	-5.92	4.3e-09	0.00299	-0.23	-0.18	Coronary artery disease;	chr3:48301179	chr1:27649419~27649610:+
BRCA	trans	rs2117029	0.619	rs10747562	ENSG00000214391.3	TUBAP2	5.92	4.32e-09	0.003	0.18	0.18	Intelligence (multi-trait analysis);	chr12:49111401	chr11:90282560~90284172:+
BRCA	trans	rs2117029	0.619	rs11168862	ENSG00000214391.3	TUBAP2	5.92	4.32e-09	0.003	0.18	0.18	Intelligence (multi-trait analysis);	chr12:49112175	chr11:90282560~90284172:+
BRCA	trans	rs7617773	0.78	rs13082859	ENSG00000235912.1	RP1-159A19.3	-5.92	4.33e-09	0.00301	-0.24	-0.18	Coronary artery disease;	chr3:48303185	chr1:27649419~27649610:+
BRCA	trans	rs7617773	0.78	rs35778847	ENSG00000235912.1	RP1-159A19.3	-5.92	4.33e-09	0.00301	-0.24	-0.18	Coronary artery disease;	chr3:48305495	chr1:27649419~27649610:+
BRCA	trans	rs7617773	0.78	rs34749846	ENSG00000235912.1	RP1-159A19.3	-5.92	4.33e-09	0.00301	-0.24	-0.18	Coronary artery disease;	chr3:48305678	chr1:27649419~27649610:+
BRCA	trans	rs7617773	0.78	rs79089926	ENSG00000235912.1	RP1-159A19.3	-5.92	4.33e-09	0.00301	-0.24	-0.18	Coronary artery disease;	chr3:48307074	chr1:27649419~27649610:+
BRCA	trans	rs1459104	1	rs12576361	ENSG00000134612.10	FOLH1B	-5.92	4.33e-09	0.00301	-0.38	-0.18	Body mass index;	chr11:55424925	chr11:89639227~89698718:+
BRCA	trans	rs11098499	0.863	rs3775841	ENSG00000253326.2	RP11-261C10.7	5.92	4.35e-09	0.00302	0.26	0.18	Corneal astigmatism;	chr4:119504622	chr1:243054861~243056394:-
BRCA	trans	rs7824557	0.701	rs2060465	ENSG00000254153.1	CTA-398F10.2	5.92	4.36e-09	0.00303	0.24	0.18	Retinal vascular caliber;	chr8:11305100	chr8:8456909~8461337:-
BRCA	trans	rs7617773	0.78	rs35297395	ENSG00000235912.1	RP1-159A19.3	-5.92	4.36e-09	0.00303	-0.24	-0.18	Coronary artery disease;	chr3:48301392	chr1:27649419~27649610:+
BRCA	trans	rs11098499	0.754	rs10213554	ENSG00000276997.3	RP11-378J18.9	-5.92	4.38e-09	0.00304	-0.22	-0.18	Corneal astigmatism;	chr4:119339630	chr1:222477252~222504622:-
BRCA	trans	rs10791097	0.694	rs1050071	ENSG00000264570.1	SNX19P3	5.92	4.39e-09	0.00304	0.21	0.18	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:130877336	chr18:14629832~14632806:-
BRCA	trans	rs10754283	0.535	rs1215507	ENSG00000268751.1	SCGB1B2P	-5.92	4.39e-09	0.00305	-0.21	-0.18	Amyotrophic lateral sclerosis (sporadic);	chr1:89623336	chr19:34576733~34577701:-
BRCA	trans	rs875971	0.545	rs316328	ENSG00000213640.3	EEF1DP4	5.92	4.4e-09	0.00305	0.24	0.18	Aortic root size;	chr7:66143851	chr7:64862999~64864370:+
BRCA	trans	rs1178101	0.851	rs1178118	ENSG00000269800.1	PLEKHA3P1	-5.92	4.4e-09	0.00305	-0.22	-0.18	Monobrow;	chr7:18712375	chr19:41521043~41521989:-
BRCA	trans	rs45509595	0.556	rs34409918	ENSG00000281831.1	HCP5B	5.92	4.4e-09	0.00306	0.46	0.18	Breast cancer;	chr6:27717569	chr6:29871895~29873783:-
BRCA	trans	rs801193	0.613	rs2659900	ENSG00000164669.11	INTS4P1	-5.92	4.4e-09	0.00306	-0.22	-0.18	Aortic root size;	chr7:66719456	chr7:65141225~65234216:+
BRCA	trans	rs7927771	1	rs11039412	ENSG00000134612.10	FOLH1B	-5.92	4.41e-09	0.00306	-0.24	-0.18	Subjective well-being;	chr11:47820029	chr11:89639227~89698718:+
BRCA	trans	rs7927771	0.965	rs11039416	ENSG00000134612.10	FOLH1B	-5.92	4.41e-09	0.00306	-0.24	-0.18	Subjective well-being;	chr11:47825159	chr11:89639227~89698718:+
BRCA	trans	rs7927771	0.965	rs35985502	ENSG00000134612.10	FOLH1B	-5.92	4.41e-09	0.00306	-0.24	-0.18	Subjective well-being;	chr11:47825876	chr11:89639227~89698718:+
BRCA	trans	rs3812762	0.833	rs10500707	ENSG00000266891.1	RP11-692N5.2	-5.92	4.41e-09	0.00306	-0.23	-0.18	Hypospadias;	chr11:8796033	chr18:9734882~9735602:-
BRCA	trans	rs11098499	0.708	rs1546506	ENSG00000276997.3	RP11-378J18.9	5.92	4.43e-09	0.00307	0.21	0.18	Corneal astigmatism;	chr4:119320085	chr1:222477252~222504622:-
BRCA	trans	rs1459104	0.925	rs35535067	ENSG00000134612.10	FOLH1B	-5.92	4.44e-09	0.00308	-0.34	-0.18	Body mass index;	chr11:55228072	chr11:89639227~89698718:+
BRCA	trans	rs12497850	0.765	rs12487580	ENSG00000197582.5	GPX1P1	5.92	4.45e-09	0.00308	0.19	0.18	Parkinson's disease;	chr3:49145499	chrX:13378735~13379340:-
BRCA	trans	rs12497850	0.797	rs61583136	ENSG00000197582.5	GPX1P1	5.92	4.45e-09	0.00308	0.19	0.18	Parkinson's disease;	chr3:49151762	chrX:13378735~13379340:-
BRCA	trans	rs11098499	0.644	rs34835603	ENSG00000120555.12	SEPT7P9	5.91	4.5e-09	0.00312	0.22	0.18	Corneal astigmatism;	chr4:119632273	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.615	rs28850368	ENSG00000120555.12	SEPT7P9	5.91	4.5e-09	0.00312	0.22	0.18	Corneal astigmatism;	chr4:119633158	chr10:38383069~38402916:-
BRCA	trans	rs875971	0.545	rs1796219	ENSG00000213640.3	EEF1DP4	5.91	4.54e-09	0.00315	0.26	0.18	Aortic root size;	chr7:66645977	chr7:64862999~64864370:+
BRCA	trans	rs45509595	0.556	rs34409918	ENSG00000204709.4	LINC01556	5.91	4.55e-09	0.00315	0.48	0.18	Breast cancer;	chr6:27717569	chr6:28943877~28944537:+
BRCA	trans	rs6831352	0.734	rs1154400	ENSG00000228407.2	RP4-800M22.1	-5.91	4.55e-09	0.00315	-0.24	-0.18	Alcohol dependence;	chr4:99088859	chr1:52160261~52160600:-
BRCA	trans	rs7927771	1	rs34128973	ENSG00000134612.10	FOLH1B	-5.91	4.55e-09	0.00315	-0.24	-0.18	Subjective well-being;	chr11:47829824	chr11:89639227~89698718:+
BRCA	trans	rs853679	0.513	rs13437444	ENSG00000253570.1	RNF5P1	5.91	4.56e-09	0.00316	0.34	0.18	Depression;	chr6:28103220	chr8:38600661~38601200:-
BRCA	trans	rs7927771	1	rs1317149	ENSG00000134612.10	FOLH1B	-5.91	4.56e-09	0.00316	-0.24	-0.18	Subjective well-being;	chr11:47465333	chr11:89639227~89698718:+
BRCA	trans	rs11098499	0.863	rs3822192	ENSG00000253326.2	RP11-261C10.7	5.91	4.57e-09	0.00316	0.26	0.18	Corneal astigmatism;	chr4:119524565	chr1:243054861~243056394:-
BRCA	trans	rs853679	0.607	rs67040724	ENSG00000228078.1	HLA-U	-5.91	4.59e-09	0.00318	-0.48	-0.18	Depression;	chr6:27937731	chr6:29934101~29934286:+
BRCA	trans	rs17507216	0.718	rs72751662	ENSG00000235370.6	DNM1P51	-5.91	4.61e-09	0.00319	-0.27	-0.18	Excessive daytime sleepiness;	chr15:82594705	chr15:84398316~84411701:-
BRCA	trans	rs11098499	0.863	rs13134665	ENSG00000253326.2	RP11-261C10.7	5.91	4.64e-09	0.00321	0.26	0.18	Corneal astigmatism;	chr4:119505275	chr1:243054861~243056394:-
BRCA	trans	rs3096299	0.967	rs2965935	ENSG00000215030.5	RPL13P12	5.91	4.64e-09	0.00322	0.18	0.18	Multiple myeloma (IgH translocation);	chr16:89414866	chr17:17383377~17384012:-
BRCA	trans	rs7824557	0.767	rs2060463	ENSG00000254153.1	CTA-398F10.2	5.91	4.66e-09	0.00322	0.24	0.18	Retinal vascular caliber;	chr8:11304101	chr8:8456909~8461337:-
BRCA	trans	rs4929949	0.752	rs11041982	ENSG00000266891.1	RP11-692N5.2	5.91	4.66e-09	0.00323	0.22	0.18	Body mass index;	chr11:8557691	chr18:9734882~9735602:-
BRCA	trans	rs4713118	0.955	rs9468201	ENSG00000204709.4	LINC01556	5.91	4.66e-09	0.00323	0.26	0.18	Parkinson's disease;	chr6:27719256	chr6:28943877~28944537:+
BRCA	trans	rs1568889	1	rs9783281	ENSG00000174912.7	METTL15P1	5.91	4.67e-09	0.00323	0.2	0.18	Bipolar disorder;	chr11:28012239	chr3:156713884~156714928:-
BRCA	trans	rs7617773	0.78	rs4511916	ENSG00000235912.1	RP1-159A19.3	-5.91	4.67e-09	0.00323	-0.24	-0.18	Coronary artery disease;	chr3:48308876	chr1:27649419~27649610:+
BRCA	trans	rs7617773	0.815	rs6793150	ENSG00000235912.1	RP1-159A19.3	-5.91	4.67e-09	0.00323	-0.24	-0.18	Coronary artery disease;	chr3:48310070	chr1:27649419~27649610:+
BRCA	trans	rs7617773	0.78	rs6793239	ENSG00000235912.1	RP1-159A19.3	-5.91	4.67e-09	0.00323	-0.24	-0.18	Coronary artery disease;	chr3:48310128	chr1:27649419~27649610:+
BRCA	trans	rs7617773	0.78	rs6782166	ENSG00000235912.1	RP1-159A19.3	-5.91	4.67e-09	0.00323	-0.24	-0.18	Coronary artery disease;	chr3:48310193	chr1:27649419~27649610:+
BRCA	trans	rs7617773	0.78	rs4130522	ENSG00000235912.1	RP1-159A19.3	-5.91	4.67e-09	0.00323	-0.24	-0.18	Coronary artery disease;	chr3:48310823	chr1:27649419~27649610:+
BRCA	trans	rs7617773	0.78	rs13081169	ENSG00000235912.1	RP1-159A19.3	-5.91	4.67e-09	0.00323	-0.24	-0.18	Coronary artery disease;	chr3:48315307	chr1:27649419~27649610:+
BRCA	trans	rs11098499	0.82	rs13122709	ENSG00000253326.2	RP11-261C10.7	5.91	4.68e-09	0.00324	0.25	0.18	Corneal astigmatism;	chr4:119634201	chr1:243054861~243056394:-
BRCA	trans	rs6831352	0.84	rs35073321	ENSG00000233859.2	ADH5P4	5.91	4.7e-09	0.00325	0.26	0.18	Alcohol dependence;	chr4:99132125	chr6:65836930~65838039:-
BRCA	trans	rs6831352	0.879	rs29001196	ENSG00000233859.2	ADH5P4	5.91	4.7e-09	0.00325	0.26	0.18	Alcohol dependence;	chr4:99132965	chr6:65836930~65838039:-
BRCA	trans	rs6831352	0.918	rs17817359	ENSG00000233859.2	ADH5P4	5.91	4.7e-09	0.00325	0.26	0.18	Alcohol dependence;	chr4:99133046	chr6:65836930~65838039:-
BRCA	trans	rs6831352	0.918	rs29001195	ENSG00000233859.2	ADH5P4	5.91	4.7e-09	0.00325	0.26	0.18	Alcohol dependence;	chr4:99133093	chr6:65836930~65838039:-
BRCA	trans	rs6831352	0.918	rs17217949	ENSG00000233859.2	ADH5P4	5.91	4.7e-09	0.00325	0.26	0.18	Alcohol dependence;	chr4:99133161	chr6:65836930~65838039:-
BRCA	trans	rs6831352	0.879	rs17218003	ENSG00000233859.2	ADH5P4	5.91	4.7e-09	0.00325	0.26	0.18	Alcohol dependence;	chr4:99133572	chr6:65836930~65838039:-
BRCA	trans	rs6831352	0.918	rs29001194	ENSG00000233859.2	ADH5P4	5.91	4.7e-09	0.00325	0.26	0.18	Alcohol dependence;	chr4:99133693	chr6:65836930~65838039:-
BRCA	trans	rs6831352	0.918	rs13143133	ENSG00000233859.2	ADH5P4	5.91	4.7e-09	0.00325	0.26	0.18	Alcohol dependence;	chr4:99133819	chr6:65836930~65838039:-
BRCA	trans	rs6831352	0.879	rs7672728	ENSG00000233859.2	ADH5P4	5.91	4.7e-09	0.00325	0.26	0.18	Alcohol dependence;	chr4:99134022	chr6:65836930~65838039:-
BRCA	trans	rs6831352	0.918	rs7689753	ENSG00000233859.2	ADH5P4	5.91	4.7e-09	0.00325	0.26	0.18	Alcohol dependence;	chr4:99134424	chr6:65836930~65838039:-
BRCA	trans	rs6831352	0.918	rs17218073	ENSG00000233859.2	ADH5P4	5.91	4.7e-09	0.00325	0.26	0.18	Alcohol dependence;	chr4:99134588	chr6:65836930~65838039:-
BRCA	trans	rs6831352	0.918	rs17218108	ENSG00000233859.2	ADH5P4	5.91	4.7e-09	0.00325	0.26	0.18	Alcohol dependence;	chr4:99134604	chr6:65836930~65838039:-
BRCA	trans	rs6831352	0.918	rs13112176	ENSG00000233859.2	ADH5P4	5.91	4.7e-09	0.00325	0.26	0.18	Alcohol dependence;	chr4:99134674	chr6:65836930~65838039:-
BRCA	trans	rs6831352	0.918	rs17218141	ENSG00000233859.2	ADH5P4	5.91	4.7e-09	0.00325	0.26	0.18	Alcohol dependence;	chr4:99134757	chr6:65836930~65838039:-
BRCA	trans	rs6831352	0.918	rs17218162	ENSG00000233859.2	ADH5P4	5.91	4.7e-09	0.00325	0.26	0.18	Alcohol dependence;	chr4:99134909	chr6:65836930~65838039:-
BRCA	trans	rs6831352	0.877	rs29001183	ENSG00000233859.2	ADH5P4	5.91	4.7e-09	0.00325	0.26	0.18	Alcohol dependence;	chr4:99135388	chr6:65836930~65838039:-
BRCA	trans	rs6831352	0.918	rs17218239	ENSG00000233859.2	ADH5P4	5.91	4.7e-09	0.00325	0.26	0.18	Alcohol dependence;	chr4:99135869	chr6:65836930~65838039:-
BRCA	trans	rs6831352	0.918	rs13133633	ENSG00000233859.2	ADH5P4	5.91	4.7e-09	0.00325	0.26	0.18	Alcohol dependence;	chr4:99137546	chr6:65836930~65838039:-
BRCA	trans	rs6831352	0.918	rs13133647	ENSG00000233859.2	ADH5P4	5.91	4.7e-09	0.00325	0.26	0.18	Alcohol dependence;	chr4:99137576	chr6:65836930~65838039:-
BRCA	trans	rs6831352	0.918	rs28987088	ENSG00000233859.2	ADH5P4	5.91	4.7e-09	0.00325	0.26	0.18	Alcohol dependence;	chr4:99137988	chr6:65836930~65838039:-
BRCA	trans	rs6831352	0.918	rs7670241	ENSG00000233859.2	ADH5P4	5.91	4.7e-09	0.00325	0.26	0.18	Alcohol dependence;	chr4:99138468	chr6:65836930~65838039:-
BRCA	trans	rs7570469	0.959	rs2902061	ENSG00000276390.1	RP1-197B17.5	-5.91	4.7e-09	0.00325	-0.23	-0.18	Response to antipsychotic treatment;	chr2:79480189	chr12:47699401~47699917:-
BRCA	trans	rs9467711	0.722	rs13201782	ENSG00000204709.4	LINC01556	5.91	4.7e-09	0.00325	0.48	0.18	Autism spectrum disorder or schizophrenia;	chr6:26650825	chr6:28943877~28944537:+
BRCA	trans	rs7568458	0.87	rs1009	ENSG00000223886.3	RP11-251G23.2	5.91	4.71e-09	0.00326	0.21	0.18	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr2:85581614	chr7:105530209~105530671:+
BRCA	trans	rs10946940	1	rs10946940	ENSG00000204709.4	LINC01556	-5.91	4.72e-09	0.00326	-0.23	-0.18	Systemic lupus erythematosus;	chr6:27592808	chr6:28943877~28944537:+
BRCA	trans	rs11098499	0.826	rs4472123	ENSG00000276997.3	RP11-378J18.9	5.91	4.72e-09	0.00327	0.21	0.18	Corneal astigmatism;	chr4:119315475	chr1:222477252~222504622:-
BRCA	trans	rs7927771	0.69	rs35496532	ENSG00000134612.10	FOLH1B	-5.91	4.72e-09	0.00327	-0.24	-0.18	Subjective well-being;	chr11:47428787	chr11:89639227~89698718:+
BRCA	trans	rs9733	0.715	rs7534124	ENSG00000180764.13	PIPSL	5.91	4.72e-09	0.00327	0.22	0.18	Tonsillectomy;	chr1:150766597	chr10:93958191~93961540:-
BRCA	trans	rs6831352	0.918	rs1126672	ENSG00000233859.2	ADH5P4	5.91	4.73e-09	0.00327	0.26	0.18	Alcohol dependence;	chr4:99126661	chr6:65836930~65838039:-
BRCA	trans	rs6831352	0.879	rs1230154	ENSG00000233859.2	ADH5P4	-5.91	4.74e-09	0.00327	-0.25	-0.18	Alcohol dependence;	chr4:99067508	chr6:65836930~65838039:-
BRCA	trans	rs853679	0.556	rs34706883	ENSG00000243753.4	HLA-L	-5.91	4.74e-09	0.00328	-0.48	-0.18	Depression;	chr6:27837477	chr6:30259584~30293014:+
BRCA	trans	rs6831352	0.918	rs7669636	ENSG00000233859.2	ADH5P4	5.91	4.75e-09	0.00328	0.26	0.18	Alcohol dependence;	chr4:99138161	chr6:65836930~65838039:-
BRCA	trans	rs7826222	0.552	rs694477	ENSG00000253893.2	FAM85B	5.91	4.75e-09	0.00328	0.32	0.18	Adiposity;	chr8:10033678	chr8:8167819~8226614:-
BRCA	trans	rs6121246	0.559	rs6121038	ENSG00000279352.1	RP11-411B10.7	5.91	4.76e-09	0.00329	0.26	0.18	Mean corpuscular hemoglobin;	chr20:31666970	chr18:14010054~14010917:+
BRCA	trans	rs546131	0.559	rs12803664	ENSG00000225531.1	RP11-196I18.3	-5.91	4.76e-09	0.00329	-0.29	-0.18	Lung disease severity in cystic fibrosis;	chr11:34830382	chr9:107116829~107117557:+
BRCA	trans	rs6940116	1	rs6940116	ENSG00000253570.1	RNF5P1	5.91	4.77e-09	0.00329	0.34	0.18	Intelligence (multi-trait analysis);Autism spectrum disorder or schizophrenia;	chr6:27740953	chr8:38600661~38601200:-
BRCA	trans	rs7746199	0.736	rs13212318	ENSG00000281831.1	HCP5B	5.9	4.77e-09	0.0033	0.46	0.18	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27721062	chr6:29871895~29873783:-
BRCA	trans	rs2220004	1	rs11231676	ENSG00000134612.10	FOLH1B	-5.9	4.78e-09	0.0033	-0.23	-0.18	Odorant perception (&beta-damascenone);	chr11:55954800	chr11:89639227~89698718:+
BRCA	trans	rs9644568	0.599	rs12679834	ENSG00000246582.2	RP11-1149O23.3	5.9	4.79e-09	0.00331	0.29	0.18	Hypertriglyceridemia;HDL cholesterol;	chr8:19962922	chr8:23224471~23230926:+
BRCA	trans	rs2117029	0.619	rs2753	ENSG00000214391.3	TUBAP2	5.9	4.79e-09	0.00331	0.17	0.18	Intelligence (multi-trait analysis);	chr12:49127889	chr11:90282560~90284172:+
BRCA	trans	rs7570469	0.689	rs17017088	ENSG00000276390.1	RP1-197B17.5	5.9	4.79e-09	0.00331	0.23	0.18	Response to antipsychotic treatment;	chr2:79428471	chr12:47699401~47699917:-
BRCA	trans	rs12545912	0.609	rs633777	ENSG00000253893.2	FAM85B	-5.9	4.81e-09	0.00332	-0.28	-0.18	Multiple myeloma (hyperdiploidy);	chr8:9942505	chr8:8167819~8226614:-
BRCA	trans	rs875971	0.545	rs75840613	ENSG00000213640.3	EEF1DP4	-5.9	4.83e-09	0.00333	-0.25	-0.18	Aortic root size;	chr7:66376399	chr7:64862999~64864370:+
BRCA	trans	rs16975963	0.644	rs78644049	ENSG00000247498.8	RP11-392P7.6	5.9	4.84e-09	0.00334	0.32	0.18	Longevity;	chr19:37622141	chr12:12927726~12984645:+
BRCA	trans	rs16975963	0.644	rs75499934	ENSG00000247498.8	RP11-392P7.6	5.9	4.84e-09	0.00334	0.32	0.18	Longevity;	chr19:37622142	chr12:12927726~12984645:+
BRCA	trans	rs1933488	0.898	rs11155895	ENSG00000180015.12	RP11-756P10.3	-5.9	4.84e-09	0.00334	-0.23	-0.18	Prostate cancer;	chr6:153100410	chr4:188738373~188739494:+
BRCA	trans	rs9649213	0.555	rs7785612	ENSG00000225169.1	BRI3P1	5.9	4.86e-09	0.00335	0.23	0.18	Prostate cancer (SNP x SNP interaction);	chr7:98304555	chr1:100213293~100213670:+
BRCA	trans	rs4713118	0.696	rs2394002	ENSG00000204709.4	LINC01556	5.9	4.87e-09	0.00336	0.25	0.18	Parkinson's disease;	chr6:27780236	chr6:28943877~28944537:+
BRCA	trans	rs7927771	1	rs10838738	ENSG00000134612.10	FOLH1B	-5.9	4.88e-09	0.00337	-0.24	-0.18	Subjective well-being;	chr11:47641497	chr11:89639227~89698718:+
BRCA	trans	rs6121246	0.559	rs6060932	ENSG00000279352.1	RP11-411B10.7	5.9	4.88e-09	0.00337	0.26	0.18	Mean corpuscular hemoglobin;	chr20:31762742	chr18:14010054~14010917:+
BRCA	trans	rs6121246	0.583	rs28815498	ENSG00000279352.1	RP11-411B10.7	5.9	4.88e-09	0.00337	0.26	0.18	Mean corpuscular hemoglobin;	chr20:31763757	chr18:14010054~14010917:+
BRCA	trans	rs6121246	0.512	rs6060938	ENSG00000279352.1	RP11-411B10.7	5.9	4.88e-09	0.00337	0.26	0.18	Mean corpuscular hemoglobin;	chr20:31775842	chr18:14010054~14010917:+
BRCA	trans	rs6121246	0.512	rs6060941	ENSG00000279352.1	RP11-411B10.7	5.9	4.88e-09	0.00337	0.26	0.18	Mean corpuscular hemoglobin;	chr20:31779580	chr18:14010054~14010917:+
BRCA	trans	rs6121246	0.559	rs6087779	ENSG00000279352.1	RP11-411B10.7	5.9	4.88e-09	0.00337	0.26	0.18	Mean corpuscular hemoglobin;	chr20:31782763	chr18:14010054~14010917:+
BRCA	trans	rs6121246	0.559	rs6060944	ENSG00000279352.1	RP11-411B10.7	5.9	4.88e-09	0.00337	0.26	0.18	Mean corpuscular hemoglobin;	chr20:31784311	chr18:14010054~14010917:+
BRCA	trans	rs4538475	0.79	rs11934811	ENSG00000187952.9	HS6ST1P1	5.9	4.88e-09	0.00337	0.27	0.18	Parkinson's disease;	chr4:15736630	chr1:21428303~21429536:+
BRCA	trans	rs34421088	0.603	rs10086064	ENSG00000253893.2	FAM85B	-5.9	4.89e-09	0.00338	-0.23	-0.18	Neuroticism;	chr8:11726332	chr8:8167819~8226614:-
BRCA	trans	rs7617773	0.817	rs936427	ENSG00000235912.1	RP1-159A19.3	5.9	4.9e-09	0.00338	0.24	0.18	Coronary artery disease;	chr3:48259584	chr1:27649419~27649610:+
BRCA	trans	rs875971	0.545	rs17138149	ENSG00000213640.3	EEF1DP4	-5.9	4.91e-09	0.00338	-0.25	-0.18	Aortic root size;	chr7:66228193	chr7:64862999~64864370:+
BRCA	trans	rs12570188	1	rs12570188	ENSG00000120055.7	C10orf95	-5.9	4.91e-09	0.00339	-0.44	-0.18	Asthma (childhood onset);	chr10:99095945	chr10:102449837~102451543:-
BRCA	trans	rs6734238	0.702	rs6731551	ENSG00000212789.4	ST13P5	5.9	4.92e-09	0.00339	0.19	0.18	Fibrinogen levels;C-reactive protein levels or total cholesterol levels (pleiotropy);Fibrinogen;C-reactive protein;White blood cell count;C-reactive protein levels;	chr2:113086976	chr11:18261982~18263091:+
BRCA	trans	rs7927771	1	rs11039426	ENSG00000134612.10	FOLH1B	-5.9	4.93e-09	0.0034	-0.24	-0.18	Subjective well-being;	chr11:47841567	chr11:89639227~89698718:+
BRCA	trans	rs7746199	0.736	rs13202291	ENSG00000281831.1	HCP5B	5.9	4.94e-09	0.0034	0.46	0.18	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27731078	chr6:29871895~29873783:-
BRCA	trans	rs7746199	0.736	rs17750424	ENSG00000281831.1	HCP5B	5.9	4.94e-09	0.0034	0.46	0.18	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27733343	chr6:29871895~29873783:-
BRCA	trans	rs7617773	0.78	rs34630841	ENSG00000235912.1	RP1-159A19.3	-5.9	4.94e-09	0.0034	-0.24	-0.18	Coronary artery disease;	chr3:48301771	chr1:27649419~27649610:+
BRCA	trans	rs1580019	0.563	rs13244332	ENSG00000213492.2	NT5C3AP1	-5.9	4.94e-09	0.0034	-0.25	-0.18	Cognitive ability;	chr7:32498067	chr4:117574512~117576174:-
BRCA	trans	rs4925540	1	rs7546342	ENSG00000226121.2	AC009487.6	5.9	4.94e-09	0.00341	0.24	0.18	Response to taxane treatment (docetaxel);	chr1:247049990	chr2:161500885~161507705:-
BRCA	trans	rs2243480	1	rs73142122	ENSG00000230295.1	RP11-458F8.2	-5.9	4.94e-09	0.00341	-0.24	-0.18	Diabetic kidney disease;	chr7:65846311	chr7:66880708~66882981:+
BRCA	trans	rs2243480	0.901	rs73142137	ENSG00000230295.1	RP11-458F8.2	-5.9	4.94e-09	0.00341	-0.24	-0.18	Diabetic kidney disease;	chr7:65878455	chr7:66880708~66882981:+
BRCA	trans	rs853679	0.607	rs34166054	ENSG00000204338.7	CYP21A1P	-5.9	4.96e-09	0.00342	-0.43	-0.18	Depression;	chr6:28098023	chr6:32005636~32008451:+
BRCA	trans	rs853679	0.607	rs13203816	ENSG00000204338.7	CYP21A1P	-5.9	4.96e-09	0.00342	-0.43	-0.18	Depression;	chr6:28111820	chr6:32005636~32008451:+
BRCA	trans	rs853679	0.556	rs34588114	ENSG00000204338.7	CYP21A1P	-5.9	4.96e-09	0.00342	-0.43	-0.18	Depression;	chr6:28112850	chr6:32005636~32008451:+
BRCA	trans	rs853679	0.607	rs68188794	ENSG00000204338.7	CYP21A1P	-5.9	4.96e-09	0.00342	-0.43	-0.18	Depression;	chr6:28112999	chr6:32005636~32008451:+
BRCA	trans	rs853679	0.546	rs34371502	ENSG00000204338.7	CYP21A1P	-5.9	4.96e-09	0.00342	-0.43	-0.18	Depression;	chr6:28113980	chr6:32005636~32008451:+
BRCA	trans	rs853679	0.607	rs66886492	ENSG00000204338.7	CYP21A1P	-5.9	4.96e-09	0.00342	-0.43	-0.18	Depression;	chr6:28121953	chr6:32005636~32008451:+
BRCA	trans	rs853679	0.607	rs35345226	ENSG00000204338.7	CYP21A1P	-5.9	4.96e-09	0.00342	-0.43	-0.18	Depression;	chr6:28123802	chr6:32005636~32008451:+
BRCA	trans	rs4925540	1	rs7512150	ENSG00000226121.2	AC009487.6	5.9	4.97e-09	0.00342	0.24	0.18	Response to taxane treatment (docetaxel);	chr1:247049024	chr2:161500885~161507705:-
BRCA	trans	rs875971	1	rs1981798	ENSG00000164669.11	INTS4P1	-5.9	4.97e-09	0.00342	-0.22	-0.18	Aortic root size;	chr7:66489916	chr7:65141225~65234216:+
BRCA	trans	rs9733	0.744	rs12125650	ENSG00000180764.13	PIPSL	5.9	4.99e-09	0.00343	0.22	0.18	Tonsillectomy;	chr1:150787698	chr10:93958191~93961540:-
BRCA	trans	rs9733	0.688	rs12725667	ENSG00000180764.13	PIPSL	5.9	4.99e-09	0.00343	0.22	0.18	Tonsillectomy;	chr1:150793594	chr10:93958191~93961540:-
BRCA	trans	rs10838687	0.736	rs3781619	ENSG00000134612.10	FOLH1B	5.9	4.99e-09	0.00344	0.28	0.18	Proinsulin levels;	chr11:47233766	chr11:89639227~89698718:+
BRCA	trans	rs690037	0.78	rs690437	ENSG00000266643.1	MIR3677	5.9	5e-09	0.00344	0.19	0.18	Optic nerve measurement (cup-to-disc ratio);Optic nerve measurement (cup area);	chr3:16339383	chr16:2270713~2270772:+
BRCA	trans	rs4879656	0.866	rs10971227	ENSG00000215007.3	DNAJA1P3	-5.9	5.02e-09	0.00346	-0.22	-0.18	Menopause (age at onset);	chr9:32934619	chrX:107351650~107352843:-
BRCA	trans	rs875971	0.545	rs17138149	ENSG00000234585.5	CCT6P3	5.9	5.02e-09	0.00346	0.19	0.18	Aortic root size;	chr7:66228193	chr7:65038354~65074713:+
BRCA	trans	rs7829975	0.509	rs7838674	ENSG00000270154.1	RP11-419I17.1	-5.9	5.03e-09	0.00346	-0.2	-0.18	Mood instability;	chr8:8939563	chr8:12476462~12477122:+
BRCA	trans	rs11098499	0.866	rs3756156	ENSG00000276805.1	RP11-291L22.6	5.9	5.04e-09	0.00347	0.22	0.18	Corneal astigmatism;	chr4:119603686	chr10:38451030~38451785:+
BRCA	trans	rs7570469	0.839	rs399885	ENSG00000276390.1	RP1-197B17.5	5.89	5.06e-09	0.00349	0.23	0.18	Response to antipsychotic treatment;	chr2:79460126	chr12:47699401~47699917:-
BRCA	trans	rs7568458	0.684	rs7593969	ENSG00000223886.3	RP11-251G23.2	-5.89	5.09e-09	0.0035	-0.22	-0.18	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr2:85582547	chr7:105530209~105530671:+
BRCA	trans	rs853679	0.607	rs71559070	ENSG00000204338.7	CYP21A1P	-5.89	5.09e-09	0.0035	-0.43	-0.18	Depression;	chr6:28071151	chr6:32005636~32008451:+
BRCA	trans	rs853679	0.607	rs35902873	ENSG00000204338.7	CYP21A1P	-5.89	5.09e-09	0.0035	-0.43	-0.18	Depression;	chr6:28091171	chr6:32005636~32008451:+
BRCA	trans	rs853679	0.607	rs13197574	ENSG00000204338.7	CYP21A1P	-5.89	5.09e-09	0.0035	-0.43	-0.18	Depression;	chr6:28092461	chr6:32005636~32008451:+
BRCA	trans	rs1864585	0.806	rs17778223	ENSG00000254153.1	CTA-398F10.2	5.89	5.1e-09	0.00351	0.24	0.18	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr8:10872182	chr8:8456909~8461337:-
BRCA	trans	rs7617773	0.78	rs77044321	ENSG00000235912.1	RP1-159A19.3	-5.89	5.1e-09	0.00351	-0.25	-0.18	Coronary artery disease;	chr3:48307824	chr1:27649419~27649610:+
BRCA	trans	rs7617773	0.743	rs13081633	ENSG00000235912.1	RP1-159A19.3	-5.89	5.1e-09	0.00351	-0.25	-0.18	Coronary artery disease;	chr3:48315791	chr1:27649419~27649610:+
BRCA	trans	rs7568458	0.66	rs6547623	ENSG00000223886.3	RP11-251G23.2	5.89	5.1e-09	0.00351	0.22	0.18	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr2:85574841	chr7:105530209~105530671:+
BRCA	trans	rs7927771	0.965	rs3817335	ENSG00000134612.10	FOLH1B	-5.89	5.11e-09	0.00352	-0.24	-0.18	Subjective well-being;	chr11:47622339	chr11:89639227~89698718:+
BRCA	trans	rs11098499	0.954	rs13145352	ENSG00000253326.2	RP11-261C10.7	-5.89	5.11e-09	0.00352	-0.25	-0.18	Corneal astigmatism;	chr4:119488808	chr1:243054861~243056394:-
BRCA	trans	rs7746199	0.736	rs13202291	ENSG00000204709.4	LINC01556	5.89	5.12e-09	0.00352	0.48	0.18	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27731078	chr6:28943877~28944537:+
BRCA	trans	rs7746199	0.736	rs17750424	ENSG00000204709.4	LINC01556	5.89	5.12e-09	0.00352	0.48	0.18	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27733343	chr6:28943877~28944537:+
BRCA	trans	rs12497850	0.931	rs62262517	ENSG00000197582.5	GPX1P1	5.89	5.13e-09	0.00353	0.19	0.18	Parkinson's disease;	chr3:49097481	chrX:13378735~13379340:-
BRCA	trans	rs6831352	0.879	rs56272995	ENSG00000233859.2	ADH5P4	5.89	5.13e-09	0.00353	0.26	0.18	Alcohol dependence;	chr4:99139731	chr6:65836930~65838039:-
BRCA	trans	rs6831352	0.879	rs56295995	ENSG00000233859.2	ADH5P4	5.89	5.13e-09	0.00353	0.26	0.18	Alcohol dependence;	chr4:99139748	chr6:65836930~65838039:-
BRCA	trans	rs11098499	0.863	rs3822190	ENSG00000253326.2	RP11-261C10.7	5.89	5.14e-09	0.00353	0.26	0.18	Corneal astigmatism;	chr4:119506943	chr1:243054861~243056394:-
BRCA	trans	rs11098499	0.863	rs3822191	ENSG00000253326.2	RP11-261C10.7	5.89	5.14e-09	0.00353	0.26	0.18	Corneal astigmatism;	chr4:119506946	chr1:243054861~243056394:-
BRCA	trans	rs902774	0.759	rs4919707	ENSG00000223940.1	KRT8P8	-5.89	5.14e-09	0.00353	-0.37	-0.18	Prostate cancer;	chr12:52895864	chrX:152479577~152481024:+
BRCA	trans	rs13261217	0.645	rs7832586	ENSG00000253200.1	RP11-582J16.5	-5.89	5.14e-09	0.00353	-0.17	-0.18	Schizophrenia;	chr8:4353224	chr8:22613908~22616657:-
BRCA	trans	rs853679	0.882	rs4713140	ENSG00000228078.1	HLA-U	-5.89	5.15e-09	0.00354	-0.36	-0.18	Depression;	chr6:28129415	chr6:29934101~29934286:+
BRCA	trans	rs11098499	0.954	rs6848389	ENSG00000253326.2	RP11-261C10.7	5.89	5.15e-09	0.00354	0.25	0.18	Corneal astigmatism;	chr4:119481467	chr1:243054861~243056394:-
BRCA	trans	rs6831352	0.918	rs13110764	ENSG00000233859.2	ADH5P4	5.89	5.16e-09	0.00355	0.26	0.18	Alcohol dependence;	chr4:99141315	chr6:65836930~65838039:-
BRCA	trans	rs6831352	0.918	rs17218288	ENSG00000233859.2	ADH5P4	5.89	5.17e-09	0.00355	0.26	0.18	Alcohol dependence;	chr4:99136879	chr6:65836930~65838039:-
BRCA	trans	rs875971	0.545	rs66594357	ENSG00000213640.3	EEF1DP4	-5.89	5.19e-09	0.00357	-0.25	-0.18	Aortic root size;	chr7:66327797	chr7:64862999~64864370:+
BRCA	trans	rs11098499	0.535	rs7671759	ENSG00000276997.3	RP11-378J18.9	5.89	5.19e-09	0.00357	0.22	0.18	Corneal astigmatism;	chr4:119326939	chr1:222477252~222504622:-
BRCA	trans	rs10838687	0.8	rs10838686	ENSG00000134612.10	FOLH1B	5.89	5.2e-09	0.00357	0.27	0.18	Proinsulin levels;	chr11:47289816	chr11:89639227~89698718:+
BRCA	trans	rs1459104	1	rs1974931	ENSG00000134612.10	FOLH1B	-5.89	5.21e-09	0.00358	-0.36	-0.18	Body mass index;	chr11:55430984	chr11:89639227~89698718:+
BRCA	trans	rs11098499	0.566	rs17051356	ENSG00000253326.2	RP11-261C10.7	5.89	5.21e-09	0.00358	0.26	0.18	Corneal astigmatism;	chr4:119664153	chr1:243054861~243056394:-
BRCA	trans	rs801193	1	rs17566701	ENSG00000164669.11	INTS4P1	-5.89	5.21e-09	0.00358	-0.22	-0.18	Aortic root size;	chr7:66728196	chr7:65141225~65234216:+
BRCA	trans	rs12210905	1	rs9368494	ENSG00000242375.1	RP11-498P14.3	-5.89	5.22e-09	0.00358	-0.37	-0.18	Hip circumference adjusted for BMI;	chr6:27269522	chr9:97195351~97197687:-
BRCA	trans	rs6831352	0.734	rs1311620	ENSG00000228407.2	RP4-800M22.1	-5.89	5.23e-09	0.00359	-0.24	-0.18	Alcohol dependence;	chr4:99091940	chr1:52160261~52160600:-
BRCA	trans	rs7617773	0.78	rs35190747	ENSG00000235912.1	RP1-159A19.3	-5.89	5.23e-09	0.00359	-0.24	-0.18	Coronary artery disease;	chr3:48301800	chr1:27649419~27649610:+
BRCA	trans	rs7617773	0.78	rs4511915	ENSG00000235912.1	RP1-159A19.3	-5.89	5.23e-09	0.00359	-0.24	-0.18	Coronary artery disease;	chr3:48302368	chr1:27649419~27649610:+
BRCA	trans	rs7617773	0.78	rs13066758	ENSG00000235912.1	RP1-159A19.3	-5.89	5.23e-09	0.00359	-0.24	-0.18	Coronary artery disease;	chr3:48302387	chr1:27649419~27649610:+
BRCA	trans	rs7617773	0.78	rs4392440	ENSG00000235912.1	RP1-159A19.3	-5.89	5.23e-09	0.00359	-0.24	-0.18	Coronary artery disease;	chr3:48302430	chr1:27649419~27649610:+
BRCA	trans	rs76228276	0.737	rs72674605	ENSG00000260318.1	COX6CP1	5.89	5.24e-09	0.0036	0.46	0.18	Childhood ear infection;	chr8:99396268	chr16:11903923~11904137:-
BRCA	trans	rs7927771	0.832	rs896816	ENSG00000134612.10	FOLH1B	5.89	5.28e-09	0.00363	0.23	0.18	Subjective well-being;	chr11:47372787	chr11:89639227~89698718:+
BRCA	trans	rs9467711	0.659	rs72844462	ENSG00000220721.1	OR1F12	5.89	5.29e-09	0.00363	0.38	0.18	Autism spectrum disorder or schizophrenia;	chr6:26563636	chr6:28073316~28074233:+
BRCA	trans	rs7824557	0.701	rs4568582	ENSG00000254153.1	CTA-398F10.2	5.89	5.29e-09	0.00363	0.24	0.18	Retinal vascular caliber;	chr8:11302986	chr8:8456909~8461337:-
BRCA	trans	rs11098499	0.754	rs7672372	ENSG00000276997.3	RP11-378J18.9	5.89	5.33e-09	0.00366	0.21	0.18	Corneal astigmatism;	chr4:119327251	chr1:222477252~222504622:-
BRCA	trans	rs4834770	1	rs4834770	ENSG00000275858.1	RP11-291L22.8	5.89	5.33e-09	0.00366	0.2	0.18	Blood protein levels;	chr4:119320694	chr10:38450738~38451069:-
BRCA	trans	rs11782517	0.92	rs4563888	ENSG00000253893.2	FAM85B	-5.89	5.33e-09	0.00366	-0.25	-0.18	Nose size;	chr8:10248151	chr8:8167819~8226614:-
BRCA	trans	rs9467711	0.651	rs2051539	ENSG00000253570.1	RNF5P1	5.89	5.34e-09	0.00366	0.44	0.18	Autism spectrum disorder or schizophrenia;	chr6:25947031	chr8:38600661~38601200:-
BRCA	trans	rs7617773	0.815	rs7624450	ENSG00000235912.1	RP1-159A19.3	-5.89	5.34e-09	0.00367	-0.24	-0.18	Coronary artery disease;	chr3:48308885	chr1:27649419~27649610:+
BRCA	trans	rs11098499	0.532	rs12512646	ENSG00000120555.12	SEPT7P9	5.89	5.35e-09	0.00367	0.22	0.18	Corneal astigmatism;	chr4:119664578	chr10:38383069~38402916:-
BRCA	trans	rs853679	0.546	rs36116761	ENSG00000243753.4	HLA-L	-5.88	5.36e-09	0.00368	-0.48	-0.18	Depression;	chr6:27850704	chr6:30259584~30293014:+
BRCA	trans	rs853679	0.546	rs34194357	ENSG00000243753.4	HLA-L	-5.88	5.36e-09	0.00368	-0.48	-0.18	Depression;	chr6:27850757	chr6:30259584~30293014:+
BRCA	trans	rs9368481	0.645	rs10456350	ENSG00000242375.1	RP11-498P14.3	5.88	5.38e-09	0.00369	0.26	0.18	Autism spectrum disorder or schizophrenia;	chr6:27007802	chr9:97195351~97197687:-
BRCA	trans	rs8177876	0.822	rs8177959	ENSG00000224837.1	GCSHP5	5.88	5.38e-09	0.00369	0.34	0.18	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81082082	chr1:168055901~168056422:-
BRCA	trans	rs6831352	0.918	rs13129488	ENSG00000233859.2	ADH5P4	5.88	5.39e-09	0.00369	0.26	0.18	Alcohol dependence;	chr4:99131874	chr6:65836930~65838039:-
BRCA	trans	rs902774	0.818	rs55999178	ENSG00000223940.1	KRT8P8	-5.88	5.39e-09	0.00369	-0.37	-0.18	Prostate cancer;	chr12:52890576	chrX:152479577~152481024:+
BRCA	trans	rs9393777	0.623	rs2093169	ENSG00000253570.1	RNF5P1	5.88	5.39e-09	0.00369	0.33	0.18	Intelligence (multi-trait analysis);	chr6:26494871	chr8:38600661~38601200:-
BRCA	trans	rs2243480	1	rs3885839	ENSG00000230295.1	RP11-458F8.2	-5.88	5.39e-09	0.00369	-0.24	-0.18	Diabetic kidney disease;	chr7:65825416	chr7:66880708~66882981:+
BRCA	trans	rs7746199	0.736	rs35848276	ENSG00000243753.4	HLA-L	-5.88	5.4e-09	0.0037	-0.48	-0.18	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27553317	chr6:30259584~30293014:+
BRCA	trans	rs660899	0.857	rs56352978	ENSG00000231007.5	CDC20P1	5.88	5.4e-09	0.0037	0.24	0.18	Hypertension risk in short sleep duration;	chr1:43765809	chr9:87011652~87013151:+
BRCA	trans	rs7746199	0.736	rs13192965	ENSG00000204709.4	LINC01556	5.88	5.4e-09	0.0037	0.47	0.18	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27704046	chr6:28943877~28944537:+
BRCA	trans	rs13217239	0.646	rs4403259	ENSG00000216901.1	AL022393.7	-5.88	5.43e-09	0.00372	-0.22	-0.18	Schizophrenia;	chr6:27029838	chr6:28176188~28176674:+
BRCA	trans	rs902774	0.818	rs73108429	ENSG00000228753.1	EIF4BP2	5.88	5.45e-09	0.00373	0.35	0.18	Prostate cancer;	chr12:52877887	chr10:21028999~21030792:+
BRCA	trans	rs7829975	0.56	rs17154599	ENSG00000270154.1	RP11-419I17.1	-5.88	5.46e-09	0.00374	-0.21	-0.18	Mood instability;	chr8:8693908	chr8:12476462~12477122:+
BRCA	trans	rs6121246	0.559	rs1484994	ENSG00000279352.1	RP11-411B10.7	5.88	5.47e-09	0.00374	0.26	0.18	Mean corpuscular hemoglobin;	chr20:31718172	chr18:14010054~14010917:+
BRCA	trans	rs4948102	0.655	rs4947533	ENSG00000186940.6	CHCHD2P9	-5.88	5.48e-09	0.00375	-0.23	-0.18	Plasma homocysteine levels (post-methionine load test);	chr7:56003589	chr9:79391304~79391759:+
BRCA	trans	rs34421088	0.532	rs2409754	ENSG00000253893.2	FAM85B	-5.88	5.5e-09	0.00376	-0.24	-0.18	Neuroticism;	chr8:11298104	chr8:8167819~8226614:-
BRCA	trans	rs6121246	0.559	rs6060857	ENSG00000279352.1	RP11-411B10.7	5.88	5.5e-09	0.00376	0.26	0.18	Mean corpuscular hemoglobin;	chr20:31712419	chr18:14010054~14010917:+
BRCA	trans	rs7568458	0.777	rs12473819	ENSG00000223886.3	RP11-251G23.2	5.88	5.5e-09	0.00376	0.21	0.18	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr2:85545938	chr7:105530209~105530671:+
BRCA	trans	rs546131	0.642	rs11605381	ENSG00000225531.1	RP11-196I18.3	-5.88	5.5e-09	0.00376	-0.29	-0.18	Lung disease severity in cystic fibrosis;	chr11:34825646	chr9:107116829~107117557:+
BRCA	trans	rs7927771	0.77	rs11039203	ENSG00000134612.10	FOLH1B	-5.88	5.52e-09	0.00378	-0.23	-0.18	Subjective well-being;	chr11:47363046	chr11:89639227~89698718:+
BRCA	trans	rs7927771	0.832	rs67116452	ENSG00000134612.10	FOLH1B	-5.88	5.52e-09	0.00378	-0.23	-0.18	Subjective well-being;	chr11:47363643	chr11:89639227~89698718:+
BRCA	trans	rs319204	1	rs2082405	ENSG00000226498.2	RP11-182B22.2	5.88	5.55e-09	0.00379	0.2	0.18	Schizophrenia;	chr5:146879033	chr1:236819634~236820518:+
BRCA	trans	rs17507216	0.588	rs28864981	ENSG00000235370.6	DNM1P51	-5.88	5.57e-09	0.00381	-0.26	-0.18	Excessive daytime sleepiness;	chr15:82695420	chr15:84398316~84411701:-
BRCA	trans	rs17507216	0.628	rs8032321	ENSG00000235370.6	DNM1P51	-5.88	5.57e-09	0.00381	-0.26	-0.18	Excessive daytime sleepiness;	chr15:82698956	chr15:84398316~84411701:-
BRCA	trans	rs17507216	0.628	rs8040488	ENSG00000235370.6	DNM1P51	-5.88	5.57e-09	0.00381	-0.26	-0.18	Excessive daytime sleepiness;	chr15:82699081	chr15:84398316~84411701:-
BRCA	trans	rs801193	0.569	rs10950050	ENSG00000224316.1	RP11-479O9.2	5.88	5.57e-09	0.00381	0.18	0.18	Aortic root size;	chr7:66774601	chr7:65773620~65802067:+
BRCA	trans	rs7927771	0.864	rs112060627	ENSG00000134612.10	FOLH1B	-5.88	5.58e-09	0.00381	-0.24	-0.18	Subjective well-being;	chr11:47405405	chr11:89639227~89698718:+
BRCA	trans	rs7927771	0.864	rs7107726	ENSG00000134612.10	FOLH1B	-5.88	5.58e-09	0.00381	-0.24	-0.18	Subjective well-being;	chr11:47407694	chr11:89639227~89698718:+
BRCA	trans	rs11098499	0.754	rs11732087	ENSG00000276997.3	RP11-378J18.9	5.88	5.59e-09	0.00382	0.21	0.18	Corneal astigmatism;	chr4:119318676	chr1:222477252~222504622:-
BRCA	trans	rs10946940	0.965	rs4713112	ENSG00000204709.4	LINC01556	-5.88	5.59e-09	0.00382	-0.23	-0.18	Systemic lupus erythematosus;	chr6:27549054	chr6:28943877~28944537:+
BRCA	trans	rs9733	0.744	rs11204725	ENSG00000180764.13	PIPSL	5.88	5.6e-09	0.00383	0.22	0.18	Tonsillectomy;	chr1:150770224	chr10:93958191~93961540:-
BRCA	trans	rs6831352	0.918	rs17218602	ENSG00000233859.2	ADH5P4	5.88	5.62e-09	0.00384	0.26	0.18	Alcohol dependence;	chr4:99139922	chr6:65836930~65838039:-
BRCA	trans	rs4929949	0.724	rs9300088	ENSG00000266891.1	RP11-692N5.2	5.88	5.64e-09	0.00385	0.22	0.18	Body mass index;	chr11:8555186	chr18:9734882~9735602:-
BRCA	trans	rs7824557	0.767	rs17797443	ENSG00000254153.1	CTA-398F10.2	5.88	5.65e-09	0.00386	0.24	0.18	Retinal vascular caliber;	chr8:11306503	chr8:8456909~8461337:-
BRCA	trans	rs6424115	0.644	rs2267960	ENSG00000228217.1	AL390877.1	-5.88	5.66e-09	0.00387	-0.22	-0.18	Immature fraction of reticulocytes;	chr1:23742054	chr1:117778087~117778506:-
BRCA	trans	rs875971	0.545	rs75840613	ENSG00000234585.5	CCT6P3	5.88	5.67e-09	0.00387	0.19	0.18	Aortic root size;	chr7:66376399	chr7:65038354~65074713:+
BRCA	trans	rs902774	0.818	rs55914512	ENSG00000223940.1	KRT8P8	-5.88	5.67e-09	0.00387	-0.37	-0.18	Prostate cancer;	chr12:52888490	chrX:152479577~152481024:+
BRCA	trans	rs902774	0.818	rs73108466	ENSG00000223940.1	KRT8P8	-5.88	5.67e-09	0.00387	-0.37	-0.18	Prostate cancer;	chr12:52889857	chrX:152479577~152481024:+
BRCA	trans	rs801193	0.967	rs3800823	ENSG00000164669.11	INTS4P1	5.88	5.68e-09	0.00388	0.22	0.18	Aortic root size;	chr7:66682123	chr7:65141225~65234216:+
BRCA	trans	rs7617773	0.746	rs4371540	ENSG00000235912.1	RP1-159A19.3	-5.88	5.68e-09	0.00388	-0.25	-0.18	Coronary artery disease;	chr3:48312053	chr1:27649419~27649610:+
BRCA	trans	rs6831352	0.879	rs29001215	ENSG00000233859.2	ADH5P4	5.87	5.71e-09	0.0039	0.26	0.18	Alcohol dependence;	chr4:99130571	chr6:65836930~65838039:-
BRCA	trans	rs6831352	0.918	rs29001214	ENSG00000233859.2	ADH5P4	5.87	5.71e-09	0.0039	0.26	0.18	Alcohol dependence;	chr4:99130582	chr6:65836930~65838039:-
BRCA	trans	rs6831352	0.879	rs29001212	ENSG00000233859.2	ADH5P4	5.87	5.71e-09	0.0039	0.26	0.18	Alcohol dependence;	chr4:99130726	chr6:65836930~65838039:-
BRCA	trans	rs3750082	0.852	rs6462425	ENSG00000176826.14	FKBP9P1	5.87	5.71e-09	0.0039	0.22	0.18	Glomerular filtration rate (creatinine);	chr7:32858983	chr7:55681074~55713252:-
BRCA	trans	rs4879656	0.735	rs10733465	ENSG00000215007.3	DNAJA1P3	-5.87	5.72e-09	0.0039	-0.23	-0.18	Menopause (age at onset);	chr9:32932196	chrX:107351650~107352843:-
BRCA	trans	rs7746199	0.736	rs35848276	ENSG00000204709.4	LINC01556	5.87	5.72e-09	0.0039	0.48	0.18	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27553317	chr6:28943877~28944537:+
BRCA	trans	rs9733	0.566	rs11204675	ENSG00000180764.13	PIPSL	5.87	5.73e-09	0.00391	0.22	0.18	Tonsillectomy;	chr1:150598509	chr10:93958191~93961540:-
BRCA	trans	rs6011368	0.765	rs7270745	ENSG00000226210.3	WASH7P	-5.87	5.74e-09	0.00392	-0.2	-0.18	Clozapine-induced cytotoxicity;	chr20:64261403	chr12:14522~32015:-
BRCA	trans	rs7840128	0.661	rs7830364	ENSG00000231177.4	LINC00852	5.87	5.75e-09	0.00392	0.41	0.18	Neurocognitive impairment in HIV-1 infection (dichotomous);	chr8:3824501	chr3:10284419~10285746:+
BRCA	trans	rs1459104	0.866	rs28822225	ENSG00000134612.10	FOLH1B	-5.87	5.76e-09	0.00393	-0.33	-0.18	Body mass index;	chr11:55051130	chr11:89639227~89698718:+
BRCA	trans	rs11098499	0.754	rs12510269	ENSG00000276997.3	RP11-378J18.9	5.87	5.79e-09	0.00395	0.21	0.18	Corneal astigmatism;	chr4:119320491	chr1:222477252~222504622:-
BRCA	trans	rs6121246	0.559	rs6060621	ENSG00000279352.1	RP11-411B10.7	5.87	5.79e-09	0.00395	0.26	0.18	Mean corpuscular hemoglobin;	chr20:31673759	chr18:14010054~14010917:+
BRCA	trans	rs9467711	0.79	rs13198716	ENSG00000281831.1	HCP5B	-5.87	5.8e-09	0.00395	-0.43	-0.18	Autism spectrum disorder or schizophrenia;	chr6:26581807	chr6:29871895~29873783:-
BRCA	trans	rs11098499	0.722	rs7673476	ENSG00000276997.3	RP11-378J18.9	5.87	5.85e-09	0.00399	0.21	0.18	Corneal astigmatism;	chr4:119327528	chr1:222477252~222504622:-
BRCA	trans	rs902774	0.818	rs73108429	ENSG00000223940.1	KRT8P8	-5.87	5.85e-09	0.00399	-0.37	-0.18	Prostate cancer;	chr12:52877887	chrX:152479577~152481024:+
BRCA	trans	rs4929949	0.809	rs10769929	ENSG00000266891.1	RP11-692N5.2	5.87	5.86e-09	0.00399	0.21	0.18	Body mass index;	chr11:8606509	chr18:9734882~9735602:-
BRCA	trans	rs7022762	1	rs7022762	ENSG00000225361.3	PPP1R26-AS1	-5.87	5.86e-09	0.00399	-0.46	-0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr9:108091224	chr9:135462727~135480777:-
BRCA	trans	rs7824557	0.836	rs765731	ENSG00000254153.1	CTA-398F10.2	-5.87	5.86e-09	0.004	-0.24	-0.18	Retinal vascular caliber;	chr8:11263989	chr8:8456909~8461337:-
BRCA	trans	rs9834975	0.544	rs2332285	ENSG00000267076.1	CCDC58P3	5.87	5.87e-09	0.004	0.2	0.18	Diastolic blood pressure;	chr3:122569363	chr18:12211378~12211807:+
BRCA	trans	rs7089973	0.641	rs12772737	ENSG00000249267.5	LINC00939	5.87	5.87e-09	0.004	0.22	0.18	Bipolar disorder or attention deficit hyperactivity disorder;	chr10:114981742	chr12:125958688~125983374:-
BRCA	trans	rs9467711	0.606	rs35076545	ENSG00000220721.1	OR1F12	5.87	5.88e-09	0.00401	0.38	0.18	Autism spectrum disorder or schizophrenia;	chr6:26603696	chr6:28073316~28074233:+
BRCA	trans	rs9467711	0.651	rs72832596	ENSG00000253570.1	RNF5P1	5.87	5.89e-09	0.00401	0.44	0.18	Autism spectrum disorder or schizophrenia;	chr6:25962723	chr8:38600661~38601200:-
BRCA	trans	rs3740713	0.669	rs34740438	ENSG00000213574.2	LDHAP5	5.87	5.92e-09	0.00403	0.31	0.18	Amyotrophic lateral sclerosis (sporadic);	chr11:18393783	chr10:118932674~118933295:-
BRCA	trans	rs7570469	0.762	rs6714400	ENSG00000276390.1	RP1-197B17.5	5.87	5.95e-09	0.00405	0.23	0.18	Response to antipsychotic treatment;	chr2:79428391	chr12:47699401~47699917:-
BRCA	trans	rs9393777	0.623	rs9358946	ENSG00000277241.1	RP11-114M1.3	5.87	5.96e-09	0.00406	0.28	0.18	Intelligence (multi-trait analysis);	chr6:26478699	chr3:177700346~177701072:-
BRCA	trans	rs9393777	0.623	rs9358947	ENSG00000277241.1	RP11-114M1.3	5.87	5.96e-09	0.00406	0.28	0.18	Intelligence (multi-trait analysis);	chr6:26478772	chr3:177700346~177701072:-
BRCA	trans	rs9329221	0.537	rs6986911	ENSG00000154316.13	TDH	-5.87	5.97e-09	0.00407	-0.22	-0.18	Neuroticism;	chr8:10121013	chr8:11339637~11368452:+
BRCA	trans	rs4713118	0.869	rs7773070	ENSG00000204709.4	LINC01556	5.87	5.97e-09	0.00407	0.25	0.18	Parkinson's disease;	chr6:27761048	chr6:28943877~28944537:+
BRCA	trans	rs4759042	0.527	rs1044931	ENSG00000121089.4	NACA3P	-5.87	5.99e-09	0.00408	-0.21	-0.18	Migraine;	chr12:57056027	chr4:164943290~164943937:+
BRCA	trans	rs6831352	0.819	rs1154401	ENSG00000228407.2	RP4-800M22.1	-5.87	6e-09	0.00409	-0.23	-0.18	Alcohol dependence;	chr4:99088587	chr1:52160261~52160600:-
BRCA	trans	rs35146811	0.659	rs863450	ENSG00000228546.2	CTA-313A17.3	5.87	6.02e-09	0.0041	0.25	0.18	Coronary artery disease;	chr7:100224062	chr7:102337316~102339115:+
BRCA	trans	rs853679	0.546	rs35819751	ENSG00000228078.1	HLA-U	-5.87	6.02e-09	0.0041	-0.48	-0.18	Depression;	chr6:27842791	chr6:29934101~29934286:+
BRCA	trans	rs7826238	0.539	rs2945891	ENSG00000270154.1	RP11-419I17.1	5.86	6.03e-09	0.0041	0.21	0.18	Systolic blood pressure;	chr8:8297953	chr8:12476462~12477122:+
BRCA	trans	rs853679	0.556	rs34706883	ENSG00000281831.1	HCP5B	5.86	6.05e-09	0.00412	0.45	0.18	Depression;	chr6:27837477	chr6:29871895~29873783:-
BRCA	trans	rs7824557	0.806	rs10503418	ENSG00000254153.1	CTA-398F10.2	-5.86	6.07e-09	0.00413	-0.23	-0.18	Retinal vascular caliber;	chr8:11261474	chr8:8456909~8461337:-
BRCA	trans	rs902774	0.818	rs4919742	ENSG00000228753.1	EIF4BP2	5.86	6.08e-09	0.00414	0.36	0.18	Prostate cancer;	chr12:52879180	chr10:21028999~21030792:+
BRCA	trans	rs11098499	0.863	rs13136462	ENSG00000276805.1	RP11-291L22.6	5.86	6.08e-09	0.00414	0.21	0.18	Corneal astigmatism;	chr4:119622018	chr10:38451030~38451785:+
BRCA	trans	rs2950393	0.572	rs10783794	ENSG00000257210.1	NACAP3	-5.86	6.1e-09	0.00415	-0.21	-0.18	Platelet distribution width;	chr12:56593395	chr12:93124063~93124543:-
BRCA	trans	rs7927771	1	rs4752873	ENSG00000134612.10	FOLH1B	-5.86	6.1e-09	0.00415	-0.24	-0.18	Subjective well-being;	chr11:47835968	chr11:89639227~89698718:+
BRCA	trans	rs11098499	0.754	rs2036860	ENSG00000276997.3	RP11-378J18.9	5.86	6.1e-09	0.00415	0.21	0.18	Corneal astigmatism;	chr4:119327779	chr1:222477252~222504622:-
BRCA	trans	rs875971	0.545	rs10950036	ENSG00000213640.3	EEF1DP4	-5.86	6.11e-09	0.00416	-0.25	-0.18	Aortic root size;	chr7:66353241	chr7:64862999~64864370:+
BRCA	trans	rs12210905	0.92	rs9393802	ENSG00000242375.1	RP11-498P14.3	-5.86	6.11e-09	0.00416	-0.36	-0.18	Hip circumference adjusted for BMI;	chr6:27275326	chr9:97195351~97197687:-
BRCA	trans	rs11098499	0.691	rs9996644	ENSG00000276997.3	RP11-378J18.9	5.86	6.12e-09	0.00416	0.21	0.18	Corneal astigmatism;	chr4:119317722	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.691	rs9996494	ENSG00000276997.3	RP11-378J18.9	5.86	6.12e-09	0.00416	0.21	0.18	Corneal astigmatism;	chr4:119317725	chr1:222477252~222504622:-
BRCA	trans	rs6121246	0.559	rs6121172	ENSG00000279352.1	RP11-411B10.7	5.86	6.12e-09	0.00416	0.26	0.18	Mean corpuscular hemoglobin;	chr20:31708292	chr18:14010054~14010917:+
BRCA	trans	rs1568889	1	rs7933332	ENSG00000174912.7	METTL15P1	5.86	6.13e-09	0.00417	0.19	0.18	Bipolar disorder;	chr11:28014845	chr3:156713884~156714928:-
BRCA	trans	rs1568889	1	rs6484346	ENSG00000174912.7	METTL15P1	5.86	6.13e-09	0.00417	0.19	0.18	Bipolar disorder;	chr11:28019220	chr3:156713884~156714928:-
BRCA	trans	rs875971	0.545	rs1796217	ENSG00000234585.5	CCT6P3	-5.86	6.16e-09	0.00419	-0.19	-0.18	Aortic root size;	chr7:66620931	chr7:65038354~65074713:+
BRCA	trans	rs9858542	0.953	rs6997	ENSG00000197582.5	GPX1P1	-5.86	6.17e-09	0.00419	-0.2	-0.18	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49416401	chrX:13378735~13379340:-
BRCA	trans	rs11638815	0.906	rs4779048	ENSG00000235370.6	DNM1P51	5.86	6.19e-09	0.0042	0.23	0.18	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82692911	chr15:84398316~84411701:-
BRCA	trans	rs11638815	0.954	rs4779049	ENSG00000235370.6	DNM1P51	5.86	6.19e-09	0.0042	0.23	0.18	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82693022	chr15:84398316~84411701:-
BRCA	trans	rs853679	0.556	rs45509595	ENSG00000243753.4	HLA-L	-5.86	6.19e-09	0.00421	-0.49	-0.18	Depression;	chr6:27873148	chr6:30259584~30293014:+
BRCA	trans	rs11098499	0.954	rs9993199	ENSG00000276805.1	RP11-291L22.6	-5.86	6.2e-09	0.00421	-0.21	-0.18	Corneal astigmatism;	chr4:119471718	chr10:38451030~38451785:+
BRCA	trans	rs1459104	1	rs12789864	ENSG00000134612.10	FOLH1B	5.86	6.21e-09	0.00422	0.35	0.18	Body mass index;	chr11:55429735	chr11:89639227~89698718:+
BRCA	trans	rs4879656	0.872	rs10758180	ENSG00000215007.3	DNAJA1P3	-5.86	6.22e-09	0.00422	-0.21	-0.18	Menopause (age at onset);	chr9:33045149	chrX:107351650~107352843:-
BRCA	trans	rs11098499	0.566	rs7664440	ENSG00000276805.1	RP11-291L22.6	5.86	6.23e-09	0.00423	0.22	0.18	Corneal astigmatism;	chr4:119657385	chr10:38451030~38451785:+
BRCA	trans	rs4883201	0.611	rs1805727	ENSG00000179899.8	PHC1P1	-5.86	6.23e-09	0.00423	-0.23	-0.18	Total cholesterol levels;Cholesterol, total;	chr12:8944802	chr12:55411727~55414787:-
BRCA	trans	rs9393777	0.92	rs67859638	ENSG00000243753.4	HLA-L	-5.86	6.24e-09	0.00424	-0.49	-0.18	Intelligence (multi-trait analysis);	chr6:27390199	chr6:30259584~30293014:+
BRCA	trans	rs66887589	0.616	rs13113885	ENSG00000120555.12	SEPT7P9	5.86	6.24e-09	0.00424	0.21	0.18	Diastolic blood pressure;	chr4:119300021	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.604	rs2389886	ENSG00000253326.2	RP11-261C10.7	5.86	6.25e-09	0.00424	0.26	0.18	Corneal astigmatism;	chr4:119649267	chr1:243054861~243056394:-
BRCA	trans	rs76228276	0.737	rs16897302	ENSG00000260318.1	COX6CP1	5.86	6.25e-09	0.00424	0.45	0.18	Childhood ear infection;	chr8:99351561	chr16:11903923~11904137:-
BRCA	trans	rs2965280	0.793	rs16969161	ENSG00000270983.1	RP11-137J7.3	-5.86	6.26e-09	0.00425	-0.42	-0.18	Colorectal cancer;	chr19:34287205	chr6:142062717~142063053:+
BRCA	trans	rs6831352	0.918	rs29001201	ENSG00000233859.2	ADH5P4	5.86	6.27e-09	0.00426	0.26	0.18	Alcohol dependence;	chr4:99132710	chr6:65836930~65838039:-
BRCA	trans	rs35306767	0.953	rs11253520	ENSG00000187984.11	ANKRD19P	-5.86	6.27e-09	0.00426	-0.19	-0.18	Eosinophil percentage of granulocytes;	chr10:930021	chr9:92809388~92888693:+
BRCA	trans	rs7824557	0.843	rs2736375	ENSG00000254153.1	CTA-398F10.2	-5.86	6.27e-09	0.00426	-0.23	-0.18	Retinal vascular caliber;	chr8:11258240	chr8:8456909~8461337:-
BRCA	trans	rs7746199	0.736	rs17693963	ENSG00000204709.4	LINC01556	5.86	6.28e-09	0.00426	0.43	0.18	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27742386	chr6:28943877~28944537:+
BRCA	trans	rs17507216	0.718	rs7165690	ENSG00000235370.6	DNM1P51	-5.86	6.3e-09	0.00427	-0.26	-0.18	Excessive daytime sleepiness;	chr15:82654804	chr15:84398316~84411701:-
BRCA	trans	rs853679	0.607	rs13194781	ENSG00000281831.1	HCP5B	5.86	6.3e-09	0.00427	0.46	0.18	Depression;	chr6:27847861	chr6:29871895~29873783:-
BRCA	trans	rs1459104	0.929	rs2017467	ENSG00000134612.10	FOLH1B	-5.86	6.3e-09	0.00428	-0.36	-0.18	Body mass index;	chr11:55467129	chr11:89639227~89698718:+
BRCA	trans	rs1459104	1	rs35882309	ENSG00000134612.10	FOLH1B	-5.86	6.3e-09	0.00428	-0.36	-0.18	Body mass index;	chr11:55469988	chr11:89639227~89698718:+
BRCA	trans	rs6601327	0.613	rs12677507	ENSG00000253893.2	FAM85B	5.86	6.3e-09	0.00428	0.23	0.18	Multiple myeloma (hyperdiploidy);	chr8:9624177	chr8:8167819~8226614:-
BRCA	trans	rs875971	0.545	rs221986	ENSG00000234585.5	CCT6P3	-5.86	6.33e-09	0.00429	-0.2	-0.18	Aortic root size;	chr7:66105323	chr7:65038354~65074713:+
BRCA	trans	rs12497850	0.543	rs6446218	ENSG00000197582.5	GPX1P1	5.86	6.33e-09	0.0043	0.19	0.18	Parkinson's disease;	chr3:49038080	chrX:13378735~13379340:-
BRCA	trans	rs9467711	0.659	rs36033628	ENSG00000281831.1	HCP5B	5.86	6.34e-09	0.0043	0.43	0.18	Autism spectrum disorder or schizophrenia;	chr6:26455846	chr6:29871895~29873783:-
BRCA	trans	rs902774	0.818	rs56095813	ENSG00000230716.3	KRT8P7	-5.86	6.36e-09	0.00431	-0.37	-0.18	Prostate cancer;	chr12:52900963	chr11:119602875~119604306:-
BRCA	trans	rs2117029	0.555	rs10747561	ENSG00000214391.3	TUBAP2	5.86	6.36e-09	0.00431	0.17	0.18	Intelligence (multi-trait analysis);	chr12:49106726	chr11:90282560~90284172:+
BRCA	trans	rs902774	0.759	rs4919707	ENSG00000224520.2	KRT8P45	-5.86	6.36e-09	0.00431	-0.37	-0.18	Prostate cancer;	chr12:52895864	chr1:157073257~157074703:+
BRCA	trans	rs2242330	1	rs10017445	ENSG00000226982.4	CENPCP1	5.86	6.37e-09	0.00432	0.26	0.18	Parkinson's disease;	chr4:67558069	chr12:89500093~89502670:+
BRCA	trans	rs1459104	1	rs35453180	ENSG00000134612.10	FOLH1B	-5.86	6.37e-09	0.00432	-0.36	-0.18	Body mass index;	chr11:55557439	chr11:89639227~89698718:+
BRCA	trans	rs11098499	0.754	rs7672594	ENSG00000276997.3	RP11-378J18.9	5.86	6.38e-09	0.00432	0.21	0.18	Corneal astigmatism;	chr4:119327388	chr1:222477252~222504622:-
BRCA	trans	rs6831352	0.589	rs2602836	ENSG00000233859.2	ADH5P4	5.85	6.41e-09	0.00434	0.22	0.18	Alcohol dependence;	chr4:99093654	chr6:65836930~65838039:-
BRCA	trans	rs9858542	0.953	rs6779524	ENSG00000197582.5	GPX1P1	-5.85	6.42e-09	0.00435	-0.2	-0.18	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49413016	chrX:13378735~13379340:-
BRCA	trans	rs11098499	0.954	rs12499324	ENSG00000276805.1	RP11-291L22.6	5.85	6.42e-09	0.00435	0.21	0.18	Corneal astigmatism;	chr4:119472631	chr10:38451030~38451785:+
BRCA	trans	rs7570469	0.762	rs417597	ENSG00000276390.1	RP1-197B17.5	5.85	6.43e-09	0.00436	0.23	0.18	Response to antipsychotic treatment;	chr2:79462184	chr12:47699401~47699917:-
BRCA	trans	rs6831352	0.959	rs6532796	ENSG00000233859.2	ADH5P4	5.85	6.45e-09	0.00437	0.25	0.18	Alcohol dependence;	chr4:99121091	chr6:65836930~65838039:-
BRCA	trans	rs7568458	0.846	rs6738645	ENSG00000223886.3	RP11-251G23.2	5.85	6.45e-09	0.00437	0.2	0.18	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr2:85556005	chr7:105530209~105530671:+
BRCA	trans	rs875971	0.545	rs313828	ENSG00000234585.5	CCT6P3	-5.85	6.47e-09	0.00438	-0.2	-0.18	Aortic root size;	chr7:66087627	chr7:65038354~65074713:+
BRCA	trans	rs9649213	0.574	rs7802541	ENSG00000225169.1	BRI3P1	5.85	6.48e-09	0.00439	0.23	0.18	Prostate cancer (SNP x SNP interaction);	chr7:98304543	chr1:100213293~100213670:+
BRCA	trans	rs16975963	0.644	rs12462505	ENSG00000247498.8	RP11-392P7.6	5.85	6.48e-09	0.00439	0.31	0.18	Longevity;	chr19:37647224	chr12:12927726~12984645:+
BRCA	trans	rs10946940	0.965	rs6456799	ENSG00000204709.4	LINC01556	-5.85	6.49e-09	0.0044	-0.23	-0.18	Systemic lupus erythematosus;	chr6:27605757	chr6:28943877~28944537:+
BRCA	trans	rs6121246	0.559	rs6060933	ENSG00000279352.1	RP11-411B10.7	5.85	6.51e-09	0.00441	0.26	0.18	Mean corpuscular hemoglobin;	chr20:31764100	chr18:14010054~14010917:+
BRCA	trans	rs4713118	0.786	rs200503	ENSG00000204709.4	LINC01556	5.85	6.52e-09	0.00442	0.26	0.18	Parkinson's disease;	chr6:27818104	chr6:28943877~28944537:+
BRCA	trans	rs4713118	0.786	rs200502	ENSG00000204709.4	LINC01556	5.85	6.52e-09	0.00442	0.26	0.18	Parkinson's disease;	chr6:27820284	chr6:28943877~28944537:+
BRCA	trans	rs7617773	0.743	rs7621785	ENSG00000235912.1	RP1-159A19.3	-5.85	6.54e-09	0.00443	-0.24	-0.18	Coronary artery disease;	chr3:48302218	chr1:27649419~27649610:+
BRCA	trans	rs7570469	0.762	rs1986232	ENSG00000276390.1	RP1-197B17.5	5.85	6.54e-09	0.00443	0.23	0.18	Response to antipsychotic treatment;	chr2:79421942	chr12:47699401~47699917:-
BRCA	trans	rs4713118	0.824	rs2179095	ENSG00000204709.4	LINC01556	-5.85	6.54e-09	0.00443	-0.25	-0.18	Parkinson's disease;	chr6:27783079	chr6:28943877~28944537:+
BRCA	trans	rs902774	0.818	rs55999178	ENSG00000224520.2	KRT8P45	-5.85	6.54e-09	0.00443	-0.37	-0.18	Prostate cancer;	chr12:52890576	chr1:157073257~157074703:+
BRCA	trans	rs7746199	0.736	rs13210634	ENSG00000243753.4	HLA-L	-5.85	6.56e-09	0.00444	-0.47	-0.18	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27678713	chr6:30259584~30293014:+
BRCA	trans	rs7746199	0.736	rs13215275	ENSG00000243753.4	HLA-L	-5.85	6.56e-09	0.00444	-0.47	-0.18	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27679730	chr6:30259584~30293014:+
BRCA	trans	rs7746199	0.736	rs17749927	ENSG00000243753.4	HLA-L	-5.85	6.56e-09	0.00444	-0.47	-0.18	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27702197	chr6:30259584~30293014:+
BRCA	trans	rs2235573	0.789	rs4821733	ENSG00000258501.1	EIF3LP1	5.85	6.57e-09	0.00445	0.19	0.18	Glioma;Glioblastoma;	chr22:38053387	chr14:81916231~81917888:+
BRCA	trans	rs1459104	1	rs34696917	ENSG00000134612.10	FOLH1B	-5.85	6.58e-09	0.00446	-0.34	-0.18	Body mass index;	chr11:55423463	chr11:89639227~89698718:+
BRCA	trans	rs12509991	0.901	rs4382051	ENSG00000262298.1	RP5-1107A17.3	5.85	6.6e-09	0.00447	0.25	0.18	Response to Homoharringtonine (cytotoxicity);	chr4:126080653	chr17:56939932~56941275:+
BRCA	trans	rs7570469	0.806	rs723933	ENSG00000276390.1	RP1-197B17.5	-5.85	6.64e-09	0.00449	-0.23	-0.18	Response to antipsychotic treatment;	chr2:79485407	chr12:47699401~47699917:-
BRCA	trans	rs902774	0.818	rs55999178	ENSG00000228753.1	EIF4BP2	5.85	6.64e-09	0.0045	0.35	0.18	Prostate cancer;	chr12:52890576	chr10:21028999~21030792:+
BRCA	trans	rs875971	1	rs10215948	ENSG00000164669.11	INTS4P1	5.85	6.65e-09	0.0045	0.22	0.18	Aortic root size;	chr7:66282799	chr7:65141225~65234216:+
BRCA	trans	rs1945213	0.527	rs17543683	ENSG00000134612.10	FOLH1B	-5.85	6.66e-09	0.0045	-0.31	-0.18	Acute lymphoblastic leukemia (childhood);	chr11:56389513	chr11:89639227~89698718:+
BRCA	trans	rs6831352	1	rs6831352	ENSG00000233859.2	ADH5P4	-5.85	6.67e-09	0.00452	-0.25	-0.18	Alcohol dependence;	chr4:99142374	chr6:65836930~65838039:-
BRCA	trans	rs6831352	0.879	rs36034266	ENSG00000233859.2	ADH5P4	5.85	6.69e-09	0.00453	0.26	0.18	Alcohol dependence;	chr4:99140237	chr6:65836930~65838039:-
BRCA	trans	rs546131	0.642	rs11603751	ENSG00000225531.1	RP11-196I18.3	-5.85	6.7e-09	0.00453	-0.29	-0.18	Lung disease severity in cystic fibrosis;	chr11:34799262	chr9:107116829~107117557:+
BRCA	trans	rs1459104	0.641	rs12790762	ENSG00000134612.10	FOLH1B	-5.85	6.74e-09	0.00455	-0.33	-0.18	Body mass index;	chr11:55166233	chr11:89639227~89698718:+
BRCA	trans	rs11098499	0.754	rs1546503	ENSG00000276997.3	RP11-378J18.9	5.85	6.74e-09	0.00456	0.21	0.18	Corneal astigmatism;	chr4:119320012	chr1:222477252~222504622:-
BRCA	trans	rs875971	0.545	rs73148639	ENSG00000213640.3	EEF1DP4	-5.85	6.74e-09	0.00456	-0.25	-0.18	Aortic root size;	chr7:66390342	chr7:64862999~64864370:+
BRCA	trans	rs867371	0.929	rs7173852	ENSG00000259295.5	CSPG4P12	-5.85	6.75e-09	0.00457	-0.22	-0.18	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82169512	chr15:85191438~85213905:+
BRCA	trans	rs7568458	0.811	rs1446668	ENSG00000223886.3	RP11-251G23.2	5.85	6.76e-09	0.00457	0.21	0.18	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr2:85537837	chr7:105530209~105530671:+
BRCA	trans	rs7647973	0.621	rs3774800	ENSG00000197582.5	GPX1P1	-5.85	6.76e-09	0.00457	-0.18	-0.18	Menarche (age at onset);	chr3:49297335	chrX:13378735~13379340:-
BRCA	trans	rs902774	0.818	rs55914512	ENSG00000224520.2	KRT8P45	-5.84	6.78e-09	0.00458	-0.37	-0.18	Prostate cancer;	chr12:52888490	chr1:157073257~157074703:+
BRCA	trans	rs902774	0.818	rs73108466	ENSG00000224520.2	KRT8P45	-5.84	6.78e-09	0.00458	-0.37	-0.18	Prostate cancer;	chr12:52889857	chr1:157073257~157074703:+
BRCA	trans	rs801193	0.66	rs2659914	ENSG00000164669.11	INTS4P1	-5.84	6.79e-09	0.00459	-0.22	-0.18	Aortic root size;	chr7:66691927	chr7:65141225~65234216:+
BRCA	trans	rs801193	0.591	rs2707839	ENSG00000164669.11	INTS4P1	-5.84	6.79e-09	0.00459	-0.22	-0.18	Aortic root size;	chr7:66728097	chr7:65141225~65234216:+
BRCA	trans	rs9467711	0.659	rs35277236	ENSG00000220721.1	OR1F12	5.84	6.81e-09	0.0046	0.38	0.18	Autism spectrum disorder or schizophrenia;	chr6:26562041	chr6:28073316~28074233:+
BRCA	trans	rs9393777	0.778	rs67457459	ENSG00000253570.1	RNF5P1	5.84	6.82e-09	0.00461	0.4	0.18	Intelligence (multi-trait analysis);	chr6:27230564	chr8:38600661~38601200:-
BRCA	trans	rs801193	0.636	rs2659895	ENSG00000164669.11	INTS4P1	-5.84	6.83e-09	0.00461	-0.22	-0.18	Aortic root size;	chr7:66731484	chr7:65141225~65234216:+
BRCA	trans	rs902774	0.818	rs4919737	ENSG00000224520.2	KRT8P45	-5.84	6.83e-09	0.00462	-0.36	-0.18	Prostate cancer;	chr12:52877011	chr1:157073257~157074703:+
BRCA	trans	rs7927771	0.689	rs10734557	ENSG00000134612.10	FOLH1B	5.84	6.9e-09	0.00466	0.23	0.18	Subjective well-being;	chr11:47358510	chr11:89639227~89698718:+
BRCA	trans	rs17742757	0.521	rs2736324	ENSG00000253893.2	FAM85B	-5.84	6.9e-09	0.00466	-0.23	-0.18	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:11470673	chr8:8167819~8226614:-
BRCA	trans	rs4713118	0.824	rs9468223	ENSG00000204709.4	LINC01556	5.84	6.92e-09	0.00467	0.25	0.18	Parkinson's disease;	chr6:27772887	chr6:28943877~28944537:+
BRCA	trans	rs4713118	0.866	rs2179094	ENSG00000204709.4	LINC01556	5.84	6.92e-09	0.00467	0.25	0.18	Parkinson's disease;	chr6:27774046	chr6:28943877~28944537:+
BRCA	trans	rs4925540	1	rs56884994	ENSG00000226121.2	AC009487.6	5.84	6.94e-09	0.00469	0.24	0.18	Response to taxane treatment (docetaxel);	chr1:247047755	chr2:161500885~161507705:-
BRCA	trans	rs11098499	0.82	rs28394116	ENSG00000276805.1	RP11-291L22.6	5.84	6.94e-09	0.00469	0.21	0.18	Corneal astigmatism;	chr4:119603128	chr10:38451030~38451785:+
BRCA	trans	rs875971	0.545	rs1796222	ENSG00000213640.3	EEF1DP4	5.84	6.96e-09	0.0047	0.25	0.18	Aortic root size;	chr7:66592167	chr7:64862999~64864370:+
BRCA	trans	rs2048656	0.605	rs13249234	ENSG00000253893.2	FAM85B	-5.84	6.97e-09	0.00471	-0.24	-0.18	Schizophrenia;	chr8:9792891	chr8:8167819~8226614:-
BRCA	trans	rs11098499	0.754	rs12506610	ENSG00000276997.3	RP11-378J18.9	5.84	6.98e-09	0.00471	0.21	0.18	Corneal astigmatism;	chr4:119320504	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.743	rs10003567	ENSG00000276997.3	RP11-378J18.9	5.84	6.98e-09	0.00471	0.21	0.18	Corneal astigmatism;	chr4:119320519	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.754	rs10006259	ENSG00000276997.3	RP11-378J18.9	5.84	6.98e-09	0.00471	0.21	0.18	Corneal astigmatism;	chr4:119320990	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.754	rs28652763	ENSG00000276997.3	RP11-378J18.9	5.84	6.98e-09	0.00471	0.21	0.18	Corneal astigmatism;	chr4:119321157	chr1:222477252~222504622:-
BRCA	trans	rs9467711	0.659	rs34246779	ENSG00000220721.1	OR1F12	5.84	6.99e-09	0.00471	0.38	0.18	Autism spectrum disorder or schizophrenia;	chr6:26548984	chr6:28073316~28074233:+
BRCA	trans	rs71537559	1	rs71537559	ENSG00000204709.4	LINC01556	5.84	6.99e-09	0.00472	0.43	0.18	Squamous cell lung carcinoma;	chr6:27342000	chr6:28943877~28944537:+
BRCA	trans	rs2066819	1	rs17118403	ENSG00000273654.1	CTB-52I2.4	5.84	6.99e-09	0.00472	0.46	0.18	Psoriasis vulgaris;	chr12:56236283	chr19:18022403~18032099:+
BRCA	trans	rs2066819	1	rs17118409	ENSG00000273654.1	CTB-52I2.4	5.84	6.99e-09	0.00472	0.46	0.18	Psoriasis vulgaris;	chr12:56236980	chr19:18022403~18032099:+
BRCA	trans	rs6121246	0.559	rs10439608	ENSG00000279352.1	RP11-411B10.7	5.84	7.03e-09	0.00474	0.26	0.18	Mean corpuscular hemoglobin;	chr20:31671011	chr18:14010054~14010917:+
BRCA	trans	rs9542236	0.807	rs9542855	ENSG00000276768.1	RP5-1116H23.5	5.84	7.05e-09	0.00475	0.19	0.18	Age-related macular degeneration;	chr13:31264030	chr20:5049857~5050321:-
BRCA	trans	rs10946940	0.93	rs12215012	ENSG00000204709.4	LINC01556	-5.84	7.07e-09	0.00477	-0.23	-0.18	Systemic lupus erythematosus;	chr6:27539715	chr6:28943877~28944537:+
BRCA	trans	rs11098499	0.789	rs9991166	ENSG00000276997.3	RP11-378J18.9	5.84	7.07e-09	0.00477	0.21	0.18	Corneal astigmatism;	chr4:119316696	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.708	rs10005237	ENSG00000276997.3	RP11-378J18.9	5.84	7.07e-09	0.00477	0.21	0.18	Corneal astigmatism;	chr4:119316742	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.754	rs10213267	ENSG00000276997.3	RP11-378J18.9	5.84	7.07e-09	0.00477	0.21	0.18	Corneal astigmatism;	chr4:119317919	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.754	rs10212775	ENSG00000276997.3	RP11-378J18.9	5.84	7.07e-09	0.00477	0.21	0.18	Corneal astigmatism;	chr4:119318089	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.754	rs2964	ENSG00000276997.3	RP11-378J18.9	5.84	7.07e-09	0.00477	0.21	0.18	Corneal astigmatism;	chr4:119318976	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.754	rs1511025	ENSG00000276997.3	RP11-378J18.9	5.84	7.07e-09	0.00477	0.21	0.18	Corneal astigmatism;	chr4:119319083	chr1:222477252~222504622:-
BRCA	trans	rs7746199	0.736	rs13210634	ENSG00000204709.4	LINC01556	5.84	7.08e-09	0.00477	0.47	0.18	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27678713	chr6:28943877~28944537:+
BRCA	trans	rs7746199	0.736	rs13215275	ENSG00000204709.4	LINC01556	5.84	7.08e-09	0.00477	0.47	0.18	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27679730	chr6:28943877~28944537:+
BRCA	trans	rs7746199	0.736	rs17749927	ENSG00000204709.4	LINC01556	5.84	7.08e-09	0.00477	0.47	0.18	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27702197	chr6:28943877~28944537:+
BRCA	trans	rs12477438	0.539	rs12999417	ENSG00000276576.1	MRPL30P1	-5.84	7.08e-09	0.00477	-0.22	-0.18	Chronic sinus infection;	chr2:99249085	chr6:57029521~57029988:+
BRCA	trans	rs11098499	0.954	rs7436506	ENSG00000276805.1	RP11-291L22.6	5.84	7.11e-09	0.00479	0.21	0.18	Corneal astigmatism;	chr4:119472614	chr10:38451030~38451785:+
BRCA	trans	rs9858542	0.953	rs3811699	ENSG00000197582.5	GPX1P1	-5.84	7.12e-09	0.0048	-0.2	-0.18	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49358927	chrX:13378735~13379340:-
BRCA	trans	rs10838687	0.736	rs4647741	ENSG00000134612.10	FOLH1B	5.84	7.12e-09	0.0048	0.28	0.18	Proinsulin levels;	chr11:47232459	chr11:89639227~89698718:+
BRCA	trans	rs11098499	0.663	rs9996501	ENSG00000276997.3	RP11-378J18.9	5.84	7.12e-09	0.0048	0.21	0.18	Corneal astigmatism;	chr4:119317763	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.697	rs28458294	ENSG00000276997.3	RP11-378J18.9	5.84	7.12e-09	0.0048	0.21	0.18	Corneal astigmatism;	chr4:119317769	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.663	rs28369503	ENSG00000276997.3	RP11-378J18.9	5.84	7.12e-09	0.0048	0.21	0.18	Corneal astigmatism;	chr4:119317770	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.82	rs13122709	ENSG00000276805.1	RP11-291L22.6	5.84	7.14e-09	0.00481	0.21	0.18	Corneal astigmatism;	chr4:119634201	chr10:38451030~38451785:+
BRCA	trans	rs9462846	0.802	rs1819324	ENSG00000231579.3	RPL7P21	5.84	7.16e-09	0.00483	0.25	0.18	Blood protein levels;	chr6:42891985	chr5:143332605~143333239:+
BRCA	trans	rs875971	0.964	rs778708	ENSG00000164669.11	INTS4P1	-5.84	7.17e-09	0.00483	-0.22	-0.18	Aortic root size;	chr7:66391332	chr7:65141225~65234216:+
BRCA	trans	rs4925540	1	rs1112137	ENSG00000226121.2	AC009487.6	5.83	7.19e-09	0.00485	0.23	0.18	Response to taxane treatment (docetaxel);	chr1:247052073	chr2:161500885~161507705:-
BRCA	trans	rs2066819	1	rs78495928	ENSG00000273654.1	CTB-52I2.4	5.83	7.2e-09	0.00485	0.46	0.18	Psoriasis vulgaris;	chr12:56241296	chr19:18022403~18032099:+
BRCA	trans	rs2066819	1	rs59626664	ENSG00000273654.1	CTB-52I2.4	5.83	7.2e-09	0.00485	0.46	0.18	Psoriasis vulgaris;	chr12:56243191	chr19:18022403~18032099:+
BRCA	trans	rs2066819	1	rs74673257	ENSG00000273654.1	CTB-52I2.4	5.83	7.2e-09	0.00485	0.46	0.18	Psoriasis vulgaris;	chr12:56244293	chr19:18022403~18032099:+
BRCA	trans	rs2066819	1	rs117683816	ENSG00000273654.1	CTB-52I2.4	5.83	7.2e-09	0.00485	0.46	0.18	Psoriasis vulgaris;	chr12:56244483	chr19:18022403~18032099:+
BRCA	trans	rs2066819	1	rs75265219	ENSG00000273654.1	CTB-52I2.4	5.83	7.2e-09	0.00485	0.46	0.18	Psoriasis vulgaris;	chr12:56246557	chr19:18022403~18032099:+
BRCA	trans	rs2066819	1	rs79718165	ENSG00000273654.1	CTB-52I2.4	5.83	7.2e-09	0.00485	0.46	0.18	Psoriasis vulgaris;	chr12:56250467	chr19:18022403~18032099:+
BRCA	trans	rs9467711	0.659	rs72845428	ENSG00000220721.1	OR1F12	5.83	7.2e-09	0.00485	0.38	0.18	Autism spectrum disorder or schizophrenia;	chr6:26549916	chr6:28073316~28074233:+
BRCA	trans	rs13217239	0.646	rs10946897	ENSG00000216901.1	AL022393.7	-5.83	7.22e-09	0.00486	-0.22	-0.18	Schizophrenia;	chr6:27027472	chr6:28176188~28176674:+
BRCA	trans	rs9858542	0.953	rs9878943	ENSG00000197582.5	GPX1P1	-5.83	7.22e-09	0.00486	-0.2	-0.18	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49397221	chrX:13378735~13379340:-
BRCA	trans	rs860295	0.58	rs867549	ENSG00000241627.3	UBQLN4P1	-5.83	7.23e-09	0.00487	-0.2	-0.18	Body mass index;	chr1:155910368	chr3:148985868~148987668:-
BRCA	trans	rs1459104	1	rs59570125	ENSG00000134612.10	FOLH1B	-5.83	7.23e-09	0.00487	-0.34	-0.18	Body mass index;	chr11:55412581	chr11:89639227~89698718:+
BRCA	trans	rs11098499	0.754	rs878372	ENSG00000276997.3	RP11-378J18.9	5.83	7.25e-09	0.00488	0.21	0.18	Corneal astigmatism;	chr4:119317625	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.532	rs4504231	ENSG00000120555.12	SEPT7P9	5.83	7.26e-09	0.00489	0.22	0.18	Corneal astigmatism;	chr4:119665736	chr10:38383069~38402916:-
BRCA	trans	rs17507216	0.718	rs72751657	ENSG00000235370.6	DNM1P51	-5.83	7.27e-09	0.00489	-0.27	-0.18	Excessive daytime sleepiness;	chr15:82581259	chr15:84398316~84411701:-
BRCA	trans	rs9858542	0.953	rs9814873	ENSG00000197582.5	GPX1P1	-5.83	7.28e-09	0.0049	-0.2	-0.18	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49416679	chrX:13378735~13379340:-
BRCA	trans	rs7570469	0.762	rs6754949	ENSG00000276390.1	RP1-197B17.5	5.83	7.3e-09	0.00491	0.23	0.18	Response to antipsychotic treatment;	chr2:79430993	chr12:47699401~47699917:-
BRCA	trans	rs853679	0.769	rs17720293	ENSG00000281831.1	HCP5B	5.83	7.3e-09	0.00491	0.39	0.18	Depression;	chr6:28246920	chr6:29871895~29873783:-
BRCA	trans	rs6593122	0.575	rs1526758	ENSG00000225484.5	NUTM2B-AS1	5.83	7.31e-09	0.00492	0.27	0.18	Vaccine-related adverse events;	chr7:54027058	chr10:79663088~79826594:-
BRCA	trans	rs7927771	1	rs4752857	ENSG00000134612.10	FOLH1B	-5.83	7.31e-09	0.00492	-0.24	-0.18	Subjective well-being;	chr11:47634200	chr11:89639227~89698718:+
BRCA	trans	rs902774	0.818	rs56095813	ENSG00000240668.1	KRT8P36	-5.83	7.33e-09	0.00493	-0.37	-0.18	Prostate cancer;	chr12:52900963	chr3:138101478~138102917:-
BRCA	trans	rs11098499	0.863	rs3733525	ENSG00000253326.2	RP11-261C10.7	5.83	7.33e-09	0.00493	0.25	0.18	Corneal astigmatism;	chr4:119525893	chr1:243054861~243056394:-
BRCA	trans	rs11098499	0.863	rs3775847	ENSG00000253326.2	RP11-261C10.7	5.83	7.33e-09	0.00493	0.25	0.18	Corneal astigmatism;	chr4:119526487	chr1:243054861~243056394:-
BRCA	trans	rs11098499	0.863	rs3775848	ENSG00000253326.2	RP11-261C10.7	5.83	7.33e-09	0.00493	0.25	0.18	Corneal astigmatism;	chr4:119526569	chr1:243054861~243056394:-
BRCA	trans	rs853679	0.607	rs13211507	ENSG00000228078.1	HLA-U	-5.83	7.34e-09	0.00494	-0.45	-0.18	Depression;	chr6:28289600	chr6:29934101~29934286:+
BRCA	trans	rs853679	0.607	rs34691223	ENSG00000228078.1	HLA-U	-5.83	7.34e-09	0.00494	-0.45	-0.18	Depression;	chr6:28290431	chr6:29934101~29934286:+
BRCA	trans	rs6831352	0.801	rs2602897	ENSG00000233859.2	ADH5P4	-5.83	7.34e-09	0.00494	-0.25	-0.18	Alcohol dependence;	chr4:99125142	chr6:65836930~65838039:-
BRCA	trans	rs6831352	0.918	rs29001232	ENSG00000233859.2	ADH5P4	5.83	7.34e-09	0.00494	0.25	0.18	Alcohol dependence;	chr4:99125503	chr6:65836930~65838039:-
BRCA	trans	rs6831352	0.918	rs29001231	ENSG00000233859.2	ADH5P4	5.83	7.34e-09	0.00494	0.25	0.18	Alcohol dependence;	chr4:99125529	chr6:65836930~65838039:-
BRCA	trans	rs875971	1	rs778696	ENSG00000164669.11	INTS4P1	-5.83	7.35e-09	0.00494	-0.22	-0.18	Aortic root size;	chr7:66405826	chr7:65141225~65234216:+
BRCA	trans	rs875971	1	rs778694	ENSG00000164669.11	INTS4P1	-5.83	7.35e-09	0.00494	-0.22	-0.18	Aortic root size;	chr7:66406571	chr7:65141225~65234216:+
BRCA	trans	rs875971	1	rs4718344	ENSG00000164669.11	INTS4P1	-5.83	7.35e-09	0.00494	-0.22	-0.18	Aortic root size;	chr7:66409394	chr7:65141225~65234216:+
BRCA	trans	rs875971	0.737	rs7803424	ENSG00000164669.11	INTS4P1	-5.83	7.35e-09	0.00494	-0.22	-0.18	Aortic root size;	chr7:66415618	chr7:65141225~65234216:+
BRCA	trans	rs875971	0.83	rs7799834	ENSG00000164669.11	INTS4P1	-5.83	7.35e-09	0.00494	-0.22	-0.18	Aortic root size;	chr7:66415707	chr7:65141225~65234216:+
BRCA	trans	rs3740713	1	rs73436668	ENSG00000236090.2	LDHAP3	5.83	7.37e-09	0.00495	0.34	0.18	Amyotrophic lateral sclerosis (sporadic);	chr11:18421546	chr2:41819747~41820754:+
BRCA	trans	rs11122895	0.509	rs6708131	ENSG00000233673.5	ANAPC1P1	5.83	7.38e-09	0.00496	0.2	0.18	Allergic sensitization;	chr2:111688082	chr2:86861825~86922693:+
BRCA	trans	rs11666377	0.83	rs7256009	ENSG00000197320.5	AC060834.2	5.83	7.38e-09	0.00496	0.26	0.18	Brain lesion load;	chr19:16992129	chr7:9726241~9728272:+
BRCA	trans	rs12497850	0.864	rs4279134	ENSG00000197582.5	GPX1P1	5.83	7.4e-09	0.00497	0.19	0.18	Parkinson's disease;	chr3:49119243	chrX:13378735~13379340:-
BRCA	trans	rs546131	0.642	rs58210900	ENSG00000225531.1	RP11-196I18.3	-5.83	7.4e-09	0.00498	-0.29	-0.18	Lung disease severity in cystic fibrosis;	chr11:34816500	chr9:107116829~107117557:+
BRCA	trans	rs546131	0.642	rs61881104	ENSG00000225531.1	RP11-196I18.3	-5.83	7.4e-09	0.00498	-0.29	-0.18	Lung disease severity in cystic fibrosis;	chr11:34816836	chr9:107116829~107117557:+
BRCA	trans	rs546131	0.642	rs7131074	ENSG00000225531.1	RP11-196I18.3	-5.83	7.4e-09	0.00498	-0.29	-0.18	Lung disease severity in cystic fibrosis;	chr11:34817558	chr9:107116829~107117557:+
BRCA	trans	rs11098499	0.863	rs7664986	ENSG00000253326.2	RP11-261C10.7	5.83	7.41e-09	0.00498	0.25	0.18	Corneal astigmatism;	chr4:119508797	chr1:243054861~243056394:-
BRCA	trans	rs11098499	0.818	rs10008791	ENSG00000253326.2	RP11-261C10.7	5.83	7.41e-09	0.00498	0.25	0.18	Corneal astigmatism;	chr4:119510314	chr1:243054861~243056394:-
BRCA	trans	rs11098499	0.863	rs11736416	ENSG00000253326.2	RP11-261C10.7	5.83	7.41e-09	0.00498	0.25	0.18	Corneal astigmatism;	chr4:119510506	chr1:243054861~243056394:-
BRCA	trans	rs4925540	0.928	rs10924895	ENSG00000226121.2	AC009487.6	5.83	7.41e-09	0.00498	0.24	0.18	Response to taxane treatment (docetaxel);	chr1:247033301	chr2:161500885~161507705:-
BRCA	trans	rs481331	0.741	rs683538	ENSG00000253739.1	U6	-5.83	7.41e-09	0.00498	-0.25	-0.18	Systemic juvenile idiopathic arthritis;	chr10:42653406	chr8:38166012~38166118:-
BRCA	trans	rs9393777	0.778	rs13219354	ENSG00000253570.1	RNF5P1	5.83	7.41e-09	0.00498	0.4	0.18	Intelligence (multi-trait analysis);	chr6:27217885	chr8:38600661~38601200:-
BRCA	trans	rs11098499	0.954	rs10008459	ENSG00000276805.1	RP11-291L22.6	5.83	7.47e-09	0.00502	0.21	0.18	Corneal astigmatism;	chr4:119473076	chr10:38451030~38451785:+
BRCA	trans	rs11098499	0.863	rs7699064	ENSG00000253326.2	RP11-261C10.7	-5.83	7.49e-09	0.00503	-0.25	-0.18	Corneal astigmatism;	chr4:119507154	chr1:243054861~243056394:-
BRCA	trans	rs4883201	0.536	rs2377676	ENSG00000179899.8	PHC1P1	-5.83	7.51e-09	0.00504	-0.23	-0.18	Total cholesterol levels;Cholesterol, total;	chr12:8978211	chr12:55411727~55414787:-
BRCA	trans	rs11098499	0.644	rs10009566	ENSG00000276997.3	RP11-378J18.9	5.83	7.51e-09	0.00504	0.21	0.18	Corneal astigmatism;	chr4:119637453	chr1:222477252~222504622:-
BRCA	trans	rs11638815	0.668	rs1877242	ENSG00000259774.1	RP11-182J1.13	5.83	7.51e-09	0.00505	0.22	0.18	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82728706	chr15:84422618~84425882:+
BRCA	trans	rs13217239	0.646	rs35691005	ENSG00000216901.1	AL022393.7	-5.83	7.55e-09	0.00507	-0.22	-0.18	Schizophrenia;	chr6:27004291	chr6:28176188~28176674:+
BRCA	trans	rs13217239	0.646	rs10946891	ENSG00000216901.1	AL022393.7	-5.83	7.55e-09	0.00507	-0.22	-0.18	Schizophrenia;	chr6:27005436	chr6:28176188~28176674:+
BRCA	trans	rs13217239	0.646	rs12201393	ENSG00000216901.1	AL022393.7	-5.83	7.55e-09	0.00507	-0.22	-0.18	Schizophrenia;	chr6:27007911	chr6:28176188~28176674:+
BRCA	trans	rs875971	1	rs11971949	ENSG00000164669.11	INTS4P1	5.83	7.58e-09	0.00509	0.22	0.18	Aortic root size;	chr7:66161027	chr7:65141225~65234216:+
BRCA	trans	rs875971	1	rs7781698	ENSG00000164669.11	INTS4P1	-5.83	7.6e-09	0.0051	-0.22	-0.18	Aortic root size;	chr7:66431325	chr7:65141225~65234216:+
BRCA	trans	rs11098499	0.754	rs12513083	ENSG00000276997.3	RP11-378J18.9	5.83	7.6e-09	0.0051	0.21	0.18	Corneal astigmatism;	chr4:119328457	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.754	rs12509621	ENSG00000276997.3	RP11-378J18.9	5.83	7.6e-09	0.0051	0.21	0.18	Corneal astigmatism;	chr4:119328505	chr1:222477252~222504622:-
BRCA	trans	rs9467711	0.722	rs13201782	ENSG00000220721.1	OR1F12	5.82	7.61e-09	0.00511	0.42	0.18	Autism spectrum disorder or schizophrenia;	chr6:26650825	chr6:28073316~28074233:+
BRCA	trans	rs9860340	0.77	rs56202453	ENSG00000259370.2	RP11-1069G10.1	5.82	7.63e-09	0.00512	0.21	0.18	Electroencephalographic traits in alcoholism;	chr3:87676162	chr15:62827675~62884034:-
BRCA	trans	rs902774	0.818	rs56095813	ENSG00000220378.3	KRT8P42	-5.82	7.63e-09	0.00512	-0.38	-0.18	Prostate cancer;	chr12:52900963	chr6:134296997~134298695:-
BRCA	trans	rs9860340	0.853	rs4859093	ENSG00000259370.2	RP11-1069G10.1	5.82	7.66e-09	0.00514	0.2	0.18	Electroencephalographic traits in alcoholism;	chr3:87695160	chr15:62827675~62884034:-
BRCA	trans	rs13217239	0.646	rs12209886	ENSG00000216901.1	AL022393.7	-5.82	7.67e-09	0.00515	-0.21	-0.18	Schizophrenia;	chr6:27016978	chr6:28176188~28176674:+
BRCA	trans	rs6940638	0.531	rs12211984	ENSG00000216901.1	AL022393.7	-5.82	7.67e-09	0.00515	-0.21	-0.18	Intelligence (multi-trait analysis);	chr6:27018275	chr6:28176188~28176674:+
BRCA	trans	rs853679	0.607	rs13199906	ENSG00000228078.1	HLA-U	-5.82	7.68e-09	0.00515	-0.48	-0.18	Depression;	chr6:27866361	chr6:29934101~29934286:+
BRCA	trans	rs7829975	0.56	rs17154599	ENSG00000227888.4	FAM66A	-5.82	7.69e-09	0.00516	-0.22	-0.18	Mood instability;	chr8:8693908	chr8:12362019~12388296:+
BRCA	trans	rs4713118	0.868	rs2893928	ENSG00000204709.4	LINC01556	5.82	7.69e-09	0.00516	0.26	0.18	Parkinson's disease;	chr6:27770651	chr6:28943877~28944537:+
BRCA	trans	rs7927771	0.864	rs3781625	ENSG00000134612.10	FOLH1B	-5.82	7.7e-09	0.00516	-0.23	-0.18	Subjective well-being;	chr11:47421529	chr11:89639227~89698718:+
BRCA	trans	rs11638815	0.603	rs7171180	ENSG00000235370.6	DNM1P51	5.82	7.7e-09	0.00516	0.19	0.18	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82640357	chr15:84398316~84411701:-
BRCA	trans	rs10946940	0.896	rs12208078	ENSG00000204709.4	LINC01556	-5.82	7.7e-09	0.00516	-0.23	-0.18	Systemic lupus erythematosus;	chr6:27530802	chr6:28943877~28944537:+
BRCA	trans	rs1864585	0.806	rs17778223	ENSG00000245281.5	CTD-2547L16.1	5.82	7.71e-09	0.00517	0.23	0.18	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr8:10872182	chr8:18084868~18096394:+
BRCA	trans	rs7662987	0.517	rs2602882	ENSG00000233859.2	ADH5P4	-5.82	7.72e-09	0.00518	-0.26	-0.18	Smoking initiation;	chr4:99119614	chr6:65836930~65838039:-
BRCA	trans	rs7662987	0.517	rs2602883	ENSG00000233859.2	ADH5P4	-5.82	7.72e-09	0.00518	-0.26	-0.18	Smoking initiation;	chr4:99119763	chr6:65836930~65838039:-
BRCA	trans	rs875971	0.545	rs10950029	ENSG00000213640.3	EEF1DP4	-5.82	7.74e-09	0.00519	-0.25	-0.18	Aortic root size;	chr7:66169334	chr7:64862999~64864370:+
BRCA	trans	rs9393777	0.623	rs7756567	ENSG00000277241.1	RP11-114M1.3	5.82	7.76e-09	0.0052	0.27	0.18	Intelligence (multi-trait analysis);	chr6:26481414	chr3:177700346~177701072:-
BRCA	trans	rs9393777	0.623	rs9358948	ENSG00000277241.1	RP11-114M1.3	5.82	7.76e-09	0.0052	0.27	0.18	Intelligence (multi-trait analysis);	chr6:26483578	chr3:177700346~177701072:-
BRCA	trans	rs853679	0.567	rs16894091	ENSG00000228078.1	HLA-U	5.82	7.79e-09	0.00522	0.26	0.18	Depression;	chr6:28422360	chr6:29934101~29934286:+
BRCA	trans	rs853679	0.607	rs13199772	ENSG00000228078.1	HLA-U	-5.82	7.8e-09	0.00523	-0.48	-0.18	Depression;	chr6:27866307	chr6:29934101~29934286:+
BRCA	trans	rs641862	1	rs641862	ENSG00000274605.1	RP11-12G12.7	5.82	7.81e-09	0.00523	0.37	0.18	Obesity-related traits;	chr13:110137885	chr13:100086031~100088848:-
BRCA	trans	rs9467711	0.659	rs36162392	ENSG00000220721.1	OR1F12	5.82	7.82e-09	0.00524	0.38	0.18	Autism spectrum disorder or schizophrenia;	chr6:26568907	chr6:28073316~28074233:+
BRCA	trans	rs66887589	0.616	rs11098498	ENSG00000276997.3	RP11-378J18.9	5.82	7.84e-09	0.00525	0.2	0.18	Diastolic blood pressure;	chr4:119265964	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.954	rs12506546	ENSG00000276805.1	RP11-291L22.6	5.82	7.84e-09	0.00525	0.21	0.18	Corneal astigmatism;	chr4:119380463	chr10:38451030~38451785:+
BRCA	trans	rs7568458	0.709	rs2043675	ENSG00000223886.3	RP11-251G23.2	-5.82	7.87e-09	0.00527	-0.22	-0.18	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr2:85542852	chr7:105530209~105530671:+
BRCA	trans	rs875971	0.964	rs778723	ENSG00000164669.11	INTS4P1	-5.82	7.88e-09	0.00528	-0.22	-0.18	Aortic root size;	chr7:66364510	chr7:65141225~65234216:+
BRCA	trans	rs35146811	0.625	rs2906645	ENSG00000228546.2	CTA-313A17.3	5.82	7.9e-09	0.00529	0.25	0.18	Coronary artery disease;	chr7:100220236	chr7:102337316~102339115:+
BRCA	trans	rs35146811	0.735	rs858506	ENSG00000228546.2	CTA-313A17.3	5.82	7.9e-09	0.00529	0.25	0.18	Coronary artery disease;	chr7:100222427	chr7:102337316~102339115:+
BRCA	trans	rs35146811	0.695	rs858508	ENSG00000228546.2	CTA-313A17.3	5.82	7.9e-09	0.00529	0.25	0.18	Coronary artery disease;	chr7:100223758	chr7:102337316~102339115:+
BRCA	trans	rs12439619	0.705	rs17354185	ENSG00000235370.6	DNM1P51	5.82	7.9e-09	0.00529	0.26	0.18	Intelligence (multi-trait analysis);	chr15:82133829	chr15:84398316~84411701:-
BRCA	trans	rs902774	0.818	rs4919763	ENSG00000223940.1	KRT8P8	-5.82	7.9e-09	0.00529	-0.37	-0.18	Prostate cancer;	chr12:52885839	chrX:152479577~152481024:+
BRCA	trans	rs9858542	0.953	rs11711485	ENSG00000197582.5	GPX1P1	-5.82	7.9e-09	0.00529	-0.21	-0.18	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49454550	chrX:13378735~13379340:-
BRCA	trans	rs2243480	1	rs4149468	ENSG00000164669.11	INTS4P1	5.82	7.91e-09	0.0053	0.35	0.18	Diabetic kidney disease;	chr7:66360703	chr7:65141225~65234216:+
BRCA	trans	rs12497850	0.864	rs3212	ENSG00000197582.5	GPX1P1	5.82	7.91e-09	0.0053	0.19	0.18	Parkinson's disease;	chr3:49108308	chrX:13378735~13379340:-
BRCA	trans	rs12497850	0.864	rs4513485	ENSG00000197582.5	GPX1P1	5.82	7.92e-09	0.0053	0.19	0.18	Parkinson's disease;	chr3:49102533	chrX:13378735~13379340:-
BRCA	trans	rs7927771	0.864	rs55927797	ENSG00000134612.10	FOLH1B	-5.82	7.94e-09	0.00532	-0.23	-0.18	Subjective well-being;	chr11:47424741	chr11:89639227~89698718:+
BRCA	trans	rs4366490	0.534	rs7109114	ENSG00000186676.3	EEF1GP1	5.82	7.95e-09	0.00532	0.28	0.18	Conotruncal heart defects;	chr11:63043691	chr7:125033453~125035301:+
BRCA	trans	rs941207	0.526	rs4759028	ENSG00000257210.1	NACAP3	5.82	7.96e-09	0.00533	0.21	0.18	Platelet count;	chr12:56686399	chr12:93124063~93124543:-
BRCA	trans	rs7829975	0.606	rs891570	ENSG00000270154.1	RP11-419I17.1	-5.82	7.98e-09	0.00534	-0.2	-0.18	Mood instability;	chr8:8936944	chr8:12476462~12477122:+
BRCA	trans	rs34421088	0.506	rs2409755	ENSG00000253893.2	FAM85B	-5.82	7.98e-09	0.00534	-0.23	-0.18	Neuroticism;	chr8:11312474	chr8:8167819~8226614:-
BRCA	trans	rs4925540	1	rs12122290	ENSG00000226121.2	AC009487.6	5.82	8.01e-09	0.00536	0.23	0.18	Response to taxane treatment (docetaxel);	chr1:247052508	chr2:161500885~161507705:-
BRCA	trans	rs4925540	0.89	rs12118487	ENSG00000226121.2	AC009487.6	5.82	8.01e-09	0.00536	0.23	0.18	Response to taxane treatment (docetaxel);	chr1:247052540	chr2:161500885~161507705:-
BRCA	trans	rs2921073	0.605	rs2976933	ENSG00000255046.1	RP11-297N6.4	-5.82	8.02e-09	0.00536	-0.21	-0.18	Parkinson's disease;	chr8:8397365	chr8:11797928~11802568:-
BRCA	trans	rs11098499	0.954	rs17006190	ENSG00000276805.1	RP11-291L22.6	5.82	8.03e-09	0.00537	0.21	0.18	Corneal astigmatism;	chr4:119497683	chr10:38451030~38451785:+
BRCA	trans	rs16975963	0.644	rs73035158	ENSG00000247498.8	RP11-392P7.6	5.82	8.04e-09	0.00538	0.31	0.18	Longevity;	chr19:37650979	chr12:12927726~12984645:+
BRCA	trans	rs7570469	0.726	rs1669060	ENSG00000276390.1	RP1-197B17.5	5.82	8.05e-09	0.00538	0.23	0.18	Response to antipsychotic treatment;	chr2:79464297	chr12:47699401~47699917:-
BRCA	trans	rs1568889	1	rs35343234	ENSG00000174912.7	METTL15P1	5.81	8.06e-09	0.00539	0.2	0.18	Bipolar disorder;	chr11:28012832	chr3:156713884~156714928:-
BRCA	trans	rs7746199	0.736	rs13192965	ENSG00000243753.4	HLA-L	-5.81	8.07e-09	0.0054	-0.47	-0.18	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27704046	chr6:30259584~30293014:+
BRCA	trans	rs546131	0.642	rs35617374	ENSG00000225531.1	RP11-196I18.3	-5.81	8.08e-09	0.0054	-0.29	-0.18	Lung disease severity in cystic fibrosis;	chr11:34810826	chr9:107116829~107117557:+
BRCA	trans	rs66887589	0.616	rs11731675	ENSG00000276997.3	RP11-378J18.9	5.81	8.08e-09	0.00541	0.2	0.18	Diastolic blood pressure;	chr4:119291359	chr1:222477252~222504622:-
BRCA	trans	rs10838687	0.8	rs10838689	ENSG00000134612.10	FOLH1B	5.81	8.09e-09	0.00541	0.27	0.18	Proinsulin levels;	chr11:47312973	chr11:89639227~89698718:+
BRCA	trans	rs9733	0.744	rs2039590	ENSG00000180764.13	PIPSL	5.81	8.09e-09	0.00541	0.22	0.18	Tonsillectomy;	chr1:150840839	chr10:93958191~93961540:-
BRCA	trans	rs2243480	1	rs34815098	ENSG00000232546.1	RP11-458F8.1	-5.81	8.11e-09	0.00542	-0.23	-0.18	Diabetic kidney disease;	chr7:65827267	chr7:66848496~66858136:+
BRCA	trans	rs2243480	1	rs35735127	ENSG00000232546.1	RP11-458F8.1	-5.81	8.11e-09	0.00542	-0.23	-0.18	Diabetic kidney disease;	chr7:65835436	chr7:66848496~66858136:+
BRCA	trans	rs2243480	0.901	rs35256305	ENSG00000232546.1	RP11-458F8.1	-5.81	8.11e-09	0.00542	-0.23	-0.18	Diabetic kidney disease;	chr7:65841418	chr7:66848496~66858136:+
BRCA	trans	rs2243480	0.803	rs34004500	ENSG00000232546.1	RP11-458F8.1	-5.81	8.11e-09	0.00542	-0.23	-0.18	Diabetic kidney disease;	chr7:65847191	chr7:66848496~66858136:+
BRCA	trans	rs2117029	0.521	rs1056875	ENSG00000214391.3	TUBAP2	5.81	8.11e-09	0.00542	0.17	0.18	Intelligence (multi-trait analysis);	chr12:49186397	chr11:90282560~90284172:+
BRCA	trans	rs16975963	0.644	rs11666662	ENSG00000247498.8	RP11-392P7.6	-5.81	8.11e-09	0.00542	-0.31	-0.18	Longevity;	chr19:37663801	chr12:12927726~12984645:+
BRCA	trans	rs9467711	0.659	rs36033628	ENSG00000220721.1	OR1F12	5.81	8.11e-09	0.00542	0.39	0.18	Autism spectrum disorder or schizophrenia;	chr6:26455846	chr6:28073316~28074233:+
BRCA	trans	rs6831352	0.879	rs29001229	ENSG00000233859.2	ADH5P4	5.81	8.12e-09	0.00543	0.25	0.18	Alcohol dependence;	chr4:99125672	chr6:65836930~65838039:-
BRCA	trans	rs902774	0.818	rs4919742	ENSG00000224520.2	KRT8P45	-5.81	8.12e-09	0.00543	-0.37	-0.18	Prostate cancer;	chr12:52879180	chr1:157073257~157074703:+
BRCA	trans	rs11098499	0.644	rs2389880	ENSG00000276997.3	RP11-378J18.9	5.81	8.12e-09	0.00543	0.21	0.18	Corneal astigmatism;	chr4:119638715	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.909	rs2127821	ENSG00000276805.1	RP11-291L22.6	5.81	8.13e-09	0.00544	0.21	0.18	Corneal astigmatism;	chr4:119473380	chr10:38451030~38451785:+
BRCA	trans	rs2220004	1	rs2512789	ENSG00000134612.10	FOLH1B	5.81	8.15e-09	0.00545	0.22	0.18	Odorant perception (&beta-damascenone);	chr11:56134735	chr11:89639227~89698718:+
BRCA	trans	rs853679	0.769	rs7752608	ENSG00000227766.1	HCG4P5	-5.81	8.18e-09	0.00547	-0.4	-0.18	Depression;	chr6:28333418	chr6:29942075~29943067:-
BRCA	trans	rs7617773	0.78	rs36121690	ENSG00000235912.1	RP1-159A19.3	-5.81	8.2e-09	0.00548	-0.24	-0.18	Coronary artery disease;	chr3:48304021	chr1:27649419~27649610:+
BRCA	trans	rs853679	0.607	rs17763089	ENSG00000228078.1	HLA-U	-5.81	8.2e-09	0.00548	-0.48	-0.18	Depression;	chr6:27867440	chr6:29934101~29934286:+
BRCA	trans	rs853679	0.546	rs17695758	ENSG00000228078.1	HLA-U	-5.81	8.2e-09	0.00548	-0.48	-0.18	Depression;	chr6:27869405	chr6:29934101~29934286:+
BRCA	trans	rs11098499	0.954	rs6848389	ENSG00000276805.1	RP11-291L22.6	5.81	8.21e-09	0.00549	0.21	0.18	Corneal astigmatism;	chr4:119481467	chr10:38451030~38451785:+
BRCA	trans	rs6831352	0.918	rs2602896	ENSG00000233859.2	ADH5P4	5.81	8.22e-09	0.00549	0.25	0.18	Alcohol dependence;	chr4:99125056	chr6:65836930~65838039:-
BRCA	trans	rs11098499	0.754	rs12711071	ENSG00000120555.12	SEPT7P9	5.81	8.25e-09	0.00551	0.21	0.18	Corneal astigmatism;	chr4:119319779	chr10:38383069~38402916:-
BRCA	trans	rs875971	0.929	rs778712	ENSG00000164669.11	INTS4P1	-5.81	8.25e-09	0.00552	-0.22	-0.18	Aortic root size;	chr7:66384991	chr7:65141225~65234216:+
BRCA	trans	rs1459104	1	rs12576386	ENSG00000134612.10	FOLH1B	-5.81	8.26e-09	0.00552	-0.36	-0.18	Body mass index;	chr11:55484889	chr11:89639227~89698718:+
BRCA	trans	rs1459104	1	rs12788969	ENSG00000134612.10	FOLH1B	-5.81	8.26e-09	0.00552	-0.36	-0.18	Body mass index;	chr11:55485881	chr11:89639227~89698718:+
BRCA	trans	rs853679	0.607	rs17763089	ENSG00000204709.4	LINC01556	5.81	8.26e-09	0.00552	0.48	0.18	Depression;	chr6:27867440	chr6:28943877~28944537:+
BRCA	trans	rs853679	0.546	rs17695758	ENSG00000204709.4	LINC01556	5.81	8.26e-09	0.00552	0.48	0.18	Depression;	chr6:27869405	chr6:28943877~28944537:+
BRCA	trans	rs148734725	1	rs148734725	ENSG00000197582.5	GPX1P1	-5.81	8.26e-09	0.00552	-0.2	-0.18	Educational attainment (college completion);	chr3:49369275	chrX:13378735~13379340:-
BRCA	trans	rs9858542	0.953	rs34588335	ENSG00000197582.5	GPX1P1	-5.81	8.26e-09	0.00552	-0.2	-0.18	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49370227	chrX:13378735~13379340:-
BRCA	trans	rs1459104	0.866	rs35456973	ENSG00000134612.10	FOLH1B	-5.81	8.27e-09	0.00552	-0.35	-0.18	Body mass index;	chr11:55071336	chr11:89639227~89698718:+
BRCA	trans	rs11098499	0.863	rs3775845	ENSG00000253326.2	RP11-261C10.7	5.81	8.27e-09	0.00552	0.25	0.18	Corneal astigmatism;	chr4:119511292	chr1:243054861~243056394:-
BRCA	trans	rs7746199	0.736	rs13202295	ENSG00000243753.4	HLA-L	-5.81	8.27e-09	0.00553	-0.48	-0.18	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27731058	chr6:30259584~30293014:+
BRCA	trans	rs902774	0.818	rs55914512	ENSG00000228753.1	EIF4BP2	5.81	8.27e-09	0.00553	0.35	0.18	Prostate cancer;	chr12:52888490	chr10:21028999~21030792:+
BRCA	trans	rs902774	0.818	rs73108466	ENSG00000228753.1	EIF4BP2	5.81	8.27e-09	0.00553	0.35	0.18	Prostate cancer;	chr12:52889857	chr10:21028999~21030792:+
BRCA	trans	rs875971	1	rs55962648	ENSG00000164669.11	INTS4P1	5.81	8.28e-09	0.00553	0.22	0.18	Aortic root size;	chr7:66160764	chr7:65141225~65234216:+
BRCA	trans	rs16975963	0.644	rs73033129	ENSG00000247498.8	RP11-392P7.6	5.81	8.3e-09	0.00554	0.31	0.18	Longevity;	chr19:37589634	chr12:12927726~12984645:+
BRCA	trans	rs16975963	0.644	rs12162238	ENSG00000247498.8	RP11-392P7.6	5.81	8.3e-09	0.00554	0.31	0.18	Longevity;	chr19:37591484	chr12:12927726~12984645:+
BRCA	trans	rs9858542	0.953	rs4625	ENSG00000197582.5	GPX1P1	-5.81	8.32e-09	0.00556	-0.2	-0.18	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49534707	chrX:13378735~13379340:-
BRCA	trans	rs875971	1	rs1565531	ENSG00000164669.11	INTS4P1	5.81	8.32e-09	0.00556	0.22	0.18	Aortic root size;	chr7:66198126	chr7:65141225~65234216:+
BRCA	trans	rs45509595	0.841	rs17751184	ENSG00000281831.1	HCP5B	5.81	8.34e-09	0.00557	0.45	0.18	Breast cancer;	chr6:27807250	chr6:29871895~29873783:-
BRCA	trans	rs1459104	1	rs34391788	ENSG00000134612.10	FOLH1B	-5.81	8.34e-09	0.00557	-0.36	-0.18	Body mass index;	chr11:55504245	chr11:89639227~89698718:+
BRCA	trans	rs1459104	1	rs36082455	ENSG00000134612.10	FOLH1B	-5.81	8.34e-09	0.00557	-0.36	-0.18	Body mass index;	chr11:55504337	chr11:89639227~89698718:+
BRCA	trans	rs1459104	1	rs35317943	ENSG00000134612.10	FOLH1B	-5.81	8.34e-09	0.00557	-0.36	-0.18	Body mass index;	chr11:55507381	chr11:89639227~89698718:+
BRCA	trans	rs11098499	0.575	rs907204	ENSG00000276997.3	RP11-378J18.9	5.81	8.35e-09	0.00557	0.21	0.18	Corneal astigmatism;	chr4:119317499	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.575	rs907205	ENSG00000276997.3	RP11-378J18.9	5.81	8.35e-09	0.00557	0.21	0.18	Corneal astigmatism;	chr4:119317509	chr1:222477252~222504622:-
BRCA	trans	rs2243480	1	rs1499614	ENSG00000164669.11	INTS4P1	5.81	8.37e-09	0.00559	0.34	0.18	Diabetic kidney disease;	chr7:66265811	chr7:65141225~65234216:+
BRCA	trans	rs9860340	0.77	rs55835547	ENSG00000259370.2	RP11-1069G10.1	5.81	8.37e-09	0.00559	0.21	0.18	Electroencephalographic traits in alcoholism;	chr3:87646132	chr15:62827675~62884034:-
BRCA	trans	rs45509595	0.841	rs17751184	ENSG00000204709.4	LINC01556	5.81	8.38e-09	0.00559	0.47	0.18	Breast cancer;	chr6:27807250	chr6:28943877~28944537:+
BRCA	trans	rs7570469	0.762	rs993607	ENSG00000276390.1	RP1-197B17.5	5.81	8.39e-09	0.0056	0.23	0.18	Response to antipsychotic treatment;	chr2:79444098	chr12:47699401~47699917:-
BRCA	trans	rs7819412	0.502	rs11777918	ENSG00000253893.2	FAM85B	-5.81	8.4e-09	0.00561	-0.23	-0.18	Triglycerides;	chr8:11179410	chr8:8167819~8226614:-
BRCA	trans	rs6831352	0.918	rs29001224	ENSG00000233859.2	ADH5P4	5.81	8.4e-09	0.00561	0.25	0.18	Alcohol dependence;	chr4:99126222	chr6:65836930~65838039:-
BRCA	trans	rs6831352	0.918	rs6813415	ENSG00000233859.2	ADH5P4	5.81	8.4e-09	0.00561	0.25	0.18	Alcohol dependence;	chr4:99127358	chr6:65836930~65838039:-
BRCA	trans	rs6831352	0.879	rs67311928	ENSG00000233859.2	ADH5P4	5.81	8.4e-09	0.00561	0.25	0.18	Alcohol dependence;	chr4:99127848	chr6:65836930~65838039:-
BRCA	trans	rs6831352	0.877	rs28987101	ENSG00000233859.2	ADH5P4	5.81	8.4e-09	0.00561	0.25	0.18	Alcohol dependence;	chr4:99128102	chr6:65836930~65838039:-
BRCA	trans	rs6831352	0.918	rs28987097	ENSG00000233859.2	ADH5P4	5.81	8.4e-09	0.00561	0.25	0.18	Alcohol dependence;	chr4:99128428	chr6:65836930~65838039:-
BRCA	trans	rs6831352	0.918	rs13112733	ENSG00000233859.2	ADH5P4	5.81	8.4e-09	0.00561	0.25	0.18	Alcohol dependence;	chr4:99129168	chr6:65836930~65838039:-
BRCA	trans	rs6831352	0.918	rs13140423	ENSG00000233859.2	ADH5P4	5.81	8.4e-09	0.00561	0.25	0.18	Alcohol dependence;	chr4:99129249	chr6:65836930~65838039:-
BRCA	trans	rs6831352	0.918	rs13113166	ENSG00000233859.2	ADH5P4	5.81	8.4e-09	0.00561	0.25	0.18	Alcohol dependence;	chr4:99129377	chr6:65836930~65838039:-
BRCA	trans	rs6831352	0.918	rs34805407	ENSG00000233859.2	ADH5P4	5.81	8.4e-09	0.00561	0.25	0.18	Alcohol dependence;	chr4:99129635	chr6:65836930~65838039:-
BRCA	trans	rs6831352	0.918	rs35662508	ENSG00000233859.2	ADH5P4	5.81	8.4e-09	0.00561	0.25	0.18	Alcohol dependence;	chr4:99129823	chr6:65836930~65838039:-
BRCA	trans	rs6831352	0.918	rs34071486	ENSG00000233859.2	ADH5P4	5.81	8.4e-09	0.00561	0.25	0.18	Alcohol dependence;	chr4:99129936	chr6:65836930~65838039:-
BRCA	trans	rs6831352	0.879	rs34360292	ENSG00000233859.2	ADH5P4	5.81	8.4e-09	0.00561	0.25	0.18	Alcohol dependence;	chr4:99130152	chr6:65836930~65838039:-
BRCA	trans	rs6831352	0.918	rs29001216	ENSG00000233859.2	ADH5P4	5.81	8.4e-09	0.00561	0.25	0.18	Alcohol dependence;	chr4:99130405	chr6:65836930~65838039:-
BRCA	trans	rs9393777	0.92	rs41269265	ENSG00000281831.1	HCP5B	5.81	8.41e-09	0.00561	0.41	0.18	Intelligence (multi-trait analysis);	chr6:27457570	chr6:29871895~29873783:-
BRCA	trans	rs875971	0.789	rs28815324	ENSG00000213640.3	EEF1DP4	5.81	8.41e-09	0.00561	0.25	0.18	Aortic root size;	chr7:66100789	chr7:64862999~64864370:+
BRCA	trans	rs2899832	0.568	rs17597281	ENSG00000215414.4	PSMA6P1	-5.81	8.42e-09	0.00562	-0.32	-0.18	Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:35313094	chrY:13286638~13287378:+
BRCA	trans	rs4929949	0.78	rs10769923	ENSG00000266891.1	RP11-692N5.2	-5.81	8.42e-09	0.00562	-0.21	-0.18	Body mass index;	chr11:8600861	chr18:9734882~9735602:-
BRCA	trans	rs7746199	0.736	rs58616630	ENSG00000204709.4	LINC01556	5.81	8.44e-09	0.00563	0.47	0.18	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27506936	chr6:28943877~28944537:+
BRCA	trans	rs7927771	0.965	rs35184771	ENSG00000134612.10	FOLH1B	-5.81	8.45e-09	0.00563	-0.24	-0.18	Subjective well-being;	chr11:47453637	chr11:89639227~89698718:+
BRCA	trans	rs902774	0.818	rs4919742	ENSG00000223940.1	KRT8P8	-5.81	8.48e-09	0.00566	-0.37	-0.18	Prostate cancer;	chr12:52879180	chrX:152479577~152481024:+
BRCA	trans	rs7647973	1	rs9860055	ENSG00000235912.1	RP1-159A19.3	5.81	8.48e-09	0.00566	0.23	0.18	Menarche (age at onset);	chr3:49469467	chr1:27649419~27649610:+
BRCA	trans	rs7647973	1	rs74471041	ENSG00000235912.1	RP1-159A19.3	5.81	8.48e-09	0.00566	0.23	0.18	Menarche (age at onset);	chr3:49505110	chr1:27649419~27649610:+
BRCA	trans	rs7647973	1	rs7644148	ENSG00000235912.1	RP1-159A19.3	5.81	8.48e-09	0.00566	0.23	0.18	Menarche (age at onset);	chr3:49507808	chr1:27649419~27649610:+
BRCA	trans	rs76228276	0.737	rs16897325	ENSG00000260318.1	COX6CP1	5.81	8.51e-09	0.00567	0.45	0.18	Childhood ear infection;	chr8:99388063	chr16:11903923~11904137:-
BRCA	trans	rs11098499	0.754	rs1511017	ENSG00000276997.3	RP11-378J18.9	5.81	8.53e-09	0.00568	0.21	0.18	Corneal astigmatism;	chr4:119329650	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.789	rs12498994	ENSG00000276997.3	RP11-378J18.9	5.81	8.53e-09	0.00568	0.21	0.18	Corneal astigmatism;	chr4:119329663	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.754	rs12507565	ENSG00000276997.3	RP11-378J18.9	5.81	8.53e-09	0.00568	0.21	0.18	Corneal astigmatism;	chr4:119329966	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.826	rs12511640	ENSG00000276997.3	RP11-378J18.9	5.81	8.53e-09	0.00568	0.21	0.18	Corneal astigmatism;	chr4:119330093	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.754	rs1980026	ENSG00000276997.3	RP11-378J18.9	5.81	8.53e-09	0.00568	0.21	0.18	Corneal astigmatism;	chr4:119330488	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.743	rs11098501	ENSG00000276997.3	RP11-378J18.9	5.81	8.53e-09	0.00568	0.21	0.18	Corneal astigmatism;	chr4:119330862	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.754	rs11098502	ENSG00000276997.3	RP11-378J18.9	5.81	8.53e-09	0.00568	0.21	0.18	Corneal astigmatism;	chr4:119330908	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.708	rs11732686	ENSG00000276997.3	RP11-378J18.9	5.81	8.53e-09	0.00568	0.21	0.18	Corneal astigmatism;	chr4:119331175	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.754	rs11724409	ENSG00000276997.3	RP11-378J18.9	5.81	8.53e-09	0.00568	0.21	0.18	Corneal astigmatism;	chr4:119331206	chr1:222477252~222504622:-
BRCA	trans	rs6921919	0.789	rs11970439	ENSG00000253570.1	RNF5P1	5.8	8.54e-09	0.00569	0.29	0.18	Autism spectrum disorder or schizophrenia;	chr6:28335687	chr8:38600661~38601200:-
BRCA	trans	rs875971	0.545	rs6460298	ENSG00000234585.5	CCT6P3	5.8	8.56e-09	0.0057	0.19	0.18	Aortic root size;	chr7:66442783	chr7:65038354~65074713:+
BRCA	trans	rs7746199	0.736	rs58616630	ENSG00000243753.4	HLA-L	-5.8	8.56e-09	0.0057	-0.47	-0.18	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27506936	chr6:30259584~30293014:+
BRCA	trans	rs66887589	0.616	rs11098497	ENSG00000276997.3	RP11-378J18.9	5.8	8.58e-09	0.00572	0.2	0.18	Diastolic blood pressure;	chr4:119265913	chr1:222477252~222504622:-
BRCA	trans	rs2220004	0.533	rs11231522	ENSG00000134612.10	FOLH1B	-5.8	8.59e-09	0.00572	-0.28	-0.18	Odorant perception (&beta-damascenone);	chr11:55910691	chr11:89639227~89698718:+
BRCA	trans	rs853679	0.546	rs36116761	ENSG00000228078.1	HLA-U	-5.8	8.63e-09	0.00575	-0.48	-0.18	Depression;	chr6:27850704	chr6:29934101~29934286:+
BRCA	trans	rs853679	0.546	rs34194357	ENSG00000228078.1	HLA-U	-5.8	8.63e-09	0.00575	-0.48	-0.18	Depression;	chr6:27850757	chr6:29934101~29934286:+
BRCA	trans	rs66887589	0.616	rs7659403	ENSG00000276997.3	RP11-378J18.9	5.8	8.63e-09	0.00575	0.2	0.18	Diastolic blood pressure;	chr4:119286099	chr1:222477252~222504622:-
BRCA	trans	rs875971	0.545	rs73136346	ENSG00000234585.5	CCT6P3	-5.8	8.63e-09	0.00575	-0.19	-0.18	Aortic root size;	chr7:66101095	chr7:65038354~65074713:+
BRCA	trans	rs11098499	0.619	rs28502463	ENSG00000276997.3	RP11-378J18.9	5.8	8.64e-09	0.00576	0.21	0.18	Corneal astigmatism;	chr4:119335868	chr1:222477252~222504622:-
BRCA	trans	rs875971	0.964	rs60193905	ENSG00000164669.11	INTS4P1	-5.8	8.65e-09	0.00576	-0.22	-0.18	Aortic root size;	chr7:66506273	chr7:65141225~65234216:+
BRCA	trans	rs4713118	0.868	rs35069907	ENSG00000204709.4	LINC01556	5.8	8.65e-09	0.00576	0.26	0.18	Parkinson's disease;	chr6:27778913	chr6:28943877~28944537:+
BRCA	trans	rs7617773	0.746	rs4130995	ENSG00000235912.1	RP1-159A19.3	-5.8	8.66e-09	0.00576	-0.21	-0.18	Coronary artery disease;	chr3:48316765	chr1:27649419~27649610:+
BRCA	trans	rs7927771	0.864	rs4752838	ENSG00000134612.10	FOLH1B	-5.8	8.67e-09	0.00577	-0.23	-0.18	Subjective well-being;	chr11:47444454	chr11:89639227~89698718:+
BRCA	trans	rs546131	0.614	rs7106579	ENSG00000225531.1	RP11-196I18.3	-5.8	8.67e-09	0.00577	-0.29	-0.18	Lung disease severity in cystic fibrosis;	chr11:34813955	chr9:107116829~107117557:+
BRCA	trans	rs16975963	0.644	rs11083427	ENSG00000247498.8	RP11-392P7.6	5.8	8.67e-09	0.00577	0.31	0.18	Longevity;	chr19:37583251	chr12:12927726~12984645:+
BRCA	trans	rs11098499	0.863	rs10013305	ENSG00000253326.2	RP11-261C10.7	5.8	8.67e-09	0.00577	0.25	0.18	Corneal astigmatism;	chr4:119529269	chr1:243054861~243056394:-
BRCA	trans	rs11098499	0.863	rs3775849	ENSG00000253326.2	RP11-261C10.7	5.8	8.67e-09	0.00577	0.25	0.18	Corneal astigmatism;	chr4:119529753	chr1:243054861~243056394:-
BRCA	trans	rs11098499	0.818	rs7688802	ENSG00000253326.2	RP11-261C10.7	5.8	8.67e-09	0.00577	0.25	0.18	Corneal astigmatism;	chr4:119530513	chr1:243054861~243056394:-
BRCA	trans	rs11098499	0.863	rs7695620	ENSG00000253326.2	RP11-261C10.7	5.8	8.67e-09	0.00577	0.25	0.18	Corneal astigmatism;	chr4:119531621	chr1:243054861~243056394:-
BRCA	trans	rs11098499	0.863	rs12502389	ENSG00000253326.2	RP11-261C10.7	5.8	8.67e-09	0.00577	0.25	0.18	Corneal astigmatism;	chr4:119533036	chr1:243054861~243056394:-
BRCA	trans	rs11098499	0.821	rs3775852	ENSG00000253326.2	RP11-261C10.7	5.8	8.67e-09	0.00577	0.25	0.18	Corneal astigmatism;	chr4:119533401	chr1:243054861~243056394:-
BRCA	trans	rs11098499	0.82	rs6534140	ENSG00000253326.2	RP11-261C10.7	5.8	8.67e-09	0.00577	0.25	0.18	Corneal astigmatism;	chr4:119534156	chr1:243054861~243056394:-
BRCA	trans	rs11098499	0.863	rs7657849	ENSG00000253326.2	RP11-261C10.7	5.8	8.67e-09	0.00577	0.25	0.18	Corneal astigmatism;	chr4:119534339	chr1:243054861~243056394:-
BRCA	trans	rs11098499	0.863	rs10034450	ENSG00000253326.2	RP11-261C10.7	5.8	8.67e-09	0.00577	0.25	0.18	Corneal astigmatism;	chr4:119534494	chr1:243054861~243056394:-
BRCA	trans	rs11098499	0.863	rs1480939	ENSG00000253326.2	RP11-261C10.7	5.8	8.67e-09	0.00577	0.25	0.18	Corneal astigmatism;	chr4:119535772	chr1:243054861~243056394:-
BRCA	trans	rs7824557	0.652	rs12677504	ENSG00000270154.1	RP11-419I17.1	-5.8	8.68e-09	0.00578	-0.22	-0.18	Retinal vascular caliber;	chr8:11275666	chr8:12476462~12477122:+
BRCA	trans	rs11098499	0.604	rs2389882	ENSG00000253326.2	RP11-261C10.7	5.8	8.69e-09	0.00578	0.25	0.18	Corneal astigmatism;	chr4:119645578	chr1:243054861~243056394:-
BRCA	trans	rs902774	0.818	rs4919763	ENSG00000224520.2	KRT8P45	-5.8	8.71e-09	0.0058	-0.36	-0.18	Prostate cancer;	chr12:52885839	chr1:157073257~157074703:+
BRCA	trans	rs6121246	0.559	rs6119652	ENSG00000279352.1	RP11-411B10.7	5.8	8.72e-09	0.0058	0.26	0.18	Mean corpuscular hemoglobin;	chr20:31671642	chr18:14010054~14010917:+
BRCA	trans	rs7746199	0.736	rs6904596	ENSG00000228078.1	HLA-U	-5.8	8.74e-09	0.00581	-0.38	-0.18	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27523520	chr6:29934101~29934286:+
BRCA	trans	rs875971	1	rs10244498	ENSG00000164669.11	INTS4P1	-5.8	8.77e-09	0.00583	-0.22	-0.18	Aortic root size;	chr7:66651069	chr7:65141225~65234216:+
BRCA	trans	rs6601327	0.641	rs12542457	ENSG00000253893.2	FAM85B	5.8	8.77e-09	0.00583	0.22	0.18	Multiple myeloma (hyperdiploidy);	chr8:9707090	chr8:8167819~8226614:-
BRCA	trans	rs2899832	0.5	rs112106731	ENSG00000215414.4	PSMA6P1	5.8	8.78e-09	0.00584	0.31	0.18	Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:35298279	chrY:13286638~13287378:+
BRCA	trans	rs2899832	0.568	rs10142113	ENSG00000215414.4	PSMA6P1	5.8	8.78e-09	0.00584	0.31	0.18	Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:35298623	chrY:13286638~13287378:+
BRCA	trans	rs902774	0.759	rs4919707	ENSG00000228753.1	EIF4BP2	5.8	8.8e-09	0.00585	0.35	0.18	Prostate cancer;	chr12:52895864	chr10:21028999~21030792:+
BRCA	trans	rs7157940	0.692	rs4905163	ENSG00000271737.1	CTB-113I20.2	-5.8	8.81e-09	0.00586	-0.15	-0.18	Anthropometric traits;	chr14:94104424	chr5:134005147~134005562:+
BRCA	trans	rs6831352	0.918	rs35784540	ENSG00000233859.2	ADH5P4	5.8	8.82e-09	0.00586	0.25	0.18	Alcohol dependence;	chr4:99140541	chr6:65836930~65838039:-
BRCA	trans	rs2950393	0.929	rs10876916	ENSG00000257210.1	NACAP3	5.8	8.84e-09	0.00588	0.21	0.18	Platelet distribution width;	chr12:56692728	chr12:93124063~93124543:-
BRCA	trans	rs2950393	0.794	rs1563897	ENSG00000257210.1	NACAP3	5.8	8.84e-09	0.00588	0.21	0.18	Platelet distribution width;	chr12:56699316	chr12:93124063~93124543:-
BRCA	trans	rs1671400	1	rs919586	ENSG00000253982.1	CTD-2336O2.1	5.8	8.84e-09	0.00588	0.24	0.18	Obesity-related traits;	chr8:13317162	chr8:1761990~1764502:-
BRCA	trans	rs6934970	1	rs4945915	ENSG00000267560.1	RP11-173A16.1	-5.8	8.85e-09	0.00588	-0.22	-0.18	Bipolar disorder (body mass index interaction);	chr6:112809472	chr18:62300036~62300998:-
BRCA	trans	rs17767294	0.708	rs6908688	ENSG00000242375.1	RP11-498P14.3	-5.8	8.86e-09	0.00589	-0.46	-0.18	Parkinson's disease;	chr6:27918273	chr9:97195351~97197687:-
BRCA	trans	rs11098499	0.954	rs10518328	ENSG00000276805.1	RP11-291L22.6	5.8	8.86e-09	0.00589	0.21	0.18	Corneal astigmatism;	chr4:119480624	chr10:38451030~38451785:+
BRCA	trans	rs10946940	0.897	rs6456801	ENSG00000204709.4	LINC01556	5.8	8.89e-09	0.0059	0.23	0.18	Systemic lupus erythematosus;	chr6:27657753	chr6:28943877~28944537:+
BRCA	trans	rs11098499	0.866	rs3756156	ENSG00000253326.2	RP11-261C10.7	5.8	8.92e-09	0.00592	0.25	0.18	Corneal astigmatism;	chr4:119603686	chr1:243054861~243056394:-
BRCA	trans	rs875971	0.597	rs11763224	ENSG00000213640.3	EEF1DP4	-5.8	8.94e-09	0.00594	-0.25	-0.18	Aortic root size;	chr7:66518628	chr7:64862999~64864370:+
BRCA	trans	rs7927771	1	rs4752797	ENSG00000134612.10	FOLH1B	-5.8	8.95e-09	0.00594	-0.24	-0.18	Subjective well-being;	chr11:47852812	chr11:89639227~89698718:+
BRCA	trans	rs4929949	0.809	rs10743080	ENSG00000266891.1	RP11-692N5.2	-5.8	8.95e-09	0.00594	-0.21	-0.18	Body mass index;	chr11:8601030	chr18:9734882~9735602:-
BRCA	trans	rs1459104	0.636	rs12577480	ENSG00000134612.10	FOLH1B	-5.8	8.96e-09	0.00595	-0.37	-0.18	Body mass index;	chr11:55218528	chr11:89639227~89698718:+
BRCA	trans	rs853679	0.546	rs36116761	ENSG00000281831.1	HCP5B	5.8	8.99e-09	0.00597	0.45	0.18	Depression;	chr6:27850704	chr6:29871895~29873783:-
BRCA	trans	rs853679	0.546	rs34194357	ENSG00000281831.1	HCP5B	5.8	8.99e-09	0.00597	0.45	0.18	Depression;	chr6:27850757	chr6:29871895~29873783:-
BRCA	trans	rs11098499	0.954	rs6822679	ENSG00000276805.1	RP11-291L22.6	5.8	8.99e-09	0.00597	0.21	0.18	Corneal astigmatism;	chr4:119481547	chr10:38451030~38451785:+
BRCA	trans	rs853679	0.607	rs17763089	ENSG00000243753.4	HLA-L	-5.8	9e-09	0.00597	-0.48	-0.18	Depression;	chr6:27867440	chr6:30259584~30293014:+
BRCA	trans	rs853679	0.546	rs17695758	ENSG00000243753.4	HLA-L	-5.8	9e-09	0.00597	-0.48	-0.18	Depression;	chr6:27869405	chr6:30259584~30293014:+
BRCA	trans	rs45509595	0.556	rs34409918	ENSG00000228078.1	HLA-U	-5.8	9.04e-09	0.006	-0.47	-0.18	Breast cancer;	chr6:27717569	chr6:29934101~29934286:+
BRCA	trans	rs7829975	0.582	rs6982832	ENSG00000270154.1	RP11-419I17.1	-5.79	9.06e-09	0.00601	-0.2	-0.18	Mood instability;	chr8:8934707	chr8:12476462~12477122:+
BRCA	trans	rs10946940	0.965	rs10946935	ENSG00000204709.4	LINC01556	-5.79	9.06e-09	0.00602	-0.23	-0.18	Systemic lupus erythematosus;	chr6:27533566	chr6:28943877~28944537:+
BRCA	trans	rs66887589	0.776	rs10518337	ENSG00000276805.1	RP11-291L22.6	-5.79	9.07e-09	0.00602	-0.19	-0.18	Diastolic blood pressure;	chr4:119653719	chr10:38451030~38451785:+
BRCA	trans	rs546131	0.642	rs11600239	ENSG00000225531.1	RP11-196I18.3	-5.79	9.11e-09	0.00604	-0.29	-0.18	Lung disease severity in cystic fibrosis;	chr11:34800152	chr9:107116829~107117557:+
BRCA	trans	rs546131	0.642	rs1897203	ENSG00000225531.1	RP11-196I18.3	-5.79	9.11e-09	0.00604	-0.29	-0.18	Lung disease severity in cystic fibrosis;	chr11:34800441	chr9:107116829~107117557:+
BRCA	trans	rs6087771	0.89	rs6089056	ENSG00000279352.1	RP11-411B10.7	5.79	9.11e-09	0.00604	0.25	0.18	Putamen volume;Subcortical brain region volumes;	chr20:31737970	chr18:14010054~14010917:+
BRCA	trans	rs6121246	0.559	rs6060919	ENSG00000279352.1	RP11-411B10.7	5.79	9.11e-09	0.00604	0.25	0.18	Mean corpuscular hemoglobin;	chr20:31744119	chr18:14010054~14010917:+
BRCA	trans	rs6121246	0.559	rs6060922	ENSG00000279352.1	RP11-411B10.7	5.79	9.11e-09	0.00604	0.25	0.18	Mean corpuscular hemoglobin;	chr20:31746106	chr18:14010054~14010917:+
BRCA	trans	rs902774	0.818	rs73108429	ENSG00000224520.2	KRT8P45	-5.79	9.12e-09	0.00605	-0.36	-0.18	Prostate cancer;	chr12:52877887	chr1:157073257~157074703:+
BRCA	trans	rs9467711	0.591	rs17586553	ENSG00000253570.1	RNF5P1	5.79	9.13e-09	0.00606	0.42	0.18	Autism spectrum disorder or schizophrenia;	chr6:25928547	chr8:38600661~38601200:-
BRCA	trans	rs4713118	0.868	rs10484401	ENSG00000204709.4	LINC01556	-5.79	9.15e-09	0.00607	-0.26	-0.18	Parkinson's disease;	chr6:27778811	chr6:28943877~28944537:+
BRCA	trans	rs13217239	0.646	rs10456352	ENSG00000216901.1	AL022393.7	-5.79	9.18e-09	0.00609	-0.21	-0.18	Schizophrenia;	chr6:27022579	chr6:28176188~28176674:+
BRCA	trans	rs13217239	0.646	rs4583981	ENSG00000216901.1	AL022393.7	-5.79	9.18e-09	0.00609	-0.21	-0.18	Schizophrenia;	chr6:27024244	chr6:28176188~28176674:+
BRCA	trans	rs3732378	0.666	rs56703951	ENSG00000183298.5	RP11-556K13.1	5.79	9.18e-09	0.00609	0.28	0.18	Monocyte count;Lymphocyte counts;Granulocyte percentage of myeloid white cells;Monocyte percentage of white cells;	chr3:39257314	chr1:101786340~101787219:-
BRCA	trans	rs9467711	0.659	rs35433030	ENSG00000220721.1	OR1F12	5.79	9.2e-09	0.0061	0.38	0.18	Autism spectrum disorder or schizophrenia;	chr6:26529662	chr6:28073316~28074233:+
BRCA	trans	rs9467711	0.659	rs66941101	ENSG00000220721.1	OR1F12	5.79	9.2e-09	0.0061	0.38	0.18	Autism spectrum disorder or schizophrenia;	chr6:26530148	chr6:28073316~28074233:+
BRCA	trans	rs16975963	0.644	rs11666738	ENSG00000247498.8	RP11-392P7.6	5.79	9.22e-09	0.00611	0.3	0.18	Longevity;	chr19:37639418	chr12:12927726~12984645:+
BRCA	trans	rs875971	0.545	rs1638724	ENSG00000234585.5	CCT6P3	-5.79	9.23e-09	0.00612	-0.19	-0.18	Aortic root size;	chr7:66575494	chr7:65038354~65074713:+
BRCA	trans	rs9858542	0.953	rs6809216	ENSG00000197582.5	GPX1P1	-5.79	9.25e-09	0.00613	-0.2	-0.18	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49375126	chrX:13378735~13379340:-
BRCA	trans	rs9858542	0.953	rs7623659	ENSG00000197582.5	GPX1P1	-5.79	9.25e-09	0.00613	-0.2	-0.18	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49377358	chrX:13378735~13379340:-
BRCA	trans	rs9858542	0.953	rs35169793	ENSG00000197582.5	GPX1P1	-5.79	9.25e-09	0.00613	-0.2	-0.18	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49385841	chrX:13378735~13379340:-
BRCA	trans	rs950037	0.935	rs305221	ENSG00000231916.1	AC006033.22	5.79	9.28e-09	0.00615	0.2	0.18	Coronary artery disease;	chr1:88733302	chr7:38311383~38311808:+
BRCA	trans	rs4948102	0.691	rs4470984	ENSG00000186940.6	CHCHD2P9	-5.79	9.31e-09	0.00617	-0.23	-0.18	Plasma homocysteine levels (post-methionine load test);	chr7:55965865	chr9:79391304~79391759:+
BRCA	trans	rs7833986	0.501	rs2976044	ENSG00000244245.1	RP11-120B7.1	5.79	9.32e-09	0.00617	0.2	0.18	Height;	chr8:56074178	chr5:108593609~108593967:+
BRCA	trans	rs1814175	0.527	rs10769595	ENSG00000134612.10	FOLH1B	-5.79	9.33e-09	0.00618	-0.24	-0.18	Height;	chr11:49616660	chr11:89639227~89698718:+
BRCA	trans	rs34421088	0.532	rs1369368	ENSG00000253893.2	FAM85B	-5.79	9.35e-09	0.0062	-0.23	-0.18	Neuroticism;	chr8:11292704	chr8:8167819~8226614:-
BRCA	trans	rs7824557	0.767	rs2164273	ENSG00000254153.1	CTA-398F10.2	5.79	9.37e-09	0.00621	0.23	0.18	Retinal vascular caliber;	chr8:11310990	chr8:8456909~8461337:-
BRCA	trans	rs113793030	0.661	rs73275637	ENSG00000253785.1	CTC-308K20.3	5.79	9.37e-09	0.00621	0.47	0.18	Cognitive decline rate in late mild cognitive impairment;	chr10:70204673	chr5:172975511~172976374:+
BRCA	trans	rs113793030	0.661	rs10999179	ENSG00000253785.1	CTC-308K20.3	5.79	9.37e-09	0.00621	0.47	0.18	Cognitive decline rate in late mild cognitive impairment;	chr10:70204718	chr5:172975511~172976374:+
BRCA	trans	rs113793030	0.661	rs10999180	ENSG00000253785.1	CTC-308K20.3	5.79	9.37e-09	0.00621	0.47	0.18	Cognitive decline rate in late mild cognitive impairment;	chr10:70204720	chr5:172975511~172976374:+
BRCA	trans	rs9858542	0.953	rs10640	ENSG00000197582.5	GPX1P1	-5.79	9.38e-09	0.00621	-0.2	-0.18	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49416844	chrX:13378735~13379340:-
BRCA	trans	rs1459104	1	rs12577374	ENSG00000134612.10	FOLH1B	-5.79	9.38e-09	0.00621	-0.36	-0.18	Body mass index;	chr11:55449445	chr11:89639227~89698718:+
BRCA	trans	rs3732378	0.666	rs11711391	ENSG00000183298.5	RP11-556K13.1	5.79	9.39e-09	0.00622	0.28	0.18	Monocyte count;Lymphocyte counts;Granulocyte percentage of myeloid white cells;Monocyte percentage of white cells;	chr3:39256068	chr1:101786340~101787219:-
BRCA	trans	rs60515486	0.527	rs2254240	ENSG00000134612.10	FOLH1B	5.79	9.39e-09	0.00622	0.26	0.18	Lymphocyte counts;	chr11:47335619	chr11:89639227~89698718:+
BRCA	trans	rs7089973	0.641	rs7079234	ENSG00000249267.5	LINC00939	5.79	9.4e-09	0.00623	0.21	0.18	Bipolar disorder or attention deficit hyperactivity disorder;	chr10:114982051	chr12:125958688~125983374:-
BRCA	trans	rs877636	0.702	rs773112	ENSG00000227586.5	RP11-162A23.5	5.79	9.4e-09	0.00623	0.23	0.18	Cognitive function;	chr12:55982097	chr10:123171535~123171875:-
BRCA	trans	rs4948102	0.731	rs4689	ENSG00000186940.6	CHCHD2P9	-5.79	9.43e-09	0.00624	-0.23	-0.18	Plasma homocysteine levels (post-methionine load test);	chr7:55999323	chr9:79391304~79391759:+
BRCA	trans	rs641862	1	rs641862	ENSG00000207652.1	MIR621	5.79	9.43e-09	0.00624	0.32	0.18	Obesity-related traits;	chr13:110137885	chr13:40810766~40810861:+
BRCA	trans	rs877636	0.847	rs2017445	ENSG00000212829.8	RPS26P3	5.79	9.43e-09	0.00625	0.36	0.18	Cognitive function;	chr12:56013288	chr9:9090898~9091245:+
BRCA	trans	rs9393777	0.72	rs34864993	ENSG00000253570.1	RNF5P1	5.79	9.44e-09	0.00625	0.38	0.18	Intelligence (multi-trait analysis);	chr6:27003116	chr8:38600661~38601200:-
BRCA	trans	rs13217239	0.646	rs10946898	ENSG00000216901.1	AL022393.7	-5.79	9.45e-09	0.00626	-0.21	-0.18	Schizophrenia;	chr6:27036105	chr6:28176188~28176674:+
BRCA	trans	rs875971	1	rs6979382	ENSG00000164669.11	INTS4P1	-5.79	9.47e-09	0.00627	-0.22	-0.18	Aortic root size;	chr7:66421388	chr7:65141225~65234216:+
BRCA	trans	rs875971	1	rs6961990	ENSG00000164669.11	INTS4P1	-5.79	9.47e-09	0.00627	-0.22	-0.18	Aortic root size;	chr7:66423583	chr7:65141225~65234216:+
BRCA	trans	rs875971	0.545	rs313830	ENSG00000234585.5	CCT6P3	-5.79	9.48e-09	0.00627	-0.19	-0.18	Aortic root size;	chr7:66086944	chr7:65038354~65074713:+
BRCA	trans	rs853679	0.607	rs13199906	ENSG00000243753.4	HLA-L	-5.79	9.48e-09	0.00628	-0.48	-0.18	Depression;	chr6:27866361	chr6:30259584~30293014:+
BRCA	trans	rs902774	0.818	rs11831919	ENSG00000255815.3	KRT8P11	-5.79	9.49e-09	0.00628	-0.36	-0.18	Prostate cancer;	chr12:52878231	chr9:99305176~99306611:+
BRCA	trans	rs875971	1	rs778710	ENSG00000164669.11	INTS4P1	-5.79	9.52e-09	0.0063	-0.21	-0.18	Aortic root size;	chr7:66389847	chr7:65141225~65234216:+
BRCA	trans	rs875971	0.545	rs6950988	ENSG00000213640.3	EEF1DP4	-5.79	9.53e-09	0.0063	-0.25	-0.18	Aortic root size;	chr7:66511428	chr7:64862999~64864370:+
BRCA	trans	rs11098499	0.954	rs4309825	ENSG00000276805.1	RP11-291L22.6	-5.79	9.54e-09	0.00631	-0.21	-0.18	Corneal astigmatism;	chr4:119393726	chr10:38451030~38451785:+
BRCA	trans	rs11098499	0.954	rs10034623	ENSG00000276805.1	RP11-291L22.6	5.79	9.55e-09	0.00632	0.21	0.18	Corneal astigmatism;	chr4:119476674	chr10:38451030~38451785:+
BRCA	trans	rs9860340	0.73	rs4528977	ENSG00000259370.2	RP11-1069G10.1	5.78	9.59e-09	0.00634	0.21	0.18	Electroencephalographic traits in alcoholism;	chr3:87598653	chr15:62827675~62884034:-
BRCA	trans	rs853679	0.607	rs13199906	ENSG00000204709.4	LINC01556	5.78	9.6e-09	0.00635	0.47	0.18	Depression;	chr6:27866361	chr6:28943877~28944537:+
BRCA	trans	rs11098499	0.754	rs28643450	ENSG00000276997.3	RP11-378J18.9	5.78	9.61e-09	0.00636	0.21	0.18	Corneal astigmatism;	chr4:119324087	chr1:222477252~222504622:-
BRCA	trans	rs7746199	0.673	rs72847313	ENSG00000204709.4	LINC01556	5.78	9.64e-09	0.00638	0.47	0.18	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27762303	chr6:28943877~28944537:+
BRCA	trans	rs7746199	0.611	rs17750747	ENSG00000204709.4	LINC01556	5.78	9.64e-09	0.00638	0.47	0.18	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27762555	chr6:28943877~28944537:+
BRCA	trans	rs4929949	0.607	rs10840038	ENSG00000266891.1	RP11-692N5.2	5.78	9.65e-09	0.00638	0.21	0.18	Body mass index;	chr11:8419402	chr18:9734882~9735602:-
BRCA	trans	rs61869271	0.692	rs61869274	ENSG00000249267.5	LINC00939	5.78	9.65e-09	0.00638	0.21	0.18	Tonsillectomy;	chr10:114982570	chr12:125958688~125983374:-
BRCA	trans	rs853679	0.546	rs13214023	ENSG00000228078.1	HLA-U	5.78	9.66e-09	0.00639	0.42	0.18	Depression;	chr6:28364364	chr6:29934101~29934286:+
BRCA	trans	rs4970988	0.556	rs6695123	ENSG00000180764.13	PIPSL	5.78	9.67e-09	0.0064	0.22	0.18	Urate levels;	chr1:150591007	chr10:93958191~93961540:-
BRCA	trans	rs4906172	0.659	rs1004903	ENSG00000181359.5	HSP90AA6P	5.78	9.68e-09	0.0064	0.23	0.18	Menopause (age at onset);	chr14:102048678	chr4:170581470~170605450:-
BRCA	trans	rs7568458	0.684	rs7579147	ENSG00000223886.3	RP11-251G23.2	5.78	9.68e-09	0.0064	0.22	0.18	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr2:85578531	chr7:105530209~105530671:+
BRCA	trans	rs853679	0.546	rs71537572	ENSG00000204338.7	CYP21A1P	-5.78	9.69e-09	0.0064	-0.41	-0.18	Depression;	chr6:28002937	chr6:32005636~32008451:+
BRCA	trans	rs67340775	0.834	rs13218875	ENSG00000243753.4	HLA-L	-5.78	9.71e-09	0.00642	-0.47	-0.18	Lung cancer in ever smokers;	chr6:27916234	chr6:30259584~30293014:+
BRCA	trans	rs11098499	0.863	rs34868248	ENSG00000253326.2	RP11-261C10.7	5.78	9.73e-09	0.00643	0.25	0.18	Corneal astigmatism;	chr4:119521275	chr1:243054861~243056394:-
BRCA	trans	rs853679	0.599	rs188015	ENSG00000228078.1	HLA-U	-5.78	9.73e-09	0.00643	-0.37	-0.18	Depression;	chr6:27909668	chr6:29934101~29934286:+
BRCA	trans	rs7113874	0.589	rs7127684	ENSG00000266891.1	RP11-692N5.2	5.78	9.76e-09	0.00645	0.2	0.18	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8441172	chr18:9734882~9735602:-
BRCA	trans	rs7568458	0.684	rs3731828	ENSG00000223886.3	RP11-251G23.2	5.78	9.81e-09	0.00648	0.22	0.18	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr2:85579143	chr7:105530209~105530671:+
BRCA	trans	rs7570469	0.959	rs12616530	ENSG00000276390.1	RP1-197B17.5	-5.78	9.83e-09	0.00649	-0.22	-0.18	Response to antipsychotic treatment;	chr2:79477914	chr12:47699401~47699917:-
BRCA	trans	rs7570469	0.959	rs10496228	ENSG00000276390.1	RP1-197B17.5	-5.78	9.83e-09	0.00649	-0.22	-0.18	Response to antipsychotic treatment;	chr2:79477990	chr12:47699401~47699917:-
BRCA	trans	rs7570469	0.881	rs13405677	ENSG00000276390.1	RP1-197B17.5	-5.78	9.83e-09	0.00649	-0.22	-0.18	Response to antipsychotic treatment;	chr2:79478552	chr12:47699401~47699917:-
BRCA	trans	rs4759042	0.527	rs324021	ENSG00000121089.4	NACA3P	-5.78	9.83e-09	0.00649	-0.21	-0.18	Migraine;	chr12:57052061	chr4:164943290~164943937:+
BRCA	trans	rs7746199	0.736	rs13212318	ENSG00000228078.1	HLA-U	-5.78	9.84e-09	0.0065	-0.47	-0.18	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27721062	chr6:29934101~29934286:+
BRCA	trans	rs1933488	0.509	rs485381	ENSG00000278974.1	RP11-756P10.6	5.78	9.84e-09	0.0065	0.23	0.18	Prostate cancer;	chr6:153144153	chr4:188740507~188741281:-
BRCA	trans	rs7647973	0.807	rs4955416	ENSG00000235912.1	RP1-159A19.3	-5.78	9.88e-09	0.00652	-0.23	-0.18	Menarche (age at onset);	chr3:49070995	chr1:27649419~27649610:+
BRCA	trans	rs35146811	0.735	rs858512	ENSG00000228546.2	CTA-313A17.3	5.78	9.91e-09	0.00654	0.25	0.18	Coronary artery disease;	chr7:100226830	chr7:102337316~102339115:+
BRCA	trans	rs35146811	0.7	rs858513	ENSG00000228546.2	CTA-313A17.3	5.78	9.91e-09	0.00654	0.25	0.18	Coronary artery disease;	chr7:100227935	chr7:102337316~102339115:+
BRCA	trans	rs13217239	0.646	rs12527111	ENSG00000216901.1	AL022393.7	-5.78	9.91e-09	0.00654	-0.21	-0.18	Schizophrenia;	chr6:27038696	chr6:28176188~28176674:+
BRCA	trans	rs7824557	0.652	rs12677504	ENSG00000254153.1	CTA-398F10.2	-5.78	9.93e-09	0.00655	-0.23	-0.18	Retinal vascular caliber;	chr8:11275666	chr8:8456909~8461337:-
BRCA	trans	rs66887589	0.616	rs11732621	ENSG00000276997.3	RP11-378J18.9	5.78	9.93e-09	0.00656	0.2	0.18	Diastolic blood pressure;	chr4:119291728	chr1:222477252~222504622:-
BRCA	trans	rs9393777	0.623	rs9348719	ENSG00000277241.1	RP11-114M1.3	5.78	9.93e-09	0.00656	0.27	0.18	Intelligence (multi-trait analysis);	chr6:26469804	chr3:177700346~177701072:-
BRCA	trans	rs853679	0.607	rs67040724	ENSG00000243753.4	HLA-L	-5.78	9.94e-09	0.00656	-0.47	-0.18	Depression;	chr6:27937731	chr6:30259584~30293014:+
BRCA	trans	rs7829975	0.582	rs6983150	ENSG00000270154.1	RP11-419I17.1	-5.78	9.94e-09	0.00656	-0.2	-0.18	Mood instability;	chr8:8934916	chr8:12476462~12477122:+
BRCA	trans	rs3740713	1	rs73440615	ENSG00000213574.2	LDHAP5	5.78	9.96e-09	0.00657	0.3	0.18	Amyotrophic lateral sclerosis (sporadic);	chr11:18445736	chr10:118932674~118933295:-
BRCA	trans	rs875971	0.965	rs10267430	ENSG00000164669.11	INTS4P1	5.78	9.97e-09	0.00658	0.22	0.18	Aortic root size;	chr7:66278036	chr7:65141225~65234216:+
BRCA	trans	rs877636	0.74	rs772920	ENSG00000227586.5	RP11-162A23.5	5.78	9.98e-09	0.00658	0.23	0.18	Cognitive function;	chr12:55996580	chr10:123171535~123171875:-
BRCA	trans	rs7260598	1	rs8110727	ENSG00000261770.1	CTC-459F4.1	5.78	1e-08	0.0066	0.3	0.18	Response to taxane treatment (placlitaxel);	chr19:24048114	chr19:27757184~27760849:-
BRCA	trans	rs12497850	0.864	rs4521268	ENSG00000197582.5	GPX1P1	5.78	1e-08	0.0066	0.19	0.18	Parkinson's disease;	chr3:49100471	chrX:13378735~13379340:-
BRCA	trans	rs7746199	0.736	rs13195636	ENSG00000243753.4	HLA-L	-5.78	1e-08	0.00662	-0.47	-0.18	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27541714	chr6:30259584~30293014:+
BRCA	trans	rs7746199	0.736	rs34965299	ENSG00000228078.1	HLA-U	-5.78	1e-08	0.00662	-0.46	-0.18	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27554077	chr6:29934101~29934286:+
BRCA	trans	rs9733	0.635	rs486836	ENSG00000180764.13	PIPSL	5.78	1e-08	0.00663	0.22	0.18	Tonsillectomy;	chr1:150903491	chr10:93958191~93961540:-
BRCA	trans	rs7570469	0.689	rs445812	ENSG00000276390.1	RP1-197B17.5	5.78	1.01e-08	0.00666	0.23	0.18	Response to antipsychotic treatment;	chr2:79471093	chr12:47699401~47699917:-
BRCA	trans	rs6995541	0.647	rs6991499	ENSG00000253893.2	FAM85B	-5.78	1.01e-08	0.00667	-0.22	-0.18	Triglyceride levels;	chr8:10831487	chr8:8167819~8226614:-
BRCA	trans	rs6831352	0.851	rs1230164	ENSG00000233859.2	ADH5P4	-5.78	1.01e-08	0.00668	-0.25	-0.18	Alcohol dependence;	chr4:99064872	chr6:65836930~65838039:-
BRCA	trans	rs319204	0.843	rs319171	ENSG00000226498.2	RP11-182B22.2	5.78	1.01e-08	0.00668	0.2	0.18	Schizophrenia;	chr5:146909243	chr1:236819634~236820518:+
BRCA	trans	rs853679	0.607	rs13208096	ENSG00000204338.7	CYP21A1P	-5.78	1.01e-08	0.00669	-0.42	-0.18	Depression;	chr6:28257533	chr6:32005636~32008451:+
BRCA	trans	rs7927771	0.832	rs4752990	ENSG00000134612.10	FOLH1B	-5.78	1.01e-08	0.00669	-0.24	-0.18	Subjective well-being;	chr11:47388842	chr11:89639227~89698718:+
BRCA	trans	rs546131	0.642	rs11603640	ENSG00000225531.1	RP11-196I18.3	-5.77	1.02e-08	0.00671	-0.29	-0.18	Lung disease severity in cystic fibrosis;	chr11:34811360	chr9:107116829~107117557:+
BRCA	trans	rs13196561	0.855	rs6916312	ENSG00000216895.7	AC009403.2	5.77	1.02e-08	0.00672	0.25	0.18	Menarche (age at onset);	chr6:100254301	chr7:155611231~155645205:-
BRCA	trans	rs9462846	0.96	rs12194860	ENSG00000231579.3	RPL7P21	5.77	1.02e-08	0.00673	0.25	0.18	Blood protein levels;	chr6:42895196	chr5:143332605~143333239:+
BRCA	trans	rs7746199	0.736	rs34573979	ENSG00000243753.4	HLA-L	-5.77	1.02e-08	0.00675	-0.47	-0.18	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27512747	chr6:30259584~30293014:+
BRCA	trans	rs6831352	0.76	rs1311616	ENSG00000233859.2	ADH5P4	-5.77	1.02e-08	0.00675	-0.25	-0.18	Alcohol dependence;	chr4:99091152	chr6:65836930~65838039:-
BRCA	trans	rs7662987	0.517	rs1311617	ENSG00000233859.2	ADH5P4	-5.77	1.02e-08	0.00675	-0.25	-0.18	Smoking initiation;	chr4:99091274	chr6:65836930~65838039:-
BRCA	trans	rs7662987	0.517	rs1311618	ENSG00000233859.2	ADH5P4	-5.77	1.02e-08	0.00675	-0.25	-0.18	Smoking initiation;	chr4:99091461	chr6:65836930~65838039:-
BRCA	trans	rs7746199	0.736	rs34965299	ENSG00000281831.1	HCP5B	5.77	1.03e-08	0.00675	0.43	0.18	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27554077	chr6:29871895~29873783:-
BRCA	trans	rs11098499	0.908	rs11098527	ENSG00000276805.1	RP11-291L22.6	5.77	1.03e-08	0.00676	0.21	0.18	Corneal astigmatism;	chr4:119478751	chr10:38451030~38451785:+
BRCA	trans	rs35491132	1	rs35491132	ENSG00000228078.1	HLA-U	-5.77	1.03e-08	0.00677	-0.45	-0.18	Urinary tract infection frequency;	chr6:27559449	chr6:29934101~29934286:+
BRCA	trans	rs7824557	0.619	rs7012218	ENSG00000253893.2	FAM85B	-5.77	1.03e-08	0.00677	-0.24	-0.18	Retinal vascular caliber;	chr8:11288167	chr8:8167819~8226614:-
BRCA	trans	rs3808502	0.501	rs7012219	ENSG00000253893.2	FAM85B	-5.77	1.03e-08	0.00677	-0.24	-0.18	Neuroticism;	chr8:11288170	chr8:8167819~8226614:-
BRCA	trans	rs875971	0.83	rs4718358	ENSG00000164669.11	INTS4P1	-5.77	1.03e-08	0.00678	-0.22	-0.18	Aortic root size;	chr7:66508681	chr7:65141225~65234216:+
BRCA	trans	rs9467711	0.651	rs35778245	ENSG00000253570.1	RNF5P1	5.77	1.03e-08	0.00679	0.43	0.18	Autism spectrum disorder or schizophrenia;	chr6:25944575	chr8:38600661~38601200:-
BRCA	trans	rs9467711	0.659	rs13195509	ENSG00000220721.1	OR1F12	5.77	1.03e-08	0.00679	0.37	0.18	Autism spectrum disorder or schizophrenia;	chr6:26463432	chr6:28073316~28074233:+
BRCA	trans	rs877636	0.702	rs61937249	ENSG00000227586.5	RP11-162A23.5	5.77	1.03e-08	0.00679	0.23	0.18	Cognitive function;	chr12:55988132	chr10:123171535~123171875:-
BRCA	trans	rs6011368	0.678	rs6062359	ENSG00000226210.3	WASH7P	-5.77	1.03e-08	0.0068	-0.19	-0.18	Clozapine-induced cytotoxicity;	chr20:64269027	chr12:14522~32015:-
BRCA	trans	rs13217239	0.646	rs10456351	ENSG00000216901.1	AL022393.7	-5.77	1.03e-08	0.00681	-0.21	-0.18	Schizophrenia;	chr6:27019013	chr6:28176188~28176674:+
BRCA	trans	rs6934970	0.932	rs7738384	ENSG00000267560.1	RP11-173A16.1	-5.77	1.04e-08	0.00682	-0.22	-0.18	Bipolar disorder (body mass index interaction);	chr6:112819440	chr18:62300036~62300998:-
BRCA	trans	rs875971	0.522	rs1617484	ENSG00000213640.3	EEF1DP4	-5.77	1.04e-08	0.00682	-0.22	-0.18	Aortic root size;	chr7:65998108	chr7:64862999~64864370:+
BRCA	trans	rs9393777	0.622	rs13191326	ENSG00000204709.4	LINC01556	5.77	1.04e-08	0.00683	0.36	0.18	Intelligence (multi-trait analysis);	chr6:27063250	chr6:28943877~28944537:+
BRCA	trans	rs853679	0.607	rs67998226	ENSG00000228078.1	HLA-U	-5.77	1.04e-08	0.00683	-0.45	-0.18	Depression;	chr6:28270281	chr6:29934101~29934286:+
BRCA	trans	rs546131	0.642	rs35833762	ENSG00000225531.1	RP11-196I18.3	-5.77	1.04e-08	0.00683	-0.29	-0.18	Lung disease severity in cystic fibrosis;	chr11:34824311	chr9:107116829~107117557:+
BRCA	trans	rs6142102	0.625	rs4911137	ENSG00000280327.1	LA16c-313F4.1	-5.77	1.04e-08	0.00683	-0.18	-0.18	Skin pigmentation;	chr20:33947657	chr16:1576716~1578371:-
BRCA	trans	rs7746199	0.673	rs35501037	ENSG00000204709.4	LINC01556	5.77	1.04e-08	0.00685	0.44	0.18	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27771787	chr6:28943877~28944537:+
BRCA	trans	rs45509595	0.749	rs401763	ENSG00000253570.1	RNF5P1	5.77	1.04e-08	0.00687	0.39	0.18	Breast cancer;	chr6:27814750	chr8:38600661~38601200:-
BRCA	trans	rs45509595	0.659	rs390764	ENSG00000253570.1	RNF5P1	5.77	1.04e-08	0.00687	0.39	0.18	Breast cancer;	chr6:27814757	chr8:38600661~38601200:-
BRCA	trans	rs45509595	0.841	rs401754	ENSG00000253570.1	RNF5P1	5.77	1.04e-08	0.00687	0.39	0.18	Breast cancer;	chr6:27814760	chr8:38600661~38601200:-
BRCA	trans	rs35306767	0.909	rs12264390	ENSG00000187984.11	ANKRD19P	5.77	1.04e-08	0.00687	0.21	0.18	Eosinophil percentage of granulocytes;	chr10:913171	chr9:92809388~92888693:+
BRCA	trans	rs9860340	0.73	rs7617101	ENSG00000259370.2	RP11-1069G10.1	5.77	1.04e-08	0.00687	0.21	0.18	Electroencephalographic traits in alcoholism;	chr3:87584406	chr15:62827675~62884034:-
BRCA	trans	rs9860340	0.69	rs7619452	ENSG00000259370.2	RP11-1069G10.1	5.77	1.04e-08	0.00687	0.21	0.18	Electroencephalographic traits in alcoholism;	chr3:87584553	chr15:62827675~62884034:-
BRCA	trans	rs9860340	0.69	rs2048292	ENSG00000259370.2	RP11-1069G10.1	5.77	1.04e-08	0.00687	0.21	0.18	Electroencephalographic traits in alcoholism;	chr3:87585121	chr15:62827675~62884034:-
BRCA	trans	rs801193	0.66	rs2659897	ENSG00000164669.11	INTS4P1	5.77	1.05e-08	0.00688	0.22	0.18	Aortic root size;	chr7:66722728	chr7:65141225~65234216:+
BRCA	trans	rs16975963	0.644	rs11083430	ENSG00000247498.8	RP11-392P7.6	5.77	1.05e-08	0.00689	0.31	0.18	Longevity;	chr19:37648587	chr12:12927726~12984645:+
BRCA	trans	rs875971	1	rs709595	ENSG00000164669.11	INTS4P1	-5.77	1.05e-08	0.0069	-0.21	-0.18	Aortic root size;	chr7:66352346	chr7:65141225~65234216:+
BRCA	trans	rs875971	1	rs811880	ENSG00000164669.11	INTS4P1	-5.77	1.05e-08	0.0069	-0.21	-0.18	Aortic root size;	chr7:66353659	chr7:65141225~65234216:+
BRCA	trans	rs616147	0.627	rs9871799	ENSG00000244722.1	RP11-179A18.1	5.77	1.05e-08	0.0069	0.21	0.18	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39442829	chr3:110682286~110683154:-
BRCA	trans	rs1568889	1	rs61889027	ENSG00000174912.7	METTL15P1	5.77	1.05e-08	0.0069	0.21	0.18	Bipolar disorder;	chr11:28260361	chr3:156713884~156714928:-
BRCA	trans	rs9467711	0.606	rs13190739	ENSG00000220721.1	OR1F12	5.77	1.05e-08	0.00691	0.38	0.18	Autism spectrum disorder or schizophrenia;	chr6:26587145	chr6:28073316~28074233:+
BRCA	trans	rs9467711	0.606	rs34781270	ENSG00000220721.1	OR1F12	5.77	1.05e-08	0.00691	0.38	0.18	Autism spectrum disorder or schizophrenia;	chr6:26592809	chr6:28073316~28074233:+
BRCA	trans	rs7746199	0.736	rs35848276	ENSG00000228078.1	HLA-U	-5.77	1.05e-08	0.00691	-0.47	-0.18	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27553317	chr6:29934101~29934286:+
BRCA	trans	rs853679	0.556	rs45509595	ENSG00000204709.4	LINC01556	5.77	1.05e-08	0.00691	0.48	0.18	Depression;	chr6:27873148	chr6:28943877~28944537:+
BRCA	trans	rs853679	0.556	rs34706883	ENSG00000228078.1	HLA-U	-5.77	1.05e-08	0.00693	-0.47	-0.18	Depression;	chr6:27837477	chr6:29934101~29934286:+
BRCA	trans	rs875971	1	rs1540651	ENSG00000164669.11	INTS4P1	5.77	1.05e-08	0.00693	0.22	0.18	Aortic root size;	chr7:66185134	chr7:65141225~65234216:+
BRCA	trans	rs6934970	1	rs6927096	ENSG00000267560.1	RP11-173A16.1	-5.77	1.06e-08	0.00695	-0.22	-0.18	Bipolar disorder (body mass index interaction);	chr6:112808546	chr18:62300036~62300998:-
BRCA	trans	rs9649213	0.537	rs6971825	ENSG00000225169.1	BRI3P1	5.77	1.06e-08	0.00696	0.22	0.18	Prostate cancer (SNP x SNP interaction);	chr7:98350236	chr1:100213293~100213670:+
BRCA	trans	rs10028773	0.515	rs9994651	ENSG00000276805.1	RP11-291L22.6	5.77	1.06e-08	0.00696	0.2	0.18	Educational attainment;	chr4:119666648	chr10:38451030~38451785:+
BRCA	trans	rs4925540	0.962	rs7549105	ENSG00000226121.2	AC009487.6	5.77	1.06e-08	0.00697	0.23	0.18	Response to taxane treatment (docetaxel);	chr1:247041754	chr2:161500885~161507705:-
BRCA	trans	rs9650657	0.665	rs7002117	ENSG00000253893.2	FAM85B	-5.77	1.06e-08	0.00697	-0.21	-0.18	Neuroticism;	chr8:10758659	chr8:8167819~8226614:-
BRCA	trans	rs673253	0.556	rs2274465	ENSG00000231007.5	CDC20P1	-5.77	1.06e-08	0.00697	-0.23	-0.18	Intelligence (multi-trait analysis);	chr1:43655886	chr9:87011652~87013151:+
BRCA	trans	rs13217239	0.608	rs6930508	ENSG00000216901.1	AL022393.7	5.77	1.06e-08	0.00698	0.21	0.18	Schizophrenia;	chr6:27085363	chr6:28176188~28176674:+
BRCA	trans	rs13217239	0.646	rs2142685	ENSG00000216901.1	AL022393.7	5.77	1.06e-08	0.00698	0.21	0.18	Schizophrenia;	chr6:27086718	chr6:28176188~28176674:+
BRCA	trans	rs9860340	0.73	rs2202916	ENSG00000259370.2	RP11-1069G10.1	5.77	1.06e-08	0.00698	0.21	0.18	Electroencephalographic traits in alcoholism;	chr3:87596957	chr15:62827675~62884034:-
BRCA	trans	rs11098499	0.954	rs9998585	ENSG00000276805.1	RP11-291L22.6	5.77	1.06e-08	0.00699	0.21	0.18	Corneal astigmatism;	chr4:119475647	chr10:38451030~38451785:+
BRCA	trans	rs11098499	0.909	rs6842762	ENSG00000276805.1	RP11-291L22.6	5.77	1.06e-08	0.00699	0.21	0.18	Corneal astigmatism;	chr4:119477081	chr10:38451030~38451785:+
BRCA	trans	rs3732378	0.666	rs11709600	ENSG00000183298.5	RP11-556K13.1	5.77	1.07e-08	0.007	0.28	0.18	Monocyte count;Lymphocyte counts;Granulocyte percentage of myeloid white cells;Monocyte percentage of white cells;	chr3:39258178	chr1:101786340~101787219:-
BRCA	trans	rs3750082	0.852	rs2392152	ENSG00000176826.14	FKBP9P1	-5.77	1.07e-08	0.007	-0.22	-0.18	Glomerular filtration rate (creatinine);	chr7:32860937	chr7:55681074~55713252:-
BRCA	trans	rs11098499	0.566	rs7664440	ENSG00000253326.2	RP11-261C10.7	5.77	1.07e-08	0.00701	0.26	0.18	Corneal astigmatism;	chr4:119657385	chr1:243054861~243056394:-
BRCA	trans	rs35491132	1	rs35491132	ENSG00000281831.1	HCP5B	5.77	1.07e-08	0.00702	0.43	0.18	Urinary tract infection frequency;	chr6:27559449	chr6:29871895~29873783:-
BRCA	trans	rs7927771	0.832	rs7924485	ENSG00000134612.10	FOLH1B	5.77	1.07e-08	0.00702	0.23	0.18	Subjective well-being;	chr11:47397578	chr11:89639227~89698718:+
BRCA	trans	rs7746199	0.736	rs13202291	ENSG00000228078.1	HLA-U	-5.77	1.07e-08	0.00703	-0.47	-0.18	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27731078	chr6:29934101~29934286:+
BRCA	trans	rs7746199	0.736	rs17750424	ENSG00000228078.1	HLA-U	-5.77	1.07e-08	0.00703	-0.47	-0.18	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27733343	chr6:29934101~29934286:+
BRCA	trans	rs875971	1	rs11974219	ENSG00000164669.11	INTS4P1	5.77	1.07e-08	0.00704	0.22	0.18	Aortic root size;	chr7:66182423	chr7:65141225~65234216:+
BRCA	trans	rs71537559	1	rs71537559	ENSG00000281831.1	HCP5B	5.77	1.07e-08	0.00704	0.41	0.18	Squamous cell lung carcinoma;	chr6:27342000	chr6:29871895~29873783:-
BRCA	trans	rs4948102	0.727	rs4948097	ENSG00000186940.6	CHCHD2P9	-5.77	1.07e-08	0.00705	-0.23	-0.18	Plasma homocysteine levels (post-methionine load test);	chr7:55988878	chr9:79391304~79391759:+
BRCA	trans	rs546131	0.642	rs12794294	ENSG00000225531.1	RP11-196I18.3	-5.77	1.07e-08	0.00705	-0.28	-0.18	Lung disease severity in cystic fibrosis;	chr11:34805971	chr9:107116829~107117557:+
BRCA	trans	rs9649213	0.593	rs7797943	ENSG00000225169.1	BRI3P1	5.76	1.08e-08	0.00707	0.22	0.18	Prostate cancer (SNP x SNP interaction);	chr7:98317590	chr1:100213293~100213670:+
BRCA	trans	rs7568458	0.87	rs1010	ENSG00000223886.3	RP11-251G23.2	-5.76	1.08e-08	0.00707	-0.2	-0.18	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr2:85581859	chr7:105530209~105530671:+
BRCA	trans	rs875971	0.545	rs75577046	ENSG00000234585.5	CCT6P3	5.76	1.08e-08	0.00707	0.19	0.18	Aortic root size;	chr7:66493729	chr7:65038354~65074713:+
BRCA	trans	rs11098499	0.954	rs4577559	ENSG00000276805.1	RP11-291L22.6	5.76	1.08e-08	0.00708	0.21	0.18	Corneal astigmatism;	chr4:119482888	chr10:38451030~38451785:+
BRCA	trans	rs11098499	0.954	rs7656252	ENSG00000276805.1	RP11-291L22.6	5.76	1.08e-08	0.00708	0.21	0.18	Corneal astigmatism;	chr4:119483113	chr10:38451030~38451785:+
BRCA	trans	rs11098499	0.865	rs28845498	ENSG00000276805.1	RP11-291L22.6	5.76	1.08e-08	0.00708	0.21	0.18	Corneal astigmatism;	chr4:119484031	chr10:38451030~38451785:+
BRCA	trans	rs11098499	0.954	rs56270433	ENSG00000276805.1	RP11-291L22.6	5.76	1.08e-08	0.00708	0.21	0.18	Corneal astigmatism;	chr4:119484875	chr10:38451030~38451785:+
BRCA	trans	rs7829975	0.564	rs2921060	ENSG00000255046.1	RP11-297N6.4	5.76	1.08e-08	0.00708	0.21	0.18	Mood instability;	chr8:8460307	chr8:11797928~11802568:-
BRCA	trans	rs16975963	0.644	rs1478462	ENSG00000247498.8	RP11-392P7.6	5.76	1.08e-08	0.0071	0.31	0.18	Longevity;	chr19:37656124	chr12:12927726~12984645:+
BRCA	trans	rs6831352	0.918	rs2602894	ENSG00000233859.2	ADH5P4	-5.76	1.08e-08	0.00711	-0.25	-0.18	Alcohol dependence;	chr4:99124496	chr6:65836930~65838039:-
BRCA	trans	rs6831352	0.918	rs2602895	ENSG00000233859.2	ADH5P4	-5.76	1.08e-08	0.00711	-0.25	-0.18	Alcohol dependence;	chr4:99124689	chr6:65836930~65838039:-
BRCA	trans	rs4713118	0.615	rs9348772	ENSG00000243753.4	HLA-L	-5.76	1.08e-08	0.00711	-0.23	-0.18	Parkinson's disease;	chr6:27688311	chr6:30259584~30293014:+
BRCA	trans	rs12497850	0.897	rs6795025	ENSG00000197582.5	GPX1P1	5.76	1.08e-08	0.00711	0.19	0.18	Parkinson's disease;	chr3:49043814	chrX:13378735~13379340:-
BRCA	trans	rs7568458	0.846	rs7605975	ENSG00000223886.3	RP11-251G23.2	5.76	1.09e-08	0.00712	0.2	0.18	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr2:85545425	chr7:105530209~105530671:+
BRCA	trans	rs7568458	0.846	rs6547621	ENSG00000223886.3	RP11-251G23.2	5.76	1.09e-08	0.00712	0.2	0.18	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr2:85547553	chr7:105530209~105530671:+
BRCA	trans	rs62295889	0.602	rs62295919	ENSG00000232228.1	RP11-77O7.1	-5.76	1.09e-08	0.00712	-0.26	-0.18	Obesity-related traits;	chr4:12535456	chr2:69594741~69595058:-
BRCA	trans	rs62295889	0.602	rs60391312	ENSG00000232228.1	RP11-77O7.1	-5.76	1.09e-08	0.00712	-0.26	-0.18	Obesity-related traits;	chr4:12536196	chr2:69594741~69595058:-
BRCA	trans	rs62295889	0.602	rs55646236	ENSG00000232228.1	RP11-77O7.1	-5.76	1.09e-08	0.00712	-0.26	-0.18	Obesity-related traits;	chr4:12536471	chr2:69594741~69595058:-
BRCA	trans	rs62295889	0.602	rs58048371	ENSG00000232228.1	RP11-77O7.1	-5.76	1.09e-08	0.00712	-0.26	-0.18	Obesity-related traits;	chr4:12536526	chr2:69594741~69595058:-
BRCA	trans	rs62295889	0.602	rs58099533	ENSG00000232228.1	RP11-77O7.1	-5.76	1.09e-08	0.00712	-0.26	-0.18	Obesity-related traits;	chr4:12536590	chr2:69594741~69595058:-
BRCA	trans	rs62295889	0.602	rs62293665	ENSG00000232228.1	RP11-77O7.1	-5.76	1.09e-08	0.00712	-0.26	-0.18	Obesity-related traits;	chr4:12536977	chr2:69594741~69595058:-
BRCA	trans	rs62295889	0.673	rs62293666	ENSG00000232228.1	RP11-77O7.1	-5.76	1.09e-08	0.00712	-0.26	-0.18	Obesity-related traits;	chr4:12537265	chr2:69594741~69595058:-
BRCA	trans	rs35146811	0.731	rs2257213	ENSG00000228546.2	CTA-313A17.3	5.76	1.09e-08	0.00718	0.25	0.18	Coronary artery disease;	chr7:100212490	chr7:102337316~102339115:+
BRCA	trans	rs6929812	0.546	rs2393962	ENSG00000242375.1	RP11-498P14.3	5.76	1.1e-08	0.00719	0.24	0.18	Neuroticism (multi-trait analysis);	chr6:27495045	chr9:97195351~97197687:-
BRCA	trans	rs7312770	1	rs7312770	ENSG00000227586.5	RP11-162A23.5	-5.76	1.1e-08	0.00721	-0.2	-0.18	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr10:123171535~123171875:-
BRCA	trans	rs853679	0.666	rs200956	ENSG00000253570.1	RNF5P1	5.76	1.1e-08	0.00721	0.32	0.18	Depression;	chr6:27871968	chr8:38600661~38601200:-
BRCA	trans	rs641862	1	rs641862	ENSG00000243406.5	MRPS31P5	5.76	1.1e-08	0.00722	0.23	0.18	Obesity-related traits;	chr13:110137885	chr13:52167709~52194465:-
BRCA	trans	rs6831352	0.918	rs2851246	ENSG00000233859.2	ADH5P4	-5.76	1.1e-08	0.00723	-0.25	-0.18	Alcohol dependence;	chr4:99124953	chr6:65836930~65838039:-
BRCA	trans	rs9649213	0.593	rs6945554	ENSG00000225169.1	BRI3P1	5.76	1.1e-08	0.00723	0.22	0.18	Prostate cancer (SNP x SNP interaction);	chr7:98343634	chr1:100213293~100213670:+
BRCA	trans	rs17834760	0.507	rs56145023	ENSG00000215190.7	LINC00680	-5.76	1.1e-08	0.00723	-0.2	-0.18	Antipsychotic drug-induced QTc interval change in schizophrenia;	chr6:61159604	chr6:57946074~57961501:-
BRCA	trans	rs7829975	0.606	rs6422352	ENSG00000270154.1	RP11-419I17.1	-5.76	1.1e-08	0.00723	-0.2	-0.18	Mood instability;	chr8:8936683	chr8:12476462~12477122:+
BRCA	trans	rs9393777	0.623	rs56296968	ENSG00000277241.1	RP11-114M1.3	5.76	1.1e-08	0.00723	0.27	0.18	Intelligence (multi-trait analysis);	chr6:26474343	chr3:177700346~177701072:-
BRCA	trans	rs941207	0.507	rs7297289	ENSG00000257210.1	NACAP3	5.76	1.1e-08	0.00723	0.21	0.18	Platelet count;	chr12:56682703	chr12:93124063~93124543:-
BRCA	trans	rs16975963	0.644	rs12459013	ENSG00000247498.8	RP11-392P7.6	5.76	1.1e-08	0.00723	0.31	0.18	Longevity;	chr19:37638596	chr12:12927726~12984645:+
BRCA	trans	rs4948102	0.824	rs11238389	ENSG00000186940.6	CHCHD2P9	-5.76	1.1e-08	0.00724	-0.23	-0.18	Plasma homocysteine levels (post-methionine load test);	chr7:56012051	chr9:79391304~79391759:+
BRCA	trans	rs801193	0.66	rs10950049	ENSG00000164669.11	INTS4P1	-5.76	1.1e-08	0.00724	-0.22	-0.18	Aortic root size;	chr7:66765873	chr7:65141225~65234216:+
BRCA	trans	rs17161791	1	rs17161757	ENSG00000233589.1	RP4-694A7.2	5.76	1.1e-08	0.00724	0.2	0.18	Pulmonary function in asthmatics;	chr7:9559939	chr1:68479129~68483539:+
BRCA	trans	rs546131	0.642	rs1039841	ENSG00000225531.1	RP11-196I18.3	-5.76	1.11e-08	0.00725	-0.28	-0.18	Lung disease severity in cystic fibrosis;	chr11:34811592	chr9:107116829~107117557:+
BRCA	trans	rs546131	0.642	rs1594426	ENSG00000225531.1	RP11-196I18.3	-5.76	1.11e-08	0.00725	-0.28	-0.18	Lung disease severity in cystic fibrosis;	chr11:34811912	chr9:107116829~107117557:+
BRCA	trans	rs546131	0.642	rs12793173	ENSG00000225531.1	RP11-196I18.3	-5.76	1.11e-08	0.00725	-0.28	-0.18	Lung disease severity in cystic fibrosis;	chr11:34812657	chr9:107116829~107117557:+
BRCA	trans	rs546131	0.614	rs12791769	ENSG00000225531.1	RP11-196I18.3	-5.76	1.11e-08	0.00725	-0.28	-0.18	Lung disease severity in cystic fibrosis;	chr11:34812721	chr9:107116829~107117557:+
BRCA	trans	rs546131	0.614	rs35264793	ENSG00000225531.1	RP11-196I18.3	-5.76	1.11e-08	0.00725	-0.28	-0.18	Lung disease severity in cystic fibrosis;	chr11:34813297	chr9:107116829~107117557:+
BRCA	trans	rs875971	1	rs10257427	ENSG00000164669.11	INTS4P1	5.76	1.11e-08	0.00726	0.21	0.18	Aortic root size;	chr7:66278221	chr7:65141225~65234216:+
BRCA	trans	rs35146811	0.624	rs1727134	ENSG00000228546.2	CTA-313A17.3	5.76	1.11e-08	0.00726	0.25	0.18	Coronary artery disease;	chr7:100216049	chr7:102337316~102339115:+
BRCA	trans	rs35146811	0.735	rs1636978	ENSG00000228546.2	CTA-313A17.3	5.76	1.11e-08	0.00726	0.25	0.18	Coronary artery disease;	chr7:100216289	chr7:102337316~102339115:+
BRCA	trans	rs35146811	0.735	rs858505	ENSG00000228546.2	CTA-313A17.3	5.76	1.11e-08	0.00726	0.25	0.18	Coronary artery disease;	chr7:100221954	chr7:102337316~102339115:+
BRCA	trans	rs7570469	0.722	rs7371189	ENSG00000276390.1	RP1-197B17.5	-5.76	1.11e-08	0.00727	-0.23	-0.18	Response to antipsychotic treatment;	chr2:79488176	chr12:47699401~47699917:-
BRCA	trans	rs4929949	0.809	rs1900272	ENSG00000266891.1	RP11-692N5.2	5.76	1.11e-08	0.00727	0.21	0.18	Body mass index;	chr11:8546112	chr18:9734882~9735602:-
BRCA	trans	rs4879656	0.843	rs10813918	ENSG00000215007.3	DNAJA1P3	-5.76	1.11e-08	0.00728	-0.21	-0.18	Menopause (age at onset);	chr9:32996372	chrX:107351650~107352843:-
BRCA	trans	rs4948102	0.731	rs4543497	ENSG00000186940.6	CHCHD2P9	-5.76	1.12e-08	0.00732	-0.23	-0.18	Plasma homocysteine levels (post-methionine load test);	chr7:55979522	chr9:79391304~79391759:+
BRCA	trans	rs4948102	0.767	rs4948096	ENSG00000186940.6	CHCHD2P9	-5.76	1.12e-08	0.00732	-0.23	-0.18	Plasma homocysteine levels (post-methionine load test);	chr7:55985425	chr9:79391304~79391759:+
BRCA	trans	rs11039131	0.629	rs67871383	ENSG00000134612.10	FOLH1B	-5.76	1.12e-08	0.00732	-0.24	-0.18	Schizophrenia;	chr11:47314287	chr11:89639227~89698718:+
BRCA	trans	rs9467711	0.659	rs36162392	ENSG00000281831.1	HCP5B	5.76	1.12e-08	0.00734	0.4	0.18	Autism spectrum disorder or schizophrenia;	chr6:26568907	chr6:29871895~29873783:-
BRCA	trans	rs2242330	1	rs28371412	ENSG00000226982.4	CENPCP1	5.76	1.12e-08	0.00735	0.26	0.18	Parkinson's disease;	chr4:67549807	chr12:89500093~89502670:+
BRCA	trans	rs7927771	0.832	rs11039212	ENSG00000134612.10	FOLH1B	5.76	1.13e-08	0.00736	0.23	0.18	Subjective well-being;	chr11:47371752	chr11:89639227~89698718:+
BRCA	trans	rs1459104	0.925	rs34245100	ENSG00000134612.10	FOLH1B	-5.76	1.13e-08	0.00738	-0.36	-0.18	Body mass index;	chr11:55443715	chr11:89639227~89698718:+
BRCA	trans	rs875971	0.545	rs1638724	ENSG00000213640.3	EEF1DP4	5.76	1.13e-08	0.00738	0.25	0.18	Aortic root size;	chr7:66575494	chr7:64862999~64864370:+
BRCA	trans	rs7824557	0.67	rs2736381	ENSG00000254153.1	CTA-398F10.2	-5.76	1.13e-08	0.00741	-0.22	-0.18	Retinal vascular caliber;	chr8:11275257	chr8:8456909~8461337:-
BRCA	trans	rs7746199	0.736	rs13209332	ENSG00000243753.4	HLA-L	-5.76	1.13e-08	0.00741	-0.46	-0.18	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27552973	chr6:30259584~30293014:+
BRCA	trans	rs9467711	0.659	rs3734542	ENSG00000220721.1	OR1F12	5.76	1.13e-08	0.00742	0.37	0.18	Autism spectrum disorder or schizophrenia;	chr6:26468098	chr6:28073316~28074233:+
BRCA	trans	rs1459104	1	rs7925158	ENSG00000134612.10	FOLH1B	-5.76	1.14e-08	0.00743	-0.32	-0.18	Body mass index;	chr11:55391087	chr11:89639227~89698718:+
BRCA	trans	rs78944489	0.867	rs12104774	ENSG00000236165.1	PRADC1P1	5.75	1.14e-08	0.00745	0.34	0.18	Schizophrenia;	chr2:73245296	chr3:36976316~36976840:+
BRCA	trans	rs12497850	0.897	rs7432989	ENSG00000197582.5	GPX1P1	5.75	1.14e-08	0.00746	0.19	0.18	Parkinson's disease;	chr3:49067703	chrX:13378735~13379340:-
BRCA	trans	rs875971	1	rs2420168	ENSG00000164669.11	INTS4P1	5.75	1.14e-08	0.00746	0.21	0.18	Aortic root size;	chr7:66165644	chr7:65141225~65234216:+
BRCA	trans	rs6921919	0.848	rs6903652	ENSG00000253570.1	RNF5P1	5.75	1.14e-08	0.00748	0.29	0.18	Autism spectrum disorder or schizophrenia;	chr6:28354343	chr8:38600661~38601200:-
BRCA	trans	rs6011368	0.63	rs1570520	ENSG00000226210.3	WASH7P	5.75	1.15e-08	0.0075	0.19	0.18	Clozapine-induced cytotoxicity;	chr20:64279601	chr12:14522~32015:-
BRCA	trans	rs875971	0.964	rs55748098	ENSG00000164669.11	INTS4P1	5.75	1.15e-08	0.0075	0.21	0.18	Aortic root size;	chr7:66298631	chr7:65141225~65234216:+
BRCA	trans	rs9860340	0.73	rs77455828	ENSG00000259370.2	RP11-1069G10.1	5.75	1.15e-08	0.00752	0.21	0.18	Electroencephalographic traits in alcoholism;	chr3:87597128	chr15:62827675~62884034:-
BRCA	trans	rs4948102	0.731	rs6593292	ENSG00000186940.6	CHCHD2P9	-5.75	1.15e-08	0.00753	-0.23	-0.18	Plasma homocysteine levels (post-methionine load test);	chr7:55975344	chr9:79391304~79391759:+
BRCA	trans	rs11098499	0.73	rs78971550	ENSG00000120555.12	SEPT7P9	5.75	1.15e-08	0.00753	0.21	0.18	Corneal astigmatism;	chr4:119359886	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.645	rs78422072	ENSG00000120555.12	SEPT7P9	5.75	1.15e-08	0.00753	0.21	0.18	Corneal astigmatism;	chr4:119359887	chr10:38383069~38402916:-
BRCA	trans	rs6489882	0.867	rs1859335	ENSG00000250770.2	RP5-1063M23.1	5.75	1.16e-08	0.00756	0.23	0.18	Chronic lymphocytic leukemia;	chr12:112929520	chr12:3296202~3300224:-
BRCA	trans	rs6489882	0.807	rs1859334	ENSG00000250770.2	RP5-1063M23.1	5.75	1.16e-08	0.00756	0.23	0.18	Chronic lymphocytic leukemia;	chr12:112929527	chr12:3296202~3300224:-
BRCA	trans	rs6489882	0.836	rs2384071	ENSG00000250770.2	RP5-1063M23.1	5.75	1.16e-08	0.00756	0.23	0.18	Chronic lymphocytic leukemia;	chr12:112929538	chr12:3296202~3300224:-
BRCA	trans	rs853679	0.882	rs9461432	ENSG00000228078.1	HLA-U	-5.75	1.16e-08	0.00757	-0.36	-0.18	Depression;	chr6:28119105	chr6:29934101~29934286:+
BRCA	trans	rs7829975	0.572	rs28730413	ENSG00000270154.1	RP11-419I17.1	-5.75	1.16e-08	0.00757	-0.2	-0.18	Mood instability;	chr8:8937937	chr8:12476462~12477122:+
BRCA	trans	rs6831352	0.918	rs4699712	ENSG00000233859.2	ADH5P4	5.75	1.16e-08	0.00758	0.25	0.18	Alcohol dependence;	chr4:99139339	chr6:65836930~65838039:-
BRCA	trans	rs7647973	0.925	rs7429661	ENSG00000235912.1	RP1-159A19.3	-5.75	1.16e-08	0.00758	-0.23	-0.18	Menarche (age at onset);	chr3:49191367	chr1:27649419~27649610:+
BRCA	trans	rs6921919	0.848	rs56131013	ENSG00000253570.1	RNF5P1	5.75	1.16e-08	0.00759	0.29	0.18	Autism spectrum disorder or schizophrenia;	chr6:28352900	chr8:38600661~38601200:-
BRCA	trans	rs3812762	0.917	rs905289	ENSG00000266891.1	RP11-692N5.2	-5.75	1.17e-08	0.00762	-0.21	-0.18	Hypospadias;	chr11:8732005	chr18:9734882~9735602:-
BRCA	trans	rs17507216	0.671	rs4779035	ENSG00000235370.6	DNM1P51	-5.75	1.17e-08	0.00763	-0.26	-0.18	Excessive daytime sleepiness;	chr15:82591686	chr15:84398316~84411701:-
BRCA	trans	rs17507216	0.718	rs4779033	ENSG00000235370.6	DNM1P51	5.75	1.17e-08	0.00764	0.25	0.18	Excessive daytime sleepiness;	chr15:82576634	chr15:84398316~84411701:-
BRCA	trans	rs11098499	0.954	rs11940028	ENSG00000276805.1	RP11-291L22.6	5.75	1.17e-08	0.00765	0.21	0.18	Corneal astigmatism;	chr4:119490752	chr10:38451030~38451785:+
BRCA	trans	rs11098499	0.954	rs11935596	ENSG00000276805.1	RP11-291L22.6	5.75	1.17e-08	0.00765	0.21	0.18	Corneal astigmatism;	chr4:119491302	chr10:38451030~38451785:+
BRCA	trans	rs11098499	0.954	rs12507964	ENSG00000276805.1	RP11-291L22.6	5.75	1.17e-08	0.00765	0.21	0.18	Corneal astigmatism;	chr4:119491906	chr10:38451030~38451785:+
BRCA	trans	rs11098499	0.909	rs11098530	ENSG00000276805.1	RP11-291L22.6	5.75	1.17e-08	0.00765	0.21	0.18	Corneal astigmatism;	chr4:119491999	chr10:38451030~38451785:+
BRCA	trans	rs902774	0.818	rs79377635	ENSG00000255815.3	KRT8P11	-5.75	1.18e-08	0.00767	-0.36	-0.18	Prostate cancer;	chr12:52883148	chr9:99305176~99306611:+
BRCA	trans	rs9467711	0.606	rs13190739	ENSG00000281831.1	HCP5B	5.75	1.18e-08	0.00769	0.4	0.18	Autism spectrum disorder or schizophrenia;	chr6:26587145	chr6:29871895~29873783:-
BRCA	trans	rs9467711	0.606	rs34781270	ENSG00000281831.1	HCP5B	5.75	1.18e-08	0.00769	0.4	0.18	Autism spectrum disorder or schizophrenia;	chr6:26592809	chr6:29871895~29873783:-
BRCA	trans	rs714543	0.566	rs13231886	ENSG00000234397.3	RP11-415K20.1	-5.75	1.18e-08	0.00769	-0.2	-0.18	Plateletcrit;	chr7:44774573	chr1:22322840~22323331:-
BRCA	trans	rs7568458	0.636	rs11126995	ENSG00000223886.3	RP11-251G23.2	5.75	1.18e-08	0.00769	0.22	0.18	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr2:85565285	chr7:105530209~105530671:+
BRCA	trans	rs6831352	0.918	rs1042364	ENSG00000233859.2	ADH5P4	-5.75	1.18e-08	0.00772	-0.25	-0.18	Alcohol dependence;	chr4:99124423	chr6:65836930~65838039:-
BRCA	trans	rs367943	0.871	rs348940	ENSG00000213212.3	NCLP1	5.75	1.19e-08	0.00773	0.2	0.18	Type 2 diabetes;	chr5:113488833	chr9:136812788~136815536:-
BRCA	trans	rs367943	0.871	rs348938	ENSG00000213212.3	NCLP1	5.75	1.19e-08	0.00773	0.2	0.18	Type 2 diabetes;	chr5:113489335	chr9:136812788~136815536:-
BRCA	trans	rs11098499	0.604	rs12642411	ENSG00000276805.1	RP11-291L22.6	5.75	1.19e-08	0.00775	0.22	0.18	Corneal astigmatism;	chr4:119659370	chr10:38451030~38451785:+
BRCA	trans	rs11098499	0.954	rs7681544	ENSG00000276805.1	RP11-291L22.6	5.75	1.19e-08	0.00775	0.21	0.18	Corneal astigmatism;	chr4:119490100	chr10:38451030~38451785:+
BRCA	trans	rs66887589	0.592	rs2175383	ENSG00000276997.3	RP11-378J18.9	5.75	1.19e-08	0.00775	0.2	0.18	Diastolic blood pressure;	chr4:119294681	chr1:222477252~222504622:-
BRCA	trans	rs9467711	0.79	rs67777156	ENSG00000204709.4	LINC01556	5.75	1.19e-08	0.00775	0.46	0.18	Autism spectrum disorder or schizophrenia;	chr6:26633483	chr6:28943877~28944537:+
BRCA	trans	rs6831352	0.837	rs2924583	ENSG00000233859.2	ADH5P4	-5.75	1.19e-08	0.00777	-0.25	-0.18	Alcohol dependence;	chr4:99123489	chr6:65836930~65838039:-
BRCA	trans	rs9467711	0.606	rs34104395	ENSG00000281831.1	HCP5B	5.75	1.19e-08	0.00777	0.4	0.18	Autism spectrum disorder or schizophrenia;	chr6:26478024	chr6:29871895~29873783:-
BRCA	trans	rs9467711	0.659	rs3823158	ENSG00000220721.1	OR1F12	5.75	1.19e-08	0.00778	0.38	0.18	Autism spectrum disorder or schizophrenia;	chr6:26463043	chr6:28073316~28074233:+
BRCA	trans	rs7973618	1	rs7973618	ENSG00000257210.1	NACAP3	-5.75	1.19e-08	0.00778	-0.21	-0.18	Mean platelet volume;	chr12:56625659	chr12:93124063~93124543:-
BRCA	trans	rs9393777	0.841	rs13191474	ENSG00000281831.1	HCP5B	5.75	1.2e-08	0.00782	0.41	0.18	Intelligence (multi-trait analysis);	chr6:27445566	chr6:29871895~29873783:-
BRCA	trans	rs11098499	0.954	rs12508504	ENSG00000276805.1	RP11-291L22.6	5.75	1.2e-08	0.00783	0.21	0.18	Corneal astigmatism;	chr4:119489452	chr10:38451030~38451785:+
BRCA	trans	rs3812762	0.868	rs7934519	ENSG00000266891.1	RP11-692N5.2	-5.75	1.2e-08	0.00784	-0.21	-0.18	Hypospadias;	chr11:8770434	chr18:9734882~9735602:-
BRCA	trans	rs7647973	0.922	rs7620024	ENSG00000235912.1	RP1-159A19.3	5.74	1.21e-08	0.00787	0.22	0.18	Menarche (age at onset);	chr3:49414258	chr1:27649419~27649610:+
BRCA	trans	rs7570469	0.959	rs12620205	ENSG00000276390.1	RP1-197B17.5	-5.74	1.21e-08	0.00789	-0.22	-0.18	Response to antipsychotic treatment;	chr2:79476375	chr12:47699401~47699917:-
BRCA	trans	rs6684992	0.722	rs12407252	ENSG00000231806.2	PCAT7	-5.74	1.21e-08	0.00789	-0.3	-0.18	Eosinophil counts;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;	chr1:87277468	chr9:94555069~94568127:+
BRCA	trans	rs7570469	0.762	rs6751959	ENSG00000276390.1	RP1-197B17.5	5.74	1.21e-08	0.0079	0.23	0.18	Response to antipsychotic treatment;	chr2:79430933	chr12:47699401~47699917:-
BRCA	trans	rs4948102	0.731	rs4535700	ENSG00000186940.6	CHCHD2P9	-5.74	1.21e-08	0.0079	-0.23	-0.18	Plasma homocysteine levels (post-methionine load test);	chr7:55977755	chr9:79391304~79391759:+
BRCA	trans	rs4948102	0.691	rs10435504	ENSG00000186940.6	CHCHD2P9	-5.74	1.21e-08	0.0079	-0.23	-0.18	Plasma homocysteine levels (post-methionine load test);	chr7:55991898	chr9:79391304~79391759:+
BRCA	trans	rs7647973	1	rs9871024	ENSG00000235912.1	RP1-159A19.3	5.74	1.22e-08	0.00792	0.22	0.18	Menarche (age at onset);	chr3:49516808	chr1:27649419~27649610:+
BRCA	trans	rs7647973	1	rs13322887	ENSG00000235912.1	RP1-159A19.3	5.74	1.22e-08	0.00792	0.22	0.18	Menarche (age at onset);	chr3:49518150	chr1:27649419~27649610:+
BRCA	trans	rs801193	0.66	rs1016265	ENSG00000164669.11	INTS4P1	-5.74	1.22e-08	0.00792	-0.22	-0.18	Aortic root size;	chr7:66749580	chr7:65141225~65234216:+
BRCA	trans	rs801193	0.66	rs4610622	ENSG00000164669.11	INTS4P1	-5.74	1.22e-08	0.00792	-0.22	-0.18	Aortic root size;	chr7:66759510	chr7:65141225~65234216:+
BRCA	trans	rs2950393	0.929	rs2958155	ENSG00000257210.1	NACAP3	5.74	1.22e-08	0.00792	0.21	0.18	Platelet distribution width;	chr12:56670761	chr12:93124063~93124543:-
BRCA	trans	rs11098499	0.722	rs28713555	ENSG00000276997.3	RP11-378J18.9	5.74	1.22e-08	0.00793	0.21	0.18	Corneal astigmatism;	chr4:119330840	chr1:222477252~222504622:-
BRCA	trans	rs66887589	0.616	rs1052633	ENSG00000276997.3	RP11-378J18.9	5.74	1.22e-08	0.00794	0.2	0.18	Diastolic blood pressure;	chr4:119294159	chr1:222477252~222504622:-
BRCA	trans	rs6121246	0.559	rs6058352	ENSG00000279352.1	RP11-411B10.7	5.74	1.22e-08	0.00794	0.25	0.18	Mean corpuscular hemoglobin;	chr20:31681376	chr18:14010054~14010917:+
BRCA	trans	rs13217239	0.646	rs7747454	ENSG00000216901.1	AL022393.7	5.74	1.22e-08	0.00794	0.21	0.18	Schizophrenia;	chr6:27066474	chr6:28176188~28176674:+
BRCA	trans	rs4713118	0.525	rs9357042	ENSG00000204709.4	LINC01556	5.74	1.22e-08	0.00795	0.23	0.18	Parkinson's disease;	chr6:27615016	chr6:28943877~28944537:+
BRCA	trans	rs66887589	0.592	rs11731571	ENSG00000276997.3	RP11-378J18.9	5.74	1.22e-08	0.00796	0.2	0.18	Diastolic blood pressure;	chr4:119300030	chr1:222477252~222504622:-
BRCA	trans	rs4929949	0.752	rs10840089	ENSG00000266891.1	RP11-692N5.2	-5.74	1.23e-08	0.00797	-0.2	-0.18	Body mass index;	chr11:8601308	chr18:9734882~9735602:-
BRCA	trans	rs11098499	0.697	rs4560394	ENSG00000276805.1	RP11-291L22.6	5.74	1.23e-08	0.00798	0.21	0.18	Corneal astigmatism;	chr4:119392280	chr10:38451030~38451785:+
BRCA	trans	rs2122469	0.655	rs17603934	ENSG00000253982.1	CTD-2336O2.1	5.74	1.23e-08	0.00799	0.27	0.18	Serum tamsulosin hydrochloride concentration;	chr8:20718833	chr8:1761990~1764502:-
BRCA	trans	rs7089973	0.641	rs17795104	ENSG00000249267.5	LINC00939	5.74	1.23e-08	0.00803	0.21	0.18	Bipolar disorder or attention deficit hyperactivity disorder;	chr10:114979772	chr12:125958688~125983374:-
BRCA	trans	rs1459104	1	rs34965777	ENSG00000134612.10	FOLH1B	-5.74	1.23e-08	0.00803	-0.36	-0.18	Body mass index;	chr11:55471272	chr11:89639227~89698718:+
BRCA	trans	rs11098499	0.909	rs11723839	ENSG00000276805.1	RP11-291L22.6	5.74	1.24e-08	0.00804	0.21	0.18	Corneal astigmatism;	chr4:119378518	chr10:38451030~38451785:+
BRCA	trans	rs11098499	0.779	rs7699346	ENSG00000276805.1	RP11-291L22.6	5.74	1.24e-08	0.00804	0.21	0.18	Corneal astigmatism;	chr4:119389387	chr10:38451030~38451785:+
BRCA	trans	rs9649213	0.593	rs7807555	ENSG00000225169.1	BRI3P1	5.74	1.24e-08	0.00806	0.22	0.18	Prostate cancer (SNP x SNP interaction);	chr7:98328205	chr1:100213293~100213670:+
BRCA	trans	rs9649213	0.593	rs6465667	ENSG00000225169.1	BRI3P1	5.74	1.24e-08	0.00806	0.22	0.18	Prostate cancer (SNP x SNP interaction);	chr7:98328573	chr1:100213293~100213670:+
BRCA	trans	rs9649213	0.593	rs6949214	ENSG00000225169.1	BRI3P1	5.74	1.24e-08	0.00806	0.22	0.18	Prostate cancer (SNP x SNP interaction);	chr7:98330921	chr1:100213293~100213670:+
BRCA	trans	rs11098499	0.913	rs56122576	ENSG00000276997.3	RP11-378J18.9	5.74	1.24e-08	0.00806	0.23	0.18	Corneal astigmatism;	chr4:119208181	chr1:222477252~222504622:-
BRCA	trans	rs9329221	0.651	rs2975648	ENSG00000255046.1	RP11-297N6.4	5.74	1.25e-08	0.00811	0.2	0.18	Neuroticism;	chr8:10278466	chr8:11797928~11802568:-
BRCA	trans	rs9650657	0.645	rs4841409	ENSG00000270154.1	RP11-419I17.1	5.74	1.25e-08	0.00814	0.21	0.18	Neuroticism;	chr8:10658864	chr8:12476462~12477122:+
BRCA	trans	rs9860340	0.73	rs4859089	ENSG00000259370.2	RP11-1069G10.1	-5.74	1.25e-08	0.00814	-0.2	-0.18	Electroencephalographic traits in alcoholism;	chr3:87599403	chr15:62827675~62884034:-
BRCA	trans	rs2965280	0.793	rs2377572	ENSG00000270983.1	RP11-137J7.3	5.74	1.25e-08	0.00815	0.38	0.18	Colorectal cancer;	chr19:34385628	chr6:142062717~142063053:+
BRCA	trans	rs1459104	1	rs35597725	ENSG00000134612.10	FOLH1B	-5.74	1.25e-08	0.00815	-0.35	-0.18	Body mass index;	chr11:55544352	chr11:89639227~89698718:+
BRCA	trans	rs2769264	0.602	rs11204777	ENSG00000180764.13	PIPSL	5.74	1.25e-08	0.00815	0.26	0.18	Blood trace element (Cu levels);	chr1:151099573	chr10:93958191~93961540:-
BRCA	trans	rs1948368	0.668	rs1199578	ENSG00000243181.2	RP11-734J24.1	-5.74	1.26e-08	0.00817	-0.19	-0.18	Bipolar disorder;	chr1:101522063	chr8:34874159~34874633:+
BRCA	trans	rs704840	0.659	rs67638449	ENSG00000251484.3	RP5-1065J22.4	5.74	1.26e-08	0.00817	0.25	0.18	Systemic lupus erythematosus;Systemic lupus erythematosus and Systemic sclerosis;	chr1:173280199	chr1:109103535~109104766:-
BRCA	trans	rs641862	1	rs641862	ENSG00000261553.4	RP11-29G8.3	5.74	1.26e-08	0.00819	0.37	0.17	Obesity-related traits;	chr13:110137885	chr13:75549773~75807120:+
BRCA	trans	rs16975963	0.644	rs73033139	ENSG00000247498.8	RP11-392P7.6	5.74	1.26e-08	0.0082	0.31	0.17	Longevity;	chr19:37600784	chr12:12927726~12984645:+
BRCA	trans	rs11098499	0.913	rs10006304	ENSG00000276997.3	RP11-378J18.9	5.74	1.26e-08	0.0082	0.23	0.17	Corneal astigmatism;	chr4:119203150	chr1:222477252~222504622:-
BRCA	trans	rs9467711	0.79	rs67777156	ENSG00000220721.1	OR1F12	5.74	1.26e-08	0.00821	0.41	0.17	Autism spectrum disorder or schizophrenia;	chr6:26633483	chr6:28073316~28074233:+
BRCA	trans	rs6011368	0.642	rs6062362	ENSG00000226210.3	WASH7P	5.74	1.27e-08	0.00826	0.19	0.17	Clozapine-induced cytotoxicity;	chr20:64279876	chr12:14522~32015:-
BRCA	trans	rs875971	1	rs9986696	ENSG00000164669.11	INTS4P1	5.74	1.27e-08	0.00826	0.22	0.17	Aortic root size;	chr7:66239589	chr7:65141225~65234216:+
BRCA	trans	rs7927771	0.965	rs12364432	ENSG00000134612.10	FOLH1B	-5.74	1.28e-08	0.00829	-0.24	-0.17	Subjective well-being;	chr11:47881331	chr11:89639227~89698718:+
BRCA	trans	rs7113874	0.61	rs7950870	ENSG00000266891.1	RP11-692N5.2	5.73	1.28e-08	0.00829	0.21	0.17	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8523938	chr18:9734882~9735602:-
BRCA	trans	rs9581094	0.591	rs9581043	ENSG00000237917.1	PARP4P1	-5.73	1.28e-08	0.00831	-0.31	-0.17	Sudden cardiac arrest;	chr13:24449798	chrY:26594851~26634652:-
BRCA	trans	rs6121246	0.559	rs6119728	ENSG00000279352.1	RP11-411B10.7	5.73	1.28e-08	0.00833	0.25	0.17	Mean corpuscular hemoglobin;	chr20:31825318	chr18:14010054~14010917:+
BRCA	trans	rs11098499	0.954	rs10008392	ENSG00000276805.1	RP11-291L22.6	5.73	1.28e-08	0.00833	0.21	0.17	Corneal astigmatism;	chr4:119397684	chr10:38451030~38451785:+
BRCA	trans	rs7829975	0.593	rs2921077	ENSG00000255046.1	RP11-297N6.4	-5.73	1.29e-08	0.00835	-0.2	-0.17	Mood instability;	chr8:8446992	chr8:11797928~11802568:-
BRCA	trans	rs853679	0.546	rs13213152	ENSG00000204338.7	CYP21A1P	-5.73	1.29e-08	0.00837	-0.42	-0.17	Depression;	chr6:28381921	chr6:32005636~32008451:+
BRCA	trans	rs9649213	0.593	rs7807455	ENSG00000225169.1	BRI3P1	5.73	1.29e-08	0.00837	0.22	0.17	Prostate cancer (SNP x SNP interaction);	chr7:98328310	chr1:100213293~100213670:+
BRCA	trans	rs6498482	0.963	rs1364363	ENSG00000270157.1	RP5-894A10.6	-5.73	1.29e-08	0.00838	-0.18	-0.17	Egg allergy;	chr16:13892870	chr7:141662922~141663846:-
BRCA	trans	rs714543	0.688	rs12702087	ENSG00000219797.2	PPIAP9	-5.73	1.29e-08	0.00838	-0.21	-0.17	Plateletcrit;	chr7:44773008	chr6:31519480~31520291:-
BRCA	trans	rs6121246	0.512	rs6058384	ENSG00000279352.1	RP11-411B10.7	5.73	1.3e-08	0.00841	0.25	0.17	Mean corpuscular hemoglobin;	chr20:31688606	chr18:14010054~14010917:+
BRCA	trans	rs16975963	0.644	rs73035164	ENSG00000247498.8	RP11-392P7.6	5.73	1.3e-08	0.00841	0.3	0.17	Longevity;	chr19:37655819	chr12:12927726~12984645:+
BRCA	trans	rs853679	0.546	rs13213986	ENSG00000204338.7	CYP21A1P	-5.73	1.3e-08	0.00841	-0.42	-0.17	Depression;	chr6:28390232	chr6:32005636~32008451:+
BRCA	trans	rs853679	0.546	rs34546986	ENSG00000204338.7	CYP21A1P	-5.73	1.3e-08	0.00841	-0.42	-0.17	Depression;	chr6:28394532	chr6:32005636~32008451:+
BRCA	trans	rs853679	0.546	rs34871267	ENSG00000204338.7	CYP21A1P	-5.73	1.3e-08	0.00841	-0.42	-0.17	Depression;	chr6:28396455	chr6:32005636~32008451:+
BRCA	trans	rs853679	0.546	rs35883476	ENSG00000204338.7	CYP21A1P	-5.73	1.3e-08	0.00841	-0.42	-0.17	Depression;	chr6:28400731	chr6:32005636~32008451:+
BRCA	trans	rs11098499	0.909	rs2127821	ENSG00000253326.2	RP11-261C10.7	5.73	1.3e-08	0.00844	0.25	0.17	Corneal astigmatism;	chr4:119473380	chr1:243054861~243056394:-
BRCA	trans	rs4929949	0.78	rs7929120	ENSG00000266891.1	RP11-692N5.2	5.73	1.31e-08	0.00848	0.2	0.17	Body mass index;	chr11:8545877	chr18:9734882~9735602:-
BRCA	trans	rs11098499	0.954	rs6849561	ENSG00000276805.1	RP11-291L22.6	-5.73	1.31e-08	0.0085	-0.21	-0.17	Corneal astigmatism;	chr4:119488539	chr10:38451030~38451785:+
BRCA	trans	rs1459104	0.866	rs12804916	ENSG00000134612.10	FOLH1B	-5.73	1.31e-08	0.00852	-0.34	-0.17	Body mass index;	chr11:55064287	chr11:89639227~89698718:+
BRCA	trans	rs9858542	0.953	rs7646366	ENSG00000197582.5	GPX1P1	-5.73	1.32e-08	0.00853	-0.2	-0.17	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49433235	chrX:13378735~13379340:-
BRCA	trans	rs9393777	0.623	rs3757150	ENSG00000277241.1	RP11-114M1.3	5.73	1.32e-08	0.00854	0.27	0.17	Intelligence (multi-trait analysis);	chr6:26476554	chr3:177700346~177701072:-
BRCA	trans	rs9393777	0.623	rs16891717	ENSG00000277241.1	RP11-114M1.3	5.73	1.32e-08	0.00854	0.27	0.17	Intelligence (multi-trait analysis);	chr6:26476915	chr3:177700346~177701072:-
BRCA	trans	rs56114371	0.777	rs200481	ENSG00000228078.1	HLA-U	-5.73	1.32e-08	0.00855	-0.34	-0.17	Breast cancer;	chr6:27806054	chr6:29934101~29934286:+
BRCA	trans	rs853679	0.607	rs34661125	ENSG00000228078.1	HLA-U	-5.73	1.32e-08	0.00856	-0.45	-0.17	Depression;	chr6:28314117	chr6:29934101~29934286:+
BRCA	trans	rs853679	0.607	rs13190888	ENSG00000228078.1	HLA-U	-5.73	1.32e-08	0.00856	-0.45	-0.17	Depression;	chr6:28318208	chr6:29934101~29934286:+
BRCA	trans	rs11098499	0.754	rs1814813	ENSG00000120555.12	SEPT7P9	-5.73	1.33e-08	0.00859	-0.2	-0.17	Corneal astigmatism;	chr4:119337052	chr10:38383069~38402916:-
BRCA	trans	rs902774	0.818	rs73108429	ENSG00000240668.1	KRT8P36	-5.73	1.33e-08	0.00859	-0.37	-0.17	Prostate cancer;	chr12:52877887	chr3:138101478~138102917:-
BRCA	trans	rs1232027	0.7	rs1222809	ENSG00000188985.6	DHFRP1	-5.73	1.33e-08	0.0086	-0.23	-0.17	Huntington's disease progression;	chr5:80621698	chr18:26170726~26171284:-
BRCA	trans	rs11098499	0.789	rs10212719	ENSG00000276997.3	RP11-378J18.9	5.73	1.33e-08	0.00861	0.21	0.17	Corneal astigmatism;	chr4:119333282	chr1:222477252~222504622:-
BRCA	trans	rs6831352	0.918	rs2602893	ENSG00000233859.2	ADH5P4	-5.73	1.33e-08	0.00863	-0.25	-0.17	Alcohol dependence;	chr4:99122944	chr6:65836930~65838039:-
BRCA	trans	rs6831352	0.918	rs2851251	ENSG00000233859.2	ADH5P4	-5.73	1.33e-08	0.00863	-0.25	-0.17	Alcohol dependence;	chr4:99122960	chr6:65836930~65838039:-
BRCA	trans	rs6831352	0.838	rs2851250	ENSG00000233859.2	ADH5P4	-5.73	1.33e-08	0.00863	-0.25	-0.17	Alcohol dependence;	chr4:99122962	chr6:65836930~65838039:-
BRCA	trans	rs875971	0.965	rs9969301	ENSG00000164669.11	INTS4P1	5.73	1.34e-08	0.00865	0.21	0.17	Aortic root size;	chr7:66316668	chr7:65141225~65234216:+
BRCA	trans	rs8024058	0.666	rs12148410	ENSG00000227854.1	RP11-307O1.1	-5.73	1.34e-08	0.00866	-0.23	-0.17	Night sleep phenotypes;	chr15:88628491	chr1:239052748~239052903:-
BRCA	trans	rs7746199	0.673	rs72847313	ENSG00000243753.4	HLA-L	-5.73	1.34e-08	0.0087	-0.47	-0.17	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27762303	chr6:30259584~30293014:+
BRCA	trans	rs7746199	0.611	rs17750747	ENSG00000243753.4	HLA-L	-5.73	1.34e-08	0.0087	-0.47	-0.17	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27762555	chr6:30259584~30293014:+
BRCA	trans	rs902774	0.818	rs4919737	ENSG00000240668.1	KRT8P36	-5.72	1.35e-08	0.00875	-0.37	-0.17	Prostate cancer;	chr12:52877011	chr3:138101478~138102917:-
BRCA	trans	rs3808502	0.534	rs1529858	ENSG00000253893.2	FAM85B	-5.72	1.36e-08	0.00877	-0.23	-0.17	Neuroticism;	chr8:11288153	chr8:8167819~8226614:-
BRCA	trans	rs1459104	1	rs34008069	ENSG00000134612.10	FOLH1B	-5.72	1.36e-08	0.00878	-0.33	-0.17	Body mass index;	chr11:55510432	chr11:89639227~89698718:+
BRCA	trans	rs11098499	0.954	rs11729521	ENSG00000276805.1	RP11-291L22.6	5.72	1.36e-08	0.00879	0.21	0.17	Corneal astigmatism;	chr4:119495633	chr10:38451030~38451785:+
BRCA	trans	rs1459104	0.789	rs28896554	ENSG00000134612.10	FOLH1B	-5.72	1.36e-08	0.00881	-0.34	-0.17	Body mass index;	chr11:55045161	chr11:89639227~89698718:+
BRCA	trans	rs1459104	0.866	rs28873990	ENSG00000134612.10	FOLH1B	-5.72	1.36e-08	0.00881	-0.34	-0.17	Body mass index;	chr11:55045272	chr11:89639227~89698718:+
BRCA	trans	rs1459104	0.866	rs67929427	ENSG00000134612.10	FOLH1B	-5.72	1.36e-08	0.00881	-0.34	-0.17	Body mass index;	chr11:55056706	chr11:89639227~89698718:+
BRCA	trans	rs6929812	0.605	rs12526495	ENSG00000242375.1	RP11-498P14.3	5.72	1.36e-08	0.00881	0.24	0.17	Neuroticism (multi-trait analysis);	chr6:27426092	chr9:97195351~97197687:-
BRCA	trans	rs12497850	0.931	rs13064911	ENSG00000197582.5	GPX1P1	5.72	1.37e-08	0.00883	0.18	0.17	Parkinson's disease;	chr3:48914952	chrX:13378735~13379340:-
BRCA	trans	rs7570469	0.762	rs17017080	ENSG00000276390.1	RP1-197B17.5	5.72	1.37e-08	0.00884	0.23	0.17	Response to antipsychotic treatment;	chr2:79426478	chr12:47699401~47699917:-
BRCA	trans	rs9393777	0.92	rs13196692	ENSG00000243753.4	HLA-L	-5.72	1.37e-08	0.00884	-0.45	-0.17	Intelligence (multi-trait analysis);	chr6:27411340	chr6:30259584~30293014:+
BRCA	trans	rs875971	0.52	rs160645	ENSG00000234585.5	CCT6P3	-5.72	1.37e-08	0.00885	-0.19	-0.17	Aortic root size;	chr7:66091320	chr7:65038354~65074713:+
BRCA	trans	rs11098499	0.954	rs6834796	ENSG00000276805.1	RP11-291L22.6	5.72	1.37e-08	0.00886	0.21	0.17	Corneal astigmatism;	chr4:119493538	chr10:38451030~38451785:+
BRCA	trans	rs11098499	0.954	rs11734241	ENSG00000276805.1	RP11-291L22.6	5.72	1.37e-08	0.00886	0.21	0.17	Corneal astigmatism;	chr4:119495717	chr10:38451030~38451785:+
BRCA	trans	rs7568458	0.846	rs1078004	ENSG00000223886.3	RP11-251G23.2	5.72	1.37e-08	0.00887	0.2	0.17	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr2:85542588	chr7:105530209~105530671:+
BRCA	trans	rs6831352	0.918	rs29001202	ENSG00000233859.2	ADH5P4	5.72	1.37e-08	0.00888	0.25	0.17	Alcohol dependence;	chr4:99132631	chr6:65836930~65838039:-
BRCA	trans	rs6831352	0.918	rs13127153	ENSG00000233859.2	ADH5P4	5.72	1.37e-08	0.00888	0.25	0.17	Alcohol dependence;	chr4:99136970	chr6:65836930~65838039:-
BRCA	trans	rs6831352	0.918	rs7670060	ENSG00000233859.2	ADH5P4	5.72	1.37e-08	0.00888	0.25	0.17	Alcohol dependence;	chr4:99138417	chr6:65836930~65838039:-
BRCA	trans	rs13326165	0.585	rs11708811	ENSG00000211639.2	IGLV4-60	-5.72	1.38e-08	0.0089	-0.29	-0.17	HDL cholesterol levels;HDL cholesterol;	chr3:52294591	chr22:22162199~22162681:+
BRCA	trans	rs11098499	0.954	rs3733519	ENSG00000276805.1	RP11-291L22.6	5.72	1.38e-08	0.00891	0.21	0.17	Corneal astigmatism;	chr4:119502293	chr10:38451030~38451785:+
BRCA	trans	rs902774	0.818	rs55999178	ENSG00000220378.3	KRT8P42	-5.72	1.38e-08	0.00891	-0.38	-0.17	Prostate cancer;	chr12:52890576	chr6:134296997~134298695:-
BRCA	trans	rs9858542	0.953	rs35115732	ENSG00000197582.5	GPX1P1	-5.72	1.38e-08	0.00892	-0.2	-0.17	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49437722	chrX:13378735~13379340:-
BRCA	trans	rs902774	0.759	rs4919707	ENSG00000220378.3	KRT8P42	-5.72	1.38e-08	0.00892	-0.38	-0.17	Prostate cancer;	chr12:52895864	chr6:134296997~134298695:-
BRCA	trans	rs17507216	0.667	rs72753916	ENSG00000259295.5	CSPG4P12	-5.72	1.38e-08	0.00893	-0.26	-0.17	Excessive daytime sleepiness;	chr15:82684001	chr15:85191438~85213905:+
BRCA	trans	rs11098499	0.754	rs17049949	ENSG00000276997.3	RP11-378J18.9	5.72	1.38e-08	0.00893	0.21	0.17	Corneal astigmatism;	chr4:119334135	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.754	rs7689729	ENSG00000276997.3	RP11-378J18.9	5.72	1.38e-08	0.00893	0.21	0.17	Corneal astigmatism;	chr4:119335037	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.865	rs3956464	ENSG00000276997.3	RP11-378J18.9	5.72	1.38e-08	0.00893	0.21	0.17	Corneal astigmatism;	chr4:119335609	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.648	rs2002047	ENSG00000276997.3	RP11-378J18.9	5.72	1.38e-08	0.00893	0.21	0.17	Corneal astigmatism;	chr4:119336073	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.775	rs2002049	ENSG00000276997.3	RP11-378J18.9	5.72	1.38e-08	0.00893	0.21	0.17	Corneal astigmatism;	chr4:119336262	chr1:222477252~222504622:-
BRCA	trans	rs11638815	0.906	rs1431717	ENSG00000235370.6	DNM1P51	5.72	1.38e-08	0.00894	0.22	0.17	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82676117	chr15:84398316~84411701:-
BRCA	trans	rs9858542	0.953	rs9859556	ENSG00000197582.5	GPX1P1	-5.72	1.39e-08	0.00895	-0.2	-0.17	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49418553	chrX:13378735~13379340:-
BRCA	trans	rs9393813	0.529	rs12526864	ENSG00000242375.1	RP11-498P14.3	-5.72	1.39e-08	0.00895	-0.24	-0.17	Bipolar disorder;	chr6:27488463	chr9:97195351~97197687:-
BRCA	trans	rs9649213	0.555	rs6948346	ENSG00000225169.1	BRI3P1	5.72	1.39e-08	0.00896	0.22	0.17	Prostate cancer (SNP x SNP interaction);	chr7:98330644	chr1:100213293~100213670:+
BRCA	trans	rs7829975	0.617	rs4841071	ENSG00000270154.1	RP11-419I17.1	5.72	1.39e-08	0.00897	0.2	0.17	Mood instability;	chr8:8933634	chr8:12476462~12477122:+
BRCA	trans	rs7570469	0.762	rs10496224	ENSG00000276390.1	RP1-197B17.5	5.72	1.39e-08	0.00898	0.23	0.17	Response to antipsychotic treatment;	chr2:79432314	chr12:47699401~47699917:-
BRCA	trans	rs9858542	0.953	rs9858280	ENSG00000197582.5	GPX1P1	-5.72	1.39e-08	0.00898	-0.2	-0.17	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49560304	chrX:13378735~13379340:-
BRCA	trans	rs9649213	0.593	rs2240349	ENSG00000225169.1	BRI3P1	5.72	1.39e-08	0.00899	0.22	0.17	Prostate cancer (SNP x SNP interaction);	chr7:98355351	chr1:100213293~100213670:+
BRCA	trans	rs9649213	0.593	rs13307593	ENSG00000225169.1	BRI3P1	5.72	1.39e-08	0.00899	0.22	0.17	Prostate cancer (SNP x SNP interaction);	chr7:98356834	chr1:100213293~100213670:+
BRCA	trans	rs875971	0.545	rs6961853	ENSG00000213640.3	EEF1DP4	-5.72	1.39e-08	0.009	-0.24	-0.17	Aortic root size;	chr7:66537035	chr7:64862999~64864370:+
BRCA	trans	rs7927771	0.965	rs4752881	ENSG00000134612.10	FOLH1B	-5.72	1.39e-08	0.009	-0.24	-0.17	Subjective well-being;	chr11:47876983	chr11:89639227~89698718:+
BRCA	trans	rs3812762	0.871	rs10734637	ENSG00000266891.1	RP11-692N5.2	-5.72	1.39e-08	0.009	-0.21	-0.17	Hypospadias;	chr11:8766678	chr18:9734882~9735602:-
BRCA	trans	rs16975963	0.644	rs2290999	ENSG00000247498.8	RP11-392P7.6	5.72	1.4e-08	0.00901	0.3	0.17	Longevity;	chr19:37647986	chr12:12927726~12984645:+
BRCA	trans	rs9858542	0.953	rs9837027	ENSG00000197582.5	GPX1P1	-5.72	1.4e-08	0.00902	-0.19	-0.17	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49559580	chrX:13378735~13379340:-
BRCA	trans	rs877636	0.702	rs773111	ENSG00000227586.5	RP11-162A23.5	5.72	1.4e-08	0.00903	0.23	0.17	Cognitive function;	chr12:55981956	chr10:123171535~123171875:-
BRCA	trans	rs7927771	1	rs4752856	ENSG00000134612.10	FOLH1B	-5.72	1.4e-08	0.00904	-0.24	-0.17	Subjective well-being;	chr11:47626490	chr11:89639227~89698718:+
BRCA	trans	rs9649213	0.537	rs35997266	ENSG00000225169.1	BRI3P1	5.72	1.41e-08	0.00907	0.22	0.17	Prostate cancer (SNP x SNP interaction);	chr7:98336254	chr1:100213293~100213670:+
BRCA	trans	rs673253	0.686	rs2819334	ENSG00000231007.5	CDC20P1	-5.72	1.41e-08	0.00908	-0.21	-0.17	Intelligence (multi-trait analysis);	chr1:43549064	chr9:87011652~87013151:+
BRCA	trans	rs7927771	0.965	rs1064608	ENSG00000134612.10	FOLH1B	-5.72	1.41e-08	0.00909	-0.24	-0.17	Subjective well-being;	chr11:47618877	chr11:89639227~89698718:+
BRCA	trans	rs7927771	0.793	rs12803525	ENSG00000134612.10	FOLH1B	-5.72	1.41e-08	0.00909	-0.23	-0.17	Subjective well-being;	chr11:47391924	chr11:89639227~89698718:+
BRCA	trans	rs11098499	0.865	rs28753180	ENSG00000276805.1	RP11-291L22.6	5.72	1.41e-08	0.00911	0.21	0.17	Corneal astigmatism;	chr4:119484212	chr10:38451030~38451785:+
BRCA	trans	rs7829975	0.623	rs10092965	ENSG00000270154.1	RP11-419I17.1	5.72	1.41e-08	0.00911	0.2	0.17	Mood instability;	chr8:8515975	chr8:12476462~12477122:+
BRCA	trans	rs11098499	0.82	rs28394116	ENSG00000253326.2	RP11-261C10.7	5.72	1.41e-08	0.00911	0.25	0.17	Corneal astigmatism;	chr4:119603128	chr1:243054861~243056394:-
BRCA	trans	rs7647973	1	rs11710434	ENSG00000197582.5	GPX1P1	5.72	1.41e-08	0.00911	0.19	0.17	Menarche (age at onset);	chr3:49308697	chrX:13378735~13379340:-
BRCA	trans	rs7647973	0.925	rs4955439	ENSG00000235912.1	RP1-159A19.3	5.72	1.42e-08	0.00914	0.23	0.17	Menarche (age at onset);	chr3:49208212	chr1:27649419~27649610:+
BRCA	trans	rs9649213	0.555	rs6956686	ENSG00000225169.1	BRI3P1	5.72	1.42e-08	0.00914	0.22	0.17	Prostate cancer (SNP x SNP interaction);	chr7:98368633	chr1:100213293~100213670:+
BRCA	trans	rs3732378	0.666	rs73060524	ENSG00000183298.5	RP11-556K13.1	5.72	1.42e-08	0.00915	0.28	0.17	Monocyte count;Lymphocyte counts;Granulocyte percentage of myeloid white cells;Monocyte percentage of white cells;	chr3:39259632	chr1:101786340~101787219:-
BRCA	trans	rs9467711	0.606	rs34104395	ENSG00000220721.1	OR1F12	5.72	1.42e-08	0.00915	0.37	0.17	Autism spectrum disorder or schizophrenia;	chr6:26478024	chr6:28073316~28074233:+
BRCA	trans	rs941207	0.526	rs7303216	ENSG00000257210.1	NACAP3	5.72	1.42e-08	0.00915	0.21	0.17	Platelet count;	chr12:56680909	chr12:93124063~93124543:-
BRCA	trans	rs10815468	1	rs10815468	ENSG00000215210.3	RBMXP2	5.72	1.42e-08	0.00918	0.23	0.17	Bipolar disorder and schizophrenia;	chr9:6784726	chr9:30689105~30690272:+
BRCA	trans	rs12497850	0.931	rs13316620	ENSG00000197582.5	GPX1P1	5.72	1.43e-08	0.00918	0.18	0.17	Parkinson's disease;	chr3:49007922	chrX:13378735~13379340:-
BRCA	trans	rs853679	0.599	rs188015	ENSG00000204709.4	LINC01556	5.72	1.43e-08	0.0092	0.36	0.17	Depression;	chr6:27909668	chr6:28943877~28944537:+
BRCA	trans	rs875971	0.545	rs3735147	ENSG00000234585.5	CCT6P3	5.72	1.43e-08	0.00921	0.19	0.17	Aortic root size;	chr7:66505541	chr7:65038354~65074713:+
BRCA	trans	rs902774	0.818	rs4919763	ENSG00000228753.1	EIF4BP2	5.72	1.43e-08	0.00921	0.34	0.17	Prostate cancer;	chr12:52885839	chr10:21028999~21030792:+
BRCA	trans	rs4879656	0.835	rs1332096	ENSG00000215007.3	DNAJA1P3	5.71	1.43e-08	0.00922	0.21	0.17	Menopause (age at onset);	chr9:32936041	chrX:107351650~107352843:-
BRCA	trans	rs9649213	0.593	rs3801263	ENSG00000225169.1	BRI3P1	5.71	1.43e-08	0.00924	0.22	0.17	Prostate cancer (SNP x SNP interaction);	chr7:98335704	chr1:100213293~100213670:+
BRCA	trans	rs6921919	0.789	rs6912584	ENSG00000253570.1	RNF5P1	5.71	1.43e-08	0.00924	0.28	0.17	Autism spectrum disorder or schizophrenia;	chr6:28341813	chr8:38600661~38601200:-
BRCA	trans	rs9393777	0.72	rs57713596	ENSG00000253570.1	RNF5P1	5.71	1.43e-08	0.00924	0.37	0.17	Intelligence (multi-trait analysis);	chr6:27036319	chr8:38600661~38601200:-
BRCA	trans	rs6831352	0.959	rs6532795	ENSG00000233859.2	ADH5P4	5.71	1.44e-08	0.00924	0.24	0.17	Alcohol dependence;	chr4:99121070	chr6:65836930~65838039:-
BRCA	trans	rs7746199	0.736	rs13202295	ENSG00000228078.1	HLA-U	-5.71	1.44e-08	0.00925	-0.47	-0.17	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27731058	chr6:29934101~29934286:+
BRCA	trans	rs877636	0.702	rs773109	ENSG00000227586.5	RP11-162A23.5	5.71	1.44e-08	0.00928	0.23	0.17	Cognitive function;	chr12:55980911	chr10:123171535~123171875:-
BRCA	trans	rs6489882	0.867	rs4766675	ENSG00000250770.2	RP5-1063M23.1	5.71	1.44e-08	0.00929	0.23	0.17	Chronic lymphocytic leukemia;	chr12:112927648	chr12:3296202~3300224:-
BRCA	trans	rs9393777	0.92	rs13195040	ENSG00000228078.1	HLA-U	5.71	1.44e-08	0.00929	0.41	0.17	Intelligence (multi-trait analysis);	chr6:27446145	chr6:29934101~29934286:+
BRCA	trans	rs10838687	0.61	rs4647737	ENSG00000134612.10	FOLH1B	5.71	1.44e-08	0.0093	0.27	0.17	Proinsulin levels;	chr11:47231693	chr11:89639227~89698718:+
BRCA	trans	rs7568458	0.905	rs17026396	ENSG00000223886.3	RP11-251G23.2	-5.71	1.45e-08	0.00931	-0.2	-0.17	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr2:85532004	chr7:105530209~105530671:+
BRCA	trans	rs875971	0.545	rs801199	ENSG00000213640.3	EEF1DP4	5.71	1.45e-08	0.00932	0.24	0.17	Aortic root size;	chr7:66560286	chr7:64862999~64864370:+
BRCA	trans	rs875971	0.545	rs73152714	ENSG00000213640.3	EEF1DP4	-5.71	1.45e-08	0.00932	-0.24	-0.17	Aortic root size;	chr7:66534641	chr7:64862999~64864370:+
BRCA	trans	rs875971	0.545	rs4718364	ENSG00000213640.3	EEF1DP4	-5.71	1.45e-08	0.00932	-0.24	-0.17	Aortic root size;	chr7:66536353	chr7:64862999~64864370:+
BRCA	trans	rs7729723	0.837	rs11745596	ENSG00000226666.1	HSPA9P1	5.71	1.45e-08	0.00932	0.2	0.17	Amyotrophic lateral sclerosis (C9orf72 mutation interaction);	chr5:138498450	chr2:221961737~221963765:+
BRCA	trans	rs1459104	0.636	rs67936622	ENSG00000134612.10	FOLH1B	-5.71	1.45e-08	0.00934	-0.33	-0.17	Body mass index;	chr11:55479802	chr11:89639227~89698718:+
BRCA	trans	rs9860340	0.73	rs1509778	ENSG00000259370.2	RP11-1069G10.1	-5.71	1.46e-08	0.00937	-0.2	-0.17	Electroencephalographic traits in alcoholism;	chr3:87595906	chr15:62827675~62884034:-
BRCA	trans	rs9860340	0.73	rs57541218	ENSG00000259370.2	RP11-1069G10.1	5.71	1.46e-08	0.00937	0.2	0.17	Electroencephalographic traits in alcoholism;	chr3:87594080	chr15:62827675~62884034:-
BRCA	trans	rs9649213	0.593	rs13246843	ENSG00000225169.1	BRI3P1	5.71	1.46e-08	0.00937	0.22	0.17	Prostate cancer (SNP x SNP interaction);	chr7:98373349	chr1:100213293~100213670:+
BRCA	trans	rs13217239	0.646	rs9379956	ENSG00000216901.1	AL022393.7	5.71	1.46e-08	0.00938	0.21	0.17	Schizophrenia;	chr6:27065956	chr6:28176188~28176674:+
BRCA	trans	rs7927771	0.826	rs2293578	ENSG00000134612.10	FOLH1B	-5.71	1.46e-08	0.0094	-0.23	-0.17	Subjective well-being;	chr11:47415852	chr11:89639227~89698718:+
BRCA	trans	rs7647973	1	rs1464569	ENSG00000235912.1	RP1-159A19.3	-5.71	1.46e-08	0.00941	-0.22	-0.17	Menarche (age at onset);	chr3:49422917	chr1:27649419~27649610:+
BRCA	trans	rs1568889	1	rs12796293	ENSG00000174912.7	METTL15P1	-5.71	1.46e-08	0.00941	-0.19	-0.17	Bipolar disorder;	chr11:28156176	chr3:156713884~156714928:-
BRCA	trans	rs2950393	0.509	rs10459247	ENSG00000257210.1	NACAP3	-5.71	1.46e-08	0.00941	-0.24	-0.17	Platelet distribution width;	chr12:56777732	chr12:93124063~93124543:-
BRCA	trans	rs6121246	0.559	rs6087771	ENSG00000279352.1	RP11-411B10.7	5.71	1.46e-08	0.00942	0.25	0.17	Mean corpuscular hemoglobin;	chr20:31718921	chr18:14010054~14010917:+
BRCA	trans	rs11098499	0.754	rs9991959	ENSG00000276997.3	RP11-378J18.9	-5.71	1.47e-08	0.00944	-0.2	-0.17	Corneal astigmatism;	chr4:119332618	chr1:222477252~222504622:-
BRCA	trans	rs7824557	0.836	rs2736378	ENSG00000254153.1	CTA-398F10.2	-5.71	1.47e-08	0.00944	-0.23	-0.17	Retinal vascular caliber;	chr8:11262251	chr8:8456909~8461337:-
BRCA	trans	rs864643	0.838	rs58141864	ENSG00000214263.2	RPSAP53	-5.71	1.47e-08	0.00945	-0.35	-0.17	Attention deficit hyperactivity disorder;	chr3:39505344	chr13:67266845~67267706:-
BRCA	trans	rs950776	0.72	rs11637890	ENSG00000274376.3	ADAMTS7P1	5.71	1.47e-08	0.00947	0.2	0.17	Sudden cardiac arrest;	chr15:78643077	chr15:82298553~82334609:+
BRCA	trans	rs9649213	0.593	rs1468340	ENSG00000225169.1	BRI3P1	5.71	1.47e-08	0.00947	0.22	0.17	Prostate cancer (SNP x SNP interaction);	chr7:98358364	chr1:100213293~100213670:+
BRCA	trans	rs9649213	0.593	rs6969234	ENSG00000225169.1	BRI3P1	5.71	1.47e-08	0.00947	0.22	0.17	Prostate cancer (SNP x SNP interaction);	chr7:98358674	chr1:100213293~100213670:+
BRCA	trans	rs9649213	0.593	rs3801256	ENSG00000225169.1	BRI3P1	5.71	1.47e-08	0.00947	0.22	0.17	Prostate cancer (SNP x SNP interaction);	chr7:98362783	chr1:100213293~100213670:+
BRCA	trans	rs2205829	0.563	rs4413607	ENSG00000242375.1	RP11-498P14.3	5.71	1.48e-08	0.00948	0.24	0.17	Bipolar disorder;	chr6:27507341	chr9:97195351~97197687:-
BRCA	trans	rs2727020	0.619	rs1829979	ENSG00000134612.10	FOLH1B	-5.71	1.48e-08	0.00949	-0.24	-0.17	Coronary artery disease;	chr11:49415323	chr11:89639227~89698718:+
BRCA	trans	rs7927771	0.832	rs11601173	ENSG00000134612.10	FOLH1B	-5.71	1.48e-08	0.00949	-0.23	-0.17	Subjective well-being;	chr11:47379507	chr11:89639227~89698718:+
BRCA	trans	rs7927771	0.832	rs11607981	ENSG00000134612.10	FOLH1B	-5.71	1.48e-08	0.00949	-0.23	-0.17	Subjective well-being;	chr11:47379509	chr11:89639227~89698718:+
BRCA	trans	rs7927771	0.832	rs11601603	ENSG00000134612.10	FOLH1B	-5.71	1.48e-08	0.00949	-0.23	-0.17	Subjective well-being;	chr11:47379620	chr11:89639227~89698718:+
BRCA	trans	rs9393777	0.72	rs36022097	ENSG00000253570.1	RNF5P1	5.71	1.48e-08	0.0095	0.37	0.17	Intelligence (multi-trait analysis);	chr6:27027389	chr8:38600661~38601200:-
BRCA	trans	rs7617773	0.78	rs7653152	ENSG00000235912.1	RP1-159A19.3	-5.71	1.48e-08	0.00952	-0.24	-0.17	Coronary artery disease;	chr3:48320607	chr1:27649419~27649610:+
BRCA	trans	rs11666377	0.891	rs11669497	ENSG00000197320.5	AC060834.2	-5.71	1.48e-08	0.00952	-0.24	-0.17	Brain lesion load;	chr19:17000864	chr7:9726241~9728272:+
BRCA	trans	rs16975963	0.644	rs73033145	ENSG00000247498.8	RP11-392P7.6	5.71	1.48e-08	0.00953	0.31	0.17	Longevity;	chr19:37606412	chr12:12927726~12984645:+
BRCA	trans	rs62295889	0.602	rs62293667	ENSG00000232228.1	RP11-77O7.1	-5.71	1.49e-08	0.00954	-0.25	-0.17	Obesity-related traits;	chr4:12537394	chr2:69594741~69595058:-
BRCA	trans	rs319204	0.759	rs319139	ENSG00000226498.2	RP11-182B22.2	-5.71	1.49e-08	0.00957	-0.2	-0.17	Schizophrenia;	chr5:146927699	chr1:236819634~236820518:+
BRCA	trans	rs6831352	0.918	rs13138294	ENSG00000233859.2	ADH5P4	5.71	1.49e-08	0.00958	0.25	0.17	Alcohol dependence;	chr4:99141524	chr6:65836930~65838039:-
BRCA	trans	rs332507	0.789	rs10755078	ENSG00000234253.1	RPL7P13	5.71	1.5e-08	0.00959	0.22	0.17	Plateletcrit;	chr3:124659565	chr2:49878623~49879363:+
BRCA	trans	rs4929949	0.78	rs10160804	ENSG00000266891.1	RP11-692N5.2	-5.71	1.5e-08	0.00961	-0.2	-0.17	Body mass index;	chr11:8578693	chr18:9734882~9735602:-
BRCA	trans	rs704840	0.694	rs35691278	ENSG00000251484.3	RP5-1065J22.4	5.71	1.5e-08	0.00962	0.25	0.17	Systemic lupus erythematosus;Systemic lupus erythematosus and Systemic sclerosis;	chr1:173285979	chr1:109103535~109104766:-
BRCA	trans	rs332507	0.83	rs3772789	ENSG00000234253.1	RPL7P13	5.71	1.5e-08	0.00963	0.23	0.17	Plateletcrit;	chr3:124676760	chr2:49878623~49879363:+
BRCA	trans	rs332507	0.789	rs13097459	ENSG00000234253.1	RPL7P13	5.71	1.5e-08	0.00963	0.23	0.17	Plateletcrit;	chr3:124679265	chr2:49878623~49879363:+
BRCA	trans	rs875971	0.545	rs73378304	ENSG00000234585.5	CCT6P3	5.71	1.51e-08	0.00966	0.18	0.17	Aortic root size;	chr7:66175760	chr7:65038354~65074713:+
BRCA	trans	rs1933488	0.835	rs9371280	ENSG00000180015.12	RP11-756P10.3	-5.71	1.51e-08	0.00967	-0.22	-0.17	Prostate cancer;	chr6:153093138	chr4:188738373~188739494:+
BRCA	trans	rs1933488	0.898	rs6557261	ENSG00000180015.12	RP11-756P10.3	-5.71	1.51e-08	0.00967	-0.22	-0.17	Prostate cancer;	chr6:153094233	chr4:188738373~188739494:+
BRCA	trans	rs1933488	0.898	rs9479505	ENSG00000180015.12	RP11-756P10.3	-5.71	1.51e-08	0.00967	-0.22	-0.17	Prostate cancer;	chr6:153094516	chr4:188738373~188739494:+
BRCA	trans	rs1933488	0.866	rs7756810	ENSG00000180015.12	RP11-756P10.3	-5.71	1.51e-08	0.00967	-0.22	-0.17	Prostate cancer;	chr6:153094998	chr4:188738373~188739494:+
BRCA	trans	rs7746199	0.736	rs13202295	ENSG00000204709.4	LINC01556	5.71	1.51e-08	0.00968	0.47	0.17	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27731058	chr6:28943877~28944537:+
BRCA	trans	rs4713118	0.911	rs9461406	ENSG00000204709.4	LINC01556	-5.71	1.51e-08	0.00969	-0.25	-0.17	Parkinson's disease;	chr6:27751985	chr6:28943877~28944537:+
BRCA	trans	rs2122469	0.655	rs17603934	ENSG00000272375.1	RP11-51J9.6	5.71	1.51e-08	0.0097	0.32	0.17	Serum tamsulosin hydrochloride concentration;	chr8:20718833	chr8:30197404~30198048:+
BRCA	trans	rs11098499	0.697	rs35280960	ENSG00000276997.3	RP11-378J18.9	5.71	1.51e-08	0.0097	0.21	0.17	Corneal astigmatism;	chr4:119335904	chr1:222477252~222504622:-
BRCA	trans	rs853679	0.607	rs13211507	ENSG00000243753.4	HLA-L	-5.71	1.52e-08	0.00971	-0.44	-0.17	Depression;	chr6:28289600	chr6:30259584~30293014:+
BRCA	trans	rs853679	0.607	rs34691223	ENSG00000243753.4	HLA-L	-5.71	1.52e-08	0.00971	-0.44	-0.17	Depression;	chr6:28290431	chr6:30259584~30293014:+
BRCA	trans	rs9649213	0.593	rs3801255	ENSG00000225169.1	BRI3P1	5.7	1.52e-08	0.00973	0.22	0.17	Prostate cancer (SNP x SNP interaction);	chr7:98371617	chr1:100213293~100213670:+
BRCA	trans	rs45509595	0.841	rs9368531	ENSG00000253570.1	RNF5P1	5.7	1.52e-08	0.00976	0.38	0.17	Breast cancer;	chr6:27814094	chr8:38600661~38601200:-
BRCA	trans	rs45509595	0.841	rs2747054	ENSG00000253570.1	RNF5P1	5.7	1.52e-08	0.00976	0.38	0.17	Breast cancer;	chr6:27815581	chr8:38600661~38601200:-
BRCA	trans	rs6934970	1	rs6928046	ENSG00000267560.1	RP11-173A16.1	-5.7	1.52e-08	0.00977	-0.21	-0.17	Bipolar disorder (body mass index interaction);	chr6:112808791	chr18:62300036~62300998:-
BRCA	trans	rs66887589	0.616	rs6843509	ENSG00000276997.3	RP11-378J18.9	5.7	1.52e-08	0.00977	0.2	0.17	Diastolic blood pressure;	chr4:119299041	chr1:222477252~222504622:-
BRCA	trans	rs1459104	0.929	rs67114977	ENSG00000134612.10	FOLH1B	-5.7	1.53e-08	0.00977	-0.37	-0.17	Body mass index;	chr11:55455547	chr11:89639227~89698718:+
BRCA	trans	rs11098499	0.863	rs1383533	ENSG00000253326.2	RP11-261C10.7	5.7	1.53e-08	0.00979	0.25	0.17	Corneal astigmatism;	chr4:119513421	chr1:243054861~243056394:-
BRCA	trans	rs9393777	0.778	rs35608615	ENSG00000204709.4	LINC01556	5.7	1.53e-08	0.0098	0.36	0.17	Intelligence (multi-trait analysis);	chr6:27072623	chr6:28943877~28944537:+
BRCA	trans	rs9393777	0.623	rs9366658	ENSG00000277241.1	RP11-114M1.3	5.7	1.53e-08	0.00981	0.27	0.17	Intelligence (multi-trait analysis);	chr6:26469638	chr3:177700346~177701072:-
BRCA	trans	rs9393777	0.623	rs9358944	ENSG00000277241.1	RP11-114M1.3	5.7	1.53e-08	0.00981	0.27	0.17	Intelligence (multi-trait analysis);	chr6:26469647	chr3:177700346~177701072:-
BRCA	trans	rs1039766	1	rs268882	ENSG00000213985.4	AC078899.1	-5.7	1.53e-08	0.00982	-0.24	-0.17	Lung adenocarcinoma;Lung cancer;	chr2:65275668	chr19:20257720~20259418:+
BRCA	trans	rs853679	0.607	rs13199906	ENSG00000281831.1	HCP5B	5.7	1.53e-08	0.00982	0.45	0.17	Depression;	chr6:27866361	chr6:29871895~29873783:-
BRCA	trans	rs1459104	1	rs12802877	ENSG00000134612.10	FOLH1B	-5.7	1.54e-08	0.00983	-0.36	-0.17	Body mass index;	chr11:55502556	chr11:89639227~89698718:+
BRCA	trans	rs11098499	0.863	rs2291185	ENSG00000253326.2	RP11-261C10.7	5.7	1.54e-08	0.00985	0.25	0.17	Corneal astigmatism;	chr4:119513678	chr1:243054861~243056394:-
BRCA	trans	rs11666377	0.891	rs11669570	ENSG00000197320.5	AC060834.2	5.7	1.54e-08	0.00988	0.26	0.17	Brain lesion load;	chr19:17001057	chr7:9726241~9728272:+
BRCA	trans	rs11098499	0.954	rs10006525	ENSG00000276805.1	RP11-291L22.6	5.7	1.55e-08	0.00989	0.2	0.17	Corneal astigmatism;	chr4:119487776	chr10:38451030~38451785:+
BRCA	trans	rs1568889	1	rs61889026	ENSG00000174912.7	METTL15P1	5.7	1.55e-08	0.00989	0.21	0.17	Bipolar disorder;	chr11:28253256	chr3:156713884~156714928:-
BRCA	trans	rs8177876	0.822	rs10514514	ENSG00000224837.1	GCSHP5	5.7	1.55e-08	0.0099	0.34	0.17	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081668	chr1:168055901~168056422:-
BRCA	trans	rs9462846	0.919	rs12202901	ENSG00000231579.3	RPL7P21	5.7	1.55e-08	0.0099	0.24	0.17	Blood protein levels;	chr6:42860812	chr5:143332605~143333239:+
BRCA	trans	rs654950	0.934	rs641974	ENSG00000243260.3	RN7SL558P	-5.7	1.55e-08	0.00991	-0.21	-0.17	Airway imaging phenotypes;	chr1:41536466	chr4:39761000~39761298:+
BRCA	trans	rs66887589	0.592	rs62320740	ENSG00000120555.12	SEPT7P9	5.7	1.55e-08	0.00991	0.2	0.17	Diastolic blood pressure;	chr4:119358331	chr10:38383069~38402916:-
BRCA	trans	rs9858542	0.953	rs67216675	ENSG00000197582.5	GPX1P1	-5.7	1.56e-08	0.00995	-0.2	-0.17	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49455718	chrX:13378735~13379340:-
BRCA	trans	rs11098499	0.82	rs28535956	ENSG00000253326.2	RP11-261C10.7	-5.7	1.56e-08	0.00996	-0.25	-0.17	Corneal astigmatism;	chr4:119615703	chr1:243054861~243056394:-
BRCA	trans	rs11098499	0.789	rs1980024	ENSG00000276997.3	RP11-378J18.9	5.7	1.56e-08	0.00997	0.2	0.17	Corneal astigmatism;	chr4:119331892	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.754	rs34425882	ENSG00000276997.3	RP11-378J18.9	5.7	1.56e-08	0.00997	0.2	0.17	Corneal astigmatism;	chr4:119332022	chr1:222477252~222504622:-
BRCA	trans	rs6934970	1	rs11153383	ENSG00000267560.1	RP11-173A16.1	-5.7	1.56e-08	0.00998	-0.22	-0.17	Bipolar disorder (body mass index interaction);	chr6:112804783	chr18:62300036~62300998:-
BRCA	trans	rs7927771	0.965	rs12787112	ENSG00000134612.10	FOLH1B	-5.7	1.56e-08	0.00998	-0.24	-0.17	Subjective well-being;	chr11:47665595	chr11:89639227~89698718:+
BRCA	trans	rs6601327	0.67	rs12545250	ENSG00000253893.2	FAM85B	-5.7	1.56e-08	0.00999	-0.22	-0.17	Multiple myeloma (hyperdiploidy);	chr8:9563056	chr8:8167819~8226614:-
BRCA	trans	rs7647973	0.731	rs13084037	ENSG00000235912.1	RP1-159A19.3	-5.7	1.56e-08	0.01	-0.24	-0.17	Menarche (age at onset);	chr3:49176633	chr1:27649419~27649610:+
BRCA	trans	rs11098499	0.954	rs10518328	ENSG00000253326.2	RP11-261C10.7	5.7	1.57e-08	0.01	0.24	0.17	Corneal astigmatism;	chr4:119480624	chr1:243054861~243056394:-
BRCA	trans	rs7746199	0.736	rs13202291	ENSG00000243753.4	HLA-L	-5.7	1.57e-08	0.01	-0.46	-0.17	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27731078	chr6:30259584~30293014:+
BRCA	trans	rs7746199	0.736	rs17750424	ENSG00000243753.4	HLA-L	-5.7	1.57e-08	0.01	-0.46	-0.17	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27733343	chr6:30259584~30293014:+
BRCA	trans	rs9467711	0.591	rs13203673	ENSG00000253570.1	RNF5P1	5.7	1.57e-08	0.01	0.43	0.17	Autism spectrum disorder or schizophrenia;	chr6:25978894	chr8:38600661~38601200:-
BRCA	trans	rs7916663	0.522	rs4748309	ENSG00000235115.3	CHCHD2P8	-5.7	1.57e-08	0.01	-0.34	-0.17	Obesity-related traits;	chr10:16681140	chr13:28107431~28107877:+
BRCA	trans	rs17507216	1	rs3850610	ENSG00000235370.6	DNM1P51	5.7	1.57e-08	0.01	0.21	0.17	Excessive daytime sleepiness;	chr15:82552642	chr15:84398316~84411701:-
BRCA	trans	rs7746199	0.736	rs13210634	ENSG00000228078.1	HLA-U	-5.7	1.57e-08	0.0101	-0.46	-0.17	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27678713	chr6:29934101~29934286:+
BRCA	trans	rs7746199	0.736	rs13215275	ENSG00000228078.1	HLA-U	-5.7	1.57e-08	0.0101	-0.46	-0.17	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27679730	chr6:29934101~29934286:+
BRCA	trans	rs7746199	0.736	rs17749927	ENSG00000228078.1	HLA-U	-5.7	1.57e-08	0.0101	-0.46	-0.17	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27702197	chr6:29934101~29934286:+
BRCA	trans	rs7927771	0.864	rs755555	ENSG00000134612.10	FOLH1B	-5.7	1.58e-08	0.0101	-0.23	-0.17	Subjective well-being;	chr11:47410415	chr11:89639227~89698718:+
BRCA	trans	rs853679	0.607	rs34878803	ENSG00000243753.4	HLA-L	-5.7	1.58e-08	0.0101	-0.44	-0.17	Depression;	chr6:28282402	chr6:30259584~30293014:+
BRCA	trans	rs853679	0.607	rs34396849	ENSG00000243753.4	HLA-L	-5.7	1.58e-08	0.0101	-0.44	-0.17	Depression;	chr6:28283178	chr6:30259584~30293014:+
BRCA	trans	rs853679	0.607	rs17763089	ENSG00000281831.1	HCP5B	5.7	1.58e-08	0.0101	0.45	0.17	Depression;	chr6:27867440	chr6:29871895~29873783:-
BRCA	trans	rs853679	0.546	rs17695758	ENSG00000281831.1	HCP5B	5.7	1.58e-08	0.0101	0.45	0.17	Depression;	chr6:27869405	chr6:29871895~29873783:-
BRCA	trans	rs7773004	0.601	rs13210340	ENSG00000281831.1	HCP5B	5.7	1.58e-08	0.0101	0.46	0.17	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;	chr6:26326086	chr6:29871895~29873783:-
BRCA	trans	rs10838687	0.736	rs7120158	ENSG00000134612.10	FOLH1B	5.7	1.59e-08	0.0102	0.27	0.17	Proinsulin levels;	chr11:47243643	chr11:89639227~89698718:+
BRCA	trans	rs12497850	0.931	rs4072859	ENSG00000197582.5	GPX1P1	5.7	1.59e-08	0.0102	0.18	0.17	Parkinson's disease;	chr3:48994772	chrX:13378735~13379340:-
BRCA	trans	rs11098499	0.644	rs2389880	ENSG00000276805.1	RP11-291L22.6	5.7	1.59e-08	0.0102	0.2	0.17	Corneal astigmatism;	chr4:119638715	chr10:38451030~38451785:+
BRCA	trans	rs3732378	0.666	rs11713282	ENSG00000183298.5	RP11-556K13.1	5.7	1.59e-08	0.0102	0.27	0.17	Monocyte count;Lymphocyte counts;Granulocyte percentage of myeloid white cells;Monocyte percentage of white cells;	chr3:39263058	chr1:101786340~101787219:-
BRCA	trans	rs7662987	0.517	rs1154405	ENSG00000233859.2	ADH5P4	-5.7	1.6e-08	0.0102	-0.25	-0.17	Smoking initiation;	chr4:99087599	chr6:65836930~65838039:-
BRCA	trans	rs9649213	0.593	rs62478177	ENSG00000225169.1	BRI3P1	5.7	1.6e-08	0.0102	0.22	0.17	Prostate cancer (SNP x SNP interaction);	chr7:98335299	chr1:100213293~100213670:+
BRCA	trans	rs7113874	0.655	rs67257872	ENSG00000266891.1	RP11-692N5.2	5.7	1.6e-08	0.0102	0.21	0.17	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8508671	chr18:9734882~9735602:-
BRCA	trans	rs875971	0.545	rs1796226	ENSG00000213640.3	EEF1DP4	-5.7	1.6e-08	0.0102	-0.24	-0.17	Aortic root size;	chr7:66622723	chr7:64862999~64864370:+
BRCA	trans	rs875971	0.545	rs4718348	ENSG00000234585.5	CCT6P3	5.7	1.6e-08	0.0102	0.19	0.17	Aortic root size;	chr7:66441589	chr7:65038354~65074713:+
BRCA	trans	rs12497850	0.805	rs6446198	ENSG00000197582.5	GPX1P1	5.7	1.6e-08	0.0102	0.18	0.17	Parkinson's disease;	chr3:48970205	chrX:13378735~13379340:-
BRCA	trans	rs7113874	0.569	rs11041999	ENSG00000266891.1	RP11-692N5.2	-5.69	1.6e-08	0.0102	-0.2	-0.17	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8584192	chr18:9734882~9735602:-
BRCA	trans	rs902774	0.759	rs4919707	ENSG00000230716.3	KRT8P7	-5.69	1.61e-08	0.0103	-0.36	-0.17	Prostate cancer;	chr12:52895864	chr11:119602875~119604306:-
BRCA	trans	rs17507216	1	rs17356118	ENSG00000235370.6	DNM1P51	-5.69	1.61e-08	0.0103	-0.23	-0.17	Excessive daytime sleepiness;	chr15:82569149	chr15:84398316~84411701:-
BRCA	trans	rs12497850	0.897	rs9681717	ENSG00000197582.5	GPX1P1	5.69	1.62e-08	0.0103	0.18	0.17	Parkinson's disease;	chr3:48835565	chrX:13378735~13379340:-
BRCA	trans	rs9876781	0.624	rs12491849	ENSG00000225528.1	RP3-370M22.8	-5.69	1.62e-08	0.0103	-0.21	-0.17	Longevity;	chr3:48489975	chr22:39960397~39964683:+
BRCA	trans	rs6934970	1	rs3851231	ENSG00000267560.1	RP11-173A16.1	-5.69	1.62e-08	0.0103	-0.22	-0.17	Bipolar disorder (body mass index interaction);	chr6:112807750	chr18:62300036~62300998:-
BRCA	trans	rs2964802	0.505	rs7737359	ENSG00000269888.1	RP11-3P17.5	5.69	1.62e-08	0.0103	0.19	0.17	Major depressive disorder;Recurrent major depressive disorder;	chr5:10831992	chr3:161429112~161429613:+
BRCA	trans	rs953492	0.565	rs10158537	ENSG00000233885.6	YEATS2-AS1	5.69	1.62e-08	0.0103	0.18	0.17	Diastolic blood pressure;	chr1:243324884	chr3:183806457~183810783:-
BRCA	trans	rs10028773	0.7	rs7690338	ENSG00000276997.3	RP11-378J18.9	5.69	1.62e-08	0.0103	0.21	0.17	Educational attainment;	chr4:119335313	chr1:222477252~222504622:-
BRCA	trans	rs7568458	0.875	rs2044474	ENSG00000223886.3	RP11-251G23.2	5.69	1.62e-08	0.0103	0.2	0.17	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr2:85531667	chr7:105530209~105530671:+
BRCA	trans	rs877636	0.702	rs773110	ENSG00000227586.5	RP11-162A23.5	5.69	1.62e-08	0.0103	0.23	0.17	Cognitive function;	chr12:55981353	chr10:123171535~123171875:-
BRCA	trans	rs853679	0.607	rs13199772	ENSG00000243753.4	HLA-L	-5.69	1.62e-08	0.0104	-0.47	-0.17	Depression;	chr6:27866307	chr6:30259584~30293014:+
BRCA	trans	rs11098499	0.954	rs12499324	ENSG00000253326.2	RP11-261C10.7	5.69	1.62e-08	0.0104	0.24	0.17	Corneal astigmatism;	chr4:119472631	chr1:243054861~243056394:-
BRCA	trans	rs902774	0.818	rs55999178	ENSG00000230716.3	KRT8P7	-5.69	1.62e-08	0.0104	-0.36	-0.17	Prostate cancer;	chr12:52890576	chr11:119602875~119604306:-
BRCA	trans	rs66887589	0.592	rs28580295	ENSG00000120555.12	SEPT7P9	5.69	1.62e-08	0.0104	0.19	0.17	Diastolic blood pressure;	chr4:119357718	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.954	rs6849171	ENSG00000276805.1	RP11-291L22.6	5.69	1.63e-08	0.0104	0.2	0.17	Corneal astigmatism;	chr4:119488394	chr10:38451030~38451785:+
BRCA	trans	rs10946940	0.864	rs13201411	ENSG00000204709.4	LINC01556	-5.69	1.63e-08	0.0104	-0.22	-0.17	Systemic lupus erythematosus;	chr6:27530438	chr6:28943877~28944537:+
BRCA	trans	rs2237234	0.848	rs2237235	ENSG00000253570.1	RNF5P1	5.69	1.63e-08	0.0104	0.29	0.17	Autism spectrum disorder or schizophrenia;	chr6:26391167	chr8:38600661~38601200:-
BRCA	trans	rs6142102	0.961	rs2300204	ENSG00000280327.1	LA16c-313F4.1	-5.69	1.63e-08	0.0104	-0.18	-0.17	Skin pigmentation;	chr20:34000967	chr16:1576716~1578371:-
BRCA	trans	rs4713118	0.824	rs7759217	ENSG00000204709.4	LINC01556	5.69	1.63e-08	0.0104	0.24	0.17	Parkinson's disease;	chr6:27762684	chr6:28943877~28944537:+
BRCA	trans	rs4713118	0.784	rs9468219	ENSG00000204709.4	LINC01556	5.69	1.63e-08	0.0104	0.24	0.17	Parkinson's disease;	chr6:27763976	chr6:28943877~28944537:+
BRCA	trans	rs9467711	0.659	rs13220261	ENSG00000220721.1	OR1F12	5.69	1.63e-08	0.0104	0.37	0.17	Autism spectrum disorder or schizophrenia;	chr6:26498957	chr6:28073316~28074233:+
BRCA	trans	rs9467711	0.659	rs35555795	ENSG00000220721.1	OR1F12	5.69	1.63e-08	0.0104	0.37	0.17	Autism spectrum disorder or schizophrenia;	chr6:26509154	chr6:28073316~28074233:+
BRCA	trans	rs616147	0.627	rs9871799	ENSG00000237506.3	RPSAP15	5.69	1.63e-08	0.0104	0.19	0.17	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39442829	chrX:87703343~87704203:-
BRCA	trans	rs4245116	0.64	rs11223459	ENSG00000241782.1	RP11-91P24.1	5.69	1.64e-08	0.0104	0.21	0.17	Coffee consumption (cups per day);	chr11:133380595	chr11:77868722~77869195:-
BRCA	trans	rs13394619	0.775	rs10200851	ENSG00000273980.1	RP13-49I15.6	-5.69	1.64e-08	0.0104	-0.21	-0.17	Endometriosis;	chr2:11581956	chr10:133257144~133257551:-
BRCA	trans	rs902774	0.818	rs55914512	ENSG00000230716.3	KRT8P7	-5.69	1.64e-08	0.0105	-0.36	-0.17	Prostate cancer;	chr12:52888490	chr11:119602875~119604306:-
BRCA	trans	rs902774	0.818	rs73108466	ENSG00000230716.3	KRT8P7	-5.69	1.64e-08	0.0105	-0.36	-0.17	Prostate cancer;	chr12:52889857	chr11:119602875~119604306:-
BRCA	trans	rs2242330	0.716	rs28849739	ENSG00000226982.4	CENPCP1	5.69	1.64e-08	0.0105	0.24	0.17	Parkinson's disease;	chr4:67414845	chr12:89500093~89502670:+
BRCA	trans	rs1568889	0.877	rs34351528	ENSG00000174912.7	METTL15P1	5.69	1.64e-08	0.0105	0.21	0.17	Bipolar disorder;	chr11:28282746	chr3:156713884~156714928:-
BRCA	trans	rs332507	0.83	rs13069961	ENSG00000234253.1	RPL7P13	5.69	1.64e-08	0.0105	0.22	0.17	Plateletcrit;	chr3:124639868	chr2:49878623~49879363:+
BRCA	trans	rs9649213	0.574	rs6979373	ENSG00000225169.1	BRI3P1	5.69	1.64e-08	0.0105	0.22	0.17	Prostate cancer (SNP x SNP interaction);	chr7:98332532	chr1:100213293~100213670:+
BRCA	trans	rs9649213	0.574	rs34717219	ENSG00000225169.1	BRI3P1	5.69	1.64e-08	0.0105	0.22	0.17	Prostate cancer (SNP x SNP interaction);	chr7:98332959	chr1:100213293~100213670:+
BRCA	trans	rs332507	0.83	rs62265580	ENSG00000234253.1	RPL7P13	5.69	1.64e-08	0.0105	0.22	0.17	Plateletcrit;	chr3:124640995	chr2:49878623~49879363:+
BRCA	trans	rs9841829	0.531	rs10865610	ENSG00000280063.1	RP11-295D4.3	-5.69	1.65e-08	0.0105	-0.13	-0.17	Alcohol consumption;	chr3:85545545	chr16:4346694~4348648:-
BRCA	trans	rs4947534	1	rs4947534	ENSG00000186940.6	CHCHD2P9	-5.69	1.65e-08	0.0105	-0.23	-0.17	Blood metabolite levels;Amino acid levels;	chr7:56011401	chr9:79391304~79391759:+
BRCA	trans	rs6831352	0.918	rs2851249	ENSG00000233859.2	ADH5P4	-5.69	1.65e-08	0.0105	-0.25	-0.17	Alcohol dependence;	chr4:99123671	chr6:65836930~65838039:-
BRCA	trans	rs7829975	0.84	rs572366	ENSG00000255046.1	RP11-297N6.4	-5.69	1.65e-08	0.0105	-0.2	-0.17	Mood instability;	chr8:8721284	chr8:11797928~11802568:-
BRCA	trans	rs6831352	0.918	rs2851248	ENSG00000233859.2	ADH5P4	-5.69	1.65e-08	0.0105	-0.25	-0.17	Alcohol dependence;	chr4:99124823	chr6:65836930~65838039:-
BRCA	trans	rs853679	0.607	rs72846780	ENSG00000228078.1	HLA-U	-5.69	1.65e-08	0.0105	-0.48	-0.17	Depression;	chr6:28151277	chr6:29934101~29934286:+
BRCA	trans	rs853679	0.607	rs13205911	ENSG00000228078.1	HLA-U	-5.69	1.65e-08	0.0105	-0.48	-0.17	Depression;	chr6:28156336	chr6:29934101~29934286:+
BRCA	trans	rs853679	0.607	rs13197176	ENSG00000228078.1	HLA-U	-5.69	1.65e-08	0.0105	-0.48	-0.17	Depression;	chr6:28161454	chr6:29934101~29934286:+
BRCA	trans	rs853679	0.607	rs13201308	ENSG00000228078.1	HLA-U	-5.69	1.65e-08	0.0105	-0.48	-0.17	Depression;	chr6:28162311	chr6:29934101~29934286:+
BRCA	trans	rs853679	0.607	rs34505829	ENSG00000228078.1	HLA-U	-5.69	1.65e-08	0.0105	-0.48	-0.17	Depression;	chr6:28165461	chr6:29934101~29934286:+
BRCA	trans	rs853679	0.607	rs35098436	ENSG00000228078.1	HLA-U	-5.69	1.65e-08	0.0105	-0.48	-0.17	Depression;	chr6:28166443	chr6:29934101~29934286:+
BRCA	trans	rs853679	0.607	rs72846794	ENSG00000228078.1	HLA-U	-5.69	1.65e-08	0.0105	-0.48	-0.17	Depression;	chr6:28169721	chr6:29934101~29934286:+
BRCA	trans	rs853679	0.607	rs13217984	ENSG00000228078.1	HLA-U	-5.69	1.65e-08	0.0105	-0.48	-0.17	Depression;	chr6:28171932	chr6:29934101~29934286:+
BRCA	trans	rs853679	0.505	rs35781323	ENSG00000228078.1	HLA-U	-5.69	1.65e-08	0.0105	-0.48	-0.17	Depression;	chr6:28177054	chr6:29934101~29934286:+
BRCA	trans	rs7746199	0.736	rs34105070	ENSG00000281831.1	HCP5B	5.69	1.66e-08	0.0106	0.44	0.17	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27593026	chr6:29871895~29873783:-
BRCA	trans	rs7746199	0.668	rs34864796	ENSG00000228078.1	HLA-U	-5.69	1.66e-08	0.0106	-0.39	-0.17	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27492144	chr6:29934101~29934286:+
BRCA	trans	rs1933488	0.898	rs1971152	ENSG00000180015.12	RP11-756P10.3	-5.69	1.66e-08	0.0106	-0.22	-0.17	Prostate cancer;	chr6:153104109	chr4:188738373~188739494:+
BRCA	trans	rs11098499	0.691	rs12510133	ENSG00000276997.3	RP11-378J18.9	5.69	1.66e-08	0.0106	0.2	0.17	Corneal astigmatism;	chr4:119350189	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.754	rs12506487	ENSG00000276997.3	RP11-378J18.9	5.69	1.66e-08	0.0106	0.2	0.17	Corneal astigmatism;	chr4:119350206	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.863	rs1480940	ENSG00000253326.2	RP11-261C10.7	5.69	1.67e-08	0.0106	0.25	0.17	Corneal astigmatism;	chr4:119536527	chr1:243054861~243056394:-
BRCA	trans	rs76228276	0.737	rs72672374	ENSG00000260318.1	COX6CP1	5.69	1.67e-08	0.0106	0.45	0.17	Childhood ear infection;	chr8:99344162	chr16:11903923~11904137:-
BRCA	trans	rs11098499	0.569	rs10023641	ENSG00000276997.3	RP11-378J18.9	5.69	1.67e-08	0.0106	0.2	0.17	Corneal astigmatism;	chr4:119337255	chr1:222477252~222504622:-
BRCA	trans	rs12497850	0.931	rs4974087	ENSG00000197582.5	GPX1P1	5.69	1.67e-08	0.0106	0.18	0.17	Parkinson's disease;	chr3:48881799	chrX:13378735~13379340:-
BRCA	trans	rs1459104	1	rs3930352	ENSG00000134612.10	FOLH1B	-5.69	1.67e-08	0.0106	-0.33	-0.17	Body mass index;	chr11:55450108	chr11:89639227~89698718:+
BRCA	trans	rs10783779	0.647	rs705708	ENSG00000196933.5	RPS26P11	5.69	1.68e-08	0.0107	0.21	0.17	Educational attainment;	chr12:56095129	chrX:72044545~72044892:+
BRCA	trans	rs10838687	0.736	rs7118396	ENSG00000134612.10	FOLH1B	5.69	1.68e-08	0.0107	0.27	0.17	Proinsulin levels;	chr11:47248385	chr11:89639227~89698718:+
BRCA	trans	rs875971	1	rs6963646	ENSG00000164669.11	INTS4P1	5.69	1.68e-08	0.0107	0.21	0.17	Aortic root size;	chr7:66220780	chr7:65141225~65234216:+
BRCA	trans	rs10838687	0.736	rs11039144	ENSG00000134612.10	FOLH1B	5.69	1.68e-08	0.0107	0.27	0.17	Proinsulin levels;	chr11:47242493	chr11:89639227~89698718:+
BRCA	trans	rs319204	0.918	rs2963080	ENSG00000226498.2	RP11-182B22.2	5.69	1.68e-08	0.0107	0.19	0.17	Schizophrenia;	chr5:146881526	chr1:236819634~236820518:+
BRCA	trans	rs78944489	0.867	rs12471835	ENSG00000236165.1	PRADC1P1	5.69	1.68e-08	0.0107	0.36	0.17	Schizophrenia;	chr2:73230296	chr3:36976316~36976840:+
BRCA	trans	rs9467711	0.659	rs3734542	ENSG00000281831.1	HCP5B	5.69	1.68e-08	0.0107	0.39	0.17	Autism spectrum disorder or schizophrenia;	chr6:26468098	chr6:29871895~29873783:-
BRCA	trans	rs9462846	0.959	rs9462845	ENSG00000231579.3	RPL7P21	5.69	1.68e-08	0.0107	0.25	0.17	Blood protein levels;	chr6:42893220	chr5:143332605~143333239:+
BRCA	trans	rs11098499	0.909	rs10020034	ENSG00000276805.1	RP11-291L22.6	5.69	1.68e-08	0.0107	0.21	0.17	Corneal astigmatism;	chr4:119373176	chr10:38451030~38451785:+
BRCA	trans	rs1568889	1	rs12804198	ENSG00000174912.7	METTL15P1	5.69	1.69e-08	0.0107	0.19	0.17	Bipolar disorder;	chr11:28121567	chr3:156713884~156714928:-
BRCA	trans	rs9393777	0.92	rs35716472	ENSG00000228078.1	HLA-U	-5.69	1.69e-08	0.0107	-0.42	-0.17	Intelligence (multi-trait analysis);	chr6:27438828	chr6:29934101~29934286:+
BRCA	trans	rs1459104	0.925	rs35019440	ENSG00000134612.10	FOLH1B	-5.69	1.69e-08	0.0107	-0.35	-0.17	Body mass index;	chr11:55450794	chr11:89639227~89698718:+
BRCA	trans	rs6831352	0.879	rs2602888	ENSG00000233859.2	ADH5P4	-5.69	1.69e-08	0.0107	-0.25	-0.17	Alcohol dependence;	chr4:99120555	chr6:65836930~65838039:-
BRCA	trans	rs7746199	0.736	rs13209332	ENSG00000281831.1	HCP5B	5.69	1.69e-08	0.0107	0.44	0.17	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27552973	chr6:29871895~29873783:-
BRCA	trans	rs7746199	0.673	rs72847313	ENSG00000228078.1	HLA-U	-5.69	1.69e-08	0.0107	-0.46	-0.17	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27762303	chr6:29934101~29934286:+
BRCA	trans	rs7746199	0.611	rs17750747	ENSG00000228078.1	HLA-U	-5.69	1.69e-08	0.0107	-0.46	-0.17	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27762555	chr6:29934101~29934286:+
BRCA	trans	rs11098499	0.722	rs10025925	ENSG00000276997.3	RP11-378J18.9	5.69	1.69e-08	0.0108	0.2	0.17	Corneal astigmatism;	chr4:119350589	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.731	rs10015579	ENSG00000276997.3	RP11-378J18.9	5.69	1.69e-08	0.0108	0.2	0.17	Corneal astigmatism;	chr4:119350647	chr1:222477252~222504622:-
BRCA	trans	rs3735478	0.632	rs7799345	ENSG00000226038.5	PPIAP21	-5.69	1.7e-08	0.0108	-0.2	-0.17	Intelligence (multi-trait analysis);	chr7:44726336	chr20:43230760~43231260:+
BRCA	trans	rs9649213	0.593	rs13232181	ENSG00000225169.1	BRI3P1	5.69	1.7e-08	0.0108	0.22	0.17	Prostate cancer (SNP x SNP interaction);	chr7:98306359	chr1:100213293~100213670:+
BRCA	trans	rs9649213	0.574	rs7791321	ENSG00000225169.1	BRI3P1	5.68	1.7e-08	0.0108	0.22	0.17	Prostate cancer (SNP x SNP interaction);	chr7:98314813	chr1:100213293~100213670:+
BRCA	trans	rs875971	0.571	rs160647	ENSG00000234585.5	CCT6P3	-5.68	1.71e-08	0.0108	-0.19	-0.17	Aortic root size;	chr7:66089365	chr7:65038354~65074713:+
BRCA	trans	rs1568889	1	rs11604085	ENSG00000174912.7	METTL15P1	5.68	1.71e-08	0.0108	0.19	0.17	Bipolar disorder;	chr11:28119455	chr3:156713884~156714928:-
BRCA	trans	rs6601327	0.641	rs6601350	ENSG00000253893.2	FAM85B	5.68	1.71e-08	0.0109	0.22	0.17	Multiple myeloma (hyperdiploidy);	chr8:9716446	chr8:8167819~8226614:-
BRCA	trans	rs2727020	0.554	rs2866490	ENSG00000134612.10	FOLH1B	-5.68	1.72e-08	0.0109	-0.24	-0.17	Coronary artery disease;	chr11:49403911	chr11:89639227~89698718:+
BRCA	trans	rs45509595	0.556	rs34409918	ENSG00000243753.4	HLA-L	-5.68	1.72e-08	0.0109	-0.46	-0.17	Breast cancer;	chr6:27717569	chr6:30259584~30293014:+
BRCA	trans	rs11098499	0.754	rs10518300	ENSG00000276997.3	RP11-378J18.9	-5.68	1.72e-08	0.0109	-0.21	-0.17	Corneal astigmatism;	chr4:119328344	chr1:222477252~222504622:-
BRCA	trans	rs10838687	0.736	rs2242262	ENSG00000134612.10	FOLH1B	5.68	1.72e-08	0.0109	0.27	0.17	Proinsulin levels;	chr11:47244989	chr11:89639227~89698718:+
BRCA	trans	rs10838687	0.736	rs2242261	ENSG00000134612.10	FOLH1B	5.68	1.72e-08	0.0109	0.27	0.17	Proinsulin levels;	chr11:47245257	chr11:89639227~89698718:+
BRCA	trans	rs1580019	0.563	rs34319173	ENSG00000213492.2	NT5C3AP1	-5.68	1.72e-08	0.0109	-0.23	-0.17	Cognitive ability;	chr7:32546292	chr4:117574512~117576174:-
BRCA	trans	rs1948368	0.668	rs263918	ENSG00000243181.2	RP11-734J24.1	-5.68	1.72e-08	0.0109	-0.19	-0.17	Bipolar disorder;	chr1:101519376	chr8:34874159~34874633:+
BRCA	trans	rs941207	0.526	rs12229457	ENSG00000257210.1	NACAP3	-5.68	1.73e-08	0.011	-0.21	-0.17	Platelet count;	chr12:56639896	chr12:93124063~93124543:-
BRCA	trans	rs7824557	0.707	rs3808518	ENSG00000254153.1	CTA-398F10.2	-5.68	1.73e-08	0.011	-0.22	-0.17	Retinal vascular caliber;	chr8:11285763	chr8:8456909~8461337:-
BRCA	trans	rs1580019	0.563	rs896137	ENSG00000213492.2	NT5C3AP1	-5.68	1.73e-08	0.011	-0.24	-0.17	Cognitive ability;	chr7:32539733	chr4:117574512~117576174:-
BRCA	trans	rs1580019	0.523	rs9791770	ENSG00000213492.2	NT5C3AP1	-5.68	1.73e-08	0.011	-0.24	-0.17	Cognitive ability;	chr7:32542640	chr4:117574512~117576174:-
BRCA	trans	rs7570469	0.762	rs34824031	ENSG00000276390.1	RP1-197B17.5	5.68	1.74e-08	0.011	0.23	0.17	Response to antipsychotic treatment;	chr2:79425431	chr12:47699401~47699917:-
BRCA	trans	rs16975963	0.644	rs11665759	ENSG00000247498.8	RP11-392P7.6	5.68	1.74e-08	0.011	0.3	0.17	Longevity;	chr19:37548773	chr12:12927726~12984645:+
BRCA	trans	rs16975963	0.644	rs73037036	ENSG00000247498.8	RP11-392P7.6	5.68	1.74e-08	0.011	0.3	0.17	Longevity;	chr19:37670169	chr12:12927726~12984645:+
BRCA	trans	rs16975963	0.644	rs111319455	ENSG00000247498.8	RP11-392P7.6	5.68	1.74e-08	0.011	0.3	0.17	Longevity;	chr19:37671746	chr12:12927726~12984645:+
BRCA	trans	rs10838687	0.736	rs16938581	ENSG00000134612.10	FOLH1B	5.68	1.74e-08	0.011	0.27	0.17	Proinsulin levels;	chr11:47249488	chr11:89639227~89698718:+
BRCA	trans	rs11098499	0.954	rs6822679	ENSG00000253326.2	RP11-261C10.7	5.68	1.74e-08	0.011	0.24	0.17	Corneal astigmatism;	chr4:119481547	chr1:243054861~243056394:-
BRCA	trans	rs1568889	1	rs34337978	ENSG00000174912.7	METTL15P1	5.68	1.74e-08	0.011	0.19	0.17	Bipolar disorder;	chr11:28115199	chr3:156713884~156714928:-
BRCA	trans	rs11098499	0.954	rs12508504	ENSG00000253326.2	RP11-261C10.7	5.68	1.75e-08	0.0111	0.24	0.17	Corneal astigmatism;	chr4:119489452	chr1:243054861~243056394:-
BRCA	trans	rs9368481	0.761	rs4358615	ENSG00000242375.1	RP11-498P14.3	5.68	1.75e-08	0.0111	0.25	0.17	Autism spectrum disorder or schizophrenia;	chr6:27030788	chr9:97195351~97197687:-
BRCA	trans	rs10791097	0.72	rs6590517	ENSG00000264570.1	SNX19P3	5.68	1.75e-08	0.0111	0.19	0.17	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:130863610	chr18:14629832~14632806:-
BRCA	trans	rs10838687	0.736	rs7933246	ENSG00000134612.10	FOLH1B	5.68	1.75e-08	0.0111	0.27	0.17	Proinsulin levels;	chr11:47241097	chr11:89639227~89698718:+
BRCA	trans	rs7927771	0.832	rs1317164	ENSG00000134612.10	FOLH1B	-5.68	1.75e-08	0.0111	-0.23	-0.17	Subjective well-being;	chr11:47398206	chr11:89639227~89698718:+
BRCA	trans	rs1232027	0.7	rs1650717	ENSG00000188985.6	DHFRP1	-5.68	1.75e-08	0.0111	-0.22	-0.17	Huntington's disease progression;	chr5:80634760	chr18:26170726~26171284:-
BRCA	trans	rs1232027	0.7	rs1650712	ENSG00000188985.6	DHFRP1	-5.68	1.75e-08	0.0111	-0.22	-0.17	Huntington's disease progression;	chr5:80639694	chr18:26170726~26171284:-
BRCA	trans	rs3812762	0.957	rs6484008	ENSG00000266891.1	RP11-692N5.2	-5.68	1.75e-08	0.0111	-0.21	-0.17	Hypospadias;	chr11:8732601	chr18:9734882~9735602:-
BRCA	trans	rs875971	1	rs4718307	ENSG00000164669.11	INTS4P1	5.68	1.75e-08	0.0111	0.21	0.17	Aortic root size;	chr7:66146001	chr7:65141225~65234216:+
BRCA	trans	rs875971	1	rs7801282	ENSG00000164669.11	INTS4P1	5.68	1.75e-08	0.0111	0.21	0.17	Aortic root size;	chr7:66148700	chr7:65141225~65234216:+
BRCA	trans	rs6121246	0.609	rs1009453	ENSG00000279352.1	RP11-411B10.7	5.68	1.75e-08	0.0111	0.25	0.17	Mean corpuscular hemoglobin;	chr20:31817037	chr18:14010054~14010917:+
BRCA	trans	rs1459104	1	rs35992551	ENSG00000134612.10	FOLH1B	-5.68	1.76e-08	0.0111	-0.33	-0.17	Body mass index;	chr11:55573155	chr11:89639227~89698718:+
BRCA	trans	rs1864585	0.806	rs17778223	ENSG00000253476.1	RP11-395I14.2	5.68	1.76e-08	0.0111	0.17	0.17	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr8:10872182	chr8:25425521~25426580:-
BRCA	trans	rs149866169	1	rs149866169	ENSG00000228078.1	HLA-U	-5.68	1.76e-08	0.0111	-0.39	-0.17	Subjective well-being (multi-trait analysis);Lung cancer;Neuroticism (multi-trait analysis);Lung cancer in ever smokers;Squamous cell lung carcinoma;	chr6:27473944	chr6:29934101~29934286:+
BRCA	trans	rs7773004	0.601	rs13210340	ENSG00000204709.4	LINC01556	5.68	1.76e-08	0.0112	0.48	0.17	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;	chr6:26326086	chr6:28943877~28944537:+
BRCA	trans	rs853679	0.628	rs9368560	ENSG00000253570.1	RNF5P1	5.68	1.76e-08	0.0112	0.28	0.17	Depression;	chr6:28192182	chr8:38600661~38601200:-
BRCA	trans	rs3812762	0.871	rs3844100	ENSG00000266891.1	RP11-692N5.2	-5.68	1.77e-08	0.0112	-0.21	-0.17	Hypospadias;	chr11:8796261	chr18:9734882~9735602:-
BRCA	trans	rs6121246	0.559	rs6060952	ENSG00000279352.1	RP11-411B10.7	5.68	1.77e-08	0.0112	0.25	0.17	Mean corpuscular hemoglobin;	chr20:31794305	chr18:14010054~14010917:+
BRCA	trans	rs12156238	1	rs12156238	ENSG00000253893.2	FAM85B	-5.68	1.77e-08	0.0112	-0.28	-0.17	Cisplatin-induced ototoxicity;	chr8:11427626	chr8:8167819~8226614:-
BRCA	trans	rs9467711	0.659	rs35433030	ENSG00000281831.1	HCP5B	5.68	1.77e-08	0.0112	0.4	0.17	Autism spectrum disorder or schizophrenia;	chr6:26529662	chr6:29871895~29873783:-
BRCA	trans	rs9467711	0.659	rs66941101	ENSG00000281831.1	HCP5B	5.68	1.77e-08	0.0112	0.4	0.17	Autism spectrum disorder or schizophrenia;	chr6:26530148	chr6:29871895~29873783:-
BRCA	trans	rs7746199	0.736	rs13212318	ENSG00000243753.4	HLA-L	-5.68	1.77e-08	0.0112	-0.46	-0.17	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27721062	chr6:30259584~30293014:+
BRCA	trans	rs12497850	0.931	rs7430198	ENSG00000197582.5	GPX1P1	5.68	1.78e-08	0.0113	0.18	0.17	Parkinson's disease;	chr3:48951327	chrX:13378735~13379340:-
BRCA	trans	rs12497850	0.866	rs6791234	ENSG00000197582.5	GPX1P1	5.68	1.78e-08	0.0113	0.18	0.17	Parkinson's disease;	chr3:48958704	chrX:13378735~13379340:-
BRCA	trans	rs12497850	0.931	rs6446196	ENSG00000197582.5	GPX1P1	5.68	1.78e-08	0.0113	0.18	0.17	Parkinson's disease;	chr3:48967290	chrX:13378735~13379340:-
BRCA	trans	rs950776	0.72	rs11633223	ENSG00000274376.3	ADAMTS7P1	-5.68	1.78e-08	0.0113	-0.2	-0.17	Sudden cardiac arrest;	chr15:78643134	chr15:82298553~82334609:+
BRCA	trans	rs875971	1	rs709597	ENSG00000164669.11	INTS4P1	5.68	1.78e-08	0.0113	0.21	0.17	Aortic root size;	chr7:66360996	chr7:65141225~65234216:+
BRCA	trans	rs10791097	0.72	rs4936121	ENSG00000264570.1	SNX19P3	5.68	1.78e-08	0.0113	0.19	0.17	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:130863983	chr18:14629832~14632806:-
BRCA	trans	rs9467711	0.659	rs13220261	ENSG00000281831.1	HCP5B	5.68	1.78e-08	0.0113	0.4	0.17	Autism spectrum disorder or schizophrenia;	chr6:26498957	chr6:29871895~29873783:-
BRCA	trans	rs9467711	0.659	rs35555795	ENSG00000281831.1	HCP5B	5.68	1.78e-08	0.0113	0.4	0.17	Autism spectrum disorder or schizophrenia;	chr6:26509154	chr6:29871895~29873783:-
BRCA	trans	rs7566780	0.516	rs4550668	ENSG00000224631.4	RP11-51O6.1	5.68	1.78e-08	0.0113	0.16	0.17	Cleft lip with or without cleft palate;Orofacial clefts;	chr2:16482226	chr16:61055399~61055964:-
BRCA	trans	rs6142102	0.923	rs3787230	ENSG00000280327.1	LA16c-313F4.1	-5.68	1.78e-08	0.0113	-0.18	-0.17	Skin pigmentation;	chr20:34052466	chr16:1576716~1578371:-
BRCA	trans	rs875971	0.528	rs801213	ENSG00000213640.3	EEF1DP4	5.68	1.79e-08	0.0113	0.24	0.17	Aortic root size;	chr7:66549931	chr7:64862999~64864370:+
BRCA	trans	rs875971	0.545	rs801212	ENSG00000213640.3	EEF1DP4	5.68	1.79e-08	0.0113	0.24	0.17	Aortic root size;	chr7:66550643	chr7:64862999~64864370:+
BRCA	trans	rs902774	0.818	rs55914512	ENSG00000220378.3	KRT8P42	-5.68	1.79e-08	0.0113	-0.38	-0.17	Prostate cancer;	chr12:52888490	chr6:134296997~134298695:-
BRCA	trans	rs902774	0.818	rs73108466	ENSG00000220378.3	KRT8P42	-5.68	1.79e-08	0.0113	-0.38	-0.17	Prostate cancer;	chr12:52889857	chr6:134296997~134298695:-
BRCA	trans	rs9852859	0.665	rs7612213	ENSG00000228223.2	HCG11	5.68	1.79e-08	0.0113	0.24	0.17	Body mass index;	chr3:85740704	chr6:26523450~26526579:+
BRCA	trans	rs2242330	1	rs13151390	ENSG00000226982.4	CENPCP1	5.68	1.79e-08	0.0113	0.26	0.17	Parkinson's disease;	chr4:67556631	chr12:89500093~89502670:+
BRCA	trans	rs9393777	0.778	rs35526527	ENSG00000204709.4	LINC01556	5.68	1.79e-08	0.0113	0.36	0.17	Intelligence (multi-trait analysis);	chr6:27074508	chr6:28943877~28944537:+
BRCA	trans	rs11098499	0.954	rs17005535	ENSG00000276805.1	RP11-291L22.6	5.68	1.79e-08	0.0113	0.2	0.17	Corneal astigmatism;	chr4:119490407	chr10:38451030~38451785:+
BRCA	trans	rs6144337	1	rs6144337	ENSG00000134612.10	FOLH1B	5.68	1.79e-08	0.0114	0.27	0.17	Lymphocyte percentage of white cells;	chr11:47262763	chr11:89639227~89698718:+
BRCA	trans	rs2134046	0.587	rs11854289	ENSG00000259295.5	CSPG4P12	5.68	1.8e-08	0.0114	0.21	0.17	Cognitive ability;	chr15:82266461	chr15:85191438~85213905:+
BRCA	trans	rs7647973	1	rs9842132	ENSG00000235912.1	RP1-159A19.3	5.67	1.8e-08	0.0114	0.22	0.17	Menarche (age at onset);	chr3:49390500	chr1:27649419~27649610:+
BRCA	trans	rs875971	1	rs11974264	ENSG00000164669.11	INTS4P1	5.67	1.8e-08	0.0114	0.21	0.17	Aortic root size;	chr7:66182595	chr7:65141225~65234216:+
BRCA	trans	rs11098499	0.863	rs58452170	ENSG00000253326.2	RP11-261C10.7	5.67	1.8e-08	0.0114	0.25	0.17	Corneal astigmatism;	chr4:119538519	chr1:243054861~243056394:-
BRCA	trans	rs6121246	0.609	rs6089075	ENSG00000279352.1	RP11-411B10.7	5.67	1.81e-08	0.0114	0.25	0.17	Mean corpuscular hemoglobin;	chr20:31805081	chr18:14010054~14010917:+
BRCA	trans	rs1568889	1	rs16917735	ENSG00000174912.7	METTL15P1	-5.67	1.81e-08	0.0114	-0.19	-0.17	Bipolar disorder;	chr11:28098433	chr3:156713884~156714928:-
BRCA	trans	rs11098499	0.954	rs17006190	ENSG00000253326.2	RP11-261C10.7	5.67	1.81e-08	0.0114	0.25	0.17	Corneal astigmatism;	chr4:119497683	chr1:243054861~243056394:-
BRCA	trans	rs1945213	0.527	rs10400362	ENSG00000134612.10	FOLH1B	-5.67	1.81e-08	0.0114	-0.31	-0.17	Acute lymphoblastic leukemia (childhood);	chr11:56405499	chr11:89639227~89698718:+
BRCA	trans	rs4929949	0.644	rs10840042	ENSG00000266891.1	RP11-692N5.2	-5.67	1.81e-08	0.0115	-0.21	-0.17	Body mass index;	chr11:8422431	chr18:9734882~9735602:-
BRCA	trans	rs875971	1	rs3981131	ENSG00000164669.11	INTS4P1	-5.67	1.82e-08	0.0115	-0.21	-0.17	Aortic root size;	chr7:66486690	chr7:65141225~65234216:+
BRCA	trans	rs13217239	0.621	rs12527231	ENSG00000216901.1	AL022393.7	-5.67	1.82e-08	0.0115	-0.21	-0.17	Schizophrenia;	chr6:27033509	chr6:28176188~28176674:+
BRCA	trans	rs13217239	0.646	rs12523820	ENSG00000216901.1	AL022393.7	-5.67	1.82e-08	0.0115	-0.21	-0.17	Schizophrenia;	chr6:27033723	chr6:28176188~28176674:+
BRCA	trans	rs654950	0.934	rs638859	ENSG00000243260.3	RN7SL558P	5.67	1.82e-08	0.0115	0.21	0.17	Airway imaging phenotypes;	chr1:41535773	chr4:39761000~39761298:+
BRCA	trans	rs13217239	0.646	rs6937880	ENSG00000216901.1	AL022393.7	-5.67	1.82e-08	0.0115	-0.21	-0.17	Schizophrenia;	chr6:27032457	chr6:28176188~28176674:+
BRCA	trans	rs11098499	0.913	rs68128210	ENSG00000276997.3	RP11-378J18.9	5.67	1.83e-08	0.0116	0.22	0.17	Corneal astigmatism;	chr4:119216664	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.913	rs13126596	ENSG00000276997.3	RP11-378J18.9	5.67	1.83e-08	0.0116	0.22	0.17	Corneal astigmatism;	chr4:119219574	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.954	rs10017543	ENSG00000276805.1	RP11-291L22.6	5.67	1.83e-08	0.0116	0.2	0.17	Corneal astigmatism;	chr4:119400265	chr10:38451030~38451785:+
BRCA	trans	rs7662987	0.517	rs1154410	ENSG00000233859.2	ADH5P4	-5.67	1.84e-08	0.0116	-0.25	-0.17	Smoking initiation;	chr4:99085494	chr6:65836930~65838039:-
BRCA	trans	rs11638815	0.859	rs11631182	ENSG00000235370.6	DNM1P51	5.67	1.84e-08	0.0116	0.23	0.17	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82725328	chr15:84398316~84411701:-
BRCA	trans	rs1459104	0.778	rs72916044	ENSG00000134612.10	FOLH1B	-5.67	1.84e-08	0.0116	-0.35	-0.17	Body mass index;	chr11:55747019	chr11:89639227~89698718:+
BRCA	trans	rs9393777	0.623	rs34313099	ENSG00000253570.1	RNF5P1	5.67	1.84e-08	0.0116	0.32	0.17	Intelligence (multi-trait analysis);	chr6:26489379	chr8:38600661~38601200:-
BRCA	trans	rs45509595	0.822	rs200484	ENSG00000253570.1	RNF5P1	5.67	1.84e-08	0.0116	0.38	0.17	Breast cancer;	chr6:27807896	chr8:38600661~38601200:-
BRCA	trans	rs7903456	0.953	rs7087038	ENSG00000232706.3	NUTM2HP	5.67	1.85e-08	0.0117	0.23	0.17	Gout;Renal underexcretion gout;	chr10:87106372	chr10:50676743~50686326:+
BRCA	trans	rs7903456	0.953	rs9421583	ENSG00000232706.3	NUTM2HP	5.67	1.85e-08	0.0117	0.23	0.17	Gout;Renal underexcretion gout;	chr10:87106959	chr10:50676743~50686326:+
BRCA	trans	rs10838687	0.736	rs830083	ENSG00000134612.10	FOLH1B	-5.67	1.86e-08	0.0117	-0.27	-0.17	Proinsulin levels;	chr11:47232500	chr11:89639227~89698718:+
BRCA	trans	rs1039766	0.929	rs55843720	ENSG00000213985.4	AC078899.1	5.67	1.86e-08	0.0117	0.25	0.17	Lung adenocarcinoma;Lung cancer;	chr2:65268436	chr19:20257720~20259418:+
BRCA	trans	rs11122895	0.509	rs55937046	ENSG00000233673.5	ANAPC1P1	5.67	1.86e-08	0.0117	0.19	0.17	Allergic sensitization;	chr2:111689719	chr2:86861825~86922693:+
BRCA	trans	rs12497850	0.931	rs9876848	ENSG00000197582.5	GPX1P1	5.67	1.86e-08	0.0117	0.18	0.17	Parkinson's disease;	chr3:48806626	chrX:13378735~13379340:-
BRCA	trans	rs7566780	0.549	rs6746795	ENSG00000224631.4	RP11-51O6.1	-5.67	1.86e-08	0.0117	-0.17	-0.17	Cleft lip with or without cleft palate;Orofacial clefts;	chr2:16500898	chr16:61055399~61055964:-
BRCA	trans	rs11098499	0.954	rs7436506	ENSG00000253326.2	RP11-261C10.7	5.67	1.86e-08	0.0118	0.24	0.17	Corneal astigmatism;	chr4:119472614	chr1:243054861~243056394:-
BRCA	trans	rs9462846	1	rs56158882	ENSG00000231579.3	RPL7P21	5.67	1.86e-08	0.0118	0.25	0.17	Blood protein levels;	chr6:42893002	chr5:143332605~143333239:+
BRCA	trans	rs9462846	0.959	rs57514728	ENSG00000231579.3	RPL7P21	5.67	1.86e-08	0.0118	0.25	0.17	Blood protein levels;	chr6:42893010	chr5:143332605~143333239:+
BRCA	trans	rs7746199	0.736	rs34105070	ENSG00000243753.4	HLA-L	-5.67	1.87e-08	0.0118	-0.46	-0.17	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27593026	chr6:30259584~30293014:+
BRCA	trans	rs9467711	0.606	rs35076545	ENSG00000281831.1	HCP5B	5.67	1.87e-08	0.0118	0.4	0.17	Autism spectrum disorder or schizophrenia;	chr6:26603696	chr6:29871895~29873783:-
BRCA	trans	rs902774	0.818	rs4919742	ENSG00000240668.1	KRT8P36	-5.67	1.87e-08	0.0118	-0.37	-0.17	Prostate cancer;	chr12:52879180	chr3:138101478~138102917:-
BRCA	trans	rs11098499	0.691	rs12502524	ENSG00000276997.3	RP11-378J18.9	5.67	1.87e-08	0.0118	0.2	0.17	Corneal astigmatism;	chr4:119350259	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.954	rs28685688	ENSG00000276805.1	RP11-291L22.6	5.67	1.87e-08	0.0118	0.21	0.17	Corneal astigmatism;	chr4:119499179	chr10:38451030~38451785:+
BRCA	trans	rs11098499	0.954	rs7687843	ENSG00000276805.1	RP11-291L22.6	5.67	1.87e-08	0.0118	0.21	0.17	Corneal astigmatism;	chr4:119500056	chr10:38451030~38451785:+
BRCA	trans	rs9876781	0.563	rs4858821	ENSG00000225528.1	RP3-370M22.8	5.67	1.88e-08	0.0118	0.21	0.17	Longevity;	chr3:48512515	chr22:39960397~39964683:+
BRCA	trans	rs704840	0.729	rs4916315	ENSG00000251484.3	RP5-1065J22.4	5.67	1.88e-08	0.0118	0.25	0.17	Systemic lupus erythematosus;Systemic lupus erythematosus and Systemic sclerosis;	chr1:173246233	chr1:109103535~109104766:-
BRCA	trans	rs877636	1	rs2292239	ENSG00000227586.5	RP11-162A23.5	5.67	1.88e-08	0.0118	0.21	0.17	Cognitive function;	chr12:56088396	chr10:123171535~123171875:-
BRCA	trans	rs875971	0.545	rs73378304	ENSG00000213640.3	EEF1DP4	-5.67	1.88e-08	0.0119	-0.23	-0.17	Aortic root size;	chr7:66175760	chr7:64862999~64864370:+
BRCA	trans	rs1933488	0.931	rs9397587	ENSG00000180015.12	RP11-756P10.3	-5.67	1.88e-08	0.0119	-0.22	-0.17	Prostate cancer;	chr6:153095777	chr4:188738373~188739494:+
BRCA	trans	rs7927771	0.832	rs56030824	ENSG00000134612.10	FOLH1B	-5.67	1.89e-08	0.0119	-0.24	-0.17	Subjective well-being;	chr11:47375802	chr11:89639227~89698718:+
BRCA	trans	rs11098499	0.644	rs3986377	ENSG00000276997.3	RP11-378J18.9	5.67	1.89e-08	0.0119	0.2	0.17	Corneal astigmatism;	chr4:119339115	chr1:222477252~222504622:-
BRCA	trans	rs10028773	0.556	rs4473640	ENSG00000276997.3	RP11-378J18.9	5.67	1.89e-08	0.0119	0.2	0.17	Educational attainment;	chr4:119339282	chr1:222477252~222504622:-
BRCA	trans	rs113793030	0.661	rs10999181	ENSG00000253785.1	CTC-308K20.3	5.67	1.89e-08	0.0119	0.46	0.17	Cognitive decline rate in late mild cognitive impairment;	chr10:70204780	chr5:172975511~172976374:+
BRCA	trans	rs11098499	0.954	rs10006706	ENSG00000276805.1	RP11-291L22.6	5.67	1.9e-08	0.0119	0.2	0.17	Corneal astigmatism;	chr4:119487997	chr10:38451030~38451785:+
BRCA	trans	rs11098499	0.863	rs10030660	ENSG00000253326.2	RP11-261C10.7	5.67	1.9e-08	0.012	0.25	0.17	Corneal astigmatism;	chr4:119515549	chr1:243054861~243056394:-
BRCA	trans	rs11098499	0.863	rs13149407	ENSG00000253326.2	RP11-261C10.7	5.67	1.9e-08	0.012	0.25	0.17	Corneal astigmatism;	chr4:119516670	chr1:243054861~243056394:-
BRCA	trans	rs45509595	0.841	rs17751184	ENSG00000228078.1	HLA-U	-5.66	1.9e-08	0.012	-0.46	-0.17	Breast cancer;	chr6:27807250	chr6:29934101~29934286:+
BRCA	trans	rs902774	0.818	rs4919763	ENSG00000230716.3	KRT8P7	-5.66	1.91e-08	0.012	-0.36	-0.17	Prostate cancer;	chr12:52885839	chr11:119602875~119604306:-
BRCA	trans	rs9858542	0.953	rs3811697	ENSG00000197582.5	GPX1P1	-5.66	1.91e-08	0.012	-0.19	-0.17	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49553337	chrX:13378735~13379340:-
BRCA	trans	rs7746199	0.736	rs13212093	ENSG00000281831.1	HCP5B	5.66	1.91e-08	0.0121	0.44	0.17	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27638937	chr6:29871895~29873783:-
BRCA	trans	rs7746199	0.736	rs34038546	ENSG00000281831.1	HCP5B	5.66	1.91e-08	0.0121	0.44	0.17	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27639881	chr6:29871895~29873783:-
BRCA	trans	rs141342723	1	rs141342723	ENSG00000281831.1	HCP5B	5.66	1.91e-08	0.0121	0.44	0.17	Autism spectrum disorder or schizophrenia;	chr6:27654305	chr6:29871895~29873783:-
BRCA	trans	rs7746199	0.736	rs34543938	ENSG00000281831.1	HCP5B	5.66	1.91e-08	0.0121	0.44	0.17	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27656861	chr6:29871895~29873783:-
BRCA	trans	rs7746199	0.736	rs56405707	ENSG00000281831.1	HCP5B	5.66	1.91e-08	0.0121	0.44	0.17	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27672467	chr6:29871895~29873783:-
BRCA	trans	rs9693857	0.518	rs35589912	ENSG00000253893.2	FAM85B	5.66	1.92e-08	0.0121	0.24	0.17	Systolic blood pressure;	chr8:9420478	chr8:8167819~8226614:-
BRCA	trans	rs9649213	0.593	rs6465675	ENSG00000225169.1	BRI3P1	-5.66	1.92e-08	0.0121	-0.22	-0.17	Prostate cancer (SNP x SNP interaction);	chr7:98352791	chr1:100213293~100213670:+
BRCA	trans	rs4713118	0.824	rs9366702	ENSG00000204709.4	LINC01556	5.66	1.92e-08	0.0121	0.24	0.17	Parkinson's disease;	chr6:27766691	chr6:28943877~28944537:+
BRCA	trans	rs853679	0.607	rs13194781	ENSG00000204709.4	LINC01556	5.66	1.92e-08	0.0121	0.46	0.17	Depression;	chr6:27847861	chr6:28943877~28944537:+
BRCA	trans	rs1948368	0.668	rs1199579	ENSG00000243181.2	RP11-734J24.1	-5.66	1.92e-08	0.0121	-0.19	-0.17	Bipolar disorder;	chr1:101521577	chr8:34874159~34874633:+
BRCA	trans	rs1459104	1	rs35851721	ENSG00000134612.10	FOLH1B	-5.66	1.93e-08	0.0121	-0.32	-0.17	Body mass index;	chr11:55431622	chr11:89639227~89698718:+
BRCA	trans	rs11098499	0.863	rs1383532	ENSG00000253326.2	RP11-261C10.7	-5.66	1.93e-08	0.0121	-0.24	-0.17	Corneal astigmatism;	chr4:119513249	chr1:243054861~243056394:-
BRCA	trans	rs7746199	0.673	rs72845046	ENSG00000281831.1	HCP5B	5.66	1.93e-08	0.0121	0.44	0.17	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27607489	chr6:29871895~29873783:-
BRCA	trans	rs17556665	0.597	rs2697825	ENSG00000236360.2	RP11-334A14.2	5.66	1.93e-08	0.0122	0.28	0.17	Inflammatory biomarkers;	chr11:14067884	chr1:52993201~52993702:-
BRCA	trans	rs17556665	0.627	rs2697826	ENSG00000236360.2	RP11-334A14.2	5.66	1.93e-08	0.0122	0.28	0.17	Inflammatory biomarkers;	chr11:14067893	chr1:52993201~52993702:-
BRCA	trans	rs35146811	0.961	rs35991721	ENSG00000228546.2	CTA-313A17.3	-5.66	1.93e-08	0.0122	-0.25	-0.17	Coronary artery disease;	chr7:100131167	chr7:102337316~102339115:+
BRCA	trans	rs7647973	1	rs13088309	ENSG00000197582.5	GPX1P1	5.66	1.94e-08	0.0122	0.19	0.17	Menarche (age at onset);	chr3:49330884	chrX:13378735~13379340:-
BRCA	trans	rs9860340	0.73	rs55641563	ENSG00000259370.2	RP11-1069G10.1	5.66	1.94e-08	0.0122	0.2	0.17	Electroencephalographic traits in alcoholism;	chr3:87600397	chr15:62827675~62884034:-
BRCA	trans	rs9393813	0.805	rs2205829	ENSG00000242375.1	RP11-498P14.3	-5.66	1.94e-08	0.0122	-0.23	-0.17	Bipolar disorder;	chr6:27512448	chr9:97195351~97197687:-
BRCA	trans	rs7746199	0.736	rs67652222	ENSG00000281831.1	HCP5B	5.66	1.94e-08	0.0122	0.44	0.17	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27618441	chr6:29871895~29873783:-
BRCA	trans	rs7647973	1	rs6785045	ENSG00000235912.1	RP1-159A19.3	5.66	1.94e-08	0.0122	0.22	0.17	Menarche (age at onset);	chr3:49397810	chr1:27649419~27649610:+
BRCA	trans	rs7647973	1	rs7648995	ENSG00000235912.1	RP1-159A19.3	5.66	1.94e-08	0.0122	0.22	0.17	Menarche (age at onset);	chr3:49401370	chr1:27649419~27649610:+
BRCA	trans	rs7647973	1	rs2140270	ENSG00000235912.1	RP1-159A19.3	5.66	1.94e-08	0.0122	0.22	0.17	Menarche (age at onset);	chr3:49402007	chr1:27649419~27649610:+
BRCA	trans	rs7647973	1	rs2177268	ENSG00000235912.1	RP1-159A19.3	5.66	1.94e-08	0.0122	0.22	0.17	Menarche (age at onset);	chr3:49402292	chr1:27649419~27649610:+
BRCA	trans	rs16975963	0.644	rs111694872	ENSG00000247498.8	RP11-392P7.6	5.66	1.94e-08	0.0122	0.3	0.17	Longevity;	chr19:37555429	chr12:12927726~12984645:+
BRCA	trans	rs282544	0.686	rs282547	ENSG00000231752.4	EMBP1	-5.66	1.95e-08	0.0122	-0.23	-0.17	Myopia (pathological);	chr5:50761895	chr1:121519112~121571892:+
BRCA	trans	rs35306767	0.903	rs11253462	ENSG00000187984.11	ANKRD19P	5.66	1.95e-08	0.0123	0.21	0.17	Eosinophil percentage of granulocytes;	chr10:843383	chr9:92809388~92888693:+
BRCA	trans	rs11098499	0.954	rs4577559	ENSG00000253326.2	RP11-261C10.7	5.66	1.96e-08	0.0123	0.24	0.17	Corneal astigmatism;	chr4:119482888	chr1:243054861~243056394:-
BRCA	trans	rs11098499	0.954	rs7656252	ENSG00000253326.2	RP11-261C10.7	5.66	1.96e-08	0.0123	0.24	0.17	Corneal astigmatism;	chr4:119483113	chr1:243054861~243056394:-
BRCA	trans	rs11098499	0.865	rs28845498	ENSG00000253326.2	RP11-261C10.7	5.66	1.96e-08	0.0123	0.24	0.17	Corneal astigmatism;	chr4:119484031	chr1:243054861~243056394:-
BRCA	trans	rs11098499	0.954	rs56270433	ENSG00000253326.2	RP11-261C10.7	5.66	1.96e-08	0.0123	0.24	0.17	Corneal astigmatism;	chr4:119484875	chr1:243054861~243056394:-
BRCA	trans	rs4879656	0.864	rs7861851	ENSG00000215007.3	DNAJA1P3	5.66	1.96e-08	0.0123	0.22	0.17	Menopause (age at onset);	chr9:33037351	chrX:107351650~107352843:-
BRCA	trans	rs4879656	0.931	rs7875733	ENSG00000215007.3	DNAJA1P3	5.66	1.96e-08	0.0123	0.22	0.17	Menopause (age at onset);	chr9:33037352	chrX:107351650~107352843:-
BRCA	trans	rs11098499	0.662	rs13108589	ENSG00000276997.3	RP11-378J18.9	5.66	1.96e-08	0.0123	0.21	0.17	Corneal astigmatism;	chr4:119346947	chr1:222477252~222504622:-
BRCA	trans	rs893818	0.56	rs67182653	ENSG00000214826.5	DDX12P	-5.66	1.97e-08	0.0124	-0.19	-0.17	Exfoliation glaucoma or exfoliation syndrome;	chr15:73946966	chr12:9418673~9448229:-
BRCA	trans	rs12363310	0.581	rs1939065	ENSG00000134297.6	PLEKHA8P1	-5.66	1.97e-08	0.0124	-0.23	-0.17	Systemic sclerosis;	chr11:101817894	chr12:45173064~45216041:-
BRCA	trans	rs9393777	0.72	rs56874662	ENSG00000253570.1	RNF5P1	5.66	1.97e-08	0.0124	0.37	0.17	Intelligence (multi-trait analysis);	chr6:27017828	chr8:38600661~38601200:-
BRCA	trans	rs9393777	0.72	rs35212793	ENSG00000253570.1	RNF5P1	5.66	1.97e-08	0.0124	0.37	0.17	Intelligence (multi-trait analysis);	chr6:27030914	chr8:38600661~38601200:-
BRCA	trans	rs9393777	0.72	rs35769282	ENSG00000253570.1	RNF5P1	5.66	1.97e-08	0.0124	0.37	0.17	Intelligence (multi-trait analysis);	chr6:27032129	chr8:38600661~38601200:-
BRCA	trans	rs853679	0.882	rs4713139	ENSG00000228078.1	HLA-U	-5.66	1.97e-08	0.0124	-0.36	-0.17	Depression;	chr6:28124907	chr6:29934101~29934286:+
BRCA	trans	rs853679	0.882	rs3757188	ENSG00000228078.1	HLA-U	-5.66	1.97e-08	0.0124	-0.36	-0.17	Depression;	chr6:28139579	chr6:29934101~29934286:+
BRCA	trans	rs7636839	0.688	rs9822622	ENSG00000164669.11	INTS4P1	-5.66	1.97e-08	0.0124	-0.22	-0.17	EGFR mutation-positive lung adenocarcinoma;	chr3:189608257	chr7:65141225~65234216:+
BRCA	trans	rs7662987	0.517	rs3018048	ENSG00000233859.2	ADH5P4	-5.66	1.97e-08	0.0124	-0.25	-0.17	Smoking initiation;	chr4:99084387	chr6:65836930~65838039:-
BRCA	trans	rs1568889	1	rs66702115	ENSG00000174912.7	METTL15P1	5.66	1.97e-08	0.0124	0.19	0.17	Bipolar disorder;	chr11:28160156	chr3:156713884~156714928:-
BRCA	trans	rs10838687	0.736	rs3824866	ENSG00000134612.10	FOLH1B	5.66	1.97e-08	0.0124	0.27	0.17	Proinsulin levels;	chr11:47237302	chr11:89639227~89698718:+
BRCA	trans	rs6921919	0.789	rs11970439	ENSG00000228078.1	HLA-U	-5.66	1.98e-08	0.0124	-0.26	-0.17	Autism spectrum disorder or schizophrenia;	chr6:28335687	chr6:29934101~29934286:+
BRCA	trans	rs6142102	0.517	rs6142046	ENSG00000280327.1	LA16c-313F4.1	-5.66	1.98e-08	0.0124	-0.18	-0.17	Skin pigmentation;	chr20:33926255	chr16:1576716~1578371:-
BRCA	trans	rs11098499	0.863	rs12508173	ENSG00000276805.1	RP11-291L22.6	5.66	1.98e-08	0.0124	0.2	0.17	Corneal astigmatism;	chr4:119397371	chr10:38451030~38451785:+
BRCA	trans	rs11098499	0.908	rs12504149	ENSG00000276805.1	RP11-291L22.6	5.66	1.98e-08	0.0124	0.2	0.17	Corneal astigmatism;	chr4:119397422	chr10:38451030~38451785:+
BRCA	trans	rs9858542	0.953	rs7622302	ENSG00000197582.5	GPX1P1	-5.66	1.98e-08	0.0124	-0.2	-0.17	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49510128	chrX:13378735~13379340:-
BRCA	trans	rs35146811	1	rs35146811	ENSG00000228546.2	CTA-313A17.3	-5.66	1.98e-08	0.0124	-0.25	-0.17	Coronary artery disease;	chr7:100123371	chr7:102337316~102339115:+
BRCA	trans	rs875971	0.965	rs28682868	ENSG00000164669.11	INTS4P1	5.66	1.98e-08	0.0124	0.21	0.17	Aortic root size;	chr7:66224822	chr7:65141225~65234216:+
BRCA	trans	rs4834770	0.718	rs4833618	ENSG00000253326.2	RP11-261C10.7	-5.66	1.98e-08	0.0124	-0.22	-0.17	Blood protein levels;	chr4:119388345	chr1:243054861~243056394:-
BRCA	trans	rs853679	0.607	rs67998226	ENSG00000243753.4	HLA-L	-5.66	1.98e-08	0.0125	-0.44	-0.17	Depression;	chr6:28270281	chr6:30259584~30293014:+
BRCA	trans	rs2122469	0.655	rs17603934	ENSG00000249898.6	CTD-2541M15.1	5.66	1.99e-08	0.0125	0.31	0.17	Serum tamsulosin hydrochloride concentration;	chr8:20718833	chr8:6618475~6708209:-
BRCA	trans	rs1933488	0.504	rs1281951	ENSG00000278974.1	RP11-756P10.6	5.66	1.99e-08	0.0125	0.23	0.17	Prostate cancer;	chr6:153141422	chr4:188740507~188741281:-
BRCA	trans	rs7089973	0.526	rs17722042	ENSG00000249267.5	LINC00939	5.66	2e-08	0.0125	0.21	0.17	Bipolar disorder or attention deficit hyperactivity disorder;	chr10:114978785	chr12:125958688~125983374:-
BRCA	trans	rs673253	0.556	rs10789442	ENSG00000231007.5	CDC20P1	-5.66	2e-08	0.0125	-0.23	-0.17	Intelligence (multi-trait analysis);	chr1:43674404	chr9:87011652~87013151:+
BRCA	trans	rs11098499	0.909	rs11723757	ENSG00000276805.1	RP11-291L22.6	5.66	2e-08	0.0125	0.2	0.17	Corneal astigmatism;	chr4:119378514	chr10:38451030~38451785:+
BRCA	trans	rs11782517	0.92	rs4295669	ENSG00000253893.2	FAM85B	-5.66	2e-08	0.0125	-0.24	-0.17	Nose size;	chr8:10247917	chr8:8167819~8226614:-
BRCA	trans	rs6601327	1	rs6601327	ENSG00000253893.2	FAM85B	5.66	2e-08	0.0126	0.21	0.17	Multiple myeloma (hyperdiploidy);	chr8:9538022	chr8:8167819~8226614:-
BRCA	trans	rs11098499	0.722	rs1814814	ENSG00000120555.12	SEPT7P9	5.66	2e-08	0.0126	0.2	0.17	Corneal astigmatism;	chr4:119336969	chr10:38383069~38402916:-
BRCA	trans	rs6601327	0.641	rs11780399	ENSG00000253893.2	FAM85B	5.66	2.01e-08	0.0126	0.22	0.17	Multiple myeloma (hyperdiploidy);	chr8:9731657	chr8:8167819~8226614:-
BRCA	trans	rs387619	0.553	rs353604	ENSG00000235720.1	RP11-340I6.6	5.66	2.01e-08	0.0126	0.2	0.17	Systemic lupus erythematosus;	chr11:35084151	chr7:63893286~63894641:+
BRCA	trans	rs11638815	0.728	rs4779056	ENSG00000235370.6	DNM1P51	5.66	2.01e-08	0.0126	0.22	0.17	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82719974	chr15:84398316~84411701:-
BRCA	trans	rs902774	0.818	rs55999178	ENSG00000240668.1	KRT8P36	-5.66	2.01e-08	0.0126	-0.37	-0.17	Prostate cancer;	chr12:52890576	chr3:138101478~138102917:-
BRCA	trans	rs11098499	0.691	rs28396837	ENSG00000276997.3	RP11-378J18.9	5.66	2.01e-08	0.0126	0.2	0.17	Corneal astigmatism;	chr4:119350386	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.629	rs28369518	ENSG00000276997.3	RP11-378J18.9	5.66	2.01e-08	0.0126	0.2	0.17	Corneal astigmatism;	chr4:119350475	chr1:222477252~222504622:-
BRCA	trans	rs9649213	0.593	rs7795176	ENSG00000225169.1	BRI3P1	5.65	2.01e-08	0.0126	0.22	0.17	Prostate cancer (SNP x SNP interaction);	chr7:98348975	chr1:100213293~100213670:+
BRCA	trans	rs9649213	0.593	rs62478200	ENSG00000225169.1	BRI3P1	5.65	2.01e-08	0.0126	0.22	0.17	Prostate cancer (SNP x SNP interaction);	chr7:98350733	chr1:100213293~100213670:+
BRCA	trans	rs6011368	0.84	rs2427638	ENSG00000273823.1	AC215219.2	5.65	2.02e-08	0.0126	0.19	0.17	Clozapine-induced cytotoxicity;	chr20:64269364	chr12:17484~17551:-
BRCA	trans	rs7647973	1	rs3448	ENSG00000235912.1	RP1-159A19.3	-5.65	2.02e-08	0.0127	-0.22	-0.17	Menarche (age at onset);	chr3:49359318	chr1:27649419~27649610:+
BRCA	trans	rs7647973	1	rs11130190	ENSG00000235912.1	RP1-159A19.3	-5.65	2.02e-08	0.0127	-0.22	-0.17	Menarche (age at onset);	chr3:49364704	chr1:27649419~27649610:+
BRCA	trans	rs6934970	1	rs1857099	ENSG00000267560.1	RP11-173A16.1	-5.65	2.02e-08	0.0127	-0.21	-0.17	Bipolar disorder (body mass index interaction);	chr6:112799227	chr18:62300036~62300998:-
BRCA	trans	rs11098499	0.863	rs7678400	ENSG00000253326.2	RP11-261C10.7	5.65	2.02e-08	0.0127	0.25	0.17	Corneal astigmatism;	chr4:119540802	chr1:243054861~243056394:-
BRCA	trans	rs11098499	0.863	rs1480936	ENSG00000253326.2	RP11-261C10.7	5.65	2.02e-08	0.0127	0.25	0.17	Corneal astigmatism;	chr4:119541706	chr1:243054861~243056394:-
BRCA	trans	rs7113874	0.589	rs7101471	ENSG00000266891.1	RP11-692N5.2	-5.65	2.02e-08	0.0127	-0.2	-0.17	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8442075	chr18:9734882~9735602:-
BRCA	trans	rs113793030	0.661	rs10999183	ENSG00000253785.1	CTC-308K20.3	5.65	2.03e-08	0.0127	0.45	0.17	Cognitive decline rate in late mild cognitive impairment;	chr10:70205136	chr5:172975511~172976374:+
BRCA	trans	rs113793030	0.661	rs10999184	ENSG00000253785.1	CTC-308K20.3	5.65	2.03e-08	0.0127	0.45	0.17	Cognitive decline rate in late mild cognitive impairment;	chr10:70205238	chr5:172975511~172976374:+
BRCA	trans	rs113793030	0.661	rs57113544	ENSG00000253785.1	CTC-308K20.3	5.65	2.03e-08	0.0127	0.45	0.17	Cognitive decline rate in late mild cognitive impairment;	chr10:70205763	chr5:172975511~172976374:+
BRCA	trans	rs7746199	0.736	rs13193542	ENSG00000228078.1	HLA-U	-5.65	2.03e-08	0.0127	-0.46	-0.17	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27734646	chr6:29934101~29934286:+
BRCA	trans	rs7746199	0.736	rs13193480	ENSG00000228078.1	HLA-U	-5.65	2.03e-08	0.0127	-0.46	-0.17	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27734782	chr6:29934101~29934286:+
BRCA	trans	rs7746199	0.736	rs13212093	ENSG00000243753.4	HLA-L	-5.65	2.03e-08	0.0127	-0.46	-0.17	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27638937	chr6:30259584~30293014:+
BRCA	trans	rs7746199	0.736	rs34038546	ENSG00000243753.4	HLA-L	-5.65	2.03e-08	0.0127	-0.46	-0.17	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27639881	chr6:30259584~30293014:+
BRCA	trans	rs141342723	1	rs141342723	ENSG00000243753.4	HLA-L	-5.65	2.03e-08	0.0127	-0.46	-0.17	Autism spectrum disorder or schizophrenia;	chr6:27654305	chr6:30259584~30293014:+
BRCA	trans	rs7746199	0.736	rs34543938	ENSG00000243753.4	HLA-L	-5.65	2.03e-08	0.0127	-0.46	-0.17	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27656861	chr6:30259584~30293014:+
BRCA	trans	rs7746199	0.736	rs56405707	ENSG00000243753.4	HLA-L	-5.65	2.03e-08	0.0127	-0.46	-0.17	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27672467	chr6:30259584~30293014:+
BRCA	trans	rs7695732	0.595	rs1921679	ENSG00000227191.5	TRGC2	-5.65	2.03e-08	0.0127	-0.16	-0.17	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr4:88969633	chr7:38239580~38368091:-
BRCA	trans	rs9649213	0.593	rs7458551	ENSG00000225169.1	BRI3P1	5.65	2.03e-08	0.0127	0.22	0.17	Prostate cancer (SNP x SNP interaction);	chr7:98322855	chr1:100213293~100213670:+
BRCA	trans	rs11638815	1	rs11638815	ENSG00000235370.6	DNM1P51	5.65	2.03e-08	0.0127	0.22	0.17	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82683530	chr15:84398316~84411701:-
BRCA	trans	rs1568889	1	rs7945367	ENSG00000174912.7	METTL15P1	5.65	2.03e-08	0.0127	0.19	0.17	Bipolar disorder;	chr11:28144725	chr3:156713884~156714928:-
BRCA	trans	rs11098499	0.754	rs4107728	ENSG00000276997.3	RP11-378J18.9	5.65	2.04e-08	0.0128	0.2	0.17	Corneal astigmatism;	chr4:119332755	chr1:222477252~222504622:-
BRCA	trans	rs3732378	0.666	rs11129819	ENSG00000183298.5	RP11-556K13.1	5.65	2.04e-08	0.0128	0.27	0.17	Monocyte count;Lymphocyte counts;Granulocyte percentage of myeloid white cells;Monocyte percentage of white cells;	chr3:39263111	chr1:101786340~101787219:-
BRCA	trans	rs893818	0.682	rs66481504	ENSG00000214826.5	DDX12P	-5.65	2.04e-08	0.0128	-0.18	-0.17	Exfoliation glaucoma or exfoliation syndrome;	chr15:73938838	chr12:9418673~9448229:-
BRCA	trans	rs7151302	0.667	rs17100390	ENSG00000254326.1	IGHV7-27	5.65	2.04e-08	0.0128	0.23	0.17	Plasma amyloid beta peptide concentrations (ABx-40);	chr14:33217607	chr14:106317823~106318236:-
BRCA	trans	rs6142102	0.58	rs9753679	ENSG00000280327.1	LA16c-313F4.1	-5.65	2.05e-08	0.0128	-0.18	-0.17	Skin pigmentation;	chr20:33953054	chr16:1576716~1578371:-
BRCA	trans	rs4879656	0.762	rs7868944	ENSG00000215007.3	DNAJA1P3	-5.65	2.05e-08	0.0129	-0.21	-0.17	Menopause (age at onset);	chr9:32938861	chrX:107351650~107352843:-
BRCA	trans	rs13394619	0.875	rs7576826	ENSG00000273980.1	RP13-49I15.6	-5.65	2.05e-08	0.0129	-0.21	-0.17	Endometriosis;	chr2:11582895	chr10:133257144~133257551:-
BRCA	trans	rs9649213	0.593	rs6465666	ENSG00000225169.1	BRI3P1	-5.65	2.05e-08	0.0129	-0.22	-0.17	Prostate cancer (SNP x SNP interaction);	chr7:98307946	chr1:100213293~100213670:+
BRCA	trans	rs11098499	0.863	rs10019674	ENSG00000253326.2	RP11-261C10.7	-5.65	2.06e-08	0.0129	-0.25	-0.17	Corneal astigmatism;	chr4:119522334	chr1:243054861~243056394:-
BRCA	trans	rs6142102	0.602	rs4911145	ENSG00000280327.1	LA16c-313F4.1	5.65	2.06e-08	0.0129	0.18	0.17	Skin pigmentation;	chr20:34027417	chr16:1576716~1578371:-
BRCA	trans	rs7568458	0.837	rs6547624	ENSG00000223886.3	RP11-251G23.2	5.65	2.06e-08	0.0129	0.2	0.17	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr2:85575011	chr7:105530209~105530671:+
BRCA	trans	rs7647973	1	rs6446275	ENSG00000235912.1	RP1-159A19.3	5.65	2.06e-08	0.0129	0.22	0.17	Menarche (age at onset);	chr3:49429438	chr1:27649419~27649610:+
BRCA	trans	rs11098499	0.618	rs35265692	ENSG00000253326.2	RP11-261C10.7	5.65	2.06e-08	0.0129	0.24	0.17	Corneal astigmatism;	chr4:119403980	chr1:243054861~243056394:-
BRCA	trans	rs11098499	0.618	rs28491261	ENSG00000276805.1	RP11-291L22.6	5.65	2.06e-08	0.0129	0.2	0.17	Corneal astigmatism;	chr4:119373745	chr10:38451030~38451785:+
BRCA	trans	rs853679	0.607	rs13199772	ENSG00000204709.4	LINC01556	5.65	2.06e-08	0.0129	0.47	0.17	Depression;	chr6:27866307	chr6:28943877~28944537:+
BRCA	trans	rs9467711	0.659	rs35680819	ENSG00000220721.1	OR1F12	5.65	2.07e-08	0.0129	0.38	0.17	Autism spectrum disorder or schizophrenia;	chr6:26455586	chr6:28073316~28074233:+
BRCA	trans	rs7570469	0.762	rs451090	ENSG00000276390.1	RP1-197B17.5	5.65	2.07e-08	0.013	0.22	0.17	Response to antipsychotic treatment;	chr2:79470256	chr12:47699401~47699917:-
BRCA	trans	rs4929949	0.649	rs4344491	ENSG00000266891.1	RP11-692N5.2	-5.65	2.07e-08	0.013	-0.21	-0.17	Body mass index;	chr11:8589864	chr18:9734882~9735602:-
BRCA	trans	rs1459104	0.929	rs35627018	ENSG00000134612.10	FOLH1B	-5.65	2.07e-08	0.013	-0.32	-0.17	Body mass index;	chr11:55432163	chr11:89639227~89698718:+
BRCA	trans	rs11098499	0.779	rs80242894	ENSG00000276805.1	RP11-291L22.6	5.65	2.08e-08	0.013	0.2	0.17	Corneal astigmatism;	chr4:119454597	chr10:38451030~38451785:+
BRCA	trans	rs853679	0.607	rs34662244	ENSG00000228078.1	HLA-U	-5.65	2.08e-08	0.013	-0.48	-0.17	Depression;	chr6:28106103	chr6:29934101~29934286:+
BRCA	trans	rs35952432	1	rs35952432	ENSG00000228078.1	HLA-U	-5.65	2.08e-08	0.013	-0.48	-0.17	Lung cancer;	chr6:28107123	chr6:29934101~29934286:+
BRCA	trans	rs9649213	0.593	rs6961438	ENSG00000225169.1	BRI3P1	5.65	2.08e-08	0.013	0.22	0.17	Prostate cancer (SNP x SNP interaction);	chr7:98376537	chr1:100213293~100213670:+
BRCA	trans	rs228614	0.509	rs223482	ENSG00000211782.2	TRAV8-1	-5.65	2.08e-08	0.013	-0.13	-0.17	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102766051	chr14:21797287~21797886:+
BRCA	trans	rs7568458	0.87	rs6757263	ENSG00000223886.3	RP11-251G23.2	5.65	2.09e-08	0.0131	0.2	0.17	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr2:85576419	chr7:105530209~105530671:+
BRCA	trans	rs4879656	0.897	rs1537256	ENSG00000215007.3	DNAJA1P3	5.65	2.09e-08	0.0131	0.22	0.17	Menopause (age at onset);	chr9:33004419	chrX:107351650~107352843:-
BRCA	trans	rs4883201	0.536	rs1121401	ENSG00000179899.8	PHC1P1	5.65	2.1e-08	0.0131	0.22	0.17	Total cholesterol levels;Cholesterol, total;	chr12:8984026	chr12:55411727~55414787:-
BRCA	trans	rs9858542	0.953	rs9841110	ENSG00000197582.5	GPX1P1	-5.65	2.1e-08	0.0131	-0.2	-0.17	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49455048	chrX:13378735~13379340:-
BRCA	trans	rs902774	0.818	rs55914512	ENSG00000240668.1	KRT8P36	-5.65	2.1e-08	0.0131	-0.37	-0.17	Prostate cancer;	chr12:52888490	chr3:138101478~138102917:-
BRCA	trans	rs902774	0.818	rs73108466	ENSG00000240668.1	KRT8P36	-5.65	2.1e-08	0.0131	-0.37	-0.17	Prostate cancer;	chr12:52889857	chr3:138101478~138102917:-
BRCA	trans	rs2055729	0.507	rs814424	ENSG00000253893.2	FAM85B	5.65	2.11e-08	0.0132	0.27	0.17	Multiple myeloma (hyperdiploidy);	chr8:10085414	chr8:8167819~8226614:-
BRCA	trans	rs703108	0.731	rs7898954	ENSG00000213293.4	CTD-2666L21.3	5.65	2.12e-08	0.0132	0.24	0.17	Monocyte percentage of white cells;	chr10:22034717	chr19:12260126~12260537:+
BRCA	trans	rs62295889	0.602	rs73096518	ENSG00000232228.1	RP11-77O7.1	-5.65	2.12e-08	0.0132	-0.25	-0.17	Obesity-related traits;	chr4:12535319	chr2:69594741~69595058:-
BRCA	trans	rs7617480	0.648	rs6796790	ENSG00000235912.1	RP1-159A19.3	-5.65	2.12e-08	0.0132	-0.22	-0.17	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48742884	chr1:27649419~27649610:+
BRCA	trans	rs12497850	0.864	rs4955410	ENSG00000197582.5	GPX1P1	5.65	2.12e-08	0.0132	0.18	0.17	Parkinson's disease;	chr3:49143785	chrX:13378735~13379340:-
BRCA	trans	rs1232027	0.666	rs1677666	ENSG00000188985.6	DHFRP1	-5.64	2.13e-08	0.0133	-0.22	-0.17	Huntington's disease progression;	chr5:80626006	chr18:26170726~26171284:-
BRCA	trans	rs6940638	0.615	rs9393801	ENSG00000204709.4	LINC01556	5.64	2.13e-08	0.0133	0.22	0.17	Intelligence (multi-trait analysis);	chr6:27274902	chr6:28943877~28944537:+
BRCA	trans	rs9467603	0.8	rs4236040	ENSG00000253570.1	RNF5P1	-5.64	2.13e-08	0.0133	-0.4	-0.17	Intelligence (multi-trait analysis);	chr6:25760981	chr8:38600661~38601200:-
BRCA	trans	rs6142102	0.625	rs7263727	ENSG00000280327.1	LA16c-313F4.1	-5.64	2.13e-08	0.0133	-0.18	-0.17	Skin pigmentation;	chr20:33953133	chr16:1576716~1578371:-
BRCA	trans	rs6142102	0.625	rs6142056	ENSG00000280327.1	LA16c-313F4.1	-5.64	2.13e-08	0.0133	-0.18	-0.17	Skin pigmentation;	chr20:33953349	chr16:1576716~1578371:-
BRCA	trans	rs875971	0.545	rs13311962	ENSG00000213640.3	EEF1DP4	5.64	2.14e-08	0.0133	0.24	0.17	Aortic root size;	chr7:66603142	chr7:64862999~64864370:+
BRCA	trans	rs12497850	0.897	rs6446252	ENSG00000197582.5	GPX1P1	5.64	2.14e-08	0.0133	0.18	0.17	Parkinson's disease;	chr3:48873692	chrX:13378735~13379340:-
BRCA	trans	rs12497850	0.931	rs9840684	ENSG00000197582.5	GPX1P1	5.64	2.14e-08	0.0134	0.18	0.17	Parkinson's disease;	chr3:48856347	chrX:13378735~13379340:-
BRCA	trans	rs660899	0.894	rs3791035	ENSG00000231007.5	CDC20P1	5.64	2.14e-08	0.0134	0.23	0.17	Hypertension risk in short sleep duration;	chr1:43688808	chr9:87011652~87013151:+
BRCA	trans	rs902774	0.818	rs4919763	ENSG00000240668.1	KRT8P36	-5.64	2.14e-08	0.0134	-0.37	-0.17	Prostate cancer;	chr12:52885839	chr3:138101478~138102917:-
BRCA	trans	rs6601327	0.606	rs9644707	ENSG00000253893.2	FAM85B	5.64	2.14e-08	0.0134	0.22	0.17	Multiple myeloma (hyperdiploidy);	chr8:9732606	chr8:8167819~8226614:-
BRCA	trans	rs11098499	0.954	rs59866101	ENSG00000276805.1	RP11-291L22.6	5.64	2.15e-08	0.0134	0.2	0.17	Corneal astigmatism;	chr4:119375436	chr10:38451030~38451785:+
BRCA	trans	rs11098499	0.618	rs6858383	ENSG00000276805.1	RP11-291L22.6	5.64	2.15e-08	0.0134	0.2	0.17	Corneal astigmatism;	chr4:119375617	chr10:38451030~38451785:+
BRCA	trans	rs11098499	0.697	rs6832410	ENSG00000276805.1	RP11-291L22.6	5.64	2.15e-08	0.0134	0.2	0.17	Corneal astigmatism;	chr4:119375645	chr10:38451030~38451785:+
BRCA	trans	rs11098499	0.865	rs1112817	ENSG00000276805.1	RP11-291L22.6	5.64	2.15e-08	0.0134	0.2	0.17	Corneal astigmatism;	chr4:119376645	chr10:38451030~38451785:+
BRCA	trans	rs11098499	0.779	rs10016060	ENSG00000276805.1	RP11-291L22.6	5.64	2.15e-08	0.0134	0.2	0.17	Corneal astigmatism;	chr4:119377257	chr10:38451030~38451785:+
BRCA	trans	rs11098499	0.954	rs10005644	ENSG00000276805.1	RP11-291L22.6	5.64	2.15e-08	0.0134	0.2	0.17	Corneal astigmatism;	chr4:119377322	chr10:38451030~38451785:+
BRCA	trans	rs11098499	0.697	rs10016448	ENSG00000276805.1	RP11-291L22.6	5.64	2.15e-08	0.0134	0.2	0.17	Corneal astigmatism;	chr4:119377690	chr10:38451030~38451785:+
BRCA	trans	rs11098499	0.657	rs9996569	ENSG00000276805.1	RP11-291L22.6	5.64	2.15e-08	0.0134	0.2	0.17	Corneal astigmatism;	chr4:119377849	chr10:38451030~38451785:+
BRCA	trans	rs11098499	0.908	rs11729050	ENSG00000276805.1	RP11-291L22.6	5.64	2.15e-08	0.0134	0.2	0.17	Corneal astigmatism;	chr4:119378911	chr10:38451030~38451785:+
BRCA	trans	rs11098499	0.954	rs28429722	ENSG00000276805.1	RP11-291L22.6	5.64	2.15e-08	0.0134	0.2	0.17	Corneal astigmatism;	chr4:119378938	chr10:38451030~38451785:+
BRCA	trans	rs11098499	0.954	rs10014845	ENSG00000276805.1	RP11-291L22.6	5.64	2.15e-08	0.0134	0.2	0.17	Corneal astigmatism;	chr4:119379922	chr10:38451030~38451785:+
BRCA	trans	rs11098499	0.779	rs7674500	ENSG00000276805.1	RP11-291L22.6	5.64	2.15e-08	0.0134	0.2	0.17	Corneal astigmatism;	chr4:119382438	chr10:38451030~38451785:+
BRCA	trans	rs11098499	0.909	rs28884220	ENSG00000276805.1	RP11-291L22.6	5.64	2.15e-08	0.0134	0.2	0.17	Corneal astigmatism;	chr4:119386056	chr10:38451030~38451785:+
BRCA	trans	rs11098499	0.909	rs28793658	ENSG00000276805.1	RP11-291L22.6	5.64	2.15e-08	0.0134	0.2	0.17	Corneal astigmatism;	chr4:119386059	chr10:38451030~38451785:+
BRCA	trans	rs11098499	0.697	rs4373140	ENSG00000276805.1	RP11-291L22.6	5.64	2.15e-08	0.0134	0.2	0.17	Corneal astigmatism;	chr4:119386543	chr10:38451030~38451785:+
BRCA	trans	rs11098499	0.954	rs13113483	ENSG00000276805.1	RP11-291L22.6	5.64	2.15e-08	0.0134	0.2	0.17	Corneal astigmatism;	chr4:119387884	chr10:38451030~38451785:+
BRCA	trans	rs11098499	0.542	rs10440343	ENSG00000276805.1	RP11-291L22.6	5.64	2.15e-08	0.0134	0.2	0.17	Corneal astigmatism;	chr4:119388632	chr10:38451030~38451785:+
BRCA	trans	rs11098499	0.779	rs10011097	ENSG00000276805.1	RP11-291L22.6	5.64	2.15e-08	0.0134	0.2	0.17	Corneal astigmatism;	chr4:119389204	chr10:38451030~38451785:+
BRCA	trans	rs11098499	0.542	rs7677836	ENSG00000276805.1	RP11-291L22.6	5.64	2.15e-08	0.0134	0.2	0.17	Corneal astigmatism;	chr4:119389483	chr10:38451030~38451785:+
BRCA	trans	rs11098499	0.909	rs10002083	ENSG00000276805.1	RP11-291L22.6	5.64	2.15e-08	0.0134	0.2	0.17	Corneal astigmatism;	chr4:119389997	chr10:38451030~38451785:+
BRCA	trans	rs11098499	0.954	rs10024844	ENSG00000276805.1	RP11-291L22.6	5.64	2.15e-08	0.0134	0.2	0.17	Corneal astigmatism;	chr4:119390373	chr10:38451030~38451785:+
BRCA	trans	rs11098499	0.954	rs4345162	ENSG00000276805.1	RP11-291L22.6	5.64	2.15e-08	0.0134	0.2	0.17	Corneal astigmatism;	chr4:119391804	chr10:38451030~38451785:+
BRCA	trans	rs11098499	0.657	rs4463052	ENSG00000276805.1	RP11-291L22.6	5.64	2.15e-08	0.0134	0.2	0.17	Corneal astigmatism;	chr4:119392103	chr10:38451030~38451785:+
BRCA	trans	rs11098499	0.954	rs13151285	ENSG00000276805.1	RP11-291L22.6	5.64	2.15e-08	0.0134	0.2	0.17	Corneal astigmatism;	chr4:119393586	chr10:38451030~38451785:+
BRCA	trans	rs7746199	0.673	rs72845046	ENSG00000243753.4	HLA-L	-5.64	2.15e-08	0.0134	-0.46	-0.17	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27607489	chr6:30259584~30293014:+
BRCA	trans	rs10838687	0.736	rs11039148	ENSG00000134612.10	FOLH1B	5.64	2.15e-08	0.0134	0.27	0.17	Proinsulin levels;	chr11:47252575	chr11:89639227~89698718:+
BRCA	trans	rs6121246	0.559	rs12479491	ENSG00000279352.1	RP11-411B10.7	5.64	2.15e-08	0.0134	0.25	0.17	Mean corpuscular hemoglobin;	chr20:31677647	chr18:14010054~14010917:+
BRCA	trans	rs902774	0.818	rs4919763	ENSG00000220378.3	KRT8P42	-5.64	2.15e-08	0.0134	-0.37	-0.17	Prostate cancer;	chr12:52885839	chr6:134296997~134298695:-
BRCA	trans	rs11098499	0.909	rs79026312	ENSG00000253326.2	RP11-261C10.7	5.64	2.16e-08	0.0134	0.25	0.17	Corneal astigmatism;	chr4:119519522	chr1:243054861~243056394:-
BRCA	trans	rs11098499	0.909	rs35111518	ENSG00000253326.2	RP11-261C10.7	5.64	2.16e-08	0.0134	0.25	0.17	Corneal astigmatism;	chr4:119519527	chr1:243054861~243056394:-
BRCA	trans	rs11098499	0.722	rs17595727	ENSG00000120555.12	SEPT7P9	-5.64	2.16e-08	0.0135	-0.2	-0.17	Corneal astigmatism;	chr4:119340919	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.562	rs13101722	ENSG00000276997.3	RP11-378J18.9	-5.64	2.16e-08	0.0135	-0.2	-0.17	Corneal astigmatism;	chr4:119634820	chr1:222477252~222504622:-
BRCA	trans	rs9649213	0.555	rs12667634	ENSG00000225169.1	BRI3P1	5.64	2.16e-08	0.0135	0.22	0.17	Prostate cancer (SNP x SNP interaction);	chr7:98336130	chr1:100213293~100213670:+
BRCA	trans	rs9470366	0.772	rs9918353	ENSG00000257004.1	RP11-180M15.3	5.64	2.17e-08	0.0135	0.2	0.17	QRS duration;	chr6:36654900	chr12:12668982~12685075:+
BRCA	trans	rs9649213	0.593	rs7789380	ENSG00000225169.1	BRI3P1	5.64	2.17e-08	0.0135	0.22	0.17	Prostate cancer (SNP x SNP interaction);	chr7:98326868	chr1:100213293~100213670:+
BRCA	trans	rs11098499	0.954	rs28572238	ENSG00000276805.1	RP11-291L22.6	5.64	2.17e-08	0.0135	0.2	0.17	Corneal astigmatism;	chr4:119395531	chr10:38451030~38451785:+
BRCA	trans	rs2950393	0.895	rs2958154	ENSG00000257210.1	NACAP3	-5.64	2.18e-08	0.0136	-0.21	-0.17	Platelet distribution width;	chr12:56671929	chr12:93124063~93124543:-
BRCA	trans	rs9393777	0.92	rs13207689	ENSG00000243753.4	HLA-L	-5.64	2.19e-08	0.0136	-0.45	-0.17	Intelligence (multi-trait analysis);	chr6:27401925	chr6:30259584~30293014:+
BRCA	trans	rs9733	0.744	rs12126004	ENSG00000180764.13	PIPSL	5.64	2.19e-08	0.0136	0.21	0.17	Tonsillectomy;	chr1:150917401	chr10:93958191~93961540:-
BRCA	trans	rs7927771	0.929	rs12787646	ENSG00000134612.10	FOLH1B	-5.64	2.19e-08	0.0136	-0.23	-0.17	Subjective well-being;	chr11:47648113	chr11:89639227~89698718:+
BRCA	trans	rs9858542	0.953	rs9853683	ENSG00000197582.5	GPX1P1	-5.64	2.19e-08	0.0136	-0.2	-0.17	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49475155	chrX:13378735~13379340:-
BRCA	trans	rs9858542	0.953	rs12330269	ENSG00000197582.5	GPX1P1	-5.64	2.19e-08	0.0136	-0.2	-0.17	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49476477	chrX:13378735~13379340:-
BRCA	trans	rs9858542	0.953	rs6766581	ENSG00000197582.5	GPX1P1	-5.64	2.19e-08	0.0136	-0.2	-0.17	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49501968	chrX:13378735~13379340:-
BRCA	trans	rs1568889	1	rs7931847	ENSG00000174912.7	METTL15P1	5.64	2.19e-08	0.0136	0.19	0.17	Bipolar disorder;	chr11:28153698	chr3:156713884~156714928:-
BRCA	trans	rs54211	1	rs137580	ENSG00000226121.2	AC009487.6	5.64	2.19e-08	0.0136	0.33	0.17	Sudden cardiac arrest;	chr22:39281736	chr2:161500885~161507705:-
BRCA	trans	rs7568458	0.905	rs6739015	ENSG00000223886.3	RP11-251G23.2	5.64	2.2e-08	0.0137	0.2	0.17	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr2:85528234	chr7:105530209~105530671:+
BRCA	trans	rs853679	0.607	rs13199772	ENSG00000281831.1	HCP5B	5.64	2.2e-08	0.0137	0.45	0.17	Depression;	chr6:27866307	chr6:29871895~29873783:-
BRCA	trans	rs11098499	0.909	rs9759478	ENSG00000276805.1	RP11-291L22.6	5.64	2.2e-08	0.0137	0.21	0.17	Corneal astigmatism;	chr4:119446843	chr10:38451030~38451785:+
BRCA	trans	rs11098499	0.954	rs10008459	ENSG00000253326.2	RP11-261C10.7	5.64	2.2e-08	0.0137	0.24	0.17	Corneal astigmatism;	chr4:119473076	chr1:243054861~243056394:-
BRCA	trans	rs62295889	0.602	rs56660601	ENSG00000232228.1	RP11-77O7.1	-5.64	2.2e-08	0.0137	-0.25	-0.17	Obesity-related traits;	chr4:12534739	chr2:69594741~69595058:-
BRCA	trans	rs62295889	0.602	rs73096514	ENSG00000232228.1	RP11-77O7.1	-5.64	2.2e-08	0.0137	-0.25	-0.17	Obesity-related traits;	chr4:12535307	chr2:69594741~69595058:-
BRCA	trans	rs62295889	0.602	rs62295918	ENSG00000232228.1	RP11-77O7.1	-5.64	2.2e-08	0.0137	-0.25	-0.17	Obesity-related traits;	chr4:12535387	chr2:69594741~69595058:-
BRCA	trans	rs7617480	0.648	rs6801211	ENSG00000235912.1	RP1-159A19.3	-5.64	2.21e-08	0.0137	-0.22	-0.17	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48736987	chr1:27649419~27649610:+
BRCA	trans	rs6954796	1	rs6954796	ENSG00000278035.1	RP11-234K24.6	-5.64	2.21e-08	0.0138	-0.29	-0.17	Non-word repetition;	chr7:20047359	chr20:36233851~36234297:+
BRCA	trans	rs1568889	1	rs7112860	ENSG00000174912.7	METTL15P1	5.64	2.21e-08	0.0138	0.19	0.17	Bipolar disorder;	chr11:28130062	chr3:156713884~156714928:-
BRCA	trans	rs12546962	0.626	rs17149797	ENSG00000253893.2	FAM85B	5.64	2.21e-08	0.0138	0.26	0.17	Body mass index;	chr8:9332461	chr8:8167819~8226614:-
BRCA	trans	rs4879656	0.797	rs2297218	ENSG00000215007.3	DNAJA1P3	5.64	2.21e-08	0.0138	0.21	0.17	Menopause (age at onset);	chr9:33025253	chrX:107351650~107352843:-
BRCA	trans	rs11098499	0.954	rs9998585	ENSG00000253326.2	RP11-261C10.7	5.64	2.22e-08	0.0138	0.24	0.17	Corneal astigmatism;	chr4:119475647	chr1:243054861~243056394:-
BRCA	trans	rs11098499	0.909	rs6842762	ENSG00000253326.2	RP11-261C10.7	5.64	2.22e-08	0.0138	0.24	0.17	Corneal astigmatism;	chr4:119477081	chr1:243054861~243056394:-
BRCA	trans	rs902774	0.759	rs4919707	ENSG00000240668.1	KRT8P36	-5.64	2.22e-08	0.0138	-0.37	-0.17	Prostate cancer;	chr12:52895864	chr3:138101478~138102917:-
BRCA	trans	rs1568889	1	rs12797689	ENSG00000174912.7	METTL15P1	5.64	2.22e-08	0.0138	0.2	0.17	Bipolar disorder;	chr11:28054495	chr3:156713884~156714928:-
BRCA	trans	rs1580019	0.563	rs10486509	ENSG00000213492.2	NT5C3AP1	5.64	2.22e-08	0.0138	0.23	0.17	Cognitive ability;	chr7:32545831	chr4:117574512~117576174:-
BRCA	trans	rs12682352	0.715	rs332039	ENSG00000270154.1	RP11-419I17.1	5.64	2.22e-08	0.0138	0.21	0.17	Neuroticism;	chr8:8866141	chr8:12476462~12477122:+
BRCA	trans	rs11098499	0.82	rs13128602	ENSG00000253326.2	RP11-261C10.7	-5.64	2.22e-08	0.0138	-0.24	-0.17	Corneal astigmatism;	chr4:119538211	chr1:243054861~243056394:-
BRCA	trans	rs853679	0.607	rs34166054	ENSG00000228078.1	HLA-U	-5.64	2.22e-08	0.0138	-0.47	-0.17	Depression;	chr6:28098023	chr6:29934101~29934286:+
BRCA	trans	rs853679	0.607	rs13203816	ENSG00000228078.1	HLA-U	-5.64	2.22e-08	0.0138	-0.47	-0.17	Depression;	chr6:28111820	chr6:29934101~29934286:+
BRCA	trans	rs853679	0.556	rs34588114	ENSG00000228078.1	HLA-U	-5.64	2.22e-08	0.0138	-0.47	-0.17	Depression;	chr6:28112850	chr6:29934101~29934286:+
BRCA	trans	rs853679	0.607	rs68188794	ENSG00000228078.1	HLA-U	-5.64	2.22e-08	0.0138	-0.47	-0.17	Depression;	chr6:28112999	chr6:29934101~29934286:+
BRCA	trans	rs853679	0.546	rs34371502	ENSG00000228078.1	HLA-U	-5.64	2.22e-08	0.0138	-0.47	-0.17	Depression;	chr6:28113980	chr6:29934101~29934286:+
BRCA	trans	rs853679	0.607	rs66886492	ENSG00000228078.1	HLA-U	-5.64	2.22e-08	0.0138	-0.47	-0.17	Depression;	chr6:28121953	chr6:29934101~29934286:+
BRCA	trans	rs853679	0.607	rs35345226	ENSG00000228078.1	HLA-U	-5.64	2.22e-08	0.0138	-0.47	-0.17	Depression;	chr6:28123802	chr6:29934101~29934286:+
BRCA	trans	rs17507216	0.718	rs4779034	ENSG00000235370.6	DNM1P51	-5.64	2.23e-08	0.0138	-0.23	-0.17	Excessive daytime sleepiness;	chr15:82576799	chr15:84398316~84411701:-
BRCA	trans	rs7089973	0.534	rs61869275	ENSG00000249267.5	LINC00939	5.64	2.23e-08	0.0139	0.21	0.17	Bipolar disorder or attention deficit hyperactivity disorder;	chr10:114989841	chr12:125958688~125983374:-
BRCA	trans	rs12497850	0.931	rs28642807	ENSG00000197582.5	GPX1P1	5.64	2.24e-08	0.0139	0.18	0.17	Parkinson's disease;	chr3:48889383	chrX:13378735~13379340:-
BRCA	trans	rs7113874	0.569	rs10840095	ENSG00000266891.1	RP11-692N5.2	-5.64	2.24e-08	0.0139	-0.2	-0.17	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8606428	chr18:9734882~9735602:-
BRCA	trans	rs7647973	1	rs11720542	ENSG00000197582.5	GPX1P1	5.64	2.24e-08	0.0139	0.19	0.17	Menarche (age at onset);	chr3:49319994	chrX:13378735~13379340:-
BRCA	trans	rs4879656	0.897	rs1537255	ENSG00000215007.3	DNAJA1P3	5.64	2.25e-08	0.0139	0.22	0.17	Menopause (age at onset);	chr9:33004377	chrX:107351650~107352843:-
BRCA	trans	rs7746199	0.736	rs67652222	ENSG00000243753.4	HLA-L	-5.64	2.25e-08	0.014	-0.46	-0.17	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27618441	chr6:30259584~30293014:+
BRCA	trans	rs660899	0.857	rs3791044	ENSG00000231007.5	CDC20P1	5.63	2.26e-08	0.014	0.23	0.17	Hypertension risk in short sleep duration;	chr1:43754262	chr9:87011652~87013151:+
BRCA	trans	rs6921919	0.789	rs6912584	ENSG00000228078.1	HLA-U	-5.63	2.26e-08	0.014	-0.26	-0.17	Autism spectrum disorder or schizophrenia;	chr6:28341813	chr6:29934101~29934286:+
BRCA	trans	rs6782228	0.883	rs11712115	ENSG00000229178.1	AC069513.4	-5.63	2.26e-08	0.014	-0.23	-0.17	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128685426	chr3:195655565~195657927:-
BRCA	trans	rs11098499	0.908	rs11098527	ENSG00000253326.2	RP11-261C10.7	5.63	2.26e-08	0.014	0.24	0.17	Corneal astigmatism;	chr4:119478751	chr1:243054861~243056394:-
BRCA	trans	rs1816854	1	rs10880570	ENSG00000178082.6	TWF1P1	-5.63	2.26e-08	0.014	-0.2	-0.17	Inflammatory bowel disease;	chr12:43808662	chr17:29203426~29204474:-
BRCA	trans	rs35306767	0.903	rs1341741	ENSG00000187984.11	ANKRD19P	5.63	2.26e-08	0.014	0.21	0.17	Eosinophil percentage of granulocytes;	chr10:842133	chr9:92809388~92888693:+
BRCA	trans	rs6142102	0.625	rs9753690	ENSG00000280327.1	LA16c-313F4.1	-5.63	2.27e-08	0.0141	-0.18	-0.17	Skin pigmentation;	chr20:33952995	chr16:1576716~1578371:-
BRCA	trans	rs7113874	0.531	rs10840094	ENSG00000266891.1	RP11-692N5.2	-5.63	2.27e-08	0.0141	-0.2	-0.17	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8606427	chr18:9734882~9735602:-
BRCA	trans	rs853679	0.546	rs36116761	ENSG00000204709.4	LINC01556	5.63	2.27e-08	0.0141	0.46	0.17	Depression;	chr6:27850704	chr6:28943877~28944537:+
BRCA	trans	rs853679	0.546	rs34194357	ENSG00000204709.4	LINC01556	5.63	2.27e-08	0.0141	0.46	0.17	Depression;	chr6:27850757	chr6:28943877~28944537:+
BRCA	trans	rs6984305	0.541	rs17716118	ENSG00000246089.3	RP11-115C21.2	5.63	2.27e-08	0.0141	0.33	0.17	Liver enzyme levels (alkaline phosphatase);	chr8:9322624	chr8:6403551~6407142:-
BRCA	trans	rs893818	0.682	rs72745365	ENSG00000214826.5	DDX12P	-5.63	2.28e-08	0.0141	-0.18	-0.17	Exfoliation glaucoma or exfoliation syndrome;	chr15:73939110	chr12:9418673~9448229:-
BRCA	trans	rs9393777	0.623	rs9358946	ENSG00000253570.1	RNF5P1	5.63	2.28e-08	0.0141	0.32	0.17	Intelligence (multi-trait analysis);	chr6:26478699	chr8:38600661~38601200:-
BRCA	trans	rs9393777	0.623	rs9358947	ENSG00000253570.1	RNF5P1	5.63	2.28e-08	0.0141	0.32	0.17	Intelligence (multi-trait analysis);	chr6:26478772	chr8:38600661~38601200:-
BRCA	trans	rs10946940	0.965	rs9393830	ENSG00000204709.4	LINC01556	5.63	2.28e-08	0.0142	0.22	0.17	Systemic lupus erythematosus;	chr6:27619248	chr6:28943877~28944537:+
BRCA	trans	rs801193	0.591	rs9986881	ENSG00000213640.3	EEF1DP4	-5.63	2.29e-08	0.0142	-0.22	-0.17	Aortic root size;	chr7:66708053	chr7:64862999~64864370:+
BRCA	trans	rs6954796	0.614	rs4721863	ENSG00000278035.1	RP11-234K24.6	-5.63	2.29e-08	0.0142	-0.28	-0.17	Non-word repetition;	chr7:20051388	chr20:36233851~36234297:+
BRCA	trans	rs12497850	0.931	rs4974079	ENSG00000197582.5	GPX1P1	5.63	2.29e-08	0.0142	0.18	0.17	Parkinson's disease;	chr3:48869036	chrX:13378735~13379340:-
BRCA	trans	rs9860340	0.652	rs57087351	ENSG00000259370.2	RP11-1069G10.1	5.63	2.31e-08	0.0143	0.2	0.17	Electroencephalographic traits in alcoholism;	chr3:87588385	chr15:62827675~62884034:-
BRCA	trans	rs9860340	0.73	rs57368400	ENSG00000259370.2	RP11-1069G10.1	5.63	2.31e-08	0.0143	0.2	0.17	Electroencephalographic traits in alcoholism;	chr3:87590605	chr15:62827675~62884034:-
BRCA	trans	rs11098499	0.954	rs7437420	ENSG00000276805.1	RP11-291L22.6	5.63	2.31e-08	0.0143	0.2	0.17	Corneal astigmatism;	chr4:119391748	chr10:38451030~38451785:+
BRCA	trans	rs11748023	0.605	rs155943	ENSG00000224848.1	RP11-535M15.1	5.63	2.31e-08	0.0143	0.21	0.17	Intelligence (multi-trait analysis);	chr5:140150402	chr9:96687056~96721121:+
BRCA	trans	rs9858542	0.953	rs9814873	ENSG00000235912.1	RP1-159A19.3	-5.63	2.32e-08	0.0144	-0.22	-0.17	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49416679	chr1:27649419~27649610:+
BRCA	trans	rs7746199	0.736	rs10484399	ENSG00000281831.1	HCP5B	5.63	2.32e-08	0.0144	0.41	0.17	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27566749	chr6:29871895~29873783:-
BRCA	trans	rs7568458	0.87	rs6719046	ENSG00000223886.3	RP11-251G23.2	5.63	2.32e-08	0.0144	0.2	0.17	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr2:85530248	chr7:105530209~105530671:+
BRCA	trans	rs7568458	0.87	rs6733913	ENSG00000223886.3	RP11-251G23.2	5.63	2.32e-08	0.0144	0.2	0.17	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr2:85530256	chr7:105530209~105530671:+
BRCA	trans	rs6440475	0.679	rs1502100	ENSG00000240338.4	RP11-331F4.4	5.63	2.32e-08	0.0144	0.21	0.17	Response to paliperidone in schizophrenia (positive Marder score);	chr3:147116216	chr16:75226074~75228197:+
BRCA	trans	rs4948102	0.653	rs6593294	ENSG00000186940.6	CHCHD2P9	-5.63	2.33e-08	0.0144	-0.22	-0.17	Plasma homocysteine levels (post-methionine load test);	chr7:55995508	chr9:79391304~79391759:+
BRCA	trans	rs228614	0.536	rs223478	ENSG00000211782.2	TRAV8-1	-5.63	2.34e-08	0.0145	-0.13	-0.17	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102768648	chr14:21797287~21797886:+
BRCA	trans	rs228614	0.536	rs150898	ENSG00000211782.2	TRAV8-1	-5.63	2.34e-08	0.0145	-0.13	-0.17	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102769234	chr14:21797287~21797886:+
BRCA	trans	rs654950	0.934	rs654220	ENSG00000243260.3	RN7SL558P	-5.63	2.34e-08	0.0145	-0.21	-0.17	Airway imaging phenotypes;	chr1:41536885	chr4:39761000~39761298:+
BRCA	trans	rs6121246	0.609	rs6060948	ENSG00000279352.1	RP11-411B10.7	5.63	2.34e-08	0.0145	0.25	0.17	Mean corpuscular hemoglobin;	chr20:31788590	chr18:14010054~14010917:+
BRCA	trans	rs12497850	0.931	rs9682444	ENSG00000197582.5	GPX1P1	5.63	2.34e-08	0.0145	0.18	0.17	Parkinson's disease;	chr3:48815206	chrX:13378735~13379340:-
BRCA	trans	rs12497850	0.931	rs9835307	ENSG00000197582.5	GPX1P1	5.63	2.34e-08	0.0145	0.18	0.17	Parkinson's disease;	chr3:48820372	chrX:13378735~13379340:-
BRCA	trans	rs12497850	0.931	rs9755490	ENSG00000197582.5	GPX1P1	5.63	2.34e-08	0.0145	0.18	0.17	Parkinson's disease;	chr3:48834231	chrX:13378735~13379340:-
BRCA	trans	rs11950121	0.639	rs7729734	ENSG00000226253.1	MRPL35P3	-5.63	2.34e-08	0.0145	-0.2	-0.17	Alcoholic chronic pancreatitis;	chr5:53895313	chr10:74527584~74527947:+
BRCA	trans	rs7568458	0.837	rs3770098	ENSG00000223886.3	RP11-251G23.2	5.63	2.35e-08	0.0145	0.2	0.17	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr2:85578244	chr7:105530209~105530671:+
BRCA	trans	rs9649213	0.593	rs10953257	ENSG00000225169.1	BRI3P1	-5.63	2.35e-08	0.0146	-0.21	-0.17	Prostate cancer (SNP x SNP interaction);	chr7:98331352	chr1:100213293~100213670:+
BRCA	trans	rs10924970	1	rs10924970	ENSG00000241014.1	RP11-244H3.1	5.63	2.36e-08	0.0146	0.14	0.17	Asthma;	chr1:235199645	chr1:34974356~34985313:-
BRCA	trans	rs1568889	1	rs34667360	ENSG00000174912.7	METTL15P1	5.63	2.36e-08	0.0146	0.2	0.17	Bipolar disorder;	chr11:28034103	chr3:156713884~156714928:-
BRCA	trans	rs228614	0.509	rs223481	ENSG00000211782.2	TRAV8-1	-5.63	2.36e-08	0.0146	-0.13	-0.17	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102766860	chr14:21797287~21797886:+
BRCA	trans	rs7568458	0.846	rs2028900	ENSG00000223886.3	RP11-251G23.2	-5.63	2.36e-08	0.0146	-0.2	-0.17	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr2:85540612	chr7:105530209~105530671:+
BRCA	trans	rs11098499	0.82	rs2389885	ENSG00000253326.2	RP11-261C10.7	5.63	2.37e-08	0.0146	0.26	0.17	Corneal astigmatism;	chr4:119612776	chr1:243054861~243056394:-
BRCA	trans	rs902774	0.818	rs11831919	ENSG00000223940.1	KRT8P8	-5.63	2.37e-08	0.0146	-0.34	-0.17	Prostate cancer;	chr12:52878231	chrX:152479577~152481024:+
BRCA	trans	rs9860340	0.73	rs4859086	ENSG00000259370.2	RP11-1069G10.1	5.63	2.37e-08	0.0146	0.2	0.17	Electroencephalographic traits in alcoholism;	chr3:87586907	chr15:62827675~62884034:-
BRCA	trans	rs9860340	0.73	rs67302043	ENSG00000259370.2	RP11-1069G10.1	5.63	2.37e-08	0.0147	0.2	0.17	Electroencephalographic traits in alcoholism;	chr3:87591883	chr15:62827675~62884034:-
BRCA	trans	rs9393813	0.516	rs4711152	ENSG00000242375.1	RP11-498P14.3	-5.63	2.37e-08	0.0147	-0.23	-0.17	Bipolar disorder;	chr6:27412423	chr9:97195351~97197687:-
BRCA	trans	rs1336472	0.509	rs4916032	ENSG00000233381.3	AK4P3	-5.63	2.37e-08	0.0147	-0.23	-0.17	Venous thromboembolism (SNP x SNP interaction);	chr1:65215939	chr12:31615771~31616439:-
BRCA	trans	rs16975963	0.644	rs35205379	ENSG00000247498.8	RP11-392P7.6	-5.63	2.38e-08	0.0147	-0.3	-0.17	Longevity;	chr19:37685941	chr12:12927726~12984645:+
BRCA	trans	rs11098499	0.738	rs34965784	ENSG00000276805.1	RP11-291L22.6	5.63	2.38e-08	0.0147	0.2	0.17	Corneal astigmatism;	chr4:119440431	chr10:38451030~38451785:+
BRCA	trans	rs9649213	0.593	rs7796611	ENSG00000225169.1	BRI3P1	5.63	2.38e-08	0.0147	0.22	0.17	Prostate cancer (SNP x SNP interaction);	chr7:98278911	chr1:100213293~100213670:+
BRCA	trans	rs9649213	0.574	rs13238610	ENSG00000225169.1	BRI3P1	5.63	2.38e-08	0.0147	0.22	0.17	Prostate cancer (SNP x SNP interaction);	chr7:98279965	chr1:100213293~100213670:+
BRCA	trans	rs2243480	1	rs316329	ENSG00000164669.11	INTS4P1	5.63	2.38e-08	0.0147	0.33	0.17	Diabetic kidney disease;	chr7:66143429	chr7:65141225~65234216:+
BRCA	trans	rs11098499	0.954	rs59394118	ENSG00000276805.1	RP11-291L22.6	5.63	2.38e-08	0.0147	0.2	0.17	Corneal astigmatism;	chr4:119374396	chr10:38451030~38451785:+
BRCA	trans	rs11098499	0.865	rs9996417	ENSG00000276805.1	RP11-291L22.6	5.63	2.38e-08	0.0147	0.2	0.17	Corneal astigmatism;	chr4:119374707	chr10:38451030~38451785:+
BRCA	trans	rs11098499	0.58	rs12509234	ENSG00000276805.1	RP11-291L22.6	5.62	2.38e-08	0.0147	0.2	0.17	Corneal astigmatism;	chr4:119398279	chr10:38451030~38451785:+
BRCA	trans	rs11098499	0.909	rs10014719	ENSG00000276805.1	RP11-291L22.6	5.62	2.38e-08	0.0147	0.2	0.17	Corneal astigmatism;	chr4:119399560	chr10:38451030~38451785:+
BRCA	trans	rs6995541	0.647	rs7000939	ENSG00000253893.2	FAM85B	5.62	2.38e-08	0.0147	0.22	0.17	Triglyceride levels;	chr8:10831364	chr8:8167819~8226614:-
BRCA	trans	rs11098499	0.908	rs7695996	ENSG00000276805.1	RP11-291L22.6	5.62	2.39e-08	0.0147	0.2	0.17	Corneal astigmatism;	chr4:119400878	chr10:38451030~38451785:+
BRCA	trans	rs853679	0.556	rs34706883	ENSG00000204709.4	LINC01556	5.62	2.39e-08	0.0148	0.45	0.17	Depression;	chr6:27837477	chr6:28943877~28944537:+
BRCA	trans	rs853679	0.546	rs34295134	ENSG00000228078.1	HLA-U	-5.62	2.39e-08	0.0148	-0.35	-0.17	Depression;	chr6:27860373	chr6:29934101~29934286:+
BRCA	trans	rs9393777	0.623	rs7756567	ENSG00000253570.1	RNF5P1	5.62	2.39e-08	0.0148	0.32	0.17	Intelligence (multi-trait analysis);	chr6:26481414	chr8:38600661~38601200:-
BRCA	trans	rs9393777	0.623	rs9358948	ENSG00000253570.1	RNF5P1	5.62	2.39e-08	0.0148	0.32	0.17	Intelligence (multi-trait analysis);	chr6:26483578	chr8:38600661~38601200:-
BRCA	trans	rs9650657	0.665	rs7002117	ENSG00000255495.1	AC145124.2	5.62	2.4e-08	0.0148	0.19	0.17	Neuroticism;	chr8:10758659	chr8:12194467~12196280:+
BRCA	trans	rs2243480	1	rs316322	ENSG00000164669.11	INTS4P1	5.62	2.4e-08	0.0148	0.33	0.17	Diabetic kidney disease;	chr7:66146246	chr7:65141225~65234216:+
BRCA	trans	rs9393813	0.529	rs73395360	ENSG00000242375.1	RP11-498P14.3	5.62	2.4e-08	0.0148	0.23	0.17	Bipolar disorder;	chr6:27489538	chr9:97195351~97197687:-
BRCA	trans	rs11098499	0.82	rs28535956	ENSG00000276805.1	RP11-291L22.6	-5.62	2.41e-08	0.0149	-0.21	-0.17	Corneal astigmatism;	chr4:119615703	chr10:38451030~38451785:+
BRCA	trans	rs11098499	0.874	rs7661020	ENSG00000276997.3	RP11-378J18.9	5.62	2.41e-08	0.0149	0.22	0.17	Corneal astigmatism;	chr4:119185827	chr1:222477252~222504622:-
BRCA	trans	rs7830939	0.586	rs9918809	ENSG00000253893.2	FAM85B	5.62	2.41e-08	0.0149	0.22	0.17	Neuroticism;	chr8:9463449	chr8:8167819~8226614:-
BRCA	trans	rs12497850	0.931	rs7627404	ENSG00000197582.5	GPX1P1	5.62	2.41e-08	0.0149	0.18	0.17	Parkinson's disease;	chr3:48782235	chrX:13378735~13379340:-
BRCA	trans	rs6601327	0.641	rs7462070	ENSG00000253893.2	FAM85B	5.62	2.42e-08	0.0149	0.22	0.17	Multiple myeloma (hyperdiploidy);	chr8:9713854	chr8:8167819~8226614:-
BRCA	trans	rs875971	0.545	rs12670811	ENSG00000234585.5	CCT6P3	5.62	2.42e-08	0.0149	0.19	0.17	Aortic root size;	chr7:66358032	chr7:65038354~65074713:+
BRCA	trans	rs13217239	0.646	rs10946888	ENSG00000216901.1	AL022393.7	-5.62	2.42e-08	0.0149	-0.21	-0.17	Schizophrenia;	chr6:26983899	chr6:28176188~28176674:+
BRCA	trans	rs877636	0.74	rs705702	ENSG00000227586.5	RP11-162A23.5	-5.62	2.42e-08	0.0149	-0.23	-0.17	Cognitive function;	chr12:55996852	chr10:123171535~123171875:-
BRCA	trans	rs6142102	0.625	rs6142051	ENSG00000280327.1	LA16c-313F4.1	-5.62	2.42e-08	0.0149	-0.18	-0.17	Skin pigmentation;	chr20:33945212	chr16:1576716~1578371:-
BRCA	trans	rs6790105	1	rs6790105	ENSG00000235912.1	RP1-159A19.3	-5.62	2.42e-08	0.015	-0.22	-0.17	Childhood ear infection;	chr3:49355976	chr1:27649419~27649610:+
BRCA	trans	rs10838687	0.736	rs76832686	ENSG00000134612.10	FOLH1B	5.62	2.43e-08	0.015	0.27	0.17	Proinsulin levels;	chr11:47225736	chr11:89639227~89698718:+
BRCA	trans	rs6934970	1	rs6933881	ENSG00000267560.1	RP11-173A16.1	-5.62	2.43e-08	0.015	-0.21	-0.17	Bipolar disorder (body mass index interaction);	chr6:112802658	chr18:62300036~62300998:-
BRCA	trans	rs6934970	1	rs6934919	ENSG00000267560.1	RP11-173A16.1	-5.62	2.43e-08	0.015	-0.21	-0.17	Bipolar disorder (body mass index interaction);	chr6:112802939	chr18:62300036~62300998:-
BRCA	trans	rs6934970	0.932	rs6914487	ENSG00000267560.1	RP11-173A16.1	-5.62	2.43e-08	0.015	-0.21	-0.17	Bipolar disorder (body mass index interaction);	chr6:112802991	chr18:62300036~62300998:-
BRCA	trans	rs6934970	1	rs6934785	ENSG00000267560.1	RP11-173A16.1	-5.62	2.43e-08	0.015	-0.21	-0.17	Bipolar disorder (body mass index interaction);	chr6:112803037	chr18:62300036~62300998:-
BRCA	trans	rs9649213	0.593	rs6944262	ENSG00000225169.1	BRI3P1	5.62	2.43e-08	0.015	0.22	0.17	Prostate cancer (SNP x SNP interaction);	chr7:98356103	chr1:100213293~100213670:+
BRCA	trans	rs1526687	0.632	rs34742649	ENSG00000257052.1	RP11-881M11.2	5.62	2.43e-08	0.015	0.21	0.17	Cardiac Troponin-T levels;	chr2:52492429	chr11:60906789~60909742:+
BRCA	trans	rs9393777	0.92	rs41269265	ENSG00000228078.1	HLA-U	-5.62	2.44e-08	0.015	-0.41	-0.17	Intelligence (multi-trait analysis);	chr6:27457570	chr6:29934101~29934286:+
BRCA	trans	rs2727020	0.53	rs7113153	ENSG00000134612.10	FOLH1B	-5.62	2.44e-08	0.015	-0.24	-0.17	Coronary artery disease;	chr11:49436405	chr11:89639227~89698718:+
BRCA	trans	rs6831352	0.84	rs29001223	ENSG00000233859.2	ADH5P4	5.62	2.44e-08	0.015	0.25	0.17	Alcohol dependence;	chr4:99126282	chr6:65836930~65838039:-
BRCA	trans	rs4948102	1	rs4948102	ENSG00000186940.6	CHCHD2P9	-5.62	2.44e-08	0.015	-0.22	-0.17	Plasma homocysteine levels (post-methionine load test);	chr7:56029572	chr9:79391304~79391759:+
BRCA	trans	rs6430585	0.528	rs12476127	ENSG00000224043.6	CCNT2-AS1	-5.62	2.44e-08	0.0151	-0.29	-0.17	Corneal structure;	chr2:136005672	chr2:134735464~134918710:-
BRCA	trans	rs1568889	1	rs61236373	ENSG00000174912.7	METTL15P1	5.62	2.44e-08	0.0151	0.19	0.17	Bipolar disorder;	chr11:28191173	chr3:156713884~156714928:-
BRCA	trans	rs7113874	0.524	rs4929943	ENSG00000266891.1	RP11-692N5.2	-5.62	2.44e-08	0.0151	-0.2	-0.17	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8603807	chr18:9734882~9735602:-
BRCA	trans	rs7113874	0.524	rs4929944	ENSG00000266891.1	RP11-692N5.2	-5.62	2.44e-08	0.0151	-0.2	-0.17	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8603894	chr18:9734882~9735602:-
BRCA	trans	rs7113874	0.524	rs4929945	ENSG00000266891.1	RP11-692N5.2	-5.62	2.44e-08	0.0151	-0.2	-0.17	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8603904	chr18:9734882~9735602:-
BRCA	trans	rs11638815	0.859	rs34125390	ENSG00000235370.6	DNM1P51	5.62	2.45e-08	0.0151	0.22	0.17	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82730221	chr15:84398316~84411701:-
BRCA	trans	rs9860340	0.73	rs1509782	ENSG00000259370.2	RP11-1069G10.1	5.62	2.45e-08	0.0151	0.2	0.17	Electroencephalographic traits in alcoholism;	chr3:87592376	chr15:62827675~62884034:-
BRCA	trans	rs8177876	0.642	rs10514513	ENSG00000224837.1	GCSHP5	5.62	2.45e-08	0.0151	0.33	0.17	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81080578	chr1:168055901~168056422:-
BRCA	trans	rs11748023	0.605	rs152409	ENSG00000224848.1	RP11-535M15.1	5.62	2.45e-08	0.0151	0.21	0.17	Intelligence (multi-trait analysis);	chr5:140142223	chr9:96687056~96721121:+
BRCA	trans	rs1707322	0.963	rs34907901	ENSG00000255397.1	AC022182.2	-5.62	2.46e-08	0.0151	-0.23	-0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45939542	chr8:60937705~60939871:-
BRCA	trans	rs7113874	0.543	rs11041993	ENSG00000266891.1	RP11-692N5.2	5.62	2.46e-08	0.0151	0.2	0.17	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8575007	chr18:9734882~9735602:-
BRCA	trans	rs7746199	0.736	rs17693963	ENSG00000228078.1	HLA-U	-5.62	2.47e-08	0.0152	-0.42	-0.17	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27742386	chr6:29934101~29934286:+
BRCA	trans	rs11098499	0.909	rs28668716	ENSG00000276805.1	RP11-291L22.6	5.62	2.47e-08	0.0152	0.2	0.17	Corneal astigmatism;	chr4:119388720	chr10:38451030~38451785:+
BRCA	trans	rs6142102	0.517	rs8119076	ENSG00000280327.1	LA16c-313F4.1	-5.62	2.47e-08	0.0152	-0.18	-0.17	Skin pigmentation;	chr20:33937909	chr16:1576716~1578371:-
BRCA	trans	rs7746199	0.736	rs58616630	ENSG00000228078.1	HLA-U	-5.62	2.48e-08	0.0153	-0.46	-0.17	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27506936	chr6:29934101~29934286:+
BRCA	trans	rs4713118	0.869	rs4713121	ENSG00000204709.4	LINC01556	5.62	2.48e-08	0.0153	0.24	0.17	Parkinson's disease;	chr6:27754285	chr6:28943877~28944537:+
BRCA	trans	rs902774	0.818	rs79377635	ENSG00000254285.3	KRT8P3	-5.62	2.49e-08	0.0153	-0.35	-0.17	Prostate cancer;	chr12:52883148	chr8:61578220~61579668:+
BRCA	trans	rs225245	0.817	rs12150359	ENSG00000234130.2	RP13-88F20.1	-5.62	2.49e-08	0.0153	-0.18	-0.17	High light scatter reticulocyte count;Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;	chr17:35697565	chrX:93222220~93225015:-
BRCA	trans	rs1568889	1	rs12800354	ENSG00000174912.7	METTL15P1	5.62	2.49e-08	0.0153	0.2	0.17	Bipolar disorder;	chr11:28026176	chr3:156713884~156714928:-
BRCA	trans	rs6430585	0.528	rs6750549	ENSG00000224043.6	CCNT2-AS1	-5.62	2.49e-08	0.0153	-0.29	-0.17	Corneal structure;	chr2:135949910	chr2:134735464~134918710:-
BRCA	trans	rs6011368	0.74	rs6062357	ENSG00000226210.3	WASH7P	5.62	2.5e-08	0.0154	0.19	0.17	Clozapine-induced cytotoxicity;	chr20:64261386	chr12:14522~32015:-
BRCA	trans	rs9858542	0.953	rs34363169	ENSG00000197582.5	GPX1P1	-5.62	2.5e-08	0.0154	-0.2	-0.17	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49500279	chrX:13378735~13379340:-
BRCA	trans	rs2243480	1	rs67536397	ENSG00000164669.11	INTS4P1	5.62	2.5e-08	0.0154	0.34	0.17	Diabetic kidney disease;	chr7:66482930	chr7:65141225~65234216:+
BRCA	trans	rs2243480	1	rs58669269	ENSG00000164669.11	INTS4P1	5.62	2.5e-08	0.0154	0.34	0.17	Diabetic kidney disease;	chr7:66486966	chr7:65141225~65234216:+
BRCA	trans	rs11098499	0.874	rs13139045	ENSG00000276997.3	RP11-378J18.9	5.62	2.51e-08	0.0154	0.2	0.17	Corneal astigmatism;	chr4:119247433	chr1:222477252~222504622:-
BRCA	trans	rs9467711	0.79	rs35400317	ENSG00000220721.1	OR1F12	5.62	2.51e-08	0.0155	0.4	0.17	Autism spectrum disorder or schizophrenia;	chr6:26593047	chr6:28073316~28074233:+
BRCA	trans	rs10202497	0.571	rs2646263	ENSG00000232445.1	RP11-132A1.4	5.62	2.52e-08	0.0155	0.26	0.17	Aging (time to event);	chr2:237348710	chr7:101308346~101310985:+
BRCA	trans	rs7032940	1	rs7032940	ENSG00000228236.2	TXNP5	-5.62	2.52e-08	0.0155	-0.23	-0.17	Height;	chr9:110183125	chr2:149068596~149068910:-
BRCA	trans	rs1039766	1	rs268862	ENSG00000213985.4	AC078899.1	5.62	2.52e-08	0.0155	0.25	0.17	Lung adenocarcinoma;Lung cancer;	chr2:65261404	chr19:20257720~20259418:+
BRCA	trans	rs35306767	0.855	rs11253459	ENSG00000187984.11	ANKRD19P	5.61	2.52e-08	0.0155	0.21	0.17	Eosinophil percentage of granulocytes;	chr10:840462	chr9:92809388~92888693:+
BRCA	trans	rs332507	0.83	rs3772781	ENSG00000234253.1	RPL7P13	5.61	2.52e-08	0.0155	0.22	0.17	Plateletcrit;	chr3:124668592	chr2:49878623~49879363:+
BRCA	trans	rs11098499	0.874	rs13123591	ENSG00000276997.3	RP11-378J18.9	5.61	2.52e-08	0.0155	0.22	0.17	Corneal astigmatism;	chr4:119184835	chr1:222477252~222504622:-
BRCA	trans	rs17711722	0.503	rs453835	ENSG00000182722.5	SEPHS1P1	5.61	2.53e-08	0.0155	0.23	0.17	Calcium levels;	chr7:66046172	chr7:64852397~64853354:-
BRCA	trans	rs3812762	0.868	rs7952335	ENSG00000266891.1	RP11-692N5.2	-5.61	2.53e-08	0.0156	-0.21	-0.17	Hypospadias;	chr11:8732484	chr18:9734882~9735602:-
BRCA	trans	rs9649213	0.593	rs1859482	ENSG00000225169.1	BRI3P1	5.61	2.54e-08	0.0156	0.22	0.17	Prostate cancer (SNP x SNP interaction);	chr7:98354462	chr1:100213293~100213670:+
BRCA	trans	rs9649213	0.593	rs13246868	ENSG00000225169.1	BRI3P1	5.61	2.54e-08	0.0156	0.22	0.17	Prostate cancer (SNP x SNP interaction);	chr7:98357141	chr1:100213293~100213670:+
BRCA	trans	rs9649213	0.593	rs12672092	ENSG00000225169.1	BRI3P1	5.61	2.54e-08	0.0156	0.22	0.17	Prostate cancer (SNP x SNP interaction);	chr7:98357245	chr1:100213293~100213670:+
BRCA	trans	rs6831352	0.918	rs34876213	ENSG00000233859.2	ADH5P4	5.61	2.54e-08	0.0156	0.25	0.17	Alcohol dependence;	chr4:99141065	chr6:65836930~65838039:-
BRCA	trans	rs853679	0.55	rs6901017	ENSG00000253570.1	RNF5P1	5.61	2.54e-08	0.0156	0.27	0.17	Depression;	chr6:28184805	chr8:38600661~38601200:-
BRCA	trans	rs9649213	0.593	rs6948540	ENSG00000225169.1	BRI3P1	5.61	2.54e-08	0.0156	0.21	0.17	Prostate cancer (SNP x SNP interaction);	chr7:98330754	chr1:100213293~100213670:+
BRCA	trans	rs1814175	0.527	rs7128827	ENSG00000134612.10	FOLH1B	5.61	2.54e-08	0.0156	0.23	0.17	Height;	chr11:49644092	chr11:89639227~89698718:+
BRCA	trans	rs7746199	0.736	rs58616630	ENSG00000281831.1	HCP5B	5.61	2.55e-08	0.0156	0.43	0.17	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27506936	chr6:29871895~29873783:-
BRCA	trans	rs853679	0.607	rs35749575	ENSG00000228078.1	HLA-U	-5.61	2.55e-08	0.0157	-0.47	-0.17	Depression;	chr6:28147040	chr6:29934101~29934286:+
BRCA	trans	rs4883201	0.536	rs7974486	ENSG00000179899.8	PHC1P1	5.61	2.55e-08	0.0157	0.22	0.17	Total cholesterol levels;Cholesterol, total;	chr12:8979368	chr12:55411727~55414787:-
BRCA	trans	rs9393777	0.92	rs13196692	ENSG00000204709.4	LINC01556	5.61	2.55e-08	0.0157	0.44	0.17	Intelligence (multi-trait analysis);	chr6:27411340	chr6:28943877~28944537:+
BRCA	trans	rs9467711	0.79	rs13195401	ENSG00000220721.1	OR1F12	5.61	2.55e-08	0.0157	0.4	0.17	Autism spectrum disorder or schizophrenia;	chr6:26463346	chr6:28073316~28074233:+
BRCA	trans	rs9467711	0.79	rs13195402	ENSG00000220721.1	OR1F12	5.61	2.55e-08	0.0157	0.4	0.17	Autism spectrum disorder or schizophrenia;	chr6:26463347	chr6:28073316~28074233:+
BRCA	trans	rs9467711	0.79	rs35400317	ENSG00000204709.4	LINC01556	5.61	2.55e-08	0.0157	0.45	0.17	Autism spectrum disorder or schizophrenia;	chr6:26593047	chr6:28943877~28944537:+
BRCA	trans	rs7568458	0.811	rs3755014	ENSG00000223886.3	RP11-251G23.2	5.61	2.56e-08	0.0157	0.2	0.17	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr2:85536883	chr7:105530209~105530671:+
BRCA	trans	rs7568458	0.811	rs3755015	ENSG00000223886.3	RP11-251G23.2	5.61	2.56e-08	0.0157	0.2	0.17	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr2:85536918	chr7:105530209~105530671:+
BRCA	trans	rs11098499	0.863	rs10019674	ENSG00000276805.1	RP11-291L22.6	-5.61	2.56e-08	0.0157	-0.21	-0.17	Corneal astigmatism;	chr4:119522334	chr10:38451030~38451785:+
BRCA	trans	rs7089973	0.526	rs1045657	ENSG00000249267.5	LINC00939	5.61	2.56e-08	0.0157	0.21	0.17	Bipolar disorder or attention deficit hyperactivity disorder;	chr10:114977226	chr12:125958688~125983374:-
BRCA	trans	rs10838687	0.673	rs77532017	ENSG00000134612.10	FOLH1B	5.61	2.56e-08	0.0157	0.27	0.17	Proinsulin levels;	chr11:47262766	chr11:89639227~89698718:+
BRCA	trans	rs7927771	0.832	rs55677087	ENSG00000134612.10	FOLH1B	-5.61	2.57e-08	0.0158	-0.23	-0.17	Subjective well-being;	chr11:47376163	chr11:89639227~89698718:+
BRCA	trans	rs1972460	0.506	rs62012050	ENSG00000259774.1	RP11-182J1.13	5.61	2.57e-08	0.0158	0.22	0.17	Intelligence (multi-trait analysis);	chr15:82239933	chr15:84422618~84425882:+
BRCA	trans	rs546131	0.642	rs34999475	ENSG00000225531.1	RP11-196I18.3	-5.61	2.57e-08	0.0158	-0.28	-0.17	Lung disease severity in cystic fibrosis;	chr11:34808301	chr9:107116829~107117557:+
BRCA	trans	rs2243480	0.901	rs34807232	ENSG00000164669.11	INTS4P1	5.61	2.59e-08	0.0159	0.34	0.17	Diabetic kidney disease;	chr7:66500146	chr7:65141225~65234216:+
BRCA	trans	rs2243480	0.901	rs35823062	ENSG00000164669.11	INTS4P1	5.61	2.59e-08	0.0159	0.34	0.17	Diabetic kidney disease;	chr7:66500834	chr7:65141225~65234216:+
BRCA	trans	rs6831352	0.879	rs2851255	ENSG00000233859.2	ADH5P4	-5.61	2.59e-08	0.0159	-0.25	-0.17	Alcohol dependence;	chr4:99120952	chr6:65836930~65838039:-
BRCA	trans	rs875971	0.522	rs7784623	ENSG00000213640.3	EEF1DP4	-5.61	2.59e-08	0.0159	-0.21	-0.17	Aortic root size;	chr7:65930047	chr7:64862999~64864370:+
BRCA	trans	rs1933488	0.504	rs1281956	ENSG00000278974.1	RP11-756P10.6	5.61	2.59e-08	0.0159	0.23	0.17	Prostate cancer;	chr6:153137213	chr4:188740507~188741281:-
BRCA	trans	rs11098499	0.865	rs28634456	ENSG00000276805.1	RP11-291L22.6	5.61	2.6e-08	0.0159	0.2	0.17	Corneal astigmatism;	chr4:119454623	chr10:38451030~38451785:+
BRCA	trans	rs9467711	0.72	rs35627490	ENSG00000220721.1	OR1F12	5.61	2.6e-08	0.016	0.38	0.17	Autism spectrum disorder or schizophrenia;	chr6:26461876	chr6:28073316~28074233:+
BRCA	trans	rs7695732	0.595	rs6532091	ENSG00000227191.5	TRGC2	5.61	2.61e-08	0.016	0.16	0.17	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr4:88956216	chr7:38239580~38368091:-
BRCA	trans	rs2243480	1	rs1499613	ENSG00000164669.11	INTS4P1	-5.61	2.61e-08	0.016	-0.33	-0.17	Diabetic kidney disease;	chr7:66265873	chr7:65141225~65234216:+
BRCA	trans	rs1568889	1	rs11603799	ENSG00000174912.7	METTL15P1	5.61	2.62e-08	0.0161	0.19	0.17	Bipolar disorder;	chr11:28174941	chr3:156713884~156714928:-
BRCA	trans	rs10838687	0.736	rs3781620	ENSG00000134612.10	FOLH1B	5.61	2.62e-08	0.0161	0.26	0.17	Proinsulin levels;	chr11:47237713	chr11:89639227~89698718:+
BRCA	trans	rs6831352	0.918	rs34936974	ENSG00000233859.2	ADH5P4	-5.61	2.62e-08	0.0161	-0.24	-0.17	Alcohol dependence;	chr4:99131233	chr6:65836930~65838039:-
BRCA	trans	rs4133168	0.702	rs4350646	ENSG00000201820.1	Y_RNA	5.61	2.62e-08	0.0161	0.2	0.17	Mitochondrial DNA levels;	chr18:25281954	chr14:51253933~51254023:-
BRCA	trans	rs1459104	0.778	rs17147447	ENSG00000134612.10	FOLH1B	-5.61	2.62e-08	0.0161	-0.35	-0.17	Body mass index;	chr11:55728709	chr11:89639227~89698718:+
BRCA	trans	rs1459104	0.778	rs17147450	ENSG00000134612.10	FOLH1B	-5.61	2.62e-08	0.0161	-0.35	-0.17	Body mass index;	chr11:55729238	chr11:89639227~89698718:+
BRCA	trans	rs9393813	0.509	rs10946915	ENSG00000242375.1	RP11-498P14.3	5.61	2.62e-08	0.0161	0.23	0.17	Bipolar disorder;	chr6:27410051	chr9:97195351~97197687:-
BRCA	trans	rs2243480	1	rs7456042	ENSG00000230295.1	RP11-458F8.2	-5.61	2.63e-08	0.0161	-0.22	-0.17	Diabetic kidney disease;	chr7:65834791	chr7:66880708~66882981:+
BRCA	trans	rs2243480	1	rs73142121	ENSG00000230295.1	RP11-458F8.2	-5.61	2.63e-08	0.0161	-0.22	-0.17	Diabetic kidney disease;	chr7:65846219	chr7:66880708~66882981:+
BRCA	trans	rs2243480	1	rs34702770	ENSG00000230295.1	RP11-458F8.2	-5.61	2.63e-08	0.0161	-0.22	-0.17	Diabetic kidney disease;	chr7:65879836	chr7:66880708~66882981:+
BRCA	trans	rs77948430	0.881	rs17188957	ENSG00000246089.3	RP11-115C21.2	-5.61	2.63e-08	0.0161	-0.32	-0.17	Itch intensity from mosquito bite adjusted by bite size;	chr8:13241170	chr8:6403551~6407142:-
BRCA	trans	rs6142102	0.538	rs6142058	ENSG00000280327.1	LA16c-313F4.1	-5.61	2.63e-08	0.0161	-0.18	-0.17	Skin pigmentation;	chr20:33954995	chr16:1576716~1578371:-
BRCA	trans	rs9649213	0.593	rs3801264	ENSG00000225169.1	BRI3P1	5.61	2.63e-08	0.0161	0.21	0.17	Prostate cancer (SNP x SNP interaction);	chr7:98321308	chr1:100213293~100213670:+
BRCA	trans	rs9649213	0.593	rs1468338	ENSG00000225169.1	BRI3P1	5.61	2.63e-08	0.0161	0.21	0.17	Prostate cancer (SNP x SNP interaction);	chr7:98321806	chr1:100213293~100213670:+
BRCA	trans	rs9649213	0.593	rs2158553	ENSG00000225169.1	BRI3P1	5.61	2.63e-08	0.0161	0.21	0.17	Prostate cancer (SNP x SNP interaction);	chr7:98321819	chr1:100213293~100213670:+
BRCA	trans	rs9649213	0.613	rs10953256	ENSG00000225169.1	BRI3P1	5.61	2.63e-08	0.0161	0.21	0.17	Prostate cancer (SNP x SNP interaction);	chr7:98322574	chr1:100213293~100213670:+
BRCA	trans	rs9649213	0.613	rs2286074	ENSG00000225169.1	BRI3P1	5.61	2.63e-08	0.0161	0.21	0.17	Prostate cancer (SNP x SNP interaction);	chr7:98322699	chr1:100213293~100213670:+
BRCA	trans	rs6831352	0.691	rs2602887	ENSG00000233859.2	ADH5P4	-5.61	2.64e-08	0.0162	-0.25	-0.17	Alcohol dependence;	chr4:99120322	chr6:65836930~65838039:-
BRCA	trans	rs11098499	0.954	rs10034623	ENSG00000253326.2	RP11-261C10.7	5.61	2.65e-08	0.0162	0.24	0.17	Corneal astigmatism;	chr4:119476674	chr1:243054861~243056394:-
BRCA	trans	rs1568889	1	rs61889046	ENSG00000174912.7	METTL15P1	5.61	2.65e-08	0.0162	0.19	0.17	Bipolar disorder;	chr11:28275477	chr3:156713884~156714928:-
BRCA	trans	rs7568458	0.905	rs6547620	ENSG00000223886.3	RP11-251G23.2	5.61	2.66e-08	0.0163	0.2	0.17	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr2:85528805	chr7:105530209~105530671:+
BRCA	trans	rs10486963	0.966	rs10229213	ENSG00000213280.2	RP11-212P7.1	-5.6	2.67e-08	0.0163	-0.14	-0.17	Energy expenditure (24h);	chr7:82523068	chr7:128570241~128570688:-
BRCA	trans	rs76228276	0.737	rs11986652	ENSG00000260318.1	COX6CP1	5.6	2.67e-08	0.0164	0.47	0.17	Childhood ear infection;	chr8:99271882	chr16:11903923~11904137:-
BRCA	trans	rs11098499	0.874	rs12502503	ENSG00000276997.3	RP11-378J18.9	5.6	2.67e-08	0.0164	0.22	0.17	Corneal astigmatism;	chr4:119195100	chr1:222477252~222504622:-
BRCA	trans	rs31864	0.745	rs4704968	ENSG00000260123.1	RP11-326A19.4	5.6	2.67e-08	0.0164	0.2	0.17	Pulse pressure;	chr5:158837012	chr15:89041223~89082819:+
BRCA	trans	rs714543	0.688	rs12702087	ENSG00000214975.4	PPIAP29	-5.6	2.67e-08	0.0164	-0.2	-0.17	Plateletcrit;	chr7:44773008	chr6:24976419~24976982:+
BRCA	trans	rs9649213	0.593	rs7776638	ENSG00000225169.1	BRI3P1	5.6	2.68e-08	0.0164	0.22	0.17	Prostate cancer (SNP x SNP interaction);	chr7:98364194	chr1:100213293~100213670:+
BRCA	trans	rs7695732	0.595	rs34749134	ENSG00000227191.5	TRGC2	5.6	2.68e-08	0.0164	0.16	0.17	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr4:88958337	chr7:38239580~38368091:-
BRCA	trans	rs9393777	0.92	rs34150729	ENSG00000204709.4	LINC01556	5.6	2.68e-08	0.0164	0.44	0.17	Intelligence (multi-trait analysis);	chr6:27420975	chr6:28943877~28944537:+
BRCA	trans	rs9393777	0.92	rs13191227	ENSG00000204709.4	LINC01556	5.6	2.68e-08	0.0164	0.44	0.17	Intelligence (multi-trait analysis);	chr6:27422336	chr6:28943877~28944537:+
BRCA	trans	rs7829975	0.806	rs2428	ENSG00000270154.1	RP11-419I17.1	5.6	2.68e-08	0.0164	0.19	0.17	Mood instability;	chr8:8783635	chr8:12476462~12477122:+
BRCA	trans	rs6142102	0.625	rs2050208	ENSG00000280327.1	LA16c-313F4.1	-5.6	2.69e-08	0.0164	-0.18	-0.17	Skin pigmentation;	chr20:33955767	chr16:1576716~1578371:-
BRCA	trans	rs16975963	0.644	rs73031326	ENSG00000247498.8	RP11-392P7.6	5.6	2.69e-08	0.0165	0.3	0.17	Longevity;	chr19:37552120	chr12:12927726~12984645:+
BRCA	trans	rs875971	0.867	rs1002053	ENSG00000164669.11	INTS4P1	5.6	2.69e-08	0.0165	0.21	0.17	Aortic root size;	chr7:66333558	chr7:65141225~65234216:+
BRCA	trans	rs9959259	0.834	rs1017747	ENSG00000257605.2	RP11-680A11.5	5.6	2.69e-08	0.0165	0.17	0.17	Obesity-related traits;	chr18:75816207	chr12:53298655~53300314:-
BRCA	trans	rs9581094	0.591	rs2275659	ENSG00000237917.1	PARP4P1	-5.6	2.69e-08	0.0165	-0.31	-0.17	Sudden cardiac arrest;	chr13:24452779	chrY:26594851~26634652:-
BRCA	trans	rs332507	0.83	rs1846891	ENSG00000234253.1	RPL7P13	5.6	2.7e-08	0.0165	0.21	0.17	Plateletcrit;	chr3:124680550	chr2:49878623~49879363:+
BRCA	trans	rs1944866	0.764	rs10791383	ENSG00000253948.1	RP11-410L14.2	-5.6	2.7e-08	0.0165	-0.31	-0.17	Myopia (pathological);	chr11:134594120	chr8:98996763~99013044:-
BRCA	trans	rs11098499	0.954	rs3733519	ENSG00000253326.2	RP11-261C10.7	5.6	2.7e-08	0.0165	0.24	0.17	Corneal astigmatism;	chr4:119502293	chr1:243054861~243056394:-
BRCA	trans	rs10838687	0.736	rs4647725	ENSG00000134612.10	FOLH1B	5.6	2.71e-08	0.0166	0.27	0.17	Proinsulin levels;	chr11:47223838	chr11:89639227~89698718:+
BRCA	trans	rs10838687	0.736	rs4647726	ENSG00000134612.10	FOLH1B	5.6	2.71e-08	0.0166	0.27	0.17	Proinsulin levels;	chr11:47223943	chr11:89639227~89698718:+
BRCA	trans	rs16975963	0.644	rs59426132	ENSG00000247498.8	RP11-392P7.6	5.6	2.71e-08	0.0166	0.29	0.17	Longevity;	chr19:37601869	chr12:12927726~12984645:+
BRCA	trans	rs6601327	0.606	rs4841204	ENSG00000253893.2	FAM85B	5.6	2.72e-08	0.0166	0.21	0.17	Multiple myeloma (hyperdiploidy);	chr8:9725897	chr8:8167819~8226614:-
BRCA	trans	rs10411161	0.63	rs12462816	ENSG00000185433.7	LINC00158	5.6	2.72e-08	0.0166	0.32	0.17	Breast cancer;	chr19:51929462	chr21:25385820~25431701:-
BRCA	trans	rs7568458	0.905	rs59877521	ENSG00000223886.3	RP11-251G23.2	5.6	2.72e-08	0.0166	0.2	0.17	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr2:85532371	chr7:105530209~105530671:+
BRCA	trans	rs2243480	1	rs316326	ENSG00000164669.11	INTS4P1	5.6	2.72e-08	0.0166	0.33	0.17	Diabetic kidney disease;	chr7:66144466	chr7:65141225~65234216:+
BRCA	trans	rs2243480	1	rs316325	ENSG00000164669.11	INTS4P1	5.6	2.72e-08	0.0166	0.33	0.17	Diabetic kidney disease;	chr7:66144531	chr7:65141225~65234216:+
BRCA	trans	rs7662987	0.517	rs2851260	ENSG00000233859.2	ADH5P4	-5.6	2.73e-08	0.0167	-0.25	-0.17	Smoking initiation;	chr4:99112423	chr6:65836930~65838039:-
BRCA	trans	rs7662987	0.517	rs2602865	ENSG00000233859.2	ADH5P4	-5.6	2.73e-08	0.0167	-0.25	-0.17	Smoking initiation;	chr4:99113690	chr6:65836930~65838039:-
BRCA	trans	rs7662987	0.517	rs2602866	ENSG00000233859.2	ADH5P4	-5.6	2.73e-08	0.0167	-0.25	-0.17	Smoking initiation;	chr4:99113846	chr6:65836930~65838039:-
BRCA	trans	rs7662987	0.517	rs2602873	ENSG00000233859.2	ADH5P4	-5.6	2.73e-08	0.0167	-0.25	-0.17	Smoking initiation;	chr4:99117881	chr6:65836930~65838039:-
BRCA	trans	rs7662987	0.517	rs2851256	ENSG00000233859.2	ADH5P4	-5.6	2.73e-08	0.0167	-0.25	-0.17	Smoking initiation;	chr4:99118398	chr6:65836930~65838039:-
BRCA	trans	rs7662987	0.517	rs4235436	ENSG00000233859.2	ADH5P4	-5.6	2.73e-08	0.0167	-0.25	-0.17	Smoking initiation;	chr4:99118469	chr6:65836930~65838039:-
BRCA	trans	rs6831352	0.879	rs2602879	ENSG00000233859.2	ADH5P4	-5.6	2.73e-08	0.0167	-0.25	-0.17	Alcohol dependence;	chr4:99119501	chr6:65836930~65838039:-
BRCA	trans	rs7662987	0.517	rs2602880	ENSG00000233859.2	ADH5P4	-5.6	2.73e-08	0.0167	-0.25	-0.17	Smoking initiation;	chr4:99119502	chr6:65836930~65838039:-
BRCA	trans	rs6142102	0.625	rs4911381	ENSG00000280327.1	LA16c-313F4.1	5.6	2.73e-08	0.0167	0.18	0.17	Skin pigmentation;	chr20:33962539	chr16:1576716~1578371:-
BRCA	trans	rs7746199	0.736	rs13209332	ENSG00000228078.1	HLA-U	-5.6	2.73e-08	0.0167	-0.45	-0.17	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27552973	chr6:29934101~29934286:+
BRCA	trans	rs7570469	0.684	rs4852149	ENSG00000276390.1	RP1-197B17.5	-5.6	2.73e-08	0.0167	-0.22	-0.17	Response to antipsychotic treatment;	chr2:79475522	chr12:47699401~47699917:-
BRCA	trans	rs7570469	0.722	rs4852490	ENSG00000276390.1	RP1-197B17.5	-5.6	2.73e-08	0.0167	-0.22	-0.17	Response to antipsychotic treatment;	chr2:79475529	chr12:47699401~47699917:-
BRCA	trans	rs1568889	1	rs12797712	ENSG00000174912.7	METTL15P1	5.6	2.73e-08	0.0167	0.19	0.17	Bipolar disorder;	chr11:28269343	chr3:156713884~156714928:-
BRCA	trans	rs1459104	1	rs116220196	ENSG00000134612.10	FOLH1B	-5.6	2.74e-08	0.0167	-0.35	-0.17	Body mass index;	chr11:55525745	chr11:89639227~89698718:+
BRCA	trans	rs7829975	0.617	rs4841072	ENSG00000270154.1	RP11-419I17.1	-5.6	2.74e-08	0.0167	-0.19	-0.17	Mood instability;	chr8:8933743	chr8:12476462~12477122:+
BRCA	trans	rs1933488	1	rs1442744	ENSG00000180015.12	RP11-756P10.3	-5.6	2.74e-08	0.0168	-0.22	-0.17	Prostate cancer;	chr6:153120598	chr4:188738373~188739494:+
BRCA	trans	rs1933488	1	rs6927516	ENSG00000180015.12	RP11-756P10.3	-5.6	2.74e-08	0.0168	-0.22	-0.17	Prostate cancer;	chr6:153120696	chr4:188738373~188739494:+
BRCA	trans	rs17834760	1	rs62424606	ENSG00000215190.7	LINC00680	-5.6	2.75e-08	0.0168	-0.23	-0.17	Antipsychotic drug-induced QTc interval change in schizophrenia;	chr6:61559769	chr6:57946074~57961501:-
BRCA	trans	rs9649213	0.574	rs36099592	ENSG00000225169.1	BRI3P1	5.6	2.75e-08	0.0168	0.22	0.17	Prostate cancer (SNP x SNP interaction);	chr7:98373019	chr1:100213293~100213670:+
BRCA	trans	rs11098499	0.874	rs6851169	ENSG00000276997.3	RP11-378J18.9	5.6	2.76e-08	0.0168	0.22	0.17	Corneal astigmatism;	chr4:119196355	chr1:222477252~222504622:-
BRCA	trans	rs875971	0.789	rs28815324	ENSG00000234585.5	CCT6P3	-5.6	2.76e-08	0.0168	-0.19	-0.17	Aortic root size;	chr7:66100789	chr7:65038354~65074713:+
BRCA	trans	rs1063857	0.656	rs216292	ENSG00000241717.1	VWFP1	5.6	2.76e-08	0.0168	0.2	0.17	vWF levels;Coagulation factor levels;	chr12:6043810	chr22:16690103~16704477:-
BRCA	trans	rs11098499	0.754	rs12711071	ENSG00000276997.3	RP11-378J18.9	5.6	2.76e-08	0.0169	0.2	0.17	Corneal astigmatism;	chr4:119319779	chr1:222477252~222504622:-
BRCA	trans	rs4879656	0.931	rs10971314	ENSG00000215007.3	DNAJA1P3	5.6	2.76e-08	0.0169	0.21	0.17	Menopause (age at onset);	chr9:33013945	chrX:107351650~107352843:-
BRCA	trans	rs2243480	1	rs10807701	ENSG00000164669.11	INTS4P1	-5.6	2.76e-08	0.0169	-0.33	-0.17	Diabetic kidney disease;	chr7:66259699	chr7:65141225~65234216:+
BRCA	trans	rs6429082	0.51	rs2789369	ENSG00000241014.1	RP11-244H3.1	5.6	2.76e-08	0.0169	0.14	0.17	Adiposity;	chr1:235340200	chr1:34974356~34985313:-
BRCA	trans	rs660899	0.894	rs17531412	ENSG00000231007.5	CDC20P1	5.6	2.77e-08	0.0169	0.23	0.17	Hypertension risk in short sleep duration;	chr1:43716573	chr9:87011652~87013151:+
BRCA	trans	rs6831352	0.589	rs2924584	ENSG00000233859.2	ADH5P4	-5.6	2.77e-08	0.0169	-0.21	-0.17	Alcohol dependence;	chr4:99067057	chr6:65836930~65838039:-
BRCA	trans	rs2243480	1	rs4718315	ENSG00000164669.11	INTS4P1	-5.6	2.77e-08	0.0169	-0.33	-0.17	Diabetic kidney disease;	chr7:66183554	chr7:65141225~65234216:+
BRCA	trans	rs2243480	1	rs4718316	ENSG00000164669.11	INTS4P1	-5.6	2.77e-08	0.0169	-0.33	-0.17	Diabetic kidney disease;	chr7:66183744	chr7:65141225~65234216:+
BRCA	trans	rs11098499	0.874	rs6822498	ENSG00000276997.3	RP11-378J18.9	5.6	2.77e-08	0.0169	0.22	0.17	Corneal astigmatism;	chr4:119199028	chr1:222477252~222504622:-
BRCA	trans	rs6601327	0.613	rs4612345	ENSG00000253893.2	FAM85B	5.6	2.77e-08	0.0169	0.21	0.17	Multiple myeloma (hyperdiploidy);	chr8:9722491	chr8:8167819~8226614:-
BRCA	trans	rs11748023	0.605	rs156090	ENSG00000224848.1	RP11-535M15.1	5.6	2.77e-08	0.0169	0.21	0.17	Intelligence (multi-trait analysis);	chr5:140142099	chr9:96687056~96721121:+
BRCA	trans	rs11587682	0.76	rs7552883	ENSG00000180764.13	PIPSL	5.6	2.78e-08	0.017	0.25	0.17	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr1:150493446	chr10:93958191~93961540:-
BRCA	trans	rs11587682	0.76	rs11811950	ENSG00000180764.13	PIPSL	5.6	2.78e-08	0.017	0.25	0.17	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr1:150494082	chr10:93958191~93961540:-
BRCA	trans	rs11098499	0.865	rs28753180	ENSG00000253326.2	RP11-261C10.7	5.6	2.78e-08	0.017	0.24	0.17	Corneal astigmatism;	chr4:119484212	chr1:243054861~243056394:-
BRCA	trans	rs9393777	0.841	rs34332556	ENSG00000243753.4	HLA-L	-5.6	2.78e-08	0.017	-0.41	-0.17	Intelligence (multi-trait analysis);	chr6:27389635	chr6:30259584~30293014:+
BRCA	trans	rs6921919	0.887	rs7766356	ENSG00000253570.1	RNF5P1	5.6	2.78e-08	0.017	0.33	0.17	Autism spectrum disorder or schizophrenia;	chr6:28432761	chr8:38600661~38601200:-
BRCA	trans	rs7824557	0.707	rs3808519	ENSG00000270154.1	RP11-419I17.1	5.6	2.79e-08	0.017	0.21	0.17	Retinal vascular caliber;	chr8:11285461	chr8:12476462~12477122:+
BRCA	trans	rs11098499	0.874	rs17839089	ENSG00000276997.3	RP11-378J18.9	5.6	2.79e-08	0.017	0.22	0.17	Corneal astigmatism;	chr4:119189914	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.874	rs6826823	ENSG00000276997.3	RP11-378J18.9	5.6	2.79e-08	0.017	0.22	0.17	Corneal astigmatism;	chr4:119190943	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.874	rs12509054	ENSG00000276997.3	RP11-378J18.9	5.6	2.79e-08	0.017	0.22	0.17	Corneal astigmatism;	chr4:119193920	chr1:222477252~222504622:-
BRCA	trans	rs7113874	0.655	rs7945659	ENSG00000266891.1	RP11-692N5.2	5.6	2.79e-08	0.017	0.2	0.17	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8508378	chr18:9734882~9735602:-
BRCA	trans	rs7239679	0.577	rs2847348	ENSG00000269720.1	CTD-2521M24.5	5.6	2.8e-08	0.017	0.2	0.17	Dementia and core Alzheimer's disease neuropathologic changes;	chr18:10451698	chr19:17391429~17392284:-
BRCA	trans	rs1568889	1	rs66857704	ENSG00000174912.7	METTL15P1	5.6	2.8e-08	0.0171	0.19	0.17	Bipolar disorder;	chr11:28190799	chr3:156713884~156714928:-
BRCA	trans	rs11122895	0.527	rs10186692	ENSG00000233673.5	ANAPC1P1	5.6	2.81e-08	0.0171	0.19	0.17	Allergic sensitization;	chr2:111686719	chr2:86861825~86922693:+
BRCA	trans	rs7927771	0.8	rs55876153	ENSG00000134612.10	FOLH1B	-5.6	2.81e-08	0.0171	-0.23	-0.17	Subjective well-being;	chr11:47395085	chr11:89639227~89698718:+
BRCA	trans	rs703108	0.731	rs7898954	ENSG00000220842.6	RP11-572P18.1	5.6	2.81e-08	0.0171	0.18	0.17	Monocyte percentage of white cells;	chr10:22034717	chr10:120354701~120355183:-
BRCA	trans	rs2243480	1	rs6964245	ENSG00000164669.11	INTS4P1	-5.6	2.81e-08	0.0171	-0.33	-0.17	Diabetic kidney disease;	chr7:66253730	chr7:65141225~65234216:+
BRCA	trans	rs13217239	0.646	rs6456767	ENSG00000216901.1	AL022393.7	5.6	2.81e-08	0.0171	0.21	0.17	Schizophrenia;	chr6:27102764	chr6:28176188~28176674:+
BRCA	trans	rs6934970	1	rs7763826	ENSG00000267560.1	RP11-173A16.1	5.6	2.82e-08	0.0171	0.21	0.17	Bipolar disorder (body mass index interaction);	chr6:112748931	chr18:62300036~62300998:-
BRCA	trans	rs6934970	1	rs12213231	ENSG00000267560.1	RP11-173A16.1	5.6	2.82e-08	0.0171	0.21	0.17	Bipolar disorder (body mass index interaction);	chr6:112751726	chr18:62300036~62300998:-
BRCA	trans	rs853679	0.607	rs67662114	ENSG00000204338.7	CYP21A1P	-5.6	2.82e-08	0.0172	-0.4	-0.17	Depression;	chr6:27964523	chr6:32005636~32008451:+
BRCA	trans	rs853679	0.607	rs13216117	ENSG00000204338.7	CYP21A1P	-5.6	2.82e-08	0.0172	-0.4	-0.17	Depression;	chr6:27970706	chr6:32005636~32008451:+
BRCA	trans	rs853679	0.607	rs36101351	ENSG00000204338.7	CYP21A1P	-5.6	2.82e-08	0.0172	-0.4	-0.17	Depression;	chr6:27975591	chr6:32005636~32008451:+
BRCA	trans	rs853679	0.607	rs28360499	ENSG00000204338.7	CYP21A1P	-5.6	2.82e-08	0.0172	-0.4	-0.17	Depression;	chr6:27977618	chr6:32005636~32008451:+
BRCA	trans	rs7927771	0.832	rs10838704	ENSG00000134612.10	FOLH1B	-5.6	2.82e-08	0.0172	-0.23	-0.17	Subjective well-being;	chr11:47403166	chr11:89639227~89698718:+
BRCA	trans	rs6940638	0.662	rs6915678	ENSG00000204709.4	LINC01556	5.6	2.82e-08	0.0172	0.22	0.17	Intelligence (multi-trait analysis);	chr6:27268087	chr6:28943877~28944537:+
BRCA	trans	rs902774	0.818	rs79377635	ENSG00000223940.1	KRT8P8	-5.59	2.82e-08	0.0172	-0.34	-0.17	Prostate cancer;	chr12:52883148	chrX:152479577~152481024:+
BRCA	trans	rs853679	0.607	rs34661125	ENSG00000243753.4	HLA-L	-5.59	2.83e-08	0.0172	-0.44	-0.17	Depression;	chr6:28314117	chr6:30259584~30293014:+
BRCA	trans	rs853679	0.607	rs13190888	ENSG00000243753.4	HLA-L	-5.59	2.83e-08	0.0172	-0.44	-0.17	Depression;	chr6:28318208	chr6:30259584~30293014:+
BRCA	trans	rs7927771	0.864	rs4752999	ENSG00000134612.10	FOLH1B	-5.59	2.84e-08	0.0173	-0.23	-0.17	Subjective well-being;	chr11:47407014	chr11:89639227~89698718:+
BRCA	trans	rs853679	0.607	rs34950484	ENSG00000228078.1	HLA-U	-5.59	2.85e-08	0.0173	-0.44	-0.17	Depression;	chr6:28310911	chr6:29934101~29934286:+
BRCA	trans	rs6121246	0.609	rs2377317	ENSG00000279352.1	RP11-411B10.7	-5.59	2.85e-08	0.0173	-0.25	-0.17	Mean corpuscular hemoglobin;	chr20:31814699	chr18:14010054~14010917:+
BRCA	trans	rs11098499	0.908	rs28559989	ENSG00000276805.1	RP11-291L22.6	5.59	2.86e-08	0.0174	0.2	0.17	Corneal astigmatism;	chr4:119465472	chr10:38451030~38451785:+
BRCA	trans	rs11098499	0.954	rs3733524	ENSG00000253326.2	RP11-261C10.7	5.59	2.86e-08	0.0174	0.25	0.17	Corneal astigmatism;	chr4:119502574	chr1:243054861~243056394:-
BRCA	trans	rs673253	0.556	rs517191	ENSG00000231007.5	CDC20P1	5.59	2.87e-08	0.0174	0.22	0.17	Intelligence (multi-trait analysis);	chr1:43650795	chr9:87011652~87013151:+
BRCA	trans	rs11098499	0.954	rs12502423	ENSG00000253326.2	RP11-261C10.7	5.59	2.87e-08	0.0174	0.24	0.17	Corneal astigmatism;	chr4:119503017	chr1:243054861~243056394:-
BRCA	trans	rs9467711	0.659	rs34246779	ENSG00000281831.1	HCP5B	5.59	2.87e-08	0.0174	0.39	0.17	Autism spectrum disorder or schizophrenia;	chr6:26548984	chr6:29871895~29873783:-
BRCA	trans	rs4879656	0.866	rs10971316	ENSG00000215007.3	DNAJA1P3	5.59	2.87e-08	0.0174	0.2	0.17	Menopause (age at onset);	chr9:33013964	chrX:107351650~107352843:-
BRCA	trans	rs7819412	0.811	rs2409691	ENSG00000270154.1	RP11-419I17.1	-5.59	2.87e-08	0.0175	-0.2	-0.17	Triglycerides;	chr8:11085766	chr8:12476462~12477122:+
BRCA	trans	rs853679	0.607	rs71559070	ENSG00000228078.1	HLA-U	-5.59	2.87e-08	0.0175	-0.47	-0.17	Depression;	chr6:28071151	chr6:29934101~29934286:+
BRCA	trans	rs853679	0.607	rs35902873	ENSG00000228078.1	HLA-U	-5.59	2.87e-08	0.0175	-0.47	-0.17	Depression;	chr6:28091171	chr6:29934101~29934286:+
BRCA	trans	rs853679	0.607	rs13197574	ENSG00000228078.1	HLA-U	-5.59	2.87e-08	0.0175	-0.47	-0.17	Depression;	chr6:28092461	chr6:29934101~29934286:+
BRCA	trans	rs9467711	0.606	rs13212985	ENSG00000281831.1	HCP5B	5.59	2.88e-08	0.0175	0.39	0.17	Autism spectrum disorder or schizophrenia;	chr6:26609761	chr6:29871895~29873783:-
BRCA	trans	rs9650657	0.537	rs7016385	ENSG00000270154.1	RP11-419I17.1	5.59	2.88e-08	0.0175	0.2	0.17	Neuroticism;	chr8:10921962	chr8:12476462~12477122:+
BRCA	trans	rs76228276	0.737	rs11990888	ENSG00000260318.1	COX6CP1	5.59	2.88e-08	0.0175	0.46	0.17	Childhood ear infection;	chr8:99190449	chr16:11903923~11904137:-
BRCA	trans	rs11098499	0.874	rs10022508	ENSG00000276997.3	RP11-378J18.9	5.59	2.88e-08	0.0175	0.22	0.17	Corneal astigmatism;	chr4:119194073	chr1:222477252~222504622:-
BRCA	trans	rs72934570	1	rs9966779	ENSG00000267390.1	RP11-635N19.1	-5.59	2.88e-08	0.0175	-0.34	-0.17	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr18:55953225	chr18:63367328~63381629:+
BRCA	trans	rs1933488	0.504	rs639286	ENSG00000278974.1	RP11-756P10.6	5.59	2.89e-08	0.0175	0.23	0.17	Prostate cancer;	chr6:153138661	chr4:188740507~188741281:-
BRCA	trans	rs7824557	0.751	rs2099456	ENSG00000270154.1	RP11-419I17.1	5.59	2.89e-08	0.0175	0.2	0.17	Retinal vascular caliber;	chr8:11269492	chr8:12476462~12477122:+
BRCA	trans	rs7624766	0.873	rs1378659	ENSG00000257511.1	RP11-278C7.1	-5.59	2.89e-08	0.0175	-0.17	-0.17	Response to methotrexate in rheumatoid arthritis;	chr3:160688537	chr12:32726383~32727387:-
BRCA	trans	rs13394619	0.775	rs10165819	ENSG00000273980.1	RP13-49I15.6	-5.59	2.89e-08	0.0176	-0.21	-0.17	Endometriosis;	chr2:11581976	chr10:133257144~133257551:-
BRCA	trans	rs11098499	0.954	rs6849171	ENSG00000253326.2	RP11-261C10.7	5.59	2.9e-08	0.0176	0.23	0.17	Corneal astigmatism;	chr4:119488394	chr1:243054861~243056394:-
BRCA	trans	rs16975963	0.644	rs73031322	ENSG00000247498.8	RP11-392P7.6	5.59	2.9e-08	0.0176	0.3	0.17	Longevity;	chr19:37549977	chr12:12927726~12984645:+
BRCA	trans	rs5758511	0.573	rs5996074	ENSG00000268568.1	AC007228.9	-5.59	2.91e-08	0.0177	-0.22	-0.17	Birth weight;	chr22:41840333	chr19:56672574~56673901:-
BRCA	trans	rs853679	0.882	rs9468300	ENSG00000228078.1	HLA-U	-5.59	2.91e-08	0.0177	-0.35	-0.17	Depression;	chr6:28159062	chr6:29934101~29934286:+
BRCA	trans	rs12984174	1	rs403439	ENSG00000235884.3	LINC00941	-5.59	2.91e-08	0.0177	-0.25	-0.17	Pulmonary function in asthmatics;	chr19:18031265	chr12:30795681~30802711:+
BRCA	trans	rs6831352	0.877	rs2602890	ENSG00000233859.2	ADH5P4	-5.59	2.91e-08	0.0177	-0.24	-0.17	Alcohol dependence;	chr4:99122028	chr6:65836930~65838039:-
BRCA	trans	rs6831352	0.918	rs2602891	ENSG00000233859.2	ADH5P4	-5.59	2.91e-08	0.0177	-0.24	-0.17	Alcohol dependence;	chr4:99122133	chr6:65836930~65838039:-
BRCA	trans	rs2243480	1	rs4548056	ENSG00000232546.1	RP11-458F8.1	-5.59	2.91e-08	0.0177	-0.22	-0.17	Diabetic kidney disease;	chr7:65833886	chr7:66848496~66858136:+
BRCA	trans	rs6121246	0.559	rs6058462	ENSG00000279352.1	RP11-411B10.7	5.59	2.92e-08	0.0177	0.25	0.17	Mean corpuscular hemoglobin;	chr20:31779871	chr18:14010054~14010917:+
BRCA	trans	rs7943953	0.661	rs2204168	ENSG00000206897.1	SNORA9	5.59	2.92e-08	0.0177	0.21	0.17	Odorant perception (&beta-ionone);	chr11:59309363	chr12:123616708~123616840:+
BRCA	trans	rs11098499	0.909	rs78332141	ENSG00000276805.1	RP11-291L22.6	5.59	2.92e-08	0.0177	0.2	0.17	Corneal astigmatism;	chr4:119454627	chr10:38451030~38451785:+
BRCA	trans	rs6601327	0.606	rs7006985	ENSG00000253893.2	FAM85B	5.59	2.92e-08	0.0177	0.22	0.17	Multiple myeloma (hyperdiploidy);	chr8:9706927	chr8:8167819~8226614:-
BRCA	trans	rs13217239	0.646	rs7451149	ENSG00000216901.1	AL022393.7	5.59	2.92e-08	0.0177	0.21	0.17	Schizophrenia;	chr6:27089739	chr6:28176188~28176674:+
BRCA	trans	rs11098499	0.954	rs11098525	ENSG00000276805.1	RP11-291L22.6	5.59	2.92e-08	0.0177	0.2	0.17	Corneal astigmatism;	chr4:119468997	chr10:38451030~38451785:+
BRCA	trans	rs853679	0.546	rs35017208	ENSG00000204338.7	CYP21A1P	-5.59	2.92e-08	0.0177	-0.39	-0.17	Depression;	chr6:28377505	chr6:32005636~32008451:+
BRCA	trans	rs11098499	0.954	rs10518331	ENSG00000276805.1	RP11-291L22.6	5.59	2.93e-08	0.0178	0.2	0.17	Corneal astigmatism;	chr4:119402440	chr10:38451030~38451785:+
BRCA	trans	rs1459104	1	rs34819157	ENSG00000134612.10	FOLH1B	-5.59	2.93e-08	0.0178	-0.33	-0.17	Body mass index;	chr11:55701628	chr11:89639227~89698718:+
BRCA	trans	rs7927771	0.832	rs10838697	ENSG00000134612.10	FOLH1B	-5.59	2.94e-08	0.0178	-0.22	-0.17	Subjective well-being;	chr11:47362933	chr11:89639227~89698718:+
BRCA	trans	rs12439619	0.921	rs4778672	ENSG00000259295.5	CSPG4P12	5.59	2.94e-08	0.0178	0.24	0.17	Intelligence (multi-trait analysis);	chr15:82245013	chr15:85191438~85213905:+
BRCA	trans	rs9393777	0.72	rs13217285	ENSG00000204709.4	LINC01556	5.59	2.94e-08	0.0178	0.35	0.17	Intelligence (multi-trait analysis);	chr6:27032066	chr6:28943877~28944537:+
BRCA	trans	rs9852859	0.634	rs9825885	ENSG00000228223.2	HCG11	5.59	2.94e-08	0.0178	0.24	0.17	Body mass index;	chr3:85739415	chr6:26523450~26526579:+
BRCA	trans	rs1459104	1	rs12789360	ENSG00000134612.10	FOLH1B	-5.59	2.94e-08	0.0178	-0.35	-0.17	Body mass index;	chr11:55522275	chr11:89639227~89698718:+
BRCA	trans	rs1459104	0.929	rs12794656	ENSG00000134612.10	FOLH1B	-5.59	2.94e-08	0.0178	-0.35	-0.17	Body mass index;	chr11:55522402	chr11:89639227~89698718:+
BRCA	trans	rs853679	0.546	rs36092177	ENSG00000204338.7	CYP21A1P	-5.59	2.94e-08	0.0179	-0.39	-0.17	Depression;	chr6:28390030	chr6:32005636~32008451:+
BRCA	trans	rs853679	0.546	rs2232429	ENSG00000204338.7	CYP21A1P	-5.59	2.94e-08	0.0179	-0.39	-0.17	Depression;	chr6:28391855	chr6:32005636~32008451:+
BRCA	trans	rs853679	0.546	rs2232426	ENSG00000204338.7	CYP21A1P	-5.59	2.94e-08	0.0179	-0.39	-0.17	Depression;	chr6:28392882	chr6:32005636~32008451:+
BRCA	trans	rs853679	0.546	rs2232423	ENSG00000204338.7	CYP21A1P	-5.59	2.94e-08	0.0179	-0.39	-0.17	Depression;	chr6:28398374	chr6:32005636~32008451:+
BRCA	trans	rs1526687	0.655	rs35922403	ENSG00000257052.1	RP11-881M11.2	5.59	2.95e-08	0.0179	0.21	0.17	Cardiac Troponin-T levels;	chr2:52477780	chr11:60906789~60909742:+
BRCA	trans	rs1568889	1	rs35697240	ENSG00000174912.7	METTL15P1	5.59	2.95e-08	0.0179	0.19	0.17	Bipolar disorder;	chr11:28265795	chr3:156713884~156714928:-
BRCA	trans	rs6831352	0.918	rs29001203	ENSG00000233859.2	ADH5P4	5.59	2.95e-08	0.0179	0.24	0.17	Alcohol dependence;	chr4:99131940	chr6:65836930~65838039:-
BRCA	trans	rs11098499	0.754	rs10212714	ENSG00000276997.3	RP11-378J18.9	5.59	2.96e-08	0.0179	0.2	0.17	Corneal astigmatism;	chr4:119333147	chr1:222477252~222504622:-
BRCA	trans	rs6142102	0.602	rs4911380	ENSG00000280327.1	LA16c-313F4.1	-5.59	2.96e-08	0.0179	-0.18	-0.17	Skin pigmentation;	chr20:33958418	chr16:1576716~1578371:-
BRCA	trans	rs704840	0.694	rs35634597	ENSG00000251484.3	RP5-1065J22.4	5.59	2.96e-08	0.018	0.24	0.17	Systemic lupus erythematosus;Systemic lupus erythematosus and Systemic sclerosis;	chr1:173279044	chr1:109103535~109104766:-
BRCA	trans	rs9649213	0.593	rs10808107	ENSG00000225169.1	BRI3P1	5.59	2.96e-08	0.018	0.21	0.17	Prostate cancer (SNP x SNP interaction);	chr7:98322359	chr1:100213293~100213670:+
BRCA	trans	rs9462846	0.853	rs7757363	ENSG00000231579.3	RPL7P21	5.59	2.97e-08	0.018	0.22	0.17	Blood protein levels;	chr6:42908648	chr5:143332605~143333239:+
BRCA	trans	rs34421088	0.586	rs2272594	ENSG00000253893.2	FAM85B	-5.59	2.97e-08	0.018	-0.23	-0.17	Neuroticism;	chr8:11285116	chr8:8167819~8226614:-
BRCA	trans	rs1568889	0.938	rs11601602	ENSG00000174912.7	METTL15P1	5.59	2.97e-08	0.018	0.2	0.17	Bipolar disorder;	chr11:28212221	chr3:156713884~156714928:-
BRCA	trans	rs11168854	0.651	rs12227770	ENSG00000214391.3	TUBAP2	5.59	2.97e-08	0.018	0.17	0.17	Body mass index;	chr12:49183065	chr11:90282560~90284172:+
BRCA	trans	rs641862	1	rs641862	ENSG00000267868.1	RP11-120K24.3	5.59	2.97e-08	0.018	0.35	0.17	Obesity-related traits;	chr13:110137885	chr13:112964835~112966131:-
BRCA	trans	rs7570469	0.806	rs4852491	ENSG00000276390.1	RP1-197B17.5	-5.59	2.98e-08	0.018	-0.22	-0.17	Response to antipsychotic treatment;	chr2:79475649	chr12:47699401~47699917:-
BRCA	trans	rs1568889	1	rs7949057	ENSG00000174912.7	METTL15P1	5.59	2.98e-08	0.0181	0.18	0.17	Bipolar disorder;	chr11:28233506	chr3:156713884~156714928:-
BRCA	trans	rs2243480	0.708	rs35825036	ENSG00000164669.11	INTS4P1	5.58	2.99e-08	0.0181	0.34	0.17	Diabetic kidney disease;	chr7:66521515	chr7:65141225~65234216:+
BRCA	trans	rs2243480	1	rs13237037	ENSG00000164669.11	INTS4P1	5.58	2.99e-08	0.0181	0.34	0.17	Diabetic kidney disease;	chr7:66532895	chr7:65141225~65234216:+
BRCA	trans	rs2243480	1	rs1796228	ENSG00000164669.11	INTS4P1	5.58	2.99e-08	0.0181	0.34	0.17	Diabetic kidney disease;	chr7:66568097	chr7:65141225~65234216:+
BRCA	trans	rs875971	0.522	rs1880556	ENSG00000213640.3	EEF1DP4	-5.58	2.99e-08	0.0181	-0.21	-0.17	Aortic root size;	chr7:65967557	chr7:64862999~64864370:+
BRCA	trans	rs6087771	0.926	rs6058431	ENSG00000279352.1	RP11-411B10.7	5.58	3e-08	0.0182	0.25	0.17	Putamen volume;Subcortical brain region volumes;	chr20:31709330	chr18:14010054~14010917:+
BRCA	trans	rs7662987	0.54	rs2851257	ENSG00000233859.2	ADH5P4	-5.58	3e-08	0.0182	-0.25	-0.17	Smoking initiation;	chr4:99118348	chr6:65836930~65838039:-
BRCA	trans	rs1459104	1	rs12574577	ENSG00000134612.10	FOLH1B	-5.58	3e-08	0.0182	-0.34	-0.17	Body mass index;	chr11:55539266	chr11:89639227~89698718:+
BRCA	trans	rs6142102	0.625	rs4911138	ENSG00000280327.1	LA16c-313F4.1	-5.58	3e-08	0.0182	-0.18	-0.17	Skin pigmentation;	chr20:33959893	chr16:1576716~1578371:-
BRCA	trans	rs804280	0.565	rs1466785	ENSG00000253893.2	FAM85B	-5.58	3.01e-08	0.0182	-0.21	-0.17	Myopia (pathological);	chr8:11765947	chr8:8167819~8226614:-
BRCA	trans	rs11098499	0.954	rs71629403	ENSG00000276805.1	RP11-291L22.6	5.58	3.01e-08	0.0182	0.2	0.17	Corneal astigmatism;	chr4:119451412	chr10:38451030~38451785:+
BRCA	trans	rs11098499	0.909	rs28571712	ENSG00000276805.1	RP11-291L22.6	5.58	3.01e-08	0.0182	0.2	0.17	Corneal astigmatism;	chr4:119454825	chr10:38451030~38451785:+
BRCA	trans	rs2243480	1	rs1873494	ENSG00000164669.11	INTS4P1	-5.58	3.02e-08	0.0183	-0.33	-0.17	Diabetic kidney disease;	chr7:66184912	chr7:65141225~65234216:+
BRCA	trans	rs2243480	1	rs6959002	ENSG00000164669.11	INTS4P1	-5.58	3.02e-08	0.0183	-0.33	-0.17	Diabetic kidney disease;	chr7:66185509	chr7:65141225~65234216:+
BRCA	trans	rs7520050	0.831	rs61783170	ENSG00000177335.9	C8orf31	-5.58	3.02e-08	0.0183	-0.21	-0.17	Reticulocyte count;Red blood cell count;	chr1:45790657	chr8:143039209~143059942:+
BRCA	trans	rs9649213	0.613	rs6961129	ENSG00000225169.1	BRI3P1	5.58	3.02e-08	0.0183	0.22	0.17	Prostate cancer (SNP x SNP interaction);	chr7:98346230	chr1:100213293~100213670:+
BRCA	trans	rs11098499	0.954	rs3733520	ENSG00000253326.2	RP11-261C10.7	5.58	3.02e-08	0.0183	0.24	0.17	Corneal astigmatism;	chr4:119502325	chr1:243054861~243056394:-
BRCA	trans	rs6831352	0.918	rs13110176	ENSG00000233859.2	ADH5P4	-5.58	3.03e-08	0.0183	-0.24	-0.17	Alcohol dependence;	chr4:99141279	chr6:65836930~65838039:-
BRCA	trans	rs6831352	0.918	rs2851253	ENSG00000233859.2	ADH5P4	5.58	3.04e-08	0.0184	0.24	0.17	Alcohol dependence;	chr4:99122354	chr6:65836930~65838039:-
BRCA	trans	rs6087990	0.899	rs998382	ENSG00000258732.1	RP11-603B24.1	5.58	3.04e-08	0.0184	0.2	0.17	Ulcerative colitis;	chr20:32796330	chr15:22278971~22282872:+
BRCA	trans	rs76228276	0.737	rs72674616	ENSG00000260318.1	COX6CP1	5.58	3.04e-08	0.0184	0.45	0.17	Childhood ear infection;	chr8:99420451	chr16:11903923~11904137:-
BRCA	trans	rs6142102	0.625	rs6141431	ENSG00000280327.1	LA16c-313F4.1	-5.58	3.05e-08	0.0184	-0.18	-0.17	Skin pigmentation;	chr20:33952508	chr16:1576716~1578371:-
BRCA	trans	rs7662987	0.517	rs2602858	ENSG00000233859.2	ADH5P4	-5.58	3.06e-08	0.0185	-0.25	-0.17	Smoking initiation;	chr4:99109310	chr6:65836930~65838039:-
BRCA	trans	rs7829975	0.714	rs11784052	ENSG00000270154.1	RP11-419I17.1	5.58	3.06e-08	0.0185	0.19	0.17	Mood instability;	chr8:8814452	chr8:12476462~12477122:+
BRCA	trans	rs6142102	0.625	rs1883707	ENSG00000280327.1	LA16c-313F4.1	5.58	3.06e-08	0.0185	0.18	0.17	Skin pigmentation;	chr20:33964781	chr16:1576716~1578371:-
BRCA	trans	rs2122469	0.655	rs17603934	ENSG00000254064.1	CTD-2530N21.4	5.58	3.06e-08	0.0185	0.27	0.17	Serum tamsulosin hydrochloride concentration;	chr8:20718833	chr8:22254576~22275162:-
BRCA	trans	rs853679	0.585	rs201004	ENSG00000253570.1	RNF5P1	5.58	3.06e-08	0.0185	0.3	0.17	Depression;	chr6:27837156	chr8:38600661~38601200:-
BRCA	trans	rs2243480	1	rs6974723	ENSG00000164669.11	INTS4P1	-5.58	3.06e-08	0.0185	-0.33	-0.17	Diabetic kidney disease;	chr7:66172952	chr7:65141225~65234216:+
BRCA	trans	rs2243480	1	rs9769882	ENSG00000164669.11	INTS4P1	-5.58	3.06e-08	0.0185	-0.33	-0.17	Diabetic kidney disease;	chr7:66177938	chr7:65141225~65234216:+
BRCA	trans	rs2243480	1	rs6966322	ENSG00000164669.11	INTS4P1	-5.58	3.06e-08	0.0185	-0.33	-0.17	Diabetic kidney disease;	chr7:66181767	chr7:65141225~65234216:+
BRCA	trans	rs2243480	1	rs4145008	ENSG00000164669.11	INTS4P1	-5.58	3.06e-08	0.0185	-0.33	-0.17	Diabetic kidney disease;	chr7:66182524	chr7:65141225~65234216:+
BRCA	trans	rs853679	0.585	rs201001	ENSG00000253570.1	RNF5P1	5.58	3.07e-08	0.0185	0.3	0.17	Depression;	chr6:27841121	chr8:38600661~38601200:-
BRCA	trans	rs853679	0.585	rs201000	ENSG00000253570.1	RNF5P1	5.58	3.07e-08	0.0185	0.3	0.17	Depression;	chr6:27841381	chr8:38600661~38601200:-
BRCA	trans	rs6601327	0.518	rs13264850	ENSG00000253893.2	FAM85B	5.58	3.07e-08	0.0186	0.22	0.17	Multiple myeloma (hyperdiploidy);	chr8:9717821	chr8:8167819~8226614:-
BRCA	trans	rs11638815	0.954	rs11635476	ENSG00000235370.6	DNM1P51	5.58	3.07e-08	0.0186	0.22	0.17	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82670748	chr15:84398316~84411701:-
BRCA	trans	rs6142102	0.961	rs4911392	ENSG00000280327.1	LA16c-313F4.1	-5.58	3.08e-08	0.0186	-0.18	-0.17	Skin pigmentation;	chr20:33982712	chr16:1576716~1578371:-
BRCA	trans	rs6142102	0.961	rs4911393	ENSG00000280327.1	LA16c-313F4.1	-5.58	3.08e-08	0.0186	-0.18	-0.17	Skin pigmentation;	chr20:33983120	chr16:1576716~1578371:-
BRCA	trans	rs7647973	1	rs62259933	ENSG00000235912.1	RP1-159A19.3	5.58	3.09e-08	0.0187	0.22	0.17	Menarche (age at onset);	chr3:49432270	chr1:27649419~27649610:+
BRCA	trans	rs13256369	0.802	rs11249885	ENSG00000253982.1	CTD-2336O2.1	-5.58	3.09e-08	0.0187	-0.19	-0.17	Obesity-related traits;	chr8:8704498	chr8:1761990~1764502:-
BRCA	trans	rs11098499	0.954	rs1480931	ENSG00000276805.1	RP11-291L22.6	5.58	3.09e-08	0.0187	0.2	0.17	Corneal astigmatism;	chr4:119474654	chr10:38451030~38451785:+
BRCA	trans	rs11587682	0.76	rs72698868	ENSG00000180764.13	PIPSL	5.58	3.09e-08	0.0187	0.25	0.17	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr1:150495338	chr10:93958191~93961540:-
BRCA	trans	rs11587682	0.76	rs72698870	ENSG00000180764.13	PIPSL	5.58	3.09e-08	0.0187	0.25	0.17	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr1:150495341	chr10:93958191~93961540:-
BRCA	trans	rs902774	0.818	rs73108429	ENSG00000230716.3	KRT8P7	-5.58	3.09e-08	0.0187	-0.35	-0.17	Prostate cancer;	chr12:52877887	chr11:119602875~119604306:-
BRCA	trans	rs7662987	0.517	rs2602881	ENSG00000233859.2	ADH5P4	-5.58	3.1e-08	0.0187	-0.24	-0.17	Smoking initiation;	chr4:99119544	chr6:65836930~65838039:-
BRCA	trans	rs45509595	0.841	rs200501	ENSG00000253570.1	RNF5P1	5.58	3.1e-08	0.0187	0.37	0.17	Breast cancer;	chr6:27821164	chr8:38600661~38601200:-
BRCA	trans	rs9649213	0.593	rs2107716	ENSG00000225169.1	BRI3P1	5.58	3.1e-08	0.0187	0.21	0.17	Prostate cancer (SNP x SNP interaction);	chr7:98315432	chr1:100213293~100213670:+
BRCA	trans	rs7662987	0.517	rs2851263	ENSG00000233859.2	ADH5P4	-5.58	3.11e-08	0.0188	-0.24	-0.17	Smoking initiation;	chr4:99109203	chr6:65836930~65838039:-
BRCA	trans	rs6831352	0.76	rs2602859	ENSG00000233859.2	ADH5P4	-5.58	3.11e-08	0.0188	-0.24	-0.17	Alcohol dependence;	chr4:99109432	chr6:65836930~65838039:-
BRCA	trans	rs6921919	0.832	rs17312661	ENSG00000253570.1	RNF5P1	5.58	3.11e-08	0.0188	0.32	0.17	Autism spectrum disorder or schizophrenia;	chr6:28332559	chr8:38600661~38601200:-
BRCA	trans	rs875971	1	rs6460292	ENSG00000164669.11	INTS4P1	5.58	3.11e-08	0.0188	0.21	0.17	Aortic root size;	chr7:66345088	chr7:65141225~65234216:+
BRCA	trans	rs875971	0.964	rs778735	ENSG00000164669.11	INTS4P1	-5.58	3.11e-08	0.0188	-0.21	-0.17	Aortic root size;	chr7:66349822	chr7:65141225~65234216:+
BRCA	trans	rs9649213	0.574	rs3801257	ENSG00000225169.1	BRI3P1	5.58	3.11e-08	0.0188	0.21	0.17	Prostate cancer (SNP x SNP interaction);	chr7:98362480	chr1:100213293~100213670:+
BRCA	trans	rs9649213	0.593	rs7803372	ENSG00000225169.1	BRI3P1	5.58	3.11e-08	0.0188	0.21	0.17	Prostate cancer (SNP x SNP interaction);	chr7:98362945	chr1:100213293~100213670:+
BRCA	trans	rs445114	1	rs443053	ENSG00000213693.4	SEC14L1P1	5.58	3.11e-08	0.0188	0.19	0.17	Prostate cancer;Prostate cancer (SNP x SNP interaction);	chr8:127323551	chr11:43897456~43899636:+
BRCA	trans	rs35306767	0.953	rs11253521	ENSG00000187984.11	ANKRD19P	5.58	3.11e-08	0.0188	0.2	0.17	Eosinophil percentage of granulocytes;	chr10:930476	chr9:92809388~92888693:+
BRCA	trans	rs4879656	0.966	rs10971309	ENSG00000215007.3	DNAJA1P3	5.58	3.11e-08	0.0188	0.21	0.17	Menopause (age at onset);	chr9:33009857	chrX:107351650~107352843:-
BRCA	trans	rs9649213	0.502	rs6465680	ENSG00000225169.1	BRI3P1	5.58	3.11e-08	0.0188	0.22	0.17	Prostate cancer (SNP x SNP interaction);	chr7:98376466	chr1:100213293~100213670:+
BRCA	trans	rs941207	0.526	rs2255074	ENSG00000257210.1	NACAP3	-5.58	3.12e-08	0.0188	-0.21	-0.17	Platelet count;	chr12:56636242	chr12:93124063~93124543:-
BRCA	trans	rs1499614	0.901	rs3936	ENSG00000164669.11	INTS4P1	5.58	3.12e-08	0.0188	0.34	0.17	Gout;	chr7:66661502	chr7:65141225~65234216:+
BRCA	trans	rs7089973	0.61	rs61869271	ENSG00000249267.5	LINC00939	5.58	3.12e-08	0.0188	0.21	0.17	Bipolar disorder or attention deficit hyperactivity disorder;	chr10:114971570	chr12:125958688~125983374:-
BRCA	trans	rs11098499	0.954	rs11729521	ENSG00000253326.2	RP11-261C10.7	5.58	3.12e-08	0.0188	0.24	0.17	Corneal astigmatism;	chr4:119495633	chr1:243054861~243056394:-
BRCA	trans	rs17711722	0.727	rs35850374	ENSG00000213640.3	EEF1DP4	-5.58	3.12e-08	0.0188	-0.21	-0.17	Calcium levels;	chr7:65892789	chr7:64862999~64864370:+
BRCA	trans	rs9467711	0.591	rs13203673	ENSG00000281831.1	HCP5B	5.58	3.13e-08	0.0189	0.37	0.17	Autism spectrum disorder or schizophrenia;	chr6:25978894	chr6:29871895~29873783:-
BRCA	trans	rs4879656	0.966	rs12000958	ENSG00000215007.3	DNAJA1P3	5.58	3.13e-08	0.0189	0.21	0.17	Menopause (age at onset);	chr9:33031432	chrX:107351650~107352843:-
BRCA	trans	rs9858542	0.953	rs11713474	ENSG00000197582.5	GPX1P1	-5.58	3.13e-08	0.0189	-0.19	-0.17	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49574024	chrX:13378735~13379340:-
BRCA	trans	rs9858542	0.953	rs9811982	ENSG00000197582.5	GPX1P1	-5.58	3.13e-08	0.0189	-0.19	-0.17	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49586944	chrX:13378735~13379340:-
BRCA	trans	rs6777098	0.793	rs13067249	ENSG00000250328.4	MGC32805	5.58	3.13e-08	0.0189	0.25	0.17	Response to paliperidone in schizophrenia (positive Marder score);	chr3:167230453	chr5:122436497~122479087:-
BRCA	trans	rs875971	0.929	rs4122249	ENSG00000164669.11	INTS4P1	-5.58	3.13e-08	0.0189	-0.21	-0.17	Aortic root size;	chr7:66455949	chr7:65141225~65234216:+
BRCA	trans	rs7662987	0.517	rs2851277	ENSG00000233859.2	ADH5P4	-5.58	3.14e-08	0.0189	-0.25	-0.17	Smoking initiation;	chr4:99101759	chr6:65836930~65838039:-
BRCA	trans	rs9467603	0.858	rs972087	ENSG00000253570.1	RNF5P1	5.58	3.14e-08	0.0189	0.37	0.17	Intelligence (multi-trait analysis);	chr6:25872351	chr8:38600661~38601200:-
BRCA	trans	rs6489882	0.867	rs4766663	ENSG00000250770.2	RP5-1063M23.1	-5.58	3.14e-08	0.0189	-0.22	-0.17	Chronic lymphocytic leukemia;	chr12:112925169	chr12:3296202~3300224:-
BRCA	trans	rs875971	0.545	rs2707851	ENSG00000213640.3	EEF1DP4	5.58	3.14e-08	0.019	0.24	0.17	Aortic root size;	chr7:66624178	chr7:64862999~64864370:+
BRCA	trans	rs1459104	1	rs34440381	ENSG00000134612.10	FOLH1B	-5.58	3.15e-08	0.019	-0.33	-0.17	Body mass index;	chr11:55703133	chr11:89639227~89698718:+
BRCA	trans	rs7746199	0.736	rs13193542	ENSG00000243753.4	HLA-L	-5.57	3.16e-08	0.019	-0.46	-0.17	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27734646	chr6:30259584~30293014:+
BRCA	trans	rs7746199	0.736	rs13193480	ENSG00000243753.4	HLA-L	-5.57	3.16e-08	0.019	-0.46	-0.17	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27734782	chr6:30259584~30293014:+
BRCA	trans	rs11168854	0.93	rs10783302	ENSG00000214391.3	TUBAP2	-5.57	3.16e-08	0.019	-0.16	-0.17	Body mass index;	chr12:49104347	chr11:90282560~90284172:+
BRCA	trans	rs11098499	0.954	rs2306455	ENSG00000276805.1	RP11-291L22.6	5.57	3.16e-08	0.0191	0.2	0.17	Corneal astigmatism;	chr4:119500814	chr10:38451030~38451785:+
BRCA	trans	rs35306767	0.903	rs12761424	ENSG00000187984.11	ANKRD19P	5.57	3.17e-08	0.0191	0.2	0.17	Eosinophil percentage of granulocytes;	chr10:921355	chr9:92809388~92888693:+
BRCA	trans	rs4948102	0.924	rs13240915	ENSG00000186940.6	CHCHD2P9	-5.57	3.17e-08	0.0191	-0.22	-0.17	Plasma homocysteine levels (post-methionine load test);	chr7:56023059	chr9:79391304~79391759:+
BRCA	trans	rs11098499	0.954	rs10031483	ENSG00000276805.1	RP11-291L22.6	5.57	3.17e-08	0.0191	0.2	0.17	Corneal astigmatism;	chr4:119501481	chr10:38451030~38451785:+
BRCA	trans	rs11098499	0.954	rs10031665	ENSG00000276805.1	RP11-291L22.6	5.57	3.17e-08	0.0191	0.2	0.17	Corneal astigmatism;	chr4:119501697	chr10:38451030~38451785:+
BRCA	trans	rs11098499	0.954	rs3733523	ENSG00000276805.1	RP11-291L22.6	5.57	3.17e-08	0.0191	0.2	0.17	Corneal astigmatism;	chr4:119502564	chr10:38451030~38451785:+
BRCA	trans	rs9858542	0.953	rs11719996	ENSG00000197582.5	GPX1P1	-5.57	3.17e-08	0.0191	-0.2	-0.17	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49488525	chrX:13378735~13379340:-
BRCA	trans	rs7746199	0.736	rs13192965	ENSG00000228078.1	HLA-U	-5.57	3.18e-08	0.0191	-0.45	-0.17	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27704046	chr6:29934101~29934286:+
BRCA	trans	rs16975963	0.644	rs73031321	ENSG00000247498.8	RP11-392P7.6	5.57	3.18e-08	0.0192	0.29	0.17	Longevity;	chr19:37549956	chr12:12927726~12984645:+
BRCA	trans	rs4879656	0.966	rs7469374	ENSG00000215007.3	DNAJA1P3	5.57	3.19e-08	0.0192	0.21	0.17	Menopause (age at onset);	chr9:33035116	chrX:107351650~107352843:-
BRCA	trans	rs4879656	0.966	rs4879661	ENSG00000215007.3	DNAJA1P3	5.57	3.19e-08	0.0192	0.21	0.17	Menopause (age at onset);	chr9:33035248	chrX:107351650~107352843:-
BRCA	trans	rs11098499	0.779	rs28495013	ENSG00000276805.1	RP11-291L22.6	5.57	3.19e-08	0.0192	0.2	0.17	Corneal astigmatism;	chr4:119454676	chr10:38451030~38451785:+
BRCA	trans	rs11098499	0.644	rs10009566	ENSG00000276805.1	RP11-291L22.6	5.57	3.19e-08	0.0192	0.19	0.17	Corneal astigmatism;	chr4:119637453	chr10:38451030~38451785:+
BRCA	trans	rs1232027	0.7	rs1677695	ENSG00000188985.6	DHFRP1	-5.57	3.19e-08	0.0192	-0.22	-0.17	Huntington's disease progression;	chr5:80640457	chr18:26170726~26171284:-
BRCA	trans	rs1232027	0.7	rs1677693	ENSG00000188985.6	DHFRP1	-5.57	3.19e-08	0.0192	-0.22	-0.17	Huntington's disease progression;	chr5:80640499	chr18:26170726~26171284:-
BRCA	trans	rs5006884	0.547	rs12796030	ENSG00000258626.2	COX7A2P1	5.57	3.2e-08	0.0193	0.21	0.17	Fetal hemoglobin levels;	chr11:5369045	chr14:67652300~67652614:-
BRCA	trans	rs11888559	0.655	rs10180815	ENSG00000237973.1	RP5-857K21.6	5.57	3.2e-08	0.0193	0.37	0.17	Height;	chr2:203138086	chr1:631074~632616:+
BRCA	trans	rs11098499	0.82	rs28578366	ENSG00000253326.2	RP11-261C10.7	-5.57	3.2e-08	0.0193	-0.24	-0.17	Corneal astigmatism;	chr4:119615750	chr1:243054861~243056394:-
BRCA	trans	rs4879656	0.966	rs10971358	ENSG00000215007.3	DNAJA1P3	5.57	3.2e-08	0.0193	0.21	0.17	Menopause (age at onset);	chr9:33038051	chrX:107351650~107352843:-
BRCA	trans	rs9368481	0.761	rs4713062	ENSG00000242375.1	RP11-498P14.3	-5.57	3.21e-08	0.0193	-0.25	-0.17	Autism spectrum disorder or schizophrenia;	chr6:26980416	chr9:97195351~97197687:-
BRCA	trans	rs2950393	0.804	rs2926748	ENSG00000257210.1	NACAP3	5.57	3.21e-08	0.0193	0.2	0.17	Platelet distribution width;	chr12:56715628	chr12:93124063~93124543:-
BRCA	trans	rs9733	0.687	rs12410050	ENSG00000180764.13	PIPSL	5.57	3.21e-08	0.0193	0.21	0.17	Tonsillectomy;	chr1:150884665	chr10:93958191~93961540:-
BRCA	trans	rs6504622	0.905	rs736603	ENSG00000266644.1	RP11-927P21.2	-5.57	3.21e-08	0.0193	-0.17	-0.17	Orofacial clefts;	chr17:46947379	chr17:64899766~64900716:+
BRCA	trans	rs1218282	0.655	rs9565452	ENSG00000230581.2	ACTG1P14	-5.57	3.22e-08	0.0194	-0.34	-0.17	Response to statin therapy;	chr13:78876141	chr9:6834456~6835577:+
BRCA	trans	rs9292918	0.806	rs10060015	ENSG00000231752.4	EMBP1	-5.57	3.22e-08	0.0194	-0.26	-0.17	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:45339141	chr1:121519112~121571892:+
BRCA	trans	rs6142102	0.961	rs1883524	ENSG00000280327.1	LA16c-313F4.1	-5.57	3.22e-08	0.0194	-0.18	-0.17	Skin pigmentation;	chr20:34038301	chr16:1576716~1578371:-
BRCA	trans	rs11098499	0.954	rs6834796	ENSG00000253326.2	RP11-261C10.7	5.57	3.23e-08	0.0194	0.24	0.17	Corneal astigmatism;	chr4:119493538	chr1:243054861~243056394:-
BRCA	trans	rs11098499	0.954	rs11734241	ENSG00000253326.2	RP11-261C10.7	5.57	3.23e-08	0.0194	0.24	0.17	Corneal astigmatism;	chr4:119495717	chr1:243054861~243056394:-
BRCA	trans	rs877636	0.74	rs705698	ENSG00000227586.5	RP11-162A23.5	5.57	3.23e-08	0.0194	0.23	0.17	Cognitive function;	chr12:55990903	chr10:123171535~123171875:-
BRCA	trans	rs864643	0.945	rs614453	ENSG00000188856.6	RPSAP47	5.57	3.23e-08	0.0194	0.27	0.17	Attention deficit hyperactivity disorder;	chr3:39541076	chr8:80558870~80559757:+
BRCA	trans	rs11098499	0.954	rs13133522	ENSG00000276805.1	RP11-291L22.6	5.57	3.24e-08	0.0195	0.2	0.17	Corneal astigmatism;	chr4:119403269	chr10:38451030~38451785:+
BRCA	trans	rs11098499	0.954	rs35091806	ENSG00000276805.1	RP11-291L22.6	5.57	3.24e-08	0.0195	0.2	0.17	Corneal astigmatism;	chr4:119404374	chr10:38451030~38451785:+
BRCA	trans	rs11098499	0.909	rs35165976	ENSG00000276805.1	RP11-291L22.6	5.57	3.24e-08	0.0195	0.2	0.17	Corneal astigmatism;	chr4:119404475	chr10:38451030~38451785:+
BRCA	trans	rs11098499	0.954	rs6846442	ENSG00000276805.1	RP11-291L22.6	5.57	3.24e-08	0.0195	0.2	0.17	Corneal astigmatism;	chr4:119405168	chr10:38451030~38451785:+
BRCA	trans	rs11098499	0.954	rs71614438	ENSG00000276805.1	RP11-291L22.6	5.57	3.24e-08	0.0195	0.2	0.17	Corneal astigmatism;	chr4:119450097	chr10:38451030~38451785:+
BRCA	trans	rs11098499	0.954	rs66506550	ENSG00000276805.1	RP11-291L22.6	5.57	3.24e-08	0.0195	0.2	0.17	Corneal astigmatism;	chr4:119450290	chr10:38451030~38451785:+
BRCA	trans	rs11098499	0.909	rs7659501	ENSG00000276805.1	RP11-291L22.6	5.57	3.24e-08	0.0195	0.2	0.17	Corneal astigmatism;	chr4:119450397	chr10:38451030~38451785:+
BRCA	trans	rs7617773	0.78	rs11706277	ENSG00000235912.1	RP1-159A19.3	-5.57	3.24e-08	0.0195	-0.23	-0.17	Coronary artery disease;	chr3:48318943	chr1:27649419~27649610:+
BRCA	trans	rs2950393	0.929	rs7980835	ENSG00000257210.1	NACAP3	5.57	3.24e-08	0.0195	0.2	0.17	Platelet distribution width;	chr12:56676847	chr12:93124063~93124543:-
BRCA	trans	rs2950393	0.929	rs10747769	ENSG00000257210.1	NACAP3	5.57	3.24e-08	0.0195	0.2	0.17	Platelet distribution width;	chr12:56677056	chr12:93124063~93124543:-
BRCA	trans	rs3808502	0.527	rs2736374	ENSG00000253893.2	FAM85B	5.57	3.24e-08	0.0195	0.22	0.17	Neuroticism;	chr8:11256319	chr8:8167819~8226614:-
BRCA	trans	rs7662987	0.517	rs2924580	ENSG00000233859.2	ADH5P4	-5.57	3.25e-08	0.0195	-0.25	-0.17	Smoking initiation;	chr4:99111017	chr6:65836930~65838039:-
BRCA	trans	rs9649213	0.593	rs12704983	ENSG00000225169.1	BRI3P1	5.57	3.25e-08	0.0195	0.21	0.17	Prostate cancer (SNP x SNP interaction);	chr7:98297733	chr1:100213293~100213670:+
BRCA	trans	rs9393813	0.529	rs7761966	ENSG00000242375.1	RP11-498P14.3	5.57	3.25e-08	0.0195	0.23	0.17	Bipolar disorder;	chr6:27477924	chr9:97195351~97197687:-
BRCA	trans	rs6142102	0.961	rs8119937	ENSG00000280327.1	LA16c-313F4.1	-5.57	3.25e-08	0.0195	-0.18	-0.17	Skin pigmentation;	chr20:34057745	chr16:1576716~1578371:-
BRCA	trans	rs1671400	1	rs919586	ENSG00000245281.5	CTD-2547L16.1	5.57	3.26e-08	0.0196	0.26	0.17	Obesity-related traits;	chr8:13317162	chr8:18084868~18096394:+
BRCA	trans	rs11098499	0.954	rs10006706	ENSG00000253326.2	RP11-261C10.7	5.57	3.26e-08	0.0196	0.24	0.17	Corneal astigmatism;	chr4:119487997	chr1:243054861~243056394:-
BRCA	trans	rs11098499	0.954	rs28685688	ENSG00000253326.2	RP11-261C10.7	5.57	3.27e-08	0.0196	0.24	0.17	Corneal astigmatism;	chr4:119499179	chr1:243054861~243056394:-
BRCA	trans	rs11098499	0.954	rs7687843	ENSG00000253326.2	RP11-261C10.7	5.57	3.27e-08	0.0196	0.24	0.17	Corneal astigmatism;	chr4:119500056	chr1:243054861~243056394:-
BRCA	trans	rs6601327	0.641	rs4129360	ENSG00000253893.2	FAM85B	5.57	3.27e-08	0.0196	0.21	0.17	Multiple myeloma (hyperdiploidy);	chr8:9715774	chr8:8167819~8226614:-
BRCA	trans	rs11098499	0.82	rs28578366	ENSG00000276805.1	RP11-291L22.6	-5.57	3.27e-08	0.0196	-0.2	-0.17	Corneal astigmatism;	chr4:119615750	chr10:38451030~38451785:+
BRCA	trans	rs6995541	0.776	rs4840517	ENSG00000253893.2	FAM85B	-5.57	3.28e-08	0.0197	-0.21	-0.17	Triglyceride levels;	chr8:10810537	chr8:8167819~8226614:-
BRCA	trans	rs9467711	0.79	rs13195401	ENSG00000243753.4	HLA-L	-5.57	3.28e-08	0.0197	-0.44	-0.17	Autism spectrum disorder or schizophrenia;	chr6:26463346	chr6:30259584~30293014:+
BRCA	trans	rs9467711	0.79	rs13195402	ENSG00000243753.4	HLA-L	-5.57	3.28e-08	0.0197	-0.44	-0.17	Autism spectrum disorder or schizophrenia;	chr6:26463347	chr6:30259584~30293014:+
BRCA	trans	rs3799379	0.53	rs10456045	ENSG00000253570.1	RNF5P1	-5.57	3.29e-08	0.0198	-0.27	-0.17	Intelligence (multi-trait analysis);	chr6:26404730	chr8:38600661~38601200:-
BRCA	trans	rs9649213	0.593	rs2394854	ENSG00000225169.1	BRI3P1	5.57	3.3e-08	0.0198	0.22	0.17	Prostate cancer (SNP x SNP interaction);	chr7:98397994	chr1:100213293~100213670:+
BRCA	trans	rs11098499	0.874	rs6832670	ENSG00000276997.3	RP11-378J18.9	5.57	3.3e-08	0.0198	0.22	0.17	Corneal astigmatism;	chr4:119197637	chr1:222477252~222504622:-
BRCA	trans	rs9393813	0.868	rs4711154	ENSG00000242375.1	RP11-498P14.3	5.57	3.3e-08	0.0198	0.23	0.17	Bipolar disorder;	chr6:27478580	chr9:97195351~97197687:-
BRCA	trans	rs9393777	0.623	rs3734544	ENSG00000253570.1	RNF5P1	5.57	3.3e-08	0.0198	0.31	0.17	Intelligence (multi-trait analysis);	chr6:26468432	chr8:38600661~38601200:-
BRCA	trans	rs7113874	0.524	rs4244804	ENSG00000266891.1	RP11-692N5.2	-5.57	3.3e-08	0.0198	-0.2	-0.17	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8596003	chr18:9734882~9735602:-
BRCA	trans	rs7929679	0.875	rs1891291	ENSG00000225531.1	RP11-196I18.3	-5.57	3.3e-08	0.0198	-0.22	-0.17	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;	chr11:34792073	chr9:107116829~107117557:+
BRCA	trans	rs11098499	0.954	rs12502423	ENSG00000276805.1	RP11-291L22.6	5.57	3.31e-08	0.0198	0.2	0.17	Corneal astigmatism;	chr4:119503017	chr10:38451030~38451785:+
BRCA	trans	rs9649213	0.593	rs6949718	ENSG00000225169.1	BRI3P1	5.57	3.31e-08	0.0198	0.22	0.17	Prostate cancer (SNP x SNP interaction);	chr7:98295171	chr1:100213293~100213670:+
BRCA	trans	rs2243480	0.803	rs13224048	ENSG00000164669.11	INTS4P1	5.57	3.31e-08	0.0198	0.33	0.17	Diabetic kidney disease;	chr7:66528779	chr7:65141225~65234216:+
BRCA	trans	rs7647973	1	rs56127630	ENSG00000235912.1	RP1-159A19.3	5.57	3.31e-08	0.0198	0.22	0.17	Menarche (age at onset);	chr3:49400603	chr1:27649419~27649610:+
BRCA	trans	rs2055729	0.591	rs17150950	ENSG00000253893.2	FAM85B	-5.57	3.31e-08	0.0198	-0.23	-0.17	Multiple myeloma (hyperdiploidy);	chr8:10023499	chr8:8167819~8226614:-
BRCA	trans	rs11098499	0.644	rs10012252	ENSG00000276805.1	RP11-291L22.6	5.57	3.31e-08	0.0199	0.19	0.17	Corneal astigmatism;	chr4:119637984	chr10:38451030~38451785:+
BRCA	trans	rs11098499	0.698	rs4422403	ENSG00000276997.3	RP11-378J18.9	5.57	3.32e-08	0.0199	0.2	0.17	Corneal astigmatism;	chr4:119337039	chr1:222477252~222504622:-
BRCA	trans	rs6601327	0.641	rs7461939	ENSG00000253893.2	FAM85B	5.57	3.32e-08	0.0199	0.21	0.17	Multiple myeloma (hyperdiploidy);	chr8:9714111	chr8:8167819~8226614:-
BRCA	trans	rs9467711	0.659	rs72845428	ENSG00000281831.1	HCP5B	5.57	3.32e-08	0.0199	0.39	0.17	Autism spectrum disorder or schizophrenia;	chr6:26549916	chr6:29871895~29873783:-
BRCA	trans	rs16975963	0.644	rs11083428	ENSG00000247498.8	RP11-392P7.6	5.57	3.33e-08	0.0199	0.3	0.17	Longevity;	chr19:37593066	chr12:12927726~12984645:+
BRCA	trans	rs9936075	0.75	rs8047052	ENSG00000260910.1	LINC00565	5.57	3.33e-08	0.0199	0.23	0.17	Platelet-derived growth factor BB levels;	chr16:7270495	chr13:113926514~113928844:-
BRCA	trans	rs11782517	0.924	rs58868895	ENSG00000253893.2	FAM85B	-5.56	3.34e-08	0.02	-0.23	-0.17	Nose size;	chr8:10251833	chr8:8167819~8226614:-
BRCA	trans	rs1568889	0.938	rs7128045	ENSG00000174912.7	METTL15P1	5.56	3.35e-08	0.0201	0.19	0.17	Bipolar disorder;	chr11:28168633	chr3:156713884~156714928:-
BRCA	trans	rs1232027	0.7	rs1643655	ENSG00000188985.6	DHFRP1	-5.56	3.35e-08	0.0201	-0.22	-0.17	Huntington's disease progression;	chr5:80657957	chr18:26170726~26171284:-
BRCA	trans	rs1232027	0.7	rs2405880	ENSG00000188985.6	DHFRP1	-5.56	3.35e-08	0.0201	-0.22	-0.17	Huntington's disease progression;	chr5:80657974	chr18:26170726~26171284:-
BRCA	trans	rs11122895	0.509	rs3860380	ENSG00000233673.5	ANAPC1P1	-5.56	3.35e-08	0.0201	-0.19	-0.17	Allergic sensitization;	chr2:111693810	chr2:86861825~86922693:+
BRCA	trans	rs35306767	0.953	rs11253509	ENSG00000187984.11	ANKRD19P	5.56	3.35e-08	0.0201	0.2	0.17	Eosinophil percentage of granulocytes;	chr10:918366	chr9:92809388~92888693:+
BRCA	trans	rs12497850	1	rs10865952	ENSG00000197582.5	GPX1P1	5.56	3.36e-08	0.0201	0.17	0.17	Parkinson's disease;	chr3:48707051	chrX:13378735~13379340:-
BRCA	trans	rs6921919	0.789	rs11970439	ENSG00000176998.4	HCG4	-5.56	3.36e-08	0.0201	-0.24	-0.17	Autism spectrum disorder or schizophrenia;	chr6:28335687	chr6:29791753~29792750:-
BRCA	trans	rs704840	0.694	rs12405577	ENSG00000251484.3	RP5-1065J22.4	5.56	3.36e-08	0.0201	0.25	0.17	Systemic lupus erythematosus;Systemic lupus erythematosus and Systemic sclerosis;	chr1:173280855	chr1:109103535~109104766:-
BRCA	trans	rs7662987	0.517	rs2851268	ENSG00000233859.2	ADH5P4	-5.56	3.37e-08	0.0202	-0.25	-0.17	Smoking initiation;	chr4:99106727	chr6:65836930~65838039:-
BRCA	trans	rs71537559	1	rs71537559	ENSG00000243753.4	HLA-L	-5.56	3.37e-08	0.0202	-0.41	-0.17	Squamous cell lung carcinoma;	chr6:27342000	chr6:30259584~30293014:+
BRCA	trans	rs875971	0.898	rs6977501	ENSG00000164669.11	INTS4P1	5.56	3.37e-08	0.0202	0.21	0.17	Aortic root size;	chr7:66228355	chr7:65141225~65234216:+
BRCA	trans	rs11098499	0.954	rs11098526	ENSG00000276805.1	RP11-291L22.6	5.56	3.37e-08	0.0202	0.2	0.17	Corneal astigmatism;	chr4:119469204	chr10:38451030~38451785:+
BRCA	trans	rs10009321	0.574	rs5019104	ENSG00000225071.1	GS1-184P14.2	-5.56	3.38e-08	0.0202	-0.2	-0.17	Neurofibrillary tangles;	chr4:129334387	chrX:24429573~24429920:-
BRCA	trans	rs6430585	0.528	rs6430594	ENSG00000224043.6	CCNT2-AS1	5.56	3.38e-08	0.0202	0.29	0.17	Corneal structure;	chr2:135961603	chr2:134735464~134918710:-
BRCA	trans	rs6934970	1	rs9487967	ENSG00000267560.1	RP11-173A16.1	5.56	3.38e-08	0.0202	0.21	0.17	Bipolar disorder (body mass index interaction);	chr6:112744352	chr18:62300036~62300998:-
BRCA	trans	rs10791097	0.694	rs7107595	ENSG00000264570.1	SNX19P3	5.56	3.38e-08	0.0202	0.19	0.17	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:130888661	chr18:14629832~14632806:-
BRCA	trans	rs9860340	0.73	rs4859088	ENSG00000259370.2	RP11-1069G10.1	5.56	3.38e-08	0.0203	0.2	0.17	Electroencephalographic traits in alcoholism;	chr3:87599139	chr15:62827675~62884034:-
BRCA	trans	rs11098499	0.698	rs4422403	ENSG00000120555.12	SEPT7P9	5.56	3.38e-08	0.0203	0.2	0.17	Corneal astigmatism;	chr4:119337039	chr10:38383069~38402916:-
BRCA	trans	rs9393777	0.557	rs7759741	ENSG00000253570.1	RNF5P1	5.56	3.39e-08	0.0203	0.3	0.17	Intelligence (multi-trait analysis);	chr6:27273264	chr8:38600661~38601200:-
BRCA	trans	rs9650657	0.562	rs10090444	ENSG00000254153.1	CTA-398F10.2	5.56	3.39e-08	0.0203	0.21	0.17	Neuroticism;	chr8:10887959	chr8:8456909~8461337:-
BRCA	trans	rs11098499	0.615	rs59867181	ENSG00000276997.3	RP11-378J18.9	-5.56	3.4e-08	0.0203	-0.2	-0.17	Corneal astigmatism;	chr4:119635312	chr1:222477252~222504622:-
BRCA	trans	rs9393777	0.92	rs34150729	ENSG00000243753.4	HLA-L	-5.56	3.4e-08	0.0203	-0.44	-0.17	Intelligence (multi-trait analysis);	chr6:27420975	chr6:30259584~30293014:+
BRCA	trans	rs9393777	0.92	rs13191227	ENSG00000243753.4	HLA-L	-5.56	3.4e-08	0.0203	-0.44	-0.17	Intelligence (multi-trait analysis);	chr6:27422336	chr6:30259584~30293014:+
BRCA	trans	rs771390	0.506	rs771398	ENSG00000269985.1	RP1-232P20.1	-5.56	3.4e-08	0.0203	-0.18	-0.17	Epilepsy (generalized);	chr1:34264549	chr6:5451683~5458075:-
BRCA	trans	rs11098499	0.697	rs11941899	ENSG00000276805.1	RP11-291L22.6	5.56	3.4e-08	0.0204	0.2	0.17	Corneal astigmatism;	chr4:119461603	chr10:38451030~38451785:+
BRCA	trans	rs11098499	0.909	rs7681978	ENSG00000276805.1	RP11-291L22.6	5.56	3.4e-08	0.0204	0.2	0.17	Corneal astigmatism;	chr4:119462620	chr10:38451030~38451785:+
BRCA	trans	rs11098499	0.821	rs28665282	ENSG00000276805.1	RP11-291L22.6	5.56	3.4e-08	0.0204	0.2	0.17	Corneal astigmatism;	chr4:119463031	chr10:38451030~38451785:+
BRCA	trans	rs11098499	0.738	rs10026493	ENSG00000276805.1	RP11-291L22.6	5.56	3.4e-08	0.0204	0.2	0.17	Corneal astigmatism;	chr4:119463039	chr10:38451030~38451785:+
BRCA	trans	rs11098499	0.909	rs7681214	ENSG00000276805.1	RP11-291L22.6	5.56	3.4e-08	0.0204	0.2	0.17	Corneal astigmatism;	chr4:119464165	chr10:38451030~38451785:+
BRCA	trans	rs11098499	0.909	rs28632018	ENSG00000276805.1	RP11-291L22.6	5.56	3.4e-08	0.0204	0.2	0.17	Corneal astigmatism;	chr4:119465575	chr10:38451030~38451785:+
BRCA	trans	rs11098499	0.908	rs71614449	ENSG00000276805.1	RP11-291L22.6	5.56	3.4e-08	0.0204	0.2	0.17	Corneal astigmatism;	chr4:119465900	chr10:38451030~38451785:+
BRCA	trans	rs11098499	0.954	rs35063680	ENSG00000276805.1	RP11-291L22.6	5.56	3.4e-08	0.0204	0.2	0.17	Corneal astigmatism;	chr4:119465947	chr10:38451030~38451785:+
BRCA	trans	rs11098499	0.954	rs34858317	ENSG00000276805.1	RP11-291L22.6	5.56	3.4e-08	0.0204	0.2	0.17	Corneal astigmatism;	chr4:119465955	chr10:38451030~38451785:+
BRCA	trans	rs11098499	0.954	rs17046116	ENSG00000276805.1	RP11-291L22.6	5.56	3.4e-08	0.0204	0.2	0.17	Corneal astigmatism;	chr4:119466104	chr10:38451030~38451785:+
BRCA	trans	rs11098499	0.909	rs17046118	ENSG00000276805.1	RP11-291L22.6	5.56	3.4e-08	0.0204	0.2	0.17	Corneal astigmatism;	chr4:119466341	chr10:38451030~38451785:+
BRCA	trans	rs11098499	0.954	rs7654587	ENSG00000276805.1	RP11-291L22.6	5.56	3.4e-08	0.0204	0.2	0.17	Corneal astigmatism;	chr4:119467251	chr10:38451030~38451785:+
BRCA	trans	rs332507	0.83	rs11718359	ENSG00000234253.1	RPL7P13	5.56	3.41e-08	0.0204	0.22	0.17	Plateletcrit;	chr3:124677140	chr2:49878623~49879363:+
BRCA	trans	rs332507	0.673	rs2242426	ENSG00000234253.1	RPL7P13	5.56	3.41e-08	0.0204	0.22	0.17	Plateletcrit;	chr3:124679184	chr2:49878623~49879363:+
BRCA	trans	rs2841307	0.925	rs61068331	ENSG00000225751.2	AC087501.1	5.56	3.41e-08	0.0204	0.26	0.17	Bipolar disorder and schizophrenia;	chr6:100241489	chr17:9452197~9470014:+
BRCA	trans	rs7927771	0.8	rs11039200	ENSG00000134612.10	FOLH1B	-5.56	3.41e-08	0.0204	-0.24	-0.17	Subjective well-being;	chr11:47358095	chr11:89639227~89698718:+
BRCA	trans	rs13042473	0.656	rs13041905	ENSG00000224126.2	UBE2SP2	5.56	3.41e-08	0.0204	0.28	0.17	Fractional exhaled nitric oxide (childhood);	chr20:42795381	chr17:18677261~18677757:+
BRCA	trans	rs9649213	0.593	rs6465673	ENSG00000225169.1	BRI3P1	5.56	3.41e-08	0.0204	0.21	0.17	Prostate cancer (SNP x SNP interaction);	chr7:98339575	chr1:100213293~100213670:+
BRCA	trans	rs6921919	0.789	rs6912584	ENSG00000176998.4	HCG4	-5.56	3.42e-08	0.0204	-0.24	-0.17	Autism spectrum disorder or schizophrenia;	chr6:28341813	chr6:29791753~29792750:-
BRCA	trans	rs11098499	0.569	rs10023641	ENSG00000120555.12	SEPT7P9	5.56	3.42e-08	0.0204	0.2	0.17	Corneal astigmatism;	chr4:119337255	chr10:38383069~38402916:-
BRCA	trans	rs7647973	1	rs1009051	ENSG00000235912.1	RP1-159A19.3	-5.56	3.42e-08	0.0204	-0.21	-0.17	Menarche (age at onset);	chr3:49484116	chr1:27649419~27649610:+
BRCA	trans	rs7647973	1	rs3870339	ENSG00000235912.1	RP1-159A19.3	-5.56	3.42e-08	0.0204	-0.21	-0.17	Menarche (age at onset);	chr3:49499430	chr1:27649419~27649610:+
BRCA	trans	rs9649213	0.593	rs6963210	ENSG00000225169.1	BRI3P1	5.56	3.42e-08	0.0205	0.21	0.17	Prostate cancer (SNP x SNP interaction);	chr7:98315674	chr1:100213293~100213670:+
BRCA	trans	rs9393813	0.626	rs2235232	ENSG00000242375.1	RP11-498P14.3	-5.56	3.43e-08	0.0205	-0.23	-0.17	Bipolar disorder;	chr6:27359084	chr9:97195351~97197687:-
BRCA	trans	rs7463166	0.965	rs17349258	ENSG00000268295.1	POLR3GP1	5.56	3.43e-08	0.0205	0.21	0.17	Menarche (age at onset);	chr8:4983502	chr14:91603173~91603433:-
BRCA	trans	rs6934970	0.932	rs6934953	ENSG00000267560.1	RP11-173A16.1	-5.56	3.44e-08	0.0206	-0.21	-0.17	Bipolar disorder (body mass index interaction);	chr6:112803073	chr18:62300036~62300998:-
BRCA	trans	rs4879656	0.797	rs10971389	ENSG00000215007.3	DNAJA1P3	5.56	3.44e-08	0.0206	0.22	0.17	Menopause (age at onset);	chr9:33081125	chrX:107351650~107352843:-
BRCA	trans	rs11782517	0.889	rs56730365	ENSG00000253893.2	FAM85B	-5.56	3.44e-08	0.0206	-0.23	-0.17	Nose size;	chr8:10251869	chr8:8167819~8226614:-
BRCA	trans	rs35306767	0.953	rs10904581	ENSG00000187984.11	ANKRD19P	5.56	3.45e-08	0.0206	0.2	0.17	Eosinophil percentage of granulocytes;	chr10:918745	chr9:92809388~92888693:+
BRCA	trans	rs11098499	0.954	rs11940028	ENSG00000253326.2	RP11-261C10.7	5.56	3.45e-08	0.0206	0.24	0.17	Corneal astigmatism;	chr4:119490752	chr1:243054861~243056394:-
BRCA	trans	rs11098499	0.954	rs11935596	ENSG00000253326.2	RP11-261C10.7	5.56	3.45e-08	0.0206	0.24	0.17	Corneal astigmatism;	chr4:119491302	chr1:243054861~243056394:-
BRCA	trans	rs11098499	0.954	rs12507964	ENSG00000253326.2	RP11-261C10.7	5.56	3.45e-08	0.0206	0.24	0.17	Corneal astigmatism;	chr4:119491906	chr1:243054861~243056394:-
BRCA	trans	rs11098499	0.909	rs11098530	ENSG00000253326.2	RP11-261C10.7	5.56	3.45e-08	0.0206	0.24	0.17	Corneal astigmatism;	chr4:119491999	chr1:243054861~243056394:-
BRCA	trans	rs11098499	0.954	rs3890049	ENSG00000276805.1	RP11-291L22.6	5.56	3.45e-08	0.0206	0.2	0.17	Corneal astigmatism;	chr4:119405128	chr10:38451030~38451785:+
BRCA	trans	rs2950393	0.777	rs2926747	ENSG00000257210.1	NACAP3	5.56	3.45e-08	0.0206	0.2	0.17	Platelet distribution width;	chr12:56716147	chr12:93124063~93124543:-
BRCA	trans	rs7824557	0.836	rs765731	ENSG00000270154.1	RP11-419I17.1	-5.56	3.45e-08	0.0206	-0.21	-0.17	Retinal vascular caliber;	chr8:11263989	chr8:12476462~12477122:+
BRCA	trans	rs2243480	1	rs778679	ENSG00000164669.11	INTS4P1	5.56	3.45e-08	0.0206	0.33	0.17	Diabetic kidney disease;	chr7:66375924	chr7:65141225~65234216:+
BRCA	trans	rs853679	0.607	rs67101035	ENSG00000204709.4	LINC01556	5.56	3.46e-08	0.0206	0.44	0.17	Depression;	chr6:27831109	chr6:28943877~28944537:+
BRCA	trans	rs1232027	0.666	rs1643646	ENSG00000188985.6	DHFRP1	-5.56	3.46e-08	0.0206	-0.22	-0.17	Huntington's disease progression;	chr5:80652822	chr18:26170726~26171284:-
BRCA	trans	rs1232027	0.7	rs1677670	ENSG00000188985.6	DHFRP1	-5.56	3.46e-08	0.0206	-0.22	-0.17	Huntington's disease progression;	chr5:80652835	chr18:26170726~26171284:-
BRCA	trans	rs1232027	0.7	rs1478834	ENSG00000188985.6	DHFRP1	-5.56	3.46e-08	0.0206	-0.22	-0.17	Huntington's disease progression;	chr5:80653756	chr18:26170726~26171284:-
BRCA	trans	rs1232027	0.7	rs1478835	ENSG00000188985.6	DHFRP1	-5.56	3.46e-08	0.0206	-0.22	-0.17	Huntington's disease progression;	chr5:80653781	chr18:26170726~26171284:-
BRCA	trans	rs7824557	0.564	rs13260727	ENSG00000270154.1	RP11-419I17.1	5.56	3.46e-08	0.0207	0.2	0.17	Retinal vascular caliber;	chr8:11375351	chr8:12476462~12477122:+
BRCA	trans	rs9914988	0.943	rs3181215	ENSG00000267449.1	RP11-264B14.2	-5.56	3.46e-08	0.0207	-0.22	-0.17	Glycated hemoglobin levels;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr17:28750313	chr17:61069856~61070356:-
BRCA	trans	rs11098499	0.588	rs2389874	ENSG00000276997.3	RP11-378J18.9	-5.56	3.47e-08	0.0207	-0.2	-0.17	Corneal astigmatism;	chr4:119633836	chr1:222477252~222504622:-
BRCA	trans	rs864643	0.735	rs76417541	ENSG00000214263.2	RPSAP53	-5.56	3.47e-08	0.0207	-0.34	-0.17	Attention deficit hyperactivity disorder;	chr3:39519802	chr13:67266845~67267706:-
BRCA	trans	rs227275	0.556	rs7676765	ENSG00000211782.2	TRAV8-1	5.56	3.48e-08	0.0208	0.14	0.17	Allergic disease (asthma, hay fever or eczema);	chr4:103016776	chr14:21797287~21797886:+
BRCA	trans	rs3785888	0.548	rs197922	ENSG00000266644.1	RP11-927P21.2	-5.56	3.48e-08	0.0208	-0.18	-0.17	Cleft lip with or without cleft palate;	chr17:46931204	chr17:64899766~64900716:+
BRCA	trans	rs1580019	0.547	rs56981934	ENSG00000213492.2	NT5C3AP1	-5.56	3.49e-08	0.0208	-0.23	-0.17	Cognitive ability;	chr7:32495590	chr4:117574512~117576174:-
BRCA	trans	rs2950393	0.804	rs2290894	ENSG00000257210.1	NACAP3	5.56	3.49e-08	0.0208	0.2	0.17	Platelet distribution width;	chr12:56714911	chr12:93124063~93124543:-
BRCA	trans	rs11638815	0.668	rs11635460	ENSG00000259774.1	RP11-182J1.13	-5.56	3.49e-08	0.0208	-0.2	-0.17	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82725801	chr15:84422618~84425882:+
BRCA	trans	rs902774	0.818	rs4919742	ENSG00000230716.3	KRT8P7	-5.56	3.49e-08	0.0208	-0.35	-0.17	Prostate cancer;	chr12:52879180	chr11:119602875~119604306:-
BRCA	trans	rs332507	0.789	rs11928787	ENSG00000234253.1	RPL7P13	5.56	3.49e-08	0.0209	0.22	0.17	Plateletcrit;	chr3:124689302	chr2:49878623~49879363:+
BRCA	trans	rs2243480	1	rs1553174	ENSG00000164669.11	INTS4P1	-5.56	3.5e-08	0.0209	-0.33	-0.17	Diabetic kidney disease;	chr7:66266207	chr7:65141225~65234216:+
BRCA	trans	rs2243480	1	rs10950032	ENSG00000164669.11	INTS4P1	-5.56	3.5e-08	0.0209	-0.33	-0.17	Diabetic kidney disease;	chr7:66273604	chr7:65141225~65234216:+
BRCA	trans	rs11098499	0.865	rs10213221	ENSG00000276997.3	RP11-378J18.9	5.56	3.5e-08	0.0209	0.2	0.17	Corneal astigmatism;	chr4:119334771	chr1:222477252~222504622:-
BRCA	trans	rs853679	0.545	rs35949109	ENSG00000228078.1	HLA-U	-5.56	3.51e-08	0.0209	-0.34	-0.17	Depression;	chr6:28058148	chr6:29934101~29934286:+
BRCA	trans	rs11638815	0.954	rs35734713	ENSG00000235370.6	DNM1P51	5.56	3.51e-08	0.0209	0.22	0.17	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82669753	chr15:84398316~84411701:-
BRCA	trans	rs7746199	0.736	rs13192965	ENSG00000281831.1	HCP5B	5.56	3.51e-08	0.0209	0.43	0.17	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27704046	chr6:29871895~29873783:-
BRCA	trans	rs10838687	0.669	rs830084	ENSG00000134612.10	FOLH1B	-5.56	3.51e-08	0.0209	-0.26	-0.17	Proinsulin levels;	chr11:47230101	chr11:89639227~89698718:+
BRCA	trans	rs6142102	0.502	rs58393429	ENSG00000280327.1	LA16c-313F4.1	-5.56	3.52e-08	0.021	-0.18	-0.17	Skin pigmentation;	chr20:33957996	chr16:1576716~1578371:-
BRCA	trans	rs875971	0.838	rs2173570	ENSG00000164669.11	INTS4P1	5.56	3.52e-08	0.021	0.21	0.17	Aortic root size;	chr7:66297976	chr7:65141225~65234216:+
BRCA	trans	rs9467711	0.659	rs35277236	ENSG00000281831.1	HCP5B	5.56	3.52e-08	0.021	0.39	0.17	Autism spectrum disorder or schizophrenia;	chr6:26562041	chr6:29871895~29873783:-
BRCA	trans	rs445114	1	rs620861	ENSG00000213693.4	SEC14L1P1	5.55	3.53e-08	0.021	0.19	0.17	Prostate cancer;Prostate cancer (SNP x SNP interaction);	chr8:127323428	chr11:43897456~43899636:+
BRCA	trans	rs11098499	0.532	rs4833624	ENSG00000276997.3	RP11-378J18.9	5.55	3.53e-08	0.021	0.21	0.17	Corneal astigmatism;	chr4:119664342	chr1:222477252~222504622:-
BRCA	trans	rs12439619	0.693	rs9944185	ENSG00000235370.6	DNM1P51	-5.55	3.53e-08	0.0211	-0.21	-0.17	Intelligence (multi-trait analysis);	chr15:82157927	chr15:84398316~84411701:-
BRCA	trans	rs6142102	0.517	rs6059577	ENSG00000280327.1	LA16c-313F4.1	-5.55	3.53e-08	0.0211	-0.18	-0.17	Skin pigmentation;	chr20:33939880	chr16:1576716~1578371:-
BRCA	trans	rs4366490	0.534	rs11231322	ENSG00000186676.3	EEF1GP1	-5.55	3.53e-08	0.0211	-0.27	-0.17	Conotruncal heart defects;	chr11:63046762	chr7:125033453~125035301:+
BRCA	trans	rs17818399	0.89	rs34752561	ENSG00000253869.1	PIGFP1	5.55	3.54e-08	0.0211	0.26	0.17	Height;	chr2:46623011	chr5:178922064~178922716:+
BRCA	trans	rs6934970	1	rs4945480	ENSG00000267560.1	RP11-173A16.1	5.55	3.54e-08	0.0211	0.21	0.17	Bipolar disorder (body mass index interaction);	chr6:112799651	chr18:62300036~62300998:-
BRCA	trans	rs1232027	0.7	rs2560423	ENSG00000188985.6	DHFRP1	-5.55	3.54e-08	0.0211	-0.22	-0.17	Huntington's disease progression;	chr5:80633355	chr18:26170726~26171284:-
BRCA	trans	rs4948102	0.731	rs10229446	ENSG00000186940.6	CHCHD2P9	5.55	3.54e-08	0.0211	0.22	0.17	Plasma homocysteine levels (post-methionine load test);	chr7:55996569	chr9:79391304~79391759:+
BRCA	trans	rs9470366	0.816	rs1321311	ENSG00000257004.1	RP11-180M15.3	5.55	3.54e-08	0.0211	0.2	0.17	QRS duration;	chr6:36655123	chr12:12668982~12685075:+
BRCA	trans	rs67340775	0.748	rs13212651	ENSG00000228078.1	HLA-U	-5.55	3.54e-08	0.0211	-0.45	-0.17	Lung cancer in ever smokers;	chr6:27839207	chr6:29934101~29934286:+
BRCA	trans	rs1039766	1	rs10116	ENSG00000213985.4	AC078899.1	5.55	3.54e-08	0.0211	0.24	0.17	Lung adenocarcinoma;Lung cancer;	chr2:65269595	chr19:20257720~20259418:+
BRCA	trans	rs1039766	0.929	rs268881	ENSG00000213985.4	AC078899.1	5.55	3.54e-08	0.0211	0.24	0.17	Lung adenocarcinoma;Lung cancer;	chr2:65274249	chr19:20257720~20259418:+
BRCA	trans	rs2950393	0.929	rs7973157	ENSG00000257210.1	NACAP3	-5.55	3.55e-08	0.0211	-0.2	-0.17	Platelet distribution width;	chr12:56655409	chr12:93124063~93124543:-
BRCA	trans	rs7113874	0.524	rs10840092	ENSG00000266891.1	RP11-692N5.2	-5.55	3.55e-08	0.0212	-0.19	-0.17	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8603368	chr18:9734882~9735602:-
BRCA	trans	rs9368481	0.594	rs7768643	ENSG00000216901.1	AL022393.7	-5.55	3.56e-08	0.0212	-0.21	-0.17	Autism spectrum disorder or schizophrenia;	chr6:26924140	chr6:28176188~28176674:+
BRCA	trans	rs9368481	0.594	rs7768814	ENSG00000216901.1	AL022393.7	-5.55	3.56e-08	0.0212	-0.21	-0.17	Autism spectrum disorder or schizophrenia;	chr6:26924257	chr6:28176188~28176674:+
BRCA	trans	rs11098499	0.697	rs28655325	ENSG00000276805.1	RP11-291L22.6	5.55	3.56e-08	0.0212	0.2	0.17	Corneal astigmatism;	chr4:119451844	chr10:38451030~38451785:+
BRCA	trans	rs11098499	0.954	rs10006525	ENSG00000253326.2	RP11-261C10.7	5.55	3.56e-08	0.0212	0.24	0.17	Corneal astigmatism;	chr4:119487776	chr1:243054861~243056394:-
BRCA	trans	rs228614	0.509	rs223476	ENSG00000211782.2	TRAV8-1	-5.55	3.56e-08	0.0212	-0.13	-0.17	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102771000	chr14:21797287~21797886:+
BRCA	trans	rs228614	0.509	rs150896	ENSG00000211782.2	TRAV8-1	-5.55	3.56e-08	0.0212	-0.13	-0.17	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102771186	chr14:21797287~21797886:+
BRCA	trans	rs704840	0.729	rs35086785	ENSG00000251484.3	RP5-1065J22.4	5.55	3.57e-08	0.0212	0.24	0.17	Systemic lupus erythematosus;Systemic lupus erythematosus and Systemic sclerosis;	chr1:173251110	chr1:109103535~109104766:-
BRCA	trans	rs1459104	0.778	rs34718072	ENSG00000134612.10	FOLH1B	-5.55	3.57e-08	0.0213	-0.34	-0.17	Body mass index;	chr11:55722362	chr11:89639227~89698718:+
BRCA	trans	rs875971	0.522	rs781144	ENSG00000213640.3	EEF1DP4	-5.55	3.57e-08	0.0213	-0.21	-0.17	Aortic root size;	chr7:65975357	chr7:64862999~64864370:+
BRCA	trans	rs11122895	0.509	rs10174353	ENSG00000233673.5	ANAPC1P1	5.55	3.58e-08	0.0213	0.19	0.17	Allergic sensitization;	chr2:111690311	chr2:86861825~86922693:+
BRCA	trans	rs11098499	0.909	rs28714195	ENSG00000276805.1	RP11-291L22.6	5.55	3.59e-08	0.0214	0.2	0.17	Corneal astigmatism;	chr4:119395795	chr10:38451030~38451785:+
BRCA	trans	rs902774	0.818	rs79377635	ENSG00000228753.1	EIF4BP2	5.55	3.59e-08	0.0214	0.33	0.17	Prostate cancer;	chr12:52883148	chr10:21028999~21030792:+
BRCA	trans	rs6954796	0.504	rs9639354	ENSG00000278035.1	RP11-234K24.6	5.55	3.59e-08	0.0214	0.27	0.17	Non-word repetition;	chr7:20063833	chr20:36233851~36234297:+
BRCA	trans	rs9467711	0.79	rs13198716	ENSG00000228078.1	HLA-U	5.55	3.59e-08	0.0214	0.42	0.17	Autism spectrum disorder or schizophrenia;	chr6:26581807	chr6:29934101~29934286:+
BRCA	trans	rs11098499	0.954	rs6838814	ENSG00000276805.1	RP11-291L22.6	5.55	3.59e-08	0.0214	0.2	0.17	Corneal astigmatism;	chr4:119471288	chr10:38451030~38451785:+
BRCA	trans	rs9467711	0.79	rs13220495	ENSG00000220721.1	OR1F12	5.55	3.6e-08	0.0214	0.4	0.17	Autism spectrum disorder or schizophrenia;	chr6:26441412	chr6:28073316~28074233:+
BRCA	trans	rs7338174	0.655	rs9316535	ENSG00000250299.4	MRPS31P4	5.55	3.6e-08	0.0214	0.34	0.17	Mitochondrial DNA levels;	chr13:51329329	chr13:52600119~52637446:+
BRCA	trans	rs6142102	0.625	rs6142061	ENSG00000280327.1	LA16c-313F4.1	-5.55	3.61e-08	0.0215	-0.18	-0.17	Skin pigmentation;	chr20:33960529	chr16:1576716~1578371:-
BRCA	trans	rs11748023	0.605	rs155949	ENSG00000224848.1	RP11-535M15.1	5.55	3.61e-08	0.0215	0.21	0.17	Intelligence (multi-trait analysis);	chr5:140144099	chr9:96687056~96721121:+
BRCA	trans	rs1232027	0.7	rs865647	ENSG00000188985.6	DHFRP1	-5.55	3.61e-08	0.0215	-0.22	-0.17	Huntington's disease progression;	chr5:80646457	chr18:26170726~26171284:-
BRCA	trans	rs1232027	0.7	rs844370	ENSG00000188985.6	DHFRP1	-5.55	3.61e-08	0.0215	-0.22	-0.17	Huntington's disease progression;	chr5:80647183	chr18:26170726~26171284:-
BRCA	trans	rs1232027	0.7	rs836822	ENSG00000188985.6	DHFRP1	-5.55	3.61e-08	0.0215	-0.22	-0.17	Huntington's disease progression;	chr5:80647957	chr18:26170726~26171284:-
BRCA	trans	rs1232027	0.7	rs865645	ENSG00000188985.6	DHFRP1	-5.55	3.61e-08	0.0215	-0.22	-0.17	Huntington's disease progression;	chr5:80648285	chr18:26170726~26171284:-
BRCA	trans	rs9462846	1	rs9471942	ENSG00000231579.3	RPL7P21	5.55	3.62e-08	0.0215	0.25	0.17	Blood protein levels;	chr6:42893794	chr5:143332605~143333239:+
BRCA	trans	rs9462846	1	rs9462846	ENSG00000231579.3	RPL7P21	5.55	3.62e-08	0.0215	0.25	0.17	Blood protein levels;	chr6:42893843	chr5:143332605~143333239:+
BRCA	trans	rs3740713	0.669	rs2896526	ENSG00000213574.2	LDHAP5	5.55	3.62e-08	0.0215	0.28	0.17	Amyotrophic lateral sclerosis (sporadic);	chr11:18398259	chr10:118932674~118933295:-
BRCA	trans	rs7943953	0.661	rs7932805	ENSG00000206897.1	SNORA9	5.55	3.62e-08	0.0215	0.21	0.17	Odorant perception (&beta-ionone);	chr11:59308999	chr12:123616708~123616840:+
BRCA	trans	rs2243480	1	rs34703416	ENSG00000230295.1	RP11-458F8.2	-5.55	3.62e-08	0.0215	-0.22	-0.17	Diabetic kidney disease;	chr7:65835655	chr7:66880708~66882981:+
BRCA	trans	rs1232027	0.7	rs1677680	ENSG00000188985.6	DHFRP1	-5.55	3.62e-08	0.0215	-0.22	-0.17	Huntington's disease progression;	chr5:80659216	chr18:26170726~26171284:-
BRCA	trans	rs1232027	0.7	rs1643652	ENSG00000188985.6	DHFRP1	-5.55	3.62e-08	0.0215	-0.22	-0.17	Huntington's disease progression;	chr5:80659260	chr18:26170726~26171284:-
BRCA	trans	rs1568889	0.938	rs6484358	ENSG00000174912.7	METTL15P1	5.55	3.63e-08	0.0216	0.18	0.17	Bipolar disorder;	chr11:28238817	chr3:156713884~156714928:-
BRCA	trans	rs13042473	0.656	rs13036500	ENSG00000224126.2	UBE2SP2	5.55	3.64e-08	0.0216	0.28	0.17	Fractional exhaled nitric oxide (childhood);	chr20:42794965	chr17:18677261~18677757:+
BRCA	trans	rs11098499	0.618	rs35265692	ENSG00000276805.1	RP11-291L22.6	5.55	3.64e-08	0.0216	0.2	0.17	Corneal astigmatism;	chr4:119403980	chr10:38451030~38451785:+
BRCA	trans	rs332507	0.83	rs2242425	ENSG00000234253.1	RPL7P13	5.55	3.64e-08	0.0216	0.22	0.17	Plateletcrit;	chr3:124679797	chr2:49878623~49879363:+
BRCA	trans	rs2117029	0.521	rs7953169	ENSG00000214391.3	TUBAP2	5.55	3.64e-08	0.0216	0.16	0.17	Intelligence (multi-trait analysis);	chr12:49184389	chr11:90282560~90284172:+
BRCA	trans	rs1232027	0.666	rs34965641	ENSG00000188985.6	DHFRP1	-5.55	3.64e-08	0.0216	-0.22	-0.17	Huntington's disease progression;	chr5:80646557	chr18:26170726~26171284:-
BRCA	trans	rs7570469	0.762	rs446017	ENSG00000276390.1	RP1-197B17.5	5.55	3.64e-08	0.0217	0.22	0.17	Response to antipsychotic treatment;	chr2:79471242	chr12:47699401~47699917:-
BRCA	trans	rs7927771	0.725	rs11570094	ENSG00000134612.10	FOLH1B	5.55	3.65e-08	0.0217	0.24	0.17	Subjective well-being;	chr11:47338155	chr11:89639227~89698718:+
BRCA	trans	rs11098499	0.954	rs28572238	ENSG00000253326.2	RP11-261C10.7	5.55	3.66e-08	0.0217	0.23	0.17	Corneal astigmatism;	chr4:119395531	chr1:243054861~243056394:-
BRCA	trans	rs1232027	0.7	rs1677694	ENSG00000188985.6	DHFRP1	-5.55	3.67e-08	0.0218	-0.22	-0.17	Huntington's disease progression;	chr5:80640478	chr18:26170726~26171284:-
BRCA	trans	rs7647973	1	rs10865956	ENSG00000235912.1	RP1-159A19.3	-5.55	3.67e-08	0.0218	-0.22	-0.17	Menarche (age at onset);	chr3:49544126	chr1:27649419~27649610:+
BRCA	trans	rs2841307	0.925	rs4140483	ENSG00000225751.2	AC087501.1	5.55	3.67e-08	0.0218	0.26	0.17	Bipolar disorder and schizophrenia;	chr6:100245132	chr17:9452197~9470014:+
BRCA	trans	rs2243480	1	rs316327	ENSG00000164669.11	INTS4P1	-5.55	3.68e-08	0.0218	-0.32	-0.17	Diabetic kidney disease;	chr7:66144214	chr7:65141225~65234216:+
BRCA	trans	rs9393813	0.529	rs4711155	ENSG00000242375.1	RP11-498P14.3	5.55	3.68e-08	0.0219	0.23	0.17	Bipolar disorder;	chr6:27478667	chr9:97195351~97197687:-
BRCA	trans	rs2841307	0.925	rs58379285	ENSG00000225751.2	AC087501.1	5.55	3.68e-08	0.0219	0.26	0.17	Bipolar disorder and schizophrenia;	chr6:100243802	chr17:9452197~9470014:+
BRCA	trans	rs2055729	0.71	rs13257396	ENSG00000253893.2	FAM85B	-5.55	3.69e-08	0.0219	-0.25	-0.17	Multiple myeloma (hyperdiploidy);	chr8:9878873	chr8:8167819~8226614:-
BRCA	trans	rs11740474	0.522	rs17115870	ENSG00000213058.3	RP4-765C7.2	-5.55	3.69e-08	0.0219	-0.23	-0.17	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr5:154297388	chr1:178411616~178411972:+
BRCA	trans	rs9368481	0.546	rs12664610	ENSG00000216901.1	AL022393.7	-5.55	3.69e-08	0.0219	-0.21	-0.17	Autism spectrum disorder or schizophrenia;	chr6:26917252	chr6:28176188~28176674:+
BRCA	trans	rs11098499	0.909	rs28714195	ENSG00000253326.2	RP11-261C10.7	5.55	3.7e-08	0.0219	0.23	0.17	Corneal astigmatism;	chr4:119395795	chr1:243054861~243056394:-
BRCA	trans	rs10028773	0.6	rs4001390	ENSG00000276997.3	RP11-378J18.9	5.55	3.7e-08	0.0219	0.19	0.17	Educational attainment;	chr4:119344628	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.691	rs2136911	ENSG00000276997.3	RP11-378J18.9	5.55	3.7e-08	0.0219	0.19	0.17	Corneal astigmatism;	chr4:119344704	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.779	rs6815934	ENSG00000276997.3	RP11-378J18.9	5.55	3.7e-08	0.0219	0.19	0.17	Corneal astigmatism;	chr4:119346155	chr1:222477252~222504622:-
BRCA	trans	rs10028773	0.568	rs6838457	ENSG00000276997.3	RP11-378J18.9	5.55	3.7e-08	0.0219	0.19	0.17	Educational attainment;	chr4:119346212	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.535	rs10005542	ENSG00000276997.3	RP11-378J18.9	5.55	3.7e-08	0.0219	0.19	0.17	Corneal astigmatism;	chr4:119347147	chr1:222477252~222504622:-
BRCA	trans	rs7647973	1	rs9862534	ENSG00000235912.1	RP1-159A19.3	-5.55	3.7e-08	0.022	-0.22	-0.17	Menarche (age at onset);	chr3:49560631	chr1:27649419~27649610:+
BRCA	trans	rs11098499	0.738	rs34566984	ENSG00000276805.1	RP11-291L22.6	5.55	3.7e-08	0.022	0.2	0.17	Corneal astigmatism;	chr4:119440115	chr10:38451030~38451785:+
BRCA	trans	rs11098499	0.954	rs9685777	ENSG00000276805.1	RP11-291L22.6	5.55	3.7e-08	0.022	0.2	0.17	Corneal astigmatism;	chr4:119444810	chr10:38451030~38451785:+
BRCA	trans	rs9649213	0.593	rs7781916	ENSG00000225169.1	BRI3P1	5.55	3.71e-08	0.022	0.21	0.17	Prostate cancer (SNP x SNP interaction);	chr7:98300426	chr1:100213293~100213670:+
BRCA	trans	rs9649213	0.593	rs736753	ENSG00000225169.1	BRI3P1	5.55	3.71e-08	0.022	0.21	0.17	Prostate cancer (SNP x SNP interaction);	chr7:98302177	chr1:100213293~100213670:+
BRCA	trans	rs9649213	0.593	rs736754	ENSG00000225169.1	BRI3P1	5.55	3.71e-08	0.022	0.21	0.17	Prostate cancer (SNP x SNP interaction);	chr7:98302247	chr1:100213293~100213670:+
BRCA	trans	rs801193	0.839	rs12534943	ENSG00000164669.11	INTS4P1	5.55	3.72e-08	0.0221	0.21	0.17	Aortic root size;	chr7:66605533	chr7:65141225~65234216:+
BRCA	trans	rs11098499	0.908	rs9995234	ENSG00000253326.2	RP11-261C10.7	5.55	3.72e-08	0.0221	0.25	0.17	Corneal astigmatism;	chr4:119400672	chr1:243054861~243056394:-
BRCA	trans	rs6939532	0.522	rs9358933	ENSG00000242375.1	RP11-498P14.3	-5.55	3.72e-08	0.0221	-0.25	-0.17	Autism spectrum disorder or schizophrenia;	chr6:26363460	chr9:97195351~97197687:-
BRCA	trans	rs1232027	0.666	rs1650701	ENSG00000188985.6	DHFRP1	-5.55	3.72e-08	0.0221	-0.22	-0.17	Huntington's disease progression;	chr5:80648612	chr18:26170726~26171284:-
BRCA	trans	rs1232027	0.666	rs1650700	ENSG00000188985.6	DHFRP1	-5.55	3.72e-08	0.0221	-0.22	-0.17	Huntington's disease progression;	chr5:80648613	chr18:26170726~26171284:-
BRCA	trans	rs11098499	0.954	rs6820115	ENSG00000253326.2	RP11-261C10.7	5.54	3.73e-08	0.0221	0.23	0.17	Corneal astigmatism;	chr4:119477027	chr1:243054861~243056394:-
BRCA	trans	rs875971	0.545	rs1267814	ENSG00000213640.3	EEF1DP4	5.54	3.73e-08	0.0221	0.24	0.17	Aortic root size;	chr7:66579422	chr7:64862999~64864370:+
BRCA	trans	rs4879656	0.931	rs3758275	ENSG00000215007.3	DNAJA1P3	5.54	3.73e-08	0.0221	0.21	0.17	Menopause (age at onset);	chr9:33024960	chrX:107351650~107352843:-
BRCA	trans	rs6954796	0.614	rs4721862	ENSG00000278035.1	RP11-234K24.6	-5.54	3.74e-08	0.0222	-0.27	-0.17	Non-word repetition;	chr7:20051228	chr20:36233851~36234297:+
BRCA	trans	rs10791323	0.593	rs11223599	ENSG00000277383.1	CTD-3001H11.2	-5.54	3.74e-08	0.0222	-0.15	-0.17	Childhood ear infection;	chr11:133848007	chr19:47607873~47608454:-
BRCA	trans	rs7647973	1	rs3905330	ENSG00000235912.1	RP1-159A19.3	-5.54	3.74e-08	0.0222	-0.21	-0.17	Menarche (age at onset);	chr3:49513341	chr1:27649419~27649610:+
BRCA	trans	rs227275	0.554	rs223485	ENSG00000211782.2	TRAV8-1	-5.54	3.75e-08	0.0222	-0.13	-0.17	Allergic disease (asthma, hay fever or eczema);	chr4:102764018	chr14:21797287~21797886:+
BRCA	trans	rs2055729	0.71	rs112406488	ENSG00000253893.2	FAM85B	-5.54	3.75e-08	0.0222	-0.25	-0.17	Multiple myeloma (hyperdiploidy);	chr8:9878852	chr8:8167819~8226614:-
BRCA	trans	rs332507	0.83	rs3821532	ENSG00000234253.1	RPL7P13	5.54	3.75e-08	0.0222	0.22	0.17	Plateletcrit;	chr3:124683771	chr2:49878623~49879363:+
BRCA	trans	rs6684992	0.722	rs12407239	ENSG00000231806.2	PCAT7	-5.54	3.75e-08	0.0222	-0.32	-0.17	Eosinophil counts;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;	chr1:87277364	chr9:94555069~94568127:+
BRCA	trans	rs11098499	0.554	rs2175381	ENSG00000276997.3	RP11-378J18.9	5.54	3.75e-08	0.0223	0.19	0.17	Corneal astigmatism;	chr4:119344812	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.599	rs3864142	ENSG00000276997.3	RP11-378J18.9	5.54	3.75e-08	0.0223	0.19	0.17	Corneal astigmatism;	chr4:119345036	chr1:222477252~222504622:-
BRCA	trans	rs4879656	0.966	rs4879658	ENSG00000215007.3	DNAJA1P3	5.54	3.76e-08	0.0223	0.21	0.17	Menopause (age at onset);	chr9:33029017	chrX:107351650~107352843:-
BRCA	trans	rs2243480	0.708	rs13242216	ENSG00000164669.11	INTS4P1	5.54	3.76e-08	0.0223	0.34	0.17	Diabetic kidney disease;	chr7:66433290	chr7:65141225~65234216:+
BRCA	trans	rs2066819	1	rs871130	ENSG00000273654.1	CTB-52I2.4	-5.54	3.76e-08	0.0223	-0.41	-0.17	Psoriasis vulgaris;	chr12:56254993	chr19:18022403~18032099:+
BRCA	trans	rs1232027	0.666	rs13161245	ENSG00000188985.6	DHFRP1	-5.54	3.76e-08	0.0223	-0.22	-0.17	Huntington's disease progression;	chr5:80648914	chr18:26170726~26171284:-
BRCA	trans	rs875971	1	rs937495	ENSG00000164669.11	INTS4P1	5.54	3.77e-08	0.0223	0.21	0.17	Aortic root size;	chr7:66314811	chr7:65141225~65234216:+
BRCA	trans	rs875971	1	rs2036264	ENSG00000164669.11	INTS4P1	5.54	3.77e-08	0.0223	0.21	0.17	Aortic root size;	chr7:66334917	chr7:65141225~65234216:+
BRCA	trans	rs875971	1	rs7783613	ENSG00000164669.11	INTS4P1	5.54	3.77e-08	0.0223	0.21	0.17	Aortic root size;	chr7:66340274	chr7:65141225~65234216:+
BRCA	trans	rs9649213	0.593	rs6970990	ENSG00000225169.1	BRI3P1	5.54	3.77e-08	0.0223	0.21	0.17	Prostate cancer (SNP x SNP interaction);	chr7:98296070	chr1:100213293~100213670:+
BRCA	trans	rs9649213	0.555	rs34695842	ENSG00000225169.1	BRI3P1	5.54	3.77e-08	0.0223	0.21	0.17	Prostate cancer (SNP x SNP interaction);	chr7:98301750	chr1:100213293~100213670:+
BRCA	trans	rs7113874	0.591	rs2311436	ENSG00000266891.1	RP11-692N5.2	5.54	3.77e-08	0.0224	0.2	0.17	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8385174	chr18:9734882~9735602:-
BRCA	trans	rs853679	0.607	rs67101035	ENSG00000228078.1	HLA-U	-5.54	3.78e-08	0.0224	-0.45	-0.17	Depression;	chr6:27831109	chr6:29934101~29934286:+
BRCA	trans	rs11098499	0.865	rs9994730	ENSG00000276805.1	RP11-291L22.6	5.54	3.78e-08	0.0224	0.2	0.17	Corneal astigmatism;	chr4:119460409	chr10:38451030~38451785:+
BRCA	trans	rs11098499	0.954	rs13107475	ENSG00000276805.1	RP11-291L22.6	5.54	3.79e-08	0.0224	0.2	0.17	Corneal astigmatism;	chr4:119471856	chr10:38451030~38451785:+
BRCA	trans	rs11098499	0.722	rs17595727	ENSG00000276997.3	RP11-378J18.9	-5.54	3.79e-08	0.0224	-0.2	-0.17	Corneal astigmatism;	chr4:119340919	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.908	rs7696649	ENSG00000276805.1	RP11-291L22.6	5.54	3.79e-08	0.0224	0.2	0.17	Corneal astigmatism;	chr4:119401022	chr10:38451030~38451785:+
BRCA	trans	rs6504622	0.905	rs736604	ENSG00000266644.1	RP11-927P21.2	-5.54	3.79e-08	0.0224	-0.17	-0.17	Orofacial clefts;	chr17:46947443	chr17:64899766~64900716:+
BRCA	trans	rs7113874	0.55	rs10840085	ENSG00000266891.1	RP11-692N5.2	-5.54	3.79e-08	0.0224	-0.2	-0.17	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8592402	chr18:9734882~9735602:-
BRCA	trans	rs11587682	0.76	rs7542068	ENSG00000180764.13	PIPSL	-5.54	3.8e-08	0.0225	-0.24	-0.17	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr1:150491296	chr10:93958191~93961540:-
BRCA	trans	rs6601327	0.54	rs6982148	ENSG00000253893.2	FAM85B	5.54	3.8e-08	0.0225	0.21	0.17	Multiple myeloma (hyperdiploidy);	chr8:9723560	chr8:8167819~8226614:-
BRCA	trans	rs7943953	0.661	rs10750916	ENSG00000206897.1	SNORA9	5.54	3.8e-08	0.0225	0.2	0.17	Odorant perception (&beta-ionone);	chr11:59325649	chr12:123616708~123616840:+
BRCA	trans	rs1039766	1	rs268878	ENSG00000213985.4	AC078899.1	5.54	3.81e-08	0.0225	0.24	0.17	Lung adenocarcinoma;Lung cancer;	chr2:65270437	chr19:20257720~20259418:+
BRCA	trans	rs45509595	0.841	rs370155	ENSG00000228078.1	HLA-U	-5.54	3.82e-08	0.0226	-0.33	-0.17	Breast cancer;	chr6:27814253	chr6:29934101~29934286:+
BRCA	trans	rs11098499	0.954	rs7681544	ENSG00000253326.2	RP11-261C10.7	5.54	3.82e-08	0.0226	0.24	0.17	Corneal astigmatism;	chr4:119490100	chr1:243054861~243056394:-
BRCA	trans	rs6831352	0.918	rs17817958	ENSG00000233859.2	ADH5P4	-5.54	3.82e-08	0.0226	-0.25	-0.17	Alcohol dependence;	chr4:99140094	chr6:65836930~65838039:-
BRCA	trans	rs1232027	0.7	rs1650696	ENSG00000188985.6	DHFRP1	-5.54	3.84e-08	0.0227	-0.22	-0.17	Huntington's disease progression;	chr5:80655461	chr18:26170726~26171284:-
BRCA	trans	rs1232027	0.7	rs1650695	ENSG00000188985.6	DHFRP1	-5.54	3.84e-08	0.0227	-0.22	-0.17	Huntington's disease progression;	chr5:80655563	chr18:26170726~26171284:-
BRCA	trans	rs1232027	0.7	rs1643641	ENSG00000188985.6	DHFRP1	-5.54	3.84e-08	0.0227	-0.22	-0.17	Huntington's disease progression;	chr5:80655672	chr18:26170726~26171284:-
BRCA	trans	rs7624766	0.869	rs7649322	ENSG00000257511.1	RP11-278C7.1	5.54	3.85e-08	0.0228	0.17	0.17	Response to methotrexate in rheumatoid arthritis;	chr3:160687989	chr12:32726383~32727387:-
BRCA	trans	rs7746199	0.668	rs7749305	ENSG00000228078.1	HLA-U	-5.54	3.85e-08	0.0228	-0.38	-0.17	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27478787	chr6:29934101~29934286:+
BRCA	trans	rs12586478	0.538	rs2221451	ENSG00000266957.1	RP11-49K24.4	5.54	3.85e-08	0.0228	0.19	0.17	Post bronchodilator FEV1;	chr14:86322665	chr18:47077361~47091280:-
BRCA	trans	rs11587682	0.76	rs12731738	ENSG00000180764.13	PIPSL	5.54	3.86e-08	0.0228	0.25	0.17	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr1:150496098	chr10:93958191~93961540:-
BRCA	trans	rs11587682	0.76	rs1343965	ENSG00000180764.13	PIPSL	5.54	3.86e-08	0.0228	0.25	0.17	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr1:150496366	chr10:93958191~93961540:-
BRCA	trans	rs9467711	0.79	rs13198716	ENSG00000204709.4	LINC01556	-5.54	3.86e-08	0.0228	-0.42	-0.17	Autism spectrum disorder or schizophrenia;	chr6:26581807	chr6:28943877~28944537:+
BRCA	trans	rs11748023	0.605	rs185123	ENSG00000224848.1	RP11-535M15.1	5.54	3.87e-08	0.0228	0.21	0.17	Intelligence (multi-trait analysis);	chr5:140137612	chr9:96687056~96721121:+
BRCA	trans	rs728478	1	rs9913367	ENSG00000187870.7	RNFT1P3	5.54	3.87e-08	0.0229	0.22	0.17	QT interval;	chr17:59370661	chr17:20743333~20754501:-
BRCA	trans	rs2243480	1	rs6964530	ENSG00000164669.11	INTS4P1	-5.54	3.87e-08	0.0229	-0.33	-0.17	Diabetic kidney disease;	chr7:66253864	chr7:65141225~65234216:+
BRCA	trans	rs9649213	0.593	rs6970801	ENSG00000225169.1	BRI3P1	5.54	3.88e-08	0.0229	0.21	0.17	Prostate cancer (SNP x SNP interaction);	chr7:98295928	chr1:100213293~100213670:+
BRCA	trans	rs9649213	0.593	rs12704982	ENSG00000225169.1	BRI3P1	5.54	3.88e-08	0.0229	0.21	0.17	Prostate cancer (SNP x SNP interaction);	chr7:98296741	chr1:100213293~100213670:+
BRCA	trans	rs9649213	0.593	rs34129434	ENSG00000225169.1	BRI3P1	5.54	3.88e-08	0.0229	0.21	0.17	Prostate cancer (SNP x SNP interaction);	chr7:98297152	chr1:100213293~100213670:+
BRCA	trans	rs7113874	0.569	rs9736791	ENSG00000266891.1	RP11-692N5.2	5.54	3.89e-08	0.023	0.2	0.17	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8568101	chr18:9734882~9735602:-
BRCA	trans	rs6934970	1	rs3862842	ENSG00000267560.1	RP11-173A16.1	-5.54	3.9e-08	0.023	-0.21	-0.17	Bipolar disorder (body mass index interaction);	chr6:112812349	chr18:62300036~62300998:-
BRCA	trans	rs902774	0.818	rs56095813	ENSG00000228753.1	EIF4BP2	5.54	3.9e-08	0.023	0.33	0.17	Prostate cancer;	chr12:52900963	chr10:21028999~21030792:+
BRCA	trans	rs16975963	0.644	rs112666969	ENSG00000247498.8	RP11-392P7.6	5.54	3.91e-08	0.0231	0.28	0.17	Longevity;	chr19:37556743	chr12:12927726~12984645:+
BRCA	trans	rs6142102	0.58	rs4911139	ENSG00000280327.1	LA16c-313F4.1	-5.54	3.91e-08	0.0231	-0.18	-0.17	Skin pigmentation;	chr20:33963729	chr16:1576716~1578371:-
BRCA	trans	rs35306767	0.953	rs1106064	ENSG00000187984.11	ANKRD19P	5.54	3.91e-08	0.0231	0.21	0.17	Eosinophil percentage of granulocytes;	chr10:911271	chr9:92809388~92888693:+
BRCA	trans	rs9467711	0.659	rs34605993	ENSG00000220721.1	OR1F12	5.54	3.92e-08	0.0231	0.37	0.17	Autism spectrum disorder or schizophrenia;	chr6:26454135	chr6:28073316~28074233:+
BRCA	trans	rs4948102	0.961	rs7776550	ENSG00000186940.6	CHCHD2P9	-5.54	3.92e-08	0.0231	-0.22	-0.17	Plasma homocysteine levels (post-methionine load test);	chr7:56024698	chr9:79391304~79391759:+
BRCA	trans	rs10783779	0.647	rs705708	ENSG00000223416.3	RPS26P15	5.54	3.92e-08	0.0232	0.2	0.17	Educational attainment;	chr12:56095129	chr1:58056133~58056480:-
BRCA	trans	rs1232027	0.7	rs1677692	ENSG00000188985.6	DHFRP1	-5.54	3.92e-08	0.0232	-0.22	-0.17	Huntington's disease progression;	chr5:80641195	chr18:26170726~26171284:-
BRCA	trans	rs11098499	0.954	rs1546505	ENSG00000276805.1	RP11-291L22.6	5.54	3.93e-08	0.0232	0.2	0.17	Corneal astigmatism;	chr4:119320069	chr10:38451030~38451785:+
BRCA	trans	rs7824557	0.628	rs11782706	ENSG00000270154.1	RP11-419I17.1	5.54	3.93e-08	0.0232	0.2	0.17	Retinal vascular caliber;	chr8:11328706	chr8:12476462~12477122:+
BRCA	trans	rs6813195	0.554	rs1516819	ENSG00000275665.1	CTB-58E17.9	5.53	3.94e-08	0.0233	0.21	0.17	Type 2 diabetes;	chr4:152512299	chr17:38715328~38720272:-
BRCA	trans	rs11098499	0.691	rs10010355	ENSG00000276997.3	RP11-378J18.9	5.53	3.95e-08	0.0233	0.2	0.17	Corneal astigmatism;	chr4:119339888	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.691	rs9307471	ENSG00000276997.3	RP11-378J18.9	5.53	3.95e-08	0.0233	0.2	0.17	Corneal astigmatism;	chr4:119340107	chr1:222477252~222504622:-
BRCA	trans	rs3019286	0.573	rs7845271	ENSG00000260318.1	COX6CP1	-5.53	3.95e-08	0.0233	-0.21	-0.17	Suicide behavior;	chr8:98786873	chr16:11903923~11904137:-
BRCA	trans	rs13326165	0.585	rs10461027	ENSG00000211639.2	IGLV4-60	-5.53	3.95e-08	0.0233	-0.26	-0.17	HDL cholesterol levels;HDL cholesterol;	chr3:52307110	chr22:22162199~22162681:+
BRCA	trans	rs9393777	0.92	rs35716472	ENSG00000281831.1	HCP5B	5.53	3.96e-08	0.0234	0.39	0.17	Intelligence (multi-trait analysis);	chr6:27438828	chr6:29871895~29873783:-
BRCA	trans	rs2242330	0.862	rs55792839	ENSG00000226982.4	CENPCP1	5.53	3.96e-08	0.0234	0.26	0.17	Parkinson's disease;	chr4:67522594	chr12:89500093~89502670:+
BRCA	trans	rs1232027	0.7	rs2560424	ENSG00000188985.6	DHFRP1	-5.53	3.98e-08	0.0234	-0.22	-0.17	Huntington's disease progression;	chr5:80629486	chr18:26170726~26171284:-
BRCA	trans	rs1232027	0.7	rs2618372	ENSG00000188985.6	DHFRP1	-5.53	3.98e-08	0.0234	-0.22	-0.17	Huntington's disease progression;	chr5:80629791	chr18:26170726~26171284:-
BRCA	trans	rs1232027	0.632	rs60244599	ENSG00000188985.6	DHFRP1	-5.53	3.98e-08	0.0234	-0.22	-0.17	Huntington's disease progression;	chr5:80630608	chr18:26170726~26171284:-
BRCA	trans	rs1232027	0.7	rs1677634	ENSG00000188985.6	DHFRP1	-5.53	3.98e-08	0.0234	-0.22	-0.17	Huntington's disease progression;	chr5:80632505	chr18:26170726~26171284:-
BRCA	trans	rs1232027	0.7	rs1643636	ENSG00000188985.6	DHFRP1	-5.53	3.98e-08	0.0234	-0.22	-0.17	Huntington's disease progression;	chr5:80632948	chr18:26170726~26171284:-
BRCA	trans	rs1232027	0.666	rs1643637	ENSG00000188985.6	DHFRP1	-5.53	3.98e-08	0.0234	-0.22	-0.17	Huntington's disease progression;	chr5:80633090	chr18:26170726~26171284:-
BRCA	trans	rs1232027	0.7	rs1643638	ENSG00000188985.6	DHFRP1	-5.53	3.98e-08	0.0234	-0.22	-0.17	Huntington's disease progression;	chr5:80634437	chr18:26170726~26171284:-
BRCA	trans	rs1232027	0.632	rs1650718	ENSG00000188985.6	DHFRP1	-5.53	3.98e-08	0.0234	-0.22	-0.17	Huntington's disease progression;	chr5:80634457	chr18:26170726~26171284:-
BRCA	trans	rs1232027	0.632	rs1677706	ENSG00000188985.6	DHFRP1	-5.53	3.98e-08	0.0234	-0.22	-0.17	Huntington's disease progression;	chr5:80634484	chr18:26170726~26171284:-
BRCA	trans	rs1232027	0.7	rs1650715	ENSG00000188985.6	DHFRP1	-5.53	3.98e-08	0.0234	-0.22	-0.17	Huntington's disease progression;	chr5:80634922	chr18:26170726~26171284:-
BRCA	trans	rs1232027	0.632	rs1677701	ENSG00000188985.6	DHFRP1	-5.53	3.98e-08	0.0234	-0.22	-0.17	Huntington's disease progression;	chr5:80635513	chr18:26170726~26171284:-
BRCA	trans	rs1232027	0.7	rs1677700	ENSG00000188985.6	DHFRP1	-5.53	3.98e-08	0.0234	-0.22	-0.17	Huntington's disease progression;	chr5:80635600	chr18:26170726~26171284:-
BRCA	trans	rs1232027	0.7	rs67837398	ENSG00000188985.6	DHFRP1	-5.53	3.98e-08	0.0234	-0.22	-0.17	Huntington's disease progression;	chr5:80636677	chr18:26170726~26171284:-
BRCA	trans	rs1232027	0.7	rs71578847	ENSG00000188985.6	DHFRP1	-5.53	3.98e-08	0.0234	-0.22	-0.17	Huntington's disease progression;	chr5:80636685	chr18:26170726~26171284:-
BRCA	trans	rs1232027	0.7	rs1643662	ENSG00000188985.6	DHFRP1	-5.53	3.98e-08	0.0234	-0.22	-0.17	Huntington's disease progression;	chr5:80637416	chr18:26170726~26171284:-
BRCA	trans	rs1232027	0.7	rs1643660	ENSG00000188985.6	DHFRP1	-5.53	3.98e-08	0.0234	-0.22	-0.17	Huntington's disease progression;	chr5:80638208	chr18:26170726~26171284:-
BRCA	trans	rs1232027	0.7	rs1643659	ENSG00000188985.6	DHFRP1	-5.53	3.98e-08	0.0234	-0.22	-0.17	Huntington's disease progression;	chr5:80639017	chr18:26170726~26171284:-
BRCA	trans	rs1232027	0.7	rs1677696	ENSG00000188985.6	DHFRP1	-5.53	3.98e-08	0.0234	-0.22	-0.17	Huntington's disease progression;	chr5:80639198	chr18:26170726~26171284:-
BRCA	trans	rs1232027	0.666	rs1650710	ENSG00000188985.6	DHFRP1	-5.53	3.98e-08	0.0234	-0.22	-0.17	Huntington's disease progression;	chr5:80640342	chr18:26170726~26171284:-
BRCA	trans	rs1232027	0.7	rs1643658	ENSG00000188985.6	DHFRP1	-5.53	3.98e-08	0.0234	-0.22	-0.17	Huntington's disease progression;	chr5:80640522	chr18:26170726~26171284:-
BRCA	trans	rs1232027	0.7	rs1643657	ENSG00000188985.6	DHFRP1	-5.53	3.98e-08	0.0234	-0.22	-0.17	Huntington's disease progression;	chr5:80640598	chr18:26170726~26171284:-
BRCA	trans	rs1232027	0.7	rs1677691	ENSG00000188985.6	DHFRP1	-5.53	3.98e-08	0.0234	-0.22	-0.17	Huntington's disease progression;	chr5:80641209	chr18:26170726~26171284:-
BRCA	trans	rs1232027	0.7	rs1650709	ENSG00000188985.6	DHFRP1	-5.53	3.98e-08	0.0234	-0.22	-0.17	Huntington's disease progression;	chr5:80641355	chr18:26170726~26171284:-
BRCA	trans	rs1232027	0.7	rs1677688	ENSG00000188985.6	DHFRP1	-5.53	3.98e-08	0.0234	-0.22	-0.17	Huntington's disease progression;	chr5:80642188	chr18:26170726~26171284:-
BRCA	trans	rs1232027	0.7	rs1677687	ENSG00000188985.6	DHFRP1	-5.53	3.98e-08	0.0234	-0.22	-0.17	Huntington's disease progression;	chr5:80642517	chr18:26170726~26171284:-
BRCA	trans	rs1232027	0.666	rs1677686	ENSG00000188985.6	DHFRP1	-5.53	3.98e-08	0.0234	-0.22	-0.17	Huntington's disease progression;	chr5:80642709	chr18:26170726~26171284:-
BRCA	trans	rs1232027	0.7	rs1643647	ENSG00000188985.6	DHFRP1	-5.53	3.98e-08	0.0234	-0.22	-0.17	Huntington's disease progression;	chr5:80642749	chr18:26170726~26171284:-
BRCA	trans	rs1232027	0.7	rs1643648	ENSG00000188985.6	DHFRP1	-5.53	3.98e-08	0.0234	-0.22	-0.17	Huntington's disease progression;	chr5:80642796	chr18:26170726~26171284:-
BRCA	trans	rs1232027	0.666	rs1677685	ENSG00000188985.6	DHFRP1	-5.53	3.98e-08	0.0234	-0.22	-0.17	Huntington's disease progression;	chr5:80643122	chr18:26170726~26171284:-
BRCA	trans	rs1232027	0.7	rs58490646	ENSG00000188985.6	DHFRP1	-5.53	3.98e-08	0.0234	-0.22	-0.17	Huntington's disease progression;	chr5:80644715	chr18:26170726~26171284:-
BRCA	trans	rs1232027	0.7	rs836818	ENSG00000188985.6	DHFRP1	-5.53	3.98e-08	0.0235	-0.22	-0.17	Huntington's disease progression;	chr5:80652137	chr18:26170726~26171284:-
BRCA	trans	rs1232027	0.632	rs863215	ENSG00000188985.6	DHFRP1	-5.53	3.98e-08	0.0235	-0.22	-0.17	Huntington's disease progression;	chr5:80652186	chr18:26170726~26171284:-
BRCA	trans	rs1232027	0.7	rs861373	ENSG00000188985.6	DHFRP1	-5.53	3.98e-08	0.0235	-0.22	-0.17	Huntington's disease progression;	chr5:80652243	chr18:26170726~26171284:-
BRCA	trans	rs282544	1	rs10737958	ENSG00000231752.4	EMBP1	-5.53	3.98e-08	0.0235	-0.22	-0.17	Myopia (pathological);	chr5:50727540	chr1:121519112~121571892:+
BRCA	trans	rs282544	1	rs2594708	ENSG00000231752.4	EMBP1	-5.53	3.98e-08	0.0235	-0.22	-0.17	Myopia (pathological);	chr5:50728834	chr1:121519112~121571892:+
BRCA	trans	rs282544	1	rs2463796	ENSG00000231752.4	EMBP1	-5.53	3.98e-08	0.0235	-0.22	-0.17	Myopia (pathological);	chr5:50729856	chr1:121519112~121571892:+
BRCA	trans	rs7746199	0.736	rs13195636	ENSG00000281831.1	HCP5B	5.53	3.99e-08	0.0235	0.43	0.17	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27541714	chr6:29871895~29873783:-
BRCA	trans	rs902774	0.818	rs4919737	ENSG00000230716.3	KRT8P7	-5.53	3.99e-08	0.0235	-0.35	-0.17	Prostate cancer;	chr12:52877011	chr11:119602875~119604306:-
BRCA	trans	rs853679	0.607	rs34950484	ENSG00000243753.4	HLA-L	-5.53	3.99e-08	0.0235	-0.44	-0.17	Depression;	chr6:28310911	chr6:30259584~30293014:+
BRCA	trans	rs17150703	0.722	rs10503396	ENSG00000253893.2	FAM85B	-5.53	3.99e-08	0.0235	-0.31	-0.17	Obesity (early onset extreme);	chr8:9923351	chr8:8167819~8226614:-
BRCA	trans	rs654950	0.806	rs1535505	ENSG00000243260.3	RN7SL558P	5.53	4e-08	0.0235	0.22	0.17	Airway imaging phenotypes;	chr1:41560481	chr4:39761000~39761298:+
BRCA	trans	rs223116	0.529	rs2145565	ENSG00000226982.4	CENPCP1	-5.53	4e-08	0.0235	-0.24	-0.17	Resting heart rate;	chr14:23451255	chr12:89500093~89502670:+
BRCA	trans	rs9393777	0.623	rs3734544	ENSG00000277241.1	RP11-114M1.3	5.53	4e-08	0.0235	0.26	0.17	Intelligence (multi-trait analysis);	chr6:26468432	chr3:177700346~177701072:-
BRCA	trans	rs67340775	0.748	rs13212651	ENSG00000204709.4	LINC01556	5.53	4e-08	0.0236	0.44	0.17	Lung cancer in ever smokers;	chr6:27839207	chr6:28943877~28944537:+
BRCA	trans	rs12545912	0.909	rs4841179	ENSG00000253893.2	FAM85B	5.53	4.01e-08	0.0236	0.23	0.17	Multiple myeloma (hyperdiploidy);	chr8:9602939	chr8:8167819~8226614:-
BRCA	trans	rs5006884	0.526	rs12808394	ENSG00000258626.2	COX7A2P1	5.53	4.02e-08	0.0237	0.21	0.17	Fetal hemoglobin levels;	chr11:5361551	chr14:67652300~67652614:-
BRCA	trans	rs5006884	0.526	rs12802814	ENSG00000258626.2	COX7A2P1	5.53	4.02e-08	0.0237	0.21	0.17	Fetal hemoglobin levels;	chr11:5361574	chr14:67652300~67652614:-
BRCA	trans	rs11098499	0.532	rs12512646	ENSG00000276997.3	RP11-378J18.9	5.53	4.02e-08	0.0237	0.2	0.17	Corneal astigmatism;	chr4:119664578	chr1:222477252~222504622:-
BRCA	trans	rs7829975	0.593	rs2979241	ENSG00000270154.1	RP11-419I17.1	5.53	4.04e-08	0.0238	0.2	0.17	Mood instability;	chr8:8445843	chr8:12476462~12477122:+
BRCA	trans	rs11098499	0.863	rs3822192	ENSG00000276805.1	RP11-291L22.6	5.53	4.04e-08	0.0238	0.21	0.17	Corneal astigmatism;	chr4:119524565	chr10:38451030~38451785:+
BRCA	trans	rs11098499	0.657	rs71614442	ENSG00000276805.1	RP11-291L22.6	5.53	4.05e-08	0.0238	0.2	0.17	Corneal astigmatism;	chr4:119458191	chr10:38451030~38451785:+
BRCA	trans	rs11098499	0.954	rs2892848	ENSG00000276805.1	RP11-291L22.6	5.53	4.05e-08	0.0238	0.2	0.17	Corneal astigmatism;	chr4:119460186	chr10:38451030~38451785:+
BRCA	trans	rs7746199	0.668	rs7749305	ENSG00000204709.4	LINC01556	5.53	4.06e-08	0.0239	0.38	0.17	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27478787	chr6:28943877~28944537:+
BRCA	trans	rs902774	0.818	rs4919737	ENSG00000220378.3	KRT8P42	-5.53	4.06e-08	0.0239	-0.36	-0.17	Prostate cancer;	chr12:52877011	chr6:134296997~134298695:-
BRCA	trans	rs7568458	0.837	rs3731827	ENSG00000223886.3	RP11-251G23.2	5.53	4.06e-08	0.0239	0.19	0.17	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr2:85578945	chr7:105530209~105530671:+
BRCA	trans	rs13217239	0.646	rs62401067	ENSG00000216901.1	AL022393.7	-5.53	4.06e-08	0.0239	-0.21	-0.17	Schizophrenia;	chr6:27050322	chr6:28176188~28176674:+
BRCA	trans	rs6921919	0.583	rs2041230	ENSG00000228078.1	HLA-U	-5.53	4.07e-08	0.0239	-0.23	-0.17	Autism spectrum disorder or schizophrenia;	chr6:28397738	chr6:29934101~29934286:+
BRCA	trans	rs2243480	1	rs778729	ENSG00000164669.11	INTS4P1	5.53	4.07e-08	0.0239	0.33	0.17	Diabetic kidney disease;	chr7:66359432	chr7:65141225~65234216:+
BRCA	trans	rs9393777	0.528	rs35982103	ENSG00000253570.1	RNF5P1	5.53	4.08e-08	0.024	0.3	0.17	Intelligence (multi-trait analysis);	chr6:27275355	chr8:38600661~38601200:-
BRCA	trans	rs801193	0.773	rs801207	ENSG00000164669.11	INTS4P1	5.53	4.09e-08	0.024	0.21	0.17	Aortic root size;	chr7:66555603	chr7:65141225~65234216:+
BRCA	trans	rs6601327	0.641	rs11778555	ENSG00000253893.2	FAM85B	5.53	4.09e-08	0.024	0.21	0.17	Multiple myeloma (hyperdiploidy);	chr8:9730064	chr8:8167819~8226614:-
BRCA	trans	rs6601327	0.641	rs11785923	ENSG00000253893.2	FAM85B	5.53	4.09e-08	0.024	0.21	0.17	Multiple myeloma (hyperdiploidy);	chr8:9730164	chr8:8167819~8226614:-
BRCA	trans	rs7662987	0.517	rs1377689	ENSG00000233859.2	ADH5P4	-5.53	4.1e-08	0.0241	-0.24	-0.17	Smoking initiation;	chr4:99100636	chr6:65836930~65838039:-
BRCA	trans	rs7662987	0.517	rs1453873	ENSG00000233859.2	ADH5P4	-5.53	4.1e-08	0.0241	-0.24	-0.17	Smoking initiation;	chr4:99101420	chr6:65836930~65838039:-
BRCA	trans	rs7662987	0.517	rs1453874	ENSG00000233859.2	ADH5P4	-5.53	4.1e-08	0.0241	-0.24	-0.17	Smoking initiation;	chr4:99101573	chr6:65836930~65838039:-
BRCA	trans	rs7662987	0.517	rs1133485	ENSG00000233859.2	ADH5P4	-5.53	4.1e-08	0.0241	-0.24	-0.17	Smoking initiation;	chr4:99102660	chr6:65836930~65838039:-
BRCA	trans	rs7662987	0.517	rs2602845	ENSG00000233859.2	ADH5P4	-5.53	4.1e-08	0.0241	-0.24	-0.17	Smoking initiation;	chr4:99102793	chr6:65836930~65838039:-
BRCA	trans	rs7662987	0.517	rs2034696	ENSG00000233859.2	ADH5P4	-5.53	4.1e-08	0.0241	-0.24	-0.17	Smoking initiation;	chr4:99103171	chr6:65836930~65838039:-
BRCA	trans	rs6831352	0.725	rs2602846	ENSG00000233859.2	ADH5P4	-5.53	4.1e-08	0.0241	-0.24	-0.17	Alcohol dependence;	chr4:99104000	chr6:65836930~65838039:-
BRCA	trans	rs6831352	0.744	rs2602847	ENSG00000233859.2	ADH5P4	-5.53	4.1e-08	0.0241	-0.24	-0.17	Alcohol dependence;	chr4:99104812	chr6:65836930~65838039:-
BRCA	trans	rs6939532	0.761	rs3799378	ENSG00000242375.1	RP11-498P14.3	5.53	4.1e-08	0.0241	0.26	0.17	Autism spectrum disorder or schizophrenia;	chr6:26404146	chr9:97195351~97197687:-
BRCA	trans	rs1232027	0.7	rs1650692	ENSG00000188985.6	DHFRP1	-5.53	4.1e-08	0.0241	-0.21	-0.17	Huntington's disease progression;	chr5:80657574	chr18:26170726~26171284:-
BRCA	trans	rs9393813	0.901	rs12529756	ENSG00000242375.1	RP11-498P14.3	5.53	4.11e-08	0.0242	0.23	0.17	Bipolar disorder;	chr6:27503669	chr9:97195351~97197687:-
BRCA	trans	rs13217239	0.646	rs11756275	ENSG00000216901.1	AL022393.7	5.53	4.12e-08	0.0242	0.21	0.17	Schizophrenia;	chr6:27039334	chr6:28176188~28176674:+
BRCA	trans	rs1499614	0.803	rs1796229	ENSG00000164669.11	INTS4P1	5.53	4.12e-08	0.0242	0.33	0.17	Gout;	chr7:66654674	chr7:65141225~65234216:+
BRCA	trans	rs7570469	0.762	rs386271	ENSG00000276390.1	RP1-197B17.5	5.53	4.13e-08	0.0242	0.22	0.17	Response to antipsychotic treatment;	chr2:79475030	chr12:47699401~47699917:-
BRCA	trans	rs11098499	0.863	rs1552095	ENSG00000276805.1	RP11-291L22.6	5.53	4.13e-08	0.0242	0.21	0.17	Corneal astigmatism;	chr4:119539151	chr10:38451030~38451785:+
BRCA	trans	rs11098499	0.644	rs3806808	ENSG00000276805.1	RP11-291L22.6	5.53	4.13e-08	0.0242	0.19	0.17	Corneal astigmatism;	chr4:119629930	chr10:38451030~38451785:+
BRCA	trans	rs9644568	0.599	rs12679834	ENSG00000246339.5	EXTL3-AS1	5.53	4.14e-08	0.0243	0.21	0.17	Hypertriglyceridemia;HDL cholesterol;	chr8:19962922	chr8:28696198~28701464:-
BRCA	trans	rs2950393	0.895	rs2958123	ENSG00000257210.1	NACAP3	5.53	4.14e-08	0.0243	0.2	0.17	Platelet distribution width;	chr12:56668441	chr12:93124063~93124543:-
BRCA	trans	rs11098499	0.954	rs17009122	ENSG00000276805.1	RP11-291L22.6	5.53	4.14e-08	0.0243	0.2	0.17	Corneal astigmatism;	chr4:119441248	chr10:38451030~38451785:+
BRCA	trans	rs875971	0.508	rs6947808	ENSG00000164669.11	INTS4P1	5.53	4.15e-08	0.0244	0.21	0.17	Aortic root size;	chr7:66580095	chr7:65141225~65234216:+
BRCA	trans	rs17711722	0.701	rs55773927	ENSG00000213640.3	EEF1DP4	-5.53	4.16e-08	0.0244	-0.21	-0.17	Calcium levels;	chr7:65872915	chr7:64862999~64864370:+
BRCA	trans	rs864643	0.729	rs7616236	ENSG00000214263.2	RPSAP53	-5.53	4.16e-08	0.0244	-0.34	-0.17	Attention deficit hyperactivity disorder;	chr3:39500645	chr13:67266845~67267706:-
BRCA	trans	rs4713118	0.866	rs9468217	ENSG00000204709.4	LINC01556	5.52	4.16e-08	0.0244	0.24	0.17	Parkinson's disease;	chr6:27758688	chr6:28943877~28944537:+
BRCA	trans	rs4713118	0.911	rs9295746	ENSG00000204709.4	LINC01556	5.52	4.16e-08	0.0244	0.24	0.17	Parkinson's disease;	chr6:27762285	chr6:28943877~28944537:+
BRCA	trans	rs875971	0.522	rs34973832	ENSG00000213640.3	EEF1DP4	-5.52	4.16e-08	0.0244	-0.21	-0.17	Aortic root size;	chr7:65931217	chr7:64862999~64864370:+
BRCA	trans	rs893818	0.56	rs2304722	ENSG00000214826.5	DDX12P	-5.52	4.17e-08	0.0245	-0.18	-0.17	Exfoliation glaucoma or exfoliation syndrome;	chr15:73949408	chr12:9418673~9448229:-
BRCA	trans	rs7113874	0.524	rs11041990	ENSG00000266891.1	RP11-692N5.2	5.52	4.17e-08	0.0245	0.19	0.17	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8564068	chr18:9734882~9735602:-
BRCA	trans	rs6601327	0.641	rs12155819	ENSG00000253893.2	FAM85B	5.52	4.17e-08	0.0245	0.21	0.17	Multiple myeloma (hyperdiploidy);	chr8:9715169	chr8:8167819~8226614:-
BRCA	trans	rs6601327	0.7	rs12114661	ENSG00000253893.2	FAM85B	5.52	4.17e-08	0.0245	0.21	0.17	Multiple myeloma (hyperdiploidy);	chr8:9715644	chr8:8167819~8226614:-
BRCA	trans	rs10815468	0.624	rs7045291	ENSG00000255063.1	RP11-718B12.1	5.52	4.18e-08	0.0245	0.22	0.17	Bipolar disorder and schizophrenia;	chr9:6786418	chr11:82805354~82806509:+
BRCA	trans	rs1232027	0.7	rs1643661	ENSG00000188985.6	DHFRP1	-5.52	4.18e-08	0.0245	-0.22	-0.17	Huntington's disease progression;	chr5:80637757	chr18:26170726~26171284:-
BRCA	trans	rs701145	0.585	rs17766586	ENSG00000249921.2	CTC-329H14.1	-5.52	4.19e-08	0.0246	-0.26	-0.17	Coronary artery disease;	chr3:154061129	chr5:108784098~108785552:+
BRCA	trans	rs6921919	0.789	rs17301128	ENSG00000176998.4	HCG4	-5.52	4.19e-08	0.0246	-0.24	-0.17	Autism spectrum disorder or schizophrenia;	chr6:28340257	chr6:29791753~29792750:-
BRCA	trans	rs11098499	0.821	rs10032151	ENSG00000276805.1	RP11-291L22.6	5.52	4.2e-08	0.0246	0.2	0.17	Corneal astigmatism;	chr4:119470473	chr10:38451030~38451785:+
BRCA	trans	rs11098499	0.865	rs10032158	ENSG00000276805.1	RP11-291L22.6	5.52	4.2e-08	0.0246	0.2	0.17	Corneal astigmatism;	chr4:119470477	chr10:38451030~38451785:+
BRCA	trans	rs45509595	0.841	rs200501	ENSG00000228078.1	HLA-U	-5.52	4.2e-08	0.0246	-0.34	-0.17	Breast cancer;	chr6:27821164	chr6:29934101~29934286:+
BRCA	trans	rs9393777	0.545	rs56303243	ENSG00000253570.1	RNF5P1	5.52	4.21e-08	0.0247	0.31	0.17	Intelligence (multi-trait analysis);	chr6:26485499	chr8:38600661~38601200:-
BRCA	trans	rs11098499	0.865	rs4507344	ENSG00000276805.1	RP11-291L22.6	5.52	4.21e-08	0.0247	0.2	0.17	Corneal astigmatism;	chr4:119386330	chr10:38451030~38451785:+
BRCA	trans	rs1459104	0.778	rs56080425	ENSG00000134612.10	FOLH1B	-5.52	4.22e-08	0.0247	-0.34	-0.17	Body mass index;	chr11:55729615	chr11:89639227~89698718:+
BRCA	trans	rs4970988	0.556	rs6681426	ENSG00000180764.13	PIPSL	5.52	4.22e-08	0.0247	0.21	0.17	Urate levels;	chr1:150614495	chr10:93958191~93961540:-
BRCA	trans	rs902774	0.818	rs11831919	ENSG00000224520.2	KRT8P45	-5.52	4.22e-08	0.0247	-0.34	-0.17	Prostate cancer;	chr12:52878231	chr1:157073257~157074703:+
BRCA	trans	rs2122469	0.655	rs17603934	ENSG00000272293.1	RP11-91J19.3	5.52	4.22e-08	0.0247	0.29	0.17	Serum tamsulosin hydrochloride concentration;	chr8:20718833	chr8:450714~451343:-
BRCA	trans	rs73110464	0.591	rs11829997	ENSG00000248568.1	KRT8P48	-5.52	4.22e-08	0.0247	-0.4	-0.17	Cancer (pleiotropy);	chr12:52921875	chr5:146706381~146707600:-
BRCA	trans	rs450533	0.533	rs2324	ENSG00000229619.3	MBNL1-AS1	-5.52	4.23e-08	0.0248	-0.18	-0.17	Cancer;	chr4:106905548	chr3:152262616~152269555:-
BRCA	trans	rs11587682	0.76	rs12145082	ENSG00000180764.13	PIPSL	5.52	4.23e-08	0.0248	0.24	0.17	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr1:150491050	chr10:93958191~93961540:-
BRCA	trans	rs9393777	0.92	rs34953377	ENSG00000243753.4	HLA-L	-5.52	4.24e-08	0.0248	-0.4	-0.17	Intelligence (multi-trait analysis);	chr6:27413881	chr6:30259584~30293014:+
BRCA	trans	rs9393777	0.778	rs66841633	ENSG00000243753.4	HLA-L	-5.52	4.24e-08	0.0248	-0.4	-0.17	Intelligence (multi-trait analysis);	chr6:27414607	chr6:30259584~30293014:+
BRCA	trans	rs9858542	0.953	rs11715915	ENSG00000197582.5	GPX1P1	5.52	4.24e-08	0.0248	0.2	0.17	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49417897	chrX:13378735~13379340:-
BRCA	trans	rs12497850	0.863	rs4974084	ENSG00000197582.5	GPX1P1	5.52	4.24e-08	0.0248	0.18	0.17	Parkinson's disease;	chr3:48901647	chrX:13378735~13379340:-
BRCA	trans	rs11098499	0.954	rs10017371	ENSG00000276805.1	RP11-291L22.6	5.52	4.25e-08	0.0249	0.2	0.17	Corneal astigmatism;	chr4:119372621	chr10:38451030~38451785:+
BRCA	trans	rs7746199	0.736	rs13212093	ENSG00000228078.1	HLA-U	-5.52	4.25e-08	0.0249	-0.45	-0.17	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27638937	chr6:29934101~29934286:+
BRCA	trans	rs7746199	0.736	rs34038546	ENSG00000228078.1	HLA-U	-5.52	4.25e-08	0.0249	-0.45	-0.17	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27639881	chr6:29934101~29934286:+
BRCA	trans	rs141342723	1	rs141342723	ENSG00000228078.1	HLA-U	-5.52	4.25e-08	0.0249	-0.45	-0.17	Autism spectrum disorder or schizophrenia;	chr6:27654305	chr6:29934101~29934286:+
BRCA	trans	rs7746199	0.736	rs34543938	ENSG00000228078.1	HLA-U	-5.52	4.25e-08	0.0249	-0.45	-0.17	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27656861	chr6:29934101~29934286:+
BRCA	trans	rs7746199	0.736	rs56405707	ENSG00000228078.1	HLA-U	-5.52	4.25e-08	0.0249	-0.45	-0.17	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27672467	chr6:29934101~29934286:+
BRCA	trans	rs7826222	1	rs545854	ENSG00000253893.2	FAM85B	5.52	4.26e-08	0.0249	0.29	0.17	Adiposity;	chr8:10002570	chr8:8167819~8226614:-
BRCA	trans	rs1568889	1	rs7951681	ENSG00000174912.7	METTL15P1	5.52	4.26e-08	0.0249	0.18	0.17	Bipolar disorder;	chr11:28252347	chr3:156713884~156714928:-
BRCA	trans	rs7824557	0.836	rs1435278	ENSG00000270154.1	RP11-419I17.1	-5.52	4.26e-08	0.0249	-0.21	-0.17	Retinal vascular caliber;	chr8:11265520	chr8:12476462~12477122:+
BRCA	trans	rs6545883	0.507	rs4672427	ENSG00000260091.1	RP11-33B1.4	-5.52	4.26e-08	0.0249	-0.14	-0.17	Tuberculosis;	chr2:61242115	chr4:119409333~119410233:+
BRCA	trans	rs11122895	0.846	rs11692656	ENSG00000233673.5	ANAPC1P1	5.52	4.27e-08	0.025	0.21	0.17	Allergic sensitization;	chr2:111685147	chr2:86861825~86922693:+
BRCA	trans	rs7554511	1	rs7554511	ENSG00000244144.1	RP11-757F18.3	5.52	4.27e-08	0.025	0.23	0.17	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200908434	chr3:112185480~112185998:-
BRCA	trans	rs332507	0.83	rs4678144	ENSG00000234253.1	RPL7P13	-5.52	4.27e-08	0.025	-0.21	-0.17	Plateletcrit;	chr3:124685552	chr2:49878623~49879363:+
BRCA	trans	rs7746199	0.736	rs13195636	ENSG00000228078.1	HLA-U	-5.52	4.28e-08	0.025	-0.45	-0.17	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27541714	chr6:29934101~29934286:+
BRCA	trans	rs9649213	0.574	rs9648908	ENSG00000225169.1	BRI3P1	5.52	4.28e-08	0.025	0.21	0.17	Prostate cancer (SNP x SNP interaction);	chr7:98315924	chr1:100213293~100213670:+
BRCA	trans	rs11638815	0.954	rs11635442	ENSG00000235370.6	DNM1P51	5.52	4.28e-08	0.025	0.21	0.17	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82659790	chr15:84398316~84411701:-
BRCA	trans	rs875971	0.502	rs2946580	ENSG00000234585.5	CCT6P3	-5.52	4.28e-08	0.025	-0.19	-0.17	Aortic root size;	chr7:66066855	chr7:65038354~65074713:+
BRCA	trans	rs875971	0.522	rs6960048	ENSG00000213640.3	EEF1DP4	-5.52	4.29e-08	0.0251	-0.21	-0.17	Aortic root size;	chr7:65943052	chr7:64862999~64864370:+
BRCA	trans	rs9841829	0.531	rs17023032	ENSG00000280063.1	RP11-295D4.3	-5.52	4.29e-08	0.0251	-0.12	-0.17	Alcohol consumption;	chr3:85573092	chr16:4346694~4348648:-
BRCA	trans	rs7943953	0.661	rs2177244	ENSG00000206897.1	SNORA9	5.52	4.29e-08	0.0251	0.2	0.17	Odorant perception (&beta-ionone);	chr11:59307067	chr12:123616708~123616840:+
BRCA	trans	rs9860340	0.73	rs1509779	ENSG00000259370.2	RP11-1069G10.1	5.52	4.29e-08	0.0251	0.2	0.17	Electroencephalographic traits in alcoholism;	chr3:87593312	chr15:62827675~62884034:-
BRCA	trans	rs9860340	0.73	rs57108523	ENSG00000259370.2	RP11-1069G10.1	5.52	4.29e-08	0.0251	0.2	0.17	Electroencephalographic traits in alcoholism;	chr3:87594505	chr15:62827675~62884034:-
BRCA	trans	rs1488665	0.623	rs75731897	ENSG00000249532.3	RP11-148B6.1	-5.52	4.3e-08	0.0251	-0.32	-0.17	Obesity-related traits;	chr11:45484247	chr4:112646476~112650051:-
BRCA	trans	rs9467711	0.79	rs13198716	ENSG00000220721.1	OR1F12	-5.52	4.3e-08	0.0251	-0.37	-0.17	Autism spectrum disorder or schizophrenia;	chr6:26581807	chr6:28073316~28074233:+
BRCA	trans	rs35306767	0.953	rs1539174	ENSG00000187984.11	ANKRD19P	5.52	4.3e-08	0.0251	0.2	0.17	Eosinophil percentage of granulocytes;	chr10:928930	chr9:92809388~92888693:+
BRCA	trans	rs853679	0.556	rs45509595	ENSG00000228078.1	HLA-U	-5.52	4.3e-08	0.0251	-0.46	-0.17	Depression;	chr6:27873148	chr6:29934101~29934286:+
BRCA	trans	rs11098499	0.874	rs9995277	ENSG00000276997.3	RP11-378J18.9	5.52	4.3e-08	0.0252	0.22	0.17	Corneal astigmatism;	chr4:119187448	chr1:222477252~222504622:-
BRCA	trans	rs166870	1	rs166870	ENSG00000207392.1	SNORA20	5.52	4.3e-08	0.0252	0.23	0.17	Disease-free survival in breast cancer;	chr15:79777420	chr6:159780250~159780381:-
BRCA	trans	rs902774	0.818	rs4919742	ENSG00000220378.3	KRT8P42	-5.52	4.3e-08	0.0252	-0.37	-0.17	Prostate cancer;	chr12:52879180	chr6:134296997~134298695:-
BRCA	trans	rs76228276	0.737	rs72672316	ENSG00000260318.1	COX6CP1	5.52	4.31e-08	0.0252	0.44	0.17	Childhood ear infection;	chr8:99192534	chr16:11903923~11904137:-
BRCA	trans	rs76228276	0.737	rs72674626	ENSG00000260318.1	COX6CP1	5.52	4.33e-08	0.0253	0.41	0.17	Childhood ear infection;	chr8:99455996	chr16:11903923~11904137:-
BRCA	trans	rs45509595	0.841	rs370155	ENSG00000253570.1	RNF5P1	5.52	4.34e-08	0.0253	0.37	0.17	Breast cancer;	chr6:27814253	chr8:38600661~38601200:-
BRCA	trans	rs1232027	0.7	rs73765838	ENSG00000188985.6	DHFRP1	-5.52	4.34e-08	0.0253	-0.21	-0.17	Huntington's disease progression;	chr5:80652003	chr18:26170726~26171284:-
BRCA	trans	rs1232027	0.7	rs73765839	ENSG00000188985.6	DHFRP1	-5.52	4.34e-08	0.0253	-0.21	-0.17	Huntington's disease progression;	chr5:80652004	chr18:26170726~26171284:-
BRCA	trans	rs1232027	0.7	rs1677633	ENSG00000188985.6	DHFRP1	-5.52	4.34e-08	0.0253	-0.22	-0.17	Huntington's disease progression;	chr5:80632405	chr18:26170726~26171284:-
BRCA	trans	rs6984305	0.541	rs17716118	ENSG00000253893.2	FAM85B	5.52	4.34e-08	0.0254	0.36	0.17	Liver enzyme levels (alkaline phosphatase);	chr8:9322624	chr8:8167819~8226614:-
BRCA	trans	rs2749592	0.611	rs176888	ENSG00000276997.3	RP11-378J18.9	5.52	4.35e-08	0.0254	0.21	0.17	Age-related hearing impairment (SNP x SNP interaction);	chr10:38117233	chr1:222477252~222504622:-
BRCA	trans	rs1232027	0.7	rs1382539	ENSG00000188985.6	DHFRP1	-5.52	4.35e-08	0.0254	-0.21	-0.17	Huntington's disease progression;	chr5:80656335	chr18:26170726~26171284:-
BRCA	trans	rs1232027	0.666	rs1643639	ENSG00000188985.6	DHFRP1	-5.52	4.35e-08	0.0254	-0.21	-0.17	Huntington's disease progression;	chr5:80656571	chr18:26170726~26171284:-
BRCA	trans	rs1232027	0.7	rs1650694	ENSG00000188985.6	DHFRP1	-5.52	4.35e-08	0.0254	-0.21	-0.17	Huntington's disease progression;	chr5:80656607	chr18:26170726~26171284:-
BRCA	trans	rs1232027	0.7	rs1677667	ENSG00000188985.6	DHFRP1	-5.52	4.35e-08	0.0254	-0.21	-0.17	Huntington's disease progression;	chr5:80656722	chr18:26170726~26171284:-
BRCA	trans	rs1232027	0.666	rs1650693	ENSG00000188985.6	DHFRP1	-5.52	4.35e-08	0.0254	-0.21	-0.17	Huntington's disease progression;	chr5:80657008	chr18:26170726~26171284:-
BRCA	trans	rs1232027	0.7	rs1382541	ENSG00000188985.6	DHFRP1	-5.52	4.35e-08	0.0254	-0.21	-0.17	Huntington's disease progression;	chr5:80657665	chr18:26170726~26171284:-
BRCA	trans	rs4929949	0.752	rs9300089	ENSG00000266891.1	RP11-692N5.2	5.52	4.36e-08	0.0254	0.2	0.17	Body mass index;	chr11:8563605	chr18:9734882~9735602:-
BRCA	trans	rs4925540	0.962	rs7418825	ENSG00000226121.2	AC009487.6	5.52	4.36e-08	0.0254	0.22	0.17	Response to taxane treatment (docetaxel);	chr1:247042439	chr2:161500885~161507705:-
BRCA	trans	rs7324845	1	rs4942487	ENSG00000243406.5	MRPS31P5	-5.52	4.37e-08	0.0255	-0.18	-0.17	Non-alcoholic fatty liver disease histology (other);	chr13:46135254	chr13:52167709~52194465:-
BRCA	trans	rs5006884	0.547	rs17356445	ENSG00000258626.2	COX7A2P1	5.52	4.37e-08	0.0255	0.21	0.17	Fetal hemoglobin levels;	chr11:5368920	chr14:67652300~67652614:-
BRCA	trans	rs1232027	0.656	rs28027	ENSG00000188985.6	DHFRP1	5.52	4.37e-08	0.0255	0.21	0.17	Huntington's disease progression;	chr5:80756984	chr18:26170726~26171284:-
BRCA	trans	rs11098499	0.909	rs73842633	ENSG00000276805.1	RP11-291L22.6	5.52	4.38e-08	0.0255	0.2	0.17	Corneal astigmatism;	chr4:119454309	chr10:38451030~38451785:+
BRCA	trans	rs11098499	0.863	rs6835635	ENSG00000276805.1	RP11-291L22.6	5.52	4.38e-08	0.0256	0.21	0.17	Corneal astigmatism;	chr4:119537712	chr10:38451030~38451785:+
BRCA	trans	rs7943953	0.661	rs2105792	ENSG00000206897.1	SNORA9	5.52	4.38e-08	0.0256	0.2	0.17	Odorant perception (&beta-ionone);	chr11:59324544	chr12:123616708~123616840:+
BRCA	trans	rs875971	0.965	rs6971509	ENSG00000164669.11	INTS4P1	5.52	4.39e-08	0.0256	0.21	0.17	Aortic root size;	chr7:66249983	chr7:65141225~65234216:+
BRCA	trans	rs875971	0.508	rs10950045	ENSG00000164669.11	INTS4P1	5.52	4.4e-08	0.0257	0.21	0.17	Aortic root size;	chr7:66601386	chr7:65141225~65234216:+
BRCA	trans	rs801193	0.839	rs6968619	ENSG00000164669.11	INTS4P1	5.52	4.4e-08	0.0257	0.21	0.17	Aortic root size;	chr7:66603880	chr7:65141225~65234216:+
BRCA	trans	rs801193	0.805	rs12532355	ENSG00000164669.11	INTS4P1	5.52	4.4e-08	0.0257	0.21	0.17	Aortic root size;	chr7:66605597	chr7:65141225~65234216:+
BRCA	trans	rs1039766	0.925	rs268850	ENSG00000213985.4	AC078899.1	5.51	4.41e-08	0.0257	0.24	0.17	Lung adenocarcinoma;Lung cancer;	chr2:65281152	chr19:20257720~20259418:+
BRCA	trans	rs9425766	0.64	rs2067079	ENSG00000213331.4	RP11-713C19.2	5.51	4.41e-08	0.0257	0.23	0.17	Life satisfaction;	chr1:173866073	chr4:187970273~187971284:+
BRCA	trans	rs853679	0.607	rs67340775	ENSG00000243753.4	HLA-L	-5.51	4.41e-08	0.0257	-0.43	-0.17	Depression;	chr6:28336607	chr6:30259584~30293014:+
BRCA	trans	rs35146811	0.735	rs1138417	ENSG00000228546.2	CTA-313A17.3	5.51	4.42e-08	0.0258	0.24	0.17	Coronary artery disease;	chr7:100209523	chr7:102337316~102339115:+
BRCA	trans	rs2055729	0.71	rs6981023	ENSG00000253893.2	FAM85B	5.51	4.43e-08	0.0258	0.23	0.17	Multiple myeloma (hyperdiploidy);	chr8:9889075	chr8:8167819~8226614:-
BRCA	trans	rs6601327	0.641	rs7014663	ENSG00000253893.2	FAM85B	5.51	4.44e-08	0.0259	0.21	0.17	Multiple myeloma (hyperdiploidy);	chr8:9729765	chr8:8167819~8226614:-
BRCA	trans	rs7113874	0.531	rs7934396	ENSG00000266891.1	RP11-692N5.2	-5.51	4.44e-08	0.0259	-0.2	-0.17	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8594085	chr18:9734882~9735602:-
BRCA	trans	rs9368481	0.524	rs12530345	ENSG00000216901.1	AL022393.7	-5.51	4.46e-08	0.026	-0.21	-0.17	Autism spectrum disorder or schizophrenia;	chr6:26916464	chr6:28176188~28176674:+
BRCA	trans	rs11082490	0.522	rs11082498	ENSG00000263624.1	RP11-45M22.3	5.51	4.47e-08	0.026	0.2	0.17	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);	chr18:45922762	chr17:17167946~17185554:-
BRCA	trans	rs1933488	1	rs2119992	ENSG00000180015.12	RP11-756P10.3	-5.51	4.48e-08	0.0261	-0.22	-0.17	Prostate cancer;	chr6:153128535	chr4:188738373~188739494:+
BRCA	trans	rs35306767	0.953	rs7908138	ENSG00000187984.11	ANKRD19P	5.51	4.48e-08	0.0261	0.21	0.17	Eosinophil percentage of granulocytes;	chr10:917038	chr9:92809388~92888693:+
BRCA	trans	rs2243480	0.711	rs2420172	ENSG00000164669.11	INTS4P1	-5.51	4.48e-08	0.0261	-0.33	-0.17	Diabetic kidney disease;	chr7:66170354	chr7:65141225~65234216:+
BRCA	trans	rs4929949	0.932	rs10840087	ENSG00000266891.1	RP11-692N5.2	-5.51	4.49e-08	0.0261	-0.2	-0.17	Body mass index;	chr11:8594708	chr18:9734882~9735602:-
BRCA	trans	rs7113874	0.55	rs11042002	ENSG00000266891.1	RP11-692N5.2	-5.51	4.49e-08	0.0261	-0.2	-0.17	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8595099	chr18:9734882~9735602:-
BRCA	trans	rs11098499	0.954	rs1480931	ENSG00000253326.2	RP11-261C10.7	5.51	4.49e-08	0.0261	0.24	0.17	Corneal astigmatism;	chr4:119474654	chr1:243054861~243056394:-
BRCA	trans	rs6121246	0.609	rs2376998	ENSG00000279352.1	RP11-411B10.7	5.51	4.49e-08	0.0262	0.24	0.17	Mean corpuscular hemoglobin;	chr20:31752860	chr18:14010054~14010917:+
BRCA	trans	rs6866344	0.57	rs1071882	ENSG00000267383.5	CTC-260E6.6	-5.51	4.49e-08	0.0262	-0.23	-0.17	Neutrophil percentage of white cells;	chr5:178709039	chr19:20125377~20321305:-
BRCA	trans	rs1933488	0.931	rs3870364	ENSG00000180015.12	RP11-756P10.3	-5.51	4.5e-08	0.0262	-0.22	-0.17	Prostate cancer;	chr6:153105544	chr4:188738373~188739494:+
BRCA	trans	rs853679	0.599	rs156743	ENSG00000228078.1	HLA-U	-5.51	4.5e-08	0.0262	-0.35	-0.17	Depression;	chr6:27999311	chr6:29934101~29934286:+
BRCA	trans	rs5006884	0.507	rs12801179	ENSG00000258626.2	COX7A2P1	5.51	4.51e-08	0.0262	0.21	0.17	Fetal hemoglobin levels;	chr11:5361473	chr14:67652300~67652614:-
BRCA	trans	rs9733	0.593	rs10888384	ENSG00000180764.13	PIPSL	5.51	4.51e-08	0.0262	0.21	0.17	Tonsillectomy;	chr1:150601780	chr10:93958191~93961540:-
BRCA	trans	rs10716881	1	rs10716881	ENSG00000257210.1	NACAP3	-5.51	4.51e-08	0.0263	-0.2	-0.17	High light scatter reticulocyte count;	chr12:56644387	chr12:93124063~93124543:-
BRCA	trans	rs10838687	0.736	rs2279238	ENSG00000134612.10	FOLH1B	5.51	4.51e-08	0.0263	0.26	0.17	Proinsulin levels;	chr11:47260473	chr11:89639227~89698718:+
BRCA	trans	rs1459104	1	rs12577585	ENSG00000134612.10	FOLH1B	-5.51	4.52e-08	0.0263	-0.34	-0.17	Body mass index;	chr11:55535127	chr11:89639227~89698718:+
BRCA	trans	rs1864585	0.806	rs17778223	ENSG00000253930.1	RP11-1149O23.2	5.51	4.53e-08	0.0264	0.23	0.17	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr8:10872182	chr8:23189279~23190675:+
BRCA	trans	rs7746199	0.736	rs34105070	ENSG00000228078.1	HLA-U	-5.51	4.53e-08	0.0264	-0.45	-0.17	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27593026	chr6:29934101~29934286:+
BRCA	trans	rs1933488	0.965	rs13215402	ENSG00000180015.12	RP11-756P10.3	-5.51	4.54e-08	0.0264	-0.22	-0.17	Prostate cancer;	chr6:153126415	chr4:188738373~188739494:+
BRCA	trans	rs11098499	0.644	rs17517414	ENSG00000276997.3	RP11-378J18.9	5.51	4.54e-08	0.0264	0.19	0.17	Corneal astigmatism;	chr4:119340946	chr1:222477252~222504622:-
BRCA	trans	rs9368481	0.569	rs10946868	ENSG00000216901.1	AL022393.7	-5.51	4.56e-08	0.0265	-0.21	-0.17	Autism spectrum disorder or schizophrenia;	chr6:26920151	chr6:28176188~28176674:+
BRCA	trans	rs11098499	0.661	rs10015965	ENSG00000276997.3	RP11-378J18.9	5.51	4.56e-08	0.0265	0.19	0.17	Corneal astigmatism;	chr4:119347082	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.532	rs4504231	ENSG00000276997.3	RP11-378J18.9	5.51	4.57e-08	0.0266	0.2	0.17	Corneal astigmatism;	chr4:119665736	chr1:222477252~222504622:-
BRCA	trans	rs453301	0.624	rs330049	ENSG00000270154.1	RP11-419I17.1	5.51	4.57e-08	0.0266	0.18	0.17	Joint mobility (Beighton score);	chr8:9229789	chr8:12476462~12477122:+
BRCA	trans	rs7746199	0.736	rs34573979	ENSG00000281831.1	HCP5B	5.51	4.57e-08	0.0266	0.43	0.17	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27512747	chr6:29871895~29873783:-
BRCA	trans	rs1568889	1	rs12797155	ENSG00000174912.7	METTL15P1	5.51	4.57e-08	0.0266	0.18	0.17	Bipolar disorder;	chr11:28269319	chr3:156713884~156714928:-
BRCA	trans	rs1459104	0.778	rs1504674	ENSG00000134612.10	FOLH1B	-5.51	4.58e-08	0.0266	-0.34	-0.17	Body mass index;	chr11:55716745	chr11:89639227~89698718:+
BRCA	trans	rs13217239	0.572	rs9379958	ENSG00000216901.1	AL022393.7	5.51	4.58e-08	0.0266	0.2	0.17	Schizophrenia;	chr6:27098384	chr6:28176188~28176674:+
BRCA	trans	rs13217239	0.646	rs9393789	ENSG00000216901.1	AL022393.7	5.51	4.58e-08	0.0266	0.2	0.17	Schizophrenia;	chr6:27099249	chr6:28176188~28176674:+
BRCA	trans	rs7662987	0.517	rs1154406	ENSG00000233859.2	ADH5P4	-5.51	4.59e-08	0.0267	-0.25	-0.17	Smoking initiation;	chr4:99087343	chr6:65836930~65838039:-
BRCA	trans	rs950037	0.935	rs6677967	ENSG00000231916.1	AC006033.22	5.51	4.59e-08	0.0267	0.19	0.17	Coronary artery disease;	chr1:88851889	chr7:38311383~38311808:+
BRCA	trans	rs7113874	0.569	rs4418812	ENSG00000266891.1	RP11-692N5.2	-5.51	4.6e-08	0.0267	-0.2	-0.17	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8590453	chr18:9734882~9735602:-
BRCA	trans	rs6954796	1	rs1019248	ENSG00000278035.1	RP11-234K24.6	-5.51	4.6e-08	0.0267	-0.29	-0.17	Non-word repetition;	chr7:20046372	chr20:36233851~36234297:+
BRCA	trans	rs17711722	0.701	rs4467826	ENSG00000213640.3	EEF1DP4	-5.51	4.6e-08	0.0267	-0.21	-0.17	Calcium levels;	chr7:65903721	chr7:64862999~64864370:+
BRCA	trans	rs6142102	0.625	rs6141436	ENSG00000280327.1	LA16c-313F4.1	-5.51	4.6e-08	0.0268	-0.17	-0.17	Skin pigmentation;	chr20:33966765	chr16:1576716~1578371:-
BRCA	trans	rs2243480	1	rs6958289	ENSG00000164669.11	INTS4P1	-5.51	4.61e-08	0.0268	-0.33	-0.17	Diabetic kidney disease;	chr7:66192124	chr7:65141225~65234216:+
BRCA	trans	rs319204	0.959	rs319194	ENSG00000226498.2	RP11-182B22.2	5.51	4.62e-08	0.0268	0.19	0.17	Schizophrenia;	chr5:146889154	chr1:236819634~236820518:+
BRCA	trans	rs332507	0.83	rs3772786	ENSG00000234253.1	RPL7P13	5.51	4.62e-08	0.0268	0.22	0.17	Plateletcrit;	chr3:124676403	chr2:49878623~49879363:+
BRCA	trans	rs1232027	0.666	rs1643634	ENSG00000188985.6	DHFRP1	-5.51	4.62e-08	0.0268	-0.21	-0.17	Huntington's disease progression;	chr5:80632080	chr18:26170726~26171284:-
BRCA	trans	rs7113874	0.569	rs10769916	ENSG00000266891.1	RP11-692N5.2	5.51	4.62e-08	0.0268	0.2	0.17	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8576667	chr18:9734882~9735602:-
BRCA	trans	rs4427176	0.507	rs13273033	ENSG00000255046.1	RP11-297N6.4	-5.51	4.62e-08	0.0269	-0.21	-0.17	Mosquito bite size;	chr8:9683183	chr8:11797928~11802568:-
BRCA	trans	rs867371	0.929	rs1045508	ENSG00000259295.5	CSPG4P12	5.51	4.62e-08	0.0269	0.21	0.17	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82157565	chr15:85191438~85213905:+
BRCA	trans	rs11782517	0.924	rs35474349	ENSG00000253893.2	FAM85B	-5.51	4.63e-08	0.0269	-0.23	-0.17	Nose size;	chr8:10252144	chr8:8167819~8226614:-
BRCA	trans	rs7113874	0.569	rs9300093	ENSG00000266891.1	RP11-692N5.2	5.51	4.63e-08	0.0269	0.2	0.17	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8569278	chr18:9734882~9735602:-
BRCA	trans	rs6142102	0.625	rs1883706	ENSG00000280327.1	LA16c-313F4.1	-5.51	4.64e-08	0.0269	-0.17	-0.17	Skin pigmentation;	chr20:33965071	chr16:1576716~1578371:-
BRCA	trans	rs6142102	0.625	rs1883705	ENSG00000280327.1	LA16c-313F4.1	-5.51	4.64e-08	0.0269	-0.17	-0.17	Skin pigmentation;	chr20:33965072	chr16:1576716~1578371:-
BRCA	trans	rs2117029	0.523	rs12227296	ENSG00000214391.3	TUBAP2	5.51	4.64e-08	0.027	0.16	0.17	Intelligence (multi-trait analysis);	chr12:49136712	chr11:90282560~90284172:+
BRCA	trans	rs704840	0.729	rs2840317	ENSG00000251484.3	RP5-1065J22.4	-5.5	4.65e-08	0.027	-0.23	-0.17	Systemic lupus erythematosus;Systemic lupus erythematosus and Systemic sclerosis;	chr1:173257359	chr1:109103535~109104766:-
BRCA	trans	rs7746199	0.736	rs10484399	ENSG00000243753.4	HLA-L	-5.5	4.65e-08	0.027	-0.42	-0.17	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27566749	chr6:30259584~30293014:+
BRCA	trans	rs660899	0.894	rs11805774	ENSG00000231007.5	CDC20P1	5.5	4.65e-08	0.027	0.22	0.17	Hypertension risk in short sleep duration;	chr1:43687044	chr9:87011652~87013151:+
BRCA	trans	rs660899	0.894	rs17401357	ENSG00000231007.5	CDC20P1	5.5	4.65e-08	0.027	0.22	0.17	Hypertension risk in short sleep duration;	chr1:43687948	chr9:87011652~87013151:+
BRCA	trans	rs1232027	0.7	rs1643650	ENSG00000188985.6	DHFRP1	-5.5	4.65e-08	0.027	-0.21	-0.17	Huntington's disease progression;	chr5:80644324	chr18:26170726~26171284:-
BRCA	trans	rs6142102	0.625	rs4012234	ENSG00000280327.1	LA16c-313F4.1	-5.5	4.66e-08	0.0271	-0.17	-0.17	Skin pigmentation;	chr20:33965241	chr16:1576716~1578371:-
BRCA	trans	rs6142102	0.649	rs4911382	ENSG00000280327.1	LA16c-313F4.1	-5.5	4.66e-08	0.0271	-0.17	-0.17	Skin pigmentation;	chr20:33965289	chr16:1576716~1578371:-
BRCA	trans	rs7570469	0.92	rs4458235	ENSG00000276390.1	RP1-197B17.5	-5.5	4.67e-08	0.0271	-0.21	-0.17	Response to antipsychotic treatment;	chr2:79483399	chr12:47699401~47699917:-
BRCA	trans	rs11048434	0.626	rs1805736	ENSG00000179899.8	PHC1P1	-5.5	4.67e-08	0.0271	-0.16	-0.17	Sjögren's syndrome;	chr12:8932335	chr12:55411727~55414787:-
BRCA	trans	rs4713118	0.826	rs2893929	ENSG00000204709.4	LINC01556	5.5	4.68e-08	0.0271	0.25	0.17	Parkinson's disease;	chr6:27770953	chr6:28943877~28944537:+
BRCA	trans	rs4713118	0.666	rs4140646	ENSG00000204709.4	LINC01556	5.5	4.68e-08	0.0271	0.25	0.17	Parkinson's disease;	chr6:27771022	chr6:28943877~28944537:+
BRCA	trans	rs4713118	0.666	rs2893930	ENSG00000204709.4	LINC01556	5.5	4.68e-08	0.0271	0.25	0.17	Parkinson's disease;	chr6:27771027	chr6:28943877~28944537:+
BRCA	trans	rs7829975	0.624	rs7823056	ENSG00000255046.1	RP11-297N6.4	-5.5	4.68e-08	0.0272	-0.19	-0.17	Mood instability;	chr8:8525195	chr8:11797928~11802568:-
BRCA	trans	rs9852859	0.634	rs9858244	ENSG00000228223.2	HCG11	5.5	4.68e-08	0.0272	0.23	0.17	Body mass index;	chr3:85738249	chr6:26523450~26526579:+
BRCA	trans	rs7570469	0.762	rs12478921	ENSG00000276390.1	RP1-197B17.5	5.5	4.68e-08	0.0272	0.23	0.17	Response to antipsychotic treatment;	chr2:79424133	chr12:47699401~47699917:-
BRCA	trans	rs2243480	1	rs1546059	ENSG00000164669.11	INTS4P1	-5.5	4.68e-08	0.0272	-0.33	-0.17	Diabetic kidney disease;	chr7:66189722	chr7:65141225~65234216:+
BRCA	trans	rs2243480	1	rs2420170	ENSG00000164669.11	INTS4P1	-5.5	4.68e-08	0.0272	-0.33	-0.17	Diabetic kidney disease;	chr7:66191066	chr7:65141225~65234216:+
BRCA	trans	rs7746199	0.736	rs34573979	ENSG00000228078.1	HLA-U	-5.5	4.68e-08	0.0272	-0.45	-0.17	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27512747	chr6:29934101~29934286:+
BRCA	trans	rs2243480	0.615	rs34363376	ENSG00000164669.11	INTS4P1	5.5	4.7e-08	0.0272	0.33	0.17	Diabetic kidney disease;	chr7:66474549	chr7:65141225~65234216:+
BRCA	trans	rs641862	1	rs641862	ENSG00000237082.1	COX5BP6	5.5	4.7e-08	0.0273	0.32	0.17	Obesity-related traits;	chr13:110137885	chr13:100623875~100624429:-
BRCA	trans	rs6424115	0.618	rs10917420	ENSG00000228217.1	AL390877.1	-5.5	4.71e-08	0.0273	-0.2	-0.17	Immature fraction of reticulocytes;	chr1:23736497	chr1:117778087~117778506:-
BRCA	trans	rs11098499	0.865	rs11098513	ENSG00000276805.1	RP11-291L22.6	5.5	4.71e-08	0.0273	0.2	0.17	Corneal astigmatism;	chr4:119394920	chr10:38451030~38451785:+
BRCA	trans	rs4879656	0.966	rs10971361	ENSG00000215007.3	DNAJA1P3	5.5	4.71e-08	0.0273	0.21	0.17	Menopause (age at onset);	chr9:33042564	chrX:107351650~107352843:-
BRCA	trans	rs7520050	0.933	rs12045165	ENSG00000177335.9	C8orf31	-5.5	4.71e-08	0.0273	-0.21	-0.17	Reticulocyte count;Red blood cell count;	chr1:45790350	chr8:143039209~143059942:+
BRCA	trans	rs1039766	1	rs1039766	ENSG00000213985.4	AC078899.1	-5.5	4.73e-08	0.0274	-0.24	-0.17	Lung adenocarcinoma;Lung cancer;	chr2:65293011	chr19:20257720~20259418:+
BRCA	trans	rs6601327	0.54	rs12542912	ENSG00000253893.2	FAM85B	5.5	4.73e-08	0.0274	0.21	0.17	Multiple myeloma (hyperdiploidy);	chr8:9727686	chr8:8167819~8226614:-
BRCA	trans	rs3934285	0.559	rs12116936	ENSG00000232383.1	AC010677.5	5.5	4.74e-08	0.0275	0.28	0.17	Obesity-related traits;	chr1:104095032	chr7:26276195~26276606:+
BRCA	trans	rs11098499	0.505	rs75122014	ENSG00000276805.1	RP11-291L22.6	5.5	4.75e-08	0.0275	0.2	0.17	Corneal astigmatism;	chr4:119441271	chr10:38451030~38451785:+
BRCA	trans	rs1933488	0.931	rs6934121	ENSG00000180015.12	RP11-756P10.3	-5.5	4.75e-08	0.0275	-0.22	-0.17	Prostate cancer;	chr6:153127117	chr4:188738373~188739494:+
BRCA	trans	rs11098499	0.644	rs3986377	ENSG00000120555.12	SEPT7P9	5.5	4.77e-08	0.0276	0.2	0.17	Corneal astigmatism;	chr4:119339115	chr10:38383069~38402916:-
BRCA	trans	rs10028773	0.556	rs4473640	ENSG00000120555.12	SEPT7P9	5.5	4.77e-08	0.0276	0.2	0.17	Educational attainment;	chr4:119339282	chr10:38383069~38402916:-
BRCA	trans	rs6934970	0.932	rs3844152	ENSG00000267560.1	RP11-173A16.1	-5.5	4.77e-08	0.0277	-0.21	-0.17	Bipolar disorder (body mass index interaction);	chr6:112807007	chr18:62300036~62300998:-
BRCA	trans	rs875971	0.508	rs10242423	ENSG00000164669.11	INTS4P1	5.5	4.77e-08	0.0277	0.21	0.17	Aortic root size;	chr7:66594188	chr7:65141225~65234216:+
BRCA	trans	rs875971	0.508	rs10253883	ENSG00000164669.11	INTS4P1	5.5	4.77e-08	0.0277	0.21	0.17	Aortic root size;	chr7:66596151	chr7:65141225~65234216:+
BRCA	trans	rs9860340	0.73	rs4643731	ENSG00000259370.2	RP11-1069G10.1	5.5	4.78e-08	0.0277	0.2	0.17	Electroencephalographic traits in alcoholism;	chr3:87602101	chr15:62827675~62884034:-
BRCA	trans	rs7943953	0.661	rs4360718	ENSG00000206897.1	SNORA9	5.5	4.78e-08	0.0277	0.2	0.17	Odorant perception (&beta-ionone);	chr11:59307364	chr12:123616708~123616840:+
BRCA	trans	rs9368481	0.569	rs6907403	ENSG00000216901.1	AL022393.7	-5.5	4.79e-08	0.0277	-0.21	-0.17	Autism spectrum disorder or schizophrenia;	chr6:26909518	chr6:28176188~28176674:+
BRCA	trans	rs9368481	0.502	rs3933232	ENSG00000216901.1	AL022393.7	-5.5	4.79e-08	0.0277	-0.21	-0.17	Autism spectrum disorder or schizophrenia;	chr6:26909667	chr6:28176188~28176674:+
BRCA	trans	rs282544	1	rs32396	ENSG00000231752.4	EMBP1	5.5	4.79e-08	0.0278	0.22	0.17	Myopia (pathological);	chr5:50810605	chr1:121519112~121571892:+
BRCA	trans	rs17507216	1	rs17158413	ENSG00000235370.6	DNM1P51	-5.5	4.8e-08	0.0278	-0.22	-0.17	Excessive daytime sleepiness;	chr15:82566658	chr15:84398316~84411701:-
BRCA	trans	rs6601327	0.606	rs13268319	ENSG00000253893.2	FAM85B	5.5	4.8e-08	0.0278	0.21	0.17	Multiple myeloma (hyperdiploidy);	chr8:9721739	chr8:8167819~8226614:-
BRCA	trans	rs10992471	0.603	rs11794346	ENSG00000256650.1	RERG-IT1	5.5	4.8e-08	0.0278	0.15	0.17	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr9:92485006	chr12:15112363~15114698:-
BRCA	trans	rs76228276	0.737	rs72672349	ENSG00000260318.1	COX6CP1	5.5	4.81e-08	0.0278	0.46	0.17	Childhood ear infection;	chr8:99288629	chr16:11903923~11904137:-
BRCA	trans	rs741301	0.536	rs6462712	ENSG00000272192.1	CTD-2532N20.1	5.5	4.82e-08	0.0279	0.2	0.17	Type 2 diabetes nephropathy;	chr7:36826338	chr8:65842752~65843331:+
BRCA	trans	rs4713118	0.868	rs760587	ENSG00000204709.4	LINC01556	5.5	4.83e-08	0.028	0.25	0.17	Parkinson's disease;	chr6:27772521	chr6:28943877~28944537:+
BRCA	trans	rs11098499	0.954	rs10031483	ENSG00000253326.2	RP11-261C10.7	5.5	4.84e-08	0.028	0.24	0.17	Corneal astigmatism;	chr4:119501481	chr1:243054861~243056394:-
BRCA	trans	rs11098499	0.954	rs10031665	ENSG00000253326.2	RP11-261C10.7	5.5	4.84e-08	0.028	0.24	0.17	Corneal astigmatism;	chr4:119501697	chr1:243054861~243056394:-
BRCA	trans	rs11098499	0.954	rs3733523	ENSG00000253326.2	RP11-261C10.7	5.5	4.84e-08	0.028	0.24	0.17	Corneal astigmatism;	chr4:119502564	chr1:243054861~243056394:-
BRCA	trans	rs9860340	0.687	rs6806250	ENSG00000259370.2	RP11-1069G10.1	5.5	4.85e-08	0.028	0.2	0.17	Electroencephalographic traits in alcoholism;	chr3:87602801	chr15:62827675~62884034:-
BRCA	trans	rs11098499	0.863	rs1010739	ENSG00000253326.2	RP11-261C10.7	5.5	4.85e-08	0.0281	0.24	0.17	Corneal astigmatism;	chr4:119542316	chr1:243054861~243056394:-
BRCA	trans	rs9393777	0.623	rs9348719	ENSG00000253570.1	RNF5P1	5.5	4.85e-08	0.0281	0.31	0.17	Intelligence (multi-trait analysis);	chr6:26469804	chr8:38600661~38601200:-
BRCA	trans	rs9329221	0.655	rs656319	ENSG00000154316.13	TDH	5.5	4.86e-08	0.0281	0.21	0.17	Neuroticism;	chr8:9956901	chr8:11339637~11368452:+
BRCA	trans	rs7647973	1	rs7619789	ENSG00000235912.1	RP1-159A19.3	-5.5	4.86e-08	0.0281	-0.21	-0.17	Menarche (age at onset);	chr3:49438830	chr1:27649419~27649610:+
BRCA	trans	rs7647973	0.922	rs57273516	ENSG00000235912.1	RP1-159A19.3	-5.5	4.86e-08	0.0281	-0.21	-0.17	Menarche (age at onset);	chr3:49445641	chr1:27649419~27649610:+
BRCA	trans	rs12586478	0.519	rs4143946	ENSG00000266957.1	RP11-49K24.4	5.5	4.87e-08	0.0282	0.19	0.17	Post bronchodilator FEV1;	chr14:86323635	chr18:47077361~47091280:-
BRCA	trans	rs17485419	0.516	rs62805862	ENSG00000215105.4	TTC3P1	5.5	4.88e-08	0.0282	0.22	0.17	Monocyte count;	chr8:78357383	chrX:75740831~75746911:-
BRCA	trans	rs6142102	0.625	rs4243974	ENSG00000280327.1	LA16c-313F4.1	-5.5	4.88e-08	0.0282	-0.17	-0.17	Skin pigmentation;	chr20:33960062	chr16:1576716~1578371:-
BRCA	trans	rs6142102	0.625	rs6142062	ENSG00000280327.1	LA16c-313F4.1	-5.5	4.88e-08	0.0282	-0.17	-0.17	Skin pigmentation;	chr20:33960706	chr16:1576716~1578371:-
BRCA	trans	rs6142102	0.625	rs6141432	ENSG00000280327.1	LA16c-313F4.1	-5.5	4.88e-08	0.0282	-0.17	-0.17	Skin pigmentation;	chr20:33960791	chr16:1576716~1578371:-
BRCA	trans	rs6142102	0.602	rs6141433	ENSG00000280327.1	LA16c-313F4.1	-5.5	4.88e-08	0.0282	-0.17	-0.17	Skin pigmentation;	chr20:33961056	chr16:1576716~1578371:-
BRCA	trans	rs853679	0.607	rs13211507	ENSG00000204338.7	CYP21A1P	-5.5	4.88e-08	0.0282	-0.37	-0.17	Depression;	chr6:28289600	chr6:32005636~32008451:+
BRCA	trans	rs853679	0.607	rs34691223	ENSG00000204338.7	CYP21A1P	-5.5	4.88e-08	0.0282	-0.37	-0.17	Depression;	chr6:28290431	chr6:32005636~32008451:+
BRCA	trans	rs3785888	0.569	rs1838105	ENSG00000266644.1	RP11-927P21.2	5.5	4.88e-08	0.0282	0.17	0.17	Cleft lip with or without cleft palate;	chr17:46931569	chr17:64899766~64900716:+
BRCA	trans	rs7943953	0.661	rs7105556	ENSG00000206897.1	SNORA9	5.5	4.89e-08	0.0283	0.2	0.17	Odorant perception (&beta-ionone);	chr11:59335028	chr12:123616708~123616840:+
BRCA	trans	rs11098499	0.954	rs13145352	ENSG00000276805.1	RP11-291L22.6	-5.49	4.91e-08	0.0284	-0.2	-0.17	Corneal astigmatism;	chr4:119488808	chr10:38451030~38451785:+
BRCA	trans	rs1232027	0.7	rs1643649	ENSG00000188985.6	DHFRP1	-5.49	4.92e-08	0.0284	-0.21	-0.17	Huntington's disease progression;	chr5:80643630	chr18:26170726~26171284:-
BRCA	trans	rs6934970	1	rs3911395	ENSG00000267560.1	RP11-173A16.1	-5.49	4.92e-08	0.0284	-0.21	-0.17	Bipolar disorder (body mass index interaction);	chr6:112811534	chr18:62300036~62300998:-
BRCA	trans	rs7826222	0.786	rs613080	ENSG00000253893.2	FAM85B	5.49	4.92e-08	0.0284	0.3	0.17	Adiposity;	chr8:10021941	chr8:8167819~8226614:-
BRCA	trans	rs6831352	0.918	rs1042365	ENSG00000233859.2	ADH5P4	5.49	4.92e-08	0.0284	0.24	0.17	Alcohol dependence;	chr4:99124349	chr6:65836930~65838039:-
BRCA	trans	rs76228276	0.737	rs16897326	ENSG00000260318.1	COX6CP1	-5.49	4.93e-08	0.0285	-0.42	-0.17	Childhood ear infection;	chr8:99388554	chr16:11903923~11904137:-
BRCA	trans	rs9393777	0.623	rs9366658	ENSG00000253570.1	RNF5P1	5.49	4.94e-08	0.0285	0.31	0.17	Intelligence (multi-trait analysis);	chr6:26469638	chr8:38600661~38601200:-
BRCA	trans	rs9393777	0.623	rs9358944	ENSG00000253570.1	RNF5P1	5.49	4.94e-08	0.0285	0.31	0.17	Intelligence (multi-trait analysis);	chr6:26469647	chr8:38600661~38601200:-
BRCA	trans	rs6795744	1	rs6795744	ENSG00000252147.1	RNY3P16	-5.49	4.95e-08	0.0286	-0.26	-0.17	Glomerular filtration rate (creatinine);	chr3:13865353	chrX:119456558~119456658:+
BRCA	trans	rs9860340	0.73	rs12108006	ENSG00000259370.2	RP11-1069G10.1	5.49	4.95e-08	0.0286	0.2	0.17	Electroencephalographic traits in alcoholism;	chr3:87587438	chr15:62827675~62884034:-
BRCA	trans	rs902774	0.818	rs73108429	ENSG00000220378.3	KRT8P42	-5.49	4.96e-08	0.0286	-0.36	-0.17	Prostate cancer;	chr12:52877887	chr6:134296997~134298695:-
BRCA	trans	rs7113874	0.524	rs10769922	ENSG00000266891.1	RP11-692N5.2	-5.49	4.97e-08	0.0287	-0.19	-0.17	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8600205	chr18:9734882~9735602:-
BRCA	trans	rs9858542	0.953	rs7648841	ENSG00000215326.3	GPX1P2	5.49	4.98e-08	0.0287	0.2	0.17	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49379392	chr21:27143344~27143949:-
BRCA	trans	rs9858542	0.953	rs6446264	ENSG00000215326.3	GPX1P2	5.49	4.98e-08	0.0287	0.2	0.17	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49379810	chr21:27143344~27143949:-
BRCA	trans	rs11098499	0.863	rs1155576	ENSG00000253326.2	RP11-261C10.7	5.49	4.99e-08	0.0288	0.23	0.17	Corneal astigmatism;	chr4:119529004	chr1:243054861~243056394:-
BRCA	trans	rs4720118	1	rs975791	ENSG00000213492.2	NT5C3AP1	-5.49	5e-08	0.0289	-0.22	-0.17	Leprosy;	chr7:33419144	chr4:117574512~117576174:-
BRCA	trans	rs801193	0.967	rs2420827	ENSG00000164669.11	INTS4P1	5.49	5.02e-08	0.0289	0.21	0.17	Aortic root size;	chr7:66682114	chr7:65141225~65234216:+
BRCA	trans	rs10128264	0.841	rs2790766	ENSG00000232527.6	RP11-14N7.2	-5.49	5.03e-08	0.029	-0.2	-0.17	Response to methotrexate in juvenile idiopathic arthritis;	chr10:79200859	chr1:144227030~144250288:-
BRCA	trans	rs3740713	1	rs75740864	ENSG00000213574.2	LDHAP5	5.49	5.03e-08	0.029	0.29	0.17	Amyotrophic lateral sclerosis (sporadic);	chr11:18449142	chr10:118932674~118933295:-
BRCA	trans	rs2950393	0.804	rs11171951	ENSG00000257210.1	NACAP3	5.49	5.04e-08	0.029	0.2	0.17	Platelet distribution width;	chr12:56718853	chr12:93124063~93124543:-
BRCA	trans	rs801193	0.844	rs732465	ENSG00000164669.11	INTS4P1	-5.49	5.04e-08	0.0291	-0.21	-0.17	Aortic root size;	chr7:66533463	chr7:65141225~65234216:+
BRCA	trans	rs17711722	0.701	rs781143	ENSG00000213640.3	EEF1DP4	-5.49	5.04e-08	0.0291	-0.21	-0.17	Calcium levels;	chr7:65974892	chr7:64862999~64864370:+
BRCA	trans	rs9393813	0.626	rs2393926	ENSG00000242375.1	RP11-498P14.3	-5.49	5.04e-08	0.0291	-0.23	-0.17	Bipolar disorder;	chr6:27352965	chr9:97195351~97197687:-
BRCA	trans	rs853679	0.546	rs35819751	ENSG00000204709.4	LINC01556	5.49	5.05e-08	0.0291	0.45	0.17	Depression;	chr6:27842791	chr6:28943877~28944537:+
BRCA	trans	rs6498482	1	rs6498482	ENSG00000270157.1	RP5-894A10.6	5.49	5.05e-08	0.0291	0.18	0.17	Egg allergy;	chr16:13893862	chr7:141662922~141663846:-
BRCA	trans	rs6489882	0.867	rs7298184	ENSG00000250770.2	RP5-1063M23.1	5.49	5.05e-08	0.0291	0.22	0.17	Chronic lymphocytic leukemia;	chr12:112930444	chr12:3296202~3300224:-
BRCA	trans	rs7568458	0.591	rs55971080	ENSG00000223886.3	RP11-251G23.2	5.49	5.05e-08	0.0291	0.19	0.17	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr2:85585623	chr7:105530209~105530671:+
BRCA	trans	rs11098499	0.863	rs6833334	ENSG00000253326.2	RP11-261C10.7	5.49	5.05e-08	0.0291	0.24	0.17	Corneal astigmatism;	chr4:119583072	chr1:243054861~243056394:-
BRCA	trans	rs11098499	0.908	rs9995234	ENSG00000276805.1	RP11-291L22.6	5.49	5.06e-08	0.0292	0.21	0.17	Corneal astigmatism;	chr4:119400672	chr10:38451030~38451785:+
BRCA	trans	rs4713118	0.868	rs7756968	ENSG00000204709.4	LINC01556	5.49	5.06e-08	0.0292	0.25	0.17	Parkinson's disease;	chr6:27767175	chr6:28943877~28944537:+
BRCA	trans	rs9733	0.536	rs10888385	ENSG00000180764.13	PIPSL	5.49	5.07e-08	0.0292	0.21	0.17	Tonsillectomy;	chr1:150601826	chr10:93958191~93961540:-
BRCA	trans	rs7829975	0.533	rs13274028	ENSG00000270154.1	RP11-419I17.1	5.49	5.07e-08	0.0292	0.19	0.17	Mood instability;	chr8:8871683	chr8:12476462~12477122:+
BRCA	trans	rs11098499	0.82	rs11737395	ENSG00000253326.2	RP11-261C10.7	5.49	5.07e-08	0.0292	0.24	0.17	Corneal astigmatism;	chr4:119599549	chr1:243054861~243056394:-
BRCA	trans	rs489286	0.823	rs17313034	ENSG00000224090.1	AC097468.4	5.49	5.07e-08	0.0292	0.21	0.17	Blood protein levels;	chr1:160744058	chr2:219002215~219015721:+
BRCA	trans	rs7570469	0.582	rs1430636	ENSG00000276390.1	RP1-197B17.5	-5.49	5.08e-08	0.0293	-0.22	-0.17	Response to antipsychotic treatment;	chr2:79475187	chr12:47699401~47699917:-
BRCA	trans	rs13326165	0.585	rs56352611	ENSG00000211639.2	IGLV4-60	-5.49	5.08e-08	0.0293	-0.24	-0.17	HDL cholesterol levels;HDL cholesterol;	chr3:52304574	chr22:22162199~22162681:+
BRCA	trans	rs332507	0.83	rs1846892	ENSG00000234253.1	RPL7P13	5.49	5.08e-08	0.0293	0.21	0.17	Plateletcrit;	chr3:124680446	chr2:49878623~49879363:+
BRCA	trans	rs332507	0.83	rs879535	ENSG00000234253.1	RPL7P13	5.49	5.08e-08	0.0293	0.21	0.17	Plateletcrit;	chr3:124681260	chr2:49878623~49879363:+
BRCA	trans	rs11098499	0.754	rs1849457	ENSG00000276997.3	RP11-378J18.9	5.49	5.09e-08	0.0293	0.2	0.17	Corneal astigmatism;	chr4:119333200	chr1:222477252~222504622:-
BRCA	trans	rs16975050	0.793	rs16974654	ENSG00000235576.1	AC092580.4	-5.49	5.1e-08	0.0293	-0.23	-0.17	Amyotrophic lateral sclerosis (sporadic);	chr18:41417411	chr2:7725801~7730705:+
BRCA	trans	rs6831352	0.819	rs1230155	ENSG00000228407.2	RP4-800M22.1	-5.49	5.1e-08	0.0294	-0.23	-0.17	Alcohol dependence;	chr4:99068108	chr1:52160261~52160600:-
BRCA	trans	rs228614	0.51	rs223472	ENSG00000211782.2	TRAV8-1	-5.49	5.1e-08	0.0294	-0.13	-0.17	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102774327	chr14:21797287~21797886:+
BRCA	trans	rs9368481	0.729	rs10946881	ENSG00000242375.1	RP11-498P14.3	5.49	5.12e-08	0.0295	0.25	0.17	Autism spectrum disorder or schizophrenia;	chr6:26946832	chr9:97195351~97197687:-
BRCA	trans	rs2749592	0.611	rs2505199	ENSG00000276997.3	RP11-378J18.9	5.49	5.13e-08	0.0295	0.21	0.17	Age-related hearing impairment (SNP x SNP interaction);	chr10:38103529	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.604	rs2389882	ENSG00000276805.1	RP11-291L22.6	5.49	5.13e-08	0.0295	0.2	0.17	Corneal astigmatism;	chr4:119645578	chr10:38451030~38451785:+
BRCA	trans	rs9649213	0.593	rs35535338	ENSG00000225169.1	BRI3P1	5.49	5.13e-08	0.0295	0.21	0.17	Prostate cancer (SNP x SNP interaction);	chr7:98333007	chr1:100213293~100213670:+
BRCA	trans	rs7647973	1	rs11720542	ENSG00000235912.1	RP1-159A19.3	-5.49	5.14e-08	0.0296	-0.21	-0.17	Menarche (age at onset);	chr3:49319994	chr1:27649419~27649610:+
BRCA	trans	rs7566780	0.596	rs1991584	ENSG00000224631.4	RP11-51O6.1	-5.49	5.14e-08	0.0296	-0.17	-0.17	Cleft lip with or without cleft palate;Orofacial clefts;	chr2:16465782	chr16:61055399~61055964:-
BRCA	trans	rs7647973	1	rs3866330	ENSG00000197582.5	GPX1P1	5.49	5.14e-08	0.0296	0.19	0.17	Menarche (age at onset);	chr3:49545561	chrX:13378735~13379340:-
BRCA	trans	rs35146811	0.961	rs11771139	ENSG00000228546.2	CTA-313A17.3	-5.49	5.14e-08	0.0296	-0.24	-0.17	Coronary artery disease;	chr7:100138436	chr7:102337316~102339115:+
BRCA	trans	rs875971	0.508	rs10258739	ENSG00000164669.11	INTS4P1	5.49	5.16e-08	0.0297	0.2	0.17	Aortic root size;	chr7:66597948	chr7:65141225~65234216:+
BRCA	trans	rs2117029	0.521	rs12229524	ENSG00000214391.3	TUBAP2	5.49	5.16e-08	0.0297	0.16	0.17	Intelligence (multi-trait analysis);	chr12:49191570	chr11:90282560~90284172:+
BRCA	trans	rs56114371	0.777	rs200482	ENSG00000253570.1	RNF5P1	5.49	5.16e-08	0.0297	0.36	0.17	Breast cancer;	chr6:27806126	chr8:38600661~38601200:-
BRCA	trans	rs2128614	0.902	rs4931575	ENSG00000277373.1	RP11-462D18.4	-5.49	5.17e-08	0.0297	-0.19	-0.17	Sleep duration;	chr12:31851840	chr20:17565501~17565851:-
BRCA	trans	rs9650657	0.547	rs11250099	ENSG00000270154.1	RP11-419I17.1	5.49	5.17e-08	0.0297	0.2	0.17	Neuroticism;	chr8:10961147	chr8:12476462~12477122:+
BRCA	trans	rs11098499	0.866	rs7665125	ENSG00000253326.2	RP11-261C10.7	5.49	5.18e-08	0.0298	0.22	0.17	Corneal astigmatism;	chr4:119480924	chr1:243054861~243056394:-
BRCA	trans	rs1457614	1	rs1457614	ENSG00000233325.3	MIPEPP3	5.49	5.18e-08	0.0298	0.25	0.17	Major depressive disorder;	chr12:13488772	chr13:21298139~21306373:+
BRCA	trans	rs11098499	0.863	rs11098531	ENSG00000253326.2	RP11-261C10.7	5.49	5.18e-08	0.0298	0.24	0.17	Corneal astigmatism;	chr4:119543846	chr1:243054861~243056394:-
BRCA	trans	rs11098499	0.863	rs28718422	ENSG00000253326.2	RP11-261C10.7	5.49	5.18e-08	0.0298	0.24	0.17	Corneal astigmatism;	chr4:119545149	chr1:243054861~243056394:-
BRCA	trans	rs11098499	0.818	rs12498599	ENSG00000253326.2	RP11-261C10.7	5.49	5.18e-08	0.0298	0.24	0.17	Corneal astigmatism;	chr4:119547348	chr1:243054861~243056394:-
BRCA	trans	rs11098499	0.863	rs10009626	ENSG00000253326.2	RP11-261C10.7	5.49	5.18e-08	0.0298	0.24	0.17	Corneal astigmatism;	chr4:119548850	chr1:243054861~243056394:-
BRCA	trans	rs453301	0.658	rs12114954	ENSG00000270154.1	RP11-419I17.1	-5.49	5.18e-08	0.0298	-0.19	-0.17	Joint mobility (Beighton score);	chr8:9047352	chr8:12476462~12477122:+
BRCA	trans	rs9368481	0.524	rs9393768	ENSG00000216901.1	AL022393.7	-5.48	5.2e-08	0.0299	-0.21	-0.17	Autism spectrum disorder or schizophrenia;	chr6:26917840	chr6:28176188~28176674:+
BRCA	trans	rs4713118	0.868	rs9468220	ENSG00000204709.4	LINC01556	-5.48	5.2e-08	0.0299	-0.24	-0.17	Parkinson's disease;	chr6:27765197	chr6:28943877~28944537:+
BRCA	trans	rs166870	1	rs282802	ENSG00000207392.1	SNORA20	5.48	5.21e-08	0.0299	0.22	0.17	Disease-free survival in breast cancer;	chr15:79780478	chr6:159780250~159780381:-
BRCA	trans	rs1232027	0.656	rs966762	ENSG00000188985.6	DHFRP1	-5.48	5.21e-08	0.03	-0.21	-0.17	Huntington's disease progression;	chr5:80640980	chr18:26170726~26171284:-
BRCA	trans	rs1232027	0.656	rs836795	ENSG00000188985.6	DHFRP1	-5.48	5.21e-08	0.03	-0.22	-0.17	Huntington's disease progression;	chr5:80716252	chr18:26170726~26171284:-
BRCA	trans	rs332507	0.83	rs12639478	ENSG00000234253.1	RPL7P13	5.48	5.22e-08	0.03	0.21	0.17	Plateletcrit;	chr3:124686111	chr2:49878623~49879363:+
BRCA	trans	rs332507	0.83	rs12631364	ENSG00000234253.1	RPL7P13	5.48	5.22e-08	0.03	0.21	0.17	Plateletcrit;	chr3:124686195	chr2:49878623~49879363:+
BRCA	trans	rs332507	0.83	rs35816663	ENSG00000234253.1	RPL7P13	5.48	5.22e-08	0.03	0.21	0.17	Plateletcrit;	chr3:124686666	chr2:49878623~49879363:+
BRCA	trans	rs7647973	1	rs3870341	ENSG00000197582.5	GPX1P1	5.48	5.22e-08	0.03	0.19	0.17	Menarche (age at onset);	chr3:49547312	chrX:13378735~13379340:-
BRCA	trans	rs4929949	0.901	rs4475924	ENSG00000266891.1	RP11-692N5.2	-5.48	5.23e-08	0.03	-0.19	-0.17	Body mass index;	chr11:8598462	chr18:9734882~9735602:-
BRCA	trans	rs7113874	0.524	rs4612809	ENSG00000266891.1	RP11-692N5.2	-5.48	5.23e-08	0.03	-0.19	-0.17	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8598491	chr18:9734882~9735602:-
BRCA	trans	rs2117029	0.521	rs10875925	ENSG00000214391.3	TUBAP2	5.48	5.23e-08	0.03	0.16	0.17	Intelligence (multi-trait analysis);	chr12:49142575	chr11:90282560~90284172:+
BRCA	trans	rs2117029	0.586	rs11168882	ENSG00000214391.3	TUBAP2	5.48	5.23e-08	0.03	0.16	0.17	Intelligence (multi-trait analysis);	chr12:49143560	chr11:90282560~90284172:+
BRCA	trans	rs6121246	0.609	rs6088997	ENSG00000279352.1	RP11-411B10.7	-5.48	5.23e-08	0.0301	-0.24	-0.17	Mean corpuscular hemoglobin;	chr20:31702021	chr18:14010054~14010917:+
BRCA	trans	rs12681792	0.576	rs6471923	ENSG00000266994.1	RP11-127I20.7	-5.48	5.25e-08	0.0301	-0.2	-0.17	Migraine;	chr8:61101185	chr16:4730115~4752565:-
BRCA	trans	rs10964378	0.541	rs7849770	ENSG00000270246.3	RP11-701H24.8	-5.48	5.25e-08	0.0301	-0.18	-0.17	Asthma;	chr9:20005450	chr15:25041918~25042428:+
BRCA	trans	rs10486963	1	rs6963806	ENSG00000213280.2	RP11-212P7.1	5.48	5.25e-08	0.0302	0.14	0.17	Energy expenditure (24h);	chr7:82520424	chr7:128570241~128570688:-
BRCA	trans	rs6601327	0.641	rs11782886	ENSG00000253893.2	FAM85B	5.48	5.26e-08	0.0302	0.21	0.17	Multiple myeloma (hyperdiploidy);	chr8:9730381	chr8:8167819~8226614:-
BRCA	trans	rs11098499	0.954	rs10006877	ENSG00000276805.1	RP11-291L22.6	5.48	5.26e-08	0.0302	0.2	0.17	Corneal astigmatism;	chr4:119321638	chr10:38451030~38451785:+
BRCA	trans	rs12497850	0.931	rs6446205	ENSG00000197582.5	GPX1P1	5.48	5.26e-08	0.0302	0.18	0.17	Parkinson's disease;	chr3:48997778	chrX:13378735~13379340:-
BRCA	trans	rs1459104	0.778	rs4544022	ENSG00000134612.10	FOLH1B	-5.48	5.26e-08	0.0302	-0.33	-0.17	Body mass index;	chr11:55743956	chr11:89639227~89698718:+
BRCA	trans	rs4948102	0.731	rs4948099	ENSG00000186940.6	CHCHD2P9	5.48	5.27e-08	0.0302	0.21	0.17	Plasma homocysteine levels (post-methionine load test);	chr7:56004557	chr9:79391304~79391759:+
BRCA	trans	rs9470366	0.816	rs7742159	ENSG00000257004.1	RP11-180M15.3	5.48	5.28e-08	0.0303	0.19	0.17	QRS duration;	chr6:36651675	chr12:12668982~12685075:+
BRCA	trans	rs950037	0.935	rs6658204	ENSG00000231916.1	AC006033.22	-5.48	5.28e-08	0.0303	-0.2	-0.17	Coronary artery disease;	chr1:88840972	chr7:38311383~38311808:+
BRCA	trans	rs2950393	0.777	rs12828563	ENSG00000257210.1	NACAP3	5.48	5.28e-08	0.0303	0.2	0.17	Platelet distribution width;	chr12:56709378	chr12:93124063~93124543:-
BRCA	trans	rs950037	0.901	rs786910	ENSG00000231916.1	AC006033.22	5.48	5.3e-08	0.0304	0.19	0.17	Coronary artery disease;	chr1:88797686	chr7:38311383~38311808:+
BRCA	trans	rs2055729	0.591	rs6987670	ENSG00000253893.2	FAM85B	-5.48	5.31e-08	0.0305	-0.22	-0.17	Multiple myeloma (hyperdiploidy);	chr8:10025667	chr8:8167819~8226614:-
BRCA	trans	rs11098499	0.738	rs28408407	ENSG00000276805.1	RP11-291L22.6	5.48	5.32e-08	0.0305	0.19	0.17	Corneal astigmatism;	chr4:119454875	chr10:38451030~38451785:+
BRCA	trans	rs7113874	0.569	rs9300092	ENSG00000266891.1	RP11-692N5.2	-5.48	5.32e-08	0.0305	-0.2	-0.17	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8568945	chr18:9734882~9735602:-
BRCA	trans	rs11212260	0.522	rs1789163	ENSG00000235552.4	RPL6P27	5.48	5.32e-08	0.0305	0.21	0.17	IgG glycosylation;	chr11:107506284	chr18:6462144~6463015:-
BRCA	trans	rs7097397	0.636	rs2663054	ENSG00000279252.1	AC092670.1	-5.48	5.34e-08	0.0306	-0.17	-0.17	Systemic lupus erythematosus;	chr10:48893932	chr4:118459923~118460328:-
BRCA	trans	rs1368013	0.683	rs11105575	ENSG00000276952.1	RP5-965G21.6	5.48	5.34e-08	0.0306	0.21	0.17	Number of children (6+ vs. 0 or 1);	chr12:90343044	chr20:25284915~25285588:-
BRCA	trans	rs6601327	0.635	rs10099122	ENSG00000253893.2	FAM85B	5.48	5.34e-08	0.0306	0.22	0.17	Multiple myeloma (hyperdiploidy);	chr8:9710493	chr8:8167819~8226614:-
BRCA	trans	rs6142102	0.602	rs4911396	ENSG00000280327.1	LA16c-313F4.1	-5.48	5.34e-08	0.0306	-0.17	-0.17	Skin pigmentation;	chr20:33992139	chr16:1576716~1578371:-
BRCA	trans	rs11098499	0.954	rs13107475	ENSG00000253326.2	RP11-261C10.7	5.48	5.35e-08	0.0307	0.23	0.17	Corneal astigmatism;	chr4:119471856	chr1:243054861~243056394:-
BRCA	trans	rs17161791	1	rs10258079	ENSG00000233589.1	RP4-694A7.2	5.48	5.35e-08	0.0307	0.19	0.17	Pulmonary function in asthmatics;	chr7:9562796	chr1:68479129~68483539:+
BRCA	trans	rs660899	0.857	rs3791047	ENSG00000231007.5	CDC20P1	5.48	5.35e-08	0.0307	0.21	0.17	Hypertension risk in short sleep duration;	chr1:43770443	chr9:87011652~87013151:+
BRCA	trans	rs6934970	1	rs6934970	ENSG00000267560.1	RP11-173A16.1	5.48	5.36e-08	0.0307	0.2	0.17	Bipolar disorder (body mass index interaction);	chr6:112803099	chr18:62300036~62300998:-
BRCA	trans	rs7617773	0.709	rs4404473	ENSG00000235912.1	RP1-159A19.3	-5.48	5.36e-08	0.0307	-0.23	-0.17	Coronary artery disease;	chr3:48312136	chr1:27649419~27649610:+
BRCA	trans	rs2540917	0.967	rs13011022	ENSG00000280388.1	RP11-229D13.3	5.48	5.37e-08	0.0307	0.17	0.17	Mean corpuscular volume;	chr2:60399687	chr7:76043977~76045963:-
BRCA	trans	rs11098499	0.909	rs10026736	ENSG00000276805.1	RP11-291L22.6	5.48	5.39e-08	0.0309	0.2	0.17	Corneal astigmatism;	chr4:119463167	chr10:38451030~38451785:+
BRCA	trans	rs7566780	0.516	rs12710703	ENSG00000224631.4	RP11-51O6.1	5.48	5.39e-08	0.0309	0.16	0.17	Cleft lip with or without cleft palate;Orofacial clefts;	chr2:16484157	chr16:61055399~61055964:-
BRCA	trans	rs11098499	0.954	rs2306455	ENSG00000253326.2	RP11-261C10.7	5.48	5.4e-08	0.0309	0.24	0.17	Corneal astigmatism;	chr4:119500814	chr1:243054861~243056394:-
BRCA	trans	rs6489882	0.867	rs6489877	ENSG00000250770.2	RP5-1063M23.1	5.48	5.4e-08	0.0309	0.22	0.17	Chronic lymphocytic leukemia;	chr12:112930274	chr12:3296202~3300224:-
BRCA	trans	rs6121246	0.609	rs6089054	ENSG00000279352.1	RP11-411B10.7	5.48	5.41e-08	0.031	0.24	0.17	Mean corpuscular hemoglobin;	chr20:31735338	chr18:14010054~14010917:+
BRCA	trans	rs6087771	0.851	rs6087775	ENSG00000279352.1	RP11-411B10.7	5.48	5.41e-08	0.031	0.24	0.17	Putamen volume;Subcortical brain region volumes;	chr20:31737962	chr18:14010054~14010917:+
BRCA	trans	rs6121246	0.609	rs4453755	ENSG00000279352.1	RP11-411B10.7	5.48	5.41e-08	0.031	0.24	0.17	Mean corpuscular hemoglobin;	chr20:31743244	chr18:14010054~14010917:+
BRCA	trans	rs1368013	0.683	rs11105578	ENSG00000276952.1	RP5-965G21.6	5.48	5.42e-08	0.031	0.21	0.17	Number of children (6+ vs. 0 or 1);	chr12:90352897	chr20:25284915~25285588:-
BRCA	trans	rs2243480	1	rs2420171	ENSG00000164669.11	INTS4P1	-5.48	5.42e-08	0.031	-0.33	-0.17	Diabetic kidney disease;	chr7:66172773	chr7:65141225~65234216:+
BRCA	trans	rs6601327	0.678	rs10106040	ENSG00000253893.2	FAM85B	-5.48	5.44e-08	0.0311	-0.21	-0.17	Multiple myeloma (hyperdiploidy);	chr8:9754903	chr8:8167819~8226614:-
BRCA	trans	rs2841307	0.925	rs2073264	ENSG00000225751.2	AC087501.1	5.48	5.44e-08	0.0311	0.25	0.17	Bipolar disorder and schizophrenia;	chr6:100233247	chr17:9452197~9470014:+
BRCA	trans	rs9328573	1	rs8037666	ENSG00000279048.1	RP11-511H23.2	5.48	5.44e-08	0.0311	0.16	0.17	Urate levels in lean individuals;	chr15:99971874	chr7:17940503~17942922:+
BRCA	trans	rs73110464	0.591	rs11829997	ENSG00000240668.1	KRT8P36	-5.48	5.46e-08	0.0312	-0.39	-0.17	Cancer (pleiotropy);	chr12:52921875	chr3:138101478~138102917:-
BRCA	trans	rs7568458	0.846	rs6705971	ENSG00000223886.3	RP11-251G23.2	-5.48	5.46e-08	0.0312	-0.19	-0.17	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr2:85534294	chr7:105530209~105530671:+
BRCA	trans	rs11638815	0.859	rs11633991	ENSG00000235370.6	DNM1P51	-5.48	5.47e-08	0.0312	-0.21	-0.17	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82726588	chr15:84398316~84411701:-
BRCA	trans	rs853679	0.766	rs9368561	ENSG00000281831.1	HCP5B	5.48	5.47e-08	0.0313	0.33	0.17	Depression;	chr6:28200565	chr6:29871895~29873783:-
BRCA	trans	rs4645904	0.807	rs11083956	ENSG00000226608.3	FTLP3	-5.48	5.47e-08	0.0313	-0.14	-0.17	Asthma;	chr19:48949205	chr20:4023917~4024444:+
BRCA	trans	rs11098499	0.644	rs28787668	ENSG00000276805.1	RP11-291L22.6	5.48	5.48e-08	0.0313	0.19	0.17	Corneal astigmatism;	chr4:119633532	chr10:38451030~38451785:+
BRCA	trans	rs7943953	0.661	rs7949055	ENSG00000206897.1	SNORA9	5.48	5.48e-08	0.0313	0.2	0.17	Odorant perception (&beta-ionone);	chr11:59349573	chr12:123616708~123616840:+
BRCA	trans	rs853679	0.769	rs7752608	ENSG00000176998.4	HCG4	-5.48	5.48e-08	0.0313	-0.34	-0.17	Depression;	chr6:28333418	chr6:29791753~29792750:-
BRCA	trans	rs11098499	0.863	rs10004484	ENSG00000253326.2	RP11-261C10.7	5.47	5.49e-08	0.0314	0.23	0.17	Corneal astigmatism;	chr4:119521273	chr1:243054861~243056394:-
BRCA	trans	rs9837602	1	rs34626154	ENSG00000188451.8	SRP72P2	-5.47	5.5e-08	0.0314	-0.26	-0.17	Breast cancer;	chr3:100037468	chr6:158237336~158242797:-
BRCA	trans	rs17711722	0.565	rs73372653	ENSG00000182722.5	SEPHS1P1	-5.47	5.5e-08	0.0314	-0.22	-0.17	Calcium levels;	chr7:65977808	chr7:64852397~64853354:-
BRCA	trans	rs6142102	0.625	rs4911384	ENSG00000280327.1	LA16c-313F4.1	-5.47	5.51e-08	0.0315	-0.17	-0.17	Skin pigmentation;	chr20:33968001	chr16:1576716~1578371:-
BRCA	trans	rs7943953	0.661	rs1403331	ENSG00000206897.1	SNORA9	5.47	5.51e-08	0.0315	0.2	0.17	Odorant perception (&beta-ionone);	chr11:59323462	chr12:123616708~123616840:+
BRCA	trans	rs6489882	0.836	rs12322160	ENSG00000250770.2	RP5-1063M23.1	5.47	5.51e-08	0.0315	0.22	0.17	Chronic lymphocytic leukemia;	chr12:112930700	chr12:3296202~3300224:-
BRCA	trans	rs9860340	0.73	rs66772967	ENSG00000259370.2	RP11-1069G10.1	5.47	5.51e-08	0.0315	0.2	0.17	Electroencephalographic traits in alcoholism;	chr3:87590009	chr15:62827675~62884034:-
BRCA	trans	rs9860340	0.73	rs66468250	ENSG00000259370.2	RP11-1069G10.1	5.47	5.51e-08	0.0315	0.2	0.17	Electroencephalographic traits in alcoholism;	chr3:87590027	chr15:62827675~62884034:-
BRCA	trans	rs12497850	0.931	rs6442130	ENSG00000197582.5	GPX1P1	5.47	5.51e-08	0.0315	0.18	0.17	Parkinson's disease;	chr3:48740594	chrX:13378735~13379340:-
BRCA	trans	rs7647973	1	rs4241407	ENSG00000235912.1	RP1-159A19.3	-5.47	5.53e-08	0.0316	-0.21	-0.17	Menarche (age at onset);	chr3:49562886	chr1:27649419~27649610:+
BRCA	trans	rs4879656	0.897	rs1537042	ENSG00000215007.3	DNAJA1P3	5.47	5.53e-08	0.0316	0.21	0.17	Menopause (age at onset);	chr9:33045278	chrX:107351650~107352843:-
BRCA	trans	rs7570469	0.577	rs11126723	ENSG00000262227.1	RP5-1050D4.5	-5.47	5.53e-08	0.0316	-0.16	-0.17	Response to antipsychotic treatment;	chr2:79415008	chr17:4987706~4988446:+
BRCA	trans	rs6934970	0.932	rs3862840	ENSG00000267560.1	RP11-173A16.1	-5.47	5.54e-08	0.0316	-0.21	-0.17	Bipolar disorder (body mass index interaction);	chr6:112806453	chr18:62300036~62300998:-
BRCA	trans	rs9462846	1	rs2092555	ENSG00000231579.3	RPL7P21	5.47	5.54e-08	0.0316	0.23	0.17	Blood protein levels;	chr6:42896104	chr5:143332605~143333239:+
BRCA	trans	rs4879656	0.872	rs12375624	ENSG00000215007.3	DNAJA1P3	5.47	5.55e-08	0.0317	0.2	0.17	Menopause (age at onset);	chr9:33017140	chrX:107351650~107352843:-
BRCA	trans	rs902774	1	rs11831942	ENSG00000223940.1	KRT8P8	-5.47	5.55e-08	0.0317	-0.28	-0.17	Prostate cancer;	chr12:52878329	chrX:152479577~152481024:+
BRCA	trans	rs10486963	0.966	rs10224677	ENSG00000213280.2	RP11-212P7.1	-5.47	5.55e-08	0.0317	-0.14	-0.17	Energy expenditure (24h);	chr7:82521744	chr7:128570241~128570688:-
BRCA	trans	rs12024301	0.557	rs6699011	ENSG00000260803.1	Z84812.4	-5.47	5.55e-08	0.0317	-0.4	-0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:183653244	chr16:17514~35195:-
BRCA	trans	rs7746199	0.736	rs6904596	ENSG00000204709.4	LINC01556	5.47	5.57e-08	0.0318	0.36	0.17	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27523520	chr6:28943877~28944537:+
BRCA	trans	rs853679	0.607	rs201002	ENSG00000228078.1	HLA-U	-5.47	5.57e-08	0.0318	-0.33	-0.17	Depression;	chr6:27840414	chr6:29934101~29934286:+
BRCA	trans	rs10899021	0.92	rs11236181	ENSG00000237188.3	RP11-337C18.8	5.47	5.59e-08	0.0319	0.27	0.17	Response to metformin (IC50);	chr11:74634778	chr1:147172771~147211568:+
BRCA	trans	rs853679	0.607	rs34878803	ENSG00000204338.7	CYP21A1P	-5.47	5.6e-08	0.0319	-0.37	-0.17	Depression;	chr6:28282402	chr6:32005636~32008451:+
BRCA	trans	rs853679	0.607	rs34396849	ENSG00000204338.7	CYP21A1P	-5.47	5.6e-08	0.0319	-0.37	-0.17	Depression;	chr6:28283178	chr6:32005636~32008451:+
BRCA	trans	rs11098499	0.863	rs59732491	ENSG00000253326.2	RP11-261C10.7	5.47	5.6e-08	0.032	0.24	0.17	Corneal astigmatism;	chr4:119568433	chr1:243054861~243056394:-
BRCA	trans	rs11098499	0.863	rs11723090	ENSG00000253326.2	RP11-261C10.7	5.47	5.6e-08	0.032	0.24	0.17	Corneal astigmatism;	chr4:119569437	chr1:243054861~243056394:-
BRCA	trans	rs9467773	0.935	rs11752946	ENSG00000216901.1	AL022393.7	-5.47	5.61e-08	0.032	-0.21	-0.17	Intelligence (multi-trait analysis);	chr6:26560136	chr6:28176188~28176674:+
BRCA	trans	rs1232027	0.7	rs1623489	ENSG00000188985.6	DHFRP1	-5.47	5.61e-08	0.032	-0.21	-0.17	Huntington's disease progression;	chr5:80630296	chr18:26170726~26171284:-
BRCA	trans	rs6440475	0.741	rs9819867	ENSG00000240338.4	RP11-331F4.4	5.47	5.61e-08	0.032	0.2	0.17	Response to paliperidone in schizophrenia (positive Marder score);	chr3:147130374	chr16:75226074~75228197:+
BRCA	trans	rs9882792	0.784	rs1447948	ENSG00000229465.1	ACTG1P11	-5.47	5.62e-08	0.032	-0.33	-0.17	Breast cancer;	chr3:190032497	chrY:18147884~18149008:+
BRCA	trans	rs7113874	0.569	rs10160430	ENSG00000266891.1	RP11-692N5.2	-5.47	5.62e-08	0.032	-0.19	-0.17	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8578329	chr18:9734882~9735602:-
BRCA	trans	rs9467711	0.659	rs72844462	ENSG00000281831.1	HCP5B	5.47	5.63e-08	0.0321	0.38	0.17	Autism spectrum disorder or schizophrenia;	chr6:26563636	chr6:29871895~29873783:-
BRCA	trans	rs1322281	0.83	rs1322282	ENSG00000272170.1	RP11-387M24.5	-5.47	5.65e-08	0.0322	-0.2	-0.17	Non-response to antidepressants and depression;	chr9:10582586	chr6:43074331~43074739:-
BRCA	trans	rs6684992	0.722	rs7547003	ENSG00000231806.2	PCAT7	-5.47	5.66e-08	0.0322	-0.3	-0.17	Eosinophil counts;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;	chr1:87257940	chr9:94555069~94568127:+
BRCA	trans	rs1488665	0.623	rs11038489	ENSG00000249532.3	RP11-148B6.1	-5.47	5.66e-08	0.0323	-0.32	-0.17	Obesity-related traits;	chr11:45486346	chr4:112646476~112650051:-
BRCA	trans	rs1488665	0.623	rs57159059	ENSG00000249532.3	RP11-148B6.1	-5.47	5.66e-08	0.0323	-0.32	-0.17	Obesity-related traits;	chr11:45487133	chr4:112646476~112650051:-
BRCA	trans	rs1039766	1	rs268861	ENSG00000213985.4	AC078899.1	5.47	5.67e-08	0.0323	0.24	0.17	Lung adenocarcinoma;Lung cancer;	chr2:65261026	chr19:20257720~20259418:+
BRCA	trans	rs17818399	0.926	rs13033177	ENSG00000253869.1	PIGFP1	5.47	5.68e-08	0.0323	0.25	0.17	Height;	chr2:46603923	chr5:178922064~178922716:+
BRCA	trans	rs4366490	0.534	rs7130710	ENSG00000186676.3	EEF1GP1	-5.47	5.68e-08	0.0323	-0.25	-0.17	Conotruncal heart defects;	chr11:63101829	chr7:125033453~125035301:+
BRCA	trans	rs10838687	0.736	rs2306353	ENSG00000134612.10	FOLH1B	5.47	5.68e-08	0.0324	0.26	0.17	Proinsulin levels;	chr11:47235157	chr11:89639227~89698718:+
BRCA	trans	rs6489882	0.867	rs6489875	ENSG00000250770.2	RP5-1063M23.1	5.47	5.68e-08	0.0324	0.22	0.17	Chronic lymphocytic leukemia;	chr12:112930225	chr12:3296202~3300224:-
BRCA	trans	rs6489882	0.867	rs6489876	ENSG00000250770.2	RP5-1063M23.1	5.47	5.68e-08	0.0324	0.22	0.17	Chronic lymphocytic leukemia;	chr12:112930250	chr12:3296202~3300224:-
BRCA	trans	rs6489882	0.836	rs6489878	ENSG00000250770.2	RP5-1063M23.1	5.47	5.68e-08	0.0324	0.22	0.17	Chronic lymphocytic leukemia;	chr12:112930320	chr12:3296202~3300224:-
BRCA	trans	rs875971	0.516	rs6945322	ENSG00000213640.3	EEF1DP4	-5.47	5.68e-08	0.0324	-0.21	-0.17	Aortic root size;	chr7:65871069	chr7:64862999~64864370:+
BRCA	trans	rs1568889	0.877	rs7933326	ENSG00000174912.7	METTL15P1	5.47	5.69e-08	0.0324	0.18	0.17	Bipolar disorder;	chr11:28266869	chr3:156713884~156714928:-
BRCA	trans	rs61921502	0.529	rs9668269	ENSG00000256006.1	AC084117.3	5.47	5.69e-08	0.0324	0.23	0.17	Subcortical brain region volumes;Hippocampal volume;	chr12:65286246	chr11:18405609~18406731:+
BRCA	trans	rs3799378	0.579	rs9348715	ENSG00000242375.1	RP11-498P14.3	-5.47	5.69e-08	0.0324	-0.25	-0.17	Intelligence (multi-trait analysis);	chr6:26375414	chr9:97195351~97197687:-
BRCA	trans	rs6777098	0.537	rs4352376	ENSG00000250328.4	MGC32805	5.47	5.69e-08	0.0324	0.25	0.17	Response to paliperidone in schizophrenia (positive Marder score);	chr3:167218379	chr5:122436497~122479087:-
BRCA	trans	rs5006884	0.547	rs884222	ENSG00000258626.2	COX7A2P1	5.47	5.7e-08	0.0325	0.21	0.17	Fetal hemoglobin levels;	chr11:5371742	chr14:67652300~67652614:-
BRCA	trans	rs9393777	0.841	rs13191474	ENSG00000228078.1	HLA-U	-5.47	5.7e-08	0.0325	-0.41	-0.17	Intelligence (multi-trait analysis);	chr6:27445566	chr6:29934101~29934286:+
BRCA	trans	rs669446	0.561	rs571862	ENSG00000235358.1	RP11-399E6.1	-5.47	5.7e-08	0.0325	-0.24	-0.17	Amyotrophic lateral sclerosis (age of onset);	chr1:43617439	chr1:41242373~41284861:+
BRCA	trans	rs1336472	0.509	rs4916031	ENSG00000233381.3	AK4P3	-5.47	5.71e-08	0.0325	-0.23	-0.17	Venous thromboembolism (SNP x SNP interaction);	chr1:65215860	chr12:31615771~31616439:-
BRCA	trans	rs6489882	0.867	rs916972	ENSG00000250770.2	RP5-1063M23.1	5.47	5.71e-08	0.0325	0.22	0.17	Chronic lymphocytic leukemia;	chr12:112928244	chr12:3296202~3300224:-
BRCA	trans	rs1459104	1	rs56359124	ENSG00000134612.10	FOLH1B	-5.47	5.73e-08	0.0326	-0.34	-0.17	Body mass index;	chr11:55367599	chr11:89639227~89698718:+
BRCA	trans	rs11098499	0.73	rs12505735	ENSG00000276805.1	RP11-291L22.6	5.47	5.74e-08	0.0327	0.2	0.17	Corneal astigmatism;	chr4:119611801	chr10:38451030~38451785:+
BRCA	trans	rs9393813	0.516	rs4713098	ENSG00000242375.1	RP11-498P14.3	5.47	5.74e-08	0.0327	0.23	0.17	Bipolar disorder;	chr6:27435826	chr9:97195351~97197687:-
BRCA	trans	rs16975963	0.644	rs73031309	ENSG00000247498.8	RP11-392P7.6	5.47	5.75e-08	0.0327	0.29	0.17	Longevity;	chr19:37541082	chr12:12927726~12984645:+
BRCA	trans	rs9467711	0.79	rs13204572	ENSG00000220721.1	OR1F12	5.47	5.76e-08	0.0327	0.41	0.17	Autism spectrum disorder or schizophrenia;	chr6:26189128	chr6:28073316~28074233:+
BRCA	trans	rs7709377	0.951	rs2112570	ENSG00000183458.12	RP11-958N24.1	-5.47	5.76e-08	0.0328	-0.13	-0.17	Metabolite levels  (X-11787);	chr5:116211897	chr16:14911551~14935708:+
BRCA	trans	rs17818399	0.926	rs13032670	ENSG00000253869.1	PIGFP1	5.47	5.76e-08	0.0328	0.25	0.17	Height;	chr2:46603655	chr5:178922064~178922716:+
BRCA	trans	rs853679	0.825	rs8180562	ENSG00000228078.1	HLA-U	-5.47	5.77e-08	0.0328	-0.35	-0.17	Depression;	chr6:28173682	chr6:29934101~29934286:+
BRCA	trans	rs853679	0.882	rs9380064	ENSG00000228078.1	HLA-U	-5.47	5.77e-08	0.0328	-0.35	-0.17	Depression;	chr6:28175340	chr6:29934101~29934286:+
BRCA	trans	rs450533	0.54	rs419764	ENSG00000229619.3	MBNL1-AS1	5.47	5.78e-08	0.0329	0.17	0.17	Cancer;	chr4:106923000	chr3:152262616~152269555:-
BRCA	trans	rs7568458	0.846	rs6743030	ENSG00000223886.3	RP11-251G23.2	5.47	5.79e-08	0.0329	0.19	0.17	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr2:85536397	chr7:105530209~105530671:+
BRCA	trans	rs11098499	0.908	rs2017057	ENSG00000253326.2	RP11-261C10.7	5.47	5.79e-08	0.0329	0.24	0.17	Corneal astigmatism;	chr4:119336556	chr1:243054861~243056394:-
BRCA	trans	rs7395581	0.918	rs3816725	ENSG00000134612.10	FOLH1B	5.47	5.79e-08	0.0329	0.22	0.17	HDL cholesterol;	chr11:47284118	chr11:89639227~89698718:+
BRCA	trans	rs1178101	0.851	rs1178116	ENSG00000269800.1	PLEKHA3P1	5.46	5.79e-08	0.0329	0.23	0.17	Monobrow;	chr7:18710579	chr19:41521043~41521989:-
BRCA	trans	rs7617480	0.519	rs6790914	ENSG00000197582.5	GPX1P1	5.46	5.8e-08	0.033	0.17	0.17	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:49168885	chrX:13378735~13379340:-
BRCA	trans	rs11098499	0.909	rs10017335	ENSG00000253326.2	RP11-261C10.7	-5.46	5.8e-08	0.033	-0.24	-0.17	Corneal astigmatism;	chr4:119460368	chr1:243054861~243056394:-
BRCA	trans	rs875971	0.543	rs801191	ENSG00000164669.11	INTS4P1	5.46	5.81e-08	0.033	0.2	0.17	Aortic root size;	chr7:66567968	chr7:65141225~65234216:+
BRCA	trans	rs35306767	0.807	rs11253513	ENSG00000187984.11	ANKRD19P	5.46	5.81e-08	0.033	0.2	0.17	Eosinophil percentage of granulocytes;	chr10:922510	chr9:92809388~92888693:+
BRCA	trans	rs35306767	0.953	rs12259338	ENSG00000187984.11	ANKRD19P	5.46	5.81e-08	0.033	0.2	0.17	Eosinophil percentage of granulocytes;	chr10:923437	chr9:92809388~92888693:+
BRCA	trans	rs6777098	0.793	rs9830639	ENSG00000250328.4	MGC32805	-5.46	5.82e-08	0.033	-0.25	-0.17	Response to paliperidone in schizophrenia (positive Marder score);	chr3:167208229	chr5:122436497~122479087:-
BRCA	trans	rs9425766	0.64	rs61827925	ENSG00000213331.4	RP11-713C19.2	5.46	5.82e-08	0.0331	0.23	0.17	Life satisfaction;	chr1:173862619	chr4:187970273~187971284:+
BRCA	trans	rs1568889	1	rs12794100	ENSG00000174912.7	METTL15P1	5.46	5.82e-08	0.0331	0.19	0.17	Bipolar disorder;	chr11:28311238	chr3:156713884~156714928:-
BRCA	trans	rs11098499	0.865	rs11098513	ENSG00000253326.2	RP11-261C10.7	5.46	5.82e-08	0.0331	0.23	0.17	Corneal astigmatism;	chr4:119394920	chr1:243054861~243056394:-
BRCA	trans	rs12545912	0.821	rs1055328	ENSG00000253893.2	FAM85B	5.46	5.82e-08	0.0331	0.23	0.17	Multiple myeloma (hyperdiploidy);	chr8:9781806	chr8:8167819~8226614:-
BRCA	trans	rs7746199	0.668	rs34864796	ENSG00000204709.4	LINC01556	5.46	5.82e-08	0.0331	0.37	0.17	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27492144	chr6:28943877~28944537:+
BRCA	trans	rs35306767	0.953	rs12259801	ENSG00000187984.11	ANKRD19P	5.46	5.82e-08	0.0331	0.2	0.17	Eosinophil percentage of granulocytes;	chr10:913366	chr9:92809388~92888693:+
BRCA	trans	rs11098499	0.954	rs17005535	ENSG00000253326.2	RP11-261C10.7	5.46	5.82e-08	0.0331	0.23	0.17	Corneal astigmatism;	chr4:119490407	chr1:243054861~243056394:-
BRCA	trans	rs7568458	0.811	rs10175792	ENSG00000223886.3	RP11-251G23.2	5.46	5.84e-08	0.0332	0.19	0.17	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr2:85534531	chr7:105530209~105530671:+
BRCA	trans	rs7568458	0.846	rs10179195	ENSG00000223886.3	RP11-251G23.2	5.46	5.84e-08	0.0332	0.19	0.17	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr2:85535638	chr7:105530209~105530671:+
BRCA	trans	rs4713118	0.738	rs200465	ENSG00000204709.4	LINC01556	5.46	5.85e-08	0.0332	0.23	0.17	Parkinson's disease;	chr6:27789875	chr6:28943877~28944537:+
BRCA	trans	rs17711722	0.701	rs781145	ENSG00000213640.3	EEF1DP4	-5.46	5.85e-08	0.0332	-0.21	-0.17	Calcium levels;	chr7:65975383	chr7:64862999~64864370:+
BRCA	trans	rs1437396	0.565	rs3111412	ENSG00000250334.4	LINC00989	-5.46	5.86e-08	0.0333	-0.2	-0.17	Alcohol dependence;	chr2:55362298	chr4:79492416~79576460:+
BRCA	trans	rs6934970	0.789	rs7747244	ENSG00000267560.1	RP11-173A16.1	-5.46	5.87e-08	0.0333	-0.21	-0.17	Bipolar disorder (body mass index interaction);	chr6:112805730	chr18:62300036~62300998:-
BRCA	trans	rs6934970	1	rs3862839	ENSG00000267560.1	RP11-173A16.1	-5.46	5.87e-08	0.0333	-0.21	-0.17	Bipolar disorder (body mass index interaction);	chr6:112806385	chr18:62300036~62300998:-
BRCA	trans	rs3096299	0.933	rs28608022	ENSG00000215030.5	RPL13P12	-5.46	5.88e-08	0.0334	-0.17	-0.17	Multiple myeloma (IgH translocation);	chr16:89387884	chr17:17383377~17384012:-
BRCA	trans	rs8022296	0.72	rs727069	ENSG00000234718.6	AC007161.5	5.46	5.88e-08	0.0334	0.23	0.17	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr14:97524463	chr7:7738524~7742574:-
BRCA	trans	rs1933488	0.931	rs9479510	ENSG00000180015.12	RP11-756P10.3	5.46	5.88e-08	0.0334	0.22	0.17	Prostate cancer;	chr6:153106382	chr4:188738373~188739494:+
BRCA	trans	rs228614	0.536	rs150897	ENSG00000211782.2	TRAV8-1	-5.46	5.89e-08	0.0334	-0.13	-0.17	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102769309	chr14:21797287~21797886:+
BRCA	trans	rs9467603	0.925	rs6456701	ENSG00000253570.1	RNF5P1	-5.46	5.89e-08	0.0334	-0.4	-0.17	Intelligence (multi-trait analysis);	chr6:25773902	chr8:38600661~38601200:-
BRCA	trans	rs1933488	1	rs6901126	ENSG00000180015.12	RP11-756P10.3	5.46	5.9e-08	0.0335	0.21	0.17	Prostate cancer;	chr6:153118927	chr4:188738373~188739494:+
BRCA	trans	rs12775980	1	rs12771815	ENSG00000233956.1	BTF3P6	-5.46	5.9e-08	0.0335	-0.36	-0.17	Bone fracture in osteoporosis;	chr10:29579679	chr21:33518610~33519108:-
BRCA	trans	rs11098499	0.691	rs10028773	ENSG00000276997.3	RP11-378J18.9	-5.46	5.91e-08	0.0335	-0.19	-0.17	Corneal astigmatism;	chr4:119344104	chr1:222477252~222504622:-
BRCA	trans	rs10815468	0.542	rs6477109	ENSG00000215210.3	RBMXP2	5.46	5.91e-08	0.0335	0.22	0.17	Bipolar disorder and schizophrenia;	chr9:6794938	chr9:30689105~30690272:+
BRCA	trans	rs853679	0.546	rs200948	ENSG00000228078.1	HLA-U	-5.46	5.91e-08	0.0335	-0.34	-0.17	Depression;	chr6:27867494	chr6:29934101~29934286:+
BRCA	trans	rs853679	0.546	rs200950	ENSG00000228078.1	HLA-U	-5.46	5.91e-08	0.0335	-0.34	-0.17	Depression;	chr6:27867994	chr6:29934101~29934286:+
BRCA	trans	rs6545883	0.56	rs11677776	ENSG00000260091.1	RP11-33B1.4	-5.46	5.91e-08	0.0335	-0.13	-0.17	Tuberculosis;	chr2:61275978	chr4:119409333~119410233:+
BRCA	trans	rs853679	0.599	rs149990	ENSG00000228078.1	HLA-U	-5.46	5.92e-08	0.0336	-0.34	-0.17	Depression;	chr6:28030480	chr6:29934101~29934286:+
BRCA	trans	rs4245116	0.64	rs11223460	ENSG00000241782.1	RP11-91P24.1	-5.46	5.94e-08	0.0337	-0.2	-0.17	Coffee consumption (cups per day);	chr11:133380646	chr11:77868722~77869195:-
BRCA	trans	rs7647973	1	rs10155014	ENSG00000197582.5	GPX1P1	5.46	5.96e-08	0.0338	0.18	0.17	Menarche (age at onset);	chr3:49394888	chrX:13378735~13379340:-
BRCA	trans	rs10486963	0.966	rs17156383	ENSG00000213280.2	RP11-212P7.1	-5.46	5.96e-08	0.0338	-0.14	-0.17	Energy expenditure (24h);	chr7:82520997	chr7:128570241~128570688:-
BRCA	trans	rs9467711	0.651	rs13200797	ENSG00000253570.1	RNF5P1	5.46	5.96e-08	0.0338	0.41	0.17	Autism spectrum disorder or schizophrenia;	chr6:26122729	chr8:38600661~38601200:-
BRCA	trans	rs66887589	0.592	rs11731571	ENSG00000120555.12	SEPT7P9	5.46	5.97e-08	0.0338	0.19	0.17	Diastolic blood pressure;	chr4:119300030	chr10:38383069~38402916:-
BRCA	trans	rs16975050	0.557	rs16974659	ENSG00000235576.1	AC092580.4	-5.46	5.97e-08	0.0338	-0.23	-0.17	Amyotrophic lateral sclerosis (sporadic);	chr18:41418756	chr2:7725801~7730705:+
BRCA	trans	rs1933488	0.931	rs3870365	ENSG00000180015.12	RP11-756P10.3	-5.46	5.98e-08	0.0339	-0.22	-0.17	Prostate cancer;	chr6:153105797	chr4:188738373~188739494:+
BRCA	trans	rs1459104	0.85	rs1847548	ENSG00000134612.10	FOLH1B	-5.46	5.98e-08	0.0339	-0.33	-0.17	Body mass index;	chr11:55588148	chr11:89639227~89698718:+
BRCA	trans	rs1459104	1	rs67536351	ENSG00000134612.10	FOLH1B	-5.46	5.98e-08	0.0339	-0.33	-0.17	Body mass index;	chr11:55588988	chr11:89639227~89698718:+
BRCA	trans	rs10089	1	rs17764954	ENSG00000235584.2	AC008268.1	-5.46	5.99e-08	0.0339	-0.18	-0.17	Ileal carcinoids;	chr5:128178744	chr2:95666084~95668715:+
BRCA	trans	rs3105169	0.8	rs7829780	ENSG00000260318.1	COX6CP1	-5.46	6.02e-08	0.0341	-0.32	-0.17	Smoking initiation;	chr8:99062124	chr16:11903923~11904137:-
BRCA	trans	rs11098499	0.954	rs878373	ENSG00000276805.1	RP11-291L22.6	5.46	6.03e-08	0.0341	0.2	0.17	Corneal astigmatism;	chr4:119316329	chr10:38451030~38451785:+
BRCA	trans	rs1459104	0.706	rs35228933	ENSG00000134612.10	FOLH1B	-5.46	6.03e-08	0.0341	-0.35	-0.17	Body mass index;	chr11:55260197	chr11:89639227~89698718:+
BRCA	trans	rs17834760	1	rs62423504	ENSG00000215190.7	LINC00680	-5.46	6.03e-08	0.0342	-0.22	-0.17	Antipsychotic drug-induced QTc interval change in schizophrenia;	chr6:61656516	chr6:57946074~57961501:-
BRCA	trans	rs9292918	0.806	rs6451795	ENSG00000231752.4	EMBP1	5.46	6.04e-08	0.0342	0.26	0.17	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:45341699	chr1:121519112~121571892:+
BRCA	trans	rs7824557	0.843	rs2736375	ENSG00000270154.1	RP11-419I17.1	-5.46	6.04e-08	0.0342	-0.2	-0.17	Retinal vascular caliber;	chr8:11258240	chr8:12476462~12477122:+
BRCA	trans	rs11024102	1	rs11024101	ENSG00000231105.1	RP5-1071N3.1	-5.46	6.04e-08	0.0342	-0.2	-0.17	Glaucoma (primary angle closure);	chr11:16983997	chr1:21293290~21299774:+
BRCA	trans	rs12681366	0.708	rs2445699	ENSG00000233473.2	RAD1P2	-5.46	6.04e-08	0.0342	-0.16	-0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94334289	chr1:159081133~159081795:-
BRCA	trans	rs504458	0.739	rs615583	ENSG00000254479.1	SLC25A1P1	-5.46	6.04e-08	0.0342	-0.22	-0.17	Childhood ear infection;	chr1:88324998	chr11:85934737~85935663:+
BRCA	trans	rs11098499	0.908	rs28499576	ENSG00000276805.1	RP11-291L22.6	5.46	6.04e-08	0.0342	0.19	0.17	Corneal astigmatism;	chr4:119465522	chr10:38451030~38451785:+
BRCA	trans	rs13196561	0.855	rs11759084	ENSG00000216895.7	AC009403.2	5.46	6.05e-08	0.0342	0.23	0.17	Menarche (age at onset);	chr6:100281629	chr7:155611231~155645205:-
BRCA	trans	rs7851693	0.789	rs7021911	ENSG00000277142.1	LINC00235	-5.46	6.05e-08	0.0342	-0.16	-0.17	Bone mineral density;	chr9:130625631	chr16:525155~527407:-
BRCA	trans	rs1933488	1	rs9479517	ENSG00000180015.12	RP11-756P10.3	-5.46	6.06e-08	0.0343	-0.22	-0.17	Prostate cancer;	chr6:153121654	chr4:188738373~188739494:+
BRCA	trans	rs9649213	0.593	rs6975156	ENSG00000225169.1	BRI3P1	5.46	6.07e-08	0.0344	0.21	0.17	Prostate cancer (SNP x SNP interaction);	chr7:98296222	chr1:100213293~100213670:+
BRCA	trans	rs11098499	0.954	rs10008392	ENSG00000253326.2	RP11-261C10.7	5.46	6.07e-08	0.0344	0.23	0.17	Corneal astigmatism;	chr4:119397684	chr1:243054861~243056394:-
BRCA	trans	rs7113874	0.524	rs6484485	ENSG00000266891.1	RP11-692N5.2	-5.46	6.08e-08	0.0344	-0.19	-0.17	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8599193	chr18:9734882~9735602:-
BRCA	trans	rs6601327	0.606	rs4841203	ENSG00000253893.2	FAM85B	5.46	6.08e-08	0.0344	0.21	0.17	Multiple myeloma (hyperdiploidy);	chr8:9725220	chr8:8167819~8226614:-
BRCA	trans	rs1499614	1	rs2659913	ENSG00000164669.11	INTS4P1	5.46	6.08e-08	0.0344	0.33	0.17	Gout;	chr7:66692349	chr7:65141225~65234216:+
BRCA	trans	rs1499614	1	rs2659911	ENSG00000164669.11	INTS4P1	5.46	6.08e-08	0.0344	0.33	0.17	Gout;	chr7:66693433	chr7:65141225~65234216:+
BRCA	trans	rs1499614	1	rs2707838	ENSG00000164669.11	INTS4P1	5.46	6.08e-08	0.0344	0.33	0.17	Gout;	chr7:66694214	chr7:65141225~65234216:+
BRCA	trans	rs1499614	1	rs60326618	ENSG00000164669.11	INTS4P1	5.46	6.08e-08	0.0344	0.33	0.17	Gout;	chr7:66701371	chr7:65141225~65234216:+
BRCA	trans	rs1499614	1	rs2707830	ENSG00000164669.11	INTS4P1	5.46	6.08e-08	0.0344	0.33	0.17	Gout;	chr7:66702658	chr7:65141225~65234216:+
BRCA	trans	rs1499614	1	rs2707828	ENSG00000164669.11	INTS4P1	5.46	6.08e-08	0.0344	0.33	0.17	Gout;	chr7:66706390	chr7:65141225~65234216:+
BRCA	trans	rs1499614	0.803	rs1922723	ENSG00000164669.11	INTS4P1	5.46	6.08e-08	0.0344	0.33	0.17	Gout;	chr7:66710076	chr7:65141225~65234216:+
BRCA	trans	rs4118325	0.734	rs1762495	ENSG00000232110.6	RP11-149I23.3	-5.46	6.08e-08	0.0344	-0.25	-0.17	AIDS;	chr1:107091494	chr10:89283765~89292125:+
BRCA	trans	rs6142102	0.961	rs1055857	ENSG00000280327.1	LA16c-313F4.1	-5.46	6.08e-08	0.0344	-0.18	-0.17	Skin pigmentation;	chr20:34026067	chr16:1576716~1578371:-
BRCA	trans	rs9328573	1	rs10468183	ENSG00000279048.1	RP11-511H23.2	-5.46	6.08e-08	0.0344	-0.16	-0.17	Urate levels in lean individuals;	chr15:99971842	chr7:17940503~17942922:+
BRCA	trans	rs6489882	0.867	rs4766672	ENSG00000250770.2	RP5-1063M23.1	5.46	6.09e-08	0.0345	0.22	0.17	Chronic lymphocytic leukemia;	chr12:112927343	chr12:3296202~3300224:-
BRCA	trans	rs9393813	0.626	rs12664996	ENSG00000242375.1	RP11-498P14.3	5.46	6.09e-08	0.0345	0.23	0.17	Bipolar disorder;	chr6:27395865	chr9:97195351~97197687:-
BRCA	trans	rs11098499	0.691	rs10010355	ENSG00000120555.12	SEPT7P9	5.46	6.09e-08	0.0345	0.19	0.17	Corneal astigmatism;	chr4:119339888	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.691	rs9307471	ENSG00000120555.12	SEPT7P9	5.46	6.09e-08	0.0345	0.19	0.17	Corneal astigmatism;	chr4:119340107	chr10:38383069~38402916:-
BRCA	trans	rs9858542	0.953	rs7633271	ENSG00000197582.5	GPX1P1	-5.45	6.12e-08	0.0346	-0.19	-0.17	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49518530	chrX:13378735~13379340:-
BRCA	trans	rs660899	0.752	rs7511800	ENSG00000231007.5	CDC20P1	5.45	6.13e-08	0.0347	0.22	0.17	Hypertension risk in short sleep duration;	chr1:43748598	chr9:87011652~87013151:+
BRCA	trans	rs1568889	0.877	rs57202579	ENSG00000174912.7	METTL15P1	5.45	6.13e-08	0.0347	0.18	0.17	Bipolar disorder;	chr11:28200130	chr3:156713884~156714928:-
BRCA	trans	rs6954796	1	rs2041664	ENSG00000278035.1	RP11-234K24.6	5.45	6.14e-08	0.0347	0.28	0.17	Non-word repetition;	chr7:20046762	chr20:36233851~36234297:+
BRCA	trans	rs7570469	0.612	rs12623875	ENSG00000262227.1	RP5-1050D4.5	-5.45	6.14e-08	0.0347	-0.16	-0.17	Response to antipsychotic treatment;	chr2:79415053	chr17:4987706~4988446:+
BRCA	trans	rs9860340	0.73	rs56841747	ENSG00000259370.2	RP11-1069G10.1	5.45	6.15e-08	0.0347	0.2	0.17	Electroencephalographic traits in alcoholism;	chr3:87675755	chr15:62827675~62884034:-
BRCA	trans	rs66887589	0.72	rs2036858	ENSG00000276997.3	RP11-378J18.9	5.45	6.15e-08	0.0348	0.18	0.17	Diastolic blood pressure;	chr4:119328082	chr1:222477252~222504622:-
BRCA	trans	rs1039766	0.925	rs268863	ENSG00000213985.4	AC078899.1	5.45	6.15e-08	0.0348	0.24	0.17	Lung adenocarcinoma;Lung cancer;	chr2:65261669	chr19:20257720~20259418:+
BRCA	trans	rs4879656	0.835	rs10813927	ENSG00000215007.3	DNAJA1P3	5.45	6.15e-08	0.0348	0.21	0.17	Menopause (age at onset);	chr9:33047912	chrX:107351650~107352843:-
BRCA	trans	rs9467773	0.935	rs4573	ENSG00000216901.1	AL022393.7	-5.45	6.15e-08	0.0348	-0.21	-0.17	Intelligence (multi-trait analysis);	chr6:26546580	chr6:28176188~28176674:+
BRCA	trans	rs9393813	0.626	rs9357038	ENSG00000242375.1	RP11-498P14.3	-5.45	6.16e-08	0.0348	-0.23	-0.17	Bipolar disorder;	chr6:27366794	chr9:97195351~97197687:-
BRCA	trans	rs11098499	0.909	rs71614422	ENSG00000276805.1	RP11-291L22.6	5.45	6.16e-08	0.0348	0.2	0.17	Corneal astigmatism;	chr4:119438185	chr10:38451030~38451785:+
BRCA	trans	rs16854884	0.58	rs16855002	ENSG00000226746.2	SMCR5	-5.45	6.16e-08	0.0348	-0.21	-0.17	Economic and political preferences (feminism/equality);	chr3:144130667	chr17:17776686~17779529:-
BRCA	trans	rs11098499	0.738	rs72918577	ENSG00000276805.1	RP11-291L22.6	5.45	6.17e-08	0.0348	0.19	0.17	Corneal astigmatism;	chr4:119405546	chr10:38451030~38451785:+
BRCA	trans	rs853679	0.546	rs200981	ENSG00000228078.1	HLA-U	-5.45	6.17e-08	0.0348	-0.34	-0.17	Depression;	chr6:27865396	chr6:29934101~29934286:+
BRCA	trans	rs6489882	0.867	rs7972033	ENSG00000250770.2	RP5-1063M23.1	5.45	6.17e-08	0.0349	0.22	0.17	Chronic lymphocytic leukemia;	chr12:112925478	chr12:3296202~3300224:-
BRCA	trans	rs6489882	0.867	rs7958379	ENSG00000250770.2	RP5-1063M23.1	5.45	6.17e-08	0.0349	0.22	0.17	Chronic lymphocytic leukemia;	chr12:112925479	chr12:3296202~3300224:-
BRCA	trans	rs1459104	1	rs12791192	ENSG00000134612.10	FOLH1B	-5.45	6.18e-08	0.0349	-0.32	-0.17	Body mass index;	chr11:55282510	chr11:89639227~89698718:+
BRCA	trans	rs12497850	0.897	rs7373778	ENSG00000197582.5	GPX1P1	5.45	6.18e-08	0.0349	0.17	0.17	Parkinson's disease;	chr3:48798959	chrX:13378735~13379340:-
BRCA	trans	rs1499614	1	rs2707840	ENSG00000164669.11	INTS4P1	5.45	6.18e-08	0.0349	0.33	0.17	Gout;	chr7:66693028	chr7:65141225~65234216:+
BRCA	trans	rs7746199	0.736	rs13210634	ENSG00000281831.1	HCP5B	5.45	6.18e-08	0.0349	0.42	0.17	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27678713	chr6:29871895~29873783:-
BRCA	trans	rs7746199	0.736	rs13215275	ENSG00000281831.1	HCP5B	5.45	6.18e-08	0.0349	0.42	0.17	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27679730	chr6:29871895~29873783:-
BRCA	trans	rs7746199	0.736	rs17749927	ENSG00000281831.1	HCP5B	5.45	6.18e-08	0.0349	0.42	0.17	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27702197	chr6:29871895~29873783:-
BRCA	trans	rs17161791	0.739	rs10225720	ENSG00000233589.1	RP4-694A7.2	-5.45	6.18e-08	0.0349	-0.2	-0.17	Pulmonary function in asthmatics;	chr7:9568942	chr1:68479129~68483539:+
BRCA	trans	rs11098499	0.954	rs10017543	ENSG00000253326.2	RP11-261C10.7	5.45	6.18e-08	0.0349	0.23	0.17	Corneal astigmatism;	chr4:119400265	chr1:243054861~243056394:-
BRCA	trans	rs11098499	0.82	rs2389885	ENSG00000276805.1	RP11-291L22.6	5.45	6.19e-08	0.0349	0.21	0.17	Corneal astigmatism;	chr4:119612776	chr10:38451030~38451785:+
BRCA	trans	rs4948102	0.732	rs6951810	ENSG00000186940.6	CHCHD2P9	-5.45	6.19e-08	0.0349	-0.22	-0.17	Plasma homocysteine levels (post-methionine load test);	chr7:56008905	chr9:79391304~79391759:+
BRCA	trans	rs17161791	1	rs10263376	ENSG00000233589.1	RP4-694A7.2	5.45	6.19e-08	0.0349	0.18	0.17	Pulmonary function in asthmatics;	chr7:9564692	chr1:68479129~68483539:+
BRCA	trans	rs9649213	0.593	rs6969731	ENSG00000225169.1	BRI3P1	5.45	6.19e-08	0.035	0.21	0.17	Prostate cancer (SNP x SNP interaction);	chr7:98295259	chr1:100213293~100213670:+
BRCA	trans	rs2839619	0.901	rs1571741	ENSG00000233045.1	AC097523.1	5.45	6.19e-08	0.035	0.19	0.17	Biochemical measures;	chr21:43013571	chr2:138278574~138279210:+
BRCA	trans	rs4148883	0.645	rs2851264	ENSG00000233859.2	ADH5P4	-5.45	6.2e-08	0.035	-0.21	-0.17	Alcohol dependence;	chr4:99108564	chr6:65836930~65838039:-
BRCA	trans	rs9757252	0.58	rs7649306	ENSG00000224043.6	CCNT2-AS1	-5.45	6.22e-08	0.0351	-0.23	-0.17	Prostate cancer (SNP x SNP interaction);	chr3:86915772	chr2:134735464~134918710:-
BRCA	trans	rs11774066	1	rs11774066	ENSG00000260318.1	COX6CP1	-5.45	6.23e-08	0.0352	-0.25	-0.17	Nonsyndromic cleft lip with cleft palate;	chr8:98443083	chr16:11903923~11904137:-
BRCA	trans	rs11098499	0.954	rs10518331	ENSG00000253326.2	RP11-261C10.7	5.45	6.24e-08	0.0352	0.23	0.17	Corneal astigmatism;	chr4:119402440	chr1:243054861~243056394:-
BRCA	trans	rs864643	0.524	rs9822783	ENSG00000214263.2	RPSAP53	-5.45	6.28e-08	0.0354	-0.3	-0.17	Attention deficit hyperactivity disorder;	chr3:39463311	chr13:67266845~67267706:-
BRCA	trans	rs67340775	0.541	rs200973	ENSG00000243753.4	HLA-L	-5.45	6.28e-08	0.0354	-0.27	-0.17	Lung cancer in ever smokers;	chr6:27890643	chr6:30259584~30293014:+
BRCA	trans	rs9393813	0.626	rs7772739	ENSG00000242375.1	RP11-498P14.3	-5.45	6.28e-08	0.0354	-0.23	-0.17	Bipolar disorder;	chr6:27351069	chr9:97195351~97197687:-
BRCA	trans	rs11098499	0.863	rs1010740	ENSG00000253326.2	RP11-261C10.7	-5.45	6.29e-08	0.0354	-0.24	-0.17	Corneal astigmatism;	chr4:119542254	chr1:243054861~243056394:-
BRCA	trans	rs35306767	0.953	rs12354639	ENSG00000187984.11	ANKRD19P	5.45	6.29e-08	0.0355	0.2	0.17	Eosinophil percentage of granulocytes;	chr10:917741	chr9:92809388~92888693:+
BRCA	trans	rs11098499	0.954	rs3733524	ENSG00000276805.1	RP11-291L22.6	5.45	6.3e-08	0.0355	0.21	0.17	Corneal astigmatism;	chr4:119502574	chr10:38451030~38451785:+
BRCA	trans	rs7943953	0.661	rs4939283	ENSG00000206897.1	SNORA9	5.45	6.32e-08	0.0356	0.2	0.17	Odorant perception (&beta-ionone);	chr11:59356341	chr12:123616708~123616840:+
BRCA	trans	rs660899	0.894	rs12410444	ENSG00000231007.5	CDC20P1	5.45	6.32e-08	0.0356	0.22	0.17	Hypertension risk in short sleep duration;	chr1:43723048	chr9:87011652~87013151:+
BRCA	trans	rs7829975	0.688	rs7826654	ENSG00000270154.1	RP11-419I17.1	5.45	6.32e-08	0.0356	0.19	0.17	Mood instability;	chr8:8521596	chr8:12476462~12477122:+
BRCA	trans	rs7829975	0.688	rs7826660	ENSG00000270154.1	RP11-419I17.1	5.45	6.32e-08	0.0356	0.19	0.17	Mood instability;	chr8:8521597	chr8:12476462~12477122:+
BRCA	trans	rs11098499	0.863	rs1480940	ENSG00000276805.1	RP11-291L22.6	5.45	6.33e-08	0.0356	0.2	0.17	Corneal astigmatism;	chr4:119536527	chr10:38451030~38451785:+
BRCA	trans	rs11098499	0.605	rs6833140	ENSG00000276997.3	RP11-378J18.9	5.45	6.33e-08	0.0356	0.19	0.17	Corneal astigmatism;	chr4:119345667	chr1:222477252~222504622:-
BRCA	trans	rs9649213	0.593	rs6947208	ENSG00000225169.1	BRI3P1	5.45	6.33e-08	0.0357	0.21	0.17	Prostate cancer (SNP x SNP interaction);	chr7:98282892	chr1:100213293~100213670:+
BRCA	trans	rs6142102	0.517	rs6142050	ENSG00000280327.1	LA16c-313F4.1	-5.45	6.33e-08	0.0357	-0.17	-0.17	Skin pigmentation;	chr20:33939322	chr16:1576716~1578371:-
BRCA	trans	rs11098499	0.954	rs67265404	ENSG00000276805.1	RP11-291L22.6	5.45	6.34e-08	0.0357	0.2	0.17	Corneal astigmatism;	chr4:119438115	chr10:38451030~38451785:+
BRCA	trans	rs902774	0.818	rs79377635	ENSG00000224520.2	KRT8P45	-5.45	6.34e-08	0.0357	-0.33	-0.17	Prostate cancer;	chr12:52883148	chr1:157073257~157074703:+
BRCA	trans	rs875971	0.545	rs73376394	ENSG00000213640.3	EEF1DP4	-5.45	6.35e-08	0.0357	-0.23	-0.17	Aortic root size;	chr7:66172694	chr7:64862999~64864370:+
BRCA	trans	rs853679	0.882	rs9468287	ENSG00000228078.1	HLA-U	-5.45	6.35e-08	0.0358	-0.35	-0.17	Depression;	chr6:28111963	chr6:29934101~29934286:+
BRCA	trans	rs2033732	0.706	rs7839360	ENSG00000251429.1	RP11-597D13.7	5.45	6.35e-08	0.0358	0.17	0.17	Body mass index;	chr8:84157484	chr4:158270378~158278676:+
BRCA	trans	rs13217239	0.646	rs7768407	ENSG00000216901.1	AL022393.7	-5.45	6.35e-08	0.0358	-0.2	-0.17	Schizophrenia;	chr6:27049016	chr6:28176188~28176674:+
BRCA	trans	rs902774	0.818	rs11831919	ENSG00000228753.1	EIF4BP2	5.45	6.36e-08	0.0358	0.32	0.17	Prostate cancer;	chr12:52878231	chr10:21028999~21030792:+
BRCA	trans	rs9649213	0.593	rs7787858	ENSG00000225169.1	BRI3P1	5.45	6.36e-08	0.0358	0.21	0.17	Prostate cancer (SNP x SNP interaction);	chr7:98380602	chr1:100213293~100213670:+
BRCA	trans	rs9649213	0.593	rs3801254	ENSG00000225169.1	BRI3P1	5.45	6.36e-08	0.0358	0.21	0.17	Prostate cancer (SNP x SNP interaction);	chr7:98381499	chr1:100213293~100213670:+
BRCA	trans	rs660899	0.894	rs4660257	ENSG00000231007.5	CDC20P1	5.45	6.37e-08	0.0359	0.22	0.17	Hypertension risk in short sleep duration;	chr1:43682497	chr9:87011652~87013151:+
BRCA	trans	rs7647973	1	rs13088309	ENSG00000235912.1	RP1-159A19.3	-5.45	6.38e-08	0.0359	-0.21	-0.17	Menarche (age at onset);	chr3:49330884	chr1:27649419~27649610:+
BRCA	trans	rs7566780	0.516	rs7566990	ENSG00000224631.4	RP11-51O6.1	-5.45	6.38e-08	0.0359	-0.16	-0.17	Cleft lip with or without cleft palate;Orofacial clefts;	chr2:16487455	chr16:61055399~61055964:-
BRCA	trans	rs7113874	0.569	rs10769915	ENSG00000266891.1	RP11-692N5.2	5.45	6.38e-08	0.0359	0.19	0.17	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8575902	chr18:9734882~9735602:-
BRCA	trans	rs6429082	0.51	rs2789367	ENSG00000241014.1	RP11-244H3.1	5.45	6.4e-08	0.036	0.13	0.17	Adiposity;	chr1:235343603	chr1:34974356~34985313:-
BRCA	trans	rs4366490	0.534	rs7120661	ENSG00000186676.3	EEF1GP1	-5.45	6.41e-08	0.036	-0.24	-0.17	Conotruncal heart defects;	chr11:63096913	chr7:125033453~125035301:+
BRCA	trans	rs875971	1	rs875971	ENSG00000164669.11	INTS4P1	5.45	6.41e-08	0.0361	0.2	0.17	Aortic root size;	chr7:66152608	chr7:65141225~65234216:+
BRCA	trans	rs2243480	0.901	rs778732	ENSG00000164669.11	INTS4P1	5.45	6.42e-08	0.0361	0.33	0.17	Diabetic kidney disease;	chr7:66357373	chr7:65141225~65234216:+
BRCA	trans	rs13394619	0.875	rs9287734	ENSG00000273980.1	RP13-49I15.6	-5.45	6.42e-08	0.0361	-0.2	-0.17	Endometriosis;	chr2:11584349	chr10:133257144~133257551:-
BRCA	trans	rs703108	0.731	rs7898954	ENSG00000227081.5	RP11-543P15.1	5.45	6.42e-08	0.0361	0.16	0.17	Monocyte percentage of white cells;	chr10:22034717	chr12:3211663~3211917:-
BRCA	trans	rs6939532	0.517	rs733528	ENSG00000242375.1	RP11-498P14.3	-5.45	6.43e-08	0.0361	-0.25	-0.17	Autism spectrum disorder or schizophrenia;	chr6:26374675	chr9:97195351~97197687:-
BRCA	trans	rs9460635	0.919	rs9466086	ENSG00000267259.1	CTD-2008P7.9	5.45	6.43e-08	0.0361	0.18	0.17	Metabolite levels (HVA-5-HIAA Factor score);	chr6:21450903	chr17:28232590~28235281:-
BRCA	trans	rs9649213	0.593	rs36017146	ENSG00000225169.1	BRI3P1	5.45	6.44e-08	0.0362	0.21	0.17	Prostate cancer (SNP x SNP interaction);	chr7:98345305	chr1:100213293~100213670:+
BRCA	trans	rs11098499	0.532	rs12512646	ENSG00000238035.7	AC138035.2	5.44	6.46e-08	0.0363	0.17	0.17	Corneal astigmatism;	chr4:119664578	chr5:181306502~181324685:+
BRCA	trans	rs1526687	0.655	rs12469086	ENSG00000257052.1	RP11-881M11.2	5.44	6.47e-08	0.0364	0.2	0.17	Cardiac Troponin-T levels;	chr2:52477698	chr11:60906789~60909742:+
BRCA	trans	rs11748023	0.531	rs155947	ENSG00000224848.1	RP11-535M15.1	5.44	6.47e-08	0.0364	0.2	0.17	Intelligence (multi-trait analysis);	chr5:140140971	chr9:96687056~96721121:+
BRCA	trans	rs1391576	1	rs1391576	ENSG00000134612.10	FOLH1B	-5.44	6.48e-08	0.0364	-0.32	-0.17	Body mass index;	chr11:54724348	chr11:89639227~89698718:+
BRCA	trans	rs11098499	0.532	rs4833624	ENSG00000238035.7	AC138035.2	5.44	6.49e-08	0.0364	0.17	0.17	Corneal astigmatism;	chr4:119664342	chr5:181306502~181324685:+
BRCA	trans	rs6568490	0.556	rs6568495	ENSG00000228057.1	SEC63P1	5.44	6.51e-08	0.0365	0.24	0.17	Lymphocyte counts;	chr6:107769445	chr1:97545701~97546958:+
BRCA	trans	rs7113874	0.569	rs10769924	ENSG00000266891.1	RP11-692N5.2	-5.44	6.52e-08	0.0366	-0.2	-0.17	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8601646	chr18:9734882~9735602:-
BRCA	trans	rs2975734	0.68	rs1052453	ENSG00000253893.2	FAM85B	5.44	6.53e-08	0.0367	0.22	0.17	Chronotype;Morning vs. evening chronotype;	chr8:10250815	chr8:8167819~8226614:-
BRCA	trans	rs9292918	0.806	rs1501358	ENSG00000231752.4	EMBP1	5.44	6.54e-08	0.0367	0.26	0.17	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr5:45338114	chr1:121519112~121571892:+
BRCA	trans	rs875971	0.545	rs1796217	ENSG00000213640.3	EEF1DP4	5.44	6.54e-08	0.0367	0.23	0.17	Aortic root size;	chr7:66620931	chr7:64862999~64864370:+
BRCA	trans	rs17834760	1	rs62423505	ENSG00000215190.7	LINC00680	-5.44	6.54e-08	0.0367	-0.22	-0.17	Antipsychotic drug-induced QTc interval change in schizophrenia;	chr6:61656812	chr6:57946074~57961501:-
BRCA	trans	rs9649213	0.593	rs6967457	ENSG00000225169.1	BRI3P1	5.44	6.54e-08	0.0367	0.21	0.17	Prostate cancer (SNP x SNP interaction);	chr7:98282909	chr1:100213293~100213670:+
BRCA	trans	rs11098499	0.908	rs7695996	ENSG00000253326.2	RP11-261C10.7	5.44	6.55e-08	0.0367	0.23	0.17	Corneal astigmatism;	chr4:119400878	chr1:243054861~243056394:-
BRCA	trans	rs2950393	0.804	rs10783796	ENSG00000257210.1	NACAP3	5.44	6.55e-08	0.0368	0.2	0.17	Platelet distribution width;	chr12:56733387	chr12:93124063~93124543:-
BRCA	trans	rs282544	1	rs27964	ENSG00000231752.4	EMBP1	5.44	6.55e-08	0.0368	0.22	0.17	Myopia (pathological);	chr5:50856633	chr1:121519112~121571892:+
BRCA	trans	rs6934970	1	rs3844154	ENSG00000267560.1	RP11-173A16.1	-5.44	6.56e-08	0.0368	-0.21	-0.17	Bipolar disorder (body mass index interaction);	chr6:112812295	chr18:62300036~62300998:-
BRCA	trans	rs9470366	0.816	rs4331968	ENSG00000257004.1	RP11-180M15.3	5.44	6.56e-08	0.0368	0.19	0.17	QRS duration;	chr6:36655466	chr12:12668982~12685075:+
BRCA	trans	rs703108	0.731	rs7898954	ENSG00000279744.1	RP13-20L14.10	5.44	6.57e-08	0.0368	0.15	0.17	Monocyte percentage of white cells;	chr10:22034717	chr17:82462601~82464255:+
BRCA	trans	rs11098499	0.863	rs1552095	ENSG00000253326.2	RP11-261C10.7	5.44	6.57e-08	0.0369	0.24	0.17	Corneal astigmatism;	chr4:119539151	chr1:243054861~243056394:-
BRCA	trans	rs7113874	0.569	rs11041983	ENSG00000266891.1	RP11-692N5.2	5.44	6.58e-08	0.0369	0.2	0.17	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8559072	chr18:9734882~9735602:-
BRCA	trans	rs1814175	0.527	rs7110797	ENSG00000134612.10	FOLH1B	-5.44	6.58e-08	0.0369	-0.22	-0.17	Height;	chr11:49622544	chr11:89639227~89698718:+
BRCA	trans	rs1816854	0.938	rs7966902	ENSG00000178082.6	TWF1P1	5.44	6.58e-08	0.0369	0.2	0.17	Inflammatory bowel disease;	chr12:43806682	chr17:29203426~29204474:-
BRCA	trans	rs660899	0.894	rs12410155	ENSG00000231007.5	CDC20P1	5.44	6.58e-08	0.0369	0.22	0.17	Hypertension risk in short sleep duration;	chr1:43722794	chr9:87011652~87013151:+
BRCA	trans	rs11024102	0.962	rs34927905	ENSG00000231105.1	RP5-1071N3.1	-5.44	6.58e-08	0.0369	-0.2	-0.17	Glaucoma (primary angle closure);	chr11:16979880	chr1:21293290~21299774:+
BRCA	trans	rs7829975	0.54	rs2976909	ENSG00000270154.1	RP11-419I17.1	-5.44	6.6e-08	0.037	-0.2	-0.17	Mood instability;	chr8:8489180	chr8:12476462~12477122:+
BRCA	trans	rs7570469	0.762	rs449529	ENSG00000276390.1	RP1-197B17.5	5.44	6.6e-08	0.037	0.22	0.17	Response to antipsychotic treatment;	chr2:79474817	chr12:47699401~47699917:-
BRCA	trans	rs7943953	0.629	rs1608213	ENSG00000206897.1	SNORA9	5.44	6.61e-08	0.0371	0.19	0.17	Odorant perception (&beta-ionone);	chr11:59328553	chr12:123616708~123616840:+
BRCA	trans	rs1816854	1	rs10880569	ENSG00000178082.6	TWF1P1	5.44	6.62e-08	0.0371	0.2	0.17	Inflammatory bowel disease;	chr12:43807833	chr17:29203426~29204474:-
BRCA	trans	rs6142102	0.602	rs4911395	ENSG00000280327.1	LA16c-313F4.1	-5.44	6.63e-08	0.0372	-0.17	-0.17	Skin pigmentation;	chr20:33992095	chr16:1576716~1578371:-
BRCA	trans	rs7824557	0.872	rs1347410	ENSG00000270154.1	RP11-419I17.1	-5.44	6.63e-08	0.0372	-0.2	-0.17	Retinal vascular caliber;	chr8:11253733	chr8:12476462~12477122:+
BRCA	trans	rs4879656	0.966	rs10758178	ENSG00000215007.3	DNAJA1P3	5.44	6.63e-08	0.0372	0.21	0.17	Menopause (age at onset);	chr9:32999421	chrX:107351650~107352843:-
BRCA	trans	rs853679	0.607	rs35749575	ENSG00000204338.7	CYP21A1P	-5.44	6.64e-08	0.0372	-0.39	-0.17	Depression;	chr6:28147040	chr6:32005636~32008451:+
BRCA	trans	rs902774	0.818	rs11831919	ENSG00000254285.3	KRT8P3	-5.44	6.65e-08	0.0373	-0.33	-0.17	Prostate cancer;	chr12:52878231	chr8:61578220~61579668:+
BRCA	trans	rs1039766	1	rs268864	ENSG00000213985.4	AC078899.1	-5.44	6.66e-08	0.0373	-0.24	-0.17	Lung adenocarcinoma;Lung cancer;	chr2:65262608	chr19:20257720~20259418:+
BRCA	trans	rs7570469	0.647	rs621074	ENSG00000276390.1	RP1-197B17.5	5.44	6.66e-08	0.0373	0.2	0.17	Response to antipsychotic treatment;	chr2:79454932	chr12:47699401~47699917:-
BRCA	trans	rs1568889	1	rs12802830	ENSG00000174912.7	METTL15P1	5.44	6.67e-08	0.0373	0.19	0.17	Bipolar disorder;	chr11:28299649	chr3:156713884~156714928:-
BRCA	trans	rs801193	0.548	rs2659904	ENSG00000164669.11	INTS4P1	-5.44	6.67e-08	0.0373	-0.21	-0.17	Aortic root size;	chr7:66713615	chr7:65141225~65234216:+
BRCA	trans	rs11098499	0.58	rs12509234	ENSG00000253326.2	RP11-261C10.7	5.44	6.67e-08	0.0373	0.23	0.17	Corneal astigmatism;	chr4:119398279	chr1:243054861~243056394:-
BRCA	trans	rs11098499	0.909	rs10014719	ENSG00000253326.2	RP11-261C10.7	5.44	6.67e-08	0.0373	0.23	0.17	Corneal astigmatism;	chr4:119399560	chr1:243054861~243056394:-
BRCA	trans	rs9860340	0.652	rs17024791	ENSG00000259370.2	RP11-1069G10.1	5.44	6.67e-08	0.0373	0.19	0.17	Electroencephalographic traits in alcoholism;	chr3:87588825	chr15:62827675~62884034:-
BRCA	trans	rs7568458	0.905	rs6714709	ENSG00000223886.3	RP11-251G23.2	5.44	6.7e-08	0.0375	0.19	0.17	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr2:85529252	chr7:105530209~105530671:+
BRCA	trans	rs703108	0.731	rs7898954	ENSG00000226084.5	RP4-706A16.3	5.44	6.7e-08	0.0375	0.2	0.17	Monocyte percentage of white cells;	chr10:22034717	chr1:77129114~77129668:+
BRCA	trans	rs6921919	0.848	rs56131013	ENSG00000176998.4	HCG4	-5.44	6.71e-08	0.0375	-0.24	-0.17	Autism spectrum disorder or schizophrenia;	chr6:28352900	chr6:29791753~29792750:-
BRCA	trans	rs6934970	1	rs9400572	ENSG00000267560.1	RP11-173A16.1	-5.44	6.71e-08	0.0376	-0.21	-0.17	Bipolar disorder (body mass index interaction);	chr6:112804833	chr18:62300036~62300998:-
BRCA	trans	rs2950393	0.804	rs2926752	ENSG00000257210.1	NACAP3	5.44	6.71e-08	0.0376	0.2	0.17	Platelet distribution width;	chr12:56710144	chr12:93124063~93124543:-
BRCA	trans	rs2950393	0.777	rs2958148	ENSG00000257210.1	NACAP3	5.44	6.71e-08	0.0376	0.2	0.17	Platelet distribution width;	chr12:56710153	chr12:93124063~93124543:-
BRCA	trans	rs4148883	0.689	rs2602861	ENSG00000233859.2	ADH5P4	-5.44	6.71e-08	0.0376	-0.21	-0.17	Alcohol dependence;	chr4:99109745	chr6:65836930~65838039:-
BRCA	trans	rs7570469	0.762	rs449552	ENSG00000276390.1	RP1-197B17.5	5.44	6.73e-08	0.0377	0.22	0.17	Response to antipsychotic treatment;	chr2:79474902	chr12:47699401~47699917:-
BRCA	trans	rs17507216	0.718	rs28587782	ENSG00000235370.6	DNM1P51	-5.44	6.74e-08	0.0377	-0.23	-0.17	Excessive daytime sleepiness;	chr15:82576881	chr15:84398316~84411701:-
BRCA	trans	rs11098499	0.863	rs12508173	ENSG00000253326.2	RP11-261C10.7	5.44	6.75e-08	0.0377	0.23	0.17	Corneal astigmatism;	chr4:119397371	chr1:243054861~243056394:-
BRCA	trans	rs11098499	0.908	rs12504149	ENSG00000253326.2	RP11-261C10.7	5.44	6.75e-08	0.0377	0.23	0.17	Corneal astigmatism;	chr4:119397422	chr1:243054861~243056394:-
BRCA	trans	rs9467711	0.591	rs3752417	ENSG00000253570.1	RNF5P1	5.44	6.75e-08	0.0377	0.39	0.17	Autism spectrum disorder or schizophrenia;	chr6:26045677	chr8:38600661~38601200:-
BRCA	trans	rs7927771	0.864	rs11604680	ENSG00000134612.10	FOLH1B	-5.44	6.75e-08	0.0378	-0.23	-0.17	Subjective well-being;	chr11:47435988	chr11:89639227~89698718:+
BRCA	trans	rs7746199	0.736	rs17693963	ENSG00000281831.1	HCP5B	5.44	6.75e-08	0.0378	0.39	0.17	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27742386	chr6:29871895~29873783:-
BRCA	trans	rs11098499	0.866	rs10518329	ENSG00000253326.2	RP11-261C10.7	5.44	6.76e-08	0.0378	0.22	0.17	Corneal astigmatism;	chr4:119480680	chr1:243054861~243056394:-
BRCA	trans	rs319204	0.918	rs2436401	ENSG00000226498.2	RP11-182B22.2	5.44	6.77e-08	0.0379	0.19	0.17	Schizophrenia;	chr5:146907620	chr1:236819634~236820518:+
BRCA	trans	rs17161791	0.739	rs10250765	ENSG00000233589.1	RP4-694A7.2	5.44	6.77e-08	0.0379	0.2	0.17	Pulmonary function in asthmatics;	chr7:9568508	chr1:68479129~68483539:+
BRCA	trans	rs3096299	0.967	rs2965827	ENSG00000215030.5	RPL13P12	5.44	6.79e-08	0.0379	0.17	0.17	Multiple myeloma (IgH translocation);	chr16:89390942	chr17:17383377~17384012:-
BRCA	trans	rs1459104	1	rs35756956	ENSG00000134612.10	FOLH1B	-5.44	6.79e-08	0.038	-0.33	-0.17	Body mass index;	chr11:55556151	chr11:89639227~89698718:+
BRCA	trans	rs4713118	0.824	rs742046	ENSG00000204709.4	LINC01556	5.44	6.8e-08	0.038	0.23	0.17	Parkinson's disease;	chr6:27771475	chr6:28943877~28944537:+
BRCA	trans	rs11098499	0.863	rs10013305	ENSG00000276805.1	RP11-291L22.6	5.44	6.8e-08	0.038	0.2	0.17	Corneal astigmatism;	chr4:119529269	chr10:38451030~38451785:+
BRCA	trans	rs11098499	0.863	rs3775849	ENSG00000276805.1	RP11-291L22.6	5.44	6.8e-08	0.038	0.2	0.17	Corneal astigmatism;	chr4:119529753	chr10:38451030~38451785:+
BRCA	trans	rs11098499	0.818	rs7688802	ENSG00000276805.1	RP11-291L22.6	5.44	6.8e-08	0.038	0.2	0.17	Corneal astigmatism;	chr4:119530513	chr10:38451030~38451785:+
BRCA	trans	rs11098499	0.863	rs7695620	ENSG00000276805.1	RP11-291L22.6	5.44	6.8e-08	0.038	0.2	0.17	Corneal astigmatism;	chr4:119531621	chr10:38451030~38451785:+
BRCA	trans	rs11098499	0.863	rs12502389	ENSG00000276805.1	RP11-291L22.6	5.44	6.8e-08	0.038	0.2	0.17	Corneal astigmatism;	chr4:119533036	chr10:38451030~38451785:+
BRCA	trans	rs11098499	0.821	rs3775852	ENSG00000276805.1	RP11-291L22.6	5.44	6.8e-08	0.038	0.2	0.17	Corneal astigmatism;	chr4:119533401	chr10:38451030~38451785:+
BRCA	trans	rs11098499	0.82	rs6534140	ENSG00000276805.1	RP11-291L22.6	5.44	6.8e-08	0.038	0.2	0.17	Corneal astigmatism;	chr4:119534156	chr10:38451030~38451785:+
BRCA	trans	rs11098499	0.863	rs7657849	ENSG00000276805.1	RP11-291L22.6	5.44	6.8e-08	0.038	0.2	0.17	Corneal astigmatism;	chr4:119534339	chr10:38451030~38451785:+
BRCA	trans	rs11098499	0.863	rs10034450	ENSG00000276805.1	RP11-291L22.6	5.44	6.8e-08	0.038	0.2	0.17	Corneal astigmatism;	chr4:119534494	chr10:38451030~38451785:+
BRCA	trans	rs11098499	0.863	rs1480939	ENSG00000276805.1	RP11-291L22.6	5.44	6.8e-08	0.038	0.2	0.17	Corneal astigmatism;	chr4:119535772	chr10:38451030~38451785:+
BRCA	trans	rs9368481	0.547	rs2093303	ENSG00000216901.1	AL022393.7	-5.44	6.82e-08	0.0381	-0.21	-0.17	Autism spectrum disorder or schizophrenia;	chr6:26896627	chr6:28176188~28176674:+
BRCA	trans	rs12586478	0.568	rs17122114	ENSG00000266957.1	RP11-49K24.4	5.44	6.82e-08	0.0381	0.19	0.17	Post bronchodilator FEV1;	chr14:86322561	chr18:47077361~47091280:-
BRCA	trans	rs62295889	0.602	rs1476237	ENSG00000232228.1	RP11-77O7.1	-5.44	6.82e-08	0.0381	-0.24	-0.17	Obesity-related traits;	chr4:12544837	chr2:69594741~69595058:-
BRCA	trans	rs7824557	0.767	rs3808513	ENSG00000253981.4	ALG1L13P	-5.43	6.84e-08	0.0382	-0.21	-0.17	Retinal vascular caliber;	chr8:11299951	chr8:8236003~8244667:-
BRCA	trans	rs853679	0.599	rs149943	ENSG00000228078.1	HLA-U	-5.43	6.85e-08	0.0383	-0.34	-0.17	Depression;	chr6:28034610	chr6:29934101~29934286:+
BRCA	trans	rs5006884	0.526	rs2736557	ENSG00000258626.2	COX7A2P1	5.43	6.87e-08	0.0384	0.21	0.17	Fetal hemoglobin levels;	chr11:5361361	chr14:67652300~67652614:-
BRCA	trans	rs9860340	0.69	rs67833493	ENSG00000259370.2	RP11-1069G10.1	5.43	6.88e-08	0.0384	0.2	0.17	Electroencephalographic traits in alcoholism;	chr3:87586659	chr15:62827675~62884034:-
BRCA	trans	rs319204	0.959	rs319187	ENSG00000226498.2	RP11-182B22.2	5.43	6.88e-08	0.0384	0.19	0.17	Schizophrenia;	chr5:146891974	chr1:236819634~236820518:+
BRCA	trans	rs56114371	0.53	rs9357045	ENSG00000253570.1	RNF5P1	5.43	6.88e-08	0.0384	0.29	0.17	Breast cancer;	chr6:27721148	chr8:38600661~38601200:-
BRCA	trans	rs7943953	0.63	rs7950935	ENSG00000206897.1	SNORA9	5.43	6.88e-08	0.0384	0.2	0.17	Odorant perception (&beta-ionone);	chr11:59327895	chr12:123616708~123616840:+
BRCA	trans	rs7107770	1	rs4935913	ENSG00000233517.1	AC005162.5	-5.43	6.89e-08	0.0384	-0.26	-0.17	Photic sneeze reflex;	chr11:125233250	chr7:28987028~28988899:+
BRCA	trans	rs9860340	0.73	rs73137449	ENSG00000259370.2	RP11-1069G10.1	5.43	6.89e-08	0.0385	0.2	0.17	Electroencephalographic traits in alcoholism;	chr3:87591899	chr15:62827675~62884034:-
BRCA	trans	rs9393777	0.623	rs9358945	ENSG00000277241.1	RP11-114M1.3	-5.43	6.9e-08	0.0385	-0.25	-0.17	Intelligence (multi-trait analysis);	chr6:26471886	chr3:177700346~177701072:-
BRCA	trans	rs7943953	0.661	rs4939276	ENSG00000206897.1	SNORA9	5.43	6.9e-08	0.0385	0.2	0.17	Odorant perception (&beta-ionone);	chr11:59327090	chr12:123616708~123616840:+
BRCA	trans	rs6504622	0.905	rs9889741	ENSG00000266644.1	RP11-927P21.2	-5.43	6.91e-08	0.0385	-0.17	-0.17	Orofacial clefts;	chr17:46948967	chr17:64899766~64900716:+
BRCA	trans	rs10028773	0.515	rs9994651	ENSG00000276997.3	RP11-378J18.9	5.43	6.92e-08	0.0386	0.2	0.17	Educational attainment;	chr4:119666648	chr1:222477252~222504622:-
BRCA	trans	rs6489882	0.867	rs2384072	ENSG00000250770.2	RP5-1063M23.1	5.43	6.93e-08	0.0386	0.22	0.17	Chronic lymphocytic leukemia;	chr12:112929617	chr12:3296202~3300224:-
BRCA	trans	rs11098499	0.954	rs2389803	ENSG00000253326.2	RP11-261C10.7	-5.43	6.94e-08	0.0387	-0.23	-0.17	Corneal astigmatism;	chr4:119472356	chr1:243054861~243056394:-
BRCA	trans	rs998808	0.947	rs1568111	ENSG00000215190.7	LINC00680	-5.43	6.95e-08	0.0387	-0.21	-0.17	Antipsychotic drug-induced QTc interval change in schizophrenia;	chr6:61995629	chr6:57946074~57961501:-
BRCA	trans	rs11098499	0.863	rs6858592	ENSG00000253326.2	RP11-261C10.7	5.43	6.96e-08	0.0388	0.23	0.17	Corneal astigmatism;	chr4:119537537	chr1:243054861~243056394:-
BRCA	trans	rs73110464	0.591	rs11829997	ENSG00000255815.3	KRT8P11	-5.43	6.97e-08	0.0388	-0.39	-0.17	Cancer (pleiotropy);	chr12:52921875	chr9:99305176~99306611:+
BRCA	trans	rs9860340	0.73	rs4858965	ENSG00000259370.2	RP11-1069G10.1	5.43	6.97e-08	0.0389	0.2	0.17	Electroencephalographic traits in alcoholism;	chr3:87591213	chr15:62827675~62884034:-
BRCA	trans	rs7566780	0.516	rs7567636	ENSG00000224631.4	RP11-51O6.1	-5.43	6.98e-08	0.0389	-0.16	-0.17	Cleft lip with or without cleft palate;Orofacial clefts;	chr2:16482748	chr16:61055399~61055964:-
BRCA	trans	rs7566780	0.541	rs4645016	ENSG00000224631.4	RP11-51O6.1	-5.43	6.98e-08	0.0389	-0.16	-0.17	Cleft lip with or without cleft palate;Orofacial clefts;	chr2:16483024	chr16:61055399~61055964:-
BRCA	trans	rs2108622	0.527	rs67617968	ENSG00000220614.1	RP11-480N24.4	-5.43	6.98e-08	0.0389	-0.19	-0.17	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15866755	chr6:43328134~43328476:+
BRCA	trans	rs2243480	1	rs316321	ENSG00000164669.11	INTS4P1	5.43	6.99e-08	0.0389	0.32	0.17	Diabetic kidney disease;	chr7:66146626	chr7:65141225~65234216:+
BRCA	trans	rs2243480	1	rs316318	ENSG00000164669.11	INTS4P1	5.43	6.99e-08	0.0389	0.32	0.17	Diabetic kidney disease;	chr7:66147917	chr7:65141225~65234216:+
BRCA	trans	rs2243480	1	rs316317	ENSG00000164669.11	INTS4P1	5.43	6.99e-08	0.0389	0.32	0.17	Diabetic kidney disease;	chr7:66148650	chr7:65141225~65234216:+
BRCA	trans	rs2243480	1	rs316304	ENSG00000164669.11	INTS4P1	5.43	6.99e-08	0.0389	0.32	0.17	Diabetic kidney disease;	chr7:66151907	chr7:65141225~65234216:+
BRCA	trans	rs11098499	0.954	rs2389802	ENSG00000276805.1	RP11-291L22.6	5.43	6.99e-08	0.039	0.2	0.17	Corneal astigmatism;	chr4:119404577	chr10:38451030~38451785:+
BRCA	trans	rs319204	0.877	rs662354	ENSG00000226498.2	RP11-182B22.2	5.43	7e-08	0.039	0.19	0.17	Schizophrenia;	chr5:146897729	chr1:236819634~236820518:+
BRCA	trans	rs12497850	0.931	rs4974080	ENSG00000197582.5	GPX1P1	5.43	7e-08	0.039	0.17	0.17	Parkinson's disease;	chr3:48993395	chrX:13378735~13379340:-
BRCA	trans	rs9393777	0.92	rs34071253	ENSG00000228078.1	HLA-U	-5.43	7e-08	0.039	-0.39	-0.17	Intelligence (multi-trait analysis);	chr6:27424023	chr6:29934101~29934286:+
BRCA	trans	rs11098499	0.909	rs1809406	ENSG00000276805.1	RP11-291L22.6	5.43	7e-08	0.039	0.19	0.17	Corneal astigmatism;	chr4:119455967	chr10:38451030~38451785:+
BRCA	trans	rs11098499	0.865	rs2389809	ENSG00000276805.1	RP11-291L22.6	5.43	7e-08	0.039	0.19	0.17	Corneal astigmatism;	chr4:119456244	chr10:38451030~38451785:+
BRCA	trans	rs11098499	0.909	rs9994810	ENSG00000276805.1	RP11-291L22.6	5.43	7e-08	0.039	0.19	0.17	Corneal astigmatism;	chr4:119460435	chr10:38451030~38451785:+
BRCA	trans	rs11098499	0.697	rs10020027	ENSG00000276805.1	RP11-291L22.6	5.43	7e-08	0.039	0.19	0.17	Corneal astigmatism;	chr4:119460724	chr10:38451030~38451785:+
BRCA	trans	rs11098499	0.779	rs7356491	ENSG00000276805.1	RP11-291L22.6	5.43	7e-08	0.039	0.19	0.17	Corneal astigmatism;	chr4:119460819	chr10:38451030~38451785:+
BRCA	trans	rs6436559	0.504	rs76264800	ENSG00000237604.1	AP001056.1	5.43	7.01e-08	0.039	0.31	0.17	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;	chr2:225452647	chr21:44175489~44176453:+
BRCA	trans	rs6436559	0.504	rs7597786	ENSG00000237604.1	AP001056.1	5.43	7.01e-08	0.039	0.31	0.17	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;	chr2:225454836	chr21:44175489~44176453:+
BRCA	trans	rs1421334	0.679	rs2160935	ENSG00000261457.3	AC002519.6	-5.43	7.01e-08	0.0391	-0.22	-0.17	Intelligence (multi-trait analysis);	chr8:30983135	chr16:31802947~31807973:+
BRCA	trans	rs1976714	0.647	rs1533394	ENSG00000236605.1	AC023115.4	-5.43	7.01e-08	0.0391	-0.24	-0.17	Fibrinogen levels;	chr3:123143932	chr2:67324627~67325304:+
BRCA	trans	rs4713118	0.868	rs742047	ENSG00000204709.4	LINC01556	5.43	7.02e-08	0.0391	0.24	0.17	Parkinson's disease;	chr6:27771601	chr6:28943877~28944537:+
BRCA	trans	rs7113874	0.524	rs10769921	ENSG00000266891.1	RP11-692N5.2	-5.43	7.02e-08	0.0391	-0.19	-0.17	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8599596	chr18:9734882~9735602:-
BRCA	trans	rs4957798	0.666	rs3816024	ENSG00000206878.1	SNORA51	5.43	7.03e-08	0.0391	0.31	0.17	Asthma;Asthma (childhood onset);	chr5:109100313	chr1:228652436~228652560:+
BRCA	trans	rs546131	0.642	rs10836315	ENSG00000225531.1	RP11-196I18.3	5.43	7.03e-08	0.0392	0.26	0.17	Lung disease severity in cystic fibrosis;	chr11:34831799	chr9:107116829~107117557:+
BRCA	trans	rs11098499	0.526	rs10026625	ENSG00000120555.12	SEPT7P9	5.43	7.04e-08	0.0392	0.19	0.17	Corneal astigmatism;	chr4:119358981	chr10:38383069~38402916:-
BRCA	trans	rs11696739	0.866	rs1535882	ENSG00000207119.2	U3	5.43	7.06e-08	0.0393	0.19	0.17	Mean platelet volume;	chr20:1619878	chr15:69457941~69458149:-
BRCA	trans	rs6939532	0.522	rs2073528	ENSG00000242375.1	RP11-498P14.3	-5.43	7.06e-08	0.0393	-0.25	-0.17	Autism spectrum disorder or schizophrenia;	chr6:26374915	chr9:97195351~97197687:-
BRCA	trans	rs12497850	0.931	rs9840050	ENSG00000197582.5	GPX1P1	5.43	7.06e-08	0.0393	0.17	0.17	Parkinson's disease;	chr3:49095877	chrX:13378735~13379340:-
BRCA	trans	rs16837677	0.826	rs3795737	ENSG00000227183.3	HDGFP1	-5.43	7.07e-08	0.0393	-0.38	-0.17	Sjögren's syndrome;	chr1:156727264	chrX:131646639~131646890:+
BRCA	trans	rs853679	0.546	rs200989	ENSG00000228078.1	HLA-U	-5.43	7.07e-08	0.0394	-0.34	-0.17	Depression;	chr6:27848664	chr6:29934101~29934286:+
BRCA	trans	rs7829975	0.593	rs2921077	ENSG00000270154.1	RP11-419I17.1	5.43	7.08e-08	0.0394	0.19	0.17	Mood instability;	chr8:8446992	chr8:12476462~12477122:+
BRCA	trans	rs1232027	0.7	rs1382540	ENSG00000188985.6	DHFRP1	5.43	7.08e-08	0.0394	0.21	0.17	Huntington's disease progression;	chr5:80656346	chr18:26170726~26171284:-
BRCA	trans	rs6939532	0.544	rs10946816	ENSG00000242375.1	RP11-498P14.3	-5.43	7.08e-08	0.0394	-0.25	-0.17	Autism spectrum disorder or schizophrenia;	chr6:26361718	chr9:97195351~97197687:-
BRCA	trans	rs853679	0.546	rs200952	ENSG00000228078.1	HLA-U	-5.43	7.08e-08	0.0394	-0.34	-0.17	Depression;	chr6:27869198	chr6:29934101~29934286:+
BRCA	trans	rs3019286	0.573	rs4292660	ENSG00000260318.1	COX6CP1	5.43	7.08e-08	0.0394	0.21	0.17	Suicide behavior;	chr8:98784068	chr16:11903923~11904137:-
BRCA	trans	rs319204	0.959	rs319188	ENSG00000226498.2	RP11-182B22.2	5.43	7.09e-08	0.0394	0.19	0.17	Schizophrenia;	chr5:146891254	chr1:236819634~236820518:+
BRCA	trans	rs1368013	0.645	rs11615609	ENSG00000276952.1	RP5-965G21.6	5.43	7.09e-08	0.0394	0.21	0.17	Number of children (6+ vs. 0 or 1);	chr12:90354324	chr20:25284915~25285588:-
BRCA	trans	rs450533	0.533	rs439392	ENSG00000229619.3	MBNL1-AS1	5.43	7.09e-08	0.0394	0.18	0.17	Cancer;	chr4:106916724	chr3:152262616~152269555:-
BRCA	trans	rs4631830	0.9	rs11006274	ENSG00000228789.5	HCG22	-5.43	7.09e-08	0.0394	-0.2	-0.17	Prostate-specific antigen levels;	chr10:46055531	chr6:31053450~31059890:+
BRCA	trans	rs6489882	0.867	rs2384073	ENSG00000250770.2	RP5-1063M23.1	5.43	7.1e-08	0.0395	0.22	0.17	Chronic lymphocytic leukemia;	chr12:112929790	chr12:3296202~3300224:-
BRCA	trans	rs6934970	1	rs3851232	ENSG00000267560.1	RP11-173A16.1	-5.43	7.1e-08	0.0395	-0.2	-0.17	Bipolar disorder (body mass index interaction);	chr6:112809920	chr18:62300036~62300998:-
BRCA	trans	rs7826238	0.72	rs12546760	ENSG00000270154.1	RP11-419I17.1	-5.43	7.1e-08	0.0395	-0.18	-0.17	Systolic blood pressure;	chr8:8517326	chr8:12476462~12477122:+
BRCA	trans	rs332507	0.711	rs3772793	ENSG00000234253.1	RPL7P13	5.43	7.11e-08	0.0395	0.21	0.17	Plateletcrit;	chr3:124686876	chr2:49878623~49879363:+
BRCA	trans	rs9860340	0.73	rs1509781	ENSG00000259370.2	RP11-1069G10.1	5.43	7.11e-08	0.0395	0.2	0.17	Electroencephalographic traits in alcoholism;	chr3:87592418	chr15:62827675~62884034:-
BRCA	trans	rs6489882	0.966	rs7955267	ENSG00000250770.2	RP5-1063M23.1	5.43	7.11e-08	0.0395	0.21	0.17	Chronic lymphocytic leukemia;	chr12:112941234	chr12:3296202~3300224:-
BRCA	trans	rs7647973	1	rs11928090	ENSG00000235912.1	RP1-159A19.3	-5.43	7.11e-08	0.0396	-0.21	-0.17	Menarche (age at onset);	chr3:49567471	chr1:27649419~27649610:+
BRCA	trans	rs332507	0.83	rs333355	ENSG00000234253.1	RPL7P13	5.43	7.12e-08	0.0396	0.2	0.17	Plateletcrit;	chr3:124674748	chr2:49878623~49879363:+
BRCA	trans	rs11098499	0.644	rs7693919	ENSG00000276805.1	RP11-291L22.6	5.43	7.16e-08	0.0398	0.19	0.17	Corneal astigmatism;	chr4:119619416	chr10:38451030~38451785:+
BRCA	trans	rs853679	0.546	rs200954	ENSG00000228078.1	HLA-U	-5.43	7.16e-08	0.0398	-0.34	-0.17	Depression;	chr6:27870986	chr6:29934101~29934286:+
BRCA	trans	rs7113874	0.569	rs11041994	ENSG00000266891.1	RP11-692N5.2	5.43	7.16e-08	0.0398	0.19	0.17	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8576319	chr18:9734882~9735602:-
BRCA	trans	rs7113874	0.569	rs11041995	ENSG00000266891.1	RP11-692N5.2	5.43	7.16e-08	0.0398	0.19	0.17	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8576686	chr18:9734882~9735602:-
BRCA	trans	rs10838687	0.736	rs2633083	ENSG00000134612.10	FOLH1B	-5.43	7.17e-08	0.0398	-0.26	-0.17	Proinsulin levels;	chr11:47227869	chr11:89639227~89698718:+
BRCA	trans	rs250585	0.764	rs4967958	ENSG00000237738.1	RNF216-IT1	5.43	7.17e-08	0.0398	0.24	0.17	Egg allergy;	chr16:23516802	chr7:5662432~5680461:-
BRCA	trans	rs6954796	0.504	rs4721869	ENSG00000278035.1	RP11-234K24.6	-5.43	7.18e-08	0.0399	-0.27	-0.17	Non-word repetition;	chr7:20064423	chr20:36233851~36234297:+
BRCA	trans	rs6921919	0.583	rs9468370	ENSG00000228078.1	HLA-U	-5.43	7.18e-08	0.0399	-0.23	-0.17	Autism spectrum disorder or schizophrenia;	chr6:28401163	chr6:29934101~29934286:+
BRCA	trans	rs7395581	0.918	rs10838692	ENSG00000134612.10	FOLH1B	5.43	7.18e-08	0.0399	0.22	0.17	HDL cholesterol;	chr11:47323549	chr11:89639227~89698718:+
BRCA	trans	rs11098499	0.863	rs2306456	ENSG00000253326.2	RP11-261C10.7	5.43	7.19e-08	0.0399	0.24	0.17	Corneal astigmatism;	chr4:119551267	chr1:243054861~243056394:-
BRCA	trans	rs11098499	0.863	rs11947234	ENSG00000253326.2	RP11-261C10.7	5.43	7.19e-08	0.0399	0.24	0.17	Corneal astigmatism;	chr4:119553704	chr1:243054861~243056394:-
BRCA	trans	rs11098499	0.863	rs11933966	ENSG00000253326.2	RP11-261C10.7	5.43	7.19e-08	0.0399	0.24	0.17	Corneal astigmatism;	chr4:119555560	chr1:243054861~243056394:-
BRCA	trans	rs11098499	0.863	rs36040693	ENSG00000253326.2	RP11-261C10.7	5.43	7.19e-08	0.0399	0.24	0.17	Corneal astigmatism;	chr4:119556461	chr1:243054861~243056394:-
BRCA	trans	rs9649213	0.593	rs6465678	ENSG00000225169.1	BRI3P1	5.43	7.19e-08	0.04	0.21	0.17	Prostate cancer (SNP x SNP interaction);	chr7:98374745	chr1:100213293~100213670:+
BRCA	trans	rs4925540	0.926	rs10924896	ENSG00000226121.2	AC009487.6	5.43	7.19e-08	0.04	0.23	0.17	Response to taxane treatment (docetaxel);	chr1:247033429	chr2:161500885~161507705:-
BRCA	trans	rs2243480	1	rs1979823	ENSG00000164669.11	INTS4P1	-5.42	7.21e-08	0.04	-0.33	-0.17	Diabetic kidney disease;	chr7:66239626	chr7:65141225~65234216:+
BRCA	trans	rs45509595	0.749	rs401763	ENSG00000228078.1	HLA-U	-5.42	7.21e-08	0.04	-0.33	-0.17	Breast cancer;	chr6:27814750	chr6:29934101~29934286:+
BRCA	trans	rs45509595	0.659	rs390764	ENSG00000228078.1	HLA-U	-5.42	7.21e-08	0.04	-0.33	-0.17	Breast cancer;	chr6:27814757	chr6:29934101~29934286:+
BRCA	trans	rs45509595	0.841	rs401754	ENSG00000228078.1	HLA-U	-5.42	7.21e-08	0.04	-0.33	-0.17	Breast cancer;	chr6:27814760	chr6:29934101~29934286:+
BRCA	trans	rs2950393	0.804	rs2958127	ENSG00000257210.1	NACAP3	5.42	7.22e-08	0.0401	0.2	0.17	Platelet distribution width;	chr12:56720523	chr12:93124063~93124543:-
BRCA	trans	rs72932726	0.72	rs1066373	ENSG00000263627.1	PPP4R1-AS1	5.42	7.22e-08	0.0401	0.27	0.17	Heschl's gyrus morphology;	chr3:99158818	chr18:9615264~9619363:+
BRCA	trans	rs11722779	0.903	rs13130741	ENSG00000211782.2	TRAV8-1	-5.42	7.22e-08	0.0401	-0.13	-0.17	Schizophrenia;	chr4:103035799	chr14:21797287~21797886:+
BRCA	trans	rs1853207	0.786	rs7896133	ENSG00000272764.1	RP11-318E3.9	-5.42	7.23e-08	0.0401	-0.3	-0.17	Blood metabolite levels;	chr10:94704973	chr10:5813985~5814441:+
BRCA	trans	rs508977	0.608	rs625837	ENSG00000232386.8	RP11-66B24.2	-5.42	7.24e-08	0.0402	-0.23	-0.17	Growth-regulated protein alpha levels;	chr4:73898143	chr15:100849561~100861756:+
BRCA	trans	rs7824557	0.65	rs2572406	ENSG00000254153.1	CTA-398F10.2	5.42	7.24e-08	0.0402	0.19	0.17	Retinal vascular caliber;	chr8:11234743	chr8:8456909~8461337:-
BRCA	trans	rs2284367	1	rs4755373	ENSG00000256103.2	RP1-96H9.5	5.42	7.25e-08	0.0402	0.2	0.17	Blood protein levels;	chr11:34462687	chr12:6270168~6270425:-
BRCA	trans	rs9649213	0.593	rs6465677	ENSG00000225169.1	BRI3P1	5.42	7.26e-08	0.0403	0.21	0.17	Prostate cancer (SNP x SNP interaction);	chr7:98374240	chr1:100213293~100213670:+
BRCA	trans	rs6489882	0.966	rs10735079	ENSG00000250770.2	RP5-1063M23.1	-5.42	7.26e-08	0.0403	-0.21	-0.17	Chronic lymphocytic leukemia;	chr12:112942203	chr12:3296202~3300224:-
BRCA	trans	rs7829975	0.688	rs6995407	ENSG00000255046.1	RP11-297N6.4	-5.42	7.26e-08	0.0403	-0.19	-0.17	Mood instability;	chr8:8527137	chr8:11797928~11802568:-
BRCA	trans	rs7647973	1	rs8897	ENSG00000235912.1	RP1-159A19.3	-5.42	7.27e-08	0.0403	-0.21	-0.17	Menarche (age at onset);	chr3:49422974	chr1:27649419~27649610:+
BRCA	trans	rs2950393	0.804	rs898609	ENSG00000257210.1	NACAP3	5.42	7.27e-08	0.0403	0.2	0.17	Platelet distribution width;	chr12:56713026	chr12:93124063~93124543:-
BRCA	trans	rs2950393	0.804	rs4902	ENSG00000257210.1	NACAP3	5.42	7.27e-08	0.0403	0.2	0.17	Platelet distribution width;	chr12:56714419	chr12:93124063~93124543:-
BRCA	trans	rs660899	0.765	rs112984125	ENSG00000231007.5	CDC20P1	5.42	7.28e-08	0.0404	0.22	0.17	Hypertension risk in short sleep duration;	chr1:43707752	chr9:87011652~87013151:+
BRCA	trans	rs1814175	0.533	rs4528310	ENSG00000134612.10	FOLH1B	-5.42	7.29e-08	0.0404	-0.3	-0.17	Height;	chr11:49961556	chr11:89639227~89698718:+
BRCA	trans	rs2836974	0.897	rs2836923	ENSG00000229237.2	HMGN1P37	5.42	7.31e-08	0.0405	0.23	0.17	Cognitive function;	chr21:39152310	chrX:154817099~154817401:-
BRCA	trans	rs9470366	0.848	rs9470361	ENSG00000257004.1	RP11-180M15.3	5.42	7.35e-08	0.0407	0.19	0.17	QRS duration;	chr6:36655602	chr12:12668982~12685075:+
BRCA	trans	rs877636	1	rs4759229	ENSG00000227586.5	RP11-162A23.5	-5.42	7.36e-08	0.0407	-0.21	-0.17	Cognitive function;	chr12:56080696	chr10:123171535~123171875:-
BRCA	trans	rs17161791	0.705	rs10254565	ENSG00000233589.1	RP4-694A7.2	5.42	7.36e-08	0.0407	0.2	0.17	Pulmonary function in asthmatics;	chr7:9569258	chr1:68479129~68483539:+
BRCA	trans	rs7662987	0.517	rs1311615	ENSG00000233859.2	ADH5P4	-5.42	7.37e-08	0.0408	-0.24	-0.17	Smoking initiation;	chr4:99091110	chr6:65836930~65838039:-
BRCA	trans	rs1232027	0.656	rs1650737	ENSG00000188985.6	DHFRP1	-5.42	7.38e-08	0.0408	-0.21	-0.17	Huntington's disease progression;	chr5:80705966	chr18:26170726~26171284:-
BRCA	trans	rs7647973	1	rs940045	ENSG00000197582.5	GPX1P1	5.42	7.39e-08	0.0409	0.18	0.17	Menarche (age at onset);	chr3:49412205	chrX:13378735~13379340:-
BRCA	trans	rs6489882	0.867	rs6489874	ENSG00000250770.2	RP5-1063M23.1	5.42	7.39e-08	0.0409	0.22	0.17	Chronic lymphocytic leukemia;	chr12:112930090	chr12:3296202~3300224:-
BRCA	trans	rs35306767	0.953	rs35174953	ENSG00000187984.11	ANKRD19P	5.42	7.4e-08	0.0409	0.2	0.17	Eosinophil percentage of granulocytes;	chr10:915251	chr9:92809388~92888693:+
BRCA	trans	rs704840	0.729	rs12048385	ENSG00000251484.3	RP5-1065J22.4	5.42	7.41e-08	0.041	0.23	0.17	Systemic lupus erythematosus;Systemic lupus erythematosus and Systemic sclerosis;	chr1:173256620	chr1:109103535~109104766:-
BRCA	trans	rs1969253	0.803	rs863615	ENSG00000274767.1	AC131056.3	5.42	7.41e-08	0.041	0.19	0.17	Major depressive disorder;	chr3:184147075	chr17:36183235~36196471:+
BRCA	trans	rs1459104	1	rs34091524	ENSG00000134612.10	FOLH1B	-5.42	7.42e-08	0.041	-0.33	-0.17	Body mass index;	chr11:55562420	chr11:89639227~89698718:+
BRCA	trans	rs6142102	0.923	rs6059586	ENSG00000280327.1	LA16c-313F4.1	-5.42	7.43e-08	0.0411	-0.18	-0.17	Skin pigmentation;	chr20:33952695	chr16:1576716~1578371:-
BRCA	trans	rs2055729	0.677	rs10104353	ENSG00000253893.2	FAM85B	5.42	7.43e-08	0.0411	0.23	0.17	Multiple myeloma (hyperdiploidy);	chr8:9882848	chr8:8167819~8226614:-
BRCA	trans	rs601162	0.731	rs10969316	ENSG00000217733.2	CCT7P1	5.42	7.44e-08	0.0412	0.24	0.17	Lupus nephritis in systemic lupus erythematosus;	chr9:29668722	chr6:149879962~149881572:+
BRCA	trans	rs7570469	1	rs7570469	ENSG00000276390.1	RP1-197B17.5	5.42	7.44e-08	0.0412	0.21	0.17	Response to antipsychotic treatment;	chr2:79482228	chr12:47699401~47699917:-
BRCA	trans	rs228614	0.509	rs223480	ENSG00000211782.2	TRAV8-1	-5.42	7.46e-08	0.0412	-0.13	-0.17	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102766881	chr14:21797287~21797886:+
BRCA	trans	rs2134046	0.555	rs11854483	ENSG00000259295.5	CSPG4P12	-5.42	7.46e-08	0.0412	-0.2	-0.17	Cognitive ability;	chr15:82267217	chr15:85191438~85213905:+
BRCA	trans	rs17161791	0.739	rs10245895	ENSG00000233589.1	RP4-694A7.2	5.42	7.47e-08	0.0413	0.2	0.17	Pulmonary function in asthmatics;	chr7:9570668	chr1:68479129~68483539:+
BRCA	trans	rs6142102	0.58	rs761233	ENSG00000280327.1	LA16c-313F4.1	-5.42	7.47e-08	0.0413	-0.17	-0.17	Skin pigmentation;	chr20:33981080	chr16:1576716~1578371:-
BRCA	trans	rs4146922	0.793	rs7601401	ENSG00000275882.1	IKBKGP1	5.42	7.49e-08	0.0414	0.2	0.17	Height;	chr2:55777457	chrX:154639978~154648275:-
BRCA	trans	rs5006884	0.507	rs12802968	ENSG00000258626.2	COX7A2P1	5.42	7.49e-08	0.0414	0.21	0.17	Fetal hemoglobin levels;	chr11:5361636	chr14:67652300~67652614:-
BRCA	trans	rs7647973	1	rs974495	ENSG00000197582.5	GPX1P1	5.42	7.5e-08	0.0414	0.18	0.17	Menarche (age at onset);	chr3:49363049	chrX:13378735~13379340:-
BRCA	trans	rs7647973	1	rs11719762	ENSG00000197582.5	GPX1P1	5.42	7.5e-08	0.0414	0.18	0.17	Menarche (age at onset);	chr3:49371569	chrX:13378735~13379340:-
BRCA	trans	rs7121538	0.756	rs1003077	ENSG00000236360.2	RP11-334A14.2	-5.42	7.5e-08	0.0414	-0.28	-0.17	HDL cholesterol;	chr11:14386594	chr1:52993201~52993702:-
BRCA	trans	rs1816752	0.721	rs7399656	ENSG00000224976.2	PARP4P2	-5.42	7.5e-08	0.0414	-0.2	-0.17	Obesity-related traits;	chr13:24415708	chr13:19349137~19407962:+
BRCA	trans	rs3914502	0.512	rs654146	ENSG00000268154.2	Metazoa_SRP	-5.42	7.51e-08	0.0415	-0.19	-0.17	Autism spectrum disorder;	chr3:174704221	chr1:154950210~154950492:-
BRCA	trans	rs1459104	1	rs34382934	ENSG00000134612.10	FOLH1B	-5.42	7.51e-08	0.0415	-0.33	-0.17	Body mass index;	chr11:55547780	chr11:89639227~89698718:+
BRCA	trans	rs1459104	1	rs12797013	ENSG00000134612.10	FOLH1B	-5.42	7.51e-08	0.0415	-0.33	-0.17	Body mass index;	chr11:55550812	chr11:89639227~89698718:+
BRCA	trans	rs1499614	1	rs1267817	ENSG00000164669.11	INTS4P1	5.42	7.52e-08	0.0415	0.33	0.17	Gout;	chr7:66645053	chr7:65141225~65234216:+
BRCA	trans	rs7568458	0.783	rs1561198	ENSG00000223886.3	RP11-251G23.2	5.42	7.52e-08	0.0415	0.19	0.17	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr2:85582866	chr7:105530209~105530671:+
BRCA	trans	rs853679	0.55	rs9295762	ENSG00000253570.1	RNF5P1	-5.42	7.53e-08	0.0416	-0.26	-0.17	Depression;	chr6:28187640	chr8:38600661~38601200:-
BRCA	trans	rs714543	0.934	rs10275962	ENSG00000234397.3	RP11-415K20.1	-5.42	7.55e-08	0.0417	-0.2	-0.17	Plateletcrit;	chr7:44809141	chr1:22322840~22323331:-
BRCA	trans	rs864643	0.524	rs77309543	ENSG00000214263.2	RPSAP53	-5.42	7.55e-08	0.0417	-0.33	-0.17	Attention deficit hyperactivity disorder;	chr3:39489578	chr13:67266845~67267706:-
BRCA	trans	rs227275	0.525	rs17215211	ENSG00000211782.2	TRAV8-1	-5.42	7.57e-08	0.0418	-0.13	-0.17	Allergic disease (asthma, hay fever or eczema);	chr4:103025961	chr14:21797287~21797886:+
BRCA	trans	rs660899	0.857	rs7529895	ENSG00000231007.5	CDC20P1	5.42	7.57e-08	0.0418	0.22	0.17	Hypertension risk in short sleep duration;	chr1:43776199	chr9:87011652~87013151:+
BRCA	trans	rs6593122	0.575	rs6954698	ENSG00000225484.5	NUTM2B-AS1	5.42	7.58e-08	0.0418	0.26	0.17	Vaccine-related adverse events;	chr7:54022391	chr10:79663088~79826594:-
BRCA	trans	rs11098499	0.865	rs9994730	ENSG00000253326.2	RP11-261C10.7	5.42	7.58e-08	0.0418	0.23	0.17	Corneal astigmatism;	chr4:119460409	chr1:243054861~243056394:-
BRCA	trans	rs1494508	0.929	rs11175742	ENSG00000252202.1	Y_RNA	5.42	7.59e-08	0.0419	0.19	0.17	Temperament;	chr12:65388818	chr5:179847035~179847130:-
BRCA	trans	rs11098499	0.863	rs1552092	ENSG00000276805.1	RP11-291L22.6	5.42	7.59e-08	0.0419	0.2	0.17	Corneal astigmatism;	chr4:119567341	chr10:38451030~38451785:+
BRCA	trans	rs3013169	0.603	rs13203058	ENSG00000266456.1	RP11-806L2.2	-5.42	7.6e-08	0.0419	-0.2	-0.17	Schizophrenia;	chr6:64197078	chr18:650229~652843:+
BRCA	trans	rs2252521	1	rs2252521	ENSG00000279035.1	RP11-649A18.3	5.42	7.6e-08	0.0419	0.21	0.17	Cognitive performance;	chr7:29001574	chr17:75130883~75133043:+
BRCA	trans	rs1232027	0.622	rs245332	ENSG00000188985.6	DHFRP1	-5.41	7.61e-08	0.042	-0.21	-0.17	Huntington's disease progression;	chr5:80730449	chr18:26170726~26171284:-
BRCA	trans	rs5006884	0.507	rs17355388	ENSG00000258626.2	COX7A2P1	5.41	7.61e-08	0.042	0.21	0.17	Fetal hemoglobin levels;	chr11:5361512	chr14:67652300~67652614:-
BRCA	trans	rs893818	0.682	rs28758267	ENSG00000214826.5	DDX12P	-5.41	7.61e-08	0.042	-0.17	-0.17	Exfoliation glaucoma or exfoliation syndrome;	chr15:73943506	chr12:9418673~9448229:-
BRCA	trans	rs113793030	0.661	rs10999185	ENSG00000253785.1	CTC-308K20.3	5.41	7.62e-08	0.042	0.43	0.17	Cognitive decline rate in late mild cognitive impairment;	chr10:70206037	chr5:172975511~172976374:+
BRCA	trans	rs2950393	0.777	rs7966391	ENSG00000257210.1	NACAP3	5.41	7.63e-08	0.0421	0.2	0.17	Platelet distribution width;	chr12:56745272	chr12:93124063~93124543:-
BRCA	trans	rs12586478	0.585	rs12879709	ENSG00000266957.1	RP11-49K24.4	5.41	7.64e-08	0.0421	0.18	0.17	Post bronchodilator FEV1;	chr14:86320796	chr18:47077361~47091280:-
BRCA	trans	rs7520050	0.807	rs12025621	ENSG00000177335.9	C8orf31	-5.41	7.65e-08	0.0421	-0.2	-0.17	Reticulocyte count;Red blood cell count;	chr1:45762719	chr8:143039209~143059942:+
BRCA	trans	rs1499614	1	rs2707832	ENSG00000164669.11	INTS4P1	5.41	7.65e-08	0.0422	0.32	0.17	Gout;	chr7:66671562	chr7:65141225~65234216:+
BRCA	trans	rs2117029	0.521	rs12227610	ENSG00000214391.3	TUBAP2	5.41	7.65e-08	0.0422	0.16	0.17	Intelligence (multi-trait analysis);	chr12:49146153	chr11:90282560~90284172:+
BRCA	trans	rs7569426	0.74	rs6751223	ENSG00000259744.1	RP11-138H8.6	5.41	7.65e-08	0.0422	0.2	0.17	Subjective well-being;	chr2:34210168	chr15:70848883~70849770:-
BRCA	trans	rs9650657	0.771	rs4840516	ENSG00000255495.1	AC145124.2	5.41	7.65e-08	0.0422	0.19	0.17	Neuroticism;	chr8:10809825	chr8:12194467~12196280:+
BRCA	trans	rs57506017	0.651	rs62435694	ENSG00000279233.1	RP11-158L12.4	5.41	7.66e-08	0.0422	0.19	0.17	Neuroticism;	chr7:12205793	chr12:125138245~125141711:+
BRCA	trans	rs7943953	0.629	rs7950699	ENSG00000206897.1	SNORA9	5.41	7.67e-08	0.0423	0.2	0.17	Odorant perception (&beta-ionone);	chr11:59327684	chr12:123616708~123616840:+
BRCA	trans	rs7943953	0.6	rs6591522	ENSG00000206897.1	SNORA9	5.41	7.67e-08	0.0423	0.2	0.17	Odorant perception (&beta-ionone);	chr11:59328037	chr12:123616708~123616840:+
BRCA	trans	rs7570469	0.633	rs406471	ENSG00000276390.1	RP1-197B17.5	5.41	7.68e-08	0.0423	0.2	0.17	Response to antipsychotic treatment;	chr2:79456117	chr12:47699401~47699917:-
BRCA	trans	rs7570469	0.717	rs383974	ENSG00000276390.1	RP1-197B17.5	5.41	7.68e-08	0.0423	0.2	0.17	Response to antipsychotic treatment;	chr2:79456258	chr12:47699401~47699917:-
BRCA	trans	rs11098499	0.863	rs3733525	ENSG00000276805.1	RP11-291L22.6	5.41	7.7e-08	0.0424	0.2	0.17	Corneal astigmatism;	chr4:119525893	chr10:38451030~38451785:+
BRCA	trans	rs11098499	0.863	rs3775847	ENSG00000276805.1	RP11-291L22.6	5.41	7.7e-08	0.0424	0.2	0.17	Corneal astigmatism;	chr4:119526487	chr10:38451030~38451785:+
BRCA	trans	rs11098499	0.863	rs3775848	ENSG00000276805.1	RP11-291L22.6	5.41	7.7e-08	0.0424	0.2	0.17	Corneal astigmatism;	chr4:119526569	chr10:38451030~38451785:+
BRCA	trans	rs6939532	0.522	rs4712981	ENSG00000242375.1	RP11-498P14.3	-5.41	7.7e-08	0.0424	-0.25	-0.17	Autism spectrum disorder or schizophrenia;	chr6:26361202	chr9:97195351~97197687:-
BRCA	trans	rs2243480	0.901	rs12530490	ENSG00000164669.11	INTS4P1	-5.41	7.7e-08	0.0424	-0.32	-0.17	Diabetic kidney disease;	chr7:66226660	chr7:65141225~65234216:+
BRCA	trans	rs2243480	1	rs7778911	ENSG00000164669.11	INTS4P1	-5.41	7.7e-08	0.0424	-0.32	-0.17	Diabetic kidney disease;	chr7:66229519	chr7:65141225~65234216:+
BRCA	trans	rs12541595	0.93	rs7461129	ENSG00000250746.1	RP11-39C10.1	5.41	7.72e-08	0.0425	0.21	0.17	Left ventricle diastolic internal dimension;	chr8:124849132	chr4:164188311~164190367:+
BRCA	trans	rs10089	0.953	rs10463839	ENSG00000235584.2	AC008268.1	-5.41	7.73e-08	0.0426	-0.17	-0.17	Ileal carcinoids;	chr5:128183983	chr2:95666084~95668715:+
BRCA	trans	rs2856321	0.874	rs1009951	ENSG00000226525.5	RPS7P10	-5.41	7.75e-08	0.0427	-0.15	-0.17	Height;	chr12:11739962	chr13:21628413~21629015:-
BRCA	trans	rs875971	1	rs6956179	ENSG00000164669.11	INTS4P1	5.41	7.76e-08	0.0427	0.2	0.17	Aortic root size;	chr7:66341672	chr7:65141225~65234216:+
BRCA	trans	rs1668357	0.541	rs2722274	ENSG00000228629.2	AC092295.4	5.41	7.76e-08	0.0427	0.28	0.17	Myopia (pathological);	chr7:37948431	chr19:36528318~36535235:+
BRCA	trans	rs660899	0.857	rs11590279	ENSG00000231007.5	CDC20P1	5.41	7.76e-08	0.0427	0.22	0.17	Hypertension risk in short sleep duration;	chr1:43778512	chr9:87011652~87013151:+
BRCA	trans	rs228614	0.536	rs223484	ENSG00000211782.2	TRAV8-1	-5.41	7.77e-08	0.0427	-0.13	-0.17	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102764314	chr14:21797287~21797886:+
BRCA	trans	rs2727020	0.619	rs11040300	ENSG00000134612.10	FOLH1B	5.41	7.77e-08	0.0427	0.23	0.17	Coronary artery disease;	chr11:49248432	chr11:89639227~89698718:+
BRCA	trans	rs654950	0.806	rs1535505	ENSG00000257551.1	HLX-AS1	5.41	7.78e-08	0.0428	0.19	0.17	Airway imaging phenotypes;	chr1:41560481	chr1:220832763~220880140:-
BRCA	trans	rs7520050	0.778	rs12404197	ENSG00000177335.9	C8orf31	-5.41	7.79e-08	0.0428	-0.2	-0.17	Reticulocyte count;Red blood cell count;	chr1:45766748	chr8:143039209~143059942:+
BRCA	trans	rs7520050	0.801	rs6703960	ENSG00000177335.9	C8orf31	-5.41	7.79e-08	0.0428	-0.2	-0.17	Reticulocyte count;Red blood cell count;	chr1:45767051	chr8:143039209~143059942:+
BRCA	trans	rs319204	0.885	rs319174	ENSG00000226498.2	RP11-182B22.2	5.41	7.81e-08	0.043	0.19	0.17	Schizophrenia;	chr5:146896589	chr1:236819634~236820518:+
BRCA	trans	rs9649213	0.593	rs3823740	ENSG00000225169.1	BRI3P1	5.41	7.82e-08	0.043	0.21	0.17	Prostate cancer (SNP x SNP interaction);	chr7:98327792	chr1:100213293~100213670:+
BRCA	trans	rs5006884	0.507	rs4910765	ENSG00000258626.2	COX7A2P1	5.41	7.82e-08	0.043	0.21	0.17	Fetal hemoglobin levels;	chr11:5362173	chr14:67652300~67652614:-
BRCA	trans	rs5006884	0.507	rs4910770	ENSG00000258626.2	COX7A2P1	5.41	7.82e-08	0.043	0.21	0.17	Fetal hemoglobin levels;	chr11:5362568	chr14:67652300~67652614:-
BRCA	trans	rs11098499	0.908	rs7696649	ENSG00000253326.2	RP11-261C10.7	5.41	7.83e-08	0.043	0.23	0.17	Corneal astigmatism;	chr4:119401022	chr1:243054861~243056394:-
BRCA	trans	rs2243480	1	rs2533288	ENSG00000164669.11	INTS4P1	5.41	7.84e-08	0.0431	0.32	0.17	Diabetic kidney disease;	chr7:66591724	chr7:65141225~65234216:+
BRCA	trans	rs2034764	0.84	rs7048820	ENSG00000254967.5	RP11-680F20.6	5.41	7.86e-08	0.0432	0.18	0.17	Alzheimer's disease (age of onset);	chr9:2735053	chr11:125950116~125956319:+
BRCA	trans	rs7746199	0.736	rs67652222	ENSG00000228078.1	HLA-U	-5.41	7.86e-08	0.0432	-0.44	-0.17	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27618441	chr6:29934101~29934286:+
BRCA	trans	rs17507216	0.671	rs28582623	ENSG00000235370.6	DNM1P51	-5.41	7.87e-08	0.0433	-0.22	-0.17	Excessive daytime sleepiness;	chr15:82577381	chr15:84398316~84411701:-
BRCA	trans	rs6489882	0.867	rs7315441	ENSG00000250770.2	RP5-1063M23.1	5.41	7.87e-08	0.0433	0.21	0.17	Chronic lymphocytic leukemia;	chr12:112927882	chr12:3296202~3300224:-
BRCA	trans	rs11098499	0.657	rs10434028	ENSG00000276805.1	RP11-291L22.6	5.41	7.88e-08	0.0433	0.19	0.17	Corneal astigmatism;	chr4:119373309	chr10:38451030~38451785:+
BRCA	trans	rs9379774	0.872	rs443641	ENSG00000261664.4	TTC39A-AS1	-5.41	7.89e-08	0.0433	-0.21	-0.17	Coronary artery disease;	chr6:25505215	chr1:51329654~51335324:+
BRCA	trans	rs7121538	0.551	rs16930448	ENSG00000187952.9	HS6ST1P1	5.41	7.91e-08	0.0435	0.25	0.17	HDL cholesterol;	chr11:14702166	chr1:21428303~21429536:+
BRCA	trans	rs9858542	0.953	rs3811699	ENSG00000215326.3	GPX1P2	5.41	7.92e-08	0.0435	0.19	0.17	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49358927	chr21:27143344~27143949:-
BRCA	trans	rs9467603	0.925	rs4712969	ENSG00000253570.1	RNF5P1	-5.41	7.93e-08	0.0435	-0.37	-0.17	Intelligence (multi-trait analysis);	chr6:25763964	chr8:38600661~38601200:-
BRCA	trans	rs11098499	0.57	rs6832740	ENSG00000276805.1	RP11-291L22.6	5.41	7.95e-08	0.0436	0.19	0.17	Corneal astigmatism;	chr4:119624981	chr10:38451030~38451785:+
BRCA	trans	rs11098499	0.644	rs6855918	ENSG00000276805.1	RP11-291L22.6	5.41	7.95e-08	0.0436	0.19	0.17	Corneal astigmatism;	chr4:119625144	chr10:38451030~38451785:+
BRCA	trans	rs6121246	0.609	rs2149281	ENSG00000279352.1	RP11-411B10.7	5.41	7.97e-08	0.0437	0.24	0.17	Mean corpuscular hemoglobin;	chr20:31830115	chr18:14010054~14010917:+
BRCA	trans	rs34198350	0.636	rs55802119	ENSG00000276566.1	IGKV1D-13	5.41	7.97e-08	0.0437	0.21	0.17	QT interval in Tripanosoma cruzi seropositivity;	chr2:48222213	chr2:90154073~90154574:+
BRCA	trans	rs361433	0.541	rs17163364	ENSG00000244459.2	RP11-1398P2.1	5.41	7.97e-08	0.0437	0.34	0.17	Capecitabine sensitivity;	chr7:142491573	chr4:1574062~1580253:-
BRCA	trans	rs12497850	0.931	rs9846123	ENSG00000197582.5	GPX1P1	-5.41	7.98e-08	0.0438	-0.17	-0.17	Parkinson's disease;	chr3:49050679	chrX:13378735~13379340:-
BRCA	trans	rs5006884	0.547	rs2647606	ENSG00000258626.2	COX7A2P1	5.41	7.99e-08	0.0438	0.21	0.17	Fetal hemoglobin levels;	chr11:5363376	chr14:67652300~67652614:-
BRCA	trans	rs11098499	0.954	rs3733520	ENSG00000276805.1	RP11-291L22.6	5.41	7.99e-08	0.0438	0.19	0.17	Corneal astigmatism;	chr4:119502325	chr10:38451030~38451785:+
BRCA	trans	rs17507216	0.958	rs28648832	ENSG00000235370.6	DNM1P51	-5.41	7.99e-08	0.0439	-0.22	-0.17	Excessive daytime sleepiness;	chr15:82567642	chr15:84398316~84411701:-
BRCA	trans	rs7829975	0.688	rs13270194	ENSG00000270154.1	RP11-419I17.1	5.41	8e-08	0.0439	0.19	0.17	Mood instability;	chr8:8520592	chr8:12476462~12477122:+
BRCA	trans	rs6011368	0.84	rs6062361	ENSG00000273823.1	AC215219.2	-5.41	8e-08	0.0439	-0.18	-0.17	Clozapine-induced cytotoxicity;	chr20:64273189	chr12:17484~17551:-
BRCA	trans	rs9393813	0.529	rs2064093	ENSG00000242375.1	RP11-498P14.3	-5.41	8e-08	0.0439	-0.22	-0.17	Bipolar disorder;	chr6:27474468	chr9:97195351~97197687:-
BRCA	trans	rs2242330	0.749	rs7687991	ENSG00000226982.4	CENPCP1	5.41	8e-08	0.0439	0.23	0.17	Parkinson's disease;	chr4:67430785	chr12:89500093~89502670:+
BRCA	trans	rs12586478	0.56	rs12888523	ENSG00000266957.1	RP11-49K24.4	5.41	8e-08	0.0439	0.18	0.17	Post bronchodilator FEV1;	chr14:86318811	chr18:47077361~47091280:-
BRCA	trans	rs7647973	0.6	rs11920267	ENSG00000197582.5	GPX1P1	5.41	8e-08	0.0439	0.17	0.17	Menarche (age at onset);	chr3:49238531	chrX:13378735~13379340:-
BRCA	trans	rs6440475	0.967	rs7648125	ENSG00000240338.4	RP11-331F4.4	5.41	8.01e-08	0.0439	0.2	0.17	Response to paliperidone in schizophrenia (positive Marder score);	chr3:147194917	chr16:75226074~75228197:+
BRCA	trans	rs66887589	0.616	rs10032299	ENSG00000276997.3	RP11-378J18.9	5.41	8.02e-08	0.044	0.19	0.17	Diastolic blood pressure;	chr4:119285264	chr1:222477252~222504622:-
BRCA	trans	rs4366490	0.534	rs7130316	ENSG00000186676.3	EEF1GP1	-5.41	8.02e-08	0.044	-0.24	-0.17	Conotruncal heart defects;	chr11:63101478	chr7:125033453~125035301:+
BRCA	trans	rs7830939	0.586	rs10108359	ENSG00000253893.2	FAM85B	-5.41	8.02e-08	0.044	-0.22	-0.17	Neuroticism;	chr8:9469576	chr8:8167819~8226614:-
BRCA	trans	rs1538138	1	rs6910919	ENSG00000232400.1	RAD17P1	-5.4	8.03e-08	0.0441	-0.15	-0.17	Corneal structure;	chr6:82071672	chr7:16864267~16866308:-
BRCA	trans	rs6489882	0.867	rs7306205	ENSG00000250770.2	RP5-1063M23.1	5.4	8.04e-08	0.0441	0.22	0.17	Chronic lymphocytic leukemia;	chr12:112929094	chr12:3296202~3300224:-
BRCA	trans	rs5006884	0.507	rs2647600	ENSG00000258626.2	COX7A2P1	5.4	8.06e-08	0.0442	0.21	0.17	Fetal hemoglobin levels;	chr11:5355220	chr14:67652300~67652614:-
BRCA	trans	rs35146811	0.961	rs1880949	ENSG00000228546.2	CTA-313A17.3	5.4	8.06e-08	0.0442	0.23	0.17	Coronary artery disease;	chr7:100124643	chr7:102337316~102339115:+
BRCA	trans	rs10498091	0.895	rs2392775	ENSG00000263072.4	ZNF213-AS1	-5.4	8.06e-08	0.0442	-0.19	-0.17	Echocardiographic traits;	chr2:221008770	chr16:3116042~3134882:-
BRCA	trans	rs1561288	0.729	rs2028195	ENSG00000261039.2	RP11-417E7.2	-5.4	8.08e-08	0.0443	-0.16	-0.17	Body mass index;	chr2:25176084	chr6:169175304~169182740:-
BRCA	trans	rs9393777	0.92	rs34071253	ENSG00000281831.1	HCP5B	5.4	8.08e-08	0.0443	0.36	0.17	Intelligence (multi-trait analysis);	chr6:27424023	chr6:29871895~29873783:-
BRCA	trans	rs3747547	0.685	rs72726068	ENSG00000229007.1	EXOSC3P1	-5.4	8.09e-08	0.0443	-0.44	-0.17	Metabolite levels (Dihydroxy docosatrienoic acid);	chr9:38101221	chr21:32496812~32497311:+
BRCA	trans	rs7829975	0.846	rs7005216	ENSG00000255046.1	RP11-297N6.4	5.4	8.11e-08	0.0444	0.19	0.17	Mood instability;	chr8:8689600	chr8:11797928~11802568:-
BRCA	trans	rs10822407	0.58	rs7097087	ENSG00000248015.5	AC005329.7	5.4	8.11e-08	0.0445	0.22	0.17	Diastolic blood pressure;	chr10:65272145	chr19:1392170~1396467:-
BRCA	trans	rs7113874	0.569	rs10840077	ENSG00000266891.1	RP11-692N5.2	-5.4	8.11e-08	0.0445	-0.19	-0.17	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8579663	chr18:9734882~9735602:-
BRCA	trans	rs853679	0.546	rs200953	ENSG00000228078.1	HLA-U	-5.4	8.13e-08	0.0445	-0.33	-0.17	Depression;	chr6:27869489	chr6:29934101~29934286:+
BRCA	trans	rs9858542	0.953	rs9878943	ENSG00000215326.3	GPX1P2	5.4	8.13e-08	0.0445	0.19	0.17	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49397221	chr21:27143344~27143949:-
BRCA	trans	rs4836390	0.656	rs11241969	ENSG00000235236.1	RP13-131K19.1	5.4	8.14e-08	0.0446	0.24	0.17	Coronary artery disease;	chr5:128706064	chr3:48979918~48983985:-
BRCA	trans	rs332507	0.789	rs13064861	ENSG00000234253.1	RPL7P13	5.4	8.15e-08	0.0446	0.21	0.17	Plateletcrit;	chr3:124633389	chr2:49878623~49879363:+
BRCA	trans	rs660899	0.857	rs7516647	ENSG00000231007.5	CDC20P1	-5.4	8.16e-08	0.0447	-0.22	-0.17	Hypertension risk in short sleep duration;	chr1:43771794	chr9:87011652~87013151:+
BRCA	trans	rs877636	0.859	rs3741499	ENSG00000227586.5	RP11-162A23.5	-5.4	8.17e-08	0.0447	-0.2	-0.17	Cognitive function;	chr12:56080595	chr10:123171535~123171875:-
BRCA	trans	rs7566780	0.596	rs1465614	ENSG00000224631.4	RP11-51O6.1	-5.4	8.18e-08	0.0448	-0.16	-0.17	Cleft lip with or without cleft palate;Orofacial clefts;	chr2:16472025	chr16:61055399~61055964:-
BRCA	trans	rs72899866	0.539	rs72898290	ENSG00000280120.1	RP11-546D6.3	5.4	8.18e-08	0.0448	0.18	0.17	Periodontitis (CDC/AAP);	chr2:140433899	chr12:123152324~123153377:-
BRCA	trans	rs11098499	0.863	rs58452170	ENSG00000276805.1	RP11-291L22.6	5.4	8.19e-08	0.0448	0.2	0.17	Corneal astigmatism;	chr4:119538519	chr10:38451030~38451785:+
BRCA	trans	rs1499614	1	rs2659903	ENSG00000164669.11	INTS4P1	5.4	8.2e-08	0.0449	0.33	0.17	Gout;	chr7:66715944	chr7:65141225~65234216:+
BRCA	trans	rs12586478	0.519	rs4904314	ENSG00000266957.1	RP11-49K24.4	5.4	8.21e-08	0.0449	0.18	0.17	Post bronchodilator FEV1;	chr14:86329430	chr18:47077361~47091280:-
BRCA	trans	rs11098499	0.863	rs13140391	ENSG00000253326.2	RP11-261C10.7	5.4	8.21e-08	0.0449	0.23	0.17	Corneal astigmatism;	chr4:119582282	chr1:243054861~243056394:-
BRCA	trans	rs11098499	0.863	rs13140409	ENSG00000253326.2	RP11-261C10.7	5.4	8.21e-08	0.0449	0.23	0.17	Corneal astigmatism;	chr4:119582305	chr1:243054861~243056394:-
BRCA	trans	rs7927771	0.931	rs12361256	ENSG00000134612.10	FOLH1B	-5.4	8.22e-08	0.045	-0.21	-0.17	Subjective well-being;	chr11:47889271	chr11:89639227~89698718:+
BRCA	trans	rs2242330	0.716	rs28583273	ENSG00000226982.4	CENPCP1	5.4	8.22e-08	0.045	0.23	0.17	Parkinson's disease;	chr4:67431755	chr12:89500093~89502670:+
BRCA	trans	rs4840097	0.502	rs6916517	ENSG00000227077.3	AC107983.4	-5.4	8.23e-08	0.045	-0.17	-0.17	Age-related macular degeneration (smoking status interaction);	chr6:99874542	chr17:18572752~18572961:+
BRCA	trans	rs2243480	0.901	rs778687	ENSG00000164669.11	INTS4P1	5.4	8.23e-08	0.045	0.33	0.17	Diabetic kidney disease;	chr7:66370832	chr7:65141225~65234216:+
BRCA	trans	rs2243480	1	rs778704	ENSG00000164669.11	INTS4P1	5.4	8.23e-08	0.045	0.33	0.17	Diabetic kidney disease;	chr7:66398480	chr7:65141225~65234216:+
BRCA	trans	rs2243480	0.901	rs778693	ENSG00000164669.11	INTS4P1	5.4	8.23e-08	0.045	0.33	0.17	Diabetic kidney disease;	chr7:66407358	chr7:65141225~65234216:+
BRCA	trans	rs2243480	1	rs778691	ENSG00000164669.11	INTS4P1	5.4	8.23e-08	0.045	0.33	0.17	Diabetic kidney disease;	chr7:66408105	chr7:65141225~65234216:+
BRCA	trans	rs2243480	1	rs13235972	ENSG00000164669.11	INTS4P1	5.4	8.23e-08	0.045	0.33	0.17	Diabetic kidney disease;	chr7:66418618	chr7:65141225~65234216:+
BRCA	trans	rs2243480	1	rs34192067	ENSG00000164669.11	INTS4P1	5.4	8.23e-08	0.045	0.33	0.17	Diabetic kidney disease;	chr7:66422670	chr7:65141225~65234216:+
BRCA	trans	rs7113874	0.504	rs10743081	ENSG00000266891.1	RP11-692N5.2	-5.4	8.23e-08	0.045	-0.19	-0.17	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8602553	chr18:9734882~9735602:-
BRCA	trans	rs7568458	0.87	rs1562323	ENSG00000223886.3	RP11-251G23.2	5.4	8.24e-08	0.045	0.19	0.17	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr2:85582588	chr7:105530209~105530671:+
BRCA	trans	rs1499614	1	rs1882655	ENSG00000164669.11	INTS4P1	-5.4	8.24e-08	0.045	-0.33	-0.17	Gout;	chr7:66682070	chr7:65141225~65234216:+
BRCA	trans	rs1499614	0.831	rs3800822	ENSG00000164669.11	INTS4P1	-5.4	8.24e-08	0.045	-0.33	-0.17	Gout;	chr7:66682162	chr7:65141225~65234216:+
BRCA	trans	rs1499614	1	rs1638731	ENSG00000164669.11	INTS4P1	5.4	8.24e-08	0.045	0.33	0.17	Gout;	chr7:66679692	chr7:65141225~65234216:+
BRCA	trans	rs6039763	0.834	rs6032822	ENSG00000184844.6	CYCSP45	-5.4	8.24e-08	0.045	-0.18	-0.17	Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide);	chr20:10197539	chrX:153841251~153841565:+
BRCA	trans	rs2243480	1	rs6958420	ENSG00000164669.11	INTS4P1	-5.4	8.24e-08	0.045	-0.32	-0.17	Diabetic kidney disease;	chr7:66286184	chr7:65141225~65234216:+
BRCA	trans	rs2243480	1	rs1392104	ENSG00000164669.11	INTS4P1	-5.4	8.24e-08	0.045	-0.32	-0.17	Diabetic kidney disease;	chr7:66294120	chr7:65141225~65234216:+
BRCA	trans	rs7113874	0.524	rs10769925	ENSG00000266891.1	RP11-692N5.2	-5.4	8.24e-08	0.045	-0.19	-0.17	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8602038	chr18:9734882~9735602:-
BRCA	trans	rs7113874	0.524	rs10769926	ENSG00000266891.1	RP11-692N5.2	-5.4	8.24e-08	0.045	-0.19	-0.17	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8602127	chr18:9734882~9735602:-
BRCA	trans	rs7570469	0.806	rs6547242	ENSG00000276390.1	RP1-197B17.5	5.4	8.24e-08	0.045	0.22	0.17	Response to antipsychotic treatment;	chr2:79482201	chr12:47699401~47699917:-
BRCA	trans	rs319204	0.885	rs319183	ENSG00000226498.2	RP11-182B22.2	5.4	8.24e-08	0.045	0.19	0.17	Schizophrenia;	chr5:146893308	chr1:236819634~236820518:+
BRCA	trans	rs9393777	0.546	rs9366673	ENSG00000253570.1	RNF5P1	5.4	8.26e-08	0.0451	0.29	0.16	Intelligence (multi-trait analysis);	chr6:26925550	chr8:38600661~38601200:-
BRCA	trans	rs11098499	0.954	rs71629403	ENSG00000253326.2	RP11-261C10.7	5.4	8.26e-08	0.0451	0.23	0.16	Corneal astigmatism;	chr4:119451412	chr1:243054861~243056394:-
BRCA	trans	rs11098499	0.909	rs28571712	ENSG00000253326.2	RP11-261C10.7	5.4	8.26e-08	0.0451	0.23	0.16	Corneal astigmatism;	chr4:119454825	chr1:243054861~243056394:-
BRCA	trans	rs6601327	0.607	rs13276086	ENSG00000253893.2	FAM85B	5.4	8.29e-08	0.0453	0.21	0.16	Multiple myeloma (hyperdiploidy);	chr8:9721472	chr8:8167819~8226614:-
BRCA	trans	rs7647973	1	rs1982861	ENSG00000235912.1	RP1-159A19.3	-5.4	8.29e-08	0.0453	-0.21	-0.16	Menarche (age at onset);	chr3:49540232	chr1:27649419~27649610:+
BRCA	trans	rs669446	0.527	rs667676	ENSG00000235358.1	RP11-399E6.1	-5.4	8.3e-08	0.0453	-0.24	-0.16	Amyotrophic lateral sclerosis (age of onset);	chr1:43616545	chr1:41242373~41284861:+
BRCA	trans	rs2220004	1	rs10897441	ENSG00000134612.10	FOLH1B	-5.4	8.3e-08	0.0454	-0.21	-0.16	Odorant perception (&beta-damascenone);	chr11:55921935	chr11:89639227~89698718:+
BRCA	trans	rs4148883	0.689	rs2851275	ENSG00000233859.2	ADH5P4	-5.4	8.31e-08	0.0454	-0.21	-0.16	Alcohol dependence;	chr4:99103732	chr6:65836930~65838039:-
BRCA	trans	rs11098499	0.954	rs11722872	ENSG00000253326.2	RP11-261C10.7	5.4	8.32e-08	0.0455	0.23	0.16	Corneal astigmatism;	chr4:119311875	chr1:243054861~243056394:-
BRCA	trans	rs7566780	0.596	rs7558680	ENSG00000224631.4	RP11-51O6.1	-5.4	8.34e-08	0.0455	-0.17	-0.16	Cleft lip with or without cleft palate;Orofacial clefts;	chr2:16464438	chr16:61055399~61055964:-
BRCA	trans	rs10486963	1	rs10486963	ENSG00000213280.2	RP11-212P7.1	-5.4	8.34e-08	0.0455	-0.13	-0.16	Energy expenditure (24h);	chr7:82517986	chr7:128570241~128570688:-
BRCA	trans	rs6934970	1	rs7745564	ENSG00000267560.1	RP11-173A16.1	5.4	8.34e-08	0.0455	0.21	0.16	Bipolar disorder (body mass index interaction);	chr6:112780378	chr18:62300036~62300998:-
BRCA	trans	rs7568458	0.846	rs6705839	ENSG00000223886.3	RP11-251G23.2	5.4	8.35e-08	0.0456	0.19	0.16	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr2:85534156	chr7:105530209~105530671:+
BRCA	trans	rs11098499	0.691	rs28396837	ENSG00000120555.12	SEPT7P9	5.4	8.35e-08	0.0456	0.19	0.16	Corneal astigmatism;	chr4:119350386	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.629	rs28369518	ENSG00000120555.12	SEPT7P9	5.4	8.35e-08	0.0456	0.19	0.16	Corneal astigmatism;	chr4:119350475	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.909	rs1809406	ENSG00000253326.2	RP11-261C10.7	5.4	8.36e-08	0.0456	0.23	0.16	Corneal astigmatism;	chr4:119455967	chr1:243054861~243056394:-
BRCA	trans	rs11098499	0.865	rs2389809	ENSG00000253326.2	RP11-261C10.7	5.4	8.36e-08	0.0456	0.23	0.16	Corneal astigmatism;	chr4:119456244	chr1:243054861~243056394:-
BRCA	trans	rs11098499	0.909	rs9994810	ENSG00000253326.2	RP11-261C10.7	5.4	8.36e-08	0.0456	0.23	0.16	Corneal astigmatism;	chr4:119460435	chr1:243054861~243056394:-
BRCA	trans	rs11098499	0.697	rs10020027	ENSG00000253326.2	RP11-261C10.7	5.4	8.36e-08	0.0456	0.23	0.16	Corneal astigmatism;	chr4:119460724	chr1:243054861~243056394:-
BRCA	trans	rs11098499	0.779	rs7356491	ENSG00000253326.2	RP11-261C10.7	5.4	8.36e-08	0.0456	0.23	0.16	Corneal astigmatism;	chr4:119460819	chr1:243054861~243056394:-
BRCA	trans	rs2243480	1	rs2707844	ENSG00000164669.11	INTS4P1	5.4	8.36e-08	0.0456	0.32	0.16	Diabetic kidney disease;	chr7:66594522	chr7:65141225~65234216:+
BRCA	trans	rs2243480	1	rs1796220	ENSG00000164669.11	INTS4P1	5.4	8.36e-08	0.0456	0.32	0.16	Diabetic kidney disease;	chr7:66597113	chr7:65141225~65234216:+
BRCA	trans	rs2243480	1	rs2707831	ENSG00000164669.11	INTS4P1	5.4	8.36e-08	0.0456	0.32	0.16	Diabetic kidney disease;	chr7:66597524	chr7:65141225~65234216:+
BRCA	trans	rs9368481	0.7	rs6911401	ENSG00000242375.1	RP11-498P14.3	5.4	8.37e-08	0.0457	0.24	0.16	Autism spectrum disorder or schizophrenia;	chr6:26945435	chr9:97195351~97197687:-
BRCA	trans	rs2117029	0.586	rs11168874	ENSG00000214391.3	TUBAP2	5.4	8.38e-08	0.0457	0.16	0.16	Intelligence (multi-trait analysis);	chr12:49133753	chr11:90282560~90284172:+
BRCA	trans	rs780094	0.528	rs1728918	ENSG00000232024.2	LSM12P1	-5.4	8.39e-08	0.0458	-0.19	-0.16	Urate levels in overweight individuals;C-reactive protein;Metabolic syndrome;Red blood cell count;Renal underexcretion gout;Nonalcoholic fatty liver disease;Age-related diseases, mortality and associated endophenotypes;Crohn's disease;Calcium levels;Fasting plasma glucose;Metabolic traits;Fasting blood glucose;Fasting blood insulin;Urate levels in obese individuals;Alcohol consumption (drinks per week);Height;Urate levels;Gondoic acid (20:1n-9) levels;Uric acid levels;Age-related disease endophenotypes;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Homeostasis model assessment of insulin resistance;Alcohol consumption;Fasting blood insulin (BMI interaction);Triglycerides;Fasting blood glucose (BMI interaction);Hypertriglyceridemia;LDL cholesterol;Type 2 diabetes;Triglyceride levels;	chr2:27412596	chr8:35525176~35525763:-
BRCA	trans	rs7458938	0.93	rs7795027	ENSG00000227136.2	LINC00595	-5.4	8.4e-08	0.0458	-0.19	-0.16	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr7:125806034	chr10:78267328~78330595:+
BRCA	trans	rs1549118	0.665	rs8015596	ENSG00000235400.1	RP4-641G12.4	5.4	8.4e-08	0.0458	0.23	0.16	Resting heart rate;	chr14:77856459	chr1:78749073~78750659:+
BRCA	trans	rs1549118	0.629	rs7158755	ENSG00000235400.1	RP4-641G12.4	5.4	8.4e-08	0.0458	0.23	0.16	Resting heart rate;	chr14:77856877	chr1:78749073~78750659:+
BRCA	trans	rs1549118	0.595	rs10134142	ENSG00000235400.1	RP4-641G12.4	5.4	8.4e-08	0.0458	0.23	0.16	Resting heart rate;	chr14:77858934	chr1:78749073~78750659:+
BRCA	trans	rs6489882	0.867	rs7316586	ENSG00000250770.2	RP5-1063M23.1	5.4	8.4e-08	0.0458	0.21	0.16	Chronic lymphocytic leukemia;	chr12:112928023	chr12:3296202~3300224:-
BRCA	trans	rs6142102	0.602	rs6141435	ENSG00000280327.1	LA16c-313F4.1	-5.4	8.41e-08	0.0458	-0.17	-0.16	Skin pigmentation;	chr20:33963473	chr16:1576716~1578371:-
BRCA	trans	rs9329221	0.662	rs13254942	ENSG00000255046.1	RP11-297N6.4	5.4	8.41e-08	0.0459	0.2	0.16	Neuroticism;	chr8:10400168	chr8:11797928~11802568:-
BRCA	trans	rs66887589	0.72	rs11724758	ENSG00000276997.3	RP11-378J18.9	5.4	8.41e-08	0.0459	0.18	0.16	Diastolic blood pressure;	chr4:119318723	chr1:222477252~222504622:-
BRCA	trans	rs5006884	0.515	rs9704071	ENSG00000258626.2	COX7A2P1	5.4	8.41e-08	0.0459	0.21	0.16	Fetal hemoglobin levels;	chr11:5360025	chr14:67652300~67652614:-
BRCA	trans	rs9649213	0.574	rs3801251	ENSG00000225169.1	BRI3P1	5.4	8.43e-08	0.046	0.21	0.16	Prostate cancer (SNP x SNP interaction);	chr7:98398306	chr1:100213293~100213670:+
BRCA	trans	rs9649213	0.593	rs3779193	ENSG00000225169.1	BRI3P1	5.4	8.43e-08	0.046	0.21	0.16	Prostate cancer (SNP x SNP interaction);	chr7:98399154	chr1:100213293~100213670:+
BRCA	trans	rs9649213	0.593	rs12704989	ENSG00000225169.1	BRI3P1	5.4	8.43e-08	0.046	0.21	0.16	Prostate cancer (SNP x SNP interaction);	chr7:98400126	chr1:100213293~100213670:+
BRCA	trans	rs9307551	0.6	rs1440857	ENSG00000207720.1	MIR555	-5.4	8.43e-08	0.046	-0.2	-0.16	Refractive error;	chr4:79616866	chr1:155346350~155346445:-
BRCA	trans	rs2220004	1	rs11231558	ENSG00000134612.10	FOLH1B	-5.4	8.45e-08	0.046	-0.21	-0.16	Odorant perception (&beta-damascenone);	chr11:55921487	chr11:89639227~89698718:+
BRCA	trans	rs2117029	0.521	rs11168885	ENSG00000214391.3	TUBAP2	5.4	8.46e-08	0.0461	0.16	0.16	Intelligence (multi-trait analysis);	chr12:49146204	chr11:90282560~90284172:+
BRCA	trans	rs666930	0.519	rs532303	ENSG00000260473.1	RP11-923I11.4	-5.4	8.48e-08	0.0462	-0.21	-0.16	Breast cancer;	chr1:119722821	chr12:51823503~51835496:+
BRCA	trans	rs950037	1	rs950037	ENSG00000231916.1	AC006033.22	-5.39	8.48e-08	0.0462	-0.2	-0.16	Coronary artery disease;	chr1:88685915	chr7:38311383~38311808:+
BRCA	trans	rs2749592	0.588	rs2505192	ENSG00000276997.3	RP11-378J18.9	5.39	8.49e-08	0.0463	0.21	0.16	Age-related hearing impairment (SNP x SNP interaction);	chr10:38106095	chr1:222477252~222504622:-
BRCA	trans	rs1568889	1	rs33937991	ENSG00000174912.7	METTL15P1	5.39	8.49e-08	0.0463	0.18	0.16	Bipolar disorder;	chr11:28023713	chr3:156713884~156714928:-
BRCA	trans	rs319204	0.851	rs319189	ENSG00000226498.2	RP11-182B22.2	5.39	8.5e-08	0.0463	0.19	0.16	Schizophrenia;	chr5:146890792	chr1:236819634~236820518:+
BRCA	trans	rs4879656	0.966	rs10758181	ENSG00000215007.3	DNAJA1P3	5.39	8.51e-08	0.0464	0.2	0.16	Menopause (age at onset);	chr9:33045163	chrX:107351650~107352843:-
BRCA	trans	rs4148883	0.713	rs3828541	ENSG00000233859.2	ADH5P4	-5.39	8.51e-08	0.0464	-0.2	-0.16	Alcohol dependence;	chr4:99121111	chr6:65836930~65838039:-
BRCA	trans	rs11098499	0.863	rs6833334	ENSG00000276805.1	RP11-291L22.6	5.39	8.52e-08	0.0464	0.2	0.16	Corneal astigmatism;	chr4:119583072	chr10:38451030~38451785:+
BRCA	trans	rs11098499	0.863	rs11098532	ENSG00000253326.2	RP11-261C10.7	5.39	8.54e-08	0.0465	0.23	0.16	Corneal astigmatism;	chr4:119569571	chr1:243054861~243056394:-
BRCA	trans	rs9467711	0.651	rs72834677	ENSG00000253570.1	RNF5P1	5.39	8.55e-08	0.0465	0.4	0.16	Autism spectrum disorder or schizophrenia;	chr6:26106376	chr8:38600661~38601200:-
BRCA	trans	rs7113874	0.589	rs10840060	ENSG00000266891.1	RP11-692N5.2	-5.39	8.55e-08	0.0466	-0.19	-0.16	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8478498	chr18:9734882~9735602:-
BRCA	trans	rs6142102	0.602	rs2268079	ENSG00000280327.1	LA16c-313F4.1	-5.39	8.56e-08	0.0466	-0.17	-0.16	Skin pigmentation;	chr20:34008944	chr16:1576716~1578371:-
BRCA	trans	rs45509595	0.841	rs9368531	ENSG00000228078.1	HLA-U	-5.39	8.57e-08	0.0466	-0.33	-0.16	Breast cancer;	chr6:27814094	chr6:29934101~29934286:+
BRCA	trans	rs45509595	0.841	rs2747054	ENSG00000228078.1	HLA-U	-5.39	8.57e-08	0.0466	-0.33	-0.16	Breast cancer;	chr6:27815581	chr6:29934101~29934286:+
BRCA	trans	rs227275	0.525	rs1080081	ENSG00000211782.2	TRAV8-1	-5.39	8.58e-08	0.0467	-0.13	-0.16	Allergic disease (asthma, hay fever or eczema);	chr4:103029268	chr14:21797287~21797886:+
BRCA	trans	rs227275	0.525	rs4699049	ENSG00000211782.2	TRAV8-1	-5.39	8.58e-08	0.0467	-0.13	-0.16	Allergic disease (asthma, hay fever or eczema);	chr4:103030467	chr14:21797287~21797886:+
BRCA	trans	rs2727020	0.796	rs7131672	ENSG00000134612.10	FOLH1B	5.39	8.59e-08	0.0468	0.23	0.16	Coronary artery disease;	chr11:49252869	chr11:89639227~89698718:+
BRCA	trans	rs7746199	0.673	rs72845046	ENSG00000228078.1	HLA-U	-5.39	8.6e-08	0.0468	-0.44	-0.16	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27607489	chr6:29934101~29934286:+
BRCA	trans	rs66887589	0.777	rs4643791	ENSG00000276997.3	RP11-378J18.9	-5.39	8.61e-08	0.0468	-0.18	-0.16	Diastolic blood pressure;	chr4:119344464	chr1:222477252~222504622:-
BRCA	trans	rs11098499	0.738	rs28408407	ENSG00000253326.2	RP11-261C10.7	5.39	8.61e-08	0.0468	0.23	0.16	Corneal astigmatism;	chr4:119454875	chr1:243054861~243056394:-
BRCA	trans	rs6142102	0.602	rs1054534	ENSG00000280327.1	LA16c-313F4.1	-5.39	8.61e-08	0.0469	-0.17	-0.16	Skin pigmentation;	chr20:34017521	chr16:1576716~1578371:-
BRCA	trans	rs7746199	0.736	rs10484399	ENSG00000204709.4	LINC01556	5.39	8.62e-08	0.0469	0.41	0.16	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27566749	chr6:28943877~28944537:+
BRCA	trans	rs11098499	0.657	rs71614442	ENSG00000253326.2	RP11-261C10.7	5.39	8.63e-08	0.0469	0.23	0.16	Corneal astigmatism;	chr4:119458191	chr1:243054861~243056394:-
BRCA	trans	rs11098499	0.954	rs2892848	ENSG00000253326.2	RP11-261C10.7	5.39	8.63e-08	0.0469	0.23	0.16	Corneal astigmatism;	chr4:119460186	chr1:243054861~243056394:-
BRCA	trans	rs4710520	0.636	rs13328254	ENSG00000256746.4	RP11-17G12.3	-5.39	8.65e-08	0.047	-0.26	-0.16	IgG glycosylation;	chr6:65574913	chr11:47270657~47272110:-
BRCA	trans	rs7395581	0.798	rs10769252	ENSG00000134612.10	FOLH1B	5.39	8.66e-08	0.047	0.21	0.16	HDL cholesterol;	chr11:47322404	chr11:89639227~89698718:+
BRCA	trans	rs17711722	0.727	rs1880555	ENSG00000213640.3	EEF1DP4	-5.39	8.66e-08	0.0471	-0.2	-0.16	Calcium levels;	chr7:65967580	chr7:64862999~64864370:+
BRCA	trans	rs9858542	0.953	rs11706370	ENSG00000215326.3	GPX1P2	5.39	8.66e-08	0.0471	0.19	0.16	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49403658	chr21:27143344~27143949:-
BRCA	trans	rs11098499	0.78	rs7692994	ENSG00000253326.2	RP11-261C10.7	5.39	8.66e-08	0.0471	0.22	0.16	Corneal astigmatism;	chr4:119506334	chr1:243054861~243056394:-
BRCA	trans	rs690037	0.773	rs689779	ENSG00000266643.1	MIR3677	5.39	8.67e-08	0.0471	0.18	0.16	Optic nerve measurement (cup-to-disc ratio);Optic nerve measurement (cup area);	chr3:16351804	chr16:2270713~2270772:+
BRCA	trans	rs8024058	0.632	rs16942113	ENSG00000227854.1	RP11-307O1.1	5.39	8.67e-08	0.0471	0.26	0.16	Night sleep phenotypes;	chr15:88628746	chr1:239052748~239052903:-
BRCA	trans	rs9832625	0.521	rs6549922	ENSG00000260267.1	RP11-452L6.5	-5.39	8.68e-08	0.0472	-0.24	-0.16	Response to radiotherapy in cancer (late toxicity);	chr3:29291139	chr16:31456711~31459736:-
BRCA	trans	rs17531088	0.646	rs11706404	ENSG00000214049.6	UCA1	-5.39	8.69e-08	0.0472	-0.22	-0.16	Kawasaki disease;	chr3:175154526	chr19:15828961~15836320:+
BRCA	trans	rs6489882	0.867	rs6489869	ENSG00000250770.2	RP5-1063M23.1	5.39	8.7e-08	0.0473	0.22	0.16	Chronic lymphocytic leukemia;	chr12:112926117	chr12:3296202~3300224:-
BRCA	trans	rs6489882	0.867	rs6489870	ENSG00000250770.2	RP5-1063M23.1	5.39	8.7e-08	0.0473	0.22	0.16	Chronic lymphocytic leukemia;	chr12:112926167	chr12:3296202~3300224:-
BRCA	trans	rs6489882	0.51	rs61478890	ENSG00000250770.2	RP5-1063M23.1	5.39	8.7e-08	0.0473	0.22	0.16	Chronic lymphocytic leukemia;	chr12:112926570	chr12:3296202~3300224:-
BRCA	trans	rs6489882	0.607	rs4767033	ENSG00000250770.2	RP5-1063M23.1	5.39	8.7e-08	0.0473	0.22	0.16	Chronic lymphocytic leukemia;	chr12:112926577	chr12:3296202~3300224:-
BRCA	trans	rs6580649	0.941	rs4760615	ENSG00000223486.1	AC092198.1	-5.39	8.72e-08	0.0473	-0.26	-0.16	Lung cancer;	chr12:48034367	chrX:40009276~40012182:+
BRCA	trans	rs78761021	0.597	rs1402657	ENSG00000176933.5	TOB2P1	5.39	8.73e-08	0.0474	0.19	0.16	Type 2 diabetes;	chr17:9886035	chr6:28217643~28218634:-
BRCA	trans	rs11098499	0.863	rs59732491	ENSG00000276805.1	RP11-291L22.6	5.39	8.75e-08	0.0475	0.2	0.16	Corneal astigmatism;	chr4:119568433	chr10:38451030~38451785:+
BRCA	trans	rs11098499	0.863	rs11723090	ENSG00000276805.1	RP11-291L22.6	5.39	8.75e-08	0.0475	0.2	0.16	Corneal astigmatism;	chr4:119569437	chr10:38451030~38451785:+
BRCA	trans	rs1948368	0.668	rs406138	ENSG00000243181.2	RP11-734J24.1	-5.39	8.76e-08	0.0475	-0.18	-0.16	Bipolar disorder;	chr1:101505709	chr8:34874159~34874633:+
BRCA	trans	rs319204	0.851	rs319190	ENSG00000226498.2	RP11-182B22.2	5.39	8.76e-08	0.0475	0.19	0.16	Schizophrenia;	chr5:146890678	chr1:236819634~236820518:+
BRCA	trans	rs7647973	1	rs10155014	ENSG00000235912.1	RP1-159A19.3	-5.39	8.76e-08	0.0475	-0.21	-0.16	Menarche (age at onset);	chr3:49394888	chr1:27649419~27649610:+
BRCA	trans	rs11098499	0.644	rs10050092	ENSG00000276805.1	RP11-291L22.6	5.39	8.76e-08	0.0475	0.19	0.16	Corneal astigmatism;	chr4:119610930	chr10:38451030~38451785:+
BRCA	trans	rs10899021	1	rs61900635	ENSG00000237188.3	RP11-337C18.8	5.39	8.77e-08	0.0476	0.29	0.16	Response to metformin (IC50);	chr11:74647965	chr1:147172771~147211568:+
BRCA	trans	rs2117029	0.521	rs2114845	ENSG00000214391.3	TUBAP2	5.39	8.79e-08	0.0477	0.16	0.16	Intelligence (multi-trait analysis);	chr12:49164750	chr11:90282560~90284172:+
BRCA	trans	rs2117029	0.554	rs12579015	ENSG00000214391.3	TUBAP2	5.39	8.81e-08	0.0478	0.16	0.16	Intelligence (multi-trait analysis);	chr12:49162648	chr11:90282560~90284172:+
BRCA	trans	rs11098499	0.722	rs10006192	ENSG00000120555.12	SEPT7P9	5.39	8.81e-08	0.0478	0.19	0.16	Corneal astigmatism;	chr4:119341867	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.615	rs28551750	ENSG00000120555.12	SEPT7P9	5.39	8.81e-08	0.0478	0.19	0.16	Corneal astigmatism;	chr4:119343746	chr10:38383069~38402916:-
BRCA	trans	rs11098499	0.691	rs9995716	ENSG00000120555.12	SEPT7P9	5.39	8.81e-08	0.0478	0.19	0.16	Corneal astigmatism;	chr4:119343841	chr10:38383069~38402916:-
BRCA	trans	rs6430585	0.528	rs78274583	ENSG00000224043.6	CCNT2-AS1	-5.39	8.82e-08	0.0478	-0.29	-0.16	Corneal structure;	chr2:135976999	chr2:134735464~134918710:-
BRCA	trans	rs228614	0.509	rs223486	ENSG00000211782.2	TRAV8-1	-5.39	8.83e-08	0.0479	-0.13	-0.16	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102763796	chr14:21797287~21797886:+
BRCA	trans	rs853679	0.607	rs13208096	ENSG00000176998.4	HCG4	-5.39	8.83e-08	0.0479	-0.43	-0.16	Depression;	chr6:28257533	chr6:29791753~29792750:-
BRCA	trans	rs6430585	0.528	rs12474975	ENSG00000224043.6	CCNT2-AS1	-5.39	8.83e-08	0.0479	-0.29	-0.16	Corneal structure;	chr2:135944548	chr2:134735464~134918710:-
BRCA	trans	rs11098499	0.954	rs11098526	ENSG00000253326.2	RP11-261C10.7	5.39	8.86e-08	0.048	0.23	0.16	Corneal astigmatism;	chr4:119469204	chr1:243054861~243056394:-
BRCA	trans	rs11098499	0.82	rs6829903	ENSG00000253326.2	RP11-261C10.7	5.39	8.87e-08	0.048	0.23	0.16	Corneal astigmatism;	chr4:119585729	chr1:243054861~243056394:-
BRCA	trans	rs6954796	0.614	rs7777159	ENSG00000278035.1	RP11-234K24.6	-5.39	8.87e-08	0.0481	-0.27	-0.16	Non-word repetition;	chr7:20044978	chr20:36233851~36234297:+
BRCA	trans	rs6777098	0.915	rs12486752	ENSG00000250328.4	MGC32805	-5.39	8.87e-08	0.0481	-0.24	-0.16	Response to paliperidone in schizophrenia (positive Marder score);	chr3:167255186	chr5:122436497~122479087:-
BRCA	trans	rs11231420	1	rs11231420	ENSG00000260290.2	CTD-2033A16.2	-5.39	8.88e-08	0.0481	-0.18	-0.16	Pelvic organ prolapse (moderate/severe);	chr11:55877258	chr16:69756536~69757937:-
BRCA	trans	rs17711722	0.727	rs2658585	ENSG00000213640.3	EEF1DP4	-5.39	8.88e-08	0.0481	-0.2	-0.16	Calcium levels;	chr7:65996954	chr7:64862999~64864370:+
BRCA	trans	rs9467711	0.659	rs34605993	ENSG00000204709.4	LINC01556	5.39	8.91e-08	0.0483	0.41	0.16	Autism spectrum disorder or schizophrenia;	chr6:26454135	chr6:28943877~28944537:+
BRCA	trans	rs6142102	0.961	rs6120487	ENSG00000280327.1	LA16c-313F4.1	-5.39	8.92e-08	0.0483	-0.17	-0.16	Skin pigmentation;	chr20:34034802	chr16:1576716~1578371:-
BRCA	trans	rs445114	1	rs622853	ENSG00000213693.4	SEC14L1P1	5.39	8.93e-08	0.0484	0.18	0.16	Prostate cancer;Prostate cancer (SNP x SNP interaction);	chr8:127320936	chr11:43897456~43899636:+
BRCA	trans	rs13028485	0.5	rs480525	ENSG00000232389.1	RP11-134K13.2	-5.39	8.93e-08	0.0484	-0.35	-0.16	Multiple myeloma (IgH translocation);	chr2:173666736	chr6:70608234~70609334:-
BRCA	trans	rs951005	0.808	rs10972208	ENSG00000260947.1	RP11-384P7.7	-5.39	8.94e-08	0.0484	-0.21	-0.16	Rheumatoid arthritis;	chr9:34714362	chr9:33697459~33700986:+
BRCA	trans	rs6087771	0.781	rs6089067	ENSG00000279352.1	RP11-411B10.7	5.39	8.94e-08	0.0484	0.24	0.16	Putamen volume;Subcortical brain region volumes;	chr20:31771091	chr18:14010054~14010917:+
BRCA	trans	rs11098499	0.691	rs12502524	ENSG00000120555.12	SEPT7P9	5.39	8.94e-08	0.0484	0.19	0.16	Corneal astigmatism;	chr4:119350259	chr10:38383069~38402916:-
BRCA	trans	rs453301	0.631	rs17700611	ENSG00000270154.1	RP11-419I17.1	-5.39	8.95e-08	0.0484	-0.2	-0.16	Joint mobility (Beighton score);	chr8:8936144	chr8:12476462~12477122:+
BRCA	trans	rs2117029	0.555	rs2279596	ENSG00000214391.3	TUBAP2	5.39	8.95e-08	0.0485	0.16	0.16	Intelligence (multi-trait analysis);	chr12:49104968	chr11:90282560~90284172:+
BRCA	trans	rs3747547	0.685	rs11787995	ENSG00000229007.1	EXOSC3P1	-5.38	8.96e-08	0.0485	-0.44	-0.16	Metabolite levels (Dihydroxy docosatrienoic acid);	chr9:38098517	chr21:32496812~32497311:+
BRCA	trans	rs12497850	0.931	rs6414613	ENSG00000197582.5	GPX1P1	5.38	8.97e-08	0.0486	0.17	0.16	Parkinson's disease;	chr3:48998452	chrX:13378735~13379340:-
BRCA	trans	rs4710520	0.706	rs16896825	ENSG00000256746.4	RP11-17G12.3	-5.38	8.98e-08	0.0486	-0.29	-0.16	IgG glycosylation;	chr6:65542868	chr11:47270657~47272110:-
BRCA	trans	rs4710520	0.706	rs5001652	ENSG00000256746.4	RP11-17G12.3	-5.38	8.98e-08	0.0486	-0.29	-0.16	IgG glycosylation;	chr6:65544433	chr11:47270657~47272110:-
BRCA	trans	rs4631830	0.828	rs10763567	ENSG00000228789.5	HCG22	-5.38	9e-08	0.0487	-0.2	-0.16	Prostate-specific antigen levels;	chr10:46057653	chr6:31053450~31059890:+
BRCA	trans	rs34311235	0.58	rs16847952	ENSG00000225756.1	DBH-AS1	-5.38	9e-08	0.0487	-0.17	-0.16	Motion sickness;	chr2:142029654	chr9:133654586~133657313:-
BRCA	trans	rs7647973	1	rs7619789	ENSG00000197582.5	GPX1P1	5.38	9.01e-08	0.0487	0.18	0.16	Menarche (age at onset);	chr3:49438830	chrX:13378735~13379340:-
BRCA	trans	rs7647973	0.922	rs57273516	ENSG00000197582.5	GPX1P1	5.38	9.01e-08	0.0487	0.18	0.16	Menarche (age at onset);	chr3:49445641	chrX:13378735~13379340:-
BRCA	trans	rs7792596	0.861	rs6970279	ENSG00000236493.2	EIF2S2P3	5.38	9.01e-08	0.0487	0.24	0.16	Intelligence;	chr7:94385577	chr10:92668745~92669743:-
BRCA	trans	rs34421088	0.506	rs10091637	ENSG00000253893.2	FAM85B	-5.38	9.03e-08	0.0488	-0.22	-0.16	Neuroticism;	chr8:11286805	chr8:8167819~8226614:-
BRCA	trans	rs59888335	0.858	rs12630087	ENSG00000229393.1	RP3-395M20.3	-5.38	9.03e-08	0.0488	-0.18	-0.16	Schizophrenia;	chr3:80886020	chr1:2493437~2494479:-
BRCA	trans	rs7113874	0.569	rs11041985	ENSG00000266891.1	RP11-692N5.2	5.38	9.03e-08	0.0488	0.19	0.16	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8561137	chr18:9734882~9735602:-
BRCA	trans	rs9649213	0.593	rs1132971	ENSG00000225169.1	BRI3P1	5.38	9.04e-08	0.0489	0.21	0.16	Prostate cancer (SNP x SNP interaction);	chr7:98292221	chr1:100213293~100213670:+
BRCA	trans	rs319204	0.885	rs319185	ENSG00000226498.2	RP11-182B22.2	5.38	9.05e-08	0.0489	0.19	0.16	Schizophrenia;	chr5:146892840	chr1:236819634~236820518:+
BRCA	trans	rs45509595	0.841	rs200485	ENSG00000253570.1	RNF5P1	5.38	9.06e-08	0.049	0.35	0.16	Breast cancer;	chr6:27807919	chr8:38600661~38601200:-
BRCA	trans	rs7647973	0.58	rs4955432	ENSG00000197582.5	GPX1P1	5.38	9.06e-08	0.049	0.17	0.16	Menarche (age at onset);	chr3:49229339	chrX:13378735~13379340:-
BRCA	trans	rs11098499	0.863	rs1552092	ENSG00000253326.2	RP11-261C10.7	5.38	9.06e-08	0.049	0.23	0.16	Corneal astigmatism;	chr4:119567341	chr1:243054861~243056394:-
BRCA	trans	rs4879656	0.966	rs7869475	ENSG00000215007.3	DNAJA1P3	5.38	9.07e-08	0.049	0.21	0.16	Menopause (age at onset);	chr9:32986250	chrX:107351650~107352843:-
BRCA	trans	rs7943953	0.661	rs4939278	ENSG00000206897.1	SNORA9	5.38	9.08e-08	0.0491	0.2	0.16	Odorant perception (&beta-ionone);	chr11:59336218	chr12:123616708~123616840:+
BRCA	trans	rs1933488	0.504	rs1281952	ENSG00000278974.1	RP11-756P10.6	5.38	9.08e-08	0.0491	0.22	0.16	Prostate cancer;	chr6:153141261	chr4:188740507~188741281:-
BRCA	trans	rs11098499	0.779	rs28495013	ENSG00000253326.2	RP11-261C10.7	5.38	9.1e-08	0.0492	0.23	0.16	Corneal astigmatism;	chr4:119454676	chr1:243054861~243056394:-
BRCA	trans	rs9936075	0.918	rs7195576	ENSG00000237248.4	LINC00987	-5.38	9.1e-08	0.0492	-0.18	-0.16	Platelet-derived growth factor BB levels;	chr16:7275693	chr12:9240003~9243052:+
BRCA	trans	rs12682352	0.652	rs1567398	ENSG00000270154.1	RP11-419I17.1	-5.38	9.11e-08	0.0492	-0.18	-0.16	Neuroticism;	chr8:8869294	chr8:12476462~12477122:+
BRCA	trans	rs4929949	0.839	rs11041997	ENSG00000266891.1	RP11-692N5.2	-5.38	9.12e-08	0.0493	-0.19	-0.16	Body mass index;	chr11:8580469	chr18:9734882~9735602:-
BRCA	trans	rs675026	0.963	rs612512	ENSG00000264859.4	DSG2-AS1	5.38	9.12e-08	0.0493	0.2	0.16	Hypertension;	chr6:154128560	chr18:31542146~31556911:-
BRCA	trans	rs1232027	0.7	rs13185915	ENSG00000188985.6	DHFRP1	-5.38	9.13e-08	0.0493	-0.22	-0.16	Huntington's disease progression;	chr5:80609592	chr18:26170726~26171284:-
BRCA	trans	rs941207	0.507	rs2958124	ENSG00000257210.1	NACAP3	-5.38	9.13e-08	0.0493	-0.2	-0.16	Platelet count;	chr12:56633837	chr12:93124063~93124543:-
BRCA	trans	rs2160050	0.667	rs80015304	ENSG00000251586.1	TET2-AS1	5.38	9.13e-08	0.0493	0.34	0.16	Response to amphetamines;	chr3:118980815	chr4:105171354~105178063:-
BRCA	trans	rs6436559	0.504	rs13404618	ENSG00000237604.1	AP001056.1	-5.38	9.13e-08	0.0493	-0.31	-0.16	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;	chr2:225435717	chr21:44175489~44176453:+
BRCA	trans	rs730566	0.64	rs6442112	ENSG00000235912.1	RP1-159A19.3	-5.38	9.14e-08	0.0494	-0.21	-0.16	Prion diseases;	chr3:48274544	chr1:27649419~27649610:+
BRCA	trans	rs11587682	0.714	rs41264059	ENSG00000180764.13	PIPSL	5.38	9.15e-08	0.0494	0.24	0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr1:150488366	chr10:93958191~93961540:-
BRCA	trans	rs11587682	0.714	rs41264139	ENSG00000180764.13	PIPSL	5.38	9.15e-08	0.0494	0.24	0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr1:150488374	chr10:93958191~93961540:-
BRCA	trans	rs11098499	0.82	rs6829903	ENSG00000276805.1	RP11-291L22.6	5.38	9.15e-08	0.0494	0.19	0.16	Corneal astigmatism;	chr4:119585729	chr10:38451030~38451785:+
BRCA	trans	rs5006884	0.507	rs4910760	ENSG00000258626.2	COX7A2P1	5.38	9.15e-08	0.0494	0.21	0.16	Fetal hemoglobin levels;	chr11:5354153	chr14:67652300~67652614:-
BRCA	trans	rs11098499	0.863	rs2306456	ENSG00000276805.1	RP11-291L22.6	5.38	9.16e-08	0.0494	0.2	0.16	Corneal astigmatism;	chr4:119551267	chr10:38451030~38451785:+
BRCA	trans	rs11098499	0.863	rs11947234	ENSG00000276805.1	RP11-291L22.6	5.38	9.16e-08	0.0494	0.2	0.16	Corneal astigmatism;	chr4:119553704	chr10:38451030~38451785:+
BRCA	trans	rs11098499	0.863	rs11933966	ENSG00000276805.1	RP11-291L22.6	5.38	9.16e-08	0.0494	0.2	0.16	Corneal astigmatism;	chr4:119555560	chr10:38451030~38451785:+
BRCA	trans	rs11098499	0.863	rs36040693	ENSG00000276805.1	RP11-291L22.6	5.38	9.16e-08	0.0494	0.2	0.16	Corneal astigmatism;	chr4:119556461	chr10:38451030~38451785:+
BRCA	trans	rs875971	0.545	rs1796226	ENSG00000234585.5	CCT6P3	5.38	9.17e-08	0.0495	0.18	0.16	Aortic root size;	chr7:66622723	chr7:65038354~65074713:+
BRCA	trans	rs8177876	0.822	rs16954582	ENSG00000224837.1	GCSHP5	5.38	9.18e-08	0.0495	0.3	0.16	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81080552	chr1:168055901~168056422:-
BRCA	trans	rs7829975	0.688	rs7837587	ENSG00000270154.1	RP11-419I17.1	5.38	9.18e-08	0.0496	0.19	0.16	Mood instability;	chr8:8521482	chr8:12476462~12477122:+
BRCA	trans	rs9467711	0.591	rs28360595	ENSG00000281831.1	HCP5B	5.38	9.18e-08	0.0496	0.35	0.16	Autism spectrum disorder or schizophrenia;	chr6:26029816	chr6:29871895~29873783:-
BRCA	trans	rs7647973	1	rs974495	ENSG00000235912.1	RP1-159A19.3	-5.38	9.19e-08	0.0496	-0.21	-0.16	Menarche (age at onset);	chr3:49363049	chr1:27649419~27649610:+
BRCA	trans	rs7647973	1	rs11719762	ENSG00000235912.1	RP1-159A19.3	-5.38	9.19e-08	0.0496	-0.21	-0.16	Menarche (age at onset);	chr3:49371569	chr1:27649419~27649610:+
BRCA	trans	rs7943953	0.661	rs1403332	ENSG00000206897.1	SNORA9	-5.38	9.19e-08	0.0496	-0.19	-0.16	Odorant perception (&beta-ionone);	chr11:59323329	chr12:123616708~123616840:+
BRCA	trans	rs11098499	0.954	rs12510138	ENSG00000276805.1	RP11-291L22.6	5.38	9.19e-08	0.0496	0.19	0.16	Corneal astigmatism;	chr4:119502780	chr10:38451030~38451785:+
BRCA	trans	rs12497850	0.931	rs13064784	ENSG00000197582.5	GPX1P1	5.38	9.2e-08	0.0496	0.17	0.16	Parkinson's disease;	chr3:49098528	chrX:13378735~13379340:-
BRCA	trans	rs1580019	0.665	rs34147895	ENSG00000213492.2	NT5C3AP1	-5.38	9.21e-08	0.0497	-0.23	-0.16	Cognitive ability;	chr7:32492184	chr4:117574512~117576174:-
BRCA	trans	rs6430585	0.528	rs16832440	ENSG00000224043.6	CCNT2-AS1	-5.38	9.21e-08	0.0497	-0.29	-0.16	Corneal structure;	chr2:135996613	chr2:134735464~134918710:-
BRCA	trans	rs10988802	1	rs4743090	ENSG00000269956.1	MKNK1-AS1	5.38	9.22e-08	0.0497	0.21	0.16	Chemerin levels;	chr9:95614085	chr1:46538696~46570255:+
BRCA	trans	rs12497850	0.931	rs7626445	ENSG00000197582.5	GPX1P1	5.38	9.23e-08	0.0498	0.17	0.16	Parkinson's disease;	chr3:49077111	chrX:13378735~13379340:-
BRCA	trans	rs17531088	0.646	rs11706435	ENSG00000214049.6	UCA1	-5.38	9.24e-08	0.0498	-0.22	-0.16	Kawasaki disease;	chr3:175154586	chr19:15828961~15836320:+
BRCA	trans	rs11074306	0.602	rs4238493	ENSG00000267416.1	CTD-2319I12.2	5.38	9.24e-08	0.0498	0.21	0.16	Uveal melanoma;	chr15:27796781	chr17:60079309~60088695:+
BRCA	trans	rs853679	0.546	rs71537572	ENSG00000243753.4	HLA-L	-5.38	9.24e-08	0.0498	-0.44	-0.16	Depression;	chr6:28002937	chr6:30259584~30293014:+
BRCA	trans	rs10498091	0.895	rs75261866	ENSG00000263072.4	ZNF213-AS1	-5.38	9.24e-08	0.0499	-0.18	-0.16	Echocardiographic traits;	chr2:221010553	chr16:3116042~3134882:-
BRCA	trans	rs2243480	0.901	rs13237344	ENSG00000164669.11	INTS4P1	5.38	9.24e-08	0.0499	0.32	0.16	Diabetic kidney disease;	chr7:66557269	chr7:65141225~65234216:+
BRCA	trans	rs9535495	0.965	rs9535498	ENSG00000244480.1	AC005154.7	5.38	9.25e-08	0.0499	0.15	0.16	High light scatter reticulocyte count;Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;	chr13:50821440	chr7:30523143~30524535:-
BRCA	trans	rs7089973	0.61	rs34461950	ENSG00000249267.5	LINC00939	5.38	9.26e-08	0.0499	0.2	0.16	Bipolar disorder or attention deficit hyperactivity disorder;	chr10:114968514	chr12:125958688~125983374:-
BRCA	trans	rs239339	1	rs239339	ENSG00000271420.1	RP5-1057J7.7	5.38	9.27e-08	0.05	0.2	0.16	Obesity-related traits;	chr1:4384479	chr1:23378380~23379029:-
BRCA	trans	rs12637928	0.56	rs6778144	ENSG00000268601.1	AC115522.3	-5.38	9.27e-08	0.05	-0.21	-0.16	Neuroticism;	chr3:110527015	chr19:43794309~43795658:-